id|nct_id|group_type|title|description
89176873|NCT00537108|Experimental|HV|Intervention arm.
89176874|NCT00537108|No Intervention|Cntr|Usual care control
89188791|NCT00841360||HIV Status Unknown|"Participant self-discloses as HIV negative (no history of prior HIV testing, or HIV screening more than 12 months prior to date of study consent).~Sexually experienced females between the ages of 13 and 24 years old and of African American race, Hispanic/Latina ethnicity, or mixed-race/ethnicity, which must include African American race and/or Hispanic/Latina ethnicity."
88821762|NCT01780844|Active Comparator|Standard of Care|Basiliximab induction + Tacrolimus + MMF + Corticosteroids
88821763|NCT01780844|Experimental|CNI avoidance|Basiliximab induction + ASKP1240 + MMF + Corticosteroids
88821764|NCT01780844|Experimental|CNI minimization-MMF avoidance|Basiliximab induction + ASKP1240 + Tacrolimus + Corticosteroids
88821765|NCT01756222||Bicuspid Aortic Valve Disease Patients|Patients with the diagnosis of BAV disease.
88821766|NCT01655784|Active Comparator|Eighteen Coils (0.014-0.0155 inch)|Subjects who randomize to this arm will receive larger diameter bare platinum coils for treatment of their cerebral aneurysm. Subjects in this arm could receive a combination of the following protocol approved intracranial coils depending on the phase: Target XL 360 Standard, Target XL 360 Soft, Target XL 360 Helical, GDC-18 360 Standard, GDC-18 3D, GDC-18 2D, GDC-18 Soft, and/or 0.014-0.0155 inch diameter bare platinum intracranial coils.
88821767|NCT01655784|Active Comparator|Standard Coils (0.014 inch)|Subjects who randomize to this arm will receive the standard diameter bare platinum coils for treatment of their cerebral aneurysm. Subjects in this arm could receive a combination of the following protocol approved intracranial coils depending on the phase: Target 360 Standard, Target 360 Soft, Target 360 Ultra, Target 360 NANO, Target 360 Helical Ultra, GDC-10 360 Standard SR, GDC-10 360 Soft SR, GDC-10 UltraSoft, GDC-10 3D, GDC-10 2D, GDC-10 Soft 2D SR, GDC-10 Soft SR, GDC-10 Soft, and/or any additional 0.014 inch or less diameter bare platinum intracranial coils.
88821768|NCT01622192|Experimental|Automated probe|
88875160|NCT02491788|Placebo Comparator|Placebo|Placebo pill 30 minutes prior to daytime sleep opportunity
89355333|NCT04501354|Experimental|UC-Mesenchymal Stem Cell|Allogeneic Mesenchymal Stem Cell from umbilical cord
89176875|NCT00589602|Experimental|T-Cell Depletion Transplant|"Our protocol is designed to attempt to improve the current results of matched unrelated donor (MUD) allo bone marrow transplant (BMT) and will be a major step towards the introduction and refinement of graft engineering. Our approach will address in a rational fashion all major technical and clinical aspects of MUD allo BMT.~Peripheral blood lymphocyte therapy; cyclophosphamide, tacrolimus, peripheral blood stem cell transplantation; total-body irradiation; 'allogeneic hematopoietic stem cell transplantation'"
89176876|NCT00794157|Experimental|Indacaterol 150 µg|Patients received indacaterol 150 μg delivered via a single dose dry powder inhaler (SDDPI) once daily (od) in the morning (between 8:00 and 11:00 AM). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
89176877|NCT00794157|Experimental|Indacaterol 300 µg|Patients received indacaterol 300 μg delivered via a single dose dry powder inhaler (SDDPI) once daily (od) in the morning (between 8:00 and 11:00 AM). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
89176878|NCT00794157|Placebo Comparator|Placebo|Patients received placebo delivered via a single dose dry powder inhaler (SDDPI) once daily (od) in the morning (between 8:00 and 11:00 AM). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
89176879|NCT02607072|Experimental|Aspirin 200 mg daily|Aspirin 200 mg daily
89176880|NCT02607072|Experimental|Aspirin 100 mg daily|Aspirin 100 mg daily
89176881|NCT02607072|Placebo Comparator|Placebo control|Placebo control
89176882|NCT04110093|Experimental|Immunotherapy Combination treatment|All colorectal cancer patients received regorafenib plus PD-1 inhibitor
89176883|NCT03180918|Experimental|testicular tissue cryopreservation|
89176884|NCT00588237|Experimental|1|Paclitaxel, Cisplatin, Bevacizumab
89176885|NCT02605746|Experimental|2-4 hours|All patients will be orally-administered 10-14 doses of ceritinib 750mg with the final dose occurring at one of three intervals before brain tumor resection. This arm has the last ceritinib dose 2-4 hours prior to craniotomy for tumor resection.
89176886|NCT02605746|Experimental|4-8 hours|All patients will be orally-administered 10-14 doses of ceritinib 750mg with the final dose occurring at one of three intervals before brain tumor resection. This arm has the last ceritinib dose 4-8 hours prior to craniotomy for tumor resection.
89176887|NCT02605746|Experimental|22-26 hours|All patients will be orally-administered 10-14 doses of ceritinib 750mg with the final dose occurring at one of three intervals before brain tumor resection. This arm has the last ceritinib dose 22-26 hours prior to craniotomy for tumor resection.
89176888|NCT02604381|Experimental|Glucosamine Sulfate Potassium Chloride/Ginkgo Biloba Extract|2 capsules daily, immediately following a meal. 1 capsule in the morning, and 1 capsule in the evening, at approximately the same time each day.
89176889|NCT02604381|Placebo Comparator|Placebo|2 capsules daily, immediately following a meal. 1 capsule in the morning, and 1 capsule in the evening, at approximately the same time each day.
89176890|NCT04109781|Other|Patients with Lumbar disc herniation|Patients with lumbar disc herniation with no response to conservative treatment and were treated with Microdiscectomy
89176891|NCT04115436||stroke (+)|Patients experiencing thromboembolic events following a brief discontinuation of anticoagulant or having thrombus on the LAA occlusion device
89355334|NCT01199549||Lycopene group|Mixed age and gender group of healthy volunteers for testing bio-availability of Lycopene containing supplement
89355335|NCT01199549||Resveratrol group|Mixed age and gender group of healthy volunteers for testing bio-availability of Resveratrol containing supplement
89355336|NCT01199549||Laflavon group|Mixed age and gender group of healthy volunteers for testing bio-availability of Soy Isoflavones containing supplement
89355337|NCT03844139||Feeding pump group(continous)|Using the feeding pump to give patients prescribed enteral nutrient solution through nasogastric tube in 24 hours
89355338|NCT03844139||Glycerin syringe group(intermittent)|Using the glycerin syringe to give patients prescribed enteral nutrient solution through nasogastric tube in 4-5 times
89355339|NCT03579862||Chronic Thromboembolic Pulmonary Hypertension (CTEPH)|
89355340|NCT03579862||Pulmonary Embolism (PE)|
89176892|NCT04115436||No-stroke|Patients remaining stroke-free months after discontinuation of anticoagulants
89355341|NCT03579862||Pulmonary Arterial Hypertension (PAH)|
89355342|NCT03346408||Patients|data collection obtained from patient (self-questionnaire) and algologist physician (questionnaire).
89355343|NCT04500496|Experimental|INH|3 tablet of INH 900 mg inserted by the patient 12 hours before the scheduled office hysteroscopy.
89355344|NCT04500496|Active Comparator|dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia & Upjohn, Puurs, Belgium) inserted by the patient 12 hours before the scheduled office hysteroscopy.
89355345|NCT01199627|Experimental|A|"Group A: 1st dose 15mg/kg of TXA (tranexamic acid) in 100ml saline 0.9% after the completion of regional anesthesia, and before the start of surgery.~2nd dose: intravenous infusion over 10 minutes in 100ml of saline 0.9% at three hours after the first administration."
89355346|NCT01199627|Experimental|B|"Group B: 1st dose: 10mg/kg of TXA (tranexamic acid) in 100ml 0.9% saline after the completion of regional anesthesia, and before the start of surgery.~2nd dose: intravenous infusion over 10 minutes of 10mg/kg of TXA in 100ml saline 0.9% at three hours after the first administration."
89355347|NCT01199627|Placebo Comparator|C|Placebo
89399032|NCT04050267|Placebo Comparator|Control group - air|Breathing air with 21 % of oxygen (0% nitrous oxide). Performing cognitive tests as per protocol.
89176893|NCT04109859|Experimental|Methylene blue group|Before the anesthesia was intubated, the patients in the methylene blue group were given a 2 mg/Kg methylene blue 50 ml intravenously for 10 min; continuous constant speed pumping methylene blue(0.5mg/Kg/h).
89176894|NCT04109859|Placebo Comparator|Placebo group|Before the anesthesia was intubated, the placebo group was given 50 ml of normal saline for 10 min.continuous constant speed pumpingnormal saline (10ml/h).
88821769|NCT01606878|Experimental|Part A (crizotinib, cyclophosphamide, topotecan hydrochloride)|Patients receive crizotinib (oral solution) PO BID on days 1-21, cyclophosphamide IV QD on days 1-5, and topotecan hydrochloride IV QD on days 1-5. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity. (closed to accrual 10/3/14)
88821770|NCT01606878|Experimental|Part B (crizotinib, vincristine, dexrazoxane, doxorubicin)|Patients receive crizotinib (oral solution) PO BID as in Part A. Patients also receive vincristine sulfate IV on day 1, dexrazoxane hydrochloride IV on day 1, and doxorubicin hydrochloride IV over 15 minutes on day 1. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity. (closed to accrual 10/3/14)
88821771|NCT01606878|Experimental|Part C (crizotinib, cyclophosphamide, topotecan hydrochloride)|Patients receive crizotinib (capsule formulation) PO BID, cyclophosphamide IV QD, and topotecan hydrochloride IV QD as in Part A. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
88821772|NCT01606878|Experimental|Part D (crizotinib, cyclophosphamide, topotecan hydrochloride)|Patients receive crizotinib (microsphere formulation) PO BID, cyclophosphamide IV QD, and topotecan hydrochloride IV QD as in Part A. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
88821773|NCT01546493|Experimental|Controls|Asymptomatic control subjects with no deformity. All patients will undergo all 3 interventions: MRI, qCT, and motion analysis.
88821774|NCT01546493|Experimental|Symptomatics|Subjects with bilateral cam deformity and unilateral symptoms. All patients will undergo all 3 interventions: MRI, qCT, and motion analysis. Select patients will be asked to participate in a PET-MRI scan being conducted at The Royal Ottawa.
88821775|NCT01546493|Experimental|Asymptomatic|Asymptomatic subjects with cam deformity. All patients will undergo all 3 interventions: MRI, qCT, and motion analysis. Select patients will be asked to participate in a PET-MRI scan being conducted at The Royal Ottawa.
88821776|NCT01315288|Active Comparator|Video presentation absolute risk|absolute risk
88821777|NCT01315288|Active Comparator|Video presentation absolute event-free survival|absolute event-free survival
88821778|NCT01315288|Active Comparator|Video presentation annualized absolute risk|annualized absolute risk
88821779|NCT01315288|Active Comparator|Video presentation relative risk|relative risk
88821780|NCT01315288|Active Comparator|Video presentation qualitative description|qualitative description
88821781|NCT01224665|Active Comparator|Arm I|therapeutic conventional surgery therapeutic standard lymphadenectomy
88821782|NCT01224665|Experimental|Arm II|therapeutic conventional surgery therapeutic extended lymphadenectomy
88821783|NCT01209000||FSGS/MCD Cohort (Cohort A)|"Focal Segmental Glomerulosclerosis/Minimal Change Disease (FSGS/MCD) Cohort~Participants enrolled in NEPTUNE with a biopsy proven histological diagnosis for FSGS or MCD.~Eligible participants must be scheduled for a clinically indicated renal biopsy."
89176895|NCT00790023|Experimental|80 mcg Ciclesonide|80 mcg Ciclesonide once daily
89176896|NCT00790023|Experimental|160 mcg Ciclesonide|160 mcg Ciclesonide once daily
89176897|NCT00790023|Placebo Comparator|Placebo|Placebo once daily
89176898|NCT00588822|Experimental|Rituximab|"Subjects will receive rituximab administered at the standard dose and schedule as an initial cycle of therapy, followed by a re-evaluation at 6 months. If the neuropathy is stable or responding at 6 months, the subject will receive Cycle 2 of rituximab, followed by a re-evaluation at 12 months.~Rituximab will be given as a 375 mg/m^2 intravenous infusion once weekly for four doses (days 1, 8, 15, and 22)."
89176899|NCT04115202||posterior spinal approach group|Lumbar arthrodesis performed by a posterior spinal approach.
89176900|NCT04115202||anterior spinal approach group|Lumbar arthrodesis performed by a anterior spinal approach.
89176901|NCT05563467|Experimental|Pembrolizumab Treatment|
89176902|NCT00589914|Active Comparator|RISPERDAL CONSTA|RISPERDAL CONSTA 25-50 mg eq every 2 weeks
89176903|NCT00589914|Experimental|R092670|Paliperidone Palmitate 50-150 mg eq every 4 wks
89176904|NCT00789555|Experimental|PATANASE|Olopatadine hydrochloride 0.6% nasal spray (PATANASE), two sprays in each nostril twice a day (morning and evening) for up to 12 months
89176905|NCT00789555|Placebo Comparator|Patanase Vehicle, pH 3.7|Olopatadine nasal spray vehicle, pH 3.7, two sprays in each nostril twice a day (morning and evening) for up to 12 months
89176906|NCT00789555|Placebo Comparator|Patanase Vehicle, pH 7.0|Olopatadine nasal spray vehicle, pH 7.0, two sprays in each nostril twice a day (morning and evening) for up to 12 months
89176907|NCT04112472|Experimental|Examination of participants|Examination of participants by means of the investigational device as well as the comparative devices.
89176908|NCT04115046||Treatment Arm|Consecutive, eligible patients reporting for an ultrasound and liver biopsy for evaluation of fibrosis will be enrolled. Each subject will undergo both procedures (FibroScan and EUS with SW Elastography).
89176909|NCT00451321|Experimental|otelixizumab|
89176910|NCT03770455|Experimental|Avelumab + 2nd generation ADT|Avelumab 10mg/kg every 2 weeks (Q2W) + 2nd generation ADT
89176911|NCT01025869|Other|Stent System|Cinatra™ Corolimus Eluting Coronary Stent System
89176912|NCT01025947||Study group|Patients with cryptogenic stroke (TOAST criteria) and with an implantable EKG loop recorder implanted
89176913|NCT01026025|Experimental|Duet TRS|This is a single arm study.
89176914|NCT01026259|Experimental|Local incision warming|Local warming applied to surgical incision for 6 treatments beginning in post anesthesia recovery through the second postoperative day.
89176915|NCT01026259|Active Comparator|No warming to surgical incision|Incisions covered with same postoperative dressing as in Arm 1 but without warming treatments.
89176916|NCT03753997|No Intervention|Conventional therapy|Patiens´s will come to the clinic for regular contact with a diabetes nurse.
89176917|NCT03753997|Experimental|Treatment by a Psychologist|Patients will meet with a diabetes educated psychologist over 9 months and will come to the clinic for regular contact with a diabetes nurse
89176918|NCT01026337||Arm I|"Patients receive oral sunitinib malate once daily on days 1-28. Treatment repeats every 42 days in the absence of disease progression or unacceptable toxicity.~Patients undergo dynamic contrast-enhanced MRI at baseline and after the first 4 weeks of sunitinib malate."
89176919|NCT03746275||CAD/PAD-patients|Adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) from Europe, Asia, Latin America and Canada, who are treated with a combination of rivaroxaban and acetylsalicylic acid to prevent atherothrombotic events
89176920|NCT01026415|Experimental|1|midazolam +/- brentuximab vedotin
89176921|NCT01026415|Experimental|2|brentuximab vedotin +/- rifampin
89176922|NCT01026415|Experimental|3|brentuximab vedotin +/- ketoconazole
89176923|NCT01026415|Experimental|4|special populations
89176924|NCT03731611|Active Comparator|Group A|umbilical cord milking will be done for preterm infants <34 gestational age without placental insufficiency
89176925|NCT03731611|Active Comparator|Group B|umbilical cord milking will be done for preterm infant <34 gestational age with placental insufficiency
89176926|NCT03731611|No Intervention|Group C|Immediate cord clamping for preterm infants <34 gestational age with placental insufficiency
89176927|NCT01026649|Experimental|2 stage|Approach the internal jugular vein in a 2 stage fashion during central venous catheterization
89355348|NCT02512744|No Intervention|Capping trial protocol|"Decannulation protocol based on tolerance to 24 hours capping trial to decide when to decannulate.~Decapping during the capping trial for aspiration of respiratory secretions is considered a failure criteria of the trial.~High flow conditioned oxygen therapy through tracheal cannula will be applied during periods out of capping trials."
88821784|NCT01209000||MN Cohort (Cohort A)|"Membranous Nephropathy (MN) Cohort~Participants enrolled in NEPTUNE with a biopsy proven histological diagnosis for MN.~Eligible participants must be scheduled for a clinically indicated renal biopsy."
88821785|NCT01209000||Other glomerulopathies cohort|"Participants enrolled in NEPTUNE and determined to not have FSGS/MCD or MN will be followed in a third group.~Eligible participants must be scheduled for a clinically indicated renal biopsy."
88821786|NCT01209000||cNEPTUNE (Cohort B)|Participants < 19 years of age, with < 30 days exposure to immunosuppression therapy who are not scheduled for renal biopsy.
88821787|NCT01175356|Experimental|Treatment (131I-MIBG, chemotherapy)|See Detailed Description.
88821788|NCT01151605|Experimental|obese subjects|obese (BMI >30Kg/m2) subjects infused with insulin dextrose or saline 1 week apart. Each infusion will continue for up to 14 hr
88821789|NCT01151605|Active Comparator|Normal weight subjects|Normal weight subjects infused with insulin dextrose or saline 1 week apart. Each infusion will continue for up to 14 hr
88821790|NCT01151605|Experimental|obese type 2 diabetes subjects|obese (BMI >30Kg/m2) subjects with type 2 diabetes infused with insulin dextrose or saline 1 week apart. Each infusion will continue for up to 14 hr
88821791|NCT01064466|Experimental|ETOPOSIDE - Usual|"Etoposide Injection~Chemotherapy~Etoposide Injection~Usual Approach Group"
88821792|NCT01064466|Experimental|ETOPOSIDE - Study|"Etoposide Capsule~Chemotherapy~Etoposide Capsule~Study Approach Group"
88821793|NCT01005745|Experimental|TIL With High Dose IL-2|"Day -7 and -6: Cyclophosphamide 60 mg/kg/day I.V. in 250 ml NS over approximately 2 hours. Mesna 20 mg/kg with D5W or NS at 125 ml/hour infused intravenously over 24 hours.~Day -5 to Day -1: Fludarabine 25 mg/m^2 intravenous piggyback (IVPB0 daily over approximately 30 minutes for 5 days.~Day 0: T cell infusion in 250-1000 ml NS over approximately 15-60 minutes depending on volume to be infused.~Days 1-5: High dose IL-2, 720,000 IU/kg IV bolus (about 15 minutes) every 8-16 hours for up to 15 doses, beginning approximately 12-16 hours after T cell infusion."
89355349|NCT02512744|Experimental|Suctioning frequency protocol|"Decannulation protocol based on suctioning frequency to decide when to decannulate (criteria: ≤2 aspirations every 8 h along 24 consecutive hours).~Intervention: suctioning frequency of respiratory secretions will be recorded untill fulfill decannulation criteria. Capping trials will not be allowed in this group.~High flow conditioned oxygen therapy will be applied through tracheal cannula during all the study period."
89355350|NCT03146507|Other|Normal pregnant women at 32-34 weeks group|
88821794|NCT00832325||1 individual interviews|The patient will be asked to come in to the Counseling Center at MSKCC (641 Lexington Avenue, 7th Floor) and participate in an individual interview at their convenience.
88821795|NCT00832325||2 Focus Groups|The patient will be asked to come in to the Counseling Center at MSKCC (641 Lexington Avenue, 7th Floor) and participate in a focus group at their convenience.
88821796|NCT00832325||3 Questionnaire|The patient will be asked to participate in three 60-90 minute telephone interviews scheduled at their convenience.
88821797|NCT00762866||MDD|Unipolar Major Depressive Disorder, any subtype
88821798|NCT00762866||Bipolar|Bipolar I or II Disorder or Bipolar Disorder NOS
88821799|NCT00762866||Psychosis|Psychotic Disorder including Schizophrenia, Schizoaffective, Schizophreniform, Brief Psychotic Disorder, and Psychotic Disorder NOS
88821800|NCT00756262|Active Comparator|1|Lactobacillus rhamnosus LGG
89355351|NCT03146507|Other|Intrauterine growth restriction at 32-34 weeks group|
89355352|NCT02512588|Experimental|BTD-001|
88821801|NCT00756262|Placebo Comparator|2|Microcrystalline cellulose capsules
88821802|NCT00706420|Experimental|1|Islet cell transplantation alone
88821803|NCT00664508|Active Comparator|Lateral approach|Lateral approach Intervention: Motion Analysis. Standard AP/Lateral x-rays of the hips, functional assessment questionnaires and 3D joint mechanic assessment at the Biomechanics Laboratory
88821804|NCT00664508|Active Comparator|Anterior approach|Anterior approach Intervention: Motion Analysis. Standard AP/Lateral x-rays of the hips, functional assessment questionnaires and 3D joint mechanic assessment at the Biomechanics Laboratory
88821805|NCT00664508|Active Comparator|Posterior approach|Posterior approach Intervention: Motion Analysis. Standard AP/Lateral x-rays of the hips, functional assessment questionnaires and 3D joint mechanic assessment at the Biomechanics Laboratory
88821806|NCT00579072||Longitudinal Study|Take part in this study because subject has prostate cancer and are over 64 years old. To run this study,need men from two groups. First, we need men who are about to start hormone treatment. Second, we need men who do not plan to use this treatment in the future. We will use this second group as a control group and compare this group to the men who are using this treatment.
88821807|NCT00579072||Group Comparison|Take part in this study because subject has prostate cancer and are over 64 years old. Also, because subject has been on hormone therapy for about two to three years.
88821808|NCT00381121||Kidney disease cohort|Individuals with a clinically indicated biopsy are recruited and/or surplus tissue that remains from past clinical interventions is obtained.
88821809|NCT00335816|Experimental|Group 1 (Closed to Enrollment)|All patients undergo chemoradiation therapy comprising radiation therapy once daily 5 days a week for 5 weeks and fluorouracil intravenously continuously over 24 hours 7 days a week for 6 weeks. Patients undergo standard surgical resection after completion of chemoradiation therapy..
88875161|NCT02491944|Experimental|Bioavailability of AZD9291|To assess the absolute bioavailability of a single oral dose of AZD9291 with respect to an intravenous microdose of [14C]AZD9291
89355353|NCT02512588|Experimental|Placebo|
89355354|NCT01566617|Other|Standard Care|(1) group who will receive standard care
88821810|NCT00335816|Experimental|Group 2 (Closed to Enrollment)|All patients undergo chemoradiation therapy comprising radiation therapy once daily 5 days a week for 5 weeks and fluorouracil IV continuously over 24 hours 7 days a week for 6 weeks. Beginning 4 weeks after completion of chemoradiation therapy, patients receive modified FOLFOX-6 chemotherapy comprising oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1 and fluorouracil IV continuously over 46 hours on days 1-2. Treatment repeats every 14 days for 2 courses. After the last week of post-radiation chemotherapy, patients undergo standard surgical resection.
88821811|NCT00335816|Experimental|Group 3 (chemotherapy, FOLFOX, conventional surgery)|All patients undergo chemoradiation therapy comprising radiation therapy once daily 5 days a week for 5 weeks and fluorouracil IV continuously over 24 hours 7 days a week for 6 weeks. Beginning 4 weeks after completion of chemoradiation therapy, patients receive modified FOLFOX-6 chemotherapy as in group II. Treatment repeats every 14 days for 4 courses. After the last week of post-radiation chemotherapy, patients undergo standard surgical resection.
88821812|NCT00335816|Experimental|Group 4 (chemotherapy, FOLFOX, conventional surgery)|All patients undergo chemoradiation therapy comprising radiation therapy once daily 5 days a week for 5 weeks and fluorouracil IV continuously over 24 hours 7 days a week for 6 weeks. Beginning 4 weeks after completion of chemoradiation therapy, patients receive modified FOLFOX-6 chemotherapy as in group II. Treatment repeats every 14 days for 6 courses. After the last week of post- radiation chemotherapy, patients undergo standard surgical resection. Patients then receive 3 additional courses of FOLFOX-6 chemotherapy or other chemotherapy off study as directed by the physician.
88821813|NCT00295893|Active Comparator|Docetaxel, Doxorubicin Hydrochloride, and Cyclophosphamide|Patients receive doxorubicin hydrochloride IV, cyclophosphamide IV, and docetaxel IV on day 1. Treatment repeats every 21 days for 6 courses.
88821814|NCT00295893|Experimental|Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel and Carboplatin|Patients receive doxorubicin hydrochloride IV and cyclophosphamide IV on day 1; treatment repeats every 2 weeks for 4 courses. Patients then receive carboplatin IV on day 1 and paclitaxel IV on days 1, 8, and 15; treatment with carboplatin and paclitaxel repeats every 4 weeks for 3 courses.
89355355|NCT01566617|Other|Standard Care and Pharmaceutical Care|(2) group who will receive standard care and pharmaceutical care
89355356|NCT02516254|Experimental|fortified bread|daily intake of fortified bread (1000IU vitamin D per 50 g) plus placebo
89355357|NCT02516254|Experimental|supplement|daily intake of plain bread (50 g) plus supplement (1000 IU per tablet)
89355358|NCT02516254|Placebo Comparator|placebo|daily intake of plain bread plus placebo
89355359|NCT02516176|Experimental|Treadmill Training|Paretic leg step training while standing on a treadmill sideways and responding to treadmill being turned on suddenly.
89355360|NCT04810169||Smart inhaler|Children with smart inhaler
89355361|NCT01199081|Experimental|Group A|"Dronedarone 400 mg twice daily for 8 weeks starting from randomization.~The last 2 months regimen of Amiodarone 200 mg/day is continued until randomization."
89355362|NCT01199081|Experimental|Group B|"Dronedarone 400 mg twice daily for 6 weeks starting 2 weeks after randomization.~The last 2 months regimen of Amiodarone 200 mg/day is continued until randomization."
89355363|NCT01199081|Experimental|Group C|"Dronedarone 400 mg twice daily for 4 weeks starting 4 weeks after randomization.~The last 2 months regimen of Amiodarone 200 mg/day is continued until randomization."
89355364|NCT02512354||Fetus|
89355365|NCT02516020|Active Comparator|Global|EmbryoSingle step culture medium Embryos are cultured in single step culture from day 1 to day 5 Other Name: Global medium (LifeGlobal)
89355366|NCT02516020|Active Comparator|Origio|Sequential media Embryos are cultured in sequential medium from Day1 to Day 3 and from Day 3 to Day 5 (Sequential Blast) Other Name: Sequential Blast (Origio)
89355367|NCT03841955|Experimental|Experimental group|Peripheral implantation of central venous catheters and accessories with high pressure tolerance
89355368|NCT03841955|Experimental|Control group|Peripheral intubation of central venous catheter
89355369|NCT04500886|Experimental|PEG-rhG-CSF group|Patients received subcutaneous injection of PEG-rhG-CSF(Jinyouli®)24 hours after the end of chemotherapy, 6mg for patients with body weight ≥ 45kg and 3mg for patients with body weight less than 45kg, once per chemotherapy cycle
89355370|NCT04500886|Active Comparator|rhG-CSF group|Patients received subcutaneous injection of rhG-CSF 24 hours after the end of chemotherapy, 300ug for patients with body weight ≥45kg and 150ug for patients with body weight less than 45kg, Once a day for 3-5 days until the absolute count of neutrophils ≥2×109/L.
89355371|NCT03346018||uveitis of tuberculous etiology|Analysis of aqueous humor and plasma samples: The patients with diagnosis of uveitis of tuberculous etiology, undergone to paracentesis of anterior chamber, will can able to grant their aqueous humor and a sample of venous blood to the study of immunological markers to distinguish between uveitis of tuberculous etiology from uveitis by sarcoidosis through the analysis of the aqueous humor and the analysis of the plasma samples.
89355372|NCT03346018||uveitis of suspect sarcoidosis|Analysis of aqueous humor and plasma samples:The patients with diagnosis of uveitis of suspect sarcoidosis, undergone to paracentesis of anterior chamber, will can able to grant their aqueous humor and a sample of venous blood to the study of immunological markers to distinguish between uveitis of tuberculous etiology from uveitis by sarcoidosis through the analysis of the aqueous humor and the analysis of the plasma samples.
89355373|NCT03346018||uveitis of undifferentiated origin|Analysis of aqueous humor and plasma samples:The patients with diagnosis of uveitis of undifferentiated origin (tuberculosis/sarcoidosis), undergone to paracentesis of anterior chamber, will can able to grant their aqueous humor and a sample of venous blood to the study of immunological markers to distinguish between uveitis of tuberculous etiology from uveitis by sarcoidosis through the analysis of the aqueous humor and the analysis of the plasma samples.
89399033|NCT04050267|Experimental|Intervention Group - 5% nitrous oxide|Breathing 5% nitrous oxide in air with 21 % of oxygen. Performing cognitive tests as per protocol.
89399034|NCT04050267|Experimental|Intervention Group - 7% nitrous oxide|Breathing 7% nitrous oxide in air with 21 % of oxygen. Performing cognitive tests as per protocol.
89399035|NCT04050267|Experimental|Intervention Group - 10% nitrous oxide|Breathing 10% nitrous oxide in air with 21 % of oxygen. Performing cognitive tests as per protocol.
89399036|NCT04050267|Experimental|Intervention Group - 12% nitrous oxide|Breathing 12% nitrous oxide in air with 21 % of oxygen. Performing cognitive tests as per protocol.
88821815|NCT00295893|Experimental|Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel, Carboplatin and trastuzumab|Patients receive chemotherapy as in arm II. They also receive trastuzumab (Herceptin®) IV weekly, beginning with the first doses of paclitaxel and carboplatin.
88821816|NCT00046189||1|Patients with XP
88821817|NCT00046189||2|Family members from XP families with known DNA repair gene mutations
88821818|NCT05045937||COVID-19 patients treated with Ivermectin|This group of patients will be those who requested to be treated with Ivermectin and whom have been prescribed such by different physicians. This group may or may not include those treated with Monoclonal Antibodies or Remdesivir.
88821819|NCT05045937||COVID-19 patients declining Ivermectin and wanting traditional treatment|This group of patients will be those who do not request to be treated with Ivermerctin and who want to be treated with a more traditional, minimalist approach. This group may or may not include those treated with Monoclonal Antibodies or Remdesivir.
89355374|NCT04800029|Experimental|TIPS Alone|The TIPS synchronous telehealth protocol will consist of (a) two-way televideo evaluation with enhanced suicide risk components, performed by a Masters-level evaluator from Community HealthLink, and (b) telephone consultation and, in some cases, televideo evaluation by a psychiatrist for patients the evaluator judges should be admitted. The primary evaluation will gather data form the ED providers, patient, and any other collateral sources available. The core of the evaluation itself will consist of Community HealthLink's existing standard adult emergency mental health evaluation, which is a semi-structured evaluation focused primarily on informing a disposition decision on whether to admit the patient to a psychiatric unit. The evaluators will use this same evaluation to guide the telehealth evaluation.
89355375|NCT04800029|Experimental|TIPS and ED-SAFE|"Half of the ED discharged patients with suicide risk will also be invited to receive post-discharge telephone counseling originally developed by Principal Investigator in a previous study, Emergency Department Safety Assessment and Follow-up Evaluation (ED-SAFE). The participant will receive three calls, clustered within three months of the index visit, with some flexibility to continue beyond that if desired. These coaching calls will still follow the original structure and content from ED-SAFE, with modifications guided by study investigators."
89355376|NCT04800029|Active Comparator|No intervention, Treatment as Usual|No study related intervention, just monitoring of current practices used to provide suicide-related care in the non-intervention EDs.
89355377|NCT03345940|Active Comparator|Fingolimod 0.5 mg/day|"The study drugs, FTY and DMT, are approved and available on the market and safety and tolerability profile of both the drugs is well known. In our study, patients will be treated according to the clinical practice.~Dose: FTY 0.5 mg/day or DMF 240 mg twice daily"
89355378|NCT03345940|Active Comparator|Dimethyl Fumarate 240 mg twice daily|"The study drugs, FTY and DMT, are approved and available on the market and safety and tolerability profile of both the drugs is well known. In our study, patients will be treated according to the clinical practice.~Dose: FTY 0.5 mg/day or DMF 240 mg twice daily"
89176928|NCT01026649|Active Comparator|1 stage|Approach the internal jugular vein in a traditional one stage fashion during central venous catheterization
89355379|NCT05670353|Experimental|Cannabis Derivatives|"Cannabis Derivatives (98% CBD, 2% THC) will be given orally starting at 10 mg daily and up-titrated to a maximum dose of 150 mg daily. Dose up-titration will be based on clinical response or side effects, whichever comes first. After 63 days of treatment, gradual withdrawal will be performed during one week.~All patients will take hormonal contraceptives, preferably progestagen-only.~All participants will perform invasive and non-invasive procedures with the nursing team. The invasive will be blood collections, to evaluate laboratory parameters. The non-invasive ones refer to the measurement of height, weight, body temperature, and sleep pattern, as will pain threshold. In addition, they will be monitored through weekly self-assessment scales, applied remotely, electronically (cell phones or computers), with an estimated duration of ten minutes each, which will have their responses recorded in an electronic database, by the study coordination team."
89399037|NCT04050267|Experimental|Intervention Group - 15% nitrous oxide|Breathing 15% nitrous oxide in air with 21 % of oxygen. Performing cognitive tests as per protocol.
89399038|NCT04050267|Experimental|Intervention Group - 20% nitrous oxide|Breathing 20% nitrous oxide in air with 21 % of oxygen. Performing cognitive tests as per protocol.
89176929|NCT01026727|Experimental|MPC-4326 plus a 2-3 drug optimized background regimen (OBR)|MPC-4326 300 mg or 400mg BID plus a 2-3 drug optimized background regimen (OBR)for 24 weeks.
89176930|NCT01026727|Active Comparator|3-4 drug antiretroviral drugs|3-4 commercially available antiretroviral (ARV)drugs for 24 weeks.
89176931|NCT00802464|Experimental|GSK1437173A formulation 1 Group|Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/ASO1B and gE/ASO1E) formulation 1 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm on a 0, 2 month schedule.
89176932|NCT00802464|Experimental|GSK1437173A formulation 2 Group|Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/ASO1B and gE/ASO1E) GSK1437173A formulation 2 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm on a 0, 2 month schedule.
88821820|NCT00373581|Experimental|Vigabatrin, cocaine|
88821821|NCT00373581|Placebo Comparator|placebo, cocaine|
88821822|NCT01470170|Experimental|Group1|Alfentanil 2.5μg/kg before propofol
88821823|NCT01470170|Experimental|Group2|Alfentanil 5μg/kg before propofol
88821824|NCT01470170|Experimental|Group 3|Alfentanil 2.5μg/kg two minutes before propofol
88821825|NCT01470170|Experimental|Group 4|Alfentanil 5μg/kg two minutes before propofol
88821826|NCT01470170|Placebo Comparator|Group 5 Control|propofol alone
88821827|NCT04311567|Experimental|Tofacitinib|Oral tablet tofacitinib 5 mg BID for 48 weeks
88821828|NCT04311567|Active Comparator|Methotrexate|Oral tablet methotrexate 2.5 mg: 8 tablets in one dose (=20 mg) once weekly for 48 weeks
88821829|NCT04259775|Active Comparator|Automated Insulin Dose Adjustment (AIDA)|Using the AIDA system to assist the parents of children with T1D make insulin dose adjustments
88821830|NCT04259775|Active Comparator|Control|Standard Care - change in therapy settings effected a regularly scheduled patients visits
88821831|NCT01572428|Active Comparator|Narrow-Band Imaging (NBI)|Inspection with Narrow-Band Imaging(NBI) versus inspection with standard white light(usual care)
88821832|NCT01572428|Active Comparator|Standard White Light|Inspection with Standard White Light versus Narrow-Band Imaging(NBI)
88821833|NCT01573052|Active Comparator|Chlordiazepoxide|Chlordiazepoxide 25mg capsule or matching placebo capsule
88821834|NCT01573052|Experimental|Gabapentin|Gabapentin 300mg capsule or matching placebo capsule
88821835|NCT04993599|Experimental|Pediatric patients|<Intervention> The participants(Pediatric patients) mainly interact with the social robot which is controlled by the researcher behind the scene
88821836|NCT04993599|Experimental|Carers|<Intervention> The participants(Carers) interact with the social robot and watch how their child interact with the robot which is controlled by the researcher behind the scene
88821837|NCT01521260|Placebo Comparator|Placebo group|Implants with peri-implantitis lesions will be surgically exposed, followed by a mechanical cleansing using curettes and gauzes and cotton pellets soaked in saline, 1 minute of rinsing with a placebo solution (saline with appearance of chlorhexidine + CPC) and 1 minute of saline rinsing.
88821838|NCT01521260|Active Comparator|Chlorhexidine group|Implants with peri-implantitis lesions will be surgically exposed, followed by a mechanical cleansing using curettes and gauzes and cotton pellets soaked in saline, 1 minute of chemical cleansing using 0,12% chlorhexidine + cetylpyridinium chloride (CPC) without alcohol (Perio-aid®) and 1 minute of saline rinsing.
88821839|NCT01523834|Experimental|Panobinosat|"The treatment is divided in three phases: induction phase (course 1 to 6), consolidation phase (courses 7 to 12), maintenance phase (from course 13 until the end of therapy for any reason). The duration of a treatment course will be 28 days. The first dose of panobinostat in course 1 defines day 1 of the treatment cycle, and each cycle thereafter will begin 28 days later.~Treatment:~Panobinostat should be taken p.o. at the dose of 40 mg/day three-times every week (QW) (e.g., on Monday, Wednesday, and Friday or Tuesday, Thursday, and Saturday), as part of a 4 week (28 days) treatment cycle."
88821840|NCT01575080|Experimental|Intended Users of the Monitoring System|Untrained subjects with diabetes use Contour TS Blood Glucose Monitoring System.
88821841|NCT01472432|Placebo Comparator|Placebo|In the placebo group, the dose of other concomitant hypoglycemic medication was changed to obtain a similar profile of metabolic parameters. All patients had diabetes and at least one full-thickness wound below the ankle for >3 months. All patients were examined weekly for the first 4 weeks (day 28) then every other week until day 120 or ulcer closure by any means. At each visit, tracings of the wound margins were made for computer planimetry to document changes in wound size, and photographs were taken for a visual record. All patients followed the regular treatment at the multidisciplinary diabetes foot clinic, included treatment of infection, debridement, off-loading, and metabolic control according to high international standards and standard good medical practice.
88821842|NCT01472432|Experimental|Vildagliptin|The experimental arm followed the same treatment of placebo group, but received also vildagliptin 50 mg per os b.i.d. for 4 months
88821843|NCT02797821|Experimental|Asfotase Alfa 0.5 mg/kg Dose|Participants received 0.5 milligrams (mg) per kilogram (kg) of asfotase alfa administered subcutaneously (SC) 3 times a week from Weeks 3 through 9 following the initial single dose on Day 1 in Week 1.
88821844|NCT02797821|Experimental|Asfotase Alfa 2.0 mg/kg Dose|Participants received 2.0 mg/kg of asfotase alfa administered SC 3 times a week from Weeks 3 through 9 following the initial single dose on Day 1 in Week 1.
88821845|NCT02797821|Experimental|Asfotase Alfa 3.0 mg/kg Dose|Participants received 3.0 mg/kg of asfotase alfa administered SC 3 times a week from Weeks 3 through 9 following the initial single dose on Day 1 in Week 1.
88821846|NCT05566028|Experimental|Expermental group 1|Pateints assigned to this group are treated with D150, D759 and D745 formulation I
88999274|NCT02903641|No Intervention|Control|All households in the study were given general child nutrition educational messaging, immediately after the baseline survey and prior to any treatments. This messaging focused on appropriate feeding habits complemented by breastfeeding and ways to maintain proper hygiene during food preparation and consumption.
88999275|NCT02903641|Experimental|Personalized information only|Household received the personalized information about the index child's height.
89399039|NCT03086057|Experimental|Strength Based Case Management|Stage 1: Support, facilitate, and assist in linkage to PrEP clinic and to facilitate initiation of, and obtaining, PrEP medications.
89399040|NCT03086057|Experimental|PrEP adherence training and counseling|Stage 2: Up to three adherence training and counseling intervention sessions (once per week for two to three weeks) with a clinical interventionist.
89399041|NCT03086057|No Intervention|Standard of Care:Stage 1|Stage 1: Referral to The Miriam Hospital PrEP Clinic.
89399042|NCT03086057|No Intervention|Standard of Care: Stage 2|Stage 2: Doctor visit every three months to assess for side effects and receive a HIV test.
89399043|NCT03697317|Experimental|Televideo Lifestyle Coaching|
89399044|NCT03697317|Active Comparator|Enhanced Usual Care|
89399045|NCT02759120|Experimental|Antimicrobial therapy|Co-trimoxazole OR doxycycline
89399046|NCT02759120|Other|Standard of care|Standard of care for patients with IPF for comparison
89399047|NCT01569113|Experimental|ellaOne + microgynon 30|
89399048|NCT01569113|Placebo Comparator|placebo + microgynon 30|
89399049|NCT04435821|Experimental|Pediatric Chronic Pain Patients|Individuals 11-18 years old, with chronic pain (lasting at least 2 months).
89399050|NCT03699033|Experimental|Radiation|2.5 Gy/Fraction
89399051|NCT03697239|Experimental|AA NABPLAGEM|ascorbic acid paclitaxel protein-bound cisplatin gemcitabine
89399052|NCT03629015|Experimental|Stemchymal®|Biological: Stemchymal® ALF/ ACLF patients will receive low (0.5 x 10^6 cells/kg) or high (2 x 10^6 cells/kg) dose of Stemchymal® through intravenous infusion
89399053|NCT02164682||IV PCA group|
89399054|NCT02164682||IV PCA+ caudal block group|
89399055|NCT01378559||Penis prosthesis cohort|
89399056|NCT02164760|Experimental|Dermal substitute with STSG|Novomaix dermal substitute in combination with STSG
89399057|NCT02164760|No Intervention|STSG alone|STSG alone
89399058|NCT01380431|Experimental|A|Subjects received the Par formulated product.
89399059|NCT01380431|Active Comparator|B|Subjects received the IPR (Zeneca Pharmaceuticals) formulated product.
89399060|NCT01380431|Active Comparator|C|Subjects received the IPR (Zeneca Pharmaceuticals) formulated product.
89399061|NCT03697161|Experimental|OV101 (gaboxadol) Regimen 1|Once Daily
88821847|NCT05566028|Experimental|Experimental group 2|Pateints assigned to this group are treated with D150, D759 and D745 formulation II
88821848|NCT05566028|Placebo Comparator|Placebo group|Pateints assigned to this group are treated with D150, D759 and D745 placebo
88821849|NCT02798289|Experimental|Active - Device|The Oculeve Intranasal Neurostimulator will be administered once to induce aqueous tear production once following study enrollment.
88821850|NCT01524302|Active Comparator|Levofloxacin|Pharmacodynamics
88821851|NCT01524302|Active Comparator|Ceftaroline|Pharmacodynamics
88821852|NCT04202991||COPD with pain|People with COPD who also report pain more often than not over the previous 3 months
88821853|NCT04202991||COPD with no pain|People with COPD who do not report pain more often than not over the previous 3 months
88821854|NCT02247284|Experimental|group 1|patient with a diagnosis of primary open angle glaucoma will undergo 'RNFL and BMO-MRW SD-OCT' measurements with Heidelberg Spectralis SD-OCT old protocoll and Glaucoma Premium Module (new) protocoll, which in addition to RNFL measurements include measurement of Bruch's Membrane Opening-based minimum rim width (BMO-MRW).
88821855|NCT01525862|Experimental|Balloon sinus dilation|Balloon dilation of the maxillary sinus using a transnasal approach.
88821856|NCT02802111|Experimental|Albuterol 5 mg first, then levalbuterol 2.5 mg|Patient receives albuterol 5 mg aerosolized first and then 4 hours or greater after receives levalbuterol 2.5 mg aerosolized. Oxygen consumption and vital signs are measured for 1 hour after intervention.
88821857|NCT02802111|Experimental|Levalbuterol 2.5 mg first, then albuterol 5 mg|Patient receives levalbuterol 2.5 mg aerosolized first and then 4 hours or greater after receives albuterol 5 mg aerosolized. Oxygen consumption and vital signs are measured for 1 hour after intervention.
88821858|NCT01576874|Experimental|oxytocin|Participants will be administered 40 IUs of oxytocin nasal spray at one study visit.
88821859|NCT01576874|Placebo Comparator|placebo|Participants will be administered 40 IUs of placebo nasal spray at one study visit.
88821860|NCT01528124|Placebo Comparator|Placebo|0.9% sodium chloride given as a single subcutaneous injection
88821861|NCT01528124|Experimental|LY3025876|Single escalating doses of LY3025876 given as subcutaneous injections
88821862|NCT01576952|Experimental|ISV-303|0.075% bromfenac in DuraSite vehicle dosed BID
88821863|NCT01576952|Placebo Comparator|DuraSite Vehicle|DuraSite Vehicle dosed BID
89176933|NCT00802464|Experimental|GSK1437173A formulation 3 Group|Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/ASO1B and gE/ASO1E) formulation 3 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm on a 0, 2 month schedule.
89176934|NCT00802464|Placebo Comparator|Control Group|Male or female subjects, 50 years of age or above, who received 2 doses of saline solution (placebo), administered intramuscularly in the upper deltoid region of the non-dominant arm on a 0, 2 month schedule.
89176935|NCT04112082|Experimental|Home-Based Neurofeedback Training|
89176936|NCT04112082|Active Comparator|Treatment as Usual|
89176937|NCT02604966|Experimental|Artesunate (AS) group|P. falciparum infected patients randomly allocated to this arm will be treated with AS (50mg/tablet) 4 mg/kg body weight once daily for three days followed by DHA-PPQ (40mg of DHA +320mg of PPQ/tablet) once daily for three days.
89176938|NCT02604966|Active Comparator|DHA - PPQ group|P. falciparum infected patients randomly allocated to this arm will be treated with the combination DHA-PPQ (40mg of DHA +320mg of PPQ/tablet) once daily for three days.
89176939|NCT02605668|Experimental|Intensified Psychological Intervention|Intensified psychological intervention (Cognitive Behavioral Therapy), based on optimized extinction learning
89176940|NCT02605668|Active Comparator|Treatment As Usual|Standard intervention (Cognitive Behavioral Therapy) without optimized extinction learning
89176941|NCT00914160|Experimental|1|Diclofenac Sodium 50 mg Tablets Under Fasting Conditions (Geneva Pharmaceuticals, Inc)
89176942|NCT00914160|Experimental|2|Diclofenac Sodium 50 mg Tablets Under Fed Conditions (Geneva Pharmaceuticals, Inc)
89176943|NCT00914160|Active Comparator|3|Voltaren 50 mg Tablets Under Fed Conditions (Geigy Pharmaceuticals)
89176944|NCT02605590|Experimental|1.25 mg|Part 1: single inhaled dose of 1.25 mg AIR-DNase followed by Part 2: once daily inhaled dose of 1.25 mg AIR DNase for 5 consecutive days.
89176945|NCT02605590|Experimental|2.5 mg|Part 1: single inhaled dose of 2.5 mg AIR-DNase followed by Part 2: once daily inhaled dose of 2.5 mg AIR DNase for 5 consecutive days.
89176946|NCT02605590|Experimental|5 mg|Part 1: single inhaled dose of 5 mg AIR-DNase followed by Part 2: once daily inhaled dose of 5 mg AIR DNase for 5 consecutive days.
89399062|NCT03697161|Experimental|OV101 (gaboxadol) Regimen 2|Twice Daily
88821864|NCT01577108|Experimental|Probiotics, GBS Test|Treated with 2 oral probiotics once daily before sleeping for 14 days
88821865|NCT01577108|Placebo Comparator|Non-probiotics, GBS test|Treated with 2 placebo capsules once daily before sleeping for 14 days
88821866|NCT01577732|Experimental|Infanrix-IPV+Hib Group|Subjects aged between, and including 12 and 24 months received a single dose of Infanrix-IPV+Hib™. The vaccine was administered intramuscularly in the anterolateral side of the thigh.
88821867|NCT01577966|Experimental|Sulfasalazine|
88821868|NCT01578044|Experimental|Intervention|"Patient education: Patients will receive information on dabigatran, including risks, benefits and potential side effects. This information will be re-enforced during the study on a monthly basis during the IVR calls and during the pharmacy service calls to patients.~Tele-monitoring: We will use IVR technology to send patients an automated reminder to refill their dabigatran, rivaroxaban, and apixaban prescriptions. This call will be delivered on day 20 following each dabigatran, rivaroxaban, and apixaban prescription.~Pharmacists follow-up: If dabigatran, rivaroxaban, and apixaban has not been refilled, the pharmacy staff will contact the patient to assess reasons that the patient has not refilled the medication."
88821869|NCT01578044|Placebo Comparator|Control|Usual care
88821870|NCT02345226|Experimental|FTC/RPV/TAF|FTC/RPV/TAF plus EFV/FTC/TDF placebo for at least 96 weeks.
88821871|NCT02345226|Active Comparator|EFV/FTC/TDF|EFV/FTC/TDF plus FTC/RPV/TAF placebo for at least 96 weeks.
88875162|NCT02492802||posaconazole-group|patients receiving posaconazole for prophylaxis or treatment of invasive fungal infection
88875163|NCT02493036|Experimental|High Dose SYN-010|42-mg SYN-010
88999276|NCT02903641|Experimental|Labeled cash transfer only|Household received the labeled cash transfer.
88821872|NCT02345226|Experimental|Open Label Extension Phase|After the Week 96 visit, participants will be given the option to receive open label FTC/RPV/TAF for up to an additional 48 weeks. In countries where FTC/RPV/TAF is not yet commercially available, participants will be given the option to receive open-label FTC/RPV/TAF and attend visits every 12 weeks until FTC/RPV/TAF becomes commercially available, or until Gilead elects to discontinue the study, whichever occurs first.
88821873|NCT02802501|Experimental|DHA-PQP plus tafenoquine 300 mg single dose|Subjects will receive open label DHA-PQP, 3 or 4 tablets per day (according to the body weight) from Day 1 to Day 3. They will receive double-blind 300 mg single dose of tafenoquine (TQ) on Day 1 and matched-placebo for primaquine (PQ) from Day 1 to Day 14.
88821874|NCT02802501|Active Comparator|DHA-PQP plus primaquine 15 mg for 14 days|Subjects will receive open label DHA-PQP, 3 or 4 tablets per day (according to body weight) from Day 1 to Day 3. They will receive double-blind 15 mg primaquine (PQ) from Day 1 to Day 14 and matched-placebo for tafenoquine (TQ) on Day 1.
88821875|NCT02802501|Placebo Comparator|DHA-PQP alone (placebo arm)|Subjects will receive open label DHA-PQP, 3 or 4 tablets per day (according to body weight) from Day 1 to Day 3. They will receive double-blind matched-placebo for tafenoquine (TQ) on Day 1 and matched-placebo for primaquine (PQ) from Day 1 to Day 14.
88821876|NCT01528592|Experimental|On / Off medication|Subjects undergo MRI scanning in the medication off state and 1 hour after receiving medications.
88821877|NCT01578278|Experimental|Bepotastine besilate formulation|Nasal Spray
88821878|NCT01578278|Experimental|Fluticasone propionate|Nasal Spray
88821879|NCT01578278|Experimental|Bepotastine besilate-fluticasone propionate|Nasal Spray
88821880|NCT01578278|Placebo Comparator|Placebo Comparator|Nasal Spray
88821881|NCT01578902|Experimental|Hypofractionated radiotherapy using SABR|Stereotactic radiation: 35Gy in 5 fractions over 29 days
88821882|NCT02803749|Experimental|Buspirone|Flexible dosage buspirone (maximum dosage 30 mg twice daily) for 12 weeks.
88821883|NCT02803749|Placebo Comparator|Placebo|Flexible dosage placebo for 12 weeks.
88821884|NCT01578980|Experimental|Outpatient Control-to-Range|Outpatient Control-to-Range: Testing system connectivity
88821885|NCT01529060|Active Comparator|Phenylbutyrate|Study Drug
88821886|NCT01529060|Placebo Comparator|Inactive Powder|Placebo powder
88821887|NCT05565014|Experimental|Virus Activated Killer immune Cells（VAK）|The VAK should be given once a week, three times a circle. The VAK could given 1 or 2 circle for each subject. The dosage of Pleural Effusion（more than 10^5/kg cells in 30-50mL solvent） differs from Peritoneal Effusion（more than 10^4/kg cells in 30-50mL solvent）
88821888|NCT05565014|Placebo Comparator|saline|50ml of saline was injected once a week,three times a circle.The saline could given 1 or 2 circle for each subject.
88821889|NCT00372879|Experimental|Crossover group 1|Vitamin E first and placebo second
89355380|NCT05670353|Placebo Comparator|Placebo|"Placebo will be given at the same protocol described before. The bottle, label, color and density of the contents will be the same.~All patients will take hormonal contraceptives, preferably progestagen-only. Then, at 70 days, there will be an open-label extension wherein all participants from control group will be offered a course of active treatment according to the same previous protocol.~All participants will perform invasive and non-invasive procedures with the nursing team. The invasive will be blood collections, to evaluate laboratory parameters. The non-invasive ones refer to the measurement of height, weight, body temperature, and sleep pattern, as will pain threshold. In addition, they will be monitored through weekly self-assessment scales, applied remotely, electronically (cell phones or computers), with an estimated duration of ten minutes each, which will have their responses recorded in an electronic database, by the study coordination team."
89355381|NCT02512120|Experimental|volume controlled ventilation|Randomized 23 patients will be applied VCV during RALP.
89355382|NCT02512120|Active Comparator|autoflow-volume controlled ventilation|Randomized 23 patients will be applied autoflow-VCV during RALP.
89355383|NCT01202201||Study Cohort|Subjects hospitalized with acute gastroenteritis or rotavirus gastroenteritis
89355384|NCT03345862|Experimental|Intervention|Non-pharmacological multicomponent intervention
89355385|NCT03345862|No Intervention|Control|Not intervention, usual attention
89355386|NCT01199159|Active Comparator|preoperative misoprostol|400mcg misoprostol given preoperatively
89355387|NCT01199159|Placebo Comparator|Placebo|
88821890|NCT00372879|Experimental|Crossover group 2|Placebo first then vitamin E
88821891|NCT01579214|Active Comparator|Direct Text Message|Participants in the intervention period (September 2012 - November 2013) received daily short message service (SMS) messages for up to seven days with messages reporting an abnormal result
88821892|NCT01579214|No Intervention|Pre-Intervention|Participants enrolled in the pre-intervention period (January - August 2012) served as a control group.
88821893|NCT02806869|Experimental|Arm #1 - Fasting State, 2 study visits|"Single dose of ibuprofen (800 mg tablet) administered with 250 mL of water containing phenol red~Washout period of at least 7 days~Single dose of ibuprofen (800 mg tablet) administered with 250 mL of water containing phenol red"
88821894|NCT02806869|Experimental|Arm #2 - Fed State, 2 study visits|"Pulmocare, two 8.0 oz (236.6 mL) cans, followed by single dose of ibuprofen (800 mg tablet) administered with 250 mL of water containing phenol red~Washout period of at least 7 days~Pulmocare, two 8.0 oz (236.6 mL) cans, followed by single dose of ibuprofen (800 mg tablet) administered with 250 mL of water containing phenol red"
88821895|NCT02809911|Other|Sham of Provant|Sham of Provant Therapy System
88821896|NCT02809911|Other|Active Provant|Active Provant Treatment
88821897|NCT03910101|Active Comparator|Hand surgery and intensive rehabilitation|"The surgical treatment for reducing spasticity comprises lengthening of tendons, muscle release and occasionally correction of deformities. Lengthening of a tendon or releasing a muscle from its insertion, results in relaxation of the whole muscle-tendon unit. Hence, the spasticity is not gone, but reduced in strength.~The tendon lengthening procedures is performed by a stair-step incision technique followed by reattachment in the lengthened position using a side-to-side, cross-stich technique. The load to failure of the sutured tendon is approximately 200Newton, which gives a sufficient safety margin for early active mobilization of the tendons involved. This suture technique thus enables active training directly after surgery.~Postoperative rehabilitation includes wrapping and a custom-made splint, for day and night use, muscle activation and passive stretching 2-4 times per day without the splint."
89355388|NCT05669963|Active Comparator|study group|"study group receiving lactoferrin (2 capsules/day for 5 days followed by further 10 consecutive days at the dosage of 1 capsule/day) by oral intake.(pravotinR).~During follow-up period, all women ingested 1 capsule of lactoferrin or placebo per day, for 10 consecutive days per month."
89355389|NCT05669963|Placebo Comparator|control group|not recieving lactoferrin
88821898|NCT03910101|Active Comparator|Botulinum toxin injections|Botulinum toxin injections are given in spastic muscles of the upper extremity. Dosage and number of injections per muscle vary depending on the degree and extent of spasticity. For optimal effect on hand function, botulinum toxin is accompanied by the treatment of individualized exercise and splinting when needed.
88821899|NCT01529450|Active Comparator|Refractory Group|Patients previously treated with non-LDE225 Smo inhibitor who were refractory.
88821900|NCT01529450|Active Comparator|Resistance Developed Group|Patients previously treated with non-LDE225 Smo inhibitor who were initially responsive but became resistant with progressive disease.
88821901|NCT03795675|Experimental|Meniere's Disease/Vestibular Schwannoma|Individuals diagnosed with Meniere's disease and undergoing labyrinthectomy or diagnosed with vestibular schwannoma and undergoing surgical excision via translabyrinthine approach for treatment will receive cochlear implant at the time of surgery.
88821902|NCT01580072|No Intervention|Control group|Participants in the control group receive usual care.
88821903|NCT01580072|Experimental|Self monitoring for patients with COPD|
88821904|NCT01580072|Experimental|Nurse monitoring for patients with COPD|
88821905|NCT01580306|Experimental|BI 201335 relevant treatment dose (A)|Capsule for oral administration
88821906|NCT01580306|Experimental|BI 201335 relevant treatment dose (B)|Capsule for oral administration
88821907|NCT02813265|Active Comparator|KPI-121 0.25% Ophthalmic Suspension|
88821908|NCT02813265|Placebo Comparator|Vehicle of KPI-121 0.25% Ophthalmic Suspension|
88821909|NCT02247206|Experimental|Behavior Therapy for Tics (CBIT)|The child 1) learns to become more aware of any sensations, or urges that may trigger tics, and 2) learn some other behavior (competing response) to do every time he/she feels the urge to tic. The child's parent is trained to provide prompts and praise for use of the competing response. The parent and family also receive psychoeducation about tics, and learn ways to reduce the impact of environmental stimuli on tic severity. The child learns relaxation techniques to reduce stress and make it easier for him/her to resist his or her tics. Prior to treatment sessions, the parent and child spend about 10 minutes discussing with the therapist any problematic issues he/she is having. At the end of treatment sessions the child is assigned some tasks to practice prior to the next session.
88821910|NCT02247206|No Intervention|Waitlist-control Group|Participants in the waitlist-control group, do not receive behavior therapy for tics or any other treatment during the 10-week acute treatment period. Instead they child are placed on a waitlist to receive videoconference-delivered treatment following the end of the study period.
88821911|NCT05564858|Experimental|FDA022-BB05|"phase Ia: Participants with locally advanced or metastatic tumor will be administered FDA022-BB05 intravenously once at escalated doses in each cycle (of 21 days) during Phase Ia part of the study until disease progression or intolerable toxicity.~phase Ib: Cohort expansion, Recommended doses from phase Ia."
88821912|NCT05564780|Experimental|Treatment|"Antihypertensive drugs will be provided to the participants in the arm, including RASI and/or a single pill combination based on RASI.~If the blood pressure of a participant elevates to above 140/90 mmHg, antihypertensive therapy will be provided."
88821913|NCT05564780|No Intervention|Control|If the blood pressure of a participant elevates to above 140/90 mmHg, antihypertensive therapy will be provided.
88821914|NCT05564234|Active Comparator|Neoadjuvant chemotherapy|cases with predictive index value score 8 or greater in which primary cytoreductive surgery was not feasible were were referred for neoadjuvant chemotherapy then interval cytoreductive surgery was done
88821915|NCT05564234|Active Comparator|primary cytoreductive surgery|cases with predictive index value score less than 8 were offered primary cytoreductive surgery.
88821916|NCT05564000|Experimental|Experimental group|"Experimental group: accept three weeks Dating Violence Prevention Program online; every week 20-30 minutes.~The measurements of dating violence myths, bystander attitude, subjective norm, self-efficacy, intention, and behavior were implemented with a pre-, post-test, and 2-month follow-up design to analyze the immediate and continued educational effects."
89355390|NCT02507440|Active Comparator|Viscous Lidocaine|Five minutes prior to intravenous sedation the patients will be asked to gargle with 7.5 ml of 2% lidocaine viscous solution and swallow.
89355391|NCT02507440|Placebo Comparator|Placebo|Five minutes prior to intravenous sedation the patients will be asked to gargle with 7.5 ml of placebo and then swallow. Placebo will be 3% methylcellulose which will be flavored and colored to match the characteristics of 2 % lidocaine.
88821917|NCT05564000|No Intervention|Control group|Control group: no intervention. The measurements of dating violence myths, bystander attitude, subjective norm, self-efficacy, intention, and behavior were implemented with a pre-, post-test, and 2-month follow-up.
88821918|NCT02814279|Active Comparator|CAF plus connective tissue graft|CAF treatment was performed by starting with two divergent releasing incisions lateral to the recessed area. A sulcular incision was made to unite the releasing incisions and the flap was raised beyond the mucogingival junction (MGJ) in split-full-split thickness. The connective tissue graft was removed from the palate according to Bruno technique (1994) and sutured in position. Sling sutures were placed to stabilize the flap in a coronal position 2 mm above the CEJ, followed by interrupted sutures to close the releasing incisions.
88821919|NCT02814279|Experimental|Tunnel plus connective tissue graft|The tunnel flap was performed according to Zuhr et al., 2007. Following initial sulcular incisions, spit thickness flap was prepared using specific tunneling knives beyond the mucogingival junction and until flap gain mobility. The flap was laterally extended to adjacent papillae that were carefully detached by means of a full-thickness preparation. The connective tissue graft was insert into the tunnel. Sling sutures were performed involving the flap and graft to coronally cover 2 mm above the CEJ.
88821920|NCT03658083||Thoracotomy|Individuals referred for a lung resection via thoracotomy with a primary or secondary diagnosis of lung cancer. Those with a tumor >7cm will be excluded.
89355392|NCT04962659|Experimental|Mindfulness-Based Music and Songwriting|The Mindfulness-Based Music and Songwriting (MBMS) program involves up to 8 weekly sessions (~1 hour) delivered via telehealth.
88821921|NCT03658083||Robotic-assisted thoracic surgery|Individuals referred for a lung resection via robotic-assisted thoracic surgery with a primary or secondary diagnosis of lung cancer. Those with a tumor >7cm will be excluded.
89355393|NCT04962659|No Intervention|Business as Usual Control|No treatment control.
89355394|NCT02507362|Experimental|experimental|Radiation: adjusted corneal collagen cross-linking (9mW/cm2 UV-A irradiation for 7 minutes after 30 mitunes of riboflavin instillation) riboflavin 0.1%: after mechanical epithelial removal riboflavin drop will be instilled every 5 minutes for 30 minutes and then instillation will be continued during irradiation epithelial debridement: corneal epithelium will be removed by a cottons swab
89355395|NCT02507362|Active Comparator|control|radiation: accelerated corneal collagen cross-linking (9mW/cm2 UV-A irradiation for 10 minutes after 30 minutes of riboflavin instillation) riboflavin 0.1%: after mechanical epithelial removal riboflavin drop will be instilled every 5 minutes for 30 minutes and then instillation will be continued during irradiation epithelial debridement: corneal epithelium will be removed by a cottons swab
89355396|NCT04958369|Active Comparator|Ultrasound-guided axillary venous access|Cardiac device implantation will be performed with ultrasound-guided axillary venous access.
89355397|NCT04958369|Active Comparator|Cephalic venous access|Cardiac device implantation will be performed with conventional cephalic venous access (cut-down technique).
89355398|NCT03196284|Experimental|Concizumab|Concizumab administered in both the main phase and extension phase, with eptacog alfa administered on-demand during bleeding episodes
89355399|NCT03196284|Active Comparator|Eptacog alfa and concizumab|Eptacog alfa administered on-demand during bleeding episodes as the only intervention during the main phase. Concizumab given in the extension phase
89355400|NCT05640830|Experimental|TREAZURE|This is a single arm study. Trastuzumab has been administered at 6 mg/kg every 3 weeks after initial loading of 8 mg/kg during the first anticancer treatment, so in the second anticancer treatment, 4 mg/kg is administered every 2 weeks to maintain the same concentration. Bevacizumab is administered at 5 mg/kg at 2-weekly intervals used in metastatic colorectal cancer. Paclitaxel is administered on a standard schedule of 80 mg/m2 for 3 consecutive weeks followed by a 1-week break as an existing weekly regimen, and when side effects occur, the weekly dose is reduced by 25% to 60 mg/m2 for 3 weeks or administered every 2 weeks. Administer 80 mg/m2. Administration of this drug is set as one cycle of 4 weeks.
88821922|NCT01533038|Active Comparator|UroLift System|UroLift System procedure
88821923|NCT01533038|Active Comparator|Transurethral Resection of the Prostate|Transurethral Resection of the Prostate surgery
88821924|NCT05563064|Experimental|Karika Syrup|Karika syrup has been used to treat thrombocytopenia
88821925|NCT02885025|Active Comparator|BSE + Nasal Fluticasone|"subjects will be randomized into 1 of 4 arms:~Broccoli Sprout Extract + Nasal Fluticasone~Broccoli Sprout Extract + normal saline nasal spray~Placebo Pill + Nasal Fluticasone~Placebo Pill + normal saline nasal spray"
88821926|NCT02885025|Active Comparator|Broccoli Sprout Extract + normal saline nasal spray|"subjects will be randomized into 1 of 4 arms:~Broccoli Sprout Extract + Nasal Fluticasone~Broccoli Sprout Extract + normal saline nasal spray~Placebo Pill + Nasal Fluticasone~Placebo Pill + normal saline nasal spray"
88821927|NCT02885025|Active Comparator|Placebo Pill + Nasal Fluticasone|"subjects will be randomized into 1 of 4 arms:~1. Broccoli Sprout Extract + Nasal Fluticasone 2 Broccoli Sprout Extract + normal saline nasal spray 3. Placebo Pill + Nasal Fluticasone 4. Placebo Pill + normal saline nasal spray"
88821928|NCT02885025|Placebo Comparator|Placebo Pill + normal saline nasal spray|"subjects will be randomized into 1 of 4 arms:~Broccoli Sprout Extract + Nasal Fluticasone~Broccoli Sprout Extract + normal saline nasal spray~Placebo Pill + Nasal Fluticasone~Placebo Pill + normal saline nasal spray"
88821929|NCT01580618|Placebo Comparator|Normal Saline|Loculated pleural effusion infused with normal saline twice a day for three days.
88821930|NCT01580618|Active Comparator|TNKase|Loculated pleural effusion infused with TNK twice a day for three days.
88821931|NCT03612687||Laparoscopic Liver Surgery|Laparoscopic Liver Surgical Procedures with minimally invasive hemodynamic monitoring
88821932|NCT03612687||Laparoscopic Pancreas Surgery|Laparoscopic Pancreas Surgical Procedures with minimally invasive hemodynamic monitoring
88821933|NCT03612687||Open Liver Surgery|Open Liver Surgical Procedures with minimally invasive hemodynamic monitoring
88821934|NCT03612687||Open Pancreas Surgery|Open Pancreas Surgical Procedures with minimally invasive hemodynamic monitoring
88821935|NCT01581008|Experimental|Collaborative Care to Alleviate Symptoms and Adjust to Illness|A palliative symptom management and psychosocial care intervention named Collaborative Care to Alleviate Symptoms and Adjust to Illness (CASA) that includes (a) evidence-based palliative symptom management of breathlessness, fatigue, and pain, provided by a nurse; (b) a 6-session structured psychosocial care protocol targeting depression and adjustment to illness, supplemented by informal (family) caregiver assessment and support, provided by a social worker or psychologist; and (c) brief weekly team meetings with the nurse, social worker/psychologist and a palliative care specialist, cardiologist, and primary care provider.
88821936|NCT01581008|Active Comparator|Psychospiritual|A psychospiritual intervention that is home-based, self-guided, and requires minimal resources. It will be delivered in written modular form via US Mail along with brief weekly telephone support.
88821937|NCT01581710|Active Comparator|montelukast to placebo|14 days
88821938|NCT01581710|No Intervention|Washout|14 days
88821939|NCT01581710|Active Comparator|Placebo to montelukast|14 days
88821940|NCT01582490|Active Comparator|Infiltration - EXPAREL|Group 2 will receive diluted EXPAREL (i.e., the contents of one 20 mL vial, 266 mg, diluted with 20 mL of preservative-free 0.9% normal saline to a total of 40 mL) for postsurgical analgesia. Half of the resulting mixture (i.e., 20 mL) will be administered via local infiltration into each surgical site per the surgeon's normal practice at the beginning of surgery.
88821941|NCT01582490|Experimental|Instillation - EXPAREL|Group 1 will receive diluted EXPAREL (i.e., the contents of one 20 mL vial, 266 mg, diluted with 20 mL of preservative-free 0.9% normal saline to a total of 40 mL) for postsurgical analgesia. Half of the resulting mixture (i.e., 20 mL) will be instilled into each breast pocket at the beginning of surgery.
88821942|NCT01582880|Experimental|Riboflavin Cross-linked donor cornea|the donor cornea used as a carrier for the Boston Keratoprosthesis will undergo crosslinking treatment before being trephined and prepared for implantation with the Keratoprosthesis.
88999277|NCT02903641|Experimental|Personalized information and labeled cash transfer|The household received both the personalized information intervention and labeled cash transfer intervention.
89176947|NCT02605590|Placebo Comparator|Placebo|Placebo comparator for each of the dose levels, administered accordingly as single inhaled dose in Part 1 followed by once daily inhaled dose for 5 consecutive days in Part 2.
89176948|NCT04009200||circumcision|"Modified Yale Preoperative Anxiety Scores (m-YPAS), Visual Analogue Scale Anxiety (VAS-anxiety) will be evaluated when patients are taken to the preoperative waiting room.~After awakening, patients will be taken to the postoperative wake-up room where Pediatric Anesthesia Recovery Delirium Scores (PAED), Recovery Agitation 5-point Scores (EA), FLACC scores will be evaluated every 5 minutes and mean arterial pressure, pulse, SPO2 values will be recorded. Duration of stay in recovery unit will be recorded"
89176949|NCT04009200||inguinal hernia|"Modified Yale Preoperative Anxiety Scores (m-YPAS), Visual Analogue Scale Anxiety (VAS-anxiety) will be evaluated when patients are taken to the preoperative waiting room.~After awakening, patients will be taken to the postoperative wake-up room where Pediatric Anesthesia Recovery Delirium Scores (PAED), Recovery Agitation 5-point Scores (EA), FLACC scores will be evaluated every 5 minutes and mean arterial pressure, pulse, SPO2 values will be recorded. Duration of stay in recovery unit will be recorded"
89176950|NCT00450619|Experimental|Arm A -EDTMP Alone|Patients receive samarium Sm 153 lexidronam pentasodium 1 mCi/Kg intravenous (IV) over 1 minute on day 8. Treatment repeats every 12 weeks in the absence of disease progression or unacceptable toxicity.
89176951|NCT00450619|Experimental|Arm B - 153SmEDTMP with vaccine|Patients receive recombinant vaccinia-TRICOM vaccine 2 x 10^8 PFU subcutaneously (SC) on day 1. Patients also receive recombinant fowlpox-TRICOM vaccine 1 x 10^9 PFU SC on days 15 and 29 and sargramostim (GM-CSF)100 mcg/injection SC x 4 days. Treatment with recombinant fowlpox-TRICOM vaccine and GM-CSF* repeats every 4 weeks in the absence of disease progression or unacceptable toxicity. Patients also receive samarium Sm 153 lexidronam pentasodium 1 mCi/Kg as in arm I.
89176952|NCT03704857|Active Comparator|Foraminal enlargement with sodium hypochlorite as irrigant|Unirradicular teeth will be submitted to endodontic treatment with foraminal enlargement, instrumentation with reciprocating rotation, sodium hypochlorite as irrigant, lateral condensation filling with MTA Fillapex. The analysis of the postoperative symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th, 14th and 30th days and by the clinical evaluation of edema in 48 and 72 hours. The periapical lesion repair will be evaluated clinically and radiographically at 3, 6, 12, 18 and 24 months. The longevity of rehabilitations will be performed clinically and radiographically for 24 months. In addition, patients will respond a quality of life questionnaire (OHIP-14) on the day of endodontic treatment, on the 7th day and on the 30th day.
89188792|NCT00841360||Friendship Network Members|Friendship network members will also consist of sexually experienced females, aged 13 years and older. Although most members are expected to be of African American race and/or Hispanic/Latina ethnicity, all races and ethnicities will be included.
88821943|NCT02889393|Experimental|Standard of Care followed by Teduglutide|"Participants in this group will receive standard of care treatment for the first 8 weeks followed by daily Teduglutide for the next 8 weeks.~Subjects with a favorable response will be offered an open label extension during which they will continue to receive teduglutide for up to another 12 months or permanent fistula closure."
88821944|NCT02889393|Experimental|Teduglutide followed by Standard of Care|"Participants in this group will receive daily Teduglutide treatment for the first 8 weeks followed by standard of care for the next 8 weeks.~Subjects with a favorable response will be offered an open label extension during which they will continue to receive teduglutide for up to another 12 months or permanent fistula closure"
88821945|NCT02818569|Experimental|Oral Dexmedetomidine, Then Placebo|This arm will enroll healthy control subjects, who will have an acclimation night followed by a night's sleep with oral dexmedetomidine and then a night's sleep with a placebo comparator.
88821946|NCT02818569|Experimental|Placebo, Then Oral Dexmedetomidine|This arm will enroll healthy control subjects, who will have an acclimation night followed by a night's sleep with a placebo comparator and then a night's sleep with oral dexmedetomidine .
88821947|NCT02819973|Experimental|Educational Video 1|African American/ Black Video
88821948|NCT02819973|Experimental|Educational Video 2|Caucasian Video
88821949|NCT02819973|Experimental|Usual Care (no video) 3|Standard Care/ No video
88821950|NCT03581409|Experimental|dual-antiplatelet|Patients with unruptured aneurysms received dual antiplatelet agents (100 mg of aspirin and 75 mg of clopidogrel) for at least five days before embolization. One day prior to coil embolization, P2Y12 reaction units were measured using VerifyNow. Patients with clopidogrel resistance (greater than 220 PRU) received prasugrel 20mg. After that, dual-antiplatelet (aspirin 100mg & prasugrel 5mg) treatment continued for 3 months through study completion.
88821951|NCT03581409|Experimental|triple-antiplatelet|Patients with unruptured aneurysms received dual antiplatelet agents (100 mg of aspirin and 75 mg of clopidogrel) for at least five days before embolization. One day prior to coil embolization, P2Y12 reaction units (PRU) were measured using VerifyNow. Patients with clopidogrel resistance (greater than 220 PRU) received cilostazol 200mg. After that, triple-antiplatelet (aspirin 100mg, clopidogrel 75mg, and cilostazol 200mg) treatment continued for 3 months through study completion.
88999278|NCT02903719|Other|Group A|"st intervention: A single ultrasound guided perineural injection of Ropivacaine 7,5 mg/ml, 3 ml~nd intervention (approx. 15 minutes after 1st intervention): A single ultrasound guided perineural injection of isotonic saline solution 9 mg/ml, 3 ml"
88999279|NCT02903719|Other|Group B|"st Intervention: A single ultrasound guided perineural injection of isotonic saline solution 9 mg/ml, 3 ml~nd Intervention (approx. 15 minutes after 1st intervention):A single ultrasound guided perineural injection of Ropivacaine 7,5 mg/ml, 3 ml"
89533488|NCT04484272|Active Comparator|Control Group|(Self-monitoring of pain, stress, and opioid use + alerts/reminders). During efficacy trial (Weeks 1-8), patients will monitor their stress, pain, and opioid use daily. We will send system-generated alerts/reminders every 24 hours to patients via phone call, text, or email to facilitate data entry. During the long-term period (months 3-6), patients will continue to monitor their stress, pain, and opioid use daily and receive only system generated alerts/reminders via messaging service or staff cell phone.
88821952|NCT01533116|Experimental|5 mg BIA 9-1067|5 mg BIA 9-1067 once-daily for 28 days single-dose of levodopa/carbidopa 100/25 mg on Day 21 single-dose of levodopa/benserazide 100/25 mg on Day 28
88821953|NCT01533116|Experimental|Placebo|Placebo once-daily for 28 days single-dose of levodopa/carbidopa 100/25 mg on Day 21 single-dose of levodopa/benserazide 100/25 mg on Day 28.
88821954|NCT01533116|Experimental|15 mg BIA 9-1067|15 mg BIA 9-1067 once-daily for 28 days single-dose of levodopa/carbidopa 100/25 mg on Day 21 single-dose of levodopa/benserazide 100/25 mg on Day 28
88821955|NCT01533116|Experimental|30 mg BIA 9-1067|30 mg BIA 9-1067 once-daily for 28 days single-dose of levodopa/carbidopa 100/25 mg on Day 21 single-dose of levodopa/benserazide 100/25 mg on Day 28
88821956|NCT02821455||Lung Surgery with One-Lung Ventilation|A single cohort of patients undergoing one-lung ventilation during lung surgery
88821957|NCT03510741|Active Comparator|Sodium Benzoate|Sodium Benzoate added to TAU will be administered at 1000mg daily
88821958|NCT03510741|Active Comparator|N-Acetylcysteine|N-Acetylcysteine added to TAU 1000 mgs twice daily dose
88821959|NCT03510741|Active Comparator|Placebo|Placebo added to TAU
89188793|NCT02573558||DEX|patients who received dexmedetomidine during the operation
89188794|NCT02573558||PPF|patients who received propofol during the operation
89355401|NCT02512198|Experimental|Bronchodilators|"Prescription Data Feedback to GP Practices - practices will be fed back data for people with presumed asthma who have either been dispensed more than 12 short-acting beta-agonist bronchodilators in the last 12 months who are not concurrently prescribed inhaled corticosteroids (poor asthma control with inadequate prevention) or been dispensed a long-acting beta-agonist bronchodilator as a single agent in the last 12 months who are not or are only infrequently concurrently prescribed inhaled corticosteroids (potentially harmful prescribing). To minimise inclusion of people with COPD, patient aged 35 years and older prescribed long-acting antimuscarinic bronchodilators will be excluded.~Practices in the bronchodilator arm are controls for the antibiotic experimental arm (below)."
89355402|NCT02512198|Experimental|Antibiotics|"Prescription Data Feedback to GP Practices - number of women in the GP practice aged 12 years and older dispensed more than 6 courses of urinary tract infection (UTI) antibiotics in the last year. UTI antibiotics are defined as trimethoprim, nitrofurantoin, co-trimoxazole, quinolones and cefalexin.~Practices in the antibiotic arm are controls for the bronchodilator experimental arm (above)."
89355403|NCT04938947|Experimental|High-Intensity Resistance Training Group|Participants in this group will complete 3 resistance training sessions per week for 6 weeks (18 sessions total). During each resistance training session, participants will perform 3 sets of bilateral leg-extensions (performed with both legs) to volitional failure (likely 8-12 repetitions) using 80% of their 1-repetition maximum (the most weight they are able to perform 1 complete repetition with, but not 2).
89355404|NCT04938947|Experimental|Low-Intensity Resistance Training with Blood Flow Restriction Group|Participants in this group will complete 3 resistance training sessions per week for 6 weeks (18 sessions total). During each training session, participants will perform 3 sets of bilateral leg-extensions (performed with both legs) to volitional failure using 30% of their 1-repetition maximum (the most weight they are able to perform 1 complete repetition with, but not 2). Participants in this group will perform all leg extensions with blood flow restriction cuffs applied to the proximal thigh of both legs. The pressure that the cuffs are inflated to will be calculated based on estimates of each subject's arterial occlusion pressure from their thigh circumference. Once the target pressure is reached, the cuffs will not be deflated until after the final set of the training session.
89355405|NCT03636594|Experimental|Dance|This was a single arm study with all participants receiving the same intervention.
89355406|NCT04500262|Active Comparator|Open-tip pulsed needle biopsy|"Biopsy procedure using the NeoNavia biopsy system. The needle used in this study is of the same outside diameter as a standard biopsy needle used in the breast or axilla (14-gauge) but does not have a notched trochar like a conventional spring-loaded device. It does not have a redundant portion of needle beyond the sampling zone and takes full circumference cylindrical cores.~A pneumatic system powered by a floor-standing base unit connected via a handheld driver to the biopsy device provides impulses to the needle, allowing the operator to advance the needle through tissue with little manual force (NeoNavia biopsy system, NeoDynamics, Sweden)."
89355407|NCT04500262|Active Comparator|Conventional core needle biopsy (CNB)|Standard of care core needle biopsy used currently in clinics for biopsy procedures
89355408|NCT03730961|Experimental|Placebo+Diuretic to BMS-986231+Diuretic|Administered in a cross over design with 8-hour continuous infusions and 7-28 day wash-out periods
89355409|NCT03730961|Experimental|BMS-986231+Diuretic to Placebo+Diuretic|Administered in a cross over design with 8-hour continuous infusions and 7-28 day wash-out periods
89355410|NCT01078454|Experimental|ARM A (Mel-Dex)|Patients receive melphalan 0.22 mg/kg orally (PO) and dexamethasone 40 mg PO on days 1-4 every 4 weeks. Treatment repeats every 4 weeks for up to 9 courses in the absence of disease progression or unacceptable toxicity.
89355411|NCT01078454|Experimental|ARM B (B-Mel-Dex)|Patients receive melphalan 0.22 mg/kg PO and dexamethasone 40 mg PO on days 1-4 and bortezomib 1.3 mg/m^2 intravenously (IV) on days 1, 4, 8, and 11 every 4 weeks. Treatment repeats every 4 weeks for 2 cycles. Patients then receive melphalan PO and dexamethasone PO on days 1-4 and bortezomib IV on days 1, 8, 15, and 22 every 5 weeks. Treatment repeats every 5 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
88821960|NCT03510741|Active Comparator|Sodium Benzoate Plus N-Acetylcysteine|Sodium Benzoate will be administered at 1000mg daily and NAC 1000 mgs twice daily dose
88821961|NCT01533974|Experimental|ACT|We will use a five-session (90 minutes per session) group-delivered adaptation of Dr. Bricker's ACT treatment program.
88821962|NCT01533974|Active Comparator|CBT|
88821963|NCT03500835|Experimental|App Plus Coaching (AC)|6 month addiction model based weight loss intervention in the form of an iPhone app coupled with personalized coaching.
88821964|NCT03500835|Experimental|App Alone (AA)|6 month addiction model based weight loss intervention in the form of an iPhone app.
88821965|NCT03500835|Experimental|Clinic|In-Clinic Multi-disciplinary monthly weight management program. Curriculum adapted from the KidsNFitness Program and administered by an MD, RD, Psychologist and Health Educator over 90 minute sessions
89355412|NCT02968602|Experimental|Minocycline|Participants will take 50 mg minocycline capsules twice daily for 1 week, then take 100 mg capsules twice daily for 1 week.
88821966|NCT05556980|Experimental|totally laparoscopic distal gastrectomy|patients in this arm will receive totally laparoscopic distal gastrectomy
88821967|NCT05556980|No Intervention|laparoscopy-assisted distal gastrectomy|patients in this group will receive laparoscopy-assisted distal gastrectomy
88821968|NCT04333719||terminally ill patients in specialized palliative|terminally ill patients in specialized palliative care facilities
88821969|NCT01583894||Chronic pain patients|
88821970|NCT02899689|Active Comparator|Foley Bulb Group|Patients will have a Foley catheter inserted into the internal cervical os.
88821971|NCT02899689|Experimental|Dilapan Group|Patients will have Dilapan sticks inserted into the internal cervical os.
89355413|NCT02968602|Placebo Comparator|Placebo|Participants will take capsules that match active drug, but contain no active ingredients, twice daily for week 1, and then will take capsules that match active drug, but contain no active ingredients, twice daily for week 2.
88821972|NCT03237897||Class attendees|A cohort of patients who are scheduled to undergo colorectal surgical procedures and attend the preoperative education class. Patients will be affixed with a pedometer in the postoperative period until discharge.
88821973|NCT03237897||Class non-attendees|A cohort of patients who are scheduled to undergo colorectal surgical procedures and do not attend the scheduled preoperative education class. Patients will be affixed with a pedometer in the postoperative period until discharge.
88821974|NCT01534052|Experimental|Enzalutamide|Participants received 160 mg enzalutamide orally once a day. Participants continued on treatment unless the dose was reduced or treatment was interrupted during the study.
88821975|NCT01584518|Active Comparator|CHF peptide|Diuresis based on CHF-P
88821976|NCT01584518|Active Comparator|Non CHF peptide|Diuresis based on clinical judgement without data for CHF-P
88821977|NCT03138369|Experimental|Vestibular nerve stimulation|Usage of wearable vestibular nerve stimulator that non-invasively stimulates the vestibular nerves by administering a small electrical current through the skin behind the ears. Should be worn up to one hour a day and at least 5 hours a week.
88821978|NCT03138369|Sham Comparator|Sham vestibular nerve stimulation|Usage of wearable control device that appears identical to active device. Instead of stimulating the vestibular nerves this device will discharge its battery into an internal resistor. Should be worn up to one hour a day and at least 5 hours a week.
88821979|NCT01534910|Placebo Comparator|Sugar pill|placebo
88821980|NCT01534910|Active Comparator|Aged Garlic Extract|2400 mg of aged garlic extract
88821981|NCT03101007|Experimental|ATTUNE|Total Knee Replacement Surgery with cementless ATTUNE Rotating Platform Knee Prosthesis by DePuy
88821982|NCT03101007|Active Comparator|LCS|Total Knee Replacement Surgery with cementless LCS Rotating Platform Knee Prosthesis by DePuy
89188795|NCT00656799|Experimental|Sugammadex|IV single bolus dose of 4.0 mg/kg sugammadex
89188796|NCT00764699|Experimental|rhIGF|Treatment with rhIGF (Increlex)
88821983|NCT02901249|Experimental|Sertraline|"Group Started: sertraline (50mg-200mg)~Subjects evaluated for responsiveness every 2 weeks. Responsive to treatment patients remain in the same step. Max. step duration of 8 weeks.~First step: Monotherapy with sertraline (50-200mg). Non responsive patients: 2nd step.~Second step: Sertraline 200mg + lithium (900mg-1500mg)~Non responsive patients: 3rd step.~Third step: Nortriptyline 100mg~Non responsive patients: 4th step.~Fourth step: Nortriptyline 100mg + lithium (900mg-1500mg)~Non responsive patients : 5th step~Fifth step : Nortriptyline 100mg + sertraline 200mg Non responsive patients~sixth step: Nortriptyline 100mg + sertraline 200mg + Lithium ( 900mg- 1500mg)"
88821984|NCT02212028|Experimental|Prasugrel crush|Prasugrel 60mg loading dose as crushed tablets
88821985|NCT02212028|Active Comparator|Prasugrel tablets|Prasugrel 60 mg loading dose as whole tablets
88821986|NCT03007784|Experimental|2 mA anodal tDCS stimulation|Anodal tDCS stimulation at 2 mA applied to the left dorsolateral prefrontal during 20 minutes five days a week for two consecutive weeks
88821987|NCT03007784|Active Comparator|0.2 mA anodal tDCS stimulation|Anodal tDCS stimulation at 0.2 mA applied to the left dorsolateral prefrontal during 20 minutes five days a week for two consecutive weeks
88821988|NCT02901951|Experimental|HBV Group|Subjects aged 40 to 60 years old who received 3 or 4 doses of Engerix-B (HBV vaccine) 20 to 30 years ago and were administered with a single challenge dose of HBV vaccine in this study at Day 0 (Visit 1).
88821989|NCT01586312|Experimental|Allogenic mesenchymal stromal cells injection|Mesenchymal stem cells (MSC) prepared from bone marrow from healthy donor expanded ex vivo for 3-4 weeks. Intraarticular injection of 40 millions MSC.
88821990|NCT01586312|Active Comparator|Hyaluronic acid (Durolane)|Intraarticular injection of hyaluronic acid (60 mg)
88821991|NCT02977299|Experimental|Aripiprazole Augmentation|Patients randomized to this treatment arm will be instructed to continue all permitted psychotropics at their current dose throughout the 8-week trial and initiate adjunctive aripiprazole. The starting dose will be 5mg daily. The dose may be reduced to as low as 2mg for tolerability issues (this will be the lowest dose permitted for continuation in the trial). The dose may be adjusted in 2 or 5mg increments. The minimum time per increment will be 7 days. The maximum dose will be set at 15mg daily. For patients who are not on potent cytochrome 2D6 inhibitors (such as paroxetine, fluoxetine, duloxetine) or on potent cytochrome 3A4 inhibitors (such as fluvoxamine and nefazodone) and who are able to tolerate 15mg daily, the maximum dose can be raised to 20mg daily for efficacy.
88821992|NCT02977299|Experimental|rTMS Augmentation|Patients randomized to this treatment arm will be instructed to continue all permitted psychotropics at their current dose throughout the 8-week trial. We will use clinical TMS stimulators with focal figure-of-eight coils. We will start by measuring the patient´s motor threshold (MT), which is a measure of cortical excitability used to standardize the intensity of stimulation across subjects.
88821993|NCT02977299|Experimental|Switching To Venlafaxine XR|Patients randomized to this treatment arm will be instructed to continue all permitted psychotropics throughout the 8-week trial, except for their antidepressant(s). They will be instructed to discontinue all antidepressants and initiate venlafaxine that day, as direct switch to serotonergic antidepressants is well tolerated and avoids loss of precious therapeutic time (Montgomery et al., 2014), including to switching to venlafaxine in STAR*D (Rush et al., 2006b). For patients who do not prefer a direct switch, or when clinically indicated otherwise in the opinion of the site investigator, a gradual tapering during the screening period will be permitted as long as a direct switch to venlafaxine is made on the baseline visit from the final antidepressant dose. The starting dose of venlafaxine will be 75mg daily. The dose may be reduced to as low as 37.5mg for tolerability issues (this will be the lowest dose permitted for continuation in the trial).
88821994|NCT02212106|Experimental|bioCSL Trivalent Influenza Virus Vaccine (CSL TIV)|The bioCSL study vaccine is a sterile, thiomersal-free suspension containing 45 mcg total haemagglutinin antigen per 0.5 mL dose (15 mcg each of the three recommended influenza strains for the Northern Hemisphere 2014/2015 influenza season).
88821995|NCT02212106|Active Comparator|Comparator Quadrivalent Influenza Virus Vaccine|The comparator vaccine is a US-licensed product containing four recommended influenza strains for the Northern Hemisphere 2014/2015 influenza season.
88821996|NCT02903121|Experimental|Tamoxifen|Tamoxifen 10 mg (oral) twice daily for 7 days to be started following 3 consecutive days of bleeding
88821997|NCT02903121|Placebo Comparator|Placebo|Placebo (oral) twice daily for 7 days to be started following 3 consecutive days of bleeding
88821998|NCT02869425|Experimental|Arbaclofen ER Tablets|AERT 10 mg twice daily (BID) (20 mg/day) for 7 days, followed by AERT 15 mg BID (30 mg/day) for 7 days
88821999|NCT02869425|Placebo Comparator|Placebo for Arbaclofen ER Tablets|Matching placebo AERT 10 mg twice daily (BID) (20 mg/day) for 7 days, followed by matching placebo AERT 15 mg BID (30 mg/day) for 7 days
88822000|NCT02904057|Experimental|Treatment Group|The treatment group will receive Radiesse (+) injectable implant up to 3.0 cc per jawline.
88999280|NCT02903251|Experimental|oxytocin|"intranasal oxytocin spray Day 1-3: Twice daily intranasal oxytocin spray administered by health personnel.~Day 3-30: Self-administered intranasal spray as needed, max thrice daily intranasal spray without oxytocin"
89176953|NCT03704857|Experimental|Foraminal enlargement with sodium hypochlorite and photobiomodulation|Unirradicular teeth will be submitted to endodontic treatment with foraminal enlargement, instrumentation with reciprocating rotation, sodium hypochlorite as irrigant, photobiomodulation (antimicrobial photodynamic therapy and low-level laser therapy), lateral condensation filling with MTA Fillapex. The analysis of the postoperative symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th, 14th and 30th days and by the clinical evaluation of edema in 48 and 72 hours. The periapical lesion repair will be evaluated clinically and radiographically at 3, 6, 12, 18 and 24 months. The longevity of rehabilitations will be performed clinically and radiographically for 24 months. In addition, patients will respond a quality of life questionnaire (OHIP-14) on the day of endodontic treatment, on the 7th day and on the 30th day.
89188797|NCT02547142|Experimental|Early Palliative Care Group|This is the intervention group and will consist of patients that have been randomized into the early palliative group, with a consultation expected to take place within one week of randomization. Patients in this group will still receive appropriate guideline based oncologic care including any surgical, brachytherapy, chemotherapy or radiotherapy services, along with palliative services.
89188798|NCT00715286|Active Comparator|A|Conventional arm: primary surgery followed by chemotherapy
89188799|NCT00715286|Experimental|B|Neoadjuvant chemotherapy followed by interval debulking
89399063|NCT03697161|Experimental|OV101 (gaboxadol) Regimen 3|Three Times Daily
89399064|NCT02168192|Placebo Comparator|Traditional Lecture|These subjects received a 10 minute power point lecture on BBN skills.
89188800|NCT00844012|Experimental|Experimental group|
89188801|NCT00844012|Active Comparator|Control|
89188802|NCT02574962|Experimental|Acthar® Gel|For the first two weeks participants will receive 1 mL of study drug subcutaneously every other day. After that, participants will received 1 mL of study drug twice a week for up to 6 months.
89188803|NCT00802035|Active Comparator|IR am|30 mg, single dose, morning administration (immediate release [IR])
89188804|NCT00802035|Experimental|ER am|30 mg; single dose; morning administration (extended release [ER])
89188805|NCT00802035|Experimental|ER pm|30 mg; single dose; evening administration
89188806|NCT00802035|Active Comparator|IR pm|30 mg; single dose; evening administration
89188807|NCT00836212|Experimental|LPV|Patients with blood levels measured 2 times at 2 weeks intervals in the upper quartile (>percentile 75) of concentrations reported under standard therapy (i.e. EFV 600 mg q.d. or LPV/r 400 or 533 mg bid) will have their dose reduced by approximately one third, with the aim to bring their concentration in the 25-75% percentile range.
88822001|NCT02904057|No Intervention|Control Group|The control group is not treated. They will undergo assessments such as photographs, jaw grading and jaw function tests.
88822002|NCT02904915|Active Comparator|Paracervical block|Intrauterine device (IUD) placement with paracervical block with 1% lidocaine.
88822003|NCT02904915|Active Comparator|No analgesia|IUD placement with no analgesia.
88822004|NCT04737291|Experimental|Angioplasty by DCB|angioplasty of stenotic , ocluded or recoil segment using drug coated ballon
88822005|NCT02907489|No Intervention|Control: Calcium Hydroxide|Non-setting Calcium Hydroxide
88822006|NCT02907489|Other|Test: Triple Antibiotic Paste and Anti-Inflammatory Drug|Mixture of ciprofloxacin, metronidazole and minocycline.and diclofenac potassium 50 mg (Catafast)
88822007|NCT01535924|Experimental|Treatment (combination chemotherapy)|Patients receive gemcitabine hydrochloride IV over 30 minutes on day 1 and bendamustine hydrochloride IV over 30 minutes on days 1 and 2. Treatment repeats every 21-28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
88822008|NCT02909439|Active Comparator|Neostigmine|Patients in this arm will receive neostigmine for reversal of neuromuscular blockade. Neostigmine is historically the medication that has been used for this purpose.
88822009|NCT02909439|Active Comparator|Sugammadex|Patients in this arm will receive sugammadex for reversal of neuromuscular blockade. Sugammadex is a newer, FDA approved, medication for this purpose.
88822010|NCT02193009|Experimental|SIPsmartER, behavioral intervention|Aimed at decreasing sugar-sweetened beverage consumption
88822011|NCT02193009|Active Comparator|Move More, behavioral intervention|Aimed at physical activity promotion
88822012|NCT01587950|Placebo Comparator|Sterile water|Participants to receive 250 microlitres (μL) of sterile water.
88822013|NCT01587950|Experimental|Potassium nitrate 5% solution|Participants to receive 250 μL of potassium nitrate 5% solution.
88822014|NCT01587950|Experimental|Potassium nitrate 2.5% solution|Participants to receive 250 μL of potassium nitrate 2.5% solution.
88822015|NCT02833857|Experimental|Etelcalcetide|Participants received a single, intravenous (IV) bolus administration of 0.035 mg/kg etelcalcetide at the end of hemodialysis on study day 1.
89176954|NCT03704857|Experimental|Foraminal enlargement with chlorhexidine as irrigant|Unirradicular teeth will be submitted to endodontic treatment with foraminal enlargement, instrumentation with reciprocating rotation, chlorhexidine as irrigant, lateral condensation filling with MTA Fillapex. The analysis of the postoperative symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th, 14th and 30th days and by the clinical evaluation of edema in 48 and 72 hours. The periapical lesion repair will be evaluated clinically and radiographically at 3, 6, 12, 18 and 24 months. The longevity of rehabilitations will be performed clinically and radiographically for 24 months. In addition, patients will respond a quality of life questionnaire (OHIP-14) on the day of endodontic treatment, on the 7th day and on the 30th day.
89176955|NCT03704857|Active Comparator|Foraminal enlargement with sodium hypochlorite and AH Plus|Unirradicular teeth will be submitted to endodontic treatment with foraminal enlargement, instrumentation with reciprocating rotation, sodium hypochlorite as irrigant, lateral condensation filling with AH Plus.The analysis of the postoperative symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th, 14th and 30th days and by the clinical evaluation of edema in 48 and 72 hours. The periapical lesion repair will be evaluated clinically and radiographically at 3, 6, 12, 18 and 24 months. The longevity of rehabilitations will be performed clinically and radiographically for 24 months. In addition, patients will respond a quality of life questionnaire (OHIP-14) on the day of endodontic treatment, on the 7th day and on the 30th day.
89176956|NCT03704857|Active Comparator|Foraminal enlargement with conventional irrigation|Molars will be submitted to endodontic treatment with foraminal enlargement, instrumentation with reciprocating rotation, conventional irrigation with sodium hypochlorite, lateral condensation filling with MTA Fillapex. The analysis of the postoperative symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th, 14th and 30th days and by the clinical evaluation of edema in 48 and 72 hours. The periapical lesion repair will be evaluated clinically and radiographically at 3, 6, 12, 18 and 24 months. The longevity of rehabilitations will be performed clinically and radiographically for 24 months. In addition, patients will respond a quality of life questionnaire (OHIP-14) on the day of endodontic treatment, on the 7th day and on the 30th day.
89188808|NCT00836212|Experimental|EFV|Patients with blood levels measured 2 times at 2 weeks intervals in the upper quartile (>percentile 75) of concentrations reported under standard therapy (i.e. EFV 600 mg q.d. or LPV/r 400 or 533 mg bid) will have their dose reduced by approximately one third, with the aim to bring their concentration in the 25-75% percentile range.
89188809|NCT04069676||Autism Spectrum Condition (ASC)|Adults males and females with a formal autism diagnosis, without intellectual disability
89188810|NCT04069676||Typically developped (TD)|Adults males and females without any neurodevelopemental issue (or health issue which could impaired task performances)
89188811|NCT00782717|Experimental|NEVANAC|One drop three times a day starting on the day prior to cataract surgery (Day -1) and continuing on the day of surgery (Day 0) and for 90 days thereafter.
88822016|NCT01536938|Active Comparator|Calcipotriol|"Calcipotriol aerosol foam: calcipotriol 50 mcg/g.~Applied once daily for up to 4 weeks"
88822017|NCT01536938|Active Comparator|Betamethasone|"Betamethasone dipropionate aerosol foam: betamethasone 0.5 mg/g (as dipropionate)~Applied once daily for up to 4 weeks"
88822018|NCT01536938|Experimental|LEO 90100|"LEO 90100 aerosol foam: calcipotriol 50 mcg/g and betamethasone 0.5 mg/g (as dipropionate)~Applied once daily for up to 4 weeks"
88822019|NCT01588418|Experimental|Exenatide first, then Placebo|Exenatide 5mcg was injected subcutaneously 30 min before Oral Glucose Tolerance Test (OGTT)-PET study. The same subject was studied again a few weeks later with the same protocol with Placebo injection.
88822020|NCT01588418|Experimental|Placebo first, then Exenatide|Placebo was injected subcutaneously 30 min before OGTT-PET study. The same subject was studied again a few weeks later with the same protocol with injection of Exenatide 5mcg .
88822021|NCT03007550|Experimental|Laparoscopic total gastrectomy|The surgeon will perform LTG with D1+/D2-10 lymphadenectomy for patients enrolled in this group.
88822022|NCT03007550|Other|Open total gastrectomy|The surgeon will perform OTG with D1+/D2-10 lymphadenectomy for patients enrolled in this group.
89355414|NCT03345004|Active Comparator|Active arm|Patients will be assigned to receive i) three (3) intralymphatic injections with Recombinant human Glutamic Acid Decarboxylase adsorbed to Alhydrogel (Diamyd) on Days 30, 60, and 90 and; ii) oral vitamin D 2000 IU/daily for 4 months (from Day 1 through Day 120)
89399065|NCT02168192|Experimental|Simulation-Debrief|These subjects received a formal debrief process, reviewing their prior baseline simulation.
88822023|NCT01657383||Hepatopancreaticobiliary (HPB) Surgery Patients|Patients undergoing surgical HPB procedures
89176957|NCT03704857|Experimental|Foraminal enlargement with passive ultrasonic irrigation|Molars will be submitted to endodontic treatment with foraminal enlargement, instrumentation with reciprocating rotation, passive ultrasonic irrigation with sodium hypochlorite, lateral condensation filling with MTA Fillapex. The analysis of the postoperative symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th, 14th and 30th days and by the clinical evaluation of edema in 48 and 72 hours. The periapical lesion repair will be evaluated clinically and radiographically at 3, 6, 12, 18 and 24 months.The longevity of rehabilitations will be performed clinically and radiographically for 24 months. In addition, patients will respond a quality of life questionnaire (OHIP-14) on the day of endodontic treatment, on the 7th day and on the 30th day.
88999281|NCT02903251|Placebo Comparator|Placebo|"intranasal spray without oxytocin Day 1-3: Twice daily intranasal spray without oxytocin, administered by health personnel.~Day 3-30: Self-administered intranasal spray as needed, max thrice daily"
88999282|NCT02903173||Women who undergo cesarean delivery|
89188812|NCT00782717|Placebo Comparator|Nepafenac Vehicle|One drop three times a day starting on the day prior to cataract surgery (Day -1) and continuing on the day of surgery (Day 0) and for 90 days thereafter.
89188813|NCT00656175|Active Comparator|Immediate|Immediate switch of PI or NNRTI to Raltegravir
89188814|NCT00656175|Active Comparator|Delayed|Continue current therapy unchanged for 24 weeks, then switch PI or NNRTI to Raltegravir
89188815|NCT02572622|Experimental|spinal decompression group|only 15 sessions of spinal decompression therapy were applied.
88822024|NCT03001856|Experimental|Oblique Intradermal Suture|OIS is very similar to conventional interrupted intradermal suture (IS), except that the suture in OIS is canted or angled relative to the vertical plane (Figure 1). To perform OIS, the needle is passed from deep to superficial dermis and canted 30°-60° from the normal vertical plane. The needle is then inserted into the opposite wound edge from superficial to deep dermis in a mirror-image fashion. The thread is tied with a square knot to finish the suture.
88822025|NCT03001856|Experimental|Intradermal Suture|Conventional interrupted intradermal suture
88822026|NCT02911857|Experimental|Canakinumab (ACZ885)|Participants continued the study drug based on the final dose and regimen administered at the end of the CACZ885N2301 study. All participants received 1 or 2 ACZ885 subcutaneous injections every 4 or 8 weeks.
88822027|NCT03007316|Experimental|Immediate Implants + VIP graft.|Immediate implants placed with simultaneous vascularized interpositional periosteal (VIP) connective tissue graft augmentation.
88822028|NCT03007316|No Intervention|Immediate Implants only|Immediate Implants only without soft tissue augmentation.
88822029|NCT03007160|Experimental|Experimental group|Potassium Citrate Extended-release Tablets
88822030|NCT03007160|No Intervention|Blank control group|Subjects do not take the investigational product
88822031|NCT03004911|Experimental|Mobile application|
88822032|NCT03004911|Active Comparator|Paper booklet|
88822033|NCT03007004|Experimental|Botulinum toxin group|400 units in one injection site（0.2mL） Total 2000 units（1.0mL） （For both hands total 4000 units; 2.0 mL）
88822034|NCT03007004|Sham Comparator|Physiological saline (control drug) group|"0.2mL in one injection site~Total 1.0mL (For both hands total 2.0 mL)"
88822035|NCT02914119||Eligible patients|"Patients ≥15 years of age who received general anaesthesia with neuromuscular blockade in the last 18 months up until the time of data collection.~Patients, who are eligible more than once, i.e. undergoing general anaesthesia on more than one occasion, will be included in the analyses as a case for every general anaesthetic received."
88822036|NCT01589510||Lumigan® 0.01%|Lumigan® 0.01% (bimatoprost 0.01% ophthalmic solution) as prescribed by physician per standard practice for up to 14 weeks.
88822037|NCT02914509|Experimental|OTX-TP (sustained release travoprost) Intracanalicular Depot|OTX-TP (sustained release travoprost) Intracanalicular Depot
88822038|NCT02914509|Placebo Comparator|PV (Placebo Vehicle) Intracanalicular Depot|PV (Placebo Vehicle) Intracanalicular Depot
88822039|NCT02837913|Experimental|Underbody warmer on|Underbody warmer will be underneath the patient and turned on.
88822040|NCT02837913|Placebo Comparator|Underbody warmer off|Underbody warmer will be underneath the patient but not turned on.
88822041|NCT02840097|Experimental|Tranexamic acid dose A|Subjects will receive a 15 mg/kg bolus of tranexamic acid over 10 minutes followed by a 2mg/kg/h over 8 hours. This represents 31mg/kg total dose of TXA.
88822042|NCT02840097|Experimental|Tranexamic acid dose B|Subjects will receive a 30 mg/kg bolus of tranexamic acid over 10 minutes followed by a 4 mg/kg/h over 8 hours. This represents 62 mg/kg total dose of TXA.
88822043|NCT02840097|Placebo Comparator|Placebo|Subjects in the placebo group will receive a bolus dose of normal saline over 10 minutes followed by a normal saline infusion over 8 hours.
88822044|NCT02841033|Experimental|Daratumumab|Daratumumab, 16mg/kg body weight in 1000 mL for the first dose, followed by 500mL for subsequent doses, once weekly for two months, then every 2 weeks for four months, then once each month.
88822045|NCT02841189|Other|Video laryngoscope intubation|The King Vision Video Laryngoscope will be used for intubation
88822046|NCT02738489|Experimental|Injection SHR-1210 60mg Cohort|
88822047|NCT02738489|Experimental|Injection SHR-1210 200mg Cohort|
89399066|NCT03619317||Cancer esophagus and gastroesophageal junction|EGEJ cancer patients referred to combined therapy of chemoRT and surgery can be included.
88822048|NCT02738489|Experimental|Injection SHR-1210 400mg Cohort|
88822049|NCT02988089|Experimental|clarithromycin dependant group|"Patients in this group will receive 14-day bismuth-based quadruple therapies guided by the susceptibility of clarithromycin. Ilaprazole 5 mg b.i.d is used as the proton pump inhibitor (PPI). The dose of colloidal bismuth pectin is 200 mg b.i.d.~The kinds of 2 antibiotics will be depend on the susceptibility of clarithromycin.~If clarithromycin is susceptible, amoxicillin 1 g b.i.d and clarithromycin 500 mg b.i.d will be chosen; If clarithromycin is resistant, amoxicillin 1 g bid and furazolidone 100 mg b.i.d will be chosen."
88822050|NCT02988089|Experimental|6 antibiotics dependant group|"Patients in this group will receive a 14-day bismuth-based quadruple regimen to eradicate H. pylori. The regimen is consist of a PPI, a bismuth and 2 susceptible antibiotics which are determined by AST. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline will be evaluated.~Ilaprazole 5 mg b.i.d is used as the proton pump inhibitor (PPI). The dose of colloidal bismuth pectin is 200 mg b.i.d."
88822051|NCT02988089|Other|salvage therapy for negative culture|when the results of culture are negative, patients will receive Ilaprazole 5 mg, amoxicillin 1 g, furazolidone 100 mg, Colloidal Bismuth Pectin 200 mg (IAFB regimen) or Ilaprazole 5 mg, amoxicillin 1 g, furazolidone 100 mg, tetracycline 750 mg (IAFT regimen)，all are used twice daily except tetracycline which is taken 3 times daily.
88822052|NCT02988089|Other|salvage therapy for failed eradication|If failed with AST guided eradication therapy, patients will take another therapy according to the former AST results. One susceptible antibiotics not involved in last therapy will be used as a component of 14-day bismuth-based quadruple regimen with Ilaprazole 5 mg b.i.d, amoxicillin 1 g b.i.d and Colloidal Bismuth Pectin 200 mg b.i.d.
88822053|NCT02430233|Experimental|micronized progesterone 400 mg|participants receive vaginal micronized progesterone (Utrogestan- 200mg×2 PV(per vagina) per day)
88822054|NCT02430233|No Intervention|No treatment|No treatment
88822055|NCT00551369|Experimental|SBRT|Stereotactic body radiation therapy (SBRT)
88822056|NCT01589978|Experimental|PROMUS Element|Subjects who receive the PROMUS Element everolimus-eluting coronary stent
88822057|NCT05474807|Experimental|Intervention group|The experimental arm will receive the online strengths use intervention program over a period of 6 weeks, through an LMS software solution.
88822058|NCT01592006|Experimental|HCV, LT, Pegasys, ribavirin, telaprevir|Patients are being asked to be part of this arm because they are orthotopic liver transplant recipients (OLT) and have the Hepatitis C Virus (HCV). They will be given the study drugs Pegasys, ribavirin and telaprevir
88822059|NCT00551291|Experimental|Mycophenolate Mofetil + Prednisone + Erythropoietin Beta|Mycophenolate mofetil (MMF) 1 gm twice daily orally and prednisone 10 mg/day orally until the end of the study. Recombinant human erythropoietin beta 30,000 IU/week, subcutaneously for 6 weeks was added in case of no significant response at Week 12.
88822060|NCT01592396|Experimental|Tralokinumab 300 mg|Participants aged 12 to 14 years and 15 to 17 years will receive a single dose of tralokinumab (CAT-354) 300 milligram (mg), subcutaneously on Day 1.
88822061|NCT02988323|Experimental|Cervicovestibular Physio (CV PT)|In addition to the standard protocol of rest followed by exertion, the CV PT group will participate in a combination of cervical spine and vestibular rehabilitation as per a standardized treatment algorithm based on individual assessment findings. This form of therapy combines treatment techniques for both the cervical spine and vestibular system that are commonly used in physiotherapy practice. Cervical spine treatments may include neuromotor retraining, sensorimotor retraining, manual therapy, soft tissue techniques, and range of motion exercises. Vestibular rehabilitation may include gaze stabilization, habituation, standing balance, dynamic balance and canalith repositioning maneouvers.
88822062|NCT02988323|Experimental|Low-Level Aerobic Exercise (LLAE)|Participants will exercise at 60% maximum heart rate for 15 minutes. This heart rate will be calculated by taking 220-age (in years) and multiplying by 0.6 to determine the target heart rate while performing the low level aerobic exercise. Aerobic exercises may include treadmill, walking or stationary cycling. Exercise will be performed 5-6 times per week independently at home and monitored by their parents. Individuals will be taught how to monitor their heart rate. This protocol has previously been found to be feasible and of minimal risk to participants.
88822063|NCT02988323|Other|Combination (LLAE and CV PT)|The combination group will complete a protocol that includes both the cervicovestibular physiotherapy and LLAE interventions described above. As described above, the study participants will be seen once weekly by the study physiotherapist for CV PT and also complete a protocol of LLAE at home.
88822064|NCT02981420|No Intervention|Pre-intervention|Pre-intervention baseline comparison
88822065|NCT02981420|Experimental|Safety Planning|Intervention group
88822066|NCT02981420|No Intervention|Regression discontinuity|Subthreshold no intervention
88822067|NCT02278289|Active Comparator|ultrasound therapy group|Patients in the ultrasound therapy group were treated with US therapy for 5 minutes each session, twice per week for 8 weeks.
88822068|NCT02278289|Active Comparator|paraffin therapy group|Patients in the paraffin therapy group were treated with the dip-and-wrap method of paraffin bath therapy in the hospital twice per week for 8 weeks. The temperature of the paraffin bath was maintained at approximately 55°C
88822069|NCT03001622|Other|IFX-1|
88822070|NCT02981264|Active Comparator|Transcricoid|Lignocaine delivery using transcricoid injection
88822071|NCT02981264|Active Comparator|Spray as You go|Lignocaine delivery using spray as you go method
88822072|NCT01593722|Active Comparator|diethylcarbamazine|diethylcarbamazine 8 mg/kg single oral dose
88822073|NCT01593722|Active Comparator|ivermectin|ivermectin 200 mcg/kg single oral dose
88822074|NCT03001934||Nephrotic syndrome patients|Patients diagnosis as nephrotic syndrome (NS)
88822075|NCT03001544|Experimental|Experimental Ascending Dose Cohort|TS23
88822076|NCT01594424|Experimental|IVIG + Tocilizumab|
88822077|NCT01595282|Experimental|Ketorolac|Intramuscular injection of ketorolac 60 mg in 2cc -plus- placebo tablet (calcium carbonate 600 mg tablet). For subjects who are 50 kg or less, intramuscular injection of ketorolac 30 mg in 1cc -plus- placebo tablet (calcium carbonate 600 mg tablet)
88822078|NCT01595282|Active Comparator|Ibuprofen|Ibuprofen 800 mg tablet -plus- intramuscular injection of 2cc saline placebo. For subjects weighing 50 kg or less, ibuprofen 600 mg tablet -plus- intramuscular injection of 2cc saline placebo
88822079|NCT01595516|Active Comparator|Nebivolol|
88822080|NCT01595516|Active Comparator|Metoprolol|
88822081|NCT01595516|Placebo Comparator|Placebo|
88822082|NCT01595516|Other|Bradykinin|
88822083|NCT01595516|Other|Saline|
88822084|NCT01595516|Other|Vitamin C|
88822085|NCT03006770|Experimental|PLX-PAD|PLX-PAD will be administered via 30 IM injections (0.5 mL each). Each subject will be treated twice, with an interval of 8 weeks between treatments.
89399067|NCT01380353|Experimental|Breast Group|Diclofenac epolamine patch applied to the breast
88822086|NCT03006770|Placebo Comparator|Placebo|Placebo will be administered via 30 IM injections (0.5 mL each). Each subject will be treated twice, with an interval of 8 weeks between treatments.
88822087|NCT03001700|Experimental|Treatment|Subjects will be treated with the Serranator™ Alto PTA Serration Balloon Catheter device
88822088|NCT01596842|Active Comparator|Omega-3 fatty acid|
88822089|NCT01596842|Placebo Comparator|Olive oil|
88822090|NCT02217800|Other|Saline, then DG3173, then octreotide|Interventions: saline, DG3173 and octreotide. Eligible patients are to receive a constant 23 hour subcutaneous infusion of saline as placebo comparator and will be randomized in an equal ratio to one of three treatment sequences of doses of 920, 2760 and 5520 µg DG3173 by constant 23 hour subcutaneous infusions in a random sequence followed by three subcutaneous injections of 300 µg octreotide at approximately 8 hour intervals as an active comparator.
88822091|NCT02218190|Experimental|Alvimopan|Alvimopan 12mg once orally two hours prior to surgery and then 2 mg orally twice a day until post-operative day (POD) seven.
88822092|NCT02218190|Placebo Comparator|Placebo - Sugar Pill|Placebo Sugar Pill orally two hours prior to surgery and then one sugar pill orally twice a day until post-operative day (POD) seven
88822093|NCT03006614|Experimental|PERS:NVB,DDP,GEM,CAP,H etc.|vinorelbine 25mg/m2 d1,d8 iv,q3w cisplatin 70mg/m2 d1，q3w gemcitabine 1000mg/m2 d1,d8,q3w capecitabine 1000mg/m2,bid,d1-14,q3w Trastuzumab
89399068|NCT01380353|Experimental|Abdomen Group|Diclofenac epolamine patch applied to the abdomen
89399069|NCT02168348||Diabetic patients with a lesion on the foot|
89399070|NCT01384175|Active Comparator|intravenous analgesia|Patients received postoperative analgesia by intravenous fentanyl 10 µg/ml 3-8 mL/h.
89399071|NCT01384175|Active Comparator|epiduaral infusion|Patients received epidural analgesia intraoperatively with ropivacaine 0.75% 1 mg/kg and fentanyl 1 µg/kg followed by continuous epidural infusion of ropivacaine 0.2% 3-8 mL/h and fentanyl 2 µg/mL postoperatively.
88822094|NCT03006614|Active Comparator|EPI+CTX-T+/-H|Epirubicin 90mg/m2 d1+ CTX 600mg/m2 d1 q2w, Docetaxel 75mg/m2 +/-herceptin d1,q3w
88822095|NCT03001466|Experimental|urea-loaded nanoparticles eye drops|This arm include 40 cases (67 eyes) received urea-loaded nanoparticles eye drops (one drop five times a day for 8 weeks)
88822096|NCT03001466|Placebo Comparator|Balance Salt Solution eye drops|This arm include 11 cases (22 eyes) recieved Balance Salt Solution eye drops (one drop five times a day for 8 weeks)
88822097|NCT03006380|Experimental|oxytocin before placental delivery|patients who will receive 10 IU of oxytocin (syntocinon®, NOVARTIS, Egypt) intramuscularly at delivery of anterior shoulder of the fetus and an identical placebo injection (normal saline, NACL 0.9%) intramuscularly following delivery of the placenta.
88822098|NCT03006380|Experimental|oxytocin after placental delivery|patients who will receive placebo injection (normal saline, NACL 0.9%) intramuscularly at delivery of anterior shoulder of the fetus and 10 IU of oxytocin (syntocinon®, NOVARTIS, Egypt) intramuscularly following delivery of the placenta.(opposite medication sequence)
88822099|NCT02981030|Experimental|Simplified medical abortion|Women seeking medical abortion will be offered the option self-administering the medications, mifepristone and misoprostol at home.
88822100|NCT02980952|Placebo Comparator|Energy-balanced diet|Forearm immobilization whilst consuming an energy-balanced diet
88822101|NCT02980952|Experimental|High-fat overfeeding|Forearm immobilization whilst consuming a high-fat diet, 50% energy excess
88822102|NCT03006692||Take arterial blood gas|Patients with impaired consciousness are randomised into having analysed a arterial blood gas.
88822103|NCT03006692||Do not take arterial blood gas|Patients with impaired consciousness are randomised into not having analysed a arterial blood gas.
88822104|NCT05566808|Other|Autologous Costal Cartilage Graft|Patients undergoing rhinoplasty will receive autologous rib graft.
88999283|NCT02903329|Active Comparator|Protocol A|In program A, patients underwent detoxification without any acute medication during a two months period (complete stop of acute medication intake).
88822105|NCT05566808|Other|Costal Cartilage Allograft|Patients undergoing rhinoplasty will receive costal cartilage allograft.
88822106|NCT03001232|Experimental|Movement-oriented Dementia Care|The experimental group received movement-oriented dementia care for a period of twelve months.Movement-oriented dementia care is a multidisciplinary approach in which all involved disciplines focus on stimulating physical activity and independence as much as possible. This way physical activity is stimulated at all times for the participants.
88822107|NCT03001232|No Intervention|Care as usual|The control group received care as usual
88999284|NCT02903329|Active Comparator|Protocol B|In program B, patients were allowed to take up to 2 days a week with analgesics or migraine medication during the two months detoxification period (restricted acute medication intake).
88999285|NCT04723589|No Intervention|Standard Arm|Participants randomized to standard care will not receive an intervention but will participate in other study procedures, which are blood collection and data collection.
88999286|NCT04723589|Experimental|Intervention Arm|Participants randomized to the intervention arm will receive standard care plus an infusion of thawed plasma, starting rate 30 ml/hour for 24 hours, increased to 50 ml/hour if deemed to be hypovolemic (low fluid volume). Only non-convalescent (COVID-antibody-free) plasma will be used.
88999287|NCT02903134||Newborn from obese and nonobese pregnant|Obese (BMI>30) or normal weight (BMI<25) women at their first antenatal visit were invited to participate in the study at the moment of delivery at Sotero del Rio Hospital, Santiago. Information regarding birth outcomes, parental history, as well as environmental conditions was collected at recruitment. Follow-up questionnaires by phone were completed every 6 months. Umbilical cord blood samples were collected to measure IL-12, TNF-α, IL-10, IL-4; to evaluate metabolic status; to isolated monocytes and macrophage differentiation; and for DNA methylation status of the promoter regions of the genes coding for TNF-α, IL-12, IL-10, and IL-4Rα. Also, fasting blood samples of the mothers within 48 hours after delivery; and blood samples and skin prick test were collected.
88999288|NCT02903056||Rett Syndrome|Rett Syndrome is a neurodevelopmental disease that primarily affects girls. Clinically, patients are normal before six months to one and half years old, and then develop progressive severe problems with communication, learning, co-ordination and neurodevelopment, with loss of motor skills around the age of two. At the same time, stereotyped hand movement typically appears.
88999289|NCT02903056||Control-normal|Healthy people
88999290|NCT00195936|Experimental|Overall Study|Calcimimetics as an Adjuvant Treatment for Familial Hypophosphatemic Rickets
88999291|NCT02903095|Experimental|TD-1439|Capsule formulation
88999292|NCT02903095|Placebo Comparator|Placebo|Capsule formulation
88999293|NCT02902783||Consented deceased organ donors|Data will be collected on deceased donors, declared by neurological determination of death (DND) and by circulatory determination of death (DCD).
88999294|NCT02902939|No Intervention|Uncomplicated cardiac surgery patients|Patients after scheduled cardiac surgery procedures
88999295|NCT02902939|Active Comparator|Complicated cardiac surgery patients|MECC systems Cytokines modulation by CytoSorb and PMMA membranes
88999296|NCT02902861|Active Comparator|methotrexate|Once weekly (every 7 days) s.c. administration of 17.5 mg MTX. If PASI50 is not reached after 8 weeks (week 8) or PASI75 is not reached after 24 weeks, the dosing will be increased to 22.5 mg MTX/week. If patients were already dosed with 22.5 mg MTX/week in week 24 and PASI50 is not reached, patients will be excluded from treatment. Primary endpoint after 16 weeks.
89188816|NCT02572622|Experimental|combine group|10 patients participated in this group. for two weeks electrotherapy, deep friction massage and traction and last two weeks electrotherapy and exercise totally 15 session of treatment were applied.
88822108|NCT05566418|No Intervention|Group A|Group A will get standard therapy and the Mulligan mobilization technique for 12 sessions. A Mulligan mobilization belt will be wrapped around the subject's proximal forearm, close to the elbow joint line, and then wrapped around the therapist's shoulder. This will be done with the therapist's other hand on the distal humerus. The belt will give the subject's forearm a 10-to 15-second lateral glide. The patient will be instructed to constantly extend their wrists while the therapist applies manual resistance to their attempts, and the therapist will continue to work on the patient. When the user can fully extend their wrist without discomfort, the lateral glide will be abolished. Three repeats will be performed, each separated by a fifteen-to twenty-second interval.
88999297|NCT02902861|Placebo Comparator|Placebo (NaCl-Solution)|Once weekly (every 7 days) s.c. administration of 0.35 mL placebo If PASI50 is not reached after 8 weeks (week 8), the dosing will be increased to 0.45 mL placebo/week. Primary endpoint after 16 weeks. After 16 weeks patients will receive 17.5 mg MTX / week. If PASI50 is not reached after 8 weeks of MTX treatment (week 24), uptitration to 22.5 mg MTX/ 0.45 mL Plac / week will be done. Patients, who will reach PASI75 under placebo treatment after 16 weeks, will be dosed neither with placebo nor with MTX until relapse. After relapse the patients will be dosed with a starting dose of 17.5 mg MTX / week.
88999298|NCT00195975||1|Children with FD
88999299|NCT00195975||4|Healthy controls
88999300|NCT02902705|Experimental|Chronic Kidney disease patients - stage V|Male adults non-diabetic and non-dialyzed CKD stage 5 patients. All the CKD patient will be recruited at the Department of Nephrology of Edouard Herriot University Hospital (Lyon, France).
88999301|NCT02902705|Other|Non Chronic Kidney Disease patients|Non CKD male adults matched for age, gender and body mass index (BMI) with CKD patients. All the non - CKD patient will recruited from Department of recruited at the Department of Urology of Edouard Herriot University Hospital (Lyon, France).
88999302|NCT02902978|Experimental|Cohort 1 to 7|Participants will receive a single dose of E6130 or placebo, administered in a dose-ascending manner under the fasted condition.
88999303|NCT02902978|Experimental|Cohort 8|Participants will receive a single dose of E6130 (determined in Cohort 1 to 7), administered in the specified order (fed/fasted or fasted/fed) to evaluate the food effect.
88999304|NCT02903017|Active Comparator|Tranexamic acid 5%|Tranexamic acid 5%, 2000 mg (40 mL) in 60 mL normal saline (0.9%) solution (total 100 mL)
88999305|NCT02903017|Placebo Comparator|Placebo|0.9% normal saline solution (total 100 mL)
88999306|NCT02902744|Experimental|ILUVIEN 0.19 MG|
88999307|NCT02902666|Experimental|Paracetamol 1000 mg/codeine phosphate hemihydrate 30 mg tablet|"A single dose of the experimental drug will be administered to healthy male and female volunteers under fasting conditions before (treatment arm 1) or after (treatment arm 2) a wash-out interval of at least 7 days between the active comparator administration.~Test formulation will be administered as a single dose of one paracetamol 1000 mg/codeine 30 mg tablet."
88999308|NCT02902666|Active Comparator|paracetamol 500mg/codeine phosphate hemihydrate 30mg 2 tablets|A single dose of active comparator will be administered to healthy male and female volunteers under fasting conditions before (treatment arm 2) or after (treatment arm 1) a wash-out interval of at least 7 days between the experimental drug administration. Reference formulation will be administered as a single dose of two 500 mg/30 mg tablets.
88999309|NCT02902822|Active Comparator|Screening|This arm includes all subjects randomized to regular dermatological follow-up visits on annual basis.
88999310|NCT02902822|Experimental|Tele-dermatology|This arm includes all subjects randomized to the use of a tele-dermatology system for the evaluation of newly onset non-widespread skin lesions.
88999311|NCT02902354|Other|Nifedipine for tocolysis|Only women receiving nifedipine (as standard of care) for tocolysis
88999312|NCT02902393||Success of revascularisation|
88999313|NCT02902510|Experimental|Experimental|The experimental group is the group that received yoga. The individuals originally assigned to the WLC who completed the yoga intervention AFTER the 8 weeks WLC period also are considered part of the experimental group.
88999314|NCT02902510|No Intervention|Wait List Control|There was no intervention during the WLC.
88999315|NCT02902315|Active Comparator|1ª Session of resistance exercises|Exercise session are based on previous studies (TEIXEIRA et al., 2012; TEIXEIRA et al., 2014) and will be randomized according to the sequence of exercises (extensor bench, squat and leg press) and the interventions by drawing sealed brown envelopes. Forty minutes before basal blood collection and of the exercise session the volunteers will receive placebo (two pills wheat flour) and the remaining procedures will be conserved. The exercise sessions were comprised of four series of 10 maximum repetitions, with an interval of one minute between series and two minutes between exercises. Before the 10 maximum repetitions test and data collection, standard instructions will be given concerning the experimental procedure and execution technique of the exercises.
88999316|NCT02902315|Active Comparator|2ª Session of resistance exercises|Exercise session are based on previous studies (TEIXEIRA et al., 2012; TEIXEIRA et al., 2014) and will be randomized according to the sequence of exercises (extensor bench, squat and leg press) and the interventions by drawing sealed brown envelopes. Forty minutes before basal blood collection and of the exercise session the volunteers will receive placebo (two pills wheat flour) and the remaining procedures will be conserved. The exercise sessions were comprised of four series of 10 maximum repetitions, with an interval of one minute between series and two minutes between exercises. Before the 10 maximum repetitions test and data collection, standard instructions will be given concerning the experimental procedure and execution technique of the exercises.
88999317|NCT02902315|Active Comparator|3ª Session of resistance exercises|Exercise session are based on previous studies (TEIXEIRA et al., 2012; TEIXEIRA et al., 2014) and will be randomized according to the sequence of exercises (extensor bench, squat and leg press) and the interventions by drawing sealed brown envelopes. Forty minutes before basal blood collection and of the exercise session the volunteers will receive placebo (two pills wheat flour) and the remaining procedures will be conserved. The exercise sessions were comprised of four series of 10 maximum repetitions, with an interval of one minute between series and two minutes between exercises. Before the 10 maximum repetitions test and data collection, standard instructions will be given concerning the experimental procedure and execution technique of the exercises.
88999318|NCT02902315|Active Comparator|4ª Session of resistance exercises|Exercise session are based on previous studies (TEIXEIRA et al., 2012; TEIXEIRA et al., 2014) and will be randomized according to the sequence of exercises (extensor bench, squat and leg press) and the interventions by drawing sealed brown envelopes. Forty minutes before basal blood collection and of the exercise session the volunteers will receive placebo (two pills wheat flour) and the remaining procedures will be conserved. The exercise sessions were comprised of four series of 10 maximum repetitions, with an interval of one minute between series and two minutes between exercises. Before the 10 maximum repetitions test and data collection, standard instructions will be given concerning the experimental procedure and execution technique of the exercises.
89188817|NCT02572622|Experimental|exercise group|10 patients participated in this group. for two weeks electrotherapy, deep friction massage and last two weeks electrotherapy and exercise totally 15 session of treatment were applied whi
88822109|NCT05566418|Experimental|Group B|In addition to the standard treatment, Group B participants will receive 12 sessions of myofascial release technique and Mulligan mobilization. Participants will be instructed to lie supine on the plinth with the afflicted arm internally rotated, elbow slightly flexed and pronated, and palm of hand on the plinth. While standing on the side of the body affected by the ailment being treated, the therapist turned their body to face the affected hand. Myofascial release will be performed on the patient The therapeutic session will last five minutes and will be repeated twice.
88822110|NCT05566340||isolated aortic valve replacement group|Isolated aortic valve replacement surgery.
88822111|NCT05566340||aortic valve replacement with mitral valve repair group|Aortic valve replacement with mitral valve repair
88822112|NCT03006224|Active Comparator|Group S (non smoking and secondary smoking)|I want to see the effects of seconder smoking to intraoperative arterial oxygen tension during one lung ventilation for lobectomy surgery.
88822113|NCT03006224|Active Comparator|Group SS (secondary smoking)|I want to see the effects of seconder smoking to intraoperative arterial oxygen tension during one lung ventilation for lobectomy surgery.
88822114|NCT03006146|Experimental|Sargramostim|Participants will receive a single administration of inhaled sargramostim (either 125 mcg or 250 mcg dose)
88822115|NCT03005990|Experimental|Exercise training group|Exercise group will attend a supervised aerobic plus resistance exercise training class 3 times a week totally for 24 weeks.
88822116|NCT03005990|No Intervention|Control group|Control group only provide standard outpatient care program.
88822117|NCT03001154|Experimental|One-session VRET face-to-face|One-session Virtual Reality Exposure Therapy led by therapist (face-to-face), followed by a 4-week therapist-guided Internet-administered progressive maintenance program.
88822118|NCT03001154|Experimental|Waiting-list, then Internet-administered VRET|4-week waiting list, followed by therapist-guided, Internet-administered VRET with a 4-week progressive maintenance program.
88822119|NCT00551213|Experimental|Robatumumab→Robatumumab|Participants receive 1 dose of robatumumab 0.3 mg/kg intravenously (IV) followed by 1 dose of robatumumab 10 mg/kg IV once every 2 weeks (Q2W) until disease progression. A cycle of robatumumab is defined as 2 weeks of treatment (i.e., 1 dose of robatumumab) with no recovery period between cycles.
88822120|NCT00551213|Active Comparator|Chemotherapy→Robatumumab|Participants receive 1 cycle of standard colorectal cancer chemotherapy currently approved and available on the market for use in colorectal cancer (to be selected by the Investigator based on participant's prior treatment) followed by 1 dose of robatumumab 10 mg/kg IV Q2W until disease progression. A cycle of robatumumab is defined as 2 weeks of treatment (i.e., 1 dose of robatumumab) with no recovery period between cycles.
88822121|NCT02247830|Experimental|1 Chamomilla recutita gel|Experimental Group 01: usual care + topical application of the gel recutita chamomile. Such intervention will be characterized by topical application of the gel C. recutita, concomitantly to the initiation of radiotherapy, should be applied on the irradiated three times daily throughout the period of realization of radiotherapy sessions area, and nursing consultations with equipment instructional (usual care).
89355415|NCT03345004|Placebo Comparator|Placebo arm|Patients will be assigned to receive i) three (3) intralymphatic injections of Placebo for Diamyd on Days 30, 60, and 90 and; ii) oral Placebo for vitamin D once a day for 4 months (from Day 1 through Day 120)
88822122|NCT02247830|Experimental|2 Urea cream|Experimental Group 02: usual care + Topical Application of Urea cream. The intervention will be characterized by topical application of urea-based cream on the area irradiated three times daily throughout the period of realization of radiotherapy sessions, in addition to nursing consultation with instructional material (usual care).
88822123|NCT02247830|No Intervention|Control Group (Usual Care)|The usual care consists of nursing consultation with instructional material (Manual guidelines) that is already done systematically in service. This query is made with all patients starting radiotherapy. Here, guidelines are provided about skin care and hydration, using topical moisturizing soap solution over the bath. Such information is contained in the manual that is provided to the patient during the consultation.
88822124|NCT04769882|Active Comparator|Er:YAG laser therapy group|The removal of caries was performed with Er:YAG laser (Doctor Smile, Lambda SRL,Italy) with BOOST handpiece to cut the enamel and open the cavity, and 90° handpiece to remove the carious dentin with tips of 800 µ in diameter and 8 mm or 12 mm in length, in relation to the depth and distance of the lesion.
88822125|NCT04769882|No Intervention|Traditional therapy group|The removal of caries was performed with manual and rotating instruments, such as dentin spoon (ASA Dental S.p.a.), turbine (NSK Dental Italy S.r.l.) with diamond burs (Kerr Dental Italia S.r.l.) to cut the enamel and open the cavity and drill handpiece (KaVo Dental Italia S.r.l.) with tungsten carbide burs (Kerr Dental Italia S.r.l.) to remove the infected dentin.
88822126|NCT03005834||Atherosclerotic CVD|Atherosclerotic cardiovascular diseases (CVD) included coronary artery diseases, aortic diseases and peripheral artery diseases.
88822127|NCT03005834||Non-atherosclerotic CVD|Non-atherosclerotic cardiovascular diseases (CVD) were any CVD except atherosclerotic CVD and congenital CVD.
88822128|NCT03005912|Placebo Comparator|Conventional acoustic telephony|Telephone speech comprehension in hearing aided patients (Cochlear Implant or GN Resound hearing aid) for a conventional mobile phone call with acoustic transmission of the speech signal.
89355416|NCT03552757|Experimental|Semaglutide 1.0 mg|Participants will receive semaglutide 1.0 mg and semaglutide placebo I during 68-week treatment period in addition to a reduced-calorie diet and increased physical activity.
88822129|NCT03005912|Active Comparator|Conventional bluetooth telephony|Telephone speech comprehension in hearing aided patients (Cochlear Implant or GN Resound hearing aid) for a conventional mobile phone call with direct bluetooth transmission of the speech signal to the cochlear implant or hearing aid.
88822130|NCT03005912|Active Comparator|VoIP acoustic telephony|Telephone speech comprehension in hearing aided patients (Cochlear Implant or GN Resound hearing aid) for a VoIP mobile phone call with acoustic transmission of the speech signal.
88822131|NCT03005912|Active Comparator|VoIP bluetooth telephony|Telephone speech comprehension in hearing aided patients (Cochlear Implant or GN Resound hearing aid) for a VoIP mobile phone call with direct bluetooth transmission of the speech signal to the cochlear implant or hearing aid.
88999319|NCT02902588|Experimental|ICG washout kinetics assessment|Intravenous administration of 5-10 mg indocyanine green (ICG-PULSION), once per subject
88822132|NCT02841267|Active Comparator|Low Dose, Cohort 1|4 subjects will be enrolled in cohort 1 and will receive an initial dose of 5mg/kg PF 06252616 IV every 4 weeks. Following 32 weeks of treatment and a safety review, if no stopping rules have been met, subjects will be receive an additional 32 weeks of treatment with 40 mg/kg PF 06252616 IV every 4 weeks.
88822133|NCT02841267|Active Comparator|Middle dose, Cohort 2|8 subjects will be enrolled in cohort 2 and receive 20 mg/kg of PF 06252616 IV every 4 weeks for 32 weeks.
88822134|NCT02841267|Active Comparator|High dose, Cohort 3|8 subjects will be enrolled in cohort 3 and receive 40 mg/kg of PF06252616 IV every 4 weeks for 32 weeks.
89355417|NCT03552757|Experimental|Semaglutide 2.4 mg|Participants will receive semaglutide 2.4 mg and semaglutide placebo II during 68-week treatment period in addition to a reduced-calorie diet and increased physical activity.
89355418|NCT03552757|Placebo Comparator|Semaglutide placebo I/II|Participants will receive semaglutide placebo I and II during 68-week treatment period in addition to a reduced-calorie diet and increased physical activity.
89355419|NCT03050346||CAD patients|Consecutive patients scheduled for a coronary angiography on the basis of cardiac symptoms and a test positive for inducible coronary ischemia, who are affected by one-vessel or two-vessel CAD at the time of the OS-CMR with breathing maneuvers (HVBH).
89355420|NCT03050346||Healthy subjects|Subjects without current or pre-existing cardiovascular and lung disease and absence of medication with cardiovascular effects.
88822135|NCT03005756|Experimental|Robot-assisted Radiofrequency Ablation|CT-guided radiofrequency ablation of hepatocellular carcinoma using needle guiding robot
88822136|NCT03000920|No Intervention|1_Control|Classic screening invitation strategy with at least an invitation mail and then one or two reminder by mail if necessary.
88822137|NCT03000920|Experimental|2_SMS Reminder 1|Invitation by mail then reminder 1 by SMS if necessary then reminder 2 by mail if necessary
89355421|NCT03730103|No Intervention|Historical control group|The investigators will use data from a historical control group discharged on POD 1 after minimally invasive sacrocolpopexy to examine Aim 1 and Aim 2. This is a cohort of 60 women matching our eligibility criteria from a prospective randomized trial of two different types of lightweight polypropylene mesh (IRB #14-354). This study completed recruitment 2017. It consists of a group of women who underwent minimally invasive sacrocolpopexy using the same surgical approaches, at the same institutions
89355422|NCT03730103|Experimental|Same day discharge group|47 women will be recruited for same day discharge after laparoscopic sacrocolpopexy. We will compare aim 1 and 2 (serious adverse events and procedure-related costs) between the two groups
89355423|NCT03345706|Experimental|Selective cerebral hypothermia|Selective cerebral hypothermia
88822138|NCT03000920|Experimental|3_SMS before invitation|One SMS a few days before the Invitation by mail and then one or two reminder(s) by mail if necessary.
88822139|NCT03000920|Experimental|4_SMS before invitation + SMS Reminder 1|One SMS a few days before the Invitation by mail then reminder 1 by SMS if necessary then reminder 2 by mail if necessary
88822140|NCT03006471|Experimental|Dapagliflozin|Dapagliflozin capsules, 10 mg, one per day before breakfast during 12 weeks.
88822141|NCT03006471|Placebo Comparator|Placebo|Placebo capsules, one per day before breakfast during 12 weeks.
88822142|NCT05044052|Experimental|Intervention Group - Viral prescription pad + emphasis|Physicians in this group will receive their usual MyPractice: Primary Care report from Ontario Health. This report will include antibiotic prescribing indicators as well as a link to the viral prescription pad. As part of the intervention, these physicians will also receive additional emphasis on the viral prescription pad by 1) encouraging it in the dissemination email of the MyPractice feedback report, and (2) mailing a paper version of the viral prescription pad with instructions on embedding the viral prescription pad into the recipient's EMR.
88822143|NCT05044052|No Intervention|Control group|Physicians in this group will receive their usual MyPractice: Primary Care report from Ontario Health. This report will include antibiotic prescribing indicators as well as a link to the viral prescription pad. This group will not receive any additional emphasis on the viral prescription pad and will not receive a paper copy in the mail.
88822144|NCT02988947|Experimental|Intervention Group (PNE+HyP)|Patients in this group will have 3 pre-surgical + 1 (or 2) reinforcement sessions in adition to standard TKA care. These interventions are based on Pain Neuroscience Education and Hypnosis and delivered according to standardized scripts.
88822145|NCT02988947|No Intervention|Control Group|No intervention / Standard care
88822146|NCT05042726|Experimental|cTBS First|The first stage, participants received cTBS treatment for a total of 10 times during two weeks, then followed up for eight weeks; the second stage, participants are treated with pseudo-stimulation for a total of 10 times during two weeks, then followed up for 8 weeks similarly.
88822147|NCT05042726|Experimental|Pseudo-stimulation First|The first stage, participants received pseudo-stimulation treatment for a total of 10 times during two weeks, then followed up for eight weeks; the second stage, participants are treated with cTBS for a total of 10 times during two weeks, then followed up for 8 weeks similarly.
88822148|NCT03000842|Experimental|Healthy Subjects|transcutaneous vagal nerve stimulation
88822149|NCT03000842|Experimental|Hypertensive Subjects|transcutaneous vagal nerve stimulation
88822150|NCT03005600||Asian Indian|"Recruitment to the Indian cohort will be carried out in urban areas of Chennai and be coordinated from Madras Diabetes Research Foundation (MDRF).~As a part of their routine care, all pregnant women will undergo regular blood tests at presentation, a dating scan if the last menstrual period is unknown and an ultrasound at 20 weeks of pregnancy for foetal anomalies.~3400 pregnant women in early pregnancy will be studied in this cohort."
88822151|NCT03005600||African|"Recruitment to the Kenyan cohort will be based and coordinated from Moi Teaching and Referral hospital (MTRH). The bulk of the recruitment will happen at MTRH with significant contribution from Usain Gisu District hospital (UGDH) and Medi-Heal.~4000 pregnant women in early pregnancy will be studied in this cohort."
88822152|NCT03000764|Experimental|Biomarkers|
88822153|NCT03005678|Active Comparator|Denosumab|denosumab subcutaneous 60mg every 6 months
88822154|NCT03005678|Placebo Comparator|Alendronate|alendronate 70mg orally every week
88822155|NCT02247908|Experimental|Graphic Warning|Graphic warnings that include text and an image depicting a health effect of smoking will be applied on labels that cover the top half of the front and back of participants' cigarette packs each week for 4 weeks. Within the graphic warning condition, participants will be assigned to receive 1 of 4 warnings for 4 weeks. The text for these warnings was selected from the 2009 Family Smoking Prevention and Tobacco Control Act and the images were proposed by the FDA.
89355424|NCT03345706|Active Comparator|Regular hypothermia|Regular hypothermia
89355425|NCT03003468|Experimental|Arm A - Phase Ib|"Dose Escalation Cohort Cohort 1 will consist of 3-6 patients who will receive pembrolizumab 200mg IV on Day 1 of each 21 day cycle. Imprime PGG will be administered at 2mg/kg on Day 1,8, and 15 of cycles 1-4, and on Day 1 of cycles 5-16. On Day 1 of each cycle, the Imprime PGG intravenous infusion is given first followed 15-30 minutes later by the pembrolizumab.~Experimental: Arm A - Phase II Investigational Treatment The maximum safe dose of Imprime PGG in combination with pembrolizumab (as determined in the phase Ib cohort) will be given on Day 1,8, and 15 for cycles 1-4, and on Day 1 of cycles 5-16.~Cohort 2 will consist of 3-6 patients who will receive pembrolizumab 200mg IV on Day 1 and Imprime PGG at 4mg/kg on Day 1,8, and 15 for Cycles 1-4 and on Day 1 only for Cycles 5-16. On Day 1 of each cycle, the Imprime PGG intravenous infusion is given first followed 15-30 minutes later by the pembrolizumab."
89355426|NCT02511808|Active Comparator|Step-up Treatment: MI|After receiving one session of Brief Advice (BA), participants will be assessed at week 4 for response to this treatment. Those who are deemed non-responders to the BA will be randomly assigned to receive either Motivational Interviewing (MI) or more BA. In this arm, participants will receive two sessions of MI.
88822156|NCT02247908|Active Comparator|Surgeon General's Warning|Labels with Surgeon General's Warning text will be applied to the side of participants' cigarette packs each week for 4 weeks, on top of the Surgeon General's Warning printed by the manufacturer.
89355427|NCT02511808|Other|Control: BA|After receiving one session of Brief Advice (BA), participants will be assessed at week 4 for response to this treatment. Those who are deemed non-responders to the BA will be randomly assigned to receive either Motivational Interviewing (MI) or more BA. In this arm, participants will receive one additional session of BA.
88822157|NCT03000296|Experimental|Hematopoietic Stem Cell Transplantation|High doses immunosuppression Cyclophosphamide (200 mg/kg total dose for four days) and rabbit antithymocyte globulin (6.5 mg/kg total dose for four days) followed by unselected autologous hematopoietic stem cell transplantation rescue.
89355428|NCT02511808|Active Comparator|Step-up Treatment: Specialist Care|After receiving one session of Brief Advice (BA) and two sessions of Motivational Interviewing (MI) or one session of BA over the first 8 weeks of the study, participants will be assessed at week 8 for response to this treatment. Those who are deemed non-responders will be randomly assigned to receive Behavioral Self-Control Training (BSCT) or more MI if they were randomized to MI at week 4 or five sessions of combined MI and BSCT or one more session of MI if they were randomized to BA at week 4. In this arm, participants will receive four sessions of BSCT if they received MI at the previous randomization or five sessions of combined MI and BSCT if they received BA at the previous randomization.
88822158|NCT03008889|Experimental|Participants taking NAC|Participants randomized to the active treatment study arm will receive gradually increasing doses of N-acetylcysteine (NAC) given as a dissolving tablet in juice or water. NAC is an over-the-counter oral dietary supplement that will be used a higher than usual doses in this study.
88822159|NCT03008889|Placebo Comparator|Participants taking Placebo|Participants randomized to placebo will receive dissolving tablets identical in size and appearance to the active treatment. Placebo capsules contain inactive ingredients.
88822160|NCT03005210|Experimental|T test|Test drug (Magicbuvir Plus)1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
88822161|NCT03005210|Active Comparator|B reference (first dose)|Reference drug (Harvoni) 1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
88822162|NCT03005210|Active Comparator|B reference (second dose)|Reference drug (Harvoni) 1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
88822163|NCT03010137|Placebo Comparator|Standard Closure|After surgical closure is complete, the patient receives standard of care operative incision treatment (dermabond/topical skin adhesive).
88822164|NCT03010137|Active Comparator|Incisional Negative Pressure Wound Therapy|After surgical closure is complete, an incisional negative pressure wound therapy device is applied to the incision in its entirety. This device is placed on the wound, sterilely, in the operating room, at the conclusion of the procedure. The incisional negative pressure wound therapy device is to remain in place for 7 days, and is removed in clinic after completion.
88822165|NCT03000218|Experimental|UDCA 8 wks|Day 1 to 56: Ursodeoxycholic acid 300mg bid
88822166|NCT03000218|Experimental|UDCA for 4wks/UDCA+metformin for 4wks|Day 1 to 28: Ursodeoxycholic acid 300mg bid Day 29 to 56: Ursodeoxycholic acid 300mg and Metformin 500mg bid
88822167|NCT03000218|Placebo Comparator|Placebo|Day 1 to 56: Placebo bid
88822168|NCT03010683|Active Comparator|liraglutide|
88822169|NCT03010683|Active Comparator|Metformin|
88822170|NCT04877678|Active Comparator|Treatment group|Participants will be treated with bepotastine.
88822171|NCT04877678|Placebo Comparator|Placebo group|Participants will be treated with identical looking placebo.
88822172|NCT02918097|Experimental|Lithium Carbonate|"Group Started: Lithium Carbonate (900mg-1500mg)~Subjects evaluated for responsiveness every 2 weeks. Responsive to treatment patients remain in the same step. Max. step duration of 8 weeks.~First step: Monotherapy with Lithium (LSL 0.6-0.8). Non responsive patients: 2nd step.~Second step: Monotherapy with lithium (LSL 1.0-1.2). Non responsive patients: 3rd step.~Third step: Lithium + Sertraline (50mg-200mg). Non responsive patients: 4th step.~Fourth step: Lithium + Nortriptyline 100mg. Non responsive patients: 5th step.~Fifth step: Lithium + Nortriptyline 100mg + Sertraline (100mg-200mg). Non responsive patients: 6th step~Sixth step: Lithium + Nortriptyline 100mg + Sertraline 200mg + Risperidone (1mg-6mg)."
88822173|NCT03000140|Experimental|High Intensity Interval Training|Cycling on cycle ergometers (OXFORDTM, model BE2601, OXOFORD Inc, Santiago, Chile) for 1 min at a subjective intensity of 8-10 points of the modified Borg scale of 1-10 points, and interspersed by inactive (without movement over the bicycle) of 2 minutes as recovery period.
88822174|NCT03000140|Active Comparator|Control group|Pre-hypertensive group was compared with healthy groups in the 2 manin variables systolic/diastolic blood pressure, as well as in other co-variables in pre-post changes. Thus, after the training intervention, and following the R and NR classification, we will compare the NR prevalence between both Pre-hypertensive and Healthy group.
88822175|NCT03000062|Experimental|Intervention group|"12 Family physicians in primary care will constitute the Intervention group. They will enroll 10 patients each from their ordinary practice. The physicians will be provided with a specific course on the treatment model of the study, including how to collect and register data. They will have a detailed manual indicating the content of each visit.~Following recruitment and consent, the patient will meet for the first visit in the study one week later. At this visit the patient will be provided with detailed information on the content and preparation for all meals. Data will be collected.~The manual describes a diet in accordance with official guidelines providing the patient 1600Kcal per day.~The following visits will take place after 4 weeks, 8 weeks, 4 months, 8 months and 12 months from the first visit. Data will be collected at all visits, and also at 6 and 12 months follow-up."
88875164|NCT02494518|Active Comparator|Forced Exercise & Upper Extremity Repetitive Task Practice|"Participants will perform the following:~45 minutes of cycling on a recumbent stationary bike with a specialized motor that forces the individual to cycle approximately 30-35% faster than your self-selected speed~45 minutes of upper extremity repetitive arm exercises"
88875165|NCT02494518|Active Comparator|Voluntary Exercise & Upper Extremity Repetitive Task Practice|"Participants will perform the following:~45 minutes of cycling on a recumbent stationary bike at your self-selected speed~45 minutes of upper extremity repetitive arm exercises"
88875166|NCT02494518|Active Comparator|Stroke Education & Upper Extremity Repetitive Task Practice|"Participants will perform the following:~45 minutes of stroke education~45 minutes of upper extremity repetitive arm exercises"
89355429|NCT02511808|Other|Control: MI|After receiving one session of Brief Advice (BA) and two sessions of Motivational Interviewing (MI) or one session of BA over the first 8 weeks of the study, participants will be assessed at week 8 for response to this treatment. Those who are deemed non-responders will be randomly assigned to receive Behavioral Self-Control Training (BSCT) or more MI if they were randomized to MI at week 4 or five sessions of combined MI and BSCT or one more session of MI if they were randomized to BA at week 4. In this arm, participants will receive one session of MI if they received MI at the previous randomization or two sessions of MI if they received BA at the previous randomization.
89355430|NCT02506972|Other|30g oats|Classic Quick Quaker Oats
89355431|NCT02506972|Other|30g oats plus 9g sugar|Classic Quick Quaker Oats
89355432|NCT02506972|Other|40g oats|Classic Quick Quaker Oats
89355433|NCT02506972|Other|60g oats|Classic Quick Quaker Oats
88999320|NCT02902588|Other|Pulse oximeter monitor|Monitoring of a person's oxygen saturation (SO2), peripheral oxygen saturation
88999321|NCT02902588|Experimental|Gadolinium washout kinetics assessment|20 mL of gadolinium (Gadovist, Bayer, Germany) injection at 5 mL/s, once per subject
88999322|NCT02902627|Experimental|Metastatic cancer|
89355434|NCT02506972|Other|22g cream of rice cereal|Cream of Rice Cereal, B&G Foods, Inc.
89355435|NCT02506972|Other|29g cream of rice cereal|Cream of Rice Cereal, B&G Foods, Inc.
89355436|NCT02506972|Other|33g cream of rice cereal|Cream of Rice Cereal, B&G Foods, Inc.
89533489|NCT04484272|Experimental|Experimental Group|(Self-monitoring of pain, stress, and opioid use + alerts/reminders + use of YCWS [three video banks of RDE + Support]). Self-monitoring, using video banks, and getting support elements comprise the YCWS intervention. The YCWS App is comprised of three tabs displayed across the top of the screen, namely, self-monitoring, video banks, and support. During the short-term trial (Weeks 1-8), patients will monitor their stress and pain daily and have access to three video banks from which to choose their daily intervention. We will send automated system-generated alerts/reminders every 24 hours to experimental group patients via phone call, text, or email to facilitate intervention use. During the long-term period (months 3-6), only system-generated alerts/reminders will be available.
88999323|NCT02902432|Placebo Comparator|SCCHN|patients with advanced squamous cell carcinoma of the head and neck.IMRT.
89533490|NCT04463719|Experimental|Intervention group|Counseling using the electronic conversation aid
89533491|NCT04463719|Active Comparator|Control Group|Routine counseling only
89533492|NCT04443413|Experimental|Arm I (x-ray therapy)|Within 12 weeks of the last breast cancer surgery or last dose of adjuvant chemotherapy and no sooner than 14 days since the last chemotherapy, patients undergo x-ray therapy over 25 fractions in the absence of disease progression or unacceptable toxicity. Optionally, patients may then receive a 4-fraction boost of x-ray therapy.
89533493|NCT04443413|Experimental|Arm II (proton beam radiation therapy)|Within 12 weeks of the last breast cancer surgery or last dose of adjuvant chemotherapy and no sooner than 14 days since the last chemotherapy, patients undergo proton beam radiation therapy over 5 fractions in the absence of disease progression or unacceptable toxicity. Optionally, patients may receive a concurrent 5-fraction boost of proton beam radiation therapy.
89533494|NCT04441905|Experimental|Cohort 1|0.3 mg/kg of SAR440894 (n=6) or placebo (n=2) administered once during a 60-minute intravenous (IV) infusion. 2 sentinel subjects will receive dosing for review of safety data (SAR440894 n=1, placebo n=1) before remainder of cohort.
88999324|NCT02902432|Experimental|SCCHN-Endostar|patients with advanced squamous cell carcinoma of the head and neck.Endostar will be continuously intravenous pumped (7.5 mg/m2) for 14 days (d1-d14) during chemotherapy and for 5 days/week(d-5-d-1, d3-d7, d10-d14, d17-d21)during IMRT.
88999325|NCT02902471|Experimental|Group A|Patients with bronchiolitis obliterans syndrome after bone marrow transplantation
88999326|NCT02902042|Experimental|Arm A: Triple therapy|Encorafenib, binimetinib and pembrolizumab. Doses as determined in phase I
88999327|NCT02902042|Experimental|Arm B: Pembrolizumab alone|Pembrolizumab with a dose of 200 mg every 3 weeks.
88999328|NCT02902159|Experimental|BWW|Free access to online peer support through BWW for 6 months
88999329|NCT02902159|Experimental|MZ|Access to NHS Moodzone Information Only
88999330|NCT02901847|Other|Intervention|PAD tailored care
88999331|NCT02901925|Experimental|ABY-029|ABY-029 will be administered prior to surgery. Probe will be used in vivo to determine if signal is detectable, and ex vivo tissue pathology will measure extent of binding with EGFR positive tumor tissue.
88999332|NCT02901964|Experimental|Group Hip Abductor Exercise|12 treatments sessions at 6 weeks: Heating, lower limb stretching, tibiofemoral and patellofemoral mobilization, strengthening the quadriceps, hamstrings, triceps sural and hip abductors.
88999333|NCT02901964|Active Comparator|Group Hip Aductor Exercise|12 treatments sessions at 6 weeks: Heating, lower limb stretching, tibiofemoral and patellofemoral mobilization, strengthening the quadriceps, hamstrings, triceps sural and hip aductors.
88999334|NCT02901886|Experimental|Intensive smoking cessation intervention|"The intervention includes 1) Individual motivational counseling in combination with 2) nicotine replacement therapy.~The intervention consists of five individual motivational counselling sessions, each lasting 20 to 40 minutes over a period of six weeks with a trained smoking cessation counsellor. The principles of motivational counselling are based on the trans theoretical model of change. The smoking cessation counsellor has also been trained in motivational counselling techniques specific to this intervention.~2. Nicotine replacement therapy The participants in the intervention group will be offered nicotine replacement therapy (NRT) free of charge and if accepted it will be tailored individually according to the Fagerström's Test for Nicotine Dependence.~The participants will note their tobacco and NRT consumption in a smoking diary."
88999335|NCT02901886|No Intervention|Control|The control group will receive the standard treatment and care in the rheumatology outpatient clinic. The participants will be encouraged to write a diary describing their tobacco use during the trial period. If participants in the control group express an interest in receiving smoking cessation counselling, they will be informed about municipal programs.
88999336|NCT04681300||Patients with atopic Prurigo nodularis , non-atopic Prurigo nodularis or atopic dermatitis|
88999337|NCT04681300||Patients with plastic surgery interventions|
88999338|NCT04681222||LFCN|Patients received LFCN + PENG blocks
88999339|NCT04681222||Wound Infiltration|Patients received wound infiltration + PENG blocks
88999340|NCT03455335|Experimental|low dose cohort|20 million hMSCs .
89355437|NCT02506972|Other|44g cream of rice cereal|Cream of Rice Cereal, B&G Foods, Inc.
88999341|NCT03455335|Experimental|mid dose cohort|40 million hMSCs
88999342|NCT03455335|Experimental|high dose cohort|80 million hMSCs .
88999343|NCT02901808||NOMI|Patients suffering from NOMI
88999344|NCT02901808||No-NOMI|Patients not suffering from NOMI
88999345|NCT00196092|Other|1|Roll-in
88999346|NCT00196092|Other|2|Surgical
88999347|NCT00196092|Other|3|Standard Risk
88999348|NCT00196092|Other|4|High Risk
88999349|NCT00196092|Other|5|Compassionate Use
88999350|NCT00196092|Other|6|Treatment for females.
89355438|NCT03727841|Experimental|1/Arm 1 Marizomib|Marizomib at days 1, 8, and 15 of each 28-day cycle
88999351|NCT00196092|Other|7|Standard Risk Continued Access
88999352|NCT00196092|Other|8|High Risk Continued Access
88999353|NCT02901613|No Intervention|Retrospective|Standard dry sterile dressing
88999354|NCT02901613|Experimental|Prospective|Negative-pressure wound therapy
88999355|NCT02901652|Active Comparator|NIPPV|"noninvasive respiratory support devices~This group receiving Nasal Intermittent Positive Pressure Ventilation (NIPPV) treatment."
89355439|NCT03727841|No Intervention|P/Pregnancy Evaluation|Data collection on pregnancy, birth and Health of Child
88822176|NCT03000062|No Intervention|Control group|"12 Family physicians in primary care will constitute the Control group. They will enroll 10 patients each from their ordinary practice. The physicians will not be provided with any information of the treatment model of the study but they will have all information about how to collect and register data.~The patients on this group will also sign consent to provide data and therefore they will know about the study but they do not get any specific information about weight loss other than the general information that their physician may tell them.~The patients in the Control Group will be asked to give data on inclusion visit and again 12 months later, and also at 6 and 12 months thereafter (i.e. 0, 12, 18 and 24 months from inclusion)."
89355440|NCT03345628||sedated|infants requiring intubation and ventilation who received sedatives for at least 3 days
88822177|NCT02999516|Experimental|Motor imaginary|Intervention with Motor imaginary with video
88822178|NCT02999516|Experimental|Non Motor imaginary|Intervention with Rest without motor imaginary
88822179|NCT02999516|Experimental|tDCS|tDCS stimulation during 20 minutes in the motor cortex.
88822180|NCT02999516|Sham Comparator|tDCS sham|tDCS stimulation during 30 seconds in the motor cortex and then 19 minutes and 30 seconds without any stimulation.
88822181|NCT02999516|Experimental|Neurofeedback|EEG monitoring in real time with positive feedback in the computer screen when participants motor cortex is activated.
88822182|NCT02999516|Sham Comparator|Neurofeedback sham|EEG monitoring in real time with randomized feedback in the computer screen despite the motor cortex activation.
88822183|NCT05408585|Active Comparator|"SIFIB with concentration A"|"The patients were placed in a supine position, and their skin was disinfected and draped. A linear ultrasonography probe was positioned parasagittally and slightly medially on the anterior superior iliac spine. The sartorius, iliacus, internal oblique muscles and deep circumflex iliac artery were visualized. A 80-mm peripheral nerve block needle was advanced, using the in-plane technique, from cranial to caudal until the tip was positioned between the internal oblique and iliacus muscles. Suprainguinal fascia iliaca block will be performed with concentration A."
88822184|NCT05408585|Active Comparator|"SIFIB with concentration B"|"The patients were placed in a supine position, and their skin was disinfected and draped. A linear ultrasonography probe was positioned parasagittally and slightly medially on the anterior superior iliac spine. The sartorius, iliacus, internal oblique muscles and deep circumflex iliac artery were visualized. A 80-mm peripheral nerve block needle was advanced, using the in-plane technique, from cranial to caudal until the tip was positioned between the internal oblique and iliacus muscles.Suprainguinal fascia iliaca block performed with concentration B"
88822185|NCT03005132||Normal brain tissue|Normal brain tissue from GBM patients
88822186|NCT03005132||GBM tissues|GBM tissues from GBM patients
88822187|NCT03005132||Metastasis tissues|Metastasis tissues from GBM patients
88822188|NCT04749407||chemoradiotherapy|
88822189|NCT05460182|Experimental|CAF+CTG|"After local anaesthesia, a split-full-split thickness flap was elevated. The papillae adjacent to the involved tooth were then de-epithelialized. A gentle root debridement was performed.~A 1-2-mm-thick CTG was harvested using a single incision approach from the palate in the area between the second pre-molar and the second molar. The wound on the donor site of the palate was then sutured. The graft was positioned on the instrumented root surface immediately apical or at the level of the CEJ and then stabilized using a compressive crossing suture, anchored to the periosteum apical to the graft and closed with a palatal knot. The flap was coronally displaced 1-2 mm above the CEJ and sutured"
88822190|NCT05460182|Active Comparator|CAF|After local anaesthesia, a split-full-split thickness flap was elevated. The papillae adjacent to the involved tooth were then de-epithelialized. A gentle root debridement was performed. The flap was coronally displaced 1-2 mm above the CEJ and sutured
88822191|NCT02999204|Active Comparator|Vitamin D3 5,000 units per week|Patient receive a dose that is considered within the standard dosing range for Vitamin D3 for one year.
88822192|NCT02999204|Experimental|Vitamin D3 50,000 units per week|Patients receive a more aggressive Vitamin D3 dosing regimen of 50,000 units weekly for the first 3 months. At this point Vitamin D3 levels are measured. If the patient is Vitamin D3 replete (>75 nmol/L) then the dose is reduced to the equivalent of 25,000 units per week for the next 9 months. If the level is below this threshold then 50,000 units per week is continued for the next 9 months
88822193|NCT03012477|Experimental|cisplatin + AZD1775|"Treatment will consist of one cycle of cisplatin monotherapy (cisplatin 75 mg/m2 IV x1) followed by combination therapy of AZD1775 plus cisplatin starting 21 days(1 cycle) later.~AZD1775 will be administered 200 mg as twice daily oral dosing predetermined dosing schedule, in combination with Cisplatin predetermined dosage every 21 days.~At least 10 patients will undergo a research biopsy within 5-48 hours after beginning cisplatin (Cycle 1 Day 1) and then again within 5-8 hours after the last dose of AZD1775 in cycle 2 (Cycle 2 Day 3)."
88822194|NCT02276963|Experimental|Ublituximab Plus Glucocorticoids|Ublituximab 450 mg intravenously once on day 1, plus glucocorticoids 1000 mg intravenously daily on days 1-5
88999356|NCT02901652|Active Comparator|BİPAP|"noninvasive respiratory support devices~This group receive Bi-Level Positive Airway Pressure (BIPAP) treatment."
89355441|NCT03345628||non-sedated|infants who received respiratory support by non-invasive ventilation and were not sedated
88999357|NCT02901691|Experimental|Deaf children|
88999358|NCT02901691|Placebo Comparator|healthy volonteer children|
88999359|NCT02901730|Experimental|532nm laser group|LPI with 532nm laser.
88999360|NCT02901730|Experimental|561nm laser group|LPI with 561nm laser.
88999361|NCT02901535|Active Comparator|Control|Spirometry in baseline Spirometry - 20 weeks
89355442|NCT03552523|Other|Usual Care|Subject will wear a continuous glucose monitoring device (the Dexcom G5) and use the study provided glucose meter.. Subject will not change their prescribed home insulin therapy regimen during this arm whether that be an insulin pump or multiple daily injections.
89355443|NCT03552523|Experimental|Bionic Pancreas|During this arm the subject will ONLY use our bionic pancreas device with an insulin only configuration using a rapid-acting insulin analog. Subjects will wear a continuous glucose monitoring device (the Dexcom G5) as part of the bionic pancreas, and use the study provided glucose meter.
89355444|NCT03345550|Experimental|Omega-3 Polyunsaturated Fatty Acid Treatment Arm|Participants randomized to this study arm will receive 6g DHA+EPA for one month followed by 1.2 g DHA+EPA for two months. Capsules contain fish oil 1000 mg (contains 500 mg DHA & 100 mg EPA) or placebo capsules.
88822195|NCT02999048|No Intervention|control group|Patients in the control group received conventional therapy for 17 days.conventional therapy consists of: (1) dehydration therapy by 20%mannitol (Tianjin Bane Medical Drugs Ltd., Co., China.) with the dosage from 125 to 250 ml every 8 h for 7 days depending on their clinically presumed intracranial pressure, (2) therapy to deal with complications including glucose-lowering treatment for hyperglycemia, antihypertensive treatment for hypertension, anti-inflammatory treatment for infection, acid inhibitor for peptic ulcer, and (3) supportive therapy, such as physical cooling, nutritional support, fluid, and electrolyte balance, which was provided as needed.
88822196|NCT02999048|Other|intervention group|Patients in the intervention group received the same conventional therapy as in the control group for 3 days, brain CT was re-scanned at the 4th day, and was then given conventional therapy plus XUESAITONG Injection,which was mainly composed of Panax notoginseng saponins for 14 days from the 4th day.
88822197|NCT03017937|Experimental|Q- collar|All subjects will wear 3 sizes of the q-collar and ultrasound images of the jugular vein will be measured with each collar. Also, each subject will wear a pressure collar and ultrasound images of the jugular vein will be captured at each pressure point (0.1-0.5)
88822198|NCT02999282|Experimental|Presymptomatic real tDCS|Asymptomatic subjects - 10 days anodal transcranial direct current stimulation
88822199|NCT02999282|Sham Comparator|Presymptomatic sham tDCS|Asymptomatic subjects - 10 days sham transcranial direct current stimulation
88822200|NCT02999282|Experimental|Symptomatic real tDCS|Symptomatic patients - 10 days anodal transcranial direct current stimulation
88822201|NCT02999282|Sham Comparator|Symptomatic sham tDCS|Symptomatic patients - 10 days sham transcranial direct current stimulation
88822202|NCT03019107|Experimental|VentFree Stimulation|Breath synchronized abdominal NMES
88822203|NCT03019107|Sham Comparator|Sham Stimulation|Sham breath synchronized abdominal NMES
88822204|NCT04784780|Experimental|Elobixibat|AJG533 (elobixibat) 10 mg orally once a day before meals for 12 weeks
88822205|NCT04784780|Placebo Comparator|Placebo|AJG533 placebo orally once a day before meals for 12 weeks
88822206|NCT04770584|Other|PTSD group|After the initial screening / baseline assessment visit, Post Traumatic Stress Disorder participants will undergo two Experimental Visits, which included participation in an emotional learning paradigm and an fMRI scan over the course of two consecutive days. Participants will be asked to look at pictures on a computer screen to measure physiological response physiological response (skin conductance response) and brain responses using a functional Magnetic Resonance Imaging (fMRI) machine. These two visits will be scheduled within a month from the baseline assessment visit.
88822207|NCT04770584|Other|Trauma-Exposed Healthy Controls (TEHC)|After the initial screening / baseline assessment visit, trauma-exposed healthy participants will undergo two Experimental Visits, which included participation in an emotional learning paradigm and an fMRI scan over the course of two consecutive days. Participants will be asked to look at pictures on a computer screen to measure physiological response physiological response (skin conductance response) and brain responses using a functional Magnetic Resonance Imaging (fMRI) machine. These two visits will be scheduled within a month from the baseline assessment visit.
88822208|NCT02919111|Experimental|Ga-68 labeled PSMA-11 PET|PSMA PET imaging: Patients will receive Ga-68 labeled PSMA-11 PET and then undergo PET/CT or PET/MRI approximately 55-70 minutes later.
88822209|NCT02919423|Active Comparator|10 Hz TMS|active TMS will be administered
88822210|NCT02919423|Active Comparator|1 Hz TMS|active TMS will be administered
88822211|NCT03004898|Experimental|education arm|multidisciplinary education: multidisciplinary CKD education involving case management nurse, dietitian, social worker, pharmacists.
88822212|NCT02919657|Active Comparator|Genepro Gen2 Protein|"1 tablespoon Serving of Genepro Gen2 Protein daily will be used in each subject.~Intervention: Weekly blood draws will determine the effect on blood protein levels."
88822213|NCT02919657|Active Comparator|Whey Protein Isolate|"30g Serving of Whey Isolate Protein will be used daily in each subject.~Intervention: Weekly blood draws will determine the effect on blood protein levels."
88822214|NCT03004742|Experimental|Flavonoid|Flavonoid supplement
88822215|NCT03004742|Placebo Comparator|Placebo|Placebo
88822216|NCT03004820|Experimental|Remote Ischemic Conditioning|RIC (remote ischemic conditioning) consists of five cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on bilateral upper limbs twice a day. Medication strategy is based on physician's best judgement.
88822217|NCT02850159|Experimental|dual-mode group|the dual-mode NIBS with high-frequency rTMS and tDCS simultaneously
88822218|NCT02850159|Active Comparator|rTMS group|high-frequency rTMS and sham tDCS
88822219|NCT02999126|Experimental|Group 1|Patients < 65 years old Propofol 1% TCI induction using plasma concentration, Marsh model (Ke0=0.26 min-1) at 1 mcg/ml, increasing the target concentration by 0.5 mcg/ml every minute until LOC. Remifentanil TCI 6 ng/ml and a neuromuscular relaxant will be administered afterwards in order to perform endotracheal intubation. CeLOC propofol concentration will be established and it will be observed for another 30 minutes. If BIS <40 or >65 propofol target concentration will be modified by 0,3 mcg/ml.
88822220|NCT02999126|Experimental|Group 2|Patients ≥ 65 years old Propofol 1% TCI induction using plasma concentration, Marsh model (Ke0=0.26 min-1) at 1 mcg/ml, increasing the target concentration by 0.5 mcg/ml every minute until LOC. Remifentanil TCI 6 ng/ml and a neuromuscular relaxant will be administered afterwards in order to perform endotracheal intubation. CeLOC propofol concentration will be established and it will be observed for another 30 minutes. If BIS <40 or >65 propofol target concentration will be modified by 0,3 mcg/ml.
88822221|NCT03019887|Experimental|reduction group|dose reduction of antipsychotics at a rate not exceeding 50mg chlorpromazine equivalent/week
88822222|NCT02998970|Placebo Comparator|Placebo|The placebo group acts as a control group. This is in order to objectively isolate empagliflozin's effect on cardiac structure and function as determined by CMR imaging.
88999362|NCT02901535|Experimental|Intervention|Spirometry in baseline Teleconsultation Telemonitoring Spirometry - 20 weeks
89355445|NCT03345550|Placebo Comparator|Placebo Arm|Participants randomized to this study arm will receive placebo drug for 3 months.
89355446|NCT03728101|Experimental|Single arm|"Dabigatran etexilate~Simvastatin + Dabigatran etexilate"
88822223|NCT02998970|Active Comparator|Empagliflozin|The study medication (Jardiance) is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death. The generic name is empagliflozin and will be provided by Boehringer-Ingelheim. If the patient is randomized into the study drug group patients will receive empagliflozin 10 mg tablets once daily for a duration of 6 months.
88822224|NCT05422742|Active Comparator|SRP|Scaling and rooting planning
88822225|NCT05422742|Experimental|SRP + MM|Scaling and rooting planning in combination with minocycline microspheres
88822226|NCT05422742|No Intervention|Periodontally-Healthy Subjects|No Intervention
88822227|NCT02919813|Active Comparator|M-gCBT Group|Mindfulness Based Group Cognitive Behavior Therapy (M-gCBT Group) is a type of counseling that teaches women to have more control over their pain.
88822228|NCT02919813|Active Comparator|Educational Seminars|Educational seminars teach women about the different aspects of PLV that affect emotional and physical health.
88822229|NCT05406752|Experimental|paracetamol Uniflash (125 mg/ 1.25 mL)|1 sachet of paracetamol Uniflash 125mg / 1.25 mL
88822230|NCT00550043|Experimental|Cohort 1: Treatment Group A|INCB018424 15 mg twice daily (BID) or matching placebo
88822231|NCT00550043|Experimental|Cohort 2: Treatment Group B|INCB018424 5 mg BID or matching placebo
88822232|NCT00550043|Experimental|Cohort 2: Treatment Group C|INCB018424 25 mg BID or matching placebo
88822233|NCT00550043|Experimental|Cohort 2: Treatment Group D|INCB018424 50 mg once daily (QD) or matching placebo
88822234|NCT00550043|Placebo Comparator|Placebo|Matching placebo, oral
88822235|NCT02247362|Experimental|Vaccine Dose Group 12 mcg|VAX2012Q, 12 mcg dose
88822236|NCT02247362|Experimental|Vaccine Dose Group 20 mcg|VAX2012Q, 20 mcg dose
88822237|NCT02247362|Experimental|Vaccine Dose Group 16 mcg|VAX2012Q; 16 mcg dose
88822238|NCT02247362|Placebo Comparator|Vaccine Diluent|Vaccine Diluent, F147, as placebo control
88822239|NCT02920749|Other|Sevoflurane group A|Anaesthesia was maintained with sevoflurane (1-2% end-tidal concentration, MAC 1.0-1.5) in 50% air and 50% oxygen mixture.
88822240|NCT02920749|Other|Sevoflurane group B|Anaesthesia was maintained with sevoflurane (1-2% end-tidal concentration, MAC 1.0-1.5) in 50% air and 50% oxygen mixture. Sevoflurane dosing was set to maintain target BIS levels of 40 to 60 and MAP for controlled hypotension within 60-85 mmHg.
89355447|NCT03186378|Experimental|Exposure Group|This group is open label and allows for up to 16 subjects with 21 or more molluscum lesions will be enrolled. They must complete all blood draws or will be replaced. Intervention Drug: Subjects will receive treatment to their molluscum contagiosum lesions per protocol with VP-102 using the VP-102 applicator.
88822241|NCT02920749|Other|Propofol group C|During anaesthesia TIVA was applied with a protocol (6 to 8 mg/kg/h propofol).
88822242|NCT02920749|Other|Propofol group D|Propofol dosing was set to maintain target BIS levels of 40 to 60 and MAP for controlled hypotension within 60-85 mmHg.
89355448|NCT03186378|Experimental|Standard Group|This group is open label allowing up to 16 subjects with 20 lesions or less to be enrolled. Drug: Subjects will receive treatment to their molluscum lesions with VP-102 using the VP-102 applicator.
89355449|NCT02511964|Experimental|Interval Training at 1% incline|Six Sessions of High Intensity Interval Running (100% VO2Max) at 1% incline; Group metabolically balanced.
89355450|NCT02511964|Experimental|Interval Training at 10% incline|Six Sessions of High Intensity Interval Running (100% VO2Max) at 10% incline; Group metabolically balanced.
89355451|NCT02511964|No Intervention|Control|Only Dependent Variables Measures
89355452|NCT03844217|Experimental|Macimorelin 0.5mg/kg body weight|"Visit 1: oral Macimorelin stimulation test with the dose of 0.5mg/kg body weight Macimorelin.~Visit 2: After a washout-phase of 1 week, participants will undergo the oral Macimorelin stimulation test with the dose of 0.75mg/kg body weight. Study procedures are equal compared to visit 1.~Macimorelin 0.75mg/kg body weight"
89355453|NCT04170972|Experimental|Exercise and vivo insulin stimulation in TBC1D4 gene-variants|Acute exercise and in vivo insulin stimulation in homozygote carriers of a p.ARg684T TBC1D4 gene-variant.
89355454|NCT04170972|Experimental|Exercise and vivo insulin stimulation in matched controls|Acute exercise and in vivo stimulation in none carriers (matched controls) of the p.Arg684T TBC1D4 gene-variant.
89355455|NCT02515864|Experimental|FYU-981 anticipated therapeutic dose|Drug: FYU-981, FYU-981 Placebo, Moxifloxacin Placebo (Oral)
88822243|NCT02248142||RLS patients|
88822244|NCT04667780|Experimental|Colchicine|"This arm will receive Standard COVID-19 care + Colchicine~The Colchicine treatment includes an initial dose of 1.5 mg (1 mg and 0.5 mg two hours after), followed by 0.5 mg every 12 hours during the next 7 days and 0.5 mg every 24 hours until the completion of 14 days of total treatment. In patients receiving ritonavir or lopinavir or with reduced renal clearance (<50 ml/min/1.37m2), weight <70 kg or age >75 years old, the dose will be adjusted to the half."
88822245|NCT04667780|Other|Control - Standard COVID-19 care|This arm will receive standard COVID-19 care as per the hospital guidelines.
88822246|NCT02854059|Experimental|Treatment IdeS (0.25 mg/kg)|A single 30 minutes i.v. infusion of IdeS (0.25 mg/kg). Following an evaluation of safety and efficacy in 3 patients receiving 0.25 mg/kg there will be a potential to increase the IdeS dose to 0.5 mg/kg for the remaining 3 patients.
88822247|NCT02854059|Experimental|Treatment IdeS (0.50 mg/kg)|A single 30 minutes i.v. infusion of IdeS (0.50 mg/kg).
88822248|NCT02248220||Parkinson's disease patients|
88822249|NCT03004508|Experimental|Gingko biloba Extract|
88822250|NCT03004508|Placebo Comparator|Placebo|
88822251|NCT03021759|No Intervention|Control|No intervention
88822252|NCT03021759|Experimental|Active choice|Physicians will be asked to review a list of their patients eligible for statin therapy who are not yet prescribed a statin and make an active choice whether or not to prescribe a statin.
88822253|NCT03021759|Experimental|Active choice with social comparison feedback|Physicians will be asked to review a list of their patients eligible for statin therapy who are not yet prescribed a statin and make an active choice whether or not to prescribe a statin. Physicians will receive social comparison feedback informing them of how their performance compares to their peers
88822254|NCT03004586|Experimental|EBUS-TBNA:First Using a 25-Gauge Needle Then 22-gauge Needle|Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) performed by first using a 25-gauge needle, followed by a 22-gauge needle.
88999363|NCT02901769|Experimental|Depressed suicide attempters|20 subjects
88999364|NCT02901769|Experimental|Depressed patients with past history of|20 subjects
89355456|NCT02515864|Experimental|FYU-981 supratherapeutic dose|Drug: FYU-981, Moxifloxacin Placebo (Oral)
89355457|NCT02515864|Placebo Comparator|Placebo|Drug: FYU-981 Placebo, Moxifloxacin Placebo (Oral)
89355458|NCT02515864|Active Comparator|Moxifloxacin|Drug: Moxifloxacin, FYU-981 Placebo (Oral)
89355459|NCT00687596|Experimental|TAC-101|Participants with advanced hepatocellular carcinoma who had previously received Sorafenib (as first line therapy) were administered a dose of 20 milligram per day (mg/day) of TAC-101 (as second line treatment) oral tablets within 1 hour post morning meals on Days 1 to 14 followed by a recovery period on Days 15 to 21 in 21-day cycle until disease progression or participant met a treatment discontinuation criterion.
88999365|NCT02901769|Experimental|Depressed patients with no history of|20 subjects
88999366|NCT02901769|Placebo Comparator|Healthy controls|20 subjects
88999367|NCT00196131|No Intervention|0|
88999368|NCT02901418||control group|In this group,these children born in about two hours, we injected HBIG 200 iu and 10 micrograms of hepatitis b vaccine in their left and right thigh respectively, then injected 10 micrograms again in 1 and 6 months.
89355460|NCT00687596|Placebo Comparator|Placebo|Participants with advanced hepatocellular carcinoma who had previously received Sorafenib (as first line therapy) were administered a matching placebo for TAC-101 oral tablets within 1 hour post morning meals on Days 1 to 14 followed by a recovery period from on 15 to 21 in 21-day cycle until disease progression or participant met a treatment discontinuation criterion.
89355461|NCT02507206|Experimental|DAR 0-100A then Placebo|15 mg is dissolved in 150 cc NS administered over 30 minutes x 3 consecutive days. Subjects will return a minimum of two weeks later for Visit 5 to receive drug (if randomized initially to placebo) or placebo (if randomized to drug).
88822255|NCT03004586|Experimental|EBUS-TBNA:First Using a 22-Gauge Needle Then 25-gauge Needle|Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) performed by first using a 22-gauge needle, followed by a 25-gauge needle.
89355462|NCT02507206|Placebo Comparator|Placebo then DAR 0-100A|15 mg dissolved in 150 cc NS saline is administered over 30 minutes x 3 consecutive days. Subjects will return a minimum of two weeks later for Visit 5 to receive drug (if randomized initially to placebo) or placebo (if randomized to drug).
89355463|NCT02507206|No Intervention|Healthy Control|patients without diagnosis of SPD
89355464|NCT03844373|Experimental|Experimental|Patients established on an oral nutritional supplement, being prescribed oral nutritional supplement (ONS) providing at least 300 kcal/day will be changed onto an equivalent prescription of STOCKHOLM for a period of 9 days.
89355465|NCT02892409|Active Comparator|Clarithromycin + Amoxicillin + Bismuth + Lansoprazole|Clarithromycin 500 milligram (mg), tablets, orally, twice daily, along with amoxicillin 1000 mg capsules, orally, twice daily, tripotassium bismuth dicitrate 600 mg, tablets, orally, twice daily, and lansoprazole 30 mg, capsules, orally, twice daily on Days 1 to 14.
89355466|NCT02892409|Experimental|Clarithromycin + Amoxicillin + Bismuth + TAK-438|Clarithromycin 500 mg, tablets, orally, twice daily, along with amoxicillin 1000 mg, capsules, orally, twice daily, tripotassium bismuth dicitrate 600 mg, tablets, orally, twice daily, and TAK-438 20 mg, tablets, orally, twice daily on Days 1 to 14.
89355467|NCT03219216|Experimental|Arm A: Glecaprevir (GLE)/Pibrentasvir (PIB) for 8 weeks|Arm A: Hepatitis C virus (HCV) genotype (GT) 1 to GT6 participants without cirrhosis (fibrosis stage F2 to F3) received glecaprevir (GLE)/pibrentasvir (PIB) 300 mg/120 mg once daily (QD) for 8 weeks.
88822256|NCT03004430|Experimental|MAM|Mantra Meditation Group
88822257|NCT03004430|Active Comparator|PMR|Progressive Muscle Relaxation Group
89355468|NCT03219216|Experimental|Arm B: GLE/PIB for 12 Weeks|Arm B: HCV GT1 to GT6 participants with compensated cirrhosis (F4) received GLE/PIB 300 mg/120 mg QD for 12 weeks.
89355469|NCT05668169|Experimental|Family-centered support program for caregivers of stroke survivors|Participants receive usual hospital care and our intervention
89533495|NCT04441905|Experimental|Cohort 2|1 mg/kg of SAR440894 (n=6) or placebo (n=2) administered once during a 60-minute intravenous (IV) infusion. 2 sentinel subjects will receive dosing for review of safety data (SAR440894 n=1, placebo n=1) before remainder of cohort.
89533496|NCT04441905|Experimental|Cohort 3|3 mg/kg of SAR440894 (n=6) or placebo (n=2) administered once during a 60-minute intravenous (IV) infusion. 2 sentinel subjects will receive dosing for review of safety data (SAR440894 n=1, placebo n=1) before remainder of cohort.
89533497|NCT04441905|Experimental|Cohort 4|10 mg/kg of SAR440894 (n=6) or placebo (n=2) administered once during a 60-minute intravenous (IV) infusion. 2 sentinel subjects will receive dosing for review of safety data (SAR440894 n=1, placebo n=1) before remainder of cohort.
89533498|NCT04441905|Experimental|Cohort 5|20 mg/kg of SAR440894 (n=6) or placebo (n=2) administered once during a 60-minute intravenous (IV) infusion. 2 sentinel subjects will receive dosing for review of safety data (SAR440894 n=1, placebo n=1) before remainder of cohort.
88999369|NCT02901418||experimental group|In this group,about 2 hours after birth, respectively injecting HBIG 200 IU and 10 micrograms of hepatitis b vaccine in the right and left thigh, and in 1 and 6 months again taking 10 micrograms of standard solution, in addition, offering the additional injection of 200 IU HBIG within 24 hours.
89533499|NCT04433091|Active Comparator|2-HOBA|2-Hydroxybenzylamine(2-HOBA) 250 mg three tabs TID (po) for seven days prior to ablation and 28 days post ablation.
89533500|NCT04433091|Placebo Comparator|Placebo|Placebo- three tabs TID (po) for seven days prior to ablation and 28 days post-ablation
89355470|NCT05668169|No Intervention|No Intervention: Control group|Participants receive only usual hospital care
89355471|NCT02507128|Experimental|GLP-1 group|The treatment started 30 min before PCI with a dose of 1.8 mg liraglutide (the treatment was administered in the ambulance).
89355472|NCT02507128|Placebo Comparator|Control group|the treatment started 30 min before PCI with a dose of 1.8 mg placebo (the treatment was administered in the ambulance).
89355473|NCT03731377|Experimental|Intubated group|Patient in this group will receive general anesthesia with endotracheal tube intubation to perform one lung ventilation. Patient will be paralyzed and controlled ventilation will be implied.
89355474|NCT03731377|Experimental|Non-intubated group|Patient in this group will receive general anesthesia with laryngeal mask insertion. Patients in this group will not be paralyzed and keep spontaneous breathing to maintain one lung ventilation.
88999370|NCT02901379|Experimental|Atorvastatin 80mg|Subjects who will receive atorvastatin 80mg for two weeks
88999371|NCT02901379|Active Comparator|Atorvastatin 10mg|Subject who will receive atorvastatin 10mg
89355475|NCT02507050|Experimental|Intervention|Patients randomised to stop beta blockers and start Ivabradine. Initial dose of 5mg BD, titrated to 7.5mg BD if possible.
88999372|NCT00196170|Experimental|1|8mm tip ablation catheter for ablation of cavotricuspid isthmus
89355476|NCT02507050|No Intervention|Standard therapy|Bisoprolol given as standard beta blocker treatment i.e. Bisoprolol (maximum dose 10mg OD).
89355477|NCT03844529|Experimental|Sunmax FULLSGEN with Lidocaine|A subject would only receive single injection treatment(day 1) using Sunmax FULLSGEN , and there would be 6 follow-up visits at 4th, 12th, 24th, 36th and 52nd week after injection treatment.
89533501|NCT04428281|Experimental|Cohort A1 RO7248824|Participants 5-12 Years
89176958|NCT03704857|Experimental|Foraminal enlargement with cryotherapy|Unirradicular teeth will be submitted to endodontic treatment with foraminal enlargement, instrumentation with reciprocating rotation, sodium hypochlorite as irrigant, cryotherapy with saline solution, lateral condensation filling with MTA Fillapex. The analysis of the postoperative symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th, 14th and 30th days and by the clinical evaluation of edema in 48 and 72 hours. The periapical lesion repair will be evaluated clinically and radiographically at 3, 6, 12, 18 and 24 months. The longevity of rehabilitations will be performed clinically and radiographically for 24 months. In addition, patients will respond a quality of life questionnaire (OHIP-14) on the day of endodontic treatment, on the 7th day and on the 30th day.
89176959|NCT03704857|Experimental|Foraminal enlargement with cryotherapy and AH Plus|Unirradicular teeth will be submitted to endodontic treatment with foraminal enlargement, instrumentation with reciprocating rotation, sodium hypochlorite as irrigant, cryotherapy with saline solution, lateral condensation filling with AH Plus. The analysis of the postoperative symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th, 14th and 30th days and by the clinical evaluation of edema in 48 and 72 hours. The periapical lesion repair will be evaluated clinically and radiographically at 3, 6, 12, 18 and 24 months. The longevity of rehabilitations will be performed clinically and radiographically for 24 months. In addition, patients will respond a quality of life questionnaire (OHIP-14) on the day of endodontic treatment, on the 7th day and on the 30th day.
89176960|NCT03704857|Experimental|Foraminal enlargement with ozone therapy|Unirradicular teeth will be submitted to endodontic treatment with foraminal enlargement, instrumentation with reciprocating rotation, sodium hypochlorite as irrigant, ozone therapy, lateral condensation filling with MTA Fillapex. The analysis of the postoperative symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th, 14th and 30th days and by the clinical evaluation of edema in 48 and 72 hours. The periapical lesion repair will be evaluated clinically and radiographically at 3, 6, 12, 18 and 24 months. The longevity of rehabilitations will be performed clinically and radiographically for 24 months. In addition, patients will respond a quality of life questionnaire (OHIP-14) on the day of endodontic treatment, on the 7th day and on the 30th day.
89355478|NCT03844529|Active Comparator|Sumax FACIALGAIN collagen Implant with Lidocaine|A subject would only receive single injection treatment(day 1) using Sumax FACIALGAIN collagen Implant with Lidocaine, and there would be 6 follow-up visits at 4th, 12th, 24th, 36th and 52nd week after injection treatment.
88822258|NCT02921061|Experimental|Treatment (decitabine, G-CLAM)|"INDUCTION: Patients receive decitabine IV over 1 hour on days 1-10. Patients also receive filgrastim SC on days 0-5, cladribine IV over 2 hours on days 1-5, cytarabine IV over 2-4 hours on days 1-5, and mitoxantrone hydrochloride IV over 60 minutes on days 1-3.~RE-INDUCTION: Patients who do not achieve MRDneg CR after first induction are eligible for re-induction. Patients receive the same treatment as during induction except that decitabine is omitted.~CONSOLIDATION THERAPY: Beginning 6 weeks after achieving MRDneg CR or CR/CR with CRi after induction and/or re-induction, patients are eligible to receive filgrastim, cladribine, and cytarabine as in Induction. Treatment may be repeated for up to 4 courses in the absence of disease progression or unacceptable toxicity. Subsequent consolidation cycles would be given after recovery from the previous cycle (roughly 4-6 weeks)."
88822259|NCT03004352|Experimental|control subjects-retrograde flow|Retrograde flow was induced in control subjects.
88822260|NCT03004352|No Intervention|control subjects-control|
88822261|NCT03004352|Experimental|hypoxemic COPD-retrograde flow|Retrograde flow was induced in hypoxemic COPD patients.
88822262|NCT03004352|No Intervention|hypoxemic COPD-control|
88822263|NCT03004352|Experimental|normoxemic COPD-retrograde flow with oxygen|Retrograde flow was induced in COPD patients with normalized arterial oxygen saturation.
88822264|NCT03004352|Experimental|normoxemic COPD-control with oxygen|COPD patients with normalized arterial oxygen saturation.
88822265|NCT02921295|Active Comparator|Sidekick Stubbies|"Conventional Stubby prostheses were used for baseline measures. In the sequential crossover design, articulated stubby prostheses (Sidekick manufactured by College Park Ind.) were used as intervention"
88822266|NCT05289674|Experimental|Interventional study with a pre-, post-test design|"After the subject are diagnosed with infection (tuberculosis/TB or urinary tract infection/ UTI), they will receive 400 kcal/day (96 g/day divided 4 times consumption) of high calorie formula prescribed by the researcher (A pediatrician) for 90 days consumption ( 8640 g). the subject will be monitored every 30 days for acceptance, tolerance, weight increment, length increment evaluation.~The blood are withdrawn at day 0 (before invention) and day 90 (after intervention) to measure the IL-6 and IL-10 levels"
88822267|NCT03023553|Other|TIV Group|Healthy adult males and females, 18-30 years of age. Immunization with standard trivalent, inactivated influenza vaccine (TIV), Fluzone®.
89355479|NCT03728023|Experimental|AZD4205|Single ascending dose: 5mg, 20mg, 50mg, 100mg, 150mg Multiple ascending dose: low, medium and high dose once daily X 14 days
88822268|NCT03023553|Other|LAIV Group|Healthy adult males and females, 18-30 years of age. Immunize with intranasal live, attenuated influenza vaccine (LAIV), FluMist®.
89355480|NCT03728023|Placebo Comparator|Placebo|placebo single dose in SAD and once daily for 14 days
89355481|NCT03344926|Experimental|ACTsmart|ACT treatment via a smart phone application
88822269|NCT02248298|Experimental|2h-AFL-PDT|All 440 AK lesions of the 93 patients were randomly assigned to treatment with MAL-PDT (3h-MAL-PDT) or AFL-PDT with 2 hours (2h-AFL-PDT) and 3 hours (3h-AFL-PDT) of incubation time, using restricted randomization, with a computer-generated program.
88822270|NCT02248298|Active Comparator|3hr-AFL-PDT|All 440 AK lesions of the 93 patients were randomly assigned to treatment with MAL-PDT (3h-MAL-PDT) or AFL-PDT with 2 hours (2h-AFL-PDT) and 3 hours (3h-AFL-PDT) of incubation time, using restricted randomization, with a computer-generated program.
88822271|NCT02248298|Active Comparator|3hr-MAL-PDT|All 440 AK lesions of the 93 patients were randomly assigned to treatment with MAL-PDT (3h-MAL-PDT) or AFL-PDT with 2 hours (2h-AFL-PDT) and 3 hours (3h-AFL-PDT) of incubation time, using restricted randomization, with a computer-generated program.
88822272|NCT02921841|Experimental|DSTAR|Digital HIV Prevention intervention developed to specifically address the needs of youth in mental health treatment. Sessions introduce affect regulation and cognitive monitoring in sexual situations, and provide basic sexual health skills and education.
88822273|NCT02921841|Active Comparator|DHEALTH|Digital general health promotion intervention. Time and attention matched intervention that targets health behaviors relevant to youth including exercise, nutrition, sleep, and smoking. Basic information about HIV and sexuality is also included.
88822274|NCT03004118|Active Comparator|Ursochol|About 10.5mg/kg/day of ursochol (calculated before start study for each participant individually) (combination of ursochol 150 and 300) divided in 2 doses per day (during lunch and dinner). Oral intake. Tablets. 4 weeks.
88822275|NCT03004118|Placebo Comparator|Placebo|Same amount of pills as ursochol (calculated before start study for each participant individually) divided in 2 doses per day (during lunch and dinner). Oral intake. Tablets. 4 weeks.
88822276|NCT03004196|Active Comparator|Control Group|They were not given probiotic toothpaste or chlorhexidine mouthwash
88822277|NCT03004196|Experimental|Probiotic Group|"Patients were asked to brush twice daily with given G.D Probiotic Toothpaste and were asked not to eat or drink anything for half-an-hour."
88822278|NCT03004196|Experimental|Chlorhexidine Mouthwash Group|"Patients were asked to rinse daily with Dr. Reddy's Clohex chlorhexidine mouthwash of 10ml without dilution for three times a day after meals (Breakfast, Lunch Dinner) for 3-4 minutes and were asked not to eat or drink anything for half-an-hour."
88822279|NCT03004274|Active Comparator|Running sutures|Deep layers will be closed using running sutures
88822280|NCT03004274|Experimental|Interrupted sutures|Deep layers will be closed using interrupted sutures
88822281|NCT02281409|Experimental|Phase I: Mogamulizumab (KW-0761)|Patients will be enrolled to receive a weekly intravenous (IV) dose of KW-0761 ranging from 0.5 mg/kg to 10.0 mg/kg as feasible starting on Day 1 for 4 weeks. In the absence of toxicity or progression of disease, patients may continue receiving KW-0761 for up to 12 months. Subsequent treatment courses will consist of an infusion every other week. Following end of treatment or treatment completion date, a 24-week short term follow-up (STFU) period of observation will begin.
88822282|NCT02281409|Experimental|Phase II: Mogamulizumab (KW-0761)|Phase II of the study will enroll a total of 48 subjects, 16 patients in 3 tumor-specific expansion cohorts each treated at the RP2D (MTD, or highest dose tested in Phase I part of trial).
88822283|NCT02858349|Experimental|Arm 1|4-week control period with no intervention and 4-weeks of high-intensity interval training
88822284|NCT02282111|Active Comparator|EUS-CNB|Using a linear EUS with color and pulsed Doppler to scan the area for vessels, the lesion was then sampled with a 22-gauge beveled needle (using the slow capillary suction and fanning techniques with 5 to 15 to-and-fro movements with each pass). A total of 4 passes were performed and after that the procedure terminated.
88822285|NCT02282111|Active Comparator|SINK|Using a conventional needle-knife sphincterotome connected to an electrosurgical unit, and under direct endoscopic vision, a 6-12mm linear incision was made from the periphery of the lesion to its highest convexity zone. A conventional biopsy forceps was then deeply introduced through the hole, and 2 bites were obtained per pass. A total of 4 passes were performed by passing the biopsy forceps through the incision on each occasion. The mucosal incision was then closed with endoclips whenever possible.
88822286|NCT03023709|Other|Pilot phase|Participants will receive the current seasonal quadrivalent, inactivated influenza vaccine (IIV4)/Fluzone® given intramuscularly to confirm the safety of administering the seasonal influenza vaccine 3-14 days prior to tonsillectomy.
88822287|NCT03023709|Other|Study phase|Participants will be given the current year's quadrivalent, live, attenuated seasonal influenza vaccine (LAIV4)/FluMist® intranasally 3-14 days prior to tonsillectomy.
88822288|NCT05215184||Chronic Pain Patients|
88822289|NCT05215184||Healthy Controls|
88822290|NCT02248376|Experimental|Gel +|Patients aged of more than 18 years-old coming for a natural miscarriage who will have the stick gel application at the end of the scraping surgery.
88822291|NCT02248376|No Intervention|Gel -|Patients aged of more than 18 years-old coming for a natural miscarriage who will not have the non-stick gel application at the end of the scraping surgery.
88822292|NCT02859441|Experimental|E10030 and Ranibizumab|Intravitreal injections of E10030 and Ranibizumab
88822293|NCT03004040||Case|older adult patients (over the age of 65) admitted to Health Sciences North with laboratory confirmed influenza illness (LCII)
88822294|NCT03004040||Control|matched control subjects (non-LCII)
88822295|NCT05198882|Experimental|LITT technology|Laser-induced thermocoagulation of intracerebral lesions responsible for drug-resistant epilepsy.
88822296|NCT02859597|Experimental|High Flow Nasal Cannula|High flow nasal cannula will be utilized to deliver oxygen to morbidly obese patients undergoing deep sedation for gastrointestinal procedures.
88822297|NCT02859597|Active Comparator|Nasal Cannula|Typical nasal cannula will be utilized to deliver oxygen to morbidly obese patients undergoing deep sedation for gastrointestinal procedures.
89355482|NCT02878044|Experimental|Implementation Arm|
88822298|NCT01880099|Placebo Comparator|placebo|Placebo (sugar Pill) will be given daily for 7 weeks.
88822299|NCT01880099|Active Comparator|galantamine 8mg|Galantamine extended release (8mg) will be given daily for 7 weeks.
89355483|NCT01199315|Experimental|1|Oral capsule. Dose single and followed by 5-day repeated dosing. Specific doses depend on panel.
89355484|NCT01199315|Placebo Comparator|2|Oral capsule. Dose single and followed by 5-day repeated dosing.
89533502|NCT04428281|Experimental|Cohort A2 RO7248824|Participants 5-12 Years
89176961|NCT03704857|Experimental|Foraminal enlargement with ozone therapy and AH Plus|Unirradicular teeth will be submitted to endodontic treatment with foraminal enlargement, instrumentation with reciprocating rotation, sodium hypochlorite as irrigant, ozone therapy, lateral condensation filling with AH Plus. The analysis of the postoperative symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th, 14th and 30th days and by the clinical evaluation of edema in 48 and 72 hours. The periapical lesion repair will be evaluated clinically and radiographically at 3, 6, 12, 18 and 24 months. The longevity of rehabilitations will be performed clinically and radiographically for 24 months. In addition, patients will respond a quality of life questionnaire (OHIP-14) on the day of endodontic treatment, on the 7th day and on the 30th day.
89533503|NCT04428281|Experimental|Cohort A3 RO7248824|Participants 5-12 Years
89533504|NCT04428281|Experimental|Cohort A4 RO7248824|Participants 5-12 Years
89533505|NCT04428281|Experimental|Cohort A5 RO7248824|Participants 5-12 Years
89533506|NCT04428281|Experimental|Cohort B1 RO7248824|Participants 1-4 Years
89533507|NCT04428281|Experimental|Cohort B2 RO7248824|Participants 1-4 Years
88999373|NCT00196170|Experimental|2|irrigated tip ablation catheter for ablation of cavotricuspid isthmus
89533508|NCT04428281|Experimental|Cohort B3 RO7248824|Participants 1-4 Years
88999374|NCT00196170|Experimental|3|cryo 10mm tip ablation catheter for ablation of cavotricuspid isthmus
88999375|NCT00196170|Experimental|4|Cryo 6.5mm tip ablation catheter for ablation of cavotricuspid isthmus
88999376|NCT02901340||Borderline isolated oligohydramnios|"Borderline idiopathic isolated oligohydramnios was defined according to the four quadrants technical with ultrasound examination and diagnosed with amniotic fluid index>5.0 and ≤8.0cm.~The borderline idiopathic isolated oligohydramnios group was formed of the patients who meets the inclusion criteria and between 34-37 weeks gestation (n:40)"
89533509|NCT04428281|Experimental|Cohort B4 RO7248824|Participants 1-4 Years
89533510|NCT04428281|Experimental|Cohort B5 RO7248824|Participants 1-4 Years
89533511|NCT04428281|Experimental|Cohort EA1 RO7248824|New participants (age 5-12) enrolling directly in the LTE part
88822300|NCT01880099|Active Comparator|Galantamine 16mg|Galantamine extended release (16mg) will be given daily for 5 weeks starting at week 3 after a two week titration with 8mg galantamine.
88822301|NCT04287803|Experimental|intervention Arm|Methoxyflurane will be introduced and data will be captured to inform future multicentred step wedge design study. (This study is a feasibility study)
88822302|NCT02860845|Experimental|Boric acid and probiotics|Boric acid with L.gasseri and L.rhamnosus
88822303|NCT02860845|Active Comparator|Antibiotic/Antifungal|Antibiotic: Clindamicine Antifungal: Clotrimazol
88822304|NCT03003884|Experimental|Remimazolam Tosilate 1|IV of Remimazolam Tosilate at 5mg for initial dose
88822305|NCT03003884|Experimental|Remimazolam Tosilate 2|IV of Remimazolam Tosilate at 7mg for initial dose
88822306|NCT03003884|Experimental|Remimazolam Tosilate 3|IV of Remimazolam Tosilate at 8mg for initial dose
88822307|NCT03003884|Experimental|Remimazolam Tosilate 4|IV of Remimazolam Tosilate at 5mg for initial dose.At the end of the endoscopy, flumazenil was injected.
88822308|NCT03003884|Active Comparator|Propofol|IV of Propofol at 1.5mg/kg for initial dose
88822309|NCT02923167|Experimental|Robotic-assisted training of the hand|Training will be performed using the Amadeo®. The computer-controlled device maintains participants' forearm in a secure position using Velcro straps. Each training session will include 30 minutes of active movements that can be divided into up to 3 bouts of 10 minutes depending on participant's fatigue. Training will take place up to 4 times per week for a total of 18 sessions over up to 7 weeks. Sessions will last approximately 60 minutes (including setup, training, and rest between each bout).
88822310|NCT02248454|Experimental|Insulin bolus dose/type|Lispro insulin, dose calculated by modeling analysis
88822311|NCT01881113|Experimental|AC-170 0.24%|
88822312|NCT01881113|Placebo Comparator|AC-170 0%|
88822313|NCT05140694|Experimental|Empagliflozin|Empagliflozin 10mg p.o. once daily (available to control over ~25mg)
88822314|NCT05140694|Experimental|Dulaglutide|Dulaglutide 0.75mg s.c. once weekly (available to control over ~1.5mg)
88822315|NCT05140694|Experimental|Empagliflozin and Dulagludie|Empagliflozin 10mg p.o. once daily and dulaglutide 0.75mg s.c. once weekly
88822316|NCT03003806|Experimental|DreaMed Advisor Pro|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted using the DreaMed Advisor Pro
88822317|NCT03003806|Active Comparator|Control group-medical guided recommendations|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted by the medical team
89533512|NCT04428281|Experimental|Cohort EA2 RO7248824|Participants continuing from MAD cohorts A1 and A2
88822318|NCT02987699|Experimental|Full Dosage|Full Dosage Chemotherapy regimen administered by HAI
89533513|NCT04428281|Experimental|Cohort EA3 RO7248824|Participants continuing from MAD cohorts A3 and A4
88822319|NCT02987699|Experimental|Low Dosage of 5-Fu|Low Dose of 5-Fu Chemotherapy regimen administered by HAI
88822320|NCT02987699|Experimental|Low Dosage of oxaliplatin|Low Dose of oxaliplatin Chemotherapy regimen administered by HAI
88822321|NCT05673044|Experimental|modified Studer ileal neobladder|the segment of the iso-peristaltic segment is 8 cm and the total length of the ileum used is 40 cm instead of 60 cm.
88822322|NCT05673044|Experimental|modified spiral ileal neobladder|the chimney of the spiral neobladder will be an angled one instead of straight.
88822323|NCT03003728|Experimental|Study Treatment|Elotuzumab 10 mg/kg via intravenous infusion on days -16, -3, 12, and 26; Melphalan 200 mg/m2 Ivia intravenous infusion on day -3; ASCT on day -2; ENK infusion on day 0; ALT-803 (Interleukin-15 superagonist) 10 ug/kg via subcutaneous injection on days 1, 8, 15, and 22.
89176962|NCT00802074|Active Comparator|Group A|Period 1-Raltegravir 400mg BID Period 2- Fosamprenavir 1400mg BID Period 3- Fosamprenavir 1400mg BID + Raltegravir 400mg BID
89176963|NCT00802074|Active Comparator|Group B|Period 1-Raltegravir 400mg BID Period 2-Fosamprenavir 1400mg BID + Raltegravir 400mg BID Period 3 Fosamprenavir 1400mg BID
89176964|NCT00802074|Active Comparator|Group C|Period 1-Raltegravir 400mg BID Period2- Fosamprenavir 700mg BID + Ritonavir 100mg BID Period 3- Fosamprenavir 700mg BID + Ritonavir 100mg BID + Raltegravir 400mg BID
89176965|NCT00802074|Active Comparator|Group D|Period 1-Raltegravir 400mg BID Period 2- Fosamprenavir 700mg BID + Ritonavir 100mg BID + Raltegravir 400mg BID Period 3-Fosamprenavir 700mg BID + Ritonavir 100mg BID
89533514|NCT04428281|Experimental|Cohort EA4 RO7248824|Participants continuing from MAD Cohort A5
89533515|NCT04428281|Experimental|Cohort EB1 RO7248824|New participants (age 1-4) enrolling directly into the LTE
89533516|NCT04428281|Experimental|Cohort EB2 RO7248824|Participants continuing from MAD cohorts B1 and B2
88822324|NCT01883141|Experimental|Electrophysiological Study|Subjects will receive pacing from one right ventricular lead and one left ventricular catheter/lead with multiple LV pacing spots during electrophysiological study procedure
88822325|NCT00559247|Experimental|or Placebo - Dose Panel 1|Oral Suspension, 10 mg
88822326|NCT00559247|Experimental|or Placebo - Dose Panel 2|Oral Suspension 50 mg
88822327|NCT00559247|Experimental|or Placebo - Dose Panel 3|Oral Suspension, 200 mg
88822328|NCT00559247|Experimental|or Placebo - Dose Panel 4|Oral Suspension or Solution, 2.5 to 600 mg
88822329|NCT00558311|Experimental|Clazosentan|A continuous intravenous infusion of clazosentan was started within 56 hours post-aSAH and was scheduled to continue during the hospitalization until Day 14 post-aSAH, or at least until Day 10.
88822330|NCT00558311|Placebo Comparator|Placebo|A continuous intravenous infusion of placebo-matching clazosentan was started within 56 hours post-aSAH and was scheduled to continue during the hospitalization until Day 14 post-aSAH, or at least until Day 10.
88822331|NCT03003650|Experimental|Symetis ACURATE TF™|Patient implanted with ACURATE TF™Bioprosthesis.
88822332|NCT02248610||Rivaroxaban|All participants will be treated with rivaroxaban.
88822333|NCT05351723|Experimental|Exercise + cognitive training + education|Intervention group: each session comprises (1) 50 min of physical exercise, (2) 20 min of break time or education on dementia and lifestyle habits, and (3) 50 min of cognitive training.
88822334|NCT05351723|Other|Education|Control group: education on dementia and lifestyle habits.
88822335|NCT03003416||OZURDEX®|Patients prescribed dexamethasone intravitreal implant (OZURDEX®) in clinical practice for the treatment of Diabetic Macular Edema.
88822336|NCT02988869|Experimental|Tiotropium/Formoterol|Tiotropium/Formoterol 18/12 mcg Inhalation Powder (1 puff) once daily via Discair®
88822337|NCT02988869|Active Comparator|Tiotropium|Tiotropium 18 mcg Inhalation Powder (1 puff) once daily via Handihaler
88822338|NCT02988869|Active Comparator|Tiotropium + Formoterol|Tiotropium 18 mcg Inhalation Powder (1 puff) once daily via Handihaler + Formoterol 12 mcg Inhalation Powder (1 puff) twice daily via Aerolizer
88822339|NCT03028467|Experimental|GSK3196165 Dose 1|Participants will receive GSK3196165 Dose 1 weekly as a single subcutaneous (SC) injection by an un-blinded administrator. There will be 5 weekly injections (Days 1, 8, 15, 22 and 29), then every other week (EOW) injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants will also receive a stable dose of methotrexate during the Treatment Period.
88822340|NCT03028467|Experimental|GSK3196165 Dose 2|Participants will receive GSK3196165 Dose 2 weekly as a single SC injection by an un-blinded administrator. There will be 5 weekly injections (Days 1, 8, 15, 22 and 29), then EOW injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants will also receive a stable dose of methotrexate during the Treatment Period.
88822341|NCT03028467|Experimental|GSK3196165 Dose 3|Participants will receive GSK3196165 Dose 3 weekly as a single SC injection by an un-blinded administrator. There will be 5 weekly injections (Days 1, 8, 15, 22 and 29), then EOW injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants will also receive a stable dose of methotrexate during the Treatment Period.
88822342|NCT03028467|Placebo Comparator|Placebo|Participants will receive placebo weekly as a single SC injection by an un-blinded administrator. There will be 5 weekly injections (Days 1, 8, 15, 22 and 29), then EOW injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants will also receive a stable dose of methotrexate during the Treatment Period.
88822343|NCT03003260|Experimental|Treatment A - Treatment B|20 patients receive first 3 weeks treatment A and after a week wash-out 3 weeks treatment B
89176966|NCT00802074|Active Comparator|Group E|Period 1-Raltegravir 400mg BID Period 2- Fosamprenavir 1400mg QD + Ritonavir 100mg QD Period 3- Fosamprenavir 1400mg QD + Ritonavir 100mg QD + Raltegravir 400mg BID
89176967|NCT00802074|Active Comparator|Group F|Period 1-Raltegravir 400mg BID Period 2-Fosamprenavir 1400mg QD + Ritonavir 100mg QD + Raltegravir 400mg BID Period 3-Fosamprenavir 1400mg QD + Ritonavir 100mg QD
89355485|NCT03727945|Experimental|abdominopelvic exercise and posture|N=21 received supervised physiotherapy abdominopelvic exercise previous postural correction.
89176968|NCT03995719|Other|Preoperative education|Each patient had individual consultation several days before surgery with the stoma nurse specialist, following standard ostomy teaching plans
89176969|NCT03995719|Other|Postoperative education|Each patient had individual consultationseveral days before surgery with the stoma nurse specialist, following standard ostomy teaching plans
89176970|NCT04112004||Liver Transplant Recipients|All elective liver transplant recipients done between study period
89176971|NCT04112394|Experimental|ESP Group|In addition to routine standard perioperative and postoperative analgesia protocol patients will receive a single shot of local anesthetic injection at the erector spinae plane.
89533517|NCT04428281|Experimental|Cohort EB3 RO7248824|Participants continuing from MAD cohorts B3 and B4
89533518|NCT04428281|Experimental|Cohort EB4 RO7248824|Participants continuing from MAD Cohort B5
88822344|NCT03003260|Experimental|Treatment B - Treatment A|20 patients receive first 3 weeks treatment B and after a week wash-out 3 weeks treatment A
88822345|NCT04251143||Ectasia|Keratoconus, Keratoconus suspects
88822346|NCT02981186|Experimental|IOL Implantation experimental|Implantation of POD F GF in one of the eyes of the study subject
89176972|NCT04112394|Other|Control|Patients will receive standard perioperative and postoperative analgesia protocol.
89355486|NCT03727945|Experimental|abdominopelvic exercise|N=21 received supervised physiotherapy abdominopelvic exercise.
89355487|NCT02506582|Experimental|Test group|jerusalem artichoke and fermented soybeans powder mixture supplementation
89533519|NCT04421482|Other|Very Low Birth Weight Preterm Infants|Very Low Birth Weight Preterm Infants (birth weight less than 1,500g and less than 32 weeks gestation) admitted to NYU Winthrop NICU. (n=42)
89533520|NCT04421014|Active Comparator|Ketone Ester drink/ Arm 1|25 participants
89533521|NCT04421014|Placebo Comparator|Placebo/ Arm 2|25 participants
88822347|NCT02981186|Active Comparator|IOL Implantation Comparator|Implantation of POD F in the contralateral eye of the study subject
88822348|NCT04249973||IgE-mediated cow's milk allergy|Feces and urine samples are collected by the parents at home. Feces is collected out of the diaper or using a fecotainer. Urine is collected directly or using a urine collection pad. Additionally, the parents fill in a short questionnaire regarding the symptoms of their child, their clinical history and relevant information regarding the development of food allergies.
88822349|NCT04249973||Suspected of cow's milk allergy, but with negative diagnosis|Feces and urine samples are collected by the parents at home. Feces is collected out of the diaper or using a fecotainer. Urine is collected directly or using a urine collection pad. Additionally, the parents fill in a short questionnaire regarding the symptoms of their child, their clinical history and relevant information regarding the development of food allergies.
88822350|NCT04249973||IgE-mediated food allergy, other than cow's milk|Feces and urine samples are collected by the parents at home. Feces is collected out of the diaper or using a fecotainer. Urine is collected directly or using a urine collection pad. Additionally, the parents fill in a short questionnaire regarding the symptoms of their child, their clinical history and relevant information regarding the development of food allergies.
88999377|NCT02901340||Control group|The control group was formed of the patients who had normal amniotic volume and 34-37 weeks gestation who meets the inclusion criteria (n:100)
89355488|NCT02506582|Placebo Comparator|Placebo group|placebo supplementation
89176973|NCT00450385|Experimental|R-CHOP|"Patients will receive R-CHOP for 6 to 8 cycles:~Rituximab 375 mg/m2 on day 1~Cyclophosphamide 750 mg/m2 IV on day 1~Doxorubicin 50 mg/m2 on day 1~Vincristine 1.4 mg/m2 (maximum = 2 mg) IV on day 1~Prednisone 100 mg orally days 1-5, repeated every 21 days."
88822351|NCT04249973||Healthy brothers and sisters|Feces and urine samples are collected by the parents at home. Feces is collected out of the diaper or using a fecotainer. Urine is collected directly or using a urine collection pad. Additionally, the parents fill in a short questionnaire regarding the symptoms of their child, their clinical history and relevant information regarding the development of food allergies.
88999378|NCT02901106|Experimental|Patient with recurring-remitting MS|
89355489|NCT02292758|Experimental|Arm I (cetuximab, bevacizumab, irinotecan)|Patients receive cetuximab IV over 90-120 minutes, bevacizumab IV over 30-90 minutes, and irinotecan IV over 90 minutes on day 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.
88822352|NCT01883999|Experimental|GORE® EXCLUDER® Iliac Branch Endoprosthesis|GORE® EXCLUDER® Iliac Branch Endoprosthesis
89176974|NCT01026883|Other|Healthy subjects|Hematocrit level of each subject will be assessed by two different techniques
89355490|NCT02292758|Active Comparator|Arm II (cetuximab, placebo, irinotecan)|Patients receive cetuximab IV over 90-120 minutes, placebo IV over 30-90 minutes, and irinotecan IV over 90 minutes on day 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.
89355491|NCT04721249|Active Comparator|Verum|
89355492|NCT04721249|Placebo Comparator|Placebo|
89355493|NCT02511652|Active Comparator|Ambu AuraGain|Insertion of the supraglottic device and evaluation of its clinical performance
89176975|NCT01566019|Experimental|Patients with non curable metastatic cancer|
89176976|NCT00588354|Experimental|Clonidine|Transforaminal epidural clonidine injection
89176977|NCT00588354|Active Comparator|Steroid|Transforaminal epidural steroid injection
89355494|NCT02511652|Active Comparator|LMA Supreme|Insertion of the supraglottic device and evaluation of its clinical performance
89355495|NCT03727867|Placebo Comparator|Drug group|Participants were under prescription of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI) at the beginning and continued until disease progressed.
89355496|NCT03727867|Experimental|Drug plus SBRT group|After the first month of EGFR TKI orally, participants were given Stereotactic Body Radiation Therapy (SBRT) in dose of 50 Gy/5 F or 60 Gy/8 F for peripheral and central primary tumor, respectively, combined with oral EGFR TKI continually until the primary end point.
89355497|NCT03843983|Other|Lipiflow treatment|Lipiflow® application: Treated with Lipiflow. All patients in this study are treated with Lipiflow once.
88999379|NCT00553579||DE|All subjects will have clinically significant dry eye.
88999380|NCT04723628|Experimental|Experimental group|Then, each patient was given 45-60 minutes of individual instruction. The patient training content was prepared based on the Knowledge, Motivation and Behavioral Skills Model (IMB). A total of 12 weeks of follow-up was performed with a weekly short reminder message and a two-weekly phone call. The research data were collected again at the end of 12 weeks.
88999381|NCT04723628|No Intervention|Control group|All data forms were then completed, and the HbA1c value was taken from the medical data. No additional procedure was performed to the control group. The research data were collected again at the end of 12 weeks.
88999382|NCT02901223|Active Comparator|Quadrantectomy group|35 female patients with non metastatic breast cancer who had standard conservative breast surgery by general breast surgeons.
89355498|NCT02832648|Experimental|selenase 200mcg|selenium as selenase 200mcg once daily, oral
89355499|NCT02832648|Experimental|selenase 50mcg|selenium as selenase 50mcg once daily, oral
88822353|NCT02218424|Experimental|Magnesium|Intravenous magnesium. After IV placed intraoperatively, a bolus dose of magnesium 30 mg/kg is given over 15 minutes, followed by a continuous infusion of magnesium at 10 mg/kg/hr until the completion of the procedure.
88822354|NCT02218424|Placebo Comparator|Placebo infusion|Intravenous normal saline will be given as placebo. An equal amount of volume normal saline will be given intravenously as the control group.
88822355|NCT00374049|Experimental|One|MUC1 vaccine in conjunction with GM-CSF and Poly-ICLC (Hiltonol)in Arm ONE
88822356|NCT02861937|No Intervention|healthy|"Ten patients with clinically healthy gingiva with probing depth less than 3mm and less than or equal to 10% sites with gingival bleeding on probing present.~As there was no attachment loss, it was not necessary for us to calculate RAL ( Relative Attachment Level)"
88822357|NCT02861937|Active Comparator|chronic gingivitis|"Chronic gingivitis was defined as having probing depth (PD) less than or equal to 4mm and more than to 25% sites with the gingival bleeding present (BOP)~As there was no attachment loss, it was not necessary for us to calculate RAL ( Relative Attachment Level)~Non surgical periodontal therapy (SRP) was concluded in 3 weeks. Within the duration of the study, all subjects received supportive therapy"
88822358|NCT02861937|Active Comparator|chronic periodontitis|"Chronic periodontitis was defined as having probing depth more than or equal to 5mm, RAL more than or equal to 8mm, with more than or equal to 10% sites with BOP positive and evidence of bone loss determined radiographically.~Non surgical periodontal therapy (SRP) was concluded in 3 weeks. Within the duration of the study, all subjects received supportive therapy"
88822359|NCT01885871|Experimental|Picosecond QS Nd:YAG Laser|Laser Treatment with Investigational Device
88822360|NCT02222870|Experimental|Fluzone Study Group 1|Participants at 6 months to < 36 months age at enrollment
88822361|NCT02222870|Experimental|Fluzone Study Group 2|Participants at 3 years to < 9 years of age at enrollment
88822362|NCT03029741|Experimental|Bioavailability of AZD0284|"To assess the absolute bioavailability of a single oral dose of AZD0284 in healthy subjects.~To assess the pharmacokinetics (PK) of a single intravenous (IV) microdose of [14C]AZD0284 in healthy subjects."
88822363|NCT02223260|Experimental|dabigatran|open label arm with dabigatran oral liquid formulation as single dose
88822364|NCT02863263|Other|Foam Dressing|Over the course of 12 weeks, dressing is performed twice weekly, but additional dressing changes are allowed, depending on the condition of the pressure ulcer such as excessive exudates on the ulcer. The frequency of dressing change is limited to once daily.
88822365|NCT02863263|Other|Foam Dressing with Povidone Iodine|Over the course of 12 weeks, dressing is performed twice weekly, but additional dressing changes are allowed, depending on the condition of the pressure ulcer such as excessive exudates on the ulcer. The frequency of dressing change is limited to once daily.
88822366|NCT01886807|Other|(DL group)|direct laryngoscopy for nasotracheal intubation without oxygen insufflation
88822367|NCT01886807|Other|(DL-O2 Group)|direct laryngoscopy for nasotracheal intubation with oxygen insufflation
88822368|NCT01886807|Experimental|(VL Group)|nasotracheal intubation using the Truview PCD video laryngoscope
88822369|NCT02223338|Active Comparator|Ciprofloxacin|"Ciprofloxacin:~Patients with choroidal neovascularization due to wet age-related macular degeneration or any other cause, clinically significant macular edema or cystoid macular edema over age 18 who have been treated with at least 3 monthly intravitreal injections of an anti-Vascular Endothelial Growth Factor (anti-VEGF) agent in the last 6 months. These patients must have been instructed to use post-injection topical ciprofloxacin 0.3% 4x daily for 3 days. On the visit of their next injection, a conjunctival swab will be taken in the inferior fornix prior to instillation of any ophthalmic drops."
88822370|NCT02223338|Active Comparator|Standard Aseptic Technique|"Standard Aseptic Technique:~Patients with choroidal neovascularization due to wet age-related macular degeneration or any other cause, clinically significant macular edema or cystoid macular edema over age 18 who have been treated with at least 3 monthly intravitreal injections of an anti-Vascular Endothelial Growth Factor (anti-VEGF) agent in the last 6 months. These injections must have been given with povidone-iodine only applied to the injection site and conjunctival fornix prior to injection, but no post-injection antibiotics were given. On the visit of their next injection, a conjunctival swab will be taken in the inferior fornix prior to instillation of any ophthalmic drops."
88822371|NCT01887587|Experimental|(modified VXLD) plus MLN9708|"Vincristine-1.5 mg/m2 to a max dose of 2 mg IV on days 1, 8, 15 and 22~Dexamethasone- 10 mg/m2 orally or IV on days 1-14~Doxorubicin- 60 mg/m2 on day 1 by IV bolus.~MLN9708 (Ixazomib)- 2.3 mg orally on days 1, 8 and 15. Escalations will be to 3mg or 4 mg, respectively, on days 1, 8 and 15 based on the dosing schema.~For patients without central nervous system (CNS) involvement:~Cytarabine 100 mg administered intrathecally on day 1 (cytarabine dose should be reduced to 50 mg if given through a central ommaya reservoir)~Methotrexate 12 mg administered intrathecally on day 8~For patients with CNS involvement:~-Cytarabine 100 mg administered intrathecally on day 1 (+/-1 day) (cytarabine dose should be reduced to 50 mg if given through a central ommaya reservoir) Triple intrathecal chemotherapy with cytarabine 30 mg, methotrexate 15 mg and hydrocortisone 15 mg on (Day 1, 8, 15 and 22 (+/-1 day))."
89355500|NCT02832648|Placebo Comparator|placebo|matched placebo, once daily, oral
89355501|NCT02506738|Active Comparator|Intervention using mHealth|Patients in the intervention used at home a mobile system to monitor their clinical and health status.
88999383|NCT02901223|Active Comparator|oncoplastic group|35 female patients with non metastatic breast cancer who had oncoplastic techniques for tumor resection by well trained oncoplastic breast surgeons.
88999384|NCT00196209|Experimental|1|catheter ablation to treat persistent atrial fibrillation
88999385|NCT00196209|Experimental|2|cardioversion and drug prophylaxis to treat persistent atrial fibrillation
88999386|NCT02901145|Experimental|progressive/relapsed solid tumors|patient with progressive/relapsed solid tumors who failed first line therapy
88999387|NCT02901301|Experimental|4 combination|pembrolizumab 200mg, IV, q3weeks, Day 1 trastuzumab 6mg/kg (8mg loading dose), IV, q3weeks, Day 1 capecitabine 1000mg/m2, PO, BID, Day 1-14 cisplatin 80mg/m2 (level 1), IV, q3weeks, Day 1
88999388|NCT02901028|Experimental|Collar Device|The Device is a standard hockey neck guard, adapted for the purposes of this study. The Device incorporates two bulges localized over the site of the internal jugular veins bilaterally. Experiments performed with jugular Doppler ultrasound demonstrate that while wearing the Device, flows within the jugular veins are reduced, while flow within the carotid arteries and all portions of the cerebrum are preserved (JA Fisher, unpublished data). Thus, application of the Device to the subject will not cause any untoward health risks. The pressure exerted by the Device on the region of the neck superficial to the internal jugular vein is akin to the pressure felt when a person yawns or wears a snugly fitting necktie.
88999389|NCT02901028|Sham Comparator|Arm Device|the subject is wearing a sham arm device, which will be placed on the upper arm and not cause venous engorgement. The subject will undergo the same testing as when wearing the collar device (strength, Vo2, vision, blood, urine, etc)
88999390|NCT02900989|Other|ASQ-Fr|Adolescents undergo the ASQ-Fr questionnaire composed of 5 items.
88999391|NCT02900989|Other|SIQ-Fr|Adolescents undergo the SIQ-Fr questionnaire composed of 30 items if >=15 yo and the SIQ-Fr Junior composed of 15 items if <15 yo
88999392|NCT02900950|Experimental|Arm A-Multicolour inking specimen|"After performing the pancreaticoduodenectomies, the surgeon intraoperatively inked the surfaces/margins of the specimen with different colours. The surfaces/margins inked were the following:~Anterior surface of the pancreas (yellow);~Posterior surface of the pancreas (orange);~Superior mesenteric/portal vein groove (blu);~Superior mesenteric artery margin (retroperitoneal margin) (red);~Transection margin of the bile duct (green) The trans-section pancreatic and gastric margins were not inked."
88999393|NCT02900950|Other|Arm B-Monocolour inking specimen|In arm B, only the superior mesenteric artery margin and the pancreatic margin were intraoperatively indicated by the surgeon in the specimen: a single stitch to identify the transection pancreatic margin and a continuous suture to identify the superior mesenteric artery margin. Monochromatic inking of the superior mesenteric artery margin was subsequently carried out by the pathologist.
89355502|NCT02506738|No Intervention|Control|Patients in the control group received the usual care.
89355503|NCT03727711|Experimental|Home Treatment|Participants will be taught home treatment with TPTNS - twice weekly, 30 minute sessions for 6 weeks
88822372|NCT05672420|Experimental|umbilical cord derived mesenchymal stem cells (UC-MSCs)|In the Phase Ib study, participants will be those with treatment-induced myelosuppression and acute myeloid leukemia/acute lymphoblastic leukemia, UC-MSCs will be preset with 5 escalation dose levels: dose A , dose B, dose C ,dose D and dose E, frequency of infusion will be preset with 3 escalation levels: frequency 1, frequency 2, frequency 3, total course of treatment: 2 weeks; In the Phase II study, participants will be those with treatment-induced myelosuppression and acute myeloid leukemia/acute lymphoblastic leukemia/primary hematological maligancies who are going to receive hematopoietic stem cell transplantation, UC-MSCs will be preset according to the recommended phase II dose (RP2D) from the Phase Ib study, total course of treatment: 2 weeks.
88822373|NCT03029091|Experimental|EoE +/- CTD|Participants with EoE with and without CTD receive Losartan Potassium, 0.7 - 0.9 mg/kg (titration)/1.0 - 1.4 mg/kg (maintenance) daily for 16 weeks
88822374|NCT03029091|Experimental|EoE + CTD|Participants with EoE with CTD receive Losartan Potassium, 0.7 - 0.9 mg/kg (titration)/1.0 - 1.4 mg/kg (maintenance) daily for 16 weeks
88822375|NCT03029091|Experimental|EoE - CTD|Participants with EoE without CTD receive Losartan Potassium, 0.7 - 0.9 mg/kg (titration)/1.0 - 1.4 mg/kg (maintenance) daily for 16 weeks
88822376|NCT02997410|Experimental|Ozone|Ozone application to the greatest points of pain in the related muscle, 3 times per week for 2 weeks
88822377|NCT02997410|Placebo Comparator|Placebo|Sham ozone application to the greatest points of pain in the related muscle, 3 times per week for 2 weeks
88822378|NCT02997410|Experimental|Occlusal splint|Occlusal splint use every night over a period of 4 weeks.
88822379|NCT03003182||in clinical trials|
88822380|NCT03003182||out of clinical trials|
88822381|NCT02864355|Active Comparator|Goal Directed Therapy|In this arm patient will have the FloTrac monitor and a Goal Directed Therapy algorithm will be used to manage blood pressures.
88822382|NCT02864355|No Intervention|Usual Care|Standard of care will be used to manage blood pressures.
88822383|NCT02980796|Experimental|Exercise + practice|Individuals will complete 20 minutes of exercise on a recumbent bicycle before practicing a novel motor task.
88822384|NCT02980796|Active Comparator|Rest + practice|Individuals will rest for 20 minutes before practicing a novel motor task. Attention will be controlled during this time.
88822385|NCT03003104|Experimental|DMT210 Topical Gel|DMT210 Topical Gel 5% applied to the face twice daily for 12 weeks
89355504|NCT03727711|Active Comparator|Hospital Treatment|Participants will receive hospital treatment with TPTNS - twice weekly, 30 minute sessions for 6 weeks
89355505|NCT03195660|Experimental|ASV Therapy|ASV Therapy
88822386|NCT03003104|Placebo Comparator|Vehicle Control|Topical Gel vehicle applied to the face twice daily for 12 weeks
88822387|NCT00374205|Experimental|AL|Artemether plus Lumefantrine 6 dose 3 days treatment
88822388|NCT00374205|Active Comparator|ASAQ|Artesunate plus Amodiaquine
88999394|NCT02900911|Experimental|Early rehabilitation|Early intervention consisting in standard swallow therapy and instructions to train respiratory muscles starting 2 weeks before Radiotherapy during 6 months
88999395|NCT02900911|Active Comparator|Later rehabilitation|Late intervention consists of standard swallow therapy and instructions to train respiratory muscles starting after completing Radiotherapy
88999396|NCT02900716|Experimental|Phase Ia|DTRMWXHS-12: oral capsules, daily x 21 days every 28 days
88999397|NCT02900716|Experimental|Phase Ib, DTRM-505|DTRMWXHS-12 oral capsules and everolimus oral tablets: daily x 21 days every 28 days
88999398|NCT02900716|Experimental|Phase Ib, DTRM-555|"DTRMWXHS-12 and pomalidomide oral capsules, everolimus oral tablets:~daily x 21 days every 28 days"
88999399|NCT02900677|Experimental|Physical and nutrition program|6 education programs with physical enhancement and nutrition related information for 12 weeks.
88999400|NCT02900677|No Intervention|Control|usual care
88999401|NCT02900794|Other|Contrast Arm (Microdebridement)|Typical pre-operative intervention including injectable local anesthetic into the inferior and middle turbinates followed by topical anesthetic on soaked cottonoids or pledgets placed in the nasal cavity floor, medial to the middle turbinate, behind the uncinate process will be performed. Using endoscopy, the nasal passage is located. Under endoscopic visualization, the microdebrider will be utilized to perform 1) excision of the concha bullosa, 2) maxillary antrostomy, and 3) submucosal cauterization of the turbinates. Suction/irrigation will be utilized as necessary.
88999402|NCT02900794|Other|Treatment Arm (Gold Laser)|Typical pre-operative intervention including injectable local anesthetic into the inferior and middle turbinates followed by topical anesthetic on soaked cottonoids or pledgets placed in the nasal cavity floor, medial to the middle turbinate, behind the uncinate process will be performed. Using endoscopy, the nasal passage is located. Under endoscopic visualization, the Gold Laser will be utilized to perform 1) excision of the concha bullosa, 2) maxillary antrostomy, and 3) submucosal cauterization of the turbinates. Suction/irrigation will be utilized as necessary. If the Investigator determines that the sinus is not sufficiently dilated or cannot be accessed, the need for and the type of additional treatment will be at the discretion of the Investigator.
89355506|NCT04497532|No Intervention|Control|
89355507|NCT04497532|Experimental|Diet|
89355508|NCT04497766|Experimental|Nebulized magnesium sulphate|100mg of mgso4 in 20ml of normal saline via ultrasonic nebulizer
89355509|NCT04497766|Experimental|Intravenous magnesium sulphate|Magnesium sulphate according to weight will be given intravenously.
89355510|NCT03841721|Experimental|linezolid 300 mg|
89355511|NCT03194490|Experimental|The combined intervention group|The combined intervention group will receive the cervical passive mobilization, stretching, and home program (Stretching and ROM exercise).
89355512|NCT03194490|Active Comparator|The standard intervention|The standard intervention group will receive cervical mobilization and home program (ROM exercises).
88822389|NCT02248844||Botulinum Toxin Type A|Subjects who receive botulinum toxin Type A injected into crow's feet line areas per clinical practice.
88822390|NCT03029715|Other|Intravenous anaesthesia|Propofol Dexmedetomidine Remifentanil
88822391|NCT03029715|Other|Inhalation anaesthesia|Desflurane Remifentanil
88822392|NCT04064762|Experimental|Vagus Nerve Stimulation + Prolonged Exposure Therapy|Study treatment is vagus nerve stimulation (VNS) delivered during Prolonged Exposure Therapy.
89355513|NCT03841643|Active Comparator|C group|In the C group, the cranial bone defect will be reconstructed with HydrosetTM (Stryker, New Jersey, USA), calcium phosphate cement, according to the current standard practice at the department.
89355514|NCT03841643|Experimental|P group|In the P group, the cranial bone defect will be reconstructed with a patient-specific implant (KLS Martin, Tuttlingen, Germany).
88822393|NCT03035487|Experimental|Micro-ultrasound|"Transrectal micro-ultrasound guided prostate biopsy, where images will be compared with images from standard of care modalities:~Low resolution transrectal ultrasound examination (LR-TRUS)~Multi-parametric MRI (mpMRI) examination performed according to the PI-RADS v2 protocol"
88822394|NCT05672264|Experimental|WB-EMS group|WB-EMS application
88822395|NCT05672264|Active Comparator|Control|Standardised physiotherapy (six sessions)
88822396|NCT02988635|Experimental|Early Palliative Care|Subjects receive standard of care with early palliative care.
88822397|NCT02988635|No Intervention|Standard of Care|Subjects receive standard of care.
88822398|NCT05430464|Experimental|1726nm Laser Treatment|
88822399|NCT05430464|Sham Comparator|Sham Laser Treatment|
88822400|NCT02926677|Experimental|Cue-Centered Therapy (CCT)|Cue-Centered Therapy provides 15 sessions of treatment. Focuses on developing skills in recognizing stress cues and coping skills. Taught to self-soothe without the active involvement of a guardian. Teaches emotional, cognitive, and physiological conditioning to deal with ongoing traumatic stress. Will have a fNIR (NIRScout) scan at 4 time points throughout study (baseline, midpoint, end of treatment, and 3 month post-treatment)
88822401|NCT02926677|Experimental|Trauma-Focused CBT (TF-CBT)|Trauma-Focused CBT provides 15 sessions of treatment. Focuses on reframing subconscious thought and emotions with emotional and cognitive conditioning. Uses the active involvement and support of guardians. Addresses discrete traumatic incidents in the past. Will have a fNIR (NIRScout) scan at 4 time points throughout study (baseline, midpoint, end of treatment, and 3 month post-treatment)
88822402|NCT02926677|Experimental|Treatment as Usual (TAU)|TAU is the current Standard treatment at Stanford Youth Solutions will serve as the control. The treatment is known as flexible integrated services. Will have a fNIR (NIRScout) scan at 4 time points throughout study (baseline, midpoint, end of treatment, and 3 month post-treatment)
88822403|NCT04177511|Experimental|Transcutaneous auricular vagus nerve stimulation|"A 30-minute session twice a day during 3 months of transcutaneous auricular vagus nerve stimulation using the TENS Eco Plus.~Standard treatment will be continued by the patients of this arm."
88822404|NCT04177511|No Intervention|Standard treatment|Patients of this arm will continue their standard treatment.
88822405|NCT03002948||Low orgasm|Female Sexual Function Index orgasm score below 3.6
88822406|NCT02996630|Other|Healthy fetuses|Pregnant patients carrying a healthy fetus. Interventions in this group will be: cord blood sample, sonography, Magnetic Resonance Imaging and bailey test.
88822407|NCT02996630|Other|Congenital Hearth Disease|Pregnant patients carrying a fetus with a moderate-severe congenital heart disease Interventions in this group will be: cord blood sample, sonography, Magnetic Resonance Imaging, Surgical intervention, brain monitoring and bailey test.
88822408|NCT02988011|Active Comparator|Gastric by-pass surgery|Gastric by-pass surgery without prior low-caloric diet
88822409|NCT02988011|Active Comparator|Low-caloric diet|Low-caloric diet followed by gastric by-pass surgery
88822410|NCT03035955|Active Comparator|Azelaic acid|azelaic acid (Finacea® Gel, 15%) twice daily on either the left side or the right side of the face and no treatment on the other side of the face
88822411|NCT03035955|No Intervention|no treatment|no treatment on the other side of the face
88822412|NCT03830060||Group I:|Fifty AP patients on admission
88822413|NCT03830060||Group II:|The previous AP patients after 72 hours
88822414|NCT02927223|Experimental|Treadmill then Treadmill with Atropine|Patients will undergo treadmill exercise at baseline, then Patients will undergo treadmill exercise after IV atropine
88822415|NCT04769804||Patients with recurrent pityriasis versicolor|
89355515|NCT02515786|Experimental|oxygen humidification|Oxygen by nasal catheter delivery will be humidified by bubles.
89355516|NCT02515786|No Intervention|Dry oxygen|oxygen by nasal catheter delivery will be dry
89355517|NCT03843827|Active Comparator|Group A (LMA Group)|Active Comparator: Group A (LMA Group) LMA-Classic™ laryngeal mask airway (Classic™LMA) by Dr. Archie Brain into clinical practice in 1988 brought about a revolution in anesthesia. In the literature, there are over 2,500 studies supporting Classic™ LMA usage. Following the success and popularity of Classic™ LMA, many different variants of this device have been designed and marketed,trying to offer a simple and effective alternative to the endotracheal intubation.
89355518|NCT03843827|Active Comparator|Group B (I gel Group)|I gel is a new type of laryngeal mask and doesn't have an inflatable cuff. Because of its thermoplastic elastomer structure, it exactly adapts to the supraglottic tissue by binding with body temperature,thus minimising air leakage
89355519|NCT04500184||Exercise group|patients who underwent cardiac rehabilitation
89355520|NCT04500184||Control group|patients who did not undergo cardiac rehabilitation
89355521|NCT01203683|Experimental|Active Computer-Based Program|Putatively therapeutic computer program.
89355522|NCT01203683|Placebo Comparator|Placebo computer-based program|Inert computer program.
89355523|NCT04073238|No Intervention|Single vision spectacle lens|Single vision lens with power for correcting distance refraction.
89355524|NCT04073238|Experimental|Repeated low-level red-light therapy|Single vision lens & repeated low-level red-light therapy
89533522|NCT04417660|Experimental|Bintrafusp alfa (M7824)|Bintrafusp alfa will be administered at a dose of 1200 mg intravenously once every two weeks until disease progression or development of intolerable adverse events.
88822416|NCT04769804||Healthy age and sex-matched controls|
89355525|NCT04500340|Experimental|Group Cognitive Behavioral Therapy (Group CBT)|Intervention Group will receive ten-session group CBT for test anxiety. Two sessions will be carried out each week.
89533523|NCT04402788|Active Comparator|Arm I (atezolizumab)|Patients receive atezolizumab IV over 30 minutes +/- 10 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo PET/CT scan, CT, and MRI throughout the trial. Patients also undergo blood and tissue collection throughout the trial.
89176978|NCT01566097|Experimental|Intervention group|This study is cluster randomized trial, and the randomization level is physician. Current smokers seen by physician allocated into intervention group were provided with Smoking Cessation Decision Aids along with study questionnaires. The intervention was Smoking Cessation Decision Aids provided to current smokers.
89176979|NCT01566097|No Intervention|Control group|Current smokers seen by physician allocated into control group were provided with only study questionnaires and usual care.
89176980|NCT04114968||Intervention group|Eligible women residing in the Central Denmark Region will be assigned to intervention group. Women in the intervention group receive an invitation for HPV-based cervical cancer screening by attending either 1) GP-based screening or 2) HPV self-sampling. The self-sampling kit includes the dry Evalyn brush self-sampling device (Rovers Medical Devices B.V, Oss, Netherlands), written and picture-based user instructions on how to collect and mail the self-sample, and a prestamped return envelope addressed to the Department of Pathology, Randers Regional Hospital.
89355526|NCT04500340|No Intervention|Control Group|The Control group will be waiting for the control group who will receive intervention if they demand after final assessment for outcome measure.
89355527|NCT05282303||DIESPB|Dual injection of erector spinae plane block
89355528|NCT05282303||TPVB|Thoracic paravertebral block
88822417|NCT04350437|Other|induction of labor monitoring|meticulous data collection from patients and plotting that data in a machine learning model
88822418|NCT03002792||general anesthesia|caries treatment under general anesthesia
88822419|NCT03002792||caries treatment only|caries treatment without general anesthesia
88822420|NCT03002714|Experimental|Exercise|Performance of two resistance exercise sessions
88822421|NCT02927457|Experimental|Group A1- Skin Sites A/C/D (A/P/A)|Skin areas A to E in group A are identified skin areas across the back of the subject. Subjects will be receiving GSK2646264 1% (A) for Area A- PV lesion, Placebo (P) for Area C- PV lesion and GSK2646264 1% for Area D- uninvolved skin once daily for 28 days according to randomisation. Skin areas B- PV lesion and E- uninvolved skin will not be assigned any treatment and will be used for the baseline biopsy.
88822422|NCT02927457|Experimental|Group A2- Skin Sites A/C/D (A/P/P)|Skin areas A to E in group A are identified skin areas across the back of the subject. Subjects will be receiving GSK2646264 1% for Area A- PV lesion, Placebo for Area C- PV lesion and Placebo for Area D- uninvolved skin once daily for 28 days according to randomisation. Skin areas B- PV lesion and E- uninvolved skin will not be assigned any treatment and will be used for the baseline biopsy.
88822423|NCT02927457|Experimental|Group A3- Skin Sites A/C/D (P/A/A)|Skin areas A to E in group A are identified skin areas across the back of the subject. Subjects will be receiving Placebo for Area A- PV lesion, GSK2646264 1% for Area C- PV lesion and GSK2646264 1% for Area D- uninvolved skin once daily for 28 days according to randomisation. Skin areas B- PV lesion and E- uninvolved skin will not be assigned any treatment and will be used for the baseline biopsy.
88822424|NCT02927457|Experimental|Group A4- Skin Sites A/C/D (P/A/P)|Skin areas A to E in group A are identified skin areas across the back of the subject. Subjects will be receiving Placebo for Area A- PV lesion, GSK2646264 1% for Area C- PV lesion and Placebo for Area D- uninvolved skin once daily for 28 days according to randomisation. Skin areas B- PV lesion and E- uninvolved skin will not be assigned any treatment and will be used for the baseline biopsy.
88822425|NCT02927457|Experimental|Group B1- Skin Sites F/ G (A/P)|In group B, two chosen lesions will be labeled F and G based on size (F >G). Subjects will be receiving GSK2646264 1% for lesion F and Placebo for lesion G once daily for 28 days according to randomisation. Skin area H- uninvolved skin will not be assigned any treatment and will be used for the baseline biopsy.
88822426|NCT02927457|Experimental|Group B2- Skin Sites F/ G (P/A)|In group B, two chosen skin lesions will be labeled F and G based on size (F >G). Subjects will be receiving Placebo for lesion F and GSK2646264 1% for lesion G once daily for 28 days according to randomisation. Skin area H- uninvolved skin will not be assigned any treatment and will be used for the baseline biopsy.
88822427|NCT01891331|Experimental|VT-1161 300mg QD|
88822428|NCT01891331|Experimental|VT-1161 600mg QD|
88822429|NCT01891331|Experimental|VT-1161 600mg BID|
88822430|NCT01891331|Active Comparator|Fluconazole 150mg|
89176981|NCT04114968||Control group|Eligible women residing in the other five Danish regions (North, Central, South, Zealand and Capital ) will be assigned to control group. Women in the control group will receive usual care, which for 65-69 year-old women is opportunistic cervical cancer screening at the GP
88822431|NCT02247518|Other|Group1: Treatment A + Treatment B, PO|Treatment A : Tadarafil 5mg*1t/day for 5days, Treatment B : Tadarafil 5mg*1t/day and Tamsulosin 0.2mg*1t/day for 5days, Each treatment period was separated by a washout period of at least 10 days.
88822432|NCT02247518|Other|Group2: Treatment B + Treatment A, PO|Treatment A : Tamsulosin 0.2mg*1t for 5days, Treatment B : Tamsulosin 0.2mg*1t/day and Tadalafil 5mg*1t/day for 5days, Each treatment period was separated by a washout period of at least 10 days.
88822433|NCT05671952|Experimental|intervention group|Application of integrated intervention system programs
89355529|NCT05282303||SAB|Serratus anterior plane block
89355530|NCT05282303||PIB|Parasternal ıntercostal block
89355531|NCT02515708|Experimental|Normothermic Liver perfusion|This group has the liver grafts preserved using the Normothermic Liver perfusion Device.
88999403|NCT00169091|Experimental|Clozapine|Clozapine 12.5-300 mg taken orally per day for 12 weeks in the acute phase of the study and up to 130 weeks (total) in the Follow-up portion of the study.
88999404|NCT00169091|Active Comparator|Haloperidol|Haloperidol 2-12 mg taken orally per day for 12 weeks in the acute phase of the study and up to 130 weeks (total) in the Follow-up portion of the study.
88999405|NCT02900755|Experimental|Epilepsy|Epilepsy patients (focal onset seizure with or without secondary generalization)
88999406|NCT02900638|Experimental|Intervention (Mentor/Mentee)|
88999407|NCT02900638|No Intervention|Wait list control|
88999408|NCT02900209||COPD frequent exacerbators|Aged 65-85 years with a diagnosis of COPD according to Global Initiative for Chronic Obstructive Lung Disease criteria (post bronchodilator FEV1/FVC ratio <0.70). Moderate to severe airflow limitation (FEV1 30-80% predicted). Patients have experienced 2 or more exacerbations requiring oral steroids/antibiotics treatment and/or hospitalisation in the previous 12 months.
88999409|NCT02900209||COPD infrequent exacerbators|Aged 65-85 years with a diagnosis of COPD according to Global Initiative for Chronic Obstructive Lung Disease criteria (post bronchodilator FEV1/FVC ratio <0.70). Moderate to severe airflow limitation (FEV1 30-80% predicted). Patients have experienced no more than 1 course of oral steroids/antibiotics and none exacerbations requiring hospital admission in the previous 12 months.
88999410|NCT02900209||Healthy controls|Aged 65-85 years and do not have any symptoms of lung disease and have normal spirometry.
88999411|NCT02900404||NVAF Patients|Adult female and male patients with non-valvular atrial fibrillation (NVAF) treated with rivaroxaban before and after surgery
88999412|NCT02900404||VTE/PE Patients|Adult female and male patients with venous thromboembolism/pulmonary embolism (VTE/PE) treated with rivaroxaban before and after surgery
88999413|NCT02900248||Provider Determined Treatment|Participants with advanced solid or hematologic malignancy or myelodysplasia (MDS), will have their tumor or tissue tested by a standardized next generation sequencing (NGS) panel. They will be treated by physician determined treatment including FDA approved or compendia-listed biomarker directed therapy. All patients will be followed for time to progression by line of therapy, overall survival by line of therapy.
88999414|NCT00178620|Experimental|Group A: Full dose pre-hospital fibrinolysis|Patients transported by participating EMS units and that were fibrinolytic eligible and treated with full dose, pre-hospital fibrinolysis with reteplase (treated in the ambulance with 10 units reteplase and randomized to a second 10-unit dose of reteplase).
88999415|NCT00178620|Experimental|Group B: Half dose pre-hospital fibrinolysis followed by urgent PCI|Patients transported by participating EMS units and that were fibrinolytic eligible and treated with a half dose pre-hospital fibrinolysis with reteplase (treated in the ambulance with 10 units reteplase) and randomized to urgent catheterization with percutaneous coronary intervention (PCI).
88999416|NCT00178620|Active Comparator|Group C: Fibrinolytic ineligible patients receiving primary PCI|Patients transported by participating EMS units and that were fibrinolytic ineligible and treated with primary PCI alone and that were prospectively analyzed for comparison.
88999417|NCT00178620|Active Comparator|Group D: Patients transferred in and treated with primary PCI|Patients not transported by participating EMS units but were transferred in and treated with primary PCI alone and that were prospectively analyzed for comparison.
88999418|NCT02900365|Experimental|Early cataract surgery group|"Eyes which presented with cataract and underwent surgery within 1 week were included in the early procedure group. They underwent early cataract surgery & IOL implantation"
88999419|NCT02900365|Experimental|Late cataract surgery group|"Eyes which presented with cataract and underwent surgery at least 1 month after trauma were included in the secondary procedure group.They underwent Late cataract surgery & IOL implantation."
89355532|NCT02515708|Other|Normothermic Machine Perfusion (single pump)|This group has the liver grafts preserved using a single-pump variant of the Normothermic Liver perfusion Device.
88999420|NCT02900131|Experimental|trial group 1|Participants will receive Jaungo and placebo once a day for three weeks.
88999421|NCT02900131|Experimental|trial group 2|Participants will receive Jaungo twice a day for three weeks.
88999422|NCT02900131|Placebo Comparator|control group|Participants will receive placebo twice a day for three weeks.
88999423|NCT00169208|Experimental|Experimental|4 cycles of rituximab + fludarabine + mitoxantrone
88999424|NCT02899975|Other|Validation Swiss|20 german talking elderly and the non-professional caregiver will validate a Fitness and Information software
88999425|NCT02899936|Active Comparator|2 drug dose - DA|Drug treatment with two-drug regimen diethylcarbamazine and albendazole (DA)
88822434|NCT05671952|No Intervention|Control group|No intervention
88999426|NCT02899936|Experimental|3 drug dose - IDA|Triple-drug regimen Ivermectin, diethylcarbamazine and albendazole (IDA)
89176982|NCT00449761|Experimental|Panobinostat|Participants received panobinostat 20 milligrams (mg) orally once daily (OD), three times a week as part of a 4 week (28 day) treatment cycle. Panobinostat was administered at the same time each morning, and with an 8oz/240 milliliter (ml) of water after a fasting period of at least two hours (water was allowed). Participants could continue this treatment until an unacceptable toxicity that precludes further treatment was experienced, or until disease progression.
89176983|NCT00800982|Active Comparator|1 (Etanercept only)|Subjects will only be treated with etanercept. This is given at the standard FDA approved dosage of 50 mg twice weekly x 3 months then 50 mg once weekly x 3 months. No UVB will be given. Sham UVB will not be used because the subjects are not blinded because they often know they are receiving sham UVB due to differences in light intensity and heat.
89355533|NCT02515552|Other|All applicants|Study applicants who consented and completed the application to participate in the Fibromyalgia Wellness Project. From that point forward all subjects used the intervention program to at whatever frequency they chose voluntarily. It was recommended subjects complete a SMARTLog at least three times per week for at least three months.
89355534|NCT03620526|Experimental|Iloprost|patients received inhaled iloprost 10 mcg/mL x 1 dose after baseline and exercise test and then received measurements for hemodynamic data again for both baseline and after exercise test.
89355535|NCT03620526|Placebo Comparator|Placebo|patients received inhaled normal saline with the same amount x 1 dose after baseline and exercise test and then received measurements for hemodynamic data again for both baseline and after exercise test.
89355536|NCT04499560|Experimental|Intervention|Participants consume 2 ounces of the supplement each morning for 60 days.
89355537|NCT04499560|No Intervention|Control|Participants do not make any changes to their health related routines
88999427|NCT00178698|Other|1|Thermochemotherapy
88999428|NCT02899819|Experimental|meconium|The meconium will be sampled in the first 2 days of life
88999429|NCT02899702|Experimental|IVIG|PRIVIGEN (CSL Behring) NORMAL HUMAN IMMUNOGLOBULINS L-PROLINE, Water for injection
88999430|NCT02899702|Placebo Comparator|control|"Single administration of Albumin 4% diluted albumin (LFB), within 12 hours following PICU admission (or outbreak of first shock signs). Isovolume - so dose of 0.8 g/kg We chose as placebo albumin diluted to 4% because this solution has the advantage of having a comparable osmolality.~The treatment of toxic shock will be standardized. It consists of antibiotics: Amoxicillin-clavulanate and clindamycin (or Rifampicin, Rifadine® if allergic). Antibiotics are not considered as experimental treatments for this study. All treatments essential for the treatment of acute condition will be allowed and are not considered as experimental treatments for this study."
88999431|NCT02899780|Experimental|Ultraviolet arm|This arm will have their dialysis catheters treated with an ultraviolet light emitting optical fiber.
88999432|NCT02899741|Experimental|Omega-3|One group of this study. Omega-3 will be administered for thee months.
88999433|NCT02899624|Experimental|Bicuspid aortic valve (BAV)|patient with bicuspid aortic valve
88999434|NCT02899624|Active Comparator|healthy subjects related patients with BAV|healthy control, related to patient with bicuspid aortic valve, at the 1st, 2nd or 3rd degree
88999435|NCT02899624|Active Comparator|Tricuspid aortic valve (TAV)|patient with aortic stenosis on tricuspid valve
88999436|NCT02899585|Experimental|Group A|Elaboration of the questionnaires
88999437|NCT02899585|Experimental|Group B|Patients taken care for more less than 6 days by the health care team palliatives EIVA and they eventual family caregiver. Score
88999438|NCT02899507|Experimental|Prophylactic antibiotic|Amoxicillin-Clavulanic acid 1.2g every 8h
88999439|NCT02899507|No Intervention|Clinically-driven antibiotics|Administration of antibiotics in clinically-driven group was at the discretion of attending intensivist. Selection of antibiotic in clinically-driven group was empirical or based on the results of bacterial cultures if already available.
88999440|NCT00178776|Experimental|Transtheoretical Model Group|
88999441|NCT00178776|Active Comparator|Education / Advice|
88999442|NCT02899234|Active Comparator|Nicotine-free e-cigarette|Subjects will actively inhale nicotine-free vapor prior to blood samples and various non-invasive cardiopulmonary tests.
88999443|NCT02899234|Active Comparator|Nicotine e-cigarette|Subjects will actively inhale nicotine containing vapor prior to blood samples and various non-invasive cardiopulmonary tests.
88999444|NCT02899390|Experimental|Lifestyle Intervention|All the participants will be offered group and individual sessions to help them accomplish weight loss and also increase physical activity.
88999445|NCT02899273||Dentistry students|Dentistry students of the University of Göttingen
88999446|NCT02899273||Psychology students|Psychology students of the University of Hildesheim
88999447|NCT02899351||Infants less than 12 months|intubated infants in ICU
88999448|NCT02899468|Experimental|Active Treatment Group|Active treatment will consist of the BrightBrainer Virtual Reality (BBVR) Rehabilitation System therapy intervention (3 sessions per week x 6 weeks). Standard validated outcome measures which assess various domains of function, will be obtained at baseline and then at 3 and 6 weeks for those randomized to the Active Treatment group.
88999449|NCT02899468|Other|Wait-List Control Group|Subjects randomized to the Wait-List Control (WLC) group will wait 3 weeks before beginning the Active Treatment program intervention (3 sessions per week x 6 weeks) using the BrightBrainer Virtual Reality (BBVR) Rehabilitation System. For those randomized to the WLC group, outcome measures will be assessed at baseline, completion of waiting period (3 weeks), then at 3 and 6 weeks after initiating active treatment.
88999450|NCT02899117|Experimental|Yoga intervention|Patients in the yoga intervention group will have 4 yoga sessions with a certified yoga instructor while they are in the cancer clinic or on the inpatient floor.
88999451|NCT00196365|Experimental|1|
88999452|NCT00196365|Active Comparator|2|
88999453|NCT02898844|No Intervention|Control Condition|Neither roommate dieted.
88999454|NCT02898844|Experimental|Mixed Diet Condition|Low-calorie diet: One roommate in each pair was randomly assigned to a 1200-calorie/day diet, while the other roommate was instructed to eat normally.
88999455|NCT02898844|Experimental|Both Diet Condition|Low-calorie diet: Both roommates in each pair were randomly assigned to a 1200-calorie/day diet.
88999456|NCT02898922|Experimental|HCV group|Three doses of hepatitis B vaccine made by Recombinant DNA Techniques in Saccharomyces Cerevisiae (20 μg HBsAg/1.0ml per dose, Shenzhen Kangtai Biological Products Co., Ltd., Shenzhen, Guangdong Province, China) were given intramuscularly in the deltoid region to all participants at 0, 1 and 6 months respectively.
88999457|NCT02898922|Active Comparator|Healthy control group|Three doses of hepatitis B vaccine made by Recombinant DNA Techniques in Saccharomyces Cerevisiae (20 μg HBsAg/1.0ml per dose, Shenzhen Kangtai Biological Products Co., Ltd., Shenzhen, Guangdong Province, China) were given intramuscularly in the deltoid region to all participants at 0, 1 and 6 months respectively.
88999458|NCT02898961|Experimental|The study population|"ICU patients with severe sepsis treated with aminoglycosides were recruited.~Intervention: 30 mg/kg amikacin or 8 mg/kg gentamicin"
88999459|NCT02898805|Experimental|LopiGLIK®|first two weeks: Placebo + prescribed Diet then 16 weeks LopiGLIK® a tablet/day after a meal + Diet
88999460|NCT02898805|Active Comparator|Armolipid Plus|first two weeks: Placebo + prescribed Diet then 16 weeks Armolipid Plus a tablet/day after a meal + Diet
88999461|NCT00196404|Experimental|1|
88999462|NCT00196404|Experimental|2|
88999463|NCT00196404|Placebo Comparator|3|
88822435|NCT02867163||Knee replacement patients receiving TXA|Patients who receive tranexamic acid during total knee replacement surgery
88822436|NCT03002480|Other|Severe Hemophilia A subjects w/ inhibitors|Males age 4-70 years diagnosed with severe hemophilia A with inhibitors who are currently treated with prophylaxis or on-demand treatment will be enrolled.
88822437|NCT03835754|Experimental|OCS Preservation|
88822438|NCT03037203|Experimental|Arm A|JZP-110 and Placebo
88822439|NCT03037203|Experimental|Arm B|JZP-110 and Placebo
88822440|NCT03037203|Placebo Comparator|Arm C|Placebo
88822441|NCT03806738|Experimental|Shared Decision Making Questionnaire|"Patients randomized to the intervention arm will receive the intervention-specific Carevive questionnaire, which includes standard questions with additional decision-making questions. These surveys will be repeated every 6 months until the patient has received a TP.~One month or at the next visit following the decision, the patient will be asked to complete a research survey using REDCap."
88822442|NCT03806738|Other|Standard of Care Questionnaire|"Patients randomized to standard of care will receive the standard-of-care Carevive questionnaire used to generate TPs at time of enrollment and then every 6 months for patients with MBC who have not made a treatment decision until a treatment decision is made.~One month or at the next visit following the decision, the patient will be asked to complete a post-treatment survey using REDCap."
88822443|NCT01892267|Experimental|Self-propelled PEGJ feeding tube|Patients in this arm will receive self-propelled balloon PEGJ tube.
88822444|NCT01892267|Active Comparator|Standard PEGJ feeding tube|Patients in this arm will receive the standard commercially availabel PEGJ tube.
88822445|NCT03705104|Experimental|EPIO (e-health intervention)|Participants will get access to one module every third day (total 9 modules). The app consists of cognitive behavioral pain self-management material, including educational material and relaxation training exercises.
88822446|NCT03705104|No Intervention|treatment as usual|Participants will get treatment as usual during the study. All participants will get access to the app after ended study if interested.
88822447|NCT03705104|Active Comparator|Experimental without introduction group and follow up phone calls|One extra arm (non randomized) has been included to examine whether participants who receive the EPIO intervention without receiving an introduction session and follow up phone calls will still describe benefiting from the receiving the intervention
88822448|NCT03022097|Experimental|Experimental 1|Aclidinium bromide 400μg/Formoterol fumarate 12 μg
88822449|NCT03022097|Experimental|Experimental 2|Aclidinium bromide 400 μg
88822450|NCT03022097|Active Comparator|Comparator|Formoterol fumarate 12 μg
88822451|NCT03022097|Placebo Comparator|Placebo|Placebo
88822452|NCT03002636|Experimental|Morbid Obesity group|Morbid Obesity group(n=300)
88822453|NCT03002636|Experimental|severe Obesity group|severe Obesity group (n=300)
88822454|NCT03002636|Other|non-Obesity group|non-Obesity group(n=300)
88822455|NCT03037281||Septic|Patients admitted to the intensive care unit with a diagnosis of sepsis. For the purposes of this study, patients must have a diagnosis of sepsis; SIRS (2 of pulse >90, WCC, BP, Oxygen(Dellinger et al., 2013)) with microbiological evidence of infection (positive blood culture, urine dipstick, compatible history or examination, radiographic evidence)
88822456|NCT03037281||Healthy volunteers|Healthy volunteers will be approached within the Department of Cardiovascular Sciences, and provided with the PIS, with consent taken by one of the investigating team.
88822457|NCT03002324|Active Comparator|Current CDC Message Arm|Participants randomized to this arm will receive a message developed to directly follow the current message on the CDC's website.
88822458|NCT03002324|Experimental|Cervical Cancer Message Arm|Participants randomized to this arm will receive a message focused on cervical cancer risks and prevention and framed to highlight perceived susceptibility, perceived benefit, and self-efficacy.
88822459|NCT03002324|Sham Comparator|Control Message|Participants randomized to the control arm will be provided with a short message about the costs and benefits of bird feeding.
89355538|NCT02850588||TCAR treatment|All patients, both high risk and standard risk surgical patients undergoing transcarotid revascularization with a carotid stent during carotid artery flow reversal in hospitals that participate in the Carotid Artery Stent Registry of the Society for Vascular Surgery Patient Safety Organization
89355539|NCT02850588||CEA treatment|All patients undergoing carotid endarterectomy in hospitals that participate in the Carotid Endarterectomy Registry of the Society for Vascular Surgery Patient Safety Organization
88822460|NCT03037905|Experimental|SignatureSuite OR|The intervention is exposure to the operating room environment created by the device SignatureSuite OR Integration System by STERIS Corporation.
88822461|NCT03037905|No Intervention|Standard OR|Standard operating room without SignatureSuite OR Integration System by STERIS Corporation.
88822462|NCT03002402|Experimental|Internet-based CBT-I|"Sleep Healthy Using the Internet (SHUTi) is a self-guided, automated, interactive, and tailored web-based program modeled on the primary tenets of cognitive-behavioral treatment for insomnia (CBT-I): sleep restriction, stimulus control, cognitive restructuring, sleep hygiene, and relapse prevention. Intervention content is allocated out over time through 6 Cores. Users obtain access to a new Core based on a time and event-based schedule (e.g., 7 days after completion of previous Core). SHUTi uses online sleep diaries to track progress and to tailor treatment (e.g., assign a sleep restriction window)."
88822463|NCT01893983|Experimental|Motivational Coaching|Telephone based Motivational Coaching sessions
88822464|NCT01893983|No Intervention|Referral alone|This is the current standard of care
88822465|NCT03037983|Active Comparator|Active rTMS|Subjects will receive actual rTMS treatment.
88822466|NCT03037983|Sham Comparator|Sham rTMS|Subjects will attend and sit through the session, but no rTMS treatment will be actually delivered to them.
88822467|NCT02988791|Experimental|Probiotic (Bifidobacterium)|Active, Bifidobacterium BB12
89355540|NCT02987153|Experimental|KYPHO-IORT - 10 Gy and Kyphoplasty|Intra-operative radiation therapy followed by standard kyphoplasty
89355541|NCT03217968|Experimental|Active|120 minutes of Cefaly® Abortive Program device stimulation as abortive treatment of an early stage migraine attack
89355542|NCT03843749|Experimental|HER2-positive Metastatic Colorectal Cancar|
89355543|NCT03841877|Experimental|AH Plus-Cervical|"The objective is evaluate the color change (ΔE00) originated from epoxy resin (AH Plus) endodontic sealer, sectioned at the cervical level.~The ΔE00 will be evaluated using the measurements data obtained in a period between the immediate endodontic treatment versus after 3, 6 and 12 months.~The values of ΔE00 obtained for each sealer, cut and time will be analyzed by multifactorial analysis to verify associations of the outcomes with the ΔE00."
89355544|NCT03841877|Experimental|MTA Fillapex-Cervical|"The objective is evaluate the color change (ΔE00) originated from mineral trioxide aggregate (MTA Fillapex) endodontic sealer, sectioned at the cervical level.~The ΔE00 will be evaluated using the measurements data obtained in a period between the immediate endodontic treatment versus after 3, 6 and 12 months.~The values of ΔE00 obtained for each sealer, cut and time will be analyzed by multifactorial analysis to verify associations of the outcomes with the ΔE00."
88822468|NCT02988791|Placebo Comparator|Placebo|Placebo
88822469|NCT03039543|Active Comparator|moderate neuromuscular blockade|During operation, intravenous rocuronium was used to maintain moderate (TOF count of 1 or 2). Patients in moderate neuromuscular blockade are reversed with 2 mg/kg sugammadex at a TOF count of 1 or 2.
88822470|NCT03039543|Experimental|deep neuromuscular blockade|During operation, intravenous rocuronium was used to maintain deep (TOF count of 0 with post-tetanic count of 2) neuromuscular blockade. Patients in the deep neuromuscular blockade are reversed with 4 mg/kg sugammadex at post-tetanic count of 2.
88822471|NCT04047875|Experimental|Norethisterone 10mg/day|NET-only pill (Norethisterone, Primolut-Nor®), 10 mg/day, 1 pill per day until 2 consecutive days without bleeding/spotting (maximum use of 1 box of Primolut-Nor® per bleeding episode)
88822472|NCT04047875|Placebo Comparator|Placebo|Identically appearing placebo to Primolut-Nor®, 1 pill per day until 2 consecutive days without bleeding/spotting (maximum use of 1 box of Placebo per bleeding episode)
88822473|NCT03610568|Experimental|Growing up GREAT! Intervention|
88822474|NCT03610568|No Intervention|Control|
88822475|NCT03002246||Average for Gestational Age|This cohort will include a sample size of 90 subjects. Fetuses will have an estimated fetal weight greater than 10th percentile and less than 90th percentile based on clinical ultrasound assessment. This cohort will receive an ultrasound examination 4-7 days before their delivery.
88822476|NCT03002246||Large for Gestational Age|This cohort will include a sample size of 30 subjects. Fetuses will have an estimated fetal weight greater than 90th percentile based on clinical ultrasound assessment.This cohort will receive an ultrasound examination 4-7 days before their delivery.
88822477|NCT03002246||Small for Gestational Age|This cohort will include a sample size of 30 subjects. Fetuses will have an estimated fetal weight less than 10th percentile based on clinical ultrasound assessment.This cohort will receive an ultrasound examination 4-7 days before their delivery.
88822478|NCT02870205|Experimental|GSP 301 NS|
88822479|NCT02870205|Active Comparator|GOM-NS|
88822480|NCT02870205|Active Comparator|GMM-2 NS|
88822481|NCT02870205|Placebo Comparator|GSP 301 placebo NS|
88822482|NCT03002168|Active Comparator|Alpha-cyclodextrin|Two 1 gram Alpha-cyclodextrin tablets given per fat-containing meal. A total of 6 tablets (6 grams) per day for the first two consecutive days of active treatment period. Triolein radiolabeled with 100 microcuries of 3^Hydrogen and Tripalmitin radiolabeled with 20 microcuries of 14^Carbon given orally with liquid breakfast meal.
88822483|NCT03002168|Placebo Comparator|Placebo|Two Placebo Alpha-cyclodextrin tablets given per fat-containing meal. A total of 6 tablets per day for the first two consecutive days of placebo treatment period.Triolein radiolabeled with 100 microcuries of 3^Hydrogen and Tripalmitin radiolabeled with 20 microcuries of 14^Carbon given orally with liquid breakfast meal.
89355545|NCT03841877|Experimental|AH Plus-2mm|"The objective is evaluate the color change (ΔE00) originated from epoxy resin (AH Plus) endodontic sealer, sectioned 2 mm below cervical level.~The ΔE00 will be evaluated using the measurements data obtained in a period between the immediate endodontic treatment versus after 3, 6 and 12 months.~The values of ΔE00 obtained for each sealer, cut and time will be analyzed by multifactorial analysis to verify associations of the outcomes with the ΔE00."
89355546|NCT03841877|Experimental|MTA Fillapex-2mm|"The objective is evaluate the color change (ΔE00) originated from mineral trioxide aggregate (MTA Fillapex) endodontic sealer, sectioned 2 mm below cervical level.~The ΔE00 will be evaluated using the measurements data obtained in a period between the immediate endodontic treatment versus after 3, 6 and 12 months.~The values of ΔE00 obtained for each sealer, cut and time will be analyzed by multifactorial analysis to verify associations of the outcomes with the ΔE00."
89355547|NCT01203761||Preoperative patients|ENT surgical patients, approximately 1 day before their procedure undertaken
88822484|NCT03002090|Experimental|Iron trained|
88822485|NCT03002090|Experimental|Iron Untrained|
88822486|NCT03002090|Experimental|BZKL Trained|
88822487|NCT03002090|Experimental|BZKL Untrained|
88822488|NCT03002090|Experimental|Placebo Trained|
88822489|NCT03002090|Placebo Comparator|Placebo Untrained|
88822490|NCT02328755|Experimental|peg-IFN-α|"peg-IFN-α will be administered prior to HCT (Hematopoietic Cell Transplant) and at three subsequent time points post HCT. (Maximum of 4 doses) It will be administered by subcutaneous injection every 14 days beginning with dose level 1.~Dose Level -1 - 45mcg Dose Level 1 - 90mcg Dose Level 2 - 180 mcg"
88822491|NCT02870283|Active Comparator|Lithium|"Subjects were randomized into three groups: (lithium, valproic acid, or carbamazepine).~Group (A) Started Lithium (900mg-1500mg)~Subjects evaluated for responsiveness every 2 weeks. Responsive to treatment patients remain in the same step. Max. step duration of 8 weeks.~First step: Monotherapy with Lithium (900-1500mg) Non responsive patients: 2nd step.~Second step: Randomization for lithium (900mg-1500mg) + valproic acid (1000mg-1500mg) OR lithium (900mg-1500mg) + carbamazepine (600mg-1200mg).~Non responsive patients: 3rd step.~Third step: Crossover lithium (900mg-1500mg) + valproic acid (1000mg-1500mg) X lithium (900mg-1500mg) + carbamazepine (600mg-1200mg).~Non responsive patients: 4th step.~Fourth step: Association with risperidone (1-6mg)"
89355548|NCT01203761||Postoperative patients|ENT surgical patients during their postoperative hospitalization
88822492|NCT02870283|Active Comparator|Acid Valproic|"Subjects were randomized into three groups: (lithium, valproic acid, or carbamazepine).~Group (B) Started Valproic Acid (1000mg-1500mg).~Subjects evaluated for responsiveness every 2 weeks. Responsive to treatment patients remain in the same step. Max. step duration of 8 weeks.~First step: Monotherapy with Valproic Acid (1000mg-1500mg) Non responsive patients: 2nd step.~Second step: Association with lithium (900mg-1500mg). Non responsive patients: 3rd step.~Third step: Crossover: lithium (900mg-1500mg) + carbamazepine (600mg-1200mg). Non responsive patients: 4th step.~Fourth step: Association with risperidone (1-6mg)"
88822493|NCT02870283|Active Comparator|Carbamazepine|"Subjects were randomized into three groups: (lithium, valproic acid, or carbamazepine).~Group (C) Started Carbamazepine (600mg-1200mg).~Subjects evaluated for responsiveness every 2 weeks. Responsive to treatment patients remain in the same step. Max. step duration of 8 weeks.~First step: Monotherapy with Carbamazepine (600mg-1200mg). Non responsive patients: 2nd step.~Second step: Association with lithium (900mg-1500mg). Non responsive patients: 3rd step.~Third step: Crossover: lithium (900mg-1500mg) + valproic acid (1000mg-1500mg). Non responsive patients: 4th step.~Fourth step: Association with risperidone (1-6mg)"
89355549|NCT01203761||Family members|Family members of ENT surgical patients, during the perioperative period
89355550|NCT03192306|Active Comparator|Merlin|glycolic acid and ethanol mixture
88822494|NCT02224508||Opioid Risk Reduction Initiative|Opioid risk reduction initiative for chronic opioid therapy patients implemented in Group Health integrated group practice clinics.
88822495|NCT02224508||Usual Care|Usual care for management of chronic opioid therapy patients implemented in Group Health network care settings.
88822496|NCT02931045|Active Comparator|Ticagrelor|Ticagrelor: oral, 180 mg once (loading dose) followed by 90 mg twice daily (maintenance dose)
88822497|NCT02931045|Active Comparator|Clopidogrel|Clopidogrel: oral, 300 mg or 600 mg once (loading dose) followed by 75 mg once daily (maintenance dose)
88822498|NCT02224820|Experimental|Intravenous IdeS|One or two doses of IdeS in ascending doses
88822499|NCT03040011|Experimental|Bupivacaine/Dexamethasone Arm|After sterile preparation in lithotomy position, investigators will perform bilateral levator ani muscle injection via the obturator foramen (transobturator). After transobturator injections are performed on each side, bilateral pudendal nerve blocks will be performed transvaginally as described in the literature. The solution injected at all 4 of the above injections sites will consist of a mixture of 20 milliliters of 0.25% bupivacaine (2.5mg/milliliter ) and 2 milliliters of dexamethasone (4mg/milliliter). The total amount of the bupivacaine/dexamethasone solution will be divided equally between the four injection sites.
88822500|NCT03040011|Active Comparator|Bupivacaine Arm|After sterile preparation in lithotomy position, investigators will perform bilateral levator ani muscle injection via the obturator foramen (transobturator). After transobturator injections are performed on each side, bilateral pudendal nerve blocks will be performed transvaginally as described in the literature. The solution injected at all 4 of the above injections sites will consist of 20 milliliters 0.25% bupivacaine (2.5mg/milliliter). The total amount will be divided equally between the four injection sites.
88822501|NCT03040011|Placebo Comparator|Placebo Arm|After sterile preparation in lithotomy position, investigators will perform bilateral levator ani muscle injection via the obturator foramen (transobturator). After transobturator injections are performed on each side, bilateral pudendal nerve blocks will be performed transvaginally as described in the literature. The solution injected at all 4 of the above injections sites will consist of 20 milliliters 0.9% saline (normal saline). The total amount will be divided equally between the four injection sites.
88822502|NCT02225132|Experimental|1|This is a one arm, open-label, non- randomized pilot study to evaluate the effect of algorithm- based HU dosing on the HbF response, the ability to titrate each patient to the MTD of HU, acute complications, and organ function in patients with HbSS.
88822503|NCT03598166|No Intervention|Control|"Patients will receive a letter noting that they are not up-to-date on screening and encouraging them to contact a study number if they choose to screen with colonoscopy or FIT. Patients who call will speak to a research assistant who is trained in patient navigation and can facilitate referrals for colonoscopy or FIT. Patients will receive a follow-up telephone call that reiterates information in the letter.~Patients will also be asked to complete a questionnaire about their beliefs and attitudes regarding CRC screening. The questionnaire will be mailed with the invitation letter and will also be administered over the telephone by the research assistant."
89355551|NCT03192306|Placebo Comparator|Ethanol|
89355552|NCT04066829|Experimental|Experimental: Default setting intervention|The arm will include all patients undergoing tonsillectomy at C.S. Mott Hospital by a pediatric otolaryngology faculty member at the University of Michigan.
89355553|NCT04066829|No Intervention|No Intervention: Control (Usual Care)|The arm will include all patients undergoing tonsillectomy at University Hospital, Brighton Center for Specialty Care, or Livonia Center for Specialty Care by a general otolaryngology faculty member at the University of Michigan.
89355554|NCT01203995|No Intervention|Usual Care|
89355555|NCT01203995|Experimental|brief nutrition education|
89355556|NCT01203995|Active Comparator|In Center training|
89533524|NCT04402788|Experimental|Arm II (atezolizumab, radiation therapy)|Patients receive atezolizumab IV over 30 minutes +/- 10 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo radiation therapy QD on days 1-5 during weeks 1-5 only. Patients undergo PET/CT scan, CT, and MRI throughout the trial. Patients also undergo blood and tissue collection throughout the trial.
89533525|NCT04398628||Hemophilia|"This cohort includes three Arms and five Modules:~Previously Untreated Patients (PUPs) Arm~ALTUVIIIO® Module INHIBIT Module~Hemophilia Natural History Arm~Hemlibra® Module Rebinyn® Module~Hemophilia Gene Therapy Outcomes Arm~HEMGENIX® Module"
89533526|NCT04398628||Congenital Platelet Disorders|"This cohort includes one Arm and Module:~Congenital Platelet Disorders (CPD) Natural History Arm Glanzmann Thrombasthenia (GT) Module"
88822504|NCT03598166|Experimental|Septin9|"Patients will receive a letter noting that they are not up-to-date on screening and encouraging them to contact a study number if they choose to screen with colonoscopy or FIT. Letters will also include an option to participate in the blood test, with instructions to call the study number to schedule the blood draw. This option will not appear in the letters sent to the control group. Patients will also receive a follow-up telephone call and a questionnaire.~Participants who choose to the blood test (Septin9) will undergo phlebotomy. The blood sample will be run by an off-site commercial laboratory. The study team will notify patients and their primary care physicians of blood test results and will facilitate a colonoscopy referral for those with positive tests."
89355557|NCT01203995|Experimental|Video Conference training|
89355558|NCT03216954|Placebo Comparator|Placebo|Subjects will receive oral placebo capsules two times daily.
89355559|NCT03216954|Experimental|Low Dose n-Acetylcysteine|Subjects will receive 0.6 g oral n-acetylcysteine two times daily.
89355560|NCT03216954|Experimental|High Dose n-Acetylcysteine|Subjects will receive 1.2 g oral n-acetylcysteine two times daily.
89533527|NCT04398628||Von Willebrand Disease|No arms or modules
88822505|NCT02223650|Experimental|Overminus Treatment|2.50D overminus spectacles
88822506|NCT02223650|Active Comparator|Non-overminus Treatment|spectacles without overminus or no spectacles
88822507|NCT03040479|Experimental|Mild hepatic impairment|lasmiditan 200 mg single dose
88822508|NCT03040479|Experimental|Moderate hepatic impairment|lasmiditan 200 mg single dose
88822509|NCT03040479|Experimental|Healthy participants|lasmiditan 200 mg single dose
88822510|NCT01895855|Experimental|PXVX0200|Biological: PXVX0200 Single dose; liquid suspension after reconstitution with buffer; 5x10^8 CFU
88822511|NCT01895855|Placebo Comparator|Placebo|Biological: Placebo physiological saline
88822512|NCT03531164|Experimental|Kayak ergometer group|Intervention: Training in kayak ergometer: 3 minutes of warming (pre-charge) , 3-5 intervals of training with moderate to high intensity and pauses of 2-4 minutes (charge) and 2 minutes of cooling down (post-charge) to complete 30 minutes.
88822513|NCT03531164|Active Comparator|Control group|Intervention: 30 minutes of proprioceptive neurofacilitation focused on trunk control
88822514|NCT05207423||Participants With Advanced NSCLC With EGFR Exon-20 Mutations|Participants diagnosed with advanced NSCLC with EGFR exon 20 insertions (ex20ins) mutations who were treated according to routine clinical practice will be observed retrospectively up to 6 months or until the end of follow-up.
88822515|NCT03442400|Experimental|FFR/iFR arm|Volcano iFR/FFR Verrata Plus coronary pressure/flow wire
88822516|NCT02872857|Placebo Comparator|Placebo|
88822517|NCT02872857|Experimental|8mg galantamine twice daily|
88822518|NCT02872857|Experimental|12mg galantamine twice daily|
88822519|NCT03958409|Experimental|Rigorous evaluation|Participants will be evaluated for the rigorous evaluation received.
88822520|NCT03958409|Active Comparator|Standard care|The participants will be evaluated for the standard of care received.
88822521|NCT02996318|Experimental|Sirolimus coated Balloon|treatment of coronary DES-ISR with a sirolimus coated balloon
88822522|NCT02996318|Active Comparator|Paclitaxel coated balloon (SeQuent Please)|treatment of coronary DES-ISR with a paclitaxel coated balloon
88822523|NCT00374673|Experimental|transcranial magnetic stimulation|repetitive transcranial magnetic stimulation of the motor cortex
88822524|NCT00374673|Sham Comparator|placebo stimulation|repetitive placebo stimulation of the motor cortex
88822525|NCT02219282|Active Comparator|Group Dentulous|Laryngeal Mask Unique insertion
88822526|NCT02219282|Experimental|Group Edentulous|Laryngeal Mask Unique insertion
88822527|NCT03945461|Experimental|Gum chewing|Chew xylitol based, peppermint flavored gum for 30 minutes every two hours during the hours of 7 am to 9 pm, for the first 24 hours after your surgery
88822528|NCT03945461|No Intervention|Standard Care|Standard hospital management with no deviations from usual care
88822529|NCT02873481|Experimental|Yoga (CPC+Y)|Women in Centering Pregnancy Care (CPC) will receive the intervention which is a 30 minute yoga sessions during each of the 2-hour CPC meetings (CPC+Y)
88822530|NCT02873481|No Intervention|Comparison (CPC alone)|To strengthen our ability to examine causal relationships between the intervention and outcomes, we will use longitudinal comparison group data contributed from deidentified archival data from an existing IRB-approved study (PI: Masho) which includes pregnant women who participated in the CPC model of care alone (without the yoga component) and were followed throughout their pregnancies using numerous measures identical to those in the proposed study, including weight/BMI, depressive symptoms, anxiety, and stress.
88822531|NCT05197751|Experimental|3 µg dose cohort|3 µg MSP3-CRM-Vac4All/Alhydrogel®
88822532|NCT05197751|Experimental|10 µg dose cohort|10 µg MSP3-CRM-Vac4All/Alhydrogel®
88822533|NCT05197751|Experimental|30 µg dose cohort|30 µg MSP3-CRM-Vac4All/Alhydrogel®
88822534|NCT03921281|Experimental|treatment group|The treatment group (n=38) will receive scalp acupuncture combined with rehabilitation treatment for 3 times per week for 12 weeks.
88822535|NCT03921281|Other|control group|The control group (n=38) will receive rehabilitation treatment for 3 times per week for 12 weeks.
88822536|NCT02876055|Active Comparator|Single shot interscalene nerve block|An interscalene nerve block will be performed under continuous live ultrasound guidance, obtaining visualization of the roots or trunks of the brachial plexus in between the anterior and middle scalene muscles. 15 to 20 mL of Bupivacaine 0.5% with 1:200,000 Epinephrine will be administered.
88822537|NCT02876055|Active Comparator|Continuous interscalene nerve block|"An interscalene nerve block and delivery of a catheter will be performed under continuous live ultrasound guidance, obtaining visualization of the roots or trunks of the brachial plexus in between the anterior and middle scalene muscles.~Initial loading bolus includes 15 to 20 mL of Bupivacaine 0.5% with 1:200,000 Epinephrine. After surgery, the continuous interscalene nerve block catheter will be loaded in the post-anesthesia care unit (PACU) with bupivacaine 0.2% 10 milliliters (mL), and then an infusion will be initiated of bupivacaine 0.2% at 8 to 10 mL per hour."
88822538|NCT02876055|Experimental|Local Infiltration Analgesia (LIA)|"The LIA group will utilize weight based dosing of Ropivacaine as part of a cocktail solution containing ropivacaine, epinephrine, ketorolac, and normal saline 0.9%. Patients will receive a total volume of 120 mL injected strategically in the periarticular structures by the surgeon. This is a one-time injection. This will occur after implantation of the final prostheses, but prior to closure of the fascia."
88822539|NCT02994602|Experimental|Nestorone (NES) + testosterone (T) combined gel|A combination gel with Nestorone® (NES) and Testosterone (T) applied transdermally. The volume of gel to be applied will be approximately 5 mL. This gel volume will contain 62.5 mg of T that will deliver approximately 6 mg T to the body per day and will also contain 8.3 mg of NES that will deliver about 0.8 mg NES to the body per day (NES 8 mg/d + T 60 mg/d (NES8/T60) gel) in 5 ml of combined gel.
89355561|NCT04497922|Active Comparator|Treatment as usual in emergency department|Individuals triaged to a pod in the emergency department without rooms that are fitted with a virtual display screen
89355562|NCT04497922|Experimental|Virtual white board|Individuals triaged to a pod in the emergency department in a room that is fitted with a virtual display screen
89355563|NCT03978702|Experimental|Indication for pancreatectomy|Blood sampling at different time points before and after pancreatectomy
89355564|NCT03841487||Aspiration thrombectomy|In the aspiration thrombectomy group, aspiration thrombectomy was performed for patients with ST elevation myocardial infarction who underwent primary percutaneous coronary intervention (PCI).
89355565|NCT03841487||PCI alone|In the PCI alone group, the STEMI patient received conventional primary PCI without aspiration thrombectomy during the procedure.
89355566|NCT05669807|Experimental|A: Camrelizumab+Albumin-bound paclitaxel|Camrelizumab 200mg d1, one cycle every 14 days on the first day; albumin binding paclitaxel: 100 mg/m2, one cycle every 28 days on the first, eighth and fifteenth days
89355567|NCT05669807|Experimental|B: Camrelizumab+Irinotecan|Camrelizumab 200mg d1, the first day, every 14 days as a cycle Irinotecan: 180 mg/m2, the first day, every 14 days as a cycle
88822540|NCT01897025|Active Comparator|real-tDCS with MI-BCI|"10 sessions of the following: 20 minutes of tDCS prior to each session of motor training with the MI-BCI system.~Direct current at an intensity of 1mA with anode placed over the M1 motor cortex of the affected hemisphere and the cathode placed over the unaffected M1.~After initial calibration, MI-BCI training will involve motor imagery of reaching tasks using the clock game interface of the MIT-Manus robotic system to perform multi-directional reaching movements. Upon detection of the intention to move towards the target on BCI, the robotic arm will complete the reaching movement towards the target. Each training session will last for 40 minutes excluding set-up time."
89355568|NCT03599089|Active Comparator|CA-008 (vocacapsaicin) 0.7 mg (0.05 mg/mL concentration)|Each patient will receive a single dose of 0.7 mg CA-008 injected during an elective Bunionectomy with a multimodal analgesia regimen including a Nonsteroidal anti-inflammatory drug (NSAID) and regional Mayo block with bupivacaine.
89355569|NCT03599089|Active Comparator|CA-008 (vocacapsaicin) 2.1 mg (0.15 mg/mL concentration)|Each patient will receive a single dose of 2.1 mg CA-008 injected during an elective Bunionectomy with a multimodal analgesia regimen including a Nonsteroidal anti-inflammatory drug (NSAID) and regional Mayo block with bupivacaine.
89533528|NCT04398628||Rare Disorders|No arms or modules
89355570|NCT03599089|Active Comparator|CA-008 (vocacapsaicin) 4.2 mg (0.3 mg/mL concentration)|Each patient will receive a single dose of 4.2 mg CA-008 injected during an elective Bunionectomy with a multimodal analgesia regimen including a Nonsteroidal anti-inflammatory drug (NSAID) and regional Mayo block with bupivacaine.
88822541|NCT01897025|Sham Comparator|sham-tDCS with MI-BCI|"10 sessions of sham tDCS with BCI motor training, each session of which will be conducted as follows:~The same electrode placement and stimulation parameters will be employed for sham tDCS as for real tDCS. However, the current will be applied for 30 seconds only, to give subjects the sensation of the stimulation. This method of sham stimulation has also been validated (Gandiga et al., 2006). Current intensity will be increased and decreased gradually to decrease perception.~MI-BCI training will be the same as the real-tDCS group and will similarly last for 40 minutes."
88822542|NCT02934555|Placebo Comparator|Control|Patients in the control group will receive a liquid placebo, which is 50 mL of Ensure (a dietary supplement). This will be given every 12 hours for 7 days, until neurologic recovery, or until hospital discharge.
88822543|NCT02934555|Experimental|Ubiquinol|Patients in the experimental group will receive 300 mg of Ubiquinol in a liquid mixture. The liquid Ubiquinol will be mixed with 50 mL of Ensure (a dietary supplement) to ensure blinding. This will be given every 12 hours for 7 days, until neurologic recovery, or until hospital discharge.
88822544|NCT03297710|Experimental|Treatment (TAS-102, radiation therapy)|Patients receive trifluridine/tipiracil hydrochloride combination agent TAS-102 PO BID and undergo radiation therapy in 10 fractions on days 1-5 and 8-12 in the absence of disease progression or unacceptable toxicity.
88822545|NCT04350671|Experimental|Interferon-β 1a|Interferon-β 1a + Lopinavir / Ritonavir + Single Dose of Hydroxychloroquine
88822546|NCT04350671|Active Comparator|Control|Lopinavir / Ritonavir + Single Dose of Hydroxychloroquine
88822547|NCT03029507|Experimental|ACT enhanced ShipShape (ACT +SS)|"The ACT+SS intervention will be delivered in 8 1.5-hour weekly group sessions. The ACT~+SS protocol integrates ACT concepts and strategies within the existing standard SS protocol."
88822548|NCT03029507|Active Comparator|Standard ShipShape (SS)|Standard ShipShape (SS) The standard SS-only protocol will be delivered in 8 1.5-hour weekly group psychoeducation sessions.
88822549|NCT02935179|Placebo Comparator|Control Group|Normal diet with 1500~2000 kcal
88822550|NCT02935179|Experimental|Treatment Group|White sweet potato diet with 1500~2000 kcal
88822551|NCT03248258||Metastatic Breast Interview Participants - Shared Decision Making|Metastatic Breast Patient Participants will be interviewed on the topic of Shared Decision Making. This will be a one time, one-on-one interview with a trained interviewer.
88822552|NCT03248258||Early Stage Breast Interview Participants - Shared Decision Making|Early Stage Breast Patient Participants will be interviewed on the topic of Shared Decision Making. This will be a one time, one-on-one interview with a trained interviewer.
88822553|NCT03248258||Provider Focus Group -Shared Decision Making|Clinic Provider Participants will participate in a focus group on the topic of Shared Decision Making. This will be a one time, focus group interview with a trained moderator.
89533529|NCT04398628||Bleeding NOS|No arms or modules
89533530|NCT04398628||Thrombosis/Thrombophilia|No arms or modules
89533531|NCT04398628||Non-Neoplastic Hematologic Conditions|No arms or modules
88822554|NCT03248258||Non-UAB Provider Shared Decision Making|Non-UAB Provider Participants will be interviewed on the topic of Shared Decision Making. This will be a one time, one-on-one interview with a trained interviewer.
88822555|NCT03248258||Early Stage de-escalation Interview Participants|Early Stage Breast Patient Participants will be interviewed on the topic of de-escalation of cancer treatment. This will be a one time, one-on-one interview with a trained interviewer.
88822556|NCT03248258||Patient Advocate de-escalation Interview Participants|Patient Advocate Participants will be interviewed on the topic of de-escalation of cancer treatment. This will be a one time, one-on-one interview with a trained interviewer.
88822557|NCT03248258||Physician de-escalation Interview Participants|Physician Participants will be interviewed on the topic of de-escalation of cancer treatment. This will be a one time, one-on-one interview with a trained interviewer.
88822558|NCT03248258||Early Stage Feedback Interview Participants|Early Stage Breast Patient Participants will be interviewed to provide feedback on a decision making tool (video). This will be a one time, one-on-one interview with a trained interviewer.
88822559|NCT00374751|Experimental|Samarium (153SM)|Injection of Samarium (153SM)
88822560|NCT01898429|Active Comparator|Left-sided SCC DBS|Active Stimulation of the left-sided electrode
89533532|NCT04388163|Experimental|Gentian Violet Treatment|A single application of gentian violet will be topically applied to the site(s) of active HS involvement by a trained staff member. The sites will then be bandaged by staff and patients will be instructed about home maintenance procedures.
89533533|NCT04381143|Active Comparator|Aspirin|Aspirin tablet 100mg daily
89533534|NCT04381143|Placebo Comparator|Matching Placebo|Placebo tablet 1 pill daily
89533535|NCT04370795|Active Comparator|Group 1|Patients will be treated with Total Body Irradiation (TBI)
89533536|NCT04370795|Active Comparator|Group 2|Patients will not be treated with Total Body Irradiation (TBI)
89355571|NCT03599089|Placebo Comparator|Placebo|Each patient will receive a single dose of CA-008 vehicle (identical to active treatment but without CA-008) injected during an elective Bunionectomy with a multimodal analgesia regimen including a Nonsteroidal anti-inflammatory drug (NSAID) and regional Mayo block with bupivacaine.
88822561|NCT01898429|Active Comparator|Right-sided SCC DBS|Active stimulation of the right-sided electrode
88822562|NCT02249000|Experimental|BIOVALVE prosthesis|Transcatheter Aortic Valve Replacement (TAVR)
89355572|NCT01200173|Active Comparator|1 = Tested product|
88822563|NCT03188822|Experimental|Bioabsorbable steroid releasing sinus implant & nasal dressing impregnated with steroid|Patients will undergo bilateral endoscopic sinus surgery which will include bilateral frontal sinusotomy of Draf 2a or 2b type as previously described in the literature. At the conclusion of the procedure, if the patient still meets all inclusion criteria, one frontal sinus will be randomly assigned using the envelop method to receive a bioabsorbable steroid releasing implant and the other frontal sinus will receive a bioabsorbable nasal dressing impregnated with steroid
88822564|NCT01899677|Experimental|symbiotic|symbiotic preparation 1/2 sachet twice daily during 30 days
88822565|NCT01899677|Placebo Comparator|distilled water|2 x 0.5 cc distilled water will be given during 30 days
88822566|NCT03044691|No Intervention|Control Clinic|The control group will have to complete the Adaptive Reserve and Change Process Capability Questionnaire and Clinician Survey at baseline and 9 months. Clinicians will provide their usual care related to tobacco and nicotine product use screening and cessation recommendations. Medical record of patients will be reviewed at baseline and at 6 months.
88822567|NCT03044691|Experimental|Intervention Clinic|Participants will be asked to complete the Youth Tobacco and Nicotine Product Questionnaire and Parent Brief Questionnaire (PBQ) using the ResearchACTS software at the point of care. A follow-up survey Youth Tobacco and Nicotine Product Primary Care survey will be administered to participants at least 30 days after their clinic visit.
88822568|NCT04850846|Experimental|Metformin|"Randomly assigned participants receive a stepped dose escalation until target daily dose of 1500mg Metformin XR is reached (3 x 500mg pills/day). The intervention duration will last an additional 6 months.~Metformin Extension:~Participants will have the option of unblinding at the end of their 6months treatment and those who were randomly assigned to the metformin experimental arm can continue taking metformin if they opt in. The extended intervention duration will last an additional 6 months. (1500mg Metformin XR or highest tolerated dose )"
88822569|NCT04850846|Experimental|Placebo|Randomly assigned participants receive a stepped dose escalation until target daily dose of 3 pills/day is reached. The intervention duration will last 6 months.
88822570|NCT03028961|Experimental|Group I (Stanford Letter, interview)|Patients listen to a dialogue on the purpose of ACP. Patients receive a paper copy and online web link to the Stanford Letter and complete and return the form by the day of BMT. After completion of the Stanford Letter, patients undergo a semi-structured, research staff-led interview to evaluate personal perceptions of uncertainty with end-of-life decisions, understanding of the ACP form received, and satisfaction with the ACP form.
88822571|NCT03028961|Active Comparator|Group II (traditional advance directive, interview)|Patients listen to a dialogue on the purpose of ACP. Patients receive a paper copy and online web link to the CA Advance Health Care Directive Form and complete and return the form by the day of BMT. After completion of the CA Advance Health Care Directive Form, patients undergo interview as in Group I.
88822572|NCT03027323|Other|AxoTrack System guided CVC insertion|AxoTrack System guided CVC
88822573|NCT03027323|No Intervention|CVC insertion guided by landmark|Anatomical landmarks to guide CVC
89355573|NCT01200173|Sham Comparator|2 = Control product|
89355574|NCT03192150|Experimental|ISV-305|0.1% dexamethasone in DuraSite® 2
89355575|NCT03192150|Placebo Comparator|Vehicle|DuraSite® 2 vehicle
89355576|NCT01204073|Experimental|TAK-441|
88999464|NCT02898883|Experimental|Intervention group|Early intervention Program The early intervention program (EIP) will consist of 4 sessions with one parent/guardian of the injured child and a clinical psychology graduate student therapist. All sessions are one on one for one hour. The first session will be conducted in the hospital within an average of 24- 48 hours after the traumatic event. The subsequent three sessions will be conducted electronically via web-based video chat once per week. In general, the EIP will utilize psychoeducation, skills implementation, and daily monitoring to facilitate communication regarding the traumatic event, maintain daily and sleep routines, increase child's access to social support and mitigate the impact of life stress.
88999465|NCT02898883|No Intervention|Treatment as Usual (TAU)|As part of routine hospital protocol, all participants who screen positively for PTSD risk are provided with a packet of educational materials and potential referrals for behavioral healthcare.
88999466|NCT02898688|Other|Control Site + Control Patient|The obstetric practice site is randomized to be a control site and the patient is randomized to the control group.
88999467|NCT02898688|Experimental|Control Site + Intervention Patient|The obstetric practice site is randomized to be a control site and the patient is randomized to receive the intervention.
88999468|NCT02898688|Experimental|Intervention Site + Control Patient|The obstetric practice site is randomized to be an intervention site and the patient is randomized to the control group.
88822574|NCT02987933||Chronic Pain|Adults, > 6 months duration, daily pain
88999469|NCT02898688|Experimental|Intervention Site + Intervention Patient|The obstetric practice site is randomized to be an intervention site and the patient is randomized to receive the intervention.
88999470|NCT02898766|Active Comparator|Enteral Nutrition Formula 1|Enteral Nutrition Formula
88999471|NCT02898766|Active Comparator|Enteral Nutrition Formula 2|Enteral Nutrition Formula
88999472|NCT02898571|Placebo Comparator|Placebo|360ml water based drink containing 50g mix of glucose and fructose plus flavouring
88999473|NCT02898571|Experimental|Vitamin C|360ml water based drink containig 60mg vitamin C and 50g mix of glucose and fructose plus flavouring
88999474|NCT02898571|Experimental|Epicatechin|360ml water based drink containig 80mg epicatechin and 50g mix of glucose and fructose plus flavouring
88999475|NCT02898649|Experimental|IRE|The intervention group
89355577|NCT03838523|Experimental|OLP group|"At baseline, patients are given an explanation about why placebos without deception might be effective.~Women allocated to this group receive an 4-week Open Label Placebo treatment. After 4 weeks, they are randomized again to either continue or discontinue the OLP treatment for another 4 weeks."
88822575|NCT02987933||Healthy Normals|Age and gender matched controls
88822576|NCT04743440||Physicians|We will include specialists in anaesthesiology who work at the Anaesthesiology Department, Hillerød hospital, during the trial period. It is an inclusion criterion that they take part in the Anaesthesiology Department's specialist in-house on-call rotation (i.e., attending physician). Each of the included physician participants will be responsible for conducting the airway management in four patient participants; two who have been randomised to the i-gelTM LMA, and two to the Ambu® AuraGainTM LMA, respectively.
88822577|NCT01899911|Experimental|Vital Signs Patch (VSP)|Infrared and Red absorbance measurement on chest
88999476|NCT00553618|Experimental|Proleukin/DTIC Arm|Adjucant proleukin and DTIC
88999477|NCT02898337||Methadone-induced QTc interval prolongation|
88999478|NCT02898337||Methadone-treated patients, no QT interval prolongation|
88999479|NCT02898376|Experimental|combination tocopherol/pentoxifylline + spa care|pentoxifylline (400 mg bid) + tocopherol (500 mg x bid) during at least 6 months AND skin-oriented spa care (18 days)
88999480|NCT02898376|Active Comparator|combination tocopherol/pentoxifylline|pentoxifylline (400 mg bid) + tocopherol (500 mg x bid) during at least 6 months
88999481|NCT02898532|Active Comparator|Intervention group|The intervention is organised in collaboration between the local school, the Danish Shooting Association, and the national DGI (The Danish Gymnastics and Sporting Organization). The intervention is available geographical nationwide. The children will practise target-shooting sport in local Shooting Association once a week during school hours for a period of 6 months. Selected schools are either special schools or municipal schools with special educational programmes for children diagnosed with either ADHD or severe difficulties of hyperactivity, inattention and impulsivity. Teachers accompany the children to the Shooting Association where the instructors meet them.
88999482|NCT02898532|No Intervention|Control group|The same target group as children in the intervention group. In the control group children are not practicing target shooting sport, neither in school or free time.
88999483|NCT02898415||Training set|Consecutive patients who underwent liver transplantation for HCC at Italian transplant centers
89533537|NCT04356352|Active Comparator|Lidocaine|1 mg/kg lidocaine to a max of 100 mg
89533538|NCT04356352|Active Comparator|Esmolol|0.5 mg/kg esmolol to a max of 50 mg
88999484|NCT02898298|Experimental|Immediate|Immediate group receives the Positive Emotion Regulation training immediately.
88999485|NCT02898298|Active Comparator|Waitlist control group|Waitlist control group receives the Positive Emotion Regulation training 4 weeks later.
88999486|NCT02898064|Other|Standard care + brace|Spinal brace (thoracolumbosacral orthosis or cervico-thoraco-lumbar orthosis) to be fitted to the participant in addition to receiving standard of care treatment which can include radiotherapy, chemotherapy or surgery including vertebral augmentation and also medication including bisphosphonates
88999487|NCT02898064|Other|Standard care|Participant will receive standard of care treatment which can include radiotherapy, chemotherapy or surgery including vertebral augmentation and also medication including bisphosphonates
88999488|NCT02897947||treated in Norway included in NORspine|patients having had surgery for lumbar spinal stenosis in Norway and are included in the national register NORspine
88822578|NCT04701866|Experimental|Music|Music will be provided for participant's six 40 minute IV infusions of 0.5mg/kg ketamine administered over four weeks (biweekly for 2 weeks, then weekly for 2 weeks).
88822579|NCT04701866|No Intervention|Usual Care|Participant's six 40 minute IV infusions of 0.5mg/kg ketamine administered over four weeks (biweekly for 2 weeks, then weekly for 2 weeks) will be administered as per usual care. That is, without music provided or permitted. Contact time with clinicians before, during, and after ketamine treatments will be matched.
88822580|NCT01900067|Active Comparator|Active warming|BARRIER® EasyWarm Active Self-Warming Blanket
88822581|NCT01900067|No Intervention|Control|no active warming, standard of care
88999489|NCT02897947||treated in Sweden included in Swespine|patients having had surgery for lumbar spinal stenosis in Sweden and are included in the national register Swespine
89355578|NCT03838523|No Intervention|No-treatment group|"At baseline, patients are given an explanation about why placebos without deception might be effective.~Women assigned to the no-treatment group do not receive any treatment as part of the study."
88822582|NCT02995928|Experimental|Decompressive craniectomy|Decompressive craniectomy and best medical treatment
88822583|NCT02995928|Active Comparator|Control|Only best medical treatment. Decompressive craniectomy is employed only if intracranial pressure >25 mm Hg for 1-12 hours to keep the patients safe.
88822584|NCT01902953|Experimental|Lymphoseek and VBD SLN dissection|Ex-Vivo Lymphoseek and VBD SLN dissection
88822585|NCT02902250|Experimental|Decompression|bone marrow decompression at fractured vertebral body
89355579|NCT03597529|Experimental|Low-Dose Melatonin (mg)|melatonin 2mg (equal to or over 40kg) melatonin 1mg (under 40kg) Melatonin: melatonin
89355580|NCT03597529|Experimental|High-Dose Melatonin (mg)|melatonin 8mg (equal to or over 40kg) melatonin 4mg (under 40kg) Melatonin: melatonin
89355581|NCT01204151|Experimental|Math intervention|
89355582|NCT03906240|No Intervention|No intervention|Veterans will access the online portal and complete session measures, but will not be presented with any intervention content (i.e., videos, journaling exercise, and goal setting exercise)
89355583|NCT03906240|Experimental|Moral Elevation Intervention|Moral Elevation Intervention (described in intervention section).
89355584|NCT01202357|Experimental|Case Management (1 year)|
88822586|NCT02902250|Active Comparator|Conservative Treatment|Conservative Treatment for compression fracture
89355585|NCT01202357|No Intervention|Standard Care (1 year)|
88822587|NCT02759588|Experimental|GL-ONC1|
88822588|NCT02219438|Experimental|RIGHT side BOLUS and left side basal|Bilateral adductor canal catheters were inserted and ropivacaine 0.2% administered concurrently. For the right catheter, the ropivacaine was administered as hourly bolus doses of 8 mL each a total of 8 times: one at time point zero and 1 on the hour for the following 7 hours. For the left catheter, the ropivacaine was administered as a continuous basal infusion (8 mL/h) from time point zero for the following 8 hours
88822589|NCT02219438|Active Comparator|RIGHT side BASAL and left side bolus|Bilateral adductor canal catheters were inserted and ropivacaine 0.2% administered concurrently. For the right catheter, the ropivacaine was administered as a continuous basal infusion (8 mL/h) from time point zero for the following 8 hours. For the left catheter, the ropivacaine was administered as hourly bolus doses of 8 mL each a total of 8 times: one at time point zero and 1 on the hour for the following 7 hours.
89355586|NCT05420454|Active Comparator|TCbHP|HER2-positive breast cancer
89355587|NCT05420454|Experimental|nPCbHP|HER2-positive breast cancer
89355588|NCT05420454|Active Comparator|EC-T|Luminal breast cancer (HER2-, LN+), and triple negative breast cancer
89355589|NCT05420454|Experimental|ddEC-wnP|Luminal breast cancer (HER2-, LN+), and triple negative breast cancer
89355590|NCT02961959|Experimental|Surgery|Arthrodesis of SI-joint/s, physiotherapy
88822590|NCT03045861|Experimental|Cohort 1-GSK2838232 100 mg + Cobicistat 150 mg in Part A|During Part A (Cohort 1), subjects will receive a single dose of GSK2838232 100 mg and Cobicistat 150 mg once daily each morning with a light breakfast meal and 240 mL of water from Day 1 to Day 10. Subjects will be followed up to Day 22.
88822591|NCT03045861|Experimental|Cohort 2-GSK2838232 200 mg + Cobicistat 150 mg in Part B|During Part B (Cohort 2), subjects will receive a single dose of GSK2838232 200 mg and Cobicistat 150 mg once daily each morning with a light breakfast meal and 240 mL of water from Day 1 to Day 10. Subjects will be followed up to Day 22.
88822592|NCT03045861|Experimental|Cohort 3-GSK2838232 50 mg + Cobicistat 150 mg in Part B|During Part B (Cohort 3), subjects will receive a single dose of GSK2838232 50 mg and Cobicistat 150 mg once daily each morning with a light breakfast meal and 240 mL of water from Day 1 to Day 10. Subjects will be followed up to Day 22.
88822593|NCT03045861|Experimental|Cohort 4-GSK2838232 20 mg + Cobicistat 150 mg in Part B|During Part B (Cohort 4), subjects will receive a single dose of GSK2838232 20 mg and Cobicistat 150 mg once daily each morning with a light breakfast meal and 240 mL of water from Day 1 to Day 10. Subjects will be followed up to Day 22.
88822594|NCT01903187|Experimental|Renal Denervation|Renal artery ablation with the EnligHTN™ Renal Denervation System.
88822595|NCT01903187|Active Comparator|Sham procedure|Sham procedure
88822596|NCT02249078|Experimental|Cohort 1|100 mg subcutaneous once every 2 weeks with initial double dose (200 mg total)
88822597|NCT02249078|Experimental|Cohort 2|200 mg subcutaneous once every 2 weeks with initial double dose (400 mg total)
88822598|NCT02249078|Experimental|Cohort 3|400 mg subcutaneous once every 2 weeks with initial double dose (800 mg total)
89355591|NCT02961959|Active Comparator|Non-surgery|Non-surgery, physiotherapy
89355592|NCT03180528|Experimental|Treatment (remetinostat)|Patients receive topical remetinostat 1% gel applied TID directly to the lesion, for 6 weeks in the absence of disease progression or unacceptable toxicity.
88822599|NCT02249078|Experimental|Cohort 4|10 mg/kg IV at Day 1, Day 8, Day 15, and every 2 weeks thereafter
88822600|NCT02249078|Placebo Comparator|Placebo|Placebo 2-mL vial solution for injection
88822601|NCT03029975|Active Comparator|RDA|Participants will be asked to consume the RDA for protein for a 10 week period while also undergoing progressive resistance training exercise three times a week. Beef protein consumption will be emphasized and participants will consume a beef meal after each training session.
88822602|NCT03029975|Experimental|2x RDA|Participants will be asked to consume the twice the RDA for protein for a 10 week period while also undergoing progressive resistance training exercise three times a week. Beef protein will be emphasized and participants will consume a beef meal after each training session.
88822603|NCT01903265|Experimental|TNX-102 SL 2.8 mg|Patients will take 1 tablet of TNX-102 SL sublingually each day at bedtime for 12 weeks.
88822604|NCT01903265|Placebo Comparator|Placebo|Patients will take 1 tablet of placebo sublingually each day at bedtime for 12 weeks.
88822605|NCT03049215|Active Comparator|Lumen Apposing Metal Stent (LAMS)|Subjects randomized to LAMS alone will undergo EUS-guided transmural placement of an Axios stent with a 15 mm luminal diameter.
88822606|NCT03049215|Active Comparator|LAMS plus double pigtail stent|Subjects randomized to LAMS plus double pigtail stent will undergo EUS-guided transmural placement of a single Axios stent with a 15 mm luminal diameter. Following this, wire access across the stent lumen will be achieved using a 0.035 inch hydrophilic guidewire, and a double pigtail plastic biliary stent (6 French, 7 French, or 10 French at the discretion of the endoscopist) will be deployed over the wire.
88822607|NCT01907321|Experimental|Expiratory muscle strength training (EMST)|Participants will complete 5 weeks of EMST training, 5 repetitions per set, 5 sets per day, 5 days per week.
88822608|NCT01907321|Placebo Comparator|Placebo expiratory training|Same look and feel of EMST with no resistance. Same protocol - 5 repetitions of 5 sets, 5 days per week
88822609|NCT02940249|Experimental|1.2 g apple polyphenols|1200 mg apple polyphenols delivered in a low sugar drink.
88822610|NCT02940249|Experimental|0.9 g apple polyphenols|900 mg apple polyphenols delivered in a low sugar drink.
88822611|NCT02940249|Experimental|0.6 g apple polyphenols|600 mg apple polyphenols delivered in a low sugar drink.
88822612|NCT02940249|Placebo Comparator|Placebo|No polyphenols delivered in a low sugar drink.
88822613|NCT02219516|Experimental|Cohort 1: Mild renal impairment|RDEA3170 15 mg once daily fasted
88822614|NCT02219516|Experimental|Cohort 2: Moderate renal impairment|RDEA3170 15 mg once daily fasted
88822615|NCT02219516|Experimental|Cohort 3: Severe renal impairment|RDEA3170 15 mg once daily fasted
88822616|NCT02219516|Experimental|Cohort 4: Control subjects with normal renal function|RDEA3170 15 mg once daily fasted
88822617|NCT04580654|Experimental|CSL312 (Cohort 1a, low dose)|Factor XIIa antagonist monoclonal antibody administered subcutaneously
88822618|NCT04580654|Experimental|CSL312 (Cohort 1b, low dose)|Factor XIIa antagonist monoclonal antibody administered subcutaneously
88822619|NCT04580654|Experimental|CSL312 (Cohort 2, high dose)|Factor XIIa antagonist monoclonal antibody administered subcutaneously
88822620|NCT04580654|Experimental|CSL312 (Cohort 3, low dose)|Factor XIIa antagonist monoclonal antibody administered intravenously
88822621|NCT04580654|Experimental|CSL312 (Cohort 4, high dose)|Factor XIIa antagonist monoclonal antibody administered intravenously
88822622|NCT04976777|Experimental|Updated Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) 0.7 mg|DEX PS DDS 0.7 mg implant was administered intravitreally into the study eye using updated applicator at Day 1 and followed until Day 7.
88822623|NCT04976777|Active Comparator|Approved DEX PS DDS 0.7 mg|DEX PS DDS 0.7 mg implant was administered into the study eye using currently approved applicator at Day 1 and followed until Day 7.
88822624|NCT02247596|Placebo Comparator|Placebo|Sugar pill 1g tds for 2 weeks
89355593|NCT04667507|Experimental|Dextenza (Group A)|Dextenza (dexamethasone ophthalmic insert 0.4mg) 1-3 days prior to cataract surgery
89355594|NCT04667507|Experimental|Dextenza (Group B)|Dextenza (dexamethasone ophthalmic insert 0.4mg) 6-8 days prior to surgery
89533539|NCT04356352|Placebo Comparator|Placebo|Saline water
89355595|NCT04667507|Experimental|Dextenza (Group C)|Dextenza (dexamethasone ophthalmic insert 0.4mg) 13-15 days prior to surgery
88822625|NCT02247596|Experimental|Resveratrol|Trans-resveratrol extract from Polygonum Cuspidatum 1g three times a day for 2 weeks
88822626|NCT04522232|Placebo Comparator|group A|women that underwent conventional Total laparoscopic hysterectomy
88822627|NCT04522232|Experimental|group B|women that underwent Total laparoscopic hysterectomy with prior uterine artery ligation at its origin
88822628|NCT03686657|No Intervention|Healthy adults with NGT|Healthy adults with normal glucose tolerance (NGT) and beta cell function will be administered placebo.
88822629|NCT03686657|Active Comparator|Metformin-Drug naive patients & Patients with inadequate glycemic control with Metformin|Patients receive metformin once daily
88822630|NCT03686657|Experimental|RK-01 Low|Patients receive valsartan, celecoxib and metformin (low dose) once daily
88822631|NCT03686657|Experimental|RK-01 High|Patients receive valsartan, celecoxib and metformin (high dose) once daily
88822632|NCT02993510|Active Comparator|microfracture|Microfracture is an arthroscopic surgical technique involving placement of microfracture penetrations within the cartilage defect to provide stem cells and growth factors from the bone marrow to aid cartilage repair
88822633|NCT02993510|Experimental|Microfracture with Chondro-Gide sutured|Microfracture covered with a collagen membrane (Chondro-Gide®) using atraumatic sutures in a one-step mini-arthrotomy procedure
88822634|NCT02993510|Experimental|Microfracture with Chondro-Gide glued|Microfracture covered with a collagen membrane (Chondro-Gide®) using fibrin glue in a one-step mini-arthrotomy procedure
88822635|NCT03587987|Active Comparator|Neopuff|neopuff
88822636|NCT03587987|Experimental|r PAP|rPap device
88822637|NCT02476058|Experimental|JNJ-42847922|JNJ-428479, 20 milligram (mg) capsule, orally, once daily, at bedtime for 10 days in women of childbearing potential (WOCBP) or for 4 weeks in all other participants.
88822638|NCT02476058|Experimental|Diphenhydramine|Diphenhydramine 25 mg capsule, orally, once daily, at bedtime for 10 days in women of childbearing potential (WOCBP) or for 4 weeks in all other participants.
88822639|NCT02476058|Placebo Comparator|Placebo|Matching placebo (capsules containing neutral pellets), orally, once daily, at bedtime for 10 days in women of childbearing potential (WOCBP) or for 4 weeks in all other participants.
88822640|NCT03049917|No Intervention|No incentive|No incentive
88822641|NCT03049917|Experimental|KES financial incentive 1|Kenyan Shillings conditional cash transfer upon HIV testing
88822642|NCT03049917|Experimental|KES financial incentive 2|Kenyan Shillings conditional cash transfer upon HIV testing
89355596|NCT04667507|Experimental|Dextenza (Group D)|Dextenza (dexamethasone ophthalmic insert 0.4mg) 19-23days prior to surgery
89355597|NCT04667507|Experimental|Dextenza (Group E)|Dextenza (dexamethasone ophthalmic insert 0.4mg) 26-31 days prior to surgery
88822643|NCT03049917|Experimental|KES financial incentive 3|Kenyan Shillings conditional cash transfer upon HIV testing
88822644|NCT03049917|Experimental|KES financial incentive 4|Kenyan Shillings conditional cash transfer upon HIV testing
88822645|NCT05473208|No Intervention|Control Group|Participants randomly assigned to control group will not wear an exoskeleton during working hours.
88822646|NCT05473208|Experimental|Exoskeleton Group|Participants randomly assigned to exoskeleton group will be given instructions and explanations on how to use/adjust/loosen the exoskeleton, and after a period of familiarisation, they will be wearing an exoskeleton during their working hours for a period of one year.
88999490|NCT02897947||treated in Denmark included in Danespine|patients having had surgery for lumbar spinal stenosis in Denmark and are included in the national register DANEspine
88999491|NCT02897986|Experimental|patients with refractory/relapsing solid tumors|
89355598|NCT04667507|No Intervention|Control|Will not receive Dextenza (dexamethasone ophthalmic insert 0.4mg)
89355599|NCT03597295|Experimental|Retifanlimab 500 mg|Retifanlimab 500 milligrams (mg) intravenously every 4 weeks (Q4W).
88822647|NCT02249156||Financial incentive group|Employees of employers who have introduced the Rewards program. Currently there are two employers who have introduced the Rewards program, but there might be others that introduce it in the coming months. All intervention (and control) employers are customers of Castlight and use their price transparency product.
88822648|NCT02249156||Control population|Large employers who have not introduced the Rewards program, but work with Castlight and use their transparency product. It will be ideal if the control population looks similar to the intervention population in key characteristics - age, level of illness, industry of the employer (for example, manufacturing), pre-intervention spending, and geographic distribution. If possible, across a pool of potential control employers, we will identify control employers that look the most similar across these characteristics in the pre-intervention period. Another possible strategy we might use is to weight the individuals in the control population in our analyses by how similar they appear to those in the intervention population.
89355600|NCT03180138|No Intervention|Controls|
89355601|NCT03180138|Active Comparator|Reminders alone|
88822649|NCT03050541|Experimental|MDMA at Memory Encoding|20 healthy adult volunteers will be randomly assigned to the encoding group (MDMA at Encoding). This group will receive capsules before viewing the study materials, and at retrieval two days later, but they will receive MDMA only in the capsule appropriate to their condition, and the next session capsule will contain placebo.
89355602|NCT03180138|Active Comparator|Reminders + compliance-linked incentives|
89355603|NCT04652921|Experimental|Creatine-guanidinoacetic acid|2 grams of creatine and 2 grams of GAA Administered one dose two times per day on an empty stomach in the morning and at the evening
88822650|NCT03050541|Experimental|MDMA at Memory Retrieval|20 healthy adult volunteers will be randomly assigned to the retrevial group (MDMA at Retrevial). This group will receive placebo before viewing the study materials, and MDMA at retrieval two days later..
88822651|NCT03050541|Placebo Comparator|Placebo at both sessions|20 healthy adult volunteers will be randomly assigned to the placebo group (no drug at either session). This group will receive only placebo during study, session before viewing the study materials, and at retrieval two days later.
88822652|NCT01910831|Experimental|DerMend Moisturizing Bruise Formula|Apply LEFT treatment to LEFT arm or (vica versa) RIGHT treatment to RIGHT arm. Will not be known to the subject which arm is on the active treatment and which is on the placebo control. Applied twice daily for 12 weeks. Each subject will have one arm/hand that is either a)the experimental treatment or b) the placebo control.
88822653|NCT01910831|Placebo Comparator|Non-active placebo control|Apply LEFT treatment to LEFT arm or (vica versa) RIGHT treatment to RIGHT arm. Will not be known to the subject which arm is on the active treatment and which is on the placebo control. Each subject will have one arm/hand that is either a)the experimental treatment or b) the placebo control.
88822654|NCT03050619||New users of Empagliflozin|New users of empagliflozin
88822655|NCT03050619||New users of Other SGLT2 inhibitors|New users of other SGLT2 inhibitors
88822656|NCT03050619||New users of Other non-insulin GLDs|New users of other non-insulin GLDs
88822657|NCT02071394|Experimental|72h cooling + 18h xenon inhalation|Babies in poor condition at birth and referred to our neonatal unit for standard therapy of cooling to 33.5 degree C body temperature will be randomised to receive xenon gas at 50% concentration for 18 hours
88822658|NCT02071394|Active Comparator|Standard 72 h whole body cooling therapy|Whole body cooling therapy to rectal temperature of 33.5 degree Centigrade (standard therapy)
88822659|NCT01911065|Experimental|Zostavax™ vaccine group|Participants > 50 years will receive a single dose 0.65 ml Zostavax™ (live, attenuated zoster vaccine) administered by subcutaneous injection.
88822660|NCT01911065|No Intervention|Natural-acquired VZV immunity|Participants 40-49 years of age will not receive any intervention with the objective of examining the influence of age and inherited factors on the varicella zoster virus (VZV)-specific immune response in those with a naturally-acquired VZV immunity (a prior history of chicken pox).
88822661|NCT04420130|Experimental|Camrelizumab combined with ablation and chemotherapy|First, patients with liver metastases from pancreatic cancer are given ablation of liver metastases, and conventional chemotherapy plus camrelizumab is performed 1 week after surgery. If patients have multiple metastases, ablation treatment needs to be performed in stages, each ablation After 1 week of treatment, sequential chemotherapy + camrelizumab were reinfused, and the efficacy was evaluated every 2 cycles until the disease progressed or the patient could not tolerate it.
88822662|NCT01911221|Experimental|rMenB+OMV NZ|A single 0.5mL dose of the study vaccine will be administered intramuscularly in the deltoid muscle.
88822663|NCT03050697|Experimental|HMTIOL|HARMONI® Modular Toric Intraocular Lens implanted in the capsular bag following removal of the cataractous lens, intended for lifetime use
88822664|NCT02993978||Control group|Pediatric patients and their parents who were treated with radiotherapy during baseline period and enrolled in the study. Recruitment to the Control Group took Place during one year.
88822665|NCT02993978||Case group|Pediatric patients and their parents who were treated with radiotherapy during case period and enrolled in the study. Recruitment to the case group took place during one year after introduction of new methods and equipment in the in the clinic..
88822666|NCT02995772|Active Comparator|Neoadjuvant hormonal therapy|Neoadjuvant hormonal therapy: Aromatase inhibitors (Arimidex, Femara, Aromasin), Tamoxifen, SOB and AI, SOB and Tamoxifen
88822667|NCT02995772|Active Comparator|Neoadjuvant chemotherapy|Neoadjuvant chemotherapy: FAC 6 cycles
88822668|NCT01911689||acute pancreatitis|acute pancreatitis group：(a) acute onset of abdominal pain; (b) pancreatitis at first onset; (c) three-fold elevated amylase or lipase, excluding other causes of elevated enzymes; and (5) abdominal MR examination.
88822669|NCT01911689||controlgroup|normal control group：without pancreatic disorders.The exclusion criteria in this study were as follows: (a) inability to cooperate when MR imaging was performed; (b) a history of chronic pancreatitis; (c) AP due to pancreatic carcinoma; (d) hypoproteinemia; and (e) with hypoproteinemia and other peritoneal/ retroperitoneal infection diseases ;(f) with iron deposition disorder (e.g. diabetes or blood system diseases).
88822670|NCT04280822|Experimental|Neoadjuvant immunochemotherapy|"Neo-adjuvant chemotherapy(cisplatin and paclitaxel):~Paclitaxel, 175mg/m2, d1, Cisplatin, 75mg/m2, d1, 3 week, 2 cycles. JS001, 240mg ivgtt, d3, >30min, 3week, 2 cycles~Surgery:~2-3weeks after Neo-adjuvant chemotherapy Surgeons: the operation shall be performed by senior thoracic surgeons. Try to achieve the consistency of operation quality.~Operation: the thoracic esophagectomy must be through right thoracic cavity. (open and minimally invasive McKeown or Ivor Lewis). Total two-field lymphadenectomy (right and left recurrent laryngeal nerve lymph nodes must be included).~After surgery/ maintain period:~JS001, 240mg ivgtt, d3, >30min, 3week (8 cycles at most)"
88822671|NCT04280822|Active Comparator|Neoadjuvant chemotherapy|"Neo-adjuvant chemotherapy(cisplatin and paclitaxel):~Paclitaxel, 175mg/m2, d1, Cisplatin, 75mg/m2, d1, 3 week, 2 cycles.~Surgery:~2-3weeks after Neo-adjuvant chemotherapy Surgeons: the operation shall be performed by senior thoracic surgeons. Try to achieve the consistency of operation quality.~Operation: the thoracic esophagectomy must be through right thoracic cavity. (open and minimally invasive McKeown or Ivor Lewis). Total two-field lymphadenectomy (right and left recurrent laryngeal nerve lymph nodes must be included)."
88822672|NCT03050775|Experimental|Heated Ventilator Circuit|Heated and humidified inspired gases using the ANAPOD™ Heat and Humidification System (Westmed; Tucson, Arizona, USA) circuit prior to induction of general anesthesia in addition to standard ventilation and temperature management.
88999492|NCT00169559|Placebo Comparator|Arm 1|Placebo
89533540|NCT04353674|Sham Comparator|Control|Patients diagnosed with severe COVID-19: Those admitted to the intensive care unit with evidence of severe respiratory distress syndrome will undergo standard of care
88822673|NCT03050775|Active Comparator|Standard Ventilator Circuit|Standard ventilation and temperature management.
88822674|NCT03051633|Experimental|Be Under Your Own Influence Intervention|School-based anti-substance use communications campaign
88822675|NCT03051633|No Intervention|Control|Assessment only
88822676|NCT02227316|Experimental|Intravenous Ibuprofen|Ibuprofen 800mg IV piggyback and Saline IVP q 6 hours x 4 during uterine fibroid embolization
88822677|NCT02227316|Experimental|Intravenous acetaminophen|Acetaminophen 1 gram IV piggyback and Saline IVP q6 hours x 4 during uterine fibroid embolization
88822678|NCT02227316|Experimental|IV ibuprofen/IV acetaminophen|Ibuprofen 800 mg/ Acetaminophen 1 gram IV piggyback and Saline IVP 6 hours x 4 during uterine fibroid embolization
88822679|NCT02227316|Active Comparator|Intravenous placebo/Intravenous placebo|Saline/Saline IV piggyback and IVP Ketorolac 30 mg q6 hours x 4 during uterine fibroid embolization
88822680|NCT00555971|Placebo Comparator|Placebo Group|Subjects randomized to placebo
88822681|NCT00555971|Active Comparator|Omalizumab Group|Subjects randomized to omalizumab
88822682|NCT02943213|Experimental|Treatment Period 1|First dosing period in which all enrolled subjects are administered a single dose of 25 mg Chlorpromazine Hydrochloride Tablet.
88822683|NCT02943213|Experimental|Treatment Period 2|Second dosing period in which all enrolled subjects are administered a single dose of 25 mg Chlorpromazine Hydrochloride Tablet.
88822684|NCT02987855|Experimental|Lipoaspiration Arm 1|Acquisition of Adipose-Derived tissue Stromal Vascular Fraction (AD-tSVF) via closed syringe lipoaspiration harvest of subdermal fat
88822685|NCT02987855|Experimental|AD-cSVF Arm 2|ADcSVF Isolation of cellular stem/stromal cells from subdermal adipose-derived cellular stromal vascular fraction
88822686|NCT02987855|Experimental|Normal Saline IV Arm 3|Normal Saline IV with AD-cSVF cells
88822687|NCT03052257|Experimental|Intervention|"Participants will be randomized to receive either a general eye health educational session (control arm) or an educational intervention developed to improve glaucoma medication adherence (intervention arm). All participants will be provided with a smart bottle to house one of their glaucoma medications. The smart bottle records the date and time that the bottle is opened."
88999493|NCT00169559|Active Comparator|Arm 2|Fenofibrate
89355604|NCT04652921|Placebo Comparator|Inulin|4 grams of inulin Administered one dose two times per day on an empty stomach in the morning and at the evening
88822688|NCT03052257|Active Comparator|Control|"Participants will be randomized to receive either a general eye health educational session (control arm) or an educational intervention developed to improve glaucoma medication adherence (intervention arm). All participants will be provided with a smart bottle to house one of their glaucoma medications. The smart bottle records the date and time that the bottle is opened."
88822689|NCT02249234|Experimental|Botox|Botox 200 units reconstituted in 10ml of normal saline for a one-time injection
88822690|NCT02249234|Placebo Comparator|Saline|Saline 10ml of normal saline for a one-time injection
88999494|NCT00408213|Experimental|1|
88999495|NCT00408213|Placebo Comparator|2|
88822693|NCT03054051|Experimental|Tumaini Mobile Phone Game|Participants randomized to this arm will be invited to play the Tumaini game.
88822694|NCT03054051|No Intervention|Standard of Care|Participants randomized to this arm will receive no intervention beyond the current standard of care for sexual education.
88822695|NCT01338740||Switch from Adalimumab to Infliximab|Moderately to severely active Crohn's disease patients with primary non-response or loss of response to Adalimumab, will switch to Infliximab.
88822696|NCT04226768|Experimental|"Enhanced Haematology Palliative Care (Fast-track) Group"|"Patients who are assigned to enhanced haematology palliative care (fast-track group) will be seen, within 2 days of enrollment, at the out-patient clinic or in-patient setting by the haematology palliative care team that comprises a palliative medicine specialist or a haematologist with palliative care experience, a full-time palliative care nurse, and a medical social worker concentrating on haematology palliative patients."
88999496|NCT02898142|Experimental|Isolated HTG without metabolic syndrome|Postprandial test : The preparation used for this test consists of a semi standardized liquid meal (400 ml energy drink Fresubin® 2 cal / ml, Fresenius Kabi, France), containing 800 kcal, 50% calories from carbohydrates, 15% in as protein, and 35% as lipid. The test meal will be performed in the morning during 6 hours (between 8:00 and 14:00) after 10 hours of fasting.
88999497|NCT02898142|Experimental|HTG with metabolic syndrome|Postprandial test : The preparation used for this test consists of a semi standardized liquid meal (400 ml energy drink Fresubin® 2 cal / ml, Fresenius Kabi, France), containing 800 kcal, 50% calories from carbohydrates, 15% in as protein, and 35% as lipid. The test meal will be performed in the morning during 6 hours (between 8:00 and 14:00) after 10 hours of fasting.
89355605|NCT01314612|Experimental|Group Intervention|Subjects randomly assigned to this arm of the study will receive the 9-week insomnia and nightmare intervention group once per week for 90 minutes in addition to continuing treatment as usual with medical and mental health providers.
88822697|NCT04226768|Active Comparator|Conventional Supportive Care Group|"Patients who are assigned to the conventional supportive care group will be under care of haematologists and nurse specialists in haematology After 12 weeks of conventional supportive care, patients randomized to this group will receive services from the palliative care team and assessed every two weeks same the fast-track group"
88822698|NCT02944461|Experimental|Dapsone gel 7.5%|Dapsone gel 7.5% to be applied to truncal acne once daily for 16 weeks.
88822699|NCT04737213|Experimental|SGM-101|Patients included with colorectal lung metastases, SGM-101 7.5-12.5mg, 3-5 days prior to surgery
88822700|NCT02945553|Experimental|NMES|Neuromuscular electrical stimulation (NMES) group
88822701|NCT02945553|Active Comparator|Microstimulation|Microstimulation
88822702|NCT05376722|Experimental|pamiparib|Subjects received pamiparib 40 mg orally, twice a day; abiraterone acetate 1000 mg orally, once a day; prednisone acetate tablets (prednisone) 5 mg, once a day; every 30 days Treatment cycle, treatment for 4-6 cycles, that is, 4-6 months. Robot-assisted laparoscopic radical prostatectomy and extended lymph node dissection within 30 days of the end of 4 months of neoadjuvant therapy. If the subjects have intolerable toxic reactions during the treatment period, the dose adjustment can be carried out. Day 1 of cycle 1, day 15 and day 1±3 days of each cycle thereafter, and 1 follow-up within 30 days after the end of treatment and before surgery; 1 prostate MRI during the screening period and within 30 days after the end of treatment and before surgery Scan, PSMA PET/CT scan or CT scan
88822703|NCT05349500|Experimental|OA CARE|Participants assigned to the OA CARE intervention will receive a 12-month Medical Membership to a local YMCA and participate in a 12-week weight loss program. Participants will also work with an OA CARE Navigator, who, in partnership with their primary care provider (PCP), will identify any additional programs or resources that may help them manage their osteoarthritis (OA) symptoms.
88822704|NCT05349500|Placebo Comparator|Usual Care|Participants assigned to this group will receive no additional treatment from the study for about 12 months.
88822705|NCT02946021|Experimental|Pneumatic Compression-1 session per day|Head and neck garments for pneumatic compression device for treatment of lymphedema (1 session per day) with imaging using NIRFLI with ICG (Indocyanine green).
88822706|NCT02946021|Experimental|Pneumatic Compression-2 sessions per day|Head and neck garments for pneumatic compression device for treatment of lymphedema (2 sessions per day) with imaging using NIRFLI with ICG (Indocyanine green).
88822707|NCT03110601|Active Comparator|Control - Conventional SCS|Conventional SCS parameters for 4 days plus/minus 1 day using an external SCS modulator.
88822708|NCT03110601|No Intervention|Washout Period|1 day where no stimulation is provided
88822709|NCT03110601|Experimental|Test - Stimgenics SCS|Stimgenics SCS parameters for 4 days plus/minus 1 day using an external SCS modulator.
89355606|NCT01314612|No Intervention|Treatment as Usual|This group is randomly assigned to receive only treatment as usual and does not receive the active intervention of the insomnia and nightmare group treatment. This treatment will be made available to these members once the study is completed
88822710|NCT04737057|Active Comparator|Hall Technique|The Hall Technique is a non-invasive treatment for decayed molar teeth. Decay is sealed under preformed (stainless steel) crowns, avoiding injections and drilling. It is one of a number of biologically orientated strategies for managing dental decay
88822711|NCT04737057|Experimental|SDF|a clear liquid that combines the antibacterial effects of silver and the remineralizing effects of fluoride, is a promising therapeutic agent for managing caries lesions in young children and those with special care needs
88822712|NCT03111381|Experimental|Intervention Group|The intervention group in this study will receive a one-time dose of Ketorolac 30mg intravenously after undergoing general anesthesia. Because the participants will be under general anesthesia, they will not know if they received the medication. The surgeon will also be blinded to this. The anesthesiologist will not be blinded as he/she will deliver the agent and because the use of Toradol may alter their usage of other intra-operative agents and post-operative agents
88822713|NCT03111381|No Intervention|Non-Intervention Group|In the no-treatment group, participants will not receive a dose of intra-operative Ketorolac.
88822714|NCT02946489|Experimental|CI-581a+MET+MBRP|Administration of CI-581a during wk 2 and possibly at wk 3 or 4 at 0.71 mg/kg in the context of a 2 wk course of MET followed by a 4 wk course of MBRP
88822715|NCT03059901|Experimental|More App Notifications|Participants receive more notifications than the Active Comparator group from the Caminamos app to walk.
88999498|NCT02898025|Active Comparator|G1 (Active IFC and Active Laser)|42 patients with knee (s) osteoarthritis. All patients will receive guidance on the disease and on joint protection and energy conservation over a period of 50 minutes in a single session. This group (G1) will receive the treatment of Active Interferential Current and Active Laser for 12 sessions.
88999499|NCT02898025|Active Comparator|G2 (Active IFC and Placebo Laser)|42 patients with knee (s) osteoarthritis. All patients will receive guidance on the disease and on joint protection and energy conservation over a period of 50 minutes in a single session. This group (G2) will receive the treatment of Active Interferential Current and Placebo Laser for 12 sessions.
89355607|NCT01200251|Experimental|Bimatoprost treated eyelid|one eyelid of the patient was randomized to the treatment arm and given the gel to use
88822716|NCT03059901|Active Comparator|Normal App Notifications|Participants receive less notifications than the Experimental group from the Caminamos app to walk.
88822717|NCT02949141|Experimental|Ultrasound|All patients will initially get an ultrasound (interpreted by emergency department physician) followed by chest x-ray (read by independent radiologist) and computed tomography (read by radiologist)
88822718|NCT03112473|Active Comparator|Bilateral TENS (Bi-TENS) group|All subjects will undergo 20 sessions of their assigned intervention (60 minutes, thrice a week, for 8 weeks). All subjects will receive 60 minutes task-oriented upper limb training (TOT) with bilateral electrical stimulation
88822719|NCT03112473|Placebo Comparator|Unilateral TENS (uni-TENS) group|All subjects will undergo 20 sessions of their assigned intervention (60 minutes, thrice a week, for 8 weeks). All subjects will receive 60 minutes task-oriented upper limb training (TOT) with unilateral electrical stimulation on paretic side and sham electrical stimulation on the non-paretic side
88822720|NCT03112473|Placebo Comparator|Placebo group|All subjects will undergo 20 sessions of their assigned intervention (60 minutes, thrice a week, for 8 weeks). All subjects will receive 60 minutes task-oriented upper limb training (TOT) with bilateral sham electrical stimulation
88822721|NCT03112473|No Intervention|Control group|No Active intervention
88822722|NCT02227706|Experimental|EVICEL® Fibrin Sealant|EVICEL® is a human plasma-derived fibrin sealant. EVICEL® consists of two components: a concentrate of Human Clottable Protein (referred to as Biological Component 2; BAC2) and a solution of Human Thrombin. No material of animal origin is present in the product
88822723|NCT02227706|Active Comparator|SURGICEL® Absorbable Hemostat|SURGICEL® Absorbable Hemostat (oxidized regenerated cellulose) is a sterile absorbable knitted fabric prepared by the controlled oxidation of regenerated cellulose.
88822724|NCT03112863|Experimental|Bakuchiol|Bakuchiol 0.5% applied to face twice daily
88822725|NCT03112863|Active Comparator|Retinol|0.5% retinol applied to face nightly
88822726|NCT02228174|Experimental|Subjects Treated with Sonata|Intervention: Intrauterine Ultrasound-Guided Radiofreq. Ablation System or the Sonata, which is a sonography guided transcervical ablation device intended for treatment of symptomatic uterine fibroids. Subjects with symptomatic uterine fibroids and heavy menstrual bleeding who met the study population selection criteria received treatment with Sonata.
88822727|NCT02950467|Experimental|Group therapy plus psilocybin|Modified brief Supportive-Expressive Group Therapy will be administered as ten twice-weekly sessions. Oral psilocybin will be administered once in a clinical setting.
88822728|NCT02280317|Experimental|Cohort 1: 0.5 mg/kg|VAL201-001 Sub-cutaneous injection. 0.5 mg/kg
88822729|NCT02280317|Experimental|Cohort 2: 1 mg/kg|VAL201-001 Sub-cutaneous injection. 1.0 mg/kg
88822730|NCT02280317|Experimental|Cohort 3: 2 mg/kg|VAL201-001 Sub-cutaneous injection. 2.0 mg/kg
88822731|NCT02280317|Experimental|Cohort 4: 4 mg/kg|VAL201-001 Sub-cutaneous injection. 4.0 mg/kg
88822732|NCT02280317|Experimental|Cohort 5: up to 8 mg/kg|VAL201-001 Sub-cutaneous injection. 8.0 mg/kg; potential to escalate to 16 mg/kg after 3 cycles according to clinician decision Flexibility of dosing enabled under protocol.
88822733|NCT02249312|Experimental|BIIIL|
88822734|NCT02249312|Placebo Comparator|Placebo|
88822735|NCT01930487|Experimental|supplement w/ antioxidants then placebo|dietary supplement with antioxidants, followed by placebo supplement
88822736|NCT01930487|Experimental|placebo then supplement w/ antioxidants|placebo supplement, followed by dietary supplement with antioxidants
89533541|NCT04353674|Active Comparator|SLEDD with a L-MOD|Patients diagnosed with severe COVID-19: Those admitted to the intensive care unit with evidence of severe respiratory distress syndrome will undergo slow low efficiency daily dialysis for approximately 12 hours, 2 days in a row with a leukocyte modulatory device.
88822737|NCT03060759|Active Comparator|Light Therapy-Spectrum 1|Light from 'active' spectrum
88822738|NCT03060759|Placebo Comparator|Light Therapy-Spectrum 2|Light from 'placebo' spectrum
88822739|NCT02247674|Placebo Comparator|Education & training consultation|Education and training consultations were provided for subjects in control group during study period.
88822740|NCT02247674|Experimental|Bilateral movement training|Exercise training of bilateral isometric handgrip force training group consisted of 60 minutes of bilateral isometric handgrip force training 3 days per week for 4 weeks (total 12 sessions)
88822741|NCT03063255|Active Comparator|Obturator block|Comparing the incidence of adductor spasm in patients undergoing general anesthesia with obturator block.
88822742|NCT03063255|Active Comparator|Neuromuscular block|Comparing the incidence of adductor spasm in patients undergoing general anesthesia with neuromuscular blocking agents.
88822743|NCT05249114|Experimental|Cohort 1|Cabozantinib 20 mg daily with Lu-177 DOTATE administration IV. For cycles 5+, single-agent maintenance of cabozantinib is given at 20 mg qd.
88822744|NCT05249114|Experimental|Cohort 2|Cabozantinib 40 mg qod alternating with 20 mg qod with Lu-177 DOTATE administration IV. For cycles 5+, single-agent maintenance of cabozantinib is given at 40 mg qd.
88822745|NCT05249114|Experimental|Cohort 3|Cabozantinib 40 mg qd with Lu-177 DOTATE administration IV. For cycles 5+, single-agent maintenance of cabozantinib is given at 40 mg qd.
88822746|NCT05249114|Experimental|Cohort 4|Cabozantinib 60 mg qod alternating with 40 mg qod with Lu-177 DOTATE administration IV. For cycles 5+, single-agent maintenance of cabozantinib is given at 60 mg qd.
88822747|NCT05249114|Experimental|Cohort 5|Cabozantinib 60 mg qd with Lu-177 DOTATE administration IV. For cycles 5+, single-agent maintenance of cabozantinib is given at 60 mg qd until disease progression.
88822748|NCT03065205|Experimental|Single Arm|Patients will have adherence monitoring devices placed on their asthma inhalers (both daily and rescue medication). Adherence information will be sent to their PCP, specialist and school nurse monthly. Additionally, the navigator will speak with families every 2 months to discuss adherence data and address barriers.
88822749|NCT01930643|Experimental|Electric muscle stimulation(EMS)|EMS:use programmed middle frequency electric stimulation device(HELEX 573)for both quadriceps stimulation, 32 minutes per day, 5 time per week.
88822750|NCT01930643|No Intervention|Control|Patients with routine passive rehabilitation program.
88822751|NCT03115827|Experimental|Arm 1|Droxidopa 600mg by mouth twice a day and carbidopa 200mg by mouth twice a day for 4 weeks
88822752|NCT02993432|Active Comparator|Prostaglandin|Administration of the prostaglandin for cervical ripening of the clinician's choice, ie Prostin (Prostin E2 Vaginal Gel 1mg intravaginally) or Cervidil (dinoprostone, 10 mg vaginal insert)
89533542|NCT04341623|Other|Control Group|All patients will receive Cetaphil Pro Eczema moisturizer equipped with an electronic monitor to measure adherence to daily treatment of xerosis
89533543|NCT04341623|Other|Digital Interaction Group|The digital interaction group will receive a survey by email each week asking about their Cetaphil use in addition to the electronic monitor measuring the adherence.
89533544|NCT04341623|Other|GPSkin group|The patients in the GPSkin group will receive the GPSkin Barrier® to measure the moisture level of their inner wrist, inner elbow, and dorsal hand daily.
88999500|NCT02898025|Active Comparator|G3 (Placebo IFC and Active Laser)|42 patients with knee (s) osteoarthritis. All patients will receive guidance on the disease and on joint protection and energy conservation over a period of 50 minutes in a single session. This group (G3) will receive Placebo Interferential Current and Active Laser for 12 sessions.
88999501|NCT02898025|Placebo Comparator|G4 (Placebo IFC and Placebo Laser)|42 patients with knee (s) osteoarthritis. All patients will receive guidance on the disease and on joint protection and energy conservation over a period of 50 minutes in a single session. The placebo group (G4) will receive Placebo Interferential Current and Placebo Laser for 12 sessions.
88999502|NCT02897752|Experimental|WalkAide|
88999503|NCT02897752|Active Comparator|Usual gait Training|
88999504|NCT02897713|Experimental|intensive EN|Intensive enteral nutrition is to performed until discharge with max during of 7 days
88999505|NCT02897713|Active Comparator|routine EN|Routine enteral nutrition is to performed until discharge with max during of 7 days
88999506|NCT02897635|Experimental|Integrative Medicine Intervention|Study participants will attend 14 visits with an integrative medicine clinician over the course of 6 months followed by a 6 month maintenance phase. The treatment modalities employed in the study will include nutrition and lifestyle recommendations.
88999507|NCT02897674|Experimental|Normal weight|Participants will BMI 18.5-24.9 kg/m2 will consume 20% of their calories from one of the three dietary fats Intervention: palm olei Intervention: interesterified palm olein Intervention: soybean oil
88999508|NCT02897674|Experimental|Overweight|Participants will BMI 25-29.9 kg/m2 will consume 20% of their calories from one of the three dietary fats Intervention: palm olei Intervention: interesterified palm olein Intervention: soybean oil
88999509|NCT00408252|Experimental|Arm A|patients will receive SU011248 in monotherapy
88999510|NCT02897869|Experimental|Treatment sequence 1|Participants will be randomized to one of two treatment sequences. Sequence 1 is: Period 1, POL7080; Period 2, Amikacin; Period 3,POL7080+Amikacin. Each period is separated by a wash-out period of at least 12 days between last dose and start of next treatment.
88999511|NCT02897869|Experimental|Treatment sequence 2|Participants will be randomized to one of two treatment sequences. Sequence 1 is: Period 1, Amikacin; Period 2, POL7080; Period 3,POL7080+Amikacin. Each period is separated by a wash-out period of at least 12 days between last dose and start of next treatment.
88999512|NCT02897830|Experimental|Study treatment|Ixazomib, Lenalidomide, Dexamethasone Induction and extended Consolidation followed by Lenalidomide Maintenance
88999513|NCT02897518|Experimental|endotracheal intubation with Imago V-blade|Patients in this arm will receive endotracheal intubation with the Imago V-Blade videolaryngoscopes.
88999514|NCT02897518|Active Comparator|endotracheal intubation with Glidescope|Patients in this arm will receive endotracheal intubation with the glidescope videolaryngoscopes.
88822753|NCT02993432|Experimental|Foley catheter filled to 80cc|Insertion of a Foley catheter through the cervix and filling to 80cc
88999515|NCT02897557|Experimental|Single Cohort in CRC|This study is a single-arm, multi-center, observational clinical trial being conducted in a Clinical Research Center (CRC) setting.
88999516|NCT00169676||cohort|Registry and Database
88999517|NCT02897596|Experimental|Genotype 1b|Grazoprevir 100 mg/d during 8 weeks. Elbasvir 50 mg/d during 8 weeks.
88999518|NCT02897596|Experimental|Genotype 1a and 4|Grazoprevir 100 mg/d during 12 weeks. Elbasvir 50 mg/d during 12 weeks.
88999519|NCT02897791|Experimental|Impaired Rt. Hemisphere patients|20 first stroke patients
88999520|NCT02897791|Experimental|control|20 healthy adults without any known damage to the right hemisphere. The two groups will be matched concerning sex, age, educational level and socio-economic status.
88999521|NCT02897440||Full Repairing of soft tissue surrounding the hip|Full repairing soft tissue surrounding the hip damaged during the procedure of hip dislocation and prosthesis implanting
88999522|NCT02897440||Partial Repairing of soft tissue surrounding the hip|Partial repairing soft tissue surrounding the hip damaged during the procedure of hip dislocation and prosthesis implanting
88999523|NCT04681027|Active Comparator|Pediatric Age Groups: 7 to ≤12 years|Participants expected to require ATC opioids for an extended period of time
88999524|NCT04681027|Active Comparator|Pediatric Age Groups: 13 to ≤17 years|Participants expected to require ATC opioids for an extended period of time
88999525|NCT00408330|Active Comparator|1|azelaic acid 15%
88999526|NCT00408330|Placebo Comparator|2|Inactive 15% gel base
88999527|NCT00169715|Other|A|
88999528|NCT02897245||Patient with intentionally stop|
88999529|NCT02897167||PAFIP patients (1)|"Individuals included in the First Episode Psychosis Clinical Program (PAFIP) between June 2011 and February 2016.~Retrospective study of frozen samples: samples at baseline and 3 months will be analyzed."
88999530|NCT02897167||PAFIP patients (2)|"Individuals included in the First Episode Psychosis Clinical Program (PAFIP) between September 2016 and September 2017.~Prospective study of fresh samples: samples at baseline and 3 months will be analyzed."
88999531|NCT02897167||Controls|Healthy subjects without psychotic disorder.
88999532|NCT02897206|Experimental|Imipenem group|Imipenem 3 x 500 mg i.v. daily ideally for 10 days (minimum 7 days, maximum 21 days)
88999533|NCT02897206|Placebo Comparator|Placebo group|Identical placebo administered in identical dosage, timing and duration.
88999534|NCT02897401|Experimental|Smocker|Cigarette consumption in the context of their habit (not related to the particiapion under study).
88999535|NCT02897401|Experimental|Electronic cigarette|Electronic cigarette consumption in the context of their habit (not related to the particiapion under study).
88999536|NCT02897401|Experimental|Nicotine replacement therapy|Nicotine replacement therapy (only patch) consumption in the context of their habit (not related to the particiapion under study).
88999537|NCT02897401|Placebo Comparator|Without nicotine|No consumption in the context of their habit (not related to the particiapion under study).
88999538|NCT02897362||Adolescents with ADHD|Adolescents, male or female, ages 13-17, confirmed diagnosis of Attention Deficit Hyperactivity Disorder (inattentive, hyperactive/impulsive, or combined presentations), medically healthy, no comorbid psychiatric diagnosis other than ODD, intelligence within normal limits. Participants will complete 3 nights of ambulatory polysomnography at home and a neuropsychological assessment in the lab.
88822754|NCT03694028|Experimental|Limb Loading|This group will be exposed to a sudden unilateral lowering of the supporting surface to induce lateral weight transfer of the paretic limb.
88822755|NCT03694028|Active Comparator|Conventional Training|This group will practice weight shifting and step training that focuses on the paretic limb.
88822756|NCT01915823|Active Comparator|Dymista|"(azelastine hydrochloride and fluticasone propionate) Nasal Spray, 137mcg/50mcg: Mode of Administration: Topical/intranasal spray~Dose: 548 mcg azelastine hydrochloride / 200 mcg fluticasone propionate, total daily dose Regimen: 1 spray per nostril twice daily"
88822757|NCT01915823|Placebo Comparator|Dymista vehicle|Dose: vehicle only Regimen: 1 spray per nostril twice daily
88822758|NCT03065283|Active Comparator|Diaphragmatic release|The stretching of the peripheral fibers of the diaphragm
88822759|NCT03065283|Placebo Comparator|Diaphragmatic release control|In both placebo techniques, only the light touching of the contacts of the volunteers' skin
88822760|NCT03068091|Other|Pulmonary Assessment|All participants will undergo a Chest CT scan and pulmonary function testing
88822761|NCT05014880|Placebo Comparator|ICR (Intensive Cardiac Rehabilitation)|"20 patients will be randomly assigned to the standard of care group, which will receive the standard health and nutritional wellness guidelines that are required of UCSD's 9-week ICR program, referred to as the ICR group."
88822762|NCT05014880|Experimental|ICR x TRE (Intensive Cardiac Rehabilitation x Time-Restricted Eating)|"20 patients will be randomly assigned to the Time-Restricted Eating (TRE) group which will be asked to limit the number of hours they eat in a day to 10 hours in addition to receiving the standard of care health and nutritional wellness guidelines that are required of UCSD's 9-week ICR program, referred to as the ICR x TRE group."
88822763|NCT03116841|Experimental|Vonoprazan 20 mg|Vonoprazan 20 mg orally administered once daily
88822764|NCT01916681|Experimental|Cervical foley & Misoprostol|Patients randomized to this arm will receive a cervical foley and misoprostol to induce their labor.
88822765|NCT01916681|Experimental|Misoprostol only|Patients randomized to this arm will receive misoprostol only to induce their labor.
88822766|NCT01916681|Experimental|Cervical foley alone|Patients randomized to this arm will receive a cervical foley to induce their labor.
88822767|NCT01916681|Experimental|Cervical foley & Pitocin|Patients randomized to this arm will receive a cervical foley and pitocin to induce their labor.
88822768|NCT00374361||Caucasian Adolescents|Caucasian Adolescents
88822769|NCT00374361||African-American Adolescents|African-American Adolescents
88822770|NCT05735951|Experimental|Mild renally impaired patients|Mild renally impaired patients
88822771|NCT05735951|Experimental|Moderate renally impaired patients|Moderate renally impaired patients
88822772|NCT05735951|Experimental|Severe renally impaired patients|Severe renally impaired patients
88822773|NCT05735951|Experimental|Matching controls|Matching volunteer without renal impairement
88822774|NCT01917773|Experimental|Octreotide|All patient received octreotide. We compared pre (fasting) and post octreotide colonic motility index.
88822775|NCT02283749|Experimental|Xofigo|Xofigo, 50 kBq/kg body weight, will be administered in the nuclear medicine department as a bolus intravenous (IV) injection (up to 1 minute) at intervals of every 4 weeks for up to 6 cycles.
88822776|NCT01934231|Experimental|Single arm|Each participant will take Potassium Clavulanate (CVA)/ Amoxicillin (AMPC) corresponding 6.4/90 mg/kg/day in two divided doses (every 12 hours) just before lactation or meal for 7 days depending on his/her body weight at the start of treatment (Day 1). The actual daily dose depends on the body weight of the participant.
88822777|NCT01935791|Active Comparator|Period 1 Visit 1 - Cold PET-CT Vehicle, Visit 2 -Warm PET-CT Vehicle|"Visit 1. Participants underwent F-fluorodeoxyglucose (18F-FDG) positron emission tomography, computerised tomography-(PET)CT, whilst wearing a cooling vest and receiving an infusion of gelofusine.~Visit 2 Participants underwent F-fluorodeoxyglucose (18F-FDG) positron emission tomography, computerised tomography-(PET)CT, whilst receiving an infusion of gelofusine without a cooling vest."
88822778|NCT01935791|Experimental|Period 1 Visit 1 - Cold PET-CT Vehicle, Visit 2 -Warm PET-CT Glucagon|Visit 1. Participants underwent F-fluorodeoxyglucose (18F-FDG) positron emission tomography, computerised tomography-(PET)CT, whilst wearing a cooling vest and receiving an infusion of gelofusine Visit 2 Participants underwent F-fluorodeoxyglucose (18F-FDG) positron emission tomography, computerised tomography-(PET)CT, whilst receiving an infusion of Glucagon at a dose of 50ng/kg/min without a cooling vest.
88822779|NCT01935791|Active Comparator|Period 1 Visit 1 - Cold PET-CT Vehicle, no visit 2 as BAT negative|"Visit 1. Participants underwent F-fluorodeoxyglucose (18F-FDG) positron emission tomography, computerised tomography-(PET)CT, whilst wearing a cooling vest and receiving an infusion of gelofusine.~No brown adipose tissue (BAT) identified on visit 1, therefore no visit 2."
88822780|NCT01935791|Experimental|Period 2 - Visit 1 Warm Control vehicle, Visit 2 Warm Glucagon, Visit 3 Cold control|"Visit 1- Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of gelofusine. They were situated in an ambient temperature of 22-25 degrees celsius.~Visit 2 - Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of Glucagon at a dose of 50ng/kg/min. They were situated in an ambient temperature of 22-25 degrees celsius. Visit 3 - Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of gelofusine and wearing a cooling vest."
88822781|NCT01935791|Experimental|Period 2 - Visit 1 Warm Glucagon, Visit 2 Cold control , Visit 3 Warm control|"Visit 1- Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of Glucagon at a dose of 50ng/kg/min. They were situated in an ambient temperature of 22-25 degrees celsius.~Visit 2 - Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of gelofusine and wearing a cooling vest.~Visit 3 Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of gelofusine. They were situated in an ambient temperature of 22-25 degrees celsius."
88822782|NCT01935791|Experimental|Period 2 -Visit 1 cold control, Visit 2 warm control, Visit 3 Warm glucagon|"Visit 1 - Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of gelofusine and wearing a cooling vest.~Visit 2 - Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of gelofusine. They were situated in an ambient temperature of 22-25 degrees celsius.~Visit 3 - Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of Glucagon at a dose of 50ng/kg/min. They were situated in an ambient temperature of 22-25 degrees celsius."
88999539|NCT02897362||Healthy Control Adolescents|Adolescents, male or female, ages 13-17, medically healthy, no psychiatric diagnoses, intelligence within normal limits. Participants will complete 3 nights of ambulatory polysomnography at home and a neuropsychological assessment in the lab.
88999540|NCT00196560|Experimental|exernal rotation|external rotation at 90 degrees
88999541|NCT00169754|Other|cohort|mapping and data collection
88999542|NCT02897089|No Intervention|acid-etch|Acid etch+fissure sealant
88999543|NCT02897089|Other|All Bond universal adhesive|Acid etch+ All Bond universal adhesive agent+fissure sealant
88999544|NCT02897089|Other|All Bond universal|All Bond universal adhesive agent+fissure sealant
88999545|NCT02897089|Other|Scotchbond universal adhesive|Acid etch+ Scotchbond universal adhesive agent+fissure sealant
88999546|NCT02897089|Other|Scotchbond universal|Scotchbond universal adhesive agent+fissure sealant
89176984|NCT00800982|Experimental|2 (Etanercept + nb-UVB)|"Subjects will receive etanercept. This is given at the standard FDA approved dosage of 50 mg twice weekly x 3 months then 50 mg once weekly x 3 months.~In addition, for months 3-6, subjects will receive Narrow Band Ultraviolet B phototherapy three times a week for 12 weeks in addition to the etanercept maintenance dose. The safety and efficacy of the combination therapy will be evaluated by the registered phototherapy nurses at each phototherapy visit and by the study investigator at monthly visits. NB-UVB therapy will be adjusted according to the clinical judgment of the University of California San Francisco Psoriasis Treatment Center phototherapy staff."
89176985|NCT01019395|Experimental|Group 1|Group 1: Ages 13 months to 24 months inclusive. Six subjects dosed at 6 mg/kg as a 30 minute infusion.
89176986|NCT01019395|Experimental|Group 2|Group 2: Ages 7 months to 12 months inclusive: Six subjects will receive a dose of 4 mg/kg as a 30 minute infusion
88999547|NCT02897089|Other|Clearfil universal adhesive|Acid etch+ Clearfil universal adhesive agent+fissure sealant
88999548|NCT02897089|Other|Clearfil universal|Clearfil universal adhesive agent+fissure sealant
88999549|NCT02897089|Other|Total-etch Dental Adhesive|Acid etch+ Single Bond adhesive agent+fissure sealant
89176987|NCT01019395|Experimental|Group 3|Group 3: Ages 3 months to 6 months inclusive: Six subjects will receive a dose of 4 mg/kg as a 30 minute infusion.
89176988|NCT04115124|Experimental|E-PAR Arm|Exposed to media, information and communication technology through ethnographic participatory action research.
88999550|NCT02897284|Experimental|Mindfulness 8 weeks|Mindfulness-based intervention with 8 weekly sessions
88999551|NCT02897284|Active Comparator|Mindfulness 2 weeks|Mindfulness-based intervention with 2 weekly sessions
89176989|NCT00830960|Experimental|Prasugrel 60/10 Primary|Loading dose 60 mg followed by maintenance dose 10 mg/day
89176990|NCT00830960|Experimental|Prasugrel 30/7.5 Primary|Loading dose 30 mg followed by maintenance dose 7.5 mg/day
89176991|NCT00830960|Experimental|Prasugrel 30/5 Primary|Loading dose 30 mg followed by maintenance dose 5 mg/day
89176992|NCT00830960|Active Comparator|Clopidogrel 300/75 Primary|Loading dose 300 mg followed by maintenance dose 75 mg/day
89176993|NCT00830960|Experimental|Prasugrel 30/5 Low Weight/Elderly|Loading dose 30 mg followed by maintenance dose 5 mg/day
89176994|NCT00830960|Active Comparator|Clopidogrel 300/75 Low Weight/Elderly|Loading dose 300 mg followed by maintenance dose 75 mg/day
88999552|NCT02897284|No Intervention|Control|waiting list
88999553|NCT02896933||patients with multiple sclerosis|recruited in a former study
88999554|NCT02896933||healthy control subjects|
88999555|NCT00169793|Other|A|
88999556|NCT04680754|Experimental|Experimental Arm|"Routine nursing care (use of analgesics, IV fluid therapy and wound care) was applied to patients in experimental group after thyroidectomy. A brochure was developed in line with the literature on head-neck stretching exercises. Since the patients came to the clinic on surgery day, the exercises were examined by the patient on the first postoperative day. The patient was asked to perform the exercises 3 times a day, in the morning, noon and evening for a month, provided that each movement was 5 times. Then, the Patient and Observer Scar Rating Scale (POSAS)  was applied.~The pain level of the patient on postoperative day 1 was evaluated using VAS. For further evaluations, the patient was called by phone at the 1st week and 1st month. Neck pain and discomfort status was evaluated with the Neck Pain and Disability Scale (NPAD), and then the scar appearances with the Patient and Observer Scar Assessment Scale by requesting neck photographs at the 1st week and 1st month."
88999557|NCT04680754|No Intervention|Control Arm|"Routine nursing care (use of analgesics, IV fluid therapy and wound care) was applied to the control group after thyroidectomy. Follow-up of the patients with the scales applied in the experimental group were also performed to the control group at the same intervals. After thyroidectomy, patients were called by phone in the 1st week and 1st month. Neck pain and discomfort scale and Patient and Observer Scar Rating Scale were applied again in both phone calls. Photographs of the scar appearance at the 1st week and the 1st month were requested from the patients."
88999558|NCT02896894|Experimental|Immediate Treatment Group|The Immediate Treatment Group will receive access to the study intervention - the Big White Wall, immediately after consenting for a total duration of 3 months.
88999559|NCT02896894|Other|Delayed Treatment Group|The Delayed Treatment Group will have no access to the study intervention - the Big White Wall for the first 3 months, then receive access to the BWW for 3 consecutive months.
88999560|NCT02896894|Experimental|Immediate Treatment Group - Extension|Immediate Treatment Group participants who opt in to the nested study and are randomized to the The Immediate Treatment Group - Extension, will receive access to the Big White Wall for an additional 3 months (months 4-6), immediately after receiving the initial 3 months of access.
88822783|NCT01935791|Experimental|Period 2 -Visit 1 cold control, visit 2 warm glucagon, visit 3 warm control|"Visit 1 - Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of gelofusine and wearing a cooling vest.~Visit 2- Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of Glucagon at a dose of 50ng/kg/min. They were situated in an ambient temperature of 22-25 degrees Celsius.~Visit 3 - Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of gelofusine. They were situated in an ambient temperature of 22-25 degrees Celsius."
88822784|NCT01935791|Experimental|Period 2- Visit 1 Warm glucagon, visit 2 warm control, visit 3 cold control|"Visit 1- Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of Glucagon at a dose of 50ng/kg/min. They were situated in an ambient temperature of 22-25 degrees Celsius.~Visit 2 Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of gelofusine. They were situated in an ambient temperature of 22-25 degrees Celsius.~Visit 3- Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of gelofusine and wearing a cooling vest."
88822785|NCT01935791|Experimental|Period 2 - Visit 1 Warm control, visit 2 cold control, visit 3 warm glucagon|"Visit 1 Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of gelofusine. They were situated in an ambient temperature of 22-25 degrees Celsius.~Visit 2- Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of gelofusine and wearing a cooling vest.~Visit 3 Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of Glucagon at a dose of 50ng/kg/min. They were situated in an ambient temperature of 22-25 degrees Celsius"
88822786|NCT01936259|Active Comparator|Comprehensive Mini Humeral Stem|"The Comprehensive® Shoulder System with mini stem component, which will be the control device for this clinical investigation and was 510(k) cleared under K060692 on May 30, 2006.~The humeral stem component is manufactured from Ti6Al4V alloy. The taper has a machine finish and accepts the taper adaptor of the humeral head component. The proximal region of the bone-contacting outer surface features a porous coating of plasma-sprayed titanium alloy, while the distal portion is polished. Seventeen stem diameters are available - 4 mm to 20 mm, in 1-mm increments."
88822787|NCT01936259|Experimental|Comprehensive Nano Humeral Component|The stemless humeral component is manufactured from Ti6Al4V alloy. It consists of a central tapered region and six outer wings. The taper has a machine finish and accepts the taper adaptor of the humeral head component. A small groove is included just below the taper to accept an inserter/impactor. The bone-contacting outer surface features a porous coating of plasma-sprayed titanium alloy for cementless fixation in the proximal humerus. Six sizes are available - 30 mm, 32 mm, 34 mm, 36 mm, 38 mm, and 40 mm.
88822788|NCT01937195|Experimental|AccuCath Intravenous Catheter System|AccuCath Intravenous Catheter System will be used for IV therapy during inpatient stay. Intervention includes vascular access, fluid infusion, and blood sample removal.
88822789|NCT03068949|Active Comparator|FluBlok|FluBlok 0.5 mL given IM X1
88822790|NCT03068949|Active Comparator|Fluzone|Fluzone 0.5 mL given IM X1
88822791|NCT03068949|Active Comparator|FluCelVax|FluCelVax 0.5 mL given IM X 1
88822792|NCT03068949|Active Comparator|Fluzone HD|Fluzone HD 0.5 mL given IM X1
88822793|NCT03074409|Experimental|oxytocin|intranasal administration of oxytocin
89176999|NCT01026961|Experimental|Phenylephrine HCL/Acetaminophen/Dimethindene Maleate|Phenylephrine HCL/Acetaminophen/Dimethindene Maleate
89177000|NCT01026961|Active Comparator|Phenylephrine hydrochloride|Phenylephrine hydrochloride 10mg
89177001|NCT01566253|Experimental|PCOA|The PCOA arm receiving oral self administered multimodal analgesic protocol (paracetamol, ketoprofen, morphine) by oral use.
89177002|NCT01566253|Active Comparator|Standard/ IV|The standard/IV arm will be received the analgesic treatment by intravenous use, administered by nursing staff.
88822794|NCT03074409|Placebo Comparator|placebo|intranasal administration of the same ingredient except oxytocin
88822795|NCT00374439|Experimental|Cognitive-behavioral|Participants in this arm received a cognitive-behavioral program
88822796|NCT00374439|Experimental|Interpersonal Therapy|Participants in this arm received a prevention program based on interpersonal therapy for depression
88822797|NCT00374439|No Intervention|No intervention|Participants in this arm did not receive an intervention, but complete assessments only
88822798|NCT02955147|Experimental|Ustekinumab plus prednisone|"Ustekinumab: 90 mg of ustekinumab will be administered subcutaneously at baseline, week 4, week 12, week 20, week 28, week 36 and week 44.~Prednisone: All patients will receive a prednisone course tapered according to predefined schedules starting at either 60 mg, 40 mg or 20 mg. The initial dose of prednisone will be chosen by the investigators according to disease severity and comorbid medical conditions. The duration of the prednisone taper will be 6 months in all cases."
88822799|NCT03119025|Experimental|Autologous DC-vaccines|Thirty patients with chronic hepatitis C (genotype 1) will receive the initiating and maintaining courses of autologous of autologous monocyte-derived dendritic cells, generated in the presence of IFN-α/GM-CSF and pulsed with recombinant HCV Core (1-120) and NS3 (1192-1457) proteins.
88822800|NCT03119181|Experimental|Active Tymbion Iontophoresis|Unilateral treatment with active iontophoresis of Tymbion (2% lidocaine HCl/ 1:100,000 epinephrine) using the Tusker Medical Tula Iontophoresis System.
88822801|NCT03119181|Sham Comparator|Sham Tymbion Iontophoresis|The sham iontophoresis procedure will be identical to the active Tymbion iontophoresis in that Tymbion (2% lidocaine/ 1:100,000 epinephrine solution) will be placed in the external ear canal, however the iontophoresis current delivery (which facilitates penetration of drug into the tympanic membrane tissue) will not be activated.
88822802|NCT03119571|Experimental|Initial CCL admission|Admission to the CCL to evaluate the coronary artery disease
88822803|NCT03119571|Active Comparator|Initial ICU admission|Admission to the ICU to be evaluated by clinical team and the clinical treatment will be decided by the admitting/attending team.
88822804|NCT01691534|Experimental|TMC207, PA-824, pyrazinamide and clofazimine (J-PA-Z-C)|TMC207 400 mg Day 1; 300mg Day 2; 200mg Days 3-14 plus PA-824 200mg Days 1-14 plus pyrazinamide 1500mg Days 1-14 plus clofazimine 300mg Days 1-3 and Clofazamine 100mg Days 4-14
88822805|NCT01691534|Experimental|TMC207, PA-824 and pyrazinamide (J-PA-Z)|TMC207 400 mg Day 1; 300mg Day 2; 200mg Days 3-14 plus PA-824 200mg Days 1-14 plus pyrazinamide 1500mg Days 1-14
88822806|NCT01691534|Experimental|TMC207, PA-824 and clofazimine (J-PA-C)|TMC207 400 mg Day 1; 300mg Day 2; 200mg Days 3-14 plus PA-824 200mg Days 1-14 plus clofazimine 300mg Days 1-3 and clofazimine 100mg Days 4-14
88822807|NCT01691534|Experimental|TMC207, pyrazinamide and clofazimine (J-Z-C)|TMC207 400 mg Day 1; 300mg Day 2; 200mg Days 3-14 plus pyrazinamide 1500mg Days 1-14 plus clofazimine 300mg Days 1-3 and Clofazimine 100mg Days 4-14
88822808|NCT01691534|Experimental|pyrazinamide (Z)|pyrazinamide 1500mg Days 1-14
88822809|NCT01691534|Experimental|clofazimine (C)|Clofazimine 300mg Days 1-3 and Clofazimine 100mg Days 4-14
88822810|NCT01691534|Active Comparator|Rifafour|Rifafour e-275 mg dosed by weight
88822811|NCT04967066||children with febrile convulsions|"Inclusion criteria~Age from 6 months to 6 years.~Seizures.~Fever (≥38°C).~Exclusion criteria~Central nervous system infection.~Epilepsy.~Previous neurological abnormalities.~Inborn errors of metabolism.~Immunological diseases.~Endocrinal diseases (e.g., diabetes mellitus).~Obesity.~Eating disorders.~Gastrointestinal disorders (e.g., diarrhea)."
88822812|NCT04967066||Febrile children without convulsions|"Inclusion criteria~Age from 6 months to 6 years.~Fever (≥38°C) due to acute infection.~Exclusion criteria~Seizures.~Central nervous system infection.~Previous neurological abnormalities.~Inborn errors of metabolism.~Immunological diseases.~Endocrinal diseases (e.g., diabetes mellitus).~Obesity.~Eating disorders.~Gastrointestinal disorders (e.g., diarrhea)."
88822813|NCT04967066||Healthy control children|"Inclusion criteria~Age from 6 months to 6 years.~Presented for routine check-up.~Exclusion criteria~Fever.~Seizures.~Central nervous system infection.~Previous neurological abnormalities.~Inborn errors of metabolism.~Immunological diseases.~Endocrinal diseases (e.g., diabetes mellitus).~Obesity.~Eating disorders.~Gastrointestinal disorders (e.g., diarrhea).~Any illness in the last month."
88822814|NCT04959344|Experimental|Kleb4V target dose|Study participants receive 2 target doses of the non-adjuvanted investigational product 2 months apart.
88822815|NCT04959344|Experimental|Kleb4V target dose + AS03|Study participants receive 2 target doses of the adjuvanted investigational product 2 months apart.
88822816|NCT04959344|Experimental|Kleb4V low dose|Study participants receive 2 low doses of the non-adjuvanted investigational product 2 months apart.
88822817|NCT04959344|Experimental|Kleb4V low dose + AS03|Study participants receive 2 low doses of the adjuvanted investigational product 2 months apart.
88822818|NCT04959344|Placebo Comparator|Placebo (Diluent)|Study participants receive 2 doses of the Placebo 2 months apart.
88822819|NCT01691690|Experimental|IV Acetaminophen|Patients will receive pre-medication with oral midazolam Participants of this experimental arm of the study will receive Acetaminophen IV to evaluate opioid-sparing effect and pain score reduction..
88822820|NCT01691690|Placebo Comparator|Saline placebo infused intraoperatively|For this arm Morphine will be administered to manage pain.
88822821|NCT03538574|Active Comparator|CBT-I|Cognitive behavioral therapy for insomnia (CBT-I), considered the treatment of choice by the American Academy of Sleep Medicine, combines cognitive therapy, stimulus control, sleep restriction, sleep hygiene, and relaxation to improve sleep outcomes, with demonstrated efficacy in adult and older adult populations
88822822|NCT03538574|Experimental|MAP-I|The Mindful Awareness Practices (MAPs) is a validated and curriculum-based meditation similar to Mindfulness Based Stress Reduction, with the exception that MAPs does not include a day-long retreat or yoga and hence takes a more practical and accessible approach that focuses specifically on the practice of mindfulness and its application in everyday life. (http://marc.ucla.edu) MAP for Insomnia (MAP-I) is a modified version of MAPs that incorporates practice prior to bed, use of practice in the bed during night-time awakenings, and daily body scan.
88822823|NCT01694108|Experimental|BCG-vaccine (SSI)|"Children born to mothers, who have accepted to participate, will be randomised to either intervention group or to the control group at birth. Block-randomisation stratified by hospital, gender and gestational age (≥37 weeks of gestation vs. < 37 weeks of gestation) will be performed electronically just before vaccination by the overall study electronic case report system (e-crf).~Children randomised to the BCG vaccination group will receive an intradermal BCG vaccine (Statens Serum Institute CG vaccine in the standard dose 0.05 ml in the upper, lateral part of the arm of the child by a specially trained midwife or a study physician."
88822824|NCT01694108|No Intervention|No Intervention|Control children will be treated as usual, since no suitable placebo exists.
88822825|NCT03499418||newborns with TTN|Group of late preterm and full-term newborns with TTN evaluated by modified Silverman scale
88822826|NCT03499418||newborns with PPHN|Group of late preterm and full-term newborns with respiratory failure with PPHN evaluated by echocardiography
88822827|NCT01694186|Sham Comparator|sham injection|sham injection
88822828|NCT01694186|Experimental|FAI insert|FAI insert (0.18 mg fluocinolone acetonide)
89355608|NCT01200251|No Intervention|control arm - no gel|the other fellow eyelid of the patient did not receive any treatment until month 4 and the patient crossed over to treating both eyelids
88822829|NCT02283827|Experimental|Group A BIA 2-093 + Phenytoin (PHT)|Day 1 to 2: Pre-treatment 1: 600 mg ESL Day 3 to 8: Treatment 1: 1200 mg ESL Day 9 to 10: Treatment 1 + Pre-treatment 2: 1200 mg ESL+ 100 mg PHT Day 11 to 27: Treatment 1 + Treatment 2: 1200 mg ESL + 300 mg PHT
88822830|NCT02283827|Experimental|Group B BIA 2-093 + Phenytoin (PHT)|Day 1 to 2: Pre-treatment 2: 100 mg PHT Day 3 to 8: Treatment 2: 300 mg PHT Day 9 to 10: Treatment 2 + Pre-treatment 1: 300 mg PHT + 600 mg ESL Day 11 to 27: Treatment 1 + Treatment 2: 1200 mg ESL + 300 mg PHT
88822831|NCT01626092|Experimental|Intent-To-Treat Patients|Patients with high-risk lysosomal and peroxisomal disorders treated with preparative regimen (Campath-1H 0.3 mg/kg intravenous (IV) on days -12 through -8, clofarabine 40 mg/m^2 IV on days -9 through -5, melphalan 140 mg/m^2 IV on day -4 and Total Body Irradiation with Marrow Boosting [ first dose of 200 cGy single dose; 5 doses of 160cGy for marrow boosting - 1000cGy cumulative exposure] by Volumetric-Modulated Arc Therapy [VMAT] on days -3 through -1). Hematopoietic stem cell transplantation will be infused on Day 0. Post-transplant immunosuppression to follow: Mycophenolate mofetil (MMF) begin day -3 and continue to day +30 or 7 days after engraftment, whichever is later; Cyclosporine A (CsA) begin day -3 and then taper at day +100 if related donor, day +180 for unrelated donor.
88822832|NCT01694966|Active Comparator|Methylene Blue MMX® 200mg|Oral dose, 8 Methylene Blue MMX® tablets over a 4hr schedule
89533545|NCT04340258|Experimental|Pembrolizumab & Cesium-131|200 mg Pembrolizumab (Day -14 pre-surgery; Every 3 weeks after surgery) + Cesium-131 Seeds to deliver 60-70Gy of radiation (Single dose at the time of salvage surgery)
89533546|NCT04339751|Experimental|single center, prospective pilot study|effectiveness of vorinostat to reduce midnight ACTH levels in patients with Cushing s Disease
88822833|NCT01694966|Active Comparator|Methylene Blue MMX® 100mg|Oral dose, 4 Methylene Blue MMX® tablets and 4 Placebo tablets over a 4hr schedule
88822834|NCT01694966|Placebo Comparator|Placebo|Oral dose, 8 Placebo tablets over a 4hr schedule
88822835|NCT01937975|Experimental|Participants with End Stage Renal Disease on Hemodialysis|Participants with End Stage Renal Disease on hemodialysis received once daily Grazoprevir 100 mg tablet and Elbasvir 50 mg tablet for 10 days..
88822836|NCT01937975|Experimental|Participants with Severe Renal Impairment|Participants with Severe Renal Impairment (estimated glomerular filtration rate <30 mL/min/1.73 m^2) received once daily Grazoprevir 100 mg tablet and Elbasvir 50 mg tablet for 10 days.
88822837|NCT01937975|Experimental|Healthy Participants|Healthy participants (estimated glomerular filtration rate >=80 mL/min/1.73 m^2) received once daily Grazoprevir 100 mg tablet and Elbasvir 50 mg tablet for 10 days.
88822838|NCT01628042|Experimental|Participants With Severe Renal Insufficiency|Participants will receive a single oral dose of vibegron 100 mg on Day 1.
88822839|NCT01628042|Experimental|Participants With Moderate Renal Insufficiency|Participants will receive a single oral dose of vibegron 100 mg on Day 1.
88822840|NCT01628042|Experimental|Participants With Mild Renal Insufficiency|Participants will receive a single oral dose of vibegron 100 mg on Day 1.
88822841|NCT01628042|Experimental|Healthy Matched Control Participants|Participants receive a single oral dose of vibegron 100 mg on Day 1.
88822842|NCT01628588||POAG or OHT|Patients with POAG or OHT prescribed Lumigan® (bimatoprost 0.01%) treatment in a dose determined by the physician prior to study entry
88822843|NCT03399656|Placebo Comparator|Placebo|4 placebo tablets
88822844|NCT03399656|Active Comparator|Low Dose Avmacol|2 tablets Avmacol and 2 placebo tablets
88822845|NCT03399656|Active Comparator|High Dose Avmacol|4 Avmacol tablets
89355609|NCT03597139|Experimental|Voclosporin ophthalmic solution (VOS)|0.2% VOS, Twice Daily (BID), both eyes for 28 days
89355610|NCT03597139|Active Comparator|Comparator|0.05% cyclosporine ophthalmic emulsion (Restasis®) BID, both eyes for 28 days
88822848|NCT03369080||Danish National Cohort|This study includes all patients with a new Spinal Cord Injury hospitalized at Clinic for Spinal Cord Injuries, Rigshospitalet or Spinal Cord Injury Center of Western Denmark
88822849|NCT03119649|Experimental|Cohort A: GLPG2222 50 mg once daily (QD)|Participants received a single GLPG2222 50 mg tablet and two matching placebo tablets orally, QD for 29 days.
89355611|NCT01202435|Experimental|Pregabalin controlled release, 82.5 mg|
89355612|NCT01202435|Other|Pregabalin immediate release, 25 mg|Reference Treatment
89355613|NCT03179202|Experimental|Peripheral Nerve Stimulation|All study subjects will have up to 4 Leads placed in their low back, will use the SPRINT Peripheral Nerve Stimulation (PNS) System, and will receive electrical stimulation.
88822850|NCT03119649|Experimental|Cohort A: GLPG2222 100 mg QD|Participants received a single GLPG2222 100 mg tablet and two matching placebo tablets orally, QD for 29 days.
88822851|NCT03119649|Experimental|Cohort B: GLPG2222 200 mg QD|Participants received two GLPG2222 100 mg tablets and one matching placebo tablet orally, QD for 29 days.
88822852|NCT03119649|Experimental|Cohort B: GLPG2222 400 mg QD|Participants received two GLPG2222 150 mg tablets and one GLPG2222 100 mg tablet orally, QD for 29 days.
89355614|NCT03843671|Experimental|Group 1|Hyperbaric oxygen Hyperbaric chamber
89355615|NCT03843671|Sham Comparator|Group 2|Sham for hyperbaric oxygen Hyperbaric chamber
89533547|NCT04338269|Experimental|Atezo+Cabo|Participants will receive atezolizumab every 3 weeks on Day 1 of each 21-day cycle (1 cycle=21 days) plus oral tablets of cabozantinib every day.
89533548|NCT04338269|Active Comparator|Cabozantinib|Participants will receive cabozantinib every day.
89533549|NCT04336995|Other|Exercise|Everyone is in this arm
89533550|NCT04332471|Active Comparator|Control|Patients in the control group will be treated using the home therapy protocol only.
89533551|NCT04332471|Active Comparator|Radial shockwave therapy|Patients will receive 4 sessions of radial shockwave therapy.
88822853|NCT03119649|Placebo Comparator|Cohort A Placebo|Participants received three matching placebo tablets, orally, QD for 29 days.
88822854|NCT03119649|Placebo Comparator|Cohort B Placebo|Participants received three matching placebo tablets, orally, QD for 29 days.
88822855|NCT00374985|Experimental|one arm|
88822856|NCT01695044|Experimental|Arm 1: PSMA ADC|Prostate Specific Membrane Antigen Antibody Drug Conjugate (PSMA ADC) administered IV at 2.5 mg/kg Q3W for 8 cycles or 2.3 mg/kg Q3W for 8 cycles.
88822857|NCT03121365|Active Comparator|Standard/Board Book Arm|Parent-infant dyads randomized to the standard/board book arm will receive developmentally appropriate early reader board books at the time of their infant's 6, 9, and 12 month well visits. In addition to the books, parent-infant dyads will be provided information on the importance of early parent-child reading activity by pediatric clinicians using the Reach Out and Read framework.
88822858|NCT03121365|Experimental|Digital/E-Book Arm|Parent-infant dyads randomized to the digital/e-book arm will receive developmentally appropriate e-books at the time of their infant's 6, 9, and 12 month well visits. In addition to the books, parent-infant dyads will be provided information on the importance of early parent-child reading activity by pediatric clinicians using the Reach Out and Read framework.
88822859|NCT01695668|Experimental|Lotemax|Loteprednol Etabonate 0.5%
88822860|NCT01695668|Active Comparator|Restasis|Cyclosporine
88822861|NCT03270020|Experimental|Treatment arm|This is a single arm study; the study arm include all patients participating in the study who will all receive Denosumab 70 MG/ML [Xgeva]
88822862|NCT01921751|Experimental|Chemotherapy + high intensity radiation|Induction chemotherapy with four cycles of gemcitabine and nab-paclitaxel [randomized to this arm after 3rd cycle and no progression]; followed by concurrent high intensity radiation therapy and capecitabine; followed by consolidation chemotherapy with gemcitabine and nab-paclitaxel until progression or unacceptable toxicity
88822863|NCT01921751|Experimental|Chemotherapy + low intensity radiation|Induction chemotherapy with four cycles of gemcitabine and nab-paclitaxel [randomized to this arm after 3rd cycle and no progression]; followed by concurrent low intensity radiation therapy and capecitabine; followed by consolidation chemotherapy with gemcitabine and nab-paclitaxel until progression or unacceptable toxicity
88822864|NCT01921751|Active Comparator|Chemotherapy|Gemcitabine and nab-paclitaxel until progression or unacceptable toxicity [randomized to this arm after 3rd cycle and no progression]
88822865|NCT02958345|Active Comparator|Zostavax|Subjects will receive 0.65 mL of Zostavax subcutaneously in the deltoid region of the upper arm.
88822866|NCT02958345|Placebo Comparator|Placebo|Subjects randomized to placebo will receive an injection of 0.65 mL of sterile normal saline subcutaneously in the deltoid region of the upper arm.
89355616|NCT05406102|Experimental|Remimazolam group|Patients were slowly injected of 0.08 ug/kg of sufentanil. Patients received remimazolam 0.1mg/kg to maintain sufficient sedation (sufficient sedation as judged by MOAA/S ≤ 4 for 3 consecutive measurements) during endoscopy procedure.
89355617|NCT05406102|Active Comparator|Propofol group|Patients were slowly injected of 0.08 ug/kg of sufentanil for 1 min during the examination.Patients received Propofol 1.5mg/kg to maintain sufficient sedation (sufficient sedation as judged by MOAA/S ≤ 4 for 3 consecutive measurements) during endoscopy procedure.
88822867|NCT01629134||Volbella|Subjects treated with JUVÉDERM VOLBELLA™ according to the physician's experience and Directions for Use
88822868|NCT04333329|Experimental|AD Patients|"All patients were treated with the TPS device (new name: NEUROLITH (Storz Medical AG))~- 6 sessions within 2 weeks, each sessions consisting of 6000 TPS pulses of 0.2 mJ/mm²"
88822869|NCT01922219|Other|Cognitive Behavioral Therapy|Depressed individuals who enroll in this study will receive 14 sessions of cognitive behavioral therapy provided by an experienced psychiatrist or psychologist over 12 weeks (twice-a-week for the first two weeks, and weekly after that).
89355618|NCT01200563|Active Comparator|Group 1|Subjects assigned to receive MIST Therapy will be treated 3 times per week. The duration of each MIST treatment will be dependent on the wound's area measured at baseline and at each weekly assessment.
88822870|NCT01629290|Active Comparator|Enamel Pro|Varnish containing 5%NaF
88822871|NCT01629290|Active Comparator|Duraphat|Varnish containing 5%NaF
88822872|NCT01629290|Active Comparator|Vanish|Varnish containing 5%NaF
88822873|NCT01629290|Placebo Comparator|Placebo|Bland varnish containing no NaF
88822874|NCT03076359|Active Comparator|Standard of Care|Intervention: This group will receive only standard of care HIV treatment, including ART medications (First-line ART will consist of two nucleoside reverse-transcriptase inhibitors (NRTIs) plus a non-nucleoside reverse-transcriptase inhibitor (NNRTI)- TDF + 3TC (or FTC) + EFV as a fixed-dose combination to be taken twice a day for the rest of the patient's life), clinic-based counseling, and community searches if lost to follow up.
88822875|NCT03076359|Experimental|Traditional Healer Support Program|"This group will receive standard of care as described above. In addition, the investigators will assess an intervention partnership with traditional healer including: community and clinic based support from a trained traditional healer.~The intervention includes: (1) healer visits to the patient at home, healer support for couples counseling, healer provision of nutritional advice, and healer counsel about the importance of adherence. If anything is amiss, the healer will accompany the patient to the health facility for additional clinical services. In addition, the healer will accompany the patient on all regularly scheduled clinical visits."
88822876|NCT01696760|Experimental|Arm I (acetylsalicylic acid and PCD)|Patients receive acetylsalicylic acid orally PO BID and wear PCD on days 1-28 after surgery.
88822877|NCT01696760|Experimental|Arm II (enoxaparin and PCD)|Patients receive enoxaparin subcutaneously SC QD and wear PCD on days 1-28 after surgery.
89355619|NCT01200563|Active Comparator|Group 2|Subjects assigned to receive Negative Pressure Wound Therapy will be treated with the Vacuum Assisted Closure system. For administration of this study treatment, e.g., treatment cycle, target pressure and dressing changes, the manufacturer's recommended guidelines will be followed.
89355620|NCT01200563|Active Comparator|Group 3|Subjects assigned to this group will receive MIST Therapy treatments and Negative Pressure Wound Therapy.
88999561|NCT02896894|No Intervention|Immediate Treatment Group - No Extension|Immediate Treatment Group participants who opt in to the nested study and are randomized to The Immediate Treatment Group - No extension, will not receive extended access to the Big White Wall.
88822878|NCT01924169|Experimental|Lenalidomide|Lenalidomide administered at the dose of 5 mg/day on Monday, Wednesday and Friday for 3 months. If Immunoglobulin G (IgG) levels improve by at least 25% of baseline, lenalidomide administration continued for 3 months on, and 3 months off for 2 years. If IgG levels do not improve, frequency of lenalidomide increased to 5 mg/day for additional 3 months and if response is achieved, lenalidomide continued at 5mg/day 3 month on/3 month off for a total of 2 years. Seasonal influenza vaccination (Trivalent Influenza Vaccine, Fluzone High Dose) administered yearly, during the fall/winter season and pneumococcal immunization (Pneumococcal Polysaccharide Vaccine, Pneumovax) administered once between month 6 and month 21.
88822879|NCT02958969|Experimental|Apixaban|apixaban 2.5 mg orally twice daily for primary prevention of VTE for a duration of 6 months
88822880|NCT02238782|Experimental|selumetinib 75mg single dose|3 capsules of 25 mg administered orally
88822881|NCT01924559|Active Comparator|Direct Laryngoscopy & standard clothing|Residents will intubate manikin using DL while wearing standard clothing.
88822882|NCT01924559|Active Comparator|Direct Laryngoscopy & Biohazard Gear|Residents will intubate manikins using DL while in Biohazard gear.
88822883|NCT01924559|Experimental|Glidescope & standard clothing|Residents will intubate manikins using Glidescope while wearing standard clothing.
88822884|NCT01924559|Active Comparator|Glidescope & Biohazard Gear|Residents will intubate manikins using Glidescope while wearing Biohazard gear.
88822885|NCT01924559|Active Comparator|Supraglottic Airway & standard clothing|Residents will intubate manikins using Supraglottic Airway while wearing standard clothing.
88822886|NCT01924559|Active Comparator|Supraglottic Airway and Biohazard gear|Residents will intubate manikins using Supraglottic airway while wearing biohazard gear.
88822887|NCT02959827||Iodinated contrast agents|Children under age 4 in the Kaiser Permanente Northern California database, who had a diagnostic procedure with an iodinated contrast agent
88822888|NCT03137108|Experimental|Incomplete Spinal cord injury|
88822889|NCT01630694|Active Comparator|Difficult intubation patients|patients who were difficult to intubate during previous anesthetics provided by the staff anesthesiologists.
88822890|NCT01630694|Placebo Comparator|Control|The control group will consist of patients with the easy laryngoscopy and intubation, recruited prospectively.
88822891|NCT01924871|Active Comparator|Desflurane group|1.5 MAC desflurane until extubation
88822892|NCT01924871|Active Comparator|Desflurane with remifentanil group|1.0 MAC desflurane with 1.0ng/ml targeted concentration infusion of remifentanil
88822893|NCT03076983||ICU Patients|Patients currently on or scheduled for ventilator care in the intensive-care-unit (ICU)
88822894|NCT03076983||OLV Patients|Patients scheduled for elective surgery receiving one-lung-ventilation (OLV)
88822895|NCT01698710|Experimental|Albumin bound paclitaxel|Albumin bound paclitaxel will be administered into the mucinous cyst of pancreas in endoscopy procedure.
88822896|NCT01924949|Experimental|LDV/SOF|Participants will receive LDV/SOF FDC for 12 weeks.
88822897|NCT01938989|Other|Clear, then Blue Light Filter|Clear clip-on glasses first, followed by blue light filter clip-on glasses, as worn over habitual correction
88822898|NCT01938989|Other|Blue Light Filter, then Clear|Blue light filter clip-on glasses first, followed by clear clip-on glasses, as worn over habitual correction
89355621|NCT02821182|Experimental|Anti-PD1 treatment in combination with SBRT|Patients receiving anti-PD1 treatment will be treated with high-dose radiotherapy to one lesion in 3 fractions prior to the second cycle of systemic therapy.
89355622|NCT01204229|Experimental|MCID|
88822899|NCT02960295|Experimental|Virtual visit|"Self-monitoring of blood glucose (four times daily).~Self-weighing (weekly).~Self-checking of blood pressure (weekly).~Checking fetal heart rate (weekly).~Visits with caregivers."
88822900|NCT01939145|Active Comparator|Normal Saline|The use of Normal Saline as the solution for Negative Pressure Wound Therapy with instillation.
88822901|NCT01939145|Active Comparator|Prontosan|The use of Prontosan as the solution in Negative Pressure Wound Therapy with Instillation.
89355623|NCT01204229|Experimental|BMI|
89355624|NCT01204307|Experimental|docetaxel/cisplatin|The treatment schedule comprises a maximum of six 3-week treatment cycles consisting of weekly docetaxel (30 mg/m2) and cisplatin (37.5 mg/m2) for 2 consecutive weeks followed by a 1-week treatment-free period. The patients will be assessed after each cycle and a final assessment will be done after three and six cycles.
89533552|NCT04332471|Active Comparator|Focused shockwave therapy|Patients will receive 4 sessions of focused shockwave therapy.
89533553|NCT04318548|Experimental|MenB+MenACWY Group|Subjects will receive 1 dose rMenB+OMV NZ given concomitantly with MenACWY at Day 1, 1 dose of rMenB+OMV NZ at Day 61 and 1 dose of placebo at Day 91.
89533554|NCT04318548|Experimental|MenB Group|Subjects will receive 1 dose of rMenB+OMV NZ and placebo concomitantly at Day 1, 1 dose of rMenB+OMV NZ at Day 61 and 1 dose of MenACWY at Day 91.
89533555|NCT04318548|Experimental|MenACWY Group|Subjects will receive 1 dose of MenACWY and placebo concomitantly at Day 1, 1 dose of rMenB+OMV NZ each at Day 61 and at Day 91.
88822902|NCT01939301|Active Comparator|Inhaled Nitric Oxide|Inhaled nitric oxide
88822903|NCT01939301|Placebo Comparator|Placebo|Oxygen
88822904|NCT01941485|Experimental|WaveLight Refractive Suite|LASIK surgery (laser in situ keratomileusis) per standard of care
88822905|NCT03078075|Experimental|Active Medication Combination (AMC)|injectable extended release naltrexone plus once daily oral extended-release bupropion tablets
88822906|NCT03078075|Placebo Comparator|Matched Placebo (PLB)|injectable matching placebo plus once-daily oral placebo tablets
88822907|NCT01926977|Active Comparator|Ranibizumab 0.5mg Intravitreal injection|Intravitreal injection of Ranibizumab 0.5mg once
88822908|NCT01926977|Active Comparator|Aflibercept 2.0mg Intravitreal injection|Intravitreal Aflibercept 2.0mg once
88822909|NCT05735405|Experimental|Experimental Group|The experimental group will first perform 30 minutes of pedaling as a moderate intensity aerobic activity. Subsequently it will carry out a daily cognitive training of 60 minutes to improve attentional, working memory and executive functions.
88822910|NCT05735405|Experimental|Control Group|The control group will first carry out a daily 60-minute cognitive training to improve attentional, working memory and executive functions. It will then perform 30 minutes of pedaling as a moderate intensity aerobic activity.
88822911|NCT05735249|Experimental|ARN-75039|Escalating single or multiple doses of ARN-75039 oral capsules
88999562|NCT02896816|Experimental|Parkinson's subjects|"The participants with Parkinson's disease should have symptoms only on one side of the body, and they should not be taking any dopamine replacement medication such as levodopa or dopamine agonists.~Surface EMG, MRI and PET scan will be performed at baseline."
88999563|NCT02896816|Active Comparator|Control subjects|Participants not affected by neurological disorders. Surface EMG will be performed at baseline.
88999564|NCT02897011|Sham Comparator|Group 1: MTX continue|Group will continue MTX after vaccination
88999565|NCT02897011|Experimental|Group 2: MTX hold|will hold MTX for 2 weeks after vaccination
88999566|NCT00169832|Experimental|Rosiglitazone (Avandia)|
88999567|NCT00169832|Placebo Comparator|Placebo|
88999568|NCT02896972|Active Comparator|Inverted ILM flap group|Eyes underwent vitrectomy with inverted internal limiting membrane technique
88999569|NCT02896972|Active Comparator|ILM peeling group|Eyes underwent vitrectomy with internal limiting membrane peeling
88999570|NCT02896543||STEMI group|The study population consists of 30 patients with ST-elevated acute myocardial infarction (STEMI,n = 30) who are admitted within 24 hours after chest pain attacks. They will all undergo coronary angiography.The diagnosis is made according to American Heart Association (AHA, 2014 and 2015) guidelines. Patients who had obvious blood system diseases,severe liver dysfunction, severe renal insufficiency,severe heart failure (NYHA class 3 and 4), acute or chronic infectious diseases, disease of immune system, asthma, malignant tumor, other advanced disease are excluded.
88999571|NCT02896543||Control group|15 age and body mass index matched healthy subjects with neither coronary artery disease nor any of the components of the metabolic syndrome are enrolled as Control group.
88999572|NCT02896660|Experimental|ActiGraph Link|Study participants will wear an actigraphy device, the ActiGraph Link, continuously for 90 days
88999573|NCT00178971|Active Comparator|1|buspirone 15-30 mg qd
88999574|NCT00178971|Placebo Comparator|2|placebo
88999575|NCT02896621|Experimental|Chlorthalidone plus amiloride|"Chlorthalidone plus amiloride group received 25 mg of chlortalidone and amiloride, 5 mg.~A capsule with both drugs was taken once daily in the morning for eight weeks."
88999576|NCT02896621|Active Comparator|Amlodipine|Amlodipine group received 10 mg. A capsule was taken once daily in the morning for eight weeks. Capsules of amlodipine had identical presentation of that the intervention drug.
88999577|NCT02896504||Chemotherapy|Breast Cancer patients undergoing conventional postsurgical adjuvant chemotherapy treatment
88999578|NCT02896504||Hormonal Therapy|Breast Cancer patients undergoing conventional postsurgical adjuvant hormonal therapy treatment (with no Chemotherapy)
88999579|NCT02896504||Healthy Control|Healthy age, height and body-mass matched healthy controls
88999580|NCT02896426|Experimental|Collaborative Problem Solving|Participants will attend parent group sessions led by trained group leaders and learn the Collaborative Problem Solving approach.
88999581|NCT02896426|Active Comparator|Positive Solutions For Families|Participants will attend parent group sessions and learn the Positive Solutions for Families approach, a group that is usually offered by Head Start.
88999582|NCT02896153||Adult population going to a pharmacy|Adult population going to a pharmacy will be asked to complete a questionnaire.
88999583|NCT02896270|Experimental|single arm|"Patients will start study treatment on Day1 and will be treated with a dose of 250mg twice daily of the valproic acid slow release formulation (Depakine Chrono© - Sanofi Pharma Belgium).~Control of valproic acid serum levels after 4 to 7 days. The dose will be progressively increased targeting valproic acid serum levels in the target range for use of the drug as an anti-epileptic (50-100µg/ml).~During the study, visits will be performed every month and at the end of treatment. The duration of the study is 12 months. Continuation of valproic acid after completion of the study will be at the investigators discretion."
88999584|NCT02896465|Active Comparator|ORS+ZINC|Oral rehydration solution + Zinc
89177003|NCT01023763|No Intervention|Usual care|"Nursing home residents who require intravenous fluids and intravenous antibiotics was treated as usual (hospital admissions for intravenous treatment).~In control nursing homes that had not completed the training program (intervention period), nursing home residents who require intravenous fluids and intravenous antibiotics was treated as usual. The majority of these patients were admitted to hospital for intravenous treatment. A few nursing homes or nursing home departments had sufficient expertise and capacity to provide treatment locally."
88822912|NCT05735249|Placebo Comparator|Placebo|Matching placebo capsules in a same SAD and MAD dosing regimen as ARN-75039
88999585|NCT02896465|Experimental|ORS+ZINC+HMO|Oral rehydration solution + Zinc + Human milk oligosaccharides
88999586|NCT02896465|Placebo Comparator|ORS+ZINC+Breastfeeding|Oral rehydration solution + Zinc + Breastfeeding
89177004|NCT01023763|Other|A training program in iv treatment|"A structured training program in intravenous treatment in nursing homes:~Each of 30 participating nursing homes sequentially received theory and practical training in intravenous treatment. In nursing homes that had completed the training program (intervention period), and had sufficient expertise and capacity, nursing home residents in need of intravenous fluids or antibiotics were treated locally; otherwise they were hospitalized."
88999587|NCT02896309|Experimental|Sodium bicarbonate|Oral sodium bicarbonate tablets three times daily 1000mg
88999588|NCT02896309|Active Comparator|Sodium chloride|Oral sodium chloride capsules two times daily 1000mg
88999589|NCT02896309|No Intervention|No treatment|No treatment
88999590|NCT02896231|Experimental|PLB1001|There are 5 dose cohorts, including 50mg BID, 100mg BID, 150mg BID, 200mg BID and 275mg BID in the dose escalation stage and PLB1001 will be administered orally to patients twice daily for each dose cohort.
88999591|NCT02895958|Other|Administration of Zepatier|
88999592|NCT02896192|Experimental|Setmelanotide|Participants received titrated doses of setmelanotide once daily, by subcutaneous (SC) injection during titration period for 2 - 12 weeks. Thereafter, participants continued setmelanotide at their specific therapeutic dose for an additional 10 weeks during the open label treatment period. Participants who achieved at least a 5 kilograms (kg) weight loss (or at least 5% weight loss if baseline body weight was <100 kg) at the end of the open label treatment period, continued into the 8-week double-blind withdrawal period and received 4 weeks setmelanotide and 4 weeks placebo. Following the withdrawal period, participants entered open label treatment period and received setmelanotide to complete approximately 52 weeks (~1 year) of treatment at a therapeutic dose.
88999593|NCT02896036|Experimental|Veress needle entry with concomitant CO2|For the group of participants who will be randomized to concomitant CO2 insufflation; the Veress will be connected to the CO2 tubing, and a skin incision will be made with the scalpel, followed by starting the CO2 gas insufflation and insertion of the Veress needle. If the opening pressure is less than or equal to 10 mmHg, the process of insufflation will be allowed to continue. In case of a higher opening pressure, the veress will be withdrawn and reinserted up to 3 times. A failed entry will be called if the peritoneal cavity cannot be insufflated after 3 attempts.
89177005|NCT02604888|Other|Volunteers|20 volunteers both men and women with an age between 18 and 70 years suffering from Alopecia Areata in several types apply on the scalp drops of the MEXIS/M6S PATENT - lotion against Alopecia
89177006|NCT03849313|Experimental|AVT02 100mg/mL|Biosimilar Adalimumab AVT02
89177007|NCT03849313|Active Comparator|EU-Humira 100mg/mL|EU Approved Adalimumab originator Humira
89533556|NCT04310670|Experimental|Patients with FND|Diagnosis of Functional Neurological Disorder of movement clinically established according to Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 criteria
88822913|NCT01928693|Active Comparator|Besivance 0.6% Ophthalmic Suspension|A topical fluoroquinolone antimicrobial indicated for the treatment of bacterial conjunctivitis.
88822914|NCT01928693|Active Comparator|Zymaxid 0.5% Ophthalmic Solution|A topical fluoroquinolone anti-infective indicated for the treatment of bacterial conjunctivitis.
88822915|NCT01928693|Active Comparator|Vigamox 0.5% Ophthalmic Solution|A topical fluoroquinolone anti-infective indicated for the treatment of bacterial conjunctivitis.
88822916|NCT01928849|Placebo Comparator|Cherry syrup|"Cherry Syrup: Patients randomized to the Control arm of the trial will receive standard regional anesthesia catheters (either peripheral nerve or epidural catheter), anesthetic management and the placebo."
88822917|NCT01928849|Experimental|Valproic Acid|"Intervention arm patients will receive standard regional anesthesia catheters (either peripheral nerve or epidural catheter), anesthetic management, and valproic acid."
88822918|NCT01631552|Experimental|Sacituzumab Govitecan-hziy (SG) 8 mg/kg|Participants will receive sacituzumab govitecan-hziy (SG) 8 mg/kg of body weight via intravenous (IV) infusion on Days 1 and 8 of a 21-day treatment cycle until disease progression or unacceptable toxicity.
88822919|NCT01631552|Experimental|SG 10 mg/kg|Participants will receive SG 10 mg/kg of body weight via intravenous (IV) infusion on Days 1 and 8 of a 21-day treatment cycle until disease progression or unacceptable toxicity.
88822920|NCT01631552|Experimental|SG 12 mg/kg|Participants will receive SG 12 mg/kg of body weight via intravenous (IV) infusion on Days 1 and 8 of a 21-day treatment cycle until disease progression or unacceptable toxicity.
88822921|NCT01631552|Experimental|SG 18 mg/kg|Participants will receive SG 18 mg/kg of body weight via intravenous (IV) infusion on Days 1 and 8 of a 21-day treatment cycle until disease progression or unacceptable toxicity.
88822922|NCT03081117|Experimental|Insulin, intranasal|Regular insulin, 20 IU intranasal twice a day for 24 weeks; 0.2 mL per dose
88822923|NCT03081117|Placebo Comparator|Placebo, intranasal|Saline solution (placebo), intranasal twice a day for 24 weeks; 0.2 mL per dose
88822924|NCT03124797|Experimental|RD DCI Sensor|All subjects are enrolled into the test group and all subjects received the RD DCI Sensor
88822925|NCT01944293|Experimental|Ketamine|0.5 mg/kg, I.V. (in the vein)
88822926|NCT01944293|Active Comparator|Midazolam|0.02 mg/kg, I.V. (in the vein)
88822927|NCT03083379|Active Comparator|Volumetric Incentive Spirometry|Incentive Spirometry
88822928|NCT03083379|Experimental|EzPAP® POSITIVE AIRWAY PRESSURE|EzPAP
88822929|NCT01944371|Experimental|disulfiram 500mg|500mg disulfiram by mouth per day for 3 days
89177008|NCT03849313|Active Comparator|US-Humira 100mg/mL|US licensed Adalimumab originator Humira
89177009|NCT04111614|Experimental|Arm 1|Single dose of 5 mL tofacitinib oral solution on Day 1 of Period 1 and Singe dose of 5 mg tofacitinib tablet on Day 1 of Period 2
89177010|NCT04111614|Experimental|Arm 2|Single dose of 5 mg tofacitinib tablet on Day 1 of Period 1 and Singe dose of 5 mL tofacitinib oral solution on Day 1 of Period 2
89177011|NCT01019473|Experimental|AFQ056A|
89177012|NCT01019473|Placebo Comparator|Placebo|
89177013|NCT01023919|Active Comparator|Group B: Non-DM|Coronary artery disease with diabetes mellitus
89177014|NCT01023919|Active Comparator|Group A: DM|Coronary artery disease with diabetes mellitus
89177015|NCT04028622|Experimental|TCAD (telemedicine anesthesia consultation)|Patients having a telemedicine anesthesia consultation
88822930|NCT01944371|Experimental|disulfiram 1000mg|1000mg disulfiram by mouth per day for 3 days
88822931|NCT01944371|Experimental|disulfiram 2000mg|2000mg disulfiram per mouth per day for 3 days
88822932|NCT02343120|Experimental|Zanubrutinib|Participants were administered up to 320 mg total daily dose of zanubrutinib until disease progression, intolerance or death, withdrawal of consent, or loss to follow-up
88822933|NCT03125031|Experimental|Group- Sensor 1|All subjects are enrolled into the test group and receive the Rainbow adhesive adult/pediatric sensors.
88822934|NCT03125031|Experimental|Group- Sensor 2|All subjects are enrolled into the test group and receive the Rainbow adhesive adult/neonatal sensors.
88822935|NCT03083769||Cohort 1|The retrospective cohort consists of about 839 kidney transplant recipients from Nanfang Hospital. These patients used tacrolimus as immunosuppressive drug for preventing the rejection.The side effects (acute rejection, nephrotoxicity and neurotoxicity) will be recorded.
88822936|NCT03083769||Cohort 2|The retrospective cohort consists of about 663 kidney transplant recipients from Guilin No. 924 Hospital. These patients used tacrolimus as immunosuppressive drug for preventing the rejection.The side effects (acute rejection, nephrotoxicity and neurotoxicity) will be recorded.
88822937|NCT01946243|Experimental|Physician Readers|Physician readers will interpret Amyvid scans using qualitative analysis followed by the use of quantitation. No subjects will be exposed to Florbetapir F 18 as part of this study.
88822938|NCT03086265|Experimental|THRIVE|high flow nasal oxygen
88822939|NCT03086265|Active Comparator|Endotracheal tube|tracheal intubation
88822940|NCT01631630|Experimental|Pioglitazone|Subjects received pioglitazone, 15mg/day for 3 days; 30mg day for 3 days; 45mg/day thereafter, for a minimum total of 13 days
88822941|NCT01631630|Placebo Comparator|Placebo|Subjects received placebo on a similar dosing schedule, for a minimum total of 13 days
88822942|NCT01947335|No Intervention|Angiography-guided PCI|Angiography-guided percutaneous coronary intervention
88822943|NCT01947335|Active Comparator|IVUS-guided PCI|Intravascular ultrasound guided percutaneous coronary intervention
88875167|NCT02495454|Experimental|Ga101-miniCHOP|"6 courses of GA101-miniCHOP regimen and 2 additional infusions of GA101, every 21 days (for a total of 6 courses of miniCHOP and 10 infusions of GA101).~GA101-miniCHOP regimen:~Cycle 1 GA101: 1000 mg day 1, day 8 and day 15, iv Cyclophosphamide: 400 mg/mq, day 1, iv Doxorubicin: 25 mg/mq, day 1, iv Vincristine: 1 mg, day 1, iv Prednisone: 40 mg/mq, days 1-5, os~Cycles 2-6 GA101: 1000 mg day 1, iv Cyclophosphamide: 400 mg/mq, day 1, iv Doxorubicin: 25 mg/mq, day 1, iv Vincristine: 1 mg, day 1, iv Prednisone: 40 mg/mq, days 1-5, os~Two additional infusions of GA101: 1000 mg day 1, iv, every 21 days."
88875168|NCT02500368|Experimental|silicone hydrogel lens (test)|Participants were randomized to wear silicone hydrogel lens (test) for 1 week during the cross over study.
88875169|NCT02500368|Active Comparator|enfilcon A lens (control)|Participants were randomized to wear enfilcon A lens (control) for 1 week during the cross over study.
89177016|NCT03844087|Experimental|multiplanar neuromuscular training arm|The intervention arm will be involved in the training intervention outlined. Briefly, each participant will be asked to train on the TopSpin360 3 times per week for 3-5 sets for the duration of the study. Each set will take roughly 15-30 seconds to perform and training will take part during regularly scheduled training sessions.
89177017|NCT00830804|Experimental|RAL + DRV/RTV|Raltegravir (400 mg BID) plus Darunavir/Ritonavir (800 mg/100 mg QD) for 52 weeks
89177018|NCT01023997||primary open-angle glaucoma|
88822944|NCT01947647|Experimental|Transdiagnostic Behavior Therapy|A new transdiagnostic CBT protocol for the depressive/anxiety disorders was developed and revised through two demonstration studies and one focus group. The resulting protocol involves several primary components, including psychoeducation on the symptoms of depression and anxiety (session 1), assessment of motivation and setup of treatment plans (session 2), exposure therapy (sessions 3-15), and relapse prevention (final session). In addition to these primary components, optional modules are included to supplement exposure therapy later in treatment to address secondary symptoms (e.g., anger, sleep, hypervigilance, drinking to cope). The goal of these modules is to allow providers to tailor treatment to specific symptoms that may be present in any single or set of diagnoses that may be reducing the effects from the primary exposure approach. Session will be weekly for 45-60 minutes with homework assignments to be completed between sessions.
88822945|NCT01947647|Active Comparator|Behavioral Activation Therapy|To provide an evidence-based comparison for the transdiagnostic CBT condition, a second group of participants will receive manualized BAT. In general, BAT involves teaching patients to monitor their mood and daily activities with the goal of increasing pleasant, reinforcing activities and reducing unpleasant events. In the present study, the BAT condition will be manualized, following an existing protocol in the literature. BAT will be structurally equivalent to the transdiagnostic CBT with the same session length (45-60 minutes), frequency of sessions (weekly), duration of treatment (12-16 sessions), and amount of homework.
88822946|NCT04333251|Experimental|convalescent plasma|This arm will receive convalescent plasma
88822947|NCT04333251|Placebo Comparator|best supportive care|Oxygen therapy
88822948|NCT03837860|Active Comparator|Oxycodone/Placebo|Each study participant will receive all three study interventions in random order.In this arm, the participant receives oxycodone or placebo
88822949|NCT03837860|Active Comparator|Oxycodone/Risperidone|Each study participant will receive all three study interventions in random order. In this arm the participant receives a combination of oxycodone or risperidone
88822950|NCT03837860|Active Comparator|Oxycodone/Ziprasidone|Each study participant will receive all three study interventions in random order. In this arm the participant receives a combination of oxycodone or ziprasidone
88822951|NCT02289989|Active Comparator|Standard: Hydrocortisone 1% ointment|Intervention: hydrocortisone 1% ointment will be applied to one patient's forearm
88822952|NCT02289989|Experimental|Experimental: oregano extract cream|Intervention: Oregano extract cream for mild to moderate atopic dermatitis will be applied to the other patient's forearm
88822953|NCT03091179|Experimental|THRIVE|high flow nasal oxygen
88822954|NCT03091179|Active Comparator|Endotracheal tube|tracheal intubation
88822955|NCT03076112|Experimental|Ipragliflozin|"Ipragliflozin 50 mg in addition to their preexisting sulfonylurea and metformin~** Metformin and sulfonylurea's dosages~Metformin 500 mg - 2550 mg~Sulfonylurea: Glimepiride 1 mg - 8 mg or Gliclazide MR 30 mg - 120 mg"
88822956|NCT03076112|Active Comparator|Sitagliptin|"Sitagliptin 100 mg in addition to their preexisting sulfonylurea and metformin~** Metformin and sulfonylurea's dosages~Metformin 500 mg - 2550 mg~Sulfonylurea: Glimepiride 1 mg - 8 mg or Gliclazide MR 30 mg - 120 mg"
88822957|NCT03129945|Active Comparator|Nifedipine|Participants will be given this medication orally
88822958|NCT03129945|Active Comparator|Indomethacin|Participants will be given this medication orally
88822959|NCT01948739|Experimental|BMI control of MAHI Exo-II|MAHI EXO-II exoskeleton augmented with BMI system will be used to actively include the patient in the control loop, thereby making the therapy 'active' and engaging patients with various impairment severity in rehabilitation tasks. Patients will receive longitudinal training with the BMI-robotic interface for 3-4 sessions per week, over a period of 3 months.
88822960|NCT01700036|Experimental|Treatment arm|Alpha-1-Antitrypsin (AAT) for the treatment of Steroid Refractory Acute Graft vs Host Disease.
88822961|NCT02965989|Experimental|Online training of a nursing technique|Participants receives an individual online training of extraction of blood culture for 3 months (This platform aims to improve knowledge and skills), they are sent 3 homework (one per month) and are evaluated at the end of each.
88822962|NCT02965989|No Intervention|not receive online training|Participants don´t receives an individual online training of extraction of blood culture.Do their work as usual.
88822963|NCT04768205|Active Comparator|Study group|The therapy and Kinesio tex gold tape that was affixed to stretched and neck localised were applied
88822964|NCT04768205|Placebo Comparator|Sham control group|The therapy and Kinesio tex gold tape that was affixed to different neck localised as no-stretched were applied
88822965|NCT01700816|Experimental|Bright light therapy|2500 Lux gaze directed every morning from 8 am until 8:30 am
88822966|NCT01700816|Placebo Comparator|Sham light|<1000 Lux gaze directed every morning from 8 am until 8:30 am
88822967|NCT01950299|Experimental|Anakinra (standard dose)|Anakinra 100 mg daily for 14 days
88822968|NCT01950299|Experimental|Anakinra (high dose)|Anakinra 100 mg twice daily for 14 days
88822969|NCT01950299|Placebo Comparator|Placebo|Placebo for 14 days
89177019|NCT01023997||ocular hypertension patients|
89177020|NCT01023997||normal controls|
89177021|NCT01023997||Exfoliation patients|patients with exfoliation syndrome or exfoliative glaucoma
89177022|NCT00789477|Experimental|Intravitreal Aflibercept Injection .5Q4|Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) .5 mg every 4 weeks
89177023|NCT00789477|Experimental|Intravitreal Aflibercept Injection 2Q4|Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2 mg every 4 weeks
89177024|NCT00789477|Experimental|Intravitreal Aflibercept Injection 2Q8|Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2mg every 4 weeks for 3 visits followed by every 8 weeks
89177025|NCT00789477|Experimental|Intravitreal Aflibercept Injection 2PRN|Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2mg every 4 weeks for 3 visits followed by PRN (as-needed) dosing according to the re-treatment criteria
89177026|NCT00789477|Active Comparator|Laser Photocoagulation|Focal laser at week 1, and one week after visits at which the participant met laser re-treatment criteria to the end of the study (week 52) starting at week 16; laser re- treatment was permitted no more than once every 16 weeks.
89177027|NCT01024075|Placebo Comparator|Saline|Sinufoam is mixed with saline and placed within the ethmoid cavity at the completion of sinus surgery
88822970|NCT02967393|Active Comparator|IIV4|0.5 mL intramuscular injection
88822971|NCT02967393|Active Comparator|cc IIV4|0.5 mL intramuscular injection
88822972|NCT05734703|Experimental|Standard Topical Daily Dose|Only one arm in the study. Subjects treated with the topical daily for 90 days. The comparison will be 'before' and 'after' treatment skin biopsy results.
88822973|NCT03093207|Placebo Comparator|Control group|In this group (n = 17), patients will take placebo pills and open flap debridement will be performed to treat residual pockets.
88822974|NCT03093207|Experimental|Test Group|In this group (n = 17), patients will take 3 g of omega-3 polyunsaturated fatty acids plus 100 mg of aspirin daily supplementation over a period of 180 days and open flap debridement will be performed to treat residual pockets.
88822975|NCT01703702|Experimental|Intervention|Subjects will receive florbetapir (18F) PET scans and physicians will have immediate access to PET scan results.
88822976|NCT01703702|Experimental|Control|Subjects will receive florbetapir (18F) PET scans but physicians will be blinded to PET scan results for 12 months
88822977|NCT02986763||Professional pesticides|A specific questionnaire with professional information about pesticide uses is added for this arm Questionnaire to collect domestic pesticide use, diet, household characteristics Dust sampling Blood sampling Urine sampling Hair sampling
88822978|NCT02986763||Volunteers|Questionnaire to collect domestic pesticide use, diet, household characteristics Dust sampling Blood sampling Urine sampling Hair sampling
88822979|NCT03096873|No Intervention|No Exercise (CON)|Twenty obese adolescent girls. This arm did not perform any exercise training for 12 weeks. Caloric intake: 1921.7 kcal/day
88822980|NCT03096873|Experimental|Exercise (EX)|Twenty obese adolescent girls. This arm performed combined exercise training 5 times a week for 12 weeks. Caloric intake: 1921.7 kcal/day
88822981|NCT02646098|Active Comparator|CD34+ cell selection|CD34+ cell selection applying CliniMACS device (Miltenyi Biotec, Bergisch Gladbach, Germany)
88822982|NCT02646098|No Intervention|No CD34+ cell selection|No CD34+ cell selection
88822983|NCT02969031|Experimental|Enhanced SCOPE training|Complete a baseline questionnaire, administer satisfaction surveys anonymously to a sample of their patients, audio record (using a smartphone application) eight clinic visits with eight different patients. Receive survey feedback as well as the enhanced SCOPE program that provides feedback on their audio-recorded encounters via a web-based interactive program.
88822984|NCT02969031|Active Comparator|Standard Communication training|"Complete a baseline questionnaire, administer satisfaction surveys anonymously to a sample of their patients. Receive the results of the patient surveys and be asked to conduct a quality improvement activity of their own design that responds to the feedback (the current standard communication PIM)."
88822985|NCT05482451|Experimental|Nivolumab + all-trans retinoic acid|"Nivolumab: 3mg/kg intravenously on day 1.~All-trans retinoic acid (Vesanoid) 45 mg/m2 on days 1-14. The dose of Vesanoid can be increased with addition of 15 mg/m2 in next course of treatment if there is no severe adverse effects. Therefore, the dose of Vesanoid could be 60 mg/m2 from the second course, 75 mg/m2 from the third course, till the maximal dose of 150 mg/m2 if patients tolerated the treatment. The decision of dose escalation is left to in-charge physician.~The treatment cycle will repeat every 2 weeks."
88822986|NCT02969421|Active Comparator|Slow Tenaculum Placement|This group will have their tenaculum placed using the slow method
88822987|NCT02969421|Active Comparator|Cough Method|This group will have their tenaculum placed using the cough method
88822988|NCT04350203||Intracorporeal Anatomosis (IA)|Laparoscopic Right colectomy with intracorporeal (IA) side-to-side isoperistaltic anastomosis
88822989|NCT04350203||Extracorporeal Anastomosis (EA)|Patients submitted to a Laparoscopic Right Colectomy with extracorporeal anastomosis (EA)
88822990|NCT03134313|Experimental|R1-25 Sensor|All subjects will be enrolled in the test group and will receive Rainbow Adhesive Noninvasive R1 Pulse Oximeter Sensor
88822991|NCT02228408|Experimental|Hydralazine/Isorsorbide Dinitrate|"Hydralazine/Isorsorbide Dinitrate (ISD/HY) will be administered with a target dose of 40 mg of ISD and 75 mg of Hydralazine 3x/daily. Doses will be titrated between weeks 0-4 and may be decreased as necessary for treatment of adverse events.~Allowable Dosage Forms:~ISD/HY 10 mg/10-3x/day ISD/HY 20 mg/35mg-3x/day ISD/HY 40 mg/75 mg-3x/day"
88822992|NCT02228408|Active Comparator|Placebo|Placebo will be administered Doses will be titrated between weeks 0-4 and may be decreased as necessary for treatment of adverse events.
88822993|NCT01951391|Other|Control Soap vs. Benzalkonium Chloride Soap|Each subject's will have one forearm washed with a control soap and then the other forearm will be washed with benzalkonium chloride soap. The control forearm will be swabbed for bacteria at baseline, 10 minutes, 6 hours, and 24 hours. The benzalkonium chloride forearm will be swabbed at baseline and 6 hours.
88822994|NCT01951391|Other|Control Soap vs. Triclocarban Soap|Each subject's will have one forearm washed with a control soap and then the other forearm will be washed with triclocarban soap. The control forearm will be swabbed for bacteria at baseline, 10 minutes, 6 hours, and 24 hours. The triclocarban forearm will be swabbed at baseline and 6 hours.
88822995|NCT01953575|Experimental|Active Eosinophilic Esophagitis|Subjects with an eosinophil count greater than 15 eosinophil per high-powered field (Eos/HPF) and do not have trouble swallowing during the clinical endoscopy
88822996|NCT01953575|Experimental|Inactive Eosinophilic Esophagitis|Subjects with an eosinophil count less than 15 eosinophil per high-powered field (Eos/HPF) and do not have trouble swallowing during the clinical endoscopy
88822997|NCT01953575|Placebo Comparator|Control group|Subjects are those undergoing clinically indicated upper endoscopy for nonesophageal symptoms in whom a normal-appearing esophagus was found at the time of endoscopy
88822998|NCT05734469|Other|Popliteal sciatic nerve block|A local anesthetic solution of 30ml of ROPIVACAINE 0,5% (4mg/kg maximum) will be used for the popliteal sciatic nerve block (popliteal sciatic, saphenous) by real-time ultrasound guidance (associated with a standardized general anesthesia)
88822999|NCT05734469|Other|Ankle block|A maximum solution of 15ml of ROPIVACAINE 0. 5%( 4mg/kg maximum) for the ankle block (saphenous, superficial peroneal, deep peroneal and tibial nerves) by real-time ultrasound guidance (associated with a standardized general anesthesia)
88999594|NCT02896036|Active Comparator|Veress needle entry with subsequent CO2|For the other group of participants who will be randomized to subsequent CO2 insufflation; the Veress needle will be connected to the CO2 tubing, and a skin incision will be made with the scalpel, followed by insertion of the Veress needle. The gas insufflation will be started and the opening pressure will be noted. If the opening pressure is less than or equal to 10 mmHg, the process of insufflation will be allowed to continue. In case of a higher opening pressure, the Veress needle will be withdrawn and reinserted up to 3 times. Each time the needle is to reinserted, the CO2 insufflator will be switched off until the location of the Veress needle is felt to be adequate.
88999595|NCT02895997|Experimental|Clinical Operations Room Staff|Clinicians and critical care nurse volunteers from the clinical operations room (COR) staff at Emory University Hospital will travel to Sydney Australia to deliver telemedicine.
88823000|NCT01955369||Amyotrophic lateral sclerosis patients|Patients were included into the registry if they had a new diagnosis of ALS, a minimum age of 18 years and lived in Rhineland-Palatinate for at least 6 months before date of diagnosis. Diagnosis was based upon the revised El Escorial criteria.
88823001|NCT02342886|Experimental|MDR-TB|moxifloxacin 400 mg + PA-824 200 mg + pyrazinamide 1500 mg for 26 weeks.
88823002|NCT02342886|Active Comparator|DS-TB (HRZE), HR|"26 consecutive weeks to DS-TB subjects only, as follows:~HRZE (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol combination) Weeks 1-8 with daily dose per the subjects weight~HR (Rifampicin plus isoniazid combination tablets) Weeks 9 - 26 with daily dose per the subjects weight~Daily dose per the subjects weight as follows: 30-39kg: 2 tablets; 40-54kg: 3 tablets; 55 - 70kg: 4 tablets; 71kg and over: 5 tablets."
88823003|NCT02342886|Experimental|DS-TB PA-824 200mg 26 weeks|moxifloxacin 400 mg + PA-824 200 mg + pyrazinamide 1500 mg orally once daily for 26 weeks
88823004|NCT02342886|Experimental|DS-TB PA-824 200mg 17 weeks|moxifloxacin 400 mg + PA-824 200 mg + pyrazinamide 1500 mg orally once a day for 17 weeks
88823005|NCT02342886|Experimental|DS-TB PA-824 100mg 17 weeks|moxifloxacin 400 mg + PA-824 100 mg + pyrazinamide 1500 mg orally once daily for 17 weeks
88823006|NCT04350281|Active Comparator|Treatment group|Subcutaneous injection of interferon β-1b 1mL (0.25mg; 8 million IU) consecutively on day 1 to day 3 and hydroxychloroquine 800mg on day 1, then 400mg daily for 2 days plus standard care
88823007|NCT04350281|Active Comparator|Control group|Hydroxychloroquine 800mg on day 1, then 400mg daily for 2 days plus standard care alone.
88823008|NCT04350047||Transabdominal inferior vena cava thrombectomy|Patients undergoing radical nephrectomy and inferior vena cava thrombectomy transabdominal without thoracotomy
88823009|NCT03097341|Experimental|xisomab 3G3- Dose 1|Participants will receive a single intravenous dose of 0.1 mg/kg xisomab 3G3.
88823010|NCT03097341|Experimental|xisomab 3G3- Dose 2|Participants will receive a single intravenous dose of 0.5 mg/kg xisomab 3G3.
88823011|NCT03097341|Experimental|xisomab 3G3- Dose 3|Participants will receive a single intravenous dose of 2.0 mg/kg xisomab 3G3.
88823012|NCT03097341|Experimental|xisomab 3G3- Dose 4|Participants will receive a single intravenous dose of 5.0 mg/kg xisomab 3G3.
88823013|NCT03097341|Placebo Comparator|Placebo|Participants will receive a single intravenous dose of placebo.
88823014|NCT02390076|Active Comparator|Left active LLLT|Active LLLT targeting the left forehead Attention Bias Modification Left low level light therapy
88823015|NCT02390076|Active Comparator|Right active LLLT|Active LLLT targeting the right forehead Attention Bias Modification Right low level light therapy
88823016|NCT02390076|Sham Comparator|Sham LLLT|Sham LLLT targeting the right forehead Attention Bias Modification Sham low level light therapy
88823017|NCT03097653|Experimental|Decision-aid|
88823018|NCT03097653|Active Comparator|Standard information|
88999596|NCT02895919||Control group - blood culture bottles|Standard of care group for control - will inoculate all samples in blood culture bottles for ascitic fluid culture
89177028|NCT01024075|Active Comparator|Dexamethasone|Sinufoam is mixed with dexamethasone and placed within the ethmoid cavity at the completion of sinus surgery
89177029|NCT00913874|Experimental|1|Divalproex Sodium 500 mg DR Tablets (Sandoz Inc., USA)
89177030|NCT00913874|Active Comparator|2|Depakote 500 mg DR Tablets (Abbott Laboratories, USA)
88823019|NCT02389998|Experimental|Placebo|Arm 1: Subjects take 1/4 teaspoon placebo suspension 2 times a day (morning and night), and a third dose if necessary for a period of three weeks. Subjects will also have access to hyoscyamine as a rescue medication.
88823020|NCT02389998|Other|No Treatment|Arm 2: Subjects receive no treatment but have access to hyoscyamine as a rescue medication.
88823021|NCT02330627|Experimental|Positive Valence System Treatment|10 one-hour individual sessions comprised of psychoeducation and positive activity interventions designed to increase positive emotions, cognitions, and behaviors.
89177031|NCT04106661|Experimental|Tai Chi Intervention 1|The intervention group and control group were recruited during the same time frame. The intervention group received Tai Chi instruction via a weekly group session and home use of a DVD. The control group received no formal instruction in physical activity.
88823022|NCT02330627|No Intervention|Delayed Treatment (Waitlist)|
88823023|NCT02128958|Experimental|CF102|orally q12h
88823024|NCT02128958|Placebo Comparator|Placebo tablets of CF102|orally q12h
88823025|NCT02389764|Experimental|BIBF 1120|Initial dose of BIBF 1120 is 200 mg twice daily orally for a 28 day cycle. Participant called by a member of the study staff every 3 months for up to 1 year after end-of-treatment visit. Participant called by a member of the study staff every 3 months for up to 1 year after end-of-treatment visit.
88823026|NCT03135015|Other|Lean Participants|Participants with BMI >18.5 and <25.0kg/m²
88823027|NCT03135015|Other|Overweight/Obese Participants|Participants with BMI ≥25.0 and <35.0kg/m²
88823028|NCT01647932|Active Comparator|Loop plus thiazide-type diuretic|Loop diuretic plus hydrochlorothiazide
88823029|NCT01647932|Placebo Comparator|Loop diuretic plus placebo|Loop diuretic plus placebo
88823030|NCT01597856|Experimental|SBIRT|"The SBIRT-VA manual codifies basic substance abuse screening, treatment, Motivational Interviewing and referral procedures. It is designed for providers with minimal substance abuse expertise and is easy for experienced substance abuse providers to deliver.~Study sessions include identifying the Veterans' values through a card sort, the change ruler, on which the Veteran rates his/her willingness to change current behavior, listing the pros and cons of changing."
88823031|NCT01597856|No Intervention|No additional treatment|Veterans assigned to the control condition will not receive any study-related therapy. A Veteran who completes a Compensation examination ordinarily has no further treatment, referral, or debriefing as part of the Compensation examination.
88823032|NCT02366130|Experimental|Ra-223 dichloride + Denosumab|"Ra-223 dichloride 55 kBq/kg administered as a bolus intravenous (IV) injection (over 1 minute) through a secure in-dwelling catheter on day 1 of the study and then every four weeks thereafter for 6 cycles.~Denosumab 120 mg by subcutaneous (SC) injections on Day 1 of Cycles 2-5.~A single hormonal agent (ie, Tamoxifen or Aromatase Inhibitor or Fulvestrant) administered daily while on study. Physician to decide what type of hormone therapy participant will receive."
88823033|NCT01633892|Experimental|Fat Grafting|
88823034|NCT03098745|Active Comparator|Omafilcon A|Participants are randomized to wear omafilcon A lens pair bilaterally for 1 hour during the study.
88823035|NCT03098745|Active Comparator|Somofilcon A|Participants are randomized to wear somofilcon A lens pair bilaterally for 1 hour during the study.
88823036|NCT03098745|Active Comparator|Omafilcon A - Proclear (PC)|Participants are randomized to wear omafilcon A - PC lens pair bilaterally for 1 hour during the study.
88823037|NCT01635062|Experimental|calcitriol|Subjects will receive calcitriol (titrated up to 0.75 mcg daily) for 3 weeks.
88823038|NCT01635062|Placebo Comparator|placebo|Subjects will receive placebo for 3 weeks.
88823039|NCT03099369|Experimental|Daily Step-based Exercise Group|"The experimental group will receive the following 12-week step-based exercise prescription with the eventual goal of walking at least 5,000 steps a day (based on evidence that at least 5,000 a day is associated with better health). The Fitbit Fitness Monitor used for tracking.~Week 1: walk at least 3,000 steps every day.~Week 2: walk at least 3,500 steps every day.~Week 3: walk at least 4,000 steps every day.~Week 4: walk at least 4,500 steps every day.~Weeks 5-12: walk at least 5,000 steps every day."
88823040|NCT03099369|Active Comparator|Symptom-based Exercise Group|"The active comparator group (ie. control group) will receive the following 12-week symptom-based exercise prescription (adapted from practice guidelines).~Walk on a flat surface at a constant speed until there is mild to moderate pain~Rest until the pain has completely ceased~Resume walking at the same speed~Increase the speed when you can walk 8 minutes without stopping for leg symptoms~Continue this exercise routine for 45 consecutive minutes, 3 to 5 days a week."
88823041|NCT01637090|Experimental|all patients on study|"This will be a prospective, phase II non-randomized, open label study of single agent everolimus for the treatment of CTCL recurrent or refractory to at least one previous treatment other than topical medication. The purpose will be evaluation of safety and anti-tumor response as evaluated by serial skin examinations and assessment of tumor burden in tissue and blood.~This study will be conducted in 2 stages. During stage 1 we will enroll a maximum of 11 subjects to evaluate response rate and will only continue to stage 2, if we observe two or more responses. During stage 2, we will expand the study to an overall N of 28 patients."
88823042|NCT01637246||POAG or OHT|Patients with POAG or OHT previously treated with monotherapy and currently treated with any fixed combination therapy
88823043|NCT02389452|Experimental|Synvisc-One|Single 6 mL IA injection of Synvisc-One (48 mg of cross-linked hylan polymer) at Day 0 (Initial Treatment). Participants received repeat injection based on physician's discretion of safety and efficacy (no major safety concerns and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) A1 subscore [measurement of pain while walking on flat surface] between 40-80 mm, measured on a 0-100 mm scale with 0 represents no pain and 100 represents worst possible pain) at Week 26, 39 or 52 (Repeat treatment).
88823044|NCT01637870|Experimental|Negative pressure pump|Will have the Prevena negative pressure wound system placed at the time of surgery.
88823045|NCT01955837|Experimental|TAS-102|
88823046|NCT01955837|Placebo Comparator|Placebo|
88823047|NCT01638416|Active Comparator|Standard of care|Blood Transfusion Standard of care- oldest blood.
88823048|NCT01638416|Other|Arm B|Blood Transfusion Freshest blood.
88823049|NCT02971293|Experimental|AZD8871 100 µg|The subjects will receive AZD8871 100 µg once daily, by dry powder inhaler (DPI) device. The treatment will be administered via single dose DPI that is an adaptation of the multi-dose Genuair™ used in approved inhalation products.
88823050|NCT02971293|Placebo Comparator|Placebo|The placebo will be administered via single dose DPI that is an adaptation of the commercially available Genuair® with a smaller internal volume to enable delivery of single doses. To maintain blinding, each patient will receive one inhaled dose from placebo DPI provided to him/her on each day of the treatment period.
88823051|NCT02971293|Experimental|AZD8871 600 µg|The subjects will receive AZD8871 600 µg once daily by DPI device via single dose DPI that is an adaptation of the multi-dose Genuair™ used in approved inhalation products.
88823052|NCT02365584|Experimental|Standard care and Lanreotide Autogel|Standard care according to site clinical practice and Lanreotide Autogel 120 mg by deep subcutaneous route, at the maximal scheduled standard dose of 120 mg/28 days, just for 1 administration.
88823053|NCT02365584|No Intervention|Standard care|Standard care according to site clinical practice.
88999597|NCT02895919||Study group - sample to lab for culture|Study group - will send a sample of ascitic fluid to lab for inoculation in addition to control sample
88999598|NCT02895880||usual care|first 25 participants will receive usual care (i.e. no risk communication tool)
88999599|NCT02895880||risk communication tool|next 25 participants, clinicians will use the risk communication tool in their discussion about statins and cardiovascular risk reduction
88999600|NCT00196755|Experimental|Sevelamer Hydrochloride (Renagel®)|
88999601|NCT00196755|Active Comparator|Calcium acetate (PhosLo® )|
88999602|NCT02895529|Experimental|Itraconazole|
88999603|NCT02895529|Active Comparator|Caspofungin|
88823054|NCT01956071|Experimental|WAPD|Participants were asked to complete three tasks while simultaneously pedaling at a sustainable and self-selected pace. The three tasks were: 1) compose and send an email; 2) search a topic on the internet, and 3) complete an on-line questionnaire.
88823055|NCT02342418|Active Comparator|Morbidly obese|The morbidly obese (BMI ≥ 40 kg/m2) arm will be recruited first. Each morbidly obese subject will be matched to a non-obese subject (BMI 18.5-29.9 kg/m2) based on age (± 5 years), sex, and ideal body weight (± 4.6 kg, i.e. ± 5 cm in height). Each group will receive a single dose of tedizolid phosphate 200 mg through a peripheral intravenous catheter.
88823056|NCT02342418|Active Comparator|Non-obese|Each non-obese subject will be matched to a morbidly obese subject (BMI 18.5-29.9 kg/m2) based on age (± 5 years), sex, and ideal body weight (± 4.6 kg, i.e. ± 5 cm in height). Each group will receive a single dose of tedizolid phosphate 200 mg through a peripheral intravenous catheter.
88823057|NCT01957085||Hospitalized Patients|Observation only. All patients admitted to Temple University Hospital on the study day. Observational only, no intervention.
88823058|NCT05727449||General Anesthesia for Cesarean Delivery|
88823059|NCT05727449||Spinal Anesthesia for Cesarean Delivery|
88823060|NCT03102645|Experimental|Imipramine first|A: Imipramine Hydrochloride 25 MG x2 B: Placebo Oral Tablet x2
88823061|NCT03102645|Experimental|Placebo first|A: Placebo Oral Tablet x2 B: Imipramine Hydrochloride 25 MG x2
88823062|NCT01639352|Experimental|SOM230|60mg of SOM230 via injection intramuscularly every 28 days
88823063|NCT05740085||Rheumatoid Arthritis Patients|Patients that are diagnosed with rheumatoid arthritis
88823064|NCT03102879|Experimental|Regenerative Endodontic Procedure (REP)|umbilical cord-derived mesenchymal stem cells encapsulated in a plasma-derived biomaterial.
88823065|NCT03102879|Active Comparator|Conventional Root Canal Treatment|Conventional endodontic procedure
88823066|NCT05439317||knee osteoarthritis group|individuals being diagnosed with osteoarthritis and classified by K-L grading
88823067|NCT05439317||healthy group|individuals without knee pain or diagnosis of knee osteoarthritis
88823068|NCT02365506|Experimental|Eleclazine 24 mg + Eleclazine 48 mg + Placebo|Participants will receive placebo to match eleclazine on Days 1 and 4, eleclazine 24 mg on Day 2 and eleclazine 48 mg on Day 3.
88823069|NCT02365506|Experimental|Eleclazine 48 mg + Placebo|Participants will receive placebo to match eleclazine on Days 1, 2 and 4, and eleclazine 48 mg on Day 3.
88823070|NCT02365506|Placebo Comparator|Placebo|Participants will receive placebo to match eleclazine on Days 1 to 4.
88823071|NCT01639664|Experimental|High doses CPFA|High doses CPFA (coupled plasma-filtration adsorption) with AMPLYA™ (BELLCO ITALY): >0.20 L/kg/day of plasma treated in the first 3 days after randomization.
88823072|NCT01639664|No Intervention|Control group|standard practice
88823073|NCT03104985|Active Comparator|Conventional treatment|"Conventional treatment only.~An elastic compression of lower extremities: elastic bandages or compression hosiery of class 2~Pharmacotherapy: Anavenol, Aescusan, Glyvenol; drugs of the Benzopyrone group, including Troxevasin and Venoruton. Trental, Aspirin and Ticlid (Ticlopidine). Nonsteroidal anti-inflammatory drugs (Nimesil, OKI), various ointments containing Heparin, corticosteroids, as well as nonsteroidal anti-inflammatory drugs. Antibiotic therapy.~Topical treatment: in the presence of purulent discharge (phase I of the wound healing process) - bandaging with antiseptic solutions (1% Iodopiron solution, 0.1% Chlorhexidine solution) and hydrophilic ointments (Levosin, Levomecol). In phases II and III - after ulcer cleansing the preparations based on Hyaluronic acid (Curiozin)."
88823074|NCT03104985|Experimental|Conventional therapy and combined LLLT|"Conventional therapy and combined LLLT (LASMIK device) was performed. External exposure was conducted on the 1-4 affected area during one session for 2 minutes per zone in pulsed mode, light pulse duration - 100-130ns, wavelength - 635nm, by a matrix emitter consisting of eight laser diodes with a surface area of 8cm2, at a distance of up to 7cm, with pulsed power of 40W. ILBI was conducted in continuous mode with wavelength between 365-405nm (UV-spectrum) and 520-525nm (green spectrum) alternately, during 12 daily treatment sessions according to the scheme:~- 365-405nm, power 1-2mW, exposure 2 min;~- 520-525nm, 1-2mW, 5 min;~- 365-405nm, 1-2mW, 2 min;~- 520-525nm, 1-2mW, 5 min;~- 365-405nm, 1-2mW, 2 min;~- 520-525nm, 1-2mW, 5 min;~- 365-405nm, 1-2mW, 2 min;~- 520-525nm, 1-2mW, 5 min;~- 365-405nm, 1-2mW, 2 min;~- 520-525nm, 1-2mW, 5 min;~- 365-405nm, 1-2mW, 2 min;~- 520-525nm, 1-2mW, 5 min"
88823075|NCT04707105||Second Affiliated Hospital, School of Medicine, Zhejiang University|a prospective cohort of patients of primary intracerebral hemorrhage in Second Affiliated Hospital, School of Medicine, Zhejiang University
88823076|NCT04707105||Second People's Hospital of Hangzhou City, Zhejiang Province|a prospective cohort of patients of primary intracerebral hemorrhage in Second People's Hospital of Hangzhou City, Zhejiang Province
88823077|NCT04707105||4th Affiliated Hospital, School of Medicine at Zhejiang University|a prospective cohort of patients of primary intracerebral hemorrhage in 4th Affiliated Hospital, School of Medicine at Zhejiang University
88823078|NCT01705496|Experimental|[124I]FIAU|Single dose study of [124I]FIAU in patients presenting with pain in a prosthetic knee or hip joint who will undergo PET-CT scanning.
88999604|NCT02895802|Other|Verbal instructions with picture diagram|hand washing is scored prior and after educational intervention with verbal instructions of handwashing and a picture diagram of handwashing.
88823079|NCT02287415|Experimental|Group 1|Phase A: Warfarin Phase B: Warfarin + BIA 2-093 (ESL) Phase C: Warfarin
88823080|NCT02312934|Experimental|Transdermal Nicotine|"Nicotine will be delivered by a transdermal patch delivery system for topical application. Each patch will contain approximately 1.75mg nicotine/cm2, and releases 7, and 14mg of nicotine, respectively, over 24 hours. Patches will be applied for 16 hours per day. Participants will be titrated over the course of the 6-week treatment period in order to avoid initial side effects as follows:~Week 1: ½ 7 mg patch per day, Week 2: 7 mg patch per day, Weeks 3-4: ¾ 14 mg patch per day, Weeks 5-6: 14 mg per day, Weeks 7-8: Treatment withdrawal"
88823081|NCT02312934|Placebo Comparator|Placebo|"Matching transdermal placebo patches will be used. Participants will follow the same titration schedule as the transdermal nicotine arm.~Week 1: ½ 7 mg patch per day, Week 2: 7 mg patch per day, Weeks 3-4: ¾ 14 mg patch per day, Weeks 5-6: 14 mg per day, Weeks 7-8: Treatment withdrawal"
88823082|NCT04707027|Sham Comparator|complete polypoidal regression arm|follow up monthly with color fundus photography and OCT at each visit
89355625|NCT01204307|Active Comparator|Pemetrexed/cisplatin|The patients are given pemetrexed (500 mg/m2 as a 10-min intravenous infusion) and cisplatin (75 mg/m2) on day 1 every 21 days. Dexamethasone (4 mg) is administered twice daily on the day before, the day of, and the day after each dose of pemetrexed. Oral folic acid supplementation (1000 mg) is administered daily, beginning approximately 2 weeks prior to the first dose of pemetrexed and continues until 3 weeks after treatment discontinuation. A 1000 mg vitamin B12 injection is administered intramuscularly approximately 1-2 weeks before the first dose of pemetrexed and is repeated approximately every 9 weeks until 3 weeks after therapy discontinuation.
89355626|NCT03725137||Group A (young stroke)|Young stroke patients (≤ 55); Analysis of T-lymphocytes regarding: post-stroke t-cell priming (activation marker, polarization), cognitive tests; structural MRI
89355627|NCT01204385||Study Group|
89355628|NCT03727555|Experimental|Lentivirus-mediated delivery of ABCD1 to the CNS.|Intracerebral injection with lentiviral TYF-ABCD1 vector carrying the functional gene
89355629|NCT01567241|Placebo Comparator|Relaxation music|
89355630|NCT01567241|Experimental|Clinical hypnosis|
89355631|NCT05223296|Active Comparator|Group I LigaSure (n=100)|100 patients subjected to LigaSure pile excision
88823083|NCT04707027|Active Comparator|incomplete polypoidal regression arm|continue treatment with aflibercept injection (treat and extend regimen)
89533557|NCT04310540|Experimental|Diagnostic (gallium Ga 68 gozetotide PET/MRI, PET/CT, biopsy)|Patients receive gallium Ga 68 gozetotide IV, and undergo PET/MRI over 60 minutes or PET/CT over 30 minutes at baseline and 12 weeks after completion of hepatic locoregional therapy or 8-12 weeks after completion of systemic therapy. Patients undergoing hepatic locoregional therapy may also undergo a liver biopsy.
88823084|NCT01602068|Experimental|Dexamethasone Phosphate Ophthalmic|Dexamethasone Phosphate Ophthalmic: (40 mg/mL) solution delivered by ocular iontophoresis consisting of 4.0 mA-min at 1.5 mA on Day -1 (the day before cataract surgery)
88823085|NCT01602068|Placebo Comparator|100 mM Sodium Citrate Buffer|Placebo (100 mM sodium citrate buffer solution) delivered by ocular iontophoresis consisting of 4.0 mA-min at 1.5 mA on Day -1 (the day before cataract surgery)
88823086|NCT02978157|Active Comparator|esomeprazole+amox+levo|esomeprazole 40 mg b.d., amoxicillin 500 mg q.d.s., and levofloxacin 500 mg o.d.
88823087|NCT02978157|Experimental|esomeprazole+bismuth+tetra+levo|esomeprazole 40 mg b.d., bismuth 120 mg q.d.s., tetracycline 500 mg q.d.s., and levofloxacin 500 mg o.d.
88823088|NCT01705964|Experimental|IM epinephrine 1:1000|IM epinephrine 1:1000. The dose will be 0.2 mg for subjects 20-30 kg and 0.3 mg for subjects greater than 30 kg. This will be injected intramuscularly by an ED nurse into the anterior thigh muscles of the subject using a 1 ml syringe and a 23 gauge one inch needle.
88823089|NCT01705964|Sham Comparator|No intervention|A sham band-aid will be applied to the anterior thigh of subjects who are randomized to the no intervention group.
88999605|NCT02895802|Other|Verbal instructions with video of ADSC|hand washing is scored prior and after educational intervention with verbal instructions of handwashing and a video of the adult down syndrome center
89177032|NCT04106661|Experimental|Tai Chi Intervention 2|The intervention group and control group were recruited during the same time frame. The intervention group received Tai Chi instruction via a weekly group session and home use of a DVD. The control group received no formal instruction in physical activity.
89177033|NCT00796614|Placebo Comparator|Placebo|Participants received matching placebo to tamsulosin hydrochloride via opened capsules every day for 14 weeks
89177034|NCT00796614|Experimental|Low dose|Participants received 0.001 - 0.002 mg/kg tamsulosin hydrochloride via opened capsules every day for 14 weeks
88823090|NCT02341482|Experimental|PF-04958242 and itraconazole|"PF-04958242 will be provided in a capsule. Participants will receive a 0.10 mg loading dose of PF-04958242 twice daily (BID) on Day 1 then 0.025 mg BID on Day 2-Day 16, with the last dose occurring in the morning on Day 17.~Itraconazole will be provided as a solution starting on Day 4. On Day 4, a 200 mg dose of itraconazole will be administered approximately 1 hour before PF-04958242 morning administration and for 13 additional days (Day 4-Day 17)."
89533558|NCT04305431|Experimental|1/All Subjects|Second phase participants
88999606|NCT02895802|Other|verbal instructions w. video of w/o DS|hand washing is scored prior and after educational intervention with verbal instructions of handwashing and viewing an educational video depicting a person without down syndrome washing their hands.
88999607|NCT02895802|Other|verbal instructions w.video w/DS|hand washing is scored prior and after educational intervention with verbal instructions of handwashing and watching an educational video depicting a person with down syndrome washing their hands.
88999608|NCT02895646||Beta-lactam antibiotic allergy|Diagnosis based on clinical symptomatology and skin test positive for allergen and negative for other drugs and substances. Skin tests are performed 6 weeks after allergic reaction.
88999609|NCT02895646||Control|No specific clinical investigation for control subjects
88999610|NCT00169910|Active Comparator|1|AUC monitored withdrawal of MMF
88999611|NCT00169910|Active Comparator|2|AUC monitored withdrawal of CNI
88999612|NCT02895763||Neuro Muscular disease patients|French Patients, young adults and adults, with a diagnosed neuromuscular disease, of any known form.
88999613|NCT02895490|Experimental|Arm I (DVD)|Patients receive a DVD containing educational information about patients' legal rights in the workplace and communication skills demonstrated through four scenarios depicting a variety of employer-employee communication challenges for patients, provided by LINC group.
88999614|NCT02895490|Active Comparator|Arm II (control)|Patients receive information about the LINC group.
89533559|NCT04303117|Experimental|Arm 1/Monotherapy|Treatment with NHS-IL12 at de-escalating doses if necessary
88999615|NCT02895412|Experimental|Transplant Recipient|"The T cell product administration is personalized cellular therapy product, individually prepared for each participant.~Donor-derived WT1-CTL and P-CTL.~It's exact make up and effect is dependent on both donor and recipient characteristics and as such variability is expected in the response. These variations will be adjusted for by multiple samplings over time and collation and analysis of response in both individuals an the group as a whole.~One infusion of 2 x 107/m2 P-CTLs prophylactically on or after day 28 post-allogeneic peripheral blood haemopoietic stem cell transplant (HSCT), combined with up to four infusions of 2x107/m2 WT1-CTLs."
88999616|NCT02895685|Experimental|Dyad training|Participants randomized to train in pairs during the whole 6-week course
89533560|NCT04303117|Experimental|Arm 1a/Monotherapy Expansion|Treatment with NHS-IL12 at MTD
89533561|NCT04303117|Experimental|Arm 2/Combination therapy|Treatment with NHS-IL12 at MTD and M7824 at a fixed dose
88999617|NCT02895685|No Intervention|Control group: individually training|If randomized to train individually, participants will be instructed to do all the training individually. Participants will be instructed not to practice with others when practising at home and will only receive feedback from the expert during the expert-guided self-training. At the training at CAMES, participants will sit at separate tables.
88999618|NCT02895724|Experimental|HBOT receivers|Participants in a post breast cancer surgery randomized controlled trial detected with lymphedema 1 year postoperatively are invited to 40 consequtive treatments of hyperbaric oxygen therapy to reduce lymphedema. The experimental drug is 100% medical oxygen given in a pressure chamber of 2,4 bar,every treatment lasting approximately 100 minutes.
88999619|NCT02895724|No Intervention|blodsample comparison|Matched Lymphedema free participants from LYCA Exercise recruited to donate blood samples for comparison on important blod biomarkers and collagen levels.
88999620|NCT00553774|Experimental|Flavanol|Cocoa Flavanol
88999621|NCT00553774|Placebo Comparator|Placebo|
88999622|NCT00553852|Experimental|1|The clinical examination will determine anthropometric indexes (weight, height, BMI, waist circumference). The biochemical evaluation will include the measurement of lipid profile, fasting plasma glucose and insulin, liver test function, FT3, FT4, GHRH + Arginine test to detect GHD, plasma IGF-I levels. The instrumental evaluation will include DEXA Total Body and bioimpedance analysis to determine body composition, and liver ultrasounds.
88999623|NCT00553852|Placebo Comparator|2|PHASE II: In the medical treatment protocol very severe obese patients with persistent GHD after LASGB will be inclosed. Starting from 15-day, GHD patients were re-evaluated by GHRH + Arginine test. After evaluation, the patients with persistent GHD will be randomized to be treated with Recombinant GH replacement therapy (Group A: Recombinant GH replacement therapy at the initial dose 0.15-0.30 mg/die; dose adjustment will be made according to IGF-I levels; Group B: no GH treatment).
88999624|NCT03455296|Active Comparator|central venous oxygen saturation ScVO2 normalization|Fluid therapy is initiated with maintenance fluid (Ringer or Ringer acetate) plus replacement with crystalloids (Ringer, Ringer acetate or saline 0.9%) 500ml / 30 min. guided by ScVO2with target value ≥ 70%
88999625|NCT03455296|Active Comparator|Lactate clearance|Fluid therapy is initiated with maintenance fluid (Ringer or Ringer acetate) plus replacement with crystalloids 500ml / 30 min. guided by lactate clearance (LCR) with target value ≤ 2mmol/L (or decline ≥ 10%) by the end of the study
88999626|NCT02895061|Experimental|A: Daily|A: oral daily alfacalcidol treatments total 6 microgram/week
88999627|NCT02895061|Experimental|B: Pulse|B: pulse (trice a week) alfacalcidol treatments total 6 microgram/week
88999628|NCT02895139|Experimental|Additive Manufactured Orthotic Device|Device will be produced via additive manufacture to the specification of a Health and Care Professions Council (HCPC) registered orthotist based on a digital foot scan.
88999629|NCT02895139|Other|Moulded Orthotic Device|Historic control collected using same protocol. Intervention was a moulded orthotic device produced from an impression box of the foot shape.
88999630|NCT02895139|Other|Milled Orthotic Device|Historic control collected using same protocol. Device will be produced via Computer Aided Design/Computer Aided Manufacture (CAD/CAM) milling to the specification of a HCPC registered orthotist based on a digital foot scan.
89355632|NCT05223296|Active Comparator|Group II Conventional diathermy (n=108)|108 patients subjected to conventional diathermy for grade IV pile excision
88999631|NCT04680559|Experimental|MCBI Group|Training in mindfulness and compassion (MCBI) is facilitated in eight weekly sessions of 2 hours. With a didactic format, through theory, class discussions, and guided meditation practices.
89355633|NCT03920111|Other|Group 1 - Any status|Up to 3-4 healthy adults
89533562|NCT04300855|Experimental|Sunphenon® 90D|Participants will be administered a standardized formulation of whole Green Tea Catechin for 24 months. The daily dose of Green Tea Catechin will be taken in divided doses, three capsules in the morning and 3 capsules in the evening, with food (within one hour of eating a substantial meal). On the day of monthly follow-up visit, capsules should be taken within 4 hours of visit and blood draw for required lab work. If the participant is scheduled to come in the afternoon, dose should be taken with lunch that day instead of with dinner for that day.
89177035|NCT00796614|Experimental|Medium dose|Participants received 0.002 - 0.004 mg/kg tamsulosin hydrochloride via opened capsules every day for 14 weeks
89177036|NCT00796614|Experimental|High dose|Participants received 0.004 - 0.008 mg/kg tamsulosin hydrochloride via opened capsules every day for 14 weeks
88999632|NCT04680559|Active Comparator|Active-Wait List Group|Completion of a record during these 8 weeks. Active work of introspection about one's own sensations, thoughts, distractions, judgments, etc. in therapy sessions. Registered after each session.
88999633|NCT00179166|Active Comparator|1|supplement contains protein content of 1.4 g/kg/day
88999634|NCT00179166|Active Comparator|2|supplement contains protein content of 2.0 g/kg/day
88999635|NCT02895334|Experimental|MyHeartBaby|Caregivers will complete Telehealth Psychosocial Sessions and 4 follow up assessments.
89177037|NCT02603445|Experimental|Follicular lymphoma (FL)|
89177038|NCT02603445|Experimental|Mantle cell lymphoma (MCL)|
89177039|NCT04106505|Experimental|Biofeedback|The treatment comprises an app containing biofeedback training, instructions for self-delivery and a headache diary. The treatment utilizes these functionalities by a push-reminder in the app to complete a daily headache diary entry and a biofeedback session of 10 minutes duration daily. Prior to commencing treatment participants will be given basic information on the rationale behind biofeedback treatment, given instructions on how to use the equipment and software and instructions on how to complete a biofeedback session. The biofeedback is based on wireless sensors measuring muscle tension, finger temperature and heart rate.
89177040|NCT04106505|Sham Comparator|Sham-biofeedback|Sham-biofeedback will be made by disrupting the connection between input of physiological parameters and the feedback. Thus, the feedback will simply be displayed as positive feedback occurring at random intervals throughout the sessions. The looks and contents of the normal app and the sham-app will be completely similar. The participants being allocated to the sham-goup will also use exactly the same sensor setup as the biofeedback group. The only difference between the two arms/interventions is the internal software algorithm, which will be inaccessible to the user. All participants in both groups will be given the same information and instructions.
89177041|NCT00448747|Experimental|AEZS-130 ( formerly ARD-07)|A single oral administration of AEZS-130 (0.5 mg/kg po) as Growth Hormone Stimulation Test
88999636|NCT02895334|No Intervention|Standard of Care|Caregivers will complete 4 follow up assessments.
88999637|NCT02894983|Other|Arm 1|Conservative treatment chosen by physician on-call for dorsally displaced radius fracture.
88999638|NCT02894983|Other|Arm 2|Conservative treatment chosen by physician on-call for dorsally displaced radius fracture.
89177042|NCT00448747|Active Comparator|L-ARG+GHRH|This trial was set up as a multi-center, randomized, cross-over study investigating AEZS-130 as a Growth Hormone Stimulation Tests in terms of safety and efficacy compared to L-ARG+GHRH. When GHRH became unavailable on the US market, this comparator arm was no longer available, which was addressed by Amendment No. 3 (version 27-March-2010). Control subject enrolled under Amendment No. 3 were not randomized as there was no cross-over due to unavailability of L-ARG+GHRH. These control subjects received only AEZS-130
89177043|NCT00830180|Experimental|Anti-NGF AB|
88999639|NCT02895022|Experimental|Lidocaine 2% adrénalinée|The main objective is to determine the ED95 dose of 2% lidocaine with epinephrine injected into the epidural catheter for which it does not arise from failure to surgical anesthesia for cesarean during labor.
88999640|NCT05424094|Experimental|'kinderleicht' programme|Children receive coaching in the areas of behaviour, exercise, nutrition and medicine from qualified professionals.
88999641|NCT05423977|Experimental|Experimental:ZV0203|
88999642|NCT05423938|Experimental|Bi1 diacare hp-hc|During 6 days, patients received 2 ONS of a specific formula for diabetes, high energy (300 kcal/unit) and high protein (20%), with fiber, EPA&DHA, EVOO and a specific mix of low glycemic index of carbohydrate
88999643|NCT05423938|Active Comparator|Control|During 6 days, patients received 2 ONS of a standar formula, high energy (300 kcal/unit) and high protein (20%), without fiber, without EPA&DHA, without EVOO and without a specific mix of low glycemic index of carbohydrate
88999644|NCT00179205|Active Comparator|1|
88999645|NCT00179205|Placebo Comparator|2|
88999646|NCT05423899|Experimental|Humanoid Robot|
88999647|NCT05423899|Active Comparator|Treatment as Usual|
88999648|NCT05423704|Experimental|Proton radiotherapy|Proton radiotherapy according to the guidelines defined by the Danish Head-Neck Cancer Group (DAHANCA). Treatment: 66-68 Gy/ 33-34 fx/ 6/W,with cisplatin 40 mg/m2/W and nimorazole to suitable patients
88999649|NCT05423626|Experimental|technologies of robotic mechanotherapy with FES|"In the course of this study, each patient will be given 10 sessions using the ExoAtlet I robotic simulator. The duration of the procedure, according to the patient's condition, is up to 1 hour (taking into account the time for reconfiguring the exoskeleton and positioning the patient). Measurement of pulse, pressure and saturation in the preparatory, main and final parts. The length of stay in an upright position depends on the patient's condition. In order to study and monitor the state of the cardiovascular system during the procedure, the system of remote monitoring of ECG, breathing and movement Accordis will be connected. If necessary, a pause is made to rest in a standing or sitting position. The transition to the formation of subsequent skills is recommended after mastering the skills of the previous procedure."
88999650|NCT05423626|Experimental|biofeedback virtual reality technologies|"The group will have 10 classes on a simulator using the technology of virtual reality with biofeedback ReviVR. The total duration of the procedure is 30 minutes. Before the procedure, blood pressure and heart rate are measured, the size of the pneumatic cuffs on the feet is selected. After instructing the patient and selecting the virtual environment and the optimal speed of movement in VR, VR glasses are installed. Then rehabilitation exercises are carried out for 15 minutes. The patient moves in a virtual environment, receiving visual, auditory and tactile signals that form the correct walking pattern. At the end of the training, the VR glasses are dismantled. Then blood pressure and heart rate are measured and information about the state of health and sensations during the procedure is recorded."
88999651|NCT05423626|Experimental|Complex application of robotic mechanotherapy technologies with FES and VR with biological feedback|The group plans to carry out comprehensive rehabilitation with the use of robotic mechanotherapy and virtual reality with BOS. In this group, patients will first practice for 30 minutes on a VR simulator with a BFB (the duct is identical to group 2), then after 2 hours on an exoskeleton with a FES (the protocol of the lesson is identical to group 1)
88999652|NCT05423626|No Intervention|Control group|control group with basic course of reabilitation
88999653|NCT05423002|Placebo Comparator|Control|Dim light condition as a baseline
89177044|NCT02603679|Active Comparator|A: Weekly Paclitaxel|Patients receive weekly paclitaxel 80mg/m2, eventually dose-adjusted in relation to side effects, for a 12-week period. Thereafter, treatment is switched to endocrine treatment in combination with palbociclib. Pre- or perimenopausal women and all men are treated with tamoxifen, alternatively with an LHRH analogue in combination with an aromatase inhibitor (only women); postmenopausal women receive an aromatase inhibitor together with palbociclib 125 mg orally days 1-21, followed by a 7-days rest period, repeated twice during the second 12-week period
88823091|NCT03140631|No Intervention|Control|Patients in the control arm will undergo routine post-procedure management prior to removal of vascular sheaths. This includes routine measurements of ACT beginning 90 min after the cessation of the procedure with a goal ACT of <200s or return to pre-procedural baseline prior to sheath removal.
88823092|NCT03140631|Active Comparator|Protamine|Patients in the active comparator arm will receive protamine sulfate for rapid reversal of heparin prior to sheath removal. They will first receive a small test dose with close hemodynamic monitoring followed by therapeutic dose if no reaction occurs.ACT levels will then be monitored with a goal ACT of <200s or return to preprocedural baseline prior to removal of vascular sheaths.
88823093|NCT01602614||Group 1|≤ 27 weeks 6 days gestational age at birth and ≤ 30 days chronologic age at study enrollment. Dose and duration of intravenous ganciclovir therapy is at the discretion of the treating physician and will not be dictated by the research protocol.
88823094|NCT01602614||Group 2|≤ 27 weeks 6 days gestational age at birth and > 30 days chronologic age at study enrollment. Dose and duration of intravenous ganciclovir therapy is at the discretion of the treating physician and will not be dictated by the research protocol.
88823095|NCT01602614||Group 3|≥ 28 weeks 0 days gestational age at birth and ≤ 30 days chronologic age at study enrollment. Dose and duration of intravenous ganciclovir therapy is at the discretion of the treating physician and will not be dictated by the research protocol.
88823096|NCT01602614||Group 4|≥ 28 weeks 0 days gestational age at birth and > 30 days chronologic age at study enrollment. Dose and duration of intravenous ganciclovir therapy is at the discretion of the treating physician and will not be dictated by the research protocol.
88823097|NCT04420260|Experimental|Treatment oropharyngeal spray + immunostimulant emulsion|Active principle oropharyngeal spray + Active principle immunostimulant taken PO.
88823098|NCT04420260|Placebo Comparator|Placebo|Placebo oropharyngeal spray + Placebo emulsion was taken PO.
88823099|NCT02312856|Experimental|PulseRider aneurysm|Endovascular treatment of intracranial aneurysms
88823100|NCT00375453|Experimental|Arm 1|
88823101|NCT01706588|Experimental|Diclofenac sodium 5 mg/mL|
88823102|NCT01706588|Experimental|Diclofenac sodium 12.5 mg/mL|
88823103|NCT01706588|Experimental|Diclofenac sodium 25 mg/mL|
88823104|NCT01706588|Experimental|Diclofenac sodium 50 mg/mL|
88823105|NCT01706588|Placebo Comparator|Placebo 1 mL|
88823106|NCT02987075|Other|Early compaction embryo group|patients have compacting embryos at 66±2 hours after ICSI
88823107|NCT02987075|Other|Cleavage stage embryo group|patients have non-compacting embryos with 7-9 cells, under 20% fragmentation. at 66±2 hours after ICSI
88823108|NCT01602692|Active Comparator|Tumescent solution with dilute epinephrine|Subjects in this arm of the study will be randomized to receive tumescent solution containing dilute epinephrine (1:1,000,000) during their breast reduction.
88823109|NCT01602692|Active Comparator|Tumescent solution with dilute lidocaine and epinephrine|Subjects in this arm of the study will receive tumescent solution containing both dilute lidocaine (0.05%) and dilute epinephrine (1:1,000,000).
88823110|NCT02984709|Experimental|Positive Psychology Intervention|The text message group will receive the intervention components via text message. They will be instructed to think about things that make them feel good when they are struggling with diabetes management (i.e. gratitude). Also they will be instructed to think about a positive value when they are in a situation that makes it hard to check their blood sugar (i.e. Self-Affirmation). Additionally, to induce positive mood they will be texted gift cards codes valued at $5.00. Further, caregivers will be asked to provide weekly positive affirmations to their adolescents, focused on non-diabetes strengths. All adolescents will be given developmentally-appropriate diabetes education material at the time of enrollment.
88823111|NCT02984709|Active Comparator|Education Group|The education group will be given developmentally-appropriate diabetes education material at the time of enrollment.
88823112|NCT05405205|Experimental|synbiotic|synbiotic consisting of three different strains of Lactobacillus fermentum + acacia gum (gum arabic)
88823113|NCT05405205|Experimental|probiotic|probiotic consisting of the identical three different strains of Lactobacillus fermentum
88823114|NCT05405205|Placebo Comparator|placebo|microcrystalline cellulose
89355634|NCT03920111|Other|Group 2 - FlaviPrime Naive|Up to 6-8 healthy adults who have never travelled to a flavivirus endemic area and are negative in screening tests for flavivirus immunity.
88999654|NCT05423002|Active Comparator|Modulation|Flickering light will be added sinusoidally onto the background light.
88823115|NCT05739851|Experimental|Sequence A(Before→ After)|
88823116|NCT05739851|Experimental|Sequence B(After→ Before)|
88823117|NCT01603940|Active Comparator|Losartan|This group will receive 100 mg of losartan per day. Amlodipine will be maintained.
88823118|NCT01603940|Active Comparator|Benazepril|This group will receive 20 mg of benazepril per day. Amlodipine will be maintained.
88823119|NCT05739773|Experimental|Study|the five-element music group
88823120|NCT05739773|Placebo Comparator|Control|binaural beats group
88823121|NCT01605032|Experimental|Treatment (busulfan, melphalan, bortezomib, autologous PBSCT)|"CONDITIONING: Patients receive busulfan IV over 3 hours on days -6 to -3, melphalan IV over 20 minutes on day -2, and bortezomib IV over 3-5 seconds on days -6, -3, 1, and 4.~TRANSPLANT: Patients undergo autologous PBSCT on day 0."
88823122|NCT05739695|Experimental|VBN|Virtual bronchoscopy
88823123|NCT05739695|Experimental|VBN+rEBUS|Combination of VBN and radial EBUS
88823124|NCT05739695|Active Comparator|rEBUS|Radial EBUS as a gold standard
88823125|NCT01706666|Experimental|Arm A (bortezomib)|Patients receive bortezomib SC on days 1 and 15 of courses 1-12 and day 1 of courses 13-24.
88823126|NCT01706666|Experimental|Arm B (bortezomib, cyclophosphamide, dexamethasone)|Patients receive bortezomib SC as in Arm A, cyclophosphamide PO on days 1 and 15 of courses 1-12 and day 1 of courses 13-24, and dexamethasone PO on days 1 and 15 of courses 1-12 and day 1 of courses 13-24.
88823127|NCT01706666|Experimental|Arm C (bortezomib, lenalidomide)|Patients receive bortezomib SC as in Arm A and lenalidomide PO QD on days 1-28.
88823128|NCT03149991|Active Comparator|Ketamine/Brexpiprazole Arm|brexpiprazole up to 3 mg/day for four weeks in combination with bi-weekly administration of intranasal ketamine (40 mg) for two weeks, followed by weekly administration of intranasal ketamine (40 mg) for two weeks
88823129|NCT03149991|Placebo Comparator|Ketamine/Placebo Arm|placebo for four weeks in combination with bi-weekly administration of intranasal ketamine (40 mg) for two weeks, followed by weekly administration of intranasal ketamine (40 mg) for two weeks
88823130|NCT05708807||Observational - all|All included stroke patients.
88823131|NCT05739461||triangular cross-section neck implant|
88823132|NCT05739461||round cross-section neck implant|
88823133|NCT05704439|Active Comparator|Model 1-Neurologist Initiation of Treatment for Hypertension or Hyperlipidemia|Neurologist Initiation of antihypertensive or treatment for hyperlipidemia
88823134|NCT05704439|Placebo Comparator|Model 2-Usual Care|Usual care
88823135|NCT01706822|Experimental|Covidien Radial Reload Stapler with Tri-Staple Technology|Covidien Radial Reload Stapler with Tri-Staple Technology in laparoscopic LAR or proctosigmoidectomy
88823136|NCT01706978|Experimental|Soft Tissue Trephination|"Ten days prior to the standard rotator cuff repair, a trephination procedure will be carried out. The trephination procedure will take approximately 30 minutes to complete and will be carried out under local anesthesia. A needle will be placed through the skin over the shoulder and either into the bone or into the edge of the cuff tendon, depending on whether you are allocated to the bone trephination or soft tissue trephination groups. The needle will be used to make 6 small holes in either bone or the tendon in the shoulder in the area where the cuff is to be repaired."
88823137|NCT01706978|Active Comparator|Bone Trephination|"Ten days prior to the standard rotator cuff repair, a trephination procedure will be carried out. The trephination procedure will take approximately 30 minutes to complete and will be carried out under local anesthesia. A needle will be placed through the skin over the shoulder and either into the bone or into the edge of the cuff tendon, depending on whether you are allocated to the bone trephination or soft tissue trephination groups. The needle will be used to make 6 small holes in either bone or the tendon in the shoulder in the area where the cuff is to be repaired."
88823138|NCT05405127|Active Comparator|Traditional physical therapy|breathing exercises
88823139|NCT05405127|Experimental|Core stability exercise|core stability exercise along with breathing exercises and pain pressure algometer is used
88823140|NCT01707368||all eligible patients|Daivobet® Gel once daily on areas with plaque psoriasis, treatment duration up to 8 weeks for body skin areas except scalp (scalp up to 4 weeks), treatment may be repeated under medical surveillance.
88823141|NCT05404347||Gallbladder Cancer|Patients with confirmed diagnosis of gallbladder cancer
88823142|NCT05400993|Experimental|treatment group|Chidamide combined with EC -- T regimen was treated with 1 cycle every 21 days, followed by 4 cycles of EC followed by 4 cycles of T, a total of 8 cycles
88823143|NCT01605890|Experimental|raltegravir / emtricitabine / tenofovir disoproxil fumarate|
88823144|NCT05121285|Experimental|Contrast fluid by lower GI endoscopy and enema with and without positioning|There is a washout period of at least four weeks between the two interventions (delivery by lower GI endoscopy and enema)
88823145|NCT02288273|Experimental|Bydureon|Once weekly injected exenatide
88823146|NCT02288273|Placebo Comparator|Placebo|Placebo comparator
88823147|NCT03160287|Experimental|Motivational interview and text messages|Multidimensional, tailored intervention for sleep deficiency in for older adults with OA
89355635|NCT03920111|Other|Group 3 - Flavivirus Exposed|Up to 8-10 healthy adults who have had JE vaccine and/or are previously flavivirus exposed, either through receiving yellow fever vaccine up to 5 years before the study, or from being diagnosed with a flavivirus illness (e.g. dengue or Zika).
89355636|NCT00708214|Experimental|BIBW 2992|To study BIBW 2992 in association with letrozole in hormonoresistant metastatic breast cancer
89355637|NCT00708214|Other|Letrozole|Hormonotherapy for metastatic breast cancer
89355638|NCT04906694|Experimental|COVI-DROPS|10, 20, or 40 mg of COVI-DROPS administered intranasally
89355639|NCT04906694|Placebo Comparator|Placebo|2 mL administered intranasally
89399072|NCT01384175|Active Comparator|patient-controlled epidural analgesia|In addition to epidural anesthesia and epidural infusion, postoperatively patients received patient-controlled epidural analgesia with ropivacaine/fentanyl bolus 1 mL, lock-out interval 12 min.
89399073|NCT02171312||Concussion Cohort|Participants with possible concussion related dizziness will complete iDETECT battery testing and routine balance and vestibular testing.
89399074|NCT02171312||Healthy Controls|Participants without possible concussion related dizziness will complete iDETECT battery testing and routine balance and vestibular testing.
88823148|NCT01606124|Experimental|Arm I (Green Tea Catechin Extract)|Patients receive Polyphenon E PO BID. Courses repeat every 28 days for 6 months in the absence of disease progression or unacceptable toxicity.
88823149|NCT01606124|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID. Courses repeat every 28 days for 6 months in the absence of disease progression or unacceptable toxicity.
88999655|NCT05423002|Sham Comparator|Background|Constant light with maximum half irradiance (50%) of all primaries.
88999656|NCT00196872|Experimental|ETC-with Ibandronat|ETC follwoed by Ibandronat
88999657|NCT00196872|Experimental|ETC without Ibandronat|ETC not followed by Ibandronat
89399075|NCT02168426|Active Comparator|Guardix|6g per body
89399076|NCT02168426|Active Comparator|Seprafilm|1 sheet per body
89399077|NCT01380275|Experimental|Docetaxel and Irinotecan (DI)|"Combination chemotherapy of Docetaxel and Irinotecan (DI) in recurrent or refractory bone and soft tissue sarcomas.~Docetaxel and Irinotecan (DI) have different biologic targets, mode of action and mechanism of resistance. Preclinical studies have demonstrated an additive or synergistic effect of irinotecan and taxanes when used in combination in human.~Docetaxel 100 mg/m2 mixed in D5W or N/S IV over 60 min: Day 1 Irinotecan 80 mg/m2 mixed in D5W IV over 90 min: Days 1 and 8 Therapy consists of 3-week cycles comprising weekly treatment for 2 weeks (docetaxel on D1 and irinotecan on D1 and D8) followed by 1-week rest, and will be continued in the absence of disease progression or unacceptable toxicity."
88823150|NCT03163017|Experimental|2D Fluoroscopy then 3D Fluoroscopy|"Patients with syndesmotic instability will undergo reduction of the syndesmosis followed by provisional fixation with a clamp or Kirshner wire. The reduction quality will be initially compared to the contralateral ankle mortise and talar-dome lateral radiographs using the technique of Summers et al (2D Fluoroscopy). After the attending surgeon is satisfied with the reduction quality, 3D fluoroscopy will be used to generate additional images to assess syndesmotic and fibular reductions. Both 2D and 3D Fluoroscopy will be performed using device Ziehm Vision RFD 3D image-intensified fluoroscopic x-ray system."
89533563|NCT04300855|Placebo Comparator|Placebo|Participants will be administered a placebo for 24 months. The daily dose of placebo will be taken in divided doses, three capsules in the morning and 3 capsules in the evening, with food (within one hour of eating a substantial meal). On the day of monthly follow-up visit, capsules should be taken within 4 hours of visit and blood draw for required lab work. If the participant is scheduled to come in the afternoon, dose should be taken with lunch that day instead of with dinner for that day.
88823151|NCT05739227|Experimental|allogenic CD19-CAR-NK|Enrolled patients will receive prespecified dose of allogenic CD19-CAR-NK cells.
88823152|NCT05739071|Experimental|Experimental (group 1)|This group will receive two sachets of JING SI HERBAL TEA a day (one in the morning and one in the evening).
88823153|NCT05739071|Placebo Comparator|Control (group 2)|This group will receive two sachets of placebo a day (same way as group 1).
88823154|NCT01607450|Other|Saline|12 hour saline (control) infusion prior to PET study
88823155|NCT01607450|Experimental|GLP-1 Low dose|GLP-1 Low Dose: 0.5 pmol/kg/min for 12 hours prior to PET study
88823156|NCT01607450|Experimental|GLP-1 Mid-Range Dose|GLP-1 Mid-Range Dose: 1.5 pmol/kg/min for 12 hours prior to PET study
88823157|NCT01607450|Experimental|GLP-1 High Dose|GLP-1 High Dose: 4.0 pmol/kg/min for 12 hours prior to PET study
88823158|NCT05738993|Experimental|BCD-178 group|single IV infusion of BCD-178 at a dose of 420 mg
88823159|NCT05738993|Active Comparator|Perjeta Group|single IV infusion of Perjeta at a dose of 420 mg
88823160|NCT01709474|Experimental|Vitamin D3 6000 IU|6000 IU of vitamin D3 by mouth daily until the subject's serum 25(OH) level is ≥ 40ng/mL at which point the supplementation dose is reduced to 4,000 IU/day. Note: Subjects weighing <40 kilograms (kg) at study entry will receive their dose five days a week and all other subjects seven days a week.
88823161|NCT01709474|Active Comparator|Vitamin D3 400 IU|400 IU/day of vitamin D3 by mouth daily.
88823162|NCT02992808|Active Comparator|Recombinant preparations|
88823163|NCT02992808|Active Comparator|HP-HMG|Highly purified human menopausal gonadotropin
88823164|NCT02992886|Experimental|preCRT+surgery|Treatment including preoperative chemoradiotherapy (preoperative radiation with concurrent chemotherapy) with Raltitrexed followed by surgery. Radiotherapy will be delivered to a planning target volume with a dose of 45-50.4Gy (1.8-2.0Gy daily) using with Intensity-Modulated Radiotherapy or Volumetric-Modulated Arc Therapy technique. During the radiation treatment, concurrent chemotherapy will be delivered (Raltitrexed, intravenous infusion, 3 mg/m2, on d1 and d22). Pelvic surgery is planned 6 weeks after completion of CRT based on the decision of MDT.
88823165|NCT02331095|Active Comparator|Anticoagulation|Patients will be treated with warfarin with dose adjusted to goal International Normalized Ratio (INR) of 2-3 or rivaroxaban standard dose (15 mg twice daily for 3 weeks then 20 mg daily)
88823166|NCT02331095|Experimental|Atorvastatin + anticoagulation|In addition to standard anticoagulation, patients will be given concurrent atorvastatin 40 mg daily for the study period of 9 months, starting from the time of enrollment
88823167|NCT01640834|Experimental|100 mg LY2409021|"LY2409021: 100 milligrams (mg), 1 capsule, administered as a single oral dose on Day 2.~Placebo: 2 capsules, administered as a single oral dose on Day 2.~Glucagon: 1 mg administered via intramuscular injection on Day 3."
88823168|NCT01640834|Experimental|300 mg LY2409021|"LY2409021: 300 milligrams (mg), 3 capsules (3 X 100-mg capsules), administered as a single oral dose on Day 2.~Glucagon: 1 mg administered via intramuscular injection on Day 3."
88823169|NCT01640834|Placebo Comparator|Placebo|"Placebo: 3 capsules administered as a single oral dose on Day 2.~Glucagon: 1 milligram (mg) administered via intramuscular injection on Day 3."
88823170|NCT03029273|Experimental|Anti-NY-ESO-1 TCR-transduced T cells|"NYESO-1 TCR-T cell are prepared via lentiviral infection. DLT was administered in a dose escalation test according to the 3 + 3 design. Seven days prior to infusion of TCR-T cell, subjects receive cytoreductive chemotherapy with Cyclophosphamide (250-500mg/m2/day) and Fludarabine (25mg/m2/day) for 3 days.~A single dose of Anti-NY-ESO-1 TCR transduced T cells (about 5×109) will be intravenously (i.v.) administered Additionally, following infusion of Anti-NY-ESO-1 TCR transduced T cells, IL-2 subcutaneous injections (500,000 IU/day) will be administered for 14 days concomitantly to each subject."
88823171|NCT01641380|No Intervention|Control|Adolescents in the Control Arm received standard of care. They continue to receive the DepoProvera injections through scheduled appointment, but would not receive a call from the nurse case manager regarding DepoProvera appointments until they have missed their scheduled DepoProvera appointment.
88823172|NCT01641380|Experimental|Text Messaging Intervention|Adolescents in the intervention arm receive text message reminders for appointments and positive sexual health messages regarding use of DepoProvera in between scheduled appointments. They are encouraged to seek care for assistance with obtaining condoms and/or if they are having problems with the medication.
88823173|NCT05327855|Experimental|OPL-0301 Dose 1|Participants are randomized to OPL-0301 Dose 1 administered once daily for 90 days
88823174|NCT05327855|Experimental|OPL-0301 Dose 2|Participants are randomized to OPL-0301 Dose 2 administered once daily for 90 days
88823175|NCT05327855|Placebo Comparator|Placebo|Participants are randomized to matching placebo administered once daily for 90 days
88823176|NCT01709786||Patients with Suspected Hemorrhage|There is a single group of patients in this study -- those with suspected hemorrhage who satisfy the inclusion and exclusion criteria. The same set of measurements will be take from each patients and those measurements will be compared with one another to determine accuracy.
88823178|NCT05711186|Other|Structured SDM|Structured shared decision making for the choice between SAVR and TAVR
88823179|NCT05711186|Other|Usual Care|Usual care for the choice between SAVR and TAVR
88823180|NCT05738759|Experimental|Epidural Anesthetic Cocktail|Patients which received epidural anesthetic cocktail following endoscopic discectomy
88823181|NCT05738759|Placebo Comparator|Placebo|Patients which received placebo following endoscopic discectomy
89355640|NCT05669495||No dementia, increased risk of dementia|"Meets criteria for No Dementia and one of the following (according to CCNA Criteria):~Cognitively Unimpaired~Cognitively Unimpaired plus Subjective Cognitive Impairment~Mild Cognitive Impairment (MCI)~AND Classified as being at increased risk of dementia based on at least one of the following:~First-degree family history of dementia~Self-Reported or documented current and/or history at midlife (45-60 years) of the following risk factors:~i. Hypertension ii. Hypercholesterolemia iii. Body Mass Index > 30 kg/m2 iv. Physical Inactivity v. Insomnia vi. Vascular-metabolic risk"
88823182|NCT05738681|Experimental|NAC group|Tuberculosis patients who had standard regimen treatment, non-HIV, no severe co-morbidity, no chronic hepatitis B or C using NAC-long 1,200 mg/day for 8 weeks (NAC long group). Genetic test (acetylator status of NAT2), CBC, Cr, coagulogram were assessed at baseline. LFT were assessed at baseline, 2 weeks, 8 weeks and 24 weeks.
88823183|NCT05738681|No Intervention|Non-NAC group|Tuberculosis patients who had standard regimen treatment, non-HIV, no severe co-morbidity, no chronic hepatitis B or C were using anti-TB alone (non-NAC group). Genetic test (Acetylator status of NAT2), CBC, Cr, coagulogram were assessed at baseline. LFT were assessed at baseline, 2 weeks, 8 weeks and 24 weeks.
88823184|NCT05738447|Experimental|Treatment Cohort|With 20ug as the starting point, the dose was increased using a dose escalation scheme. Each subject only received one corresponding dose, and the intramuscular injection was administered again every 7 days, and after 4 doses, the 5th dose was given after 1-month interval.
88823185|NCT05644925|Experimental|PICSO+PCI|
88823186|NCT05644925|Active Comparator|Standard PCI|
88823187|NCT01642082|Experimental|Treatment (dalantercept)|Patients receive dalantercept SC on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
88823188|NCT02288819|Experimental|Loop diuretic downtitration|Scheduled downtitration of maintenance loop diuretic dose while monitoring weight
88823189|NCT05280509|Experimental|Phase 1b - Dose Level 1|150 mg of TL-895 will be administered orally, twice daily (BID) continuously starting on Day 1 in a 28-day cycle combined with the subject's pre-study stable dose of ruxolitinib.
88823190|NCT05280509|Experimental|Phase 1b - Dose Level 2|300 mg of TL-895 will be administered orally, twice daily (BID) continuously starting on Day 1 in a 28-day cycle combined with the subject's pre-study stable dose of ruxolitinib.
88823191|NCT05280509|Experimental|Phase 1b - Dose Level 3|450 mg of TL-895 will be administered orally, twice daily (BID) continuously starting on Day 1 in a 28-day cycle combined with the subject's pre-study stable dose of ruxolitinib.
88823192|NCT05280509|Experimental|Phase 2 - Cohort 1 JAKi treatment-naïve MF|"The RP2D of TL-895 as determined in Phase 1b will be administered orally, twice daily (BID) continuously starting on Day 1 in a 28-day cycle.~The dose of ruxolitinib will be based on the subject's baseline platelet count."
88823193|NCT05280509|Experimental|Phase 2 - Cohort 2 suboptimal response to Ruxolitinib|"The RP2D of TL-895 as determined in Phase 1b will be administered orally, twice daily (BID) continuously starting on Day 1 in a 28-day cycle.~The dose schedule will be the stable ruxolitinib dose schedule as the subject is currently taking prior to entry into the study."
88823194|NCT01642238|Experimental|Ticagrelor + ASA + Bivalirudin|Single loading dose of Ticagrelor (180 mg given as two 90 mg tablets), plus single dose of ASA (one 81 mg tablet) + bivalirudin administered as 0.75 mg/kg IV bolus followed by 1.75 mg/kg/hour for 1 hour.
88823195|NCT01642238|Active Comparator|Clopidogrel + ASA + Bivalirudin|Single loading dose of Clopidogrel (600 mg given as two 300 mg tablets), plus single dose of ASA (one 81 mg tablet) + bivalirudin administered as 0.75 mg/kg IV bolus followed by 1.75 mg/kg/hour for 1 hour.
88823196|NCT05738369|Experimental|Probiotic|Participants received treatment with Biogaia L. reuteri Prodentis® lozenges
88823197|NCT05738369|Placebo Comparator|Sugar free lozenges|Participants received Hersheyland Ice Breakers Mints sugar free lozenges
88823198|NCT05738369|No Intervention|Negative control|Participants received no lozenges or supplements
88823199|NCT01643876|Experimental|Palatal brushing|Palatal brushing after each meal for 3 months.
88823200|NCT05259995|Experimental|Sustained Acoustic Medicine Device Group 1|Patients receive treatment from the SAM Ultrasonic Diathermy Device 1 for 4 hours. The SAM device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity.
88823201|NCT05259995|Active Comparator|Sustained Acoustic Medicine Device Group 2|Patients receive treatment from the SAM Ultrasonic Diathermy Device 2 for 4 hours. The SAM device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity.
88823202|NCT05256563||Right brain stroke survivors|People with right brain stroke who are recruited to the study.
88823203|NCT03028883||buprenorphine dose adjustments|To determine if a relationship exists between buprenorphine dose adjustments and gestational age in opioid-maintained pregnant women
88823204|NCT02986919|Experimental|CPI-0610 Treatment|CPI-0610 will be administered 200mg orally once a daily for 14 consecutive days followed by a 7-day break.
88823205|NCT05238467||A|Group A will consist of 50 participants with a diagnosis of one of the following cancers: breast, colorectal, or prostate cancers who received myelosuppressive cytotoxic chemotherapy at the time of COVID vaccination, or who received chemotherapy within 30 days prior to the initial or booster vaccination, or who started on chemotherapy within 30 days after the initial or booster COVID vaccination. Cytotoxic chemotherapy can be given either in the neoadjuvant/adjuvant setting or metastatic setting.
89355641|NCT01568216|Experimental|AMG 747 - Dose 1|
89355642|NCT01568216|Experimental|AMG 747 - Dose 2|
88823206|NCT05238467||B|Group B will consist of 25 participants with a diagnosis of breast, colorectal, or prostate cancers who are on non-myelosuppressive treatment including endocrine therapy, tyrosine kinase inhibitor or anti-HER 2 therapy.
88823207|NCT05238467||C|Group C will consist of 25 age matched adult participants with no prior history of cancer or prior history of non-metastatic solid cancer invasive cancer treated with a curative intent, without evidence of disease recurrence, and >12 months from completion of chemotherapy or radiation.
88823208|NCT02290613|Experimental|Ambrisentan Verum|Study medication will be ambrisentan 10 mg (starting with 5 mg in the beginning of the study and then up-titrated to 10 mg/day).
88823209|NCT02290613|Placebo Comparator|Placebo|Placebo tablet
88823210|NCT02331407|Experimental|Robot arm rehabilitation therapy|Arm training using the ReoGo robotic device, 3 times a week for 3 weeks.
88999658|NCT00196872|Experimental|EC-TX with Ibandronat|EC-TX followed by Ibandronat
89355643|NCT01568216|Experimental|AMG 747 - Dose 3|
89355644|NCT01568216|Placebo Comparator|Placebo Comparator|
89355645|NCT02749955|Experimental|PS-PrEP Intervention Group|
89355646|NCT02749955|Active Comparator|PrEPLine Control Group|
88823211|NCT05611697|Experimental|Single anastomosis sleeve ileal bypass|A Single anastomosis sleeve ileal bypass procedure is performed.
89355647|NCT02749955|No Intervention|CDPH Prevention Projects|
88823212|NCT05611697|Active Comparator|Sleeve gastrectomy|A sleeve gastrectomy procedure is performed.
88823213|NCT02986685|Experimental|trimebutine maleate + rabeprazole|trimebutine maleate 200mg three times daily combined with rabeprazole 20mg once daily
88823214|NCT02986685|Other|rabeprazole|rabeprazole 20mg once daily
88823215|NCT01610570|Experimental|Phase I Dose Level -1|Dose Escalation Phase 9.0 mcg/kg.dose
88823216|NCT01610570|Experimental|Phase I Dose Level 1|Dose Escalation Phase 13.0 mcg/kg.dose
88823217|NCT01610570|Experimental|Phase I Dose Level 2|Dose Escalation Phase 17.5 mcg/kg.dose
88823218|NCT01610570|Experimental|Phase II - Expansion Phase|Expansion phase 17.5 mcg/kg.dose
88823219|NCT05736263|Experimental|Moderate intensity exercise|Individuals with type 1 diabetes on intensive insulin treatment with hybrid closed-loop systems will perform moderate-intensity aerobic exercise
88823220|NCT05736263|Experimental|High intensity interval exercise|Individuals with type 1 diabetes on intensive insulin treatment with hybrid closed-loop systems will perform High intensity interval exercise
88823221|NCT05736263|Experimental|Combined exercise|Individuals with type 1 diabetes on intensive insulin treatment with hybrid closed-loop systems will perform combined exercise
88823222|NCT05736263|Experimental|Resistance exercise|Individuals with type 1 diabetes on intensive insulin treatment with hybrid closed-loop systems will perform resistance exercise
88823223|NCT01611662|Experimental|Treatment (gemcitabine hydrochloride, cisplatin, surgery)|Patients receive gemcitabine hydrochloride IV over 30 minutes on day 1 and cisplatin IV on day 1 or divided over days 1 and 2. Treatment repeats every 14 days for 3 courses in the absence of disease progression or unacceptable toxicity. Beginning 3-8 weeks after chemotherapy, patients undergo radical cystectomy.
88823224|NCT05589467|Experimental|DASH Diet and Fried Potatoes|DASH-FP (fried potatoes) group
88823225|NCT05589467|Experimental|DASH Diet and Non-Fried Potatoes|DASH-NFP (non-fried potatoes) group
88823226|NCT05589467|Experimental|DASh Diet and No Potatoes|DASH-NP (no potatoes) group
88823227|NCT05200481|Other|Brigatinib monotherapy Arm A|Brigatinib 180mg QD (1 x 180mg tablet) until progression
88823228|NCT05200481|Experimental|Brigatinib Carboplatin-Pemetrexed combination therapy Arm B|Brigatinib 180mg QD (1 x 180mg tablet) until progression + Carboplatin AUC of 5 mg/mL/min IV infusion every 3 weeks for 4 infusions + pemetrexed 500 mg/m² IV infusion every 3 weeks for 4 infusions
88823229|NCT02239562|Experimental|SAD sPIF 0.1|single ascending dose (SAD) 3 patients with normal liver function tests (LFTs) and 3 patients with abnormal LFTs randomized in a 2:1 ratio (active drug:placebo) as follows: Single subcutaneous (SQ) dose 0.1 mg/kg sPIF or Placebo Day 1
88823230|NCT02239562|Experimental|SAD sPIF 0.5|single ascending dose (SAD) 3 patients with normal LFTs and 3 patients with abnormal LFTs randomized in a 2:1 ratio (active drug:placebo) as follows: single SQ dose 0.5 mg/kg sPIF or Placebo Day 1
88823231|NCT02239562|Experimental|SAD sPIF 1.0|single ascending dose (SAD) 3 patients with normal LFTs and 3 patients with abnormal LFTs randomized in a 2:1 ratio (active drug:placebo) as follows: Cohort 3: single SQ dose 1.0 mg/kg sPIF or Placebo Day 1
88823232|NCT02239562|Experimental|MAD sPIF 0.1|multiple ascending dose (MAD) 3 patients with normal LFTs and 3 patients with abnormal LFTs randomized in a 2:1 ratio (active drug:placebo) to multiple doses of sPIF SQ (one time) 1X day for 5 consecutive days (Days 1 to 5) Cohort 1: SQ 0.1 mg/kg sPIF or Placebo Days 1-5
88999659|NCT00196872|Experimental|EC-TX without Ibandronat|EC-TX not followed by Ibandronat
88999660|NCT05422963||severe and critical COVID-19|"hospital admission time more than 24 hours~meet the standard of definition of severe and critical COVID-19 in Diagnosis and Treatment Plan for new Coronavirus Pneumonia (Ninth Edition)"
88999661|NCT04680325|Placebo Comparator|Placebo juice|
88999662|NCT04680325|Active Comparator|Cranberry juice|
88999663|NCT00170456|Active Comparator|1|Low dose rPA vaccine regime 1
88823233|NCT02239562|Experimental|MAD sPIF 0.5|multiple ascending dose (MAD) 3 patients with normal LFTs and 3 patients with abnormal LFTs randomized in a 2:1 ratio (active drug:placebo) to multiple doses of sPIF SQ 1X day for 5 consecutive days (Days 1 to 5) Cohort 1: SQ 0.5 mg/kg sPIF or Placebo Days 1-5
88823234|NCT02239562|Experimental|MAD sPIF 1.0|multiple ascending dose (MAD) 3 patients with normal LFTs and 3 patients with abnormal LFTs randomized in a 2:1 ratio (active drug:placebo) to multiple doses of sPIF SQ 1X day for 5 consecutive days (Days 1 to 5) Cohort 1: SQ 1.0 mg/kg sPIF or Placebo Days 1-5
88823235|NCT01613768|Experimental|Treatment (eribulin mesylate)|Patients receive eribulin mesylate IV over 2-5 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
88823236|NCT01614392|Experimental|High velocity low force Power Training|Lower Extremity high velocity power training performed at lower external resistance (40% of the 1 repetition maximum muscle strength). Leg and knee extension exercises were performed twice per week (3 sets of each exercise consisting of 10 repetitions).
88823237|NCT01614392|Experimental|Low velocity high force Power Training|Lower extremity low velocity power training performed at high external resistance (70% of the 1 repetition maximum muscle strength). Leg and knee extension exercises were performed twice per week (3 sets of each exercise consisting of 10 repetitions).
88823238|NCT05176691|Experimental|Treatment|All patients to receive HMPL-760 daily.
89355648|NCT04894214||"Sequential baseline PCV - FCV - VCV"|Each participant will be subjected to baseline pressure controlled ventilation (PCV) during 5 minutes, followed by 30 minutes of FCV with an evone respirator (Ventinova Medical B.V., Eindhoven, The Netherlands) and eventually 30 minutes of VCV. Respiratory rate (RR), positive end-expiratory pressure (PEEP) and inspiratory fraction of oxygen (FiO2) will be held constant. According to the manufacturers guidelines, an I:E ratio of 1:1 will be pursued during FCV. During FCV, the respirator will be set with the same PIP as during baseline PCV. For VCV, the same tidal volume as during baseline PCV will be set.
88823239|NCT02233478|Active Comparator|Pomegranate Juice|Subjects will be asked to take a dietary supplement on the day of intervention. Prior to intervention, subjects will be asked to avoid high-polyphenol foods, certain vitamins, minerals, herbs and dietary supplements for 4 days, dietary instruction will be provided. Blood samples will be taken at screen for safety labs. On study days 5, 13 and 21 a spot urine will be collected and a 7 hr serial blood draw will be performed at 0 hr, 30 min, 1 hr, 2 hr, 3 hr, 4 hr and 6 hr. Subjects will be provided with a light lunch with foods low in polyphenols. Subjects will only be able to eat the foods provided on the intervention days. Subjects will be asked to drink 32oz of water during the 7-hr period. Subjects will also be asked to collect all of their urines for 24 hrs, 2 consecutive days.
88823240|NCT02233478|Active Comparator|Soybean Flour Protein|Subjects will be asked to take a dietary supplement on the day of intervention. Prior to intervention, subjects will be asked to avoid high-polyphenol foods, certain vitamins, minerals, herbs and dietary supplements for 4 days, dietary instruction will be provided. Blood samples will be taken at screen for safety labs. On study days 5, 13 and 21 a spot urine will be collected and a 7 hr serial blood draw will be performed at 0 hr, 30 min, 1 hr, 2 hr, 3 hr, 4 hr and 6 hr. Subjects will be provided with a light lunch with foods low in polyphenols. Subjects will only be able to eat the foods provided on the intervention days. Subjects will be asked to drink 32oz of water during the 7-hr period. Subjects will also be asked to collect all of their urines for 24 hrs, 2 consecutive days.
88823241|NCT02233478|Active Comparator|Soy Isolate Protein|Subjects will be asked to take a dietary supplement on the day of intervention. Prior to intervention, subjects will be asked to avoid high-polyphenol foods, certain vitamins, minerals, herbs and dietary supplements for 4 days, dietary instruction will be provided. Blood samples will be taken at screen for safety labs. On study days 5, 13 and 21 a spot urine will be collected and a 7 hr serial blood draw will be performed at 0 hr, 30 min, 1 hr, 2 hr, 3 hr, 4 hr and 6 hr. Subjects will be provided with a light lunch with foods low in polyphenols. Subjects will only be able to eat the foods provided on the intervention days. Subjects will be asked to drink 32oz of water during the 7-hr period. Subjects will also be asked to collect all of their urines for 24 hrs, 2 consecutive days.
88823242|NCT05736029||Non-operable NSCLC patients receiving ICI therapy|Patients with non-operable stage IIIB-IV NSCLC treated with immune check inhibitor anti cancer treatment as a standard of care
88823243|NCT05736029||Operable NSCLC Patients Receiving ICI as Neoadjuvant or Adjuvant Therapy|Patients with operable stage II-IIIA NSCLC, treated with immune check inhibitor in the neoadjuvant or adjuvant setting
88823244|NCT05736029||Healthy volunteers|Sex and aged matched non-diseased volunteers
88823245|NCT02324972|Experimental|AQX-1125|1 x AQX-1125 Capsule daily
88823246|NCT02324972|Placebo Comparator|Placebo|1 x placebo capsule daily
88823247|NCT02992184||HCV patients|228 HCV patients
88823248|NCT02992184||control|189 controls
88823249|NCT01615484|Experimental|Ex-vivo lung perfusion (EVLP) with STEEN Solution™|The perfusion of the lungs will be performed using STEEN Solution™. The lungs will be physiologically assessed during ex vivo perfusion with STEEN Solution™ perfusate.
88823250|NCT01615484|No Intervention|Lung transplant from conventional brain-dead organ donor|No experimental procedures will be carried out.
88823251|NCT01616576|Experimental|Control first, then Experimental (Group A)|Initial subject use of Control Sound Processing Strategy for the first week, followed by subject use of Experimental (HiRes™ Optima) Sound Processing Strategy for the HiResolution™ Bionic Ear System for the second week.
88823252|NCT01616576|Experimental|Experimental first, then Control (Group B)|Initial subject use of Experimental (HiRes™ Optima) Sound Processing Strategy for the first week for the HiResolution™ Bionic Ear System, followed by subject use of the Control Sound Processing Strategy for the second week.
88823253|NCT05034185||Patients with one or more polyps detected|"During colonoscopy, the Clinician inspect for the presence of polyps as per routine clinical practice with the CAD EYE function turned off. When a polyp is encountered, the Clinician will make a prediction on the histology based on the white light and BLI features of the polyp with and without optical magnification, as per routine clinical practice. Following this, the CAD EYE function will be switched on and the Clinician will take note of the CADx prediction for the same polyp, which will be either neoplastic or hyperplastic.~In addition, other polyp features such as the size and location will be recorded, which is similar to what is performed in routine clinical practice. The polyp will be resected and sent for pathological examination, which will form the gold standard for the diagnosis of polyp histology."
88823254|NCT05546801|Experimental|questionnaire|Questionnaire on postnatal development
88823255|NCT01646762|Experimental|Treatment (chemotherapy)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
88823256|NCT05136131|Experimental|True cardioversion|"Following anaesthesia administration, the unblinded team (non-MRP cardiologist / anesthesiologist will open the envelope indicating which arm the patient has been randomized to. Other members of the team will step out of the room. The unblinded non-MRP cardiologist will call out as per usual All clear, following which a shock is delivered as per the Ottawa Cardioversion Protocol in the 'shock' arm."
88823257|NCT05136131|Sham Comparator|Sham cardioversion|"Following anaesthesia administration, the unblinded team (non-MRP cardiologist / anesthesiologist will open the envelope indicating which arm the patient has been randomized to. Other members of the team will step out of the room. No shock is delivered in the sham shock arm."
88823258|NCT01647464||Contrast administration|Patients undergoing contrast-enhanced echo.
88823259|NCT02289755|Experimental|ALLN-177|"Recurrent Calcium Oxalate Stone Formers with Hyperoxaluria Subjects with Enteric or Idiopathic hyperoxaluria~Dosing: 5 capsules of ALLN-177 orally (p.o.) up to 3 times daily (TID) with meals for 4 consecutive days."
88823260|NCT04997525|Active Comparator|Natural cycle|These women will follow their natural cycle and receive one injection of hCG for stimulation of ovulation before embryo transfer
88823261|NCT04997525|Active Comparator|Estradiol and progesterone|These women will receive daily estradiol and progesterone tablets/capsules before and after embryo transfer. Treatment will continue until gestational age 9+6
88823262|NCT04997525|Active Comparator|Gonadotropin|These women will receive daily gonadotropin injection before embryo tranfer. Ovulation will be stimulated using hCG injection.
88823263|NCT01648322|Experimental|80 µg/kg/dose of F-627|This dose of F-627 given only to subjects that are to have TC chemotherapy.
89355649|NCT02506894|Active Comparator|magnesium sulfate|this group will receive magnesium sulfate loading dose 6 g in 500 cc of ringer solution over 20 minutes then maintenance dose of 1 g/ hour for 24 hours.
89533564|NCT04299464|Placebo Comparator|Placebo|Participants will receive placebo matched to RO7017773 for approximately 12 weeks.
88823264|NCT01648322|Experimental|240 µg/kg/dose of F-627|This dose of F-627 given to subjects receiving TC or TAC chemotherapy.
89399078|NCT02171390|Active Comparator|Daily testosterone transdermal gel|
89399079|NCT02171390|Active Comparator|Injectable Testosterone esters|Testosteron 250mg injection per 3-4 weeks for 6 months
89399080|NCT03697005|Experimental|BioHPP PEEK single posterior crowns|BioHPP PEEK copings veneered with composite resin
89399081|NCT03697005|Active Comparator|zirconia-based single posterior crowns|yttria stabilized tetragonal zirconia used as copings to be veneered with porcelain
89399082|NCT01378481|Experimental|Treatment (vorinostat, surgery, FSRT)|Patients receive high-dose vorinostat PO at 48, 27, and 3 hours prior to surgery. Beginning 2-6 weeks later, patients receive vorinostat PO QD on days 1-3 in weeks 1-2and undergo fractionated stereotactic body radiation therapy on days 1-5 in weeks 1-2. Treatment continues in the absence of disease progression or unacceptable toxicity.
89399083|NCT02168504||Healthy controls|Healthy male and female subjects older than 18 years of age without the symptoms of Parkinson's disease. The ages of subjects in this group will be matching to the ages of subjects in Parkinson's disease group
89399084|NCT02168504||Parkinson's disease patients|male and female subjects older than 18 years of age at the early stage the disease
89399085|NCT02168582||low back pain|
89533565|NCT04299464|Experimental|RO7017773 Low Dose|Participants will receive a fixed low dose of RO7017773 for approximately 12 weeks.
88999664|NCT00170456|Active Comparator|2|Low dose rPA vaccine regime 2
88823265|NCT01648322|Experimental|320 µg/kg/dose of F-627|This dose of F-627 given to subjects receiving TC or TAC chemotherapy.
89355650|NCT02506894|Placebo Comparator|placebo group|this group will receive sodium chloride 0.9% solution for 24 hours.
88823266|NCT01648322|Active Comparator|Neulasta® (pegfilgrastim)|Given to subjects receiving TC or TAC chemotherapy.
89177045|NCT02603679|Experimental|B: Tamoxifen + Palbociclib|Pre- or perimenopausal women and all men are treated with tamoxifen together with palbociclib 125 mg orally days 1-21, followed by a 7-days rest period, repeated twice during a 12-week period. Thereafter, treatment is switched to weekly paclitaxel 80mg/m2, eventually dose-adjusted in relation to side effects, for further 12 weeks.
89533566|NCT04299464|Experimental|RO7017773 High Dose|Participants will receive a fixed high dose of RO7017773 for approximately 12 weeks.
89355651|NCT04891250|Experimental|Intervention|Patients with moderate to severe COVID-19 disease will be randomized to either Ivermectin (Intervention) or Standard of Care (Control arm) in a 1:1 ratio
89355652|NCT04891250|Experimental|Prophylaxis|An additional group of patients will be recruited will be randomized to either Ivermectin as prophylaxis (Intervention) or Standard of Care with no ivermectin (Control arm) in a 1:1 ratio
89533567|NCT04291573|Active Comparator|HD-tDCS and Virtual Reality Therapy|Patients will receive their usual rehabilitation program each day, which includes a conventional session (30min) and virtual reality therapy session (Armeo Spring) combined with real stimulation (30min) over 13 consecutive training days (3 weeks)
89533568|NCT04291573|Sham Comparator|Sham stimulation and Virtual Reality Therapy|Patients will receive their usual rehabilitation program each day, which includes a conventional session (30min) and virtual reality therapy session (Armeo Spring) combined with Sham stimulation (30min) over 13 consecutive training days (3 weeks)
88823273|NCT01649180|Experimental|Axitinib|Axitinib will be given orally and will continue until progression of disease.
88823274|NCT04427033||CHL & MHL (18 years and older)|CHL= conductive hearing loss, MHL= mixed hearing loss
88823275|NCT04427033||CHL & MHL (5 to 17 years)|
88823276|NCT04427033||SSD (5 years and older)|SSD= single sided deafness
88823277|NCT01619774|Experimental|GSK2118436 + GSK1120212|GSK1120212 2 mg by mouth once a day, and GSK2118436 150 mg by mouth 2 times every day (1 time in the morning and 1 time in the evening, about 12 hours apart).
88823278|NCT01650584|Experimental|ISTA Tears|Sterile ophthalmic solution
88823279|NCT01650584|Active Comparator|Systane|Sterile ophthalmic solution
88823280|NCT01651442|Active Comparator|Non-drug Sleep Therapy 1|
88823281|NCT01651442|Active Comparator|Sleep Medication 1|
88823282|NCT01651442|Active Comparator|Non-drug Sleep Therapy 2 Following Non-drug Sleep Therapy 1|
88823283|NCT01651442|Active Comparator|Sleep Medication 2 Following Sleep Medication 1|
88823284|NCT01651442|Active Comparator|Non-drug Sleep Therapy 1 Following Sleep Medication 1|
88823285|NCT01651442|Active Comparator|Sleep Medication 1 Following Non-drug Sleep Therapy 1|
88823286|NCT04960553|Experimental|Device : Post Market Clinical Follow-up Investigation applying Exufiber® and Mepilex® Border Flex|Post Market Clinical Follow-up investigation : Up to 102 subjects with exuding chronic wounds deemed adequate by the Principle Investigator and Clinical Team for assigned treatment
88823287|NCT05428592|Experimental|LVRNA009 study group|
88823288|NCT05428592|Active Comparator|CoronaVac® control group|
88823289|NCT05078489|Experimental|Action-observation arm|Participants will be asked to watch videos of neck exercises without performing any exercise. The intervention will take approximately 15 minutes.
88823290|NCT05078489|Placebo Comparator|Placebo intervention|Participants will be asked to watch videos of landscapes. The intervention will take approximately 15 minutes.
88823291|NCT05710250|Experimental|Mindfulness based stress reduction (MBSR) program|15 students will follow a 6-week MBSR program with 2h30 sessions per week in group and daily exercises lasting 30-40 minutes per day.
88823292|NCT05710250|Active Comparator|Muscular relaxation program|15 students will follow a 6-week muscular relaxation program with 2h30 group sessions per week in group and daily exercises lasting 30-40 minutes per day.
88823293|NCT04876235|Experimental|LAMS group|place LAMS under endoscopic ultrasound. Direct endoscopic necrosectomy(DEN) was performed through the LAMS with a forward viewing gastroscope if necessary
88823294|NCT04876235|Active Comparator|DPPS group|Place DPPS under endoscopic ultrasound. When required, DEN was performed once the cystogastrostomy/duodenostomy tract had matured. This was done by first removing the stents followed by dilation of the tract with a radial expansion balloon and insertion of a forward viewing gastroscope through the tract for DEN
88823295|NCT04868045|Experimental|Patients with a history of thyroid hormone suppression (TSH<0.5 mU/L) for at least 5 years|Study subjects will be given 200mcg of TRH as a single intravenous (IV) bolus in endocrine clinic on Day 1 and Day 5. LT3 will be administered orally, twice a day (12 hours apart i.e. 8 AM and 8 PM) at a dosage of 10 mcg on Day 2-4. Levothyroxine will be taken after the TRH stimulation tests on Day 1 and day 5. Levothyroxine will be taken on Days 2-4 of the study. *Patients will take their own LT4 that they are prescribed by their endocrinologist. The dose of Levothyroxine is titrated for each patient.
88823296|NCT04868045|Experimental|Patients with no history of TSH suppression|Study subjects will be given 200mcg of TRH as a single intravenous (IV) bolus in endocrine clinic on Day 1 and Day 5. LT3 will be administered orally, twice a day (12 hours apart i.e. 8 AM and 8 PM) at a dosage of 10 mcg on Day 2-4. Levothyroxine will be taken after the TRH stimulation tests on Day 1 and day 5. Levothyroxine will be taken on Days 2-4 of the study. *Patients will take their own LT4 that they are prescribed by their endocrinologist. The dose of Levothyroxine is titrated for each patient.
88823297|NCT04841135|Other|Alzheimer disease group|
88823298|NCT04841135|Other|Control|
88823299|NCT04841135|Other|Neurotypicals|
88999665|NCT00170456|Active Comparator|3|High dose rPA vaccine regime 1
88999666|NCT00170456|Active Comparator|4|High dose rPA vaccine regime 2
88999667|NCT05422807|Active Comparator|Psychological intervention|Families randomized to the intervention group will receive 12 sessions of Behavioral Family Systems Therapy for Teens with type 2 diabetes (BFST-DM2) over 6 months.
88999668|NCT05422807|No Intervention|Control group|The participants assigned to the control group will receive their standard medical care for diabetes.
88999669|NCT04679974|Experimental|MBCT treatment|Melodic-based communication treatment
88999670|NCT00170495||observation|male and female adults age 65 and older with acute respiratory illness (common colds, flu, bronchitis, pneumonia)
88999671|NCT05420506|Experimental|NROT1|Intestinal device placement in subjects and their follow up
88999672|NCT05420389|Experimental|breast massage|The mothers who were included in the breast massage group were informed about the use of milking pumps in the routine application of the hospital, the data collection form and the state anxiety scale were filled out on the first day. These mothers were shown breast massage during the use of milking pumps, they were provided with their own application and a brochure was given explaining the application.As long as the breast milk follow-up form to record the amounts of milk they milked was in the hospital, the researcher explained how to fill it out when discharged and was asked to fill out the last-day state anxiety scale (SATI-I). Milk amounts are measured in ml.
88999673|NCT05420389|Experimental|hot compress|Mothers who were included in the hot application group were informed about the use of milking pumps in the routine application of the hospital and the state anxiety scale (STAI-I) was filled out on the first day. These mothers were shown the hot application they would make during the use of milking pumps, they were provided with the application and a brochure was given explaining the application.The hot chest compress to be used in this group will be used in the Lansinoh brand Thera°Pearl® Hot Breast Therapy pad, which is sold in medical medicines in pharmacies approved by the Ministry of Health.The breast milk follow-up form, in which they will record the amounts of milk they milk, was explained by the researcher in the hospital and how to fill it out when they were discharged, and they were asked to fill out a last-day anxiety scale.
88999674|NCT05420389|Experimental|breast massage-hot compress|Mothers who were included in the breast massage and hot application group were informed about the use of milking pumps in the routine application of the hospital, the data collection form and the state anxiety scale were filled out on the first day. These mothers were shown breast massage and hot application during the use of milking pumps, they were provided with their own application and a brochure was given explaining the application.The breast milk follow-up form, in which they will record the amounts of milk they milk, was explained by the researcher in the hospital and how to fill it out when they were discharged, and they were asked to fill out a last-day anxiety scale.
88999675|NCT05420389|No Intervention|control group|The mothers who were included in the control group were informed about the use of milking pumps in the routine application of the hospital, the data collection form and the state anxiety scale were filled out on the first day. These mothers were told by the researcher how to fill out the breast milk follow-up form for 4 days as long as they were in the hospital. Milk amounts are measured in ml. On the last day, the state anxiety scale has been filled.
88999676|NCT05420350|Active Comparator|Lamotrigine and Bupropion|"Lamotrigine will be taken orally for a duration of 28 weeks, consisting of a six-week titration, 20-week study period, and two-week taper. Possible doses are 25mg one a day, 50mg once a day, 50mg twice a day, 75mg twice a day during titration; 125mg twice a day for the study period; and 125mg once a day during the two-week taper. Patients who discontinue at any point of the study will have a two-week taper of lamotrigine.~Bupropion will be taken orally for the duration of 20 week at the dosage of 100mg twice a day."
88999677|NCT05420350|Placebo Comparator|Placebo|The placebo will match the lamotrigine and bupropion dosage, frequency, and duration.
88999678|NCT03043768||PD patients|Male and female PD patients (idiopathic parkinsonism, Hoehn and Yahr [H&Y] scores 1-2) aged 35 to 80 years
88999679|NCT03043768||Control subjects|Age-and gender matched healthy control subjects
88999680|NCT03014635|Experimental|DaxibotulinumtoxinA 40 units|Biological/Vaccine: Botulinum Toxins, Type A Intramuscular injection
88999681|NCT03014635|Placebo Comparator|Placebo|Biological/Vaccine: Placebos Intramuscular injection
88999682|NCT00170573|Experimental|Caelyx|
88999683|NCT02885272|Experimental|Diagnostic (PET/CT)|Patients receive fluorodeoxyglucose F-18 IV over 1 minute and then undergo PET/CT scans over 30 minutes at 1 hour, 4-5 hours, and 7-8 hours after injection. Patients also undergo a standard of care MRI scan over 45 minutes if not already completed as part of standard of care.
88999684|NCT02793583|Experimental|Umbralisib + Ublituximab|Umbralisib oral daily dose in combination with Ublituximab intravenous administration
88999685|NCT02793583|Experimental|Umbralisib|Umbralisib oral daily dose
88999686|NCT02793583|Experimental|Umbralisib + Ublituximab + Bendamustine|Umbralisib oral daily dose in combination with Ublituximab intravenous administration and Bendamustine intravenous administration
88999687|NCT00170612|Experimental|A|PCV at 6 weeks, 10 weeks, and 14 weeks; PPS at 18 months
88999688|NCT00170612|Experimental|B|PCV at 6 weeks, 10 weeks, and 14 weeks; PPS at 12 months and 18 months
88999689|NCT00170612|Experimental|C|PCV at 6 weeks and 14 weeks; PPS at 18 months
88999690|NCT00170612|Experimental|D|PCV at 6 weeks and 14 weeks; PPS at 12 months and 18 months
88999691|NCT00170612|Experimental|E|PCV at 14 weeks; PPS at 18 months
88999692|NCT00170612|Experimental|F|PCV at 14 weeks; PPS at 12 months and 18 months
88999693|NCT00170612|Experimental|G|No PCV; PPS at 12 months and 18 months
88999694|NCT00170612|Active Comparator|H|No PCV; PPS at 18 months
88823300|NCT01654796|Active Comparator|Low Field Magnetic Stimulation|Patients in this arm will receive 2 days of active low field magnetic stimulation (LFMS) in phase 1, followed by 2 days of active low field magnetic stimulation (LFMS) in phase 2. LFMS is a novel, non-contact neuromodulation technique. LFMS is administered through a device while the patient lies on his/her back for 20 minutes.
88823301|NCT01654796|Placebo Comparator|Sham (LFMS)|Patients in this arm will receive 2 days of sham (not active) low field magnetic stimulation (LFMS) in phase 1, followed by 2 days of sham (not active) low field magnetic stimulation (LFMS) in phase 2.
88823302|NCT01654796|Other|Crossover Arm|Patients in this group will receive two days of sham (not active) low field magnetic stimulation (LFMS) in phase 1, followed by two days of active low field magnetic stimulation (LFMS) in phase 2.
88823303|NCT04803539|Active Comparator|Capecitabine|Patients assigned to this group will receive oral capecitabine at a dose of 650 mg/m2 twice a day by mouth for 1 year
88823304|NCT04803539|Experimental|Capecitabine + Apatinib + Camrelizumab|Patients assigned to this group will receive oral capecitabine at a dose of 650 mg/m2 twice a day, Camrelizumab 200mg intravenously, once every two weeks (Q2W), oral apatinib, 250mg, PO, qd for 1 year
88823305|NCT05710094|Experimental|Group 1|Single dose of 500ppm HOCl + 1 % HAc, or placebo
88823306|NCT05710094|Experimental|Group 2|Single dose of 500ppm HOCl + 2 % HAc, or placebo
88823307|NCT05710094|Experimental|Group 3|Single dose of 500ppm HOCl + 3 % HAc, or placebo
88823308|NCT05710094|Experimental|Group 4|Single dose of 1000ppm HOCl + 3 % HAc, or placebo
88823309|NCT05710094|Experimental|Group 5|Multiple doses (OD for 5 days) of xppm HOCl + x% HAc#
88823310|NCT05710094|Experimental|Group 6|Multiple doses (BID for 5 days) of xppm HOCl + x% HAc#
88823311|NCT05710094|Experimental|Group 7|Multiple doses (TID for 5 days) of xppm HOCl + x% HAc#
88823312|NCT04788251|Experimental|Exercise-based fall prevention intervention|To receive 7 weeks of exercise-based programme
88823313|NCT04788251|Other|Wait-list controls|To receive fall prevention resources while waiting for programme
88823314|NCT04349345||sperm count over time|observation
88823315|NCT03028805|No Intervention|Usual care and order set A|Usual care. Providers may still search for a COPD order set, and in this arm will see version A, the static list of orders, which is the current state.
88823316|NCT03028805|Active Comparator|Usual care and order set B|Usual care in the sense that COPD orders are not automatically included in admission orders despite likelihood of a COPD admission based on the predictive model. However, providers may still search for a COPD order set, and in this arm will see version B, the dynamic list of orders that has been end user tested prior to launch.
88823317|NCT03028805|Active Comparator|Automatic inclusion and order set A|COPD order set is automatically included in admission orders as a static list.
88823318|NCT03028805|Active Comparator|Automatic inclusion and order set B|COPD order set is automatically included in admission orders as a dynamic and end user tested version.
88823319|NCT01602120|Experimental|CFD4870g Sham|Participants who were administered sham comparator in Study NCT01229215 (CFD4870g), will receive lampalizumab 10 milligrams (mg), intravitreally (ITV), either once in every 4 weeks (Q4W) or once in every 8 weeks (Q8W) in accordance with their previously assigned treatment frequency assignment in Study CFD4870g followed by Q4W administration for the remainder of the extension study up to approximately 96 months.
88823320|NCT01602120|Experimental|CFD4870g Lampalizumab|Participants will receive lampalizumab 10 mg, ITV, Q4W or Q8W in accordance with their previously assigned treatment frequency assignment in Study NCT01229215 (CFD4870g) followed by Q4W administration for the remainder of the extension study up to approximately 96 months.
88823321|NCT01602120|Experimental|GX29455 Sham|Participants who were administered sham comparator in Study NCT02288559 (GX29455), will receive lampalizumab 10 mg, ITV, Q4W throughout the extension study up to approximately 54 months.
88823322|NCT01602120|Experimental|GX29455 Lampalizumab|Participants who were administered lampalizumab in Study NCT02288559 (GX29455), will receive lampalizumab 10 mg, ITV, Q4W throughout the extension study up to approximately 54 months.
88823323|NCT01658228|Other|Donepezil Treatment Group|For the initial 16 weeks of open-label antidepressant treatment, citalopram up to 20 mg daily or venlafaxine up to 225 mg daily was prescribed. At 16 weeks, all patients were randomized, double-blind, to add-on donepezil or placebo for 62 weeks. Donepezil was started at 5 mg and increased to 10 mg daily or maximum tolerated dose while continuing antidepressants.
88823324|NCT01658228|Other|Placebo Treatment Group|For the initial 16 weeks of open-label antidepressant treatment, citalopram up to 20 mg daily or venlafaxine up to 225 mg daily was prescribed. At 16 weeks, all patients were randomized, double-blind, to add-on donepezil or placebo for 62 weeks. Placebo dose was increased during the study to match Donepezil dose increases while continuing antidepressants.
88823325|NCT01658228|Other|Citalopram|An open treatment 8 week flexible dosing schedule starting with citalopram 10mg/day for the first week, then increasing to 20 mg/day thereafter to treat the depression. At the week 8 visit, citalopram responders will continue citalopram treatment and will be randomized to add-on donepezil or placebo at the week 16 visit.
88823326|NCT01658228|Other|Venlafaxine|For patients who did not respond to citalopram, open treatment 8 week flexible dosing schedule starting with venlafaxine 37.5mg/day for the first week, then 75mg/day for the second week, then 150mg/day for the third and fourth week, then 225mg/day for the fifth through eighth weeks. At the end of the eighth week, we will assess patients for antidepressant response. At this time-point, venlafaxine responders will be randomized to add-on donepezil or placebo.
88823327|NCT05709938|Experimental|Glargine|Glargine-regular insulin regimen
88823328|NCT05709938|Active Comparator|NPH|NPH- regular insulin regimen
88823329|NCT03029039||patients with severe sepsis|Blood samples will be collected at inclusion.
88823330|NCT03029039||patients with inflammatory syndrome without sepsis|Blood samples will be collected at inclusion.
88823331|NCT03029039||blood donor voluntary|Blood samples will be collected.
88823332|NCT01659866|Other|Cipro-susceptible|Patients with ciprofloxacin-susceptible bacteria on their rectal swab cultures will receive ciprofloxacin, the standard of care, as prophylaxis for their prostate biopsy
88999695|NCT02773966|Experimental|Arm A: Kypho-IORT|balloon kyphoplasty/vertebroplasty + intraoperative radiotherapy
88999696|NCT02773966|Active Comparator|Arm B: EBRT|external beam radiotherapy with 30 Gy during 10 days (3 Gy/day)
88999697|NCT00170690|Experimental|1|Treosulfan 7000 mg/m² i.v. on day 1, 29, 57 etc
88999698|NCT00170690|Experimental|2|Treosulfan 600 mg/m² p.o. on day 1-28, 57-84, etc
88999699|NCT02675569|Active Comparator|Catheter|Catheter is a method of vascular access for hemodialysis. It consists of a long, thin plastic tube and may be either tunnelled or non-tunnelled.
88999700|NCT02675569|Experimental|Fistula|Fistula is a type of vascular access strategy for hemodialysis in which a direct connection of an artery to a vein is created. It is intended to provide an access with good blood flow that can last for decades.
88999701|NCT00170768|Experimental|1|Darifenacin
88999702|NCT00170768|Active Comparator|2|Oxybutynin
88999703|NCT00170768|Placebo Comparator|3|Placebo
88999704|NCT02655562|Experimental|biomarker treatment arm|Patients in biomarker treatment arm and FENO≥25ppb were given Montelukast Sodium Tablets (p.o., 10mg, qd) . Patients in biomarker reatment arm and FENO<25ppb were given placebo (p.o., 10mg, qd).All treatment regimens lasted for 10 days and no other antitussive/decongestant or bronchodilators are given to any patients.
88999705|NCT02655562|Placebo Comparator|standard treatment arm|Patients in standard treatment arm and FENO≥25ppb were given placebo (p.o., 10mg, qd). Patients in standard treatment arm and FENO<25ppb were given Montelukast Sodium Tablets (p.o., 10mg, q.d.).All treatment regimens lasted for 10 days and no other antitussive/decongestant or bronchodilators are given to any patients.
88999706|NCT02607748|Experimental|18F-NaF PET and coronary CTA imaging|18F-NaF PET and coronary CTA imaging
88999707|NCT02502253|Experimental|Low dose|
88999708|NCT02502253|Experimental|moderate dose|
88999709|NCT02502253|Experimental|High dose|
88999710|NCT05412667|Placebo Comparator|Placebo|Pea protein without TWK10 (20g/day)
88999711|NCT05412667|Experimental|TWK10|Pea protein (20g/day) with TWK10 (10 billion CFU/day)
88999712|NCT01356940|Active Comparator|dalfampridine ER 10mg bid-placebo|4 week administration of dalfampridine ER 10mg bid followed by 2 week washout and 4 weeks of placebo control
88999713|NCT01356940|Placebo Comparator|placebo-dalfampridine ER 10mg bid|placebo tablet administered bid for four weeks followed by 2 week washout and 4 weeks of dalfampridine ER 10mg bid
88999714|NCT05405959|Experimental|Kinesiotaping (KT) with EDF technique|the patients were seated and asked to flex their neck laterally to the contralateral side and to rotate their head to the same side while the shoulder was adducted. I band was first fold in half and then divided into 5 lines without cutting the ends to form a web shape. Two pieces of web shaped 20-25 cm length KT were used. The end of the KT was applied to the acromion, and the spinal process of C7 vertebra without stretching, but the web on the muscle had %10-15 tension. The second web shaped band was applied using the same technique between acromion and thoracal vertebral insertion of the middle trapezius muscle. Kinesio tape was planned to stay on for five days; it was applied twice, with two days of rest between applications Trapezius stretching exercises were given to patients as home exercise program.
88999715|NCT05405959|Sham Comparator|Sham Kinesiotaping|The sham group received improper KT application consisting two I strips (same material as the real application) applied with no tension on c7 spinal process as cross sign. For sham taping, the cervical spine of the participants was placed in a neutral position. Kinesio tape was planned to stay on for five days; it was applied twice, with two days of rest between applications Trapezius stretching exercises were given to patients as home exercise program
88999716|NCT02492776|Experimental|Gefapixant + Omeprazole|Gefapixant oral tablets (25mg, 50 mg) administered twice daily for 13 days + Omeprazole oral capsules (20 mg) administered once daily for 8 days
88999717|NCT02447614||Surgery|Adenotonsillectomy
88999718|NCT02447614||Conservative treatment|Mometasone Furoate Aqueous Nasal Spray or uticasone propionate (1/once qd) and（or）Leukotriene antagonists(4 or 5mg/once qn) or H1 receptor antagonists
88999719|NCT02447614||no treatment|just regular follow-up
88999720|NCT02963883|Experimental|SVO2 group|After optimization of oxygenation and blood volume, concentrate transfusion (s) of red blood cells by the individual value of ScvO2, whose value must be greater than 70% after elimination of hypovolemia, hypotension or hypoxemia.
88999721|NCT02963883|Active Comparator|control group|After optimization of oxygenation and blood volume, concentrate transfusion (s) of red blood cells based on the hemoglobin values, as recommended by the National Health Authority for Anesthesiology, Surgery, Emergency (November 2014 ): transfusion threshold of <9 g / dl for patients with cardiovascular antecedents.
88999722|NCT05392699|Experimental|Human single chain IL-12 mRNA-single dose|Human single chain IL-12 mRNA-single dose
88999723|NCT05392699|Experimental|Human single chain IL-12 mRNA-multiple dose|Human single chain IL-12 mRNA-multiple dose
88999724|NCT05391568|Experimental|Dry Needling|One single session of DN
88999725|NCT05391568|Sham Comparator|Sham Dry Needling|One single session of Sham DN
88999726|NCT02229877|Experimental|Gefapixant + Omeprazole|"Gefapixant oral tablets (25mg, 50 mg, 150 mg) administered twice daily for 18 days~+ Omeprazole oral capsules (40 mg) administered twice daily for 8.5 days"
88999727|NCT02122666||Metabolic Syndrome|Muscle biopsy to determine sarcoplasmic reticulum composition and function, Oral Glucose tolerance test with insulin levels at time points to determine Insulin sensitivity, DEXA scan to determine lean muscle and fat mass
88999728|NCT02122666||Control|Muscle biopsy to determine sarcoplasmic reticulum composition and function, Oral Glucose tolerance test with insulin levels at time points to determine Insulin sensitivity, DEXA scan to determine lean muscle and fat mass
88999729|NCT02963961|Experimental|Cognitive Training|Patients will engage in a daily preoperative cognitive training battery (BrainHQ, Posit Science) that aims to improve attention, memory, and visuospatial processing.
89355653|NCT03570697|Experimental|Evolocumab|Participants receive evolocumab subcutaneous injection once every month (QM) for 48 weeks. As prescribed and provided by the investigator, participants will be treated with maximally tolerated statin therapy, not expected to change for the duration of the study participation.
88823333|NCT01659866|Active Comparator|Cipro-resistant|"Patients with ciprofloxacin-resistant bacteria on their rectal swab will receive one of the following drugs:~trimethoprim-sulfamethoxazole 1 double strength tablet orally 2 hours before the procedure and again 12 hours later~cefuroxime 500 mg orally 2 hours before the procedure then again 12 hours later~ceftriaxone 500 mg intramuscularly 2 hours before the procedure~gentamicin 2mg/kg intramuscularly 2 hours before the procedure~amikacin 5 mg/kg intramuscularly 2 hours before the procedure~aztreonam 500 mg intramuscularly 2 hours before the procedure~imipenem 500 mg intramuscularly 2 hours before the procedure~ceftriaxone 2000 mg intravenously 1 hour before the procedure~gentamicin 2 mg/kg intravenously 1 hour before the procedure~amikacin 5mg/kg intravenously 1 hour before the procedure~aztreonam 2000 mg intravenously 1 hour before the procedure~imipenem 1000 mg intravenously 1 hour before the procedure"
88999730|NCT02963961|No Intervention|No Training|Patients will not undergo preoperative cognitive training. Patients will receive standard preoperative care.
89355654|NCT03570697|Placebo Comparator|Placebo|Participants receive placebo subcutaneous injection QM for 48 weeks. As prescribed and provided by the Investigator, participants will be treated with maximally tolerated statin therapy, not expected to change for the duration of the study participation.
89355655|NCT03878381|Experimental|Compounded Skin Care Cream|One side of the face will be randomly chosen as the treatment side
88823335|NCT03068663|Experimental|Pchir|"Non small cell lung carcinoma patients designated for immediate surgery. Intervention in this group is sampling. The sampling will be done for:~blood and saliva: at consultations after inclusion in the study~faeces: day before the surgery~lung/tumour tissue, bronchoalveolar lavage: during surgery after lobectomy"
88823336|NCT03068663|Experimental|Pct-chir|"Non small cell lung carcinoma patients who will receive neoadjuvant chemotherapy before the surgery. Intervention in this group is sampling. The sampling will be done for:~blood and saliva: 1st time at consultations after inclusion in the study, 2nd time at consultations after chemotherapy and before surgery~faeces: 1st time the day before the chemotherapy, 2nd time the day before the surgery~lung/tumour tissue, bronchoalveolar lavage: during surgery after lobectomy"
88823337|NCT03024671|Experimental|patch test|Patients with patch test of cosmetics
88823338|NCT02249702|Experimental|Trabectedin|Trabectedin 1.3 mg/m2 will be administered via a central venous catheter as a 24-hour infusion on day 1 of 21-days treatment cycles. Trabectedin treatment can be continued until progressive disease, major toxicity, patient's intolerance or unwillingness to continue treatment or medical decision by the responsible physician.
88823339|NCT02249702|Active Comparator|gemcitabine + docetaxel|Gemcitabine 900 mg/m2 will be administered via a central venous catheter on days one and eight over 90 min, followed by docetaxel 75 mg/m2 on day eight iv over 1 h. Gemcitabine+docetaxel treatment is planned for six cycles, unless there is evidence of disease progression, unacceptable toxicity or patient's intolerance or unwillingness to continue treatment, or medical decision by the responsible physician. Patients with continued response after six cycles can receive two additional cycles of combination therapy or continue with Gemcitabine alone.
88823340|NCT02947529|Placebo Comparator|Hemiarthroplasty - Placebo|Patients are placed into this arm based on the type of surgery performed and are randomized to receive placebo
88999731|NCT00553228|Experimental|group I|Tdap
88999732|NCT00553228|Active Comparator|group 2|Td
88999733|NCT02963688||KGOG 3019|Korean women with HG serous and/or endometrioid epithelial ovarian cancer
89355656|NCT03878381|Placebo Comparator|Placebo|The other side of the face will be randomly chosen as the control
89355657|NCT02511574|Experimental|cervical pessary|Patients with uterine cervical length ≤ 25 mm are randomized to use the cervical pessary or natural progesterone to compare their effectiveness in the reduction of preterm birth rates.
89355658|NCT02511574|Active Comparator|natural progesterone|Patients with uterine cervical length ≤ 25 mm are randomized to use the cervical pessary or natural progesterone to compare their effectiveness in the reduction of preterm birth rates.
89355659|NCT02506504|Experimental|Inspiratory help then sham ventilation|The initial evaluation is performed using an Inspiratory Pressure Support. After the training, the final evaluation is performed using an Inspiratory help (sham ventilation).
89355660|NCT02506504|Experimental|Sham ventilation then Inspiratory help|"The initial evaluation is performed using an inspiratory help (sham ventilation).~After the training, the final evaluation is performed using an Inspiratory Pressure Support."
88999734|NCT01744171|Experimental|Treatment (recombinant hsp110-gp100 chaperone complex vaccine)|Patients receive recombinant hsp110-gp100 chaperone complex vaccine ID on days 1, 15, and 43 in the absence of unacceptable toxicity.
88999735|NCT05357521||Borderline personality disorder|female patients between 18 and 25 years old meeting DSM V criteria for borderline personality disorder
89355661|NCT01200641|Active Comparator|melatonin|"ninety patients scheduled for cataract surgery by phacoemulsification were randomly allocated to three study groups to receive melatonin 6~mg (Group M, n = 30) , gabapentin 600mg(GroupG, n = 30)or placebo(GroupP, n=30) orally 90 minutes before retrobulbar injection( for all of three groups)."
89355662|NCT01200641|Active Comparator|gabapentin|"ninety patients scheduled for cataract surgery by phacoemulsification were randomly allocated to three study groups to receive melatonin 6~mg (Group M, n = 30) , gabapentin 600mg(GroupG, n = 30)or placebo(GroupP, n=30) orally 90 minutes before retrobulbar injection( for all of three groups)."
89533569|NCT04288427|Experimental|Finasteride Treatment|Patients who are eligible will be given 5ARI therapy, Finasteride, for medical management of Benign Prostatic Hyperplasia (BPH) symptoms. Only patients with lower urinary tract symptoms (LUTS) as assessed by American Urologic Association (AUA) urinary symptom score > than 8, (suggestive of moderate LUTS) prostate size > 40cc, no prostate nodule/tenderness/firmness and increased PSA between 4-10ng/ml requiring prostate biopsy will be enrolled. Then, they will have prostate MRIs/needle biopsies and blood/urine collection followed by treatment with Finasteride (standard of care). They will be followed in urology clinic for assessment of LUTS every 6 months and Finasteride responsiveness at the 12-month time point. Prostate biopsy samples will be evaluated for SRD5A2 gene expression/methylation, hormonal androgen/estrogen levels (which will be repeated in blood samples). Prostate MRIs will assess size/inflammatory changes at the start and 3-year time points.
89355663|NCT01200641|Placebo Comparator|placebo|"ninety patients scheduled for cataract surgery by phacoemulsification were randomly allocated to three study groups to receive melatonin 6~mg (Group M, n = 30) , gabapentin 600mg(GroupG, n = 30)or placebo(GroupP, n=30) orally 90 minutes before retrobulbar injection( for all of three groups)."
89355664|NCT03731143|Experimental|study arm|surgical opening the lower punctum using the pig tail probe and a scalpel followed by insertion of self retaining bicanalicular stent (FCI®; Paris, France).
88999736|NCT05357521||Control|female participants between 18 and 25 years old, with no psychiatric history, not meeting criteria for borderline personality disorder
89355665|NCT01856270|Experimental|Amitriptyline Immediate|The Amitriptyline Immediate group will begin study drug immediately after enrollment. Immediate Drug participants will be started on one 10 mg capsule each evening. The dosage will be adjusted upwards to 25 mg daily for Week 2 to a maximum of 50 mg daily by Week 3.
89355666|NCT01856270|Experimental|Amitriptyline Delayed|The Amitriptyline Delayed group will start the study drug at the Day 30 visit on one 10 mg capsule each evening. The dosage will be adjusted upwards to 25 mg daily for Week 2 to a maximum of 50 mg daily by Week 3.
89355667|NCT02506270|Active Comparator|AirSeal Trocar valveless|patients are treated with the AirSeal-CO2-insufflator and trocar-system
89355668|NCT02506270|Sham Comparator|Conventional trocar|patients are treated with a conventional insufflation and trocar system
89355669|NCT03727321|Placebo Comparator|Placebo|Placebo: Placebo will consist of cellulose powder (Microcrystalline cellulose:Blanver) in foil packets.
89355670|NCT03727321|Experimental|Fecal Microbial Transplant and cellulose|"Fecal Microbial Transplant - Fecal microbiome transplant (FMT): 50grams of FMT from a single, universal donor will be administered in 20-30 capsules taken by mouth.~Cellulose x 6weeks"
89355671|NCT03727321|Experimental|Fiber|Soluble corn fiber (PROMITOR®: Tate&Lyle), Resistant Wheat Starch 4 (Fibersym®: MGP Ingredients), Acacia Gum (Pre-Hydrated Gum Arabic: TIC GUMS).
89355672|NCT03727321|Experimental|Fecal Microbial Transplant and Fiber|"Fecal Microbial Transplant~Soluble corn fiber (PROMITOR®: Tate&Lyle), Resistant Wheat Starch 4 (Fibersym®: MGP Ingredients), Acacia Gum (Pre-Hydrated Gum Arabic: TIC GUMS)."
88823341|NCT02947529|Experimental|Intramedullary nail - Tranexamic Acid|Patients are placed into this arm based on the type of surgery performed and are randomized to receive tranexamic acid
89533570|NCT04270942|Experimental|Teplizumab treated|Administration of teplizumab by intravenous infusion
89355673|NCT02511340|Experimental|Flumatinib mesylate tablet 600 mg qd|Flumatinib, 600mg, qd
89355674|NCT02506348|Experimental|Diclofenac+Nepafenac|one drop Diclofenac in one eye one drop Nepafenac in other eye
88823342|NCT02947529|Experimental|Hemiarthroplasty - Tranexamic Acid|Patients are placed into this arm based on the type of surgery performed and are randomized to receive tranexamic acid
88823343|NCT02947529|Placebo Comparator|Intramedullary nail - Placebo|Patients are placed into this arm based on the type of surgery performed and are randomized to receive placebo
88823344|NCT01660802|Experimental|700 μg Dexamethasone|700 μg Dexamethasone intravitreal injection in the study eye on Day 1.
88823345|NCT01660802|Sham Comparator|Sham|Sham administered in the study eye on Day 1.
88823346|NCT02986529|Active Comparator|GV-971 150mg/capsule|900mg, oral
88823347|NCT02986529|Experimental|GV-971 300mg/capsule|900mg, oral
88823348|NCT02986529|Experimental|GV-971 450mg/capsule|900mg, oral
88823349|NCT02986529|Placebo Comparator|Placebo|Oral
88823350|NCT02296853|Experimental|Severe Hepatic Impairment Group|Participants with severe hepatic impairment will receive a single oral dose of TAF 25 mg on Day 1.
88823351|NCT02296853|Active Comparator|Matched Normal Hepatic Function Group|Participants with normal hepatic function will receive a single oral dose of TAF 25 mg on Day 1.
88823352|NCT01661114|Experimental|Gemcitabine, 5-FU and Cisplatin|4 cycles - Gemcitabine, 5-FU and Cisplatin (2 months)-Continue treatment until progression of disease or intolerable toxicity
88823353|NCT02683265|Experimental|Aptensio XR|Optimized dose of Aptensio XR (10, 15, 20, 30 or 40 mg Aptensio XR)
88823354|NCT02683265|Placebo Comparator|Placebo comparator|Placebo capsules
88823355|NCT02987829|Experimental|Dose Level 1: TRC253 40 mg daily|40 mg of single-agent TRC253 to be administered as oral capsules once daily
88823356|NCT02987829|Experimental|Dose Level 2: TRC253 80 mg|80 mg of single-agent TRC253 to be administered as oral capsules once daily
88823357|NCT02987829|Experimental|Dose Level 3: TRC253 160 mg|160 mg of single-agent TRC253 to be administered as oral capsules once daily
88823358|NCT02987829|Experimental|Dose Level 4: TRC253 240 mg|240 mg of single-agent TRC253 to be administered as oral capsules once daily
88999737|NCT05349448|Active Comparator|solo group|Bupivacaine 5 mg (1 mL) + Triamcinolone 40 mg (1 mL) + Saline solution (2 mL) + Hyaluronidase 1,500 IU reconstituted in 1 mL distilled water (HYL)
88999738|NCT05349448|Active Comparator|dex plus hyalase group|Bupivacaine 5 mg (1 mL) + Triamcinolone 40 mg (1 mL) + Dexmedetomidine 0.5mic/kg + Hyaluronidase 1,500 IU reconstituted in 1 mL distilled water (HYL)+ Saline solution (2 mL)
88999739|NCT05347810|Experimental|Study group|All participants in the study will receive the same investigational treatment (application of prolonged repetitive forces) and provide continuous comfort ratings.
89355675|NCT05223140||Cases|Admission to NICU or early perinatal death
89355676|NCT05223140||Controls|No admission to NICU or early perinatal death
89355677|NCT02511262||Specimen Collection|Prospective patients with symptoms of upper respiratory infections which may be attributable to Mycoplasma pneumoniae, or from patients suspected of having Mycoplasma pneumoniae.
88823359|NCT02987829|Experimental|Dose Level 5: TRC253 280 mg|280 mg of single-agent TRC253 to be administered as oral capsules once daily
88823360|NCT02987829|Experimental|Dose Level 6: TRC253 320 mg|320 mg of single-agent TRC253 to be administered as oral capsules once daily
88823361|NCT02988843|Experimental|Brentuximab Vedotin & Bevacizumab|"Bevacizumab will be administered at a dose of 15 mg/kg IV every 21 days; over 90 minutes during 1st infusion, over 60 minutes as 2nd infusion and over 30 minutes for subsequent infusions if prior infusions well tolerated.~Brentuximab vedotin will be administered first at 1.8 mg/kg (maximum dose of 180 mg) IV over 30 minutes every 21 days."
88823362|NCT02989545|No Intervention|Off treatment|2 week period without intervention
88823363|NCT02989545|Experimental|Treatment period|2 week period with intervention
88823364|NCT02991729|Active Comparator|Routine care|These patients will receive routine care at our institution for counseling on aneuploidy screening; they will be counseled by a genetic counselor on options, and following counseling, will select their test of choice. All patients will complete a knowledge and demographics questionnaire prior to genetic counseling. Patients in this arm will then complete a knowledge and decisional conflict survey immediately following genetic counseling.
88823365|NCT02991729|Experimental|Experimental|These patients will use an iPad-based decision aid explaining options for aneuploidy screening and testing. They will then immediately be counseled by a genetic counselor on their options as is routine at our institution, and following counseling, will select their test of choice. All patients will complete a knowledge and demographics questionnaire prior to genetic counseling. Patients in this arm will then complete a knowledge and decisional conflict survey following use of the decision aid, and again immediately following genetic counseling.
88823366|NCT02992197|Active Comparator|Rotarix, single dose|Rotarix 1.5 mL (standard single dose) and 1.5 mL of placebo by mouth (sterile, pharmacy-grade water) at both 6 and 10 weeks of life
88999740|NCT01656343||Belatacept treated kidney-only transplant recipients|
88999741|NCT01656343||CNI treated kidney-only transplant recipients|
89355678|NCT03569371|Experimental|INCB054707|
89355679|NCT02506426|Active Comparator|Endoscopic Sinus Surgery + Septoplasty|A surgery that uses special telescopes through the nostrils to make the nasal septum straight and open the facial sinuses without any incisions. The sinuses are opened using special microscopic instruments and the procedure takes approximately 90 - 120 minutes.
89355680|NCT02506426|Experimental|Septoplasty alone|A surgery that is performed to straighten a bent nasal septum. It is shorter (take approximately 25 - 30 minutes) and less invasive (do not open the facial sinuses) that might provide the same benefits compared to the larger and longer endoscopic sinus surgery.
89533571|NCT04230252|Experimental|Treatment Sequence 1: Reference Drug + Test Drug (RT)|Participants will receive 8 hour (H) extended-release (ER) acetaminophen tablet orally in period 1 (Reference) followed by newly formulated acetaminophen tablet orally in period 2 (Test). Each period will be separated by a washout period of at least 7 days.
88823367|NCT02992197|Experimental|Rotarix, double dose|Rotarix 3 mL by mouth (two standard doses administered simultaneously) at both 6 and 10 weeks of life
89533572|NCT04230252|Experimental|Treatment Sequence 2: Test Drug + Reference Drug (TR)|Participants will receive newly formulated acetaminophen tablet orally in period 1 (Test) followed by 8 hour ER acetaminophen tablet orally in period 2 (Reference). Each period will be separated by a washout period of at least 7 days.
88823368|NCT02993445|Experimental|Alternate Nostril Breathing|The procedure for ANB begins by bringing the right hand up to the nose; with the ring finger over the left nostril and the thumb over the right nostril, so that the nostrils may be closed by the fingers. The first step in the cycle is to hold the right nostril closed with the thumb, and exhale completely through the left nostril in a slow and controlled fashion, free from exertion and jerkiness. At the end of the exhalation, the patient will inhale slowly and completely back through the left nostril. At this point the patient will close the left nostril with the ring finger, open the right nostril by releasing the thumb, and repeat the exhale-inhale process through the right nostril, completing one cycle. Then the patient will switch back to the left nostril and begin the cycle again. This cycle will be performed for one session lasting approximately 5 minutes.
88823369|NCT02993445|Experimental|Foot Reflexology|The procedure for FR focuses on activating specific reflex areas on the foot linked with the eye and eye disease, via massage. Although in the interest of repeatable precision, we have decided to use a FR board (fig.1) to conduct the procedure. This board has two foot shaped pieces of wood mounted on a flat board with springs. On top of these wooden feet are small wooden nodes, which are organized at precise locations to activate the reflexology of the foot by stimulation certain pressure points. The patient will be instructed to rest their feet on these boards with a comfortable pressure for a period of 5 minutes.
89533573|NCT04222972|Experimental|Pralsetinib|Participants randomized to the Experimental Arm will receive Pralsetinib
88823370|NCT01661270|Placebo Comparator|Placebo|Placebo for aflibercept intravenous (IV) infusion on Day 1 of each cycle (1 cycle = 2 weeks) in combination with FOLFIRI regimen until disease progression, unacceptable toxicity or participant's refusal. FOLFIRI regimen: Irinotecan 180 mg/m^2 IV infusion and leucovorin 400 mg/m^2 IV infusion, 5-Fluorouracil IV bolus 400 mg/m^2 followed by continuous IV infusion 2400 mg/m^2.
88823371|NCT01661270|Experimental|Aflibercept|Aflibercept 4 mg/kg IV infusion on Day 1 of each cycle (1 cycle = 2 weeks) in combination with FOLFIRI regimen until disease progression, unacceptable toxicity or participant's refusal. FOLFIRI regimen: Irinotecan 180 mg/m^2 IV infusion and leucovorin 400 mg/m^2 IV infusion, 5-Fluorouracil IV bolus 400 mg/m^2 followed by continuous IV infusion 2400 mg/m^2.
88823372|NCT05108571|Experimental|Sequence A|
88823373|NCT05108571|Experimental|Sequence B|
88823374|NCT05098275|Experimental|Sequence A|
88823375|NCT05098275|Experimental|Sequence B|
88823376|NCT05031351|Experimental|High dosage Withania somnifera|544mg oral twice a day
88823377|NCT05031351|Experimental|Medium dosage Withania somnifera|272mg oral twice a day
88823378|NCT05031351|Placebo Comparator|Placebo|Matched capsules twice a day
88823379|NCT05709704||Postpartum Women WITH DRA|Participants who have the diagnosis of diastasis rectus abdominis
88823380|NCT05709704||Postpartum Women WITHOUT DRA|Participants who do not have a diagnosis of diastasis rectus abdominis
88823381|NCT02997735|Experimental|Electronic Quitline Referral|The electronic quitline referral will be embedded within the Tobacco Treatment CDS tool, a CDS system previously developed to help pediatricians provide smoking cessation counseling and treatment to parents who smoke, modeled off the CEASE intervention, an evidence-based approach for implementing smoking cessation treatment of parents in the pediatric setting. The parental tobacco treatment CDS tool prompts the pediatric clinician to ask the parent about smoking status and assess interest in quitting (at all well-child and acute visits), links to an electronic nicotine replacement therapy prescription for parents interested in quitting, and guides appropriate documentation. Electronic referral to the quitline will be made by clicking an automated link embedded in the tool that will send the parent smokers' names and telephone numbers (entered by the clinician) directly to the Pennsylvania (PA) Free Quitline.
88823382|NCT02997735|Other|Standard of Practice|All procedures implemented in the standard referral approach will be identical to those in the electronic referral approach with the exception of providing the telephone number for the Quitline to the parent (rather than electronic referral). The clinician workflow will be nearly the same, in that the clinician will use the link embedded in the tobacco treatment CDS tool to add the quitline to the patient's discharge paperwork (rather than automatically refer to the quitline).
88823383|NCT01662752|Other|Indocyanine green|Indocyanine green is used for intraoperative identification of sentinel lymph nodes in patients with early colonic cancer using near infrared laparoscopic imaging
88823384|NCT05274230|Experimental|MDMA-Assisted Psychotherapy Participants|Participants who have completed the MDMA-Assisted Psychotherapy and consented to be part of this study will use an Apollo Device TVS (10-200 Hz) attached to the subject's wrist or ankle via a commercially available wearable vibration technology can deliver TVS (Transcutaneous Vibratory Stimulation). The intensity will be targeted for the sensory threshold (the level at which the vibration is just noticeable) as this is where the TVS seems to be most effective from prior studies. Similar vibratory stimuli have been demonstrated to be safe in the literature.10-14 The intensity of the vibration will be adjusted to the subjects' comfort and can be controlled by the subject at any time.
88823385|NCT04905459||Retinal Imaging and Mydriatic Agents|Subjects will undergo several types of retinal imaging before and after administration of mydriatic agent. Subjects will be administered mydriatic medication to dilate their pupils.
88823386|NCT02999763|Experimental|Abdominal fat reduction treatment|SlimShape treatments will be administered for up to 3 sessions to the abdomen of all study participants.
88823387|NCT05231798|Experimental|Down Syndrome|Adults between 18-55 with Down Syndrome.
88823388|NCT03000309|Other|Apremilast|Apremilast, 30 mg. tablets, two times a day for 16 weeks
88823389|NCT02992028|Experimental|Intravenous vitamin C injection|During the first 30 min after beginning of the rotator cuff repair, treatment group received infusion of 3 g vitamin C (ascorbic acid) in 500 ml of Ringer.
89355681|NCT02515396|Experimental|Treatment Group A|MMI-0100 Inhaled, once daily x 5, followed by 3 week washout period, followed by Placebo Inhaled, once daily x 5
88823390|NCT02992028|Placebo Comparator|Intravenous saline injection|During the first 30 min after beginning of the rotator cuff repair, sham group received 6 ml normal saline in 500 ml of Ringer.
88823391|NCT03165981|Other|Simultaneous vaccination arm|In the study arm, subjects will receive PCV13, DTaP and IIV vaccines during visit 1. Approximately 2 weeks later, subjects will receive a health education visit without vaccination during study visit 2.
88823392|NCT03165981|Other|Sequential vaccination arm|In the study arm, subjects will receive PCV13 and DTaP during study visit 1. Approximately 2 weeks later, subjects will receive the IIV vaccine during study visit 2.
89355682|NCT02515396|Experimental|Treatment Group B|Placebo Inhaled, once daily x 5, followed by 3 week washout period, followed by MMI-0100 Inhaled, once daily x 5
88823393|NCT02249780|Experimental|New treatment|In patients with at least one well perfused parathyroid gland on ICG parathyroid angiography, no postoperative parathyroid dosage and supplementation will be done. Calcium and parathormone dosage will be done 10 days after surgery.
88823394|NCT02249780|Active Comparator|Standart treatment|In those patients in whom at least on of the four parathyroid glands is well perused, postoperative parathyroid function test and parathyroid supplementation will be done. Calcium and parathormone dosage will be done at 24 hours and 10 days after surgery. Prophylactic supplementation of calcium and Vitamin D will be given.
88823395|NCT03167541|Experimental|1|Treatment Order: Test, Reference
88823396|NCT03167541|Experimental|2|Treatment Order: Reference, Test
88823397|NCT03168321|Experimental|IDP-123 Lotion|Tazarotene 0.045% Lotion
88823398|NCT03168321|Placebo Comparator|IDP-123 Vehicle Lotion|Vehicle Lotion
88823399|NCT04817085|Experimental|Visant Medical Canalicular Plug|Bilateral placement of the Visant Canalicular Plug inserted on Day 1
88823400|NCT04817085|Active Comparator|Commercially available canalicular plug|Bilateral placement of commercially available canalicular plug inserted on Day 1
88823401|NCT04786587||Pregnant woman|
88823402|NCT04531293|Other|Total-breath method followed by standard method|Total Lung Capacity (TLC) measurement performed on device EasyOne Pro (TM) according to total-breath method followed by TLC measurement performed on device MasterScreen (TM) according to standard method.
88823403|NCT04531293|Other|Standard method followed by total breath method|Total Lung Capacity (TLC) measurement performed on device Masterscreen (TM) according to standard method followed by TLC measurement performed on device EasyOne Pro (TM) according to total-breath method.
88823404|NCT03170661|No Intervention|Moderate neuromuscular block|Subjects will receive moderate neuromuscular block, aimed at 1-2 twitches train of four
88823405|NCT03170661|Experimental|Deep neuromuscular block|Subjects will receive deep neuromuscular block, aimed at 1-2 twitches post tetanic count
88823406|NCT03171051|Other|Lipolysis treatment|"The right flank of the abdomen will be treated with the 950nm LED device. The treatment area will be heated initially for 4 minutes at 41W followed by a duty cycle of 25 sec on and 10 sec off time at 29W for 16 minutes. Total treatment time will be 24 minutes.~The left flank of the abdomen will be treated with the 1050nm diode laser device. The treatment area will be heated initially for 4 minutes at 41W followed by a duty cycle of 25 sec on and 10 sec off time at 29W for 16 minutes. Total treatment time will be 24 minutes."
88823407|NCT03175731|Experimental|Proton Pump Inhibitors|Pantoprazole 40mg per day intravenously or orally for 2 weeks after endoscopic treatment.
89355683|NCT03731065|Active Comparator|Fructose-maltodextrin ingestion|Ingestion of fructose and maltodextrin (glucose polymers) at a rate of 90 g carbohydrate per hour during two hours of treadmill running at 60%VO2peak.
89355684|NCT03731065|Experimental|Fructose-maltodextrin hydrogel ingestion|Ingestion of fructose and maltodextrin (glucose polymers) encapsulated in alginate-pectin hydrogel, drinks at a rate of 90 g carbohydrate per hour during two hours of treadmill running at 60%VO2peak.
89355685|NCT03731065|Active Comparator|Glucose-maltodextrin ingestion|Ingestion of glucose and maltodextrin (glucose polymers) at a rate of 90 g carbohydrate per hour during two hours of treadmill running at 60%VO2peak.
89355686|NCT01200719|Experimental|tACS group|
89355687|NCT01200719|No Intervention|Control group|Patients in the control group followed exactly the same protocol but without receiving the transcranial alternating current stimulation .
89355688|NCT01318070|Experimental|Alogliptin 12.5 mg QD and Pioglitazone 15 or 30mg QD|
89355689|NCT01318070|Experimental|Alogliptin 25 mg QD and Pioglitazone 15 or 30 mg QD|
89355690|NCT01318070|Active Comparator|Pioglitazone (15mg or 30mg ) QD|
89355691|NCT03345316|Experimental|FFI-1010|
89355692|NCT03727243||Septic/septic shock patients|Patients with underlying confirmed or probable cause of infection leading to sepsis or septic shock will form the active group of interest.
89355693|NCT03727243||Non-septic/sterile inflammation patients|Patient with severe trauma, severe burns and patients admitted to ICU after major surgery or pancreatitis. Active comparator group.
89355694|NCT03727243||Healthy control patients|Active comparator group.
89355695|NCT01202513|Experimental|Bimatoprost application|
89355696|NCT03345238|Experimental|Active MTP|
89355697|NCT03345238|Experimental|Latent MTP|
89355698|NCT03345238|Experimental|Out of MTP|
89355699|NCT03730909|Experimental|Lactate infusion|Subjects will receive an intravenous lactate infusion to elevate plasma lactate levels
89355700|NCT03730909|Placebo Comparator|NaCl infusion|As a control condition, subjects will receive intravenous NaCl infusion
89355701|NCT04497688|Experimental|PEG-rhG-CSF group|Patients received subcutaneous injection of PEG-rhG-CSF(Jinyouli®) 48 hours after the end of chemotherapy, 6mg for patients with body weight≥45kg and 3mg for patients with body weight less than 45kg, once per chemotherapy cycle
89355702|NCT03835715|Experimental|Vortioxetine|
89355703|NCT02510716|Experimental|Scheduled Gradual Reduction (SGR)|Four week SGR program plus support text messages.
89355704|NCT02510716|Active Comparator|Support Message Only|Support text messages only.
89355705|NCT03727087||Melanoma|Subjects with clinically confirmed melanoma or high suspicion of a primary malignancy of melanoma based on skin exam or imaging and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
89355706|NCT04877366|Active Comparator|ARM A: Sprinkled Format REDUCOSE|2 G powder sprinkle containing 250 mg REDUCOSE (mulberry leaf extract - 250 mg - 5% DNJ) + fiber, vitamin D, and chromium picolinate
89355707|NCT04877366|Placebo Comparator|ARM B: Placebo B: Standard Meal|A placebo matching to the test product will be used as control
89355708|NCT04877366|Placebo Comparator|ARM C: Placebo C: Acarbose|Acarbose 100 mg tablet (provided in open-label format)
89355709|NCT01202669||Epilepsy patients, EMU stay|
89355710|NCT02505802|Experimental|BoNT-A treatment group|In BoNT-A treatment group patients received 200 units BoNT-A injection in the triceps surae (150iu) and tibial muscle posterior (50iu). Both groups received comprehensive rehabilitation for 8 weeks.
89355711|NCT02505802|No Intervention|Control group|No special treatment was performed in the control group. Both groups received comprehensive rehabilitation for 8 weeks.
89355712|NCT03627884|Active Comparator|Normal Saline Catheter Lock Solution Group|Patients receiving normal saline catheter locking solution
89355713|NCT03627884|Active Comparator|Sodium Bicarbonate Catheter Lock Solution|Patients receiving sodium bicarbonate catheter locking solution
89355714|NCT03835559|Active Comparator|Cyanoacrylate closure|After successful access of target vein and insertion of guidewire under any type of anesthesia, the procedure of cyanoacrylate closure for treatment of incompetent Saphenous Veins is performed. A 5 French introducer and catheter is advanced and positioned 5.0 cm caudal to the junction with proximal saphenous vein compression by the ultrasound probe, two injections of approximately 0.10 mL glue are given 1 cm apart, followed by a 3min period of compression, and then repeat injections and 30sec ultrasound probe and hand compression sequences until the entire length of the target vein is treated. The catheter is removed.
89355715|NCT03835559|Active Comparator|Surgical stripping|For treatment of incompetent Saphenous Veins, surgical stripping is performed with a proper incision in the groin, with division and ligation of the saphenous vein and division of all tributaries under all types of anesthesia (general, spinal, regional block, or local anesthesia). The saphenous vein is then removed using a stripper. Compression stocking is apply.
89355716|NCT05222282|Experimental|Intervention|"Intervention with~nurseled sexual consultations with screening questionnaire prior to consultation~genital examintaion with doctor"
89355717|NCT05222282|Other|Kontrol|Usual care
88823408|NCT03175731|Placebo Comparator|Placebo|Placebo 40mg per day intravenously or orally for 2 weeks after endoscopic treatment.
89355718|NCT02895295|Active Comparator|Control|Study subjects randomized to the control arm will receive information on how to download their prescription drug information from their electronic medical record and will be provided with a list of resources available in the community to help them choose a prescription drug plan.
89355719|NCT02895295|Experimental|Expert Recommendation|"Participants randomized to the Expert Recommendation arm will receive access to a decision support tool that provides personalized expert scores for particular plans based on individual's likely annual out-of-pocket spending, including plan premiums and spending on prescription drugs, and the Medicare star ratings (a measure of customer satisfaction)."
89355720|NCT02895295|Active Comparator|Individual Analysis|"Participants randomized to Individual Analysis arm will receive access to a decision support tool that provides individualized cost information for each plan but not the expert scores for particular plans."
89355721|NCT02505724|Active Comparator|Conventional training|Participants received access to a web-based tutorial for laparoscopic suturing and a box trainer for independent practice
89355722|NCT02505724|Experimental|Intervention|Participants received access to a web-based tutorial for laparoscopic suturing and a box trainer for independent practice. In addition, they received two 1/2 hour peer-coaching sessions
88823409|NCT01662908|Experimental|edoxaban tosylate|
88823410|NCT01662908|Active Comparator|heparin/warfarin|
89355723|NCT03843281|Experimental|Paracetamol|Paracetamol 1 g (100 mL) IV + Morphine 0.1 mg/kg IV (repeatable in Doses of 0.05 mg/kg), 100 patients over 4 hours
89355724|NCT03843281|Placebo Comparator|Placebo|Placebo (NaCl 0.9% 100 mL IV) + Morphine 0.1 mg/kg IV (repeatable in Doses of 0.05 mg/kg), 100 patients over 4 hours
89355725|NCT02515240|Active Comparator|healthy controls|healthy individuals, HIV negative, 19-50 yrs if age, immunized with one shot of PPV23 vaccine.
89355726|NCT02515240|Active Comparator|newly diagnosed HIV >200|Newly diagnosed HIV positive patients with CD4 count >200, immunized with one shot of PPV23 vaccine.
89355727|NCT02515240|Active Comparator|newly diagnosed HIV <200|Newly diagnosed HIVpositive patients with CD4 count <200, immediately immunized with one shot of PPV23 vaccine.
88999742|NCT01550185|Experimental|Treatment (eltrombopag olamine)|Patients receive eltrombopag olamine PO QD from day 1 up to day 62. Treatment continues for up to 9 weeks in the absence of disease progression or unacceptable toxicity.
88999743|NCT01539811|Active Comparator|Short course antibiotics|Surgical intervention followed by short course of antibiotics (<2 weeks)
88999744|NCT01539811|Active Comparator|Long course antibiotics|Surgical intervention followed by a long course of antibiotics (>2 weeks)
89355728|NCT02515240|Active Comparator|newly diagnosed HIV <200 delayed|Newly diagnosed HIV positive patients with CD4 count <200 delayed immunization with one shot of PPV23 vaccine, treated for 6-12 months with Highly Active Anti-Retroviral Therapy (HAART) first.
89355729|NCT02515240|Active Comparator|HAART experienced HIV>200|HIV positive, on HAART treatment for 5 years, nadir CD4 count <200, but at present CD4 count is >200, immunized with one shot of PPV23 vaccine.
89355730|NCT02515240|Active Comparator|HAART experienced HIV<200|HIVpositive, on HAART treatment for 5 years, nadir CD4 count <200, and at present CD4 count is <200, immunized with one shot of PPV23 vaccine.
89355731|NCT03727009||Hematologic Malignancy|Subjects with clinically confirmed hematologic malignancy and who are treatment naive will provide a blood sample at the time of enrollment. No additional blood draws will occur.
88999745|NCT01527136|Experimental|Treatment (entolimod)|Patients receive entolimod IM or SC on days 1, 4, 8, and 11. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity.
89177046|NCT02603679|Experimental|B: Aromatase Inhibitor + Palbociclib|Postmenopausal women receive an aromatase inhibitor together with palbociclib 125 mg orally days 1-21, followed by a 7-days rest period, repeated twice during a 12-week period. Thereafter, treatment is switched to weekly paclitaxel 80mg/m2, eventually dose-adjusted in relation to side effects, for further 12 weeks.
89177047|NCT02603679|Experimental|B: Goserelin + Aromatase Inhibitor + Palbociclib|Pre- or perimenopausal women may be treated with goserelin and an aromatase inhibitor together with palbociclib 125 mg orally days 1-21, followed by a 7-days rest period, repeated twice during a 12-week period. Thereafter, treatment is switched to weekly paclitaxel 80mg/m2, eventually dose-adjusted in relation to side effects, for further 12 weeks.
89177048|NCT03995485|Experimental|KW-136+SOF|Treatment-naive and experienced subjects were medicated with KW-136 capsules 60 mg once daily and fixed-dose (400 mg once daily) sofosbuvir tablets for 12 successive weeks.
89177049|NCT02605434|Experimental|AP-CD/LD|Accordion Pill™ Carbidopa/Levodopa Capsule 50/400mg , b.i.d or t.i.d or Accordion Pill™ Carbidopa/Levodopa Capsule 50/500mg , b.i.d or t.i.d and Placebo IR Carbidopa/ levodopa
89177050|NCT02605434|Active Comparator|SINEMET®|IR Carbidopa/ levodopa tablets 25/100 mg at least 4 times a day and placebo AP-CD/LD
89355732|NCT03843515|Experimental|Neoadjuvant nivolumab|All subject will receive 400mg flat dose nivolumab in the neoadjuvant setting
89355733|NCT02515318|Experimental|Physiotherapy program|Patients with COPD are included in this group. They will receive a physiotherapy program during the hospitalization due to acute exacerbation of COPD, additionally to the standard medical treatment
89355734|NCT02515318|Active Comparator|Control group|Patients with COPD are included in this group. They will receive the medical standard treatment during the hospitalization due to acute exacerbation of COPD.
89399086|NCT03698799||LPV|Patients receive LPV strategy at the initiation of MV support. The LPV strategy is defined as ventilation with tidal volume of <8 mL/kg of PBW plus applying PEEP of at least 5 cm H2O.
89177051|NCT05758298|Placebo Comparator|Non-medicated gum Arm|Participants in this group will receive the non-medicated gum in mint flavor.
89177052|NCT05758298|Experimental|Nicotine 2mg gum Arm|Participants in this group will receive the 2mg Nicotine gum in mint flavor.
89177053|NCT05758298|Experimental|Nicotine 4mg gum Arm|Participants in this group will receive the 4mg Nicotine gum in mint flavor.
89177054|NCT00789321|Experimental|1|amlodipine
89399087|NCT03698799||Non-LPV|Patients do not receive LPV strategy at the initiation of MV support.
89399088|NCT02171468|Experimental|Dabigatran high dose|
89399089|NCT02171468|Experimental|Dabigatran low dose|
88823411|NCT02234180|Experimental|Arm I (regorafenib)|Within 6-12 weeks after surgery, patients receive regorafenib PO QD on days 1-21. Courses repeat every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
88823412|NCT02234180|Placebo Comparator|Arm II (placebo)|Within 6-12 weeks after surgery, patients receive placebo PO QD on days 1-21. Courses repeat every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
88823413|NCT03177603|Experimental|GSK2586881 - 0.1 mg/kg|Eligible subjects will receive a single dose of 0.1 mg/kg GSK2586881. Dose escalation up to maximum dose of 0.8 mg/kg will occur after 4 subjects have been dosed per cohort and review of safety, tolerability, PK and hemodynamic data up to 24 hours post dose has taken place.
88823414|NCT03177603|Experimental|GSK2586881 - 0.2 mg/kg|Eligible subjects will receive a single dose 0.2 mg/kg of GSK2586881 IV infusion. Dose escalation up to maximum dose of 0.8 mg/kg will occur after 4 subjects have been dosed per cohort and review of safety, tolerability, PK and hemodynamic data up to 24 hours post dose has taken place.
88823415|NCT03177603|Experimental|GSK2586881 - 0.4 mg/kg|Eligible subjects will receive a single dose of 0.4 mg/kg of GSK2586881 IV infusion. Dose escalation up to maximum dose of 0.8 mg/kg will occur after 4 subjects have been dosed per cohort and review of safety, tolerability, PK and hemodynamic data up to 24 hours post dose has taken place.
88823416|NCT03177603|Experimental|GSK2586881 - 0.8 mg/kg|Eligible subjects will receive single dose of 0.8 mg/kg of GSK2586881 IV infusion. Dose escalation will occur after 4 subjects have been dosed per cohort and review of safety, tolerability, PK and hemodynamic data up to 24 hours post dose has taken place.
88823417|NCT03717207||type 2 diabetes mellitus (T2DM) patients under SGLT2-I therapy (SGLT2-I users)|"T2DM patients affected by vaso vagal syncope, and under SGLT2-I therapy. All these patients were in stable sinus rate before performing the HUT They performed a 24 hours ECG Holter to assess sinus rhythm, HR, HRV, and the MIBG myocardial scintigraphy before receiving a HUT.~."
88823418|NCT03717207||type 2 diabetes mellitus (T2DM) patients without SGLT2-I therapy (Non-SGLT2-I users)|T2DM patients affected by vaso vagal syncope, and without SGLT2-I therapy. All these patients were in stable sinus rate before performing the HUT They performed a 24 hours ECG Holter to assess sinus rhythm, HR, HRV, and the MIBG myocardial scintigraphy before receiving a HUT.
88823419|NCT02234570|Experimental|Group 1|N=8 subjects receive single oral dose 0.5mg/kg of oxfendazole; N= 2 subjects receive single oral dose placebo
88823420|NCT02234570|Experimental|Group 2|N=8 subjects receive single oral dose 1mg/kg of oxfendazole; N=2 subjects receive single oral dose placebo
88823421|NCT02234570|Experimental|Group 3|N=8 subjects receive single oral dose 3mg/kg of oxfendazole; N= 2 subjects receive single oral dose placebo
88823422|NCT02234570|Experimental|Group 4|N=8 subjects receive single oral dose 7.5mg/kg of oxfendazole; N=2 subjects receive single oral dose placebo
88823423|NCT02234570|Experimental|Group 5|N=8 subjects receive single oral dose 15mg/kg of oxfendazole; N= 2 subjects receive single oral dose placebo
88823424|NCT02234570|Experimental|Group 6|N=8 subjects receive single oral dose 30mg/kg of oxfendazole; N=2 subjects receive single oral dose placebo
88823425|NCT02234570|Experimental|Group 7|N=8 subjects receive single oral dose 60mg/kg of oxfendazole; N=2 subjects receive single oral dose placebo
88823426|NCT03693105|Active Comparator|Dorsolateral prefrontal cortex|The accelerated theta burst stimulation protocol will be applied to the left dorsolateral prefrontal cortex (DLPFC)
88823427|NCT03693105|Sham Comparator|Sham stimulation|Sham (non-active) stimulation will be applied to the left dorsolateral prefrontal cortex (DLPFC) region
88823428|NCT03681249|Experimental|ShenqiDihuang Decoction|ShenqiDihuang Decoction 150ml by mouth, twice a day for 24 weeks
88823429|NCT03681249|Placebo Comparator|ShenqiDihuang Decoction placebo|ShenqiDihuang Decoction placebo 150ml by mouth, twice a day for 24 weeks
88823430|NCT04525599|Experimental|Group 1, ASP3772 Low Dose|Participants will receive a single intramuscular injection of ASP3772 administered on Day 1 at a low-dose level.
88823431|NCT04525599|Active Comparator|Group 1, PCV13 Comparator|Participants will receive a single intramuscular injection of the approved dose of PCV13 on Day 1.
88823432|NCT04525599|Experimental|Group 2, ASP3772 Medium Dose|Participants will receive a single intramuscular injection of ASP3772 administered on Day 1 at a medium-dose level.
88823433|NCT04525599|Active Comparator|Group 2, PCV13 Comparator|Participants will receive a single intramuscular injection of the approved dose of PCV13 on Day 1.
88823434|NCT04525599|Experimental|Group 3, ASP3772 High Dose|Participants will receive a single intramuscular injection of ASP3772 administered on Day 1 at a high-dose level.
89355735|NCT03776201|Experimental|Internal Focus|"The internal focus group will receive 20 minutes of balance training 2 times per week. All training sessions will include a 5-minute walking warm-up, a 20-minute balance training program, and a 5-minute walking cool-down. The balance training will use a 30 wobble board with five bases ranging from 1 (easy) to 3 (very difficult). 20 trials of balance practice for 30-second intervals with 30-second breaks in between trials will be used every day. The Internal Focus group will be reminded to focus their attention internally via the prompt keep your feet as level as possible prior to each balance trial. To monitor whether the experimental groups are focusing as asked and to what extent, a compliance check that has been used in similar attentional focus literature will be used."
88823435|NCT04525599|Active Comparator|Group 3, PCV13 Comparator|Participants will receive a single intramuscular injection of the approved dose of PCV13 on Day 1.
88823436|NCT02240030|Experimental|CVT-301 Low Dose|Capsules of levodopa inhalational powder used up to 5 times/day for OFF episodes for 3 months duration
88823437|NCT02240030|Experimental|CVT-301 High Dose|Capsules of levodopa inhalational powder used up to 5 times/day for OFF episodes for 3 months duration
88823438|NCT02240030|Placebo Comparator|Placebo|Capsules of inhalation-grade lactose used up to 5 times/day for OFF episodes for 3 months duration.
88823439|NCT03543111|Experimental|Zest|Zest is an internet-based psychological health enhancement program for women with spinal cord injury. The intervention will occur in Second Life (SL), which is an online virtual word simulator with a group of women with spinal cord injury.The Zest program will consist of 10 weekly 2-hour group sessions with approximately 8 women using avatars to represent themselves.
88823440|NCT03543111|No Intervention|Control|No intervention - Control participants are provided intervention materials at the end of the study.
89177055|NCT00789321|Placebo Comparator|2|Placebo to amlodipine
89355736|NCT03776201|Experimental|External Focus|"The external focus group will receive 20 minutes of balance training 2 times per week. All training sessions will include a 5-minute walking warm-up, a 20-minute balance training program, and a 5-minute walking cool-down. The balance training will use a 30 wobble board with five bases ranging from 1 (easy) to 3 (very difficult). 20 trials of balance practice for 30-second intervals with 30-second breaks in between trials will be used every day. The external focus group will be reminded to focus their attention externally via the prompt please keep the board as level as possible prior to each balance trial. To monitor whether the experimental groups are focusing as asked and to what extent, a compliance check that has been used in similar attentional focus literature will be used."
89355737|NCT03776201|No Intervention|Control|The control group will not receive any balance training
89355738|NCT00245960|Active Comparator|A|Period 1 (Double Blind): 50mg bi-weekly (BIW) for weeks 1-12. Period 2 (Open Label): 50 mg weekly (QW).
89355739|NCT00245960|Active Comparator|B|Period 1 (Double Blind): 50mg weekly (QW) with matching placebo for weeks 1-12. Period 2 (Open Label): 50 mg weekly (QW) for weeks 13-24.
89355740|NCT04443322|Experimental|Durvalumab and Lenvatinib|"Participants receive intravenous (IV) durvalumab at 1500mg on Day 1 of each 28-day cycle. Number of cycles: until unacceptable toxicity develops or >42 days before liver transplantation (If patients with locally advanced HCC would undergo liver transplant).~Patients receive Lenvatinib 8-12mg(basing on weight), once a day, oral at least 38 days of each 6 weeks cycle until >7 days before liver transplantation(If patients with locally advanced HCC would undergo liver transplant)."
89355741|NCT01202825|Experimental|001|
89355742|NCT01202825|Placebo Comparator|008|
89177056|NCT02603367|Experimental|Supportive care (COMFORT communication intervention)|"Participants receive the printed communication tool A Communication Guide for Caregivers, a guide developed from the COMFORT communication curriculum, a national training program for palliative care communication. After a 1 week period to review the material, participants undergo communication coaching with a research nurse by phone over approximately 1 hour."
89177057|NCT04105959|Experimental|RIST4721 300mg|RIST4721 as once-daily 300mg oral solution for 6 days with a placebo crossover.
89177058|NCT04105959|Experimental|RIST4721 150mg|RIST4721 as once-daily 150mg oral solution for 6 days with a placebo crossover.
89355743|NCT01202825|Placebo Comparator|002|
88999746|NCT05331586|No Intervention|control intervention|The control group will receive the standard prenatal care in Hospital Center of São Joao (CHUSJ). The standard prenatal care will be regular appointments with obstetrician and midwife nurses, ultrasounds and nutritional appointments. The pregnant women in control group will also receive a pamphlet with the benefits of physical exercise during pregnancy and recommendations for adequate gestational weight gain. Pregnant women in control group will not be discouraged from exercising on their own.
89355744|NCT01202825|Experimental|009|
89355745|NCT01202825|Experimental|003|
89355746|NCT01202825|Placebo Comparator|004|
89355747|NCT01202825|Experimental|005|
89355748|NCT01202825|Experimental|010|
89355749|NCT01202825|Placebo Comparator|006|
89355750|NCT01202825|Experimental|007|
89355751|NCT02515162|Experimental|Fischer Cone Biopsy Excisor|Conization Methode using a triangular electrode , i.e. Fischer Cone Biopsy Excisor
89355752|NCT02515162|Active Comparator|Loop Excision Procedure|Conization Methode using a circular electrode , i.e. Loop excision Procedure
89355753|NCT03843203|Sham Comparator|s-tDCS|- Intervention: 'Transcranial Direct Current Stimulation - tDCS The patients will receive tDCS sham treatment. The patients will receive sham tDCS treatment over primary motor cortex. According to 10-20 EEG system, anode will be placed at left C3 and cathode at o contralateral F3. In sham stimulation the device only release flow current, in the first 30 s of session and in the remaining 30s in the end of the session, during 20 minutes.
89355754|NCT03843203|Active Comparator|M1 a-tDCS|"Intervention: 'Transcranial Direct Current Stimulation - tDCS~The patients will receive tDCS active treatment over primary motor cortex.~According to 10-20 EEG system, anode will be placed at left C3 and cathode at contralateral supraorbital Fp2.~Active stimulation uses a 2 milliamperes current during 20 minutes."
89399090|NCT03502031|Active Comparator|RAAS alone|RAAS (Lisinopril, Enalapril, Perindopril, Losartan, and Valsartan taken each day at maximum tolerated dose that will different for each subject)
88999747|NCT05331586|Experimental|Exercise intervention|The exercise group intervention will perform home-based remotely monitored exercise
88999748|NCT05331430|Experimental|Experimental group 1: Dry needling on cervical trigger point|Dry needling of the trigger point of the upper fibres of the trapezius muscle. Using the Hong technique.
88999749|NCT05331430|Experimental|Experimental group 2: Trapezius muscle stretch|Manual passive stretching of the upper trapezius muscle fibres.
88999750|NCT05331430|No Intervention|Control group: Informative talks|Informative talks on breathing techniques, relaxation techniques and posture hygiene.
88999751|NCT01330030|Experimental|Drug Selegiline|6 mg selegiline patch (transdermal) worn for 24 hours for 8 weeks
88999752|NCT01330030|Placebo Comparator|Matching placebo|matching placebo worn 24 hours for 8 weeks
88999753|NCT00179634|No Intervention|1|Usual Care
88999754|NCT00179634|Experimental|2|Usual care and exposure to a visually enriched milieu (landscape photograph)
88999755|NCT00179634|Experimental|3|Usual care, exposure to a visually enriched milieu and audio taped guided visualization with healing suggestions.
88999756|NCT01280032|Experimental|Kypho-IORT|
88999757|NCT01196299||Severe Traumatic Brain Injury Group|The severe traumatic brain injury group are patients admitted to the study with an admission GCS between 3 and 8.
88999758|NCT01196299||Moderate Head Injury Group|The moderate head injury group are patients admitted to the study with an admission GCS from 9 to 12.
88999759|NCT01196299||Mild Head Injury Group|The mild head injury group are patients admitted to the study with an admission GCS from 13 to 15.
88999760|NCT01196299||Healthy Volunteer Group|Healthy volunteers will be selected to match the age distribution of the TBI groups. They must be absent of any abnormal radiological findings.
88999761|NCT00171509|Active Comparator|BID cyclosporine|control group continuing with a BID administration of cyclosporine and C2 monitoring.
88999762|NCT00171509|Experimental|OAD cyclosporine|conversion to OAD administration of cyclosporine with the same daily dose as received prior to conversion
88999763|NCT00171509|Experimental|OAD cyclosporine reduced|OAD administration of cyclosporine with a daily dose adjusted to a reduced C2
88999764|NCT00941356|Experimental|1|Bio-K+ CL1285 contains 50 billion of live bacteria
88999765|NCT00941356|Placebo Comparator|2|placebo devoid of bacteria
88999766|NCT05309512|Experimental|KN052 single drug group|The 8 dose groups in the dose increasing period were intravenous administration of 0.01mg/kg, 0.1mg/kg, 0.3mg/kg, 1mg/kg, 2mg/kg, 4mg/kg, 6mg/kg and 9mg/kg every two weeks, respectively. Based on the selected maximum tolerated dose of Q2W and in combination with the pharmacokinetic model, the sponsor would consider adding 1-2 Q3W treatment groups, with 6-12 patients in each dose group for DLT observation to explore the optimal dose regimen. The queue extension period is dose RP2D; Give it intravenously every two weeks or three weeks.
88999767|NCT00611572|Active Comparator|1|Active iomazenil and ketamine
88823441|NCT01663922|Experimental|St John's Wort, then Boceprevir|D 1-14 St. John's Wort 2 x 300mg (Ucalm(r)) QD D 22-35 St. John's Wort 2 x 300mg (Ucalm(r)) QD D 31-35 Boceprevir 800mg tds D 52-56 Boceprevir 800mg tds
88999768|NCT00611572|Placebo Comparator|2|placebo iomazenil and ketamine
88999769|NCT05261893|Experimental|Elongation Longitudinaux Avec Decoaption Osteo Articulaire|"In this we will use myofascial stretching Elongation Longitudinaux Avec Decoaption Osteo Articulaire for knee osteoarthritis. Each patient perform half kneeling posture with homolateral foot and knee in alignment with hip while knee flex to 90° and retrovulsion of the pelvis. Chin tucked in and head towards ceiling. Patient elbow and wrist in extension and arms in external rotation. In this homolateral arm directed anteriorly and pushing arm away from body and contralateral arm directed superiorly and tibia externally rotated.~This position maintained for 1 minute with 15 secs rest. This group will receive 40 mins of session."
88999770|NCT05261893|Experimental|Post Facilitation Stretching|"This group will receive post facilitation stretching technique. In this all the major muscles of the lower limb (quadriceps, hamstrings ,upper and lower calf muscles) are stretched .And the physiotherapist instruct the patient how to perform stretch . When we target a muscle and perform stretch patient feels sensation of stretch .~The stretch was hold on to 60 secs and repeated 3 times on each muscle group on each leg."
88999771|NCT05261854|Experimental|Deep cervical muscle training using pressure biofeedback and conventional Exercises|"The duration of preesure biofeedback includes 3 sets in a session with 10 repetitions each with 2 minutes of rest between sets and 5 days a week for 6 weeks.~Conventional exercises like Stretching and strengthening of neck flexor muscles will include 10 repetitions, each held for 10s with rest of 2 minutes between sets. The session will be conducted for 6 weeks, 5 days a week."
88999772|NCT05261854|Experimental|conventional exercises for Neck pain|Only conventional exercises like stretching and strengthening of neck flexor muscles will be given.
88999773|NCT04723290|Experimental|Serological tests|All staff at GHdC who want to know their level of antibodies against SARS CoV-2
88999774|NCT05261815|Experimental|Ultrasound therapy|"Continuous ultrasound therapy for 15 minutes~Traction for 30 minutes~Spinal decompression exercises for 20 min"
88999775|NCT05261815|Experimental|High Intensity Laser Therapy|"High intensity laser for 10 minutes~Traction for 30 minutes~Spinal decompression exercises for 20 min"
88999776|NCT05259358|Active Comparator|exercise|"In addition to routine treatment:~Postural evenness~Chin tuck exercise~Range of motion exercises for all angles of the cervical joint~Neck isometric exercises~Cervical stabilization exercises (with ball)~Stretching exercises of pectoralis, latissimus dorsi, trapezius upper part, levator scapula, rhomboid and scalene muscles"
88999777|NCT05259358|No Intervention|routine|only routine treatment
88999778|NCT04710459|Active Comparator|Group 1|it included 30 patients, they were subjected to chemoradiotherapy plus endobronchial cryotherapy.
88999779|NCT04710459|No Intervention|Group 2|it included include 30 patients, they were subjected to chemoradiotherapy.
88999780|NCT02417701|Experimental|Treatment (sapanisertib)|Patients receive sapanisertib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88999781|NCT04723745||VTRACTS|We will target post-9/11 Veterans with TBI or blast exposure who self-report ongoing post-concussive neurobehavioral symptoms, but V-TRACTS will be open to all post-9/11 Veterans irrespective of any diagnoses.
88999782|NCT05101369|Experimental|INCB086550|Participants will be administered INCB086550 orally, followed approximately 10 minutes later by an oral dose solution of radio labeled INCB086550.
89355755|NCT03843203|Active Comparator|DLPFC a-tDCS|"Intervention: 'Transcranial Direct Current Stimulation - tDCS~The patients will receive tDCS active treatment over dorsolateral prefrontal cortex.~According to 10-20 EEG system, anode will be placed at left F3 and cathode at contralateral F4.~Active stimulation uses a 2 milliamperes current during 20 minutes."
89355756|NCT03725215|Experimental|Split-Belt Treadmill Training 1:2|Split-Belt Training with a steady ratio of 1:2.
88999783|NCT00171821|Experimental|ICL670 (Deferasirox)|
88999784|NCT05070442|No Intervention|Control Arm (Arm 1)|Participants will experience an unmodified version of NUSMart which replicates the traditional shopping experience of online grocery stores.
89355757|NCT03725215|Experimental|Split-Belt Treadmill Training 3:4|Split-Belt Training with a steady ratio of 3:4.
88999785|NCT05070442|Experimental|Norms Arm (Arm 2)|Participants will experience a modified version of NUSMart with norm-based messaging and peer comparison features enabled. Nutri-Score labels will be enabled and displayed on all products within the store. A floating side panel will provide a visual indicator of the participants' average weighted Nutri-Score.
88999786|NCT05070442|Experimental|Norms and Incentive Arm (Arm 3)|Same as Arm 2, except participants are notified that they have been awarded an additional $5 towards their participation reimbursement. However, this additional $5 will be forfeited if their basket average weighted Nutri-Score falls below the average of their peers'. (Financial incentive leveraging on loss aversion).
88999787|NCT05054023|Active Comparator|Piroxicam gel|50g tubes that contained 0.5% piroxicam. the gel was gently massaged in the injured site for 1 minute, 3 times a day for 7 days.
88999788|NCT05054023|Active Comparator|Soulagel®; Belpharma Tunisia|50 ml tubes that contained rosemary essential oil (Romarinus offienalus), mint essential oil, clove essential oil (Eugenda caryophyllus), harpgophytum natural extract (Harpagophytum procumbens), meadowsweet natural extract (Filipendula ulmaria), aqua, methyl salicylate, menthol, camphre, carbomer, triethanolamine, polysorbate-20, sodium polyacrylate, trideceth-6, methylchloroisothiazolinone, methylisothiazolinone , magnesim Chloride and magnesium nitrate. the gel was gently massaged in the injured site for 1 minute, 3 times a day for 7 days.
88999789|NCT00171860|Experimental|STI571|
88999790|NCT00553930|Experimental|G 2/3|Patients with chronic hepatitis or compensated cirrhosis by hepatitis C virus, genotypes 2 or 3, and HIV-coinfected.
88999791|NCT00171899|Experimental|STI571|
88999792|NCT05003050|Experimental|Meditation Based Group|8 sessions weekly for 8 weeks Each session for 1hour Sessions on line (virtual) Self-care tools and techniques, mindfulness and meditation
88999793|NCT05003050|Experimental|Energy Therapy (Pranic Healing)|8 Sessions Weekly sessions for 8 weeks Each session 1 hour Pranic Healing (Energy Therapy)
88999794|NCT05003050|No Intervention|Stanrd of Care Group|Routine medical care and appointments
88999795|NCT02351947|Experimental|persons with chronic stroke|upper limb rehabilitation for chronic stroke
88999796|NCT02351947|No Intervention|Healthy, age matched control group|Healthy aged match control group undergoing MRI/EEG testing
88999797|NCT00171977|Experimental|Imatinib Mesylate|400 mg once per day
88999798|NCT04679662|Experimental|Single-arm study of PLAR Implant and Delivery System to treat severe mitral regurgitation|All enrolled patients will receive the study device
89355758|NCT03725215|Experimental|Split-Belt Treadmill Training Changing|Split-Belt Training with changing ratios between 3:4 to 1:2.
89355759|NCT03725215|Active Comparator|Split-Belt Treadmill Training Tied-Belt|Split-Belt Training with tied belts.
89355760|NCT02510872|Experimental|18F-FDG PET combined with CT with iodinated contrast injection|18F-FDG PET combined with CT with iodinated contrast injection
89355761|NCT02510872|Sham Comparator|18F-FDG PET combined with CT without injection|18F-FDG PET combined with CT without injection
88999799|NCT04679545|Experimental|CBD|Subject will receive a 28-day supply of 20 mg CBD sublingual tablets to be taken 3 times a day for 28 days.
88999800|NCT04679545|Placebo Comparator|Placebo Control|A placebo sublingual tablet to be taken three times a day for 28 days.
88999801|NCT04679701||Recruited Amputees|The amputee participants will be recruited over the course of 6 months. Once a patient is recruited and has given consent, they will be fitted with a prosthesis using the Confidence Socket technology and be administered an initial survey. A follow-up meeting for one month after the fitting is scheduled. At the follow-up appointment adjustments to the prosthesis are made as needed and the patient is administered another survey.
89177059|NCT04126421|Active Comparator|E1 Vitamin E infused HXLPE|E1 Vitamin E infused highly cross-linked polyethylene (HXLPE)
89177060|NCT04126421|Active Comparator|Marathon HXLPE|Marathon highly cross-linked polyethylene (HXLPE)
89177061|NCT02614625||Normal subjects|Patient with healthy, normal eyes
89355762|NCT05222204|Experimental|IP|intravenous AG+ IP cisplatin
89355763|NCT02515006|Experimental|Homeopathy|Individualized homeopathy treatment as a supportive care
89355764|NCT02515006|No Intervention|Control|Usual Care
89355765|NCT02558465||Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxavban administration group
89355766|NCT02515084|Experimental|18F-FDG-PET and dw-MRI|At the inclusion, both all patients, a 18F-FDG-PET/CT and a dw-MRI will be performed
89355767|NCT03834467|Experimental|Arm 1 - Elevation Stimulus Video|All subjects complete the Levenson Psychopathy Scale first. Arm 1 then presents the Moral Elevation stimulus video after playing the first AlAn's Short Game v.2 (session 1). Participants will then play the AlAn's Short Game v.2 (session 2) for a second time and then fill out an Adverse Childhood Experiences Questionnaire (ACES), Social Connectedness survey, and Demographics form.
89355768|NCT03834467|Sham Comparator|Arm 2 - Control Stimulus Video|All subjects complete the Levenson Psychopathy Scale first. Arm 2 then presents the control stimulus (nature video) after playing the first AlAn's Short Game v.2 (session 1). Participants will then play the AlAn's Short Game v.2 (session 2) for a second time and then fill out an Adverse Childhood Experiences Questionnaire (ACES), Social Connectedness survey, and Demographics form.
88999802|NCT02240407|Experimental|rAAV9-DES-hGAA vector|Each subject will receive Rituxan and Rapamycin prior to the initial exposure to the study agent in one leg and the subsequent exposure of the same vector to the contralateral leg after four months. Diphenhydramine and acetaminophen will be provided before each Rituxan dose. Immune Globulin will be administered to each subject every other month after first exposure to Rituxan and as clinical necessary. Lidocaine will be administered through percutaneous infiltration before injection of the study agent. Side of administration will be randomized at first Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase injection.
89355769|NCT03840785|Experimental|interventional group A|2 tango session per week during 6 month (M0 to M6)
89355770|NCT03840785|Placebo Comparator|Control group B|2 tango session per week during 3 month (M3 to M6)
89177062|NCT02614625||Eyes with corneal disease|"Subjects that have any of the following conditions~Corneal dystrophy or degeneration~Corneal scarring~Corneal ulcer~Corneal injury~Keratoconus~Patients who had undergone corneal surgery~Patients with other corneal disease"
89355771|NCT04825184|Experimental|Body image chatbot|The artificial intelligence chatbot, Topity, is designed to target sociocultural risk and protective factors for body image using eight therapeutic techniques derived from several evidence-based theories, including media literacy, cognitive behaviour theory and positive body image. The intervention aims to engage users in techniques that teaches users how to 1) Critically analyse and evaluate media content to reduce vulnerability to negative media influences (i.e., media literacy theory; 10); 2) Identify and challenge unhelpful thinking styles and behaviours that perpetuate body image distress (i.e., cognitive behaviour theory; 11); and 3) Appreciating the features, functions and health of the body, beyond it's appearance (i.e., positive body image theory; 12). Users will be assessed on state body satisfaction and affect before and after engaging with a technique to assess the immediate impact of the micro-intervention.
89355772|NCT04825184|No Intervention|Assessment only|The comparison control condition will be assessment only. This is informed by a care as usual framework; whereby, Brazilian adolescents are not currently offered online body image prevention or intervention resources at school or within the community.
88823442|NCT01663922|Experimental|Boceprevir, then St John's Wort|D 10-14 Boceprevir 800mg tds D 22-35 St. John's Wort 2 x 300mg (Ucalm(r)) QD D 31-35 Boceprevir 800mg tds D 43-56 St. John's Wort 2 x 300mg (Ucalm(r)) QD
88823443|NCT03180489|Experimental|Dapagliflozin with dietary counseling|Daily oral administration of dapagliflozin tablet with dietary counseling to promote weight loss.
88823444|NCT03180489|Placebo Comparator|Placebo with dietary counseling|Daily oral administration of placebo tablet with dietary counseling to promote weight loss.
88823445|NCT02240186|Experimental|Prosthetic knee joints|Each subject will be tested using their current Non-Microprocessor Knee (NMPK) , fit and tested with a Microprocessor Knee (MPK), and then tested again with their NMPK, e.g. A-B-A design.
88823446|NCT05709236|Experimental|Completely edentulous maxillary arch digital impression|treated with Maxillary screw-retained prosthesis with digital full-arch impression
88823447|NCT05709236|Active Comparator|Completely edentulous maxillary arch conventional impression|treated with Maxillary screw-retained prosthesis with conventional full-arch impression
88823448|NCT04360239|Experimental|Fish Oil|Fish-Oil naïve subjects will be started on fish oil 4 weeks prior to surgery and continued until the 6 week follow up. Subjects already taking fish oil will be switched to the study fish-oil formulation of two capsules twice daily (3000 mg of EPA and DHA).
89355773|NCT02729194|Experimental|Pazopanib|Registered subjects will take pazopanib by mouth with a low-fat meal (containing less than 400 calories and less than 10% fat or 10 grams per meal) approximately, some sample meals are described in appendix 1) every day in 14 day cycles, with a starting dose of 400 mg and adjusted for the next cycle (dose level +1:600 mg; dose level +2: 800 mg; dose level -1: 200 mg) based on toxicity assessment during or at the end of each cycle.
88823449|NCT04360239|No Intervention|Control|No fish oil supplementation
88823450|NCT01664858|Active Comparator|3T CMR-guided management|Patient to be managed according to the results of 3T CMR imaging
88823451|NCT01664858|Active Comparator|SPECT-guided management|Patients to be managed according to the results of SPECT
88823452|NCT01664858|Active Comparator|NICE-guidelines based management|"Patients will be receive NICE-guidelines based management and will receive the imaging strategy specified by NICE according to their pre-test likelihood of having CHD.~10-29% - CT calcium score +/- CT coronary angiography; 30-60% - SPECT; 61-90% - X-Ray coronary angiography"
88823453|NCT01665092|Placebo Comparator|Control|Normal saline
88823454|NCT01665092|Experimental|Carnitine Low|Levo-Carnitine 6g
88823455|NCT01665092|Experimental|Carnitine Medium|Levo-Carnitine 12 g
88823456|NCT01665092|Experimental|Carnitine High|Levo-Carnitine 18 g
88823457|NCT04348695|Experimental|Ruxolitinib plus simvastatin|"Ruxolitinib 5 mg orally every 12 hours for 7 days, which will be increased to 10 mg every 12 hours for a total of 14 days.~Simvastatin 40 mg orally every 24 hours for 14 days."
88823458|NCT04348695|Other|Standard of Care|Patients will receive treatment according to usual clinical practice in the participant site.
88823459|NCT04344561|Experimental|Postural Positioning|Participants in the group will have hospital beds placed in 15 degree (reverse Trendelenburg).
88823460|NCT04344561|No Intervention|Standard Care|Participants in this group will have beds managed per standard nursing protocol.
89355774|NCT05218616|Other|Sequence TR|
88823461|NCT05709158||Case: G4 neutropenia occurs after palbociclib initiation|Grade 4 neutropenia occurs after initiation of palbociclib Note that: Case patients are categorized as control before incurring grade 4 neutropenia
88823462|NCT05709158||Control: G4 neutropenia does not occur after palbociclib initiation|Grade 4 neutropenia does not occur after initiation of palbociclib
88823463|NCT04316871|Placebo Comparator|Group D|where patients will receive epidural 15 ml of Marcaine 25% and and epinephrine 1:200,000.
88823464|NCT04316871|Active Comparator|Group A|where patients will receive epidural 15 ml volume of 1.5 mg morphine sulphate (MS), Marcaine 25% and and epinephrine 1:200,000.
88823465|NCT04316871|Active Comparator|Group B|where patients will receive epidural 15 ml volume of 3 mg morphine sulphate (MS), Marcaine 25% and and epinephrine 1:200,000.
88823466|NCT04316871|Active Comparator|Group C|where patients will receive epidural 15 ml volume of 4.5 mg morphine sulphate (MS), Marcaine 25% and and epinephrine 1:200,000.
88823467|NCT02663063|Experimental|SSP treatment group|Case on SSP treatment
88823468|NCT02663063|Sham Comparator|Non-SSP treatment group|Sham SSP treatment
88823469|NCT01665170|Placebo Comparator|Placebo|Placebo arm
88823470|NCT01665170|Active Comparator|Verum|Verum arm - Pascoflair 425mg
89355775|NCT05218616|Other|Sequence RT|
89355776|NCT01204541||AMD|
89355777|NCT01204541||Young normals|
89355778|NCT01204541||Older normals|
89355779|NCT02505880|Active Comparator|1: General anesthesia|General anesthesia
89355780|NCT02505880|Experimental|2: Hypnosis|Hypnosis with local anesthesia
89355781|NCT03840629||Hypotonic fluid maintenance|exclusive administration of 0.33% saline mixed with potassium and dextrose 5%
89355782|NCT03840629||Isotonic fluid maintenance|exclusive administration of 0.9% saline
89355783|NCT05218304|No Intervention|Sample|questionnaires physical measurements (height, weight, perimeter abdominal and blood pressure)
89355784|NCT05218304|Experimental|Sub-sample - blood test|questionnaires physical measurements (height, weight, perimeter abdominal and blood pressure) Blood samples
89355785|NCT02505490|Experimental|No Television|The purpose is to determine whether a change in liking of food will occur with a lack of television.
89355786|NCT02505490|Experimental|Television|The purpose is to determine whether a change in liking of food will occur while watching television.
88823471|NCT01665872|Experimental|Cognitive-Behavioral Group Therapy|8-session Cognitive-Behavioral intervention based on Munoz et al's Mother Baby Manual, modified to meet the needs of mothers of children of all ages residing in public housing in New Haven, CT. Intervention co-facilitated by mental health clinician and a Community Mental Health Ambassador (peer).
88823472|NCT01665872|Active Comparator|Standard of care - Cognitive-Behavioral Group Therapy|8-session Cognitive-Behavioral intervention based on Munoz et al's Mother Baby Manual, modified to meet the needs of mothers of children of all ages residing in public housing in New Haven, CT. Intervention administered by mental health clinician.
88823473|NCT05364567|Experimental|Study group|They were treated with phototherapy including 308-nm excimer laser or narrowband ultraviolet B (NB-UVB). They had vitamin D supplementation through the injection of cholecalciferol additionally. The study group with vitamin D deficiency was treated with intramuscular injection of 200,000 IU cholecalciferol (Kwangdong Pharmaceutical Co., Seoul, Korea) once at baseline. Total study period was 6 months and the clinical assessments with checking adverse events were conducted every month.
88823474|NCT05364567|Active Comparator|Control group|They were treated with phototherapy including 308-nm excimer laser or narrowband ultraviolet B (NB-UVB). Total study period was 6 months and the clinical assessments with checking adverse events were conducted every month.
88823475|NCT02298491|Experimental|H.P. Acthar Gel|
88823476|NCT03325647|Experimental|Visit 1 Drug, Visit 2 Placebo|Subjects in this group will be randomized to receive Testosterone Cypionate 200 Milligram/Milliliter Injectable Solution every 4 weeks x 3 doses, beginning at visit 1, and Placebo Injectable Saline beginning at visit 2.
88823477|NCT03325647|Experimental|Visit 1 Placebo, Visit 2 Drug|Subjects in this group will be randomized to receive Placebo Injectable Saline beginning at visit 1, and Testosterone Cypionate 200 Milligram/Milliliter Injectable Solution every 4 weeks x 3 doses beginning at visit 2.
88823478|NCT01665950|Experimental|Simvastatin-Simvastatin|Subjects will receive simvastatin in phase 1 (4 weeks) and phase 2 (4 weeks)
88823479|NCT01665950|Experimental|Placebo->Simvastatin|Placebo non-responders after the 1st 4 weeks will be re-randomized 1:1 to placebo or simvastatin for the next 4 weeks
88823480|NCT01665950|Placebo Comparator|Placebo-Placebo|Placebo nonresponders for the 1st 4 weeks will be re-randomized 1:1 to placebo or simvastatin for the subsequent 4 weeks
88823481|NCT04707339||Acute Appendicitis pre-COVID management|Audit of Acute appendicitis management in 2017-18
88823482|NCT04707339||Acute Appendicitis during COVID management|Audit of Acute appendicitis management in 2020
88823483|NCT05698706|Experimental|De-novo BCC with thickness not more than 2.0 mm|Areas with de-novo BCC of thickness not more than 2.0 mm (as confirmed by ultrasound imaging or histopathological examination) will be treated by high intensity focused ultrasound
88823484|NCT04086615|Experimental|NMES and exercise supplemented with high BFR|"All participants receive a standard exercise rehabilitation protocol for PFPS to be performed singularly at home/work, synchronously with NMES and concurrently with NMES/BFR in-clinic. The PFPS exercises teach muscle strengthening exercises and self-management strategies to prevent recurrence. Participants will receive a portable battery-operated device, KneeHAB® XP (Bio-Medical Research, Galway, Ireland) with the thigh garment. NMES training will consist of 20-minute stimulation sessions performed concurrently with the exercise program.~For the BFR training, the automatic Delfi's PTS Personalized Tourniquet System for Blood Flow Restriction (Delfi Medical, Vancouver, BC, Canada) with variable contour nylon cuff (11.5 cm × 86 cm, 2.5 mm thick) will be used. The Delfi PTS system automatically adjusts pressure around the set occlusion pressure. The High BFR group will have the pressure set at 80% of limb occlusion pressure."
88823485|NCT04086615|Sham Comparator|NMES and exercise supplemented with low BFR|"All participants receive a standard exercise rehabilitation protocol for PFPS to be performed singularly at home/work, synchronously with NMES and concurrently with NMES/BFR in-clinic. The PFPS exercises teach muscle strengthening exercises and self-management strategies to prevent recurrence. Participants will receive a portable battery-operated device, KneeHAB® XP (Bio-Medical Research, Galway, Ireland) with the thigh garment. NMES training will consist of 20-minute stimulation sessions performed concurrently with the exercise program.~For the BFR training, the automatic Delfi's PTS Personalized Tourniquet System for Blood Flow Restriction (Delfi Medical, Vancouver, BC, Canada) with variable contour nylon cuff (11.5 cm × 86 cm, 2.5 mm thick) will be used. The Delfi PTS system automatically adjusts pressure around the set occlusion pressure. The Low BFR group will have the pressure set at 20 mmHg."
88823486|NCT01667978|Experimental|PI|Study group with PI: atazanavir ritonavir
88823487|NCT01667978|Placebo Comparator|Control|o PI therapy, control group
88823488|NCT03282669|Active Comparator|Intrathecal Morphine|Administration of 100µg intrathecal morphine to be given in the operative area.
88823489|NCT03282669|Active Comparator|Intravenous Hydromorphone|Administration of intravenous hydromorphone give IV pca in the post operative area.
88823490|NCT00375843|Active Comparator|Level 1 Treatment: Escitalopram|Level 1 participants who are assigned to escitalopram
89355787|NCT03840863|Experimental|Commercially-Available Energy drink|Healthy volunteers willing to consume two cans of energy drinks (16 oz./can) daily for 4 weeks
89533574|NCT04222972|Active Comparator|Platinum-based chemotherapy with or without pembrolizumab|"Participants randomized to the Active Comparator Arm will receive 1 of 6 platinum-based chemotherapy treatment regimens (with or without pembrolizumab) at the study center as chosen by the treating Investigator (based on histology)~Nonsquamous histology~Carboplatin or cisplatin / pemetrexed (with vitamin supplementation); with optional pemetrexed (with vitamin supplementation) maintenance.~Pembrolizumab / carboplatin or cisplatin / pemetrexed (with vitamin supplementation); followed by pembrolizumab and optional pemetrexed (with vitamin supplementation) maintenance.~Squamous histology~Carboplatin or cisplatin / gemcitabine~Carboplatin with paclitaxel/nab-paclitaxel and pembrolizumab"
89533575|NCT04221932||Pre Intervention|Retrospective evaluation of data from 2 years prior to the implementation of our CRRT KPI reports. This will include approximately 1500 participants.
88823491|NCT00375843|Active Comparator|Level 2: Sertraline|Participants from Level 1 who do not achieve remission with escitalopram enter Level 2 and switch to sertraline
88823492|NCT05364177|Experimental|68Ga-pentixather PET/CT and 68Ga-pentixafor PET/CT scan|Participants with multiple myeloma will perform 68Ga-pentixather PET/CT and 68Ga-pentixafor PET/CT within 7-day interval
89355788|NCT04745624||manual compression cohort|Manual compression cohort: Patients who underwent coronary or peripheral angiograms via CFA access with moderate to severe stenosis were hemostasis was achieved via manual compression
89355789|NCT04745624||VASCADE cohort|VASCADE cohort: Patients who underwent coronary or peripheral angiograms via CFA access with moderate to severe stenosis were hemostasis was achieved via VASCADE device closure
89533576|NCT04221932||Post Intervention|This will be a prospective evaluation of all new ICU patients receiving CRRT in Alberta over a 2 year periods. This will include approximately 1500 participants
89355790|NCT02510950|Experimental|Arm 1: Peptide/poly-ICLC|"For all patients, concurrent chemoradiation with temozolomide will be given per standard of care and is outside the scope of this study as per standard of care.~The long peptide + poly-ICLC will be given on Cycle 1 Day 1 of maintenance temozolomide.~If the vaccine is not ready by this time, the first vaccination will begin on Day 1 of the next cycle of maintenance temozolomide.~The peptide + poly-ICLC vaccine will be given again on Days 8, 15, and 22 of the first cycle, as a priming strategy.~On all subsequent cycles, the peptide vaccine + poly-ICLC will be given on Day 22 (+/-3 days)."
89355791|NCT05670197||Service users|Service users with experience of schizophrenia spectrum psychosis
89355792|NCT05670197||Mental health staff|Mental health staff who work within an adult NHS service providing mental health support to people who experience schizophrenia spectrum psychosis / severe mental health problems
89355793|NCT04499872||Patient/family Participant|Advance Care Plan with the Trajectory Touchpoint Technique
88999803|NCT02240407|Sham Comparator|Excipient|Each subject will receive Rituxan and Rapamycin prior to the initial exposure to the study agent in one leg and the subsequent exposure of the same vector to the contralateral leg after four months. Diphenhydramine and acetaminophen will be provided before each Rituxan dose. Immune Globulin will be administered to each subject every other month after first exposure to Rituxan and as clinical necessary. Lidocaine will be administered through percutaneous infiltration before injection of the study agent. Side of administration will be randomized at first saline injection.
88999804|NCT00172016|Experimental|ZOL446 (zoledronic acid)|
88999805|NCT00179985||Training|Behavioral: Newborn Individualized Care and Assessment Program (NIDCAP)
88999806|NCT04950673||Subjects who had COVID-19 infection and recovered at 3 months|500 subjects who have had a history of COVID19 infection and recovered 3 months prior to the enrollment
88999807|NCT04950673||Subjects who never had COVID-19 infection|500 subjects who never had a history of COVID19 infection prior to the enrollment
88999808|NCT00172055|Experimental|ZOL446 (zoledronic acid)|
88999809|NCT00197652||Diarrheal specimens from infants born to HIV infected mothers|400 diarrheal specimens will suffice to determine the prevalence of specific pathogens in the region. Of these, 300 specimens will be collected from infants born to HIV infected mothers, and 100 specimens will be collected from infants born to HIV uninfected mothers.
88999810|NCT00197652||Breast milk from HIV infected and HIV uninfected women|Breast milk from HIV infected and HIV uninfected women who are breastfeeding is collected at 2 days, 2 weeks, 2 months, and 5 months post-partum. This breast milk will be compared for in vitro functional quality of immunoglobulins to selected diarrheal and respiratory pathogens.
88999811|NCT04941313|Experimental|Single Dose Escalation-3D229|two sequential dose escalation cohorts - patients are randomized either to investigational drug or matching placebo
88999812|NCT04941313|Placebo Comparator|Single Dose Escalation- placebo|two sequential dose escalation cohorts - patients are randomized either to investigational drug or matching placebo
88999813|NCT04941313|Experimental|Repeat Dose-3D229|Four single doses of the investigational drug or matching placebo - patients are randomized either to investigational drug or matching placebo
88999814|NCT04941313|Placebo Comparator|Repeat Dose-placebo|Four single doses of the investigational drug or matching placebo - patients are randomized either to investigational drug or matching placebo
88999815|NCT04934449|Experimental|Hard splint group- 2 mm thicknesss|This group of patients was allocated to use 2 mm-thickness, hard occlusal splints for 2 months during sleep
88999816|NCT04934449|Experimental|Hard splint group- 3 mm thicknesss|This group of patients was allocated to use 3 mm-thickness, hard occlusal splints for 2 months during sleep
88999817|NCT04934449|Experimental|Soft splint group- 2 mm thicknesss|This group of patients was allocated to use 2 mm-thickness, soft occlusal splints for 2 months during sleep
88999818|NCT04934449|Experimental|Soft splint group- 3 mm thicknesss|This group of patients was allocated to use 3 mm-thickness, soft occlusal splints for 2 months during sleep
88999819|NCT04682275|Other|Female Group|Females with periodontal disease (71 subjects with gingivitis, 100 subjects with periodontitis)
88999820|NCT04682275|No Intervention|Male Group|males with periodontal disease (72 subjects with gingivitis, 96 subjects with periodontitis)
88999821|NCT00172094|Placebo Comparator|1|PLACEBO
88999822|NCT00172094|Experimental|2|400 mg 1776 powder
88999823|NCT00172094|Experimental|3|1776 (800 mg)
89355794|NCT03840473|Experimental|MET+ICT+Conventional intervention|Hot packs (75°C) for 20 minutes and supervised active stretching exercises for upper trapezius muscle (slow, 5 repetitions per session, 10-second hold and 10-second relaxation between two repetitions) followed by ICT (90-second hold-time) and MET (5-second hold-time, 3-second relaxation by exhalation while reaching the new barrier).
88999824|NCT03455179|Experimental|Slow-speed traditional resistance training|Resistance training with variable resistances (elastic band) at high intensity and slow-speed (2s of concentric contraction and 2s of eccentric contraction) twice a week over 20 weeks.
88999825|NCT03455179|Experimental|High-speed resistance training|Resistance training with variable resistances (elastic band) at low intensity and high-speed (''as fast as possible´´ for the concentric contraction, pause for 1 second and 2-3 seconds for the eccentric contraction) twice a week over 20 weeks.
88999826|NCT03455179|Experimental|Multicomponent training|Training sessions with balance, resistance, aerobic, flexibility and coordination components twice a week over 20 weeks.
88999827|NCT03455179|No Intervention|Control|Participants randomized into the CONTROL group will not undertake any formal intervention and will be asked to maintain their usual physical activity habits and diet.
88999828|NCT04682002|Experimental|OMT + multidisciplinary path|Patients in the experimental group will follow the obstetrician's and multidisciplinary path which provides osteopathic treatments, mindfulness, yoga, clinical nutrition, coaching and usual obstetric care.
88999829|NCT04682002|Other|Usual care|Patients in control group will continue the routine obstetrical care as established by international guidelines
88999830|NCT04895254||Experimental: Motorized spiral Enteroscopy|Consecutive patients with difficult colonoscopies to be enrolled to achieve total colonoscopy using the motorized spiral enteroscope.
88999831|NCT02909062||Electronic Activity Monitoring (EAM)|This is a prospective, observational study. The study aims to examine the role of EAM as an objective, assessment of patient fitness in patients receiving chemotherapy for gastrointestinal malignancy. Physical activity level measured by EAM will be compared with standard measurement tools used by the oncology community to predict chemotherapy tolerability.
89355795|NCT03840473|Experimental|MET+Conventional Intervention|Hot packs (75°C) for 20 minutes and supervised active stretching exercises for upper trapezius muscle (slow, 5 repetitions per session, 10-second hold and 10-second relaxation between two repetitions) followed by MET (5-second hold-time, 3-second relaxation by exhalation while reaching the new barrier).
89533577|NCT04216316|Experimental|Arm A (pembrolizumab, gemcitabine, carboplatin, M6620)|Patients receive pembrolizumab IV over 30 minutes on day 1, gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, carboplatin IV over 30 minutes on day 1, and berzosertib IV over 60 minutes on days 2 and 9. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive pembrolizumab IV over 30 minutes on day 1 and berzosertib IV over 60 minutes on days 2 and 9. Cycles repeat every 21 days for up to 9 months in the absence of disease progression or unacceptable toxicity. Patients then receive pembrolizumab alone IV over 30 minutes on day 1. Cycles repeat every 6 weeks for up to 1 more year in the absence of disease progression or unacceptable toxicity. Patients undergo MRI scans and/or CT scans, and undergo blood specimen collection on study.
89177063|NCT02614625||Eyes with retinal disease|"Subjects that have any of the following conditions:~Diabetic macular edema~Cystoid macular edema~Age related macular degeneration~Retinal vascular disorders (e.g. retinal artery occlusion)~Epiretinal membrane~Choroidal nevus~Macular hole~Patients who had undergone retinal surgery~Patients with other retinal disease"
89533578|NCT04216316|Active Comparator|Arm B (pembrolizumab, gemcitabine, carboplatin)|Patients receive pembrolizumab, gemcitabine, and carboplatin as in Arm A. Patients undergo MRI scans and/or CT scans, and undergo blood specimen collection on study.
89533579|NCT04209868|Placebo Comparator|Pre-PVB with saline|Placebo (20ml Saline) pre-PVB performed post-induction and pre-incision.
89533580|NCT04209868|Experimental|Pre-PVB with 0.5% Levo-bupivacaine|20ml 0.5% Levo-bupivacaine pre-PVB performed post-induction and pre-incision.
89533581|NCT04206319|Experimental|1|Participants will receive radium-223 treatment every 4 weeks for up to 6 cycles. 18F-NaF PET scans will be used to assess response in bone.
89355796|NCT03840473|Active Comparator|Conventional Intervention|Received hot packs (75°C) for 20 minutes and supervised active stretching exercises for upper trapezius muscle (slow, 5 repetitions per session, 10-second hold and 10-second relaxation between two repetitions) only.
89533582|NCT04194736|Experimental|Children|Minor patients hospitalized in pediatric intensive care unit having a percutaneous central venous catheter.
89533583|NCT04166409|Active Comparator|Arm I (vincristine sulfate, carboplatin)|"INDUCTION: Patients receive vincristine sulfate IV over 1 minute on days 1, 8, 15, 22, 29, 36, 43, 50, 57, and 64, and carboplatin IV over 60 minutes on days 1, 8, 15, 22, 43, 50, 57, and 64 in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood and magnetic resonance imaging (MRI) at baseline and end of induction.~MAINTENANCE: Patients receive vincristine sulfate IV over 1 minute on days 1, 8, and 15, and carboplatin IV over 60 minutes on days 1, 8, 15, and 22. Treatment repeats every 42 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood and undergo MRI at baseline, throughout the trial, and during follow up."
89177064|NCT02614625||Eyes with glaucoma|Eyes diagnosed with glaucoma of any type and any stage
89177065|NCT00811928|Active Comparator|Posaconazole|Posaconazole oral suspension 200 mg three times a day (TID)
89355797|NCT02514928|Experimental|pancreatoduodenectomy & nerve resection|Resection of the nerve plexus on the right half of celiac and SMA associated with extended pancreatoduodenectomy. Regional lymph nodes includes group 5,6,8a,8p,9,12a,12b,12c,12p,13,14a,14b,14c,16,17, according to the 2003 edition of lymph nodes group system defined by Japan Pancreas Society (JPS).
89355798|NCT02514928|Active Comparator|pancreatoduodenectomy|Standard pancreatoduodenectomy with regional lymph nodes includes group 5,6,8a,12b,12c,13,14a,14b,17, according to the 2003 edition of lymph nodes group system defined by Japan Pancreas Society (JPS).
89355799|NCT05221736|Experimental|Warthin tumor in parotid tumor|Comparison between Ultrasound-Guided Ethanol Sclerotherapy (UGES) & surgical excision in management of warthin tumor of parotid gland.
89355800|NCT02510560|Experimental|NTRA-2112 A|NTRA-2112 A - Dose 1 To be administered orally with daily feed for 28 days or until discharge from hospital.
89355801|NCT02510560|Experimental|NTRA-2112 B|NTRA-2112 B - Dose 2 To be administered orally with daily feed for 28 days or until discharge from hospital.
89355802|NCT02510560|Placebo Comparator|Placebo|Placebo To be administered orally with daily feed for 28 days or until discharge from hospital.
89355803|NCT05361252|Active Comparator|the low-SVV group|the value of stroke volume variation will be less than or equal to 10 this group
88999832|NCT00172133|Experimental|1|All patients entering the study will receive 100mcg daily for up to 6 months, making their total exposure 24 months
88999833|NCT00202293|Experimental|Lithium and olanzapine|
88999834|NCT00202293|Active Comparator|Lithium and chlorpormazine|
88999835|NCT02908867||Therapeutic strategies group|To know the main therapeutic strategies used by men with spinal cord injury in sexual dysfunctions, mainly medicinal plants.
88999836|NCT00197730|Experimental|Multivitamins|Vitamin E, Vitamin C, and Vitamin B complex
88999837|NCT00197730|Placebo Comparator|Placebo|Placebo
88999838|NCT02909023||Hepatitis B infected patients or cured|blood samples are performed to measure active T cellular immune response during a routine visit
88999839|NCT02908828|Experimental|Calanus oil|4 capsules of 500 mg Calanus oil once every day
88999840|NCT02908828|Placebo Comparator|Placebo|4 capsules of 500 mg dietary oil once every day
88999841|NCT00172172|Experimental|1|PTH 100 mcg and 700 mg calcium
88999842|NCT00172172|Experimental|2|PTH 100 mcg and placebo
88999843|NCT00172172|Placebo Comparator|3|Placebo and 700 mg calcium
88999844|NCT02908711|Active Comparator|Patients receiving ACB before primary TKA|"Patients receiving adductor canal block (ACB) before primary total knee arthroplasty (TKA).~Patients randomized to this group will receive the block prior to incision after induction of general anesthesia"
88999845|NCT02908711|Active Comparator|Patients receiving ACB after primary TKA|"Patients receiving adductor canal block (ACB) immediately after primary total knee arthroplasty (TKA).~Patients randomized to this group will receive the block at the end of the surgery."
88999846|NCT04804774|Experimental|WW program modified for people with Type 2 diabetes|Includes weekly Virtual Workshops and use of the WW App.
88999847|NCT04799938|Active Comparator|İntevention group|Prediabetic patients with age 30-50 and overweight Standart recommendations Exercise intervention will be made.
88999848|NCT04799938|No Intervention|Control group|Prediabetic patients with age 30-50 and overweight Only Standart recommendations
88999849|NCT04799938|No Intervention|Metformin Group|Prediabetic patients who received metformin Standart recommendations
88999850|NCT04798846|Active Comparator|External fixator|patient treated by external fixator
89177066|NCT00811928|Active Comparator|Fluconazole|Fluconazole 400 mg once daily (QD)
89355804|NCT05361252|Active Comparator|the high-SVV group|the value of stroke volume variation will be higher than 10 this group
89355805|NCT01204619|No Intervention|Conventional training group|in-center conventional training programs + two home visits
89355806|NCT01204619|Experimental|Intensive training group|in-center conventional training programs + an extra structured patient home visits repeatedly and regularly
89355807|NCT03636750|Experimental|HB002.1T 2mg/kg|Participants received a 2mg/kg dose of HB002.1T via intravenous injection.
88999851|NCT04798846|Active Comparator|Dorsal plate|patient treated by dorsal spanning plate
89355808|NCT03636750|Experimental|HB002.1T 4mg/kg|Participants received a 4mg/kg dose of HB002.1T via intravenous injection.
88999852|NCT02908594|Experimental|exercise group|Using the Medical Exercise Peddler 3000, Medi-Bike, Taiwan as an exercise tool. Exercise group received routine care and 3- months exercise. The exercise was performed during the first 2 hr of each haemodialysis session (30 min per session, 3 sessions per week for 3 months).
88999853|NCT02908594|No Intervention|control group|The control group received routine care
88999854|NCT04791280||patients with systemic sclerosis|"On the day of inclusion, the faeces collection will be carried out by the patient using adapted equipment, either at the hospital or at home. In the case of a home collection, it will be carried out on the day of a planned hospital and preserved using equipment provided and tested to maintain the quality of the collection before storage.~6 months after inclusion (+/- 2 months) a follow-up visit will be carried out and the patient will perform a second faecal sample.~At the inclusion visit and at M6 the UCLA SCTC GIT 2.0 questionnaire will be completed by the patient."
88999855|NCT04723901|Experimental|Treatment group|Dual target CAR-T cell therapy
88999856|NCT04791241|Experimental|check-list with ultrasound|check-list including lung ultrasound for the management of patients with acute respiratory failure at the emergency department during the COVID-19 era
88999857|NCT04768855|Experimental|LY3540378 (Part A)|Single ascending doses of LY3540378 administered either intravenously (IV) or subcutaneously (SC).
88999858|NCT04768855|Experimental|LY3540378 (Part B)|Multiple ascending doses of LY3540378 administered SC.
88999859|NCT04768855|Experimental|LY3540378 (Part C)|Multiple ascending doses of LY3540378 administered SC in Japanese Participants.
88999860|NCT04768855|Experimental|LY3540378 (Part D)|Multiple ascending doses of LY3540378 administered SC in Chinese Participants.
89177067|NCT00698321|Experimental|1|Participating schools will deliver HIV/STD prevention modules.
89355809|NCT03636750|Experimental|HB002.1T 8mg/kg|Participants received a 8mg/kg dose of HB002.1T via intravenous injection.
89355810|NCT03636750|Experimental|HB002.1T 12mg/kg|Participants received a 12mg/kg dose of HB002.1T via intravenous injection.
89355811|NCT03636750|Experimental|HB002.1T 16mg/kg|Participants received a 16mg/kg dose of HB002.1T via intravenous injection.
88999861|NCT04768855|Placebo Comparator|Placebo (Part A, B, C & D)|Placebo administered either IV or SC.
88999862|NCT02908633|Active Comparator|canaloplasty ab externo and phacoemulsification|As soon as the two scleral flaps: deep and superficial -similar to deep sclerectomy are dissected, the phacoemulsification with PCIOL insertion is performed. After excision of the deep flap the descemets window and ostia of Schlemm canal are created, the microcatheter is placed in the canal and guided for 360 degrees within the canal. Surgeon observes the location of beacon tip through sclera and injects the Healon GV. Then a suture is tied to the distal tip and the microcatheter is withdrawn. As it appears at the other ostium of canal the microcatheter it separated from the suture.Then suture loop is tightened to tension the trabecular meshwork. The superficial flap is sutured watertight to prevent bleb formation
89355812|NCT03636750|Experimental|HB002.1T 20mg/kg|Participants received a 20mg/kg dose of HB002.1T via intravenous injection.
89355813|NCT01982357||premature infant|Laser Speckle Imaging and Diffuse Optical Spectroscopy
88823493|NCT01668602|Experimental|Cohort 1 - FastFES Training|Participants with chronic stroke in Cohort 1 will receive 18 training sessions of FastFES (fast treadmill walking with electrical stimulation).
88823494|NCT01668602|Experimental|Cohort 2 - FastFES and Fast Walking|Participants with chronic stroke in Cohort 2 who complete 3 sessions of FastFES and 3 sessions of fast walking.
88823495|NCT03247569||Edoxaban|Patients treated with Edoxaban
88823496|NCT01668836|Experimental|men with resveratrol|12 men will receive a pill with 500mg of resveratrol daily for 30 days
88823497|NCT01668836|Experimental|women with resveratrol|12 women will receive a pill with 500mg of resveratrol daily for 30 days
88823498|NCT01668836|Active Comparator|men with caloric restriction|12 men will follow a 1000 calories per day diet for 30 days
88823499|NCT01668836|Active Comparator|women with caloric restriction|12 women will follow a 1000 calories per day diet for 30 days
88823500|NCT03008733|Active Comparator|NMMCB|patient with Neuropathies with Motrices Multifocal Conduction Block
88823501|NCT03008733|Active Comparator|PICD|patient with Inflammatory demyelinating polyneuropathy Chronicle
88823502|NCT03008733|Active Comparator|anti MAG|patient with neuropathy antibody Anti-MAG
89355814|NCT02510404|Experimental|mCTLs against three viruss|The investigator will use 3 different dose levels starting with 5 x 106 (a T cell number more than an order of magnitude lower than that administered at the time of an unmanipulated marrow infusion), followed by 1 x 107 and a final dose 2 x 107 mCTLs/m2. They will give the option of administering 2 additional doses (at the same level) of the same or different cell lines, 28 days after the first dose, in subjects that have limited or no improvement in viral count after one dose in the absence of any toxicities attributable to the infusion,or who receive other therapy that may affect the persistence or function of the infused mCTLs.
89355815|NCT01314456|Experimental|NaviGo|Video recording of a normal TRUS guided prostate biopsy with additional 2 , non invasive,electromagnetic sensors attached to the TRUS probe and the patient's back,- to allow for a 3D modeling of the prostate.
88823503|NCT03008733|Placebo Comparator|healthy|healthy patient
88823504|NCT03751449|Experimental|Group I (active treatment)|Participants complete a home-based aerobic and resistance exercise program and receive nutrition education for 12 weeks.
88823505|NCT03751449|Active Comparator|Group II (waitlist)|Participants are placed on a waitlist for 12 weeks and then complete a home-based aerobic and resistance exercise program and receive nutrition education for 12 weeks.
89355816|NCT05218226|Experimental|50 subjects with chemotherapy-induced thrombocytopenia|50 enrolled subjects will be picked up to take Avatrombopag at the indicated dose.
89355817|NCT05282537||In person academic activities group|"University students of health sciences area returning to in person academic activities in Mexico.~All unviersity students will return to in person academic activities in March, 2022, for that reason a limitation is that it is no possible to have a control group (Nobody is goint to continue in virtual academic activities)."
88823506|NCT05690828|Experimental|Group 1 (Cognitive remediation)|
88823507|NCT05690828|No Intervention|Group 2 (No cognitive remediation)|
88823508|NCT03744663|Active Comparator|Suboxone® SL|Patients assigned to this group will continue with their already established dose of Suboxone ® SL films for 24 weeks along with weekly therapy.
88823509|NCT03744663|Experimental|Sublocade®|Patients assigned to the Sublocade® group will receive the study drug (300 mg subcutaneously) every 4 weeks for a total of 6 doses along with weekly therapy.
88823510|NCT05086952|Experimental|B-A-D-C|4-fold crossover design with 4 interventions, 4 intervention periods, and 4 intervention sequences. (according to Williams design [balanced for 1-period-carry-over]).
89355818|NCT02514850|Experimental|Biochaperone Combo|single subcutaneous injection of 0.8 U/kg + injection of placebo (0.9% NaCl) to ensure the double dummy
89355819|NCT02514850|Active Comparator|Humalog Mix25|single subcutaneous dose of 0.8 U/kg + injection of placebo (0.9% NaCl) to ensure the double dummy
88823511|NCT05086952|Experimental|C-D-A-B|4-fold crossover design with 4 interventions, 4 intervention periods, and 4 intervention sequences. (according to Williams design [balanced for 1-period-carry-over]).
88823512|NCT05086952|Experimental|D-B-C-A|4-fold crossover design with 4 interventions, 4 intervention periods, and 4 intervention sequences. (according to Williams design [balanced for 1-period-carry-over]).
88823513|NCT05086952|Experimental|A-C-B-D|4-fold crossover design with 4 interventions, 4 intervention periods, and 4 intervention sequences. (according to Williams design [balanced for 1-period-carry-over]).
89355820|NCT02514850|Active Comparator|Humalog and Lantus|simultaneous subcutaneous injections of 0.2 U/kg Humalog and 0.6 U/kg Lantus
89177068|NCT00698321|Active Comparator|2|Participating schools will deliver general health promotion modules.
89177069|NCT02611544|Active Comparator|Acceptance and Commitment Therapy|6 weeks, the ACT group will meet weekly for 2 hours at one of three facilities.
88823514|NCT01669538|Experimental|Galantamine|"Galantamine hydrobromide-ER (extended release) is currently marketed for the treatment of Alzheimer's disease. The dosing regimen follows the FDA-approved guidelines. For the first week of study treatment, participants will take 8mg daily of galantamine-ER, preferably with food. 8mg is the lowest dose and this period is designed to introduce the medication into their system. After the initial week, participants will increase their daily dose to 16mg. They will remain on 16mg daily until the end of the treatment period for a total of 23 days on active study medication.~Galantamine will be purchased, encapsulated, and packaged into blister packs by the Investigational Drug Service at the University of Pennsylvania. Both active medication and placebo will look identical."
88823515|NCT01669538|Placebo Comparator|Placebo|"Participants assigned to the placebo (sugar pill) arm will take one capsule daily, preferably with food, for a total of 23 days. They will follow the same instructions and complete the same procedures as those in the active treatment.~Placebo ingredients (sucrose filler and gel capsules) will be purchased, encapsulated, and packaged into blister packs by the Investigational Drug Service at the University of Pennsylvania. Both active medication and placebo will look identical."
88823516|NCT05363475|Experimental|Prospective|Participants will be monitored by the ForeSite Intelligent Surface system for 2-3 weeks.
89355821|NCT03178266||Zip Closure Device|Patients will receive the Zip Closure Device for final skin closure after knee arthroplasty.
88823517|NCT05690750||Case|Cirrhosis with GAVE
88823518|NCT05690750||Control|Cirrhosis without GAVE
88823519|NCT02781285||1group one|patients with standard TCM diagnosis and treatment of gastric cancer
88823520|NCT02781285||2 group two|patients take Chinese Medicine but not with standard TCM diagnosis and treatment of gastric cancer
88823521|NCT02781285||3group three|patients take no Chinese Medicine
88823522|NCT02757417|Active Comparator|Sodium Fluorescein|Patients will receive an intravenous dose of 0.25 mL of 10% (500 mg, 5 mL) sodium fluorescein at the time of cystoscope insertion, for a total dose of 25 mg. Cystoscopy will be performed in the standard fashion during the course of the operation.
88823523|NCT02757417|Active Comparator|oral phenazopyridine|Patients randomized to the phenazopyridine arm will be given a 200 mg pill with a sip of water in the pre-operative area 1 hour before their scheduled procedure. Cystoscopy will be performed in the standard fashion during the course of the operation.
88823524|NCT01671176|Other|Wide diameter bone anchored implant|Intervention: Implantation of a wide diameter bone anchored auditory implant either 3 or 4 mm in length, into the skull on the side of the ear where intervention is intended in order to restore hearing. In the case of a conductive or mixed hearing loss, that side is chosen. In patients with unilateral, profound sensori-neural hearing loss the implant is implanted on that side but the sound is transmitted to the side with the normal hearing ear via bone conduction stimulation.
88823525|NCT02746965|Experimental|magnetic seizure therapy|10 treatment sessions of MST, three times per week in the first two weeks, two times per in the following two weeks.
88823526|NCT02746965|Active Comparator|electroconvulsive therapy|10 treatment sessions of modified-ECT, three times per week in the first two weeks, two times per in the following two weeks.
88823527|NCT01672658|Experimental|Sensory Kinectics Balance System|Subjects will be randomized in to one of two groups. The group that will receive training on the SKBS device along with traditional vestibular and balance training.
88823528|NCT01672658|Active Comparator|Traditional Vestibular Rehabilitation|Traditional vestibular rehabilitation will include VOT exercises that will work toward increasing the gain of the system as well as walking, balance re-training, and functional mobility.
88823529|NCT03505281||Patients|
88823530|NCT03505281||Healthy volunteers|
88823531|NCT04333095|Active Comparator|Liposomal Bupivacaine Block|Liposomal Bupivacaine (1.3%) solution (20 mL dose). This solution has demonstrated increased efficacy in prolonged analgesia following injection. This solution will be injected as an ultrasound-guided subpectoral interfacial plane block.
88823532|NCT04333095|Placebo Comparator|Saline Block|Normal saline (0.9%) will be used as the control solution for patients not receiving the liposomal bupivacaine solution. Injection procedure of this solution will be identical to that of the liposomal bupivacaine solution.
88823533|NCT03334149|Experimental|Self-Monitoring of Blood Pressure|BUMP 1: using a validated home blood pressure monitor at least 3 times a week to record blood pressure BUMP 2: using a validated home blood pressure monitor daily to record blood pressure Women in the intervention groups will be encouraged to use a simple mobile tele monitoring system.
88823534|NCT03334149|No Intervention|Usual Care|Women randomised to usual care will continue to have all their BP monitoring completed by the clinical team at their antenatal assessments.
88823535|NCT05039684||Primary open angle glaucoma / ocular hypertension - Treatment with Xalatan|Patients with primary open angle glaucoma or ocular hypertension treated with Xalatan
88823536|NCT05039684||Primary open angle glaucoma / ocular hypertension - Treatment with Monoprost|Patients with primary open angle glaucoma or ocular hypertension treated with Monoprost
88823537|NCT05039684||Primary open angle glaucoma / ocular hypertension - Treatment with Saflutan|Patients with primary open angle glaucoma or ocular hypertension treated with Saflutan
88823538|NCT05039684||Ocular hypertension - No treatment|Patients ocular hypertension untreated
89177070|NCT02611544|Active Comparator|Survivorship Education|6 weeks, SE group will meet weekly for 2 hours at one of three facilities.
89177071|NCT02611544|Active Comparator|Enhanced Usual Care|"Continue to meet with their health care team + receive a variety of readings at each data collection point on coping with common survivorship concerns, including a booklet from the National Cancer Institute entitled Facing Forward: Life After Cancer Treatment."
89177072|NCT00788775|Experimental|Nilotinib|Nilotinib was given at a dose of 400 mg orally daily (200 mg pills twice per day). Patients received treatment up to 12 months as long as they were receiving clinical benefit.
89355822|NCT03178266||Metal Staples|Patients will receive Metal Staples for final skin closure after knee arthroplasty.
88823539|NCT03330093|Experimental|Sleep Extension|1-month educational and problem solving behavioral intervention about sleep.
89355823|NCT03837197|Experimental|Kidney-Hypothermic oxygenated|Belzer machine perfusion solution at 4°C-10°C in sterile conditions and continuous oxygenation (partial pressure of oxygen=500-600 mmHg) will be used for perfusion 2000 ml for kidneys.
89355824|NCT03837197|No Intervention|Kidney-Static Cold Storage|Kidneys undergoing SCS will be stored in sterile organ bags with Celsior or University of Wisconsin solution and cooled in ice.
88823540|NCT03330093|Active Comparator|Health and Safety|1-month educational and problem solving behavioral intervention about health and safety.
88823541|NCT02249468||Mild and Moderate Alzheimer's Disease|
88823542|NCT02249468||Cognitively intact healthy people|
88823543|NCT03281031|Other|Additional MRI Examination|Single arm, all patient will undergo CT followed by additional MRI examination
88823544|NCT01658241|Experimental|Single Arm Main population|
88823545|NCT01455051|Experimental|Ofatumumab|We plan to add five doses of ofatumumab to the standard conditioning regimen (fludarabine + melphalan). Ofatumumab will be administered on days -20 (300 mg), -13 (2000 mg), -6 (2000 mg), +1 (1000 mg) and +8 (1000 mg) of the transplantation (day 0 being the day of the hematopoietic cell infusion). If the patient requires donor lymphocyte infusions within 3 years after the procedure, these infusions will also include one administration of 300 mg of ofatumumab, followed by a 1000 mg dose, 7 days later).
88823546|NCT05352945|No Intervention|control arm|"conventional anaesthesia~The botulinum toxin injection procedure will be carried out in the standard way, according to the recommendations applicable in France, and after local anaesthesia."
88823547|NCT05352945|Experimental|interventional arm|"conventional anaethesia and use of the self-hypnosis mask~The mask and the helmet are positioned and activated 10 minutes before the procedure, with the travel to india programme chosen because it was developed for pain management and its duration is compatible with the procedure (25 minutes)."
88823548|NCT01673828|Experimental|Allopregnanolone|Allopregnanolone injection (intravenous solution) continuous infusion for 5 days
88823549|NCT01673828|Placebo Comparator|Placebo|Placebo injection (intravenous solution) continuous infusion for 5 days
89355825|NCT03837197|Experimental|Liver-Hypothermic oxygenated|Belzer machine perfusion solution at 4°C-10°C in sterile conditions and continuous oxygenation (partial pressure of oxygen=500-600 mmHg) will be used for perfusion 3000 ml for livers.
89355826|NCT03837197|No Intervention|Liver-Static Cold Storage|Livers undergoing SCS will be stored in sterile organ bags with Celsior or University of Wisconsin solution and cooled in ice.
88823550|NCT05344053|Experimental|Community-based precise management|
88823551|NCT05344053|Active Comparator|Standard community-based management|
88823552|NCT02249858||Control Group: Cranial Vault Protocol Group|Cranial vault protocol group will receive cranial vault hold.
88823553|NCT02249858||Experimental Group: HVLA Protocol Group|HVLA protocol group will receive cervical HVLA to the key somatic dysfunction C2-C7 segment.
88823554|NCT05325099|Experimental|AKI patient with azacitidine treatment|azacitidine (subcutaneous injection)
88823555|NCT05325099|Placebo Comparator|AKI patient with placebo treatment|Placebo drug (subcutaneous injection)
88999863|NCT02908633|Active Comparator|canaloplasty ab interno and phacoemulsification|This variant of canaloplasty spares conjunctival surface. First phacoemulsification and PCIOL placement is performed. The Schlemm's canal is reached through goniotomy through anterior chamber. Similarly microcatheter is inserted and viscodilatator applicated. The key difference, is that no tensioning suture is left after the catheter is withdrawn. phacoemulsification is performed.
88823556|NCT02296775|Experimental|DRL_RI|
88823557|NCT02296775|Active Comparator|Rituxan|
88823558|NCT02296775|Active Comparator|MabThera|
88823559|NCT01675778|Other|Hydromorphone|Every enrolled patients will receive a fixed dose (1mg) of intravenous hydromorphone. Pain scale change, patients' satisfaction, requirements for additional pain medications, side effects and adverse events will be recorded at 15 and 30 minutes. Patients' weight and height will be measured. Age, gender, and race/ethnicity will also be recorded. Blood draw for genetic study will be performed.
88823560|NCT04736589|Experimental|Inetetamab plus Rapamycin plus Chemotherapy|"Drug: Inetetamab Initial dose of 8mg/kg, completed in 90 minutes IV infusion, and then 6 mg/kg over 30-90 minutes IV infusion every 3 weeks, until disease progression (PD) or other termination criteria are met;~Drug: Rapamycin Oral 2mg, once a day;~Drug: Chemotherapy drugs are not limited in this trial, please refer to their instructions for specific usage."
89355827|NCT05221268|Experimental|downhill|Received downhill walking training.
89355828|NCT05221268|Experimental|Level -walking|Received level walking training.
89399091|NCT03502031|Active Comparator|RAAS in Combination with Spironolactone|RAAS (Lisinopril, Enalapril, Perindopril, Losartan, and Valsartan taken each day at maximum tolerated dose that will different for each subject); Spironolactone taken each day at 25mg
88823561|NCT04736589|Active Comparator|Pyrotinib plus chemotherapy|"Drug:Pyrotinib Oral 400mg, once a day;~Drug: Chemotherapy drugs are not limited in this trial, please refer to their instructions for specific usage."
88823562|NCT05201859|Experimental|Adjuvant Sintilimab Plus Capecitabine|Lead-in Phase: Sintilimab (200mg, D1, D14 for 2 cycles); Adjuvant Phase: Sintilimab ( 200mg D1, every three weeks, a total of 24 weeks, 8 cycles) + Capecitabine ( 1000 mg/m2, BID, D1-14 every three weeks, a total of 24 weeks, 8 cycles).
88823563|NCT05201859|Active Comparator|Adjuvant Capecitabine|Capecitabine 1000 mg/m2, BID, D1-14, every three weeks, a total of 24 weeks, 8 cycles.
88823564|NCT02594111|Active Comparator|Colchicine|Colchicine 1.8 mg PO over 1 hour
88823565|NCT02594111|Placebo Comparator|Placebo|Matching placebo
88823566|NCT03186261|Experimental|Nano silver fluoride solution|Nano silver fluoride solution (Prepared in Nanotech Co., Egypt) based on silver nanoparticles, chitosan and fluoride. Each tooth will receive two drops of NSF with a micro brush, equivalent to a dose of 10 mg of the solution.
88823567|NCT03186261|Active Comparator|Cavity Cleanser|Chlorhexidine digluconate 2 % solution (Cavity Cleanser, Bisco, USA). Each tooth will receive two drops of cavity cleanser with a micro brush, equivalent to a dose of 10 mg of the solution.
88823568|NCT02589353|Experimental|Acarbose|Acarbose solution will be swabbed on the tip of the tongue to inhibit salivary alpha amylase activity; each swab will contain ~484 microgram acarbose; total maximum exposure of each subject to acarbose will be ~14-30 mg each session (1-20 sessions)
88823569|NCT02298803|Other|Holter and Glucose monitoring|In this study the interventions will be the simultaneous monitoring of glucose and QT interval via a subcutaneous continuous glucose monitor and a Hoter monitor, respectively.
88823570|NCT01676714|Experimental|Dovitinib|500 mg of dovitinib (5 capsules) once a day for 5 continuous days and stop for 2 days. Continue to take dovitinib capsules in this manner until until progression or unacceptable toxicity develops.
88823571|NCT03187119|Experimental|Pictorial Asthma Action Plan|Young people in the Pictorial Asthma Action Plan (PAAP) arm will receive a PAAP generated by their asthma provider using a software program developed for the study. The PAAP will be personalized according to the young person's gender, race, favorite sport/activity, provider's gender, provider's clinic contact details, and hospital in emergency situations. The PAAP contains minimal text, instead illustrating each participant's asthma regimen using pictures, such as color-coded daily controller and rescue inhalers. Each participant will receive multiple copies of their PAAP, after receiving a brief education session with their provider, outlining the treatment summarized in the PAAP.
88823572|NCT03187119|Active Comparator|Written Asthma Action Plan|Young people in the Written Asthma Action Plan (WAAP) arm will receive a WAAP generated by their asthma provider using using the National Heart, Lung, and Blood Institute (NHLBI) template. The WAAP will be personalized according to the young person's treatment plan. Each participant will receive multiple copies of their WAAP, after receiving a brief education session with their provider, outlining the treatment summarized in the WAAP.
88823573|NCT01678196|Experimental|VA-CRAFT|Family participants complete an on-line training course (VA-CRAFT) over a 3 month period
88823574|NCT01678196|Placebo Comparator|Control|Participants will have the opportunity to complete the VA-CRAFT training program after 3 months; otherwise no intervention
88823575|NCT02941965|Experimental|ICSI without PGS|Selection of embryos are based on blastocyst morphology criteria on day 5. A maximum of 2 embryos will be transferred for each treatment cycle.
88823576|NCT02941965|Experimental|ICSI with PGS|"PGS will be applied to select embryos on day 5, only euploid embryos will be transferred.~A maximum of 2 embryos will be transferred for each treatment cycle."
88823577|NCT03029117||corrected and uncorrected rheumatic valve lesions|
88823578|NCT03028727|Active Comparator|Ultrasonic Scaling, Root planing|Ultrasonic Scaling and Root planing at day 0 and at 1 week.
88823579|NCT03028727|Experimental|980 nm diode Laser irradiation|Irradiation of periodontal pockets with with 980 nm diode Laser after scaling and root planing at day 0 and after 1 week.
88823580|NCT02986607|Experimental|Hypoparathyroidism|"Subcutaneous 24h microdialysis before PTH treatment and during continous subcutaneous PTH treatment. PTH, Natpara (parathyroid hormone 1-84) 50 µg doses with a concentration of 800 µg/ml, will be delivered by an insulin-pump (OmniPod) which delivers the infusion gear continous subcutaneously based on units (U) of insulin. 1 µg Natpara equals 0.125 U of infusion. The starting dose for pump treatment will be 0.50 µg per kilo per day and adjusted according to Calcium levels.~Controls: patients With hyperparathyroidism and healthy volunteers will perform 24h microdialysis."
88823581|NCT01678976|Experimental|Group 1 BIA 2-093 + Oxcarbazepine|Period 1 - Subjects recieved 900 mg of BIA 2-093 Period 2 - Subjects recieved 900 mg of oxcarbazepine
88823582|NCT01678976|Active Comparator|Group 2 Oxcarbazepine + BIA 2-093|Period 1 - Subjects recieved 900 mg of oxcarbazepine Period 2 - Subjects recieved 900 mg of BIA 2-093
88999864|NCT02908633|Active Comparator|minicanaloplasty and phacoemulsification|The dissected conjunctival flap is of minimal size. The scleral flaps are sized: superficial flap 3x1mm, and deep flap: 1x1 mm- with no removal of the deep flap. Afterwards phacoemulsification part is performed. The microcatheterization and viscodilatation are conducted as in the traditional procedure.The conjunctiva is closed with one suture or coagulation
89399092|NCT02168738|Active Comparator|13-C labeled PC-DHA|
89399093|NCT02168738|Active Comparator|13-C labeled TG-DHA|
88999865|NCT02908438|Experimental|GnRHa group|Intervention: additional GnRHa for routine LPS GnRHa group receive three injections of GnRHa(Decapeptyl) ,0.1 mg s.c. on the day of ET, and D3 and D6 after ET in addition to routine LPS.
88999866|NCT02908438|No Intervention|control group|Control group receive only the routine LPS.
88999867|NCT00202410|Placebo Comparator|physiologic solution|subcutaneous administration of physiologic solution
88999868|NCT00202410|Experimental|Bacille Calmette-Guèrin (BCG) Vaccine|Anti-Tubercular Vaccination
88999869|NCT04756999|Experimental|Intervention|informed consent forms, nine sessions of foot reflexology massage will be given to reflex points including the solar plexus, brain, pituitary, thyroid, diaphragm, upper lymphs, lung, spinal cord and adrenal glands for 3 weeks. Then data collection tools were applied.
88999870|NCT04756999|Placebo Comparator|Control|informed consent forms, foot massage were performed. Then data collection tools were applied.
88999871|NCT02908555||no intervention|Descriptive study without groups
88999872|NCT02908321|Active Comparator|CBT|
88999873|NCT02908321|No Intervention|WL|
88999874|NCT04743895|Active Comparator|Stainless Steel Wire Cerclage|Sternotomy closure using Stainless Steel Wire Cerclage
88999875|NCT04743895|Active Comparator|FiberTape Cerclage|Sternotomy closure using FiberTape
88999876|NCT04742296|Active Comparator|Treatment group of low level laser therapy|
88999877|NCT04742296|Placebo Comparator|Sham group of low level laser therapy|
88999878|NCT00197808|Experimental|Vaccine schedule 1|Menjugate vaccine at 2 and 3 months
88999879|NCT00197808|Experimental|Vaccine schedule 2|Menjugate vaccine at 2 and 4 months
88999880|NCT00197808|Experimental|vaccine schedule3|Neissvacc at 2 and 3 months
88999881|NCT00197808|Experimental|vaccine schedule 4|Neissvacc at 2 and 4 months
88999882|NCT00197808|Experimental|Vaccine schedule 5|Meningitec at 2 and 3 months
88999883|NCT00197808|Experimental|Vaccine schedule 6|Meningitec at 2 and 4 months
88999884|NCT04710394|Active Comparator|Unimodal Olfactory Training with Conventional Odors|Participants will undergo smell training without a visual component, and train using 4 pre-determined scents: rose, lemon, eucalyptus, and clove.
88999885|NCT04710394|Experimental|Unimodal Olfactory Training with Patient-Preferred Odors|Participants will undergo smell training without a visual component, and undergo an odor selection process in which they choose four scents to train with that they identify as important. A total of 24 scents will be included for patients to select from, including: Lemon, Orange, Grapefruit, Lime, Eucalyptus, Peppermint, Spearmint, Tea Tree, Rose, Lavender, Jasmine, Geranium, Frankincense, Cedarwood, Juniper, Sandalwood, Black Pepper, Oregano, Rosemary, Clove, Vanilla, Coffee, Cinnamon, Nutmeg.
88999886|NCT04710394|Experimental|Bimodal Visual, Olfactory Training with Conventional Odors|Participants will undergo smell training while simultaneously focusing on a picture of the odor, and train using 4 pre-determined scents: rose, lemon, eucalyptus, and clove.
88999887|NCT04710394|Experimental|Bimodal Visual, Olfactory Training with Patient-Preferred Odors|Participants will undergo smell training while simultaneously focusing on a picture of the odor, and undergo an odor selection process in which they choose four scents to train with that they identify as important. A total of 24 scents will be included for patients to select from, including: Lemon, Orange, Grapefruit, Lime, Eucalyptus, Peppermint, Spearmint, Tea Tree, Rose, Lavender, Jasmine, Geranium, Frankincense, Cedarwood, Juniper, Sandalwood, Black Pepper, Oregano, Rosemary, Clove, Vanilla, Coffee, Cinnamon, Nutmeg.
88823583|NCT02479997|Active Comparator|Radioisotope (RI)|"Using RI only as SLNB mapping in breast cancer patients who receive neoadjuvant chemotherapy.~Interventions - patient assigend RI groups are injected only RI~fill the Primay Case Report Form during surgery~PCRF including SLN detection time, duration of SLN approch time to 1st sentinel node dection time, incision length , depth, RI +/- ."
88999888|NCT04632316|Experimental|oNKord®|Allogeneic ex vivo-generated Natural Killer (NK) cells from CD34+ umbilical cord blood progenitor cells
88999889|NCT04630327||Female Cancer Patients|Female cancer patients with no history of previously diagnosed depression or anxiety and who have been referred to or have been receiving treatment at Almaty Oncology Center or Kazakh Scientific Research Institute of Oncology and Radiology
89355829|NCT04450511|Active Comparator|Group 1: Bladder Training (BT)|BT, consisting of four stages, did not contain any PFM training programs in all groups. In these stages, including urgency suppression strategies, it was aimed to delay urination, to inhibit detrusor contraction and to prevent urgency; by squeezing the PFM several times in a row (women were encouraged to pause/stop their work, sit down if possible, relax the entire body and squeeze PFM repeatedly), breathing deeply, giving their attention to another job for a while and self-motivating (I can do it, I can check the urination, etc.).
89399094|NCT02168738|Experimental|13-C labeled AceDoPC-DHA|
89399095|NCT02171546|Active Comparator|Dabigatran etexilate capsules|
89399096|NCT02171546|Experimental|Dabigatran etexilate capsules and quinidine sulfate tablets|
89399097|NCT02171546|Active Comparator|Fexofenadine tablets|
88999890|NCT04626427|Experimental|WavelinQ™ EndoAVF System|The WavelinQ™ EndoAVF System is indicated for the cutting and coagulation of blood vessel tissue in the peripheral vasculature for the creation of an AVF used for HD. The device is intended to be used in patients suffering from chronic kidney disease requiring HD by physicians trained and experienced in endovascular techniques. The WavelinQ™ EndoAVF System will be used for these intended purposes as part of this clinical investigation according to its instructions for use (IFU).
88999891|NCT04612114||Possible OSA|Patients with OSA symptoms (snoring, excessive daytime sleepiness or witnessed apnea, etc.)
88999892|NCT02908204||Endoscopic treatment|Patients underwent endoscopic treatment including Endoscopic Mucosal Resection (EMR), Endoscopic Submucosal Dissection (ESD), Multiband Mucosectomy (MBM), Endoscopic Mucosal Band Ligation(EMBL) and so on.
88999893|NCT02908204||Traditional surgery|Patients underwent traditional surgery
88999894|NCT02908360||Patients with allergic rhinitis|Patients with rhinitis and / or allergic conjunctivitis duly diagnosed according to the ARIA criteria
88999895|NCT02908360||Patients with atopic dermatitis|The patient has moderate classified atopic dermatitis (SCORAD 25 to 50) or severe (SCORAD> 50).
88999896|NCT02908360||Patients with allergic asthma|The patient has allergic asthma diagnosed according to the criteria GINA21
88999897|NCT02908399|Experimental|Thermal Imaging|Imaging using a thermal camera
89533584|NCT04166409|Experimental|Arm II (selumetinib sulfate)|Patients receive selumetinib sulfate PO BID on days 1-28. Treatment repeats every 28 days for up to 27 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood and undergo MRI at baseline, throughout the trial, and during follow up.
88823584|NCT02479997|Active Comparator|Indocyanine green (ICG) +RI|"Dual sentinel node staining method using mixture of indocyanine green (ICG) and radioisotope (RI) in breast cancer patients who receive neoadjuvant chemotherapy.~Interventions - patient assigend RI groups are injected RI +ICG~prepare fluorescence camera when the surgery begin~surgeon uses the camera to decect fluorescence flow on SLN~fill the Primay Case Report Form during surgery~PCRF including SLN detection time, duration of SLN approch time to 1st sentinel node dection time, incision length , depth, RI +/- , ICG+/-"
88823585|NCT03188523|Experimental|MK-8504 100 mg (Panel A)|Participants receive a single oral dose of MK-8504 100 mg.
88823586|NCT03188523|Experimental|MK-8504 240 mg (Panel B)|Participants receive a single oral dose of MK-8504 240 mg.
88823587|NCT03188523|Experimental|MK-8504 ≤240 mg (Panel C)|Participants receive a single oral dose of MK-8504 ≤240 mg.
88823588|NCT03188523|Experimental|MK-8504 ≤240 mg (Panel D)|Participants receive a single oral dose of MK-8504 ≤240 mg.
88823589|NCT01679600|Experimental|FC-RATE|Feedback-controlled robotics-assisted treadmill exercise
88823590|NCT01679600|Active Comparator|RATE|Robotics-assisted treadmill exercise
88823591|NCT02249936|Experimental|AZD1722 HCl Capsule|15 mg bid AZD1722 HCl and 20 mg bid Omeprazole
88823592|NCT02249936|Experimental|AZD1722 HCl Tablet|15 mg bid AZD1722 HCl and 20 mg bid Omeprazole
88823593|NCT02249936|Experimental|AZD1722 Free-base Tablet|15 mg bid AZD1722 and 20 mg bid Omeprazole
88823594|NCT03190005||group 1|placebo control without medication.
88823595|NCT03190005||group 2|hyper-reactive responser after clopidogrel.
88823596|NCT03190005||group 3|hypo-reactive responser after clopidogrel.
88823597|NCT03190005||group 4|normo-reactive responser after clopidogrel.
88823598|NCT03190005||group 5|reaction after OPC-13013
89533585|NCT04123795|Experimental|Cohort A - certolizumab pegol|Enrolling study participants aged 12 to 17 years (inclusive). Study participants in this arm will receive weight-based subcutaneous doses of certolizumab pegol from Week 1 to Week 52 and through the subsequent Open-Label Extension Period.
88823599|NCT03190005||group 6|reaction after AR-C
88823600|NCT03190005||group 7|reaction after simastatin
88823601|NCT03190083|Experimental|3-dimensional tomosynthesis mammogram|The patients assigned a Breast imaging-reporting and data system (BIRADS) 5 category at the time of diagnosis and all new diagnosed breast cancer patients, will undergo a separate 2-D plus DBT in addition to the standard 2-D mammogram
88823602|NCT04798118|Experimental|group treated with toilet bronchoscope|"Toilet bronchoscopy will be done as supportive care to sixty five (COPD,asthma,cystic bronchiectasis ) mechanically ventilated patients who fulfill the following criteria :~Copious secretion~Radiologically diagnosed atelectasis and absent air-bronchograms. Standard care of treatment will be carried out then assessment of a radiological, gasometric improvement and lung mechanics changes."
88999898|NCT02908243||Prophylaxis|Severe hemophilia A patients who receive factor VIII with dose of 15-25 IU/Kg, 2-3 times/week Severe hemophilia B patients who receive factor IX with dose of 30-50 IU/Kg, 1-2 times/week
89533586|NCT04123795|Placebo Comparator|Cohort A - placebo|Enrolling study participants aged 12 to 17 years (inclusive). Study participants in this arm will receive weight-based subcutaneous doses of placebo from Week 1 to 16 and certolizumab pegol to Week 52 and through the subsequent Open-Label Extension Period.
88823603|NCT04798118|Active Comparator|group treated with standered care|"sixty five (COPD,asthma,cystic bronchiectasis ) mechanically ventilated patients who fulfill the following criteria :~Copious secretion~Radiologically diagnosed atelectasis and absent air-bronchograms. Standard care of treatment will be carried out then assessment of a radiological, gasometric improvement and lung mechanics changes."
89355830|NCT04450511|Experimental|Group 2: Bladder Training+Magnetic Stimulation|Patients are told to sit on the chair with a magnetic coil below the chair. When a volume conductor is inserted by this magnetic ﬁeld, an eddy current ﬂow is generated. This eddy current stimulates nerve or muscle of the pelvic ﬂoor. To apply MS, the device was set to generate its maximum stimuli, with a stimulation pulse width of 200 μs and a stimulation repetition cycle of 10 Hz in accordance with the literature. When setting the device at each treatment session, patients were interviewed so that they received stimuli at the maximum stimulation intensity (maximum tolerable stimulation intensity) .
89355831|NCT02505568|Experimental|Infliximab|Participants will receive infliximab 5 milligram per kilogram (mg/kg) infusion at Week 0, Week 2, and Week 6 and will be evaluated for the induction phase at Week 8. Participants who complete the induction phase will continuously receive 5 mg/kg infliximab infusion at Week 14, Week 22, and Week 30 in the maintenance phase and will be evaluated at Week 32.
88823604|NCT03193593|Placebo Comparator|Placebo Injections|"Intervention: Drug: Placebo~Single Saline Injection into the Pectoralis Muscle"
88823605|NCT03193593|Active Comparator|EB-001 Dose 1|"Intervention: Drug: EB-001~1st Dose in escalation paradigm. Single Injection of active drug into the pectoralis muscle"
89355832|NCT03627572||Active cohort (N=1000)|Participants in this group will complete questionnaires at baseline (birth) and after 1-2-3 years. At baseline samples will be collected (blood/nasopharyngeal/urine/feces/buccal). During the RSV season(Oct-May) active sampling for RSV will be done when infants experience a respiratory infection.
89533587|NCT04123795|Experimental|Cohort B - certolizumab pegol|Enrolling study participants aged 6 to 11 years (inclusive). Study participants in this arm will receive weight-based subcutaneous doses of certolizumab pegol from Week 1 to Week 52 and through the subsequent Open-Label Extension Period.
88823606|NCT03193593|Active Comparator|EB-001 Dose 2 (1.6X)|"Intervention: Drug: EB-001~2nd Dose in escalation paradigm, 1.6X Dose 1. Single Injection of active drug into the pectoralis muscle"
88823607|NCT03193593|Active Comparator|EB-001 Dose 3 (3.3X)|"Intervention: Drug: EB-001~3rd Dose in escalation paradigm, 3.3X Dose 1. Single Injection of active drug into the pectoralis muscle"
88823608|NCT03193593|Active Comparator|EB-001 Dose 4 (6.7X)|"Intervention: Drug: EB-001~4th Dose in escalation paradigm, 6.7X Dose 1. Single Injection of active drug into the pectoralis muscle"
88823609|NCT03193593|Active Comparator|EB-001 Dose 5 (10X)|"Intervention: Drug: EB-001~5th Dose in escalation paradigm, 10X Dose 1. Single Injection of active drug into the pectoralis muscle"
88823610|NCT03193593|Active Comparator|EB-001 Dose 6 (13.3X)|"Intervention: Drug: EB-001~6th Dose in escalation paradigm, 13.3X Dose 1. Single Injection of active drug into the pectoralis muscle"
88823611|NCT01461915|Experimental|Run-in|"During the Run-In Period, patients will receive gemcitabine + nab-paclitaxel + dociparstat to assess the compatibility of the combination.~• Nab-paclitaxel + gemcitabine + dociparstat:~Nab-paclitaxel 125 mg/m2 will be administered intravenously (IV) over 30 minutes followed by the administration of gemcitabine IV infusion at 1000 mg/m2 over 30 minutes. Nab paclitaxel + gemcitabine will be administered weekly for 3 weeks followed by 1 week of rest (28-day cycle).~Dociparstat IV bolus at 4 mg/kg will be administered in 5 minutes immediately following the completion of gemcitabine administration.~Dociparstat 48-hour IV continuous infusion at 0.375 mg/kg/hr will be administered immediately following the dociparstat IV bolus administration."
88823612|NCT01461915|Experimental|Arm A|"Patients randomized to Arm A will receive gemcitabine + nab-paclitaxel + dociparstat.~• Nab-paclitaxel + gemcitabine + dociparstat:~Nab-paclitaxel 125 mg/m2 will be administered IV over 30 minutes followed by the administration of gemcitabine IV infusion at 1000 mg/m2 over 30 minutes. Nab paclitaxel + gemcitabine will be administered weekly for 3 weeks followed by 1 week of rest (28-day cycle).~Dociparstat IV bolus at 4 mg/kg will be administered in 5 minutes immediately following the completion of gemcitabine administration.~Dociparstat 48-hour IV continuous infusion at 0.375 mg/kg/hr will be administered immediately following the dociparstat IV bolus administration."
88823613|NCT01461915|Active Comparator|Arm B|"Patients randomized to Arm B will receive gemcitabine + nab-paclitaxel. • Nab-paclitaxel + gemcitabine:~o Nab-paclitaxel 125 mg/m2 will be administered IV over 30 minutes followed by the administration of gemcitabine IV infusion at 1000 mg/m2 over 30 minutes. Nab paclitaxel + gemcitabine will be administered weekly for 3 weeks followed by 1 week of rest (28-day cycle)."
88823614|NCT01682642|Active Comparator|Zoladex|After surgical vaporization of endometriosis patients are treated with Zoladex for 3 months.
88999899|NCT02908243||On-demand|Severe hemophilia A patients who receive factor VIII injection when bleeding occurs with the dose according to the criteria of World Federation of Hemophilia (WFH); Severe hemophilia B patients who receive factor IX injection when bleeding occurs with the dose according to the criteria of World Federation of Hemophilia (WFH)
88999900|NCT02908243||Collection of baseline data in all hemophilia A and B patients|All severe, moderate and mild types of hemophilia A and B patients
89355833|NCT03627572||Passive cohort (N=9000)|Parents who agree with participation in the study will be asked to fill out a questionnaire at inclusion in the first week(s) after birth and at age one year. Only children who were admitted to the hospital for ARTI during the first year of life will be followed up to the age of maximum 3 years by yearly questionnaires.
89355834|NCT05356728|Active Comparator|Thealoz Duo|Thealoz Duo, a combination of trehalose and hyaluronate, will be used on one of the selected eyes of a patient, at least 3 times daily
89355835|NCT05356728|Active Comparator|Hyabak|Hyabak, sodium hyaluronate, will be used on the other eye of the patient, at least 3 times daily
89533588|NCT04121065||Relapsing MS patients|Single Arm: Relapsing Multiple Sclerosis patients ADA SNPs and other biomarkers analyses in blood samples.
89533589|NCT04119791|Experimental|Wild rice|Participants will consume one serving of the test food containing wild rice every day over 28 days.
88999901|NCT02908165|Experimental|Group A- continuous schedule|Subjects with HCC randomized to group A
88999902|NCT02908165|Active Comparator|Group B- sequential schedule|Subjects with HCC randomized to group B
88823615|NCT01682642|No Intervention|vaporization only|Surgical vaporization of the endometriosis is done and patients start IVF without additional treatment.
88823616|NCT01682954|Experimental|Lifestyle counseling|Diabetes Prevention Program lifestyle intervention
88823617|NCT01682954|No Intervention|Usual Care|Usual care from primary care physician
88823618|NCT01683422|Experimental|Proton Radiation|"Pre-Proton-chemotherapy (PCT) Patients will receive a combination of the agents (Gemcitabine plus Erlotinib) for 8 weeks prior to PCT Gemcitabine 1000 mg/m2 IV, days 1, 8, 15, 29, 36 and 43 Erlotinib 100 mg po qd days 1-43~PCT to be started in 4 to 8 weeks after completion of Pre-PCT Proton therapy: 50.4 Gy/28 fractions (1.8 Gy per fraction) once a day for 5 ½ weeks.~Chemotherapy: Capecitabine 825mg/m2 po bid M-F, starting on day 1 of proton therapy until proton therapy completed~Post-PCT to be started in 4 to 6 weeks after completion of PCT Oxaliplatin 130 mg/m2, day 1 Capecitabine 1000 mg/m2 po bid on days 2 to 15 for 14 days The CapOx regimen (Capecitabine plus Oxaliplatin) is repeated every 3 weeks for 4 cycles"
88823619|NCT03194373|Experimental|Palbociclib and Carboplatin|"Treatment with Palbociclib and Carboplatin for up to 6 cycles:~Palbociclib (Ibrance) (PO), dose= 125 mg PO daily, days=1-14, cycle length: 21 days Carboplatin (IV), dose= AUC 5, day= 1, cycle length: 21 days~Maintenance Palbociclib after 6 cycles Palbociclib (Ibrance) 125 mg PO daily, days 1-21, cycle length: 28 days"
88823620|NCT02240654||Dabigatran etexilate|
88823621|NCT00027183||1|Healthy Volunteers
88823622|NCT00027183||2|Cystic Fibrosis subjects
88823623|NCT05066061|Active Comparator|standard|Only use local anesthetic cream
88823624|NCT05066061|Experimental|anxiolytic gas|Use local anesthetic cream and anesthetic and anxiolytic gas
88823625|NCT05066061|Experimental|virtual reality|Use local anesthetic cream and virtual reality mask
88823626|NCT02240810||PLATINUM Diversity (Overall)|PLATINUM Diversity (Overall) population. Test device is Promus PREMIER Everolimus-Eluting Platinum Chromium Coronary Stent System (CSS)
88823627|NCT01683812|Experimental|Cranial Cup Arm|Single arm
88823628|NCT03197025|Experimental|1/Arm 1 - Dose Escalation|Patients will undergo leukapheresis, then treatment with E6 T Cell Receptor (TCR) cells (at escalating doses) + aldesleukin
88823629|NCT03197025|Experimental|2/Arm 2 - Maximum Tolerated Dose (MTD)|Patients will undergo leukapheresis, then treatment with E6 T Cell Receptor (TCR) cells (at the MTD) + aldesleukin
88823630|NCT02249546|Experimental|Acetylcysteine + PPI-amoxicillin-clarithromycin|N-acetylcysteine 600mg bid Dexlansoprazole 60mg qd Amoxicillin 1000mg bid Clarithromycin 500mg bid All for 14 days
88823631|NCT02249546|Active Comparator|PPI-amoxicillin-clarithromycin|Dexlansoprazole 60mg qd Amoxicillin 1000mg bid Clarithromycin 500mg bid All for 14 days
88823632|NCT04333173||Active endovascular treatment|Patients with erectile dysfunction (ED) and no-response to phosphodiesterase-5 inhibitors for at least 6 months before enrollment
88823633|NCT04663737|Experimental|Group A|Group A will receive the best supportive care and/or recommended standard of care (at this point no standard of care drugs are recommended by CDC for patients with moderate COVID-19) in combination with the study drug Silmitasertib
88823634|NCT04663737|Active Comparator|Group B|Group B (control) that will receive the same care as the Group A but without Silmitasertib
88823635|NCT01684436|Experimental|Punctal plug|Punctal plugs inserted into the study eye on Day 1.
88823636|NCT02303093||Octagam|Patient receiving Octagam 5% or 10% IVIG
88823637|NCT02303093||Panzyga|Patient receiving panzyga
88823638|NCT04960215|Active Comparator|Coenzyme Q10|
88823639|NCT04960215|Placebo Comparator|Placebo|
88823640|NCT01684592|Active Comparator|Standard care|Standard care for smokers during pregnancy and referral to 24/7 quitline postpartum (passive)
88823641|NCT01684592|Experimental|Standard care plus PPCC|Standard care for smoking during pregnancy and proactive phone-based postpartum continuing care (PPCC) for 6 months postpartum
88823642|NCT02333045|Experimental|Truvada qd|Women will be assigned at random Truvada 1 tablet PO daily
88823643|NCT02333045|Experimental|Maraviroc 300 qd|Women will be assigned at random Maraviroc 300 mg PO daily
88823644|NCT01684748|Experimental|Olmesartan Medoxomil first, then No Drug|During the First Intervention (8 weeks), subjects will be provided with daily 20 mg of olmesartan for the first 2 weeks. Subjects receive additional daily doses of 40 mg olmesartan for the remainder of the study period (6 weeks). The dose remains at 20 mg per day, however, if BP falls below 110/70 during the first 2 weeks. In addition, subjects will continue taking the drug during the 2-week follow-up testing period. Subjects will then proceed to the Washout period (2 weeks). During the Second Intervention (8 weeks), no drug will be administered to the subjects.
88823645|NCT01684748|Experimental|No Drug first, then Olmesartan Medoxomil|During the First Intervention (8 weeks), no drug will be administered to the subjects. Subjects will then proceed to the Washout period (2 weeks). During the Second Intervention (8 weeks), subjects will be provided with daily 20 mg of olmesartan for the first 2 weeks. Subjects then receive daily doses of 40 mg olmesartan for the remainder of the study period (6 weeks). The dose remains at 20 mg per day, however, if BP falls below 110/70 during the first 2 weeks. In addition, subjects will continue taking the drug during the 2-week follow-up testing period.
88823646|NCT03200535|No Intervention|Usual care|Usual care
88823647|NCT03200535|Active Comparator|"Electronic health record gaps"|Gaps will appear in the electronic health record and patient portal in order to prompt referral by provider or patient
88823648|NCT03200535|Active Comparator|Bulk outreach|Gaps will appear in the electronic health record and patient portal in order to prompt referral by provider or patient; in addition a bulk letter or email will be sent
88999903|NCT04534270|Experimental|Dapagliflozin treatment|
88999904|NCT02908282|Other|PUFA (polyunsaturated fatty acids)-group|REMOGEN OMEGA: Usage according to instructions for use.
88999905|NCT02908282|Other|C (control)-group|Povidone: Usage according to instructions for use.
89355836|NCT02514694|Active Comparator|LEO 32731|Active
89355837|NCT02514694|Placebo Comparator|Placebo|Placebo
88823649|NCT03200535|Active Comparator|Personalized outreach|Gaps will appear in the electronic health record and patient portal in order to prompt referral by provider or patient; in addition a bulk letter or email will be sent and patients will receive a personalized call by a registered dietitian
88823650|NCT03200925|No Intervention|Group A - no video group|"Group A will be asked a short survey:~their intention to practice skin to skin at the time of delivery~if they participated in skin to skin in a previous pregnancy~if they had any formal education about skin to skin~if they did have formal education was it either~a.) Provided at a prenatal appointment,~b.) A formal class led by either a nurse or a lactation consultant.~We will also look at patient's medical record number, age, gestational age, any pregnancy complications, race, type of insurance, and the number of times the patient has been pregnant. We will also examine data that is already collected by this hospital after delivery regarding skin to skin. This includes gestational age in weeks at the time of delivery, 5 minute APGAR, delivery date/time, skin to skin initiation time, skin to skin end time, delivery to skin to skin duration (minutes), and skin to skin duration (minutes)."
88823651|NCT03200925|Experimental|Group B - video group|"Group B will be asked the same short survey as group A.~The patient would then immediately watch Jumping into Kangaroo Care, and then immediately take the post survey which would ask if they intended to practice skin to skin at the time of delivery.~We will also look at patient's medical record number, age, gestational age, any pregnancy complications, race, type of insurance, and the number of times the patient has been pregnant. We will also examine data that is already collected by this hospital after delivery regarding skin to skin. This includes gestational age in weeks at the time of delivery, 5 minute APGAR, delivery date/time, skin to skin initiation time, skin to skin end time, delivery to skin to skin duration (minutes), and skin to skin duration (minutes)."
88823652|NCT01685684|Experimental|Oxycodone DETERx|
88823653|NCT01685684|Placebo Comparator|Placebo|
88823654|NCT02305433|Experimental|Physiotherapy (physical exercise) for frail elderly|Individually tailored, long-term home-based physiotherapy (physical exercise)twice a week for 12 months. The duration of one session is 60 minutes.
88823655|NCT02305433|Experimental|Physiotherapy (physical exercise) for operated hip fracture patients|Individually tailored, long-term home-based physiotherapy (physical exercise)twice a week for 12 months. The duration of one session is 60 minutes.
89355838|NCT05344482||Overall cohort: Secukinumab|Included all the patients treated with secukinumab
88823656|NCT02305433|No Intervention|Usual care for frail elderly|Usual care follows the standard care procedures in the South Karelia Social and Health Care District in health care and in assisted home living.
89355839|NCT01201109||Diabetics|Diabetic patients operated for carpal tunnel syndrome
88823657|NCT02305433|No Intervention|Usual care for operated hip fracture patients|Usual care follows the standard care procedures in the South Karelia Social and Health Care District in health care and in assisted home living.
88823658|NCT04505319|Experimental|DEFINISSE CORE FILLER|"Cross linked sodium hyaluronate 25 mg/ml with 0,3% lidocaine hydrochloride will be inject during the first visit and a touch up after one month if indicated by the physician.~The filler will inject in the face."
88823659|NCT02295059|Experimental|Omega 3 fatty acids - high dose|~5 g EPA+DHA in 5 capsules per day
88823660|NCT02295059|Experimental|Omega 3 fatty acids - low dose|~0.9 g EPA+DHA + fatty acids based on the typical American diet in 5 capsules per day
88823661|NCT04438395||Enrolled AFL and AF Patients|All subjects that are enrolled are group one, as there is only one group of subjects in this study
88823662|NCT04568213|Experimental|Hypochlorous Gel Application|
88999906|NCT02908126|Experimental|Oxytocin intravenous|single dose of intravenous (IV) oxytocin
89355840|NCT01201109||Non-diabetics|Non-diabetic patients operated for carpal tunnel syndrome
89355841|NCT02514616|Active Comparator|Active Electric Stimulation Therapy|The subject receives Active Electric Stimulation Therapy for 12 weeks, 2 weeks after laparoscopic IPG and lead implant procedure. The subject and physician will be blinded to the randomization group assignment. The subject continues on stimulation treatment after 14 weeks and an extended open-label follow-up phase includes annual visits through 5 years.
89355842|NCT02514616|Sham Comparator|Delayed Electric Stimulation Therapy|The subject receives no active Electric Stimulation Therapy for 12 weeks, 2 weeks after laparoscopic IPG and lead implant procedure. The subject and physician will be blinded to the randomization group assignment. The subject will receive Active Electric Stimulation Therapy at week 14 visit, and an extended open-label follow-up phase includes annual visits through 5 years.
89355843|NCT03842735|Experimental|exercise and rehabilitation counselling|Subjects enrolled in exercise group make physical exercises and receive rehabilitative counselling indications
89355844|NCT03842735|Other|rehabilitation counselling|Subjects enrolled in exercise group only receive rehabilitative counseling indications.
89355845|NCT03833843||TGA|
89355846|NCT02510482||Aortic valve stenosis|Individuals with clinically stable moderate aortic valve stenosis
88999907|NCT02908126|Experimental|Oxytocin tablet|single dose of oxytocin tablet
88999908|NCT02907931|Experimental|Subjects|Lower Body Negative Pressure
88999909|NCT04455334|Other|healthy|year 1 study
88999910|NCT04455334|Other|stroke|year 1 study
88999911|NCT04455334|Active Comparator|active control group|year 2 study
88999912|NCT04455334|Experimental|Error-augmented treadmill training|year 2 study
88999913|NCT04455334|Experimental|Error-augmented concept combined physical therapy group|year 3 study
88999914|NCT04455334|Active Comparator|conventional physical therapy group|year 3 study
88999915|NCT02907853|Experimental|Contingency Management|In exchange for consecutive urine samples documenting methamphetamine abstinence, participants receive increasingly valuable reinforcers.
88999916|NCT02907658|Experimental|PROTECT intervention group|The PROTECT intervention group receives the preventive intervention PROTECT (4 modules in 4 subsequent weeks à 90 min). Participants are assessed at T1 (baseline), T2 (post treatment, 1-month follow-up), T3 (4-months follow-up), and T4 (12-months follow-up).
88999917|NCT02907658|No Intervention|Assessment-only control group|The assessment-only control group is an observational condition without intervention. Participants are assessed at T1 (baseline), T2 (1-month follow-up), T3 (4-months follow-up), and T4 (12-months follow-up).
88999918|NCT02907775|Active Comparator|Transcutaneous Electric Nerve Stimulus|Researcher 1 who is blind to patients' allocation group will perform the baseline assessments. The researcher 2 will determine the maximum tolerable level of stimulation. The researcher 2 will demonstrate to the participant how to apply the stimulation and will instruct the participant. The participant will revive the first intervention in the Royal Hallamshire Hospital under supervision of researcher 2. The researcher 2 will then issue the participants in Group-2 (SBS) with Shefstim and six multichannel electrodes. They will instruct each participant to change the electrode once every 3 days. On the 15th day the researcher 2 will visit them at home and issue further 6 multichannel electrodes and collect back the previous set. At the end of week 4, the patient will come to Hospital.
88999919|NCT02907775|Active Comparator|Sensory Barrage Stimulation|Researcher 1 who is blind to patients' allocation group will perform the baseline assessments. The researcher 2 will determine the maximum tolerable level of stimulation. The researcher 2 will demonstrate to the participant how to apply the stimulation and will instruct the participant. The participant will revive the first intervention in the Royal Hallamshire Hospital under supervision of researcher 2. The researcher 2 will then issue the participants in Group-2 (SBS) with Shefstim and six multichannel electrodes. They will instruct each participant to change the electrode once every 3 days. On the 15th day the researcher 2 will visit them at home and issue further 6 multichannel electrodes and collect back the previous set. At the end of week 4, the patient will come to Hospital.
88999920|NCT02907580|Experimental|Local educational data|Local-based educational handout
88999921|NCT02907580|Experimental|National educational data|National-based educational handout
88999922|NCT02907580|No Intervention|Usual care|No educational information other than provided as usual care by health care providers
88999923|NCT04682080|Active Comparator|Needle-free injection group|In needle-free injection techniques, 4% articaine with 1/100.000 epinephrine (Ultracaine DS forte) was injected using the Comfort-In system. Pain intensity and anxiety levels of patients were measured.
88999924|NCT04682080|Active Comparator|Dental injection group|In the conventional dental-injection method, 4% articaine with 1/100.000 epinephrine (Ultracaine DS forte) was injected using a 27G, 50-mm, disposable syringe with a needle. Pain intensity and anxiety levels of patients were measured.
88999925|NCT00407732|No Intervention|SC|standard care
88999926|NCT00407732|Experimental|INT|psychosocial intervention
88999927|NCT04682119|Experimental|LY3526318 (Part A)|LY3526318 administered orally as single ascending doses.
88999928|NCT04682119|Experimental|LY3526318 (Part B)|LY3526318 administered orally as multiple doses.
88999929|NCT04682119|Placebo Comparator|Placebo (Part A)|Placebo administered orally.
88999930|NCT04682119|Placebo Comparator|Placebo (Part B)|Placebo administered orally.
88999931|NCT02907385|Experimental|LifeSeal™ Kit|Stapled Anastomosis is performed according to Standard of Care (SoC) with the addition of LifeSeal™ Kit application during surgery.
88999932|NCT02907385|No Intervention|Standard of Care|Stapled Anastomosis is performed according to SoC without LifeSeal™ reinforcement.
88999933|NCT00198120|Experimental|1|Participants will receive D-Cycloserine for 8 weeks.
88999934|NCT00198120|Placebo Comparator|2|Participants will receive placebo for 8 weeks.
88999935|NCT02907541|Experimental|QI4U Group|Group 1 - Learners who will learn QI methods using eLearning through QI4U
88999936|NCT02907541|Active Comparator|Facilitated Learning Group|Group 2 - Learners who will learn QI methods by facilitated teaching
88999937|NCT02907541|Active Comparator|QI4U and Facilitated Learning Group|Group 3 - Learners who will learn QI methods using a combination of QI4U and facilitated teaching
88999938|NCT02907424|Active Comparator|BP-100|standard treatment
88999939|NCT02907424|Experimental|Num Trey|locally produced RUTF
88999940|NCT02964065|Experimental|LAIV|a single dose of Live-Attenuated influenza Vaccine;Dose: 0.2 ml; Each dose contains not less than 6.9 lg EID50 of type A live attenuated influenza virus reassortants(H1N1 and H3N2), and not less than 6.4 lg EID50 of type B live attenuated influenza virus reassortants.
89399098|NCT02171546|Experimental|Fexofenadine and quinidine sulfate tablets|
88999941|NCT02964065|Placebo Comparator|Placebo|a single dose of Placebo. Inactivated placebo will be identical to LAIV in appearance, ingredients and concentrations, attenuated influenza virus free.
88999942|NCT02907346|Experimental|Reinforcement for wearing CGM|The intervention will reinforce patients for wearing CGM and for uploading it and reviewing its data.
88999943|NCT02907112|No Intervention|Control|Participants to continue on their habitual diet for 4 weeks
88999944|NCT02907112|Experimental|Meat Reduction|Participants asked to reduce their red and processed meat intake by 50% for 12 weeks
88999945|NCT02907190|Experimental|Bean Type|Beans (black; cranberry; great northern; navy; pinto; red) soaked overnight and boiled. 1/2 cup serving eaten by participants at study visit
89399099|NCT04385693|Experimental|Pulpotomy|Group A: The patient will benefit from an experimental treatment: a Pulpotomy. The pulpotomy aims at removing the coronal part of the pulp (the pulp present in the pulp chamber) and filling the pulp chamber with a bioactive material.
89399100|NCT04385693|Active Comparator|Control Group|Group B: Extracted teeth will serve as controls, and information regarding the need or not of space maintenance, and the impact on the occlusion and eruption of the succedaneous permanent tooth will be noted.
89399101|NCT02171624|Experimental|dabigatran etexilate|quinidine run-in, followed by dabigatran+quinine and dabigatran alone in randomized order
89399102|NCT02171624|Experimental|quinidine|quinidine run-in, followed by dabigatran+quinine and dabigatran alone in randomized order
88999946|NCT02907190|Active Comparator|Starchy Foods|1/2 cup serving of rice or paste or potato or corn will be eaten by participants on different study visit
88999947|NCT02964026||Pulmonary artery catheter (PAC)|Patients received a PAC for monitoring purposes
88999948|NCT02964026||No pulmonary artery catheter (PAC)|Patients did not receive a PAC for monitoring purposes
88999949|NCT02907307|Experimental|LactiSal vaginal gel 1%|5g of 1%LactiSal Gel vaginal gel once daily for 6 days
88999950|NCT02907307|Experimental|LactiSal vaginal tablet 50 mg|50 mg of LactiSal vaginal tablet daily for 6 days
88999951|NCT02907307|Active Comparator|Clotrimazole vaginal tablet 100mg|100 mg Clotrimazole vaginal tablet daily for 6 days
88999952|NCT02907229|Experimental|Treatment group|neuroendovascular therapy(NCVC-CS1)
88999953|NCT02907151||pre-consultation survey group|The group completing a pre consultation survey filled the same questionnaire in post consultation but the doctor will see the result in the consultation.
88999954|NCT02907151||Group absence of pre-consultation survey|This group will be a control group to see if there is a difference between completing a pre-consultation survey before or not.
88999955|NCT02206087|Experimental|Cohort 1|100 mg PER977 or placebo administered following heparin sodium
88999956|NCT02206087|Experimental|Cohort 2|200 mg PER977 or placebo administered following heparin sodium
88999957|NCT02206087|Experimental|Cohort 3|300 mg PER977 or placebo administered following heparin sodium
88999958|NCT02206087|Experimental|Cohort 4|400 mg PER977 or placebo administered as a single agent followed by 3-day wash-out. A second dose of 400 mg PER977 or placebo will be administered following heparin sodium injection
88999959|NCT02206087|Experimental|Cohort 5|500 mg PER977 or placebo will be administered following heparin sodium injection
88999960|NCT02206087|Experimental|Cohort 6|600 mg PER977 or placebo will be administered following heparin sodium injection
88999961|NCT02193139|Experimental|WL8713, 6 mg|6 mg WL8713 administered daily
88999962|NCT02193139|Experimental|WL8713, 12 mg|12 mg WL8713 administered daily
88999963|NCT02193139|Experimental|WL8713, 18 mg|18 mg WL8713 administered daily
89533590|NCT04114578||Neonatal profile|ECHO in first 24 hours of life - ideally ECHO at Day 3-5 of life ECHO at 2-3 weeks of life or before discharge (whichever comes first) Data collected at each echocardiography: blood pressure at beginning of ECHO, pre and post-ductal saturation, respiratory support, use of inotropes and dosages, use of iNO and dosage and last blood gas
89533591|NCT04114578||Infant profile ( 4 month and/or 9 month)|Echocardiography Age and stage questionnaires CAT/CLAMS assessment
89533592|NCT04114578||Pediatric profile 3, 5 and/or 8years|Echocardiography Age and stage questionnaires CAT/CLAMS assessment Results from 18 months PMA Bailey will be retrieved
89533593|NCT04114578||Pre-adolescent/adolescent profile 11,14 and/or 17 years|Echocardiography Pediatric Quality of Life inventory survey
88823663|NCT03978767|Experimental|NSAID Analgesic bundle|Ibuprofen 600mg PO q 6 hrs as needed for pain, Acetaminophen 1000mg q 8 hrs as needed for pain, and Oxycodone 5 to 10 mg q 4 hrs as needed for pain. In patients undergoing cesarean section, ketorolac 30mg IV q 6 hrs may be substituted as an IV alternative to ibuprofen for the first 24 hours after surgery
88999964|NCT02193139|Experimental|WL8713, 24 mg|24 mg WL8713 administered daily
89533594|NCT04114435||Neonatal profile|"Echocardiography at:~7 to 10 days of chronological age~35 to 37 weeks post-menstrual age (PMA = corrected age);~39 to 44 weeks PMA; Term equivalent"
89533595|NCT04114435||Infant profile ( between 4 months and 9 months)|"Echocardiography~Ages & stages questionnaires CAT/CLAMS assessment"
89533596|NCT04114435||Pediatric profile (36 months and 5 years)|"Echocardiography~Ages & stages questionnaires CAT/CLAMS assessment~Results from 18 months PMA Bayley will be retrieved Figure 1: Premature population - Groups Recruited simultaneously"
88999965|NCT02193139|Placebo Comparator|Placebo|placebo administered daily
88999966|NCT02191774||Gestational length up to 63 days|Medical abortion at home using 200 mg of Mifepristone orally at the clinic followed by 0.8 mg Cytotec vaginally at home 48 hours later
88999967|NCT02191774||Gestational length 64-70 days|Medical abortion at home using 200 mg of Mifepristone orally at the clinic followed by 0.8 mg Cytotec vaginally at home 48 hours later
88999968|NCT04723550|Experimental|Telemedicine|Diabetes education and support by telemedicine
88999969|NCT04723550|Active Comparator|Usual care|Diabetes education and support in person
88999970|NCT02161627|Experimental|Automatic Control|Automatic Control using Saluda Medical External Trial System
88999971|NCT02161627|Active Comparator|Manual Control|Manual Control using Saluda Medical External Trial System
89533597|NCT04090398|Experimental|Arm I (paclitaxel, radium Ra 223 dichloride)|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15 and radium Ra 223 dichloride IV over 1 minute on day 1 of each cycle. Treatment with radium Ra 223 dichloride repeats every 28 days for 6 cycles and treatment with paclitaxel repeats every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT scan, bone scan and/or MRI, as well as collection of blood samples throughout trial. Patients may optionally undergo SPECT on trial.
88999972|NCT00198354|Experimental|A: pre-operative chemotherapy|pre-operative chemotherapy (gemcitabine+cisplatine, 4 cycles)
88999973|NCT00198354|Experimental|B: pre-operative chemotherapy|pre-operative chemotherapy (paclitaxel+carboplatin, 4 cycles)
88999974|NCT00198354|Experimental|C: peri-operative chemotherapy|peri-operative chemotherapy (gemcitabine+cisplatine, 4 cycles)
88999975|NCT00198354|Experimental|D: peri-operative chemotherapy|peri-operative chemotherapy (paclitaxel+carboplatin, 4 cycles)
88999976|NCT02160262|Experimental|Dasotraline|Dasotraline 4 mg, 6 mg, 8 mg, flexibly dosed
88823664|NCT03978767|Active Comparator|NSAID free analgesic bundle|Acetaminophen 1000mg q 8 hrs as needed for pain, and Oxycodone 5 to 10 mg q 4 hrs as needed for pain.
88823665|NCT04436133|Experimental|vaccine group|
88823666|NCT04436133|Active Comparator|Positive control group|
88823667|NCT01685996|Experimental|zonisamide|participants will receive zonisamide capsules (up to 300 mg) to take once a day.
88823668|NCT01685996|Placebo Comparator|Placebo|Participants will receive placebo capsules to take once a day
88823669|NCT03207399|Other|Epclusa|Epclusa (sofosbuvir 400mg/velpatasvir 100mg) 1 tablet oral or via tube daily for 12 weeks, taken with or without food.
88823670|NCT01687088||chronic migraineurs|At least 8 migraine days per week and headache at least 15 days per month.
88823671|NCT01687088||controls|No significant headache or disability as defined by migraine disability scale.
88823672|NCT04651790|Active Comparator|Vaccine 0-14|Inactivated vaccine against SARS-CoV-2 2 doses on day 0 and 14
88823673|NCT04651790|Experimental|Vaccine 0-28|Inactivated vaccine against SARS-CoV-2 2 doses on day 0 and 28
88823674|NCT04543955|Experimental|Arm 1: Low-Dose Telotristat|Participants in this group will receive 750mg Telotristat per day.
88823675|NCT04543955|Experimental|Arm 2: High-Dose Telotristat|Participants in this group will receive 1500mg Telotristat per day.
88823676|NCT03209505|Other|Eye 1: Low coefficient of friction|Subjects will be fit in a different contact lens brand in each eye. Assignment of the contact lens to each eye will be randomized. Eye 1 will be fit in a contact lens with a low coefficient of friction, Acuvue Oasys.
88823677|NCT03209505|Other|Eye 2: High coefficient of friction|Subjects will be fit in a different contact lens brand in each eye. Assignment of the contact lens to each eye will be randomized. Eye 2 One eye will be fit in a contact lens with a high coefficient of friction, Air Optix Night & Day Aqua
88823678|NCT02196155|Active Comparator|BTX-A|Botulinum A toxin is injected each 100 U in both gastrocnemius muscle-bellies and 50 U in the soleus muscle, i.e. a total of 250 U.
88823679|NCT02196155|Active Comparator|Cortisone|Depot Medrol is injected at the plantar fascia insertion site at the calcaneus
88823680|NCT02196155|Placebo Comparator|Saline|Placebo saline is injected in both gastrocnemius muscle-bellies and in the soleus muscle
88823681|NCT02175173||E2080|Children ages >= 4 years: Patients weighing 15.0-30.0 kg: oral daily dose of 200 mg in two divided doses after meals for the first 2 days. The dose will be increased by up to 200 mg/day every two days. The maintenance dose should be 1000 mg/day in two divided doses after meals. The dose can be increased or decreased within a range not exceeding 1000 mg/day, and should be increased by up to 200 mg/day at intervals not less than 2 days. Patients weighing >= 30.1 kg: Adults: oral daily dose of 400 mg in two divided doses after meals for the first 2 days, then increased by up to 400 mg/day every two days. The maintenance dose should be 1800 mg/day for patients weighing 30.1-50.0 kg, 2400 mg/day for patients weighing 50.1-70.0 kg, and 3200 mg/day for patients weighing 70.1 kg or over in two divided doses after meals. Dose can be increased or decreased within a range not exceeding the above maintenance dose, and should be increased by up to 400 mg/day at intervals not less than 2 days.
88823682|NCT03213405|Active Comparator|Conventional BCG full dose|Participants will receive one full dose of the Conventional BCG vaccine administered as an intradermal injection at study entry.
88823683|NCT03213405|Experimental|rBCG-N-hRSV 1/100 dose|Participants will receive one 1/100 dose of the rBCG-N-hRSV vaccine administered as an intradermal injection at study entry.
88823684|NCT03213405|Experimental|rBCG-N-hRSV 1/10 dose|Participants will receive one 1/10 dose of the rBCG-N-hRSV vaccine administered as an intradermal injection at study entry.
88823685|NCT03213405|Experimental|rBCG-N-hRSV full dose|Participants will receive one full dose of the rBCG-N-hRSV vaccine administered as an intradermal injection at study entry.
88823686|NCT04736043||Patients with resected pancreatic cancer who require adjuvant chemotherapy|
88823687|NCT03215901|Experimental|A Beautiful Future Video|Participants randomized to intervention will view intervention video.
88823688|NCT03215901|Sham Comparator|Active Control Video|Participants randomized to control will watch a video of similar length as the intervention video on a different topic.
88823689|NCT03215901|No Intervention|Pure Control|Participants view no video.
88823690|NCT04121403|Active Comparator|Rituximab|Biosimilar rituximab concentrate for solution for infusion
88823691|NCT04121403|Active Comparator|Cladribine|Mavenclad oral cladribine tablets
88823692|NCT05406141|Experimental|children with food protein allergy|
88823693|NCT04047537|Other|Experimental: WBF-0011|2 capsules/day (one in the morning and one in the evening), taken with meal for 12 weeks
88823694|NCT04047537|Other|Experimental: WBF-0011 (0.2X concentration)|2 capsules/day (one in the morning and one in the evening), taken with meal for 12 weeks
88823695|NCT04047537|Other|Placebo|2 capsules/day (one in the morning and one in the evening), taken with meal for 12 weeks
88823696|NCT03984201|Active Comparator|iTBS over L-DLPFC to dACC|"Participants will receive iTBS (intermittent theta burst stimulation) to the left dorsal lateral prefrontal cortex (L-DLPFC) with high connectivity to the dorsal anterior cingulate cortex (dACC). The L-DLPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 90% of resting motor threshold adjust to the skull to cortical surface distance.~Stimulation will be delivered to L-DLPFC using the MagPRo stimulator."
88823697|NCT03984201|Active Comparator|iTBS over L-DLPFC to sgACC|"Participants will receive iTBS (intermittent theta burst stimulation) to the left dorsal lateral prefrontal cortex (L-DLPFC) with high connectivity to the subgenual cingulate cortex (sgACC). The L-DLPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 90% of resting motor threshold adjust to the skull to cortical surface distance.~Stimulation will be delivered to L-DLPFC using the MagPRo stimulator."
88823698|NCT03984201|Sham Comparator|Sham iTBS over L-DLPFC|"Participants will receive sham iTBS (intermittent theta burst stimulation) to the left DLPFC. The L-DLPFC will be targeted utilizing the Localite neuronavigation system.~Sham stimulation will be delivered to L-DLPFC using the MagPRo stimulator."
88999977|NCT02158585|Placebo Comparator|Placebo|The placebo will match the lamotrigine dosage, frequency and duration.
89355847|NCT02505178|Experimental|Problem Solving Therapy|Study participation will involve 9 study visits over a total of 12 weeks. This includes 5 sessions of Case Manager implemented PST over a period of 8 weeks (week 1, 3, 5, 7, and 9) and 4 assessment visits (baseline, week 4, week 8, and week 12).
89355848|NCT05217524||Pennington and Univ. of Hawaii cohorts|Same protocol but two different sites.
89355849|NCT05217524||Pennington|Primarily non-Hispanic (NH) White and NH Black at PBRC and more Asian and Native Hawaii or Pacific Islander (NHOPI) at Hawaii.
89355850|NCT02510248|Experimental|Study Drug|Study drug will be AL-704 once or twice daily for up to 7 days in dosages ranging from 100 mg to 1500 mg.
88823699|NCT03285555|Active Comparator|STRATAFIX GROUP|For the active arm of the study, wound closure will be performed similarly in 3 layers with the use of barbed equivalents at every layer: STRATIFIX symmetric PDS Plus #1 will be used to close the deep fascia and muscles . The subcutaneous fat layer will be then closed with simple interrupted knots using number 2-0 braided absorbable sutures (Vicryl), followed by closure of the subcutaneous layer using a number 2-0 monofilament absorbable suture with inverted interrupted knots (Monocryl, Ethicon; Johnson & Johnson) followed by the use of steri-strips and glue
88823700|NCT03285555|Placebo Comparator|CONTROL GROUP|For the control arm of the study, wound closure will be performed similarly in 3 layers with the use of vicryl to closure the deep fascia and muscles. The subcutaneous fat layer will be then closed with simple interrupted knots using number 2-0 braided absorbable sutures (Vicryl), followed by closure of the subcutaneous layer using a number 2-0 monofilament absorbable suture with inverted interrupted knots (Monocryl, Ethicon; Johnson & Johnson) followed by the use of steri-strips and glue
88823701|NCT03221595|Experimental|Operative|Patients in the operative arm will undergo best medical management, in addition to surgical stabilization of their displaced rib fractures within 72 hours of admission to the hospital.
88823702|NCT03221595|No Intervention|Non-operative|Patients in the non operative arm will undergo best medical management of their displaced rib fractures.
88823703|NCT03425019|Experimental|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation (tDCS) involves the application of weak direct electric current to the head in a noninvasive and painless manner. tDCS with a constant current intensity of 2 milliamps (mA) will be applied for 20 minutes per session daily for 2 weeks (Monday to Friday) via the Soterix 1x1 tDCS mini-CT Stimulator device. Participants will self-administer tDCS at their home or a private room for two weeks (Mondays-Fridays) under real-time supervision by the research staff.
88823704|NCT01687244|Experimental|rAd-IFN Dose 1x10^11vps/ml|Subjects will be randomly assigned to one of two INSTILADRIN arms.
88823705|NCT01687244|Experimental|rAd-IFN dose 3x10^11 vps/ml|Subjects will be randomly assigned to one of two INSTILADRIN arms.
88823706|NCT03224403|Experimental|Test acetaminophen|Test acetaminophen 1000 mg dose
88823707|NCT03224403|Active Comparator|Commercial acetaminophen|Commercial acetaminophen 1000 mg dose
88823708|NCT03224403|Active Comparator|Commercial ibuprofen|Commercial ibuprofen, 400 mg dose
88823709|NCT03224403|Placebo Comparator|Placebo|Placebo
88823710|NCT02334059|Active Comparator|Ketamine|Ketamine: 0.5 mg/kg IV dose
88823711|NCT02334059|Active Comparator|Ketamine plus magnesium|Ketamine plus magnesium group: 0.5 mg/kg IV dose as well as Magnesium 2 grams IV
88823712|NCT02334059|Placebo Comparator|Placebo|Placebo (normal saline)
88823713|NCT02242994|Experimental|Dynavox Maestro and Experimental App|Receives both Experimental App and Dynavox Maestro to communicate. Each participant will receive both devices. Order of device received is randomly assigned.
88823714|NCT04501523|Experimental|A|ctDNA positive, non-pCR Intervention: Tislelizumab(anti-PD1 antibody) combined with capecitabine
88823715|NCT04501523|Active Comparator|B|ctDNA positive, non-pCR Intervention: capecitabine(standard care)
88823716|NCT04501523|Experimental|C|ctDNA positive, pCR Intervention: capecitabine
88823717|NCT04501523|No Intervention|D|Follow up(standard care)
88823718|NCT04499573|Experimental|intervention/treatment|"Intervention:~Patient (cohort 1 and 2) or donor (cohort 3) leukapheresis~Drug therapy:~Fludarabine 120 mg/m2~Cyclophosphamide 750 mg/m2~Etoposide 450 mg/m2~Cytarabine 900 mg/m2~Dexamethasone 30 mg/m2~Tocilizumab 8 mg/kg BW~Biological:~Cohort 1 and 2: autologous CD19/CD22 CAR-T lymphocytes, dose 0.15 - 1.5х106/kg~Cohort 3: allogeneic CD19/CD22 CAR-T lymphocytes, dose 0.1х106/kg + allogeneic HSCT from a haploidentical or matched related donor"
88823719|NCT01933295|Active Comparator|Sleep Education|Weekly educational emails sent to participants with information about sleep science and tips for better sleep.
88823720|NCT01933295|Experimental|Cognitive Behavioral Therapy for Insomnia|Behavioral treatment (5 component)
88823721|NCT01933295|Experimental|Sleep Restriction Therapy|Brief sleep restriction therapy.
88823722|NCT03425097|Experimental|Fexofenadine then Placebo|Patients in this group will get 2 weeks of fexofenadine, then 1 week of nothing, then 2 weeks of placebo.
88823723|NCT03425097|Experimental|Placebo then Fexofenadine|Patients in this group will get 2 weeks of placebo, then 1 week of nothing, then 2 weeks of fexofenadine.
88823724|NCT03895697|Experimental|Dasiglucagon batch A crossover to dasiglucagon batch B|V2: Single fixed dose (subcutaneous injection) of dasiglucagon batch A then at V3: Single fixed dose (subcutaneous injection) of dasiglucagon batch B
88823725|NCT03895697|Experimental|Dasiglucagon batch B crossover to dasiglucagon batch A|V2: Single fixed dose (subcutaneous injection) of dasiglucagon batch B then at V3: Single fixed dose (subcutaneous injection) of dasiglucagon batch A
88823726|NCT04706871|Experimental|taVNS group|
88823727|NCT04706871|Placebo Comparator|tnVNS group|
88823728|NCT01926041|Experimental|Intervention|A 16-week FIT2 program that combines smoking cessation therapy with individualized behavior coaching in diet and physical activity for PCWG restriction.
88823729|NCT01926041|No Intervention|Control|Usual care
88823730|NCT05440773|Experimental|Treatment group 1 (TG 1)|Group of 8 persons receiving A. afra infusions of 5g/1liter of water, 3drinks a day, daily for 1week (7 days) (current recommendation)
89355851|NCT02510248|Placebo Comparator|Placebo|Placebo to match study drug dosing.
89355852|NCT03833453|Active Comparator|PTSD-EMDR|PTSD treatment
89355853|NCT03833453|Experimental|Integrated DBT-EMDR|Integrated PTSD-PD-treatment
89355854|NCT03886064|No Intervention|Control group|Only measurement of clinical endpoints at time zero, then at 6, 12, 18 and 24 months and minimal counseling.
89355855|NCT03886064|Other|Interventional group|Measurement of clinical endpoints at time zero, then at 6, 12, 18 and 24 months and minimal counseling followed by multi-behavioral intervention adapted to local resources.
89399103|NCT02691767|Experimental|pazopanib|pazopanib 800 mg will be administered orally daily every 3weeks
88823731|NCT05440773|Experimental|Treatment group 2 (TG 2)|Group of 8 persons receiving A. afra infusions of 5g/500ml of water, 2drinks a day, daily for 1week (7 days) (increase concentration and decrease dose frequency).
88823732|NCT05440773|Experimental|Treatment group 3 (TG 3)|Group of 8 persons receiving A. afra infusions,5g/1liter of water, 3drinkss a day, weekly for 4weeks (decrease dose frequency and increase length of treatment).
88823733|NCT05440773|Experimental|Treatment group 4 (TG 4)|Group of 8 persons receiving flavored A. afra infusions, 5g/1liter of water, 3drinks a day, daily for1week (7 days) (current treatment with improved taste).
88823734|NCT05440773|Experimental|Treatment group 5 (TG 5)|Group of 8 persons flavored A. afra infusions, 5g/500ml of water, 2drinks a day, daily for 1 week (7 days) (improved taste, increase concentration and decrease dose frequency).
88823735|NCT05440773|Experimental|Treatment group 6 (TG 6)|Group of 8 persons receiving flavored A. afra infusions, 5g/1liter of water, 3drinks a day, weekly for 4weeks (improved taste, decrease dose frequency and increase length of treatment).
88823736|NCT05440773|Placebo Comparator|Treatment group 7|Group of 4 persons receiving flavored placebo infusions, 5g/liter of water, 3drinks a day, daily for 1week (7 days) (improved taste with no active molecule)
88823737|NCT05440773|Placebo Comparator|Treatment group 8|Group of 4 participants receiving regular tea placebo taken as desired, daily for 1 week (7 days) (Regular tea with no active molecule).
88823738|NCT04736277||Noncardiac surgery|Documentation of HbA1c in patients undergoing noncardiac surgery under general anesthesia
88823739|NCT01769027|Active Comparator|SSRI+AB|Intervention: sertraline+antibiotic (penicillin/azithromycin) 12 weeks treatment with a combination of sertraline (to a maximum of 200 mg/day)and one antibiotic ( benzathine penicillin G 1.200.000 U every 3 weeks or, in case of allergy, azithromycin 500 mg/week ). Patients who will not respond to SSRI+antibiotic (penicillin/azithromycin) will be treated with IVIG (2g/kg over 5 days for 5 consecutive months)
88823740|NCT01769027|Placebo Comparator|SSRI+placebo|Intervention: Sertraline+placebo 12 weeks treatment with a combination of sertraline (to a maximum of 200 mg/day) and a placebo
88823741|NCT04706637|Experimental|evogliptin|evogliptin 5 mg + metformin, oral administration once a day for 48 weeks
88823742|NCT04706637|Active Comparator|dapagliflozin|dapagliflozin 10mg + metformin, oral administration once a day for 48 weeks
88823743|NCT04735809|Placebo Comparator|Placebo|Microcystalline Cellulose
88823744|NCT04735809|Experimental|Treatment|Whole Cell Algae Fermentate
88823745|NCT03294213||aScope 4 Broncho|The only data to be obtained are evaluation forms directly related to the users' perception of the aScope™ 4 Broncho
88823746|NCT04706949|Experimental|Pyrotinib combined with pemetrexed plus carboplatin|
88823747|NCT03434457||Prenatal and 3 to 72 months|
88823748|NCT01582763||GBS|Guillain-Barré syndrome >1000, follow-up 1-3 years
88823749|NCT01582763||NC|Normal controls (NC)
88823750|NCT01582763||IC|Infectious controls (IC)
88823751|NCT01582763||OND|Other neurological diseases (OND)
88823752|NCT02299349|Experimental|bupivacaine liposome suspension|bupivacaine liposome suspension periarticular injection
88823753|NCT02299349|Active Comparator|concentrated multi drug injection|concentrated multi drug periarticular injection
88823754|NCT01239095|Experimental|Green Tea and Milk Thistle Supplements|Patients will receive green tea extract and milk thistle extract supplements for one week prior to surgery and for 30 days after surgery.
88823755|NCT03750461|Experimental|Intervention|Patients undergoing mesh implantation during ileostomy closure to reinforce the abdominal wall
88823756|NCT03296163|Experimental|MB02 (Bevacizumab Biosimilar Drug)|MB02 (Bevacizumab Biosimilar Drug) + Carboplatin/Paclitaxel
88823757|NCT03296163|Active Comparator|EU-approved Avastin®|EU-approved Avastin® + Carboplatin/Paclitaxel
88823758|NCT01987349|Other|Group A: age 8-17 yo identical twins|Participants will be randomized to receive either Fluzone® (intramuscular) or FluMist® (intranasal)
88823759|NCT01987349|Other|Group B: 18-30 yo identical twins|Participants to receive FluMist® (intranasal)
88823760|NCT01987349|Other|Group C: 18-30 yo fraternal twins|Participants to receive FluMist® (intranasal)
88823761|NCT01987349|Other|Group D: 40-49 yo identical twins|Participants to receive FluMist® (intranasal)
88823762|NCT01987349|Other|Group E: 40-49 yo fraternal twins|Participants to receive FluMist® (intranasal)
88823763|NCT01987349|Other|Group F: 70-100 yo twins|Participants to receive Fluzone® (intramuscular)
88823764|NCT01987349|Other|Group G: 70-100 yo non-twins|Participants to receive Fluzone® (intramuscular)
88823765|NCT01987583|Experimental|Wet cupping and conventional treatment|"Wet cupping: Will be administered through 3 sessions every other day, on the 17th, 19th and 21st days of the lunar month.~Conventional treatment: Is the usual anti-HTN treatment taken by the patients at the King Abdulaziz university hospital outpatient department."
89399104|NCT03696849|Active Comparator|glazed emax Press|
88823766|NCT01987583|Active Comparator|Conventional treatment|Conventional treatment: Is the usual anti-HTN treatment taken by the patients at the King Abdulaziz university hospital outpatient department
88823767|NCT03435783|Experimental|Intervention|
88823768|NCT03435783|Active Comparator|Attention-matched control|
88823769|NCT01988129|Experimental|Intervention|Workplace-based fatigue risk management program consisting of sleep health education and sleep disorders screening. The 32 fire department stations were paired according to the previous calendar years' workload. One station from each pair was randomly assigned to receive the intervention program. Sleep education sessions were scheduled according to station. On the education day(s) assigned to that stations, all personnel present that day were instructed to attend, and 542/601 did so.
88823770|NCT01988129|No Intervention|Control|"Current practice. Firefighters in the Control Stations continued their normal role and were not invited to attend the sleep education and sleep disorders screening program. There was no formal contact with the control group.~As part of normal operational requirements, a small number of firefighters are reassigned to other stations each day and therefore 18/588 firefighters from control stations happened to be reassigned to an intervention station on the day of the education session and attended the session."
88823771|NCT02300285|Experimental|CGM Protocol|Subjects will receive continuous glucose monitoring and caregivers will be able to view continuous glucose measurements.
89399105|NCT03696849|Experimental|Polished emax Press|
88823772|NCT02300285|Placebo Comparator|Standard of Care|Subjects will receive continuous glucose monitoring but caregivers will not be able to view continuous glucose measurements.
88823773|NCT01989221|Other|Placebo followed by Sancuso|Placebo at baseline for one week followed by Sancuso® (granisetron transdermal system) 3.1 mg/24 hours for two weeks
88823774|NCT03226899|Active Comparator|Lesinurad + XOI|lesinurad 200 mg oral tablet QD plus a stable, medically appropriate dose of an XOI
88823775|NCT03226899|Placebo Comparator|Placebo + XOI|placebo tablet QD plus a stable, medically appropriate dose of an XOI
88823776|NCT01990703|Experimental|Early IUD Insertion Group|Immediate post-placental placement of the levonorgestrel IUD
88823777|NCT01990703|Active Comparator|Standard Postpartum Insertion Group|Placement of the levonorgestrel IUD 4-6 weeks postpartum
88823778|NCT01958645|Experimental|A|MEDI8111
88823779|NCT01958645|Placebo Comparator|B|Placebo for MEDI8111
88823780|NCT03437031|No Intervention|Latent-Control|Patients in the latent phase of labor who will receive no intervention.
88823781|NCT03437031|Experimental|Latent-Virtual Reality (VR)|Patients in the latent phase of labor who will receive the Virtual Reality (VR) intervention.
88823782|NCT01959113|Experimental|Autologous Microbiome Transplant|Each individual's autologous microbiome transplant cream will be applied to one of their arms. This arm is the treatment arm.
88823783|NCT01959113|Placebo Comparator|Placebo Arm|This arm will have a base moisturizer alone applied to it during the third visit.
88823784|NCT03438045|Experimental|Partnered Intervention|The aspects of the partnering package of evidence-based intervention strategies are: (1) written agreements of collaboration for dental screening, health promotion, and incentives; (2) culturally-tailored and language-specific adaptation of materials; (3) demonstrations with role-playing of proper brushing with fluoride toothpaste and flossing techniques; and (4) CHW follow-up with patients of oral health care receipt and dental hygiene behaviors. Additionally, bilingual (English and Mandarin Chinese) CHWs will receive additional training in oral health promotion demonstration, oral health services and programs available at local clinics and hospitals, information about dental and health insurance, and evidence-based oral health behaviors.
88823785|NCT02301299||Community-based Stroke Awareness Program|Neighborhoods in the south side of Chicago surrounding a primary stroke center hospital will be targeted for a community-partnered stroke awareness and action educational campaign. To assess the effectiveness of this intervention, the investigators will monitor early hospital arrival and EMS use for stroke over a 60-month period comparing performance at the primary stroke center hospital using an interrupted time-series analysis.
88823786|NCT03230175|Experimental|TTAX01 plus standard care|Eligible consenting subjects will undergo a baseline aggressive debridement in the operating room to remove infected and devitalized bone and soft tissue. A six week course of systemic antibiotics will be used to resolve baseline infection. TTAX01 will be applied to the debrided wound bed at baseline, and if healing is not evident, it will be applied again at 4 week intervals. At each weekly visit the wound will be further debrided as necessary.
88823787|NCT01992185|Active Comparator|Photocil for Vitiligo|Active Drug - Photocil for Vitiligo
88823788|NCT01992185|Placebo Comparator|Placebo - Sunscreen (SPF 2)|Placebo - Sunscreen (SPF 2)
88823789|NCT03231345|Experimental|US guided IJ|A physician placed ultrasound-guided IV in the internal jugular vein
88823790|NCT03296787|Experimental|Group A TAK-954 0.2 mg: Healthy Participants|Participants with normal renal function receive TAK-954 0.2 milligram (mg), infusion, intravenously in fasted state, once on Day 1 of a 6-day period.
88823791|NCT03296787|Experimental|Group B TAK-954 0.2 mg: Mild Renal Impairment|Participants receive TAK-954 0.2 mg, infusion, intravenously in fasted state, once on Day 1 of a 6-day period.
88823792|NCT03296787|Experimental|Group C TAK-954 0.2 mg: Moderate Renal Impairment|Participants receive TAK-954 0.2 mg, infusion, intravenously in fasted state, once on Day 1 of a 6-day period.
88823793|NCT03296787|Experimental|Group D TAK-954 0.2 mg: Severe Renal Impairment|Participants without hemodialysis or End-stage Renal Disease (ESRD) receive TAK-954 0.2 mg, infusion, intravenously in fasted state, once on Day 1 of a 6-day period.
88823794|NCT03296787|Experimental|Group E TAK-954 0.2 mg: End-stage Renal Disease (ESRD)|Participants with hemodialysis receive TAK-954 0.2 mg, infusion, intravenously in fasted state, once on Day 1 of a 4-day period followed by a minimum 13-day washout period, further followed by TAK-954 0.2 mg, infusion, intravenously in fasted state, once on Day 1 of a 4-day period.
88823795|NCT02301377|Active Comparator|Intervention Group|Participants will receive a Spiro PD personal spirometer that will allow them to measure their lung function at home and provide medication reminders. Participants will be instructed to use the device to check their lung function once a week. They will also be asked to use the medication reminder feature of their device daily. Participants in this group will receive a telephone call once a week from the research team to review lung function results and answer questions. All participants need to fill out a quality of life questionnaire at the time of enrollment and at the end of the study. Participants will be asked to sign a release form so their pharmacies can be contacted for prescription refill data to monitor adherence over the course of the study. All participants will be asked to come to their quarterly clinic visits with their pediatric pulmonologist where their height, weight, body mass index, lung function and frequency of hospitalizations will be assessed.
88823796|NCT02301377|No Intervention|Control|Participants will be asked to fill out a quality of life questionnaire at the time of enrollment and at the end of the study. All participants will be asked to come to their quarterly clinic visits with their pediatric pulmonologist where their height, weight, body mass index, lung function and frequency of hospitalizations will be assessed. All participants will be asked to sign a release form so their pharmacies can be contacted for prescription refill data to monitor adherence over the course of the study.
88823797|NCT04332627|Active Comparator|sugammadex|sugammadex 2mg/kg or 4mg/kg according to Train-of-four count (TOF 0 : 4mg/kg, TOF 1-4 : 2mg/kg)
88823798|NCT04332627|Placebo Comparator|neostigmine|with glycopyrrolate 0.4mg, neostigmine 0.02mg/kg or 0.04mg/kg or 0.05mg/kg according to Train-of-four count (TOF 0 : wait until TOF 2, TOF2-3: 0.05mg/kg, TOF4: 0.04mg/kg)
88823799|NCT03440229|No Intervention|Emuslfier-free diet|This is western style diet prepared without any emulsifiers. Emulsifier free brownies and sorbet are provided daily.
88823800|NCT03440229|Experimental|Emulsifier-containing diet|This is a western style diet prepared without any emulsifiers with the exception of the CMC that is included in brownies and sorbet that are provided daily.
89533598|NCT04090398|Active Comparator|Arm II (paclitaxel)|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT scan, bone scan, and/or MRI, as well as collection of blood samples throughout trial. Patients may optionally undergo SPECT on trial.
88823801|NCT01961921|Experimental|ALN-TTR02 (patisiran)|
88823802|NCT01963091|Experimental|oxytocin|
88823803|NCT01963091|Placebo Comparator|placebo|
88823804|NCT01963169|Experimental|TO-BoneHealth Group|The group will use the 8-week TO-BoneHealth program, which includes: (1) web learning modules, (2) moderated discussion boards, (3) an Ask-the-Experts section, and (4) a virtual library. In addition, a tool kit and video lecture library are also available to participants. The program will be closed after 8 weeks, and there will be no eNewsletter or bi-weekly follow-ups of bone health behavior goal attainment. After 8 weeks, participants will receive a monthly e-mail informing them of the upcoming surveys.
88823805|NCT01963169|Experimental|TO-BoneHealth Plus Group|The group will use the TO-BoneHealth Plus program intervention, which includes the 8-week TO-BoneHealth program followed by bi-weekly theory-based eNewsletters with follow-up of each individual's maintenance of bone health behaviors for 10 months.
88823806|NCT01963169|No Intervention|Control Group|No specific intervention will be provided to the control group participants. To keep in contact with participants, a monthly e-mail will be sent to inform them of upcoming follow-up surveys. At the end of the study (upon completion of all five surveys), the control group participants will receive a CD version of the TO-BoneHealth program via mail.
88823807|NCT03298035|Active Comparator|NCPAP as mode for apnea prevention|With recurrence of apneic events, infants on NCPAP will have changes made in NCPAP settings per the clinical team's discretion in attempt to prevent future apneic events. If apneic events persist despite NCPAP adjustments, clinicians may intubate based on clinical judgment.
88823808|NCT03298035|Experimental|NIPPV as rescue mode for apnea prevention|With recurrence of apneic events, infants will be placed on NIPPV with settings and adjustments per the clinical team's discretion. If apneic events persist despite NIPPV placement and setting adjustments, clinicians may intubate based on clinical judgment.
88823809|NCT02306759|Experimental|Treatment|Ketamine 0.3mg/kg intravenous piggyback (IVPB) in 50ml NS over 15 minutes Morphine 0.1mg/kg intravenous push (IVP) PRN at designated intervals
88823810|NCT02306759|Placebo Comparator|Placebo|Normal saline 50ml intravenous piggyback (IVPB) over 15 minutes Morphine 0.1mg/kg intravenous push (IVP) PRN at designated intervals
88823811|NCT03592589|No Intervention|control group|standard general anesthesia using sevoflurane delivered by a pediatric high concentration mask
88823812|NCT03592589|Experimental|Intervention group|sevoflurane will be deliver by a pediatric high flow nasal canula (2L/KG/min)
88823813|NCT03298113|Experimental|Cavilon Advanced Skin Protectant|Product applicator contains liquid barrier and is applied according to the 3M manufacturer's instructions for use.
88823814|NCT03298113|Other|IAD Hospital Standard Care|Marketed products are applied according to the IAD hospital standard care routine.
88823815|NCT03440619|Experimental|INVSENSOR00013 Test group|All subjects will be enrolled into the test group and will receive the INVSENSOR00013 investigational device.
88823816|NCT03232749|Other|symptomatic primary osteoarthritis of the shoulder|Subjects enrolled into the study will be those who have failed previous treatment including over-the-counter analgesics and activity modification, and have elected to receive a medically-indicated, ultrasound-guided IACSI in the shoulder
88823817|NCT03232827|Active Comparator|Flavored-sweetened|Flavored-sweetened (FS) WP tobacco will be associated with longer and more frequent puffing resulting in the greatest overall levels of smoke inhalation (mL of smoke inhaled), highest abuse potential, and greatest levels of exposure to nicotine and carbon monoxide (CO). , followed by unflavored-sweetened WP, and lastly unflavored-very low sweetened WP. (H1d) A majority of WP smokers will report having initiated WP smoking with flavored-sweetened tobacco and report flavoring as an important reason for trying WP.
88823818|NCT03232827|Active Comparator|Unflavored-sweetened|Unflavored-sweetened (US) WP will be associated with the second longest and slightly less frequent puffing than FS resulting in the second greatest overall levels of smoke inhalation (mL of smoke inhaled), abuse potential, and levels of exposure to nicotine and carbon monoxide (CO).
89355856|NCT02514538|Experimental|Non-effervescent tablets|Comparing the effect of two different formulations of paracetamol (effervescent or non-effervescent tablets) in the blood pressure of hypertensive patients after 3 weeks treatment . The washing time between the two periods is approximately 1 week (minimum 3 days).
88823819|NCT03232827|Active Comparator|Unflavored very low sweetened|Unflavored-very low sweetened (UU) WP will be associated with the shortest and the least frequent puffing resulting in the least overall levels of smoke inhalation (mL of smoke inhaled), abuse potential, and levels of exposure to nicotine and carbon monoxide (CO).
88823820|NCT03232827|Active Comparator|Flavored-very low sweetened waterpipe|Flavored-very low sweetened WP will be associated with the third longest and slightly less frequent puffing than US resulting in the third greatest overall levels of smoke inhalation (mL of smoke inhaled), abuse potential, and levels of exposure to nicotine and carbon monoxide (CO).
88823821|NCT01687400|Experimental|Decitabine|Patients receive decitabine IV over 1 hour on days 1-10 of a 28-day cycle. Treatment continues for 2 cycles. Patients then receive decitabine IV over 1 hour on days 1-10, 1-5, or 1-3 (depending on response). Treatment continues in the absence of disease progression or unacceptable toxicity.
88823822|NCT01687790|Experimental|molecular breast imaging|
89177073|NCT00448669|Active Comparator|TDF-FTC,condoms,adh/risk counseling|Eligible participants were randomized to oral Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg (TDF-FTC) once daily in the form of a single tablet. The ratio of randomization was 1:1. Participants randomized to the active arm received male and female condoms, risk reduction counseling, adherence counseling, and routine monitoring for HIV infection, laboratory abnormalities, and adverse events.
89355857|NCT02514538|Active Comparator|Effervescent Paracetamol|Comparing the effect of two different formulations of paracetamol (effervescent or non-effervescent tablets) in the blood pressure of hypertensive patients after 3 weeks treatment . The washing time between the two periods is approximately 1 week (minimum 3 days).
89533599|NCT04083235|Experimental|Irinotecan liposome injection + Oxaliplatin + 5-FU/LV|Irinotecan liposome injection, oxaliplatin, 5 FU/LV, will be administered on Days 1 and 15 of each 28-day cycle (until progression or unacceptable toxicity).
88823823|NCT01688102|Active Comparator|Oral Vitamin D3|Participants will receive oral vitamin D3 50,000 units weekly for 8 weeks. If 25(OH)D levels remain <35 ng/ml, subjects will receive additional doses of oral vitamin D.
88823824|NCT01688102|Active Comparator|Ultraviolet Light|Subjects will receive 16 treatments with ultraviolet light (narrow band UVB) over 8 weeks. If 25(OH)D levels remain <35 ng/ml, subjects will receive additional doses of narrow band UVB.
88823825|NCT01994993|Active Comparator|Group 1 (ampicillin +gentamycin +metronidazole)|Ampicillin and gentamycin and metronidazole
88823826|NCT01994993|Active Comparator|Group 2 (ampicillin +gentamicin+clindamycin)|ampicillin and gentamicin and clindamycin
88823827|NCT01994993|Active Comparator|Group 3 (piperacillin-tazobactam and gentamicin)|piperacillin-tazobactam and gentamicin
88823828|NCT01994993|Active Comparator|Group 4 (metronidazole)|Per standard of care antibiotics, and Metronidazole
88823829|NCT01994993|Active Comparator|Group 5 (metronidazole/clindamycin/piperacillin-tazobactam)|metronidazole, clindamycin, or piperacillin-tazobactam
88823830|NCT04735887|Experimental|SADL-eM & conventional therapy|Patients with SCI treated in an inpatient rehabilitation setting who receive a copy of the SADL-eM in addition to conventional therapy.
88823831|NCT04735887|No Intervention|Conventional therapy|Patients with SCI treated in an inpatient rehabilitation setting who receive conventional therapy.
88823832|NCT01688336|Experimental|FOLFIRINOX|FOLFIRINOX given to all subjects
88823833|NCT03300843|Experimental|Peptide loaded dendritic cell vaccine|Peptide loaded dendritic cell vaccine on days 0, 14, 28, and 42
88823834|NCT01963481|Experimental|Exemestane and cyclophosphamide|"A treatment cycle is defined as 4 weeks:~One tablet (25 mg) of exemestane and one tablet (50 mg) of cyclophosphamide given daily by mouth until disease progression or unacceptable adverse events."
88823835|NCT03301779|Experimental|Investigational Product|Blood product from these donors will be processed and stored using the Hemanext Red Blood Cell Processing System
88823836|NCT03301779|No Intervention|Control Product|Blood product from these donors will be stored in a Haemonetics Leukotrap Whole Blood System.
88823837|NCT01689350|No Intervention|Control Group|The cases in control group received traditional therapy that the initial dose of cyclophosphamide (CPA) was 0.2-0.6g/week injection according to clinical experience.
89355858|NCT05219786|Experimental|Decision Support Tool|In this arm study participants saw a decision support tool consisting of a video and a interactive decision aid (www.appyornot.org).
88823838|NCT01689350|Experimental|Experimental Group|Genetic: Genotype Detection To Genotype cases in the experimental group and divide them into three groups, including extensive metaboliser (EM), intermediate metaboliser (IM) and poor metaboliser (PM),with initial dose of CPA as 0.2g, 0.4g and 0.6g per week by injection, respectively.
88823839|NCT03302091|Experimental|BI 1467335 Normal (R)|Participants with normal renal function.
88823840|NCT03302091|Experimental|BI 1467335 Moderate (T)|Participants with moderate renal impairment.
88823841|NCT03442725|Experimental|Severely decreased renal function group|Subjects will receive a single oral 250-mg tablet dose of Telotristat etiprate (Xermelo® 250 mg) on day 1 under fed conditions (i.e. between 15 minutes before and 1 hour after the meal or snack).
88823842|NCT03442725|Active Comparator|Normal renal function group|Subjects will receive a single oral 250-mg tablet dose of Telotristat etiprate (Xermelo® 250 mg) on day 1 under fed conditions (i.e. between 15 minutes before and 1 hour after the meal or snack).
88823843|NCT03442725|Experimental|Mildly decreased renal function group|Subjects will receive a single oral 250-mg tablet dose of Telotristat etiprate (Xermelo® 250 mg) on day 1 under fed conditions (i.e. between 15 minutes before and 1 hour after the meal or snack).
88823844|NCT03442725|Experimental|Moderately decreased renal function group|Subjects will receive a single oral 250-mg tablet dose of Telotristat etiprate (Xermelo® 250 mg) on day 1 under fed conditions (i.e. between 15 minutes before and 1 hour after the meal or snack).
88823845|NCT04436744|Experimental|Giredestrant + Palbociclib|
88823846|NCT04436744|Active Comparator|Anastrozole + Palbociclib|
88823847|NCT03447015|Experimental|Ambulation during labour|"women will be encouraged to ambulate Ambulation during labour here will refer to moving from place to place during the first stage of labour that reduces the amount of time a woman spends laying down during this stage (measured by recording the number of minutes spend on walking)."
88823848|NCT03447015|No Intervention|Standard Maternity care|women will receive usual maternity care.
88823849|NCT03302793|Experimental|BreEStim and tDCS sham, then combined BreEStim and tDCS|BreEStim is voluntary breathing controlled electrical stimulation.
88823850|NCT03302793|Experimental|Combined BreEStim and tDCS, then BreEStim and tDCS sham|BreEStim is voluntary breathing controlled electrical stimulation. tDCS is transcranial direct current stimulation.
88823851|NCT01963793|Other|placebo (left) / aprepitant (right)|placebo (on defined treatment area on left side of the body) / aprepitant (on defined treatment area on right side of the body)
88823852|NCT01963793|Other|aprepitant (left) / placebo (right)|aprepitant (on a treatment area on the left side of the body) / placebo (on a treatment area on the right side of the body)
88823853|NCT03449433|Experimental|LY900014|T1DM participants received a single, individualized, subcutaneous (SC) dose of LY900014.
88823854|NCT03449433|Active Comparator|Insulin Lispro (Humalog®)|T1DM participants received a single, individualized, SC dose of insulin lispro.
88823855|NCT03449433|Active Comparator|Insulin Aspart (NovoRapid®)|T1DM participants received a single, individualized, SC dose of insulin aspart.
88823856|NCT03449433|Active Comparator|Insulin Aspart (Fiasp®)|T1DM participants received a single, individualized, SC dose of insulin aspart.
89355859|NCT05219786|Active Comparator|Infographic|Participant saw a static infographic providing information about the two treatments for appendicitis.
88823857|NCT03449433|No Intervention|Healthy Participants|Healthy participants who received no study drug.
88823858|NCT03241485|Placebo Comparator|Placebo|60 patients will be randomly assigned to this arm. The patients in this arm will receive intrathecal saline.
88823859|NCT03241485|Active Comparator|Intrathecal morphine|60 patients will be randomly assigned to this arm. The patients in this arm will receive intrathecal morphine.
88823860|NCT01965665|Experimental|Medihoney HCS dressing|weekly Medihoney pin site care until frame removal. Standard size dressings and application technique will be used at each pin site with prefabricated materials.
88823861|NCT03304119||Patellar instability group|Group of patients with patellar instability stemming from a recurrent patellar dislocation
88823862|NCT03304119||Control group control|Group that has not been checked for patellar instability.
88823863|NCT01965899|Experimental|Insertable Cardiac Monitor Implant|
88823864|NCT03415880|Other|Control group|Participants attend 4 workshops and undergo all measurements at t=0, t=3, t=6, and t=12 months.
88823865|NCT03415880|Experimental|Intervention group|Participants attend 4 workshops, receive a wrist-worn feedback physical activity monitor, a smartphone app, and telephone coaching. All participants undergo all measurements at t=0, t=3, t=6, and t=12 months.
88823866|NCT03450369|Experimental|NB01|"NB01 is a live probiotic containing a single strain of P. acnes, frozen, on a pad, in a single use pouch, for topical application.~Open label and dose escalation of a single application of NB01 to subjects with moderate acne, with approximately 5 subjects assigned to lower bound dose before escalation to upper bound dose."
88823867|NCT01996943|Placebo Comparator|Placebo|The placebo will be administered to participants after the baseline electrophysiologic measurements are recorded.
88823868|NCT01996943|Active Comparator|Ethanol|Ethanol (alcohol) will be administered to participants after the baseline electrophysiologic measurements are recorded.
88823869|NCT04812626|Experimental|Group A: Intralesional (IL) triamcinolone acetonide (TAC) alone;|Group A: 1 ml of 40mg/ml triamcinolone acetonide will be mixed with 1ml of normal saline. 5 units (0.125ml) of the mixture will be given intralesional with the help of 1ml insulin syringe of 40units,covering an area of 0.5X0.5 cm2 of scar. Each extra area of 0.5x0.5cm2 will be given 5 units of injection of above mixture of drugs( maximum dose=2ml). Follow up Injection will be given at 2 weeks interval for total of 6 sessions (at 0,2, 4, 6,8,10 weeks) Post treatment follow up: at 12 weeks.
88823870|NCT04812626|Experimental|Group B: Intralesional triamcinolone acetonide and 5-fluorouracil (5-FU) combination|"Group B: 1 ml of 40 mg/ml triamcinolone acetonide will be mixed with 1ml of 50 mg/ml FU.~Injection Method: Five units (0.125ml) of the mixture will be given intralesional with the help of 1ml insulin syringe of 40units, that covers an area of about 0.5X0.5 cm2 of scar, each extra area of 0.5x0.5cm2 will be given 5 units of injection of above mixture of drugs. (maximum dose 2ml). Follow up Injection will be given at 2 weeks interval for total of 6 sessions (at 0,2, 4, 6,8,10 weeks), Post treatment follow up: at 12 weeks."
88823871|NCT04265222|Other|Conventional Fluoroscopy|Participants undergoing femoroplasty with conventional treatment
88823872|NCT04265222|Experimental|HipCheck|Participants undergoing femoroplasty with Stryker HipCheck System
88823873|NCT04249700|Experimental|Whole-body Hyperthermia (WBH)|All participants receive WBH for 80-110 minutes in the Curve Sauna Dome infrared sauna. Participants lay supine in the sauna during this time, and their head is external to the sauna.
88823874|NCT04197986|Experimental|Infigratinib 125 mg|Participants will be randomly assigned (1:1) to receive oral infigratinib administered once daily for the first 3 weeks (21 days) of each 28-day cycle for a maximum of 52 weeks
88823875|NCT04197986|Placebo Comparator|Placebo|Participants will be randomly assigned (1:1) to receive oral placebo administered once daily for the first 3 weeks (21 days) of each 28-day cycle for a maximum of 52 weeks
88823876|NCT01997411|Experimental|Nasal Glucagon (NG)|Nasal glucagon (NG) doses of 2.0 mg and 3.0 mg for participants 4 to less than 12 years of age and 3.0 mg for those 12 to less than 17 years of age were administered in a nostril with a prefilled delivery device that delivered a single dose upon activation.
88823877|NCT01997411|Active Comparator|Intramuscular (IM) Glucagon|Participants who weighed at least 25 kilograms (kg)/55 pounds (lbs) were dosed 1 mg of IM glucagon; participants who weighed less than 25 kg/55 lbs, IM glucagon dosed with 0.5 mg
88823878|NCT01997723|Experimental|OSA testing|Cross-over design, single group/arm Interventions: polysomnography with simultaneous portable monitoring and home portable monitoring administered to each participant in random order.
88823879|NCT03534635|Experimental|Pembrolizumab|"Pembrolizumab 200 mg will be administered intravenously every 3 weeks, for a maximum of 2 years, until progression, unacceptable toxicity, or withdrawal of consent, whichever happens first.~Patients may be treated for up to one year of additional treatment with pembrolizumab via the Second Course Phase, and according to defined criteria."
88823880|NCT01998269||Adult patients with diabetes and hypertension|
88823881|NCT03464201|Experimental|Enzalutamide|Enzalutamide 160 mg daily p.o. (4 capsules 40mg per day)
88823882|NCT02243306|Experimental|Cohort 1|Subjects on continuous ambulatory peritoneal dialysis (CAPD) will receive 5 mg of GSK1278863 orally, once daily for 14 days.
88823883|NCT02243306|Experimental|Cohort 2|Subjects on automated peritoneal dialysis (APD) will receive 5 mg of GSK1278863 orally, once daily for 14 days
88823884|NCT01999517|Active Comparator|Intravenous Nitroglycerin|IV Nitroglycerin with IV Fluids
88823885|NCT01999517|Placebo Comparator|Placebo|IV Fluids
88823886|NCT01999985|Experimental|Dose Escalation and Dose Expansion|"Dose escalation followed by dose expansion. Escalation cohort: Afatinib and Dasatinib. This study is divided into two parts. The first 8 - 18 people will be entered in the first part, called Phase 1A. Then this part will end.~Expansion cohort:: Afatinib and Dasatinib. The next 20 people will enter into the second part, called Phase 1B."
88823887|NCT01968317|Experimental|Megestrol acetate and metformin|Patients will receive metformin 500 mg by mouth third daily and megestrol acetate 160 mg by mouth daily for 3 months.Then an hysteroscope will be used to evaluate the endometrial condition, and the findings will be recorded.
88823888|NCT01968317|Experimental|Megestrol acetate|Patients will receive megestrol acetate 160 mg by mouth daily for 3 months.Then an hysteroscope will be used to evaluate the endometrial condition, and the findings will be recorded.
88823889|NCT02002871|Experimental|Blue light|Irradiation with PSOCT02 device emitting blue light at a wavelength of 453nm
88823890|NCT02002871|No Intervention|Control|contralateral untreated control plaque on the same patient.
88823891|NCT03450915|Experimental|M-001|Participants will be vaccinated with 1mg dose of M-001 twice: Once at Day 0, and once at Day 21.
88823892|NCT03450915|Placebo Comparator|Saline|Participants will be vaccinated with saline twice: Once at Day 0, and once at Day 21.
88823893|NCT02004977|Experimental|Intervention arm|The role of the intervention arm (schools) is to improve access to the school breakfast program
88823894|NCT02004977|No Intervention|Comparison arm|the role of the comparison arm (schools) is to maintain usual breakfast program at school
88823895|NCT01971593|Other|Eplerenone after drug free period|Patients will be given eplerenone 50mg for 12 months after an initial 3 month drug free period
88823896|NCT01971593|Other|Eplerenone before drug free period|Patients will be given eplerenone 50mg for 12 months, followed by a 3 month drug free period
88823897|NCT03454581|Experimental|Photobiomodulation group (PBM)|"Gallium-aluminium-arsenide (GaAlAs) diode laser (MM Optics Recover, São Carlos, São Paulo, Brazil) with a wavelength of 808 nm, punctual contact mode,spot size of 0.03 cm2, power output of 100 mW, output density of 333 mW∕cm2, energy density of 13.3 J ∕cm2, 40 s exposure time per point, and 4 Joules (J) of total energy per point.~18 individuals"
88823898|NCT03454581|Experimental|Manual Therapy group (MT)|"At masticatory muscles were performed circular movements, slip and compression with fingers movements. At the temporomandibular joint (TMJ) was performed a caudal distraction with anterior projection, placing the thumb on the second or third molar.~16 individuals."
88823899|NCT03454581|Experimental|Combined therapy group (CT)|Applied the protocols of PBM group and immediately after, to MT group. 17 individuals.
88823900|NCT01972061|Experimental|CMG group|Foot stimulation will be applied during a cystometrogram (CMG).
88823901|NCT01972061|Active Comparator|3 hours group|Foot stimulation will be applied daily for 3 hours in the evening.
88823902|NCT01972061|Active Comparator|1/2 hour group|Foot stimulation will be applied daily for 1/2 hour in the evening.
88823903|NCT01972061|Active Comparator|3 hour hand group|Hand stimulation will be applied daily for 3 hours in the evening.
88823904|NCT03243981|Experimental|Open label study-- single arm|All patients will receive Skintyte treatment as well as Skintyte plus broadband light
88823905|NCT02986451|Experimental|Intervention|All patients received clarithromycin, lenalidomide, and dexamethasone in 28-day cycles. Dexamethasone (40 mg) was given orally on days 1, 8, 15, and 22. Clarithromycin (500 mg) was given orally twice daily.Lenalidomide (25 mg) was given orally daily on days 1 to 21
88823906|NCT03458871|Experimental|4-week TTNS home based protocol|Transcutaneous Tibial Nerve Stimulation (TTNS) applied to subjects for 4-week protocol.
88823907|NCT01973777|Experimental|IUB|There is one arm of women who will have IUBs inserted
88823908|NCT01974089||Pneumonia and dysphagia|Patients with community aquired pneumonia and oropharyngea dysphagia
88823909|NCT01974089||Pneumonia|Patients with community aquired pneumonia
88823910|NCT03245463|Active Comparator|Teaching Method A|Patient will receive an educational handout on self-management strategies. Patient will be asked to take the handout home to read and to call the office if he/she has any questions.
88823911|NCT03245463|Active Comparator|Teaching Method B|Patient will receive an educational handout on self-management strategies. A provider will review the handout with the patient (approximately 5 minutes including a question-and-answer session).
88823912|NCT01974245|Placebo Comparator|Placebo|100 drops/week for 12 weeks
88823913|NCT01974245|Active Comparator|Cholecalciferol|Drug: Cholecalciferol - 100,000 IU/week
88823914|NCT03307005|Experimental|Intervention|
88823915|NCT03307005|Placebo Comparator|Control|
88823916|NCT02005601|Experimental|Duloxetine|Patients will receive 60mg of duloxetine per dose. 1 capsule will be taken preoperatively. Starting on postoperative day (POD) 1, patients will take one capsule once a day until end of POD14.
88823917|NCT02005601|Placebo Comparator|Control|Patients will receive 0mg of duloxetine
88823918|NCT03214679|Experimental|Accessible Care|"Accessible Care for PWID is low-threshold care provided in the needle exchange programs, where they can comfortably access services without fear of the shame or stigma that often attends them in mainstream institutions.It includes features such as an informal, nonjudgmental atmosphere, availability of walk-in appointments, and a harm reduction framework to help them identify and pursue their own personal health goals. Accessible Care will be provided by co-locating a hepatitis treatment provider, together with a Hepatitis C Care Coordinator, on-site at our collaborating needle exchange program."
88823919|NCT03214679|Active Comparator|Usual Care|Usual care represents the current process after someone tests positive for HCV antibody on site at the syringe exchange program. An on site care coordinator (not provided by study) assists with insurance and linkage to HCV medical provider at sites throughout NYC through the NYC Dept of Health Check Hep C program.
88823920|NCT03308097|Experimental|PrEP Mobile Messaging Intervention|Participants from the STI/HIV testing clinic will receive Enhanced Standard of Care (described below) plus texted messages with the intervention content and follow-up questions over the next 4 weeks on their cell phones. Participants will receive approximately 8-16 interactive text messages with links to web content. Texts will be sent twice a week over the next 4 weeks. Participants will return for 2 more appointments over the next couple of months to fill out questionnaires.
88823921|NCT03308097|Active Comparator|Enhanced Standard of Care|As part of the enhanced standard of care, participants seen in the STI/HIV testing clinic are given feedback regarding PrEP eligibility and current risk behaviors. Participants are also given an informational handout about PrEP, shown a brief video, and given contact information for the PrEP Clinic Care Coordinator. Participants will return for 2 more visits over the next couple months to fill out questionnaires.
88823922|NCT02007863|Experimental|Umbilical Cord Blood + Chemotherapy|Umbilical Cord Blood transfusion + Chemotherapy (Fludarabine + Busulfan + Melphalan)
89355860|NCT05281913|Experimental|Intervention Group|A web-based Simulation Game concerning marital positive skills in remarriage, positive co-parenting strategies and positive stepparent-stepchild relationship skills.
88823923|NCT03460899|Experimental|Clamp Arm|All 14 subjects will undergo an Euglycaemic Clamp at Visit 2 as well as a Hyperinsulinaemic/Hypoglycaemic Clamp at Visit 3 with the Intervention of reaching certain plasma glucose levels for blood sampling regarding platelet activity parameters. Infusion of Dextrose and human soluble insulin (Actrapid) will be used to reach certain plasma glucose levels.
88823924|NCT02009501|Active Comparator|VAC VeraFlo with Dakins Instillation|VAC VeraFlo with Dakins .125% instillation will be initially applied in the OR after surgical debridement. Dressing will be changed on day 4 and and removed on day 7. Wound assessments will continue at weeks 2, 3, and 4.
88823925|NCT02009501|Active Comparator|VAC Ulta Therapy|VAC ULTA Therapy will be initially applied in the OR after surgical debridement. Dressing will be changed on day 4 and and removed on day 7. Wound assessments will continue at weeks 2, 3, and 4.
89355861|NCT05281913|No Intervention|Control|No intervention
88823926|NCT03308799|Experimental|MC2-01 Cream|MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%) cream. One application daily for 8 weeks
89355862|NCT05202392|Experimental|Myofascial release with Isometric Exercises|Myofascial release technique combined with isometric exercises will be given to first group. Patients in this group will be given muscle stretching along with trigger point release for following muscles. For the trapezius muscle as the patient will be in sitting and restrained friction for 30 seconds will be applied to a primary trigger point along with passive trapezius stretching on the alternative side. A chin tuck will be applied to stretch the sub-occipital muscles. Flexion and slight rotation of head will stretch the posterior rotator muscles. The extension of neck and its rotation will stretch sternocleidomastoid muscle. Combining lateral bend to alternative medial head will stretch the scalene muscles. Isometrics for this group will be neck flexion, isometric neck extension, isometric neck side flexion, Isometric neck rotation, neck extensors stretch, neck flexors and side flexors stretch, stretch for right side and lateral rotation stretch
89355863|NCT05202392|Experimental|Myofascial Release with Scapular Stabilization Exercise|These individuals will only receive same myofascial release therapy as 1st group combined with stabilization exercises. The stabilization exercises will include total 5 stages. The patient will be instructed to get into a supine position and to relax their body and will be instructed to place their feet flat on floor while bending their knees and holding this posture without and involvement of neck movements. After this, the subjects will be taught to raise their shoulder arm up to 90° combined with full scapular protraction and elbow extension and to hold this position for 10 seconds before returning to the prior positions doing this for 3 laps and 10 repetitions and with a minute break in between. For a quadruped position the individuals will alternatively lift their arms along with 120° flexion and shoulder abduction and hold this for ten seconds for ten repetitions for 3 laps and a 30 second break in between
89355864|NCT01202981||Group 1|Patients who had cataract surgery by the Investigators between July 1, 2007 and June 30, 2008.
88823927|NCT03308799|Active Comparator|Cal/BDP combination|Calcipotriene/betamethasone (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%). One application daily for 8 weeks.
88823928|NCT03308799|Placebo Comparator|Cream vehicle|One application daily for 8 weeks.
88823929|NCT02305277|Experimental|BIA 9-1067 5 mg Sequence 1|"volunteers received a single oral dose of 5 mg BIA 9-1067: Period 1: CM Formulation Period 2: TBM Formulation~CM - clinical micronized TBM - to-be-marketed"
88823930|NCT02305277|Experimental|BIA 9-1067 25 mg Sequence 1|"volunteers received a single oral dose of 25 mg BIA 9-1067: Period 1: CM Formulation Period 2: TBM Formulation~CM - clinical micronized TBM - to-be-marketed"
88823931|NCT02305277|Experimental|BIA 9-1067 50 mg Sequence 1|"volunteers received a single oral dose of 50 mg BIA 9-1067: Period 1: CM Formulation Period 2: TBM Formulation~CM - clinical micronized TBM - to-be-marketed"
88823932|NCT02305277|Experimental|BIA 9-1067 5 mg Sequence 2|"volunteers received a single oral dose of 5 mg BIA 9-1067: Period 1: TBM Formulation Period 2: CM Formulation~CM - clinical micronized TBM - to-be-marketed"
88823933|NCT02305277|Experimental|BIA 9-1067 25 mg Sequence 2|"volunteers received a single oral dose of 25 mg BIA 9-1067: Period 1: TBM Formulation Period 2: CM Formulation~CM - clinical micronized TBM - to-be-marketed"
88823934|NCT02305277|Experimental|BIA 9-1067 50 mg Sequence 2|"volunteers received a single oral dose of 50 mg BIA 9-1067: Period 1: TBM Formulation Period 2: CM Formulation~CM - clinical micronized TBM - to-be-marketed"
88823935|NCT03462927|Experimental|MC2-01 Cream|MC2-01 cream (CAL and BDP, w/w 0.005%/ 0.064%).
89177074|NCT00448669|Placebo Comparator|Placebo,condoms,adh/risk counseling|Eligible participants were randomized to the placebo arm and received placebo oral tablets that were visually identical to the TDF-FTC tablet and taken once daily. The placebo tablets contained no active ingredients. The ratio of randomization was 1:1. Participants randomized to the placebo arm received male and female condoms, personalized risk reduction counseling, adherence counseling, and routine monitoring for HIV infection, laboratory abnormalities, and adverse events.
88823936|NCT03462927|Active Comparator|CAL/BDP combination|CAL/BDP ointment (w/w 0.005%/0.064%).
88823937|NCT03309657|Experimental|Ceftolozane Tazobactam|Infected patients with external intraventricular drain will receive a single dose of Ceftolozane/ tazobactam (3000mg) over 1 hour and will undergo blood , csf and urine sampling at specific times over an 8 hour period.
88823938|NCT03463161|Experimental|Acquired Resistance Group|"Participants that have benefited from prior treatment with immunotherapy. Defined as response to prior treatment and/or stable disease lasting at least 5 months and disease worsening seen on most recent imaging.~Participants will receive Pembrolizumab and Epacadostat."
88823939|NCT03463161|Experimental|Suboptimal Benefit Group|"Participants that have not benefited from prior treatment with immunotherapy. Defined as stable disease lasting at least 5 months or suboptimal response (11-49% shrinkage of tumors). Disease continues to be stable on most recent imaging.~Participants will receive Pembrolizumab and Epacadostat."
88823940|NCT03463941|Experimental|African American church members|
88823941|NCT03466047|Experimental|Protein stomach|Encapsulated protein released in the stomach
88823942|NCT03466047|Experimental|Protein distal small intestine|Encapsulated protein released in the distal small intestine
88823943|NCT03466047|Experimental|CHO stomach|Encapsulated CHO released in the stomach
88823944|NCT03466047|Experimental|CHO distal small intestine|Encapsulated CHO released in the distal small intestine
88823945|NCT03466047|Experimental|Fat stomach|Encapsulated Fat released in the stomach
88823946|NCT03466047|Experimental|Fat distal small intestine|Encapsulated Fat released in the distal small intestine
88823947|NCT03467685|Placebo Comparator|VAD Off arm|This will be the group that has the VAD placed on their skin in the off mode, i.e. no vibration
88823948|NCT03467685|Experimental|VAD On arm|This will be the group that has the VAD placed on their skin in the on mode, i.e. vibration
88823949|NCT03468075|Experimental|Gemcitabine + High-Dose Ascorbate|Subjects will receive ascorbate, 75g, on Days 1, 2, 8, 9, 15 and 16 of a 28-day cycle. Gemcitabine will be administered on Days 1, 8 and 15, after the infusion of ascorbate. Concomitant treatment will continue for 6 cycles. Patients whose disease has not progressed while receiving gemcitabine and ascorbate and who are tolerating therapy may continue either single agent gemcitabine or concomitant treatment beyond 6 cycles at the discretion of the investigator.
88823950|NCT03250689|Experimental|Danirixin 35 mg|Eligible subjects will receive danirixin 35 mg tablet with food twice daily for 14 Days.
88823951|NCT03250689|Experimental|Placebo Comparator|Eligible subjects will receive placebo tablet with food twice daily for 14 Days.
88823952|NCT03468933|Active Comparator|Fibrinolytic therapy group|Patients randomized to the Fibrinolytic group will receive intrapleural therapy of combined tissue plasminogen activator (tPA) and human recombinant deoxyribonuclease (DNase) via chest tube.
88823953|NCT03468933|Active Comparator|Medical Thoracoscopy group|Patients randomized to the Thoracoscopy group will undergo medical thoracoscopy.
88823954|NCT03470493|Experimental|Participants|ApneaLink Air
88823955|NCT03471975|Active Comparator|direct laryngoscope|teaching tracheal intubation using McGrath video laryngoscope as direct laryngoscope. Only trainer can see the monitor.
88823956|NCT03471975|Active Comparator|video laryngoscope|"teaching tracheal intubation using McGrath video laryngoscope using video function.~Trainer and Trainee both see the monitor."
88823957|NCT02296580|Experimental|Nativis Voyager RFE Therapy|Subjects will be treated with Nativis Voyager therapy until tumor progression.
88823958|NCT03472287|Experimental|Cohort 1 (Adolescents, Adults)|Adolescent and adult subjects with EB (aged 12 years and older) received diacerein 1% ointment daily for 10 days.
88823959|NCT03472287|Experimental|Cohort 2 (Children)|Children with EB (aged 4 to 11 years, inclusive) received diacerein 1% ointment daily for 10 days.
88823960|NCT02219984||patients anticoagulated|
88823961|NCT04735029|Experimental|Thermal Gun group|"The thermal gun applied on acupressure points in TCM. The thermal gun used a heat-generating ceramic head to apply a dual effect called heat-and-light-pressure on the acupuncture points."
88823962|NCT04735029|Active Comparator|Heat Pack group|A hydrocollator heat pack used to simulate traditional thermal therapy. The application of the heat pack was wrapped with six layers of terry towels to bring the temperature down to around 43°C.
88823963|NCT02067416|Active Comparator|taxane-based chemotherapy|physician choice: taxane-based chemotherapy to include Paclitaxel, Docetaxel, Abraxane or Ixabepilone given as standard of care
88823964|NCT02067416|Active Comparator|anthacycline based chemotherapy|Physician choice: anthracycline based chemotherapy including Adriamycin, Epirubicin give as standard of care
88823965|NCT03258645||Acute ischemic stroke|Non-valvular atrial fibrillation patients hospitalized with an acute ischemic stroke
88823966|NCT02248766|Active Comparator|enfilcon A|All participants are habitual wearers of enfilcon A lens who are refitted with somofilcon A lens
88823967|NCT02248766|Experimental|somofilcon A|All participants are habitual wearers of enfilcon A lens who are refitted with somofilcon A lens
88823968|NCT03477279|No Intervention|Individual (SOC)|HIV-infected pregnant women enrolled in the individual arm of the study will receive Standard of Care Option B+ procedures.
88823969|NCT03477279|Experimental|Couple (Intervention)|In addition to receiving standard of care procedures, HIV-infected pregnant women in the couple arm will be provided with an intervention aimed at recruiting their male partners, providing enhanced couple counseling and testing, engaging their male partners in their care, and supporting male partners to receive care and treatment services.
88823970|NCT03477279|No Intervention|HIV-Uninfected Cohort|HIV-uninfected pregnant women will be invited to participate in a cross-sectional study. No intervention will be provided and no follow-up will be conducted.
88823971|NCT04735497||Failed Weaning|Patients who failed to be liberated from mechanical ventillation
88823972|NCT04735497||Successful Weaning|Patients who were liberated from mechanical ventillation and needed no respiratory support
89177075|NCT00591734|Experimental|Intervention|All patients received bevacizumab 15 mg/kg, administered by intravenous (IV) infusion on day 1 of each 21 day course. In addition, patients received everolimus 10 mg orally on a daily basis.
88823973|NCT02248922|Experimental|Tobramycin ALL|300mg nebulized Tobramycin (Tobramycin inhalation solution(TIS)) or TOBI Podhaler (Tobramycin inhalation powder(TIP), equivalent dry powder)twice a day (BID) 28days on / 28 days off
88823974|NCT03319173|Experimental|Experimental group|"Dietary interventions for subjects in the experimental group include clinically regulated meal plans designed to facilitate prolonged benign dietary ketosis (BDK) in order to regulate glucose with restored insulin sensitivity focused at reversing the impaired capacity to switch between fat and carbohydrate oxidation. Subjects will consume 3 meals per day with the following approximate macronutrient breakdown per meal: 65% fat, 25% protein, 10% carbohydrate.~Both groups will play the Advanced PEAK brain training games on iPhone, iPad or Android devices for 75 minutes per week."
88823975|NCT03319173|Active Comparator|Control group|"Dietary interventions for subjects in the control group include the subjects' current dietary protocol (Standard American Diet-SAD). Subjects will consume 4-6 small meals per day with the following approximate macronutrient breakdown per meal: 50% carbohydrate, 35% protein, 15% fat.~Both groups will play the Advanced PEAK brain training games on iPhone, iPad or Android devices for 75 minutes per week."
89533600|NCT04083235|Active Comparator|Nab-paclitaxel + Gemcitabine|Nab-paclitaxel and gemcitabine will be administered on Days 1, 8 and 15 of each 28-day cycle (until progression or unacceptable toxicity).
88823976|NCT03482583|Other|Cognitive Behavior Therapy with NRT|Cognitive Behavior Therapy (CBT) will be provided by a certified tobacco treatment specialist (CTTS) using vidyo, a HIPAA-compliant video based platform. Participants in this arm, if interested will be provided a 2 week supply of nicotine replacement therapy (NRT). The intervention in this arm would be NRT along with the CBT counseling.
88823977|NCT03482583|Other|Referral to Area Health Education Center|The Area Health Education Center (AHEC) is a locally available tobacco cessation program aimed at strengthening the capacity of Florida's healthcare system to deliver effective evidence based tobacco use treatment, and prevention services throughout the state. The intervention is education on the health effects related to tobacco use, and benefits of quitting and what to expect when quitting. A tobacco cessation specialist of trained facilitator guides participants as they identify triggers and withdrawal symptoms, and discuss ways to cope with them. The program offers free nicotine replacement therapy, educational materials, goodies for their quit day and follow up support.
88823978|NCT03482583|Other|Referral to Qutiline|"Quitline is a local program in the state where smokers can call a toll free number to talk to coach who can help them quit. There is also an option of online program if they prefer to engage in online help to quit tobacco use.~The intervention in this arm is counseling support by phone or online with an option of Nicotine replacement therapy. If participants prefer this option, our nurse will refer them to locally available quitline service using EPIC."
88823979|NCT02010203|Experimental|Phase I: HS-410 Low Dose|In the open label Phase 1 portion, HS-410 is given as 1*10^6 cells per dose for 12 weekly injections followed by 3 monthly injections.
88823980|NCT02010203|Experimental|Phase II: HS-410 Low-Dose Plus BCG|In the Phase 2 portion, HS-410 is given as 1*10^6 cells per dose weekly for 6 weeks in combination with BCG, followed by 6 weeks of HS-410 alone, and then 3 courses of three once-weekly doses of HS-410 in combination with BCG.
88823981|NCT02010203|Experimental|Phase II: High-Dose HS-410 Plus BCG|In the Phase 2 portion, HS-410 is given as 1*10^7 cells per dose weekly for 6 weeks in combination with BCG, followed by 6 weeks of HS-410 alone, and then 3 courses of three once-weekly doses of HS-410 in combination with BCG.
88823982|NCT02010203|Placebo Comparator|Phase II: Placebo Plus BCG|In the Phase 2 portion, a placebo is given weekly for 6 weeks in combination with BCG, followed by 6 weeks of placebo alone, and then 3 courses of three once-weekly doses of placebo in combination with BCG.
88823983|NCT02010203|Experimental|Phase II: High-Dose HS-410|In the Phase II portion, if patients will not receive BCG, HS-410 is given as 1*10^7 cells per dose weekly for 12 weeks, and then 3 courses of three once-weekly doses of HS-410.
88823984|NCT03323307|Experimental|OCT imaging|OCT device images retina
88823985|NCT03323853|Experimental|CARS-SA Report|Emergency care providers for subjects in this group will receive a copy of the subject's CARS-SA summary results.
88823986|NCT03323853|Other|No CARS-SA Report|Emergency care providers for subjects in this group will not receive a copy of the subject's CARS-SA summary results.
88823987|NCT03460587|Experimental|Home-based Telerehabilitation|Home-based Telerehabilitation
88823988|NCT03260595|Experimental|Crisaborole ointment 2%|
88823989|NCT03260595|Placebo Comparator|Vehicle|
88823990|NCT03261999|Experimental|Leuprolide Mesylate 25mg|"All subjects will be males with prostate cancer. They will be injected twice with a depot formulation containing 25 mg of Leuprolide Mesylate.~The first dose on day 0 and the second dose on day 84 (twelve weeks apart). Subjects will be followed until day 168."
88823991|NCT03482973|Experimental|Interventional Bupivacaine|20 cc of 0.25% bupivacaine on each side of the sternum at two time points after surgery and POD1
88823992|NCT03482973|Placebo Comparator|Interventional Placebo|20 cc of saline on each side of the sternum at two time points after surgery and POD1
88823993|NCT02302157|Experimental|AST-OPC1|Open label, dose escalation, cross-sequential cohort of subjects who receive an injection or two injections of AST-OPC1 at a single time-point
88823994|NCT02010359|Experimental|Lovaza|Lovaza 4 grams daily (2 1-gram capsules twice daily) will be given for 8 weeks
88823995|NCT02010359|Placebo Comparator|Placebo|An inactive Placebo (2 pills twice daily) will be given for 8 weeks
89533601|NCT04082520|Experimental|Treatment (gallium Ga 68-DOTATATE PET/MRI, Lutathera)|Patients receive gallium Ga 68-DOTATATE IV and undergo a PET/MRI or PET/CT before cycles 1 and 4. Patients then receive lutetium Lu 177 dotatate IV over 30-40 minutes. Treatment repeats every 8 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo MRI on study and during follow-up, as well as blood sample collection and possible SEPCT/CT dosimetry on study.
89533602|NCT04073563|Experimental|Group #1|Investigational Infuse™ 2.1 mg/level with available local bone autograft and supplemented with cancellous allograft as needed
88823996|NCT01976819|Experimental|TW speaking valve/HME|Use of the TW speaking valve/HME
88823997|NCT01976975||Mood disorder patients|Patients with depressive and/or manic or hypomanic symptoms
88823998|NCT01976975||Healthy controls|Participants with no lifetime history of psychiatric illness
89533603|NCT04073563|Experimental|Group #2|Investigational Infuse™ 4.2 mg/level with available local bone autograft and supplemented with cancellous allograft as needed
88823999|NCT03483675|Active Comparator|Arm I (discontinued IST)|Participants have their IST tapered and discontinued per the plan.
88824000|NCT03483675|Experimental|Arm II (continued IST)|Participants continue to receive a fixed dose IST for an additional 9 months with no taper.
88824001|NCT02057081|Experimental|Treatment|Intensive 14-session psychoeducational rehabilitation and skills-building intervention for couples.
88824002|NCT02057081|Active Comparator|Control|Didactic 14-session educational group intervention for families.
88824003|NCT01977599|No Intervention|No Text Message Reminder (Control) Arm|Control Arm, in which patients are invited to breast screening as per standard West of London Breast Screening Protocol (i.e. without a text message appointment reminder). Uptake of breast screening in this group will be compared with the text message reminder group to test for significant differences.
89355865|NCT01202981||Group 2|Patients who had cataract surgery by the Investigators between July 1, 2008 and July 1, 2009.
88824004|NCT01977599|Experimental|Text Message Reminder Arm|Patients randomly allocated to this arm of the study will be sent a text message reminding them of the time, date and venue of their breast screening appointment 48 hours in advance.
88824005|NCT03493815|Experimental|Transabdominal Ultrasound Guided IUD Insertion|Ultrasound Guided IUD Insertion: Comparing the utility of ultrasound-guided intrauterine device (IUD) insertion compared to traditional blind insertion
88824006|NCT03493815|Active Comparator|Traditional Blind IUD Insertion|Traditional blind IUD insertion: Comparing the utility of ultrasound-guided intrauterine device (IUD) insertion compared to traditional blind insertion
88824007|NCT01979159|Experimental|Combined Aphasia-ApraxiaTreatment|Administration of Combined Aphasia and Apraxia of Speech Treatment )(CAAST) to 4 persons with aphasia and apraxia of speech in the context of single-subject designs
88824008|NCT03273543|Experimental|Nasal Tip Projection|
88824009|NCT03273543|Experimental|Upper Lip Position|
88824010|NCT03959072||Robotic Chronic Total Occlusion PCI|The procedure will be randomized in a 1:1 fashion to either CorPath GRX robotic-assisted Chronic Total Occlusion PCI or conventional manual Chronic Total Occlusion PCI.
88824011|NCT03959072||Conventional (manual) Chronic Total Occlusion PCI|The procedure will be randomized in a 1:1 fashion to either CorPath GRX robotic-assisted Chronic Total Occlusion PCI or conventional manual Chronic Total Occlusion PCI.
88824012|NCT03326895|Experimental|Group 1|Powered circular stapler used to complete anastomosis of colon
88824013|NCT02980718|Experimental|intensive olfactory training|90 participants will undergo intensive olfactory training. They will sniff on four selected odors (10 seconds on each odor bottle in a total of 4 minutes) every morning and evening for 3 months and they will be instructed in the principles of the logbook for olfactory training.
88824014|NCT02980718|Experimental|ordinary olfactory training|90 participants will undergo ordinary olfactory training. They will sniff on four selected odors (10 seconds on each odor bottle in a total of 40 seconds) every morning and evening for 3 months and they will be instructed in the principles of the logbook for olfactory training.
88824015|NCT02980718|No Intervention|controls|20 participants represent a control group with no olfactory training
88824016|NCT03327051|Active Comparator|Omeprazole and VSL #3|Participants will receive a proton pump inhibitor (Omeprazole) and VSL #3 Probiotics
88824017|NCT03327051|Placebo Comparator|Placebo and VSL #3|Participants will receive placebo and VSL #3 Probiotics
88824018|NCT03919994||ABILIFY MAINTENA®|Subjects newly initiated
88824019|NCT03919994||ARISTADA®|Subjects newly initiated
88824020|NCT03919994||INVEGA SUSTENNA®|Subjects newly initiated
88824021|NCT03919994||RISPERDAL CONSTA®|Subjects newly initiated
88824022|NCT02057939|Experimental|Enzalutamide|Enzalutamide, Androgen Deprivation, and Radiation Therapy
88824023|NCT03496467|Active Comparator|Nepafenac PPDS|N-PPDS (Nepafenac Punctal Plug Deliver System) is an L-shaped, silicone punctal plug with a drug eluting core that contains nepafenac (active)
88824024|NCT03496467|Placebo Comparator|Placebo PPDS|p-PPDS (placebo Punctal Plug Delivery System) is an L-shaped, silicone punctal plug with a drug insert that contains no active ingredient (placebo).
88824025|NCT02058251|Experimental|Oxytocin|Each participant will self-administer a 40 IU dose of intranasal oxytocin.
88824026|NCT02058251|Placebo Comparator|Control|Each participant will self-administer a 40 IU dose of intranasal saline.
88824027|NCT04513964||Control|Patient not suffering from COVID-19
88824028|NCT04513964||COVID-19|Patient who has been infected with COVID-19 with suggestive signs and authentication by PCR or thoracic CT or serology
89355866|NCT04499794||FISH diagnosed EML4-ALK fusion positive NSCLC group|
89355867|NCT04499794||FISH diagnosed EML4-ALK fusion negative NSCLC group|
88824029|NCT03329937|Experimental|Participants with HER2-negative and BRCAmut breast cancer|Participants with HER2-negative and BRCAmut localized breast cancer (primary tumor >=1 cm) will receive niraparib (200 mg PO).
88824030|NCT01710254|Experimental|Regadenoson MRI|Participants with AF receiving regadenoson stress MRI, using Gadobenate dimeglumine
88824031|NCT04768283|No Intervention|Control group|Cardiac rehabilitation physical training program included: respiratory muscle training (7 days/week, for 15 minutes) and aerobic exercises on cycle ergometers (6 days/week, for 10-30 minutes, 30-50% watts or 30-50% HRmax).
88824032|NCT04768283|Experimental|Intervention group 1|"Combinated physical training program:~Respiratory exercises, aerobic training will be the same as in the control group.~Additional exercises: balance training and strength exercises with weights, elastic resistance rubbers."
88824033|NCT04768283|Experimental|Intervention group 2|"Combinated physical training program:~Respiratory exercises, aerobic training will be the same as in the control group.~Additional exercises: balance training with static and dynamic balance training device Biodex Balance System TM SD and strength exercises with HUR strength training machines."
88824034|NCT03496545|Active Comparator|Acetaminophen|Standard of care - acetaminophen 650mg every 4 hours PO/NG/FT (per oral, nasogastric tube, feeding tube) for 48 hours, initiated within 1 hour after temperature reading ≥ 38.3ºC.
88824035|NCT03496545|Experimental|Bromocriptine and Acetaminophen|Bromocriptine 5mg every 4 hours PO/NG/FT for 48 hours and acetaminophen 650mg every 4 hours PO/NG/FT for 48 hours, initiated within 1 hour after temperature reading ≥ 38.3ºC.
88824036|NCT01710332|Experimental|Intravitreal Aflibercept Injection (x4)|2 mg / Intravitreal / every 1 month x 3 months and at month 4 (Drug administered 4 times).
88824037|NCT01710332|Experimental|Intravitreal Aflibercept Injection (x6)|2 mg / Intravitreal / every 1 month x 6 months ((Drug administered 6 times).
89355868|NCT01566851||Patient|Patients with rheumatoid arthritis
89355869|NCT03840395|Active Comparator|Active PES|Patients randomized to receive active Pharyngeal Electrical Stimulation (PES) via a Phagenyx Catheter.
88999978|NCT02158585|Active Comparator|Lamotrigine|Lamotrigine will be taken orally for the duration of 20 weeks, consisting of a six-week titration, 12-week study period, and two-week taper. Possible doses are 25mg twice a day, 50mg twice a day, and 100 mg twice a day during titration; 150mg twice a day for the 12-week study period; 150mg once a day for Week 1 of the taper; and 75mg once a day for Week 2 of the taper. Patients who withdraw at any point of the study will have a two-week taper consisting of the current dose once a day for one week followed by half the dose once a day for another week.
88999979|NCT02145364|Experimental|Ultherapy® treatment of acne scars|Subjects receiving dual depth treatment of acne scars using the 7MHz,3.0mm and 10MHz,1.5mm transducers.
88999980|NCT02135536|Experimental|NGM282 Dose 1|NGM282 Dose 1
88999981|NCT02135536|Experimental|NGM282 Dose 2|NGM282 Dose 2
88999982|NCT02135536|Experimental|NGM282 Dose 3|NGM282 Dose 3
88999983|NCT02109406|Experimental|AZD2115 Dose 1|AZD 2115, Dose 1 administered as two inhalations BID
88999984|NCT02109406|Experimental|AZD 2115 Dose 2|AZD 2115, Dose 2 administered as two inhalations BID
88999985|NCT02109406|Placebo Comparator|Placebo MDI|Placebo MDI administered as two inhalations BID
88999986|NCT02109016|Experimental|Lucitanib|Lucitanib given orally once daily on a continuous schedule. Starting dose is 10 mg/day.
88999987|NCT00202995|Experimental|1|Glatiramer Acetate 20 mg s.c. daily
88999988|NCT00202995|Active Comparator|2|Betaseron 250 ug every other day or Rebif 44 ug 3 times a week
88999989|NCT04678219|Experimental|Low-Protein/Vegan/Low-Sulfur Diet|This is a specific diet that is both vegan and low in protein. The vegan diet eliminates all animal products, (including meats, eggs, dairy products) and animal by-products such as honey.
88999990|NCT04678219|Experimental|Specific Carbohydrate Diet|"The Specific Carbohydrate Diet emphasizes consumption of specific carbohydrates that require minimal digestion. Therefore, it eliminates most carbohydrates, including grains, starches, dairy and sugars.~The idea behind this diet is that it reshapes the microbiome of the intestines. The diet restricts the intake of certain carbohydrates that may increase the growth of bad bacteria possibly contributing to inflammation. By restricting the amount of these carbohydrates in the microbiome, the diet aims to reduce their activity in the gut and reduce inflammation."
89355870|NCT03840395|Sham Comparator|Sham PES|Patients randomized to sham will not receive any Pharyngeal Electrical Stimulation (PES) but will still have the Phagenyx Catheter inserted.
88999991|NCT04677868|Experimental|MTX and corticosteroid|Methylprednisolone 1 mg/kg/day MTX (10 mg/day) was given on days 1, 3, and 8, and repeated weekly until aGVHD was less than grade II;
88999992|NCT00198393|Experimental|A|Gefitinib
88999993|NCT00198393|Experimental|B|Gemcitabine
88999994|NCT00198393|Experimental|C|Docetaxel
88999995|NCT02104336|Experimental|EPI-743|15 mg/kg EPI-743 to be administered three times per day for 1 year
88999996|NCT02103322|Experimental|Imatinib Mesylate Tablets, 400 mg|Imatinib Mesylate Tablets, 400 mg. Once daily for 14 days.
88999997|NCT02103322|Active Comparator|Gleevec Tablets, 400 mg|Imatinib Mesylate Tablets, 400 mg. Once daily for 14 days.
88999998|NCT02100436|Experimental|Cohort 3-8 years old|up to 100 subjects receive 2 doses of H3N2v MIV, IM as 15mcg HA/0.5mL dose, 21 days apart.
88999999|NCT02100436|Experimental|Cohort 6-35 months old|up to 100 subjects receive 2 doses of H3N2v MIV, intramuscularly (IM) as 7.5 micrograms (mcg) of hemagglutinin (HA)/0.25 milliliter (mL) dose, 21 days apart. up to 100 subjects receive 2 doses of H3N2v MIV, IM as 15mcg HA/0.5mL dose, 21 days apart.
89399106|NCT04360083||Overweight and obese children|Overweight and obese children included in RéPPOP care programs between 2007 and 2010.
89000000|NCT02100436|Experimental|Cohort 9-17 years old|up tp 100 subjects receive 2 doses of H3N2v MIV, IM as 15mcg HA/0.5mL dose, 21 days apart.
89000001|NCT00554827|Experimental|Pralatrexate Injection (FOLOTYN,PDX,Pralatrexate(R|"Intravenous (IV) push over 3-5 minutes into a patent IV line containing normal saline (0.9% sodium chloride).~Pralatrexate will be administered via intravenous (IV) push over 3-5 minutes. The frequency of pralatrexate will be administered weekly for 3 or 4 weeks (depending on cohort), with 1 week of rest."
89000002|NCT00203034|Experimental|Experimental 1|0.5 mg rasagiline mesylate oral once daily
89000003|NCT00203034|Experimental|Experimental 2|1.0 mg rasagiline mesylate oral once daily
89000004|NCT00203034|Placebo Comparator|Placebo|Placebo Comparator
89000005|NCT04677673|Experimental|NAC PLUS SURGERY|Patients receive three cycles of the modified dose of TGO plus oxaliplatin before curative gastrectomy.
89000006|NCT04677673|Active Comparator|SURGERY FIRST|Patients undergo curative gastrectomy without any prior chemotherapy.
89399107|NCT04398849||14-19 year olds residing in the Northern Territory|All consenting 14-19 year olds residing in the Northern Territory in 2020-2021
89399108|NCT03696693||children with chronic rhinosinusitis|Children aged 6-18 years presented with symptoms of chronic rhinosinusitis will be recruited from the otorhinolaryngology out-patient clinic and department at Assiut University Hospital from October, 2018 to October, 2019.
89399109|NCT03696693||children without chronic rhinosinusitis|Children have the same age and number in the study group which are presented with vocal symptoms and have not chronic rhinosinusitis will be recruited for the same duration.
89355871|NCT05707052|Experimental|Neck-Trunk Stabilization exercises|First neck and trunk exercise involved lifting the head in a modified bridge exercise position so that lower abdominal muscles contracted when the neck was bent, thereby activating the neck flexor muscle and the lower abdominal muscles simultaneously. Second exercise involved pushing the neck backward in supine position to activate the erector muscles of the neck and the upper thoracic vertebrae through the extension of the muscles of the back of the neck. Third exercise activated the deep abdominal muscles in bridge exercise positions so that the participants would experience the posterior inclined movement of the pelvis. Keep each posture for 10 seconds at a time and repeat 10 times with a rest interval of 3 seconds per each.
88824038|NCT02309489|Experimental|Intervention|"Receive standard maternity care~Woman and partner attend one extra couple counselling session during pregnancy (A)~Partner attends one group education session for men (B)~Partner participates in pre-discharge consultation (C)"
88824039|NCT02309489|No Intervention|Control|"Receive standard maternity care~No active encouragement of partner involvement, no extra sessions offered"
88824040|NCT01711424||OPTIVE PLUS®|Patients with dry eye prescribed OPTIVE PLUS® in accordance with physician standard practice.
88824041|NCT02311907|Experimental|Arm I (glutathione, carboplatin)|Patients receive glutathione intravenously (IV) over 15 minutes, paclitaxel* IV over 1 or 3 hours depending on planned dose cycle length and carboplatin IV over 30 minutes.
88824042|NCT02311907|Placebo Comparator|Arm II (placebo, paclitaxel)|Patients receive placebo IV over 15 minutes, paclitaxel* IV over 1 or 3 hours depending on planned dose cycle length and carboplatin IV over 30 minutes.
88824043|NCT02013245|Experimental|MTBVAC group 1|Intervention: MTBVAC live vaccine (low dose 5 x 10E03 CFU/0.1mL)
88824044|NCT02013245|Experimental|MTBVAC Group 2|Intervention: MTBVAC live vaccine (middle dose 5 x 10E04 CFU/0.1mL)
88824045|NCT02013245|Experimental|MTBVAC Group 3|Intervention: MTBVAC live vaccine (high dose 5 x 10E05 CFU/0.1mL)
88824046|NCT02013245|Active Comparator|BCG Control Group|Intervention: Commercially available BCG live vaccine (dose 5 x 10E05 CFU/0.1mL)
88824047|NCT01980485|Active Comparator|Feedback on lung age and exhaled carbon monoxide|
88824048|NCT01980485|Sham Comparator|No lung age feedback|Those allocated to the control group will simply be informed of their scores on the spirometry.
88824049|NCT01981967|Experimental|Primary Vaccination Group|Participants who never received a JE vaccine, or who received a single dose of inactivated JE vaccine, or whose JE vaccination history is unknown or not documented.
88824050|NCT01981967|Active Comparator|Booster Vaccination Group|Participants who received at least 2 doses of inactivated JE vaccine (at least 1 year earlier for the last dose), or received a single dose of IMOJEV®, THAIJEV®, or IMOJEV® MD as part of the routine vaccination schedule (i.e., outside of Study JEC17) at least 1 year earlier
88824051|NCT01982123|Experimental|SPECT/CT Mid-& Post-RT|Investigational 99mTc-MAA and 99mTc-DTPA SPECT/CT mid-radiation therapy (up to 1 week post-treatment), and at 3-6 months post-treatment.
88824052|NCT02061683|Experimental|Bimatoprost 0.03%|Bimatoprost 0.03% (LUMIGAN®) 1 drop in the affected eye(s) once daily as monotherapy or adjunctive therapy for 3 months.
88824053|NCT01983839||Pharmacokinetics Moxifloxacin|Patients with community-acquired pneumonia treated with moxifloxacin
88824054|NCT02063087|Active Comparator|Decision Aid|Head CT Decision Aid
88824055|NCT02063087|No Intervention|Usual Care|Clinicians and patients do not have access to the Head CT Decision Aid
88824056|NCT02395991||Observe1|Patients who are referred to MR unit for hepatocyte-specific contrast (gadoxetic acid) enhanced liver magnetic resonance imaging (MRI)
88824057|NCT01712360|Experimental|NAFT500 (pediatric)|Topical once a day for two weeks
88824058|NCT01712360|Experimental|NAFT600 (pediatric)|Topical once a day for two weeks
88824059|NCT01712360|Experimental|NAFT500 (adult)|Topical once a day for two weeks
88824060|NCT01712360|Experimental|NAFT600 (adult)|Topical once a day for two weeks
88824061|NCT02396147|Experimental|Arm 1: T2-A + T4B-B + T4B-C|T2 Formulation Regimen A (T2-A) TAK-385, 120 mg tablet (80 mg + 40 mg tablets), orally, under fasted conditions, T4 Formulation B Regimen B (T4B-B) TAK-385, 120 mg tablet, orally, under fasted conditions, and T4 Formulation B Regimen C (T4B-C) TAK-385, 120 mg tablet, orally, under fed conditions. There were 6 randomized sequences. Study medication was administered as a single dose on Days 1, 11 and 21. There was a 10-day washout period between each dose.
88824062|NCT02396147|Experimental|Arm 2: T2-A + T4C-D + T4C-E|T2 Formulation Regimen A (T2-A) TAK-385, 120 mg tablet (80 mg + 40 mg tablets), orally, under fasted conditions, T4 Formulation C Regimen D (T4C-D) TAK-385, 120 mg tablet, orally, under fasted conditions, and T4 Formulation C Regimen E (T4C-E) TAK-385, 120 mg tablet, orally, under fed conditions. There were 6 randomized sequences. Study medication was administered as a single dose on Days 1, 11 and 21. There was 10-day washout period between each dose.
88824063|NCT01713608|Experimental|OZ439 Dose level 1 (300mg)|• Cohort 1 (12 subjects: 8 Active [A] and 4 on Placebo [P]) Active dose will consist of 300mg OZ439 drinking solution administered once daily for 3 days
88824064|NCT01713608|Experimental|OZ439 Dose level 2|• Cohort 2 (12 subjects: 8 A, 4P). Subjects on active will receive X amount of OZ439 (dose level to be determined based on safety and tolerability of previous dose level) drinking solution once daily for 3 days
88824065|NCT01713608|Experimental|OZ439 dose level 3|Cohort 3 (12 subjects: 8 A, 4P). Subjects on active will receive X amount of OZ439 (dose level to be determined based on safety and tolerability of previous dose level) drinking solution once daily for 3 days
88824066|NCT02018315|Experimental|Triheptanoin|Triheptanoin (C7 oil, liquid) dosed at 1 g/kg body weight divided and administered 4 times per day via mouth or g-tube for 3 months.
88824067|NCT02018627|Experimental|Xeris glucagon|Xeris glucagon 50 micrograms, subcutaneous injection
88824068|NCT02018627|Active Comparator|Lilly glucagon|Lilly glucagon 30 micrograms, subcutaneous injection
88824069|NCT01714232|Experimental|Study Staff Test BGMSs|All testing and lancing were performed by the study staff; subjects did not perform any lancing or self-testing in this study. Study Staff lanced the fingers of subjects and tested the blood samples using five Blood Glucose Monitoring Systems (BGMS): Contour® PLUS BGMS; OneTouch® SelectSimple™ BGMS; Accu-Chek® Performa BGMS; Accu-Chek® Active BGMS; Freestyle Freedom® BGMS.
89000007|NCT00203073|Active Comparator|Copaxone 20 mg|Copaxone 20 mg
89000008|NCT00203073|Active Comparator|Copaxone 20mg with Novantrone induction|Copaxone 20mg with Novantrone induction
88824070|NCT02019563|Experimental|MTA/FS pulpotomy Group|Children randomized to this arm will undergo a mineral trioxide aggregate (MTA) pulpotomy after hemostasis is achieved using ferric sulfate (FS).
89533604|NCT04073563|Active Comparator|Control|Local bone autograft and supplemented with cancellous allograft as needed.
89533605|NCT04057534|Experimental|CB-CRT AUD group|experimental group AUD: patients receive standard clinical therapy and an add-on chess based - cognitive remediation treatment (CB-CRT)
89533606|NCT04057534|Active Comparator|Control group AUD|control group: patients with AUD receive standard clinical therapy
88824071|NCT02019563|Active Comparator|RCT Group|Children randomized to this group will undergo the root canal therapy (RCT) technique.
88824072|NCT04413344|Active Comparator|Active|
88824073|NCT04413344|Placebo Comparator|Placebo|
88824074|NCT04408196||Patients|100 patients admitted to an inpatient rehabilitation facility
88824075|NCT04408196||Caregivers|100 caregivers of patients admitted to an inpatient rehabilitation facility
88824076|NCT03441152|Experimental|tDCS+CT|application of tDCS in combination with CT
88824077|NCT03441152|Sham Comparator|Sham tDCS|application of sham tDCS in combination with CT
88824078|NCT03441152|Active Comparator|CT|application of CT
88824079|NCT02063867|No Intervention|Arm 1: Usual Care|Routine policy for showering or bathing non-critical care patients
88824080|NCT02063867|Active Comparator|Arm 2: Decolonization|"Daily chlorhexidine (CHG) shower or CHG cloth bath for all non-critical care patients.~Topical intranasal mupirocin ointment (bilateral nares, twice daily) x5 days if non-critical care patients are MRSA+ by history, culture, or screen."
88824081|NCT03435146|Experimental|Groups 1,2,3 and 4|"Group 1: The first 12 participants (Group 1A) will undergo semi-intensive PK sampling and will be key to determining whether an increased dosing of dolutegravir is required in groups 1B. Group 1B will receive dolutegravir at the new dose (if applicable) and will also undergo semi-intensive PK sampling. All will undergo safety and HIV VL assessments.~3HP plus DTG +2NRTIs~Group 2: The next 30 (Group 2) will receive dolutegravir at the new dose and will only have sparse PK sampling. All will undergo safety and HIV VL assessments.~3HP plus DTG +2NRTIs~Group 3: The next 25 (Group 3) will receive dolutegravir at the same dose as Group 2 and will only have sparse PK sampling. All will undergo safety and HIV VL assessments.~IPT plus DTG +2NRTIs~Group 4: The next 50 (Group 4) will receive dolutegravir at the same dose as Group 2 and will only have sparse PK sampling. All will undergo safety and HIV VL assessments.~3HP plus DTG +2NRTIs"
88824082|NCT01715948|Experimental|CROS hearing aid|The CROS uses two hearing aids that fit behind each ear. The hearing aid fitted with a retainer earhook on the side of the poor ear houses a microphone and a transmitter. The hearing aid fitted on the normal ear side houses a receiver that is connected to a slim tube and open ear tip. The CROS does not amplify sound but rather transmits sound from the side of the unaidable ear to the contralateral ear, overcoming the head shadow effect that presents with SSD.
88824083|NCT01715948|Experimental|Bone-anchored hearing device (BAHD)|The BAHD (such as the Baha by Cochlear or Bone-Bridge by MED-EL) also helps to alleviate the negative effect of head shadow and the difficulty with speech perception in noise that present with SSD. Also known as an osseointegrated aural prosthesis, the BAHD is implanted in individuals with SSD to stimulate the ear with the normal cochlea. The BAHD requires that a titanium screw be surgically implanted in the temporal bone on the side of the poor ear. This titanium screw is connected to a percutaneous abutment. An electromechanical sound processor (external transducer) is coupled onto the abutment and can be removed when necessary. Sound can now be routed to the better ear by transcranial bone conduction.
88824084|NCT04280354||patients with severe community acquired pneumonia (cases)|Cases: Patients with severe community acquired pneumonia with required ICU admission.
88824085|NCT04280354||patients without pneumonia or sepsis (controls)|Controls: Clinical phenotype of inflammation not due to suspected sepsis; patients with fever >38°C, C reactive Protein (CRP) >100mg/L, no infection focus expected in ≥ 24h.
88824086|NCT02021669|Experimental|Omega-3 supplement|Two grams of the EPA form of omega-3 plus 50 mg of sertraline daily for 10 weeks
88824087|NCT02021669|Placebo Comparator|Placebo|Two grams of corn oil plus 50 mg of sertraline daily for 10 weeks.
88824088|NCT01717742|Active Comparator|tPA and placebo|
89177076|NCT00788697|Other|Patients who received SonoVue|"Patients with at least 1 target lesion requiring work-up for characterization to undergo~Unenhanced ultrasound of the target lesion (UE-US): gray scale and Doppler (color or power imaging) ultrasound investigations of the target lesion using commercially available ultrasound equipment and standard techniques (B-mode or Harmonic imaging) to study the anatomy of the target lesion and surrounding parenchyma;~SonoVue-enhanced ultrasound of the target lesion (CE-US): procedures described in protocol Section 7.5.1.2, to study the lesion vascularity in comparison to the surrounding parenchyma; and~Truth standard"
88824089|NCT01717742|Experimental|tPA and DNase|
88824090|NCT01717898|Experimental|Abiraterone/prednisone + BEZ235|In Phase I, a dose escalation of BEZ235 will be performed using a standard 3 + 3 design to determine the maximum tolerated dose (MTD) of BEZ235 given in combination with continuous fixed doses of Abiraterone Acetate and prednisone. This BEZ235 dose will be used in the phase II portion of the study.
88824091|NCT01718522||Intervention Group|Patients treated with sensor augmented pump (SAP) therapy with insulin pump Paradigm VEO® and use continuous glucose monitoring (CGM).
88824092|NCT02064959|Experimental|Hypothermia|Hypothermia to 33°C
88824093|NCT02064959|Active Comparator|Normothermia|standard care - normothermia (37°C)
88824094|NCT01736930|Active Comparator|Predictive pump suspension algorithm|The study laptop will be running actively during the night and suspending the patient's pump if the algorithm predicts hypoglycemia based on the patient's continuous glucose sensor trend.
88824095|NCT01736930|No Intervention|Standard of Care|The control algorithm will run passively and not recommend suspensions or resumption to the patient's pump.
88824096|NCT02397707|Experimental|Moderate Hepatic Impaired|Participants with moderate hepatic impairment and matched healthy controls will receive a single dose of voxilaprevir on Day 1.
88824097|NCT02397707|Experimental|Severe Hepatic Impaired|Participants with severe hepatic impairment and matched healthy controls will receive a single dose of voxilaprevir on Day 1.
88824098|NCT01737944|Experimental|10mg Methotrexate (MTX) Group|Treatment Arm A - SC injection with Vibex device, Treatment Arm B - SC injection without device and Treatment Arm C - IM injection
88824099|NCT01737944|Experimental|15mg Methotrexate (MTX) Group|Treatment Arm A - SC injection with Vibex device, Treatment Arm B - SC injection without device and Treatment Arm C - IM injection
88824100|NCT01737944|Experimental|20mg Methotrexate (MTX) Group|Treatment Arm A - SC injection with Vibex device, Treatment Arm B - SC injection without device and Treatment Arm C - IM injection
88824101|NCT01737944|Experimental|25mg Methotrexate (MTX) Group|Treatment Arm A - SC injection with Vibex device, Treatment Arm B - SC injection without device and Treatment Arm C - IM injection
89177077|NCT05755880|No Intervention|General anesthesia|
89177078|NCT05755880|Active Comparator|Dexamethason|
88824102|NCT02397785|Experimental|ApexM Device|InControl Medical created a line of products FDA approved for urinary incontinence and fecal incontinence (10). These devices are non-implanted, customizable, battery-operated vaginal probes made of medical grade silicon and provide electrical stimulation to the pelvic floor. One of the devices, ApexM™ provides electrical stimulation at frequencies alternating between 13 Hz and 50 Hz and allows the clinician to adjust the intensity as well as the duration of the electrical stimulation. The investigators propose the use of low power electrical stimulation for the treatment of pain in patients diagnosed with CPP. The electrical stimulation is delivered using ApexM™, adjusting the power to a sensory threshold to prevent muscle contraction.
88824103|NCT02397785|Sham Comparator|Sham Device|"Subjects in the control arm will use a sham ApexM device. The original ApexM device will be modified to disable its electrical stimulation functionality. Otherwise, the devices are indistinguishable and possess identical dimensions. Although the sham device can be powered on, the circuitry will be disconnected so that electrical stimulation is disabled."
88824104|NCT01740206|Active Comparator|Amphetamine and/or methylphenidate|Patients who took their amphetamine and/or methylphenidate the morning of surgery.
88824105|NCT01740206|Experimental|Hold stimulant medication|Patients who did not take their stimulant medication the morning of surgery.
88824106|NCT01740362|Other|Healthy volunteers|Healthy volunteers
89177079|NCT00848549|Active Comparator|ZNS|
88824107|NCT01740362|Experimental|Mild renal impairment|patients with mild (>50 and ≤80 mL/min) renal impairment
88824108|NCT01740362|Experimental|Moderate renal impairment|patients with moderate (≥30 and ≤50 mL/min) renal impairment
88824109|NCT01740362|Experimental|severe renal impairment|patients with severe (<30 mL/min) renal impairment
88824110|NCT03251937|Experimental|Spinal Cord Stimulation|Spectra WaveWriter SCS System
88824111|NCT02068157|Experimental|Treatment (porfimer sodium, image-guided I-PDT)|Patients receive porfimer sodium IV over 3-5 minutes on day 0. Patients then undergo image-guided I-PDT on day 2.
88824112|NCT04232852|Active Comparator|Probiotics|"Demographics, anthropometric measurements (weight, height, waist circumference, BMI) will be recorded, clinical data related to the patient's cardiovascular risk (MI with or without angioplasty, acute coronary syndrome with or without angioplasty). Systolic and diastolic pressure will be measured before and after the 12-week intervention.~This group will receive a probiotic mix, which will contain strains of Streptococcus thermophilus, Saccharomyces cerevisiae, Lactobacillus acidophilus, L. rhamnosus L. helveticus, L. gasseri, L. plantarum, Bifidobacterium bifidum, Enterococcus faecium at a daily dose of 7 × 1010 CFU in the form of a capsule. During the intervention, participants will follow their eating habits as well as the physical activity of their personal routine, with the advice not to consume fermented dairy products."
88824113|NCT04232852|Placebo Comparator|Placebo supplement|"Demographics, anthropometric measurements (weight, height, waist circumference, BMI) will be recorded, clinical data related to the patient's cardiovascular risk (MI with or without angioplasty, acute coronary syndrome with or without angioplasty). Systolic and diastolic pressure will be measured before and after the 12-week intervention.~Patients of this group will receive an identical capsule of maltodextrin (placebo). During the intervention, participants will follow their eating habits as well as the physical activity of their personal routine, with the advice not to consume fermented dairy products."
88824114|NCT02398409|Experimental|ANSWERS-VA|"8 week telephone intervention with nurse case manager using Acquiring New Skills While Enhancing Remaining Strengths (ANSWERS)"
88824115|NCT02398409|Other|Control|8 week telephone usual care with education with nurse case manager
88824116|NCT01741454|Active Comparator|Tamsulosin plus placebo 7-day treatment|Tamsulosin is a selective α1a-blocker (FlomaxTM), generic since 2009. It is an antagonist of α1-mediated contraction of prostate, bladder and proximal urethral smooth muscle, and as such, reduces urethral pressure and resistance, bladder outlet resistance, bladder hyperactivity, and consequently lower urinary tract symptoms.
88824117|NCT01741454|Experimental|Tamsulosin plus Tolterodine ER 7-day treatment|"Tamsulosin is a selective α1a-blocker (FlomaxTM), generic since 2009. It is an antagonist of α1-mediated contraction of prostate, bladder and proximal urethral smooth muscle, and as such, reduces urethral pressure and resistance, bladder outlet resistance, bladder hyperactivity, and consequently lower urinary tract symptoms.~Tolterodine ER is an anticholinergic agent, which is used as one of the first line agents for detrusor overactivity."
88824118|NCT01741454|Active Comparator|Tamsulosin plus placebo 21-day treamtnet|Tamsulosin is a selective α1a-blocker (FlomaxTM), generic since 2009. It is an antagonist of α1-mediated contraction of prostate, bladder and proximal urethral smooth muscle, and as such, reduces urethral pressure and resistance, bladder outlet resistance, bladder hyperactivity, and consequently lower urinary tract symptoms.
89355872|NCT05707052|Experimental|Bobath Therapy|"trunk-pelvic-hip neutral alignment with anterior-posterior weight shifts on the ball,~bilateral upper extremity abduction-traction for lateral weight shift,~prone extension on the ball,~forward weight shift for the trunk and hip extension and forward protective extension,~diagonal weight shifts in flexion-rotation direction,~lateral weight shift for simultaneous activation of flexors and extensors,~bilateral shoulder flexion for latissimus dorsi elongation,~pectoral elongation exercise for trunk extension,~preparatory trunk activities (with continuous and/or intermittent compression and intermittent support),~positioning and holding of the head-trunk Keep each posture for 10 seconds at a time with a rest interval of 3 seconds per each."
89355873|NCT02514460|Active Comparator|Intervention: Stents|Stents group
88824119|NCT01741454|Experimental|Tamsulosin plus Tolterodine ER 21-day treatment|"Tamsulosin is a selective α1a-blocker (FlomaxTM), generic since 2009. It is an antagonist of α1-mediated contraction of prostate, bladder and proximal urethral smooth muscle, and as such, reduces urethral pressure and resistance, bladder outlet resistance, bladder hyperactivity, and consequently lower urinary tract symptoms.~Tolterodine ER is an anticholinergic agent, which is used as one of the first line agents for detrusor overactivity."
88824120|NCT01720316|Active Comparator|glycine|Glycine, up to 0.8 g/kg, administered with TID dosing for 6 weeks Double-blind
88824121|NCT01720316|Placebo Comparator|Placebo|placebo, TID dosing, 6 weeks Double-blind
88824122|NCT01720316|Active Comparator|glycine, open-label|glycine, up to 0.8 g/kg, administered with TID dosing for 6 weeks
89177080|NCT00848549|Active Comparator|CBZ|
89355874|NCT02514460|Active Comparator|Intervention: Atherectomy|Direct Atherectomy group
89355875|NCT01567007|No Intervention|control|session of 15-20 minutes duration. It took place guidelines on physical activity, delivering a manual with general information about physical activity
89399110|NCT04263207||anti-Tat Ab positive subjects|
89399111|NCT04263207||anti-Tat Ab negative subjects|
89399112|NCT03692793|Experimental|Pulmonary rehabilitation|The PRP (24-session, three times for week) will be delivered according to ATS/ERS (Spruit et al, 2013),
89399113|NCT03692637|Experimental|anti-Mesothelin Car NK Cells|Total dose of 0.5-3 million /kg cells will be administered at day0
89399114|NCT03692559|Experimental|full sterile dressing|Patients receive full sterile dressing
88824123|NCT02399345|Experimental|Ombitasvir/Paritaprevir/r, Dasabuvir, and SOF plus RBV|Ombitasvir/paritaprevir/ritonavir (ombitasvir/paritaprevir/r) (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) and sofosbuvir (SOF) (400 mg once daily), plus weight-based ribavirin (RBV) (dosed 1,000 or 1,200 mg daily divided twice a day) for 6 weeks.
88824124|NCT02400437|Experimental|IDR|"- IDR The study treatment will consist on an induction and a maintenance phase. Dose modification will be permitted for toxicity~Induction cycles will be 4 weeks long, Maintenance cycles 8 weeks long.~Ixazomib- administered orally on predetermined days and dosage during Induction and Maintenance Phase~Dexamethasone- administered via IV or orally on predetermined days and dosage during Induction and Maintenance Phase~Rituximab- administered via IV on predetermined days and dosage during Induction and Maintenance Phase"
88824125|NCT02402153|Other|Sydvestjysk Hospital|Investigation of EEG recording with the Hyposafe device
88824126|NCT02024165||Electrode Sensor, FSE|Pregnant women between the ages of 18-50 with a single viable fetus in cephalic presentation monitored with Electrode Sensor, and/or FSE
88824127|NCT02024165||Electrode Sensor, Ultrasound|Pregnant women between the ages of 18-50 with a single viable fetus in cephalic presentation monitored with Electrode Sensor, and/or Ultrasound
88824128|NCT02024477|Placebo Comparator|Placebo|Matching placebo 1 pill daily for 12 weeks
88824129|NCT02024477|Active Comparator|saxagliptin|Saxagliptin 5mg once daily for 12 weeks
88824130|NCT02024711|Experimental|EYEFILL® C.-US Viscoelastic|EYEFILL ® C.-US is designed for use during cataract extraction and intraocular lens implantation surgery to protect the corneal endothelium, and other intraocular tissues and to manipulate tissues during these anterior chamber ocular surgeries.
89355876|NCT01567007|Experimental|Individual counseling|Consisting of three sessions within a maximum period of 3 months. We conducted a counseling, aimed at increasing physical activity, aiming to raise steps. Furthermore, we discuss the importance of physical activity, such as overcoming barriers to physical activity and targets agreed between the parties. The pedometer is given along with a diary to record the number of steps and returned in the last session.
88824131|NCT02024711|Active Comparator|Healon® Viscoelastic (CONTROL)|Healon® is designed for use during cataract extraction and intraocular lens implantation surgery to protect the corneal endothelium, and other intraocular tissues and to manipulate tissues during these anterior chamber ocular surgeries.
88824132|NCT02071823|Experimental|Group A Fed/Fasted|"A single 50 mg dose of BIA 9-1067 (2 x 25 mg capsules) was to be administered on:~Period 1: Fed Washout Period (7days) Period 2: Fasted"
88824133|NCT02071823|Experimental|Group B Fasted/Fed|"A single 50 mg dose of BIA 9-1067 (2 x 25 mg capsules) was to be administered on:~Period 1: Fasted Washout Period (7days) Period 2: Fed"
88824134|NCT02025647||Innerview MHCDS|Innerview, Mental Health Clinical Decision Support tool
89533607|NCT04057534|Experimental|CB-CRT TUD group|experimental group TUD: patients receive standard smoking cessation therapy and an add-on CB-CRT
88824135|NCT02026193|Experimental|oocyte vitrification|All retrieved mature oocytes will be vitrified.
88824136|NCT02026193|Active Comparator|embryo freezing|All retrieved oocytes will be fertilized, and resulting embryos will be frozen.
89355877|NCT01567007|Experimental|group counseling|The counseling was conducted in groups (10-12 individuals) for 6 sessions at weekly intervals, and two sessions with fortnightly. Each session lasts 60 minutes. The advice is aimed at behavioral changes using the following approaches: advantages and disadvantages of behavior change, how to overcome barriers to physical activity, self-monitoring of physical activity by using the pedometer and setting goals (number of steps / day) in the short term and what to do in case of relapse (not accomplish what was represented) besides livings practices.
89355878|NCT01567007|Experimental|aerobic training|The fitness program is held two times per week with individuals and groups with three sessions lasts for 40 minutes performed on a treadmill
88824137|NCT02029703|Sham Comparator|Sham injection|Subjects randomized into this group will receive, under sterile conditions, a sham injection of lidocaine 1% (10 mg/ml) 1-2 ml. Sterile preparation of the affected knee (treatment site) and the sham injection procedure will take place after sterile preparation into subcutaneous tissue without involving treatment to the intra-articular joint. The sham procedure will be performed by the unblinded treating physician ONLY. This procedure will include an 22-25 gauge needle stick through the skin into the subcutaneous tissue without violating the joint capsule or performing arthrocentesis.
88824138|NCT02029703|Active Comparator|Synvisc-One Injection|Subjects randomized into the Synvisc-One group will receive a single 6 mL intra-articular injection of Synvisc-One under sterile conditions. The unblinded treating physician will prepare the treatment site according to his/her standard practice guidelines (i.e. after cutaneous numbing with a vasocoolant spray and / or local lidocaine injection), an 18 gauge needle will be advanced into one of three compartments of the knee using the injectors' technique of choice. Subjects will be monitored for a minimum 5 minutes post injection to evaluate for adverse events.
89355879|NCT05706896|Experimental|Monthly injection|The patients will recive 12 intravitreal injections in one eye and 12 sham injections in the other eye each month
89355880|NCT05706896|Experimental|Bimonthly injection|The patients will receive 6 intravitreal injections in one eye and 6 sham injections in the other eye each two months
89355881|NCT05706896|Experimental|Quarterly injection|The patients will receive 4 intravitreal injections in one eye and 4 sham injections in the other eye each three months
89355882|NCT05281445|Experimental|Tic suppression|Children with tics will undergo a tic suppression experimental paradigm.
89533608|NCT04057534|Active Comparator|Control group TUD|control group: patients with TUD receive standard smoking cessation therapy
89533609|NCT04050163|Experimental|Low Dose|Cells dosage, 0.5x10^7 cells/kg body weight
89533610|NCT04050163|Experimental|Intermediate Dose (aka Effective or High)|Cells dosage, 1.6x10^7 cells/kg body weight
89533611|NCT04050163|Experimental|Toxic Dose|Cells dosage, 5.0 x10^7 cells/kg body weight
89533612|NCT04029688|Experimental|Dose Escalation: Solid Tumors: Idasanutlin Single Agent|
89355883|NCT03343912|Experimental|Test 1 vaginal ring|Single intravaginal application of 1 vaginal ring of Estriol 0.400 mg/day and Trimegestone 0.06 mg/day (Test 1) over 21 days
89355884|NCT03343912|Experimental|Test 2 vaginal ring|Single intravaginal application of 1 vaginal ring of Estriol 0.300 mg/day and Trimegestone 0.12 mg/day (Test 2) over 21 days
89533613|NCT04029688|Experimental|Neuroblastoma: Idasanutlin + Venetoclax|
88824139|NCT02406443|Experimental|Experimental arm|sitagliptin (DPP-4 inhibitor) oral tablet (100 mg); Januvia; administered once daily for 28 days
88824140|NCT02406443|Placebo Comparator|Placebo arm|placebo (no medicinal ingredients) oral tablet (100 mg); administered once daily for 28 days
88824141|NCT02339831|Active Comparator|active motion device|An active motion device (CAM) known as a CAMOPED was given after surgery. The device was used for 3 sessions of 20 minutes for 3 weeks.
88824142|NCT02339831|Active Comparator|CPM passive motion device|A continuous passive motion device (CPM) given after surgery. The device bends and moved the knee passively. It was used for 4 hours daily for 3 weeks.
89000009|NCT04677634|Other|Tolerability Arm|This is a single arm study. All subjects will receive the test material. The test material is ISOThrive. It is an approximately 90% pure maltosyl-isomalto-oligosacchride (MIMO) prebiotic syrup produced by bacterial fermentation/bio-conversion of sucrose and maltose. It is taken 1g daily for 30 days.
89533614|NCT04029688|Experimental|Neuroblastoma: Idasanutlin + Cyclophosphamide + Topotecan|
89533615|NCT04029688|Experimental|AML: Idasanutlin + Venetoclax|
89533616|NCT04029688|Experimental|AML: Idasanutlin + Fludarabine + Cytarabine|
89533617|NCT04029688|Experimental|ALL: Idasanutlin + Venetoclax|
89533618|NCT04026113|Experimental|Linaclotide 72 μg|FC Participants: Single dose, once daily at approximately the same time each day, 30 minutes before any meal
89533619|NCT04026113|Experimental|Placebo|FC Participants: Single dose, once daily at approximately the same time each day, 30 minutes before any meal
89355885|NCT03343912|Experimental|Test 3 vaginal ring|Single intravaginal application of 1 vaginal ring of Estriol 0.200 mg/day and Trimegestone 0.18 mg/day (Test 3) over 21 days
89355886|NCT03833219|No Intervention|Control (monitor only)|Continue in monitoring only mode
88824143|NCT02340299|Experimental|nHFOV|"Immediately after extubation, nHFOV is provided via binasal prongs. Ventilator settings: Frequency set at 10 Hz, I:E ratio 33:66, amplitude 20 cm H2O, Pmean 8 cm H2O, flow 7 l/min. Set FiO2 to maintain SpO2 at 90-94%.~The weaning process is left to the discretion of the attending physician. Maximum amplitude 30 cm H2O, minimum frequency 9 Hz, maximum Pmean 8 cm H2O.~For infants in the nHFOV-group who fail nHFOV (see definition below), but do not need immediate reintubation, a non-invasive Rescue-Treatment may be provided. The decision to attempt Rescue-Treatment, the mode of respiratory support and the ventilator settings used are at the discretion of the attending clinician."
88824144|NCT02340299|Active Comparator|nCPAP|"Immediately after extubation, nCPAP is provided via binasal prongs. Ventilator settings: CPAP level set at 8 cm H2O, flow 7 l/min. Set FiO2 to maintain SpO2 at 90-94%.~The weaning process is left to the discretion of the attending physician. Maximum CPAP level 8 cm H2O, maximum flow 8 l/min.~For infants in the nCPAP-group who fail nCPAP (see definition below), but do not need immediate reintubation, Rescue-nHFOV via binasal prongs may be provided. The decision to attempt Rescue-nHFOV and the ventilator settings used are at the discretion of the attending clinician."
88824145|NCT02409329|Experimental|REACH|"Participants will receive REACH text messages (individual-focused text messaging tailored to user's individual barriers to adherence and targeted to address other self-care behaviors) for 12 months.~All participants will also receive text messages advising how to access their study A1c test results, receive quarterly newsletters on healthy living with diabetes, and have access to a Helpline for study- and diabetes medication-related questions."
88824146|NCT02409329|Experimental|REACH + FAMS|"In addition to the REACH text messages tailored to user's individual barriers to adherence, participants will receive FAMS components (monthly phone coaching and text messages supporting a goal set in coaching, plus the option to invite a family member/support person to receive text messages) for six months. After six months, participants in this arm will receive REACH text messages only.~All participants will also receive text messages advising how to access their study A1c test results, receive quarterly newsletters on healthy living with diabetes, and have access to a Helpline for study- and diabetes medication-related questions."
88824147|NCT02409329|Active Comparator|Helpline and A1c results|"Participants assigned to the control group will complete measures at each time point and maintain care as usual (i.e., medical treatment and physician monitoring).~All participants will receive text messages advising how to access their study A1c test results, receive quarterly newsletters on healthy living with diabetes, and have access to a Helpline for study- and diabetes medication-related questions."
88824148|NCT02032433|Active Comparator|Extended-Release Naltrexone|Extended-Release Naltrexone (Vivitrol)
88824149|NCT02032433|Active Comparator|Buprenorphine-Naloxone|Buprenorphine-Naloxone (Suboxone)
88824150|NCT01721096||XIENCE PRIME - Long Length (LL)|Long Lesion Arm patients (n=323) are treated by at least one Long Size stent (28, 33 and 38 mm length).There are no significant difference between both the groups with respect to patient background, ischemic status, risk factors and medical history, numbers of target lesions and the lesion types, target lesion treatment, number of stents implanted, and target lesion characteristics other than lesion lengths.
88824151|NCT01721096||XIENCE PRIME - Core Size|Core Size Arm patients (n=213) are treated with small size stent (8, 12, 15, 18 and 23 mm length). There are no significant difference between both the groups with respect to patient background, ischemic status, risk factors and medical history, numbers of target lesions and the lesion types, target lesion treatment, number of stents implanted, and target lesion characteristics other than lesion lengths.
88824152|NCT02403479|Experimental|Saline then Silver Colloid|Each participant uses 6 weeks of Saline first (Frequency= 2 sprays twice daily; Route= topical intra-nasal spray; Duration= 6 weeks) followed by 6 weeks of silver colloid (Dose= 6.7mcg silver daily; Frequency= 2 sprays twice daily; Route= Topical intra-nasal spray; Duration= 6 weeks)
88824153|NCT02403479|Experimental|Silver Colloid then Saline|Each participant uses 6 weeks of Silver Colloid first (Dose= 6.7mcg silver daily; Frequency= 2 sprays twice daily; Route= Topical intra-nasal spray; Duration= 6 weeks) followed by 6 weeks of saline (Frequency= 2 sprays twice daily; Route= topical intra-nasal spray; Duration= 6 weeks).
88824154|NCT02340767|No Intervention|No Device Clinicians|The clinicians will not receive any additional training.
88824155|NCT02340767|Experimental|Spectra Device Clinicians|The clinicians in the Spectra Device Arm will be trained to the device according to the manufacturers' usual care for training. The training will consist of viewing the manufacturer's instructions for the device. Training will also consist of clinicians familiarizing themselves with the device through unsupervised clinical use with patients.
88824156|NCT02340767|Experimental|DIAGNOdent Device Practitioners|The clinicians in the DIAGNOdent Device Arm will be trained to the device according to the manufacturers' usual care for training. The training will consist of viewing the manufacturer's instructions for the device. Training will also consist of clinicians familiarizing themselves with the device through unsupervised clinical use with patients.
88824157|NCT02341859|Active Comparator|stenfilcon A and delefilcon A|Participants randomized wear the stenfilcon A and the delefilcon A contralaterally.
88824158|NCT02341859|Active Comparator|stenfilcon A and narafilcon A|Participants randomized wear the stenfilcon A and the narafilcon A contralaterally
88824159|NCT02250092|Active Comparator|tDCS/CIMT|Intervention Group will receive 20 minutes of 1.0 mA tDCS to the contralesional hemisphere concurrent with CIMT.
88824160|NCT02250092|Placebo Comparator|tDCS sham/CIMT|Placebo Group will receive 20 minutes of sham 1.0 mA tDCS to the contralesional hemisphere concurrent with CIMT.
88824161|NCT04194398||OCS Expand Trial Cohort|All patients previously enrolled in the EXPAND Lung trial.
88824162|NCT01742936|Experimental|Spinal fusion|Patients undergoing a posterior spinal fusion and having clotting factors checked by both hand held CoaguChek and Hospital Laboratory.
88824163|NCT01742936|Experimental|Cardiac bypass|Patients undergoing surgery requiring cardiopulmonary bypass and having clotting factors checked by both hand held CoaguChek and Hospital Laboratory.
88824164|NCT02312765|Experimental|Intervention|Study participants will receive a tablet computer with the AirCare system.
88824165|NCT02312765|No Intervention|Control|Standard care
89355887|NCT03833219|Experimental|Social comparison feedback|Report user's handheld phone use/ hour of driving for week. Compare this week's performance to distribution for driver cohort.
89399115|NCT03692559|No Intervention|usual standard care|Patients receive usual standard care
89533620|NCT04026113|Experimental|Linaclotide 145 μg|IBS-C Participants: Single dose, once daily at approximately the same time each day, 30 minutes before any meal
88824166|NCT02252666|Experimental|Neuromodulation Rehabilitation|Balance, posture and gait activities; therapeutic exercise for isolated muscle control; transfer training; and relaxation training using neurostimulation modulation. 2-week in lab intervention training, training at home and periodic return for follow-up testing and instruction on the next phase of the intervention.
88824167|NCT02342015|Experimental|Atorvastatin|Atorvastatin 40 mg/day for three months
88824168|NCT02342327|Other|Continue smoking menthol cigarettes|Menthol cigarette smokers continue to smoke menthol cigarettes for a four week period before attempting to quit smoking
88824169|NCT02342327|Other|Switch to non-menthol cigarettes|Menthol cigarette smokers switch to non-menthol cigarettes for a four week period before attempting to quit smoking
88824170|NCT01721564|Experimental|Bosentan|62.5 mg Bosentan twice a day for 1 month 125 mg Bosentan twice a day for 5 months
88824171|NCT02033213|Active Comparator|Restrictive group|Patients who received ≤ 8ml/kg/h of intraoperative fluid. A fluid administered during surgery: Plasma-Lyte 148 (pH 7.4; Viaflo, Baxter, US), 10% Aminoven (Fresenius Kabi AG, Bad Homburg, Germany) at 0.5 ml/kg/h, 5 ml/kg of colloid (6% Voluven 130/0.4, Fresenius Kabi AG, Bad Homburg, Germany), packed red blood cells.
88824172|NCT02033213|Active Comparator|Liberal group|Patients who received > 8 ml/kg/h of fluid. A fluid used during surgery: Plasma-Lyte 148 (pH 7.4; Viaflo, Baxter, US), 10% Aminoven (Fresenius Kabi AG, Bad Homburg, Germany) at 0.5 ml/kg/h, 5 ml/kg of colloid (6% Voluven 130/0.4, Fresenius Kabi AG, Bad Homburg, Germany), packed red blood cells.
88824173|NCT02410967|Experimental|Attention Bias Modification|Attention Bias Modification is a computer-based attention training program.
89533621|NCT04026113|Experimental|Linaclotide 290 μg|IBS-C Participants: Single dose, once daily at approximately the same time each day, 30 minutes before any meal
89533622|NCT04014348||Female|Diagnostic
88824174|NCT02410967|Placebo Comparator|Placebo Attention Task|The Placebo Attention Task uses the same computer-based format and stimuli as the Attention Bias Modification Task, but does not train attention toward or away from stimuli.
88824175|NCT02342561|Experimental|Intervention knees (Drape side)|One knee of the patient is randomly selected to be drape with an Ioban 2 incision drape.
88824176|NCT02342561|No Intervention|Control knees (no-drape side)|The knee that is not drape is left uncovered during the intervention.
88824177|NCT02343575|Experimental|Valproic Acid|"Start:~VPA PO/NGT 500 mg BID~If need to increase in 24 or more hours:~VPA 500 mg PO/NGT q am, 1000 mg PO/NGT QHS~If need to increase in 24 or more hours:~VPA 500 mg PO/NGT q am, 1500 mg PO/NGT QHS~If need to increase in 24 or more hours:~VPA 500 mg PO/NGT Q am, 2000 mg PO/NGT QHS~Rescue at all stages: HAL IV 2-5 mg Q4hr PRN"
88824178|NCT02343575|Placebo Comparator|Placebo|"Placebo: PO/NGT BID~Rescue: HAL IV 2-5 mg Q4hr PRN"
88824179|NCT01744340|Experimental|head and neck|Cetuximab, 400 mg/m2 cycle 1 week 1, then 250 mg/m2/weekly there after Eribulin Mesylate 1.4mg/m2
88824180|NCT01744340|Experimental|Colon- closed as of May 2014|"Eribulin Mesylate:~1.4 mg/m2 IV infusion days 1 and 8 of 21 day cycle"
88824181|NCT04130906|Active Comparator|Intermittent Theta Burst Stimulation|The Magstim Rapid2 Magnetic Stimulator (Magstim ®, UK) will be used to administer active iTBS.
88824182|NCT04130906|Sham Comparator|Sham Intermittent Theta Burst Stimulation|The Magstim Rapid2 Magnetic Stimulator (Magstim ®, UK) will be used to administer TBS using a sham Magstim coil.
88824183|NCT01744574|Placebo Comparator|Placebo|Placebo - subjects will take 200 mg twice daily, orally (approximately 8am and 8pm) for twelve weeks starting seven days prior to the assigned quit date. They will also receive smoking cessation behavioral counseling.
88824184|NCT01744574|Experimental|Progesterone|The progesterone will be given in the form of an active micronized natural progesterone (Prometrium). All subjects will take 200 mg twice daily, orally (approximately 8am and 8pm) for twelve weeks starting seven days prior to the assigned quit date. They will also receive smoking cessation behavioral counseling.
88824185|NCT01744730|Active Comparator|Clindamycin IV-ages 2 to 11 Years Old (BMI 85-95th Percentile)|Clindamycin IV: Children ages 2 to 11 years old with BMI 85th to 95th percentile. Their schedule of IV Clindamycin administration included 30-40 mg/kg/day dosed every 6 or every 8 hours with a maximum daily dose of 2.7 grams/day. Dosing greater than 2.7g/day was allowed for children receiving clindamycin as part of clinical care.
88824186|NCT01744730|Active Comparator|Clindamycin IV-ages 2 to 11 Years Old (BMI Greater Than 95th)|Clindamycin IV: Children ages 2 to 11 years old with BMI greater than 95th percentile. Their schedule of IV Clindamycin administration included 30-40 mg/kg/day dosed every 6 or every 8 hours with a maximum daily dose of 2.7 grams/day. Dosing greater than 2.7g/day was allowed for children receiving clindamycin as part of clinical care.
88824187|NCT01744730|Active Comparator|Clinidamycin IV-ages 12 to 17 (BMI 85-95th Percentile)|Clindamycin IV: Children ages 12 to 17 years old with BMI 85th to 95th percentile. Their schedule of IV Clindamycin administration included 30-40 mg/kg/day dosed every 6 or every 8 hours with a maximum daily dose of 2.7 grams/day. Dosing greater than 2.7g/day was allowed for children receiving clindamycin as part of clinical care.
88824188|NCT01744730|Active Comparator|Clindamycin IV-ages 12 to 17 (BMI Greater Than 95th)|Clindamycin IV: Children ages 12 to 17 years old with BMI greater than 95th percentile. Their schedule of IV Clindamycin administration included 30-40 mg/kg/day dosed every 6 or every 8 hours with a maximum daily dose of 2.7 grams/day. Dosing greater than 2.7g/day was allowed for children receiving clindamycin as part of clinical care.
88824189|NCT01722734|No Intervention|Control|Patients in the control arm only got a generic health message at the end of the study.
88824190|NCT01722734|Active Comparator|Short Message|Patients in this arm receive six short text message reminders within 60 hours of treatment initiation at 12 hour intervals.
88824191|NCT01722734|Active Comparator|Long message|Patients in this arm receive six long text message reminders (reminders including justification for why patients should finish medication) within 60 hours of treatment initiation at 12 hour intervals.
88824192|NCT04129970|Experimental|Intermittent Theta Burst Stimulation|The Magstim Rapid2 Magnetic Stimulator (Magstim ®, UK) will be used to administer active iTBS.
88824193|NCT02413151|Experimental|Exercise Training Program|The exercise sessions will be hospital-based, 3 times a week for 60 minutes each, on non-consecutive days for 6 months. Selected the aerobic interval training (AIT) method for the development of cardiopulmonary system and the inclusion of resistance and sensorimotores exercises. The AIT comprises 4 interval training periods (high intensity) and 3 active pauses (moderate intensity) between interval training periods.
89355888|NCT03833219|Experimental|End of rating period incentive|Monitor throughout intervention period and compare overall use to distribution for cohort. Notify participant at end of intervention period regarding the amount they have earned.
89355889|NCT03833219|Experimental|End of rating period incentive + social comparison feedback|Monitor throughout intervention period and compare weekly phone use to driver cohort distribution. Send weekly push notification to provide feedback. Notify participant at end of intervention period regarding the amount they have earned.
88824194|NCT02413151|Active Comparator|Control|Regular lifestyle
88824195|NCT02346383|Active Comparator|program 1|preset program - epidural and peripheral lead to cover pain Randomized selection of epidural and/or peripheral lead programs from 3 possible programs
88824196|NCT02346383|Active Comparator|program 2|preset program - epidural and peripheral lead to cover pain Randomized selection of epidural and/or peripheral lead programs from 3 possible programs
88824197|NCT02346383|Active Comparator|program 3|preset program - epidural and peripheral lead to cover pain Randomized selection of epidural and/or peripheral lead programs from 3 possible programs
88824198|NCT02413463|Active Comparator|Augmented recession|The medial rectus muscle will be exposed and hooked through a limbal approach. The muscle will then be secured with 6-0 polyglactin sutures. The medial rectus muscles will then be recessed using standard tables with the surgical dose targeting the average of the largest and smallest angles
88824199|NCT02413463|Active Comparator|Faden|Medial rectus muscle recession will be performed as described above with the surgical dose targeting the smallest pre-operative angle. The muscle will then fixated to the sclera using 6/0 polyester sutures placed in a mattress like with the anterior and the posterior sutures passing through both the edge of muscle and the sclera 12 mm and 14 mm from the muscle insertion, respectively.
88824200|NCT00354965|Experimental|ARM 1|
88824201|NCT02037347|Experimental|Palifermin|Palifermin 60 micrograms/kg/day IV for 3 consecutive days
88824202|NCT02037425|Other|onabotulinumtoxinA|At visit 2, subjects will receive their first treatment at Day 29 (+/-3 days). All subjects will receive 155 U Botulinum Toxin Type A Purified Neurotoxin Complex administered at 31 fixed-site, fixed-dose injections across seven (7) specific head/neck muscle areas. Injections will be repeated at day 113 (+/- 3 days) and at day 197 (+/- 3 days).
88824203|NCT02346461|Active Comparator|Cohort A|6 subjects on Cohort A will receive oral ManNAc 3 g twice daily (6 g/day) for 7 days and, if safe, continue on 6 g twice daily (12 g/day) for the remainder of the study.
88824204|NCT02346461|Active Comparator|Cohort B|6 subjects on Cohort B will receive oral ManNAc 6 g twice daily (12 g/day) for the duration of the study.
88824205|NCT01349465|Other|Group 1: TMC 435 - Patients With SVR at LPVPS|Patients with sustained virologic response (SVR) who completed last post-therapy follow-up visit of the previous study (LPVPS) [Phase IIb or Phase III] in which they received a TMC435-containing regimen for the treatment of HCV infection.
88824206|NCT01349465|Other|Group 2: TMC 435 - Patients With No SVR at LPVPS|Patients with no sustained virologic response (SVR) who completed last post-therapy follow-up visit of the previous study (LPVPS) [Phase IIb or Phase III] in which they received a TMC435-containing regimen for the treatment of HCV infection.
88824207|NCT02414243|Experimental|New Amino Acid formula|New Amino-Acid based Infant Formula
88824208|NCT02414243|Active Comparator|Control formula|Commercially available Amino Acid Formula
88824209|NCT02414633||Humira|Subjects with Psoriatic Arthritis taking adalimumab under conditions of daily clinical practice.
88824210|NCT02037893|Experimental|Antipyrine and Benzocaine Otic solution|antipyrine 54 mg and benzocaine 14 mg. Apply drops along the wall of the ear canal until filled and repeating every 3 hours for 24 hours unless the subject is sleeping
88824211|NCT02037893|Active Comparator|Antipyrine Otic Solution|Antipyrine 54 mg and glycerine dehydrated to 1.0 mL. Apply drops along the wall of the ear canal until filled and repeating every 3 hours for 24 hours unless the subject is sleeping
88824212|NCT02037893|Active Comparator|Benzocaine Otic Solution|benzocaine 14 mg and glycerine dehydrated to 1.0 ml. Apply drops along the wall of the ear canal until filled and repeating every 3 hours for 24 hours unless the subject is sleeping
89355890|NCT03833219|Experimental|Weekly loss-framed incentive + social comparison feedback|Monitor throughout intervention period and compare weekly phone use to driver cohort distribution. Send weekly push notification to provide feedback. Notify participant weekly regarding the amount they have earned.
89355891|NCT03833219|Experimental|Larger weekly loss-framed incentive+social comparison feedback|"Monitor throughout intervention period and compare weekly phone use to driver cohort distribution. Send weekly push notification to provide feedback. Notify participant weekly regarding the amount they have earned. Incentive amount is higher than Weekly loss-framed incentive + social comparison feedback Arm."
88824213|NCT02037893|Placebo Comparator|Placebo|Placebo otic solution will be glycerin that is dehydrated . Apply drops along the wall of the ear canal until filled and repeating every 3 hours for 24 hours unless the subject is sleeping
88824214|NCT02353091|No Intervention|APD Control Group|Comprised 13 children diagnosed with APD and acts as a control without using any form of intervention.
88824215|NCT02353091|Experimental|APD Intervention Group|Comprised 13 children diagnosed with APD and received the Remote Microphone Hearing AId intervention at the start of the study, after baseline testing, and used for 6 months.
89355892|NCT02509858|Active Comparator|thyroxine in eythyroid diabetics|50 μg of thyroxine once daily, for 2 months.
89355893|NCT02509858|Active Comparator|thyroxine in euthyroid healthy humans|50 μg of thyroxine once daily, for 2 months.
89355894|NCT02509858|Placebo Comparator|placebo in euthyroid diabetics|50 μg of placebo once daily, for 2 months.
89355895|NCT05706662|Experimental|ProFlor|patients underwent to inguinal hernia repair with use of ProFlor dynamic scaffold
89355896|NCT05706662|Active Comparator|Lichtenstein|patients underwent to Lichtenstein inguinal hernia repair
88824216|NCT02040077|Experimental|Computer + Fluency|Will receive computerized intervention and will be required to periodically demonstrate mastery of information before proceeding to the next module in the computerized intervention.
88824217|NCT02040077|Active Comparator|Computer Only|Will receive computerized intervention but will not be required to demonstrate mastery of information as part of the intervention.
88824218|NCT02040077|Active Comparator|Treatment as Usual|Will receive publicly available pamphlets that contain same information as the computerized intervention. Will not have access to computerized intervention and will not be required to demonstrate mastery of information as part of the intervention.
88824219|NCT02040623|Active Comparator|R348 Ophthalmic Solution, 0.2%|R348 Ophthalmic Solution 0.2% 2 drops per eye twice a day
89000010|NCT00554866|Experimental|VLBW between 6 and12 hours after birth|"Blood sample and buccal swab sample. One blood sample (500 mL) will be obtained from each VLBW infant between 6 and12 hours after birth from an umbilical-artery or peripheral artery catheter.~Additional DNA collection buccal cell samples were obtained with a sterile OmniSwab."
89000011|NCT02078674|Experimental|Group A|Placebo
89355897|NCT01201187|Experimental|YY-162|YY-162(Ginkgo extract 30mg+Ginseng extract 50mg) 1T/twice a day(bid) for 8weeks, po medication
88824220|NCT02040623|Active Comparator|R348 Ophthalmic Solution, 0.5%|R348 Ophthalmic Solution, 0.5% 2 drops per eye twice a day
89355898|NCT01201187|Placebo Comparator|Placebo|Placebo 1T/twice a day(bid) for 8weeks, po medication
88824221|NCT02040623|Placebo Comparator|Placebo|Placebo Ophthalmic Solution 2 drops per eye twice a day
88824222|NCT02041325|Experimental|Lenalidomide|Subjects will receive oral CC-5013 (lenalidomide) at 25 mg qd for 7 days prior to and 7 days after the vaccine.
88824223|NCT02041325|Placebo Comparator|Placebo|Subjects will receive placebo for 7 days prior to and 7 days after the vaccine.
88824224|NCT02043197||Outpatients with neurological disorders and depression.|Outpatients with mild or moderate symptoms of depression prescribed by Fevarin® in accordance with the approved local label.
88824225|NCT01723514|Experimental|Erenumab|Healthy participants and participants with migraine received subcutaneous doses of erenumab on days 1, 29 and 57.
88824226|NCT01723514|Placebo Comparator|Placebo|Healthy participants and participants with migraine received subcutaneous doses of placebo on days 1, 29 and 57.
88824227|NCT02044367|Experimental|Test 1 (Treatment A)|multiple dose of dabigatran
88824228|NCT02044367|Experimental|Test 2 (Treatment B)|multiple dose of dabigatran
88824229|NCT02044367|Experimental|Reference|multiple dose of dabigatran
88824230|NCT02044991|Active Comparator|Treatment|Participants randomized to this arm will receive a corticosteroid. This is 40mg of a non-fluorinated injectable glucocorticoid, methylprednisolone acetate (1cc) combined with 1cc of 1% Lidocaine
88824231|NCT02044991|Placebo Comparator|Placebo|Participant's randomized to this condition will receive a placebo injection once weekly
88824232|NCT05719259||Specific patient group developing Ventilator Associated Pneumonia in ICU|"Participants will be followed up to 28 days after VAP onset or until ICU discharge, whichever comes latest.~Visit 0: Screening Screening of every eligible subject for inclusion/exclusion criteria, from the moment of initiation of IMV.~Visit 1: Enrolment Takes place within the 48h after meeting eligibility criteria.~Daily:~Screening for the FDA criteria for VAP diagnosis up to the occurrence of VAP or until ICU discharge."
88824233|NCT01745822|Experimental|Tenofovir disoproxil fumarate|tenofovir disoproxil fumarate, 300 mg tablets
88824234|NCT01745822|Placebo Comparator|Placebo|matching placebo (of tenofovir disoproxil fumarate)
88824235|NCT05719181|Experimental|control group|group consist of 16 patients with no protein application
88824236|NCT04122950|Experimental|Exergaming|The participants in the Exergaming group will use the PlayPulse exergame for 45 minutes a minimum of two times per week for 8 weeks. Between 8 and 12 weeks the exergaming group will be provided with free access to the exergame but without the two mandatory exergaming sessions
88824237|NCT04122950|No Intervention|Control|Continue with normal daily routine.
88824238|NCT05719025||HIV + COVID+|
88824239|NCT05719025||HIV + COVID -|
88824240|NCT05719025||HIV - COVID +|
89000012|NCT02078674|Experimental|Group B|High dose Monovalent Avian Influenza VLP (H7N9); IM; Day 0 and Day 21
89355899|NCT05706584|No Intervention|control grup (skill lab.)|"After the control group was determined from the students attending the child health and diseases nursing course in the 2023 -2024 fall semester.~The control group will be informed and approved.~The control group will be pre-tested~The control group will go to the skill laboratory."
89399116|NCT03705195|No Intervention|No Intervention|All participants in study will complete two matched clamp studies (OGTT + IGII). The first matched clamp without any intervention the second matched clamp with low dose gliclazide
89530228|NCT05045183|Experimental|Treatment E: Antiseptic Wash Plus Antibiotic Ointment Plus SoC Adhesive Bandage|Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist. On the randomized wound site, antiseptic wash plus antibiotic ointment plus SoC adhesive bandage will be applied. This treatment will be applied and changed daily from Day 0 through Day 2 and all wound sites will be uncovered after Day 3 to Day 16 for assessments.
88824241|NCT05719025||HIV- COVID-|
88824242|NCT04002050|Active Comparator|CBTm Course Intervention|Participants placed in the intervention group will receive the CBTm Course. The CBTm Course consists of 5 classes, 90 minutes each, and held in-person on a weekly basis.
88824243|NCT04002050|No Intervention|Comparison Group|Participants in the comparison group will not receive the intervention during the study, but will be offered intervention once the study has been completed (i.e. 3 month waiting-period). However, in the event that a stressful situation arises while a participant is placed in the comparison group, the participant may seek assistance from the usual mental health supports offered through their respective occupational organizations, EAP programs, and other programs in the community. Following completion of the study, participants in the comparison group will be invited to attend the CBTm Course.
89000013|NCT02078674|Experimental|Group C|High dose Monovalent Avian Influenza VLP (H7N9) with Low dose Matrix-M1™ adjuvant; IM; Day 0 and Day 21
89000014|NCT02078674|Experimental|Group D|Intermediate dose Monovalent Avian Influenza VLP (H7N9) with Low dose Matrix-M1™ adjuvant; IM; Day 0 and Day 21
89000015|NCT02078674|Experimental|Group E|Low dose Monovalent Avian Influenza VLP (H7N9) with Low dose Matrix-M1™ adjuvant; IM; Day 0 and Day 21
88824244|NCT02354339|Experimental|Irvingia gabonensis|Irvingia gabonensis will be administered 150 mg before breakfast and 150 before dinner during 12 weeks
88824245|NCT02354339|Placebo Comparator|Placebo|Placebo will be administered 150 mg before breakfast and 150 before dinner during 12 weeks
88824246|NCT01747850|Experimental|Sativex|Intervention consist on Sativex Spray (Δ9-tetrahydrocannabinol/cannabidiol). Study subjects will be randomized in blocks of ten to one of the two groups (Sativex vs. placebo) in a double blind manner. There will be a gradual increase of the maximal allowed dose starting at five sprays per day for the first two days and increasing of five sprays per day until reaching the max number of 42 sprays per day at the end of week 2. There will be a total of 12 weeks of drug exposure. All participants will receive a combination of pharmacotherapy (Sativex or Placebo) associated with a weekly intervention of combined Motivational Enhancement/Cognitive Behavioral Therapy.
88824247|NCT01747850|Placebo Comparator|Placebo spray|Participants will receive a combination of Placebo spray associated with a weekly intervention of combined Motivational Enhancement Therapy and Cognitive Behavioral Therapy
88824248|NCT01747850|Experimental|Pilot Study|The first five subjects will be treatment-seekers that fit our inclusion/exclusion criteria and that will be treated open-label. These subjects will be instructed to use the Sativex Spray according to the induction schedule provided above. These first subjects will allow us to determine if our schedule for dosing is appropriate for the subsequent phase of the study.
88824249|NCT02046005|Active Comparator|General Rheumatoid Arthritis Education|Arm 1 participants will receive general information about RA.
89530229|NCT05045183|Experimental|Treatment F: Antiseptic Wash Plus Antibiotic Ointment Plus SoC Adhesive Bandage|Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist. On the randomized wound site, antiseptic wash plus antibiotic ointment plus SoC adhesive bandage will be applied. This treatment will be applied and changed daily from Day 1 through Day 6 and all wound sites will be uncovered from Day 7 to Day 16 for assessments.
88824250|NCT02046005|Experimental|PRE-RA|Arm 2 participants will receive personalized RA risk education by the PRE-RA risk tool.
88824251|NCT02046005|Experimental|PRE-RA Plus|Arm 3 participants will receive personalized RA risk education by the PRE-RA risk tool and health educator.
88824252|NCT01747928|Experimental|Group 1|
88824253|NCT02046317|Experimental|Echogenic needle|The experimental arm will receive ultrasound-guided femoral nerve block using echogenic needles, which are micro laser etched near the tip to reflect sound waves back to the transducer and make the tip visible.
88824254|NCT02046317|Active Comparator|Standard of care needle|The control group will receive ultrasound-guided femoral nerve block using standard of care needles.
88824255|NCT02355275|Experimental|Home Exercise Program|
88824256|NCT01724060||Gastric bypass|Patients due for gastric bypass surgery
88824257|NCT01724060||Gastric banding|Patients due for gastric banding
88824258|NCT01724060||Sleeve gastrectomy|Patients due for sleeve gastrectomy
88824259|NCT01724060||Endobarrier|Patients due to undergo endoscopic Endobarrier insertion
88824260|NCT01724060||Exenatide|Patients due to be commenced on Exenatide
88824261|NCT01724060||Liraglutide|Patients due to be commenced on Liraglutide
88824262|NCT01724060||Lifestyle|Patients due to be commenced on a lifestyle intervention programme
88824263|NCT01724060||Elective surgery or endoscopy|Patients due to have non bariatric surgery (i.e. cholecystectomy) or an elective diagnostic endoscopy
89000016|NCT02078674|Experimental|Group F|High dose Monovalent Avian Influenza VLP (H7N9) with High dose Matrix-M1™ adjuvant; IM; Day 0 and Day 21
89000017|NCT02078674|Experimental|Group G|Intermediate dose Monovalent Avian Influenza VLP (H7N9) with High dose Matrix-M1™ adjuvant; IM; Day 0 and Day 21
89000018|NCT02078674|Experimental|Group H|Low dose Monovalent Avian Influenza VLP (H7N9) with High dose Matrix-M1™ adjuvant; IM; Day 0 and Day 21
88824264|NCT02046863|Experimental|Automated Programming|Subjects will have DBS settings changed as guided by prototype DBS-Expert software. Tremor, bradykinesia, and dyskinesia will be assessed at each DBS setting.
88824265|NCT01727180||Chronic kidney disease|
88824266|NCT02046941|Experimental|Speech Production Treatment|This treatment employs a response-contingent hierarchy made up of verbal modeling/repetition, graphic cueing, integral stimulation, and articulatory placement instruction. The investigators chose this treatment for the following reasons: 1) rigor of development demonstrated across multiple studies, 2) large and predictable effects with published, quantified effect sizes, 3) a demonstrated pattern of generalization to untrained items, illustrating experimental control, 4) an established multi-modal stimulation protocol, and 5) use of repeated practice, which is associated with neural plasticity.
88824267|NCT01727414|Other|OROS-Methylphenidate and placebo for inattentive type pts|Children with ADHD-inattentive type. Every participant receives low dose MPH, medium dose MPH, high dose MPH, and placebo for one week each in a triple-blinded fashion.
88824268|NCT01727414|Other|OROS-Methylphenidate and placebo for combined type pts|Children with ADHD-combined type type. Every participant receives low dose MPH, medium dose MPH, high dose MPH, and placebo for one week each in a triple-blinded fashion.
88824269|NCT02047643|Experimental|On-algorithm first, then Off-algorithm|Users will participate in two sports camp sessions while wearing an insulin pump, continuous glucose monitor, and accelerometer/heart rate monitor (to detect exercise), which can communicate electronically to a pump shutoff algorithm that insulin delivery should be shut off. On one sports day, the algorithm is turned on; on the other day, the algorithm is turned off.
88824270|NCT02047643|Experimental|Off-algorithm first, then On-algorithm|Users will participate in two sports camp sessions while wearing an insulin pump, continuous glucose monitor, and accelerometer/heart rate monitor (to detect exercise), which can communicate electronically to a pump shutoff algorithm that insulin delivery should be shut off. On one sports day, the algorithm is turned on; on the other day, the algorithm is turned off.
88824271|NCT02048891|Active Comparator|hCG trigger|Ovulation trigger with Ovitrelle 250 microgram, luteal support with vaginal progesterone: gel Crinone 8% daily.
88824272|NCT02048891|Experimental|GnRH agonist trigger|ovulation trigger with Decapeptyl 0.2 mg, luteal support with 2 injections of 1,500 U hCG.
88824273|NCT01727726|Placebo Comparator|Placebo + ADT|Matching Placebo and assigned ADT
88824274|NCT01727726|Experimental|Brexpiprazole + ADT|Brexpiprazole, flexible dose and assigned ADT
88824275|NCT01727726|Active Comparator|Seroquel XR + ADT|Seroquel XR, flexible dose and assigned ADT
88824276|NCT05718401||Intervention group|Patients With Multiple Myeloma Myocardial Amyloidosis
88824277|NCT05718401||Control group|Patients With Multiple Myeloma but without Myocardial Amyloidosis.
88824278|NCT02355821|Experimental|Moxonidine|0.4 mg moxonidine QD titration up to 0.6 mg moxonidine BID
88824279|NCT02355821|Active Comparator|Bisoprolol|5 mg Bisoprolol QD titration up to 7.5 mg Bisoprolol BID
88824280|NCT00354575|Experimental|A|Chinese Herb (CCH1)
88824281|NCT00354575|Placebo Comparator|B|Starch powder as placebo
88824282|NCT01748240|Experimental|Azacitidine and oral vorinostat|"Patients who meet eligibility criteria will be administered vorinostat orally at 300mg two times daily for 7 days. AZA will be administered SC at 75 mg/m2/day x 7 consecutive days or at maximum tolerated dose if a dose reduction of AZA was needed before entering the trial with a minimum dose of 50mg/m2/d for 7 consecutive days.~Each cycle will last 28 days with AZA starting on day 1 of each cycle and vorinostat starting on day 3."
88824283|NCT02049749|No Intervention|Delayed CARE|40 child-caregiver pairs will be randomized to usual treatment plus delayed CARE (control). Under usual treatment, patients will be referred to a behavioral health specialist at the discretion of their pediatrician and the office social worker for additional diagnosis and treatment and/or provided with a 1-2 page informational handout on child behavior problems from the CHOP patient care manual. Following the final interview (3-4 months after enrollment for each subject) all participants randomized to the control arm (usual treatment plus delayed CARE) will receive the CARE training, if desired.
88824284|NCT02049749|Experimental|Immediate CARE|40 child-caregiver pairs will be randomized to usual treatment plus immediate CARE. The trainings are administered to groups of 4-10 caregivers at a time and are led by two mental health providers trained in the CARE curriculum. The children do not attend the training; however, caregivers are expected to practice the skills that they learn in CARE with their child between sessions. The curriculum involves 6 sessions over 6-8 weeks. Each session will be 1-2 hours.
88824285|NCT04769180||Patients affected with NCWS|100 patients with a definitive diagnosis of NCWS, based on DBPC gluten/wheat challenge.
88824286|NCT04769180||Patients affected with CD|50 patients affected with CD, sex- (± 5%) and age-matched (± 2 years) with the NCWS patients, selected at random during the study period.
88824287|NCT04769180||Patients affected with IBS not related to NCWS or other food allergies/intolerances|50 patients affected with IBS, according to the Rome IV criteria, not related to NCWS or other food allergies/intolerances, sex- (± 5%) and age-matched (± 2 years) with the NCWS patients, selected at random during the study period.
88824288|NCT01748942|Experimental|Arm I (treatment)|Patients receive dexamethasone IV at the time of surgery and PO every 8 hours for up to 4 days following surgery.
88824289|NCT01748942|Active Comparator|Arm II (control)|Patients receive dexamethasone IV at the time of surgery and placebo PO every 8 hours for up to 4 days following surgery.
88824290|NCT02050841|Experimental|Octaplas|Qualified patients will receive Octaplas as per protocol.
88824291|NCT02355977|Active Comparator|surface and root planning|surface and root planning is performed in a single-visit, one-stage, full mouth pattern using periodontal ultrasonic scaler (Satelec, Mérignac, France)
88824292|NCT02355977|Active Comparator|locally delivered minocycline|Locally delivered minocycline is administered directly into the periodontal pocket up to the gingival margin of the selected teeth
88824293|NCT02355977|Experimental|surface and root planning+minocycline|surface and root planning+locally delivered minocycline is the combined administration of both surface and root planning and locally delivered minocycline.
88824294|NCT01749410||All participants|Previous treatment with onabotulinumtoxinA for Chronic Migraine based on retrospective medical record review.
88824295|NCT04769336||Patient|Each patient will undergo simultaneous testing with two different CBC analyzers.
88824296|NCT02359955|Experimental|Zero-Degree Teeth, then Anatomic Teeth|edentulous patients who were first treated with zero-degree teeth complete denture, then with anatomic teeth complete denture
88824297|NCT02359955|Experimental|Anatomic Teeth, then Zero-Degree Teeth|edentulous patients who were first treated with anatomic teeth complete denture, the with zero degree teeth complete denture
88824298|NCT01729598|Experimental|Valproic Acid|Valproic acid 250 mg or 500mg by mouth twice daily.
88824299|NCT01729598|Placebo Comparator|Placebo|Placebo capsule by mouth twice daily.
88824300|NCT05718011|Experimental|dexmedetomidine|0.5 micrograms/kg
88824301|NCT05718011|Active Comparator|ketamine|0.5 milligram/kg
88824302|NCT01730846|Experimental|Doxazosin 4mg/day|doxazosin 4mg/day
88824303|NCT01730846|Placebo Comparator|Placebo|placebo control
88824304|NCT01730846|Experimental|Doxazosin 8mg/day|doxazosin 8mg/day
89000019|NCT02075281|Experimental|HM11260C|HM11260C 4 mg weekly sc injection
88824305|NCT04348799||BPD group|premature infants diagnosed with BPD after postnatal day 28
88824306|NCT04348799||control group|premature infants without BPD after postnatal day 28
88824307|NCT01732406||Acomegaly with Pegvisomant|Patients receiving pegvisomant monotherapy from own doctor to treat acromegaly.
88824308|NCT01732406||Acromegaly with somatostatin analog|Patients receiving somatostatin analog monotherapy from own doctor to treat acromegaly
88824309|NCT01732406||Active Acromegaly|Patients not on drugs for treatment of acromegaly
88875170|NCT02500602|Experimental|Doxazosin|Participants randomly assigned to receive doxazosin (target dose of 16 mg/day). Doxazosin will be initiated at 1 mg/day for the first week, 2mg/day for the second week, 4mg/day for the third week, 8mg/day for the fourth week, and then increase to 16 mg/day for the remaining eight weeks (as tolerated). Research staff administered the study medication at the weekly visits, and participants were given take-home doses of the medication to self-administer on the days in between study visits.
89000020|NCT02075281|Placebo Comparator|Placebo|Placebo weekly sc injection
88824310|NCT02314403|Experimental|Combined Bone Marrow and Kidney Transplantation|Recipients will receive a conditioning regimen that starts with Rituximab on day -7 (and days -2, 5, 12), Whole Body Irradiation 1.5 Gy x2 on study days -6 and -5, followed by ATG on Days -2, -1, 0. Belatacept 10mg/kg on Days 0, 3, 10, 17, 24, 38, 52. Thymic irradiation (7 Gy) will be given on study day -1, and combined renal and bone marrow transplant will be done on study day 0. Prednisone will be started at 2 mg/kg on day 4 and tapered off by day 20. Tacrolimus will be administered on study days -1 through 60, and then tapered if weaning criteria are met.
88824311|NCT03870230|Experimental|POAG MD<10dB|patients with primary open angle glaucoma with MD in visual field less than or equal 10dB
88824312|NCT03870230|Experimental|POAG MD>10dB|patients with primary open angle glaucoma with MD in visual field more than 10dB
88824313|NCT03870230|Experimental|NTG MD<10dB|patients with normal tension glaucoma with MD in visual field less than or equal 10dB
88824314|NCT03870230|Experimental|NTG MD>10dB|patients with normal tension glaucoma with MD in visual field more than 10dB
89355900|NCT05706584|Experimental|experimental group (metaverse skill lab.)|"After the experimental group was determined from the students attending the pediatric health and diseases nursing course in the fall semester of 2023-2024, respectively.~Pre-test will be applied to the experimental group.~Informed consent and demographic data collection form will be obtained from the experimental group.~The experimental group will be informed about the metaverse and approval will be obtained.~Premature infant nutrition training will be given to the experimental group in a metaverse-based skill laboratory environment.~The experimental group will enter the metaverse skill laboratory environment one by one, select their avatar and switch to the patient room in the environment,~The experimental group will evaluate the feeding pattern of the premature baby on the scenario given first in the metaverse-based skills laboratory."
88824315|NCT03870230|Experimental|OHT|patients with ocular hypertension
88824316|NCT03870230|Experimental|controls|healthy, age and sex matched, control subjects
88824317|NCT02052557|Active Comparator|Bupivacaine|30 milliliters (ml) of 0.5% marcaine with epinephrine
88824318|NCT02052557|Active Comparator|Bupivacaine liposome suspension|exparel 20ml, diluted with 10ml sterile saline for total of 30ml
89355901|NCT03842579|Experimental|Exercise and Protein (EXEPROT)|Participants in EXEPROT receive: a high-protein diet combined with Resistance training. The high-protein diet is based on milk-based protein-rich products to supplement the habitual diet (corresponding to a protein intake of 1.5 g/kg/day). 4-day food records are used to estimate the needed protein. Of the shelf-products (e.g. milk, cheese) are used considering the individually preferences. Products are delivered once a week. The training intervention includes progressive explosive type heavy-resistance training two times per week. The intervention runs for 16 weeks. Adherence to the training protocol is monitored at each session. Adherence with the nutrition protocol is monitored daily plus at phone follow-ups where participants are asked about e.g. appetite, weight, habitual intake.
88824319|NCT02052635|Experimental|Ticagrelor|90 mg oral tablet
88824320|NCT02052635|Active Comparator|Clopidogrel|300 mg oral tablet
88824321|NCT01732718|Experimental|Atorvastatin, then Placebo|Participants first received Atorvastatin 40 mg tablets once daily for 6 weeks. After a washout period of 4 weeks, they then received placebo (matching Atorvastatin 40 mg tablets) once daily for 6 weeks.
88824322|NCT01732718|Placebo Comparator|Placebo, Then Atorvastatin|Participants first received Placebo (matching Atorvastatin 40 mg tablets) once daily for 6 weeks. After a washout period of 4 weeks, they then received Atorvastatin 40 mg tablets once daily for 6 weeks.
88824323|NCT02053259|Experimental|Adaptive Goals with Immediate Reinforcement|Adaptive Physical Activity Goals, Immediate Financial Reinforcement
89533623|NCT04009499|Experimental|Bimekzumab dosage regimen|Subjects participating in the study will receive assigned bimekizumab dosage regimen during the Treatment Period.
88824324|NCT02053259|Experimental|Adaptive Goals with Delayed Reinforcement|Adaptive Physical Activity Goals, Delayed Financial Reinforcement
88824325|NCT02053259|Experimental|Static Goals with Immediate Reinforcement|Static Physical Activity Goals, Immediate Financial Reinforcement
88824326|NCT02053259|Active Comparator|Static Goals with Delayed Reinforcement|Static Physical Activity Goals, Delayed Financial Reinforcement
88824327|NCT05317520|Experimental|Intervention group|Cold vapor was applied 3 times in total at 0th,2nd and 6th hours.
88824328|NCT05317520|No Intervention|Control group|No cold vapor was applied at 0th,2nd and 6th hours.
88824329|NCT02362373|Other|levonorgestrel IUS|all women in the study underwent placement of the levonorgestrel IUS in an open-label fashion, outcomes were compared before and after placement.
88824330|NCT02363621|Active Comparator|Ranibizumab 0.3 Intravitreal injection|Intravitreal injection of Ranibizumab 0.3 mg once
88824331|NCT02363621|Active Comparator|Aflibercept 2.0 mg intravitreal injection|Intravitreal Aflibercept 2.0 mg once
88824332|NCT01749956|Experimental|FOLFOX6/Aflibercept/Radiation/Surgery|"Preoperative Chemoradiation: (6 weeks)~5-FU: 225 mg/m2 per day by intravenous continuous infusion (IVCI), Days 1 thru 42;~Radiation: 50.4 Gy (1.8 Gy/day or 28 fractions) Mon thru Fri, Weeks 1 thru 6;~Aflibercept: 4 mg/ kg, via IV infusion, Days 1 and 15.~Surgery at least 6 weeks after last day of aflibercept: Patients will undergo abdominoperineal or low anterior resection with total mesorectal excision, per standard treatment guidelines.~Postoperative Chemotherapy and Aflibercept Treatments (four 28-day cycles):~Aflibercept (administered first): 4 mg/kg IV for approximately 1 hour (no more than 2 hours) on Days 1 and 15 of each cycle.~Modified FOLFOX6:~Leucovorin: 400 mg/m2 as a 2-hour infusion prior to 5-FU on Days 1 and 15 of each cycle.~Oxaliplatin: 85 mg/m2 IV as a 2-hour infusion prior to 5-FU on Days 1 and 15 of each cycle.~5-FU: 400-mg/m2 bolus for 2 to 4 minutes followed by 2400 mg/m2 for 46 hours on Days 1 and 15 of each cycle."
88824333|NCT02363933|Experimental|Perampanel + Current Anti-Epileptic Drug|Primary glioma patients will receive perampanel along with their current AED for a total of 20 weeks. Perampanel will be titrated from 2 mg in weeks 1 and 2 and up to 8 mg daily by week 5 if well tolerated by the patient. They will then receive a maintenance dose of 8 mg per day through 16 weeks. After 16 weeks, subjects will be tapered off perampanel over a 4 week period.
89000021|NCT02075281|Experimental|HM11260C 6 mg/week|HM11260C 6 mg weekly sc injection
89000022|NCT02075281|Experimental|HM11260C 6 mg/biweekly|HM11260C 6 mg biweekly sc injection
89000023|NCT02075281|Experimental|HM11260C 8 mg/biweekly|HM11260C 8 mg biweekly sc injection
88824334|NCT05537051|Experimental|PM1021 150 mg, 450 mg, 900 mg or 1200 mg monotherapy or in combination with PM8001 (20 mg/kg)|Participants will be administered with PM1021 on Part A Day 1. Participants will be administered with PM1021 and PM8001 on Part B Day 1. PM1021 and PM8001 combination therapy administrated every 3 weeks from Part C Day 1 until disease progression, intolerable toxicity, until the patient withdraws/is withdrawn, or study completion.
88824335|NCT01750502||coronary-artery-disease group|Participants, who are diagnosed as coronary-artery-disease which including acute coronary syndromes and stable ischemic heart disease, will receive at least one stent.
88824336|NCT01750502||non-coronary-artery-disease group|Participants, who are diagnosed as non-coronary-artery-disease without acute coronary syndromes and stable ischemic heart disease, will not receive stent.
88824337|NCT03868904||OCS Lung INSPIRE Trial|
88824338|NCT02365961|Experimental|FI Block|Fascia iliaca block consisting of up to 60 mL of 0.35% ropivicaine at a dose of 3 mg/kg (with adjuvants of 100 mcg clonidine [per 60 mL] and epinephrine 1:400,000)
88824339|NCT02365961|Active Comparator|Local Injection|Local anesthetic in the hip joint consisting of 30cc of 0.5% Noropin
88824340|NCT03809234|Experimental|Ondansetron with Tariquidar|The participants will receive an IV ondansetron infusion with tariquidar. Participants will receive either 8mg or 16 mg of iv ondansetron, with 4mg/kg tariguidar.
88824341|NCT03809234|Placebo Comparator|Ondansetron with Placebo|The participants will receive an IV ondansetron infusion with D5W as placebo. Participants will receive either 8mg or 16 mg of iv ondansetron.
88824342|NCT05525039|Placebo Comparator|Control Group|Subjects assigned to Contro Group will not receive VT or HMB. They will receive daily protein supplement for 6 months.
88824343|NCT05525039|Active Comparator|HMB only Group|Subjects assigned to HMB only Group will receive HMB supplement at 3g/day and daily protein supplement for 6 months.
88824344|NCT05525039|Active Comparator|VT only Group|Subjects assigned to VT only Group will receive VT (0.3g, 35Hz, at least 3 times/week) and daily protein supplement for 6 months
88824345|NCT05525039|Experimental|HMB + VT Group|Subjects assigned to HMB + VT Group will receive HMB supplement at 3g/day, VT at least 3 times/week and daily protein supplement for 6 months.
89355902|NCT03842579|Active Comparator|Protein-only (PROT)|"Participants in PROT-group receive the nutritional intervention: The high-protein diet.~The diet is based on daily milk-based protein-rich products to supplement the habitual diet (corresponding to a total protein intake of 1.5 g/kg/day). The needed amount of protein supplementation is estimated from 4-day food records. Of the shelf-products (e.g. milk, skyr, cheeses) are used considering the individually preferences. Products will be delivered once a week at the home of the participant. The intervention runs for 16 weeks.~Adherence with the nutrition protocol is monitored daily (registration of compliance with the dietary plan) as well as at phone follow-ups where participants are asked about e.g. changes in appetite, weight, and habitual intake."
89355903|NCT03842579|Active Comparator|Recommendations (REC)|"Participants in the REC-Group receive the comparative intervention: Recommendations.~The official national dietary recommendations for adults >65 years, developed by the Ministry of Environment and Food of Denmark, and related materials is given to the participants and they are encouraged to follow the guidelines (recommending a protein intake of 1.0-1.3 g/kg/day). The intervention runs for 16 weeks.~During the intervention all groups will receive two seminars on specific topics related to healthy ageing (e.g. talks on physical activity, sedentary behaviour, and nutrition)."
88824346|NCT05317130||This is an observational study.|The cohort will consist of elite Para athletes (athletes with an impairment).
88824347|NCT03754244|Experimental|TQB3456|p.o. qd
88824348|NCT03711188|Experimental|IMM-101 (and nivolumab or ipilimumab)|IMM-101 given in combination with nivolumab. Patients in cohort B who fail to respond to treatment with IMM-101 and nivolumab, and who meet certain criteria, have the option to change treatment on study to IMM-101 and ipilimumab.
88824349|NCT05316818|Experimental|Triplet regimen (FOLFOXIRI)|The treatment planned consisted of irinotecan 160 mg/m² in 250 ml of NaCl 0.9% over 1 hr, followed by 85 mg/m² oxaliplatin in 250 ml dextrose 5% given concurrently with a 400 mg/m² leucovorin intra venous infusion in 250 ml dextrose 5% for 120 min, followed by 2400 mg/m² for 44-hr continuous infusion
88824350|NCT05316818|Active Comparator|standard duplet regimen (FOLFOX or FOLFIRI)|Regimen consisted of 180 mg/m² intravenous infusion of irinotecan for 60 min OR 85 mg/m² oxaliplatin day 1 only followed by a 200 mg/m² intra venous infusion of leucovorin for 120 min, a 400 mg/m² intravenous bolus of fluorouracil, and a 600 mg/m² continuous infusion of fluorouracil for 22 hr to be repeated on day 2
88824351|NCT02366663|Experimental|Arm I (ZBEAM)|Patients receive rituximab IV on days -21 and -14, and 90-yttrium ibritumomab tiuxetan IV on day -14. Patients also receive BEAM comprising carmustine IV over 4 hours on day -6; cytarabine IV over 2 hours BID on days -5 to -2; etoposide IV over 1 hour BID or QD on days -5 to -2; and melphalan IV on day -1. Patients then undergo autologous hematopoietic stem cell transplant on day 0.
88824352|NCT02366663|Active Comparator|Arm II (BEAM)|Patients receive BEAM comprising carmustine IV over 4 hours on day -6; cytarabine IV over 2 hours BID on days -5 to -2; etoposide IV over 1 hour BID or QD on days -5 to -2; and melphalan IV on day -1. Patients then undergo autologous hematopoietic stem cell transplant on day 0.
88824353|NCT01754480|Experimental|Fibrin Sealant Grifols|Fibrin Sealant Grifols consisting of 3 mL fibrinogen and 3 mL thrombin in separate syringes assembled on a syringe holder (6 mL of solution in total).
88824354|NCT01754480|Active Comparator|Surgicel®|Surgicel® is a sterile, absorbable knitted fabric prepared by the controlled oxidation of regenerated cellulose.
88824355|NCT02367599|Active Comparator|Vitamin D Supplement + PrEP|Subjects enrolled into this sub-study will be provided Vitamin D 4000IU/day for 24 Weeks in addition to their PrEP provided through the main study.
88824356|NCT02367599|No Intervention|PrEP Only|Subjects not enrolled into this sub-study will continue receiving PrEP through the main study. Subjects taking unsupplemented PrEP may still be used as matched controls to sub-study subjects.
88824357|NCT02368457|Experimental|Pentoxifylline and Tocopherol|Drug: pentoxifylline with tocopherol Combination of pentoxifylline and tocopherol during a minimum of 6 months and a maximum of 24 months.
88824358|NCT02368457|No Intervention|CONTROL|No drug treatment
88824359|NCT01754714|Experimental|1000 mg SAMe (S-adenosyl-L-methionine)|
88824360|NCT01754714|Experimental|1500 mg SAMe|
88824361|NCT01754714|Experimental|2000 mg SAMe|
88824362|NCT01754714|No Intervention|No treatment|
89533624|NCT03999788|Experimental|multiple sclerosis patients|lumbar puncture, microRNAs quantification in CSF samples, SNPs analysis in blood samples
88824363|NCT02370407|Experimental|Laparoscopic simulator|20 study participants will be randomized to perform peg transfer task on a laparoscopic simulator 10 times (Fundamentals of Laparoscopic Surgery (FLS), VT Medical Inc, Waltham, MA).
88824364|NCT02370407|Experimental|Mimic da Vinci robotic simulator|20 study participants will be randomized to perform peg board 1 exercise 10 times on a Mimic da Vinci robotic simulator (Mimic da Vinci Simulator, Intuitive Surgical, Sunnyvale, CA).
88824365|NCT01756976||Investigational Device|The 510k cleared OrthoPAT Advance will be used in this standard of care arm.
88824366|NCT01756976||Control Group|The commercially available OrthoPAT will be used in this arm. This is an observational trial and there is no intervention.
88824367|NCT02371187|Experimental|Dapagliflozin|The dose of Dapagliflozin will begin as one 5 mg tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two 5 mg tablets per day for the remainder of the study.
88824368|NCT02371187|Placebo Comparator|Placebo|Matching placebo for Dapagliflozin 5 mg will begin as one tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two tablets for the remainder of the study.
88824369|NCT02373137|Other|DSAEK|Type of corneal transplant; Tissue grafts will be cut to the right thickness using a microkeratome prepared at the eye bank per standard eye bank protocol (about 60-90 microns thick). A 4 mm corneal incision will be used, with Endoserter as the means of inserting the graft, an FDA approved device for this purpose.
88824370|NCT02373137|Other|DMEK|Type of corneal transplant; Endothelial grafts will be pre-peeled at the eyebank (70%). In the operating room the remaining 30% will be peeled, and the endothelium will be stained with trypan blue. A 3.5 mm corneal incision will be used and the graft will be inserted with a modified jones tube injector. The tap technique will be used to position the graft.
88824371|NCT01757678|Other|Standard of care: FFR, ICA, cCTA, FFRct|(ICA) Invasive coronary angiography with (FFR) fractional flow reserve measurement in standard of care environment, and cCTA (computed coronary tomography angiography) and FFRct Analysis (fractional flow reserve computed tomography)
88824372|NCT05316272|Experimental|Exercise and placebo|supervised bone-loading exercise 3 days per week and one placebo pill per day for 36 weeks
88824373|NCT05316272|Experimental|Exercise and DHEA|supervised bone-loading exercise 3 days per week and one dose of DHEA (50 milligrams) per day for 36 weeks
88824374|NCT05316272|Experimental|no exercise and DHEA|no supervised bone exercise and one dose of DHEA (50 milligrams) per day for 36 weeks
88824375|NCT05316272|Experimental|no exercise and placebo|no supervised bone-loading exercise and one placebo pill per day for 36 weeks
88824376|NCT05316038||Belatacept cohort|Kidney transplanted patients for whom a conversion from Tacrolimus to belatacept has been decided will be included in this cohort.
88824377|NCT02373371|Experimental|Daylight|Metvix® (160mg/g) and Photodynamic Therapy Daylight One session at baseline
88824378|NCT02373371|Active Comparator|Conventional treatment|Metvix® (160mg/g) and Photodynamic Therapy Blue light One session at baseline
88824379|NCT01759160|Active Comparator|Marsh|Marsh Plasma TCI with high initial target
88824380|NCT01759160|Active Comparator|Schnider|Schnider Plasma TCI with high initial target
88824381|NCT05458739||Treatment Group|The removed specimen (as part of BCS) is scanned with the ClearCoast MR System.
88824382|NCT05458739||Historical Group|Historical data of patients undergone BCS, under the same eligibility criteria and performed by the same study surgeons, thus minimizing inter-groups and inter-surgeon variability and bias, will serve as a control group for the comparison of the complete resection rate.
88824383|NCT05315882||Allogeneic stem cell transplantation|Observational, no interventional
88824384|NCT00354731|Active Comparator|corticosteroid|Oral prednisolone (1 mg/kg/day) x 3 M, followed by gradual tapering (0.5 mg/kg/day at 6 M, 0.25 mg/day at 12 M, and discontinued at 18 M
89000024|NCT02074579|Experimental|TU-100|15g TU-100 (oral, daily) for 4 consecutive weeks (administered as 5g three times daily)
89533625|NCT03999788|Experimental|control subjects|lumbar puncture, microRNAs quantification in CSF samples, SNPs analysis in blood samples
89000025|NCT02074579|Placebo Comparator|Matching placebo|Matching placebo given 5g three times daily orally for 4 consecutive weeks
89533626|NCT03999788|Experimental|multiple sclerosis patients with spasticity and selected SNPs|iTBS therapeutic protocol
89533627|NCT03997253|Experimental|blood, bile and urine samples|blood and urine samples at D0,D1, D3 D7, D14, M1, M3, M6 and M12
89533628|NCT03994601|Experimental|Arm A: BMS-986288 Monotherapy|
89000026|NCT02072863|Experimental|Oprozomib with Melphalan and Prednisone (OMP)|"Subjects will receive oprozomib administered orally.~The combination of oprozomib, melphalan, and prednisone (OMP) will be administered until progression of disease, unacceptable toxicity, discontinuation of study treatment for reasons other than progression or toxicity, or a maximum of 9 cycles (54 weeks), whichever occurs first."
89000027|NCT02072161|Experimental|ETC-1002 120 mg/day|Orally, once daily in morning as capsules
89000028|NCT02072161|Experimental|ETC-1002 180 mg/day|Orally, once daily in morning as capsules
89000029|NCT02072161|Placebo Comparator|Placebo|Orally, once daily in morning
89000030|NCT00198471|Experimental|Vitrase|A single intravitreous injection of Vitrase 93 USP Units (75 IU) on Study Day 1.
89000031|NCT02067793|Placebo Comparator|Placebo|Placebo
89000032|NCT02067793|Experimental|NRX-1074 1 mg|NRX-1074 1 mg, intravenous
89000033|NCT02067793|Experimental|NRX-1074 5 mg|NRX-1074 5 mg, intravenous
89000034|NCT02067793|Experimental|NRX-1074 10 mg|NRX-1074 10 mg, intravenous
89000035|NCT02066545|Placebo Comparator|Vehicle Gel|
89000036|NCT02066545|Experimental|CLS001 topical gel 1%|Topical application once daily
89000037|NCT02066545|Experimental|CLS001 topical gel 1.75%|Topical application once daily
89000038|NCT02066545|Experimental|CLS001 topical gel 2.5%|Topical application once daily
89000039|NCT04723121|Other|High risk NMIBC|Patients with primary or recurrent NMIBC for whom primary TURBT was done and intravesical BCG was administered
89000040|NCT00203112|Active Comparator|Glatiramer Acetate injection with oral minocycline|Glatiramer Acetate 20mg with oral minocycline 100mg
89000041|NCT00203112|Experimental|Glatiramer Acetate with placebo|Glatiramer acetate injection 20mg with oral placebo
89000042|NCT00554905|Experimental|1|TACE first, then RFA within 2 weeks
89000043|NCT00554905|Active Comparator|2|RFA alone
89000044|NCT00173108|No Intervention|Term group|
89000045|NCT00173108|No Intervention|Usual care program group|
89000046|NCT00173108|Experimental|Clinic-based interveniton program group|
89000047|NCT00173108|Experimental|Home-based interveniton program group|
89355904|NCT05217290|Experimental|experiment group|
89000048|NCT02062060|Active Comparator|Abametapir Lotion 0.74% w/w|Single topical treatment administered to scalp and hair for 10 minutes. Applied at home by subject/caregiver.
89355905|NCT05217290|No Intervention|control group|
89355906|NCT02505256||case group|cases who presented as breast pain or breast lumps, and no intervention will be administered.
89355907|NCT02510092|Active Comparator|Coronary artery diseae with revascularization indicated|Subjects with coronary artery disease, that require and are eligible for percutaneous revascularization.
89355908|NCT02510092|No Intervention|Coronary artery disease not requiring revascularization|Subjects with coronary artery disease that do not require revascularization.
89000049|NCT02062060|Placebo Comparator|Vehicle Lotion|Single topical treatment administered to scalp and hair for 10 minutes. Applied at home by subject/caregiver.
89000050|NCT00198510|Experimental|Vitrase|A single dose of 0.05 cc of Vitrase (hyaluronidase) for ophthalmic intravitreal injection is injected into the vitreous chamber.
89000051|NCT00198510|No Intervention|Observation|Observation only, no medication or intravitreal injection
89000052|NCT02057380|Experimental|Arm A: High dose linsitinib twice daily monotherapy|Arm A includes subjects from Protocol OSI-906-301
89000053|NCT02057380|Experimental|Arm B: High dose linsitinib BID plus high dose erlotinib QD|Arm B includes subjects from Protocol OSI-906-205
89000054|NCT02057380|Experimental|Arm C: High dose erlotinib monotherapy once daily|Arm C includes subjects from Protocol OSI-906-205 and OSI-906-207
89000055|NCT02057380|Experimental|Arm D: High dose linsitinib BID plus weekly paclitaxel|Arm D includes subjects from Protocol OSI-906-202
89000056|NCT02057380|Experimental|Arm E: Highest dose linsitinib intermittent once daily|Arm E includes subjects from Protocol OSI-906-202, linsitinib on Days 1-3 of each week plus weekly paclitaxel
89000057|NCT02057380|Experimental|Arm F: Paclitaxel alone weekly|Arm F includes subjects from Protocol OSI-906-202
89000058|NCT02057380|Experimental|Arm G: Lowest dose linsitinib twice daily + low dose erlotinib|Arm G includes subjects from Protocol OSI-906-103
89000059|NCT02057380|Experimental|Arm H: high dose linsitinib twice daily|includes subjects from protocols SARC 022/CTEP 8945, linsitinib x28 days (each cycle)
89000060|NCT02057380|Experimental|Arm I: highest dose linsitinib once daily|includes subjects from EuroSARC protocol, linsitinib on Days 1-3; Days 8-10 and Days 15-17
89000061|NCT02057380|Experimental|Arm J: Low dose linsitinib 2x daily+bortezomib & dexamethasone|includes subjects from protocol MM-001; Days 1, 4, 8 & 11 (cycles 1-8) and Days 1, 8, 15 & 22 (cycles 9+)
89000062|NCT02057380|Experimental|Arm K: med. dose linsitinib 2x daily+bortezomib&dexamethasone|includes subjects from protocol MM-001; Days 1, 4, 8 & 11 (cycles 1-8) and Days 1, 8, 15 & 22 (cycles 9+)
89000063|NCT02057380|Experimental|Arm L: high dose linsitinib 2x daily+bortezomib&dexamethasone|includes subjects from protocol MM-001; Days 1, 4, 8 & 11 (cycles 1-8) and Days 1, 8, 15 & 22 (cycles 9+)
89000064|NCT02057341|Experimental|ARRY-371797 (Dose 1)|
89000065|NCT02057341|Experimental|ARRY-371797 (Dose 2)|
89000066|NCT00203151|Experimental|1|
89000067|NCT00203151|Placebo Comparator|2|
89000068|NCT02050828|Experimental|AKB-9778 15 mg BID monotherapy|Subcutaneous AKB-9778 15 mg BID (total daily dose of 30 mg/day) plus monthly sham intravitreal injection for 3 months.
89355909|NCT02505100|Experimental|Touching relaxant|session of massage
89355910|NCT02505100|Experimental|Hypnoses|session of hypnoses
89355911|NCT02505100|No Intervention|Standared care|standard care
89533629|NCT03994601|Experimental|Arm B: BMS-986288 in combination with Nivolumab|
88824385|NCT00354731|Experimental|Pentoxifylline + corticosteroid|Oral pentoxifylline 1,200 mg/day (for estimated GFR ≧60 ml/min) or 800 mg/day (estimated GFR 59-30 ml/min) x 6 months, followed by stepwise reduction (800 mg/day x 6 M, 400 mg/day x 6 M and discontinued at 18 M + oral prednisolone (1 mg/kg/day) x 3 M, followed by gradual tapering (0.5 mg/kg/day at 6 M, 0.25 mg/day at 12 M, and discontinued at 18 M
88824386|NCT03461978|Other|10 patients with meibomian gland dysfunction|
89355912|NCT02513992|Experimental|intra-arterial injection of tracer|The perfusion tracer 99m-Technetium Ethyl Cysteinate Dimer will be injected via an intra-arterial catheter by a pressure injector to obtain a subtracted ictal SPECT co-registered with MRI (SISCOM)
88824387|NCT03461978|Other|10 patients with cataract|
88824388|NCT03461978|Other|10 patients after minimally invasive glaucoma surgery (MIGS)|
88824389|NCT03461978|Other|10 patients after partial corneal transplantation|
88824390|NCT03461978|Other|5 patients with demodicosis|
88824391|NCT03461978|Other|5 patients with conjunctival pathologies|
88824392|NCT03461978|Other|5 patients with Acanthamoeba keratitis|
88824393|NCT03461978|Other|5 patients with aniridia|
88824394|NCT04769492|Other|Pilot Intervention|Tailored violence prevention intervention (#ChopViolence/#ChopHIV) for B-YGBMSM and B-TW in the Chicago HBC.
88824395|NCT02979275||BRAIN+THENAR MUSCLE INVOS|Patients undergoing open heart surgery on cardiopulmonary bypass.
88824396|NCT03423758||Healthy controls|Healthy subjects with age more than 60 years
88824397|NCT03423758||Pseudoexfoliation Glaucoma|Already diagnosed Pseudoexfoliation glaucoma patients with age more than 50 years
88824398|NCT03423758||Angle closure Glaucoma|Already diagnosed Angle closure Glaucoma patients with age more than 21 years
88824399|NCT03423758||Primary open-angle Glaucoma|Already diagnosed primary open-angle glaucoma with age more than 30 years
88824400|NCT04769258||Patients with IBD treated with immunomodulatory drugs|
89355913|NCT03832673|Experimental|Pembrolizumab + Epacadostat|Pembrolizumab 200 mg IV every 3 weeks (for 3 cycles) Epacadostat 300 mg (BID) orally continuously every 28 days (for 3 cycles)
89355914|NCT04499716|Active Comparator|Arm 1: ITO group|Arm 1: IPACK combined with femoral triangle and obturator nerve blocks
89355915|NCT04499716|Experimental|Arm 2 : Quadri-block group|Arm 2 : Femoral, sciatic, obturator and lateral femoral cutaneous nerve blocks
88824401|NCT04769258||Patients with IBD not treated with the immunomodulatory drugs|
88824402|NCT02376179||Cuffed ETT|Pediatric patients intubated with a cuffed endotracheal tube for adenotonsillectomy.
88824403|NCT01762904|Experimental|Whole group of 135 units of measurement|"The arm is composed of 135 units of measurement, it means, 540 determinations to test 2% chlorhexidine gluconate in 70% isopropyl alcohol and 1% triclosan in 70% isopropyl alcohol and two controls.~The principal unit of measurement it will be four determinations of bacterial counts in a subject for antiseptics and controls to test each of the application sites, and determination as to each separately sampling for each area for each antiseptic forearm. The same subject may be assessed up to three separate occasions provided only after a minimum period of two weeks between each determination.~Interventions:~Biological: Bacterial culture of the prepared skin's areas with two antiseptics and two controls~Other: Preparing skin's areas to be tested with two antiseptics and two controls"
89355916|NCT03832283|Other|Usual Care Depression Screening|Patients randomized to this intervention arm will receive usual care annual depression screening when they come in for a clinic visit and are due for screening. When the patient comes in for a visit, a best practice alert in the EHR will indicate that the patient requires depression screening. The CAD-MDD/CAT-DI screening during clinic visit will occur in a patient room, prior to their appointment with a primary care provider.
89355917|NCT03832283|Experimental|Population MyChart Depression Screening|Patients randomized to this intervention arm will continue to receive usual care annual depression screening when they come in for a clinic visit and are due for screening. In addition, they will receive email invitations to complete the CAD-MDD/CAT-DI screening via MyChart. Email invitations will be sent at preset intervals until depression screening is completed, or the end of the 1-year follow-up period, whichever comes first.
89355918|NCT03832283|Other|Usual Care Depression Monitoring|Patients who have depression and are randomized to this intervention arm will receive usual care PHQ-9 monitoring during clinic visits. When the patient comes in for a visit, a best practice alert in the EHR will indicate that the patient requires depression assessment.
89533630|NCT03994601|Experimental|Part 2C: BMS-986288 in combination with Nivolumab and Regorafenib|
88824404|NCT02376257|Active Comparator|250 mg DCS|Baseline assessment (week 1), two weekly sessions when 250mg DCS is administered, and final week (week 4) when retention is assessed.
88824405|NCT02376257|Active Comparator|100 mg modafinil|Baseline assessment (week 1), two weekly sessions when 100 mg modafinil is administered, and final week (week 4) when retention is assessed.
88824406|NCT02376257|Placebo Comparator|Placebo|Baseline assessment (week 1), two weekly sessions when placebo is administered, and final week (week 4) when retention is assessed.
88824407|NCT01762982|Experimental|Test|Benzalkonium chloride (0.13%) Disinfectant Spray water
88824408|NCT01762982|Active Comparator|Positive Control|Sodium lauryl sulfate (SLS) (0.3% weight by weight [w/w]) water solution
89000069|NCT02050828|Experimental|AKB-9778 15 mg BID + ranibizumab 0.3 mg|Subcutaneous AKB-9778 15 mg BID (total daily dose of 30 mg/day) plus ranibizumab 0.3 mg monthly intravitreal injection for 3 months.
88824409|NCT01762982|Placebo Comparator|Negative Control 1|Normal saline water (0.9% weight by volume [w/v])
88824410|NCT01762982|Placebo Comparator|Negative Control 2|Empty Finn Chamber
88824411|NCT05315492|Experimental|Intervention communes|CCC intervention
88824412|NCT05315492|No Intervention|Control communes|Standard care
88824413|NCT02990780|Active Comparator|Conventionally fractionated CRT|Induction chemotherapy followed by conventionally fractionated concurrent chemo-radiotherapy,with prophylactic cranial irradiation for those who achieve a good response after combined chemoradiotherapy.
88824414|NCT02990780|Experimental|Accelerated hypofractionated CRT|Induction chemotherapy followed by accelerated hypofractionated concurrent chemo-radiotherapy,with prophylactic cranial irradiation for those who achieve a good response after combined chemoradiotherapy.
89533631|NCT03981445|Experimental|On-site Integrated Care with Adherence Counseling|Participants randomized to the on-site integrated care with adherence counselling arm will be prescribed pre-exposure prophylaxis (PrEP) (Truvada®) and, if indicated, Hepatitis C (HCV) treatment (Epclusa®) at the OAT clinic or SAP from which they were recruited. In addition to PrEP and, if indicated, HCV care, participants in the on-site integrated care arm will receive any required health care services as per local standard of care. Addiction treatment, OAT, and mental health services will be provided, if necessary and available. Participants recruited at syringe access programs (SAP) will be offered addiction counseling and treatment, including OAT when in the integrated care arm in addition to site standard of care.
88824415|NCT02990234|Active Comparator|Capsular Repair|Capsular Repair arm. The first hip is randomized, opposite treatment on second hip. One Hip will receive the capsular repair while the other hip will not.
88824416|NCT02990234|Placebo Comparator|No Capsular Repair|Placebo arm. One hip is randomized to capsular repair while the other hip has no capsular repair.
88824417|NCT03211286|Active Comparator|TXA group|Tranexamic acid, a single dose of 1 g intravenous diluted in 100 mL saline solution at the time of surgical incision
88824418|NCT03211286|Placebo Comparator|Control group|Saline solution, 100 mL intravenous at the time of surgical incision
88824419|NCT01763606|Experimental|Enoxaparin|Patients assigned to enoxaparin.
88824420|NCT01763606|Experimental|Aspirin|Patients assigned to Aspirin.
88824421|NCT05315180|Experimental|dose exploration|Enrollment into the dose exploration cohorts may be from any eligible solid tumor type. Dose escalation will begin with 1-6 subjects treated at the lowest planned dose level. If no DLT is observed, dose escalation will continue to the next planned dose cohort
88824422|NCT05315180|Experimental|dose expansion|dose expansion may proceed with 2 groups consisting of subjects with KRAS p.G12C mutant advanced solid tumors. Dose expansion in these 2 groups may be done concurrently
88824423|NCT03161756|Experimental|Arm A|Patients in Arm A will receive nivolumab 3 mg/kg intravenously (IV) every 2 weeks for 4 doses and denosumab 120 mg subcutaneously (SC) given D1, D8, D15, D29 (induction phase). Thereafter, nivolumab 480 mg IV and denosumab 120 mg SC every 4 weeks for a total of 24 months (maintenance phase).
88824424|NCT03161756|Experimental|Arm B|Patients in Arm B will receive ipilimumab at 3 mg/kg combined with nivolumab at 1 mg/kg IV every 3 weeks for 4 doses with denosumab 120 mg SC given D1, D8, D15, D29, D57 (induction phase). This will be followed by nivolumab 480 mg IV and denosumab 120 mg SC ever 4 weeks for a total of 24 months (maintenance phase).
88824425|NCT01765712|Placebo Comparator|Control Group|Patients will be randomized into the treatment arm using a computer generated randomization table (simple randomization). Patients in the control arm of the study will undergo Anterior cruciate ligament reconstruction using Autologous bone patellar tendon bone autograft. At the end of the surgery, their graft donor site will have bone graft chips placed into the bony defect and the wound will be closed using sutures.
88824426|NCT01765712|Experimental|Platelet Rich Plasma|Patients randomized into the treatment arm of the study will undergo Anterior cruciate ligament reconstruction with Autologous bone patellar tendon bone autografts. At the start of the surgery,just after the administration of anesthesia, 10cc of blood will be withdrawn from the patients IV by the anesthesiologist. This sample will be spun down into 3-5cc of Platelet Rich Plasma which will be added to the patients bone graft chips and placed into the donor site at the end of the case.
88824427|NCT02378207|Experimental|Group 1 H4:IC31|15 mcg H4/500 nmol IC31 administered IM as 0.5 mL in alternating deltoid muscle at Days 0 and 56.
88824428|NCT02378207|Experimental|Group 2 H56:IC31|5 mcg H56/500 nmol IC31 administered IM as 0.5 mL in alternating deltoid muscle at Days 0 and 56.
88824429|NCT02378207|Active Comparator|Group 3 BCG (2-8 x 105 CFU)|Administered IM as 0.1 mL in either deltoid muscle at Day 0.
88824430|NCT02378207|Placebo Comparator|Group 4 Control Sodium Chloride 0.9%|Administered IM as 0.5 mL in alternating deltoid muscle at Days 0 and 56.
88824431|NCT01766024|Experimental|BCD-033 → Rebif|Volunteers in this group initially will receive a single sc injection of the study drug BCD-033 (interferon beta-1a) at a dose of 44 µg (on Day 1) and then, after at least 14 days, a single sc injection of the reference drug Rebif® (interferon beta-1a) at a dose of 44 µg.
88824432|NCT01766024|Experimental|Rebif → BCD-033|Volunteers in this group initially will receive a single sc injection of active comparator Rebif (interferon beta-1a) at a dose of 44 µg (on Day 1) and then, after at least 14 days, a single sc injection of the study drug BCD-033 (interferon beta-1a) at a dose of 44 µg.
88824433|NCT01766102|Active Comparator|Intra-operative Mammography|Intra-operative Specimen Mammography
88824434|NCT01766102|Active Comparator|Standard Mammography|Standard Specimen Mammography
88824435|NCT05297084||Aggressive periodontitis|25 young medically free patients with deep periodontal pockets >5mm
88824436|NCT05297084||Periodontally healthy individuals|25 young medically free individuals with no periodontal inflammation signs
88824437|NCT05296850|Experimental|Manual release group|Manual release will perform with plantar fascia and flexor hallucis longus stretching and tissue mobilization. Stretching/mobilization will applied for approximately 3 minutes.
88824438|NCT05296850|Experimental|Kinesio taping group|Two techniques will be used in kinesio taping application; first technique is the gastrocnemius muscle inhibition technique and the plantar fascia ligament correction technique and other technique is the transverse arch ligament correction technique.
88824439|NCT04351022|Experimental|CD38 positive relapsed or refractory acute myeloid leukemia|
88824440|NCT05252936|Experimental|Spanish language content|Social media campaign content with Spanish language voiceover
88824441|NCT05252936|Experimental|K'iche' language content|Social media campaign content with K'iche' language voiceover
88824442|NCT05252936|Experimental|Kaqchikel language content|Social media campaign content with Kaqchikel language voiceover
88824443|NCT05252936|Active Comparator|Control|A control group that is not exposed to any of the social media campaign content will serve as control to allow for comparison of outcomes with treatment arms.
88824444|NCT05229068|Experimental|Prior_RSV MAT Group|Maternal participants who received a single 120 µg dose of RSV MAT vaccine at Day 1 in RSV MAT-004 (NCT04126213), RSV MAT-009 (NCT04605159) or RSV MAT-012 (NCT04980391) parent studies, will receive a single dose of RSV MAT vaccine at Day 1 in the current study and are followed-up until the study end (Day 181 post-delivery).
88824445|NCT05229068|Experimental|Prior_Placebo Group|Maternal participants who received a single dose of placebo at Day 1 in RSV MAT-004 (NCT04126213), RSV MAT-009 (NCT04605159) or RSV MAT-012 (NCT04980391) parent studies or who did not participate in the parent studies and did not receive any RSV vaccine in the past*, will receive a single dose of RSV MAT vaccine at Day 1 in the current study and are followed-up until the study end (Day 181 post-delivery). *The unvaccinated participants are enrolled if the study cannot enroll sufficient numbers of the maternal participants who received placebo in the parent studies.
88824446|NCT02378753|Experimental|rVSVΔG-ZEBOV (immediate vaccination)|One intramuscular (deltoid) injection of rVSVΔG-ZEBOV (2 x 10^7 plaque forming units)
88824447|NCT02378753|Experimental|rVSVΔG-ZEBOV (deferred vaccination)|One intramuscular (deltoid) injection of rVSVΔG-ZEBOV (2 x 10^7 plaque forming units) in participants randomized to receive deferred vaccination (18-24 weeks after enrollment).
88824448|NCT02990936||head and neck squamous cell carcinoma|Patients with T1 to T4 head and neck squamous cell carcinoma from oral cavity, oropharynx, larynx and hypopharynx eligible for radiotherapy or concomitant chemoradiotherapy
88824449|NCT01767506|Experimental|Intervention|Communities will receive usual care, including annual mass drug administration with azithromycin if trachoma infection level is greater than 1% or TF is 5% or more. Communities will have MDA stopped if infection is 1% or less, or TF is less than 5%. MDA will be reinstated if infection re-emerges to 6% or more. In addition, surveillance and treatment with azithromycin of newcomer and traveler families within 2 weeks of arrival to or return to the community.
88824450|NCT01767506|Active Comparator|Usual Care|Communities will receive usual care, including annual mass drug administration with azithromycin if trachoma infection level is greater than 1% or TF is 5% or more. Communities will have MDA stopped if infection is 1% or less, or TF is less than 5%. MDA will be reinstated if infection re-emerges to 6% or more.
88824451|NCT02381015|Experimental|Genetic Risk Score: Number Format|Genetic Risk Score: Number Format Subjects receive genetic risk scores in a number format.
88824452|NCT02381015|Experimental|Genetic Risk Score: Number + Pictograph|Genetic Risk Score: Number + Pictograph Subjects receive genetic risk scores in a number and pictograph format.
88824453|NCT02381015|Experimental|Family History: Number Format|Family History: Number Format Subjects receive family history risk in a number format.
88824454|NCT02381015|Experimental|Family History: Number + Pictograph|Family History: Number + Pictograph Subjects receive family history risk in a number and pictograph format.
88824455|NCT02383043|Experimental|Active Treatment|Cocaine choice during d-amphetamine maintenance
88824456|NCT02383043|Placebo Comparator|Placebo Treatment|Cocaine choice during placebo maintenance
89355919|NCT03832283|Experimental|Population MyChart Depression Monitoring|Patients who have depression and are randomized to this intervention arm will continue to receive usual care depression monitoring when they come for clinic visits. In addition, they will receive email invitations at preset intervals to complete the CAT-DI monitoring via MyChart. Invitations will be sent until major depressive disorder (MDD) remission is achieved, or the 1-year follow-up period ends, whichever comes first.
88824457|NCT05176808|Active Comparator|Telehealth Parent Coaching (TC)|"A family-centered, collaborative coaching approach, Practice-Based Coaching (Snyder et al., 2015), will be used. Coaches will use an NDBI coaching curriculum to support parents in targeting the child social-communication skills during interactions with their toddlers with ASD. The duration of the coaching period is 12 weeks with 2 sessions per week. Parents will be coached to implement NDBI strategies during daily routines with their young child with ASD following the coach and parent NDBI manuals developed in the Landa lab.~Trained study coaches will join families in their homes remotely via Kennedy Krieger Institute's secure Zoom password-protected account to provide coaching."
88824458|NCT05176808|Active Comparator|In-person Coaching(IPC)|"A family-centered, collaborative coaching approach, Practice-Based Coaching (Snyder et al., 2015), will be used. Coaches will use an NDBI coaching curriculum to support parents in targeting child social-communication skills during interactions with their toddlers with ASD. The duration of the coaching period is12 weeks with sessions 2 times per week. Parents will be coached to implement NDBI strategies during daily routines with their young child with ASD following the coach and parent NDBI manuals developed in the Landa lab.~Coaching will be delivered in families' homes by trained study coaches to support parent implementation of NDBI strategies during daily life activities with their toddler with ASD."
88824459|NCT01768520|Experimental|Entelon tab. 150mg|
88824460|NCT01768520|Active Comparator|Celebrex cap.|
88824461|NCT01768520|Placebo Comparator|Placebo|
89355920|NCT04499638||Non type 2 diabetic patient|Tracking the catheter from insertion to removal. Collection of any patients complication associated with these devices and what different treatments has been administered
89355921|NCT04499638||Diabetic type 2 patient|Tracking the catheter from insertion to removal.Collection of any patients complication associated with these devices and what different treatments has been administered
89355922|NCT03548935|Experimental|Semaglutide s.c. 2.4 mg once weekly|Participants will receive semaglutide for 68 weeks.
89355923|NCT03548935|Placebo Comparator|Semaglutide placebo|Participants will receive semaglutide matching placebo for 68 weeks.
88824462|NCT01768832|Experimental|Treadmill|Individuals assigned to the Treadmill group will complete two one hour treadmill training sessions per week for 12 weeks.
88824463|NCT01768832|Experimental|Tango|Individuals assigned to the Tango group will complete two one hour dance classes twice per week for 12 weeks.
88824464|NCT01768832|Active Comparator|Stretching|Individuals assigned to Stretching will complete two one hour stretching classes per week for 12 weeks.
88824465|NCT02383667||Patients with Electrocardiograms|"Any patient within the hospital either for procedure or for admission will be screened. Patients will be simultaneously be hooked up to two ambulatory Holter monitors for the period of time to be not less than one hour.~One holter will use standard electrodes in a standard electrode distribution. The second holter will use dry electrodes in a derived; data will be collected for 1-6 hours. After the data is collected the Holters will be removed and the data will be downloaded into the reading software to be scanned."
89355924|NCT04499014|Experimental|ultrasound|ultrasound : a frequency of 1 MHz and an intensity of 1 W/cm2, 5 days a week, a total of 10 sessions
89355925|NCT04499014|Experimental|phonophoresis|an intensity of 1 W/cm2 and a frequency of 1 MHz and phonophoresis with 0.1% dexamethasone pomade,5 days a week, a total of 10 sessions
89533632|NCT03981445|Experimental|Off-site Referral to Specialized Care with Patient Navigation|Participants randomized to the off-site referral to specialized care and patient navigation group will be linked to primary care for PrEP and, if necessary, HCV treatment by a patient navigator. Given the replicated success of the AntiRetroviral Treatment Access Study (ARTAS) intervention regarding linking HIV-infected individuals to HIV primary care, we adapted ARTAS to facilitate people who inject drugs linkage with PrEP and, if necessary, HCV treatment services. Participants in the off-site care arm will be prescribed PrEP and, if necessary, HCV treatment by their off-site physician. All necessary care will also be provided to participants by their off-site physician. Off-site physicians will be notified that if their patients are placed on a waiting list, unable to afford, or are otherwise unable to immediately access PrEP or HCV treatment, Truvada® and Epclusa® are available to participants of the M2HepPrEP study immediately and free of charge.
89533633|NCT03968211|Experimental|Vaccine|Subjects who meet enrollment criteria will be administered a single intramuscular dose of the Salmonella typhi polysaccharide vaccine
89533634|NCT03941314|Experimental|Supera® Peripheral Stent System|Femoro-popliteal arterial stenting with Supera® Peripheral Stent System as CE-marked by the manufacturer Abbott
88824466|NCT02386319|Active Comparator|Melatonin|"Melatonin 10 mg, gelatin capsules. Pharmacokinetic study: 10 mg x 2. In the morning before surgery and in the evening after surgery.~Anxiolytic and analgesic study: 10 mg x 4. Evening the day before surgery, the morning before surgery, immediately after surgery and the evening after surgery."
88824467|NCT02386319|Placebo Comparator|Placebo|Gelatin capsules. Anxiolytic and analgesic study. Evening the day before surgery, the morning before surgery, immediately after surgery and the evening after surgery.
88824468|NCT05164562||type 1 diabetes|"type 1 diabetes group: patients with type 1 diabetes"
88824469|NCT02585414||85 healthy subjects with no history of DES|
88824470|NCT02585414||255 subjects with DES|
88824471|NCT02240888|Active Comparator|vaccinated patients|patients with different inflammatory rheumatic disease immunized with 0,5 mg pneumococcal conjugate vaccine i.m.
88824472|NCT02240888|Active Comparator|vaccinated controls|healthy controls immunized with 0,5 mg pneumococcal conjugate vaccine i.m.
88824473|NCT02240888|Active Comparator|seasonal influenza vaccine|patients with different inflammatory rheumatic diseases immunized with 0,5 mg seasonal influenza vaccine i.m.
88824474|NCT02240888|Active Comparator|non-vaccinated controls|healthy controls immunized with 0,5 mg seasonal influenza vaccine i.m.
88824475|NCT05129306||Patients|Patients with moderate to severe Allergic Rhinitis who have been prescribed RYALTRIS® nasal spray by their healthcare professional. Observational.
89355926|NCT04499014|Placebo Comparator|placebo ultrasound|same ultrasound device as described above seemed to be working but without delivering any output, 5 days a week, a total of 10 sessions
89355927|NCT03832205||Capaciflector monitoring group|Patients undergoing their pre-planned, routine cardiopulmonary exercise test (CPET). Additional, non-invasive capaciflector monitoring only - no therapeutic intervention.
88824476|NCT05128994|Experimental|Non-invasive FES|Wearable FES sleeve with non-invasive user controls
88824477|NCT01769612||CL Detect Rapid Test and Microsopy Samples|Samples taken to be evaluated in the CL Detect and Microscopy assays
88824478|NCT02387801|Experimental|Ixekizumab Dosing Q2W|160 milligrams (mg) ixekizumab given as two subcutaneous (SC) injections at week 0 followed by 80 mg ixekizumab given as a single SC injection once (Q2W) every 2 weeks through week 12. After week 12 participants will receive 80 mg ixekizumab every 4 weeks through week 44.
88824479|NCT02387801|Experimental|Ixekizumab Dosing Q4W|160 mg ixekizumab given as two SC injections at week 0 followed by 80 mg ixekizumab given as a single SC injection once (Q4W) every 4 weeks through week 44.
88824480|NCT01770314|Experimental|Experimental|Participants will be given instructions via email to review eleven online lessons about opioid medication safety. Instructions will suggest that participants view one lesson per day for eleven consecutive days. Each educational lesson focuses on one or two aspects of medication safety, including how to safely store medication, and the importance of taking medication exactly as prescribed.
88824481|NCT01770314|No Intervention|Control|The control group is a waitlist control. Participants will be given access to painACTION after the intervention period and follow up assessments are completed.
88824482|NCT02259608|Experimental|BCG vaccine SSI|Healthy volunteers are vaccinated with yBCG. Blood will be drawn before and at several timepoints after vaccination. Cytokine production before vaccination will be used as reference to compare later timepoints with.
88824483|NCT05284097|Experimental|Study Intervention|"Subjects will receive the following study vaccines as a 0.5 mL IM injection into the deltoid:~Ad26.ZEBOV at a dose of 5x10^10 vp on Day 1~MVA-BN-Filo at a dose of 1x10^8 Inf U on Day 57"
88824484|NCT02326844|Experimental|Ovarian Cancer Patients|Ovarian cancer patients with germline breast cancer mutation (gBRCAm) who have progressed on prior poly (ADP-ribose) polymerase inhibitor (PARPi) therapy
88824485|NCT02548676||Glaucoma Patients|Patients with primary open angle glaucoma
88824486|NCT02548676||Healthy controls|age- and sex matched controls
88824487|NCT05283629|Experimental|Neuroplasticity-based Computerized Cognitive Remediation|"Behavioral: Neuroplasticity-based Computerized Cognitive Remediation The nCCR has two major components: Bottom up and Top down training.~Bottom up training: The training includes selected tasks from Brain HQ, a program designed for older adults, that enhances basic processing of sensory stimuli with the goal to improve fidelity of auditory and visual encoding.~Top down training: We designed programs to target cognitive control functions associated with poor treatment response, i.e., initiation and use of verbal strategy and susceptibility to interference. These Top Down Programs include a visual attention program, either Catch the Ball or Neurogrow, and a semantic strategy program, Semantic Organization."
88824488|NCT05283629|Active Comparator|Education Comparison Control|The education control condition is a learning-based approach that utilizes DVDs on history, art, science, etc. This active condition is comparable to nCCR in length of exposure, audio-visual presentation, computer use and contact with research staff.
89533635|NCT03941314|Active Comparator|EverFlex™ Self-Expanding Peripheral Stent System|Femoro-popliteal arterial stenting with EverFlex™ Self-Expanding Peripheral Stent System with Entrust™ Delivery System or as Protégé™ EverFlex™
88824489|NCT02533154|Experimental|BAC treatment group|20 patients with mild or moderate dry eye syndrome receiving BAC containing Prosicca eyedrops for 1 month
88824490|NCT02533154|Active Comparator|non-BAC treatment group|20 patients with mild or moderate dry eye syndrome receiving preservative-free Prosicca sine eyedrops for 1 month
88824491|NCT02388815|Experimental|Intervention|FreeStyle Libre Flash Glucose Monitoring System
89533636|NCT03940196|Experimental|NovoTTF-100L(O)|Patients receive TTFields using the NovoTTF-100L(O) System together with weekly Paclitaxel
89533637|NCT03940196|Active Comparator|Best Standard of Care|Patients receive best standard of care with weekly Paclitaxel
89177081|NCT00788151|Experimental|CYD Dengue vaccine group|Participants received three injections of the CYD Dengue vaccine at 0, 6, and 12 months. Participants were followed for 6 months after the last vaccination (up to 18 months).
89177082|NCT00788151|Placebo Comparator|Control group|Participants received two injections of placebo, and one injection of pneumococcal polysaccharide vaccine (Pneumo23®) at 0, 6, and 12 months, respectively. Participants were followed for 6 months after the last vaccination (up to 18 months).
89533638|NCT03926741|Experimental|GSNOR Challenge testing|patient will use a nebulizer to inhale (breathe in) a solution of GSNO followed by repeated measurements of airway function (breathing tests)
88824492|NCT02239874|Placebo Comparator|Vitamin D placebo and fish oil placebo|vitamin D placebo + fish oil placebo
88824493|NCT02239874|Active Comparator|Fish oil and vitamin D placebo|Vitamin D placebo and 840 mg of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])
88824494|NCT02239874|Active Comparator|Vitamin D and fish oil placebo|Vitamin D3 (cholecalciferol), 2000 IU per day and fish oil placebo
88824495|NCT02239874|Active Comparator|Vitamin D and fish oil|Vitamin D3 (cholecalciferol), 2000 IU per day and 840 mg of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])
88824496|NCT01771952|Experimental|Synvisc-One™|Patients randomized into this group will receive a single 6cc dose of Synvisc-One™ under sterile conditions. After cutaneous numbing with vasocoolant spray, the superolateral aspect of the patellofemoral joint will be draped and prepared with betadine soaked sterile gauze using concentric circles around the injection site. A 22 gauge needle will be advanced into the patellofemoral joint using a superolateral approach. Subjects will be monitored for minimum 5 minutes post injection to evaluate for adverse events.
89533639|NCT03922555|Experimental|ASTX727 (Cedazuridine + Cytidine Antimetabolite Decitabine)|-ASTX727 administered orally for 5 or 6 consecutive days every 28d cycle and will de-escalate to 4 consecutive days every 28 d cycle.
89533640|NCT03922555|Experimental|Expansion Cohort|"Oral ASTX727 will be administered daily for 4, 5 or 6 consecutive days~Surgical resection will take place 12 days (+/- 1 day) after initiation of treatment"
89533641|NCT03921515|Other|1|Blister Induction
88824497|NCT01771952|Sham Comparator|Sham Treatment|Patients randomized into this group will receive, under sterile conditions, a sham injection. Sterile preparation and injection procedures will be exactly the same as described above except, nothing will be injected into the joint. This procedure will include a needle stick through the joint without arthrocentesis or injection.
88824498|NCT01772654|Experimental|Left Temporal Lobe Epilepsy Subjects|Arterial Spin Labeled (ASL) MRI sequence
88824499|NCT01772654|Active Comparator|Control Subjects|Arterial Spin Labeled (ASL) MRI sequence
88824500|NCT02389361|Experimental|Group Z|Postoperative Analgesia with Zaldiar
89177083|NCT04116359|Experimental|Non-BRD4 exploratory cohort (molibresib, cisplatin, etoposide)|Patients receive molibresib besylate PO QD on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients who experience disease progression may receive molibresib besylate, etoposide phosphate and cisplatin as in Phase I and II Cohort at the discretion of the principal investigator.
89177084|NCT04116359|Experimental|Phase I and II cohort (molibresib, etoposide, cisplatin)|Patients receive molibresib besylate PO QD on days 1-14 (may switch to days 1-21 after completion of etoposide and cisplatin cycles). Patients also receive etoposide phosphate IV over 60 minutes on days 1-3 and cisplatin IV over 60 minutes on day 1 of cycles 1-4. Treatments repeat every 21 days in the absence of disease progression or unacceptable toxicity. After completion of cycle 4, patients may receive etoposide phosphate and cisplatin for up to 8 cycles total in the absence of disease progression or unacceptable toxicity at the investigator's discretion.
89177085|NCT00788073|Active Comparator|STX209|STX209 variable dose from 1mg bid to 10mg tid, capsule, oral, 4 weeks
89177086|NCT00788073|Placebo Comparator|Placebo|variable dose (same flexible dose titration protocol), bid to tid, capsule, Oral, 4 weeks
89177087|NCT04118153|Experimental|Abatacept|Abatacept will be given by a subcutaneous (SC) formulation weekly for three months.
89533642|NCT03921515|Other|2|Skin Biopsies
88824501|NCT02389361|Active Comparator|Group PT|Postoperative Analgesia with Paracetamol-Tramadol
88824502|NCT02251496|Active Comparator|Oral nutrition supplement (ONS-group)|The subjects in this group will be provided with and encouraged to take two ready to drink oral nutrition supplements (ONS) daily, providing ~ 600 kcal/d in addition to the hospital food (during hospitalisation) or in addition to their daily diet at home (after discharge from the hospital).
88824503|NCT02251496|Active Comparator|In between meals snacks (Snacks-group)|In between meals snacks (Snacks-group): The subjects in this group will be provided with and encouraged to select in-between-meals snacks providing ~ 600 kcal/d in addition to the hospital food (during hospitalisation) or in addition to their daily diet at home (after discharge from the hospital).
88824504|NCT05266001|Active Comparator|GM-CSF|Intravenous GM-CSF 125 mcg/m2/day x 7 days
89000070|NCT02050828|Active Comparator|ranibizumab 0.3 mg monotherapy|Placebo subcutaneous injection (BID) plus ranibizumab 0.3 mg monthly intravitreal injection for 3 months.
89000071|NCT02048059|Experimental|ANG1005|Participants received ANG1005 intravenously (IV) at a dose of 600 mg/m^2 on Day 1 of each 21-day cycle. ANG1005 will be administered for up to a maximum of one year, or until disease progression or adverse events (AE) that are not tolerated.
89000072|NCT02046694|Experimental|Allopurinol|Patients will stop taking their 6-MP and methotrexate at week 0. One week later (week 1), patients will begin allopurinol daily (100 mg for weight >30 kg, 50 mg for weight ≤30 kg) and will restart 6-MP and methotrexate at 50 percent of the most recent dose. Patients will continue taking allopurinol in combination with 6-MP and methotrexate for the duration of the study (total of 8 weeks). Dose adjustments of 6-MP and methotrexate will be directed by the guidelines outlined in the study protocol.
89000073|NCT02044081|Other|Mouth Rinse Administration|Day 0, three consecutive C16G2 or placebo rinse administrations followed by three single C16G2 or placebo rinse administrations. Days 1 to 6 two additional C16G2 or placebo rinse administrations.
89000074|NCT02044081|Other|Dental Tray Gel Administration|Day 0, two C16G2 or placebo gel dental tray applications and four C16G2 or placebo rinse administrations. Days 1 to 6, two C16G2 or placebo dental tray applications and two C16G2 or placebo rinse administrations.
89000075|NCT02044081|Other|Electric Toothbrush Gel Application|Day 0, four C16G2 or placebo gel administrations applied with an electric toothbrush and four C16G2 or placebo rinse administrations. Days 1 to 6, two C16G2 or placebo gel administrations applied with a electric toothbrush and two C16G2 or placebo rinse administrations.
89000076|NCT02044081|Other|Manual Toothbrush Gel Application|Day 0, four C16G2 or Placebo gel administrations applied with a manual toothbrush and four C16G2 or Placebo rinse administrations. Days 1 to 6, two C16G2 or Placebo gel administrations applied with a electric toothbrush and two C16G2 or Placebo rinse administrations.
89000077|NCT02019589|Active Comparator|Progesterone 225 mg/day|Progesterone + Placebo
89000078|NCT02019589|Active Comparator|Progesterone, 300 mg/ day|Progesterone + Placebo
89000079|NCT02019589|Placebo Comparator|Placebo|Placebo
89000080|NCT02018926|Experimental|Mocetinostat and azacitidine|"Drug: Mocetinostat (MGCD0103) Mocetinostat (a histone deacetylase [HDAC] inhibitor) 70 mg or 90 mg dose, oral capsules 3 times weekly beginning on day 5 for 10 doses in each 28 day cycle~Drug: Azacitidine (Vidaza) Azacitidine (a hypomethylating agent [HMA]) 75 mg/m2 dose, by intravenous (IV) infusion or subcutaneous (SC) injection beginning on day 1 for 7 doses in each 28 day cycle"
89000081|NCT02017912|Active Comparator|Autologous MSC-NTF cells|Single autologous MSC-NTF cells treatment by combined intramuscular and intrathecal administration
89000082|NCT02017912|Placebo Comparator|Excipient|Combined intramuscular and intrathecal placebo administration
89000083|NCT02013310|Experimental|HT-0712 (50mg)|HT-0712 capsules administered once daily.
89000084|NCT02013310|Placebo Comparator|Placebo|Placebo capsules administered once daily.
89000085|NCT01989325|Experimental|Carfilzomib + Filanesib|"Single agent + Carfilzomib arm.~Patients will be hydrated prior to and following carfilzomib administration and will be premedicated with dexamethasone, per the carfilzomib prescribing information.~Filgrastim to be administered per the approved product prescribing information and institutional guidelines."
89000086|NCT01989325|Experimental|Carfilzomib|"Single agent arm.~Patients will be hydrated prior to and following carfilzomib administration and will be premedicated with dexamethasone, per the carfilzomib prescribing information."
89000087|NCT01978366|Experimental|Cohort 1: HT-100 tablet, Dose 1|• Multiple dose administration: Dose 1
89000088|NCT01978366|Experimental|Cohort 2: HT-100 tablet, Dose 2|• Multiple dose administration: Dose 2
89000089|NCT01978366|Experimental|Cohort 3: HT-100 tablet, Dose 3|• Multiple dose administration: Dose 3
89000090|NCT01978366|Experimental|Cohort 4: HT-100 tablet, Dose 4|• Multiple dose administration: Dose 4
89000091|NCT01978366|Experimental|Cohort 5: HT-100 tablet, Dose 5|• Multiple dose administration: Dose 5
89000092|NCT03455023|Experimental|pharmaceutical care intervention group|Patients will receive individualized pharmaceutical care in addition to usual medical care.
89000093|NCT03455023|No Intervention|control group|Patients will receive usual medical care.
89000094|NCT02962986|Active Comparator|norepinephrine 6mcg|norepinephrine, given as 1mL IV boluses, to treat post-spinal hypotension
89000095|NCT02962986|Active Comparator|phenylephrine 100mcg|phenylephrine, given as 1mL IV boluses, to treat post-spinal hypotension
89000096|NCT04676893|Experimental|Reference-Test|
89000097|NCT04676893|Experimental|Test-Reference|
89000098|NCT04677361|Experimental|MILs™ in Combination with Pembrolizumab|"Each patient will have their bone marrow collected, MILs produced, and the patient will be dosed with all of the MILs produced for that individual patient. The minimum requirement for treatment is 2 x 108 cells. The MILs™ must be administered via a central catheter which could either be a PICC line, port or central line.~Subjects will be treated with MILs™ and pembrolizumab (200 mg Q3W) combination. MILs™ will be administered on Day 0 and pembrolizumab administered on Day 1. Pembrolizumab will be administered as a 30 minute IV infusion with a window of -5 minutes and +10 minutes is permitted."
89000099|NCT01972867|Experimental|NanoKnife Procedure|The NanoKnife procedure will be performed on focal prostate tumors, under ultrasound guidance.
89000100|NCT04677127|Experimental|Intervention|The intervention group was given training based on the health belief model with groups of 10-12-13 people every week for 6 weeks in the Family Health Center, followed by telephone counseling in the following 6 weeks and follow-up for 12 weeks.
89000101|NCT04677127|No Intervention|Control|Patients in the control group were assessed at the first interview and the last interview, received routine health care, and no intervention was performed during the research.
89000102|NCT00409968||Screening Study|Screening study to find out if Patients with non-small cell lung cancer (NSCLC) that has spread to other parts of the body are eligible to take part in 1 of 4 different research studies.
89000103|NCT04677088|Experimental|HBV/ TCR T cell infusion|Autologous T cells with HBV antigen-specific TCR
89000104|NCT04676971|Experimental|100 mg hzVSF-v13 IV + SOC|100 mg hzVSF-v13 IV + SOC
89000105|NCT04676971|Experimental|200 mg hzVSF-v13 IV + SOC|200 mg hzVSF-v13 IV + SOC
89000106|NCT04676971|Placebo Comparator|Placebo (saline) IV + SOC|Placebo (saline) IV + SOC
89355928|NCT02513758||HIV patients|Men will have blood sampling tubes of 10 ml each, a saliva sample and a sample of sperm Women will have a two blood sampling tubes of 10 ml each, a saliva sample and a sampling cervicovaginal secretions
89355929|NCT01485497|Other|3D endoscopic Fourier Domain OCT|3D endoscopic Fourier Domain OCT
89355930|NCT02504944|Experimental|Propranolol 0.2% eye drops|Enrolled preterm newborns will receive propranolol as ophthalmic solution (0.2%). The treatment will be started as soon as the diagnosis of stage 1 ROP is made and will be continue until the development of retinal vascularization is completed, but no more than 90 days. Cardiovascular and respiratory parameters will be continuously monitored. Blood samplings checking metabolic, renal and liver functions will be performed periodically, as well as cardiac function, in order to verify the treatment safety. Propranolol concentrations will be measured on dried blood spots at the steady state (10th day). Serial ophthalmological evaluations will be planned to monitor the efficacy of the treatment, the ROP progression and the possible complications.
88824505|NCT05266001|Placebo Comparator|Placebo|Intravenous placebo x 7 days
88824506|NCT02251886|Active Comparator|Moxibustion in primiparae|Moxibustion added to the acupuncture point Bl 67 for 15-20 minutes daily from week 32 to 36 in primiparae
88824507|NCT02251886|Active Comparator|Moxibustion in multiparae|Moxibustion added to the acupuncture point Bl 67 for 15-20 minutes daily from week 32 to 36 in multiparae
88824508|NCT02251886|No Intervention|Control primiparae|No intervention. Routine control schedule for primiparae with midwife
88824509|NCT02251886|No Intervention|Control multiparae|No intervention. Routine control schedule for multiparae with midwife
88824510|NCT00421655|Experimental|1|
88824511|NCT00421655|Placebo Comparator|2|
88824512|NCT02391701|Experimental|Diet group|Diet program 1 day a month for 3 months in 120-minute diet sessions + Freely they receive AD food: vegetables, cheese, olive oil, mussels and wine.
88824513|NCT02391701|No Intervention|Control|No intervention
88824514|NCT05257499|Experimental|On line debfriefing|Participants in this group will practice the skills taught as above but in the presence of the same certified instructor who will guide them throughout all the steps of HBB using a virtual platform (Webex® or Zoom®).
88824515|NCT05257499|No Intervention|In person debriefing|Participants in this group will practice the skills taught in the virtual class on the neonatal mannequin. They are expected to work as a small group of 3 to 4 at a time. They will receive coaching, debriefing and feedback from a certified instructor who will conduct the traditional in-person training with face-to-face feedback and debriefing.
88824516|NCT02252354|Experimental|Part 1: [14C]-TAK-385|[14C]-TAK-385 80 mg, solution, orally, once on Day 1.
88824517|NCT02252354|Experimental|Part 2: TAK-385 + [14C]-TAK-385 IV|TAK-385 80 mg, tablets, orally, and [14C]-TAK-385 80 μg, infusion, intravenous once on Day 1.
89355931|NCT01201499|Active Comparator|Intrathecal morphine|A single shot of intrathecal morphine given before the induction of general anesthesia. Followed by postoperative IV patient-controlled morphine analgesia.
88824518|NCT02393339|Active Comparator|study group|Study group will receive syrup paracetamol (15 mg/kg) 15 min before the dental treatment
88824519|NCT02393339|Placebo Comparator|controll group|Control group will receive placebo syrup, designed to mimic paracetamol syrup, similar in color and viscosity, 15 min before dental treatment.
88824520|NCT05093660||Patients with acute appendicitis|Patients with acute appendicitis, after surgery and with pathohistological specimen confirmation.
88824521|NCT05093660||Patients without acute appendicitis|Patients without acute appendicitis, after laboratory, clinical and/or radiological exclusion of acute admittance.
88824522|NCT05235191|Experimental|methadone|In this arm patients will take methadone 5mg
88824523|NCT05235191|Placebo Comparator|placebo|In this arm patients will take placebo tablets (the same number, color and physical aspects as the methadone tablets).
88824524|NCT05072990||Observational group|
89355932|NCT01201499|Active Comparator|Continuous IV remifentanil|Continuous administration of IV remifentanil during surgery, supported by a single bolus of IV morphine at the end of surgery. Followed by postoperative IV patient-controlled morphine analgesia.
88824525|NCT05066204|Other|Sequence: self-study, then teaching video|Participants first do self-study, then right afterwards watch a teaching video, then become tested on a simulator and are videorecorded for evaluation
88824526|NCT05066204|Other|Sequence: teaching video, then self study|Participants first watch a teaching video, then do self-study, then become tested on a simulator and are videorecorded for evaluation
88824527|NCT01774604|Experimental|Indomethacin|Indomethacin 100 mg Per Rectum (PR) x 1 in peri-procedural period
88824528|NCT01774604|Placebo Comparator|Placebo|Placebo suppositories (#2)
89000107|NCT01968733|Active Comparator|Moxifloxacin|Intravenous with the potential step-down to oral moxifloxacin
88824529|NCT01774760|Experimental|Patients with stage III-IV head and neck cancer|18F-EF5 PET/CT scan
88824530|NCT01775774|Experimental|Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells|A dose-escalation with 3 cohorts with 3 subjects/cohort who receive doses of 1, 5 and 10 million cells/kg predicted body weight (PBW). Proceed from lower dose to next higher dose if no safety concerns for each cohort.
88824531|NCT02393417|Experimental|Cohort 1|0.3 mL of CANDIN administered intralesionally in the largest common wart
88824532|NCT02393417|Experimental|Cohort 2|0.5 mL of CANDIN administered intralesionally in the largest common wart
88824533|NCT02393417|Experimental|Cohort 3|0.3 mL of CANDIN administered intralesionally in up to 4 warts at the same visit (up to 1.2 mL total injected volume)
88824534|NCT02393417|Placebo Comparator|Pooled Placebo|0.3 mL or 0.5 mL administered intralesionally in the largest common wart, or 0.3 mL administered intralesionally in up to 4 warts at the same visit (up to 1.2 mL total injected volume)
88824535|NCT01775852|Active Comparator|ACT-IM|The ACT-IM arm is a brief, one-day intervention that includes two components: 1) Illness Management for Migraine and, 2) Acceptance and Commitment Therapy for emotional difficulties that go along with, or are exacerbated by migraine.
88824536|NCT01775852|No Intervention|Waitlist/Treatment as Usual|The Waitlist/Treatment as Usual (WL/TAU)condition completes the same assessments as the active treatment group but does not undergo the active treatment (workshop) until after the 12-week follow-up visit. At that point, the WL/TAU participants are given the opportunity to join a treatment workshop.
89000108|NCT01968733|Experimental|Solithromycin|Intravenous with potential step-down to oral solithromycin
89355933|NCT02504632|Experimental|test group|Patient with severe, symptomatic AS (Aortic valve area < 0,6 cm2/m2 SC), deemed, after multidisciplinary heart team evaluation, contra-indicated or at high risk for surgery and suitable for TF TAVI with a MCV prosthesis.
89355934|NCT02504632|Other|control group|Patient with stable coronary artery disease, unscathed of AS Patient under aspirin treatment (75-160 mg/d for at least one week)
89355935|NCT01204931||Gastroesophageal Reflux Disease (GERD) Cases|"Erosive disease - presence of esophageal mucosal injuries documented endoscopically.~Non-erosive disease - normal esophagogastroduodenoscopy with symptoms"
89355936|NCT01204931||Control Group|normal subjects without symptoms of gastroesophageal reflux disease (GERD)
89355937|NCT03473639|Experimental|Entinostat and Capecitabine|"Dose escalation of the combination of entinostat and capecitabine in MBC patients. This dose will be given to MBC patients and to BC patients with residual invasive disease after neoadjuvant chemotherapy and surgery.~The dose combinations include:~Combination 1: 3 mg/week entinostat, 800 mg/m2 twice a day for 14 days of capecitabine Combination 2: 5 mg/week entinostat, 800 mg/m2 twice a day for 14 days of capecitabine Combination 3: 3 mg/week entinostat, 1000 mg/m2 twice a day for 14 days of capecitabine Combination 4: 5 mg/week entinostat, 1000 mg/m2 twice a day for 14 days of capecitabine~If a participant experiences unacceptable side effects, he or she will receive the next lowest dose combination. If he or she is on Combination 1, he or she will stop study treatment."
89355938|NCT02504710|Active Comparator|Traditional Learning System|Traditional systems of manual therapy teaching
89355939|NCT02504710|Experimental|Kinematic Real-Time Feedback|Kinematic real time feedback to learn Manual therapy
89355940|NCT03547687|Experimental|Electrical Stimulation Treatment|Patient will receive electrical stimulation to the quadriceps muscle groups on both lower extremities simultaneously for 45 minutes at a time, for a total of 5 treatments each week (Mon-Sun), for up to 14 days or until ICU discharge, whichever comes first.
89355941|NCT03840317|Experimental|Senl_1904A CD19 CAR-T|Autologous CD19-targeting CAR T cells, dosage 3*10^5/kg, intravenous injection once
89355942|NCT03840317|Experimental|Senl_1904B CD19 CAR-T|Autologous CD19-targeting CAR T cells,dosage 3*10^5/kg, intravenous injection once
89355943|NCT02509780|Experimental|Vichy|
89355944|NCT03121690|Experimental|prednisone|prednisone 40 mg/day for 7 days
89355945|NCT03121690|Experimental|placebo|5ml saline /day for 7 days
89355946|NCT01483703||Diagnostic tool|Laser Speckle Imaging of Critical Care Neonates
89355947|NCT03730831|Experimental|Intervention|Narrative Exposure Therapy The Narrative Exposure Therapy (NET) is a brief manualized trauma-focussed treatment and will be performed according to the manual of Schauer et al., 2011. In the NET the experiences experienced as traumatic are worked on and placed in the context of the entire life story.
89355948|NCT03730831|No Intervention|Control|Waiting List
89355949|NCT03840551|Other|Subjects|Subjects involved are required to do some specific motor tasks, commonly found in all main sports. Evaluated with inertial sensors (XSENS) and marker-based motion capture (BTS)
89355950|NCT03724591|Experimental|a high ligation of IMA|total mesorectal excision (TME) for rectal cancer by a high ligation of IMA without preservation of left colic artery
89355951|NCT03724591|Active Comparator|a low ligation of IMA|total mesorectal excision (TME) for rectal cancer by a low ligation of IMA with preservation of left colic artery
89530230|NCT05045183|Experimental|Treatment G: Hydrocolloid Pad|Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist. On the randomized wound site, hydrocolloid pad will be applied. This treatment will be changed daily from Day 1 through Day 6 and all wound sites will be uncovered from Day 7 to Day 16 for assessments.
88824537|NCT01776632|Experimental|Physical activity|Latinas exposed to multi-level Faith in Action intervention promoting physical activity.
88824538|NCT01776632|Active Comparator|Cancer screening|Latinas exposed to Faith in Action intervention on cancer screening and prevention.
89355952|NCT03831269|Active Comparator|Azithromycin|The dose of azithromycin will be 10mg/kg/day oral suspension for 3 consecutive days for pediatric patients (<12 years old) and 500mg/day in three consecutive days for adults. The cycle will be repeated every seven days (3 cycles/month) and will be repeated if required according to patient's response up to 6 cycles. Side effects of therapy will be recorded. This protocol is based on previous case reports.
88824539|NCT05209061||Colo-rectal cancer patients|Patients receiving right colectomy or ileo-ceacal resection for colorectal cancer
88824540|NCT01777412|Experimental|Bevacizumab|Bevacizumab 10 mg/kg intravenous infusion at onset of exacerbation and, if needed, a second time during the plasma exchange phase.
88824541|NCT01777568|Experimental|30% oxygen|Inspired oxygen will be maintained at 30%.
88824542|NCT01777568|Experimental|80% oxygen|Inspired oxygen will be maintained at 80%.
88824543|NCT05173883|Experimental|A cohort of CU-20401|Subcutaneous injection in the subcutaneous fat area，0.2ml of CU-20401, 6 injections，0.04mg/ml（A1)，0.075mg/ml(A2)，0.15mg/ml(A3)
88824544|NCT05173883|Experimental|B cohort of CU-20401|Subcutaneous injection in the subcutaneous fat area，0.2ml of CU-20401, 12 injections，0.075mg/ml（B1)，0.10mg/ml(B2)
88824545|NCT05173883|Experimental|C cohort and D cohort of CU-20401|Subcutaneous injection in the subcutaneous fat area，0.2ml of CU-20401, 24 injections，0.075mg/ml（C1)，0.10mg/ml(C2)，0.12mg/ml(D2),
88824546|NCT05173883|Placebo Comparator|A cohort of placebo|Subcutaneous injection in the subcutaneous fat area，0.2ml of placebo, 1 injections，0.04mg/ml（A1)，0.075mg/ml(A2)，0.15mg/ml(A3)
88824547|NCT05173883|Placebo Comparator|B cohort of placebo|Subcutaneous injection in the subcutaneous fat area，0.2ml of placebo, 1 injections，0.075mg/ml（B1)，0.10mg/ml(B2)
88824548|NCT02166788|Other|Arm 1: Inguinal Lymphadenectomy|Inguinal Lymphadenectomy (IL) is removal of the easily accessible superficial groin lymph nodes (LNs) and has a median LN retrieval of 11 lymph nodes
88824549|NCT02166788|Other|Arm 2: Ilio-inguinal Lymphadenectomy|Ilio-inguinal Lymphadenectomy (I-IL) is the removal of the same superficial groin lymp nodes (LN) removed during an IL but also combined with the more surgically complex removal of the ipsilateral pelvic LN. About twice as many LN are removed with I-IL compared to IL.
88824550|NCT05166707|Experimental|BIXINK OC Free|A 6 week ERP-based intervention
88824551|NCT02057588|Other|LV Paced sites|LV pacing sites : Patients will be paced from various left ventricular origin, defined by their 3D localization.
88824552|NCT05153837|Experimental|oral water|Experimental group: oral administration of 500 ml of water.
88824553|NCT05153837|Active Comparator|intravenous|Active comparator: Administration of 500 mL of saline (NaCl 0.9%) administered by the venous route
88824554|NCT04911335|Experimental|phase 2 open intervention|All patients assisted by the palliative care center (hospice and home) will receive the oral hygiene protocol and the propolis-based product. The oral hygiene protocol will be applied starting from the day of taking care of the patient in the service and until discharge / death. Administration of the study product will be continued for 2 weeks or stopped sooner if the patient loses the ability to swallow.
88824555|NCT05136755|Experimental|NMDAE|An NMDA enhancer
88824556|NCT05136755|Placebo Comparator|Placebo|Placebo
88824557|NCT01778426||Patients with Medtronic neurostimulator|Patients suffering from chronic neuropathic pain syndrome implanted (first implant or replacements) with a Medtronic neurostimulator.
88824558|NCT01809548|Experimental|Early complementary feeding group|"Early intervention group:~Introduction of early complementary feedings between the 10th -12th week of gestation corrected for prematurity"
88824559|NCT01809548|Experimental|Late complementary feeding group:|"Late intervention group:~Introduction of late complementary feedings between the 16th and 18th week of life corrected for prematurity"
88824560|NCT04873349|Active Comparator|Olive leaf capsules|Non-hospitalized COVID-19 patients who have positive PCR results and show mild to moderate clinical manifestations and symptoms (20-30 patients) will receive a 50% standardized olive leaf capsule 750 mg (700 mg oleuropein/day; the active principle in olive leaf) two times daily for a period of ten days alongside with the Egyptian protocol medications. All the active comparator participants should be adults, with no chronic diseases (except hypertension and diabetes), non addict or alcoholics.
88824561|NCT04873349|Placebo Comparator|Starch capsules|Non-hospitalized COVID-19 patients who have positive PCR results and show mild to moderate clinical manifestations and symptoms (20-30 patients) will receive a placebo starch capsules (750 mg) two times daily for a period of ten days alongside with the Egyptian protocol medications. All the placebo comparator participants should be adults, with no chronic diseases (except hypertension and diabetes), non addict or alcoholics.
89177088|NCT00848393|Active Comparator|Fentanyl (High Dose)|This arm will receive a total of 25 mcg/kg of Fentanyl (High Dose) in two divided doses. First half-dose given at induction and second half-dose given before incision.
88824562|NCT01780454|Experimental|Combined Bone Marrow and Kidney Transplantation|Conditioning regimen consisting of Rituximab, MEDI-507, Total Body Irradiation, Thymic Irradiation followed by simultaneous bone marrow and kidney transplantation
88824563|NCT04867187|Experimental|rTMS active and active mirror-based therapy using virtual reality|The patient will have an amount of 4 sessions (S3, S5, S7 and S9) for 1.5 months: 1 session every 2 weeks. The patient will receive rTMS active and active mirror-based therapy using virtual reality.
88824564|NCT04867187|Sham Comparator|rTMS active and sham mirror-based therapy using virtual reality|The patient will have an amount of 4 sessions (S3, S5, S7 and S9) for 1.5 months: 1 session every 2 weeks. The patient will receive rTMS active and sham mirror-based therapy using virtual reality.
88824565|NCT05116709|Experimental|BAT6005 single drug dose escalation study|"The whole is divided into two phases.The first stage: 10mg group, 30mg group, 100mg group using accelerated titration method to increase the dose.The second stage: 300mg group, 600mg group, 900mg group according to the standard 3+3 rule dose increase study."
89355953|NCT03831269|Active Comparator|Nb UVB|Patients recruited for nbUVB phototherapy will have an initial dose of 0.3J-0.5J according to Fitzpatrick's skin type. The dosage will be increased by 0.3J in every other treatment session. The sessions will be given 3 times weekly until improvement is noted or reaching 8 weeks at the EOS. We arrived at this initial dose based on our previous experience with Egyptian patients in Kasr Alainy phototherapy unit in Dermatology Department, Cairo University.
89355954|NCT02513836|Experimental|Pre-education intervention|All study participants will be tested with a questionnaire (POEM; Patient Opioids Education Measurement) on their opioid knowledge during 1st visit at the pain clinic.
89355955|NCT02513836|Other|Post-education intervention|All study participants will be educated on opioids via an education sheet, pamphlet and video from the Institute for Safe Medication Practices (ISMP) Canada. They will repeat the questionnaire (POEM) after this education on opioid knowledge on the same day.
89533643|NCT03919071|Experimental|Treatment (radiation therapy, dabrafenib, trametinib)|Patients undergo standardized local RT 5 days a week (Monday-Friday) for 6-7 weeks. Four weeks after completion of RT, patients receive dabrafenib mesylate PO BID and trametinib dimethyl sulfoxide PO QD on days 1-28 of each cycle. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo MRI at baseline, on day 1 of cycles 1, 3, 5, 7, 11, 14, 17, 20, and 23 while on treatment, then at time of relapse, every 3 months for year 1, every 4 months for year 2, every 6 months for year 3, and annually for years 4-5. Patients may also undergo lumbar puncture for CSF testing during treatment. Patients also undergo collection of blood on study.
88824566|NCT01780922|Active Comparator|Low Calorie Cranberry Juice Cocktail|Beverage containing cranberry: one dose of 15.2 ounces consumed within 15 minutes
88824567|NCT01780922|Active Comparator|Cranberry Extract Beverage|Beverage containing cranberry: one dose of 15.2 ounces consumed within 15 minutes
88824568|NCT01780922|Placebo Comparator|Non-Cranberry Beverage|Beverage absent cranberry: one dose of 15.2 ounces consumed within 15 minutes
89355956|NCT02513680|Active Comparator|LASER and LED therapy application|The first group will use the two techniques under study combined: Infrared Laser + Amber LED (830 nm - 150mW + 590 nm - 1.500 mW)
89355957|NCT02513680|Active Comparator|LED Therapy application|The second group will use only Amber LED (590 nm - 1.500 mW)
89355958|NCT03547531|Active Comparator|Natural Tooth Brushing Method|Natural tooth brushing method is the method that is naturally used by the people with horizontal, rotary, or simple up and down motions and any position of the brush without any instruction of particular tooth brushing method.
88824569|NCT04838951|Experimental|Intervention arm|CADe system will be used during withdrawal phase of colonoscopy.
88824570|NCT04838951|No Intervention|Control arm|Colonoscopy will be performed according to hospital protocol.
88824571|NCT05104619||tumor samples|(SCC of the tongue)
89355959|NCT03547531|Experimental|Modified Circular Tooth Brushing Method|Modified Circular tooth brushing method is a combination of small circular motion of brushing with the position of the brush slightly reach underneath the gingival that are applied for each jaw in all facial surfaces and posterior lingual of tooth arches.
88824572|NCT05104619||healthy tissues|
88824573|NCT04835519|Experimental|chimeric antigen receptor T cell treatment|
88824574|NCT05099315||Dupilumab treated Patients (observational)|Patients with atopic dermatitis with indication for dupilumab treatment will be observed.
88824575|NCT05099315||Cyclosporine treated Patients (observational)|Patients with atopic dermatitis with indication for cyclosporine treatment will be observed.
88824576|NCT05099315||Baricitinib treated Patients (observational)|Patients with atopic dermatitis with indication for baricitinib treatment will be observed.
88824577|NCT02979041|Active Comparator|control|Patients in the control group will receive standard physiotherapy and medical care, as provided to all patients with neck pain in the aviation medicine clinic. This will reflect the standard care that has been provided to all patients.
88824578|NCT02979041|Experimental|intervention|Standard care (as provided to controls) with the addition of virtual reality training (a self-exercise program) using a VR system to address the fast, accurate head control required in flying tasks.
88824579|NCT05063591|Experimental|Intervention arm|Patients with aggressive hematologic malignancies who are hospice eligible, not pursuing further cancer directed therapy, and whose primary hematologist is planning to initiate a conversation regarding transition to hospice will be eligible for enrollment.
88824580|NCT01648764|Experimental|LY2334737 - Arm A|LY2334737 administered orally at escalating doses [40 milligrams (mg) - 200 mg] every other day for 21 days followed by 7 days without study drug (28 day treatment cycle). Participants may receive additional treatment cycles until discontinuation criterion is met.
88824581|NCT01648764|Experimental|LY2334737 - Arm B|LY2334737 administered orally at escalating doses (40 mg - 200 mg) every day for 7 days followed by 7 days without study drug then repeated (28 day treatment cycle). Participants may receive additional treatment cycles until discontinuation criterion is met.
88824582|NCT05055089||new-generation bioprostheses|Patients undergoing surgical aortic valve replacement with new-generation bioprostheses
88824583|NCT05055089||traditional bioprosthesis|patients who received a traditional bioprosthesis
88824584|NCT05051969|Experimental|8 Week Remote Mindfulness-Based Stress Reduction Program|8 Week Remote MBSR Course for MNPS Employees.
88824585|NCT05051969|No Intervention|8 week waitlist control|8 week waitlist control. They will complete the same assessments at baseline, 8 and 12 weeks
89355960|NCT02513602||TEST group (kidney transplanted)|"Kidney transplanted patients, passed through dialysis phase presenting a mandibular edentulism. It will be scheduled one or two dental implants to be inserted in mandible.~This group will be subjected to a dental implant insertion procedure."
89355961|NCT02513602||CONTROL group (healthy patients)|Healthy patients, with an inserted mandibular implant, retrospectively enrolled with a preoperative cbct scan.
89355962|NCT01333553||Image-guided remove Port Wine Stain|Image-guided surgery remove Port Wine Stain
89355963|NCT02504476|Active Comparator|AMG 581 - Dose 1|
89355964|NCT02504476|Active Comparator|AMG 581 - Dose 2|
88824586|NCT05043623|Experimental|Arm 1 - Clinician Collected/supervised Rhinoswab first, then CTDN swab|Rhinoswab test administered and immediately followed by CTDN. Rhinoswab swab tested on respiratory panel vs CTDN swab tested on respiratory panel (standard of care).
89355965|NCT02504476|Active Comparator|AMG 581 - Dose 3|
89355966|NCT02504476|Active Comparator|AMG 581 - Dose 4|
88824587|NCT05043623|Experimental|Arm 2 - Clinician Collected/supervised CTDN swab first, then Rhinoswab|CTDN test administered and immediately followed by Rhinoswab. CTDN swab tested on respiratory panel (standard of care) vs Rhinoswab swab tested on respiratory panel.
88824588|NCT05043623|Experimental|Arm 3 - Self-collected Rhinoswab, saliva swab, CTDN|In children 5-18 years, the child/parent/guardian collects the three samples, in order of patient/parent preference. All samples will be tested on the SARS-CoV-2 laboratory panel (Allplex™ SARS-CoV-2 Assay - Seegene Inc)
88824589|NCT05043623|Experimental|Arm 4 - Self-collected RAT, saliva, CTDN|In children 1 month -5 years, the child/parent/guardian collects the three samples, in order of patient/parent preference. Saliva and CTDN samples will be tested on the SARS-CoV-2 laboratory panel (Allplex™ SARS-CoV-2 Assay - Seegene Inc), RAT test kit will be Abbott PanBio
88824590|NCT00355667|Active Comparator|A|Patients with chronic heart failure with NYHA II or III are given furosemide.Patients discontinued taking previous loop diuretic(s) and were directly rolled over to the arm with furosemide 20-40 mg/day, without a placebo run-in period. The dose of each diuretic was appropriately adjusted according to symptoms of each patient, and patients were maintained for the rest of the study. Thereafter, patients were reviewed every 2 to 8 weeks. The planned minimum follow-up period for each patient was 2 years, and electrocardiography, chest X-ray and blood sample were conducted at the study entry and every 12 months after the randomization.
88824591|NCT00355667|Active Comparator|B|Patients with chronic heart failure with NYHA II or III are given azosemide.Patients discontinued taking previous loop diuretic(s) and were directly rolled over to the arm with azosemide 30-60 mg/day without a placebo run-in period. The dose of azosemide was appropriately adjusted according to symptoms of each patient, and patients were maintained for the rest of the study. Thereafter, patients were reviewed every 2 to 8 weeks. The planned minimum follow-up period for each patient was 2 years, and electrocardiography, chest X-ray and blood sample were conducted at the study entry and every 12 months after the randomization.
88824592|NCT02364336|Experimental|HBeAg positive|Patients who have been treated with one or more nucleos(t)ides for at least 192 weeks who have known serum HBsAg and HBeAg positivity
88824593|NCT02364336|Experimental|HBeAg negative|Patients who have been treated with one or more nucleos(t)ides for at least 192 weeks who have known serum HBsAg positivity and HBeAg negativity
88824594|NCT04976933||Primary Caregivers|Primary caregivers of children receiving Tacrolimus or cyclosporine immunosuppression for an allogeneic transplant will be introduced to the mHealth adherence app and allowed the opportunity to interact with the app alongside research staff. Following this session primary caregivers are asked to use the app at home until Day 100 or weaning of immunosuppressant, whichever is first.
89355967|NCT02504476|Placebo Comparator|Placebo - Dose 1|
89355968|NCT02504476|Placebo Comparator|Placebo - Dose 2|
89355969|NCT02504476|Placebo Comparator|Placebo - Dose 3|
89355970|NCT02504476|Placebo Comparator|Placebo - Dose 4|
89355971|NCT02504476|Other|AMG 581/Midazolam - Drug Interaction|
89355972|NCT04313855|Experimental|Chronic post-operative pain|"7 days after the intervention, the patient receives a standardized questionnaire by SMS, to determine whether the patient has pain at the operating site and whether this pain has the characteristics of neuropathic pain. After replying to the SMS, the patient will be contacted by phone to assess: the intensity of pain at the operating site using a numerical scale and the existence of neuropathic pain. Depending on the responses received by SMS and/or phone, a consultation appointment with an anesthesiologist specializing in pain may be offered within a maximum of 2 weeks.~Ninety days after your surgery, the patient receives the same standardized questionnaire by SMS. The patient will be contacted by telephone, in order to assess the intensity of pain at the operating site and the existence of neuropathic pain using. If the patient has post-operative pain, a consultation appointment with an anesthesiologist specializing in pain will be offered to him within a maximum of 2 weeks."
89355973|NCT02504398|Experimental|Fast injection|Vaccine injections will be given at a rate of approximately 2-4 ml/sec by the immunizer
89355974|NCT02504398|Active Comparator|Slow injection|Vaccine injections will be given at a rate of approximately 10 ml/sec by the immunizer
89355975|NCT03842501|Placebo Comparator|Placebo|
89355976|NCT03842501|Experimental|Release supplement|
89355977|NCT02509390|Experimental|Severe trauma patients|All severe trauma patients (ISS>15) admitted in our trauma center Blood samples (additional blood tubing)
89355978|NCT01205009|Active Comparator|Ovitrelle supplemantation|The women will be given 250 mcg of Ovitrelle prior to their IVF cycle
89355979|NCT01205009|No Intervention|no Ovitrelle supplementation|
88824595|NCT04419948|Experimental|Control|100g white bread plus 40ml butter
89355980|NCT02504242|Experimental|Inject BMP|ExcelOS Inject / rhBMP-2
88824596|NCT04419948|Experimental|Positive control|100g white bread plus 40ml butter and 400mg ibuprofen
88824597|NCT04419948|Experimental|Refined olive oil|100g white bread plus 40ml refined olive oil
88824598|NCT04419948|Experimental|EVOO with moderate concentration of oleocanthal|100g white bread plus 40ml EVOO containing 250 mg/kg oleocanthal
88824599|NCT04419948|Experimental|EVOO with high concentration of oleocanthal|100g white bread plus 40ml EVOO containing 500 mg/kg oleocanthal
88824600|NCT01781078|Experimental|MRI Group|Those subjects randomized to the MRI Group will undergo a study-specific MRI scan 6-9 weeks post-implant.
88824601|NCT01781078|Experimental|Control Group|Those subjects randomized to the Control Group will not undergo s study-specific MRI scan. All follow-up time requirements are the same for the two groups.
88824602|NCT03820739||Cohort 1|Subjects who received an Ebola vaccine prime vaccination in EBOVAC-Salone are eligible for enrolment in this study. Adults are defined as participants 18 years of age or older at the time of prime vaccination, and children are defined as participants aged 1 to 17 years at the time of prime vaccination in EBOVAC-Salone.
88824603|NCT03820739||Cohort 2 (offspring)|Infants conceived by a female participant in EBOVAC-Salone during the 3 months following vaccination with Ad26.ZEBOV or during the 28 days following vaccination with MVA-BN®-Filo.
88824604|NCT03810755|Other|Control group|Personalized program (PVS), of proven effectiveness for the promotion of physical activity, diet and smoking cessation.
88824605|NCT03810755|Other|Supervision group|Personalized Supervised physical activity: personalized exercise program for patients, supervised during 3 months by nursing in primary and autonomous care afterwards, with support from community resources
88824606|NCT01312922|Experimental|PNB01|oral, once daily administration
89177089|NCT00848393|Active Comparator|Fentanyl (Low Dose)|This arm will receive a total of 10 mcg/kg of Fentanyl (Low Dose). First half-dose will be given at induction and second half -dose given before incision.
89355981|NCT02504242|Active Comparator|Locally Harvested Bone|Locally Harvested Bone
89355982|NCT01297205|Experimental|PNEUMOSTEM®|
89355983|NCT02513524||Direct Observed Therapy test|Patients with resistant hypertension (as defined in the eligibility criteria) will be enrolled. They will all have undergone 24 hour ambulatory blood pressure monitoring (ABPM) before enrollment. As part of the study, the subjects will undergo direct observed therapy testing, followed by another 24 hour ABPM, which will be repeated at 1 month.
89355984|NCT03830489|Experimental|Large volume based preparation|This strategy will consist of split dose 4 L polyethylene glycol plus 10 mg bisacodyl plus 3 days of fiber-free diet.
89355985|NCT03830489|Active Comparator|Low volume based preparation|This strategy will consist of split dose 2 L polyethylene glycol plus Ascorbic acid plus 1 day of fiber-free diet
89533644|NCT03914092|Experimental|study group|female patients with vocal fold nodules undergoing intralesional steroid injection
88824607|NCT01312922|Active Comparator|citalopram|oral, once daily administration
88824608|NCT01312922|Sham Comparator|pipamperone|oral, once daily administration
88824609|NCT00356213|Experimental|A|laparoscopic sleeve gastrectomy
88824610|NCT00356213|Active Comparator|B|laparoscopic gastric bypass
88824611|NCT03694145||Diabetic patients w. risk of retinopathy|The 300-500 patients to be enrolled for the study are diabetic patients normally seen by the Los Angeles County Department of Health Services (LACDHS) Teleretinal Diabetic Retinopathy Screening Program and Reading Center. In addition to receiving their recommended LACDHS annual teleretinal screening, for the study, participants will receive an additional in-person eye examination.
88824612|NCT01783574|Active Comparator|Testosterone|Testosterone cream will be applied to skin for 8 weeks. Starting dose is 10 mg daily and will be titrated based on blood levels.
88824613|NCT01783574|Placebo Comparator|Placebo|Placebo cream will appear identical to the testosterone cream and will be applied to skin for 8 weeks.
89355986|NCT02509468|No Intervention|Observational|"Patients will first be included in an observational period, then, at a randomized time different from one to another, will all receive the experimental treatment (i.e. sirolimus).~This design has been defined a the randomized placebo-phase design (Feldman et al. J Clin Epidemiol. 2001 Jun;54(6):550-7)"
89355987|NCT02509468|Experimental|Experimental|At a randomized date, patients will start treatment with sirolimus (beginning dose: 0.08mg/kg/day)
89533645|NCT03914092|Active Comparator|control group|female patients with vocal fold nodules undergoing Smith Accent voice therapy
89533646|NCT03907735||2nd trimester|Second trimester myometrial tissue samples will be collected by core needle biopsy under ultrasound guidance in anesthetized women. Samples will be obtained primarily after second trimester surgical abortions or Dilation and Evacuation (D&E) procedures as well as after rare gravid hysterectomies or after late second trimester cesarean deliveries.
89533647|NCT03907735||Non-pregnant|Myometrial tissue samples will be collected by core needle biopsy under ultrasound guidance in non-pregnant women undergoing gynecologic surgery under anesthesia for laparoscopic tubal ligation.
88824614|NCT04371653|Experimental|Active group|Patients with NAFLD will receive orally fecal microbiota capsules from healthy donors
88824615|NCT04371653|Placebo Comparator|Placebo group|Placebo capsules will be identical to the active capsules, but not contain intestinal bacteria
89355988|NCT03344614|Experimental|raltitrexed combined with apatinib|therapeutic regimen : raltitrexed, 3 mg/㎡, ivgtt, d1, apatinib 500 mg, QD po, d1-21, Every 3 weeks for 1 cycles.
89355989|NCT01205087|Placebo Comparator|Placebo|
89355990|NCT01205087|Active Comparator|OKT3 - 0.2|
88824616|NCT00119912|Active Comparator|A 1 Intervention arm Flex Sig|Randomised from the population registry, age 50-64 years and invited for Flexible Sigmoidoscopy (Flex Sig) screening. Half of invitees are additionally invited to provide a stool sample for fecal occult blood testing (Intervention arm A 2). They are drawn directly from the population registry without prior consent to be randomized - approved by Regional Ethics Committees of South-East Norway..
88824617|NCT00119912|No Intervention|B Control arm|"No screening group randomised from population age 50-64 years. As for the active intervention arm, the control group was not informed about being randomized to 'no screening' since 'no screening' was the current usual care (and still is in 2015) in Norway - approved by Regional Ethics Committees of South-East Norway."
88824618|NCT00119912|Active Comparator|A 2 Intervention arm Flex Sig + iFOBT|Randomised from the population registry, age 50-64 years and invited for Flexible Sigmoidoscopy (Flex Sig) screening plus an immunochemical test for fecal occult blood (iFOBT). As for arms A 1 and B, they are drawn directly from the population registry without prior consent to be randomized.
88824619|NCT00356837|Experimental|A|Those with extremity fractures.
88824620|NCT03656783|Other|HIV patients on stable therapy|HIV patients on stable therapy switching from Abacavir/Lamivudine/Dolutegravir (ABC/3TC/DTG) to the Bictegravir/ Emtricitabine/Tenofovir Alafenamide (B/F/TAF)
88824621|NCT01784588|Active Comparator|Solyx Single Incision Sling System|Solyx Single Incision Sling System
88824622|NCT01784588|Active Comparator|Obtryx II Sling System|Obtryx II Sling System
88824623|NCT01733186|Experimental|CARTISTEM®|Drug name and ingredients: CARTISTEM [allogeneic-unrelated, umbilical cord blood-derived mesenchymal stem cells, ex vivo cultured, combined with sodium hyaluronate] Dosage: Administer 0.5 mL of the combination product per cm^2 of the cartilage defect
88824624|NCT01734746|Experimental|Tracerinjection|The intervention concerns tracerinjection (both blue dye and the radioactive isotope beingtechnetium-99-m-labeled albumin nanocolloid) in the ligamentum ovarii proprium (median side) and the ligamentum infundibulo-pelvicum (lateral side), close to the ovary and just below the peritoneum.
88824625|NCT01785134|Sham Comparator|Control|Gastric bypass operation without omentectomy.
89355991|NCT01205087|Active Comparator|OKT3 - 1|
88824626|NCT01785134|Active Comparator|Omentectomy|Gastric bypass operation in conjunction with removal of greater omentum
88824627|NCT03599843|Experimental|ACCESS|Individuals that consent to the study will be assigned to a 12-week exercise program (ACCESS)
89355992|NCT01205087|Active Comparator|OKT3 - 5|
89355993|NCT02513368|Experimental|Bio-Oss®, Bio-Gide®|augmentation procedure with Bio-Oss® and Bio-Gide®
88824628|NCT03462875||Crohn's Disease Patients|Subjects having confirmed diagnosis of Crohn's disease which is defined by endoscopy, radiology and histology; and having documented ileocaecal or right-sided colonic disease
88824629|NCT03462875||Non-household Controls|Non-affected subjects who will under colonoscopy for polyp or colorectal cancer screening, or investigations of gastrointestinal symptoms other than Inflammatory Bowel Disease
88824630|NCT03462875||First Degree Relatives|Non-affected first degree relatives of cases
88824631|NCT03462875||Household/co-habitant Controls|Non-affected subjects living in the same household with the cases in the recent 6 months
89355994|NCT02513368|Active Comparator|connective tissue graft|augmentation procedure with connective tissue graft
89355995|NCT01205243||ZIAGEN®|Patients administrated ZIAGEN® at the site
88824632|NCT01785680|Active Comparator|Current protocol|These treatment arm is the standard care for moderate malnutrition. This includes a fortified cereal supplement treatment until the child reaches MUAC of above 12.5. Currently, MAM and SAM are treated separately, overseen by different agencies. Breastfeeding is often overlooked.
88824633|NCT01785680|Experimental|Integrated Protocol|Integrated protocol for treatment of children with MAM and SAM in humanitarian emergencies has the potential to result in a more streamlined, cost-effective program, higher recovery, and higher program coverage, allowing easier access to malnourished children, thus curing more children of malnutrition and preventing its lifelong effects.
88824634|NCT03457493|Experimental|Baseline Cohort Healthy Controls, DPA-714-PET/MRI|n-105
88824635|NCT03457493|Experimental|Baseline Cohort Early Parkinson's Disease, DPA-714-PET/MRI|n-100
88824636|NCT03457493|Experimental|UDALL 5-year Follow-up Cohort|n-67 from baseline early Parkinson's disease cohort
88824637|NCT03457493|Experimental|Metabolite Analysis Cohort|n-5 from baseline early Parkinson's disease cohort
88824638|NCT03420989|Active Comparator|Active snack food|snack food with carob and seaweeds 50 gr per day
89355996|NCT02504164|Experimental|No premedication|No premedication before sedation
89355997|NCT02504164|Active Comparator|Midazolam|Premedication with midazolam before sedation
89355998|NCT01203137||tricuspid regurgitation, severe|To be included in the present study, the following 3 criteria for severe TR should be met based on the preoperative echocardiography: (1) TR jet > 30% of right atrial area, (2) inadequate cusp coaptation, and (3) systolic flow reversal in the hepatic vein.
88824639|NCT03420989|Placebo Comparator|Control snack food|snack food without carob and seaweeds 50 gr per day
88824640|NCT01784666|Experimental|Isradipine-Isradipine|Subjects will receive isradipine in phase 1 (4 weeks) and phase 2 (4 weeks)
88824641|NCT01784666|Experimental|Placebo -> Isradipine|Placebo non-responders after the 1st 4 weeks will be re-randomized 1:1 to placebo or isradipine for the next 4 weeks
89355999|NCT02504086|Experimental|Online Support|3 months online support, including access to online personal health record and 2.5 hours of online video teleconsultations with certified health professionals
89356000|NCT01205321|Experimental|Arm 1|
89356001|NCT01205321|Experimental|Arm 2|
89356002|NCT02504008|Experimental|AXS-02 (oral zoledronate)|Administered orally in the morning on Days 1, 8, 15, 22, 29, and 36
89356003|NCT02504008|Placebo Comparator|Placebo|Administered orally in the morning on Day 1, 8, 15, 22, 29, and 36
89356004|NCT01203293|Experimental|Cognitive Behavior Therapy|
89356005|NCT01203293|Active Comparator|Treatment as usual|
89356006|NCT01297361|Other|Plasma Vitamin B12 and Folic acid levels|Blood sample was drawn
89177090|NCT00848393|Active Comparator|Fentanyl (Low Dose) + Dexmedetomidine|This arm will receive10 mcg/kg of Fentanyl (Low Dose) -2 divided doses. Dexmedetomidine (Dex) loading dose-1 mcg/kg over 10 min, then Dex infusion at 0.5mcg/kg/hr.
89177091|NCT00815516|Experimental|Micafungin|Infants received micafungin at a dose of 10 mg/kg per day by intravenous infusion for a minimum of 21 days to a maximum of 28 days for infants without end-organ dissemination or for a maximum of 42 days for infants with end-organ dissemination.
89356007|NCT03566485|Experimental|Phase 2 (atezolizumab, cobimetinib)|Participants with TP53 gene mutation receive atezolizumab IV over 60 minutes starting with day 15 of course 1 and then on days 1 and 15 of subsequent courses, and cobimetinib PO daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89356008|NCT03566485|Experimental|Phase 1b - Atezolizumab 840mg IV + Idasanutlin 100mg PO|
89356009|NCT02503930|Experimental|Active tDCS|The active tDCS condition will consist of 20 min of continuous stimulation. This amount of stimulation is safe for healthy young and older adults and has been shown to induce acute beneficial changes in cortical excitability and cognitive functions.
89356010|NCT02503930|Sham Comparator|Sham tDCS|The Sham tDCS - an inactive stimulation.
89356011|NCT05281367|Experimental|Breast milk odor group|It is a non-pharmacological method of pain control in which 3 cc of breast milk will be dripped onto a sterile pad and It will be placed at a distance of 10 cm from the nose of the newborn. Precisely, premature newborns' own mothers' milk will be used. For this, mothers of newborns will be contacted and breast milk will be provided for the day of the procedure.
89356012|NCT05281367|Experimental|Facilitated tucking group|It is a non-pharmacological method of pain control in which the arms and legs are slowly contracted and placed close to the body. In this method, the baby is placed on its side, the baby's back is gently bent, the legs are folded at an angle of more than 90 degrees, the shoulders are folded up to 90 degrees, and the care hands are placed either on the head near the mouth or Placed on the baby's face.
89356013|NCT05281367|Experimental|Non-nutritive sucking group|It is a non-pharmacological method used to control pain in infants. In this method, babies suck without receiving the nutrient. This can be done by a pacifier, a parent's hand or a nurse.
89356014|NCT05281367|Experimental|control grup|The control group will consist of 36 premature newborns who are routinely applied in the clinic. In the clinic where the research was conducted, no attempt is made to reduce pain during heel stick.
89356015|NCT02513290|Experimental|Bilastine group|Bilastine 20 mg administered once a day for ten days.
89356016|NCT02513290|Experimental|Loratadine group|Loratadine 10 mg administered once a day for ten days.
89356017|NCT01297439|Other|group M|"Normal delivery without pushing maneuver suctioning of fetal nose and mouth during delivery"
89356018|NCT01297439|Experimental|group C|"Pushing maneuver on the fetal head"
89356019|NCT03839927||Evaluation Group|Survey Application
89356020|NCT02508844|Experimental|Vivomixx®|Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasei, Lactobacillus bulgaricus and Streptococcus thermophilus
89356021|NCT02508844|Placebo Comparator|Placebo|microcrytalline cellulose, magnesium stearate and silicon dioxide.
89356022|NCT05669651|Experimental|Low dose of group|"Complete the fecal bacteria transplantation through the upper digestive tract:~Intestinal preparation: Amoxicillin 0.5g bid, metronidazole 0.4g bid and levofloxacin 0.5g qd for 3 days.~FMT: After 12h of antibiotic discontinuation, the total amount of bacterial liquid was 400ml, 100ml each time, Q12h, 2 days after 12h of antibiotic discontinuation."
89356023|NCT05669651|Experimental|High dose of group|"Complete the fecal bacteria transplantation through the upper digestive tract:~Intestinal preparation: Amoxicillin 0.5g bid, metronidazole 0.4g bid and levofloxacin 0.5g qd for 3 days.~FMT: After 12h of antibiotic discontinuation, the total amount of bacterial liquid was 800ml, 100ml each time, Q12h, 4 days ."
89356024|NCT02501200|Experimental|TR group|CKD-391 and combination dose of Atrovastatin and Ezetimibe in order
89356025|NCT02501200|Experimental|RT group|combination dose of Atrovastatin and Ezetimibe and CKD-391 in order
89356026|NCT01205477|Experimental|Methylprednisolone|Infiltration of 40 mg of methylprednisolone acetate plus 1 mL of xylocaine
89356027|NCT01205477|Placebo Comparator|Placebo|Infiltration of 1 mL of xylocaine
89000109|NCT00410553|Experimental|Treatment (combination chemotherapy)|Patients receive eribulin mesylate IV and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15 OR on days 1 and 8. Courses repeat every 28 or 21 days* in the absence of disease progression or unacceptable toxicity.
89356028|NCT02501278|Experimental|Arm A: Immunotherapy during and after CRT + vaccine boost|INO-3112 dosing during chemoradiotherapy plus immunotherapy dosing after chemoradiotherapy in an adjuvant setting and vaccine boost one year after last vaccine dosing.
89000110|NCT00410007|Other|Patients with ADPKD, HS|Each subject was studied on 2 separate days at least 3 weeks apart. During 4 days before the study day, the subjects consumed either a high sodium diet or a low sodium diet in randomized order (HS-LS/ LS-HS). On the study day a hypertonic saline infusion was given.
89356029|NCT02501278|Experimental|Arm B: Immunotherapy during CRT + vaccine boost|INO-3112 dosing during chemoradiotherapy, and vaccine boost one year after last vaccine dosing.
89356030|NCT02501278|Active Comparator|CRT without immunotherapy|Standard chemoradiotherapy without immunotherapy
89356031|NCT03176238|Experimental|everolimus + exemestane|Everolimus (10 mg) and exemestane (25 mg) tablets taken orally in combination once daily
89356032|NCT03565315|Experimental|Group 1: 10E8VLS (5 mg/kg) SC Single Dose Group|10E8VLS (5 mg/kg) administered by the subcutaneous (SC) route (Day 0)
89356033|NCT03565315|Experimental|Group 2: 10E8VLS (5 mg/kg) SC Multiple Dose Group* (*Only One Dose Received)|"10E8VLS (5 mg/kg) administered by the SC route (Day 0, Week 12*, Week 24*)~*Participants received only one product administration on Day 0 because of the voluntary study pause and termination by the IND Sponsor/PI decision."
89356034|NCT03565315|Experimental|Group 3: 10E8VLS+VRC07-523LS (5 mg/kg each) SC Single Dose Group|10E8VLS (5 mg/kg)+VRC07-523LS (5 mg/kg) administered by the SC route (Day 0)
89356035|NCT03565315|Experimental|Group 4: 10E8VLS+VRC07-523LS (5 mg/kg each) SC Multiple Dose Group* (*Only One Dose Received)|"10E8VLS (5 mg/kg)+VRC07-523LS (5 mg/kg) administered by the SC route (Day 0, Week 12*, Week 24*)~*Participants received only one product administration on Day 0 because of the voluntary study pause and termination by the IND Sponsor/PI decision."
89356036|NCT02503618||HIV-negative YBMSM|Subjects are young black men who have sex with men in Atlanta, Georgia and are HIV-negative
89356037|NCT02503618||HIV-positive YBMSM|Subjects are young black men who have sex with men in Atlanta, Georgia and are HIV-positive
89356038|NCT01205555|No Intervention|ultrasound alone group|Patients in the control group will have a standard ultrasound monitoring with HCG administered when the leading follicle reaches 18 mm, and IUI 36 h afterward.
89356039|NCT01205555|Experimental|LH testing combined with ultrasound monitoring|
88824642|NCT01784666|Placebo Comparator|Placebo-Placebo|Placebo nonresponders for the 1st 4 weeks will be re-randomized 1:1 to placebo or isradipine for the subsequent 4 weeks
89356040|NCT01957332|Experimental|Molecular imaging|All patients receive 18F-FES (~200MBq) injection followed by a FES-PET. On the same day or the day after 18F-FES injection 89Zr-trastuzumab (~37 MBq) will be injected. The HER2-PET will be performed 4 days after tracerinjection.
89356041|NCT03840083|Experimental|Sleep|Individuals will either nap (Exps 1, 4) or have overnight sleep (Exps 2, 3, 5, 6)
89356042|NCT03840083|No Intervention|Wake|Individuals will stay awake for the same amount of time as they slept in the sleep condition
89356043|NCT02509000|Active Comparator|Active-mode|Air purifier in active-mode
89356044|NCT02509000|Sham Comparator|Sham-mode|Air purifier in sham-mode
89356045|NCT02501122||Adenotonsillectomy|Measuring quality of care in patients undergoing adenotonsillectomy.
89356046|NCT01205633||CNS draining vein abnormalities|
89356047|NCT01923636|Other|detection of CMV|Cohort of neonates less than 1 month with congenital CMV infection at birth objectified by the detection of CMV in a urine sample, in saliva or blood (fresh or Guthrie card) obtained in the first 10 days life
89356048|NCT03565237|Experimental|All Study Participants|Study participants with Hemophilia B in India receiving Rixubis
89356049|NCT02501044||Hemodialysis Patients|
89356050|NCT02508922|Experimental|Vitamin D3|2000iu vitamin D will be taken daily for 20 weeks.
89356051|NCT02508922|Placebo Comparator|Placebo|Matching placebo drops will be taken daily for 20 weeks
89356052|NCT02894437||patients|SCI recruited Physical Medicine and Nantes University Hospital Rehabilitation. Recruitment will try to balance the number of people in four sub-groups followed and complicated (= history of pelvic pressure sores), not followed and uncomplicated, monitored and uncomplicated, not followed and complicated
89356053|NCT02894437||health professionals|those involved in the chain of care Spinal Cord concerning various professions (including medical, paramedical and administrative) decision and variable influence on the organization of the die care of spinal injuries.
89356054|NCT01205789||Universal Registry|Subjects who are either not eligible for randomization or for other reasons are not randomized will be consented for the Universal Registry
89356055|NCT03730675|Experimental|irradiation stent plus TACE|Portal irradiation stent placement will be performed before TACE procedures.
89356056|NCT03730675|Active Comparator|Sorafenib plus TACE|TACE will be performed in patients randomized to Arm B, with sequential sorafenib.
89356057|NCT04495738|Active Comparator|Control Feeding Group|Ready to feed milk-based product
89356058|NCT04495738|Experimental|Experimental Feeding Group|Ready to feed milk-based product with oligosaccharides
89356059|NCT04495738|Other|Human Milk (HM) Reference Group|HM from infant's own mother and as needed supplemental infant formula and toddler milk-based product
89356060|NCT01297673||Spinal cord injury|Patients with neurogenic lower urinary tract dysfunction due to spinal cord injury with regular urodynamic examination
89356061|NCT03726853|Experimental|CKD-497 200mg|CKD-497 200mg
89356062|NCT03726853|Experimental|CKD-497 300mg|CKD-497 300mg
89356063|NCT03726853|Active Comparator|Active Comparator|compartor
89356064|NCT03726853|Placebo Comparator|Placebo|CKD-497 placebo and comparator placebo
89356065|NCT01205867|Experimental|1|AZD8848 given to BChE deficient subjects and age & gender matched control subjects
89356066|NCT05219214||Chinese medicine group|
89356067|NCT03343288|Experimental|Silver HA coated implants|Silver doped hydroxyapatite coated implants
89356068|NCT01345682|Experimental|Afatinib (BIBW 2992)|Once daily
89000111|NCT00410007|Other|Patients with ADPKD, LS|Each subject was studied on 2 separate days at least 3 weeks apart. During 4 days before the study day, the subjects consumed either a high sodium diet or a low sodium diet in randomized order (HS-LS/ LS-HS). On the study day a hypertonic saline infusion was given.
89356069|NCT01345682|Active Comparator|Methotrexate|Weekly
89356070|NCT05295264|Experimental|Exercise group|"The design of the physical exercise program will be supported by the Canadian and Spanish Guidelines for exercise throughout pregnancy and published by Barakat model.~Frequency: The program will consist of three weekly sessions. The duration of every session will be 55-60 minutes. The intensity of the workload will be 55-60% of the maximum maternal Heart Rate, and controlled by Polar monitor (FT60). Likewise, once a week, the Borg Scale of Perceived Effort will be administered to participants, in order to have a more reliable assessment of the intensity of the activities, 12-14 (moderate; out of a 20 point scale) will be the level used.~The minimum adherence required for the participants will be 80% of the total sessions (approximately 80 sessions)."
89356071|NCT05295264|No Intervention|Control group|"Women randomly assigned to the control group (CG) received general advice from their health care provider about the positive effects of physical activity. Participants in the CG had their usual visits with health care providers during pregnancy, which were equal to the exercise group. Women were not discouraged from exercising on their own. However, women in the CG were asked about their exercise once each trimester using a Decision Algorithm (by telephone)."
89356072|NCT03343210|Experimental|cancer patient|cancer patient
89356073|NCT03343210|Active Comparator|no cancer patient|no cancer patient
89356074|NCT03839849|Experimental|i-PRF (Test)|injected subgingivally i-PRF after scaling and root planing
89356075|NCT03839849|Active Comparator|saline (Control)|injected subgingivally saline after scaling and root planing
89356076|NCT02503696||IBD|Subjects will be men and women, 18-84 years of age, inclusive, who have been diagnosed with IBD. Each with a screening colonoscopy resulting in normal findings.
89356077|NCT03562117|Experimental|Normal Hepatic function, Part 1 (Group D)|The eligible subjects, with normal hepatic function, in this arm will receive a single oral dose of gepotidacin as 1500 milligram (mg), administered as 2 × 750 mg tablets on Day 1.
89356078|NCT03562117|Experimental|Moderate hepatic impairment, Part 1 (Group B)|The subjects in this arm, will be the one's with a Child-Pugh score of 7 to 9, and will receive a single oral dose of gepotidacin, as 1500 mg, administered as 2 × 750 mg tablets on Day 1.
89356079|NCT03562117|Experimental|Mild hepatic impairment, Part 2 (Group A)|The subjects in this arm, will be the one's with a Child-Pugh score of 5 to 6, and will receive a single oral dose of gepotidacin, as 1500 mg, administered as 2 × 750 mg tablets on Day 1. This will be optional arm.
89356080|NCT03562117|Experimental|Severe hepatic impairment, Part 2 (Group C)|The subjects in this arm, will be the one's, with a Child-Pugh score of 7 to 9, and will receive a single oral dose of gepotidacin, as 1500 mg, administered as 2 × 750 mg tablets, on Day 1.
89356081|NCT03562117|Experimental|Normal Hepatic function, Part 2 (Group E)|The eligible subjects, with normal hepatic function, will be matching with those enrolled in Part1, and will receive a single oral dose of gepotidacin as 1500 mg, administered as 2 × 750 mg tablets on Day 1.
89356082|NCT01314846||Control Group|sequential culture system
89356083|NCT01314846||Co-culture system|
89356084|NCT01314924|Experimental|Responders|Patients who present an increase in flow-mediated dilation of brachial artery.
89356085|NCT01314924|Experimental|Non responders|Patients who do not present an increase in flow-mediated dilation of brachial artery.
89356086|NCT02503462|Experimental|darunavir/ritonavir vs cobicistat|All HIV infected patients will be treated with a darunavir/ritonavir (800/100 mg) once daily containing regimen. Darunavir/ritonavir concentrations will be measured simultaneously in CSF and plasma after 1 month of treatment. The treatment will be switched to darunavir/cobicistat (800/150 mg) once daily and darunavir/cobicistat levels will be measured in CSF and plasma after 1 month of treatment.
89356087|NCT01203215|Experimental|JumpStart|
89356088|NCT01203215|Experimental|Choose to Move|
88824643|NCT04336397|Active Comparator|High Intensity|navigated tribal health worker outreach, a mailed MT-sDNA kit, mailed culturally appropriate educational material describing CRC screening options available and follow-up reminders
88824644|NCT04336397|Active Comparator|Medium Intensity|navigated tribal health worker outreach, a mailed MT-sDNA kit, mailed culturally appropriate educational material describing CRC screening options available and follow-up reminders
88824645|NCT04336397|No Intervention|Usual Care|usual care (i.e., opportunistic screening recommendation at a clinic visit)
88824646|NCT04296695|Experimental|B/F/TAF|50mg/600mg/300mg
88824647|NCT04296695|Active Comparator|TDF/3TC/EFV|300mg/300mg/400mg
88824648|NCT03283397|Experimental|EK-12|This arm will be treated with 12 mg EK-12 in 2 mL 0.9 % NaCl solution (SC, three times per week) for 144 weeks
88824649|NCT03283397|Active Comparator|INF Beta-1a|This arm will be treated with 44 mg INF Beta-1a in 0.5 mL solution (SC, three times per week) for 144 weeks
88824650|NCT04281251|Experimental|ERAT arm|This is the treatment arm where endoscopic therapy of acute appendicitis would be performed
88824651|NCT03240263|Experimental|Inspiratory muscle training|High intensity inspiratory muscle training
88824652|NCT03240263|Sham Comparator|Sham endurance training|Sham inspiratory muscle training at low intensity
88824653|NCT04259645|Active Comparator|Low Volume group|30 subjects randomized to Low Volume will receive unilateral Quadratus Lumborum block type II. Each block of 0.375% Bupivacaine x 20 ml
88824654|NCT04259645|Experimental|High Volume group|30 subjects randomized to High Volume will receive unilateral Quadratus lumborum block Type II. Each block of 0.375% Bupivacaine x 20 mL + Normal Saline Solution 20 mL
88824655|NCT00356291|Experimental|1|Participants will receive Skill-Building and Motivational Interviewing.
88824656|NCT00356291|Active Comparator|2|Participants will receive Skill-Building.
88824657|NCT03218345|Experimental|EUS-guided RFA|EUS-guided RFA would be performed using a 19-gauge RFA electrode and a VIVA RF generator (STARmed, Korea)
88824658|NCT01787006|Experimental|Cetuximab, Cisplatin, 5-FU, Radiotherapy|"Cetuximab: Initial doses 400mg/m2 (day 1), followed by weekly doses of 250mg/m2 for 14 weeks in total, IV~5-fluorouracil (5-FU): 1000mg/m2 per day as continuous infusion on day 8-11 and 36-39, 750mg/m2/day as continuous infusion on day 71-74 and 99-102~Cisplatin 20mg/m2/day as intravenous bolus over 60 min on day 1-4 of every cycle (day 8-11, 36-39, 71-74 and 99-102)~radiotherapy: 59.4 Gy (33 fractions of 1.8 Gy) over 6.5-7 weeks (5 x 1.8 Gy per week)on primary tumor. 50.4 Gy on locoregional lymphnodes. If resectability is reached after 4-4.5 weeks (36-41.4 Gy) the radiotherapy stops after 45 Gy and the patient undergoes surgery."
88824659|NCT01787006|Active Comparator|Cisplatin, 5-FU, Radiotherapy|"5-FU: 1000mg/m2 per day as continuous infusion on day 1-4 and 29-32, 750mg/m2/day as continuous infusion on day 64-67 and 92-95~Cisplatin 20mg/m2/day as intravenous bolus over 60 min on day 1-4 of every cycle (day 1-4, 29-32, 64-67 and 92-95)~radiotherapy: 59.4 Gy (33 fractions of 1.8 Gy) over 6.5-7 weeks (5 x 1.8 Gy per week)on primary tumor. 50.4 Gy on locoregional lymphnodes. If resectability is reached after 4-4.5 weeks (36-41.4 Gy) the radiotherapy stops after 45 Gy and the patient undergoes surgery."
88824660|NCT02260622|Active Comparator|clopidogrel plus aspirin|Clopidogrel 75 mg daily X 90 days plus ASA 81 mg daily
88824661|NCT02260622|Experimental|rivaroxaban plus aspirin|Rivaroxaban 2.5 mg BID X 90 days plus ASA 81 mg daily
88824662|NCT02261714|Experimental|TG01/GM-CSF and Gemcitabine|
88824663|NCT04204655||Cohort|rehabilitants of the phase B, C and D during neurological rehabilitation
88824664|NCT03186209|Experimental|Benralizumab|Benralizumab administered subcutaneously
88824665|NCT03186209|Placebo Comparator|Placebo|Placebo administered subcutaneously
88824666|NCT02261948|Active Comparator|Levosimendan|Levosimendan must be diluted before the administration (500 ml of glucose). The intravenous infusion may be administered either by the peripheral or central. The dose and duration of therapy should be decided according to the patient's clinical condition and response to the drug. Treatment should be initiated with a loading dose of 6-12 mcg / kg infused over 10 minutes followed by a continuous infusion of 0.1 mcg / kg / min. A low infusion bolus (6 mcg / kg) is recommended for patients who have a concomitant intravenous treatment with vasodilators or inotropic. The patient's response should be evaluated during the infusion bolus or within 30 to 60 minutes and a dose adjustment based on clinical response.
88824667|NCT02261948|Placebo Comparator|Placebo|Placebo must be diluted before the administration (500 ml of glucose). The intravenous infusion may' be administered either by the peripheral or central. The dose and duration of therapy should be decided according to the patient's clinical condition and response to the drug. Treatment should be initiated with a loading dose of 6-12 mcg / kg infused over 10 minutes followed by a continuous infusion of 0.1 mcg / kg / min. A low infusion bolus (6 mcg / kg) is recommended for patients who have a concomitant intravenous treatment with vasodilators or inotropic. The patient's response should be evaluated during the infusion bolus or within 30 to 60 minutes and a dose adjustment based on clinical response.
88824668|NCT03278067||Vaccinated_Fluarix Tetra Group|Volunteered subjects who received GlaxoSmithKline's (GSK's) influenza vaccination (Fluarix Tetra) in 10 volunteer GP practices between 01 September and 30 November 2017.
88824669|NCT03278067||Vaccinated_Non GSK Group|Volunteered subjects who received non-GSK influenza vaccination in 10 volunteer GP practices between 01 September and 30 November 2017.
88824670|NCT03278067||Vaccinated_Unknown Group|Volunteered subjects who received influenza vaccination (GSK or non-GSK not known) in 10 volunteer GP practices between 01 September and 30 November 2017.
88824671|NCT04141709|Experimental|local ablative radiotherapy|The therapy is performed for all patients in the intervention arm using high-dose radiation therapy, either as conventional fractional irradiation with 2 Gy/fraction up to a total dose of 50 Gy or as hypofractional irradiation with a single dose of 10 Gy up to a total dose of 30 Gy.
88824672|NCT04141709|No Intervention|Observational group|"Effectiveness is measured as the rate in patients with PSA progression one year after randomization (defined as PSA nadir after randomization +2 ng/ml).~There is a 2:1 randomization between intervention and observation group."
88824673|NCT01787240|Placebo Comparator|Placebo|After a screening visit, the patient will undergo a baseline assessment and will be randomized to escitalopram 10mg or placebo.
88824674|NCT01787240|Experimental|Escitalopram 10mg|After a screening visit, the patient will undergo a baseline assessment and will be randomized to escitalopram 10mg or placebo.
89356089|NCT01203215|Active Comparator|Wellness|
89356090|NCT03561883|Experimental|1500 mg IW-3718 BID|Three 500 mg IW-3718 tablets administered twice daily (BID), immediately after the morning and evening meals. Standard-dose PPIs administered QD approximately 30-60 minutes before the morning meal each day.
89356091|NCT03561883|Placebo Comparator|Placebo|Three placebo tablets administered BID immediately after the morning and evening meals. Standard-dose PPIs administered QD approximately 30-60 minutes before the morning meal each day.
89356092|NCT04495426||Presence of symptomatic ataxic disease|Presence of symptomatic ataxic disease with definite molecular diagnosis of SCA10 or whose first-degree relative has a molecular diagnosis of SCA10.
89356093|NCT04495426||Premanifest for SCA10|Asymptomatic participants of either sex aged ≥18 with definite molecular diagnosis of SCA10 (Premanifest carriers)
89356094|NCT04495426||At risk for SCA10|Asymptomatic participants of either sex, aged ≥18 whose first-degree relative has a molecular diagnosis of SCA10 (50%-at-risk relatives*).
89356095|NCT04495426||Non-carrier for SCA10 (Control)|At risk participants who test negative for the SCA10 mutation will serve as non-carriers. Exclusion criteria described above also applies to non-carrier subjects. If the number of non-carriers were less than 10, we will recruit additional participants from normal population to supplement the controls.
89356096|NCT05217056||1/Measurement|All of the infants with high risk of cerebral palsy
89356097|NCT02503306|Experimental|Avanafil dose 1|Administered 30 minutes prior to initiation of sexual activity for a duration of 8 weeks to use no more than one dose in any 24-hour period
89356098|NCT02503306|Experimental|Avanafil dose 2|Administered 30 minutes prior to initiation of sexual activity for a duration of 8 weeks to use no more than one dose in any 24-hour period
89356099|NCT02503306|Placebo Comparator|Placebo|Administered 30 minutes prior to initiation of sexual activity for a duration of 8 weeks to use no more than one dose in any 24-hour period
89356100|NCT02508766|Experimental|Plantar stimulation|The manipulation was performed with the subject in the supine position. The intervention lasted ten minutes and consisted of four stages: 5 glide pressures focused on each interdigital space, that lasted 10 seconds in duration, 5 compression-decompression of each metatarsophalangeal joint, 5 glide pressures applied for 5 seconds each, on the region of metatarsal heads, 5 static pressures applied for 10 seconds each, focused on four points of the sole.
89356101|NCT02508766|No Intervention|Control group|Volunteers received no intervention. They just sat there for 20 minutes before being evaluated.
89356102|NCT05706350|Experimental|Plant stanol group (2 grams per day)|Dietary Supplement: 4 soft chews containing 0.5g plant stanols each (delivered as plant stanol esters) Soft chews containing 0.5g plant stanols each delivered as plant stanol esters
89356103|NCT05706350|Experimental|Plant stanol group (3 grams per day)|Dietary Supplement: 6 soft chews containing 0.5g plant stanols each (delivered as plant stanol esters) Soft chews containing 0.5g plant stanols each delivered as plant stanol esters
89356104|NCT05706350|Experimental|Plant stanol group (4 grams per day)|Dietary Supplement: 8 soft chews containing 0.5g plant stanols each (delivered as plant stanol esters) Soft chews containing 0.5g plant stanols each delivered as plant stanol esters
89356105|NCT05706350|Placebo Comparator|Placebo group|Dietary Supplement: 6 placebo soft chews Soft chews that do not contain plant stanols
89356106|NCT03343678|Experimental|Venetoclax + BI 836826|
89356107|NCT03724279|Experimental|ByCross Atherectomy and Thrombectomy|Percutaneous intervention including ByCross atherectomy and Thrombectomy potentially followed with PTA and/or stent placement
89356108|NCT02500966|Experimental|DUDA device|"The number of patients to be recruited in this arm will be 145. Note: The first twenty-five patients who will be included in the study will be allocated in the intervention arm to safety analysis (phase 1); after that all eligible candidates will be randomized 1:1 (phase 2).~Procedure: Loop Electrosurgical Excision Procedure (LEEP) followed by implantation of the device called DUDA (plastic device developed in barretos cancer hospital that will be placed after conization. It has 2.5 cm in length and 5mm in diameter and remains within the endocervical canal for 30 days and is set at 4 points with nonabsorbable sutures in the ectocervix.)"
89356109|NCT02500966|Active Comparator|Control group|"The number of patients to be recruited in this arm will be 120.~Procedure: Loop Electrosurgical Excision Procedure (LEEP) without DUDA device"
89356110|NCT05216822|Experimental|children received ORS and racecadotril as treatment|25 children received ORS and racecadotril as treatment (at a dose of 1.5 mg/kg/day, an oral single daily dose for three days)
89356111|NCT05216822|Active Comparator|children received ORS alone as treatment|25 children received ORS alone for treatment as a control group
88824675|NCT00357149|Active Comparator|A|Cisplatin from day 1 to day 4 and 5-FU for 4 days starting immediately after the end of cisplatin infusion on day 1. Both drugs were administered during week 1 and 6 of irradiation, starting from day 1 of weekly radiotherapy.
88824676|NCT00357149|Experimental|B|Docetaxel followed by cisplatin and 5-FU from day 1 to day 4 starting after the end of cisplatin infusion. The cycle was repeated every 3 weeks up to a total of 3 cycles. After 3-6 weeks from the end of neoadjuvant chemotherapy, patients will receive with the same modality of arm A (reference arm).
88824677|NCT04926116|Experimental|AK3280 Cohort 1|Eligible subjects will be administered a single oral dose of 200 mg AK3280 under fasted conditions on Day 1. A multiple dosing period follows with daily 200 mg AK3280 b.i.d. administered with a concurrent low-fat meal intake from Day 4 to Day 16 and a 200 mg AK3280 q.d. dosing on Day 17.
88875171|NCT02500602|Placebo Comparator|Placebo|Participants randomly assigned to placebo. Research staff administered the study medication at the weekly visits, and participants were given take-home doses of the medication to self-administer on the days in between study visits.
89356112|NCT02508688|Experimental|thoracoscopic mesh repair group|63 patients with refractory HH (> 3 times thoracentesis and failure to maximal doses of diuretics) who underwent thoracoscopic diaphragmatic repair were included in this study.
89356113|NCT04495036||dermatology patients|
89356114|NCT04495036||physicians and medical staff|
89356115|NCT02503072|Active Comparator|Prizes conditional on adherence|Participants in this group are eligible for a prize drawing if they come on their scheduled clinic day. They receive the intervention 'Behavioral: Small lottery prizes based on adherence'.
89356116|NCT02503072|Active Comparator|Prizes conditional on clinic visits|Participants in this group are eligible for a prize drawing if they show 95% adherence or higher based on their MEMS-cap measured adherence. They receive the intervention 'Behavioral: Small lottery prizes based on timely clinic visits'.
89000112|NCT00410007|Other|Healthy Control Subjects, HS|Each subject was studied on 2 separate days at least 3 weeks apart. During 4 days before the study day, the subjects consumed either a high sodium diet or a low sodium diet in randomized order (HS-LS/ LS-HS). On the study day a hypertonic saline infusion was given.
89356117|NCT03627338||Norfloxacin|evaluate medication adherence, patient history, medication beliefs and medication satisfaction, depression, anxiety and health-related quality of life
89356118|NCT03627338||Non-selective beta blockers|evaluate medication adherence, patient history, medication beliefs and medication satisfaction, depression, anxiety and health-related quality of life
89356119|NCT03627338||diuretics|evaluate medication adherence, patient history, medication beliefs and medication satisfaction, depression, anxiety and health-related quality of life
89356120|NCT04498936|Experimental|Sofosbuvir/Ledipasvir|This group will receive a fixed combination of Sofosbuvir/Ledipasvir (400 mg and 90 mg, orally) once daily for 14 days, plus the standard care treatment regimen (SCT) for COVID-19 patients according to the Egyptian Ministry of Health (MOH) protocol.
89356121|NCT04498936|Experimental|Nitazoxanide|This group will receive nitazoxanide (500 mg, orally) four times per day for 14 days, plus the standard care treatment regimen (SCT) for COVID-19 patients according to the Egyptian Ministry of Health (MOH) protocol.
89356122|NCT04498936|No Intervention|Standard care treatment|This group will receive only the standard care treatment regimen (SCT) for COVID-19 patients according to the Egyptian Ministry of Health (MOH) protocol.
89356123|NCT02502994|Other|Intervention|Single arm of the castration resistant prostate cancer
89000113|NCT00410007|Other|Healthy Control Subjects, LS|Each subject was studied on 2 separate days at least 3 weeks apart. During 4 days before the study day, the subjects consumed either a high sodium diet or a low sodium diet in randomized order (HS-LS/ LS-HS). On the study day a hypertonic saline infusion was given.
89000114|NCT01968187|Experimental|FE 992097|
89356124|NCT02503150|Experimental|APDC + Chemotherapy|Patients in Arm APDC + Chemotherapy will receive APDC combined with chemotherapy.
89356125|NCT02503150|Active Comparator|Chemotherapy|Patients in Arm Chemotherapy will receive chemotherapy only.
89356126|NCT02500810|Experimental|monosialoganglioside|patients receive monosialoganglioside.
89000115|NCT01968187|Placebo Comparator|Placebo|
89000116|NCT01966549|Experimental|CNTO 6785|
89000117|NCT01966549|Placebo Comparator|Placebo|
89356127|NCT02500810|No Intervention|control|blank control
89356128|NCT03546907|Placebo Comparator|Placebo|Participants received placebo matched to SAR440340 administered as 2 subcutaneous (SC) injections every 2 weeks (Q2W). Participants were treated for a minimum of 24 weeks and up to a maximum of 52 weeks (last dose administered at Week 50, End of Treatment (EOT) visit occurred 2 weeks after last administration of IMP i.e., at Week 52).
89356129|NCT03546907|Experimental|SAR440340|Participants received SAR440340 300 milligrams (mg) administered as 2 SC injections Q2W. Participants were treated for a minimum of 24 weeks and up to a maximum of 52 weeks (last dose administered at Week 50, EOT visit occurred 2 weeks after last administration of IMP i.e., at Week 52).
89356130|NCT02500888|Experimental|Treatment|Radiosurgery by linear accelerator.
89356131|NCT05126264|Experimental|Modified dosage|Ibuprofen pill at morning and afternoon; Placebo at night
89356132|NCT05126264|Active Comparator|Normal dosage|Ibuprofen three times a day: morning, afternoon and night
89000118|NCT01965613|Experimental|open label-Xilonix|Open label-Xilonix
89356133|NCT02508298|Active Comparator|Indocyanine green retention test|A baseline venous sample of 5 ml of venous will be drawn for pre-infusion measurement. Under sterile conditions 0.5 mg/kg body weight of ICG will be injected into vein. Further blood samples (5 ml each) will be collected at 5, 10, 15 and 20 minute intervals after the injection from a peripheral vein in the opposite arm using another intravenous catheter. After serum is separated by centrifugation, optical densities will be measured at 804 nm using a calibrated method for measurement of ICG level s. ICG retention at 15 minutes and elimination rate constant will be calculated by fitting the serum disappearance curve to a single exponential decay equation.This will be compared to portal pressure measured by Hepatic Venous Portal Gradient (HVPG).
89000119|NCT01965106|Active Comparator|QPI-1007 Injection|single intravitreal (IVT) injection of QPI-1007
89000120|NCT01965106|Sham Comparator|Control|Placebo (Sham injection procedure)
89000121|NCT00173537|Other|other|
88824678|NCT04926116|Experimental|AK3280 Cohort 2|The dose level of AK3280 for Cohort 2 will be determined by the SRC (Safety Review Committee) based on the safety and PK data gleaned in Cohort 1. Subjects will receive AK3280 following the same dosing schedule as that in Cohort 1, i. e., a single oral dose of AK3280 under fasted conditions on Day 1, multiple AK3280 b.i.d. administration with a concurrent low-fat meal intake from Day 4 to Day 16, and an AK3280 q.d. dose on Day 17.
88824679|NCT04926116|Experimental|AK3280 Optional Cohort|This is an optional dose cohort that the SRC will determine depending on the results of Cohorts 1 and 2, including the proposed dose level. Potential subjects in this cohort will also follow the same dosing scheme as those for Cohorts 1 and 2.
88824680|NCT04926116|Placebo Comparator|Control Arm|There are placebo controls in each dose cohort to assess the safety profile of the study medication. Subjects will be randomized to receive a placebo simultaneously as those subjects randomized to AK3280.
89533648|NCT03907735||1st trimester|First trimester myometrial tissue samples will be collected by core needle biopsy under ultrasound guidance in anesthetized women. Samples will be obtained after first trimester surgical abortions or suction dilation and curettage (D&C).
89533649|NCT03907735||After term pregnancy (3rd trimester)|Third trimester myometrial tissue samples will be collected by core needle biopsy under ultrasound guidance in anesthetized women. Samples will be obtained at the time of cesarean delivery.
88824681|NCT04903652|Experimental|Pyrotinib plus Vinorelbine|
88824682|NCT04769102|Experimental|Spastic Cerebral Palsy|spastic Cerebral palsy children will be adapted in adaptive seat with flat and then Contoured cushions while kinematic changes of upper limb reaching movement are monitored through video capture with kinovea 2D software motion analysis system.
88824683|NCT04071821|Experimental|A: Test under Fasted Condition|Single oral dose of cetirizine HCl Gummy 10 mg, chewed, administered with approximately 240 mL of room temperature water, under fasted conditions
89356134|NCT02508298|Active Comparator|Liver stiffness measurement|ARFI measurements of the liver will be obtained using a standard ultrasound probe. The patient will be lying on his back and will be asked to hold his/her breath for 2-5 seconds during measurements.These will be compared to portal pressure measured by Hepatic Venous Portal Gradient (HVPG).
89533650|NCT03901300|Experimental|Fundamental Motor Skills (FMS)|The FMS group will utilize the PLAY FMS app that provides instructional lessons, peer modeling videos, and activity breaks to deliver 720 minutes of targeted, structured FMS instruction time to the child over a 12 week period.
88824684|NCT04071821|Active Comparator|B: Reference under Fasted Condition|Reference: Single oral dose of cetirizine HCl oral tablets 10 mg, administered with approximately 240 mL of room temperature water, under fasted conditions
88824685|NCT04071821|Experimental|C: Test under Fed Condition|Test: Single oral dose of cetirizine HCl Gummy 10 mg, chewed, administered with approximately 240 mL of room temperature water, under fed conditions
88824686|NCT04071821|Experimental|D: Test under Fasted Condition with No Water|Single oral dose of cetirizine HCl Gummy 10 mg, chewed, administered with no water, under fasted conditions
88824687|NCT04071821|Experimental|E: Test Swallowed Whole with Water, under Fasted Condition|Single oral dose of cetirizine HCl Gummy 10 mg, swallowed whole, administered with approximately 240 mL of room temperature water, under fasted conditions
88824688|NCT01735214||Patients with POAG or OHT|Patients with POAG or OHT on current IOP-lowering therapy who are prescribed a prostaglandin analogue -containing IOP-lowering therapy by the physician. The decision to prescribe a change in IOP-lowering therapy lies with the physician according to their standard practice.
88824689|NCT03064295||Healthy Volunteers|60 healthy male or female (18 or older) adults will receive Myocardial Perfusion Cardiac MRI, including administration of contrast and a pharmacologic stress agent
88824690|NCT03064295||CAD Patients|110 male or female adults (18 or older) who have undergone clinical myocardial perfusion imaging at CSMC and been diagnosed with Coronary Disease (CAD) will receive Myocardial Perfusion Cardiac MRI, including administration of contrast and a pharmacologic stress agent.
88824691|NCT03064295||CMD Patients|50 female adults (21 or older) who have undergone coronary reactivity testing at CSMC and been diagnosed with coronary microvascular disease (CMD) will receive Myocardial Perfusion Cardiac MRI, including administration of contrast and a pharmacologic stress agent.
88824692|NCT01789814|Active Comparator|Prasugrel|Prasugrel oral loading dose of 60 mg administered preceding cardiac intervention
88824693|NCT01789814|Active Comparator|Clopidogrel|Clopidogrel oral loading dose of 600 mg administered preceding cardiac intervention
88824694|NCT00356447|Active Comparator|Arm 1|
88824695|NCT00356447|Placebo Comparator|Arm 2|
89356135|NCT02508298|Active Comparator|Spleen stiffness measurement|ARFI measurements of the spleen will be obtained using a standard ultrasound probe. The patient will be lying on his back and will be asked to hold his/her breath for 2-5 seconds during measurements.These will be compared to portal pressure measured by Hepatic Venous Portal Gradient (HVPG).
89533651|NCT03901300|Active Comparator|Unstructured Physical Activity|The active comparator group will use a version of the PLAY app that provides instructional lessons to promote the equivalent dosage of unstructured physical activity for the child.
89533652|NCT03896126||Gastroparesis Patients|20 gastroparesis patient ages 20-49
88824696|NCT01736852|Experimental|CRB plus Pitocin|
88824697|NCT01736852|Active Comparator|Pitocin|
88824698|NCT01790750|Other|PES first, then FFES|A 5-minute Pocket echocardiography system scan (PES) scan will be performed to detect PDA on neonates. This scan will be followed by a Full Featured Echocardiography System Scan (FFES) and scan results will be compared.
88824699|NCT04068623||Triple negative breast cancer|
88824700|NCT01809938|Active Comparator|Black Tea|
88824701|NCT01809938|Active Comparator|Tea with Milk|
88824702|NCT02922413|Experimental|Hemin for injection|Double blind doses of Panhematin 4 mg/kg body weight reconstituted with 25% human albumin and infused over at least one hour.
88824703|NCT02922413|Placebo Comparator|Placebo|A double blind dose of saline.
89000122|NCT01951690|Experimental|VS-6063 (defactinib)|Administered orally BID in a 21 day cycle
89000123|NCT01941043|Experimental|CERC-301, Treatment Sequence 1|Treatment Sequence 1 - 7 days on placebo and 28 days on study drug (either 12mg or 8mg)
89533653|NCT03896126||Healthy Controls|40 healthy controls ages 20-49
89533654|NCT03895658|Experimental|ECT|ECT treatment, Within subject cross-over
89356136|NCT03730597|Active Comparator|glenosphere 42|patients receiving a reverse shoulder arthroplasty with a glenosphere sized 42. reverse shoulder prosthesis implantation X-Ray analysis to detect scapular notch
89356137|NCT03730597|Active Comparator|glenosphere 38 ECC|patients receiving a reverse shoulder arthroplasty with a glenosphere sized 38 ECC reverse shoulder prosthesis implantation X-Ray analysis to detect scapular notch
89356138|NCT02500654|Experimental|Surgery and Emdogain®|access peri-implant surgery with Emdogain® applied after cleaning of implant surface with saline
89356139|NCT02500654|Placebo Comparator|Surgery alone|access peri-implant surgery and cleaning of implant surface with saline
89356140|NCT01318382|Experimental|TOF-Watch SX®|Participants who have undergone elective open or laparoscopic abdominal surgery, received general anesthesia, received at least one dose of non-depolarizing neuromuscular blocker and had the extent of their recovery from NMB monitored by a TOF-Watch SX®.
89356141|NCT04495114|No Intervention|Control Arm|Modern fasting guidelines without the carbohydrate load preoperatively.
89177092|NCT00815516|Active Comparator|Amphotericin B deoxycholate|Infants received amphotericin B deoxycholate (CAB) at a dose of 1.0 mg/kg per day by intravenous infusion for a minimum of 21 days to a maximum of 28 days for infants without end-organ dissemination or for a maximum of 42 days for infants with end-organ dissemination.
89356142|NCT04495114|Experimental|Intervention Arm|40g carbohydrate load preoperatively.
89356143|NCT03001817|Placebo Comparator|12 Week Efficacy|K-877 or placebo comparator twice daily for 12 weeks
89356144|NCT03001817|Active Comparator|40 Week Extension|K-877 with placebo matching fenofibrate or fenofibrate with placebo matching K-877 for 40 weeks
89356145|NCT03726697|Experimental|Tahneek|Infants receiving a single dose of soft date, prepacked by the pharmacy containing glucose equivalent to 200mg/kg at 1 hour after birth in the nursery.
89356146|NCT03726697|No Intervention|CONTROL|Infants at risk for transient neonatal hypoglycemia following standard-of-care.
89356147|NCT02508376|Experimental|ID93 (10 mcg) + AP10-602 (10 mcg)|N=20 subjects will receive intervention on Days 1, 29, 57
89356148|NCT02508376|Experimental|ID93 (10 mcg) + AP10-602 (5 mcg)|N=20 subjects will receive intervention on Days 1, 29, 57
89356149|NCT02508376|Experimental|ID93 (10 mcg) + GLA-SE (5 mcg)|N=20 subjects will receive intervention on Days 1, 29, 57
89000124|NCT01941043|Experimental|CERC-301, Treatment Sequence 2|Treatment Sequence 2 - Placebo for 7 days and study drug for 28 days (8 mgs)
89000125|NCT01941043|Placebo Comparator|Placebo, Treatment Sequence 3|Treatment Sequence 3 - Placebo for 35 Day treatment period
89000126|NCT01938742|Experimental|Group 1|100 subjects receive 3.75mcg sanofi A/H7N9 antigen plus Novartis MF59 adjuvant on Day 0 and 21
89356150|NCT02508376|Experimental|ID93 (10 mcg) alone|N=10 subjects will receive intervention on Days 1, 29, 57
89356151|NCT03053180||Paritaprevir/Ritonavir + Ombitasvir + Dasabuvir|"Participants with chronic hepatitis C (CHC) genotype 1b (GT1b) and compensated liver cirrhosis received paritaprevir/ritonavir (r), ombitasvir and dasabuvir (3DAA ABBVIE REGIMEN) for 12 weeks.~The prescription of a treatment regimen was at the discretion of the physician in accordance with local clinical practice and label, was made independently from this observational study and preceded the decision to offer a patient the opportunity to participate in this study."
89356152|NCT03560869|Experimental|Normal hydration then dehydration|Participants will consume water to maintain proper hydration for three days prior to testing (visit 1). Seven to 60 days later, participants will reduce water intake over three days and abstain from any water for the final 16 hours prior to testing (visit 2).
89356153|NCT03560869|Experimental|Dehydration than normal hydration|Participants will reduce water intake over three days and abstain from any water for the final 16 hours prior to testing (visit 1). Seven to 60 days later, participants will consume water to maintain proper hydration for three days prior to testing (visit 2).
89356154|NCT04498624|Active Comparator|inverted flap|
89356155|NCT04498624|Active Comparator|peeling internal limiting membrane (ILM)|
89356156|NCT02502682|No Intervention|Control|Receive the bathing standard of care.
89356157|NCT02502682|Experimental|Interventional|Receive daily bathing with 2% Chlorhexidine gluconate bathing wipes.
89356158|NCT03590743|Active Comparator|Apixaban|Apixaban 5mg (10 mg twice daily for 7 days followed by 5 mg twice daily for 3 months).
89356159|NCT03590743|Placebo Comparator|Placebo|Patients will receive matching placebo.
89533655|NCT03895658|Experimental|MRI|Structural and functional neuroimaging pre and post ECT treatment
89533656|NCT03895658|Experimental|TMS|Transcranial magnetic stimulation measurements of cortical excitability pre and post ECT treatment
89177093|NCT04118309|Experimental|High-intensity interval training|Three sessions of high-intensity interval training per week for nine weeks. Following a three minute warm up, a session contained twenty minutes of alternating between a sprint (80% of maximum workload, 90-95% of maximum heart rate) and active rest (30% of maximum workload) at a one minute to one minute ratio. Every session ended with a two and a half minute cool down.
89356160|NCT03053102|Experimental|Danicopan|Starting doses of danicopan ranged from 100 to 150 milligrams (mg) three times daily (TID), with subsequent dose escalation up to 200 mg TID based on response (clinical and biochemical) for 28 days (Part 1). Participants with reductions in lactate dehydrogenase (LDH) meeting specified criteria were offered continued dosing beyond Day 28, for up to 8 additional weeks (Part 2).
89356161|NCT02502916||Preterm infant|Preterm infants born from October 2009 to June 2010 at a gestational age of less than 32 weeks or with birth weight of less than 1,200 g
89356162|NCT03344380||Prospective cohort|Adult patients undergoing liver transplantation will be included and followed up during the first 72 hours post-liver transplantation in order to confirm the development of acute kidney injury. The patients will be divided into two groups (AKI group vs. non-AKI group) according to the development of acute kidney injury. The GWAS will be performed with the blood obtained from enrolled patients.
89356163|NCT03344380||Retrospective cohort|In previous study performed in adult patients undergoing liver transplantation (NCT02489474, 4-2015-0411), we enrolled patients and collected data regarding the development of acute kidney injury during the first 72 hours post-liver transplantation. Among these patients enrolled in this previous study, only patients who agreed to additional use of the blood sample for research purposes will be included in the present study. The GWAS will be performed with the blood obtained from enrolled patients.
89356164|NCT03726619|Experimental|e-CHEC-uP|Group 1 will receive the education study intervention after the first baseline questionnaire. Participants will be asked to take part in a one-time, 1 to 1.5-hour online education on breast and cervical cancer prevention followed by monthly phone calls and navigation assistance by a community health worker to help address any barriers in order to help receive a mammogram or a Pap test.
89356165|NCT03726619|Active Comparator|CHEC-uP|Group 2 will receive a similar education intervention but the education is offered face-to-face instead. Participants will be asked to take part in a one-time, 1 to 1.5-hour face-to-face education on breast and cervical cancer prevention followed by monthly phone calls and navigation assistance by a community health worker.
89356166|NCT05705960|Experimental|Chestnut|
89356167|NCT03343600|Experimental|Imatinib|Imatinib (100 mg/tablet) 2# per day till D+100 after allo-HSCT or prophylaxis failure.
89356168|NCT03343600|Placebo Comparator|Placebo|Placebo 2# per day till D+100 after allo-HSCT or prophylaxis failure.
89356169|NCT02502760|Experimental|Prehabilitation|"Immediately after randomization and until surgery, patients in this arm will:~- Receive a personalized physical exercise program~- Receive nutritional counselling with Whey protein isolate powder~- Receive relaxation techniques"
89356170|NCT02502760|Active Comparator|Rehabilitation|Patients in this arm will receive the same personalized physical exercise program, nutritional intervention and relaxation techniques as patients in the other arm but to be started after surgery.
89356171|NCT05085938||Gonadal veins embolisation|This group includes patients who have undergone coil embolization of gonadal vein
89356172|NCT02502604|Experimental|Goal Management Training|Participants in this arm of the study will attend GMT sessions, which will be administered weekly over a nine-week period following a script with accompanying slides and participant workbooks.
89356173|NCT02502604|No Intervention|Wait List Control|Participants in this category will be placed on a wait-list to receive goal management training following completion of their study participation.
89000127|NCT01938742|Experimental|Group 2|100 subjects receive 7.5mcg sanofi A/H7N9 antigen plus Novartis MF59 adjuvant on Day 0 and 21
89356174|NCT05152706|Experimental|Intervention aerobic (IAER)|Patients assigned to the IAER participated in fourty-eigth aerobic exercise therapy sessions over the course of six months.
89356175|NCT05152706|Experimental|Intervention photobiomodulation (IPBM)|Patients assigned to the IPBM participated in fourty-eigth transcraneal photobiomodulation (PBM) theraphy sessions, using a therapeutic laser console, over the course of six months.
89356176|NCT05152706|Experimental|Intervention aerobic and photobiomodulation (IAER+PBM9|Patients assigned to the IAER+PBM participated in the aerobic exercise therapy and the PBM one at the same time, during six months.
89356177|NCT05152706|No Intervention|Control (CO)|Patients assigned to the control (CO) did not participated in any kind of therapy, they just followed their usual weekly routine during six months
89356178|NCT04498702|Experimental|APL-1202 treatment|
89356179|NCT03589885|Placebo Comparator|Placebo 2 mL auto-injector|Placebo to secukinumab s.c., provided in 2 mL auto-injector form
89356180|NCT03589885|Placebo Comparator|Placebo 1 mL prefilled syringe|Placebo to secukinumab s.c., provided in 2 * 1 ml prefilled syringe form
89356181|NCT03589885|Experimental|Secukinumab 2 mL auto-injector|Secukinumab 300 mg provided in 2 mL auto-injector form
89356182|NCT03589885|Active Comparator|Secukinumab 1 mL prefilled syringe|Secukinumab 300 mg provided as 2x 1 mL prefilled syringe of 150 mg/mL
89356183|NCT03121222|Placebo Comparator|Lactose|The placebo group received orally two lactose tablets per day for 30 days. Each individual received the capsules pre-packed in daily doses labeled with the day of consumption.
89533657|NCT03893539|Other|Robotic Bronchoscopy|The Ion™ Endoluminal System assists the user in navigating a catheter and endoscopic tools in the pulmonary tract using endoscopic visualization of the tracheobronchial tree for diagnostic and therapeutic procedures. The Ion™ Endoluminal System enables fiducial marker placement. It does not make a diagnosis and is not for pediatric use.
89000128|NCT01938742|Experimental|Group 3|100 subjects receive 15mcg sanofi A/H7N9 antigen plus Novartis MF59 adjuvant on Day 0 and 21
89000129|NCT01938742|Experimental|Group 4|100 subjects receive 15mcg sanofi A/H7N9 antigen plus Novartis MF59 adjuvant on Day 0 and 15mcg sanofi A/H7N9 antigen on Day 21
89000130|NCT01938742|Experimental|Group 5|100 subjects receive 15mcg sanofi A/H7N9 antigen on Day 0 and 15mcg sanofi A/H7N9 antigen plus Novartis MF59 adjuvant on Day 21
89000131|NCT01938742|Experimental|Group 6|100 subjects receive 15mcg sanofi A/H7N9 antigen on Day 0 and 21
89000132|NCT01938742|Experimental|Group 7|100 subjects receive 45mcg sanofi A/H7N9 antigen on Day 0 and 21
89356184|NCT03121222|Experimental|N-acetylcysteine|The antioxidant group received orally two N-acetylcysteine tablets (each tablet contained 600 mg of NAC; Lamberts Health Care Ltd, Kent, United Kingdom). The participants were instructed to receive the capsules every twelve hours in order to achieve high concentration of N-acetylcysteine throughout the 24 h. Each individual received the capsules pre-packed in daily doses labeled with the day of consumption.
89356185|NCT05074394|Experimental|COVI-DROPS|40 mg of COVI-DROPS administered intranasally
89356186|NCT05074394|Placebo Comparator|Placebo|2 mL placebo administered intranasally
89356187|NCT02502838||Prolapse surgery without TVT|Patients who plan to undergo prolapse repair alone
89356188|NCT02502838||Prolapse surgery with TVT|Patients who plan to undergo prolapse repair with an additional TVT procedure
89356189|NCT05059964|Experimental|Circuit Training program|circuit training for 4 weeks
89356190|NCT05059964|Active Comparator|Continuous aerobic exercise Group|aerobic exercise for 4 weeks
89356191|NCT03120988|Experimental|Lavage with Platelet Poor Plasma (PPP)|"Lavage using 50 cc of PPP in the knee joint. Using visual guidance, the PPP lavage will be conducted, introducing a solution of platelet poor plasma into the knee joint with subsequent removal of the fluid, in effect washing out the joint space."
89356192|NCT03639493|Experimental|Sequence 1|"Period 1: receive Exforge® tab 10/160mg, Crestor® tab 20mg~Period 2: receive CJ-30060 10/160/20mg"
89356193|NCT03639493|Experimental|Sequence 2|"Period 1: receive CJ-30060 10/160/20mg~Period 2: receive Exforge® tab 10/160mg, Crestor® tab 20mg"
89177094|NCT04118309|Placebo Comparator|Placebo exercise group|No changes in physical activity behaviour occurred (already engaging in less than 150 minutes per week, instructed to maintain their current inactivity). They were told they needed to stay inactive since they were part of an 'acute' exercise group, aiming to see how long the effects of their baseline maximal exercise test would last. Thus, the cover story gave them the impression they were also in an exercise group, as oppose to a non-exercise control group.
89356194|NCT03120910|Experimental|Test Subjects|All subjects are enrolled into this arm and will receive an investigational pulse CO-Oximeter sensor, including nasal sensors, with the same or similar technology and materials as the Masimo FDA cleared devices and sensors.
89356195|NCT03724045|Experimental|Back Side of the Moon|"Patients will be screened and enrolled at the ICU. Extraordinary measurements concerning nutritional status will be performed, to investigate whether patients at the ICU actually meet their nutritional needs. The same patients as above will be followed up, once discharge from ICU to a low-care ward has taken place. From there, they will be followed up until discharge from the hospital. The procedures are the same as in the ICU. The results obtained at the low-care ward will be compared to those from the ICU. 6 months after hospital discharge, morbidity and mortality will be assessed.~A substudy of included COVID-19 positive patients will be analysed and compared to non COVID-19 patients."
89356196|NCT05150678|Experimental|removal of cs scar|gruop 1 will remove the scar
89356197|NCT05150678|Experimental|non removal of the scar|gruop2 will not remove the scar
89177095|NCT00705926|Experimental|A1|Antiretroviral therapy followed by discontinuation at Week 12.
89177096|NCT00705926|Experimental|A2|Antiretroviral therapy followed by discontinuation at Week 32.
89177097|NCT00705926|Placebo Comparator|B|No treatment.
89356198|NCT03344302|Experimental|study group|100 women were assigned to receive an intravenous infusion of oxytocin 30 units in a rate 125 mL/hour minutes diluted into 500 mL of normal 0.9% sodium chloride) immediately after opening the visceral peritoneum just before incising the uterine wall during Cesarean section
89356199|NCT03344302|Active Comparator|Control group|100 women were assigned to an intravenous infusion of oxytocin 30 units in a rate 125 mL/hour diluted into 500 mL of normal 0.9% sodium chloride) immediately after clamping the umbilical cord during cesarean section
89356200|NCT02502292|Experimental|Intervention: Fotonovela|The Photo Novel Intervention is presented to users of four different facilities (sports clubs, senior homes) who are older than 50 years. The researchers welcome scheduled eligible participants, introduce the study and ask them for their consent. Afterwards, the participants are asked to fill in the questionnaire. Then, participants are randomized to one of the four groups and are presented with the photo novel or traditional brochure either as a hard copy brochure or as pdf on a tablet computer (2x2 group design). They are instructed to read the material in their own pace and answer the accompanying questions after each story / tip.and the accompanying questionnaire.
89177098|NCT05755724|Experimental|Remote immersive virtual reality group (3D) teaching|Telesimulation using immersive VR technology. Briefly, students will have a 360° camera mounted to their head, which will broadcast their first-person perspective to their teachers. Teachers will be able to immerse themselves in the perspective of the trainee using a virtual reality HMD (Oculus Quest 2), which allows them to look around freely and view equipment, hand movements, etc. and offer instruction accordingly.
89356201|NCT03545503|Active Comparator|Etomidate|Etomidate will be dosed once at a standard of 0.3 mg/kg via IV Push
89177099|NCT05755724|Placebo Comparator|Remote 2 D teaching|Telesimulation using standard teleconferencing software and equipment including 2D computer monitors, webcams, and an ultrasound machine linked to a computer (enabling ultrasound images to be transmitted).
89356202|NCT03545503|Active Comparator|Ketamine|Ketamine will be dosed once at a standard 2 mg/kg via IV Push
89000133|NCT01930357|Experimental|VRVg Group|Participants will receive receive 3 vaccinations of Purified Vero Rabies Vaccine Serum Free (VRVg)
89356203|NCT01297829|Active Comparator|IV Caldolor|
89356204|NCT01297829|Placebo Comparator|Placebo|
89356205|NCT05685992||Infertile couples infected or not infected with COVID-19|Infertile couples infected or not infected with COVID-19 were included.This is an observational study with no interventions.
89356206|NCT04496440||Trial Group|Contracture correction therapy
89356207|NCT04496440||Control Group|No new intervention, patients continued with the previous treatment.
89356208|NCT03829943||Vitamin D deficiency|The study group will be males discovered to have Vitamin D deficiency.
88824704|NCT01810952|Experimental|Glargine/Lispro Insulin Arm|"Drug: Glargine insulin was administered per above.~Drug: Lispro insulin 0.2 unit/kg/day was administered per above. A coverage dose of 0.1 unit/kg/day of lispro for each 10 mg of prednisone or its equivalent was divided between 3 meals. The maximum starting coverage dose was 0.4 units/kg per day.~The prandial dose of lispro was increased by 10% if the pre-lunch, pre-dinner, or bedtime SG was between 141-200 mg/dL, and by 20% if the pre-lunch, pre-dinner or bedtime SG is >200 mg/dL. The prandial dose of lispro was decreased by 10% if the pre-lunch, pre-dinner, or bedtime SG is between 70-89 mg/dL, and by 20% if the pre-lunch, pre-dinner or bedtime SG was less than 70 mg/dL.~Drug: prednisone or equivalent dose was determined by severity of exacerbation and clinician's judgement."
89000134|NCT01930357|Active Comparator|Imovax® Rabies Group|Participants will receive receive 3 vaccinations of Human Diploid Cell Vaccine (HDCV), Imovax® Rabies
89000135|NCT01913158|Placebo Comparator|Placebo suppository|Hydrogenated palm kernel oil suppositories
89000136|NCT01913158|Active Comparator|Anucort-HC, 25 Mg Rectal Suppository|Hydrocortisone Acetate suppositories
89000137|NCT01908595|Experimental|M518101|Proper quantity twice daily
89000138|NCT01903954|Active Comparator|Active Comparator|Pplacebo in combination with standard of care Pegasys (peginterferon alfa-2a) and Copegus (ribavirin)
89000139|NCT01903954|Experimental|Setrobuvir|Setrobuvir (800 mg orally b.i.d loading dose followed by 200 mg orally .b.i.d.) in combination with standard of care Pegasys (peginterferon alfa-2a) and Copegus (ribavirin)
89000140|NCT01893190|Active Comparator|Nimodipine|Nimodipine 60mg q4h for 21 days - oral
89000141|NCT01893190|Experimental|Nimodipine Microparticles|Single intraventricular injection
89000142|NCT01887886|Experimental|Onartuzumab + Erlotinib|
89000143|NCT01887886|Active Comparator|Placebo + Erlotinib|
89000144|NCT01885156|Placebo Comparator|Placebo Cream|Topically applied once daily
89000145|NCT01885156|Experimental|Naftin 1% Cream|Topically applied once daily
89000146|NCT01882699|Experimental|Cereve sleep system|Cereve sleep system
89000147|NCT01877395|Experimental|Purified Vero Rabies Vaccine Group|Participants will receive the Purified Vero Rabies Vaccine (VRVg)
89000148|NCT01877395|Experimental|Imovax® Rabies Vaccine Group|Participants will receive the Imovax® Rabies vaccine
89000149|NCT01874938|Experimental|LY2875358|LY2875358 will be administered intravenously (IV) at 2000 milligram (mg) bi-weekly in 28 day Cycle.
88824705|NCT01810952|Experimental|Glargine/Lispro/NPH Insulin Arm|"Drugs Glargine and Lispro insulin included similar starting doses of glargine and lispro.~Drug: A coverage dose of NPH insulin 0.1 unit/kg/day for each 10 mg of prednisone or its equivalent was given twice daily with the administration of the glucocorticoid. Maximum starting coverage dose was 0.4 units/kg per day. NPH dose was increased by 10% if the pre-lunch, pre-dinner, or bedtime SG is between 141-200 mg/dL, and by 20% if the pre-lunch, pre-dinner or bedtime SG was greater than 200 mg/dL. It was decreased by 10% if the pre-lunch, pre-dinner, or bedtime SG was between 70-89 mg/dL, and by 20% if the pre-lunch, pre-dinner or bedtime SG was less than 70 mg/dL.~Drug: the dose of prednisone or equivalent glucocorticoid was determined by severity of exacerbation and clinician's judgement."
88824706|NCT02867033|Other|Study procedure|Tumor biobank realization (biopsy...) and biobank constitution. coloscopy associated with colonic chromoscopy. Blood sampling (facultative). Pain evaluation
88824707|NCT04059887|Experimental|Atezolizumab|Atezolizumab 1200 mg will be administrated every 3 week cycle
89356209|NCT03829943||Control group|The control group will be males with normal Vitamin D status
89356210|NCT03545113|Experimental|Upper extremity arteriovenous graft (AVG) - first|Participants randomized to receive an AVG will undergo surgery to have an AVG placed.
88824708|NCT04025411|Experimental|Experimental group|Patient with stroke ischemic or hemorrhagic will be included. They will have visual motor simulation with the Intensive Visual Simulation 3 (IVS3) device and electroencephalography (EEG).
88824709|NCT04025411|Active Comparator|Control group|Patient with stroke ischemic or hemorrhagic will be included. They will have simulation with the traditional Mirror Therapy (TM) and electroencephalography (EEG).
88824710|NCT01877642|Other|Open Label (lorazepam 1 mg + Inhaled loxapine 10 mg)|Inhaled Staccato loxapine 10 mg + IM lorazepam 1 mg to confirm tolerability of combined treatment
89356211|NCT03545113|Active Comparator|Upper extremity arteriovenous fistula (AVF) - first|Participants randomized to receive an AVF will undergo surgery to have an AVF created.
88824711|NCT01877642|Other|Treatment Sequence ABC|Treatment: A = Lorazepam 1 mg IM + inhaled placebo, B = Lorazepam 1 mg IM + inhaled loxapine 10 mg, C= Placebo IM + inhaled loxapine 10 mg
88824712|NCT01877642|Other|Treatment Sequence ACB|Treatment: A = Lorazepam 1 mg IM + inhaled placebo, B = Lorazepam 1 mg IM + inhaled loxapine 10 mg, C= Placebo IM + inhaled loxapine 10 mg
89356212|NCT02508142|Active Comparator|Hyoscine-N-Butylbromide|20 mg Hyoscine-N-Butylbromide in 98 mL normal saline (totally 100 mL)
88824713|NCT01877642|Other|Treatment Sequence BCA|Treatment: A = Lorazepam 1 mg IM + inhaled placebo, B = Lorazepam 1 mg IM + inhaled loxapine 10 mg, C= Placebo IM + inhaled loxapine 10 mg
88824714|NCT01877642|Other|Treatment Sequence BAC|Treatment: A = Lorazepam 1 mg IM + inhaled placebo, B = Lorazepam 1 mg IM + inhaled loxapine 10 mg, C= Placebo IM + inhaled loxapine 10 mg
88824715|NCT01877642|Other|Treatment Sequence CAB|Treatment: A = Lorazepam 1 mg IM + inhaled placebo, B = Lorazepam 1 mg IM + inhaled loxapine 10 mg, C= Placebo IM + inhaled loxapine 10 mg
88824716|NCT01877642|Other|Treatment Sequence CBA|Treatment: A = Lorazepam 1 mg IM + inhaled placebo, B = Lorazepam 1 mg IM + inhaled loxapine 10 mg, C= Placebo IM + inhaled loxapine 10 mg
88824717|NCT01811030|Experimental|755nm Alexandrite Laser|755nm Alexandrite Laser
88824718|NCT02810951|Experimental|FCX-007|"In Phase I, a target of three adult subjects will be enrolled into Group A and a target of three adult subjects will be enrolled into Group B.~In Phase II the study will target enrolling subjects (aged seven (7 years or older) to each arm, but will allow a disproportionate distribution of subjects between Group A and Group B to equal approximately 6 total subjects.~All subjects will receive FCX-007 into one or more paired target wounds as well as to intact skin at least one time during the study with a possible second administration pending laboratory results.~One wound in each target wound pair will be used as control for efficacy and safety evaluations."
88824719|NCT01878656|Active Comparator|Sevoflurane|administration of sevoflurane with oxygen and nitrous oxide as same ratio of 3 L/min for maintenance of general anesthesia
88824720|NCT01878656|Active Comparator|Desflurane|administration of desflurane with oxygen and nitrous oxide as same ratio of 3 L/min for maintenance of general anesthesia
88824721|NCT04015895||Patient with cancer|Patient with cancer will be included. They will have to answer at DEFCO tool.
88824722|NCT01811654|No Intervention|Standard Care|Patients in this group will receive treatment per standard care. Standard Care is defined as consisting of physical therapy, activity modification (relative rest), and/or oral analgesic therapy. A specific physical therapy (PT) protocol will be implemented.
88824723|NCT01811654|Active Comparator|Intra-Articular Hyaluronic Acid-Euflexxa|Patients assigned to this group will receive treatment per standard care AND three (3) consecutive weekly injections of intra-articular hyaluronan (Euflexxa). Oral analgesics will be used at the lowest dose and for the shortest time possible to treat PFPS symptoms.
88824724|NCT04012697|Experimental|Peer Support|Peer support services from a peer support worker in the emergency department.
88824725|NCT04012697|No Intervention|Usual care|Usual care in the emergency department.
88824726|NCT01794806|Experimental|Tooth extraction and grafting|Tooth extraction and grafting with allograft
88824727|NCT01794806|Sham Comparator|Tooth extraction|Tooth extraction
88824728|NCT03983603|Experimental|Plant stanol group|This arm receives soft chews containing 0.5g of plant stanols (delivered as plant stanol esters).
88824729|NCT03983603|Placebo Comparator|Placebo group|This arm receives soft chews that do not contain 0.5g of plant stanols (delivered as plant stanol esters).
88824730|NCT03496701|Experimental|Stenfilcon A / Test lens|All subjects will first wear stenfilcon A contact lenses for one week, then refitted with test contact lenses to wear for one week.
88824731|NCT02266472|Experimental|Fixed dose combination|Single dose empagliflozin/metformin
88824732|NCT02266472|Active Comparator|Single tablets combination|single doses empagliflozin and metformin
88824733|NCT02756507|Experimental|video-based transdiagnostic REBT|Children and adolescents in the experimental group attend 6 modules of video-based transdiagnostic rational emotive behavioral therapy (REBT). Each of the six modules aimes a different component: Psychoeducation, Relaxation, Relationship between cognitive distortions/irrational beliefs and emotions, Cognitive restructuring, Exposure/ behavior activation and problem solving, Maintenance of gaining.
88824734|NCT02756507|Sham Comparator|wait list|The wait-list is a delayed treatment condition.
88824735|NCT02738411||The study population|The study population corresponds to infants born at less than 33 weeks of gestation.
88824736|NCT03500289|Experimental|Ketamine|
89356213|NCT02508142|Placebo Comparator|Placebo|100 mL normal saline
89356214|NCT02508220|Other|Oxy-Placebo|Syntocinon first, Placebo second 2 puffs in each nostril
89356215|NCT02508220|Other|Placebo-Oxy|Placebo first, Syntocinon second 2 puffs in each nostril
88824737|NCT03500289|Placebo Comparator|Midazolam|
88824738|NCT01812044|Other|subtenons anesthetic and topical control|Group 1 (subtenons anesthetic and topical control): 0.5 cc of local anesthetic (preservative-free bupivacaine 0.75%) administered via a cannula subtenons through each surgical wound with 0.5 cc of Hypromellose 0.3% gel applied topically to each surgical wound at end of surgery
89000150|NCT01874626|Active Comparator|Active|SST-0225 Topical Ibuprofen Cream (investigational product) Dose: 2.7 grams of cream containing 200 mg ibuprofen
89000151|NCT01874626|Placebo Comparator|Placebo|Placebo topical formulation (Reference product)
89356216|NCT01297907||Crohn's Patients|Random Crohn's Disease Patients that can perform Methacholine Challenge Test (MCT)
89356217|NCT01297907||Negative MCT|Patients evaluated for functional cough who had negative Methacholine Challenge Test (MCT)
88824739|NCT01812044|Other|topical anesthetic and subtenons control|Group 2 (topical anesthetic and subtenons control): 0.5 cc of lidocaine 3.5% ophthalmic gel applied topically to each surgical wound and 0.5 cc of normal saline (NS) administered via a cannula subtenons through each surgical wound at end of surgery
88824740|NCT01812044|Other|topical control and subtenons control|Group 3 (topical control and subtenons control): 0.5 cc of topical Hypromellose 0.3% gel applied topically to each surgical wound and 0.5 cc of NS administered via a cannula subtenons through each surgical wound at end of surgery
88824741|NCT03331185|Active Comparator|Freeze Dried Bone Allograft|Socket filled with Mineralized Cortical Freeze Dried Bone Allograft
88824742|NCT03331185|Experimental|L-PRF Clot|Socket filled with L-PRF Clot
89356218|NCT02508064|Experimental|Part 1|BMS-663068 1 × 600 mg extended-release (ER) tablet formulation
89533658|NCT03871257|Active Comparator|Arm I (carboplatin, vincristine)|"INDUCTION: Patients receive carboplatin IV over 60 minutes on days 1, 8, 15, 22, 43, 50, 57, and 64 and vincristine IV or IV push over 1 minute on days 1, 8, 15, 22, 29, 36, 43, 50, 57, and 64 in the absence of disease progression or unacceptable toxicity. Patients also undergo MRI during screening and on study.~MAINTENANCE: Patients receive carboplatin IV over 60 minutes on days 1, 8, 15, and 22 and vincristine IV or IV push over 1 minute on days 1, 8, and 15. Treatment repeats every 6 weeks for 8 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo MRI on study and during follow-up."
88824743|NCT03974789||Suspected Cushing Disease|
88824744|NCT01812668|Experimental|Treatment (cabozantinib-s-malate)|Patients receive cabozantinib-s-malate PO daily in the absence of disease progression or unacceptable toxicity.
89000152|NCT01873534|Experimental|FMX-8 (0.5 mg/kg)|0.5 mg/kg FMX-8 IV twice per week for 29 days (9 doses)
89356219|NCT02508064|Experimental|Part 1: Prototype 1|BMS-663068 600 mg ER low-dose tablet formulation (Prototype 1)
89356220|NCT02508064|Experimental|Part 1: Prototype 2|BMS-663068 600 mg ER low-dose tablet formulation (Prototype 2)
89356221|NCT02508064|Experimental|Part 1: Prototype 3|BMS-663068 600 mg ER low-dose tablet formulation (Prototype 3)
89356222|NCT02508064|Experimental|Part 1: Prototype 4|BMS-663068 600 mg ER low-dose tablet formulation (Prototype 4)
89356223|NCT02508064|Experimental|Part 1: Prototype 5|BMS-663068 600 mg ER low-dose tablet formulation (Prototype 5)
89356224|NCT02508064|Experimental|Part 2|BMS-663068 1 × 600 mg ER tablet formulation
89356225|NCT02508064|Experimental|Part 2: Prototype 1|BMS-663068 600 mg ER prototype multi-particulate formulation (Prototype 1)
89533659|NCT03871257|Experimental|Arm II (selumetinib sulfate)|Patients receive selumetinib sulfate PO BID on days 1-28. Treatment is continuous and repeats every 28 days for 27 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo MRI throughout the trial.
88824745|NCT02570477|Active Comparator|Fecal Microbiota Transplantatio|Fecal Microbiota Transplantation of stool from healthy donor to recipient.
88824746|NCT02570477|Active Comparator|Standard Therapy|125mg Vancomycin four times per day
88824747|NCT04344821|Placebo Comparator|Control|No diet or exercise intervention
89356226|NCT02508064|Experimental|Part 2: Prototype 2|BMS-663068 600 mg ER prototype multi-particulate formulation (Prototype 2)
89356227|NCT02508064|Experimental|Part 2: Prototype 3|BMS-663068 600 mg ER prototype multi-particulate formulation (Prototype 3)
89356228|NCT02508064|Experimental|Part 2: Prototype 4|BMS-663068 600 mg ER prototype multi-particulate formulation (Prototype 4)
89533660|NCT03867448||Adults with Endocrine Disorder|Adults referred to NIH with possible endocrine conditions
88824748|NCT04344821|Experimental|No Diet plus Exercise|No diet, exercise only intervention
88824749|NCT04344821|Experimental|High Protein Diet plus Exercise|High protein diet and exercise intervention
88824750|NCT04344821|Experimental|High Carbohydrate Diet plus Exercise|High carbohydrate diet and exercise intervention
88824751|NCT01878812|Experimental|Fluarix/Influsplit Tetra® Adult Group|Subjects 18-60 years of age receiving Fluarix/Influsplit Tetra® 2013-2014, administered intramuscularly in the deltoid region of the non-dominant arm.
88824752|NCT01878812|Experimental|Fluarix/Influsplit Tetra® Elderly Group|Subjects >60 years of age receiving Fluarix/Influsplit Tetra® 2013-2014, administered intramuscularly in the deltoid region of the non-dominant arm.
88824753|NCT04351100||Diacerein group|Osteoarthritis and dry eye patients treated with Diacerein
88824754|NCT02310906|Experimental|Part 1: SRP-4053|Patients will receive SRP-4053 (golodirsen) intravenous (IV) infusions, weekly, at escalating dose levels as follows: Weeks 1-2, 4 mg/kg/week; Weeks 3-4, 10 mg/kg/week; Weeks 5-6, 20 mg/kg/week; Weeks 7-12, 30 mg/kg/week. Dosing will be interrupted or halted if specific predefined stopping criteria are met or if warranted at the discretion of the Sponsor or Investigator.
88824755|NCT02310906|Placebo Comparator|Part 1: Placebo|Patients will receive SRP-4053 placebo-matching IV infusions, weekly, for 12 weeks. Dosing will be interrupted or halted if specific predefined stopping criteria are met or if warranted at the discretion of the Sponsor or Investigator.
88824756|NCT02310906|Experimental|Part 2: SRP-4053|All eligible patients from Part 1, as well as new patients, will receive SRP-4053 (golodirsen) 30 mg/kg/week IV infusions, weekly, for up to 168 weeks.
88824757|NCT02310906|No Intervention|Part 2: Untreated Group|Patients with DMD who have a genotypically confirmed deletion of exon(s) not amenable to treatment by exon 53 skipping, but who otherwise meet the same eligibility criteria as treated patients newly recruited to Part 2, will undergo the same study assessments as treated Patients (except for pharmacokinetic [PK] sampling and muscle biopsies), but at a reduced schedule through Week 144. The untreated patients are not considered as control group.
89356229|NCT05705570|Experimental|Cyclophosphamide + Fludarabine + Infusion of CAR-T Cells|Lymphodepleting regimen, consisting of Cyclophosphamide 60mg/kg IV on day -6 and Fludarabine 25mg/m2 IV on days -5 to -3. Followed by infusion of Chimeric antigen receptor T-cells (CAR-T) on day 0
88824758|NCT02978963|Experimental|Cognitive Behavioral Therapy|All participants will receive cognitive behavioral therapy for excessive worry. Focus in treatment will be on reducing participants' intolerance uncertainty through in vivo and imaginary exposure to uncertainty inducing situations and thoughts. Treatment will also contain psycho education about anxiety and worry, as well as planning for maintenance of treatment gains. Parents of the participants will receive support and education about worry through an internet-delivered program.
88824759|NCT01796912|Active Comparator|First Lipoprotein Apheresis, then sham apheresis|Three months of weekly lipoprotein apheresis, 1 month washout, then three month sham apheresis
89356230|NCT01203527||Tamiflu use during first trimester|This group will consist of twenty-five pregnant women who are being treated with Oseltamivir for clinical indications during the first trimester of their pregnancy.
89356231|NCT01203527||Tamiflu use during second trimester|This group will consist of twenty-five pregnant women who are being treated with Oseltamivir for clinical indications during the second trimester of their pregnancy.
89356232|NCT01203527||Tamiflu use during third trimester|This group will consist of twenty-five pregnant women who are being treated with Oseltamivir for clinical indications during the first trimester of their pregnancy.
89356233|NCT01203527||Tamiflu use in non-pregnant women|This group will consist of twenty-five non-pregnant healthy female volunteers who are being treated with Oseltamivir.
89356234|NCT01206023||Multiple Sclerosis|Multiple Sclerosis patients
89356235|NCT01206023||Healthy controls|healthy individuals
88824760|NCT01796912|Sham Comparator|First Sham Apheresis, then Lipoprotein Apheresis|Three months of weekly sham apheresis, 1 month washout, then three month lipoprotein Apheresis
88824761|NCT04345133|Active Comparator|Undersized Drilling Group|Exposed patients to the reduction of the final drill dimensions at the insertion implants protocol sequence
88824762|NCT04345133|Other|Conventional Drilling Group|Group with the conventional protocol recommended by the manufacturer
88824763|NCT05328674|Active Comparator|Microfracture method|
88824764|NCT05328674|Experimental|Method of autogenous PRP (Auto Cart-Arthrex) cartilage transplant|
88824765|NCT01798316|Active Comparator|IV Acetaminophen|IV Acetaminophen administered on admission to post-anesthesia care unit
88824766|NCT01798316|Active Comparator|Standard of care|Standard of care pain management regimen including opioids administered on admission to post-anesthesia care unit
89177100|NCT05087576|Experimental|Expressive Helping writing|During the first writing session, participants will be informed that people benefit from learning about other cancer caregivers' experiences, and that the first three sessions will consist of writing exercises designed to help them think about their cancer caregiving experiences and to prepare them for writing a helpful letter to other Chinese cancer caregivers during the fourth and final writing session.
89177101|NCT05087576|Active Comparator|Caregiving Facts writing|During each week, participants in the control group will be asked to write facts about their experience with cancer caregiving (e.g., type of treatment their loved one is receiving) and will be asked to avoid writing about their emotions. Participants in this group will be told that their writing will not be shared with others outside of the research team.
89177102|NCT00787917|Experimental|Omalizumab|"Eligible participants received a maximum dose of 600 mg omalizumab via subcutaneous injection for 6 months in the double-blind phase of the study. The study medication was to be administered at the same time of day. Study medication was injected subcutaneously into the upper arm in the area of the deltoid or to the thigh. A maximum 600 mg dose required 4 injections. All participants who entered the study received itraconazole twice daily, while receiving oral corticosteroids, with a maximum daily dose of 400 mg.~Participants who completed double-blinded phase, entered open-label treatment period of 6 months and continued the same regimen of omalizumab of double-blinded phase."
89177103|NCT00787917|Placebo Comparator|Placebo|Eligible participants received placebo comparator via subcutaneous injection for 6 months in the double-blind phase of the study. The study medication was to be administered at the same time of day. Study medication was injected subcutaneously into the upper arm in the area of the deltoid or to the thigh. All participants who entered the study received itraconazole twice daily, while on oral corticosteroids, with a maximum daily dose of 400 mg.
89177104|NCT04106271|Experimental|Experimental group|dyadic pain management program will be accessible by the intervention group
89177105|NCT04106271|No Intervention|Control group|No intervention for the control group, only one-page simple material related to pain will be provided.
89177106|NCT05758064|Active Comparator|Oral dydrogesterone|60 patients in HRT frozen embryo transfer with low serum progesterone less than 10 ng/ml 24 hours before the embryo transfer will be given oral 10 mg dydrogesterone (Duphaston®, Abbott) twice daily
89177107|NCT05758064|Active Comparator|subcutaneous progesterone|60 patients in HRT frozen embryo transfer with low serum progesterone less than 10 ng/ml 24 hours before the embryo transfer will be subcutaneous injection 25mg daily (Prolutex®, IBSA).
89177108|NCT00814892|Experimental|DC-APCC|Patients undergo standard leukapheresis to harvest peripheral blood mononuclear cells for dendritic cell vaccine preparation. Patients receive the APCC vaccine and autologous dendritic cells derived from CD14-positive myeloid peripheral blood cells ID on days 0, 14, and 28 and then every 28 days for up to 14 courses in the absence of disease progression or unacceptable toxicity.
89177109|NCT00787839||Group 1|Atlanta VA Medical Center patients who meet criteria for screening for prediabetes and early diabetes based on standard guidelines of the VA, the American Diabetes Association, and the National Institutes of Health
89177110|NCT02610764|Experimental|Experimental diagnostic test|"Evaluation and enumeration of circulating Tumor cells from the blood with two different CTC-detection platforms: one established test (CellSearch) and one experimental test (ScreenCell).~Control diagnostic test: CT-Scan of the Chest and the Abdomen, Endoscopy and Endosonography, Clinical response and histo pathologic response. (% Of vital tumor Cells in the histologic specimen)."
89177111|NCT04105647|Experimental|Experimental group|Patients in the experimental group will receive a face-to-face group session and a package of healthy lifestyle instant messages, including lifestyle-integrated exercise and physical activity.
89177112|NCT04105647|Placebo Comparator|Control group|The control group will receive a face-to-face group session and a package of healthy lifestyle instant messages, but not related to lifestyle-integrated exercise and physical activity.
89177113|NCT02602977|Experimental|multiple-dose RIPC|Multiple-dose Remote Ischemic Preconditioning. A group of 10 subjects that will receive 4 cycles of remote ischemic preconditioning of the upper limb per day in the 7 consecutive days before the endotoxemia experiment. The last dose will be applied 40 minutes before LPS administration.
89177114|NCT02602977|Experimental|single-dose RIPC|Single-dose Remote Ischemic Preconditioning. A group of 10 subjects that will receive a single RIPC dose, starting 40 minutes before LPS administration.
89177115|NCT02602977|Active Comparator|control group|Only LPS infusion. A group of 10 subjects that will be administered LPS without RIPC.
89177116|NCT00829244|Experimental|CONSORT Dosing|GONAL-f® dose based on subject baseline characteristics determined according to the CONSORT calculator
88824767|NCT03883763|Experimental|Hyperbaric Novabupi® 0.5% (bupivacaine S75:R25 + 8% glucose)|
88824768|NCT03883763|Active Comparator|Hyperbaric Neocaine® 0.5% (bupivacaine S50:R50 + 8% glucose)|
88824769|NCT02421731|Experimental|Robot-assisted gait training|This group will receive rehabilitation treatment based on robot-assisted gait training.
88824770|NCT02421731|Active Comparator|Conventional therapy|This group will receive conventional rehabilitation therapy.
88824771|NCT01798394|Active Comparator|Progesterone|Take micronized natural progesterone capsule by mouth, twice daily (approximately at 8 am and 8 pm) for four weeks beginning on postpartum day 4.
88824772|NCT01798394|Placebo Comparator|Placebo|Take placebo capsule by mouth, twice daily (approximately at 8 am and 8 pm) for 4 weeks beginning on postpartum day 4.
88824773|NCT02390297||Single|Collection of blood samples for general health (complete blood count) and Cal-1 specific analyses
88824774|NCT02340078|Active Comparator|HA IDF II|cross-linked HA filler
88824775|NCT02340078|Experimental|HA IDF II plus|cross-linked HA filler with lidocaine
88824776|NCT01798550|Experimental|Reduced Dose (0.8 mg/kg)|Enoxaparin 0.8 mg/kg (using total body weight) twice daily
88824777|NCT01798550|Active Comparator|Standard Dose (1 mg/kg)|Enoxaparin 1 mg/kg (using total body weight) twice daily
88824778|NCT00357305|Experimental|Treatment (enzyme inhibitor, chemotherapy)|Patients receive oral SAHA two or three times daily on days 1-7 and cytarabine IV over 3 hours twice daily and etoposide IV over 1 hour once daily on days 11-14. Treatment repeats approximately every 6-7 weeks for up to 3 courses in the absence of disease progression or unacceptable toxicity.
88824779|NCT03833414||(Group1)|Triceps lifting approach .
88824780|NCT03833414||(Group 2)|olecranon osteotomy approach
88824781|NCT02340000|Active Comparator|standard dose|amoxicillin/clavulanate 875/125 mg + placebo tablet twice a day for 7 days
88824782|NCT02340000|Experimental|high dose|Time Period I (November 18, 2014-January 5, 2016): extended-release amoxicillin/clavulanate 1000/62.5 mg 2 tablets (by different manufacturer) twice a day for 7 days Time Period 2 (February 6, 2016-February 27, 2017): immediate-release amoxicillin/clavunate 875/125 mg plus standard immediate-release amoxicillin 875 mg twice a day for 7 days
88824783|NCT01800890|Other|Treatment sequence 1|"Subjects randomised to Treatment sequence 1 will test three different products:~Coloplast A~Coloplast B~SenSura Click~The subjects test the three test products in a randomized order: ABS; BSA, SAB"
88824784|NCT01800890|Experimental|Treatment sequence 2|"Subjects randomised to Treatment sequence 2 will test three different products:~Coloplast C (C)~Coloplast B (B)~SenSura Click (S)~The subjects test the three test products in a randomized order: CBS; BSC, SCB"
88824785|NCT01800890|Experimental|Treatment sequence 3|"Subjects randomised to Treatment sequence 3 will test three different products:~Coloplast A (A)~Coloplast C (C)~SenSura Click (S)~The subjects test the three test products in a randomized order: ACS; CSA, SAC"
88824786|NCT02364180|Other|Electromyography|Subjects taking pyridostigmine bromide for more than 6 weeks for a condition other than myasthenia gravis were observed with Electromyography (EMG)
88824787|NCT01813214|Experimental|Vemurafenib Monotherapy|Vemurafenib 960 mg po BID until unacceptable toxicity or progression of disease
88824788|NCT01813214|Experimental|Vemurafenib + Cobimetinib Combination Therapy|"Vemurafenib 960 mg po BID until unacceptable toxicity or progression of disease~Cobimetinib will be given 60mg QD for 21 days on, then 7 days off, in a 28-day treatment cycle."
88824789|NCT01814774||BOTOX®|Retrospective chart review of doses of BOTOX® (onabotulinumtoxinA) used as standard of care in clinical practice. No treatment (intervention) was administered.
88824790|NCT01814774||Xeomin®|Retrospective chart review of doses of Xeomin® (incobotulinumtoxinA) used as standard of care in clinical practice. No treatment (intervention) was administered.
88824791|NCT01815008|Experimental|Clopidogrel|Clopidogrel 75 mg daily by mouth for 1 week then Clopidogrel 75 mg daily with aspirin 81 mg daily
88824792|NCT01818518||Preterm Labor|Group who goes into labor prior to 32 weeks of gestation
88824793|NCT01818518||Prelabor rupture of membranes|Group who have prelabor rupture of membranes are those who break their bag of water prior to 32 weeks gestation in the absence of labor.
88824794|NCT01818518||Premature birth before 32 weeks gestation|Premature birth before 32 weeks gestation not including PTL or PROM
88824795|NCT01801124|Experimental|EXPAREL|undiluted EXPAREL 266 mg
88824796|NCT05328596|Experimental|CBT treatment|The CBT-treatment arm includes a review of the patient´s social conditions and overall health. It also includes manual based Cognitive Behavioural Treatment (CBT) in 10 individual sessions.
88824797|NCT05328596|Active Comparator|Wait list control|The control treatment includes a review of the patient´s social conditions, overall health and psychoeducation.
88824798|NCT03501069|Experimental|Non-Japanese Cohort 1: TAK-418 120 mg and TAK-418 160 mg|TAK-418 120 milligram (mg) or TAK-418 matching placebo, capsule, orally, once on Day 1 of Period A followed by a minimum of 14 days of washout period, followed by TAK-418 160 mg or TAK-418 matching placebo, capsule, orally, once on Day 1 of Period B. The actual TAK-418 dose for Period B will be determined based on safety, tolerability, and PK data available from the previous dose in Period A.
88824799|NCT03501069|Experimental|Non-Japanese Cohort 2: TAK-418 20 mg|TAK-418 20 mg or TAK-418 matching placebo, capsule, orally, once daily for 10 days.
88824800|NCT03501069|Experimental|Non-Japanese Cohort 3: TAK-418 40 mg|TAK-418 40 mg or TAK-418 matching placebo, capsule, orally, once daily for 10 days. The actual TAK-418 dose for Cohort 3 will be determined based on safety, tolerability, and PK data available from the previous doses.
88824801|NCT03501069|Experimental|Non-Japanese Cohort 4: TAK-418 60 mg|TAK-418 60 mg or TAK-418 matching placebo, capsule, orally, once daily for 10 days. The actual TAK-418 dose for Cohort 4 will be determined based on safety, tolerability, and PK data available from the previous doses.
88824802|NCT03501069|Experimental|Japanese Cohort 5: TAK-418 20 mg|TAK-418 20 mg or TAK-418 matching placebo, capsule, orally, once daily for 10 days. The actual TAK-418 dose for Cohort 5 will be determined based on safety, tolerability, and PK data available from the previous doses.
88824803|NCT03501069|Experimental|Japanese Cohort 6: TAK-418 40 mg|TAK-418 40 mg or TAK-418 matching placebo, capsule, orally, once daily for 10 days. The actual TAK-418 dose for Cohort 6 will be determined based on safety, tolerability, and PK data available from the previous doses.
88824804|NCT01819844|Experimental|Closed-loop blood glucose control|Type 1 diabetes, Type 2 diabetes, total daily dose (TDD) of insulin that is > 1 u/kg or > 2 u/kg.
88824805|NCT01819922|Experimental|PF-05175157|
88824806|NCT01819922|Placebo Comparator|Placebo|
89000153|NCT01873534|Experimental|FMX-8 (5 mg/kg)|5 mg/kg FMX-8 IV twice per week for 29 days (9 doses)
89000154|NCT01873534|Experimental|FMX-8 (15 mg/kg)|15 mg/kg FMX-8 IV twice per week for 29 days (9 doses)
89000155|NCT01871428|Experimental|Aleglitazar|
88824807|NCT03331965|Experimental|Metoclopramide|A one-time dose of promotility agent (2 mL of Metoclopramide 5 MG/ML Injectable Solution in 8 mL saline IV) will be administered at the time of GJ placement. After administration of the pro-motility drug, the GJ placement procedure will be performed using conventional technique. An IR technologist observing the procedure will record the fluoroscopy time, air kerma, and chronological time will be recorded by an IR technologist at the following routine events during GJ tube placement procedures: 1) start of gastric insufflation, 2) needle access to the stomach, 3) wire intubation of the duodenum, 4) wire intubation of the jejunum, 5) and procedure completion.
88824808|NCT03331965|Placebo Comparator|Saline|A one-time dose of a placebo (10 mL saline IV) will be administered at the time of GJ placement. After administration of the placebo, the GJ placement procedure will be performed using conventional technique. An IR technologist observing the procedure will record the fluoroscopy time, air kerma, and chronological time will be recorded by an IR technologist at the following routine events during GJ tube placement procedures: 1) start of gastric insufflation, 2) needle access to the stomach, 3) wire intubation of the duodenum, 4) wire intubation of the jejunum, 5) and procedure completion.
89356236|NCT02502448|No Intervention|Control group|patients undergoing cardiac surgery supposed not to get aucte normovolemic hemodilution (ANH) before CPB
89356237|NCT02502448|Active Comparator|Acute normovolemic hemodilution group|patients undergoing cardiac surgery supposed to get aucte normovolemic hemodilution (ANH) before CPB
89356238|NCT03839615|Active Comparator|guided bone regeneration using ptfe|"Augmented anterior maxillary bone ridge using ptfe with 1:1 autogenous bone and xenograft mixture~Patients of both groups will be subjected to CBCT (diagnostic for upper arch).~Intra operative procedures (for both groups) followed by CBCT will be taken for every patient.~Local anesthesia will be given to the patient.~Scrubbing and draping of the patient will be carried out in a standard fashion for intra oral procedures.~intervention:~Flap will be done.~In the group: bone decortication will be done using surgical round bur, autogenous bone will be harvested by trephine bur ,mixed 1:1 with anorganic bovine bone derived mineral mineral will be packed then covered at the defected area by a ptfe membrane which will be stabilized by tacks."
89356239|NCT03839615|Experimental|collagen membrane|"Local anesthesia will be given to the patient. intervention:~Flap will be done.~In the group: bone decortication will be done using surgical round bur, autogenous bone will be harvested by trephine bur ,mixed 1:1 with anorganic bovine bone derived mineral mineral will be packed then covered at the defected area by a native collagen membrane which will be stabilized by tacks."
89356240|NCT02502370|Active Comparator|Group1 Arm A Observation|
89356241|NCT02502370|Experimental|Group 1 Arm B LV5FU2|
89356242|NCT02502370|Active Comparator|Group 2 Arm C LV5FU2|
89356243|NCT02502370|Experimental|Group 2 ARM D FOLFOX|
89356244|NCT03829709|Experimental|Intervention Group|The inspiratory muscle training (IMT) will be performed in the morning shift for 30 minutes, 3 times a week for 5 weeks. The first training session each week will be held at the LAERF under the direct supervision of the investigator and the other two home-based training sessions under the supervisor's distance supervision. They will receive the Threshold® IMT linear loading device, and guidelines for handling, posture and asepsis. The initial training load for each participant will be adjusted to 25% of PiMáx. Participants will be trained and instructed to do the exercise program on their own at home. Once a week, during the return to the laboratory the researcher will determine the new values for load (1st week 25%, 2nd week 35%, 3rd week 40%, 4th week 45%, 5th week 50%).
89356245|NCT02502136|Experimental|CO2 in sedated colonoscopy|Carbon dioxide insufflation during colonoscopy with sedation
89356246|NCT02502136|Placebo Comparator|Air in sedated colonoscopy|Room air insufflation during colonoscopy with sedation
89356247|NCT02502136|Experimental|CO2 in mild sedated colonoscopy|Carbon dioxide insufflation during colonoscopy with mild sedation
88824809|NCT05328362|Active Comparator|CanCope mindfulness|"The CanCope intervention was delivered through the MetricWire app which was available to each participant on their personal smartphone. The intervention included a push component which was responsive to a participant's level of craving (based on self-report assessed via EMA) and sent messages to each participant via the MetricWire app according to a decision rule. MetricWire randomized delivery of the push component with a probability of 0.33 for receiving a mindfulness coping strategy, 0.33 for receiving a distraction coping strategy, and 0.33 for receiving a thank-you message (attention control) at each decision point when participants were available for the intervention."
89356248|NCT02502136|Placebo Comparator|Air in deep sedated colonoscopy|Room air insufflation during colonoscopy with deep sedation
89356249|NCT02502136|Experimental|CO2 in sedated panendoscopy|Carbon dioxide insufflation during panendoscopy with sedation
89356250|NCT02502136|Placebo Comparator|Air in sedated panendoscopy|Room air insufflation during panendoscopy with sedation
88824810|NCT05328362|Active Comparator|CanCope distraction|"The CanCope intervention was delivered through the MetricWire app which was available to each participant on their personal smartphone. The intervention included a push component which was responsive to a participant's level of craving (based on self-report assessed via EMA) and sent messages to each participant via the MetricWire app according to a decision rule. MetricWire randomized delivery of the push component with a probability of 0.33 for receiving a mindfulness coping strategy, 0.33 for receiving a distraction coping strategy, and 0.33 for receiving a thank-you message (attention control) at each decision point when participants were available for the intervention."
89000156|NCT01871428|Placebo Comparator|Placebo|
89000157|NCT01870609|Active Comparator|defactinib (VS-6063)|2 x 200 mg defactinib (VS-6063) tablets, administered orally, twice daily
89000158|NCT01870609|Placebo Comparator|Placebo|2 placebo tablets, administered orally, twice daily
89000159|NCT01867762|Experimental|JNJ 49095397|
89000160|NCT01867762|Placebo Comparator|Placebo|
89000161|NCT01862224|Experimental|JNJ-38518168|JNJ-38518168 30 mg once daily for 52 weeks.
89356251|NCT02502136|Experimental|CO2 in mild sedated panendoscopy|Carbon dioxide insufflation during panendoscopy with mild sedation
89356252|NCT02502136|Placebo Comparator|Air in deep sedated panendoscopy|Room air insufflation during panendoscopy with deep sedation
89177117|NCT00829244|Active Comparator|Standard Dosing|GONAL-f® at a standard dose of 150 IU per day
89177118|NCT00787605|Active Comparator|Amlodipine|Amlodipine 5 mg for 1 week followed by Amlodipine 10 mg for 7 weeks
89356253|NCT01206179|Experimental|non union|Patients with nonunion fracture of long bones
89356254|NCT03214380|Experimental|LY900014|LY900014 given subcutaneously (SC) with each meal with either 100 U/mL (U-100) basal insulin glargine given SC once or twice daily or U-100 or 200 U/mL (U-200) insulin degludec given SC once daily. Prandial insulin doses were individualized and titrated according to protocol-defined targets.
89356255|NCT03214380|Active Comparator|Insulin Lispro (Humalog)|Insulin lispro given SC with each meal with either U-100 basal insulin glargine given SC once or twice daily or U-100 or U-200 insulin degludec given SC once daily. Prandial insulin doses were individualized and titrated according to protocol-defined targets.
89356256|NCT03214380|Experimental|LY900014 Maximum Extended Enrollment (MEE)|LY900014 given subcutaneously (SC) with each meal with either U-100 basal insulin glargine given SC once or twice daily or U-100 or U-200 insulin degludec given SC once daily. Prandial insulin doses were individualized and titrated according to protocol-defined targets.
88824811|NCT05328362|Placebo Comparator|CanCope attention control|"The CanCope intervention was delivered through the MetricWire app which was available to each participant on their personal smartphone. The intervention included a push component which was responsive to a participant's level of craving (based on self-report assessed via EMA) and sent messages to each participant via the MetricWire app according to a decision rule. MetricWire randomized delivery of the push component with a probability of 0.33 for receiving a mindfulness coping strategy, 0.33 for receiving a distraction coping strategy, and 0.33 for receiving a thank-you message (attention control) at each decision point when participants were available for the intervention."
88824812|NCT03278223|Active Comparator|Test solution|A Multi-purpose soft contact lens care solution containing polyaminopropyl biguanide, polyquaternium-2.
88824813|NCT03278223|Active Comparator|Control solution|A Multi-purpose soft contact lens care solution containing polyaminopropyl biguanide, polyquaternium-1.
88824814|NCT03279237|Experimental|FOLFIRINOX + pre-operative radiation|"FOLFIRINOX is a combination of 4 drugs that is administered twice per cycle~Oxaliplatin is administered intravenously~Leucovorin is administered intravenously~Irinotecan is administered intravenously~5-Fluorouracil is administered intravenously~Paclitaxel and Carboplatin will be given concurrently with radiation therapy every 7 days"
88824815|NCT03282591|Experimental|5 mg Serlopitant Tablets|Serlopitant Tablets
89356257|NCT03214380|Active Comparator|Insulin Lispro (Humalog) MEE|Insulin lispro given SC with each meal with either U-100 basal insulin glargine given SC once or twice daily or U-100 or U-200 insulin degludec given SC once daily. Prandial insulin doses were individualized and titrated according to protocol-defined targets.
89356258|NCT03344224||normal blood lipid/protein group|
88824816|NCT03282591|Placebo Comparator|Matching Placebo Tablets|Placebo Tablets
88824817|NCT03502941|Experimental|A single dose of EAAs/whey|Subjects will consume 6.3 g of EAAs/whey in ~12 oz water.
88824818|NCT03502941|Experimental|A double dose of EAAs/whey|Subjects will consume 12.6 g of EAAs/whey in ~12 oz water
88824819|NCT03502941|Experimental|Whey protein alone|Subjects will consume 12.6 g of whey protein isolate which is an equal amount to the double dose of EAAs/whey.
88824820|NCT03503565||Moderate block group|maintaining moderate intraoperative neuromuscular blockade (TOF count 1 or 2) during surgery and reversal using sugammadex 2 mg/kg after surgery
88824821|NCT03503565||Deep block group|maintaining deep intraoperative neuromuscular blockade (PTC 1 or 2) during surgery and reversal using sugammadex 4 mg/kg after surgery
88824822|NCT03506295|Other|Control|Standard of Care - Transbronchial cryobiopsies are obtained as a standard of care under fluoroscopy guidance
88824823|NCT03506295|Experimental|Intervention|In the intervention arm , radial ultrasound probe will be used in addition to standard of care described above to confirm adequate position of the cryoprobe before transbronchial cryobiopsy is obtained.
88824824|NCT03509883|Experimental|Apixaban sprinkle capsules followed by apixaban tablets|Apixaban (BMS-562247) sprinkle capsules followed by apixaban tablets
88824825|NCT03509883|Active Comparator|Apixaban tablets followed by apixaban sprinkle capsules|Apixaban (BMS-562247) tablets followed by apixaban sprinkle capsules
88824826|NCT03336645|Experimental|SHP615|Participants will receive a single age-specific dose (approximately 0.25 to 0.5 milligram per kilogram [mg/kg] as midazolam) of SHP615 oromucosal solution through buccal route upon onset of seizures.
88824827|NCT03510195|Experimental|MEDICORP HO PREPARATORY MODULE|The participants that will have intervention which is the module
88824828|NCT03511521|Experimental|NPH Insulin|"NPH will be given at the time of steroid administration to the patient in addition to standard basal/bolus insulin the patient may be receiving in the following doses:~Prednisone Dose (mg/day) - NPH dose (U=Units): 10-20 mg/day - 1.2U (units)/mg; 21-40 mg/day - 0.6U/mg; 41-60 mg/day - 0.45U/mg; 61-80 mg/day - 0.3U/mg; >80 mg/day - no additional NPH. Note that the amounts of NPH are added to each other for the various prednisone doses. For example, a dose of 75 mg/day of prednisone would come out to be (1.2U x 20mg = 24U) + (0.6U x 20mg = 12U) + (0.45U x 20mg = 9U) + 0.3U x 15 mg = 4.5U) for a total of 24 + 12 + 9 + 4.5 = 49.5U of NPH for 75 mg of prednisone."
88824829|NCT03511521|Active Comparator|Basal/Bolus Insulin|"Basal insulin (glargine) and Bolus insulin (insulin aspart) will be increased (doses given in U [units]/kg) according to the Prednisone dose (mg/day) as follows:~Prednisone Dose (mg/day) - doses of insulin (U/kg): Prednisone 0 mg - Glargine 0.25U/kg, Bkfst Aspart 0.08U/kg, Lunch Aspart 0.08U/kg, Dinner Aspart - 0.08U/kg; Prednisone 10-20 mg - Glargine 0.25U/kg, Bkfst Aspart 0.1U/kg, Lunch Aspart 0.15U/kg, Dinner Aspart - 0.2U/kg; Prednisone 21-40 mg - Glargine 0.25U/kg, Bkfst Aspart 0.1U/kg, Lunch Aspart 0.2U/kg, Dinner Aspart - 0.25U/kg; Prednisone 41-60 mg - Glargine 0.30U/kg, Bkfst Aspart 0.15U/kg, Lunch Aspart 0.25U/kg, Dinner Aspart - 0.30U/kg; Prednisone 61-80 mg - Glargine 0.30U/kg, Bkfst Aspart 0.15U/kg, Lunch Aspart 0.30U/kg, Dinner Aspart - 0.35U/kg; Prednisone >80 mg - Glargine 0.30U/kg, Bkfst Aspart 0.15U/kg, Lunch Aspart 0.35U/kg, Dinner Aspart - 0.40U/kg."
89000162|NCT01862224|Placebo Comparator|Placebo/JNJ-38518168|Matching placebo once daily for 12 weeks followed by JNJ-38518168 30 mg once daily for 40 weeks.
89177119|NCT00787605|Experimental|Aliskiren / HCTZ|Aliskiren / HCTZ 150/12.5 mg for 1 week followed by 300/25 mg for 7 weeks
89177120|NCT00448591|Experimental|1|
89356259|NCT03344224||abnormal blood lipid/protein group|
89356260|NCT01203605||In-patient adult non-cardiac surgery|Consecutive patients admitted to participating centres undergoing elective and non-elective non-cardiac surgery commencing during the seven day study period with a planned overnight stay. All eligible patients undergoing surgery within the seven day study period will be recruited wherever possible.
89356261|NCT03819179|Experimental|Serum|Burt's Bees Serum
89000163|NCT01861249|Experimental|SAR339658|SAR339658, every 2 weeks (Q2W) or every 4 weeks (Q4W) according to clinical response at Week 8 in the ACT12688 trial
89356262|NCT03819179|Experimental|Serum with Biulin|Burt's Bees Serum with Biulin
89000164|NCT01859962|Active Comparator|PPI-668, BI 207127 Dose 1, Faldaprevir, and Ribavirin|PPI-668, BI 207127 Dose 1, Faldaprevir, and Ribavirin dosed in combination
89000165|NCT01859962|Active Comparator|PPI-668, BI 207127 Dose 2, Faldaprevir, and Ribavirin|PPI-668, BI 207127 Dose 2, BI 207127 Placebo, Faldaprevir, and Ribavirin dosed in combination
89000166|NCT01859962|Active Comparator|PPI-668, BI 207127 Dose 1, and Faldaprevir|PPI-668, BI 207127 Dose 1, and Faldaprevir dosed in combination
89000167|NCT00198666|Experimental|Treatment|Children with severe pneumonia were randomly assigned to receive supplementation with elemental zinc.
89356263|NCT03819179|Experimental|Serum with Berenew Complex|Burt's Bees Serum with Berenew Complex
88824830|NCT00376077|Active Comparator|Placebo and IVIG|"The trial site is blinded to the randomization process. Patients are assigned an arm by a research pharmacist. Patients on this arm receive an infusion of placebo (0.9% NaCl) over one hour. Immediately following this dosing, 1 g/kg IVIG (Gammunex ©) is infused over 2 - 3 hours. Following this treatment, complete blood counts are drawn at:~completion of IVIG infusion,~8 hours following the start of the placebo/solumedrol infusion~24 hours following the start of the placebo/solumedrol infusion~72 hours following the start of the placebo/solumedrol infusion~7 days post infusion~21 days post infusion"
88824831|NCT00376077|Experimental|Methylprednisolone and IVIG|"The trial site is blinded to the randomization process. Patients are assigned an arm by a research pharmacist.Patients on this arm receive IV Methylprednisolone 30 mg/kg (1 gram maximum) infused over one hour. Immediately following this dosing, 1 g/kg IVIG Gammunex © is infused over 2 - 3 hours. Following this treatment, complete blood counts are drawn at:~completion of IVIG infusion,~8 hours following the start of the placebo/solumedrol infusion~24 hours following the start of the placebo/solumedrol infusion~72 hours following the start of the placebo/solumedrol infusion~7 days post infusion~21 days post infusion"
88824832|NCT03512067|Experimental|Patients given EMV Ventilation|Baseline mechanical ventilation data with conventional pressure-limited assist/control ventilation mode will then be collected for a 4-hour period. The patients will then be transitioned to pressure-limited entrainment-based ventilation for a 4-hour period. Baseline ventilation monitoring will be carried out either immediately preceding or immediately following EMV in the same patient. The sequence of the control/baseline phase and the experimental phase of the study will be randomized.
88824833|NCT03512457|Experimental|Intensive Intervention|Participants receive brochure, card advising how to make an appointment with dermatology, and reminder in one week to perform SSE.
88824834|NCT03512457|Active Comparator|Minimal Intervention|Participants receive brochure, card advising how to make an appointment with dermatology, and reminder in one week to perform SSE.
88824835|NCT03519243|Experimental|BCD-131 1,05 mcg/kg * conversion ratio|subcutaneously monthly
88824836|NCT03519243|Experimental|BCD-131 1,7 mcg/kg * conversion ratio|subcutaneously monthly
88824837|NCT03519243|Experimental|BCD-131 2,75 mcg/kg * conversion ratio|Subcutaneously monthly
88824838|NCT03519243|Active Comparator|Mircera|subcutaneously monthly
88824839|NCT03577275|Placebo Comparator|Placebo oral capsule|Single dose of placebo to match NST-4016
88824840|NCT03577275|Active Comparator|Moxifloxacin 400mg|Single 400mg dose of active comparator moxifloxacin (open label)
88824841|NCT03577275|Experimental|NST-4016 600mg|Likely therapeutic dose of NST-4016
88824842|NCT03577275|Experimental|NST-4016 2000mg|Supratherapeutic dose of NST-4016
89177121|NCT00651664|Experimental|Alisertib 5 mg QD 7D|Alisertib 5 mg, capsules, orally, once daily (QD) for 7 days (D) followed by a 14-day recovery period in each cycle until disease progression or unacceptable alisertib-related toxicity (up to 3 cycles).
89177122|NCT00651664|Experimental|Alisertib 80 mg QD 7D|Alisertib 80 mg, capsules, orally, QD for 7 days followed by a 14-day recovery period in each cycle until disease progression or unacceptable alisertib-related toxicity (up to 4 cycles).
89177123|NCT00651664|Experimental|Alisertib 150 mg QD 7D|Alisertib 150 mg, capsules, orally, QD for 7 days followed by a 14-day recovery period in each cycle until disease progression or unacceptable alisertib-related toxicity (up to 6 cycles).
89177124|NCT00651664|Experimental|Alisertib 50 mg BID 7D|Alisertib 50 mg, capsules, orally, twice daily (BID) for 7 days followed by a 14-day recovery period in each cycle until disease progression or unacceptable alisertib-related toxicity (up to 29 cycles).
89177125|NCT00651664|Experimental|Alisertib 60 mg BID 7D|Alisertib 60 mg, capsules, orally, BID for 7 days followed by a 14-day recovery period in each cycle until disease progression or unacceptable alisertib-related toxicity (up to 6 cycles).
89177126|NCT00651664|Experimental|Alisertib 75 mg BID 7D|Alisertib 75 mg, capsules, orally, BID for 7 days followed by a 14-day recovery period in each cycle until disease progression or unacceptable alisertib-related toxicity (up to 8 cycles).
88824843|NCT03581097|Experimental|Video Group|Patients in the film group watched the film using a laptop computer equipped with headphones, and Visual Analog Pain Scale (VAS) was repeated after the movie. Video was recorded by the Anaesthesiology department team, in order to explain and show in a detailed way on a model, the sequence of events, which occurs between the arrival of patients in the operating room and the performance of intravenous regional anesthesia
88824844|NCT03581097|No Intervention|Control Group|Patients assigned to this control group were not shown the video and underwent an otherwise identical preoperative preparation procedure.
88824845|NCT03521505|Experimental|Dexmedetomidine arm|Dexmedetomidine will be administrated for sedation of EBUS-TBNA
88824846|NCT03521505|Active Comparator|Propofol arm|Propofol will be administrated for sedation of EBUS-TBNA
88824847|NCT03522441|Experimental|Clindamycin 1% gel (Akorn Pharmaceuticals)|
88824848|NCT03522441|Active Comparator|Clindamycin 1% gel (Greenstone LLC)|
88824849|NCT03522441|Placebo Comparator|Placebo|
88824850|NCT03529461|Other|Control|Intervention: nasal cannula (6L O2) + non invasive positive pressure nasal mask (not connected to machine)
88824851|NCT03529461|Experimental|Experimental|Intervention: Non invasive positive pressure nasal mask (connect to machine once patient is sedated)
88824852|NCT03585543|Experimental|Single group intervention arm|
88824853|NCT04332549|Active Comparator|Reconstitution Method 1|
88824854|NCT04332549|Active Comparator|Reconstitution Method 2|
88824855|NCT03346161|Experimental|Arm 1: BREASTChoice (Decision Tool)|Investigators recruited patients scheduled for a plastic/reconstruction consult. Investigators identified patients who completed a mastectomy, or were scheduled for one, and considering reconstruction, but didn't have an appointment with a plastic/reconstructive surgeon. A study team member called the patient to determine their interest and offered for them to come to their scheduled appointment 30 minutes early to meet a coordinator or offered them the option to complete pre-appointment procedures at home. Patients randomized using computer random assignment. If the patient didn't have an appointment, she scheduled a convenient time to complete study procedures with research staff. Patients interacted with the decision tool. They were asked to answer a survey. After the appointment, the team collected information consult duration, decision process quality, and measures of shared decision making. Patient participation was approximately 30 minutes.
89177127|NCT00651664|Experimental|Alisertib 100 mg BID 7D|Alisertib 100 mg, capsules, orally, BID for 7 days followed by a 14-day recovery period in each cycle until disease progression or unacceptable alisertib-related toxicity (up to 21 cycles).
89356264|NCT03819179|Experimental|Serum with Ecoskin|Burt's Bees Serum with Ecoskin
89356265|NCT03819179|Experimental|Serum with Bonicell|Burt's Bees Serum with Bonicell
89177128|NCT00651664|Experimental|Alisertib 50 mg QD 14D|Alisertib 50 mg, capsules, orally, QD for 14 days followed by a 14-day recovery period in each cycle until disease progression or unacceptable alisertib-related toxicity (up to 25 cycles).
89356266|NCT01206257||Group 1|
89000168|NCT00198666|No Intervention|Control|Children with severe pneumonia were randomly assigned to receive supplementation with placebo tablets.
89000169|NCT01853995|Experimental|FLMGM Treatment Group|Cl II/1 patients treated with Fixed Lingual Mandibular Growth Modificator (FLMGM)
89000170|NCT01853995|No Intervention|Untreated Class II Control Group|control group
89000171|NCT00173888|Experimental|A|
89000172|NCT00173888|Active Comparator|B|
89000173|NCT01853722|Experimental|DCN01|
89000174|NCT01853722|Placebo Comparator|Unisol|
89000175|NCT00554983|Placebo Comparator|2|
89000176|NCT00554983|Experimental|1|
89000177|NCT00555022|Experimental|All subjects|Eligible subjects will receive one of the following treatment in cohort I and cohort II in five different treatment periods; Placebo, GSK1160724 (10 micrograms, 50 micrograms or 125 micrograms) and tiotropium bromide
89000178|NCT00203385|Experimental|Divalproex|Divalproex; oral up to 2000mg/d; open label
89000179|NCT00555139|Experimental|GW876008|The subjects will be randomized to one of the six sequences A/B/D A/D/B B/A/D B/D/A D/A/B D/B/A across three treatment periods where A represents placebo, B represents GW876008 and D represents alprazolam.
89000180|NCT00555139|Experimental|GSK561679|The subjects will be randomized to one of the six sequences A/C/D A/D/C C/A/D C/D/A D/A/C D/C/A across three treatment periods where A represents placebo, C represents GSK561679 and D represents alprazolam.
89000181|NCT01842451|Experimental|VX-135 High Dose with Daclatasvir|12 weeks of a high dose of VX-135 in combination with Daclatasvir
89000182|NCT01842451|Experimental|VX-135 Low Dose with Daclatasvir|12 weeks of a low dose of VX-135 in combination with Daclatasvir
89000183|NCT01825954|Active Comparator|12-week RINCE|RINCE - active RINCE therapy involving 24 total treatment applications from NeuroPoint device
89000184|NCT01825954|Active Comparator|8-week RINCE|RINCE - active RINCE therapy involving 16 total treatment applications from NeuroPoint device, followed by 8 sham applications from the NeuroPoint device
89000185|NCT01825954|Sham Comparator|Sham RINCE|Sham RINCE - sham RINCE therapy involving 24 total sham applications from NeuroPoint device
89000186|NCT04676620||CK surgery|Conductive keratoplasty (CK) had shown to be a safe and effective procedure for the treatment of low to moderate hypeopia. It had been approved by the U.S. Food and Drug Administration (FDA) to treat presbyope in early 2004. CK appeals to both surgeons and patients as it avoids the need for flap creation, the use of high intraocular pressure (IOP), or tissue ablation.
89000187|NCT04676620||LASIK surgery|LASIK surgery is femtosecond laser assisted conventional refractive surgery and has also been proved to offer many advantages in terms of visual acuity, corneal sensitivity, and corneal biomechanics compared with traditional refractive surgeries.
89000188|NCT04676581||Aeromonas infection|
89000189|NCT04676581||No infected|
89177129|NCT00651664|Experimental|Alisertib 50 mg QD 21D|Alisertib 50 mg, capsules, orally, QD for 21 days followed by a 14-day recovery period in each cycle until disease progression or unacceptable alisertib-related toxicity (up to 10 cycles).
89000190|NCT04676581||bacterial infection|
89000191|NCT04676503|Experimental|Test Arm - Biovaginil 480 mg capsules|All patients will be treated with 1 capsule/day of BIOVAGINIL for two treatment cycles of 14 days each.
89177130|NCT00651664|Experimental|Alisertib 70 mg QD 21D|Alisertib 70 mg, capsules, orally, QD for 21 days followed by a 14-day recovery period in each cycle until disease progression or unacceptable alisertib-related toxicity (up to 2 cycles).
89000192|NCT04676269|Sham Comparator|Amnion only|Amnion bilayer as a scaffold to overlay the endometrium, with minor curettage prior to stick the scaffold.
89000193|NCT04676269|Experimental|Amnion- self endometrium stem cells (EnSC)|Amnion bilayer as a scaffold, seeded with endometrium stem cells to regenerate the thin endometrium.
89000194|NCT04676269|Experimental|Amnion- amnion epithelial stem cells (AESC)|Amnion bilayer as a scaffold, seeded with amnion epithelial stem cells to regenerate the thin endometrium.
89000195|NCT04676269|Experimental|Amnion- co culture self EnSC - AESC|Amnion bilayer as a scaffold, seeded with co-culture of endometrium stem cells and amnion epithelial stem cells to regenerate the thin endometrium.
89000196|NCT01819909|Experimental|Postoperative Jackins Exercise Protocol|Jackin's exercises were initially designed for patients with difficulty performing forward elevation. The patient initially is positioned supine to perform shoulder flexion. When the patient can actively elevate in the supine position, one to two pounds of weight is placed in the patients hand and the patient is asked to repeat the maneuver of supine active elevation. When the patient can do this with little difficulty, the head of the bed is elevated approximately 20 degrees from the supine position and the sequence is repeated. Once the patient is able to perform flexion in this elevated head position, the inclination of the patient is increased in 20 degree increments until the patient is able to perform upright sitting shoulder flexion.
89000197|NCT01819909|Experimental|Postoperative Pulleys Exercise Protocol|Pulleys have been used in postoperative shoulder rehabilitation to improve passive as well as active range of motion and develop strength.
89000198|NCT01818154|Experimental|Minimal Erythema Dose LED|A 2 x 2 cm section of skin will be exposed to LED light.
89000199|NCT01818154|Placebo Comparator|Minimal Erythema Dose narrow band UVB|A 2 x 2 cm section of skin will be exposed to narrow band UVB light.
89000200|NCT01818076|Experimental|Dose A|Dose A: Botulinum toxin type A
89000201|NCT01809964|Experimental|Dose 1|ANT-1401
89000202|NCT01809964|Experimental|Dose 2|ANT-1401
89000203|NCT01809964|Placebo Comparator|Vehicle|Placebo Vehicle
89000204|NCT01807546|Experimental|rigosertib|Oral rigosertib capsules at a dose of 560 mg twice a day for 14 consecutive days of a 21-day cycle (2 weeks on, 1 week off regimen).
89000205|NCT01803412|Experimental|Alternate Intravenous Dosing Arm|Subjects will receive drisapersen as a regimen of 3 mg/kg over 1 hr IV weekly throughout the duration of participation.
89000206|NCT01803412|Experimental|Primary continuous Dosing Arm|Subjects will receive drisapersen 6 mg/kg as SC injection(s) once a week, continuously throughout their duration of participation.
89177131|NCT00787527|Experimental|Zolinza + CHOP|Zolinza (vorinostat) + CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)
89177132|NCT04105881||Full term labor|Measured by flow cytometry and ELUSA
89177133|NCT04105881||Preterm labor|Measured by flow cytometry and ELISA
89177134|NCT04105881||Control|For comparison
89177135|NCT00804388|Active Comparator|1|Uncemented total hip replacement, 32 mm caput
89177136|NCT00804388|Active Comparator|2|Uncemented total hip replacement, 36 mm caput
89177137|NCT04025151|Experimental|Intervention group|Alcohol brief intervention, leaflets, regular personalized messages on ABI through IM Apps, real-time chat-based support through IM Apps
89177138|NCT04025151|Active Comparator|control group|Alcohol brief intervention, leaflets, regular messages on general health through SMS
89177139|NCT00804466|Experimental|Women referred to colposcopy clinic|Triage tests for diagnosis of cervical pre-cancer amongHPV positive women
89000207|NCT01803412|Experimental|Alternate Intermittent Dosing Arm|Subjects will receive drisapersen intermittently, as a regimen of 6 mg/kg as SC injection(s) once a week for 8 weeks followed by 4 weeks of no dosing, throughout their duration of participation.
89000208|NCT02963220|Experimental|CBT-AR|There is only one arm in this study - all participants will be in the same arm, as all participants will receive CBT-AR. There is no control group.
89000209|NCT01802866|Experimental|ACU-4429 2.5 mg|2.5 mg tablet
89000210|NCT01802866|Experimental|ACU-4429 5 mg|5 mg tablet
89000211|NCT01802866|Experimental|ACU-4429 10 mg|10 mg tablet
89000212|NCT01802866|Placebo Comparator|Placebo|Includes identical tablets with only inactive ingredients (0 mg).
89000213|NCT03454984|Experimental|SGI-110|"SGI 110 (Guadecitabine) will start on day 40, In case the patient is not eligible yet, he should be assessed again each 30 days until day 130, after what, he is not considered eligible for a preventive treatment by SGI.~Initial dose will be 30/m2/day SQ for 5 days~total 10 cycles of SGI-110"
89000214|NCT01785433|Experimental|Treatment ABCD|"The following treatments are to be studied in a 4-period, crossover design with once daily (QD) dosing for 7 days and at least 21 day washout period between treatments:~Treatment A: Tiotropium HFA BAI 4.5 mcg/day~Treatment B: Tiotropium HFA BAI 9.0 mcg/day~Treatment C: SPIRIVA® HandiHaler® 18 mcg/day~Treatment D: Spiriva® Respimat® 5 mcg/day"
89000215|NCT01785433|Experimental|Treatment BDAC|"The following treatments are to be studied in a 4-period, crossover design with once daily (QD) dosing for 7 days and at least 21 day washout period between treatments:~Treatment B: Tiotropium HFA BAI 9.0 mcg/day~Treatment D: Spiriva® Respimat® 5 mcg/day~Treatment A: Tiotropium HFA BAI 4.5 mcg/day~Treatment C: SPIRIVA® HandiHaler® 18 mcg/day"
89000216|NCT01785433|Experimental|Treatment CADB|"The following treatments are to be studied in a 4-period, crossover design with once daily (QD) dosing for 7 days and at least 21 day washout period between treatments:~Treatment C: SPIRIVA® HandiHaler® 18 mcg/day~Treatment A: Tiotropium HFA BAI 4.5 mcg/day~Treatment D: Spiriva® Respimat® 5 mcg/day~Treatment B: Tiotropium HFA BAI 9.0 mcg/day"
89000217|NCT01785433|Experimental|Treatment DCBA|"The following treatments are to be studied in a 4-period, crossover design with once daily (QD) dosing for 7 days and at least 21 day washout period between treatments:~Treatment D: Spiriva® Respimat® 5 mcg/day~Treatment C: SPIRIVA® HandiHaler® 18 mcg/day~Treatment B: Tiotropium HFA BAI 9.0 mcg/day~Treatment A: Tiotropium HFA BAI 4.5 mcg/day"
89000218|NCT01781104|Active Comparator|RM-131|
89000219|NCT01781104|Placebo Comparator|Placebo|
89000220|NCT01777594|Experimental|G-202 (Mipsagargin)|G-202 (mipsagargin) administered by intravenous infusion on 3 consecutive days of a 28-day cycle
89000221|NCT01777555|Experimental|CVT-301|CVT-301 at Dose Level 1 for 1st 14 days of treatment then increased to Dose level 2 for last 14 days of treatment.
89000222|NCT01777555|Placebo Comparator|Inhaled Placebo|Subjects randomized to receive placebo in a 1:1 randomization scheme
89000223|NCT01777165|Experimental|Arm 1 ABT-719 lower dose|
89000224|NCT01777165|Experimental|Arm 2 ABT-719 intermediate dose|
89000225|NCT01777165|Experimental|Arm 3 ABT-719 higher dose|
89000226|NCT01777165|Placebo Comparator|Arm 4 placebo|
89000227|NCT00203619|Experimental|1|Wireless capsule endoscopy
89000228|NCT00203619|Active Comparator|2|Standard care
89000229|NCT01773928|Experimental|VCIV - Modified manufacturing process (18-49 Years Old) Lot 1|Vero cell-derived trivalent influenza vaccine (VCIV)
89000230|NCT01773928|Experimental|VCIV - Modified manufacturing process (18-49 Years Old) Lot 2|Vero cell-derived trivalent influenza vaccine (VCIV)
89000231|NCT01773928|Experimental|VCIV - Modified manufacturing process (18-49 Years Old) Lot 3|Vero cell-derived trivalent influenza vaccine (VCIV)
88824856|NCT03346161|Active Comparator|Arm 2: Enhanced Usual Care (Surgical Care Booklet)|"Investigators recruited patients scheduled for plastic/reconstruction consultation. Investigators identified patients who completed or scheduled a mastectomy, and considering reconstruction, but didn't have an appointment with a plastic/reconstructive surgeon. A study team member called the patient to determine their interest and offered for them to come to their scheduled appointment 30 minutes early to meet a coordinator or to complete the pre-appointment procedures at home. Patients were randomized using computer random assignment. If the patient didn't have an appointment, she scheduled a convenient time to complete study procedures with research staff. Patients interacted with American Society of Plastic Surgeons booklet Breast Reconstruction. They were asked to answer a survey. After the appointment, the team collected information about consult duration, decision process quality, and measures of shared decision making. Patient participation was approximately 30 minutes."
88824857|NCT03530631|Experimental|Adderall/Truth|Participants will be told they are receiving Adderall and will actually be administered Adderall.
88824858|NCT03530631|Placebo Comparator|Placebo/Truth|Participants will be told they are receiving placebo and will actually be administered placebo.
88824859|NCT03530631|Experimental|Adderall/Deception|Participants will be told they are receiving Adderall and will actually be administered placebo.
88824860|NCT03530631|Experimental|Placebo/Deception|Participants will be told they are receiving placebo and will actually be administered Adderall.
88824861|NCT03533829|Active Comparator|Buzzy®|Buzzy® Drug Free Pain Relief which is a medical device designed to reduce vaccination pain when applied to the arm prior to and during a vaccination.
88824862|NCT03533829|Active Comparator|Music|Music will be selected and listened to as a distraction before and during vaccination.
88824863|NCT03533829|Active Comparator|Buzzy® and Music|Buzzy® will be applied to the arm prior to and during vaccination and music will be selected and listened to before and during vaccination.
88824864|NCT03350217|Active Comparator|Eleview|This arm will be administered the Eleview Injectate (up to 50 mL's) solution upon randomization, provided the lesion is equal to or greater than 11 millimeters.
88824865|NCT03350217|Active Comparator|Hetastarch|This arm will be administered Hetastarch (w/Methylene blue as a contrast agent) as the injection solution upon randomization, provided the lesion is equal to or greater than 11 millimeters.
88824866|NCT04735107|Experimental|Reinforcement|Low anterior resection + mucosa flap reinforcement + vacuum sponge endoluminal drainage
88824867|NCT03350919|Experimental|Training in the blind field|Training in the blind field using software
88824868|NCT03350919|Experimental|Training in the intact field|Training in the intact field using software
88824869|NCT03351699|Experimental|Panel A: MK-4250 150 mg|Participants will receive MK-4250 150 mg tablet by mouth on Day 1 after an 8-hour fast.
88824870|NCT03351699|Experimental|Panel B: MK-4250 600 mg|Participants will receive MK-4250 600 mg tablet by mouth on Day 1 after an 8-hour fast. The decision to enroll Panel B and the dose selected (i.e., ≤600 mg) will be made based on evaluation of pharmacokinetics and 7-day safety and viral load data from Panel A.
88824871|NCT03351699|Experimental|Panel D: MK-4250 900 mg|Participants will receive MK-4250 900 mg tablet by mouth on Day 1 after an 8-hour fast. The decision to enroll Panel D will be made upon completion of Panels A and B and evaluation of safety and viral load data from those panels.
88824872|NCT03351699|Experimental|Panel E: MK-4250 ≤900 mg with a Low-fat Meal|Participants will receive MK-4250 ≤900 mg tablet by mouth on Day 1 with a low-fat meal. The decision to enroll Panel E will be made upon completion of Panel D and evaluation of safety and viral load data from that panel.
88824873|NCT03351699|Experimental|Panel F: MK-4250 ≤900 mg with a Moderate-fat Meal|Participants will receive MK-4250 ≤900 mg tablet by mouth on Day 1 with a moderate-fat meal. The decision to enroll Panel F will be made upon completion of Panel D and evaluation of safety and viral load data from that panel. The decision to enroll Panel F will be made based on evaluation of PK and safety data from other studies with MK-4250.
88824874|NCT03351933|Experimental|Immune Globulin (Human) GamaSTAN|The healthy subjects received a single IM dose of GamaSTAN (0.2 mL/kg), followed by a PK sampling period of 150 days.
88824875|NCT03594045|Experimental|Apixaban for HIT|Patients with Heparin Induced Thrombocytopenia (HIT) will receive Apixaban, at an initial dose of 10 mg orally twice a day for 7 days followed by 5 mg twice a day for a total of 30 days.
88824876|NCT03594045|Experimental|Apixaban for HITT|Patients with Heparin Induced Thrombocytopenia with Thrombosis (HITT) will receive Apixaban, at an initial dose of 10 mg orally twice a day for 7 days followed by 5 mg twice a day for a total of 3 months.
88824877|NCT03595215|Experimental|TENS Treatment Arm|This study is an early feasibility study which will be treating all patients at least 3 times per week, for 8 weeks, using the device.
88824878|NCT03595449|Active Comparator|Lidocaine jelly|This is the group that will have lidocaine jelly applied during Mohs surgery
88824879|NCT03595449|Sham Comparator|Surgilube|This is the group that will have surgilube (placebo) applied during Mohs surgery
88824880|NCT03597009|Experimental|Open-label, single-arm Phase I|Talimogene laherparepvec (TVEC) administered into the intrapleural space of subjects with malignant pleural effusion (MPE) via a pleurX catheter with or without nivolumab
88824881|NCT03352323|Experimental|oxymetazoline cream|
88824882|NCT04734639|Experimental|Obese adolescents|20 adolescents with obesity are involved and will perform the three conditions.
88824883|NCT03597789|Other|Helping the NonCompliant Child Treatment|"Families will participate in an average of 8 to 12 weeks of Behavioral Parent Training (BPT), by way of the standard-of-care training program Helping the Noncompliant Child (HNC) via weekly sessions and mid-week calls."
88824884|NCT03598647|Active Comparator|Physical activity information - for non-exercisers only|Non-exercisers randomized to this condition will receive basic information about physical activity. This includes the national physical activity guidelines,clarification of 'moderate-intensity', exercise safety, and the progression of physical activity within the weight loss program.
88824885|NCT03598647|Experimental|Affect and physical activity - for non-exercisers only|Non-exercisers randomized to this condition will receive the same basic information about physical activity as described above, but they will also receive a brief intervention focused on affective responses to exercise.
88824886|NCT03598647|No Intervention|Exercisers|Engaging in >=150 min/week of moderate-intensity exercise over the past 6 months and a most recent typical week
88824887|NCT03598647|No Intervention|Non-exercisers|Engaging in <30 min/week of moderate-intensity exercise over the past 6 months and a most recent typical week
88824888|NCT03599271|Experimental|Drug-Coated Device|Randomized cohort: Drug-Coated Device to dilate randomized frontal sinus ostium.
88824889|NCT03599271|Active Comparator|Control Sinus Dilation Device|Randomized cohort: Control Device to dilate randomized contralateral frontal sinus ostium.
88824890|NCT03599271|Experimental|PK cohort- Drug-Coated Device|PK cohort: One Drug-Coated Device to dilate both frontal sinus ostia.
88824891|NCT04734561|Experimental|Inspiratory muscle training group|Participants will perform an inspiratory muscle training by a threshold device at home, twice a day for 8 weeks supervised by a physiotherapist through a virtual platform.
88824892|NCT04734561|Sham Comparator|Inspiratory muscle training placebo group|Participants will perform an inspiratory muscle training by a placebo threshold device at home, twice a day for 8 weeks supervised by a physiotherapist through a virtual platform.
88824893|NCT04734561|Experimental|Inspiratory + expiratory muscle training group|Participants will perform an inspiratory and expiratory muscle training by a threshold device at home, twice a day for 8 weeks supervised by a physiotherapist through a virtual platform.
88824894|NCT04734561|Sham Comparator|Inspiratory + expiratory muscle training placebo group|Participants will perform an inspiratory and expiratory muscle training by a placebo threshold device at home, twice a day for 8 weeks supervised by a physiotherapist through a virtual platform.
88824895|NCT03357393|Active Comparator|Midazolam and morphine-scopolamine|Sedation during bronchoscopy with midazolam and morphine-scopolamine as premedication.
88824896|NCT03357393|Experimental|PCS (propofol) with morphine-scopolamine|Sedation during bronchoscopy with propofol using PCS and morphine-scopolamine as premedication
88824897|NCT03357393|Experimental|PCS (propofol) with glycopyrronium bromide|Sedation during bronchoscopy with propofol using PCS and glycopyrronium bromide as premedication.
88824898|NCT04734717|Experimental|COVID19|
88824899|NCT04734717|Experimental|Controll|
88824900|NCT03539211|Experimental|Rotation Exercises|8 minute program of rotation based exercises
88824901|NCT03539211|Active Comparator|Control Exercises|8 minute program of traditional exercises
88824902|NCT03358251|Other|SRP+Pocket-X Gel, split-mouth|This arm is a split-mouth arm, i.e., participants will receive conventional treatment for periodontitis (scaling and root planing) for the entire mouth, and, in addition, will receive experimental treatment (Pocket-X Gel) for periodontal pockets present in one/two mouth segments (quadrants), while the contralateral quadrants will serve as control and will not undergo any further intervention.
88824903|NCT03604263|Experimental|Treatment Arm|Subjects enrolled and treated with ArcticLine Cardiac Cryoablation Catheter
88824904|NCT03540147|Experimental|Exercise with Hokanson cuffs|Participants will walk on the treadmill with Hokanson cuffs inflated.
88824905|NCT03540147|Experimental|Exercise with BStrong Bands|Participants will walk on the treadmill with BStrong bands inflated.
88824906|NCT03540147|Sham Comparator|Exercise without inflated bands/cuffs|Participants will walk on the treadmill with non-inflated BStrong bands.
88824907|NCT03540147|Experimental|Yoga poses with BStrong bands inflated|Participants will perform 15-20 yoga poses with BStrong bands inflated.
88824908|NCT03540147|Sham Comparator|Yoga poses with BStrong bands uninflated|Participants will perform 15-20 yoga poses with uninflated BStrong bands.
88824909|NCT03541941|Experimental|Exparel|Solution of 266mg of Exparel + 150mg Bupivacaine HCL + 40cc normal saline= 120cc administered through a transversus abdominis plane block performed intraoperatively by the surgeon under direct visualization
88824910|NCT03541941|Active Comparator|Bupivacaine Hcl 0.25% Inj|Solution of 150mg Bupivacaine HCL expanded with 60cc of normal saline=120cc administered through a transversus abdominis plane block performed intraoperatively by the surgeon under direct visualization
88824911|NCT03541941|Placebo Comparator|Placebo|120 cc of normal saline administered through a transversus abdominis plane block performed intraoperatively by the surgeon under direct visualization
88824912|NCT04734483|Active Comparator|functional findings|Participants with laryngeal stenosis
88824913|NCT04734483|Active Comparator|to find anatomic feathers of larynx|Participants with laryngeal stenosis
88824914|NCT04734483|Active Comparator|to determine the type of stenosis of larynx and method of surgical treatment|Participants with laryngeal stenosis
88824915|NCT04734483|Active Comparator|determining the motor abilities of the muscles of the larynx|Participants with laryngeal stenosis
88824916|NCT03542019|Active Comparator|Lithium disilicate|Lithium disilicate: a type of ceramic material used to make a dental prosthesis that replaces missing tooth structure following root canal treatment. Other names might include: E-max crowns, computer-aided design and computer-aided manufacturing (CAD CAM) crowns
88824917|NCT03542019|Active Comparator|Monolithic zirconia|Monolithic zirconia: a type of ceramic material used to make a dental prosthesis that replaces the missing tooth structure following root canal treatment. Other names might include: Zolid crown, Bruxzir, Bretau, CAD CAM crowns
88824918|NCT03542019|Active Comparator|Hybrid ceramic|Hybrid ceramic: a type of ceramic material used to make a dental prosthesis that replaces the missing tooth structure following root canal treatment. Other names might include: Enamec, Lava Ultimate, CAD CAM crowns
88824919|NCT03550989||Non-Smokers|"Each participant can participate in one Non-Exposure Event and one Exposure Event only.~Abstinent for at least 12 months from the use of any nicotine and/or tobacco-containing product based on self-reporting.~Must not be exposed to tobacco or nicotine-containing products use in any other substantial way (family, partner, workplace, etc.)."
88824920|NCT03550989||Cigarette Smokers|"Each participant can participate in one Non-Exposure Event and one Exposure Event only.~Used at least 100 cigarettes~Smokes cigarettes daily > 1/day~Uses IQOS less than daily~Uses less than 30 HeatSticks/month~Cigarette is > 95% of tobacco/nicotine product (all product use)"
88824921|NCT03550989||IQOS Passive Users (not using IQOS)|"Each participant can participate in one Non-Exposure Event and one Exposure Event only.~Used at least 100 HeatSticks~Uses IQOS daily > 1/day~Smokes a cigarette less than daily~Smokes less than 30 cigarettes/month~IQOS is > 95% of tobacco/nicotine product (all product use) - excluding other products (e-cig/Ploom/etc.)"
89000232|NCT01773928|Active Comparator|VCIV manufactured with current process (18-49 Years Old)|Vero cell-derived trivalent influenza vaccine (VCIV)
88824922|NCT03550989||IQOS Active Users (using IQOS)|"Each participant can participate in one Exposure Event only.~Used at least 100 HeatSticks~Uses IQOS daily > 1/day~Smokes a cigarette less than daily~Smokes less than 30 cigarettes/month~IQOS is > 95% of tobacco/nicotine product (all product use) - excluding other products (e-cig/Ploom/etc.)"
88824923|NCT03611829|Active Comparator|Standard Care|Participants in the standard care condition were provided with diet and exercise counselling and psychoeducation from their physicians over the course of 8 sessions, as was routinely done at the clinic. Standard care did not involve any targeted intervention to reduce emotional eating.
88824924|NCT03611829|Experimental|ACT Intervention|In addition to receiving standard care, participants in the ACT condition were taught techniques to reduce their emotional eating. Three overarching skills were taught over the course of the ACT intervention: (1) values clarification and commitment, (2) metacognitive awareness, and (3) distress tolerance. Throughout the sessions, physicians formed if-then plans with the patients to specify how to habitually use the ACT techniques to reduce emotional eating in their everyday lives. At the end of each session, participants were given a one-page homework sheet that asked them to monitor their behavior and their use of the ACT techniques during the week.
88824925|NCT03556761|Experimental|Oral furosemide|Oral furosemide 20 mg/day for a total of 5 consecutive doses.
88824926|NCT03556761|Placebo Comparator|Placebo Oral Tablet|Placebo once per day for a total of 5 consecutive doses.
88824927|NCT03361917|No Intervention|Control Arm (Standard Colonscopy)|Standard colonoscopy with no device attachments
88824928|NCT03361917|Experimental|Endocuff Vision|Colonoscopy with Endocuff Vision attached to distal end of scope
88824929|NCT03559179|Experimental|Waivered Providers Receive the Opioid Wizard|All providers who have a buprenorphine waiver will receive the OUD clinical decision support tool (Opioid Wizard).
88824930|NCT03559179|No Intervention|Does not Receive the Opioid Wizard|All non-buprenorphine waivered providers will be randomized to receive or not receive the Opioid Wizard. This arm of providers will continue to treat their patients as usual.
88824931|NCT03559179|Experimental|Non-Waivered Providers who receive Opioid Wizard|All non-buprenorphine waivered providers will be randomized to receive or not receive the Opioid. This arm of providers will receive the OUD clinical decision support tool (Opioid Wizard).
88824932|NCT03366207|Experimental|Ciprofloxacin|Ciprofloxacin for the treatment of uncomplicated urinary tract infection
88824933|NCT03368235|Experimental|AZD9567|oral suspension of 40 mg AZD9567 once daily (OD) for two weeks
88824934|NCT03368235|Active Comparator|Prednisolone|oral OD treatment of 20 mg prednisolone administered as capsules
88824935|NCT03615183|Experimental|Panel A: 10 mg MK-8527|Single oral dose of 10 mg MK-8527 capsule after an 8-hour fast
88824936|NCT03615183|Experimental|Panel B: 3 mg MK-8527|Single oral dose of 3 mg MK-8527 capsule after an 8-hour fast
88824937|NCT03615183|Experimental|Panel C: 1 mg MK-8527|Single oral dose of 1 mg MK-8527 capsule after an 8-hour fast. Dose level determined by results of previous panels.
88824938|NCT03615183|Experimental|Panel D: ≤50 mg MK-8527|Single oral dose of ≤50 mg MK-8527 capsule after an 8-hour fast. Dose level determined by results of previous panels.
88824939|NCT03615183|Experimental|Panel E: ≤50 mg MK-8527|Single oral dose of ≤50 mg MK-8527 capsule after an 8-hour fast. Dose level determined by results of previous panels.
88824940|NCT02310750|Experimental|PF-06700841 Oral Solution/Suspension|
88824941|NCT02310750|Experimental|PF-06700841 Tablet|
88824942|NCT02310750|Placebo Comparator|Placebo|Oral placebo comparator for the healthy subject single and multiple ascending dose periods, and the psoriasis multiple dose period. No placebo used for the bioavailability investigation.
88824943|NCT03615807|Experimental|Short antibiotic arm|10 days for soft tissue infections 3 weeks for osteomyelitis
88824944|NCT03615807|Active Comparator|Standard antibiotic arm|20 days for soft tissue infections 6 weeks for osteomyelitis
88824945|NCT03563313|Experimental|Closed Loop Control (CLC)|Participants randomized to the closed loop control (CLC) arm will use the t:slim X2 with Control-IQ Technology & Dexcom G6 CGM for 6 months.
89177140|NCT00806884|Other|Control Arm1|Normal optimal medical and physiotherapy treatment
88824946|NCT03563313|Active Comparator|Sensor-Augmented Pump (SAP)|Participants randomized to sensor-augmented pump (SAP) will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months.
88824947|NCT02310672|Experimental|Macitentan|All patients take open-label macitentan 10mg o.d.
88824948|NCT03616899|Active Comparator|KPI-121 0.25% Ophthalmic Suspension|
88824949|NCT03616899|Placebo Comparator|Vehicle of KPI-121 0.25% Ophthalmic Suspension|
88824950|NCT03568539|Experimental|IBI308|
88824951|NCT03569397|Experimental|Music Therapy|Administer music therapy during the operation
88824952|NCT03569397|No Intervention|Non-Music Therapy|No headphones or music therapy during the operation
88824953|NCT03570255|Experimental|RD SET Neo SpO2|All subjects enrolled in the study will receive the investigational sensor (RD SET Neo SpO2) for evaluation of SpO2.
88824954|NCT03576183|Active Comparator|VLA1701|"VLA1701 is an investigational oral vaccine against LT-ETEC (Labile Toxin-Enterotoxigenic E coli)~The vaccine is administered orally in 2 doses about 1 week apart."
88824955|NCT03576183|Placebo Comparator|Placebo|"The buffer component of VLA1701 will be used as Placebo.~The vaccine is administered orally in 2 doses about 1 week apart."
88824956|NCT03377127|Active Comparator|Standard of Care (SOC)|The control group patients will be managed by their assigned PCPs, per Standard of Care (SOC), per American Diabetes Association Guidelines. Management per standard of care includes referrals to ophthalmology for dilated eye exam, nephrology for nephropathy management, cardiology for macrovascular complications management, neurology for neuropathy or neurologic complications, diabetic education, laboratory studies, and vaccinations and will be ordered or performed at the discretion of each patient's PCP
88824957|NCT03377127|Experimental|SOC and PMDC|The intervention group patients will be managed by their assigned primary care physicians (PCPs), per American Diabetes Association Guidelines for Standard of Care (SOC) and will have scheduled six extra face-to-face visits with the pharmacists for the 6 month duration of the intervention. The pharmacy managed diabetes clinic (PMDC) visit encounters will focus on patient identified goals for the management of their diabetes. Pharmacists have the discretion to make medication adjustments and initiate new medications pertinent to the management of diabetic comorbidities. The model is a collaborative practice agreement between the pharmacist and the primary care physician.
88824958|NCT03378921|Experimental|donors feces|Fecal microbiota transplantation (FMT) is performed by experienced endoscopists through flexible endoscopy into the afferent limb. The second FMT is installed via transanal catheter into the pouch 4 weeks after the first FMT.
88824959|NCT03378921|Placebo Comparator|patients own feces|Fecal microbiota transplantation (FMT) is performed by experienced endoscopists through flexible endoscopy into the afferent limb. The second FMT is installed via transanal catheter into the pouch 4 weeks after the first FMT.
88824960|NCT03626415|Experimental|PF-04965842|PF 04965842 is an orally bioavailable small molecule that selectively inhibits JAK1.
88824961|NCT04373421|Active Comparator|chlorhexidine gluconate plus benzydamine hydrochloride|Chlorhexidine is one of the most commonly used medications after tooth extraction. It exhibits a wide spectrum of antiseptic, bactericidal and bacteriostatic effects. The most common side effect of chlorhexidine is oral discoloration, taste changes and allergic responses. Furthermore, it has been reported that chlorhexidine has cytotoxic effect on gingival fibroblasts, epithelial cells, neutrophils and red blood cells; also shows incremental trend in genotoxicity as the duration of usage is increased. Benzydamine hydrochloride is a nonsteroidal anti-inflammatory drug that elicits anti-inflammatory, analgesic, anesthetic and antimicrobial effects. It is often used in addition to the topical application of chlorhexidine.. However, side effects such as urticaria, erythema, pruritus, photosensitivity, bronchospasm and renal problems can be observed associated with the use of benzydamine.
88824962|NCT04373421|Active Comparator|St. John's wort oil|St. John's Wort (Hypericum perforatum) is a European medicinal plant with a history of more than 2000 years which possessing a variety of important constituents including phloroglucinols (hyperforin and adhyperforin), naphthodianthrones (hypericin and pseudohypericin), xanthones, essential oil, biflavones (biapigenin and amentoflavone), flavonol derivatives and phenolic compounds. The important components of St. John's Wort such as hypericin and hyperforin exert anti-inflammatory, antimicrobial, anticancer effects as well as stimulating tissue growth and differentiation. Hypericin exhibits anti-inflammatory effects by inhibiting the production of interleukin-12; whereas hyperforin reveals this effect by inhibiting the mechanisms of cyclooxygenase 1, 5-lipoxygenase and prostaglandin E2. St. John's Wort oil is extracted by maceration of the hypericum herb in carrier oil, such as virgin olive oil.
88824963|NCT04373421|Active Comparator|Virgin olive oil|The olive oil, a product extracted from the fruit of Olea europaea, exerts also antioxidant and anti-inflammatory effects due to its important contents including oleic acids, phenolic acids, secoiridoids and flavonoids. The oral application of olive oil has been shown to have protective anti-inflammatory effects and accelerated epithelial healing.
88824964|NCT03629535|Experimental|Patients in SICU|Patients in the SICU with an intra-arterial blood pressure monitor already in place will be considered as subjects.
88824965|NCT03379545|Other|3D MR and 3D CT Imaging|All shoulder arthroplasty candidates with glenohumeral osteoarthritis will be receiving both 3D computed tomography (CT) and 3D non-contrast magnetic resonance (MR) imaging.
88824966|NCT04528017|Other|PRECISION1, then Clariti 1-Day|Verofilcon A contact lenses worn first, with somofilcon A contact lenses worn second, as randomized. Each study lens type will be worn bilaterally (in both eyes) for 8 -0/+3 days in a daily disposable modality.
88824967|NCT04528017|Other|Clariti 1-Day, then PRECISION1|Somofilcon A contact lenses worn first, with verofilcon A contact lenses worn second, as randomized. Each study lens type will be worn bilaterally (in both eyes) for 8 -0/+3 days in a daily disposable modality.
88824968|NCT03382509|Experimental|Single Dose Group|
88824969|NCT03382509|Experimental|Multiple Dose Group|
88824970|NCT03632109|Experimental|Single Arm|Men who have sex with men (MSM) with pharyngeal gonorrhea will be treated with 360mg intramuscular gentamicin x 1.
88824971|NCT04332315|Active Comparator|VALS|Vaginally asissted laparoscopic sacrocolpopexy
88824972|NCT04332315|Active Comparator|AS|Abdominal Sacrocolpopexy
89177141|NCT00806884|Experimental|Treatment Arm 2|Physiotherapy musculoskeletal interventions in addition to normal optimal medical and physiotherapy care
88824973|NCT02363946|Experimental|Part A: 0.38 mg/kg|Single dose administration of ARC-AAT intravenous (IV) injection, 0.38 mg/kg in healthy volunteers
89177142|NCT04025073|Experimental|Intervention Group|The intervention group will be assigned to the DASH diet with moderately reduced caloric intake and will participate in a nutrition education program.
89177143|NCT04025073|Experimental|Control Group|The control group will continue to follow the standard hospital diet and will participate in the same nutrition education program as the intervention group.
89177144|NCT00810238|Experimental|1|Optimal standard of care + C-Cure
89177145|NCT00810238|No Intervention|2|Optimal standard of care
89177146|NCT00806962|Experimental|Vaccine Arm 1|50 µg Norwalk VLP Vaccine + Adjuvant/Excipients
89356267|NCT03343444|Active Comparator|Arm 1|Treatment-naïve is defined as having never received treatment for HCV with any interferon (IFN), ribavirin , or other approved or experimental HCV specific direct acting antivirals.
89356268|NCT03343444|Active Comparator|Arm 2|"Treatment-experienced is defined as:~IFN Intolerant~Non-response~Relapse/Breakthrough"
89177147|NCT00806962|Experimental|Vaccine Arm 2|100 µg Norwalk VLP Vaccine + Adjuvant/Excipients
89177148|NCT00806962|Active Comparator|Adjuvant/Excipients (MPL)|14 mg chitosan, 3 mg mannitol, 3 mg sucrose, and 50 mcg MPL
89356269|NCT03343444|Experimental|Short Track|Treatment-naïve or Treatment-experienced who achived very rapid virological responce - Negative HCV PCR after treatment with (Sofosbuvir 400mg/Ledipasvir 90mg) for 1 week
89356270|NCT03819023|No Intervention|Normal subjects|
89356271|NCT03819023|Active Comparator|respiratory suppressing drugs|
89356272|NCT04498390|Experimental|LY3493269|LY3493269 administered orally.
89356273|NCT04498390|Placebo Comparator|Placebo|Placebo administered orally.
89356274|NCT03819101|No Intervention|Arm A|Standard of Care (SOC) for CRPC
88824974|NCT02363946|Experimental|Part A: 1.0 mg/kg|Single dose administration of ARC-AAT IV injection, 1.0 mg/kg in healthy volunteers
88824975|NCT02363946|Experimental|Part A: 2.0 mg/kg|Single dose administration of ARC-AAT IV injection, 2.0 mg/kg in healthy volunteers
89356275|NCT03819101|Experimental|Arm B|SOC + acetylsalicylic acid 100 mg daily
89356276|NCT03819101|Experimental|Arm C|SOC + atorvastatin 80 mg daily
89356277|NCT03819101|Experimental|Arm D|SOC + acetylsalicylic acid 100 mg daily + atorvastatin 8
88824976|NCT02363946|Experimental|Part A: 3.0 mg/kg|Single dose administration of ARC-AAT IV injection, 3.0 mg/kg in healthy volunteers
88824977|NCT02363946|Experimental|Part A: 4.0 mg/kg|Single dose administration of ARC-AAT IV injection, 4.0 mg/kg in healthy volunteers
89533661|NCT03861572|Experimental|Isokinetic eccentric group|The isokinetic eccentric training will be carried out with the volunteers positioned seated on the dynamometer with the apparent axis of the ankle joint rotation aligned with the dynamometer's axis of rotation. Movement will be executed in the angular velocity of 30°·s-1. Ankle range of motion (ROM) will be standardized for all participants in 50º, which shall respect each individual's maximal dorsiflexion amplitude. The 50° eccentric training ROM will start from each subject's 80% of the maximal dorsiflexion. This procedure will be used to ensure that all subjects perform training on the same plantar flexor muscular length, which should promote the same level of muscular requirement among the participants. This methodology was recently used by GEREMIA and VAZ (2016) study.
88824978|NCT02363946|Experimental|Part A: 5.0 mg/kg|Single dose administration of ARC-AAT IV injection, 5.0 mg/kg in healthy volunteers
89356278|NCT02507830||Glubran 2 fixation|Mesh fixation with Glubran 2 glue in primary inguinal hernia repair
88824979|NCT02363946|Experimental|Part A: 6.0 mg/kg|Single dose administration of ARC-AAT IV injection, 6.0 mg/kg in healthy volunteers
89356279|NCT05705102||OMI/NOMI group|In this group, the patients will be managed according to OMI/NOMI paradigm. OMI patients, even without STEMI criteria, will be taken immediately to the cath lab.
89356280|NCT05705102||STEMI/NSTEMI group|Standard care
89177149|NCT00806962|Sham Comparator|Empty device|Empty device that contains no dry powder formulation. Actuation of the empty intranasal delivery device will deliver a puff of air per device.
89356281|NCT02501746|Active Comparator|Usual Clinical Care (UC)|This will be the current standard of care delivered by the AMPATH CDM Program, in accordance with the management protocol for diabetes and hypertension.
89356282|NCT02501746|Experimental|Usual clinical care plus microfinance groups only (MF)|Usual clinical care as described above. In addition, participants will be encouraged to create microfinance groups organized and supported by AMPATH's Safety Net Program.
89356283|NCT02501746|Experimental|Group medical visits only (GMV)|Participants randomized to this arm will be invited to create a group that will attend monthly group medical visits at the rural health facility. Each group medical visit will be staffed by both the rural clinician and the local CHW (educator). Groups will consist of the same patients at each of 12 monthly visits. Each visit will begin with the measurement of fasting blood glucose and resting electronic BP, as well as the ascertainment of medication regimens for BP and diabetes, and extent of adherence to the prescribed regimen.
89356284|NCT02501746|Experimental|GMV integrated into GMV-MF|Clinical care will be provided in the form of group medical visits, and the participants will be actively recruited to create microfinance groups. Thus, the monthly group medical visit will be integrated into the microfinance groups, wherein the visit will consist of an initial microfinance portion, followed by the group medical visit.
89356285|NCT05704010|Experimental|Lynch Syndrome|Video capsule endoscopy every 2 years
89356286|NCT03818867|Experimental|Cerclage arm|Pregnancies which had cervical cerclage inserted.
89356287|NCT03818867|No Intervention|No-cerclage arm|Pregnancies which did not have cervical cerclage inserted.
89356288|NCT03343366|Experimental|Test Group 1|The participants in this group will receive a combination of ultrasonic scaling and hand instrumentation required for planing of the root surfaces (SRP) followed by systemic AAT followed by routine warm salt water rinses for 3-5 days and OHI. SRP will be performed using ultrasonic scaling device at medium intensity. In addition to ultrasonic scalar, hand instrumentation (using sharpened and sterilized curettes) may also be used if required to smoothen certain irregular areas of root surface until the surfaces are smooth. Systemic AAT would contain Metronidazole (MET) 400 mg x 3 for 10 days. OHI would include brushing teeth using soft bristles toothbrush and fluoridated toothpaste twice daily (morning after breakfast and night before sleeping) using Modified Bass Technique.
89356289|NCT03343366|Active Comparator|Test Group 2|The participants in this group will receive a combination of Scaling Root Planing followed by routine warm salt water rinses for 3-5 days and OHI. Same procedure for SRP and OHI will be followed as that followed in Test Group 1
89356290|NCT03343366|Other|Control Group 3|The participants in this group will receive only routine warm salt water rinses for 3-5 days and Oral Hygiene Instructions as that followed in Test Group 1 and Test Group 2. However, after completing six (6) months of evaluation they will be provided DT either in the form of SRP+MET or SRP only in addition to OHI, whichever would be found to have a significant beneficial effect on CP.
89356291|NCT05044416|Experimental|VieScope|intubation with the VieScope laryngoscope
89356292|NCT05044416|Active Comparator|Videolaryngoscopy|intubation with videolaryngoscope
88824980|NCT02363946|Experimental|Part A: 7.0 mg/kg|Single dose administration of ARC-AAT IV injection, 7.0 mg/kg in healthy volunteers
88824981|NCT02363946|Experimental|Part A: 8.0 mg/kg|Single dose administration of ARC-AAT IV injection, 8.0 mg/kg in healthy volunteers
88824982|NCT02363946|Placebo Comparator|Part A: Placebo|Single dose administration of 0.9% normal saline IV injection in healthy volunteers
88824983|NCT02363946|Experimental|Part B: 2.0 mg/kg|Single dose administration of ARC-AAT IV injection, 2.0 mg/kg in participants with AATD
89356293|NCT05622773|Experimental|one-group quasi-experimental study|Materials for Introductory Information Form, Visual Analog Scale (VAS), Visual Similarity Scale for Fatigue (VAS-F), Lower Leg Circumference Measurement Monitoring Form, Lower Extremity Edema Monitoring Form, Anti-Fatigue Mat, Foot Bath will be used in data collection. During the data collection process, the basic measurements of the operating room nurses will be made and then the measurements will be repeated using an anti-fatigue mat. The collection of data will be interrupted for 1 month, and basic measurements will be taken again and the nurses will be provided with a foot bath. After the footbath applications, the measurements will be repeated and recorded.
88824984|NCT02363946|Experimental|Part B: 4.0 mg/kg|Single dose administration of ARC-AAT IV injection, 4.0 mg/kg in participants with AATD
88824985|NCT02363946|Experimental|Part B: 6.0 mg/kg|Single dose administration of ARC-AAT IV injection, 6.0 mg/kg in participants with AATD
88824986|NCT02363946|Experimental|Part B: 7.0 mg/kg|Single dose administration of ARC-AAT IV injection, 7.0 mg/kg in participants with AATD
88824987|NCT02363946|Placebo Comparator|Part B: Placebo|Single dose administration of 0.9% normal saline IV injection in participants with AATD
88824988|NCT02363478|Experimental|buspirone|4-weeks buspirone administration (20mg) in patients with SSc and esophageal involvement
88824989|NCT02310126|Active Comparator|etafilcon A(sphere)/etafilcon A(multi-focal)|Subjects were randomized to one of two lens wear sequences. subjects randomized to this sequence received etafilcon A (sphere) contact lens first and then the etafilcon A (multi-focal) contact lens second.
89000233|NCT01773928|Active Comparator|Fluzone® (18-49 Years Old)|Fluzone®, licensed trivalent influenza vaccine (TIV)
89000234|NCT01773928|Experimental|VCIV - Modified manufacturing process (≥50 Years Old) Lot 1|Vero cell-derived trivalent influenza vaccine (VCIV)
89000235|NCT01773928|Experimental|VCIV - Modified manufacturing process (≥50 Years Old) Lot 2|Vero cell-derived trivalent influenza vaccine (VCIV)
89000236|NCT01773928|Experimental|VCIV - Modified manufacturing process (≥50 Years Old) Lot 3|Vero cell-derived trivalent influenza vaccine (VCIV)
89000237|NCT01773928|Active Comparator|Fluzone® (≥50 Years Old)|Fluzone®, licensed trivalent influenza vaccine (TIV)
89000238|NCT01768975|Experimental|OLT1177 Gel|4 mL per dose, applied 3 times per day on Days 1 - 13 with only one dose administered on Day 14, assuming TID on Day 1
89000239|NCT01768975|Placebo Comparator|Placebo gel|Identical dose and dosing regimen as the Investigational Drug (OLT1177 Gel)
89000240|NCT01756924|Experimental|CEM-102 plus Rifampin|
89000241|NCT01756924|Active Comparator|Standard of Care|
89000242|NCT00198861||Injection and Non-Injection Drug Users|(1) the degree to which specific executive dysfunctions predispose heroin and cocaine users to high-risk injection practices or sex behaviors, and (2) whether observed relationship between executive dysfunction and HIV-risk behaviors can be understood independent of levels of drug -taking frequency, or whether the observed data are more consistent with complex patterns of interdependency between executive dysfunction, drug-taking frequency, and HIV-risk-behaviors
89000243|NCT01756339|Experimental|Solithromycin|Solithromycin 800 mg orally (PO) on Day 1 followed by 400 mg PO daily on Days 2 through 5, followed by placebo on Days 6 and 7
89000244|NCT01756339|Active Comparator|Moxifloxacin|Moxifloxacin 400 mg PO daily on Day 1 through Day 7
89000245|NCT01754935|Experimental|VX-509 100 mg qd Arm|
89000246|NCT01754935|Experimental|VX-509 200 mg qd Arm|
89000247|NCT01754935|Experimental|VX-509 300 mg qd Arm|
89000248|NCT01754935|Placebo Comparator|Placebo Arm|
89000249|NCT01751152|Experimental|NNC0114-0006|
89000250|NCT01751152|Placebo Comparator|Placebo|
89000251|NCT00555178||1|Patients with polymorphic light eruption without medical photohardening treatment
89000252|NCT00555178||2|Patients with polymorphic light eruption treated with medical photohardening
89000253|NCT00555178||3|Patients with other disorders (including psoriasis) treated with phototherapy
89000254|NCT00555178||4|Normal healthy subjects
89533662|NCT03861572|Active Comparator|Traditional eccentric training|Participants will be engaged in an intervention program consisting of 12 weeks of traditional eccentric training. The training will be carried out with the volunteers at gym in stand position. Concentric phase will be realized with both legs and the eccentric one only with one of them. Training progression will be the same from de isokinetic eccentric group. The same periodization from eccentric group will be used to permit us a posteriori comparison between groups. Training sessions will be performed at university gym, twice a week, with a minimum interval of 72 hours between sessions. Each training session will comprise the same specific warming protocol for the ankle joint from the eccentric training.
89000255|NCT01750957|Placebo Comparator|Placebo|
89000256|NCT01750957|Experimental|RO4917523 Dose A|
89000257|NCT01750957|Experimental|RO4917523 Dose B|
89000258|NCT01746082|Experimental|Subjects 18 - 64 years|100 (up to 120) subjects 18 - 64 years old receive two doses of monovalent inactivated influenza H3N2 variant (MIV), delivered intramuscularly as 15 micrograms (mcg) of hemagglutinin (HA)/0.5 milliliter (mL) dose, 21 days apart.
89000259|NCT01746082|Experimental|Subjects > /= 65 years|100 (up to 120) subjects greater than or equal to 65 years old receive two doses of monovalent inactivated influenza H3N2 variant (MIV), delivered intramuscularly as 15 micrograms (mcg) of hemagglutinin (HA)/0.5 milliliter (mL) dose, 21 days apart.
89000260|NCT01745497|Experimental|Ferrous Sulfate|3mg/kg divided twice per day, 30 minutes before a meal or 2 hours after a meal
89000261|NCT01745497|Placebo Comparator|Placebo|Equivalent volume of liquid placebo administered twice daily, before a meal or 2 hours after a meal
89000262|NCT01743625|Experimental|COV155|COV155, loading dose of 3 tablets followed by 2 tablets every 12 hours for 48 hours.
89000263|NCT01743625|Placebo Comparator|Placebo|Matching tablet to COV155 without containing active ingredients, loading dose of 3 tablets followed by 2 tablets every 12 hours for 48 hours.
89000264|NCT01737892|Experimental|Arm T-Epinephrine Inhalation Aerosol HFA|Experimental arm utilizing Epinephrine HFA-MDI (E004)
89000265|NCT01737892|Active Comparator|Arm C-Epinephrine Inhalation Aerosol CFC|Active comparator arm utilizing Epinephrine CFC-MDI
89000266|NCT01731730|Placebo Comparator|Placebo (Vehicle) Injection|Single Intrathecal (spinal) administration of Placebo Injection just prior to intrathecal administration of spinal anesthetic for knee surgery
89000267|NCT01731730|Experimental|AYX1 Injection 110 mg|Single Intrathecal (spinal) administration of AYX1 Injection (110 mg) just prior to intrathecal administration of spinal anesthetic for knee surgery
89000268|NCT01731730|Experimental|AYX1 Injection 330 mg|Single Intrathecal (spinal) administration of AYX1 Injection (330 mg) just prior to intrathecal administration of spinal anesthetic for knee surgery
89000269|NCT01718938|Experimental|Sequence 1|3-way crossover of velusetrag or placebo
89000270|NCT01718938|Experimental|Sequence 2|3-way crossover of velusetrag or placebo
89000271|NCT01718938|Experimental|Sequence 3|3-way crossover of velusetrag or placebo
89000272|NCT01718938|Experimental|Sequence 4|3-way crossover of velusetrag or placebo
89000273|NCT00198939|Active Comparator|Psychoeducation|Drug education curriculum was delivered to participants assigned to this condition.
89000274|NCT00198939|Experimental|Conitive Behavorial Therapy|The cognitive-behavioral program introduces youths to problem-solving behavior change principles and study skills to promote school achievement.
88824990|NCT02310126|Active Comparator|etafilcon A(multi-focal)/etafilcon A(sphere)|Subjects were randomized to one of two lens wear sequences. subjects randomized to this sequence received etafilcon A (multi-focal) contact lens first and then the etafilcon A (sphere) contact lens second.
88824991|NCT02338362|Active Comparator|Fluticasone|10 participants will be asked to use fluticasone propionate 250 µg metered-dose inhaler 1 puff twice-daily for 6 weeks.
88824992|NCT02338362|Placebo Comparator|Saline placebo|10 participants will be asked to use a saline placebo metered-dose inhaler 1 puff twice-daily for 6 weeks.
88824993|NCT02363322|Active Comparator|A/Current Standard of Care Alone|A/Current Standard of Care Alone: Optimized standard of care to include aggressive fluid resuscitation, hemodynamic support, and other interventions available in an optimized care setting
88824994|NCT02363322|Experimental|B/Current Standard of Care Plus ZMapp|"B/Current Standard of Care Plus ZMapp: ZMapp (Trademark) + Optimized standard of care to include aggressive fluid resuscitation, hemodynamic support, and other interventions available in an optimized care setting.~ZMapp 50mg/kg IV administered every third day for 3 infusions."
88824995|NCT02361762|Experimental|Training|Computerized executive control training
88824996|NCT02361762|No Intervention|Waitlist|The waitlist group will not initially receive the training program. At the end of the study, the waitlist group will be offered training if it is efficacious.
88824997|NCT02337738|Experimental|TVP-1012 1mg|TVP-1012 1 mg once daily orally, before or after breakfast, concomitantly with levodopa tablet for 26 weeks as treatment period after 2 weeks of run-in period.
88824998|NCT02337738|Experimental|TVP-1012 0.5mg|TVP-1012 0.5 mg once daily orally, before or after breakfast, concomitantly with levodopa tablet for 26 weeks as treatment period after 2 weeks of run-in period.
88824999|NCT02337738|Placebo Comparator|Placebo|One placebo tablet once daily orally, before or after breakfast, concomitantly with levodopa tablet for 26 weeks as treatment period after 2 weeks of run-in period.
88825000|NCT02309112|Experimental|Yoga Group A: Minimum Exposure|The minimum-exposure yoga package, this intervention included 45-minutes of contact time with a trained yoga professional. In Week 1, this session included a 30-minute introductory session focussing on pranayama (breathing techniques), as well as a brief introduction to available community-based and online yoga to encourage a safe home-based practice (15-minutes). Financial subsidy, compensation or special promotion of any particular yoga was not provided. Participants were invited to stay for a social discussion following the yoga class.
88825001|NCT02309112|Experimental|Yoga Group B: Medium Exposure|The medium-exposure yoga package, this intervention included the components of Group A, with an additional 30-minute orientation and safety training of how to practice yoga dhyana (meditation techniques) and asana (physical postures) in Week 1. Participants were then invited to stay and ask questions following the yoga class. A pre-paid online yoga membership to http://www.myyogaonline.com was offered for the duration of the study (Weeks 1 to 4). In addition to this, one 120-minute workshop to further develop yoga pranayama, dhyana and asana training was administered by an expert instructor during Week 2 or 3.
88825002|NCT02309112|Experimental|Yoga Group C: Maximum Exposure|The maximum-dose yoga package, this intervention includes the components of Group A, with the same 30-minute orientation and safety training of how to practice yoga dhyana (meditation techniques) and asana (physical postures) in Week 1. Participants were invited to stay and ask questions following the yoga class. As in Group B, a pre-paid online yoga membership to http://www.myyogaonline.com was also provided for the duration of the study (Weeks 1 to 4). Participants were then invited to attend three 60-minute yoga group classes led by an expert yoga instructor per week (Weeks 1 to 4). These yoga sessions were held in a clinical setting in proximity to their treatment location and delivered at no cost to the patient.
88825003|NCT02361216|Experimental|Ingenol mebutate gel|Treatment once daily for 3 days
88825004|NCT02361216|Placebo Comparator|Vehicle|Treatment once daily for 3 days
88825005|NCT01803074|Experimental|Part A-Group 1: BMS-955176 (5 mg) or Placebo|"BMS-955176 5 mg solution by mouth once daily for 10 days~OR~Placebo matching with BMS-955176 0 mg solution by mouth once daily for 10 days"
88825006|NCT01803074|Experimental|Part A-Group 2: BMS-955176 (10 mg) or Placebo|"BMS-955176 10 mg solution by mouth once daily for 10 days~OR~Placebo matching with BMS-955176 0 mg solution by mouth once daily for 10 days"
88825007|NCT01803074|Experimental|Part A-Group 3: BMS-955176 (20 mg) or Placebo|"BMS-955176 20 mg solution by mouth once daily for 10 days~OR~Placebo matching with BMS-955176 0 mg solution by mouth once daily for 10 days"
88825008|NCT01803074|Experimental|Part A-Group 4: BMS-955176 (40 mg) or Placebo|"BMS-955176 40 mg solution by mouth once daily for 10 days~OR~Placebo matching with BMS-955176 0 mg solution by mouth once daily for 10 days"
88825009|NCT01803074|Experimental|Part B-Group 5: BMS-955176 + Atazanavir|"BMS-955176 40 mg solution by mouth once daily for 28 days~Atazanavir 2 x 200 mg capsules by mouth once daily for 28 days"
88825010|NCT01803074|Experimental|Part B-Group 6: BMS-955176 + Atazanavir + Ritonavir|"BMS-955176 40 mg solution by mouth once daily for 28 days~Atazanavir 1 x 300 mg capsules by mouth once daily for 28 days~Ritonavir 1 x 100 mg tablet by mouth once daily for 28 days"
88825011|NCT01803074|Experimental|Part B-Group 7: Atazanavir+Ritonavir+Tenofovir+Emtricitabine|"Atazanavir 1 x 300 mg capsule by mouth once daily for 28 days~Ritonavir 1 x 100 mg tablet by mouth once daily for 28 days~Tenofovir 1 x 300 mg tablet by mouth once daily for 28 days~Emtricitabine 1 x 200 mg capsule once daily for 28 days"
88825012|NCT01803074|Experimental|Part C-Group 8: BMS-955176 (40 mg) or Placebo|"BMS-955176 40 mg solution by mouth once daily for 10 days~OR~Placebo matching with BMS-955176 0 mg solution by mouth once daily for 10 days"
88825013|NCT01803074|Experimental|Part A-Group 9: BMS-955176 (80 mg) or Placebo|"BMS-955176 80 mg solution by mouth once daily for 10 days~OR~Placebo matching with BMS-955176 0 mg solution by mouth once daily for 10 days"
89000275|NCT00198939|Experimental|Family Therapy|Participants assigned to the Family Therapy arm received a family-centered intervention to support targeted adolescent behavior change. The family therapy component of IFCBT includes engagement, active treatment, and maintenance phases.
89533663|NCT03856515|Experimental|E-Cig placebo dose followed by E-Cig nicotine dose|Participants will be instructed to smoke their usual brand cigarette as they normally would in weeks 1-2 (Phase I) and to use only the SREC (with or without nicotine) in weeks 3-4 (Phase II) and in weeks 5-6 (Phase III). Participant assignment to SREC type at Phases II and III will be counter-balanced within group, with half of men and women receiving the placebo SREC during Phase II and half during Phase III. Participants will attend 4 laboratory visits with study investigators for 3 hours each over 6 weeks of study participation.
88825014|NCT01803074|Experimental|Part A-Group 10: BMS-955176 (120 mg) or Placebo|"BMS-955176 120 mg solution by mouth once daily for 10 days~OR~Placebo matching with BMS-955176 0 mg solution by mouth once daily for 10 days"
88825015|NCT01803074|Experimental|Part A-Group 11 (Optional): BMS-955176 (≤120 mg) or Placebo|"BMS-955176 ≤120 mg solution by mouth once daily for 14 days~OR~Placebo matching with BMS-955176 0 mg solution by mouth once daily for 14 days"
88825016|NCT01803074|Experimental|Part B-Group 12: BMS-955176 (80 mg) + Atazanavir|"BMS-955176 80 mg solution by mouth once daily for 28 days~Atazanavir 2 x 200 mg capsules by mouth once daily for 28 days"
88825017|NCT01803074|Experimental|Part C-Group 13: BMS-955176 (120 mg) or Placebo|"BMS-955176 120 mg solution by mouth once daily for 10 days~OR~Placebo matching with BMS-955176 0 mg solution by mouth once daily for 10 days"
88825018|NCT05328284||PASCAL|patients treated with PASCAL leaflet repair system in the treatment of TR in a commercial use setting
88825019|NCT05328206||Standard of care for intubated children with a cuffed endotracheal tube (c-ETT)|
88825020|NCT01805024|Experimental|Omigapil|Omigapil treatment oral administration once per day after breakfast Cohort 1 Cohort 1 0.02 mg/kg/day Cohort 2 0.08 mg/kg/day Cohort 3a 0.04 mg/kg/day Cohort 3b 0.06 mg/kg/day
88825021|NCT05328128|Experimental|Study Group|Children and families included in the study group were directed to the child development unit to receive toilet training.
88825022|NCT05328128|No Intervention|Control Group|The control group consisted of families who wanted to manage toilet training process themselves.
88825023|NCT05327894|Other|Medium Risk (MR)|Subject is defined as MR if > 6months of age at diagnosis, OR < 6 months of age with White Blood cell Count (WBC) < 300 at diagnosis and good prednisone response. Subject gets 1st cycle of blinatumomab. If MRD is >0.01%, after 1st cycle of blinatumomab, subject will be allocated to HR treatment from that phase, and will be eligible for HSCT. If MRD is undetectable or < 0.01% after the 1st cycle of blinatumomab (TP2) patient will be eligible for replacement of MARMA by 2nd cycle of blinatumomab after receipt of lymphoid style consolidation (Protocol IB) or of myeloid style consolidation (ADE/MAE).
88825024|NCT05327894|Other|High risk (HR)|"Subject is defined as HR if < 6 months of age with WBC > 300 at diagnosis OR poor prednisone response. Also MR patients with end of induction MRD ≥ 1%, or MRD > 0.01% after the 1st cycle of blinatumomab, will be allocated to HR treatment. Subject gets 1 cycle of blinatumomab.~Thereafter patient is eligible for hematopoietic stem cell transplantation (HSCT) with or without experimental therapy in an investigational window."
88825025|NCT02989766|Active Comparator|A - Intervention|Education on Breast Feeding 3 activity sheets prenatally-study related. Complete a pre-questionnaire, a pre-delivery and a postpartum questionnaire
88825026|NCT02989766|No Intervention|B - Standard of Care|Complete a pre-questionnaire, a pre-delivery and a postpartum questionnaire
88825027|NCT05327660|Active Comparator|Quitline treatment as usual (TAU)|Quitline services provided by participating state quitlines
88825028|NCT05327660|Experimental|Quitline TAU plus remote CO monitoring|Quitline service plus daily CO monitoring via a smartphone app
88825029|NCT05327660|Experimental|Quitline TAU plus incentivized remote CO monitoring|Quitline TAU plus remote CO monitoring with small monetary incentives
88825030|NCT01822574|Active Comparator|Cutting Guide Technique|The guide is clamped onto the patella and tightened so that it remains stable. The guide has a slot that allows insertion of a standard sagittal saw blade, and this slot guides the blade as it is advanced across the patella. The thickness is then measured in the center of the patella to ensure that the resection goal is achieved. Additional resection may be performed as needed.
88825031|NCT01822574|Active Comparator|Haptic Feedback Technique|It consists of a free hand cut (no guide used) with a standard sagittal saw that is oriented based on osteo-cartilaginous landmarks and haptic palpation of the patella by the surgeon. The resection thickness/obliquity can be altered based on haptic feedback (use of the sense of touch) of the patella. The thickness is then measured in the center of the patella to ensure that the resection goal is achieved. Additional resection may be performed as needed.
88825032|NCT01822574|Active Comparator|Four Quadrant Technique|Resection is performed in a free handed fashion, but after resection, the thickness of the patella is measured separately in all four quadrants (superolateral, superomedial, inferomedial, and inferolateral). Additional resection is performed as needed based on the quadrant measurements and the measurements are repeated after each resection until satisfactory resection thickness and symmetry are obtained.
88825033|NCT01822886|Experimental|Romidepsin, Gemcitabine|Romidepsin 12 mg/m2 day 1,8, 15 + Gemcitabine 800 mg/m2 day 1, 15 for 6 cycles by 28 days followed by Romidepsin 14 mg/m2 day 1, 15 to PD (progression disease)
88825034|NCT01823510|Experimental|Ticagrelor + Aspirin|Loading-dose plus daily-dosing for 5-7 days.
88825035|NCT01823510|Active Comparator|Clopidogrel + Aspirin|Loading-dose plus daily-dosing for 5-7 days.
89000276|NCT00198939|Experimental|Intergrated Family and Cognitve Behavioral Therapy|Participants assigned to the IFCBT arm received the Cognitive Behavioral Therapy and Family Therapy intervention components.
89000277|NCT01718158|Experimental|Peginterferon Lambda-1a + Ribavirin + Daclatasvir|"Peginterferon Lambda-1a 180 µg solution for subcutaneous injection, once a week for 24 Weeks~Ribavirin 200 mg tablets [1000-1200 mg total daily dose: subjects should take either 400 mg (2 tablets for subjects < 75 kg) or 600 mg (3 tablets for subjects ≥ 75 kg) in the morning with food and 600 mg (3 tablets) in the evening with food] by mouth, twice daily, for 24 weeks~Daclatasvir 60 mg tablets by mouth, once a day for 12 weeks"
89000278|NCT01718158|Experimental|Peginterferon Alfa-2a + Ribavirin + Telaprevir|"Peginterferon Alfa-2a 180 µg solution for subcutaneous injection, once a week for 24 to 48 weeks depending on response~Ribavirin 200 mg tablets [1000-1200 mg total daily dose: subjects should take either 400 mg (2 tablets for subjects < 75 kg) or 600 mg (3 tablets for subjects ≥ 75 kg) in the morning with food and 600 mg (3 tablets) in the evening with food] by mouth, twice daily, for 24 to 48 weeks depending on response~Telaprevir 375 mg tablets [2250 mg total daily dose: subjects should take 750 mg (two 375 mg tablets) orally three times a day, approximately 7-9 hours apart) for 12 weeks"
89000279|NCT00555256|Experimental|1|Patients will be instructed to take sunitinib and rapamycin every morning for 4 weeks, then to take 2 weeks off. The sunitinib dose will be 25mg in the first cohort and the rapamycin dose will be 2 mg.
89000280|NCT01703923|Experimental|FP01 6mg or Placebo|FP01 6mg Oral
89000281|NCT01703923|Experimental|FP01 12mg or Placebo|FP01 12mg Oral
89000282|NCT01703533|Experimental|NNZ-2566|Glycyl-L-2-Methylpropyl-L-Glutamic Acid
89000283|NCT01703533|Placebo Comparator|Placebo (strawberry flavored solution)|Strawberry flavored solution and Water for Injection
89000284|NCT00174434|Experimental|A|
89000285|NCT01702441|Experimental|AKB-9778|Up to 4 dose levels of subcutaneous AKB-9778 will be evaluated. Doses will be administered daily for 28 days.
89000286|NCT01691755|Placebo Comparator|Placebo|
89000287|NCT01691755|Experimental|aleglitazar|
89000288|NCT01674361|Experimental|Bitopertin 30 mg|"Participants in Stratum 1 will receive bitopertin 30 mg from Day 1 to Week 16 in addition to their background therapy with an SSRI.~Participants in Stratum 2 will receive placebo from Day 1 and will then start bitopertin 30 mg at the Week 2 until Week 16 in addition to their background therapy with an SSRI."
89000289|NCT01674361|Experimental|Bitopertin 10 mg|"Participants in Stratum 1 will receive bitopertin 10 mg from Day 1 to Week 16 in addition to their background therapy with an SSRI.~Participants in Stratum 2 will receive placebo from Day 1 and will then start bitopertin 10 mg at the Week 2 until Week 16 in addition to their background therapy with an SSRI."
89000290|NCT01674361|Placebo Comparator|Placebo|Participants (both Stratum 1 and Stratum 2) will receive placebo from Day 1 to Week 16 in addition to their background therapy with an SSRI.
89000291|NCT01667341|Experimental|Low Dose GEN-003 with Matrix M-2|10µg GEN-003, 50µg Matrix M-2 Adjuvant
89000292|NCT01667341|Experimental|Mid Dose GEN-003 with Matrix M-2|30µg GEN-003, 50µg Matrix M-2 Adjuvant
89000293|NCT01667341|Experimental|High Dose GEN-003 with Matrix M-2|100µg GEN-003, 50µg Matrix M-2 Adjuvant
89000294|NCT01667341|Experimental|Low Dose GEN-003 Only|10µg GEN-003
89000295|NCT01667341|Experimental|Mid Dose GEN-003 Only|30µg GEN-003
89000296|NCT01667341|Experimental|High Dose GEN-003 Only|100µg GEN-003
89000297|NCT01667341|Placebo Comparator|Placebo|0.5 mL phosphate buffered saline
89000298|NCT01665391|Experimental|fresolimumab 1 mg/kg total body weight|
89000299|NCT01665391|Experimental|fresolimumab 4 mg/kg total body weight|
89000300|NCT01665391|Placebo Comparator|Placebo|
89000301|NCT01665352|Experimental|TTP054 400 mg|
89000302|NCT01665352|Experimental|TTP054 200 mg|
89000303|NCT01665352|Experimental|TTP054 800 mg|
89000304|NCT01665352|Placebo Comparator|Placebo|
89000305|NCT01660633|Other|High-Dose Melphalan HCL for Injection (Propylene Glycol-Free)|Subjects will receive only High-Dose Melphalan HCL for Injection (Propylene Glycol-free) at 200mg/m2 (100mg/m2/day for two days).
89356294|NCT02507518|Experimental|Experimental|Two Pet scan Imaging will be done : 14 days before and 16 days after the beginning of maintenance therapy
89356295|NCT01298297|Active Comparator|Buprenorphine + Placebo|
89356296|NCT01298297|Placebo Comparator|Morphine + Placebo|
89356297|NCT04498312|Experimental|Shock wave group|Received Extracorporeal shock wave therapy twice/week for 4 weeks
89356298|NCT04498312|Experimental|Manual lympharic group|Received manual lymphatic drainage twice a week for four weeks
89356299|NCT01300715|Active Comparator|MBRF|
89356300|NCT02674464|Active Comparator|Standard of Care Plus|The standard of care plus arm will include audit and feedback of blood pressure control rates at the provider level along with web-based training about: 1) barriers to blood pressure and cardiovascular disease (CVD) risk factors management in at-risk patient populations; 2) strategies to address healthcare disparities in clinical settings; and 3) appropriate blood pressure (BP) measurement techniques for all clinical staff. The Hopkins research team will help clinics develop audit and feedback mechanisms if they are lacking and will provide all blood pressure measurement and web-based training.
89356301|NCT02674464|Experimental|Collaborative Care/Stepped Care (CC/SC)|The CC/SC arm includes: -BP training -Audit and feedback dashboard, data stratified by race, ethnicity, payor status -A 4 hour workshop for organizational leaders in quality improvement and disparities reduction, with follow up meetings for problem-solving and support, and web-based, patient-centered communication skills training program for providers and staff -Support and guidance in establishing collaborative care model (CCM): team-based care targeting health behaviors and medication adherence. The primary care provider (PCP), care manager, CHW, and specialists in: medication management, psychosocial/behavioral, and self-management will make up the CCM team -Community health workers (CHW) working on contextualized patient interactions focused on problem-solving skills and patient self-management. CHWs will visit their patients in their homes and communities -Provider access to on-call specialists for help with patients who do not achieve BP control under the CC/SC
89000306|NCT04676659|Experimental|Group 1 (rhTNK-tPA 0.10 mg/kg)|Dissolve one vial of rhTNK-tPA in 3 ml sterile water for injection to prepare a solution of 5.33 mg/ml. Calculate the required volume according to the body weight of the subject, then measure the required volume. Administer as a single 0.10 mg/kg IV bolus over 5-10 seconds.
89000307|NCT04676659|Experimental|Group 2 (rhTNK-tPA 0.25 mg/kg)|Dissolve one vial of rhTNK-tPA in 3 ml sterile water for injection to prepare a solution of 5.33 mg/ml. Calculate the required volume according to the body weight of the subject, then measure the required volume. Administer as a single 0.25 mg/kg IV bolus over 5-10 seconds.
89000308|NCT04676659|Experimental|Group 3 (rhTNK-tPA 0.32 mg/kg)|Dissolve one vial of rhTNK-tPA in 3 ml sterile water for injection to prepare a solution of 5.33 mg/ml. Calculate the required volume according to the body weight of the subject, then measure the required volume. Administer as a single 0.32 mg/kg IV bolus over 5-10 seconds.
89356302|NCT05525338|Experimental|TDM-guided dosing arm|
89356303|NCT05525338|No Intervention|Standard dose arm|Alectinib plasmaconcentration will be blinded untill the end of the trial. No intervention based on the alectinib plasmaconcentrion will be performed. In case of unacceptable toxicity (i.e. unbearable or persistent grade 2 toxicity and grade 3/4 toxicity), the alectinib dose can be reduced by 150mg BID.
89356304|NCT04302467|Experimental|GDFT group|Fluid maintenance with 2 ml/kg/h of Ringer's solution of sodium acetate, when SVV>13%, 4 mL/kg bolus of hydroxyethyl starch will be infused within 5 min. If SVV falls below 13%, the bolus will be suspended. If SVV is still more than 13%, 100 μg of phenylephrine will be administered when CI is more than 2.5 L/min/m2, 1 mg of dopamine will be administered when CI is less than 2.5 L/min/m2. When SVV<13%, but mean arterial pressure (MAP)<65 mmHg, 8 μg of norepinephrine will be administered. The hemodynamic status will be repeatedly measured every 10 min.
89000309|NCT04676659|Active Comparator|Group 4 (rt-PA 0.9 mg/kg)|10% of rt-PA 0.9 mg/kg administered as an initial IV bolus followed by the remaining 90% as an IV infusion over the next 1 hour.
89000310|NCT01655680|Experimental|ABT-126 Low Dose|ABT-126 Low Dose
89000311|NCT01655680|Experimental|ABT-126 Middle Dose|ABT-126 Middle Dose
89000312|NCT01655680|Experimental|ABT-126 High Dose|ABT-126 High Dose
89000313|NCT01655680|Placebo Comparator|Placebo|Placebo
89356305|NCT04302467|Experimental|restrictive fluid therapy group|fluid maintenance with 2 ml/kg/h of Ringer's solution of sodium acetate, hydroxyethyl starch will be infused to supply blood loss, the ratio of hydroxyethyl starch to blood loss is 1:1. 0.01-0.1 μg/kg/min of norepinephrine will be administered to maintain MAP>65 mmHg.
89356306|NCT03818945|Other|Sodium Fluoride Varnish|
89000314|NCT01653379|Experimental|DP001|DP001 softgel capsules; 55 ng to 550 ng per dose, administered 3 times weekly for 4 weeks
89000315|NCT01652482|Active Comparator|FOLFIRI + Cetuximab|
89000316|NCT01652482|Experimental|FOLFIRI + MEHD7945A|
89000317|NCT00174629|Experimental|1|
89000318|NCT00174629|Active Comparator|2|
89000319|NCT02962947|Placebo Comparator|PLACEBO|Placebo will be taken daily during the study period
89000320|NCT02962947|Active Comparator|PROPRANOLOL|Study participants in the treated group will take 80 mgR propranolol once daily .
89000321|NCT00555334|Experimental|1|nucleoid antiviral therapy after RFA
89000322|NCT00555334|Active Comparator|2|RFA only
89000323|NCT01640080|Experimental|Esketamine (Group 1)|
89000324|NCT01640080|Experimental|Esketamine (Group 2)|
89000325|NCT01640080|Placebo Comparator|Placebo|
89000326|NCT00174668|Experimental|1|Mealtime insulin glulisine 3x daily and insulin glargine 1 x daily subcutaneously
89000327|NCT00174668|Active Comparator|2|Two daily injection conventional insulin therapy
89000328|NCT01636843|Experimental|60 mg|
89000329|NCT01636843|Experimental|120 mg|
89000330|NCT01636843|Experimental|240 mg|
89000331|NCT01636843|Experimental|Placebo|
89000332|NCT00174707|Active Comparator|A|Sequential Epidoxorubicin followed by CMF: ciclophosphamide/Methotrexate/fluorouracile (±TAM: tamoxifen)
89000333|NCT00174707|Experimental|B|Sequential Epidoxorubicin followed by Docetaxel followed by ciclophosphamide/methotrexate/fluorouracile (± TAM)
89000334|NCT00174707|Experimental|C|Sequential Intensified Epidoxorubicin followed by Docetaxel followed by Cyclophosphamide (± TAM)
89000335|NCT01635907|Experimental|Dovitinib|
89000336|NCT01633372|Experimental|itacitinib 100 mg|itacitinib 100 mg twice a day
89356307|NCT03818945|Active Comparator|PRG barrier Giomer|
89000337|NCT01633372|Experimental|itacitinib 200 mg|itacitinib 200 mg twice a day
89177150|NCT04105569|Experimental|Healthy Volunteers|Enrolled subjects will be included in an experimental gingivitis model (SIBO) for 21 days and use an acrylic stent fabricated before and dispensed at the baseline appointment
89356308|NCT02501824|Experimental|speech therapy first|11 sessions of speech therapy (anthroposophic therapeutic speech), then waiting phase
89356309|NCT02501824|Experimental|speech therapy second|10 weeks of waiting, then 11 sessions of speech therapy (anthroposophic therapeutic speech)
89000338|NCT01633372|Experimental|itacitinib 300 mg|itacitinib 300 mg once a day
89000339|NCT01633372|Experimental|itacitinib 400 mg|itacitinib 400 mg once a day
89000340|NCT01633372|Experimental|itacitinib 600 mg|itacitinib 600 mg once a day
89000341|NCT01235923|Active Comparator|three times weekly Epo|Epo 400 units/kg three times weekly given subcutaneously for 4 weeks
89000342|NCT01235923|Active Comparator|weekly Epo|1,200 units/kg given once a week subcutaneously for 4 weeks
89000343|NCT01144741||Freeman-Sheldon syndrome Classic Type|"Patients who have all features required by the Stevenson criteria, including: very small mouth (microstomia); whistling-face appearance (pursed lips); H or V shaped chin dimple; very obvious down-slanting crease from the nostril to the corners of the mouth (nasolabial creases); and restricted movement in joints (contractures) of two or more body areas, often hands and feet, with fingers and toes frequently overlapping."
89000344|NCT01144741||Freeman-Sheldon syndrome Craniofacial Type|"Patients who have only the face and skull physical findings required by the Stevenson criteria, including: very small mouth (microstomia), whistling-face appearance (pursed lips), H or V shaped chin dimple, very obvious down-slanting crease from the nostril to the corners of the mouth (nasolabial creases)."
89000345|NCT01144741||Freeman-Sheldon syndrome Mixed Type|Patients who have the face and skull physical findings required by the Stevenson criteria and some but not all required joint problems.
89000346|NCT01144741||Sheldon-Hall syndrome|Patients who have all features required by the Stevenson criteria, including: small mouth (not microstomia); neck webbing (pterygium colli); small but prominent chin; very obvious down-slanting crease from the nostril to the corners of the mouth (nasolabial creases); and restricted movement in joints (contractures) of two or more body areas, often hands and feet, with fingers and toes frequently overlapping.
89000347|NCT01144741||Distal Arthrogryposis Type 1|Patients with features consistent with this diagnosis, including restricted movement in joints (contractures) of two or more body areas, often hands and feet, with fingers and toes frequently overlapping.
89000348|NCT01144741||Distal Arthrogryposis Type 3|Patients with features consistent with this diagnosis, including: gap in the roof of the mouth (cleft palate); drooping eyelid (blepharoptosis); and backbones curve problems; and restricted movement in joints (contractures) of two or more body areas, often hands and feet, with fingers and toes frequently overlapping.
89000349|NCT01080196|Experimental|RENEW|"RENEW will occur on a recumbent ergometer that appears like a normal stepper ergometer. While resisting the foot pedal movement the participant experiences eccentric muscle contractions about the knee and hip while performing negative work. The progression of the 3 x/week (every other day), 12 week RENEW program will be determined as a function of the rating of perceived exertion (RPE) using a target workload on the monitor. RENEW will be increased very slowly over the first 3 weeks and, subsequently, to maintain an 11-13 perceived exertion. During the formal RENEW training regimen the participants become fully acclimated to the device (week 3-4) the total RENEW load will increase weekly with no increase in their RPE."
88825036|NCT00971828||Idiopathic inflammatory myopathy|IIM patients will be recruited via the Adult Onset Myositis clinic, Salford Royal NHS Foundation Trust. Suitable patients will be asked if they are willing to partake in the study, via a letter, including a patient information leaflet. If willing, they will contact our study co-ordinator, who will facilitate the visit to the WTCRF. The patient will then sign a consent form and be able to enter the study.
88825037|NCT05327582|Experimental|PLENA regimen|Subject received PLENA regimen every 3 weeks until achieving a second assessable complete response or up to a maximum of 8 cycles. Treatment continued until progressive disease or intolerable toxicity, or withdrawal of consent.
88825038|NCT00681200|Active Comparator|Enhanced health education program|This active treatment group consists of classes in health education and a social support group to enhance participant motivation and positive reinforcement to make healthier lifestyle choices (e.g. wholesome diet, increased exercise, reduced salt intake, and decreased use of alcohol and smoking). Note that this comparison group does not have a stress management component.
88825039|NCT00681200|Experimental|Transcendental Meditation program|Transcendental Meditation program plus health education. Basic American Heart Association (AHA) recommendations for lifestyle modification to reduce risk of heart disease will be given in a didactic classroom context.
88825040|NCT05327036||pregnant women with Single Umbilical Artery|pregnant women with Single Umbilical Artery
88825041|NCT05327036||pregnant women with Umbilical Artery Embolism|pregnant women with Umbilical Artery Embolism
88825042|NCT05327036||Normal pregnant women|Normal pregnant women without pregnancy complications
88825043|NCT01824446|Experimental|Radiolabeled SPD602|
88825044|NCT02263040|Experimental|High Dose Fluzone|Fluzone High-Dose® Licensed for use in the USA in persons ≥ 65 years of age as a single dose of 0.5 mL containing 60μg hemagglutinin per virus strain
88825045|NCT02263040|Active Comparator|Fluzone (standard dose)|Fluzone ® Licensed for the prevention of influenza as a single dose of 0.5 mL containing 15μg hemagglutinin per virus strain for adults
89356310|NCT05281289|Experimental|Kinesio-tape application+stretchinge exercises|"the patient received AYstripof KT was applied to the testing leg 30% tension for 48h and was asked to assume comfortable supine position and the therapist applied 15 seconds of passive stretch to the calf muscle followed by 30 seconds of rest and this exercise was repeated 6 times per session for 2 days and ecieved instructions about dealing with calf cramps with self low sustained stretch of calf muscle."
88825046|NCT02271698|Active Comparator|Dexamethasone 6mg|Patients receive 6mg iv dexamethasone at surgical incision and a repeat dose of 6mg of dexamethasone 24h after incision. Pain scores and opioid consumption will be assessed using iv opioid patient controlled analgesia totals.
88825047|NCT02271698|Active Comparator|Dexamethasone 12mg|Patients receive 12mg iv dexamethasone at surgical incision and a repeat dose of 12mg of dexamethasone 24h after incision. Pain scores and opioid consumption will be assessed using iv opioid patient controlled analgesia totals.
88825048|NCT02271698|Active Comparator|Dexamethasone 24mg|Patients receive 24mg iv dexamethasone at surgical incision and a repeat dose of 24mg of dexamethasone 24h after incision. Pain scores and opioid consumption will be assessed using iv opioid patient controlled analgesia totals.
88825049|NCT02271698|Placebo Comparator|Placebo|Patients receive a placebo injection of saline at surgical incision and a repeat placebo saline injection 24h after incision. Pain scores and opioid consumption will be assessed using iv opioid patient controlled analgesia totals.
88825050|NCT02272244|Active Comparator|Standard|SI Group participants will be mailed a set of standard materials. The materials will include a letter from the participant's primary care practice encouraging selection and performance of either (1) colonoscopy screening, or (2) stool blood test (SBT) screening. Accompanying the letter will be instructions for arranging a colonoscopy appointment and instructions for completing an enclosed immunochemical SBT kit. Print materials and contacts will be provided, in both English and Spanish, after the baseline survey. At 45 days following random assignment that encourages screening.
88825051|NCT02272244|Experimental|Decision Support & Navigation|DSNI Group will be mailed print materials, including a letter from the practice on CRC screening, an informational booklet, and instructions for arranging a colonoscopy appointment and for completing an enclosed immunochemical SBT kit. All materials will be provided in both English and Spanish. Within 7 days after this mailing, participants will receive a telephone call from a trained bilingual study navigator. Following the call, the navigator will enter the participant's screening plan into the participant's electronic medical record, send the participant a letter describing the screening plan, and send the participant's primary care provider a copy of that same letter. At 45 days following random assignment, research staff will send participants a reminder letter encouraging the participant's preferred test. At 6 months after randomization, the navigator will send the provider and their office manager a participant CRC screening status report.
88825052|NCT02328404|Active Comparator|vitamin D3 (Biodal 50,000 IU)|50,000 IU Vitamin D3 tablet given orally once weekly for 3 months
88825053|NCT02328404|Placebo Comparator|placebo|Placebo tablet given orally once weekly for 3 months
88825054|NCT02989376|Experimental|carotid duplex ultrasound|Single arm study. After detection of occluded vessels by vascular imaging using carotid duplex ultrasound, digital subtraction angiography is immediately performed before acute endovascular treatment.
88825055|NCT01829516|Experimental|Oxytocin|50 moderate to heavy social alcohol users will receive a single dose 40 IU of intranasal oxytocin.
88825056|NCT01829516|Placebo Comparator|Placebo|"50 moderate to heavy social alcohol users will receive a single dose 40 IU of intranasal placebo.~NOTE: This is a cross-over design and subjects will participate in both arms."
88825057|NCT01830140|Experimental|Bimatoprost 0.01%|Bimatoprost 0.01% (LUMIGAN® 0.01%) administered each evening in both eyes for 6 weeks.
88825058|NCT01830140|Active Comparator|Bimatoprost 0.03%|Bimatoprost 0.03% (LUMIGAN® 0.03%) administered each evening in both eyes for 6 weeks.
88825059|NCT01830842|Placebo Comparator|Nicotine, placebo|Nonsmokers will be measured following a nicotine polacrilex lozenge (2mg) on one occasion and placebo on another occasion.
88825060|NCT01830842|Other|Nicotine withdrawal or satiety|Smokers will be measured in a normal satiated condition and following 24-hours of smoking abstinence
89177151|NCT00804544|Experimental|1|Mammoscintigraphy with SPECT-CT optimized 99mTc-MIBI imaging (experimental arm) will be compared to conventional planar imaging. Mammoscintigraphy results before and after chemotherapy and radiation therapy, will be compared to the histopathological results after surgery.
89177152|NCT01019551|Experimental|ARM A : ART intensification alone|Raltegravir PO 400 mg BID Maraviroc PO 150, 300 or 600 mg BID depending on the concomitant ART regimen
89177153|NCT01019551|Experimental|ARM B : ART intensification + Immunomodulation|Raltegravir PO 400 mg BID during 56 weeks Maraviroc PO 150, 300 or 600 mg BID depending on the concomitant ART regimen during 56 weeks 3 weekly injections of r-hIL-7 (CYT107) at a 20 micrograms/kg dose starting at Week 8
89177154|NCT00787137|Experimental|PG102 0.3 mg/kg|Lowest dose PG102
89177155|NCT00787137|Experimental|PG102 1 mg/kg|Second dose PG102
89177156|NCT00787137|Placebo Comparator|Placebo (phosphate-buffered saline)|Control
89177157|NCT02553226|Active Comparator|Continued group|Recieve routine treatment with oxytocin according to the danish national guidelines.
89177158|NCT02553226|Placebo Comparator|discontinued group (placebo)|The routine treatment with oxytocin will be discontinued and replaced with isotonic saline, when the active phase of labour is established.
89177159|NCT00810316|Other|Treatment A|
89177160|NCT00810316|Other|Treatment B|
89177161|NCT00810316|Other|Treatment C|
89177162|NCT00448435|Active Comparator|SLM+FP First|SLM(salmeterol) 25mcg + FP(fluticasone propionate) 50mcg twice daily in first intervention period and SFC(salmeterol/fluticasone propionate) 25/50mcg twice daily in second intervention period and (after washout period).
89177163|NCT00448435|Active Comparator|SFC First|SFC (Salmeterol/Fluticasone propionate combination) 25/50mcg twice daily in first intervention period and SLM (Salmeterol) 25mcg + FP (Fluticasone Propionate) 50mcg twice daily in second intervention period (after washout period).
89177164|NCT00448435|Experimental|SFC|SFC (salmeterol/fluticasone propionate combination) 25/50mcg twice daily in Extension period (after cross-over period).
89177165|NCT00804622|Active Comparator|1|tenofovir disproxil fumarate 300 mg monotherapy
89177166|NCT00804622|Active Comparator|2|telbivudine 600 mg monotherapy
89177167|NCT00804622|Active Comparator|3|telbivudine 600 mg and tenofovir disproxil fumarate 300 mg
89177168|NCT02603055|Experimental|30μg/0.5ml Hepatitis E vaccine|three doses, 30μg/0.5ml per dose
89177169|NCT02603055|Active Comparator|30μg/0.5ml Recombinant Hepatitis E vaccine|30μg/0.5ml Hepatitis E vaccine developed by Xiamen innovax biotech Co., Ltd. three doses, 30μg/0.5ml per dose
89177170|NCT00810472|Experimental|HLA Matching|HLA matching is exerted by selecting the donor with least-most additional HLA alleles. We will predict the waiting time for such a donor in order to assess eligibility for the trial [8]. In addition, we will dynamically adopt the degree of matching that is aimed at depending on the predicted time interval and actual waiting time: the first donors not exerting more than 7 mismatches at the triplet-amino-acid-residue-level (HLAMatchmaker method [6]) is accepted if the patient is waiting less than half of his predicted waiting time. The next available donor exerting a 2/6 match (or better) is assigned thereafter. The next graft will be assigned, regardless of HLA matching after 6 months.
89177171|NCT00810472|Placebo Comparator|Random graft assignment|
89177172|NCT02603289||Teen|< 17 years of age
89177173|NCT02603289||Adult|17 years of age or older
89177174|NCT02603289||Adult with Primer Aligners|17 years of age or older This group will get Primer Aligners
89177175|NCT00804700|Active Comparator|Control Group|Subjects will be given a 60 minute lecture on the benefits of regular exercise and how music can enhance the exercise experience. Subjects will be individually instructed how to use the Precor elliptical trainer at the Yates fitness center while listening to music. Subjects are instructed to exercise using the elliptical trainer for periods of 45 -55 minutes at a time as frequently as they like with a minimum frequency of once per week. Subjects will also be encouraged to exercise regularly by walking, jogging or engaging in other forms of physical activity during the intervention period. A fitness attendant will be on hand to supervise their exercise activity, but will not give specific advice how to exercise, other than to make sure they are exercising safely.
89177176|NCT00804700|Experimental|Intervention Arm|Subjects will be instructed to exercise while listening to four audio tutorials that are stored on their MP-3 player. These tutorials guide the subject on how to synchronize his or her body movements to the beat of the music.
89356311|NCT05281289|Experimental|self low sustained strestch|the patient recieved instructions about dealing with calf cramps with self low sustained stretch of calf muscle.
89356312|NCT02631798|Experimental|Dye staining|Food grade dye mucosal staining
89177177|NCT02602899|Experimental|PINS Deep Brain Stimulator|Deep Brain Stimulator is on,continuous stimulation to the brain,
89177178|NCT02553070||Pharmacy Students|Participants will be asked to indicate their perception of poisoning severity by answering a short survey.
89177179|NCT02602743|Experimental|remifentanyl, ketamine|Experimental:Remifentanyl and ketamine Remifentanyl vial 2 mg, Ketamine vial 500mg/10 mlt by intravenous. 2 mg/kg ketamine and 0,25 µg/kg remifentanyl will be administered for induction in 1 minute. Then 0,1 µg/kg/h remifentanyl infusion will be started.
89356313|NCT03344068|Experimental|Experimental Group|The patients in the Experimental Group are allocated to receive radical radiotherapy with or without chemotherapy plus Nutren® Optimum of 7 scoops tid at begin of radiotherapy.
89356314|NCT03344068|Active Comparator|Controlled Group|The patients in the Controlled Group are allocated to receive radical radiotherapy with or without chemotherapy plus routine diet guidance at begin of radiotherapy.
89356315|NCT01330056|Active Comparator|FOPS|"Functional organ preservation surgery (FOPS) group as a first-line treatment modality~Postoperative RT or CRT may be included for the patients of this group"
89356316|NCT01330056|Active Comparator|CRT|"Concurrent chemoradiotherapy or radiotherapy group as a first-line treatment modality~Salvage surgery may be applied for the patients for persistent or recurrent cancers after CRT or RT"
89356317|NCT01206335|Experimental|OHR/AVR118|Experimental Drug
89356318|NCT02501668||Lung cancer in population|Lung cancer cases in sample population (670,258 cases)
89356319|NCT02501668||COPD in population|COPD cases (670,258 cases)
89356320|NCT02501668||COPD with lung cancer|Lung cancer in COPD
89356321|NCT02501668||ILD without IPF|Interstitial lung disease (ILD) cases without idiopathic pulmonary fibrosis (IPF)
89356322|NCT02501668||ILD with lung cancer|Lung cancer cases in ILD
89356323|NCT02501668||Idiopathic pulmonary fibrosis|Idiopathic pulmonary fibrosis cases
89356324|NCT02501668||IPF with lung cancer|Lung cancer cases in IPF patients
89356325|NCT02501668||Connective tissue disorder with ILD|CTD with ILD cases
89356326|NCT02501668||CTD ILD with lung cancer|Lung cancer cases in CTD with ILD
89356327|NCT02501668||CTD without ILD|CTD with ILD cases in sample population
89356328|NCT02501668||CTD without ILD with lung cancer|Lung cancer in CTD without ILD
89356329|NCT02562612|Experimental|SM-88|SM-88 multiple ascending doses
89356330|NCT02501356|Active Comparator|ISOThrive supplement 1|Participants assigned to the ISOThrive supplement arm will be provided with daily servings of a supplement for 3 months. Participants will be instructed to take the supplement with water daily, once/day in the morning during the treatment period.
89356331|NCT02501356|Active Comparator|ISOThrive supplement 2|Participants assigned to the ISOThrive supplement arm will be provided with daily servings of a supplement for 3 months. Participants will be instructed to take the supplement with water daily, once/day in the morning during the treatment period.
89356332|NCT02501356|Placebo Comparator|Placebo supplement|Participants assigned to the placebo supplement arm will be provided with daily servings of a supplement for 3 months. Participants will be instructed to take the supplement with water daily, once/day in the morning during the treatment period.
89177180|NCT02602743|Active Comparator|propofol, ketamine|"Active comparator:Propofol and ketamine Propofol injectable emulsion vial 200 mg/20 mlt, Ketamine vial 500mg/10 mlt by intravenous.~2 mg/kg ketamine and 1 mg/kg propofol will be administered for induction and then 1 mg/kg/h propofol infusion will be started."
89177181|NCT00810550|Other|LV systolic dysfunction|Diagnostic Testing
89177182|NCT00807118|Experimental|A (Cohort I)|
89177183|NCT00807118|Experimental|B (Cohort I)|
89177184|NCT00807118|Experimental|C (Cohort I)|
89177185|NCT00807118|Experimental|B (Cohort II)|
89177186|NCT00807118|Experimental|D (Cohort II)|
89177187|NCT00807118|Experimental|E (Cohort II)|
89177188|NCT00804778||CABG,general anesthesia|their CO and CI was measured with USCOM and Swan-ganz cco respectively.
89177189|NCT00804778||group 1|co measured with swan-ganz cco combined with vigilance
89177190|NCT02552446||All patients|All ICU patients mechanically ventilated staying more than 72 hours were included and indirect calorimetry was performed and compared to predictive energy expenditure formulas using different body weights.
89177191|NCT00810628|Experimental|1|All subjects in same investigative group with same CBT intervention.
89356333|NCT03636516|Active Comparator|jj stent yes|
89177192|NCT00448279|Active Comparator|Chemotherapy Alone|Chemotherapy, schedule and dose at the investigator's discretion.
89177193|NCT00448279|Experimental|Chemotherapy, Trastuzumab|Trastuzumab, at the investigator's discretion, either 2 milligrams per kilogram (mg/kg) intravenous (i.v.) every 7 days or 6 mg/kg i.v. every 3 weeks. Chemotherapy, schedule and dose at the investigator's discretion.
89356334|NCT03636516|Active Comparator|jj stent no|
89356335|NCT05622695||Catheterization Arm|Participants will be limited to adults older than 18 years of age, able to consent, planned for the cardiac catheterization lab for a right heart catheterization or in the cardiac care unit with an existing arterial line or Swan-Ganz catheter actively measuring the pulmonary artery pressure on a continuous basis.
89177194|NCT01024153|Experimental|Active video game play|
89177195|NCT00810706|No Intervention|1: observation only|Patients have completed at least 5 years and not more than 7 years of continued treatment with tamoxifen (20 mg/day). Tamoxifen could have been discontinued up to 6 months prior to study entry.
89177196|NCT00810706|Active Comparator|2: Exemestane|Patients randomised to receive exemestane (25 mg/day) for 5 years, following completion of 5-7 years of Tamoxifen treatment
89356336|NCT03343990||group A|Interlocking multi-twisted wires techniqe in sternal closure
89356337|NCT03343990||group B|Eight Figure techniqe in sternal closure
89356338|NCT03842423||Study Group|All patients under the age of 18 who were treated for upper extremity injuries between 2002 and 2018 and receiving brachial plexus anaesthesia.
89356339|NCT03172026|Experimental|Maraviroc + Augmented Rehabilitation|Participants will take Maraviroc 300 mg daily for 60 days, plus receive rehabilitation therapy as prescribed by the doctors and via telerehabilitation.
89356340|NCT03172026|Placebo Comparator|Placebo + Augmented Rehabilitation|Participants will take placebo 300 mg daily for 60 days, plus receive rehabilitation therapy as prescribed by the doctors and via telerehabilitation.
89356341|NCT01201577|Active Comparator|Placebo/Probiotic|
89356342|NCT01201577|Active Comparator|Placebo/Prebiotic|
89356343|NCT01201577|Active Comparator|Prebiotic/Probiotic|
89000350|NCT01080196|No Intervention|TRADITIONAL|"The TRAD group will perform their lower extremity resistance exercise for 15 minutes per session with isotonic weight machines and cuff weights as part of their multicomponent exercise fall reduction program (MCERFP). The progression of the 3 x/week, 12 week TRAD program will be determined as a relative function of their 1 repetition maximum (1RM) weight that can be lifted in a safe and successful manner. The 1RM will be measured before the 12 week training program and every 2 weeks thereafter. A target resistance workload (i.e., weight level) commensurate with 60-70% of the 1RM of the knee and hip extensors will be calculated bi-monthly and 3 sets of 15 repetitions of 3-4 different knee and hip exercises will be used over a 15 minute time period."
89000351|NCT00199134|Other|Letrozole|Letrozole 2.5 mg per day
89000352|NCT00712582|Experimental|Consolidation A|"Induction: RR-CHOP-14 Chemotherapy for Three Cycles Each cycle lasts approximately 14 days. A total of 3 cycles of RR-CHOP-14 will be given. One cycle of CHOP will follow.~Patients whose disease is FDG-PET negative or patients whose FDG-PET scan is positive but repeat biopsy is negative and whose initial Ki-67 expression is < 80% will receive 3 cycles of standard dose ICE Chemotherapy."
89000353|NCT00712582|Experimental|Consolidation B|"Induction: RR-CHOP-14 Chemotherapy for Three Cycles Each cycle lasts approximately 14 days. A total of 3 cycles of RR-CHOP-14 will be given. One cycle of CHOP will follow.~Patients whose disease is FDG-PET negative or patients whose FDG-PET scan is positive but repeat biopsy is negative and whose initial Ki-67 expression is ≥80% will receive 2 cycles of augmented RICE Chemotherapy (as per MSKCC protocol 03-075)."
89000354|NCT00712582|Experimental|Consolidation C|"Induction: RR-CHOP-14 Chemotherapy for Three Cycles Each cycle lasts approximately 14 days. A total of 3 cycles of RR-CHOP-14 will be given. One cycle of CHOP will follow.~Consolidation C: Patients with biopsy proven disease after induction therapy. Patients whose bone marrow remain positive at interim restaging will have the option of getting an allogeneic[m3] stem cell transplant, in lieu of an ASCT, if they have an acceptable HLA match donor. The allogeneic[m4] stem cell transplant regimen will be decided by the MSK Bone Marrow Transplant Service."
89000355|NCT02894359||CD patients|10 patients with a cervical dystonia
89000356|NCT02894359||control subjects|10 healthy patients
89000357|NCT00175058|No Intervention|1|Control - Patients with acute anterior myocardial infarction revascularized by means of PCI with stenting within 6 hours of onset of symptoms, no experimental intervention
89000358|NCT00175058|Experimental|2|AO Therapy group - anterior acute myocardial infarction patients revascularized by means of PCI with stenting within 6 hours of symptom onset, receiving adjunctive infusion of hyperoxemic blood into target coronary artery for 90 minutes post-PCI.
89000359|NCT00555373|Other|Sirolimus|Single arm
89000360|NCT00555412|Experimental|A - 10 mg loxapine q 4 h x 3 (30 mg total)|
89000361|NCT00555412|Experimental|B - 10 mg x 1, 5 mg x 2 loxapine q 4 h (20 mg total)|
89000362|NCT00555412|Experimental|C - 5 mg loxapine q 4 h x 3 (15 mg total)|
89000363|NCT00555412|Placebo Comparator|D - inhaled placebo q 4 h x 3|
89000364|NCT00555490|Experimental|1|
89000365|NCT00175097|Other|soybeans and products made thereof|Diet: soybeans and products made thereof (soynuts, soynut butter, soy flakes & grits)
89000366|NCT00175097|Other|soybean flour and products made thereof|Diet: soybean flour and products made thereof (textured soybean)
89000367|NCT00175097|Other|soybean milk|Diet: soybean milk (tofu, soybean yogurt, cheese, etc.)
89000368|NCT00175097|Other|animal protein based diet|Diet: animal protein based diet
89000369|NCT02894242|Experimental|F&P Deimos Nasal Pillows Mask|Participants to use nasal pillows mask in-home for 2 weeks.
89000370|NCT02894281||Measure of pupillary light reflex|patients without optic neuritis
89000371|NCT02894281||patients with optic neuritis|clinical database of 22 patients (measurement of pupillary light reflex already performed for the same purpose, in a former study)
89000372|NCT02894125||old subject|
89000373|NCT02894320||Parkinson's disease|
89000374|NCT02894320||Healthy subjects|gender and age matched with Parkinson's disease patients, whose data will be extracted from an existing database
89000375|NCT00199290|Placebo Comparator|P|
89000376|NCT00199290|Experimental|L|low dose (0.2 %)
89000377|NCT00199290|Experimental|M|medium dose (0.3 %)
89000378|NCT00199290|Experimental|H|high dose (0.4 %)
89000379|NCT04676542|Experimental|One group taking part in 2 separate conditions|The proposed research design will be utilizing a randomized cross over repeated measures design. Subjects will take part in two separate conditions: 1) One hour of a beginning martial art class (EP), and 2) One hour walk at 4.0 mph pace (IP).
89000380|NCT04676776|Experimental|Missed period pill regimen|1.5 mg levonorgestrel given on day 1 200 mg mifepristone given on day 3
89000381|NCT04676464||ultra- sound|ultra- sound assessment of their quadriceps muscle layer thickness (QMLT)
89000382|NCT04676230|Experimental|Experimental group|caries management based on the ICCMSTM: Patient intervention according to the caries risk likelihood: high, moderate or low. Surfaces intervention according to the surface diagnosis decision matrix (ICCMSTM): Mi: Initial caries management, Mm: Moderate caries management, and Me: Extensive caries management.
89000383|NCT04676230|Active Comparator|Control group|Systematic patient caries risk intervention (all managed as high risk patients). Surfaces intervention with conventional caries management of cavitated/dentin caries lesions (restorative treatment).
89000384|NCT04676074|No Intervention|control group|the participant will not do any exercise program but just they will take the routine medication.
89177197|NCT00807196|Experimental|T|
89000385|NCT04676074|Experimental|study group|will receive normal routine medication with the treatment program of moderate intensity upper limb ergometer for 15 minute with frequency three times per week for four weeks.
89000386|NCT04676113||Pediatric Patients with Sickle Disease who are overweight/obese|Pediatric Patients age 10-19 years diagnosed with Sickle cell disease who have a BMI of >85%ile.
89000387|NCT04676113||Pediatric Patients with Sickle Cell Disease who are underweight/normal weight|Pediatric Patients age 10-19 years diagnosed with Sickle Cell disease who have a BMI<85%ile.
89000388|NCT04675645|Other|HU-Go app intervention arm|Participants will use HU-Go app intervention arm for a total of 12 weeks.
89000389|NCT04675684|Experimental|Recovery-group|"The recovery group consists of:~Physical, mental and social health education, advice and feedback from a health investigator.~Daily self-monitoring about their mood and health in an app, Monsenso.~Intersectoral collaboration between 1) Mental Health Centre Copenhagen Rigshospitalet, IAOC 2) Centre for Research and Education in General Practice, University of Copenhagen 2) Centre for Social Medicine at Frederiksberg Hospital, 3) Competence Centre for Rehabilitation and Recovery, Mental Health Centre Ballerup, and 5) Private Practicing Psychiatrists."
89000390|NCT04675684|No Intervention|Control-group|The control group consists of usual treatment at their General Practitioner and / or Private Practicing Psychiatrist.
89000391|NCT00555529||1|
89000392|NCT00555529||2|
89000393|NCT00555607|Active Comparator|steroid|Group receiving oral prednisolone (0.5 mg/kg bodyweight per day) during 14 days.
89000394|NCT00555607|Placebo Comparator|placebo|Group receiving placebo tablets during 14 days, followed by an open prednisolone treatment (0.5 mg/kg bodyweight per day) during a following 14 days.
89000395|NCT02963792|Experimental|Structured group intervention|"Experimental: Structured group intervention a 'structured' intervention, leaning mostly on tools designed to prevent burnout and promote resilience, including predetermined exercises and topics as discussion goals in each meeting.~Fidelity will be checked and monitored at the end of each meeting, when facilitators fill out a form that summarizes the content, topics and coping skills acquired in each session."
89000396|NCT02963792|Experimental|Semi-Structured group intervention|"Experimental: Semi-Structured group intervention a 'semi-structured' intervention, based on tools for developing an emotional discourse, building a supporting team and self reflection.~The 'semi-structured' intervention offers predetermined contents that are discussed through the stories and needs presented by group members.~Fidelity will be checked and monitored at the end of each meeting, when facilitators fill out a form that summarizes the content, topics and coping skills acquired in each session."
89000397|NCT00555685|Active Comparator|A|Group of patients that will receive hypertonic saline solution (NaCl 7,5%)
89000398|NCT00555685|Placebo Comparator|B|Group of patients that will receive placebo
89000399|NCT00555724|Experimental|BIIB022|
89000400|NCT00555763|Active Comparator|1|
89000401|NCT04675528|Experimental|Fasting treatment|
89000402|NCT04675528|Experimental|Fed treatment|
89000403|NCT04675177|Active Comparator|Polidocanol foam sclerotherapy|Patients submitted to polidocanol foam sclerotherapy
89000404|NCT04675177|Active Comparator|Doppler-guided hemorrhoidal artery ligation|Patients submitted to doppler-guided hemorrhoidal artery ligation
89000405|NCT00204243|Experimental|Naltrexone implant|Naltrexone implant (GoMedical Inc. 6 months implant)
89000406|NCT00204243|Active Comparator|Methadone|Methadone Maintenance Treatment
89000407|NCT04675372|Experimental|Group 1|Dexmedetomidine group (Group DEX) was given 1.5ug/kg/h Dexmedetomidine continuous infusion Dexmedetomidine group (Group DEX)
89000408|NCT04675372|Active Comparator|Group 2|Midazolam group (Group MID) was continuously pumped with 0.05mg/kg/h midazolam
89000409|NCT00175409|Active Comparator|1|Infants will be randomized to two interventions which will take place during two separate blood collections that are required for clinical management. For the standard care condition, infants will remain in their isolettes and will be positioned in prone and given a pacifier to suck on throughout the blood collection.
89000410|NCT00175409|Active Comparator|2|Infants will be randomized to two interventions which will take place during two separate blood collections that are required for clinical management. For the feeding condition, infants will be held and then breast fed by their mother during the blood collection.
89000411|NCT04424602|Experimental|cyclophosphamide|participants will receive intra venous cyclophosphamide 500mg once every two weeks for 6months.
89000412|NCT04424602|Active Comparator|mycophenolate|participants will receive oral mycophenolat 2 to 3mg/kg for 6 months.
89000413|NCT04389892|Experimental|study participants|After a careful endoscopic ultrasound examination in B mode of the entire pancreas, contrast enhancement was administrated to the participants. The uptake and the wash-out of the agent were followed and then a morphological diagnose was established. EUS-fine needle aspiration of the cyst wall, septa or solid components was guided by the enhancing pattern.
89000414|NCT04314973|Active Comparator|Evaluation sessions|Patients will be evaluated while walking without wearing the robotic device, once before the intervention phase, once right after, and once a month after.
89000415|NCT04314973|Experimental|Intervention phase|Patients will walk with the robotic device, for 12 sessions of 10 min.
89000416|NCT04306393|Experimental|Treatment Group|Inhaled Nitric Oxide until PaO2/FiO2 >/= 300 mmHg
89000417|NCT04306393|No Intervention|Control Group|
89000418|NCT04304092|Experimental|Low amount, low intensity|
89000419|NCT04304092|Experimental|Low amount, high intensity|
89000420|NCT04304092|Experimental|High Amount, low intensity|
89000421|NCT04304092|Experimental|High Amount, high intensity|
89000422|NCT04304092|No Intervention|Control|
89177198|NCT00448123|Placebo Comparator|Placebo|Placebo
89356344|NCT01201577|Placebo Comparator|Placebo/Placebo|
89177199|NCT00448123|Active Comparator|Tamsulosin|Intervention - Tamsulosin
89356345|NCT02496520|Experimental|Vaccines with autologous dendritic cells|Vaccines with autologous dendritic cells
89356346|NCT03058770|Experimental|sensorimotor retraining program|Fifteen 40-minute sensorimotor retraining sessions will be provided over a 5-week period.
89177200|NCT00810784||1|Patients cared for before our intervention.
89177201|NCT00810784||2|Patients cared for after our intervention.
89177202|NCT00804934||0|
89177203|NCT00805012|Active Comparator|1|docetaxel+CDDP
89177204|NCT00805012|Experimental|2|docetaxel+S-1
89177205|NCT00922324|Experimental|STP206|STP206 administered either as a single dose or as a daily dose for seven consecutive days
89177206|NCT00922324|Placebo Comparator|Vehicle Control|STP206 vehicle administered as either a single dose or as a daily dose for 7 consecutive days
89177207|NCT00447499|Experimental|Somatuline Autogel (lanreotide acetate)|Somatuline Autogel (lanreotide acetate) Injection
89177208|NCT00805090|Active Comparator|Sporanox|Active arm approved as an anti-fungal being used to compare HPβCD when administered in DIC075V compared to Sporanox.
89177209|NCT00805090|Experimental|Dyloject|Diclofenac Sodium
89177210|NCT02552758|Experimental|Omega-3 fatty acid|omega-3 fatty acid
89177211|NCT02552758|Placebo Comparator|placebo|placebo
89177212|NCT00810862|Experimental|Pimecrolimus|Pimecrolimus 1% cream
89177213|NCT00810862|Placebo Comparator|2|Placebo cream over affected study area
89177214|NCT00800436|Experimental|Part 1: Cohort 1|Healthy male participants will receive Herceptin 6 mg/kg IV on Day 1.
89177215|NCT00800436|Experimental|Part 1: Cohort 2|Female participants with HER2-positive breast cancer will receive Herceptin 6 mg/kg IV on Day 1.
89177216|NCT00800436|Experimental|Part 1: Cohort 3|Healthy male participants will receive Herceptin 6 mg/kg SC on Day 1.
89177217|NCT00800436|Experimental|Part 1: Cohort 4|Healthy male participants will receive Herceptin 10 mg/kg SC on Day 1.
89177218|NCT00800436|Experimental|Part 1: Cohort 5|Healthy male participants will receive Herceptin SC at an adjusted dose level based on preliminary PK analysis of Cohorts 1, 2, 3, and 4.
89177219|NCT00800436|Experimental|Part 2: Cohort A|Female participants with HER2-positive breast cancer will receive Herceptin SC at the dose level determined in Part 1.
89177220|NCT00800436|Experimental|Part 2: Cohort B|Female participants with HER2-positive breast cancer will receive Herceptin SC at an adjusted dose level based on preliminary PK analysis of Cohort A.
89177221|NCT00810940|Active Comparator|1|Control: Standard treatment for severe head trauma including mannitol
89177222|NCT00810940|Experimental|2|Study drug plus standard treatment
89177223|NCT04109508|Experimental|Sequence 1|Current form 3 mg in treatment period 1, followed by current form 7 mg in treatment period 2, followed by new form 11.2 mg in treatment period 3
89177224|NCT04109508|Experimental|Sequence 2|Current form 3 mg in treatment period 1, followed by new form 5.6 mg in treatment period 2, followed by current form 14 mg in treatment period 3
89177225|NCT04109508|Experimental|Sequence 3|New form 2.4 mg in treatment period 1, followed by current form 7 mg in treatment period 2, followed by current form 14 mg in treatment period 3
89177226|NCT04109508|Experimental|Sequence 4|New form 2.4 mg in treatment period 1, followed by new form 5.6 mg in treatment period 2, followed by current form 14 mg in treatment period 3
89177227|NCT04109508|Experimental|Sequence 5|New form 2.4 mg in treatment period 1, followed by current form 7 mg in treatment period 2, followed by new form 11.2 mg in treatment period 3
89177228|NCT04109508|Experimental|Sequence 6|Current form 3 mg in treatment period 1, followed by new form 5.6 mg in treatment period 2, followed by new form 11.2 mg in treatment period 3
89177229|NCT00655564|Experimental|Alefacept|Alefacept's FDA indication is for the treatment of adult subjects with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy. The approved dosing regimen is 15mg once weekly as an intramuscular injection or 7.5mg given once weekly as an intravenous bolus. The recommended regimen is a course of 12 weeks.
89177230|NCT00447421|Experimental|A|
89177231|NCT00651118|Active Comparator|fluticasone propionate|
89177232|NCT00651118|Experimental|azelastineHcl/fluticasone propionate|
89177233|NCT00651118|Placebo Comparator|Placebo|
89177234|NCT00651118|Active Comparator|azelastine Hcl|
89177235|NCT00447265|Experimental|Etanercept|Participants in this group will self-administer 50 mg etanercept injections once a week for 24 weeks. They will continue receiving their usual treatment with corticosteroids and either mycophenolate mofetil (MMF), mycophenolic acid, or azathioprine (AZA).
89177236|NCT00447265|Placebo Comparator|Placebo|Participants in this group will self-administer 50 mg placebo injections once a week for 24 weeks. They will continue receiving their usual treatment with corticosteroids and either mycophenolate mofetil (MMF), mycophenolic acid, or azathioprine (AZA).
89533664|NCT03856515|Experimental|E-Cig nicotine dose followed by E-Cig placebo dose|Participants will be instructed to smoke their usual brand cigarette as they normally would in weeks 1-2 (Phase I) and to use only the SREC (with or without nicotine) in weeks 3-4 (Phase II) and in weeks 5-6 (Phase III). Participant assignment to SREC type at Phases II and III will be counter-balanced within group, with half of men and women receiving the placebo SREC during Phase II and half during Phase III. Participants will attend 4 laboratory visits with study investigators for 3 hours each over 6 weeks of study participation.
89533665|NCT03856177|Experimental|Neutral|A neutral mood induction will include reading a dull text while listening to non-evocative music for 5-15 minutes.
88825061|NCT01831154|Experimental|Tight Glycemic Group|The tight glycemic group received a continuous intravenous infusion of regular insulin in the intraoperative period titrated per a modified Portland Protocol from Vanderbilt University Medical Center, Tennessee. The initial bolus of insulin and insulin infusion was initiated prior to induction of anesthesia if the morning blood glucose was greater than 149 mg/dl or any time intraoperatively the blood glucose elevated above 149 mg/dl.The titration of insulin for the tight glycemic group maintained blood glucose levels between 110-149 mg/dl throughout the intraoperative period. The intraoperative blood glucose was titrated to blood glucose levels sampled every 30 minutes.Upon transfer to the intensive care unit the protocol ended and all subjects received the same glycemic control.
88825062|NCT01831154|Experimental|Conventional Glycemic Group|The conventional glycemic group received a continuous intravenous infusion of regular insulin in the intraoperative period titrated per a modified Portland Protocol from Vanderbilt University Medical Center, Tennessee. The initial insulin bolus and infusion was initiated prior to induction of anesthesia if the morning blood glucose was greater than 180 mg/dl or any time intraoperatively that the blood glucose elevated above 180 mg/dl. The insulin infusion was titrated throughout the intraoperative period to maintain blood glucose levels between 150-180 mg/dl.The intraoperative blood glucose was titrated to blood glucose levels sampled every 30 minutes. Upon transfer to the ICU the intraoperative protocol ended and all subjects received the standardized glycemic control for the ICU.
88825063|NCT01831154|Experimental|Standard Glycemic Group|The standard glycemic group received intravenous injections of regular insulin in the intraoperative period titrated per the usual care protocol utilized at the study site. The initial bolus of insulin was initiated prior to induction of anesthesia if the morning blood glucose is greater than 180 mg/dl or any time intraoperatively that the blood glucose rises above 180 mg/dl. The intraoperative blood glucose was titrated to blood glucose levels sampled every 30 minutes.Upon transfer to the ICU the intraoperative protocol ended and all subjects received the standardized glycemic control for the ICU.
88825064|NCT04544787|Experimental|Group 1: One Dose of Novel OPV2 Candidate 1|Participants previously vaccinated with oral polio vaccine (OPV) received one dose of novel OPV2 candidate 1 on Day 0, administered orally as six drops (0.3 mL total; approximately 10⁶ 50% cell culture infectious dose units [CCID50]).
88825065|NCT04544787|Experimental|Group 2: Two Doses of Novel OPV2 Candidate 1|Participants previously vaccinated with OPV received two doses of novel OPV2 candidate 1 28 days apart (Day 0 and Day 28), administered orally as six drops (0.3 mL total; approximately 10⁶ CCID50).
88825066|NCT04544787|Experimental|Group 3: One Dose of Novel OPV2 Candidate 2|Participants previously vaccinated with OPV received one dose of novel OPV2 candidate 2 on study Day 0, administered orally as six drops (0.3 mL total; approximately 10⁶ CCID50).
88825067|NCT04544787|Experimental|Group 4: Two Doses of Novel OPV2 Candidate 2|Participants previously vaccinated OPV received two doses novel OPV2 candidate 2 28 days apart (Day 0 and Day 28), administered orally as six drops (0.3 mL total; approximately 10⁶ CCID50).
88825068|NCT04544787|Experimental|Group 5: Two Doses of Novel OPV2 Candidate 1|Participants previously vaccinated with inactivated polio vaccine (IPV) received two doses of novel OPV2 candidate 1 28 days apart (Day 0 and Day 28), administered orally as six drops (0.3 mL total; approximately 10⁶ CCID50).
88825069|NCT04544787|Experimental|Group 6: Two Doses of Novel OPV2 Candidate 2|Participants previously vaccinated with IPV received two doses of novel OPV2 candidate 2 28 days apart (Day 0 and Day 28), administered orally as six drops (0.3 mL total; approximately 10⁶ CCID50).
88825070|NCT04544787|Placebo Comparator|Group 7: Two Doses of Placebo|Participants previously vaccinated with IPV received two doses of placebo 28 days apart (Day 0 and Day 28), administered orally as six drops (0.3 mL total).
88825071|NCT02989220|Experimental|Intervention group|Will receive the PRCI in addition to the current recommended care pathway
88825072|NCT02989220|No Intervention|Control Group|Will follow the current recommended care pathway
88825073|NCT01831232|Experimental|Treatment (pravastatin sodium, idarubicin, and cytarabine)|Patients receive pravastatin sodium PO QD on days 1-8, idarubicin IV over 10-15 minutes on days 4-6, and cytarabine IV continuously on days 4-7. Treatment repeats every 28-56 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
88825074|NCT04470375|Experimental|VR pain education|Students receiving the 45 minute pain education through Virtual Reality
88825075|NCT01831934|Experimental|MELAS group:13-60 years of age.|Fluzone® 2010-2011 Formula or 2011-2012 depending on year
88825076|NCT01831934|Experimental|Control Group: 18-65 years of age|Fluzone® 2010-2011 Formula or 2011-2012 depending on year
88825077|NCT01832090|Experimental|Radiesse® Injectable Dermal Filler|Device: Radiesse Dermal Filler mixed with 2% lidocaine-HCl (final concentration: 0.3% lidocaine-HCl)
88825078|NCT01832090|Active Comparator|Delayed Treatment|Untreated controls crossed over to treatment with Radiesse Dermal Filler mixed with 2% lidocaine-HCl (final concentration: 0.3% lidocaine) at 3 months
88825079|NCT01833026|Experimental|COPD assessment and management recommendations|"Patients with a physician-diagnosed COPD or asthma suspicious for COPD being managed by the physician randomized to the intervention group will perform a spirometry test and provide information regarding their medical history on their initial visit, which is 90 minutes before their doctor's appointment. A letter containing the interpretation of spirometry test results, and recommendations for guideline based therapy based on GOLD guidelines will be available to the primary care doctor at the time of the patient's clinic visit. The doctor may review the results and use his or her own judgment in moving forward with the subject's diagnosis and management. A copy of the spirometry results and assessment based on the GOLD criteria at the time of the test of your subject will be uploaded to his or her electronic health record for future reference.~Outcomes will be assessed every 3 months for up to one year through patient telephone calls and medical chart reviews."
88825080|NCT01833026|Placebo Comparator|Usual Care|"Patients with a physician-diagnosed COPD or physician-diagnosed asthma suspicious for COPD being managed by the physician randomized to the usual care group will provide medical history, not initially have a spirometry, and will be observed as usual care.~Outcomes will be assessed every 3 months for up to one year through patient telephone calls and medical chart reviews. At the conclusion of the research study which will be 12 months from the patients' initial visit, patients being managed by the physician randomized to the usual care group will have a spirometry test and these results will not be shared with the doctor or the patients during the study but will be uploaded to the electronic health record after the end of the study for future reference."
88825081|NCT03383523|Experimental|Part 1a - treatment A|5 mg emodepside LSF, fasted
88825082|NCT03383523|Experimental|Part 1a - treatment B|5 mg emodepside IR-tablet #406, fasted
88825083|NCT03383523|Experimental|Part 1a - treatment C|5 mg emodepside IR-tablet #416, fasted
88825084|NCT03383523|Experimental|Part 1b - treatment D|5 mg emodepside IR-tablet #406, fed
88825085|NCT03383523|Experimental|Part 1b - treatment E|5 mg emodepside IR-tablet #416, fed
88825086|NCT03383523|Experimental|Part 2 - treatment F|2 x 5 mg emodepside IR-tablet #406, fasted (may be tested or not, depending on the results of the part 1)
88825087|NCT03383523|Experimental|Part 2 - treatment G|2 x 5 mg emodepside IR-tablet #416, fasted (may be tested or not, depending on the results of the part 1)
88825088|NCT03383757|Experimental|SpO2 Sensor Application & Blood draw|All subjects will undergo the same study procedures of having their SpO2 levels measured with an external sensor applied to the skin and blood SpO2 level measured
88825089|NCT05748080|Experimental|Apple intervention|the eating of 2 apples a day for a period of 6 weeks
88825090|NCT03387033|Experimental|VR intervention session|The patients will give a pain score as well as fill out GAD-7 and PHQ-9 scores initially. The VR intervention session consists of relaxation narration WITH Virtual Reality session for 20 minutes while wearing the VR device. They will then be again asked to give a pain score and fill out GAD-7, PHQ-9, and PGIC.
88825091|NCT03387267|Other|single-arm Dysphagia Detection System|An operationally seamless single-arm, prospective, multicenter, single-blinded for central outcomes assessors trial to test DDS in assessing swallowing safety and efficiency in patients at risk of oropharyngeal dysphagia.
88825092|NCT02989688|Active Comparator|modified carbohydrate drink|Dietary Supplement - renal specific slow release carbohydrate ONS (220 ml Nepro HP (Abbott Nutrition)
88825093|NCT02989688|Active Comparator|macronutrient matched drink|Dietary Supplement - 125 ml Fortisip Compact Protein (Nutricia) plus 20ml Calogen (Nutricia)
88825094|NCT02989688|Active Comparator|standard drink|Dietary Supplement - 125 ml Fortisip compact (Nutricia)
88825095|NCT05011994|Experimental|Maintenance intervention|Participants will receive a 12-week mobile health (mHealth) intervention that consists of action planning, text messages, and coordinator support.
88825096|NCT01835756|Active Comparator|Erchonia MLS|The Erchonia® MLS contains 10 independent diodes, each emitting 17 milliwatts (mW), 635 nanometers (nm) of red laser light.
88825097|NCT01835756|Placebo Comparator|Placebo Laser|The Placebo Laser has the same appearance as the Erchonia MLS but does not emit any therapeutic light.
88825098|NCT04462731|Experimental|Obturation technique: WVT|Warm vertical compaction technique (WVT): Teeth filled with AH Plus Jet Root Canal Sealer were filled with .04 taper gutta-percha points by WVT. The sealer was introduced with the master cone. The depth of heated plugger was within 3-5 mm of WL in the WVT group, and the remaining canal space was backfilled with additional sealer and thermoplasticized gutta-percha.
88825099|NCT04462731|Active Comparator|Obturation technique: SBT|Sealer-based filling technique (SBT): Teeth filled with SBT were obturated with EndoSequence BC Sealer by injecting the sealer into the coronal third of each canal. Size 30 Lentulo spiral coated with additional sealer was introduced 3 mm short of WL depth at 300rpm. Bioceramic coated gutta-percha was dipped in BC sealer and introduced into the canal to WL. A heated plugger was used to sear the gutta-percha point at each orifice.
88825100|NCT01835912|Placebo Comparator|Flavoured water placebo for acute dosing|500 milliliters flavoured water (placebo for the acute dosing intervention of sodium citrate)
88825101|NCT01835912|Experimental|Sodium Citrate Dihydrate Acute|dose: 0.5 g/kg of body mass dissolved in 500 milliliters of flavoured water
88825102|NCT01835912|Placebo Comparator|Flavoured water placebo chronic dosing|500 milliliters flavoured water (placebo for the chronic dosing intervention of sodium citrate)
88825103|NCT01835912|Experimental|Sodium Citrate Dihydrate Chronic|3 days of 0.1g/kg of body mass of sodium citrate and 4th day at 0.3 g/kg of body mass of sodium citrate in 500 milliliters of flavoured water
88825104|NCT05747768|Experimental|Healthy Volunteers|Healthy volunteer received drug combinations（10 µg midazolam, 375 µg dabigatran etexilate, 10 µg pitavastatin, 50 µg rosuvastatin, and 100 µg atorvastatin） on an empty stomach
88825105|NCT05747768|Experimental|Patients with mild-to-moderate renal impairment|Patients with mild-to-moderate renal impairment received drug combinations（10 µg midazolam, 375 µg dabigatran etexilate, 10 µg pitavastatin, 50 µg rosuvastatin, and 100 µg atorvastatin） on an empty stomach
89177237|NCT00807352||level 2|Patients triaged level 2
89177238|NCT00807352||level 3|patients triaged level 3
89177239|NCT00807352||level 4|patients triaged level 4
89177240|NCT00807352||level 5|patients triaged level 5
89533666|NCT03856177|Experimental|Evocative|A mood induction procedure will be utilized. The procedure consists of a combination of re-experiencing an autobiographical sad personal event while listening to their choice of one of four sad music selections commonly used in mood induction. Visual analogue scale ratings will assess momentary sadness prior to, following, and at subsequent time points around the mood induction procedure.
88825106|NCT05747768|Experimental|Patients with moderate to severe renal impairment|Patients with moderate to severe renal impairment received drug combinations（10 µg midazolam, 375 µg dabigatran etexilate, 10 µg pitavastatin, 50 µg rosuvastatin, and 100 µg atorvastatin） on an empty stomach
88825107|NCT05747768|Experimental|Patients with severe renal impairment|Patients with severe renal impairment received drug combinations（10 µg midazolam, 375 µg dabigatran etexilate, 10 µg pitavastatin, 50 µg rosuvastatin, and 100 µg atorvastatin） on an empty stomach
88825108|NCT05747768|Experimental|Patients with end-stage renal disease|Patients with end-stage renal disease received drug combinations（10 µg midazolam, 375 µg dabigatran etexilate, 10 µg pitavastatin, 50 µg rosuvastatin, and 100 µg atorvastatin） on an empty stomach
88825109|NCT01837550|Active Comparator|Control group|no professional support
88825110|NCT01837550|Experimental|Intervention group|Professional support via Internet
88825111|NCT04452435|Experimental|C21 100 mg twice daily|Oral C21 treatment 100 mg twice daily for 7 days
88825112|NCT04452435|Placebo Comparator|Placebo|Oral placebo treatment 100 mg twice daily for 7 days
88825113|NCT04994210|Experimental|Sintilimab+Chidamide|Sintilimab：200mg(fixed dosage), ivd, qd, q21d Chidamide: 30mg,biw,continued oral
88825114|NCT04410159|Experimental|Povidone-iodine|gargle with povidone-iodine 10mL, 30 seconds, 3 times per day, 7 days
88825115|NCT04410159|Experimental|Essential Oils|gargle with essential oils 20mL, 30 seconds, 3 times per day, 7 days
88825116|NCT04410159|Experimental|Tap water|gargle with tap water 100 mL, 30 seconds, 3 times per day, 7 days
88825117|NCT04410159|No Intervention|Control|This group will receive the standard treatment protocol without any additional intervention
88825118|NCT05314803|Experimental|Yoga|Participants receive online, group-based yoga classes 2 times/week for 60 minutes/class over 12 weeks.
88825119|NCT00559988|Experimental|Home Monitoring Guided OAC|Home Monitoring is fully enabled and continuous remote surveillance data is available to investigators. Patients will be treated according to a predefined anticoagulation plan, which uses the total duration of AF/AFL combined with patients' CHADS2 score to determine the start, stop, and restart of OAC.
88825120|NCT00559988|Active Comparator|Physician-Directed OAC|"In Control (Group 2), Home Monitoring is active for Safety Net alerts, but the remote AF/AFL data is not revealed to the patient or treating physician. These patients receive physician-directed OAC consistent with current standards of care.~Safety Net data include:~ERI/EOS~Special Implant Status~Implant in Backup Mode (ROM)~VT/ VF Detection Inactive~Emergency Pacing~250 Ω > RV Pacing Impedance > 1500 Ω~Symptomatic VT/VF therapies including both ATP and shock~VT/VF storm~HM transmission failure >3 days"
88825121|NCT03398265|Experimental|Intervention|Initial discussion regarding opioid treatment options followed by 6 months of treatment navigation.
88825122|NCT03398265|Other|Control|Referrals to treatment from corrections staff.
88825123|NCT03398421|Experimental|Subjects receiving nemiralisib and itraconazole|Eligible subjects will receive a single dose of 100 micrograms (mcg) nemiralisib on Day 1 in Period 1. Subjects will also receive a single dose of 200 milligrams (mg) itraconazole in the morning from Day 1 to Day 10 and single dose of 100 mcg nemiralisib on Day 5, one hour after the dose of itraconazole in Period 2. There will be a washout of at least 14 days between the administration of nemiralisib in Period 1 and Period 2.
88825124|NCT01839110|Active Comparator|Ranolazine|Ranolazine at 500mg by mouth twice per day and after two weeks will increase to 1000mg by mouth twice per day
88825125|NCT01839110|Placebo Comparator|Placebo|Placebo by mouth twice per day
88825126|NCT01839110|No Intervention|Observational|Patients with pulmonary hypertension who have normal RV function (RVEF >=45%) will undergo same procedures in the observational arm but will not receive an intervention.
88825127|NCT04396665|Experimental|Precam Group (Intervention Group)|150 Women without breast cancer, aged from 25 to 50 years old
88825128|NCT04396665|No Intervention|Control Group|150 Women without breast cancer, aged from 25 to 50 years old
88825129|NCT05314881|Experimental|SLE patients|
88825130|NCT03400449|Active Comparator|Video counseling|The video group watched a 13.75 minute video of a local Colombian counselor reading a script of the same information provided by conversational counseling and had a chance to ask questions at the end.
88825131|NCT03400449|Active Comparator|Conversational counseling|The conversation group participated in a structured, face-to-face conversation with a trained counselor.
88825132|NCT00559754|Experimental|1|
88825133|NCT03402243|Experimental|Menthol ban only for cigarettes|Participants will have available to them non-menthol cigarettes, menthol and tobacco flavored versions of a cigarette-like e-cigarette, menthol and tobacco flavored versions of a tank like e-cigarette and nicotine gum and lozenge
88825134|NCT03402243|Experimental|Menthol ban for cigarettes and e-cigarettes|Participants will have available to them non-menthol cigarettes, tobacco flavored version of a cigarette-like e-cigarette, tobacco flavored version of a tank like e-cigarette and nicotine gum and lozenge
88825135|NCT03402243|Other|No Menthol Ban|Participants will have available to them menthol and non-menthol cigarettes, menthol and tobacco flavored versions of a cigarette-like e-cigarette, menthol and tobacco flavored versions of a tank like e-cigarette and nicotine gum and lozenge
88825136|NCT04714125||Patients with COVID-19|Patients hospitalized with COVID-19 from the General Hospital of the University of Sao Paulo, Brazil.
88825137|NCT01841216|Experimental|Low Back Pain|Lower Body Exercises with and without resistance
88825138|NCT01841216|Experimental|Healthy|Lower Body Exercises with and without resistance
88825139|NCT01841606|Experimental|Ondansetron|4mg of IV ondansetron 5 minutes prior to initiation of spinal anesthesia
88825140|NCT01841606|Placebo Comparator|Placebo|10mL of IV normal saline 5 minutes prior to initiation of spinal anesthesia
89533667|NCT03821935|Experimental|Dose Escalation: Cohort 1 Livmoniplimab|Various doses of Livmoniplimab administered during dose escalation to determine the Recommended Phase 2 Dose (RP2D).
89533668|NCT03821935|Experimental|Dose Escalation: Cohort 2 Livmoniplimab + Budigalimab|Various doses of Livmoniplimab + Budigalimab administered during dose escalation to determine the Recommended Phase 2 Dose (RP2D).
89533669|NCT03821935|Experimental|Dose Expansion: Cohort 3 Livmoniplimab + Budigalimab|Participants with programmed cell death protein 1 (PD-1)-naïve pancreatic adenocarcinoma will receive livmoniplimab at the RP2D Q2W plus budigalimab Dose A administered Q4W.
89533670|NCT03821935|Experimental|Dose Expansion: Cohort 4 Livmoniplimab + Budigalimab|Participants with PD-1-ref urothelial cancer will receive livmoniplimab at the RP2D Q2W plus budigalimab Dose A administered Q4W.
89533671|NCT03821935|Experimental|Dose Expansion: Cohort 5 Livmoniplimab + Budigalimab|Participants with PD-1-naïve hepatocellular carcinoma (HCC) will receive livmoniplimab at the RP2D Q2W plus budigalimab Dose A administered Q4W.
89533672|NCT03821935|Experimental|Dose Expansion: Cohort 6 Livmoniplimab + Budigalimab|Participants with PD-1-ref head and neck squamous cell carcinoma (HNSCC) will receive livmoniplimab at the RP2D Q2W plus budigalimab Dose A administered Q4W.
88825141|NCT04392141|Experimental|Standard Treatment|Patients diagnosed with COVID-19 which receive the standard treatment national guideline
88825142|NCT04392141|Experimental|Colchicine and Herbal Phenolic Monoterpene Fractions|Patients diagnosed with COVID-19 which receive the standard treatment national guideline plus Colchicine and Herbal Phenolic Monoterpene Fractions
88825143|NCT01842464||Anterior Sacro-Spinous Support|Anterior sacro-spinous mesh implants supported patients
88825144|NCT04838054|Experimental|Test - stabilized chlorine dioxide rinse|Subjects will receive CloSYS Ultra Sensitive Rinse
88825145|NCT04838054|Placebo Comparator|Placebo - oral rinse, no active ingredients|Subjects will receive oral rinse - no active ingredients
88825146|NCT02263118|Experimental|Uni-directional SMS|Participants in this group received breastfeeding promoting messages based on the MAMA (http://www.mobilemamaalliance.org/) breastfeeding database. Individuals could only receive text messages.
88825147|NCT02263118|Experimental|Virtual communities|Participants were made part of virtual communities in which could exchange about infant's health as groups, via SMS, following the SHM Foundation's (http://www.shmfoundation.org/) m-health methodology.
88825148|NCT02263118|Experimental|Hybrid setup|Participants were made part of virtual communities in which they could exchange about infant's health as groups, via SMS. Additionally, a health professional was included in the virtual community.
89356347|NCT03058770|Active Comparator|Relaxation technique|Subjects will perform fifteen 40-minute relaxation sessions over a 5-week period.
88825149|NCT02263118|Experimental|Control group|Individuals were given a feature phone (simple mobile phone)
88825150|NCT05747300|Active Comparator|MTA pulpotomy|Vital pulpotomy primary Molars using MTA
88825151|NCT05747300|Experimental|Wellroot PT pulpotomy|Vital pulpotomy primary Molars using premixed bioceramic paste wellroot PT
88825152|NCT04739462|Experimental|Intervention|Participants in this arm will receive the study intervention.
88825153|NCT04739462|No Intervention|Routine Antenatal Care|Participants in this arm will receive no intervention.
88825154|NCT01846988|Active Comparator|Group 1 crossover treatment|crossover treatment (REMstar Auto A-Flex) Placed on REMstar Auto A-Flex machine with APAP settings for 4-8 weeks then randomized to 4 weeks APAP settings then 4 weeks CPAP settings.
88825155|NCT01846988|Active Comparator|Group 2 crossover treatment|crossover treatment (REMstar Auto A-Flex) Placed on REMstar Auto A-Flex machine with APAP settings for 4-8 weeks then randomized to 4 weeks CPAP settings then 4 weeks APAP settings.
88825156|NCT01846988|Active Comparator|APAP pressurized comparison|randomization periods for 6-8 weeks. An in-hospital APAP titration study will average 90th pressure percentile and average CPAP pressure derived from the device will be compared to the CPAP pressure determined by CPAP titration PSG. Subjects will then be randomized to Group 1 first, or Group 2 first, then crossover to the other group.
88825157|NCT04625036||Group 1: COVID-19 patients|Patients, from acute care hospitals, diagnosed with COVID-19 pneumonia, with documented positive throat swab, within one month from discharge.
88825158|NCT02268500|Active Comparator|Standard dose influenza vaccine|Standard dose (45ug) influenza vaccine will be administered intramuscularly
88825159|NCT02268500|Active Comparator|High dose influenza vaccine|High dose (180ug) influenza vaccine will be administered intramuscularly
88825160|NCT00559364|Experimental|Viokase® 16|
88825161|NCT00559364|Placebo Comparator|Placebo|
88825162|NCT05746676|Active Comparator|group 1|
88825163|NCT05746676|Active Comparator|group 2|
88825164|NCT01848158|Experimental|Acupuncture|Acupuncture treatment three times per week for up to two weeks.
88825165|NCT01848158|Sham Comparator|Sham Acupuncture|Sham acupuncture three times per week for up to two weeks
88825166|NCT04574336|Experimental|Surgical Treatment|Primary surgery of humeral shaft fracture with surgeons choice of osteosynthesis method
89356348|NCT01298609|Active Comparator|Suprathreshold Stimulation|Patients will be stimulated at supra-sensory threshold levels for two weeks using occipital stimulation
88825167|NCT04574336|Active Comparator|Non-surgical treatment|Treatment of humeral shaft fracture with sling and/or functional brace
88825168|NCT01849172|Experimental|electroacupuncture|Electroacupuncture at RN4, EX-CA1，ST25, SP6 (double sides). One session will be given every two days, 3 sessions per week (24 sessions in all) and each session lasts for 30 minutes.
88825169|NCT01849172|Sham Comparator|sham electroacupuncture|Sham electroacupuncture at non-points proximate to RN4 (P1), EX-CA1(P2)，ST25 (P3) and SP6 (P4) (double sides).Specially constructed EA apparatus were used with no skin penetration, electricity output, or de qi requirement for needle manipulation One session will be given every two days, 3 sessions per week (24 sessions in all) and each session lasts for 30 minutes.
88825170|NCT05746598||1|NSCLC patients Who developed Toxicity to Chemotherapeutic agents
88825171|NCT05746598||2|NSCLC patients Who did not developToxicity to Chemotherapeutic agents
88825172|NCT04297436|Other|Bexsero|Each participant is compared to baseline (before vaccination)
88825173|NCT05744492|Experimental|Supervised Vivifrail (S-ViF)|A 12-week intervention program that consists of walking every day (the time is individually adjusted) and exercising 3 times a week. Shared features of the different programs are the inclusion of resistance, cardiovascular, balance and flexibility components. All exercises will be individually tailored. Once-per-week, subjects assigned to this group will attend the primary care center to execute one of the three exercise sessions per week under the supervision of the physical therapist.
88825174|NCT05744492|Experimental|Non-supervised Vivifrail Group (NS-ViF)|A 12-week intervention program that consists of walking every day (the time is individually adjusted) and exercising 3 times a week. Shared features of the different programs are the inclusion of resistance, cardiovascular, balance and flexibility components. All exercises will be individually tailored. Subjects assigned to this group will follow a domiciliary-based program and they will not attend the primary care center to execute the exercises.
89356349|NCT01298609|Sham Comparator|minimal stimulation|Patients will be stimulated at minimal stimulation for two weeks using occipital stimulation
89533673|NCT03821935|Experimental|Dose Expansion: Cohort 7 Livmoniplimab + Budigalimab|Participants with PD-1-naïve microsatellite stable colorectal cancer (MSS-CRC) [unselected] will receive livmoniplimab at the RP2D Q2W plus budigalimab Dose A administered Q4W.
89533674|NCT03821935|Experimental|Dose Expansion: Cohort 8 Livmoniplimab + Budigalimab|Participants with non-small cell lung cancer (NSCLC) [programmed death ligand 1 (PDL1) relapsed/refractory (R/R)] will receive livmoniplimab at the RP2D Q2W plus budigalimab Dose A administered Q4W.
89533675|NCT03821935|Experimental|Dose Expansion: Cohort 10A Livmoniplimab + Budigalimab|Participants with microsatellite stable colorectal cancer (MSS-CRC) [consensus molecular subtype 4 (CMS4) enriched] will receive livmoniplimab at the dose B Q3W plus budigalimab Dose B administered Q3W.
89533676|NCT03821935|Experimental|Dose Expansion: Cohort 10B Livmoniplimab + Budigalimab|Participants with MSS-CRC (CMS4 enriched) will receive livmoniplimab at the dose C Q3W plus budigalimab Dose B administered Q3W.
89533677|NCT03821935|Experimental|Dose Expansion: Cohort 11A Livmoniplimab + Budigalimab|Participants with PD-1-ref urothelial cancer will receive livmoniplimab at the Dose B Q3W plus budigalimab Dose B administered Q3W.
89533678|NCT03821935|Experimental|Dose Expansion: Cohort 11B Livmoniplimab + Budigalimab|Participants with PD-1-ref urothelial cancer will receive livmoniplimab at the Dose C Q3W plus budigalimab Dose B administered Q3W.
89533679|NCT03821935|Experimental|Dose Expansion: Cohort 11C Budigalimab|Participants with PD-1-ref urothelial cancer will receive budigalimab Dose B administered Q3W.
89533680|NCT03821935|Experimental|Dose Expansion: Cohort 12A Livmoniplimab + Budigalimab|Participants with PD-1-naïve ovarian granulosa (OG) cell tumors will receive livmoniplimab at the Dose B Q3W plus budigalimab Dose B administered Q3W.
89533681|NCT03821935|Experimental|Dose Expansion: Cohort 12B Livmoniplimab + Budigalimab|Participants with PD-1-naïve ovarian granulosa (OG) cell tumors will receive livmoniplimab at the Dose C Q3W plus budigalimab Dose B administered Q3W.
89533682|NCT03816527||AUD patients|Individuals with alcohol use disorder
89533683|NCT03816527||Healthy controls|Healthy controls
89533684|NCT03816345|Experimental|Treatment (nivolumab)|Patients receive nivolumab IV over 30 minutes every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood, CSF, tissue, stool, and urine samples throughout the trial.
89533685|NCT03815890|Experimental|1A; LumB|Nivolumab
89533686|NCT03815890|Experimental|1B; TNBC|Nivolumab
89533687|NCT03815890|Experimental|2A; LUMB|Nivolumab and ipilimumab
89533688|NCT03815890|Experimental|2B; TNBC|Nivolumab and ipilimumab
89533689|NCT03815890|Experimental|3B; TNBC, High TIL|Nivolumab and ipilimumab
89533690|NCT03814603||African Americans|
89533691|NCT03814603||Non-Hispanic Whites|
89533692|NCT03810950|Experimental|Social Stress Test|Participants undergo the Trier Social Stress Test before Barlab-Exposure
88825175|NCT05744492|No Intervention|Control group (UCG)|Subjects will receive usual care following prevention protocols of Primary Care Services in Madrid. Concisely, the benefits of physical activity are individually explained and subjects are advised to walk as much as possible with the aim of reaching at least 30 minutes a day, 5 days a week, following the recommendations of the World Health Organization. No structured exercise-based interventions are programmed in this group.
88825176|NCT01853774|Experimental|Tailored Navigation|Participants will receive tailored navigation phone calls to assist them with barriers in making a clinic appointment or attending the clinic. The tailored navigation intervention protocol will be used to guide individuals from an especially hard-to-reach, multicultural, and underinsured population into primary care clinics and, subsequently, track the effects of this intervention through a clinic navigation program to complete Colorectal cancer screening.
88825177|NCT01853774|No Intervention|Control|Participants in the control arm will receive phone calls to support data collection and tracking, but not receive tailored messages
88825178|NCT01853930|Other|Laboratory training|Patients will be trained in the laboratory with feedback by a rehabilitation therapist
88825179|NCT01853930|Other|Home-based training|Patients will self instruct using the computer-based training with remote intervention by a therapist
89177241|NCT00657358|Experimental|Lidocaine|Lidocaine 2% (2mg/ml) was administered via a computer assisted infusion to achieve a target plasma concentration of 2 mcg/ml; infused within 20 minutes.
89177242|NCT00457639|Experimental|Cholic Acid active capsules|Cholic Acid weight based dose for 6 months double-blind
88825180|NCT01854242||Glycogen Storage Disease type Ia patients|The participants will have one blood draw for this study. The test will be performed on the blood.
88825181|NCT04275752|No Intervention|Usual Care Group|Subjects will receive no formal exercise recommendations
88825182|NCT04275752|Experimental|Exercise Intervention Group|Subjects will complete an exercise program
89177243|NCT00457639|Placebo Comparator|Placebo for Cholic Acid|Placebo for Cholic Acid for 6 months double-blind
89177244|NCT00805246||Pulmonary Embolism (PE)|Subjects diagnosed with PE by CT will be recruited.
89533693|NCT03810950|Active Comparator|Control Condition|Participants reads newspaper before Barlab-Exposure
89533694|NCT03793166|Active Comparator|Arm A (nivolumab)|"INDUCTION: Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.~TREATMENT:~Patients with iuPD with clinical instability receive cabozantinib PO daily on days 1-28. Treatment repeats every 28 days until further disease progression or unacceptable toxicity~Patients with iCR receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.~Patients with non-CR/non-PD with clinical stability receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.~Patients undergo CT scan, MRI and blood sample collection throughout the study."
89356350|NCT01298609|Active Comparator|Subthreshold Stimulation|Patients will be stimulated at sub-sensory threshold stimulation for two weeks using occipital stimulation
89533695|NCT03793166|Experimental|Arm B (nivolumab, cabozantinib)|"INDUCTION: Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.~TREATMENT:~Patients with iuPD with clinical instability receive cabozantinib PO daily on days 1-28. Treatment repeats every 28 days until further disease progression or unacceptable toxicity.~Patients with iCR receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.~Patients with non-CR/non-PD rwith clinical stability eceive nivolumab IV over 30 minutes on day 1 and cabozantinib PO daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.~Patients undergo CT scan, MRI and blood sample collection throughout the study."
89533696|NCT03778931|Experimental|Elacestrant|Subjects in Arm 1 will receive elacestrant
89533697|NCT03778931|Active Comparator|Standard of Care (SoC)|Subjects in Arm 2 will receive Investigator's choice of one of the Standard of Care drugs (fulvestrant, anastrozole, letrozole, or exemestane)
89533698|NCT03765476|Active Comparator|TAU|treatment as usual
89533699|NCT03765476|Experimental|TAU plus SALIENCE|"treatment as usual plus computer-based intervention SALIENCE"
89356351|NCT04496050||one|there is only one patient group. This group of patients, given the same dose and at the same time, is examined by ultrasonography to determine the thickness of the pyloric muscle.
89356352|NCT03342040|Experimental|TAP block|Patients undergoing laparoscopic ventral hernia repair with TAP block with 0.2% ropivacaine under ultrasound guidance
89356353|NCT03342040|Active Comparator|No TAP block|Patients undergoing laparoscopic ventral hernia repair without TAP block
89356354|NCT02495974||Patients with mCRPC prescribed enzalutamide|Oral
89356355|NCT01206413|Experimental|LGI|Low glycemic index
89356356|NCT01206413|Active Comparator|HGI|High glycemic index
89356357|NCT01206413|Experimental|HB|Home-based exercise
89533700|NCT03756792|Active Comparator|First Time Control|Patients with no prior experience of Mohs surgery will be randomly assigned to the control group. The control group will receive the normal education material that MMS patients receive from Wake Forest Baptist Health Dermatology, then fill out a brief survey.
89533701|NCT03756792|Experimental|First Time Intervention|Patients with no prior experience of Mohs surgery will be randomly assigned to the intervention group. The intervention group will receive the normal education material that MMS patients receive from Wake Forest Baptist Health Dermatology and read a vignette about the typical experience of a Mohs patient, then fill out a brief survey.
89533702|NCT03756792|Active Comparator|Previous Experience Control|Patients with prior experience of Mohs surgery will be randomly assigned to the control group. The control group will receive the normal education material that MMS patients receive from Wake Forest Baptist Health Dermatology, then fill out a brief survey.
88825183|NCT01854632|Experimental|SIIL Live Attenuated Influenza Vaccine|Single 0.5 mL dose of trivalent live-attenuated influenza vaccine 2012/2013 Northern Hemisphere vaccine containing A/California/7/2009 (H1N1), A/Victoria/361/2011 (H3N2), B/Wisconsin/1/2010
88825184|NCT01854632|Placebo Comparator|Matched placebo|Single 0.5mL inactive placebo will be identical to reconstituted SIIL LAIV in ingredients and concentrations except A/California/7/2009 (H1N1), A/Victoria/361/2011 (H3N2), B/Wisconsin/1/2010 will be replaced with egg allantoic fluid.
88825185|NCT02989454||Tako Tsubo Cardiomyopathy patients|Any patient who has suffered from Tako Tsubo Cardiomyopathy since 2011.
88825186|NCT05735054||endoscopic group|the patients who underwent endoscopic transaxillary thyroidectomy
88825187|NCT05735054||open group|the patients who underwent open thyroidectomy
89000423|NCT04257799||Women with breast cancer diagnosis|Women with diagnosis of invasive breast cancer based on pre-surgical biopsy, and scheduled for breast-conserving surgery in the Dartmouth-Hitchcock (DH) Outpatient Surgical Center.
89177245|NCT00800202|Experimental|1|
89356358|NCT01206413|Active Comparator|CONTROL|Non-exercisers
89356359|NCT03818633|Experimental|Elastic abdominal binder|
89356360|NCT03818633|No Intervention|No binder|
89356361|NCT03818789|Experimental|Mindfulness|A mindfulness training is applied to see if it supports exercise endurance in-lab and during follow-up
89356362|NCT03818789|Placebo Comparator|Control|A study skills video is shown intended to have no effect on exercise but to match for time.
89356363|NCT03337048|Experimental|Measurement of endpoints|"In healthy volunteers the endpoint are measured while spontaneous voiding of the bladder and while emptying the bladder using a standard intermittent catheter (SpeediCath).~In subjects with spinal cord injury or enlarged prostata the endpoint are measured while emptying the bladder using a standard intermittent catheter."
89356364|NCT03120364|Experimental|NBP608|Single dose 0.5mL of NBP608 by subcutaneous injection into the outer aspect of the upper arm
89356365|NCT03120364|Active Comparator|Zostavax|Single dose 0.65mL of Zostavax by subcutaneous injection into the outer aspect of the upper arm
89356366|NCT01298843|Other|Study of Blood Levels of Ceftaroline Fosamil|Study of Blood Levels of Ceftaroline Fosamil in Children Who Are Receiving Antibiotic Therapy in the Hospital
89356367|NCT03336970|Active Comparator|Single visit root canal treatment|The teeth were treated in single-visit (SV) root canal treatment. Final root canal irrigation was performed with 5% EDTA, followed by 2.5% NaOCl and received an additional final rinse with 2% CHX before obturation.
89356368|NCT03336970|Active Comparator|Multiple visit root canal treatment|The teeth were treated in multiple visit (MV) root canal treatment. After completion of root canal instrumentation, calcium hydroxide paste was placed into the root canal. In second visit, all root canals were irrigated with 5% EDTA followed by 2.5% NaOCl before obturation.
89356369|NCT01567319|Experimental|Allergic Subjects|
89356370|NCT01567319|Active Comparator|Atopic Subjects|Patients sensitized to other allergenic sources but the allergen extracts under investigation.
89356371|NCT01567319|Active Comparator|No Atopic Subjects|Healthy volunteers.
89533703|NCT03756792|Experimental|Previous Experience Intervention|Patients with prior experience of Mohs surgery will be randomly assigned to the intervention group. The intervention group will receive the normal education material that MMS patients receive from Wake Forest Baptist Health Dermatology and read a vignette about the typical experience of a Mohs patient, then fill out a brief survey.
89177246|NCT00800202|Experimental|2|
88825188|NCT02308020|Experimental|Part A Abemaciclib: HR+, HER2+ Breast Cancer|Abemaciclib 200 milligram (mg) was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or in combination with endocrine therapy (ET). Participants with hormone receptor positive (HR+), HER2+ breast cancer receiving concurrent trastuzumab, 150 mg abemaciclib was given orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
89177247|NCT00811096|Experimental|Treatment Arm|
89177248|NCT00811096|Active Comparator|Comparator Arm|Comparator Arm
89177249|NCT00805402|Experimental|1 flow cytometry|flow cytometry
89533704|NCT03733132|Placebo Comparator|Placebo|Participants in placebo group will receive Placebo Oral Tablets identical to the metformin tablets for 10 months.
89177250|NCT04045756|Experimental|ECHOLASER X4 Socratelite|Optic fiber of 300um will be inserted at a distance of 8-10mm from the urethra. Each ablation lasts 6 minutes. Each fiber ablates at an energy of 1800J with a power of 2-3W. Treatment lasts for about 30 minutes.
89533705|NCT03733132|Active Comparator|Metformin|Participants in placebo group will receive an escalating dose of Metformin hydrochloride tablets up to a dose of 2500mg for 10 months.
88825189|NCT02308020|Experimental|Part B Abemaciclib: HR+, HER2- Breast Cancer|"Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or for participants in combination with endocrine therapy (ET).~Participants may continue to receive treatment until discontinuation criteria are met."
88825190|NCT02308020|Experimental|Part C Abemaciclib: Surgical Resection|Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or for participants with breast cancer in combination with endocrine therapy (ET). Participants with HR+, HER2+ breast cancer, NSCLC, or melanoma with intracranial lesions for which surgical resection is clinically indicated receiving concurrent trastuzumab, gemcitabine, or pemetrexed, 150 mg abemaciclib was given orally once every 12 hours for 5-14 days prior to surgical resection. Dosing may resume following wound healing on a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
88825191|NCT02308020|Experimental|Part D Abemaciclib: Non-Small Cell Lung Cancer (NSCLC)|Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle. Participants with NSCLC receiving concurrent gemcitabine or pemetrexed, 150 mg abemaciclib was given orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
88825192|NCT02308020|Experimental|Part E Abemaciclib: Melanoma|Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
88825193|NCT02308020|Experimental|Part F Abemaciclib: HR+ Breast Cancer, NSCLC, or Melanoma|Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or for participants with breast cancer in combination with endocrine therapy (ET). Participants with HR+ (either HER2+ or HER2-) breast cancer, NSCLC, or melanoma and leptomeningeal metastases received concurrent trastuzumab, gemcitabine, or pemetrexed, 150 mg abemaciclib was given orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
88825194|NCT04420494|Experimental|Patients treated with umbilical cord blood|
88825195|NCT02359890|Experimental|Treatment Group|Pulmonary vein isolation by RF ablation treatment with the THERMOCOOL® SMARTTOUCH® SF family of contact force sensing catheters (study device)
88825196|NCT02306850|Experimental|Pembrolizumab|Open-label non-randomized trial. All subjects will receive active drug (pembrolizumab).
88825197|NCT02306694|Experimental|Open label|Everyone receives Advate (antihemophilic factor) on Day 1 and 3.
88825198|NCT03647475|Experimental|Medtronic Resolute Onyx Zotarolimus-Eluting Coronary Stent|Subjects who fulfilled the inclusion criteria and none of the exclusion criteria were treated with a Resolute Onyx stent followed by one-month DAPT. The clinical safety of the Resolute Onyx stent as compared to a performance goal was evaluated using a composite safety endpoint of cardiac death and myocardial infarction at 1 year for a one-month clear population.
88825199|NCT01648140|Experimental|T40|Hepatitis C virus (HCV) genotype 1 GSK2336805 40 mg, pegylated interferon alpha-2a, and ribavirin arm
88825200|NCT01648140|Experimental|T60|Hepatitis C virus (HCV) genotype 1 GSK2336805 60 mg, pegylated interferon alpha-2a, and ribavirin arm
89177251|NCT05608278|Experimental|Bergen 4-Day Treatment (B4DT)|"Patients in this arm will receive an intensive treatment delivered mostly in group format. The group sizes will be 3-6 participants with a 1:1 patient to therapist ratio. In the week before the intensive part of the treatment, participants will have two scheduled phone/video calls with a therapist. Day 1 (half-day) of the intensive treatment includes psychoeducation and deciding on exposure tasks. Days 2 and 3 (whole days) focus on individually tailored and therapist-assisted ERP in as many most relevant settings as possible. In the evenings, patients are encouraged to continue with self-guided ERP and may receive therapist support via text messages or phone calls on demand. On day 3, patients can invite relatives to a psychoeducation session. Day 4 (half-day) of the intensive treatment focuses on treatment summary and relapse prevention, as well as planning self-guided ERP for the upcoming 3 weeks.~After 16 weeks, participants have individual follow-up sessions without ERP."
89177252|NCT05608278|Active Comparator|Gold standard cognitive behavioral therapy (gold standard CBT)|Patients will receive 16 sessions of individual CBT for OCD with an emphasis on ERP, delivered over a time period of 14 weeks according to a validated protocol. Sessions will be held twice weekly at a specialist clinic during the first 2 weeks and once a week for the remaining 12 weeks. Sessions 1-2 contain psychoeducation about OCD and CBT, goal setting, and planning of ERP exercises. Sessions 3-14 include therapist-guided ERP (at the clinic, in the patients' homes or elsewhere as needed) with planned self-practice ERP between sessions. Sessions 15-16 contain a summary of the treatment and lessons learned, as well as relapse prevention and planning of continued self-practice ERP.
89177253|NCT05146804|Other|BroccoCress/Affilla Cress|Potential participants will be screened after showing their interest to participate to the study. When they are considered eligible to participate (after a phone call with the executing researcher), participants will be randomized into one of the two groups in this study: either consuming the broccoli sprouts on day one (visit 1) and the placebo product in the second visit, or the other way around (placebo product on day 1 and the intervention during the second visit). Both days, participants will consume the PhenFlex, the challenge product with the high caloric load. This will allow for analyzing the effectiveness of the intervention on different biomarkers of chronic, low-grade inflammation, with the main objective being on endothelial activation.
89533706|NCT03727061|Experimental|Arm A(porfimer sodium, I-PDT|Patients receive porfimer sodium IV over 3-5 minutes and undergo I-PDT approximately 48 hours later.
89533707|NCT03723252|Experimental|Dapagliflozin group|Participants will receive dapagliflozin 10mg po qd.
88825201|NCT01648140|Active Comparator|PRT|Hepatitis C virus (HCV) genotype 1 Telaprevir, pegylated interferon alpha-2a, and ribavirin arm
88825202|NCT01648140|Experimental|G4|Hepatitis C virus (HCV) genotype 4 GSK2336805 60 mg, pegylated interferon alpha-2a, and ribavirin arm
88825203|NCT02336178|Experimental|Benefix|This is a single arm study. Subjects will be treated with Benefix by the investigator according to usual care in China and in accord with the China BeneFIX Package Insert.
88825204|NCT05369910|Experimental|Flash first|"Light exposure (Flash) first, light deprivation (Dark) second:~Both interventions (Flash and Dark) are administered for one hour on 7 consecutive days. During the light exposure, participants are seated 120 cm in front of a white curtain that is illuminated by an LED light source. During the light deprivation, participants are seated in the same room used for light exposure, but in complete darkness."
88825205|NCT05369910|Experimental|Dark first|"Light deprivation (Dark) first, Light exposure (Flash) second:~Both interventions (Flash and Dark) are administered for one hour on 7 consecutive days. During the light exposure, participants are seated 120 cm in front of a white curtain that is illuminated by an LED light source. During the light deprivation, participants are seated in the same room used for light exposure, but in complete darkness."
88825206|NCT02357940|Experimental|Adult Tolerance Assessment|Apply thin layer of experimental product to the affected skin areas at least 2 times per day and massage gently into skin
88825207|NCT02357940|Experimental|Baby (infants, toddlers, young children) Tolerance Assessment|Apply thin layer of experimental product to the affected skin areas at least 2 times per day and massage gently into skin
88825208|NCT02335242|Placebo Comparator|Placebo tablets (resembling Revatio)|Placebo Drug: Placebo tablets (resembling Revatio)
88825209|NCT02335242|Experimental|Sildenafil 20 mg tablets (Revatio)|Active Drug: Sildenafil tablets (Revatio)
88825210|NCT05437770|Experimental|BFR (Blood-Flow Restricted exercise)|The BFR training intervention group will perform low load blood-flow restricted exercise. Training twice a week for 12 weeks. The group will also attend a two hours education lecture with osteoarthritis information.
88825211|NCT05437770|Active Comparator|Standard rehabilitation|The standard rehabilitation group will be offered participation in the Good Life with osteoArthritis in Denmark programme (GLA:D). The programme includes supervised team group training twice a week for 8 weeks and an education lecture. The GLA:D programme will be followed by 4 weeks of team group training continuing the exercises from the GLA:D programme.
88825212|NCT02334384|Experimental|Antimicrobial TheraGauze|Antimicrobial TheraGauze (i.e. tobramycin impregnated TheraGauze) will be used as a wound packing after incision and drainage of skin abscess (i.e. furunculosis). Antimicrobial TheraGauze will be administered once.
88825213|NCT02334384|No Intervention|Standard of care - standard wound packing|In this control arm the subject will receive standard of care with standard wound packing. The ED physician will have the choice to use plain cotton wick or iodoform wick. Standard wound packing will be administered once.
88825214|NCT04893486|Experimental|Active|
88825215|NCT04893486|Placebo Comparator|Vehicle|
88825216|NCT02334306|Experimental|MEDI5872 210 mg|Participants will receive a fixed SC dose of 210 mg MEDI5872 every week (QW) from Days 1 to 15 and then every 2 weeks (Q2W) from Days 29 to 85 in double-blind period. In open-label period, participants will continue dosing of MEDI5872 210mg Q2W from Days 99 to 183 and will receive an additional dose of blinded placebo on Day 106.
88825217|NCT02334306|Placebo Comparator|Placebo/MEDI5872 210 mg|Participants will receive a SC dose of placebo matching with MEDI5872 QW on Days 1, 8, and 15 and then Q2W from Days 29 to 85 in double-blind period. In open-label period, participants will receive a fixed SC dose of 210 mg MEDI5872 QW (Days 99 to 113) and Q2W (Days 127 to 183) in open-label period.
88825218|NCT02305758|Experimental|Veliparib + modified FOLFIRI ± bevacizumab|Dosing of oral veliparib (200 mg) began 2 days prior to the start of FOLFIRI and continued twice a day (BID) for a total of 7 consecutive days. At the discretion of the Investigator, bevacizumab (5 mg/kg) could be administered intravenously (IV) immediately preceding FOLFIRI. Modified FOLFIRI was administered as irinotecan 180 mg/m^2 (90-minute infusion ± 30 minutes); leucovorin 400 mg/m^2 (90-minute infusion ± 30 minutes); and saline bolus (up to 15-minute infusion) immediately followed by fluorouracil 2400 mg/m^2 (46-hour continuous infusion ± 4 hours) starting on Day 1 of each 14-day cycle.
88825219|NCT02305758|Placebo Comparator|Placebo + FOLFIRI ± bevacizumab|Dosing of oral placebo (200 mg) began 2 days prior to the start of FOLFIRI and continued twice a day (BID) for a total of 7 consecutive days. At the discretion of the Investigator, bevacizumab (5 mg/kg) could be administered intravenously (IV) immediately preceding FOLFIRI. Standard FOLFIRI was administered as irinotecan 180 mg/m^2 (90-minute infusion ± 30 minutes); leucovorin 400 mg/m^2 (90-minute infusion ± 30 minutes); and fluorouracil bolus 400 mg/m^2 (up to 15-minute infusion) immediately followed by fluorouracil 2400 mg/m^2 (46-hour continuous infusion ± 4 hours) on Day 1 of each 14-day cycle.
88825220|NCT02305446|Experimental|rMenB+OMV NZ|Subjects who received two doses of rMenB+OMV NZ according to a 0, 2-month schedule
88825221|NCT04392219|Experimental|EIDD-2801|EIDD-2801: Part 1: Participants were randomized to receive 50 to 1600 mg EIDD-2801 powder-in bottle (fasted); Part 2: Participants were randomized to receive two single 200 mg doses (fed or fasted); Part 3: Participants were randomized to receive twice daily doses of EIDD-2801 in an open-label manner.
88825222|NCT04392219|Placebo Comparator|Placebo|Placebo: Part 1: Participants were randomized to receive placebo (fasted); Part 3: Participants were randomized to receive placebo (fasted).
88825223|NCT03649815|Experimental|Use of mHealth Technology|This single arm of the study involves the provision of the mobile health technology entitled App4Independence.
88825224|NCT04365153|Active Comparator|High Dose Intervention|600 mg of canakinumab (8 mg/kg for patients </= 40 kg)
88825225|NCT04365153|Active Comparator|Low Dose Intervention|300 mg of canakinumab (4 mg/kg for patients </= 40 kg)
88825226|NCT04365153|Placebo Comparator|Control|Placebo
88825227|NCT03654417|Active Comparator|EMLA|
88825228|NCT03654417|Active Comparator|Lidocaine|
88825229|NCT00376701|Experimental|1|Reduced fluence PDT plus intravitreal Kenalog (2 mg) plus intravitreal Avastin 1.25 mg
88825230|NCT00376701|Experimental|2|Reduced fluence PDT plus intravitreal Avastin
88825231|NCT00376701|Experimental|3|Intravitreal Avastin and sham reduced fluence PDT
88825232|NCT04358991||invasive bacterial infections|patients who are receiving Ceftazidime-avibactam are asked to provide blood samples around a dosing of the medication for analysis of samples
88825233|NCT04338009|Experimental|Discontinuation arm|The randomized intervention will be the discontinuation of ACEI/ARBs
88825234|NCT04338009|Experimental|Continuation arm|The randomized intervention will be the continuation of ACEI/ARBs
88825235|NCT03403491|Other|Sequence 1|Usual care for 2 weeks followed by using patientMpower application [+digital weighing scales & BP monitor] for 4 weeks followed by sham application (without digital scales or BP monitor) for 4 weeks.
88825236|NCT03403491|Other|Sequence 2|Usual care for 2 weeks followed by sham application (without digital scales or BP monitor) for 4 weeks followed by using patientMpower application [+digital weighing scales & BP monitor] for 4 weeks.
88825237|NCT02303574|Experimental|AZD7986, single and mulltiple doses|In Part 1 up to 8 cohorts with single doses starting with 5 mg AZD7986 as oral solution. In Part 2 up to 5 cohorts with multiple doses of AZD7986 as oral solution
89533708|NCT03723252|Placebo Comparator|Placebo group|Participants will receive placebo po qd.
88825238|NCT02303574|Placebo Comparator|Placebo, single and multiple doses|In Part 1 up to 8 cohorts and in Part 2 up to 5 cohorts with matching placebo to AZD7986 as oral solution
89533709|NCT03718767|Experimental|1/Nivolumab|IV nivolumab
89356372|NCT02496130||minilaparotomy|Subjects in this group will have tissue (uterus) extracted via mini-laparotomy incision with knife morcellation. Morcellation will be performed within a containment system. Method of extraction/group assignment will be determined clinically by the operating surgeon based on patient characteristics and patient preference.
89356373|NCT02496130||vaginal extraction|Subjects in this group will have tissue (uterus) extracted via vaginal extraction with knife morcellation. Morcellation will be performed within a containment system. Method of extraction/group assignment will be determined clinically by the operating surgeon based on patient characteristics and patient preference.
88825239|NCT02354976|Placebo Comparator|Placebo|
89356374|NCT03829163|Active Comparator|Conventional Walker Group|
89356375|NCT03829163|Experimental|HAW Group|
89356376|NCT01343888|Active Comparator|PegIFN/RBV|PegIFN/RBV for 48 weeks
89533710|NCT03706664|Other|Training of machine learning algorithm|113 MR Enterography images labelled by Radiologists will be used to develop a machine learning algorithm to (1) localise the terminal ileum, (2) classify the terminal ileum as normal or abnormal.
88825240|NCT02354976|Experimental|Omega-3 carboxylic acids 4g / day|
88825241|NCT02354976|Active Comparator|Fenofibrate 200mg|
88825242|NCT02303262|Experimental|Mocetinostat and gemcitabine|For each 21-day cycle, gemcitabine is administered on days 5 and 12 and mocetinostat is administered 3 days a week.
88825243|NCT00558896|Experimental|Relapsed Myeloma (<4 Prior Regimens)|"Pomalidomide: 2 mg orally once daily, days 1-28 of 28 day cycle~Dexamethasone: 40 mg on days 1, 8, 15 ad 22 of 28 day cycle"
88825244|NCT00558896|Experimental|Lenalidomide Refractory Myeloma|"Pomalidomide: 2 mg orally once daily, days 1-28 of 28 day cycle~Dexamethasone: 40 mg on days 1, 8, 15 ad 22 of 28 day cycle"
88825245|NCT00558896|Experimental|Bortezomib/Lenalidomide Refractory/Relapsed Myeloma|"Pomalidomide: 2 mg orally once daily, days 1-28 of 28 day cycle~Dexamethasone: 40 mg on days 1, 8, 15 ad 22 of 28 day cycle"
88825246|NCT00558896|Experimental|Bortezomib/Lenalidomide Relapsed/Refractory Myeloma|"Pomalidomide: 4 mg orally once daily, days 1-28 of 28 day cycle~Dexamethasone: 40 mg on days 1, 8, 15 ad 22 of 28 day cycle"
88825247|NCT00558896|Experimental|Relapsed Myeloma (< 4 Prior Regimens)|"Pomalidomide: 4 mg orally once daily, days 1-28 of 28 day cycle~Dexamethasone: 40 mg on days 1, 8, 15 ad 22 of 28 day cycle"
88825248|NCT00558896|Experimental|Relapsed/Refractory Myeloma|"Pomalidomide: 4 mg orally once daily, days 1-21 of 28 day cycle~Dexamethasone: 40 mg on days 1, 8, 15 ad 22 of 28 day cycle"
88825249|NCT00558896|Experimental|Relapsed Amyloidosis|"Pomalidomide: 2 mg orally once daily, days 1-28 of 28 day cycle~Dexamethasone: 40 mg on days 1, 8, 15 ad 22 of 28 day cycle"
88825250|NCT01857362|Active Comparator|Nitisinone 2 x 10 mg|Two nitisinone 10 mg capsules by mouth as a single dose
88825251|NCT01857362|Experimental|Nitisinone 1 x 20 mg capsule|One nitisinone 20 mg capsule by mouth as a single dose
88825252|NCT01857986|Experimental|Study group|Subjects in the study group will be connected to the AnapnoGuard 100 control unit operating in the normal clinical mode (automatic CO2 leak measurement above the cuff, cuff pressure control, evacuation of secretions and tracheal rinsing)
88825253|NCT01857986|Active Comparator|Control group|Subjects in the control group will be connected to the AnapnoGuard 100 control unit. In the control group, the cuff pressure control of the AnapnoGuard 100 control unit will be disabled (OFF). CO2 level above the cuff will be recorded. Suction and rinsing function will operate after the system detects no CO2.
88825254|NCT02265224|Experimental|Test - Reference|N-acetylcysteine (NAC) 600 mg uncoated tablet (single dose) followed by NAC 600 mg film-coated tablet (single dose)
88825255|NCT02265224|Active Comparator|Reference - Test|N-acetylcysteine (NAC) 600 mg film-coated tablet (single dose) followed by NAC 600 mg uncoated tablet (single dose)
88825256|NCT02265848|Active Comparator|Treatment group A|Subjects assigned to treatment group A will begin the 7 week study with high frequency stimulation for first 3 weeks of the study. After first 3 weeks, subject will return to clinic to turn off the SCS device, and will start 7-10 days of wash off period. At the end of the wash off period, subject will return to clinic and have the SCS device turned on to have it programmed to deliver the low frequency stimulation for the next 3 weeks. At the end of the 7th week, the subject will return for final end of treatment visit for conclusion of the study.
88825257|NCT02265848|Active Comparator|Treatment group B|Subjects assigned to treatment group B will begin the 7 week study with low frequency stimulation for first 3 weeks of the study. After first 3 weeks, subject will return to clinic to turn off the SCS device, and will start 7-10 days of wash off period. At the end of the wash off period, subject will return to clinic and have the SCS device turned on to have it programmed to deliver the high frequency stimulation for the next 3 weeks. At the end of the 7th week, the subject will return for final end of treatment visit for conclusion of the study.
88825258|NCT03403725|Experimental|MEN1309 (Step 1-Solid Tumors)/(Step 2-NHL)|"Step1: Accelerated Titration Design with 1 single pt per cohort and double dose level per cohort until grade ≥ 2 drug related toxicity. Then, study reverts to 3+3 design. Any cohort in which 1 pt experiences a DLT (along ATD or 3+3) will be expanded up to 6 pts.~Step2: MTD defined in Step 1, 3 MEN1309 dose levels will be tested (MTD-2, MTD-1, and MTD), with 6 pts per each dose level. A further MTD-3 level will be explored if 2 DLTs occur at the MTD-2 dose level."
88825259|NCT04332081|Experimental|Hyperbaric oxygen therapy (HBOT)|
88825260|NCT04332081|No Intervention|Standard of Care|
88825261|NCT01859078|Experimental|Baricitinib + Digoxin|"Digoxin - 0.5 milligrams (mg) administered orally, twice daily (BID), 12 hours apart on Day 1. Then, 0.25 mg administered orally, once daily (QD) on Days 2 through 16.~Baricitinib - 10 mg administered orally, QD, on Days 8 through 16."
88825262|NCT03662139||Cerebral Palsy Group|16 patients will be included. Dynamic Gait Index and other assessments will be performed twice with a 7 - 10 day interval by two evaluators
88825263|NCT03662139||Healthy Control Group|16 healthy children will be included. Dynamic Gait Index and other assessments will be performed twice with a 7 - 10 day interval by two evaluators
88825264|NCT03663231|Experimental|Biotene|People who present with dry mouth and will receive a single dose of Biotene.
88825265|NCT03663231|Placebo Comparator|Placebo|People who present with dry mouth and will receive a single dose of an alternative agent.
88825266|NCT05314725|Experimental|SGLT-2 inhibitor|
88825267|NCT05314725|Placebo Comparator|placebo|
88825268|NCT03405363||new users of Olodaterol|COPD patients using Olodaterol for the first time
88825269|NCT03405363||new users of other LABAs|COPD patients using other long-acting beta2 agonists for the first time
88825270|NCT04310085|Experimental|PfSPZ-DVI challenge and artemether lumefantrine|"16 healthy, malaria-naïve males and females, aged 18-55 years, were enrolled in 2 cohorts (8 participants/cohort; a participant may be enrolled in one cohort only). There were two target levels of parasitaemia previously achieved in healthy participants in malaria VIS at other study sites, i.e., 5000 parasites/mL blood in Cohort 1 and 10000 parasites/mL blood in Cohort 2. (Based on observed levels of parasitaemia in Cohort 1, the target threshold for treatment in Cohort 2 was maintained at 5,000 p/mL).~qPCR was performed, malaria clinical score assessed twice daily and participants were administered registered antimalarial therapy, i.e., Riamet®, when the following criteria were met:~Cohort 1: ≥5000 parasites/mL blood or earlier if a participant has a malaria clinical score >6 or at Investigator's discretion.~Cohort 2: ≥10000 parasites/mL blood or earlier if a participant has a malaria clinical score >6 or at Investigator's discretion."
88825271|NCT03406377|Placebo Comparator|Placebo|Water for injection, Sorbitol, L-Methionine, Sodium Acetate Trihydrate
89356377|NCT01343888|Experimental|BI 201335 for 12 or 24 weeks|BI 201335 once daily low dose for 12 or 24 weeks in combination with PegIFN/RBV for 24 or 48 weeks
89000424|NCT04251208||Integrated Care|This is an observational study and no intervention will be administered. The Integrated Cohort consists of pregnant women with identified opioid use disorder who are receiving prenatal care in a maternity setting that provides medication assisted treatment for opioid use.
89356378|NCT01343888|Active Comparator|Placebo and PegIFN/RBV|Placebo (oral) once daily plus PegIFN/RBV (subcutaneous injection/oral) for 24 weeks, followed by PegIFN/RBV alone up to Week 48.
89356379|NCT03336892|Experimental|Intervention|Enhanced usual care with written mental health resources and system navigation information in addition to individualized mental health care coordination by a dedicated specially trained mental health care coordinator.
89356380|NCT03336892|No Intervention|Control|Enhanced usual care with written mental health resources and system navigation information.
89356381|NCT03829085|Active Comparator|Early oral refeeding|"The patients will be started the oral refeeding from the first day of admission in the hospital.~Patients will receive a low fat solid diet with more and less 1500 calories, 35 g fat day"
89356382|NCT03829085|No Intervention|FASTING|The oral diet will be reintroduced in a traditional stepwise manner until the symptoms, signs, inflammatory parameters of AP have resolved
89356383|NCT02495740|Experimental|E-bike intervention|Intervention is active commuting to work by an electric assisted bike to work for a period of 4 weeks at least 3 times per week with a minimal distance of 6 km per way
89533711|NCT03706664|Other|Testing of machine learning algorithm|"113 MR Enterography images labelled by Radiologists will be used to test the accuracy of the machine learning algorithm to (1) localise the terminal ileum, (2) classify the terminal ileum as normal or abnormal compared to Radiologists opinion.~Cross Validation analysis will be used for data analysis."
89533712|NCT03684460|Experimental|Bright Light|"Intervention: Daytime Bright Light~Patients will be eligible if they were admitted within 30 hours of noon on enrollment day (e.g. at or after 06:00 on the prior calendar day). Enrollment will occur before noon, and the day of enrollment is termed study day 1.~Patients will undergo monitoring (light levels, circadian alignment), starting on study day 1. Patients will be exposed to bright light from 09:00 to 13:00 starting on study day 2 and continuing through study day 5 or MICU discharge whichever is longer up to 30 days. Bright light exposure will occur in the Intensive Care Unit (ICU) and on the floor, if the patient is transferred (prior to study day 5). Feasibility metrics will also be collected."
89356384|NCT02495740|Active Comparator|Bike intervention|Intervention is active commuting to work by classic bike for a period of 4 weeks at least 3 times per week with a minimal distance of 6 km per way
89356385|NCT04185389||Control|Women in the original HPV FOCAL control arm who completed the 48 month exit screen (HPV/LBC co-test) and who had no CIN2+ detected during the trial or at trial exit will be invited to submit another LBC sample for HPV and cytology co-testing.
89356386|NCT03336814|Experimental|terlipressin associated with norepinephrine|
89356387|NCT03336814|Placebo Comparator|placebo (physiologic serum) associated with norepinephrine|
89356388|NCT03818555|Other|Sebacia Microparticles Treatment|
89000425|NCT04251208||Referral-Based Care|This is an observational study and no intervention will be administered. The Referral-Based Cohort consists of pregnant women with identified opioid use disorder who are receiving prenatal care in a maternity setting and are referred to substance use treatment at a specialty care setting.
89000426|NCT04251013|Active Comparator|Group A: RX Cytology brush, Boston Scientific FIRST|A first biliary brushing will be carried out during ERCP using a standard brush RX Cytology Brush, Boston Scientific, then a second brushing will be carried out using a brush INFINITY®, US Endoscopy
89000427|NCT04251013|Active Comparator|Group B: Infinity®, US Endoscopy FIRST|A first biliary brushing will be carried out during ERCP using an INFINITY® brush, US Endoscopy then a second brushing will be carried out using standard RX Cytology Brush, Boston Scientific
89356389|NCT02495584|Experimental|Treatment 1|500ml fortified milk (10µg vitamin D3) +1 supplement capsule (10µg vitamin D3) daily for 24 weeks
89533713|NCT03684460|Active Comparator|Usual Light|"Intervention: Usual Care~Patients will be eligible if they were admitted within 30 hours of noon on enrollment day (e.g. at or after 06:00 on the prior calendar day). Enrollment will occur before noon, and the day of enrollment is termed study day 1.~Patients will undergo monitoring (light levels, circadian alignment), but otherwise, have usual care."
89533714|NCT03683186|Experimental|Ralinepag|Ralinepag once daily extended-release tablets (oral) 50, 250, and 400 mcg titrated to the highest tolerated dose.
89533715|NCT03632239||Reverse Phenotyping Core|Individuals undergoing phenotyping by the Reverse Phenotyping Core (RPC)
89000428|NCT04242043||AI|
89000429|NCT04230187|Experimental|mFOLFOXIRI Plus Bevacizumab|Patients will receive mFOLFOXIRI plus bevacizumab once every two weeks for 8 cycles as the first-line treatment.
89000430|NCT04230187|Active Comparator|mFOLFOX6 Plus Bevacizumab|Patients will receive mFOLFOX6 plus bevacizumab once every two weeks for 8 cycles as the first-line treatment.
89000431|NCT00199485|Experimental|1|Angelica Sinensis
89356390|NCT02495584|Experimental|Treatment 2|500ml fortified milk (10µg vitamin D3) +1 supplement capsule (placebo) daily for 24 weeks
89356391|NCT02495584|Experimental|Treatment 3|500ml unfortified milk (placebo) +1 supplement capsule (10µg vitamin D3) daily for 24 weeks
89356392|NCT02495584|Placebo Comparator|Treatment 4|500ml unfortified milk (placebo) +1 supplement capsule (placebo) daily for 24 weeks
89356393|NCT03828851|Experimental|Experimental group|ADL training program.
89356394|NCT03828851|No Intervention|Control group|Receive rehabilitation program in the hospital.
89356395|NCT03336736||Pulmonary Sarcoidosis|"Self-reported and self-referred self-reported medically diagnosed pulmonary sarcoidosis.~Exercise capacity and function will be assessed."
89356396|NCT03336736||Control|Healthy age-matched control group with no known lung disease. Exercise capacity and function will be assessed.
89356397|NCT05623904|Active Comparator|Carotid Revascularization|Carotid Artery Stenting/Carotid endarterectomy + Best Medical Treatment
89356398|NCT05623904|Active Comparator|Medical Treatment|Best Medical Treatment
88825272|NCT03406377|Experimental|OPK-88003|70 mg/vial (extractable volume 1 mL) (20mg for 4 weeks, 40 mg for 4 weeks and 70 mg for 22 weeks)
88825273|NCT00558272|Experimental|AZD0530 175 mg|AZD0530 (saracatinib) 175 mg once daily
88825274|NCT00558272|Experimental|Zoledronic Acid 4 mg|Zoledronic Acid 4 mg on Day 1 of the 4-week treatment period
88825275|NCT03407313|Experimental|Rotational fractional resection (1.5mm diameter device)|Single treatment of skin resection and focal lipectomy (removal of loose skin and fat)
88825276|NCT01859312|Experimental|Continuous Subcutaneous Hydrocortisone Infusion|Enrolled participants with congenital adrenal hyperplasia (CAH) received continuous subcutaneous hydrocortisone (Solucortef) infusion (CSHI) via insulin pump (Medtronic) (MMT-722Na) to achieve near-physiologic cortisol replacement therapy. Participants were their own controls; participant's baseline outcomes/lab values while on conventional glucocorticoid therapy were compared to outcomes/lab values after 6 months of treatment using CSHI via insulin pump.
88825277|NCT03407625|Experimental|Foley bulb plus Oral Misoprostol|Patients will received initial transcervical foley bulb, followed by oral misoprostol 100 micrograms given every 4 hours for a maximum of 2 doses.
88825278|NCT03407625|Active Comparator|Oral Misoprostol|Patients will receive oral misoprostol 100 micrograms given every 4 hours for a maximum of 2 doses.
88825279|NCT03408171|Active Comparator|19-gauge FNA needle|A 19-gauge FNA needle will be used to obtain liver tissue during an endoscopic-ultrasound guided liver biopsy. Tissue yield and diagnostic accuracy will be assessed and compared to that of the 19-gauge FNB needle.
88825280|NCT03408171|Active Comparator|19-gauge FNB needle|A 19-gauge FNB needle will be used to obtain liver tissue during an endoscopic-ultrasound guided liver biopsy. Tissue yield and diagnostic accuracy will be assessed and compared to that of the 19-gauge FNA needle.
88825281|NCT03803540|Experimental|Fecal Microbiota Transplantation|Lean healthy donor frozen fecal microbiota will be administered via duodenal infusion in an upper gastrointestinal endoscopy
88825282|NCT01860950|Active Comparator|anodal tDCS plus BCI|Participants underwent Brief Cognitive intervention (BCI) during a single 20-minute session of transcranial direct current stimulation (tDCS) with the anode electrode placed over the left DLPFC and the cathode electrode attached to the right shoulder (Brand Phoresor-II Auto) . BCI entails listening to a 3-minute audio recording designed to mimic key components of cognitive behavioral therapy (CBT) for pain.
88825283|NCT01860950|Active Comparator|anodal tDCS plus pain-education|"Participants were provided pain education during a single 20-minute session of transcranial direct current stimulation (tDCS) with the anode electrode placed over the left DLPFC and the cathode electrode attached to the right shoulder.~Pain Education information included Pain Physiology, info on the Gate Theory of Pain, and Central Pain Processing."
88825284|NCT01860950|Experimental|cathodal tDCS plus BCI|Participants underwent Brief Cognitive intervention (BCI) during a single 20-minute session of transcranial direct current stimulation (tDCS) with the anode attached to the right shoulder and the cathode electrode placed over the left DLPFC. BCI entails listening to a 3-minute audio recording designed to mimic key components of cognitive behavioral therapy (CBT) for pain.
88825285|NCT01860950|Experimental|cathodal tDCS plus pain-education|Participants were provided pain education during a single 20-minute session of transcranial direct current stimulation (tDCS) with the anode electrode attached to the right shoulder and the cathode electrode was placed over the left DLPFC. Pain Education information included Pain Physiology, info on the Gate Theory of Pain, and Central Pain Processing.
89533716|NCT03630991|Experimental|Cohort I (edetate calcium disodium, multivitamin)|During standard of care chemotherapy, patients receive edetate calcium disodium IV daily over 30 minutes for 4 doses for each cycle. Treatment continues for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive up to 12 multivitamin capsules PO daily while on study.
88825286|NCT01860950|Sham Comparator|sham tDCS plus BCI|Participants underwent Brief Cognitive intervention (BCI) during 20 minutes of sham tDCS. For sham, the device was turned on for 30 seconds to temporarily mimic tingling and skin sensations of real tDCS and then ramped-down to 0mA for the duration of the 20-minute session.
88825287|NCT01860950|Sham Comparator|sham tDCS plus pain-education|Participants were provided pain education during 20 minutes of sham tDCS. For sham, the device was turned on for 30 seconds to temporarily mimic tingling and skin sensations of real tDCS and then ramped-down to 0mA for the duration of the 20-minute session. Pain Education information included Pain Physiology, info on the Gate Theory of Pain, and Central Pain Processing.
88825288|NCT03666663|Experimental|Lidocaine|Participants will receive SPG blocks with lidocaine.
88825289|NCT03666663|Experimental|Bupivacaine|Participants will receive SPG blocks with bupivacaine
88825290|NCT03666663|Experimental|Ropivacaine|Participants will receive SPG blocks with ropivacaine
88825291|NCT03666663|Placebo Comparator|Placebo (saline)|Participants will receive SPG blocks with placebo (saline)
88825292|NCT03670017|Other|Time In Range during OptiScanner Connection|Participants will be connected to the OptiScanner 5000 for up to 72 hours.
88825293|NCT04309617||patients with Renal Cell Carcinoma(RCC)|Patients diagnosed with RCC who received a nephrectomy between 01Apr2014 and 31Mar2019
88825294|NCT01861574|Experimental|Both Real TMS|Participants in the Both Real TMS group receive 20 minutes of Real TMS 45 minutes after gastric-bypass surgery and then another 20 minutes of Real TMS 4 hours after surgery.
88825295|NCT01861574|Sham Comparator|Sham then Real TMS|Participants in the Sham then Real TMS group, receive Sham TMS 45 minutes after gastric-bypass surgery and 20 minutes of Real TMS 4 hours after surgery.
88825296|NCT01861574|Sham Comparator|Real then Sham TMS|Participants in the Real then Sham TMS group receive 20 minutes of Real TMS 45 minutes after gastric-bypass surgery and then 20 minutes of Sham TMS 4 hours after surgery.
88825297|NCT01861574|Sham Comparator|Both Sham TMS|Participants in the Both Sham TMS group, receive Sham TMS 45 minutes after gastric-bypass surgery and then another 20 minutes of Sham TMS 4 hours after surgery
88825298|NCT01863134|Experimental|Eptifibatide|Patients were given a bolus of eptifibatide (Integrillin; 180µg/kg of body weight) and an intravenous infusion of 2 µg/kg/min followed by acetylsalicylic acid (150mg orally daily until the day of the procedure) and enoxaparin (1mg/kg subcutaneous - with the last dose 12 hours before surgery).
89000432|NCT00199485|Placebo Comparator|2|placebo
89000433|NCT00554008|Active Comparator|1|children randomized to open appendectomy
89356399|NCT03589807|Experimental|Heterologous Arm 1|3.75 mcg per 0.5 ml dose of 2013 A/H7N9 Inactivated Influenza Virus Vaccine (IIV) + AS03 adjuvant administered intramuscularly on Day 1 and 3.75 mcg per 0.5 ml dose of 2017 A/H7N9 IIV + ASO3 adjuvant administered intramuscularly on Day 22. Phosphate buffered saline (PBS) diluent may be used to achieve targeted dosages. N=30
89356400|NCT03589807|Experimental|Heterologous Arm 2|3.75 mcg per 0.5 ml dose of 2013 A/H7N9 IIV + AS03 adjuvant administered intramuscularly on Day 1 and 3.75 mcg per 0.5 ml dose of 2017 A/H7N9 IIV + ASO3 adjuvant administered intramuscularly on Day 121. PBS diluent may be used to achieve targeted dosages. N=30
89356401|NCT03589807|Experimental|Heterologous Arm 3|3.75 mcg per 0.5 ml dose of 2013 A/H7N9 IIV + AS03 adjuvant administered intramuscularly on Day 1 and 15 mcg per 0.5 ml dose of 2017 A/H7N9 IIV administered intramuscularly on Day 121. PBS diluent may be used to achieve targeted dosages. N=30
89356402|NCT03589807|Experimental|Homologous Arm 1|3.75 mcg per 0.5 ml dose of 2017 A/H7N9 IIV + AS03 adjuvant administered intramuscularly on Day 1 and Day 22. PBS diluent may be used to achieve targeted dosages. N=30
89356403|NCT03589807|Experimental|Homologous Arm 2|3.75 mcg per 0.5 ml dose of 2017 A/H7N9 IIV + AS03 adjuvant administered intramuscularly on Day 1 and Day 121. PBS diluent may be used to achieve targeted dosages. N=30
89356404|NCT03589807|Experimental|Homologous Arm 3|3.75 mcg per 0.5 ml dose of 2017 A/H7N9 IIV + AS03 Adjuvant administered intramuscularly on Day 1 and 15 mcg per 0.5 ml dose of 2017 A/H7N9 IIV administered intramuscularly on Day 121. PBS diluent may be used to achieve targeted dosages. N=30
89356405|NCT02495818|Experimental|Lidocaine|Suprascapular nerve block with infusion of 5ml lidocaine at 2%, guided by Ultrasound combined with homemade exercises (Codman and Hughston exercises).
89356406|NCT02495818|Sham Comparator|Saline solution|Intervention with suprascapular nerve block with 5ml saline solution guided by Ultrasound combined with homemade exercises (Codman and Hughston exercises).
88825299|NCT01863134|Placebo Comparator|Placebo|Patients were given placebo infusion (0,9% Natrium Chloride) and an intravenous infusion of 2 µg/kg/min followed by acetylsalicylic acid (150mg orally daily until the day of the procedure) and enoxaparin (1mg/kg subcutaneous - with the last dose 12 hours before surgery).
88825300|NCT03676803|Experimental|Mixed spices intervention group|healthy participants consume a capsule containing 5 g of mixed spices at culinary dose
88825301|NCT03676803|Placebo Comparator|placebo group|healthy participants consume placebo capsule containing 5 g of maltodextrin
88825302|NCT01864538|Experimental|TH-302|480 mg/m2 by iv infusion over 30 - 60 min on Days 1, 8, and 15 of a 28-day cycle.
88825303|NCT04267575|Experimental|Primary Arm|After the gross solid tumor is removed, cold plasma is sprayed in the area of the resected tumor margins.
89356407|NCT01201733|Experimental|Traditional Thai massage|The participants will receive a thirty minutes session of traditional Thai massage onto the scapular region
89356408|NCT01201733|Active Comparator|Ultrasound therapy and hot pack|The participants will receive a thirty minutes session of Ultrasound therapy and hot pack
89356409|NCT02495662|Experimental|Liposomal prednisolone|Treatment with polyethylene glycol (PEG)-liposomal prednisolone sodium phosphate 150mg in 500ml saline intravenously at 1 and 15 days post surgery.
89356410|NCT02495662|Placebo Comparator|Placebo|Treatment with 500ml normal 0.9% saline intravenously at 1 and 15 days post surgery.
89356411|NCT03827915|No Intervention|Third trial of DC cardioversion|Patients with atrial fibrillation who fail to revert to sinus rhythm after two failed DC cardioversion attempts will receive a third trial of DC cardioversion (Standard of care)
88825304|NCT03415581|Placebo Comparator|Doxazosin (Placebo First)|Maintenance on a daily dose of oral doxazosin (0 mg) for 4 weeks, followed by 4-week maintenance on active doxasozin (up to 16mg/day or the highest tolerated dose. During this time subjects complete testing sessions (Self-administration, Cue session) assessing the abuse potential of intranasal oxycodone.
88825305|NCT03415581|Active Comparator|Doxazosin (Active First)|Maintenance on a daily dose of oral doxazosin (16 mg, or the highest tolerated dose) for 4-weeks, followed by 4-week maintenance on placebo doxasozin. During this time subjects complete testing sessions (Self-administration, Cue session) assessing the abuse potential of intranasal oxycodone.
88825306|NCT00557492|Experimental|Single Arm|"Intervention: Drug: Avastin (bevacizumab) 10 mg/kg, days 1, 15, 29 and 43~Intervention: Drug: Gemzar (Gemcitabine) On days 1, 15, and 29, subjects will receive gemcitabine 1500 mg/m2 IV over 150 minutes at the fixed-dose rate (10 mg/m2/min).~Intervention:Radiation: external beam radiotherapy 3 Gy/fraction utilizing a 95% isodose field over 10 consecutive weekdays, Monday to Friday, for a total of 30 Gy"
88825307|NCT03416985|Active Comparator|Manual Toothbrush|Patients will be asked to use a manual toothbrush for 30 days
88825308|NCT03416985|Active Comparator|Sonic Toothbrush|Patients will be asked to use a sonic toothbrush for 30 days
88825309|NCT03416985|Active Comparator|Pulsating Toothbrush|Patients will be asked to use a pulsating toothbrush for 30 days
88825310|NCT03682809|Experimental|Systane Complete|Subjects randomized to this group will be asked to use Systane Complete once before and after contact lens use.
88825311|NCT03682809|No Intervention|No Treatment|Subjects randomized to this group will not receive a treatment.
88825312|NCT03682965|Experimental|Intra-lymphatic allergenic extract|A series of three injections of 0.1 mL (about 2 drops) of the allergenic extract of Mountain Cedar Pollen given every four weeks into a superficial inguinal lymph node through guidance via ultrasonography using a 1-mL hypodermic syringe with a 25-gauge or smaller needle.
88825313|NCT03682965|Placebo Comparator|Intra-lymphatic placebo|Diluent as placebo control (sterile saline solution containing 0.4% phenol as a preservative and matched concentration of glycerin) given as a series of three injections of 0.1 mL (about 2 drops) every four weeks into a superficial inguinal lymph node through guidance via ultrasonography using a 1-mL hypodermic syringe with a 25-gauge or smaller needle.
88825314|NCT02989298||PD patients|End stage renal disease patients receiving peritoneal dialysis treatment
89000434|NCT00554008|Active Comparator|2|children randomized to laparoscopic appendectomy
89000435|NCT00554047|Experimental|1|Multidisciplinary Memory Clinic
89000436|NCT00554047|Active Comparator|2|General practitioner
89000437|NCT04173364|Experimental|Experimental group : ropivacaine 0.1%|Interscalene block for arthroscopic shoulder surgery with small volume of low concentration (0.1%) of ropivacaine
89356412|NCT03827915|Experimental|Double sequential external defibrillation|Patients with atrial fibrillation who fail to revert to sinus rhythm after two failed DC cardioversion attempts will receive DSED
89356413|NCT01300871||Postmenopausal Women on Endocrine Therapy|Postmenopausal women with Breast Cancer that undergo Endocrine Therapy.
89356414|NCT02496052|Experimental|dried biological amnion graft|patients, who are with IUA, treated by uterine application of amnion membrane + Foley balloon+ hormones (estradiol valerate tablets+dydrogesterone Tablets) following hysteroscopic adhesiolysis.
89356415|NCT02496052|Sham Comparator|Foley catheter balloon only|patients, who are with IUA, treated by uterine application of Foley balloon only+ hormones (estradiol valerate tablets+dydrogesterone Tablets) following hysteroscopic adhesiolysis.
89356416|NCT01206569|Experimental|advagraf|Long-acting tacrolimus (Advagraf, Astellas Pharma) will be started at single daily dose of 0.15-0.2 mg/kg/day for 6 months.
89356417|NCT03544333|Experimental|real transcranial magnetic stimulation|In the treatment arm, patients will receive 1Hz of repetitive transcranial magnetic stimulation (rTMS) over the left Sylvian parietal temporal area (area Spt) four times on 1 day (1 pulse/second and a total of 1'000 pulses: 16 minutes' protocol at 100 % of motor threshold modified based on Hoffman et al.,1999). Area Spt will be localized via baseline structural imaging and our Localite TMS navigation system.
89356418|NCT03544333|Placebo Comparator|sham transcranial magnetic stimulation|In the comparator arm, patients will receive no stimulation. The TMS coil adjusted to the patients head will not be plugged into the TMS machine and can thus not have an effect on the brain. Yet, patients will hear the same noises from a coil that is plugged in, see the TMS machine running, and area Spt localized via baseline structural imaging and our Localite TMS navigation system.
89356419|NCT01206647|No Intervention|Control arm|The patients randomized to the control arm will continue their current therapy, as individually prescribed. Insulin will be administered via subcutaneous injection and OADs (if applicable) will be administered orally, as individually prescribed.
89356420|NCT01206647|Experimental|Saxagliptin & metformin|Saxagliptin and metformin tablets will be administered orally. Pioglitazione (Rescue medication) tablets will be administered orally. Insulin glargine (Rescue medication) will be administered via subcutaneous injection as individually prescribed.
88825315|NCT03683901|Experimental|TENS/t-NMES/No stimulation|TENS stimulation parameters were of a symmetric waveform, a frequency of 100 Hz, and a pulse duration of 300 microseconds (EMPI 300PVTM program PPR #7) applied for 10 seconds. t-NMES parameters were a symmetric waveform with 2 second ramp-up and 2 second ramp-down, a frequency of 35Hz, and a pulse duration of 300 microseconds (EMPI 300PVTM program PPR #3). The t-NMES current intensity was set by adjusting the amplitude to yield the strongest contraction of the underlying muscles without initiating pain. Device and electrodes remained in place but no stimulation was delivered over the 10 second interval. Exposed to each stimulation 3 times for each shoulder ROM.
88825316|NCT01865708|Other|Ethanol lock|Ethanol lock, utilizing 74% ethanol, will begin within 24 hours of urinary catheter placement. The lock will be done every 24 hours for 1 hour. The volume that will be instilled depends upon the fill volume of the catheter, which is imprinted by the manufacturer on each catheter. Once the alcohol is in the catheter, the proximal end of the catheter will be clamped for 1 hour. After the 1 hour dwell time, the clamp will be removed and the alcohol in the lumen of the catheter will be flushed out by the patient's own urine output.
88825317|NCT04203225|Active Comparator|Single LET|One (single) application of LET topical gel [Lidocaine (4%), Epinephrine (0.1%), and Tetracaine (0.5%)] applied for 30 minutes
88825318|NCT04203225|Experimental|Triple LET|Three applications of LET topical gel, one applied every 10 minutes
88825319|NCT03949335|Experimental|Investigational|Bilateral implantation with investigational IOL Model ZFR00V
88825320|NCT03949335|Active Comparator|Control|Bilateral implantation with control IOL Model ZCB00
88825321|NCT05314257|Active Comparator|Group G|IV granisetron 1mg
89356421|NCT02495506|Experimental|Cold stored platelets|Intervention: Leukoreduced platelet concentrates stored at 4 degrees C for treatment of bleeding after Cardiac surgery
88825322|NCT05314257|Placebo Comparator|Group C|IV 5ml of 0.9% normal saline
88825323|NCT03690375|Experimental|BBL Left|Left arm selected to be treated with BBL, right arm not treated
88825324|NCT03690375|Experimental|BBL Right|Right arm selected to be treated with BBL, left arm not treated
88825325|NCT00377715|Experimental|Dimebon|Dimebon 20 mg three times a day x 26 weeks
88825326|NCT00377715|Placebo Comparator|Placebo|Placebo 20 mg three times a day x 26 weeks
88825327|NCT03695913|Experimental|Normal Diet + CGM then low carb + CGM|"Phase I (part 1) - regular diet:~Patients will wear a CGM sensor (with no real time feedback) for 11 days; document what they eat on a food log; and rate their postprandial fatigue and cravings.~Phase II (part 2) - low carb diet:~Patients will wear a CGM sensor (with real time feedback) for 11 days; document what they eat on a food log; and rate their postprandial fatigue and cravings; document their blood sugar before and two hours after eating (as well as before breakfast and before going to bed)."
88825328|NCT04234425|Experimental|Experimental Group|18 high school students in a weight training class will be assigned to this experimental group and will receive the one-hour intervention twice weekly for 8 weeks.
89533717|NCT03630991|Experimental|Cohort II (succimer, multivitamin)|During standard of care chemotherapy, patients receive succimer PO daily for 8 or 21 days of each cycle beginning day 1. Treatment continues for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive up to 12 multivitamin capsules PO daily while on study.
89533718|NCT03595124|Experimental|Arm A (axitinib, nivolumab)|Patients receive axitinib PO BID on days 1-28 and nivolumab intravenously (IV) over 30 minutes, or per institutional guidelines, on days 1 and 15 (if < 18 years old) or on day 1 (if >= 18 years old). Treatment repeats every 28 days for up to 26 cycles (2 years) in the absence of disease progression or unacceptable toxicity.
89533719|NCT03595124|Experimental|Arm B (axitinib)|Patients receive axitinib PO BID on days 1-28. Treatment repeats every 28 days for up to 26 cycles (2 years) in the absence of disease progression or unacceptable toxicity. (CLOSED TO ACCRUAL AS OF 1/23/2020 - PROSPECTIVE PATIENTS ARE RANDOMLY ASSIGNED TO ARMS A OR C)
89533720|NCT03595124|Experimental|Arm C (nivolumab)|Patients receive nivolumab IV over 30 minutes, or per institutional guidelines, on days 1 and 15 (if < 18 years old) or on day 1 (if >= 18 years old). Treatment repeats every 28 days for up to 26 cycles (2 years) in the absence of disease progression or unacceptable toxicity.
89533721|NCT03575325|Experimental|CPX-351 Treatment|"Participants will receive induction with CPX-351 at a dose of 100 u/m^2 administered intravenously over 90 minutes on days 1, 3 and 5 of a 28 day cycle.~This may be followed by consolidation with CPX-351 at a dose of 65 u/m^2 administered intravenously over 90 minutes on days 1 and 3 of a 28 day cycle (up to 3 cycles)."
88825329|NCT03697083|Experimental|Reminders Through Association Arm|participants will be prompted to think of a reminder cue that will help them remember to pick up the prescription.
88825330|NCT03697083|Active Comparator|Active Control Arm|Participants will be asked to think about where they will store their prescription.
88825331|NCT03697083|Active Comparator|Baseline Control Arm|Participants are thanked for enrolling in the reminder program.
88825332|NCT02354586|Experimental|Niraparib|
88825333|NCT00377247|Experimental|Dendritic Cells w/Tumor DNA|
88825334|NCT01866410|Experimental|Treatment (cabozantinib-s-malate, erlotinib hydrochloride)|Patients receive cabozantinib-s-malate PO daily and erlotinib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88825335|NCT00377325|Experimental|1|Participants will receive full dose cyclosporin.
88825336|NCT00377325|Experimental|2|Participants will receive active drug full dose until cleared, then one dose every 4 days.
88825337|NCT00377325|Placebo Comparator|3|Participants will receive active drug full dose until clear, then full dose every 4 days with placebo on the intervening days.
88825338|NCT04224753|Experimental|INVSENSOR00027 Test group|The subjects will be enrolled into the test group and will receive the INVSENSOR00027 investigational sensor.
88825339|NCT04196907|Experimental|Test subjects|All subjects are enrolled and receive Rad-67 Pulse Oximeter and DCI Mini sensor for measurement of hemoglobin.
88825340|NCT02332824|Placebo Comparator|Placebo|"TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet orally, once daily for up to 12 weeks.~Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14)."
88825341|NCT02332824|Experimental|TAK-272 5 mg|"TAK-272 5 mg one tablet, TAK-272 placebo 3 tablets and Candesartan cilexetil placebo one tablet, orally, once daily for up to 12 weeks.~Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14)."
88825342|NCT02332824|Experimental|TAK-272 20 mg|"TAK-272 20 mg one tablet, TAK-272 placebo 3 tablets and Candesartan cilexetil placebo one tablet, orally, once daily for up to 12 weeks.~Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14)."
88825343|NCT02332824|Experimental|TAK-272 40 mg|"TAK-272 20 mg 2 tablets, TAK-272 placebo 2 tablets, and Candesartan cilexetil placebo one tablet, orally, once daily for up to 12 weeks.~Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14)."
88825344|NCT02332824|Experimental|TAK-272 80 mg|"TAK-272 20 mg 4 tablets and Candesartan cilexetil placebo one tablet, orally, once daily for up to 12 weeks.~Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14)."
89000438|NCT04173364|Active Comparator|control group : ropivacaine 0.5%|Interscalene block for arthroscopic shoulder surgery with small volume of standard concentration (0.5%) of ropivacaine
89533722|NCT03573882|Other|Voxelotor|Participants will receive voxelotor (GBT440) at the highest dose (either 900 mg or 1500 mg) deemed safe by the Data Safety Monitoring Board (DSMB).
89533723|NCT03570749|Experimental|Baricitinib High Dose|Baricitinib administered orally. Placebo administered orally to maintain the blind.
89533724|NCT03570749|Experimental|Baricitinib Low Dose|Baricitinib administered orally. Placebo administered orally to maintain the blind.
89533725|NCT03570749|Placebo Comparator|Placebo|Participants administered orally.
89533726|NCT03570749|Experimental|Open-Label Addenda Baricitinib High Dose|Baricitinib will be administered orally during the open-label addenda.
89533727|NCT03569956|Active Comparator|Razor Group|Subject will use the 556 razor with regular shaving products, and shave at least 5 or more times per week
89533728|NCT03569956|Experimental|Regimen|Subject will use the 556 razor with the Pre-shave Gel, Cleaning Brush, and Shaving Gel and shave at least 5 or more times per week.
89533729|NCT03535584|Experimental|Exercise Program|All participants will attend a 16-session exercise program based on pulmonary rehabilitation and will complete questionnaires and frailty testing.
89533730|NCT03535129|No Intervention|Stage 1|Pilot portion to optimize intervention and achievecorrelational research aims
89533731|NCT03535129|Experimental|Stage 2|Main Clinical Trial with random assignment
89533732|NCT03532932||UC Participants|Participants diagnosed with moderate to severe UC from approximately 35 investigational sites will be observed retrospectively for previous 2 years before enrollment until Visit 1 and will be observed prospectively for 1 year after participant's enrollment into the study to assess treatment patterns and treatment outcomes in UC participants particularly on the use of available biological therapies.
89000439|NCT04171453||Open-label|This study was open-label with only one treatment group. Lyrica CR was prescribed in accordance with usual clinical practice.
89000440|NCT00199524|Active Comparator|1|ureteroscopy with ureteral access sheath
89000441|NCT00199524|No Intervention|2|ureteroscopy without ureteral access sheath
89000442|NCT02963753||hyperemesis gravidarum group|The study group consisted of women hospitalized for hyperemesis during first trimester of their pregnancy
89000443|NCT02963753||the control group|whereas the control group included all other women who delivered in the same period.
89000444|NCT04138732|Experimental|Intervention treatment group|This arm will receive the intervention treatment aimed to help improve their health behaviors. Interventions will include nutrition workshops and personal consultation for employees at risk, environmental intervention that includes brief exercise session prior to weekly meetings, placement of sports equipment in the department, and pedometer program, and stress reduction workshops. Healthy options will be demarcated in the hospital cafeteria.
89000445|NCT04138732|Other|Control group|This arm will be the control group and not receive the intervention treatment aimed to help improve their health behaviors.Once completing their time as the control group, they will continue into another phase of the trial and receive the intervention treatment.
89000446|NCT00204516|Experimental|mRNA Vacc|
89000447|NCT04105582|Experimental|Neo-antigen pulsed Dendritic cell|Autologous dendritic cells pulsed with tumor-specific neo-antigen (synthetic peptide)
89000448|NCT04093180|Experimental|Experimental group|Experimental group undergoing treatment course according to INRS
89000449|NCT04093180|Other|Control group|Wait-list delayed intervention. Control group continues usual activity and care while staying in the waiting list.
89000450|NCT04679584||Populationbased Platform (POP) of the National Pandemic Cohort Network (NAPKON)|Streamlined sampling of biomaterials and core data elements (GErman Corona COnsensu data set, GECCO) with other NAPKON study platforms (HAP, SUEP).
89000451|NCT04679584||High-Resolution Platform (HAP) of the National Pandemic Cohort Network (NAPKON)|Streamlined sampling of biomaterials and core data elements (GErman Corona COnsensu data set, GECCO) with other NAPKON study platforms (POP, SUEP).
89000452|NCT04679584||Intersectoral Platform (SUEP) of the National Pandemic Cohort Network (NAPKON)|Streamlined sampling of biomaterials and core data elements (GErman Corona COnsensu data set, GECCO) with other NAPKON study platforms (HAP, POP).
89000453|NCT00199563|Active Comparator|active drug|Viagra 100 mg / daily for 12 weeks.
89000454|NCT00199563|Placebo Comparator|Placebo|placebo/daily for 12 weeks
89000455|NCT02962830|Experimental|Sufentanil|
89000456|NCT04065100|Experimental|Study group|Maternal PCOS
89000457|NCT04065100|Active Comparator|Comaprator|Non-PCOS pregnant women
89000458|NCT00199602|No Intervention|lack of drug prophylaxis|
89000459|NCT00199602|Experimental|HBPM 2500 UI anti Xa in one subcutaneous injection per day|
89000460|NCT00199602|Experimental|warfarine 1mg daily|
89000461|NCT00554125|Active Comparator|2, III ,intervention|
89000462|NCT00175838|Active Comparator|Intermediate risk group|Intermediate risk patients are randomised to a either a group receiving Aspirin only, or a group receiving both Hydroxyurea and Aspirin.
89000463|NCT00175838|Active Comparator|Low risk group|Patients are given Aspirin only with observation.
89000464|NCT03986671|Experimental|EMG Testing|Examination of the electromyographic signal from oropharyngeal muscles obtained using an investigational transmenbrane sensor attached to a rigid probe and an FDA-approved very fine concentric needle electrode (Ambu Neuroline 25 mm x 30G).
89000465|NCT03964441||control|fetus with at least 2 ultrasound abnormalities and both parents
89000466|NCT03964441||comparison|fetus with at least 2 ultrasound abnormalities with ES diagnosis on invasive fetal sampling
89000467|NCT03964441||professional|obstetrician, midwife, geneticist, biologist
89000468|NCT03847909|Experimental|DCR-PHXC|Intervention, drug, DCR-PHXC
89000469|NCT03847909|Placebo Comparator|Placebo - Sterile Normal Saline (0.9% NaCl)|Placebo, sterile normal saline (0.9% NaCl) for subcutaneous (SC) injection
89000470|NCT03758287|Experimental|CT053PTSA +Gefitinib|"Patients will receive CT053PTSA and gefitinib over a 28-day cycle until progressive disease, intolerable toxicity or subject's withdrawal from treatment.~CT053PTSA will be administered daily, at a dose of 30 mg/40mg/60mg orally .~Gefitinib will be administered daily, at a dose of 250 mg orally ."
89000471|NCT03726346|Experimental|Toffee Full Face Mask|Participants will be placed on this arm for a total of 14+- 4 days from visit 2. Participants will be using the Toffee mask during this treatment arm.
89000472|NCT00204594|Experimental|Antibody|
89000473|NCT04679779|Experimental|control group|receive occupational therapy program
89000474|NCT04679779|Experimental|study group|receive wii virtual reality
89000475|NCT04679077|Other|Cytocam-IDF Imaging|All patients will undergo the same interventional test.
89000476|NCT03722953|Other|Aerobic Exercise|"Control: Cerebrovascular function and peripheral vascular function will be measured.~Aerobic Exercise: Across four separate visits, participants will perform light intensity exercise, light intensity exercise plus an additional task, vigorous intensity exercise and vigorous intensity exercise to match the energy expenditure of light intensity exercise visit."
89000477|NCT03635515|Active Comparator|Standard Protocol (Control) Group|Patients will be given a VAS scale to record their highest level of pain 6 hrs prior to treatment. The standard endodontic protocol will be followed. The same VAS scale from pretreatment will be used to record pain level at 6, 24, 72, and 168 hours post-treatment.
89000478|NCT03635515|Active Comparator|Gentlewave Treatment Group|Patients will be given a VAS scale to record their highest level of pain 6 hrs prior to treatment. The standard endodontic protocol will be followed through working length verification. For the Gentlewave treatment group, each canal will be shaped to a canal size of 20.06 and to 0.5 - 1mm short of the apical terminus. An occlusal platform will be prepared using the Kool-dam material recommended by Sonendo. The Gentlewave system will be held on the tooth by the clinician and will cycle through five minutes of 3% sodium hypochlorite, two minutes of 8% EDTA, and a final rinse of distilled water. Canals will be obturated with root canal sealer and gutta-percha. The same VAS scale from pretreatment to take home and asked to record their level of pain at 6, 24, 72, and 168 hours post-treatment.
89356422|NCT02495506|Active Comparator|Room temperature platelets|Intervention: Leukoreduced platelet concentrates stored at 22 degrees C for treatment of bleeding after Cardiac surgery
89356423|NCT05599256|Experimental|The group of daGOAT model prevention|"Model-predicted high-risk patients: weight ≤ 25 kg, ruxolitinib, 2.5mg bid po until at least day 60 post-transplant and terminated after day 100; weight > 25 kg, ruxolitinib, 5mg bid po until at least day 60 post-transplant and terminated after day 100. If 'azoles' are taken concomitantly, ruxolitinib will start at half dose. If the patient tolerates ruxolitinib, the dose can be increased to 10mg bid po.~Model-predicted low risk: regular aGVHD prophylactic regimens."
89356424|NCT03336580|Experimental|PRX004|"Dose escalation in up to 6 dose levels~Expansion of previously studied cohort(s) from Dose Escalation~Extended dosing at RP2D"
89356425|NCT03726541|Experimental|Early physiotherapy group|breathing exercise incentive spirometry training ambulation coughing
89356426|NCT03814655|Experimental|Full digital workflow|"Intraoral scan of the partially edentulous site, antagonists and occlusion registration. Radiopaque tray customization over the partially edentulous arch.~CBCT with customized radiopaque tray.~Merging files in R2 Gate software and implant planning.~Guided implant insertion with immediate loading, if possible. Megagen dental implants will be inserted.~Digital impression for final screw-retained crown/bridge.~Assessment of accuracy by comparing stl files (planned and postimplant insertion)."
89356427|NCT03814655|Active Comparator|Partially digital workflow|"Impression of the edentulous arch and antagonist, occlusion registration. Radiopaque tray customization over the edentulous arch.~CBCT with customized radiopaque tray.~Stone models alone, maximum intercuspal position and customized radiopaque tray will be scanned using a desktop scanner.~Merging files (CBCT and model stl) in R2 Gate software and implant planning.~Guided implant insertion with immediate loading, if possible. Megagen dental implants will be inserted.~Classic impression in customized tray with Impregum.~Functional models will be scanned using the same desktop scanner.~Final screw-retained crown/bridge manufacturing.~Assessment of accuracy by comparing stl files (planned and postimplant insertion)."
88825345|NCT02332824|Active Comparator|Candesartan cilexetil 8 mg|"TAK-272 placebo 4 tablets and Candesartan cilexetil 8 mg one tablet, orally, once daily for up to 12 weeks.~Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14)."
88825346|NCT03701061|Experimental|Participants that received AS03 Adjuvant|Subjects that participated in HIPCVAX-010 Systems Biology of Influenza A (H5N1) Virus Monovalent Vaccine with AS03 Adjuvant study are included in the study. Subjects will receive a single dose of the FDA-approved 2018-2019 seasonal influenza vaccine (Fluarix Quadrivalent).
88825347|NCT03701061|Active Comparator|Participants that did not receive AS03 Adjuvant|Subjects that participated in HIPCVAX-010 Systems Biology of Influenza A (H5N1) Virus Monovalent Vaccine without AS03 Adjuvant study are included in the study. Subjects will receive a single dose of the FDA-approved 2018-2019 seasonal influenza vaccine (Fluarix Quadrivalent).
88825348|NCT03705273|Experimental|Dexamethasone IV for PO|Dexamethasone IV for PO solution mixed with sugar syrup to be given orally
88825349|NCT03705273|Active Comparator|Dexamethasone crushed tablets|Dexamethasone tablet crushed and placed in apple sauce or pudding to be given orally
88825350|NCT03708393|Active Comparator|Imagio IUS|Read 1 - Mammo (as available) + Imagio Ultrasound
88825351|NCT03708393|Experimental|Imagio (IUS+OA)|Read 2 - Mammo (as available) + (Imagio Ultrasound + OA)
88825352|NCT03946059|Experimental|iTBS then cTBS|"Participants in this arm first receive the iTBS brain stimulation in week 1, then have a one-week washout period and then receive cTBS brain stimulation in week 2.~intermittent Theta-Burst-Stimulation (iTBS) entails a 2 second train of stimuli (stimuli occurring as a 50 Hz burst of three pulses separated by 200ms). Each 2 second train is followed by an 8 second pause, followed by another 2 second train. In total, 20 trains will be delivered, for a total of 200 bursts and 600 total pulses.~continuous Theta-Burst-Stimulation (cTBS) consists of a continuous stimulus train (stimuli occurring as a 50 Hz burst of three pulses separated by 200ms). In total, 200 bursts and 600 total pulses will be delivered."
89356428|NCT03341884|Experimental|Normal Hepatic Function|Participants with normal hepatic function will be administered a single oral dose of ipatasertib (100 mg).
89356429|NCT03341884|Experimental|Mild Hepatic Impairment|Participants with mild hepatic impairment (Child-Pugh Class A, score of 5 to 6, inclusive) will be administered a single dose of ipatasertib (100 mg).
89356430|NCT03341884|Experimental|Moderate Hepatic Impairment|Participants with moderate hepatic impairment (Child-Pugh Class B, score of 7 to 9, inclusive) will be administered a single dose of ipatasertib (100 mg).
89533733|NCT03532932||CD Participants|Participants diagnosed with moderate to severe CD from approximately 35 investigational sites will be observed retrospectively for previous 2 years before enrollment until Visit 1 and will be observed prospectively for 1 year after participant's enrollment into the study to assess treatment patterns and treatment outcomes in CD participants particularly on the use of available biological therapies.
89533734|NCT03506061|Experimental|Participants With Evidence of Partial Function (sweat chloride < 80 mEq/L or pancreatic sufficiency)|Participants with CF with evidence of partial function (sweat chloride < 80 milliequivalents per liter (mEq/L) or pancreatic sufficiency) will receive Trikafta for 28 days.
89533735|NCT03506061|Experimental|Participants who Encode the N1303K Variant|Participants with CF who encode the N1303K variant will receive Trikafta for 28 days.
89533736|NCT03481829||Children|Children of mothers enrolled in the study
89533737|NCT03481829||Pregnant women and mothers|Pregnant women/mothers
89533738|NCT03481205|Experimental|Ischemic Conditioning|Doctormate device used en route to the comprehensive stroke center
88825353|NCT03946059|Experimental|cTBS then iTBS|Participants in this arm first receive the cTBS brain stimulation in week 1, then have a one-week washout period and then receive iTBS brain stimulation in week 2.
88825354|NCT04184271|Experimental|38% silver diamine fluoride|38% silver diamine fluoride, topical, 1 drop, single application
88825355|NCT03938337|Experimental|Cohort 1 Not Previously Treated|Patients with metastatic or recurrent head and neck cancer who have not been treated previously with immunotherapy.
88825356|NCT03938337|Experimental|Cohort 2 Treated Previously|Patients with metastatic or recurrent head and neck cancer who have been treated previously with immunotherapy.
88825357|NCT03937791|Experimental|Arm 1/1x10^11 E7 T Cell Receptor (TCR) T cells|1x10^11 E7 TCR T cells will be administered intravenously over 20 to 30 minutes on day 0.
88825358|NCT03936387|Experimental|Bilateral erector spinae blocks|Bilateral erector spinae block catheters are placed at end of the sternotomy procedure, bolused with 1ml/kg 0.2% ropivacaine, then started on a 0.2ml/kg/hour continuous infusion of 0.2% ropivacaine. Patients will have access to rescue opiates as needed by means of the standard PCA/NCA demand protocols utilized at BCH.
88825359|NCT04173429|Experimental|nadroparin calcium-warfarin sequential therapy group|nadroparin calcium every 12 hours for 1 month followed by an oral administration of warfarin for 5 months
88825360|NCT04173429|No Intervention|Control group|No anticoagulation therapy.
89533739|NCT03474718|Experimental|Group A|At the baseline visit subjects will be randomized to either group A or group B. Group A will receive PRP on left side of scalp and placebo (saline solution) on right side of scalp.
88825361|NCT03710187|Experimental|Combination|Hydrocortisone 50 mg IV Q6h plus Fludrocortisone 50 mcg PO/PFT Q24h
88825362|NCT03710187|Active Comparator|Hydrocortisone only|Hydrocortisone 50 mg IV Q6h
88825363|NCT03710577|Experimental|Yoga|40 minutes of Vinyasa yoga
88825364|NCT03710577|Placebo Comparator|Quiet Rest|40 minutes of quiet rest
88825365|NCT04167189|Other|Observational study of prevalence in hard-to-treat ADHD|Subjects will be tested with lidocaine gel.
88825366|NCT03929367|Other|Oxytocin (Pitocin®), 10 IU|Oxytocin 10 IU administered once per intravenous injection
88825367|NCT03715803||Calistar A|Calistar A mesh to treat anterior and apical POP
88825368|NCT03715803||Calistar S|Calistar S mesh to treat anterior and apical POP
88825369|NCT04155567|Experimental|TAK-123|TAK-123 as 3.75 gram per square meter (g/m^2) of sodium phenylacetate and 3.75 g/m^2 of sodium benzoate, intravenous administration over 90 minutes, followed by TAK-123 as 3.75 g/m^2 of sodium phenylacetate and 3.75 g/m^2 of sodium benzoate, intravenous administration over 24 hours.
88825370|NCT04149405|Active Comparator|Group A|"Subjects with chronic periodontitis and osteoporosis.~Phase 1 periodontal therapy and bisphosphonate therapy ( Aclasta: intravenous infusion of 5 mg of zoledronic acid once a year) were administered to the subjects."
88825371|NCT04149405|Active Comparator|Group B|"Subjects with chronic periodontitis and systemically healthy.~Phase 1 periodontal theraphy was administered to the subjects."
88825372|NCT04149405|Active Comparator|Group C|"Subjects with periodontally healthy and osteoporosis.~Bisphosphonate therapy ( Aclasta: intravenous infusion of 5 mg of zoledronic acid once a year) were administered to the subjects."
88825373|NCT04149405|No Intervention|Group D|"Systemically and periodontally healthy controls~No intervention has been made."
88825374|NCT00556712|Experimental|Erlotinib|Participants received erlotinib, 150 milligrams (mg), orally (PO), daily from randomization until progressive disease (PD), death, or unacceptable toxicity.
88825375|NCT00556712|Placebo Comparator|Placebo|Participants received a placebo, PO, daily, from randomization until PD, death, or unacceptable toxicity.
88825376|NCT04137783||homozygous or compound heterozygous ABCA3 mutations|patients meet the criteria for fatal respiratory distress sydrome and undergone exome sequencing, which indicated homozgyous or compound heterozygous ABCA3 mutations.
89533740|NCT03474718|Experimental|Group B|At the baseline visit subjects will be randomized to either group A or group B. Group B will receive PRP on right side of scalp and placebo (saline solution) on left side of scalp.
89533741|NCT03465774||Group 2 (IPC alone)|Patients undergo IPC placement.
89533742|NCT03465774||Group I (IPC, doxycycline)|Patients undergo IPC placement and receive doxycycline via IPC 5 days later.
89533743|NCT03461900|Experimental|Minifluid challenge|100 ml of 4% Albumin will be deliver to assess fluid responsiveness
89533744|NCT03461900|Experimental|Control|Patient will be treated as defined by most recent surviving sepsis campaign guidelines
89533745|NCT03459079|Active Comparator|lanifibranor arm|Two arm, randomized (1:1), double-blind, placebo-controlled, 24-week treatment study receiving lanifibranor 800 mg/day.
88825377|NCT04137783||single ABCA3 mutation|patients meet the criteria for fatal respiratory distress sydrome and undergone exome sequencing, which indicated single mutations.
88825378|NCT04137783||no ABCA3 mutations|patients meet the criteria for fatal respiratory distress sydrome and undergone exome sequencing, which exclude all gene mutations involving in the respiratory disease.
88825379|NCT03717051|Experimental|Intervention|The intervention group will receive nicotine replacement therapy (NRT) sampling and medication counseling. The nurse will help the subject to decide which NRT product (patch or gum) he/she can use and advise how to use the NRT based on his/her smoking habit and amount of cigarette consumption. In addition, the nurse will deliver medication counselling which addresses five main components: (1) the benefits for using NRT in quitting, (2) withdrawal symptoms due to smoking cessation, (3) side effects of NRT, (4) instructions for using NRT, and (5) making appointments for TWGHs SC clinics. Afterwards, the participant will receive 1-week free NRT, an education card about NRT and a one-page leaflet provided by the SC clinics.
89533746|NCT03459079|Placebo Comparator|Placebo|Two arm, randomized (1:1), double-blind, placebo-controlled, 24-week treatment study receiving placebo.
89533747|NCT03450057|Experimental|Single arm trial receiving daratumumab with dexamethasone (DaraD)|Daratumumab was given at a dose of 16 mg/kg administered as an intravenous (IV) infusion at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter. Dexamethasone was administered according to the standard recommended dose of 40 mg (20 mg for patients > 75 years of age) orally once daily on Days 1, 8, 15, and 22 of each 28-day treatment cycle.
89533748|NCT03440567|Experimental|Cohort I (avelumab, utomilumab, RICE)|Patients receive rituximab IV on day 1, etoposide phosphate IV on days 1-3, avelumab IV over 60 minutes on day 2, ifosfamide IV over 24 hours on day 2, and carboplatin IV on day 2 or rituximab IV on day 1, etoposide phosphate IV on days 1-3, avelumab IV over 60 minutes on days 2, utomilumab IV over 60 minutes on day 2, ifosfamide IV over 24 hours on day 2, and carboplatin IV on day 2. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients may then undergo autologous hematopoietic stem cell transplantation.
88825380|NCT03717051|Active Comparator|Control|The control group subjects will receive medication counseling. They will be advised to obtain free NRT by enrolling in the smoking cessation services, but will not be given the sampling. The same one-page leaflet will be provided by the SC clinics.
88825381|NCT04147455|Experimental|RealConsent|Participants randomized to this study arm will receive an adapted program of RealConsent.
88825382|NCT04147455|Active Comparator|Health Education Control Condition|Participants in the control arm will receive a web-based health promotion program.
88825383|NCT04350320|Experimental|COLCHICINE|"The colchicine treatment includes an initial dose of 1.5 mg (1 mg and 0.5 mg two hours after), followed by 0.5 mg every 12 hours during the next 7 days and 0.5 mg every 24 hours until the completion of 28 days of total treatment. In patients receiving ritonavir or lopinavir or with reduced renal clearance (<50 ml/min/1.37m2), weight <70 kg or age >75 years old, the dose will be adjusted to the half.~+ standard therapy for COVID-19 according to the stablished hospital protocols."
88825384|NCT04350320|Placebo Comparator|control group|Standard therapy for COVID-19 according to the stablished hospital protocols.
88825385|NCT04143945|Experimental|DV3396 followed by PDS290|The 2 treatments will be administered at least 30 minutes apart, one in each side of the stomach
88825386|NCT04143945|Experimental|PDS290 followed by DV3396|The 2 treatments will be administered at least 30 minutes apart, one in each side of the stomach
88825387|NCT04134429||Everion®|The Everion® will be given to the participants for the duration of 2 weeks (fourteen days) with the instruction to wear it all the time, with exception of the time needed for battery charging and the patients' hygiene.
88825388|NCT03920865|Experimental|Part 1|Participants with mild hepatic impairment and demographically matched healthy participants with normal hepatic function will be enrolled. Participants will receive a single oral dose of 5 mg risdiplam.
88825389|NCT03920865|Experimental|Part 2|Participants with moderate hepatic impairment and demographically matched healthy participants with normal hepatic function will be enrolled. Participants will receive a single oral dose of 5 mg risdiplam.
88825390|NCT00556322|Experimental|1|
88825391|NCT00556322|Active Comparator|2|
88825392|NCT04137627|Experimental|Melatonin|The group received standard treatment with the oral administration of Melatonin
88825393|NCT04137627|Placebo Comparator|Placebo|The group received standard treatment with the oral administration of Placebo
88825394|NCT00556166|Experimental|Enterra Therapy|The Enterra Therapy Gastric Stimulator will be used on subjects who have failed all other medical options to treat gastroparesis and all have a gastric stimulator implanted.
88825395|NCT01869374|Experimental|Magnetic Seizure Therapy (MST)|MagVenture MagPro MST device
88825396|NCT01869374|Active Comparator|RUL ECT|Right Unilateral ECT with the Somatics Thymatron device using Ultrabrief stimulus
88825397|NCT04136145|Experimental|Belimumab SC|Subjects will be administered a single dose of belimumab 200 mg via the SC route. The dose will be administered in the front of the thigh via auto-injector device.
88825398|NCT04136145|Experimental|Belimumab IV|Subjects will be administered a single dose of belimumab 200 mg via the IV route administered over approximately 1 hour.
88825399|NCT01869686|Experimental|Denosumab|single subcutaneous injection
89533749|NCT03440567|Experimental|Cohort II (avelumab, utomilumab, rituximab, ibrutinib)|Patients receive rituximab IV on day 1, avelumab IV over 60 minutes on days 2 and 16, and ibrutinib PO QD or rituximab IV on day 1, avelumab IV over 60 minutes on days 2 and 16, utomilumab IV on day 2, and ibrutinib PO QD. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity. (Closed as of 12/12/2019)
88825400|NCT04109703|Active Comparator|High level pulsed heat|Subjects randomized to this arm received a generation 5 device (Soovu Labs Inc.) that produced 30 minutes of heat. The heat was delivered as waves peaking at 45° C.
88825401|NCT04109703|Placebo Comparator|Low level steady heat|Subjects randomized to this arm received an identical generation 5 device (Soovu Labs Inc.) that produced 30 minutes of heat. The heat was delivered in a steady manner at 37° C.
88825402|NCT01870388|Experimental|Baricitinib (Healthy)|Group 1: 4 milligrams (mg) baricitinib administered once, orally, to participants with normal hepatic function.
88825403|NCT01870388|Experimental|Baricitinib (Moderate)|Group 2: 4 mg baricitinib administered once, orally, to participants with moderate hepatic impairment.
88825404|NCT01870388|Experimental|Baricitinib (Mild)|Group 3: 4 mg baricitinib administered once, orally, to participants with mild hepatic impairment. Enrollment is contingent on data from Groups 1 and 2.
88825405|NCT03909009|Active Comparator|Active rTMS|Group 1 will receive high frequency repetitive transcranial magnetic stimulation (10hz-HF-rTMS) A total 14 sessions of HF-rTMS, 10 sessions daily (5 days/week, 2 weeks) and 4 sessions weekly (1 day/week, 4 weeks).
88825406|NCT03909009|Sham Comparator|Sham rTMS|Group 2 will receive sham stimulation. A total 14 sessions of sham-rTMS, 10 sessions daily (5 days/week, 2 weeks) and 4 sessions weekly (1 day/week, 4 weeks).
88825407|NCT01870856|Experimental|Spectacles, Stage 1|Spectacles per participant's habitual perscription worn for 2 weeks
88825408|NCT01870856|Active Comparator|1-DAY ACUVUE, Stage 1|Etafilcon A contact lenses worn in both eyes at least 5 days per week, at least 6 hours per day, for 2 weeks in a daily disposable mode
89533750|NCT03388606||Adolescents with major depression|Adolescents with a current or past history of meeting full critieria for major depressive disorder
88825409|NCT01870856|Experimental|DAILIES TOTAL1, Stage 2|Delefilcon A contact lenses worn in both eyes at least 5 days per week, at least 6 hours per day, for 2 weeks in a daily disposable mode
88825410|NCT01870856|Active Comparator|1-DAY ACUVUE, Stage 2|Etafilcon A contact lenses worn in both eyes at least 5 days per week, at least 6 hours per day, for 2 weeks in a daily disposable mode
88825411|NCT03739983|Experimental|VRP Therapy|All subjects on this study will receive the Vaginal Renewal Program intervention. Enrolled subjects will receive inperson instruction on how to perform the VRP. Subjects will be encouraged to use the device for 3-4 days per week for 5 minutes at a time.
88825412|NCT02270060|Experimental|Music Therapy Group|Patient receives a single 20-minute music therapy session with a music therapist. Patient will interact with specially composed music tailored to the patient's preferences using an iPad.
88825413|NCT02270060|Active Comparator|Music Listening Group|Patient listens to his/her preferred music on an iPod touch for 20 minutes without the presence of a music therapist.
88825414|NCT02270060|No Intervention|Control Group|Patient receives standard care and waits in treatment room/bay for twenty minutes.
88825415|NCT03764007|Experimental|18F-Fluorocholine PET|Patients will undergo a single fluorocholine PET imaging study prior to surgery.
88825416|NCT02271386|Experimental|Intervention|Clinicians in the intervention arm will receive the three-part intervention (Supporting Practice for ADHD, or SPA) which includes: education about ADHD management and communication training, collaborative consultation, and performance feedback, for the first 8 months of the study.
88825417|NCT02271386|Other|Control|Clinicians in the control arm will receive no intervention for the first 8 months of the study, then will receive the full SPA intervention for the last 8 months of the study.
88825418|NCT04091061|Experimental|PF-06865571 Moderate Hepatic Impairment|This arm includes participants with moderate hepatic impairment who will receive an oral dose of PF-06865571 100 mg on Day 1
88825419|NCT04091061|Experimental|PF-06865571 Severe Hepatic Impairment|This arm includes participants with severe hepatic impairment who will receive an oral dose of PF-06865571 100 mg on Day 1
88825420|NCT04091061|Experimental|PF-06865571 Mild Hepatic Impairment|This arm includes participants with mild hepatic impairment who will receive an oral dose of PF-06865571 100 mg on Day 1
88825421|NCT04091061|Experimental|PF-06865571 Healthy Participants|This arm includes healthy participants who will receive an oral dose of PF-06865571 100 mg on Day 1
88825422|NCT03360890|Experimental|Cohort 1: salivary gland tumors without SOC treatment option|All patients will receive pembrolizumab and docetaxel. First pembrolizumab and docetaxel will be given together. After which patients will receive pembrolizumab alone until disease progression or up to 35 cycles (about 2 years).
88825423|NCT03360890|Experimental|Cohort 2: 'aggressive' thyroid cancer without SOC treatment op|All patients will receive pembrolizumab and docetaxel. First pembrolizumab and docetaxel will be given together. After which patients will receive pembrolizumab alone until disease progression or up to 35 cycles (about 2 years).
88825424|NCT01872338|Active Comparator|Mindfulness-Based Cognitive Therapy + Treatment As Usual|Psychotherapeutic intervention that integrates mindfulness meditation with Safety Planning, with a specific focus on reducing suicide risk.
88825425|NCT01872338|Other|Treatment As Usual|VA standard care for suicide prevention
88825426|NCT04079127||Patients suffering from severe hip pain and disability|Patients in need of a total hip arthroplasty.
88825427|NCT03862755|Experimental|Thromboprophylaxis|All surgical patients classified into low risk and moderate/high risk groups based on Caprini score and received different thromboprophylaxis strategies Briefly, early ambulation alone was used in patients at low risk, early ambulation plus chemoprophylaxis with Low Molecular Weight Heparin was used in patients at moderate/high risk.
88825428|NCT01874132|Experimental|Aerobic exercise training|Dose response
88825429|NCT01874132|Experimental|Aerobic and resistance exercise training|Dose response
88825430|NCT01874132|No Intervention|Control|Non-exercising control group
88825431|NCT02332590|Active Comparator|Adalimumab 40 mg/Sarilumab 200 mg|Adalimumab 40 milligrams (mg) subcutaneous (SC) injection in combination with placebo for sarilumab every 2 weeks (q2w) for 24 weeks during the double-blind (DB) period. The dosing frequency of adalimumab was adjusted to 40 mg every week (qw) dosing in case of participants with inadequate response (less than [<] 20% improvement from baseline in tender joint count [TJC] and swollen joint count [SJC] for 2 consecutive visits) at or after Week 16 until Week 23. Participants who completed 24 weeks in the DB period had the option to continue in open label extension (OLE) period and received sarilumab 200 mg q2w until commercial availability of sarilumab in their country or up to a maximum of an additional 276 weeks (i.e. up to Week 300).
88825432|NCT02332590|Experimental|Sarilumab 200 mg/Sarilumab 200 mg|Sarilumab 200 mg SC injection in combination with placebo for adalimumab q2w for 24 weeks during the DB period. The dosing frequency of placebo for adalimumab was adjusted to 40 mg qw dosing in case of participants with inadequate response (<20% improvement from baseline in TJC and SJC for 2 consecutive visits) at or after Week 16 until Week 23. Participants who completed 24 weeks in the DB period had the option to continue in OLE period and received sarilumab 200 mg q2w until commercial availability of sarilumab in their country or up to a maximum of an additional 276 weeks (i.e. up to Week 300).
88825433|NCT03869541||Intensive care patients|Adult intensive care patients receiving vasoactive drugs
88825434|NCT03869541||Intensive care unit clinicians|Clinicians for participation in a survey on the hypothetical randomization of patient participants in a future randomized controlled trial.
88825435|NCT03869541||ICU rehabilitation clinicians|Clinicians for participation in a survey on the feasibility of an ICU physical rehabilitation adverse event tool.
88825436|NCT01874756|Experimental|LY500307 150mg|LY500307 150mg
88825437|NCT01874756|Placebo Comparator|placebo|placebo 6 pills of inactive drug
88825438|NCT01874756|Experimental|LY500307 75mg|LY500307 75mg
88825439|NCT01874756|Experimental|LY500307 25mg|LY500307 25mg
88825440|NCT04076787||Favorable IMDC risk group|The cohort of mRCC patients receiving sunitinib as first-line treatment and classified as favorable IMDC risk group for having 0 individual risk factor
89356431|NCT03341884|Experimental|Severe Hepatic Impairment|Participants with severe hepatic impairment (Child-Pugh Class C, score of 10 to 15, inclusive) will be administered a single dose of ipatasertib (100 mg).
89533751|NCT03388606||Healthy volunteer adolescents/young adults|Adolescents with no history of significant psychiatric or medical disorders (as defined in the protocol) currently or in the past.
89533752|NCT03388606||Parents of adolescent participants|biological parent or legal guardian of an enrolled adolescent (who is a healthy volunteer, has s MDD [subthreshold depression], or has MDD [Major Depressive Disorder]) participant
89533753|NCT03366116|Experimental|1|Aza-TdCyd will be administered orally once a day for 5 days of each week for 2 weeks, with one week off, in 21-day cycles
89533754|NCT03329963|Experimental|Lifestyle intervention Group|Behavioral therapy for weight loss and Exercise Training
89533755|NCT03329963|Active Comparator|Healthy lifestyle intervention Group|Group education sessions that focus on diet exercise and social support.
89533756|NCT03327792|Experimental|200 mg Mavoglurant|200 mg mavoglurant once daily for 7-10 days
89533757|NCT03327792|Placebo Comparator|Placebo|Placebo once daily for 7-10 days
89533758|NCT03297606|Experimental|Group 1 - Arm CLOSED, no patients recruited|VEGFR1, VEGFR2, VEGFR3
89533759|NCT03297606|Experimental|Group 2 - Arm CLOSED, no patients recruited|BCR-ABL, SRC
89533760|NCT03297606|Experimental|Group 3 - Arm CLOSED|ALK, ROS1, MET
89533761|NCT03297606|Experimental|Group 4 - Arm CLOSED, no patients recruited|KIT, PDGFRA, PDGFRB, ABL1
89533762|NCT03297606|Experimental|Group 5|EGFR
89533763|NCT03297606|Experimental|Group 6 - Arm CLOSED|high mutation burden, POLE, POLD1
89533764|NCT03297606|Experimental|Group 7|BRCA1, BRCA2, mutations in HRD
89533765|NCT03297606|Experimental|Group 8|CDKN2A, CDK4, CCND1, SMARCA4
89533766|NCT03297606|Experimental|Group 9 Arm CLOSED|CSF1R, PDGFRA, PDGFRB,VEGFR1, VEGFR2, VEGFR3, KIT, FLT3, RET, FGFR1, FGFR2, FGFR3, VHL
89533767|NCT03297606|Experimental|Group 10|AKT1, AKT2, AKT3, FBXW7, FLCN, mTOR, NF1, NF2, NTRK3, PIK3CA, PIK3R1, PTEN, RHEB, STK11, TSC1, TSC2
89533768|NCT03297606|Experimental|Group 11 - Arm CLOSED|ERBB2
89356432|NCT05358899|Experimental|Real stimulation|Participants in the real stimulation group will receive accelerated cTBS with 1800 stimulation per session for 10 consecutive days, 5 sessions per day with a gap at least one hour, 50 sessions in total. The stimulation will be conducted at left M1 area.
89356433|NCT05358899|Sham Comparator|Sham stimulation|Participants in the sham stimulation group will receive the stimulation with coil vertical to the surface with other settings same as the real stimulation group.
89356434|NCT02495194|Experimental|Active Horticultural Therapy|15 sessions of Horticultural Therapy program teaching the elderly about gardening techniques and for them to benefit from the therapeutic effects of the parks
89356435|NCT02495194|Other|Waitlist Control Group|Participants will receive the same horticultural therapy program at the end of the assessments
89356436|NCT03827837|Experimental|SHR-1210 combined with Famitinb|SHR-1210 + Famitinib
89356437|NCT03560245|Experimental|Bryostatin 20µg|20µg Bryostatin administered IV over 45 minutes every other week after 2 initial loading doses of 24 micrograms administered weekly. A total of 7 doses administered over 12 weeks.
89356438|NCT03560245|Placebo Comparator|Placebo|"Placebo administered IV over 45 minutes every other weekafter 2 initial doses administered weekly. A total of 7 doses administered over 12 weeks.~The placebo is a sterile, pyrogen-free, lyophilized powder identical in appearance to the active drug, intended for IV infusion upon reconstitution and dilution."
89356439|NCT03336424|Experimental|Non-invasive investigations group|Non-invasive investigations include: ultrasound, blood exam, urine analysis and culture, uroflowmetry
89356440|NCT03336424|Experimental|Invasive investigations group|urodynamic study including: cystomanometry, pressure flow study, EMG
89356441|NCT02495272|Active Comparator|Control Group|Oxytocin 10IU im was administered after placental delivery
89533769|NCT03297606|Experimental|Group 12|BRAFV600
89533770|NCT03297606|Experimental|Group 13|PTCH1, SMO
89533771|NCT03297606|Experimental|Group 14|ERBB2
89533772|NCT03297554|Experimental|m-health approach|See intervention description
89533773|NCT03245814|Experimental|Service Dog|Participants in the service dog arm will receive unrestricted, non-study usual care, in addition to a trained service dog.
89533774|NCT03245814|No Intervention|Waitlist Control|Participants in the control arm will receive unrestricted, non-study usual care, while on the waitlist for a service dog.
88825441|NCT04076787||Intermediate IMDC risk group|The cohort of mRCC patients receiving sunitinib as first-line treatment and classified as intermediate IMDC risk group for having 1 or 2 individual risk factors
88825442|NCT04076787||Poor IMDC risk group|The cohort of mRCC patients receiving sunitinib as first-line treatment and classified as poor IMDC risk group for having 3 or more individual risk factors
88825443|NCT04063371||Control Group 1|At least one location will serve as the control office and will continue to conduct their visits including screening for cognitive impairment as they normally do using their usual method based on the primary care provider's normal practice.
88825444|NCT04063371||Intervention Group|At least one different location will serve as the intervention office where all the providers, as their standard of care, use a standardized method for screening for cognitive impairment consisting of using the SAGE or eSAGE test and having a conversation with an individual who knows the patient well (if possible) to ascertain if a significant change (based on primary care provider opinion) occurred in the patient's cognitive skills over the previous year.
88825445|NCT04063371||Control Group 2|Control group 2 consists of patients handled by the intervention office who did not complete the SAGE or eSAGE.
88825446|NCT03200678|Experimental|ACLR Group|experimental: ACL surgery Intervention: isokinetic assessment
88825447|NCT03200678|Other|Control group|other Intervention: isokinetic assessment
88825448|NCT00554840|Active Comparator|varenicline|
88825449|NCT00554840|Placebo Comparator|placebo|
88825450|NCT05652140||High-Risk with increased CRF|ApoE e4 carriers with increased CRF from Baseline to the Follow-Up Stages.
88825451|NCT05652140||High-Risk with decreased CRF|ApoE e4 carriers with decreased CRF from Baseline to the Follow-Up Stages.
89356442|NCT02495272|Experimental|Study Group|Oxytocin 10IU im was administered after the anterior shoulder could be seen.
89356443|NCT03814811||Bone metastasis(+) with low cOC|Patients who have bone metastasis with low number of circulating osteocalcin-positive (cOC) cells
88825452|NCT05652140||Low-Risk with increased CRF|Non-ApoE e4 carriers with increased CRF from Baseline to the Follow-Up Stages.
88825453|NCT05652140||Low-Risk with decreased CRF|Non-ApoE e4 carriers with decreased CRF from Baseline to the Follow-Up Stages.
88825454|NCT04069221|Experimental|Part 1, single arm|"This was an open-label study in 8 healthy subjects to determine the absolute bioavailability of OZ439 following a single oral dose of OZ439 and co-administration of a single iv infusion of a [14C]-OZ439 radiolabeled microdose at the anticipated Tmax of the oral dose. Subjects received the following treatment:~Treatment A: A single oral dose of 800 mg OZ439 simple granules administered as a 100-mL dispersion followed by a 15-minute 10-mL iv infusion of 100 μg [14C]-OZ439 (47 kBq [1.27 μCi]) beginning 3 hours after the oral dose administration."
89356444|NCT03814811||Bone metastasis(+) with high cOC|Patients who have bone metastasis with high number of circulating osteocalcin-positive (cOC) cells
89356445|NCT03814811||Bone metastasis(-) with low cOC|Patients who have metastasis only in extraskeletal sites with low number of circulating osteocalcin-positive (cOC) cells
89356446|NCT03814811||Bone metastasis(-) with high cOC|Patients who have metastasis only in extraskeletal sites with high number of circulating osteocalcin-positive (cOC) cells
89533775|NCT03223610|Experimental|Arm 1: Dose Escalation|iPOR (ibrutinib, prednisone, obinutuzumab, lenalidomide) for cycle 1; followed by ViPOR (venetoclax, ibrutinib, prednisone, obinutuzumab, lenalidomide) for cycles 2-6
89533776|NCT03223610|Experimental|Arm 2: Dose Escalation|ViPOR (venetoclax, ibrutinib, prednisone, obinutuzumab, lenalidomide) for cycles 1-6
89533777|NCT03223610|Experimental|Arm 3: Dose Expansion|ViPOR (venetoclax, ibrutinib, prednisone, obinutuzumab, lenalidomide) for cycles 1-6
89000479|NCT03523117|Active Comparator|Ferric Caroboxymaltose|Ferric Carboxymaltose - 2 doses (day 0 and day 7) at 15 mg/kg to a maximum single dose of 750 mg (whichever is smaller) up to a maximum of total dose of 1500 mg administered as either an undiluted IV push at a rate of 100 mg (2mL)/minute OR in no more than 250 mL of normal saline and infused over 15 minutes.
88825455|NCT04069221|Experimental|Part 2, Treatment B: single oral dose of 800 mg OZ439|This was an open-label, randomized, single-dose, 3-way cross-over study in 18 healthy subjects. Each subject participated in 3 treatment periods and each subject received a single dose of each of the following 3 treatments in a randomized order with a 14-day wash-out period between each treatment: Treatment B: A single oral dose of 800 mg OZ439 simple granules administered as a 64.5-mL dispersion Treatment C: A single oral dose of 400 mg OZ439 simple granules administered as a 64.5-mL dispersion Treatment D: A single oral dose of 400 mg OZ439 simple granules administered as a 64.5-mL dispersion and co-administered with a 150 mg cobicistat tablet (CYP3A4 inhibitor)
89356447|NCT03336346||DTG group|Reproductive-aged HIV-infected women taking dolutegravir-based ART and using single-rod, etonogestrel-releasing, subdermal implant (ENG implant)
88825456|NCT04069221|Experimental|Part 2, Treatment C: single oral dose of 400 mg OZ439|This was an open-label, randomized, single-dose, 3-way cross-over study in 18 healthy subjects. Each subject participated in 3 treatment periods and each subject received a single dose of each of the following 3 treatments in a randomized order with a 14-day wash-out period between each treatment: Treatment B: A single oral dose of 800 mg OZ439 simple granules administered as a 64.5-mL dispersion Treatment C: A single oral dose of 400 mg OZ439 simple granules administered as a 64.5-mL dispersion Treatment D: A single oral dose of 400 mg OZ439 simple granules administered as a 64.5-mL dispersion and co-administered with a 150 mg cobicistat tablet (CYP3A4 inhibitor)
88825457|NCT04069221|Experimental|Part 2, Treatment D:single oral dose 400 mg OZ439+cobicistat|This was an open-label, randomized, single-dose, 3-way cross-over study in 18 healthy subjects. Each subject participated in 3 treatment periods and each subject received a single dose of each of the following 3 treatments in a randomized order with a 14-day wash-out period between each treatment: Treatment B: A single oral dose of 800 mg OZ439 simple granules administered as a 64.5-mL dispersion Treatment C: A single oral dose of 400 mg OZ439 simple granules administered as a 64.5-mL dispersion Treatment D: A single oral dose of 400 mg OZ439 simple granules administered as a 64.5-mL dispersion and co-administered with a 150 mg cobicistat tablet (CYP3A4 inhibitor)
88825458|NCT03054038|Experimental|Experimental|Patients receive afatinib PO QD on days 1-28 and necitumumab IV over 60 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89356448|NCT03336346||No ART group|Reproductive-aged HIV-uninfected women using single-rod, etonogestrel-releasing, subdermal implant (ENG implant)
89356449|NCT03336346||EFV group|Reproductive-aged HIV-infected women taking efavirenz-based ART and using single-rod, etonogestrel-releasing, subdermal implant (ENG implant)
89356450|NCT03841292|Active Comparator|Active tDCS+Varenicline|Active 2mA tDCS (Nuraleve, Canada) with the anode placed over the left dorsolateral prefrontal cortex (dlPFC) and the cathode placed over the right dlPFC for 20 minutes per session. Daily stimulation between Monday to Friday for the first two weeks and then booster sessions every other week for the next 10 weeks.
89356451|NCT03841292|Sham Comparator|Sham tDCS+Varenicline|Sham tDCS (Nuraleve, Canada)(30 seconds of 2mA and 19.5 minutes of 0 mA) with the anode placed over the left dorsolateral prefrontal cortex (dlPFC) and the cathode placed over the right dlPFC for 20 minutes per session. Daily stimulation between Monday to Friday for the first two weeks and then booster sessions every other week for the next 10 weeks.
88825459|NCT02302716|Experimental|LY2963016|Insulin naive participants started on 10 units (U) LY2963016 given subcutaneously (SC) once a day (QD) for 24 weeks. Participants entering the study on LANTUS®, insulin detemir or neutral protamine hagedorn (NPH) QD will begin the study at their current dose SC. Participants will self titrate LY2963016 based on fasting blood glucose (FBG). Participants entering on insulin detemir or NPH twice a day will be started at 80% of the total daily dose SC. Participants will continue oral antihyperglycemic medication (OAM).
88825460|NCT02302716|Active Comparator|LANTUS®|Insulin naive participants started on 10 U LANTUS® given SC QD for 24 weeks. Participants entering the study on LANTUS®, insulin detemir or NPH QD will be started at the same dose SC. Participants entering on insulin detemir or NPH twice a day will be started at 80% of the total daily dose SC. Participants will self titrate LANTUS® based on FBG. Participants will continue OAM.
88825461|NCT03881007|Experimental|LCM, then placebo|Mouthwash with LCM for 3 months followed by mouthwash with placebo for 3 months.
88825462|NCT03881007|Experimental|Placebo, then LCM|Mouthwash with placebo for 3 months followed by mouthwash with LCM for 3 months
88825463|NCT03958071||Subjects with Idiopathic Pulmonary Fibrosis|
88825464|NCT00554606|Experimental|Canakinumab|Participants received one single dose of 600 mg canakinumab via intravenous infusion on Day 1 and thereafter every 6 weeks until completion of the 54-week treatment period.
88825465|NCT04332159|Experimental|Intervention group|Inhalation of Methoxyflurane through a Penthrox inhaler
88825466|NCT04332159|Placebo Comparator|Control group|Inhalation of placebo (0.9% salin solution) through a Penthrox inhaler
88825467|NCT04066647|Experimental|Dexamthesone|Single arm study in which all healthy controls will receive 1 mg of dexamethasone intravenous (IV) injection.
88825468|NCT04041453|Active Comparator|Albendazole 400mg|Albendazole 400mg in single dose
88825469|NCT04041453|Experimental|Albendazole/Ivermectin|Combination of albendazole 400mg + ivermectin 600mcg/kg in single dose.
88825470|NCT04041453|Experimental|Albendazole 400mg x 3|Albendazole 400mg/day for 3 consecutive days
88825471|NCT04041453|Experimental|Albendazole/Ivermectin x 3|Combination of albendazole 400mg/day + ivermectin 600mcg/kg/day for 3 consecutive days
88825472|NCT04350476|Other|Vital Connect Patch Arm|"This is a non-randomized study. Based on clinical assessment, patients will be provided with the following home monitoring system:~VitalConnect Vital Sign Patch (FDA approved for this indication)"
88825473|NCT03998163|Experimental|CR845 0.5mcg/kg|IV CR845 0.5 mcg/kg administered after each dialysis session (3 times/week)
89356452|NCT05659199|Experimental|extracorporeal shockwave therapy|extracorporeal shockwave group: Patients will be treated with extracorporeal shockwave therapy (ESWT) with bladder lithotomy position, twice a week for 4 weeks, 3,000 individually with a maximum total energy flow density of 0.25 mJ/mm2, rate 3Hz each time. Extracorporeal shockwave (RUIDI.SWT001, Shenzhen, China) can provide a kind of physical spark wave energy, that will be delivered by the probe. The water sac probe will be moved slowly over the groin, perineum and crura of the penis.
88825474|NCT02354508|Experimental|Pasireotide LAR|Patients who qualify for the core phase of the study will be treated with pasireotide LAR 40 mg initially. Patients not achieving biochemical control can be up-titrated to pasireotide LAR 60 mg.
89356453|NCT05659199|Experimental|myofascial release therapy|myofascial release group: Based on the palpation findings, pressure was applied at 1 kg/cm2 (within the patient's tolerable range depending on the individual) to the points where patients had a VAS pain score of 4 or more during palpation. Intermittent pressure will be applied for 180-210s at the tenderness until the muscle relaxed.
89356454|NCT05659199|Experimental|extracorporeal shockwave combined with myofascial release therapy|Combined therapy group: On top of the routine palpation, the combined intervention group will be then treated with extracorporeal shockwave and myofascial release therapy in identical format as that in the intervention A and B
89356455|NCT02495350||Initially didn't want an epidural and didn't receive one.|
89356456|NCT02495350||Initially didn't want an epidural and did receive one.|
89356457|NCT02495350||Initially wanted an epidural and didn't received one|
89356458|NCT02495350||Initially wanted an epidural and did receive one.|
89356459|NCT04805996|Experimental|Diabetes remission using total diet replacement and eHealth contact with the healthcare provider|This study has only one arm and no comparator.
89356460|NCT05665231|Experimental|V3 Mis® implant|Implant with coronal triangular neck
89356461|NCT05665231|Active Comparator|C1 MIS® implant|Implant with coronal cylindrical neck (regular)
89356462|NCT02495428|Experimental|Kinesio Tape Group|muscle Kinesio Taping in Triceps Surae, Tibialis anterior, and Quadriceps according Kenzo Kase Method
89356463|NCT02495428|No Intervention|Control group|They will do the same measurement of lactate and exercise protocol in treadmill, but always without kinesio tape intervention
89356464|NCT03726463||polycystic kidney disease|patients with polycystic kidney disease who receive kidney transplantation at Asan Medical Center
89356465|NCT03814577|Active Comparator|Desflurane|Anesthesia will be maintained with Desflurane inhalation with a flow of 2 L/min in 0.5 O2 oxygen air mixture.Total Intravenous Anesthesia will not be used in this group. While target desflurane minimum alveolar concentration (MAC) will be 1-1.5 and Bispectral Index values will be between 40-60, the flow rate will be adjusted to 2 L/min. Total Antioxidant Status and Total Oxidant Status will be then measured. Invasive arterial monitorization will be performed to right radial artery under local anesthesia to follow up hemodynamic changes and take the blood samples.
89356466|NCT03814577|Experimental|Total Intravenous Anesthesia|Total Intravenous Anesthesia: Anesthesia will be maintained with inhalation with a flow of 2 L/min in 0.5 O2 oxygen air mixture. Desflurane will not be used in this group. Total Intravenous Anesthesia (propofol and remifentanyl infusion) will be performed to the patients while target Bispectral Index values were between 40-60. Also the flow rate will be adjusted to 2 L/min. Total Antioxidant Status and Total Oxidant Status will be then measured. Invasive arterial monitorization will be performed to right radial artery under local anesthesia to follow up hemodynamic changes and take the blood samples.
89356467|NCT03730363|Experimental|Pentamidine + ICE|Pentamidine, Ifosfamide, Carboplatin, and Etoposide (ICE) by IV Infusion.
88825475|NCT00554216|Experimental|VI-0521 Low|VI-0521; low dose phentermine/topiramate (PHEN/TPM 3.75 mg/23 mg)
89356468|NCT02493166|Active Comparator|patients with Multiple sclerosis Dual task cost|Dual task cost (cognitive-motor interference), comparing single versus dual task performance (on both motor and cognitive task)
89356469|NCT02493166|Active Comparator|Healthy volontiers Dual task cost|Dual task cost (cognitive-motor interference), comparing single versus dual task performance (on both motor and cognitive task)
89356470|NCT01206725|Other|. Moderate Intensity Exercise Group|Exercise equivalent to the current exercise guidelines. In total 210 minutes per week of continuous moderate intensity (70% HRmax) exercise. Home based training.
89533778|NCT03223610|Experimental|Arm 4: Dose Expansion|iPOR (ibrutinib, prednisone, obinutuzumab, lenalidomide) for cycle 1; followed by ViPOR (venetoclax, ibrutinib, prednisone, obinutuzumab, lenalidomide) for cycles 2-6
89356471|NCT01206725|Other|Aerobic interval training|Exercise equivalent to the current guidelines achieved through high-intensity interval training.The exercise starts with warming-up for 10-min at 70% of HRmax before performing 4x4min intervals at 90-95% of HRmax, with 3-min active recovery at 70% of HRmax between each interval, and a 5-min cool-down period, giving a total of 40-min.
89356472|NCT00707434|Experimental|Glucose Monitoring Device|Continuous glucose monitoring in critically ill patients.
89356473|NCT03818009||women undergoing elective CS under general anesthesia|Early postoperative assessment of the cognitive function of patients through evaluation document which will be filled by the anesthesiologist.
89356474|NCT03818009||women undergoing emergency CS under general anesthesia|Early postoperative assessment of the cognitive function of patients through evaluation document which will be filled by the anesthesiologist.
89533779|NCT03220022|Experimental|Treatment (R-da-EPOCH)|Patients receive rituximab IV on day 1 (for CD20 positive patients only), etoposide IV over 96 hours on days 1-4, doxorubicin hydrochloride IV over 96 hours on days 1-4, vincristine sulfate IV over 96 hours on days 1-4, prednisone PO daily on days 1-5, cyclophosphamide IV over 1 hour on day 5, and ibrutinib PO QD on days 1-21. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients also receive pegfilgrastim SC from 1 calendar day up to 48 hours or filgrastim SC beginning on day 6 for up to 10 days until ANC is satisfactory.
88825476|NCT00554216|Experimental|VI-0521 Top|Top Dose VI-0521 consisting of 15 mg of Phentermine and 92 mg of Topiramate.
88825477|NCT00554216|Placebo Comparator|Placebo|Placebo to match
89356475|NCT03054428|Experimental|Placebo|Participants received placebo matching dupilumab once every 2 weeks (Q2W) (including doubling the amount of placebo on day 1 to match the loading dose). In order to maintain blinding for the study, participants in the <60 kilogram (kg) weight stratum received, in a 1:1 ratio, either placebo matching 200 milligram (mg) dupilumab (including doubling the amount of placebo on day 1 to match the loading dose) or placebo matching 300 milligram (mg) dupilumab (including doubling the amount of placebo on day 1 to match the loading dose). In the ≥60 kg weight stratum, the participants randomized to the placebo group received placebo matching 300 mg dupilumab (including doubling the amount of placebo on day 1 to match the loading dose).
89533780|NCT03213652|Experimental|Treatment (ensartinib)|Patients receive ensartinib PO QD on days 1-28. Cycles repeat every 28 days for 2 years (up to 26 cycles) in the absence of disease progression or unacceptable toxicity. Patients undergo an x-ray, CT scan, MRI, PET scan, radionuclide imaging, and/or bone scan, as well as a bone marrow aspiration and/or biopsy during screening and on study. Patients also undergo blood sample collection on study.
89533781|NCT03192722|Experimental|Immediate exposure to near vision glasses with filters|Participants immediately provided with near vision glasses with colored filters
88825478|NCT04001517|Experimental|Neflamapimod|40 mg capsules administered orally, BID or TID with food for 16 weeks; subjects will follow the BID regimen if weighing <80 kg or the TID regimen if weighing ≥80 kg
89356476|NCT03054428|Experimental|Dupilumab 300 mg Q4W|Participants received once every 4 weeks (Q4W) subcutaneous (SC) injections of 300 milligrams (mg) dupilumab following a loading dose of 600 mg on day 1. In order to maintain blinding, all participants received an injection once every 2 weeks (Q2W) from day 1 to week 14. Participants received placebo 2 milliliter (mL) injection at the weeks dupilumab was not given.
88825479|NCT04001517|Placebo Comparator|Placebo|40 mg matching placebo capsules administered orally, BID or TID with food for 16 weeks; subjects will follow the BID regimen if weighing <80 kg or the TID regimen if weighing ≥80 kg
88825480|NCT03040856|Experimental|Alpha Linolenic Acid enriched diet|Enriched diet with 2 capsules of ALA supplementation a day - 630 mg in each capsule. Total amount of 1260 mg (Daily recommended dose is 1-2 g).
88825481|NCT03040856|Experimental|Omega 3 enriched diet ( DHA+EPA)|Enriched diet with 2 capsules of DHA+EPA supplementation a day (Each capsule consist of 240 mg DHA and 360 mg EPA).
89356477|NCT03054428|Experimental|Dupilumab 200 mg or 300 mg Q2W|Participants with baseline weight <60 kg received once every 2 weeks (Q2W) subcutaneous (SC) injections of 200 milligrams (mg) dupilumab following a loading dose of 400 mg on day 1. Participants with baseline weight ≥60 kg received Q2W SC injections of 300 mg dupilumab following a loading dose of 600 mg on day 1.
89356478|NCT03335956|Placebo Comparator|SAD Part 1 Placebo Cohort 1 Period 1|
89356479|NCT03335956|Experimental|SAD Part 1 Active Cohort Period 1|
89356480|NCT03335956|Placebo Comparator|SAD Part 1 Placebo Cohort 1 Period 2|
89356481|NCT03335956|Experimental|SAD Part 1 Active Cohort 1 Period 2|
89356482|NCT03335956|Placebo Comparator|SAD Part 1 Placebo Cohort 1 Period 3|
89356483|NCT03335956|Experimental|SAD Part 1 Active Cohort 1 Period 3|
89356484|NCT03335956|Placebo Comparator|SAD Part 2 Placebo Cohort 2 Period 4|
89356485|NCT03335956|Experimental|SAD Part 2 Active Cohort 2 Period 4|
89356486|NCT03335956|Placebo Comparator|SAD Part 2 Placebo Cohort 2 Period 5|
88825482|NCT03040856|Placebo Comparator|Placebo|Control group - Will receive 2 placebo capsule a day - containing olive oil
88825483|NCT02353572|Experimental|Melphalan, Bortezomib, Autologous transplant|Patients receive melphalan IV continuously on days -5 to -2 and bortezomib IV over 3-5 seconds on days -4 and -1. Patients also receive dexamethasone IV on day -1 prior to the second dose of bortezomib. Beginning two days after completion of melphalan infusion, patients undergo autologous hematopoietic stem cell transplant. Eligible patients may undergo a second transplant 2-4 months after completion of the first transplant.
88825484|NCT02990156|Experimental|Coil Embolization System|Coil Embolization System,or deposits coils in the aneurysm sac by electrolytical detachment; coil types include Complex Finish, Complex Frame,and Helical. The coils are made of a platinum - tungsten alloy, have a minimum diameter of 2 mm and a maximum diameter of 24mm.
88825485|NCT02990156|Active Comparator|Control device from Medronic|Control device from Medronic,include AxiumTM Detachable Coils and AxiumTM Prime Detachable Coils, which are manufactured by ev3 (Medtronic, Irvine, California, USA);
88825486|NCT03886701|Experimental|Experimental|Period 1: DOR twice-daily alone (Study days 1-4) and Period 2: DOR twice-daily with RPT and INH once-weekly (Study days 7-21)
88825487|NCT00552578|Active Comparator|Tapering doses of buprenorphine|Participants assigned to this arm will receive tapering doses of buprenorphine for detoxification.
88825488|NCT00552578|Experimental|Steady doses of buprenrophine|Participants assigned to this arm will receive a steady dose of buprenorphine for maintenance.
89356487|NCT03335956|Experimental|SAD Part 2 Active Cohort 2 Period 5|
89356488|NCT03335956|Placebo Comparator|SAD Part 2 Placebo Cohort 2 Period 6|
89356489|NCT03335956|Experimental|SAD Part 2 Active Cohort 2 Period 6|
89356490|NCT03335956|Placebo Comparator|MAD Placebo Cohort 1|
89356491|NCT03335956|Experimental|MAD Active Cohort 1|
89356492|NCT03335956|Placebo Comparator|MAD Placebo Cohort 2|
89356493|NCT03335956|Experimental|MAD Active Cohort 2|
89356494|NCT03335956|Placebo Comparator|MAD Placebo Cohort 3|
89356495|NCT03335956|Experimental|MAD Active Cohort 3|
89356496|NCT03335956|Placebo Comparator|MAD Placebo Cohort 4|
89356497|NCT03335956|Experimental|MAD Active Cohort 4|
89356498|NCT02494960|Placebo Comparator|Control Group|The doctor will offer a placebo intervention.
89356499|NCT02494960|Experimental|Intervention Group A|"The doctor will offer the brief smoking cessation AWARD model .~At 1-month follow-up survey, trained study personnel will repeat the brief smoking cessation AWARD model ."
89356500|NCT02494960|Experimental|Intervention Group B|The doctor will offer the brief smoking cessation AWARD model.
89356501|NCT02494804|Other|Temozolomide|Capsules supplied in 5-mg, 20-mg, 100-mg, 140-mg, 180-mg, and 250-mg strengths; dosed at 200 mg/m2/day for 5 consecutive days, repeated every 28 days
89356502|NCT02494804|Other|Temozolomide+CIK|Autologous cytokine-induced killer cells were transfer via venous one week after Temozolomide treat
89356503|NCT01299155|Experimental|ReSTOR +3|Bilateral implantation of a ReSTOR +3 Intraocular Lens (IOL) Model SN6AD1
89356504|NCT01299155|Active Comparator|LENTIS MPlus|Bilateral implantation of a LENTIS MPlus Intraocular Lens (IOL) Model
89356505|NCT02494726||Ischemic Stroke|Ischemic stroke patients who have had blood analyzed using thromboelastography (TEG)
89356506|NCT02494726||Healthy Controls|Healthy controls who have had their blood analyzed using thromboelastography (TEG)
88825489|NCT02301936|Experimental|LDV/SOF 12 weeks|Treatment-naive or treatment-experienced participants without cirrhosis will receive LDV/SOF for 12 weeks.
89356507|NCT02494726||Hemorrhagic Stroke|Intracerebral hemorrhage patients who have had their blood analyzed by thromboelastography (TEG)
89356508|NCT01301105|Placebo Comparator|Health Enhancement Program (HEP)|Intervention designed to be effective and structurally equivalent to Mindfulness Based Stress Reduction (MBSR) but without a mindfulness component. Designed as an active control for MBSR to isolate mindfulness as an active ingredient.
88825490|NCT02301936|Experimental|LDV/SOF 24 weeks|Treatment-experienced participants with cirrhosis will receive LDV/SOF for 24 weeks.
88825491|NCT03881163|Experimental|Single dose regime of N-acetylcysteine (NAC)|On day 1 at 08:00 ±1 hours, one dose of 600 mg of NAC (300 + 300 mg ampoule) will be administered under fasting conditions.
88825492|NCT03881163|Experimental|Multiple dose regime of N-acetylcysteine (NAC)|On days 4 and 5 at 08:00 ±1 hours and 20:00 ±1 hours and at 08:00 ±1 on day 6, 5 doses of 600 mg of NAC (300 + 300 mg ampoule) will be administered.
88825493|NCT02895152|Experimental|Feedback|Those randomised to the feedback arm will receive weekly feedback on their activity levels and tailored advice on how to improve activity levels.
88825494|NCT02895152|No Intervention|Control|Control arm will wear the activity monitor as specified in the protocol but will not receive feedback on activity levels
88825495|NCT03848871|Experimental|Enstilar foam|Subjects will receive calcipotriene hydrate/betamethasone dipropionate (Enstilar) foam and apply to affected areas once daily. A target lesion located on elbow or knee will be identified by the Investigator for daily treatment with the medicated foam from Baseline through week 4.
88825496|NCT04032327|Active Comparator|Plain Bupivacaine|20 mL of 0.25% plain bupivacaine
88825497|NCT04032327|Active Comparator|Exparel plus plain bupivacaine|10 mL of extended release liposomal bupivacaine (Exparel) plus 10 mL of 0.25% plain bupivacaine mixed
88825498|NCT04041219|Experimental|Allogeneic blood or marrow transplantation|Subjects undergoing allogeneic blood or marrow transplantation (BMT) at Mayo Clinic in Rochester Minnesota
88825499|NCT04037865|Experimental|PF-06651600 Severe Renal Impairment|This arm includes participants with severe renal impairment who will receive oral doses of PF-06651600 50 mg on Day 1 through Day 10
88825500|NCT04037865|Experimental|PF-06651600 Normal Renal Function|This arm includes participants with normal renal function who will receive oral doses of PF-06651600 50 mg on Day 1 through Day 10
88825501|NCT04037865|Experimental|PF-06651600 Moderate Renal Impairment|This arm is in Part 2 which will be conducted if decision criterion to proceed to Part 2 is met. This arm includes participants with moderate renal impairment who will receive oral doses of PF-06651600 50 mg on Day 1 through Day 10
88825502|NCT04037865|Experimental|PF-06651600 Mild Renal Impairment|This arm is in Part 2 which will be conducted if the decision criterion to proceed to Part 2 is met. The arm includes participants with mild renal impairment who will receive oral doses of PF-06651600 50 mg on Day 1 through Day 10.
88825503|NCT03847233|Experimental|Jetstream Atherectomy System|
88825504|NCT00552344|Experimental|Certolizumab Pegol|Certolizumab Pegol 200 mg/vial; 400 mg subcutaneously at Week 0, 2 and 4, thereafter 400 mg subcutaneously at every 4 weeks.
88825505|NCT02814968|Experimental|Single arm|Subjects will receive 1 dd 160 mg Enzalutamide orally continuously until progressive disease occurs. Serial PSA measurements, PET/CT scans, Whole Body MRI, bone scans will be performed to assess metastatic tumour load, progressive disease and response to treatment.
88825506|NCT03879603|Experimental|Group 1: 6 mcg WEVEE vaccine|6 mcg of WEVEE vaccine (VRC-WEVVLP073-00-VP) administered IM on Day 0 and Week 8
88825507|NCT03879603|Experimental|Group 2: 6 mcg WEVEE vaccine + alum|6 mcg of WEVEE vaccine (VRC-WEVVLP073-00-VP) and 500 mcg of Alum (VRC-GENMIX083-AL-VP) administered IM on Day 0 and Week 8
88825508|NCT03879603|Experimental|Group 3: 30 mcg WEVEE vaccine|30 mcg of WEVEE vaccine (VRC-WEVVLP073-00-VP) administered IM on Day 0 and Week 8
88825509|NCT03879603|Experimental|Group 4: 30 mcg WEVEE vaccine + alum|30 mcg of WEVEE vaccine (VRC-WEVVLP073-00-VP) and 500 mcg of Alum (VRC-GENMIX083-AL-VP) administered IM on Day 0 and Week 8
89356509|NCT01301105|Active Comparator|Mindfulness Based Stress Reduction (MBSR)|
89356510|NCT01299233||control group|age matched healthy controls
89356511|NCT01299233||Glaucoma|patients with diagnosis of primary open angle glaucoma
89356512|NCT01206959||monitor method|"blood pressure monitor Cuff circumference:22cm-48cm~stethoscopy Cuff circumference: 22cm-48cm"
89356513|NCT03341650|Experimental|High Pasta|Habitual pasta consumption equal or higher than 5 times/week.
89356514|NCT03341650|Experimental|Low Pasta|Habitual pasta consumption equal or lower than 3 times/week.
88825510|NCT03879603|Experimental|Group 5: 60 mcg WEVEE vaccine|60 mcg of WEVEE vaccine (VRC-WEVVLP073-00-VP) administered IM on Day 0 and Week 8
88825511|NCT03879603|Experimental|Group 6: 60 mcg WEVEE vaccine + alum|60 mcg of WEVEE vaccine (VRC-WEVVLP073-00-VP) and 500 mcg of Alum (VRC-GENMIX083-AL-VP) administered IM on Day 0 and Week 8
88825512|NCT00553514|Experimental|AS900672-Enriched 10 mcg|
88825513|NCT00553514|Experimental|AS900672-Enriched 20 mcg|
88825514|NCT00553514|Experimental|AS900672-Enriched 30 mcg|
88825515|NCT00553514|Experimental|AS900672-Enriched 40 mcg|
88825516|NCT00553514|Active Comparator|Follitropin alfa 75 IU|
88825517|NCT03878745|Experimental|BD Nano™ PRO 32G pen needle|Participants are to perform 6 pairs of injections.
88825518|NCT03878745|Active Comparator|Terumo Nanopass® 34G pen needle|Participants are to perform 6 pairs of injections.
88825519|NCT00553436|Experimental|Enrolled Subjects treated with TAS device|All enrolled subjects treated with the Tissue Apposition System (TAS) device
88825520|NCT04034121|Other|DESolve Cx|DESolve Cx Novolimus Eluting Bioresorbable Coronary Scaffold System
88825521|NCT02813642|Experimental|Cardiovascular risk evaluation|Measurement of plasma osteoprotegerin level, plasma fibroblast growth factor 23 level, vascular calcification score and record of cardiovascular events during the 2 year follow-up
88825522|NCT04714203||cohort|Sarcopenia assessment
88825523|NCT02542514|Experimental|Ibrutinib|ibrutinib in monotherapy 28 days/cycles
88825524|NCT04026399|Experimental|stimulation + therapy|The participant receives stimulation and home therapy.
89533782|NCT03192722|Other|Delayed exposure to near vision glasses with filters|Participants provided with near vision glasses with colored filters after 8 weeks of wearing clear near vision glasses
89356515|NCT03558997|Experimental|Placebo|Participants received placebo matched to Dupilumab and placebo matched to Timothy grass subcutaneous immunotherapy (SCIT) every 2 weeks (Q2W) for 16 weeks. Both placebo doses were administered with a gap of 1 or 7 days.
89356516|NCT03558997|Experimental|Dupilumab|Participants received placebo matched to SCIT and subcutaneous (SC) injections of Dupilumab at a loading dose of 600 milligrams (mg) on Day 1, followed by a 300 mg for Q2W for 16 weeks. Both placebo matched to SCIT and Dupilumab doses were administered with a gap of 1 or 7 days.
89356517|NCT03558997|Experimental|SCIT|Participants received SCIT titrated up to a 4000 bioequivalent allergy unit (BAU) for 8 weeks followed by maintenance dose of 4000 BAU for following 8 weeks and SC injections of placebo matched to Dupilumab Q2W for 16 weeks. Both SCIT and placebo matched to Dupilumab doses were administered with a gap of 1 or 7 days.
89356518|NCT03558997|Experimental|Dupilumab + SCIT|Participants received SC injections of Dupilumab at a loading dose of 600 mg on Day 1, followed by 300 mg Q2W for 16 weeks and SCIT titrated up to 4000 BAU for 8 weeks followed by maintenance dose of 4000 BAU for following 8 weeks. Both SCIT and Dupilumab doses were administered with a gap of 1 or 7 days.
89533783|NCT03192722|Other|Immediate exposure to LuxIQ/2|Participants are examined with LuxIQ/2 to determine preferred lighting as determined by device followed by examination with OttLite Cobra
89533784|NCT03192722|Other|Immediate exposure to OttLite Cobra|Participants are examined with OttLite Cobra to determine preferred lighting followed by LuxIQ/2
89533785|NCT03189108||Cohort 1|Patients with a diagnosis of malignant solid tumor
89533786|NCT03136146|Experimental|Treatment (combination chemotherapy)|See detailed description
89177254|NCT05146804|Other|Affilla Cress/Broccocress|Potential participants will be screened after showing their interest to participate to the study. When they are considered eligible to participate (after a phone call with the executing researcher), participants will be randomized into one of the two groups in this study: either consuming the broccoli sprouts on day one (visit 1) and the placebo product in the second visit, or the other way around (placebo product on day 1 and the intervention during the second visit). Both days, participants will consume the PhenFlex, the challenge product with the high caloric load. This will allow for analyzing the effectiveness of the intervention on different biomarkers of chronic, low-grade inflammation, with the main objective being on endothelial activation.
89356519|NCT03814421|Experimental|Low dose intermittent|Pantoprazole 40mg as a bolus injection daily for 72hours
89356520|NCT03814421|Active Comparator|High dose continous|Pantoprazole 40mg as a bolus injection followed by continuous infusion at 8mg/hr for 72hours
89533787|NCT03125070|Experimental|Group I (INSPIRE, survivorship care plan)|Patients receive immediate access to the INSPIRE online program and personalized survivorship care plan.
88825525|NCT04026399|Sham Comparator|no stimulation + therapy|The participant receives no stimulation and receives home therapy.
88825526|NCT03852537|Active Comparator|Usual Care|Usual care as determined by the patient's primary team.
88825527|NCT03852537|Experimental|Biomarker-adjusted Steroid Dosing|Individualized, biomarker concordant steroid use: dosing, titration and duration according to CRP level. This is a predetermined dosing table that adjusts dose of steroid by CRP level. Specifically: if CRP < 50 mmol/L: discontinue steroid; if CRP is between 51-100 mmol/L: 0.5 mg methylprednisolone (or dose equivalent of oral prednisone); if CRP is between 101-150 mmol/L: 0.75 mg/kg methylprednisolone (or dose equivalent of oral prednisone); if CRP level is between 151-200 mmol/L: 1 mg/kg methylprednisolone (or dose equivalent of oral prednisone); if CRP level > 200 mmol/L: 1.5 mg/kg methylprednisolone (or dose equivalent of oral prednisone).
88825528|NCT03875859|Experimental|Remetinostat|Subjects will apply remetinostat gel 1% to at least 1 SCC: Topical remetinostat gel 1% applied 3 times daily.
88825529|NCT00553202|Experimental|Treatment (chemotherapy and allogeneic SCT)|"Patients receive busulfan IV every 6 hours on days -9 to -6, high-dose cyclophosphamide IV over 1 hour on days -5 to -2, anti-thymocyte globulin IV once or twice daily over 4 hours on days -3 to -1, and methylprednisolone IV on days -3 to -1.~Patients undergo allogeneic hematopoietic stem cell transplantation (SCT) or allogeneic bone marrow transplantation (BMT) on day 0.~Patients receive cyclosporine or tacrolimus IV or orally beginning on day -2 and continuing until day 50, followed by a taper until week 24. Patients also receive methotrexate IV on days 1, 3, 6, and 11.~Blood samples will be collected periodically from both patients and donors for studies of natural killer cells in support of the pharmacological study objectives"
88825530|NCT04133415|Experimental|Lattice stereotactic body radiation therapy|-Lattice SBRT prescribed to a dose of 20 Gy in 5 fractions with a simultaneous integrated boosts of 66.7 Gy in 5 fractions
88825531|NCT02989142|No Intervention|Control arm|No intervention
88825532|NCT02989142|Experimental|INTER-ACT arm|"Four pre-conception coaching sessions : postpartum week 6, week 8, week 12, 6 months.~Three pregnancy coaching sessions: at the time of the planned ultrasound scans."
88825533|NCT04016259|Experimental|Self-CES|
88825534|NCT04016259|Placebo Comparator|Sham-CES|
88825535|NCT03874377|Experimental|Mindfulness|The mindfulness intervention consists of 6 weekly sessions, blending material from the evidence-based Learning to BREATHE and Mindfulness-Based Eating Awareness Training manualized interventions. Sessions will focus on: experiential mindfulness exercises, such as mindful eating, loving kindness practices, breath awareness, and mindful movement; hunger and satiety awareness; improving responses to emotions; practicing acceptance and being non-judgmental; and tolerating negative feelings and sensations, including those related to hunger and cravings. Participants will be assigned brief homework exercises (approximately 10 minutes) daily in between appointments.Participants in this arm will also receive the usual care provided by the weight management clinic.
88825536|NCT00552188|Experimental|VIA-2291|VIA-2291 100mg
89356521|NCT02493244|Experimental|Treatment|Participants clean their eyelids with Cliradex wipes before going to bed at night.
88825537|NCT00552188|Placebo Comparator|Placebo|Matching placebo
88825538|NCT05546294|Experimental|RA patients receiving aerobic and home exercise|A total of 20 sessions of aerobic exercises using bicycle ergometer, five times a week and once a day for four weeks, were applied to the patients. Then the patients were showed a daily home exercise program to apply once a day at their home.
88825539|NCT05546294|Active Comparator|RA patients receiving only home exercise|The patients were showed only a daily home exercise program to apply once a day at their home.
88825540|NCT05546294|Other|Healthy control group|There is no intervention to this group.
88825541|NCT00377793|Experimental|Arm 1|
88825542|NCT00377793|Placebo Comparator|Arm 2|
88825543|NCT04027803|Experimental|BCD-148|39 healthy subjects received BCD-148, 900 mg, a single drip infusion over 25-45 min
88825544|NCT04027803|Active Comparator|Soliris|39 healthy subjects received Soliris, 900 mg, a single drip infusion over 25-45 min
88825545|NCT00552110|Experimental|Combination1|Mometasone Furoate nasal spray (MFNS) with oxymetazoline nasal spray (OXY) 1 spray once daily
89356522|NCT02493244|No Intervention|Control|No treatment
88825546|NCT00552110|Experimental|Combination3|MFNS with OXY 3 sprays once daily
88825547|NCT00552110|Active Comparator|Mometasone|MFNS once daily
88825548|NCT00552110|Active Comparator|Oxymetazoline|OXY twice daily
88825549|NCT00552110|Placebo Comparator|Placebo|Placebo nasal spray
88825550|NCT05594888||PART 1- Group A|"Male and female volunteers (age 18-64 years) working at University Hospital Balgrist. Assessment of validity and intrasubject reliability of maximum isometric grip strength assessed with:~JAMAR© Smart Dynamometer [kg]~JAMAR© Hydraulic Dynamometer [kg]~Martin Vigorimeter [kPa]"
88825551|NCT05594888||PART 1 - Group B|"Male and female volunteers (age 18-64 years) working at University Hospital Balgrist. Assessment of validity and intrasubject reliability and assessment of intersession reliability of maximum isometric grip strength assessed with:~JAMAR© Smart Dynamometer [kg]~JAMAR© Hydraulic Dynamometer [kg]~Martin Vigorimeter [kPa]"
89177255|NCT00655486|Experimental|Lacosamide|Lacosamide 100 to 800 mg/day, flexible dosing, administered twice daily throughout the duration of the study (up to 2 years)
89356523|NCT03814343|Active Comparator|Active comparator|10 patients with NDMs onychomycosis treated with amphotericin B in 30% DMSO.
89533788|NCT03125070|Active Comparator|Group II (usual care)|Patients receive an online program linking to existing online survivor resources and a personalized survivorship care plan. Patients may receive access to the INSPIRE online program after 12 months.
89533789|NCT03117621||Patients initiating Blinatumomab|Patients initiating Blinatumomab after Country-Specific Reimbursement approval in routine clinical practice.
89533790|NCT03111745||1|Retrospective chart review of patients who have underwent hematopoietic stem cell transplantation (HSCT)
89533791|NCT03109288|Experimental|Combination Therapy|Any two-drug combination of study interventions
89356524|NCT03814343|Placebo Comparator|control comparator|10 patients with NDMs onychomycosis treated with 30% DMSO.
89356525|NCT03341572|Experimental|high response group|patients undergo 5,10 and 15cmH2O positive end expiratory pressure ,the change of central venous pressure is more than 2.5cmH2O
89356526|NCT03341572|Placebo Comparator|low response group|the change of CVP is less than 2.5cmH2O
89356527|NCT04603274|Other|upper extremity diagnosed with carpal tunnel syndrome|8 sessions of electroacupuncture, 2 days a week for 1 month by experienced physicians
89356528|NCT03817541|Experimental|Bariatric surgery|Patients due for bariatric surgery, BMI > 30
89356529|NCT03817541|Experimental|Cholecystectomy|Normal weight patients due for cholecystectomies
89356530|NCT03341494|Experimental|Gefitinib 250mg qd thalidomide 200mg qn|
89356531|NCT03341494|Active Comparator|Gefitinib 250mg qd|
89356532|NCT03814265|Experimental|Intervention|Laughter yoga group
89356533|NCT03814265|No Intervention|Control|No intervention
88825552|NCT05594888||PART 2|"Male and female volunteers (age ≥ 10 years).~Maximum isometric grip strength is assessed (no intervention):~JAMAR© Smart Dynamometer [kg]~JAMAR© Hydraulic Dynamometer [kg]~Martin Vigorimeter [KPa]"
88825553|NCT05313789||Intensive Care Patients (Cardiovascular)|Intensive care unit patients, mechanically ventilated and lacking communication. Will examine whether the positive inotropic/vasoconstrictor agents will have any effect on Analgesia Nociception Index.
88825554|NCT05313789||Intensive Care Patients (Internal diseases)|Intensive care unit patients, both mechanically ventilated and lacking communication and mechanically ventilated and conscious. Will examine whether the positive inotropic/vasoconstrictor agents will have any effect on Analgesia Nociception Index.
88825555|NCT05313789||Intensive Care Patients (Obese)|Intensive care unit patients. Will examine whether the positive inotropic/vasoconstrictor agents will have any effect on Analgesia Nociception Index.
88825556|NCT02051972||Indicated for a VVI(R) pacemaker|
88825557|NCT03854253|Experimental|Long introducer 6Fr-25cm|The investigators will perform transradial coronary angiography and percutaneous coronary interventions using long introducer sheath 6Fr-25cm
88825558|NCT03854253|Active Comparator|Short introducer 6Fr-10cm|The investigators will perform transradial coronary angiography and percutaneous coronary interventions using short introducer sheath 6Fr-10cm
89356534|NCT03341416|Experimental|Device - deep brain stimulation ON|"Intervention type: device (deep brain stimulation of the dentate nucleus in cerebellum). The intervention is a device called deep brain stimulation bilaterally placed in the sub thalamic nucleus.~The stimulation will remained turned ON during 3 months - phase 1 - blinded and continuous during the open-label phase"
89356535|NCT03341416|Sham Comparator|Device - deep brain stimulation Sham|"Sham stimulation: device (deep brain stimulation of the dentate nucleus in cerebellum). Intervention type: device (deep brain stimulation of the dentate nucleus in cerebellum). The intervention is a device called deep brain stimulation bilaterally placed in the sub thalamic nucleus.~During the sham stimulation the intervention will remained turned OFF during 3 months"
89356536|NCT03827135|Active Comparator|Traditional physical therapy|Cervical isometrics and Muscle Stretching
88825559|NCT02301624|Experimental|Eculizumab/Eculizumab|"Blind Induction Phase: Participants who had received blinded treatment with eculizumab in Study ECU-MG-301 were administered eculizumab (4 vials/1200 milligrams [mg]) on Day 1 and Week 2 and placebo (4 vials/0 mg) at Weeks 1 and 3.~Open-Label Maintenance Phase: Participants received open-label eculizumab (4 vials/1200 mg) every 2 weeks starting at Week 4 and continued throughout the study.~Eculizumab 1200 mg was administered for up to 4 years in this extension study."
89177256|NCT04111302|Experimental|IV-PCA|use IV-PCA for postoperative pain
89177257|NCT04111302|Experimental|IV-dezocine|use IV-dezocine for postoperative pain
89177258|NCT04111302|Experimental|IV-PCA+AA|use IV-PCA and AA for postoperative pain
89356537|NCT03827135|Experimental|Cyriax manipulation|Experimental group was given cyriax manipulation protocol along with the cervical isometrics and muscle stretching.
89356538|NCT01207037|Other|Intervention|
89356539|NCT03817619|Active Comparator|Treatment R (reference)|Single-dose ELB/GZR as a whole tablet in a fasted state.
89356540|NCT03817619|Experimental|Treatment T (test)|Single-dose crushed ELB/GZR in a fasted state.
89356541|NCT05480774|Active Comparator|KRG hard capsules|Each KRG hard capsule contains 500 mg of red ginseng extract. Dosage of KRG hard capsule: oral administration of 1 capsule twice daily for 12 weeks.
89356542|NCT05480774|Placebo Comparator|Placebo hard capsules|The composition of the Placebo hard capsule contains red ginseng flavor. Dosage of Placebo hard capsule: oral administration of 1 capsule twice daily for 12 weeks.
89533792|NCT03109288|Experimental|Monotherapy|Any of the study Interventions
89177259|NCT04111302|Experimental|IV-dezocine+AA|use IV-dezocine and AA for postoperative pain
89356543|NCT03335410||shoulder surgery|18-85 years, undergoing day case shoulder surgery during 15th Sept- 15th Oct 2017, possibility to e-mail and an internet connection, understands Finnish,
89356544|NCT03725995|Active Comparator|A (Midazolam)|21 children received 0.5 mg/kg intranasal medication (midazolam), with a maximum dose of 10 mg, via a spray of 0.2 ml per puff, administering the drug was alternated between the two nostrils of the child.
89356545|NCT03725995|Experimental|B (Lidocaine-Midazolam)|21 children received a puff of lidocaine 2% in each nostril, after 60 seconds, they received 0.5 mg/kg intranasal medication (midazolam),administering the drug was alternated between the two nostrils of the child, with a maximum dose of 10 mg via a spray of 0.2 ml per puff.
89356546|NCT03725995|Placebo Comparator|C (Placebo)|21 children received intranasal medication (saline 9% as placebo), 0.5 mg/kg, with a maximum dose of 10 mg via a spray of 0.2 ml per puff,administering the drug was alternated between the two nostrils of the child.
88825560|NCT02301624|Experimental|Placebo/Eculizumab|"Blind Induction Phase: Participants who had received blinded treatment with placebo in Study ECU-MG-301 were administered eculizumab/placebo (3 vials/900 mg, plus 1 vial/0 mg, respectively) on Day 1 and Weeks 1 through 3.~Open-Label Maintenance Phase: Participants received open-label eculizumab (4 vials/1200 mg) every 2 weeks starting at Week 4 and continued throughout the study.~Eculizumab 1200 mg was administered for up to 4 years in this extension study."
88825561|NCT02007122|Experimental|IRRT|Ceftaroline levels are measured in patients receiving intermittent renal replacement therapy
88825562|NCT02007122|Experimental|CRRT|Ceftaroline levels are measured in patients receiving continuous renal replacement therapy
88825563|NCT03860181|Active Comparator|Traditional Dermabond + subcuticular sutures - Surgeon 1|Subcuticular sutures with traditional Dermabond applied to incision.
88825564|NCT03860181|Active Comparator|Metal staples - Surgeon 2|Metal staples
88825565|NCT03860181|Experimental|Dermabond PRINEO - Surgeon 1|Dermabond PRINEO System
88825566|NCT03860181|Experimental|Dermabond PRINEO - Surgeon 2|Dermabond PRINEO System
89533793|NCT03070184|Experimental|African-American|Healthy lean (BMI 18-25 kg/m2) African-American participants will be enrolled and each will undergo a physical exam and screening tests to determine participants' eligibility. Participants will perform exercise capacity VO2 max determination test, followed by 3 days of standardized meals and exercise challenge test. After exercise challenge test, all the participants will receive metoprolol succinate starting at 50mg/day, titrated bi-weekly up to 200 mg/day.
89533794|NCT03070184|Active Comparator|Caucasians (White)|Healthy lean (BMI 18-25 kg/m2) white participants will be enrolled and each will undergo a physical exam and screening tests to determine participants' eligibility. Participants will perform exercise capacity VO2 max determination test, followed by 3 days of standardized meals and exercise challenge test. After exercise challenge test, all the participants will receive metoprolol succinate starting at 50mg/day, titrated bi-weekly up to 200 mg/day.
88825567|NCT03250520|Experimental|glioma brain stem|
88825568|NCT03250520|Experimental|high grade recurrent brain tumor in the central nervous system|
88825569|NCT03865329|Experimental|Intervention- Home Pulmonary Rehabilitation|Participants will be offered a Home-based pulmonary rehabilitation program with health coaching.
88825570|NCT02301546|Experimental|experimental cognitive training|Participants will use experimental computerized cognitive training exercises, 1 hour per day, 3 - 5 days per week, for 13 weeks.
88825571|NCT02301546|Active Comparator|control cognitive exercises|Participants will use control computerized cognitive activities, 1 hour per day, 3 - 5 days per week, for 13 weeks.
88825572|NCT04350554||Retrospective pregnancies|Women recruited in CoRIS from January 2004 to November 2019 and who became pregnant during this period.
88825573|NCT04350554||Prospective pregnancies|Women recruited in CoRIS from January 2004 to November 2019 who will become pregnant during the year 2020 and who agree to participate in a telephone survey.
88825574|NCT03847389|Other|clobetasol propionate topical oil|clobetasol propionate 0.05% topical oil applied as thin film twice daily for 2 weeks
88825575|NCT02351934|Experimental|Furosemide + Enhanced Recovery after Surgery (ERAS)|Furosemide 10 mg IV on post-operative day #1 and/or 2, plus ERAS, as described in other arm.
88825576|NCT02351934|Active Comparator|Enhanced Recovery after Surgery (ERAS)|ERAS included administration of celecoxib and gabapentin in the pre-operative setting, single-injection intrathecal analgesic administration immediately prior to induction of general anesthesia, post-operative administration of scheduled acetaminophen and nonsteroidal anti-inflammatory drug (NSAID) or tramadol, and discontinuation of IV fluids by 0800 on postoperative day (POD) 1. Intraoperative fluid administration was dependent on the individual anesthesia provider with no unified commitment to either zero balance or goal-directed fluid therapy. Fluid status was determined based on patient weight. Patients were weighed preoperatively and daily post-operatively using either a bed scale or a unit-based scale.
88825577|NCT00377481|Experimental|1|
88825578|NCT00377481|Active Comparator|2|
88825579|NCT00377559|Experimental|1.|Myocet+docetaxel
88825580|NCT04280445|Experimental|Psychological therapy|All participants will receive psychological therapy. There will be no placebos or waiting list controlled participants to compare findings to.
89533795|NCT03067467||Brain Tumor Patients|Brain Tumor patients will receive a bolus of Hyperpolarized 13C-pyruvate during MRSI.
89533796|NCT03061019|Active Comparator|Myofunctional Oral Exercices|Parents and participants of this group will receive instructions for nasal and oral myo-functional exercises, to perform at home each day, for 5 to 10 minutes. A booklet (measure of adherence) and an Phone application for Android/Apple with descriptions/videos of those exercices will be given to them. These exercises will include nasal hygiene procedures, nasal cartilage exercices, lingual posture rehabilitation exercises, lip tone enhancement exercises, and swallowing rehabilitation exercises.
88825581|NCT04811924|Active Comparator|CXL with MMC|Patients who have undergone corneal cross-linking (CXL) with the application of Mitomycin C (MMC).
88825582|NCT04811924|Placebo Comparator|CXL without MMC|Patients who have undergone corneal cross-linking (CXL) without the application of Mitomycin C (MMC).
88825583|NCT04321239|Experimental|Intervention group|Participants will engage in a 7-week positive psychology-based chronic pain self-management program.
89177260|NCT00457249|Experimental|Adacel Vaccine Group|
89177261|NCT00457249|Active Comparator|DECAVAC Vaccine Group|
89356547|NCT01299311|No Intervention|Inactivity|4 days of inactivity, mainly sitting
89356548|NCT01299311|Active Comparator|NEAT|4 days of NEAT (everyday activities)
89533797|NCT03061019|Experimental|Soft Oral Appliance|Parents and participants will be instructed in wearing the soft/flexible oral appliance and how to perform nasal hygiene in order to better tolerate the device. The oral appliance comes in several sizes, adapted to the age of the child; it is constructed in a soft elastomer material, in a position of slight propulsion and opening of the mandible to help clear the pharynx. It has a ramp to guide the tongue in a good position, a labial screen to stretch the labial strap and prevent the tongue from protruding between front teeth.
89533798|NCT03061019|No Intervention|Control Group|Parents and Participants of this group will be reminded the nasal hygiene procedures (application of saline in each nostril three times a day), and given a diary to report daily use.
89533799|NCT03049475||Control|Healthy, between age 18-80, African/African decent
89533800|NCT03049475||Subjects in steady State|Steady state is defined as the period from at any time 8 weeks prior to or after a crisis and samples obtained during this time would be considered steady state samples .
88825584|NCT04321239|No Intervention|Usual care control group|After completing the follow-up telephone survey, individuals in the control condition will be given access to the online program, a wearable physical activity tracker to use and keep, and will be invited to attend a one-time 2.5-hour in-person or telephone workshop that summarizes intervention content and that will be led jointly by study staff and a community health worker.
88825585|NCT03218163|Experimental|MEDI-551 Treatment Arm|Medi-551 maintenance therapy will be initiated on Day 60, Day 90, or Day 120 of NM-AlloSCT based on the eligibility criteria for the initiation of maintenance therapy as described in Section 3.1. MEDI-551 will be administered on 28-day cycles at a dose of 4mg/kg, as an IV infusion over 60 ±15 minutes. Infusion sets must contain a 0.2 micron in-line filter. MEDI-551 will be administered on days 1, 8, 15, and 22 of cycle 1, then 4mg/kg IV on day1 of cycles 2 through 12. Treatment may be stopped earlier if there is unacceptable toxicity, development of Grade 3 or 4 graft-versus-host disease (GVHD), documentation of disease progression, or patient withdrawal for other reasons.
88825586|NCT04773080||esophageal cancer surgery|patients undergoing elective esophageal surgery for cancer
88825587|NCT03026348|Active Comparator|Treatment Group A|Day 0 RSV F Vaccine 135µg/0.5mL Day 21 Phosphate Buffer
88825588|NCT03026348|Active Comparator|Treatment Group B|Day 0 Treatment / Formulation 1 Day 21 Phosphate Buffer
88825589|NCT03026348|Active Comparator|Treatment Group C|Day 0 Treatment / Formulation 1 Day 21 Treatment / Formulation 1
88825590|NCT03026348|Active Comparator|Treatment Group D|Day 0 Treatment / Formulation 2 Day 21 Phosphate Buffer
88825591|NCT03026348|Active Comparator|Treatment Group E|Day 0 Treatment / Formulation 2 Day 21 Treatment / Formulation 2
88825592|NCT03026348|Active Comparator|Treatment Group F|Day 0 Treatment / Formulation 3 Day 21 Phosphate Buffer
88825593|NCT03026348|Active Comparator|Treatment Group G|Day 0 Treatment / Formulation 3 Day 21 Treatment / Formulation 3
88825594|NCT03026348|Active Comparator|Treatment Group H|Day 0 Treatment / Formulation 4 Day 21 Phosphate Buffer
88825595|NCT03026348|Active Comparator|Treatment Group J|Day 0 Treatment / Formulation 4 Day 21 Treatment / Formulation 4
88825596|NCT03026348|Active Comparator|Treatment Group K|Day 0 Treatment / Formulation 5 Day 21 Phosphate Buffer
88825597|NCT03026348|Active Comparator|Treatment Group L|Day 0 Treatment / Formulation 5 Day 21 Treatment / Formulation 5
89533801|NCT03030404||Cohort 1|Subjects with suspicious personal or family medical history of gastric cancer or gastric cancer syndrome.
89533802|NCT03017820|Experimental|Group A (VSV-IFNbeta-NIS)|Patients receive VSV-IFNbeta-NIS intravenously (IV) while on study. Patients undergo SPECT, CT scan, PET scan throughout the study. Patients may undergo tumor biopsy, bone marrow biopsy and blood sample collection throughout the study.
89533803|NCT03017820|Experimental|Group B (VSV-IFNbeta-NIS, ruxolitinib, cyclophosphamide)|Patients receive VSV-IFNbeta-NIS IV and cyclophosphamide IV while on study. Patients undergo SPECT, CT scan, PET scan throughout the study. Patients may undergo tumor biopsy, bone marrow biopsy and blood sample collection throughout the study.
89533804|NCT03017820|Experimental|Group C (VSV-IFNbeta-NIS, ruxolitinib, nivolumab)|Patients receive VSV-IFNbeta-NIS IV, ipilimumab IV and nivolumab IV while on study. Patients undergo SPECT, CT scan, PET scan throughout the study. Patients may undergo tumor biopsy, bone marrow biopsy and blood sample collection throughout the study.
88825598|NCT03026348|Placebo Comparator|Treatment Group M|Day 0 Phosphate Buffer Day 21 Phosphate Buffer
88825599|NCT00377871|Active Comparator|1|Valve design 1
88825600|NCT00377871|Active Comparator|2|Valve design 2
88825601|NCT00377871|No Intervention|Control|Healthy control
88825602|NCT03195465|Experimental|Cacao group|1 group of subjects will all receive the high antioxidant cacao bars. 4 squares of the dark chocolate will be administered twice daily between the hours of 6 a.m. and 6 p.m.
88825603|NCT04763408||Lenvatinib|Participants with advanced or unresectable HCC will initiate treatment with lenvatinib capsules based on physicians decision and will be observed until withdrawal of consent, loss to follow-up, death or until the end of the study (up to 7 years) whichever occurs first.
88825604|NCT04763408||Sorafenib|Participants with advanced or unresectable HCC will initiate treatment with sorafenib tablets based on physicians decision and will be observed until withdrawal of consent, loss to follow-up, death or until the end of the study (up to 7 years) whichever occurs first.
88825605|NCT03165747|Experimental|VSL#3|VSL#3 two active sachets [containing 450x109 colony-forming units (CFU)/sachet], taken daily in a single administration.
88825606|NCT03165747|Placebo Comparator|Control|Placebo, no supplemental probiotics.
88825607|NCT03100617|Experimental|REACH-VA family caregiver intervention|Behavioral intervention with several components including 1) caregiver education, 2) risk assessment, 3) caregiver needs assessment, 4) caregiver skill building and problem solving, and 4) caregiver stress reduction.
88825608|NCT02351856|Experimental|ARRY-371797|
89356549|NCT01299311|Active Comparator|Exercise|4 days of inactivity combined with 1 hour of exercise
89356550|NCT03341260|Experimental|Diclofenac Potassium 50mg tab|Diclofenac Potassium 50mg tablet to be administered one hour before treatment.
89356551|NCT03341260|Placebo Comparator|Placebo|Placebo to be administered one hour before treatment.
89356552|NCT03052400|Experimental|Mifepristone 600 mg daily|Mifepristone 300 mg po daily x 2 weeks, followed by mifepristone 600 mg po daily x 10 weeks
89356553|NCT03052400|Placebo Comparator|Placebo|Matching, blinded placebo 1 tablet po daily x 2 weeks, followed by matching, blinded placebo 2 tablets po daily x 10 weeks
88825609|NCT03850275|Experimental|Experimental: Placebo, then caffeinated placebo, then e+shots|Participants received placebo and were tested for 108 minutes after consumption. After a 48 hour washout period, they received the caffeinated placebo and tested for 108 minutes. After another 48 hour washout period they received the e+shot and were tested for 108 minutes
88825610|NCT03850275|Experimental|Experimental: Caffeinated placebo, then placebo, then e+shots|Participants received caffeinated placebo and were tested for 108 minutes after consumption. After a 48 hour washout period, they received the placebo and tested for 108 minutes. After another 48 hour washout period they received the e+shot and were tested for 108 minutes
89356554|NCT01301261|Active Comparator|sugammadex 2 mg/kg|2 mg/kg of sugammadex are given when a response of two counts of train of four are present
89356555|NCT01301261|Active Comparator|4 mg/kg of sugammadex|4 mg/kg of sugammadex are given when a posttetanic count 1-3 appears
88825611|NCT03850275|Experimental|Experimental: placebo, then e+shots, then caffeinated placebo|Participants received placebo and were tested for 108 minutes after consumption. After a 48 hour washout period, they received e+shots and tested for 108 minutes. After another 48 hour washout period they received the caffeinated placebo and were tested for 108 minutes.
88825612|NCT03850275|Experimental|Experimental: caffeinated placebo, then e+shots, then placebo|Participants received caffeinated placebo and were tested for 108 minutes after consumption. After a 48 hour washout period, they received the e+shots and tested for 108 minutes. After another 48 hour washout period they received the placebo and were tested for 108 minutes.
88825613|NCT03850275|Experimental|Experimental: e+shots, then caffeinated placebo, then placebo|Participants received e+shots and were tested for 108 minutes after consumption. After a 48 hour washout period, they received the caffeinated placebo and tested for 108 minutes. After another 48 hour washout period they received the placebo and were tested for 108 minutes.
88825614|NCT03850275|Experimental|Experimental: e+shots, then placebo, then caffeinated placebo|Participants received e+shots and were tested for 108 minutes after consumption. After a 48 hour washout period, they received the placebo and tested for 108 minutes. After another 48 hour washout period they received the caffeinated placebo and were tested for 108 minutes.
88825615|NCT02349360|Active Comparator|Probiotic|L. johnsonii N6.2 10^10 CFU in capsule form administered for 8 weeks
88825616|NCT02349360|Placebo Comparator|Placebo|Encapsulated starch placebo administered for 8 weeks
88825617|NCT03825939|Experimental|Intravenous Tranexamic Acid|"1g TXA administered intravenous piggyback at start of surgery OR~1g TXA administered intravenous piggyback at start and at time of closure of surgery"
89356556|NCT01301261|Active Comparator|Sugammadex 16 mg/kg|Sugammadex 16 mg/kg are given three minutes after the injection of cis-atracurium
89356557|NCT03723577|Experimental|Fibrillar Collagen Powder Dressing|
89356558|NCT03341182|Active Comparator|normal method group (group A)|A mirror is not used in tunnel view technique (conventional manner)
89356559|NCT03341182|Experimental|mirror use group (group B)|A mirror is used in tunnel view technique
89356560|NCT01299467|Experimental|Dose 1 (0.5 hours)|
89356561|NCT01299467|Experimental|Dose 1 (8 hours)|
89356562|NCT01299467|Placebo Comparator|Dose 1 (placebo)|
89356563|NCT01299467|Experimental|Dose 2 (0.5 hr)|
89356564|NCT01299467|Experimental|Dose 2 (8 hours)|
89356565|NCT01299467|Placebo Comparator|Dose 2 (placebo)|
89356566|NCT03730285|Active Comparator|Telemedicine|Discharge with telemedicine contact to emergency nurse, doctor, and municipality
89356567|NCT03730285|No Intervention|Control|Standard care with 24-48 h observation at emergency unit
89356568|NCT03335176|Experimental|Endurance and Resistance Training Exercise|
89533805|NCT03017820|Experimental|Group D (VSV-IFNbeta-NIS, ruxolitinib, cemiplimab)|Patients receive VSV-IFNbeta-NIS IV over 30 minutes on day 1, ipilimumab IV over 30 minutes on day -3 and cemiplimab IV over 30 minutes on day -3 in the absence of disease progression or unacceptable toxicity. Patients undergo SPECT, CT scan, PET scan throughout the study. Patients may undergo tumor biopsy, bone marrow biopsy and blood sample collection throughout the study.
88825618|NCT03825939|Placebo Comparator|Intravenous Placebo|- IV 0.9% sterile saline
88825619|NCT03825939|Active Comparator|Intravenous Tranexamic Acid followed by Intravenous Placebo|"1g TXA administered intravenous piggyback at start of surgery OR~1g TXA administered intravenous piggyback at start and at time of closure of surgery~IV 0.9% sterile saline"
89356569|NCT03335176|No Intervention|Control group|Usual care
89356570|NCT03538951|Experimental|Cohort 1|10% VDA-1102
89356571|NCT03538951|Experimental|Cohort 2|20% VDA-1102
89356572|NCT03335098|Experimental|Study arm|Subcutaneous bortezomib 1.3mg/m2 on days 1, 4, 8, and 11 (every 4 weeks, up to 6 cycles) Oral thalidomide 50mg daily on days 1-28 (every 4 weeks, up to 6 cycles) Intravenous or oral dexamethasone 40mg on days 1-4 (every 4 weeks, up to 6 cycles)
89356573|NCT03341026|Other|Induction day 1, 4, 7, 14|Patient will come to the hospital on day 1, 4, 7 and 14. A hypo- or hyperglycaemic experiment will start according to allocation by randomizer.
89533806|NCT02979873|Experimental|Sirolimus|sirolimus
89533807|NCT02979873|No Intervention|Standard of Care|no intervention
89356574|NCT03341026|Other|Induction day 1, 7, 10, 14|Patient will come to the hospital on day 1, 7, 10 and 14. A hypo- or hyperglycaemic experiment will start according to allocation by randomizer.
89356575|NCT01299545||a single group of patients -200 expected|polyarthrite rhumatoid patients
89356576|NCT03723499||endoscopic treatment|Patient with endoscopic treatment will be included. Some medical data collection by medical record will be collected.
89356577|NCT03120286||Overweight and obesity|Women with BMI >25
89356578|NCT03120286||Normal weight group|Women with BMI =18-24
89356579|NCT03725917|Experimental|Experimental Group|The intervention will be a progressive physiotherapy protocol formed by therapeutic exercise and manual therapy
89356580|NCT03725917|No Intervention|Control Group|The control group will not receive physiotherapy treatment.
89356581|NCT03120598|Active Comparator|ATTC strategy|Behavioral: Addiction Technology Transfer Center (ATTC) strategy: A staff-focused strategy that includes 10 discrete strategies (e.g., centralized technical assistance, conduct educational meetings, provide ongoing consultation).
89356582|NCT03120598|Experimental|ISF strategy|Behavioral: Implementation & Sustainment Facilitation (ISF) strategy: An organization-focused strategy that includes 7 discrete strategies (e.g., use of an implementation advisor, organize implementation team meetings, conduct cyclical small tests of change) and Addiction Technology Transfer Center (ATTC) strategy: A staff-focused strategy that includes 10 discrete strategies (e.g., centralized technical assistance, conduct educational meetings, provide ongoing consultation).
89356583|NCT03817385|Experimental|repetitive TMS (Transcranial Magnetic Stimulation)|rTMS and physical / occupational therapy
89356584|NCT03817385|Experimental|robotic GT (Gait Training)|robotic gait training for 20 times and physical / occupational therapy
88825620|NCT03988647|Experimental|Pembrolizumab + Palliative Radiation Therapy|Pembrolizumab will be administered at 200 mg IV every 3 weeks as standard of care. Palliative radiation therapy will be given between the first and second cycles of immunotherapy
88825621|NCT00551642|Active Comparator|Inhaled Nitric Oxide (INO)|INO administered by nasal continuous positive airway pressure, nasal cannula or face mask at 5 parts per million (ppm) for between 7 and 21 days
88825622|NCT00551642|Placebo Comparator|Placebo|Placebo gas administered by nasal continuous positive airway pressure, nasal cannula or face mask, for a maximum of 21 days.
88825623|NCT02989064|Experimental|Autologous genetically modified MAGE A10ᶜ⁷⁹⁶T cells|
88825624|NCT03040323|Experimental|biopsy with Lumason|liver biopsy performed with prior contrast enhancement with Lumason 60.7Mg Powder for Injection (experimental method)
88825625|NCT03040323|Placebo Comparator|biopsy with placebos|liver biopsy performed without prior contrast enhancement (standard method)
88825626|NCT05313399|Active Comparator|control group|the group have open bite caused by non-nutritive sucking habits and treat them with palatal crib.
88825627|NCT05313399|Experimental|experimental group|the group have open bite caused by by non-nutritive sucking habit and treat them with bonded spur.
88825628|NCT03036735|Experimental|Steroid Eluting Spacer|"Subjects will receive one steroid eluting spacer (Restora Mometasone Furate Eluting Spacer) placed into the surgical site on one side, and one spacer without drug (Silastic spacer) placed on the other side.~The Restora Mometasone Furate Eluting Spacer will be compared to the Silastic spacer."
88825629|NCT02648282|Experimental|Cyclophosphamide, Pembrolizumab, GVAX Pancreas Vaccine, SBRT|
88825630|NCT04004481||Adult patients undergoing major open abdominal surgery|Observational study. In the patients undergoing major open abdominal surgery for cancer tramadol will be used for postoperative analgesia. In the postoperative period parent compound and metabolites of tramadol will be measured. Postoperative analgesia and adverse effects will be registered and compared between CYP2D6 phenotypes observed.
88825631|NCT05453162|Experimental|Early morning PE|26 participants randomized to 10 weekly PE sessions in early morning (between 07:00-10:00) with homework exposures occurring occur at this same time of day.
88825632|NCT05453162|Experimental|Late afternoon PE|26 participants randomized to 10 weekly PE sessions in late afternoon (16:00 or later) with homework exposures occurring occur at this same time of day.
89356585|NCT03817385|No Intervention|traditional rehabilitation|patient only received traditional rehabilitation program
89356586|NCT03639571|Experimental|Test|Ibuprofen 200mg TEPI medicated plaster
89356587|NCT03639571|Placebo Comparator|Placebo|Placebo TEPI Plaster
89356588|NCT03814031||EAD|Early allograft dysfunction (EAD), which was defined by the presence of one or more of the following: total bilirubin (t-bil) ≥ 10 mg/dL (171 μmol/L) or, INR ≥ 1.6 on day 7, and ALT/AST > 2,000 IU/L within the first 7 days.
88825633|NCT03997851|Experimental|Topical 5% acetaminophen gel|Topical 5% acetaminophen gel will be applied to one 4x4 cm predefined skin area on the ventral forearm during 2 study visits. The gel will be applied to the test area and will be allowed 30 minutes to adsorb. Following this pre-treatment, residual gel will be removed and itch induction/sensory testing will commence, strictly within the pre-treated area.
88825634|NCT03997851|Experimental|Topical 2.5% acetaminophen gel|Topical 2.5% acetaminophen gel will be applied to one 4x4 cm predefined skin area on the ventral forearm during 2 study visits. The gel will be applied to the test area and will be allowed 30 minutes to adsorb. Following this pre-treatment, residual gel will be removed and itch induction/sensory testing will commence, strictly within the pre-treated area.
88825635|NCT03997851|Experimental|Topical 1% acetaminophen gel|Topical 1% acetaminophen gel will be applied to one 4x4 cm predefined skin area on the ventral forearm during 2 study visits. The gel will be applied to the test area and will be allowed 30 minutes to adsorb. Following this pre-treatment, residual gel will be removed and itch induction/sensory testing will commence, strictly within the pre-treated area.
88825636|NCT03997851|Placebo Comparator|Topical vehicle gel|Topical vehile gel will be applied to one 4x4 cm predefined skin area on the ventral forearm during 2 study visits. The gel will be applied to the test area and will be allowed 30 minutes to adsorb. Following this pre-treatment, residual gel will be removed and itch induction/sensory testing will commence, strictly within the pre-treated area.
89356589|NCT03814031||Non EAD|No EAD
89356590|NCT03052322|Experimental|MSB11022|
89356591|NCT03052322|Active Comparator|EU-Humira|
89356592|NCT05465512||good response to neoadjuvant chemotherapy (GRNC)|Tumor regression grade (TRG) =0 or 1 was defined as a good response to neoadjuvant chemotherapy (GRNC)
89356593|NCT05465512||poor response to neoadjuvant chemotherapy (PRNC)|TRG=2 or 3 was defined as a poor response to neoadjuvant chemotherapy (PRNC).
89356594|NCT05655455|Experimental|experimental group 1|group 1: walking group
89356595|NCT05655455|Experimental|experimental group 2|group 2: dance and movement therapy group
89356596|NCT05655455|No Intervention|control group|No intervention
89356597|NCT03340948|Experimental|MBSR participation|Participation in the 8 week Mindfulness Based Stress Reduction (MBSR) course.
89533808|NCT02974582|Experimental|1/Part 1|60 Participants of high and low SES
89533809|NCT02974582|Experimental|2/Part 2 - Discount Coupons|Randomized to view direct mail marketing
89533810|NCT02974582|Experimental|3/Part 2 - No Discount Coupons|Randomized to view direct mail marketing
89356598|NCT02493010|Experimental|Intervention|Participants will undergo a 4-week intervention (once per week, 1 hour each session). Each intervention session consists of approximately 30 minutes of computerized cognitive behavioral therapy, and 30 minutes of Virtual Reality Exposure Therapy with our novel arousal-based biofeedback system. For Virtual Reality Exposure Therapy, the physiological variables of participants will be continuously monitored and presented to them as feedback. Participants will have to deliver speeches to videotaped audiences while striving to regulate their physiological arousal.
88825637|NCT03989427|Experimental|Brushing First and Flossing Later (BF)|The participants in BF group were asked to use modified bass method of tooth brushing first using Colgate® tooth brush (the amount of Colgate® tooth paste used is half-length of the toothbrush's head) and then floss with Colgate® dental floss using Spool method for a 2-week period. This is followed by a one week wash out period wherein they will practice oral hygiene according to their habitual method. After this cross over is done in which participants will change the sequence to FB wherein they will floss first and brush later.
88825638|NCT03989427|Experimental|Flossing First and Brushing Later (FB)|The participants in FB group were asked to floss first with Colgate® dental floss using Spool method and then modified bass method of tooth brushing first using Colgate® tooth brush (the amount of Colgate® tooth paste used is half-length of the toothbrush's head) for a 2-week period. This is followed by a one week wash out period wherein they will practice oral hygiene according to their habitual method. After this cross over is done in which participants will change the sequence to BF wherein they will brush first and floss later.
88825639|NCT03007719|Experimental|Cohort 1: Neoadjuvant|Patients with localized bladder cancer who are eligible for the UCSF phase 2 clinical trial of neoadjuvant atezolizumab before definitive surgery (NCT02451423) (Cohort 1). For the neoadjuvant cohort, study participants will undergo whole body PET/MR imaging with [18F]F-AraG within 7 days of initiating atezolizumab and within 7 days before surgery. Approximately 12 patients will be enrolled.
88825640|NCT03007719|Experimental|Cohort 2: Standard of Care (SOC)|Patients with any cancer type who are planned to initiate standard of care (SOC) anti-PD-1 or anti-PD-L1 treatment (Cohort 2). For the SOC cohort, study participants will undergo whole body PET/MR imaging with [18F]F-AraG within 7 days of initiating Cycle 1 anti-PD-1 or anti-PD-L1, and between Cycle 1 Day 15 (C1D15) and Cycle 2 Day 7 (C2D7) anti-PD-1 or anti-PD-L1. Approximately 19 patients will be enrolled.
88825641|NCT02985801|Experimental|Placebo First, then Pancrelipase|Placebo oral capsule: 3 capsules taken with or after meals, and 2 capsules taken with or after snacks during 4 weeks in first intervention period, and Pancrelipase 3 capsules are taken with or after meals (4800 lipase units) and 2 capsules with or after snacks (3200 lipase units) during 4 weeks in second intervention period (after 2 week washout period).
88825642|NCT02985801|Experimental|Pancrelipase First, then Placebo|Pancrelipase 3 capsules are taken with or after meals (4800 lipase units) and 2 capsules with or after snacks (3200 lipase units) during 4 weeks in first intervention period, and Placebo oral capsule: 3 capsules taken with or after meals, and 2 capsules taken with or after snacks during 4 weeks in second intervention period (after 2 week washout period).
88825643|NCT03021746|Experimental|Parish Nurse plus Peer Leader|The focus of this approach is for Peer Leaders (PL) to provide Diabetes Self Management Support (DSMS) with the oversight of Parish Nurses (PN). The first component starts with group-based Diabetes Self Management Education (DSME) provided by Certified Diabetes Educators (CDE), co-facilitated by PN and PL and held at the church. PL will also facilitate activities including behavioral goal setting, monthly phone contacts, and preparation for a diabetes-related health care visit, with oversight of PN. As the study progresses, PL and PN will have progressive leadership responsibilities. Following DSME, participants will be invited to attend 12 months of monthly DSMS support groups led by the PL, with oversight from the PN. This approach allows for PN to provide direct supervision to PL in areas of clinical content, educational methods, and group facilitation and communication skills.
88825644|NCT03021746|Experimental|Peer Leader Only|This approach will contain the same elements as the PN plus PL approach, except that a PN will not be used. Rather, PL will provide all aspects of DSMS, including behavioral goal setting, monthly phone contacts, and preparation for a diabetes-related health care visit. This approach will be delivered in a group setting. DSME will be provided by CDEs and co-facilitated by a PL to ensure consistency in the DSME content. Following DSME, participants will be invited to attend 12 monthly DSMS groups led by PL. Following the group sessions, participants will transition into a period of ongoing support. During this time, participants and PL will be encouraged to foster DSMS through programs and initiatives that are meaningful to them, utilizing the existing church infrastructure. If needed, PL may contact the CDE for additional information
89177262|NCT02552290|Active Comparator|Cervicothoracic manipulation|Description of a Right C7/T1 manipulation. The subject will lie prone. The therapist will stand on the L side of the subject facing in a cephalic direction (towards the patient's head). The therapist's right hand makes contact with the thumb on the right side of the spinous process of the first thoracic vertebra. The therapist left hand supports the head making contact on the temporal bone. The hand/neck is gently laterally flexed to the right, until slight tension is palpated in the tissues. A high-velocity low-amplitude thrust will be applied towards the subjects left side. If cavitation does not occur (an audible pop) the subject will be repositioned and the manipulation attempted a second time. A maximum of 2 attempts will be performed for each side of the neck.
89356599|NCT02493010|No Intervention|Waitlist Control|Participants in Waitlist Control will receive no intervention in the first 4 weeks of the study. After the Intervention group has completed treatment, participants in the Waitlist Control will then undergo the same intervention as the Intervention group.
89356600|NCT03521791|Experimental|PRO-155|Pro-155: 1 drop 2 times a day in the period of vigil in the conjunctival cul-de-sac for 20 days
89356601|NCT03521791|Placebo Comparator|Placebo|Placebo 1 drop 2 times a day in the period of vigil in the conjunctival cul-de-sac
89356602|NCT01207193|Experimental|bone cyst|Patients with bone cyst defect are injected with mesenchymal cells.
89356603|NCT02492698|Experimental|Probiotic group|consumed 2 g of powder of a dual probiotic strains containing Lactobacillus curvatus HY7601 and Lactobacillus plantarum KY1032, twice a day after breakfast and dinner.
89356604|NCT02492698|Placebo Comparator|Placebo group|consumed 2g of powder that did not contain any probiotics, twice a day after breakfast and dinner.
89356605|NCT03817697||Drug users|The cohort will be constituted of adult patients drug users, substituted/weaned or not, consulting at the Croix-Rousse CSAPA
89533811|NCT02974582|Experimental|4/Part 2 - Control|Randomized to view direct mail marketing
88825645|NCT03021746|Experimental|Parish Nurse Only|The main focus of this approach will contain all of the same elements as the PN plus PL approach, except that PL will not be used. Rather, the PN will provide all aspects of Diabetes Self Management Support (DSMS), including facilitation of goal setting, monthly phone contacts, and preparation for a diabetes-related health care visit. Diabetes Self Management Education (DSME) will be provided by CDEs and co-facilitated by a PN to ensure consistency in the DSME content. Following DSME, participants will be invited to attend 12 months of monthly, DSMS support groups led by the PN. Following support sessions, participants will transition into a period of ongoing support, where the participants and PN will be encouraged to continue to foster DSMS through programs and initiatives that are meaningful to them, utilizing the existing church infrastructure. The PN may answer clinical questions and may contact the CDE for additional information if needed.
89356606|NCT03335020|Placebo Comparator|Normal|Healthy volunteers. Assessment using Shear Wave Elastography, Pulse Wave Imaging, Contrast-Enhanced Ultrasound, Strain Imaging and 3-D Volume ultrasound
89356607|NCT03335020|Active Comparator|Fibromuscular Dysplasia (FMD)|Subjects with diagnosis of FMD. Assessment using Shear Wave Elastography, Pulse Wave Imaging, Contrast-Enhanced Ultrasound, Strain Imaging and 3-D Volume ultrasound
88825646|NCT02988362|Experimental|Candesartan 16mg and Amlodipine 10mg|Candesartan 16mg and Amlodipine 10mg
88825647|NCT02988362|Experimental|HL068|HL068(combination of Candesartan 16 mg and Amlodipine 10 mg)
89356608|NCT03335020|Active Comparator|Atherosclerosis|Subjects with diagnosis of atherosclerosis. Assessment using Shear Wave Elastography, Pulse Wave Imaging, Contrast-Enhanced Ultrasound, Strain Imaging and 3-D Volume ultrasound
89356609|NCT03335020|Active Comparator|Spontaneous Coronary Artery Dissection (SCAD)|Subjects with diagnosis of SCAD. Assessment using Shear Wave Elastography, Pulse Wave Imaging, Contrast-Enhanced Ultrasound, Strain Imaging and 3-D Volume ultrasound
88825648|NCT02988518|Experimental|COGMED program|Cognitive remediation using COGMED program on bipolar euthymic patients with memory complaints
88825649|NCT02988440|Other|PDR001 + Sorafenib|PDR001 at 400 mg given intravenously every 4 weeks and sorafenib 400 mg taken orally once or twice per day (escalating doses)
88825650|NCT05405192|Experimental|Dostarlimab Group|Participants will receive a total of up to 20 cycles of Dostarlimab: 4 cycles of Dostarlimab at a dose of 500 mg on day 1 of each of the 21-day cycle and 16 cycles of Dostarlimab at a dose of 1000 mg on day 1 of each of the 42-day cycle.
88825651|NCT00550550|Placebo Comparator|Placebo|Matching Placebo
88825652|NCT00550550|Experimental|SCH 697243|Grass Sublingual Tablet (Phleum pratense extract)
88825653|NCT02971839|Experimental|VX-561 20 mg|
88825654|NCT02971839|Experimental|VX-561 100 mg|
88825655|NCT02971839|Experimental|VX-561 150 mg|
88825656|NCT02971839|Active Comparator|Ivacaftor|
89356610|NCT03335020|Active Comparator|Segmental Arterial Mediolysis (SAM)|Subjects with diagnosis of SAM. Assessment using Shear Wave Elastography, Pulse Wave Imaging, Contrast-Enhanced Ultrasound, Strain Imaging and 3-D Volume ultrasound
88825657|NCT02971839|Placebo Comparator|Placebo|
89356611|NCT01301339||failed and passed physical fitness test|520 subjects who have failed their Air Force physical fitness test and 520 volunteers who have passed their physical fitness test both within the last 6 months
88825658|NCT05378282||Diabetic patients without diabetic nephropathy|i. Patients with ≥ 20 years of T2D evolution with normoalbuminuria ii. Patients without a personal or family history of kidney disease in 1st degree relatives iii. Age ≥ 18 years
89356612|NCT01207271|Experimental|Cognitive Therapy|
89356613|NCT01207271|Experimental|Dynamic Therapy|
88825659|NCT05378282||Diabetic patients with diabetic nephropathy|"i. T2D diagnosed at least 5 years before initiating renal replacement therapy ii. Background or diabetic retinopathy by self-report to ensure that albuminuria was the consequence of diabetic nephropathy rather than a non-diabetic glomerulopathy iii. albuminuria ≥ 300 mg/24 h in at least two out of three sterile urine samples iv. no hematuria or signs (including cellular casts), history or predisposition to other kidney or urinary tract disease.~v. Age ≥ 18 years"
88825660|NCT03821259||Older adults with mental health history|Eligible participants, aged 65 and over, will be established in treatment for PTSD, anxiety or depression in the Older Adult Psychological Therapies service.
88825661|NCT03803085|Experimental|Control Condition|Participants only saw their own daily walking steps using the WeRun function in WeChat. They did not use WeChat to see other group members' daily steps and did not engage in social contact with their group members.
89356614|NCT03340870|Experimental|Sonazoid™ 0.12 microliter (µl)|Participants will receive single intravenous (I.V) bolus injection of Sonazoid™ 0.12 µl microbubbles (MB)/kilogram (kg) body weight.
89356615|NCT03340870|Experimental|Sonazoid™ 0.60 µl|Participants will receive single I.V bolus injection of Sonazoid™ 0.60 µl MB/kg body weight.
88825662|NCT03803085|Experimental|Treatment condition|Participants saw their own and other group member's daily walking steps using the WeRun function in WeChat and they were able to contact the other members of their group using We Chat.
88825663|NCT02988206|Other|Personalized Objects|"The item Functional Object Use was assessed by using personalized objects (e.g., cigarette, paper) and non-personalized objects, which presented in a random order.."
89356616|NCT03521635|Experimental|Pramipexole SR|
89356617|NCT03521635|Active Comparator|Pramipexole IR|
89356618|NCT03813953|Experimental|Local Anaesthetic Wound Infiltration|Wound catheter delivering local anaesthetic for 48 hours post-operatively following liver resection
89356619|NCT03813953|Active Comparator|Epidural|Conventional practice following liver resection
89356620|NCT03340792|Experimental|Exoskeleton robot ambulation training|Ambulation training utilizing an exoskeleton robot
89356621|NCT03813797|Experimental|Arm A: Low Pressure (5-7 mmHg)|Laparoscopic colectomy surgery with low pressure (5-7mmHg)
89356622|NCT03813797|Active Comparator|Arm B: Standard pressure (12-15 mmHg)|Laparoscopic colectomy surgery with standard pressure (12-15mmHg)
89356623|NCT03120754|Experimental|Experimental Group|Placement of peritoneal drainage
89356624|NCT03120754|Active Comparator|Control group|No peritoneal drainage
89356625|NCT03723421|Experimental|Rapid Injection Group Without Aspiration|The tetanus vaccine was applied into the deltoid muscle of the left arm in the sitting position by rapid injection technique without aspiration.
89356626|NCT03723421|Experimental|Control|The tetanus vaccine was applied into the deltoid muscle of the left arm in the sitting position with the standard injection technique.
89533812|NCT02964208||LAA Occluder PAS|Subjects who were treated with AMPLATZER LAA Occluders will be included.
88825664|NCT02988206|Other|non-personalized objects|"The item Functional Object Use was assessed by using non-personalized objects"
88825665|NCT03022448||Treatment Group|Trabectedin will be used according to the local SmPC. Modification of the treatment schedule should follow the standard medical practice at the discretion of the treating physician and is not part of this Observational Plan.
88825666|NCT00422877|Experimental|Taxoprexin|Starting dose of 500 mg/m2 (400 mg/m2 for patients with an elevated bilirubin at baseline) administered intravenously by a 1-hour infusion weekly for the first 5 weeks of a 6 week cycle.
88825667|NCT02974803|Experimental|Dabrafenib and Trametinib|Dabrafenib, PO, 150mg BID Continuously Trameteinib, PO 2mg OD Continuously
88825668|NCT02281136|Experimental|ALA|20% aminolevulinic acid applied via Kerastick to individual AK lesions on the upper extremities and covered with occlusive dressing for 3 hours prior to BLU-U treatment
88825669|NCT02301156|Experimental|Ublituximab + Ibrutinib|Participants will receive ublituximab intravenous (IV) infusion, up to 150 milligrams (mg) once on Day 1, 750 mg on Day 2, 900 mg on Days 8 and 15 of Cycle 1 (Cycle duration=28 days) followed by 900 mg on Day 1 of Cycles 2 to 6 and 900 mg on Day 1 of every 3rd cycle thereafter for up to 62 months along with ibrutinib 420 mg capsules, orally, once daily (QD) in each 28-day cycle for up to 62 months.
88825670|NCT02301156|Active Comparator|Ibrutinib|Participants will receive ibrutinib 420 mg capsules, orally, QD in each 28-day cycle up to 62 months.
88825671|NCT03981939||CD Participants with CPAF - The Ottawa Hospital (TOH)|Participants diagnosed with Complex Perianal Fistula (CPAF) from the Ottawa Hospital (TOH) were observed retrospectively in this arm group for the index period (April 1, 2007 to March 31, 2013).
88825672|NCT03981939||CD Participants without CPAF (ICES database)|Participants diagnosed with CD and without CPAF from Institute for Clinical Evaluative Sciences (ICES) database who did not meet the case definition were observed retrospectively in this arm group for the index period (April 1, 2007 to March 31, 2013).
88825673|NCT03981939||CD Participants with CPAF (ICES database)|Participants with CD and CPAF from ICES database who met the case definition were observed retrospectively in this arm group for the index period (April 1, 2007 to March 31, 2013).
88825674|NCT03830307|Experimental|Intervention Group|The NSS-2 BRIDGE is a battery operated and disposable percutaneous auricular nerve field stimulator (Innovative Health Solutions, Versailles, IN, USA), that was recently cleared by the FDA and assigned a Class II Risk Designation; a class which includes surgical drapes, pumps and power wheelchairs. The indication for the NSS-2 BRIDGE is for the treatment of clinical symptoms related to opioid consumption and opioid withdrawal.
88825675|NCT04768712|Experimental|Weight bearing aerobic exercise|
88825676|NCT04768712|No Intervention|Lifestyle counseling|
88825677|NCT04514276|Experimental|consecutive fetoneonatal healthcare|inclusion criteria: pregnant woman having higher risk of early fetal growth restriction, preeclempsia living in studyregion (east-Saxony or east Thuringia) the fetoneonatal pathway consists of four consecutive parts: (1) early perceiving of pregnant women with higher risks for early fetal growth restrictions via color Doppler sonography, fetal biometry, haemogram check (currently additional screenings) (2) structured care of the high risk women who are pregnant (3) concerted neonatal health care (4) adapted paediatric aftercare, certain dates and responsible persons are scheduled.
89356627|NCT03817073|Experimental|Iowa Oral Performance Instrument (IOPI)|All MS patients will be included in this arm to compare with a historical control arm. Iowa Oral Performance Instrument (IOPI).
89533813|NCT02964182|Experimental|Arm I (usual cigarettes, VLNCC, ECIG-Hi, ECIG-Lo)|"PHASE I: Patients smoke their usual cigarettes brand during week 1.~PHASE II: Patients smoke VLNCC cigarettes provided during weeks 2-4.~PHASES III-IV: Patients smoke ECIG-Hi for 3 weeks and then ECIG-Lo for 3 weeks."
89533814|NCT02964182|Experimental|Arm II (usual cigarettes, VLNCC, ECIG-Hi, ECIG-Lo)|"PHASE I: Patients smoke their usual cigarettes brand during week 1.~PHASE II: Patients smoke VLNCC cigarettes provided during weeks 2-4.~PHASES III-IV: Patients smoke ECIG-Lo for 3 weeks and then ECIG-Hi for 3 weeks."
88825678|NCT04514276|No Intervention|standard fetoneonatal healthcare|inclusion criteria: due to health insurance data by AOK PPLUS & ikk classics propsensityscorematched pregnant women living in west Saxony and Thuringia, being not part of the intervention group receiving standard health care.
89356628|NCT03170544|Experimental|Part 1, MK-1092, 4.0 nmol/kg|MK-1092, 4.0 nmol/kg, SC, as a single dose under the euglycemic clamp, in healthy participants
89356629|NCT03170544|Experimental|Part 1, MK-1092, 8.0 nmol/kg|MK-1092, 8.0 nmol/kg, SC, as a single dose under the euglycemic clamp, in healthy participants
89356630|NCT03170544|Experimental|Part 1, MK-1092, 16 nmol/kg|MK-1092, 16 nmol/kg, SC, as a single dose under the euglycemic clamp, in healthy participants
89356631|NCT03170544|Experimental|Part 1, MK-1092, 32 nmol/kg|MK-1092, 32 nmol/kg, SC, as a single dose under the euglycemic clamp, in healthy participants
89356632|NCT03170544|Experimental|Part 1, MK-1092, 64 nmol/kg|MK-1092, 64 nmol/kg, SC, as a single dose under the euglycemic clamp, in healthy participants
89356633|NCT03170544|Active Comparator|Part 1, Glargine, 3.0 nmol/kg|Glargine, 3.0 nmol/kg, SC, as a single dose under the euglycemic clamp, in healthy participants
89356634|NCT03170544|Experimental|Part 2, MK-1092, 8.0 nmol/kg + lispro, 1.2 nmol/kg|MK-1092, 8.0 nmol/kg dose selection based on Part 1 + lispro (Humalog®), 1.2 nmol/kg, as a single dose, in healthy participants
89356635|NCT03170544|Experimental|Part 3, MK-1092, 8.0 nmol/kg|MK-1092, (8.0 nmol/kg based on Part 1), SC, in participants with T1DM.
89000480|NCT03523117|Active Comparator|Oral Ferrous Sulfate|Oral Ferrous Sulfate - will receive an age-dependent formulation of oral ferrous sulfate daily for 28 days as follows: participants <12 years of age will receive 6 mg (elemental iron)/kg/day divided into 2 daily doses of an oral liquid formulation, either drops or elixir, and participants ≥12 will receive 2 daily doses of oral tablets. Infants and children (ages 1 to <4 years) will receive oral ferrous sulfate drops, while children (ages ≥4 to <12 years) will receive oral ferrous sulfate elixir. Adolescents (ages ≥12 to 17 years) will receive an oral ferrous sulfate tablet (65 mg of elemental iron/tablet/dose) twice a day (BID). The maximum daily dose for all participants is 130 mg of elemental iron.
89000481|NCT00204711||Outpatient Surgery with Sedation|SNAP II EEG data will be recorded continuously during the sedation and intermittently compared to routinely monitored parameters of sedation adequacy including vital signs, patient movement, grimacing, verbal complaints, and patient responsiveness to verbal and tactile stimuli. Following surgery, patients will be questioned to determine recall or memory of discomfort.
89000482|NCT03514186|Experimental|Intensive Comprehensive Aphasia Program|60 hours of comprehensive speech and language therapy applied intensively, 4 hours per day, 5 days a week for three weeks.
89356636|NCT03170544|Experimental|Part 3, MK-1092, 32 nmol/kg|MK-1092, 32 nmol/kg, SC, as a single dose, in participants with T1DM
89356637|NCT03170544|Active Comparator|Part 3, Glargine, 3.0 nmol/kg|Glargine, 3.0 nmol/kg, SC, as a single dose, in participants with T1DM
89356638|NCT03170544|Experimental|Part 4, MK-1092, 32 nmol/kg|MK-1092, 32 nmol/kg, SC, as a single dose, in participants with T2DM
89356639|NCT03170544|Experimental|Part 4, MK-1092, 16 nmol/kg|MK-1092, 16 nmol/kg, SC, as a single dose, in participants with T2DM
89356640|NCT03170544|Experimental|Part 4, MK-1092, 64 nmol/kg|MK-1092, 64 nmol/kg, SC, as a single dose, in participants with T2DM
89356641|NCT03170544|Active Comparator|Part 4, Glargine, 3.0 nmol/kg|Glargine, 3.0 nmol/kg, SC, as a single dose, in participants with T2DM
89356642|NCT03582943|Experimental|Remote limb ischemic conditioning (RLIC)|RLIC is achieved via blood pressure cuff inflation to 20 mmHg above systolic blood pressure on the dominant arm. RLIC requires 45 minutes and involves 5 cycles of 5 minutes blood pressure cuff inflation followed by alternating 5 minutes of cuff deflation. RLIC is performed on visits 1-7.
89356643|NCT03582943|Sham Comparator|Sham conditioning|Sham conditioning is achieved via blood pressure cuff inflation to 10 mmHg under diastolic blood pressure on the dominant arm. Sham conditioning requires 45 minutes and involves 5 cycles of 5 minutes blood pressure cuff inflation followed by alternating 5 minutes of cuff deflation. Sham conditioning is performed on visits 1-7.
89356644|NCT03813563||Mix group|Patients who used two balanced salt solutions during icu stay
89356645|NCT03813563||RL group|Patients who have only used lactated Ringer's during icu stay
89356646|NCT03813563||PLA group|Patients who have only used PlasmaLyte during icu stay
89356647|NCT03334786|Experimental|FLX-787-ODT (orally disintegrating tablet)|Single dose
89356648|NCT02494414||French prospective cohort of cardiac arrest survivors|Outcome of cardiac arrest survivors: prospective cohort of Ile-de-France
89356649|NCT03813641|Experimental|RALOX + bevacizumab|Oxaliplatin 130mg/m2, i.v.gtt 2h, d1 Raltitrexed 3mg/m2, i.v.gtt 15min ,d1 Bevacizumab 7.5mg/kg, i.v.gtt, d1 The above schemes are repeated every three weeks. After 8 cycles, such as CR, PR or SD, the regimen is changed to raltitrexed (3mg/m2, intravenous drip for 15 minutes, d1)+bevacizumab (7.5mg/kg, intravenous drip, d1). The regimen is repeated every 3 weeks until the disease progresses.
89356650|NCT03813641|Active Comparator|CAPOX + bevacizumab|Oxaliplatin 130mg/m2, i.v.gtt 2h, d1 Capecitabine 1000mg/m2, po. ,d1 Bevacizumab 7.5mg/kg, i.v.gtt, d1 The above schemes are repeated every three weeks. After 8 cycles, such as CR, PR or SD, the regimen is changed to Capecitabine (1000mg/m2 po. d1-14)+bevacizumab (7.5mg/kg, intravenous drip, d1). The regimen is repeated every 3 weeks until the disease progresses.
89356651|NCT02494492|Experimental|IVT of regulator T-cells|intravitreous administration of regulator T-cells
89356652|NCT03532009|Experimental|Sodium Zirconium Cyclosilicate (ZS)|Powder for oral suspension
89000483|NCT03514186|Active Comparator|Distributed Comprehensive Aphasia Tx|60 hours of comprehensive speech and language therapy distributed over 15 weeks (i.e. two 2-hour visits per week).
89356653|NCT03532009|Placebo Comparator|Placebo|Powder for oral suspension
89356654|NCT05207046||Patients with spinal cord injury|Patients treated with mechanical ventilation after a traumatic spine lesion with spinal cord injury
89356655|NCT05207046||Patients with NO spinal cord injury|Patients treated with mechanical ventilation after a traumatic spine lesion with NO spinal cord injury
89356656|NCT03340558|Experimental|Monotherapy Cohort|The first 10 subjects will receive Atezolizumab 840 mg IV on Day 1 and Day 15 of each 28-day cycle. Subjects will be treated for 2 cycles before undergoing metastatectomy within 42 days of completion of Cycle 2. No study treatment is administered while subjects are healing after surgery.
89356657|NCT03340558|Experimental|Combination Cohort|The next 15 subjects will receive Atezolizumab 840 mg IV on Day 1 and Day 15 and Cobimetinib 60 mg PO on Days 1-21 of each 28-day cycle. Cobimetinib must be held for the 7 days prior to metastatectomy. Subjects will be treated for 2 cycles before undergoing metastatectomy within 42 days of completion of Cycle 2.
89356658|NCT04905108|Active Comparator|Riboflavin drop every 2 minutes|Administration of one drop of Riboflavin every 2 minutes during UV exposure
89356659|NCT04905108|Active Comparator|Riboflavin drop every 10 minutes|Administration of one drop of Riboflavin every 10 minutes during UV exposure
89356660|NCT04443166|Experimental|Group A|At the beginning of the study (T0), group A will receive one course of PRP+HA program and group B will receive one HA course (a single HA injection (Hyajoint) weekly for 3 weeks). The PRP+HA program includes 3 HA injections and a single PRP injection (Arthrex double syringe system).
89356661|NCT04443166|Active Comparator|Group B|In the 6th month, alternately, group B will receive one PRP+HA program and group A will receive one HA course.
89000484|NCT03430882|Experimental|Treatment (sapanisertib, paclitaxel, carboplatin)|Patients receive sapanisertib PO QD on days 2-4, 9-11, and 16-18, paclitaxel IV over 3 hours on days 1, 8, and 15, and carboplatin IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive sapanisertib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89000485|NCT03291886|Experimental|Arm A (exemestane, Entinostat)|"5 mg KHK2375 will be administered to subjects once weekly. EXE001 will be administered at a dose of 25 mg once daily orally.~Pre/perimenopausal female patients also receive luteinizing hormone-releasing hormone (LH-RH) agonist."
89000486|NCT03291886|Placebo Comparator|Arm B (exemestane, Entinostat(placebo))|"KHK2375 Placebo will be administered to subjects once weekly. EXE001 will be administered at a dose of 25 mg once daily orally.~Pre/perimenopausal female patients also receive luteinizing hormone-releasing hormone (LH-RH) agonist."
89000487|NCT04679116|Other|Laparoscopic|laparoscopic inguinal hernia repair, TAPP
89000488|NCT04679116|Other|Open|open inguinal hernia repair
89000489|NCT00204750|Active Comparator|1|Bougie dilation
89000490|NCT00204750|Experimental|2|Needle-knife incision
89000491|NCT03184090|Experimental|Palbociclib + Endocrine Therapy|"Patients will receive palbociclib capsules orally for 21 days every four weeks in combination with endocrine therapy (physician's choice based on prior administered agent including tamoxifen, exemestane, fulvestrant, anastrozole, or letrozole).~Treatment will continue until disease progression (with the exception of patients who develop isolated progression in the brain), unacceptable toxicity, death, or discontinuation from the study treatment for any other reason."
89000492|NCT02968381|Experimental|Imagery Intervention|Participants will receive imagery intervention which includes 6 telephone sessions, an introduction to guided imagery, setting a quit date, setting guided imagery schedule, and a description of and instructions for using the study website.
89000493|NCT02968381|Active Comparator|Control Condition|Participants will receive an attention control condition which includes 6 telephone sessions, an introduction to cognitive behavioral telephone coaching, setting a quit date, creating a quit plan, and a description of and instructions for using the Arizona Smokers' Help Line website.
89000494|NCT00204828||1.|Children with asthma
89000495|NCT00204828||2.|Children without asthma
89000496|NCT02657005|Experimental|TK216 treatment|Dose escalation and expansion cohorts to determine dose-limiting toxicities, maximally tolerated dose, preliminary efficacy, and recommended phase 2 dose.
89000497|NCT00554164|Active Comparator|B1|Six cycles of the (R-)CHOP regimen.
89000498|NCT00554164|Experimental|B2|Six blocks of the B-ALL protocol.
89000499|NCT00554164|Active Comparator|A1|Four cycles of the (R-)CHOP regimen.
89000500|NCT00554164|Active Comparator|A2|Four cycles of the (R-)CHOP regimen plus two additional doses rituximab.
89000501|NCT02572141|Experimental|Perioperative chemotherapy|Perioperative chemotherapy with mFOLFOX6 or CAPOX regimens
89000502|NCT02572141|Active Comparator|Postoperative chemotherapy|Postoperative chemotherapy with mFOLFOX6 or CAPOX regimens
89000503|NCT00410865|Experimental|INGN 201|INGN201 injection + oral rinse, day 1, courses 1-6. Twice-daily oral rinses, days 2-5, courses 1-6.
89000504|NCT02470039|Experimental|Oral insulin 338 and subcutaneous placebo|
89000505|NCT02470039|Active Comparator|Subcutaneous insulin glargine and oral placebo|
89000506|NCT02459236|Experimental|CERC-301 12mg|The study includes two dose administrations 7 days apart (Day 0 and Day 7) followed by 14 days of observation for a total of 21 days.
89000507|NCT02459236|Experimental|CERC-301 20mg|The study includes two dose administrations 7 days apart (Day 0 and Day 7) followed by 14 days of observation for a total of 21 days.
89000508|NCT02459236|Placebo Comparator|Placebo|The study includes two dose administrations 7 days apart (Day 0 and Day 7) followed by 14 days of observation for a total of 21 days.
89000509|NCT00554281|No Intervention|A|Run in period
89000510|NCT00554281|Experimental|B|
89000511|NCT00554320|Active Comparator|A|During each session, the anode electrode will be placed on the motor cortex (contralateral to the most [or predominant] painful side [or the side where the symptoms begin or the left as a default]) and the cathode will be placed over the contralateral supraorbital area. In active tDCS subjects, 1 mA of transcranial direct current stimulation will be applied for 30 minutes.
89000512|NCT00554320|Placebo Comparator|C|For sham-controlled tDCS subjects, the same montage will be used; however current will be applied only for 30 seconds.
89000513|NCT03455101||Patients with diabetes mellitus|Patients with type 1 or type 2 diabetes who were under follow-up in the same center for at least a year.
89000514|NCT02429167|Experimental|PoNS Device|Cranial nerve non-invasive neuromodulation via PoNS device. The system delivers 19 V pulses to the tongue (a nominal 5.5 kilo-ohm load).
89000515|NCT02429167|Sham Comparator|Sham PoNS Device|The sham control device appears physically identical but uses a modified stimulus waveform parameter set designed to elicit a mild tactile sensation while minimizing the net energy delivered, thereby providing minimal, if any, cranial nerve non-invasive neuromodulation via PoNS device
89000516|NCT02421679|Experimental|TNX-102 SL|TNX-102 SL taken daily at bedtime for 12 weeks
89000517|NCT02389777|No Intervention|Control UV burn|No treatment of the UV Light burn will be given
89000518|NCT02389777|Active Comparator|ST266 treated UV burn immediately|ST266 will be applied topically immediately by spray to the UV light burn wound
89000519|NCT02389777|Active Comparator|ST266 treated UV burn delayed|ST266 will be applied topically by spray to the UV light burn beginning 6 - 12 hours after the burn
89000520|NCT02387788|Experimental|15 mg AKB-9778 BID for 84 days|Subcutaneous AKB-9778 15 mg BID (total dose of 30 mg/day) for 84 days
89000521|NCT00410982|Experimental|Gemcitabine + Busulfan + Melphalan + HCT|HCT = Hematopoietic Cell Transplantation
89000522|NCT02372578|Experimental|ASP3662|ASP3662 once daily (QD) and pregabalin placebo 3 times daily (TID) for Weeks 1 - 6. ASP3662 placebo QD and pregabalin placebo TID for Week 7.
89000523|NCT02372578|Active Comparator|pregabalin|pregabalin TID and ASP3662 placebo QD for Weeks 1 - 7.
88825679|NCT03973905||Pertussis Case Group|"Infant subjects of at least 2 days old and less than (<) 2 months old, who met the pertussis diagnosis definition (laboratory confirmed pertussis, epidemiological linkage to a laboratory-confirmed case, clinically compatible illness), and who met the case infants inclusion criteria (resided in the catchment area on their cough onset date, were born in a hospital in their state of residence, had at least 37 weeks gestational age at birth, were neither adopted, nor in foster care and did not live in a residential care facility).~This post-hoc analysis was limited to cases and controls whose mothers were either vaccinated with Boostrix or did not receive any Tdap vaccine. Cases with no remaining matched control were also excluded from the analysis and vice versa."
88825680|NCT03973905||Control Group|"Infant subjects of at least 2 days old and less than (<) 2 months old, who did not have a pertussis diagnosis prior to the cough onset date and who met the inclusion criteria for control infants (were born on a hospital in their state of residence, were at least 37 weeks gestational age at birth, were neither adopted, nor in foster care, did not live in a residential care facility, were born at the same hospital as the case infant).~This post-hoc analysis was limited to cases and controls whose mothers were either vaccinated with Boostrix or did not receive any Tdap vaccine. Cases with no remaining matched control were also excluded from the analysis and vice versa."
88825681|NCT02278484|Other|Balloon Sinus Dilation|
88825682|NCT02900781|Active Comparator|Active Comparator Steprite™ Device'|steprite™ device active Comparator- The steprite™ System is a monitoring and biofeedback system for the Monitoring of rehabilitation patients Measuring pressure distribution, gait and range of motion of the lower extremities while a patient performs specified rehabilitation exercises
88825683|NCT02900781|Placebo Comparator|Control|Control outcomes with no device. Standard of care physical therapy and outcomes.
88825684|NCT03971721|Experimental|Wave Mattress Support|The mattress support will be delivered at the subject's home by professional staff of the sponsor (Hill-Rom) in the presence of the research coordinator or investigator. The subject will sleep on mattress support for the duration of study participation.
88825685|NCT03979677|Experimental|Intervention Group|All participants will be provided written and verbal instructions regarding the lifestyle modification intervention.
88825686|NCT00558038|Active Comparator|1|
88825687|NCT00558038|Experimental|2|
88825688|NCT01507233|Active Comparator|IV morphine sulfate|morphine sulfate (or Sponsor-approved equivalent)
88825689|NCT01507233|Experimental|EXPAREL|EXPAREL (bupivacaine liposome injectable suspension)
88825690|NCT01517763|Placebo Comparator|Conventional CPAP|Fisher & Paykel HC244™
88825691|NCT01517763|Active Comparator|CPAP without Humidification|Fixed pressure ICON™ without ThermoSmart™
88825692|NCT01517763|Experimental|APAP with all technologies|Auto ICON™ with SensAwake™ and ThermoSmart™
88825693|NCT02301390|Active Comparator|Amiodarone only|The control group will receive amiodarone only.
88825694|NCT02301390|Experimental|Amiodarone + Catheter Ablation|The experimental group will receive amiodarone plus catheter VT ablation.
88825695|NCT02278562|Active Comparator|anakinra|100 mg of Anakinra in syringes administered subcutaneously 3 times a week for 3 months and lactose (placebo) in capsules administered orally 1 capsule per day for 3 months
88825696|NCT02278562|Active Comparator|actos|Normal saline (placebo) in syringes administered subcutaneously 3 times a week for 3 months and 30 mg of Actos in capsules administered orally 1 capsule per day for 3 months
88825697|NCT02278562|Placebo Comparator|placebo 1 and 2|Normal saline (placebo) in syringes administered subcutaneously 3 times a week for 3 months and lactose (placebo) in capsules administered orally 1 capsule per day for 3 months
88825698|NCT01497171|Active Comparator|Elevate Mesh|Elevate transvaginal mesh - surgical repair of prolapse
88825699|NCT01497171|Active Comparator|Anterior Colporrhaphy|Anterior colporrhaphy - surgical repair of prolapse
88825700|NCT01487499|Experimental|patients with limited stage SCLC|Subjects with limited stage SCLC treated sequentially with cisplatin.
88825701|NCT01487499|No Intervention|Historical Controls|No intervention
88825702|NCT01483209|Experimental|Botox injection|Use of botulinum toxin A to determine efficacy in treating vasopressor-induced digital ischemia
88825703|NCT02281448|Other|Treatment sequence A|oral once daily dose of 1200 mg of BIA 2-093 plus single-dose of a contraceptive for 15 days followed by washout and 3 days of oral single-dose contraceptive
88825704|NCT02281448|Other|Treatment sequence B|oral single-dose of a contraceptive for 3 days after pre-treatment with an oral once daily dose of 1200 mg of BIA 2-093 plus single-dose of a contraceptive for 15 days
88825705|NCT00378729|Active Comparator|A|
88825706|NCT00378729|Active Comparator|B|
88825707|NCT02281526|Other|Subjects with moderate hepatic impairment|This was an open-label, multiple-dose, single-centre study in 2 groups of subjects: subjects with moderate hepatic impairment and healthy controls
88825708|NCT02281526|Other|subjects - healthy controls|This was an open-label, multiple-dose, single-centre study in 2 groups of subjects: subjects with moderate hepatic impairment and healthy controls
88825709|NCT03802227|Experimental|Group 1|NKTR-181 400 mg and oxycodone IR placebo
88825710|NCT03802227|Experimental|Group 2|Oxycodone IR 40 mg and NKTR-181 placebo
88825711|NCT01879826|Sham Comparator|Aculaser applied to sham points|"The patient will receive aculaser, performed by licensed acupuncturist, to sham acupuncture sites. In addition, the patient will still receive standard pain control protocols with anesthetic medications like lidocaine plus ketamine or fentanyl and versed during the biopsy, along with pain management after the procedure."
88825712|NCT01879826|Experimental|Aculaser applied to kidney points|The patient will receive aculaser, performed by licensed acupuncturist, to known kidney acupuncture sites. In addition, the patient will still receive standard pain control protocols with anesthetic medications like lidocaine plus ketamine or fentanyl and versed during the biopsy, along with pain management after the procedure.
88825713|NCT01383681||All Participants|This was a retrospective chart review in patients with spasticity in the Spanish population. There was no treatment in this study.
88825714|NCT04368728|Experimental|10 µg dose, 18-55 years of age (2 doses)|
88825715|NCT04368728|Experimental|20 µg dose, 18-55 years of age (2 doses)|
88825716|NCT04368728|Experimental|30 µg dose, 18-55 years of age (2 doses)|
88825717|NCT04368728|Experimental|10 µg dose, 65-85 years of age (2 doses)|
88825718|NCT04368728|Experimental|20 µg dose, 65-85 years of age (2 doses)|
89356662|NCT04509570|Other|Treatment: ILI(Intralesional injection)|5~20mg/ml, intralesional injection every 1 month. Number of cycles: until the lesions are clinically cleared
89356663|NCT01560221|Experimental|Therapeutic Workplace|Participants will receive all standard services plus the Therapeutic Workplace intervention, in which access to stipend supported training and/or wage subsidies for community employment is contingent upon drug abstinence as verified by urinalysis.
88825719|NCT04368728|Experimental|30 µg dose, 65-85 years of age (2 doses)|
88825720|NCT04368728|Experimental|30 µg dose, ≥12 years of age (2 doses)|
89356664|NCT01560221|Active Comparator|Standard Services|Participants will receive methadone treatment or buprenorphine treatment, depending upon medical recommendations of their physicians, slot availability, and their own preferences. Participants who remain in treatment for at least 90 days will have the charge of prostitution that is pending against them dropped.
89356665|NCT03334474||young|18-35 years old
89533815|NCT02927236|Experimental|Cocaine - Active (EFS)|designed to implement the iTBS administration parameters established from P1 with a larger sample of treatment seeking CD participants. Though the schedule may change slightly based on the outcome of the pilot, a schedule of 3 daily iTBS sessions with a 20 minute interval between administrations is planned and used throughout the design.
89356666|NCT03334474||middle|35-65 years old
89533816|NCT02927236|Sham Comparator|Cocaine - Sham (EFS)|To test the efficacy of the iTBS.
89533817|NCT02927236|Other|Healthy Control-Main (EFS)|Population comparison of acute experimental iTBS.
88825721|NCT04368728|Placebo Comparator|Placebo, 18-55 years of age|
88825722|NCT04368728|Placebo Comparator|Placebo, 65-85 years of age|
88825723|NCT04368728|Placebo Comparator|Placebo, ≥12 years of age|
88825724|NCT04368728|Experimental|100 µg dose, 18-55 years of age (2 doses)|
88825725|NCT04368728|Other|Vaccination of Placebo recipients with BNT162b2 - Stage 1|Participants ≥16 years of age who originally received placebo and are eligible for COVID-19 vaccination following any local or national recommendations will be offered the opportunity to receive BNT162b2 as part of the study.
88825726|NCT04368728|Other|Vaccination of placebo recipients with BNT162b2 - Stage 2|Participants ≥16 years of age who originally received placebo will be offered the opportunity to receive BNT162b2 at defined points as part of the study.
88825727|NCT04368728|Experimental|Booster vaccination of Phase 1 participants with BNT162b2 at a dose of 30 µg|
88825728|NCT04368728|Experimental|Booster vaccination of Phase 3 participants with BNT162b2 at a dose of 30 µg|
88825729|NCT04368728|Experimental|Booster vaccination of Phase 3 participants with BNT162b2SA at a dose of 30 µg|
88825730|NCT04368728|Experimental|Vaccination of BNT162b2-naive participants with BNT162b2SA at a dose of 30 µg|
88825731|NCT04368728|Experimental|Booster and further vaccination of Phase 3 participants with BNT162b2SA at a dose of 30 µg|
88825732|NCT04368728|Experimental|Booster vaccination of Phase 3 participants with BNT162b2 at a dose of 5 µg|
88825733|NCT04368728|Experimental|Booster vaccination of Phase 3 participants with BNT162b2 at a dose of 10 µg|
88825734|NCT02749617|Experimental|apixaban|apixaban 2.5 mg PO BID
88825735|NCT02749227|Experimental|Pasireotide LAR Therapy|Subjects will receive Pasireotide LAR monthly. Safety labs and Pituitary MRI will be performed.
88825736|NCT02746263|Experimental|IV acetaminophen/Morphine|IV acetaminophen 1000 mg every 6 hours over 18 hours
89533818|NCT02927236|Experimental|Pilot|P1 is designed to establish safety and tolerability criteria for administering iTBS to treatment seeking cocaine users, initially as in-patient followed by an out-patient cohort
89533819|NCT02916680|Experimental|Pancreatic islet transplantation|Pancreatic islet transplantation in the anterior chamber of the human eye
88825737|NCT02746263|Active Comparator|Oral acetaminophen/Morphine|Oral acetaminophen two 500 mg tablets every 6 hours over 18 hours
88825738|NCT01394211|Experimental|Neoadjuvant enzyme inhibitor therapy|"Patients receive pazopanib hydrochloride* PO QD and anastrozole PO QD for 6 months in the absence of disease progression or unacceptable toxicity. Patients then undergo therapeutic conventional surgery.~NOTE: *Pazopanib hydrochloride is stopped 7-14 days before definitive surgery."
88825739|NCT02278640|Other|Harmonic ACE®+7 Shears|Single Arm study using Harmonic ACE for dissection and transection in Hysterectomy
88825740|NCT02717949|Experimental|sofosbuvir/ledipasvir|sofosbuvir and ledipasvir fixed dose combination given orally once a day for genotype 1 and 4.
88825741|NCT02717949|Experimental|sofosbuvir and ribavirin|Sofosbuvir 400 mg given orally once a day with weight-base ribavirin of 1200 mg for those >75 kg and 1000 mg for those <75kg given in divided dose twice a day. This intervention is for genotype 2 and 3
88825742|NCT02300610|Experimental|Dose Escalation|Dose Escalation: Begin with Level 1 dose of enzalutamide (orally), with standard doses of cisplatin and gemcitabine via intravenous (IV).
89356667|NCT03334474||aged|65-85 years old
89356668|NCT03813329|Placebo Comparator|Placebo|4 progressively larger doses (110 mg·kg-1 - 200 mg·kg-1) of Calcium carbonate
88825743|NCT02300610|Experimental|Dose Expansion|Dose Expansion: Enzalutamide at recommended dose level with standard doses of cisplatin and gemcitabine.
88825744|NCT01880840|Active Comparator|Astepro 0.15% Nasal Spray|Nasal Spray at a dosage of 1 spray per nostril twice daily
88825745|NCT01880840|Active Comparator|Astepro 0.1% Nasal Spray|Nasal Spray at a dosage of 1 spray per nostril twice daily
88825746|NCT03795753|Experimental|F2S Communicator|The F2S Communication System is a communication aid for use with a noninvasive ventilation (NIV) mask covering at least the mouth. It is a two-component system consisting of (1) a disposable, single patient use patch and signal cable and (2) a reusable communicator with power cable.The non-invasive aid for patients receiving BPAP/CPAP therapy delivers communication between the patient and medical personnel.
88825747|NCT03795753|Sham Comparator|Non-functioning Communicator|Non-functioning study communication device is used.
88825748|NCT01377441|Experimental|Ibuprofen|Eligible subjects will be randomized to one of the two treatment group in a 1:1 ratio to receive either IV ibuprofen or matching placebo.
88825749|NCT01377441|Placebo Comparator|Placebo/Saline solution|Eligible subjects will be randomized to one of the two treatment group in a 1:1 ratio to receive either IV ibuprofen or matching placebo
88825750|NCT01882868|Experimental|Aflibercept + FOLFIRI|Aflibercept 4 mg/kg intravenous (IV) infusion (1-2 hours) on Day 1 of Cycle 1 and every 2 weeks (q2w) thereafter, in combination with FOLFIRI regimen on Days 1-3 of Cycle 1 and q2w thereafter until disease progression (DP), unacceptable toxicity or participant's refusal. FOLFIRI regimen: IV infusions of levofolinate 200 mg/m^2 (2 hours) and irinotecan 180 mg/m^2 (90 minutes) simultaneously, followed by 5-FU 400 mg/m^2 IV bolus injection followed by continuous IV infusion of 5-FU (46 hours) at 2400 mg/m^2.
88825751|NCT01383447|Experimental|Treatment (entinostat and imatinib mesylate)|Patients receive entinostat PO daily on days 1, 8, 15, and 22 and imatinib mesylate PO twice daily on days 1-28 (days 4-28 of course 1). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88825752|NCT02300298|Experimental|Nintedanib plus Docetaxel|patients to receive backbone chemotherapy and nintedanib
88825753|NCT04332003|Active Comparator|RIC Treatment|Participants will receive active RIC treatment 3 times per week over the course of the study. Each session will last approximately 45 minutes
88825754|NCT04332003|No Intervention|SHAM Comparator|Participants will receive sham treatment 3 times per week over the course of the study. Each session will last approximately 45 minutes
88825755|NCT04749056|Experimental|EPAS screening (intervention)|"Patients undergo EPAS (electronic psycho-oncological adaptive screening), a tablet-based screening application consisting of three adaptive tests and one supportive care checklist. EPAS provides immediate feedback via a printed results page, which presents and interprets the level of distress and contains individualized recommendations for psychosocial services.~The results pages are printed by research assistants immediately after the screening on a mobile printer and given to the participants together with a brochure containing information about all psychosocial services available at the health care institution.~The treating physicians also receive a slightly modified results page, but are not expected to discuss these with the patient unless they are highly distressed.~Before and during the screening, patients are explained how to use the program by the research assistance and supported if needed.~The whole screening process takes about 30 minutes."
88825756|NCT04749056|No Intervention|Care as usual (control)|"Patients complete the assessment paper pencil. The same instruments as in the intervention condition are used except for the 3 adaptive tests (i.e., the supportive care checklist and the outcomes).~Neither patients nor physicians receive any feedback of the results. Psychosocial services are recommended by the physicians on their own discretion only, and patients are not handed out the information brochure."
88825757|NCT02300220|Active Comparator|Ciprofloxacin|500 mg, twice daily for 1 week (oral).
88825758|NCT02300220|Placebo Comparator|Placebo|one capsule, twice daily for 1 week.
88825759|NCT04748978|Experimental|symptomatic uterine fibroids|patients aged between 18 and 48 years with clinical and/or ultrasound diagnosis of uterine fibromatosis
88825760|NCT01379469|Active Comparator|Drug-Carbamazepine (Tegretol XR)|One arm receives Drug-Carbamazepine (Tegretol XR).All subjects have severe liver disease due to alpha-1-antitrypsin deficiency.
89000524|NCT02372578|Placebo Comparator|Placebo|ASP3662 placebo QD and pregabalin placebo TID for Weeks 1 - 7.
89000525|NCT02367313|Placebo Comparator|Placebo|Placebo
88825761|NCT01379469|Placebo Comparator|Drug-Carbamazepine (Tegretol XR) Placebo|One arm receives Carbamazepine (Tegretol-XR) placebo.All subjects have severe liver disease due to alpha-1-antitrypsin deficiency.
89356669|NCT03813329|Active Comparator|Acute Sodium Bicarbonate|3 doses of calcium carbonate (110 mg·kg-1, 130 mg·kg-1, 160 mg·kg-1), followed by one acute does (300 mg·kg-1) of sodium bicarbonate.
89356670|NCT03813329|Experimental|Modified Sodium Bicarbonate|4 progressively larger doses (110 mg·kg-1 - 200 mg·kg-1) of sodium bicarbonate
89356671|NCT03723343||Experimental: GP+IMRT|Test group: GP-induced chemotherapy (Gemcitabine 1000 mg/m2 d1, 8+Cisplatin 80 mg/m2 d1, once every 3 weeks, 4/6 course) + IMRT radiotherapy alone
89356672|NCT03723343||Active Comparator: TPF+IMRT|Control group: TPF-induced chemotherapy (Docetaxel: 75 mg/m2d1, Cisplatin 75 mg/m2, d1~d5, 5-fluorouracil 750 mg/m2/dd1~d5, 4/6 course) + IMRT radiotherapy alone
89356673|NCT03340480|Experimental|NVP-1402-1|NVP-1402 was administered once a day for 24 hours
89356674|NCT03340480|Experimental|NVP-1402-2|NVP-1402 was administered once a day for 24 hours
89356675|NCT03639415|Experimental|controlled-release oxycodone group|"Patients with moderate to severe pain accept CR oxycodone treatment and if any follow situations appears, then change the dose frequency from every 12 hours to every 8 hours or 6 hours.~Patients are satisfied with the pain control, but unable to tolerate nausea、vomit or dizziness, and can't get satisfactory pain control if reducing the CR oxycodone dose.~Patients are unsatisfied with the pain control, but can't increase the CR oxycodone dose because of intolerable nausea、vomit or dizziness."
89356676|NCT03334240|Experimental|CLS003|Digoxin and Furosemide topical formulation
89356677|NCT03334240|Placebo Comparator|Vehicle|Inactive vehicle
89356678|NCT03813485|Active Comparator|Dry needling in upper trapezius|"Patients receive dry needling in latent myofascial trigger point in upper trapezius. The needle was penetrated into the muscle fibers of the taut band and was moved upward and downward (fast in, fast out) in different directions with the aim to elicit LTRs"
89356679|NCT03813485|Experimental|Dry needling in lower trapezius|"Patients receive dry needling in latent myofascial trigger point in lower trapezius. The needle was penetrated into the muscle fibers of the taut band and was moved upward and downward (fast in, fast out) in different directions with the aim to elicit LTRs"
89356680|NCT03340402|Experimental|Accelerated Partial Breast Irradiation|"Accelerated partial breast irradiation using proton beam scanning will consist of;~5 daily treatments using custom prone patient immobilization, contrast-enhanced CT planning, and daily image guidance~Radiation therapy may be delivered with photons if proton treatments cannot be delivered~Dose will be prescribed such that the gross tumor (GTV) receives the prescription dose per institutional policy and standard of care~Daily target localization will also be confirmed using AlignRTTM"
89356681|NCT03721939|Experimental|FLEX Scoring Catheter plus DEB|The target lesion is prepared by the FLEX Scoring Catheter® with a 30° rotation between each passage. Angioplasty is performed during 3 minutes with paclitaxel-coated balloon(s) (PCB), all along the target lesion.
89356682|NCT01299623|Active Comparator|Evidential Group|Participants in this group will receive education about breast cancer prevention and specific information about African American women and breast cancer risk.
89356683|NCT01299623|Active Comparator|Non-Evidential Group|Participants in this group will receive general information about breast cancer prevention without anything specific to African American women.
89356684|NCT03334162|Experimental|Intervention group|Patients in the intervention group will perform a standardized, age-adjusted, specific playful sensorimotor training (SMT) program twice a week for 12 weeks in addition to usual care.
88825762|NCT01309581|Experimental|Ketamine|Participants receiving ECT for depression will be randomized 1:1 to either ketamine (experimental condition) or methohexital (standard anesthetic).
89356685|NCT03334162|No Intervention|Control group|Children in the control group will receive treatment as usual. The control group will be given the opportunity to participate in the intervention after study completion
89356686|NCT02916953|Experimental|Treatment|All subjects who meet the inclusion and exclusion criteria will receive the AGN1 Femoral Local Osteo-Enhancement Procedure (LOEP™) treatment
88825763|NCT01309581|Active Comparator|Methohexital|Participants receiving ECT for depression will be randomized 1:1 to either ketamine (experimental condition) or methohexital (standard anesthetic).
88825764|NCT02327130|Experimental|Exhaled Breath|Exhaled breath samples will be collected 6 times per day and blood samples will be collected once per day for 7 days. Subjects will be followed for an additional 3 days. We will use the Isomark Canary™ to determine the BDV of breath samples collected during this study. Analysis results of these samples will be combined with data that is abstracted from the subjects' medical records.
88825765|NCT02665221|Placebo Comparator|Control group|
88825766|NCT02665221|Experimental|Treatment group|
89000526|NCT02367313|Active Comparator|Vapendavir 264 mg|Vapendavir 264 mg and matching placebo
89000527|NCT02367313|Active Comparator|Vapendavir 528 mg|Vapendavir 528 mg and matching placebo
89000528|NCT02363491|Experimental|OPN-305|OPN-305
89000529|NCT00554359|Experimental|I5NP drug|
89356687|NCT02492542|Experimental|Electric Stimulation Treatment|Patients in the intervention group were treated with electric stimulation based on the routine clinical nursing.
89356688|NCT02492542|No Intervention|control group|patients in this group only received routine clinical nursing without electric stimulation
89356689|NCT03334084|Experimental|1|Scheme 1
89356690|NCT03334084|Experimental|2|Scheme 2
89356691|NCT03334084|Experimental|3|Scheme 3
89356692|NCT03340324|Experimental|One arm open label V-Endo recepients|This is single arm open label trial wherein active drug is V-Endo
89356693|NCT03520387|Experimental|Lumbar medial branch nerve radiofrequency ablation (LRFA)|Radiofrequency ablation of the dorsal rami of the lumbar spinal nerves
89356694|NCT03520387|Active Comparator|Simulated lumbar radiofrequency ablation (simulated LRFA)|Simulated radiofrequency ablation of the dorsal rami of the lumbar spinal nerves(simulated LRFA), with targeted steroid injections
89356695|NCT03520387|Experimental|AcTIVE-CBT|Activity-Tracker Informed Video-enabled Cognitive Behavioral Therapy (AcTIVE-CBT)
89356696|NCT03520387|Active Comparator|TBSCE|Telephone-based self-directed CBT and education (TBSCE)
89356697|NCT02492386|Experimental|Treatment|Bioabsorbable everolimus-eluting stent deployment
89356698|NCT03340168|Experimental|Bisphenol-S kinetics - oral exposure|Six female volunteers will be exposed orally acute at the reference dose level(0.1 mg / kg bw). For the administration, the product will be dissolved in ethanol (100 mg / ml equivalent to 10 mg / 100 μl) and the solution will be deposited on a cookie (deposit of about 70 μl of solution on a cookie for an individual of 70 kg) and the ethanol is allowed to evaporate before giving each volunteer, with the subsequent consumption of 100 ml of water.
89356699|NCT03340168|Experimental|Bisphenol-S kinetics - dermal exposure|volunteers will be exposed dermally acute at a dose of 1 mg / kg bw. The solution will be applied to an area of 40 cm2 of the forearm and delimited by the indelible marker. The BPS will be added in suspension in an aqueous solution containing 1% of carboxymethylcellulose and administered in the form of drops (70 .mu.l for an individual of 70 kg). The treated area will be left uncoated and unwashed for a period of 4 hours. After 4 hours, the application area will be washed with water and soap. This type of application is therefore similar to an exposure of the general population via the skin (manipulation of cash receipts).
89533820|NCT02908906|Experimental|JNJ-63723283|In Part 1, the first cohort will receive JNJ-63723283 at a starting dose of 80 milligram (mg), intravenous (IV) every 2 weeks. JNJ-63723283 doses will be escalated following a modified Continual Reassessment Method (mCRM). Multiple doses, dose administration routes (subcutaneous [SC] or IV), and dose schedules may be explored. In Part 2, participants will receive JNJ-63723283 at the recommended Phase 2 dose (RP2D) determined in Part 1. In Part 3, participants will receive JNJ-63723283 to evaluate pharmacokinetic (PK), pharmacodynamic (PD) and safety. In Part 4, participants will receive JNJ-63723283 at the dose level determined in Part 3. Additional cohorts may be enrolled in Part 4.
89533821|NCT02907398||ADHERE|This group will include 250 patients who have been implanted with the Inspire therapy system, enrolled in the ADHERE Registry, and are willing to complete a follow-up home sleep apnea test (HSAT).
89533822|NCT02907398||CONTROL|This group will include 100 patients who have been denied insurance coverage of the Inspire therapy system implant by their provider, have had no intervention (Inspire), and are willing to complete a HSAT and provide information about their OSA treatment after denial.
89533823|NCT02905318|Experimental|Palbociclib|125mg orally days 1-21 every 28 day cycle
88825767|NCT05289050|Placebo Comparator|sodium chloride (NaCl; 0.9%)|For patients in the control group,anaesthesia will be maintained with intravenous sodium chloride (NaCl; 0.9%) infusion.while anaesthesia will be maintained with propofol infusion(4-12mg/kg/h),analgesia will be maintained with remifentanil(0.15-0.3ug/kg/min).The sufentanil dose at induction and the rate of intraoperative remifentanil and propofol infusions were at the discretion of the anesthesiologist in charge of the patient. The assessment of the depth of anesthesia was based on clinical evaluation,placebo-controlled infusion will be stopped 15 minutes before the end of surgery.Propofol and remifentanil infusion will be stopped at the end of surgery.
88825768|NCT05289050|Experimental|S-ketamine|For patients in the s-ketamine group, anaesthesia will be maintained with s-ketamine infusion（0.3mg/kg/h),while anaesthesia will be maintained with propofol infusion(4-12mg/kg/h) ,analgesia will be maintained with remifentanil(0.15-0.3ug/kg/min).The sufentanil dose at induction and the rate of intraoperative remifentanil and propofol infusions were at the discretion of the anesthesiologist in charge of the patient.The assessment of the depth of anesthesia was based on clinical evaluation.S-ketamine infusion will be stopped 15 minutes before the end of surgery.Propofol and remifentanil infusion will be stopped at the end of surgery.
88825769|NCT00554294|No Intervention|Control group|Control schools had school curriculum as usual and did not receive environmental intervention.
88825770|NCT00554294|Experimental|Intervention group|Intervention schools received water dispensers, drinking bottles and lessons as intervention.
88825771|NCT03782181|Active Comparator|Whole body vibration plat|An arm type in which a group of patients with fibromyalgia receives an intervention based on the use of a whole body vibration platform, considered to be effective by clinical evidence.
88825772|NCT03782181|No Intervention|Control group|No intervention arm
88825773|NCT02987738|Experimental|dapagliflozin|two administrations of 10 mg dapagliflozin as tablet
89177263|NCT02552290|Active Comparator|Upper trapezius stretch|"The subjects will be in a supine position. A researcher will passively place the subject's head into flexion, side-bending away and rotation towards the side to be stretched until the muscle barrier is met. The researcher will depress the subject's shoulder with 100 Newtons of force measured with a Micro FET pressure dynamometer (Hoggan Health Industries, Salt Lake City, UT).) Once this pressure amount is achieved the stretch will be held for 30 seconds. This will be repeated two times on each side.~The subject will be asked to provide continuous feedback about the stretch felt and the degree of discomfort (if any) felt during the 30 second stretches."
88825774|NCT02987738|Placebo Comparator|Placebo Oral Tablets|two administrations identical to the experimental drug
88825775|NCT01292265|Experimental|CZP 200 mg|Certolizumab Pegol (CZP) subcutaneous (sc) injections of 400 mg at Weeks 0, 2 and 4, followed by 200 mg at Weeks 6, 8 and 10.
88825776|NCT01885910|Experimental|doxy + aczone|Subjects will start treatment with doxycycline 100mg once daily and Aczone 5% gel applied to the face twice daily and those who improve significantly are continued on Aczone gel alone to see if it can maintain therapeutic response
88825777|NCT02658357|Experimental|600 mg|Two, 300 mg Risperidone Implants
88825778|NCT02658357|Experimental|900 mg|Three, 300 mg Risperidone Implants
89533824|NCT02893267|Experimental|PNS + PT|The PNS+PT Group will receive peripheral nerve stimulation treatment (which will produce muscle contraction) for three weeks (6 hours daily) with an Intramuscular Electrical Stimulator following a one week electrode stabilization period, and also receive eight 60-minute sessions of outpatient physical therapy focused on shoulder pain over the same four week period.
89533825|NCT02893267|Active Comparator|PNS + sham-PT|The PNS + sham-PT Group will receive peripheral nerve stimulation treatment (which will produce muscle contraction) for three weeks (6 hours daily) with an Intramuscular Electrical Stimulator following a one week electrode stabilization period, and also receive eight 60-minute sessions of sham outpatient physical therapy not focused on shoulder pain over the same four week period.
88825779|NCT02988908|Experimental|Drug: Donepezil|"Participants received Donepezil as 5mg pills per day for 6 weeks, then 10 mg per day for the remainder of the 52-week trial.~Participants also received 2 weeks of memory training at weeks 13-14"
88825780|NCT02988908|Placebo Comparator|Placebo (Control)|"Participants received placebo as 5mg pills per day for 6 weeks, then 10 mg per day for the remainder of the 52-week trial.~Participants also received 2 weeks of memory training at weeks 13-14"
88825781|NCT05239208|Experimental|Oral Nutritional Supplement (ONS) Group|Two servings per day in addition to dietary counseling
88825782|NCT05239208|Active Comparator|Control Group|Dietary counseling
88825783|NCT02326272|Experimental|CZP 200 mg|"CZP 400 mg at Weeks 0, 2, 4, followed by CZP 200 mg every two weeks (Q2W) from Week 6 to Week 14.~Treatment received from Week 16-48 is based on initial treatment and response to treatment:~PASI50 responders at Week 16 continue to receive CZP 200 mg Q2W.~PASI50 non-responders at Week 16 will be removed from blinded study medication and escape to unblinded CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study.~PASI50 non-responders at Week 32 or a later time point will be withdrawn from the study.~Subjects who complete the Maintenance Period (with PASI50 response at Week 48) enter the Open-label Extension Period on CZP 200 mg Q2W.~Week 48 completers in the escape arm continue to receive CZP 400 mg Q2W or may switch to CZP 200 mg Q2W.~Depending on PASI50 or PASI75 responses at Week 60 or a later time point, subjects may switch to CZP 400 mg Q2W or withdraw from the study."
88825784|NCT02326272|Experimental|CZP 400 mg|"CZP 400 mg every two weeks (Q2W) through Week 14.~Treatment received from Week 16 - 48 is based on initial treatment and response to treatment:~PASI50 responders at Week 16 continue to receive CZP 400 mg Q2W.~PASI50 non-responders at Week 16 will be removed from blinded study medication and escape to CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study.~PASI50 non-responders at Week 32 or a later time point will be withdrawn from the study.~Subjects who complete the Maintenance Period (with PASI50 response at Week 48) enter the Open-label Extension (OLE) Period on CZP 200 mg Q2W. Week 48 completers in the escape arm continue to receive CZP 400 mg Q2W or may switch to CZP 200 mg Q2W.~Subjects who achieve a PASI75 response during the OLE Phase may switch to CZP 200 mg Q2W."
88825785|NCT02326272|Placebo Comparator|Placebo|"Placebo subcutaneous (sc) injection every two weeks (Q2W).~Treatment received from Week 16 - 48 is based on initial treatment and response to treatment:~PASI50 responders at Week 16, who do not achieve a PASI75 response at Week 16 receive CZP 400 mg at Weeks 16, 18 and 20 (loading doses) followed by CZP 200 mg Q2W starting at Week 22.~PASI75 responders at Week 16 continue to receive Placebo.~PASI50 non-responders at Week 16 will be removed from blinded study medication and escape to CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study.~PASI50 non-responders at Week 32 or a later time point will be withdrawn from the study.~Subjects who complete the Maintenance Period (with PASI50 response at Week 48) enter the Open-label Extension Period on CZP 200 mg Q2W. Week 48 completers in the escape arm continue to receive CZP 400 mg Q2W or may switch to CZP 200 mg Q2W."
88825786|NCT02279108|Experimental|double detection Indocyanine + isotope|intradermal injection of 2.5 milligrams of indocyanine green and 20 MBq of technetium 99 before breast surgery
88825787|NCT02279108|Active Comparator|isotope detection alone|intradermal injection of 20 MBq of technetium 99 before breast surgery
88825788|NCT04892862|Active Comparator|dorsal surgical approach|dorsal surgical approach
88825789|NCT04892862|Active Comparator|volar surgical approach|volar surgical approach
88825790|NCT04263818|Experimental|Motions during colonoscopy|Recording of endoscopist and endoscope motions right after the endoscopic exam the patient came for
88825791|NCT01887470|Experimental|Full dose preparation; AM colonoscopy|Four hourly doses of lactulose for oral solution are taken in the evening. The colonoscopy is initiated prior to noon on the following day.
88825792|NCT01887470|Experimental|Full dose preparation; PM colonoscopy|Four hourly doses of lactulose for oral solution are taken in the evening. The colonoscopy is initiated after noon on the following day.
88825793|NCT01887470|Experimental|Split dose preparation; AM colonoscopy|Three hourly doses of lactulose for oral solution are taken in the evening prior to the day of the colonoscopy procedure; one dose is taken on the morning of the procedure. The colonoscopy is initiated prior to noon.
88825794|NCT01887470|Experimental|Split dose preparation; PM colonoscopy|Three hourly doses of lactulose for oral solution are taken in the evening prior to the day of the colonoscopy procedure; one dose is taken on the morning of the procedure. The colonoscopy is initiated after noon.
88825795|NCT02325414|Experimental|Zol|Intravenous infusion of zoledronic acid (zol) 5 mg at baseline.
88825796|NCT02325414|Experimental|Placebo|Intravenous infusion of placebo at baseline.
89000530|NCT00554359|Placebo Comparator|Placebo|
89533826|NCT02893267|Active Comparator|sham-PNS + PT|The sham-PNS + PT Group will receive sham peripheral nerve stimulation treatment (which will not produce muscle contraction) for three weeks (6 hours daily) with an Intramuscular Electrical Stimulator following a one week electrode stabilization period, and also receive eight 60-minute sessions of outpatient physical therapy focused on shoulder pain over the same four week period.
89533827|NCT02891811|Experimental|Induction Arm A|"Carfilzomib + Thalidomide + Dexamethasone (KTd) for 9 cycles (day 1-28) Followed by second randomisation: maintenance arm with carfilzomib monotherapy versus observation only arm"
89533828|NCT02891811|Active Comparator|Induction Arm B|"Carfilzomib + Lenalidomide + Dexamethasone (KRd) for 9 cycles (day 1-28) Followed by second randomisation: maintenance arm with carfilzomib monotherapy versus observation only arm"
89533829|NCT02854033||Cognitively Normal (CN)|"135-500 newly enrolled participants with no apparent memory problems, and 295-300 cognitively normal participants followed from the ADNI2 study.~Currently recruiting non-Caucasian participants only for the normal cognition group."
89000531|NCT00554398|Experimental|A|MK-0518 400mg twice a day
89000532|NCT00554398|No Intervention|B|No intervention
89000533|NCT00204867||A|In vivo surveillance of 6-9 mm polyps detected at CTC
89000534|NCT02349022|Experimental|[89Zr]Df-IAB2M|A single intravenous infusion of 2.5 mCi of [89Zr]Df-IAB2M in a mass dose of 10 mg.
89000535|NCT02343445|Experimental|P-1037 in Hypertonic Saline (HS)|P-1037 Solution for Inhalation, 85 μg twice daily (BID) (28.3 μg/mL) in hypertonic saline (4.2% saline) BID
89000536|NCT02343445|Experimental|P-1037 in Saline|P-1037 Solution for Inhalation, 85 μg BID (28.3 μg/mL) in 0.17% saline BID
89000537|NCT02343445|Placebo Comparator|Saline|Placebo (0.17% saline) BID
89000538|NCT02343445|Sham Comparator|Hypertonic Saline|Hypertonic saline (4.2% saline) BID
89000539|NCT02338648|Experimental|SUN-131 1.5% TDS|Subjects will be randomly assigned to receive SUN-131 1.5% TDS for the affected eye. All patches will be worn for 16±4 hours each day for 21 days.
89000540|NCT02338648|Placebo Comparator|Placebo TDS|Placebo Patch for Blinding Purposes
89000541|NCT02336698|Placebo Comparator|Placebo|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks).
89000542|NCT02336698|Experimental|Fulranumab 1 mg|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks).
89000543|NCT02336698|Experimental|Fulranumab 3 mg|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks).
89533830|NCT02854033||Mild Cognitive Impairment (MCI)|150 - 515 newly enrolled participants with mild cognitive impairment (MCI), and 275-320 MCI participants followed from the ADNI2 study.
89533831|NCT02854033||Mild Alzheimer's Disease (AD) dementia|85 - 185 newly enrolled participants with mild Alzheimer's disease (AD) dementia, and 130 - 150 mild AD participants followed from the ADNI2 study.
89000544|NCT02335918|Experimental|Varlilumab and Nivolumab|
89000545|NCT00200109|Other|Group 1|See protocol
89000546|NCT00200109|Other|Group 2|See protocol
89000547|NCT00200109|Other|Group 3|See protocol
89000548|NCT00200109|Other|Group 4|See protocol
89000549|NCT04679155|Experimental|eTRE|participants allocated to this group will be required to eat only between 0800h and 1600h.
89000550|NCT04679155|Active Comparator|lTRE|participants allocated to this group will be required to eat only between 1200h and 2000h
89000551|NCT04678609|Experimental|Open kinetic chain exercise|In the OKC exercise group, participants will be taught by a physiotherapist about open kinetic chain exercises. Then, they will do the exercises at their home for eight weeks, with three session per week. The physiotherapist will contact the participants to monitor their adherence to the intervention. A diary is also provided to monitor their progress, pain level and any adverse events related to the intervention.
89000552|NCT04678609|Experimental|Closed kinetic chain exercise|In the OKC exercise group, participants will be taught by a physiotherapist about open kinetic chain exercises. Then, they will do the exercises at their home for eight weeks, with three session per week. The physiotherapist will contact the participants to monitor their adherence to the intervention. A diary is also provided to monitor their progress, pain level and any adverse events related to the intervention.
89000553|NCT04678609|No Intervention|Control|The untreated control group will receive patient's usual care of local government hospital which includes information about clinical manifestations, risk factors, diagnosis, treatment and nursing care for knee OA. Control group did not receive any home exercises guidance.
89000554|NCT04678375||Retinal diseases diagnosed by artificial intelligence algorithm|Retinal diseases diagnosed by artificial intelligence algorithm
88825797|NCT01888484|Experimental|Octanorm 16.5%|octanorm 16.5%, human normal immunoglobulin for subcutaneous (SC) administration.
88825798|NCT02349048|Experimental|Arm A|Chronic hepatitis C virus (HCV) genotype 1 infected participants with early stages of liver fibrosis, will receive Simeprevir (SMV) 150 milligram (mg), Daclatasvir (DCV) 60 mg and Sofosbuvir (SOF) 400 mg once daily for 6 weeks.
88825799|NCT02349048|Experimental|Arm B|Chronic HCV genotype 1 infected participants with cirrhosis, will receive SMV 150 mg, DCV 60 mg and SOF 400 mg once daily for 8 weeks.
88825800|NCT01280643|Experimental|Arm A|Patients receive FOLFIRI (FOLolinic acid (leucovorin) Fluorouracil (5-FU) IRInotecan (irinotecan)) chemotherapy comprising fluorouracil intravenously (IV) over 46 hours continuously, leucovorin calcium IV over 2 hours, and irinotecan hydrochloride IV over 90 minutes on days 1 and 15. Patients also receive cetuximab IV over 60-120 minutes on days 1 and 8.
88825801|NCT01280643|Experimental|Arm B|Patients receive FOLFOX (FOL- Folinic acid (leucovorin) F - Fluorouracil (5-FU) OX - Oxaliplatin (Eloxatin)) chemotherapy comprising fluorouracil IV over 46 hours continuously on day 1 and leucovorin calcium IV over 2 hours and oxaliplatin IV over 2 hours on days 1 and 15. Patients also receive cetuximab IV over 60-120 minutes on days 1 and 8.
88825802|NCT01280643|Experimental|Arm C|Patients receive FOLFIRI chemotherapy as in Arm A and bevacizumab IV over 30-90 minutes on days 1 and 15.
88825803|NCT01280643|Experimental|Arm D|Patients receive FOLFOX chemotherapy as in Arm B and bevacizumab IV over 30-90 minutes on days 1 and 15.
88825804|NCT01280643|Experimental|Arm E|Patients receive CapeIRI (Capecitabine and Irinotecan) chemotherapy comprising capecitabine orally (PO) twice daily (BID) on days 1-14 and irinotecan hydrochloride IV over 90 minutes on days 1 and 8. Patients also receive cetuximab IV over 60-120 minutes on days 1 and 8.
88825805|NCT01280643|Experimental|Arm F|Patients receive CapeOX (capecitabine (Xeloda) and oxaliplatin (Eloxatin)) chemotherapy comprising capecitabine PO BID on days 1-14 and oxaliplatin IV over 2 hours on day 1. Patients also receive cetuximab IV over 60-120 minutes on days 1 and 8.
88825806|NCT01280643|Experimental|ARM G|Patients receive CapeIRI chemotherapy as in Arm E and bevacizumab IV over 30-90 minutes on day 1.
88825807|NCT01280643|Experimental|Arm H|Patients receive CapeOX chemotherapy as in Arm F and bevacizumab IV over 30-90 minutes on day 1.
88825808|NCT01280643|Experimental|Arm I|Patients receive treatment as in Arm D.
89356700|NCT03170232|Experimental|Subjects receiving danirixin|Following screening and assessment of rescue medication use, subjects will receive one tablet of danirixin 35 mg (as hydrobromide hemihydrate salt) orally twice daily with food for 52 weeks during treatment period. Study treatment will be dispensed to subjects at the study visits.
89356701|NCT03170232|Placebo Comparator|Subjects receiving placebo|Following screening and assessment of rescue medication use, subjects will receive one tablet of placebo 35 mg orally twice daily with food for 52 weeks during treatment period. Placebo will be dispensed to subjects at the study visits.
88825809|NCT01888952|Experimental|Roflumilast and Prednisone|"Roflumilast 500 mcg will be administered orally daily for 21 consecutive days (a 21-day cycle).~In Cycle 1, prednisone 60 mg/m2 up to a maximum of 100 mg oral (PO) daily will be taken on Days 8 through 14 at the same time as roflumilast.~In Cycle 2 and subsequent cycles, prednisone 60 mg/m2 PO up to a maximum of 100 mg daily will be taken on Days 1 through 7 at the same time as roflumilast."
88825810|NCT02299206|Experimental|CeraVe Baby Diaper Rash Cream|Healthy 3-18 months old infants with mild to moderate diaper dermatitis.
88825811|NCT02299206|Experimental|Desitin Maximum Strength Original Paste|Healthy 3-18 months old infants with mild to moderate diaper dermatitis.
88825812|NCT01892306|Experimental|Treatment as usual plus UP CBT|Existing psychiatrist-administered psychopharmacotherapy plus weekly transdiagnostic CBT
88825813|NCT01892306|Active Comparator|Treatment as usual|Existing psychiatrist-administered psychopharmacotherapy
88825814|NCT02640573|Experimental|Hydroxurea|Initiate hydroxyurea at 10 mg/kg daily and escalate hydroxyurea dose by 5 mg/kg/day every 8 weeks up to a maximum dose of 35 mg/kg/day if blood counts meet escalation criteria.
88825815|NCT02298192|Experimental|Once weekly titration|
88825816|NCT02298192|Experimental|Twice weekly titration|
88825817|NCT01893632|Experimental|Gabapentin|All study medication will be over-capsulated with riboflavin to assess compliance using quantitative fluoroscopy. All participants will take three capsules three times per day throughout the study period. During week 1, GBP will be titrated over a five-day period to the dose target (GBP 1200 mg three times daily) or the maximum tolerated dose. Medication dosing will continue at GBP 1200 mg three times daily or placebo through the end of the study period (week 12). Dose reductions will be made for tolerability if necessary.
88825818|NCT01893632|Placebo Comparator|Placebo|Capsules filled with riboflavin.
88825819|NCT01272141|Experimental|Arm A: Lapatinib plus Everolimus|
89000555|NCT04678531|Experimental|Swabs containing tea tree oil and chamomile oil|The swabs will be applied on the eyelids twice a day for 8 weeks followed by a discontinuation period of 4 weeks.
89000556|NCT04678531|Active Comparator|Baby shampoo|Baby shampoo will be applied on the eyelids twice a day for 8 weeks followed by a discontinuation period of 4 weeks
89356702|NCT01299701|Experimental|ASA404|
89356703|NCT03340090|Experimental|Intervention|First group of patients will undergo standard CABG procedure in CPB. In addition, two pieces of Hemopatch will be applied in one patient. One piece to improve hemostasis in the bed of left internal mammary artery (LIMA) harvesting and second piece of Hemopatch will be placed beneath the sternum.
89356704|NCT03340090|No Intervention|Control|Second group of patients will undergo standard CABG procedure in CPB only.
88825820|NCT01270581|Experimental|High Flow Nasal Cannula|Unlike the nasal prongs for NCPAP (which fit tightly in the nares), the nasal cannula for HFNC have smaller, loose-fitting prong. With HFNC, positive airway pressure is achieved by high gas flow through the cannula into the external nares which provide resistance to expiration and facilitate inspiration. The distending pressure is determined by the size and structure of the nasal cannula, gas flow rate, and the neonate's airway anatomy 4,5,7. Newborns randomized to HFNC will be started on a flow rate of 4L/min and supplemental oxygen will be provided to maintain oxygen saturations between 88-93% (experimental group). Once initiated, the gas flow rate will be titrated as needed by the attending neonatologist to ameliorate signs of respiratory distress to a maximum flow rate of 6L/min. The nasal cannula size (0.2 cm or 0.3 mm outer diameter) will determined by the caliber of the subject's nares).
88825821|NCT01270581|Active Comparator|Control Group- Bubble Nasal CPAP|NCPAP provides continuous distending airway pressure during inspiration and expiration via nasal prongs; this has been shown to increase lung volume by increasing alveolar size, recruiting collapsed alveoli, and preventing atelectasis. Improved lung volumes decrease V/Q mismatch and improve the clinical course of neonates with RDS, and as such, early NCPAP use often avoids the need for intubation and mechanical ventilation. Newborns receiving bubble NCPAP will be placed on a PEEP 5cm H2O, and supplemental oxygen will be provided to maintain oxygen saturation between 88-93% (standard of care group) as is standard practice. The size of the nasal prongs used will be based on the subject's weight as per the manufacturer instructions.
88825822|NCT01894178|Active Comparator|Parker Flex-Tip® Tracheal Tube|Intubation of obese patients with the Parker Flex-Tip® Tracheal Tube
88825823|NCT01894178|Active Comparator|Portex® Tracheal Tube|Intubation of obese patients with the Portex® Tracheal Tube
88825824|NCT03836846|Placebo Comparator|Treatment As Usual|Standard of care as usual with follow-up at 1-, 3-, and 6-months
88825825|NCT03836846|Active Comparator|Intervention with CBT Mobile App|Treatment as usual with additional treatment using cognitive behavioral therapy (CBT) mobile apps (ie What's Up?)
88825826|NCT02624739|Experimental|Intervention|Reassure Non-Contact Respiration Monitor: Respiration parameters transmitted by the Reassure device will be evaluated daily by the study team and participants will be contacted for further evaluation if a change in respiration patterns is noted. Participants will continue with standard of care heart failure treatment.
88825827|NCT02624739|Active Comparator|Control|Reassure Non-Contact Respiration Monitor: Respiration parameters will be transmitted and stored, but there will be no active evaluation of respiration patterns. Participants will continue with standard of care heart failure treatment.
88825828|NCT01895036|Experimental|Naltrexone|PO naltrexone titration on a mixed inpatient/outpatient basis, followed by administration of Vivitrol four days following the 1st dose of naltrexone
88825829|NCT03781479|Experimental|Amifampridine Phosphate - Placebo|Oral tablets, 30 to 80 mg per day in divided doses 3 to 4 times a day for 4 weeks
88825830|NCT03781479|Experimental|Placebo - Amifampridine Phosphate|Oral tablets, 30 to 80 mg per day in divided doses 3 to 4 times a day for 4 weeks
88825831|NCT01223001|Active Comparator|Duloxetine|Duloxetine 30 mg. PO daily to 120mg. PO daily for nine months in patients who have suffered a traumatic brain injury at least six months previously.
88825832|NCT01223001|Placebo Comparator|Sugar pill|Sugar pills 30 mg. PO daily to 120mg. PO daily for nine months in patients who have suffered a traumatic brain injury at least six months previously.
88825833|NCT01895972|Experimental|Latanoprostene Bunod|Latanoprostene bunod 0.024% instilled into the eye once daily (QD) over a 1-year treatment period.
88825834|NCT03779997|Experimental|Video-based DOT Application|
88825835|NCT03779997|No Intervention|Treatment as Usual (TAU)|
88825836|NCT02988752|Experimental|Electronic Mobile Device|Use an Electronic Low Cost Mobile Device To Determine C/D Ratio And Compare Results With Gold Standard Optical Coherence Tomography Results. The equipment needs mydriatic conditions and does not touch the patient's eye. The equipment uses a panoptik and a camera to access eye fundus.
88825837|NCT02988752|Active Comparator|Optical Coherence Tomography|Device considered as gold standard to determine c/d ratio. Needs mydriatic conditions.
88825838|NCT01896206|Experimental|CNAP monitor|Subjects undergoing bariatric surgery and monitored using the CNAP monitor.
88825839|NCT02608905|Experimental|Dapagliflozin|Dapagliflozin 5 mg daily by mouth for 2 weeks followed by 10 mg by mouth daily for 10 weeks
88825840|NCT02608905|Placebo Comparator|Placebo|Placebo tablets by mouth daily for 12 weeks
88825841|NCT01213329|Experimental|Phase I: Alemtuzumab|During Phase I Portion: Each kidney transplant recipient received one 30mg dose (IV push)of Alemtuzmab in the operating room per Standard of Care.
88825842|NCT01897766||Somatropin|Patients administered Somatropin.
88825843|NCT02528097|Placebo Comparator|Active Comparator Standard Care|albumin administered day 1 (1.5g/kg) and day 3 (1.0g/kg)
88825844|NCT02528097|Experimental|Experimental|Albumin administered per standard care on day 1 (1.5g/kg). Second dose administered on day 2 only to those individuals with renal insufficiency and risk for renal failure (Cr > 1.0 or BUN or Cr > baseline). If albumin not administered at 48 hours, BUN and Cr will be monitored daily for 72 hours and will be administered if Cr > 1.0 or BUN or Cr are above baseline.
88825845|NCT02520297|Experimental|TRV130|Drug: TRV130
88825846|NCT03024320|Experimental|M2M|A theory-driven eHealth platform and innovative physical activity program referred to as movement-to-music (M2M), delivered customized and for the home-based for adults with physical disability.
88825847|NCT03024320|Experimental|M2Mplus|A theory-driven eHealth platform and innovative physical activity program referred to as movement-to-music (M2M), delivered customized and for the home-based for adults with physical disability. This arm also includes a social networking platform where participants will be able to interact and encourage one another through the program, as well as group-based tele-coaching session.
88825848|NCT03024320|Active Comparator|Attention Control|Participants receive health-focused articles and infographics throughout 48 weeks and receive a Fitbit.
88825849|NCT02280408|Experimental|3x10^6 plaque-forming units (pfu) Vaccine Cohort|Participants will receive a 1-mL intramuscular injection of V920 3x10^6 pfu in the deltoid on Day 0 and Day 28.
89533832|NCT02830724|Experimental|1/Phase I|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + escalating doses of anti-hCD70 CAR transduced PBL + high-dose aldesleukin
89533833|NCT02830724|Experimental|2/Phase II|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + MTD of anti-hCD70 CAR transduced PBL + high-dose aldesleukin
89533834|NCT02812420|Experimental|Treatment (tremelimumab, durvalumab)|Patients receive tremelimumab IV over 1 hour and durvalumab IV over 1 hour on day 1 of weeks 1 and 4. Beginning 4-6 weeks after the last infusion, patients undergo cystectomy with pelvic lymph node dissection surgery.
88825850|NCT02280408|Experimental|2x10^7 pfu Vaccine Cohort|Participants will receive a 1-mL intramuscular injection of V920 2x10^7 pfu in the deltoid on Day 0 and Day 28.
88825851|NCT02280408|Experimental|1x10^8 pfu Vaccine Cohort|Participants will receive a 1-mL intramuscular injection of V920 1x10^8 pfu in the deltoid on Day 0 and Day 28.
88825852|NCT02280408|Placebo Comparator|Placebo Cohort|Participants will receive a 1-mL intramuscular injection of placebo in the deltoid on Day 0 and Day 28.
88825853|NCT01189071|Active Comparator|Darifenacin|3 days of preoperative darifenacin anticholinergic medication
88825854|NCT01189071|No Intervention|no pill|The control group will have the standard of care which is no preoperative anticholinegic medication.
88825855|NCT03024164||Young adult stroke patients|Young adult (18-45 years old) patients with confirmed first-ever acute ischemic stroke
88825856|NCT03770091|Experimental|Foam and Compression Wrap|Patients will use Theraworx foam and a compression wrap
88825857|NCT03770091|Placebo Comparator|Placebo Foam and Compression Wrap|Patients will use placebo foam and a compression wrap
88825858|NCT03770091|Experimental|Foam alone|Patients will use Theraworx foam without compression wrap
88825859|NCT02515851|Active Comparator|Active Group|Group that receives actual liposomal bupivacaine injections
88825860|NCT02515851|Placebo Comparator|Placebo Group|Group that receives placebo injections
88825861|NCT02282930|Experimental|ACTH Gel|Injected does of 80 units subcutaneously twice weekly for 6 months.
88825862|NCT01151553|Other|Patients with CHF with CRT Therapy|Patients with CHF with CRT Therapy
88825863|NCT02492295|Experimental|Propofol|"Propofol is administered intravenously as a 0.5mg/kg (at a concentration of 10mg/mL, rounded to the nearest 0.5mL) initial bolus, followed by repeat 0.25mg/kg boluses (same rounding) every three to five minutes as needed to maintain RASS target -2 (light sedation - awakens to voice <10 seconds) to RASS target of -3 (moderate sedation - movement or eye opening without eye contact) for 15 minutes."
88825864|NCT02280122||gen. mod. to sev. chronic periodontitis|"Sites with probing pocket depths (PPD) ≥ 3.5 mm~Attachment loss (PAL-V) ≥ 3 mm > 30% of sites~no Intervention provided"
88825865|NCT02280122||periodontally healthy|"PPD ≤ 3 mm~PAL-V ≤ 2 mm at < 30% of sites~BOP < 20%~No radiographically detectable bone loss: distance cemento-enamel junction to provided~no Intervention but aMMP-8 test"
89177264|NCT02552290|Other|Control group|Subjects assigned to the control group will receive no intervention. They will stay behind the curtained research area for approximately 3 minutes in a seated position.
89177265|NCT04111848|Experimental|ketamine group : group (k)|-Ketamine group (group K): will receive a bolus of 0.5 mg/kg ketamine during induction of anaesthesia diluted in 100 ml normal saline, followed by ketamine infusion 0.12 mg/kg/hour continued till 24 hours after surgery. The infusion pump concentration will be 0.6mg/ml and the rate of infusion will be 0.2 ml/kg/hour
89177266|NCT04111848|Experimental|ketamine and magnesium group: group (KM)|- Ketamine and magnesium group (group KM): will receive a bolus of 0.5 mg/kg ketamine added to 50mg/kg magnesium sulfate diluted in 100 ml normal saline over 30 minutes after induction of anaesthesia, followed by ketamine infusion 0.12 mg/kg/hour added to 8mg/kg/hour of magnesium sulfate continued till 24 hours after surgery. Each ml of the administered infusion will contain 0.6mg ketamine and 40mg magnesium and the rate of infusion will be 0.2 ml/kg/hour.
89177267|NCT00457015|Experimental|DX-88 (ecallantide)|DX-88 (ecallantide) 30 mg given as three 10 mg/mL subcutaneous injections.
89177268|NCT00457015|Placebo Comparator|Placebo|Placebo, Phosphate Buffer Saline (PBS), pH 7.0 given as 3 subcutaneous injections.
89177269|NCT00654940|Active Comparator|A|
89177270|NCT00654940|Placebo Comparator|B|
89177271|NCT00588666|Experimental|Bevacizumab, Carboplatin, Gemcitabine|Patients will initially receive bevacizumab 10 mg/kg followed by a 2 week treatment-free interval. Treatment will then begin with combination therapy. Gemcitabine 1000 mg/m2 will be administered intravenously on day 1 and 8 and carboplatin AUC 4.5 on day 1 with treatment recycled every 21 days. Bevacizumab will be administered at a dose of 15 mg/kg on day 1 of each 21-day cycle. Restaging evaluations will be performed after every 3 cycles of treatment (approximately 9 weeks). Patients will receive a total of 6 cycles of chemotherapy unless disease progression or unacceptable toxicity occurs. Patients who achieve stable disease, a partial response, or a complete response after completion of 6 cycles, will be eligible to continue bevacizumab at the same dose and schedule until disease progression for a maximum of 18 additional doses.
89177272|NCT03835351|Other|Intraoperative urinary catheter|After induction of general anesthesia, a standard catheterization kit available at the institution where the surgery is being performed will be used to place the urinary catheter using standard sterile technique.
89177273|NCT03835351|No Intervention|No intraoperative urinary catheter|No intraoperative urinary catheter will be used during the case
89177274|NCT00807430|Experimental|1|24 patients receiving active treatment
89177275|NCT00807430|Placebo Comparator|2|Placebo treatment
89177276|NCT00805558|Experimental|Moxifloxacin|Scaling and root planing plus 400 mg moxifloxacin once daily for 7 days.
89177277|NCT00805558|Active Comparator|Ciprofloxacin plus metronidazole|Scaling and root planing plus ciprofloxacin 1000 mg once daily for 7 days and metronidazole 500 mg twice daily for 7 days
89177278|NCT01019785|Active Comparator|High dose Vitamin D|
89177279|NCT01019785|Sham Comparator|Low dose Vitamin D|
89177280|NCT02604186|Experimental|Botulinum Toxin Injections|Botulinum Toxin injections at adductors and triceps surae
89177281|NCT02604186|Placebo Comparator|Placebo Injections|Placebo injections at adductors and triceps surae
89356707|NCT03333850|Experimental|Visual feedback of physical activity|Participants in the exposure cohort will receive usual hospital care and continuous measurement of physical activity by sensors collecting physical activity level during hospitalisation AND a monitor placed at their bedside that displays information about their physical activity level, in terms of time spent bedridden, sitting, standing and walking. This information will be visible to the health personnel, the patients and their relatives.
89356708|NCT03333850|Active Comparator|No feedback of physical activity|The participants in the non-exposure cohort will receive usual hospital care and continuous measurement of physical activity by sensors collecting physical activity level during hospitalisation. No visual feedback is provided.
89356709|NCT01299779|Active Comparator|PEG-ELS|
89356710|NCT01299779|Active Comparator|PEG-SD|
89356711|NCT02492620|Active Comparator|Ferric Citrate|Ferric citrate (FC) will be supplied as tablets containing 210mg of ferric iron (as 1g ferric citrate) to those subjects randomized to FC. These participants will be initiated on study drug with a fixed dose of FC beginning with 2 tablet per meal.
89356712|NCT02492620|No Intervention|Standard of Care (SOC)|Participants may receive open-label, non-FC phosphate binders at the discretion of their treating physician. During the Dialysis Period, dose of phosphate binders, use of ESA, intravenous iron and blood transfusions will be at the discretion of the primary treating nephrologist. Participants assigned to the SOC treatment arm may not receive FC at any point during the study.
89356713|NCT02426034|Experimental|Treatment group|Apatinib Tablets
89356714|NCT03813251|Experimental|Assigned Interventions|ForConti Contix Fecal Incontinence Management System (FIMS)
88825866|NCT02296476|Experimental|Birabresib 80 mg|Participants received 80 mg of oral birabresib administered once daily (in a fasted state) every day in a 28-day cycle for up to 6 cycles.
88825867|NCT02296476|Experimental|Birabresib 120 mg|Participants received 120 mg of oral birabresib administered once daily (in a fasted state) every day in a 28-day cycle for up to 6 cycles.
89356715|NCT03519919|Experimental|Somofilcon A multifocal lens|Habitual wearers of multifocal contact lenses will be refit to somofilcon A multifocal lens and provide a subjective assessment.
89356716|NCT03340012|Experimental|GTR + radiation-sterilize allogenic bone graft (TEST)|The surgical procedure will be performed in line with minimally invasive surgical technique by Cortellini and Tonetti (2007). The intrabony defects will be debrided and the roots will be planned. The required quantity of radiation-sterilized allogenic bone graft will be delivered into intrabony defects. Subsequently, a trimmed collagen membrane will be placed over graft. The flaps will be sutured with non-absorbable modified internal mattress sutures.
89356717|NCT03340012|Active Comparator|GTR + xenogenic graft (CONTROL)|The surgical procedure will be performed in line with minimally invasive surgical technique by Cortellini and Tonetti (2007). The intrabony defects will be debrided and the roots will be planned. The required quantity of xenogenic graft will be delivered into intrabony defects. Subsequently, a trimmed collagen membrane will be placed over graft. The flaps will be sutured with non-absorbable modified internal mattress sutures.
88825868|NCT02296476|Experimental|Birabresib 160 mg|Participants received 160 mg of oral birabresib administered once daily (in a fasted state) every day in a 28-day cycle for up to 6 cycles.
88825869|NCT02987504|Experimental|Samalizumab 10, 15, 20 milligrams (mg)/kilogram (kg) Dose|"Participants received escalating doses of 10, 15, and 20 mg/kg of samalizumab IV every 21 days. Enrollment at each dose level and safety assessments were completed prior to enrolling at the next dose level; intra-participant dose escalation was not allowed.~3 participants were enrolled into a dose cohort: If 0/3 participants developed dose limiting toxicities (DLT) within Cycle 1, enrollment began at the next higher dose to a maximum of 20 mg/kg. If 1/3 participants developed a DLT, the dose cohort was expanded to include 3 new participants. If 0/3 new participants developed a DLT within Cycle 1, enrolment began at the next higher dose level. If ≥1 of 3 new participants developed a DLT within Cycle 1, dose-escalation was terminated, and the dose level 5 mg/kg below the current dose was considered the MTD. If ≥2 of 3 participants developed DLTs within Cycle 1, dose-escalation was terminated, and the dose level 5 mg/kg below the current dose was considered the MTD."
89356718|NCT01301417||ColonRing™|Adult Patients who underwent a laparoscopic or open colorectal resection with the creation of an anastomosis using the ColonRing™ in routine clinical practice
89356719|NCT03333772|Experimental|REAL-T Intervention|The current feasibility study will evaluate the feasibility of implementing the REAL-T RCT by enrolling 10 participants who are 18-30 years of age, conducting the REAL-T intervention with all participants over a 3-month period, evaluating pre-to-post changes in their health and quality of life, and assessing the process of implementing the study (feasibility and participant satisfaction).
89356720|NCT03813173|Active Comparator|central cervical dissection|
88825870|NCT03763929|Experimental|Trans Sodium Crocetinate|Trans sodium crocetinate (TSC) will be administered intravenously as a bolus to subjects randomized to experimental drug. The bolus dose will consist of 0.25 mg/kg of TSC based on the estimated subject weight.
89177282|NCT01024543|Sham Comparator|Placebo|Placebo
89356721|NCT03813173|Experimental|non central cervical dissection|
89356722|NCT03339856|Experimental|Treatment arm|Patients received selective retina therapy
89356723|NCT03333694|Experimental|CLL442|Cutaneous Cream application twice daily
89356724|NCT03333694|Placebo Comparator|Placebo|Placebo Cutaneous Cream application twice daily
89356725|NCT05623631|Other|Delphi study|Participants were asked to complete three rounds of surveys. These surveys collected information on which steps and errors can occur during CTI, and which of these should be included in an assessment tool.
89356726|NCT03333538|Experimental|Stage 1 (component A)|a single administration of component A (VSV) of vaccine
89356727|NCT03333538|Experimental|Stage 1 (component B)|a single administration of component B (Ad5) of vaccine
89356728|NCT03333538|Experimental|Stage 2 (Primary Group)|150 people who will receive the vaccine in the therapeutic scheme: the sequential introduction of components A and B with an interval of 21 days
89356729|NCT03333538|Placebo Comparator|Stage 2 (Controll Group)|50 people who will receive placebo in the therapeutic scheme: the sequential introduction of components A (placebo) and B (placebo) with an interval of 21 days
89356730|NCT03339700|Experimental|Unique|Patients will receive reduced Busulfan and Cyclophosphamide (BUCY 2) conditioning regimen, consisting in the administration of two medications: Busulfan and Cyclophosphamide Plus: Gemcitabine. Then patients will undergo an Allogeneic Hematopoietic Stem Cell Transplantation.
89356731|NCT05623553|Experimental|Enable high qualitative estimation of bilirubin levels in the blood of new-borns|There is only one arm in this study which is to enable high qualitative estimation of bilirubin levels in the blood of new-borns, independent of skin color, using Picterus JP.
89356732|NCT03813095|Experimental|APH-1501 400mg|Nano-encapsulated for oral delivery. The study is planned for patients to receive APH 1501 400mg BID( twice daily) for 28 days.
89356733|NCT03813095|Experimental|APH-1501 600mg|Nano-encapsulated for oral delivery. The study is planned for patients to receive APH 1501 600mg BID ( twice daily) for 28 days.
89356734|NCT03813095|Experimental|APH-1501 800mg|Nano-encapsulated for oral delivery. The study is planned for patients to receive APH 1501 800mg BID ( twice daily) for 28 days.
89356735|NCT03813095|Placebo Comparator|Placebo Comparator: Placebo|Nano-encapsulated for oral delivery. The study is planned for patients to receive a placebo dose BID ( twice daily) for 28 days.
89356736|NCT03333460|Experimental|Active Comparator: Active rTMS (15 Hz)|The intervention will be Repetitive Transcranial Magnetic Stimulation. Each patient will receive active stimulation targeting the left dorsolateral prefrontal cortex (lDLPFC) with a frequency of 15 Hz and 100% of the individual resting motor threshold, for a total of 40 trains (60 stimuli per train, inter-train interval of 15 second, total duration 13 minutes). Each session will be repeated twice/daily for 10 consecutive days for 2 weeks, during the continued treatment phase. Following this, the participants will receive the maintenance intervention of 2 sessions per week for 3 months (rTMS follow-up), at the same parameters described above. Device: MagPro R30 with the Cool-B80 figure-of-eight coil (MagVenture, Falun, Denmark).
89356737|NCT03333460|Placebo Comparator|Sham Comparator: Sham rTMS (15 Hz)|The intervention will be Repetitive Transcranial Magnetic Stimulation (Sham). rTMS will be used with the software necessary for the operator to remain blind to the stimulation condition. Also, the software will be pre-programmed by a staff member that will not be involved in data collection and analysis. The sham condition will match the number of pulses delivered during the 15Hz session and will use the same coil placement but the intensity of stimulation will be set a 3% of the individual resting motor threshold so to ensure that the participant will feel similar scalp sensations experienced by participants receiving active rTMS, but brain tissue will not be stimulated. Device: MagPro R30 with the Cool-B80 figure-of-eight coil (MagVenture, Falun, Denmark).
88825871|NCT03763929|Placebo Comparator|Placebo|The placebo consists of commercially available sterile saline. Placebo will be administered intravenously as a bolus to subjects randomized to placebo. The volume of sterile saline will be based on the estimated subject weight.
88825872|NCT03762993|Experimental|Healthy Adults|Participants will complete vocal rest and controlled phonation
88825873|NCT03762993|Experimental|Healthy Adults reporting Vocal Fatigue|Participants will complete vocal rest and controlled phonation
88825874|NCT03762213|Experimental|Oculus GO VR HMD, application Happy Place (© Mimerse)|"Oculus GO is a stand-alone, consumer-grade, virtual reality head-mounted display (HMD). The HMD is placed on the head of the user blocking off the surrounding environment. The visuals and audio are relayed through the HMD in a virtual space.Happy Place (© Mimerse) is a publicly available application with an explicit intent to be used for chronic pain patients. It has the critical elements of VR, namely immersion and interactivity.~Immersion: The scene is a serene lakeside campground with guided relaxation and soothing music. The application intends to promote positive effects such as calmness and feeling of wonder.~Interactivity: Happy Place uses an innovative 'gaze-based interaction' with the virtual world. Around 50 'gaze objects' are placed around the scene and gazing at them would trigger an event.~The entire duration of the experience will be kept at 10 minutes."
88825875|NCT03762213|Placebo Comparator|iPad, application Happy Place (© Mimerse)|An iPad with earphones (Apple Inc. Cupertino CA) will be used for controls. The participants in control group will watch the same content for the same duration on an iPad screen (flat version of Happy Place). This experience will be different from the intervention group in two ways: first, lack of an immersive environment, and second, lack of interactivity with the environment.
88825876|NCT01118013|Experimental|Treatment|"Matched-unrelated donor: Patients receive antithymocyte globulin, tacrolimus, and methotrexate as in HLA-identical donor regimen. Patients also receive oral mycophenolate mofetil twice daily on days 0 to 60.~Allogeneic Stem Cell Transplantation: Patients undergo allogeneic peripheral blood stem cell transplantation on days 0 and 1. Patients then receive filgrastim subcutaneously daily beginning on day 7 and continuing until blood counts recover.~Donor Lymphocyte Infusion (DLI): After day 180 (or day 210 for patients without an HLA-identical donor), patients with stable or progressive disease and no active GVHD may receive up to 3 DLIs every 8 weeks.~Blood samples are collected at baseline and then periodically during study therapy for pharmacokinetic studies.~After completion of study therapy, patients are followed up every 3 months for 2 years and then every 6 months for up to 5½ years."
88825877|NCT00378027||Stable Acute Pulmonary Embolism|Administer weight dosed Fondaparinux
89356738|NCT01301495|Experimental|HANAROSTENT covered Esophageal Stent|
89356739|NCT03339622|Experimental|smoked cannabis (PPP001)|280 mg dried cannabis pellet -(9% THC / 2% CBD per pellet)
89356740|NCT03339622|Placebo Comparator|THC free placebo|280 mg dried extracted cannabis pellet (0% THC / 0.6% CBD per pellet)
89356741|NCT03333304|Experimental|PCT group|Procalcitonin measurement and Discontinuation of antimicrobials according to Procalcitonin kinetics
89356742|NCT03333304|No Intervention|Standard of care|Standard practice
89356743|NCT05465356||New patients|All new referrals seen in the rheumatology outpatients department, completing pre-appointment digital questionnaires
88825878|NCT00552032|Experimental|Mometasone Furoate nasal spray|
89356744|NCT05465356||Follow-up patients|Patient with inflammatory arthritis completing ePROMs [electronic Patient Reported Outcome Measures] through the remote monitoring platform
89356745|NCT03816371|Active Comparator|supine 0 degree head-of-bed elevation|0 degree head-of-bed elevation was arranged as soon as the patient was admitted to the bed following thyroidectomy.
89356746|NCT03816371|Experimental|30 degree head-of-bed elevation|30 degree head-of-bed elevation was arranged as soon as the patient was admitted to the bed following thyroidectomy.
89356747|NCT03816371|Experimental|45 degree head-of-bed elevation|45 degree head-of-bed elevation was arranged as soon as the patient was admitted to the bed following thyroidectomy.
89356748|NCT02500420|Other|Diagnosis examens|"Cardiac MRI: is usually recommended in the diagnosis or in the follow-up of the disease. The MRI will respect the standard protocol: cineMRI sequences, perfusion sequences, LGE sequences at 10 minutes after gadolinium injection. The investigators will realize some additional sequences: T1 mapping before and after gadolinium injection to study the diffuse fibrosis and stress perfusion sequences after injection of a vasodilatator (Persantine°).~Exercice stress echocardiography: is realized almost systematically in all the diagnosis of HCM and it's very informative. The investigators will research left ventricular dysfunction: in particular segmentary hypokinesia and anomalies of deformation parameters (2D Strain) and the development of a dynamic left ventricular outflow obstruction or a mitral regurgitation at exercice."
89356749|NCT03822923|Experimental|Experimental group|Neurodynamics (Dynamic Neural Mobilization) with conventional treatment (stretching, AROM) will be applied.
89356750|NCT03822923|Active Comparator|control group|Conventional treatment (stretching, AROM) will be applied
89356751|NCT02494024|Experimental|Single dose C2N-8E12 level 1|Single IV infusion of C2N-8E12
88825879|NCT00552032|Placebo Comparator|Placebo|
88825880|NCT02429583|Active Comparator|Recombivax in HCV infected individuals|Recombivax vaccine administered IM to HCV-infected individuals
88825881|NCT02429583|Active Comparator|Recombivax in healthy volunteers|Recombivax vaccine administered IM to healthy individuals
88825882|NCT04935632||Before implementation|Prior to the implementation of the measures resulting from the SFAR recommendations on the prevention of accidental perioperative hypothermia
88825883|NCT04935632||After implementation|After implementation of the measures resulting from the SFAR recommendations on the prevention of accidental perioperative hypothermia
88825884|NCT04935632||at a distance from the implementation|Approximately 8 months after implementation of the measures resulting from the SFAR recommendations on the prevention of accidental perioperative hypothermia.
88825885|NCT02413047|Experimental|Immunomodulator|Azathioprine, 6 mercaptopurine or methotrexate.
88825886|NCT02277548|Experimental|Lyrica at 300 mg per day|
89356752|NCT02494024|Experimental|Single dose C2N-8E12 level 2|Single IV infusion of C2N-8E12
89356753|NCT02494024|Experimental|Single dose C2N-8E12 level 3|Single IV infusion of C2N-8E12
89356754|NCT02494024|Experimental|Single dose C2N-8E12 level 4|Single IV infusion of C2N-8E12
89356755|NCT02494024|Placebo Comparator|Single dose placebo|Single IV infusion of placebo
89356756|NCT03478969|Experimental|Group A: Accu-Chek® Solo|Continuous subcutaneous insulin infusion (CSII) with Accu-Chek® Solo Micropump system for 26 weeks. From Week 26 until Week 39, all Groups will be using the Accu-Chek® Solo Micropump system for CSII therapy.
89356757|NCT03478969|Experimental|Group B: MDI, then Accu-Chek® Solo|Multiple daily injections (MDI) for 26 weeks. From Week 26 until Week 39, all Groups will be using the Accu-Chek® Solo Micropump system for CSII therapy.
89356758|NCT03478969|Experimental|Group C: mylife™ OmniPod®, then Accu-Chek® Solo|Continuous subcutaneous insulin infusion (CSII) with the mylife™ OmniPod® Insulin Management system for 26 weeks. From Week 26 until Week 39, all Groups will be using the Accu-Chek® Solo Micropump system for CSII therapy.
89356759|NCT03812783|Experimental|HAIC of FOLFIRINOX plus sorafenib|
89356760|NCT03812783|Active Comparator|HAIC of FOLFOX plus sorafenib|
88825887|NCT02277548|Placebo Comparator|Placebo|
88825888|NCT02988596|Active Comparator|Enhanced Graded Exertion|At the time of the injury, participants will be given guided activity instructions regarding what activities to consider and how to observe for increases in symptoms. The focus will be on guided activity and not on restriction. Symptoms will be assessed at the end of each day. Once the patient has been asymptomatic for 24 hours or within 85% of their baseline symptom score (BSS) they will begin the enhanced graded exertion progression (Zurich/Berlin protocol). This protocol will follow the Zurich/Berlin guidelines, but will be enhanced to include sports and skill specific activities. Each step will be completed on a separate day. A medical professional will determine the symptom status of the athlete and when the graded exertion will begin.
89177283|NCT01024543|Experimental|Angiotensin II|Angiotensin II
89356761|NCT03812861|Experimental|CAMDS bundle|25 surgical teams will manage 10 standardised simulated deteriorating ward patients with the help of a cognitive aid bundle
89356762|NCT03812861|No Intervention|No bundle|25 surgical teams will manage 10 standardised simulated deteriorating ward patients without the help of a cognitive aid bundle
89356763|NCT02500342|Experimental|Drug: Levothyroxine|The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects <50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is <0.4 mU/L, dose will be reduced by 25 mcg; TSH >=0.4 and <4.6 mU/L, no change to dose; TSH >=4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
89356764|NCT02500342|Placebo Comparator|Drug: Placebo|"Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug.~Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg."
89356765|NCT02500264|Active Comparator|Protocol #1|interventions: 1.6Hz, Rampdown 0.4S, electrodes position - both L.Rectus Abdominis, 5cmX5cm Size, on inspirium
89356766|NCT02500264|Active Comparator|Protocol #2|1Hz, Rampdown 0.6S, electrodes position - both Rectus Abdominis, 5cmX5cm Size, on inspirium
89000557|NCT04678063|Experimental|Asthmatic subjects allergic to cat|Group A will be randomized into 2 subgroups of 10 subjects: group A1 and A2. Both subgroupes will be exposed to placebo on exposure 1 then Subgroup A1 will be exposed to dose A on exposure 2 and dose B on exposure 3. Subgroup A2 will be exposed to dose B on exposure 2 and dose A on exposure 3. Dose A and B correspond to different Allergen concentration in the EEC.
89000558|NCT04678063|Active Comparator|Asthmatic allergic subjects not sensitized to cat|Group B will be exposed to placebo at exposure 1, and then at exposure 2, the concentration of cat allergens corresponding to the dose that achieved the main objective (Dose A or B).
89000559|NCT02332759|Experimental|Materna Device|The device will be inserted vaginally for one hour during active phase of labor to dilate the vaginal canal.
89000560|NCT02320708|Experimental|Test Acetaminophen (ACE) (1000 mg) and placebo|
89000561|NCT02320708|Active Comparator|Commerical ACE (1000 mg) and placebo|
89356767|NCT02500264|Active Comparator|Protocol #3|1.6Hz, Rampdown 0.4S, electrodes position - L.Rectus Abdominis and L.External Oblique, 5cmX5cm Size, on inspirium Oblique
89356768|NCT02500264|Active Comparator|Protocol #4|1Hz, Rampdown 0.6S, electrodes position - L.Rectus Abdominis and L.External Oblique, 5cmX5cm Size, on inspirium
89356769|NCT03816215|Experimental|Adolescent Participants|Participants will be assigned to participate in community service (from a menu of options) for 30 hours.
89356770|NCT02500186|Experimental|High GI meal containing 55% carbohydrate|The energy intake of study patients is 1800 kcal per day. Study patients in high GI meal containing 55% carbohydrate group take 55% carbohydrate white rice diet.
89356771|NCT02500186|Experimental|Low GI meal containing 55% carbohydrate|The energy intake of study patients is 1800 kcal per day. Study patients in low GI meal containing 55% carbohydrate group take 55% carbohydrate brown rice diet
89356772|NCT02500186|Experimental|High GI meal containing 40% carbohydrate|The energy intake of study patients is 1800 kcal per day. Study patients in high GI meal containing 40% carbohydrate group take 40% carbohydrate white rice diet.
89356773|NCT02500030|Experimental|Air Stacking|Air Stacking was performed with the subject seated in his wheelchair using a manual resuscitation bag (LIFESAVER® model 5345, Hudson, Temecula, USA) connected to a corrugated tube with an internal diameter of 22 mm, a one-way valve and a pipette. The maximum capacity of the bag was 1600 mL. A chest physiotherapist insufflated the patient during the inspiratory phase, requesting that inspire as much air as possible
89356774|NCT02500030|Experimental|Glossopharyngeal Breathing|"Glossopharyngeal Breathing was also performed with the subject seated in his wheelchair and performing successive maneuvers of swallowing air until the maximum volume achieve was maintained. Then, the patient was instructed to breathe through ventilometer to register the MIC. Three measurements for each of the techniques were performed, and the highest reading was recorded. A difference of <10% between the measurements was used as the repeatability criterion"
89356775|NCT05623475|Experimental|experimental group|"face-to-face delirium care session (30 minutes in duration);~online learning delirium care activities (20 minutes in duration); and~delirium care OSCE and reflective activity (30 minutes in duration)."
89356776|NCT05623475|Active Comparator|control group|"face-to-face delirium care session (30 minutes in duration);~online learning delirium care activities (20 minutes in duration)"
89356777|NCT02499874|Experimental|Single treatment arm|All subjects will be administered oral Efavirenz 400mg together with the rest of the oral antiretroviral combination (tenofovir 245 mg/emtricitabine 200mg or tenofovir 245mg/lamivudine 300mg or lamivudine 300mg/zidovudine 600mg) throughout the study period
89356778|NCT05093777|Experimental|Intervention group|"Half of the study participants will be randomized to the intensive habilitation program the first year of program. The second year of program this group of participants will be offered habilitation as usual."
89356779|NCT05093777|Other|Control group|"Half of the study participants will be randomized to treatment as usual the first year of program, then offered the intensive program during the second year (stepped wedge design)."
89356780|NCT04495192||Patients affected by severe Acquired Brain Injury|All patients admitted in the participant IRU with a history of sABI and fulfilling our inclusion and exclusion criteria will be recruited.
89000562|NCT02320708|Active Comparator|Commerical Ibuprofen (IBU) (400 mg) and placebo|
89000563|NCT02320708|Placebo Comparator|Placebo|
89000564|NCT02310802|Experimental|OBE001 dose 1|
89000565|NCT02310802|Experimental|OBE001 dose 2|
89000566|NCT02310802|Experimental|OBE001 dose 3|
89000567|NCT02310802|Placebo Comparator|Placebo|
89000568|NCT02310412|Experimental|Amicus platelet components|The two stages of this pilot study consist of the following: single or double dose platelet apheresis collection, pathogen inactivation with INTERCEPT treatment, storage for 7 days, collection of fresh platelets, radiolabeling, infusion of fresh and stored INTERCEPT treated radiolabeled autologous platelets, and collection of blood samples for assessment of platelet recovery and survival (lifespan). In Stage 1, apheresis platelets will be collected using the Amicus separator and stored for 7 days in 35% Plasma and 65% InterSol
89000569|NCT02310412|Experimental|Trima platelet components|The two stages of this pilot study consist of the following: single or double dose platelet apheresis collection, pathogen inactivation with INTERCEPT treatment, storage for 7 days, collection of fresh platelets, radiolabeling, infusion of fresh and stored INTERCEPT treated radiolabeled autologous platelets, and collection of blood samples for assessment of platelet recovery and survival (lifespan). In Stage 2, apheresis platelets will be collected using the Trima separator and stored for 7 days in 100% plasma.
89000570|NCT02309671|Experimental|FE 999049 6 µg|
89533835|NCT02810743|Active Comparator|ddAC-CP-Olaparib|"ddAC; doxorubicin 60 mg/m² as an i.v. bolus and cyclophosphamide 600 mg/m² as an i.v. bolus on day 1 every 2 weeks ddAC must be supported with prophylactic pegfilgrastim 6 mg s.c. given 24-48 hours after completion of administration of EVERY chemotherapy cycle~CP; carboplatin/paclitaxel (CP) consisting of carboplatin (AUC 6) on day 1 and paclitaxel (80 mg/m2) on day 1,8 and 15 of a 21 days cycle. In total 4 courses of CP will be administered.~Olaparib will be administered in Dutch centers only, as monotherapy for one year at a dose of 300 mg BID, starting 3 weeks after adjuvant radiotherapy, or, if radiotherapy is not indicated, 3-5 weeks after the last CP cycle.~Patients without a (near) pCR will receive adjuvant capecitabine at a starting dose of 1000-1250 mg/m2, twice a day, on days 1-14 every 3 weeks for eight cycles."
89533836|NCT02810743|Active Comparator|ddAC-mini CTC|"ddAC; doxorubicin 60 mg/m² as an i.v. bolus and cyclophosphamide 600 mg/m² as an i.v. bolus on day 1 every 2 weeks ddAC must be supported with prophylactic pegfilgrastim 6 mg s.c. given 24-48 hours after completion of administration of EVERY chemotherapy cycle~intensified alkylating 'mini' CTC (2x) cyclophosphamide 3000 mg/m2 day 1 mesna 500 mg (push) + 2000 mg in 24 hours day 1 carboplatin (400 mg/m2; (or AUC=5 in patients with a calculated creatinine-clearance of <100 ml/min)) days 1,2 thiotepa 250 mg/m2 day 2~Patients without a (near) pCR will receive adjuvant capecitabine at a starting dose of 1000-1250 mg/m2, twice a day, on days 1-14 every 3 weeks for eight cycles."
89533837|NCT02799212|Experimental|Experimental group|postoperative somatostatin infusion during 5 days at 6mg/day, followed by one day at 3mg/day
89000571|NCT02309671|Experimental|FE 999049 9 µg|
89533838|NCT02799212|Placebo Comparator|Control group|Placebo infusion (50ml of 0.9% NaCl/day) during 6 days
89533839|NCT02760849|Experimental|Arm I (ISDO)|Patients undergo ISDO.
89533840|NCT02760849|Active Comparator|Arm II (RRSO)|Patients undergo RRSO.
89356781|NCT03816059||Hospitalized - ACS|Hospitalized patients with acute coronary syndrome
89356782|NCT03816059||Hospitalized - stroke|Hospitalized patients with stroke
89356783|NCT03816059||Hospitalized - chronic lung disease|Hospitalized patients with exacerbation of chronic lung disease
89356784|NCT03816059||Outpatient|Outpatients
89356785|NCT04495270||Clinical observation|All study patients were examined by 1 endodontist clinically and radiographically at baseline and after follow up of endodontic treatment.
89356786|NCT03815903|Active Comparator|A - induction chemotherapy|
89356787|NCT03815903|Experimental|B - chemoradiotherapy|
89356788|NCT02499796|Experimental|Single Arm|"Every patient receives 20 minutes of invasive mechanical ventilation with each of the three humidification systems in random sequence:~Heated and moisture exchanger (HME)~Heated humidifier (HH)~Hygrovent Gold"
89356789|NCT03822299|No Intervention|Placebo|Patients receive suspension of their own feces.
89356790|NCT03822299|Active Comparator|30 g donor dose|Patients receiving 30 g of a healthy donor feces.
89356791|NCT03822299|Active Comparator|60 g donor dose|Patients receiving 60 g of a healthy donor feces.
89356792|NCT03333226|Experimental|ARM lymph node preservation|All patients will be sent to both rSLNB and photodynamic Axillary Reverse Mapping (ARM) to evaluate the crossover between SLN and ARM lymph node. In case of SLN metastases, an ALND with ARM lymph node preservation will be performed.
89356793|NCT03333226|Active Comparator|ARM lymph node removal|All patients will be sent to both rSLNB and photodynamic Axillary Reverse Mapping (ARM) to evaluate the crossover between SLN and ARM lymph node. In case of SLN metastases, an ALND with ARM lymph node removal will be performed.
89356794|NCT03822221|Experimental|SK20º|MVIC and NMES with hip at 85º and knee at 20º
89356795|NCT03822221|Experimental|SK60º|MVIC and NMES with hip at 85º and knee at 60º
89356796|NCT03822221|Experimental|LK20º|MVIC and NMES with hip at 0º and knee at 20º
89356797|NCT03822221|Experimental|LK60º|MVIC and NMES with hip at 0º and knee at 60º
89533841|NCT02754752|Experimental|Group I (electroacupuncture therapy)|Patients undergo electroacupuncture therapy over 45 minutes 2-3 times per week over 4 weeks for a total of 10 sessions.
89533842|NCT02754752|Placebo Comparator|Group II (sham electroacupuncture therapy)|Patients undergo modified electroacupuncture therapy over 45 minutes 2-3 times per week over 4 weeks for a total of 10 sessions. Acupuncture needles are placed in different locations using a different technique than those used for Group I.
88825889|NCT02988596|Experimental|Multidimensional Active Rehabilitation|At injury, participants are given instructions regarding guided activities to consider and how to observe for symptom increase. Focus is on guided activity, not restriction. The intervention consists of 5 phases designed to facilitate an active approach to concussion rehabilitation. Phases are symptom stabilization, impairment reduction, activity integration, recovery acceleration, and sport specific application. Participants complete phase specific activities under direction of a clinical professional, and progress upon meeting specific requirements. Participants are required to spend at least 2 days in Phase 1; subsequent phases are completed on separate days. Once asymptomatic for 24 hours or within 85% of their BSS they begin the enhanced graded exertion progression (Zurich/Berlin protocol).
88825890|NCT02411643|Other|topical calcipotriene 0.005% ointment|Calcipotriene 0.005% applied to affected areas twice daily to all enrolled subjects
88825891|NCT02277626|Experimental|Randomized Crossover to ElectroFlo|Experimental: ElectroFlo 5000, then VEST Patients are randomized to a sequence of ElectroFlo 5000 on one visit and during the second visit, they cross-over to the Vest system.
88825892|NCT02277626|Experimental|Randomized Crossover to Vest|Experimental: VEST, then ElectroFlo 5000 Patients are randomized to a sequence of Vest system on one visit and during the second visit, they cross-over to the ElectroFlo 5000.
88825893|NCT03758157||Temperature Measurement|Each subject will have his or her temperature measured by both the welloStationX Automated Non-Contact Thermometer and the Welch Allyn SureTemp Oral Thermometer.
88825894|NCT02280200|Experimental|AFO to improve outcomes|Patients completed graded treadmill testing, followed by 12 weeks of unstructured community-based walking using the AFO ad libitum
88825895|NCT02280200|No Intervention|Historical Controls|Historical PAD control group (n = 10) received upfront advice to walk at home with no intervention
88825896|NCT01085643|Active Comparator|Lubiprostone|Same patients are included in both the Lubiprostone arm and the Placebo arm. The reason why the same patients are assigned to two arms is because an effect comparison is done after taking the placebo and later after taking the lubiprostone.
89356798|NCT03333148|Experimental|Arm A - Nestle IMPACT Immunonutrition|Treatment Arm A (n=146) - Nestlé IMPACT Advanced Recovery:Along with standard of care nutritional therapy patients will be asked to consume 3 cartons/day for 14 days of Nestle IMPACT Advanced Recovery Immunonutrition.
89356799|NCT03333148|Other|Arm B- Standard of Care|No intervention standard of care nutrition (n=146).
89533843|NCT02754752|Active Comparator|Group III (waitlist control)|Patients receive standard of care without any kind of acupuncture therapy.
89533844|NCT02682667||1/Cohort 1|Patients with cancer or a premalignant condition or at risk of cancer from an immunodeficiency
88825897|NCT01085643|Placebo Comparator|Placebo|Same patients are included in both the Lubiprostone arm and the Placebo arm. The reason why the same patients are assigned to two arms is because an effect comparison is done after taking the placebo and later after taking the lubiprostone.
89000572|NCT02309671|Experimental|FE 999049 12 µg|
89356800|NCT02492308|Experimental|SVF-MSC induction|"collection of autologous SVF~culture of SVF to abstain MSC~infusion of MSC during and after living-relative kidney transplantation"
89356801|NCT02492308|Active Comparator|Basiliximab induction|The control group will be inducted with Basiliximab
89356802|NCT01300169|Experimental|CAMS--Collaborative Driver-Treatment|"The Collaborative Assessment and Management of Suicidality (CAMS) is a suicide-specific clinical intervention that targets and treats patient-defined suicidal drivers over the course of clinical care."
89533845|NCT02680730|Experimental|Intervention only|Participants will be included in 1 pre-intervention and 2 post-assessment measures. Participants will receive the Listening Project Protocol intervention (filtered music). The duration of the intervention is approximately 60 minutes per day, for 5 consecutive days.
89533846|NCT02680730|Experimental|Intervention + Stability|Participants will be included in 2 pre-intervention and 2 post-assessment measures. The additional pre-intervention assessment will allow for assessment of stability of measures. Participants will receive the Listening Project Protocol intervention (filtered music). The duration of the intervention is approximately 60 minutes per day, for 5 consecutive days.
89533847|NCT02650401|Active Comparator|Extracranial solid tumors harboring NTRK1/2/3,|"Arm closed for further enrollment~ROS1, ALK non-gene fusion molecular alterations~Oral entrectinib (RXDX-101)"
89533848|NCT02650401|Active Comparator|CNS tumors harboring- NTRK1/2/3, ROS1, ALK|"Arm closed for further enrollment~molecular alterations, including gene fusions~Oral entrectinib (RXDX-101)"
89533849|NCT02650401|Active Comparator|Neuroblastoma|"Arm closed for further enrollment~Oral entrectinib (RXDX-101)"
88825898|NCT03028766|Experimental|Group A - Pre-operative|Patients will receive the cohort specified dose of AZD1775 by mouth, twice a day for 3 days, commencing on days 1 and 8. Cisplatin 40mg/m2 IV delivered over 1 hour on day 8. Patients in this group will commence surgery within 42 days of commencing pre-operative chemotherapy.
89533850|NCT02650401|Active Comparator|Non-neuroblastoma, extracranial solid tumors|"Arm closed for further enrollment~harboring - NTRK1/2/3, ROS1, ALK gene fusions~Oral entrectinib (RXDX-101)"
89533851|NCT02650401|Active Comparator|Any participant unable to swallow capsules|"Arm closed for further enrollment~Any participant who otherwise meet all other eligibility criteria~Oral entrectinib (RXDX-101)"
89533852|NCT02650401|Active Comparator|Expansion: CNS tumors harboring NTRK1/2/3, ROS1|"gene fusions~Oral entrectinib (RXDX-101)"
89533853|NCT02650401|Active Comparator|Expansion: Extracranial solid tumors harboring NTRK1/2/3, ROS1|"NTRK 1,2,3 and ROS1 fusions~Oral entrectinib (RXDX-101)"
89533854|NCT02639325||Patients|Patients who have solitary primary or recurrent brain tumor with associated seizures.
89533855|NCT02632448|Experimental|Part A: LY2880070|Multiple oral doses of LY2880070 during 21-day cycles
89533856|NCT02632448|Experimental|Part A: LY2880070 with Gemcitabine|Multiple oral doses of LY2880070, and Gemcitabine administered intravenously during 21-day cycles
89533857|NCT02632448|Experimental|Part A: LY2880070 (Metabolism Phenotype)|Multiple oral doses of LY2880070 administered during 21 day cycles, to participants who are poor metabolizers
89533858|NCT02632448|Experimental|Part B: LY2880070 and Gemcitabine (Breast)|Multiple oral doses of LY2880070 during 21-day cycles with Gemcitabine (administered intravenously)
89000573|NCT02309671|Active Comparator|FOLLISTIM 150 IU|follitropin beta
89533859|NCT02632448|Experimental|Part B: LY2880070 and Gemcitabine (Colorectal)|Multiple oral doses of LY2880070 during 21-day cycles with Gemcitabine (administered intravenously)
89533860|NCT02632448|Experimental|Part B:LY2880070 and Gemcitabine (Ovarian)|Multiple oral doses of LY2880070 during 21-day cycles with Gemcitabine (administered intravenously)
89533861|NCT02632448|Experimental|Part B: LY2880070 and Gemcitabine (Endometrial)|Multiple oral doses of LY2880070 during 21-day cycles with Gemcitabine (administered intravenously)
89533862|NCT02632448|Experimental|Part B: LY2880070 and Gemcitabine (Soft Tissue Sarcoma (STS))|Multiple oral doses of LY2880070 during 21-day cycles with Gemcitabine (administered intravenously)
89533863|NCT02632448|Experimental|Part B: LY2880070 and Gemcitabine (Pancreatic)|Multiple oral doses of LY2880070 during 21-day cycles with Gemcitabine (administered intravenously)
89533864|NCT02632448|Experimental|Part C: LY2880070 and Gemcitabine (High Grade Serous Ovarian Cancer)|Multiple oral doses of LY2880070 during 21-day cycles with Gemcitabine (administered intravenously)
89000574|NCT02296645|Experimental|ZuraPrep|Isopropyl alcohol (IPA) (70%)
89000575|NCT02296645|Active Comparator|ChloraPrep|Chlorhexidine gluconate (CHG) 2% / Isopropyl alcohol (IPA) 70%
89177284|NCT01024543|Active Comparator|Phenylephrine|Phenylephrine
89177285|NCT00793182|Active Comparator|1|Ioversol 320 mgI/mL
89177286|NCT00793182|Active Comparator|2|Iodixanol 320 mgI/mL
89177287|NCT01024621|Experimental|1|confocal laser endomicroscopy
89177288|NCT01024621|Active Comparator|2|standard endoscopy
89533865|NCT02622035|Experimental|1|Gain frame; Anger
89533866|NCT02622035|Experimental|1b|high visual perceptual load high interactive
89533867|NCT02622035|Experimental|2|Gain frame; Fear
89533868|NCT02622035|Experimental|2b|high visual perceptual load
89533869|NCT02622035|Experimental|3|Loss frame; Anger
89533870|NCT02622035|Experimental|3b|low visual perceptual load
89533871|NCT02622035|Experimental|4|Loss frame; Fear
89533872|NCT02579967|Experimental|1/ IOC Arm-Closed with amendment L (07/05/2019)|Immunosuppression Only Conditioning Arm
89533873|NCT02579967|Experimental|2/ RIC Arm - Closed with Amendment L (07/05/2019)|Reduced Intensity Conditioning Arm
89533874|NCT02579967|Experimental|3/ MAC Arm-Closed with amendment L (07/05/2019)|Myeloablative Conditioning Arm
89533875|NCT02579967|Experimental|4/ RIC-MMF Arm|Reduced Intensity Conditioning with MMF duration de-escalation design
89533876|NCT02579967|No Intervention|5/ Donor Arm|Donor
89533877|NCT02579967|Experimental|6/ RIC-SHORT Arm|Reduced Intensity Conditioning with shortened duration and dose-reduced PTCy
89356803|NCT01300169|Active Comparator|Enhanced Care as Usual--E-CAU|This control group treatment will reflect current clinical practices for treating suicidal soldiers in the research site setting. These are providers were on site clinicians who provided care according to their usual and customary practices for working with suicidal risk within outpatient care.
89356804|NCT05865483||Participant group: mild disease|Muscle impairment rating score (MIRS) (Mathieu et al., 2001) 1-2 (n=30)
89533878|NCT02579954|No Intervention|control group|
89533879|NCT02579954|Experimental|intervention|Rehabilitation
88825899|NCT03028766|Experimental|Group B - Post-operative:|Patients will received the cohort specified dose of AZD1775 by mouth, twice a day for 3 days on days 2, 9, 23 and 30. Cisplatin 40mg/m2 IV delivered over 1 hour on days 2, 9, 16, 23 and 30. Intensity Modulated Radiotherapy will be delivered 5 days a week (once daily, Monday to Friday) for 6 weeks commencing within 3 months of surgery.
88825900|NCT01071993|Active Comparator|atorvastatin|
88825901|NCT01071993|Placebo Comparator|placebo|
88825902|NCT03756818|Experimental|Treatment (mivavotinib and paclitaxel)|Patients receive mivavotinib PO QD and paclitaxel IV over approximately 1 hour on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88825903|NCT01065051|Experimental|Riociguat (Adempas, BAY63-2521)|Participants received a single oral dose of 1 mg riociguat.
89356805|NCT05865483||Participant group: moderate disease|Muscle impairment rating score (MIRS) (Mathieu et al., 2001) 3 (n=30)
89356806|NCT05865483||Participant group: severe disease|Muscle impairment rating score (MIRS) (Mathieu et al., 2001) 4-5 (n=30)
89356807|NCT05865483||Control group|No disease (n=60) age and sex-matched
89356808|NCT05865483||Caregiver group|Spends at least one mealtime daily assisting with a person with DM1 already enrolled in the study. Expect ratio of 1:2 caregiver:participant (approx n=45)
89533880|NCT02578875||Sample|Discarded patient samples and autopsy material
89533881|NCT02564991||Healthy Controls|125 non-substance abusing controls (NSAC)
89533882|NCT02564991||Individuals with Alcohol Use Disorder|This group includes individuals who enrolled NIAAA alcohol treatment.
89533883|NCT02560493|No Intervention|Control Condition|Participants randomly assigned to the control condition will be asked to continue their usual physical activity habits and will not interact with the intervention staff.
89356809|NCT05865470|Placebo Comparator|Placebo Comparator: Placebo|Smoked Cannabis (0 mg THC) Oral placebo (0 mg THC)
88825904|NCT01065051|Placebo Comparator|Placebo|Participants received a single oral dose of 1 mg placebo.
88825905|NCT03029936||Obesity Group|
88825906|NCT03029936||Asthma Group|
88825907|NCT03029936||Obesity-Asthma Group|
88825908|NCT03029936||Control|
88825909|NCT02376933|Experimental|Vertebroplasty with Radiotherapy|Vertebroplasty with Radiotherapy is given in either order. Radiotherapy dosage is at the discretion of the treating physician. Vertebroplasty is applied to fractured vertebrae.
88825910|NCT02379585|Active Comparator|HER2 negative breast cancer|Doxorubicin and cyclophosphamide every two weeks for four cycles (one cycle is defined as 14 days). After completing fourth cycle, paclitaxel every two weeks for an additional four cycles. The appropriate surgery will be done three to six weeks after completing the last cycle of paclitaxel.
88825911|NCT02379585|Active Comparator|HER2 positive breast cancer|Docetaxel, trastuzumab, and pertuzumab every three weeks for four cycles. Pegfilgrastim after docetaxel. Surgery three to six weeks after completing the last docatexel. If additional chemotherapy is needed patients will receive both doxorubicin and cyclophosphamide every three weeks for four cycles and after the fourth cycle then trastuzumab for one year
88825912|NCT01048125|Experimental|Study group|Subjects with documented stress cardiomyopathy who would serve as the study group. Sympathetic Nerve Activity; Mental StrCold Pressor Testess Test (Color Word Test); The Modified Oxford Technique for Baroreflex Sensitivity; Cold Pressor Test; Echocardiographic evaluation
88825913|NCT01048125|Active Comparator|Control|Control subjects will be age and sex matched otherwise healthy people with no prior cardiac disease or other severe medical conditions. Sympathetic Nerve Activity; Mental Stress Test (Color Word Test); The Modified Oxford Technique for Baroreflex Sensitivity; Cold Pressor Test; Echocardiographic evaluation
88825914|NCT01901588|Experimental|Dexmedetomidine|dexmedetomidine/precedex
88825915|NCT01901588|Placebo Comparator|Placebo|patients receive saline solution.
88825916|NCT03673124|Other|Ribociclib and letrozole|Ribociclib 600mg oral daily for 3 weeks then 1 week off plus Letrozole 2.5 mg oral daily
88825917|NCT01056315|Experimental|A GRT3983Y|Participants randomly assigned to receive GRT3983Y.
88825918|NCT01056315|Placebo Comparator|B Placebo|Participants randomly assigned to placebo.
88825919|NCT05296785|Other|Participants|patients undergoes intramedullary nail with Limb Reconstruction System
88825920|NCT01025271|Other|open label|patients meeting entry criteria enrolled and pk samples obtained around dosing of daptomycin
88825921|NCT02973555|Experimental|PRP injection|
88825922|NCT01902758|Experimental|ambrisentan and theophylline|ambrisentan (5mg) once daily for 2 consecutive days theophylline (400mg) once daily for 2 consecutive days
89533884|NCT02560493|Experimental|Exergaming Condition|Participants randomly assigned to the exergaming condition will participate in a 6 month exergaming intervention.
89533885|NCT02531893||Irritable youth|Participants meet full DMDD criteria for IBT and either full DMDD or one of two core DMDD criteria for CBT.
89356810|NCT05865470|Experimental|Experimental: Low strength cannabis|Smoked Cannabis (10 mg THC) Oral placebo (0 mg THC)
89356811|NCT05865470|Experimental|Experimental: Higher strength cannabis|Smoked Cannabis (20 mg THC) Oral placebo (0 mg THC)
89533886|NCT02522611|Experimental|Resiniferatoxin|Schedule a maximum of 3 periganglionic DRG injection(s) at contiguous level(s) to treat targeted DRG responsible for chronic CIBP
89533887|NCT02519452|Experimental|Part 1: Cohort 1|Participants will receive 1200 mg (daratumumab 1200 milligram (mg) with Recombinant Human Hyaluronidase [rHuPH20] 30,000 U) via mixing immediately before Subcutaneous (SC) infusion once weekly in Cycles 1 (each cycle is 28 days) and 2, every 2 weeks in Cycles 3-6, and then every 4 weeks in subsequent cycles until disease progression.
88825923|NCT01902758|Placebo Comparator|placebo|matched placebo tablets wil be given at the same time to the comparison group as the medications to the experimental group
88825924|NCT02336763|Experimental|Treatment (external beam radiation therapy)|Patients undergo external beam radiation therapy daily over 20 minutes on Monday-Friday for up to 10 fractions over approximately 2 weeks.
88825925|NCT02318901|Experimental|Arm 1|Pembrolizumab 2mg/kg administered intravenously over 30 minutes every 3 weeks. Intravenous (i.v.) trastuzumab 6 mg/kg on day 1 every 21 days.
88825926|NCT02318901|Experimental|Arm 2|Pembrolizumab 2mg/kg administered intravenously over 30 minutes every 3 weeks. i.v. ado-trastuzumab emtansine 3.6 mg/kg on day 1 every 21 days.
88825927|NCT02318901|Experimental|Arm 3|Pembrolizumab 2mg/kg administered intravenously over 30 minutes every 3 weeks. i.v. cetuximab 400 mg/m2 on cycle 1 day 1, then i.v. cetuximab 250 mg/m2 on day 8. Each subsequent cycle will be i.v. cetuximab 250 mg/m2 on days 1 and 8 every 21 days.
88825928|NCT01904864|Active Comparator|NovaFerrum®|Subjects randomized to this arm will receive a single daily dose (3mg/kg) of a 15 mg/ml elemental iron preparation, NovaFerrum®, for 12 weeks.
88825929|NCT01904864|Active Comparator|Ferrous Sulfate|Subjects randomized to this arm will receive a single daily dose (3mg/kg) of a 15 mg/ml elemental iron preparation, ferrous sulfate, for 12 weeks.
88825930|NCT01016847|Active Comparator|leukotriene receptor antagonist (LTRA) montelukast|Montelukast (LTRA) administered with moderate dose of inhaled steroid
88825931|NCT01016847|Placebo Comparator|Sugar Pill|High dose of inhaled steroid administered with sugar pill
88825932|NCT00989937|Experimental|Group 1|20 IU BID for the first week, 40 IU BID for the following two weeks, one week washout, 3 week placebo trial
89356812|NCT05865470|Experimental|Experimental: Low strength oral THC|Smoked Cannabis (0 mg THC) Oral THC (10 mg THC)
89356813|NCT05865470|Experimental|Experimental: Higher strength oral THC|Smoked Cannabis (0 mg THC) Oral THC (20 mg THC)
89356814|NCT05865431|Experimental|Zinc Oxide, Avobenzone, No Product|Participants have zinc oxide, avobenzone, and no product applied to 3 different spots on the forearm and singlet oxygen is measured after UV exposure.
89356815|NCT05865353||Diabetes|Ten Diabetic participants at risk of DFU/ in this cross-sectional study, participants will be asked to use the smart insole and complete sitting, standing and walking task
89356816|NCT05865353||Healthy control|Ten healthy participants without movement disorder or Diabetes. The same tasks (sitting, standing and walking) while wearing the smart insole will be repeated for the control group
89356817|NCT05865340|Other|oral health + MED diet|oral health + MED diet education
89356818|NCT05865340|Other|oral health|oral health education
89356819|NCT05865340|Other|MED diet|MED diet education
89356820|NCT05865340|No Intervention|compare|
89356821|NCT05865314|Experimental|Interventional group|
89356822|NCT05865314|Active Comparator|Control group|
89533888|NCT02519452|Experimental|Part 1: Cohort 2|Participants will receive 1800 mg (daratumumab 1800 milligram (mg) with Recombinant Human Hyaluronidase [rHuPH20] 45,000 U) via mixing immediately before SC infusion once weekly in Cycles 1 and 2, every 2 weeks in Cycles 3-6, and then every 4 weeks in subsequent cycles until disease progression.
88825933|NCT00989937|Placebo Comparator|Group 2|Three week placebo trial, one week washout, 20 IU BID for the fifth week, 40 IU BID for the following two weeks
89533889|NCT02519452|Experimental|Part 1: Cohort 3|Participants will receive mixture of daratumumab and rHuPH20 prepared immediately before administration via Subcutaneous (SC) delivery at a dose which will be decided by Study Evaluation Team (SET) once weekly by SC infusion in Cycles 1 and 2, every 2 weeks in Cycles 3-6, and then every 4 weeks in subsequent cycles until disease progression. Also up to three additional optional cohorts (Cohorts 3b, 3c, and 3d) may be enrolled to repeat a dose level of daratumumab.
88825934|NCT00982995|Experimental|Palonosetron|Palonosetron 0.25 mg I.V. bolus
89356823|NCT05865288|Experimental|Oxytocin|24IU (12IU*2) of Oxytocin, Sorbitol, Benzyl, alcohol glycerol, distilled water.
89356824|NCT05865288|Placebo Comparator|Placebo|24IU (12IU*2) of Sorbitol, Benzyl, alcohol glycerol, distilled water.
88825935|NCT01905254|Other|Transient elastography and liver biopsy|All patients with Autoimmune hepatitis (AIH) were investigated with Transient Elastography before liver biopsy
88825936|NCT00965055|Placebo Comparator|Atorvastatin|
89356825|NCT05865236|Experimental|physical therapy Dry air heat group along with kegel exercise|Woman should lie on the bed without panties or the sanitary Pad. Place towels under buttocks to absorb any vaginal discharge. She should lie on her back with the knees bent and feet flat. Let the vagina dry by holding a hair dryer 10 to 12 inches away from episiotomy. The dry heat will gives a soothing effect on the wound
89356826|NCT05865236|Active Comparator|therapeutics execise Infra-red lamp therapy along with kegel execise|The infrared the infrared lamp will be placed at distance of 45 cm away from the perineum with the heat emitted with 220 volts used for 10-15 minutes IRR is beneficial for promoting wound healing, tissue repair, and skin rejuvenation.
89356827|NCT05865223|Experimental|Mckenzie exercise program|"Group A Week 0 : Hot pack for 15 minutes, mackenzie extension exercise program for cervical regions and mobilization with movement at cervical regions for improving flexion, extension, side flexion and rotation. 3 sets of painless glides of 10 repetitions were given, with 1 minute rest between sets.~Week 2 & 4: Hot pack for 15 minutes, mckenzie exercise program at cervical region with the progression in repetition and MWM at cervical regions and then we will add progression.5 sets of painless glides of 10 repetitions were given, with 3 minute rest between sets.~Week 3 & 6: Hot pack for 15 minutes, mckenzie exercise program for cervical region and MWM at cervical region . 5 sets of painless glides for 10 repetitions were given. Progression can be introduced by increasing number of repetitions performed exercises for 3 weeks."
88825937|NCT00965055|Experimental|Atorvastatin/Ezetimibe|
88825938|NCT04331925|Other|Anxiety and depression screening|Hospital Anxiety and Depression Scale (HADS) questionnaire administered at the start of the study. After two weeks or at the time of discharge, participants will complete the HADS questionnaire again
88825939|NCT04331925|Experimental|Anxiety and depression screening with journaling|Parents randomized into the intervention group be given verbal instructions to use a journal how/when they choose for the duration of the intervention period. They will also complete the HADS questionnaire before and after the intervention period of two weeks. At the end of the intervention period, these parents will also complete a survey regarding their experience with journaling
88825940|NCT01905956|Active Comparator|IQP-AK-102|2 capsules per dose, three times daily
88825941|NCT01905956|Placebo Comparator|Placebo|2 capsules per dose, 3 times daily
88825942|NCT02266797|Active Comparator|Dexamethasone|Subject will receive doses of intravenous dexamethasone, a corticosteroid. The first dose will be given before the incision and the subsequent doses will be given 8 and 16 hours after the first dose. Dexamethasone doses will be 0.3 mg/kg for the first dose and 0.15 mg/kg for each subsequent dose.
88825943|NCT02266797|Placebo Comparator|Saline|Subject will receive doses of intravenous physiological saline solution.
88825944|NCT00936585|Other|Immunologic Monitoring|Blood draws and colonoscopy performed on patients enrolled in both intervention arms of the main study
88825945|NCT01906658|Experimental|Acthar 80 U (1.0 mL) SC twice weekly|Acthar (Repository Corticotropin Injection) 80 U (1.0 mL) SC twice weekly
88825946|NCT01906658|Experimental|Acthar 24 U (0.3 mL) SC daily|Acthar (Repository Corticotropin Injection) 24 U (0.3 mL) SC daily
89356828|NCT05865223|Active Comparator|conventional physical therapy|A routine physical therapy(joint mobilization,hot pack and home exercise program) treatment and hot pack for 15 minutes.
89533890|NCT02519452|Experimental|Part 2: Cohort 4|Participants will receive 1800 mg co-formulated daratumumab and rHuPH20 preparation initially administered by SC injection once weekly in Cycles 1 and 2, every 2 weeks in Cycles 3-6, and then every 4 weeks in subsequent cycles. The dose level and schedule for any additional cohorts would be selected based on the daratumumab pharmacokinetic profile and safety profile (reviewed by the SET) that will be observed in Cohort 4.
88825947|NCT01906658|Experimental|Acthar 56 U (0.7 mL) SC twice weekly|Acthar (Repository Corticotropin Injection) 56 U (0.7 mL) SC twice weekly
88825948|NCT01906658|Experimental|Acthar 16 U (0.2 mL) SC daily|Acthar (Repository Corticotropin Injection) 16 U (0.2 mL) SC daily
88825949|NCT02192775|Experimental|MV-NIS + Cyclophosphamide|
88825950|NCT00935649|Experimental|Randomized great toe|Subjects with both great toes infected. Right/left randomized to treatment / no treatment
88825951|NCT00935649|No Intervention|Untreated Toe|
88825952|NCT01908062|Active Comparator|Treatment as Usual|The current standard of care for treatment of opioid use disorders in HIV clinics is opioid agonist therapy. HIV-infected patients with alcohol use disorders are typically referred for residential, outpatient, and self-help groups.
88825953|NCT01908062|Experimental|Extended Release Naltrexone|Extended release naltrexone (XR-NTX), delivered by monthly injection. Dose: 380 mg. Frequency: One injection per month, for four months. Duration: 30 days.
88825954|NCT00924807|Experimental|Androgen Depr, Radiotherapy, Sorafenib|Everyone will receive Leuprolide acetate, Bicalutamide,Sorafenib and radiotherapy.
88825955|NCT02988674||Participants with Spondylarthritis|Participants with Spondylarthritis (ankylosing spondylitis and psoriatic arthritis) treated with adalimumab in routine clinical settings in the Russian Federation.
88825956|NCT00896025|Active Comparator|N-acetycylcysteine|Each eligible Acute Liver Failure patient will be given N-acetylcysteine (NAC), beginning at a dose of 150 mg/kg bodyweight in 250 ml 5% dextrose over one hour, followed by 50 mg/kg in 500 ml 5% dextrose over four hours, and 125 mg/kg in 1000 ml 5% dextrose over 19 hours, then 150 mg/kg in 1000 ml 5% dextrose per 24 hours for an additional 48 hours. The patient will be on continuous N-acetylcysteine infusion for a total of 72 hours.
88825957|NCT00896025|No Intervention|Standard of care|Each eligible Acute Liver Failure patient for whom the investigator chooses not to utilize N-acetylcysteine may serve as a control and receives standard of care.
88825958|NCT01908530|Experimental|Microprobe Glucose Sensor Phase 1|The microprobe array continuous glucose sensor will be applied to healthy volunteers for 6 hours
88825959|NCT01908530|Experimental|Microprobe Glucose Sensor Phase 2|The microprobe array continuous glucose sensor will be applied to healthy volunteers for 24 hours
88825960|NCT01908530|Experimental|Microprobe Glucose Sensor Phase 3 and 4|The microprobe array continuous glucose sensor will be applied to participants with type 1 diabetes
88825961|NCT02162979|Experimental|Viagra|subjects will be randomized to active treatment for 2 weeks, washout for 1 week, then enter the other study arm for two weeks.
88825962|NCT02162979|Placebo Comparator|Placebo comparator|subjects will be randomized to placebo treatment for 2 weeks, washout for 1 week, then enter the other study arm for two weeks.
88825963|NCT01908842|Active Comparator|Buprenorphine; then OL BNX film, then BNX tablets|Days 1-2: Generic buprenorphine sublingual tablets (blinded); Days 3 to 14: Buprenorphine/naloxone sublingual film (open-label); Days 15-21: BNX sublingual tablets (open-label); Day 22: Offered option in continuing in open-label follow-up study of BNX sublingual tablets
88825964|NCT01908842|Experimental|BNX tablets, then OL BNX tablets, then BNX film|Days 1-2: BNX sublingual tablets (blinded); Days 3 to 14: BNX sublingual tablets (open-label); Days 15-21: Buprenorphine/naloxone sublingual film (open-label); Day 22: Offered option in continuing in open-label follow-up study of BNX sublingual tablets
88825965|NCT05292261|Experimental|Team handball group|The team handball group participants were encouraged to performed at least two out of three weekly supervised team handball training sessions of 60 min each, for 36 weeks.
88825966|NCT05292261|No Intervention|Control group|The control group participants were instructed to keep their regular daily physical activity for 36 weeks.
89356829|NCT05865210|Experimental|Kegel Exercise with Myofascial release technique group:|Group A, we told patient to perform kegel exercise by hold and relax the pelvic floor muscles, initially 3-4 contractions for 3-5 seconds then we increase the repetition according to patient and apply myofascial release for trigger points. 4 session per week and post intervention assessment after 3 weeks follow-up
89533891|NCT02519452|Experimental|Part 3: Dara-CF 1800 mg|Participants will receive co-formulated daratumumab 1800 mg and rHuPH20 preparation (Dara-CF) initially administered by SC injection once weekly in Cycles 1 and 2, every 2 weeks in Cycles 3-6, and then every 4 weeks in subsequent cycles.
89533892|NCT02516241|Experimental|Combination Therapy|MEDI4736 (Durvalumab) + Tremelimumab
88825967|NCT03727425|Experimental|Robotic assisted bronchoscopy|Robotic assisted bronchoscopy procedures will be performed using the Monarch platform.
88825968|NCT02987816|Sham Comparator|Sham tDCS|Sham tDCS. 45 second ramp up to 1milliamp, 60 second current hold at 1milliamp, 45 second ramp down to 0milliamp. Anode positioned over the left primary motor cortex, and the cathode over the contralateral supraorbital area.
88825969|NCT02987816|Experimental|Anodal tDCS|Anodal tDCS. 45 second ramp up to 1milliamp, 20 minute current hold at 1milliamp, 45 second ramp down to 0milliamp. Anode positioned over the left primary motor cortex, and the cathode over the contralateral supraorbital area.
88825970|NCT00833859|Experimental|Chemotherapy followed by Radiation Treatment|GTX-SRS: Gemcitabine, Taxotere, Xeloda (GTX)-Stereotactic Radiosurgery (SRS)
88825971|NCT00832299|Experimental|6 cycles of FOLFOX pre and post TME|
88825972|NCT03723603|Experimental|Fibrillar Collagen Powder Dressing|
88825973|NCT03723447|Active Comparator|Bupivacaine/epinephrine/dexamethasone TAP block|For the bupivacaine/epinephrine/dexamethasone treatment arm, a standard weight-based dose of bupivacaine and epinephrine combined with 8mg dexamethasone will be administered.
88825974|NCT03723447|Active Comparator|Liposomal bupivacaine TAP block|For the liposomal bupivacaine treatment arm, 266mg liposomal bupivacaine (Exparel) will be administered.
89533893|NCT02516241|Experimental|Monotherapy|MEDI4736 (Durvalumab)
89533894|NCT02516241|Active Comparator|Standard of Care|Standard of Care Chemotherapy Treatment
89533895|NCT02497261||Avoiding and possibly allergic to peanut|Challenge Group: Children with positive skin prick testing to peanut who are avoiding peanut will undergo a double-blind placebo-controlled peanut challenge (gold standard for peanut allergy diagnosis) if their allergy evaluation suggests that they have a good chance of not being allergic to peanut. Children who pass the challenge are not allergic to peanut. Children who react during the challenge are allergic to peanut and will continue to avoid peanut.
89177289|NCT00811330|Experimental|1: Atorvastatin 80 mg.|Atorvastatin 80 mg PO every day for one year. The treatment will start 4 weeks before aortic valve replacement.
89177290|NCT00811330|No Intervention|2: No Atrovastatine|
89177291|NCT04110912||Cardiac arrest|Ischaemic heart disease is the leading cause of death worldwide. However, this is a registry and no interventions are taking place
88825975|NCT03718455|Experimental|Axillary Magseed|Single cohort of twenty women receiving neoadjuvant chemotherapy with breast cancer will have a Magseed inserted into a biopsy proven metastatic axillary lymph node for pre-surgical localization.
88825976|NCT00836355|Experimental|Enoxaparin|
88825977|NCT00836355|Experimental|Minocycline|Minocycline 200 mg orally once daily for 5 days
88825978|NCT00836355|Experimental|Enoxaparin and minocycline|
88825979|NCT00836355|No Intervention|Control|
89533896|NCT02497261||Not allergic to peanut|Comparison Group: Children with positive skin prick testing to peanut who are eating and tolerating peanut are not clinically allergic to peanut and may continue eating peanut.
88825980|NCT00816777|Experimental|Chemoembolization|Chemoembolization with Irinotecan Bead in combination with Intravenous Chemotherapy Group (test arm)
88825981|NCT00816777|Active Comparator|Chemotherapy|Irinotecan monotherapy: 250mg/m2 repeated every 3 weeks
88825982|NCT00823095|Experimental|Topically applied Nitric Oxide|Topically applied Nitric Oxide for 8 hours daily for 2 weeks.
88825983|NCT03703791|Active Comparator|Group 1 (AR101 Treatment + standard of care)|Subjects receiving AR101 treatment will have 3 consecutive AR101 dosing periods before exiting (completing) the study: initial dose escalation, up dosing, and maintenance.
88825984|NCT03703791|No Intervention|Group 2 (Standard of Care Treatment)|Subjects receiving standard of care alone will have approximately 18 months of observation before study exit, with an OLFC (open label food challenge) approximately 12 months after randomization.
88825985|NCT00803283|Experimental|Hydromprphone Hydrochloride (HCl) OROS|Participants will receive hydromorphone HCl OROS 8 milligram (mg) every 24 hours, for 3 to 14 days of titration phase. Hydromorphone HCl OROS will be continued as per Investigator's discretion for next 14 days of maintenance phase.
88825986|NCT00803283|Active Comparator|Morphine Sustain Release (SR)|Participants will receive morphine SR 8 mg every 24 hours, for 3 to14 days of titration phase. Morphine SR will be continued as per Investigator's discretion for next 14 days of maintenance phase.
88825987|NCT03697551|Experimental|68Ga-OPS202|A single dose of Satoreotide trizoxetan will be administered as a slow intravenous (i.v.) bolus injected over 1 minute at Baseline/Day 1.
88825988|NCT00799773|Experimental|1|Participants will receive rituximab in addition to plasma exchange and corticosteroids.
88825989|NCT00799773|Active Comparator|2|Participants will receive plasma exchange and corticosteroids.
88825990|NCT01975467||Control Group - Nonoperative|Subjects that were treated with a sling for their displaced midshaft clavicle fracture.
88825991|NCT01975467||Test Group - Intramedullary Nail|Subjects that were treated with an intramedullary nail for their displaced midshaft clavicle fracture.
88825992|NCT00760461|Other|Domperidone|
88825993|NCT00750555|Other|1|
88825994|NCT00754767|Experimental|Arm I|Patients receive oral L-carnitine L-tartrate twice daily beginning on day 2 of the first course of chemotherapy and continuing until after completion of 4 courses of chemotherapy.
88825995|NCT00754767|Placebo Comparator|Arm II|Patients receive oral placebo twice daily beginning on day 2 of the first course of chemotherapy and continuing until after completion of 4 courses of chemotherapy.
88825996|NCT00751335|Experimental|CPAP with ThermoSmart, then CPAP without ThermoSmart|"CPAP with ThermoSmart is the application of CPAP with heated humidification and a heated breathing tube.~CPAP without ThermSmart is the application of CPAP with heated humidification without a heated breathing tube."
88825997|NCT00751335|Experimental|CPAP without ThermoSmart, then CPAP with ThermoSmart|"CPAP with ThermoSmart is the application of CPAP with heated humidification and a heated breathing tube.~CPAP without ThermSmart is the application of CPAP with heated humidification without a heated breathing tube."
89533897|NCT02471365||Healthy Volunteers|Non-pregnant and non-nursing females between 35 and 74 who usesa high number (e.g., 15 or more products a day) of consumer products.
88825998|NCT01962675|Experimental|tDCS and skilled training|tDCS and skilled leg training. Transcranial direct current stimulation + step training TDCS will be delivered to the motor cortical area in conjunction with skilled locomotor training
88825999|NCT01962675|Sham Comparator|Sham tDCS and skilled leg training|Sham (Non active) tDCS and skilled leg training. 'Sham transcranial direct current stimulation + step training Sham tDCS will be delivered to the motor cortical area in conjunction with skilled locomotor training
88826000|NCT00706329|Experimental|Deflux|Treatment with Deflux.
88826001|NCT01941615|Experimental|BI 207127 + faldaprevir + Microgynon|Period A: Microgynon®; Period B: Microgynon® + FDV + BI 207127
88826002|NCT01901679|Experimental|Celebrex|10 days treatment with Celebrex to evaluate reduction of PGE-M in urine
88826003|NCT00688935|Experimental|Melatonin|Subjects may opt to enroll in this treatment sub-study involving melatonin treatment (0.1 - 3 mg, daily) for up to 1 year, with a minimum of 6 weeks. Throughout treatment, subjects will continue their saliva, plasma, and/or urine sampling to test for treatment efficacy.
88826004|NCT01877343|Experimental|CVInsight (TM)|Patient will be placed on a tilt table and pulse oximetry (Nonin Medical)and blood pressure will be measured at different table positions (different angles). A hemodynamic monitor called CVInsight(TM) will be used to monitor the pulse oximeter readings.
88826005|NCT00684255|Experimental|Reduced Intensity Regimen for Refractory SLE|RI regimen of fludarabine/busulfan and Alemtuzumab (FBA) followed by AlloSCT in selected patients with medically refractory Systemic Lupus Erythematosus (SLE).
89533898|NCT02456532|Placebo Comparator|Placebo|Intervention: Six months of nightly placebo
89533899|NCT02456532|Active Comparator|Zolpidem CR|Intervention: Six months of zolpidem cr 12.5 mg nightly use
89533900|NCT02456532|Active Comparator|Eszopiclone|Intervention: Six months of eszopiclone 3 mg nightly use
89356830|NCT05865210|Active Comparator|Kegel Exercise group|Group B, In this group we only perform kegel exercises to patients as hold and relax of pelvic floor muscle 3-4 contraction for 3-5 seconds.4 session per week and post intervention assessment after 3 weeks follow-up
89356831|NCT05865184||Passive monitoring|No intervention
89356832|NCT05865145|Experimental|Group A|will receive High Intensity Interval Training program
89356833|NCT05865145|Experimental|Group B|will receive Low Intensity Interval Training program
89356834|NCT05865132|Experimental|Palbociclib + Afatinib|The first 6 enrolled patients were treated with Palbociclib 125 mg po qd on day 1 to 21, Afatinib 40 mg po qd on day 1 to 14, every 28 days as a cycle; If there are ≥ 2 cases of dose-limiting toxicity (DLT), the following 6 patients will reduce the dose to Palbociclib 125mg po qd on day 1 to 21, Afatinib 30mg po qd on day 1 to 28, every 28 days as a cycle; If ≥ 2 cases of DLT occur again, the following 6 patients will reduce the dose to Palbociclib 100mg po qd on day 1 to 21, Afatinib 30mg po qd on day 1 to 28, every 28 days as a cycle; If ≥ 2 cases of DLT occur again, we will analyze the characteristics of adverse events and determine the subsequent dose.
88826006|NCT00684255|Experimental|Reduced Intensity Regimen for SSc|RI regimen of fludarabine/busulfan and Alemtuzumab (FBA) followed by AlloSCT in selected patients with Systemic Sclerosis (SSc).
88826007|NCT00668265|Experimental|Seroquel|
88826008|NCT01856361|Experimental|Ramipril|The initial dose of ramipril will be 2.5 mg that will be started at visit 2, week zero of the study. The dose will be increased to 5 mg during visit 3, 4 weeks into the study, for a total of 32 weeks.
88826009|NCT01856361|Sham Comparator|Placebo|The placebo group will get a similar pill that will be started at visit 2, week zero of the study. Subjects will be asked to double the dose by taking two pills during visit 3, four weeks into the study, for a total of 32 weeks.
88826010|NCT00642603|Experimental|XELOX + bevacizumab (Q2W)|
88826011|NCT00642603|Experimental|XELIRI + bevacizumab (Q2W)|
88826012|NCT03689192|Experimental|ARG1-18,19,20 peptide vaccine|One ARG1-vaccine every third week for 45 weeks.
88826013|NCT05313087||Controls - who are NOT in any of the groups listed below|Adults and children age 5 and over.
89356835|NCT05865054||Ocular GCA|GCA with clinical diagnosis of ischemic optic neuropathy or other ocular condition
88826014|NCT05313087||Previous COVID infection|Adults and children age 5 and over.
88826015|NCT05313087||Asthma receiving immunomodulator medications|Adults and children age 5 and over.
88826016|NCT05313087||Asthma receiving chronic oral steroids|Adults and children age 5 and over.
88826017|NCT05313087||Asthma - NOT receiving immunomodulator medications or chronic oral steroids|Adults and children age 5 and over.
88826018|NCT05313087||Chronic Obstructive Pulmonary Disease (COPD|Adults
88826019|NCT05313087||Rheumatoid Arthritis receiving immunomodulator medications|Adults and children age 5 and over.
88826020|NCT05313087||Rheumatoid Arthritis NOT receiving immunomodulator medications|Adults and children age 5 and over.
88826021|NCT05313087||Interstitial lung disease|Adults and children age 5 and over.
89356836|NCT05865054||Non-Ocular GCA|GCA without ocular manifestations
89533901|NCT02446145|Experimental|Experimental intervention arm|"Eltrombopag daily from day 12 to 25: 200 mg/day p.o. (100 mg for east asian patients) dose modification 100 mg up to 300 mg/d p.o. (50 - 150 mg for east asian patients)~concomitant medication: either Decitabine days 1-5 of each cycle: 20 mg/sqm i.v. over 30 minutes or Azacitidine (AZA) days 1-7 of each cycle: 75 mg/sqm s.c.~one cycle lasts 28 days"
88826022|NCT05313087||Cancer patients receiving chemotherapy|Adults and children age 5 and over.
88826023|NCT05313087||Bronchiectasis|Adults and children age 5 and over.
88826024|NCT05313087||Cystic fibrosis|Adults and children age 5 and over.
89000576|NCT02295865|Experimental|JNJ-38518168 60 mg|Participants will receive two tablets of JNJ-38518168, 30 milligram (mg) each for a total of 60 mg, together with one 30 mg matching placebo tablet and one 3 mg matching placebo tablet, orally, once daily, for 12 Weeks.
89000577|NCT02295865|Experimental|JNJ-38518168 30 mg|Participants will receive one tablet of JNJ-38518168, 30 mg, together with two 30 mg matching placebo tablets and one 3 mg matching placebo tablet, orally, once daily, for 12 Weeks.
89000578|NCT02295865|Experimental|JNJ-38518168 3 mg|Participants will receive one tablet of JNJ-38518168, 3 mg, together with three 30 mg matching placebo tablets, orally, once daily, for 12 Weeks.
89356837|NCT05865054||Non-GCA|Initially suspected to have GCA but final clinical diagnosis not GCA
88826025|NCT00610467|Experimental|Disease Group|Patients with suspicious breast diseases
88826026|NCT00610467|Experimental|Control Group|Healthy volunteers for system testing
88826027|NCT05312931||Group A|students who underwent original concept of First Aid
88826028|NCT05312931||Group B|student who underwent new concept of First Aid
88826029|NCT04713891|Experimental|Phase 1a: Cohort 1|KF-0210 tablet will be administered at 120 mg as a single agent orally once daily (QD) continuously in cycles (1 cycle=21 days) until the disease progression, intolerance, or informed consent withdrawal.
88826030|NCT04713891|Experimental|Phase 1a: Cohort 2|KF-0210 tablet will be administered at 240 mg as a single agent orally once daily (QD) continuously in cycles (1 cycle=21 days) until the disease progression, intolerance, or informed consent withdrawal.
88826031|NCT04713891|Experimental|Phase 1a: Cohort 3|KF-0210 tablet will be administered at 450 mg as a single agent orally once daily (QD) continuously in cycles (1 cycle=21 days) until the disease progression, intolerance, or informed consent withdrawal.
88826032|NCT04713891|Experimental|Phase 1a: Cohort 4|KF-0210 tablet will be administered at 600 mg as a single agent orally once daily (QD) continuously in cycles (1 cycle=21 days) until the disease progression, intolerance, or informed consent withdrawal.
88826033|NCT04713891|Experimental|Phase Ib, Cohort 1|KF-0210 (dose RP2D-2, orally once daily)+ Atezolizumab (1200 mg every 3 weeks) continuously until disease progression/recurrence or death from any cause, or serious adverse events (SAE) observed (whichever occurs earlier) for up to 2 years.
89356838|NCT05864989|Experimental|NIPSA in deep supra-alveolar defects without connective tissue graft|
89000579|NCT02295865|Experimental|Placebo|Participants will receive three tablets of JNJ-38518168, 30 mg matching placebo, together with one 3 mg matching placebo tablet, orally, once daily, for 12 Weeks.
88826034|NCT04713891|Experimental|Phase Ib, Cohort 2|KF-0210 (dose RP2D-1, orally once daily)+ Atezolizumab (1200 mg every 3 weeks) continuously until disease progression/recurrence or death from any cause, or serious adverse events (SAE) observed (whichever occurs earlier) for up to 2 years.
88826035|NCT04713891|Experimental|Phase Ib, Cohort 3|KF-0210 (dose RP2D, orally once daily)+ Atezolizumab (1200 mg every 3 weeks) continuously until disease progression/recurrence or death from any cause, or serious adverse events (SAE) observed (whichever occurs earlier) for up to 2 years.
89356839|NCT05864989|Active Comparator|NIPSA in deep supra-alveolar defects with connective tissue graft|
89356840|NCT05864963||Intervention group|18 patients treated with medial tab-type fasciocutaneous flaps
88826036|NCT00379509|Experimental|GW572016|
88826037|NCT00597909|Experimental|Arm 1|
89533902|NCT02446145|Placebo Comparator|Control intervention arm|"Placebo daily from day 1: 200 mg/day p.o. (100 mg for east asian patients) dose modification 100 mg up to 300 mg/d p.o. (50 - 150 mg for east asian patients)~concomitant medication: either Decitabine days 1-5 of each cycle: 20 mg/sqm i.v. over 30 minutes or Azacitidine (AZA) days 1-7 of each cycle: 75 mg/sqm s.c.~one cycle lasts 28 days"
88826038|NCT00597909|Experimental|Arm 2|
88826039|NCT00597909|Placebo Comparator|Arm 3|
88826040|NCT00422955|Experimental|Arm 1|
88826041|NCT00586209|Experimental|L-glutamine|"L-glutamine group will be given at the following dosage:~17-33.3 kg at 5 g 2x daily 33.4-66.6 kg at 10 g 2X daily >66.7 at 15 g 2X daily"
88826042|NCT00586209|Placebo Comparator|Placebo|"Maltodextrin group will be given at the following dosage:~17-33.3 kg at 5 g 2x daily 33.4-66.6 kg at 10 g 2X daily >66.7 at 15 g 2X daily"
88826043|NCT00588471|Active Comparator|Simvastatin|Subjects randomized to this arm will be pretreated with 80 mg (2 pills) simvastatin approximately one hour prior to percutaneous coronary intervention.
88826044|NCT00588471|Placebo Comparator|Placebo|Subjects randomized to this arm will be pretreated with 2 placebo pills approximately one hour prior to percutaneous coronary intervention.
88826045|NCT05600673|Experimental|Bimatoprost + CO2|Each patient received three CO2 fractional laser sessions 3 weeks apart with immediate and subsequent daily Bimatoprost 0.03%,1 drop for each 1cm².
88826046|NCT05600673|Active Comparator|CO2|Each patient received only three CO2 fractional laser sessions 3 weeks apart
88826047|NCT01784991|Active Comparator|1mg + 1mg Hydromorphone|Patient will receive 1 mg of hydromorphone for pain at timepoint 0. After 15 minutes, patients will be asked if the still need pain medication. If yes, patients will immediately receive 1mg hydromorphone. Patients will be under continuous monitoring for respiratory depression via capnometer. At 60 minutes, pain will be re-assessed for a second time. If needed, physician will give additional pain meds per their discretion.
89533903|NCT02379416|Experimental|treatment|The starting dose of nilotinib will be administered at 300 mg orally BID from cycle 1 day 2 and paclitaxel will be administered IV at 60 mg/m2 at dose level 1 on Days 1, 8, and 15 in 28-day cycles. For cycle 2 on, nilotinib will be administered from day 1. Dose escalation will follow a 3+3 design, with dose limiting toxicities defined during cycle 1.
88826048|NCT01784991|Active Comparator|Usual Care Group|"Patient will receive pain medicine per doctor's discretion at timepoint 0. After 15 minutes, patients will be asked if they still need pain medication. If yes, physicians will not be notified and patient will continue to have pain managed as deemed necessary by physician per usual care. Patients will be under continuous monitoring for respiratory depression via capnometer. At 60 minutes, pain will be re-assessed for a second time. If needed, physician will give additional pain meds per their discretion."
88826049|NCT01760889|Experimental|SPD489 Low Dose Range|
88826050|NCT01760889|Experimental|SPD489 High Dose Range|
88826051|NCT01760889|Placebo Comparator|Placebo|
88826052|NCT05600517|No Intervention|Standard prevention fluoride P4+|self-care prevention on diet, oral hygiene and fluoridated toothpaste 1450 ppm with checkup every second month with one occasion of fluoride varnish at the clinic.
88826053|NCT05600517|Experimental|Intensive prevention P4+|a patient-centered education on diet, oral hygiene and fluoridated toothpaste 5000ppm with check up´s and topical fluoride application (varnish) every second month.
88826054|NCT05600517|No Intervention|Standard prevention fluoride P4-|self-care prevention on diet, oral hygiene and fluoridated toothpaste 1450 ppm with checkup every second month with one occasion of fluoride varnish at the clinic.
88826055|NCT05600517|Experimental|Intensive prevention P4-|a patient-centered education on diet, oral hygiene and fluoridated toothpaste 5000ppm with check up´s and topical fluoride application (varnish) every second month.
88826056|NCT01745913|Experimental|Haplo-Cord SCT|The UCB unit must supply a minimum of 1.0 x107/kg pre-cryopreserved nucleated cell dose. The unit must match at a minimum of 4 of 6 at HLA-A, -B, -DRB1 loci with the recipient. This may include 0-2 antigen mismatches at each A or B (at the antigen level) or DRB1 (at the allele level) loci. All typing will be done using molecular typing. Though molecular level typing will be available, a match is defined at intermediate resolution for HLA-A and -B and at high resolution for -DRB1
89000580|NCT02288845|Experimental|ITI-007|ITI-007 formulated capsule will be administered orally once daily for up to 14 days in up to 14 subjects.
89000581|NCT02282761|Experimental|40 mg ITI-007|40 mg ITI-007 administered orally as formulated capsules once daily for 28 days
89000582|NCT02282761|Experimental|60 mg ITI-007|60 mg ITI-007 administered orally as formulated capsules once daily for 28 days
89356841|NCT05864963||Control group|46 patients were randomly chosen, through Propensity Score Matching (PSM) the matching was performed with the age variable. The types of flaps considered were: 15 cases with sural flap, 18 with soleus flap, and 13 with a gastrocnemius flap
89356842|NCT05864924|Experimental|BRG01 injection|Intravenous infusion
89356843|NCT05864911|Experimental|the Gastric Bypass Stent System group|all the participants were implanted with the Gastric Bypass Stent System for 12 weeks and followed up for 24 weeks.
89533904|NCT02356159|Experimental|1/Phase 1: Dose escalation arm|Induction chemotherapy, then palifermin at escalating doses, then conditioning chemotherapy, then allogeneic stem cell transplant, then immunosuppression
89533905|NCT02356159|Experimental|2/ Phase II arm|Induction chemotherapy, then palifermin at the MTDdetermined in Phase 1, then conditioning chemotherapy, then allogeneic stem cell transplant, then immunosuppression
89177292|NCT04110912||Trauma|Worldwide, trauma is the number one cause of death and disability in people younger than 40 and confirmed for Canada as well for those under the age of 45. However, this is a registry and no interventions are taking place
88826057|NCT01745913|Active Comparator|UCB SCT|For the standard arm, UCB units will be selected using the Minnesota strategy and the strategy followed in a recent CTN study.17;19Each unit must supply a minimum of 1.5 x107/kg pre-cryopreserved nucleated cell dose. Subjects must have two partially HLA-matched UCB units. Each unit must match at a minimum of 4 of 6 at HLA-A, -B, -DRB1 loci with the recipient. This may include 0-2 antigen mismatches at each A or B (at the antigen level) or DRB1 (at the allele level) loci. All typing will be done using molecular typing. Though molecular level typing will be available, a match is defined at intermediate resolution for HLA-A and -B and at high resolution for -DRB1
88826058|NCT05600361|Other|Patients having 13C Pyruvate DNP for lymphoma early treatment response evaluate|In stage 1, we expected to enroll 8 first-time diagnosed lymphoma patients referred from clinicians for 13C-pyruvate DNP MRS. In stage 2, another 8 patients with proven relapse will be referred from clinicians for 13C-pyruvate DNP MRS. We will collect related clinical information, patient follow up information, including treatment outcome, and imaging parameters from MRI and PET/CT.
88826059|NCT01693653|Active Comparator|Tocilizumab|tocilizumab infusion every 4 weeks over 3 months
88826060|NCT01693653|Placebo Comparator|Placebo|placebo infusion 0.9% sodium chloride every 4 weeks over 3 months
88826061|NCT01691079|Placebo Comparator|placebo|placebo 2 puffs prior to exercise challenge
88826062|NCT01691079|Active Comparator|ipratropium bromide|ipratropium bromide HFA 2 puffs prior to exercise challenge
88826063|NCT05599737|Experimental|Radiotherapy|"Stereotactic radiotherapy in 5 fractions (on alternate day)~Whole prostate: 36.25 Gy - 7.25Gy/fraction~GTV-RT (boost): target 50 Gy - 10 Gy/fraction"
88826064|NCT05599659|Experimental|Palliative care|Participants will receive palliative care.
88826065|NCT01673061|Active Comparator|Lidocaine|Lidocaine injection will be used for anesthesia prior to incision and drainage. 2% Lidocaine with epinephrine will be injected into the abscess site. Amount injected will be per physician discretion.
88826066|NCT01673061|Active Comparator|Vapocoolant|Vapocoolant spray will be used for anesthesia prior to incision and drainage. The spray will be administered to the abscess site for a duration of 2 seconds, from a distance of 12 cm.
88826067|NCT05599425|Active Comparator|Healthy Living Education|The basic healthy living education intervention is a 24-session program (two sessions/week for 12 weeks) designed to educate participants about major modifiable risk factors for Alzheimer's disease. The first session each week is didactic, intended to increase knowledge about each Alzheimer's disease risk factor. The second session involves repetition and practice of didactic material as well as strategizing cues to action
88826068|NCT05599425|Experimental|Enhanced Healthy Living Education|The enhanced healthy living education intervention will include the same didactic content as the basic HLE course for the first session each week. The second session will focus on personal health beliefs and how they affect specific health behaviors. This may include discussing perceived benefits, troubleshooting barriers to action, making specific action plans, and implementing natural reward systems to bolster self-efficacy.
88826069|NCT01602471|Experimental|[F-18]RDG-K5|[F-18]RDG-K5 was administred and PET scan performed
88826070|NCT05599269|Other|Examination of dentures with SR Phonares II teeth|
88826071|NCT05599113|Experimental|Extracorporeal Shock Wave Therapy|Extracorporeal shock wave therapy (ESWT) is an expedient remedy that is used in various joint and muscle pain treatments, is non-invasive, is well tolerated by patients, and has few side effects.
88826072|NCT01621737|Experimental|Oxytocin: Low Dose|42 IU BID for the six weeks
88826073|NCT01621737|Experimental|Oxytocin: High Dose|84 IU BID for six weeks
88826074|NCT01621737|Placebo Comparator|Placebo|
88826075|NCT05598801||VersaWrap|All enrolled patients will received VersaWrap applied prior to surgical closure on the affected tendon.
88826076|NCT04706169||Older adults|Participants, without symptoms in the shoulder and / or cervical area (at least the last year), were assigned to the Older adult group: over 65 years.
88826077|NCT04706169||Adults|Participants, without symptoms in the shoulder and / or cervical area (at least the last year), were assigned to the Adult groups: 20 to 64 years.
88826078|NCT04706325||COVİD19 PCR (Polymerase Chain Reaction) AND CT POSITIVE|COVİD19 PCR (Polymerase Chain Reaction) AND CT POSITIVE
88826079|NCT04706325||COVİD19 PCR (Polymerase Chain Reaction)NEGATİVE AND CT POSITIVE|COVİD19 PCR (Polymerase Chain Reaction)NEGATİVE AND CT POSITIVE
89533906|NCT02315612|Experimental|Arm 1|dose escalation of CD22-CAR
88826080|NCT04706325||COVİD19 PCR (Polymerase Chain Reaction) AND CT will be evaluated as NEGATIVE.|COVİD19 PCR (Polymerase Chain Reaction) AND CT will be evaluated as NEGATIVE.
88826081|NCT00379665|Experimental|Cisplatin|1 mg/ml at a dosage of approximately 2 mg per cubic cm of tumor. Weekly up to 6 injections.
88826082|NCT00379743|Active Comparator|2|Individuals randomized to this arm receive the following interventions: 1) educational materials on recommended cancer-preventive services, plus 2) a health coordinator (patient navigator) who helps the participant schedule and keep appointments for cancer screening and/or treatment.
88826083|NCT02056769|Experimental|CT Perfusion|All patients enrolled in the study
88826084|NCT05562687||Control group|subjects who do not have any heart disease, hypertension, or other chronic &inflammatory diseases, and their coronary arteries are normal
88826085|NCT05562687||CAD group with essential hypertension|subjects who have stenosis (at least 70%) of one of the main coronary arteries or its branches and have high blood pressure
88826086|NCT05562687||CAD group without essential hypertension|subjects who have stenosis (at least 70%) of one of the main coronary arteries or its branches and have normal blood pressure
88826087|NCT05562687||Hypertension group without CAD|the subjects were characterized by the normal coronary artery and high blood pressure
88826088|NCT02010983|Experimental|longstanding achalasia|
88826089|NCT01598025|Experimental|REGIMEN 1|"REGIMEN 1: Patients undergo hyperfractionated TBI TID for a total of 11-12 doses on days -10 to -7 and receive thiotepa IV over 4 hours QD on days -6 and -5, fludarabine phosphate IV over 30 minutes QD on days -6 to -2, and anti-thymocyte globulin IV on days -4 to -2.~TRANSPLANTATION: Patients undergo CD34-selected allogeneic PBSCT on day 0."
88826090|NCT01598025|Experimental|Regimen 2|"To be given to patients non-malignant, life-threatening diseases and patients with hematologic malignancies, with extensive prior therapy and comorbidities who are unable to receive TBI, consists of Melphalan 70mg/m2 IV x 2 days, thiotepa 5mg/kg IV x 2 days (or 10mg/kg x 1 day), and fludarabine 25 mg/m2 IV x 5 days.~TRANSPLANTATION: Patients undergo CD34-selected allogeneic PBSCT on day 0."
88826091|NCT01912313|Experimental|Rectal biopsy|
88826092|NCT01587963|Active Comparator|Ascorbic Acid|Ascorbic Acid
88826093|NCT01587963|Placebo Comparator|Ringers Lactate or Normal Saline|Ringers Lactate or Normal Saline
88826094|NCT01648751|Experimental|Vaginal estrogen|Patients in the experimental group will receive vaginal estrogen cream
88826095|NCT01648751|Placebo Comparator|Placebo cream|Patients in the comparison group will receive placebo vaginal cream
89177293|NCT04110912||Sepsis|Sepsis is a clinical syndrome that results from dysregulation of the inflammatory response to severe infection. However, this is a registry and no interventions are taking place
89177294|NCT04110912||Stroke|Stroke is the second leading cause of death worldwide, and the leading cause of chronic disability. However, this is a registry and no interventions are taking place
89177295|NCT00813514|Experimental|1|Open longitudinal study with observer masked analysis
88826096|NCT05550519|Experimental|Discontinuation of Nucleos(t)ide (NA) Treatment|Participants will receive standard of care NA treatment (Entecavir [ETV], Tenofovir Disoproxil Fumarate [TDF], Tenofovir Alafenamide [TAF]) in screening phase (up to 6 weeks) and in baseline visit (Day -1). NA treatment will be discontinued on Day 1 up to 96 weeks (Post-NA discontinuation off-treatment phase). Off-treatment refers to the phase after baseline, in which NA treatment will be discontinued.
88826097|NCT01203371|Experimental|Naftopidil|0,25 mg (2 weeks) and 0,50 mg (10 weeks)
88826098|NCT01203371|Active Comparator|Tamsusolin|0,4 mg/day
88826099|NCT05722691|Experimental|Double-stranded RNA sodium salt|Arm 1 (n=400) received the study drug RADAMIN®VIRO once intramuscularly, 5 mg (1 vial).
88826100|NCT05722691|Placebo Comparator|Placebo|Arm 2 (n = 400) received 1 vial of placebo once intramuscularly
88826101|NCT05722613||(Group A) periodontally healthy as a control|BOP <10%, PPD ≤ 3mm, intact periodontium (no probing attachment loss).
88826102|NCT05722613||(Group B) periodontitis currently unstable|Generalized periodontitis, currently unstable (PPD ≥ 5mm or PPD at ≥ 4mm with BOP).
88826103|NCT05722613||(Group C)periodontitis currently stable .|Generalized periodontitis, currently stable (BOP < 10 % PPD ≤4 mm and no BOP at 4mm sites)
88826104|NCT01549977|Experimental|Febuxostat 80 mg|Febuxostat 80 mg, tablets, orally, once daily for up to 12 weeks.
88826105|NCT01549977|Placebo Comparator|Placebo|Febuxostat placebo-matching tablets, orally, once daily for up to 12 weeks.
88826106|NCT01548651|Placebo Comparator|Placebo|Placebo 5 mg orally daily for 6 months
88826107|NCT01548651|Experimental|Saxagliptin|Saxagliptin 5 mg orally daily for 6 months
88826108|NCT05453877||subjects from Kailuan community|"1. Age from 18 to 90 years old; 2. Comes from the Kailuan Cohort, completed ≥1 visits which the medical history, physiological indicators were measured; 3. Without contraindications of CT and MR scan; 4. Can cooperate with the measurement of the medical history, physiological indicators and brain imaging.~Subjects with the following conditions should be excluded:~1. Known clinical history with congenital or acquired organic diseases (such as aortic stenosis); 2. Known history of drug abuse; 3. Pregnant and lactating women; 4. With clinical history of psychiatric diseases (such as schizophrenia)."
89177296|NCT00793104|Other|CR Plug|Placement of allograft CR Plug in primary injury site
89177297|NCT00807508|Experimental|1|daily leucine supplementation
89177298|NCT00807508|Placebo Comparator|2|daily placebo supplementation
88826109|NCT05722379||high-grade AVB patients undergoing permanent pacemaker implantations|
88826110|NCT01533753|Experimental|Arm A: Gabapentin|Gabapentin will be administered orally at a starting dose of 300mg at bedtime (titration encouraged to desired effect and tolerability per treating physician). Maximum dose allowed will be 300mg three times a day. One cycle is defined as 28 +/- 7 days.
88826111|NCT01533753|Experimental|Arm B: Venlafaxine|Venlafaxine will be administered orally at the starting dose of 37.5mg daily (titration allowed to desired effect and tolerability per treating physician). Maximum dose allowed will be 75mg per day. One cycle is defined as 28 +/- 7 days.
88826112|NCT05722301|Experimental|Testosterone Therapy|
88826113|NCT05722301|Placebo Comparator|No Testosterone Therapy|
88826114|NCT04344509||COVID19-positive patients|
88826115|NCT04344509||COVID19-negative patients|
88826116|NCT01534143|Experimental|Treatment (chemotherapy, enzyme inhibitor)|"CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -7 to -3, busulfan IV on days -6 to -3, and bortezomib IV on day -2.~GVHD PROPHYLAXIS: Patients receive thymoglobulin IV on days -3 to -1, sirolimus PO on day -3, and tacrolimus IV on day -3. Patients undergo allogeneic HSCT on day 0."
88826117|NCT02978729|Active Comparator|Telephone|Telephone telegenetics counseling: A trained Penn genetic counselor will conduct genotype disclosure visits with the participant via telephone. The participant will be in a private room at the study site. Telephone sessions will utilize a private phone line. The genetic counselor will use standardized disclosure checklist and visual aids for the disclosure session.
89000583|NCT02282761|Placebo Comparator|Placebo|Placebo administered orally as formulated capsules once daily for 28 days
89000584|NCT02282215|Experimental|CLT-008 low dose with G-CSF|Dose escalation
89000585|NCT02282215|Experimental|CLT-008 high dose with G-CSF|Dose escalation
89000586|NCT02282215|Experimental|CLT-008 with G-CSF|Randomized
89177299|NCT00446797|Active Comparator|Non-Selective NSAIDS|nsNSAIDs used in real-life standard practice for treatment of pain due to ankle sprain.
89177300|NCT00446797|Experimental|Celecoxib|
89356844|NCT05864885|Experimental|Primary safety and pharmacokinetic data|To obtain primary safety and pharmacokinetic data on the ANR- 001.1 when applied topically, once daily, for 7 days to the scalp
88826118|NCT02978729|Experimental|Videoconference|Two-way videoconferencing telegenetics counseling: A trained Penn genetic counselor will conduct genotype disclosure visits with the participant via two-way videoconferencing. The participant will be in a private room at the study site. Videoconferencing sessions will utilize tablets or laptops with web cameras and secure/confidential software for teleconferencing. The genetic counselor will use standardized disclosure checklist and visual aids for the disclosure session.
88826119|NCT05722223|Experimental|Training group|Pancreatic patients will participate in the trimodal prehabilitation: nutrition, psychological and exercise support.
88826120|NCT01528293|Active Comparator|ActiVAC System+ Compression therapy|ActiVAC System + Compression therapy group consisting of the application of this device along with compression therapy.
88826121|NCT01528293|Other|Compression therapy only|Standard of Care compression therapy only
88826122|NCT05290077|Active Comparator|Cases|group of vitiligo patients
88826123|NCT05290077|Active Comparator|control group|healthy group
88826124|NCT03831347|Experimental|Hatha Yoga|12 weeks of modified Hatha Yoga specifically designed to be administered to teens with depression.
88826125|NCT01692171|Experimental|Teste|Enoxalow (Heparin, Low-Molecular-Weight) - Blau Farmacêutica S/A.
88826126|NCT01692171|Active Comparator|Comparador|Clexane (Heparin, Low-Molecular-Weight)- Sanofi-Aventis
88826127|NCT05723315|Experimental|Experimental Group 1|The experimental group was given neoptin within 3h after PCI for 72 hours (first at 1.5μg /kg intravenous load, then at 0.015μg /kg/min).
88826128|NCT05723315|No Intervention|Control Gruop|The experimental group was given an intravenous infusion of the same amount of normal saline
88826129|NCT00490503||MRI + MRS|Patients with newly diagnosed stage II A-B or III A-C breast cancers who are scheduled to start systemic chemotherapy.
88826130|NCT05721833|Experimental|non-invasive high-frequency oscillatory ventilation|Patients were titrated for relevant parameters of non-invasive ventilation the day before the trial. In the non-invasive high-frequency oscillation ventilation mode, the support pressure is consistent with the non-invasive bi-level positive pressure mode, and the high frequency airway pressure oscillation driven by the solenoid valve is added during the expiratory phase. The amplitude is about 4cmH2O, and the oscillation frequency is about 8HZ.
88826131|NCT05721833|Active Comparator|Bilevel positive pressure ventilation|Patients were titrated for relevant parameters of non-invasive ventilation the day before the trial. Noninvasive bilevel positive pressure ventilation mode pressure titration follows previous studies.
88826132|NCT05715749|Experimental|In-home body weight support harness system|All participants will be entered into treatment arm and receive an in-home body weight support harness system
88826133|NCT05715593|Experimental|Education|
88826134|NCT05715593|No Intervention|Control|
88826135|NCT00570531|Experimental|Bevacizumab|
88826136|NCT05258565|Active Comparator|acute ischemic stroke without covid -19 infection|Administration of IV tPA: the dose of activase is ,9 mg /kg (not exceeding 90 mg total treatment dose) Infused over 90 minutes.
88826137|NCT05258565|Active Comparator|acute ischemic stroke associated with covid -19 infection|Administration of IV tPA: the dose of activase is, 9 mg /kg (not exceeding 90 mg total treatment dose) Infused over 90 minutes.
88826138|NCT04344743|Experimental|Cryoballoon ablation without contrast|Cryoballoon ablation without contrast
88826139|NCT05715515|Experimental|Nasal sampling/Testing (Self-Test) + Nasopharyngeal sampling/Testing (Professional Use)|"Lay users (self-tester or caregiver) will be provided with a Panbio™ COVID-19/Flu A&B Rapid Panel Self-Test kit. Each lay user will collect one mid-turbinate nasal swab from both nostrils, perform and interpret the Panbio™ COVID-19/Flu A&B Rapid Panel Self-Test. All procedures for testing and result interpretation, including sample collection and extraction will be conducted by the lay user following the Instructions for Use provided in the kit.~The first NP swab sample will be used to conduct a Panbio™ COVID- 19/FluA&B Rapid Panel Professional Use test.~The second NP swab sample will be eluted in Universal Transport Medium (UTM) provided by Abbott/the Core Laboratory, labelled and stored, according to the laboratory manual. UTM samples will be shipped to the Core Laboratory for testing with RT-PCR protocols for Flu A, Flu B and SARS-CoV-2, according to the laboratory manual."
88826140|NCT05715437|Experimental|Bupivacaine plus Normal Saline|30 patients will receive bolus shot 20ml of 0.5% of Bupivacaine plus 1ml Normal saline postoperative TKA.
88826141|NCT05715437|Experimental|Bupivacaine and Ketamine|30 patients will receive bolus shot 20ml of 0.5% of Bupivacaine plus 1ml ketamine (50mg) postoperative TKA.
88826142|NCT05216367|Experimental|Cohort 1 (healthy subjects)|8 healthy subjects with normal hepatic function will receive a single dose of 5 mg (1x5 mg) fruquintinib
88826143|NCT05216367|Experimental|Cohort 2 (moderate hepatic impairment)|8 subjects with moderate hepatic impairment will receive a single dose of 2 mg (2 x 1 mg) fruquintinib
88826144|NCT05216367|Experimental|Cohort 3 (mild hepatic impairment)|8 subjects with mild hepatic impairment will receive a single dose of 5 mg (1 x 5 mg) fruquintinib
88826145|NCT05721443|Experimental|Dalpiciclib+cetuximab|"The dosing regimen for cetuximab combined with dalpiciclib is: the starting dose of cetuximab is 400 mg/m2, titrated over 120 minutes, and the titration rate should be limited to 5 ml/min. A maintenance dose of 250 mg/m2, titrated over not less than 60 minutes, with pretreatment with H1 receptor blocker desensitization prior to dosing, administered once weekly.~The recommended dose of dalpiciclib is 150 mg once daily for 21 days, followed by 7 days of discontinuation (3/1 dosing regimen) for a 28-day treatment cycle. Take the drug at approximately the same time each day. If the patient vomits or misses a dose, the dose should not be made up that day. The next dose should be taken as usual.~Subjects will continue treatment with cetuximab in combination with dalpiciclib until termination criteria are met."
88826146|NCT00540969|Experimental|Arm I (percutaneous cryoablation)|Cryoprobes are inserted percutaneously under CT scan or ultrasound guidance, to the malignant soft tissue-bone interface. Patients undergo ablations using a freeze-thaw-freeze cycle lasting approximately 10-5-10 minutes, respectively.
89000587|NCT02282215|Active Comparator|G-CSF|Randomized
89533907|NCT02315612|Experimental|Arm 2|dose expansion of CD22-CAR
88826147|NCT00540969|Active Comparator|Arm II (external-beam radiotherapy)|Patients undergo external-beam radiotherapy comprising either a single 8 Gy dose or 20 Gy/5 fractions administered over 1 week.
88826148|NCT02978807||Pregnant women between 24 to 32 weeks|"Pregnant women with a singleton pregnancy who presented to care between 24 -32 weeks of their pregnancy were included in this study.~All patients enrolled in the study will receive a random point of care blood sugar, point of care and venous fasting blood sugar, point of care and venous 1 hr/2hr glucose tolerance test, and point of care and venous HbA1c."
88826149|NCT00524511|Experimental|1|Women receiving Dermabond for skin closure
88826150|NCT00524511|Active Comparator|2|Women receiving standard surgical skin staples
88826151|NCT05097807|Experimental|The impact of word-picture-based shallow reading in social media|Use Microblog on their smartphone, a word-picture-based social media service similar to twitter.
88826152|NCT05097807|Experimental|The impact of short video-based shallow reading in social media|Use Tiktok on their smartphone, a short video-based social media service.
88826153|NCT05097807|Active Comparator|The impact of full-length sci-fi novel reading|Read a full-length sci-fi novel (Three body) on their own smartphone.
88826154|NCT05097807|Active Comparator|The impact of film/TV series|Watch a film on their own smartphone.
88826155|NCT00523809|Experimental|Bevacizumab + Fludarabine + Melphalan|Bevacizumab 10 mg/kg intravenous (IV) on Day 1; Fludarabine 25 mg/m^2 IV Daily over 5 Days; Melphalan 70 mg/m^2 IV Daily over 2 Days; Thymoglobulin 0.5 mg/kg IV on Day - 3, 1.5 mg/kg IV on Day - 2, and 2 mg/kg IV on Day -1; plus Allogeneic Hematopoietic Stem Cell Transplantation on Day 8.
88826156|NCT03838211|Experimental|stimulation group|Anodal tDCS + intensive cognitive Training
88826157|NCT03838211|Sham Comparator|sham group|Sham tDCS + intensive cognitive Training
88826158|NCT05065281|Experimental|Education|Participants that have undergone the educational intervention
88826159|NCT05065281|No Intervention|Waitlist|Participants still waiting to cross over to intervention arm
88826160|NCT00511329|Experimental|Somatropin|
88826161|NCT03838055|Experimental|SLN only|Pelvic SLN's defined by ICG injected cervically
88826162|NCT00501345|Experimental|Aspirin|
88826163|NCT05721287|Active Comparator|SBS-1000|Investigational Product
88826164|NCT05721287|Placebo Comparator|Placebo|Normal saline (0.9% sodium chloride [NaCl])
89177301|NCT00855335|Experimental|Group 1: Darunavir 600 /Ritonavir 100|TMC114 (darunavir) Two 300 milligram (mg) or one 600 mg tablet twice daily up to 12 weeks postpartum / ritonavir one 100 mg tablet twice daily with darunavir up to 12 weeks postpartum.
88826165|NCT00487461|Placebo Comparator|Control Group|Placebo tablet
88826166|NCT00487461|Experimental|Study Group #1|Simvastatin 40 mg
88826167|NCT00487461|Experimental|Study Group #2|Simvastatin 80 mg
88826168|NCT02978651|Experimental|Pitolisant (BF2.649)|Histamine H3 receptor H3R antagonist/ inverse agonist
88826169|NCT02978651|Placebo Comparator|Placebo|Placebo
89177302|NCT00855335|Experimental|Group 2: Darunavir 800/Ritonavir 100|TMC114 (darunavir) 800mg tablet once daily up to 12 weeks postpartum/ ritonavir one 100 mg tablet once daily with darunavir up to 12 weeks postpartum.
89177303|NCT00855335|Experimental|Group 3: Etravirine|TMC125 (etravirine) 200 mg (1*200 mg/2*100 mg) tablets twice daily up to 12 weeks postpartum.
89177304|NCT00855335|Experimental|Group 4: Rilpivirine|TMC278 (rilpivirine) One 25 mg tablet once daily up to 12 weeks postpartum.
89177305|NCT00855335|Experimental|Group 5: Darunavir 800/Cobicistat 150|Fixed dose combination (FDC) tablet of TMC114 (darunavir) 800 mg and cobicistat 150 mg once daily up to 12 weeks postpartum.
89177306|NCT00811486|No Intervention|Usual care|Group II
89177307|NCT00811486|Experimental|Spironolactone and conivaptan|Group I
89177308|NCT00813670|Experimental|Cohort 1: Single dose of XPF-001|
89177309|NCT00813670|Experimental|Cohort 2: Single dose of XPF-001|
89177310|NCT00813670|Experimental|Cohort 3: Single dose of XPF-001|
89177311|NCT00813670|Experimental|Cohort 4: Single dose of XPF-001|
89177312|NCT00813670|Experimental|Cohort 5: Single dose of XPF-001|
89177313|NCT00813670|Experimental|Cohort A: Repeated doses of XPF-001|
89177314|NCT00813670|Experimental|Cohort B: Repeated doses of XPF-001|
89177315|NCT00813670|Experimental|Cohort C: Repeated doses of XPF-001|
89177316|NCT04114188|Experimental|Antithymocyte Immunoglobulin (Rabbit)|rATG induction on day 0 & 1 post op
89177317|NCT00915252|Experimental|5-azacytidine|Patients enrolled in this arm will receive standard induction and consolidation chemotherapy preceded by 5-azacytidine. These patients will additionally receive maintenance therapy with 5-azacytidine for one year after start of induction therapy.
89177318|NCT00915252|Active Comparator|standard chemotherapy|Patients enrolled in this arm will receive standard chemotherapy treatment.
89177319|NCT00813826|Experimental|SLC022|300mg TID
89177320|NCT00813826|Placebo Comparator|Placebo|Matching placebo capsule
89177321|NCT00799422|Active Comparator|ReNu MultiPlus|ReNu MultiPlus used as specified in the protocol for contact lens care. In this crossover study, ReNu MultiPlus was dispensed in randomized order with Complete Easy Rub and Clear Care. Each product was used for one week with a fresh pair of Acuvue Oasys contact lenses. A 36-hour washout preceded each usage period.
89177322|NCT00799422|Active Comparator|Complete Easy Rub|Complete Easy Rub used as specified in the protocol for contact lens care. In this crossover study, Complete Easy Rub was dispensed in randomized order with ReNu MultiPlus and Clear Care. Each product was used for one week with a fresh pair of Acuvue Oasys contact lenses. A 36-hour washout preceded each usage period.
89177323|NCT00799422|Active Comparator|Clear Care|Clear Care used as specified in the protocol for contact lens care. In this crossover study, Clear Care was dispensed in randomized order with Complete Easy Rub and ReNu MultiPlus. Each product was used for one week with a fresh pair of Acuvue Oasys contact lenses. A 36-hour washout preceded each usage period.
89356845|NCT05864781|No Intervention|Control group|With the students in the control group, a standard individual article review will be conducted under the supervision of the instructor.
89533908|NCT02314364|Experimental|Stereotactic body radiation therapy (SBRT) with protons or photons|"SBRT dosage determined by treating physician~Patients will continue to receive standard of care (SOC) tyrosine kinase inhibitors (TKI) in the intervals between SBRT courses, as well as after the completion of SBRT~If there is more than one active site of cancer, additional site(s) will be treated with stereotactic treatment courses. The total duration of SBRT courses (from the first day of any SBRT course to the last day of any SBRT course) will not exceed 4 months."
88826170|NCT05712629|Active Comparator|Responden Intervention|Arm 1 (Interventional) : Respondent has given bread with composit flour and vla with dadiah. pregnant women received 1 pieces bread containing 50 gram provide total fat 4 gram, protein 5 gram, carbohydrate 23.8 gram, Fe 2 mg, 2150 kcal and vla dadiah containing 30 gram provide 308 kcal.
88826171|NCT05712629|Placebo Comparator|Responden Placebo|Arm 2 (Placebo) : Respondent has given bread with original flour (wheat flour) and vla original without dadiah. pregnant women received 1 pieces bread containing 50 gram and vla containing 30 gram.
88826172|NCT04962321|Experimental|PsychoEd|These participants are enrolled to participate in the 8-session education sessions.
88826173|NCT04954443|Experimental|Removing urinary catheter at 24 hours after surgery|The participants will removing urinary catheters at 24 hour after vaginal surgery of pelvic organ prolapse.
88826174|NCT04954443|Placebo Comparator|Removing urinary catheter at 48 hours after surgery|The participants will removing urinary catheters at 48 hour after vaginal surgery of pelvic organ prolapse.
88826175|NCT05207761|Experimental|Sequence 1|"Period 1: D565 7days~Period 2: D565+D930 91days"
88826176|NCT05207761|Experimental|Sequence 2|"Period 1: D930 91days~Period 2: D565+D930 7days"
88826177|NCT05720975||Experimental: iNstroke|Study device
88826178|NCT05720897|Experimental|Auditory Alone Brief Relaxation|Participants randomized to this arm will receive earphones to listen to a guided brief relaxation recording, focusing on breathing and a body scan, prior to their dental procedure.
88826179|NCT05720897|Experimental|Relaxation Virtual Reality|Participants will receive virtual reality goggles and choose a scene of their liking to experience, prior to their dental procedure.
88826180|NCT05178979|Experimental|Intervention|The intervention arm will receive up to 4 sessions of training. Trained intervention facilitator experienced in health professional trainings will lead the training. The intervention content delivered is aimed to increase HIV providers' knowledge, motivation, skills, and empathy to: 1) equitably deliver ART program guidelines (i.e., quality of care) and 2) provide gender sensitive counseling to address ART patients' gendered barriers to HIV care engagement, increasing patient satisfaction, retention, and ART adherence, and reducing gender disparities in HIV outcomes.
88826181|NCT05178979|No Intervention|Control|The control arm will receive no training.
88826182|NCT00370695|Experimental|Precision Spinal Cord Stimulation System|Single arm Precision Spinal Cord Stimulation System.
88826183|NCT05720819|Experimental|Intervention Group (Biofeedback-VR intervention plus standard clinical care)|This arm includes individuals with chronic migraine receiving the home-based biofeedback-VR intervention plus standard medical care as treatment for chronic migraine
88826184|NCT05720819|No Intervention|Control Group (standard clinical care alone)|This arm, a wait-list control group, includes individuals with chronic migraine receiving standard medical care alone as treatment for chronic migraine.
88826185|NCT00356187|Experimental|Propranol Treatment|
88826186|NCT00356187|No Intervention|Standard of Care|
88826187|NCT02973399|Experimental|SNX-5422 plus ibrutinib|Open-label administration of SNX-5422 capsules dosed in the morning once every other day for 21 days (11 doses) followed by a 7 day drug free period and daily with the established ibrutinib dose for 28 days of a 28-days cycle. Subjects will repeat the 28-day schedule for 2 cycles after a CR or until the cancer progresses or the subject is unable to tolerate the therapy
88826188|NCT05708963||U.K. Embryologists|U.K. embryologists of all ages, career levels, and other sociodemographic groups will be asked questions about their physical and mental health related to their occupational characteristics using the nationally validated surveys and questionnaires, and also about their working conditions in the ART/IVF laboratories using a custom occupational questionnaire and the single-item work unit grade (A-F).
88826189|NCT04879563|Experimental|ASCAPE-based follow-up strategy|Follow-up through ASCAPE platform including AI-based predictions for health-related QoL issues and suggestions for personalized interventions.
88826190|NCT04680117|Other|Cases with SA, classified by age group|Patient hospitalized for assessment of severe asthma
88826191|NCT04680117|Other|Controls among children w/ SA: frequent&infrequent exacerbators|Frequent exacerbators have 2 or more asthma severe exacerbations in the past years
88826192|NCT02224729|Experimental|Bendamustine, Bortezomib, Dexamethasone (Standard)|Patients receive bendamustine hydrochloride IV over 30 minutes on days 1 and 2; bortezomib SC on days 1, 8, 15, and 22; and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 35 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients achieving less than a VGPR or with more than 10% bone marrow plasmacytosis may receive 2 additional courses.
89356846|NCT05864781|Experimental|Experimantal group|The students in the experimental group will be divided into 8 main groups of 7 students according to their academic grade point average. In these groups, each member will be responsible for one of the 7 sections of the article. Those who take the same section in the groups will unite to form expert groups and specialize by working on this section. Students will then return to their main groups and analyze an experimental article. From the groups presenting their reviews, a winner will be selected and a prize will be awarded.
88826193|NCT00320931|Experimental|Hybrid PET/CT|
88826194|NCT03004495|Experimental|CHF5259 and CHF6001|(T): CHF6001 + CHF5259 b.i.d. for 14 days
88826195|NCT03004495|Active Comparator|CHF5259 + placebo|(R1): CHF5259 25µg b.i.d. for 14 days
88826196|NCT03004495|Active Comparator|CHF6001 + placebo|(R2): CHF6001 b.i.d. for 14 days
88826197|NCT05720585|Experimental|Intervention group|
88826198|NCT03004417|Experimental|CHF 6001 Dose1|CHF6001 via NEXThaler® dry powder inhaler (DPI), b.i.d. for 32 consecutive days.
89533909|NCT02311374|Sham Comparator|Phase 2|ADC will be measured in the same subject in the wake state (following a night of regular sleep) and during sleep (following a night of sleep deprivation). The MRI scans will be done in the morning (9-12 pm), once while the subject is sleeping (following a night of sleep deprivation) and once while awake (following regular sleep 9 AM-12 PM).
88826199|NCT03004417|Experimental|CHF 6001 Dose 2|CHF6001 via NEXThaler® dry powder inhaler (DPI), b.i.d. for 32 consecutive days.
88826200|NCT03004417|Placebo Comparator|Placebo|Matching placebo via NEXThaler® dry powder inhaler (DPI), b.i.d. for 32 consecutive days.
88826201|NCT00305643|Experimental|Arm I: Celecoxib + Capecitabine|Celecoxib 200 mg given orally twice/day along with standard capecitabine treatment (Initial dose of 750-1500 mg/m^2 orally twice/day).
88826202|NCT00305643|Placebo Comparator|Arm II: Placebo + Capecitabine|Placebo with standard capecitabine treatment (Initial dose of 750-1500 mg/m^2 orally twice/day)
88826203|NCT05702801|Experimental|Exposure to stochastic vibratory stimulation|All participants will be exposed to vibratory stimulations at different levels of 0Hz, 40Hz, and 80Hz.
88826204|NCT04874623|Experimental|CDI|
88826205|NCT03004105|Experimental|Intermittent Arm - Selumetinib + Durvalumab|Intermittent Arm - Participants receive Selumetinib at 75 mg by mouth twice a day for 7 days on and 7 days off, and Durvalumab 1500 mg by vein on Day 1 of a 28 day cycle.
88826206|NCT03004105|Experimental|Safety Run In|"Short safety run-in prior to the start of randomization. Participants on the safety run-in treated with Durvalumab 1500 mg by vein on Day 1 of a 28 day cycle.~Safety run-in beginning dose is Selumetinib 50 mg by mouth twice a day on Days 1 through 28 of a 28 day cycle.~During the safety run in portion of the trial, enrollment will be open to all comers, regardless of KRAS mutation status."
88826207|NCT03004105|Experimental|Continuous Arm - Selumetinib + Durvalumab|"Continuous Arm - Participants take Selumetinib twice daily on Days 1 to 28 of a 28 day cycle. Dose determined by safety run-in.~Participants receive Durvalumab 1500 mg by vein on Day 1 of a 28 day cycle."
88826208|NCT02959385|Experimental|Definitive Radiochemotherapy|"Concurrent Radiochemotherapy:~Radiotherapy,IMRT, 60Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day."
88826209|NCT02959385|Active Comparator|Neoadjuvant Radiochemotherapy|"Concurrent Radiochemotherapy:~Radiotherapy,IMRT, 40Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day; Receive radical surgery 4 to 6 weeks later."
88826210|NCT00271011|Experimental|Mitomycin C, Irinotecan and Cetuximab|"Patients will receive mitomycin C 7 mg/m2 as a bolus infusion on day -1 of each 28 day cycle.~Patients will receive cetuximab 400 mg/m2 loading dose over 90 minutes cycle 1, day 1. All subsequent weekly cetuximab treatments will be 250 mg/m2 as a 60 minute infusion days 1, 8, 15, and 22 of each 28 day cycle.~Patients will receive irinotecan 140 mg/m2 as a 90 minute infusion on days 1 and 15 of each 28 day cycle after cetuximab infusion. Patients found to be homozygous for UGT1A1*28 allele will receive irinotecan 110 mg/m2."
88826211|NCT05720429|Experimental|Primary care workers|"Primary care health personnel who will voluntarily join the psychoeducational program of their center.~All professional profiles working in primary care centers are eligible (ie primary care nurses, physiotherapists, family doctors, pediatricians, dentists, administrative staff, etc.). Groups of 10-15 people. Several groups can be established in the same center if the demand is high enough."
88826212|NCT00214149|Experimental|1|breast brachytherapy to a dose of 34 Gy
88826213|NCT03312530|Experimental|A: Cobimetinib|Participants will receive the standard single-agent cobimetinib dose of 60 milligrams (mg) (3 tablets of 20 mg each) orally (PO) daily on Days 1-21 of each 28-day cycle until disease progression. Upon progression, participants will be allowed to receive treatment with cobimetinib and atezolizumab at the recommended Phase II dose of cobimetinib 60 mg PO on Days 1-21 plus atezolizumab intravenous (IV) infusion at a fixed dose of 840 mg on Day 1 and Day 15 of each 28-day cycle. Treatment will continue until the participant has disease progression, unacceptable toxicity, death, participant or physician decision to withdraw, or pregnancy, whichever occurs first.
89000588|NCT04678687|Other|COVID-19 group|Liver, lung, heart and kidney biopsies will be performed on each case in the COVID-19 group.
89177324|NCT00593489|Experimental|Basal Insulin Initiation Strategy|"Basal Insulin Initiation Strategy which includes:~support by community pharmacist~support by diabetes specialist"
89177325|NCT00593489|No Intervention|Usual Practice|The physicians randomized to this group proceeded with their usual practice
89177326|NCT02551900|Experimental|Warm water exercise & Cold water exercise|
89177327|NCT02551900|Active Comparator|Warm water exercise & Land cycling exercise|
89177328|NCT00446641|Experimental|1 Cilostazol|100mg of Cilostazol twice a day
89177329|NCT00446641|Placebo Comparator|Placebo|matching placebo to cilostazol
89177330|NCT00646282|Experimental|Doxercalciferol|Stable kidney transplant recipients will receive Doxercalciferol
89177331|NCT00646282|No Intervention|Control|Stable kidney transplant recipients will not receive any drug
89177332|NCT02551588||Valvular aortic stenosis surgery|"Patients with symptomatic AVS had indication for surgery. They were proposed to have per procedure cardiac biopsy.~They were followed when possible one year after surgery."
89177333|NCT02551588||Valvular aortic stenosis without surgery|These patients with asymptomatic AVS had no indication for surgery. They were followed when possible one year after inclusion.
89177334|NCT02551588||Control subject|Patients without history of cardiac infarction, primary or secondary myocardiopathy or of radiotherapy or chemotherapy.
89177335|NCT00814060|Experimental|1|40-mg tablet
89177336|NCT00814060|Experimental|2|240-mg tablet
89177337|NCT00814060|Experimental|3|80-mg capsule
89177338|NCT00792636|Experimental|sumatriptan and naproxen sodium combination|
89177339|NCT00792636|Active Comparator|sumatriptan|
89177340|NCT00792636|Active Comparator|naproxen sodium|
89177341|NCT00446563|Experimental|Amlodipine + Valsartan|Participants received 160 mg Valsartan and 5 mg amlodipine orally once a day for 52 weeks. If blood pressure was not normalized at week 4, treatment was uptitrated to valsartan/amlodipine 160/10 mg. Participants with still uncontrolled hypertension could receive add-on antihypertensive medication.
88826214|NCT03312530|Experimental|B: Cobimetinib + Venetoclax|Participants will receive cobimetinib PO daily on Days 1-21 of each 28-day cycle plus venetoclax PO daily on Days 1-28 of each 28-day cycle, at the dose level identified in the safety run-in phase. Treatment will continue until the participant has disease progression, unacceptable toxicity, death, participant or physician decision to withdraw, or pregnancy, whichever occurs first.
88826215|NCT03312530|Experimental|C: Cobimetinib + Venetoclax + Atezolizumab|Participants will receive cobimetinib PO daily on Days 1-21 of each 28-day cycle plus venetoclax PO daily on Days 1-28 of each 28-day cycle, at the dose level identified in the safety run-in phase plus atezolizumab IV infusion at a fixed dose of 840 mg on Day 1 and Day 15 of each 28-day cycle. Treatment will continue until the participant has disease progression, unacceptable toxicity, death, participant or physician decision to withdraw, or pregnancy, whichever occurs first.
88826216|NCT03312530|Experimental|Safety Run-In: Cobimetinib + Venetoclax|Participants will receive cobimetinib (on Day 1-21) plus venetoclax (on Day 1-28) at escalated doses, in 28-day cycles, to identify the dose level with acceptable safety.
88826217|NCT03312530|Experimental|Safety Run-In: Cobimetinib + Venetoclax + Atezolizumab|Participants will receive cobimetinib (on Day 1-21) plus venetoclax (on Day 1-28) at escalated doses and atezolizumab (on Day 1 and Day 15) at a fixed dose of 840 mg IV, in 28-day cycles, to identify the dose level with acceptable safety.
89000589|NCT04677985|Experimental|Menthol based topical analgesic|Menthol based topical analgesic was applied to a variety of upper and lower body muscles and tendons.
89000590|NCT04677985|Placebo Comparator|Placebo|Placebo (cream that smelled like menthol) was applied to a variety of upper and lower body muscles and tendons.
88826218|NCT05720351|Active Comparator|Lachmann maneuver|Patients undergone the Lachmann recruitment maneuver (30 CmH2O PEEP for 30 seconds)
88826219|NCT05720351|Active Comparator|Staircase maneuver|Patients undergone staircase recruitment maneuver (stepped increase in PEEP by 2 CmH2O every five breaths until reach upper deflection point
88826220|NCT05697965|Experimental|Vancomycin loaded group|applying 1 gm of vancomycin powder intracapsularly during primary total knee and hip arthroplasty operations
88826221|NCT05697965|Experimental|Non vancomycin loaded group|Total knee & hip arthroplasty done without applying local vancomycin powder comparing the results with vancomycin loaded group
88826222|NCT00179127|Experimental|Glargine|0.3u/kg of glargine, subcutaneously, once
88826223|NCT00179127|Placebo Comparator|Placebo|0.3u/kg of saline, subcutaneously, once
88826224|NCT05696249|Experimental|Group with an OhmTrak device|The intervention group will be equipped with an OhmTrak device for home self-therapy and instructed in its correct use at least 5 times a week.
88826225|NCT05696249|Other|Group without an OhmTrak device|The control group will receive identical outpatient therapy and instruction in self-therapy, except they will not have access to the OhmTrak device.
88826226|NCT00183963|No Intervention|1|
88826227|NCT00183963|Active Comparator|2|Tamoxifen 20 mg
89000591|NCT00554632|Active Comparator|1|Use of transdermal hormonal contraceptive
89000592|NCT00554632|Active Comparator|2|Use of oral hormonal contraceptive
89000593|NCT02963870|Experimental|security plan|groups of adolescents aged 12-17 hospitalized for TS and randomized to a group treated with security plan and the usual treatment
89177342|NCT00446563|Active Comparator|Losartan + Hydrochlorothiazide|Participants received 100 mg losartan and 12.5 mg Hydrochlorothiazide (HCT) orally once a day for 52 weeks. If blood pressure was not normalized at week 4, treatment was uptitrated to losartan/HCT 100/25 mg, respectively, until end of study. Participants with still uncontrolled hypertension could receive add-on antihypertensive medication.
88826228|NCT00183963|Active Comparator|3|Fulvestrant 250mg
88826229|NCT00183963|Active Comparator|4|Fulvestrant 500mg IM
88826230|NCT01930058|Experimental|Panel A: HCV GT3 MK-8876 150 mg|Participants infected with HCV GT3 received 150 mg MK-8876 once daily (q.d.) by mouth for 7 days.
88826231|NCT01930058|Experimental|Panel B: HCV GT3 MK-8876 800 mg|Participants infected with HCV GT3 received 800 mg MK-8876 q.d. by mouth for 7 days.
88826232|NCT01930058|Experimental|Panel E: HCV GT1a MK-8876 800 mg|Participants infected with HCV GT1a received 800 mg MK-8876 q.d. by mouth for 7 days.
88826233|NCT04659213|Experimental|Interventional Group|Placement of a luminal esophageal temperature probe (LET) and insertion of esolution esophageal retractor. In the intervention group, esolution will be utilized to deviate the esophagus during RF catheter ablation
88826234|NCT04659213|No Intervention|Control Group|Placement of a luminal esophageal temperature probe (LET) during RF ablation
88826235|NCT02978261|Experimental|PLB1001|There are 4 dose cohorts, including 50mg BID,100mg BID, 200mg BID and 300mg BID in the dose escalation stage and PLB1001 will be administered orally to patients twice daily for each dose cohort.
88826236|NCT04526769||COVID-19 Patients|All patients aged 18 years and above who present to Fairview/UMN ERs or ICUs with confirmed or suspect COVID-19 based on the attending physician's judgment will be included.
88826237|NCT01909154|Experimental|Mesenchymal stromal cell therapy|Autologous bone marrow adult mesenchymal stem cells expanded in vitro. Administered by Intrathecal injection (subarachnoid and intramedullary). Depending on centromedullary post-traumatic injury: bone marrow stromal stem cells administration (MSCs) at the minimum dose of 100x106 followed by subarachnoid administration of 30x106 MSCs,3 months later
88826238|NCT05684081|Experimental|INTERVENTION|Refers to the intervention arm i.e. ECASH payment of health workers
88826239|NCT05684081|No Intervention|CONTROL|Refers to status Quo or no intervention i.e. payment using cash
88826240|NCT05719961|Experimental|INS062|
88826241|NCT05719961|Active Comparator|NovoRapid ®|
88826242|NCT05719961|Experimental|HR20014|
88826243|NCT05719961|Active Comparator|BIAsp 30|
88826244|NCT01910636|Experimental|Sofosbuvir+RBV 12 weeks|Participants will receive sofosbuvir+RBV for 12 weeks.
88826245|NCT01932164|Experimental|cleft lip and palate|5 Patients with cleft unilateral lip and palate that have already performed the alignment of dental arches through the recommended orthodontic treatment will be selected to be submited to alveolar bone tissue engineering surgery
88826246|NCT00118053|Experimental|Docetaxel, Carboplatin and Trastuzumab|"A total of six cycles of TCH [(Taxotere® (75 mg/m2) + Carboplatin (AUC = 6) + Herceptin® (2 mg/kg weekly after a 4 mg/kg load on Day 1)] will be administered every 3 weeks.Three weeks after receiving the sixth cycle of TCH, all patients will be restaged.~Those determined to have localized and operable disease (as determined by surgical consultation) will undergo a modified radical mastectomy or lumpectomy and axillary node dissection. After recovery from surgery, the patients will receive whole breast or chest wall irradiation (as determined by radiologist) with concurrent Herceptin® (6 mg/kg). Following radiation, patients will continue Herceptin® (6 mg/kg) every 3 weeks until they have been on study for a total of 52 weeks.~If patients are staged and are negative they will continue Herceptin® (6 mg/kg)every 3 weeks until they have been on study for a total of 52 weeks."
88826247|NCT04225611|Experimental|Dexamethasone|Therapeutic Contact Lens Drug Delivery System (TCL-DDS) of Dexamethasone, up to 300 μg per day with a total release of 1,100 μg over 7 days
88826248|NCT05677061|Experimental|HA-coated|Hydroxyapatite coating on Screw thread of DHS
88826249|NCT05677061|Active Comparator|NON-coated|No coating on Screw thread of DHS
88826250|NCT04007601|Active Comparator|Active tDCS|Remotely delivered active tDCS + cognitive training
88826251|NCT04007601|Placebo Comparator|Sham tDCS|Remotely delivered sham tDCS + cognitive training
88826252|NCT02978573|Experimental|Cartiva|Cartiva Synthetic Cartilage Implant
88826253|NCT05717855|Other|Screening septooptic dysplasia|Displaying and measuring the width and length of the optic chiasm for screening septooptic dysplasia
88826254|NCT01996371|Other|Group 1|Unilateral pedicle screws
88826255|NCT01996371|Other|Group 2|Ipsilateral pedicle screws, contralateral facet screw
88826256|NCT01996371|Other|Group 3|Bilateral pedicle screws
88826257|NCT05719493|No Intervention|multicomponent-treatment no benefiting group|Participants in the control group will receive the care from the usual clinical practice
88826258|NCT05719493|Experimental|munticomponent-treatment benefiting group|Partcipants in the intervention group will receive the care from the usual practice plus the studied intervention.
88826259|NCT05669885|Experimental|Sildenafil|Oral administration of 100 mg sildenafil.
88826260|NCT05669885|Placebo Comparator|Placebo|
88826261|NCT00955929|Experimental|PRN Sildenafil|Placebo QHS (blinded) and sildenafil 100mgs (open-label) as required for sexual relations. The placebo will be omitted on nights that 100mgs is used. Placebo will start within 24-48 hours post-surgery.
88826262|NCT00955929|Experimental|Nightly Sildenafil Arm|Patients will be instructed to take sildenafil 50 mg QHS (blinded) except on nights that they are interested in sexual relations, they will then be instructed to use sildenafil 100mgs (open-label) and skip the 50mg dose. Sildenafil treatment will start within 24-48 hours post-surgery.
89356847|NCT05864768|Experimental|Patients with a vegan/vegetarian diet|"After excluding patients with clinical signs of periodontitis, the patients recruited at baseline underwent prophylaxis and home oral hygiene instructions were given with brushing and flossing in order to reduce the parameters of inflammation and the presence of plaque (FMPS and FMBS). The use of antiseptics (chlorhexidine mouthwash 0.20%) was prescribed twice a day for 15 days.~After 15 days from baseline (T0) all patients were recorded the parameters of FMPS, FMBS, PPD and Eastman Interdental Bleeding Index (EIBI) and were asked to stop using dental floss and mouthwash. All patients were recalled weekly 4 times after T0 (T1, T2, T3, T4) in order to monitor the parameters of inflammation and plaque accumulation by recording FMBS, FMPS and EIBI."
88826263|NCT00955929|Experimental|Combination Therapy Arm|Trimix combination (Papavarine 30mg/mL Phentholamine 1mg/mL Prostaglandin E1 10 mcg/mL), at initial dose of 5 units (0.05ml) will be given; the first 2 injections will be done in the MSKCC urology outpatient clinic (if needed, the investigator can determine appropriate amount of injections for patient training).
88826264|NCT05719415|Experimental|Pre and post BPA|
88826265|NCT03987789|Active Comparator|Low PEEP group|Patients will receive a PEEP level ≤5 cmH2O without recruitment maneuvers
88826266|NCT03987789|Experimental|Driving-pressure-guided group|Patients will receive PEEP levels individually set at the highest possible value (up to 15 cmH2O) providing a driving pressure (airway plateau pressure minus PEEP) lower than 13 cmH2O, in addition to recruitment maneuvers
88826267|NCT03482505|Experimental|INVSENSOR00004|All enrolled subjects will receive the INVSENSOR00004 sensor. The INVSENSOR00004 rainbow acoustic monitoring (RAM) acoustic respiration sensor is designed to noninvasively convert acoustical airflow patterns into respiratory rate (RRa).
88826268|NCT05719337||Hypertensive heart disease group|Systolic blood pressure exceeded 140 mmHg and/or diastolic blood pressure exceeded 90 mmHg, or a history of systemic hypertension in the absence of other cardiac or systemic disease was described as hypertension.
88826269|NCT05719337||Hypertrophic cardiomyopathy group|Wall thickness≥15 mm in the absence of other causes of hypertrophy in a non-dilated left ventricle (LV) defines HCM. End diastolic wall thickness≥13 mm can be diagnostic if there is a family history of HCM or a known disease-causing genetic mutation.
88826270|NCT05719337||Cardiac amyloidosis group|Clinical diagnosis of cardiac amyloidosis confirmed by blood tests or tissue biopsy.
88826271|NCT05719337||Fabry disease group|Clinical diagnosis of Fabray disease confirmed by blood biomarkers or genetic testing.
88826272|NCT00358319|Experimental|Phase I|Dose escalation phase
88826273|NCT00358319|Experimental|Phase II|All patients enrolled in the Phase II will be treated with Valproic Acid (VPA) and Karenitecin using the dosing schedule determined to be the Maximum Tolerated Dose (MTD) in Phase I.
88826274|NCT03981783|Active Comparator|Best available care (BAC)|
88826275|NCT03981783|Experimental|Telerehabilitation (TH)|
88826276|NCT03833765|Experimental|CAF+XCM|An envelope split-full-split thickness flap without vertical incisions will be carried out in the gingival recession area. Afterwards, a xenogenic collagen matrix (XCM) will be applied to all teeth with recession defect. The XCM will be cut into the right dimensions, measured with the probe, and its measurements recorded; then it will be placed from the CEJ to the bone crest on the recipient bed using single sutures, 7/0 PGA sutures. The matrix will be rehydrated with blood, in order to reconstitute and maintain the maximal thickness possible. The flap will be closed slightly coronal to the CEJ with a sling suture using resorbable PGA 6/0 sutures and avoiding any compression of the matrix.
89356848|NCT05864768|Active Comparator|Patients with an omnivorous diet|"After excluding patients with clinical signs of periodontitis, the patients recruited at baseline underwent prophylaxis and home oral hygiene instructions were given with brushing and flossing in order to reduce the parameters of inflammation and the presence of plaque (FMPS and FMBS). The use of antiseptics (chlorhexidine mouthwash 0.20%) was prescribed twice a day for 15 days.~After 15 days from baseline (T0) all patients were recorded the parameters of FMPS, FMBS, PPD and Eastman Interdental Bleeding Index (EIBI) and were asked to stop using dental floss and mouthwash. All patients were recalled weekly 4 times after T0 (T1, T2, T3, T4) in order to monitor the parameters of inflammation and plaque accumulation by recording FMBS, FMPS and EIBI."
89356849|NCT05864716|Experimental|probiotics-spray (PS) group|In the PS group, 1 vial of multi-strain probiotics powder via colonoscopic spray is performed once, followed by five-days of two oral placebo capsules daily. After the five-day treatment, the 2nd fecal sample will be collected. Both groups will receive a 23-day course of oral probiotics (two capsules twice daily) subsequently. The patients were asked to keep a diary to record bowel habits and register any adverse events. The 3rd fecal sample will be collected 28 days after the colonoscopy. The questionnaires will be completed 28 days and 84 days after the colonoscopy to assess responses of treatment. Polyethylene glycol and loperamide were allowed during the intervention as the rescue medication.
88826277|NCT03833765|Active Comparator|CAF alone|An envelope split-full-split thickness flap without vertical incisions will be carried out. The root surfaces will be mechanically treated with the use of curettes. A sharp dissection into the vestibular lining mucosa will be then carried out to eliminate muscle tension. Sling sutures will be performed to accomplish a precise adaptation of the buccal flap on the exposed root surfaces and to stabilize every single surgical papilla over the de-epithelialized anatomic papillae.
88826278|NCT00380055|Experimental|Screening Navigation|Individuals without a study cancer who receive services of a navigator.
89533910|NCT02311374|Sham Comparator|Phase I|ADC will be measured in the same subject in the wake state (following a night of regular sleep) and during sleep (following a night of sleep deprivation). The MRI scans will be done in the morning (9 AM-12 pm), once while the subject is sleeping (following a night of sleep deprivation) and once while awake (following regular sleep 9 AM 12 PM).
89533911|NCT02255773|Other|High-Fatigue Head and Neck (HNC) Cancer Survivors|Participants undergo assessment with three validated computerized tasks designed to measure the neurobehavioral domains of interest: the Effort Expenditure for Rewards Task (EEfRT), an associative learning task, and a set-switch task. Participants complete questionnaires assessing mood, somatic symptoms, and sleep quality, including the Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF), the Checklist Individual Strength (CIS), and others. A 10-mL blood sample drawn for assessment of inflammatory markers and COMT and DAT1 genotype.
88826279|NCT00380055|Experimental|Treatment Navigation|Individuals with a study cancer who receive navigation services.
88826280|NCT00380055|Active Comparator|Screening Education|Rather than receiving navigation, these participants receive general cancer education appropriate to Medicare enrollees.
88826281|NCT00380055|Active Comparator|Treatment Education|Rather than receiving navigation services, these participants receive cancer education appropriate to Medicare recipients.
88826282|NCT01444209|Experimental|Radiation Therapy|Interstitial Radioactive Iodine Implants
88826283|NCT05663801|Active Comparator|Group A (control group )|Patients will be given 30 mL of 0.25% bupivacaine hydrochloride in pectoral nerve block .
88826284|NCT05663801|Active Comparator|Group B ( Ketamine group)|Patients will be given 30 mL of 0.25% bupivacaine hydrochloride plus ketamine hydrochloride (1 mg/kg) in pectoral nerve block .
88826285|NCT05663801|Active Comparator|Group C (Magnesium sulfate group)|Patients will be given 30 mL 0.25% bupivacaine hydrochloride plus magnesium sulfate ( 28 ml bupivacaine 0.25% plus 2ml magnesium sulfate (50%) in pectoral nerve block
88826286|NCT02296320|Active Comparator|MEDI4893 5000 mg|Participants will receive a single intravenous (IV) dose of MEDI4893 5000 milligrams (mg) on Day 1 of the study.
88826287|NCT02296320|Placebo Comparator|Placebo|Participants will receive a single IV dose of placebo matched to MEDI4893 on Day 1 of the study.
88826288|NCT02296320|Active Comparator|MEDI4893 2000 mg|Participants will receive a single IV dose of MEDI4893 2000 mg on Day 1 of the study.
88826289|NCT05717465|Active Comparator|Standard informed consent|Video with audio narration containing information provided in the standard informed consent process for a lumbar puncture
88826290|NCT05717465|Experimental|Visual aid group|Video with identical audio narration (to the control) containing information provided in the standard informed consent process for a lumbar puncture. The video also received statistical information in the form of visual aids; anatomy diagrams, Paling diagrams and Paling scales
88826291|NCT05717231|Experimental|laughter yoga|Laughter yoga was performed face-to-face with the intervention group for 35-40 minutes twice a week and in 6 sessions in total.
88826292|NCT05717231|No Intervention|Control group|No intervention was performed for the control group
88826293|NCT00000105||Arm A: Intracel KLH|Intracel KLH 1000 mcg (1 mg) without adjuvant, subcutaneous Tetanus Toxoid 0.5 ml intramuscularly (this arm closed 1/2/02).
88826294|NCT00000105||Arm B: Biosyn KLH|Biosyn KLH 1000 mcg (1 mg) without adjuvant, subcutaneous tetanus toxoid 0.5 ml intramuscularly (this arm closed 3/18/03).
88826295|NCT00000105||Arm C: Biosyn KLH with Montanide ISA51|Biosyn KLH 1000 mcg (1 mg) with Montanide ISA51 (replaced with vegetable (VG) source after 8/31/06) and subcutaneous Tetanus toxoid 0.5 ml intramuscularly.
88826296|NCT02959151|Experimental|CAR-T for liver cancer|A single dose of CART cells will be administered by vascular interventional therapy or by intra-tumor injection with a dose of （1.25~4）×107 CAR positive T cells/cm3 tumor bulk. The volume of cell products and the time of cell perfusion process lasted would depend on the ways of cell perfused. And an interventional radiologist would operate the cell infusion.
88826297|NCT05646017||Type 1 diabetes patients|Type 1 diabetes patients using intermittently continuous glucose monitoring during the Spanish greatest heatwave in Castilla-La Mancha (Spain).
89000594|NCT02963870|Active Comparator|standard treatment only.|group receiving standard treatment only.
88826298|NCT03553719||One day point-prevalence analysis 1|Data on the management of intensive care unit patients ≥18 years will be collected. Data of approximately 170 patients per point-prevalence analysis will be collected.
89177343|NCT00650806|Experimental|Canagliflozin 50 mg|Each patient will receive 50 mg of canagliflozin (JNJ-28431754) once daily for 12 weeks.
89177344|NCT00650806|Experimental|Canagliflozin 100 mg|Each patient will receive 100 mg of canagliflozin (JNJ-28431754) once daily for 12 weeks.
88826299|NCT03553719||One day point-prevalence analysis 2|"Before the start of the second one day point-prevalence analysis a training package is conducted at each study center. This contains online lectures, instructional videos, educational handouts, and a bedside teaching component over the course of 6 weeks. The effect of a training block for intensive care unit staff on routine delirium screening rate and the change of the other outcome measures will be assessed.~During the one day point-prevalence analysis 2 data on the management of intensive care unit patients ≥18 years will be collected. Data of approximately 170 patients per point-prevalence analysis will be collected."
88826300|NCT03553719||One day point-prevalence analysis 3|Data on the management of intensive care unit patients ≥18 years will be collected. Data of approximately 170 patients per point-prevalence analysis will be collected.
88826301|NCT05711303|Active Comparator|Superba Boost|One 1000 mg capsule per day Superba Boost for 12 weeks
88826302|NCT05711303|Placebo Comparator|Placebo|One 1000 mg capsule per day placebo for 12 weeks
88826303|NCT03505203|Experimental|Sleep Soothe|An intervention in which parents are given information on how to respond to their baby's cues related to sleeping and fussiness.
88826304|NCT03505203|Active Comparator|Sleep Safe|An intervention in which parents are given information on a safe sleep environment, as well as other strategies to keep baby safe
88826305|NCT00380133|Experimental|Randomised, double-blind, five-way crossover|A randomised, double-blind, double-dummy, placebo-controlled, five-way crossover study to assess the effects of single oral doses of SB-681323 (7.5 mg and 25 mg) and prednisolone (10 mg and 30 mg) on biomarkers in induced sputum and blood in COPD patients.
88826306|NCT05642351||Alzheimer's Disease|recruited according to criteria by National Institute on Aging (McKhann et al., 2011).
88826307|NCT05642351||Behavioral variant of frontotemporal dementia|recruited following criteria by Rascovsky et al. (2011)
88826308|NCT05641805||Duchenne Muscular Dystrophy|
88826309|NCT02959229|Experimental|Early Lactoferrin Group|Oral Bovine Lactoferrin 100 mg/day once starting on day 1 of life and continued for 4-6 weeks.
88826310|NCT02959229|Experimental|Late Lactoferrin Group|Oral Bovine Lactoferrin 100 mg/day once starting on day 3 of life and continued for 4-6 weeks.
88826311|NCT02959229|Active Comparator|Placebo Group|placebo in form of distilled water once starting on day 1 of life and continued for 4-6 weeks.
88826312|NCT02953665|Active Comparator|Liraglutide|Liraglutide 6 mg/ml (Novo Nordisk A/S) will be self-administered subcutaneously once daily at a maximum dose of 1.8 mg after a 2 week titration schedule.
88826313|NCT02953665|Placebo Comparator|Placebo|Placebo will be self-administered subcutaneously once daily according to the same schedule.
88826314|NCT05707013|Experimental|HP Arize 3D-Printed Orthotics|Patients will receive the HP Arize 3D-printed orthotics for treatment of plantar fasciitis.
89177345|NCT00650806|Experimental|Canagliflozin 300 mg|Each patient will receive 300 mg of canagliflozin (JNJ-28431754) once daily for 12 weeks.
88826315|NCT05707013|Active Comparator|Traditional Orthotics|Patients will receive traditionally fabricated orthotics for treatment of plantar fasciitis.
88826316|NCT03632655|Active Comparator|Transrectal Ultrasound Guided Biopsy (TRUS)|Patients will receive a transrectal guided prostate biopsy
89177346|NCT00650806|Placebo Comparator|Placebo|Each patient will receive matching placebo once daily for 12 weeks.
88826317|NCT03632655|Active Comparator|Transperineal Prostate Biopsy|Patients will receive a transperineal prostate biopsy
88826318|NCT02276157|Experimental|MB group|Direct POC performed with third-generation prototype multibending ultra-slim endoscope (CHF-Y0010; Olympus Medical Systems, Co., Ltd., Tokyo, Japan)
88826319|NCT02276157|Active Comparator|Conventional group|Direct POC performed with conventional ultra-slim endoscope (GIF-XP290N; Olympus Medical Systems, Co., Ltd., Tokyo, Japan)
88826320|NCT03621657|Experimental|Low dose FMT Capsule DE|FMT Capsule double-encapsulated (DE) by mouth, 5 capsules once daily with antibiotic, followed by 5 capsules daily for 7 days post-antibiotic
88826321|NCT03621657|Active Comparator|Single dose FMT Capsule DE|FMT Capsule DE by mouth, 30 capsules in a single one-time dose 48-72 post-antibiotic course.
88826322|NCT03621657|Placebo Comparator|Placebo Oral Capsule|Oral placebo capsules manufactured to mimic study capsule, 5 capsules daily with antibiotic course, followed by 5 capsules for 7 days post-antibiotic
88826323|NCT05683769||erosive hand osteoarthritis|EHOA was diagnosed according to the American College of Rheumatology (ACR) criteria and to the presence of the classical central erosion in at least two IP joints. Further inclusion criteria were the availability of plain radiography of both hands performed in the previous 6 months. Plain radiographs of both hands were collected and scored by two readers according to Kallman's classification in a blind observation.
88826324|NCT05683769||psoriatic arthritis|PsA was diagnosed following the CASPAR classification guidelines and only patients with the peripheral arthritis pattern were considered; all PsA group had also the diagnosis of psoriasis confirmed by an expert dermatologist. These patients had also to be naive to conventional and biologic disease-modifying anti-rheumatic drugs (DMARDs) or have withdrawn any DMARDs for at least three months, because of inadequate response or intolerance.
89177347|NCT00863057|Experimental|1|Participants will receive treatment in the following order: (Period 1, Weeks 1 to 4) duloxetine and methadone placebo, (Period 2, Weeks 6 to 9) duloxetine placebo and methadone, (Period 3, Weeks 11 to 14) duloxetine and methadone, (Period 4, Weeks 16 to 19) duloxetine placebo and methadone placebo
89177348|NCT00863057|Experimental|2|Participants will receive treatment in the following order: (Period 1, Weeks 1 to 4) duloxetine placebo and methadone, (Period 2, Weeks 6 to 9) duloxetine placebo and methadone placebo, (Period 3, Weeks 11 to 14) duloxetine and methadone placebo, (Period 4, Weeks 16 to 19) duloxetine and methadone
89177349|NCT00863057|Experimental|3|Participants will receive treatment in the following order: (Period 1, Weeks 1 to 4) duloxetine and methadone, (Period 2, Weeks 6 to 9) duloxetine and methadone placebo, (Period 3, Weeks 11 to 14) duloxetine placebo and methadone placebo, (Period 4, Weeks 16 to 19) duloxetine placebo and methadone
89177350|NCT00863057|Experimental|4|Participants will receive treatment in the following order: (Period 1, Weeks 1 to 4) duloxetine placebo and methadone placebo, (Period 2, Weeks 6 to 9) duloxetine and methadone, (Period 3, Weeks 11 to 14) duloxetine placebo and methadone, (Period 4, Weeks 16 to 19) duloxetine and methadone placebo
89177351|NCT00699959||1|patients with heart failure
88826325|NCT05683769||Control Group|The control group was represented by healthy volunteers age-and sex-matched to study patients and were recruited among the hospital staff; HC did not exhibit symptoms or signs attributable to OA, psoriasis, as well as to autoimmune disorders and systemic inflammatory arthropathies.
88826326|NCT05634083|Experimental|Uremic Pateints group|Patients with end-stage renal failure with itching
88826327|NCT05440695||CNAP Group|The CNAP finger cuff and NIBP cuff were on the same arm of the patient while the intravenous catheter was on the contralateral side. After intrathecal injection, systolic, diastolic, and mean blood pressures were measured and were recorded manually at every minute on the CNAP monitor.
88826328|NCT05440695||NIBP Group|In the control group, only oscillometric NIBP measurements were done in pregnant women similar to the study group without a CNAP. After intrathecal injection, systolic, diastolic, and mean blood pressures with oscillometric method were set at the frequency of 3 minutes for the first 15 minutes, and at 5-minute intervals thereafter, and were recorded manually.
88826329|NCT02978105|Experimental|Experimental|self-conditioning techniques plus standard care
88826330|NCT02978105|Active Comparator|Control|Standard care: dietary recommendations, exercise recommendations, and behavioral recommendations
88826331|NCT01952223|Experimental|ADT + pelvic RT|"ADT for a total duration of 3 years i.e. luteinizing hormone-releasing hormone (LHRH) agonist or LHRH antagonist +/-Peripheral anti-androgen~Pelvic RT (by IMRT or IGRT protocol):~Phase 1: pelvic radiotherapy (prostate, seminal vesicles, ilio-obturator, presacral lymph nodes) (46 or 50 Gy according to the center)~Phase 2: prostate-only boost (EBRT) up to 74-78 Gy"
88826332|NCT01952223|Experimental|ADT + Cabazitaxel + prostate RT|"ADT Cabazitaxel: 4 CT cycles~Prostate-only RT (IMRT or IGRT):~Phase 1: prostate + seminal vesicle radiotherapy (46 or 50 Gy according to the center)~Phase 2: prostate-only boost (EBRT) up to 74-78 Gy"
89177352|NCT00699959||2|patients without heart failure
88826333|NCT01952223|Experimental|ADT + cabazitaxel + pelvic RT|"ADT Cabazitaxel: 4 CT cycles~Pelvic RT (IMRT or IGRT):~Phase 1: pelvic radiotherapy (prostate, seminal vesicles, ilio-obturator, presacral lymph nodes) (46 or 50 Gy according to the center)~Phase 2: prostate-only boost (EBRT) up to 74-78 Gy"
88826334|NCT01952223|Active Comparator|ADT + prostate radiotherapy|"ADT for a total duration of 3 years: LHRH agonist or LHRH antagonist +/- anti-androgen~Prostate-only RT (IMRt or IGRT):~Phase 1: prostate + seminal vesicle radiotherapy (46 or 50 Gy according to the center)~Phase 2: prostate-only boost (EBRT) up to 74-78 Gy"
88826335|NCT05677607||Intracranial atherosclerosis and small vessel disease|Patients diagnosed with intracranial large artery atherosclerosis and cerebral small vessel disease based on imaging screening.
88826336|NCT02296242|Experimental|BVD-523|
88826337|NCT02295774|Placebo Comparator|Group A|Biopsy samples collected during standard white light colonoscopy.
88826338|NCT02295774|Active Comparator|Group B|Subjects who have had samples collected during a Group A colonoscopy, who require a second colonoscopy within 2 weeks. Prior to this second colonoscopy the subjects take Methylene Blue MMX tablets. Biopsies collected are compared to their previous group A colonoscopy for histone gamma H2AX activity.
88826339|NCT01807611|Experimental|Transplant Recipients|"Participants undergo a preparative regimen of total lymphoid irradiation, fludarabine, cyclophosphamide, fludarabine, thiotepa, melphalan, and mycophenolate mofetil, followed by HPC,A infusion and TC-NK infusion. They also receive G-CSF and mesna.~Cells for infusion are prepared using the CliniMACS System."
88826340|NCT05653583|Active Comparator|Wrist Device|Twice daily stimulation sessions during the 4-week treatment period
88826341|NCT05653583|Active Comparator|Ear Device|Twice daily stimulation sessions during the 4-week treatment period
88826342|NCT05653583|Sham Comparator|Sham Device|"Twice daily stimulation sessions during the 4-week treatment period"
88826343|NCT02294682|Experimental|GSK2140944 1500 mg|Subjects will receive single oral dose of GSK2140944 1500 mg.
88826344|NCT02294682|Experimental|GSK2140944 3000 mg|Subjects will receive single oral dose of GSK2140944 3000 mg.
88826345|NCT01692717|Active Comparator|Atorvastatin|Citalor (Atorvastatin) - Pfizer
88826346|NCT01692717|Active Comparator|Hydrochlorothiazide + Losartan|Hyzaar (Hydrochlorothiazide + Losartan) - Merck Sharp & Dohme
88826347|NCT01692717|Experimental|Atorvastatin + Hydrochlorothiazide + Losartan|Polipílula (Atorvastatin + Hydrochlorothiazide + Losartan) - Lab Hypermarcas
88826348|NCT05640869|Experimental|Modified DPP|Participants in this arm will participate in the modified Diabetes Prevention Program curriculum.
88826349|NCT02294604|Experimental|Group R|Waterless surgical hand rub formulation containing 61% ethyl alcochol, 1% chlorhexidine and moisturizers
88826350|NCT02294604|Active Comparator|Group I|Traditional scrub formation with 10 % povidone-iodine
88826351|NCT02294604|Active Comparator|Group C|Traditional scrub formation with 4% chlorhexidine
88826352|NCT03483051|Experimental|Potassium Nitrate (KNO3)|Capsules containing 18 mmoles of KNO3 per day, given as one capsule (6 mmoles) three times a day for 4 weeks.
88826353|NCT03483051|Sham Comparator|Potassium Chloride|Capsules containing 18 mmoles of KCl per day, given as one capsule (6 mmoles) three times a day for 4 weeks.
88826354|NCT01645176|Experimental|Hydroxychloroquine/Atorvastatin open label|
89000595|NCT02254993|Experimental|Arm 1- Part A|One 30-minute C16G2 tray gel application (3.2 mg/mL) over the course of five days
89000596|NCT02254993|Experimental|Arm 2 - Part A|One 4-hour C16G2 tray gel application (3.2 mg/mL) over the course of five days
89177353|NCT02552602|Active Comparator|Group A|Study participants in this arm will be given Multivitamin A
89177354|NCT02552602|Active Comparator|Group B|Study participants in this arm will be given Multivitamin B
89177355|NCT02552602|Active Comparator|Group C|Study participants in this arm will be given Multivitamin C
89177356|NCT00814216|Experimental|QAV680|
89177357|NCT00814216|Placebo Comparator|Placebo|
89177358|NCT00814216|Active Comparator|Fluticasone Propionate Inhaler|
89177359|NCT00807976||Study group|Type 2 diabetic patients aged 70 years and older.
89533912|NCT02255773|Other|Low-Fatigue Head and Neck (HNC) Cancer Survivors|Participants undergo assessment with three validated computerized tasks designed to measure the neurobehavioral domains of interest: the Effort Expenditure for Rewards Task (EEfRT), an associative learning task, and a set-switch task. Participants complete questionnaires assessing mood, somatic symptoms, and sleep quality, including the Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF), the Checklist Individual Strength (CIS), and others. A 10-mL blood sample drawn for assessment of inflammatory markers and COMT and DAT1 genotype.
88826355|NCT05615207|Active Comparator|Standard of Care (physical practice)|Participants will be given a single one on one in person instruction session and a home exercise program corresponding to their assigned group with instructions on physical practice. The Standard of Care / Physical practice will include physically performing movements that closely or entirely mimic elements of the BBS. For example, if a subject struggles with the sit to stand portion of the BBS, they will physically practice sit to stand based on the treating physical therapist's clinical decision of appropriate task parameters and dosage. The individual subject's MS fatigue and their performance of the task will be taken into account when deciding dosage.
88826356|NCT05615207|Experimental|Motor Imagery|Participants will be given a single one on one in person instruction session and a home exercise program corresponding to their assigned group with instructions on using motor imagery to imagine themselves performing the balance task with which they struggled on the BBS. Motor imagery practice involves having the participant imagine themselves performing elements of the BBS without physically moving. The participants in this group will be guided through 1 session of motor imagery that will be recorded on their person phone for them to use as a home exercise program.
88826357|NCT05715983|Active Comparator|Bascom II procedure|Pilonidal sinus is excised, subcutaneous fat and skin are closed in the lateralization with interrupted suture.
88826358|NCT05715983|Active Comparator|Sinus Laser Closer (SiLaC)|Pilonidal sinus is locally excised by dermopunch or scalpel, curettage of the sinus tract with laser destruction
88826359|NCT03465735|Other|Standard of Care|Ultrasound of the leg with DVT and leg circumference measurement at 3 days, 10 days, and 3 months. Ultrasound data will include data on thrombus resolution, such as size and recanalization present.
88826360|NCT03465735|Other|Vascular Boot Group|"For each vascular boot session, the following data will be recorded:~Wearing the vascular boot during first 10 days of study for minimum of 30 minutes per day"
88826361|NCT04197960|Experimental|microwave ablation|ablate all tumors including at least 2mm safe margin except for tumors adjacent to thyroid capsule.
88826362|NCT04197960|Active Comparator|surgical resection|lobectomy + central lymph node dissection
88826363|NCT05637671|Active Comparator|oxybutynin|One study group will receive 10 mg of oxybutynin ER orally once daily for 12 weeks
88826364|NCT05637671|Active Comparator|paroxetine|the other group will receive 12.5 mg of paroxetine CR orally once daily for 12 weeks
88826365|NCT02322216|Experimental|PATADAY|Olopatadine hydrochloride ophthalmic solution 0.2% in the morning and olopatadine 0.2% vehicle in the evening, 1 drop in each eye for 14 days
89533913|NCT02227251|Experimental|Part 1: Selinexor 60 mg|Participants received fixed dose of 60 mg selinexor orally, twice weekly (BIW) on Days 1 and 3 (e.g., Monday and Wednesday or Tuesday and Thursday, etc.) of Weeks 1-4 of each four week (each cycle of 28 days) cycle (total of 8 doses per cycle).
88826366|NCT02322216|Active Comparator|PATANOL|Olopatadine hydrochloride ophthalmic solution 0.1%, 1 drop in each eye in the morning and evening, for 14 days
88826367|NCT03447639|Experimental|Povidone-Iodine Irrigation|Bladder irrigation with 2% povidine-iodine irrigation immediately prior to catheter removal
88826368|NCT03447639|No Intervention|Standard of Care|Catheter removal with no bladder irrigation
88826369|NCT05610215|Experimental|hybrid ablation|Participants in this group will receive concomitant thoracoscopic epicardial ablation and catheter endocardial ablation
88826370|NCT05610215|Active Comparator|catheter ablation|Participants in this group will receive catheter endocardial ablation only
88826371|NCT03425799|Placebo Comparator|Sodium Chloride 0.9%|Sodium Chloride 0.9% infused at 3 mL/kg over one hour followed by continuous infusion at 0.3 mL/kg for maximum infusion volume of 5 mL/kg
88826372|NCT03425799|Experimental|Tranexamic Acid 10 mg/mL|Tranexamic Acid 10 mg/mL infused at 3 mL/kg over one hour followed by continuous infusion at 0.3 mL/kg for maximum infusion volume of 5 mL/kg
88826373|NCT05576285||Accelerating head growth in infancy|Infants <=18 months of age referred to head ultrasound because of accelerating head growth
88826374|NCT05576285||Children at ICU with neurological symptoms that require brain MRI or CT|Children < 15 years of age who are cared for at ICU becaus of neurological symptoms that require brain MRI or CT scans
88826375|NCT05576285||Children entering the emergency department with the need of acute brain CT|Children < 2 years of age that enter the emergency department because of brainthreatening conditions that require acute brain CT scans
88826376|NCT03363633|No Intervention|Observation|
88826377|NCT03363633|Experimental|Injection + Compression|
88826378|NCT03363633|Active Comparator|Compression|
88826379|NCT05614193||Imaging group|Participants with suspecting brain stroke or vascular lesion conducted conventional CT or MR imaging and deep enhanced imaging.
88826380|NCT03360903|Experimental|Placebo then Caffeine|Anesthetized volunteers will be allowed to wake after injection of saline (placebo control) followed by a washout period and then anesthetized again and allowed to wake after injection of caffeine (15 mg/ kg).
88826381|NCT03360903|Experimental|Caffeine then Placebo|Anesthetized volunteers will be allowed to wake after injection of caffeine (15 mg/ kg) followed by a washout period and then anesthetized again and allowed to wake after injection of saline (placebo control).
88826382|NCT05607563|Experimental|PM1009 120 mg monotherapy|PM1009 120 mg
88826383|NCT05607563|Experimental|PM1009 300 mg monotherapy|PM1009 300 mg
88826384|NCT05607563|Experimental|PM1009 600 mg monotherapy|PM1009 600 mg
88826385|NCT05607563|Experimental|PM1009 1200 mg monotherapy|PM1009 1200 mg
88826386|NCT05601635|Active Comparator|High dose|Dietary supplement containing 200 mg of active ingredient tributyrin
88826387|NCT05601635|Active Comparator|Low dose|Dietary supplement containing 100 mg of active ingredient tributyrin
88826388|NCT05594927|Experimental|Icaritin soft capsule|
88826389|NCT05594927|Active Comparator|Huachansu tablet|
88826390|NCT05584085|Experimental|Acceptance and commitment therapy integrated in diabetes education (ACT-DE)|"The proposed intervention is a six-week acceptance-based diabetes education programme (ACT-DE) comprising acceptance and commitment therapy and diabetes education.~Session 1: Diabetes education and introduction of ACT-DE programme Session 2: Mindfulness cultivation Session 3: Value clarification Session 4: Integrating ACT into diabetes self-management Session 5: Booster session Session length: 120 minutes Group-based (6-8 participants) and face-to-face mode of delivery"
88826391|NCT05584085|Placebo Comparator|Diabetes education|One session of diabetes education, group-based (6-8 participants) and 120 minutes via face-to-face delivery.
88826392|NCT00000249|No Intervention|Control|Subject inhaled 0% N2O for 40 minutes with cold immersion at 10 and 30 minutes
88826393|NCT00000249|Active Comparator|20% N2O|Subject inhaled 20% N2O for 40 minutes with cold immersion at 10 & 30 minutes
88826394|NCT00000249|Active Comparator|30% N2O|Subject inhaled 30% N2O for 40 minutes with cold immersion at 10 and 30 minutes
88826395|NCT00000249|Active Comparator|40% N2O|Subject inhaled 40% N2O for 40 minutes with cold immersion at 10 and 30 minutes
88826396|NCT00000261|Experimental|Moderate drinking adults|
88826397|NCT05592587|Experimental|Distraction using eye massage device producing both vibrations and nature sounds.|
88826398|NCT05592587|Experimental|Distraction using eye massage device producing vibratory stimulations only.|
88826399|NCT05592587|Other|Using basic behavior guidance techniques and without using any type of distraction aids.|
88826400|NCT00000783||1|Sexually active HIV-infected concordant couples
89533914|NCT02227251|Experimental|Part 2: Arm A-Selinexor 40 mg|Participants received selinexor 40 mg orally BIW on Days 1 and 3 of each week of 4-week treatment cycles (28 days) until disease progression (total of 8 doses per cycle).
88826401|NCT00000783||2|Sexually active HIV-infected discordant couples
89177360|NCT00807976||Control group|Patients aged 70 years and older, with no history of type 2 diabetes mellitus.
89177361|NCT00829166|Experimental|Trastuzumab emtansine|Participants will receive trastuzumab emtansine 3.6 milligrams per kilogram (mg/kg) intravenous (IV) infusion over 30-90 minutes on Day 1 of each 21-day treatment cycle until disease progression (PD) (as assessed by the investigator), unmanageable toxicity, or study termination.
89177362|NCT00829166|Active Comparator|Lapatinib + Capecitabine|Participants will receive lapatinib 1250 mg (five 250 mg tablets) orally once daily during each 21-day cycle + capecitabine 1000 milligrams per square meter (mg/m^2) orally twice daily on Days 1-14 of each 21-day treatment cycle until PD (as assessed by the investigator), unmanageable toxicity, or study termination. Eligible participants will cross over to receive trastuzumab emtansine if second interim analysis demonstrates statistically significant overall survival benefit in favor of trastuzumab emtansine.
89177363|NCT00799266|Experimental|Zoledronic acid|Twice yearly 0.05 mg/kg (max 5 mg) i.v infusion (at least 30 minutes) of zoledronic acid
89356850|NCT05864716|Active Comparator|probiotics-oral (PO) group|In the PO group, 1 vial of placebo powder via colonoscopic spray is performed once, followed by five-days of two oral probiotics capsules daily. After the five-day treatment, the 2nd fecal sample will be collected. Both groups will receive a 23-day course of oral probiotics (two capsules twice daily) subsequently. The patients were asked to keep a diary to record bowel habits and register any adverse events. The 3rd fecal sample will be collected 28 days after the colonoscopy. The questionnaires will be completed 28 days and 84 days after the colonoscopy to assess responses of treatment. Polyethylene glycol and loperamide were allowed during the intervention as the rescue medication.
88826402|NCT02978027|Active Comparator|Brief Advice|The brief advice protocol was designed by removing MI-consistent elements from the NIAAA Clinician's Guide. The protocol involves screening and assessment using the NIAAA pre-screen and single-question screen and assessing for quantity and frequency. Patients exceeding recommended limits receive feedback, information, and advice to cut down drinking to recommended levels. All patients are provided with a tip sheet on strategies for cutting down and encouraged to follow-up with a behavioral health provider with any questions or concerns.
88826403|NCT02978027|Active Comparator|NIAAA Clinician's Guide|"The NIAAA brief intervention was adapted directly from the NIAAA publication Helping Patients Who Drink Too Much: A Clinician's Guide. The protocol screens using the NIAAA pre-screen and single-questions. Patients exceeding recommended limits receive feedback, information, and advice to cut down. For patients unwilling to make a change, the clinician restates their concern, encourages self reflection by asking the patient about reasons to cut down on drinking and barriers to change, and reaffirms willingness to help. For patients willing to make a change, the clinician helps the patient develop a plan to cut down within maximum limits, agree on specific steps and strategies, and provides a tip sheet on strategies for cutting down."
88826404|NCT02978027|Experimental|Motivational Interviewing (MI)|The MI intervention condition was also adapted from the NIAAA Clinician's Guide, with additional modification to include elements of MI. Clinicians normalize Screening and Brief Intervention (SBI) and ask the patient's permission before discussing alcohol use. The NIAAA pre-screen and single-question screen are administered. Assessment of quantity, frequency, and Alcohol Use Disorder symptoms is done using open questions. The ask-tell-ask technique is used to share feedback and exchange information regarding U.S adult drinking patterns. For patients low in readiness to make a change, clinicians build readiness using structured MI tools. For patients high in readiness to change, the ask-tell-ask technique is used to explore strategies for cutting down and develop an action plan.
88826405|NCT00358397|Experimental|Treatment arm|
88826406|NCT02977871|No Intervention|No Bladder Flap group|Routine uterine incision performed during cesarean section without incision and dissection of the bladder peritoneum.
88826407|NCT02977871|Active Comparator|Bladder Flap group|Routine uterine incision performed during cesarean section with an incision and a dissection of a bladder flap.
88826408|NCT00000273|Experimental|Opiates|Opiate-dependent individuals who were currently not seeking treatment for their drug use, completed the 6-week protocol.
88826409|NCT05371847|Active Comparator|breast cancer patients|Women and men in the prospective cohort study will be invited to participate in this additional validity and/or reliability testing
88826410|NCT05371847|Active Comparator|healthy volunteers|age- and gender-matched
88826411|NCT03835325|Experimental|Cogmax®|Research participants will receive 2 capsules of Cogmax® per day (after lunch) for 12 weeks.
88826412|NCT05362487||Swiss COPD patients|
89356851|NCT05864664|Experimental|WALANT procedure|"Patient awake with no form of sedation or analgesia~A mixture of lidocaine, adrenaline, normal saline, bicarbonate is used to get 40-50ml solution Injection is performed around incision site - superficial to deep including periosteum Incision is performed in the normal fashion Plate and screws are removed and incision is closed"
89533915|NCT02227251|Experimental|Part 2: Arm B-Selinexor 60 mg|Participants received selinexor 60 mg orally BIW on Days 1 and 3 of each week of 4-week treatment cycles) for 2 cycles (each cycle of 28 days) followed by 60 mg once weekly (QW) in the subsequent cycles until disease progression (total of 8 doses per cycle).
89533916|NCT02211755|Experimental|1|Starting doses are clofarabine at 1 mg/m2 IV on days 1 through 5 of a 21-day cycle, and bortezomib at 0.8 mg/m2 subcutaneously on days 1 and 4 of a 21-day cycle.
89533917|NCT02190266||Patients|Patients with confirmed refractory and/or disseminated coccidioidomycosis.
89533918|NCT02176148||Lupus control standard-of-care|Each person enrolled will be given fluocinonide 0.05% cream to apply twice daily to active areas.
88826413|NCT05362331|Experimental|Companion for CAR-T Web Application (CC)|Enrolled participants and caregivers will receive access to the CC web application during the participants Chimeric Antigen Receptor T-cell (CAR-T) therapy. Key components include (1) educational videos and materials, (2) appointment calendars and 'Appointment Companion' features to prepare for clinical appointments, and (3) tools to assist with vital sign and neurological monitoring at home.
88826414|NCT05139797||Artificial Intelligence Screening for Cardiac Amyloidosis|An artificial intelligence algorithm will produce a probability of cardiac amyloidosis that will trigger referral to specialty clinic for further evaluation.
88826415|NCT00359879|Experimental|1 - exenatide before breakfast and dinner|
88826416|NCT00359879|Active Comparator|2 - exenatide before lunch and dinner|
88826417|NCT04331613|Experimental|CAStem|A dose-escalation with 3 cohorts with 3 patients/cohort who receive doses of 3, 5 or 10 million cells/kg. If there is no safety concerns for each cohort, the dose will be escalated from lower dose to next higher dose.
88826418|NCT05355077|Experimental|Group 1|JT001 (VV116):200 mg, oral, Twice a day
88826419|NCT05355077|Experimental|Group 2|JT001 (VV116):400 mg, oral, Twice a day
88826420|NCT05355077|Experimental|Group 3|JT001 (VV116):600 mg, oral, Twice a day
88826421|NCT01647516|Experimental|Ozanimod 0.5 mg|Participants received 0.5 mg capsules of ozanimod hydrochloride daily during the induction period weeks 0-9 (an initial 8-day dose escalation regimen in the induction period that consisted of 4 days of ozanimod HCl 0.25 mg (equivalent to ozanimod 0.23 mg), followed by 3 days of ozanimod HCl 0.5 mg, (equivalent to ozanimod 0.46 mg) followed by the assigned treatment level for at least 8 weeks. Participants who completed the induction period and were responders at week 8, continued to receive the same dose of ozanimod during the maintenance period up to week 32. Participants who received ozanimod 0.5 mg capsules and completed the induction period and were non-responders at Week 8 and who completed the maintenance period or experienced a disease relapse, were given the option to enter the OLP and receive 1 mg ozaninod capsules daily up to 6 years. Participants who had not shown clinical improvement 8 weeks after initiation of the OLP were discontinued from the study.
88826422|NCT01647516|Experimental|Ozanimod 1 mg|Participants received 1 mg capsules of ozanimod hydrochloride daily during the induction period weeks 0-9 (an initial 8-day dose escalation regimen in the induction period that consisted of 4 days of ozanimod HCl 0.25 mg (equivalent to ozanimod 0.23 mg), followed by 3 days of ozanimod HCl 0.5 mg, (equivalent to ozanimod 0.46 mg) followed by the assigned treatment level for at least 8 weeks. Participants who completed the induction period and were responders at week 8, continued to receive the same dose of ozanimod during the maintenance period up to week 32. Participants who received ozanimod 1 mg capsules and completed the induction period and were non-responders at Week 8 and who completed the maintenance period or experienced a disease relapse, were given the option to enter the OLP and receive 1 mg ozaninod capsules daily up to 6 years. Participants who had not shown clinical improvement 8 weeks after initiation of the OLP were discontinued from the study.
88826423|NCT01647516|Placebo Comparator|Placebo|Identically matching placebo capsules daily for 32 weeks followed by an optional open label treatment period.
88826424|NCT05127551|Active Comparator|iStent Infinite|Subjects implanted with iStent Infinite system
89533919|NCT02154022||1|Patients with cancer who are currently enrolled in IRB approved NIH Intramural Research Program clinical trial
89533920|NCT02149719|Experimental|Desensitisation to peanut|Desensitisation using boiled peanut
89533921|NCT02149719|Experimental|Control|Subjects allocated to the control group will undergo routine care for 12 months, following which they will be offered the active treatment with boiled peanut (as a one-way cross-over intervention).
88826425|NCT05127551|Active Comparator|Competitor Device|Subject implanted with competitor device
88826426|NCT01647282|Experimental|Sc/RP with minocycline micropheres|Sc/RP is the subgingival mechanical removal of calculus and diseased cementum from the tooth root. Local application of minocycline microspheres will be done after scaling and root planing (Sc/RP) has been completed
88826427|NCT01647282|Active Comparator|Sc/RP alone|Sc/RP is the subgingival mechanical removal of calculus and diseased cementum from the tooth root
88826428|NCT05347979|Experimental|Dabigatran Etexilate (NIMP) and Relacorilant (IMP)|Following an overnight fast, participants will receive 75 mg dabigatran etexilate on Day 1, 400 mg dose of relacorilant QD on Days 3 to 13, and 75 mg dabigatran etexilate on Day 12. On Day 12, dabigatran etexilate will be dosed at approximately the same time as the relacorilant dose.
89000597|NCT02254993|Experimental|Arm 3- Part A|A single 4-hour C16G2 tray gel application (3.2 mg/mL)
89000598|NCT02254993|Experimental|Arm 4- Part A|One 4-hour C16G2 tray gel application (1.6 mg/mL) over the course of five days
89000599|NCT02254993|Experimental|Arm 5- Part A|One 30-minute C16G2 tray gel application (1.6 mg/mL) over the course of five days
89000600|NCT02254993|Experimental|Arm 6- Part A|One 5-minute C16G2 tray gel application (3.2 mg/mL) over the course of five days
89533922|NCT02147405||ARV naive|Patients that have not started or have ever been on ARV therapy.
89533923|NCT02147405||IRIS|Patients that are on medication but are possibly experiencing an IRIS event.
89177364|NCT00799266|Placebo Comparator|Placebo|Twice yearly i.v of infusion of Placebo (similar dosing as active drug)
89533924|NCT02138669|Other|Intacs Device|INTACS® prescription inserts are an ophthalmic medical device designed for the reduction or elimination of myopia and astigmatism in patients with keratoconus so that their functional vision may be restored and the need for a corneal transplant procedure can potentially be deferred.
88826429|NCT05118035|Experimental|Intervention|"Patients randomized to intervention will have access to the screening tool. Once the AI-ECG indicates high risk of mortality, a warning message would be immediately triggered and sent to the corresponding attending physicians. Notifications appear in the recipient's smartphone message system for the prompt attention. The message notified the physician that, An ECG was received for patient X. An ECG indicates high risk of mortality. Please intensively attend to patient's conditions. If the physicians need to further identify the ECG, click on the following link to connect the ECG and the result of AI-ECG prediction. Of note, although we will actively send a warning message for high risk cases, the AI-ECG report for low risk cases still presented the degree of risk. Physicians can check the relative severity by access EHR for patients in the intervention group."
88826430|NCT05118035|No Intervention|Control|Patients will continue routine practice.
88826431|NCT02321436|Active Comparator|Treatment group|Dysport® 500U intramuscular injection
88826432|NCT02321436|Placebo Comparator|Placebo Group|Placebo intramuscular injection
88826433|NCT05325515|Active Comparator|Fosamax (conventional alendronate)|Conventional alendronate 70mg weekly for 16 weeks
88826434|NCT05325515|Experimental|Binosto (effervescent and buffered alendronate)|Effervescent and buffered alendronate70mg weekly for 16 weeks
88826435|NCT05527691|Experimental|SupportGroove|"8-week intervention that is remotely delivered through a mobile app, consisting of daily quests (positive psychology-based activities) completed individually and as a couple."
88826436|NCT05527691|No Intervention|Waitlist control|Participants will be waitlisted for 8 weeks.
88826437|NCT04344041|Experimental|Intervention group|High dose of vitamin D3
88826438|NCT04344041|Active Comparator|Comparator group|Standard dose of vitamin D3
88826439|NCT02319642|Experimental|Certolizumab Pegol (CZP)|"Those subjects from either treatment group in RA0044 (NCT02151851) who fail to achieve an ACR20 response in RA0044 (NCT02151851) at Week 12, which is confirmed at Week 14. These subjects are withdrawn from RA0044 (NCT02151851) at Week 16 of that study, and that assessment will also be the Entry assessment for this Extension study. In this OLE study, these subjects will receive CZP 400 mg sc at Weeks 0, 2, and 4 followed by CZP 200 mg sc Q2W.~Subjects from either treatment group in RA0044 (NCT02151851) who completed RA0044 (NCT02151851) through Week 24. The Week 24 assessment in RA0044 (NCT02151851) will also be the Entry assessment for this Extension study. In this OLE study, these subjects will receive CZP 200 mg sc Q2W."
88826440|NCT05110937||Sepsis|Blood collection: Blood will be collected from patient at day 4, day 7, day 14-21 and at 3 and 6 months.
88826441|NCT05110937||Healthy Controls|"Blood Collection.~The healthy volunteer participants will donate a blood sample. These controls will allow the investigators to determine if the values obtained are accurate, reliable, and repeatable."
88826442|NCT05110937||Trauma|Blood collection: Blood will be collected from patient at day 4, day 7, day 14-21 and at 3 and 6 months.
88826443|NCT02280096|Active Comparator|4-aminopyridine treatment|4-aminopyridine is given as gelatin capsules containing 4-aminopyridine 10 mg and microcrystalline cellulose as the excipient. Each patient will take two capsules every 8 hours after meals, for a total of 6 capsules/day. The 4-aminopyridine dosage will increase 10 mg/4 weeks by substitution of placebo instead of 4-aminopyridine capsules; such that patients will receive from 40 to 60 mg. distribute in 6capsules/day throughout the study.
89177365|NCT00650104|Active Comparator|Active|Open label medication - Ropinirole CR
89533925|NCT02133196|Experimental|1/High-Dose Aldesleukin|Non-myeloablative lymphodepleting preparative regimen of cyclophosphamide and fludarabine plus young TIL plus high-dose Aldesleukin
88826444|NCT02280096|Placebo Comparator|Placebo|Patients randomized to the placebo sequence will receive placebo for 20 weeks after the run-in period. They will be blinded to the fact that they are taking placebo, and capsules will be identical in appearance to the intervention capsules.
88826445|NCT05320289|Experimental|AblaCare Procedure|AblaCare Procedure performed with use of the AblaCare Kit intended for transvaginal ablation of ovarian tissue under ultrasound visualization in women with infertility due to polycystic ovary syndrome.
88826446|NCT04877574|Experimental|ANI-guided intraoperative analgesia|Intraoperative analgesia is performed by controlling the effect-site concentration of remifentanil to maintain 50-70 of ANI index.
88826447|NCT04877574|Active Comparator|Conventional intraoperative analgesia|Intraoperative analgesia is performed by controlling the effect-site concentration of remifentanil at the discretion of attending anesthesiologists based on hemodynamic parameters.
88826448|NCT00359177|Experimental|Healthy subjects receiving GW679769|Healthy Subjects will receive single 100 milligram (mg) oral doses of GW679769 for five consecutive days.
88826449|NCT00359177|Experimental|Subjects with hepatic impairment receiving GW679769|Subjects with hepatic impairment will receive single 100 mg oral doses of GW679769 for five consecutive days.
88826450|NCT00359255|Active Comparator|1|
88826451|NCT00359255|Experimental|2|
88826452|NCT02279862|Experimental|Arm 1: Ipilimumab 3 mg/kg|Ipilimumab 3 mg/kg injection intravenously every 3 weeks for 4 doses in Induction phase. Subjects that are eligible to receive Ipilimumab in the Maintenance phase will be dosed every 12 weeks for a maximum of 3 years since the first induction dose
89177366|NCT00808054|Experimental|Glucose and EMLA|Received glucose oral and topical EMLA
89177367|NCT00808054|Experimental|Glucose and placebo|Received glucose and no EMLA
89177368|NCT00808054|Experimental|Oral placebo and EMLA|Received oral placebo and EMLA
89177369|NCT02552134|Experimental|frequent participation|After termination of a stationary stay in a health resort, participants will visit an initial standardised regional sport club based exercise programme for 12 sessions at the place of the residence.
89177370|NCT02552134|Experimental|medium participation|After termination of a stationary stay in a health resort, participants will visit an initial standardised regional sport club based exercise programme for 12 sessions at the place of the residence
89177371|NCT02552134|Experimental|low participation|After termination of a stationary stay in a health resort, participants will visit an initial standardised regional sport club based exercise programme for 12 sessions at the place of the residence
88826453|NCT02279862|Experimental|Arm 2: Ipilimumab 10 mg/kg|Ipilimumab 10 mg/kg injection intravenously every 3 weeks for 4 doses in Induction phase. Subjects that are eligible to receive Ipilimumab in the Maintenance phase will be dosed every 12 weeks for a maximum of 3 years since the first induction dose
88826454|NCT05550233|Experimental|DCB treatment|drug-coated balloon in PCI
88826455|NCT05550233|Other|DES treatment|drug-eluted stent in PCI
88826456|NCT00359957|Experimental|1|ADDED condition - behavioral intervention for modifying diet and physical activity, with greater emphasis on physical activity than the STANDARD condition
88826457|NCT00359957|Active Comparator|2|STANDARD condition - behavioral intervention for modifying diet, with little emphasis on physical activity
88826458|NCT02318940|Other|Landmark method|"installation of Central venous catheter In this arm the catheter will be installed under the usual method guided by anatomical landmarks.~access will be through the femoral vein only"
88826459|NCT02318940|Active Comparator|Ultrasound method|installation of Central venous catheter This arm of the catheter is installed using real-time ultrasound. Access will be through the femoral vein only
88826460|NCT05503901|Experimental|Group 1: STN1012600 0.002%|
88826461|NCT05503901|Experimental|Group 2: STN1012600 0.002%|
88826462|NCT05503901|Experimental|Group 3: STN1012600 0.002% + Timolol 0.5%|
88826463|NCT05079425|Experimental|Part A: Fasting|Single ascending dose (SAD).
88826464|NCT05079425|Experimental|Part A: Fed|Single ascending dose (SAD).
88826465|NCT05079425|Experimental|Part B: Fasting|Multiple Ascending Dose (MAD)
88826466|NCT02977637|Experimental|Feraheme group|All patients enrolled in the study will receive Feraheme MRI/MRA to detect vascular malformations. Ferumoxytol in its standard concentration (510 mg in 17 cc) will be administered IV at 0.15-0.21 mg/kg prior to MRI/MRA.
89356852|NCT05864664|Active Comparator|General anesthesia|The surgery is performed in the standard fashion. The patient received general anesthesia The surgery is performed normally and the plate/screws are removed
89533926|NCT02133196|Experimental|2/Low-Dose Aldesleukin|Non-myeloablative lymphodepleting preparative regimen of cyclophosphamide and fludarabine plus young TIL plus low-dose Aldesleukin
89533927|NCT02107989|Experimental|healthy volunteers|healthy volunteers
88826467|NCT05069441||Patients with extubation after a weaning trial|Patients who sucessfully complete a spontaneous breathing trial are enrolled in this group.
88826468|NCT02294058|Active Comparator|Interferon beta-1a|Participants received 30 µg interferon beta-1a by intramuscular (IM) injection weekly and matching placebo capsules (identical in physical appearance to ozanimod) orally once a day until the last participant had been treated for 12 months.
89533928|NCT02107989|Experimental|Patients|Patients
89533929|NCT02055209||1|Adults only, all genders, US born African American
88826469|NCT02294058|Experimental|Ozanimod 0.5 mg|Participants received ozanimod 0.5 mg capsules orally once a day and an intramuscular placebo injection (identical in appearance to Interferon) weekly until the last participant had been treated for 12 months.
88826470|NCT02294058|Experimental|Ozanimod 1 mg|Participants received ozanimod 1 mg capsules orally once a day and an intramuscular placebo injection (identical in appearance to Interferon) weekly until the last participant had been treated for 12 months.
88826471|NCT05491499||Youth with Chronic pain|We will recruit 38 youth with primary and secondary chronic pain syndromes[29; 31] ages 10-17 years who are admitted to the Mayo Family Pediatric Pain Rehabilitation Center at Boston Children's Hospital. This longitudinal cohort study will examine responses to the OA and Fitkids Treadmill tests at 2 timepoints: 1) within 5 days of IIPT admission and 2) within 1 week of IIPT discharge. Twelve participants will complete a 3rd visit within 5 days of the first study visit to examine OA test-retest reliability.
88826472|NCT00359333|Experimental|Single Group|
88826473|NCT04344275|Experimental|Kinesio-taping (KT)|The skin will first be properly cleaned with rubbing alcohol. An I-shaped strip of Kinesio tape with a 5-cm width was applied over the middle trapezius from origin to insertion in the KT group. Kinesio-tape size was measured from the T3 spinal process to the acromion, while the subject is in sitting position relaxed with the arm at the trunk side. The subject was then instructed to move the arm into horizontal adduction and neck flexion. At this position, the tape was applied involving the middle trapezius, ending on the acromion, with 50% tension as recommended for this technique.
88826474|NCT04344275|Placebo Comparator|Placebo Kinesio-taping (KT)|Kinesio-tape was applied with no tension and technique on the middle trapezius.
88826475|NCT00001131|Experimental|A|Patients will recieve a daily, self-administered subcutaneous injection of IL-2 while continuing treatment with their current oral anti-HIV medications
88826476|NCT00001131|Active Comparator|B|Patients will only follow their current oral anti-HIV medication regimen. No additional IL-2 injection will be given.
89000601|NCT02254993|Experimental|Arm 1 - Part B|Four manual brush gel applications on Day 0 followed by twice daily manual brush gel applications (Days 1 through 6); total of 7-day study drug administration, 3.2 mg/mL C16G2 gel concentration.
89356853|NCT05864586|Active Comparator|Young adult EC users|Young Adult EC users
89356854|NCT05864586|Active Comparator|Older adult smokers|Adult smokers
89356855|NCT05864508|Experimental|intranasal oxytocin|intranasal oxytocin treatment once a day during 6 weeks
89533930|NCT02043158||Ovarian Cancer Survivors|Short-term and long-term ovarian cancer survivors
88826477|NCT05280587|Experimental|Technological Group|Technological group (TG) patients will undergo robotic treatment for the improvement balance through the robotic platform (Hunova® Movendo Technology srl, Genova, IT), 3 times per week for 45 minutes each, in addition to the conventional treatment (total 180 minutes per day). In particular, the technological rehabilitation performed employing a footboard will be mostly aimed at improving the balance both in sitting and standing position, and will be proposed static and dynamic exercises, exercises dual-task exercises, and exercises to improve trunk control.
88826478|NCT05280587|No Intervention|Control Group|Congrol Group (CG) patients will undergo conventional rehabilitation treatment only, using the main rehabilitation methods (e.g., neurocognitive theory, Bobath Concept, Progressive neuromuscular facilitation, etc.).
88826479|NCT04714983|Experimental|Dose-level 1|The dose-level 1 arm will use a 3+3 design. A single dose of DNX-2440 will be delivered via intra-tumoral injection at Visit 1 and at Visit 3 (2 administrations in total) approximately 14 days apart.
88826480|NCT04714983|Experimental|Dose-level 2|The dose-level 2 arm will use a 3+3 design. A single dose of DNX-2440 will be delivered via intra-tumoral injection at Visit 1 and at Visit 3 (2 administrations in total) approximately 14 days apart.
88826481|NCT04714983|Experimental|Dose-level 3|The dose-level 3 arm will use a 3+3 design. A single dose of DNX-2440 will be delivered via intra-tumoral injection at Visit 1 and at Visit 3 (2 administrations in total) approximately 14 days apart.
88826482|NCT05044637|Experimental|Primaquine (3.5mg x 7d)|Primaquine 7 days Standard blood schizontocidal therapy plus 7 days of unsupervised primaquine (3.5 mg/kg total dose) administered once per day (0.5 mg/kg OD).
88826483|NCT05044637|Active Comparator|Primaquine (7.0mg x 7d)|Primaquine 7 days Standard blood schizontocidal therapy plus 7 days of unsupervised primaquine (7.0 mg/kg total dose) administered once per day (1.0 mg/kg OD).
88826484|NCT05044637|Active Comparator|Primaquine (7.0mg x 14d)|Primaquine 14 days Standard blood schizontocidal therapy plus 14 days of unsupervised primaquine (7.0 mg/kg total dose) administered once per day (0.5 mg/kg).
88826485|NCT05043077|Experimental|Study Group|Mydriasis with microdrops
88826486|NCT05043077|Active Comparator|Control Group|Mydriasis with standard drops
88826487|NCT05465369|Experimental|injectable flowable composite with giomer technology (beatifil flow plus x)|Injectable flowable Giomer composites is a material used for direct filling techniques has been developed over the past years. It has the property of Giomer technology that able to release and recharge fluoride and other beneficial ions for the life of the restoration and induce remineralization of the underlying hard dental tissues . Injectable flowable Giomer composite (Beautifil flow plus x) has a long-term clinical performance like conventional composite., it also aids in decrease acid production and formation of antiacid resistant layer, help in reduction of tooth mineral solubility also it has high survival rate and wear resistance in high stress bearing areas in posterior teeth Beautifil Flow Plus X also helps to remineralise the tooth structure for sustainable caries prevention and easily polishes for long-lasting luster
88826488|NCT05465369|Active Comparator|high viscosity glass ionomer (Equia Fil ) in ART|High viscous glass ionomer, the most suitable restorative material for ART procedure and can be used outside the dental clinic, which increases the opportunity for dental care , using a high-viscosity glass-ionomer as an ART sealant in both primary and permanent posterior teeth have a high caries preventive effect High viscosity glass ionomer (EQUIA Fil) has new technology involves ultrafine, and highly reactive glass diffused within the glass-ionomer fillers to increase and enhance matrix formation. This system allows ion availability and builds a stronger matrix structure with greater physical properties, wear resistance and fluoride release. Mechanical properties and fluoride release is the most important features to evaluate glass ionomer restorative material and it's proven that EQUIA Fil fulfilled all these requirement
88826489|NCT05031455|Experimental|Aspirin Challenge|All subjects will undergo a standardized aspirin challenge
88826490|NCT00380601|Experimental|1|
88826491|NCT05029973|Experimental|Treatment Group|HAIC Combined With Sintilimab and Bevacizumab Biosimilar
88826492|NCT00380757|Active Comparator|CPR 30:2|30 chest compressions to 2 ventilations
88826493|NCT00380757|Active Comparator|CPR 15:2|15 chest compressions to 2 ventilations
89177372|NCT02552134|Active Comparator|recommendation to be active|"During the stay in the health care resort participants are introduced to be active in the future. They will receive a brochure Physical Activity: Health for all."
89533931|NCT02015117|Experimental|Cohort A (trametinib, whole-brain radiation therapy)|Patients receive trametinib PO QD for 4 weeks. Beginning in week 2, patients undergo whole brain radiation therapy five days a week for 3 weeks. Treatment continues for 4 weeks in the absence of disease progression or unacceptable toxicity.
88826494|NCT05016713|Active Comparator|Intervention group 1|Fluoride-based toothpaste is used for tooth-brushing beside using interdental brushes.
88826495|NCT05016713|Active Comparator|Intervention group 2|Chlorhexidine mouthwash is added to the previous oral hygiene protocol being used beside fluoride-based toothpaste and interdental brushes. CHX mouthwash is used by patients according to the manufacturer's instructions 15 min after tooth-brushing: 5 mL of 0.2% CHX was applied for 60s in the morning and at bedtime. The patients will be instructed not to consume any liquid or food at least 30 min after using the prescribed mouthwash. All patients are asked to bring the mouthwash bottle, so we could determine patient compliance based on how much liquid was left.
89177373|NCT04108806|Experimental|Endovascular therapy|Outcome of endovascular therapy on PAC
89177374|NCT05102734||Topical nitroglycerin|A topical nitroglycerin solution will be applied to the area of interest
89177375|NCT05621226|Experimental|"Control condition with waiting for you message"|This control condition will use the text message that the investigators found to be the best performing in their last mega-study of vaccine text messages to recommend a COVID vaccination.
89533932|NCT02015117|Experimental|Cohort B (trametinib, surgery)|Patients receive trametinib PO QD on days 1-14 followed by surgical resection of the tumor.
89533933|NCT02008903||EoE active disease|Inflammation as defined by >15 eos / HPF
88826496|NCT05016713|Placebo Comparator|Control group|Regular tooth-brushing is carried out using fluoride-based toothpaste supplied only.
88826497|NCT05253521||South Asian Origin|Individuals who identify as having Anglo-Indian, Bangladeshi, Bengali, Bhutanese, Goan, Gujarati, Indian, Jatt, Kashmiri, Maharashtrian, Malayali, Nepali, Pakistani, Punjabi, Sindhi, Sinhalese, Sri Lankan, Tamil, Telugu, or other South Asian origin
88826498|NCT05253521||White Individuals of European Origin|Individuals who identify as having western European, other northern European, southern European, eastern European or other European origin
88826499|NCT05430269|Experimental|Intervention group|ICU patients who developed diarhea after a course of antibiotic therapy treated with Faecal bacteriotherapy (FBT) delivered as enema
88826500|NCT05430269|Active Comparator|Control group|ICU patients who developed diarhea after a course of antibiotic therapy treated standard-of-care protocolised treatment of postantibiotic diarhea
88826501|NCT05231369|Experimental|group 1: 25 ug of ChulaCov19 BNA159 mRNA vaccine|The participants will receive 25 ug of the vaccine.
88826502|NCT05231369|Experimental|group 2: 50 ug of ChulaCov19 BNA159 mRNA vaccine|If 25 ug is safe, then will proceed to enroll 12 more participants to receive 50 ug.
88826503|NCT05422625|Active Comparator|Active PTNS|Once a week induction consisting of active PTNS treatments for 30 minutes for 12 consecutive weeks.
88826504|NCT05422625|Placebo Comparator|Sham PTNS|Once a week induction consisting of Sham PTNS treatments for 30 minutes for 12 consecutive weeks.
88826505|NCT05226533|Experimental|Niclosamide 432mg|Niclosamide 432mg (intramuscular injection) + Remdesivir
88826506|NCT05226533|Experimental|Niclosamide 960mg|Niclosamide 960mg (intramuscular injection) + Remdesivir
88826507|NCT05226533|Placebo Comparator|Placebo|Placebo (intramuscular injection) + Remdesivir
88826508|NCT00359567|Experimental|1|palonosetron
88826509|NCT00359567|Active Comparator|2|granisetron hydrochloride
88826510|NCT05210465||patients with stable angina pectoris and prior MI|
88826511|NCT05199857|Experimental|Wellness education and Home exercise programs|
89533934|NCT02008903||EoE remission|No inflammation in EoE patients after treatment
89533935|NCT02008903||normal control|No inflammation
88826512|NCT05421923|Experimental|SR1375 capsules|Ascending single and multiple doses of SR1375 orally
88826513|NCT05421923|Placebo Comparator|Placebo|Ascending single and multiple doses of SR1375 placebo orally
88826514|NCT05418023||Autism Spectrum Disorder (ASD)|
88826515|NCT05418023||Non-ASD|
88826516|NCT05416541||pregnant patients|
88826517|NCT05188235|Experimental|Infants with developmental dysplasia of the hip|Infant participants putting on a device for 15 minutes to take different measurements of the hip
88826518|NCT05188235|Active Comparator|Infants without developmental dysplasia of the hip|Infant participants putting on a device for 15 minutes to take different measurements of the hip
88826519|NCT05406947||Low risk group|Based on clinicopathological diagnosis and molecular pathological diagnosis, the children were classified into low risk groups, individualized radiotherapy and chemotherapy plan was made, and a perfect registration and follow-up system was established.
88826520|NCT05406947||Middle risk group|Based on clinicopathological diagnosis and molecular pathological diagnosis, the children were classified into middle risk groups, individualized radiotherapy and chemotherapy plan was made, and a perfect registration and follow-up system was established.
88826521|NCT05406947||High risk group|Based on clinicopathological diagnosis and molecular pathological diagnosis, the children were classified into high risk groups, individualized radiotherapy and chemotherapy plan was made, and a perfect registration and follow-up system was established.
88826522|NCT05440539|Experimental|Written Group|Participants received only written handouts with information about pelvic floor disorders, including risk factors, prevention strategies, and information about possible treatments. They receive these handouts at the time of recruitment during pregnancy and again after delivery.
88826523|NCT05440539|Experimental|Workshop Group|Participants received written handouts and attend a virtual interactive workshop with information about pelvic floor disorders, including risk factors, prevention strategies, and information about possible treatments. They receive the handouts at the time of recruitment during pregnancy and again after delivery. The workshop is conducted prior to completion of pregnancy.
88826524|NCT04745429|Experimental|Intervention|19 people suffering from psoriasis were performing excersises for 10 weeks
88826525|NCT04745429|No Intervention|Control|19 people suffeing from psoriasis that didn't train the exercises
88826526|NCT02293902|Experimental|Sarilumab 150 mg/150 mg|Sarilumab 150 mg subcutaneous (SC) injection once every 2 weeks (q2w) in combination with MTX and folic acid in double-blind period up to Week 24 followed by single-blind period in which participants continued with the same treatment up to Week 52. Participants with inadequate response (defined as less than 20% improvement from baseline on 2 consecutive visits [at least 4 weeks apart] in either tender joint count [TJC] or swollen joint count [SJC], or with any other clear lack of efficacy based on investigator's judgment) by Week 16, were rescued with open label sarilumab 200 mg q2w treatment.
88826527|NCT02293902|Experimental|Sarilumab 200 mg/200 mg|Sarilumab 200 mg SC injection q2w in combination with MTX and folic acid in double-blind period up to Week 24 followed by single-blind period in which participants continued with the same treatment up to Week 52. Participants with inadequate response (defined as less than 20% improvement from baseline on 2 consecutive visits [at least 4 weeks apart] in either TJC or SJC, or with any other clear lack of efficacy based on investigator's judgment) by Week 16, were rescued with open label sarilumab 200 mg q2w treatment.
88826528|NCT02293902|Placebo Comparator|Placebo/Sarilumab 150 mg|Placebo (for sarilumab) SC injection q2w in combination with MTX and folic acid in double-blind period up to Week 24 followed by a single-blind period in which participants were switched and received sarilumab 150 mg SC injection q2w in combination with MTX and folic acid up to Week 52. Participants with inadequate response (defined as less than 20% improvement from baseline on 2 consecutive visits [at least 4 weeks apart] in either TJC or SJC, or with any other clear lack of efficacy based on Investigator's judgment) by Week 16, were rescued with open label sarilumab 200 mg q2w treatment.
89177376|NCT05621226|Experimental|Message communicating latest data on COVID transmission in patient's area|This condition will use a text message informing the participant of the latest data on COVID transmission in participant's area and recommend a COVID vaccination.
88826529|NCT02293902|Placebo Comparator|Placebo/Sarilumab 200 mg|Placebo (for sarilumab) SC injection q2w in combination with MTX and folic acid in double-blind period up to Week 24 followed by a single-blind period in which participants were switched and received sarilumab 200 mg SC injection q2w in combination with MTX and folic acid up to Week 52. Participants with inadequate response (defined as less than 20% improvement from baseline on 2 consecutive visits [at least 4 weeks apart] in either TJC or SJC, or with any other clear lack of efficacy based on Investigator's judgment) by Week 16, were rescued with open label sarilumab 200 mg q2w treatment.
88826530|NCT05400629|Experimental|Training program|12-week strength training program of the lower limbs consisting of 5 different exercises: Leg extension, leg press, hip abduction, squat and plantar flexion. All exercises will be perform between 6 and 8 maximal repetitions.
88826531|NCT04745195||Complement-mediated thrombotic microangiopathy|
88826532|NCT04745195||Thrombotic microangiopathty with normal complement regulation|
88826533|NCT00358787|Active Comparator|1|Crossed K wire orientation for surgical management of a type III Supracondylar fracture.
88826534|NCT00358787|Active Comparator|2|Lateral K wire orientation for surgical management of a type III Supracondylar fracture.
88826535|NCT02278614|Experimental|T2347|T2347: fixed combination Latanoprost 0.005% + Timolol 0.5% unpreserved eye drops
88826536|NCT02278614|Active Comparator|Xalacom|Xalacom®: Latanoprost 0.005% + Timolol 0.5% preserved eye drops
88826537|NCT00359645|No Intervention|Control|Annual auto questionnaire
88826538|NCT00359645|Experimental|Screening|Annual screening of Head and Neck cancer
88826539|NCT00359723|Experimental|Methylphenidate 0.4 mg/kg TID followed by placebo TID|As above
88826540|NCT00359723|Experimental|Placebo TID followed by methylphenidate 0.4 mg/kg TID|As above
88826541|NCT02977559|Experimental|Laryngeal Tube Suction Disposable|Laryngeal Tube Suction Disposable for ventilation
88826542|NCT02977559|Experimental|Laryngeal Mask Airway AuraGain|Laryngeal Mask Airway AuraGain for oxygenation and ventilation
88826543|NCT04973267|Experimental|Game Plan for PrEP|Participants will be asked to use Game Plan for PrEP for however long they wish. Game Plan for PrEP is a web-based intervention that provides users with feedback about how much their risk for HIV is reduced on PrEP, their risk for bacterial STIs, and helps them make a plan to take their medication regularly and reduce their risk for STIs. Game Plan for PrEP also providers users with feedback about their alcohol use compared to others in their age group and encourages them to make a plan to reduce it.
88826544|NCT04973267|Sham Comparator|Lifestyle Habits Videos|Participants in this condition will view several videos that encourage them to adopt sleep hygiene and healthy diet behaviors. The videos were selected to last as long as the average time users engage with Game Plan for PrEP in its initial modules.
88826545|NCT02977169|Experimental|Arm I (PORT)|Participants in the Arm I will receive four cycles of adjuvant chemotherapy and after that, sequential adjuvant thoracic conformal radiotherapy (50.4 Gy, 1.8 Gy once daily over 5.5 weeks) will be administered. PORT begins within 2-4 weeks after chemotherapy.
88826546|NCT02977169|Placebo Comparator|Arm II (no PORT)|Participants in the Arm II will receive four cycles of adjuvant chemotherapy and after that, do not undergo adjuvant thoracic conformal radiotherapy.
88826547|NCT05152823|Experimental|Single Intrathecal Delivery|
88826548|NCT04744805||mask wear|
88826549|NCT04744805||dry eye|
88826550|NCT05148533|Experimental|TJ1133 Injection|
88826551|NCT00381225|Experimental|Ultra-sound guided radio-frequency ablation|
88826552|NCT04967339|Experimental|Foot deformity correcting insole arm|"Patients allocated to the foot deformity correcting insole arm will receive insoles to correct their foot deformities (plano-valgus foot deformity)."
88826553|NCT04967339|Active Comparator|Lateral wedge insole arm|"Patient allocated to the Lateral wedge insole arm will receive conventional lateral wedge insole."
88826554|NCT00002463|Experimental|Combination Chemotherapy|Methotrexate, Mechlorethamine, Vincristine, Prednisone, and Procarbazine
88826555|NCT02318706|Placebo Comparator|placebo|placebo group (14 weeks)
88826556|NCT02318706|Experimental|DS-5565 15mg|DS-5565 15 mg, oral administration, Treatment period; 2-weeks titration and 12-weeks fixed dose
88826557|NCT02318706|Experimental|DS-5565 20 mg group|DS-5565 20 mg, oral administration, Treatment period; 1-week titration and 13-weeks fixed dose
88826558|NCT02318706|Experimental|DS-5565 30 mg group|DS-5565 30 mg, oral administration, Treatment period; 2-weeks titration and 12-weeks fixed dose
88826559|NCT04858607||Immunocompromised individuals|Patients with primary or secondary immunodeficiency planning on vaccination against SARS CoV-2 according to the Austrian vaccination plan.
88826560|NCT04858607||Healthy individuals|Healthy people planning on vaccination against SARS CoV-2 according to the Austrian vaccination plan.
88826561|NCT02977091||GH deficiency or idiopathic short stature|growth hormone (GH) deficiency or idiopathic short stature children before they start GH treatment
88826562|NCT02977091||short stature|healthy short children
88826563|NCT02977325||Physical activity|One group participated in therapeutic programs centered on the physical activity
88826564|NCT02977325||water cure exclusively|This group followed exclusively the water cure
88826565|NCT04916015||children (0-14 years)|
88826566|NCT04916015||AYAs (15-25 years)|
88826567|NCT00002529|Experimental|AC with concurrent tamoxifen|AC for 4 cycles with concurrent tamoxifen for 5 years
89177377|NCT00812188|Active Comparator|Medium Dose UVA-1|Medium dose (60 J/cm2) UVA-1 3x/week for 12 weeks to one morphea plaque and fluocinonide 0.05% cream to another morphea plaque twice daily for twelve weeks.
89177378|NCT00812188|Active Comparator|High Dose UVA-1|High dose UVA-1 treatment 3x/week for 12 weeks to one morphea plaque and fluocinonide 0.05% cream twice daily for 12 weeks to another morphea plaque.
89177379|NCT00915096||High Tumor Burden Follicular Lymphoma|
89000602|NCT02254993|Experimental|Arm 2 - Part B|Three manual brush gel applications followed by one tray gel application on Day 0. One manual brush application in the morning and one tray gel application in the evening on Days 1 through 6; total of 7-day study drug administration, 3.2 mg/mL C16G2 gel concentration.
89177380|NCT00814528|Experimental|1|"Application of 5-ALA PDT to some lesions on skin with Blue U light source (417 nm)."
89177381|NCT00814528|Experimental|2|5-FU, Imiquimod or treatment with cryotherapy to lesions on the skin.
89356856|NCT05864430|Experimental|Face-to-face Training Group|Students in this group will be given face-to-face training on SRH by the principal researcher accompanied by PowerPoint.
88826568|NCT00002529|Experimental|AC followed by tamoxifen|AC for 4 cycles followed by tamoxifen to 5 years from randomization.
88826569|NCT00002529|Experimental|Tamoxifen alone|Tamoxifen alone for 5 years.
88826570|NCT00002529|Experimental|AC with concurrent toremifene|AC for 4 cycles with concurrent toremifene for 5 years.
88826571|NCT00002529|Experimental|AC followed by toremifene|AC for 4 cycles followed by toremifene to 5 years from randomization.
88826572|NCT00002529|Experimental|Toremifene alone|Toremifene alone for 5 years.
88826573|NCT04826237|Experimental|Statin|"Methylprednisolone+statin (identity and dose to be determined before Trial Begins) Oral methyprednisolone, tapering dose over 11 days, beginning at 16 mg 4 x a day;~Oral statin 1 dose per day for 7 days, beginning with the first dose of methylprednisolone:~If no improvement after two weeks, offer up to 2 doses intratympanic dexamethasone (10 mg/cc) 10 days apart."
88826574|NCT04826237|Placebo Comparator|Placebo|"Methylprednisolone+ placebo. Oral methyprednisolone, tapering dose over 11 days, beginning at 16 mg 4 x a day; Oral placebo 1 dose per day for 7 days, beginning with the first dose of methylprednisolone~If no improvement after two weeks, offer up to 2 doses intratympanic dexamethasone (10 mg/cc) 10 days apart."
88826575|NCT04435769||Non-valvular Atrial Fibrillation (NVAF) on warfarin|The study follows two cohorts of Non-valvular Atrial Fibrillation (NVAF) patients, who used warfarin as a secondary stroke/TIA prevention.
88826576|NCT04435769||Non-valvular Atrial Fibrillation (NVAF) on apixaban|The study follows two cohorts of Non-valvular Atrial Fibrillation (NVAF) patients, who used apixaban as a secondary stroke/TIA prevention.
88826577|NCT00002565|Experimental|Arm I|"Sequential 4-, 5-, and 3-Drug Combination Chemotherapy. IdSHAP: IDA/CDDP/ARA-C/MePRDL; followed by BIdCOS: BLEO/IDA/CTX/VCR/MePRDL; followed by MINE: Mesna/IFF/DHAD/VP-16.~Alternating triple therapy (ATT) of IdSHAP (idarubicin, cisplatin, cytarabine, methylprednisolone), BIdCOS (idarubicin, vincristine, bleomycin, cyclophosphamide, methylprednisolone), and MINE (mesna, ifosfamide, mitoxantrone, etoposide)."
88826578|NCT00002565|Experimental|Arm II|4-Drug Combination Chemotherapy. CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone): CTX/DOX/VCR/PRED.
88826579|NCT00002571|Experimental|ProMACE-CytaBOM + G-CSF|6 cycles of 21 days each of ProMACE-CytaBOM (cyclophosphamide 490 mg/m^2 on day 1, doxorubicin 19 mg/m^2 on day 1, etoposide 90 mg/m^2 on day 1, cytarabine 225 mg/m^2 on day 8, bleomycin 5 u/m^2 on day 8, methotrexate 90 mg/m^2 on day 8, leucovorin 25 mg/m^2 q 6 hours on days 8-9, vincristine 1.4 mg/m^2 on day 8, prednisone 60 mg/m^2 on days 1-14, allopurinol 300 mg on days 1-21 of cycle 1 and days 1-8 of cycle 2 only) plus 1 double strength tablet TMP/SMX 3 days a week plus G-CSF 5 ug/kg on days 9-20. Patients also receive intrathecal cytarabine 30 mg/m^2 (BM positive: 5 doses spaced evenly during 1st 2 cycles, then on day 1 of cycles 3-6; CSF cytology positive: 5 doses spaced evenly during 1st cycle, then on day 1 of cycles 2-6; BM and CSF negative: 5 doses spaced evenly within 1 month of completion of cycle 6). All patients with CR or PR after systemic therapy and IT cytarabine receive 2400 cGy RT to the whole brain in 12 fractions.
88826580|NCT04896515||Standard Nutrition Arm|"In INTENT (the parent study) participants will be randomised to the i) Standard Nutrition or ii) Intensive Nutrition arm. A brief description of each is below.~In ICU:~After enrolment, patients allocated to the standard nutrition therapy (control) group will commence or continue nutrition via an enteral tube to a target rate according to unit protocol including the use of promotility agents and the placement of nasojejunal feeding tubes if required.~Parenteral Nutrition (PN) will only be used if the above methods have been attempted, or an absolute contraindication to enteral nutrition (EN) develops.~After ICU:~1. Nutrition management will be as per usual site management at that hospital."
88826581|NCT04896515||Intensive Nutrition Arm|"In ICU:~Supplemental PN will be commenced within 2 hours of randomisation. The starting dose will be determined by the amount of energy received in the 24 hours prior to randomisation~The need for the intervention will be based on the adequacy of nutrition provision and assessed daily until ICU discharge~If there is an interruption of EN for greater than 2 hours the PN must be run at 20 kcal/kg calculated body weight until EN is recommenced. After the interruption, EN should be recommenced as per local protocol.~After ICU:~1. An intensive nutrition intervention will be provided on the ward.~The goal of nutrition care across the hospital stay will be to ensure 80-100% of participant's estimated energy requirements are met."
88826582|NCT04417907|Placebo Comparator|Placebo|Participants will take 2mg placebo PO QD for six weeks.
88826583|NCT04417907|Experimental|PER 1 Week Titration|Participants will take 2mg perampanel PO QD for one week, followed by 4mg perampanel PO QD for five weeks.
88826584|NCT04417907|Experimental|PER 2 Week Titration|Participants will take 2mg perampanel PO QD for two weeks, followed by 4mg perampanel PO QD for four weeks.
88826585|NCT04417907|Experimental|PER 4 mg|Participants will take 4mg perampanel PO QD for six weeks
88826586|NCT00002583|No Intervention|Observation|Observation only
88826587|NCT00002583|Active Comparator|Chemotherapy|Cisplatin and Vinorelbine
88826588|NCT02191111|Experimental|Task-focused facilitation|An external, task-focused facilitation, informed by an evaluation of contextual factors using the Alberta Context Tool (ACT), will be applied to train community pharmacies to develop alternative team processes that enable a greater number of medication management services to be provided to patients with diabetes, hypertension, and/or dyslipidemia.
88826589|NCT02191111|No Intervention|Control|These sites will continue practice as usual, with no contact from study staff.
88826590|NCT02977247||Women undergoing routine diagnostic breast evaluation|Non-Interventional: Women presenting to enrollment sites for diagnostic examinations of symptoms or imaging findings, as recommended by a physician, and assigned BI-RADS category 4 or 5 (biopsy indicated).
88826591|NCT02223871|Experimental|ACT-451840 500 mg|All the participants were infected with Plasmodium falciparum parasites (malaria) using malaria-infected human erythrocytes. When the parasitemia reached 1000 counts/mL, all the participants received 500 mg of ACT-451840 as a single oral dose. Compulsory commencement of treatment with Riamet® (artemether-lumefantrine) to ensure complete clearance of any gametocytes, occurred 16 days after ACT-451840 administration (or earlier if required) for all participants. Primaquine was to be administered as a single dose only in participants for whom gametocytes were still identified after administration of Riamet® rescue medication
88826592|NCT03004339|Experimental|SOR007 Ointment 2.0%|Topical application once daily during a 12-day treatment period (10 treatments)
88826593|NCT03004339|Experimental|SOR007 Ointment 1.0%|Topical application once daily during a 12-day treatment period (10 treatments)
88826594|NCT03004339|Experimental|SOR007 Ointment 0.3%|Topical application once daily during a 12-day treatment period (10 treatments)
88826595|NCT03004339|Experimental|SOR007 Ointment 0.15%|Topical application once daily during a 12-day treatment period (10 treatments)
88826596|NCT03004339|Placebo Comparator|SOR007 Ointment Placebo|Topical application once daily during a 12-day treatment period (10 treatments)
88826597|NCT03004339|Active Comparator|Taclonex® Ointment|Topical application once daily during a 12-day treatment period (10 treatments)
88826598|NCT00002625|Experimental|Arm I|Radiosensitization plus Radiotherapy. Topotecan hydrochloride, TOPO, NSC-609699; plus external-beam irradiation using linear accelerators with photon energies between 4 and 10 MV (electrons acceptable for the boost field).
88826599|NCT00360737|Experimental|NP-018 - 1 vial|Subjects received one vials of NP-018 administered intravenously.
88826600|NCT00360737|Experimental|NP-018 - 2 vials|Subjects receive two vials of NP-018 administered intravenously.
88826601|NCT02249221|Experimental|Quadrivalent cell-culture based influenza vaccin|Day 1: GC3106, 0.5ml, intramuscular, a single dosing
88826602|NCT02249221|Active Comparator|Trivalent influenza vaccine|Day 1: GC Flu Pre-filled Syringe Inj., 0.5ml, intramuscular, a single dosing
88826603|NCT04343729|Active Comparator|Methylprednisolone|0.5mg/kg injectable methylprednisolone sodium succinate, twice daily, for 5 days.
88826604|NCT04343729|Placebo Comparator|Placebo|Saline solution, twice daily, for 5 days. Injectable.
88826605|NCT02977013||Patients with pulmonary embolism treated with enoxaparin|Anti-Xa assay correlation to the efficacy and safety of enoxaparin in the treatment of pulmonary embolism
88826606|NCT04823611|Placebo Comparator|Part A:Placebo|Placebo solution for subcutaneous injection.
88826607|NCT04823611|Experimental|Part A:AZD8233|AZD8233 for subcutaneous injection.
88826608|NCT04823611|Placebo Comparator|Part B:Placebo|Placebo solution for subcutaneous injection.
88826609|NCT04823611|Experimental|Part B:AZD8233 medium dose|AZD8233 medium dose for subcutaneous injection.
88826610|NCT04823611|Experimental|Part B:AZD8233 low dose|AZD8233 low dose for subcutaneous injection.
89177382|NCT00814606|Experimental|Single Group|8 weeks period of escalating doses of fluvastatin to a goal dose of 80mg daily, then patients will start treatment of HCV at week 9 with the usual standard of care protocol for medication dose, office visits and laboratories. Peginterferon alfa2a 180 mcg/ml SQ injection once a week for 48 weeks and ribavirin 1000-1200 mg daily orally in two divided doses for 48 weeks. Patients weighing < 75 kg will receive 1000mg per day (400mg in the morning and 600mg in the evening). Patients weighing ≥ 75 kg will receive 1200 mg per day (600mg in the morning and 600 mg in the evening).
88826611|NCT04823611|Placebo Comparator|Part C: Placebo|Placebo solution for subcutaneous injection.
88826612|NCT04823611|Experimental|Part C: AZD8233 medium dose|AZD8233 medium dose for subcutaneous injection.
88826613|NCT05752227||benign lung lesions|Patient who were diagnosed with peripheral lung lesions including consolidation, atelectasis, or cavitation
88826614|NCT05752227||malignant lung lesions|patients diagnosed with malignant lung lesions
88826615|NCT04665999||Free-cycling females|Continuous glucose monitor (CGM) data will be collected for three (3) full menstrual cycles. At the end of data collection, data will be analyzed to track insulin sensitivity and glycemic variability changes across the menstrual cycle. Participants will be asked to record meals consumed and free-cycling females will be asked to confirm ovulation by means of study-provided ovulation kits. Participants will be asked to record dates of beginning of menses and ovulation. Participants will also be provide an activity tracker to wear during the duration of the trial.
88826616|NCT04665999||Females taking Monophasic contraception|Continuous glucose monitor (CGM) data will be collected for three (3) full menstrual cycles. At the end of data collection, data will be analyzed to track insulin sensitivity and glycemic variability changes across the menstrual cycle. Participants will be asked to record meals consumed and free-cycling females will be asked to confirm ovulation by means of study-provided ovulation kits. Participants will be asked to record dates of beginning of menses and ovulation. Participants will also be provide an activity tracker to wear during the duration of the trial.
88826617|NCT05807022|Experimental|Percutaneous or transbronchial argon-helium cryoablation|
88826618|NCT05807009|Experimental|core exercise|the patients will receive seven core exercises two times a week for eight weeks
88826619|NCT05806983|Experimental|Experimental group|-The experimental group that applied the technology-based psychosocial program
89177383|NCT00814762|Experimental|HIV 732462 Group|Subjects received 2 doses of the HIV Vaccine 732462 into the deltoid muscle of the dominant arm, on a 0, 1 Month schedule.
89177384|NCT00814762|Placebo Comparator|Placebo Group|Subjects received 2 doses of the placebo vaccine into the deltoid muscle of the dominant arm, on a 0, 1 Month schedule.
89177385|NCT00654238|Experimental|1|This is a single arm study.
89177386|NCT00862979|Active Comparator|CNI-regimen|CNI-regimen: cyclosporine A (CyA) or tacrolimus (TAC) with everolimus (EVR) with corticosteroids
89177387|NCT00862979|Experimental|CNI-free-regimen|CNI-free regimen: everolimus (EVR) with MPA (either MMF or enteric coated mycophenolate sodium (EC-MPS)) and corticosteroids
89177388|NCT02605356|Experimental|Radium-223 dichloride [Phase 1, dose 1]|Phase 1: Radium-223 dichloride; 30 kiloBecquerel (kBq)/kg body weight (33 kBq/kg after implementation of National Institute of Standards and Technology [NIST] update) every 4 weeks for a total of 6 radium-223 dichloride doses plus SOC bortezomib/dexamethasone.
89356857|NCT05864430|Experimental|DataMatrix supported Face-to-face training group|Before starting the training, a QR code including PowerPoint on SRH will be given to the students in the group that receives training with QR code support (on the first slide). Students will be directed to the URL automatically determined by the researcher by scanning the QR code with the camera of their smartphones. Students will follow the lesson with the QR code given simultaneously with the training given during the education process.
88826620|NCT05806983|No Intervention|Control group|Control group receiving standard care
88826621|NCT05806970|Experimental|Intervention - Email Nudge|The intervention will include contacting UCLA Health Cardiology clinic managers with a list of all HFrEF patients eligible for an MRA who are cared for by a provider randomized to the intervention arm. Clinic managers will be asked to make an appointment in the next 60 days for these patients with the specific indication: GDMT initiation - consider MRA. If an appointment is already present in the next 60 days, the indication will be changed to: GDMT initiation - consider MRA.
88826622|NCT05806970|No Intervention|No Intervention - Control Group|Providers randomized to the control arm will perform clinical duties as usual. Their patients will receive routine clinical care.
88826623|NCT05806957||Device: Color Fundus Photography with Non-Mydriatic and Mydriatic Cameras|
88826624|NCT05806918|Experimental|Recombinant Human Interferon α-2b Gel (After the Alteration)|
88826625|NCT05806918|Active Comparator|Recombinant Human Interferon α-2b Gel (Before the Alteration)|
88826626|NCT05806879|Experimental|Maternity Napkins|"The intervention group will receive maternity napkins to manage postpartum lochia with the following specifications:~Length is 230-240mm, to be able to provide adequate coverage.~Width is 150-155mm with wings.~Thickness is 3-5mm.~The maternity napkin is curved to prevent leakage on the sides, has wings for secure attachment to the underwear and able to absorb 30-40 ml per minute"
88826627|NCT05806879|No Intervention|Continued Use of Current Methods|The control group will continue to use their current indigenous methods for managing postpartum lochia.
88826628|NCT05806853|Experimental|Dual tracer PET/MRI|All patients undergo PET/MRI with 68Ga-PSMA and 68Ga-DOTA-RM2. 68Ga-PSMA dose: 160 +-50 MBq, route of administration: intravenous 68Ga-DOTA-RM2 dose: 140 +-50 MBq, route of administration: intravenous
88826629|NCT05806840|Active Comparator|Standard Michigan Model for Health (MMH) Curriculum Implementation|Standard implementation of the MMH (Michigan Model for Health), a universal prevention intervention includes curriculum materials, foundational curriculum training and as-needed technical assistance, provided by the regional school health coordinators.
88826630|NCT05806840|Experimental|Rapid Adaptation to Prevent Drug Use (RAPD)|RAPD is a novel bundle of implementation strategies to improve the responsiveness of an existing evidence-based intervention (EBI), the Michigan Model for Health (MMH) for urgent drug events. These implementation strategies will be deployed in addition to standard implementation components.
88826631|NCT05806762||Sepsis Patients Discharged From the Hospital|We aim to apply a wearable biopatch to sepsis patients discharged from the hospital to determine if the additional data afforded by the biopatch can improve prediction of readmissions.
89356858|NCT05864430|Experimental|Online training group|The students in the online training group will be given training on SRH/RES on an online platform accompanied by PowerPoint by the principal researcher.
89356859|NCT05864378||The POCUS group|Patients who were evaluated by ED physicians who perform POCUS intestinal loops examination as part of their clinical practice
89533936|NCT02003963|Experimental|Exergame Intervention|"Participants randomly assigned to the exergame condition will participate in the intervention condition of Klub Kinect. Klub Kinect is a 12-week intervention occurring for 90-minute sessions, 3 times per week. During each 90-minute intervention session, adolescents will engage in 60-minute bouts of aerobic gaming. Adolescents attending an exergaming session will attend concurrently."
89533937|NCT02003963|No Intervention|Control (Self-Directed Care)|The control condition will receive no contact or intervention other than telephone reminders of their final clinic visit.
88826632|NCT05806736|Experimental|active transcutaneous auricular vagus nerve stimulatio|For Experimental Arm, active transcutaneous auricular vagus nerve stimulation, Patients underwent fourteen consecutive daily sessions of taVNS.
88826633|NCT05806736|Sham Comparator|sham transcutaneous auricular vagus nerve stimulation|For sham transcutaneous auricular vagus nerve stimulation arm, Sham Comparator, patients underwent fourteen consecutive daily sessions of sham-taVNS (the electrodes were fixed at the left earlobe with the same stimulation parameters).
88826634|NCT05806723|Experimental|type 2 diabetic patients at high cardio vascular risk|atorvastatin 40 mg a day for six months
88826635|NCT05806697|Other|All participants|
88826636|NCT05806671|Experimental|Dalpiciclib, Fulvestrant With Pyrotinib|Pyrotinib 320mg/day Dalpiciclib 125 mg/day Fulvestrant 500mg
88826637|NCT05806645|Experimental|Intervention|"The proposed experimental intervention will incorporate our risk prediction model which will be used to guide the hospital to home transition of care for medium and high-risk groups of patients. Patients will receive transition of care plans that are tailored to their risk and embedded within standardized discharge pathways within the EHR.~Documentation of AKI in the discharge summary~Consult for medication reconciliation~Information about AKI provided to patients through EHR~Sick day guidance provided to patients through EHR~Kidney function testing done on day of discharge~Lab requisition provided for kidney function testing at 3 months for all patients~Lab requisition provided for kidney function testing at 1 month for high risk patients~Follow-up appointment booked with a study nephrologist within 3 months of discharge for high risk patients~If patient known to have CKD prior to admission and meets CKD referral criteria, referral to nephrology"
88826638|NCT05806645|No Intervention|Usual Care|The usual care group will not receive the risk-guided transition of intervention and will receive standard hospital discharge care in accordance with local health system standards (Alberta Health Services), and additional requisitions for kidney function testing at 90 days.
88826639|NCT05806619||Patients with suspected glioma|Patients at diagnosis of both sexes with suspected glioma
88826640|NCT05806619||Patients at relapse/progression|Patients at relapse/progression with neurosurgical reoperation indication
88826641|NCT05806489|Experimental|Intermittent Fasting|
88826642|NCT05806489|Placebo Comparator|Control Diet|
88826643|NCT05806476|Experimental|C - C|caffeine intake during the run-in days and caffeine intake on the experimental day
88826644|NCT05806476|Experimental|C - P|caffeine intake during the run-in days and placebo intake on the experimental day
89533938|NCT02003209|Active Comparator|Arm I (combination chemotherapy, surgery, radiation)|"NEOADJUVANT: Patients receive docetaxel IV over 60 minutes, carboplatin IV over 30-60 minutes, trastuzumab IV over 30-90 minutes, and pertuzumab IV over 30-60 on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients enrolled after Amendment #4 undergo 2 core biopsies prior to course 3 of treatment.~SURGERY: Patients undergo lumpectomy or mastectomy.~RADIATION: Patients undergo whole breast irradiation within 8 weeks following surgery.~ADJUVANT: Patients receive trastuzumab IV over 30-60 minutes every 21 days for up to 1 year."
88826645|NCT05806476|Experimental|P - P|placebo intake during the run-in days and placebo intake on the experimental day
88826646|NCT05806476|Experimental|P - C|placebo intake during the run-in days and caffeine intake on the experimental day
88826647|NCT05806437|Experimental|Long assumption|Assumpion of SideremilVita for 30 days
88826648|NCT05806437|Active Comparator|Standard assumption|Assumpion of SideremilVita for 15 days
88826649|NCT05806333|Experimental|suspicious focal liver mass without FDG avidity|Experimental: 18F-FAPI PET/CT Imaging was performed 30-60 minutes after injection of 2-4mci 68Ga-FAPI tracer
88826650|NCT05806320|Experimental|Intrauterine Sound Listening Group 1|This group consisted of 15 infants with 26-32,6 GW. A total of one hour of noise measurement was made inside and outside the incubator before, during and after the procedure. The babies were listened to the sound obtained in 3 time periods. If the baby is fed enterally, the feeding of the baby was completed at 10.15/13.00/16.15 before the application, the baby was placed in the prone position and the baby was rested for 30 minutes to ensure gastric emptying. Before the procedure, the baby was watched with a monitor device and recorded on video between 10.45-11.00/13.30-13.45/16.45-17.00. During the baby procedure, uterine sound was listened to the baby in the prone position monitored with a monitor device and recorded on video between 11:00-11.30/13.45-14.15/17.00-17.30 hours. After the procedure, the baby was watched with a monitor device and recorded on video between 11.30-11.45/14.15 and 14.30/17.30-17.45.
88826651|NCT05806320|Experimental|Intrauterine Sound Listening Group 2|This group consisted of 15 infants with 33-36,6 GW. A total of one hour of noise measurement was made inside and outside the incubator before, during and after the procedure. The babies were listened to the sound obtained in 3 time periods. If the baby is fed enterally, the feeding of the baby was completed at 10.15/13.00/16.15 before the application, the baby was placed in the prone position and the baby was rested for 30 minutes to ensure gastric emptying. Before the procedure, the baby was watched with a monitor device and recorded on video between 10.45-11.00/13.30-13.45/16.45-17.00. During the baby procedure, uterine sound was listened to the baby in the prone position monitored with a monitor device and recorded on video between 11:00-11.30/13.45-14.15/17.00-17.30 hours. After the procedure, the baby was watched with a monitor device and recorded on video between 11.30-11.45/14.15 and 14.30/17.30-17.45.
88826652|NCT05806320|No Intervention|Control Group 1|"This group consisted of 15 infants with 26-32,6 GW. A total of one hour of noise measurement was made inside and outside the incubator before, during and after the procedure. Babies in this group were followed up at specified time intervals without any intervention.~If the baby is fed enterally, the feeding of the baby was completed at 10.15/13.00/16.15 before the application, the baby was placed in the prone position and the baby was rested for 30 minutes to ensure gastric emptying. The baby was watched with a monitor device and recorded on video between 10.45-11.00/13.30-13.45/16.45-17.00 hours; 11:00-11.30/13.45-14.15/17.00-17.30 hours; 11.30-11.45/14.15- 14.30/17.30-17.45."
88826653|NCT05806320|No Intervention|Control Group 2|"This group consisted of 15 infants with 33-36,6 GW. A total of one hour of noise measurement was made inside and outside the incubator before, during and after the procedure. Babies in this group were followed up at specified time intervals without any intervention.~If the baby is fed enterally, the feeding of the baby was completed at 10.15/13.00/16.15 before the application, the baby was placed in the prone position and the baby was rested for 30 minutes to ensure gastric emptying. The baby was watched with a monitor device and recorded on video between 10.45-11.00/13.30-13.45/16.45-17.00 hours; 11:00-11.30/13.45-14.15/17.00-17.30 hours; 11.30-11.45/14.15- 14.30/17.30-17.45."
88826654|NCT05806307|Active Comparator|misoprostol|15 patients will receive 800 microgram (tablet 200mcg X 4) misoprostol (Misotac 200 mcg, SIGMA pharmaceutical, Egypt) rectally one and half hour before operation.
88826655|NCT05806307|Active Comparator|Tourniquet|(15 patient): The operation will be performed with the use of Foleys catheter as an improvised tourniquet applied at the base of the uterus then infiltration myometrium overlying the leiomyoma with a solution composed of Bupivacaine Hcl 0.25% and 0.5 mg of epinephrine
88826656|NCT05806307|Active Comparator|Carbetocin|intramural; preparation of 100 μg of carbetocin ((Pabal, Ampoule 100 mcg in 1 ml, Carbetocin; FERRING, North York, Canada) diluted within 10 cm of saline (0.9%) in sterile syringe then will inject the substance into the multiple sites intramyometrial in a circumferential manner 1-2 cm away from the margins of the myoma in the planned uterine-incision site just before uterine incision for myoma extraction.
89177389|NCT02605356|Experimental|Radium-223 dichloride [Phase 1, dose 2]|Phase 1: Radium-223 dichloride; 50 kBq/kg body weight (55 kBq/kg after implementation of NIST update) every 4 weeks for a total of 6 radium-223 dichloride doses plus SOC bortezomib/dexamethasone.
89177390|NCT02605356|Experimental|Radium-223 dichloride [Phase 1, dose 3]|Phase 1: Radium-223 dichloride; 80 kBq/kg body weight (88 kBq/kg after implementation of NIST update) every 4 weeks for a total of 6 radium-223 dichloride doses plus SOC bortezomib/dexamethasone.
89356860|NCT05864378||The non-POCUS group|Patients who were evaluated by ED physicians who do not perform POCUS intestinal loops examination for any reason
88826657|NCT05806307|Active Comparator|Oxytocin|15 patients): who will receive oxytocin 40 I.U. intramyometrially (Syntocinon, Ampule 10 I.U. in 1 ml, Oxytocin; NOVARTIS, Basel, Switzerland) then will inject the substance into the multiple sites intramyometrial in a circumferential manner 1-2 cm away from the margins of the myoma in the planned uterine-incision site just before uterine incision for myoma extraction.
88826658|NCT05806307|Active Comparator|combined TXA and ethamsylate|(Patient 15): will receive 1 g tranexamic acid (2 ampoules of kapron 500 mg, kapron®, Amoun, Egypt) and 500 mg ethamsylate (2 ampoule of ethamsylate 250 mg, Dicynone, OM pharma, Geneva, Switzerland) IV 10 minutes before skin incision by slowly intravenous injection Then infusion was applied continuously for 24 hours within 1 liter of saline as 1 mg/kg/hour.
88826659|NCT05806307|Active Comparator|vasopressin|15 women will receive terlipressin (Glypressin, Ferring, Egypt) intramyometrial injection of one ampoule of vasopressin containing 20 units in1 ml after dilution in 19 ml of normal saline during myomectomy.
88826660|NCT05806307|Active Comparator|bupivacaine and epinephrine|15 women in which the operation will be performed after infiltration of the serosa and / or myometrium overlying the leiomyoma before uterine incision with a solution composed of 50 ml Bupivacaine Hcl 0.25% (Bucain® Weimer pharma, for Actavis Group PTC) and 0.5 mg of epinephrine Hcl (2 vials of Epinephrine® 0.25mg/1ml Misr Co. for Pharmaceutical Industries).
88826661|NCT05806268||Dab/tram|Patients received dabrafenib and trametinib treatment
88826662|NCT05806268||Enco/bini|Patients received encorafenib and binimetenib treatment
88826663|NCT05806229|Active Comparator|Group I|(Mid transverse process to pleura block ) : Patients will receive midpoint transverse process to pleura block with bupivacaine 0.5% (DBK Pharmceutical) (20ml) and dexamethazone 4 mg (SIGMATEC) (1ml) total volume 21 ml
88826664|NCT05806229|Sham Comparator|Group II|Patients will receive midpoint transverse process to pleura block with 2ml normal saline subcutaneously (shamblock)
88826665|NCT05806125||the postoperative group|All patients in the postoperative group will undergo computed tomography angiography (CTA) to evaluate the status of the preserved ascending branch and the residual uterine blood supply pattern after surgery.
88826666|NCT05806125||the preoperative group|Patients in the preoperative group will undergo CTA before RT to determine the uterine blood supply pattern in healthy individuals.
88826667|NCT05806112|Experimental|Integrated Resiliency Training and Task Sharing|A multi-component intervention combining resiliency training and task sharing implemented at the site-level (microsystem).
88826668|NCT05806112|Experimental|Workplace Improvement Learning Collaborative|A workplace improvement learning collaborative implemented at the organization level (mesosystem).
88826669|NCT05806086|Experimental|Panfoshu + conventional treatment group（program-A）|Panfoshu is commonly known as the product of bacterial dissolution. it was taken orally once a day on an empty stomach, one capsule at a time. 1 course of treatment was 6mon, which was taken 10 days a month, stopped for 20 days for 3 months, and observed for another 3 months(unmedicated). Usage and dosage: adults and adolescents above 12yrs take one capsule (7.0mg) every day, children (1yrs-12yrs) take one capsule (3.5mg) every day.
88826670|NCT05806086|Experimental|Panfoshu + conventional treatment group（program-B）|Panfoshu was taken for 30 days in the first month, stopped in the second month, taken for 10 days and stopped for 20 days in a row for 3 months, and finally observed for 1 month. Usage and dosage: adults and adolescents above 12yrs take one capsule (7.0mg) every day, children (1yrs-12yrs) take one capsule (3.5mg) every day.
88826671|NCT05806086|Other|conventional treatment group|Conventional medications are used to treat the relavant ear and nose symptoms.
88826672|NCT05806047|Experimental|chidamide combined with fulvestrant|chidamide combined with fulvestrant
88826673|NCT05805995|Experimental|intervention group|The exercise group received vertebral derotation with posterior correction in addition to routine chest physiotherapy (group A).
88826674|NCT05805995|Experimental|control|The Control group received only posterior correction with routine chest physiotherapy (group B).
88826675|NCT05805982|Experimental|Educational Video|"The patient will watch a 15-minute video on an electronic tablet that includes the following items:~What is hereditary cancer?~Inheritance risk~Who are candidates for a genetic test?~What is a genetic testing and how can it help?~What types of results can be expected from genetic testing?~Reactions to the result of the genetic test~Clinical care according to the results~Any common questions? When the patient finish watching the video, he/she would have the opportunity to resolve any doubts."
88826676|NCT05805982|Active Comparator|In-Person genetic counseling|"Patients will receive pre-test genetic counseling in person with a specialist using the usual protocols existing at the Institute and systematically includes the following:~Family history of cancer Personal cancer risk assessment Education on inheritance and disease expression Types of tests and results (positive, negative and variants of uncertain significance).~Limitations of the genetic study Preparation of possible outcomes according to results Risks Additional information: confidentiality of the results, costs and test options. Opportunity will be given to resolve doubts"
88826677|NCT05805969|Experimental|Accommodating variable-resistance training|Participants in this group received the Accommodating variable-resistance program in addition to the standard physical therapy.
88826678|NCT05805969|Active Comparator|Standard Physical Therapy|Participants in this group received the standard exercise program.
88826679|NCT05805956|Experimental|IMM2902|"Phase 1 is the dose escalation part, patients with HER2 expressing solid tumors will be enrolled in groups of different dose levels, to explore MTD, RP2D, safety, and preliminary efficacy of IMM2902.~Phase 2 is the cohort expansion part, patients with HER2 overexpressing advanced solid tumors will be enrolled in three cohorts, to explore the safety and efficacy of IMM2902."
89177391|NCT02605356|Placebo Comparator|Placebo +SoC [Phase 2]|Phase 2: Matching placebo (isotonic saline) every 4 weeks for a total of 6 doses plus SoC (Standard of care) bortezomib/dexamethasone.
88826680|NCT05805943|Experimental|IMM0306 Monotherapy|"Phase I dose escalation part, participants with relapsed or refractory CD20-positive B-cell non-Hodgkin's lymphoma (B-NHL) will be enrolled to receive IMM0306. The dose of IMM0306 will depend on when you join this study. About 1-6 participants will be enrolled at each dose level.~Phase II dose expansion part, participants will receive IMM0306 at the recommended dose that was found in dose escalation part."
88826681|NCT05805930|Active Comparator|Arm 1: Steroids|"Treatment with prednisone will be initiated at a dosage of 1 mg/kg/day (maximum 50 mg/day) in twice daily administration for 14 days. In case of complete response to treatment, prednisone will be reduced from day 14, otherwise it will be continued at 1 mg/kg/day until day 28 (week 4). Patients with complete response at day 28 will continue the study entering part 2, in which therapy will be progressively tapered.~In part 2, prednisone will be tapered progressively by 0.1-0.15 mg/kg/day of prednisone (or 5 mg in patients on the maximum dose of 50 mg/day) from current treatment every week until the break. If there is no relapse, treatment will be discontinued over a 10-week period. Patients will then be evaluated every 4 weeks until the end of the study (week 24)."
88826682|NCT05805930|Experimental|Arm 2: Anakinra|"Treatment with anakinra will be initiated at a dose of 2 mg/kg/day (maximum dose 100 mg/day) as a single daily dose and maintained until day 28 (week 4).~Patients who achieve a complete treatment response at week 4 (day 28) will continue the study into Part 2. Patients without a complete treatment response will drop out of the study.~In Part 2 patients will continue daily anakinra treatment through week 12. The treatment will then be progressively reduced through the reduction of one weekly administration of the drug. The reductions will be made every 2 weeks until the interruption. Therefore, if no relapse occurs, treatment will be discontinued at week 24."
88826683|NCT05805917|Experimental|25 subjects treated with Neoviderm Skin Emulsion|
88826684|NCT05805917|Active Comparator|25 patients treated with Connettivina 0.2% Cream|
88826685|NCT05805865|Experimental|Toothpaste Tablet|Subjects are instructed to use one toothpaste tablet for brushing. Brushing is recommended twice daily for two minutes.
88826686|NCT05805865|Active Comparator|Conventional Toothpaste|Subjects are instructed to use the toothpaste for brushing. Brushing is recommended twice daily for two minutes.
88826687|NCT05805748|Active Comparator|Group 1|Each patient received 2 rehabilitations : a serious game training and a conventional rehabilitation first (during 3 weeks) and then conventional rehabilitation alone (during 3 weeks)
88826688|NCT05805748|Active Comparator|Group 2|Each patient received 2 rehabilitations for 3 weeks: a conventional rehabilitation first (during 3 weeks) and then both serious game training and a conventional rehabilitation (during 3 weeks)
88826689|NCT05805696|Experimental|Treatment for five weeks|The patients will get questionnaires before and 12 weeks and 24 weeks after intervention. The intervention will last for 5 weeks.
88826690|NCT05805644|Experimental|Robot mediated Impairment-oriented training(RMIT)|Participant receives 20 hours of robot mediated impairment-oriented training applied via the Optimo Regen
88826691|NCT05805644|Experimental|Robot mediated impairment-oriented and task-specific training (RMIT+RMTT)|Participant receives a total of 20 hours of robotic therapy. 10 hours will be in the form of RMIT and 10 hours in the form of RMTT
88826692|NCT05805631|Experimental|Experimental arm|Intrathecal pemetrexed combined with EGFR-TKI (physician choice)
88826693|NCT05805553|Experimental|Group A|Propranolol will be given to this group
88826694|NCT05805553|Experimental|group b|steroid will be given
88826695|NCT05805553|Experimental|group c|both propranolol and steroids will be given
88826696|NCT05805540|Experimental|Cold-water immersion|Subjects were immersed, in a sitting position where legs were always covered, in cold water at 11ºC in periods of 2 minutes submerged and 2 minutes out of the water at room temperature (25ºC), repeating this process 5 times.
88826697|NCT05805540|Experimental|Protein-carbohydrates supplementation|Subjects consumed a mixed carbohydrate and protein beverage, composed of 0.3gr/kg of maltodextrin and 0.2gr/kg of neutral whey protein in 0.5 litres of water.
88826698|NCT05805540|Experimental|Active recovery|Subjects was carried out using a bicycle ergometer. The subjects pedaled for 25 minutes at 50% of the maximum heart rate (HRmax).
88826699|NCT05805540|Placebo Comparator|Placebo|Subjects drank a water-based drink and sweetener. Both the PLA and SUPPL group sat for 25 minutes until all recovery methods were completed.
88826700|NCT05805514|Experimental|Food and psychosocial intervention|In Food and psychosocial intervention, the nutrition workers will be responsible for providing egg through food voucher, psychosocial stimulation, nutrition education counselling, child water, sanitation and hygiene message, and multiple micronutrient powder among the selected mothers/infant pairs.
88826701|NCT05805514|Experimental|Food intervention|In Food intervention, nutrition workers will give food egg, nutrition education counselling, water, sanitation and hygiene message, and multiple micronutrient powder among the selected mothers/infant pairs.
88826702|NCT05805514|Placebo Comparator|Control|In terms of control group, the nutrition workers will provide only nutrition education counselling among the selected mother-child pairs.
88826703|NCT05805488|Placebo Comparator|Placebo sachet|
88826704|NCT05805488|Experimental|TCI904 sachet|
88826705|NCT05805449|Sham Comparator|Surgery|Control patients will receive usual standard of care surgical repair of their complex fistula by The ligation of intersphincteric tract (LIFT) or advancement flap technique without any biologic adjunct.
88826706|NCT05805449|Experimental|Surgery plus platelet-rich plasma (PRP)|
88826707|NCT05805449|Experimental|Surgery plus matrix|
88826708|NCT05805449|Experimental|Surgery plus PRP plus matrix material|
88826709|NCT05805332||pulmonary rehabilitation|
88826710|NCT05805319|No Intervention|Control Group|Patients in the control arm will complete the dietary survey without dietary intervention or counselling from a dietician. Control group will have dietary survey and 24-hour recall survey at baseline, at 6 weeks, and at 12 weeks relative to ICI initiation.
88826711|NCT05805319|Experimental|Intervention Group|Patients in the intervention arm will complete a dietary survey and be counselled on increasing their total fiber intake. Intervention group will have dietary survey and 24-hour recall survey at baseline, at 6 weeks, and at 12 weeks relative to ICI initiation.
88826712|NCT05804747||Edoxaban|Participants who were prescribed edoxaban within 8 weeks of study enrollment at the discretion of the physician and were prospectively followed to assess the efficacy and safety of prescribed edoxaban.
88826713|NCT05803109|Experimental|virgin cold-pressed coconut oil with Peppermint essential oil|Patients will be instructed to use one packet of the coco pull healthy blend of organic oil (virgin cold pressed coconut oil with Peppermint essential oil)and swish the oil in the mouth and pull it between teeth for 5 minutes then spit out the oil and brush their teeth with the oil for 2 minutes; such a regimen will be repeated twice daily for three months.
88826714|NCT05803109|Active Comparator|The fluoride toothpaste (Colgate Total,|Patients will be instructed to brush their teeth with the fluoride toothpaste (Colgat Total, 1450 ppm) for 2 minutes; such a regimen will be repeated two times daily for three months and use 10 ml of 0.12% chlorhexidine rinse for 1 min/day, 30 min after tooth brushing before going to bed.
88826715|NCT05802784|Active Comparator|Scissors arm|Patients in this group had undergone resection of the septum with hysteroscope and scissors, The scissors used was pointed, single action and semi rigid . Saline was used as the distending medium in the scissors group. Septal incision was carried out using shortening technique by incising the septum at the leading edge and continue dividing by moving from side to side (in narrow septum), or by thinning technique by which incisions will be made along each side of the septum alternately from one cornual end to the other (in broad septum). The operation was stopped if the fluid deficit exceeded 2500 ml of saline.
88826716|NCT05802784|Active Comparator|Resectoscope arm|Patients in this group had undergone resection of the septum with Monopolar 26 French resectoscope Dilation of cervical os with Hegar's dilator (up to hegar 8 or 9) , incision of the septum using a resectoscope with the Collins knife, monopolar energy (cut 40-70 Watt) and glycine 1.5% as the distension medium, using shortening or thinning incision. The operation was stopped if the fluid deficit exceeded 1000 ml of glycine. The delivery of distension media was conducted by automated pressure delivery system. All patients were prescribed cyclic estrogen and progesterone for two months.
88826717|NCT05802199||Training cohort|"Patients were fulfilled diagnosis of non-alcoholic fatty liver disease based on radiological and clinical manifestation.~Patients were fulfilled diagnosis of hepatic fibrosis based on radiological and clinical manifestation."
88826718|NCT05802199||Validation cohort|"Patients were fulfilled diagnosis of non-alcoholic fatty liver disease based on radiological and clinical manifestation.~Patients were fulfilled diagnosis of hepatic fibrosis based on radiological and clinical manifestation."
88826719|NCT05802095|Experimental|Experimental group|The babies in the experimental group are fed 3 meals from the day after the decision to switch to oral feeding, with supplemental feeding tube device(SFTD) (09:00-12:00-15:00) and other meals with a bottle.
89177392|NCT02605356|Experimental|Radium-223 dichloride + SoC [Phase 2]|Phase 2: Phase 1b-selected dose of radium-223 dichloride every 4 weeks for 6 doses plus SOC bortezomib/dexamethasone
89356861|NCT05864352||High TiO2 Consumer|Participants with an estimated TiO2 stool content greater than the cohort median content, μg/mg dry stool.
88826720|NCT05802095|No Intervention|Control|The babies in the control group, on the other hand, will be fed 3 meals a day (09:00-12:00-15:00) after the decision to switch to oral feeding, which is the routine feeding method of the intensive care unit, and with a bottle for other meals in the same way.
88826721|NCT05800938|Active Comparator|Isosorbid mononitrate group|Imdur 30 mg tablet AstraZeneca egypt twice daily for 4 weeks
88826722|NCT05800938|Placebo Comparator|placebo group|Tablets twice daily for 4 weeks
88826723|NCT05797935|No Intervention|Placebo group|Only the standard drugs for type 2 diabetes were given. Dapagliflozin was not given in this group.
88826724|NCT05797935|Active Comparator|Dapagliflozin group|The patients were given standard drugs for type 2 diabetes and Dapagliflozin.
88826725|NCT05796921|Active Comparator|Active|1 daily capsule of the Lacticaseibacillus rhamnosus CA15 (DSM 33960) probiotic strain (15 billion of Colony Forming Units/capsule) for 10 days
88826726|NCT05796921|Placebo Comparator|Placebo|1 daily capsule of placebo
88826727|NCT05794802|Experimental|BHB supplement condition|
88826728|NCT05794802|Placebo Comparator|Placebo solution condition|
89177393|NCT00812266|Experimental|A|Topotecan + cisplatin
89177394|NCT00812266|Active Comparator|B|Etoposide + carboplatin
88826729|NCT05794386|No Intervention|PVI only group|Patients will receive PVI alone regardless of LVA burden.
88826730|NCT05794386|Experimental|Additional LA substrate modification group|Patients will receive PVI plus additional LA substrate modification according to their LVA burden.
88826731|NCT05786586|Experimental|650 nm low-level red-light, plus single vision spectacle lenses|Children in the treatment group are expected to receive 6 minutes irradiation of 650 nm low-level red-light daily, divided into two times a day, each lasting for 3 minutes. Single vision spectacle lenses are allowed for myopic children.
88826732|NCT05786586|No Intervention|Control|Single vision spectacle lenses are allowed for myopic children. No intervention was given.
88826733|NCT05784948|Experimental|Virtual Reality Mindfulness Treatment|Experience virtual reality mindfulness treatment with a screen from a head-mounted display for 30 minutes in a comfortable sitting position.
88826734|NCT05784948|Sham Comparator|Relaxing scenery and music experience|Experience relaxing scenery and music with a screen from a head-mounted display for 30 minutes in a comfortable sitting position.
89177395|NCT00814840|Active Comparator|Triple-site group|Triple-site resynchronization group
89177396|NCT00814840|Active Comparator|Standard resynchronization group|Standard (double-site) resynchronization group
89177397|NCT00483379|Experimental|alglucosidase alfa 20 mg/kg every week|Participants were treated with alglucosidase alfa 20 mg/kg every week for 52 weeks. This was the 'frequent dose' arm.
89356862|NCT05864352||Low TiO2 Consumer|Participants with an estimated TiO2 stool content less than the cohort median content, μg/mg dry stool.
89356863|NCT05864339|Experimental|A designed empathy tutorial during the SCC course (Intervention group)|Students who participated in the designed empathy tutorial (viewing videos of four smokers' real-life scenarios, reading four smokers cases text materials, and drawing Health Empathy Map). Students will demonstrate a quit plan by role-playing and will attend focus group interviews during the wrap-up session.
89533939|NCT02003209|Experimental|Arm II (chemo, estrogen deprivation, surgery, radiation)|"NEOADJUVANT: All patients receive docetaxel, carboplatin, trastuzumab, and pertuzumab as in arm I. Premenopausal patients also receive goserelin acetate SC every 28 days until surgery and aromatase inhibition therapy at the investigator's discretion daily until 1 day before surgery. Postmenopausal patients receive aromatase inhibition therapy at the investigator's discretion daily until 1 day before surgery. Patients enrolled after Amendment #4 undergo 2 core biopsies prior to course 3 of treatment.~SURGERY: Patients undergo lumpectomy or mastectomy.~RADIATION: Patients undergo whole breast irradiation within 8 weeks following surgery.~ADJUVANT: Patients receive trastuzumab IV over 30-60 minutes every 21 days for up to 1 year."
89533940|NCT01996267|Active Comparator|FEC-T +Pertuzumab|Fluorouracil; 500 mg/m2; day 1 Epirubicine; 90 mg/m2; day 1 Cyclophosphamide; 500 mg/m2; day 1 Trastuzumab; 6 mg/kg (loading dose 8 mg/kg) Pertuzumab; 420 mg (loading dose 840 mg); day 1 Cycle is repeated every 21 days
89533941|NCT01996267|Active Comparator|PTC+Pertuzumab|Paclitaxel; 80 mg/m2; day 1,8 Trastuzumab; 6 mg/kg (loading dose 8 mg/kg); day 1 Carboplatin; AUC=6; day 1 Pertuzumab; 420 mg (loading dose 840 mg); day 1 Cycle repeated every 21 days
89533942|NCT01968109|Experimental|Relatlimab|Relatlimab (BMS-986016) specified dose on specified days
89533943|NCT01968109|Experimental|Relatlimab + Nivolumab|Relatlimab (BMS-986016) + Nivolumab (BMS-936558) specified dose on specified days
89533944|NCT01968109|Experimental|BMS-986213|Relatlimab (BMS-986016) + Nivolumab (BMS-936558)
89533945|NCT01962766|Active Comparator|complete myofunctionnal therapy|complete therapy (at least 5 sessions) to correct their swallowing pattern and tongue position
89533946|NCT01962766|Experimental|instructions|instructions to modify their tongue position (1 session)
89533947|NCT01905865||Parent|Persons aged 18 years or older who have a child with an undiagnosed medical condition, who have applied to the Undiagnosed Diseases Network, and have been assigned to the NIH.
89533948|NCT01904968||Colon cancers in patients living the Cote D'or area|
89533949|NCT01898117|Active Comparator|Carbo/cyclo|Carboplatin AUC=5 Cyclophosphamide 600 mg/m2 Q 4 weeks
89356864|NCT05864339|Active Comparator|Smoking cessation counseling tutorial (Control group)|Students will watch videos of four smokers' real-life scenarios, and read four smokers' case text materials. Students will demonstrate a quit plan by role-playing and will attend focus group interviews during the wrap-up session.
89356865|NCT05864313|Active Comparator|Real 10 Hz rTMS|Participants will receive 1 hour of real rTMS followed by 1 hour of gaze and gait training.
88826735|NCT05775237|Experimental|Curcumin Gummies|Curcumin Gummies contain energy, dietary fiber, sugar, total carbohydrate, protein, fat, and curcumin.
89356866|NCT05864313|Sham Comparator|sham rTMS|Participants will receive 1 hour of sham rTMS followed by 1 hour of gaze and gait training.
88826736|NCT05775237|Experimental|Vitamin C Gummies|Vitamin C Gummies contain Vitamin C and Zinc
88826737|NCT05775237|Experimental|Multivitamin Gummies|Multivitamin Gummies contain energy, dietary fiber, sugar, total carbohydrate, protein, fat, sodium, Vitamin C, Vitamin E, pantothenic acid, Zinc, iodine, Vitamin A, Magnesium, Folate, Vitamin D, Vitamin 12
88826738|NCT05772442||No pathological signs of rejection|Routine endomyocardial biopsy did no show pathological signs of rejection (0R) based on the International Society for Heart and Lung Transplantation (ISHLT) 2004 acute cellular rejection grading scheme.
88826739|NCT05772442||With pathological signs of rejection|Routine endomyocardial biopsy showed pathological signs of rejection (1R, 2R, and 3R) based on the International Society for Heart and Lung Transplantation (ISHLT) 2004 acute cellular rejection grading scheme.
88826740|NCT05770830||Esophageal temperature|Esophageal temperature
88826741|NCT05770830||Skin core temperature|Skin core temperature
88826742|NCT05769764||Cohort 1: NSCLC|Participants with NSCLC will be included in this cohort if they do not meet requirements for inclusion in Cohorts 2-4.
88826743|NCT05769764||Cohort 2: EGFR-mutated (EGFRm) NSCLC Previously Treated With a 3rd Generation EGFR TKI|Participants with EGFR-mutated (EGFRm) NSCLC previously treated with a 3rd generation tyrosine kinase inhibitor (TKI) with matched samples.
88826744|NCT05769764||Cohort 3: ALK+ NSCLC|Participants with ALK+ NSCLC with matched samples.
88826745|NCT05769764||Cohort 4: NSCLC Harboring a KRAS p.G12C Mutation or EGFR Exon 20 Insertion|Participants with NSCLC harboring a Kirsten rat sarcoma viral oncogene homolog (KRAS) p.G12C mutation or EGFR exon 20 insertion.
88826746|NCT05765370|Experimental|LDL-C Lower-Target Group (25mg/dL≤ LDL-C<70mg/dL)|"Participants randomized into the LDL-C lower-target arm will have a goal of 25mg/dL≤ LDL-C<70mg/dL.~Prescription of lipid-lowering agents (drug and dosage) were initiated or adjusted on the basis of the investigator according to the assigned target LDL-C level."
88826747|NCT05765370|Active Comparator|LDL-C Higher-Target Group (70mg/dL≤ LDL-C<100mg/dL)|"Participants randomized into the LDL-C lower-target arm will have a goal of 70mg/dL≤ LDL-C<100mg/dL.~Prescription of lipid-lowering agents (drug and dosage) were initiated or adjusted on the basis of the investigator according to the assigned target LDL-C level."
88826748|NCT05751044|Experimental|Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide + cytarabine|"Sub-study B~Each cycle lasts 28 days.~Cycle 1: All patients in cycle 1 will receive 28 days of of dasatinib (days 1-14), 28 days of venetoclax (days 1-28), one block of five days of dexamethasone (days 1-5), one dose of cyclophosphamide (day 3) and two blocks of four consecutive days of cytarabine (days 5 to 8 and days 12 to 15). A 1-day venetoclax ramp-up is proposed in this study.~Cycle 2 and subsequent cycles: Dasatinib and ventoclax one a day (day 1-28); one block of five days of dexamethasone (days 1-5), one dose of cyclophosphamide (day 1) and two blocks of four consecutive days of cytarabine (days 3 to 6 and days 10 to 13).~Patients in dose level -1, receive a lower dose of venetoclax. Patients in dose level 2 receive a higher dose of venetoclax.~All patients receive age adapted intrathecal chemotherapy."
89177398|NCT00483379|Experimental|alglucosidase alfa 40 mg/kg every other week|Participants were treated with alglucosidase alfa 40 mg/kg every other week for 52 weeks. This was the 'high dose' arm.
89177399|NCT00814918|Experimental|1|5-ALA Application and exposure using Blu-U light to 1/2 of face.
89177400|NCT00814918|Experimental|2|5-ALA Application and exposure using Candela V-beam Pulse Dye Laser to 1/2 of face.
89177401|NCT04113954|Experimental|Leg 1 ACB + low dose SNB-PF|Right leg and 0.375% mepivacaine popliteal fossa-sciatic
89530231|NCT05045183|Experimental|Treatment H: Hydrocolloid Pad|Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist. On the randomized wound site, hydrocolloid pad will be applied. This treatment will be changed daily from Day 1 through Day 6 and all wound sites will be uncovered from Day 7 to Day 16 for assessments.
89530232|NCT04487977||Surveyed professionals|
89530233|NCT02517671|Other|EECP Treatment|35 one hour (1hr) sessions of Enhanced External Counterpulsation (EECP).
89530234|NCT03246451|Placebo Comparator|Placebo|Placebo, oral tablet in 14 days and in liquid meal.
89530235|NCT03246451|Experimental|Metformin|Metformin, oral tablet 2-4 x 500 mg in 14 days and in liquid meal.
89530236|NCT03246451|Experimental|Saline|Saline infusion (9mg/mL) on experimental days
89530237|NCT03246451|Experimental|Exendin(9-39)|Exendin(9-39) infusion. GLP-1 receptor antagonist used as a study tool on experimental days.
89530238|NCT02517593|Other|PRS|Providing polygenic risk score (PRS)
89530239|NCT00708461|Experimental|Worksite Environmental Intervention|Changes to healthy food availability, physical activity opportunities and promotion, body weight scale access, and media enhancements to target weight gain prevention
89530240|NCT00708461|No Intervention|No-contact control|No-treatment control condition. Worksites were offered program materials upon completion of programs at intervention sites.
88826749|NCT05741125|Experimental|DSMES + ASE intervention Appetite Self-Regulation (Centering Appetite)|The Diabetes Self-Management Education and Support (DSMES) + Appetite Self-Regulation (ASE) intervention includes two, 45-60-minute group sessions delivered via telehealth. These sessions will enable participants to relearn their stomach's hunger and fullness signals and monitor their appetite. Participants will also learn strategies for glucose monitoring and carbohydrate management. Monthly booster sessions will be devoted to problem-solving, addressing barriers to emotion management, and self-monitoring type 2 diabetes mellitus symptoms. Participants will also receive weekly lessons with interactive activities delivered via a digital app.
88826750|NCT05741125|No Intervention|Control|Control group participants will attend two remotely delivered DSMES sessions that will offer content commonly. They will also receive weekly emails providing content from the American Association of Diabetes Educators.
88826751|NCT05736042|Experimental|Lens fragmentation with miLOOP|Phacoemulsification with adjunctive lens fragmentation with the microinterventional microfilament loop device (miLOOP)
88826752|NCT05736042|No Intervention|Controls|Phacoemulsification alone (no adjunctive lens fragmentation)
88826753|NCT05727202||SARS-CoV-2|50 positive samples 500 negative samples
88826754|NCT05727202||FLU A|50 positive samples 500 negative samples
88826755|NCT05727202||FLU B|30 positive samples 500 negative samples
88826756|NCT05727202||RSV|30 positive samples 500 negative samples
88826757|NCT05709093|Experimental|Lemzoparlimab in combination with AZA|
88826758|NCT05709093|Active Comparator|AZA monotherapy|
88826759|NCT05704530|Other|1. primary resection then follow-up|Scenario 1: primary resection then follow-up - Study-specific liquid biopsies will be collected in 98 patients, at the time of routine labs. Samples will be acquired before resection, at 6-8 weeks, 6 and 12 months after resection.
88826760|NCT05704530|Other|2. chemoradiation followed by resection and follow-up|Scenario 2: chemoradiation followed by resection and follow-up - Study-specific liquid biopsies will be collected in 50 patients. Samples will be acquired before the start of chemoradiation, before surgery, 6-8 weeks, 6 and 12 months after surgery. A subgroup of patients will undertake adjuvant immunotherapy and will constitute Group 3. Timing of sampling will be adjusted accordingly as per study flowcharts.
88826761|NCT05704530|Other|3. chemoradiation followed by resection followed by adjuvant immunotherapy|chemoradiation followed by resection followed by adjuvant immunotherapy - Study-specific liquid biopsies will be collected in 100 patients. Samples will be acquired before the start of chemoradiation, before surgery, 6-8 weeks after surgery and during adjuvant immunotherapy every 3 months including a sample at the end of treatment.
88826762|NCT05701566|Experimental|virtual reality group|unsedated colonoscopy using virtual reality headset.
88826763|NCT05701566|Active Comparator|colonoscopy with standard sedation|standard sedated colonoscopy.
88826764|NCT05690646|Experimental|NR group|nirmatrelvir 300mg q12h and ritonavir 100 mg q12h for 5 days
88826765|NCT05690646|Experimental|UA group|ursodeoxycholic acid group, 15mg/kg/day bid for5 days
88826766|NCT05690646|Experimental|combination group|nirmatrelvir 300mg q12h and ritonavir 100 mg q12h for 5 days and ursodeoxycholic acid group, 15mg/kg/day bid for5 days
88826767|NCT05690646|No Intervention|control group|No intervention
88826768|NCT05690165|Experimental|Exercise Group|Participants will exert a heart rate controlled aerobic walking training 3-5 times per week for 30-45 minutes per training. This exercise as well as the daily amount of steps will be assessed via smartwatch.
88826769|NCT05690165|No Intervention|No Exercise Group|Participants receive no demands regarding the daily exercise. Their daily amount of steps will be assessed via smartwach.
88826770|NCT05687708|Experimental|Non-Nutritive Sucking|Non-Nutritive Sucking
88826771|NCT05687708|No Intervention|Control|routine treatment
88826772|NCT05668624|Experimental|Full Subsidy Arm|This arm receives free LPG and stove for cooking following the baseline measures, for the duration of the 3-year follow-up period. For those households in Government of Rwanda designated areas for solar microgrids, this arm will also be connected to and provided free access to solar electricity for lighting.
88826773|NCT05668624|No Intervention|Control Arm|This arm will remain using traditional forms of energy for cooking and lighting.
88826774|NCT05668624|Experimental|Discount Subsidy Arm|This arm will be randomized to a discounted price (at baseline and every 6-months during the 3-year study) for solar electricity (in areas marker for solar grids by the Government of Rwanda) and LPG gas in a pay-as-you-go (PAYG) service model (i.e., pre-pay an affordable amount through mobile money, a common form of currency transactions in Rwanda). For example, this arm will be asked to cook as normal and decide whether or not to cook with the discounted LPG or their traditional stove (i.e., they will not be required to pay for LPG).
88826775|NCT05658627|Active Comparator|1- control group|conventional physical therapy (ultrasound therapy- stretching exercise- strengthening exercise)
88826776|NCT05658627|Experimental|2- Experimental group|Active release technique for hamstring+ conventional physical therapy(ultrasound therapy- stretching exercise- strengthening exercise)
89533950|NCT01898117|Active Comparator|Carbo/cyclo + Atezolizumab|Carboplatin AUC=5 Cyclophosphamide 600 mg/m2 atezolizumab 840 mg d1,15 Q 4 weeks
89533951|NCT01898117|Active Comparator|Paclitaxel|Paclitaxel 90 mg/m2 d1, 8, 15 Q 4 weeks
88826777|NCT05648201|Experimental|Doravirine|1 single dose of 100mg doravirine taken orally
88826778|NCT05648201|Experimental|Raltegravir|1 single dose of 1200mg raltegravir taken orally
88826779|NCT05648201|Experimental|Biktarvy|1 single dose of 25/200/50mg taken orally
88826780|NCT05641493|Experimental|HLX208 combined HLX10|"For the phase Ib study, HLX208 is administered orally at two dose levels of 600mg BID or 900 mg BID. And HLX10 is administered intravenously at a fixed dose of 300mg every 3 weeks.~For the phase II study, HLX208 is administered orally with the RP2D dose. And HLX10 is administered intravenously at a fixed dose of 300mg every 3 weeks."
88826781|NCT05635448|Experimental|Intervention|Will be offered the BT coaching intervention over 4-months (February 1st 2023- May 31st 2023).
88826782|NCT05635448|Placebo Comparator|Waitlist control|Will be offered the coaching intervention following 4-month waitlist control (September 1st 2023 - December 31st 2023).
88826783|NCT05597514|Active Comparator|Tranditional model group|Received a regular learning
88826784|NCT05597514|Experimental|3D-printed presention group|Received a regular learning plus 3D printing model
88826785|NCT05596877|No Intervention|Control Group|Recieved pulmonary rehabilitation
88826786|NCT05596877|Experimental|Intervention Group|Recieved pulmonary rehabilitation with music therapy
88826787|NCT05579275|Experimental|cohort-experimental|Patients will receive treatment observation every 21 days for up to 8 cycles. Actual follow-up will be decided according to the patient 's condition and benefit, and each test requirement and data collection will be completed at specified time during the follow-up cycle.
88826788|NCT05515497|Experimental|BMT4me 2.0 Intervention Group|The intervention group will be receiving the BMT4me 2.0 app at discharge as the primary intervention.
88826789|NCT05515497|No Intervention|BMT4me 2.0 Control Group|The control group will be receiving usual care at discharge. These participants will not be receiving the BMT4me 2.0 app.
88826790|NCT05511870|Experimental|Etripamil Nasal Spray 70mg|Etripamil Nasal Spray 70mg single dose
88826791|NCT05511870|Placebo Comparator|Etripamil Placebo Nasal Spray 70mg|Etripamil Placebo Nasal Spray 70mg single dose
88826792|NCT05492851|Active Comparator|Zilretta|"Generic Name: Triamcinolone acetonide Zilretta is an extended-release synthetic corticosteroid indicated as an intra-articular injection for the management ofosteoarthritis pain of the knee.~5mL suspension of 32 mg of triamsinolone administered as a 1 dose parapatellar intra-articular injection."
88826793|NCT05492851|Active Comparator|Synvisc One|"Generic Name: Hylan G-F 20 Synvisc-One combines the three doses of SYNVISC (hylan G-F 20) which consists of hylan A (average molecular weight6,000,000 daltons) and hylan B hydrated gel in a buffered physiological sodium chloride solution, pH 7.2.~Each 10 mL syringe of Synvisc-One combines the three 2-mL doses (16 mg each) of a complete SYNVISC treatment regimen (48 mg). Synvisc-One belongs to a class of drugs called Intra-Articular Agents; Rheumatologics, Other.~10mL of Hylan G-F 20 administered as a 1 dose parapatellar intra-articular injection."
88826794|NCT05492851|Active Comparator|Monovisc|"Generic Name: Hyaluronan The Monovisc™ device is a proprietary high molecular weight hyaluronic acid (HA) viscosupplementation intended for the treatment of pain in patients with moderate osteoarthritis (OA) of the knee who have failed conservative non-pharmacological therapy and simple analgesics. The device is administered by a single injection via the para-patellar approach under sterile conditions.~4mL injection of Hyaluronan administered as a 1 dose parapatellar intra-articular injection."
88826795|NCT05488288|Experimental|Mesh group|"ventral hernia repair with non absorbable mesh placement concomitant to bariatric procedure (sleeve gastrectomy or by-pass).~In this group, the repair technique and the type of mesh are left to the choice of the center, as there are no strong data to demonstrate which technique is the best for VH repair in this population."
88826796|NCT05488288|Active Comparator|Suture group|"suture repair of ventral hernia concomitant to bariatric procedure (sleeve gastrectomy or by-pass).~In this group, the hernia sack is resected through an open approach, and the fascial defect is systematically closed with a slowly absorbable monofilament suture."
88826797|NCT05483998|Experimental|Part A: Single Ascending Dose (SAD)|Part A will be comprised of up to 50 participants over 5 cohorts of 10. Each participant will receive a single oral dose of TLC-2716 or placebo at different dose levels (1 cohort per dose level).
88826798|NCT05483998|Experimental|Part B: Multiple Ascending Dose (MAD)|Part B will be comprised of up to 50 healthy participants over 5 cohorts of 10. Each participant will receive 14 oral doses of TLC-2716 or placebo over 14 days (given once daily) at different dose levels (1 cohort per dose level).
88826799|NCT05483998|Experimental|Part C: Adaptive SAD and/or MAD|Part C is an adaptive style where the dosing level is a single- or multiple-ascending dose design. Based on safety and pharmacokinetic data from Parts A and B, doses for Part C will be chosen. Part C will be comprised of up to 50 participants over 5 cohorts of 10. Each participant will receive an oral dose of TLC-2716 or placebo at different dose levels (1 cohort per dose level).
88826800|NCT05479305|Experimental|Intervention/Treatment|The Valiant Captivia physician fenestrated stent graft for the treatment of aneurysms/penetrating ulcers, Type B aortic dissections or residual dissection after Type A repair, of the aortic arch and the descending thoracic aorta which are candidates for revascularisation of all three supra-aortic vessels (BT, LCCA, LSA)
89533952|NCT01898117|Active Comparator|Paclitaxel + atezolizumab|Paclitaxel 90 mg/m2 d1, 8, 15 atezolizumab 840 mg d1,15 Q 4 weeks
89533953|NCT01862107||Healthy Volunteer|Any healthy volunteer getting a lumbar puncture done for either clinical care or research purposes.
89533954|NCT01862107||Patient|Any patient getting a lumbar puncture done for either clinical care or research purposes.
89533955|NCT01859299||Affected|Participants with various types of uveitis
89533956|NCT01859299||Healthy controls|Participants without uveitis
89533957|NCT01851447||Fragile Sarcolemmal Muscular Dystrophy|patients with early adulthood or late onset of a genetic disorder FSMD (LGMD 2B-F, I, L, MM, BMD and MMD3)
89533958|NCT01834001||1/Untreated prostate cancer|Patients with untreated prostate cancer
89533959|NCT01834001||2/Radiotherapy treated prostate cancer|Patients with prostate cancer who have already received definitive radiotherapy and have experienced biochemical failure
89533960|NCT01810913|Experimental|Arm 1 (IMRT, cisplatin)|Patients undergo IMRT QD five days a week for 6 weeks and receive concurrent cisplatin IV over 1-2 hours once weekly for 6 weeks. Patients undergo CT scans and/or MRI, and collection of blood during follow-up.
88826801|NCT05472935|Experimental|MBSR Intervention|Participants will engage with MBSR instructional videos. The videos are 30 minutes in length, and designed to be watched once a day, Monday-through-Friday, over an eight-week period. Additionally, a coaching video of three minutes in length will be available to participants on Mondays. Participants will watch the videos and engage with the content and activities as prompted by the videos. Activities include guided meditations, guided mindfulness activities, such as body scans where participants notice the sensations they feel in various parts of their body, and relaxation exercises. Participants will also be asked to complete light exercises to their comfort level, which involves getting comfortable, light self-guided stretching, and relaxation exercises that are no more physical exertion than they otherwise might experience while moving around completing their normal tasks/activities of daily living outside of this program.
88826802|NCT05423535|Active Comparator|Control group: Collagen Matrix|collagen matrix: Mucograft Seal®, Geistlich Pharma AG, Wolhusen, Switzerland
88826803|NCT05423535|Experimental|Test group: Hemostatic Gelatin Sponge|Hemostatic gelatin spons: Spongostan Dental® 1x1x1 cm, Ethicon, Johnson & Johnson, New Brunswick, VS
88826804|NCT05417451|Experimental|Acupuncture|All subjects will receive active acupuncture. The acupuncture intervention will consist of 10 acupuncture sessions, twice weekly for 5 weeks. There will be at least 1 day in between session.
88826805|NCT05414409|No Intervention|Comparison of microbiome by BMI Category|The gut microbiome and metabolites of 42 lean and 42 obese youth with type 1 diabetes will be evaluated cross-sectionally.
88826806|NCT05414409|Experimental|Metformin|This is a group of 30 youth with type 1 diabetes and obesity who will receive metformin for 6 months.
88826807|NCT05411575|Placebo Comparator|Placebo|continuous intravenous infusion for 7 days of Placebo
88826808|NCT05411575|Experimental|Plerixafor|Plerixafor (Mozobil®) continuous intravenous infusion for 7 days
88826809|NCT05401994|Active Comparator|conventional Erich's arch bar|• Patients will receive conventional Erich's arch bar
88826810|NCT05401994|Experimental|Screw Retained Arch Bar|patients will receive modified screw retained arch bar.
88826811|NCT05367401|Experimental|1L higher risk MDS|Participants with 1L MDS will receive sabatolimab and magrolimab in combination with azacitidine
88826812|NCT05367401|Experimental|1L unfit AML|Participants with 1L AML unfit for intensive chemotherapy will receive sabatolimab and magrolimab in combination with azacitidine
88826813|NCT05367401|Experimental|Relapsed/refractory AML previously treated with venetoclax and azacitidine|Participant with relapsed/refractory AML will receive sabatolimab and magrolimab (in absence of complete response (CR), Complete Remission with incomplete hematologic recovery (CRi) or Morphologic Leukemia-Free State (MLFS) after 2 cycles, participants will be allowed to also receive azacitidine)
88826814|NCT05344183|Experimental|Lasertherapy|
88826815|NCT05344183|Sham Comparator|Sham lasertherapy|
88826816|NCT05323461|Experimental|Cohort 1: SCTV01C|one dose of SCTV01C on D0
88826817|NCT05323461|Experimental|Cohort 1: SCTV01E|one dose of SCTV01E on D0
88826818|NCT05323461|Active Comparator|Cohort 1: Active comparator|one dose of Sinopharm inactivated COVID-19 vaccine on D0
88826819|NCT05323461|Experimental|Cohort 2: SCTV01C|one dose of SCTV01C on D0
88826820|NCT05323461|Experimental|Cohort 2: SCTV01E|one dose of SCTV01E on D0
88826821|NCT05323461|Active Comparator|Cohort 2: Active comparator|one dose of Comirnaty on D0
88826822|NCT05309980||Without Shock Team|Before January 2013, patients with refractory cardiogenic shock were implanted with short term mechanical circulatory device without involvment of a dedicated shock team
88826823|NCT05309980||With Shock Team|After April 2013, patients with refractory cardiogenic shock were implanted with short term mechanical circulatory device following a collegial meeting of a shock team (cardiac surgeon, cardiologist, intensivist) using a common algorythm.
88826824|NCT05305352|No Intervention|No intervention|The no intervention arm will not receive counselling but will follow their routine diet suggested during their routine antenatal visits.
88826825|NCT05305352|Experimental|Intervention|The intervention arm will be counselled about very low carbohydrate diet (<10%carbohydrate)
88826826|NCT05297448|Experimental|Rifaximin SSD-40mg IR|
88826827|NCT05297448|Placebo Comparator|Placebo|
88826828|NCT05288998||Patients with a previous diagnosis of ADPKD|Patients that have been diagnosed with ADPKD and meet the study's inclusion criteria
88826829|NCT05288998||Healthy Volunteers|Subjects without a family or personal history of kidney disease or concomitant systemic disorder that might affect the kidney
88826830|NCT05280964|Experimental|Intervention|Enrolled into a 6 month coaching program from January 1 2021 to June 30 2021
88826831|NCT05280964|No Intervention|Control/Wait-list|No intervention from January 1 2021 to July 1 2021 (they were offered the coaching program from July 1 2021-Dec 31 2021)
88826832|NCT05256160|Experimental|CVS subjects|Subjects diagnosed with Cyclic Vomiting Syndrome (CVS)
88826833|NCT05256160|Active Comparator|healthy, non-CVS subjects|Subjects not diagnosed with CVS
88826834|NCT05207748||patients with a history of falls|"Demographic characteristics and medical histories (age, height, weight, smoking, alcohol use, comorbidities, medications, stroke onset date, stroke side, total number of rehabilitation received, assistive device use, history of falls) of all patients participating in the study will be recorded.~Detailed physical examinations (mini-mental status assessment, brunstrum stages, spasticity assessments, orthosis use) will be performed. Berg Balance Scale, which will reveal the balance states; Functional ambulation scores and Timed Up and Go test will be applied to determine their functional status. In addition, the International Fall Efficiency Scale questionnaire will be administered. Bone mineral density will be evaluated to assess patients' bone health."
88826835|NCT05207748||patients without a history of falls|"Demographic characteristics and medical histories (age, height, weight, smoking, alcohol use, comorbidities, medications, stroke onset date, stroke side, total number of rehabilitation received, assistive device use, history of falls) of all patients participating in the study will be recorded.~Detailed physical examinations (mini-mental status assessment, brunstrum stages, spasticity assessments, orthosis use) will be performed. Berg Balance Scale, which will reveal the balance states; Functional ambulation scores and Timed Up and Go test will be applied to determine their functional status. In addition, the International Fall Efficiency Scale questionnaire will be administered. Bone mineral density will be evaluated to assess patients' bone health."
88826836|NCT05205655|Active Comparator|positive group|asymptomatic or mildly symptomatic participants positive for SARS-CoV-2 RNA
88826837|NCT05205655|Experimental|negative group|no evidence of SARS-CoV-2 by real-time RT-PCR
88826838|NCT05201287|Experimental|VIA Disc Nucleus Pulposus Allograft|A single dose, intradiscal injection of 100mg of VIA Disc NP mixed with 2ml sterile saline administered to the affected 1 or 2 levels, L1-S1.
88826839|NCT05192174|Experimental|NIB101 Dose Level 1|1 x 10^7 cells/body as chimeric antigen receptor (CAR) positive viable cells will be administered intravenously on Day 0.
88826840|NCT05192174|Experimental|NIB101 Dose Level 2|1 x 10^8 cells/body as CAR positive viable cells will be administered intravenously on Day 0.
88826841|NCT05192174|Experimental|NIB101 Expansion Cohort|Recommended dose determined on dose escalation phase will be administered intravenously on Day 0.
88826842|NCT05161156|Experimental|Treatment A: 18 mcg of Test Product (tiotropium bromide inhalation powder)|2 inhalations of test product, followed by 2 inhalations of reference placebo product
88826843|NCT05161156|Active Comparator|Treatment B: 18 mcg of Reference Product (Spiriva)|2 inhalations of reference product, followed by 2 inhalations of test placebo product
88826844|NCT05161156|Placebo Comparator|Treatment C: Zero-dose (Placebo)|2 inhalations of reference placebo powder, followed by 2 inhalations of test placebo product
88826845|NCT05155150|Experimental|Intervention group|Providing patient-reported outcome: patients receive personalized information on expected quality of life one year after ICU during ICU admission (during a family meeting)
88826846|NCT05155150|No Intervention|Control group|Family meetings take place as usual.
88826847|NCT05153824||Healthy volunteers|Healthy volunteers
88826848|NCT05129202||Chemotherapy alone or chemotherapy combined with anti-angiogenesis|patients with Chemotherapy
88826849|NCT05129202||immuntherapy|patients treated with immune checkpoint inhibitor monotherapy or combination therapy.
88826850|NCT05100641|Experimental|AV-GBM-1|Autologous dendritic cells loaded with autologous tumor antigens cryopreserved in CryoStor 5, and admixed 500 mcg GM-CSF diluted in saline
88826851|NCT05100641|Placebo Comparator|Autologous monocyte control (MC)|Autologous monocytes cryopreserved in CryoStor 5, and admixed 500 mcg GM-CSF diluted in saline
88826852|NCT05081752|No Intervention|No fixation|
88826853|NCT05081752|Active Comparator|Stent Suturing|
88826854|NCT05081752|Experimental|OTSC Stentfix|
89533961|NCT01810913|Experimental|Arm 2 (IMRT, docetaxel)|Patients undergo IMRT as in Arm I and receive concurrent docetaxel IV over 60 minutes once weekly for 6 weeks. Patients undergo CT scans and/or MRI, and collection of blood during follow-up. (CLOSED AS OF 20-MAR-2020)
88826855|NCT05062395||Observational (diet, FDG PET CT)|Patients receive a low carbohydrate and high fat diet for 48-72 hours. Patients receive FDG then undergo PET CT.
88826856|NCT05045950|Experimental|WBRT-PRDR plus memantine.|Study patients will receive WBRT-PRDR within 14 days of registration. All patients will receive single daily fractions using 3D conformal radiotherapy. A dose of 30 Gy in 10 fractions will be delivered using the PRDR technique. Memantine should ideally start two days (or one day) prior to WBRT PRDR and must start no later than the fourth WBRT PRDR treatment and will continue for a maximum of 24 weeks (≈six months). Memantine will be administered as per standard institutional guidelines.
88826857|NCT04949711|Experimental|Intervention|Participants will be asked to complete 3 surveys over 2 weeks to collect in information on their alcohol use and about themselves, and receive ridesharing vouchers.
88826858|NCT04949711|Sham Comparator|Control|Participants will be asked to complete 3 surveys over 2 weeks to collect in information on their alcohol use and about themselves, and receive online shopping voucher.
88826859|NCT04948827|Experimental|Part A - Single-Dose (Active)|In Part A, cohorts of healthy nonsmokers will be randomized to either active SBP-9330 or matching placebo. In each cohort a sentinel group of 2 subjects will be randomized and dosed ahead of the rest of the cohort. A review of safety data will be completed prior to administration of doses to the remainder of the cohort.
88826860|NCT04948827|Placebo Comparator|Part A - Single-Dose (Placebo)|In Part A, cohorts of healthy nonsmokers will be randomized to either active SBP-9330 or matching placebo. In each cohort a sentinel group of 2 subjects will be randomized and dosed ahead of the rest of the cohort. A review of safety data will be completed prior to administration of doses to the remainder of the cohort.
89177402|NCT04113954|Experimental|Leg 1 ACB + high dose SNB-PF|Right leg and 1.5% mepivacaine popliteal fossa-sciatic
89177403|NCT04113954|Experimental|Leg 2 ACB + low dose SNB-PF|Left leg and 0.375% mepivacaine popliteal fossa-sciatic
89177404|NCT04113954|Experimental|Leg 2 ACB + high dose SNB-PF|Left leg and 1.5% mepivacaine popliteal fossa-sciatic
89177405|NCT04113954|Experimental|Leg 1 ACB only|Right leg and 1.5% mepivacaine ACB
89177406|NCT04113954|Experimental|Leg 2 ACB only|Left leg and 1.5% mepivacaine ACB
89356867|NCT05864287|Other|BIM intervention participants|"Specifically, at each of the seven intervention sites, a minimum of 30 male and 30 female-identifying student athletes will participate in the BIM program across the 2022-2023 academic year. Thus, our intervention sample will be a minimum of 210 male and 210 female identifying intervention group athletes. The BIM program is a manualized intervention that consists of a 35-min introductory session, followed by four, 75-min sessions. Athletes participating in BIM who give consent (via electronic consent documentation) to share their de-identified data for research purposes will complete additional surveys beyond the standard MH-CDE set of baseline measures at one time-point and treatment-related measures at five time-points:~Pre-intervention/Baseline~Post-intervention (1-2 weeks after)~4-months post-intervention~12-months post-intervention"
89356868|NCT05864248|Experimental|HRPCI patients|Patients undergoing non-emergent, high-risk percutaneous coronary interventions.
88826861|NCT04948827|Experimental|Part A - Single-Dose Food-Effect (Active)|In this two-period food-effect cohort, each healthy nonsmoker subject will receive the randomly assigned treatment (SBP-9330 or placebo) under fasting conditions (Period 1). After a 7- to 14-day washout period, subjects will receive the same single dose of SBP-9330 or placebo in a fed state (Period 2) 30 minutes after the start of an FDA High-Fat and High-Calorie Breakfast. A sentinel group of 2 subjects will be randomized and dosed ahead of the rest of the cohort. A review of safety data will be completed prior to administration of doses to the remainder of the cohort.
88826862|NCT04948827|Placebo Comparator|Part A - Single-Dose Food-Effect (Placebo)|In this two-period food-effect cohort, each healthy nonsmoker subject will receive the randomly assigned treatment (SBP-9330 or placebo) under fasting conditions (Period 1). After a 7- to 14-day washout period, subjects will receive the same single dose of SBP-9330 or placebo in a fed state (Period 2) 30 minutes after the start of an FDA High-Fat and High-Calorie Breakfast. A sentinel group of 2 subjects will be randomized and dosed ahead of the rest of the cohort. A review of safety data will be completed prior to administration of doses to the remainder of the cohort.
88826863|NCT04948827|Experimental|Part B - Multiple-Dose (Active)|In Part B, cohorts of healthy nonsmokers will be randomized to receive once daily doses of active SBP-9330 or matching placebo for 14 consecutive days in increasing dose cohorts.
88826864|NCT04948827|Placebo Comparator|Part B - Multiple-Dose (Placebo)|In Part B, cohorts of healthy nonsmokers will be randomized to receive once daily doses of active SBP-9330 or matching placebo for 14 consecutive days in increasing dose cohorts.
88826865|NCT04948827|Experimental|Part C - Smoker Phase (Active)|In Part C, cohorts of healthy smokers will be randomized to receive once daily doses of active SBP-9330 or matching placebo for 14 consecutive days in increasing dose cohorts.
88826866|NCT04948827|Placebo Comparator|Part C - Smoker Phase (Placebo)|In Part C, cohorts of healthy smokers will be randomized to receive once daily doses of active SBP-9330 or matching placebo for 14 consecutive days in increasing dose cohorts.
88826867|NCT04947514|Other|Treatment Side (Right or Left)|Each patient undergoing routine bilateral breast reduction will be randomized to receive the study drug (topical tranexamic acid) either to the right or left breast at the conclusion of the operation, prior to closure of the incisions. The other breast will receive topical saline.
88826868|NCT04947514|Other|Non-Treatment Side (Right or Left)|Each patient undergoing routine bilateral breast reduction will be randomized to receive the study drug (topical tranexamic acid) either to the right or left breast at the conclusion of the operation, prior to closure of the incisions. The other breast will receive topical saline.
89177407|NCT00812344|Experimental|1|
89177408|NCT00812344|Active Comparator|2|AZD0837 + Ketoconazole
89177409|NCT00814996||1: employment|
89356869|NCT05864183||case group|prediabetic
89356870|NCT05864183||control group|non prediabetic
89356871|NCT05864170|Experimental|Experimental|Three transfusion-dependent β-thalassaemia subjects aged 18-35 years will be reinfused with β-globin restored autologous hematopoietic stem cells modified with LentiHBBT87Q
89356872|NCT05864131|Active Comparator|Lying|
89356873|NCT05864131|Experimental|Holding|
89356874|NCT05864092|No Intervention|Control Arm|The control arm will be a retrospective chart review of patients ages 6 to 21 who present to the pediatric emergency department with sickle cell VOC listed as one of their diagnoses with the aim of identifying pain scores in accordance with medications received and identifying final disposition and identifying time in the emergency department and time to ED disposition. We aim to review 100 charts.
89356875|NCT05864092|Experimental|Trial Arm|The trial arm will be a prospective, convenience sampling of up to 100 patients ages 6 to 21 years who present to the pediatric emergency department with VOC listed as either their main complaint or as one of multiple complaints as identified by health care provider at time of presentation and meet inclusion criteria. The intervention will be virtual reality headset which will be offered simultaneously with standard medication therapy.
89356876|NCT05864066||1|Women in preterm delivery with GA < 36 weeks.
89356877|NCT05864066||2|Women not in labor undergoing elective C-section with GA between 36 and 40 weeks.
89356878|NCT05864066||3|Women following spontaneous labor (without being induced) with GA between 36 and 40 weeks.
88826869|NCT04939324|Other|Blood samples at 2 sites: peripheral vein and tumor-draining vein|"D0: surgery (inclusion): oncological lung resection~Blood samples at 2 sites: peripheral vein and tumor-draining vein~Resected tumor analysis Standard clinical and radiological follow-up during 2 years (medical consultation or phone call)"
88826870|NCT04919109|Placebo Comparator|Placebo comparator|Administered as nose drops
88826871|NCT04919109|Experimental|Experimental: CodaVax-RSV 10^6 PFU|Respiratory syncytial virus live attenuated vaccine against RSV administered as nose drops
88826872|NCT04919109|Experimental|Experimental: CodaVax-RSV 10^5 PFU|Respiratory syncytial virus live attenuated vaccine against RSV administered as nose drops
88826873|NCT04919109|Experimental|Experimental: CodaVax-RSV 10^4 PFU|Respiratory syncytial virus live attenuated vaccine against RSV administered as nose drops
88826874|NCT04919109|Experimental|Experimental: CodaVax-RSV 10^3 PFU|Respiratory syncytial virus live attenuated vaccine against RSV administered as nose drops
88826875|NCT04917094|Experimental|Below the knee compression stocking|
88826876|NCT04878614|Active Comparator|Standard Levothyroxine Management|Participants will continue with the same regimen
88826877|NCT04878614|Experimental|Liquid Levothyroxine Management|Participants will be treated with dose equivalent regimen through enteral feeding tube
88826878|NCT04870658||Complication|Any patients with biological or mechanical complication in dental implant treatment.
88826879|NCT04862026||Telemonitoring group|The telemonitoring group will be connected to electronic medical systems, through which medical workers will remotely assess clinical and emotional status, adherence to drug therapy, and carry out nutritional adjustments.
88826880|NCT04862026||Control group|Patients with standard administration.
88826881|NCT04860011|Experimental|SGLT2i|Sodium-glucose Co-transporter-2 inhibitors
88826882|NCT04860011|Experimental|Thiazide|Thiazide or thiazide like diuretic
88826883|NCT04842500|Experimental|"Cheap Unit Price, Establishing Operation"|Pre-extinction baseline unit price for the programmed reinforcer will be its Pmax, minus one half of the distance between its Pmax and its breakpoint. Extinction will be introduced at the beginning of the relevant appointment, before within-appointment reinforcer consumption has had an opportunity to approximate demand.
88826884|NCT04842500|Experimental|"Cheap Unit Price, Abolishing Operation"|Pre-extinction baseline unit price for the programmed reinforcer will be its Pmax, minus one half of the distance between its Pmax and its breakpoint. Extinction will be introduced at the end of the relevant appointment, after within-appointment reinforcer consumption has approximated demand.
88826885|NCT04842500|Experimental|"Expensive Unit Price, Establishing Operation"|Pre-extinction baseline unit price for the programmed reinforcer will be its Pmax, plus one half of the distance between its Pmax and its breakpoint. Extinction will be introduced at the beginning of the relevant appointment, before within-appointment reinforcer consumption has had an opportunity to approximate demand.
89356879|NCT05864053|Active Comparator|Ketamine|Ketamine 0.5mg/kg 45 minute infusion x 1
88826886|NCT04842500|Experimental|"Expensive Unit Price, Abolishing Operation"|Pre-extinction baseline unit price for the programmed reinforcer will be its Pmax, plus one half of the distance between its Pmax and its breakpoint. Extinction will be introduced at the end of the relevant appointment, after within-appointment reinforcer consumption has approximated demand.
88826887|NCT04744324|Experimental|Self-supporting Care Group|Self-supporting Care in home
88826888|NCT04744324|Active Comparator|Control group|Home Health Education
88826889|NCT04704050|Active Comparator|Treatment Group|Dronedarone 400 mg orally, twice per day (BID)
88826890|NCT04704050|Placebo Comparator|Control Group|Placebo tablet orally, twice per day (BID)
88826891|NCT04684225|Experimental|Telerehabilitation|Stretching and strengthening exercises, functional exercises, massage techniques, sensory training and breathing exercises will be applied to the patients via telerehabilitation for 3 sessions per week.
88826892|NCT04684225|Experimental|Home-exercises|Stretching and strengthening exercises, functional exercises, massage techniques, sensory training and breathing exercises will be applied by their own at home for 3 sessions per week.
88826893|NCT04684225|No Intervention|Control|They will have no intervention for 8 weeks. After the period, they will do home exercises.
88826894|NCT04674761|Experimental|Odevixibat (A4250)|Capsules for oral administration once daily for 24 weeks.
88826895|NCT04674761|Placebo Comparator|Placebo|Capsules for oral administration (to match active) once daily for 24 weeks.
88826896|NCT04669210|Active Comparator|PTCY tacrolimus MMF|"Conditioning:~fludarabine 180 mg/m2 busulfan 8-14 mg/kg per os~GVHD prophylaxis:~cyclophosphamide 50 mg/kg day+3, +4 tacrolimus 0.03 mg/kg from day+5 to 100 mycophenolate mofetil 30 mg/kg from day+5 to 35"
89177410|NCT00814996||2: unemployment|
89356880|NCT05864053|Experimental|(2R,6R)-hydroxynorketamine|(2R,6R)-hydroxynorketamine 0.5mg/kg 45 minute infusion x 1
89356881|NCT05864053|Placebo Comparator|Saline|Saline 45 minute infusion x 1
89356882|NCT05864014|Experimental|Hetrombopag|
89356883|NCT05864014|Experimental|Hetrombopag plus Placebo|
89356884|NCT05864014|Placebo Comparator|Placebo|
89530241|NCT03246607||Monitoring with MicroEye & ContinuMon|72 hour study interval with monitoring using intravascular glucose monitoring system alongside routine clinical care.
89530242|NCT03249571|Experimental|Flavonoid|Flavonoid supplement
89530243|NCT03249571|Placebo Comparator|Placebo|Placebo
89530244|NCT05013437|Experimental|Evomela (Melphalan)|Participants will receive Evomela 16 mg/m2 on day 1 of the study only. Evomela will be given as IV infusion over 30 minutes after administration of 500 cc normal saline as pre-hydration and pre-medications Prochlorperazine, Acetaminophen, and Diphenhydramine.
89530245|NCT03246295||Gestational diabetes mellitus|Those women were diagnosed as gestational diabetes mellitus
89530246|NCT03246295||Control|Those women were diagnosed without gestational diabetes mellitus
89530247|NCT03347825||Robotic-assisted lobectomy|Pre-operative, intra-operative and post-operative clinical, surgical and oncological information will be obtained from institutional records for patients who underwent robotic-assisted lobectomy for lung cancer.
89533962|NCT01810913|Experimental|Arm 3 (IMRT, docetaxel, cetuximab)|Patients receive cetuximab IV over 120 minutes on week 1 and over 60 minutes once weekly on weeks 2-7. Patients undergo IMRT as in Arm I and receive concurrent docetaxel once weekly for 6 weeks. Patients undergo CT scans and/or MRI, and collection of blood during follow-up.
89533963|NCT01810913|Experimental|Arm 4 (IMRT, cisplatin, atezolizumab)|Patients undergo IMRT QD five days a week for 6 weeks and receive concurrent cisplatin IV over 1-2 hours once weekly for 6 weeks. Starting 1 week before IMRT, patients also receive atezolizumab IV over 30-60 minutes every 3 weeks for up to 8 doses (weeks -1, 3, 6, 9, 12, 15, 18, and 21) in the absence of disease progression and unacceptable toxicity. Patients undergo CT scans and/or MRI, and collection of blood during follow-up.
89356885|NCT05863988|Active Comparator|Functional Electrical Stimulation &upper limb loading exercises|The group A Will receive functional electrical stimulation and conservative treatment 30-45 min session 5 days per week for 8 weeks.
88826897|NCT04669210|Experimental|PTCY ruxolitinib|"Conditioning:~fludarabine 180 mg/m2 busulfan 8-14 mg/kg per os ruxolitinib 5 mg tid days -7 to -2~GVHD prophylaxis:~cyclophosphamide 50 mg/kg day+3, +4 ruxolitinib 5 mg tid days +5 to +21 ruxolitinib 5 mg bid days +22 to +150"
88826898|NCT04655157|Experimental|Phase 1 (cohort 1): 300mg encorafenib + 3mg/kg nivolumab + 1 mg/kg ipilimumab|Patients will be treated with 300mg encorafenib and 3mg/kg nivolumab and 1 mg/kg ipilimumab (triple therapy).
89177411|NCT00812422|Experimental|Dexibuprofen 1|Dexibuprofen 2.5 or 5 mg/kg
89356886|NCT05863988|Active Comparator|Functional Electrical Stimulation & Upper Limb Loading Exercises|The group B will receive upper limb loading exercises and conservative treatment 30-45 min session 5 days per week for 8 weeks.
89356887|NCT05863975|Experimental|Interferon group|Vaginal placement of human interferon alpha 2b vaginal effervescent capsules, one pill a day daily, 10 days, for a course of treatment, a total of 3 courses
89356888|NCT05863975|Experimental|Promestriene group|promestriene cream vaginal medication, once a day, 1g each time, 10 days, for a course of treatment, a total of 3 courses of treatment
89356889|NCT05863975|Experimental|Interferon + promestriene combination group|given one human interferon alpha 2b vaginal effervescent capsule vaginal placement + promestriene cream 1g vaginal medication, once a day, for 10 days, for a course of 1, 3 courses of continuous use.
89356890|NCT05863962|Experimental|Stretching Exercises|walking with stretching exercises
89177412|NCT00812422|Experimental|Dexibuprofen 2|Dexibuprofen 3.5 or 7 mg/kg
89356891|NCT05863962|Active Comparator|Jacobson's Technique|walking with Jacobson's Relaxation Technique.
89356892|NCT05863949|Experimental|vitamin D +/- calcium supplementation|patients given Vitamin D 1000iu daily. Also given calcium 500mg BID daily if calcium deficient.
89356893|NCT05863949|Placebo Comparator|Placebo arm|patients given 3 pills of placebo daily.
89356894|NCT05863936|Other|Belimumab and multi-target therapy group|Patients with severe lupus nephritis will be enrolled and received pulse methylprednisolone at a dose of 1.5 to 3.0g, followed by intravenous belimumab at a dose of 10mg per kilogram at weeks 2, 4, and 6, and every 4 weeks thereafter. Multitarget therapy will be also administered during the induction phase. Induction therapy will last for 24 weeks.
89356895|NCT05863923|Experimental|Intervention|The M2Q2-HIV intervention includes 3 functions: 1) Extended CHW services, 2) M2Q2 computer-tailored peer messaging, and 3) texting facilitation to quitline use and the quitline intervention. Our goals are to promote the use of an underused, available, government-funded resource for public health (quitline) and NRT that the quitline provides, thus promoting smoking cessation among PLWH.
89356896|NCT05863923|Active Comparator|Comparison|"Comparison smokers will receive five brief risk of smoking texts as minimal texting intervention, to enhance blinding to knowledge of randomization group."
89356897|NCT05863871||all enrolled patients|All patient who signed the consent form for participation to the study
89177413|NCT00812422|Active Comparator|Ibuprofen|Ibuprofen 5 or 10 mg/kg
89177414|NCT03995407|Active Comparator|Control|"Participants in the control arm will receive usual care."
89177415|NCT03995407|Experimental|100% Whey Protein|Participants will receive 100% Whey Protein oral nutritional supplements.
89177416|NCT04110834|Experimental|once daily application|the gel is applied to the affected areas once daily for one week followed by a follow-up visit to reassess the case. if complete cure is achieved, stop application. if not, repeat for one more week and then reassess.
88826899|NCT04655157|Experimental|Phase 1 (cohort 2): 450mg encorafenib + 45mg binimetinib + 3mg/kg nivolumab + 1mg/kg ipilimumab|Patients will be treated with 450mg encorafenib, 45mg binimetinib, 3mg/kg nivolumab and 1mg/kg ipilimumab (quadruple therapy).
89177417|NCT04110834|Experimental|twice daily application|the gel is applied to the affected areas twice daily for one week followed by a follow-up visit to reassess the case. if complete cure is achieved, stop application. if not, repeat for one more week and then reassess.
89177418|NCT04110834|Placebo Comparator|placebo|the gel is applied to the affected areas twice daily for one week followed by a follow-up visit to assure that the results obtained from other arms are only due to the effects of the active ingredient in the prepared gel.
89177419|NCT00812500|Experimental|1|Young men, age 21-46 years.
89177420|NCT00812500|Experimental|2|Old Men, age 63-81 years.
89177421|NCT00812500|Experimental|3|Young women, age 21-46 years.
89177422|NCT00812500|Experimental|4|Old women, age 63-81 years.
89177423|NCT04108494|Experimental|Experimental group|D2 radical gastrectomy with partial omentectomy
89177424|NCT04108494|No Intervention|Control group|D2 radical gastrectomy with total omentectom
89177425|NCT04045444|Experimental|women non active young people|women between 18 and 30 years practice less than 1h of physical activity per week
89177426|NCT04045444|Experimental|men non active young people|men between 18 and 30 years practice less than 1h of physical activity per week
89177427|NCT04045444|Experimental|women non active old people|women between 60 and 85 years practice less than 1h of physical activity per week
89177428|NCT04045444|Experimental|men non active old people|men between 60 and 85 years practice less than 1h of physical activity per week
89177429|NCT04045444|Experimental|women active old people|women between 60 and 85 years practice at least 3h of physical activity per week
89177430|NCT04045444|Experimental|men active old people|men between 60 and 85 years practice at least 3h of physical activity per week
89177431|NCT04045444|Experimental|women with parkinson's disease|women between 60 and 85 years presence of the disease according to the criteria of the UK Parkinson Disease Brain Bank
89177432|NCT04045444|Experimental|men with parkinson's disease|men between 60 and 85 years presence of the disease according to the criteria of the UK Parkinson Disease Brain Bank
89177433|NCT04108572|Experimental|Infant feeding intervention|The intervention will be delivered to parents by practice nurses and/or GPs in MPHC at each of the vaccination visits, prior to administration of the vaccination. These vaccination visits take place at 2, 4, 6, 12 and 13 months. This intervention consists of 1) verbally delivered pre-specified infant feeding messages, and 2) provision of additional infant-feeding resources including an information leaflet, a magnet, an infant bib and access to an informational website.
89177434|NCT00815074||1|Women in the military who have returned from deployment within the past 12 months.
89177435|NCT04110678|Active Comparator|NeuroEPO|The dose of NeuroEPO was a vial with a dose of 1 mL/1mg administered intra-nasally for five consecutive weeks.
89177436|NCT04110678|Placebo Comparator|Placebo|The dose of placebo was a vial with a dose of 1 mL/1mg of an intranasal inert solution administered intra-nasally for five consecutive weeks.
89177437|NCT00812578|Active Comparator|Cholecalciferol|
89177438|NCT00812578|Placebo Comparator|Placebo pill|
89177439|NCT00815152|Experimental|1|Twenty five caregivers will randomly be assigned to receive active coping skills training and 25 caregivers will randomly receive usual care at The Preston Robert Tisch Brain Tumor Center at Duke.
89177440|NCT00815152|Placebo Comparator|2|Caregivers that will receive ususal care.
89177441|NCT00796224|Active Comparator|1.|60 mg/kg azithromycin ER (Extended Release)arm
89177442|NCT00796224|Active Comparator|2.|30 mg/kg azithromycin IR (Immediate Release) arm
89177443|NCT00812656||Stroke Panel group|Patients undergoing cardiac surgery with the use of cardiopulmonary bypass
89356898|NCT05863858|Active Comparator|Levofloxacin-based sequential Therapy|"Tablets Levofloxacin 500mg BID for the first five days~Tablet Amoxicillin 1 gm BID for first five days~Capsules Omeprazole 20 mg BID for first five days followed by~1. Tablet Levofloxacin 500 mg BID for five days 2. Tablet Tinidazole 500mg BID for five days 3. Capsule Omeprazole 20 mg BID for five days~Infection eradication will be observed and confirmed by stool antigen test correlated with the signs and symptoms"
89177444|NCT00808366|Experimental|RV4104A ointment|
89177445|NCT00808366|Active Comparator|bifonazole-urea ointment|
89177446|NCT04113798|Experimental|Moderate Intensity Exercise|Day 1 Assessment, Day 2 Fear Learning, Day 3 Fear Extinction (followed by moderate intensity exercise), Day 4 Recall of Fear Extinction
89177447|NCT04113798|Active Comparator|Control|Day 1 Assessment, Day 2 Fear Learning, Day 3 Fear Extinction (followed by low intensity exercise), Day 4 Recall of Fear Extinction
89177448|NCT00812734||surgery|
89177449|NCT04113486||Renal cancer group|Patients which imaging studies have found renal mass, plan to receive surgery (except for radiofrequency ablation, cryoablation, etc.), about 100.
89177450|NCT04113486||Urothiasis group|Patients which imaging studies have found renal or ureteral stones, and rule out of renal mass, about 100.
89177451|NCT04113486||Renal cysts group|Patients which imaging studies have found renal cysts (simple or complex) about 100.
89177452|NCT04113486||Liver cancer group|Patients which imaging studies have found hepatic mass, plan to receive surgery (except for radiofrequency ablation, cryoablation, etc.), about 100.
89177453|NCT04113564|Experimental|IV remimazolam|IV remimazolam administration of 0.025 mg/kg body weight
89177454|NCT04113564|Experimental|Oral remimazolam|Oral remimazolam Administration of 0.14 mg/kg Body weight
89177455|NCT04108650|Experimental|Fit & Strong! group|The experimental group (23 participants) was enrolled in the intervention, the Fit & Strong! program. The program consists in 24 sessions each divided in two parts. The first part is the exercise component (60 minutes) and the second is the educational component (30 minutes). The program was provided in two classes, the first class took place from October to December 2017 and the second class took place from October to November 2018. The experimental group was enrolled in the intervention (8 weeks).
89177456|NCT04108650|No Intervention|Control group|To participants in the control group (8 participants) were offered the possibility of enrolling in the program the following year after posttest measurement for both the intervention and control groups was complete.
88826900|NCT04654910|Placebo Comparator|Control|enrolled subjects that do NOT receive explanation of PROMIS measures during visit.
88826901|NCT04654910|Active Comparator|Intervention|enrolled subjects that DO receive explanation of PROMIS measures during visit.
88826902|NCT04650269|Experimental|Rapid ART group|Patients will receive HIV care including Biktarvy for 6 months at the syringe services program followed by 6 months of standard of care at a traditional clinic.
88826903|NCT04643652|No Intervention|Control|Usual Care
88826904|NCT04643652|Experimental|Intervention|Implementation of a Noise Reduction Bundle
88826905|NCT04583995|Experimental|Cohort 1: SARS-CoV-2 rS/Matrix-M1 Adjuvant|2 doses of 5 µg SARS-CoV-2 rS + 50 µg Matrix-M1 adjuvant (co-formulated), 1 dose each on Days 0 and 21.
88826906|NCT04583995|Placebo Comparator|Cohort 1: Placebo|2 doses of Placebo (Saline), 1 dose each on Days 0 and 21.
88826907|NCT04583995|Experimental|Cohort 2: SARS-CoV-2 rS/Matrix-M1 Adjuvant Plus Licensed Seasonal Flu Vaccine|2 doses of 5 µg SARS-CoV-2 rS + 50 µg Matrix-M1 adjuvant (co-formulated), 1 dose each on Days 0 and 21. 1 dose of licensed seasonal flu vaccine on Day 0.
88826908|NCT04583995|Placebo Comparator|Cohort 2: Placebo Plus Licensed Seasonal Flu Vaccine|2 doses of Placebo (Saline), 1 dose each on Days 0 and 21. 1 dose of licensed seasonal flu vaccine on Day 0.
88826909|NCT04583280|Experimental|Rilematovir|Participants will receive rilematovir orally based on body weight and age group.
88826910|NCT04583280|Experimental|Placebo|Participants will receive matching placebo of rilematovir based on body weight and age group.
88826911|NCT04578600|Experimental|Treatment (lenalidomide, oral azacitidine, obinutuzumab)|Patients receive azacitidine PO QD on days 1-21, obinutuzumab IV over on days 8, 15, 22, and 29, and lenalidomide PO QD on days 8-28 of cycle 1. Treatment continues for 35 days in the absence of disease progression or unacceptable toxicity. Patients then receive azacitidine PO QD on days 1-21, obinutuzumab IV over on day 1, and lenalidomide PO QD on days 1-21. Cycles repeats every 28 days in the absence of disease progression, unacceptable toxicity, or until stem cell transplant. Patients who achieve SD, PR, or CR do not proceed to stem cell transplant may continue treatment for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
88826912|NCT04566536||Surgery|Patients ≥ 18 years old scheduled for robotic surgery (all specialties except ENT)
88826913|NCT04557930|No Intervention|Usual Care Control|The control arm occurred prior to receipt of the video game intervention. Each hospital group 'crossed over' from control to intervention at a randomized time point based on their assignment to the 'step' of the trial.
88826914|NCT04557930|Experimental|Video Game Intervention|Each hospital group 'crossed over' from control to intervention at a randomized time point. Physicians working at these hospitals, who agreed to participate in the trial, received a study iPad and were asked to play the video game loaded on the iPad for a minimum of 2 hours.
88826915|NCT04554212|Active Comparator|Standard Physical Therapy with Sham BFRT|Participants will undergo 8 weeks of sham blood flow restriction training with cuff inflated to less than 10% occlusion.
88826916|NCT04554212|Active Comparator|Standard Physical Therapy with BFRT|Participants will undergo 8 weeks of blood flow restriction training with cuff inflated to 60% occlusion.
88826917|NCT04534985|Experimental|Time Restricted Feeding|Instructed to eat within an 8-hr window, beginning within 3 hrs of waking. In addition, provide current clinical recommendations for the management of ADPKD, as well as chronic kidney disease, including moderate dietary sodium restriction (2.3-3 g), appropriate hydration, protein intake of 0.8/1.0 g/kg ideal body weight, moderate daily phosphate restriction (800 mg), and moderation in caloric intake.
88826918|NCT04534985|Active Comparator|Healthy Eating Advice without Time Restricted Feeding|Curriculum for the healthy eating control group will emphasize current clinical recommendations for the management of ADPKD, as well as chronic kidney disease, including moderate dietary sodium restriction (2.3-3 g), appropriate hydration, protein intake of 0.8/1.0 g/kg ideal body weight, moderate daily phosphate restriction (800 mg), and moderation in caloric intake.
88826919|NCT04524819||COPD participants|Saliva and Sputum will be collected from patients when they are unwell with a flare up of the COPS and when they are well
88826920|NCT04489940|Experimental|Bintrafusp alfa|
89533964|NCT01761968|Experimental|givinostat|"Patients will continue at their last tolerable dose and treatment schedule of givinostat monotherapy. Givinostat is a histone-deacetylases inhibitor. The product will be supplied as hard gelatine capsules for oral administration at the strength of 50 mg, 75 mg and/or 100 mg each.~If patients previously received givinostat in combination with other drugs during a core protocol or a compassionate use program, they will be treated at their last tolerable dose of this combination."
89177457|NCT02551276|Experimental|Experimental|Beta2-adrenergic stimulation with salbutamol and resistance training for 10 weeks
89177458|NCT02551276|Placebo Comparator|Control|Placebo and resistance training for 10 weeks
88826924|NCT04455386||stable|The anterior drawer test and/or talar tilt test are negative and the ankle joint is stable.
88826925|NCT04455386||slightly instable|The anterior drawer test and/or talar tilt test are slightly positive and the ankle joint is partially instable.
88826926|NCT04455386||obviously instable|The anterior drawer test and/or talar tilt test is significantly positive, with significantly instable. The ankle joint is completely instable and can featured with dimple sign.
88826927|NCT04389177|Experimental|Pembrolizumab+ Paclitaxel+Cisplatin|Pembrolizumab 200mg D1; Paclitaxel 135mg/m2 D2; Cisplatin 20mg/m2 D2-D4; repeated every 3 weeks
88826928|NCT04368988|Placebo Comparator|Placebo - Phase 1|2 doses of Placebo (Saline), 1 dose each on Days 0 and 21.
88826929|NCT04368988|Experimental|SARS-CoV-2 rS - 25 μg without Matrix-M - Phase 1|2 doses of SARS-CoV-2 rS - 25 μg, 1 dose each on Days 0 and 21.
89177459|NCT00815386|Experimental|PTMA implanted|Enrolled patients receiving a PTMA implant
89177460|NCT00791934|Experimental|Stratus Microflow Ethmoid Spacer|Temporary implantation of Ethmoid spacer with Triamcinolone Acetonide for 28 days.
89177461|NCT00848081|Placebo Comparator|Placebo|
89356899|NCT05863858|Active Comparator|Moxifloxacin-based Triple Therapy|"Tablet Moxifloxacin 400 mg OD for ten days~Tablet Amoxicillin 1 gm BID for ten days~Capsule Omeprazole 20 mg BID for ten days~Infection eradication will be observed and confirmed with a stool antigen test along with patient compliance and tolerability observance."
89356900|NCT05863845|Experimental|V-BEAM|"Patients in this arm will receive Venetoclax Combined With BEAM (Carmustine, Etoposide Cytarabine and Melphalan) as Pretreatment Regimen of ASCT.~Participants receive Venetoclax PO QD on days -10 to -1, Carmustine IV on day -7, Etoposide IV BID on days -6 to -3, Cytarabine IV BID on days -6 to -3, and Melphalan IV on day -2. Participants then undergo hematopoietic cell transplantation on day 0."
89356901|NCT05863845|Sham Comparator|BEAM|"Patients in this arm will receive BEAM (Carmustine, Etoposide Cytarabine and Melphalan) as Pretreatment Regimen of ASCT.~Participants receive Venetoclax PO QD on days -10 to -1, Carmustine IV on day -7, Etoposide IV BID on days -6 to -3, Cytarabine IV BID on days -6 to -3, and Melphalan IV on day -2. Participants then undergo hematopoietic cell transplantation on day 0."
89356902|NCT05863832|Experimental|Ciprodiazole|Ciprodiazole Tablets: (Ciprofloxacin 500 mg & Metronidazole 500 mg), 1 tablet every 12 hours up to 15 days
89356903|NCT05863832|Active Comparator|Ciprofloxacin 500 mg Tablets & Metronidazole 500 mg tablets|"Ciprofloxacin 500 mg Tablets: 1 tablet every 12 hours up to 15 days~Metronidazole 500 mg tablets: 1 tablet every 8 hours up to 10 days"
88826930|NCT04368988|Experimental|SARS-CoV-2 rS - 5 μg + 50 μg Matrix-M - Phase 1|2 doses of SARS-CoV-2 rS - 5 μg + 50 μg Matrix-M (mixed together for each injection), 1 dose each on Days 0 and 21.
88826931|NCT04368988|Experimental|SARS-CoV-2 rS - 25 μg + 50 μg Matrix-M - Phase 1|2 doses of SARS-CoV-2 rS - 25 μg + 50 μg Matrix-M (mixed together for each injection), 1 dose each on Days 0 and 21.
88826932|NCT04368988|Experimental|SARS-CoV-2 rS - 25 μg + 50 μg Matrix-M then Placebo - Phase 1|1 dose of SARS-CoV-2 rS - 25 μg + 50 μg Matrix-M (mixed together for injection), on Day 0 followed by 1 dose of Placebo on Day 21.
88826933|NCT04368988|Placebo Comparator|Placebo - Phase 2|3 doses of Placebo (Saline), 1 dose each on Days 0, 21, and 189.
88826934|NCT04368988|Experimental|SARS-CoV-2 rS - 5/5 μg + 50 μg Matrix-M - Phase 2|2 doses of SARS-CoV-2 rS - 5 μg + 50 μg Matrix-M (co-formulated), 1 dose each on Days 0 and 21, followed by 1 dose of Placebo on Day 189.
88826935|NCT04368988|Experimental|SARS-CoV-2 rS - Alternating 5/5 μg + 50 μg Matrix-M - Phase 2|1 dose of SARS-CoV-2 rS - 5 μg + 50 μg Matrix-M (co-formulated) on Day 0 then 1 dose of Placebo on Day 21 followed by 1 dose of SARS-CoV-2 rS - 5 μg + 50 μg Matrix-M (co-formulated) on Day 189.
88826936|NCT04368988|Experimental|SARS-CoV-2 rS - 25/25 μg + 50 μg Matrix-M - Phase 2|2 doses of SARS-CoV-2 rS - 25 μg + 50 μg Matrix-M (co-formulated), 1 dose each on Days 0 and 21, followed by 1 dose of Placebo on Day 189.
88826937|NCT04368988|Experimental|SARS-CoV-2 rS - 25 μg + 50 μg Matrix-M - Phase 2|1 dose of SARS-CoV-2 rS - 25 μg + 50 μg Matrix-M (co-formulated) on Day 0 then 2 doses of Placebo, 1 dose each on Days 21 and 189.
88826938|NCT04368988|Experimental|SARS-CoV-2 rS - 5/5/5 μg + 50 μg Matrix-M - Phase 2|3 doses of SARS-CoV-2 rS - 5 μg + 50 μg Matrix-M (co-formulated), 1 dose each on Day 0, Day 21, and Day 189.
88826939|NCT04368988|Experimental|SARS-CoV-2 rS - 5 μg + 50 μg Matrix-M - Phase 2|1 dose of SARS-CoV-2 rS - 5 μg + 50 μg Matrix-M (co-formulated) on Day 0 then 2 doses of Placebo, 1 dose each on Days 21 and 189.
88826940|NCT04365257|Experimental|Prazosin|"Prazosin 1mg given to observe if medication is tolerated or if signs or symptoms of hypotension develop (e.g. dizziness, lightheadedness).~If the patient remains asymptomatic and BP >110/60 mmHg, prazosin is continued at 1mg every 8 hours (q8h).~Day 3: If the patient remains asymptomatic and BP >110/60 mmHg, increase dose to 2mg q8h.~Day 6: If the patient remains asymptomatic and BP >110/60 mmHg, increase dose to 5mg q8h.~If the BP is <100/60 mmHg at any time, the next dose should be held, and patient continues with the highest previously tolerated dose 8 hours later.~If the patient did not tolerate dose escalation to 5mg q8h, one attempt is made to increase dose to 3mg q8h. If this is not tolerated, the patient continues with the highest previously tolerated dose 8 hours later.~If BP monitoring is not available, repeated occurrences of postural dizziness should trigger drug dose reduction or BP monitoring."
88826941|NCT04365257|Active Comparator|Standard of care|Subjects randomized to this arm will receive standard of care.
88826942|NCT04341545|Experimental|Letrozole|Participants will be given letrozole 10mg daily for one week after standard medical management for tubal ectopic pregnancy by methotrexate injection. Subsequently they will receive the standard management for medical management of tubal ectopic prengnacies.
88826943|NCT04341545|Placebo Comparator|Placebo|Participants will be given identical looking placebo for one week and receive the same standard management for medical management of tubal ectopic pregnancies.
88826944|NCT04320186|Active Comparator|Treatment|Participants viewed informational video content plus entertainment content
88826945|NCT04320186|Placebo Comparator|Control|Participants viewed entertainment content only
88826946|NCT04297384|Active Comparator|Group I (standard educational materials, surveys)|Participants receive standard chemotherapy educational materials. Participants also complete surveys over approximately 22 minutes at the time of first chemotherapy infusion, and approximately 8 weeks after first chemotherapy infusion.
88826947|NCT04297384|Experimental|Group II (personalized information, surveys)|Participants receive personalized information about their cancer, treatment, and side effects. Participants also complete surveys over approximately 22 minutes at the time of first chemotherapy infusion, and approximately 8 weeks after first chemotherapy infusion.
88826948|NCT04296994|Experimental|Open-label Dose Escalation and Expansion Study of QL1706|"Part 1 (Dose escalation): QL1706 will be administered in sequential cohorts each receiving 1 of 4 doses of QL1706 on day 1 of every 21-day cycle (3 weeks) via IV infusion. Dose escalation will continue until an MTD is reached.~Part 2 (Dose Expansion): The PK parameters of QL1706 will be tested at 2-3 doses determined during the dose-escalation phase in subjects with advanced malignant tumor cohorts."
88826949|NCT04219722|Active Comparator|Desirial only group|Administration of DESIRIAL® at Day 0 (Visit 1)
88826950|NCT04219722|Placebo Comparator|Placebo and Desirial group|Administration of placebo at Day 0 (Visit 1). If still eligible 12 weeks (Visit 3) after placebo injection, patient will be treated with DESIRIAL®
88826951|NCT04186299|Experimental|Clonidine + articaine/epinephrine|1.7mL of 4% articaine/epinephrine(1:100,000) + clonidine (15ug/ml)
88826952|NCT04186299|Active Comparator|articaine/epinephrine|1.7mL of 4% articaine with 1:100,000 epinephrine
89000603|NCT02254993|Experimental|Arm 3a or 3b or 3c - Part B|"Based on the microbiology review, one of 3 study arms will be conducted:~Arm 3a: Four manual brush gel applications on Day 0 followed by twice daily manual brush applications (Days 1 through 6); total of 7-day study drug administration, lower C16G2 concentration of 1.6 mg/mL~Arm 3b: Three manual brush gel applications followed by one tray gel application on Day 0. One manual brush application in the morning and one tray gel application in the evening on Days 1 through 6; total of 7-day study drug administration, lower C16G2 concentration of 1.6 mg/mL~Arm 3c: Three daily manual brush and/or tray gel applications for 7 days, lower C16G2 concentration of 1.6 mg/mL"
89177462|NCT00848081|Experimental|Tadalafil|
89177463|NCT02551978|Experimental|Intervention|Children in a primary school, aged between 9 and 12 years, play the serious game (two sessions, duration of each session 35 minutes, within two weeks). The game equips the children with knowledge about the core areas nutrition, physical activity, and psychosocial factors.
88826956|NCT04168580|No Intervention|OA- Older Athlete|Older adults who are regularly engaged in endurance exercise
89356904|NCT05863793|Experimental|Manual Acupuncture Group|Treatment will be performed by licensed acupuncturists who have at least 5 years of experience in acupuncture. All the acupuncturists will be trained how to locate acupoints, puncture, and manipulate needles before trials.
89356905|NCT05863793|Sham Comparator|Sham Acupuncture|The procedure and duration of treatment in the sham acupuncture group will be identical in the MA group except the needles are blunt tip and there will be no skin penetration and needle manipulation for De qi.
88826957|NCT04168580|Active Comparator|OS- Older Sedentary|Older adults who are sedentary
88826958|NCT04551872|Experimental|Obese High Risk|200 participants with BMI ≥30 and 10-year ASCVD risk ≥20%
89533965|NCT01761240|Experimental|MORAb-066 0.1 mg/kg|Participants will receive MORAb-066 0.1 milligram per kilogram (mg/kg), infusion intravenously, on Days 1, 8, 15, and 22, in each 28-day treatment cycle until disease progression, participant's discontinuation due to unacceptable toxicity, withdrawal by participants, or discontinuation by study physician decision.
88826959|NCT04551872|Experimental|Obese Low Risk|200 participants with BMI ≥30 and 10-year ASCVD risk <7.5%
88826960|NCT04551872|No Intervention|Non-Obese High Risk|100 participants with BMI 18-25 and 10-year ASCVD risk ≥20%
88826961|NCT04551872|No Intervention|Non-Obese Low Risk|100 participants with BMI 18-25 and 10-year ASCVD risk <7.5%
88826962|NCT04150874|Experimental|Lumason Microbubbles|Participants will receive an IV administrative of Lumason® microbubbles, prior to radioembolization. 2 doses of 2.5mL will be administered
88826963|NCT04118569|Experimental|Narrative Intervention Group|Patients in the narrative intervention group will participate in an interview and the resulting narrative will be uploaded to the electronic medical record. This group will also complete outcome measures (questionnaires) and exit interview.
88826964|NCT04118569|No Intervention|Usual Care Group|Patients in the usual care group will complete outcome measures (questionnaires) and exit interview only.
88826965|NCT04110249|Experimental|Diagnostic (PAI, ALTENS)|"PART I: Patients undergo PAI before the start of chemoradiation therapy, weekly during 7 weeks of chemoradiation, and again 3-4 months after completion of chemoradiation therapy.~PART II (CANCER-FREE WITH XEROSTOMIA): Patients undergo PAI at baseline, up to twice during acupuncture-like transcutaneous nerve stimulation (ALTENS) therapy, once after ALTENS, and at 3-6 months follow up."
88826966|NCT04101253|Experimental|Interventional|"Every ICD patient will undergo the standard screening process. Initial screening will be performed as usually performed by physician or Boston Scientific technical support. In case of one or more vector satisfying screening criteria, patient will be assigned in screening success group. In case of failure, a pre-determined electrode positioning protocol will be done with variation of para-sternal and axillary electrodes. Positioning variations will be left to the discretion of the operator cardiologist."
88826967|NCT04088058|Experimental|GXHPC1|One milliliter of cell suspension will be injected intrahepatically under sonographic guidance using a gauge-18 needle.
88826968|NCT04077996|Active Comparator|Peritonitis treatment with one exchange in CAPD|This group will receive peritonitis treatment with one exchange on Continuous Ambulatory Peritoneal Dialysis per day. The initial antibiotic scheme will be with ceftazidime (1500mg/day) and vancomycin (20mg/kg every 3 days) according to current management guidelines; adjusting the management according to the result of the culture, completing the antibiotic scheme for 14 to 21 days.
88826969|NCT04077996|Experimental|Peritonitis treatment placed in APD|This group will receive peritonitis treatment placed in Automated Peritoneal Dialysis. The initial antibiotic scheme will be with ceftazidime (1500mg/day) and vancomycin (20mg/kg every 3 days); adjusting the management according to the result of the culture, completing the antibiotic scheme for 14 to 21 days.
88826970|NCT03927222|Experimental|DC vaccination with Td preconditioning and GM CSF|This single-arm phase II study will assess the impact of tetanus pre-conditioning and adjuvant GM-CSF on overall survival of newly diagnosed glioblastoma (GBM) patients who have undergone definitive resection, are unmethylated, and completed standard temozolomide and radiation treatment. All enrolled patients will undergo a leukapheresis for the generation of DCs. Patients will then receive approximately 6 weeks of standard of care radiation therapy (RT) and concurrent TMZ. A single post-RT cycle of dose intensified TMZ (100 mg/m2/day for 21 days) will then be given. On day 23 (± 2 days) of the cycle, patients will receive the first of 3 pp65 DC vaccines every 2 weeks. All patients will receive up to a total of 10 DC vaccines
89356906|NCT05863780|Experimental|Carpal bone mobilization|Carpal bone mobilization will be done
88826971|NCT03845088||Children TMJA or condyle absence with Jaw Deformity|inclusion criteria: <12 years old; Unilateral temporomandibular joint ankylosis or condyle absence； Temporomandibular joint reconstructed with costochondral graft；
89177464|NCT02551978|No Intervention|Control|Children in the same primary school, aged between 9 and 12 years do receive basic information during the study phase.
89177465|NCT02605278|Experimental|Clinical program for pain and depression|Structured program with integrated management for depression and chronic musculoskeletal pain with three main components: 1) Optimized care of major depression on the basis of a Clinical Guideline 2) Care Management, and 3) Group psychoeducational intervention.
89177466|NCT02605278|Active Comparator|Control|Care as usual
89356907|NCT05863780|Experimental|Flexor retinaculum stretch|Flexor retinaculum stretch will be given.
88826972|NCT03844789|Experimental|Closed Loop Control (CLC)|Eligible participants not currently using an insulin pump and Dexcom G4, G5 or Dexcom G6 CGM with minimum data requirements will initiate a run-in phase of 2 to 4 weeks that will be customized based on whether the participant is already a pump or CGM user. Participants who skip or successfully complete the run-in will be randomly assigned 3:1 to the use of closed-loop control (CLC group) system using Tandem Control-IQ Technology & Dexcom G6 CGM vs Control Group for 16 weeks. Participants randomized to the closed loop control (CLC) arm will use the t:slim X2 with Control-IQ Technology & Dexcom G6 CGM for 16 weeks. All participants will be provided the option of continue using the t:slim X2 with Control-IQ system in a 12 week Extension Phase.
88826973|NCT03844789|Active Comparator|Control Group|Eligible participants not currently using an insulin pump and Dexcom G4, G5 or Dexcom G6 CGM with minimum data requirements will initiate a run-in phase of 2 to 4 weeks that will be customized based on whether the participant is already a pump or CGM user. Participants who skip or successfully complete the run-in will be randomly assigned 3:1 to the use of closed-loop control (CLC group) system using Tandem t:slim X2 with Control-IQ Technology vs Control Group for 16 weeks. All participants will be provided the option of using t:slim X2 with Control-IQ system in a 12 week Extension Phase.
88826974|NCT03822663|Experimental|Caffeine supplementation|Group taking oral CAF (Caffeine) supplementation in a different-dose crossover regimen.
88826975|NCT03822663|Placebo Comparator|Placebo treatment|Group taking oral supplementation with placebo.
89356908|NCT05863780|Experimental|Carpal bone mobilization and flexor retinaculum stretch|Carpal bone mobilization and flexor retinaculum stretch will be given together
88826976|NCT03801525|Experimental|Phase 2: Previously Treated CLL (BTK-Not Refractory)|
88826977|NCT03801525|Experimental|Phase 2: Previously Treated CLL (BTK-Refractory)|
88826978|NCT03801525|Experimental|Phase 2: Treatment Naïve CLL|
88826979|NCT03801525|Experimental|Phase 3: Treatment Naïve CLL/SLL: Ublituximab + Umbralisib + Venetoclax (U2-V)|
88826980|NCT03801525|Experimental|Phase 3: Treatment Naïve CLL/SLL: Ublituximab + Umbralisib (U2)|
88826981|NCT03801525|Experimental|Phase 3: Previously Treated CLL/SLL: Ublituximab + Umbralisib + Venetoclax (U2-V)|
88826982|NCT03801525|Experimental|Phase 3: Previously Treated CLL/SLL: Ublituximab + Umbralisib (U2)|
88826983|NCT03767933|Active Comparator|Non-Opioid Trial: Arm 1|Oral ibuprofen (10mg/kg, max 600mg) + Oral acetaminophen placebo, both administered once during the study at the time of recruitment.
88826984|NCT03767933|Experimental|Non-Opioid Trial: Arm 2|Oral ibuprofen (10mg/kg, max 600mg) + Oral acetaminophen (15mg/kg, maximum 1000mg), both administered once during the study at the time of recruitment.
88826985|NCT03767933|Active Comparator|Opioid Trial: Arm 1|Oral ibuprofen (10mg/kg, max 600mg) + Oral acetaminophen placebo + Oral hydromorphone placebo, all administered once during the study at the time of recruitment.
88826986|NCT03767933|Experimental|Opioid Trial: Arm 2|Oral ibuprofen (10mg/kg, max 600mg) + Oral acetaminophen (15mg/kg, maximum 1000mg) + Oral hydromorphone placebo, all administered once during the study at the time of recruitment.
88826987|NCT03767933|Experimental|Opioid Trial: Arm 3|Oral ibuprofen (10mg/kg, max 600mg) + Oral acetaminophen placebo + Oral hydromorphone (0.05mg/kg, maximum 5 mg), all administered once during the study at the time of recruitment.
88826988|NCT03743298|Experimental|AV-MEL-1|AV-MEL-1: Autologous dendritic cells loaded with autologous tumor antigens (ATA) from a short-term cell culture of autologous tumor cells. AV-MEL-1 is admixed with granulocyte-macrophage colony stimulating factor (GM-CSF) as an adjuvant, prior to injection.
88826989|NCT03713905|Experimental|GLS-010|Use Full-human anti-pd-1 monoclonal antibodies for treatment
88826990|NCT03701919|Experimental|Botulinum toxin pyloroplasty|Intraoperative laparoscopic intramuscular injection of 100units (10cc) of Botulinum toxin into the pylorus
88826991|NCT03701919|Placebo Comparator|Normal saline pyloric injection|Intraoperative laparoscopic intramuscular injection of 10cc normal saline into the pylorus
89356909|NCT05863767|Experimental|Interventional Group|Baduanjin sequential therapy consists of Six different movements including the preparatory phase. The session will account for 30 minutes twice a day for four weeks.
89533966|NCT01761240|Experimental|MORAb-066 0.3 mg/kg|Participants will receive MORAb-066 0.3 mg/kg, infusion intravenously, on Days 1, 8, 15, and 22, in each 28-day treatment cycle until disease progression, the participant discontinuation due to unacceptable toxicity, withdrawal by participants, or discontinuation by study physician decision.
88826992|NCT03690843||DCD Group|Children diagnosed with DCD or at-risk DCD at two or three years of age
88826993|NCT03690843||Control Group|Typically developing children
88826994|NCT03688503|Active Comparator|magnesium|magnesium glycinate supplement, 480 mg/day
88826995|NCT03688503|Placebo Comparator|placebo|placebo supplement
88826996|NCT03636152|Active Comparator|Hydroxychloroquine (HCQ) Group|These patients will receive HCQ for 18 months
88826997|NCT03636152|Placebo Comparator|Placebo Group|These patients will receive a matching placebo for 18 months
88826998|NCT03582371|Experimental|Aqua SUP|Patients in the Aqua SUP group will benefit from a 1 hour Aqua SUP session, twice a week, for 8 weeks in a therapeutic pool.
88826999|NCT03582371|Active Comparator|Physiotherapy|Patients in the control group will receive a conventional physiotherapy session of 1 hour, twice a week, for 8 weeks.
88827000|NCT03555916|Experimental|Drug|BOTOX®, Allergan treatment in 2 mL of saline solution (0.9% NaCl) treatment
88827001|NCT03555916|Placebo Comparator|Placebo|2 mL of saline solution (0.9% NaCl) treatment
88827002|NCT03487120|No Intervention|lumbar laminectomy|
88827003|NCT03487120|Active Comparator|lumbar laminectomy with denervation of the facet joint|
89356910|NCT05863767|Placebo Comparator|Control group|Control intervention: AROM, Breathing exercises, and stretches 5 repetitions three times a day.
89356911|NCT05863754|Experimental|Experimental: Intervention - implant neuroprosthesis|Receives implanted networked neuroprosthetic system for arm and hand function. Undergoes functional training and assessment.
89356912|NCT05863728|Experimental|Piezosurgery assisted group|A Piezosurgery assisted cavity preparation was performed using a IM4A Piezosurgery tip mounted in the handpiece of a Piezosurgery device (PIEZOSURGERY touch, Mectron, Carasco, Italy) at an operating frequency in the range of 24 to 36 kHz with power ratings 55 W for osteotomy and root-end resection
89356913|NCT05863728|Experimental|Trephine Burs assisted group|Trephine bur assisted cavity preparation was performed using a TPB-4 trephine bur mounted in 20:1 contra angled handpiece of an implant motor (ImplaNX, Micro-NX, Republic of Korea) at an operating speed in the range of 800 to 1200 / Torque 30 N for osteotomy and root-end resection
88827004|NCT03474497|Experimental|Pembrolizumab/IL-2/Radiotherapy|All patients will receive pembrolizumab and intralesional IL-2 in combination with hypofractionated radiotherapy.
88827005|NCT03395223|Experimental|ProvayBlue (Methylene Blue) arm|"Methylene Blue 0.5% will be administered.~1 mg/kg will be administered intravenously over 5-30 minutes. If methemoglobin level remains above 30% or if clinical symptoms persist, give a repeat dose of up to 1 mg/kg one hour after the first dose."
88827006|NCT03347877|Experimental|autologous bone-periosteal graft|The patients in experimental group will undergo the surgery of arthroscopic repair Hepple V osteochondral lesions of the talus with autologous osteo-periosteal cylinder graft transplantation.
88827007|NCT03347877|Active Comparator|autologous osteochondral graft|The patients in control group will undergo the surgery of arthroscopic repair Hepple V osteochondral lesions of the talus with autologous osteochondral graft transplantation.
88827008|NCT03329469||Experimental: 1: Toshiba CT-FFR Arm|All patients who consent will receive Toshiba CT-FFR and medically acceptable care based on the study protocol, commonly accepted standards of care, and the patients condition.
88827009|NCT03289650|Active Comparator|Standard of care tacrolimus twice-daily|
88827010|NCT03289650|Active Comparator|Extended-release tacrolimus once-daily|
88827011|NCT03192397|Experimental|Prevention (chemotherapy, TBI, cyclophosphamide)|"CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV over 30 minutes on days -5 to -2 and melphalan hydrochloride IV over 30 minutes on day -2. Patients undergo TBI on day -1.~STEM CELL INFUSION: Patients undergo allogeneic hematopoietic stem cell transplant on day 0.~GVHD PROPHYLAXIS REGIMEN: Patients receive cyclophosphamide IV over 2 hours on days 3-4, mycophenolate mofetil IV over 2 hours on days 5-35, and sirolimus IV and then PO once tolerated on days 5-180 with a taper beginning on day 100."
88827012|NCT02982096|Active Comparator|Cellutome treatment|Cellutome Device: Use of Cellutome on burn wounds
88827013|NCT02982096|Other|Standard of Care|Standard of Care: Acellular wound management
88827014|NCT02978183|Active Comparator|Group 1|1X ST266 dosed 4 times a day for 8 days
88827015|NCT02978183|Placebo Comparator|Group 2|Placebo dosed 4 times a day for 8 days
88827016|NCT02976792||Renal Resistive Index/NephroCheck™test|Patients undergoing a transcatheter aortic valve implantation
88827017|NCT02975492|Experimental|Cholecalciferol sequential dose|cholecalciferol : 100 000 Unit International (UI), sequential dose (2 mL)
88827018|NCT02975492|Experimental|Cholecalciferol daily dose|cholecalciferol : 1000 UI, daily dose during 28 days (0.1 ml by day)
88827019|NCT02867267|Experimental|thymosin alpha 1|1ml subcutaneous injection with 1.6 mg thymosin alpha 1, every 12±2 hours for not more than 7 days depending on the change of the subjects' condition
88827020|NCT02867267|Placebo Comparator|Placebo|1ml subcutaneous injection with placebo, every 12±2 hours for not more than 7 days depending on the change of the subjects' condition
88827021|NCT02864940|Experimental|Intervention Arm|Using the cognitive exercises on Lumosity for 10 weeks
88827022|NCT02864940|Active Comparator|Control Arm|Using online crossword puzzles for 10 weeks.
88827023|NCT02863107||Observational (questionnaire, biospecimen collection)|"PATIENTS: Patients complete questionnaires over 30-50 minutes about work, family history, medical history, health habits, and experience as a cancer survivor (quality of life, well-being, concerns, types of health care, and follow-up care received). Patients also undergo collection of blood or saliva samples. Active patients, who have undergone treatment at MD Anderson Cancer Center within the past year, complete additional questionnaires at enrollment, 6 months, 12 months after treatment completion, and then every years for up to 6 years. Also, active patients who are consented to the study more than 5 years from surgery, they may complete the survivorship questionnaire once. Patients medical records are also reviewed.~FAMILY MEMBERS: Participants complete questionnaires over 10-15 minutes. Participants also undergo collection of blood or saliva samples once."
88827024|NCT02821832|Other|Arm A - Expected high risk of relapse, standard of care TB treatment|Expected high risk of relapse, standard of care TB treatment
88827025|NCT02821832|Active Comparator|Arm B - Expected low risk of relapse, standard of care TB treatment|Expected low risk of relapse, standard of care TB treatment
88827026|NCT02821832|Experimental|Arm C - Expected low risk of relapse, shortened TB treatment|Expected low risk of relapse, shortened TB treatment
88827027|NCT02756611|Experimental|Venetoclax|"Venetoclax will be administered orally once daily (QD) beginning with a dose-titration phase. The initial venetoclax dose is 20 mg QD. After 1 week of treatment at 20 mg QD, the dose will be escalated to 50 mg QD followed by subsequent increases, each after 1 week, to 100 mg QD, 200 mg QD and the maximum dose of 400 mg QD. Participants may continue to receive venetoclax for up to 2 years provided they continue to tolerate the drug, have no evidence of disease progression (based on investigator's assessment), do not have unacceptable toxicity, and do not meet any of the criteria for discontinuation.~In countries where venetoclax is not commercially available, participants who continue to derive benefit after 2 years of treatment may be able to extend their treatment for up to 2 additional years, plus one additional year until the venetoclax extension study was open, determined on a case by case basis."
88827028|NCT02673359|Active Comparator|Progesterone group|Vaginal progesterone suppositories will be given
88827029|NCT02673359|Active Comparator|Cerclage group|Cervical cerclage will be performed.
89356914|NCT05863715|Experimental|Within-subjects Cue Type|Participants receive a target color cue (positive), a distractor color cue (negative), or a neutral non-informative cue prior to visual search.
89530248|NCT03347825||VATS (video assisted thoracic surgery) lobectomy|Pre-operative, intra-operative and post-operative clinical, surgical and oncological information will be obtained from institutional records for patients who underwent VATS lobectomy for lung cancer.
89530249|NCT03347825||Open lobectomy|Pre-operative, intra-operative and post-operative clinical, surgical and oncological information will be obtained from institutional records for patients who underwent open lobectomy for lung cancer.
89530250|NCT02455765|Experimental|White rice control|Subjects will consume white rice as control (50g carbohydrate)
89530251|NCT02455765|Experimental|co-ingest low dose of amino acid|Subjects will receive 68 ml of amino acid mixture together with white rice
89356915|NCT05863689||SLE Patients|"Patients fulfilling the 1997 revised American College of Rheumatology (ACR) criteria for the diagnosis of SLE (21) and aged between 18 and 80 years old.~Ophthalmological inclusion criteria: (1) best-corrected visual acuity ≤ 0.3 LogMAR, (2) intra-ocular pressure <21 mm Hg on diurnal testing with measurements using Goldmann applanation tonometry, (3) spherical equivalent refractive error between -6.0 and +4.0 diopters, and (4) open anterior chamber angle on slit lamp examination."
89356916|NCT05863689||Healthy Controls|Healthy controls matched for sex and age with SLE Patients. Ophthalmological inclusion criteria: (1) best-corrected visual acuity ≤ 0.3 LogMAR, (2) intra-ocular pressure <21 mm Hg on diurnal testing with measurements using Goldmann applanation tonometry, (3) spherical equivalent refractive error between -6.0 and +4.0 diopters, and (4) open anterior chamber angle on slit lamp examination.
89356917|NCT05863676||Cryopreservation|Participants will have their gonadal tissue cryopreserved.
89356918|NCT05863663||endometriosis|Women diagnosed with endometriosis between 18-50 years old
89356919|NCT05863663||healthy women without endometriosis|Women without the diagnosis of endometriosis between 18-50 years old
89356920|NCT05863650|Experimental|Hybrid Education|100 volunteer students participating in the study will start face-to-face training after preliminary evaluations are made. Afterwards, a randomized group of 20 people will be included in the simulation training every two weeks. In the face-to-face education group, a case analysis will be applied by the students themselves together with the educators in the classroom environment. In the simulation group, one case analysis will be made every week on the website designed under the supervision of researchers.
89356921|NCT05863650|Active Comparator|Face to Face Education|100 volunteer students participating in the study will start face-to-face training after preliminary evaluations are made. Afterwards, a randomized group of 20 people will be included in the simulation training every two weeks. In the face-to-face education group, a case analysis will be applied by the students themselves together with the educators in the classroom environment. In the simulation group, one case analysis will be made every week on the website designed under the supervision of researchers.
89533967|NCT01761240|Experimental|MORAb-066 1 mg/kg|Participants will receive MORAb-066 1 mg/kg, infusion intravenously, on Days 1, 8, 15, and 22, in each 28-day treatment cycle until disease progression, the participant's discontinuation due to unacceptable toxicity, withdrawal by participants, or discontinuation by study physician decision.
89533968|NCT01761240|Experimental|MORAb-066 2 mg/kg|Participants will receive MORAb-066 2 mg/kg, infusion intravenously, on Days 1, 8, 15, and 22, in each 28-day treatment cycle until disease progression, the participant's discontinuation due to unacceptable toxicity, withdrawal by participants, or discontinuation by study physician decision.
89533969|NCT01761240|Experimental|MORAb-066 3 mg/kg|Participants will receive MORAb-066 3 mg/kg, infusion intravenously, on Days 1, 8, 15, and 22, in each 28-day treatment cycle until disease progression, the participant discontinuation due to unacceptable toxicity, withdrawal by participants, or discontinuation by study physician decision.
89533970|NCT01751841||Spinal fusion patients with minimally invasive spine surgery|Spinal fusion patients for whom Silicate-Substituted Calcium Phosphate Ceramic has been used as the Bone Graft
88827030|NCT02662933|Experimental|Bedside Assessment Measures|"The study intervention consists of a bedside functional assessment to be administered to eligible, consented subjects who are hospitalized with a new diagnosis of AML or are undergoing workup for suspected AML diagnosis. All subjects will be enrolled within 5 days of admission to the hospital for known or suspected AML or within 5 days of new confirmed diagnosis of AML obtained during a hospitalization for other indications. All measures will be performed by a trained examiner during a face to face interview.~Bedside assessment measures will be repeated once for subjects who complete induction chemotherapy within 2-8 weeks post discharge from initial hospitalization."
88827031|NCT02624518|Experimental|Diagnostic (68Ga-RM2 PET/MRI)|Patients receive 68Ga-RM2 IV and beginning 45 minutes later undergoing PET/MRI scan. The 68Ga-RM2 PET/MRI may be repeated at the completion of treatment to evaluate response to therapy, if requested by the treating physician. Imaging with PET/MRI is the intervention.
88827032|NCT02413801||Psoriasis|Individuals with psoriasis
88827033|NCT02413801||Healthy|Individuals that are healthy
88827034|NCT02287623|Experimental|liposomal bupivacaine TAP|Patients will receive a TAP block with liposomal bupivacaine
88827035|NCT02287623|Active Comparator|bupivacaine TAP|Patients will receive a TAP block with bupivacaine
88827036|NCT02195310|Experimental|Prevena™ Incision Management System|Subjects will receive sternal wound treatment in the operating room using Prevena™ Incision Management System according to the intended use
88827037|NCT02195310|Active Comparator|Conventional sterile wound dressings|Subjects will receive standard conventional wound therapy (SCWT) placed in the operating room, defined as using conventional sterile wound dressings (gauze).
89356922|NCT05863611||25 individuals with frailty syndrome with type 2 diabetes|
89356923|NCT05863611||25 individuals without frailty syndrome with type 2 diabetes|
89356924|NCT05863585|Experimental|BG505 SOSIP.664 gp140 Vaccine, Adjuvanted (3M-052 AF plus alum)|BG505 SOSIP.664 gp140 Vaccine, Adjuvanted (3M-052 AF plus alum) Dosage
88827038|NCT02174159|Experimental|Panel A: Ulonivirine 600 mg|Single oral dose of ulonivirine 600 mg (supplied as 10 mg and 100 mg tablets) administered after an overnight fast
88827039|NCT02174159|Experimental|Panel B: Ulonivirine 150 mg|Single oral dose of ulonivirine 150 mg (supplied as 10 mg and 100 mg tablets) administered after an overnight fast
88827040|NCT02174159|Experimental|Panel C: Ulonivirine <=600 mg|Single oral dose of ulonivirine <=600 mg mg (supplied as 10 mg and 100 mg tablets) administered after an overnight fast. Inclusion of Panel C in the study, and the dose selected, will be decided pending evaluation of results for Panels A and B.
88827041|NCT01794520|Experimental|Phase 1: Venetoclax 300 mg|Participants in the dose-escalation cohort received 300 mg of venetoclax daily on Days 1 -21 of each cycle after a 2-week lead-in period, during which venetoclax doses were increased weekly.
88827042|NCT01794520|Experimental|Phase 1: Venetoclax 600 mg|Participants in the dose-escalation cohort received 600 mg of venetoclax daily on Days 1 -21 of each cycle after a 2-week lead-in period, during which venetoclax doses were increased weekly.
88827043|NCT01794520|Experimental|Phase 1: Venetoclax 900 mg|Participants in the dose-escalation cohort received 900 mg of venetoclax daily on Days 1 -21 of each cycle after a 2-week lead-in period, during which venetoclax doses were increased weekly.
88827044|NCT01794520|Experimental|Phase 1: Venetoclax 1200 mg|Participants in the dose-escalation cohort received 1200 mg of venetoclax daily on Days 1 -21 of each cycle after a 2-week lead-in period, during which venetoclax doses were increased weekly.
88827045|NCT01794520|Experimental|Phase 1 Safety Expansion: Venetoclax 1200 mg|Participants in the safety expansion cohort received 1200 mg of venetoclax daily on Days 1 - 21 of each cycle after a 2-week lead-in period, during which venetoclax doses were increased weekly.
88827046|NCT01794520|Experimental|Phase 1 Combination: Venetoclax 800 mg/Dexamethasone 20 or 40 mg|Participants with t(11;14) translocation multiple myeloma received daily venetoclax at a dose of 800 mg (no lead-in period) on Days 1- 21 of each cycle concomitant with weekly dexamethasone at a dose of 40 mg (20 mg for those aged ≥ 75 years).
88827047|NCT01794520|Experimental|Phase 2 Expansion: Venetoclax 800 mg/Dexamethasone 20 or 40 mg|The Phase 2 cohort further explored the efficacy of venetoclax in combination with dexamethasone in relapsed or refractory participants with t(11;14) translocation multiple myeloma. Participants received daily venetoclax at a dose of 800 mg (no lead-in period) on Days 1- 21 of each cycle concomitant with weekly dexamethasone at a dose of 40 mg (20 mg for those aged ≥ 75 years).
88827048|NCT01774019|Active Comparator|WallFlex™ Biliary RX Fully Covered/Uncovered Stent System|Patients in this group will receive a fully covered or uncovered study SEMS (self-expanding metal stent)
88827049|NCT01774019|No Intervention|None (No Pre-Operative Biliary Drainage)|Patients in this group will not receive pre-operative biliary drainage with a study SEMS
88827050|NCT01668953|Experimental|Platelet Rich Plasma (PRP) Injection|Patients in this arm will receive a platelet rich plasma injection at the site of their lateral epicondylitis, followed by post-treatment physical therapy exercises.
88827051|NCT01668953|Active Comparator|Whole Blood Injection|Patients in this arm will receive a whole blood injection at the site of their lateral epicondylitis, followed by post-treatment physical therapy exercises.
88827052|NCT01668953|Active Comparator|Dry Needle Fenestration|Patients in this arm will receive 15-25 gentle strokes of dry needling (piercing of the tendon) at the site of their lateral epicondylitis, followed by post-treatment physical therapy exercises. No blood will be injected into the tendon.
88827053|NCT01668953|Placebo Comparator|Sham Injection|Patients in this arm will receive a sham injection, followed by post-treatment physical therapy exercises. No blood will be injected into the tendon.
88827054|NCT01370811|Placebo Comparator|oxybutynin and clonidine oral solution treatment D|Placebo
89399117|NCT03705195|Experimental|Low Dose Gliclazide|"The first 8 participants will complete the dose-ranging phase of LOGIC study. Low dose gliclazide is being used a physiological stimulus. In the dose-ranging phase, 4 participants will receive 10mg gliclazide, the remaining 4 will receive 20mg gliclazide. The allocation to 10mg or 20mg will be randomised and unblinded. The study will analyse after the first 8 participants to assess which dose produces the greatest augmentation of insulin secretion when acting synergistically with the incretin effect.~The further 12 participants will complete the study with the identified best dose."
89399118|NCT03705117|Experimental|V565|V565 orally three times daily for up to 7 days
89399119|NCT03688269|Experimental|Intravenous dexamethasone|"Axillary Brachial Plexus Block with perineural Ropivacaine. Concentration determined by sequential up and down method.~Intravenous injection of 8mg/2ml Dexamethasone during the regional anesthesia"
88827055|NCT01370811|Experimental|oxybutynin and clonidine oral solution treatment C|High dose oxybutynin and clonidine
88827056|NCT01370811|Experimental|oxybutynin and clonidine oral solution treatment A|Low dose oxybutynin and clonidine
88827057|NCT01370811|Experimental|oxybutynin and clonidine oral solution treatment B|Intermediate dose oxybutynin and clonidine
88827058|NCT01323569|Placebo Comparator|Placebo|
88827059|NCT01323569|Experimental|Sativex 4 sprays|
88827060|NCT01323569|Experimental|Sativex 8 sprays|
88827061|NCT01323569|Experimental|Sativex 16 sprays|
89356925|NCT05863559|Experimental|Treatment|After completing baseline data collection, families randomized to the intervention group will receive the 4-session prototype over a period of up to 6 weeks. This will allow for illness, family vacations, school holidays, and scheduling conflicts. After completing session 4, the family will proceed to post assessment. The investigators have successfully used this approach in previous interventions. It is anticipated each session will take ~1.5 hrs to complete (online phase - ~30 minutes; home phase - ~1 hr). The parent and child will each be assigned a password with which to login to the online phase. Parents and children will be asked to keep their password private. Each will need to login at the same time to view each new online session. The session can be viewed by parent or child separately or together after the initial viewing.
88827062|NCT01323569|Active Comparator|Marinol low dose|
88827063|NCT01323569|Active Comparator|Marinol high dose|
88827064|NCT01323465|Experimental|Sequence 1A|Sativex and rifampicin
88827065|NCT01323465|Experimental|Sequence 1B|Sativex and rifampicin
89356926|NCT05863559|No Intervention|Wait-list control|Families randomized to this group will receive the intervention after the dyad completes both baseline and post intervention data collection.
89356927|NCT05863546|Experimental|control group|(control group) It will consist of 15 subjects who will receive a program of 'sham' US application, so that the US device will be working but not delivering any output plus traditional PT treatment for carpal tunnel syndrome which includes hot packs, tendon glide and nerve glide exercises, US treatment sessions will be performed for 6 min per session , once a day, three days a week, for a total of 4 weeks.
88827066|NCT01323465|Experimental|Sequence 2C|Sativex and ketoconazole
88827067|NCT01323465|Experimental|Sequence 2D|Sativex and ketoconazole
88827068|NCT01323465|Experimental|Sequence 3E|Sativex and omeprazole
88827069|NCT01323465|Experimental|Sequence 3F|Sativex and omeprazole
88827070|NCT01322464|Experimental|Group 1 Fasted-Fed|"4 sprays Sativex in fasted state, followed by wash-out followed by 4 sprays Sativex in fed state.~Followed by 4 sprays daily in fasted state."
88827071|NCT01322464|Experimental|Group 1 Fed-Fasted|"4 sprays sativex in fed state followed by wash-out followed by 4 sprays Sativex in fasted state.~Followed by 4 sprays daily in fasted state."
88827072|NCT01322464|Experimental|Group 2|2 sprays Sativex daily in fasted state.
88827073|NCT01322464|Experimental|Group 3|8 sprays sativex daily in fasted state.
88827074|NCT01322139|Placebo Comparator|High dose placebo and oral moxifloxacin placebo|24 or 36 placebo sprays (12 or 18 sprays twice daily) for 5 days and single oral moxifloxacin placebo on Day 5.
88827075|NCT01322139|Active Comparator|Low dose Sativex and oral moxifloxacin placebo|8 Sativex sprays (4 sprays twice daily) + 16 or 28 placebo sprays (8 or 14 sprays twice daily) for 5 days and single oral moxifloxacin placebo on Day 5.
88827076|NCT01322139|Active Comparator|High dose Sativex and oral moxifloxacin placebo|24 or 36 Sativex sprays (12 or 18 sprays twice daily) for 5 days and single oral moxifloxacin placebo on Day 5.
88827077|NCT01322139|Active Comparator|High dose placebo and single oral moxifloxacin 400 mg tablet|24 or 36 placebo sprays (12 or 18 sprays twice daily) for 5 days and single oral moxifloxacin 400 mg tablet on Day 5.
88827078|NCT01182623||In vivo diagnosis|Patients undergoing colonoscopy where one or more polyps up to 10mm in size are found.
88827079|NCT01158456||African Americans|Subjects will be classified as African American if they report themselves, biological parents and both sets of biological grandparents as African American or African descent.
88827080|NCT01158456||European American|Subjects will be classified as European American if they report themselves, biological parents and both sets of biological grandparents as European American or European descent.
88827081|NCT01019850|Other|Treatment for All Patients|Patients on study will receive vorinostat orally once daily on days 1 to 14. The starting dose level is 180 mg/M2. The maximum dose is 400 mg. Patients will receive 131- I Metaiodobenzylguanidine on day 3, 1hr after vorinostat dosing. Patients will initially receive 8 mCi/kg 131-I MIBG with 180 mg/m2/dose vorinostat. The dose of 131-I MIBG will be escalated in subsequent cohorts to 15 mCi/kg and then to 18 mCi/kg. Peripheral Blood Stem Cell Infusion is planned for 2 weeks after MIBG infusion (day 17). The dose for Purged PBSC is a minimum of 2 x 106 viable CD34+ cells/kg and for Unpurged PBSC: a minimum of 2 x 106 viable CD34+ cells/kg. Stem cells must be infused over 15-30 minutes and within 1.5 hours of thawing. Patients will receive filgrastim following hematopoietic stem cell infusion according to institutional guidelines.
88827082|NCT00899405||Patients with lung cancer|Collection of archival tumor specimen at the beginning of the study and collection of blood samples at the beginning of the study and then at regular intervals
89399120|NCT03688269|Placebo Comparator|Intravenous saline|"Axillary Brachial Plexus Block with perineural Ropivacaine. Concentration determined by sequential up and down method.~Intravenous injection of 2ml Saline 0.9% during the regional anesthesia"
89399121|NCT03688191|Experimental|Study Group|participants who received sirolimus treatment
89000604|NCT02254993|Experimental|Arm 4a or 4b - Part B|"Based on the microbiology review, one of 2 study arms will be conducted:~Arm 4a: Four manual brush gel applications on Day 0 followed by twice daily manual brush applications (Days 1 through 6); total of 7-day study drug administration, C16G2 concentration of 1.6 mg/mL and lower gel volume~Arm 4b: Three manual brush gel applications followed by one tray gel application on Day 0. One manual brush application in the morning and one tray gel application in the evening on Days 1 through 6; total of 7-day study drug administration, lower C16G2 concentration of 1.6 mg/mL and lower gel volume"
89000605|NCT02254993|Experimental|Arm 5 - Part B|Arm 5: Three manual brush gel applications followed by one tray gel application on Day 0, 3.2 mg/mL C16G2 gel concentration.
88827083|NCT00885326|Other|Treatment|"Bevacizumab: Every course will be 28 days. Bevacizumab 10 mg/kg/dose , will be administered intravenously every 14 days beginning on day 0 of the second course.~Cyclophosphamide will be administered as an intravenous (IV) bolus according to the protocol assigned dose level followed by daily oral dosing (25mg/m2/day) without interruption (unless toxicity supervenes).~Zoledronic acid will be administered on day 0 of course 1 and day 1 of course 2 and all subsequent courses in a dose of 4mg/m2 (max 4 mg per dose). On days when zoledronic acid (ZA) and cyclophosphamide (CTX) are given together, CTX should be given first."
88827084|NCT00759304||PROOF cohort|Healthy inhabitants of the city of Saint-Etienne, France, and aged 65 years at the inclusion date.
88827085|NCT00704626||Cohort 1|Subjects with multiple sclerosis and other autoimmune and inflammatory disease of the nervous system
88827086|NCT00685243|Active Comparator|Fraxel|Fraxel laser treatment
88827087|NCT00685243|Active Comparator|PDL|Pulsed dye laser treatment
88827088|NCT00606138|Experimental|Anti-VEGF injection|Intravitreal injection of 0.5-mg dose of ranibizumab
88827089|NCT00606138|Active Comparator|PRP Laser|Additional panretinal photocoagulation (up to 500 300-500 um laser spots)
89356928|NCT05863546|Experimental|low-dose group|(low-dose group) It will consist of 15 subjects who will receive a program of US treatments that will be administered to the carpal tunnel area with pulsed mode at a frequency of 1 MHz with an intensity of 0.25 W/cm2 and a duty cycle of 1:5 plus traditional treatment.
89356929|NCT05863546|Experimental|Mid-dose group|(Mid-dose group) It will consist of 15 subjects who will receive a program of US treatments that will be administered to the carpal tunnel area with pulsed mode at a frequency of 1 MHz with an intensity of 0.5 W/cm2 and a duty cycle of 1:5 plus traditional treatment.
89356930|NCT05863546|Experimental|high-dose group|(high-dose group) It will consist of 15 subjects who will receive a program of the same US equipment that will be set at pulsed mode at a frequency of 1 MHz, intensity of 1.0W/ cm2 and a duty cycle of 1:5 plus traditional treatment.
89356931|NCT05863494|Experimental|Treatment|For visits 1-5 (tDCS treatment visits), the investigators will start with 0.5mA ramping up to 0.75mA for 5 minutes. Followed by a brief (8 sec) EEG recording. Then, the investigators will apply .75mA to 1mA for 5 minutes. This will also be followed by 8 second EEG recording. The final application of current will be 1mA to 1.75mA for 10 minutes followed again by 8 second EEG recording.
88827090|NCT00084422|Experimental|Single Group|
88827091|NCT00005835|Experimental|Single Group|
88827092|NCT04802473|Experimental|Gingival recession treatment|Gingival recession treatment by means of tunnel technique and OrACell dermal matrix.
88827093|NCT00002643|Experimental|Arm I|See detailed description.
88827094|NCT04342559|Experimental|Group I|"Belamy with sinodor Vaginal Moisturizer with Odor Neutralizer - code: 062603-07~Participants will be instructed on how to use it as follows:~Guidance The product has individual pre-filled applicators for single use and disposable after use. The applicator has an anatomical shape, in order to facilitate use, avoiding discomfort during application.~A single application should be performed every 3 days (72 hours). I use it at night, before going to bed, before going to sleep."
88827095|NCT04342559|Experimental|Group II|"Belamy without sinodor Vaginal Moisturizer without Odor Neutralizer - code: 062603-08~Participants will be instructed on how to use it as follows:~Guidance The product has individual pre-filled applicators for single use and disposable after use. The applicator has an anatomical shape, in order to facilitate use, avoiding discomfort during application.~A single application should be performed every 3 days (72 hours). I use it at night, before going to bed, before going to sleep."
88827096|NCT00002649|Experimental|Arm I (autologous PBSCT, TBI, etoposide, cyclophosphamide)|"Part I: Autologous PBSC are harvested before study entry. Patients undergo total body irradiation twice a day on days -8 to -5, high-dose etoposide IV over 4 hours on day -4, and cyclophosphamide IV over 1 hour on day -2. PBSC are reinfused on day 0 and then G-CSF may be administered subcutaneously or IV on days 0-21.~Part II: Within 28-80 days after PBSC transplantation and after recovery from any toxic effects, patients with no active recurrent or progressive disease are randomized to 1 of 2 treatment arms.~Patients receive interleukin-2 IV continuously on days 1-4 and 9-18."
88827097|NCT00002649|No Intervention|Arm II (observation only)|Patients undergo observation only.
88827098|NCT03004027|Experimental|Enhanced|self help leaflet enhanced with implementation intentions
88827099|NCT03004027|Active Comparator|Standard|self help leaflet standard (without implementation intentions)
88827100|NCT03004027|No Intervention|Waiting list control|Baseline measures administered only. self help intervention will be made available once the study has finished.
89399122|NCT02255708|Other|Healthy group.|Group formed by healthy patients.
89399123|NCT02255708|Other|Group with demyelinating polyneuropathy|Group formed by patients with demyelinating polyneuropathy.
89399124|NCT03540602|Placebo Comparator|Placebo|Rice flour capsule
89399125|NCT03540602|Active Comparator|Polyphenol Rich Supplement|NordicCherry Tart Cherry Extract Powder 500 mg in capsule form
88827101|NCT02976857|Experimental|C-CAR011|C-CAR011 infusion In the first cell therapy 0, 1 and 2 days, respectively 10%, 30% and 60% ratio three times reinfusion.
89000606|NCT02253745|Experimental|Placebo:V81444|Placebo followed by a 7 day washout then V81444
89000607|NCT02253745|Experimental|V81444:placebo|V81444 followed by a 7 day washout then Placebo
89000608|NCT02236195|Experimental|Mocetinostat|Mocetinostat (MGCD0103) oral capsules three times weekly, 70 mg doses in first month, with increase to 90 mg doses if tolerated
89000609|NCT00200148|Experimental|1|For patients randomized to ANH
89399126|NCT02164838|Experimental|Axitinib|
89399127|NCT03688113|Experimental|Treatment|
89399128|NCT03688113|Other|Wait list|
88827102|NCT01170559|Experimental|Group 1: ILR Group|Group allocated to receiving an ILR in the A&E department.
88827103|NCT01170559|No Intervention|Group 2: Conventional|Group randomised to conventional lines of investigation
88827104|NCT04342637||Practicing gastroenterologists|Practicing physicians performing gastrointestinal endoscpy
88827105|NCT03003871|Experimental|advanced oral hygiene care programmes|participants were provided with a powered toothbrush (Oral-B® AdvancePowerTM 400 series), 0.2% chlorhexidine gluconate mouth rinse, 10 mls twice daily (CorsodylPTMP), standardized toothpaste (Colgate Maximum Cavity Protection) and oral hygiene instruction.
88827106|NCT03003871|Active Comparator|conventional oral hygiene care programme|participants were provided with a manual toothbrush (Oral-B® Pro-Health All-In-One), supply of a standardized toothpaste (Colgate Maximum Cavity Protection®) and oral hygiene instruction
88827107|NCT00381771||Objective salivary function|"Based on the salivary scintigraphy,~Objective salivary normo-function~Objective salivary dysfunction"
88827108|NCT00995059|Experimental|Arm 1|CONDITIONING: Patients receive bortezomib IV and then undergo fractionated total-body irradiation on days -5 and -2. Patients receive thymoglobulin IV over 6 hours on days -5 to -2 and melphalan IV over 30 minutes on days -4 to -3. ALLOGENEIC STEM CELL TRANSPLANTATION: Patients undergo bone marrow or peripheral blood stem cell transplant on day 0. GRAFT-VS-HOST DISEASE PROPHYLAXIS: Beginning on day -3, patients receive oral sirolimus and taper beginning on day 61. Beginning on day -2, patients receive oral or IV tacrolimus and taper beginning on day 101.
89177467|NCT00815464|Experimental|Antiviral Therapy|Liquid Acupuncture(Herb Acupoints Injection) Therapeutics was researched and developed by Herbalist Yu Ru Lin in early of 1950s and used by Yu Medical Garden till now. It is an integrated therapeutics,according to individual condition, select the Acupoints(not limit to current used common acupoints) and proper herbs made individually.It is a special medical treatment conception, which theory is utilizing patients' condition, mobilizing their individual internal curability,therefore the final efficacy can be retrieved.
89177468|NCT04111380|Experimental|Nab-paclitaxel and Cisplatin|cisplatin and nab-paclitaxel: Nab-paclitaxel, 130mg/m2, d1,d8, Cisplatin, 20mg/m2, d1-3 ,3week, 4-6 cycles.
88827109|NCT05752071|Experimental|Treatment group|A pace lead is mounted on the stomach, and exteriorized trough the skin and connected to an external pacemaker. The pacemaker is set to the following settings: 10,5 Volt, 14 hz, 330 Micro sec, Cycling 5 seconds off 0,1 sec on. The pacemaker is turned on.
88827110|NCT05752071|Sham Comparator|Control group|A pace lead is mounted on the stomach, and exteriorized trough the skin and connected to an external pacemaker. The pacemaker is turned off.
88827111|NCT04372823||Comparison|Comparison children within family child care homes not exposed to policy/program
88827112|NCT04372823||Intervention|Intervention children within family child care homes exposed to policy/program
88827113|NCT04759157|Active Comparator|Couples-based treatment|Participants will attend 3, sessions (75, 50, 50 min) over video with a study therapist to discuss education about OSA and CPAP, strategies adjust to CPAP as a couple and techniques to improve sleep health.
88827114|NCT04759157|Other|Standard Information Control|Participants will receive treatment as usual and also standardized information about OSA and CPAP.
88827115|NCT02249299|Active Comparator|Sativex Oromucosal Spray|Participants will titrate onto Sativex during the first two weeks of the study, carried out according to a standardised dosing schedule. After 2 weeks the clinician and participant will decide on the optimal dose for the remainder of the 4 week trial
88827116|NCT02249299|Placebo Comparator|Placebo|Participants will titrate onto the placebo during the first two weeks of the study, carried out according to a standardised dosing schedule. After 2 weeks the clinician and participant will decide on the optimal dose for the remainder of the 4 week trial
89399129|NCT02171702|Experimental|BIBW 2992|dose escalation
89399130|NCT02171702|Experimental|BIBW 2992, fasted|food effect part: maximum tolerated dose of BIBW 2992
88827117|NCT04627441|Experimental|TESS-EES|Transcutaneous Electrical Spinal Stimulation (TESS), used during the first month of training sessions, followed by Epidural Electrical Stimulation (EES) during the final 6-month training period.
88827118|NCT03003715|Experimental|Refractory Trigeminal Neurpathic Pain (TNP) Patients|All patients receive QST prior to PET scan used to obtain baseline measures, then placebo tDCS, followed by QST and Active tDCS, over the course of a 90 minute PET scan; QST is used again to take final measurements 30 minutes later.
88827119|NCT03003715|Experimental|Healthy volunteers|All volunteers receive QST prior to PET scan used to obtain baseline measures, then placebo tDCS, followed by QST and Active tDCS, over the course of a 90 minute PET scan; QST is used again to take final measurements 30 minutes later.
88827120|NCT04054115|Experimental|Treatment Arm|"Baseline cardiac catheterization under GA. (Standard of Care, SOC)~Transfer patient to MRI unit~Baseline MRI~Obtain ABG for pCO2 from existing femoral arterial access.~Repeat pressure measurements with existing catheters at the SVC, RA and Aorta.~MRI phase contrast imaging for flow measurements(SOC).~During the MRI, Alprostadil infusion will be started and titrated to the target dose 0.1mcg/kg/min, provided there is a less than 20% drop in blood pressure from baseline.~Post alprostadil infusion~1ml blood sample taken from existing femoral venous access for prostaglandin level.~Repeat pressure measurements with existing catheters left at the SVC, RA and Aorta.~Repeat MRI flow measurements~7.Return to cath lab if further intervention required. 8.Recovery and monitoring for 4 to 6 hours prior to discharge(SOC)."
88827121|NCT04570267|Experimental|CSL324 (Low dose)|One low dose of CSL324 administered subcutaneously on Day 1
88827122|NCT04570267|Experimental|CSL324 (High dose)|One high dose of CSL324 administered subcutaneously on Day 1
88827123|NCT04570267|Placebo Comparator|Placebo|One dose of placebo administered subcutaneously on Day 1
89177469|NCT02552056|Experimental|CAMH training|"Intervention clinics will receive a CAMH integration package comprising of:~Training PHC workers (midwives, nurses and/or clinical officers) on how to screen and refer for CAMH, based on WHO mhGAP implementation guide.~Support supervision in the clinics to reinforce training and provide on-job support to PHC staff.~Provision of job aids and training materials"
89177470|NCT02552056|No Intervention|No CAMH training|Clinics will continue to provide the standard of care.
89177471|NCT04117919|Experimental|chinese medicine medicated bath|we used the leaf of paper mulberry as chinese medicine medicated bath. Two packs per day ,and the period of treatment will be two month.
89399131|NCT02171702|Experimental|BIBW 2992, fed|food effect part: maximum tolerated dose of BIBW 2992
88827124|NCT04047719||Intent-to-Diagnose Population|All subjects enrolled in the study that have at least one Karius Test with a valid result
88827125|NCT05032807|Experimental|Novel lipid formulation then standard formulation|
88827126|NCT05032807|Experimental|Standard formulation then lipid formulation|
88827127|NCT00002715|Experimental|Combination Chemotherapy (Stanford V)|A combination chemotherapy regimen consisting of mechlorethamine, doxorubicin hydrochloride, vinblastine, vincristine, bleomycin, etoposide and prednisone, administered on a compressed schedule
88827128|NCT02976467|Experimental|Fulacimstat (BAY1142524)|30 patients with left-ventricular dysfunction after acute myocardial infarction
88827129|NCT02976467|Placebo Comparator|Placebo|30 patients with left-ventricular dysfunction after acute myocardial infarction
88827130|NCT02981095|Active Comparator|Bupivacaine|bupivacaine 0.5%, 10cc was administered to surgical field after completion of Thyroidectomy and approximately 15-30 minutes before the extubation.
88827131|NCT02981095|Placebo Comparator|Saline|Saline solution (%0.9 sodium chloride), 10cc was administered to surgical field after completion of Thyroidectomy and approximately 15-30 minutes before the extubation.
88827132|NCT00002721|Experimental|Prostate cancer patients|Prostate cancer patients that have not responded to hormon therapy
88827133|NCT04739345|Active Comparator|Group 1|Non-severe patients should meet all following conditions: (1) Epidemiology history, (2) Fever or other respiratory symptoms, (3) Typical CT image abnormities of viral pneumonia, and (4) Positive result of RT-PCR for SARS-CoV-2 RNA.
88827134|NCT04739345|Placebo Comparator|Group 2|Severe patients should meet at least one of the following conditions: (1) Shortness of breath, RR ≥ 30 times/min, (2) Oxygen saturation (Resting state) ≤ 93%, (3) PaO2/FiO2 ≤ 300 mmHg.
88827135|NCT00002727|Active Comparator|Radiation therapy - conventional fractionation|Radiation therapy - conventional fractionation (70 Gy/2 Gy once per day/7 Weeks) 35 fractions
88827136|NCT00002727|Experimental|Radiation therapy - hyperfractionation|Radiation therapy - hyperfractionation (79.2 Gy/1.2 b.i.d/6.5 weeks) 66 fractions
88827137|NCT01623739|Active Comparator|Type 1 implant placement|Placement of a dental implant: Implant is placed immediately following tooth extraction in one surgical procedure
88827138|NCT01623739|Active Comparator|Type 2 implant placement|Placement of a dental implant: Once the tooth is extracted. The site is left to heal for 4 to 8 weeks before a dental implant is placed during a second surgical procedure.
88827139|NCT01624363||Patients undergoing EUS|Patients undergoing EUS for non-pancreatic treatment.
88827140|NCT04039529|No Intervention|CT-only guided biopsy|The current standard of care for biopsy at Temple University Hospital.
88827141|NCT04039529|Experimental|SCENERGY-guided Biopsy|The use of the SCENERGY to fuse CT and Ultrasound for biopsy
88827142|NCT01625221|Experimental|Magnetic anal sphincter augmentation|The implantable single-use Magnetic Anal Sphincter (FENIX) device consists of a series of titanium beads with magnetic cores that are linked together with independent titanium wires forming an annular shape. The device is supplied sterile and is placed through an open incision.
88827143|NCT02976311|Active Comparator|Misgav-Ladach|cesarean section(C/S) via the modified 'Misgav-Ladach' technique
88827144|NCT02976311|Active Comparator|Pfannenstiel-Kerr|cesarean section(C/S) via the 'Pfannenstiel-Kerr' technique
88827145|NCT01625455|Active Comparator|Aprepitant|Aprepitant will be given orally in a dose of 125mg on day 1 and 80mg daily on each subsequent day for a total of 7 days.
88827146|NCT01625455|Placebo Comparator|Placebo|Matching placebo will be given in place of aprepitant
88827147|NCT05751681|Experimental|Group (A)|will be subjected to progestin primed ovarian stimulation protocol Women in group (A), will be prescribed 20 mg oral dose of dydrogesterone (Duphaston, Abbott) from the 2nd day of the cycle and continued until the trigger day. Transvaginal follicular monitoring will be done for all patients starting the 6th day of cycle.
88827148|NCT05751681|Active Comparator|group (B)|Gonadotropin Releasing Hormone Antagonist Protocol when the size of dominant follicles reaches 12-13 mm, 0.25 mg of cetrotide (Merck-Serono Germany) will be injected subcutaneously daily and continued until the day of trigger shot.
88827149|NCT02976623|Other|feedback group|"this group will receive the intervention metric-based feedback training on their performance. this will be based on validated metrics and errors, a trained investigator will deliver this feedback. It will be accompanied by deliberate practice"
88827150|NCT02976623|No Intervention|control group|"this control group will receive a standard type feedback on their performance no intervention. It will be delivered by a consultant anaesthetist who will be instructed to deliver feedback as they ordinarily do during their clinical practice"
88827151|NCT01625923|Experimental|Olanzapine|An open-label pilot study of 20 consecutive subjects ages 18 - 70 with documented delayed gastric emptying within the past 2 years and history of nausea, vomiting, bloating, anorexia, early satiation, post-prandial fullness, and weight loss for at least 6 months without structural or organic cause will be enrolled.
88827152|NCT00002745|Experimental|aminocamptothecin|aminocamptothecin
88827153|NCT04722185|Experimental|Evaluation of the Veriton SPECT/CT system|To determine if the Veriton system can achieve equal or better image quality than a standard SPECT/CT system.
88827154|NCT04721639|Experimental|The experimental intervention (Sphinx Yoga Therapy)|In this group, participants will be intervened with Sphinx Yoga therapy which will take place in a conserved therapy center of Koohi Goth Hospital. This stretching exercise session will take place in the afternoon and for a duration of 10 minutes followed by 30 minutes therapy session five times per week (total 12 weeks).
88827155|NCT04721639|No Intervention|The control intervention (Usual Care)|In this Group, participants won't be receiving any intervention and provided with the usual care.
88827156|NCT00002757|Active Comparator|Group A|All resected stage I and Abdominal stage II only. All Group A patients will be treated with two cycles of COPAD and will be followed in a confirmatory study of the current result of nearly 100% cure rate.
89000610|NCT00200148|Active Comparator|2|standard intraoperative management
89000611|NCT02236156|Experimental|1% SPL7013 Gel|Inserted in to the vagina on alternate days (i.e. every other day) for 16 weeks
89000612|NCT02236156|Placebo Comparator|Placebo Gel|Inserted in to the vagina on alternate days (i.e. every other day) for 16 weeks
89530252|NCT02455765|Experimental|co-ingest high dose of amino acid|Subjects will receive 136 ml of amino acid mixture together with white rice
89000613|NCT00177086|Experimental|Alfuzosin|
89177472|NCT04117919|Active Comparator|control group|Topical steroids
89533971|NCT01702883|No Intervention|Control|Randomization occurs after enrollment survey has been completed. This group will not receive the internet intervention for the twelve months. They will be asked to complete the final survey.
89533972|NCT01702883|Experimental|Intervention Group A|Randomization occurs after enrollment survey has been completed. Upon secondary randomization at week eight, this group will continue to receive weekly internet surveys for the entire twelve months. They will be asked to complete the final survey.
89533973|NCT01702883|Experimental|Intervention Group B|Randomization occurs after enrollment survey has been completed. This group will complete weekly internet surveys for eight weeks. Upon secondary randomization at week eight, this group will begin to receive monthly internet surveys. They will be asked to complete the final survey.
89177473|NCT04108338||CCRT-randomized clinical trial|Trial patients receiving CCRT
89177474|NCT04108338||CCRT-real-world database|Patients receiving CCRT from real-world database
89177475|NCT04108338||IC+CCRT-randomized clinical trial|Trial patients receiving IC+CCRT
88827157|NCT00002757|Active Comparator|Group B|Non resected stage I & II, stage III & st IV (CNS - ve, BM < 25%). Patients with bulky disease are at risk from metabolic complications secondary to tumor lysis syndrome. Vigorous measures should be taken to minimise the risk of this. Prior to any chemotherapy being administered intravenous hydration fluids should be given run at a rate of 3000 mls/m2/day. Alkalinisation may be necessary Pay close attention to fluid balance and continue hydration fluids after the administration of COP for as long as the risk of tumour lysis persists.
88827158|NCT00002757|Active Comparator|Group C|Bone marrow > 25% but CNS negative Patients with bulky disease are at risk from metabolic complications secondary to tumor lysis syndrome. Vigorous measures should be taken to minimize the risk of this. Intravenous hydration fluids should be given prior to chemotherapy. Alkalinisation may be necessary. Monitor fluid balance and continue hydration fluids after the administration of COP for as long as the risk of tumor lysis persists
88827159|NCT02976779|Experimental|OWC MGC cream|Cannabis based topical cream 3% CBD and 3% THC. The cream was designed to treat Psoriasis . The cream will be applied twice daily.
88827160|NCT02976779|Placebo Comparator|OWC Control Cream|Carrier cream. CBD and THC were taken out from the formulation. The cream will be applied twice daily.
88827161|NCT05751525||Early SU treatment|Patients with permanent neonatal diabetes (PNDM) due to the V59M mutation in the KCNJ11 gene who commenced sulfonylurea therapy in the first six months of life.
88827162|NCT05751525||Late SU treatment|Patients with permanent neonatal diabetes (PNDM) due to the V59M mutation in the KCNJ11 gene who commenced sulfonylurea older than the age of 6 months.
88827163|NCT02230579|Experimental|Cohort SAD1 Fasted|Five fasted cohorts will receive a single, ascending dose of MMV390048. The starting dose will be 5mg. Cohort SAD6 will receive a single dose in a fed state
88827164|NCT02230579|Experimental|Cohort SAD2 Fasted|Five fasted cohorts will receive a single, ascending dose of MMV390048. The starting dose will be 5mg. Cohort SAD6 will receive a single dose in a fed state
88827165|NCT02230579|Experimental|Cohort SAD3 Fasted|Five fasted cohorts will receive a single, ascending dose of MMV390048. The starting dose will be 5mg. Cohort SAD6 will receive a single dose in a fed state
88827166|NCT02230579|Experimental|Cohort SAD4 Fasted|Five fasted cohorts will receive a single, ascending dose of MMV390048. The starting dose will be 5mg. Cohort SAD6 will receive a single dose in a fed state
88827167|NCT02230579|Experimental|Cohort SAD5 Fasted|Five fasted cohorts will receive a single, ascending dose of MMV390048. The starting dose will be 5mg. Cohort SAD6 will receive a single dose in a fed state
88827168|NCT02230579|Experimental|Cohort SAD6 Fed|Cohort SAD6, reusing volunteers from one of the previous cohorts, will receive a single dose in a fed state to evaluate the effect of food on the pharmacokinetics and tolerability
88827169|NCT04707053||Intraaxial lesion group|Patients with intraaxial brainstem lesions (lesions located in the brainstem) + experienced brainstem surgery in our department during the study period
88827170|NCT04707053||Extraaxial lesion group|Patients with extraaxial brainstem lesions (lesions close to the brainstem) + experienced brainstem surgery in our department during the study period
88827171|NCT01631071|Experimental|Elderly subjects aged over 60 years|
88827172|NCT01631071|Experimental|Adults from 18 to 60 years old inclusive|
88827173|NCT01631149|Experimental|Deep surgical block|Continuous rocuronium infusion will be used to induce a deep surgical block with post tetanic twitch count of max 2. Rocuronium loading dose = 1.0 mg/kg, followed by 0.6-1.0 mg/kg per hour.
88827174|NCT01631149|Active Comparator|Moderate/normal surgical block|A normal block will be induced by an atracurium bolus dose followed by a mivacurium infusion to induce a train of four count of 1-2.
88827175|NCT05751447|Experimental|Immune cells|Lymph node puncture and/ or bronchoscopy.
88827176|NCT00002787|Experimental|Treatment (vaccine therapy)|Patients receive autologous immunoglobulin idiotype-KLH conjugate vaccine combined with sargramostim SC in weeks 0, 2, 6, and 10 and sargramostim SC QD for three days following each vaccine injection. Some patients also receive aldesleukin SC daily from weeks 2-14.
88827177|NCT01631929|Active Comparator|One bag|IV infusion of fluids, electrolytes and dextrose using one bag
88827178|NCT01631929|Experimental|Two bags|Using 2 bags with different solutions with the same electrolyte content but different dextrose concentration (0% and 10%), administered simultaneously through the same intravenous line.
88827179|NCT01632709|Active Comparator|Sympathetic nerve block of bupivacaine|Sympathetic nerve block of bupivacaine
88827180|NCT01632709|Placebo Comparator|Dry needling at the sympathetic ganglion|Placebo/ Dry needling at the sympathetic ganglion
88827181|NCT01632709|Active Comparator|Neuroma injection of bupivacaine|Neuroma injection of bupivacaine
88827182|NCT01632709|Placebo Comparator|dry needling at the neuroma|Placebo/ dry needling at the neuroma
88827183|NCT04701671||Normal Weight Control, no MRI-scan (30 participants)|Adolescents with a BMI percentile under 85% who are not randomly assigned to undergo MRI scans at baseline and 18-months.
88827184|NCT04701671||Normal Weight Control with MRI-scan (30 participants)|Adolescents with a BMI percentile under 85% who are randomly assigned to undergo MRI scans at baseline and 18-months.
88827185|NCT04701671||Overweight Control, no MRI-scan (30 participants)|Adolescents with a BMI percentile at 85% or higher who are not randomly assigned to undergo MRI scans at baseline and 18-months.
88827186|NCT04701671||Overweight Control with MRI-scan (30 participants)|Adolescents with a BMI percentile at 85% or higher who are randomly assigned to undergo MRI scans at baseline and 18-months.
88827187|NCT04701671||Overweight/Obese Experimental, no MRI-scan (30 participants)|Adolescents with a BMI percentile at 85% or higher, who report loss of control eating episodes and are not randomly assigned to undergo MRI scans at baseline and 18-months.
89177476|NCT04108338||IC+CCRT-real-world database|Patients receiving IC+CCRT from real-world database
89177477|NCT02551510|Active Comparator|Suture|Skin incision closure with standard subcuticular technique
89177478|NCT02551510|Active Comparator|Experimental: Histoacryl®|Skin incision closure with topic skin adhesive Histoacryl®
89177479|NCT00701285|Active Comparator|1|strong statin
88827188|NCT04701671||Overweight/Obese Experimental with MRI-scan (30 participants)|Adolescents with a BMI percentile at 85% or higher, who report loss of control eating episodes and are randomly assigned to undergo MRI scans at baseline and 18-months.
88827189|NCT05729217||Group 1 aged 7-12 years|Group 1 will mainly be primary school students from grade 1 to 6.
88827190|NCT05729217||Group 2 aged 13-15 years|Group 2 will mainly be middle school students from grade 13 to 15.
88827191|NCT05729217||Group 2 aged 16-18 years|Group 3 will mainly be high school students from grade 16 to 18.
88827192|NCT04299425|Experimental|NIRAF Detection Technology +|Parathyroid gland identification will be performed with PTeye using NIRAF detection technology as an adjunctive tool in patients who undergo parathyroidectomy (PTx).
88827193|NCT04299425|No Intervention|NIRAF Detection Technology -|Parathyroid gland identification will be performed with the naked eye of the surgeon without using PTeye - NIRAF detection technology in patients who undergo parathyroidectomy (PTx).
88827194|NCT05751291|Active Comparator|Group A|Group A (PENG block) patients will receive PENG block under ultrasound-guided (USG) guidance using curvilinear low-frequency ultrasound probe (2-5 MHz) will initially be placed in a transverse plane over the Anterior inferior iliac spine ( AIIS ) and then aligned with the pubic ramus by rotating the probe counterclockwise approximately 45 degrees to visualize the Iliopubic Eminence (IPE), the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle. A 22 Gauge needle will be inserted in-plane and the needle tip will be positioned in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. 20 mL of 0.25% bupivacaine will be injected in increments while observing for an adequate fluid spread in this plane.
88827195|NCT05751291|Active Comparator|Group B|"Group B (FIC) patients will receive FIC block under USG guidance using high-frequency linear transducer (6-13 MHz) will be used to identify the femoral artery at the level of the inguinal crease. Immediately lateral and deep to the femoral artery and vein the iliopsoas muscle is overlaid by a hyperechoic fascia iliaca. The femoral nerve is seen lateral to the femoral artery wedged between the iliopsoas muscle and the fascia iliaca.~Maneuvering the transducer laterally helps to visualize the Sartorius muscle covered by its own fascia alongside the fascia iliaca. A line is drawn connecting the anterior superior iliac spine to the pubic tubercle; the needle tip is positioned at lateral third of the line under the fascia iliaca. 20 mL of 0.25% bupivacaine will be injected until it spreads laterally toward the iliac spine and medially toward the femoral nerve."
88827196|NCT04691843|Active Comparator|Standard iron dose|Iron supplementation of 4mg/kg/day will start when infant is on full enteral feedings of 120-150mL/kg/day and at least two weeks old. Iron dosing will be adjusted for weight at weekly intervals to maintain dosing at 4mg/kg/day.
88827197|NCT04691843|Experimental|Early, high-dose iron|Iron supplementation will start at 3mg/kg/day when infant is on enteral feeds of 60mL/kg/day and at least one week old, then increased to 6mg/kg/day when enteral feeds are at 100mL/kg/day. Iron dosing will be adjusted to maintain ferritin level of 70-400ng/mL. At 36 weeks corrected age, iron supplementation will be adjusted to the dose routinely used for preterm infants.
88827198|NCT04684901|No Intervention|Standard of Care Group|Standard of Care - No AlloWrap used during surgery
88827199|NCT04684901|Experimental|AlloWrap Group|AlloWrap used in surgery
88827200|NCT01634191|Experimental|Elderly: Apremilast 30 mg|Participants aged 65 to 85 years received a single oral dose of 30 mg apremilast on Day 1.
88827201|NCT01634191|Experimental|Younger: Apremilast 30 mg|Participants aged 18 to 55 years received a single oral dose of 30 mg apremilast on Day 1.
88827202|NCT04005443|Other|PET at 68Ga-NODAGA-RGD|The first PET scan will be performed within a maximum of one month following the initial ophthalmologic assessment including OCT and measurement of visual acuity (M0);
88827203|NCT05751057|Experimental|NSTEMI patients|Patients will undergo CMR before ICA
88827204|NCT00361907|Active Comparator|2|Diabetic patients who meet inclusion criteria will be enrolled to start Pulsatile Intravenous Insulin Therapy on a weekly basis. Baseline testing will be performed and measured against continued testing every twelve months.
88827205|NCT00361907|Placebo Comparator|1|Circulating blood markers will be performed on diabetic control patients at baseline and every twelve months to compare and measure against patients treated with Pulsatile intravenous insulin therapy
88827206|NCT04680377||Participants receiving standard of care durvalumab|Prior to receiving treatment participants will have samples taken from three different sources to test the microbiome bacteria to determine if it will help predict toxicity to the treatment
88827207|NCT05710107|Active Comparator|PENG + LFC Block|The pericapsular nerve group (PENG) block is an ultrasound-guided approach, first described by Giron-Arango et al. for the blockade of the articular branches of the femoral, obturator and accessory obturator nerves that provide sensory innervation to the anterior hip capsule [5,6]. In the PENG block, a low-frequency, curvilinear probe is used to visualize the anterior inferior iliac spine, iliopsoas tendon, and iliopubic eminence. After placing a subcutaneous skin wheel with lidocaine, a blunt regional anesthesia needle is inserted using in-plane ultrasound guidance. The needle is advanced until the tip lies on the lateral and inferior margin of the iliopsoas tendon between the anterior inferior iliac spine (lateral) and iliopubic eminence (deep).
88827208|NCT05710107|Active Comparator|QL Block|The lateral QL block is performed by injecting local anesthetic deep to the transversus abdominis aponeurosis and superficial to the fascia transversalis with direct ultrasound guidance. After completing consent, placing monitors and providing mild sedation, the patient is positioned laterally and the muscular anatomy (external oblique, internal oblique, transverse abdominis, quadratus lumborum and latissimus dorsi muscles) identified. After placing a subcutaneous skin wheel with lidocaine, a blunt regional anesthesia needle is inserted using in-plane ultrasound guidance. Local anesthetic is deposited incrementally with frequent aspiration in the anterolateral border of the quadratus lumborum muscle at the junction of the transversalis fascia, outside the anterior layer of the thoracolumbar fascia and superficial to the fascia transversalis.
88827209|NCT05750901|Other|Treatment Arm|Patients will receive fractional ablative treatment for laxity.
88827210|NCT02975375||Preoperative geriatric consult or assessment|Patients who have a geriatric assessment of consult billed in the 4 months before surgery
88827211|NCT02975375||No Preoperative geriatric consult or assessment|Patients who do not have a geriatric assessment of consult billed in the 4 months before surgery
89000614|NCT00177086|Placebo Comparator|Placebo|
89000615|NCT02235259|Experimental|XG-104 low dose|
89000616|NCT02235259|Experimental|XG-104 intermediate dose|
88827212|NCT05693025|Active Comparator|Standard Implementation (SI)|Participants the Standard Implementation (SI) model complete a 6 week structured Walk with Ease group exercise program designed to build capacity and function in older adults. Sessions are held 3 days a week for an hour each session. Each session includes a 10 minute warmup including strength/flexibility exercises, a 30 minute bout of walking and a 10 minute cool-down including strength/flexibility exercises. Participants complete standard exercises recommended in the base program.
88827213|NCT05693025|Experimental|Enhanced Implementation (EI)|Participants the Enhanced Implementation (SI) model complete the 6 week structured Walk with Ease group exercise program designed to build capacity and function in older adults. Sessions are held 3 days a week for an hour each session. Each session includes a 10 minute warmup including strength/flexibility exercises, a 30 minute bout of walking and a 10 minute cool-down including strength/flexibility exercises. Participants complete personalized exercises prescribed by a licensed Physical Therapist to help reduce potential risks of falling.
88827214|NCT05693025|Active Comparator|Standard Training (ST)|Participants the Standard Training (ST) model receive access to on online portal with weekly tips and education content, goal setting options and a daily tracking system for logging walking and exercises performed. They receive instruction on how to use the portal and are encouraged to use the integrated eBook and resources to supplement the group exercise programming. Weekly video-based lessons provide standard knowledge-based training about how to become more physically active.
88827215|NCT05693025|Experimental|Enhanced Training (ET)|Participants the Enhanced Training (ET) model receive access to on online portal with weekly tips and education content, goal setting options and a daily tracking system for logging walking and exercises performed. They receive instruction on how to use the portal and are encouraged to use the integrated eBook and resources to supplement the group exercise programming. Weekly video-based lessons provide habit-formation training about how to form regular habits for physical activity. Participants are paired with a student 'coach' trained in motivational interviewing skills to provide virtual assistance in maintaining motivation during the programming.
88827216|NCT04266197|Experimental|RT234 0.5 mg Cohort 1|RT234 at a capsule dose strength of 0.5 mg.
88827217|NCT04266197|Experimental|RT234 1.0 mg Cohort 2|RT234 at a capsule dose strength of 1.0 mg.
88827218|NCT05750511||metastatic melanoma|1,000 subjects with metastatic melanoma stage III or IV suitable for systemic treatment from centers of the German Dermatologic Cooperative Oncology Group (DeCOG)
88827219|NCT02975531|Experimental|Simulator's construction|To build the simulator was selected a volunteer (VF) as a model. This volunteer had no complaints of pain or trauma to the cervical region. This region was used to collect the displacement of the skin and cytometry neck.
88827220|NCT02975531|Experimental|Model Features|Thirty-nine volunteers (GT) were selected men and women aged over 18 years without history of trauma in the cervical region in order to determine the characteristics of the model: skin elasticity and cirtometry neck.
88827221|NCT02975531|Experimental|Parameterization technique|Five physiotherapists (GP) with at least 5 years of experience in the technique were selected to perform the technique on the simulator and complete a questionnaire in order to evaluate the texture and skin elasticity, the curvature and size of the cervical spine format. They scored these items from the Likert scale. After evaluation they used the simulator to generate a standard guide training.
88827222|NCT02975531|Experimental|Simulator training|Twenty-six volunteers (GE) were selected, men and women, aged over 18 years without prior knowledge of the technique for simulator training.
88827223|NCT02975531|Experimental|Training Evaluation|A physical therapist (VE) was selected to evaluate the volunteers (GE) before and after training in the simulator.
88827224|NCT02972931||LoViReT|HIV-infected subjects with extremely low or undetectable HIV-1 DNA levels in peripheral blood despite having initiated cART during chronic HIV-1 infection
88827225|NCT02972931||Standard Reservoir Level|HIV-infected subjects who initiated cART during chronic HIV-1 infection and that show standard HIV-1 DNA levels in peripheral blood
88827226|NCT05669313||Adult patients planned for treatment with rivaroxaban|
88827227|NCT04665635|Active Comparator|Rectosigmoid resection|
88827228|NCT04665635|Active Comparator|Rectosigmoid seromuscular tumor shaving|
88827229|NCT00361127|Experimental|CMPD patients|Patients with CMPD with evaluation of ACE I/D polymorphism
88827230|NCT04343963|Active Comparator|Pyridostigmine|Pyridostigmine bromide tablet (60mg P.O. once per day for 14 days)
88827231|NCT04343963|Placebo Comparator|Placebo|Placebo tablet (60mg P.O. once per day for 14 days)
88827232|NCT04248179|Active Comparator|Active|Preoperative Multiple-injection Costotransverse Block (MICB) with three injections of each 10ml of Ropivacaine 5mg/ml corresponding to 3 * 10ml * 5mg/ml Ropivacaine = 150mg Ropivacaine.
88827233|NCT04248179|Placebo Comparator|Placebo|Preoperative Multiple-injection Costotransverse Block (MICB) with three injections of each 10ml of Sodium chloride 9mg/ml corresponding to 3 * 10ml * 9mg/ml Sodium chloride = 189mg Sodium chloride.
88827234|NCT00361517|Experimental|GM test|Twice weekly blood draws from the patients in this arm for serial GM monitoring. They will be given standard antifungal prophylaxis but no antifungal therapy unless two consecutive GM readings are positive.
88827235|NCT00361517|No Intervention|no GM monitoring|in this arm the patients will not have any GM monitoring and they will be given standard antifungal prophylaxis and treatment according to the published guidelines.
88827236|NCT02976233||Acute Respiratory Failure in NIV|
88827237|NCT05749965||Limit indications|Obèse (BMI>30), ACL déficiency, HKA > 10°, flessum >10° [HKA : hop knee angle]
88827238|NCT05749965||Historical indications|Patient with a BMI between 18,5 and 30, HKA <10°, functionnal ACL, no flessum or <5°
88827239|NCT05447507|Active Comparator|Remimazolam|
88827240|NCT05447507|Active Comparator|Dexmedetomidine|
88827241|NCT01634269|Experimental|MDT-2111 TAVI 23 mm|Subjects with small annuli and symptomatic severe AS deemed difficult for surgical intervention.
88827242|NCT01635439|Active Comparator|Propess|Propess insert is a preparation of PGE2 packaged in a hydrogel polymer matrix and designed for slow intravaginal release of 10 mg dinoprostone at a rate of 0.3 mg/h.
88827243|NCT01635439|Active Comparator|Prostin E2|PROSTIN E2 Vaginal Suppository, an oxytocic, contains dinoprostone as the naturally occurring prostaglandin E2 (PGE2)3 mg/suppository.
88827244|NCT05749731||post-COVID-19 patients in geriatric rehabilitation|Patients in European geriatric rehabilitation departments as the result of COVID-19 disease.
88827245|NCT01636063|Experimental|Mifepristone|Subjects will receive 200 mg of capsulized mifepristone orally for the purpose of cervical preparation before surgical abortion
88827246|NCT01636063|Active Comparator|Misoprostol|Subjects will receive 400 mcg of buccal misoprostol for the purposes of cervical preparation.
88827247|NCT05635305|Experimental|BE study|"Cohort 1 (BE) is a four-period, four-sequence, four-treatment crossover BE and food effect study of zoliflodacin granules for oral suspension manufactured by Dr. Reddy's (test product, ZoliDr) and those manufactured by Patheon (reference product, ZoliPa) as a 3 g oral dose under fasting and a [specific] fed condition. This cohort will comprise of approximately 32 subjects (8 healthy subjects per treatment sequence) in 4 x 4 BE treatment arms in fasted and [specific] fed conditions. Healthy subjects will be randomized into 4 parallel treatment sequences to receive sequential Treatments A, B, C, and D in William's Square design pattern where:~Treatment A is ZoliPa fasted~Treatment B is ZoliDr fasted~Treatment C is ZoliPa [specific] fed condition~Treatment D is ZoliDr [specific] fed condition~Based on William's Square design, below treatment sequences will be followed:~A-B-C-D B-A-D-C C-D-A-B D-C-B-A"
88827248|NCT05635305|Experimental|DDI study|This is an open-label, 2-period, 2-treatment, fixed sequence crossover DDI study in healthy subjects. It will investigate PK of zoliflodacin (ZoliPa) in the absence and presence of itraconazole. Approximately 18 subjects will receive ZoliPa on Day 1 under fasting condition. After a washout of 72 hours after dosing of ZoliPa, on Day 4, subjects will receive a 400 mg loading dose of itraconazole followed by 200 mg of itraconazole once daily from Day 5-8. From Day 4 to Day 8, itraconazole will be administered immediately after a full meal. On Day 9, both itraconazole and zoliflodacin (ZoliPa) will be administered under fasting conditions at -1 hours and 0 hours, respectively. Itraconazole will then be administered with food at 24 hours (Day 10) and 48 hours (Day 11) after administration of zoliflodacin (ZoliPa).
88827249|NCT01636297|Experimental|Forced exercise|Exercise on stationary cycle that was controlled by a motor to augment voluntary cycling rate by 35%
88827250|NCT01636297|Experimental|Voluntary Exercise|Exercise on a stationary cycle without motor assistance
88827251|NCT01636297|No Intervention|No Exercise|Participants received no exercise intervention and served as the control group
88827252|NCT01636453|Experimental|Liberty Stent arm|Patients are implanted with the Liberty Stent as an assist to embolic coiling of their wide-neck, saccular, intracranial aneurysms and follow for 12 months
88827253|NCT05749575|Experimental|Chidamide Plus Toripalimab Plus Paclitaxel|Cedaramine: 20mg, twice a week.Toripalimab: 240mg, once in 3 weeks,intravenous.Paclitaxel: 175mg / m2, once in 3 weeks, routine preventive anti-allergy treatment, surgery after 4 cycles of IV infusion.
88827254|NCT05628987||Azoospermia|After an abstinence period of 2-7 days, two basic semen analysis, the absence of spermatozoa
89533974|NCT01702883|Experimental|Intervention Group C|Randomization occurs after enrollment survey has been completed. This group will complete weekly internet surveys for eight weeks. Upon secondary randomization at week eight, the group will not receive any more internet surveys. They will be asked to complete the final survey.
88827255|NCT05628987||Oligozoospermia|After an abstinence period of 2-7 days, the total sperm number <39*10^6 per ejaculate or the sperm concentration < 15 * 10^6 per ml
88827256|NCT05628987||Asthenozoospermia|After an abstinence period of 2-7 days, the progressive motility (PR) < 32%
88827257|NCT05628987||Teratozoospermia|After an abstinence period of 2-7 days, the percentage of morphologically normal spermatozoa <4%
88827258|NCT05628987||Control|After an abstinence period of 2-7 days, the basic semen analysis is normal.
88827259|NCT05749497||NCRT+TME|Neoadjuvant chemoradiotherapy (NCRT) and total mesorectal excision (TME) Interventions
88827260|NCT05623761|Active Comparator|Group 1 - toothpaste containing thermal water of Castera-Verduzan and 1450 ppm Sodium fluoride|Subjects will receive thermal water/sodium fluoride toothpaste (BUCCOTHERM® Sensitive Gums with Fluoride)
88827261|NCT05623761|Active Comparator|Group 2 - toothpaste containing thermal water of Castera-Verduzan|Subjects will receive thermal water toothpaste (BUCCOTHERM® Sensitive Gums Fluoride-Free)
88827262|NCT05598021||Ultrasound assessment|Quantitative comparison between ultrasound images performed in active self-correction and in a spontaneous position
88827263|NCT05598021||RX assessment|Quantitative comparison between radiological images performed in active self-correction and in a spontaneous position
88827264|NCT05749185|Active Comparator|Group H ( high voltage) radiofrequency|
88827265|NCT05749185|Active Comparator|Group S ( standard) radiofrequency|
89000617|NCT02235259|Experimental|XG-104 high dose|
89533975|NCT01692015|Experimental|Diet and nosebleed questionnaire|Participants will only be required to fill in two paper questionnaires, one on dietary history, and one on nosebleed severity.
89356932|NCT05863494|Sham Comparator|Sham|"For visits 1-5 (tDCS treatment visits),The sham group will receive 1 minute from 0.0mA to no more than 0.5mA at the initiation of the treatment after which the current will be turned off. They will still proceed with the full 20 minutes as does the treatment group but no current will be further applied as indicated in the treatment group. They will still receive EEG readings at the indicated 8 seconds after current is applied but will not receive the current. This is to maintain a blind trial. 0.5mA is negligible current but mimics treatment with an initial small tingle."
89356933|NCT05863468|Experimental|ArchSinus implantation|Subjects will undergo unilateral or bilateral in-office middle turbinate medialization and subsequent ArchSinus implantation
89356934|NCT05863455|Experimental|mild sedation and analgesia|Intravenous injection of 0.1ug/kg sufentanil and 0.03mg/kg midazolam for sedation and analgesia before radial artery cannulation.
89356935|NCT05863455|Active Comparator|control|Intravenous injection of an equivalent volume of saline before radial artery cannulation.
89356936|NCT05863429||Individuals who have never been vaccinated against COVID-19|Individuals who have never been vaccinated against COVID-19 and who have applied to the study centers to be vaccinated with TURKOVAC within the scope of the routine vaccination program.
88827266|NCT02975609|Active Comparator|Conventional Fractionated Radiotherapy|The patients enrolled receive firstly 4-6 cycles chemotherapy (platinum-based doublet chemotherapy), and achieve response(stable disease or partial response or complete response). Patients will be randomized into the control group undergoing the conventional fractionated radiotherapy to all metastatic sites and the primary tumor.
88827267|NCT02975609|Experimental|Stereotactic Body Radiation Therapy|The patients enrolled receive firstly 4-6 cycles chemotherapy (platinum-based doublet chemotherapy), and achieve response(stable disease or partial response or complete response). Patients will be randomized into the experimental group undergoing SBRT to all metastatic sites and the primary tumor.
89356937|NCT05863429||Previously primary vaccinated individuals|"Those who have previously received two doses of Sinovac - Coronavac vaccine, who will receive the booster vaccine for the first time as TURKOVAC;~Those who have previously received two doses of the BioNTech Comirnaty vaccine, who will receive the booster vaccine for the first time as TURKOVAC;~Those who have previously received the primary vaccination of Sinovac - Coronavac Vaccine and who have received at least one dose of the booster vaccine of TURKOVAC and have accepted the second booster dose vaccination,~Individuals who have previously received the primary vaccination of the BioNTech Comirnaty Vaccine and who have received at least one dose of the booster vaccine of the TURKOVAC and who have agreed to the second booster dose vaccination."
89533976|NCT01692015|Experimental|Weighed food diary arm|Participants will be required to weigh their food for one week to generate a food dairy, and have a single blood test, in addition to filling in the two paper questionnaires, one on dietary history, and one on nosebleed severity.
88827268|NCT02227693|Experimental|avatrombopag 20-mg|20 mg avatrombopag (1 x 20 mg tablet and 2 x 20 mg matching placebo tablets) once daily on Days 1 through 5
88827269|NCT02227693|Experimental|avatrombopag 40-mg|40 mg avatrombopag (2 x 20 mg tablets and 1 x 20 mg matching placebo tablet) once daily on Days 1 through 5
88827270|NCT02227693|Experimental|avatrombopag 60-mg|60 mg avatrombopag (3 x 20 mg tablets) once daily on Days 1 through 5
88827271|NCT02227693|Placebo Comparator|placebo l|Placebo (3 x 20-mg matching placebo tablets) once daily on Days 1 through 5
88827272|NCT05583981||Observational (interview)|Participants participate in interview over 30-60 minutes.
89356938|NCT05863429||Individuals who have only received TURKOVAC vaccine before|Only individuals who have previously been vaccinated of TURKOVAC will also be invited to be included in the study retrospectively.
89356939|NCT05863416|Active Comparator|Group Saline|Propofol-based total intravenous anesthesia with saline infusion
89533977|NCT01661010||Control|Family members can serve as control group
89533978|NCT01661010||Sex-linked genes|Patients previously identified through outside research or diagnostic labs as having sex-chromosome variants causing deletion/duplication of sex-linked genes or entire sex chromosomes.
89533979|NCT01633021||Diabetes|Self/Family member affected by type-2 diabetes (plus self-referred family-members)
89533980|NCT01633021||Heritable Cancer Screen-Positive|Person who has screened-positive for heritable cancers on genetic tests (plus referred family-members)
88827273|NCT00361985|Experimental|1|Nexium group
88827274|NCT00362063|Experimental|growth hormone|children with proven growth hormone deficiency
89356940|NCT05863416|Experimental|Group Dexmedetomidine|Propofol-based total intravenous anesthesia with dexmedetomidine infusion
89533981|NCT01633021||Sickle Cell (Trait/Disease/Related)|Self/Family member affected by Sickle Cell Trait or Sickle Cell Disease (plus self-referred family-members)
89533982|NCT01621581|Experimental|Single Arm|AAV2-GDNF vector will be delivered to each patient
89533983|NCT01581554||Patients with HBeAg negative chronic hepatitis B|Patients with HBeAg negative chronic hepatitis B who have received a minimum of 4 years of oral nucleoside therapy with a serum HBV DNA level less than 500 IU/ml in the 6 months prior to withdrawal.
88827275|NCT00362063|No Intervention|healthy controls|No growth hormone is given
88827276|NCT00382239|Experimental|Exenatide 5 mcg/exenatide 10 mcg|
88827277|NCT00382239|Experimental|Exenatide 5 mcg/exenatide 5 mcg|
88827278|NCT00382239|Experimental|Exenatide 2.5 mcg/exenatide 2.5 mcg|
88827279|NCT00382239|Placebo Comparator|Placebo/placebo|
88827280|NCT04004845||Pregnant women|We are including only women who are age 18 or over, who have a single baby (not twins), with the baby's head down, and are between 36 weeks 6 days and 42 weeks 0 days of pregnancy.
88827281|NCT04634201|Experimental|Experimental group|
88827282|NCT04634201|Sham Comparator|control group|
89356941|NCT05863403|Experimental|Neuromuscular Training|
89533984|NCT01581554||Patients with HBeAG positive chronic hepatitis B|Patients with HBeAg positive chronic hepatitis B who have received a minimum of 4 years of oral nucleoside therapy with a serum HBV DNA level less than 500 IU/ml in the 6 months prior to withdrawal.
89533985|NCT01568671|Experimental|Healthy older lean white men|White men aged 55-75 years with BMI between 18.5 and 25.0 kg/m2
89000618|NCT02235259|Placebo Comparator|Placebo|Placebo
89000619|NCT00205023|Experimental|A|
89177480|NCT00701285|Active Comparator|2|mild statin
89356942|NCT05863403|Active Comparator|Traditional Exercise|
89356943|NCT05863390|Experimental|McKenzie exercise|
89356944|NCT05863390|Other|Trochanteric belt|
89356945|NCT05863377||Adjuvant Chemotherapy Group|The patients of this group receive adjuvant chemotherapy after surgery.
89356946|NCT05863377||No-Further Treatment Group|The patients of this group only receive regular follow-up without adjuvant therapy.
88827283|NCT05748717||Paediatric patients with sickle cell disease with normal TCD velocity without clinical stroke|Patients in this group will be aged 4 to 16 years with sickle cell anaemia with no prior history of stroke or previous Transcranial Doppler study showing a maximum time-averaged mean velocity of greater than 169 cm/sec, and who have not received a red cell transfusion in the past two months and are considered to be at steady state.
88827284|NCT05748717||Paediatric patients with sickle cell disease with an abnormal TCD velocity (with or without stroke)|Patients in this group will be aged 4 to 16 years with sickle cell anaemia with an abnormal TCD velocity, who have not received a red cell transfusion in the past two months and are considered to be at steady state.
88827285|NCT01636765||All participants|Patients with facial erythema associated with rosacea. There was no intervention in this study.
88827286|NCT01637935||Pioglitazone exposed group|Defined as those patients having filled at least two prescriptions for pioglitazone within a 6-month period. Patients in the pioglitazone group may also have exposure to other diabetic medications
88827287|NCT01637935||Pioglitazone unexposed group|Defined as patients who did not fill at least two prescriptions for pioglitazone within a 6-month period. Patients in the pioglitazone unexposed group may have been exposed to other diabetic medications. This group also included diabetic patients without any diabetic medications.
88827288|NCT05748639|Experimental|Quit Genius - Alcohol|QG-A is a smart phone application targeting alcohol use disorder. QG-A includes standardized cognitive-behavioral therapy in the form of videos, in-app text, audio recordings, and quizzes. The application provides users with information on how to reduce or abstain from alcohol use. Once successfully enrolled in QG-A, a medical provider will evaluate each QG-A participant for appropriateness for pharmacotherapy during an initial 60-minute assessment to confirm an alcohol use disorder diagnosis and collect relevant medical and psychiatric history of the patient. The medical provider will subsequently prescribe oral naltrexone via the QG-A telemedicine platform. A study counselor will provide manualized CBT-based support to QG-A participants via the video telemedicine function, as well as asynchronously via the in-app chat function.
88827289|NCT05748639|Active Comparator|Medical Management|Medical management comprises standard care for alcohol use disorder. A medical provider, upon evaluation of each participant for appropriateness for pharmacotherapy, will subsequently prescribe naltrexone via a non-QG-A telemedicine platform, according to standard clinical practice. Participants will meet with the medical provider monthly over the 6-month course of treatment. In MM, participants receive dose adjustments and brief medical management as normally provided to patients in office-based settings (session duration is 15-20 minutes). The medical provider will deliver education about the study medication and answer any participant questions. Subsequent 15-20 minute sessions will review drinking patterns, overall functioning, medication adherence, and adverse effects. Participants who discontinue medication because of intolerance can continue to attend monthly medical management sessions to support abstinence.
88827290|NCT02981017|No Intervention|Control|Subjects within the control arm will undergo the Draf III/Endoscopic Modified Lothrop procedure to address their sinus disease. At the end of the procedure, no Cook Biodesign Porcine intestinal submucosal graft will be used to cover the operative site. Light nasal packing will be placed in the nasal cavity for hemostasis. No placebo will be utilized.
88827291|NCT02981017|Experimental|Cook Biodesign|Subjects within the experimental group will undergo the Draf III/Endoscopic Modified Lothrop procedure to address their sinus disease. At the end of the procedure, a small piece of Cook Biodesign porcine intestinal submucosal xenograft will be used to cover the exposed bone of the operative site along the frontal beak. It will be bolstered with light nasal packing to keep the graft in place during healing.
88827292|NCT03003559|Experimental|High flow nasal cannula|High flow nasal cannula(OptiflowTM); Flow 25-60 L/min is set according to patients' comfort; FiO2 is adjusted to maintain peripheral capillary oxygen saturation(SpO2) 90-95%; temperature is set at 37.
88827293|NCT03003559|No Intervention|Nasal cannula|Nasal cannula;set oxygen flow to keep SpO2 90-95%
88827294|NCT04214561||SB group|Patients diagnosed with SB.
88827295|NCT04214561||Healthy controls|Patients without diagnosed SB.
88827296|NCT01640197|Placebo Comparator|Placebo|Methyl Cellulose administered in identical capsules as the active.
88827297|NCT01640197|Active Comparator|500mg resveratrol|Transmax from biotivia. 500mg resveratrol (98% purity) with 10mg piperine per capsule. 1 capsule taken daily.
88827298|NCT04207151|No Intervention|Standard of Care|Participants will receive HIV and STI testing, clinical monitoring, client centered counseling and PrEP prescriptions as standard of care, this includes scheduled visits every three months.
89177481|NCT05617638|No Intervention|Control Group|The control group will not have access to VR.
89356947|NCT05863338|Experimental|Intervention Group|Data collection tools were applied face to face. Patient education was carried out in the polyclinic. A training booklet was given at the end of the training. Afterwards, patients were called once a week by telephone for 12 weeks. The patients were followed up by the nurse over the phone and counseling was provided to the patients. Patients were able to call the research nurse when needed. Interim evaluation was made at the 12th week. Data collection tools were applied face-to-face in the outpatient clinic. Patients 13-24. Between weeks, 12 more phone calls were made, once a week. The patients were followed up by the nurse by telephone, and the patients continued to receive counseling services. Patients were able to call the research nurse when needed. At the end of the 24th week, the research forms were applied face to face in the outpatient clinic. The research has finished.
89530253|NCT02455765|Experimental|pre-load low dose15 min|Subjects will receive 68 ml of amino acid mixture 15 min before consumption of white rice
89530254|NCT02455765|Experimental|pre-load low dose 30 min|Subjects will receive 68 ml of amino acid mixture 30 min before consumption of white rice
89530255|NCT02455765|Experimental|pre-load high dose 15 min|Subjects will receive 136 ml of amino acid mixture 15 min before consumption of white rice
89530256|NCT02455765|Experimental|pre-load high dose 30 min|Subjects will receive 136 ml of amino acid mixture 30 min before consumption of white rice
89530257|NCT03254875|Experimental|Intervention|Individually tailored nurse navigation
89356948|NCT05863338|No Intervention|Control Group|Individuals meeting the sample specifications were included in the control group in accordance with the order of numbers in the lists created by randomly assigning numbers. Data collection tools were applied face to face. Routine outpatient follow-ups continued. Interim evaluation was made at the 12th week. In the interim evaluation, data collection tools were applied face to face. Then, routine outpatient follow-up between 13 and 24 weeks continued. At the end of the 24th week, data collection tools were applied face to face. The patients were educated in the outpatient clinic. A training booklet was given at the end of the training. The research has been terminated.
89356949|NCT05863273||Apremilast|Dosage of Apremilast（Otezla®） from 10mg qd, titrate to recommended dosage of 30 mg BID，recommended by specification.
89356950|NCT05863260||Intervention|Paclitaxel 135mg / m2d1 + cisplatin 60mg / m2d1 (cisplatin resistance or cisplatin intolerance changed to carboplatin AUC = 5d1), q3w × 4 and Standard IMRT and radiotherapyTislelizumab 200mg, IV, q3w, the day before radiotherapy
89356951|NCT05863221|Experimental|Group 1|ZYNRELEF® up to 200 mg/ 6mg ( 7ml vial) via instillation at all incision sites in addition to 30 ml of 0.5% Ropivacaine + 10mg dexamethasone. Postoperatively, intermittent IV acetaminophen will be administered as per need till discharge.
89533986|NCT01568671|Experimental|Healthy young lean black men|Black men aged 18-35 years with BMI between 18.5 and 25.0 kg/m2
89533987|NCT01568671|Experimental|Healthy young lean white men|White men aged 18-35 years with BMI between 18.5 and 25.0 kg/m2
89533988|NCT01568671|Experimental|Healthy young lean white women|White women aged 18-35 years with BMI between 18.5 and 25.0 kg/m2
88827299|NCT04207151|Experimental|Pre- and Post- SNAPS intervention|In addition to the standard of care treatment, approximately twenty subjects will be selected for interview pre- and post-SNAPS intervention to assess PrEP facilitators and barriers for uptake. Participants of interest include cis- and trans-women, for which there is limited data regarding PrEP and HIV prevention.
88827300|NCT03003091|Experimental|Needs-based patient education|The participants received self-administered questionnaire to choose what topics they wanted to know and how much information they would like to know. After completing the questionnaire, the participants submit the questionnaire to their physicians (investigators). The surgeon then provided patient education based on participant needs.
88827301|NCT03003091|Active Comparator|Traditional patient education|The participants received all structured information
88827302|NCT02975687|Experimental|Arm A|"CD19 CAR T cells will be administered by i.v. injection as a using a split dose (total dose of 5x10^6/kg-5x10^7/kg) approach to dosing:10% on day 0, 30% on day 1 and 60% on day 2."
88827303|NCT04610411|Experimental|surgical navigation|standard surgical method except for navigated instrumentation of pedicle screws and rod implants
88827304|NCT04610411|Active Comparator|standard surgical method|standard surgical method established at the institution
88827305|NCT04607915|Experimental|Intervention for TECC Model|
88827306|NCT01641445|Active Comparator|Topiramate|Topiramate (200 mg) taken orally daily
88827307|NCT01641445|Placebo Comparator|Sugar pill|"Placebo (sugar pill) taken orally daily"
88827308|NCT05741151|Experimental|PET-Neck Parkinsonian patients|Brain and neck PET-CT with 68Ga-PSMA scan would be administered
88827309|NCT01641835||Normals|No eye disease.
88827310|NCT04185311|Experimental|Treatment (talimogene laherparepvec, nivolumab, ipilimumab)|Participants receive talimogene laherparepvec intratumorally on days 1, 22, and 36, nivolumab IV over 60 minutes on days 1, 15, 29, and 43, and ipilimumab IV over 90 minutes on days 1 and 43 in the absence of disease progression or unacceptable toxicity.
88827311|NCT05513937|Active Comparator|Nebivolol|Single dose Phase (4 weeks): patients will be treated with Nebivolol 5mg. Combination Phase (8 weeks) uncontrolled patients will be treated with the extemporaneous combination of Nebivolol 5mg and Amlodipine 5mg for 4 weeks. Amlodipine 10mg will replace Amlodipine 5mg in uncontrolled patients for further 4 weeks while controlled patients with Nebivolol 5mg/Amlodipine 5mg will continue with the same therapy.
88827312|NCT05513937|Active Comparator|Amlodipine|Single dose Phase (4 weeks): patients will be treated with Amlodipine 5 mg. Combination Phase (8 weeks) uncontrolled patients will be treated with the extemporaneous combination of Nebivolol 5 mg and Amlodipine 5mg for 4 weeks. Amlodipine 10mg will replace Amlodipine 5mg in uncontrolled patients for further 4 weeks while controlled patients with Nebivolol 5mg/Amlodipine 5mg will continue with the same therapy.
88827313|NCT01642147|Experimental|Patients undergoing craniotomy|"Patients undergoing craniotomy who are scheduled for selective supratentorial tumor removal surgery will be randomly chosen and recruited.~Transcranial Doppler (TCD) measures,jugular venous bulb catheterization, radial artery catheterization, and tumor removal surgery under general anesthesia will be performed."
88827314|NCT01642147|Active Comparator|Patients undergoing abdominal surgery|Randomly chosen patients undergoing selective abdominal surgery. Transcranial Doppler (TCD) measures,radial artery catheterization, and major abdominal surgery under general anesthesia will be performed.
88827315|NCT04584749|Experimental|LIDOCAINE|"2% lidocaine will be administered as a bolus during anesthetic induction equivalent to 1.5 mg / kg of lidocaine. After induction, an intravenous infusion will be started at 0.1 ml / kg / h of the study preparation, equivalent to 2mg / kg / h of lidocaine.~The study medication will be prepared in a 20 ml syringe for induction and two 50 ml syringes for anesthetic maintenance containing 2% Lidocaine as assigned by the patient. The syringes prepared by the pharmacy will be identical in all cases, with a label specifying the title of this test and the identification number of the patient"
88827316|NCT04584749|Placebo Comparator|PLACEBO|"0.9% physiological saline will be used as placebo, and it will be administered as a bolus during anesthetic induction . After induction, an intravenous infusion will be started at 0.1 ml / kg / h of the study preparation, equivalent to 2mg / kg / h of lidocaine/placebo.~The study medication will be prepared in a 20 ml syringe for induction and two 50 ml syringes for anesthetic maintenance containing Physiological Serum as assigned by the patient. The syringes prepared by the pharmacy will be identical in all cases, with a label specifying the title of this test and the identification number of the patient"
88827317|NCT01643707||Phase I|Control
89533989|NCT01568671|Experimental|Healthy young white men with obesity|White men aged 18-35 years with BMI between 30.0 and 40.0 kg/m2
89533990|NCT01568658||Affected probands|Affected probands over age 4 weeks and onwards with known or suspected inherited neurological disorders of childhood onset
89533991|NCT01568658||Healthy volunteers|Healthy volunteers will be recruited for the imaging procedures in order to establish baseline and age-range matched data on the healthy, maturing muscle, spinal cord volume and dynamic breathing
88827318|NCT01643707||Phase II|Treatment
88827319|NCT02976155|No Intervention|Pre-intervention|enteral nutrition according routine practice
88827320|NCT02976155|Experimental|Post-intervention|The intervention in this arm is the application of a standard enteral nutrition protocol
88827321|NCT01644331|Experimental|Tolvaptan|Fixed-dose IV furosemide (1 x total daily oral dose given intravenously in divided doses Q12 hours OR 40 mg IV Q12 hours, whichever is greater) + oral Tolvaptan (given at 0, 24 and 48 hours)
88827322|NCT01644331|Placebo Comparator|Placebo|Fixed-dose IV furosemide (1 x total daily oral dose given intravenously in divided doses Q12 hours OR 40 mg IV Q12 hours, whichever is greater) + oral placebo (given at 0, 24 and 48 hours)
88827323|NCT05734755|Experimental|The COMB group|Participants in The COMB group will be grounded on the HAPA model and piloted by the team. It consists of three phases with 10 face-to-face hourly sessions nested with weekly telephone calls to enhance the participants' adherence to dietary behavioral change. And will be group-based, and offered weekly for about 60 minutes during the execution phase (a total 20 sessions from weeks 4-24). The combination of resistance and aerobic exercises can improve muscle quantity and strength as well as reduce body fat in people with sarcopenic obesity, and will be adopted in this study.
88827324|NCT05734755|Experimental|The EXER-only group|Participants in The EXER-only group will be group-based, and offered weekly for about 60 minutes during the execution phase (a total 20 sessions from weeks 4-24). The combination of resistance and aerobic exercises can improve muscle quantity and strength as well as reduce body fat in people with sarcopenic obesity, and will be adopted in this study.
88827325|NCT05734755|Experimental|The IDBC-only group|Participants in The IDBC-only group will be grounded on the HAPA model and piloted by the team. It consists of three phases with 10 face-to-face hourly sessions nested with weekly telephone calls to enhance the participants' adherence to dietary behavioral change. And attend centre-based health talks about the management of different health issues with the exception of sarcopenic obesity.
88827326|NCT05734755|No Intervention|The Control Group|Participants in The Control Group will attend centre-based health talks about the management of different health issues with the exception of sarcopenic obesity. As the purpose of the health talk is to control the group interactive effect in exercise training, the group size, and the frequency and the time of the health talks will be similar to those offered in the exercise programme for the COMB and EXER-only groups.
88827327|NCT04558151|Experimental|Training arm|Patients perform inspiratory muscle training containing of 30 breaths twice a day for 14-18 days before surgery.
88827328|NCT04558151|No Intervention|Control arm|No preoperative inspiratory muscle training
89177482|NCT05617638|Active Comparator|Intervention Group|Participants in the intervention group will use VR for 20 minutes for 2 consecutive days.
89177483|NCT02613767||Obese|"BMI >30 kg/m2, Protein meal,~L-[ring 13C6]Phenylalanine infusion"
89177484|NCT02613767||Overweight|"BMI >25 and < 30 kg/m2, Protein meal,~L-[ring 13C6]Phenylalanine infusion"
89177485|NCT02613767||Healthy-Weight|"BMI >18 and < 25 kg/m2, Protein meal,~L-[ring 13C6]Phenylalanine infusion"
89177486|NCT02604498|Experimental|Liver function impaired|Subject with Moderate Impaired Hepatic Function. Nemonoxacin Malate Capsules 500mg single dose oral.
89177487|NCT02604498|Experimental|Healthy Subjects|Healthy volunteers. Nemonoxacin Malate Capsules 500mg single dose oral.
89177488|NCT00700037|Experimental|1|Atorvastatin 20mg
89177489|NCT00700037|Active Comparator|2|atorvastatin 5mg
89177490|NCT00808522|Experimental|hCG|Patients at high risk for breast cancer will be treated with hCG
89177491|NCT00808522|No Intervention|routine care|Patients receiving routine care will be followed
89177492|NCT00654004||Subjects|Subjects are patients with a long-chain fatty acid oxidation disorder including CPT2, VLCAD, TFP or LCHAD deficiency.
89177493|NCT00654004||Controls|Subjects do not have a fatty acid oxidation disorder.
89177494|NCT00815542|Active Comparator|double balloon catheter|Cervical ripening by double balloon catheter
89177495|NCT00815542|Placebo Comparator|prostaglandins E2|cervical ripening using prostaglandins E2
89177496|NCT00791778|Experimental|Sorafenib (Nexavar, BAY43-9006)|Participants received 2 sorafenib tablets (200 mg each) per oral twice daily (bid)
89177497|NCT00791778|Placebo Comparator|Placebo|Participants received 2 matching placebo tablets per oral twice daily
89177498|NCT04108260|Experimental|Single arm_Idelvion treated|
89177499|NCT00798174|Experimental|Standard configuration vs. azygos coil|"The DFT with the standard Superior Vena Cava (SVC) coil vs. DFT with the azygos coil.~In this crossover study, each patient serves and own control, with defibrillation testing performed with and with the azygos coil"
89177500|NCT04113642||single group|healthy subjects
89177501|NCT04113174||SAIL databank|Anonymised records from around 5 million people in Wales, with linked primary care, ED attendance, hospital admissions, outpatient data, social care, Welsh Care Homes Dataset, and ONS mortality data. SAIL includes eFI summary scores and individual components.
89177502|NCT04113174||ResearchOne|Nationally representative, de-identified data from around 6 million primary care electronic health records on the TPP SystmOne clinical system. ResearchOne includes eFI summary scores and individual components.
89177503|NCT04113174||Leeds Data Model|Anonymised, linked primary, secondary, community and social care data from 810,000 patients across 108 practices in Leeds, including eFI summary scores and individual components.
89177504|NCT04113174||CARE75+|National prospective cohort study (n≈1,200) collecting detailed sociodemographic information, frailty measures (including eFI scores), simple instruments suitable for use in primary care (e.g. gait speed, timed-up-and-go test; activities of daily living; informal care; loneliness), and key outcomes at six, 12, 24 and 48 months. CARE75+ is a very rich dataset that provides a highly efficient method to investigate how simple instruments might augment eFI performance.
89177505|NCT02604576|Experimental|Group 1|FDC Bromopride 10 mg and Simethicone 80 mg
89177506|NCT02604576|Active Comparator|Group 2|Bromopride 10 mg (Digesan ® - Sanofi Aventis)
89177507|NCT04110600|Active Comparator|Coffee group|"This group includes 300 patients who underwent cesarean delivery under spinal anaesthesia And will have 100 ml of coffee after 2,4 and 6 hours~Then outcomes will be assessed as per time frame"
88827329|NCT02975765|Experimental|Piezosurgery|Piezosurgery-assisted corticotomy will be performed to enhance teeth alignment
88827330|NCT02975765|No Intervention|Traditional method|No intervention is going to be applied to the patients in this group.
88827331|NCT01646671|Experimental|LCZ696 200 mg|All participants were started on LCZ696 200 mg once daily on day 1. Participants who achieved mean sitting diastolic blood pressure (msDBP) of < 100 mmHg and mean sitting systolic blood pressure (msSBP) of < 160 mmHg at week 2 or a msDBP < 90 mmHg and msSBP < 140 mmHg at or after week 4 and for the duration of the study continued at 200 mg LCZ696 once daily.
88827332|NCT01646671|Experimental|LCZ696 400 mg|All participants were started on LCZ696 200 mg once daily on day 1. For participants who did not achieve mean sitting diastolic blood pressure (msDBP) of < 100 mmHg and mean sitting systolic blood pressure (msSBP) of < 160 mmHg at week 2 or a msDBP < 90 mmHg and msSBP < 140 mmHg at or after week 4, and did not have any signs of safety concerns, the LCZ696 dose was increased to 400 mg once daily.
88827333|NCT01646671|Experimental|LCZ696 400 mg plus other hypertension (HTN) medications|All participants were started on LCZ696 200 mg once daily on day 1. For participants who received LCZ696 400 mg and did not achieve msDBP < 90 mmHg and msSBP < 140 mmHg at or after week 4 and had no signs of safety concerns, another class of antihypertensive drugs (other than Angiotensin II receptor blockers or Angiotensin Converting Enzyme Inhibitor (ACEi) could be added, or the dose of concomitant antihypertensive drugs could be increased as per the package insert. Participants who received LCZ696 400 mg once daily did not change their dose for the remainder of the study.
88827334|NCT03561259|Experimental|131I-MIBG|131I-MIBG
88827335|NCT03561259|Experimental|131I-MIBG + Vorinostat|131I-MIBG + Vorinostat
88827336|NCT04449393|Experimental|Emdogain® FL|Non-surgical periodontal therapy in terms of scaling and root planing will be applied at sites with remaining periodontal pockets at reevaluation. EDTA gel will be applied for 2 minutes in the respective pockets, followed by rinsing with saline, drying and application of Emdogain® FL.
88827337|NCT04449393|Placebo Comparator|Control group|Non-surgical periodontal therapy in terms of scaling and root planing will be applied at sites with remaining periodontal pockets at reevaluation, followed by rinsing with saline.
88827338|NCT03002857|Experimental|Classical LMA|Classical LMA insertion: LMA-C insertion was done in supine position and with a standard gel pillow with the patient's head on following anesthesia induction. The insertion was verified with the manual ventilation of the patient and end-tidal carbon dioxide pressure waveform.
88827339|NCT03002857|Experimental|I-gel|I-gel LMA insertion: The I-gel LMA insertion was done in supine position and with a standard gel pillow with the patient's head on following anesthesia induction. The insertion was verified with the manual ventilation of the patient and end-tidal carbon dioxide pressure waveform.
88827340|NCT03002857|Experimental|The Baska Mask®|The Baska Mask® insertion: The Baska Mask® insertion was done in supine position and with a standard gel pillow with the patient's head on following anesthesia induction. The insertion was verified with the manual ventilation of the patient and end-tidal carbon dioxide pressure waveform.
88827341|NCT03003013|Active Comparator|Biphasic Bone Graft With Autologous Platelet-rich Fibrin|Patients will undergo complete removal of the cystic cavity with the application of SYMBIOS biphasic bone graft material in combination with PRF in the cystic cavity
88827342|NCT03003013|Active Comparator|Biphasic Bone Graft Material only|Patients will undergo complete removal of the cystic cavity with the application of SYMBIOS biphasic bone graft material without PRF in the cystic cavity
88827343|NCT03002935|Experimental|BPM31510 Oral Nanosuspension 4%|Study subjects will self-administer 80 mL (4 vials of 20 mL) of oral BPM31510 (Ubidecarenone, USP; 40 mg/mL) nano-suspension 3 times daily every 4 to 6 hours for a total daily dose 9600 mg/day of BPM31510 for 14 consecutive days. The last study dose (morning dose only) is administered at the clinic on Day 15.
88827344|NCT01647217|Experimental|Terpinen-4-ol Treatment Arm|8 patients will be randomized into the Study Group and will be subdivided into 2 subgroups (3 / 5 patients) according to the treatment regimen (once or twice per day). Changes in the mite counts will be correlated with changes in symptoms and signs.
88827345|NCT01647217|Placebo Comparator|Placepo Pads Contol Arm|9 patients will be randomized into the control group and will be treated with placebo pads. They will be divided into 2 subgroups (5 / 4 patients) according to the frequency (once or twice per day). Changes in the mite counts will be correlated with changes in symptoms and signs.
88827346|NCT05490225|Experimental|Ark Implantation|Single arm study. Depending on the clinical needs of the patient, the physician will decide if a single return Ark is needed (ex. easily cannulatable arterial pull site but the venous return access site is poorly accessible for cannulation) or two Arks (both arterial pull and venous return are poorly accessible for cannulation).
88827347|NCT03002779|Experimental|JNJ-53718678|
88827348|NCT03788291|Experimental|Acalabrutinib and Rituximab treatment|"Rituximab: administered 2 times weekly for 6 cycles. Initial dose day 1: 50 mg IV, Then 50 mg SQ thereafter.~Acalabrutinib: 100 mg po BID starting on day 8 of cycle 1.~Patients who have attained a complete response who are also MRD negative at cycle 12 will undergo a BM biopsy to confirm CR and MRD negatively. If confirmed, the patient will stop therapy and be followed until disease progression.~Patients not in a MRD negative CR, will continue acalabrutinib.~Repeat response assessments (CTs, MRD testing in blood) will be performed at 24 cycles of therapy for those continuing on acalabrutinib. If both negative the patient will undergo a BM biopsy to confirm CR and MRD negativity. If confirmed, the patient will stop therapy and be followed until disease progression. In the absence of a CR or if MRD +, acalabrutinib may be continued until disease progression, unacceptable toxicity or physician/patient discretion."
88827349|NCT05488977|Experimental|Exercise training|8 weeks of supervised high-intensity interval training (HIIT) that is 4×4 min intervals at 85-95% of maximal heart rate (HRmax) with 3-minute active breaks (~60 % HRmax) in between intervals, twice a week) on treadmills. In addition, the participants will perform exercise once a week on their own following the correct exercise intensity.
88827350|NCT05488977|No Intervention|Control|No intervention. Carry on their normal life.
88827351|NCT03002467|Experimental|PESI score|treating physicians must formally calculate PESI and report in the clinical record form* each day of hospitalization on top of routine clinical practice (standard care)
88827352|NCT03002467|No Intervention|Standard care|standard care (i.e. no formally calculation of PESI on top)
89530258|NCT03254875|No Intervention|Control|Usual care
89530259|NCT03249337|Active Comparator|Glanatec(R) 3 times a day|
88827353|NCT03784625|Experimental|therapeutic dose activity (level 1)|[131]ICF01012 at a therapeutic dose of 800 MBq/m² , single dose at D11 (intravenous administration)
88827354|NCT03784625|Experimental|therapeutic dose activity (level 2)|[131]ICF01012 at a therapeutic dose of 1600 MBq/m² , single dose at D11 (intravenous administration)
88827355|NCT03784625|Experimental|therapeutic dose activity (level 3)|[131]ICF01012 at a therapeutic dose of 2700 MBq/m² , single dose at D11 (intravenous administration)
88827356|NCT03784625|Experimental|therapeutic dose activity (level 4)|[131]ICF01012 at a therapeutic dose of 4000 MBq/m² , single dose at D11 (intravenous administration)
88827357|NCT01651195|Active Comparator|Probiotic tablet (military recruits)|Lactobacillus rhamnosus 8-9 x 10 -9 2 x 2 3 weeks
88827358|NCT01651195|Placebo Comparator|Placebo tablet (military recruits)|Crystalline cellulose 2 x 2, 3 weeks
88827359|NCT01651195|Active Comparator|Probiotic tablet (reserve officer candidates)|Lactobacillus rhamnosus 8-9 x 10 -9 2 x 2 3 weeks
88827360|NCT01651195|Placebo Comparator|Placebo tablet (reserve officer candidates)|Crystalline cellulose 2 x 2, 3 weeks
88827361|NCT04744961||Surgical site infections|
88827362|NCT04744961||Normal would healing|
88827363|NCT04593303|Active Comparator|Internal iliac artery group|Bilateral internal Iliac artery ligation will be done followed by urinary bladder dissection then bilateral uterine artery ligation then manual removal of the placenta then cervico isthmic compression suture. (holding the upper border of the cervix by 4 Allis's forceps then suturing the cervix with the anterior uterine wall using continuous suture), Nelaton catheter18 gauge or Hegar's dilator will be inserted inside cervical canal during Cervico isthmic tamponed suture to ensure patency of cervical canal. .
88827364|NCT04593303|Other|No internal iliac artery group|Bladder dissection then bilateral uterine artery ligation then cervico isthmic suture without internal iliac artery ligation
88827365|NCT03775109|Active Comparator|Canakinumab 150mg/ml solution for injection|150mg/ml solution for injection
88827366|NCT03775109|Placebo Comparator|Dextrose|
88827367|NCT03251924|Experimental|BMS-986226|administered intravenously
88827368|NCT03251924|Experimental|BMS-986226 and Nivolumab|administered intravenously
88827369|NCT03251924|Experimental|BMS-986226 and Ipilimumab|administered intravenously
88827370|NCT01651351|Experimental|Cohort 1|"Day 1:~GLASSIA at 0.04 mL/kg/min~Placebo at 0.2 mL/kg/min~Day 15:~GLASSIA at 0.2 mL/kg/min~Placebo at 0.04 mL/kg/min"
88827371|NCT01651351|Experimental|Cohort 2|"Day 1:~GLASSIA at 0.2 mL/kg/min~Placebo at 0.04 mL/kg/min~Day 15:~GLASSIA at 0.04 mL/kg/min~Placebo at 0.2 mL/kg/min"
88827372|NCT03774329|Experimental|physical activity program|Child with an adapted physical activity program
88827373|NCT03774329|Other|Usual care|
88827374|NCT03762317|Active Comparator|clonidine|Clonidine is started at 6mcg/kg/day and increased to 12 mcg/kg/d for the duration of the study period
88827375|NCT03762317|Placebo Comparator|Placebo|Placebo solution will be given for the duration of the study period
88827376|NCT01910792|Active Comparator|Group 2|Patients who have had gastric bypass surgery will be exposed to a Sperti Lamp 3x/week
88827377|NCT01910792|Active Comparator|Group 1|Patients with fat malabsorption syndromes will be exposed to a Sperti Lamp 3x/week
88827378|NCT04330911|Experimental|The HIIT Group (High Intensity Interval Training Group)|
88827379|NCT04330911|Experimental|The MICT Group (Moderate Intensity Continous Training Group)|
88827380|NCT03038269|Sham Comparator|Sham tDCS|Participant will receive a placebo-type stimulation followed by upper extremity robotic training.
88827381|NCT03038269|Active Comparator|Active tDCS|Participant will receive active transcranial direct current stimulation followed by upper extremity robotic training.
88827382|NCT02975921|No Intervention|Malignant Effusion - Usual Care|Patients who had a pleural effusion secondary to a malignant etiology and subsequently underwent tunneled pleural catheter (TPC) placement and had usual care during and afterwards. Usual care is the TPC only with no intrapleural medications. They would have nursing care in the recovery area afterwards and home nursing three times weekly.
88827383|NCT02975921|Experimental|Malignant Effusion with Pleurodesis|Patients who had a pleural effusion secondary to a malignant etiology and subsequently underwent tunneled pleural catheter (TPC) placement and had intrapleural Povidone-Iodine administered at time of placement (100mL of 2% solution). They would have nursing care in the recovery area afterwards and home nursing three times weekly.
88827384|NCT02975921|No Intervention|Benign Effusion - Usual Care|Patients who had a pleural effusion secondary to a benign etiology and subsequently underwent tunneled pleural catheter (TPC) placement and had usual care during and afterwards. Usual care is the TPC only with no intrapleural medications. They would have nursing care in the recovery area afterwards and home nursing three times weekly.
88827385|NCT02975921|Experimental|Benign Effusion with Pleurodesis|Patients who had a pleural effusion secondary to a benign etiology and subsequently underwent tunneled pleural catheter (TPC) placement and had intrapleural Povidone-Iodine administered at time of placement (100mL of 2% solution). They would have nursing care in the recovery area afterwards and home nursing three times weekly.
88827386|NCT05452785|Experimental|DFD-29 under fasting condition|In each study period, a single 40 mg dose of DFD-29 Capsules will be administered orally with approximately 240 mL of water, in the morning, following a 10-hour overnight fast.
88827387|NCT05452785|Experimental|DFD-29 after high-fat meal|In each study period, a single 40 mg dose of DFD-29 Capsules will be administered orally with approximately 240 mL of water, in the morning, following a 10-hour overnight fast and 30 minutes after the start of a high-fat, high-calorie breakfast.
88827388|NCT05452785|Active Comparator|Solodyn under fasting condition|In each study period, a single 105 mg dose of SOLODYN® Tablets will be administered orally with approximately 240 mL of water, in the morning, following a 10-hour overnight fast
88827389|NCT03002545|Placebo Comparator|Placebo|identically tasting and looking Placebo
88827390|NCT03002545|Active Comparator|Magnesium|Supplementation with 400 mg Magnesium from Magnesium citrate once daily
88827391|NCT03002701|No Intervention|Control - standard care|Prior to implementation of the intervention package the current standard of care will be maintained.
88827392|NCT03002701|Active Comparator|Intervention group|After implementation the intervention package will be implemented as standard care.
89530260|NCT03249337|Active Comparator|Glanatec (R) 6 times a day|
88827393|NCT01932242|Experimental|Sequence A|An intravenous dose of 16 mg/kg ETI-204 infused over 90 minutes on Days 1 and 14 and an intravenous dose of ETI-204-Placebo infused over 90 minutes on Day 120.
88827394|NCT01932242|Experimental|Sequence B|An intravenous dose of 16 mg/kg ETI-204 infused over 90 minutes on Days 1 and 120 and an intravenous dose of ETI-204-Placebo infused over 90 minutes on Day 14.
88827395|NCT04518215|Experimental|ESPB group|Erector Spinae Plain Block
88827396|NCT04518215|Active Comparator|IV Analgesia group|Intra-Venous Analgesia
88827397|NCT04517747|Experimental|Ramucirumab plus TAS-102|Ramucirumab 8 mg/kg i.v. on day 1 and day 15 of a 28-day cycle and TAS-102 35 mg/m2/dose p.o. twice daily on days 1 to 5 and days 8 to 12 of a 28-day cycle Each cycle will be repeated after 28 days (from day 1) for a maximum of 4 cycles.
88827398|NCT02219581|Placebo Comparator|Placebo|Subjects undergoing primary total joint arthroplasty of the knee will receive two doses of placebo intravenously in addition to a standard multimodal postoperative pain management regimen typically used for total knee arthroplasty. The first dose of placebo will be given preoperatively within 3 hours of surgery and the second dose will be administered 8 hours after the first dose in the inpatient setting.
88827399|NCT02219581|Experimental|Dexamethasone 10 mg|Subjects undergoing primary total joint arthroplasty of the knee will receive two doses of 10 mg dexamethasone. The first dose will be given preoperatively within 3 hours of surgery and the second dose will be administered 8 hours after the first dose in the inpatient setting. Additionally, subjects will also receive a standard multimodal postoperative pain management regimen typically used for total knee arthroplasty.
88827400|NCT02219581|Experimental|Dexamethasone 20 mg|Subjects undergoing primary total joint arthroplasty of the knee will receive two doses of 20 mg dexamethasone. The first dose will be given preoperatively within 3 hours of surgery and the second dose will be administered 8 hours after the first dose in the inpatient setting. Additionally, subjects will also receive a standard multimodal postoperative pain management regimen typically used for total knee arthroplasty.
88827401|NCT05212077|Experimental|Advanced Care at Home (ACH)|Patients will receive inpatient hospitalization at home.
88827402|NCT05212077|Active Comparator|Traditional Inpatient (Brick-and-Mortar) Hospital Care|Patients will receive inpatient hospitalization at the hospital.
88827403|NCT04516109|Active Comparator|Arthrosocpic labral repair|Patients undergoing arthroscopic labral repair with the use of the modified hip capsule slotted cannula.
88827404|NCT04516109|Active Comparator|Arthroscopic bone grafting|Patients undergoing arthroscopic bone grafting of subchrondral cyst with the use of the modified bone graft delivery tool set and modified hip capsule slotted cannula.
88827405|NCT05442957|Experimental|BRIGHT|BRIGHT is a manualized theory-based video tele-cognitive behavioral therapy (CBT) intervention delivered one-on-one by a licensed clinical psychologist.
88827406|NCT05442957|Active Comparator|Attention Control|The attention control arm is a manualized video tele-supportive care intervention that addresses non-body image aspects of HNC survivorship.
88827407|NCT01912274|Experimental|Pracinostat with azacitadine|60 mg of pracinostat by mouth 3 times a week for 3 weeks followed by 1 week of rest repeated every 28 days 75 mg/m2 azacitadine for the first 7 days of each 28 day cycle, via subcutaneous (SC) injection or intravenous (IV) infusion if SC injections are intolerable
88827408|NCT01654861|Experimental|HDIVC|Gemcitabine (Gemzar), Intravenous and oral Ascorbic Acid (Vitamin C).
88827409|NCT01655329||Standard chest radiographs|The radiologists will be viewing two groups of chest images. The first group are standard chest radiographs.
88827410|NCT01655329||Modified chest radiographs|This group of chest radiographs will be presented with the modified image. The modified image is intended to increase the visibility of tubes, lines and wires on chest radiographs
88827411|NCT05436717|Experimental|MINDxYOU|The online program MINDxYOU is based on the principles of 'third wave' psychotherapies, such as the promotion of wellbeing through the practice of mindfulness, compassion, acceptance, and spirituality and the estimated time for completing the whole program is 8 weeks
88827412|NCT03723707|Experimental|Intervention (INT)|(10 clinic sites and ~500 patients) which includes practice guidelines for clinicians, provider education, electronic health record support for quality DM-ADRD care, information about community/clinical resources, ongoing targeted provider feedback, and a panel manager (PM)
88827413|NCT03723707|Placebo Comparator|Control (CON)|During training the CON providers will be encouraged to do cognitive screening as well as follow the guidelines in general.
88827414|NCT05184777|Experimental|Patients undergoing ovarian stimulation for IVF/ICSI|90 patients undergoing ovarian stimulation for IVF/ICSI; Low, average and high responders will be included in equal proportions, in order to cover the widest range of hormonal values (30 blood and saliva samples per ovarian stimulation point will be taken for determination of progesterone and oestradiol).
88827415|NCT05184777|Experimental|Patients for embryo transfer (ET) undergoing hormonal replacement therapy|30 patients for embryo transfer (ET) undergoing hormonal replacement therapy. These patients will only have a progesterone determination in their blood and saliva samples on the day of ET.
88827416|NCT03721367||Urea Cycle Disorders|
88827417|NCT01912352|Experimental|Methylphenidate|Participants were treated with methylphenidate (ranging from to 63mg) for 8 weeks. Doses of methylphenidate were titrated depending on symptoms and adverse eff ects at the 2nd and 4th weeks of treatment.
88827418|NCT02975843|Experimental|CHF5993|99mTc Radiolabelled Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium Bromide administered via pMDI
88827419|NCT01655563|Active Comparator|Standard Dosing Arm|Patients in the standard arm will receive standard starting dose of tacrolimus that is clinically used i.e. 0.1 mg/kg/dose twice a day.
88827420|NCT01655563|Experimental|Pharmacogenetic Arm|"Patients in the pharmacogenetic arm will receive a starting dose that is assigned based on age and CYP3A5 expressor status. Patients that are CYP3A5 expressors will receive the higher end of the dose range compared to non-expressors. All doses recommended represent clinically acceptable and safe dose ranges used at our institution.~CYP3A5 non-expressor starting dose:~Greater than 6 years of age - 0.075 mg/kg/dose q12 hours; Less than or equal to 6 years of age - 0.1 mg/kg/dose q12 hours~CYP3A5 expressor starting dose:~Greater than 6 years of age - 0.15 mg/kg/dose q12 hours; Less than or equal to 6 years of age - 0.2 mg/kg/dose q12 hours"
89533992|NCT01568658||Single patient on Idebenone|Single patient on IND expanded access of Idebenone
89533993|NCT01568658||Unaffected family members|Families of affected probands with known or suspected inherited neurological disorders of childhood onset
89177508|NCT04110600|Active Comparator|Pepper mint oil group|"This group includes 300 patients who underwent cesarean delivery under spinal anaesthesia This group will have 100 ml of pepper mint oil After 2,4 and 6 hours~Then outcomes will be assessed as per time frame"
89177509|NCT02604654|Experimental|Yiqitongluo group|Yiqitongluo granule 12g each time, 3 times a daily for 4 weeks.
89356952|NCT05863221|No Intervention|Group 2|30 ml of 0.5% Ropivacaine and 10mg dexamethasone into all surgical sites and intermittent IV acetaminophen as per need till discharge.
89356953|NCT05861024||Ileocystoplasty|Urinary Calculi After Ileocystoplasty in Children
89356954|NCT05861024||Sigmoidocystoplasty|Urinary Calculi After Sigmoidocystoplasty in Children
89533994|NCT01563874||Cohort 1|This study involves a broad panel of lymphoma and lymphoid samples, which were previously procured under multiple protocols at the NIH, and for which there is excess tissue available for research.
88827421|NCT05180019||Patient COS IVI Bilbao|Patients will come to the IVIRMA Bilbao clinic to start their respective ART cycles (vitrification, IVF/ICSI, donors) following usual clinical practice.
88827422|NCT05172141|Experimental|IBI314|Low/medium/high dose, intravenously, once, on Day 1
88827423|NCT05172141|Placebo Comparator|Placebo|Placebo, intravenously, once, on Day 1
88827424|NCT01655719|Experimental|Pioglitazone Treatment|"If eligible, subjects can participate in 1 or both parts of this study as follows:~Part 1: In the initial main portion of the study subjects will receive 24 -28 weeks of therapy with pioglitazone at the dosage approved for the control of diabetes. Response will be evaluated per RECIST. Safety measure are outlined in the protocol including weekly weigh ins, calls, labs, exams, etc.~Part 2: A secondary protocol is then available to subjects who complete the main initial study with less than complete response per RECIST. They can undergo a radioiodine scan to see if the treatment with pioglitazone has sensitized their disease to radioiodine. If it has - they can pursue the radioiodine treatment."
88827425|NCT01913600|Other|Resolute Integrity|Resolute Integrity Stent
88827426|NCT05735756|Active Comparator|Citalopram 20mg|
88827427|NCT05735756|Placebo Comparator|Placebo|
88827428|NCT01936844|Experimental|Anakinra (short)|Anakinra 100 mg twice daily for the first 3 days followed by 100 mg daily for days 4-14
88827429|NCT01936844|Placebo Comparator|Placebo|Placebo injections twice daily for the first 3 days then once daily for days 4-14.
88827430|NCT01917188|Active Comparator|Full simulation and education|Patients who will receive full simulation and education session prior to discharge.
88827431|NCT01917188|Other|See simulation room, usual education|Patients will be shown the simulation room prior to discharge but will only receive usual education.
88827432|NCT01917188|No Intervention|Usual care|Patients will receive usual care by bedside nurse.
88827433|NCT01937624||Diagnostic ultrasound and radiographic imaging|- The diagnostic musculoskeletal ultrasound and x-rays will both be used to image bones in perpendicular and orthogonal planes over the distal radius visualizing the physis.
88827434|NCT01938170|Experimental|FluMist|Subjects receiving vaccine at home
88827435|NCT02987348||exenatide once weekly|type 2 diabetes patients who were first prescribed with exenatide once weekly in the index period identified from CPRD database of UK primary care
88827436|NCT02987348||basal insulin_1|type 2 diabetes patients who were first prescribed with basal insulin in the index period and matched with exenatide once weekly group identified from CPRD database of UK primary care
88827437|NCT02987348||exenatide twice daily|type 2 diabetes patients who were first prescribed with exenatide twice daily in the index period identified from CPRD database of UK primary care
88827438|NCT02987348||basal insulin_2|type 2 diabetes patients who were first prescribed with basal insulin in the index period and matched with exenatide twice daily group identified from CPRD database of UK primary care
88827439|NCT05735522|Active Comparator|Active group|"We are using an extracorporeal magnetic stimulation chair with two magnetic stimulators, one under the seat and one in the backrest, that generate the magnetic field. The treatment lasts for 30 minutes and has 5 steps. Each step has a defined duration and a defined frequency of magnetic field pulsations. In each step, it is also defined, which of the magnetic field generators are working. The pulsations last for 6 seconds followed by 6 seconds of rest.~Step 1: 10Hz, 7 minutes, 6 seconds on, 6 seconds off, both stimulators generate the magnetic field. Step 2: 10Hz, 4 minutes, the stimulator under the seat generates the magnetic field. Step 3: 10Hz, 7 minutes, the stimulator in the backrest generates the magnetic field. Step 4: 30Hz, 10 minutes, both stimulators generate the magnetic field. Step 5: After 5 minutes, both stimulators generate the magnetic field.~During the treatment, we adjusted the magnetic field density. It varied from 2-100%. The maximum was 3 Teslas."
88827440|NCT05735522|Sham Comparator|Sham group|We are using extracorporeal magnetic stimulation, a chair with two magnetic stimulators, one under the seat and one in the backrest, that generate the magnetic field. The treatment lasts for 30 minutes and has 5 steps. We used the same program as in the active group with the difference that the magnetic field density was always at 2% so the effects of the pulsating are negligible.
88827441|NCT01656031|Experimental|high-dose cytarabine and clofarabine|high-dose cytarabine (2000 milligram/meter squared/day) administered intravenously over 3 hours followed by clofarabine administered intravenously over 2 hours daily for 5 consecutive days
88827442|NCT01917812|Placebo Comparator|Blinded Digital Activity Tracker|Blinded Digital Activity Tracker = Group wears the tracker but is blinded to the numeric physical activity feedback information provided by the tracker.
89000620|NCT02207257|Experimental|Cohort 1|Subjects will receive 60 mg edoxaban in the morning on Days 1-2. On Day 3 and 4, they will receive a single dose of 60 mg edoxaban, followed 3 hours later by a single dose of 25 mg PER977 or placebo (n=10).
89000621|NCT02207257|Experimental|Cohort 2|Subjects will receive 60 mg edoxaban in the morning on Days 1-2. On Day 3 and 4, they will receive a single dose of 60 mg edoxaban, followed 3 hours later by a single dose of 50 mg PER977 or placebo (n=10).
89177510|NCT04107792|Experimental|Experimental|Parents of children with sensory processing issues who attend Workshop 1
89177511|NCT04107792|No Intervention|Waitlist Control|parents of children with sensory processing issues who attend Workshop 2
89177512|NCT00798096|Experimental|1|
89356955|NCT05860998||Toxoplasmosis positive|Healthy students with RhD-Negative blood with Toxoplasma gondii IgG Antibodies
89533995|NCT01553214|Other|Donors|volunteer healthy donors willing to receive G-CSF and dexamethasone and undergo leukapheresis
89533996|NCT01511588||HH patients|Clinical patients with hypogonadotropic hypogonadism (HH)
88827443|NCT01917812|Experimental|Unblinded Digital Activity Tracker / No Smart Text Messaging|"Unblinded Digital Activity Tracker = Group unblinded to the numeric physical activity feedback information provided by the digital activity tracker.~No Smart Text Messaging = Group does not receive personalized, health coaching via smart text messages.~Note that the study occurred over two study phases after the 1-week blinded run-in. In the first 2-week phase, participants were randomized to unblinded or blinded tracking. In the second 2-week phase, the unblinded participants were randomized to receive smart texts or no texts."
88827444|NCT01917812|Experimental|Unblinded Digital Activity Tracker / Smart Text Messaging|"Unblinded Digital Activity Tracker = Group unblinded to the numeric physical activity feedback information provided by the digital activity tracker.~Smart Text Messaging = Group receives personalized, health coaching via smart text messages.~Note that the study occurred over two study phases after the 1-week blinded run-in. In the first 2-week phase, participants were randomized to unblinded or blinded tracking. In the second 2-week phase, the unblinded participants were randomized to receive smart texts or no texts."
88827445|NCT05735444||Observation group|
88827446|NCT01656187|Experimental|Memantine, Then Placebo|Participants first received Memantine 10 mg capsule twice a day for 24 weeks. After a washout period of 4 weeks, they then received Placebo capsule (matching Memantine 10 mg capsule) twice a day for 24 weeks.
88827447|NCT01656187|Experimental|Placebo, Then Memantine|Participants first received Placebo capsule (matching Memantine 10 mg capsule) twice a day for 24 weeks. After a washout period of 4 weeks, they then received Memantine 10 mg capsule twice a day for 24 weeks.
88827448|NCT01658059|Experimental|group 1|homeopathic remedy first , placebo second
88827449|NCT01658059|Experimental|group 2|placebo first, homeopathic remedy second
88827450|NCT01658839|Experimental|Travoprost|Travoprost ophthalmic solution, 0.004% (new formulation), one drop administered topically in the inferior cul-de-sac of the eye each morning at 9 AM (± 60 minutes) for 7 days
88827451|NCT01658995|Active Comparator|Post ESI implant - Doxycycline|Subjects will be randomized into this arm after experiencing dissatisfaction with bleeding after 13 weeks post ESI insertion and received Doxycycline 100 mg oral capsules, twice daily for 10 days. After 10 days, subsequent treatment can requested by the subjects
88827452|NCT01658995|Placebo Comparator|Post ESI implant - Placebo|Subjects will be randomized into this arm after experiencing dissatisfaction with bleeding after 13 weeks post ESI insertion and received placebo 100 mg oral capsules, twice daily for 10 days. After 10 days, subsequent treatment can requested by the subjects
88827453|NCT01350141|Placebo Comparator|Treatment A|
88827454|NCT01350141|Experimental|Treatment B|
88827455|NCT01350141|Experimental|Treatment C|
88827456|NCT01660321|Experimental|Natroba|Natroba (Spinosad) Topical Suspension, 0.9%
88827457|NCT01597141|Experimental|Family-aided Assertive Community Treatment|The experimental treatment is a combination of family psychoeducation, assertive community treatment, supported education/employment and psychotropic medication.
88827458|NCT01597141|Active Comparator|Enhanced standard treatment|In this arm, the subjects will receive the same psychotropic drugs, but will receive individual case management, family education and crisis intervention.
88827459|NCT05164107|Experimental|Globe Mapping and Ablation System|
88827460|NCT01597687|Experimental|Malaysia Group|Malaysian adults aged >19 years with prolonged cough of 2 weeks or more.
88827461|NCT01597687|Experimental|Taiwan Group|Taiwanese adults aged >19 years with prolonged cough of 2 weeks or more.
88827462|NCT01597687|Experimental|Thailand Group|Thailandese adults aged >19 years with prolonged cough of 2 weeks or more.
88827463|NCT01597843|Experimental|First educational intervention group|Group that receives intervention first. The intervention is a series of training sessions, in person and on line, to educate post superusers who will in turn educate post members on the utility and mechanics of use of MHV.
88827464|NCT01597843|Experimental|Second intervention group|This arm receives a series of training sessions over study months 6-9. The training sessions are in person and on line and are directed at post superusers who will in turn educate post members on the utility and mechanics of use of MHV. They complete survey rounds 1 and 2 before the training and survey round 3 after the training.
89177513|NCT04113096|Experimental|Breast Cancer Stage IV|Stage IV Breast Cancer: Dibenzyl trisulphide capsules (20mg once daily)/6 months
89177514|NCT04113096|Experimental|Colon Cancer Stage IV|Stage IV Colon Cancer:Dibenzyl trisulphide capsules (20 mg one daily for 6 months
89177515|NCT04113096|Experimental|Cervical Cancer Stage IV|Stage IV Cancer of the Cervix: Dibenzyl trisulphide capsules (20 mg once daily) for 6 months
89177516|NCT04113096|Experimental|Cancer of the Prostate Stage IV|Stage IV Prostate cancer:Dibenzyl trisulphide capsules (20 mg once daily) for 6 months
89177517|NCT00795600|Experimental|insulin detemir|Insulin detemir injected subcutaneously (s.c.) in the evening in combination with insulin aspart injected s.c. as mealtime insulin for 26 weeks
89177518|NCT00795600|Active Comparator|insulin NPH|Insulin isophane (Neutral Protamine Hagedorn, NPH) injected subcutaneously (s.c.) in the evening in combination with insulin aspart injected s.c. as mealtime insulin for 26 weeks
89177519|NCT00795132|Active Comparator|Related BM PBSC|Bone Marrow Peripheral Blood Stem Cell (BM PBSC) from a donor related to the participant/recipient
89177520|NCT00795132|Active Comparator|Unrelated BM PBSC|Bone Marrow Peripheral Blood Stem Cell (BM PBSC) from a donor unrelated to the participant/recipient
89177521|NCT00795132|Active Comparator|Unrelated Blood Cord|Blood Cord donated from a donor unrelated to the participant/recipient
89177522|NCT02604420||Transplant, no TMA|Adult patients who undergo an allogeneic hematopoietic stem cell transplant but do not meet the criteria for a thrombotic microangiopathy in the one year follow up period. No interventions anticipated.
89356956|NCT05860998||Toxoplasmosis negative|Healthy students with RhD-Negative blood without Toxoplasma gondii IgG Antibodies
89533997|NCT01500447||Central Precious Puberty|CPP subjects
89533998|NCT01500447||Hypogonadotropic Hypogonadism|IHH, KS, GnRH Deficiency, BAM syndrome (arhinia), HA, CDP subjects
89533999|NCT01445483||1/Cohort 1|KPS>70; Age =65; controlled primary tumor and no extracranial metastases
89534000|NCT01445483||2/Cohort 2|KPS>70 and at least one of the following: age >65, uncontrolled or synchronous primary disease, or extracranial metastases
89534001|NCT01445483||3/Cohort 3|KPS<70
88827465|NCT01597843|No Intervention|Education after data collection complete|This group received a similar intervention, but after all quantitative data collection complete.
88827466|NCT03001999|Experimental|Intervention Arm|Participants will all undergo a 16-week PP-MI health behavior intervention.
88827467|NCT01662115|Active Comparator|Nicotine gum|100 subjects who will actually get the intervention medication
88827468|NCT01662115|Sham Comparator|regular chewing gum|100 subjects who will be part of a control group
88827469|NCT01662115|No Intervention|No gum|100 subjects who will not get neither the intervention nor the placebo gum.
88827470|NCT01662583|Experimental|Educational Text Message|Educational text message reminder
88827471|NCT01662583|Experimental|Plain Text Message|plain text message reminder
88827472|NCT01662583|Other|Written reminder only|written reminder at time of vaccination
88827473|NCT03002233|Experimental|TRK-820|PartA: 5 μg PartB: 2.5-10 μg
88827474|NCT01598545|Experimental|Hydromorphone|Laboring patients having a cesarean section will receive ED50 of hydromorphone one time intrathecally
88827475|NCT01598701|Experimental|Intravenous Acetaminophen|Patients will be receive doses of 1000 mg/100 mL of IV Acetaminophen (OFIRMEV). The drug will be infused over 15 minutes.
88827476|NCT01598701|Placebo Comparator|Placebo|Patients will be given 100 mL normal saline placebos at scheduled time intervals in place of IV acetaminophen.
88827477|NCT01694563|Other|Atrial Fibrillation|Patients with non-paroxysmal atrial fibrillation (persistent or longstanding persistent)who are scheduled to undergo elective concomitant open, on-pump cardiac surgical procedure and the Maze IV ablation procedure. This single arm registry is designed to monitor the AtriCure Synergy Ablation System for continued safety and efficacy during the peri-procedural and long term phase during commercial use.
88827478|NCT01940276|Experimental|Abiraterone Acetate and Prednisone|abiraterone acetate will be administered by the patient at a dose of 1000mg orally once daily with prednisone 5 mg BID in 4-week cycles
88827479|NCT01600495|Experimental|Experimental TENS|TENS Intervention Group(GIE) used for 30 minutes, during uterine contractions between 4-5 cm
88827480|NCT01600495|No Intervention|control Group|Formed by mothers who will not use EAC to receive the routine procedures of motherhood, but will be monitored and evaluated at the same time in the intervention group.
88827481|NCT00382395|Experimental|1|SOLX Gold Shunt
88827482|NCT00382395|Active Comparator|2|Control Ahmed FP7 Shunt
88827483|NCT01919216|Active Comparator|Open Track|Open treatment with 20mg of citalopram, increased to 40mg if depression has not remitted at week 4.
88827484|NCT01919216|Placebo Comparator|Placebo Track|Blinded treatment with either citalopram 20mg or placebo, increased to citalopram 40mg or placebo at week 4 if depression has not remitted.
88827485|NCT01600729||All Participants|Participants with facial lines. There was no intervention in this study.
89000622|NCT02207257|Experimental|Cohort 3|Subjects will receive 60 mg edoxaban in the morning on Days 1-2. On Day 3 and 4, they will receive a single dose of 60 mg edoxaban, followed 3 hours later by a single dose of 100 mg PER977 or placebo (n=10).
89000623|NCT02207257|Experimental|Cohort 4|Subjects will receive 60 mg edoxaban in the morning on Days 1-2. On Day 3 and 4, they will receive a single dose of 60 mg edoxaban, followed 3 hours later by a single dose of 300 mg PER977 or placebo (n=10). Study amendments expanded the cohort to include an additional 7 subjects (randomized 1:6 PER977:placebo) and up to an additional 4 placebo and 8 active subjects (ongoing).
89177523|NCT02604420||Transplant, +TMA|Adult patients who undergo an allogeneic hematopoietic stem cell transplant and meet the criteria for a thrombotic microangiopathy in the one year follow up period. Possible interventions include observation, treatment of an underlying infection or GvHD, use of plasma exchange, or use of anti-complement therapy (eculizumab or other anti-complement drug). Eculizumab is used as a 900mg intravenous infusion over 35 minutes, given weekly for 4 weeks, then 1200mg every other week. Patients must be vaccinated against meningococcus 2 weeks before starting drug or, if that is not feasible because of the physician's assessment of the severity of the TMA, given prophylactic antibiotics for the 2 week period before immunization has taken hold.
89177524|NCT04110210|Active Comparator|Group A(Ultrasound guided ESP block after indtiucon of GA).|Following skin sterilization and local anesthetic infiltration of the superficial tissues, an echogenic 22-G block needle is inserted in-plane to the ultrasound beam in a cranial-to-caudal direction until contact was made with the transverse process. Correct location of the needle tip in the fascial plane deep to erector spinae muscle is confirmed by injecting 0.5-1 ml saline and seeing the fluid lifting the erector spinae muscle off the transverse process while not distending the muscle. A total of 20ml bupivacaine 0.25% are then injected into the ESP. The procedure is repeated on the contralateral side.
89177525|NCT04110210|Active Comparator|Group B(GA with conventional analgesia)|After operation, patients will be transferred to post anesthesia care unit (PACU) for complete recovery and monitoring. The pain VAS scores between the studied groups will be registered every 4 hours for 24 hours postoperatively. A standard postoperative analgesia regimen will be prescribed as paracetamol 1gm every 6 hours and ketorolac 30mg every 8 hours in the first 24 hours postoperatively. Morphine 2.5 mg will be given as a rescue analgesic dose if visual analogue score was ≥ 3 or when patient suffering from pain between the assessment intervals in both groups not exceeding 0.1 mg/kg in a period of 6 hours. Metoclopramide 0.15 mg/kg IV will be prescribed for patients complaining of nausea or vomiting.
89177526|NCT00647296|Placebo Comparator|Part 1: Placebo or Dexpramipexole|During Part 1, subjects received twice daily doses of dexpramipexole (50 mg/day, 150 mg/day, or 300 mg/day) or matching placebo for approximately 12 weeks.
89177527|NCT00647296|Experimental|Part 2: Placebo washout|At the beginning of Part 2, subjects received twice daily doses of placebo for approximately 4 weeks.
89177528|NCT00647296|Experimental|Part 2: Dexpramipexole|Following the Part 2 placebo washout, subjects received dexpramipexole (50 mg/day or 300 mg/day), subjects received twice daily doses of placebo for up to 18 months.
89177529|NCT00815620||1|patients undergoing local ablative therapy such as transcatheter-arterial chemoembolization or selective interal radiotherapy
89177530|NCT00815620||2|patients undergoing surgery or radiofrequency ablation
89177531|NCT00815620||3|patients undergoing peptide receptor radiotherapy
89534002|NCT01425892||incomplete sjogren's|patients who meet criteria as incomplete sjogren's
88827486|NCT04527237|Experimental|acupressure|"The person will be given 2 applications a day at 12-hour intervals and 6 applications in 72 hours in total.Physiological measurements will be made before and after the acupressure application. Physiological measurements 10-15 min. From acupressure application. will be taken before and the same measurements after acupressure 20-30. Will be taken again in the min interval. In addition, the Continuous Anxiety Scale will be applied once before application, the State Anxiety Scale will be applied once before the application and 3 times in total after the application at the end of every 24 hours. Sleep Scale will be applied 3 times in total before the next day after application.~Application to acupressure points in a certain order; Baihui, Susanli, Hegu, Shenmen and Quchi will be held.~After 2-3 minutes of approach to the patient and proper positioning, 20 seconds of preparation of each of the notes will be prepared and then 2 minutes acupressure application will be applied to each point."
88827487|NCT04527237|Placebo Comparator|placebo|The false acupressure application steps (temperature of the environment, patient's position, application time, frequency and repetition, evaluation period etc.) will be the same as the acupressure application steps. Unlike acupressure, it will only be in contact with wearing gloves to reduce the electrical effect of touch, away from the actual acupressure points. Touching any part of the body or making skin contact can be an effect alone, as well as other meridians and points are located near the existing meridian and selected points, and entering their area of influence, pressing or scrubbing can cause other effects to be activated.
88827488|NCT02993185|Experimental|Your Move|Sex education intervention
88827489|NCT02993185|Active Comparator|Eat Smart|Nutrition education intervention
88827490|NCT01940510|Experimental|Healthy subjects|
88827491|NCT01601431|Experimental|Cap Assisted Colonoscopy|Cap Assisted Colonoscopy uses a Cap which is a transparent hood which is attached to the distal end of the colonscope and allows depressing the colon folds in order to visualize hidden polyps behind the folds.
88827492|NCT01601431|Active Comparator|Conventional colonoscopy|A conventional colonoscopy does not use a Cap in order to perform the procedure
88827493|NCT01601977|Experimental|Intervention|AVAPS-AE
88827494|NCT01601977|Active Comparator|Usual care|Non-invasive ventilation
88827495|NCT05364645|Experimental|Arm A (carboplatin, pemetrexed, selpercatinib)|Patients receive carboplatin IV over 30 minutes and pemetrexed IV over 10 minutes on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also selpercatinib PO BID in the absence of disease progression or unacceptable toxicity.
89177532|NCT00644878|Experimental|Nilotinib|
89177533|NCT04045288|Active Comparator|Standard Implementation|All schools in SWITCH receive training through webinars and an in-person conference to learn about the defining elements and school wellness programming in general. Consistent with the standard implementation, schools were added to the online content management system (CMS) and were given access to an online community of practice (CoP) to interact with other schools / teachers in the study. Schools were provided with resources and program materials (i.e. educational modules, trinkets, posters, etc.) but were given autonomy with regard to how they were used within their school. Weekly updates through the online CMS, the CoP, and via direct email correspondence provided information about the weekly corresponding weekly themes, implementation tips, recommended module activities to incorporate, upcoming evaluation needs, important SWITCH dates, and other program reminders.
89177534|NCT04045288|Experimental|Enhanced Implementation|The 'Enhanced' implementation strategy provided schools with the same training, access and resources as the standard SWITCH implementation along with more personalized, web-based training based on motivational interviewing (MI) techniques and feedback throughout the implementation process. The supplemental support was provided through participation in two online 'checkpoint sessions' that helped schools self-assess their use of the recommended quality elements and setting-specific best practices. The sessions used principles of motivational interviewing (MI) to promote autonomy and motivation for school change through the process. Schools were also provided with information about how to capitalize on support from local 4H program leaders in their county.
89177535|NCT00813046|Experimental|gpASIT+TM|
89177536|NCT00813202|Experimental|Nesiritide|
89177537|NCT00813280||hyperglycemia|hospitalized patients with BG >300 ml/dL
89177538|NCT00646906|Experimental|Phase 1a: Acetaminophen 1000mg / aspirin|"All subjects in this arm (smokers (n=8) and non-smokers (n=8) will receive 81 mg aspirin at approximately 8 am followed by 1000 mg acetaminophen at approximately 10 am during one crossover period (see Crossover period: Aspirin first intervention). During the other crossover period, beginning after a 2 week washout, the order will be reversed and the subjects will receive 1000 mg acetaminophen at 8 am followed by 81 mg aspirin at 10 am (see Crossover Period: Aspirin last intervention). The occurrence of the two crossover periods will be randomized by order. Smokers and non-smokers will be matched for age and gender."
89177539|NCT00646906|Experimental|Phase 1a: Acetaminophen 2000mg / aspirin|"All subjects in this arm (smokers (n=8) and non-smoking volunteers (n=8)) will receive 81 mg aspirin at approximately 8 am followed by 2000 mg acetaminophen at approximately 10 am during one crossover period (see Crossover Period: Aspirin first intervention). During the other crossover period, beginning after a 2 week washout, the order will be reversed and the subjects will receive 2000 mg acetaminophen at 8 am followed by 81 mg aspirin at 10 am (see Crossover Period: Aspirin last intervention). The occurrence of the two crossover periods will be randomized by order. Smokers and non-smokers will be matched for age and gender."
89177540|NCT00646906|Experimental|Phase 1b: Acetaminophen 1000 mg alone|"Eight male and non-pregnant female subjects who are healthy and non-smoking will be recruited. They will receive a daily oral dose of 1000 mg acetaminophen for six days each administered at 8 AM (see Acetaminophen 1000 mg/d intervention). Study assessments will be performed on day 1 and on day 6. This is not a crossover design. Just one treatment period."
89534003|NCT01425892||primary sjogren's|patients who meet criteria for classification for primary sjogren's
89534004|NCT01425892||secondary sjogren's|patients who meet classification criteria for secondary sjogren's
89534005|NCT01422694||Healthy control|Healthy volunteers will be recruited to serve as controls
89534006|NCT01422694||Other Inflammatory Diseases|Subjects with Other Inflammatory Diseases
89534007|NCT01422694||Patients with Spondyloarthritis|Subjects with confirmed or probable SpA will be identified predominantly by physician referral.
89534008|NCT01386424||Healthy Volunteers|Healthy Volunteers
89534009|NCT01316783||Healthy Volunteers|African ancestry and whites (who will serve as a comparison group)
89000624|NCT02207257|Experimental|Cohort 5|Subjects will receive 60 mg edoxaban in the morning on Days 1-2. On Day 3 and 4, they will receive a single dose of 60 mg edoxaban, followed 3 hours later by a single dose of 600 mg PER977 or placebo (n=10). A protocol amendment expanded the cohort to include an additional 2 placebo and up to an additional 4 active subject.
89534010|NCT01287000||1|Workers and volunteers engaged or potentially engaged in oil spill clean-up operations in the Gulf of Mexico
89534011|NCT01264055||1|Adults with idiopathic bronchiectasis
88827496|NCT05364645|Active Comparator|Arm B (carboplatin, pemetrexed)|Patients receive carboplatin IV over 30 minutes and pemetrexed IV over 10 minutes on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
89534012|NCT01260961|Active Comparator|Docosa Hexanoic Acid|
89534013|NCT01260961|Placebo Comparator|Placebo|
88827497|NCT01919450|Active Comparator|10 Second Delay|A 10 second delay is imposed between the Lexiscan (Regadenoson) injection and start of myocardial perfusion PET imaging.
89534014|NCT01251900||Patients|Hispanic women, over the age of 18, with breast cancer will be eligible.
89534015|NCT01247597||Controls|People without pathogenic DICER1 germline variation
88827498|NCT01919450|Active Comparator|2 Minute Delay|A 2 minute delay is imposed between the Lexiscan (Regadenoson) injection and start of myocardial perfusion PET imaging.
88827499|NCT01919450|Active Comparator|4 Minute Delay|A 4 minute delay is imposed between the Lexiscan (Regadenoson) injection and start of myocardial perfusion PET imaging.
88827500|NCT01919450|Active Comparator|1 Minute Delay|A 1 minute delay is imposed between the Lexiscan (Regadenoson) injection and start of myocardial perfusion PET imaging.
88827501|NCT01602679|Experimental|micronized progesterone, then placebo|Participants first received oral micronized progesterone (100 mg p.o.) suspension. After a washout period of approximately 20 days, they then received placebo (matching oral micronized progesterone suspension).
88827502|NCT01602679|Placebo Comparator|Placebo, then micronized progesterone|Participants first received placebo. After a washout period of approximately 20 days, they then received oral micronized progesterone syrup (100 mg p.o.)Placebo contains only inert ingredients and is not expected to exert any direct physiological effects
88827503|NCT01919606|Experimental|EXPAREL Group 1|EXPAREL 266 mg diluted with saline to a volume of 40 mL
88827504|NCT01919606|Experimental|EXPAREL Group 2|EXPAREL 266 mg diluted with saline to a volume of 60 mL
88827505|NCT01663363|Experimental|wavefront-guided LASIK|LASIK correction of myopic refractive errors. Surgeons will perform wavefront-guided LASIK based upon measurement obtained with the iDesign System.
88827506|NCT01919996|Experimental|Azithromycin|Azithromycin oral suspension (immediate release) 12 mg/kg/day x 5 days
88827507|NCT02234713|Experimental|Behavioural Intervention/Feedback|The behavioral interventionist will contact the patient and parent by email and telephone to schedule a telephone call to review the downloaded adherence information and discuss barriers experienced by the patient/parent using a standard script. The behavioral feedback will be administered three times: at 1-, 2- and 3-months post-baseline.
88827508|NCT02234713|Active Comparator|Video Attention Control|The patients in this arm of the study will be emailed a link to an educational video about Pediatric MS and therapy for MS at three time points: 1-, 2-, and 3-months post-baseline.
88827509|NCT01921322|Experimental|Pump|Paradigm 722 insulin pump used for insulin infusion and continuous glucose monitoring
88827510|NCT01921322|Active Comparator|MDI|Multiple daily insulin injections used for treatment
88827511|NCT01665157|Experimental|low-residue diet package (Enimaclin®)|Low-residue diet package with normal amount 2L PEG-ELS
88827512|NCT01665157|Placebo Comparator|Self-controlled diet|Self-controlled diet with normal amount of 2L PEG-ELS
88827513|NCT01665157|Experimental|Low-residue diet (Enimaclin®) package|Low-residue diet package with low volume 1.5L PEG-ELS
88827514|NCT05735132|Active Comparator|Line arm|Conventional line blocking is used in radial artery cannulation for local infiltration.
88827515|NCT05735132|Experimental|Bar arm|Bar-blocking is used in radial artery cannulation for local infiltration.
88827516|NCT05735132|Experimental|V arm|V-blocking is used in radial artery cannulation for local infiltration.
88827517|NCT01943474|Experimental|AccuCath IV Catheter Device|AccuCath IV Catheter System will be used for IV therapy during inpatient stay. Intervention includes vascular access, fluid infusion, and blood sample removal
88827518|NCT01943474|Active Comparator|Conventional IV Catheter Device|Conventional IV catheter (current catheter) will be used for IV therapy during inpatient stay. Intervention includes vascular access, fluid infusion, and blood sample removal
88827519|NCT01667029|Experimental|sulfasalazine|1 g oral twice daily for 2 weeks
88827520|NCT01667029|Placebo Comparator|placebo|oral placebo pill twice daily for two weeks.
88827521|NCT01694641|Experimental|time-lapse morphokinetic evaluation|"Embryo selection for transfer based on a combind score made up of scores for kinetic parameters and standard morphology as seen on time-lapse: upon fertilization embryos in a petri dish that allows individual assessment (Primo Vision Dish) are placed onto an automated time-lapse equipment in an incubator. The time-lapse equipment performs imaging in 10 minutes intervals. The software is presenting the up-to-date images and allows the operator to assess the time-lapse movie of the developmental history of the embryos to perform annotations and apply evaluation/selection algorithm. This morpho-kinetic TL algorithm (made up of standard moprhology as seen on time lapse and kinetci scores) is used for embryo selection, which actually describes the intervention."
88827522|NCT01694641|No Intervention|standard embryo monitoring|Upon fertilization embryos are observed once on days 1-3-5 by the embryologist to check for development. The single embryo for transfer is selected based on actual morphology as seen under light microscope.
88827523|NCT05118633|Experimental|Experimental group - HabitAware condition|This group will receive the device which alerts the participant when performing hair pulling behavior and the app which provides psychoeducation and components of Habit Reversal Training.
88827524|NCT05118633|Placebo Comparator|Control group - reminder bracelet condition|This group will receive only a device that vibrates randomly several times per hour as a reminder not to pull, as well as being asked to journal about their daily activities in an app.
88827525|NCT02992093||obese with PCOS|all the indicators
88827526|NCT02992093||nonobese with PCOS|all the indicators
88827527|NCT02992093||PCOS with IGT|all the indicators
88827528|NCT02992093||PCOS with T2DM|all the indicators
88827529|NCT02992093||Healthy volunteers|all the indicators
88827530|NCT01669603|Experimental|Bifidobacterium animalis lactis Bl-04|Bifidobacterium animalis subspecies lactis Bl-04 as powder mixed into drink.
88827531|NCT01669603|Placebo Comparator|Placebo|Placebo will be 1g of sucrose that has identical appearance, smell, and taste with the study product.
88827532|NCT01606735|Experimental|Dose 1|
88827533|NCT01606735|Experimental|Dose 2|
88827534|NCT01606735|Experimental|Dose 3|
88827535|NCT01943864|Experimental|Trametinib (single tablet)|Subjects will receive, trametinib once daily as a single tablet of 2 mg administered orally with eight ounces of water under fasting conditions either one hour before or 2 hours after a meal.
88827536|NCT01943864|Experimental|Trametinib PK study (multiple tablet)|Subjects will receive on Day 1, trametinib as four tablets of 0.5 mg administered orally with eight ounces of water under fasting conditions either one hour before or 2 hours after a meal.
88827537|NCT01943864|Experimental|Trametinib PK study (single tablet)|Subjects will receive Day 2 onwards, trametinib once daily as a single tablet of 2 mg administered orally with eight ounces of water under fasting conditions either one hour before or 2 hours after a meal.
88827538|NCT05100459|Experimental|Pasture-raised whey protein|whey protein from strictly grass fed cows
88827539|NCT05100459|Experimental|Conventional whey protein|whey protein from conventional animal feeding operation
88827540|NCT05100459|Placebo Comparator|Placebo|Maltodextrin given in iso-caloric amounts to protein
88827541|NCT01607203|Active Comparator|hCG|5000 IU Pregnyl SC
88827542|NCT01607203|Active Comparator|hCG and GnRH agonist|5000 IU Pregnyl SC + 0.2 mg Decapeptyl daily SC
88827543|NCT01921634|Other|Standard analysis|Standard pathological analysis currently used.
88827544|NCT01921634|Other|Modified Pathologic Analysis|After undergoing standard pathologic analysis, each specimen will then undergo the modified pathologic analysis.
88827545|NCT01922024||Prospective Fresh Clinical Specimens|Patients with suspicion of lower respiratory tract infection (pneumonia), samples tested with Unyvero LRT 55 cartridge and results compared against composite (comparator) which is based on routine clinical microbiology and a second PCR test
88827546|NCT01922024||Retrospective Frozen Clinical Specimens|Patients with suspicion of lower respiratory tract infection (pneumonia), samples tested with Unyvero LRT 55 cartridge and results compared against routine clinical microbiology
88827547|NCT00000387|Experimental|A,1,III|Behavioral intervention - Self management therapy
88827548|NCT00000387|Active Comparator|A,2,III|Regular treatment
88827549|NCT01922336|Experimental|SB2|SB2 (Study drug)
88827550|NCT01922336|Active Comparator|EU Remicade|EU sourced Remicade (Reference drug)
88827551|NCT01922336|Active Comparator|US Remicade|US sourced Remicade (Reference drug)
88827552|NCT01608061|Experimental|DBS-f on|DBS-f on
88827553|NCT01608061|Sham Comparator|DBS-f off|DBS-f off
88827554|NCT01924442||On-Pump|Cardiac bypass using Heart Lung Machine
88827555|NCT01924442||Off-Pump|Cardiac bypass surgery on beating heart
88827556|NCT01696357||Adolescents with asthma|Ages 13-17 with an asthma diagnosis-both symptomatic and non-symptomatic- and with currently prescribed asthma medication.
88827557|NCT01696357||Adolescents without asthma|Ages 13-17 without an asthma diagnosis and without any other respiratory condition that presents with asthma-like symptoms.
88827558|NCT04330755|Placebo Comparator|Group C|Control group will received saline
88827559|NCT04330755|Active Comparator|Group L|Levosimendan group will received levosimendan infusion
88827560|NCT04330755|Active Comparator|Group M|Levosimendan and Magnesium sulphate group will received both drugs
88827561|NCT04366323|Experimental|Experimental|
88827562|NCT04366323|No Intervention|Control|
88827563|NCT01944644|Active Comparator|Active Low Field Magnetic Stimulation|LFMS will follow a previously published protocol for the treatment of a Major Depressive Episode (Rohan et al. 2004). Active Low Field Magnetic Stimulation treatments will be delivered with a prototype LFMS device manufactured by Tal Medical. LFMS sessions consist of proton echo-planar magnetic resonance spectroscopic imaging (EP-MRSI) and will be 20min in duration. LFMS exposes subjects to magnetic fields of the same magnitude and frequency used in clinical MR-Spectroscopic imaging of the brain.
88827564|NCT01944644|Sham Comparator|Sham Low Field Magnetic Stimulation|Sham Low Field Magnetic Stimulation will consist of a three-dimensional spoiled gradient echo sequence of the same duration as active LFMS and which provides auditory stimulation indistinguishable from active treatment.
88827565|NCT01608295|Experimental|Vilazodone; Viibryd|After screening and baseline test results are reviewed and eligibility criteria are confirmed, medications will be dispensed if patients continue to meet eligibility criteria and sign the informed consent form. All eligible subjects will be randomized to vilazodone or paroxetine group using a computer-generated random assignment scheme, which assigned subjects in a 1:1 ratio to each group. Randomization will be done prior to subject's being assigned to the groups. Doses of the drugs will be adjusted according to individual tolerability and safety.
88827566|NCT01608295|Experimental|Paroxetine; Paxil|After screening and baseline test results are reviewed and eligibility criteria are confirmed, medications will be dispensed if patients continue to meet eligibility criteria and sign the informed consent form. All eligible subjects will be randomized to vilazodone or paroxetine group using a computer-generated random assignment scheme, which assigned subjects in a 1:1 ratio to each group. Randomization will be done prior to subject's being assigned to the groups. Doses of the drugs will be adjusted according to individual tolerability and safety.
89534016|NCT01247597||DICER1 (cases)|People with pathogenic DICER1 germline variation or history of DICER1-associated tumors
89356957|NCT05859425|Experimental|US-guided biofeedback intervention|This group received visual feedback using real-time ultrasound (US) for transversus abdominus (TrA) activation, while performing the exercise programme. US-guided TrA imaging was initially performed with participants in crook lying, with the US head positioned along the lateral abdominal wall with reference points at the lower point of the rib cage (last rib) and the anterior superior iliac spine, on the right side of the person, midway between these two points. The US head was moved until the user (health professional-investigator) had the best possible visualization of the lateral abdominal muscles (external oblique, internal oblique and TrA). During the execution of the exercises, the participants could watch the ultrasound screen along with the therapist's guidance, thus receiving information (US-visual feedback) of their TrA activation.
89356958|NCT05859425|Active Comparator|Control (non-US guided) group|The control group received the traditional tactile feedback from the therapist while performing the motor control exercises for TrA activation. Traditionally, assessment of TrA contraction involves palpation of the muscles. The ability to assess TrA through muscle palpation is largely dependent on examiner's skill, as TrA cannot be directly palpated (feedback sensation being limited from internal oblique muscle). To control the activation of the abdominals the therapist placed his hands on the inside of the anterior superior iliac crests (tactile feedback) and instructed the examinee to pull the abdominal wall inward without moving the spine or pelvis (verbal feedback). The same exercise protocol to the experimental group was performed in this (control) group.
89356959|NCT05857709||Cystic fibrosis|No intervention - only assessments.
89356960|NCT05857709||Healthy Control|No intervention - only assessments.
88827567|NCT04713111|Other|Lifestyle Intervention Group (Exercisers)|"All Interested and enrolled participants in the main Stress and Recovery were invited to participate in a lifestyle intervention arm. Participants were instructed to self-select into either a physical activity arm, or a meditation arm.~Participants were excluded if they were already partaking in both regular physical exercise, and meditation.~Those in the meditation arm (exercisers) were instructed to complete meditation sessions from the smartphone app, Headspace, 2 or more times a week for a duration of 4 weeks."
88827568|NCT04713111|Other|Lifestyle Intervention Group (Meditators)|"All Interested and enrolled participants in the main Stress and Recovery were invited to participate in a lifestyle intervention arm. Participants were instructed to self-select into either a physical activity arm, or a meditation arm.~Participants were excluded if they were already partaking in both regular physical exercise, and meditation.~Those in the physical activity arm (meditators) were instructed to complete 30 minutes to 1 hour of physical activity for 2 or more sessions per week for 4 weeks."
88827569|NCT04713111|No Intervention|Garmin wearable arm|Existing stress and recovery participants were invited to participate in a Garmin wearable arm where they were provided a Garmin Vivoactive 4 smartwatch to wear continuously, and in particular, while they were on shift at work for a total of 4 consecutive weeks.
88827570|NCT04713111|No Intervention|Hair cortisol arm|Interested existing stress and recovery participants were invited to participate in a one time hair sample collection for cortisol analysis.
88827571|NCT01944878||Patients with chronic hepatitis|Patients with chronic hepatitis, who experienced HVPG measurement via transjugular approach and EGD within 3 months of HVPG measurement
88827572|NCT01944878||Patients with liver cirrhosis|Patients with liver cirrhosis, who experienced HVPG measurement via transjugular approach and EGD within 3 months of HVPG measurement
88827573|NCT04713189|Experimental|Inhaled fentanyl aerosol|Participants in the stage I were randomized to 6 BTP episodes, in which 4 BTP episodes were treated with inhale fentanyl aerosol (with a starting dose of 25 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×25 µg) and 2 BTP episodes with placebo(0 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×0µg) in a random sequence.
88827574|NCT04713189|Experimental|Placebo|Participants in the stage I were randomized to 6 BTP episodes, in which 2 BTP episodes were treated with placebo (0 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×0µg) in a random sequence.
88827575|NCT01610011|Experimental|Glycine administration|Glycine will be administered once orally to all subjects to determine brain and plasma pharmacodynamics.
88827576|NCT04712955|Active Comparator|Bloodflow restricted exercise|Healthy subjects undergoing low intensity blood flow restricted resistance exercise (BFRRE) conducted as 4 sets of bilateral knee extensions at 30% of 1RM until voluntary fatigue. The sets are intercepted by 30 seconds of rest (during rest the cuff's are still inflated).
88827577|NCT04712955|No Intervention|Non-exercise control|No intervention.
88827578|NCT01945112|Experimental|Paper Tape|Paper tape will be applied to study participants' blister prone areas or a randomly selected spot (if no blister history on that foot) - with untaped areas of the same foot as control.
88827579|NCT02237989|Active Comparator|paracetamol|The 1st group includes 19 patients given 1500mg/day paracetamol for three months
88827580|NCT02237989|Experimental|native collagen type 2 + paracetamol|The 2nd group consists of 20 patients given 1500mg/day paracetamol and 10mg/day native collagen type 2 for three months
88827581|NCT00382473|Experimental|exercise|
88827582|NCT05326893|Experimental|Study Group|"Femoral nerve neurodynamic mobilization group~T1: Baseline measurements were made and blood samples were taken for biochemical analysis.~NM and placebo NM techniques were applied for three weeks, three times a week, and totaling nine visits. At the end of the third week, it was waited 3 days to eliminate the acute effect of NM.~T2: Baseline measurements and blood samples were repeated a second time.~The protocol for establishing the DOMS was applied on the same day.~T3: Following the protocol for inducing the DOMS, the baseline measurements were repeated for the third time without any interruption, and the blood sample was taken.~T4-T5-T6: The first measurements and blood sample collections were repeated for the fourth, fifth and sixth times, respectively, 24h, 48h, 72h after the DOMS protocol."
88827583|NCT05326893|Placebo Comparator|Placebo Group|"Femoral nerve placebo neurodynamic mobilization group~T1: Baseline measurements were made and blood samples were taken for biochemical analysis.~NM and placebo NM techniques were applied for three weeks, three times a week, and totaling nine visits. At the end of the third week, it was waited 3 days to eliminate the acute effect of NM.~T2: Baseline measurements and blood samples were repeated a second time.~The protocol for establishing the DOMS was applied on the same day.~T3: Following the protocol for inducing the DOMS, the baseline measurements were repeated for the third time without any interruption, and the blood sample was taken.~T4-T5-T6: The first measurements and blood sample collections were repeated for the fourth, fifth and sixth times, respectively, 24h, 48h, 72h after the DOMS protocol."
88827584|NCT05439681|Experimental|MCO - low flux - high flux - HDF|"Patients who are on hemodialysis will be treated with four different hemodialysis sessions:~Treatment 1: MCO membrane~Treatment 2: low flux membrane~Treatment 3: high flux membrane~Treatment 4: HDF treatment with high flux membrane The order of the treatment regimens with the different membranes will be randomized."
88827585|NCT05439681|Experimental|low flux - high flux - MCO - HDF|
88827586|NCT05439681|Experimental|high flux - HDF - low flux - MCO|
88827587|NCT05439681|Experimental|HDF - MCO - high flux - low flux|
88827588|NCT02992717||Patients undergoing elective general anaesthesia|Male and female adult patients undergoing elective general anaesthesia.
88827589|NCT01945970|Experimental|Black tea extract|Spray dried aqueous extract of a representative batch of black tea
88827590|NCT01945970|Active Comparator|Positive control|Spray dried aqueous extract of a batch of tea extract that has shown to improve FMD previously
88827591|NCT01945970|Placebo Comparator|Placebo|Food grade colouring, artificial tea flavour and an amount of caffeine matched to the caffeine in the Black tea extract
88827592|NCT02229487|Active Comparator|Normal Sleepers|Prediabetes patients with normal sleep duration (7-8 hours/ night) as measured objectively
88827593|NCT02229487|Experimental|Short Sleepers|Prediabetes patients with short sleep duration (<6 hours/night) as measured objectively
88827594|NCT02992561|Active Comparator|Narrative Exposure Therapy (FORNET, adapted version)|Version of Narrative Exposure Therapy for Forensic Offender Rehabilitation including one lifeline session and 5 exposure sessions as well as 6 group sessions adapted from behavioral-therapy approaches for addiction problems.
88827595|NCT02992561|No Intervention|Waitlist control or treatment as usual|No intervention or non-specific measures of support on request
88827596|NCT01946126||Chronic Migraine Diagnosis|This is a retrospective chart review for patients diagnosed with Chronic Migraine. There is no intervention in this study.
88827597|NCT01946126||Other Headache Diagnoses|This is a retrospective chart review of patients with headache diagnoses other than Chronic Migraine. There is no intervention in this study.
88827598|NCT01673113|Experimental|Cryolipolysis|All subjects were randomized to have either the left of right flank treated with single the Zeltiq CoolSculpting Device, which is an FDA approved cooling device used for non-invasive and selective reduction of fat around the flanks. Sensory testing was done before and after the procedure.
88827599|NCT01673113|No Intervention|Control|All subjects were randomized to have either the left of right flank treated with single the Zeltiq CoolSculpting Device. The untreated flank served as the internal control for each subject.
88827600|NCT01924988|Experimental|Prostatic Embolization|Therapeutic occlusion of the prostate arteries
88827601|NCT05320263|Experimental|contact aspiration first line thrombectomy|Patient randomized in this arm will have the first arm thrombectomy by contact aspiration
88827602|NCT05320263|Sham Comparator|Stent retriever first line thrombectomy|Patient randomized in this arm will have the first arm thrombectomy by Stent retriever
88827603|NCT01673191|Experimental|OZURDEX intraocular implant|OZURDEX (dexamethasone posterior segment drug delivery system (DEX PS DDS), 0.7 mg
88827604|NCT01673191|Active Comparator|Steroid plus NSAID eye drop combination therapy|NSAID eye drop: Acular LS Steriod eye drop: Pred Forte
88827605|NCT05734742|Experimental|Video|
88827606|NCT01925144|Experimental|Baricitinib|Baricitinib - 10 milligram (mg) tablet administered orally, once, on Day 1.
88827607|NCT01925144|Experimental|Baricitinib + Omeprazole|Baricitinib - 10 mg tablet administered orally, once, on Day 10. Omeprazole - 40 mg capsule administered orally once daily (QD) for 8 days (Days 3 through 10).
88827608|NCT01673893||ST elevation myocardial infarction|"The registry will record the use of the ClearWay™ Rx catheter during the index procedure, and assess whether or not the patient was readmitted within 30 days, related to the index procedure.~1st Group/Cohort - ST elevation myocardial infarction"
88827609|NCT01673893||Non-ST elevation myocardial infarction/ACS/UNSTABLE ANGINA|"The registry will record the use of the ClearWay™ Rx catheter during the index procedure, and assess whether or not the patient was readmitted within 30 days, related to the index procedure.~2nd Group/Cohort - Non-ST elevation myocardial infarction/ACS/Unstable Angina"
88827610|NCT00000435|Placebo Comparator|A|Subjects randomized to arm A received 25mg/day po of placebo
88827611|NCT00000435|Active Comparator|B|Subjects randomized to Arm B received 25mg/day po of peptide dnaJP1
89356961|NCT05856500|Placebo Comparator|basic nutrition|basic nutrition treatment, energy 30-35 kcal/kg, protein 1.0-2.0 g/kg, total nutrition and/or whey protein oral nutrition supplement or tube feeding enteral nutrition supplement if diet deficiency;
89356962|NCT05856500|Experimental|oral supplement of creatine and curcumin|On the basis of basic nutrition in group A, creatine 5g/d and curcumin 4g/d are orally added, and the intervention time is 1 month.
88827612|NCT01675063|Other|Retia Non-Invasive Sensors|Sensors will be placed on the patient and connected to an amplifier that produces a waveform for 8 hours post cardiac surgery.
88827613|NCT01927718|Experimental|Thalidomide + Lenalidomide|"Thalidomide 100 mg by mouth daily for 28 days in a 28 day cycle started after the clinical documentation of biochemical progression.~Lenalidomide continued by mouth at the previous dose of 5 mg daily for 21 days on a 28 day cycle, 5 mg daily for 28 days on a 28 day cycle, 10 mg daily for 28 days on a 28 day cycle, or 15 mg daily for 28 days on a 28 day cycle."
89356963|NCT05850806|Experimental|KmAsthma self-management smart phone app intervention|Participants assigned to the intervention arm will be given a link to download the self-management app on their Android smartphone or iPhone
89356964|NCT05850806|No Intervention|Control arm|Will emulate standard access to asthma self-management information
89356965|NCT05828303|Experimental|Repotrectinib (TPX-0005)|Phase 1 Oral repotrectinib (TPX-0005) + cocktail drugs (metformin hydrochloride, digoxin, rosuvastatin calcium)
88827614|NCT05734664|Experimental|Scan with Pulsify sensor|A trained operator will perform on each volunteer two scans with the Pulsify sensor. Both scans will have a different orientation of the sensor.
88827615|NCT05734664|Experimental|Scan with state-of-the-art ultrasound equipment|Immediately after acquisition with the Pulsify sensor, an echocardiographist will record a complete 2D and 3D ultrasound data set using a state-of-the-art equipment.
88827616|NCT02238847|Active Comparator|WallFlex Biliary RX Fully Covered Stent System|"Patients in this group will receive a fully covered study SEMS (self-expanding metal stent)~Reintervention can occur with either a WallFlex™ Biliary RX Fully Covered or Uncovered Stent System"
89356966|NCT05818761|Experimental|virtual reality|watching the application by wearing virtual glasses to the child during the phlebotomy
89356967|NCT05818761|Experimental|Stress ball|a stress ball will be given to the child's hand, and he will be asked to squeeze continuously before the blood draw attempt begins, and to continue squeezing during the procedure.
89356968|NCT05818761|No Intervention|control|standard approach
88827617|NCT02238847|Active Comparator|WallFlex Biliary RX Uncovered Stent System|"Patients in this group will receive an uncovered study SEMS (self-expanding metal stent).~Reintervention can occur with either a WallFlex™ Biliary RX Fully Covered or Uncovered Stent System"
88827618|NCT01948310|Active Comparator|Ranolazine plus Exercise|Ranolazine 1000mg pill twice per day plus aerobic exercise three times per week, 45 minutes per session at an intensity of 10-20 beats per minute below the angina threshold.
88827619|NCT01948310|Placebo Comparator|Placebo plus Exercise|Placebo pill twice per day plus aerobic exercise three times per week, 45 minutes per session at an intensity of 10-20 beats per minute below the angina threshold.
88827620|NCT04499547|Experimental|Physical activity intervention|Will receive twice-weekly, YouTube-delivered aerobic and muscle-strengthening physical activity videos for 8 weeks.
88827621|NCT04499547|No Intervention|General health education control|Will receive twice-weekly, YouTube-delivered videos with general health education information for 8 weeks.
88827622|NCT01948388|Active Comparator|corticotrophin 80 units|Ten (10) patients will receive 80 units of corticotrophin Subcutaneous (SC) weekly
88827623|NCT01948388|Active Comparator|corticotrophin 80 units twice a week|Ten (10) patients will receive 80 units of corticotrophin Subcutaneous (SC) twice a week
88827624|NCT05045625|Experimental|Study Group|Twelve patients offered SCS for standard of care were also invited to participate in this study, in which a study electrode was temporarily placed intraoperatively and neuromonitoring was done per our routine standard-of-care
89356969|NCT05816941|Other|Control Arm|Conventional Periodontal Treatment: Complete Oral Disinfection.
89356970|NCT05816941|Experimental|Experimental Arm|Conventional Periodontal Treatment (Complete Oral Disinfection) and Adjunctive Photodynamic Therapy in periodontal pockets with PPD ≥ 5 mm.
89356971|NCT05801705||OFS+AI|patients undergoing ovarian function suppression (OFS) combined with aromatase inhibitor (AI)
89356972|NCT05801705||OFS+TAM|patients undergoing ovarian function suppression (OFS) combined with tamoxifen (TAM)
89356973|NCT05801705||OFS+TOR|patients undergoing ovarian function suppression (OFS) combined with torimifene (TOR)
89356974|NCT05798624||One CS with isthmocele|
89356975|NCT05798624||More than one CS with Isthmocele|
89356976|NCT05798624||One or more CS without isthmocele|
89356977|NCT05798624||With previous vaginal delivery|
89356978|NCT05798624||With first ongoing pregnancy|
89356979|NCT05778617|Active Comparator|Ambroxol hydrochloride|"Participants will receive ambroxol hydrochloride (tablets) for 104 weeks (blinded treatment period). Participants will receive ambroxol hydrochloride 420mg daily for Days 1-5, then 840mg daily for Days 6-10, then 1260mg for the remainder of the blinded treatment period. Participants will then enter the open-label extension and will receive ambroxol hydrochloride 420mg daily for Days 1-5, then 840mg daily for Days 6-10, then 1260mg for the remainder of the open-label extension phase.~n=165"
89356980|NCT05778617|Placebo Comparator|Placebo|"Participants will receive ambroxol hydrochloride matching placebo (tablets) for 104 weeks (blinded treatment period). Participants will receive ambroxol hydrochloride matching placebo 420mg daily for Days 1-5, then 840mg daily for Days 6-10, then 1260mg for the remainder of the blinded treatment period. Participants will then enter the open-label extension and will receive ambroxol hydrochloride 420mg daily for Days 1-5, then 840mg daily for Days 6-10, then 1260mg for the remainder of the open-label extension phase.~n=165"
89356981|NCT05774886|Experimental|IMD Placement and Retrieval|"Participants with confirmed anatomic stage II-III TNBC whose planned treatment includes neoadjuvant systemic therapy with the intention to undergo surgery, including breast and/or axillary surgery, will be selected for study participation.~Participants will undergo image-guided placement of 2 microdevices within a single lesion.~Participants will undergo image-guided retrieval of the microdevices (and surrounding tissue) approximately 72 hours after placement.~Participants will be monitored for safety endpoints and clinical data will be collected for the duration of the study."
89356982|NCT05766592|Experimental|LGBTQ-affirmative CBT|Individuals assigned to LGBTQ-affirmative cognitive behavioral therapy will receive 16 weekly individually-delivered sessions, directly after baseline assessment, delivered via telehealth. Based on the Unified Protocol, sessions will address minority stress mechanisms underlying sexual and gender minority mental health disparities.
89356983|NCT05766592|Experimental|ABFT-SGM|Individuals assigned to attachment-based family therapy for sexual and gender minorities will receive a 16-session sequence of family-based therapy delivered via telehealth. This sequence will include sessions with sexual and/or gender minority adult children alone, adult children and parent(s), and parent(s) alone. Sessions will address the quality parent-child relationship in relation to child sexual orientation and gender identity to target mental health disparities.
89356984|NCT05764564|Experimental|Experimental: Patients with heart failure (Aim 1)|
89356985|NCT05764564|Active Comparator|Control: Healthy Volunteers (Aim 1)|
89356986|NCT05764564|Experimental|Experimental: Patients with heart failure (Aim 2)|
89356987|NCT05749679|Experimental|Training|Physicians participating will receive training on renal failure in type 2 diabetes and on measures to reduce nephron loss
89356988|NCT05749679|Sham Comparator|Routine care|
89356989|NCT05743777|Experimental|Pembrolizumab + MET-4|
89356990|NCT05743777|Active Comparator|Pembrolizumab + Placebo|
89356991|NCT05725811|Active Comparator|Intervention group 1|"A myofascial release technique will be performed using a foam roller (Blackroll Standard, 30 x 15 cm) on the dominant lower limb.~For the IG 1, the technique will be applied to the hamstrings muscles. In this group, participants will sit on the floor on a mat with the roller under their thighs. Their hands will be placed on the floor with their fingers pointing downwards. The foam roller will be in contact with the muscle being tested and the patient will exert a load until they feel a slight pain. In this way, the patient performs a self-massage in the direction of the muscle fibers. The limb that will not be tested will function as a lever, it will remain bent to the side, which will allow the simple realization of the glide.~A cycle of the procedure will be defined as a proximal to distal rolling movement, so the frequency in this study will be 25 cycles per minute measured with a metronome from a mobile application (Smart Metronome & Tuner v.11.8 IOS)."
89356992|NCT05725811|Active Comparator|Intervention group 2|"A myofascial release technique will be performed using a foam roller (Blackroll Standard, 30 x 15 cm) on the dominant lower limb.~The IG 2 will perform the same technique on a different muscle group: the quadriceps. In this way, the positioning will be different, the participants will be in the prone position, in a plank position, leaning on the forearms, the body well aligned and the studied lower limb well stretched. However, the participant will also perform a self-massage in the direction of the muscle fibers until they feel slight pain. The duration of the procedure will be set at 4 minutes in this study; 3 rounds of 1 minute (30 s rest).~A cycle of the procedure will be defined as a proximal to distal rolling movement, so the frequency in this study will be 25 cycles per minute measured with a metronome from a mobile application (Smart Metronome & Tuner v.11.8 IOS)."
89356993|NCT05725811|No Intervention|Control group|The participants will remain at rest in a chair for 4 minutes.
89356994|NCT05705687|Other|Favorable-BEP group|"Favorable decline of tumor markers~3 subsequent cycles of protocol BEP every 3 weeks~Cisplatin 20 mg/m2/day IV x 5 days (D1 to D5),~Etoposide 100 mg/m2/day IV x 5 days (D1 to D5)~Bleomycin 30 mg/day IV or IM D1, D8, and D15."
88827625|NCT01928030|Experimental|recombinant human hyaluronidase|Phase 1. 450 units recombinant human hyaluronidase (rHuPH20) administered SC on days 1, 3, 5, and 7 Phase 2: 900 units recombinant human hyaluronidase (rHuPH20) administered SC on days 1 to 21
88827626|NCT01675297|Experimental|Risendronate/Cholecalciferol combination|Risendronate/Cholecalciferol combination Risenex Plus tablet: one tablet once a week for 12months
88827627|NCT01675297|Active Comparator|Risedronate|Sedron tablet: one tablet once a week for 12months
88827628|NCT05295537|Active Comparator|PERCUTANEOUS LIVER BIOPSY (PLB)|Patients randomized to percutaneous liver biopsy.
88827629|NCT05295537|Experimental|ENDOSCOPIC ULTRASOUND GUIDED LIVER BIOPSY (EUS - LB)|Patients randomized to EUS-guided liver biopsy
88827630|NCT02287376|Experimental|Diclofenac Potassium|Diclofenac Potassium for Oral Solution 50 mg
89530261|NCT03346265|Experimental|Group A|"Treatment A consisted in a combined exercise program of 40 min duration RMP (Monari, 2004; Monari et al., 2016) and 20 min duration of gait training with sensory cues.~RMP. RMP protocol was based on lengthening and muscular recruitment exercises by means of complex motor skills involving muscular kinetic chains in lower limbs and trunk. Each session was divided into muscular stretching exercise, aiming to increase step length and rotating trunk movements, and tailored progressive exercise therapy."
89534017|NCT01224704|Experimental|Lean: hypertonic first|Lean: Hypertonic solution at day 6 and water deprivation at day 10
88827631|NCT01675453|Active Comparator|7.2% NaCl /hydroxyethyl starch 200/0.5|On-pump CABG. 7.2% NaCl plus 6% hydroxyethyl starch 200/0.5 solution (HyperHAES) 4 mL/kg for 30 min, IV (in the vein), once, starting after the first hemodynamic measurement is obtained (before the beginning of CPB)
88827632|NCT01675453|Placebo Comparator|0.9% NaCl|On-pump CABG. 0.9% NaCl (isotonic saline) 4 mL/kg for 30 min, IV (in the vein), once, starting after the first hemodynamic measurement is obtained (before the beginning of CPB)
88827633|NCT01928186|Experimental|Diagnostic (FLT PET)|Patients undergo FLT PET at baseline and 1-6 weeks after the start of treatment.
88827634|NCT01611571|Active Comparator|Active Risedronate Placebo Teriparatide|Active Risedronate + Placebo Teriparatide for 18 months / Active Risedronate for 6 months
88827635|NCT01611571|Active Comparator|Active Risedronate Active Teriparatide|Active Risedronate + Active Teriparatide for 18 months / Active Risedronate for 6 months
88827636|NCT01611571|Active Comparator|Placebo Risedronate Active Teriparatide|Placebo Risedronate Active Teriparatide for 18 months / Active Risedronate for 6 months
88827637|NCT05505890||SFIPB|"suprainguinal fascia iliaca plane block with 50ml of %0.25 bupivacaine will be used for postoperative analgesia~."
88827638|NCT05505890||control|Fascia iliac block will not be applied to this group. Postoperative analgesia will be provided with other analgesia modalities.
89188818|NCT02601599|Experimental|Intervention|Motivational interviewing The medical student will deliver a 15 minute consultation with the patient. The goals of this consultation will be to enhance the patient's motivation and self-efficacy regarding quitting, educate the patient about effective behavioral and pharmacological cessation strategies, and collaboratively elicit a plan to stay quit after discharge. Patients will be offered the opportunity to receive a consultation from the attending physician to determine eligibility for pharmacotherapy. Patients who elect to receive this consult with have a coloured sticker placed by the medical student on the medical chart requesting a consultation.
88827639|NCT05734430||GAP Social|Individuals ages 18+ years with an appendix cancer diagnosis in the United States.
88827640|NCT05734430||GAP Vanderbilt|Individuals ages 18+ years with an appendix cancer diagnosis seen at Vanderbilt.
88827641|NCT05734430||GAP Parent|Biological parents of active GAP (Social and Vanderbilt) Study participants.
88827642|NCT05733884|Experimental|Daily Disposable Multifocal Soft Contact lenses, PEGAVISION, Taiwan|Subjects will be asked to wear the lenses for 8 hours a day, at least 7 days a week. Contact lenses are worn and replaced every day. All subjects will be followed for 1 year after device allocation and will undergo brief clinical assessments at 1 day, 1 week, 1, 3, 6, 9, and 12 months.
88827643|NCT05733884|Active Comparator|Omafilcon A, dual-focus optical design, USA|Subjects will be asked to wear the lenses for 8 hours a day, at least 7 days a week. Contact lenses are worn and replaced every day. All subjects will be followed for 1 year after device allocation and will undergo brief clinical assessments at 1 day, 1 week, 1, 3, 6, 9, and 12 months.
88827644|NCT02238925|Experimental|CPX-351|"Single Arm Study (Patients may receive up to 2 Inductions and 4 Consolidations):~Induction 1: CPX-351 will be given intravenously at 100units/m2 on days 1, 3, and 5 over a 90 minute infusion.~Induction 2: CPX-351 will be given intravenously at 100units/m2 on days 1 and 3 over a 90 minute infusion.~Consolidations 1-4: CPX-351 will be given intravenously at 65units/m2 on days 1 and 3 over a 90 minute infusion."
88827645|NCT02987192|Experimental|traditional group|Traditional group patients will receive cutting type 22 gauge needles
88827646|NCT02987192|Experimental|minimally invasive group|minimally invasive group patients will receive pen type 27 gauge needles
88827647|NCT01950260|Experimental|Levothyroxine|In the intervention arm patients will start levothyroxine therapy at 4 weeks after RAI therapy. The initial dose of levothyroxine will be 25 mcg/day. It will be increased to 50 mcg/day 2 weeks later and then adjusted at 8 weeks post RAI based on a full face-to-face clinical and biochemical evaluation.
88827648|NCT01950260|Placebo Comparator|Placebo|In the control arm patients will receive placebo capsules and be evaluated for levothyroxine therapy during a full face-to-face evaluation at 8 weeks.
88827649|NCT01676311|Experimental|Huperzine A|Huperzine A will be administered to patients, titrating dose up from 100mcg/day to 600mcg per day over the course of 20 days - and remaining on the dose of 600mcg/day for the remainder of the drug phase (64 days) - for a total of 12 weeks on Huperzine A.
88827650|NCT01676311|Placebo Comparator|Placebo|Placebo will be administered to patients at the same frequency/intervals as the experimental arm (Huperzine-A).
88827651|NCT05036187|Experimental|Weight Loss Program Only|Participants complete an online behavioral weight loss program.
88827652|NCT05036187|Experimental|Weight Loss Program + Coping with Stress Program|Participants complete (1) an online behavioral weight loss program and (2) an adjunctive intervention that teaches strategies for coping with stress & stigma due to weight, sexual orientation, and gender & its impact on weight loss.
88827653|NCT05036187|Experimental|Weight Loss Program + Coping with Stress Program + Body Image Program|Participants complete (1) an online behavioral weight loss program, (2) an adjunctive intervention that teaches strategies for coping with stress & stigma due to weight, sexual orientation, and gender & its impact on weight loss, and (3) an adjunctive intervention for improving negative body image and reducing its impact on weight loss.
89177541|NCT00646906|Experimental|Phase 2: Acetaminophen vs. Ibuprofen|"Eight male and non-pregnant female subjects who are healthy and non-smoking will be recruited. In one period of this crossover study acetaminophen (1000 mg p.o.) will be administered orally at 8 AM, 2 PM, 8 PM and 2 AM for 3 days (see Crossover Period: Acetaminophen 4000 mg/d intervention). The last dose will be administered on day four at 8 AM In the other crossover period, after a washout period of at least 14 days, the subjects will receive ibuprofen (200 mg) orally at at 8 AM, 2 PM, 8 PM and 2 AM for 3 days (see Crossover Period: Ibuprofen 800 mg/d intervention). The last dose will be administered on day four at 8 AM Study assessments will be performed on day 1 and day 4 of each crossover period. The occurrence of the two crossover periods will be randomized by order."
89177542|NCT00808600|Other|resource-activating training, intensified exercise training|combination of the two interventions: resource-activating behavioural training and intensified exercise training
89534018|NCT01224704|Experimental|Lean: water deprivation first|Lean: Water deprivation at day 6 and hypertonic solution at day 10
88827654|NCT05036187|Experimental|Weight Loss Program + Coping with Stress Program + Body Image Program + Social Support Program|Participants complete (1) an online behavioral weight loss program, (2) an adjunctive intervention that teaches strategies for coping with stress & stigma due to weight, sexual orientation, and gender & its impact on weight loss, (3) an adjunctive Social Support Intervention that provides participants with online opportunities to give and receive real-time social support for weight loss efforts, and (4) an adjunctive intervention for improving negative body image and reducing its impact on weight loss.
88827655|NCT05036187|Experimental|Weight Loss Program + Body Image Program + Social Support Program|Participants complete (1) an online behavioral weight loss program, (2) an adjunctive Social Support Intervention that provides participants with online opportunities to give and receive real-time social support for weight loss efforts, and (3) an adjunctive intervention for improving negative body image and reducing its impact on weight loss.
88827656|NCT05036187|Experimental|Weight Loss Program + Coping with Stress Program + Social Support Program|Participants complete a (1) online behavioral weight loss program, (2) an adjunctive intervention that teaches strategies for coping with stress & stigma due to weight, sexual orientation, and gender & its impact on weight loss, and (3) an adjunctive Social Support Intervention that provides participants with online opportunities to give and receive real-time social support for weight loss efforts.
88827657|NCT05036187|Experimental|Weight Loss Program + Body Image Program|Participants complete (1) an online behavioral weight loss program and (2) an adjunctive intervention for improving negative body image and reducing its impact on weight loss.
88827658|NCT05036187|Experimental|Weight Loss Program + Social Support Program|Participants complete (1) an online behavioral weight loss program and (2) an adjunctive Social Support Intervention that provides participants with online opportunities to give and receive real-time social support for weight loss efforts.
88827659|NCT01951118|Experimental|Donepezil Treatment & Atropine Challenge|Atropine nasal spray is administered at baseline for the atropine challenge which involves administration of the 40-item UPSIT immediately before and 45 minutes after atropine administration. Immediately after the atropine challenge, donepezil treatment is started and continues for 52 weeks.
89177543|NCT00808600|Other|resource-activating training, moderate exercise training|combination of the two interventions: resource-activating training and moderate exercise training
89177544|NCT00808600|Other|relaxation training, intensified exercise training|combination of the two interventions: relaxation training and intensified exercise training
89177545|NCT00808600|Other|relaxation training, moderate exercise training|combination of the two interventions: relaxation training and moderate exercise training
89177546|NCT00813436|Experimental|1|Oxytocin
89177547|NCT00813436|Placebo Comparator|2|Placebo
89177548|NCT00642772|Experimental|Group Physical Therapy|12-week group-based program of physical therapy. Participants will meet approximately every other week for a total of 6 visits. The group sessions will include education about appropriate self-care for knee osteoarthritis and instructions and participation in group exercises. Participants will also be instructed in a home exercise program.
89177549|NCT00808678|Experimental|1|ABT-143 capsules 20/135 mg
89177550|NCT00808678|Active Comparator|2|ABT-335 135 mg and rosuvastatin 20 mg
89177551|NCT00815854|Experimental|Folate|"During Phase 1, participants will undergo screening for metabolic syndrome and have genetic makeup, body size, and endothelial functioning measured. During Phase 2, participants will receive daily folic acid as a treatment for metabolic syndrome.~Phase 2B participants will receive either daily folic acid or placebo as a treatment for metabolic syndrome."
89177552|NCT00815854|Placebo Comparator|Placebo|"During Phase 1, participants will undergo screening for metabolic syndrome and have genetic makeup, body size, and endothelial functioning measured. During Phase 2, participants will receive daily folic acid as a treatment for metabolic syndrome.~Phase 2B participants will receive either daily folic acid or placebo as a treatment for metabolic syndrome."
89177553|NCT02551354|Experimental|Patients|"Pain assess by :~Visual Analogic Scale (VAS).~Portable video pupillometer"
89177554|NCT02551198|Active Comparator|HAPREP® (PEG-Asc)|"subjects randomized to 2L polyethylene glycol with ascorbic acid (PEG-Asc) were instructed to use PEG-Asc for bowel preparation~: PEG-Asc(500mLx2 times q30min)[PM 7-9, the day before colonoscopy] + PEG-Asc(500mLx2 times q30min)[AM 5-7, the day of colonoscopy]"
89534019|NCT01224704|Experimental|Obese: hypertonic first|Obese: Hypertonic solution at day 6 and water deprivation at day 10
89177555|NCT02551198|Experimental|SUCLEAR® (OSS)|"subjects randomized to oral sulfate solution were instructed to use oral sulfate solution (OSS) for bowel preparation~: OSS(1b/177mL)[PM 7-9, the day before colonoscopy] + OSS(1b/177mL)[AM 5-7, the day of colonoscopy]"
89177556|NCT02550808||Heart failure|
89177557|NCT02550808||Chronic obstructive pulmonary disease|
89177558|NCT02550808||Chronic kidney disease|
89177559|NCT02550808||Malignancy|
89177560|NCT02550808||Controls|
89177561|NCT00817570||1|Transfemoral Amputees using the C- Leg knee.
89534020|NCT01224704|Experimental|Obese: water deprivation first|Obese: Water deprivation at day 6 and hypertonic solution at day 10
89534021|NCT01212055||Cohort 1|Patients with DOCK8 deficiency, LAD-1, or GATA2 Deficiency
89534022|NCT01200680||chordoma cohort|Chordoma patients
89534023|NCT01191853||Healthy volunteers|Healthy volunteers will have blood drawn before and after seasonal flu vaccination
89534024|NCT01150721||1/PNMI|Adult patients with Pulmonary Nontuberculous Mycobacterial Infection
89534025|NCT01150721||2/Healthy Volunteers|Healthy Volunteer adults
89534026|NCT01145196||Affected|Participants affected by Plaquenil induced retinal toxicity
89530262|NCT03346265|Experimental|Group B|Treatment B Conventional physiotherapy was composed of 4 sections of exercises, chiefly oriented to different body structures appropriate to movement (International Classification of Functioning, Disability and Health code): trunk (s760), pelvis (s750), lower extremity (s750), and upper extremity (s730) including shoulder region (s720). Domains focused on were (1) warm-up exercises, (2) trunk mobility exercises, (3) postural stability (b715), and (4) transferring oneself (d420) and changing body positions (d410).
89530263|NCT04487821|Experimental|Experimental Group|"Subjects were randomly assigned and informed consent was obtained, the subjects were educated about treatment. This contained 4 types of progressive activities. Respectively every type contains 2 to 4 tasks, performed in sets of 10 repetitions for 4 weeks.~Results were obtained by using Balance scoring system, and physical performance test for speed and agility"
89177562|NCT00817570||2|Transfemoral Amputees using a Multiaxial Knee.
89177563|NCT00817570||3|Able bodied.
89177564|NCT00446095|Experimental|fostamatinib|
89530264|NCT04487821|No Intervention|Control Group|"Control group: (Group B) Subjects were randomly assigned and informed consent was obtained, the subjects were educated about treatment. They were asked to perform the regular drills.~Results were obtained using Balance Error scoring system and physical performance test for speed and agility."
89356995|NCT05705687|Other|Unfavorable-dose-dense group|"Unfavorable decline of tumor markers, testicular or peritoneal primary tumor~2 cycles every 3 weeks of :~Paclitaxel 175 mg/m2 IV over 3 hours on Day 1,~Cisplatin 20 mg/m2/day IV x 5 days (D1 to D5),~Etoposide 100 mg/m2/day IV x 5 days (D1 to D5)~Bleomycin 30 mg/day IV or IM D1, D8, and D15.~Oxaliplatin 130 mg/m2 IV over 3 hours, given on Day 10,~G-CSF 263 microg/day SC, to be started one day after chemotherapy and stopped one day before the next scheduled chemotherapy cycle (D6-7, D9, D11-14, D16-20).~Then, 2 cycles every 3 weeks of :~Cisplatin 100 mg/m2 IV over 2 hours on Day 1,~Bleomycin 25 mg/day, by continuous IV infusion over 24 hours for 5 days from Day 10 to Day 14,~Ifosfamide 2 g/m2 IV over 3 hours on Days 10, 12, and 14,~Mesna 500 mg/m2 IV at time-points 0, 3, 7 and 11 hours on the days when ifosfamide is administered (mesna could also be given orally),~G-CSF 263 microg/day SC on Days 2 to 9 and Days 16 to 20."
89356996|NCT05705687|Experimental|Unfavorable-phase II group|"Unfavorable decline of tumor markers, mediastinal primary tumor, proposal to the patient to enter the phase II part. If patient refusal or ineligible for phase II group, the patient will enter the Unfavorable-dose-dense group.~1 additional cycle of~Paclitaxel 250 mg/m² on Day 1 over the day,~Ifosfamide 1,5 mg/m²,~Mesna 500 mg/m2 IV at time-points 0, 3, 7 and 11 hours on the days when ifosfamide is administered (mesna could also be given orally),~Cisplatin 25 mg/m² from Day 1 to Day 5,~Collection of HSC.~Then~if no metastases are detectable and the resection is technically feasible : early surgery whenever possible, followed by 2 additional cycles of TIP chemotherapy every 3 weeks~if surgery is not possible or in case of metastatic disease : HDCT (including 3 cycles of the CE regimen (carboplatin AUC 8, using the Calvert formula, from Day 1 to Day 3 and etoposide 400 mg/m² from Day 1 to Day 3)) plus HSC support, followed by surgery of residual deposits."
89530265|NCT03346187|Experimental|A|"Period 1: Active Comparator(Atorvastatin Calcium Trihydrate+Fenofibrate), 2 tablets administered under fed conditions.~Period 2: test drug(CKD-337 : Atorvastatin Calcium Trihydrate + Fenofibrate), 1 capsule administered under fed conditions."
89530266|NCT03346187|Experimental|B|"Period 1: test drug(CKD-337 : Atorvastatin Calcium Trihydrate + Fenofibrate), 1 capsule administered under fed conditions.~Period 2: Active Comparator(Atorvastatin Calcium Trihydrate+Fenofibrate), 2 tablets administered under fed conditions."
89534027|NCT01145196||Unaffected|control participants without Plaquenil induced retinal toxicity
89530267|NCT04487743|Experimental|Liraglutide|Subject receiving liraglutide 3.0 mg subcutaneous (under the skin) injection once daily for 28 weeks.
89177565|NCT00815932|Experimental|1-CRPS|10 tDCS naïve patients with CRPS-related neuropathic pain in upper limb
89177566|NCT00815932|Experimental|2-DN|20 tDCS naïve patients with diabetic neuropathy
89530268|NCT04487743|Placebo Comparator|placebo|Subject receiving placebo 3.0 mg subcutaneous (under the skin) injection once daily for 28 weeks.
89534028|NCT01143519||FLT1 C-677T|SNP
89534029|NCT01143519||MDM2 rs2279744|SNP
89177567|NCT00815932|Experimental|3-RPNP|20 tDCS naïve patients with resistant peripheral neuropathic pain
89177568|NCT00815932|Experimental|4-CIPN|10 tDCS naïve patients with CIPN-Chemotherapy Induced Pain Neuropathy patients
88827660|NCT01698463|Other|Identify Patients at Risk/Exercise Prescription|The intervention was delivered in two visits and two follow-up phone calls. Physician identifies that the patient is at risk of falls or fractures Visit one: individualized exercise prescription by a physiotherapist. Visit two: motivational interviewing (behavioural counselling) by kinesiologist Phone call 1 and 2: Kinesiologist reviews behavioural components (action planning, coping planning, coping self-efficacy, intentions.
88827661|NCT01951352|Experimental|Soap recipient|The forearms of all subjects will eventually be washed with the same soaps. There is only one arm for this study.
89177569|NCT00817648|Experimental|1|Quetiapine fumarate, flexible doses(600-750 mg/d)
89177570|NCT00817648|Active Comparator|2|risperidone, flexible doses(3-6 mg/d)
89356997|NCT05691803|Experimental|Exercise intervention|"Participants are prescribed a Physical activity on Prescription (PaP) which means that they will have a motivational interview with a physiotherapist regarding increased physical activity. The physiotherapist will then prescribe a individualized PaP with the goal to increase weekly physical activity that the participant are instructed to adhere to for the remainder of the study. A follow-up session is also included after 12 weeks.~Participants are invited to a 12 week exercise intervention at a private fitness center after they have received their PaP. The exercise, including a variety of aerobic and resistance training, is performed in a group setting starting with one session per week for the first three weeks and then two sessions per week for week 4-12. A follow-up session is also included after 12 weeks."
89356998|NCT05648851||Group 1 In person combination retrospective and prospective Natural History Study|Combination retrospective and prospective Natural History Study of patients living with Sanfilippo syndrome type D. The study will include home video of daily living activities via the RARE app, a mobile app designed for this study. In clinic visits will include neurocognitive, developmental, behavioral, biochemical, imaging measures as well as retrospective medical record analysis.
89356999|NCT05648851||Group 2 Retrospective medical record analysis|Retrospective collection and analysis of medical records of deceased or living patients.
89177571|NCT00808756|Experimental|1: Intervention|This group will be fed a diet enriched with fermentable carbohydrates.
89177572|NCT00808756|Placebo Comparator|2: Placebo.|The placebo group will be fed a diet without addition of fermentable carbohydrates. This placebo formula will have the same nutritional values than the intervention (energy, proteins, carbohydrates, fat, vitamins & minerals).
89357000|NCT05642663||Treated patients|Patients with grade II (with one or more associated comorbidities) and grade III obesity who went through sleeve, bypass and revisional bariatric surgery procedure with the use of Altus Powered Stapler
89357001|NCT05638516|Experimental|Vira Self-Care|"The Vira app is installed on the participant's phone. The app passively collects data from phone sensors (i.e., measures of physical activity, sleep patterns, mobility, and language patterns reflecting mood states and cognition) that are indicative of risk-relevant behavioral patterns and psychological states. It also so prompts users to answer a daily check in question. Mobile sensing data are processed to provide an automated assessment of the user's functioning. Users will be asked to use Vira for 12 weeks.~The Vira app can be used as a standalone product. After an initial 10-day period, during which the app assesses the relationship between the user's patterns of behavior and their day-to-day variations in mental health and wellbeing using passive mobile sensing, the user is able to access a personalized behavior change goal that is support by in app information and functionality."
89357002|NCT05638516|Experimental|Vira + Coaching|"The Vira app can also be supported by a health coach. The health coach interacts with the user (via an instant messaging platform) and who also schedules just-in-time reminders (i.e., nudges) to arrive in the user's phone at scheduled times to support their behavior change plan. The Vira Health Coach Platform therefore integrates mobile sensing, self-report assessment, and just-in-time nudges and notifications into the coach's workflow."
89357003|NCT05634837|Experimental|Decision Support System counseling|In the Intervention group (CDSS group), women receive a personalised daily dietary plan based on the Mediterranean diet and according to participant's needs, habits and preferences.
89357004|NCT05634837|Other|Standard nutritional counseling|Participants of the Control group did not have access to CDSS and only received general lifestyle guidelines.
89357005|NCT05629039|Experimental|Wave 1-Experimental Group|The experimental group in Wave 1 will complete the baseline questionnaires (the socio-demographic, FTND, and COM-B questionnaires) followed by both the if-then list and the if-then link from the Volitional-Help Sheet as manipulations. The if-then list consists of several situations and solutions linked to smoking uptake in the volitional help sheet and the group will be informed that the activity will help to stop smoking. In addition, the if-then link consists of the situations in which people are urged to smoke and then link them to solutions that are most likely to help them abstain from starting smoking
89357006|NCT05629039|No Intervention|Wave 1-Control Group|The control group participants will complete the baseline questionnaires (the socio-demographic questionnaire, the FTND, and the COM-B Questionnaire) without further intervention
89357007|NCT05629039|No Intervention|Wave 2-Control group|This group will complete the one-month follow-up questionnaires (the socio-demographic questionnaire, the FTND, and the COM-B Questionnaire) without further intervention
89177573|NCT00808756|No Intervention|BF|The 2 intervention groups will be compared with a breast-fed infants control group.
88827662|NCT01951820|Active Comparator|Benzocaine|Benzocaine topical numbing gel will be applied to the gums before injection with other intervention, injection of local anesthetic articaine.
89357008|NCT05629039|Experimental|Wave 2-Delayed VHS Group|This group will receive the (delayed) Volitional Help Sheets intervention after completing the one-month follow-up questionnaires (the socio-demographic questionnaire, the FTND, and the COM-B Questionnaire).
89357009|NCT05629039|Experimental|Wave 2-Early VHS Group|This group will complete the one-month follow-up questionnaires (the socio-demographic questionnaire, the FTND, and the COM-B Questionnaire) without further intervention
89357010|NCT05629039|Experimental|Wave 2-Repeated VHS group|This group will complete the one-month follow-up questionnaires (the socio-demographic questionnaire, the FTND, and the COM-B Questionnaire), and receive a repeated, booster VHS intervention.
89357011|NCT05629039|No Intervention|Wave 3-Control Group|This group will complete the six-month follow-up questionnaires. Due to ethical consideration, in wave three the control group will be offered the opportunity to complete the VHS form after they complete the follow-up assessments and the scores will not be included in the analysis.
89357012|NCT05629039|Experimental|Wave 3-Delayed VHS Group|This group will complete the six-month follow-up questionnaires (the socio-demographic questionnaire, the FTND, and the COM-B Questionnaire) without further intervention
89357013|NCT05629039|Experimental|Wave 3-Early VHS Group|This group will complete the six-month follow-up questionnaires (the socio-demographic questionnaire, the FTND, and the COM-B Questionnaire) without further intervention
89357014|NCT05629039|Experimental|Wave 3-Repeated VHS Group|This group will complete the six-month follow-up questionnaires (the socio-demographic questionnaire, the FTND, and the COM-B Questionnaire) without further intervention
89357015|NCT05618561||Nasopharyngeal specimen collection arm|Specimens collected in nasopharyngeal form from positive subjects with symptoms and negative subjects hospitalized and negative subjects with respiratory symptoms.
89357016|NCT05618561||Combined nasal mid-turbinate and throat specimen collection arm|Specimens collected in combined nasal mid-turbinate form from positive subjects with symptoms and negative subjects hospitalized and negative subjects with respiratory symptoms.
89357017|NCT05603169|Active Comparator|High Intensity Resistance Training|This group will perform high intensity resistance training under supervised physiotherapist in a gym setting. The training load for the first 2 weeks will be 60%-75% of 1RM and increased to 75%-90% of 1RM the following weeks. Load would be increased if the participants will be able to perform 3 sets of 12 repetitions with that load.
89357018|NCT05603169|Active Comparator|High Intensity Aerobic Training|This group will perform aerobic training under supervision of a physical therapist in gym setting. To calculate exercise intensity, the HR will be maintained at 75-90% of the maximum (HRmax). The training protocol will begin with a 5-minute warm-up and will end with a 5-minute cool down, during which the HR will be 60-75% of the HRmax. At least 90 min of exercise per week for obese PCOS patients, with treadmill walking that may include whole-body movement involving more than 2/3 of the muscles, the exercise intensity will be high intensity
89534030|NCT01143519||p53 rs1042522|SNP
88827663|NCT01951820|Experimental|Pliaglis|Pliaglis topical numbing gel will be applied to the gums before injection with other intervention, injection of local anesthetic articaine.
89357019|NCT05601661|Experimental|Treatment group|Participants in the treatment group will receive 18 goal-directed upper extremity rehabilitation therapy sessions with paired VNS over six weeks. Followed by 90 days home exercise program.
89534031|NCT01143519||RMM1 rs1465952|SNP
88827664|NCT01700725|Experimental|Nasal Irrigation - Saline|nasal irrigation using saline plus routine care for symptoms of CRS and fatigue
88827665|NCT01700725|Experimental|Nasal Irrigation - Xylitol|Nasal Irrigation with Xylitol plus routine care for symptoms of CRS and fatigue
88827666|NCT01700725|No Intervention|Control Group|Control group subjects continue to use routine care only
89177574|NCT04045054|Other|Intervention|The Link Team follows up with the participants for 6 months after they discharge from the hospital
89534032|NCT01143519||TLR8 rs3761624|SNP
89177575|NCT00816088||neutropenia|Patients undergoing stem cell transplantation or chemotherapy likely to lead to prolonged neutropenia.
89534033|NCT01139476||AHS BEEA participants|A subset of 1990 AHS cohort members who are male private pesticide applicators, living and over 50 years of age at the time contact, cancer free, and who completed AHS Phases IIII.
89534034|NCT01139476||Non-AHS BEEA participants|A group of 225 age-, race-, and countymatched, non-AHS controls, who have not lived or worked on a farm as an adult, or held a job applying pesticides.
88827667|NCT01678885|Experimental|Sub-study 1, Dig Photo, Actical & IDEEA|During one week of the doubly labeled water (DLW), participants will use digital photography of foods. During the other week of the DLW phase, participants will wear the Intelligent Device for Energy Expenditure and Activity (IDEEA) monitor and Actical monitor. Whether the participants wear the monitors first or complete digital photography first will be randomozed. Participants who complete the first two weeks and have a BMI over 25kg/m2 will receive a partial supplement low-calorie diet (LCD) for 8 weeks. This diet plan is a 1000-1150 kcal/day diet that participants will complete in a free-living environment. All participants will return to follow-up at six and twelve months after they completed the LCD. Anthropometric and questionnaire data will be collected.
89177576|NCT00829010|Experimental|HIV+/+ Group|Infants born from a HIV positive mother and confirmed as HIV infected. Subjects received 3 primary doses (at 6, 10 & 14 weeks of age, at study Months 0, 1 and 2) and 1 booster dose of Synflorix™ vaccine (at 9 months of age, at study Month 8). Subjects in the group also received 3 primary vaccine doses (at 6, 10 & 14 weeks of age, at study Months 0, 1 and 2) and 1 booster vaccine dose (at 15-18 months of age, at study Month 14) of Tritanrix™-HepB/Hib, 2 vaccine doses of Rotarix™ (at 10 & 14 weeks of age, at study Months 1 and 2), and 2 doses of measles vaccine (9-10 months of age & 15-18 months of age, at study Months 8 and 14). Measles vaccine was not considered as a study vaccine. The Synflorix™ vaccine was administered intramuscularly in the right thigh, the Tritanrix™-HepB/Hib vaccine was administered IM in the left anterolateral thigh during the primary vaccination and in the left anterolateral thigh or left deltoid region during booster vaccination. Rotarix™ was given orally.
88827668|NCT01678885|Experimental|Sub-study 2 - Dig Photo & Sensewear|During one week of the doubly labeled water (DLW) period, participants will use digital photography of foods. During the other week of the DLW phase, participants will wear the Sensewear armband. Whether the participants wear the monitor first or complete digital photography first will be randomozed. Participants who complete the first two weeks and have a BMI over 25kg/m2 will receive a partial supplement low-calorie diet (LCD) for 8 weeks. This diet plan is a 1000-1150 kcal/day diet that participants will complete in a free-living environment. All participants will return to follow-up at six and twelve months after they completed the LCD. Anthropometric and questionnaire data will be collected.
88827669|NCT01952444|Experimental|Group 1 ETI-204 and Ciprofloxacin|Participants will receive a single IV dose of 16 mg/kg ETI-204 infused over 90 minutes on Day 1, immediately followed by an IV dose of ciprofloxacin 400 mg infused over 60 minutes, followed by oral doses of ciprofloxacin (750 mg every 12 hours) from Day 2 to Day 8 and a final dose on the morning of Day 9.
88827670|NCT01952444|Other|Group 2 ETI-204 Alone|Participants will receive a single IV dose of 16 mg/kg ETI-204 infused over 90 minutes on Day 1.
88827671|NCT01952600||Chronic Kidney Disease (CKD)|Patients who have advanced chronic kidney disease, but are not currently on either hemodialysis (HD) or peritoneal dialysis (PD).
88827672|NCT01952600||Hemodialysis (HD)|Patients who have chronic kidney disease (CKD) and are currently on hemodialysis.
88827673|NCT01952600||Peritoneal Dialysis (PD)|Patients who have chronic kidney disease (CKD) and are currently on peritoneal dialysis.
88827674|NCT01679197|Experimental|Treatment|Metreleptin
88827675|NCT01952678||DaTscan™ - Non-Caucasian Participants|Non-Caucasian participants previously administered DaTscan™, with an initial diagnosis of suspected PD or ET who underwent DaTscan SPECT imaging to assist with the participant's final clinical diagnosis of PD or ET.
88827676|NCT01952678||DaTscan™- Caucasian Participants|Caucasian participants previously administered DaTscan™, with an initial diagnosis of suspected PD or ET who underwent DaTscan SPECT imaging to assist with the participant's final clinical diagnosis of PD or ET.
88827677|NCT01954628|Experimental|AQX-1125|1 x AQX-1125 capsule daily
88827678|NCT01954628|Placebo Comparator|Placebo|1 x Placebo capsule daily
89357020|NCT05601661|Sham Comparator|Control Group|Participants in the control group will receive 18 goal-directed upper extremity rehabilitation therapy sessions with sham VNS over six weeks. Followed by 90 days home exercise program.
89357021|NCT05591365|Experimental|Structured In-patient and Home plan|Structured In-patient and Home plan
88827679|NCT01680835|Experimental|Study cohort|All patients enrolled in this study will be treated with the EverFlex™ Self-Expanding Peripheral Stent System.
89357022|NCT05591365|Placebo Comparator|Conventional therapy|Conventional protocol as per guidelines
89534035|NCT01132859||1|Volunteers of 18 years of age or older willing to donate blood and tissue specimens and participate in imaging studies to evaluate the components of the immune system
89534036|NCT01109420||1/ Cohort 1|Affected with non-medullary thyroid cancer
89534037|NCT01109420||2/ Cohort 2|Non-affected members of families with non-medullary thyroid cancer
88827680|NCT01614613|Experimental|Intended BGM Users|Subjects were assigned to subgroups according to their initial glucose levels. SUBGROUP 1 goal: safely decrease subject glucose levels during the visit. SUBGROUP 2 goal: safely raise subject glucose levels. Also, blood samples were modified to obtain glucose concentrations across the needed glucose ranges while maintaining subject safety. Staff tested the blood samples using the 6 Blood Glucose Monitoring Systems. Bayer G3/Tatsu System;Accu-Chek® Aviva Nano Meter/Accu-Chek® Aviva Test Strips; Freestyle Lite® Meter and Test Strips with ZipwikTM tabs;OneTouch® Ultra®2 / OneTouch® Ultra® Blue Test Strips;One Touch® VerioTM Pro/One Touch® VerioTM Test Strips;Truetrack® Meter/Truetrack® Test Strips
88827681|NCT05732324||IVUS PCI optimization group|"PCI will be optimized according to the IVUS. IVUS will be performed before PCI and will be used to select PCI strategy.~Operators will try to reach an optimal anatomical PCI result as assessed by IVUS aiming for the following criteria:~good stent apposition;~good stent expansion (minimal stent area (MSA) >90% of distal reference lumen area and/or MSA ≥5.5mm2);~plaque burden 5mm proximal and distal to the stent <50%);~no stent edge dissection.~After stent optimization an IVUS run will be performed. The IVUS run will be considered as final when further anatomical optimization will not be thought to be possible."
88827682|NCT05732324||Historical FFR PCI optimization group|The goal will be to achieve the optimal functional result, defined as an FFR post PCI ≥ 0.95. Further stented segment post-dilatation will be mandatory if FFR post PCI < 0.95. In case of a clear evidence of significant atheroma proximal or distal to the stented segment, the operators will be encouraged to optimize the functional result further by implanting additional stents.
88827683|NCT01614847|Experimental|Isotonic hyaluronate artificial tear|At random, subjects will receive isotonic hyaluronate artificial tear or a control (normal saline).
88827684|NCT01614847|Placebo Comparator|Normal saline|
88827685|NCT01617421|Experimental|Yoga|This study used Hatha yoga (influenced by Integral, Iyengar, and Kripalu yoga) which includes postures (asanas), breathing techniques (pranayama) and meditation [9]. Biweekly, 60-minute, bilingual yoga classes were offered for 8 weeks at a yoga studio in Washington, DC. Classes were kept small (3-10 participants) to allow for pose modifications as needed for each participant. Participants were given instructions, bilingual manuals, and yoga equipment to encourage home practice. Participants were asked to keep journals to document the frequency and duration of home practice and their experience while on the study. After the last class, a yoga DVD and a list of local yoga studios were given to encourage continued practice.
88827686|NCT01617577|Experimental|G-CSF (filgrastim) first phase|Subjects assigned to this arm receive G-CSF for 5 days during the first phase of the study. At week 7 these subjects cross over to receive placebo injections for five days
88827687|NCT01617577|Placebo Comparator|Placebo first phase|Subjects assigned to this arm receive placebo injections daily for 5 days; after wk 7 they crossover to receive 5 daily injections of injections of G-CSF.
88827688|NCT05258175|Experimental|Kinesio taping muscle facilitation technique along with standardized physiotherapy protocol|"On the diaphragmatic muscle, muscle facilitation technique will be applied from proximal to distal with 10-15% tension when the participant is standing and exhaled out and the body is in extension. The base of the tape will be about 1 inch below the xiphoid area.~Then the one tail of tape applied with 10% tension on the rib cage with maximum deep inspiration followed by expiration and the other tail of tape will be applied to the subcostal area in forward bending position while taking deep breath with arms adduct and being crossed.~The tape will be changed on every fifth day and assessment will be done at baseline and 2nd week of intervention Total number of sessions: 3"
88827689|NCT05258175|Active Comparator|Standardized physiotherapy protocol|"Pursed lip breathing exercise: Patient instructed to breathe through nose and inspiration should be slowly and expiration is done through mouth by pursing the lips slowly such that if flame is held in front, then the flame should be bended but not blow off. 3 sets a day for 15 days.~Diaphragmatic breathing exercise: Patient sitting comfortably, with knees bent and shoulders, head and neck relaxed. Patient will be instructed to place one hand on upper chest and the other just below your rib cage. Breathe in slowly through nose so that stomach moves out against your hand. 3 sets a day for 15 days.~Deep breathing exercise: Patient instructed to take slow and deep breaths, inhaling through the nose and exhaling through the mouth. Participant is asked to place their hand on their abdomen and expand their abdomen to lift their hand during inhalation. 3 sets a day for 15 days."
88827690|NCT02235493||Retrospective Case Only|
88827691|NCT01955564|Experimental|Cohort 1|NW-3509a - 1mg or placebo
88827692|NCT01955564|Experimental|Cohort 2|NW-3509a 2mg or placebo
88827693|NCT01955564|Experimental|Cohort 3|NW-3509a 5mg or placebo
88827694|NCT01955564|Experimental|Cohort 4|NW-3509a 10 mg or placebo
88827695|NCT01955564|Experimental|Cohort 5|NW-3509a 20 mg or placebo
88827696|NCT01955564|Experimental|Cohort 6|NW-3509a 30 mg or placebo
88827697|NCT01701037|Experimental|Dabrafenib and Trametinib|Patients receive dabrafenib PO BID on days 1-28 adding trametinib on days 15-28 followed by surgery on days 28-30. Treatment continues in the absence of unacceptable toxicity.
88827698|NCT05249205|No Intervention|Control|Participants in the control group will be asked to maintain their regular lifestyle for the duration of the study. They will not receive an intervention.
88827699|NCT05249205|Experimental|REHIT1|Participants in the REHIT1 group will perform a single REHIT session per week for 6 weeks.
88827700|NCT05249205|Experimental|REHIT2|Participants in the REHIT2 group will perform 2 REHIT sessions per week for 6 weeks.
88827701|NCT01955720|Experimental|healthy subjects aged 45-64|Sequential Crossover to Placebo or BI 655075
88827702|NCT01955720|Experimental|healthy elderly subjects aged 65-80 year|Sequential Crossover to Placebo or BI 655075
88827703|NCT01955720|Experimental|mild renal impairment aged 45-80 years|Sequential Crossover to Placebo or BI 655075
88827704|NCT01955720|Experimental|mod renal impairment aged 45-80 years|Sequential Crossover to Placebo or BI 655075
88827705|NCT01619839|Experimental|100 mg NKTR-181|100 mg of NKTR-181 in tablet form, BID. Dosing to occur at Titration period up to 30 days and at Randomization period up to 24 days.
88827706|NCT01619839|Experimental|200 mg NKTR-181|200 mg of NKTR-181 in tablet form, BID. Dosing to occur at Titration period up to 30 days and at Randomization period up to 24 days.
88827707|NCT01619839|Experimental|300 mg NKTR-181|300 mg of NKTR-181 in tablet form, BID. Dosing to occur at Titration period up to 30 days and at Randomization period up to 24 days
88827708|NCT01619839|Experimental|400 mg NKTR-181|400 mg of NKTR-181 in tablet form, BID. Dosing to occur at Titration period up to 30 days and at Randomization period up to 24 days
88827709|NCT01619839|Placebo Comparator|Placebo|Placebo dosing will be only in the double-blind randomization arm and will be identical in form to the Experimental NKTR-181.
88827710|NCT01955954|Experimental|Canary Breathing System|Treatment with Canary Breathing System
88827711|NCT01701115|Experimental|Low Dose (20 mL) Local Anesthetic|Intervention to be administered is a total volume of 20 mL local anesthetic containing a 1:1 mixture of 1.5% Mepivacaine: 0.5% Bupivacaine.
88827712|NCT01701115|Active Comparator|Control Dose (40 mL) Local Anesthetic|Intervention to be administered is a total volume of 40 mL local anesthetic containing a 1:1 mixture of 1.5% Mepivacaine: 0.5% Bupivacaine
88827713|NCT01956032||Participants with Parkinson's disease|"Participants diagnosed with Parkinson's disease and have continued disabling motor complications despite optimized per-oral or other treatment regimens suitable for Duodopa treatment in accordance with the Swedish Summary of Products Characteristics.~Other name for Duodopa is Levodopa Carbidopa Intestinal Gel (LCIG)."
88827714|NCT01621009|Active Comparator|Active bupropion + counseling|Active bupropion SR plus eight 10-minute individual counseling sessions.
88827715|NCT01621009|Active Comparator|Active bupropion , No counseling|Active bupropion, No counseling, only medication checks
88827716|NCT01621009|Placebo Comparator|Placebo medication + counseling|Placebo bupropion plus eight 10-minute individual counseling sessions
88827717|NCT01621009|Placebo Comparator|Placebo medication, No counseling|Placebo bupropion, No counseling, just medication checks
88827718|NCT05730530|Experimental|Intervention|Classroom assigned to receive the 6-week long nutrition education curriculum
88827719|NCT05730530|No Intervention|Control|Classroom assigned to receive no intervention
88827720|NCT04830969|Experimental|A: Diabetic + SRP + SPT|The first group, A, includes diabetics with periodontal disease; they will receive standard therapy, scaling & root planing plus supportive periodontal therapy (SPT) chlorhexidine gluconate (Paroex®) mouthrinse + Soft-Picks.
88827721|NCT04830969|Experimental|B: Non-Diabetic + SRP + SPT|The second group, B, includes non-diabetics with periodontal disease; they will receive standard therapy, scaling & root planing plus supportive periodontal therapy (SPT) chlorhexidine gluconate (Paroex®) mouthrinse + Soft-Picks.
88827722|NCT04830969|Active Comparator|C: Diabetic + SRP|The third group, C, includes diabetics with periodontal disease; they will receive standard therapy, scaling and root planing (SRP).
88827723|NCT04830969|Active Comparator|D: Non-Diabetic + SRP|The second group, D, includes non-diabetics with periodontal disease; they will receive standard therapy, scaling and root planing (SRP).
88827724|NCT01683331|Active Comparator|Insulin treatment for hyperglycemia|Neutral Protamine Hagedorn (NPH) Insulin Titration Regimen, based on pre-dinner capillary blood glucose measurements (CPG) expressed in mg/dl; All NPH initiation doses and dose adjustments are presented in IU/day For pts. with CPG > 240, NPH initiation: 14, dose increases by 4; For pts. with CPG > 180 mg/dl, NPH initiation: 12, dose increases by 4; For pts. with CPG > 140 mg/dl, NPH initiation: 10, dose increases by 4; For pts. with CPG > 120 mg/dl, NPH initiation: 0, dose increases by 2; For pts. with CPG 100-119 mg/dl, NPH initiation: 0, maintain dose; For pts. with CPG 80-<100 mg/dl, NPH initiation: 0, dose decrease by 4; For pts. with CPG 60-<80 mg/dl, NPH initiation: 0, decrease by 8; For pts. with CPG <60 mg/dl, NPH initiation: 0, ½ of previous dose.
88827725|NCT01683331|No Intervention|Standard of care|Patients assigned in this arm will receive standard of care following their kidney transplantation.
88827726|NCT02986880|Experimental|Group D1|Patients receiving the toxin in SCM and the placebo in trapezius muscle and splenius capitis. Patients receiving the dose of 30 units (U) at injection point, totalling 120 U.
88827727|NCT02986880|Experimental|Group D2|Patients receiving the toxin in the SCM and the placebo in the trapezius muscle and the splenius capitis. Patients receiving the dose of 60 units (U) at injection point, totalling 240 U.
88827728|NCT02986880|Experimental|Group D3|Patients receiving the toxin in the SCM and the placebo in the trapezius muscle and the splenius capitis. Patients receiving the dose of 100 units (U) at injection point, totalling 400 U.
88827729|NCT02986880|Experimental|Group A1|Patients receiving the toxin in trapezius muscle and splenius capitis and the placebo in SCM . Patients receiving the dose of 30 units (U) at injection point, totalling 180 U.
88827730|NCT02986880|Experimental|Group A2|Patients receiving the toxin in trapezius muscle and splenius capitis and the placebo in SCM . Patients receiving the dose of 60 units (U) at injection point, totalling 360 U.
88827731|NCT02986880|Experimental|Group A3|Patients receiving the toxin in trapezius muscle and splenius capitis and the placebo in SCM . Patients receiving the dose of 100 units (U) at injection point, totalling 600 U.
88827732|NCT02986880|Experimental|Group F1|Patients receiving the toxin in the third muscles groups. Patients receiving the dose of 30 units (U) at injection point, totalling 300 U.
88827733|NCT02986880|Experimental|Group F2|Patients receiving the toxin in the third muscles groups. Patients receiving the dose of 60 units (U) at injection point, totalling 600 U.
88827734|NCT02986880|Experimental|Group F3|Patients receiving the toxin in the third muscles groups. Patients receiving the dose of 100 units (U) at injection point, totalling 1000 U.
88827735|NCT02986880|Placebo Comparator|Group P|Patients receiving placebo in the third muscles groups
88827736|NCT01701271|Experimental|Volunteers|20 volunteers both men and women with an age between 18 and 70 years suffering from Androgenetic Allopecia in several types apply on the scalp drops of the hair loss prevention lotion
88827737|NCT02290106|Experimental|Pitavastatin|pitavastatin 4mg daily by mouth for 6 months
88827738|NCT02290106|Placebo Comparator|Placebo|Identical placebo 4mg by mouth daily for 6 months
89357023|NCT05583669|Experimental|DS-2325a SC|Participants who will be randomized to receive DS-2325a as a fixed dose subcutaneous (SC) injection (starting dose 300 mg).
88827739|NCT02287688||Exposure group|Subjects aged 2-23 months who received at least one dose of the MenACWY-CRM vaccine at a Kaiser Permanente Southern California (KPSC) facility while enrolled as a KPSC health plan member.
88827740|NCT04818957|Experimental|Vitamin D Oral Thin Film (OTF)|Study subjects will receive vitamin D OTF for a maximum of 12 weeks.
88827741|NCT01621477|Experimental|Treatment|"All study participants.~Interventions: clofarabine, cytarabine, busulfan, plerixafor, cyclophosphamide, antithymocyte globulin (rabbit), stem cells, tacrolimus, mycophenolate mofetil"
88827742|NCT02987036|Experimental|Aerogen|Two doses of aerosolized Albuterol sulfate (2.5 mg dissolved in saline) At study start (T l 0) and after 6 hours (Tll0) by Aerogen
88827743|NCT02987036|Other|Jet Nebulizer|Two doses of aerosolized Albuterol sulfate (2.5 mg dissolved in saline) At study start (T l 0) and after 6 hours (Tll0) by Jet Nebulizer
88827744|NCT01621633|Experimental|Group 1: mild hepatic impairment|LCZ696 200 mg, given as a single oral dose
88827745|NCT01621633|Experimental|Group 2: moderate hepatic impairment|LCZ696 200 mg, given as a single oral dose
88827746|NCT01621633|Experimental|Group 3: healthy volunteers|LCZ696 200 mg, given as a single oral dose. Each healthy volunteer will match in race, age (±5 years), gender, weight (±15%) to an individual subject with hepatic impairment in groups 1 and 2
88827747|NCT01958606|Experimental|High-intensity interval training (HIT)|Treadmill exercise using bursts of concentrated effort alternated with recovery periods
88827748|NCT01958606|Active Comparator|Traditional aerobic training|Moderate intensity continuous aerobic exercise on a treadmill
88827749|NCT05479214|Experimental|Metformin Group|will include 75 patients who will be treated with metformin ( 1gm with the 2 main meals ) combined with insulin therapy
88827750|NCT05479214|Experimental|Insulin alone group|will include 75 patients who will be treated with insulin alone
88827751|NCT04798053|Experimental|Patient affected by a chronic inflammatory rheumatism|patient affected by a chronic inflammatory rheumatism (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, Systemic lupus, Still disease, scleroderma…),
88827752|NCT04798053|Active Comparator|Controls|patient affected by a non-inflammatory or degenerative musculo-skeletal disease during the containment period
88827753|NCT02330588|Experimental|Eat It! (Injunctive Feedback)|Parents are presented with two questions about portion size and sugar-sweetened beverages; answers are contrasted with injunctive feedback (i.e., Canadian guidelines).
88827754|NCT02330588|Experimental|Eat It! (Normative Feedback)|Parents are presented with two questions about portion size and sugar-sweetened beverages; answers are contrasted with normative feedback (i.e., referent data from Canadian children).
88827755|NCT02330588|Experimental|Move It! (Injunctive Feedback)|Parents are presented with two questions about screen time and moderate-to-vigorous physical activity (MVPA); answers are contrasted with injunctive feedback (i.e., Canadian guidelines).
88827756|NCT02330588|Experimental|Move It! (Normative Feedback)|Parents are presented with two questions about screen time and moderate-to-vigorous physical activity (MVPA); answers are contrasted with normative feedback (i.e., referent data from Canadian children).
88827757|NCT02330588|Placebo Comparator|eHealth Control|Parents randomly assigned to the control arm will include information on children's lifestyle behaviors only (no intervention questions).
88827758|NCT01701505|Experimental|Kovacaine Mist High Dose|400uL of Kovacaine Mist, as 2 sprays of 200uL.
88827759|NCT01701505|Experimental|Kovacaine Mist Mid Dose|200uL of Kovacaine Mist, as 2 sprays of 100uL.
88827760|NCT01701505|Experimental|Kovacaine Mist Low Dose|120uL of Kovacaine Mist, as 2 sprays of 60uL.
88827761|NCT01622257|Experimental|Cavitation US|Cavitation ultrasound was done using ultrasonic cavitation machine 2 times per week for 3 months
88827762|NCT01622257|Experimental|Metformin|Metformin oral tablets 500 mg were given three times daily
88827763|NCT01622257|Experimental|Cavitation US + metformin|Combination of both Cavitation US + Metformin
88827764|NCT04958031|Experimental|CVL-871 1.0 mg|Participants will receive CVL-871 tablets orally QD up to the maximum dose of 1.0 milligrams (mg) until Day 85 during the treatment period.
88827765|NCT04958031|Experimental|CVL-871 3.0 mg|Participants will receive CVL-871 tablets orally QD up to the maximum dose of 3.0 milligrams (mg) until Day 85 during the treatment period.
88827766|NCT04958031|Placebo Comparator|Placebo|Participants will receive a placebo matched to CVL-871 tablets orally QD until Day 85 during the treatment period.
88827767|NCT04950543||Meditation|
88827768|NCT05739968|Active Comparator|control group|Control Group: Usual care + oncology case manager (OCM) care, UC group or Control group
88827769|NCT05739968|Experimental|experimental group|The experimental group is Multi-domains Active-living Program (MAP) with e-health enhanced intervention + usual care + oncology case manager (OCM) care. Main contents of MAP are to (a) cope multi-domain of distress, and (b) develop an active life style to handle their life after cancer, including effective coping, relaxation, regular physical activities, and balance nutrition. Four face-to face interventions will be delivered, including: day before hospital discharge post-operation, before the last weekly instillations of induction therapy (around 6±2 weeks post operation), 2nd-time cystoscopy and before 1st maintenance therapy (around 3- month post operation) and 3rd-time cystoscopy which before the second cycle of maintenance therapy (around 6- month post operation) [section 1-4], respectively.
88827770|NCT02290184|Experimental|Intervention - PilAm Go4Health Program|In the first 3 months this groups will start with the PilAm Go4Health Weight-loss Program lifestyle intervention. After 3 months this group will transition to a 3-month maintenance phase where they will continue to maintain the physical activity and healthy eating behaviors learned in the PilAm Go4Health Weight-loss Program lifestyle intervention and will complete the study for a total of 6 months.
88827771|NCT02290184|Active Comparator|Active control - pedometer only|In the first 3 months this groups will start with a pedometer only. After 3 months, this group will transition to receive the PilAm Go4Health Weight-loss Program lifestyle intervention for the next 3 month and will complete the study for a total of 6 months
89188819|NCT02601599|No Intervention|Usual care|This group will not receive student contact, but may be counselled by the smoking cessation officer or other Connolly staff as per normal procedures.
89188820|NCT00802191||Control Group|Participants with no movement disorders.
88827774|NCT02987270|Experimental|Mass screening and treatment|Each member (approximately 30,000 individuals) residing within the mass screening and treatment arm were visited three times a year and tested for malaria by rapid diagnostic test; those testing positive were treated with an appropriate antimalarial- dihydroartemisinin-piperaquine was the first-line therapy. Long-lasting insecticidal net (LLIN) coverage was topped up prior to the intervention to universal coverage (one bednet for every two household participants).
89188821|NCT00802191||Movement Disorders Participants|Participants have a movement disorder
89357024|NCT05583669|Experimental|Placebo SC|Participants who will be randomized to receive placebo as a subcutaneous (SC) injection.
88827775|NCT02987270|No Intervention|Control arm|Members of the control arm received standard of care, which includes universal (LLIN) coverage and standard malaria case management (laboratory confirmation prior to antimalarial treatment) at the study health facilities.
88827776|NCT02987114|Experimental|PLT101|PTL101 capsules (50 or 100 mg CBD per capsule) up to 25 mg/kg/day or up to 450 mg/day, the lower of the two. Twice daily (morning and evening).
88827777|NCT04931979|Experimental|Treatment|Pembrolizumab 200mg i.v. three-weekly in combination with salvage radiation therapy (SRT) according to standard of care
88827778|NCT04929795|Experimental|at risk- RAS|At-risk individuals in the experimental group will undergo upper-limb movement training with the aid of music beat serving as a type of rhythmic auditory stimulation (RAS).
88827779|NCT04929795|Active Comparator|at risk- no RAS|At-risk individuals in the control group will receive upper-limb training without the aid of RAS.
88827780|NCT04929795|Experimental|schizophrenia- RAS|Schizophrenia patients in the experimental group will undergo upper-limb movement training with the aid of RAS.
88827781|NCT04929795|Active Comparator|schizophrenia- no RAS|Schizophrenia patients in the control group will receive upper-limb training without the aid of RAS.
88827782|NCT05739734|Experimental|CRIS100 treatment|Administration of a single dose of CRIS100
88827783|NCT02329964|Experimental|R-S group|"Rocuronium-Sugammadex group~Induction of anesthesia : 1% propofol 1.5-2.5 mg/kg with fentanyl 1.5 mcg/kg~Muscle relaxant agent : Rocuronium 1mg/kg~After endotracheal intubation : normal saline(0.025 ml/kg)~Additive dose, for ensuring that neuromuscular blockade remains below T2 during surgery : Rocuronium 0.15mg/kg~Relaxant agent reversal. at the the end of surgery : sugammadex 2mg/kg"
88827784|NCT02329964|Active Comparator|S-C-N group|"Succinylcholine-Cisatracurium-Neostigmine group~Induction of anesthesia :1% propofol 1.5-2.5 mg/kg with fentanyl 1.5 mcg/kg~Muscle relaxant agent :Succinylcholine 1mg/kg~After endotracheal intubation : Cisatracurium 0.08mg/kg~Additive dose, for ensuring that neuromuscular blockade remains below T2 during surgery : Succinylcholine 10mg~Relaxant agent reversal at the appearance of second TOF twitch (T2) : Neostigmine 0.2mg/kg with atropine 10 mcg/kg (for preventing side effects of neostigmine)"
88827785|NCT04750395|Experimental|Haloperidol|Every 24 hours, patients will receive two regular doses of OT Haloperidol 2.5mg. Patients may also receive up to two breakthrough doses within a minimum interval of one hour from the last dose. In total, up to four doses of medication will be prepared.
88827786|NCT04750395|Experimental|Olanzapine|Every 24 hours, patients will receive two regular doses of OT Olanzapine 5.0mg. Patients may also receive up to two breakthrough doses within a minimum interval of one hour from the last dose. In total, up to four doses of medication will be prepared.
88827787|NCT05707598||Laparoscopic multivisceral resection group|Patients who underwent laparoscopic multivisceral resection for clinical T4b colorectal cancer
88827788|NCT05707598||Open multivisceral resection group|Patients who underwent open multivisceral resection for clinical T4b colorectal cancer
89357025|NCT05579951|Active Comparator|Conventional|Total knee replacement with conventional instrumentation
88827789|NCT04365855|Other|Subjects at risk for NAFLD|Adult Olmsted County residents identified as at risk for NAFLD will receive Magnetic Resonance Imaging (MRE,) blood tests,and possible biopsy.
88827790|NCT04364217|Other|Treatment|Laser treatment to 3x3cm2 area. It will receive the Luminous ultra pulse fractional ablative carbon dioxide laser at 150mJ, 3% density and 250Hz
89357026|NCT05579951|Active Comparator|Patient specific instrumentation|Total knee replacement with patient specific instrumentation
88827791|NCT04920201|Experimental|Over-ground walking without GEMS-H|
88827792|NCT04920201|Experimental|Over-ground walking with GEMS-H with resist mode|
88827793|NCT04920201|Experimental|Stair ascent with GEMS-H with assist mode|
88827794|NCT04920201|Experimental|Incline walking with GEMS-H with assist mode|
88827795|NCT03438773|Other|Envarsus|Study group - Envarsus once daily in addition to standard of care.
88827796|NCT03438773|Other|Tacrolimus|Control group - Tacrolimus twice daily in addition to standard of care.
88827797|NCT04366245|Experimental|Experimental|
88827798|NCT04366245|Active Comparator|Comparator|
88827799|NCT02974985|Experimental|Women aged 40-50|"Intervention--Injections of volumizing products Restylane L and Restylane Lyft with endpoint  a dramatic result is seen that is agreed upon by both subject and injector. The number of injections will be determined (and quantified) by both the patient and the PI to achieve this endpoint."
88827800|NCT02974985|Experimental|Women aged 50-60|"Intervention--Injections of volumizing products Restylane L and Restylane Lyft with endpoint  a dramatic result is seen that is agreed upon by both subject and injector. The number of injections will be determined (and quantified) by both the patient and the PI to achieve this endpoint."
88827801|NCT01704781|Experimental|Part A: lenalidomide dose escalation|"All patient receive intradermal Vacc-4x (1.2 mg) given with Leukine® (rhu-GM-CSF) (0.06 mg) and oral lenalidomide in a dose escalation (3+3) design.~Dose level -1: 2.5 mg Lenalidomide (CC-5013) in the event Dose level 1 is non tolerated dose (NTD) Dose level 1(start): 5 mg Lenalidomide (CC-5013) Dose level 2: 10 mg Lenalidomide (CC-5013) Dose level 3: 25 mg Lenalidomide (CC-5013)"
88827802|NCT01704781|Experimental|Part B: lenalidomide|Intradermal Vacc-4x (1.2 mg) given with Leukine® (rhu-GM-CSF) (0.06 mg) and oral lenalidomide for 6 immunizations (visit 2, 3, 4, 5, 6 and 7) & lenalidomide (dose determined in Part A) two days prior to and at the day of immunization.
88827803|NCT01704781|Placebo Comparator|Part B: lenalidomide placebo|Intradermal Vacc-4x (1.2 mg) given with Leukine® (rhu-GM-CSF) (0.06 mg) and oral lenalidomide for 6 immunizations (visit 2, 3, 4, 5, 6 and 7) & lenalidomide placebo two days prior to and at the day of immunization.
88827804|NCT04804761|Experimental|Real EA group|
88827805|NCT04804761|Sham Comparator|Sham EA group|
89357027|NCT05529966|Experimental|NGENUITY|Research fellow participants utilize NGENUITY during micro-stent placement
89357028|NCT05529966|Active Comparator|Conventional microscope|Research fellow participants utilize conventional microscope during micro-stent placement
89357029|NCT05517304|Experimental|tcVNS|Stimulation twice daily with transcutaneous Vagal Nerve Stimulation (tcVNS)
89357030|NCT05517304|Active Comparator|sham|stimulation with sham
88827806|NCT02975063|Experimental|A&T IYCF intervention|A&T IYCF intervention is includes comprehensive IYCF counseling which includes intensive activity that aims to deliver one-on-one counseling at home or in a health facility.
88827807|NCT02975063|No Intervention|Control|No intervention.
88827808|NCT02288156|Active Comparator|0.1mM|
88827809|NCT02288156|Experimental|0.01mM|
88827810|NCT02288156|Experimental|0.001mM|
88827811|NCT02288156|Placebo Comparator|Placebo|
88827812|NCT04350177|Active Comparator|Single Ascending Dose (SAD)|In Part A, cohorts will consist of eight (8) subjects; six (6) of whom will receive treatment with IkT-148009 and two (2) with matching placebo.
88827813|NCT04350177|Active Comparator|Multiple Ascending Dose (MAD)|In Part B, cohorts will consist of eight (8) subjects; six (6) of whom will receive treatment with IkT-148009 and two (2) with matching placebo.
88827814|NCT04350177|Active Comparator|Multiple Ascending Dose (MAD) Parkinson's patients|In Part C, cohorts will consist of eight (8) patients; six (6) of whom will receive treatment with IkT-148009 and two (2) with matching placebo.
88827815|NCT01623037|Experimental|CoolSculpting Treatment Group|The single arm will include all subjects treated on each flank with the CoolSculpting System and CoolCurve+ applicator. Treatment temperature and duration are defined in the protocol.
88827816|NCT04087343|Experimental|Meals plus exercise|
88827817|NCT04087343|Active Comparator|Meals only|
88827818|NCT02249689|Experimental|Definitive 65|The Test product were the Definitive 65 (Filcon V4) lenses. This material is produced by Contamac Ltd. and the contact lenses were manufactured by Appenzeller Kontaktlinsen AG.
88827819|NCT02249689|Active Comparator|Definitive 74|The Control product was the commercially available Definitive 74 (Efrofilcon A) lens. This material is produced by Contamac Ltd. and the contact lenses were manufactured by Appenzeller Kontaktlinsen AG.
88827820|NCT05423132|Active Comparator|Physiological serum Group|"The cluneal nerve block is performed under ultrasound using the Thomas Dahl Nielsen and Thomas Fichtner Bendtsen method.~The patients are placed in ventral decubitus. A sensor of high linear frequency is moved toward the middle and posterior to where the aponeurosis of the transverse muscle and the thoraco-lumbar fascia meet, following the appearance of the thoracolumbar fascia and then the appearance of the posterior ilio-costalis muscle under the fascia lumbar area. The infiltration is carried out in-plane, with a lateral towards the median axis direction, in a way, that it penetrates perpendicularly the fascia~The physiological serum (NaCl 0.9%) will be injected, on each side, into the aponeurosis and the muscle in the area where the superior cluneal nerves pass. An easy separation of the thoraco- lumbar fascia and the ilio-costalis muscle is achieved during injection by slightly raising the needle towards the median axis as the space opens up gradually."
88827821|NCT05423132|Experimental|Ropivacaine Group|"The cluneal nerve block is performed under ultrasound using the Thomas Dahl Nielsen and Thomas Fichtner Bendtsen method.~The patients are placed in ventral decubitus. A sensor of high linear frequency is moved toward the middle and posterior to where the aponeurosis of the transverse muscle and the thoraco-lumbar fascia meet, following the appearance of the thoracolumbar fascia and then the appearance of the posterior ilio-costalis muscle under the fascia lumbar area. The infiltration is carried out in-plane, with a lateral towards the median axis direction, in a way, that it penetrates perpendicularly the fascia~The local anaesthetic (Ropivacaine) will be injected into the aponeurosis and the muscle in the area where the superior cluneal nerves pass. An easy separation of the thoraco- lumbar fascia and the ilio-costalis muscle is achieved during injection by slightly raising the needle towards the median axis as the space opens up gradually."
88827822|NCT03681977|Experimental|Zimmer MP Persona|Zimmer MP Persona is total knee prosthesis intended to resurface the articulating surface of the femoral, tibial and patellar bones. It employs modular components between the tibial plates and articular surfaces and a medial congruent bearing manufactured from Vivacit-E Highly Crosslinked Polyethylene (HXPE). Persona® Medial Congruent Bearing is available in several sizes and offers up to a 13mm anterior lip height to provide greater anterior constraint and subluxation resistance. Can be used with a with both cruciate retaining and posterior stabilized femoral provisionals
88827823|NCT03681977|Active Comparator|Zimmer Persona Knee-PS|Zimmer Biomet Persona® Knee-PS is a semiconstrained knee prosthesis that employs modular components between the tibial plates and articular surfaces. The device is intended to resurface the articulating surface of the femoral, tibial and patellar bones. The posterior stabilized (PS) femoral provisionals and components can be used with the PS or constrained posterior stabilized (CPS) bearings provisionals and components when the PCL is deficient and removed.The Persona Femur offers 21 distinct profiles, in 2 mm increments.
88827824|NCT03681977|No Intervention|Healthy Participants|The control group for the kinematic assessment
88827825|NCT02975219|Experimental|Treatment group|4.5mg Bevacizumab-800CW intravenously
88827826|NCT05688956|Experimental|(i) ONS + Exercise group|This group will consume whey protein ONS enriched with leucine and vitamin D, twice a day for 12 weeks. The optimal time to consume the ONS on non-exercise days will be based on each participants 24-hour dietary recall. On exercise days, participants will be asked to consume the ONS after breakfast and after the exercise class. Participants will participate in a resistance-based exercise programme twice a week for 12 weeks which will be carried out over Zoom. Standard dietary advice to increase intake of protein, leucine and vitamin D using available literature designed for those at risk of malnutrition will be provided to this group by the research nutritionist.
88827827|NCT05688956|Active Comparator|(ii) Exercise-alone group|Participants will participate in a resistance-based exercise programme twice a week for 12 weeks which will be carried out over Zoom. Standard dietary advice to increase intake of protein, leucine and vitamin D using available literature designed for those at risk of malnutrition will be provided to this group by the research nutritionist. The participants will not be provided with a placebo ONS.
88827828|NCT01686451|Experimental|XueZhiKang|Participants will receive 600mg of XueZhiKang twice a day for 4 weeks.
88827829|NCT01686451|Active Comparator|Simvastatin|Participants will receive 20mg of simvastatin daily for 4 weeks.
88827830|NCT05682638|Experimental|Vaccine group|Phase 3(Base the result of Phase 1 and Phase 2, intervent 100μg): initial vaccination stage- LVRNA009; crossover vaccination stage- placebo
88827831|NCT05682638|Placebo Comparator|Control group|Phase 3: initial vaccination stage- placebo; crossover vaccination stage- LVRNA009
88827832|NCT04899297||Quality of life|
88827833|NCT05681702|Active Comparator|DAPT de-escalation|Aspirin 81-mg od and clopidogrel 75-mg qd.
89534038|NCT01105858||Volunteers|Adult volunteers &amp; family members recruited from the Phoenix metropolitan area
88827834|NCT05681702|Experimental|Potent P2Y12 monotherapy|Potent P2Y12 inhibitor with prasugrel 10 mg od or ticagrelor 90 mg BID.
88827835|NCT04675983|Experimental|Sintilimab + Ramucirumab|Ramucirumab on days 1 and 8 in combination with Sintilimab on day 1 of each 21-day cycle until disease progression, intolerable toxicity or other criteria for treatment discontinuation
88827836|NCT04675983|Active Comparator|Cisplatin+ 5-fluorouracil/Oxaliplatin+capecitabine|Cisplatin on day 1 in combination with 5-fluorouracil, continuous pumping for 24 hours a day on days 1 to 5 of each 21-day cycle. (FP regimen) or Oxaliplatin on day 1 in combination with capecitabine on days 1 to 14 of each 21-day cycle. (XELOX regimen)
88827837|NCT03668951|Experimental|Buccal DEX 2 mcg/kg|Standard anesthesia care for a patient presenting for cardiac surgery includes induction of general anesthesia, placement of an endotracheal tube and an arterial line. Once these are accomplished, Dexmedetomidine is administered according to group assignment.
88827838|NCT03668951|Experimental|Intranasal DEX 3 mcg/kg|Standard anesthesia care for a patient presenting for cardiac surgery includes induction of general anesthesia, placement of an endotracheal tube and an arterial line. Once these are accomplished, Dexmedetomidine is administered according to group assignment.
88827839|NCT03668951|Experimental|Intranasal DEX 4 mcg/kg|Standard anesthesia care for a patient presenting for cardiac surgery includes induction of general anesthesia, placement of an endotracheal tube and an arterial line. Once these are accomplished, Dexmedetomidine is administered according to group assignment.
88827840|NCT05739344|Experimental|Experimental Group|Cognitive behavioral approach based resilience development program
88827841|NCT04890327|No Intervention|Standard of Care|Patient presents to new Gynecologic Oncology appointment, family health history is collected by the physician during the clinic visit. Both the subject and physician complete assessment survey at the completion of clinic visit. Subject's medical record reviewed 6 months following study enrollment to determine subject's diagnosis, whether or not subject underwent genetic counseling and/or genetic testing and review genetic testing results.
88827842|NCT04890327|Experimental|Office|Patient presents to new Gynecologic Oncology appointment, subject is given access to a desk top computer in office and instructed to complete web-based family health history tool. Physician reviews results of patients web-based family health history tool.Subject and physician complete assessment survey at the completion of clinic visit. Subject's medical record reviewed 6 months following study enrollment to determine subject's diagnosis, whether or not subject underwent genetic counseling and/or genetic testing and review genetic testing results.
88827843|NCT04890327|Experimental|Home|Patient is emailed a link containing web-based family health history tool prior to presenting for new Gynecologic Oncology appointment. Physician reviews results of patients web-based family health history tool. Subject and physician complete assessment survey at the completion of clinic visit. Subject's medical record reviewed 6 months following study enrollment to determine subject's diagnosis, whether or not subject underwent genetic counseling and/or genetic testing and review genetic testing results.
88827844|NCT05400356||Complication group|"Postoperative complications are defined as postoperative death, vital organ dysfunction, and mechanical ventilation duration greater than 24 hours.The vital organ dysfunction includes new developed acute kidney injury, long-term low cardiac output, severe liver function injury and neurological function injury.~The time of occurrence is defined as from the beginning of surgery to 30 days after surgery or to discharge from hospital."
88827845|NCT05400356||Non-complication group|"Patients with none of postoperative complications which showed in Complication group.~The time of occurrence is defined as from the beginning of surgery to 30 days after surgery or to discharge from hospital."
88827846|NCT04889703|Experimental|15% Trichloroacetic acid (TCA) chemical peel|15% trichloroacetic acid will be applied topically on the skin of the entire face in two separate clinic visits that are 4 weeks apart
88827847|NCT04889703|Experimental|30% Salicylic acid chemical peel|30% salicylic acid will be applied topically on the skin of the entire face in two separate clinic visits that are 4 weeks apart
88827848|NCT05739266||Before step test|"Before step test.~-Participants record their before-step-test voice."
88827849|NCT05739266||After step test|"After step test.~-Participants record their after-step-test voice."
88827850|NCT04884477||COVID-19 with previous anti-CD20 therapy and Convalescent plasma|Patients with COVID-19, treated in the past 3 years with anti-CD20 therapy and who received Convalescent plasma in addition to standard treatment for COVID-19
88827851|NCT04884477||COVID-19 with previous anti-CD20 therapy and no convalescent plasma|Patients with COVID-19, treated in the past 3 years with anti-CD20 therapy treated with standard COVID-19 treatment and who did not receive Convalescent plasma treatment for COVID-19
88827852|NCT04670523|Other|Test group|Test group: The patients of the study group are getting their chest tube removed according to the investigators' current airleak protocol (Flow <20 mL/ min on digital suction device) but already in the operating room immediately following wound closure (Postoperative day 0 (POD0)). If airleak is persisting than chest tube removal will be performed according to the traditional protocol not earlier than on postoperative day 1 (POD 1).
89534039|NCT01087307||Healthy Adult Volunteer|Healthy adult volunteer
88827853|NCT04670523|Other|Control group|In the control group, the chest tube gets removed according to the investigators' traditional standard protocol not earlier than on postoperative day 1 (POD1).
88827854|NCT05663840|Experimental|Progressive resistance exercise (exercise group)|Subjects will receive physical therapy that will predominantly include progressive resistance exercise training program along with continuation of standard of care (exercise group)
88827855|NCT05663840|Active Comparator|Standard of care (non-exercise group).|Subjects will receive continuation of standard of care (non-exercise group).
89534040|NCT01087281||1|Neurologically normal healthy volunteers in good general health.
88827856|NCT02974829||All patients|Continuing with marketed anti-HBV or off-treatment in real-life setting
88827857|NCT03029468|Experimental|Computerized CBT|Computerized cognitive behavioral therapy (cCBT) for pain via an integrated smartphone and web-based skills training program: The training plan will help users learn how to recognize negative thoughts and emotions, use cognitive skills and problem-solving, and apply coping behaviors such as distraction, activity scheduling, and relaxation. The cCBT arm emphasizes skills acquisition and learning through practice; thus, the program involves regular homework assignments, and follow-up with the care coach and social network about issues faced and what skills were or could be used. This intervention is consistent with the tailored behavioral services patients would receive individually or as a group when working with a psychologist or behavioral pain specialist.
88827858|NCT03029468|Active Comparator|e-Education|Participants will receive pain education through online modules that they will be asked to complete using their personal or study-provided smartphone. Each module includes learning tasks, a reading assignment, and a short quiz based on material. The education group will receive care coach contact on the same schedule as the cCBT group. The care coach will provide supportive therapy and encouragement to complete modules and apply the lessons to their daily life.
88827859|NCT03029468|No Intervention|Usual Care|Participants who are not eligible or who are not randomized into one of the intervention arms of this study will serve as a comparison group to ensure we are treating a representative sample of patients. Further, patients who were eligible but were not randomized into one of the intervention arms will serve as a usual care control group.
88827860|NCT04872387|Experimental|BAY2586116 Dose step 1 and Placebo|"Each participant of Dose step 1 will receive a single dose of BAY2586116 or placebo.~In this dose step, 12 participants will be included (9 on active treatment, 3 on placebo)."
88827861|NCT04872387|Experimental|BAY2586116 Dose step 2 and Placebo|"Each participant of Dose step 2 will receive a single dose of BAY2586116 or placebo.~In this dose step, 12 participants will be included (9 on active treatment, 3 on placebo)."
88827862|NCT04872387|Experimental|BAY2586116 Dose step 3 and Placebo|"Each participant of Dose step 3 will receive single and multiple doses of BAY2586116 or placebo administered once daily (OD) for 5 consecutive days.~In this dose step, 12 participants will be included (9 on active treatment, 3 on placebo)."
88827863|NCT05650892||Sample collection aortic tissue|Sample collection thoracic aorta tissue
88827864|NCT02411357|Active Comparator|Treatment as usual|The usual care condition will be given general information about contraceptive options and contact information for clinics and providers that provide contraceptive services.
88827865|NCT02411357|Experimental|WHO contraception protocol|The WHO contraception protocol condition will receive the World Health Organization's contraception protocol and will be invited to attend follow-up visits.
88827866|NCT02411357|Experimental|WHO contraception protocol + incentives|The WHO + incentives condition will receive the World Health Organization's contraception protocol and will be invited to attend follow-up visits, but will also receive financial incentives contingent on attending those follow-up visits.
88827867|NCT01687387|Experimental|IPH2102 at 1 mg/kg|lirilumab (IPH2102/BMS986015) at 1 mg/kg
88827868|NCT01687387|Experimental|IPH2102 at 0.1 mg/kg|lirilumab (IPH2102/BMS986015) at 0.1 mg/kg
88827869|NCT01687387|Placebo Comparator|Placebo (Normal saline solution)|Normal saline solution
88827870|NCT05739110||micronecrosis(+) group|Hepatocellular patients with tumor micronecrosis.
88827871|NCT05739110||micronecrosis(-) group|Hepatocellular patients without tumor micronecrosis.
88827872|NCT04638699|No Intervention|Phase 1 Survey of the actual state|
88827873|NCT04638699|Other|Phase 2 Survey after the OptiScreen training|
88827874|NCT01706263|Experimental|MAXCLARITY II|MAXCLARITY II (2.5% BPO) Foam Cleanser and Foam Treatment and (0.5% Salicylic Acid) Toner Foam. Available over-the-counter.
88827875|NCT05738798|Experimental|oral immunotherapy|oral immunotherapy, maintenance phase with daily 300 mg allergenic protein during 1 year
88827876|NCT05738798|No Intervention|routine care|strictly avoidance of the specific allergenic food
89000625|NCT00554710|Experimental|1|Patients received three infusions of infliximab 5 milligrams per kilogram (weeks 0, 2 and 6) in combination with azathioprine 2-2.5 milligrams per kilogram per day from day 0 onwards. If the patients responded and tolerated both drugs, azathioprine was continued for the duration of the trial. Patients who were intolerant to azathioprine received methotrexate at an initial dose of 25 milligrams administered subcutaneously each week for 12 weeks with dose reduction to 15 milligrams per week thereafter. Following initial therapy, patients who developed worsening symptoms were retreated with additional infusions of infliximab. If symptoms persisted methylprednisolone was initiated and azathioprine or methotrexate was continued.
88827879|NCT01690117|Experimental|GE-REACH-program|GE-REACH-program
88827880|NCT01690117|No Intervention|control group|usual care
88827881|NCT02330978|Experimental|MSC transplantion|One group of glaucomatous patients will receive 10(6) autologous bone marrow-derived mesenchymal stem cells transplantation into their worst eyes, through an unique intravitreal injections, under anesthesia.
88827882|NCT02330276|Experimental|10 mg (+)-epicatechin|4 subjects randomized to one dose of 10 mg (+)-epicatechin taken orally
88827883|NCT02330276|Experimental|30 mg (+)-epicatechin|4 subjects randomized to one dose of 30 mg (+)-epicatechin taken orally
88827884|NCT02330276|Experimental|100 mg (+)-epicatechin|4 subjects randomized to one dose of 100 mg (+)-epicatechin taken orally
88827885|NCT04632303|Experimental|Early Palliative Care|Baseline palliative care visit within 10 calendar days of registration/randomization and palliative care visits (either at clinic or at home) or phone calls (if a visit is not feasible) at least every four weeks throughout the patient's life. Referral to exercise training and nutritional specialist.
88827886|NCT04632303|No Intervention|Standard Care Arm|Palliative care visit only upon request from attending oncologist(s) or patient/family.
89534041|NCT01087281||2|Patients with unilateral or bilateral focal lesions of prefrontal, parietal, occipital or temporal cortex, or amygdala.
89534042|NCT01021033||Chronic stroke patients|Chronic stroke patients
88827887|NCT01690273|No Intervention|ankylosing spondylitis control|control group
88827888|NCT01690273|Experimental|mobility exercise|mobility exercises
88827889|NCT01690273|Experimental|mobility and elastic resistance exercise|AS patients was submitted to a program mobility exercise plus elastic resistance exercises
88827890|NCT02384993|Experimental|Enhanced Physical Activity|Those assigned to the enhanced physical activity group will train 3-4 days per week with the goal of attaining current public health recommendations of 150 minutes of moderate intensity exercise by the 7th week of training, and maintaining this level of exercise for the remainder of the 26-week intervention. A gradual increase in exercise intensity and duration will be used throughout this twenty-six week exercise intervention, with the initial speed and duration calibrated to each participant's baseline aerobic capacity. Training will occur in individual sessions supervised by exercise specialists with the appropriate education and experience. Each training session will begin with an appropriate warm-up, slowly build up, and end with an appropriate cool down period.
88827891|NCT02384993|No Intervention|Usual Physical Activity|"All study participants randomized to the usual physical activity group will receive education from study staff about the importance of maintaining a healthy and active lifestyle. They will receive standardized literature such as Exercise & Physical Activity: Your Everyday Guide from the National Institute on Aging. These booklets provide vetted and reliable information for older adults on how to exercise. Participants assigned to the usual physical activity group will not be provided additional support or guidance with an exercise program."
88827892|NCT04342247||androgen deficient|
88827893|NCT04342247||healthy|
88827894|NCT04620369|Experimental|Arm A (rose geranium in sesame oil nasal spray)|Patients instill rose geranium in sesame oil nasal spray, 1 spray in each nostril BID on days 1-14 in the absence of unacceptable toxicity.
88827895|NCT04620369|Placebo Comparator|Arm B (isotonic nasal saline)|Patients instill isotonic nasal saline, 1 spray in each nostril BID on days 1-14 in the absence of unacceptable toxicity. After 2 weeks, patients may instill rose geranium in sesame oil nasal spray as in Arm A for an additional 2 weeks in the absence of unacceptable toxicity.
88827896|NCT03628313||Aortic valve stenosis|The participants will be identified from the Transthoracic ultrasound echocardiography reports of the echocardiography laboratory of the University Hospital of Amiens and CH Philibert for the retrospective part. They are analyzed during echocardiography at the echocardiography laboratory of two participating centers when a diagnosis of aortic stenosis is made. Patients are informed by newsletter.
89534043|NCT01005654||1/ Cohort 1|Subjects with endocrine neoplasm or pre or potentially malignant condition of the endocrine system, scheduled to have surgery or biopsy
89534044|NCT00924027|Experimental|1/Radiation Therapy|Radiation therapy given as HDR Brachytherapy.
89534045|NCT00887939||1|Affected physical urticaria
89534046|NCT00887939||2|Healthy volunteer
88827897|NCT05738642|Experimental|4F-PCC group|1. Basic and normative treatment in accordance with the European Guidelines for Major Bleeding 2019: effective hemostatic measures and target-oriented correction of coagulation function. 2. 4 F- PCC by intravenous infusion of cluster
88827898|NCT05738642|No Intervention|non 4F-PCC group|1. Basic and normative treatment in accordance with the European Guidelines for Major Bleeding 2019: effective hemostatic measures and target-oriented correction of coagulation function.
88827899|NCT01690663|Placebo Comparator|Bupivacaine 0.25% mixed with 1ml normal saline|Bupivacaine 0.25% mixed with 1ml normal saline (placebo/control group)
88827900|NCT01690663|Active Comparator|Bupivacaine 0.25% with 1mg dexamethasone (1ml)|Bupivacaine 0.25% mixed with 1mg preservative free dexamethasone (1ml)
88827901|NCT01690663|Active Comparator|Bupivacaine 0.25% mixed with 2mg dexamethasone|Bupivacaine 0.25% mixed with 2mg preservative free dexamethasone (1ml)
88827902|NCT01690663|Active Comparator|Bupivacaine 0.25% mixed with 4mg dexamethasone (1ml|Bupivacaine 0.25% mixed with 4mg preservative free dexamethasone (1ml
88827903|NCT05360186|Experimental|Intervention group (Group A): NCH gel after USG-MVA|In the intervention group (Group A), a 15 cm sterile delivery cannula will be inserted through the internal os and a syringe of NCH gel (5ml) will be applied to the uterine cavity after cleansing the cervix with an antiseptic solution.
88827904|NCT05360186|No Intervention|Controlled group (Group B): No NCH gel after USG-MVA|In the control group (Group B), as the patient is conscious during the procedure, an empty 5ml syringe will be inserted into the internal os and held for 1 minute as a sham procedure.
88827905|NCT02290574|Experimental|Thermo-radio-chemotherapy arm|Hyperthermia with concurrent chemo-radiation therapy
89188822|NCT02572466||ESRD group|"Aged 18 years or older.~was diagnosed as End-stage renal disease for more than one year.~Attend hemodialysis 3 times a week consistently for more than 6 months.~Hemodialysis with Kt/V > 1.2~No urine output or is less than 500 ml per day.~No symptoms of myocardial infarction Or were hospitalized with the similar diagnosis during the two weeks."
89188823|NCT02572466||Control group|"Aged 18 years or older.~without kidney disease (eGFR > 60 ml/min/1.73m2)"
89188824|NCT00797121|Experimental|Preoperative biliary drainage|
89188825|NCT00797121|No Intervention|Controlled group|
89534047|NCT00887939||3|Unaffected relative
89188826|NCT00715364|Experimental|1|
89188827|NCT00715364|Placebo Comparator|2|
89188828|NCT02601677|Experimental|Deep Brain Stimulation|Continuous deep brain stimulation of bilateral nucleus accumbens
89188829|NCT02601677|Active Comparator|Standard Control|Fluoxetine
89188830|NCT03986333||Control|Children whose drooling was expected to remain relatively stable over 1 month
89188831|NCT03986333||Intervention|Children receiving a treatment to reduce their drooling
89188832|NCT00797199||1-Treatment Group 1|Women receiving HRT treatment of Premarin.
89534048|NCT00862433|Experimental|Arm 1|Determine optimal fat content of meal for optimal absorption of vitamin E
89534049|NCT00862433|Experimental|Arm 2|Determine optimal dose of vitamin E.
89534050|NCT00862433|Experimental|Arm 3|Investigate the relationship between vitamin C status and vitamin E turnover
88827906|NCT05738564|Active Comparator|Group (EL) Epinepherine and Lidocaone group|Group (EL) (63 patients) received a session of nebulization in the pre-induction area, consisting of 1 ml epinephrine (1:1000 Martindale Pharma, an Ethypharm Group Company, ampoule 1 mg added to 9 ml of normal saline, then 1 ml of that put in nebulization cup + 2 ml lidocaine 2%), nebulized prior to the induction of anesthesia.(63 patients) received a session of nebulization in the pre-induction area, consisting of 1 ml epinephrine (1:1000 Martindale Pharma, an Ethypharm Group Company, ampoule 1 mg added to 9 ml of normal saline, then 1 ml of that put in nebulization cup + 2 ml lidocaine 2%), nebulized prior to the induction of anesthesia.
88827907|NCT05738564|Active Comparator|Group( OL) Oxymetazoline and lidocaine group|Group OL (63 patients): These patients received five drops of lidocaine hydrochloride (Xylocaine 2%, 20 mg/ml; AstraZeneca, London, UK) using a prefilled dropper, followed by six drops of hydrochloride Oxymetazoline (Otrivin adult nasal drops 0.1%, 10 ml of 1 mg/ml; Novartis Consumer Health, UK Ltd, 980 Great West Road, Brentford, Middlesex, TW8 9GS, UK) in each nostril in the pre-induction room just before the induction of anesthesia
88827908|NCT01706965|Experimental|Kuvan|Kuvan once-daily dosing initiated with 10mg/kg for the first week followed by 20mg/kg for the remaining weeks of the study
88827909|NCT01706965|Active Comparator|Multivitamin|Daily multivitamin tablet
88827910|NCT04350086|Experimental|Experimental arm|
88827911|NCT05738408|No Intervention|Control: Usual Care|will receive standard treatment which entails referral to Vermont Quit Network. This network offers a wide range of free cessation services, including NRT and web-based modules on preparing to quit and developing a plan
88827912|NCT05738408|Experimental|Intervention: Financial incentives and nicotine replacement therapy intervention|an intervention where patients are assigned to financial incentives and NRT of their choice; use of CO monitor to assess abstinence
88827913|NCT01352117|Active Comparator|Arm A: ART alone or with delayed ET|Participants were prescribed ART (co-formulated efavirenz/emtricitabine/tenofovir disoproxil fumarate, EFV/FTC/TDF) for 96 weeks. Arm A participants who experienced KS progression on ART alone could receive ET in addition to EFV/FTC/TDF in Step 2 of the study.
88827914|NCT01352117|Experimental|Arm B: ART with immediate ET|Participants were prescribed ART (co-formulated efavirenz/emtricitabine/tenofovir disoproxil fumarate, EFV/FTC/TDF) for 96 weeks with immediate ET for up to 16 weeks.
88827915|NCT03379207||"Community Acquired Pneumonia group"|"Participants admitted to Intensive Care Unit (ICU) of University Hospital of Tours (France) for Community Acquired Pneumonia.~Interventions:~Blood samples for research purpose, taken whenever possible during blood sampling for routine purpose, at inclusion, day 1, 7, and every week during ICU stay Tracheal Aspirates for research purpose: only for mechanically ventilated participants, at inclusion, day 1, 7, and and every week during ICU stay~Surplus of Broncho-alveolar lavage fluid: only if performed for diagnosis purpose by the treating investigator (indication left at his discretion)"
88827916|NCT03379207||"Control group"|"Participants admitted to Intensive Care Unit of University Hospital of Tours (France) for whom invasive mechanical ventilation is required for an estimated duration of at least 48h, without diagnosis of pneumonia or shock.~Interventions:~Blood samples for research purpose, taken whenever possible during blood sampling for routine purpose, at inclusion, day 3, 8, and 15 during ICU stay Tracheal Aspirates for research purpose: at inclusion, day 3, 8, and 15 during invasive mechanical ventilation period,~Surplus of Broncho-alveolar lavage fluid: only if performed for diagnosis purpose by the treating investigator (indication left at his discretion)"
88827917|NCT03377569||Group #1|Patients with Parkinsons Disease who will undergo Deep Brain Stimulation surgery. At home sleep monitoring prior to DBS surgery and in patient polysomnography with neural recording after DBS surgery.
88827918|NCT03377569||Group #2|Patients with Parkinsons Disease who will undergo Deep Brain Stimulation surgery. At home sleep monitoring after DBS surgery with DBS stimulation on at night, and in patient polysomnography after DBS surgery.
88827919|NCT03377569||Group #3|Patients with Parkinsons Disease who will undergo Deep Brain Stimulation surgery. At home sleep monitoring after DBS surgery with DBS stimulation off at night, and in patient polysomnography after DBS surgery.
88827920|NCT02987426|Experimental|Mindfulness-oriented intervention|Patients will get a mindfulness-oriented intervention daily for 10 minutes.
88827921|NCT02987426|No Intervention|Treatment as Usual|This group will continue receiving their normal inpatient psychiatric care and receive information (paper brochures) about health promotion.
88827922|NCT02974673|Experimental|Ejaculatory test|Measures of sphincter pressures during ejaculation
88827923|NCT02974439|Experimental|LANDI-Amlodipine Besylate Tablet 5mg|During the study session, healthy subjects will be administered a single dose of LANDI-AmlodipineTablet 5mg under fasting and FED conditions.
88827924|NCT02974439|Active Comparator|Norvasc Tablets 5mg|During the study session, healthy subjects will be administered a single dose of Norvasc Tablets 5mg under fasting and FED conditions.
88827925|NCT02974517||Time-lapse-Auto|All embryos are cultured in EmbryoScope®; embryo scores are evaluated on day 3 by KID Score system.
88827926|NCT02974517||Time-lapse-Manual|All embryos are cultured in EmbryoScope®; embryo scores are evaluated on day 3 by embryologist.
88827927|NCT02974517||Conventional Group|All embryos are cultured in our daily used incubators; embryo scores are evaluated on day 3 by embryologist.
88827928|NCT05736614|No Intervention|Stage 1 Standard of Care (SOC) Control Condition|SOC participants will receive an informational pamphlet about the PrEP as a form of HIV prevention and referrals to local PrEP Prescribers.
88827929|NCT05736614|Experimental|Stage 1 Strength Based Case Management (SBCM) Condition|Intervention participants will receive a trained SBCM to motivate, support, and assist in linkage to PrEP prescribers to help facilitate obtaining PrEP medication to initiate treatment.
88827930|NCT05736614|No Intervention|Stage 2 SOC Control Condition|Research staff will show a brief video that describes what PrEP is and how it works to prevent HIV via sexual and injection transmission. Participants will continue to see their PrEP prescriber for routine clinical care.
88827931|NCT05736614|Experimental|Stage 2 PrEPare for Work Intervention Condition|Intervention participants will receive 1-on-1 adherence counseling and personalized daily text messaging reminders to increase PrEP adherence. Intervention participants will undergo three adherence intervention sessions (once per week for 3 weeks) with interventionist.
88827932|NCT03340727|Experimental|Caffeine Citrate|Caffeine citrate at 10 mg/kg/dose (5 mg/kg caffeine base) daily, in hospital. Infants will continue at home on the same dose of caffeine citrate for the first 28 days after hospital discharge.
88827933|NCT03340727|Placebo Comparator|Placebo|Placebo contains all of the excipients except for the active ingredient, caffeine citrate, (a volume equivalent to 10 mg/kg of caffeine citrate) and given daily. Infants will be continued at home on the same dose of placebo for the first 28 days after hospital discharge.
88827934|NCT01707043|Active Comparator|Taclonex Ointment First|All subjects will use Taclonex® (calcipotriene 0.005% and betamethasone dipropionate 0.064%) Ointment once daily for three days to affected areas, then switch to Taclonex Scalp® (calcipotriene 0.005% and betamethasone dipropionate 0.064%) Topical Suspension once daily to affected areas for three days
88827935|NCT01707043|Active Comparator|Taclonex Scalp Suspension first|All subjects will use Taclonex Scalp® (calcipotriene 0.005% and betamethasone dipropionate 0.064%) Topical Suspension once daily to affected areas for three days, then switch to Taclonex® (calcipotriene 0.005% and betamethasone dipropionate 0.064%) Ointment once daily for three days to affected areas,
88827936|NCT05736380|Active Comparator|Unilateral cerebellar rTMS|
88827937|NCT05736380|Sham Comparator|Sham cerebellar rTMS|
88827938|NCT04350164||treatment|romiplostim once weekly subcutaneously at an initial dose of 8-9 µg/kg per week for at least 1 month to 1 year.
88827939|NCT01708213|Experimental|Dermal Filler - Aline HA|Single armed study
88827940|NCT04768088|Experimental|One-week training of falling techniques on landing biomechanics associated with ACL loading|Participants will perform one-week training of single-leg falling techniques, a post-training assessment, a two-week break, and a retention assessment.
88827941|NCT04258839|Experimental|Arm 1|Brexpiprazole
88827942|NCT01708525|Experimental|Ultherapy®-treated tissue|Heavy water labeled tissue receiving an Ulthera® System Treatment
88827943|NCT05244512|Experimental|Evidence-based leadership training|The training course will take 6 months. It is divided into seven online modules. Participants join the course based on pre-structured schedule. The progress of the training course will follow specific steps to improve participants' evidence-based leadership competencies. First, each participant identifies one leadership problem on daily practice. Second, organisational data will be collected and analysed to increase the understanding of the key problem. Third, scientific literature will be searched, identified and critically appraised to find solutions. Fourth, the views of stakeholders (patients, clinicians, family members, etc.) are considered together with ethical implications. And last, all sources of information are critically appraised, new solution will be designed and implemented into the practice, and evaluated in real world context. Each module includes specific learning material. Trained tutors are responsible for mentoring each module.
88827944|NCT05244512|Active Comparator|Conventional training|The participants will join a training course with the same structure, topics, and timing as the experimental group. However, training in this group is based on independent learning methods. The participants have access to the separate learning platform, which includes reading material to be read independently. No group discussions with peers, self-reflection, assignments, or support from tutors will be offered.
88827945|NCT04258137|Experimental|Experimental procedure for colorectal cancer|Patients with Advanced colorectal cancer will be managed by initial MTB providing therapeutic recommendation based on tumor sequencing and then follow-up combining standard imaging and ctDNA analysis (subsequent MTBs at each radiological assessment)
88827946|NCT04258137|No Intervention|Standard procedure for colorectal cancer|Patients with Advanced colorectal cancer will be managedby initial MTB providing therapeutic recommendation based on tumor sequencing and then follow-up based on standard imaging.
88827947|NCT04258137|Experimental|Experimental procedure for non-small cell lung cancer|Patients with Advanced non-small cell lung cancer will be managed by initial MTB providing therapeutic recommendation based on tumor sequencing and then follow-up combining standard imaging and ctDNA analysis (subsequent MTBs at each radiological assessment)
88827948|NCT04258137|No Intervention|Standard procedure for non-small cell lung cancer|Patients with Advanced non-small cell lung cancer will be managed by initial MTB providing therapeutic recommendation based on tumor sequencing and then follow-up based on standard imaging.
88827949|NCT04257747|Sham Comparator|Healthy volunteers|
88827950|NCT04257747|Active Comparator|patients requiring radial forearm flap reconstruction|
88827951|NCT04257747|Experimental|patients having received hand allotransplantation|
88827952|NCT03029312|Experimental|Whole Body Vibration|Twice daily WBVT at home using the Galileo M device, 3x3 min, with 3 minute breaks (total daily WBVT 18 min) for 5 months. Children stand upright on the device, with knees bent (10-45 degrees, semi-squat or squat position). A schedule of increasing intensity of vibration exercise was used over time, allowing some adjustment to the patient's physical capability. Amplitude 1 was used for the first 2 weeks, then increased to amplitude 2 and further increased up to amplitude 3, if individually possible, always using frequencies between 20-25Hz. Children also perform exercises on the platform, including shifting their weight from one side to the other, increase/decrease their knee and hip angle, weight shift with trunk rotation, and alternate flexion and extension of knees.
88827953|NCT03029312|No Intervention|Regular Care|Regular Care, including physiotherapy for 5 months
88827954|NCT03634917|Active Comparator|Acamprosate|"1 capsule with Acamprosate calcium~oral use~3 times / day (morning, noon, evening)~666 mg per capsule~14 - 19 days"
88827955|NCT03634917|Active Comparator|Calcium Carbonate|"1 capsule with Calcium Carbonate~oral use~3 times / day (morning, noon, evening)~1500 mg Calcium Carbonate (= 600 mg Calcium 2+)~14 - 19 days"
88827956|NCT03634917|Placebo Comparator|Placebo|"1 capsule placebo,~oral use~3 times / day (morning, noon, evening)~14 - 19 days"
88827957|NCT03623763||Healthy individuals|Individuals without any complaints and chronic diseases
88827958|NCT03623763||Swimmers|Elite athletes - swimmers to distance of national team of Uzbekistan
88827959|NCT03623763||Synchronized swimmers|Elite athletes - swimmers of national team of Uzbekistan
88827960|NCT04595565|Experimental|Sacituzumab govitecan|Sacituzumab govitecan is administered intravenously 10 mg/kg body weight on days 1, 8 q3w for eight cycles.
88827961|NCT04595565|Other|Treatment of physician´s choice|TPC, defined as capecitabine or platinum-based chemotherapy for eight cycles or Observation.
89188833|NCT00797199||2-Treatment Group 2|Women receiving combination HRT treatment of Premarin + Provera.
89534051|NCT00862433|Experimental|NAFLD sub-study|Investigate the relationship between fatty liver disease and vitamin E turnover.
88827962|NCT03028844|No Intervention|Sucrose alone|"These infants will receive an oral sucrose solution (Sweetease) only prior to venepuncture"
88827963|NCT03028844|Experimental|Music intervention plus sucrose|These infants will receive both oral sucrose solution and music therapy prior to venepuncture.
88827964|NCT02284880|Experimental|Group 1 BIA 2-093|Subjects randomly received on period 1 and 2, either a single 400 mg tablet of ESL (MF - marketed formulation), or a single 400 mg tablet of ESL (TBM - o-be-marketed);
88827965|NCT02284880|Experimental|Group 2 BIA 2-093|Subjects randomly received on period 1 and 2, either a single 800 mg tablet of ESL (MF - marketed formulation), or a single 800 mg dose of ESL (TBM - o-be-marketed).
88827966|NCT04230681|Active Comparator|Fentanyl|
88827967|NCT04230681|Active Comparator|Hydromorphone|
88827968|NCT01708603|Experimental|210 mg brodalumab|Administered by subcutaneous (SC) injection until week 12. At week 12, participants are rerandomized to schedule 1, 2, 3, or 4.
88827969|NCT01708603|Experimental|140 mg brodalumab|Administered by subcutaneous (SC) injection until week 12. At week 12, participants are rerandomized to schedule 1, 2, 3, or 4.
88827970|NCT01708603|Active Comparator|ustekinumab|Administered by subcutaneous (SC) injection per the labeled dosing regimen.
88827971|NCT01708603|Placebo Comparator|Placebo|Administered by subcutaneous (SC) injection until week 12. At week 12 participants are assigned to 210 mg brodalumab.
88827974|NCT04526535||No B-lines|Patients with no significant B lines in the lung ultrasound at first 24 hours after acute myocardial infarction (any field with 3 or more B-lines)
88827975|NCT04526535||B lines|Patients with significant B lines in the lung ultrasound at first 24 hours after acute myocardial infarction (3 or more B-lines in at least one lung field)
88827976|NCT03579485||aging HIV positive patients|HIV-1 infected patients, aged ≥ 60 years old, naive patients receiving raltegravir based-regimen, including Nuc-sparing regimens or experienced patients with virological suppression (HIV-1 RNA<50 copies) who had switched from any antiretroviral drug to raltegravir-based regimens (including Nuc-sparing regimens) because of toxicity, convenience or other reasons.
88827977|NCT04330365|Active Comparator|Whole Health Team (WHT) Intervention Arm|The WHT intervention arm includes four core elements: 1) An interdisciplinary WHT collaborating with primary care; 2) Personalized Health Planning with prioritization of multi-modal non-pharmacological and CIH pain management approaches; 3) Whole Health Coaching sessions to assist patients in developing and implementing a Personalized Health Plan for chronic pain care; and 4) the web/mobile Whole Health Resource Directory provided to patient participants (in addition to their providers) to support non-pharmacologic/CIH chronic pain care.
88827978|NCT04330365|Active Comparator|Primary Care Group Education (PC-GE) Intervention Arm|Primary Care Group Education (PC-GE) iss the comparator arm, which is an abbreviated form of Cognitive Behavioral Therapy for Chronic Pain (CBT-CP) adapted for group use in primary care.
88827979|NCT04330365|Placebo Comparator|Usual Primary Care (UPC) Arm|In VA, patient-aligned care teams (PACTs) or primary care is step 1 of VA's Stepped Care Model in the treatment of chronic pain. PCPs are expected to possess the requisite skill set for management of common chronic pain-causing conditions, which includes biopsychosocial assessment, multi-modal treatment, and coordination of specialty pain care after shared-decision making that incorporates patient preferences and values. Participants randomized to this arm will continue to have their PCP and PACT serve in this role.
88827980|NCT03578237|Experimental|Treatment (active cryoneurolysis)|Receiving active cryoneurolysis
88827981|NCT03578237|Sham Comparator|Sham|Receiving sham cryoneurolysis procedure
88827982|NCT00362765|Experimental|1|
88827983|NCT00362765|Active Comparator|2|
88827984|NCT00362765|Active Comparator|3|
88827985|NCT00362765|Placebo Comparator|4|
88827986|NCT04342403||Sarcoidosis|Patients with sarcoidosis willing to participate
88827987|NCT03305783||Patients having cholecystectomy|Healthy, normal weight patients (BMI<27) undergoing elective cholecystectomy will have a meal test performed before and after surgery.
88827988|NCT03305783||Healthy controls|Healthy matched controls will have one meal test performed.
88827989|NCT02286518|Experimental|Cohort 1A: TAK-114 10 mg|Orally, once only.
88827990|NCT02286518|Experimental|Cohort 1B: TAK-114 10 mg|Orally, once
88827991|NCT02286518|Experimental|Cohort 2A: TAK-114 20 mg|Orally, once
88827992|NCT02286518|Experimental|Cohort 2B: TAK-114 20 mg|Orally, once
89534052|NCT00852943||Patients|Subjects, ages birth to 99 years old, known to have or suspected of having an inherited disorder of allergic inflammation or mast cell homeostasis or activation, will be eligible for enrollment.
88827993|NCT02286518|Experimental|Cohort 3A: TAK-114 50 mg|Orally, once
88827994|NCT02286518|Experimental|Cohort 3B: TAK-114 50 mg|Orally, once
89188834|NCT00797199||3- Treatment Group 3|Women receiving combination HRT treatment of Premarin + Prometrium.
88827995|NCT02286518|Experimental|Cohort 4a: TAK-114 20 mg|Period 1: Single-dose administration in a fasting state Period 2: Single-dose administration 30 minutes after breakfast
88827996|NCT02286518|Experimental|Cohort 4b: TAK-114 20 mg|Period 1: Single-dose administration 30 minutes after breakfast Period 2: Single-dose administration in a fasting state
88827997|NCT02286518|Experimental|Cohort 5A: TAK-114 20 mg|Orally, Twice daily, 10 days
88827998|NCT02286518|Experimental|Cohort 5B: TAK-114 20 mg|Orally, Twice daily, 10 days
88827999|NCT02286518|Experimental|Cohort 6A: TAK-114 50 mg|Orally, Twice daily, 10 days
88828000|NCT02286518|Experimental|Cohort 6B: TAK-114 50 mg|Orally, Twice daily, 10 days
88828001|NCT02286518|Placebo Comparator|Cohort 1A, 2A, 3A: TAK-114 placebo|Cohort 1A, 2A, 3A: Orally, once
88828002|NCT02286518|Placebo Comparator|Cohort 5A: TAK-114 placebo|Cohort 5A: Orally, Twice daily, 10 days
88828003|NCT02286518|Placebo Comparator|Cohort 6A: TAK-114 placebo|Cohort 6A: Orally, Twice daily, 10 days
88828004|NCT02294435|Experimental|Primary Study Arm|The TAAA Debranching Stent Graft System is comprised of two investigational devices including the Thoracic Bifurcation and the Visceral Manifold and the Unitary Manifold. The thoracic bifurcation and the visceral manifold as well as the unitary manifold work to facilitate endovascular stenting of the visceral vessels (renals, celiac, SMA) while maintaining flow to the visceral and infrarenal segments.
88828005|NCT02294435|Experimental|Expanded Selection Arm|The expanded selection arm is for subjects not eligible for open repair or other endovascular options due to comorbidities or anatomical limitations and do not meet inclusion in the primary study arm. The Thoracic Bifurcation and the Visceral Manifold as well as the Unitary Manifold work to facilitate endovascular stenting of the visceral vessels (renals, celiac, SMA) while maintaining flow to the visceral and infrarenal segments.
88828006|NCT05735990||640PM implanted|Patients implanted binocularly with Medicontur's intraocular lens model 640PM.
88828007|NCT05228522|Experimental|Lifestyle Intervention|16-week family-focused intervention that includes nutrition education, behavioral change skills training, and physical activity.
88828008|NCT05228522|No Intervention|Comparison control|Comparison control families meet with the Study Physician and a Registered Dietitian as a family to review laboratory results and receive lifestyle counseling. Control families will be contacted on a monthly basis for a total of 12 months.
88828009|NCT02220725|Experimental|Andexanet 800mg bolus (Part I)|Andexanet (antidote) - 800 mg bolus
88828010|NCT02220725|Experimental|Andexanet 800mg + 960mg (Part II)|800 mg bolus + 960 mg infusion (8 mg/min)
88828011|NCT05033756|Experimental|Pembrolizumab / Olaparib|All eligible participants according to the definition of cohorts 1-3 will receive pembrolizumab i.v. 200 mg q3w in combination with olaparib tablets 300 mg twice daily (total dose 600 mg per day).
88828012|NCT02980484|Experimental|Active rTMS|Subjects will receive a full course of 20 rTMS treatments over 20 consecutive weekdays as described above.
88828013|NCT02980484|Sham Comparator|Sham/crossover rTMS|Rather than receiving active treatment, subjects will receive sham treatment designed to be indistinguishable from active treatment to the patient. After completion of the sham course, patients will have the option to receive open-label active treatment at no cost.
88828014|NCT05030714|Experimental|Single Arm|Patients will perform visual field testing with the Humphrey Visual Field Analyzer and with the custom head-mounted device.
88828015|NCT03522077|Experimental|RadAR EasyCLik plus SoftSeal®-STF hemostatic pad|Hemostasis will be obtained with the SoftSeal®-STF hemostatic pad and vascular compression device by applying pressure at the point proximal and distal to the puncture site and removing the sheath. While still maintaining pressure, the SoftSeal®-STF hemostatic pad will be applied over the puncture site. The cath lab staff will allow a small amount of blood (< 0.2 mL) to contact the surface of the hemostatic pad and then will apply constant pressure with a vascular compression device.
88828016|NCT03522077|Active Comparator|TR BAND® plus SoftSeal®-STF hemostatic pad|Hemostasis will be obtained with the SoftSeal®-STF hemostatic pad and vascular compression device by applying pressure at the point proximal and distal to the puncture site and removing the sheath. While still maintaining pressure, the SoftSeal®-STF hemostatic pad will be applied over the puncture site. The cath lab staff will allow a small amount of blood (< 0.2 mL) to contact the surface of the hemostatic pad and then will apply constant pressure with a vascular compression device.
88828017|NCT03522077|Experimental|SoftSeal®-STF hemostatic|Hemostasis at the radial access site for subjects randomized to the SoftSeal®-STF hemostatic pad will be obtained by applying pressure at the point proximal and distal to the puncture site and removing the sheath. While still maintaining pressure, the SoftSeal®-STF hemostatic pad will be applied over the puncture site. The cath lab staff will allow a small amount of blood (< 0.2 mL) to contact the surface of the hemostatic pad and then will apply constant pressure.
88828018|NCT03522077|Active Comparator|VascBand™ Hemostat|Hemostasis at the radial access for subjects randomized to the VascBand™ Hemostat will be obtained in accordance to the manufacturer's instructions. The VascBand™ device will be placed proximal to the puncture site and inflated slowly while simultaneously removing the sheath, and continue to inject air (max. 18 mL) into the device until hemostasis is obtained.
88828019|NCT02980562|Active Comparator|2L Polyethylene glycols-Asc|1 L of PEG containing ascorbic acid (PEG A) was taken at 8:00 pm on the day before the colonoscopy, followed by an extra 500 mL of water. The second 1-L of PEG containing ascorbic acid was taken 4 h before the colonoscopy examination, with an additional 500 mL of water. Each liter of preparation and the extra 500 mL water had to be consumed within 2 h of the procedure. All colonoscopies were performed between 9 am and 1 pm.
88828020|NCT02980562|Active Comparator|1L PEG-Asc plus bisacodyl|10 mg bisacodyl at 9:00 pm on the day before the colonoscopy. Four hours before the colonoscopy examination, 1 L of PEG containing ascorbic acid was taken, followed by an additional 1 L of water. The preparation was completed 2 h before the examination. All colonoscopies were performed between 9 am and 1 pm.
88828021|NCT04476693|Experimental|Breakfast Consumption (BC)|"The consumption of a standardised breakfast followed by a standardised lunch 3-h after the last mouthful of breakfast meal. All the ingredients of the breakfast and lunch provided will be weighed, with the portion sizes calculated based on individual resting metabolic rate (RMR). The participants were instructed to consume the meals provided within 15 min. A minimum of seven days washout period will be provided to avoid carry-over effects between conditions.~The standardised lunch will consist of white bread without crust (Tesco), margarine 'Butter Me Up Spread' (Tesco), strawberry jam (Tesco), salted crisps (Walkers) and sparkling glucose drink (Lucozade Energy Original). This carbohydrate-rich high glycameic index lunch was designed to trigger quick and exaggerated glucose and insulin response."
89188835|NCT00797199||4- Controls|Women not on HRT or healthy controls.
89534053|NCT00788671|Experimental|Treatment (levonorgestrel-releasing intrauterine system)|Patients undergo placement of a levonorgestrel-releasing intrauterine system.
89534054|NCT00787423||COHORT 1|Individuals from 18 to 75 years of age who are current heroin users seeking treatment for addiction and who spend most of their time in Baltimore city.
88828022|NCT04476693|Experimental|Breakfast omission (BO)|"Participant will consume water, the individual volume of which was calculated based on the liquid content of the breakfast. A standardised lunch will be consumed 3-h after the last mouthful of water. All the ingredients of the breakfast and lunch provided were weighed, with the portion sizes calculated based on individual resting metabolic rate (RMR). The participants were instructed to consume the meals provided within 15 min. A minimum of seven days washout period was provided to avoid carry-over effects between conditions.~The standardised lunch consists of white bread without crust (Tesco), margarine 'Butter Me Up Spread' (Tesco), strawberry jam (Tesco), salted crisps (Walkers) and sparkling glucose drink (Lucozade Energy Original). This carbohydrate-rich high glycameic index lunch was designed to trigger quick and exaggerated glucose and insulin response."
88828023|NCT03266393|Experimental|Arm A-Tacrolimus then Envarsus|Immediate release tacrolimus (twice a day oral formulation) 14 day run-in followed by 4 months of follow-up and then crossing over to Envarsus XR® with a 14 day run-in followed by 4 months of follow-up.
88828024|NCT03266393|Experimental|Arm B-Envarsus then Tacrolimus|Envarsus XR® 14 day run-in followed by 4 months of follow-up and then crossing over to immediate release tacrolimus (twice a day oral formulation) with a 14 day run-in followed by 4 months of follow-up.
89534055|NCT00767897||CKD stage 3 or 4|Girls and Boys age 9-18 with CKD stage 3 or 4
89534056|NCT00767897||On dialysis|Girls and Boys age 9-18 who are on dialysis
89534057|NCT00767897||Transplanted|Girls and Boys age 9-18 who have had a functioning kidney transplant for longer than 6 months and are on the same immunosuppression regimen.
89534058|NCT00767897||Healthy|Girls and Boys age 9-18
88828025|NCT04349618|Active Comparator|PROTECTIVE VENTILATION|Protective ventilation with tidal volume 6 mL/kg of predicted body weight
89534059|NCT00707473|Experimental|Treatment (docetaxel, cisplatin, and fluorouracil)|"INDUCTION CHEMOTHERAPY: Patients receive docetaxel IV over 1 hour on day 1, cisplatin IV over 30-180 minutes or carboplatin IV on day 1, and fluorouracil IV continuously on days 1-4. Cycles repeat every 3 weeks for up to 2 cycles in the absence of disease progression or unacceptable toxicity.~Patients who achieve CR or PR receive 1 additional course of treatment and undergo chemoradiotherapy over 6-7 weeks. Patients who have SD or PD to induction therapy, or less than a complete response to chemoradiotherapy undergo surgery and radiation therapy."
88828026|NCT04349618|Experimental|ULTRAPROTECTIVE VENTILATION|Ultraprotective ventilation with tidal volume reduction down to 4 mL/kg further adjusted to keep plateau pressure below 30 cm H2O and pH above 7.20
88828027|NCT04117971||Staff members|Staff members in different clinical departments at Faculty of Dentistry, Cairo University.
88828028|NCT04117971||PhD students|PhD candidates in different clinical departments at Faculty of Dentistry, Cairo University.
88828029|NCT04117971||Master's students|Master's candidates in in different clinical departments at Faculty of Dentistry, Cairo University.
88828030|NCT02986568|Experimental|Cervical cancer|"Primary cervical cancer patients, FIGO stage IB1-IIB~Refractory cervical cancer patients who do not respond to concurrent chemoradiotherapy or radiotherapy~Recurrent cervical cancer after concurrent chemoradiotherapy or radiotherapy"
88828031|NCT02986568|Experimental|Uterine cancer|"Primary uterine cancer patients, FIGO stage IA, grade3, IB-IVA~Refractory uterine cancer who does not respond to concurrent chemoradiotherapy or radiotherapy~Recurrent uterine cancer after concurrent chemoradiotherapy or radiotherapy"
88828032|NCT02986568|Experimental|Cervical cancer, pelvic sidewall invasion|"Cervical cancer patients showing pelvic sidewall invasion~Primary cervical cancer~Refractory cervical cancer patients who do not respond to concurrent chemoradiotherapy or radiotherapy~Recurrent cervical cancer after concurrent chemoradiotherapy or radiotherapy"
88828033|NCT02986568|Experimental|Non-cervical cancer, pelvic sidewall invasion|"Gynecologic cancer patients other than cerivcal cancer, showing pelvic sidewall invasion with or without distant metastasis~Patients showing uncontrolled pelvic pain due to the tumor invasion"
88828034|NCT00421967|Experimental|1|
88828035|NCT00421967|Active Comparator|2|
88828036|NCT04744337|Other|orthodontic treatment|fixed orthodontic treatment in adolescent females initially treated with removable functional appliance for skeletal class II, Angle's class II division 2 malocclusion.
88828037|NCT03209687|Experimental|Human menopausal gonadotropin (HMG)|This group will take daily subcutaneous 75 IU (international unit) of human menopausal gonadotropin (HMG) in addition to the usual luteal phase support from the day of ovum pickup and will be continued for 2 weeks
88828038|NCT03209687|No Intervention|Routine care|This group will receive the routine care for luteal phase support
88828039|NCT04997798|Experimental|Dalpiciclib in combination with exemestane and trastuzumab plus pyrotinib|Patients are treated with intravenous trastuzumab (8 mg/kg loading dose followed by 6 mg/kg, Q3W) for six cycles plus oral Dalpiciclib (125 mg QD x 21，Q4W) and Exemestane (25 mg po QD ）and oral pyrotinib (320 mg po QD) for 20 weeks.
88828040|NCT05209646|Experimental|Trial (Intervention) group|Patients will receive honey for 8 weeks in a dose of 30 ml undiluted honey per day divided as 5 ml honey 30 minutes before each meal six times daily. The honey will be kept in a closed glass container and away from light until the time of use. Each patient will be provided with a well-sealed container containing 210 ml honey each week. The honey used in the study will be a raw, unprocessed Clover honey collected from AL Mahala-Gharbia governorate, Egypt. The honey will be supplied directly from a beekeeper without heating or gamma irradiation
88828041|NCT05209646|No Intervention|Control (Non-intervention) group|No honey will be given to this group
88828042|NCT04330443|Experimental|Ultrasound group|The neonatologist-researcher (NR) performed the lung ultrasound at admission during the first hour of life. The neonatologist-assistant (NA) of the baby was not blinded to the result of the lung ultrasound. If the patient had a lung ultrasound score higher than >8 or when FiO2 exceeded 30% patient received surfactant therapy during in the first 72 hours of life
88828043|NCT04330443|No Intervention|Chest X Ray|The NR performed the LUS at admission/suspicion during the first hour of life. The NA was not blinded to the result of the LUS. Patient received surfactant therapy only when FiO2 exceeded 30% during the first 72 hours of life
88828044|NCT04986332|Experimental|"GROUP COPD"|100 participants, 50 males and 50 females with COPD and multiple chronic conditions
88828045|NCT04986332|Active Comparator|"GROUP HF"|100 participants, 50 males and 50 females with HF and multiple chronic conditions
88828046|NCT04986332|Active Comparator|"GROUP HEALTHY PARTICIPANTS"|"100 healthy participants or control group which will be compared to Group A and Group B by age and sex"
89534060|NCT00702533||Healthy volunteers|Healthy volunteers between 18 and 60 years of age
89534061|NCT00702533||patients with gastric acid secretory disorders|18 years of age who have been diagnosed with Zollinger-Ellison Syndrome or acid hypersecretion.
88828047|NCT04330677|Experimental|1. Oxytocin spray, 2. Estrogen gel|
88828048|NCT04330677|Experimental|1. Oxytocin spray, 2. Placebo gel|
88828049|NCT04330677|Experimental|1. Placebo spray, 2. Estrogen gel|
88828050|NCT04330677|Placebo Comparator|1. Placebo spray, 2. Placebo gel|
89534062|NCT00682513||ATP1A3 Mutation|Those with RDP, AHC, unaffected carriers of ATP1A3 mutations, and non-carrying family members
88828051|NCT04965116|Experimental|Early Initiation d-POPs|Initiation of d-POPs 120-160 hours after delivery. Dosing is 4mg daily for 24 days followed by 4 daily inactive tablets for 2 months.
88828052|NCT04965116|Experimental|Early Initiation n-POPs|Initiation of n-POPs 120-160 hours after delivery. Dosing is 0.35mg daily for 28 days for 2 months.
89534063|NCT00605878||Grouo 3|Healthy (pediatric) controls
89534064|NCT00605878||Group 1|Healthy (adult) volunteers
89534065|NCT00605878||Group 2|AD patients
89534066|NCT00605878||Group 4|Patients diagnosed with the primary immunodeficiency hyperIgE syndrome (HIES)
89534067|NCT00605878||Group 5|Patients diagnosed with the primary immunodeficiency Wiskott-Aldrich Syndrome (WAS)
88828053|NCT04965116|Placebo Comparator|Interval Initiation of d-POPs|Placebo starting 120-160 hours after delivery, continuing for 28 days. Followed by 24 days of 4mg daily of d-POPs and 4 daily inactive tablets.
88828054|NCT02986490|Other|patient with antipsychotic/neuroleptic|Blood sample performed on patients requiring the establishment of treatment with antipsychotic / neuroleptic
88828055|NCT02986412|Experimental|CG428|Patients will self-administer the study product twice per day (morning, evening) for 6 months, for the efficacy assessment
88828056|NCT04089969|Experimental|Evaluation of Standard of care followed by CTA/FFRct|Patient received clinical recommendation based on the Standard of Care i.e 2 D echocardiogram, plus ECG, plus, pharmacological stress test followed by re-evaluation of clinical recommendation with addition of CTA/FFRct
88828057|NCT02249143|Active Comparator|CPAP and room air|Stable premature infants on CPAP and room air will be randomized to stay on CPAP for an additional two weeks.
88828058|NCT02249143|No Intervention|Room air|Premature stable infants on CPAP and room air will be randomized to transition to room air alone.
88828059|NCT02259517|Experimental|Guanfacine|Participants will be administered extended-release guanfacine, which is in tablet form, and will be instructed to take the medication once daily for 6 weeks. The daily dose will range between 1 and 4 mg.
88828060|NCT02259517|Experimental|Lisdexamfetamine|Participants will be administered lisdexamfetamine, which is in tablet form, and will be instructed to take the medication daily for 6 weeks. The daily dose will range between 30 and 70mg.
88828061|NCT04330209||LowGI/nutrigenetic|"114 overweight (n=1) and obese (n=113) subjects (M = 55, F = 59, age 24-56y, all of Romanian heritage and similar socio-economic status), who were patients at a weight management clinic (Bucharest, Romania), gave written informed consent for their weight loss data to be prospectively analysed for this study.~Upon enrolment at the weight management clinic, the subjects self-selected either a ketogenic diet or a low-GI nutrigenetic diet. 61 subjects (34 female; age 42.0 ± 6.7y) selected the low-GI nutrigenetic diet plan."
88828062|NCT04330209||Ketogenic|As above + Fifty-three subjects (25 female; age 43.0 ± 7.2y) selected the ketogenic diet plan
88828063|NCT01379287|Experimental|Patients with Advanced Solid Tumors|The trial was initially designed as a 3 hour IV infusion of iso-fludelone every 3 weeks with three dose-escalation stages (12 patients), however it has been amended to study iso-fludelone administered over 6 hours (+/- 30 minutes) every 3 weeks schedule.
88828064|NCT03166761|Experimental|Dexamethasone|dexamethasone injected into the sacroiliac joint
88828065|NCT03166761|Active Comparator|Triamcinolone|triamcinolone injected into the sacroiliac joint
88828066|NCT04323176|Experimental|Village Model|Participate as a member of the Village using a website for 12 months.
88828067|NCT05176093|Active Comparator|Engensis|Active Comparator: Engensis 64 mg Engensis per Treatment Cycle, with each of 3 cycles composed of 2 days of 128 injections each to the right and left target muscles, spaced 2 weeks apart
88828068|NCT05176093|Placebo Comparator|Placebo|Placebo Comparator: Placebo 32 mL of Placebo per Treatment Cycle, with each of 3 cycles composed of 2 days of 128 injections each to the right and left target muscles, spaced 2 weeks apart
88828069|NCT05172661|Experimental|Integrated training model|"Participants in this group will accept postural and cognitive training at the same time, e.g. naming animals while standing on the foam.~Each training session will last for 70 minutes, twice a week, and 12 sessions in total."
88828070|NCT05172661|Experimental|Consecutive training model|"Participants in this group will accept postural and cognitive training separately and for identical durations (both 30 minutes).~Each training session will last for 70 minutes, twice a week, and 12 sessions in total."
88828071|NCT05711017|Experimental|Huashibaidu|"During the study, subjects diagnosed as community-acquired pneumonia in children according to Guideline for diagnosis and treatment of community-acquired pneumonia in Children (2019 version) will be assigned to the Huashibaidu group and the placebo group. Then they will receive 5 days treatment, prescribed by investigator according to study design. At the same time, they will finish a series of examinations, including biomarkers associated with infection, screening of pathogen, imaging examination and tNGS."
89534068|NCT00605878||Group 6|Patients diagnosed with the combined immunodeficiency associated with DOCK8 mutation (DOCK8)
89534069|NCT00542373|Experimental|Diagnostic (fluorescent/reflectance imaging, spectroscopy)|Participants' oral cavities are inspected by a clinician using a standard white light headlamp. Participants then undergo oral mucosa examination using wide-field reflectance and fluorescence imaging, and/or fluorescence spectroscopy imaging. Standard oral brush biopsies are also performed and examined microscopically. Participants may undergo repeated imaging procedures and biopsy during subsequent follow up visits.
89534070|NCT00475761||Breast Cohort|Primary clinical- patients referred to diagnostic breast biopsy
88828072|NCT05711017|Placebo Comparator|Placebo|"During the study, subjects diagnosed as community-acquired pneumonia in children according to Guideline for diagnosis and treatment of community-acquired pneumonia in Children (2019 version) will be assigned to the Huashibaidu group and the placebo group. Then they will receive 5 days treatment, prescribed by investigator according to study design. At the same time, they will finish a series of examinations, including biomarkers associated with infection, screening of pathogen, imaging examination and tNGS."
88828073|NCT04220294|Active Comparator|Interrupted sutures|Subcutaneous tissue closure by interrupted sutures.
88828074|NCT04220294|Active Comparator|Continuous sutures|Subcutaneous tissue closure by continuous sutures.
88828075|NCT05710939|Active Comparator|scapular stabilization exercises|scapular stabilization exercises applied to 1st group for 5 days/week for 6 weeks
88828076|NCT05710939|Active Comparator|classic shoulder exercises|classic shoulder exercises applied to 1st group for 5 days/week for 6 weeks
88828077|NCT04213196|Experimental|HSK21542 0.2 μg/kg（15 min)|Healthy volunteers 0.2 μg/kg HSK21542
88828078|NCT04213196|Experimental|HSK21542 0.5 μg/kg|Healthy volunteers 0.5 μg/kg HSK21542 or Placebo
88828079|NCT04213196|Experimental|HSK21542 1 μg/kg （15min)|Healthy volunteers 1 μg/kg HSK21542 or Placebo
88828080|NCT04213196|Experimental|HSK21542 1 μg/kg （2min)|Healthy volunteers 1 μg/kg HSK21542 or Placebo
88828081|NCT04213196|Experimental|HSK21542 0.75 μg/kg|Healthy volunteers 0.75 μg/kg HSK21542 or Placebo
88828082|NCT04213196|Experimental|HSK21542 1.5 μg/kg|Healthy volunteers 1.5 μg/kg HSK21542 or Placebo
88828083|NCT04213196|Experimental|HSK21542 2.25 μg/kg|Healthy volunteers 2.25 μg/kg HSK21542 or Placebo
88828084|NCT04213196|Experimental|HSK21542 3.375 μg/kg|Healthy volunteers 3.375 μg/kg HSK21542 or Placebo
88828085|NCT04213196|Experimental|HSK21542 0.2 μg/kg（2min)|Healthy volunteers 0.2 μg/kg HSK21542 or Placebo
88828086|NCT02980406|Active Comparator|Fructans|Fructans (FODMAP) are oligosaccharides containing fructose chains. Since the human body lacks hydrolases to break down these saccharides, fructans are poorly absorbed molecules in everybody. The fructan solution used in this study has a concentration of 38g/L.
88828087|NCT02980406|Active Comparator|Fructose|Fructose can be found in the diet as free fructose, in sucrose or as polymer structure in fructans. Absorption varies and occurs more rapidly in the presence of glucose than for free fructose because glucose cotransport is involved in the uptake of fructose. Therefore, when fructose is in excess of glucose, it is regarded as a FODMAP. The fructose concentration used in this study is 100g/L.
88828088|NCT02980406|Active Comparator|FODMAP mix|The FODMAP mix consists of 20g fructans, 10g galacto-oligosaccharides (GOS), 30g fructose, 10g sorbitol and 10g mannitol in one liter of tap water.
88828089|NCT02980406|Placebo Comparator|Glucose|Glucose is a carbohydrate that is not classified as FODMAP, and is therefore used as a control in this study. The concentration of the glucose solution in this study is 100g/L.
88828090|NCT02331992|Experimental|Positive airway pressure adherence program|Participants will be enrolled in the automated adherence program and will receive supportive messages while they use CPAP as prescribed by their healthcare provider. These messages are designed to aid the participant towards therapy adherence.
88828091|NCT03086655|Experimental|Tel-me-box with reminder features|Participants randomly assigned to the intervention reminder condition will choose from the reminders available and convey their preferences regarding when reminders should be sent for the tel-me-box device.
88828092|NCT03086655|Other|Tel-me-box with no reminder features|The control arm will include tel-me-box monitoring only. No reminder features will be included with the device.
88828093|NCT04195256|Experimental|IN Ketodex (D4K2)|Dexmedetomidine (Pfizer, Kirkland, Quebec), single-dose, 4 mcg/kg (0.04 mL/kg) of 100 mcg/mL solution, maximum of 200 mcg (2 mL) THEN Ketamine (Sandoz, Mississauga, Ontario), single dose, 2 mg/kg (0.04 mL/kg) of 50 mg/mL solution, maximum of 200 mg (4 mL) (D4K2), both delivered intranasally using a mucosal atomizer device (MAD) and divided to both nares AND 0.9% normal saline 0.03 mL/kg delivered intravenously to a maximum of 2 mL
88828094|NCT04195256|Experimental|IN Ketodex (D3K3)|Dexmedetomidine (Pfizer, Kirkland, Quebec), single-dose, 3 mcg/kg (0.03 mL/kg) of 100 mcg/mL solution, maximum of 200 mcg (2 mL) THEN Ketamine (Sandoz, Mississauga, Ontario), single dose, 3 mg/kg (0.06 mL/kg) of 50 mg/mL solution, maximum of 300 mg (6 mL) (D3K3), both delivered intranasally using a mucosal atomizer device (MAD) and divided to both nares AND 0.9% normal saline 0.03 mL/kg delivered intravenously to a maximum of 2 mL
88828095|NCT04195256|Experimental|IN Ketodex (D2K4)|Dexmedetomidine (Pfizer, Kirkland, Quebec), single-dose, 2 mcg/kg (0.02 mL/kg) of 100 mcg/mL solution, maximum of 200 mcg (2 mL) THEN Ketamine (Sandoz, Mississauga, Ontario), single dose, 4 mg/kg (0.08 mL/kg) of 50 mg/mL solution, maximum of 400 mg (8 mL) (D2K4), both delivered intranasally using a mucosal atomizer device (MAD) and divided to both nares AND 0.9% normal saline 0.03 mL/kg delivered intravenously to a maximum of 2 mL
88828096|NCT04195256|Active Comparator|IV Ketamine|Ketamine, single dose, 1.5 mg/kg (0.03 mL/kg) of 50 mg/mL solution delivered intravenously, to a maximum of 100 mg (2 mL) AND two aliquots of 0.9% normal saline in 3 possible combinations: (i) 0.04 mL/kg (max 2 mL) then 0.04 mL/kg (max 4 mL) (placebo D4K2), (ii) 0.03 mL/kg (max 2 mL) then 0.06 mL/kg (max 6 mL) (placebo D3K3), (iii) 0.02 mL/kg (max 2 mL) then 0.08 mL/kg (max 8 mL) (placebo D2K4), delivered intranasally using a MAD and divided to both nares
88828097|NCT01710787|Experimental|Kovacaine Mist, 3 sprays unilateral|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%
88828098|NCT01710787|Experimental|Tetracaine Only, 3 sprays unilateral|Tetracaine HCl 3%
88828099|NCT01710787|Placebo Comparator|Placebo, 3 sprays unilateral|Placebo
88828100|NCT05102864|Active Comparator|Active intermittent Theta Burst Stimulation|Participants will complete 10 daily sessions of active iTBS to the left dorsolateral prefrontal cortex
88828101|NCT05102864|Sham Comparator|Sham intermittent Theta Burst Stimulation|Participants will complete 10 daily sessions of sham iTBS to the left dorsolateral prefrontal cortex
88828102|NCT01711177|Sham Comparator|Normal control|Normal patient placebo
88828103|NCT01711177|Sham Comparator|Glaucoma suspect|Patients with elevated Intraocular pressure higher than 18 mmHg (placebo)
88828104|NCT01711177|Experimental|Newly diagnosed glaucoma|Treated with Travoprost (0.04%)
88828105|NCT01714921||ICD patients|Patients with an indication for an ICD implantation according to the guidelines treated with a Protecta™, Protecta™ XT or any equivalent following product
88828106|NCT02277990|Active Comparator|TYRX™ envelope|The Medtronic TYRX™ Absorbable Antibacterial Envelope is an absorbable sterile prosthesis designed to hold a pacemaker pulse generator or defibrillator to create a stable environment when implanted in the body. The purpose of the absorbable coating is to act as a carrier for the antimicrobial agents.
88828107|NCT02277990|No Intervention|Control|No TYRX™ envelope, bare CIED
88828108|NCT01715233|Experimental|Metastatic Esophageal, Gastroesophageal & Gastric Cancer|Participants receive Modified Docetaxel 40mg/m2, Leucovorin 400mg/m2 and Fluorouracil 400mg/m2 on day 1, Fluorouracil 1000mg/m2 per day on days 1 and 2 and Cisplatin 40mg/m2 (or Carboplatin) on day 3 in Patients With Metastatic Esophageal, Gastroesophageal And Gastric Cancer.
88828109|NCT04868630||Outpatients; Atlantic Sleep Centre & SJRH Respiratory Clinic|The study population consists of approximately 80 adult, outpatient participants recruited from the Atlantic Sleep Centre and the Respiratory Clinic at the Horizon Health Network, Saint John Regional Hospital.
88828110|NCT01716013|Experimental|BondEase|Topical Skin Adhesive
88828111|NCT01716013|Active Comparator|CWCD|Conventional Wound Closure Devices (CWCD) including: sutures, staples, or adhesive strips
88828112|NCT03028922|Other|creos xenogain|Patients in need of bone augmentation prior to implant insertion will undergo GBR procedure using Creos xenogain bone graft substitute
88828113|NCT04865744|Active Comparator|Oral semaglutide 7 mg|The semaglutide 7 mg tablet taken orally with upto120 ml of water.
88828114|NCT04865744|Placebo Comparator|Placebo|The placebo tablet taken orally with 120 ml of water.
88828115|NCT04865744|Active Comparator|Oral semaglutide 14 mg|The semaglutide 14 mg tablet taken with upto 120 ml of water.
89534071|NCT00453505|Experimental|1|Healthy Volunteers
89534072|NCT00453505|Sham Comparator|1a|Healthy Volunteers
88828116|NCT02317614|Experimental|SteadyRx|This group will be assessed at monthly intervals. They will receive their usual care at their regular providers. In addition, they will be given Smartphones loaded with the SteadyRx intervention.
88828117|NCT02317614|No Intervention|Usual Care|This group will be assessed at monthly intervals. They will receive their usual care at their regular providers. They will not receive a Smartphone or the SteadyRx adherence intervention.
88828118|NCT05071508||Preterm Infants|Premature infants (born between 25 and 34 + 6 weeks gestational age) admitted to the University of Minnesota Masonic Children's Hospital NICU
88828119|NCT05056909|Active Comparator|Standard of care|CKD care, as routinely provided in the respective nephrology outpatient clinic.
88828120|NCT05056909|Experimental|Intervention|standard of care + Kidney ACTion AI-supported software for chronic kidney disease care.
88828121|NCT04826588|Active Comparator|Methylprednisolone sodium succinate 10 mg/kg|Methylprednisolone sodium succinate 10 mg/kg intravenously once daily for 3 days (max 1 g per dose)
88828122|NCT04826588|Active Comparator|Human normal immunoglobulin (IVIg)|Human normal immunoglobulin (IVIg) 2g/kg intravenously as a single dose in line with guidance for dosing and administration in Kawasaki disease
88828123|NCT01719367|Experimental|Atenolol|Patients will undergo a standardized, graded exercise protocol before and after receiving a dose of oral atenolol.
88828124|NCT02276040||Exparel|Participants will receive Exparel (periarticular bupivicaine and liposomal bupivicaine).
88828125|NCT05064956|Experimental|Ad26.ZEBOV|Ad26.ZEBOV will be given as a booster dose to all participants approximately 4 years after administration of the 2-dose Ebola regimen, Ad26.ZEBOV/MVA-BN-Filo, as part of the parent trial VAC52150EBL2002.
88828126|NCT04824872|Experimental|Sequence 1|Dasiglucagon high dose, followed by placebo, followed by dasiglucagon low dose
88828127|NCT04824872|Experimental|Sequence 2|Dasiglucagn low dose, followed by dasiglucagon high dose, followed by placebo
88828128|NCT04824872|Experimental|Sequence 3|Placebo, followed by dasiglucagon low dose, followed by dasiglucagon high dose
88828129|NCT04824872|Experimental|Sequence 4|Dasiglucagon high dose, followed by dasiglucagon low dose, followed by placebo
88828130|NCT04824872|Experimental|Sequence 5|Placebo, followed by dasiglucagon high dose, followed by dasiglucagn low dose
89177577|NCT00829010|Experimental|HIV+/- Group|Infants born from a HIV positive mother and confirmed as HIV exposed uninfected. Subjects received 3 primary doses (at 6, 10 & 14 weeks of age, at study Months 0, 1 and 2) and 1 booster dose of Synflorix™ vaccine (at 9 months of age, at study Month 8). Subjects in the group also received 3 primary vaccine doses (at 6, 10 & 14 weeks of age, at study Months 0, 1 and 2) and 1 booster vaccine dose (at 15-18 months of age, at study Month 14) of Tritanrix™-HepB/Hib, 2 vaccine doses of Rotarix™ (at 10 & 14 weeks of age, at study Months 1 and 2), and 2 doses of measles vaccine (9-10 months of age & 15-18 months of age, at study Months 8 and 14). Measles vaccine was not considered as a study vaccine. The Synflorix™ vaccine was administered IM in the right thigh, the Tritanrix™-HepB/Hib vaccine was administered IM in the left anterolateral thigh during the primary vaccination and in the left anterolateral thigh or left deltoid region during booster vaccination. Rotarix™ was given orally.
89177578|NCT00829010|Experimental|HIV- (3+1) Group|Infants born from a HIV negative mother and confirmed as HIV unexposed uninfected. Subjects received 3 primary doses (at 6, 10 & 14 weeks of age, at study Months 0, 1 and 2) and 1 booster dose of Synflorix™ vaccine (at 9 months of age, at study Month 8). Subjects in the group also received 3 primary vaccine doses (at 6, 10 & 14 weeks of age, at study Months 0, 1 and 2) and 1 booster vaccine dose (at 15-18 months of age, at study Month 14) of Tritanrix™-HepB/Hib, 2 vaccine doses of Rotarix™ (at 10 & 14 weeks of age, at study Months 1 and 2), and 2 doses of measles vaccine (9-10 months of age & 15-18 months of age, at study Months 8 and 14). Measles vaccine was not considered as a study vaccine. The Synflorix™ vaccine was administered IM in the right thigh, the Tritanrix™-HepB/Hib vaccine was administered IM in the left anterolateral thigh during the primary vaccination and in the left anterolateral thigh or left deltoid region during booster vaccination. Rotarix™ was given orally.
89534073|NCT00453505|Experimental|2|Healthy Volunteers
89534074|NCT00453505|Sham Comparator|2a|Healthy Volunteers
89534075|NCT00453505|Experimental|3|Healthy Volunteers
89534076|NCT00453505|Sham Comparator|3a|Healthy Volunteers
88828131|NCT04824872|Experimental|Sequence 6|Dasiglucagon low dose, followed by placebo, followed by dasiglucagon high dose
88828132|NCT02315664|Experimental|Immediate Intervention Group|Education session, Fitbit Flex, and remote coaching by a PT: These three components of the intervention will be delivered to the participants in Month 1 and 2. At the end of the education session, the PT will help participants set personal activity goals. In Month 1 and 2, participants will use the Fitbit Flex. The PT will review the progress with participants via 20-minute bi-weekly phone calls and progressively modify their activities. In Month 3-6, participants will keep the Fitbit and continue to use it with access to a PT via email as needed. In addition, they will receive a monthly e-newsletter about arthritis research that is not related to physical activity.
88828133|NCT02315664|Experimental|Delayed Intervention Group|Same intervention with a 2 month delay: The Delayed Intervention Group (control group) will receive the same monthly e-newsletter in Months 1-2. The full intervention will be initiated in Month 3 with a brief education session, use of Fitbit Flex, and counseling by a physiotherapist. In Month 4, they will continue the intervention without the PT phone calls. Participants will keep the Fitbit for Month 5-6, and have email access to PT as needed.
88828134|NCT02250703|Active Comparator|Midazolam|In M group, patients will be given oral midazolam 0.5mg/kg upto maximum dose of 15mg (5mg/ml parenteral preparation) mixed with flavored syrup as premedication
88828135|NCT02250703|Experimental|Dexmedetomidine|In D group, patients will be given intranasal dexmedetomidine 2mcg/kg upto maximum dose of 100mcg prepared from 100mcg/ml parenteral preparation (Hospira R) . The drug will be administered using a intranasal mucosal administration device (LMA MAD NasalTM).
88828136|NCT02298842|Active Comparator|Platelets Stored in Plasma|Platelets stored in Plasma
88828137|NCT02298842|Experimental|Test Platelets Stored in InterSol|Platelets stored in InterSol
88828138|NCT02314728|Active Comparator|Misoprostol|Those randomized to the prostaglandin arm will receive PGE1 (misoprostol) in a dose of 25mcg placed vaginally every 4 hours as per hospital protocol.
88828139|NCT02314728|Active Comparator|Oxytocin Alone|Those randomized to the oxytocin arm will receive infusion of oxytocin, which will then be titrated per hospital protocol or until adequate contractions.
88828140|NCT03135860|Experimental|Inhaled Nitric Oxide 30mcg/kg/IBW/hr|Inhaled nitric oxide 30 mcg/kg IBW/hr NO will be administered through the InoPulse Device open label for 4 weeks
88828141|NCT04083794|Other|Laboratory based assessments|The current study has no arms; it is a cross-sectional assessment where all participants will undergo the same procedures.
88828142|NCT02326363|Experimental|Mindfulness Based Relapse Prevention (MBRP):|The Introductory session provides an orientation to the intervention, basic mindfulness techniques and general description of group sessions. Each session has a central theme/topic and consists of in-session experiential practice, discussions and homework assignments. Sessions begin with a check-in followed by a 20-30 minute meditation (i.e. body scan). The therapist reviews homework assignments, discusses challenges and participants are taught a variety of mindfulness meditation (MM) practices such as breath meditation, urge surfing, walking or movement meditation.
88828143|NCT02326363|Active Comparator|Twelve-Step Facilitation Intervention (TSF)|"The Introductory session covers the 12-Step view of addiction and therapy overview. The manual, originally developed for individual sessions, has been adapted for group delivery. The eight selected sessions include four topics chosen by the manual developers as core topics and four elective topics. The intervention involves helping participants understand and incorporate core principles of 12-Step approaches while encouraging active participation in 12-Step meetings and related activities. The primary goal is to promote abstinence by facilitating the patient's acceptance and surrender of addiction. Sessions begin with a check-in during which participants introduce themselves, report on meeting attendance and participation in related activities, any alcohol/drug use or craving to use. The remainder of the session focuses on discussion of the topic content followed by a take home summary and homework assignment."
88828144|NCT02275338|Experimental|Lanreotide Autogel|120mg administered via deep subcutaneous injection at Day 0 and Day 28.
88828145|NCT04781348|Experimental|Platelet Rich Plasma and fat grafting|Group will receive Platelet Rich Plasma plus fat grafting
88828146|NCT04781348|Experimental|Fat grafting|Group will receive only fat grafting
88828147|NCT02313558|Experimental|Dentifrice Containing Ilex Rotunda Thunb|use the dentifrice containing Ilex Rotunda Thunb to brush teeth twice daily for 12 weeks
88828148|NCT02313558|Placebo Comparator|control dentifrice|use the control dentifrice to brush teeth twice daily for 12 weeks
88828149|NCT01721473||cigarette smokers with heavy marijuana use|With heavy marijuana use
88828150|NCT01721473||cigarette smokers with heavy caffeine use|with heavy caffeine use
88828151|NCT01721473||cigarette smokers w/o heavy caffeine and marijuana use|cigarette smokers without the heavy use of marijuana or caffeine
88828152|NCT01721473||non-smokers|not a regular cigarette user
88828153|NCT01721473||cigarette smokers with non-menthol cigarette preference|non-menthol cigarette preference
88828154|NCT01721473||cigarette smokers with menthol cigarette preference|menthol cigarette preference
88828155|NCT01646268|Experimental|Rotigotine|Rotigotine, daily doses, treatment group
88828156|NCT01646268|Placebo Comparator|Placebo|Placebo, daily doses, placebo group
88828157|NCT02275026|Experimental|Functional magnetic resonance imaging|Magnetic resonance images will be acquired on a 3 Tesla scanner (Skyra, Siemens, Erlangen, Germany) with a 20 channel receiver coil.
88828158|NCT04021082|Experimental|Cohort A|Cerdulatinib dosing of patients with Peripherial T-Cell Lymphoma (PTCL) not otherwise specified (NOS); Cerdulatinib 30 mg orally (PO) twice daily (BID) (60 mg daily total)
88828159|NCT04021082|Experimental|Cohort B|Cerdulatinb dosing of patients with nodal lymphomas of T follicular helper (TFH) phenotype origin, including angioimmunoblastic T cell lymphoma (AITL), follicular T-cell lymphoma (FTCL), and nodal PTCL with TFH phenotype; Cerdulatinib 30 mg orally (PO) twice daily (BID) (60 mg daily total)
88828160|NCT04021082|Experimental|Cohort C|Cerdulatinb dosing of patients with Anaplastic large cell lymphoma (ALCL) (anaplastic lymphoma kinase positive [ALK+] and negative [ALK-]); Cerdulatinib 30 mg orally (PO) twice daily (BID) (60 mg daily total)
88828161|NCT04021082|Experimental|Cohort D|Other rare types of extranodal non-cutaneous aggressive PTCL, including hepatosplenic T-cell lymphoma (HSTCL), enteropathy-associated T-cell lymphoma (EATL type I), monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL, EATL type II), and extranodal NK/T-cell lymphoma (nasal type); Cerdulatinib 30 mg orally (PO) twice daily (BID) (60 mg daily total)
88828162|NCT03988634|Experimental|sacubitril/valsartan|"randomized in a 1:1 ratio: sacubitril/valsartan to valsartan for up to approximately 20 months of double-blind treatment.~Initial dose at randomization will be determined based on the patient's previous dose of or lack of ACEi/ARB immediately prior to current WHF event (HFpEF decompensation), or at the time of post-decompensation randomization.~Study treatment will be titrated to the target dose of sacubitril/valsartan (LCZ696) 97/103 mg twice daily (Dose Level 3).~Patients will be required to take a total of two tablets twice daily (one tablet of active sacubitril/valsartan and one tablet of valsartan matching placebo pack)."
88828163|NCT03988634|Active Comparator|valsartan|"randomized in a 1:1 ratio: sacubitril/valsartan to valsartan for up to approximately 20 months of double-blind treatment.~Initial dose at randomization will be determined based on the patient's previous dose of or lack of ACEi/ARB immediately prior to current WHF event (HFpEF decompensation), or at the time of post-decompensation randomization.~Study treatment will be titrated to the target dose of valsartan 160 mg twice daily (Dose Level 3).~Patients will be required to take a total of two tablets twice daily (one tablet of active valsartan and one tablet of sacubitril/valsartan (LCZ696) matching placebo pack)."
88828164|NCT02294630|Active Comparator|Dose Schedule I|Surfactant dose to be administered as aerosol - 100 mg phospholipid/kg. Surfactant Dilution 1:1
88828165|NCT02294630|Active Comparator|Dose Schedule II|Surfactant dose to be administered as aerosol - 100 mg phospholipid/kg. Surfactant Dilution 1:2
88828166|NCT02294630|Active Comparator|Dose Schedule III|Surfactant dose to be administered as aerosol - 200 mg phospholipid/kg. Surfactant Dilution 1:1
88828167|NCT02294630|Active Comparator|Dose Schedule IV|Surfactant dose to be administered as aerosol - 200 mg phospholipid/kg. Surfactant Dilution 1:2
88828168|NCT03906110||C-Cares|Participants will be given Community Colorectal Cancer Awareness, Research, Education and Screening (C-CARES) Materials and FIT kits.
89188836|NCT00620776|Experimental|Combined Treatment|Patients who receive combined cognitive behavioral therapy (CBT) plus medication (venlafaxine XR, flexibly dosed between 75-225 mg/day) treatment for GAD. CBT was once/week sessions for 12 weeks. Medication continued for the full 6 months.
88828169|NCT03906110||C-Cares Plus|Participants will be given Community Colorectal Cancer Awareness, Research, Education and Screening (C-CARES) materials, FIT kits, and personalized one-on-one education and coaching.
89357031|NCT05492227||Fresh left-over specimens of SARS-CoV-2 positive subject swabs|All fresh swab specimens that were sent to the biobank Hospital Puerta del Hierro between March 2020 and December 2021 under the standard requirements for SARS-CoV-2 specimens (ISO 201916) were kept frozen (-80ºC) after analysis by RT-PCR (left-over samples).
89357032|NCT05492227||Fresh left-over specimens of SARS-CoV-2 negative subject swabs|All fresh swab specimens that were sent to the biobank Hospital Puerta del Hierro between March 2020 and December 2021 under the standard requirements for SARS-CoV-2 specimens (ISO 201916) were kept frozen (-80ºC) after analysis by RT-PCR (left-over samples).
89357033|NCT05489796|Experimental|Dual group|The two drugs are administered separately.
89357034|NCT05489796|Active Comparator|Single group|One drug is administered alone.
89357035|NCT05487651|Experimental|Cohort A, non-ALL relapsed/refractory|"These dose levels will be evaluated. Patients will also receive lymphodepletion chemotherapy consisting of cyclophosphamide and fludarabine followed by CD19.CAR-aNKT cell infusion.~Genetic: CD19.CAR-aNKT cells Patients will be given the T-cell product by intravenous injection (into the vein through an IV line) at the assigned dose.~Dose level 1: 1×107/m2. Dose level 2: 3×107/m2. Dose level 3: 1×108/m2).~Drug: Cyclophosphamide:~Lymphodepletion chemotherapy. Patients will receive 3 daily doses of cyclophosphamide (500mg/m2/day finishing at least 24 hours before T-cell infusion. The drug will be given intravenously (through an IV needle) Other name: Cytoxan~Drug Fludarabine Lymphodepletion chemotherapy. Patient will receive 3 daily dose of fludarabine (30mg/m2/day) finishing at least 24 hours before T-cell infusion. the drug will be given intravenously (through an IV needle) Other name: Fludara"
89357036|NCT05487651|Experimental|Cohort B, ALL releapsed/refractory|"This cohort is for patients with relapsed or refractory B-cell ALL afer 2 or more lines of therapy. Patients will also receive lymphodepletion chemotherapy consisting of cyclophosphamide and fludarabine followed by the CD19.CAR-aNKT cell infusion.~Genetic: CD19.CAR-aNKT cells Patients will be given the T-cell product by intravenous injection (into the vein through an IV line) at the assigned dose.~Dose level 1: 1×107/m2. Dose level 2: 3×107/m2. Dose level 3: 1×108/m2).~Drug: Cyclophosphamide:~Lymphodepletion chemotherapy. Patients will receive 3 daily doses of cyclophosphamide (500mg/m2/day finishing at least 24 hours before T-cell infusion. The drug will be given intravenously (through an IV needle) Other name: Cytoxan~Drug Fludarabine Lymphodepletion chemotherapy. Patient will receive 3 daily dose of fludarabine (30mg/m2/day) finishing at least 24 hours before T-cell infusion. the drug will be given intravenously (through an IV needle)"
89357037|NCT05480670|Experimental|Berberine arm|Participants in this group will receive an oral 550 mg Berberine supplement tablet BDS for 3-months as an add-on to the changes in the diet/life-style for 3-months. The changes in the diet/life-style include limiting fat and carbohydrate intake and improve dietary behavior without the application of a calorie-restricted diet program. Exercise will also be recommended to include 30 min/day of moderate to intense activity.
89357038|NCT05480670|No Intervention|Control arm|Participants in this group will undergo changes in their diet/life-style.
88828170|NCT02811614|Experimental|Experimental 1: Endoscopic Evacuation|Endoscopic hematoma evacuation with the help of a self-developed working channel.
88828171|NCT02811614|Experimental|Experimental 2: Stereotactic Aspiration|Place a catheter into the main body of the hematoma and aspirate blood.
88828172|NCT02811614|Active Comparator|Active Comparator: Craniotomy|Craniotomy with a big bone flap to for hematoma evacuation.
88828173|NCT01722487|Experimental|Ibrutinib|Ibrutinib will be supplied as hard gelatin 140-mg capsules for oral (PO) administration. Ibrutinib 420 mg (3 x 140-mg capsules) is administered orally once daily. The first dose will be delivered in the clinic on Day 1, after which subsequent dosing is typically on an outpatient basis. Ibrutinib will be dispensed to patients in bottles at each visit.
89357039|NCT05448664|Experimental|Families HBM- mobile messaging|Family- and HBM-based behavioral intervention using mobile messaging
88828174|NCT01722487|Active Comparator|Chlorambucil|Chlorambucil will be supplied as 2-mg tablets for PO administration. Chlorambucil is administered orally on Days 1 and 15 of each 28-day cycle.The starting dosage (Cycle 1) is 0.5 mg/kg. If well tolerated, the Chlorambucil dose can be increased starting at Cycle 2, with increments of 0.1 mg/kg on Day 1 of each cycle to a maximum of 0.8 mg/kg.
88828175|NCT02730962|Experimental|Antibiotics prior to FMT|One week prior to FMT, a course of three oral antibiotics are taken: Vancomycin 500mg, Neomycin 1000mg, and Clindamycin 300mg.
88828176|NCT02730962|Placebo Comparator|Placebo prior to FMT|One week prior to FMT, a course of three sugar pills identical to each antibiotic.
88828177|NCT05006989|Experimental|Intervention Group|Participants will be provided pre-made whole blueberry freeze-dried powder to be consumed.
88828178|NCT05006989|Placebo Comparator|Placebo Group|Participants will be provided placebo powder to be consumed.
88828179|NCT02249845||dehydration scales|children aged 1 - 36 months for CDS scale; 1 month - 5 years old for WHO scale and Gorelick scale
88828180|NCT04983823|Experimental|Heart failure intervention (Cardiac COVID Disease Management Plan (CC-DMP)|"Optimization of pharmacotherapy:~This will be performed by a supervising clinician and will comprise treatment with angiotensin-converting enzyme inhibitor (ACEi, Ramipril) and beta blocker (Metoprolol) for cardioprotection.~Exercise intervention: Individualized training program will be provided by an exercise physiologist"
89357040|NCT05448664|Active Comparator|Adolescents HBM- mobile messaging|Student- and HBM-based behavioral intervention using mobile messaging
89534077|NCT00453505|Experimental|4|Healthy Volunteers
89534078|NCT00453505|Sham Comparator|4a|Healthy Volunteers
88828181|NCT04983823|Active Comparator|Usual care|All medical management for participants allocated to this group will be at the discretion of their usual care healthcare professional(s).
88828182|NCT01722643|Experimental|MAxIM|This new intervention, called MAxIM (MotivAtion, Incentives, Memory) uses: 1) motivation enhancement therapy (MET) (an existing evidence-based treatment for adolescent with diabetes) supplemented with cognitive behavior therapy (CBT) to enhance behavior change; 2) financial incentives for daily blood glucose testing and parental monitoring to provide frequent positive feedback; and 3) working memory training (WMT), a method for strengthening specific cognitive processes that support decision-making and future orientation. The interventions will be delivered to families at home via the internet.
89000626|NCT00554710|Active Comparator|2|Induction with methylprednisolone (MP) or budesonide (BUD): MP 32 mg/day for 3 weeks was followed by tapering by 4 mg per week to 0; BUD 9 mg per day for 8 weeks with tapering to 0 by 3 mg per week thereafter.Patients who worsened during the tapering had the dose increased to the initial dose and tapered again. If patients worsened, azathioprine (2-2.5 mg per day) was introduced. Patients who relapsed following withdrawal of steroids received a second course in combination with azathioprine. For patients who failed 4 weeks of steroids, MP dose was given at 64 mg/day for 2 weeks, tapered by 8 mg per week; azathioprine was added. Patients who remained symptomatic despite 16 weeks of azathioprine received infliximab (5 mg/kg IV at weeks 0, 2 and 6). Patients who relapsed despite methotrexate or those intolerant to both azathioprine and methotrexate also received infliximab, without antimetabolite therapy. Infliximab was repeated upon relapse of symptoms in these patients.
89000627|NCT04659265|Active Comparator|No suspected diagnosis (control group)|Participants receive the information that the pre-treating physician thought that the patient is suffering from a medical emergency (no diagnosis).
89000628|NCT04659265|Active Comparator|Correct suspected diagnosis|Participants receive the information that the pre-treating physician thought that the patient is suffering from an acute myocardial infarction (correct diagnosis).
89000629|NCT04659265|Active Comparator|Wrong suspected diagnosis|Participants receive the information that the pre-treating physician thought that the patient is suffering from a pulmonary embolism (wrong diagnosis).
89000630|NCT04659187||All hospitalized COVID-19 patients|All consecutive hospitalized patients, tested positive for SARS-CoV-2 at 45 Asklepios hospitals in Germany
89000631|NCT04659187||Subgroup: Detailed cohort of 7 hospitals|Cohort of 7 hospitals with detailed data set
89000632|NCT04659187||Subgroup with cardiovascular events|Definition: Patients hospitalized to COVID-19, who developed a cardiovascular event, defined as (1) cardiopulmonary resuscitation in cardiac arrest, (2) cardiogenic shock, (3) acute coronary artery syndrome, including ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation myocardial infarction (NSTEMI), (4) acute myocarditis, (5) denovo cardiac arrhythmia, (6) arterial or venous thrombosis, (7) pulmonary artery embolism, (8) worsening of prior or new onset heart failure, (9) ischemic stroke
89000633|NCT04659187||Subgroup with oncological patients|Definition: Patients hospitalized to COVID-19 with prior or preexisting oncological disease
89000634|NCT04659187||Subgroup with critical ill COVID-19 patients|Definition: Patients hospitalized to COVID-19 with intensive care treatment
89000635|NCT04659109|Experimental|glenzocimab 1000 mg|
89000636|NCT04659109|Placebo Comparator|Placebo|
89000637|NCT04659070|Experimental|Experimental : Ezetimibe / Rosuvastatin + Telmisartan|Ezetimibe 10mg / Rosuvastatin 20mg + Telmisartan 80mg PO, Once daily for 8 weeks
89000638|NCT04659070|Active Comparator|Active comparator1 : Ezetimibe / Rosuvastatin|Ezetimibe 10mg / Rosuvastatin 20mg PO, Once daily for 8 weeks
89000639|NCT04659070|Active Comparator|Active comparator2 : Telmisartan|Telmisartan 80mg PO, Once daily for 8 weeks
89000640|NCT04658875|Experimental|Spirulina maxima supplementation and exercise group|Supplementation with Spirulina maxima (4.5 g/d) with a systematic physical exercise program during 12 weeks, then a 2 weeks washout, to finally proceed to the other treatment during 12 more weeks. During the 26 weeks of study duration every participant will have a personal isoenergetic diet.
89534079|NCT00410241||A1|Self-referred individuals 45-65 at enrollment, 25% of whom had coronary artery disease
89534080|NCT00410241||A2|Individuals 45-65 at enrollment who self-identified as African, African-American, or Afro-Caribbean
89000641|NCT04658875|Experimental|Spirulina maxima supplementation|Supplementation with Spirulina maxima (4.5 g/d) without exercise program during 12 weeks, then a 2 weeks washout, to finally proceed to the other treatment during 12 more weeks. During the 26 weeks of study duration every participant will have a personal isoenergetic diet.
89000642|NCT04658875|Experimental|Exercise group|Systematic physical exercise program during 12 weeks, then a 2 weeks washout, to finally proceed to the other treatment during 12 more weeks. During the 26 weeks of study duration every participant will have a personal isoenergetic diet.
89000643|NCT04658875|Active Comparator|Control group|No systematic physical exercise program and No supplementation during 12 weeks, then a 2 weeks washout, to finally proceed to the other treatment during 12 more weeks. During the 26 weeks of study duration every participant will have a personal isoenergetic diet.
89000644|NCT00205101||1|Triad allograft
89188837|NCT00620776|Active Comparator|Venlafaxine XR 75-225 mg alone|These patients receive only medication treatment for GAD. Patients take venlafaxine (flexibly dosed from 75-225 mg/day) as part of NCT00183274 and are assessed over a 6 month period. Medication continued for the full 6 months.
89000645|NCT00205101||2|other anterior lumbar interbody fusion (ALIF)
89000646|NCT00205101||3|transforaminal lumbar interbody fusion (TLIF)
89000647|NCT00205101||4|posterior lumbar interbody fusion (PLIF)
89000648|NCT04658524||Chonic kidney disease stages 3, 4 and 5|Patients with stage chronic kidney disease stages 3, 4 and 5. CKD stages were defined according to the Kidney Disease Improving Global Outcomes directives (KDIGO): a) stage 3A: eGFR 45 and 59 ml/min/1.73m2; b) stage 3B: eGFR between 30 and 44 ml/min/1.73m2; c) stage 4: eGFR between 15 and 29 ml/min/1.73 m2
89000649|NCT04658407||all patients diagnosed with a severe hepatic failure|Retrospective cohort using only data already entered in the Health data warehouse of the APHP (Public Paris Hospital)
89000650|NCT00200226|Placebo Comparator|1|Vitamin B6
89000651|NCT00200226|Active Comparator|2|misoprostol
89000652|NCT00408083|Experimental|1|MultiHance MRI contrast agent
89000653|NCT00408083|Active Comparator|2|Magnevist contrast agent for MRA
89000654|NCT04658485|Active Comparator|Active tDCS|
89000655|NCT04658485|Placebo Comparator|Sham tDCS|
89188838|NCT03912506||Patient admitted in the ICU for leptospirosis|Patient admitted in the ICU for leptospirosis None intervention was performed according to retrospective design
89188839|NCT00656019|No Intervention|Normal Vitamin D Levels|No additional Vitamin D administered
89188840|NCT00656019|Experimental|Low-normal Vitamin D Levels|2000 IU dose of Vitamin D per day administered orally
89188841|NCT00656019|Experimental|Low Vitamin D Levels|4000 IU dose of Vitamin D per day administered orally
89188842|NCT00656019|Experimental|Very-low Vitamin D Levels|6000 IU dose of Vitamin D per day administered orally
89357041|NCT05448664|Placebo Comparator|Adolescents e-pamphlets|Prevailing oral health education by e-version of pamphlets through mobile messaging
89357042|NCT05438238|Experimental|investigational group A|during TVOR +PCB addition of Oncomfort, commercially available Virtual Reality headset, consisting of headphones with smartphone glasses - see oncomfort.com/en, CE approval conform IEC62366-1:2015, EN 62304:2006/Amd1:2015, EN 82304-1:2015, EN 82304-1:2016, ISO 13485:2016, EN ISO 14971:2019, EN 60601-1-2:2015
89357043|NCT05438238|No Intervention|reference group|standard of care TVOR + PCB
89357044|NCT05435950|Experimental|Adult participants with Carpal Tunnel syndrome or with Trigger Finger/Thumb|
89357045|NCT05422131||Patients Prescribed Clozapine|
89357046|NCT05415501|Experimental|Structural priming training|Participants will be enrolled in 3 sessions of structural priming training (for experiment 1-3) or up to 15 treatment sessions (for experiment 4). Each session will be about 2 hour long, consisting of a set of tasks, including repeating, making, and remembering various types of sentences. In experiment 1-3, each participant will receive two different experimental priming conditions that are being compared within each session. In experiment 4, participants will receive a structural priming treatment in a single-subject design.
88828183|NCT01722643|Active Comparator|Usual Care|Usual Care reflects the standard treatment currently provided at the Children's Hospital at Dartmouth. Teens will be followed by their treating endocrinologist and receive the following standard services as part of that treatment-quarterly outpatient clinic visits, including an interval medical history and physical examination; routine laboratory assessment; review of glycemic control, medication adjustment, medical nutrition therapy, and diabetes self-management education; telephone consultations with a nurse/certified diabetes educator in their treating clinic are available as often as necessary between clinic visits.
89357047|NCT05414357|Experimental|Patients with chemotherapy|
89357048|NCT05414357|Active Comparator|Patients without chemotherapy|
89357049|NCT05414357|Active Comparator|cancer-free volunteers|
89357050|NCT05409638|Experimental|CBT intervention for cancer-related fatigue|Participants will receive 4 weekly sessions consisting of psycho-education around fatigue, pacing, journaling fatigue, relaxation training, CBT, and evidence-based tips to increase physical activity.
89534081|NCT00410241||A3|Adults aged 18-65 at the time of enrollment, including subjects of both sexes, who have been identified as likely to return for follow up
89534082|NCT00410241||B|Family members of Group A1, A2, or A3
89357051|NCT05409638|No Intervention|Wait-list control group|Participants assigned to this arm wait about 3-months to receive the intervention.
88828184|NCT05710393||Affected|(Affected) persons with a medical history of symptoms related to Hidradenitis Suppurativa.
88828185|NCT05710393||Unaffected-control|(Unaffected) family of participants, having no history of symptoms related to Hidradenitis Suppurativa.
88828186|NCT02296346|Active Comparator|Corticosteroid arm|Patients will receive 1 gram of IV SoluMedrol over 1 hour, once every month for 12 months.
88828187|NCT02296346|Experimental|Extracorporeal Photopheresis|"Patient will receive an Extracorporeal Photopheresis treatment at a set frequency over the course of 1 year. The treatment takes about 2-3 hours per session to complete. The treatment schedule is as follows:~ECP will be administered according to the following schedule:~Study Arm: Weeks 1-8: 3 times per week Weeks 9-16: Twice per week Weeks 17-36: Treatment on two consecutive days every 2 weeks (or optionally, one treatment per week) Weeks 37-43: Once every 2 weeks Weeks 44-52: Once every 4 Weeks"
88828188|NCT01726621|Other|Insulin dependent diabetics|Subjects currently using an insulin pump transferred to use the Medtronic MiniMed 620G and 640G insulin pumps and Guardian Link transmitter
88828189|NCT02507804|Experimental|Arm A diary arm|Patients in Arm A are required to complete a patient diary. This will be reviewed by an Investigator at every visit in order to gain Adverse Event and Concomitant Medication information.
88828190|NCT02507804|Active Comparator|Arm B standard of care|Patients will be asked to recall Adverse Events and Concomitant Medication information as standard of care practice would dictate.
88828191|NCT04687046||Cohort 1 JUVÉDERM VOLUX® with 3D Imaging|Treatment will be determined according to the physician's experience and Directions for Use. Cohort 1 will have follow-up on-site visits, including 3D imaging, at Months 1, 3, 6, and 12.
88828192|NCT04687046||Cohort 2 JUVÉDERM VOLUX®|Treatment will be determined according to the physician's experience and Directions for Use. Cohort 2 will have follow-up on-site visits at Months 1 and 3 and follow-up telephone calls at Months 6 and 12.
89534083|NCT00404560||healthy blood relatives|relatives not ill with a known or suspected infection susceptibility syndrome
88828193|NCT02296502||Autism Spectrum Disorder (DSM IV & 5)|All children and adolescents seen for autism diagnostic evaluations at the study sites who meet diagnostic criteria for ASD in both DSM-IV and DSM-5
89357052|NCT05369741|Experimental|TIME™ at Home|TIME™ at Home is a licensed, pre-recorded video-based, group, community exercise program. One program will have a maximum of 10 participants registered. March of Dimes Canada will run two programs. A 1.5-hour session will be hosted by two facilitators using Zoom twice a week for 8 weeks, starting with the Level 1 video (beginner level). All participants will switch to the Level 2 video (advanced level) mid-program.
89534084|NCT00404560||Patients|patients who either have, or are suspected of having, an infection or infection susceptibility in order to further characterize such conditions
88828194|NCT02296502||Autism Spectrum Disorder (DSM 5 only)|All children and adolescents seen for autism diagnostic evaluations at the study sites who meet diagnostic criteria for ASD in DSM-5 but not DSM-IV
88828195|NCT02296502||Autism Spectrum Disorder (DSM IV only)|All children and adolescents seen for autism diagnostic evaluations at the study sites who meet diagnostic criteria for ASD in DSM-IV but not DSM-5
89534085|NCT00378742||Participants|Participants with inherited eye diseases or relative of affected participant
89534086|NCT00369421||Healthy Volunteers|Healthy Volunteers
88828196|NCT02296502||Non-Autism Spectrum Disorder|All children and adolescents seen for autism diagnostic evaluations at the study sites who do not meet diagnostic criteria for ASD.
89534087|NCT00369421||Patients|Patients with unique disorders
89534088|NCT00369421||Unaffected family members|Unaffected family members of patients
89534089|NCT00359684||Cystinosis|Patients with a diagnosis of cystinosis
89534090|NCT00359580||AGDB|Those individuals who are listed in the Fisher Family History and other genealogy books ordatabases will be included in the AGDB.
88828197|NCT02501330||Bosutinib|
89357053|NCT05357079|Experimental|Topical TXA Treatment|2 gm TXA/100 ml of normal saline
89357054|NCT05357079|Placebo Comparator|No Topical Treatment|Normal saline
89357055|NCT05336279|Experimental|Treatment group TR|T - R
89357056|NCT05336279|Experimental|Treatment group RT|R -T
89534091|NCT00353158|Active Comparator|A|Subjects currently on or previously on chronic voriconazole or subjects who are scheduled to begin voriconazole
89534092|NCT00353158|Experimental|B|100mg twice daily for 3 days. Two hours after the last dose of doxycycline is taken in the clinic, on-medication phototesting with ssUVR, UVA, and visible light will be performed.
89534093|NCT00342888||Childhood Leukemia Cases|Cases were diagnosed at 9 hospitals in Northern California
88828198|NCT02427698|Active Comparator|cyrolipolysis|
88828199|NCT02427698|Active Comparator|cryolipolysis plus subcision|
88828200|NCT02372630|Placebo Comparator|Placebo|Patients will be treated for 12 weeks with placebo once daily
88828201|NCT02372630|Active Comparator|Linagliptin 5mg per day|Patients will be treated for 12 weeks with Linagliptin 5mg once daily.
88828202|NCT02318654|Active Comparator|Ice Pack|
88828203|NCT02318654|Active Comparator|Topical EMLA cream|
88828204|NCT04349930|Experimental|Cannabidiol|CBD vaginal suppository
88828205|NCT04349930|Placebo Comparator|Placebo|Placebo vaginal suppository
88828206|NCT02303990|Experimental|Single arm|Hypofractionated RT and Pembro
88828207|NCT03029078|Experimental|Fecal transplantation|"Patient will be transplanted with a healthy donor microbiota, free from XDR bacteria, in order to evaluate the impact on the digestive tract colonization Whole process of feces screening and reconstitution was under the responsibility of the pharmacists in charge of the study.~Patient will benefit of a naso-duodenal tube in order to perform a bowel lavage prio to the fecal microbiota transplant.~Patient will be monitored for 24h to rule out potential adverse events."
88828208|NCT04579250|Experimental|Group 1: H10ssF-6473 (20 mcg), ages 18-50 years|H10ssF-6473 (20 mcg) administered intramuscularly (IM) by Needle/Syringe (Day 0)
88828209|NCT04579250|Experimental|Group 2A: H10ssF-6473 (60 mcg), ages 18-50 years|H10ssF-6473 (60 mcg) administered IM by Needle/Syringe (Day 0 and Week 16)
88828210|NCT04579250|Experimental|Group 2B: H10ssF-6473 (60 mcg), ages 55-70 years|H10ssF-6473 (60 mcg) administered IM by Needle/Syringe (Day 0 and Week 16)
88828211|NCT04565522||Hemodialysis or peritoneal dialysis patients|Hemodialysis or peritoneal dialysis Covid negative patients
88828212|NCT04565522||dialysis staff healthcare professionals|dialysis staff Covid negative healthcare professionals
88828213|NCT01727089|Active Comparator|Arm I (bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
88828214|NCT01727089|Experimental|Arm II (bevacizumab, anti-endoglin monoclonal antibody TRC105)|Patients receive bevacizumab as in Arm I and anti-endoglin monoclonal antibody TRC105 IV over 1-4 hours on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
88828215|NCT03175367|Experimental|Group A: dosing regimen 1|SC Evinacumab QW for 16 weeks
88828216|NCT03175367|Experimental|Group A: dosing regimen 2|SC Evinacumab Q2W for 16 weeks (alternating with matching placebo on opposite weeks)
88828217|NCT03175367|Experimental|Group A: dosing regimen 3|SC Evinacumab QW for 16 weeks
88828218|NCT03175367|Experimental|Group A: matching placebo|Placebo SC QW for 16 weeks
88828219|NCT03175367|Experimental|Group B: dosing regimen 1|Intravenous (IV) Evinacumab Q4W for 24 weeks
88828220|NCT03175367|Experimental|Group B: dosing regimen 2|IV Evinacumab Q4W for 24 weeks
88828221|NCT03175367|Experimental|Group B: matching placebo|Placebo IV Q4W for 24 weeks
88828222|NCT01727791|Experimental|open label|
88828223|NCT01728337|Active Comparator|Dysport and Xeomin|30 U of Dysport® was injected on the right side of the forehead and 12 U Xeomin® was injected on the left side of the forehead (dose-equivalence 2.5:1).
88828224|NCT01728337|Active Comparator|Xeomin and Dysport|30 U Dysport® was injected on the left side of the forehead and 12 U Xeomin® was injected on the right side of the forehead (dose-equivalence 2.5:1).
88828225|NCT02980627|Experimental|Therapy with Mobile App Enhancement|Participants will complete initial assessments and then take part in a 3-month intervention consisting of 12 weekly individual therapy sessions with daily RR app use between sessions. At the end of the 3-month intervention period, an exit interview will be conducted and participants will complete a second assessment consisting of questionnaires and an ED diagnostic interview, a blood specimen for HbA1c, and 3-days of blinded CGM monitoring. Participants will then enter a 6-month follow-up period during which time they may continue to use the app, but will no longer attend individual sessions. Participants will be return to the clinic at 6 and 9 months for follow-up.
88828226|NCT02247193|Experimental|Botulinum Toxin|Injection of botulinum toxin into cleft lip at time of surgical repair.
88828227|NCT02247193|Placebo Comparator|Saline|Injection of normal saline into cleft lip at time of surgical repair.
88828228|NCT02245087|Experimental|Atorvastatin|Atorvastatin(Lipitor) in addition to the usual guideline based care
88828229|NCT02245087|No Intervention|Guideline based care|Current guidelines for lipid-management in healthy middle aged men and women only.
88828230|NCT01731691|Experimental|α1 Proteinase Inhibitor in HIV disease|α1Proteinase Inhibitor (120mg/kg Prolastin-C) weekly for 8 weeks
88828231|NCT01731691|Placebo Comparator|Placebo in HIV disease|Placebos weekly for 8 weeks
88828232|NCT01731691|No Intervention|Uninfected controls|Blood collection only for 8 weeks
88828233|NCT05317351|Active Comparator|"Standard Colonoscopy (SC)"|"Subjects enrolled to arm 1 (SC) will undergo colonoscopy using a standard colonoscope."
88828234|NCT05317351|Active Comparator|"Artificial Intelligence Aided Colonoscopy (GI Genius™) (AI)"|"Subjects enrolled to arm 2 (AI) will undergo colonoscopy using a standard colonoscope aided by Artificial Intelligence (GI Genius™)"
88828235|NCT05317351|Experimental|Combined Artificial Intelligence (GI Genius™) and G-EYE® Colonoscopy (AG)|"Subjects enrolled to arm 3 (AG) will undergo colonoscopy using the G-EYE® Colonoscope and Artificial Intelligence Aided Colonoscopy (GI Genius™)."
88828236|NCT04342013|Experimental|Perioperative Clinical Decision Support Application|Participants will be observed performing clinical tasks and documenting medication administrations with use of the clinical decision support application in the perioperative setting.
88828237|NCT04342013|No Intervention|No Perioperative Clinical Decision Support Application|Participants will be observed performing clinical tasks and documenting medication administrations without use of the clinical decision support application in the perioperative setting.
88828238|NCT02247739|Experimental|rhC1INH twice weekly|rhC1INH administered twice weekly
88828239|NCT02247739|Experimental|rhC1INH once weekly|rhC1INH administered once weekly
88828240|NCT02247739|Placebo Comparator|Placebo (Saline) twice weekly|Placebo (Saline) administered twice weekly
88828241|NCT02975141|Experimental|Afatinib 40Mg Tab, Gemzar, Abraxane +1|Dose Level +1 Afatinib 40 mg Nab-paclitaxel 125 mg/m2 BSA Gemcitabine 1000 mg/m2 BSA
88828242|NCT02975141|Experimental|Afatinib 30Mg Tab, Gemzar, Abraxane 0|Dose Level 0 Afatinib 30 mg Nab-paclitaxel 125 mg/m2 BSA Gemcitabine 1000 mg/m2 BSA
88828243|NCT02975141|Experimental|Afatinib 30Mg Tab, Gemzar, Abraxane -1|Dose Level -1 Afatinib 30 mg Nab-paclitaxel 100 mg/m2 BSA Gemcitabine 800 mg/m2 BSA
88828244|NCT02975141|Experimental|Afatinib 30Mg Tab, Gemzar, Abraxane -2|Dose Level -2 Afatinib 30 mg Nab-paclitaxel 75 mg/m2 BSA Gemcitabine 600 mg/m2 BSA
88828245|NCT04341935|Experimental|DPP4 group|Participants in the Dipeptidyl Peptidase 4 (DPP4) group will receive Linagliptin in addition to standard of care insulin regimen as per hospital protocol during hospitalization for up to 14 days
88828246|NCT04341935|Active Comparator|Control group|Participants in the control group will receive only the standard of care insulin regimen as per hospital protocol during hospitalization for up to 14 days
88828247|NCT04723303|Experimental|Treatment Arm|A single IV infusion of ULSC's in patients with DM or PM
88828248|NCT02440451|Experimental|Neurofeedback using BCI|16 (13 + 3 in case of dropoffs) ASD subjects
88828249|NCT05317039|Experimental|Group A|Group A will be treated with the buccal plate repositioning technique and grafted with SCPC.
88828250|NCT05317039|Active Comparator|Group B|Group B will be similarly managed and grafted using DFDBA
89188843|NCT04282226|Active Comparator|active tVNS|The tVNS device will be attached to the left aspect of the neck to stimulate the cervical branch of the vagal nerve and connected to an MR safe electrical
89357057|NCT05326997|Experimental|Photobiomodulation (PBM) with placebo cosmetic treatment.|Participants will receive the intervention with PBM using amber light (DMC E-Light ABR), 20 J/cm² and will also receive a product for daily home topical use containing only the cosmetic base without active.
89357058|NCT05326997|Active Comparator|Photobiomodulation (PBM) sham with 5% liposomal tranexamic acid cosmetic product|Participants will receive the simulated intervention with PBM using amber light (DMC E-Light ABR) and will also receive a product for topical home use containing 5% liposomal tranexamic acid.
89357059|NCT05326438|Experimental|CIRCLE mHealth app|"The investigators will trial a modified version of the mHealth app called Connections with Alaska Native/American Indian people who want to change the way they use alcohol."
89534094|NCT00342888||Matched Controls|Controls were matched on age, gender and race/ethnicity from birth certificates in Northern California
89534095|NCT00341237||polymorphisms|Specimens are available to investigators in coded form to anonymously screen for the presence of single-nucleotide polymorphisms (SNPs) and other mutations in DNA.
88828251|NCT05316961|Experimental|PEMF group|"Participants will receive active pulsed electromagnetic field therapy two times a week for eight weeks. The options of the appliance will be adjusted to 1.5 mT, 10Hz on one leg for 10 minutes. A total of 16 sessions will be given to each participant. Each session will last for 10 minutes. Participants will be positioned in sitting on a chair comfortably. They will receive intervention at Prince of Wales hospital.~3 sets of 10 repetitions of the eccentric exercises are carried out once daily for 6 weeks and after 6 weeks, the patients are instructed to carry out 3 sets of 10 repetitions, 3 times per week for 6 more weeks. The intensity of the exercise should be such that pain, or discomfort, is experienced in the last set of 10 repetitions."
88828252|NCT05316961|Sham Comparator|Sham group|"Participants will receive sham pulsed electromagnetic field therapy two times a week for eight weeks. The options of the appliance will be adjusted to 0 mT, 0Hz on one leg for 10 minutes. A total of 16 sessions will be given to each participant. Each session will last for 10 minutes. Participants will be positioned in sitting on a chair comfortably. They will receive intervention at Prince of Wales hospital.~3 sets of 10 repetitions of the eccentric exercises are carried out once daily for 6 weeks and after 6 weeks, the patients are instructed to carry out 3 sets of 10 repetitions, 3 times per week for 6 more weeks. The intensity of the exercise should be such that pain, or discomfort, is experienced in the last set of 10 repetitions."
88828253|NCT05316883|Other|clozapine treatment|Open label clozapine will be given to all participants in clinical doses adjusted to sideeffects and clinical effect
88828254|NCT02442869|Experimental|Stage 1 TAU plus Stage 2 CAMS|"Treatment as usual [TAU] -- the treatment typically provided by the counselor for 4-8 weeks~If participant is responding, treatment ends. Participants who don't respond are then re-randomized to~Collaborative Assessment and Management of Suicidality (CAMS) for 4-16 weeks"
88828255|NCT02442869|Experimental|Stage 1 TAU plus Stage 2 DBT|"Treatment as usual [TAU] -- the treatment typically provided by the counselor for 4-8 weeks~If participant is responding, treatment ends. Participants who don't respond are then re-randomized to~Dialectical Behavioral Therapy (DBT) for 4-16 weeks"
88828256|NCT02442869|Experimental|Stage 1 CAMS plus Stage 2 CAMS|"Collaborative Assessment and Management of Suicidality (CAMS) for 4-8 weeks~If participant is responding, treatment ends. Participants who don't respond are then re-randomized to~Additional Collaborative Assessment and Management of Suicidality (CAMS) for 4-16 weeks"
88828257|NCT02442869|Experimental|Stage 1 CAMS plus Stage 2 DBT|"Collaborative Assessment and Management of Suicidality (CAMS) for 4-8 weeks~If participant is responding, treatment ends. Participants who don't respond are then re-randomized to~Dialectical Behavioral Therapy (DBT) for 4-16 weeks"
88828258|NCT05316649||HPB group|Adult patients undergoing for elective liver or pancreas surgery at Department of Surgery, University Hospital Hradec Kralove, Czech Republic.
88828259|NCT01952873|Active Comparator|Rapid|The rapid inflation method will consist of reaching an operator determined high-pressure (16 atm) with the stent-deployment balloon and maintaining it the duration of time determined by the operator but <30 sec if the balloon is fully inflated and longer only if the balloon requires a longer duration to become fully inflated.
88828260|NCT01952873|Experimental|Prolonged|Prolonged inflation will be performed at high pressure(16 atm)and maintained for 30 sec with <0.3 atm drop during that period.
88828261|NCT03990363|Experimental|High Dose|High Dose (mg) (verinurad/allopurinol) Step 1 - titration_ 3/100 Step 2 - titration_ 7.5/200 Step 3 - target dose_ 12/300
88828262|NCT03990363|Experimental|Intermediate Dose|Intermediate Dose (mg) verinurad/allopurinol Step 1 - titration_ 3/100 Step 2 - titration_ 7.5/200 Step 3 - target dose_ 7.5/300
88828263|NCT03990363|Experimental|Low Dose|Low Dose (mg) verinurad/allopurinol Step 1 - titration_3/100 Step 2 - titration_3/200 Step 3 - target dose_3/300. As per Protocol Version 5.0, Patients from 3 mg dose will be switched to 24 mg at Visit 9.
88828264|NCT03990363|Experimental|Allopurinol alone (0/300 mg)|Step 1 - titration_0/100 Step 2 - titration_0/200 Step 3 - target dose_0/300
88828265|NCT03990363|Placebo Comparator|Placebo (0/0 mg)|Placebo (mg) in 3 steps_0/0
89534096|NCT00326482||Prior Liver Biopsy|HIV+ historical liver biopsy history
88828266|NCT02444663|Active Comparator|Clinician Valgus|Clinician performed fluoroscopic valgus and varus stress X-rays
88828267|NCT02444663|Active Comparator|Clinician Varus|Clinician performed fluoroscopic varus stress X-rays
88828268|NCT02444663|Experimental|Device Valgus - 0 Newton force|Device performed fluoroscopic valgus stress X-rays - 0 Newton force
88828269|NCT02444663|Experimental|Device Valgus - 10 Newton force|Device performed fluoroscopic valgus stress X-rays - 10 Newton force
88828270|NCT02444663|Experimental|Device Valgus - 20 Newton force|Device performed fluoroscopic valgus stress X-rays - 20 Newton force
88828271|NCT02444663|Experimental|Device Valgus - 30 Newton force|Device performed fluoroscopic valgus stress X-rays - 30 Newton force
89357060|NCT05325476|Experimental|JomPrEP App Group|Participants in the TAU group will receive the JomPrEP app with major intervention features inactivated; information and resources for HIV testing, PrEP, and available mental health and addiction services will be available along with access to risk assessment tools. The Research Assistant will assist in downloading the app and provide a tutorial in using the assessment tool of the app.
89534097|NCT00326482||Prospective Liver Biopsy with ARV|HIV+ taking c/ARV medications
89534098|NCT00326482||Prospective Liver Biopsy without ARV|HIV+ not taking c/ARV medications
89534099|NCT00246857||patients referred by physician with a suspected inherited immune deficiency|patients referred by physician with a suspected inherited immune deficiency
89534100|NCT00242723||1/Cohort 1|Subjects with potentially malignant or suspicious lesions, or biopsy proven thoracic cancers or thoracic metastases from cancers of non-thoracic origin
89534101|NCT00152451|Experimental|Seletracetam|Escalating doses twice daily were to be administered.
89534102|NCT00128960||1|Participants with different types of diseases and conditions who have undergone an allogeneic (donor) stem cell transplant.
88828272|NCT02444663|Experimental|Device Varus - 0 Newton force|Device performed fluoroscopic varus stress X-rays - 0 Newton force
88828273|NCT02444663|Experimental|Device Varus - 10 Newton force|Device performed fluoroscopic varus stress X-rays - 10 Newton force
88828274|NCT02444663|Experimental|Device Varus - 20 Newton force|Device performed fluoroscopic varus stress X-rays - 20 Newton force
88828275|NCT02444663|Experimental|Device Varus - 30 Newton force|Device performed fluoroscopic varus stress X-rays - 30 Newton force
89188844|NCT04282226|Placebo Comparator|sham tVNS|The tVNS device will be attached to anatomically distinct from the cervical branch of the vagal nerve.
89188845|NCT00841438|Active Comparator|Provisional use of Clotinab|Provisional use of clotinab
89188846|NCT00841438|Experimental|Upstream use of clotinab|early upstream use of clotinab
89188847|NCT04046367|Experimental|Intervention|Educational program and cognitive-behavioral intervention. The patient receives training in nutrition and cognitive-behavioral therapy, with specific training aimed at increasing physical activity, functional capacity and conditioning of the respiratory musculature (prehabilitation by a physiotherapist)
89188848|NCT04046367|Active Comparator|Control|Educational program and cognitive-behavioral intervention. The patient receives training in nutrition and cognitive-behavioral therapy, as well as standard instructions to increase physical activity.
89188849|NCT02573090|Experimental|Non-invasive resin based fissure sealing|Application of resin based fissure sealing after acid etching of carious occlusal surface
89188850|NCT02573090|Active Comparator|Invasive resin based restoration|Application of resin based resin restoration after operative intervention of caries lesion, excavation and preparation on occlusal surface
89188851|NCT04798521|Experimental|Tele-HCV Treatment|Participants allocated to telemedicine intervention arm are scheduled for treatment assessment by a study clinician. For a majority of participants, this will also be the treatment initiation visit. If additional studies are necessary for routine treatment decision making, peers will assist participants in navigating health system barriers and arrangement of second telemedicine visit.
89188852|NCT04798521|Active Comparator|Community Linkage to Care|Participants allocated to the community linkage-to-care arm will complete screening, be offered enrollment, and undergo informed consent as in the telemedicine arm. Following study inclusion and enrollment, research staff will refer the participant to a local community health clinic to engage in hepatitis C care and seek treatment.
89188853|NCT05505227|Active Comparator|Intervention|
89188854|NCT05505227|Placebo Comparator|Control|
89188855|NCT02546830|Experimental|FreeO2 v2.2 active|Automatic Oxygen Administration
89188856|NCT02546830|Active Comparator|FreeO2 v2.2 with manual oxygenation|Manual Oxygen Administration
89188857|NCT00715598||Neuropathic Pain|Subjects in this group experience chronic neuropathic pain.
89188858|NCT00715598||Musculoskeletal Pain|Subjects in this group experience chronic musculoskeletal pain.
89188859|NCT00802269|Experimental|Reduced Fluence Parameters|Eyes receiving retinal photocoagulation with reduced fluence parameters (time 20-50 msec, power 400-700 mW)
89188860|NCT00802269|Active Comparator|Traditional parameters|Eyes receiving retinal photocoagulation with traditional parameters (time 100-200 msec, power 200-400 mW)
89188861|NCT02601443|Experimental|Cervical Pessary|"Cervical pessary is a medical device used to treat an incompetent (or insufficient) cervix (cervix starts to shorten and open too early). Early in the pregnancy a round silicone pessary is placed at the opening to the cervix to close it, and then remove late in the pregnancy when the risk of a preterm birth has passed.~Cervical pessary has been tried as a simple, non-invasive alternative that might replace the above invasive cervical stitch operation to prevent preterm birth."
89188862|NCT02601443|No Intervention|Routine care (watch and wait)|
89188863|NCT02573480|Experimental|Wraparound Care|Wraparound care initiated in the ED at the time of injury and continuing for approximately 1 year in the community.
89188864|NCT00841516|Placebo Comparator|Placebo|Placebo was given the same way as a subcutaneous (just under the skin) injection.
89188865|NCT00841516|Experimental|80 µg rBet v1-FV Immunotherapy|All randomized patients were treated with either placebo or 80 µg rBet v1-FV (maintenance dose) for 2 years.
89188866|NCT04069832|Other|Intervention|SINGLE-SESSION CONSULTATION
89188867|NCT00841594|Active Comparator|1|"MQX-503, topical cream for nitroglycerin 0.9% vs Nitroglycerin ointment 2%, USP.~Applied to the hand."
89188868|NCT00841594|Active Comparator|2|"MQX-503, topical cream for nitroglycerin 0.9% vs Nitroglycerin ointment 2%, USP.~Applied to the chest."
89188869|NCT04068974|Experimental|Test group|Camrelizumab (SHR-1210) 200mg, once every 2 weeks, each 4 weeks is 1cycle. Apatinib :250 mg po qd
89188870|NCT00836290|Experimental|Pre-release|Participants in the pre-release intervention group will receive four sessions in the four-week period prior to release and will receive a comprehensive booster session four weeks after release.
89188871|NCT00836290|Experimental|Post-release|Participants in the post-release intervention group will receive one comprehensive introductory session four weeks before release and four sessions during the four-week period after release.
89188872|NCT00836290|No Intervention|Control|Participants in the control group do not receive education sessions during their term in the study. However, these sessions are available to them after completing the study.
89188873|NCT00782171|Active Comparator|Immediate Loading|SLActive dental implant(s) will be restored with a temporary restoration on the day of surgery.
89188874|NCT00782171|Active Comparator|Early Loading|Healing caps will be placed on the SLActive dental implant(s) immediately after surgery. A provisional restoration will be placed between day 28 to day 34 post surgery
88828276|NCT02445287|Experimental|Predicate & Invest.- Cadavers 2D & 3D|Radiation - Cadaveric specimens will be imaged with 2D devices: CARESTREAM DRX-Evolution general radiograph and CARESTREAM Cone Beam Computed Tomography (CBCT) general radiograph, and 3D devices PHILLIPS Multi Detector Computed Tomography (MDCT) and CARESTREAM Cone Beam Computed Tomography (CBCT).
88828277|NCT02445287|Experimental|Investigational - Human Subjects 3D|Radiation - Human subjects will be imaged with 3D investigational device CARESTREAM Cone Beam Computed Tomography (CBCT) only.
89534103|NCT00084305||Family|Family members of patients with pulmonary fibrosis
88828278|NCT04341857|Experimental|Sintilimab combined with FLOT regimen|Oxaliplatin#80mg/m2d1#iv infusion for 2 hours# Calcium leucovate#200mg/m2d1#iv infusion# Fluorouracil#2600mg/m2,intravenous drip for 24h# Docetaxel#50mg/m2,intravenous drip for 1 h# Every 14 days is one cycle# Sintilimab#200mg, d1#iv infusion Every 21 days is one cycle.
89534104|NCT00084305||Healthy Volunteers|Healthy Volunteers
88828279|NCT01888601||NSCLC eligible for primary surgery|NSCLC eligible for primary surgery
88828280|NCT02974283|Experimental|NBO group|Normobaric oxygen therapy is the delivery of high-flow oxygen (10L/min) via oxygen storage facemask. This therapy should start within 1 hours after diagnosis of ischemic stroke and last for 4hours. All participants will receive r-tPA thrombolytic therapy and a standard clinical therapy.
88828281|NCT02974283|No Intervention|Control group|The participants receive r-tPA thrombolytic therapy after diagnosed ischemic. All participants receive a standard clinical therapy.
88828282|NCT00002913|Experimental|Treatment (paclitaxel, cisplatin, topotecan hydrochloride)|"Patients receive paclitaxel IV over 3 hours and cisplatin IV on day 1, followed by topotecan IV over 30 minutes on days 1-3. Patients receive filgrastim (G-CSF) subcutaneously beginning on day 4 and continuing until blood counts recover. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.~Cohorts of 4-6 patients receive escalating doses of topotecan until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose limiting toxicities."
88828283|NCT03083405||Opipramol group|Patients diagnosed with SB and opipramol intervention.
88828284|NCT03083405||SB group|Patients diagnosed with SB and no drug intervention.
88828285|NCT03083405||Healthy controls|Patients without diagnosed SB.
88828286|NCT00383799|Active Comparator|Group 1|IV procainamide (single dose: 10 mg/kg over 20 min)
88828287|NCT00383799|Active Comparator|Group 2|IV Amiodarone (single dose: 5 mg/kg over 20 min)
88828288|NCT04616677|Active Comparator|Parts 1 and 2: Cohort 1 (JNJ-42847922)|Healthy participants with normal renal function [estimated glomerular filtration rate (eGFR) greater than or equal to (>=) 90 milliliter (mL)/minute (min)] will receive single oral dose of JNJ-42847922 on Day 1.
88828289|NCT04616677|Experimental|Part 1: Cohort 2 (JNJ-42847922)|Participants with severe renal impairment (eGFR 15 to 29 mL/min) will receive single oral dose of JNJ-42847922 on Day 1.
88828290|NCT04616677|Experimental|Part 2 (Optional): Cohort 3 (JNJ-42847922)|Participants with moderate renal impairment (eGFR 30 to 59 mL/min) will receive single oral dose of JNJ-42847922 on Day 1.
88828291|NCT04612075||All patients referred to fast track clinical pathway for HNC cancer|MRI as part of staging, including a 5-minute additional sequence.
88828292|NCT04612075||Patients with locally advanced HNC|FDG-PET/MRI
88828293|NCT03963453||Interventional|Regular physical exercise group
88828294|NCT03963453||Control|Standards of care treatment
88828295|NCT05709925|Other|Group A|Group A will be receiving moist heat for 10 minutes followed by myofascial release through stripping technique to the lumbar region. After that post-treatment stretching would be performed. Total treatment plan would be of 30 minutes, comprising of total 9 sessions (3 weeks), 3 sessions on alternate days
88828296|NCT05709925|Experimental|Group B|Group B will be receiving moist heat for 10 minutes followed by Instrument Assisted Soft Tissue Mobilization using long bar tool for 5-7 minutes with gentle horizontal stroking at an angle of 45 degrees. After that, post treatment stretching consisting of 2-3 sets of 10 repetitions of the targeted muscle group will be performed.Total treatment plan will be of 3 weeks comprising of total 9 sessions, 3 sessions on alternate days.
88828297|NCT02997657|Experimental|Positive Psychotherapy for Smoking Cessation|Smoking cessation treatment that incorporates exercises and text messages derived from positive psychology interventions that are designed to boost positive moods, cognitions, and behaviors.
88828298|NCT02997657|Active Comparator|Standard smoking cessation treatment|Smoking cessation counseling that provides support and problem solving skills for avoiding smoking.
88828299|NCT04545541|Experimental|Nebulised heparin|"Participants assigned to nebulised UFH will receive nebulised UFH in addition to the standard care required as determined by the treating team. Nebulised UFH (25,000 Units in 5 mL) will be administered 6-hourly via an Aerogen Solo vibrating mesh nebuliser while patients receive invasive mechanical ventilation in ICU and for a maximum of 10 days."
88828300|NCT04545541|No Intervention|Control group|"Participants assigned to 'standard care' will receive the standard care required as determined by the treating team and will not be treated with nebulised heparin (Australia, Ireland).~Participants assigned to placebo will receive Nebulised 0.9% Sodium Chloride (5 mL) administered 6-hourly via an Aerogen Solo vibrating mesh nebuliser while patients receive invasive mechanical ventilation in ICU and for a maximum of 10 days (USA)."
88828301|NCT00002925|Active Comparator|ADE|
88828302|NCT00002925|Experimental|ADEP|
88828303|NCT05316415|Experimental|Acemaşiran Music Group|Listening to Acemaşiran music for 40 minutes in successive three days and two times a day (noon and evening) Routine clinical care
88828304|NCT05316415|No Intervention|Control Group|Routine clinical care
88828305|NCT05709847|Active Comparator|Conventional coffee|Participants will be provided with a conventional, low CGA coffee to brew and consume which contains less CGA than the experimental arm.
89534105|NCT00084305||Pulmonary Fibrosis|Patients with pulmonary fibrosis
89534106|NCT00080756|Experimental|Group 1 (planned risk reduction mastectomy)|Patients receive deslorelin, estradiol, and testosterone intranasally QD for 6 months. Patients then undergo planned risk reduction mastectomy.
89357061|NCT05325476|Active Comparator|Treatment as usual|Participants in the JomPrEP group will be provided with full app access. The Research Assistant will use an onboarding checklist to orient participants to download the app and its use. Participants will be encouraged to explore and use all components of the app. Participants will be able to personalize the frequency, timing, and content for daily adherence support and weekly behavioral feedback messages and receive reminders for regular PrEP care. Participants can also contact the Research Assistant using the chat function for support and assistance with linkage to services.
89357062|NCT05315193|Experimental|Structured In-patient and Home plan|Structured In-patient and Home plan
89357063|NCT05315193|Placebo Comparator|Conventional therapy|Conventional protocol as per guidelines
89357064|NCT05309629|Experimental|QL1706+chemotherapy|Participants received intravenous infusions of QL1706 5mg/kg in combination with carboplatin to achieve an initial target area under the concentration-time curve (AUC) of 5 mg/mL/min followed by etoposide 100 mg/m^2 on Day 1 of every 21-day cycle for 4-6 cycles. On Days 2 and 3 of every 21-day cycle, etoposide 100 mg/m^2 was administered alone for 4-6 cycles. Thereafter, participants received maintenance QL1706 5mg/kg on Day 1 of every 21-day cycle until progressive disease, intolerable toxicity, withdrawal of consent, death, or study termination by the Sponsor.
89357065|NCT05307380||patients with pain|patients with acute postoperative or post-traumatic pain or chronic pain
89357066|NCT05307211|Active Comparator|GROUP 1 (CIESI Only)|Only interlaminar epidural steroid injection will be administered to patients in this arm with the same method as in the other arms (one session, week 0). Staying active will be the only recommendation, and no exercise prescription will be provided.
89357067|NCT05307211|Experimental|GROUP 2 (CIESI plus NECK STABILIZATION EXERCISES)|After the interlaminar epidural steroid injection, the patients will be taken to an exercise program in the physical therapy unit, in the company of a physiotherapist, within 24 hours, within 72 hours at the latest.
89357068|NCT05307211|Experimental|GROUP 3 ( CIESI plus NECK and SCAPULAR STABILIZATION EXERCISES)|After the interlaminar epidural steroid injection, the patients will be taken to an exercise program in the physical therapy unit, in the company of a physiotherapist, within 24 hours, within 72 hours at the latest.
89357069|NCT05283044|Other|Biopsy liquid contributive|Patients presenting for whom ct DNA sequencing
89357070|NCT05271032||Septic Patients|
89357071|NCT05269433|Active Comparator|PSE + OCAT-sham|Psycho-education video + an active placebo training consisting of 10 sessions of ±12 minutes each (during an intervention period of two weeks) will be administered. The training task is an undirected scrambled sentences task with online contingent feedback (only) on the speed with which the sentences were made. In this condition, participants will not receive feedback on emotional attention.
89357072|NCT05269433|Experimental|PSE + OCAT|Psycho-education video + an attention training consisting of 10 sessions of ±12 minutes each (during an intervention period of two weeks) will be administered. The training task is a positively directed scrambled sentences task with online contingent feedback on how much attention was paid to positive vs. negative words (emotional attention), along with feedback on the speed with which the sentences were made.
89357073|NCT05269433|Experimental|PSE + OCAT+|Psycho-education video + short motivational video before each training session + an attention training consisting of 10 sessions of ±12 minutes each (during an intervention period of two weeks) will be administered. The training task is a positively directed scrambled sentences task with online contingent feedback on how much attention was paid to positive vs. negative words (emotional attention), along with feedback on the speed with which the sentences were made.
89357074|NCT05267912|Experimental|ORGANOTREAT 01|"To assess the feasibility of timely generating chemograms from PDOs in advanced CRC.~To assess the proportion of patients treated according to the chemogram tumor board (CTB)'s recommendations on the basis of their personalized chemogram.~To assess the efficacy and safety of chemogram-driven treatment in advanced CRC."
89357075|NCT05267912|Experimental|ORGANOTREAT 02A|is a single-arm, Phase II study to evaluate the efficacy of chemogram-driven treatment in patients with advanced, pretreated solid cancers of low-to-intermediate incidence and/or with a PDO take-on rate <50%. The primary endpoint is the Growth Modulation Index (GMI), defined as PFSn/PFSn-1, where PFSn is the -progression-free survival (PFS) time on study treatment and PFSn-1 the PFS time within the previous treatment line.
88828306|NCT05709847|Experimental|CGA-rich coffee (Speciality coffee)|Participants will be provided with a single origin, CGA-rich specialty coffee as graded by the Specialty Coffee Association of America's Q-grading system to brew and consume
88828307|NCT02445911|Experimental|KQ-791 Dose 1|Single loading dose on day 1, followed by single doses on days 8, 15, 22, 29
88828308|NCT02445911|Experimental|KQ-791 Dose 2|Single loading dose on day 1, followed by a daily dose for 28 days
88828309|NCT02445911|Experimental|KQ-791 Dose 3|Single loading dose on day 1 or days 1-2, followed by a daily dose for 28 days
89534107|NCT00080756|Active Comparator|Group 2 (continued survaillance)|Patients receive deslorelin, estradiol, and testosterone intranasally QD for 10 months. Patients then undergo continued surveillance through 10 months.
89534108|NCT00078078||Methylmalonic Acidemia|Individuals with methylmalonic acidemia
88828310|NCT02445911|Placebo Comparator|Placebo|Multiple ascending doses matching KQ-791 dose
88828311|NCT02955537|No Intervention|Usual care|Usual care participants will be given a prescription for antihypertensive medications, printed educational materials on hypertension, and a home blood pressure monitor for daily use, but will receive no further intervention.
88828312|NCT02955537|Experimental|MI-BP|MI-BP participants will receive an antihypertensive medication prescription, and be asked to use technology-mediated devices/services linked to positive changes in target behavior/outcome including the MI-BP app, a secure, mHealth platform that will be installed on participant smartphones.
88828313|NCT02446223|Experimental|Active|
88828314|NCT02446613|Other|Nasal allergen challenge|Subjects do not receive study medication in this study 204509. Subjects who carried from study TL7116958 treatment group GSK2245035 will undergo NAC with pollen allergen extract.
88828315|NCT02918955|Active Comparator|Arm rA (randomized)|Concomitant chemo-radiotherapy with early salvage neck dissection if less than complete clinical response
88828316|NCT02918955|Experimental|Arm rB (randomized)|Up-front neck dissection followed by radiotherapy with concomitant chemotherapy based on the cT pN cM staging after surgery
89177579|NCT00829010|Experimental|HIV- (EPI) Group|Infants born from a HIV negative mother and confirmed as HIV unexposed uninfected.Subjects received 3 primary doses of Synflorix™ vaccine (at 6, 10 & 14 weeks of age, at study Months 0, 1 and 2). Subjects in the group also received 3 primary vaccine doses (at 6, 10 & 14 weeks of age, at study Months 0, 1 and 2) and 1 booster vaccine dose (at 15-18 months of age, at study Month 14) of Tritanrix™-HepB/Hib, 2 vaccine doses of Rotarix™ (at 10 & 14 weeks of age, at study Months 1 and 2), and 2 doses of measles vaccine (9-10 months of age & 15-18 months of age, at study Months 8 and 14). Measles vaccine was not considered as a study vaccine. The Synflorix™ vaccine was administered IM in the right thigh, the Tritanrix™-HepB/Hib vaccine was administered IM in the left anterolateral thigh during the primary vaccination and in the left anterolateral thigh or left deltoid region during booster vaccination. Rotarix™ was given orally.
89177580|NCT00829010|Experimental|HIV- (2+1) Group|Infants born from a HIV negative mother and confirmed as HIV unexposed uninfected.Subjects received 2 primary doses (at 6 & 14 weeks of age at study Months 0 and 2) and 1 booster dose of Synflorix™ vaccine (at 9 months of age, at study Month 8). Subjects in the group also received 3 primary vaccine doses (at 6, 10 & 14 weeks of age, at study Months 0, 1 and 2) and 1 booster vaccine dose (at 15-18 months of age, at study Month 14) of Tritanrix™-HepB/Hib, 2 vaccine doses of Rotarix™ (at 10 & 14 weeks of age, at study Months 1 and 2), and 2 doses of measles vaccine (9-10 months of age & 15-18 months of age, at study Months 8 and 14). Measles vaccine was not considered as a study vaccine. The Synflorix™ vaccine was administered IM in the right thigh, the Tritanrix™-HepB/Hib vaccine was administered IM in the left anterolateral thigh during the primary vaccination and in the left anterolateral thigh or left deltoid region during booster vaccination. Rotarix™ was given orally.
89177581|NCT03865810||Gastric Surgery|Adult patients undergoing elective gastric surgery for cancer
89177582|NCT00817882|Experimental|1|individually targeted vocational rehabilitation
89177583|NCT00817882|Active Comparator|2|routine back pain rehabilitation
89177584|NCT04632784|Experimental|Artiflex Presbyopic|About 125 - 140 subjects will receive the Artiflex Presbyopic lens bilaterally and will be followed for a period of 3 years.
89177585|NCT00706316|Experimental|EBV-Specific CTLs and CD45 Mab|A dose escalation schema will be employed. Three to six patients will be treated at each of the following dose levels with EBV-Specific CTLs and CD45 Mab: Dose Level I: 2 x 10^7 cells/m2. Dose Level II: 5 x 10^7 cells/m2. Dose Level III: 1 x 10^8 cells/m2. Dose escalation decisions will be made after review of the data from the current dose level. There will be no intra-patient escalation. An additional 6-10 patients with measurable disease will be treated at the recommended phase II dose to expand the experience at this dose level.
89177586|NCT00808912|Active Comparator|1|Subjects will exercise in a high air pollutant environment after ingesting a standard dose of sildenafil.
89177587|NCT00808912|Active Comparator|2|Subjects will exercise in a low pollutant environment after ingesting a standard dose of sildenafil.
89177588|NCT00808912|Placebo Comparator|3|Subjects will exercise in a high pollutant environment after ingesting a placebo.
89177589|NCT00808912|Placebo Comparator|4|Subjects will exercise in a low pollutant environment after ingesting a placebo.
89177590|NCT02551042|Experimental|Active treatment arm|Fibrogammin®P, coagulation factor XIII concentrate (Human) IV infusion
89177591|NCT02551042|Placebo Comparator|Placebo arm|Placebo will be 0.9 % Sodium chloride solution IV infusion
89177592|NCT00808990|Experimental|OSA and NAFLD patients using CPAP|OSA and NAFLD patients using CPAP being followed for 6 months.
89177593|NCT00808990|No Intervention|control|OSA and NAFLD patients not using CPAP being followed for 6 months.
89177594|NCT00445939|Experimental|Adalimumab 160 mg/80 mg|
89177595|NCT00445939|Experimental|Adalimumab 80 mg/40 mg|
89177596|NCT00445939|Placebo Comparator|Placebo|
89177597|NCT00816244|Experimental|Atorvastatin|
89177598|NCT00817960|Experimental|Methylphenidate|
89177599|NCT01027039||Patients using noise-reducing headphones|Patients using noise-reducing headphones
89177600|NCT01027039||Patients using no headphones|Patients using no headphones
89177601|NCT01027039||Patients using headphones with music|Patients using headphones with music
89177602|NCT00816322|Active Comparator|omega-3 fatty acids|EPA 2.1 g/d+DHA 1.1 g/d
89177603|NCT00816322|Placebo Comparator|Placebo|high oleic oil
89177604|NCT01565785|Experimental|Discharge Prepartion with The FSM-DPI|25 families on each of 2 units will receive the will receive the Family Self-Management-Discharge Preparation Intervention (FSM-DPI). This scripted theory-based intervention is delivered by the study nurse using a e-mobile device. Eight elements of discharge preparation are addressed, the nurse assesses the family status and documents the additional care provided.
89177605|NCT01565785|No Intervention|control group|25 parents on each unit receiving standard of care in discharge preparation.
89177606|NCT00818038||TYSABRI|Participants who are newly prescribed TYSABRI, but have not received their first infusion, will be invited to participate.
89188875|NCT02572700||Patients with psoriatic arthritis|PsA patients initiating anti-rheumatic treatment in routine care will be included as one group in the observational study. Analyses will be carried out for the overall study population as well as for subgroups (e.g., stratified according to treatment intervention) in an exploratory manner.
88828317|NCT02918955|Active Comparator|Arm oA (non-randomized)|Concomitant chemo-radiotherapy with early salvage neck dissection if less than complete clinical response
88828318|NCT02918955|Experimental|Arm oB (non-randomized)|Up-front neck dissection followed by radiotherapy with concomitant chemotherapy based on the cT pN cM staging after surgery
88828319|NCT05315869||Retrocaecal group|Patients who underwent surgery for signs of acute appendicitis and had intraoperative finding of the appendix located in the retrocaecal position.
89188876|NCT02572700||Patients with skin psoriasis without arthrits|20 patients with skin psoriasis without arthrits will be included as one group at baseline only. Baseline characteristics including status of pain, fatigue, work, comorbidity and lifestyle factors will be recorded.
89188877|NCT02572700||Healthy controls|20 healthy controls will be included as one group at baseline only. Baseline characteristics including status of pain, fatigue, work, comorbidity and lifestyle factors will be recorded.
89188878|NCT00836368|Experimental|MaxiGamma|
89534109|NCT00068003||1/Cancer Patients|Patients with a current diagnosis of cancer
88828320|NCT05315869||Non-retrocaecal group|Patients who underwent surgery for signs of acute appendicitis and had intraoperative finding of the appendix not located in the retrocaecal position.
89177607|NCT00482053|Experimental|Auto-HCT followed by Allo-HCT for Poor-risk DLBCL|"Participants will have peripheral blood stem cells (PBSC, aka progenitor / stem cells) mobilized to peripheral blood with rituximab, chemotherapy (cyclophosphamide or etoposide), and filgrastim; undergo apheresis to collect (self/autologous PBSC), and receive carmustine, etoposide, and cyclophosphamide as conditioning for PBSC infusion as a hematopoietic cell transplant (auto-HCT).~Then participants will receive allogeneic HCT (allo-HCT) transplant conditioning [total lymphoid irradiation (TLI) + anti-thymocyte globulin (ATG)] followed by allogenic PBSC (allo-HCT) obtained from a human leukocyte antigen (HLA)-matched or single mismatch filgrastim-mobilized donor. Participant allo-HCT transplant is to occur within 150 days of auto-HCT. Post-allo-HCT treatment includes cyclosporine + mycophenolate mofetil (MMF).~Subject's participation ends if donor is not identified within 150 days. Pre-medication includes acetaminophen; diphenhydramine; hydrocortisone; & methylprednisolone."
89177608|NCT00455923|Experimental|Seretide|Eligible participants received a starting dose of 50/100 mcg Seretide (combination of Sal/FP) via Diskus inhaler, twice daily. During the first 6 months, when the asthma was unstable/uncontrolled, dose was increased in a stepwise fashion to 50/250 mcg and 50/500 mcg (if still unstable). After the initial 6 months, the treatment was fixed without further changes. The total treatment period was 18 months.
89177609|NCT00455923|Experimental|Flixotide|Eligible participants received a starting dose of 100 mcg Flixotide (FP only) via Diskus inhaler, twice daily. During the first 6 months, when the asthma was unstable/uncontrolled, dose was increased in a stepwise fashion to 250 mcg and 500 mcg (if still unstable). After the initial 6 months, the treatment was fixed without further changes. The total treatment period was 18 months.
89177610|NCT00642616|Experimental|Technosphere® Insulin (Asthma)|Technosphere® Insulin Inhalation Powder administered prandially in diabetic participants with Asthma
89177611|NCT00642616|Active Comparator|Usual Care (Asthma)|Usual anti diabetic care in Diabetic participants with Asthma
89177612|NCT00642616|Experimental|Technosphere® Insulin (COPD)|Technosphere® Insulin Inhalation Powder administered prandially in diabetic participants with Chronic Obstructive Pulmonary disease (COPD)
89177613|NCT00642616|Active Comparator|Usual Care (COPD)|Usual anti diabetic care in Diabetic participants with Chronic Obstructive Pulmonary disease (COPD)
89177614|NCT00816478|Experimental|1|Galactose
89177615|NCT00809068|Active Comparator|1|fenofibrate and tibolone
89177616|NCT00809068|Sham Comparator|2|tibolone
89177617|NCT03844945|Experimental|Netarsudil Ophthalmic Solution 0.01%|1 drop daily into each eye in the evening for 28 days
89177618|NCT03844945|Experimental|Netarsudil Ophthalmic Solution 0.02%|1 drop daily into each eye in the evening for 28 days
89177619|NCT03844945|Experimental|Netarsudil Ophthalmic Solution 0.04%|1 drop daily into each eye in the evening for 28 days
89177620|NCT03844945|Placebo Comparator|Netarsudil Ophthalmic Solution Placebo|1 drop daily into each eye in the evening for 28 days
89177621|NCT01027117|Active Comparator|Treatment A|Revatio 20 mg intact tablet. This is the reference treatment arm.
89177622|NCT01027117|Experimental|Treatment B|Treatment B: Revatio 20 mg crushed tablet mixed with apple sauce.
88828321|NCT05315791|Experimental|a: ground into pieces|0~3mm
89177623|NCT01027117|Experimental|Treatment C|Treatment C: Revatio 20 mg extemporaneously prepared suspension (EP).
89177624|NCT03995563|Active Comparator|D group|0.19% Ropivacaine 8mL + Dexametasone 1mg every other day injection during 10 days
89177625|NCT03995563|Placebo Comparator|N group|0.19% Ropivacaine 8mL only every other day injection during 10 days
89177626|NCT00445549|Experimental|Vandetanib treatment|300 mg daily oral dose, 28 day cycle
89177627|NCT00445003|Experimental|Sham injection plus laser|Sham injection at baseline and 4 weeks. Focal/grid laser for diabetic macular edema was performed 3 days to 10 days after the injection for all treatment groups.
89177628|NCT00445003|Experimental|0.5mg Ranibizumab plus laser|Intravitreal injections of 0.5mg Ranibizumab at baseline and at 4 weeks. Focal/grid laser for diabetic macular edema was performed 3 days to 10 days after the injection for all treatment groups.
89177629|NCT00445003|Active Comparator|4-mg Triamcinolone Acetonide plus Laser|4-mg Triamcinolone Acetonide at baseline and sham injection at 4 weeks. Focal/grid laser for diabetic macular edema was performed 3 days to 10 days after the injection for all treatment groups.
89177630|NCT00811070|Experimental|1|
89177631|NCT02609594|Active Comparator|Standard of Care|Subjects randomized to this group will receive standard of care (multi-layer compression therapy).
89177632|NCT02609594|Experimental|Weekly application of Amnioband|Weekly application of Amnioband plus standard of care.
89534110|NCT00068003||2/Healthy Volunteers|Healthy volunteers
88828322|NCT05315791|Experimental|b: replace the bone|0~3mm
89534111|NCT00055029||Affected males and family members|Up to 500 participants, including a minimum of 150 males diagnosed with XLRS
88828323|NCT05315791|Experimental|c: turn inward|0~3mm
88828324|NCT05315791|Experimental|d: ground into pieces|3~5mm
88828325|NCT05315791|Experimental|e: replace the bone|3~5mm
88828326|NCT05315791|Experimental|f: turn inward|3~5mm
89177633|NCT02609594|Experimental|Biweekly application of Amnioband|Biweekly application of Amnioband plus standard of care.
89177634|NCT00642460|Experimental|1|
89177635|NCT00642460|Placebo Comparator|2|
89177636|NCT00814658|Experimental|Galantamine + Nimodipine|
89177637|NCT00814658|Experimental|Galantamine + Placebo|
89177638|NCT00816634|Active Comparator|1|"Chemotherapy regimen (XP):~D1- D14 Capecitabine 1000 mg/m2 bid p.o. D1 Cisplatin 75 mg/m2 + NS 150mL MIV over 1hr repeat every 3 weeks"
89177639|NCT00816634|Active Comparator|2|"XT Regimen:~D1- D14 Capecitabine 1000 mg/m2 bid p.o. D1, D8 Genexol (Paclitaxel) 80 mg/m2 + D5W 500mL MIV over 3hrs Repeat every 3 weeks"
89177640|NCT00642304|Experimental|methoxy polyethylene glycol-epoetin beta|
89357076|NCT05267912|Experimental|ORGANOTREAT 02B|is a randomized Phase II study to compare the efficacy of chemogram-driven treatment vs SoC in patients with advanced, pretreated solid cancers with a PDO take-on rate ≥50%. A cross-over will allow patients enrolled in the control arm to benefit from chemogram-based treatment. Patients for whom no chemogram can be obtained will not be randomized and they will be treated according to SoC. The primary endpoint will be PFS. The study will include multiple strata, each for a different tumor type (e.g., stratum 1, pancreatic ductal adenocarcinoma (PDAC); stratum 2, CRC; etc.). Each stratum will be conducted and analyzed independently from the other strata.
88828327|NCT02446847|Experimental|Group A: 3BNC117 IV + ART Interruption|Two intravenous infusions of 3BNC117 (30 mg/kg) at day 0 and day 21, with interruption of antiretroviral treatment (ART) at day 2.
89534112|NCT00047996||Group1|Clinical Center Patients, Healthy Volunteers
88828328|NCT02446847|Experimental|Group B: 3BNC117 IV + ART interruption|Four intravenous infusions of 3BNC117 (30 mg/kg) at day 0, day 14, day 28, and day 42 with interruption of antiretroviral treatment (ART) at day 2.
89534113|NCT00046059||ADHD|Children aged 7-17 with ADHD and their families.
89534114|NCT00044304|Experimental|Imatinib|open label imatinib mesylate treatment
89534115|NCT00044304|Experimental|Ruxolitinib|open label ruxolitinib treatment
89534116|NCT00043472||1|Eligible women at least one intact ovary who have signed written, informed consent that they will undergo screening as per protocol.
88828329|NCT04350853|Experimental|Surgical extrusion group|Surgical extrusion is performed in each patient of this group
88828330|NCT00002949|Experimental|Arm A|Vinorelbine (qwk, 10, 15, 20 or 25 mg/m2), Radiation therapy (Total pelvic RT of 45 Gy in 1.8-Gy daily fractions, 85 Gy in cervical cancer patients using intracavitary brachytherapy, 70 Gy in patients treated with interstitial brachytherapy) Paclitaxel (qwk, starting dose of 20mg/m2 with planned dose escalation increments of 5mg/m2)
88828331|NCT05315557|Experimental|Terlipressin|Terlipressin 1mg/24 hours
88828332|NCT05315557|Active Comparator|Vasopressin|Vasopressin 0.03 U/hour
88828333|NCT04322851||B-line positive|
88828334|NCT04322851||B-line negative|
88828335|NCT02991079|Active Comparator|Control: Lifestyle counseling|Counseling on physical activity and Mediterranean diet.
88828336|NCT02991079|Experimental|Intervention group|Add for three months a smartphone with an app (EVIDENT) to improve alimentation and physical activity, five cardio-health rides and feeding workshop.
88828337|NCT04320199|Experimental|Fermented Protaetia brevitarsis seulensis powder group|This group takes Fermented Protaetia brevitarsis seulensis powder for 8 weeks
88828338|NCT04320199|Placebo Comparator|Placebo group|This group takes placebo for 8 weeks
88828339|NCT00002961|Active Comparator|Total body irradiation|Total body irradiation 1200 centigray
88828340|NCT00002961|Active Comparator|Busulfan|Busulfan 16 doses
88828341|NCT05303077|Experimental|Study Infant Formula|Infant formula supplemented with omega 3 fatty acids and inactive Bifidobacteria
88828342|NCT05303077|Active Comparator|Infant Formula|Infant formula
88828343|NCT05303077|Active Comparator|Breastfeed Active comparator|Infants who are breastfed
88828344|NCT02448641|Experimental|SB623 Implant (2.5M)|2.5 million SB623 cells
88828345|NCT02448641|Experimental|SB623 Implant (5.0M)|5 million SB623 cells
88828346|NCT02448641|Sham Comparator|Sham Control|Sham surgery
89534117|NCT00043472||2|Eligible women with at least one intact ovary who have signed written, informed consent that they will undergo risk reducing surgery
88828347|NCT04744259|Experimental|Behavioural activation|The treatment is designed to be delivered to individuals alongside a carer who provides regular support to them. It is a structured, time limited, manualised psychological therapy, developed to treat those with an intellectual disability and depressive symptoms.
88828348|NCT04744259|No Intervention|Treatment as usual|This will include the existing treatments available in NHS and social care for adults with intellectual disability with depression, including anti-depressants, mood stabilizers, and any available psychological interventions. Additionally, for all those in the study, we will provide their General Practitioner with a summary of the NICE guidelines on treatment of depression for adults with intellectual disabilities.
88828349|NCT02450747|Experimental|Multifocal Test Contact Lens|Subjects will wear the etafilcon A Multifocal test lens in a daily wear modality.
88828350|NCT02248285|Experimental|Intervention|FilmArray™ GI Panel testing will be standard of care and provided at no cost. Additional testing may be ordered at the discretion of the clinician.
88828351|NCT02248285|No Intervention|Pre-intervention|Testing will be at the discretion of the clinician using standard laboratory tests, and specimens will be collected as appropriate for these methods.
88828352|NCT04330053|Experimental|Experimental|Information - Education about falls and Exercise for Fall Prevention
88828353|NCT04330053|Active Comparator|Control|Information - Education about falls without Exercise for Fall Prevention
88828354|NCT00383253|Experimental|10%|
89177641|NCT00814580|Experimental|001|Tapentadol IR First dose: one 50 mg capsule (a re-dose of 50 mg is permitted as soon as one hour after the first dose on Day 1 if needed) Subsequent doses: one or two capsules (50 mg or 100 mg) every 4 to 6 hours as needed
89534118|NCT00042614||Controls|Matched to patients for age, gender and race
89534119|NCT00042614||Patients|Who have had heart transplants, awaiting, or controls screened.
89534120|NCT00026650||1/Cohort 1|Patients who have received radiotherapy in the ROB and may or may not be officially entered on a clinical protocol.
89534121|NCT00018044||Patient Relatives|Blood relatives of enrolled patients
89534122|NCT00018044||Patients|Patients with mycobacterial infections
88828355|NCT00383253|Experimental|25%|
88828356|NCT00383253|Experimental|50%|
88828357|NCT00383253|Placebo Comparator|Control|
88828358|NCT04204837|Experimental|Nivolumab|Nivolumab will be given on Day 1 of every 14-day cycle (Q2W) at a dose of 240 mg as an IV infusion until progression, unacceptable toxicity or discontinuation for other reasons for up to 2 years.
88828359|NCT04204837|Experimental|Nivolumab plus Relatlimab|Patients wil receive a fixed-dose combination of nivolumab 480 mg and relatlimab 160 mg by intravenous infusion every four weeks (Q4W) (Group 2) for up to two years after initial dosing or until PD - or absence of investigator-assessed clinical benefit
88828360|NCT02240485|Experimental|Integrative Couple Treatment for Pathological Gambling (ICT-PG)|"Couple therapy: The experimental couple treatment is offered over 8 to 12 sessions of 90 minutes. The couple treatment called (Integrative Couple Treatment for Pathological Gambling - ICT-PG) is inspired by the Alcohol Behavior Couple Therapy from Epstein and McCrady, to which the team added diverse components to adjust to gamblers. During the sessions, the focus is on a) reducing/stopping gambling behaviors, b) helping the partner to stop behaviors facilitating gambling habits and rise the frequency of behaviors incompatible with gambling habits and c) improve marital components (communication, sharing positive moments, negotiation, mutual support)."
88828361|NCT02240485|Active Comparator|Usual individual/group treatment|Usual individual/group treatment: The control group receive individual or group treatment as already offered by the specialized centers in addiction.Their partner can receive individual intervention if desired.
88828362|NCT00003039|Experimental|Arm I|Patients receive treatment on an outpatient basis. Flavopiridol is administered as a continuous infusion over 72 hours every 2 weeks. Patients receive a minimum of 4 cycles of therapy unless unacceptable toxicity or disease progression occurs.
88828363|NCT04246203||Group A|Patients are allocated to group A according to preoperative presence of detectable ctDNA.
89534123|NCT00017914||Healthy Volunteer|Healthy subject who has not received anti-inflammatory medications and should not has undergone surgery or any major trauma within the 8 weeks prior to enrollment.
88828364|NCT04246203||Group B|Patients are allocated to group B according to preoperative absence of detectable ctDNA.
88828365|NCT02534649|Other|Experimental|Newly obtained biopsy and Blood samples collection
88828366|NCT00003045|Experimental|Hyperthermia|XRT and Hyperthermia Post-therapy evaluation PSA, Clinical Exam, and Prostate Biopsy ( @ 12 Months)
88828367|NCT02490813|Placebo Comparator|Control|This arm will receive the placebo.
88828368|NCT02490813|Experimental|Treatment - Chinese Herbal Formula - X|This arm will receive the Chinese Herbal Formula - CHFX as treatment to their existing fish, shrimp or crab allergy.
88828369|NCT03793881|Experimental|Nutritional Strategy|Nutritional counseling based on the quality of the diet, the Food Guide for the Brazilian Population and concepts of mindfulness and mindful eating; dietary guidance based on feasible goals built together (patient and nutritionist).
88828370|NCT03793881|Active Comparator|Dietary Prescription|Individualized dietary prescription according to the guidelines of the Brazilian Society of Cardiology.
88828371|NCT00003075|Experimental|Fenretinide|
88828372|NCT00003075|Placebo Comparator|Placebo|
88828373|NCT02348385||Healthy Tobacco Smokers|There is only one arm to the study. All subjects will receive amphetamine
88828374|NCT02348385||Healthy Nonsmokers|There is only one arm to the study. All subjects will receive amphetamine
88828375|NCT00003093|Experimental|Treatment|See detailed description.
88828376|NCT04149535|Experimental|TAVR with Sentinel|Patients assigned to this group will undergo TAVR with the Sentinel® Cerebral Protection System.
88828377|NCT04149535|No Intervention|TAVR without Sentinel|Patients assigned to this group will undergo TAVR without the Sentinel® Cerebral Protection System.
88828378|NCT00003099|Active Comparator|Arm 1 Tamoxifen + Fenretinide|Tamoxifen + Fenretinide daily for 14-28 days
88828379|NCT00003099|Placebo Comparator|Arm 2 Placebo|Placebo daily for 14-28 days
89534124|NCT00017914||Myositis Patient|Patient should have documented evidence that he/she meets criteria for an idiopathic inflammatory myopathy (IIM)
88828380|NCT04137445|Experimental|Study Provided Diet|A group of complementary foods provided to participants by researchers.
88828381|NCT04137445|Placebo Comparator|Traditional Diet|No study foods provided to participants by researchers. Participants will eat a typical diet provided by caregivers.
88828382|NCT02294799|Other|Intervention Group|TMD diagnosed sujects that will receive the mobilization treatment
88828383|NCT02294799|Placebo Comparator|Placebo Group|TMD diagnosed sujects that will receive the placebo treatment
88828384|NCT05228197||Calibration Stage|"Patients referred to hospital urology departments by their GP due to a clinical suspicion of prostate cancer (elevated serum prostate specific antigen [PSA], abnormal feeling prostate on rectal examination). These patients are normally recommended to undergo a prostate MRI as part of standard care.~Patients will need to meet the Inclusion/Exclusion criteria but in addition, purposive identification of cases with a variety and representative sample of different pathology features are needed for this stage (e.g. normal glands, cancer glands, high-grade PIN, inflammation)."
88828385|NCT05228197||Validation Stage|"Patients referred to hospital urology departments by their GP due to a clinical suspicion of prostate cancer (elevated serum prostate specific antigen [PSA], abnormal feeling prostate on rectal examination). These patients are normally recommended to undergo a prostate MRI as part of standard care.~Patients will need to meet the Inclusion/Exclusion."
88828386|NCT04329897|Experimental|Software Messaging|Acceptance and Commitment Therapy Subjects randomizing into this arm received the study intervention that consisted of twice-daily, AM and PM, text messages starting on postoperative day one and ending on postoperative day fourteen. Subjects were only required to read these messages, which utilized the principles of Acceptance and Commitment therapy
88828387|NCT04329897|No Intervention|Control|Subjects randomizing into this arm did not receive the text message study intervention.
88828388|NCT00003117|Experimental|Paclitaxel|Patients receive paclitaxel IV over 3 hours on day 1 of each course. Treatment is repeated every 21 days for 6 courses in the absence of tumor progression or unacceptable toxicity. Quality of life assessments are conducted before treatment and at 2, 6, 9, and 12 months. Patients are followed every 3 months for 2 years, then every 6 months until disease progression or death.
89177642|NCT00814580|Active Comparator|002|Oxycodone IR First dose: one 5 mg capsule (a re-dose of 5 mg is permitted as soon as one hour after the first dose on Day 1 if needed Subsequent doses: one or two capsules (5 mg or 10 mg) every 4 to 6 hours as needed
89534125|NCT00017914||Non-Myositis Patient|Patients with other myopathies/autoimmune diseases/complications similar to myositis patients. Close relatives of IIM patients (affected or unaffected siblings, children, parents, grandparents)
89534126|NCT00007150|Other|1/HH patients|HH patients
89534127|NCT00006518||1|Participants with HIV infection, KSHV infection, or with cancer
89534128|NCT00005902||1|250 subjects with von Hippel-Lindau (VHL) disease.
88828389|NCT00003117|Experimental|Paclitaxel + Carboplatin|Patients receives paclitaxel as in Arm I, followed by carboplatin IV over 1 hour. Treatment is repeated every 21 days for 6 courses in the absence of tumor progression or unacceptable toxicity. Quality of life assessments are conducted before treatment and at 2, 6, 9, and 12 months. Patients are followed every 3 months for 2 years, then every 6 months until disease progression or death.
88828390|NCT02240329|Other|Individuals with TBI|Individuals who have sustained a traumatic brain injury during the previous five years. Will have the following tests performed: Neuropsychological Testing and Measures of TBI severity; Cough and respiratory measures (including Maximum Respiratory Pressures); and Capsaicin cough sensitivity testing.
88828391|NCT04329741|Experimental|Intervention|6-week basic dog obedience training course
88828392|NCT04329741|No Intervention|Control|Waitlist control
88828393|NCT02241811|Placebo Comparator|Control|After wound dressing we applied hydrogel without any active ingredient everyday for two months. The same doctor observed and took photo of the wounds every week in the outpatients clinic.
88828394|NCT02241811|Experimental|3% Sodium Pentaborate Pentahydrate|For the interventional group after wound dressing we applied hydrogel with 3% Sodium pentaborate pentahydrate everyday for two months. The same doctor observed and took photo of the wounds every week in the outpatients clinic.
88828395|NCT03739905|Experimental|Blood Brain Barrier (BBB) Disruption|The ExAblate Model 4000 Type 2.0 System
88828396|NCT03965923|Experimental|Cohort 1: Dapivirine (DPV) Vaginal Ring (VR)|Participants in Cohort 1 (36 0/7 weeks - 37 6/7 weeks) will use one DPV VR continuously for approximately one month, replacing the DPV VR each month. Participants will use the DPV VR until their pregnancy outcome but no later than 41 6/7 weeks of gestation.
88828397|NCT03965923|Experimental|Cohort 1: Truvada Tablet|Participants in Cohort 1 (36 0/7 weeks - 37 6/7 weeks) will take one Truvada oral tablet daily. Participants will take Truvada until their pregnancy outcome but no later than 41 6/7 weeks of gestation.
88828398|NCT03965923|Experimental|Cohort 2: Dapivirine (DPV) Vaginal Ring (VR)|Participants in Cohort 2 (30 0/7 weeks - 35 6/7 weeks) will use one DPV VR continuously for approximately one month, replacing the DPV VR each month. Participants will use the DPV VR until their pregnancy outcome but no later than 41 6/7 weeks of gestation.
88828399|NCT03965923|Experimental|Cohort 2: Truvada Tablet|Participants in Cohort 2 (30 0/7 weeks - 35 6/7 weeks) will take one Truvada oral tablet daily. Participants will take Truvada until their pregnancy outcome but no later than 41 6/7 weeks of gestation.
88828400|NCT03965923|Experimental|Cohort 3: Dapivirine (DPV) Vaginal Ring (VR)|Participants in Cohort 3 (12 0/7 weeks - 29 6/7 weeks) will use one DPV VR continuously for approximately one month, replacing the DPV VR each month. Participants will use the DPV VR until their pregnancy outcome but no later than 41 6/7 weeks of gestation.
88828401|NCT03965923|Experimental|Cohort 3: Truvada Tablet|Participants in Cohort 3 (12 0/7 weeks - 29 6/7 weeks) will take one Truvada oral tablet daily. Participants will take Truvada until their pregnancy outcome but no later than 41 6/7 weeks of gestation.
89177643|NCT00643162|Experimental|Swedish Massage|Adding massage twice a week, for 8 weeks, and Lexapro in the treatment of depression.
88828402|NCT03962725|Active Comparator|Control Group (C)|Endotracheal intubation would be facilitated by either Rocuronium (0.6-1mg kg-1) or Succinylcholine (1-1.5mg kg-1) and further dosing of Rocuronium would be left at the discretion of the anesthesia team members. Choice and technique of induction and maintenance of anesthesia, use of vasopressors, perioperative antibiotics, analgesics/adjunct regional techniques, prophylaxis for postoperative nausea and vomiting, fluid and blood component therapy would be left at the discretion of the anesthesia team. Neuromuscular blockade would be reversed with either Sugammadex or Neostigmine (based on institutional availability) and trachea would be extubated once patient meets criteria per attending anesthesiologist.
89177644|NCT00643162|Sham Comparator|Light-Touch|Adding light touch twice a week, for 8 weeks, and Lexapro in the treatment of depression.
89177645|NCT00643006|Experimental|A. High intensive exercise|High intensive exercise
89177646|NCT00643006|Active Comparator|B. Low-intensive exercise|Low-to-moderate intensive supervised walks
89177647|NCT00814502|Active Comparator|Zolpidem CR|Subjects randomized to Zolpidem CR
89177648|NCT00814502|Placebo Comparator|Placebo|Subjects randomized to Placebo
89000656|NCT04658719|Experimental|Camstent Coated Catheter|The patented 'M4D coating' is applied to inner and outer surfaces using a 'dip/dry' process before sterilisation, creating a safe, inert, and long-lasting finish. The coating reduces friction of the catheter surface, enhancing patient comfort on insertion and withdrawal. It also incorporates the materials which virtually preclude biofilm formation. The coating doesn't elute antibacterial agents or toxins, avoiding the build-up of dead bacteria on the device surface and retaining effectiveness throughout extended use (NB. Effectiveness is not lost because of leaching away of an active antimicrobial agent). Finally, the absence of anti-bacterial moieties means that the healthy microbial flora is not disturbed.
89000657|NCT04658719|Active Comparator|Standard Care|Foley catheter, uncoated
89000658|NCT00200265|Experimental|1|Behavioral: diet
89000659|NCT00200265|Experimental|2|Behavioral: diet
89000660|NCT00200265|Placebo Comparator|3|Behavioral: diet
89000661|NCT04658563|Experimental|Group 1: Yoga|High-density HY training; average 90-110 minutes, 2 sessions per week under the supervision of the physiotherapist, once a week as a home program, will be applied for a total of 8 weeks to the first group.
89000662|NCT04658563|No Intervention|Group 2: Control|Individuals in the second group will not included in any exercise training program
89000663|NCT04658602|Active Comparator|Direct composite restoration|Bulk-fill composite (Filtek bulk flow, 3M Espe ) will be used and covered using a nanohybrid copmosite (filtek XT, 3M Espe )
89000664|NCT04658602|Active Comparator|Preformed metal crowns|Preformed stainless-steal crowns cemented by glass ionomer lutting cement (ketac cem. 3M Espe )
89000665|NCT00408161|Active Comparator|1|prize contingency management (CM) plus standard case management treatment -- patients earn the chance to win prizes by submitting negative breath samples and by complying with steps toward treatment goals
89000666|NCT00408161|Active Comparator|2|standard case management treatment
89000667|NCT00557518|Active Comparator|1|
89000668|NCT00557518|Placebo Comparator|2|
89000669|NCT00557557|Experimental|IHP with Oxaliplatin and 5-Fluorouracil (5-FU)|Isolated Hepatic Perfusion with Oxaliplatin and 5-Fluorouracil (5-FU)
89000670|NCT04657978||Substrate guided intervention arm|Participants recruited to the study will undergo High Density Wave Solution™ guided substrate mapping of the left atrium. Ablation will thereafter be performed to comprise wide area circumferential ablation of the pulmonary veins in pairs, followed by ablation of low voltage zones in the left atrium.
89000671|NCT04658134|Experimental|Glycine supplementation|Glycine supplementation
89000672|NCT04658212|Experimental|3D LCBDE group|
89000673|NCT04658212|Active Comparator|ERCP group|
89000674|NCT04658017|Experimental|GARNET device|All enrolled subjects will receive treatment with the GARNET device.
89177649|NCT00653224|Placebo Comparator|Placebo|Matched placebo tablets
89177650|NCT00653224|Experimental|LCTZ|5 mg tablet
89177651|NCT00444925|Experimental|Fesoterodine|Tablets
89177652|NCT00444925|Placebo Comparator|Placebo|Tablets and capsules
89000675|NCT04658056||WATER AQUABEAM Robotic System cohort|WATER Study subjects previously-treated with Aquablation of the prostate with the AQUABEAM Robotic System for lower urinary tract symptoms associated with BPH.
89000676|NCT04658056||WATER TURPS cohort|WATER Study subjects previously-treated with standard transurethral resection of the prostate (TURP) for lower urinary tract symptoms associated with BPH.
89000677|NCT04657744|Experimental|A test|Test drug (Sphingomod ) 1 capsule contains 0.5 mg Fingolimod
89000678|NCT04657744|Active Comparator|B reference|Reference drug (Gilenya) 1 capsule contains 0.5 mg Fingolimod
89000679|NCT04657627|Experimental|PACE plus calorie information intervention group|PACE plus calorie information intervention group will receive PACE plus calorie information of discretionary foods via social media posts.
89000680|NCT04657627|Active Comparator|Calorie-only information comparator group|Calorie-only information comparator group will receive calorie-only information of discretionary foods via social media posts.
89000681|NCT04657471|Experimental|revised HOMe-CoV|Revised HOME-CoV
89000682|NCT04657510||Proximal femur fracture AND COVID-19|Surgical treatment of femur fracture
89000683|NCT04657510||Proximal femur fracture NO COVID|Surgical treatment of femur fracture
89000684|NCT04657237|No Intervention|control group|all patients will receive general anesthesia and will receive intravenous paracetamol (1 g) before skin closure and then given every 6 hrs in the 1st postoperative day
89000685|NCT04657237|Active Comparator|TPVB group|Patients will receive total volume (20 ml) 0.25% bubivicaine divided equally at each level of T4 and T6 at thoracic paravertebral space then they will recive general anesthesia.
89000686|NCT04657042||Healthy|Healthy volunteers from the local community
89000687|NCT04657042||Liver cancer|Patients undergoing radiotherapy for liver cancer
89000688|NCT04657042||Lung cancer|Patients undergoing radiotherapy for lung cancer
89000689|NCT04656886|Experimental|Ketalar|0.5mg/kg of ketalar (ketamine). Single, intravenous, steady state infusion over 40min.
89000690|NCT04656886|Placebo Comparator|Saline|Single, intravenous, steady state infusion over 40min.
89000691|NCT04656808|Experimental|Guilt focused intervention|Following literature on factors associated with guilt experiences in caregivers (Gonyea et al., 2008; Gallego-Alberto et al., 2019; Losada et al., 2014; Prunty & Foli, 2019; Romero-Moreno et al., 2014; Spillers et al., 2008) and previous intervention studies testing an Acceptance and Commitment Therapy intervention for dementia family caregivers (Losada et al., 2015; Márquez-González et al., 2020), a guilt focused intervention was specifically designed for caregivers who experienced high levels of guilt and emotional distress. The program is based on CBT (Márquez-González et al., 2007) and Acceptance and Commitment Therapy (ACT) approaches (Losada et al., 2005; Márquez-González et al., 2010), combined with techniques of Compassion-Focused Therapy (CFT; Gilbert, 2009), which were adapted to work with guilt experienced by family dementia caregivers.
89177653|NCT00444925|Active Comparator|Tolterodine|Capsules
89177654|NCT00641056|Experimental|1|
89177655|NCT00641056|Active Comparator|2|
89177656|NCT00814346|Active Comparator|EGb 120 mg|
89177657|NCT00814346|Placebo Comparator|Placebo|
89177658|NCT00809224||ALS|ALS group should have ALS.
89177659|NCT00809224||Control|The control group should not have ALS or any other neurological/psychiatric disorder, and must be over the age of 40.
88828403|NCT03962725|Experimental|No Relaxant Group (NR)|Endotracheal intubation would be facilitated by Succinylcholine (1-1.5mg/kg) or Remifentanil (1-2mcg kg-1) if Succinylcholine use is contraindicated. No non-depolarizing NMBA would be administered to the patients randomized to the NR group. Choice and technique of induction and maintenance of anesthesia, use of vasopressors, perioperative antibiotics, analgesics/adjunct regional techniques, prophylaxis for postoperative nausea and vomiting, fluid and blood component therapy would be left at the discretion of the anesthesia team. Use of deeper plane of inhaled anesthetics or adjuncts (opioids, propofol, dexmedetomidine or ketamine) either as boluses or infusion would be recommended in case of sustained high peak airway pressures (>35mm Hg), high intra-abdominal pressure, involuntary patient/diaphragmatic movement hindering surgical exposure and dissection. Choice and dose of adjunct/s to optimize operating conditions would be left to the discretion of the anesthesia team.
88828404|NCT03820219|Placebo Comparator|Standard sterile wound dressing|Standard wound care involves the application of an occlusive dressing in the operating room, a dressing change on Post-operative Day 3 and then dressing changes as needed until suture/staple removal on Post-operative Day 14.
88828405|NCT03820219|Active Comparator|Prevena™ system|The Prevena™ System is indicated for use over clean, closed incisions that continue to drain following sutured or stapled closure. It acts by removing exudate, helping hold the edges of the incision together, protecting the surgical site from external contamination in a clean, protected postoperative wound environment, until it is removed at Post-Operative Day 7.
88828406|NCT03775837|Experimental|Panax Ginseng C.A. Mey Extract group|This group takes Panax Ginseng C.A. Mey Extract for 8 weeks
88828407|NCT03775837|Placebo Comparator|Placebo group|This group takes placebo for 8 weeks
88828408|NCT02251561|Experimental|FID 109182|Senofilcon A contact lens pre-soaked in FID 109182 worn in the right or left eye as randomized for 2 hours
88828409|NCT02251561|Active Comparator|Opti-Free Plus|Senofilcon A contact lens pre-soaked in Opti-Free Plus worn in the fellow eye for 2 hours
88828410|NCT05077345||1/Venous blood sampling|The vessel was determined for cannulation and an anatomical tourniquet was applied. Skin antiseptic was prepared. The plastic wings of the winged angioket were held open. The skin over the vein to be accessed was stretched with the fingers of the free hand. The needle was inserted into the skin a few millimeters distal to the point to be inserted, and the blood was vascularized until the education. The cannula was advanced by retracting the stylet. The tourniquet was removed and the cannula was fixed.
88828411|NCT05077345||2/Heel puncture|The skin was prepared with an antiseptic. The baby's heel was placed at an angle between the thumb and forefinger, with the other fingers grasping the ankle from behind. Pressure was applied to the back of the ankle with the other fingers by taking support against the thumb. The first drop of blood was wiped with sterile gauze by inserting the needle, and the next drops of blood were absorbed into the paper by touching the middle of the ring on the filter paper. An adhesive bandage was applied by applying pressure to the puncture site.
88828412|NCT05077345||3:Orogastric Catheter insertion|The head of the bed was raised and the newborn was placed on his back. The midpoint distance from the tip of the nose to the ear, xiphoid and umbilicus was measured to determine the insertion length. With one hand, the infant's mouth was opened while his head was stabilized. With the other hand, the MV probe was advanced to the specified depth. The position of the OG probe was confirmed and fixed.
88828413|NCT05077345||4:Umbilical Catheter insertion|The system was filled with liquid by connecting the tap to the UK. The faucet was turned off, sterile gauze was placed around the umbilical clamp and lifted out of the sterile area. The other assistant held the cord with a clamp and lifted it vertically up and away from the sterile field. The cord and its surroundings were prepared with an antiseptic solution and covered. The umbilicus was tied with a single knot and the cord was cut horizontally with a scalpel. Bleeding on the surface of the cord was wiped with sterile gauze. The cord stump was grasped with toothed forceps close to the vessel to be catheterized. The catheter was placed in the lumen of the vessel and advanced in the vessel. When the catheter exceeded 5 cm, it was aspirated to confirm the intraluminal position. The blood that came with an average of 0.5 ml bolus solution was cleaned and the catheter was fixed.
88828414|NCT05077345||5:Tracheal Intubation|The head of the infant was positioned in the midline, slightly extended, with the chin up. The head was stabilized with the right hand by turning on the light of the laryngoscope. The blade of the laryngoscope was inserted by sliding the blade over the tongue until the tip of the blade rested on the Vallecula. The blade of the laryngoscope was slid up to open the mouth even more. The other assistant gently dipped it into the suprasternal notch. The concave edge of the tube was held with the right hand, and it was advanced approximately 2 cm, passing it between the vocal cords when the vocal cords and trachea were seen.
88828415|NCT02210559|Experimental|FG-3019 + Gemcitabine + Nab-paclitaxel|Participants will receive FG-3019 35 milligrams (mg)/kilogram (kg) by intravenous (IV) infusion on Days 1 and 15 of each treatment cycle and on Day 8 of the first cycle, gemcitabine 1000 mg/square meter (m^2) and nab-paclitaxel 125 mg/m^2 by IV infusion on Days 1, 8, and 15 of each treatment cycle. Treatment will be administered over a 28-day cycle, for up to 6 cycles.
88828416|NCT02210559|Active Comparator|Gemcitabine + Nab-paclitaxel|Participants will receive gemcitabine 1000 mg/ meter squared (m^2) and nab-paclitaxel 125 mg/m^2 by IV infusion on Days 1, 8, and 15 of each treatment cycle. Treatment will be administered over a 28-day cycle, for up to 6 cycles.
89177660|NCT00828464|Experimental|clobetasol propionate foam|All subjects receive clobetasol propionate
89177661|NCT00816712|Active Comparator|A|Testosterone - 300 mg IM
89177662|NCT00816712|Active Comparator|B|Testosterone - 100 mg IM
89177663|NCT00816712|Placebo Comparator|C|Placebo - IM
89357077|NCT05258578|Experimental|Tele-CBT Group|"Participants will receive 6 weekly Tele-CBT sessions and 1 final booster session 1 month later, all approximately 55-minutes in duration. Briefly, the Tele-CBT sessions focus on introducing the cognitive behavioural model of overeating and obesity, scheduling healthy meals and snacks, scheduling pleasurable alternative activities to overeating, identifying and planning for difficult eating scenarios, and problem solving and challenging negative thoughts. Participants are encouraged to complete CBT homework between sessions (i.e., completing food records, pleasurable activities and worksheets). Five clinical psychology graduate students will work as study therapists under the supervision of Drs. Cassin and Sockalingam and will have biweekly case supervision meetings."
89534129|NCT00004847|Experimental|Adults or children with suspected PHEO/PGL|Patients are adults or children of any age with known, sporadic or familial PHEO/PGL
88828417|NCT02991001|Experimental|Normal saline hydrodissection|Ultrasound-guided hydrodissection with normal saline between carpal tunnel and median nerve.
88828418|NCT02991001|Placebo Comparator|Normal saline|Ultrasound-guided injection with normal saline at subcutaneous layer beyond the carpal tunnel region
88828419|NCT03724357|Experimental|Vaccination with Oral Cholera Vaccine (Vaxchora)|Volunteers receive immunization with Vaxchora cholera vaccine. Blood draws are performed at subsequent visits.
88828420|NCT02135679||Cohort 1|Patients with early stage NSCLC undergoing stereotactic radiotherapy
88828421|NCT02135679||Cohort 2|Patients with locally advanced NSCLC undergoing standard chemoradiotherapy
88828422|NCT02135679||Cohort 3|Patients with stage I-III NSCLC undergoing standard, fractionated radiotherapy alone
88828423|NCT02135679||Cohort 4|Patients with locally advanced NSCLC undergoing standard chemoradiotherapy with the novel signal transduction inhibitor, nelfianvir.
88828424|NCT02135679||Cohort 5|Patients with resectable stage IIIa NSCLC undergoing pre-operative chemoradiotherapy
88828425|NCT02135679||Cohort 6|(Patients with suspected (no tissue diagnosis) early stage NSCLC undergoing stereotactic radiotherapy)
88828426|NCT03546205|Experimental|Group 1: JNJ-64565111|Participants with normal renal function and no evidence of kidney damage (estimated glomerular filtration rate [eGFR] greater than or equal to [>=] 90 milliliter/minute [mL/min]) will be enrolled. Participants will receive a single subcutaneous (SC) dose of JNJ-64565111 on Day 1.
88828427|NCT03546205|Experimental|Group 2: JNJ-64565111|Participants with mild renal impairment (eGFR 60 to less than [<] 90 mL/min) will be enrolled. Participants will receive a single SC dose of JNJ-64565111 on Day 1.
88828428|NCT03546205|Experimental|Group 3: JNJ-64565111|Participants with moderate renal impairment (eGFR 30 to <60 mL/min) will be enrolled. Participants will receive a single SC dose of JNJ-64565111 on Day 1.
89534130|NCT00004738||Family Members|At least 2 family members of a patient with a confirmed diagnosis of Chiari I malformation.
88828429|NCT03546205|Experimental|Group 4: JNJ-64565111|Participants with severe renal impairment (eGFR <30 mL/min) will be enrolled. Participants will receive a single SC dose of JNJ-64565111 on Day 1.
88828430|NCT03546205|Experimental|Group 5: JNJ-64565111|Participants with end-stage renal disease (requiring hemodialysis 3 times per week for at least 3 months before screening; eGFR will not be calculated) will be enrolled. Participants will receive a single SC dose of JNJ-64565111 on Day 1.
88828431|NCT03731559|Active Comparator|DTG 50 mg OD with food|DTG 50 mg OD with food plus 2NRTIs in HIV/TB co-infected patients receiving RIF based anti-TB therapy.
88828432|NCT03731559|Active Comparator|DTG 50 mg BID|DTG 50 mg BID plus 2NRTIs in HIV/TB co-infected patients receiving RIF based anti-TB therapy.
88828433|NCT03728127|Experimental|DicaBr group and nuts (DCBN)|Brazilian cardioprotective diet plus 30g/day of mixed nuts (10g of peanuts, 10g of cashew nuts and 10g of Brazil nuts)
88828434|NCT03728127|Active Comparator|DicaBr group (DCB)|Brazilian cardioprotective diet
88828435|NCT03507673||Progynova/Dydrogesterone|
88828436|NCT03507673||Spontaneous cycle|
88828437|NCT03507673||Progynova/Crinone|
88828438|NCT03507673||Others Medication|
88828439|NCT04943575|Active Comparator|Intervention 1|EZC Pak
88828440|NCT04943575|Active Comparator|Intervention 2|EZC Pak+D
88828441|NCT04943575|Placebo Comparator|Placebo|
89177664|NCT00818194|Experimental|A. tacrolimus first|Subjects receive extended release tacrolimus in first dosing interval then cross over to cyclosporine A for second dosing interval
89177665|NCT00818194|Experimental|B. cyclosporine first|Subjects receive cyclosporine A in first dosing interval then cross over to extended release tacrolimus for second dosing interval
89177666|NCT00816010|Experimental|1|Lifestyle and compliance counseling via telephone contact with structured set of questions and reinforcements provided
88828442|NCT00003141|Experimental|Treatment (combination chemotherapy, PBSC transplant)|Pts undergo conventional surgery for diagnosis & max tumor resection. In 6 wks of surgery or when stable pts begin induction chemotherapy(cisplatin IV over 6 hrs on day 0; vincristine sulfate IV on days 0,7,14; cyclophosphamide IV over 1 hr on days 1-2; and etoposide IV over 1 hr on days 0-2. 24 hrs after the last cyclophosphamide dose, pts receive filgrastim (G-CSF) & undergo peripheral blood stem cell harvest 2 days later. Treatment repeats every 21 days for up to 3 crs. Within 6 wks after induction, pts receive consolidation (carboplatin IV over 2 hrs on days 0-1 next esc. doses of thiotepa IV over 2 hrs. Pts undergo peripheral blood stem cell transplantation 48 hrs after last thiotepa dose. Pts receive G-CSF SC daily on days 3-21. Treatment repeats every 21 days for up to 3 crs. Pts with dose-limiting toxicity due to thiotepa are removed from study. Pts are followed at 4 wks, 3 mths for 1 yr, 6 mths for 3 yrs, annually for 3 yrs or until relapse.
88828443|NCT04937959||Arm 1: MCI amyloid positive|"Meet the National Institute of Aging - Alzheimer's Association (NIA-AA) core clinical criteria (2011) for MCI due to Alzheimer's~Positive amyloid PET or amyloid CSF status.~MMSE 23-30 (inclusive)"
88828444|NCT04937959||Arm 2: MCI amyloid negative|"Non-AD Mild Cognitive Impairment (MCI)~Negative amyloid PET or amyloid CSF status.~MMSE 23-30 (inclusive)"
88828445|NCT04937959||Arm 3: CN amyloid positive|"Absence of a diagnosis of cognitive disorder and/or subjectively reported cognitive decline~Positive amyloid PET or amyloid CSF status.~MMSE 26-30 (inclusive)"
88828446|NCT04937959||Arm 4: CN amyloid negative|"Absence of a diagnosis of cognitive disorder and/or subjectively reported cognitive decline~Negative amyloid PET or amyloid CSF status.~MMSE 26-30 (inclusive)"
88828447|NCT00003147|Experimental|Arm I|Patients receive adenovirus p53 construct by percutaneous injection to a maximum of two lesions on day 1. Treatment is repeated every 28 days for up to 6 courses. In the absence of dose-limiting toxicity (DLT) in the first cohort of 6 patients treated, subsequent cohorts of 6 patients each receive escalating doses of the drug on the same schedule. If DLT occurs in 2 of 6 patients at a given dose level, then dose escalation ceases and that dose is declared the maximum tolerated dose. Study treatment may continue in the absence of disease progression and unacceptable adverse events.
88828448|NCT04867135||No Sepsis / Sepsis|To compare amikacin PK / PD models of newborns with a confirmed diagnosis of sepsis (clinical or microbiological) and with ruled out sepsis.
88828449|NCT02249455|Experimental|Acapella|Acapella is given to the patients twice daily for 20 min.
88828450|NCT02249455|Experimental|ELTGOL|Expiration with open glottis in lateral position is done twice daily for 20 min
88828451|NCT02249455|Active Comparator|conventional physiotherapy|Conventional physiotherapy like breathing exercise, active coughing, chest mobilisation was encouraged twice daily for 20 min.
88828452|NCT01738321||Cardiac patients|Patients undergoing cardiac surgery
88828453|NCT01738321||Non-cardiac patients|Patients undergoing any surgery other than cardiac surgery
88828454|NCT01740817|Experimental|Intralipid 20%, then saline|Participants first received lipid infusion of 30ml/h x48h. After a washout period of 4-6 weeks, they then received saline infusion of 30ml/h x48h.
88828455|NCT01740817|Experimental|Saline, then Intralipid|Participants first received saline infusion of 30ml/h x48h. After a washout period of 4-6 weeks, they then received lipid infusion of 30ml/h x48h.
88828456|NCT01742065|No Intervention|Usual Care|Clinics in usual care will go about clinic practices to complete recommended screening for colorectal cancer.
88828457|NCT01742065|Active Comparator|Auto Plus|Clinics randomized to the Auto-Plus arm will engage in all activities (send an introductory letter to participants, then a FIT Kit, then a reminder letter encouraging the return of the FIT Kit) in addition to a PDSA (Plan Do Study Act) cycle to refine or improve their process.
88828458|NCT05642065|Experimental|Arm 1|Participants will undergo lower extremity movement assessment on the Forward Step Down Test before and after a home exercise program (HEP) consisting of five hip activation exercises. These exercises will be performed 2x/week for 8 weeks. Surface EMG of the gluteus maximus and medius, in addition to tracking of participant compliance on the HEP program will also be assessed pre- and post-intervention.
88828459|NCT04633993|Experimental|PCSMP|Patient-centered self-management program for patients with hypertensive nephropathy into 4 units, including: Unit 1: hypertensive nephropathy brief introduction and complications. Unit 2: dietary precautions for patients with hypertensive nephropathy. Unit 3: medication treatments for patients with hypertensive nephropathy. Unit 4: the content included stress management (emotional control, spiritual support). This program was implemented in small groups with 5-10 patients. This study used patient-centered self-management group activity manual as the tool. The group activities with 4 units lasting for 400 minutes were expected to be designed. The group activities were expected to last for 4 weeks and be implemented once per week and 100 minutes per time (including: 90 minutes of group discussion and 5-10 minutes of video-waring).
88828460|NCT04633993|No Intervention|Usual Care|Routine care.
88828461|NCT04581343|Experimental|Canakinumab, spartalizumab, nab-paclitaxel and gemcitabine|Spartalizumab (PDR001),IV infusion, 400 mg, D1 of each 28-day cycle; Canakinumab (ACZ885), s.c. injection, 250 mg, Day 1 of each 28- day cycle; Gemcitabine, IV Infusion, 1000 mg/m2, Days 1, 8, 15 of each 28-day cycle; Nab-paclitaxel, IV Infusion, 125 mg/m2, Days 1, 8, 15 of each 28-day cycle.
88828462|NCT04565743|Active Comparator|Intervention|Multiprofessional education for health professionals in primary care on secondary prevention of osteoporotic fractures. Identification and referral of patients with recent osteoporotic fracture.
88828463|NCT04565743|No Intervention|Control|No intervention from study. No restrictions regarding education or the local organization of care for the prevention of osteoporotic fractures.
88828464|NCT01743859|Experimental|Azacitidine + Lenalidomide + Off Therapy|Patients will receive 7 days of azacitidine followed by 3 weeks of lenalidomide. They will then have 2 weeks off therapy, for a maximum of 12 cycles.
88828465|NCT01746043|Experimental|Armodafinil + Placebo|Armodafinil 150 mg by mouth once a day for 6 weeks. Placebo 1 capsule by mouth 2 times a day for 6 weeks. Intervention agents start the day of CXRT, or within 5 days of the start CXRT, and continue for a total of 6 weeks. Completion of symptom questionnaires before chemoradiation and then 1 time a week during Weeks 1-10 of the study. Questionnaire take up to 5 minutes to complete.
89177667|NCT00816010|No Intervention|2|Control arm with usual care as per local hospital practice
89534131|NCT00004738||Patients|Patient with a confirmed diagnosis of Chiari I malformation who has a family member with syringomyelia or Chiari I malformation
89177668|NCT02610686|Other|Chloroquine|Single treatment arm
88828466|NCT01746043|Experimental|Minocycline + Placebo|Minocycline 100 mg by mouth 2 times a day for 6 weeks. Placebo 1 capsule by mouth 2 times a day for 6 weeks. Intervention agents start the day of CXRT, or within 5 days of the start CXRT, and continue for a total of 6 weeks. Completion of symptom questionnaires before chemoradiation and then 1 time a week during Weeks 1-10 of the study. Questionnaire take up to 5 minutes to complete.
88828467|NCT01746043|Experimental|Armodafinil + Minocycline|Armodafinil 150 mg by mouth once a day for 6 weeks. Minocycline 100 mg by mouth 2 times a day for 6 weeks.Intervention agents start the day of CXRT, or within 5 days of the start CXRT, and continue for a total of 6 weeks. Completion of symptom questionnaires before chemoradiation and then 1 time a week during Weeks 1-10 of the study. Questionnaire take up to 5 minutes to complete.
88828468|NCT01746043|Placebo Comparator|Placebos|Placebo 1 capsule by mouth 2 times a day for 6 weeks. Intervention agents start the day of CXRT, or within 5 days of the start CXRT, and continue for a total of 6 weeks. Completion of symptom questionnaires before chemoradiation and then 1 time a week during Weeks 1-10 of the study. Questionnaire take up to 5 minutes to complete.
88828469|NCT05635903|Experimental|Continuous nebulisation 0.9% saline Aerogen Solo vibrating mesh Nebuliser|Continuous nebulization of 0.9% normal saline using the Aerogen Solo Nebuliser (50mls/24h continuous infusion using a syringe pump)
88828470|NCT05635903|Experimental|Intermittent nebulisation 0.9% saline Aerogen Solo vibrating mesh Nebuliser|Intermittent nebulization of 0.9% normal saline using the Aerogen Solo Nebuliser (5mls 0.9% normal saline nebulised every 6 hours)
89357078|NCT05258578|Active Comparator|Self-Help Resources Group|Participants will be directed to the CAMH COVID-19 Self-Help webpage (www.camh.ca/covid19) to access coping tools to help with COVID-19 associated stress and anxiety, loss, grief and healing, stigma, and physical isolation. Participants in the control arm will receive weekly check-in/reminder emails for the duration of the intervention period.
88828471|NCT05635903|Active Comparator|Intermittent standard nebulisation of 0.9% saline Intersurgical Cirrus 2 self sealing Jet Nebuliser|Intermittent standard nebulization of 0.9% normal saline using the Intersurgical Cirrus 2 self-sealing Jet Nebuliser ((5mls 0.9% normal saline nebulised every 6 hours)
88828472|NCT01746511|Active Comparator|Glycerin Suppository|"Based on our institution's protocol, infant will receive a glycerin shave within one hour of initiation of phototherapy and then every eight hours while under phototherapy.~Subjects will be block randomized (varying block sizes of 2 to 8). Babies in both groups will be fed according to NICU standard birth weight protocols. Stratified enrollment will occur with 2 separate groups:~Infants who are NPO (< 20 mL/kg/day of fluids enterally at the time of therapy) vs.~Those being enterally fed at least 20 mL/kg/day of total fluids at the time of therapy."
88828473|NCT01746511|Experimental|No Glycerin Suppository|"Infants will receive no scheduled glycerin suppositories, while under phototherapy (unless otherwise directed by attending physician).~Subjects will be block randomized (varying block sizes of 2 to 8). Babies in both groups will be fed according to NICU standard birth weight protocols. Stratified enrollment will occur with 2 separate groups:~Infants who are NPO (< 20 mL/kg/day of fluids enterally at the time of therapy) vs.~Those being enterally fed at least 20 mL/kg/day of total fluids at the time of therapy."
88828474|NCT01746745|Experimental|[^14C]-LY2940680|Single 100 milligram (mg) dose of LY2940680 containing 100 microCuries of carbon-14-labeled LY2940680 ([^14C]-LY2940680)
88828475|NCT01746979|Active Comparator|Gemcitabine plus TH-302|
88828476|NCT01746979|Placebo Comparator|Gemcitabine plus placebo|
88828477|NCT04552171|Experimental|Access to Game Plan app and 24-hour helpline|Participants in this condition will be provided access to the Game Plan app and encouraged to use it after they complete their baseline assessments and STI testing has been completed. These participants will also be provided with access to a 24-hour helpline that provides free HIV/STI test counseling, which they can elect to use or not.
88828478|NCT04552171|No Intervention|Access to a 24-hour helpline|"Participants in this condition will be provided access to a 24-hour helpline that provides free HIV/STI test counseling, which they can elect to use or not. Use of this comparison condition is intended to provide a real-world test of the added benefit of using Game Plan, above and beyond the current standard of care for HIV/STI self-testing, which involves providing users with access to a 24-hour helpline."
88828479|NCT05631535|Experimental|Intervention with a very low-energy diet|
88828480|NCT05631535|Active Comparator|Control group|
88828481|NCT01748227|Other|Peer-Coached Pain Self-Management|Participants (n=20) were assigned to a peer coach, who delivered self-management instruction one-on-one over a 4-month period.
88828482|NCT01748695|Experimental|Placebo followed by V158866|Placebo once per day for 4 weeks followed by V158866 450mg once per day for 4 weeks
89357079|NCT05243537||QTc time interval in former preterm neonates, or term born healthy controls|former preterms and healthy term controls are defined as described in the cohort as previously published (Salaets et al, Pediatr Res 2021; Gervais et al, Pediatr Res 2020; Bassareo et al, J Matern Fetal Neonatal Med 2011). This includes both the perinatal characteristics as well as the characteristics collected at assessment (pediatric age or young adulthood) In all cases, an ECG was collected at rest, and these individual values (preterm or healthy term controls will be pooled.
89357080|NCT05242354||Periodontal health|Periodontally healthy individuals (2017 Classification of Periodontal Diseases and Conditions) who are planned to receive crown lengthening / gingivectomy of tooth extraction involving at least one site with pocket depth ≤3mm, bleeding on probing -
89357081|NCT05242354||Peri-implant health|Periodontally healthy individuals (2017 Classification of Periodontal Diseases and Conditions) with at least one partially-exposed dental implant with no bone loss prior to the prosthetic rehabilitation
89534132|NCT00001987||Healthy Volunteers|Healthy Volunteers
89534133|NCT00001987||Patients with severe insulin resistance|patients with severe insulin resistance manifesting with acanthosis nigricans, hyperinsulinemia, type A and B insulin resistance syndromes, and patients with lipodystrophy.
89534134|NCT00001979||Patients|Patients with known or suspected immunologically-mediated kidney diseases or immunologically-mediated diseases with potential for kidney disease.
89534135|NCT00001971||Healthy individuals|Healthy individuals who have recovered from liver diseases or who are healthy volunteers
88828483|NCT01748695|Experimental|V158866 followed by Placebo|V158866 450mg once per day for 4 Weeks followed by Placebo once per day for 4 Weeks
88828484|NCT05614453|Experimental|Treatment|Tislelizumab 200mg (IV) every 21 days for up to 35 cycles Sitravatinib 100mg (oral) given daily until disease progression or unacceptable toxicity
88828485|NCT01749631||Difficult to Intubate (DTI) Participants|Male or non-pregnant females over 18 years of age with Mallampati score III or IV who were undergoing surgery using sevoflurane as the anesthetic agent as judged by the investigator and in compliance with the drug market authorization and approved product labeling.
88828486|NCT01750255|Placebo Comparator|Control|The control group will receive the usual care and verbal and written information and education about mental health and bipolar disorder for patients and their families. The written material is a brochure designed for this purpose, which focused on the goals and importance of adherence with pharmacological and nonpharmacological interventions to achieve treatment goals. Patients met again with the pharmacist every three months during one year. At each appointment will assess of parameters of efficacy and safety. Quality of life, adherence to treatment, the severity of depressive symptoms in individuals, Symptoms of Mania, the psychiatrist rated patient impairment.
88828487|NCT01750255|Active Comparator|Pharmaceutical Care|Pharmaceutical care will be provided according to Dader Method for pharmaceutical care and will be carried out in collaboration with patients and physicians.The time between admission to the group and 20 days,the pharmacist will enhance the information related to treatment adherence and investigate by certain criteria to make an approach to the effectiveness and safety of treatment, through phone calls(weeks 1,3, 4-6) and a home visit(week 2). Pharmacist will call the patient weekly in order to increase adherence. At each appointment will assess of parameters of efficacy (Depression- Mania Rating Scale, Clinical Global Assessment Scale,Quality of life, adherence to treatment.
89357082|NCT05242354||Periodontitis|Generalized Stage III Grade C periodontitis patients (2017 Classification of Periodontal Diseases and Conditions) having at least one site with pocket depth ≥6mm, bleeding on probing +
89357083|NCT05242354||Peri-implantitis|Individuals with at least one implant site with radiographic bone loss, pocket depth ≥6mm and bleeding on probing +
89357084|NCT05226091|Experimental|Intervention arm|GP practices randomised to the intervention will receive a mail and email about the result of the PLEASANT study and advising them to implement the study findings.
89534136|NCT00001971||Patients|Liver disease patients
89177669|NCT00816790|Active Comparator|Dose Adjusted|This arm will receive their broad spectrum antibiotic as an adjusted dose based on their renal function as measured when sepsis is diagnosed and antimicrobials are initiated
88828488|NCT04339933||BC|Patients who were diagnosed with bladder cancer
88828489|NCT05605015|Experimental|ACTIVE-CR INTERVENTION|Participants will complete a 6-week remote, technology-based physical activity intervention named ACTIVE-CR, in which they will be required to wear a wrist worn monitor to measure daily physical activity. Participants will be able to view their physical activity feedback on a web-based platform and will receive three online trainer sessions across the 6 weeks to help them to understand and interpret their data.
88828490|NCT05605015|No Intervention|CONTROL|Participants in the control group will receive usual care from their healthcare team (if relevant) and will be invited to have an assessment at baseline and 6-weeks. Control participants will not receive any form of intervention. At the end of the study, control participants will receive a summary of their physical activity data measured at baseline and 6-weeks (in a booklet format with guidance on how to interpret and use the information).
88828491|NCT01751971|Active Comparator|Inspired Oxygen First|Participants breathe air with additional inspired oxygen (40%) for 1 night during an overnight sleep study (15 L/min via venturi mask). 1 week later participants will crossover to Sham (sham comparator).
88828492|NCT01751971|Sham Comparator|Sham First|Participants breathe air without additional inspired oxygen for 1 night during sleep (15 L/min via Venturi mask). 1 week later participants will crossover to Inspire Oxygen (active intervention).
88828493|NCT01754389|Active Comparator|Arm A (Standard of Care)|Tacrolimus intravenously and orally, Day -3 through 3-6 months post-transplant Methotrexate intravenously on days 1, 3, 6 and 11 post-transplant
88828494|NCT01754389|Experimental|Arm B (Experimental)|Bortezomib intravenously 1, 4 and 7 days post-transplant Tacrolimus intravenously and orally, Day -3 through 3-6 months post-transplant Methotrexate intravenously 1,3,6 and 11 days post-transplant
88828495|NCT01754389|Experimental|Arm C (Experimental)|Bortezomib intravenously 1,4 and 7 days post-transplant Sirolimus, intravenously and orally, Day -3 through 3-6 months post-transplant Tacrolimus, intravenously and orally, Day -3 through 3-6 months post-transplant
88828496|NCT04288453|Experimental|Community-based activity program|Engagement in 8-week community-based activity program
89177670|NCT00816790|Experimental|Unadjusted Dose|This arm will receive their broad spectrum antibiotic as an unadjusted dose regardless of their renal function
89177671|NCT03864796||cases of newly diagnosed ITP|no intervention
89177672|NCT03864796||cases of ITP after responding to treatment|no intervention
89177673|NCT03864796||healthy subjects|no intervention
89534137|NCT00001853||Healthy volunteers|Healthy adult African Americans born in the United States, with American born parents or born in Africa with African born parents.
89534138|NCT00001823||A/Surgery Branch Protocol Candidates|Patients suspected of having, or with biopsy proven, malignant disease being evaluated for or treated on NCI Surgery Branch protocols
89534139|NCT00001604||1|Subjects with a family history of stuttering
89534140|NCT00001521|Experimental|Investigational 1|boys/flutamide, letrozole, and reduced hydrocortisone dose or conventional treatment (with hydrocortisone and fludrocortisone ) until the age of 14
89534141|NCT00001521|Experimental|Investigational 2|girls/flutamide, letrozole, and reduced hydrocortisone dose, the Letrozole will discontinue at 13 y.o. and continue flutamide until 2 years after menarche or when final height is reached, whichever occurs first
89534142|NCT00001403||Proteus Syndrome|Patients with Proteus syndrome (PS) and other overgrowth disorders hypothesized to be in the AKT/PI3K pathway
89534143|NCT00001393||African descent controls|Controls; adult healthy volunteers of African descent without kidney disease
88828497|NCT01754623|Experimental|Chemotherapy Followed by Radiation Treatment|"Gemcitabine, Taxotere, Xeloda (GTX): 21 day cycle x 3 Gemcitabine 750mg/m^2 on days 4 and 11 Taxotere® (docetaxel) 30 mg/m^2 on days 4 and 11 Xeloda® (capecitabine) 750 mg/m^2 on days 1-14 Radiation: stereotactic body radiation therapy stereotactic body radiation therapy (SBRT).~After radiation, participants will be re-evaluated for surgery."
88828498|NCT01755169|Experimental|Ketamine 0.25 mg/kg/dose|A 5mL solution of 0.25 mg/kg/dose of ketamine will be given three times daily for 2 weeks.
88828499|NCT01755169|Experimental|Ketamine 0.5 mg/kg/dose|A 5mL solution of 0.5 mg/kg/dose of ketamine will be given three times daily for 2 weeks.
88828500|NCT01755169|Experimental|Ketamine 1 mg/kg/dose|A 5mL solution of 1 mg/kg/dose of ketamine will be given three times daily for 2 weeks.
88828501|NCT01755169|Placebo Comparator|Placebo|
88828502|NCT02073279|Experimental|Satralizumab|Participants randomized to this arm for the double-blind period will receive satralizumab monotherapy. The double-blind period for the participant ends either when the participant experiences a Clinical Endpoint Committee (CEC) confirmed protocol-defined relapse, the total number of CEC confirmed protocol-defined relapses reaches 44, or 1.5 years after the last patient was randomized. In the open-label extension period, the participant will receive satralizumab SC injection at Weeks 0, 2, and 4, and Q4W thereafter, up to the end of the study.
88828503|NCT02073279|Placebo Comparator|Placebo|Participants randomized to this arm for the double-blind period will receive placebo monotherapy. The double-blind period for the participant ends either when the participant experiences a Clinical Endpoint Committee (CEC) confirmed protocol-defined relapse, the total number of CEC confirmed protocol-defined relapses reaches 44, or 1.5 years after the last patient was randomized.. In the open-label extension period, the participant will receive satralizumab SC injection at Weeks 0, 2, and 4, and Q4W thereafter, up to the end of the study.
88828504|NCT01755949|Active Comparator|Chronic atrial fibrillation, colchicine|Colchicine 0.6 mg PO BID. Subjects not undergoing ablation.
88828505|NCT01755949|Placebo Comparator|Chronic atrial fibrillation, placebo|Matching placebo. Subjects not undergoing ablation.
88828506|NCT01755949|Active Comparator|Pre-ablation, sinus rhythm, colchicine|Colchicine 0.6 mg PO BID. Subjects undergoing ablation.
88828507|NCT01755949|Placebo Comparator|Pre-ablation, sinus rhythm, placebo|Matching placebo. Subjects undergoing ablation.
88828508|NCT01755949|Active Comparator|Pre-ablation, AF, colchicine|Colchicine 0.6 mg PO BID. Subjects undergoing ablation.
88828509|NCT01755949|Placebo Comparator|Pre-ablation, AF, placebo|Matching placebo. Subjects undergoing ablation.
88828510|NCT04769245||Single donor convalescent plasma|Patients who had positive reverse-transcriptase-polymerase-chain-reaction (RT-PCR) for SARS-CoV2 and radiologically confirmed pneumonia treated with single donor plasma
88828511|NCT04769245||ACB- IP 1.0|Patients who had positive reverse-transcriptase-polymerase-chain-reaction (RT-PCR) for SARS-CoV2 and radiologically confirmed pneumonia treated with ACB- IP 1.0 pathogen-free concentrated cocktail convalescent plasma
88828512|NCT01756885|Active Comparator|Standard Varenicline Treatment|"12 weeks of active varenicline + 12 weeks of placebo + smoking cessation counseling~Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-84: 1.0mg twice daily orally~Days 85-168: Placebo - 1.0mg twice daily orally"
88828513|NCT01756885|Experimental|Extended Varenicline Treatment|"24 weeks of active varenicline + smoking cessation counseling~Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-168: 1.0mg twice daily orally"
88828514|NCT04209907|Active Comparator|the group which retrolaminar block will be approved|the retrolaminar block will be made for postoperative analgesia
88828515|NCT04209907|No Intervention|the group which retrolaminar block will not be approved|the retrolaminar block will not be made for postoperative analgesia
88828516|NCT04172701||LAMA|Chronic obstructive pulmonary disease (COPD) patients who were prescribed long-acting muscarinic antagonists (LAMA) monotherapy between 01 January 2005 and 30 April 2015.
88828517|NCT04172701||ICS/LABA|Chronic obstructive pulmonary disease (COPD) patients who were prescribed a fixed-dose combination (FDC) of inhaled corticosteroid (ICS)/long-acting beta agonists (LABA) between 01 January 2005 and 30 April 2015.
88828518|NCT04151875|Experimental|Extraction orthodontic treatment|orthodontic treatment with teeth extraction
88828519|NCT04151875|Active Comparator|Non-extraction orthodontic treatment|non-extraction orthodontic treatment
88828520|NCT01760239|Experimental|Clinical Decision Support (CDS)|The Clinical Decision Support (CDS) tool will be activated when a BP is entered in the vital sign section of the EHR during any visit to a family practice or pediatric clinic (including both preventive care and sick visits, excluding prenatal and postpartum visits). The algorithm will be embedded in the EHR. In most cases, when a normal BP <90% and <120/80 mm Hg is entered, no alerts will be triggered. In some cases, clinical staff may receive up to two alerts, either to measure height or to repeat a first elevated BP reading. In cases with confirmed elevated BP measures, providers will receive a single CDS message summarizing that patient's current BP status and recommending specific clinical actions.
88828521|NCT01760239|No Intervention|Control|Patients in this group will receive usual care from their clinic. The CDS tool will not be activated.
88828522|NCT01760473|Experimental|Bup 8|Intranasal challenge drug: 8 mg of Buprenorphine administered intranasally.
88828523|NCT01760473|Experimental|Bup 16|Intranasal challenge drug: 16 mg of Buprenorphine administered intranasally.
88828524|NCT01760473|Experimental|Bup/Nal 8/2|Intranasal challenge drug: 8 mg of Buprenorphine administered intranasally with 2 mg of Naloxone.
88828525|NCT01760473|Experimental|Bup/Nal 8/8|Intranasal challenge drug: 8 mg of Buprenorphine administered intranasally with 8 mg of Naloxone.
89177674|NCT00818350|Experimental|SUNITINIB|
88828526|NCT01760473|Experimental|Bup/Nal 8/16|Intranasal challenge drug: 8 mg of Buprenorphine administered intranasally with 16 mg of Naloxone.
89357085|NCT05226091|No Intervention|Usual care arm|GP practices randomised to control will not receive either mail or email and they will continue with usual care.
89357086|NCT05212688|Active Comparator|Acupuncture|"Weekly treatment of 15 minutes for 6 weeks using Seirin 36 g 30 mm needles applied to two upper midline sternal points, thoracic paravertebral points, 5 pairs, 2 bilateral Trapezius trigger points, LI4, TE5, ST36, GB34, SP6, LR3 bilaterally, GV20 & GV24 midline~A maximum of two upper sternal indwelling studs [Seirin Pyonex semi-permanent studs] may be used after the second treatment if dyspnoea is present~Instructions will be given to massage the studs for 1 minute prior to exercise, if dyspnoeic or if very anxious, as often as necessary up to 12 times/day~Patients will be asked to rest for 15 minutes after each acupuncture treatment.~Clear instructions about self-needling for ongoing maintenance will be given to each patient~The acupuncture will be given in 6 sessions at weekly intervals. Delays of up to 2 weeks in delivery of acupuncture are allowed within the protocol. The timing of the study questionnaires at weeks 2, 6 and 12 will remain unchanged."
89357087|NCT05212688|Active Comparator|Active Control|Patients randomised to the Active Control will be contacted once per week for 6 weeks for a semi-structured telephone consultation. Delays of up to 2 weeks in delivery of the Active Control session are allowed within the protocol. Patients will be asked during the telephone call to complete the study questionnaires at week 0, 2, 6. Participants will also be asked after the telephone call to rest for 15 minutes if they are able. The patients will also be telephoned on week 12 to complete the study assessments. Patients in Arm B will be required to attend RM in person for the baseline visit and at week 6 to perform the 1 Minute Sit to Stand Test (1-MSTS). The 1-MSTS can be performed virtually rather than in person. Other visits will be telephone calls and completion of questionnaires (paper or via patient portal) Once patients in the Active Control group have completed the 12 week study assessments, they will be offered crossover to receive acupuncture.
89357088|NCT05209620|Experimental|Orelabrutinib Combined with Pemetrexed|"Induction Chemotherapy: Orelabrutinib, 150mg/d continuous oral administration, Pemetrexed, 500mg/m2, Intravenous administration on day 5 of each 3-week cycle (Total 6 cycles).~Maintenance Treatment: Orelabrutinib, 150mg/d continuous oral administration (28d/cycle)."
89357089|NCT05204836|Experimental|Zoledronic Acid Injection|Participants will receive 1 dose of 5 mg/100 mL intravenous zoledronic acid
89357090|NCT05204836|Placebo Comparator|Placebo|Participants will receive 1 dose 100 ml Saline.
89357091|NCT05184062|Experimental|AZD7442|co-administration of a single dose of 600 mg AZD7442 (300 mg AZD8895 and 300 mg AZD1061) by intravenous (IV) infusion.
89357092|NCT05184062|Placebo Comparator|Placebo|co-administration of a single dose of 600mg placebo by intravenous (IV) infusion.
89357093|NCT05182788|Placebo Comparator|Placebo pressed candy|
89357094|NCT05182788|Experimental|CHOLESWISE pressed candy|
88828527|NCT01760473|Experimental|Bup/Nal 16/4|Intranasal challenge drug: 16 mg of Buprenorphine administered intranasally with 4 mg of Naloxone.
88828528|NCT01760473|Active Comparator|Heroin|Intranasal challenge drug: 24 mg of heroin administered intranasally.
89357095|NCT05160532|Placebo Comparator|Four injections of placebo|Subjects will receive four placebo intraarticular knee injections under ultrasound guidance. A placebo looks exactly like the study drug, but it contains no active ingredient.
89357096|NCT05160532|Experimental|One injection of DPT and three injections of placebo|Subjects will receive one intraarticular knee injection under ultrasound guidance of dextrose prolotherapy (DPT), followed by three intraarticular knee injections of placebo under ultrasound guidance.
89357097|NCT05160532|Experimental|Two injections of DPT and two injections of placebo|Subjects will receive two intraarticular knee injection under ultrasound guidance of dextrose prolotherapy (DPT), followed by two intraarticular knee injections of placebo under ultrasound guidance.
89357098|NCT05160532|Experimental|Four injections of DPT|Subjects will receive four intraarticular knee injection under ultrasound guidance of dextrose prolotherapy (DPT).
88828529|NCT01760473|Sham Comparator|Placebo|Intranasal challenge drug: Intranasal lactose powder.
88828530|NCT01760473|Active Comparator|Naloxone 4 mg|Intranasal challenge drug: Intranasal Naloxone 4mg.
88828531|NCT01760785|Active Comparator|divalproex sodium|
88828532|NCT01760785|Placebo Comparator|sugar pill|
88828533|NCT01761019|Other|Taclonex topical suspension|Taclonex topical suspension will be used daily to affected areas of skin with psoriasis for 12 weeks
88828534|NCT01761175|Active Comparator|Ultrasound-guided infraclavicular block|Ultrasound-guided single injection infraclavicular block
88828535|NCT01761175|Active Comparator|Ultrasound-guided axillary block|Ultrasound-guided double injection axillary block
88828536|NCT04769089|Experimental|Pulse Dye Laser|Treatment with PDL alone.
88828537|NCT04769089|Experimental|CO2 Laser|Treatment with CO2 alone.
88828538|NCT04769089|Experimental|Combination|Treatment with both PDL and CO2 laser.
88828539|NCT04769089|Active Comparator|No treatment|No laser treatment.
88828540|NCT04062097||dabigatran-group|Patients with the anticoagulating therapy dabigatran and onset of clinically symptomatic intracranial hemorrhage, that is treated with idarucizumab.
88828541|NCT04062097||VKA-group|Patients under effective treatment with VKA and with intracranial hemorrhage.
88828542|NCT02241655|Experimental|EEG guided protocol|Participants will have a pragmatic EEG-guided anesthetic protocol during their surgery. Practitioners will modify administration of anesthesia in an attempt to limit the occurrence of EEG burst suppression or persistent suppression.
88828543|NCT02241655|No Intervention|Control Arm|Participants will have the standard anesthetic protocol.
88828544|NCT04005079|Experimental|Treatment Group|2% pilocarpine and standard of care post op drops ( Prednisolone acetate and Ofloxacin)
88828545|NCT04005079|Active Comparator|Control Group|Standard of care post op drops-Prednisolone acetate and Ofloxacin, without pilocarpine
88828546|NCT01761643|No Intervention|Standard of Care (SoC)|"This proposal will perform a study of potential methods to improve adherence and retention by evaluating standard procedures versus the use of the iTAB platform.~All subjects will receive SoC that will include health education, clinical assessments, laboratory safety monitoring, STI and HIV screening, HIV risk reduction counseling, assessment of psycho-social barriers, adherence counseling, and completion of a computer based survey."
89357099|NCT05156346|Experimental|LEAVES + usual care|The intervention consists of LEAVES online programme + usual care. LEAVES consists of 10 modules of readings and exercises.
89177675|NCT00810602|Experimental|Vorinostat prophylaxis|Vorinostat,combined with standard GVHD prevention medications(tacrolimus, mycophenolate) for adults who received a reduced intensity, related donor stem cell transplant
89177676|NCT00816868|Experimental|non-small cell lung cancer (NSCLC)|erlotinib in combination with capecitabine as first-line treatment in elderly patients with stage IIIB/IV adenocarcinoma non-small cell lung cancer (NSCLC)
89177677|NCT00791700|Experimental|Maraviroc|"Subjects will be stratified by age and formulation into one of the following cohorts:~Cohort 1: ≥2-<6 years of age, maraviroc liquid formulation; Cohort 2: ≥6-<12 years of age, maraviroc tablet formulation; Cohort 3: ≥6-<12 years of age, maraviroc liquid formulation and Cohort 4: ≥12-<18 years of age, maraviroc tablet formulation."
89177678|NCT00816946|No Intervention|Routine LHW Advice|Arm receiving routine advice by their local Lady Health Workers (LHWs)
89177679|NCT00816946|Active Comparator|Enhanced LHW Advice|Arm receiving enhanced nutrition and health advice from the local Lady Health Workers (LHWs)during their routine community visits.
89177680|NCT00810368|Active Comparator|Carnosine treatment group|Carnosine treatment group
89177681|NCT00810368|Placebo Comparator|Placebo control group|Placebo control group
89177682|NCT02610608||Women undergoing ART|Observation of the incidence of venous and arterial thrombosis following ovarian stimulation
89177683|NCT02605200|Other|Participants|Participants will complete tests of glucose tolerance and psychosocial assessments, and will undergo medical history screening. Those children identified with diabetes and/or abnormal glucose tolerance will receive both diabetes self-management education and psychosocial support from a pediatric Certified Diabetes Educator (CDE) and a psychologist, respectively.
89177684|NCT00628108|Placebo Comparator|Placebo|
89177685|NCT00628108|Experimental|Levocetirizine|
89177686|NCT00915330|Active Comparator|TBNA alone|Arm A: TBNA alone.
89177687|NCT00915330|Experimental|TBNA with ROSE|Arm B: TBNA with ROSE.
89177688|NCT00628030|Experimental|NOURISH|The first 2 waves and second 2 waves of participants will receive a 12 and 6 week face-to-face intervention (NOURISH), respectively. The interventions differ only in duration. They cover the same concepts which are grounded in Social Cognitive Theory (SCT). Throughout the interventions the influence of social learning on behavioral outcomes (e.g., parent's modeling of healthy behavior) will be emphasized. Weekly topics provide information about implementing healthy lifestyle behaviors, authoritarian parenting approaches, and strategies for overcoming barriers to change. Parents will receive pedometers for themselves and 1 of their children. A one-hour booster session will be available for all intervention participants 2 months after completion of the interventions.
89177689|NCT00628030|Placebo Comparator|Wellness Group|The placebo control group will attend a group session moderated by an independent interventionist. This interventionist will be blinded to the Specific Aims and hypotheses of this study. The session will address the role of diet and exercise in pediatric overweight. In addition, control parents will receive pedometers (and instructions on their use) for themselves and 1 of their children. Finally, control participants will be mailed publicly available brochures on pediatric overweight on 2 occasions during the study. Control participants will also be sent home one additional packet of information (essentially a review of previous mail outs) 2 months after post-testing.
89177690|NCT03864640||Colorectal cancer|Patients with colorectal cancer
89177691|NCT02550964||HCQ/CQ|Patients who treated with HCQ(Hydroxychloroquine) or CQ(Chloroquine) for autoimmune diseases such as Rheumatoid arthritis(RA), systemic lupus erythematosus(SLE) will be recruited, and get the composite examination for toxic maculopathy.
89177692|NCT00821392|Active Comparator|1 Febuxostat 40mg|
89177693|NCT00821392|Active Comparator|2 Febuxostat 80mg|
89177694|NCT00821392|Active Comparator|3 Febuxostat 120mg|
89357100|NCT05156346|No Intervention|usual care|The control arm consists of the usual care which entails continuation of existing medication, with or without adjustments, continuation of the person's usual medical, psychological and/or nursing appointments whenever previously scheduled or deemed necessary. GRAI will also be given to participants at baseline (t0) and those meeting the criteria will be referred to specialized grief appointments.
89177695|NCT00821392|Sham Comparator|4 Allopurinol 300mg|
89177696|NCT00821392|Placebo Comparator|5 Placebo|
89177697|NCT00591578|Experimental|Azilsartan Medoxomil 40 mg QD|
89177698|NCT00591578|Experimental|Azilsartan Medoxomil 80 mg QD|
89177699|NCT00591578|Active Comparator|Valsartan 320 mg QD|
89177700|NCT00817024|Experimental|Xuefu Zhuyu Capsules|
89177701|NCT00817024|Active Comparator|Sheng Mai Capsules|
89177702|NCT00817024|Placebo Comparator|Placebo|
89177703|NCT00797862|Experimental|Aliskiren + Amlodipine|Eligible participants received oral aliskiren 150 mg + amlodipine 5 mg daily from week 1-8. From week 8 - 16, the dose of the combination treatment increased to aliskiren 300 mg + amlodipine 10 mg daily. From week 16-24, participants in this group continued combination treatment (aliskiren 300 mg + amlodipine 10 mg) for 8 weeks. At week 24, if blood pressure was not adequately controlled (systolic blood pressure >140 mmHg or diastolic blood pressure >90 mmHg) hydrochlorothiazide 12.5 mg was added to the combination (aliskiren 300 mg + amlodipine 10 mg) for an additional 8 weeks. Total treatment period =32 weeks.
89177704|NCT00797862|Experimental|Aliskiren Start - Amlodipine Add-On|Eligible participants received oral aliskiren 150 mg daily from week 1-8. From week 8 - 16, the dose of aliskiren increased to 300 mg daily. From week 16-24, amlodipine 10 mg was added to the aliskiren 300 mg for 8 weeks (aliskiren 300 mg + amlodipine 10 mg). At week 24, if blood pressure was not adequately controlled (systolic blood pressure >140 mmHg or diastolic blood pressure >90 mmHg) hydrochlorothiazide 12.5 mg was added to the combination (aliskiren 300 mg + amlodipine 10 mg) for an additional 8 weeks. Total treatment period =32 weeks.
89177705|NCT00797862|Experimental|Amlodipine Start- Aliskiren Add-On|Eligible participants received oral amlodipine 5 mg daily from week 1-8. From week 8 - 16, the dose of amlodipine increased to 10 mg daily. From week 16-24, aliskiren 300 mg was added to the amlodipine 10 mg for 8 weeks (amlodipine 10 mg + aliskiren 300 mg). At week 24, if blood pressure was not adequately controlled (systolic blood pressure >140 mmHg or diastolic blood pressure >90 mmHg) hydrochlorothiazide 12.5 mg was added to the combination (amlodipine 10 mg + aliskiren 300 mg) for an additional 8 weeks. Total treatment period =32 weeks.
89357101|NCT05153304|Experimental|anti-PD1 and personalized vaccine|
89357102|NCT05121844|Experimental|Signos digital health app and CGM|For all consented participants, the Signos app will use CGM data to provide recommendations customized to users for promoting general health and wellness.
89357103|NCT05114252|Experimental|Participants with amblyopia in the serious games intervention|Participants with amblyopia receiving the experimental intervention consisting of serious videogames focusing on binocular function (with image modification) in a virtual reality environment.
89357104|NCT05114252|Active Comparator|Participants with amblyopia in the standard care intervention|Participants with amblyopia receiving the standard care intervention consisting of wearing spectacles with individualized refractive correction.
88828547|NCT01761643|Active Comparator|SoC + iTab|"Subjects assigned to the iTAB intervention will receive daily dosing reminders that will be sent for the first 6 weeks and then continue with reminders for the duration of the study.~Subjects will have visits with the study coordinator to introduce the iTAB texting system.~Once the time is identified, the text reminder system is automated. Patients will confirm medication taking via text responses to the personalized reminders. If a participant does not respond on three consecutive occasions, a high alert message (chosen by the participant) will be sent. If the subject does not respond to this message, the study coordinator would initiate phone calls to contact the subject and explore barriers."
88828548|NCT01762501|Experimental|Azilsartan|Azilsartan 20mg/day in oral administration, single dose Treatment duration: 8 weeks
88828549|NCT01762501|Active Comparator|Amlodipine|Amlodipine 5mg/day in oral administration, single dose Treatment duration: 8 weeks
88828550|NCT02990221|Active Comparator|Ingenol mebutate|application of ingenol mebutate for 3 consecutive days on an area of face/scalp of 25 cm2
88828551|NCT02990221|Active Comparator|cryotherapy|application of criotherapy on actinic keratosis present in an area of face/scalp of 25 cm2 different from the ingenol mebutate area
88828552|NCT01764607|Experimental|Sirolimus treatment|Patients will receive sirolimus 5 weeks prior to removal of squamous cell skin carcinoma. After the 5 weeks of treatment, nephrology will determine/manage each patient's immunosuppressant therapy.
88828553|NCT01764685|Experimental|Topiramate + Medical Management|Topiramate titrated up to 150 mg/day over 5 weeks then maintained for 6 weeks + Medical Management sessions for 15-25 minutes per study visit
88828554|NCT01764685|Placebo Comparator|Placebo Pill + Medical Management|Sugar pill with dosing schedule matched to intervention group + Medical Management sessions for 15-25 minutes per study visit
88828555|NCT01764919|Experimental|[124I]FIAU|Single intravenous injection of [124I]FIAU in patients with diabetic foot infection
88828556|NCT01765465|Experimental|Rowachol|Rowachol treatment with 200mg PO tid, on postoperative 1 days to 3 months
88828557|NCT01765465|Placebo Comparator|Placebo|Placebo treatment with 200mg PO tid, on postoperative 1 days to 3 months
88828558|NCT02989831|Experimental|Vibrating insoles 'on'|Duration: 30-60 seconds
88828559|NCT02989831|No Intervention|Vibrating insoles 'off'|Duration: 30-60 seconds
89357105|NCT05114252|Active Comparator|Healthy participants|Participants without amblyopia or other conditions receiving the experimental intervention consisting of serious videogames focusing on binocular function (without any image modification) in a virtual reality environment.
89530269|NCT03246217|Experimental|Therapeutic Instrumental Music Performance|Therapeutic Instrumental Music Performance is a Neurologic Music Therapy technique in which selection of instruments, spatial configurations and sequences for playing are designed to facilitate retraining of movement patterns used in everyday life. Participants will receive nine individual forty-five minute sessions of Therapeutic Instrumental Music Performance, three sessions per week.
89534144|NCT00001393||African-Americans with FSGS|African-American patients with idiopathic or HIV-associated collapsing glomerulopathy
88828560|NCT02989909|Active Comparator|Goldmann Tonometer|Goldmann Tonometer prism will be used as a based line comparator for tolerance assessment versus the active test comparator CATS tonometer prism
88828561|NCT02989909|Experimental|CATS tonometer|CATS tonometer prism being used as the test product to assess IOP measurement versus active comparator the Goldmann Tonometer prism
88828562|NCT05115409|Experimental|Anti-PD-1 Antibody Plus Chidamide and Rituximab Regimen in Relapsed or Refractory DLBCL|Anti-PD-1 Antibody Plus Chidamide and Rituximab Regimen in Relapsed or Refractory DLBCL
88828563|NCT02249533|Experimental|Spot Light and High School RIO|"A total of 200 youth football teams (100 high school and 100 middle school-aged teams) will be enrolled. Potential participating teams, all high schools eligible to report football data to High School RIO™ as well as all Pop Warner and Middle School sponsored football teams that have a valid e-mail contact, will be e-mailed a letter inviting them to participate (Appendix 3).~Intervention: Certified Athletic Trainers will be given access to report football injuries via High School RIO and will report potential concussions using the Spot Light Concussion app."
88828564|NCT02249533|No Intervention|Control|Control: Certified Athletic Trainers will be given access to report football injuries via High School RIO.
88828565|NCT01766713|Experimental|Ezetimibe|10 mg/day of Ezetimibe
88828566|NCT01766713|Placebo Comparator|Placebo|one tablet per day (identical to ezetimibe)
88828567|NCT03821467|Experimental|Healthy subjects|Dual beam Doppler Fourier-domain OCT (DOCT) Dynamic Vessel Analyzer (DVA) Optical coherence tomography (OCT)
88828568|NCT01767103|Experimental|Normal Hepatic Function (healthy volunteers)|Healthy volunteers with normal hepatic function received a single 33 mg/kg dose of Ferriprox®.
88828569|NCT01767103|Experimental|Mild Hepatic Failure|Subjects with mild hepatic failure as defined by the Child-Pugh Class C: 5-6 points received a single 33 mg/kg dose of Ferriprox®.
88828570|NCT01767103|Experimental|Moderate Hepatic Failure|Subjects with moderate hepatic failure as defined by the Child-Pugh Class B: 7-9 points received a single 33 mg/kg dose of Ferriprox®.
89177706|NCT00817102|Other|CorCTA|Fractional Flow Reserve (FFR), Intravascular Ultrasound (IVUS), Virtual Histology (VH) or some combination of these three procedures
89530270|NCT03246217|Experimental|Therapeutic Performance with Sensory-Enhanced Motor Imagery|Participants will receive nine individual sessions, three times per week: thirty minutes of Therapeutic Instrumental Music Performance, followed by fifteen minutes of sensory-enhanced motor imagery. During sensory-enhanced motor imagery, participants will listen to a metronome set to their preferred pace for previously practised movements while engaging in motor imagery.
89000692|NCT04656808|Active Comparator|Cognitive behavioral therapy|Following the cognitive behavioral model adapted to caregiving (Losada et al., 2006) and considering other previous CBT intervention studies with dementia caregivers (Gallagher-Thompson et al., 2003), a CBT intervention developed and tested for dementia family caregivers (Márquez-González et al., 2007) was used for this study. Specifically, this intervention consists of different components that are described in more detail in Losada et al. (2011) and Márquez-González et al. (2007): a) a cognitive restructuring module aimed at modifying caregivers' dysfunctional thoughts about caregiving into other, more appropriate thoughts which promote the use of more adaptive coping strategies for caregivers; b) increasing pleasant activities or behavioral activation; c) asking for help skills; and d) relaxation techniques for reducing physiological activation.
89357106|NCT05104710||AIM 1|"Hypothesis: IMC-βγ can help to differentiate between ALS and mimic diseases at initial presentation.~Patients who present to a neuromuscular clinic with symptoms that might be from ALS but for whom a diagnosis is not yet known, will be studied. Measurements of intermuscular coherence will be made using surface electrodes. A standard neurological examination and questionnaire about ALS symptoms will be completed. No interventions will be made. A patient's final diagnosis will be determined using standard-of-care testing. Six months after initial IMC measurement, a determination will be made whether the IMC predicted the diagnosis of ALS."
89357107|NCT05104710||AIM 2|"Hypothesis: Characterization of demographic-specific distributions will improve the specificity of IMC-βγ for ALS.~To optimize cutoff values for abnormal IMC, IMC-βγ will be measured in neurotypical controls across a range of age, race, ethnicity, and sexes."
89357108|NCT05104710||AIM 3|"Hypothesis: IMC-βγ will decrease with disease progression.~Because IMC-βγ measures functional input from motor neurons in the brain, it should decrease as these neurons are lost. IMC will be measured sequentially about every 3 months in patients with ALS, and will be compared to measures of clinical progression."
89357109|NCT05078970|Active Comparator|Treatment As Usual (TAU)|Participants in this group will be studied as they proceed through treatment in the acute care setting and follow the intervention plan laid out in the discharge summary, per usual protocols at each facility. In both settings, the elements of typical care include crisis prevention planning, which outlines potential triggers, skills to use, and people and places to call in crisis, as well as referral to ongoing behavioral health treatment. We will not alter usual care but track recommendations, contacts and care through questionnaires the family completes as well as medical record review in order to understand the impact of the experimental conditions in relation to typical services.
89357110|NCT05078970|Active Comparator|Safety Planning Intervention+ (SPI+)|SPI is focused on how the risk of suicidal crisis waxes and wanes over time. At times of heightened risk, a pre-specified and individualized plan targets the internal warning signs that become the cue to use the safety plan. SPI+ strategies focus on patient's narrative of the suicidal crisis and identifying solutions that are antithetical to progressing in a suicidal crisis. The brief structured intervention is conducted in six key steps. Youth in this condition will be offered weekly follow-up, with a minimum of 4 sessions and a maximum of 8 sessions. The goal is to create a crisis response plan to reduce risk when suicidal crises emerge. With adolescents, SPI+ consists of an individual session to elicit crisis narrative and motivation to utilize the safety plan through psychoeducation and follows six steps to achieve the adolescent's goals and return to safety when suicidal urges are high.
89357111|NCT05078970|Active Comparator|Collaborative Assessment and Management of Suicidality (CAMS)|CAMS strategies focus on collaborative deconstruction and treatment of the patient-defined drivers- the problems that make suicide compelling to the patient- and utilizes these problem-focused treatment sessions to treat the drivers as directly related to wish to die. Participants will be assigned to CAMS for a minimum of 4 sessions and a maximum of eight sessions. This time frame, based on initial data from our pilot work with adolescents and emerging adults (18-25), suggests that a subset of participants resolve their STB in six to eight sessions. CAMS is a clinical intervention designed to modify how clinicians engage, assess and plan treatment with suicidal patients.
89357112|NCT05060653|Experimental|SBRT followed by surgical stabilization within 48 hours|SBRT and surgical stabilization will be performed within a 24 to 48-hour time window instead of today's standard of care of two weeks between surgical stabilization and conventional radiotherapy.
89357113|NCT05045079|Other|Severe tricuspid regurgitation due to atrial fibrillation|Subjects will receive standard of care procedure right heart catheterization with a inferior vena caval (IVC) occlusion maneuver.
89357114|NCT05038813|Experimental|Anlotinib combined with TQB2450|Anlotinib: 12mg, capsule, once a day. TQB2450: 1200mg, Injection, Once every three weeks.
89357115|NCT05034159|Experimental|Cognitive Behavioral Therapy for Insomnia|CBT-I has a specific protocol with behavioral targets that differ significantly from standard CBT. This approach focuses on implementing sleep restriction and stimulus control interventions which are fully deployed during the first session. Five CBT-I sessions will be delivered over the course of 8 weeks. Key recommendations include: 1) reduce time in bed; 2) get up at the same time every day; 3) do not go to bed unless sleepy; 4) do not stay in bed awake for more than 15 minutes; and 5) avoid napping. Participants are also taught relaxation strategies and cognitive therapy addresses arousal and catastrophizing.
89357116|NCT05034159|No Intervention|Waitlist|No intervention for 8 weeks.
89357117|NCT05004363|Active Comparator|Lokelma|Lokelma therapy
89000693|NCT00177515|Experimental|1|Computerized counseling about Emergency Contraception
89000694|NCT00177515|Active Comparator|2|Computerized counseling about peri-conception folate
89357118|NCT05004363|Placebo Comparator|Control|Placebo
89357119|NCT04982302||Non-surgical periodontal treatment NSPT|Subgingival instrumentation with ultrasonic devices and curettes of all periodontal pockets in 2 or 4 appointments
89357120|NCT04973189|Experimental|A single dose of SHR-1707 by intravenous infusion in healthy young adults.|
89357121|NCT04973189|Placebo Comparator|placebo in healthy young adults.|
89357122|NCT04973189|Experimental|A single dose of SHR-1707 by intravenous infusion in elderly subjects.|
89357123|NCT04973189|Placebo Comparator|placebo in elderly subject|
89357124|NCT04967495|Experimental|TACE-Len-I|TACE combined with lenvatinib and iodion-125 seeds brachytherapy
89357125|NCT04967495|Active Comparator|TACE-Len|TACE combined with lenvatinib
89357126|NCT04965766|Experimental|U3-1402|All participants included in the study who answer the eligibility criteria will receive a starting dose of 5.6 mg/kg of U3-1402 every 3 weeks until progression or until unacceptable toxicity
89357127|NCT04933721|Experimental|BCX7353 Capsules 150 mg once daily|Berotralstat (BCX7353) 150 mg capsule orally administered once daily.
89357128|NCT04877444|Experimental|Aerobic exercise (AEx) + upper extremity rehabilitation|Subject will receive a total of 24 intervention sessions. In each session, subjects will perform 15 minutes of AEx followed by 200 repetitions of an upper extremity rehabilitation program.
89357129|NCT04877444|Experimental|Stretching (CON) + upper extremity rehabilitation|Subjects will perform 15 minutes of lower extremity stretching. Following lower extremity stretching subjects will receive 200 repetitions of DDP.
89357130|NCT04847037|Experimental|Connected Tools|For the experimental group, the postoperative procedure requires the use of personal connected tools: a smartphone, a digital tablet or a computer with internet connection. A scale and a connected watch will also be loaned to patients so that they can take the necessary measures. Before returning home, patients must be trained to take correct measures and inform them on the dedicated platform.
89357131|NCT04847037|No Intervention|No Connected Tools|Patients randomized to the control group will be operated according to the same protocol as the experimental group. For them, there will be no home follow-up, so no special procedure to follow.
88828571|NCT02243449|Active Comparator|Once daily screening|In the 'once daily screening arm', RTs will screen invasively ventilated patients between approximately 06:00 - 08:00 hours daily. If a screening period is missed inadvertently or due to an investigation or intervention (operation/procedure) necessitating absence from the ICU, it may be conducted later on the same day and ideally within 6 hours of the scheduled screening period. Regardless of group assignment, if the SBT screening assessment is passed, an SBT will be conducted as per protocol.
89357132|NCT04845347|Experimental|Bright Light Therapy|
89357133|NCT04845347|Sham Comparator|Dim Light Therapy|
88828572|NCT02243449|Experimental|At least twice daily screening|In the 'at least twice daily' screening arm patients will be screened at a minimum between approximately 06:00 - 08:00 hours and 13:00 - 15:00 hours daily. If a screening period is missed inadvertently or due to an investigation or intervention (operation/procedure) necessitating absence from the ICU, it may be conducted later on the same day and ideally within 6 hours of the scheduled screening period. Additional screening trials in the 'at least twice daily' screening arm will be permitted at the discretion of the clinical team (RTs and physicians). Regardless of group assignment, if the SBT screening assessment is passed, an SBT will be conducted as per protocol.
88828573|NCT01767415|Experimental|Indigo Carmine|Intraoperative stereotactic injection of Indigo Carmine
88828574|NCT01769209|Experimental|Bortezomib + Chemotherapy|Patients receive bortezomib on Days 1, 4, 8, and 11; doxorubicin hydrochloride on Day 1; PEG-asparaginase on Days 5 and 22; vincristine sulfate on Days 1, 8, 15, and 22; dexamethasone daily on Days 1 to 14; cytarabine on Day 1, and methotrexate on Day 15.
88828575|NCT01769365|Experimental|7-day quadruple therapy|"pantoprazole 40 mg twice daily for 7 days,~clarithromycin 500 mg twice daily for 7 days,~amoxicillin 1 g twice daily for 7 days,~metronidazole 500 mg twice daily for 7 days"
88828576|NCT01769365|Experimental|10-day sequential therapy|"pantoprazole 40 mg twice daily for 5 days and amoxicillin 1 g twice daily for 5 days, followed by~pantoprazole 40 mg twice daily for 5 days, clarithromycin 500 mg twice daily for 5 days, metronidazole 500 mg twice daily for 5 days."
88828577|NCT01769365|Active Comparator|7-day standard triple therapy|"pantoprazole 40 mg twice daily for 7 days,~clarithromycin 500 mg twice daily for 7 days,~amoxicillin 1 g twice daily for 7 days."
88828578|NCT02327143|Experimental|200 mg LY2835219|200 mg LY2835219 administered orally on day 1.
88828579|NCT02327143|Experimental|0.4 mg ¹³C₈-LY2835219|0.4 mg ¹³C₈-LY2835219 given intravenously (IV) for 15 minutes, starting approximately 6 hours after the oral dose.
88828580|NCT01770691|Experimental|TIPI vaginal pessary|Each subject will use different SMD'S (Slightly modified designs) of the TIPI vaginal pessary. Not all subjects will use all types of SMD's
89357134|NCT04828135|Experimental|subjects with diagnosis of COVID-19 (Long-hauler)|23 subjects with a confirmed diagnosis of COVID-19 infection, and after 60 days or longer
89357135|NCT04823949|No Intervention|Standard care|Patient will be scheduled for a blood pressure check in the office 7-10 days postpartum
89534145|NCT00001393||African-Americans with HIV|Hyper-normal controls; adult African-Americans with HIV and without kidney disease
89534146|NCT00001393||European and Asian descent controls|Controls; healthy volunteers of European or Asian descent without kidney disease
89534147|NCT00001393||Kidney donors|People donating kidneys at NIH
89357136|NCT04823949|Experimental|Intervention|Patient will receive a Babyscripts blood pressure cuff(brand: A&D Medical) and Babyscripts MyJourney phone app with which to monitor their blood pressures twice daily for 16 days after discharge
89357137|NCT04817605|Experimental|Exercise Therapy|
89534148|NCT00001393||Other patients with idiopathic FSGS|Patients of other areas of descent with idiopathic FSGS
89534149|NCT00001393||Relatives of patients with familial FSGS|Relatives of patients with familial FSGS
89534150|NCT00001393||Tamils|Adults with Tamilian descent
89534151|NCT00001392||Study Cohort|Subjects with known or suspected forms of sclerosing glomerular or chronic, fibrosing tubulointerstitial kidney diseases
88828581|NCT01771627|Experimental|Arm I (varenicline)|Patients undergo general smoking cessation counseling and receive varenicline PO QD on days 1-28. Courses repeat every 28 days for up to 12 weeks.
88828582|NCT01771627|Active Comparator|Arm II (nicotine patch)|Patients undergo general smoking cessation counseling and receive nicotine patch continuously for 12 weeks.
88828583|NCT01773187|Experimental|Pacritinib|Pacritinib 400 mg QD
88828584|NCT01773187|Active Comparator|Best Available Therapy|BAT includes any physician-selected treatment for primary or secondary myelofibrosis with the exclusion of JAK inhibitors (inhibitors of Janus kinases)
88828585|NCT01774045|Experimental|PDC-1421|Dosage form: 380mg PDC-1421 per Capsule. Dosage: single dose (1, 3, 6, 10 capsule(s)). Frequency: once daily, p.o., after meal. Duration: single dose at Day 1, and observing for three Days.
89177707|NCT00818428|Active Comparator|1|Speech Production Intervention + Articulation Parent Group
89177708|NCT00818428|Experimental|2|Speech Production Intervention + Dialogic Reading Parent Group
89177709|NCT00818428|Experimental|3|Speech Perception Intervention + Articulation Parent Group
89177710|NCT00818428|Experimental|4|Speech Perception Intervention + Dialogical Reading Parent Group
89177711|NCT04025970||Cancer of Unknown Primary (CUP)|"Subjects referred, based on standardised criteria, for investigation and diagnosis for possible cancer of unknown primary (CUP).~Blood samples to be investigated for presence of circulating tumor cells and circulating tumor DNA."
89177712|NCT04025970||Suspected CANcer (SCAN)|"Subjects referred, based on standardised criteria, for investigation and diagnosis for suspected cancer (SCAN) based on serious non-specific symptoms and signs of cancer.~Blood samples to be investigated for presence of circulating tumor cells and circulating tumor DNA."
89177713|NCT00817180|Active Comparator|A|Positive Expiratory Pressure (PEP) - an airway clearance technique
89177714|NCT00817180|Active Comparator|B|High Frequency Chest Wall Oscillation (HFCWO) also known as the 'Vest technique' - an airway clearance technique.
89177715|NCT00817258|Other|1|All patients will receive radical radiotherapy with 3D-CRT or IMRT, and cisplatin (40mg/m2) weekly during external radiotherapy.
89177716|NCT00794820|Experimental|FCR-Multiple Dose Rituximab|Fludarabine phosphate + Cyclophosphamide + Rituximab
89177717|NCT00455533|Experimental|A|
89177718|NCT00455533|Active Comparator|B|
89177719|NCT00818506||Late onset MDD|Patients with major depressive disorder between 50 and 70 years of age that did not suffer from depression before the age of 50.
89177720|NCT00818506||Controls|Healthy controls (matched for age, sex, and tobacco use status)
89177721|NCT04030208|Other|Sequence A|If patient is randomly assigned to Sequence A, they will be placed on a traditional ventilator for the first period. This period will be 1 hour in duration. Delivered tidal volume, respiratory rate (RR), and peak pressure will be recorded throughout the period using the ventilator. Heart rate (HR), Blood Pressure (BP), and oxygen (O2) saturation measurements will be recorded every 5 minutes. Arterial blood gas (ABG) data will be taken at t = 1 hour if the patient is stable on the traditional ventilator. ABGs may be taken more frequently if the patient is destabilizing. Next, the study participant will be transitioned to the Umbulizer to begin Period 2. This period will also be 1 hour in duration. Delivered tidal volume, RR, and peak pressure will be recorded throughout the period using Umbulizer. HR, BP, O2 saturation measurements will be taken every 5 minutes. ABG data will be taken at t = 30 minutes and 1 hour.
89177722|NCT04030208|Other|Sequence B|If patient is randomly assigned to Sequence B, they will be shifted to the Umbulizer for the first period. This period will be 1 hour in duration. Delivered tidal volume, RR, and peak pressure will be recorded throughout the period using Umbulizer. HR, BP, O2 saturation measurements will be recorded every 5 minutes. ABG data will be taken at t = 30 minutes and 1 hour. Next, the study participant will be transitioned to a traditional ventilator to begin Period 2. This period will also be 1 hour in duration. Delivered tidal volume, RR, and peak pressure will be recorded throughout the period using the ventilator. HR, BP, O2 saturation measurements will be recorded every 5 minutes. ABG data will be taken at t = 1 hour if the patient is stable on the traditional ventilator. ABGs may be taken more frequently if the patient is destabilizing.
89177723|NCT00818584|Experimental|1. micafungin lower dose|
89177724|NCT00818584|Experimental|2. micafungin higher dose|
89177725|NCT02609516||Healthy|Patients without any of the pre-specified chronic diseases
89177726|NCT02609516||Multimorbid|Patients having any two or more of the pre-specified chronic diseases
89177727|NCT00821470|Experimental|bone marrow graft group|core decompression + bone marrow implantation into the necrotic lesion
89177728|NCT00821470|Active Comparator|control|core decompression
89177729|NCT05755490|Experimental|PROWESS|"Participants will complete study procedures as outlined:~Wear FitBit watch during the 12-week study period.~Group intervention sessions, in-person or virtually.~Two, optional follow-up sessions.~One-on-one, semi-structured interview with trained study staff to assess participant experience with intervention."
89177730|NCT00818740|Experimental|ORM-12741 i.v.|
89177731|NCT00818740|Experimental|ORM-12741 oral solution|
89177732|NCT00818740|Experimental|ORM-12741 oral capsule with food|
89177733|NCT00818740|Experimental|ORM-12741 oral capsule without food|
89177734|NCT00821548|Experimental|1|Electrostimulation of the muscles of the scapular belt and the femoris quadristocks
89177735|NCT02609438|Active Comparator|Short breaks|Participants instructed to stand/move for 1-2 minutes every half hour throughout the workday
88828586|NCT01774045|Placebo Comparator|Placebo control|Dosage form: Capsule. Dosage: single dose (1, 3, 6, 10 capsule(s)). Frequency: once daily, p.o., after meal. Duration: single dose at Day 1, and observing for three Days.
88828587|NCT01775371|Experimental|Patient Controlled Analgesia|PCA (loading dose 0.1 mg/kg morphine and demand dose of 1 mg morphine available every 6 minutes)
88828588|NCT01775371|Active Comparator|Usual Care|Usual opioid analgesia determined by the provider
88828589|NCT03749629|Active Comparator|CANMAT + GeneSight Psychotropic Test guided tx|Participant treatment will be guided by the Canadian Network for Mood and Anxiety Treatments (CANMAT) and the pharmacogenomic test GeneSight®. GeneSight® is a neuropsychiatric, combinatorial, PGx test that provides recommendations for psychotropic medications (antidepressants, mood stabilizers, hypnotics for insomnia, and antipsychotics) based on a patient's individual genetic profile.
88828590|NCT03749629|Placebo Comparator|CANMAT alone|Participant treatment will be guided by the Canadian Network for Mood and Anxiety Treatments (CANMAT) alone.
88828591|NCT03723811|Experimental|1|SJP002 BID
88828592|NCT03723811|Experimental|2|SJP002 QID
88828593|NCT03723811|Placebo Comparator|Placebo 1|SJP002 Placebo 1
88828594|NCT03723811|Placebo Comparator|Placebo 2|SJP002 Placebo 2
89177736|NCT02609438|Active Comparator|Long breaks|Participants instructed to take two 15-minute activity breaks during each workday
89177737|NCT00627094|Experimental|Biatain Ibu|Biatain Ibu
88828597|NCT03717103|Experimental|IBI188|Part A : Initial dose escalation, Part B : Maintenance dose escalation
88828598|NCT03682393|Experimental|Hydrocortisone|100mg 1x3 hydrocortison intravenously for three days after mitral valve surgery or until atrial fibrillation onset
88828599|NCT03682393|Placebo Comparator|Placebos|100mg 1x3 intravenous fysiologic saline for three days after mitral valve surgery or until atrial fibrillation onset
88828600|NCT03499483|Experimental|Open Label Biktarvy|Single arm all participants receive open label study product intervention.
88828601|NCT04350931|Active Comparator|BCG Vaccine|0.10 mL intradermal injection of BCG Vaccine over the distal insertion of the deltoid muscle onto the humerus (approximately one third down the left upper arm) slowly over 10 seconds (In Egypt, the available BCG vaccine is the Copenhagen BCG vaccine - The Danish Strain 1331 of Mycobacterium Bovis). Each 0.10 mL vaccine contains 200000-800000 colony forming units.
88828602|NCT04350931|Placebo Comparator|intradermal normal saline|placebo 0.10 mL intradermal normal saline (0.9% NaCl) over the distal insertion of the deltoid muscle onto the humerus (approximately one third down the left upper arm) slowly over 10 seconds.
88828603|NCT03406429|Experimental|PPA patients|All study participants will carry a diagnosis of Primary Progressive Aphasia (PPA), either the logopenic or the non-fluent variant. All participants will receive the same study interventions in a within-subject crossover design.
88828604|NCT02243215|Experimental|Offsite training|Access to a portable trainer for laparoscopic skills
88828605|NCT02243215|No Intervention|Onsite training|Will be able practice on-site at Center of Clinical Education and at their local hospital.
88828606|NCT03403153|Other|Pilot and Open Trial|All Participants will complete the 8-week parenting support intervention and will provide satisfaction and acceptability ratings of the intervention. In the pilot trial, participants will make these ratings after each session, in the open trial the ratings will be made pre and post intervention.
88828607|NCT03377647|Active Comparator|Year two intervention|Both interventions will occur in the Tuba City Agency during year two.
88828608|NCT03377647|Active Comparator|Year three intervention|Both interventions will occur in the Chinle Agency during year three.
88828609|NCT03377647|Active Comparator|Year four intervention|Both interventions will occur in the Fort Defiance during year four.
88828610|NCT01673867|Experimental|Arm A: Nivolumab|Nivolumab 3 mg/kg solution intravenously (IV) every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends. Eligible patients may receive nivolumab at 480mg every 4 weeks until documented disease progression, discontinuation, withdrawal of consent or the study ends.
88828611|NCT01673867|Active Comparator|Arm B: Docetaxel|Docetaxel 75 mg/m^2 concentrate for solution for intravenous infusion every 3 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends. Eligible patients may receive nivolumab at 480mg every 4 weeks until documented disease progression, discontinuation, withdrawal of consent or the study ends.
88828612|NCT03005977|Other|Urodynamics, pyridium pad & cough stress|"The Pelvic Floor Bother Questionnaire, a questionnaire standardized by Cleveland Clinic Florida, the Urogenital Distress Inventory (UDI-6), and the numerical analog scale are to be administered prior to and 6 weeks after the surgical intervention. (14, 15)~Prior to surgery, patients will be scheduled for a UDS performed by a qualified nurse practitioner or physician and will be given instructions in verbal and written form to undergo a 24 H pyridium pad test at least 72 hours before the UDS. Patients will be given pyridium TID and report if orange stain is noted on their pad in this period of time. A supine and a standing cough stress test will also be performed."
88828613|NCT03003169||ambulatory surgery description|
89177738|NCT00627094|Active Comparator|Biatain|Biatain
89177739|NCT02610530||Non-Surgery|Overweight diabetic, type 2 diabetes diagnosis longer than 3 years; BMI:25-29.9 kg/m2 who have been on medical treatment for glycemic control.
88828614|NCT01777945||Participants Receiving Capecitabine/Docetaxel|Participants received capecitabine and docetaxel according to individualized physician-prescribed regimens.
88828615|NCT01778179|Active Comparator|Group 1|"Subjects (group 1) will be treated daily for their solar lentigines with the investigational drug (Tri-Luma® cream) plus sunscreen for 2 weeks. At week 2, all the subjects will have the solar lentigines treated by cryotherapy (CRY-AC3® device).~Post-procedure phase (From Week 2 up to Week 13)~Topical antibiotic treatment phase (Week 2 up to Week 5 - visit 2 to visit 3): At week 2, all the subjects will start to apply a topical antibiotic (Neomycin/Nebacetin® ointment) for the next 3 weeks.~Treatment phase 2 (from week 5 up to week 13 - visit 3 up to visit 5):~The investigational drug (Tri-Luma® cream) plus sunscreen will be applied again (group 1) for a minimum of 4 weeks and up to 8 weeks, according to the Global Improvement of solar lentigines and absence of PIH."
89357138|NCT04815720|Experimental|pepinemab + pembrolizumab|Pepinemab will be administered at 20 mg/kg (with possible dose modifications to 15 mg/kg or 10 mg/kg, if the initial 20 mg/kg dose of pepinemab is determined not to be well tolerated) in combination with a fixed dose of 200 mg pembrolizumab, administered in separate IV infusions, Q3W.
89357139|NCT04809740|Other|Patient Group|7,500 Patients from UAB/MCI
89357142|NCT04740879|Experimental|Intervention|"The Intervention condition will be provided with access to the 4-week online Mindfulness-Based Cognitive Therapy course Be Mindful immediately after randomization to group."
89357143|NCT04740879|Other|Waitlist Control|"The Waitlist Control condition will be provided with access to the 4-week online Mindfulness-Based Cognitive Therapy course Be Mindful approximately 4 months after randomization to group."
89357144|NCT04737889|Experimental|RL-MT|"Induction Chemotherapy: Rituximab, 375mg/m2, Intravenous administration on day 0, Lenalidomide, 25mg oral administration on day 1 to 10, combined with regimen: Methotrexate, 3mg/m2, Intravenous administration (pumping for 3h) on day 1 of each 3-week cycle, Temozolomide, 150mg/m2/d oral administration on day 1 to 10.~Consolidation Treatment: Autologous hematopoietic stem cell transplantation or reduced whole brain radiotherapy after high-dose chemotherapy.~Maintenance Treatment: Lenalidomide, 10mg oral administration on day 1 to 21 of each 4-week cycle for 12 months."
89357145|NCT04735354||sacubitril/valsartan|Patients administered sacubitril/valsartan by prescription
89357146|NCT04725487|Experimental|Standard integration program with social and health promoting intervention|Participants follow the standard integration program offered by Naestved Municipality and participate in various social and health promoting activities in addition
88828616|NCT01778179|Placebo Comparator|Group 2|"Subjects (group 2) will be treated daily for their solar lentigines with sunscreen alone for 2 weeks. At week 2, all the subjects will have the solar lentigines will treated by cryotherapy (CRY-AC3® device).~Post-procedure phase (Week 2 up to Week 13)~Topical antibiotic treatment phase (Week 2 up to Week 5 - visit 2 to visit 3): At week 2, all the subjects will start to apply a topical antibiotic (Neomycin/Nebacetin® ointment) for the next 3 weeks.~Treatment phase 2 (from week 5 up to week 13 - visit 3 up to visit 5):~Sunscreen alone will be applied again (group 1) for a minimum of 4 weeks and up to 8 weeks, according to the Global Improvement of solar lentigines and absence of PIH."
88828617|NCT01538303||measurement absolute flow and resistance|
89357147|NCT04725487|Active Comparator|Standard integration program|Participants follow the standard integration program offered by Naestved Municipality
89357148|NCT04672291|Experimental|Safety Cohort|A randomized (4:1) initial safety cohort of 13 patients will receive 2 cycles of drug (N=10) or placebo (N=3)
88828618|NCT02994017|Other|cystic fibrosis patients|
88828619|NCT02917915|Experimental|New Canadian Standardized PR|"Education Content: exercise, living well with chronic lung disease, breathing management, conserving energy, pulmonary medications, inhaler devices, integrating exercise in your life, management of respiratory infections, management of aggravating environmental factors, management of stress & anxiety, nutrition, leisure & travel, getting a good night's sleep, enjoying intimacy, living in a smoke-free environment, integrating long-term oxygen into your life, keeping a healthy lifestyle.~Delivery style: During group sessions patients engage in active, participatory-based learning of program content. Workbooks are available. During one-on-one interactions motivational communication style (asking for permission before providing information, using open questions, etc.) is used."
88828620|NCT02917915|Active Comparator|Traditional PR|"Education Content: Exercise, anatomy, pulmonary diseases, healthier breathing, pulmonary medications, pulmonary devices, exercise action plan, allergies & pulmonary function tests, health and air quality, healthier eating, travel, stress management & relaxation, tips to remember/summary of content.~Delivery style: During group sessions, patients engage in passive learning of program content delivered in a lecture-style approach. Patients also receive one-on-one education regarding: dyspnea management/pacing, inhaler technique, exercise maintenance."
88828621|NCT05451043|Experimental|Pancreatic Cancer|Durvalumab will be administered once every 4 weeks, in combination with gemcitabine + nab-paclitaxel (day 1/8/15) and continuous propranolol. Tremelimumab will be given on day 1 of cycle 1, which may be repeated at the time of progression in eligible patients.
88828622|NCT05451043|Experimental|Hepatocellular Cancer|Durvalumab will be administered once every 4 weeks in combination with continuous propranolol. Tremelimumab will be given on day 1 of cycle 1, which may be repeated at the time of progression in eligible patients.
88828623|NCT05451043|Experimental|Biliary Tract Cancer|Durvalumab will be administered once every 3 weeks, in combination with cisplatin + gemcitabine (day 1/8) and continuous propranolol. Tremelimumab will be given on day 1 of cycle 1, which may be repeated at the time of progression in eligible patients.
89357149|NCT04672291|Experimental|Expansion Cohort|A randomized (4:1) expansion cohort will receive 3 cycles of drug (N=24) or placebo (N=6). A total of 30 patients will be accrued.
89530271|NCT03246217|Experimental|Therapeutic Performance with Motor Imagery|Participants will receive nine individual sessions, three times per week: thirty minutes of Therapeutic Instrumental Music Performance, followed by fifteen minutes of motor imagery. Motor imagery will involve mental practice of previous movement exercises.
89530272|NCT05584631|Experimental|Intravenous immune globulin G|Subjects will receive there current intravenous immune globulin dose.
89530273|NCT05584631|Experimental|Subcutaneous immune globulin G|The dosage will be converted from the subject's current intravenous immune globulin G dosage 1:1 (gm per gm).
89530274|NCT03249259|Experimental|Choline alfoscerate|choline alfoscerate 400mg (2 caps - 1 cap bid)
89530275|NCT03249259|Placebo Comparator|Control|Placebo (2 caps - 1 cap bid)
89530276|NCT04503005|Active Comparator|Effect of fasting duration|study the effect of different daily fasting duration on body composition and blood lipid and inflammatory markers in healthy adults.
89530277|NCT04503005|Other|Effect of time restricted eating protocol on chronotype|study the effect of 2 month of time restricted eating on the chronotype profile of healthy adults.
89357150|NCT04668365|Experimental|Zanubrutinib Combined With Standard Chemotherapy|"A: For the first-line treatment:~Rituximab, 375mg/m2, Intravenous administration on day 0, combined with regimen：CHOP (Cyclophosphamide, Epirubicin, Vincristine and Prednisone): repeated every 3 weeks, up to 6 cycles.~Zanubrutinib, 160mg twice daily continuous oral administration from 2 to 6 cycles for patients with CD79A/CD79B genetic abnormality.~Zanubrutinib combined with Rituximab for the 7 cycle.~B: For R/R DBCLC:~Rituximab, 375mg/m2, Intravenous administration on day 0, combined with regimen: GemOx(Gemcitabine, Oxaliplatin)/ DHAP(Cisplatin, Cytarabine, Dexamethasone)/ ICE(Ifosfamide, Etoposide, Carboplatin)/ GDP(Gemcitabine, Cisplatin, Dexamethasone): repeated every 3 weeks, up to 5 cycles.~Zanubrutinib, 160mg twice daily continuous oral administration from 2 to 5 cycles for patients with CD79A/CD79B genetic abnormality.~Maintenance treatment: Zanubrutinib, 160mg twice daily continuous oral administration for 12 months."
89357151|NCT04616729|Experimental|GnRH agonist Depot form|Ovarian stimulation will be performed using a fixed antagonist protocol with Follitropin Alfa (daily in the evening) and Ganirelix or Cetrorelix (daily in the morning). Selection of the daily gonadotropin dose will be based on ovarian reserve parameters (AMH and AFC) and BMI. Co-administration of 5 mg of letrozole daily (in the morning) commencing on the first day of gonadotropin administration and continuing throughout the ovarian stimulation will be performed as this reduces oestradiol concentrations. GnRH agonist Triptorelin 3.75 mg Depot form will be used for final oocyte maturation. Ganirelix/Cetrorelix 0.25mg daily (in the morning) will resume for 7 days from the evening of the day of oocyte retrieval onwards. Hormone analysis, analysis of haematology and biochemistry and a pelvic ultrasound scan will be done on days 3, 5 and 7 after oocyte retrieval.
89530278|NCT04487587|Active Comparator|Active|Cediranib 20mg tablet OD (5 days out of 7) and Olaparib 300mg tablet BD (continuous) + standard of care
89530279|NCT04487587|Placebo Comparator|Placebo|Placebo Cediranib 20mg tablet OD (5 days out of 7) and Placebo Olaparib 300mg tablet BD (continuous) + standard of care
88828624|NCT02713399||Soft Contact Lenses|healthy subjects wearing soft contact lenses
88828625|NCT02713399||Rigid Contact Lenses|healthy subjects wearing rigid contact lenses
88828626|NCT02700295||Orthokeratology contact lens group|
88828627|NCT02451839||Crohn's Disease|Participants with Crohn's disease. All participants will receive at least 3 months of treatment with adalimumab. Adalimumab was prescribed by the physician under usual and customary practice and according to the approved adalimumab New Zealand Datasheet.
88828628|NCT02451839||Rheumatoid Arthritis|Participants with rheumatoid arthritis. All participants will receive at least 3 months of treatment with adalimumab. Adalimumab was prescribed by the physician under usual and customary practice and according to the approved adalimumab New Zealand Datasheet.
88828629|NCT02451839||Psoriasis|Participants with psoriasis. All participants will receive at least 3 months of treatment with adalimumab. Adalimumab was prescribed by the physician under usual and customary practice and according to the approved adalimumab New Zealand Datasheet.
88828630|NCT02652169|Experimental|Study arm 1 - PRF plus amikacin and teicoplanin|PRF mixed with amikacin and teicoplanin is sprayed on the patients' ulcer
88828631|NCT02652169|Experimental|Study arm 2 - PRF plus normal saline|PRF mixed with normal saline is sprayed on the patients' ulcer
88828632|NCT02652169|Experimental|Study arm 3 - PRF mixed with PHMB plus Macrogolol|PRF mixed with polyhexanide and macrogolol is sprayed on the patients' ulcer
88828633|NCT02652169|Active Comparator|Study arm 4 - Acticoat 7|A silver gauze (Acticoat 7®) is applied to the patients' ulcer
88828634|NCT02478775|Experimental|Frequent Blood Sampling, Degarelix|Investigators will assess the change in inhibin B levels following repeated bolus dosing of recombinant FSH (rFHS) following Degarelix (GnRH antagonist) blockade over a 2-day period. This arm was terminated due to Adverse Events and the study was continued with the Cetrorelix product.
88828635|NCT02478775|Experimental|Frequent Blood Sampling, Cetrorelix|Investigators will assess the change in inhibin B levels following repeated bolus dosing of recombinant FSH (rFHS) following Cetrorelix blockade over a 2-day period.
88828636|NCT02451995|Experimental|Ripple Mapping guided AT ablation|Ripple Mapping (Imperial College) software (Biosense Webster) will be used to diagnose the mechanism of AT and guide ablation
88828637|NCT02451995|Active Comparator|Local activation Time Mapping AT Ablation|Standard activation mapping will be used to guide ablation.
88828638|NCT01783561|Active Comparator|early caffeine|Infants will receive a blinded dose of either placebo (IV normal saline) or IV caffeine citrate 20mg/kg infused over 15 minutes within the first 2 hours of life. If the infant is in the early caffeine group, the blinded drug will be IV caffeine citrate 20mg/kg in the first 2 hours and placebo at 12 hours of life.
88828639|NCT01783561|Placebo Comparator|Routine caffeine|Infants will receive a blinded dose of either placebo (IV normal saline) or IV caffeine citrate 20mg/kg infused over 10 minutes within the first 2 hours of life. If the infant is in the routine caffeine group, the blinded drug will be placebo in the DR and IV caffeine citrate 20mg/kg at 12 hours of life.
88828640|NCT02452931|Experimental|Assigned Intervention|Leuprolide acetate 45 mg will be administered as a subcutaneous injection at 6-month intervals for the 12 month study period.
88828641|NCT01783639|Experimental|Arm 1|"Device: WIRION™ Embolic Protection System~Interventions: Carotid Artery Stent"
88828642|NCT04744727|Active Comparator|paracetamol group|Included 48 pregnant women who received 1000 mg of intravenous paracetamol. The treatment was administered at the begining of the active phase of 1st stage of labor [roughly defined as a cervical dilatation of 3-4 cm and a cervical effacement ≥ 50%].
88828643|NCT04744727|Active Comparator|pethidine group|Included 48 pregnant women who received 50 mg of intravenous pethidine HCL diluted in 10 ml normal saline. The treatment was administered at the beginning of the active phase of 1st stage of labor [roughly defined as a cervical dilatation of 3-4 cm and a cervical effacement ≥ 50%].
88828644|NCT02243527|Experimental|Inspiratory Muscle Training|
88828645|NCT02243527|Sham Comparator|Sham-Control Inspiratory Muscle Training|Inspiratory muscle training at a low intensity meant to elicit no physiological changes.
88828646|NCT02454179|Experimental|Arm 1|pembrolizumab
88828647|NCT02454179|Experimental|Arm 2|acalabrutinib in combination with pembrolizumab
88828648|NCT01395641|Experimental|Gene therapy|Intracerebral infusion of AAV2-hAADC viral vector will be performed
88828649|NCT02041533|Experimental|Arm A: Nivolumab subjects|Nivolumab solution for Injection 3 mg/kg Intravenous every 2 weeks until disease progression, discontinuation due to unacceptable toxicity, withdrawal of consent or study closure
88828650|NCT02041533|Active Comparator|Arm B: Investigator's Choice Chemotherapy|"Investigator's Choice Chemotherapy administered in 3-week cycles up to a maximum of 6 cycles of Intravenous injection until disease progression, unacceptable toxicity or completion of the 6 cycles, whichever comes first~Squamous subjects:~Gemcitabine 1250 mg/mg(2) administered on Day 1 and Day 8 with Cisplatin 75 mg/m(2) administered on Day 1 of each cycle; or~Gemcitabine 1000 mg/mg(2) administered on Day 1 and Day 8 with Carboplatin (AUC 5) administered on Day 1 of each cycle; or~Paclitaxel 200 mg/m(2) with Carboplatin (AUC 6) administered on Day 1 of each cycle~Non-Squamous subjects:~Pemetrexed 500 mg/m(2) with Cisplatin 75 mg/m(2) administered on Day 1 of each cycle~Pemetrexed 500 mg/m(2) Carboplatin (AUC 6) administered on Day 1 of each cycle~Optional crossover:~Nivolumab solution for Injection 3 mg/kg Intravenous every 2 weeks until disease progression, discontinuation due to toxicity, withdrawal of consent or study closure"
88828651|NCT02907203|Experimental|Drug Coated Balloon|Prospective, multi-center, single-arm study characterizing outcomes in subjects with Peripheral Artery Disease (PAD) lesions treated with percutaneous transluminal angioplasty (PTA) using the GORE® DCB Catheter.
88828652|NCT01330277||Participants with Hunter syndrome|Participants diagnosed with Hunter syndrome (Mucopolisaccharidosis type 2) aged between 2 months to 50 years
88828653|NCT02887157||Specific Aim 1B|"Specific Aim 1B (implement technical innovations to improve OCT imaging in non-sedated infants in the ICN: (1B) extend imaging to the vascular-avascular junction via a wide-field lens).~Aim 1B only: 50 participants (25 healthy adult volunteers and 25 pediatric participants under going examination under anesthesia~Healthy adult volunteers will have SSOCT imaging of both eyes with the novel ultralight handpiece up to 10 times.~Pediatric participants undergoing examination under anesthesia will have SSOCT imaging of both eyes with the novel ultralight handpiece once during their EUA in the Duke Eye Center Operating Rooms (OR). These participants will be enrolled into the study at DUHS including the Duke Eye Center clinics and OR for testing the custom widefield lens."
89177740|NCT02610530||Surgery-A|Overweight diabetic, type 2 diabetes diagnosis longer than 3 years; BMI:25-29.9 kg/m2. who underwent sleeve gastrectomy with ileal transposition
89177741|NCT02610530||Surgery-B|Overweight diabetic, type 2 diabetes diagnosis longer than 3 years; BMI:25-29.9 kg/m2. who underwent sleeve gastrectomy with transit bipartition
89357152|NCT04616729|Active Comparator|GnRH agonist Daily form|Ovarian stimulation will be performed using a fixed antagonist protocol with Follitropin Alfa (daily in the evening) and Ganirelix/Cetrorelix (daily in the morning). Selection of the daily gonadotropin dose will be based on ovarian reserve parameters (AMH and AFC) and BMI. Co-administration of 5 mg of letrozole daily (in the morning) commencing on the first day of gonadotropin administration and continuing throughout the ovarian stimulation will be performed as this reduces oestradiol concentrations. GnRH agonist Triptorelin 0.2 mg Daily form will be used for final oocyte maturation. Hormone analysis, analysis of haematology and biochemistry and a pelvic ultrasound scan will be done on days 3, 5 and 7 after oocyte retrieval. The first administration of Triptorelin 3.75mg depot will be scheduled on the first day of the menstrual cycle after oocyte retrieval. To prevent the flare-up produced by the GnRH agonist, daily doses of 0.25mg of Ganirelix/Cetrorelix will be given for seven days.
89357153|NCT04594681|Placebo Comparator|Placebo|
89357154|NCT04594681|Experimental|KHK4951|
89357155|NCT04586686|Other|Group 1: right ovarian biopsy|Patients in group 1 will undergo a laparoscopy for an ovarian biopsy from the right ovary. They will then continue with a controlled ovarian stimulation, using a GnRH antagonist protocol. This will be started with Corifollitropin alfa 0.15 mg in the evening. On day six the antagonist, Ganirelix, will be added in the morning. If needed stimulation can be continued after seven days using follitropin beta daily in the evening (dosage ranging from 200-300 IE depending on AMH levels). Agonist trigger Triptorelin 0.2 mg will be administered for ovulation induction. In case of LH levels <2 IU/L at the start of ovarian stimulation, a dual ovulation strategy will be adapted: Triptorelin 0.2mg and choriongonadotropin 2500 IU (or choriongonadotropin alfa 250 µg) will be given. A transvaginal oocyte retrieval will be planned 36 hours after triggering.
89357156|NCT04586686|Other|Group 2: left ovarian biopsy|Patients in group 2 will undergo a laparoscopy for an ovarian biopsy from the left ovary. They will then continue with a controlled ovarian stimulation, using a GnRH antagonist protocol. This will be started with Corifollitropin alfa 0.15 mg in the evening. On day six the antagonist, Ganirelix, will be added in the morning. If needed stimulation can be continued after seven days using follitropin beta daily in the evening (dosage ranging from 200-300 IE depending on AMH levels). Agonist trigger Triptorelin 0.2 mg will be administered for ovulation induction. In case of LH levels <2 IU/L at the start of ovarian stimulation, a dual ovulation strategy will be adapted: Triptorelin 0.2mg and choriongonadotropin 2500 IU (or choriongonadotropin alfa 250 µg) will be given. A transvaginal oocyte retrieval will be planned 36 hours after triggering.
89357157|NCT04577859|Active Comparator|Study group|Those randomized to the study group will receive the esophageal cooling device- the ensoETM probe, during AF ablation treatment, under general anaesthetic. The cooling device is set to 4 degrees covering ablation of the left atrial posterior wall.
89357158|NCT04577859|Active Comparator|Control group|Those randomized to the control group will receive standard of care, which is an esophageal temperature monitoring probe during their AF ablation procedure, under general anaesthetic. The esophageal temperature probe is sited close to the level of ablation (the probe should be at the esophageal level where, opposite this, the ablation catheter is at, in the endocardial aspect of the posterior left atrium).
89357159|NCT04526886|Experimental|Study Arm|All patients in this single-arm study will be exposed to the experimental chemotherapy dose-adjustment algorithm.
89357160|NCT04517877|Experimental|Caring Light Training|Caring Light mobile app with coping skills training.
89357161|NCT04517877|Active Comparator|Educational Training|Traditional educational program.
89357162|NCT04499482|Experimental|Foods containing 10 g soy flour|Participants will receive foods containing 10 g of soy flour to be consumed everyday for one week. If they tolerate the dose, they will receive the next dose without any wash-out period.
89357163|NCT04499482|Experimental|Foods containing 20 g soy flour|Participants will receive foods containing 20 g of soy flour to be consumed everyday for one week. If they tolerate the dose, they will receive the next dose without any wash-out period.
89357164|NCT04499482|Experimental|Foods containing 30 g soy flour|Participants will receive foods containing 30 g of soy flour to be consumed everyday for one week.
88828654|NCT02887157||Specific Aim 2|"Specific Aim 2 (distinguish elements of retinal microanatomy that predict maldevelopment of visual pathway and poor neurodevelopment that may impact vision in preterm infants) includes 68 very preterm infants undergoing the following during evaluation for ROP.~Swept Source OCT imaging of both eyes with the novel ultralight handpiece before or after ROP examination, timed with each examination. The axial length of the eye may be measured after the ROP exam.~Non-sedated research brain Magnetic Resonance Imaging will be obtained in 68 participants prior to discharge from the nursery whenever possible (as close to term age as possible). In the case of an early infant discharge to another hospital, every effort will be made to obtain brain MRI prior to transfer or an outpatient non-sedated brain MRI at near term age.~Scavenged blood collection: Residual samples of serum/plasma in the laboratory will be collected for neuroinflammatory marker testing."
88875172|NCT02500836|Experimental|Cocaine HCI 4% Topical Solution|Cocaine HCl 4% Topical Solution, up to 4 mL, is applied for 20 minutes via cotton or rayon pledget(s), then the nasal site is tested with a Von Frey (or equivalent) filament (Size 5.88, about 60 grams of force) to determine and record whether the subject has a pain score of 0 (zero) (0 = No Pain, 10 = Unbearable pain) after treatment application compared to the Von Frey filament test right before treatment application. If a pain score of 0 (zero) is recorded, then the diagnostic procedure or surgery proceeds along with safety monitoring for at least 90 minutes after removal of the pledget(s). The subject will be followed for safety for seven days. The total number of pledgets used, and the amount of Cocaine HCl 4% topical solution used (1 mL per pledget) will be recorded.
89177742|NCT00923000|Experimental|Nubian with Long dan xie gan tang 3g|
89357165|NCT04497857|Placebo Comparator|CSC-SD|Standard clinic-based CSC model treatment. Treatment will be delivered largely in clinic for 12 months.
89357166|NCT04497857|Experimental|CSC-TH|Telehealth based CSC model treatment. Treatment will be delivered largely through telehealth for 12 months.
89357167|NCT04496401|Experimental|Tacrolimus then Envarsus|Tacrolimus will be started on the day of surgery. After a stable trough level is achieved (on postoperative day 7-17) the first PK profile will be measured. Subsequently, the switch to ENVARSUS® will be performed
89357168|NCT04489303|Experimental|Virtual Patient Behavioral Response Training|Caring Response mobile app with a behavioral training.
89357169|NCT04489303|Active Comparator|Educational Training|Traditional educational program.
89357170|NCT04471064|Experimental|XY0206-12.5mg|Drug:XY0206;Dosage form:Tablet;Dosage：12.5mg; multiple dose phase
89357171|NCT04471064|Experimental|XY0206-25mg|Drug:XY0206;Dosage form:Tablet;Dosage：25mg; multiple dose phase
89357172|NCT04471064|Experimental|XY0206-50mg|Drug:XY0206;Dosage form:Tablet;Dosage：50mg; multiple dose phase
89357173|NCT04471064|Experimental|XY0206-100mg|Drug:XY0206;Dosage form:Tablet;Dosage：100mg; multiple dose phase
89357174|NCT04471064|Experimental|XY0206-150mg|Drug:XY0206;Dosage form:Tablet;Dosage：150mg; multiple dose phase
89357175|NCT04471064|Experimental|XY0206-200mg|Drug:XY0206;Dosage form:Tablet;Dosage：200mg; multiple dose phase
89534152|NCT00001309|Other|Pharmacokinetics and Biodistribution of Ascorbic Acid|Outpatient subjects will be encouraged to consume vitamin C in foods. As inpatients, vitamin C deficiency will be induced by placing subjects on a tightly restricted scorbutic diet. Plasma vitamin C will be monitored several times per week. When subjects have achieved a plasma ascorbate concentration of 5-10 micromolar, blood sampling and urine collection over 24 hours will be performed. After platelets and leukocytes are collected, ascorbate repletion will begin. Escalating doses of ascorbate will be administered orally and intravenously for the remainder of their inpatient admission. Total daily doses of 30mg, 60mg, 100mg, 200mg, 400mg, 1000mg and 2500mg will be given in two divided doses. Bioavailability of ascorbate will be determined at each dosage increment. When plasma ascorbate concentration reaches steady state for each dose, subjects will undergo 36 hr plasma sampling and a timed 48 hr urine collection.
88828655|NCT02887157||Specific Aim 3|"Specific Aim 3 (delineate which elements and regions (posterior) or (peripheral) of preterm infant OCT-derived retinal microanatomy best inform us about severity of disease and visual outcomes in infants with ROP will include the same 68 participants plus an additional 42 very preterm infants undergoing evaluation for ROP and visual function but who will not be in the neurodevelopmental study and thus will not have brain MRI, 2-year Bayley Scales testing or neuroinflammatory marker testing on scavenged blood. The Specific Aim 3 subjects will undergo the following:~Swept Source OCT imaging of both eyes with the novel ultralight handpiece as described in Aim 2. The axial length of the eye may be measured after the ROP exam.~After imaging with the original lens (ultralight handpiece) both eyes will be imaged with the widefield OCT lens. before or after the ROP exam.~Ocular and systemic health data will be extracted from the study participant's medical record."
88828656|NCT04743869|Active Comparator|KYPHON® ActivOs™10 Bone Cement with hydroxyapatite|As a reference device KYPHON® ActivOs™10 Bone Cement with hydroxyapatite (Medtronic) for treatment of vertebral compression fractures will be used. It is a polymethylmethacrylate (PMMA) bone cement containing hydroxyapatite (HA) for use in the treatment of patients with vertebral compression fractures (VCFs) who are undergoing minimally invasive surgery with KYPHON® Balloon Kyphoplasty. This bone substitute has already been approved and is in use in the patients at the age of 50 or older.
88828657|NCT04743869|Experimental|KyphOs FS™|The test device KyphOs FS™ will be used in patients at the age of 50 and older in order to prove its superiority over the currently used PMMA bone cement.
88828658|NCT02260531|Experimental|Cohort 1 - Cabozantinib, Trastuzumab for HER2+|"HER2-positive~Cabozantinib- orally administered daily per treatment cycle, 60 mg per day~Trastuzumab- IV administered once per cycle, 8 mg/kg IV loading dose followed by 6 mg/kg IV Cycle duration equals 3 weeks. Patients are treated indefinitely based on unacceptable toxicity, disease progression, or withdrawal for other reasons."
89357176|NCT04471064|Experimental|XY0206-250mg|Drug:XY0206;Dosage form:Tablet;Dosage：250mg; multiple dose phase
89357177|NCT04470167|Experimental|TPX-115|Subjects receive ultrasound-guided intratendinous injection of TPX-115
89357178|NCT04470167|Placebo Comparator|Placebo|Subjects receive ultrasound-guided intratendinous placebo injection
89357179|NCT04437498|Experimental|nVNS|non invasive vagal nerve stimulation
89357180|NCT04437498|Sham Comparator|sham|sham stimulation
88828659|NCT02260531|Experimental|Cohort 2 - Cabozantinib for ER+ and/or PR+|"Hormone receptor-positive (ER+ and/or PR+)~- Cabozantinib- orally administered daily per treatment cycle, 60 mg per day Cycle duration equals 3 weeks. Patients are treated indefinitely based on unacceptable toxicity, disease progression, or withdrawal for other reasons."
89177743|NCT00923000|Active Comparator|Nalbuphine|
89177744|NCT00923000|Active Comparator|Morphine|
89177745|NCT00923000|Experimental|Morphine with Long dan xie gan tang|
89357181|NCT04433156|Experimental|VR-CAP|Rituximab, 375 mg/m2, Intravenous administration on day 0, Bortezomib, 1.3 mg/m2 hypodermic injection on day 1 and 4, combined with regimen: Cyclophosphamide, Epirubicin, and Prednisone: repeated every 3 weeks, up to 6 cycles.
89534153|NCT00001281||Individuals living with HIV|Individuals living with HIV
89534154|NCT00001281||Individuals living with/without HIV|Individuals living with/without HIV
89534155|NCT00001281||Individuals living with/without infectious diseases|Individuals living with/without infectious diseases of interest
89177746|NCT00923000|Experimental|Nubian with Long dan xie gan tang 3g tid|
89530280|NCT03254797|Experimental|Stepping training with feedback|"Subjects will be instructed to perform the stepping task with external feedback continuously until 20 minutes (excluding resting periods) but without fatigue. Then they continue a training program of overground walking for 10 minutes.~They have to be involved in a training program of their groups 5 times/week, for 4 weeks in total."
89534156|NCT00001281||Individuals with/without Immunodeficiencies|Individuals with/without immunodeficiencies
89534157|NCT00001265||Healthy Volunteers|Patients with no disease
89534158|NCT00001265||Patients with muscle disease|Patients with known or suspected Idiopathic Inflammatory myopathies (IIM)
89534159|NCT00001252||healthy volunteer|Normal/healthy volunteers
89357182|NCT04417231|Experimental|Apheresis group|"10 patients receive a maximum of 3 apheresis treatments at intervals of 24 ± 12 hours each (from the beginning of the preceding treatment). The first treatment starts within 72 hours after infarction or, in case of an unclear time window, within presumed 72 hours after the patient was last seen free of symptoms. No further treatments are carried out if the CRP concentration before the start of a treatment is <10 mg/l or if the patient has been discharged from hospital.~For each treatment, 1.5 - 2.5 times the plasma volume is processed. The duration of each treatment is approximately 4-6 hours."
89357183|NCT04417231|No Intervention|Control group|10 patients of the control group receive the same examinations as arm 1 (verum group) but no apheresis treatments after ischemic stroke.
89357184|NCT04411381|Active Comparator|Telemedicine-based model of care|Telemedicine associated with dried blood spot testing at home for RNA test to sustained virological response determination
89357185|NCT04411381|No Intervention|Traditional model of care|Tradiotional model of care with venipuncture for RNA test to sustained virological response determination and face-to-face consultation
89357186|NCT04408794|Experimental|Zavegepant (BHV-3500)|10 mg intranasal (IN) up to 8 times per month, up to 1 year
89357187|NCT04406623|Experimental|SL-172154|Intravenous administration
89357188|NCT04394754|No Intervention|Control|Patients will receive usual care and no digital health device.
88828660|NCT02260531|Experimental|Cohort 3 - Cabozantinib for ER-, PR-, HER2-|"Triple negative (ER-, PR-, HER2-)~- Cabozantinib- orally administered daily per treatment cycle, 60 mg per day Cycle duration equals 3 weeks. Patients are treated indefinitely based on unacceptable toxicity, disease progression, or withdrawal for other reasons."
88828661|NCT02458235|Experimental|Azacitidine/donor lymphocyte infusion|Patients will be stratified according to risk categories (low, standard and high), defined by GVHD status, mixed versus full donor chimerism, and positive versus negative Minimal Residual Disease (MRD) results. Patients will receive up to 7 cycles of low-dose azacitidine (40mg/m2 IV/SC daily x 4 days) at 6 weekly intervals, except for low risk ALL patients who may not receive treatment after withdrawal of immunosuppression. Standard risk patients will receive an additional 6 cycles of azacitidine alone. High risk patients will receive an additional 6 cycles of azacitidine plus escalating DLI.
88828662|NCT04744103|Experimental|TCA peal|Patients will have their actinic cheilitis treated with a TCA peal.
88828663|NCT02140723||preoperative short course radiation|preoperative short course radiation with 8 weeks delay of surgery
88828664|NCT02115997|Experimental|Rituximab|Participants will receive IV infusion of rituximab once weekly from Week 1 to 4. Participants will also receive one pulse of methylprednisolone, followed by a tapering dose of oral prednisolone at the discretion of the investigator. Methylprednisolone may be repeated up to total of 3 pulses at the discretion of the investigator.
88828665|NCT01805323||All Participants|Patients with macular edema previously treated with dexamethasone intravitreal implant (OZURDEX®) according to general clinical practice.
88828666|NCT01641055|Experimental|Salmon protein hydrolysate|
88828667|NCT01641055|Experimental|Herring protein hydrolysate|
88828668|NCT01641055|Sham Comparator|Cod protein|
88828669|NCT01641055|Placebo Comparator|Milk protein|
88828670|NCT02459795|Experimental|Test product|Ingenol Mebutate (Perrigo)
88828671|NCT02459795|Active Comparator|Reference product|Ingenol Mebutate (Reference)
88828672|NCT02459795|Placebo Comparator|Placebo product|Placebo gel
88828673|NCT01787383|Active Comparator|Ingenol mebutate gel 0.05 %|
89357189|NCT04394754|Experimental|BodyPort|Patients will receive the BodyPort device.
89357190|NCT04394754|Experimental|Noom|Patients will receive a subscription to the Noom platform.
89357191|NCT04394754|Experimental|Conversa|Patients will receive a subscription to the Conversa platform.
88828674|NCT01787383|Active Comparator|Ingenol mebutate gel 0.015 %|
89357192|NCT04390451|Experimental|Whole Health STEPS|Participants will immediately receive Whole Health STEPS.
89357193|NCT04390451|Other|Waitlist|Participants will receive Whole Health STEPS after a defined waiting period.
89357194|NCT04388176|Experimental|C21 followed by placebo|
89357195|NCT04388176|Experimental|Placebo followed by C21|
89357196|NCT04354896|Experimental|Levothyroxine|The intervention will start with Levothyroxine 50 mcg daily with regular blinded dosis titration.
89357197|NCT04354896|Placebo Comparator|Placebo|Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg.
89357198|NCT04354168|Experimental|Nthabi mHealth Application|About 20 women from each of the ten district hospitals will be recruited. Each district hospital will have a separate administrative page on the Nthabi server where women will be enrolled with a unique username and password. Upon enrollment, the women will be asked to engage with Nthabi for two months to discuss the relevant content areas they are interested in learning more about.
89357199|NCT04354129||PID/SID Cutaquig Treated Patients|Immunoglobulin replacement therapy with subcutaneous injections of Cutaquig® 165 mg/mL at home.
88828676|NCT02461433|Experimental|Prevena|After surgery this group will receive the Prevena device (negative pressure wound therapy).
88828677|NCT02461433|Active Comparator|Standard dressing|After surgery this group will receive standard of care dressings on their surgical wound.
88828678|NCT02462291|Experimental|Experimental group (TR)|A group of 80 patients with AD will perform a program of EET for 2 hours a day, 5 days a week for a total of 6 months.
88828679|NCT02462291|No Intervention|Control group (CTRL)|A group of 80 patients with AD will be treated with the standard therapy.
88828680|NCT02463227|Experimental|VRC01|Participants received an IV infusion of 40 mg/kg of VRC01 on study days 0, 21, and 42.
88828681|NCT00984269|No Intervention|No Tourniquet|Patients undergoing hand/wrist surgery without the use of a tourniquet.
88828682|NCT00984269|Experimental|Tourniquet|Patients undergoing hand/wrist surgery with the use of a tourniquet.
89357200|NCT04350424||Propofol Arm|Outpatients receiving anesthesiologist-administered propofol for elective outpatient endoscopic procedures
89357201|NCT04350424||Opioid / Benzodiazepine Arm|Outpatients receiving endoscopist-administered opioid / benzodiazepine for elective outpatient endoscopic procedures
89357202|NCT04311489|Experimental|Ularitide|Test product. Continuous intravenous infusion with 30 ng/kg/min for 48 hours.
89357203|NCT04311489|Placebo Comparator|Placebo|Matching placebo. Continuous IV infusion for 48 hours.
89357204|NCT04305405|Experimental|Dose 1|Below 35 kilos
89534160|NCT00001252||Impaired volunteer|volunteers with impairments of the neuromusculoskeletal system.
89534161|NCT00001248||healthy volunteers|Healthy volunteers for technique development and comparison with the patient populations.
88828683|NCT01788631|Active Comparator|Regadenoson Arm|1.44 mcg/kg/hour infused over 48 hours
88828684|NCT01788631|Placebo Comparator|Placebo Arm|Placebo infused over 48 hours
88828685|NCT00907283|Experimental|deferiprone|15 mg/Kg/twice for 1 year
89357205|NCT04305405|Experimental|Dose 2|Greater than/equal to 35 kilos
89534162|NCT00001248||MS/CIS/RIS population|Patients with a diagnosis of MS or who have typical imaging abnormalities associated with MS.
89534163|NCT00001248||Non-MS comparison population|Patients with disorders of the CNS, to include patients with diseases that share mechanisms of tissue damage with MS
89534164|NCT00001231||Healthy Women|The purpose of this protocol is to allow for the careful screening of healthy volunteers for participation in research protocols.
89534165|NCT00001231||premenopausal depressed women patients|The purpose of this protocol is to allow for the careful screening of patients for participation in research protocols.
89534166|NCT00001208||Patients|Patients will be eligible for participation if they have a movement disorder that, in the judgment of the treating physician, might be amenable to treatment with BTX.
89357206|NCT04263259|Experimental|Attentional Bias Modification|Participants complete attentional bias modification using a dot probe task on a mobile device up to 5 times per day for a 28-day period (80 trials per assessment).
89357207|NCT04263259|No Intervention|Attentional Bias Control|Participants complete attentional bias assessment-only using a dot probe task on a mobile device up to 5 times per day for a 28-day period (80 trials per assessment).
89357208|NCT04255134|Experimental|Abatacept|Drug administered to participants with active rheumatoid arthritis
89357209|NCT04255134|Active Comparator|Adalimumab|Comparator drug administered to participants with active rheumatoid arthritis
89357210|NCT04240639|Experimental|AuroShell particle infusion|Single intravenous infusion of AuroShell particles 12 to 36 hours prior to MRI/US guided laser irradiation using an FDA cleared laser and an interstitial optical fiber diffuser.
89357211|NCT04217304|Experimental|Sonothrombolysis|Diagnostic myocardial contrast echocardiography with ultrasound contrast agent 5% Definity® plus Sonothrombolysis
89357212|NCT04217304|No Intervention|Standard of Care|Diagnostic myocardial contrast echocardiography with ultrasound contrast agent 5% Definity®
89357213|NCT04210947|Experimental|Foam-roller I-II-III|Participants will use foam roller in following order of 30RPM(I), 15RPM(II) and self-determined(III)
89357214|NCT04210947|Experimental|Foam-roller I-III-II|Participants will use foam roller in following order of 30RPM(I), self-determined(III) and 15RPM(II)
89357215|NCT04210947|Experimental|Foam-roller II-I-III|Participants will use foam roller in following order of 15RPM(II), 30RPM(I) and self-determined(III)
89357216|NCT04210947|Experimental|Foam-roller II-III-I|Participants will use foam roller in following order of 15RPM(II), self-determined(III) and 30RPM(I)
89357217|NCT04210947|Experimental|Foam-roller III-I-II|Participants will use foam roller in following order of self-determined(III), 30RPM(I) and 15RPM(II)
89357218|NCT04210947|Experimental|Foam-roller III-II-I|Participants will use foam roller in following order of self-determined(III), 15RPM(II) and 30RPM(I)
89357219|NCT04192370|Experimental|Cannabidiol|As this is a single-arm, open-label study, all subjects will receive the interventional arm, specifically 600mg of oral cannabidiol once daily for 3 consecutive days.
89357220|NCT04189029||HFpEF patients|Heart failure patients (NYHA II-IV) with left ventricular ejection fraction ≥ 50%, 1000 patients anticipated among which up to 300 with extensive phenotyping
89357221|NCT04189029||HFrEF patients|Heart failure patients (NYHA II-IV) with left ventricular ejection fraction ≤ 40%, 1000 patients anticipated among which up to 100 with extensive phenotyping (age- and gender-matched on participating HFpEF patients)
89357222|NCT04189029||Subjects apparently without heart failure|Subjects without history or signs of heart failure, up to 100 subjects anticipated with extensive phenotyping (age- and gender-matched on participating HFpEF patients)
89357223|NCT04183504|Experimental|Early Steps Coaching|Coaching session on positive parenting practices and promoting child development.
89357224|NCT04180930||Cohort 1|Individuals randomized to Cohort 1 will be assigned to the CAPS-5 and will complete between two and seven research visits. Participants will be administered the CAPS-5 during visit 2, and then will be randomized a second time into groups 1-A and 1-B. Group 1-A will end participation after visit 2. Group 1-B will complete visits 3-7 and will be administered the CAPS-5 at each of these visits along with other measures of cognitive and behavioral functioning, and will provide biofluid samples.
89534167|NCT00001204||1|Longitudinal sequential cardiologic studies utilizing noninvasive techniques in homozygous patients with well-characterized LDL receptor defects
89534168|NCT00001177||healthy volunteers|healthy females
89534169|NCT00001177||patients|females with menstrually-related mood or behavioral difficulties
89534170|NCT00001163||1|primary clinical; volunteers come from all U.S.
89357225|NCT04180930||Cohort 2|Individuals randomized to Cohort 2 will be assigned to the PSSI-5 and will complete between two and seven research visits. Participants will be administered the PSSI-5 during visit 2, and then will be randomized a second time into groups 2-A and 2-B. Group 2-A will end participation after visit 2. Group 2-B will complete visits 3-7 and will be administered the PSSI-5 at each of these visits along with other measures of cognitive and behavioral functioning, and will provide biofluid samples.
89357226|NCT04180930||Cohort 3|Individuals randomized to Cohort 3 will have three office visits and will complete the CAPS-5 and the PSSI-5 in a counter-balanced order during visits 2 and 3, along with other measures of cognitive and behavioral functioning, and will provide biofluid samples.
89357227|NCT04180930||Cohort 4|Individuals randomized to Cohort 4 will have three office visits and will complete the CAPS-IV and the CAPS-5 in a counter-balanced order during visits 2 and 3, along with other measures of cognitive and behavioral functioning, and will provide biofluid samples.
89357228|NCT04180371|Experimental|Phase I - Dose escalation (BT5528)|Cohorts of participants will receive increasing doses of BT5528. It is expected that up to 72 participants will participate in this dose escalation arm.
89357229|NCT04180371|Experimental|Phase I - Dose escalation combination (BT5528 & nivolumab)|Cohorts of participants will receive increasing doses of BT5528 and a standard dose of nivolumab. It is expected that up to 24 participants will participate in this dose-escalation combination arm.
89357230|NCT04180371|Experimental|Phase II - Dose expansion 1 (BT5528)|A cohort of participants will receive the selected dose of BT5528 as a monotherapy. It is expected that up to 192 patients have solid tumors (Cohort 1: urothelial cancers, Cohort 2: ovarian cancer, Cohort 3: non-small cell lung cancer, Cohort 4: head and neck cancer, Cohort 5: triple-negative breast cancer, and Cohort 6: gastric/upper gastrointestinal cancer) historically known for high expression of EphA2 will participate in this dose-expansion arm
89357231|NCT04160910|Active Comparator|5-hydroxytryptophan|"Dosage of 5-hydroxytryptophan will be determined by weight:~If subject weighs less than 100lbs: 50mg twice a day If subject weights more than 100lbs: 100mg twice a day"
89357232|NCT04160910|Placebo Comparator|Placebo|"Dosage of placebo will be determined by weight:~If subject weighs less than 100lbs: 50mg twice a day If subject weights more than 100lbs: 100mg twice a day"
89357233|NCT04147299||HFrEF|Heart Failure with Reduced Ejection Fraction
89357234|NCT04147299||HFpEF|Heart Failure with Preserved Ejection Fraction
89357235|NCT04147299||Elite Athletes|Endurance athletes
89357236|NCT04090827|Experimental|Intervention|Nurse-led transition intervention and access to the iHeartChange website
89357237|NCT04067037|Experimental|Camrelizumab Combined With AVD regimen|Camrelizumab 200mg, Intravenous administration on day 1 and day 15 combined with regimen：AVD (Epirubicin, Vincristine and Dacarbazine): repeated every 4 weeks, up to 6 cycles.
89357238|NCT04066699||Localization|Electromagnetic navigation (EMN) guided percutaneous localization of suspicious lung lesion(s).
89357239|NCT04035980|No Intervention|Conventional care|Screening HCV with dried blod spot (DBS) testing and referral to tertiary care hospital to evaluate disease stage and treatment of HCV RNA positive patients
89357240|NCT04035980|Active Comparator|Telemedicine care|Two-way videoconference to evaluate the need of screening with DBS, disease stage evaluation and treatment of HCV RNA positive patients at drug addiction centers
89357241|NCT03996616|No Intervention|Control Group|"During the pre-intervention period, patients will receive standard CPR in the two study groups. Standard CPR will be performed according to the current guidelines.~The only changes in current practice for the control will be the monitoring of EtCO2 and cerebral oxymetry as early as possible for the firefighter. ETCO2 will be recorded using a small portable ETCO2 monitor (EMMA, Masimo, USA). EMS first responders will receive a specific training in both group to use, recording, and reporting of ETCO2 value during CPR. This device has CE mark (see related CE mark and user manual). Cerebral oximetry will be recorded using a new small portable device (HR500, Nonin, USA). This device allows using an easy to use adhesive sensor with remote Bluetooth connection to a smartphone sized monitor."
88828686|NCT01789255|Experimental|Supportive care (vorinostat, tacrolimus, methotrexate)|Patients receive vorinostat PO BID on days -10 to 100. Beginning on day -3, patients receive tacrolimus IV continuously or PO BID (or cyclosporine IV continuously or PO in patients unable to tolerate tacrolimus) with taper on days 100-180.Patients also receive methotrexate IV QD on days 1, 3, 6, and 11.
89357242|NCT03996616|Active Comparator|Assigned Intervention|During the post-intervention period, patients assigned in the intervention group will receive the evaluated intervention (i.e., HUP and ACD-ITD CPR HUP using the 3 devices in combinations, Elegard, Lucas AD and ITD-16)
89357243|NCT03948256|Active Comparator|Control intervention|Prompt closure, based on best available scientific data
89357244|NCT03948256|Experimental|Experimental intervention|Gradual weaning, based on best available scientific data
89357245|NCT03764878||Normal weight|BMI 18.5-24.9 kg/m^2 low risk pregnancy
89357246|NCT03764878||Pregestational diabetes mellitus|Type 1 or Type 2 diabetes mellitus diagnosed prior to the pregnancy or in the first trimester
89357247|NCT03764878||Obese|Pre-pregnancy BMI ≥ 30.0 kg/m^2
89357248|NCT03669640|Experimental|Part A: Monotherapy|Participants will receive RO6889450 or a dose-matched placebo. NOTE: Part A has completed enrollment.
89357249|NCT03669640|Experimental|Part B: Add-On Therapy|Participants will receive a low or high dose of RO6889450 or a dose-matched placebo in addition to their usual anti-psychotic treatment(s).
89357250|NCT03668028|Experimental|TPX-114|Subjects undergo arthroscopic rotator cuff repair with TPX-114.
89357251|NCT03668028|Placebo Comparator|Placebo|Subjects undergo arthroscopic surgery for rotator cuff repair without TPX-114.
89357252|NCT03623893|Other|Intervention group|Unilateral inguinal hernia repair with contralateral exploration.
89357253|NCT03623893|No Intervention|Control group|Unilateral inguinal hernia repair.
89357254|NCT03601507|Experimental|Treatment (Alpelisib)|Participants receive Alpelisib PO QD for 14-21 days in the absence of disease progression of unacceptable toxicity and then undergo surgery. Participants may receive Alpelisib for up to 28 days if surgery is delayed.
89534171|NCT00001159||Thyroid disorders|Patients with thyroid disorders
89534172|NCT04191811||Depression Internet-delivered CBT|12 weeks of guided internet-delivered CBT for depression.
89534173|NCT04191811||Insomnia Internet-delivered CBT|12 weeks of guided internet-delivered CBT for insomnia.
88828687|NCT02464163|Experimental|Panblok 30µg in 2% SE|30µg recombinant hemagglutinin in a 2% oil-in-water stable emulsion (rHA adjuvant). 0.5mL intramuscular injection on Day 0 and Day 21 in the deltoid muscle
88828688|NCT02464163|Experimental|Panblok 15µg in 2% SE|15µg recombinant hemagglutinin in a 2% oil-in-water stable emulsion (rHA adjuvant). 0.5mL intramuscular injection on Day 0 and Day 21 in the deltoid muscle
88828689|NCT02464163|Experimental|Panblok 7.5µg in 2% SE|7.5µg recombinant hemagglutinin in a 2% oil-in-water stable emulsion (rHA adjuvant). 0.5mL intramuscular injection on Day 0 and Day 21 in the deltoid muscle
88828690|NCT02464163|Experimental|Panblok 30µg (No Adjuvant)|30µg recombinant hemagglutinin (no adjuvant). 0.5mL intramuscular injection on Day 0 and Day 21 in the deltoid muscle
88828692|NCT02465099|Active Comparator|Electrocautery Dissection (ED)|Patients meeting the study criteria, scheduled to undergo posterior spinal fusion (PSF) using monopolar electrocautery and metal Cobb elevator (considered the current standard) for soft tissue dissection and removal from vertebral surfaces.
89188879|NCT00718796|Experimental|1|Individualized naturopathic treatment consisting of dietary and lifestyle advice and individualized supplementation
89188880|NCT00718796|Active Comparator|2|Current care control provided by participants' medical doctor
89188881|NCT00844168|Experimental|Treatment (adjuvant sorafenib tosylate after liver transplant)|Patients receive sorafenib tosylate PO twice daily on days 1-28. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
89188882|NCT02573168|Experimental|GeneSight Psychotropic (GEN)|The GeneSight Psychotropic (GEN) product is a pharmacogenomic decision support tool that helps clinicians to make informed, evidence-based decisions about proper drug selection. More specifically, patients are tested for clinically important genetic variants of multiple pharmacokinetic and pharmacodynamic genes that affect a patient's ability to metabolize, tolerate or respond to medications.
89188883|NCT02573168|Experimental|Enhanced-GeneSight Psychotropic (E-GEN)|The current GEN test lacks predictive genes for antipsychotic-induced weight gain (AIWG), a major complication of antipsychotic drug use. Therefore, the Enhanced-GeneSight Psychotropic (E-GEN), which is an enhanced version of the GEN test, was developed by incorporating 6 new genes (represented by 7 SNPs) that are predictive for AIWG, to those used in the GEN algorithm. An increasing risk level associated with AIWG is estimated by an increasing number of risk genotypes that a given patient possesses among the 7 SNPs.
89188884|NCT02573168|Active Comparator|Treatment as Usual (TAU)|"The comparator chosen for this study provides a real world comparison of standard of care for patients who receive no pharmacogenomics guidance.~Patients randomized to the TAU arm will also have their DNA collected and a pharmacogenomic-based interpretive report will be generated using GEN testing. However, this report will not be shared with the treating clinicians until completion at 12 months of the study. Therefore, patients in this arm will receive clinical treatment as usual, without the use or knowledge of genotyping results by their treating clinicians."
89188885|NCT00836446|Active Comparator|Group 1|20 min. physical activity routine
89188886|NCT00836446|Experimental|Group 2|40 min. aerobic physical activity routine
89188887|NCT00841750|Experimental|No chest tube|No chest tube left in the pleural cavity at the end of a VATS pulmonary wedge resection.
89188888|NCT00841750|Active Comparator|Chest tube|Chest tube left in the pleural cavity at the end of a VATS pulmonary wedge resection.
89188889|NCT02574884|Other|Recently infected subjects|Actual population of blood donors primo-infected with HCV with specific intervention for the study : one blood sample during the inclusion visit
89188890|NCT02574884|No Intervention|Retrospective cases|Population of infected blood donors in 2007, 2008 and 2009 No blood sample
89188891|NCT02574884|Other|Individuals sources|Specific intervention for the study : one blood sample during the inclusion visit
89188892|NCT00836524||1|Pregnant women are included when they attend nuchal transcluency examination and will during their pregnancy be examined 4 times with ultrasound
89188893|NCT00764465|Active Comparator|Group A|Period 1-Maraviroc 300mg BID Period 2- Fosamprenavir 1400mg BID Period 3- Fosamprenavir 1400mg BID + Maraviroc 300mg BID
89188894|NCT00764465|Active Comparator|Group B|Period 1-Maraviroc 300mg BID Period 2-Fosamprenavir 1400mg BID + Maraviroc 300mg BID Period 3-Fosamprenavir 1400mg BID
89188895|NCT00764465|Active Comparator|Group C|Period 1-Maraviroc 300mg BID Period 2-Fosamprenavir 700mg BID + Ritonavir 100mg BID Period 3-Fosamprenavir 700mg BID + Ritonavir 100mg BID + Maraviroc 300mg BID
89188896|NCT00764465|Active Comparator|Group D|Period 1-Maraviroc 300mg BID Period 2-Fosamprenavir 700mg BID + Ritonavir 100mg BID + Maraviroc 300mg BID Period 3-Fosamprenavir 700mg BID + Ritonavir 100mg BID
89188897|NCT00764465|Active Comparator|Group E|Period 1-Maraviroc 300mg BID Period 2-Fosamprenavir 1400mg QD + Ritonavir 100mg QD Period 3- Fosamprenavir 1400mg QD + Ritonavir 100mg QD + Maraviroc 300mg BID
89357255|NCT03596866|Experimental|Brigatinib|Brigatinib 90 milligram (mg), tablets, orally, once daily 7 days, followed by Brigatinib 180 mg, tablets, orally, once daily for until objective disease progression per RECIST version 1.1, as assessed by the investigator, or intolerable toxicity.
89357256|NCT03596866|Active Comparator|Alectinib|Alectinib 600 mg, capsules, orally twice daily until objective disease progression per RECIST version 1.1, as assessed by the investigator, or intolerable toxicity.
89357257|NCT03543410|Experimental|SEP-4199 200 mg|SEP-4199 200 mg/day (supplied in two 100mg tablets)
89357258|NCT03543410|Experimental|SEP-4199 400 mg|SEP-4199 400 mg/day (supplied in two 200mg tablets)
89357259|NCT03543410|Placebo Comparator|Placebo|Placebo (supplied in two tablets/day
89357260|NCT03502785|Experimental|Cohort A|Participants with locally advanced unresectable or metastatic/recurrent UCa, who have confirmed disease progression during or following treatment with an anti-PD-1/PD-L1 therapy. Cohort A participants will be treated with INO-5401 and INO-9012 in combination with atezolizumab.
89357261|NCT03502785|Experimental|Cohort B|Participants with locally advanced unresectable or metastatic/recurrent UCa who are treatment naïve and ineligible for cisplatin-based chemotherapy. Cohort B participants will be treated with INO-5401 and INO-9012 in combination with atezolizumab.
89357262|NCT03495960|Experimental|Lenalidomide (experimental arm of part A)|"Patients in part A will receive 2 courses of induction chemo-immunotherapy:~Rituximab 375 mg/m2 i.v. on days -6, 1, 15, 29; Methotrexate 3 g/m2 0.5 g/m2 in 15 min. +2.5 g/m2 in 3-hr inf. on days 2,16,30; Procarbazine 60 mg/m2/d oral on days 2 to 11.~The duration of each treatment course is 43 days. Patients will then be randomized to receive lenalidomide or procarbazine as maintenance therapy.~Lenalidomide is given 25 mg/d per os, days 1 to 21 every 4 weeks for 24 courses"
89357263|NCT03495960|Active Comparator|Procarbazine (comparator arm of part A)|"Patients in part A will receive 2 courses of induction chemo-immunotherapy:~Rituximab 375 mg/m2 i.v. on days -6, 1, 15, 29; Methotrexate 3 g/m2 0.5 g/m2 in 15 min. +2.5 g/m2 in 3-hr inf. on days 2,16,30; Procarbazine 60 mg/m2/d oral on days 2 to 11.~The duration of each treatment course is 43 days. Patients will then be randomized to receive lenalidomide or procarbazine as maintenance therapy.~Procarbazine is given 100 mg/d per os, days 1 to 5 every 4 weeks for 6 courses"
89357264|NCT03495960|Other|Radiotherapy, temozolomide and rituximab (single arm part B)|"Patients ineligible for high-dose-methotrexate will be treated in the single-arm phase II part B of the trial and will receive~whole-brain radiotherapy (2340 cGy in 5 weekly fractions)~temozolomide 75 mg/m2/d during radiotherapy~4 weekly doses of rituximab 375 mg/m2, starting on day 2 of the whole-brain radiotherapy.~Patients will then receive maintenance therapy with 12 courses of temozolomide administered on days 1-5, every 4 weeks at a dose of 150 mg/m2/d at the first course, and of 200 mg/m2/d at the subsequent courses."
89357265|NCT03491683|Experimental|Cohort A: Unmethylated MGMT Promoter|Cohort A will include participants with a glioblastoma tumor with an unmethylated MGMT promoter. Participants will receive INO-5401 and INO-9012 and cemiplimab as well as radiation and temozolomide (TMZ; only during radiation therapy), if clinically indicated.
89357266|NCT03491683|Experimental|Cohort B: Methylated MGMT Promoter|Cohort B will include participants with a glioblastoma tumor with a methylated MGMT promoter or with indeterminate MGMT status. Participants will receive INO-5401 and INO-9012 and cemiplimab as well as radiation and temozolomide (TMZ), if clinically indicated. Participants will continue to receive TMZ following radiation therapy, for up to six additional cycles, if clinically indicated.
89357267|NCT03438656|Experimental|Behavioral Activation Arm|See treatment description for information on Behavioral Activation. Participants will receive 12 weekly sessions of Behavioral Activation.
89357268|NCT03345823|Experimental|Substudy 1: Cohort 1 Upadacitinib Dose A|This is a maintenance group which includes participants who achieved clinical response to upadacitinib in studies M14-431 and M14-433 and will receive upadacitinib dose A for 52 weeks.
89357269|NCT03345823|Experimental|Substudy 1: Cohort 1 Upadacitinib Dose B|This is a maintenance group which includes participants who achieved clinical response to upadacitinib in studies M14-431 and M14-433 and will receive upadacitinib dose B for 52 weeks.
88828693|NCT02465099|Experimental|Ultrasonic Dissection (UD)|Patients meeting the study criteria, scheduled to undergo PSF using ultrasonic dissection and metal Cobb elevator for soft tissue dissection and removal from vertebral surfaces.
89357270|NCT03345823|Experimental|Substudy 1: Cohort 1 Placebo|This is a maintenance group which includes participants who achieved clinical response to upadacitinib in studies M14-431 and M14-433 and will receive placebo for 52 weeks.
88828694|NCT01807585|Experimental|VenaSeal SCS|Endovenous delivery of VenaSeal Adhesive (VA) to a target site in diseased great saphenous veins (GSV). The VA is dispensed in small amounts with each pull of the trigger equaling 0.10 cc. Subjects were randomized in a 1:1 ratio to either VenaSeal SCS or to RFA.
89177747|NCT04534972|No Intervention|Pre-Implementation|The control (pre-implementation) group will be burn patients admitted to the burn unit in ICU during the site's control period of the stepped-wedge implementation process (up to 22 months).
89357271|NCT03345823|Experimental|Substudy 1: Cohort 2 Placebo|This is a maintenance group which includes participants who received double-blind placebo in studies M14-431 and M14-433 and achieved clinical response will continue to receive blinded placebo for 52 Weeks.
89357272|NCT03345823|Experimental|Substudy 1: Cohort 3 Upadacitinib Dose B|This is a maintenance group which includes participants who achieved clinical response to upadacitinib from the extended treatment period of studies M14-431 and M14-433 and will receive upadacitinib Dose B for 52 Weeks.
88828695|NCT01807585|Active Comparator|RFA (ClosureFast)|Endovenous insertion of the ClosureFast radiofrequency ablation (RFA) catheter into a target site in diseased great saphenous veins (GSV). Heat is applied to the target vein using radiofrequency energy to ablate the target vein. Subjects were randomized in a 1:1 ratio to either VenaSeal SCS or RFA.
89357273|NCT03345823|Experimental|Substudy 2: Cohort 4 Upadacitinib Dose B|This is a long-term extension group which includes participants who achieved clinical response in the open-label extended treatment period of study M14-431 and will receive upadacitinib dose B for 240 weeks.
89357274|NCT03345823|Experimental|Substudy 2: Cohort 5 Upadacitinib Dose A|This is a long-term extension group which includes participants who complete Substudy 1 and will receive upadacitinib dose A for 240 weeks.
89357275|NCT03345823|Experimental|Substudy 2: Cohort 5 Upadacitinib Dose B|This is a long-term extension group which includes participants who complete Substudy 1 and will receive upadacitinib dose B for 240 weeks.
89357276|NCT03345823|Experimental|Substudy 2: Cohort 5 Placebo|This is a long-term extension group which includes participants who complete Substudy 1 and will receive placebo for 240 weeks.
89357277|NCT03345823|Experimental|Substudy 3: Cohort 6 Upadacitinib Dose A|This is the dose optimization group which includes participants from Substudy 2 who meet the criteria of stable remission will receive open-label upadacitinib dose A for up to 48 weeks.
89357278|NCT03282461|Experimental|ABY-029|Between 3-9 patients will be administered ABY-029 as a single intravenous injection approximately 1-3 hours prior to surgery.
89357279|NCT03275454|Experimental|BIVV009|Participants who weigh less than 75 kilogram (kg) will receive fixed doses of 6.5 grams of BIVV009 intravenous (IV) infusion and participants who weigh 75 kg or more will receive fixed doses of 7.5 grams of BIVV009 every 2 weeks for approximately 21 weeks in Part A (based on time to complete 11 doses of study drug). There will be a 9-week safety follow-up/washout period after administration of the last dose of study drug in Part A. Participants who have been shown to benefit from BIVV009 treatment during Part A, will receive BIVV009 (based on weight) biweekly for up to 52 weeks of BIVV009 after Last Patient In (LPI) in part B.
89357280|NCT03263260||implanted patients|Patients with native coronary artery lesions with diameter between 2.5 and 4.0 and 34 mm of length treated only with the Inspiron Sirolimus eluting Stent
89357281|NCT03138161|Experimental|Phase 1|"Phase 1: 3-6 will be treated with escalating doses of Trabectedin every 3 weeks up to 18 doses. Dose Level 1 is 1.0 mg/m2; Dose Level 2,1.2 mg/m2; Dose Level 3,1.5 mg/m2. Beginning 2 weeks after the first dose of Trabectedin, all patients will be treated with Ipilimumab at 1 mg/kg every 12 weeks up to 5 doses, and Nivolumab at 3 mg/kg every 2 weeks up to 26 doses.~Phase 2: All patients will be treated with the maximum tolerated dose of Trabectedin every 3 weeks. Beginning 2 weeks after the first dose of Trabectedin, all patients will be treated with Ipilimumab at 1 mg/kg every 12 weeks up to 5 doses, and Nivolumab at 3 mg/kg every 2 weeks up to 26 doses."
89357282|NCT03093337|Experimental|Psychomotor therapy|Early post hospital discharge psychomotor therapy.
89357283|NCT03093337|No Intervention|Control|No specific support.
89357284|NCT03078972||Advanced Heart Failure|40 patients with advanced heart failure scheduled to undergo Left Ventricular Assist Device (LVAD) insertion will be recruited for testing. Test subjects will complete testing prior to, and following LVAD implantation.
89357285|NCT03078972||Healthy controls|10 age-matched healthy individuals will be recruited to establish normal/reference values.
89357286|NCT03078972||Mild Heart Failure|A second control group comprised of 10 age-matched individuals will be recruited to establish normal/reference values for individuals with mild, medically managed heart failure.
89357287|NCT02908074|Experimental|BGS649 0.1 mg|Drug: BGS649 Dose 1 weekly
89357288|NCT02908074|Experimental|BGS649 0.3 mg|Drug: BGS649 Dose 2 weekly
89357289|NCT02908074|Experimental|BGS649 1.0 mg|Drug: BGS649 Dose 3 weekly
89357290|NCT02907359|Experimental|Guadecitabine|Participants received Guadecitabine 60 mg/m^2, SC, on Days 1-5 of each 28-day cycle for at least 6 cycles in the absence of unacceptable toxicity or disease progression requiring alternative therapy. Participants received Guadecitabine treatment beyond 6 cycles as long as the participant continued to benefit based on investigator judgment and participant response and tolerability (or up to a maximum of 36 cycles).
89357291|NCT02907359|Active Comparator|Treatment Choice|"Participants received one of the three treatment choice options:~LDAC 20 mg/m^2 SC/IV once daily for 14 days of each 28-day cycles for at least 4 cycles in absence of disease progression or unacceptable toxicity.Participants who were responding or had stable disease were to continue treatment as per standard institutional practice.~Standard IC of a 7+3 regimen:Cytarabine 100-200 mg/m^2/day given as continuous infusion for 7 days and anthracycline(daunorubicin(45-60 mg)/idarubicin(9-12 mg)/mitoxantrone(8-12 mg)/m^2) by IV infusion for 3 days of each 28-day cycles.~BSC as needed during the treatment included,but was not limited to,blood transfusions(RBCs or platelets),growth factors including erythropoiesis stimulating agents,granulocyte stimulating factors,iron chelating therapy,and broad-spectrum antibiotics and/or antifungals.~Duration for treatment choice was as per locally approved prescribing information and institutional standard practice or up to a maximum 30 cycles."
89357292|NCT02749981||Cefazolin|patients receiving cefazolin as part of routine clinical care
89357293|NCT02714205|Experimental|Transdermal Nitroglycerin|Daily transdermal nitroglycerin patch, starting at 0.2 mg/hr. Dose escalation up to 0.6 mg/hr.
89357294|NCT02714205|Placebo Comparator|Placebo|Daily transdermal placebo patch.
89357295|NCT02666781||Pilot Group|Postoperative surgical Patients with or without Obstructive Sleep Apnea
89357296|NCT02611206|Experimental|Period 1: 80% of MT|All participants who qualify will undergo 6 weeks of open-label rTMS with a stimulation intensity of 80% of MT
89357297|NCT02611206|Experimental|Period 2: 100% of MT|All participants who qualify will undergo 6 weeks of open-label rTMS with a stimulation intensity of 100% of MT
89357298|NCT02611206|Experimental|Period 3: 120% of MT|All participants who qualify will undergo 6 weeks of open-label rTMS with a stimulation intensity of 120% of MT
89357299|NCT02477124|Active Comparator|transvaginal digital colposcope (TVCD)|Each enrolled patient will undergo the standard of care for cervical cancer screening at her institution, and then the trans-vaginal colposcope will be used to collect digital images of the cervix.
89357300|NCT02477124|Active Comparator|standard of care screening|Each enrolled patient will undergo the standard of care for cervical cancer screening at her institution, and then the trans-vaginal colposcope will be used to collect digital images of the cervix.
89357301|NCT02329080|Experimental|MATRIX - R-ICE - Conditioning and ASCT|"MATRIX (courses 1,2,3): Rituximab 375 mg/m2 d0/Methotrexate 3.5 g/m2 d1/Cytarabine 2 g/m2 d2 & d3/Thiotepa 30 mg/m2 d4/Liposomial Cytarabine 50 mg* d5~R-ICE (courses 4,5,6):Rituximab 375 mg/m2 d1/Etoposide 100 mg/m2 d1,d2, d3/Ifosfamide 5 g/m2 d2/Carboplatin 5 AUC d2/Liposomial Cytarabine 50 mg* d4~*If liposomal cytarabine is not available, standard intrathecal chemotherapy with methotrexate 10 mg + cytarabine 40 mg + hydrocortisone 50 mg can be administered. Oral steroids are suggested for 2-3 days after intrathecal liposomial cytarabine delivery to prevent chemical or aseptic meningitis/ arachnoiditis.~Conditioning and ASCT: BCNU (carmustine)** 400 mg/m2 d-6/Thiotepa 5 mg/kg d-5 & d-4 ASCT: 5 x 106 CD34+cells/kg d0~**In case of BCNU unavailability, the recommended conditioning regimen (Phase IV) is: Thiotepa 5 mg/kg d-6 & d-5/Busulfan 3.2 mg/kg d-4,d -3,d-2/Clonazepam 2 mg/d d-4,d -3,d-2 ASCT: 5 x 106 CD34+cells/kg d0"
89357302|NCT02231515|Experimental|Pattern laser trabeculoplasty (PLT)|Pattern laser trabeculoplasty
89357303|NCT02231515|Active Comparator|Selective laser trabeculoplasty (SLT)|Selective laser trabeculoplasty (SLT)
89357304|NCT02229331||gait analysis|gait analysis
89357305|NCT02025543||Patient Group|Subjects with known or suspected iron overload will undergo serum ferritin measurement and an MRI scan.
89357306|NCT02025543||Control Group|Subjects with no known history of iron overload or liver disease will undergo an MRI scan.
89357307|NCT01922635|Other|1|
89357308|NCT01820910|Experimental|Doxycycline|
89357309|NCT01808599|Experimental|Chlorambucil, Rituximab i.v., Rituximab s.c.|"Chlorambucil 6 mg/m2 daily p.o for 42 consecutive days (weeks 1-6) in combination with intravenous Rituximab 375mg/m2 on days 1, 8, 15 and 22 (day 1 of weeks 1, 2, 3 and 4).~Starting from d56, (month 3) patients will receive Chlorambucil 6 mg/m2 daily p.o for 14 consecutive days (d1-14) every 28 days for 4 cycles in combination with subcutaneous Rituximab 1400mg on day 1 of each 28-day cycle. Therefore subcutaneous Rituximab 1400mg every two months for 2 years (in total 12 injections)."
89357310|NCT00583752|Experimental|Androgen deprivation therapy (ADT) + Adenovirus/PSA Vaccine|On Arm B, subjects will be started on androgen deprivation therapy (ADT) 14 days prior to beginning the vaccinations.
89357311|NCT00583752|Experimental|Adenovirus/PSA Vaccine|On Arm A, subjects can begin the three vaccinations immediately.
89357312|NCT00071071|Experimental|HuMax-CD4 280 milligrams (mg)|
89357313|NCT00071071|Experimental|HuMax-CD4 560 mg|
89357314|NCT03333070|Active Comparator|Treatment Arm|"25 consecutive children diagnosed with functional constipation will be treated with full dose PEG (Polyethylene glycol 3350) treatment (dose of ~1g/kg/day) for 12 weeks.~After 12 weeks of treatment they will be randomized: treated arm will receive probiotic containing Lactobacillus reuteri for 12 weeks while tapering the PEG dose Dose of 5 drops per day for 48 weeks"
89177748|NCT04534972|Active Comparator|Post-Implementation Targeting Normoxemia in Burn ICU|The intervention (post-implementation) group will be patients admitted to the burn unit in ICU during the targeting normoxemia intervention period of the stepped-wedge design implementation process (up to 19 months).
89357315|NCT03333070|Placebo Comparator|Placebo Arm|"25 consecutive children diagnosed with functional constipation will be treated with full dose PEG (Polyethylene glycol 3350) treatment (dose of ~1g/kg/day) for 12 weeks.~After 12 weeks of treatment they will be randomized: control arm will receive placebo for 12 weeks while tapering the PEG dose Dose of 5 drops per day for 48 weeks"
89357316|NCT03332992|Experimental|Viral changes + General intentions|Script language discusses a) that previous years' shots do not protect against current year influenza (viral changes) and b) poses a general question asking whether the respondent intends to get a flu shot (general intentions).
89357317|NCT03332992|Experimental|Viral changes + Behavioral intentions|Script language discusses a) that previous years' shots do not protect against current year influenza (viral changes) and b) poses a question asking when / where the respondent will get a flu shot (behavioral intention).
89357318|NCT03332992|Experimental|Viral changes + Accountability|Script language discusses a) that previous years' shots do not protect against current year influenza (viral changes) and b) poses a question that implies the patient's care team will be notified of intent to vaccinate (accountability to providers).
89357319|NCT03332992|Experimental|Protect others + General intentions|Script language discusses a) that getting the flu shot protects others who can get particularly sick (protect others) and b) poses a general question asking whether the respondent intends to get a flu shot (general intentions).
89534174|NCT04191811||Social Anxiety Internet-delivered CBT|12 weeks of guided internet-delivered CBT for social anxiety.
89177749|NCT01019863|Experimental|Oxaliplatin|oxaliplatin associated with Rituxan,Gemcitabine, and Dexamethasone in patients with refractory or relapsed Non hodgkinien lymphoma
89357320|NCT03332992|Experimental|Protect others + Behavioral intentions|Script language discusses a) that getting the flu shot protects others who can get particularly sick (protect others) and b) poses a question asking when / where the respondent will get a flu shot (behavioral intention).
89357321|NCT03332992|Experimental|Protect others + Accountability|Script language discusses a) that getting the flu shot protects others who can get particularly sick (protect others) and b) poses a question that implies the patient's care team will be notified of intent to vaccinate (accountability to providers).
89357322|NCT05465278|Experimental|Alirocumab|Every patient enrolled witll receive treatment witl Alirocumab
89357323|NCT01302275|Experimental|oxcarbazepine|Oxcarbazepine is gradually increased during 21 days from 300 mg x 1 daily to 2400 mg, and kept on that dose ( 2400 mg) for three weeks.
89357324|NCT01302275|Placebo Comparator|placebo|
89357325|NCT03332914|Active Comparator|First group|control group fisrt and after washing out Microcurrent therapy: Channel A: 100µA; 200 Hz Duration of each treatment session: 30 minutes Number of sessions: 10
89357326|NCT03332914|Active Comparator|Second group|"Microcurrent therapy: Channel A: 100µA; 200 Hz Duration of each treatment session: 30 minutes Number of sessions: 10~after washing out control group"
89357327|NCT03332836|Experimental|Cohort 1|Single dose subcutaneous administration (Dose A)
89357328|NCT03332836|Experimental|Cohort 2|Single dose subcutaneous administration (Dose B)
89357329|NCT03332836|Experimental|Cohort 3|Single dose subcutaneous administration (Dose C)
89357330|NCT03332758||RD treated with vitrectomy|Vitreous fluid from retinal detachment treated with pars plana vitrectomy
89357331|NCT03332758||RD treated with external drainage|Subretinal fluid from retinal detachment treated with external drainage.
89357332|NCT03332758||Macular holes treated with vitrectomy|Vitreous fluid from patients treated for macular hole
89357333|NCT03332758||ERM treated with vitrectomy|Vitreous fluid from patients treated for epiretinal membrane
89357334|NCT01301573||rAAV-GAD Treated Subjects|rAAV-GAD treated subjects who are being observed for long-term effects of the gene therapy product which they received from participating in a previous clinical study.
89357335|NCT02263014||Contralateral Prophylactic Mastectomy (CPM) Group|Group of women who decide to have contralateral prophylactic mastectomy (CPM) along with scheduled mastectomy. Screening questionnaire completed at baseline. Surgery decision questionnaires completed at surgical consult visit, and at 1, 6, and 12 months after the surgery is completed.
89357336|NCT02263014||No Contralateral Prophylactic Mastectomy (CPM) Group|Group of women who decide not to have contralateral prophylactic mastectomy (CPM) performed during scheduled mastectomy. Screening questionnaire completed at baseline. Surgery decision questionnaires completed at surgical consult visit, and at 1, 6, and 12 months after unilateral mastectomy or breast conserving surgery is completed.
89357337|NCT03339544|Experimental|Celebrex premedication|Celebrex is a NSAID with selective COX-2 inhibition properties, is given as an intervention to assess the pain
89357338|NCT03339544|Placebo Comparator|Placebo tablets|placebo tablets to compare the efficacy of Celebrex on the intra-operative and post-operative pain accompanying endodontic treatment of teeth with irreversible pulpits
89357339|NCT03332680|Experimental|EmbryoGlue® (laboratory culture medium)|"laboratory culture medium~laboratory embryo culture medium, embryos are placed in this media prior to transfer into uterus via embryo transfer procedure to facilitate IVF. EmbryoGlue contains Hyaluronic acid."
89357340|NCT03332680|Active Comparator|Standard control medium|"laboratory culture medium~In standard procedure embryos are placed in a media prior to transfer into uterus via embryo transfer procedure to facilitate IVF."
89357341|NCT05157594||All patients|A fasting blood sample will be taken on the day of the beginning and the day of the end of the radiotherapy and during the adjuvant chemotherapy (every 3 cycles). A follow-up will be performed for 9 months, with a blood sample taken every three months on the day of the follow-up MRI.
89357342|NCT02499718|Experimental|Noninvasive ventilator|noninvasive positive pressure ventilation combined with long-term oxygen therapy for severe stable chronic obstructive pulmonary disease
89357343|NCT02499718|No Intervention|LTOT|long-term oxygen therapy for severe stable chronic obstructive pulmonary disease
89357344|NCT03815747|Experimental|Treatment Group|Treatment with the investigational device - High- Intensity Focused Electromagnetic (HIFEM) Field Device
89357345|NCT05123417|Experimental|Intervention Group|Intervention group students will be educated with educational materials (lecture presentation, video) will be uploaded through the system in accordance with the flipped learning model, and students will be asked to come prepared to the planned lesson. No classical presentations will be made to the students, but the education will be carried out in the form of question and answer discussion, in line with the Flipped Learning model. After the lesson, the questions of the students who have questions will be answered.
89357346|NCT05123417|No Intervention|Control Group|The training, consisting of control group students will be trained with Powerpoint presentation, which will last 20-30 on average, will be given in accordance with the traditional education model. After the lesson, the questions of the students who have questions will be answered.
89357347|NCT03332602|Experimental|free FeSO4|wheat bread fortified with free FeSO4
89357348|NCT03332602|Experimental|free FeSO4 and empty microspheres|wheat bread fortified with free FeSO4, and empty microspheres
89357349|NCT03332602|Experimental|free FeSO4 with eudragit polymer|wheat bread fortified with free FeSO4, and eudragit polymer
89357350|NCT03332602|Experimental|free FeSO4 with Hyaluronic Acid|wheat bread fortified with free FeSO4, and hyaluronic acid
89357351|NCT03332602|Experimental|encapsulated FeSO4 3.2%|wheat bread fortified with encapsulated FeSO4 in a microsphere with 3.2% Fe loading
89357352|NCT03332602|Experimental|encapsulated FeSO4 20%|wheat bread fortified with encapsulated FeSO4 in a microsphere with 20% Fe loading
89357353|NCT03332602|Experimental|encapsulated FeSO4 3.2%, encap. Vitamin A|wheat bread fortified with encapsulated FeSO4 in a microsphere with 3.2% Fe loading, and encapsulated Vitamin A as microspheres
89357354|NCT03332602|Experimental|encapsulated FeSO4 3.2%, encap. Vitamin A, free folicacid|wheat bread fortified with encapsulated FeSO4 as microsphere with 3.2% Fe loading, encapsulated Vitamin A as microspheres and free folic acid
89357355|NCT03332602|Experimental|FeSO4 embedded in Hyaluronic Acid|wheat bread fortified with FeSO4 that is embedded in hyaluronic acid.
89357356|NCT01302353|Experimental|Arm 1 (0.0024 ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.0024ml/kg.
89357357|NCT01302353|Experimental|Arm 2 (0.006ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.006ml/kg.
89357358|NCT01302353|Experimental|Arm 3 (0.012ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.012ml/kg.
89357359|NCT01302353|Experimental|Arm 4 (0.02ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.02ml/kg.
89357360|NCT01302353|Experimental|Arm 5 (0.0301ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.0301ml/kg.
89357361|NCT01302353|Experimental|Arm 6 (0.0391ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.0391ml/kg.
89357362|NCT01302353|Experimental|Arm 7 (0.0508ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.0508ml/kg.
88828696|NCT01807585|Experimental|Roll-in (VenaSeal SCS)|Prior to initiation of the randomized cohort at each site, a non-randomized cohort of 2 subjects per clinical site (roll-in phase) were enrolled and treated with VenalSeal SCS with endovenous delivery of VenaSeal Adhesive (VA) to a target site in diseased great saphenous veins (GSV). The VA is dispensed in small amounts with each pull of the trigger equaling 0.10 cc.
88828697|NCT01808755|Experimental|D Mannose|1 gr. every 8 hours for 2 weeks, subsequently 1 gr. every 12 hours for 22 weeks
88828698|NCT01808755|Active Comparator|trimethoprim/sulfamethoxazole|intervention was a 5-days course of trimethoprim/sulfamethoxazole cp 160 mg/800 mg twice a day. Then one week of antibiotic every 4 weeks for the following 23 weeks
89357363|NCT01302353|Experimental|Arm 8 (0.066ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.066ml/kg.
89357364|NCT01302353|Experimental|Arm 9 (0.0859ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.0859ml/kg.
89357365|NCT01302353|Experimental|Arm 10 (0.1116ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.1116ml/kg.
89357366|NCT01302353|Experimental|Arm 11 (0.1451ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.1451ml/kg.
89357367|NCT01302353|Experimental|Arm 12 (0.1886ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.1886ml/kg.
88828699|NCT02694809|Experimental|Arm I (conjugated estrogens/bazedoxifene)|Patients receive conjugated estrogens/bazedoxifene orally (PO) once daily (QD) for 28 +/- 7 days in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery.
88828700|NCT02694809|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD for 28 +/- 7 days in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery.
88828701|NCT01790581|Active Comparator|Balance Training|
88828702|NCT01790581|Experimental|Balance Training w/ STARS|
88828703|NCT02648165|Experimental|ABM +|Attention Bias Modification
88828704|NCT02648165|Sham Comparator|ABM -|Sham Attention Bias Modification
88828705|NCT02648165|Experimental|ABM + and ACT|Attention Bias Modification followed by Group Acceptance and Commitment Therapy
89357368|NCT01302353|Experimental|Arm 13 (0.2452ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.2452ml/kg.
89357369|NCT01302353|Experimental|Arm 14 (0.3188ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.3188ml/kg.
89357370|NCT01302353|Experimental|Arm 15 (0.4144ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.4144ml/kg.
89534175|NCT04186247|Other|Standard of Care|SOC induction (nutritional therapy) for up to 12 weeks, as assigned by the treating gastroenterologist prior to study entry.
88828706|NCT02648165|Sham Comparator|ABM - and ACT|Sham Attention Bias Modification followed by Group Acceptance and Commitment Therapy
88828707|NCT00362687|Experimental|1|Truvada 1 tablet once a day.
88828708|NCT00362687|Experimental|2|Emtricitabine 1 capsule once a day
88828709|NCT02469389|Experimental|Engaging in Community Roles and Experiences (ENCoRE)|Engaging in Community Roles and Experiences (ENCoRE) includes evidence-based psychosocial treatment strategies to target the affective-motivational deficits, negative expectancies, and behavioral skills deficits that are central to the maintenance of negative symptoms. Behavioral strategies include motivational enhancement, psychoeducation, cognitive therapy, and social skills training.
89177750|NCT00642850|Experimental|1|
89177751|NCT00455455|Active Comparator|Optifree RepleniSH Multipurpose Disinfecting Solution|
89177752|NCT00455455|Active Comparator|ReNu Multiplus Multipurpose Solution|
89177753|NCT00817492||1|Subjects with mild to moderate kidney disease
89357371|NCT01302353|Experimental|Arm 16 (0.5387ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.5387ml/kg.
89357372|NCT03339310|Experimental|Optimizer Smart System with 2-leads|All eligible subjects will have the Optimizer Smart System implanted and receive cardiac contractility modulation therapy (CCM).
89357373|NCT03812315|Experimental|Propolis chewing gum|2 % pure raw propolis, 20-35% gum base, 2.5% flavors, 0.3% sorbitol and 0.3% coloring substance. Children will be instructed to chew the specially prepared propolis chewing gum for at least 20 minutes, twice daily, after breakfast and before bedtime.
89357374|NCT03812315|Active Comparator|Propolis mouthwash|The formulation includes 2% pure raw propolis, 40 ml flavors, 150 ml propylene glycol, 60 gm sorbitol, 0.1 g coloring substance and water. Children will be instructed to rinse using the prepared propolis mouthwash for 1 min, twice a day, after breakfast and before bedtime.
89357375|NCT03332524|Experimental|Arm 1 Product SP160412|oral route, 9 doses (Capsule) of SP160412 (Ibuprofen 400 mg and Chlorpheniramine maleate 4 mg combined) in the 72 hours-period from first dose to last dose.
89357376|NCT03332524|Placebo Comparator|capsules Ibuprofen&placebo|2 capsules Ibuprofen and 1 placebo, oral route, 9 doses of Ibuprofen 400 mg with Placebo (Capsule) in the 72 hours-period from first dose to last dose,
89357377|NCT03332524|Placebo Comparator|Capsule Chlorpheniramin&placebo|capsule Chlorpheniramine 4mg and 1 Placebo, 3/72 hours-period from first dose to last dose, oral route
89357378|NCT01301651|Experimental|virtual reality balance training|balance board training with virtual reality intervention
89357379|NCT01301651|Experimental|conventional balance training|physical therapy conventional balance training
89357380|NCT01301651|No Intervention|control group|No physical therapy
89357381|NCT03332446|Experimental|cooling|strength training and cold water immersion
89357382|NCT03332446|No Intervention|control|strength training and no cold water immersion
89357383|NCT03815513|Experimental|cases|Patient with spontaneous intracerebral hemorrhage
89357384|NCT03815513|Experimental|controls|Healthy control without history of symptomatic cerebrovascular diseases
89357385|NCT02499640|No Intervention|GC|Control group - CG (n = 20), which suffered no recuperative technique
88828710|NCT02469389|Active Comparator|Health & Wellness (H&W)|Health & Wellness (H&W) will focus on health and wellness issues and education on ways to better manage health-related concerns following a basic structure that includes: review of the previous session's material, new educational content, and discussion/application. Topics will include: 1) Overview, 2) Physical Activity (3 sessions), 3) Nutrition/Healthy Eating (3 sessions), 4) Managing Fatigue/Sleep (3 sessions), 5) Relaxation (3 sessions), 6) Tobacco cessation (3 sessions), 7) Substance Use (3 sessions), 8) Medication/Side Effects (3 sessions), 9) Review (1 session), and Closing (1session).
89357386|NCT02499640|Experimental|G1|G1 (n = 20) was subjected to a recovery procedure by immersion cold water for 5 minutes as from 9±1 degrees Celsius
89357387|NCT02499640|Experimental|G2|G2 (n = 20) was subjected to a recovery procedure by immersion cold water for 5 minutes as from 14±1 degrees Celsius
89357388|NCT02499640|Experimental|G3|G3 (n = 20) was subjected to a recovery procedure by immersion cold water for 15 minutes as from 9±1 degrees Celsius
89357389|NCT02499640|Experimental|G4|G4 (n = 20) was subjected to a recovery procedure by immersion cold water for 15 minutes as from 14±1 degrees Celsius
89357390|NCT01302431|Experimental|Nurse-Led Manualised Telephone support|Participants assigned to this arm of the study will receive 4 nurse-led telephone support calls over a three month time-frame
89357391|NCT01302431|No Intervention|Usual care|Participants randomised to this arm of the study will receive their usual care which comprises caregivers calling nurse specialists when they needs advice and support
88828711|NCT01790659|Experimental|WR 279,396|(Paromomycin and Gentamicin Topical Cream)
89357392|NCT02499484|Active Comparator|GTN and eccentric exercises|Participants will complete a 12 week eccentric exercise program and use 0.5cm of glyceryl trinitrate ointment daily for 24 weeks
89357393|NCT02499484|Placebo Comparator|Placebo and eccentric exercises|Participants will use a placebo ointment with no active ingredient for 24 weeks and complete an eccentric exercise program for 12 weeks
89357394|NCT03170154|Experimental|Clareon IOL|Clareon aspheric hydrophobic acrylic monofocal IOL implanted in one eye during routine small incision cataract surgery
88828712|NCT01790659|Experimental|Paromomycin|Paromomycin alone
89177754|NCT00817492||2|Healthy Control Subjects
89177755|NCT00913952|Experimental|1|Geneva 25 mg Clomipramine Hydrochloride Capsules Under Fasting Conditions.
89177756|NCT00913952|Experimental|2|Geneva 25 mg Clomipramine Hydrochloride Capsules Under Fed Conditions.
89357395|NCT01302509|Active Comparator|IOS, TFR|industrialized oral supplementation (IOS) and tube feeding regimen (TFR) with Nutren 1.0 or Jr (Nestlé-Clinical Nutrition).
89357396|NCT03339232|No Intervention|Usual Care|Participants will receive standardized information about a healthy diet, including the potential benefit of small, frequent meals and nighttime snacking . In addition, the treating hepatologist will counsel participants on the benefits of increased physical activity. These recommendations will be provided at the beginning of the study. The usual care arm reflects current clinical practice. Participants will be asked to keep an exercise log detailing type and duration of at home physical activity.
89357397|NCT03339232|Other|BCAA Supplement|BCAA powder (Bulk Supplements®) will be provided as the powder was found to be easier to swallow. Each teaspoon contains 1788 mg of BCAA and participants will take 7 teaspoons (12.5 grams of BCAA) per day divided into three separate servings. Each teaspoon contains L-leucine, isoleucine and valine in a 2:1:1 ratio. BCAA will be provided by the study investigators and half will be provided at baseline study visit and the second half at the week 6 visit. In addition, the treating hepatologist will provide standardized information about the potential benefits of small, frequent meals, nighttime snacking and increased physical activity at the beginning of the study. Participants will be asked to keep an exercise log detailing type and duration of at home physical activity.
89357398|NCT03339232|Other|BCAA supplement plus supervised physical activity|BCAA supplement will be as described for group 2, above. Study coordinators will supervise the physical activity program for study participants at the Loyola Fitness Center. Participants will attend the fitness center one hour each week; the fitness session will consist of low-impact aerobic physical activity, beginning with walking on the indoor track and possibly building to a recumbent exercise bicycle and light resistance training. Participants will be given a list of exercises to perform at home at least two times during the week with a goal of >90 minutes of physical activity per week. Participants will be asked to keep an exercise log detailing type and duration of at home physical activity which they will return during the weekly fitness center sessions. In addition, the treating hepatologist will provide standardized information about the potential benefits of small, frequent meals, nighttime snacking and increased physical activity at the beginning of the study.
89357399|NCT03812237|Experimental|(EWB) Early Weight Bearing (2 Weeks Post-op)|Subjects in the EWB group were allowed to begin bearing 50 pounds (lbs) through their hindfoot in either the boot or the short leg cast at the two-week visit. They were allowed to advance their weightbearing as tolerated by 25 lbs every four days until full weightbearing through the hindfoot was achieved.
89357400|NCT03812237|No Intervention|(SOC) Standard of Care Weight Bearing (6-8 Weeks Post-op)|Subjects in the SOC group were allowed to heel touch weightbear for balance only on the operative foot until the six to eight week visit. At this visit all subjects were placed into a short leg walking boot. Non-weightbearing patients were permitted to begin the progressive weightbearing protocol, without hindfoot restriction.
89357401|NCT03339154|Experimental|Methionine bioavailability in chickpeas|"Participants will be seen initially for pre-study assessment (3 hour). They will then be studied for up to 10 times. levels of phenylalanine intake (7 Study periods).~You could be expected to participate in up to 10 different sets of experiments which will take 11 weeks to 6 months. Each set of experiment consists of a 3 day period. During the first 2 days (Adaptation Days) you will be expected to consume 4 meals per day consisting of a protein liquid drink and protein freecookies and/or chickpeas with or without rice, which will be provided by the investigators"
89357402|NCT03812003|Experimental|remifentanil|After emergence and extubation of endotracheal tube, remifentanil 1mcg/kg were diluted with 0.9% saline to 50 ml, added in IV bag, and drip for 30 minutes.
89357403|NCT03812003|No Intervention|no intervention|After emergence and extubation of endotracheal tube, 0.9% saline 50ml were added in IV bag and drip for 30 minutes.
89357404|NCT03332368||TCM exposure group|TCM exposure group were treated with traditional Chinese medicine while the other do not treated with that
89357405|NCT04874610||BMI > 95|Cohort 1: greater than or equal to 95%ile body mass index
89357406|NCT04874610||BMI < 95|Cohort 2: less than 95%ile body mass index
89357407|NCT03518125|Experimental|Age ≥ 66, BioThrax (Days 1, 15, 29)|Subjects dosed on Days 1, 15, and 29 with 0.5 mL BioThrax.
89357408|NCT03518125|Experimental|Age ≥ 66, AV7909 (Days 1, 15, 29)|Subjects dosed on Days 1, 15, and 29 with 0.5 mL AV7909.
89357409|NCT03518125|Experimental|Age ≥ 66, AV7909 (Days 1 and 15)|Subjects dosed on Days 1 and 15 with 0.5 mL AV7909 and on Day 29 with 0.5 mL placebo.
89357410|NCT03518125|Experimental|Age ≥ 66, AV7909 (Days 1 and 29)|Subjects dosed on Days 1 and 29 with 0.5 mL AV7909 and on Day 15 with 0.5 mL placebo.
89357411|NCT03518125|Active Comparator|Age18-50, BioThrax (Days 1, 15, 29)|Subjects dosed on Days 1, 15, and 29 with 0.5 mL BioThrax.
89177757|NCT00913952|Active Comparator|3|Basel (Anafranil) 25 mg Clomipramine Hydrochloride Capsules Under Fed Conditions.
89357412|NCT03518125|Active Comparator|Age 18-50, AV7909 (Days 1 and 15)|Subjects dosed on Days 1 and 15 with 0.5 mL AV7909 and on Day 29 with 0.5 mL placebo.
89357413|NCT03812081|Active Comparator|Group A Baska Mask|In which Baska Mask Airway (size 3,4,5) will used for ventilation according of patient body weight.Size selection is based on the manufacturer's recommendation of weight-based estimate plus clinical judgment. The Baska Mask is available in four sizes: size three (30 to 50 kg), size four (50 to 70 kg), size five (70 to 100 kg),The membranous cuff of the Baska Mask appears bulkier than the equivalent inflatable cuff on cuffed laryngeal masks. The mask can easily be decreased in size during insertion by compressing the proximal, firmer part of the mask below the airway tube, between the thumb and two fingers
89357414|NCT03812081|Active Comparator|Group B Proseal Mask|In which Laryngeal Mask Airway- Proseal LMA (size 3,4,5) was used for ventilation according of patient body weight.Size selection is based on the manufacturer's recommendation of weight-based estimate plus clinical judgment.
89357415|NCT02492230|Active Comparator|Control Group|After successful PCI the control group will take Triple therapy (warfarin + clopidogrel+aspirin) during 45 days and after combination of warfarin+clopidogrel to 6 months after procedure and then only warfarin. Patients will be followed at 45 day, and every 3 months during 12 months of follow up.
89357416|NCT02492230|Experimental|Study Group|Left Atrial Appendage Closure Device will be implanted immediately after successful PCI procedure. It will be implanted via a trans-septal approach by use of a catheter based delivery system to seal the ostium of the LAA. The implantation will be guided by fluoroscopy and TEE to verify proper positioning and stability. The study group will take Triple therapy (warfarin+clopidogrel+aspirin) during 45 days following PCI and after control TEE, warfarin will be discontinued. Then patients from the study group will take DAPT combination (clopidogrel+aspirin) to 6 months after procedure and then only aspirin. Patients will be followed at 45 day, and every 3 months during 12 months of follow up
89357417|NCT03169530|Active Comparator|Alcohol|One standard serving of alcohol (~15 gm) daily
89357418|NCT03169530|No Intervention|Abstention|Abstention from alcohol
89177758|NCT00818818|Experimental|Meglumine antimoniate|Treated with 5mg/kg/d of pentavalent antimony (meglumine antimoniate) intravenously for 20 consecutive days.
88828713|NCT00681655|Experimental|Responses to alcohol|Each subject completed a total of 2 2.8 hr-long clamping sessions.Within each session, procedures differed only by the content of the infusate. In one session, 6% ethanol was infused. In the other session, only vehicle was infused, quantifying the placebo response for every subject. The order of alcohol or placebo sessions was counterbalanced; subjects were blind to which session was which; sessions were scheduled to occur about 2 weeks apart. Measures were collected before, and at beginning and end of infusion, and included subjective perceptions, EMG, EEG, stop-signal performance, eye movements, and auditory responses. Design allowed analysis of effect of alcohol vs placebo, initial effect of alcohol and acute tolerance to alcohol.
88828714|NCT01811875|Experimental|Optivate 500IU|Optivate 500IU
88828715|NCT02469701|Experimental|Nivolumab with ablation|"3mg/kg IV over 60 minutes on Day 1 +/- 3 days every 2 weeks until progression for a maximum of 2 years.~Either cryoablation or thermal ablation may be performed as per standard institutional policies.~As of amendment # 7 submitted to sites November 17, 2017, the dosing for Nivolumab per the FDA guidance was amended to a flat dose of 240mg IV Q2 weeks. As of amendment #8 sent to sites February 22, 2017 the dose of Nivolumab was updated to 3 mg/kg with a maximum dose of 240 mg for patients with weights that would correlate to exceed that dose instead of a flat dose secondary to the standard institutional practice and the FDA guidance ."
88828716|NCT01733407|Placebo Comparator|Sugar pill|Placebo arm
88828717|NCT01733407|Active Comparator|L-serine|amino acid supplementation with L-serine
88828718|NCT00422045|No Intervention|2|No Laser done. All outcome measures are the same.
88828719|NCT00422045|Experimental|1|Low Level Laser Therapy
88828720|NCT01733953|Experimental|Atorvastatin|6-Months Atorvastatin Therapy; 40mg oral, once daily
88828721|NCT01733953|Placebo Comparator|Sugar Pill (Placebo)|6-Months Placebo (sugar pill); oral, once daily
89357419|NCT03339076|Other|For a single-arm trial|"Inclusion Criteria with intervention replacing either a foley catheter or self intermittent catheter with the M3 Mini Catheter~Males > 50 years of age~Signed subject informed consent~Patients with actual urinary retention dependent on Foley Catheter or Intermittent Catheter~Inclusion will start once the M3 is placed and a functioning bladder is demonstrated.~Exclusion Criteria~Inability to undergo bladder catheterization with the M3 due to anatomical challenges (i.e. urethral stricture, bladder neck contracture, false passage or false passages or other history of urethral stricture)~Gross hematuria~Hypotonic Neurogenic Bladder (the placement of the M3 may isolate the cause of the retention with the bridging of the prostate as bladder dysfunction rather than prostate obstruction)."
89357420|NCT02499094|Experimental|Intervention A- Heuristic based|Behavioral-data driven support, both mobile phone application and phone-based, informed by their self-reported symptom assessment as well as simple heuristic-based behavioral measures
89357421|NCT02499094|Experimental|Intervention B- Machine Learning Based|Behavioral-data driven support, both mobile phone application and phone-based, informed by their self-reported symptom assessment as well as machine learning model-based behavioral measures
88828722|NCT00362921|Experimental|Gliadel wafers in combination with O6-benzylguanine|
88828723|NCT01734655||All Participants|Participants will be asked to complete the MEQ, the Eating Inventory Questionnaire, The Mindful Attention Awareness Scale (MAAS), and the Neighborhood Environment Walkability Scale (NEWS). Participants will then be asked to sequentially respond to each of the 28 items and the response choices from the MEQ and briefly discuss their reaction to the items and response choices. Finally, participants will either participate in a focus group or an individual cognitive interview, giving them the opportunity to elaborate on their responses to the MEQ. The first 11 participants completed focus groups and the remaining 29 participants completed individual cognitive interviews.
88828724|NCT01734889|Experimental|Orfadin suspension|Drug: nitisinone, oral suspension
88828725|NCT01735981|Experimental|video game exercise|Video game exercise using Dance Dance Revolution
88828726|NCT01735981|Other|control|hand-held video game control
88828727|NCT01736527|Experimental|LE Gel|A single dose LE Gel 0.5% administered into the study eye, tear samples collected at 6, 9, 12, and 24 hours after instillation by Schirmer strip to measures levels of LE in tears.
88828728|NCT01795105||Aripiprazole (Abilify® Tablets/Abilify® ODT)|
88828729|NCT01796665|Experimental|Test product|Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5% applied to the affected areas of the face once daily.
88828730|NCT01796665|Active Comparator|Reference product|Acanya Gel applied to the affected areas of the face once daily.
88828731|NCT01796665|Placebo Comparator|Placebo product|Placebo of the Test product applied to the affected areas of the face once daily.
88828732|NCT01796977|Active Comparator|OxyGenesys Dissolved Oxygen Dressing|OxyGenesys Dissolved Oxygen Dressing is a closed-cell foam wound dressing enriched with gaseous and dissolved oxygen for use in the management of wounds.
88828733|NCT01796977|Placebo Comparator|Standard Gauze Dressing|A sterile 4x4 covered by an adhesive Tegaderm will serve as the comparator for this study.
88828734|NCT02989987|Active Comparator|Narrative Exposure Therapy|According to the NET manual (one lifeline session and 7 exposure sessions; see Schauer et al. 2011).
88828735|NCT02989987|Active Comparator|Treatment-as-usual|Social support (provided on demand)
88828736|NCT01798225|Placebo Comparator|Control|Participants received mechanical periodontal therapy, oral hygiene instructions and placebo (antibiotic) pills.
88828737|NCT01798225|Experimental|Doxycycline|Participants received mechanical periodontal therapy, oral hygiene instructions and antibiotic (Doxycycline 100mg x 14 pills)
88828738|NCT01800877|Other|Liberal Approach|In the liberal approach group, we will titrate vasopressors to maintain mean arterial pressures between 75 and 80 mmHg.
88828739|NCT01800877|Other|Restrictive Approach|We will titrate vasopressors to maintain mean arterial pressures between 60 and 65 mmHg.
88828740|NCT02470949|Experimental|Low Social Status|Low Social Status Condition in Monopoly Game.
88828741|NCT02470949|Experimental|High Social Status|High Social Status Condition in Monopoly Game
89177759|NCT02609282|Experimental|Prompt group|Following an education session on the health benefits of breaking prolonged sitting, the prompt group will receive hourly prompts on their PC to stand. The prompts will be delivered by Microsoft Outlook and will run for a period of 10 weeks. The messages will be short in length, varied and centre around the key message of breaking prolonged sitting by standing.
89357422|NCT02499094|No Intervention|Control|No intervention
89357423|NCT03819881|Experimental|STMC-103H|"Oral administration of STMC-103H twice daily, randomized 3:1 (STMC-103H:Placebo) in three age-descending groups:~Part 1: 20 subjects 18-40 years of age Part 2: 20 subjects, 12-17 years of age Part 3: 20 subjects, 2-11 years of age"
89357424|NCT03819881|Placebo Comparator|Placebo|"Oral administration of placebo twice daily, randomized 3:1 (STMC-103H:Placebo) in three age-descending groups:~Part 1: 20 subjects 18-40 years of age Part 2: 20 subjects, 12-17 years of age Part 3: 20 subjects, 2-11 years of age"
88828742|NCT02471651|Active Comparator|Implant|Subjects randomized to dexamethasone intravitreal implant (0.7mg) will receive the initial treatment at Month 3 (visit 4) and Month 6 (visit 7) and are eligible to receive one additional dose at Month 9 (visit 10), Month 10 (visit 11) or Month 11 (visit 12) for persistent or recurrent macular edema documented on SDOCT. If dexamethasone intravitreal implant (0.7mg) is administered at Month 10 (visit 11) or Month 11 (visit 12) an additional safety study visit will be required at one to two months following Month 12 (visit 13). The investigator can withhold treatment with dexamethasone intravitreal implant (0.7mg) beginning at Month 9 if there is complete resolution of diabetic macular edema document on SDOCT.
88828743|NCT02471651|Active Comparator|Intravitreal anti-VEGF injection|Subjects randomized to continue on anti-vegf therapy will receive intravitreal anti-vegf injections at Month 3 (visit 4) Month 4 (visit 5) and Month 5 (visit 6). Beginning at Month 6 (visit 7), subjects who have received 6 intravitreal anti-vegf injections and continue to present with persistent diabetic macular edema defined as less than 10% reduction or any increase in CST compared to baseline values and CST is greater than 300 microns, will receive dexamethasone intravitreal implant (0.7mg) at Month 6 (visit 7) and Month 9 (visit 10). The follow-up period for all subjects will continue through 12 months from the baseline study visit.
88828744|NCT02476565|Experimental|LMA-Supreme supraglottic device|The LMA-Supreme is a single-use disposable supraglottic airway that utilizes an inflatable cuff
88828745|NCT02476565|Active Comparator|I-gel supraglottic device|The I-gel is an alternative supraglottic device made from thermoplastic elastomer which provides the seal over the airway versus an inflatable cuff.
88828746|NCT02477423|Active Comparator|Randomized & Blinded - Receiving Antibiotics|The infants within this arm of the study meet the inclusion criteria as being low risk. They will be randomized to receive routine ampicillin and gentamicin for the initial 48 hours of their life as a routine rule-out sepsis. Stool samples will be collected throughout hospitalization and at 18 months of life.
88828747|NCT02477423|Placebo Comparator|Randomized & Blinded - Receiving Placebo|The infants within this arm of the study meet the inclusion criteria as being low risk. They will be randomized to receive placebo (saline) in place of ampicillin and gentamicin for the initial 48 hours of their life as a routine rule-out sepsis. Stool samples will be collected throughout hospitalization and at 18 months of life.
88828748|NCT02478671|Experimental|TR Band|Each subject will have a Terumo TR Band applied to the wrist with MRI scans done at differing band pressure levels. The diameter of the radial artery will be measured at each level of band compression.
88828749|NCT02479763|No Intervention|Conventional loss-of-resistance|
88828750|NCT02479763|Experimental|Waveform-confirmed loss-of-resistance|
88828751|NCT04744571|Experimental|DCB group|Patients treated with Drug-Coated Balloon Angioplasty after revascularization of Chronic Total Occlusions
88828752|NCT04744571|Active Comparator|DES group|Patients treated with Drug eluting stents Angioplasty after revascularization of Chronic Total Occlusions
88828753|NCT02518997|Experimental|All enrolled infants|All participants will have Parental Reading Aloud at the prescribed intervals while being monitored for cardio-respiratory stability.
88828754|NCT02519387|Experimental|Buprenorphine Transdermal Patch|Buprenorphrine transdermal patch 5mg/10mg, every 7 days, for 3 months
89530281|NCT03254797|Active Comparator|Stepping training without feedback|"Subjects will be instructed to perform the stepping task without external feedback continuously until 20 minutes (excluding resting periods) but without fatigue. Then they continue a training program of overground walking for 10 minutes.~They have to be involved in a training program of their groups 5 times/week, for 4 weeks in total."
89530282|NCT04833413||Continue intensive treatment group|Patients with type 2 diabetes who continued intensive treatment within 6 months after hospital discharge
89530283|NCT04833413||Premixed insulin treatment group|Patients with type 2 diabetes who changed to premixed insulin within 6 months after hospital discharge
89530284|NCT04833413||Basic insulin treatment group|Patients with type 2 diabetes who changed to basic insulin treatment within 6 months after hospital discharge
89357425|NCT02513238|Active Comparator|Stemcells injected into submandibularis|The surgical procedure is done under local anaesthesia using ultrasonic guidance and sterile technique. After receiving the MSC-suspension , the surgeon will identify the submandibular glands and inject the suspension MSCs into the submandibular gland. Calculation of injected number of MSCs pr. participant rests on the following calculation: 2.8 x 10^6 MSC / Cm^3 X volume , where volume is the volume of the submandibular gland, and a gland-volume of app. 7-8cm3 is the norm. Therefore the amount of cells given to each participant will be app. 4.6 x 10^7 MSC in total. Afterwards the participant will be given a band-aid and over the counter analgesics.
88828755|NCT02521181|Experimental|Lower Dose Sodium Bicarbonate|Participants will receive oral 0.5 milliequivalents (mEq)/kg-lean body weight (LBW)/day of sodium bicarbonate. Half of the total daily dose is taken in the morning and the other half is taken in the evening. (If the number of capsules is an odd number, the greater number of capsules will be taken in the morning.)
88828756|NCT02521181|Experimental|Higher Dose Sodium Bicarbonate|Participants will receive 0.8 mEq/kg-LBW/day of sodium bicarbonate. Half the total daily dose is taken in the morning and the other half is taken in the evening. (If the number of capsules is an odd number, the greater number of capsules will be taken in the morning.)
88828757|NCT02521181|Placebo Comparator|Placebo|Participants will take the same number of placebo capsules as if they were assigned to receive either 0.5 mEq/kg-LBW/day or 0.8 mEq/kg-LBW/day of sodium bicarbonate. Half the total daily dose is taken in the morning and the other half is taken in the evening. (If the number of capsules is an odd number, the greater number of capsules will be taken in the morning.)
88828758|NCT02521259||low Bispectral index (BIS) group|BIS range under 40
88828759|NCT02521259||normal BIS group|BIS range from 40 to 60
88828760|NCT02257957|Experimental|Platelet -Rich Plasma (PRP)|15 patients with diagnosis of severe dry eye will receive PRP injection at day 0, 30,60 and 90
88828761|NCT02257957|Active Comparator|Standard Care|15 patients with diagnosis of severe dry eye will receive standard of care treatment and will be revised at day 0, 30,60,90
88828762|NCT02524769|Other|conjugated estrogen|All patients in the study will receive 0.625 mg conjugated estrogen/gram to use 0.5 grams twice weekly with the applicator for 12 weeks.
89357426|NCT02513238|Placebo Comparator|Saltwater injected into submandibularis|The surgical procedure is done under local anaesthesia using ultrasonic guidance and sterile technique. After receiving the placebo-suspension , the surgeon will identify the submandibular glands and inject the suspension. Placebo will be 2ml of Isotonic NaCl (0,9mg/ml) and HA 1%.
89357427|NCT03338842|Experimental|Distractor and Lower limb VR|The training sessions consist of Phase 1 (Distractor VR) in which patients will explore VR environments and Phase 2 (Lower limb VR) in which they will play games using their VR lower-limbs.
89357428|NCT05659511||healthy control group|Healthy people neither in insomnia group nor in MCI group.
89357429|NCT05659511||insomnia|Pittsburgh sleep quality index (PSQI)>5, Epworth Sleepiness Scale (ESS)>9 ，Insomnia Severity Index (ISI)>8.
89357430|NCT05659511||insomnia-MCI|Pittsburgh sleep quality index(PSQI)>5 ,Epworth Sleepiness Scale(ESS)>9 ，Insomnia Severity Indeex(ISI)>8; 20< MoCA<26.
89357431|NCT02440230|Experimental|OFS + Anastrozole|Patients who were anticipated to receive adjuvant OFS+AI endocrine therapy according to MDT discussion results were randomized to this arm,they will receive OFS+Anastrozole.
89357432|NCT02440230|Active Comparator|OFS + Exemestane|Patients who were anticipated to receive adjuvant OFS+AI endocrine therapy according to MDT discussion results were randomized to this arm,they will receive OFS+Exemestane.
89357433|NCT02499250|Experimental|RIPC arm|The subjects will be interviewed and have their baseline frequency and severity of angina pectoris recorded, then they will receive daily remote ischemic conditioning plus optimal medical treatment over 30 days.
88828763|NCT01815229|Experimental|tracheal lavages|"After the placement of the endotracheal tube (Hi-Lo™ Evac Mallinckrodt), tracheal lavages will be performed.~A simultaneous blood sample of approx 5cc, will be collected by venipuncture or by sampling from intravenous or arterial line if available. The same procedure for collection of tracheal sample and blood will be repeated at the end of the surgical procedure and immediately prior to removal of the ETT. A total of approx 10cc blood will be collected for research purposes."
88828764|NCT01815229|Placebo Comparator|Healthy Control|To replicate activation, neutrophils were isolated from 30mL blood of healthy volunteers and cocultured with TLF from subjects with or without sore throat pain.
89357434|NCT02499250|Active Comparator|Control arm|The subjects will be interviewed and have their baseline frequency and severity of angina pectoris recorded, then they will receive optimal medical treatment over 30 days.
88828765|NCT01877161|Experimental|Middle temporal gyrus|Repetitive magnetic stimulation to middle temporal gyrus
88828766|NCT01877161|Sham Comparator|Control group|Repetitive magnetic stimulation (Sham)
88828767|NCT01877161|Experimental|Superior temporal gyrus|Repetitive magnetic stimulation to superior temporal gyrus
89530285|NCT04833413||Oral hypoglycemic drug treatment group|Patients with type 2 diabetes who changed to oral hypoglycemic drug treatment within 6 months after hospital discharge
89530286|NCT02454751|Experimental|Pre-fentanyl dose/fentanyl dose|Crossover: 6-six minute walk test, subjective rating of dyspnea, heart rate, respiratory rate, oxygen saturation and participants' general appearance measured before and after a dose of fentanyl.
88828768|NCT02525549|Experimental|Test product|Adapalene and Benzoyl Peroxide Gel
88828769|NCT02525549|Active Comparator|Reference product|Adapalene and Benzoyl Peroxide Gel (Reference)
88828770|NCT02525549|Placebo Comparator|Placebo product|Placebo gel
88828771|NCT01877941|Active Comparator|Cardiac output monitoring|Patients undergoing surgery who will have their cardiac output monitored by pulmonary artery catheter (PAC) and endotracheal cardiac output monitoring (ECOM) during surgery and during post-surgical recovery, will also have sensors placed on the arm, finger and leg to calculate pulse wave transit time (PWTT) using the estimated Continuous Cardiac Output system (ecCCO).
88828772|NCT01878799|Experimental|HIV|Subjects with HIV and HCV
88828773|NCT02527265|Experimental|Afrezza (Technosphere Insulin)|"Individualized dose of Afrezza (Technosphere Insulin) for each patient at each meal (breakfast, lunch, and dinner) for 30 days.~During the trial, all patients will receive multiple injections of basal long acting insulin, in general at bedtime every day."
88828774|NCT01879345|Experimental|BIA 2-093 - 1800 mg (Group 1)|3 tablets of BIA 2-093 600 mg
89357435|NCT03036462|Experimental|Verum group (FCM)|I.v. iron administration in the form of FCM will be carried out according to SmPC. I.v. iron bolus administration (1000 mg) will be followed by an optional administration of 500-1000 mg within the first 4 weeks, (up to a total of 2000 mg which is in-label), according to the approved dosing rules, followed by administration of 500 mg FCM at every 4 months, except when haemoglobin is > 16.0 g/dL or ferritin is > 800 µg/L .In the verum group, all patients will receive a saline administration, when no iron is indicated at the time of the visit and according to the values listed above.
89357436|NCT03036462|Placebo Comparator|Placebo group (NaCL)|Administration of i.v. NaCl at a volume according to the dosing rules for FCM, i.e. as described for the verum group.
89534176|NCT04186247|Experimental|Standard of Care + Antibiotics|"SOC induction (nutritional therapy) for up to 12 weeks, as assigned by the treating gastroenterologist prior to study entry.~Azithromycin (weeks 4-12)~Metronidazole (weeks 4-12)"
89534177|NCT04183348|Experimental|Group A|10 normal hearing adults (NH) 10 unilateral deafness adults (SU) 10 mono-implanted adults (uIC) 10 bi-implanted adults (bIC)
89534178|NCT04183348|Experimental|Group B|10 normal hearing adults (NH) 10 unilateral deafness adults (SU) 10 mono-implanted adults (uIC) 10 bi-implanted adults (bIC)
88828775|NCT01879345|Experimental|BIA 2-093 - 2400 mg (Group 2)|4 tablets of BIA 2-093 600 mg
88828776|NCT01879345|Placebo Comparator|Placebo|placebo tablets
88828777|NCT05329207|Experimental|(Intervention group) Hearing impaired adolescent experimental group|Hearing Impaired Adolescent Group implemented Web-Based Adolescent Health Promotion Education Program
88828778|NCT05329207|No Intervention|(Control group) Hearing impaired adolescent control Group|Hearing Impaired Adolescent Group that did not apply Web-Based Adolescent Health Promotion Education Program
88828779|NCT05329051|Experimental|SCTV01E Group|Participants will receive one dose of SCTV01E on Day 0
88828780|NCT05329051|Active Comparator|Comirnaty Group|Participants will receive one dose of Comirnaty on Day 0
88828781|NCT01804075|Active Comparator|methadone|"Methadone (1 mg/mL) administered orally every 4 hours. The following is a dosing guide:~NAS Score Methadone 8-12 0.05 mg/kg/dose >=13 0.1 mg/kg/dose~Maximum dose of methadone will be 0.2 mg/kg/dose. (NeoFax)~Additional doses, 0.05 mg/kg, may be given every 4 hours as needed and added to the next 24 hour's doses divided every 4 hours, until NAS scores are consistently <8 for 48 hours.~If the maximum dose of methadone is reached and if withdrawal is not controlled, the infant will be started on clonazepam (0.005 mg/kg/dose q 12h) per current treatment."
88828782|NCT01804075|Active Comparator|morphine|"Morphine (1 mg/mL) administered orally every 4 hours. The following is a dosing guide:~NAS Score Morphine 8-12 0.05 mg/kg/dose >=13 0.1 mg/kg/dose~Maximum dose of morphine will be 0.2 mg/kg/dose. (NeoFax)~Additional doses, 0.05 mg/kg, may be given every 4 hours as needed and added to the next 24 hour's doses divided every 6 hours, until NAS scores are consistently <8 for 48 hours.~If the maximum dose of morphine is reached and if withdrawal is not controlled, the infant will be started on clonazepam (0.005 mg/kg/dose q 12h) per current treatment."
88828783|NCT02416193|Experimental|High Dose|50,000 IU cholecalciferol once weekly for three months
88828784|NCT02416193|Active Comparator|Low Dose|5,000 IU cholecalciferol once weekly for three months
88828785|NCT02530151|Experimental|Morphine with Clonidine|11 mL intra-articular injection of 10 mg morphine and 100 mcg clonidine in .9% NaCl solution at conclusion of hip arthroscopy procedure
88828786|NCT02530151|Placebo Comparator|Normal Saline|11 mL intra-articular injection of .9% NaCl solution at conclusion of hip arthroscopy procedure
88828787|NCT02530541|Experimental|CHG 1 min|1 min application time
88828788|NCT02530541|Experimental|CHG 2 min|2 min application time
89534179|NCT04182412|Active Comparator|Suture|laparoscopic narrowing of linea alba with continuous suture
89534180|NCT04182412|Active Comparator|suture and mesh|narrowing of linea alba with continuous suture and mesh
89534181|NCT04179578|Active Comparator|Crura|Closure of the diaphragmatic hiatus by a running suture alone
88828789|NCT02530541|Active Comparator|Comparator CHG|Marketed CHG
88828790|NCT02416973|Other|Sham of Provant|Sham of Provant
88828791|NCT02416973|Other|Active Treatment|Active Provant Treatment
88828792|NCT02416973|Other|Active Treatment with alternative settings|Active Provant Treatment with alternative settings
89534182|NCT04179578|Active Comparator|Crura and lateral release|Closure of the diaphragmatic hiatus by a running suture and an incision of 4 cm of the left diaphragm (lateral release)
89534183|NCT04166929|Experimental|Haplo-stem cell transplant followed by NK infusion|"Haplo stem cell transplant (from bone marrow or apheresis) is followed by a haplo-NK cell infusion (target dose ≥1*106/kg b.w.) at day 7.~Unstimulated haplo-NK cells are collected through apheresis Mononuclear cells are then subjected to a preliminary negative selection of CD3+ cells and to a subsequent positive selection of CD56+ cells. CD3 negative/CD56 positive cells are infused"
89534184|NCT04166929|Active Comparator|Haplo-stem cell transplant|Patients in this arm receive standard haplo stem cell transplant (from bone marrow or apheresis) transplant without subsequent NK cell infusion.
89534185|NCT04158037|Experimental|mHealth App|Participants will receive the gambling disorder mHealth app.
89534186|NCT04158037|No Intervention|Wait List Control|Participant will be placed on a wait list for 12 weeks, after which they will be offered the gambling disorder mHealth app.
88828793|NCT01804465|Experimental|Immediate IpilimumabTreatment|Arm 1 (Immediate Treatment) Ipilimumab Q3wks x 4 started 1 day following the final dose of SipT.
88828794|NCT01804465|Experimental|Delayed IpilimumabTreatment|Arm 2 (Delayed Treatment) Ipilimumab Q3wks x 4 started 3 weeks following the final dose of SipT.
88828795|NCT02531321|Experimental|Ritonavir|Participants taking antiretroviral regimens including ritonavir-boosted protease inhibitors will take a combined oral contraceptive containing 150mcg levonorgestrel and 30mcg ethinyl estradiol for 21 days.
88828796|NCT02531321|Active Comparator|Control|Participants taking antiretroviral regimens known not to interact with oral contraceptives will take a combined oral contraceptive containing 150mcg levonorgestrel and 30mcg ethinyl estradiol for 21 days.
89177760|NCT02609282|No Intervention|Control group|The control group will receive the same education session as the prompt group, but will receive no prompts on their PC.
89534187|NCT04139993|Experimental|Treatment (RBX7455)|Prior to standard of care surgery, patients receive RBX7455 orally (PO) 4 days a week for 2-4 weeks in the absence of disease progression or unacceptable toxicity.
89177761|NCT03840811|Experimental|Group 1|Subjects (n = up to 8) will receive a bacterial inoculum containing only the isogenic mutant N. gonorrhoeae strain
89177762|NCT03840811|Experimental|Group 2|Subjects (n = up to 8) will receive a bacterial inoculum containing only the wild-type (WT) N. gonorrhoeae strain.
88828797|NCT02531867|Experimental|Asfotase Alfa|Patients will receive asfotase alfa by subcutaneous injection. Asfotase alfa will be administered at either 2 mg/kg 3 times per week or 1 mg/kg 6 times per week depending on investigator's discretion.
88828798|NCT01805089|Active Comparator|Melatonin 3 mg|Taken orally, once per day, at/around 9:00pm
88828799|NCT01805089|Placebo Comparator|Placebo|Taken orally, once per day, at/around 9:00pm
88828800|NCT01409629||Activity choices|Observe individuals' activity choices after playing a computer game.
88828801|NCT02417129|Experimental|BI 695500|375 mg/m2; One intravenous infusion once a week for 4 weeks
88828802|NCT02417129|Active Comparator|Rituximab (US reference product)|375 mg/m2; One intravenous infusion once a week for 4 weeks
88828803|NCT01816711||Hip fracture, Frail elderly, Non-supplemented|Frail elderly with a hip fracture who did not received vitamin D supplementation
88828804|NCT01816711||Hip fracture, Frail elderly, Supplemented|Frail elderly with a hip fracture who received vitamin D supplementation
88828805|NCT01879735|Experimental|ICG's effect on 11C-CSar transport|"Examine the effect of ICG on the kinetics of the hepatic transport of 11C-CSar. If no effect is seen on the kinetics, ICG will be used during the infusion method experiments."
88828806|NCT01879735|Experimental|Infusion method|Determine wether bolus or constant infusion of 11C-CSar is optimal for the PET/CT scanning. If ICG does not affect the kinetics of 11C-CSar it will be used during these experiments to calculate hepatic blood flow.
88828807|NCT02417831|Active Comparator|tamsulosin capsules|
88828808|NCT02417831|Active Comparator|tamsulosin HCl capsules|
88828809|NCT02271451|Experimental|Q collar|subjects wearing the q collar
88828810|NCT02271451|No Intervention|Control|subjects not wearing the Q collar
88828811|NCT02419547|Other|Anesthesia Induction|Patients undergoing ventricular tachycardia ablation will undergo programmed stimulation (PS) with minimal sedation (Versed, Fentanyl), with intravenous agents (propofol) , and finally with volatile inhalational agent (sevoflurane).
88828812|NCT02273323|Experimental|Tea|Black tea
88828813|NCT02273323|Placebo Comparator|Placebo|Placebo
88828814|NCT02274649|Experimental|Intervention|Intervention group receiving one-to-one peer mentoring
88828815|NCT02274649|Active Comparator|Control|Control group receiving general peer support
89177763|NCT03840811|Experimental|Group 3|Subjects (n= up to 16) will receive a bacterial inoculum containing a mixture of equivalent numbers the isogenic mutant and WT strain
88828816|NCT02533427|Experimental|SOF/VEL/VOX + VOX|"Part A: Participants without a documented history of taking norgestimate/ethinyl estradiol for at least one menstrual cycle will receive norgestimate/ethinyl estradiol. Participants with a documented history of taking norgestimate/ethinyl estradiol may enroll directly into Part B of the study.~Part B: Participants will continue taking norgestimate/ethinyl estradiol for the remainder of the study and will receive SOF/VEL/VOX FDC plus VOX."
88828817|NCT05328817|Experimental|Erythromycin|Receive 1) erythromycin 250 mg iv every 6 hours for 48 hours followed by 333 mg orally (pills) every 8 hours for 5 days
88828818|NCT05328817|Experimental|Azithromycin|Receive azithromycin 500 mg iv daily for 48 hours followed by 500 mg orally (pills) for 5 days.
88828819|NCT05328739|Experimental|Home care group|"The home care program included education, counseling and nursing care to determine and meet the self-care/dependant care needs of patients and caregivers at home after brain surgery.~At preoperative period (PRP) an average of 90-120 minutes of training was given to both the patient and the caregiver until the patient was discharged. At this stage, the training was carried out in order to prepare the patient and caregiver for the transition to home. At postoperative period (POP) two home visits were made within the first month following the discharge, planned for education, counseling and nursing care. The first home visit was made in the first week after discharge (10-18 days after surgery), and the second home visit was made 30-40 days after surgery. Then, in the home visits made once in the 2nd, 3rd and 4th months.No home visits were made between the 4th-month attempt and the 6th month, but telephone counseling was provided when necessary. Home visits ranged from 60 to 120 minutes."
88828820|NCT05328739|No Intervention|Control group|The patient received routine care in the hospital until discharge. Three home visits were made to collect the data of patients and caregivers in the 1st and 3rd and 6th months of POP after discharge, but no intervention was made. The visits took about 30-45 minutes.
88828821|NCT05328583|Experimental|Treatment group A（Part A）|Drug1: HRS5685, dose 1; Drug2: Placebo
88828822|NCT05328583|Experimental|Treatment group B（Part A）|Drug1: HRS5685, dose 2; Drug2: Placebo
88828823|NCT05328583|Experimental|Treatment group C（Part A）|Drug1: HRS5685, dose 3; Drug2: Placebo
88828824|NCT05328583|Experimental|Treatment group D（Part A）|Drug1: HRS5685, dose 4; Drug2: Placebo
88828825|NCT05328583|Experimental|Treatment group E（Part A）|Drug1: HRS5685, dose 5; Drug2: Placebo
88828826|NCT05328583|Experimental|Treatment group F（Part A）|Drug1: HRS5685, dose 6; Drug2: Placebo
88828827|NCT05328583|Experimental|Treatment group G（Part B）|Drug1: HRS5685, dose 3; Drug2: Placebo
88828828|NCT05328583|Experimental|Treatment group H（Part B）|Drug1: HRS5685, dose 4; Drug2: Placebo
88828829|NCT05328427|Active Comparator|Stopping|Discontinuation of nucleoside analogue treatment
88828830|NCT05328427|No Intervention|Continue|Treatment with nucleoside analogue continued
88828831|NCT05748535|Experimental|Unilateral Right Ear|Auricular vagus nerve stimulation performed through the unilateral right ear.
88828832|NCT05748535|Experimental|Unilateral Left Ear|Auricular vagus nerve stimulation performed through the unilateral left ear.
88828833|NCT05748535|Experimental|Bilateral Ear|Auricular vagus nerve stimulation performed through the bilateral ear.
88828834|NCT01816945|Experimental|Access to MOMBA web-based application|Study will provide the subject with a smartphone, pay the data plan, and facilitate access to the web-based application for purposes of researching the acceptability of the application, the operating and functioning of it, and its impact on maternal mental health.
89177764|NCT00640510|Experimental|IM olanzapine 10mg|Patients will receive at least one injection of Intramuscular (IM) olanzapine 10mg. If patients do not respond to the study medication or if patients do not have enough improvement based on the investigator's judgment, and in addition, if the investigator judges it is reasonable, the patient will receive a second injection at the same dose strength as the first injection after 2 hours following the first injection (no later than 8 hours after the first injection).
88828835|NCT01816945|No Intervention|Smartphone only|Study will provide the subject with a smartphone and pay the data plan. Weekly assessments are completed through internet survey links sent via text message.
88828836|NCT02533505|Active Comparator|Symbicort pressurized Metered Dose Inhaler (pMDI)|Symbicort pressurized Metered Dose Inhaler (pMDI)
88828837|NCT02533505|Placebo Comparator|Placebo of reference drug|Placebo of reference drug
88828838|NCT01817491|Active Comparator|Reduced Fat Vegan Diet|Plant based diet with as few added oils and fats as possible.
88828839|NCT01817491|Active Comparator|American Heart Association Diet|Diet emphasizing fruits, vegetables and whole grains but also low fat dairy, low fat meat and fish.
89534188|NCT04109807|Experimental|6 hour Filtered Air (FA) followed by O3 exposure|For the first exposure session, participants are exposed to filtered air (FA) for 6 hours. For the second exposure session, the same participant will be exposed to ozone at a concentration of 0.07ppm for 6 hours.
88828840|NCT05328271|Placebo Comparator|Placebo|Maltodextrin
88828841|NCT05328271|Active Comparator|1500 mg L-Valine|1500 mg L-Valine
88828842|NCT05328271|Experimental|250 mg Beta-Aminoisobutryic Acid|250 mg Beta-Aminoisobutryic Acid
88828843|NCT05328271|Experimental|500 mg Beta-Aminoisobutryic Acid|500 mg Beta-Aminoisobutryic Acid
88828844|NCT05328271|Experimental|1500 mg Beta-Aminoisobutryic Acid|1500 mg Beta-Aminoisobutryic Acid
88828845|NCT02481557|Experimental|Oxalate Salt Solution|Professionally applied
88828846|NCT02481557|No Intervention|No Treatment|No Treatment
88828847|NCT01818427|Experimental|plasma|infusion of 2 units of plasma
88828848|NCT01818427|No Intervention|standard air medical care|control group
88828849|NCT05328193|Active Comparator|Teaching Kitchen Outreach|All participants (both the intervention and control condition) will receive to 11 weekly short (about 2-3 minutes) Teaching Kitchen Outreach (TKO) videos. Recipe specific groceries will be delivered to participants' homes by a third party grocery delivery company, or will be available for pickup at a central location(s). These recipes reflect foods that can be purchased with SNAP and WIC and include tested meals and snacks that were developed and evaluated in person in Parks and Recreation after-school programming.
88828850|NCT05328193|Experimental|Healthier Families, COVID Edition|Those randomized to the intervention condition will also receive a 12-weekly health coach via a virtual platform (such as Zoom, FaceTime, or What's App) to provide an adapted version of the previously tested Healthier Families program. Adaptations include: shortening each session to 30 minutes and delivering the programming via a virtual platform. The health coach will provide the Healthier Families modules either to individual child-parent pairs.
88828851|NCT05327881||Septic shock patients|"Adult patients on vasopressors for greater than 6 hours to maintain a mean arterial pressure greater than or equal to 65 mm Hg. Inclusion criteria: age over 18, urinary catheter in situ, anticipated stay >24 hours, and signed informed consent by patient or next-of-kin.~Septic shock was defined as persistent hypotension (defined as the need for vasopressors to maintain mean arterial pressure ≥ 65 mm Hg, and a serum lactate level > 18 mg/dL [2 mmol/L] despite adequate volume resuscitation"
88828852|NCT02420015|Experimental|iCOMMIT|The components of the intervention include 1) behavioral therapy in the form of mobile contingency management (mCM) designed to increase early abstinent rates; 2) pharmacotherapy for smoking cessation [including nicotine replacement therapy (NRT) and bupropion]; 3) four sessions of guideline based cognitive-behavioral smoking cessation counseling designed to increased coping skills specific to smoking cessation; 4) a smart-phone based relapse prevention application (the Stay Quit Coach) that is populated during the counseling sessions; and 5) SMS text messaging reminders to increase medication adherence.
88828853|NCT02420015|Active Comparator|Control Group|The components of the intervention include 1) pharmacotherapy for smoking cessation [including nicotine replacement therapy (NRT) and bupropion]; and 2) four sessions of guideline based cognitive-behavioral smoking cessation counseling designed to increased coping skills specific to smoking cessation.
88828854|NCT05748379|Other|Kompozite closure|Immediate implant placement and temporary closure of tapered implants with a custom-made composite shaper after tooth extraction with bone augmentation by using allogeneic bone.
88828855|NCT05748379|Other|Individual abutment|Immediate implant placement and temporary closure of tapered implant with a custom-made zirconium oxide abutment after tooth extraction with bone augmentation by using allogeneic bone.
88828856|NCT05748301||ICU Clinicians|ICU doctors at the senior registrar, ICU fellow or consultant level will evaluate the AI Clinician system.
88828857|NCT05748301||Septic patients|Septic patients meeting the inclusion criteria will be included on the system.
88828858|NCT02481713|Experimental|MI condition|motivational interview condition
88828859|NCT02481713|Sham Comparator|CI condition|learning style interview condition
88828860|NCT01819597|Other|EDAS surgery|EDAS surgery is an established form of indirect revascularization. The study arm in this study will receive EDAS surgery
88828861|NCT02482025|No Intervention|Usual care|Usual care delivered at VA Boston
88828862|NCT02482025|Active Comparator|SMMRT|Receives Usual Care PLUS SMMRT Intervention
88828863|NCT05748223|Experimental|Mindfulness Group|The patients in this group received mindfulness meditation before dental implant surgery.
88828864|NCT05748223|No Intervention|Conventional Group|The patients in this group did not receive mindfulness meditation before dental implant surgery.
88828865|NCT05327179|Experimental|Group 1|Action Observation Treatment
88828866|NCT05327179|Experimental|Group 2|Virtual Rehabilitation
88828867|NCT02420639|Experimental|Intervention|The placement of the Esophageal Cooling Device will follow standard recommendations as per Instructions for Use. The Esophageal Cooling Device will be connected to the appropriate console (Meditherm III, Blanketrol II, or Blanketrol III).
88828868|NCT02989753|Placebo Comparator|Placebo|The comparative product is a placebo with the same characteristics of appearance and packaging as studied products and in which all ingredients are replaced by maltodextrin.
88828869|NCT02989753|Experimental|VAL070-A|Studied active product n°1, named VAL070-A, is a dietary supplement in shape of capsule. VAL070-A product contains 4 active plant extracts.
88828870|NCT02989753|Experimental|VAL070-B|Studied active product n°2, named VAL070-B, is a dietary supplement in shape of capsule. VAL070-B product contains 5 active plant extracts.
88828871|NCT05326867|Active Comparator|Infiltration of 2% Lidocaine with Needle|Free needle infiltration of lidocaine can be an alternative to reduce epidural needle insertion pain. The study of Gozdemir et al. found that 10% lidocaine infiltration without needle was less painful than 2% lidocaine infiltration with a 27G needle with no significant difference in analgesia effect during epidural needle insertion. This study aimed to compare infiltration of lidocaine with and without needle for epidural needle insertion
89357437|NCT03332290|Active Comparator|sport training|training course lasting 10 days. It included 10 days of multisports practice once (2h) per day.
89357438|NCT03332290|Experimental|diving|diving course lasting 10 days. It included 10 days of diving once (2h) per day. Diving will be carried out using air at a maximum depth of 30-meters
89534189|NCT04109807|Experimental|6 hour O3 exposure followed by FA exposure|For the first exposure session, a participant will be exposed to ozone at a concentration of 0.07ppm for 6 hours. For the second exposure session, the same participant will be exposed to FA for 6 hours.
89534190|NCT04109287|Experimental|Two ultrasound scans and activation of NMES device|Participants will have their leg scanned using an ultrasound machine, before being asked to use the REVITIVE® device for 30 minutes. Their leg will then be scanned again.
89534191|NCT04105634|Experimental|Inflammation group|Patient diagnosed with Cardiac Amyloidosis
88828872|NCT05326867|Active Comparator|Infiltration of 2% Lidocaine without Needle|Free needle infiltration of lidocaine can be an alternative to reduce epidural needle insertion pain. The study of Gozdemir et al. found that 10% lidocaine infiltration without needle was less painful than 2% lidocaine infiltration with a 27G needle with no significant difference in analgesia effect during epidural needle insertion. This study aimed to compare infiltration of lidocaine with and without needle for epidural needle insertion
88828873|NCT05326789|Experimental|interventional|20 patients with inclusion criteria and without exclusion criteria will be entered in the interventional arm attempting to use REBOA during non-traumatic cardiac arrest.
88828874|NCT05324995|Experimental|Multimodal injection|The first group was treated using a preemptive periarticular injection of multimodal drugs. Therefore, a combination of drugs consisted of 50 mg bupivacaine hydrochloride 0.5% (AstraZeneca, Cenexi, France), 1 ml morphine sulfate 10 mg/ml (DarouPakhsh, Tehran, Iran), 300 mcg epinephrine (1:1000) (DarouPakhsh, Tehran, Iran) and 30 mg ketorolac (Caspian Tamin, Rasht, Iran) diluted by 0.9% sodium chloride solution to make a total 100 ml of injection drug was injected in periarticular area. The injections were done within 15 minutes before the incision in seven areas of the joint as followed: 15 ml in posterolateral soft tissue and lateral femoral periosteum, 15 ml posteromedial soft tissue and medial femoral periosteum, 20 ml inferomedial capsule, 20 ml superomedial capsule, 10 ml lateral capsule, 10 ml medial subcutaneous tissues and 10 ml lateral subcutaneous tissue.
88828875|NCT05324995|Experimental|epinephrine group (placebo group)|The second group received 300 mcg epinephrine (1:1000) (DarouPakhsh, Tehran, Iran) peri-articulary, similar to the first group.
88828876|NCT05324995|Experimental|celecoxib group (control group)|The third group administered celecoxib (200 mg) orally immediately before the surgery initiation.
88828877|NCT05318521|Active Comparator|Ibuprofen Modified-Release Tablets 800 mg (IBUMR)|Ibuprofen Modified-Release Tablets 800 mg (IBUMR), twice daily with 12h interval, for 12-week treatment period.
88828878|NCT05318521|Placebo Comparator|placebo|placebo 800mg, twice daily with 12h interval, for 12-week treatment period.
88828879|NCT05312905|Active Comparator|Mirror Therapy|Exercises including mirror therapy will be applied to the participants in the Mirror Therapy group. The mirror will be placed in such a way that the affected extremity of the patient could not be seen behind the mirror and the healthy extremity would be in front of his eyes, the patient will perform the exercises indicated by the physiotherapist with his intact extremity, looking into the mirror. The exercises will be performed in sessions lasting 60 minutes, 3 days a week, over 8 weeks.
88828880|NCT05312905|Experimental|Mirror+Cognitive Therapy|The participants in the Mirror+Cognitive Therapy will be given a cognitive task with the application of mirror therapy. Cognitive tasks with mirror therapy will be applied in sessions lasting 60 minutes, 3 days a week, over 8 weeks.
88828881|NCT02420873|Experimental|Cohort 1: CD56 Expressing Hematological Malignancies|Lorvotuzumab mertansine (IMGN901) administered intravenously at a dose of 100 mg/m2 on Day 1 and 8 of a 21-day cycle.
88828882|NCT02420873|Experimental|Cohort 2: Myelofibrosis|Lorvotuzumab mertansine (IMGN901) administered intravenously at a dose of 100 mg/m2 on Day 1 and 8 of a 21-day cycle.
88828883|NCT02420873|Experimental|Cohort 3: Blastic Plasmacytoid Dendritic Cell Neoplasm|Lorvotuzumab mertansine (IMGN901) administered intravenously at a dose of 100 mg/m2 on Day 1 and 8 of a 21-day cycle.
88828884|NCT02534129|Experimental|Single Arm|Radiation field is divided into two sections, one treated with Difinsa53 and the other with Aquaphor
88828885|NCT02420951|Experimental|Injection|Will receive injection of 30ml of .5% bupivacaine solution prior to catheter removal
89357439|NCT01300325|Placebo Comparator|0.9% saline|patients receive every 6 hours the nebulized 0.9% saline (placebo comparator) (group I) or the 3% HS (group II) in addition to aerosolized epinephrine (1.5 mg) and to the conventional treatment (oxygen, fluids).
89357440|NCT01300325|No Intervention|3% hypertonic saline|Patients receive every 6 hours the nebulized 0.9% saline (Placebo comparator) (group I) or the 3% hypertonic saline solution group II) in addition to aerosolized epinephrine (1.5 mg) and to the conventional treatment (oxygen, fluids).
89357441|NCT03332134|Experimental|Married Couple Dyad|Husband-wife dyads will receive the intimate partner violence (IPV) intervention program over the course of six weeks.
89357442|NCT03332134|No Intervention|Control Group|Husband-wife dyads in the control group will not receive an intervention.
89530287|NCT02455921|Active Comparator|sugammadex|iv sugammadex 2 mg/Kg
89530288|NCT02455921|Active Comparator|neostigmine - atropine|"iv neostigmine 0,05 mg/Kg - atropine 0,02 mg/kg~Efficacy, safety and effect on cognitive and behavioural function"
89530289|NCT03347747||Photoaged Male Subjects|45-80 year old males with visible photoaging and the desired exposure profile/driving history and who also has spent (or are spending) at least 30 minutes in a car per day (as the driver), 5 days per week for at least 15 years of their adult life to ensure they have the type of asymmetrical exposure required for hypothesis validation. This is an multi-center trial, and study sites will range from northern to southern latitudes in North America, Australia and potentially other international sites. Study Photography + Personal & Medical History Collection via a study questionnaire will be obtained.
89357443|NCT03819725|Other|Glucose monitoring|FreeStyle® Libre Pro Interstitial Glucose Meter will be applied after skin preparation with anesthetic cream (Emla® ) and glucose measurements will be monitored during 2-5 days. Oral food intake will be recorded.
88828886|NCT02420951|Active Comparator|No Injection|Will not receive injection of bupivacaine prior to catheter removal
89357444|NCT03478891|Experimental|Group 1: 5 mg/kg IV|Group 1 subjects received a single IV infusion of a Human Monoclonal Antibody (MAb), VRC-EBOMAB092-00-AB (MAb114), on Day 0 at a dose of 5 mg/kg.
89357445|NCT03478891|Experimental|Group 2: 25 mg/kg IV|Group 2 subjects received a single IV infusion of a Human Monoclonal Antibody (MAb), VRC-EBOMAB092-00-AB (MAb114), on Day 0 at a dose of 25 mg/kg.
89357446|NCT03478891|Experimental|Group 3: 50 mg/kg IV|Group 3 subjects received a single IV infusion of a Human Monoclonal Antibody (MAb), VRC-EBOMAB092-00-AB (MAb114), on Day 0 at a dose of 50 mg/kg.
89357447|NCT01585103|Experimental|Cytosponge/ brushing|Subjects with eosinophilic esophagitis undergoing clinically indicated endoscopy and biopsy either for initial diagnosis or for monitoring the activity of their disease will be asked to swallow the cytosponge two hours prior to endoscopy.
89357448|NCT03168906|Experimental|NEOD001|Study Drug given IV every 28 days at 24mg/kg
89357449|NCT03168906|Placebo Comparator|Placebo|Placebo
89357450|NCT05281133|Experimental|The group using virtual reality glasses|The video chosen by the children in the experimental group was started 1-2 minutes before the splint with virtual reality glasses and watched for an average of 7 minutes.
89357451|NCT05281133|No Intervention|The group not using virtual reality glasses|In the control group, during the splint a video was not watched.
89357452|NCT03811925|Other|DCB|
89357453|NCT03811925|Other|Stenting|
88828887|NCT02267083|Experimental|GPX-150|GPX-150 for Injection, 265 mg/m2, every 21 days for 16 cycles or until death, disease progression, or unacceptable toxicity, or subject withdrawal.
89357454|NCT00706966|Experimental|Dutasteride|Dutasteride was administered at a dose of 3.5 mg as an oral soft gelatin capsule once daily for 6 months
89534192|NCT04105634|Experimental|Amyloid group|Patient diagnosed with Cardiac Amyloidosis
88828888|NCT02534285|Sham Comparator|Control|Patients of the control group receive a Sham hearing protection with no effect on noise attenuation.
88828889|NCT02534285|Active Comparator|Intervention|Patients of the Intervention group receive a Hearing protection with a noise attenuation of 20-45 decibel.
88828890|NCT05747911||Migraine|
88828891|NCT05747911||Without Migraine|
88828892|NCT02422511|Active Comparator|Well Baby Family History Only|Parents of newborns in well-baby units receive an Annotated Family History Report only. Active Comparator: Standard of Care Only: Family History report only
88828893|NCT02422511|Experimental|Well Baby Family History + Exome Sequencing|Parents of newborns in well-baby units receive a Genome Report and an Annotated Family History Report. Main Study Experimental: Genome Report and Family History report
88828894|NCT02422511|Active Comparator|ICU Baby Family History Only|Parents of newborns in intensive care units receive an Annotated Family History Report only. Active Comparator: Standard of Care Only: Family History report only
89357455|NCT03478657|Experimental|Subjects using placebo ELLIPTA DPI|Subjects in stratum 1 and stratum 2 will be of age group from 5 to 7 years and 8 to 11 years respectively. Subjects will take placebo ELLIPTA DPI once daily. During Visit 2 (Day 28) subjects will be randomized to receive questionnaire on ELLIPTA DPI usage either version A or B.
89357456|NCT01330524|Active Comparator|Avastin and Triamcinolone|
89357457|NCT01330524|Placebo Comparator|Placebo|
89357458|NCT01560065|Other|Normospermic patients|
89357459|NCT01560065|Other|Oligoasthenospermic patients|
89357460|NCT01560065|No Intervention|Control|
89357461|NCT03331900|Placebo Comparator|Placebo|
89357462|NCT03331900|Active Comparator|COR388 TBD mg|
89534193|NCT04098393|Experimental|patients hematologic malignancies other than multiple myeloma|A. Busulfan 3.2 mg/kg/day, with dose adjustments made according to pharmacokinetic (PK) levels. B. Melphalan (70mg/m2/day) administered on days -6 and -5. C. Fludarabine (25mg/m2/ day) administered on days -6, -5, -4, -3, and -2. All patients receiving matched related or unrelated donor allografts receive anti-thymocyte globulin (ATG) 2.5 mg/kg/day on days -3 and -2 to deplete chemotherapy resistant host T-cells that could hinder engraftment, and it may provide additional GVHD prophylaxis.
88828895|NCT02422511|Experimental|ICU Baby Family History + Exome Sequencing|Parents of newborns in intensive care units receive a Genome Report and an Annotated Family History Report. Main Study Experimental: Genome Report and Family History report
89188898|NCT00764465|Active Comparator|Group F|Period 1-Maraviroc 300mg BID Period 2-Fosamprenavir 1400mg QD + Ritonavir 100mg QD + Maraviroc 300mg BID Period 3-Fosamprenavir 1400mg QD + Ritonavir 100mg QD
89188899|NCT02546752|Experimental|THEO Video Arm|"THEO is interactive patient engagement software that runs on an iPad tablet platform (developed by Noble.MD). Two programs have been developed. Parents/guardians of children who have not received the first HPV vaccine, will first assess whether the family has already decided in favor of the HPV vaccine or if they would like more information. The parent/guardian will be shown a video specific to where they are in the decision-making process. After completion, the THEO system will then ask the parent/guardian a series of Post Video questions. Parents/guardians of children who have received the first or second vaccine in the series, will emphasize the need to make the first vaccine count. Pre and post video questions have been developed."
89357463|NCT05664997||violinists|musicians who play the violin in a conservatory or orchestra
89357464|NCT03121066|Active Comparator|Experimental group|Transcranial Magnetic Stimulation + Conventional intervention
89357465|NCT03121066|Sham Comparator|Sham control group|Sham Transcranial Magnetic Stimulation + Conventional intervention
89357466|NCT03121066|No Intervention|Non TMS Control group|Conventional intervention alone
89357467|NCT01302587||Albuterol MDI|All participants in this study will receive an albuterol MDI inhaler.
89357468|NCT03338608|Experimental|Vertical Platysma Incision|Patients in this arm who have anterior cervical decompression and fusion will receive the vertical platysma incision.
89357469|NCT03338608|Experimental|Transverse Platysma Incision|Patients in this arm who have anterior cervical decompression and fusion will receive the transverse platysma incision.
88828896|NCT05747833|Experimental|Toy IV Catheter Before Peripheral Cannula application|Intervention Group: Child Fear Scale will be applied to the children who will meet the inclusion criteria. The data collection form will be filled in by the researcher according to the information received from the patient file and parents. Children in the intervention group will be shown the procedure on the doll with the IV Catheter developed by the researchers, and then it will be applied to it.
88828897|NCT05747833|No Intervention|Standard of care|Control group will not be aplied other than the normal procedure of the hospital. In both groups, at the end of the procedure, the child's reactions will be observed during the procedure and the Wong-Baker Faces Pain Scale, the Child Anxiety Scale and the Child Emotional Indicators Scale will be filled independently by the researcher and the parent in line with the child's reactions.
88828898|NCT02989285||HIV+ cognitively impaired (HAND)|Participants will be assessed based on their performance on the neuropsychological test battery at study entry. HAND status will be diagnosed per FRASCATI research criteria and this will determine which study cohort they are allocated to. Participants will continue to receive their standard of care treatment during the study period.
88828899|NCT02989285||HIV+ cognitively normal (no-HAND)|Participants will be assessed based on their performance on the neuropsychological test battery at study entry. HAND status will be diagnosed per FRASCATI research criteria and this will determine which study cohort they are allocated to. Participants will continue to receive their standard of care treatment during the study period.
88828900|NCT02989675|Experimental|Dextrose|Children in the intervention group will immediately receive intravenous 5ml/kg 10% dextrose, Dextrose administration will continue as a maintenance infusion of intravenous 10% dextrose for 24 hours at standard maintenance rates. Capillary blood glucose monitoring will be repeated at 30 minute intervals with repeated equivalent bolus doses given until levels reach ≥5.0mmol/l. All children will be kept in the emergency department for a minimum of 60 minutes and have their vital signs checked at discharge from the emergency room to the ward.
88828901|NCT02989675|No Intervention|Control|Usual care - the care that is currently provided in the hospital - will be provided. All children in the control group will be kept in the emergency department for a minimum of 60 minutes and have their vital signs checked at discharge from the emergency room to the ward.
88828902|NCT05747677|Experimental|HH-120 Nasal Spray|
88828903|NCT02535611|Active Comparator|Memantine|Patients with ischemic stroke in middle cerebral artery (MCA) territory who will receive 20 mg/d(2 tab 5mg BID) memantine for 7 days and then 10mg/d(1 tab 5mg BID) memantine for 21 days.
88828904|NCT02535611|Placebo Comparator|Placebo|Patients with ischemic stroke in middle cerebral artery (MCA) territory who will receive placebo(2 tab BID) for 7 days and continue placebo(1 tab BID) for 21 days.
89188900|NCT02546752|No Intervention|Usual Care Arm|This arm will receive usual care.
89188901|NCT00836602|Active Comparator|BMS-779788 or Placebo (Arm 1)|
89188902|NCT00836602|Active Comparator|BMS-779788 or Placebo (Arm 2)|
89188903|NCT00836602|Active Comparator|BMS-779788 or Placebo (Arm 3)|
89188904|NCT00655863|Placebo Comparator|Placebo QD|
89188905|NCT00655863|Experimental|Alogliptin 25 mg QD|
89188906|NCT00655863|Experimental|Alogliptin 25 mg QD + Pioglitazone 30 mg QD|
89188907|NCT00718874|Experimental|A, 1|low-carbohydrate (42%)
89188908|NCT00718874|Experimental|A,2|standard carbohydrate (55%) based on ADA recommendations
89188909|NCT05672030||Aspirin-exacerbated respiratory disease (AERD)|Aspirin-exacerbated respiratory disease (AERD)
89188910|NCT05672030||Aspirin-tolerant chronic rhinosinusitis with nasal polyps (CRSwNP)|Aspirin-tolerant chronic rhinosinusitis with nasal polyps (CRSwNP)
89188911|NCT05672030||Healthy controls|Individuals who do not have AERD or CRSwNP
89188912|NCT02572310|Experimental|HV Cement|Simplex High Viscosity Bone Cement
89188913|NCT00718952|Experimental|A|Patients in group A will receive vardenafil in double-blinded treatment period.
89188914|NCT00718952|Placebo Comparator|B|Patients in group A will receive placebo in double-blinded treatment period.
89188915|NCT00797433||Mechanical ventilation|All male patients with acute respiratory failure requiring mechanical ventilation
89188916|NCT00841984||1|patients with complex neurological disease of unknown cause
89188917|NCT00841984||2|positive controls : patients with already known metabolic disease for whom we already have CSF or urines
89188918|NCT00841984||3|negative controls: patients with non metabolic neurological disorders of known cause hospitalized for a lumbar puncture
89188919|NCT00806013||1|CYP2C9*1/*1 and CYP2C19*1/*1 alleles carrier
89188920|NCT00806013||2|CYP2C19 PMs (CYP2C19*2/*2, CYP2C19*2/*3 or CYP2C19*3/*3)
89188921|NCT00806013||3|CYP2C9*1/*3 and CYP2C19*1/*1 alleles carrier
89188922|NCT00719030|Experimental|1|Pomegranate pill
89188923|NCT00719030|Placebo Comparator|2|
89188924|NCT00844246|Experimental|SRS|School Readiness Specialist (SRS) will administer the screening questionnaire to the subject during the intervention period, at the subject's 9, 18, 24 and 30 month visits. They will then see their PCP for a well child visit in which the results of the test will be interpreted, developmental counseling and/or anticipatory guidance provided as per usual care. EI (Early intervention) referral will be completed, at the discretion of the providers, if the subject fails the developmental screen or the caregivers raise a specific concern about the child's development.
89188925|NCT00844246|Experimental|Provider|Primary Care Physician (PCP) will do the developmental screening at the subject's 9, 18, 24 and 30 month well child visits. Once the screening questionnaire is complete the PCP will then score the screening tool and interpret the test results. Developmental counseling and/or anticipatory guidance will be provided, as per usual care. EI (Early intervention) referral will be completed, at the discretion of the providers, if the subject fails the developmental screen or the caregivers raise a specific concern about the child's development.
89188926|NCT00844246|No Intervention|Routine|Subjects randomized to routine surveillance will receive routine preventive care as well as developmental surveillance at all well child visits, including the 9, 18, 24 and 30 month visits. EI referral will be completed, at the discretion of the provider, if the PCP observes a developmental delay during surveillance or the caregivers raise a specific concern about the child's development.
89357470|NCT03018288|Other|1/Temozolomide + Pembrolizumab + Radiation Therapy|Standard treatment with experimental treatment (pembro) added.
89357471|NCT03018288|Experimental|2/Temozolomide+Pembrolizumab|Temozolomide+Pembrolizumab
89357472|NCT03018288|Experimental|3/Temozolomide+Pembrolizumab+ Heat Shock Protein Peptide Complex-96 (HSPPC-96) Vaccine|Temozolomide+Pembrolizumab+ HSPPC96 Vaccine
89357473|NCT03018288|Placebo Comparator|4/Temozolomide+Pembrolizumab+ Placebo|Temozolomide+Pembrolizumab+ Placebo
89357474|NCT03811613|Experimental|Photobiomodulation group|"17 Parkinson´s disease patients were randomly assigned to the photobiomodulation group (experimental group).~Intervention: Photobiomodulation was administered using red light-emitting diodes (LEDs) with a 670-nm wavelength in six 1-minute blocks alternating the LEDs between the right and left temples, with a 30-second rest between blocks."
89357475|NCT03811613|Sham Comparator|Sham group|"18 Parkinson´s disease patients were randomly assigned to the sham group.~Intervention: Procedures for the sham group were identical as the photobiomodulation one, except that patients received photobiomodulation during only 5 seconds followed by 55 seconds with no treatment (equalling 1/12th of the energy used for the intervention group)."
89357476|NCT03331822|Experimental|Light|High illuminance ,white lights positioned at each nursing station throughout the hallway to generate a uniform exposure of approximately 1,000-3,000 lux.
89357477|NCT03331822|No Intervention|No Light|Ambient, standard white fluorescent environmental light will serve as control.
89357478|NCT05035290|Experimental|Negative pressure ventilation|Negative pressure application after extubation
88828905|NCT01823497|Active Comparator|Parent/Nurse Controlled Analgesia|Parent/Nurse Controlled Analgesia will be the method of morphine delivery.
88828906|NCT01823497|Active Comparator|Continuous Opioid Infusion|Continuous Opioid Infusion will be the method used to deliver morphine to group 2
88828907|NCT02423447|Active Comparator|Electro-Flo Arm|The patients were randomized to a series of airway clearance sessions with Electro-Flo on Day 1 and G5 on Day 2.
88828908|NCT02423447|Active Comparator|G5 Arm|The patients were randomized to a series of airway clearance sessions with G5 on Day 1 and Electro-Flo on Day 2.
88828909|NCT05747521|Experimental|Anrotinib hydrochloride combined with adriamycin|Anrotinib hydrochloride combined with adriamycin neoadjuvant therapy for patients with high-grade soft tissue sarcoma
88828910|NCT02537717|Experimental|Sapphire lens|Each subject will be randomized to wear the test lens in one eye and control lens in the other eye. Both test and control lenses will be used in a daily wear modality for one month.
88828911|NCT02537717|Active Comparator|enfilcon A|Each subject will be randomized to wear the test lens in one eye and control lens in the other eye. Both test and control lenses will be used in a daily wear modality for one month.
88828912|NCT05234047||CKD-5D patients receiving denosumab|
88828913|NCT02537873|Experimental|Arm 1: Lorcaserin and Cocaine IV|"Lorcaserin 10 mg administered orally once daily for 6 days then increasing to twice daily for 3 days.~Cocaine IV (intravenous) administered in ascending doses of 0, 10, 20, 40 mg on study days 1, 2, 6 and 12."
88828914|NCT02537873|Placebo Comparator|Arm 2: Placebo Comparator and Cocaine IV|Dextrose placebo in gelatin capsule identical to experimental drug. Cocaine IV (intravenous) administered in ascending doses of 0, 10, 20, 40 mg on study days 1, 2, 6 and 12.
88828915|NCT01823653|Experimental|Treated Thigh|Subjects randomly received treatment of either the left or right thigh with the Liposonix System (Model 2)
88828916|NCT05118763|Experimental|INNA-051 arm 1|INNA-051 intranasal spray low dose administered once on each of Days 1, 4, 7 and 10
88828917|NCT05118763|Experimental|INNA-051 arm 2|INNA-051 intranasal spray high dose administered once on each of Days 1, 4, 7 and 10
89357479|NCT05035290|No Intervention|Standard approach|Standard approach - oxygentherapy based on patients need
89357480|NCT03338530|Experimental|Comprehensive School-Based Intervention|Children with HFASD assigned to the CSBI received social skills groups, computer instruction in emotion recognition, therapeutic activities, and a behavioral reinforcement system (individual daily note) during the school year and their parents participated in monthly parent training. School staff received training prior to the school year and demonstrated fidelity with the protocol. Fidelity was also monitored during the school year by research assistants.
89357481|NCT03338530|No Intervention|Business-As-Usual (BAU) Control|Children with HFASD in the BAU schools received their typical special education programming as legally-mandated. The programming received by each was carefully monitored per the following: 1) Each student's IEP was reviewed to document the legally mandated services received; 2) For those receiving counseling or speech-language services, the related-service provider completed a survey indicating specific treatment targets and the protocol for service provision; 3) Parents completed a monthly survey of any external therapeutic programming their child may have received; and 4) Fidelity measures designed for the intervention group (with sequencing requirements removed) were completed for the control condition during two 60-minute classroom observations per week by research assistants.
89530528|NCT03347201|No Intervention|Control Group|Patients in the control arm will undergo routine heparin anticoagulation using a weight based initial dose of 400 units/kg, aiming for an ACT of >480 seconds. Further heparin doses (5000 to 10000 units) will be given if the ACT falls below 480 seconds whilst on bypass. At the end of CPB heparin will be reversed with protamine using 1:1 ratio based on the initial dose of heparin given pre-bypass. HMS Plus measures will also be conducted in this group for study purposes, but the results will not be made available to the clinicians.
88828918|NCT05118763|Placebo Comparator|Placebo|Placebo intranasal spray high dose administered once on each of Days 1, 4, 7 and 10
88828919|NCT02537951|Experimental|AFI intensity in healthy volunteers|10 healthy volunteers, on whose 3rd fingertips AFI intensity is measured through an AFI microscope
88828920|NCT02537951|Active Comparator|negative control 1: lidocaine/prilocaine|10 healthy volunteers, on whose 3rd fingertips AFI intensity is measured through an AFI microscope, 1hour after application of lidocaine/prilocaine creme (negative control 1)
88828921|NCT02537951|Active Comparator|negative control 2: 8% capsaicin|-10 healthy volunteers, on whose 3rd fingertips AFI intensity is measured through an AFI microscope, 1week after application of an 8% capsaicin patch (negative control 2)
88828922|NCT01824589|Active Comparator|Group A|tidal volume setting of 6ml/kg with the -7cm H2O ITPR as first device
88828923|NCT01824589|Active Comparator|Group B|tidal volume setting of 8ml/kg with the -7cm H2O ITPR as first device
89357482|NCT05013294|Experimental|Intervention|The intervention group will receive a total of 43 text messages. Text messages were developed using the Behavior Chang Wheel (BCW) through a systematic process linked to specific behavior change techniques. The text messages will provide practical information or guidance to influence selection and eating healthy diet for type 2 diabetes care. The text messages were either loss- or gain-framed to increase influence on behavioral decisions. Additionally, the participants will receive a text message to rate their ability on selection of food and eating of healthy diet based on the messages received in the month. The combination of the one-way and two-way messages in this group are designed to increase engagement of the participants.
88828924|NCT01824589|Active Comparator|Group C|tidal volume setting of 6ml/kg with the -12cm H2O ITPR as first device
88828925|NCT01824589|Active Comparator|Group D|tidal volume setting of 8ml/kg with the -12cm H2O ITPR as first device
89357483|NCT05013294|Placebo Comparator|Control Arm|The control group will continue receiving standard care in the hospitals. The control group shall also receive a reminder text messages one day prior the routine clinic appointment. The clinic appointment dates shall be derived from the hospital where the participant receives routine diabetes care.
89357484|NCT02492152|No Intervention|Control group|Women who will not be using this medicine that is checked.
89357485|NCT02492152|Experimental|Study group|Women who will use DIANATAL according to manufacturer's protocol from the stage of active labor.
89357486|NCT03515941|Experimental|Arm 1: Adjuvant Chemotherapy|Three cycles of chemo with CAPEOX (Oxaliplatin:130 mg/m2 by IV and Capecitabine: 625 or 1000 mg/m2 by PO (BID) on 21 day-cycle or FOLFOX (Oxaliplatin:85 mg/m2 by IV, Leucovorin:400 mg/m2 by IV,5-fluorouracil: 400 mg/m2 and 2400 mg/m2 by IV) on 14 day-cycle
89357487|NCT03515941|Experimental|Arm 2: Adjuvant Chemoradiation|Three cycles of chemo with Capecitabine: 750 mg/m2 by PO BID on days 1-14 of a 28 day-cycle or 5-fluorouracil (Leucovorin:400 mg/m2 by IV,5-fluorouracil: 400 mg/m2 and 1200 mg/m2 by IV) on days 1 and 15 of a 28 day cycle After 1st chemo cycle above, chemoradiation for 5 weeks with 45 Gy in 1.8 Gy/fraction, 5 days a week, to the entire gastric bed (including anastomosis) and draining lymph nodes, and a single agent fluoropyrimidine, either capecitabine or 5-fluorouracil After 5 weeks chemoradiation, 2 cycles of chemo as described above.
89357488|NCT01300403|Experimental|FLUTTER|Since this was a crossover study, all patients performed all interventions in a randomized order.
89357489|NCT01300403|Experimental|ELTGOL|Since this was a crossover study, all patients performed all interventions in a randomized order.
89357490|NCT01300403|Active Comparator|CONTROL|Since this was a crossover study, all patients performed all interventions in a randomized order.
89357491|NCT03819647|Experimental|stiripentol (Diacomit)|
89357492|NCT02498782|Active Comparator|Fexinidazole, 1800 mg, 2 weeks|1800mg (High Dose) 2 weeks (HD - 2 weeks) Group: Fexinidazole, 1800 mg QD for 2 weeks, followed by placebo to complete 8 weeks (total dose: 25,2 g)
89357493|NCT02498782|Active Comparator|Fexinidazole, 1800 mg, 4 weeks|1800mg (High Dose) 4 weeks (HD - 4 weeks) Group: Fexinidazole, 1800 mg QD for 4 weeks, followed by placebo to complete 8 weeks (total dose: 50,4 g)
89357494|NCT02498782|Active Comparator|Fexinidazole, 1800 mg, 8 weeks|1800mg (High Dose) 8 weeks (HD - 8 weeks) Group: Fexinidazole, 1800 mg QD, for 8 weeks (total dose: 100,8 g)
89357495|NCT02498782|Active Comparator|Fexinidazole, 1200 mg, 2 weeks|1200mg (Dose 2 weeks) 2 weeks (LD - 2 weeks) Group: Fexinidazole, 1200 mg QD for 2 weeks, followed by placebo to complete 8 weeks (total dose: 16,8 g)
89357496|NCT02498782|Active Comparator|Fexinidazole, 1200 mg, 4 weeks|1200mg (Low Dose) 4 weeks (LD - 4 weeks) Group: Fexinidazole, 1200 mg QD for 4 weeks, followed by placebo to complete 8 weeks (total dose: 33,6 g)
89357497|NCT02498782|Active Comparator|Fexinidazole, 1200 mg, 8 weeks|1200mg (Low Dose) 8 weeks (LD - 8 weeks) Group: Fexinidazole, 1200 mg QD for 8 weeks (total dose: 67,2 g)
88828926|NCT02486939|Experimental|CHS-0214|CHS-0214 50 mg weekly
88828927|NCT02487485|Experimental|ketamine + sirolimus (placebo at time 2)|Participants will be treated twice with ketamine 0.5 mg/kg infused over 40 minutes, combined with a single dose of sirolimus 6 mg orally. After two weeks, they will recieve another infusion of ketamine, and a single dose of placebo.
88828928|NCT02487485|Placebo Comparator|ketamine + placebo (sirolimus at time 2)|Participants will be treated twice with ketamine 0.5 mg/kg infused over 40 minutes, combined with a single dose of sirolimus 6 mg placebo. After two weeks, they will recieve another infusion of ketamine, and a single dose of sirolimus 6 mg.
88828929|NCT02487563|Experimental|Experimental Group 1|Decitabine in combination with rhTPO.
88828930|NCT02487563|Experimental|Experimental Group 2|Decitabine
88828931|NCT02487563|Active Comparator|Control Group|Conventional treatment except decitabine.
88828932|NCT02423993|Experimental|SAP + Group Education|Patients will be transferred from MDI to sensor-augmented pump (SAP) in group using specialised structured education program. CGM will be used for self monitoring of blood glucose permanently within 4 month.
88828933|NCT02423993|Active Comparator|SAP + Standard Education|Patients will be transferred from MDI to sensor-augmented pump (SAP) by endocrinologist-specialist in CSII or technical trainer individually and will be monitored by coaching specialist or local endocrinologist within 4 months prior to inclusion. All patients from this group should be educated about basic aspects of diabetes self-management at the School of Diabetes at least once earlier.
88828934|NCT02423993|Experimental|CSII + Group Education|Patients will be transferred from MDI to CSII with self-monitoring of blood glucose (SMBG) using specialised structured education program.
89357498|NCT02498782|Placebo Comparator|Placebo|Placebo (8 weeks) Group: Fexinidazole matched placebo tablets QD for 8 weeks.
89357499|NCT03338452|Experimental|participants|The participants will be subjected to low energy ketogenic diet.
89357500|NCT05623007|Experimental|Intervention|220 overweight/obese adolescents will be given Probiotics and counselling on healthy eating, physical activity, and psychosocial stimulation.
89357501|NCT05623007|Placebo Comparator|Control|220 overweight/obese adolescents will be given placebo probiotics and counselling on healthy eating, physical activity, and psychosocial stimulation.
89357502|NCT02499016|Experimental|suprapubic single-incision laparoscopic appendectomy|single incision laparoscopic surgery will be performed for patients in this group.
89357503|NCT02499016|Active Comparator|conventional multiport appendectomy|Conventional laparoscopic surgery will be performed for patients in this group.
88828935|NCT02423993|Active Comparator|CSII + Standard Education|Patients will be transferred from MDI to CSII with self-monitoring of blood glucose (SMBG) by endocrinologist-specialist in CSII or technical trainer individually and will be monitored by coaching specialist or local endocrinologist within 4 months prior to inclusion. All patients from this group should be educated about basic aspects of diabetes self-management at the School of Diabetes at least once earlier.
89357504|NCT03815201|Placebo Comparator|Group 1|exercise training program: 2 non-consecutive days per week during 12 weeks plus placebo ingestion post-training
89357505|NCT03815201|Active Comparator|Group 2|exercise training program: 2 non-consecutive days per week during 12 weeks plus leucine-enriched protein supplementation post-training
89357506|NCT02493790||Volunteers|Cognitive and motor performances were measured in a single and dual task situations.
89357507|NCT02493790||COPD patients|Cognitive and motor performances were measured in a single and dual task situations, before rehabilitation, and compared to those of healthy subjects. Then, Chronic Obstructive Pulmonary Disease patients were re-evaluated after rehabilitation.
89357508|NCT03819335|Active Comparator|Standard care|Usual follow-up of diabetes type 1 with face-to-face visits
89357509|NCT03819335|Experimental|mySugr app|Telemedical assistance with mySugr app
89357510|NCT02498938||SERPINA1 gene in COPD and periodontitis|patients aged between 30-70 yrs with COPD (satisfying Gold's criteria) and chronic periodontitis (>4mm pocket probing depth)
89357511|NCT03811691|Other|1.5 Tesla MRI Scan|Subjects will undergo 1.5T MRI exam
89357512|NCT03811691|Other|3 Tesla MRI Scan|Subjects will undergo 3T MRI exam
89357513|NCT02498860|Experimental|Pemebit plus Cisplatin|Pemetrexed (Pemebit 500 mg/m2) plus cisplatin (75 mg/m2) every 3 weeks up to 4 cycles
89357514|NCT03811457|Experimental|Welgenaleucel (UWC19)|The Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T) Dosage form：injection Dosage: 100mL in total Frequency:the first day, the second day, the third day Duration:total three times
88828936|NCT02427737|Experimental|Comfort Talk® Training|In the experimental group, MRI personnel is trained to use Comfort Talk® to help patients who are claustrophobic, anxious, and/or cannot lie still to complete their tests at the onset of the MRI scan.
88828937|NCT02427737|No Intervention|Control|MRI sites not trained in Comfort Talk®.
88828938|NCT02489123|Experimental|Treatment (enzalutamide)|Patients receive enzalutamide PO QD. Courses 1-3 repeat every 4 weeks (28 days) and subsequent courses repeat every 12 weeks (84 days) in the absence of disease progression or unacceptable toxicity.
88828939|NCT02489357|Experimental|Treatment (pembrolizumab, cryosurgery)|Patients receive standard of care degarelix SC once a month for 8 months. Within 1 month of receiving degarelix, patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Within 3 days of receiving pembrolizumab, patients undergo whole gland cryoablation of the prostate.
88828940|NCT02490293|Experimental|Group A (cephalosporin)|"During the period of hospitalization, intake of active drug ('pacetin', 2nd generation cephalosporin). 3 g per day divided into 3 times via intravenous route until the day of discharge.~After discharge, oral intakes of 500mg each (1 pill of cefaclor, the 2nd generation cephalosporin every 12 hrs) for three days."
88828941|NCT02490293|Placebo Comparator|Group B (placebo)|"During the period of hospitalization, Intake of placebo (normal saline). 30cc per day divided into 3 times via intravenous route until the day of discharge.~After discharge, oral intakes of 1000mg each (2 pill of vitamin C every 12 hrs) for three days."
88828942|NCT02538419|Active Comparator|CPAP + Peer Support|"Participants randomized to this arm will receive support from a 'CPAP Peer Leader', delivered as part of a group of other participants as well as targeted one-on-one support throughout the study.~All participants will receive CPAP in addition to this intervention."
88828943|NCT02538419|Active Comparator|CPAP + Individual Education|"Participants randomized to this arm will receive individual support and education from a trained investigator.~All participants will receive CPAP in addition to this intervention."
88828944|NCT02539511|Experimental|CI-581a+MET|Administration of CI-581a during wk 2 at 0.71 mg/kg in the context of a 5 wk course of MET
88828945|NCT02539511|Active Comparator|CI-581b+MET|Administration of CI-581b during wk 2 at 0.025 mg/kg in the context of a 5 wk course of MET
88828946|NCT02540447|Experimental|Purge|"The donor surgical team excised the right liver lobe (without inclusion of the middle hepatic vein) and preserved it on the back table with cold custodiol (4°C solution, Portal vein (PV) was completely anastomosed and the right hepatic vein (RHV) was anastomosed with the recipient hepatic vein apart from last suture that was left for drainage of the liver graft contents of the preservative solution into the peritoneal cavity using portal blood after portal declamping based on the graft volume and suctioned through an external sucker, then completed the RHV anastomosis."
89357515|NCT02498704|Sham Comparator|Sham Needling intervention, Control|Sham dry needling, group does not receive true dry needling intervention.
89357516|NCT02498704|Experimental|Dry Needling Intervention, experimental|Group receives true dry needling intervention.
89357517|NCT03011034|Experimental|Talacotuzumab|Participants will receive talacotuzumab 9 milligram per kilogram (mg/kg) intravenously (IV) on Days 1 and 15 for all cycles. Each treatment cycle is of 28 days. The talacotuzumab arm of the study is closed for enrollment.
89357518|NCT03011034|Experimental|Daratumumab|Participants will receive daratumumab 16 mg/kg IV on Days 1, 8, 15, and 22 for Cycles 1 and 2; on Days 1 and 15 for Cycles 3 to 6; and on Day 1 for all subsequent cycles. Each treatment cycle is of 28 days.
89357519|NCT01330602|Experimental|Lifestyle counseling|"All participants randomised into the IMPRESS Intervention group will undergo tailored health profiling.This individual assessment will be carried out within the clinic setting.~The key elements of the IMPRESS intervention include:~Promoting a healthy lifestyle~Supporting lifestyle and risk modification~Encouraging active self-management of risk and chronic disease~Improving coordination of care~Pharmacological therapy All the individuals in the intervention group will receive a comprehensive report on their risk status and ideal goals."
89530529|NCT02453659|Experimental|Distress Tolerance Treatment for Weight Concern (DT-W)|DT-W is delivered over a 9 week period with 1 1-hr individual session during week 1, 8 weekly 1.5-hr group counseling sessions during weeks 2-9, and 1 20-minute individual telephone session during week 4. Session content includes distress tolerance intervention for weight concern plus standard behavioral smoking cessation treatment. Participants also receive 8 weeks of nicotine patch.
89357520|NCT01330602|No Intervention|Usual care arm|"Usual Care Following the assessment of absolute cardiovascular risk, usual care participants will be provided a report outlining areas in which improvements could be made for the prevention of atherosclerotic burden.~No restrictions will be made in respect to usual care management. As such, the prescription of standard medications for primary prevention of atherosclerotic burden based on individual risk factors is anticipated in 20-30% of usual care participants.~At 18 months and three years those in the usual care arm will be invited to undergo repeat CIMT measurements, pathology, absolute risk score calculation and health-related questionnaires as part of the structured study follow-up"
89357521|NCT03331588|Active Comparator|Subxiphoid uniportal VATS|Standard Subxiphoid single-port video assisted thoracic surgery, no use of rib-spreader.
89357522|NCT03331588|Active Comparator|Intercostal uniportal VATS|Standard Intercostal single-port video assisted thoracic surgery, no use of rib-spreader.
89357523|NCT01301885||Endometriosis|Women (19-48 years of age) with surgically confirmed endometriosis.
89357524|NCT01301885||Healthy women|Healthy women (32-48 years of age), symptom free, existence of endometriosis ruled out during laparoscopy for tubal ligation
89357525|NCT03515629|Active Comparator|Pembrolizumab|Pembrolizumab
89357526|NCT03515629|Experimental|REGN2810/ipi|REGN2810/ipi
89357527|NCT03515629|Experimental|REGN2810/chemo/ipi|REGN2810/chemo/ipi
89357528|NCT02498626||venous saturations|venous saturations from the central venous line, venous side of the heart lung machine and from the pulmonary artery
89357529|NCT04581954|Active Comparator|Standard of care|
89357530|NCT04581954|Active Comparator|Fostamatinib|
89357531|NCT04581954|Active Comparator|Ruxolitinib|
88828947|NCT02540447|No Intervention|No Purge|The donor surgical team excised the right liver lobe (without inclusion of the middle hepatic vein) and preserved it on the back table with cold Custodiol (4°C solution, Both portal vein and RHV were completely anastomosed prior to portal declamping and the graft preservative contents were washed into the systemic circulation by the portal blood at portal declamping.
88828948|NCT02428595|Experimental|Treatment|Eclipse™ System
88828949|NCT02493257|Experimental|intranasal capsaicin|The capsaicin solution will be prepared by using the formula previously reported by Van Rijswijk et al; (0.1mmol/l) diluted in ethanol and 0.9% normal saline (19). Using the mucosal atomizer device (MAD), 0.8 milliliters (mL) will be delivered to each nasal cavity for a total of 24.4 ug per nasal cavity. 5 consecutive applications of capsaicin or placebo will be administered intranasally, with 1 hour between each application.
88828950|NCT02493257|Placebo Comparator|Vehicle solution|100 μL of 1% ethanol in 0.9% saline solution. 5 consecutive applications of capsaicin or placebo will be administered intranasally, with 1 hour between each application.
89357532|NCT05016089|Experimental|Simplified Pilates exercise group (SPEG)|The participants in the SPEG will participate in the 16-style simplified Pilates exercise sessions (about 60 minutes each) in a group (about 10 participants in each group) twice a week for 12 weeks. Each participant will undertake a total of 24 exercise sessions.
89357533|NCT05016089|Other|Wait-list control group (WLCG)|The participants in the WLCG will participate in the 16-style simplified Pilates exercise sessions (about 60 minutes each) in a group (about 10 participants in each group) twice a week for 12 weeks after two scheduled assessment sessions and a waiting period of 12 weeks in between. Each participant will undertake a total of 24 exercise sessions.
89357534|NCT04494178|Experimental|2.0g G-PUR® oral - Placebo|
89357535|NCT04494178|Experimental|Placebo - 2.0g G-PUR® oral|
89357536|NCT05002751||Cohort 1|1. Patients with histologically confirmed newly diagnosed advanced cervical cancer (squamous cell carcinoma, adenocarcinoma, and adenosquamous cell carcinoma): FIGO 2009 clinical stages IB2/IIA with positive para-aortic nodes, or FIGO 2009 clinical stages IIB/IIIB/IVA with positive pelvic or para-aortic lymph nodes (PALN). Pelvic or PALN nodal status confirmed by PET/CT scan or fine needle biopsy or extra peritoneal biopsy or laparoscopic biopsy. The PALN must be inferior to the T12/L1 interspace.
89357537|NCT04541940|Active Comparator|Telerehabilitation|
89357538|NCT04541940|Active Comparator|In-Person Rehabilitation|
89357539|NCT01330680|Experimental|Coffee|
89357540|NCT01330680|Active Comparator|Decaffeinated coffee|
89357541|NCT01330758|Active Comparator|40 mg AZD8931 wet granulation tablet formulation|
89357542|NCT01330758|Experimental|40 mg AZD8931 roller compacted tablet formulation|
89357543|NCT01302821|Experimental|Radiotherapy|AMT positron emission tomography with integrated computed tomography (PET/CT)scanning in metastatic breast cancer patients to identify tumors with increased AMT uptake due to up-regulated IDO expression.
89357544|NCT03331432|Placebo Comparator|Placebo|Taking daily placebo capsules for 4 weeks
89357545|NCT03331432|Experimental|Tauroursodeoxycholic acid|Taking tauroursodeoxycholic acid (1750 mg/day) capsules for 4 weeks
89357546|NCT03512353|Experimental|Carfilzomib Plus Dexamethasone|"Participants received carfilzomib administered as an intravenous (IV) infusion twice-weekly for up to six 28-day cycles followed by once-weekly for another six 28-day cycles. The carfilzomib dose was 20 mg/m² on days 1 and 2 of cycle 1, 56 mg/m² for the remaining days of cycle 1 (days 8, 9, 15, and 16) and then on days 1, 2, 8, 9, 15, and 16 of each cycle for cycles 2 to 6, and 70 mg/m² on days 1, 8, and 15 of each cycle for cycles 7 to 12.~Participants also received dexamethasone either orally or by IV infusion at a dose of 20 mg once daily on days 1, 2, 8, 9, 15, 16, 22, and 23 of cycles 1 to 6 and at a dose 40 mg once daily on days 1, 8, 15 of cycles 7 to 12."
89357547|NCT04959006|Placebo Comparator|Placebo group|Placebo drink - oral bolus (25ml) - colour/taste matched (prune juice/cola/tonic water, 1:1:1 ratio).
89357548|NCT04959006|Experimental|Antioxidant supplement|Experimental condition -oral bolus (25ml) olive extract drink(https://www.oliphenolia.it/uk/)
89357549|NCT03331276|Experimental|BBN|An experimental Infant Formula, Milk-Based Powder with Iron, for healthy term infants 0 to 12 months of age with high Sn-2 Palmitate, Alpha Lactalbumin and Osteopontin to better mimic human milk.
89357550|NCT03331276|Active Comparator|Brand|A Commercially available Infant Formula, for healthy term infants 0 to 12 months of age (Enfamil TM, Milk-Based Powder with Iron)
89357551|NCT02498314|Experimental|Grade I-II SZ mobilization|Grade I-IISZ hip traction in resting position
89357552|NCT02498314|Experimental|Grade II TZ mobilization|Grade IITZ hip traction in resting position
89357553|NCT02498314|Experimental|Grade III mobilization|Grade III hip traction in resting position
89357554|NCT01974804||Pts having an MRI|Patients will undergo a 20 minute pretreatment MRI scan and a 30 minute post treatment MRI scan with contrast agent administration. Ten patients with brain metastasis will be recruited in the study. All the patients will be undergoing SRS (Stereotactic Radiosurgery). Patients will have 1 pretreatment evaluation and 2 post treatment evaluations [1-72 hours post treatment and 8 weeks (+/- 2 weeks) post treatment] for early response. Patients are to be administered contrast prior to obtaining MRI scans. These research scans are estimated to take 20 minutes of scan time (+/- 10 minutes), which includes patient set up and conducting the research sequences..
89357555|NCT01300637|Active Comparator|metformin|metformin intervention group
89357556|NCT01300637|Placebo Comparator|placebo|placebo-controlled
89357557|NCT02493634|Other|pressure gradient measurement|Diagnostic procedure to measure pressure gradient in series of patients. Focus is on safety and absence of adverse events
89357558|NCT03819257||Patients with perianal Crohn's disease.|
89357559|NCT03342820|Experimental|Quadriceps muscle fatigue|Quadriceps muscle fatigue
89357560|NCT04851522|Experimental|Di-Dak-Sol + White Petrolatum|"Participants will receive Di-Dak-Sol (dilute bleach compresses) prior to receiving radiation. This will continue throughout their radiation therapy and for one week after.~Participants will also be asked to apply white petrolatum ointment 2x daily throughout treatment: once after radiation and once in the evening.~Participants will be provided with a log and asked to document information (dates/times of application) about the study treatment ."
89357561|NCT03331120|Active Comparator|Control Group|"1--Control group~. Conventional treatment:~moist hot pack.~manual therapy.~Therapeutic Exercise.~Home program routine."
88828951|NCT02430389|Experimental|Remifentanil|Intravenous bolus of 10 mL of remifentanil (0.7 mcg/kg based on ideal body weight) will be given ninety seconds before head pinning as well as an intravenous bolus of propofol (0.7 mg/kg).
88828952|NCT02430389|Placebo Comparator|Normal Saline|Intravenous bolus of 10 mL normal saline from study syringe will be given ninety seconds before head pinning as well as an intravenous bolus of propofol (0.7 mg/kg).
88828953|NCT02431637|Experimental|Piperaquine Phosphate after infected blood malaria challenge|Volunteers will receive a dose of 480 mg piperaquine phosphate (PQP) approx. 7 days after a challenge with P. falciparum infected red blood cells. The effects of PQP on gametocyte carriage (assessed by PCR) and infectivity to mosquitos after direct and indirect feeding on blood from volunteers will be assessed.
88828954|NCT02494817|Placebo Comparator|Control group|Couples assigned to the control group will be directed to the website that only has the following: 1) module about learning about effective HIV prevention strategies, 2) sexual health resource center, and 3) a link to download a corresponding smartphone app that will include the sexual health resource center.
89534194|NCT04098393|Experimental|patients with multiple myeloma|A. Busulfan 0.8 mg/kg every 6 hours x 10 doses, with dose adjustments made according to PK levels. B. Melphalan (70 mg/m2/day) administered on days -6 and -5. C. Fludarabine (25 mg/m2/day) administered on days -6, -5, -4, -3, -2. All patients receiving matched related or unrelated donor allografts receive anti-thymocyte globulin (ATG) 2.5 mg/kg/day on days -3 and -2 to deplete chemotherapy resistant host T-cells that could hinder engraftment, and it may provide additional GVHD prophylaxis.
89534195|NCT04095221|Experimental|Prexasertib and Irinotecan|Patients will have extent of disease scans following every 2 cycles (every 6 weeks on dose levels 0-3, and every 8 weeks on dose level -1 (if required). Patients will be allowed to continue therapy as long as they do not experience dose-limiting toxicities or progression of disease.
88828955|NCT02494817|Active Comparator|Intervention group|Couples assigned to the intervention group will first as individuals view general video about purpose of study and how to use website functions; timeline activity about their relationship; select top values about their relationship; learn about effective HIV prevention strategies; learn about sexual agreements; select what items they want to have in their agreement; explore a learning module about testing and view the sexual health resource center. As a couple, they will log back into the website to view and compare timelines and relationship values; watch a video about communicating more effectively; negotiate and decide together what items they want to include in their agreement; explore the sexual health resource center and/or any other modules from when they were logged into the website as individuals; download a corresponding smartphone app that will include a copy of their newly created agreement and sexual health resource center.
88828956|NCT02543723|Active Comparator|Nurse Coach Intervention|The nurse coach conducted an initial assessment with the participant and identified specific adherence strategies tailored to the participant's needs. The educational strategies include information about the patient's cancer treatment and expected outcomes; clear instructions about medication dosing schedule; what to do if a dose is missed or delayed; medication side effects and/or potential drug interactions; and review of cancer health literacy infographics. The behavioral skills and affective support strategies include coping strategies for side effects, skills for fitting medication regimen into daily routine, identifying a support network, communication skills for interacting with providers, and facilitating a positive perception for effective self-management experience. Patients received weekly phone calls from the nurse coach during the first month of the intervention, and then bi-monthly follow-up calls for the remainder of treatment or 6-month follow-up period.
88828957|NCT02543723|No Intervention|Control|Patients received standard of care.
89177765|NCT00640510|Placebo Comparator|IM placebo|Patients will receive at least one injection of Intramuscular placebo. If patients do not respond to the study medication or if patients do not have enough improvement based on the investigator's judgment, and in addition, if the investigator judges it is reasonable, the patient will receive a second injection at the same dose strength as the first injection after 2 hours following the first injection (no later than 8 hours after the first injection).
89357562|NCT03331120|Experimental|Study or Experimental Group|"2--Experimental or study group:~moist hot pack.~manual therapy.~Therapeutic Exercise.~Home program routine.~ambulatory mirror image functional re-training through wearing 3D adjustable cervical thoracic Posture Corrective orthosis (CTPCO) For 10 weeks(3Times/week for 20 minutes)."
89357563|NCT03512275|Experimental|400mg cohort, no prior treatment with anti-TNF agent(s)|N=10 patients that have had no prior treatment with biological agents that block TNF will receive a total of 13 X 400mg subcutaneous injections of bermekimab. Dosing will occur weekly for 12 weeks, inclusive of visit 1 and visit 13.
89534196|NCT04060212|Experimental|All Participants|All participant will eat 6 meals of tuna fish. All participants will take a prebiotic dietary supplement.
89357564|NCT03512275|Experimental|400 mg cohort, prior treatment with anti-TNF agent(s)|N=10 patients that have failed anti-TNF therapy will receive a total of 13 X 400mg subcutaneous injections of bermekimab. Dosing will occur weekly for 12 weeks, inclusive of visit 1 and visit 13.
89357565|NCT03809897|Experimental|Varenicline|Patients randomized to the experimental arm will receive 3 days of 0.5 mg of varenicline, followed by 4 days of 1 mg of varenicline (until day 7). Finally, until week 12, they will receive 2 mg of varenicline. Varenicline is supplied in capsules and taken orally.
89357566|NCT03809897|Active Comparator|Nicotine patch|Patients randomized to nicotine patch will receive 8 weeks of 21 mg patch followed by 2 weeks of 14 mg patch and 2 weeks of 7 mg patch.
89357567|NCT02491918|Active Comparator|In the bag IOL|Cataract surgery with IOL implantation in the capsular bag
89357568|NCT02491918|Active Comparator|Optic Capture of IOL|intraocular lens implantation in the capsular bag with posterior optic capture
89357569|NCT02491996|Experimental|DTIG|Outpatients who treated by DTIG at Outpatient Unit for Gambling Disorder of Kurihama Medical and Addiction Center
89357570|NCT03809195|Experimental|Hypnosis Intervention|The intervention is clinical hypnosis--a single in-person session followed by instructions to listen to audio recordings at home. The sessions consist of the provider's voice guiding the participant into a relaxed and focused state and providing therapeutic suggestions--for example, to replace discomfort with a more pleasant sensation, to ease anxiety, and to increase energy.
89357571|NCT03809195|No Intervention|Waitlist Control|This group will serve as a control comparison and be offered the intervention after control data collection is complete.
89357572|NCT03473197|Other|Single Cohort (Healthy Volunteers)|Diacerein 1% topical ointment Intra-subject photoallergy (photosensitization) test
89357573|NCT02493556|Experimental|LLLT before muscle damage|Low Level Laser Therapy (LLLT) will be applied before the exercise protocol on one lower limb, while the other will receive placebo treatment. Phototherapy will be applied with an equipment of 810nm and a cluster with five diodes on eight different points of quadriceps muscle, totalizing a dosage of 240J.
89357574|NCT02493556|Placebo Comparator|Placebo LLLT before muscle damage|Placebo LLLT will be applied before the exercise protocol on one lower limb, while the other will receive real treatment. Placebo treatment will also be applied on eight different points of quadriceps muscle, but the equipment will be turned off.
89357575|NCT02493556|Active Comparator|LLLT after muscle damage|Low Level Laser Therapy (LLLT) will be applied after the exercise protocol on one lower limb, while the other will receive placebo treatment. Phototherapy will be applied with an equipment of 810nm and a cluster with five diodes on eight different points of quadriceps muscle, totalizing a dosage of 240J.
89357576|NCT02493556|Placebo Comparator|Placebo LLLT after muscle damage|Placebo LLLT will be applied after the exercise protocol on one lower limb, while the other will receive real treatment. Placebo treatment will also be applied on eight different points of quadriceps muscle, but the equipment will be turned off.
89357577|NCT01560299|Active Comparator|group one|This group will be advised to discontinue methimazole 24-48 hour before iodine therapy
89357578|NCT01560299|Active Comparator|group two|methimazole stopped 48-72 hour before radioiodine therapy
89357579|NCT01560299|Active Comparator|group three|
89357580|NCT02491762||bilateral|bilateral breast construction candidates will go through respiratory function tests a month prior to surgery, a month after surgery and three months after surgery
89357581|NCT02491762||unilateral|unilateral breast construction candidates will go through respiratory function tests a month prior to surgery, a month after surgery and three months after surgery
89357582|NCT03511105|Experimental|Subjects receiving GSK2798745|Eligible subjects will receive two tablets of 2.4 milligrams GSK2798745 on the morning of Day 1. Subjects will then undergo segmental challenge at 2 hours after first dose wherein LPS will be instilled into the right middle segment and saline control into the lingula segment of the contralateral side. The second dose of a single tablet of 2.4 milligrams of GSK2798745 will be administered 10 hours after LPS and saline challenge.
89357583|NCT03511105|Placebo Comparator|Subjects receiving matching Placebo|Eligible subjects will receive two tablets of placebo on the morning of Day 1. Subjects will then undergo segmental challenge at 2 hours after first dose wherein LPS will be instilled into the right middle segment and saline control into the lingula segment of the contralateral side. The second dose placebo will be administered 10 hours after LPS and saline challenge.
88828958|NCT02545907|Experimental|KTD treatment|"Participants in the escalation phase will receive carfilzomib (K), thalidomide (T), and dexamethasone (D) in combination. The dose of thalidomide will be 50mg/day. The dose of dexamethasone will be 20mg on Day 1, 8, and 15. Carfilzomib will be administered on Day 1, 8, and 15, but the level of carfilzomib delivered with depend on the cohort allocation. The dose of carfilzomib may be:~Level -1 - 27mg/m2~Level 0 - 36mg/m2~Level 1 - 45mg/m2~Level 2 - 56mg/m2~Participants will receive up to six cycles of treatment. Following determination of the maximum tolerated dose and recommended dose, the trial will be opened to an expansion phase where participants will receive the RD of carfilzomib, along with thalidomide and dexamethasone, using the schedule outlined above."
88828959|NCT04340999||Manifested Group|Manifested Group , enrolled patients who had any of the following manifestations(Fatigue,muscle cramps or numbness)
89357584|NCT03811379|Experimental|Toripalimab|Toripalimab, 240mg, every 3 weeks until disease progress or intolerable toxicity
89357585|NCT03342742|Experimental|Daily Caloric Restriction|The daily caloric restriction group will be instructed to reduce energy intake by a 34% daily energy deficit from baseline individual weight maintenance energy requirements.
89357586|NCT03342742|Experimental|Intermittent Fasting|Participants in the intermittent fasting group will be instructed to reduce energy intake to ~20% of estimated energy requirement (delivered as a single meal) three non-consecutive days per week, resulting in a weekly energy deficit of ~34% (similar to the daily caloric restriction group).
89357587|NCT03807869|Experimental|coexisting glaucoma and cataract|Patients with coexisting glaucoma and cataract qualified to combined glaucoma surgery
89357588|NCT03807323|Experimental|'Lifestyle counselling and exercise' .|The study is a single-arm study where all participants undergo the same intervention 'Lifestyle counselling and exercise' .
89357589|NCT03337828|Active Comparator|Alcohol-free beer with regular composition|Two cans (33 cl.) per day of an alcohol-free beer with regular carbohydrates composition.
89357590|NCT03337828|Experimental|Alcohol-free beer with modified composition|Two cans (33 cl.) per day of alcohol-free beer with modified carbohydrates composition. This include the substitution of regular maltose by isomaltulose and the addition of maltodextrin (fiber).
89357591|NCT01303133||Adults with Down Syndrome ages 30+ (PiB-/-)|We will be recruiting healthy adults with Down syndrome ages 30 and over. Participants cannot have a diagnosis of dementia.
89357592|NCT01303133||Adults with Down Syndrome ages 30+ (PiB-/+)|
89357593|NCT01303133||Adults with Down Syndrome ages 30+ (PiB+/+)|
89357594|NCT03510715|Experimental|Alirocumab|"Participants with BW less than (<) 50 kilograms (kg) received subcutaneous (SC) injection of alirocumab 75 mg Q2W for 48 weeks. Alirocumab dose was up-titrated to 150 mg Q2W from Week 12 in case of increase in BW with BW greater than or equal to [>=] 50 kg.~Participants with BW >=50 kg received SC injection of alirocumab 150 mg Q2W for 48 weeks."
89357595|NCT03815279|Experimental|High-risk SMM and MM|"Twelve cycles of Carfilzomib-Lenalidomide-Dexamethason. Each cycle is 28 days. Carfilzomib intravenous, days 1, 8 and 15 (starting dose, 20 mg/m2 on day 1 of cycle 1; target dose, 56 mg/m2 thereafter) during cycles 1 through 12.~Lenalidomide 25 mg orally once a day (3 weeks on/one week off) for 52 weeks. Dexamethasone 40 mg weekly for 16 weeks then 20 mg weekly for 16 weeks and thereafter 10 mg weekly for 16 weeks.~Maintenance (1 year):~Carfilzomib intravenous days 1 and 15 (56 mg/m2) during cycles 13 through 24. Lenalidomide 10 mg orally once a day (3 weeks on/one week off) for 52 weeks Dexamethasone 10 mg weekly for 52 weeks."
89357596|NCT03815279|Experimental|Intermediate-risk SMM|"Lenalidomide 25 mg orally once a day (3 weeks on/one week off) for 52 weeks. Dexamethasone 40 mg weekly for 16 weeks, then 20 mg weekly for 16 weeks.~Maintenance (1 year):~Lenalidomide 10 mg orally once a day (3 weeks on/one week off) for 52 weeks."
89357597|NCT02498548|No Intervention|Control|Individuals with no spinal cord injury or other neurological deficits.
89357598|NCT02498548|No Intervention|Unexercised SCI Knee or Hip|"Individuals with spinal cord injury who have been discharged from a locomotor training program at least 6 months prior to enrollment in this study. This group will serve as unexercised control for the Trained SCI Knee group or trained SCI Hip group"
88828960|NCT04340999||Non-Manifested Group|Non-manifested group in which enrolled patients didn't report any of the following manifestations
88828961|NCT02495831|Experimental|Diclofenac sodium|Diclofenac sodium 50 mg oral tablets, single dose
88828962|NCT02495831|Active Comparator|Diclofenac sodium and safinamide|Diclofenac sodium 50 mg oral tablets, single dose, and safinamide 200 mg oral tablets, single dose
88828963|NCT02497235|Experimental|TAK-935|A single dose of TAK-935 600 milligram (mg), oral solution on Day 1 as a starting dose and up to 370 megabecquerel (MBq) (10 millicurie [mCi]) of [18F]MNI-792 with a mass of up to 5 microgram (mcg), injection intravenously (IV), prior to each PET imaging at Baseline, 45 minutes and 10 hours post-TAK-935 dose. Subsequent dose of TAK-935 oral solution and timing of PET imaging will be based on safety, tolerability and occupancy data from previous level participants.
88828964|NCT02497937|Experimental|GSK2798745 and Placebo|Each subject will be randomized to receive GSK2798745 2.4 milligrams (mg) and Placebo once daily for 7 days, each in one of the two treatment periods. Two treatment periods will be separated by a 14-day washout period.
88828965|NCT02498483|Experimental|Acetaminophen Arm|Acetaminophen 15 mg/kg PO solution administered via syringe one time immediately post circumcision.
88828966|NCT02498483|No Intervention|Non-treatment Arm|Routine circumcision without acetaminophen.
88828967|NCT02547623|Active Comparator|dexamethasone depot|dexamethasone depot 517 mcg
88828968|NCT02547623|Active Comparator|standard of care|prednisolone drops 1%
88828969|NCT02433665|Active Comparator|Fixed dose|100 of the first 200 subjects will be randomized to a fixed dose of contrast material.
88828970|NCT02433665|Active Comparator|Customized dose|100 of the first 200 subjects will be randomized to a customized dose of contrast material based on the experimental algorithm. The second group of 300 subjects will receive a customized dose of contrast material based on the experimental algorithm.
88828971|NCT02547779|Active Comparator|0.9% Saline|Patients in an ICU block randomized to physiologically-balanced isotonic fluid will receive 0.9% Saline whenever isotonic intravenous fluid administration is ordered by the treating provider.
88828972|NCT02547779|Active Comparator|Physiologically-balanced|Patients in an ICU block randomized to physiologically-balanced isotonic fluid will receive Plasma-Lyte© A or Lactated Ringer's whenever isotonic intravenous fluid administration is ordered by the treating provider.
88828973|NCT02433977|Experimental|Conjugated Linolenic Acid + NOx|"This is a single arm study~Conjugated Linolenic Acid (CLA)- daily oral dose 3 g/day~Sodium Nitrate- Capsules for daily oral administration at the dose of 1 g (2 x 500 mg)~Sodium Nitrite- Capsules for daily oral administration at the dose of 20 mg (2 x 10 mg)"
89177766|NCT04889378||Pre-habilitation|participants will join prehabilitation with very low calories diet (800-1000kcal/day) and moderate intensive aerobic exercise (1 hour per section; 3 sections per day) for 2 weeks before bariatric surgery.
89357599|NCT02498548|Experimental|Trained SCI Knee or Trained SCI Hip|Individuals with spinal cord injury who have been discharged from a locomotor training program at least 6 months prior to enrollment in this study. Training will specifically focus on rehabilitation of the knee joint or the hip joint.
89530530|NCT02453659|Active Comparator|Health Education (HE)|HE is delivered over a 9 week period with 1 1-hr individual session during week 1, 8 weekly 1.5-hr group counseling sessions during weeks 2-9, and 1 20-minute individual telephone session during week 4. Session content includes smoking health education program plus standard behavioral smoking cessation treatment. Participants also receive 8 weeks of nicotine patch.
89530531|NCT02515799|Active Comparator|Tacholiquine|Inhalation
89530532|NCT02515799|Placebo Comparator|Saline Solution 0,9%|Inhalation
89530533|NCT03802955|Experimental|ADG106 Dose escalation|
89530534|NCT03239431||Asthma group|Patients with asthma
89530535|NCT02515643||Endothelial dysfunction in Cohort 1|Assessment of endothelial dysfunction in healthy subjects who will undergo a nephrectomy as part of the living donor program at each participating center.
89530536|NCT02515643||Endothelial dysfunction in Cohort 2|Assessment of endothelial dysfunction in renal transplant recipients from cohort 1
88828974|NCT00559585|Active Comparator|Subcutaneous (SC) Abatacept|Participants received 125 mg weekly SC abatacept injections (with an intravenous [IV] abatacept loading dose on Day 1, based on weight). A double-dummy design was used to protect the blind, thus, participants also received IV injections of placebo (IV Placebo) with the exception that on Day 1 a loading dose of IV abatacept replaced the IV Placebo treatment.
88828975|NCT00559585|Active Comparator|Intravenous (IV) Abatacept|Participants received IV abatacept infusions on Days 1, 15, 29, and every 28 days, thereafter. A double-dummy design was used to protect the blind, thus, participants also received SC injections of placebo (SC Placebo).
88828976|NCT01824901|Experimental|Phase I|Patients receive docetaxel IV over 60 minutes on day 1 and FGFR inhibitor AZD4547 PO BID on days 2-15 of course 1 and days 1-14 of all subsequent courses. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
88828977|NCT01824901|Experimental|Arm I (docetaxel; phase II step I)|Patients receive docetaxel IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who experience progressive disease may then register to step II treatment and receive FGFR inhibitor AZD4547 PO BID on days 1-14.
88828978|NCT01824901|Experimental|Arm II (docetaxel and AZD4547; phase II step I)|Patients receive docetaxel IV over 60 minutes on day 1 and FGFR inhibitor AZD4547 PO BID on days 1-14. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
88828979|NCT01824901|Experimental|Phase II step II|Patients receive FGFR inhibitor AZD4547 PO BID on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
88828980|NCT01825057|Active Comparator|See One|"Providers in See One only receive MI workshop training, giving them an opportunity to see the MI intervention and learn how to conduct it. The trainer encourages them to screen their patients for substance misuse and apply MI as indicated."
88828981|NCT01825057|Experimental|Do One|Following workshop training, MI-trained CL clinicians directly supervise providers' live bedside provision of MI to patients twice before beginning the trial and once midstream. In addition, providers have the option to request additional live supervision from CL clinicians during the trial, consistent with the apprenticeship model.
88828982|NCT01825057|Experimental|Order One|"Following the workshop, providers either administer MI themselves or order a MI for delivery by one of the MI-trained CL clinicians. Only providers in Order One can specifically request MI through a separate CL order in the electronic health record. The physicians or PAs directly place MI orders. Nurses contact physicians or PAs to place the MI order. The CL clinicians are trained in MI via a clinical trials training approach: 1) a 2-day skill-building workshop; 2) three post-workshop supervised practice cases based on review of audio recorded sessions; and 3) follow-up monthly group supervision to maintain and monitor the CL clinicians' MI practice. CL clinicians also learned supervisory practices to provide live supervision to providers in Do One."
88828983|NCT05747209||Standard High-load resistance training|Standard exercise regimen utilizes a mixture of compound and isolated movements, focusing on compound exercises. The regimen is a typical standard of care resistance training program and sports performance and strength and conditioning facilities. The observed classes will take place three times per week. Warm-up exercises focused on mobility, flexibility and core activation will be performed to reduce the risk of injury. Each individual exercise workout will generally progress from most intense, CKC, compound, and athletic movements to least intense throughout the workout to maximize safety. Additionally, each workout will provide full body resistance training to focus on functional exercises, intensity, and efficiency. Each workout will take approximately 45 minutes. The total exercise regimen will last 3 months.
88828984|NCT00559507|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive saracatinib PO on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
88828985|NCT05027113|Experimental|Mind-Us|"Use of the 10% Happier app to complete at least one meditation daily -with the possibility of exceeding this goal by choosing additional meditations- for 4 weeks. Participants will be asked to complete The Basics and The Basics II courses to familiarize themselves with the principles of mindfulness meditation. Each audio-recorded session begins with a short video providing psychoeducation around mindfulness meditation and teaching specific techniques (e.g., using the breath as an anchor, redirecting attention, noting thoughts and emotions). For the last two weeks of the program, participants will be invited to complete the Essential Advice course. This additional course is composed of 14 sessions ranging in length from 15 to 18 minutes."
88828986|NCT05027113|No Intervention|Assessments First|Wait-list control group. Individuals in this group will complete baseline, mid-, and post-treatment assessments before receiving the intervention (i.e., 4 weeks after randomization).
88828987|NCT04993651|Experimental|Continuous Positive Airway Pressure|Those randomized to CPAP will be fitted with CPAP face mask or nasal device by the respiratory therapist and permitted to trial the machine to ensure proper use and fit. CPAP settings: CPAP AUTO 5-20 cm H20 will be utilized. The CPAP device will then be removed. The subject will then be placed in the supine position with a standard roll placed under the right maternal hip. Those randomized to CPAP will have the device applied and machine turned on. For those randomized to routine airway management, nasal cannula with oxygen 2L/min will be applied and this will be titrated to achieve a maternal SpO2 > 95%. End tidal CO2 monitors will be applied to both patient groups.
88828988|NCT04993651|No Intervention|Nasal Cannula|For those randomized to routine airway management, nasal cannula with oxygen 2L/min will be applied and this will be titrated to achieve a maternal SpO2 > 95%. End tidal CO2 monitors will be applied to both patient groups.
89177767|NCT01323127||Chronic back pain|This group of patients has had chronic back pain for longer than 3 months.
89357600|NCT03342508|Experimental|Fetal Pillow Inflated (FPI)|"A Fetal Pillow will be inserted vaginally by the obstetrician after catheterization of the bladder (if it has not been previously performed). Once the Fetal Pillow is in place, the woman's legs will be placed flat on the operating table. The anesthesiologist will then inflate the Fetal Pillow. The obstetrician will not be aware to inflation of Fetal Pillow~Cesarean delivery will then be performed~The circulating nurse will deflate the Fetal Pillow following delivery. The obstetrician will remove the Fetal Pillow at the end of the procedure. The obstetrician will then fill out a survey regarding the delivery."
88828989|NCT01826227|Experimental|Positron Emission Tomography|This is a pilot study to determine the ability of intraoperative PET probe to detect and localize recurrent disease. Patients with evidence for a first recurrence of ovarian, fallopian tube or primary peritoneal carcinoma, with evidence of 18F-FDG avid disease on 18F-FDG PET/CT and who are able to undergo secondary CRS are eligible. 20 patients will be studied. All patients will undergo secondary cytoreduction guided by intraoperative PET probe survey. Intraoperative count levels as well as exvivo counts of the resected specimens will be done. Specimens detected with probe only will be labeled so and will be submitted to pathology for histopathologic confirmation.
88828990|NCT04970563|Experimental|Patients infected by SARS-COV-2 (RT-PCR +) and asymptomatic|
88828991|NCT04970563|Other|"Control group: patients infected by SARS-COV-2 (RT-PCR +) and symptomatic"|
88828992|NCT04970563|Other|"Healthy controls group: not infected by SARS-COV-2 (RT-PCR-) and asymptomatic."|
88828993|NCT04969627|Active Comparator|Metformin (BMI<24)|Subjects: PCOS patients whoseBMI<24 Drug: Glucophage Generic name: Metformin Dosage form: 500mg Dosage: 1500-2000mg/day Frequency: 500mg three times a day/1000mg twice a day Duration: 3 months
88828994|NCT04969627|Experimental|Metformin (BMI≥24)|Subjects: PCOS patients whoseBMI≥24 Drug: Glucophage Generic name: Metformin Dosage form: 500mg Dosage: 1500-2000mg/day Frequency: 500mg three times a day/1000mg twice a day Duration: 3 months
88828995|NCT04969627|Experimental|Combination (BMI<24)|Subjects: PCOS patients whoseBMI<24 Drug: Byetta and Glucophage Generic name: Exenatide Dosage form: Exenatide 5ug and 10ug; Metformin 500mg Dosage: Exenatide10-20ug/day; Metformin 1500-2000mg/day Frequency: Exenatide twice a day; Metformin 500mg three times a day/1000mg twice a day Duration: 3 months
88828996|NCT04969627|Experimental|Combination (BMI≥24)|Subjects: PCOS patients whoseBMI≥24 Drug: Byetta and Glucophage Generic name: Exenatide Dosage form: Exenatide 5ug and 10ug; Metformin 500mg Dosage: Exenatide10-20ug/day; Metformin 1500-2000mg/day Frequency: Exenatide twice a day; Metformin 500mg three times a day/1000mg twice a day Duration: 3 months
88828997|NCT04953325|Experimental|Experimental Group|180 subjects (including 90 adults aged 18-59 years and 90 elderly aged 60 year and older）will receive two doses of inactivated COVID-19 vaccine on day 0 and day 28
88828998|NCT04953325|Placebo Comparator|Control Group|90 subjects (including 45 adults aged 18-59 years and 45 elderly aged 60 year and older）will receive one dose of 23-valent pneumococcal polysaccharide vaccine on day 0 and one dose of Inactivated Hepatitis A Vaccine on day 28
88828999|NCT04928131||Anorectal|Patients presenting with anorectal pain.
88829000|NCT04928131||TMJ|Patients presenting with temporomandibular joint pain.
88829001|NCT04928131||Foot/Ankle|Patients presenting with foot and ankle pain.
88829002|NCT01826851|Experimental|Exparel|266 mg Exparel, single-dose injection.
88829003|NCT01826851|Placebo Comparator|Placebo|0.9% Normal saline, single-dose injection.
88829004|NCT04893967|No Intervention|No Intervention: RMS mean hip abduction, dynamometer|Isometric peak force hip abduction pre measurement. No tape.
88829005|NCT04893967|No Intervention|No Intervention: Average force hip abduction, dynamometer|Isometric average force hip abduction pre measurement. No tape.
89530290|NCT03347747||Photoaged Female Subjects|45-80 year old females with visible photoaging and the desired exposure profile/driving history and who also has spent (or are spending) at least 30 minutes in a car per day (as the driver), 5 days per week for at least 15 years of their adult life to ensure they have the type of asymmetrical exposure required for hypothesis validation. This is an multi-center trial, and study sites will range from northern to southern latitudes in North America, Australia and potentially other international sites. Study Photography + Personal & Medical History Collection via a study questionnaire will be obtained.
89530291|NCT04786613|Active Comparator|20 mg, 1.0% hyaluronic acid injection groups|In the first group, 2 ml linearly linked 20 mg 1.0% hyaluronic acid injection in 5 sessions will be applied.
89530292|NCT04786613|Active Comparator|32 mg, 1.6% hyaluronic acid injection groups|In the second group, 2 ml linearly linked 32 mg 1.6% hyaluronic acid injection in 3 sessions will be applied.
88829006|NCT04893967|No Intervention|No Intervention: Time to reach peak force hip abduction, dynamometer|Time to reach peak force hip abduction pre measurement. No tape.
88829007|NCT04893967|No Intervention|No Intervention: RMS mean hip abduction, surface electromyogram|Isometric hip abduction pre measurement assessing the root-mean-square (RMS) mean. No tape.
88829008|NCT04893967|No Intervention|No Intervention: RMS mean per second hip abduction, surface electromyogram|Isometric hip abduction pre measurement assessing the root-mean-square (RMS) mean per second. No tape.
88829009|NCT04893967|No Intervention|No Intervention: Max. contraction test hip abduction, surface electromyogram|Isometric hip abduction pre measurement assessing the root-mean-square (RMS) Max. contraction test. No tape.
88829010|NCT04893967|Experimental|Experimental: peak force hip abduction, dynamometer|Isometric peak force hip abduction post experimental application measurement with Magnetic Tape application
88829011|NCT04893967|Experimental|Experimental: Average force hip abduction, dynamometer|Isometric average force hip abduction post experimental application measurement with Magnetic Tape application
88829012|NCT04893967|Experimental|Experimental: time to maximum force hip abduction, dynamometer|Time to maximum force hip abduction post experimental application measurement with Magnetic Tape application
88829013|NCT04893967|Experimental|Experimental: RMS mean hip abduction, surface electromyogram|Isometric hip abduction post experimental application measurement assessing the root-mean-square (RMS) with Magnetic Tape application.
89530293|NCT04786613|Active Comparator|48 mg, 2.0% hyaluronic acid injection groups|In the third group 2.4 ml linearly linked 48 mg 2.0% hyaluronic acid injection in a single sessions will be applied.
89357601|NCT03342508|No Intervention|Fetal Pillow Not Inflated (FPNI)|"A Fetal Pillow will be inserted vaginally by the obstetrician after catheterization of the bladder (if it has not been previously performed). Once the Fetal Pillow is in place, the woman's legs will be placed flat on the operating table. The Fetal Pillow will not be inflated.~Cesarean delivery will then be performed. The obstetrician will continue to be able to use conventional methods for delivery of a second stage arrest including hand from below and reverse breech extraction.~The circulating nurse will deflate the Fetal Pillow following delivery. The obstetrician will remove the Fetal Pillow at the end of the procedure. The obstetrician will then fill out a survey regarding the delivery."
89357602|NCT03814733|Experimental|Rapastinel High Dose|Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
89357603|NCT03814733|Experimental|Rapastinel Low Dose|Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
89357604|NCT03814733|Active Comparator|Alprazolam|Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
89357605|NCT03814733|Active Comparator|Ketamine|Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
89357606|NCT03814733|Placebo Comparator|Placebo for Rapastinel|Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
89357607|NCT03814733|Placebo Comparator|Placebo for Alprazolam|Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
88829014|NCT04893967|Experimental|Experimental: RMS mean per second hip abduction, surface electromyogram|Isometric hip abduction post experimental application measurement assessing the root-mean-square (RMS) mean per second. With Magnetic Tape application.
89357608|NCT03814733|Placebo Comparator|Placebo for Ketamine|Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
89357609|NCT03721627|Experimental|Treatment group|Ledipasvir/sofosbuvir fixed dose combination tablet (90 mg ledipasvir, 400 mg sofosbuvir) once daily for 12 weeks for those 12-18 years, Wt 35 kg or more and half the dose (45 mg ledipasvir, 200 mg sofosbuvir) once daily for 12 weeks for those 6-11 years, Wt Less than 35 kg.
89357610|NCT02498158||experimental protocol|Functional neural connectivity at rest of 3 groups (heat tolerant, heat intolerant and healthy subjects) will be assessed using the anatomical and functional MRI scans and compared.
89357611|NCT03806855||OAB-wet|The diagnosis of OAB in each patient was based on the presence of at least one episode of urgency in her three-day bladder diary and with the absence of stress urinary incontinence. The presence of at least one episode of urgency associated incontinence was defined to be OAB-wet.
89357612|NCT03806855||OAB-dry|The diagnosis of OAB in each patient was based on the presence of at least one episode of urgency in her three-day bladder diary and with the absence of stress urinary incontinence. The absence of urgency associated incontinence was defined to be OAB-dry.
89357613|NCT02498080|Experimental|DEB PTA|Devices: paclitaxel drug eluting balloon PTA
89357614|NCT02498080|Active Comparator|standard PTA|devices: standard balloon PTA
89357615|NCT03508843|Experimental|interactive virtual presence|install a car seat using advice from a remotely-located certified car seat technician communicating via interactive virtual presence
89357616|NCT03811223|Experimental|Evolocumab|Evolocumab 140 mg subcutaneous injection once every 2 weeks for 12 weeks
89357617|NCT03811223|Placebo Comparator|Placebo|Placebo injection once every 2 weeks for 12 weeks
89357618|NCT04915391||Group of controls|Control group of 40 patients with ≥1 bare metal stent which in a posterior catheterization performed by clinical follow-up had no restenosis
89357619|NCT04915391||Group of cases|Group of cases with 20 patients with ≥1 bare metal stent and 20 patients with ≥1 drug eluting stent which had restenosis in a posterior catheterization performed by clinical follow-up.
88829015|NCT04893967|Experimental|Experimental: Max. contraction test hip abduction, surface electromyogram|Isometric hip abduction post experimental application measurement assessing the root-mean-square (RMS) max. contraction test. With Magnetic Tape application.
88829016|NCT04893967|Placebo Comparator|Placebo: peak force hip abduction, dynamometer|Isometric peak force hip abduction post placebo measurement with kinesiology tape application
88829017|NCT04893967|Placebo Comparator|Placebo: Average force hip abduction, dynamometer|Isometric average force hip abduction post placebo application measurement with kinesiology tape application
89357620|NCT03508609|Experimental|Autologous CD34 cells|Open label active treatment arm. Subjects receive autologous CD34 cells.
89357621|NCT03639337|Experimental|Allergic Children|"Allergic children to milk or egg, aged between 10 and 14 months, confirmed by double-blind oral provocation test against placebo.~Intervention: 30 days of administration of multi-strain probiotics containing 3.5 x 109 UFC of Bifidobacterium longum BB536, Bifidobacterium breve M-16V and Bifidobacterium infantis M-63"
89357622|NCT03639337|No Intervention|Not confirmed Allergic Children|Sensible children to milk or egg, aged between 10 and 14 months, not confirmed by double-blind oral provocation test against placebo.
89357623|NCT03639337|No Intervention|Controls|Healthy controls ages between 10 and 14 months
88829018|NCT04893967|Placebo Comparator|Placebo: Time to reach peak force hip abduction, dynamometer|Time to reach peak force hip abduction post placebo application measurement with kinesiology tape application
88829019|NCT04893967|Placebo Comparator|Placebo: RMS mean hip abduction, surface electromyogram|Isometric hip abduction post placebo application measurement assessing the root-mean-square (RMS) mean. With kinesiology tape application.
89357624|NCT03508193|Experimental|Intervention|Whole-foods based smoothie as nutritional therapy
89357625|NCT03723031|Active Comparator|rectal misopristol|will receive 400 microgram misoprostol rectally preoperatively with urinary catheter insertion.
89357626|NCT03723031|Active Comparator|intrauterine misopristol|will receive 400 microgram misoprostol inserted intrauterine (200 microgram at each cornu) intraoperatively following the delivery of the placenta.
89357627|NCT03811067|No Intervention|Control group|
89357628|NCT03811067|Active Comparator|TAP group|Transversus abdominis plane block administered group
89357629|NCT03811067|Active Comparator|RS group|Rectus sheath block administered group
89357630|NCT03722875|Experimental|SHR-1210+ apatinib|"SHR-1210 (200mg fixed dose every 3 weeks, one cycle is three weeks, total~1 year ) will be administered as an intravenous infusion over 30 minutes.~apatinib 250 mg qd ， one cycle is three weeks, total 1 year"
89357631|NCT03054350|Experimental|Vadadustat, Dose 1|Daily oral dose
89357632|NCT03054350|Experimental|Vadadustat, Dose 2|Daily oral dose
89357633|NCT03054350|Experimental|Vadadustat, Dose 3|Daily oral dose
89357634|NCT03054350|Placebo Comparator|Placebo|Daily oral dose
89357635|NCT04867733|Experimental|Micropatch application|All participants will complete this arm. Three sites each on the upper arm, volar (inner) forearm, and palm will be identified. Baseline measurements of trans-epidermal water loss, electrical resistance, and color will be made at each site. Baseline optical coherence tomography (OCT) scans will be made at each site. Color will only be measured at baseline. One site at each location will undergo the following interventions: 1) micropatch application and an occlusive covering, 2) micropatch application, but remain uncovered, 3) occlusive covering, no micropatch application. Micropatch application will only occur on the first day and does not contain any drug substance. Trans-epidermal water loss and electrical resistance are re-measured after micropatch removal, along with an additional OCT scan. Electrical resistance and OCT scans will be repeated at all sites for 2 days. Measurements from the 2nd and 3rd sites allow each subject to serve as their own control in data analysis.
89357636|NCT01303211||serogroup A meningococcal disease|Cases of serogroup A meningococcal disease
89357637|NCT01303211||Community controls|Healthy members of the community controls matched with cases for age, sex and place of residence
89177768|NCT01323127||Non chronic back pain|This group of patients is hospitalized for cardio physical therapy, and has no lumbar-pelvic complications. Patients are selected from the hospitalized population according to age, sex, and BMI in order to match chronic back pain patients.
89357638|NCT01303211||Hospital controls|Patients admitted to the hospital with an acute illness other than meningitis or septicemia
89357639|NCT03528577|Experimental|Test|Albuterol Sulfate Inhalation Aerosol, eq 90 mcg
89357640|NCT03528577|Active Comparator|Reference|PROAIR® HFA (albuterol sulfate) Inhalation Aerosol, eq 90 mcg
89357641|NCT03528577|Placebo Comparator|Test Placebo|Placebo for Albuterol Sulfate Inhalation Aerosol
89357642|NCT03528577|Placebo Comparator|Reference Placebo|Placebo for Albuterol Sulfate Inhalation Aerosol
89357643|NCT03796715||Red Cell Distribution Width (RDW)|RDW was assessed as part of complete blood count analysis using SYSMEX XN-550 automated analyzer
89357644|NCT03796715||Presepsin (sCD14-ST)|Presepsin analysis was done by utilising Elisa technique using kits from (MyBioSource, San Diego, CA 92195-3308 USA)
89357645|NCT03626948|Experimental|SK-1403|Patients receive SK-1403 three times a week administered by intravenous bolus injection at the end of each hemodialysis for the whole treatment periods (52 weeks), with individual dose adjustment.
89534197|NCT04046523|Experimental|Healthy Controls|In the first phase of the experiment, 20 healthy controls will test the VO device to determine whether the camera with a CCD or CMOS lens is the most appropriate for use in ICP patients and to synchronize the VO, ECG, PPG, IOP and respiratory signals.
89177769|NCT00825838|Experimental|1|Oral ingestion of 6mg chili pepper extract
89357646|NCT01303289|Experimental|Group 1|The group 1 will receive the experimental product T-Diet plus Standard for 3 months.
89357647|NCT01303289|Active Comparator|Group 2|The group 2 will receive the control product Jevity (Abbott Laboratories) for 3 months.
89357648|NCT05281055||EVT group|Patients who received endovascular thrombectomy for acute ischemic stroke with large vessel occlusion.
89357649|NCT05452226|Experimental|Pilot Study Cohort|Every participant in this small prospective cohort study will receive the study intervention.
88829020|NCT04893967|Placebo Comparator|Placebo: RMS mean per second hip abduction, surface electromyogram|Isometric hip abduction post placebo application measurement assessing the root-mean-square (RMS) mean per second. With kinesiology tape application.
89357650|NCT03810989|Experimental|infra-red sauna|During the intervention phase, the patient will be dialysed twice weekly on Saturday and Wednesday. During the in-between three days, the patients will be subjected to an intervention as the following :- three session of infra-red sauna of 15 minutes duration separated by ten minutes rest outside the sauna.
89357651|NCT03810989|Experimental|argometer and treadmill|During the intervention phase, the patient will be dialysed twice weekly on Saturday and Wednesday. During the in-between three days, the patients will be subjected to an intervention as the following :- three session of physical exercise (by treadmill and argometer) of 20-30 minutes duration separated by 10 minutes rest.
89357652|NCT03810989|Experimental|combination of sauna and hot bath|During the intervention phase, the patient will be dialysed twice weekly on Saturday and Wednesday. During the in-between three days, the patients will be subjected to an intervention as the following :- three session of infra-red sauna as the first group then the patients will be immersed up to neck for one hour in water at 37-43 C.
89357653|NCT03810989|Experimental|combination of sauna and hot bath in CKD|During the ﬁrst month (control phase), S Cr, BUN, serum K and serum phosphorus will be measured weekly and the mean will be calculated. During the next two months (intervention phase) the patient will be subjected to three session of sauna of 15 minutes duration separated by ten minutes rest outside the sauna then the patients will be immersed up to neck for one hour in water at 37 -43 C .
89357654|NCT05432414|Experimental|Pomalidomide, Bortezomib and Dexamethasone (PVD)|Each cycle is 21 days, after 2 cycles, patients who reached MR continued treatment for 2 cycles, 4 cycles in total. Subsequent treatment regimens after 4 cycles of induction therapy were determined by the investigator.
89357655|NCT05432414|Active Comparator|Bortezomib and Dexamethasone (VD)|Each cycle is 21 days, after 2 cycles, patients who reached MR continued treatment for 2 cycles, 4 cycles in total. Subsequent treatment regimens after 4 cycles of induction therapy were determined by the investigator.
89357656|NCT03796403|Experimental|diclofenac and bupivacaine group|Twenty mL of bupivacaine was infiltrated into surgical-site peritoneum , divided in 10 sites before closure, and diclofenac 75 mg (3 mL) was intramuscularly injected immediately after complete the procedure and the operative field was covered with sterile adhesive wound dressing.
89357657|NCT03796403|Placebo Comparator|bupivacaine only group|Twenty mL of bupivacaine was infiltrated into surgical-site peritoneum, divided in 10 sites before closure and a 3 mL of sterile water was intramuscularly injected immediately after complete the procedure.
89357658|NCT03627182|Experimental|CKD-501 0.5mg|CKD-501 0.5mg
89357659|NCT03627182|Placebo Comparator|Placebo|Placebo
89357660|NCT01302977|Experimental|Fetal intervention|Composed of fetuses that undergo to fetal tracheal occlusion at 26-28 weeks.
89357661|NCT01302977|No Intervention|Control|Composed of fetuses that do not undergo fetal intervention
89357662|NCT03810833|Experimental|Participants with Brilliance sensor placement|Brilliance device sensors placed on the left and right pectoralis major, remaining for 48 hours
89534198|NCT04046523|Experimental|Transfer Function Estimation|Subjects in the second phase of the experiment (70 subjects total) will be randomized to either Group A or Group B. We anticipate that 25 adult and 10 pediatric (ages 4-17) patients will participate in each group. Individuals in Group A will have two inter-leaved examinations (1-14 days apart). Data from the first examination will serve for SVP-ICP transfer function estimation and data from the second examination will serve for the intra-group verification for the estimated transfer function.
89534199|NCT04046523|Experimental|Intra-Group Verification|Individuals in Group B will undergo one examination. Data from Group B participants will serve as the inter-group re-test verification of the estimated transfer function.
89534200|NCT04034888|Experimental|Home Exercise Program (HEX)|Customized home exercise program
89534201|NCT04014660|Active Comparator|Probiotic group|The participants in this group are provided with a dietary supplement (capsules) containing freeze dried bacteria (active lactobacilli culture) mixed with corn starch, for daily intake (1 capsule per day).
89534202|NCT04014660|Placebo Comparator|Placebo group|The participants in this group are provided with a dietary supplement (capsules) containing corn starch only, for daily intake (1 capsule per day).
89534203|NCT04011163|Experimental|VPIA analgesia|VPIA pump will be connected to patients after surgery for up to three days. The vital signs (oxygen saturation, respiratory rate, heart rate) will be closely monitored when patients are using VPIA pump. Intravenous medication (morphine) will be given intravenously.
88829021|NCT04893967|Placebo Comparator|Placebo: Max. contraction test hip abduction, surface electromyogram|Isometric hip abduction post placebo application measurement assessing the root-mean-square (RMS) max. contraction test. With kinesiology tape application.
88829022|NCT02499497|Placebo Comparator|Placebo|Subjects who meet the eligibility criteria, will be randomized, to either placebo, LY SARM Dose 1, LY SARM Dose 2 or LY SARM Dose 3 daily, oral per cycle.
89357663|NCT00706654|Experimental|Aripiprazole depot 300 or 400 mg|Patients received aripiprazole 300 mg or 400 mg depot intramuscularly every 28 days for 38 weeks.
89357664|NCT00706654|Active Comparator|Aripiprazole 10-30 mg orally|Patients received aripiprazole 10-30 mg orally daily for 38 weeks.
89357665|NCT00706654|Experimental|Aripiprazole depot 25 or 50 mg|Patients received aripiprazole 25 mg or 50 mg depot intramuscularly every 28 days for 38 weeks.
89357666|NCT03811145|Experimental|Tendoncel|Topically applied experimental gel - Tendoncel. 80ul applied once a day for 21 consecutive days.
89357667|NCT03811145|Placebo Comparator|Placebo control gel|Placebo control gel. Similar to Tendoncel but without platelet derived small molecules and growth factors. 80ul applied once a day for 21 consecutive days.
89357668|NCT03471871|Experimental|HV Cohort,Sequence A:Placebo,Lemborexant 10mg,Lemborexant 25mg|Eligible healthy adult and elderly participants will receive lemborexant-matched placebo (3 matched tablets) on the night of Day 1 of Treatment Period 1, followed by lemborexant 10 mg (1 lemborexant 10 mg tablet and 2 matching placebo tablets) on the night of Day 1 of Treatment Period 2, and then lemborexant 25 mg (2 lemborexant 10 mg tablets and 1 lemborexant 5 mg tablet) on the night of Day 1 of Treatment Period 3. A washout period of 14 days was maintained between each Treatment Period.
88829023|NCT02499497|Active Comparator|LY2452473 Dose 1|Subjects who meet the eligibility criteria, will be randomized, to either placebo, LY SARM Dose 1, LY SARM Dose 2 or LY SARM Dose 3 daily, oral per cycle.
88829024|NCT02499497|Active Comparator|LY2452473 Dose 2|Subjects who meet the eligibility criteria, will be randomized, to either placebo, LY SARM Dose 1 or LY SARM Dose 2 or LY SARM Dose 3 daily, oral per cycle.
88829025|NCT02499497|Active Comparator|LY2452473 Dose 3|Subjects who meet the eligibility criteria, will be randomized, to either placebo, LY SARM Dose 1, LY SARM Dose 2 or LY SARM Dose 3 daily, oral per cycle.
88829026|NCT01827475|Active Comparator|Ibuprofen|Ibuprofen 800 mg
88829027|NCT01827475|Active Comparator|Acetaminophen|Acetaminophen 1 gm
88829028|NCT01827475|Experimental|Ibuprofen-acetaminophen combination|Ibuprofen 800 mg plus acetaminophen 1 gm
88829029|NCT02434523|Experimental|amitriptyline|Subjects in this arm will receive pills composed of amitryptline and Avicel (cellulose filler)
88829030|NCT02434523|Placebo Comparator|Placebo|Subjects in this arm will receive pills composed only of Avicel (cellulose filler)
88829031|NCT05746741|Experimental|Telehealth solution|Telehealth solution offered
88829032|NCT05746741|No Intervention|Control|Usual care
88829033|NCT02501135||Femoral Nerve Blocks|Patients who receive ropivacaine or bupivacaine during femoral nerve block.
88829034|NCT04828837|Experimental|Bubble positive expiratory pressure training|The experimental group receives the Bubble PEP training.
88829035|NCT04828837|No Intervention|general care|The control group receives the division of chest ward routine care.
88829036|NCT04809493||patients will be receiving conventional dialysis|Patients will be receiving conventional dialysis treatment followed by isonatremic dialysis treatment during an observational period of 2 months for each treatment
88829037|NCT02550743|Experimental|Dose 1|BYL719, capectabine and radiation Dose BYL719: 200mg/day
88829038|NCT02550743|Experimental|Dose 2|BYL719, capectabine and radiation Dose BYL719: 250mg/day
88829039|NCT02550743|Experimental|Dose 3|BYL719, capectabine and radiation Dose BYL719: 300mg/day
88829040|NCT02550743|Experimental|Dose -1|BYL719, capectabine and radiation Dose BYL719: 150mg/day
88829041|NCT02502461|Sham Comparator|standard care|Intervention: Subject intubated in routine fashion by the attending anesthesiologist with cuffed endotracheal tube; endotracheal tube cuff inflated; tube taped in place; depth measured bronchoscopically; patient asked to rate soreness of throat on verbal response scale when awake postoperatively.
88829042|NCT02502461|Active Comparator|cuff palpation|Intervention: Subject intubated in routine fashion by the attending anesthesiologist with cuffed endotracheal tube; endotracheal tube cuff inflated; inflated cuff palpated and depth adjusted accordingly; tube taped in place; depth measured bronchoscopically; patient asked to rate soreness of throat on verbal response scale when awake postoperatively.
88829043|NCT02437253|Experimental|Adalimumab first, then Placebo|Participants first received Adalimumab 20 mg subQ every other week (weight 15 to <30 kg) or 40 mg subQ every other week (weight ≥30 kg) for 16 weeks. Participants then received Placebo saline subQ (volume matching Adalimumab 20 mg or 40 mg subQ) every other week for 16 weeks.
88829044|NCT02437253|Experimental|Placebo first, then Adalimumab|Participants first received Placebo saline subQ (volume matching Adalimumab 20 mg or 40 mg subQ) every other week for 16 weeks. Participants then received Adalimumab 20 mg subQ every other week (weight 15 to <30 kg) or 40 mg subQ every other week (weight ≥30 kg) for 16 weeks.
88829045|NCT02551757|Experimental|Active-CPAP|Patients assigned to active-CPAP were treated with auto-titrating CPAP, where an auto-titrator adjusted the delivered pressure between 4 to 20 cm of water to eliminate obstructive events for a goal apnea-hypopnea index less than or equal to 5.
88829046|NCT02551757|Sham Comparator|Sham-CPAP|The sham-CPAP device in our study was designed to entail no risks beyond those with standard CPAP and provide a high level of blinding. The sham-CPAP device is an auto-titrating CPAP with an internal flow restrictor and a modified elbow attached to the nasal mask. The elbow modification creates a larger than standard air leak that serves to prevent any chances of carbon dioxide rebreathing and delivers a pressure at the mask in¬terface of roughly 0.75 to 1 cm water. The elbow modification is not noticeable when the device is fully assembled to avoid the possibility of unblinding patients, providers, or study personnel. The elbow modification could only be used on standard nasal masks; consequently full facemasks and nasal pillows were excluded for patients in both active and sham-CPAP.
88829047|NCT02437487|Experimental|SER-109|SER 109 (1 × 108 SporQs)
88829048|NCT02437487|Placebo Comparator|Placebo|Placebo
88829049|NCT01828255|Experimental|SENSIMED Triggerfish®|Device: portable device that monitors the 24-hour IOP pattern by a wireless contact lens sensor placed on the eye that sends its signals via an antenna around the orbital cavity to a recorder. Upon completion, the recording can be transmitted to a computer for read-out and visualization.
89534204|NCT04007991|Experimental|Ecopipam HCI 2 mg/kg/day|Ecopipam HCl 12.5-, 50-, 75- and 100-mg tablets; 2 mg/kg/day target dose; oral administration daily in evenings
89534205|NCT04007991|Placebo Comparator|Placebo|Matching Placebo tablets taken orally in the evening
88829050|NCT02247427|Experimental|Off-pace group|Deactivated device group
88829051|NCT02247427|No Intervention|On-Pace group|Ongoing device activity group
88829052|NCT02438423|Experimental|IIV delivered by MN patch by study staff|Inactivated influenza vaccine (IIV) delivered by microneedle (MN) patch administered by study staff
88829053|NCT02438423|Active Comparator|IIV delivered IM by study staff|Inactivated influenza vaccine (IIV) delivered by intramuscular (IM) injection administered by study staff
88829054|NCT02438423|Experimental|IIV delivered by MN patch by subject|Inactivated influenza vaccine (IIV) delivered by microneedle (MN) patch self-administered by subject
88829055|NCT02438423|Placebo Comparator|Placebo MN patch by study staff|Placebo delivered by microneedle patch administered by study staff
88829056|NCT02553395|Experimental|Phenacite contact lens|Study Test Contact Lens
88829057|NCT02553395|Active Comparator|comfilcon A contact lens|Control Contact Lens
88829058|NCT01829503|Experimental|decitabine and cytarabine|
88829059|NCT04691167|Active Comparator|group 1, Active intervention group|
88829060|NCT04691167|Sham Comparator|group 2, sham controlled group|
89177770|NCT00825838|Placebo Comparator|2|Oral ingestion of 0 mg chili pepper extract (matching placebo)
89534206|NCT03999853|Experimental|Conventional Therapy / Butyrate|Subjects will be receiving usual therapy for the first study period (approx 1 month) then 500 mg Butyrate tablets to be taken at a dose of 1.5 g (3 tablets) twice daily (BID) for approx 2 months
88829061|NCT02504645|Active Comparator|IPP-201101 200-mcg plus SOC|Patients randomly assigned to IPP-201101 will be administered a dosage of 200 mcg subcutaneously (sc) every 4 weeks for 48 weeks (a total of 13 doses will be administered).
88829062|NCT02504645|Placebo Comparator|PLACEBO plus SOC|Patients randomly assigned to placebo will be administered placebo subcutaneously (sc) every 4 weeks for 48 weeks (a total of 13 doses will be administered).
88829063|NCT02267629|Experimental|Experimental:Rapastinel (formerly GLYX-13)|10 mg/kg IV Rapastinel (formerly GLYX-13) infusion followed by assessments daily for a week, and weekly for a week.
88829064|NCT05744089|Experimental|Cancer patients suffering severe or critically painful|
88829065|NCT05742763|Active Comparator|Ibuprofen and PRP|Weight based Ibuprofen provided in over-encapsulated blister pack (to ensure blinding), to be taken 3 times a day for the initial 6 months of the 12 month study period. PRP injections provided at month 1, 2, and 3.
88829066|NCT05742763|Active Comparator|Acetaminophen and PRP|Weight based Acetaminophen provided in over-encapsulated blister pack (to ensure blinding), to be taken 3 times a day for the initial 6 months of the 12 month study period. PRP injections provided at month 1, 2, and 3.
88829067|NCT05742763|Placebo Comparator|Placebo and PRP|Placebo provided in over-encapsulated blister pack (to ensure blinding), to be taken 3 times a day for the initial 6 months of the 12 month study period. PRP injections provided at month 1, 2, and 3.
88829068|NCT02504723|Experimental|Cyanoacrylate injection plus carvedilol|The patients undergo repeated endoscopic cyanoacrylate injection every 3-4 weeks until obturation of gastric varices. Oral carvedilol is administrated during the whole study period, starting at 6.25 mg daily and increased until the maximum tolerated dose.
88829069|NCT02504723|Active Comparator|Cyanoacrylate injection|The patients undergo repeated endoscopic cyanoacrylate injection every 3-4 weeks until obturation of gastric varices.
88829070|NCT02439281|Active Comparator|Ropivacaine Group|Ropivacaine Group will receive ropivacaine 0.5% (10 ml) injected bilaterally in the posterior rectus sheath, at the umbilicus location.
88829071|NCT02439281|Experimental|Ropivacaine/ Clonidine Group|Ropivacaine/ Clonidine Group will receive ropivacaine 0.5% (10 ml) and clonidine (2mcg/kg) injected bilaterally in the posterior rectus sheath, at the umbilicus location.
88829072|NCT01830205|Experimental|Group A (Normal renal function): Daclatasvir|Daclatasvir 60 mg tablet by mouth single dose on Day 1
88829073|NCT01830205|Experimental|Group B (End Stage Renal Disease): Daclatasvir|Daclatasvir 60 mg tablet by mouth single dose on Day 1
88829074|NCT01830205|Experimental|Group C (Moderate renal impairment): Daclatasvir|Daclatasvir 60 mg tablet by mouth single dose on Day 1
88829075|NCT01830205|Experimental|Group D (Severe renal impairment): Daclatasvir|Daclatasvir 60 mg tablet by mouth single dose on Day 1
88829076|NCT02505269|Experimental|Brentuximab Vedotin|"The following procedures will take place during study visits beginning after the screening procedures:~- Participants will receive combination therapy:~Brentuximab Vedotin intravenously on predetermined days per cycle~Adriamycin intravenously on predetermined days per cycle~Dacarbazine intravenously on predetermined days per cycle"
88829077|NCT02440139|No Intervention|Arm 1|Participating radiologists will perform clinical reading on ~300 cases. They will mark all locations of concern (clinically actionable nodules) on conventional thoracic CT images. Computer will measure time, readers score regions according to action and suspiciousness.
88829078|NCT02440139|Active Comparator|Arm 2|Participating radiologists will perform clinical reading on ~300 cases. They will mark all locations of concern (clinically actionable nodules) on thoracic CT images aided by ClearRead CT Insight software as the intervention. Computer will measure time, readers score regions according to action and suspiciousness.
88829079|NCT02554799|Experimental|40 mg MMV390048 tablet formulation A fasted|40 mg MMV390048 tablet formulation A, in fasted state
88829080|NCT02554799|Experimental|40 mg MMV390048 tablet formulation B fasted|40 mg MMV390048 tablet formulation B fasted
88829081|NCT02554799|Experimental|40 mg MMV390048 formulation A or B, with milk or fasted|Optional cohort: 40 mg of MMV390048 in the formulation that has been shown to have the most favourable PK profile, taken with milk or in the fed state.
89177771|NCT00913718|Experimental|1|Fluoxetine Hydrochloride 20 mg Capsules (Geneva Pharmaceutical, Inc.)
88829082|NCT00559273|Experimental|Mircera|Participants will receive Mircera (Methoxy polyethylene glycol-epoetin beta), administered subcutaneously (SC) at a starting dose of 1.2 mcg/kg once every 4 weeks for 28 weeks.
88829083|NCT00559273|Active Comparator|Darbepoetin Alfa|Participants will receive darbepoetin alfa, administered SC once weekly or once every 2 weeks according to local labeling specifications for 28 weeks.
88829084|NCT02506673|Active Comparator|Sedation only with skin conductance monitor|Patients will receive traditional sedation with 2 mg of midazolam on arrival in the OR. Patients in this group will wear the skin conductance monitor to measure changes in levels of sympathetic discharge.
88829085|NCT02506673|Experimental|Sedation & audiovisual aids with skin conductance monitor|Prior to surgery, patients will be asked to wear audiovisual equipment (Zeiss, Cinema ProMED) in the holding area. Patients in this group will also receive 2 mg of midazolam on arrival in OR. Patients in this group will also wear the skin conductance monitor to measure changes in levels of sympathetic discharge.
88829086|NCT02508077|Experimental|Treatment (panitumumab and FOLFIRI)|Patients receive panitumumab IV over 30-90 minutes, irinotecan hydrochloride IV over 90 minutes, leucovorin calcium PO, and fluorouracil IV over 46 hours on day 1. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.
89177772|NCT00913718|Active Comparator|2|Prozac Fluoxetine Hydrochloride 20 mg Capsules (Dista)
89177773|NCT00813800|Experimental|Varenicline|Open-label; subjects will receive a behavioral intervention in addition to Varenicline.
89177774|NCT00627016|Experimental|Dexlansoprazole 30 mg QD|
89177775|NCT00627016|Placebo Comparator|Placebo|
88829087|NCT02268877|Experimental|Emergency Medicine Physician Ultrasound|Patients will receive an ultrasound performed by a credentialed emergency medicine attending or resident. The ultrasound will be transabdominal, transvaginal, or both. The intervention is the personnel who performs the ultrasound.
88829088|NCT02268877|Active Comparator|Radiology Tech Ultrasound|Patients will receive an ultrasound performed by a credentialed radiology department technician. The ultrasound will be transabdominal, transvaginal, or both. This is standard-of-care.
88829089|NCT04580095|Experimental|With AI algorithm|"In the With AI algorithm arm, the sonographer will perform the echocardiographic exam using the AI algorithm."
88829090|NCT04580095|No Intervention|Without AI algorithm|"In the Without AI algorithm, the echocardiographic exam will be performed without the use of the AI algorithm."
88829091|NCT04561297|Experimental|Biopsied Patients|Patients scheduled for a breast biopsy will have breast tissue dielectric constant measurements made prior to the biopsy
88829092|NCT01831219||ROBODOC|The ROBODOC group received total hip arthroplasty using the ROBODOC Surgical system for preparation of the femoral canal for a femoral stem implant.
88829093|NCT01831219||Conventional|The conventional group received total hip arthroplasty using the conventional manual tools including a broach to prepare the femoral cavity for femoral stem replacement.
88829094|NCT04479085|Experimental|experimental group|The nursing attempt to organize the home environment for the experimental group will take 17 weeks. During this period, two home visits and two telephone calls will be made. During the first home visit, training will be organized to regulate the home environment. Temperature and humidity changes of the houses will be monitored during the operation with the heat-moisture meter device. Children in this group will be given an anti-allergic duvet cover. Home environment arrangements of mothers and changes in the quality of life of children will be examined at the beginning and end of the study. Children's symptoms will be monitored weekly for 17 weeks.
88829095|NCT04479085|No Intervention|control group|No intervention will be made on the control group. The humidity and temperature changes in the home environment of the children in this group and their symptoms will be monitored on a weekly basis during the study.
89000695|NCT04656457|Active Comparator|resistance exercises|Resistance exercises will be involved in this technique are for upper and lower limb (Exercise program including shoulder flexion, abduction and horizontal adduction, elbow extension and flexion, calf raise, leg extension and squatting) three times daily and five times per week. The 1 repetition maximum (1RM) is measured at baseline and following the intervention. Initially, participants will do two circuits using 50% of their 1RM and repeat them 10 times for the first and second weeks, progressing to two circuits, using 60% of their 1RM and repeat 10 times for the third and fourth weeks. In fifth and sixth weeks, participants will do three circuits using 60% of their 1RM and repeat 10 times. In the last 6 weeks, patients will do three circuits using 70% of their 1RM and repeat 10 times. Time of exercise equal time of rest
89177776|NCT00794664|Placebo Comparator|Placebo|Weekly subcutaneous injections for 26 weeks
89177777|NCT00794664|Experimental|Mipomersen|200 mg weekly subcutaneous injections for 26 weeks
89177778|NCT02610452|Experimental|The study population|"The study population consists of adult patients treated in the Palliative Care Unit of the University Hospital of Nimes, regardless of their original condition. In 2013 the proportion of stays connected with diagnostics for cancer was 70.16%.~Intervention: Clown therapy"
89177779|NCT02609360|Active Comparator|0.9% NaCl|Circuit priming will be performed with 0.9% NaCl solution
89177780|NCT02609360|Active Comparator|Ringer Lactate|Circuit priming will be performed with Ringer Lactated
88829103|NCT01831921|Experimental|Lifestyle Weight-Loss|Participants in the Behavioral: Lifestyle Weight Loss arm will take part in a group program aimed at achieving modest weight loss (5-7%) through promoting healthy eating and increasing physical activity. The intervention sessions will take place at churches and other community locations and will be coordinated and facilitated by Latino Health Advisors (LHAs). The lifestyle intervention will be delivered in 2 phases: Phase 1 will last for 6 months and consist of weekly group meetings; Phase 2 will last for 18 months and consist of one LHA-led group session or one telephone contact from the LHA per month. Participants in this treatment arm will also receive individual visits with a registered dietitian during months 1, 3, and 6 of phase 1. All participants will be seen for assessment visits as baseline, 6, and 12 months. Some participants will also complete 18 and 24 month visits, depending on the date of randomization.
88829104|NCT01831921|Active Comparator|Enhanced Usual Care|Participants in the Behavioral: Counseling arm will receive two individual sessions with a registered dietitian and monthly newsletters that focus on existing community resources.All participants will be seen for assessment visits as baseline, 6, and 12 months. Some participants will also complete 18 and 24 month visits, depending on the date of randomization.
88829105|NCT01833247||Epilepsy inpatients|Patients with epilepsy recorded in an inpatient video-EEG monitoring unit after a seizure.
88829106|NCT00558259|Experimental|dabigatran etexilate 150 mg BID|Patient to receive dabigatran etexilatate capsules 150 mg twice daily
88829107|NCT00558259|Placebo Comparator|matching placebo twice daily (BID)|Patient to receive dabigatran extexilate matching placebo capsules twice daily
88829108|NCT02508389|Experimental|Low Dose GC4419: 30mg/day|30 mg GC4419/day prior to IMRT
88829109|NCT02508389|Experimental|High Dose GC4419: 90mg/day|90 mg GC4419/day prior to IMRT
88829110|NCT02508389|Placebo Comparator|Placebo|Placebo daily, prior to IMRT
88829111|NCT02509481|Active Comparator|Single MDA|Single mass drug administration of ivermectin (150 µg/kg) + albendazole (400 mg) performed after the start of the rainy season as part of public health efforts to eliminate lymphatic filariasis.
88829112|NCT02509481|Experimental|Repeated MDA|Same at Active Comparator, but then followed by five more mass drug administrations of ivermectin only (150 µg/kg) every three weeks thereafter.
88829113|NCT02511587|Active Comparator|intra muscular application|intra muscular application of FSME-Immune vaccination
88829114|NCT02511587|Experimental|subcutaneous application|subcutaneous application of FSME-Immune vaccination
89357669|NCT03471871|Experimental|HV Cohort,Sequence B:Lemborexant 10mg,Lemborexant 25mg,Placebo|Eligible healthy adult and elderly participants will receive lemborexant 10 mg (1 lemborexant 10 mg tablet and 2 matching placebo tablets) on the night of Day 1 of Treatment Period 1, followed by lemborexant 25 mg (2 lemborexant 10 mg tablets and 1 lemborexant 5 mg tablet) on the night of Day 1 of Treatment Period 2, and then lemborexant-matched placebo (3 matched tablets) on the night of Day 1 of Treatment Period 3. A washout period of 14 days was maintained between each Treatment Period.
89357670|NCT03471871|Experimental|HV Cohort,Sequence C:Lemborexant 25mg,Placebo,Lemborexant 10mg|Eligible healthy adult and elderly participants will receive lemborexant 25 mg (2 lemborexant 10 mg tablet and 1 lemborexant 5 mg tablet) on the night of Day 1 of Treatment Period 1, followed by lemborexant-matched placebo (3 matched tablets) on the night of Day 1 of Treatment Period 2, and then lemborexant 10 mg (1 lemborexant 10 mg tablet and 2 matching placebo tablets) on the night of Day 1 of Treatment Period 3. A washout period of 14 days was maintained between each Treatment Period.
89357671|NCT03471871|Experimental|OSA Cohort, Sequence D: Placebo, Lemborexant 10mg|Eligible adult and elderly participants with mild OSA will receive one lemborexant-matched placebo tablet on the night of Day 1 through Day 8 of Treatment Period 1, followed by one lemborexant 10 mg tablet on the night of Day 1 through Day 8 of Treatment Period 2. A washout period of 14 days was maintained between each Treatment Period.
89357672|NCT03471871|Experimental|OSA Cohort, Sequence E: Lemborexant 10mg, Placebo|Eligible adult and elderly participants with mild OSA will receive one lemborexant 10 mg tablet on the night of Day 1 through Day 8 of Treatment Period 1, followed by one lemborexant-matched placebo tablet on the night of Day 1 through Day 8 of Treatment Period 2. A washout period of 14 days was maintained between each Treatment Period.
89357673|NCT04354922|Placebo Comparator|Attention control|Subjects in this group will receive one session of 75 minutes stretching exercise per week throughout the 12 weeks experimental period
88829117|NCT04743323||Study Participants|"Participants will be recruited whilst hospitalized for an acute episode of pancreatitis. They will be interviewed about their health behaviors including alcohol consumption during the two weeks immediately preceding the onset of pancreatitis. Blood and urine bio-specimens will be collected at this time.~Following discharge from hospital (5-26 weeks) the same participant will be interviewed again during an asymptomatic control period and blood and urine bio-specimens will be collected. This study will compare the participant's exposure immediately preceding the onset of pancreatitis to that of an asymptomatic control period from the same participant.~Participants will be followed for 24 months via review of their medical records every 6 months to assess any recurrent disease or progression of disease."
89357674|NCT04354922|Active Comparator|Moderate-intensity walking exercise ×3/wk|Subjects in this group will receive three sessions of 50 minutes vigorous walking exercise per week throughout the 12 weeks experimental period
89357675|NCT04354922|Active Comparator|Moderate-intensity walking exercise ×1/wk|Subjects in this group will receive one session of 150 minutes vigorous walking exercise per week throughout the 12 weeks experimental period
89357676|NCT04354922|Active Comparator|Vigorous-intensity walking exercise ×3/wk|Subjects in this group will receive three sessions of 25 minutes vigorous walking exercise per week throughout the 12 weeks experimental period
89357677|NCT04354922|Active Comparator|Vigorous-intensity walking exercise ×1/wk|Subjects in this group will receive one session of 75 minutes vigorous walking exercise per week throughout the 12 weeks experimental period
89357678|NCT01303367||antipsychotic agents|
89357679|NCT01303367||non-antipsychotic agents|
89357680|NCT03627104|Other|Normoprotein diet with animal protein|The patient will intake the diet assigned for a month
89357681|NCT03627104|Other|Normoprotein diet with vegetable protein|The patient will intake the diet assigned for a month
89357682|NCT03627104|Other|High-protein diet with animal protein|The patient will intake the diet assigned for a month
88829118|NCT04950881|Sham Comparator|Control group|Conventional monitor and treatment The surgery is performed after patient is under general anesthesia. If patient's heart rate significantly slows down or bradycardia/arrhythmia happens, the surgeon will be asked to suspend the operation. Meanwhile, atropine (0.01-0.02mg/kg) is given intravenously to increase the heart rate. If atropine fails to increase the heart rate, isoproterenol (1-2 μg/per time) will be given intravenously to increase the heart rate.
89357683|NCT03627104|Other|High-protein diet with vegetable protein|The patient will intake the diet assigned for a month
89357684|NCT04313153|Experimental|Vadadustat once daily (QD)|
89357685|NCT04313153|Experimental|Vadadustat three times weekly (TIW)|
89357686|NCT04313153|Active Comparator|Darbepoetin alfa|
89357687|NCT03337750|Experimental|Web-PE|Ten 60-minute psychotherapy sessions over 8 weeks, focused on gradually confronting distressing trauma-related memories and reminders. Web-PE is an internet-based version of prolonged exposure (PE) for posttraumatic stress disorder (PTSD).
89357688|NCT03804983|Active Comparator|Hybrid Closed Loop (HCL)|Eligible participants will be screened and enter the data collection period for approximately 5 days at home. Prior to participating in the 72-hour ski admission, participants will be randomized 1:1 to the use of Control-IQ with Hybrid Closed Loop (HCL) or the Control-IQ with MyTDI. Participants randomized to Control-IQ, participants will continue using their home insulin parameters during the ski admission and then 5 additional days at home.
89357689|NCT03804983|Experimental|Control-IQ with MyTDI|"Eligible participants will be screened and enter the data collection period for approximately 5 days at home. Prior to participating in the 72-hour ski admission, participants will be randomized 1:1 to the use of Control-IQ or the Control-IQ with MyTDI. Participants randomized to Control-IQ with MyTDI, participants will be adjusted as noted below during the ski admission and will then continue these parameters for 5 additional days at home:~A single basal rate equal to total daily insulin (TDI)/48 will be implemented across the whole day~A single correction factor (CF) of 1650/TDI will be implemented across the whole day~Carbohydrate ratios (CR) will be set at:~00:00-04:00 CR=450/TDI~04:00-11:00 CR=360/TDI~11:00-00:00 CR=450/TDI TDI will be set at the internal Control-IQ estimation total daily dose; if not available, total daily dose over the last 5 days will be used."
89357690|NCT03330964|Experimental|electroacupuncture group|The experimental group adopted chemotherapy combined with electro-acupuncture stimulated related acupoints for 3 days running.
89357691|NCT03330964|No Intervention|control group|The control group received chemotherapy only(same as the experimental group),but no electroacupuncture treatment.
89357692|NCT04312529|Experimental|Overhead athletes|
89357693|NCT03337672|Experimental|Dexmedetomidine group|Subjects who receive dexmedetomidine for prevention of emergence delirium
89357694|NCT03337672|Active Comparator|Midazolam group|Subjects who receive midazolam for prevention of emergence delirium
89357695|NCT04280393|Experimental|Endocuff|Colonoscopy procedure with the use of endocuff
89357696|NCT04280393|Active Comparator|Control|Standard Colonoscopy procedure
89357697|NCT03337516|Experimental|Patients treated with Cytarabine|
89357698|NCT03330808|Experimental|Epidural with general anesthesia|Epidural anesthesia with 0.2% ropivacaine 10 ml
89357699|NCT03330808|No Intervention|General anesthesia alone|Sevoflurane and nitrous oxide.
89357700|NCT03330730|Experimental|Experimental|"Patients with oncological follow up and home-care service package IsereADOM:~Objects connected to patients' home (thermometer, weight scale, tensiometer +/- oximeter, glucose meter or pedometer) with graduated protocol for medical platform support.~Digital linkbook (different from the medical file) accessible to the patient and the standard care actors.~Referent sentinel: a field actor to coordinate the care. Preferred contact of the patient outside the center Motivational coaching: 1 to 2 axes to be defined by the investigator among the following axes (physical activity, nutrition and hydration, drug compliance, medical follow-up, chronic and moral pain, acceptance of the disease and treatments)."
89534207|NCT03998670|Experimental|Prism Group|Spectacles with refractive correction and base-in relieving prism (40% of the greater of the exodeviation by prism and alternate cover test (PACT) at distance or near) equally divided between the 2 lenses will be prescribed to the participant
89357701|NCT03330730|No Intervention|Control|Patients with oncological follow up only
89357702|NCT03810599|Other|Early cardiac rehabilitation|Single Group: 5 week cardiac rehabilitation programme. Pre-post comparison.
89357703|NCT03810677||Patients with varicose veins, eligible for EVLA|
89357704|NCT02497924|Experimental|GBT440|GBT440 / [C14] GBT440
89357705|NCT03342430||Early Dieting in Girls cohort|A cohort of 197 non-Hispanic white girls, observed from age 5 to age 15 years
89357706|NCT01303055|Experimental|Alogliptin|Alogliptin 25 mg
88829119|NCT04950881|Experimental|Nerve block group|After the patient is under general anesthesia, an attending physicians perform the ultrasound-guided cervical vagus nerve block (using a 50mm Braun nerve stimulation needle, and the patients were injected with 10ml of lidocaine or ropivacaine ). Then the operation starts. If patient's heart rate significantly slows down or bradycardia/arrhythmia happens, the surgeon will be asked to suspend the operation. Meanwhile, atropine (0.01-0.02mg/kg) is given intravenously to increase the heart rate. If atropine fails to increase the heart rate, isoproterenol (1-2 μg/per time) will be given intravenously to increase the heart rate. After endotracheal tube is removed, the patient will be followed up for next 24 hours.
88829120|NCT04341077|Experimental|SHR3162|A single dose of fluzoparib was administered orally
88829121|NCT04914767|Experimental|Nigella|"The patient will receive a study treatment containing 100 capsules:~One capsule every two hours for the first three days.~From the fourth day, the patient will take one capsule, three times a day for 12 days."
88829122|NCT04914767|Placebo Comparator|Placebo Group|"The patient will also receive a study treatment containing 100 capsules:~One capsule every two hours for the first three days.~From the fourth day, the patient will take one capsule, three times a day for 12 days."
88829123|NCT02561585|Experimental|LEO 124249|LEO 124249 ointment 30 mg/g twice daily
89357707|NCT01303055|Active Comparator|Metformin|Metformin 750 mg
89534208|NCT03998670|Placebo Comparator|Non-Prism Group|Spectacles with refractive correction (or plano spectacles if no significant refractive error) and no prism will be prescribed to the participant
89534209|NCT03998176|Experimental|B/F/TAF|Participants will receive B/F/TAF for 48 weeks
89534210|NCT03991169|Experimental|Oral Iron therapy|Participant will receive oral iron therapy.
89534211|NCT03991169|No Intervention|No oral iron therapy|Participant will not receive oral iron therapy for 3 months.
88829124|NCT02561585|Placebo Comparator|Vehicle|LEO 124249 ointment vehicle twice daily
88829125|NCT02561897|Experimental|Edoxaban|Edoxaban 30 or 60 mg
89357708|NCT03810521|Experimental|CLT low-dose|Umbilical cord derived-mesenchymal stromal cells at a dose of 2x10e6 cells / 3mL injected by an intra-articular infiltration of affected knee
89534212|NCT03986047|Experimental|Thermal care|Participants will be asked to wear a heat wrap over the lower lumbar spine, during the day for 8 hours on 7 consecutive days. The Thermal care group will also receive education by a physiotherapist on acute low back pain management.
88829126|NCT02561897|Active Comparator|Warfarin|Warfarin 1 -1 0 mg
88829127|NCT02512679|Other|Cyclophosphamide Dose Level 1|"Cyclophosphamide given by Intravenous (IV) at a total dose of 105 mg/kg, to be divided into three doses of one 35 mg/kg dose per day, for 3 days on the first level.~Drug to be given in combination of Busulfan, Campath and Fludarabine"
88829128|NCT02512679|Other|Cyclophosphamide Dose Level 2|Cyclophosphamide given by intravenous (IV) at a total dose of 70 mg/kg (divided in two doses) given once a day for two days in combination with Busulfan, Campath and Fludarabine.
88829129|NCT02512679|Other|Cyclophosphamide Dose Level 3|Cyclophosphamide given by intravenous (IV) at total does of 35 mg/kg as a one time dose in combination with Busulfan, Fludarabine and Campath
88829130|NCT02512679|Other|Cyclophosphamide Dose Level 4|No cyclophosphamide given with Busulfan, Fludarabine and Campath
88829131|NCT02562521|Experimental|Smoking Cessation Treatment|The intervention will consist of Contingency management (CM) in conjunction with effective first line pharmacotherapy (dual nicotine replacement therapy [NRT] or varenicline) and brief counseling to rapidly induce cessation and to maintain abstinence long term. Pharmacotherapy will be flexible. Participants will also be given the option of receiving additional behavioral support by being referred to the CT Quitline and using text or mobile phone apps for quitting.
88829132|NCT02562521|No Intervention|Delayed Treatment Control|Participants in this arm will be offered the Smoking Cessation Treatment 6 weeks later
88829133|NCT04887779|Experimental|Intervention|Patient viewing ex-planted organ and microscopy with pathologist
88829134|NCT02562755|Experimental|Pexa-Vec followed by Sorafenib|Pexa-Vec (pexastimogene devacirepvec) will be administered as 3 bi-weekly intratumoral (IT) injections of 1e9 pfu at day 1 and weeks 2 and 4, followed by sorafenib at Week 6.
88829135|NCT02562755|Active Comparator|Sorafenib|Sorafenib (400 mg twice daily) begins on Day 1.
88829136|NCT04796129||patients with hip osteoarthritis|the patients who aged 45 and older and have paint in the hips. and also without having any other comorbidities about inflammatory status.
88829137|NCT04796129||control|the participants who have any other comorbidities for impact on the inflammatory status and also no hip pain.
88829138|NCT02562989|Experimental|Part 1, Healthy Young Participants|Healthy young participants received a single intravenous (IV) dose of ~185 megabecquerel (MBq) [18F]MK-6240 in Part 1 of the study
88829139|NCT02562989|Experimental|Part 2, Healthy Elderly Participants|Healthy elderly participants received a single IV dose of ~160 MBq [18F]MK-6240, in Part 2 of the study
88829140|NCT02562989|Experimental|Part 2, AD and Amnestic MCI Elderly Participants|AD and amnestic MCI participants received up to two IV doses of ~160 MBq [18F]MK-6240 in Part 2 of the study
89534213|NCT03986047|Experimental|Thermal care + exercises|In addition to heat wrap and pain management education as for Thermal care group, participants of this group will be asked to perform exercises at home over 7 days, targeted on functional capacity, lumbar mobility, and slight contraction of trunk muscle (posture and/or cognitive).
88829141|NCT05446883|Experimental|QL1706+chemotherapy± bevacizumab|QL1706 (5 mg/kg) + paclitaxel (175 mg/m2) + cisplatin (50 mg/m2)/carboplatin (AUC 5) ± bevacizumab (15 mg/kg)
88829142|NCT05446883|Placebo Comparator|Placebo+chemotherapy± bevacizumab|Placebo + paclitaxel (175 mg/m2) + cisplatin (50 mg/m2)/carboplatin (AUC 5) ± bevacizumab (15 mg/kg)
88829143|NCT02565485|No Intervention|Standard IV Preload|Patients in this arm will receive 500mL of Lactated Ringer's solution, which is the standard IV fluid preload used on Labor and Delivery at MetroHealth Medical Center
88829144|NCT02565485|Experimental|Volume Replacement IV Preload|Patients in this arm will receive 1500mL of Lactated Ringer's solution
88829145|NCT02515253|Experimental|Prescription group|Participants in this group will receive the standard care for benign breast pain sufferers (administered by the Queen Alexandra Hospital in Portsmouth) and will also attend the Department of Sport and Exercise Science at the University of Portsmouth for an individual bra prescription. Participants will be prescribed an appropriate bra to wear over an eight week intervention period.
88829146|NCT02515253|Other|Standard care group|Participants in this group will receive the standard care for benign breast pain sufferers administered by the Queen Alexandra Hospital in Portsmouth.
88829147|NCT02566265|Experimental|Fluzone High Dose Vaccine then Fluzone High Dose Booster|Fluzone High dose vaccine administered at Day 0. Fluzone High dose vaccine administered as a booster after 30 days from the initial vaccine.
88829148|NCT02566265|Active Comparator|Standard of Care|Fluzone High-Dose if age greater than or equal to 65 or Standard dose influenza vaccine if age less than 65 at day 0. Placebo administered 30 days after the initial vaccine.
88829149|NCT02517047|Experimental|CareTRx Device|Subject will receive CareTRx device for rescue inhaler as well as the application downloaded to their Android phone. The device will track when the rescue inhaler is administered. The information will then be loaded to phone app.
88829150|NCT04768933|Experimental|Toddler Milk Group|All enrolled subjects with be provided a new toddler milk for 28 days. Aligned with clinical and label recommendations, they will be required to intake at least 3 servings of 130 ml per day.
88829151|NCT00558103|Active Comparator|arm 1|Lapatinib
88829152|NCT00558103|Active Comparator|arm2|Pazopanib monotherapy (open label)
88829153|NCT00558103|Experimental|arm3|Lapatinib+ pazopanib
88829154|NCT02974361|Active Comparator|Part A Ibuprofen control|
88829155|NCT02974361|Experimental|Part A Ibuprofen-LDH|
88829156|NCT02974361|Experimental|Part A Ibuprofen-LDH Excipient Combo 1|
88829157|NCT02974361|Experimental|Part A Ibuprofen-LDH Excipient Combo 2|
88829158|NCT02974361|Experimental|Part A Ibuprofen-LDH Excipient Combo 3|
88829159|NCT02974361|Experimental|Part A Ibuprofen-LDH Excipient Combo 4|
88829160|NCT02974361|Active Comparator|Part A Ibuprofen Lysine|
88829161|NCT02974361|Active Comparator|Part B Ibuprofen|
88829162|NCT02974361|Experimental|Part B Ibuprofen LDH Excipient Combo 1|
88829163|NCT02974361|Experimental|Part B Ibuprofen LDH Excipient Combo 2|
88829164|NCT02974361|Experimental|Part B Ibuprofen LDH Excipient Combo 3|
88829165|NCT02974361|Experimental|Part B Ibuprofen LDH Excipient Combo 4|
88829166|NCT02974361|Active Comparator|Part C Ibuprofen|
88829167|NCT02974361|Experimental|Part C Ibuprofen LDH Excipient Combo 1|
88829168|NCT02974361|Experimental|Part C Ibuprofen LDH Excipient Combo 2|
88829169|NCT02974361|Experimental|Part C Ibuprofen LDH Excipient Combo 3|
88829170|NCT02974361|Experimental|Part B Ibuprofen LDH Excipient Combo 5|
89534214|NCT03986047|Sham Comparator|Control|Participants in the control group will receive the same education program as those of the two other groups. A sham non-heating wrap will be used to control for potential supportive and sensory influence of the heat wrap.
88829172|NCT04282603|Experimental|Experimental Meal Replacement|Participants randomized to this arm will consume 5 servings/day of experimental meal replacement in conjunction of 400 kcal of solid food for 12 weeks during the weight loss portion of the trial. This will be followed by the consumption of 1 serving/day of experimental meal replacement for 12 weeks during the weight maintenance portion of the trial.
88829173|NCT04282603|Active Comparator|Bariatrics Advantage Meal Replacement|Participants randomized to this arm will consume 5 servings/day of Bariatrics Advantage meal replacement in conjunction of 400 kcal of solid food for 12 weeks during the weight loss portion of the trial. This will be followed by the consumption of 1 serving/day of Bariatrics Advantage meal replacement for 12 weeks during the weight maintenance portion of the trial.
88829174|NCT02569541|Experimental|CEM-102 (Sodium fusidate)|"1500 mg by mouth every 12 hours for 2 doses, then 600 mg by mouth every 12 hours thereafter, until end of therapy:~6 months of treatment; or~24 months of treatment (if continued on chronic suppressive therapy)"
88829175|NCT04198675|Active Comparator|Supervised EMG Biofeedback Exercise Training Group|Frequency: 3/week Duration:6 weeks Dosage: Tolerable intensity-dependent increase in exercises program.
88829176|NCT04198675|Active Comparator|Home-Based Exercise Training Group|Frequency: 3/week Duration:6 weeks Dosage: Tolerable intensity-dependent increase in exercises program.
88829177|NCT04198675|Sham Comparator|Posture Training/Ergonomic Regulations Group|1 session, no further intervention until second evaluation for 6 weeks.
88829178|NCT04093297|Active Comparator|Group Ring|Patients in Group Ring will undergo tricuspid rigid ring annuloplasty
88829179|NCT04093297|Active Comparator|Group Band|Patients in Group Band will undergo flexible band annuloplasty
88829180|NCT04477733|Experimental|Butorphanol group|
88829181|NCT04477733|Placebo Comparator|control group|
88829182|NCT01833403|Other|Measurement of insulin sensitivity|All participants will undergo a hyperinsulinemic-euglycemic clamp to measure insulin sensitivity
88829183|NCT01833481||THA using direct-anterior surgical approach|Patients will have undergone THA using a direct-anterior surgical approach and will undergo fluoroscopy surveillance while walking.
88829184|NCT01833481||THA using anterior-lateral approach|Patients will have undergone THA using an anterior-lateral surgical approach and will undergo fluoroscopy surveillance while walking.
88829185|NCT01833481||THA using posterior-lateral approach|Patients will have undergone THA using a posterior-lateral surgical approach and will undergo fluoroscopy surveillance while walking.
88829186|NCT00558025|Experimental|Pramipexole Extended Release (ER)|Pramipexole Extended Release (ER) once daily
88829187|NCT00558025|Experimental|Pramipexole Immediate Release (IR)|Pramipexole Immediate Release (IR) once daily
88829188|NCT04125251|Active Comparator|BISP,CT & LSB to Couples|In this arm 1, the LSB intervention will be offered to the BISP-CT beneficiary women and their spouses
88829189|NCT04125251|Active Comparator|BISP,CT & LSB to Women|In this arm, the LSB intervention will be offered to the BISP-CT beneficiary women only.
88829190|NCT04125251|No Intervention|BISP,CT & No LSB|This is the control group, where neither BISP-CT beneficiary women nor their spouses will be offered the LSB intervention
88829191|NCT01834027|Experimental|Jazz music|Jazz music will be played through headphones to post-surgical hysterectomy patients while they are in the post anesthesia care unit.
88829192|NCT01834027|Active Comparator|No music|The patients in this group with have headphones but no music will be played.
88829193|NCT02576249|Active Comparator|Ropivacaine and Methylprednisolone|0.2% ropivacaine and methylprednisolone knee joint injection
88829194|NCT02576249|Experimental|Saline and Methylprednisolone|0.9% normal saline and methylprednisolone knee joint injection
88829195|NCT03868657|Active Comparator|Moxifloxacin|Per os, 800 mg, once daily for 4 days
88829196|NCT03868657|Placebo Comparator|Placebo|Per os, 800 mg, once daily for 4 days
88829197|NCT01834261|Active Comparator|Oxytocin|Healthy adult subjects will receive several puffs of Syntocinon Nasal Spray, 40IU, once, prior to MRI and/or MEG scanning.
88829198|NCT01834261|Placebo Comparator|Placebo|Healthy adult subjects will receive several puffs of Syntocinon Placebo Formulation, 40IU, once, prior to MRI and/or MEG scanning.
88829199|NCT05670925|Experimental|Camrelizumab plus Famitinib with/without nab-palitaxel|
88829200|NCT04707989|Experimental|Ketone-Promoting Food Ingredient 1|Novel ketone-promoting food ingredient (#1) administered in a beverage once daily for 28 days.
88829201|NCT04707989|Placebo Comparator|Ketone Free Placebo|Beverage matched for appearance, volume, taste and texture to experimental arm (ketone promoting food ingredient #1) that does NOT contain a ketone ingredient. Consumed once daily for 28 days.
88829202|NCT04707989|Active Comparator|Ketone-Promoting Food Ingredient 2|Previously characterized ketone-promoting food ingredient (#2) administered in a beverage once daily for 28 days.
88829203|NCT04707833|Experimental|Patient infected or cured from covid19|"Patients with an acute SARS-CoV-2 infection confirmed by a positive RT-PCR, hospitalized in COVID units or in COVID resuscitations,~Nurses at the Rouen University Hospital infected with COVID 19, and cured,~Patients with a high suggestive clinic for COVID-19 infection but with negative COVID-19 RT-PCR"
89534215|NCT03965481|Experimental|Diagnostic (CECT, PET-MRI)|Patients undergo standard of care CECT scan and PET-MRI scan over 90-120 minutes within 30 days before laparoscopy or cytoreduction. Patients who do not undergo cytoreduction based on diagnostic laparoscopy undergo additional PET-MRI and standard of care CECT scans after completion of chemotherapy and before cytoreduction.
88829204|NCT02578199|Experimental|motivational interviewing and nutrition|Motivational interviewing and nutritional counseling.
88829205|NCT02578745|Experimental|Prophylactic NPWT|Women assigned to prophylactic NPWT will have the PICO device applied and secured with fixation adhesion strips. The device will be monitored while the patient is in the hospital to confirm that it is functioning well. The device will be removed prior to discharge, typically on postoperative day 4.
88829206|NCT02578745|Active Comparator|Standard Dressing|Women assigned to standard care will receive routine postoperative wound dressing consisting of layers of gauze and adhesive tap. The dressing will be removed after 24 - 48 hours.
88829207|NCT01834651|Experimental|Treatment (cabozantinib)|Cabozantinib 60mg orally daily until disease progression
88829208|NCT00557323||1|Patients being treated for hyperphosphatemia with any marketed product
88829209|NCT02578901|Active Comparator|Tranexamic Acid (TXA)|IV or PO administered after meeting inclusion/exclusion criteria
88829210|NCT02578901|Placebo Comparator|Placebo|IV Normal Saline or PO placebo pills administered after meeting inclusion/exclusion criteria
88829211|NCT03832439|Active Comparator|Probiotic|This arm will be receiving probiotic supplements.
88829212|NCT03832439|Placebo Comparator|Placebo|This arm will be receiving placebo containing microcrystalline cellulose.
88829213|NCT02579057|Active Comparator|Furosemide Injection Solution, USP|Single dose determined by Investigator (maximum dose 160mg) administered intravenously by IV bolus over approximately 2 minutes (reference treatment)
88829214|NCT02579057|Experimental|Furosemide Injection Solution (SCP-101)|80 mg dose administered subcutaneously as 30 mg over the first hour and then as 12.5 mg per hour over the subsequent 4 hours (test treatment)
88829215|NCT00364325||001|
88829216|NCT02579135|Experimental|Project HEART|Interactive website with five modules to address safer sex motivation, knowledge, attitudes/norms, self-efficacy, and sexual communication skills. Program takes approximately 30-45 minutes to complete.
88829217|NCT02579135|Other|Control: Project Growing Minds|Attention-matched control website with five modules to address an introduction to mindsets, growth mindsets of intelligence, growth mindsets of self-control, growth mindsets of people, and an integrative summary. Program takes approximately 30-45 minutes to complete.
88829218|NCT00557245|Active Comparator|Tenofovir Disoproxil Fumarate (TDF)|TDF 300 mg tablet, once daily + Placebo FTC/TDF orally, once daily.
88829219|NCT00557245|Active Comparator|Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)|FTC/TDF - 200 mg tablet, once daily + Placebo TDF orally, once daily
88829220|NCT00557245|Placebo Comparator|Placebo|Placebo TDF + Placebo FTC/TDF orally, once daily.
88829221|NCT03583541|Experimental|Control arm: Bolstered treatment|Women in the control condition (and in the treatment arms) will receive treatment as usual (TAU) for FSW in the study area. Provided by RHSP, TAU includes: health education, HIV testing services, STI screening and treatment in a session that lasts about 2 hours, provided on a quarterly basis. This will be bolstered with 4 sessions provided twice per week for 2 weeks of an evidence-based, HIV/STI risk reduction intervention
88829222|NCT03583541|Experimental|Treatment arm: HIVRR+S+FL|Women in this arm will receive TAU for FSW and the 4 HIVRR sessions (described above) and a single session following HIVRR specifically describing bank account opening, the matching process, and how to interact with banks. In this session our partnering banks will open up matched savings accounts for women in the two treatment arms. Women in both arms will save money in their matched savings accounts over a 10-month period post HIVRR. The study team will monitor the accounts using the statements received directly from the banks holding the accounts. Participants will receive monthly bank statements indicating their own savings and the associated match (1:1 match rate). They will also receive 6 financial literacy (FL) sessions provided twice a week for 3 weeks
89177781|NCT02609360|Experimental|Balanced Solution|Circuit priming will be performed with a Balanced Solution created by mixing 0.9% NaCl, Sodium bicarbonate (8.4%) and injectable sterile water, in order to obtain a solution with constant sodium concentration (140 mEq/l) and SID equal to patient's bicarbonate level.
89177782|NCT00444535|Experimental|Oral lapatinib tablets in combination with IV bevacizumab|1500 mg oral lapatinib (once daily) plus 10 mg/kg intravenous bevacizumab (every two weeks)
88829223|NCT03583541|Experimental|Treatment arm: HIVRR+S+FLM|"Women in this arm will receive TAU and the 4 HIVRR sessions (as above). Next, they will receive the savings session (described above) and 6 financial literacy (FL) sessions provided twice a week for 3 weeks, followed by 8 mentorship (M) sessions supporting transition to vocational, educational training, employment or business development, and receipt of a matched savings account to be used on short-term and/or long term consumption and skills development per participants own discretion/choice.~*Revision note: Following COVID-19, with approval from NIMH (on record if requested), the HIVRR+S+FLM treatment of the study has been combined with the HIVRR+S+FL treatment arm. The total sample size has been revised to 532 participants, with approval from NIMH."
88829224|NCT04743011|Placebo Comparator|Placebo|Participants will receive inhalation with 5mL 0.9% saline solution (placebo), 4/4h, during the day period (5 doses).
88829225|NCT04743011|Active Comparator|Heparin sodium|Participants will receive inhalation with 5mL 0.9% saline solution + 2,5mg of high molecular weight heparin - enriched heparin, 4/4h, during the day period (5 doses).
88829226|NCT03528941||Lamivudine|Patients who received lamivudine
88829227|NCT03528941||No prophylaxis|Patients who did not receive any prophylaxis
88829228|NCT02989363|Experimental|O-Arm in deep brain stimulation surgeries (DBS)|Use of image surgery with technology O-Arm in deep brain stimulation surgeries (DBS)
88829229|NCT02989363|Experimental|Control group Not O-Arm in deep brain stimulation surgeries|Not use of image surgery with technology O-Arm in deep brain stimulation surgeries (DBS)
88829230|NCT02989363|Experimental|O-Arm in complex back surgeries (RAQUIS)|Use of image surgery with technology O-Arm in complex back surgeries (RAQUIS)
88829231|NCT02989363|Experimental|Control group Not O-Arm in complex back surgeries (RAQUIS)|Not use of image surgery with technology O-Arm in complex back surgeries (RAQUIS)
88829232|NCT00364403|Experimental|1|Low glycemic load diet
88829233|NCT00364403|Active Comparator|2|Low fat diet
88829234|NCT01835743|Active Comparator|Erchonia HPS Laser|The Erchonia HPS Laser contains 3 independent diodes mounted in scanner devices and positioned equidistant from each other and titled at a 30 degree angle. Each scanner emits 17 milliwatts (mW), 635 nm of red laser light.
88829235|NCT01835743|Placebo Comparator|Placebo Laser|The Placebo Laser is identical in appearance and operation to the Erchonia HPS Laser but does not emit any therapeutic light.
88829236|NCT02579915|Experimental|FaceAnxiety - Mental Habits|Treatment will consist of 8, 30-minute, twice-weekly sessions designed to: a) decrease attention bias to threat and b) extinguish threat interpretations/reinforce benign interpretations of ambiguity. Attention bias will be modified via a dot probe task that increases attentional control by directing attention away from threat faces via probe location. Patients will complete 256 trials per session. Interpretation bias will be modified via a word-sentence association task which provides positive feedback when participants endorse benign interpretations of ambiguous sentences and negative feedback for threat interpretations. Participants will complete 150 training trials per session. A FaceAnxiety Specialist facilitates program completion.
88829237|NCT02579915|Active Comparator|FaceAnxiety - Symptom Tracking|Treatment will consist of weekly self-assessment of anxiety and depression symptoms via on-line surveys. A FaceAnxiety Specialist will facilitate program completion.
88829238|NCT03580031|Experimental|Study group|HCG IM 10,000 IU Im 48 hours after first triggering dose
88829239|NCT03580031|Placebo Comparator|Control group|Saline 2m Injection im 48 hours after the first triggering dose
88829240|NCT02581475|Active Comparator|Group A|"Extending withdrawal time in the proximal colon: After cecal intubation, the colonoscopy is withdrawn to the hepatic flexure and then to the splenic flexure with an extended withdrawal time during colonoscopy.~From cecum to hepatic flexure, 1.5-2 min is required and 2.5-3 min is required from heptic flexure to splenic flexure."
88829241|NCT02581475|Experimental|Group B|Segmental examination twice of the proximal colon: After cecal intubation, the colonoscopy is withdrawn to the hepatic flexure and then the colonoscopy is intubated to the cecum again. The same procedure is performed in the colonic segment from hepatic flexure to splenic flexure. The withdrawal time in each colonic segment is similar to the group A.
88829242|NCT03607357|Experimental|HFNO group/Group A|The patients should receive the treatment of high flow nasal oxygen immediately after extubation.
88829243|NCT03607357|Placebo Comparator|NIV group/Group B|The patients should receive the treatment of non-invasive Ventilation immediately after extubation.
88829244|NCT05665621|Experimental|Training group|Eight-week in-school strength and balance training program
88829245|NCT05665621|No Intervention|Control|No intervention, normal activities.
88829246|NCT01836133||Erlotinib 150 mg|Participants received 150 mg erlotinib once daily, orally, as tablets, until disease progression or unacceptable toxicity, up to 3 years.
88829247|NCT02989051|Experimental|Restrictive fluid treatment|Restrictive fluid regimen
88829248|NCT02989051|Active Comparator|Liberal fluid treatment|This is seen as current standard clinical treatment, wherein patients will receive a more liberal fluid regimen.
88829249|NCT02581865|Placebo Comparator|Placebo|Placebo administered once daily for 8 weeks
88829250|NCT02581865|Experimental|Dose Group 1|Fixed dose administered once daily for 8 weeks
88829251|NCT02581865|Experimental|Dose Group 2|Fixed dose administered once daily for 8 weeks
88829252|NCT02836457||Population with Exposure to ELIQUIS (APIXABAN)|
88829253|NCT00365183|Experimental|Xcytrin® (motexafin gadolinium)|
88829254|NCT00556075|Placebo Comparator|Placebo|Placebo once daily
88829255|NCT00556075|Experimental|25 mg|Proellex 25 mg once daily
88829256|NCT00556075|Experimental|50 mg|Proellex 50 mg once daily
89177783|NCT02551120||Patients|Patients with idiopathic hypoparathyroidism, autosomal dominant hypocalcaemia and pseudohypoparathyroidism.
89357709|NCT03810521|Experimental|CLT medium-dose|Umbilical cord derived-mesenchymal stromal cells at a dose of 20x10e6 cells / 3mL injected by an intra-articular infiltration of affected knee
89534216|NCT03961399|Active Comparator|biventricular stimulation (BiV) group|patients with Abbott Medical® CRT implanted with only biventricular stimulation (BiV).
89357710|NCT03810521|Experimental|CLT high-dose|Umbilical cord derived-mesenchymal stromal cells at a dose of 80x10e6 cells / 3mL injected by an intra-articular infiltration of affected knee
89357711|NCT05484388|Experimental|SN2|new absorbing hygiene product with absorption level Normal.
89534217|NCT03961399|Experimental|SyncAVTM stimulation group|patients with Abbott Medical® CRT implanted and SyncAVTM stimulation activated
88829257|NCT03441503|Experimental|Child HCAHPS: Automated Administration|"Child HCAHPS: Automated day-of-discharge survey~On the day of discharge at the hospital, parents will be contacted to solicit survey responses using patient televisions (GetWell) as follows:~Day 0 (Day of likely discharge): Respondent will be promoted to complete Child HCAHPS on their television as part of the routine discharge process. Respondent will also be asked for their email address to complete post-discharge items and their appropriate contact information will be collected.~Days 2-42: Standard hospital protocol (i.e., mail, email, or IVR) with the post-discharge questions."
88829258|NCT03441503|No Intervention|Standard Administration of Child HCAHPS|Parents will be contacted to complete Child HCAHPS using the standard protocol for mail, email, or IVR survey administration. The surveys will be administered by the survey vendor contracted by the participating site to administer Child HCAHPS.
88829259|NCT03376451|Other|Patients in EndoSearch|EndoSearch will conduct on only one cohort divided in two groups : patients affected by endometriosis and patient unaffected (controls). All of these patients need a laparoscopic surgery for endometriosis indication (endometriosis group) or another indication which is not endometriosis (controls). However, nothing in the surgery or the patient medical care will be different between the two groups : patients will be treated exactly the same.
88829260|NCT01837069|Active Comparator|Treatment|Lifestyle counseling (nutrition, physical activity, medication compliance and smoking cessation) Atorvastatin 80mg PO QD Metoprolol 25mg PO BID if HR is elevated Lisinopril 2.5 mg PO QD if SBP is elevated
88829261|NCT01837069|No Intervention|Control|Standard of care
88829262|NCT03323489|Experimental|celiac radiosurgery, single fraction|Celiac Plexus Radiosurgery
89534218|NCT03950830|Experimental|Treatment arm|Cisplatin 50mg/m2 day 1 and 2, every 3 weeks, Disulfiram 400mg daily, continuously
88829264|NCT02289690|Experimental|Phase 1: Veliparib + Carboplatin + Etoposide|"Participants in Phase 1 will be sequentially assigned to ascending dose levels of veliparib in combination with carboplatin/etoposide for up to four 21-day cycles.~Participants without evidence of disease progression will continue on veliparib monotherapy at 400 mg BID continuous dosing (21-day cycles) until disease progression or unacceptable toxicity."
88829265|NCT02289690|Experimental|Phase 2: Veliparib + Carboplatin + Etoposide -> Veliparib|Participants will receive veliparib 240 mg in combination with carboplatin/etoposide for four to six 21-day cycles followed by veliparib monotherapy at 400 mg BID continuous dosing (21-day cycles) until disease progression or unacceptable toxicity.
88829266|NCT02289690|Experimental|Phase 2: Veliparib + Carboplatin + Etoposide -> Placebo|Participants will receive veliparib 240 mg in combination with carboplatin/etoposide for four to six 21-day cycles followed by placebo monotherapy continuous dosing (21-day cycles) until disease progression or unacceptable toxicity occurs.
88829267|NCT02289690|Active Comparator|Phase 2: Placebo + Carboplatin + Etoposide -> Placebo|Participants will receive placebo in combination with carboplatin/etoposide for four to six 21-day cycles followed by placebo monotherapy continuous dosing (21-day cycles) until disease progression or unacceptable toxicity occurs.
88829268|NCT02584673|Experimental|CAIG|The participants in this group (test group) will utilize the same procedure utilizing existing ultrasound equipment with the supplemental CAIG system.
88829269|NCT02584673|No Intervention|Control|The participants in the control group will receive the procedure with traditional ultrasound methods and equipment.
88829270|NCT02268955|Placebo Comparator|Control Group: Adults age 18-55 years|Saline-only control group
88829271|NCT02268955|Active Comparator|IV Ibuprofen: Adults age 18-55 years|Patients receiving intravenous ibuprofen therapy
88829272|NCT02585843|Experimental|High-dose|Spironolactone 100mg: 100mg/day of spironolactone (2 capsules), PO (oral) for 7 days
88829273|NCT02585843|Active Comparator|Standard of Care|Spironolactone 25mg: 25mg/day of spironolactone, PO (oral)
88829274|NCT01837537||no treatment|no treatment, prospective observational
88829275|NCT04350385|Experimental|Group 1|Agility Training
88829276|NCT04350385|Active Comparator|Group 2|.Conventional intervention
88829277|NCT02463305|Experimental|Treatment arm|6 patients with mild-moderate ulcerative colitis treated with creatine monohydrate 21 grams per day in three divided doses taken with water for 8 weeks.
88829278|NCT02463305|Placebo Comparator|Placebo arm|6 patients with mild-moderate ulcerative colitis treated with placebo (matching creatine monohydrate) 21 grams per day in three divided doses taken with water for 8 weeks.
88829279|NCT02463305|Experimental|Optional Open-Label Treatment arm|Up to 6 patients, who were randomized to the placebo arm, will be given the option to continue with open-label creatine monohydrate treatment at 21 grams per day in three divided doses, taken with water, for 8 weeks. Only non-invasive testing will be performed.
88829280|NCT03032471||DCI group|"Patients that experience DCI, defined as~Cerebral infarction identified on imaging or proven at autopsy, after exclusion of procedure-related infarctions; and~Clinical deterioration caused by DCI, after exclusion of other potential causes of clinical deterioration will be assigned to the DCI group."
88829281|NCT03032471||non-DCI group|Patients not experiencing DCI as defined above.
88829282|NCT01838317|Experimental|Pioglitazone & Chemotherapy in Patients without Diabetes|
88829283|NCT01838317|Experimental|Pioglitazone & Chemotherapy in Patients with Diabetes|
88829284|NCT05249231|Active Comparator|Hall technique|group of carious primary molars to be treated by hall technique
88829285|NCT05249231|Experimental|silver diamine fluoride|group of carious primary molars to be treated by silver diamine fluoride
89357712|NCT05484388|Experimental|SP3|new absorbing hygiene product with absorption level Plus.
89357713|NCT05484388|Other|TENA Proskin Pants Normal|Reference product currently used by the participant (control for SN2).
89357714|NCT05484388|Other|TENA Pants Original Plus|Reference product currently used by the participant (control for SP3).
89357715|NCT03796169|Experimental|Endoscopist|Intervention for personal notification, open notification and colonoscopy quality education by a GI faculty
89357716|NCT01957176|Experimental|Cohort A (Myelodysplastic syndrome (MDS)/ Acute myeloid leukemia (AML) adult subjects)|All subjects in this cohort received eltrombopag (ELT) at the dose that they were receiving at the time of the transition visit, except in the case where the subject required a dose modification. The range of doses of ELT that were used in this cohort were from 50 to 300 mg once daily (OD) for subjects of non-East Asian heritage. The dose ranges for subjects of East Asian heritage (i.e., Japanese, Chinese, Taiwanese, Thai and Korean) were 25 to 150 mg. Dose adjustments (if required) were done depending on each subject's platelet counts.
89357717|NCT01957176|Experimental|Cohort B (Idiopathic thrombocytopenic purpura (ITP) adult subjects)|All subjects in this cohort received ELT at the dose that they were receiving at the time of the transition visit, except in the case where the subject required a dose modification. The range of doses of ELT that were used in this cohort were from 12.5 to 75 mg. Dose adjustments (if required) were done depending on each subject's platelet counts.
89357718|NCT01957176|Experimental|Cohort C (Idiopathic thrombocytopenic purpura (ITP) pediatric subjects)|All subjects in this cohort received ELT at the dose that they were receiving at the time of the transition visit, except in the case where the subject required a dose modification. The range of doses of ELT that were used in this cohort were from 12.5 to 75 mg. Dose adjustments (if required) were done depending on each subject's platelet counts.
89357719|NCT03810443|Experimental|pulmonary arterial hypertension|The elements of the research consist of the Nijmegen questionnaire response, two dyspnea questionnaires (Dyspnea 12, MDP), a quality of life questionnaire (SF36), a psychological disorder screening questionnaire (HAD) and a diagnostic test: the hyperventilation test.
89357720|NCT03337438|Other|Values-PFI|
89357721|NCT03337438|Other|Traditional-PFI with values assessment|
88829286|NCT01448915||Persons with HIV and HCV coinfection|Persons with HIV and HCV coinfection who receive medical care for HIV infection at Johns Hopkins Hospital
89357722|NCT03337438|Other|Traditional PFI no values assessment|
89357723|NCT03636048|Experimental|Spinal anesthesia group|Spinal anesthesia is used for operation with epidural patient-controlled device for pain control. Bupivacaine Hcl 0.5% Inj. 9-10mg is injected into intrathecal space for anesthesia. 0.2% ropivacaine is used for postoperative pain control with continuous infusion into epidural space.
89357724|NCT03636048|Active Comparator|General anesthesia group|General anesthesia is used for operation with wound patient-controlled device for pain control. propofol (10milligram/ML) 1.5-2 mg/ml is used as bolus intravascular injection for induction of anesthesia. 0.5% ropivacaine is used for postoperative pain control with continous infusion through wound catheter.
89357725|NCT03804047|Experimental|Kinesio Tape (KTG)|Participants allocated into the KTG will receive a single time application of the kinesio tape flexible tape (Kinesio® Tex, Albuquerque, NM, USA) in the upper-body (i.e., back part of the trunk) and in the lower-body (i.e., legs and ankle) according to standardized procedures (https://kinesiotaping.com/how-to/). The tape is latex-free and wearable for weeks without causing skin irritation (i.e., hypoallergenic); and safe for populations ranging from pediatric to geriatric. The tape will be applied by a Physical Therapist with experience in tape application. Tape application will be conducted in a private room with a complete structure for the procedure.
89357726|NCT03804047|Sham Comparator|Sham Tape (STG)|Participants allocated into the STG will receive a single time application of an inflexible tape (i.e., sham tape) in the same body segments as the intervention condition. Tape application will be conducted in a private room with a complete structure for the procedure.
89357727|NCT03527173|Experimental|S. sonnei Group|Male or female subjects between, and including, 18 and 50 years of age at the time of the first vaccination, received 2 doses of the S. sonnei study vaccine at Day 1 and Day 29 respectively, by intramuscular injection into the upper deltoid region of the non-dominant arm. At 28 days after the second dose (Day 57), subjects received the challenge dose of S. sonnei 53G strain, orally.
89357728|NCT03527173|Placebo Comparator|Placebo Group|Male or female subjects between, and including, 18 and 50 years of age at the time of the first vaccination, received 2 doses of the placebo at Day 1 and Day 29 respectively, by intramuscular injection into the upper deltoid region of the non-dominant arm. At 28 days after the second dose (Day 57), subjects received the challenge dose of S. sonnei 53G strain, orally.
88829287|NCT05249153|No Intervention|Sufen|PCIA: continue with 0.05ug/kg/h sufentanil, 0.05ug/kg sufentainil bolus
88829288|NCT05249153|Experimental|Sufen with low DEX|PCIA: continue with 0.05ug/kg/h sufentanil and 0.05ug/kg/h dexmedetomidine, 0.05ug/kg/h sufentanil and 0.05ug/kg/h dexmedetomidine bolus
88829289|NCT05249153|Experimental|Sufen with high DEX|PCIA: continue with 0.05ug/kg/h sufentanil and 0.1ug/kg/h dexmedetomidine, 0.05ug/kg/h sufentanil and 0.1ug/kg/h dexmedetomidine bolus
88829290|NCT05248685|Experimental|Dual CD33/CLL1 CAR T|All patients who receive Dual CD33/CLL1 CAR T Cell infusion
89357729|NCT01952262||critically ill ICU patients|critically ill intensive care unit patients
88829291|NCT02961257|Experimental|Arm A|"Cabazitaxel 25 mg/m² intravenously over 1 hour on Day 1of a 3-week cycle, plus prednisone (or prednisolone) 10 mg orally given daily for a maximum of 10 cycles (ie 30 weeks of treatment).~Prophylactic Granulocyte colony-stimulating factor G-CSF (Granocyte) will be injected from Day 3 to Day 7 after every administration of cabazitaxel."
88829292|NCT02961257|Experimental|Arm B|Cabazitaxel 16 mg/m2 on Day 1 and Day 15 of a 4-week cycle plus prednisone (or prednisolone) 10 mg per day up to 10 cycles (ie 40 weeks of treatment). Prophylactic Granulocyte colony-stimulating factor G-CSF (Granocyte) will be injected from Day 3 to Day 7 after every administration of cabazitaxel.
88829293|NCT02271217|Placebo Comparator|Placebo|Subjects randomized 1:1:1 to receive either dalfampridine-ER 7.5mg, dalfampridine-ER 10mg, or matching placebo tablets taken twice daily 12 hours apart.
89357730|NCT04254302|No Intervention|Control|Participants randomized into the control arm will receive usual care as per the service delivery models and pathways planned in their region. As a pragmatic trial, no attempt will be made to standardize practices which may vary across professionals. Usual practices may be categorised as either reference to online websites deemed appropriate by their healthcare professional, general recommendations, referral for services, or none of the above.
89357731|NCT04254302|Experimental|Experimental|WECARE intervention include: 1) 30-minute appointments with an occupational therapist or a physiotherapist, as part of a multidisciplinary team, to problem-solve the child's motor performance issues, provide recommendations to stimulate the child's motor development, and intervene online directly with the child, if needed; offered bimonthly during the first three months, then on a patient-identified needs-basis. 2) A chat function where participants can privately contact the therapist; flexible access as per participant needs. 3) A forum open to all intervention group participants where they can communicate with each other or with the therapist, who will also act as a forum moderator; flexible access as per participant needs. 4) Access to static online information via relevant websites and resources on child development; flexible access based on participant needs.
89357732|NCT04778436|Experimental|T7082|After inclusion, the patients will consume an association of 4 food supplements including Nutrof Total.
89357733|NCT04718922|Experimental|Experimental Arm|Mouthrinse with 100 ml 0.12% chlorhexidine for 1 min
89357734|NCT04718922|No Intervention|Control Arm|No mouthrinse
89357735|NCT05344196|Experimental|Modified EAET for Prediabetes|Small groups of people with prediabetes will meet for 4, weekly, 2-hour sessions by telehealth, and will engage in modified EAET for prediabetes
89357736|NCT03722641|Placebo Comparator|Bread reference|A standardized (50 grams carbohydrates) breakfast meal will be provided based on bread.
89357737|NCT03722641|Experimental|Product 1: Milk|A standardized (50 grams carbohydrates) breakfast meal will be provided based on bread and a test product based on milk.
89357738|NCT03722641|Experimental|Product 2: Full fat milk + oat|A standardized (50 grams carbohydrates) breakfast meal will be provided based on bread and a test product based on full fat milk and oat with high fiber content.
89357739|NCT03722641|Experimental|Product 3: Skim milk + oat, high fibre|A standardized (50 grams carbohydrates) breakfast meal will be provided based on bread and a test product based on skim milk and oat with high fiber content.
89357740|NCT03722641|Experimental|Product 4: Skim milk + oat, low fibre|A standardized (50 grams carbohydrates) breakfast meal will be provided based on bread and a test product based on skim milk and oat with low fiber content.
89357741|NCT01303601|Experimental|olanzapine|
89357742|NCT01303601|Placebo Comparator|placebo|
88829294|NCT02271217|Active Comparator|dalfampridine-ER 7.5 mg|Subjects randomized 1:1:1 to receive either dalfampridine-ER 7.5mg, dalfampridine-ER 10mg, or matching placebo tablets taken twice daily 12 hours apart.
89357743|NCT01330992|Experimental|Ocular Light or Dark Exposure|Ocular Light or Dark Exposure
89357744|NCT00707980|Experimental|Vortioxetine|Vortioxetine 2.5 mg, 5 mg or 10 mg, encapsulated tablets, orally, once daily for up to 52 weeks. For the first week of treatment all participants received 5 mg/day vortioxetine, thereafter, the dose could be increased to 10 mg/day or decreased to 2.5 mg/day, based on participant's response and tolerability as judged by the investigator.
89357745|NCT03795935|Experimental|Treatment|Patients who were previously implanted with a traditional DBS lead and have subsequently developed stimulation induced side effects will gain significantly more tremor control without side effects when re-implanted with a directional DBS lead. We expect these patients' quality of life will improve. These patients typically will have had significant tremor relief (greater than 75% reduction from preoperative tremor rating scale) without side effects at their one year post operative follow-up. With the expected disease progression they will have had to increase their DBS stimulation to the degree that their DBS now causes side effects in order to block their tremor
88829295|NCT02271217|Active Comparator|dalfampridine-ER 10mg|Subjects randomized 1:1:1 to receive either dalfampridine-ER 7.5mg, dalfampridine-ER 10mg, or matching placebo tablets taken twice daily 12 hours apart.
88829296|NCT02989519|No Intervention|no progesterone|All women with preterm labor underwent standard tocolysis, which was administered for at least 48 hours, to allow corticosteroid promote fetal lung maturation
88829297|NCT02989519|Experimental|oral progesterone|All women with preterm labor underwent standard tocolysis, which was administered for at least 48 hours, to allow corticosteroid promote fetal lung maturation. All women in this arm received oral progesterone (dydrogesterone 10 mg; Duphaston™) per oral three times a day
88829298|NCT02989519|Experimental|vaginal progesterone|All women with preterm labor underwent standard tocolysis, which was administered for at least 48 hours, to allow corticosteroid promote fetal lung maturation. All women in this arm received vaginal progesterone (micronized progesterone 200 mg; Utrogestan™) at bed time.
89177784|NCT00826072||ALI|patients with acute lung injury at 24h after cardiac surgery
89177785|NCT00826072||Control|patients without acute lung injury 24h after cardiac surgery
89177786|NCT04110288||Uncoated Balloon Treatment|Patients treated for PAD with balloon angioplasty, without use of stent.
88829299|NCT02429375|Experimental|Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35)|Patients with relapsed or refractory Hodgkin lymphoma will receive brentuximab vedotin combined with mocetinostat. For the phase I portion of the study, patients will be enrolled in a traditional 3 + 3 phase 1 design on sequential dosing cohorts in order to determine the maximum tolerated dose (MTD) of mocetinostat when given with brentuximab vedotin. Once the MTD is determined, (up to) an additional 26 patients will be enrolled on to the phase II portion of the study at the MTD to determine the response rate and toxicity associated with treatment. The phase Ib and II study will include a lead-in with mocetinostat alone for 1 week followed by the combined treatment beginning day 15 following initiation of mocetinostat.
88829300|NCT02289456|Experimental|nab-Paclitaxel|"nab-Paclitaxel 100 mg/m2 intravenous (IV) infusion on Days 1 and 8 of each 21-day cycle~• Carboplatin AUC = 5 mg*min/mL IV on Day 1 of each 21-day cycle after completion of nab-paclitaxel infusion."
88829301|NCT02588573|Active Comparator|Etafilcon A (control)|Subjects in each of the habitual wearing groups will be randomized to wear either the test or control lens in either the left or right eye.
88829302|NCT02588573|Active Comparator|Somofilcon A (test)|Subjects in each of the habitual wearing groups will be randomized to wear either the test or control lens in either the left or right eye.
88829303|NCT01838785|Experimental|18F-DTBZ AV-133|18F-DTBZ AV-133 imaging
88829304|NCT02589977|Other|normal participants|"No cardiovascular abnormalities or diabetes. Estimated glomerular filtration rate (eGFR) >60.~Studies: Echocardiography for left ventricular function and LV diastolic performance; cardiac magnetic resonance (CMR) imaging using gadolinium for LV fibrosis and regadenoson for myocardial blood flow (MBF); positron-emission tomography (PET) using regadenoson for MBF and 11C-acetate for oxidative metabolism."
88829305|NCT02589977|Other|hypertensive participants|"No history of coronary artery disease or diabetes. Estimated glomerular filtration rate (eGFR) >60.~Studies: Echocardiography for left ventricular function and LV diastolic performance; cardiac magnetic resonance (CMR) imaging using gadolinium for LV fibrosis and regadenoson for myocardial blood flow (MBF); positron-emission tomography (PET) using regadenoson for MBF and 11C-acetate for oxidative metabolism."
88829306|NCT02589977|Other|HFpEF patients|"No history of coronary artery disease or diabetes. Estimated glomerular filtration rate (eGFR) >60.~Studies: Echocardiography for left ventricular function and LV diastolic performance; cardiac magnetic resonance (CMR) imaging using gadolinium for LV fibrosis and regadenoson for myocardial blood flow (MBF); positron-emission tomography (PET) using regadenoson for MBF and 11C-acetate for oxidative metabolism."
88829307|NCT02274948|Active Comparator|Metformin|8-10.99 year old children received metformin. Initially children given 250mg of metformin daily for a week and increased to 250mg twice daily for a week and then to 500 mg twice daily there after. 11-16 year old children received 500mg of metformin daily initially for one week which increased to 500mg twice daily for a week and then to 1g twice daily. The medication was continued for 12 months.
88829308|NCT02274948|Placebo Comparator|Placebo|"A placebo tablet which is physically similar to metformin tablets will be given in a similar manner as described above.~Metformin and placebo is manufactured by the State Pharmaceutical Manufacturing Corporation (SPMC)"
88829309|NCT01838863|Experimental|Plasma|If the patient is randomized to experimental arm, 2 units of frozen type AB plasma (FP24) will be thawed in the Plasmatherm Dry Thawing and Warming Device according to the operator manual as approved by the FDA in the ambulance and infusion will commence as soon as the type AB plasma is ready, and will continue during transport to the emergency department (ED). After infusion of 2 units of type AB plasma is completed, subsequent care will proceed per institutional, Advanced Trauma Life Support (ATLS) guided resuscitation with acute packed red blood cells (pRBC) administration determined by the hemodynamic response and additional blood component administration guided by rapid thrombelastography (rTEG) and coagulation panel assessment in conjunction with clinical scenario.
88829310|NCT01838863|Active Comparator|Standard|If the patient is randomized to the standard arm, the patient will be given intravenous crystalloid fluid (normal saline) as the initial resuscitation fluid with 2 large bore IVs based on the current ATLS guidelines, the standard of care. Subsequent care will proceed per institutional, ATLS guided resuscitation with acute packed red blood cells pRBC administration determined by the hemodynamic response and additional blood component administration guided by rTEG and coagulation panel assessment in conjunction with clinical scenario.
88829311|NCT05248451||Normal Renal Function|Patients undergoing inpatient non-cardiac surgery at St. Paul's Hospital with normal preoperative Estimated Glomerular Filtration Rate (eGFR) results. eGFR values considered will be from samples drawn within a one year period preceding surgery. Values from samples drawn within the 7 days immediately preceding surgery will be excluded, in order to avoid introducing bias from acute kidney injuries. All available eGFR values in the 7 to 365 days preceding an individual's surgery will be included, and the average of these values will be used as their preoperative eGFR. Investigators will include all people that have one or more measure. Depending on sample size, investigators may decide to limit inclusion to those that have two or more eGFR estimates.
89177787|NCT04110288||Bare Metal Stent Treatment|Patients treated for PAD with implantation of bare metal stent.
89177788|NCT04110288||Paclitaxel Coated Balloon|Patients treated for PAD with drug coated balloon angioplasty, without use of stent.
89357747|NCT05330468||Abbott Regent MHV|Subjects implanted with an Abbott Regent MHV replacement of the aortic valve.
89357748|NCT01304537|Experimental|Alpha-1 Antitrypsin 40mg (AAT, Glassia®)|Subjects in this arm will receive a dose of 40 mg/kg throughout the study.
89357749|NCT01304537|Experimental|Alpha-1 Antitrypsin 60mg (AAT, Glassia®)|Subjects in this arm will receive a dose of 60 mg/kg throughout the study.
89357750|NCT01304537|Experimental|Alpha-1 Antitrypsin 80mg (AAT, Glassia®)|Subjects in this arm will receive a dose of 80 mg/kg throughout the study.
89357751|NCT03506425|Experimental|Group 1|Standard care for 1 month, then standard care and Triheptanoin for 5 months.
89357752|NCT03506425|Experimental|Group 2|Standard care and Triheptanoin for 6 months.
89357753|NCT03506425|No Intervention|Group 3|Healthy controls for biomarkers
89357754|NCT03639259||Post-stroke fatigue|Participants fulfilling criteria for presence of fatigue after cerebral stroke
89357755|NCT02861183|Experimental|OVT (Sodium Hyaluronate)|Sodium hyaluronate is supplied as a 2 mL unit dose in a 3 mL glass syringe.
89357756|NCT02861183|Placebo Comparator|Saline|0.9% sterile saline is supplied as a 2 mL unit dose in a 3 mL glass syringe.
89357757|NCT05290454|Experimental|mNGS-guided treatment group|In mNGS-guided treatment group, participants undergo mNGS, using appropriate lower respiratory tract (LRT) specimen, and conventional microbiological diagnostic tests. LRT specimen, such as endotracheal aspiration (ETA), bronchoalveolar lavage fluid (BALF), or protected specimen brush (PSB), will be obtained within 24 hours after the participants entering the ICU. Conventional microbiology diagnostic techniques will be also applied using appropriate LRT specimens and other necessary specimens (such as blood, pleural fluid, urine, et al.). Clinicians alter or confirm the definitive treatment based on mNGS results, as well as results from conventional microbiology diagnostic techniques.
89357758|NCT05290454|No Intervention|Conventional treatment group|In conventional treatment group, participants undergo conventional microbiological tests using appropriate LRT specimen, and other necessary specimens (such as blood, pleural fluid, urine, et al.). LRT specimen, such as endotracheal aspiration (ETA), bronchoalveolar lavage fluid (BALF), or protected specimen brush (PSB), will be obtained within 24 hours after the participants entering the ICU. Based on results of conventional microbiology diagnostic techniques, clinicians alter or confirm the definitive treatment of participants.
89357759|NCT03803189|Experimental|Personalized eToolkit|The intervention arm will receive a personalized eToolkit with community and electronic supports each time they complete a survey, and their PCP will receive supports in the EMR to facilitate postpartum mental healthcare.
89357760|NCT03803189|No Intervention|Usual care|The control arm will not receive intervention materials, unless they express suicidality, in which case they will receive a message with supports for suicidality including local emergency departments and crisis lines and an urgent message via EMR and fax will be sent to their PCP. Control arm participants will be asked to complete a baseline e-survey in their third trimester, and a follow-up e-survey 24-weeks after their baby is born.
89357761|NCT05050760|Experimental|The experimental group|Drug：DCF+Camrelizumab Camrelizumab:200mg/time,IV,Q3W
89357762|NCT02498002|Active Comparator|Daily Calorie Restriction (DCR)|During the intervention phase, participants randomised to this treatment condition will be asked to reduce their normal energy intake by 25% on a daily basis.
89357763|NCT02498002|Experimental|Fasting with Weight Loss (IMF-WL)|During the intervention phase, participants randomised to this treatment condition will be asked to alternate between 24 hour cycles of feeding (consume 150% of normal energy intake) and fasting (no energy intake).
89357764|NCT02498002|Experimental|Fasting without Weight Loss (IMF-WS)|During the intervention phase, participants randomised to this treatment condition will be asked to alternate between 24 hour cycles of feeding (consume 200% of normal energy intake) and fasting (no energy intake).
89357765|NCT03810209|Active Comparator|magnesium sulphate group|The investigator injected 28.5 mL of bupivacaine 0.5% and 1.5 ml MgSo4 (150 mg), a total volume of 30 ml, it was confirmed visually by the ultrasound.
89357766|NCT03810209|Placebo Comparator|control group|The investigator injected 28.5 mL of Bupivacaine 0.5% and 1.5 mL of normal saline, a total volume of 30 ml, it was confirmed visually by the ultrasound.
89177789|NCT04110288||Paclitaxel Eluting Stent|Patients treated for PAD with implantation of Paclitaxel DES.
89357767|NCT03053492|Experimental|Duck Duck Punch|Subjects in this arm will engage in Duck Duck Punch Play, a custom designed computer game developed for stroke rehabilitation for 6 weeks.
89357768|NCT03053492|Active Comparator|Commercially Available Game|Subjects in this arm will engage in a Commercially Available Game Play off-the-shelf computer game for 6 weeks.
89357769|NCT02497846|Experimental|TEOSYAL® PureSense Redensity [I]/MicronJet®|"injection of the acid hyaluronic gel with lidocaine as an anesthetic and a dermo-restructuring complex (including 8 amino acids , 3 antioxidants Acid, vitamin B6 and 2 minerals).~Product will be injected in a unique device group:~in crow's feet in order to cover the zone to be treated. Quantity of product injected will be determined by the injector and noted (up to 1 ml by side). A subject can be injected in the left or/and right side.~using a MicronJet microneedle for the superficial wrinkles."
89357770|NCT04630925|Active Comparator|isCGM-arm|CGM data will be viewed real-time and used to adjust diabetes treatment
89357771|NCT04630925|No Intervention|POC-arm|POC glucose readings are used to adjust diabetes treatment. CGM data are blinded to all and only gathered for comparison purposes to intervention group.
89357772|NCT03330340||Percutaneous vertebroplasty|All PVPs are performed by experienced spine surgeons under optimal fluoroscopic guidance. The procedure takes place under sterile conditions. Local anesthesia is administered to the periosteum of the targeted pedicle via skin. Polymethylmethacrylate bone cement is injected under continuous fluoroscopic guidance using 1.0 ml syringes and 13 Gauge bone biopsy needles by bilateral procedures. Patients are encouraged to stand up and walk with brace immediately after operation and the brace are required to be worn for 3 months. Furthermore, all patients will take oral bisphosphonates treatment together with supplemental calcium and vitamin D.
89357773|NCT03330340||Conservative treatment|In conservative treatment group, the patients were required horizontal bed rest for the initial 2 weeks after diagnosis. Then, they were encouraged to stand up and walk with brace and assistance. The bed rest time was extended if the back pain worsened when they stood up and walked. The brace should be worn in 3 months. For pain medication, nonsteroidal anti-inflammatory drugs (NSAIDs) were prescribed for every patient. Additional analgesics, such as tramadol and morphine, would be added in case NSAIDs were not effective. Two weeks after diagnosis, physical therapy was started. All patients are put on osteoporosis medication, bisphosphonates together with supplemental calcium and vitamin D.
89357774|NCT05585879|Other|Pure-Vu EVS|"Rate of incomplete colonoscopies due to inadequate preparation salvaged to adequate colonoscopies with the use of the Pure-Vu EVS System.~Inadequate OCs defined as such if any of the following are met:~BBPS < 6 (Adequacy is defined as BBPS of 2 or greater in each segment)~Inability to identify > 5mm polyps The estimated rate of salvaged preparations will be calculated and presented with exact one-sided 95% confidence interval: Number of preps inadequate with SOC and adequate after Pure-VU EVS System / Number of preps inadequate with SOC.~The lower bound will be compared to a 35% performance goal."
89357775|NCT04186988|Experimental|Diagnostic ([18F]-AraG)|Patients receive [18F]-AraG IV and then undergo PET/CT over 2 hours at baseline and within 2 weeks after starting immunotherapy. Patients may also undergo blood sample collection.
89357776|NCT02491294|Experimental|School Only|Students whose schools are randomized to this condition only receive the classroom, cafeteria and SPARK active recess components
89357777|NCT02491294|Experimental|School + Family|Students whose schools are randomized to this condition receive the classroom, cafeteria and SPARK active recess components and the family component (family nights, parent blog and action packs)
89357778|NCT02491294|Experimental|School + About Eating|Students whose schools are randomized to this condition only receive the classroom, cafeteria and SPARK active recess components and their parents are invited to participate in the online 6 lesson About Eating program.
89357779|NCT02491294|Experimental|School + Family + About Eating|students whose schools are randomized to this condition receive the classroom, cafeteria and SPARK active recess components and the family component (family nights, parent blog and action packs) and their parents are invited to participate in the online 6 lesson About Eating program.
89357780|NCT02491294|No Intervention|Control|students and their parents in all schools during cohort 1 and 4 (and Ponderosa students in cohort 3) are tested but provided no intervention
89357781|NCT03337282||Observational cohort|Adults 70 years of age or older undergoing major noncardiac surgery under protocolized general anesthesia
89357782|NCT03801707|Experimental|Intervention group|kidney transplant recipients who receive kidney allograft from hepatitis C viremic donors followed by treatment with direct acting antiviral therapies.
89177790|NCT00826306|Experimental|Video-based education arm|Subjects receiving the video-based educational material
89357783|NCT03337204|Experimental|Engaged4Life|"Participants randomly assigned to this group receive: 1) technology-assisted self-monitoring of daily activity via a Fitbit Zip worn daily (for 8 weeks) and a daily tablet self-report survey (completed for a 7-day period at baseline and a second 7-day period 4-weeks later); and 2) a one-time, 3hr workshop and peer mentoring (via phone 2X/week for 3 weeks). The workshop includes psychoeducation on the relationship between active engagement and health and well-being and a goal setting activity focused on carefully assessing and then make improvements upon existing activity portfolios. Peer mentors provide support as participants implement their goals."
89357784|NCT03337204|Active Comparator|Technology-assisted self-monitoring only|Participants randomly assigned to this group receive: 1) technology-assisted self-monitoring of daily activity via a Fitbit Zip worn daily (for 8 weeks) and a daily tablet self-report survey (completed for a 7-day period at baseline and a second 7-day period 4-weeks later). While it is expected that wearing the Fitbit and raising consciousness of activity engagement may initially result in behavior change, it is not expected to have a sustained impact on outcomes over time.
89357785|NCT03330184|Experimental|Berberine Hydrochloride group|2/day, 16 weeks
89357786|NCT03330184|Experimental|Bifidobacterium group|2/day, 16 weeks
89357787|NCT03330184|Experimental|Berberine Hydrochloride and Bifidobacterium group|2/day, 16 weeks
89357788|NCT03330184|Placebo Comparator|placebo|bifidobacterium mimetic capsules berberine mimetic tablets,2/day, 16 weeks
89357789|NCT04117490|Active Comparator|Epiitalis low dose|Two capsules twice daily 30 mins before meals (breakfast & dinner).
89357790|NCT04117490|Active Comparator|Epiitalis mid dose|Two capsules twice daily 30 mins before meals (breakfast & dinner).
89357791|NCT04117490|Active Comparator|Epiitalis high dose|Two capsules twice daily 30 mins before meals (breakfast & dinner).
89177791|NCT00826306|Active Comparator|Written education arm|Subjects receiving the written educational material
89177792|NCT04832360|Experimental|Control (CTL)|Participants do not receive financial incentive intervention
89177793|NCT04832360|Experimental|Single Target (ST)|One member of each dyadic-smoking couple will receive financial incentive intervention
89177794|NCT04832360|Experimental|Dyadic Target (DT)|Both members of each dyadic-smoking couple will receive financial incentive intervention
89357792|NCT04117490|Placebo Comparator|Placebo|Two capsules twice daily 30 mins before meals (breakfast & dinner).
89534219|NCT03942770|Active Comparator|Active Comparator: Group A (Intensive incentives)|"Group A will have the opportunity to earn payments based on the results of their breathalyzer screens. Participants will receive a compliance incentive per submitted sample regardless of the results, but will also have the opportunity to earn more incentives for providing negative results. For the first 3 weeks, these additional incentives will scale based on the number of consecutive days of sustained negative samples. For the remaining weeks incentives will be based on a randomized prize drawing."
89357793|NCT03795779|Experimental|CLL1-CD33 cCAR T cells|CLL1-CD33cCAR T cells transduced with a lentiviral vector to express two distinct units of anti-CLL1 and CD33 CARs
89177795|NCT04025502||Healthy Volunteer Subjects (HV)|"Male and female subjects 21-50 years of age, who are in good and stable health with no history or evidence of clinically relevant medical or neuropsychiatric illness.~Healthy Volunteer Subjects will undergo Event-Related Potential (ERP)/electroencephalogram (EEG) testing with the COGNISION® System."
89177796|NCT04025502||Subjects with Schizophrenia (SZ)|"Otherwise healthy male and female subjects 21-50 years of age, who have a current diagnosis of Schizophrenia with a duration of illness greater than or equal to one year.~Subjects with Schizophrenia (SZ) will undergo Event-Related Potential (ERP)/electroencephalogram (EEG) testing with the COGNISION® System."
89357794|NCT03329872||Patients group|Patients follow-up in hospital will have data collection
89357795|NCT04239872|Experimental|Fluoride mouthwash alone, then Calcium mouthwash before a fluoride mouthwash|Participants with normal to dry mouth will first test a Fluoride mouthwash containing 226 ppm of fluoride, and fluoride concentration in saliva and dental biofilm will be assessed overtime for up to 2 hours. After a washout period of at least 3 days, they will then test a Calcium mouthwash (150 milimolars of calcium) immediately before the Fluoride mouthwash, and fluoride concentration in saliva and dental biofilm will be assessed overtime for up to 2 hours.
89534220|NCT03942770|Active Comparator|Active Comparator: Group B (Prize-based incentives)|"Group B will have the opportunity to earn payments based on the results of their breathalyzer screens. Participants will receive a compliance incentive per submitted sample regardless of the results, but will only have the opportunity to earn more incentives based on a randomized prize drawing if they submit a negative sample."
88829312|NCT05248451||Renal Dysfunction, Chronic Kidney Disease (CKD)|Patients undergoing non-cardiac surgery with abnormal preoperative Estimated Glomerular Filtration Rate (eGFR). eGFR values considered will be from samples drawn within a one year period preceding surgery. Values from samples drawn within the 7 days immediately preceding surgery will be excluded, in order to avoid introducing bias from acute kidney injuries. All available eGFR values in the 7 to 365 days preceding an individual's surgery will be included, and the average of these values will be used as their preoperative eGFR. Investigators will include all people that have one or more measure. Depending on sample size, investigators may decide to limit inclusion to those that have two or more eGFR estimates. As eGFR is not accurate in the setting of dialysis, patients receiving dialysis for at least 90 days prior to their surgical procedure will also be included as a separate eGFR category.
88829313|NCT02274792|Experimental|Etanercept|Participants received etanercept 50 mg subcutaneously twice a week (BIW) for 12 weeks followed by 50 mg once a week for an additional 12 weeks.
88829314|NCT05248217|Other|healthcare workers|doctors, nurses, medical secretaries, security guards, and cleaning staff
88829315|NCT02591537|Experimental|OxyGenesys Dissolved Oxygen Dressing|OxyGenesys Dissolved Oxygen Dressing will be applied.
88829316|NCT02591537|No Intervention|Standard Tegaderm Dressing|Tegaderm will be applied.
88829317|NCT05649930||Spastic paresis|Children with spastic paresis
88829318|NCT02592629|Active Comparator|no topical or subcutaneous anesthetic|Injection of 1 ml of 40 mg Kenalog combined with 4 ml of 1% lidocaine
89357796|NCT04239872|Experimental|Calcium mouthwash before a fluoride mouthwash, then Fluoride mouthwash alone|Participants with normal to dry mouth will first test a Calcium mouthwash (150 milimolars of calcium) immediately before a Fluoride mouthwash containing 226 ppm of fluoride, and fluoride concentration in saliva and dental biofilm will be assessed overtime for up to 2 hours. After a washout period of at least 3 days, they will then test the Fluoride mouthwash alone, and fluoride concentration in saliva and dental biofilm will be assessed overtime for up to 2 hours.
89357797|NCT03164772|Experimental|Arm A: BI 1361849 mRNA Vaccine + durvalumab|"The BI 1361849 mRNA vaccine comprises 6 drug product components (F2408 coding for MUC1, F2409 coding for survivin, F2410 coding for NY-ESO-1, F2624 coding for 5T4, F2625 coding for MAGE-C2, and F2626 coding for MAGE-C1), which were provided and administered separately; each component was administered twice, thus there were 12 intradermal administrations of 100 µL (80 µg) each for each dose. The PharmaJet Tropis® device was used for the administration of the BI 1361849 components.~Durvalumab 1500 mg was to be administered as an intravenous (IV) infusion every 4 weeks for 12 cycles; BI 1361849 was to be administered as 14 doses over the 12 cycles."
89534221|NCT03942770|Sham Comparator|Sham Comparator: Group C (Intensive incentives)|Group C serves as a direct control group to Group A and will follow the same incentive procedures, however participants will receive incentives regardless of the results of their samples.
89534222|NCT03942770|Sham Comparator|Sham Comparator: Group D (Price-based incentives)|Group D serves as a direct control group to Group B and will follow the same incentive procedures, however participants will receive incentives regardless of the results of their samples.
88829319|NCT02592629|Active Comparator|subcutaneous lidocaine|Injection of 1 ml of 40 mg Kenalog combined with 4 ml of 1% lidocaine after 2 ml or 1% lidocaine by subcutaneous injection
89177797|NCT04107714|Experimental|Intervention (STC)|"Study participants randomized to the experimental group receive the intervention (STC). STC is a peer-led and web-based group intervention containing four two-hour sessions within four weeks plus an additional booster session one month later.~Fidelity to manual is rated in each session by study staff."
89177798|NCT04107714|No Intervention|No intervention|Participants randomized to the control group do not receive the group program but get the accompanying workbook at the end of the study.
89177799|NCT05753852|Experimental|Active treatment|
89534223|NCT03942770|No Intervention|No Intervention: Group E (no incentives)|Group E will have no monitoring intervention, they will only complete assessment sessions.
89534224|NCT03935217|Experimental|Solosec (containing 2 grams of secnidazole)|Orally administered as a single dose with applesauce.
89534225|NCT03935217|Placebo Comparator|Placebo|Orally administered as a single dose with applesauce.
89534226|NCT03916341|Experimental|Non-user|Non- users will use, in a randomized, crossover fashion with a 4 week washout, an 1) EC with nicotine, 2) EC without nicotine, and 3) an empty EC (control)
88829320|NCT02592629|Active Comparator|topical ethyl chloride|Injection of 1 ml of 40 mg Kenalog combined with 4 ml of 1% lidocaine after applying ethyl chloride spray for 3 seconds
88829321|NCT05247983||experimental group|"Tension-free repair of inguinal hernia with Undissociate Spermatic cord"
89534227|NCT03916341|Experimental|Chronic EC user|Chronic EC users will use, in a randomized, crossover fashion with a 4 week washout, an 1) EC with nicotine, 2) EC without nicotine, and 3) an empty EC (control)
88829322|NCT05247983||control group|Tension-free repair of inguinal hernia with traditional method
88829323|NCT05372471|Other|mHealth|Intervention group (mHealth platform users).
88829324|NCT05372471|Other|Control|Usual Care
88829325|NCT02274558|Experimental|NBI-98854 40 mg|NBI-98854 administered as one (1) 40 mg capsule and one (1) placebo capsule, taken by mouth, every morning between 7:00am - 10:00am for 6 weeks. At the end of Week 6, subjects will enter a double-blind NBI-98854 treatment period and continue with their current dose.
88829326|NCT02274558|Experimental|NBI-98854 80 mg|Subjects randomized to the NBI-98854 80 mg dose will receive NBI-98854 40 mg for the first week (administered as one (1) 40 mg capsule and one (1) placebo capsule), followed by NBI-98854 80 mg administered as two (2) 40 mg capsules, taken by mouth, every morning between 7:00am - 10:00am for 5 weeks. At the end of Week 6, subjects will enter a double-blind NBI-98854 treatment period and continue with their current dose.
88829327|NCT02274558|Experimental|Placebo|Placebo administered as two (2) placebo capsules, taken by mouth, every morning between 7:00am - 10:00am for 6 weeks. At the end of Week 6, subjects will enter a double-blind NBI-98854 treatment period and be randomized to either a 40 mg or 80 mg dose. Subjects re-randomized to receive NBI-98854 80 mg will receive 40 mg for the first week.
88829328|NCT05247749|Experimental|Convivo Imaging|The brain area that the operating surgeon plans to resect will be scanned using the CONVIVO device
88829329|NCT05247671||Case|All eligible patients will be recruited to the study and will be assessed for SNPs in both ERCC1 and OCT2 and their association with cisplatin-induced nephrotoxicity through the measurement of cystatin C before taking cisplatin and after receiving the second cycle of cisplatin.
88829330|NCT05247515|Experimental|Treated group: Nexpowder application on the scar after EMR with coagulation of visible vessels|To compare of the risk of bleeding after EMR application of nexpower (not a drug but a device with CE mark) on the resect area (scar) to cover the whole surface of mucosal resection.
88829331|NCT05247515|No Intervention|standard procedure : EMR with coagulation of visible vessels|After EMR with coagulation of visible vessels, if the patient is randomized in the comparative group, not nexpowder will be applied on the scar (common practice)
88829332|NCT00284063|Active Comparator|Group 1: N; SPP; N|N = neutral MRI; SP = side posture MRI; SPP = side posture position; SMT = side posture manipulation
88829333|NCT00284063|Active Comparator|Group 2: N; SMT; N|N = neutral MRI; SP = side posture MRI; SPP = side posture position; SMT = side posture manipulation
88829334|NCT00284063|Active Comparator|Group 3: N; SMT; SP|N = neutral MRI; SP = side posture MRI; SPP = side posture position; SMT = side posture manipulation
88829335|NCT00284063|No Intervention|Group 4: N and SP|N = neutral MRI SP = side posture MRI SPP = side posture position SMT = side posture manipulation
88829336|NCT02595983|Experimental|All Patients|All patients who received at least 1 dose of revusiran (ALN-TTRSC)
88829337|NCT02287896|Experimental|Roledumab Open-label IM|"- Planned antenatal prophylaxis: A single dose of 300 µg IM of Roledumab at 28 or 29 weeks of gestation.~- Antenatal prophylaxis following sensitizing events: One or more dose(s) of 300μg IM anti-RhD antibodies (Rhophylac or Roledumab) based on the Kleihauer-test as soon as possible and no later than 72 hours after event occurrence.~- Postnatal prophylaxis: Roledumab should be administered to the mother as soon as possible within 72 hours of delivery of an RhD positive infant.~The postnatal dose must still be given even when antenatal prophylaxis has been administered.~Before Roledumab 300μg IM postnatal administration, a Kleihauer-Betke test will be performed on maternal blood sample taken no earlier than 30 min after delivery in order to determine the volume of foetomaternal hemorrhage (FMH)."
88829338|NCT02287896|Experimental|Roledumab Open-label IV|"- Planned antenatal prophylaxis: A single dose of 300 µg IV of Roledumab at 28 or 29 weeks of gestation.~- Antenatal prophylaxis following sensitizing events: One or more dose(s) of 300μg IV anti-RhD antibodies (Rhophylac or Roledumab) based on the Kleihauer-test as soon as possible and no later than 72 hours after event occurrence.~- Postnatal prophylaxis: Roledumab should be administered to the mother as soon as possible within 72 hours of delivery of an RhD positive infant.~The postnatal dose must still be given even when antenatal prophylaxis has been administered.~Before Roledumab 300μg IV postnatal administration, a Kleihauer-Betke test will be performed on maternal blood sample taken no earlier than 30 min after delivery in order to determine the volume of foetomaternal hemorrhage (FMH)."
88829339|NCT02596451|Experimental|Diclofenac Sodium gel, 1%|apply gel to the target knee
88829340|NCT02596451|Active Comparator|Voltaren® Gel|apply gel to the target knee
88829341|NCT02596451|Placebo Comparator|Placebo|apply gel to the target knee
88829342|NCT01839799|Experimental|Arm 1 - FOLFIRINOX|"FOLFIRINOX:~Irinotecan 180 mg/m2 Day 1 Oxaliplatin 85 mg/m2 Day 1 5-FU 400 mg/m2 bolus with Leucovorin 200 mg/m2 over 2h, Day 1, then 5-FU 2400 mg/m2 over 46h. Four cycles over 8 weeks~Chemoradiation:~Radiation to begin no sooner than 28 days from last day of chemotherapy.~On Day 1(+ 2days to accommodate scheduling difficulties):~Infusional 5-FU (225 mg/m2 continuous infusion during radiation) and radiation therapy as defined.~FOLFIRINOX:~Irinotecan 180 mg/m2 Day 1 Oxaliplatin 85 mg/m2 Day 1 5-FU 400 mg/m2 bolus with Leucovorin 200 mg/m2 over 2h, Day 1, then 5-FU 2400 mg/m2 over 46h. Four cycles, if tolerated"
88829343|NCT01839799|Experimental|Arm 2 - Gemcitabine / Abraxane|"Gemcitabine / Abraxane Gemcitabine 1000 mg/m2 Days 1, 8, 15 Abraxane 125 mg/m2 Days 1, 8, 15 Two cycles over 8 weeks~Chemoradiation:~Radiation to begin no sooner than 28 days from last day of chemotherapy. On Day 1 (+ 2days to accommodate scheduling difficulties) Infusional 5-FU (225 mg/m2 continuous infusion during radiation) and radiation therapy as defined.~Gemcitabine / Abraxane Gemcitabine 1000 mg/m2 Days 1, 8, 15 Abraxane 125 mg/m2 Days 1, 8, 15 Two cycles, if tolerated"
89177800|NCT00847613|Experimental|Sequence 1|
89534228|NCT03916341|Experimental|Chronic TC smoker|Chronic TC smokers will use, in a randomized, crossover fashion with a 4 week washout, a 1) TC with nicotine (own brand), 2) research TC with very low level nicotine, and 3) a straw (control)
89534229|NCT03916068|Experimental|Hyperbaric Oxygen Therapy|Hyperbaric oxygen (HBO2) - 100% oxygen at 2.4 atmospheres ATA for 90 minutes, Monday-Friday for 30 sessions (six weeks)
89000696|NCT04656457|Active Comparator|aerobic exercise|Aerobic training (AT) program of submaximal intensity will include a 45-minute session five times per week under the supervision of the researcher. Aerobic exercise will consist of three phases: warm-up, training and cool down. At the beginning of exercise session, subjects will have a ten-minute warm-up. The warm up protocol will be slowly running on treadmill. Then, the warm-up phase will be followed by the training phase. At baseline, the training phase will be commenced with two 30- minute running on treadmill at 50% of their maximal heart rate (MHR) in the first week and increased to 70% MHR by the final week of training. By the end of exercise session, subjects will have a five-minute cool down. The cool down protocol will be slowly running on treadmill. The vital measures such as HR and blood pressure was monitored before patient left the department (Dimeo et al.,2016), maximum heart rate will be calculated using the formula: (HR Max =220- age)
89000697|NCT04656613|Experimental|Vaccine|a study group of 750 subjects receiving the Gam-COVID-Vac combined vector vaccine against the SARS-СoV-2-induced coronavirus infection
89000698|NCT04656613|Placebo Comparator|Placebo|a reference group of 250 subjects receiving placebo
89000699|NCT04656769||PERI group|
89000700|NCT04656769||EV group|
89000701|NCT04656574|Experimental|Experimental Group|Experimental group received the course explaining vaginal delivery for the first timethat used simulation-based training.
89000702|NCT04656574|No Intervention|Control Group|Control group received the course explaining vaginal delivery for the first time
89000703|NCT00205335|Other|glucose monitoring|Each participant received a Bayer Breeze Monitor and glucose test strips for monitoring blood sugar.
89000704|NCT04656340|Active Comparator|Standard rehabilitative care (SC)|Twice weekly physical therapy, occupational therapy and pain psychoeducation
89000705|NCT04656340|Experimental|Complementary and Integrative Health (CIH) therapies in addition to Standard rehabilitate care (SC)|Twice weekly chiropractic, acupuncture, yoga and foam roller instruction, in addition to SC
89000706|NCT04655989|Experimental|Routine first|Group A subjects will be assigned to 4 weeks of routine dialysis (control group) followed by 4 weeks of treatment dialysis with the DBB-EXA ES Hemodialysis System (investigational group).
89000707|NCT04655989|Experimental|Investigational first|Group B subjects will be assigned to 4 weeks of treatment dialysis with the DBB-EXA ES Hemodialysis System (investigational group) followed by 4 weeks of routine dialysis (control group).
89000708|NCT04655989|Other|VARRM sub-study|Following completion of the initial 8-week treatment, subject's were eligible to participate in the sub-study, VARRM. The total participation time for the VARRM sub-study was approximately 1.5 weeks.
89000709|NCT04656106||Ryzodeg|Patients treated with any basal-insulin or premix-insulin for at least 26 weeks prior to switching to Ryzodeg® and treated for at least 26 weeks after switching to Ryzodeg®.
89000710|NCT04656262|Experimental|Metronomic cyclophosphamide|Cyclophosphamide 50 mg daily per os continuously; Patients will be visited for re-cycling every three weeks. Metronomic cyclophosphamide will be taken in the morning along with a full glass of water.
89000711|NCT04656262|Active Comparator|Doxorubicin|Doxorubicin 60 mg/mq i.v. in 10 minutes, day 1; to be repeated every three weeks up to a maximum of 6 cycles.
89000712|NCT04655872|Experimental|[14C]TPN171H|
89000713|NCT04655677|Experimental|Autologous EXP039 administered by intravenous (IV) infusion|Autologous EXP039 administered by intravenous (IV) infusion
89000714|NCT04655560||Women living with HIV|
89000715|NCT02962635||Hemodialysis patients|"A total of 30 patients~- measuring volume status by bioelectrical impedance measurement as well as clinical evaluation and comparing with the novel biomarker"
89000716|NCT02962635||Peritoneal dialysis patients|"A total of 15 patients~- measuring volume status by bioelectrical impedance measurement as well as clinical evaluation and comparing with the novel biomarker"
89000717|NCT04655794||had >= grade 2 adverse reactions|
89000718|NCT04655794||had <2 frade 2 adverse reactions|
89000719|NCT04655443||Control Group|"Patients will be scheduled for an electrocardiogram thirty days after their electrical cardioversion. Based on the electrocardiogram result, patients that maintained sinus rhythm will be assigned to Control."
89000720|NCT04655443||Afib Group|"Patients will be scheduled for an electrocardiogram thirty days after their electrical cardioversion. Based on the electrocardiogram result, patients that developed persistent atrial fibrillation will be assigned to Afib."
89000721|NCT04655209|Experimental|M1-Seq group|
89534230|NCT03916068|Active Comparator|Trental and Vitamin E|Trental (pentoxifylline), 400 milligrams three times a day in combination with Vitamin E, 400 international units orally twice daily for six months
89534231|NCT03905876|Other|assessment of psychological experience|Questionnaire
89000722|NCT04655209|Experimental|PMC-Seq group|
89000723|NCT04655209|Sham Comparator|MT with sham tDCS|
89000724|NCT04655131|Active Comparator|Protein consumption : 0 gm|Participant's glucose levels are monitored from hour 0 to hour 5 after consumption of 0 gm of whey protein isolate
89000725|NCT04655131|Experimental|Protein consumption : 12.5 gm|Participant's glucose levels are monitored from hour 0 to hour 5 after consumption of 12.5 gm of whey protein isolate
89000726|NCT04655131|Experimental|Protein consumption : 25 gm|Participant's glucose levels are monitored from hour 0 to hour 5 after consumption of 25 gm of whey protein isolate
89000727|NCT04655131|Experimental|Protein consumption :37.5 gm|Participant's glucose levels are monitored from hour 0 to hour 5 after consumption of 37.5 gm of whey protein isolate
89000728|NCT04655131|Experimental|Protein consumption : 50 gm|Participant's glucose levels are monitored from hour 0 to hour 5 after consumption of 50 gm of whey protein isolate
89000729|NCT04655131|Experimental|Protein consumption : 62.5 gm|Participant's glucose levels are monitored from hour 0 to hour 5 after consumption of 62.5 gm of whey protein isolate
89000730|NCT04655014|Experimental|High Intensity Circuit Training|The High Intensity Circuit Training comprises of 7 full body exercises as per recommendation of ACSM Where the participants shall be given total of 18 sessions of their respective protocol, comprising of 20 minutes, 3 times/ week for duration of six weeks
89000731|NCT04655599|Experimental|Olorinab, Then Placebo|Participants will first receive olorinab, followed by a washout period, and they then will receive placebo.
89000732|NCT04655599|Placebo Comparator|Placebo, Then Olorinab|Participants will first receive placebo, followed by a washout period, and they then will receive olorinab.
88829344|NCT03062059|Placebo Comparator|Normal saline|Intravesical 52.6ml normal saline instillation during radical nephroureterectomy followed by normal saline bladder irrigation
88829345|NCT03062059|Experimental|Gemcitabine|Intravesical 2000mg/52.6ml gemcitabine instillation during radical nephroureterectomy followed by normal saline bladder irrigation
88829346|NCT02597543|Experimental|Nonspecific allograft dysfunction|Patients with nonspecific allograft dysfunction will undergo stress cardiac MRI with regadenoson in addition to performing late gadolinium enhancement and obtaining mean segmental T1 values of the heart.
88829347|NCT02597543|Experimental|Normal graft function|Patients with normal graft function will undergo stress cardiac MRI with regadenoson in addition to performing late gadolinium enhancement and obtaining mean segmental T1 values of the heart.
88829348|NCT02598089|Experimental|Trivalent Seasonal Influenza Vaccine|"0.5 mL of seasonal trivalent influenza vaccine with 15 mcg of HA of each of 3 strains:~NYMC BX-51B reassortant of B/Massachusetts/2/2012~NYMC X-179A reassortant of A/California/7/2009 (H1N1)~NYMC X-223A reassortant of H3/A/Texas/50/2012 (H3N2)"
88829349|NCT02598089|Placebo Comparator|Placebo|This is the placebo comparator: 0.5 mL of Phosphate Buffered Saline
88829350|NCT05371769|Sham Comparator|Control group|The students in the control group will be given a pre-test, and two weeks later, the post-test will be applied. After the chronic pain education group completes the research, the chronic pain education program will be opened to the students in the control group, too.
88829351|NCT05371769|Experimental|Chronic pain education group|The pre-test will be opened to the students in the chronic pain education group simultaneously with the opening of the post-tests for the control group.After the students in the chronic pain education group completed the pre-test, the chronic pain management training program developed for nursing students will be applied for 2 weeks. Post test will be applied at the end of all training videos and evaluation questions.
88829352|NCT00553501|Experimental|Epratuzumab Plus Rituximab|"Induction Therapy (Month 1): Epratuzumab 360 mg/m^2 by IV days 1, 8, 15 & 22; Rituximab 375 mg/m^2 by IV day 3, 8, 15 & 22~Extended Induction (Weeks 12, 20, 28 & 36) Epratuzumab 360 mg/m^2 by IV weeks 12, 20, 28 & 36; Rituximab 375 mg/m^2 by IV weeks 12, 20, 28 & 36"
88829353|NCT02599649|Experimental|Low or Intermediate-1 MDS Group - Lirilumab|Lirilumab by vein over about 60 minutes 1 time each 28 day cycle.
88829354|NCT02599649|Experimental|Low or Intermediate-1 MDS Group - Nivolumab + Lirilumab|Nivolumab by vein over about 60 minutes every 2 weeks during Cycles 1-9. Lirilumab by vein over about 60 minutes 1 time each cycle. Cycle is 28 days.
88829355|NCT02599649|Experimental|High Risk MDS Group - Azacitidine + Lirilumab|Azacitidine by vein over about 60 minutes on Days 1-7 of each 28 day cycle. Lirilumab by vein over about 60 minutes on Day 7 of each 28 day cycle.
88829356|NCT02599649|Experimental|High Risk MDS Group - Azacitidine + Lirilumab + Nivolumab|Azacitidine by vein over about 60 minutes on Days 1-7 of each 28 day cycle. Lirilumab by vein over about 60 minutes on Day 7 of each 28 day cycle. On Days 7 and 21 of Cycles 1-9 and then on Day 7 of Cycles 10 and beyond, Nivolumab by vein over about 60 minutes.
88829357|NCT01840345|Experimental|N-acetyl-L-cysteine|n-acetyl-l-cysteine 1200 mg BID x 4 weeks
88829358|NCT02287584|Placebo Comparator|DSP-5423P Placebo|Percutaneous DSP-5423P Placebo was applied once daily for 6 weeks during the double-blinded treatment phase. Subjects who completed the double-blind treatment phase were able to entere the open-label treatment phase. The study drug was applied to the back, chest, or abdomen.
88829359|NCT02287584|Experimental|DSP-5423P 40mg|Percutaneous DSP-5423P 40mg was applied once daily for 6 weeks during the double-blinded treatment phase. Subjects who completed the double-blind treatment phase were able to entere the open-label treatment phase. The study drug was applied to the back, chest, or abdomen.
88829360|NCT02287584|Experimental|DSP-5423P 80mg|Percutaneous DSP-5423P 80mg was applied once daily for 6 weeks during the double-blinded treatment phase. Subjects who completed the double-blind treatment phase were able to entere the open-label treatment phase. The study drug was applied to the back, chest, or abdomen.
88829361|NCT02287584|Experimental|DSP-5423P Placebo-to-Flex|Percutaneous Subjects received DSP-5423P Placebo once daily for 6 weeks in the double-blind treatment phase. In the open-label treatment phase, DSP-5423P was applied as flexible dose (40, 60, or 80 mg) once daily for 28 weeks (outside Japan) or 52 weeks (in Japan). The study drug was applied to the back, chest, or abdomen.
88829362|NCT02287584|Experimental|DSP-5423P Active-to-Flex|Percutaneous Subjects received DSP-5423P 40mg or 80mg once daily for 6 weeks in the double-blind treatment phase. In the open-label treatment phase, DSP-5423P was applied as flexible dose (40, 60, or 80 mg) once daily for 28 weeks (outside Japan) or 52 weeks (in Japan). The study drug was applied to the back, chest, or abdomen.
88829363|NCT05654909||PAU group|The PAU group were patients calling 1-1-2 assigned for the prehospital assessment unit,
88829364|NCT05654909||non PAU group|The non PAU group were selected from the 1-1-2 calls (the European version of 9-1-1) EMS and were collected based on the same criteria as the patients assessed by the PAU. The control ratio was 1:10 for cases to increase power. Controls were matched on sex and age (within 5-year ranges). Matching was performed using incidence density sampling, where controls were selected for each case on the week of 1-1-2 call.
88829365|NCT04741529|Experimental|Massed condition|Participant will be asked to use the HMP app for 20 minutes per day in one 20-minute meditation session.
88829366|NCT04741529|Experimental|Spaced condition|Participant will be asked to use the HMP app for 20 minutes per day in two 10-minute meditation sessions.
88829367|NCT01841047|Other|Radiotherapy|Evaluation of the combination of radiotherapy with helical tomotherapy (54 Gy) followed by surgery in retro-peritoneal liposarcomas.
88829368|NCT02601833|Experimental|Silver Diamine Fluoride|This arm will receive Silver Diamine Fluoride applied to their carious lesion, in lieu of restoration placement, with the goal of arresting caries.
89177801|NCT00847613|Experimental|Sequence 2|
89177802|NCT00847613|Placebo Comparator|Sequence 3|
89000733|NCT04654936|Experimental|MIND diet with support|This intervention group are to follow the MIND diet guidelines for 12 weeks with the support of a 12 week online theory driven website and resources
89000734|NCT04654936|Experimental|MIND diet no support|This group are to follow the MIND diet guidelines with no website support
89000735|NCT04654936|No Intervention|Control|The group follow usual diet
89000736|NCT04654624|Experimental|Silver Diamine Fluoride|
89000737|NCT04654624|Active Comparator|Atraumatic Restorative Treatment|
89000738|NCT00200577|Experimental|TIL+IL2|TIL + IL2
89000739|NCT00200577|No Intervention|control|Patients are not treated
89000740|NCT04654585|Experimental|The STOP intervention|The stop intervention is a heath professional (medical doctor) led intervention assisting smokers with low socioeconomic position in their smoking cessation attempt. It consists of routine care and adapted advice supplemented with a free delivery of any or several type(s) of nicotine replacement therapy (NRT) (patches, inhalers, gum, tablets, etc.) and/or an e-cigarette + e-liquid. The delivery of those smoking aids is based on the smokers' preference and choice.
89000741|NCT04654585|Active Comparator|Standard Care|"Participants randomised to the standard care group will be given standard care in assisting their smoking cessation attempt, but without free delivery of NRT or e-cigarettes.~Standard care includes motivational interviewing, advice to quit and prescription for NRTs. The number and online address of the French smoking cessation support helpline could also be provided. Health professionals will also be in position to prescribe NRT or other treatments (for example: Varenicline or Bupropion) which can help with smoking cessation, according to routine practice. The health professional could also give advice on e-cigarette use if he or she finds it suitable."
89000742|NCT04654819|No Intervention|Control group|This group made anesthesia application on patients without training on simulators.
89000743|NCT04654819|Experimental|Study group|This group made anesthesia application on patients after training on simulators.
89000744|NCT04654780|Experimental|tax on purchases|"exposed to high-price purchases of high in foods, including sugary drinks."
89000745|NCT04654780|Experimental|subsidies on purchases|exposed to purchases with prices that consider subsidies in fruits and vegetables.
89000746|NCT04654780|Placebo Comparator|Control|It will not be subjected to any intervention and therefore will buy with current or market prices.
89000747|NCT04654390|Experimental|DWP16001 Amg, Dapagiflozin Bmg placebo|Tablets, Orally, Once daily
89000748|NCT04654390|Active Comparator|DWP16001 Amg placebo, Dapagliflozin Bmg|Tablets, Orally, Once daily
89000749|NCT04654741|Experimental|Progestin Primed ovarian stimulation Group|progestin 10 mg daily during ovarian stimulation
89000750|NCT04654741|Active Comparator|GnRH antagonist|GnRH antagonist 0.25 mg daily during ovarian stimulation
89534232|NCT03895502|Experimental|12-month Edoxaban|Edoxaban for 12 months
89534233|NCT03895502|Active Comparator|3-month Edoxaban|Edoxaban for 3 months
89534234|NCT03894462|Active Comparator|Zero Suicide Usual Care|"In Onondaga County, New York State (NYS) aims to implement a countywide Zero Suicide Safety Net of providers who share enhanced protocols for clinical care, staff training, and data collection (improved coding of suicidal behavior). Participating behavioral health systems have agreed to common protocols for clinical care, training, and data collection. Participating providers receive robust training in suicide prevention best practices. Because of the wide participation of mental health facilities in the NYS Office of Mental Health (OMH) Zero Suicide project, most subjects who engage in outpatient treatment will receive that treatment in facilities that are adopting NYS Zero Suicide protocols. Those who do not engage in care will nonetheless experience enhanced transition and follow-up contact from the services from which they are discharged."
89000751|NCT00177944||patients with funal infections|
89000752|NCT04654156||Pathological group|Patients with pulmonary embolism on thoracic CT angiography
89000753|NCT04654156||Healthy group|Patients without pulmonary embolism on thoracic CT angiography
89000754|NCT04654078|Experimental|Group 1|Group 1
89000755|NCT04654078|Experimental|Group 2|Group 2
89000756|NCT04654078|Experimental|Group 3|Group 3
89000757|NCT04654078|Experimental|Group 4|Group 4
89000758|NCT04654078|Experimental|Group 5|Group 5
89000759|NCT04654078|Experimental|Group 6|Group 6
89000760|NCT04654000|Experimental|Rheopheresis group|"In addition to the standards of care, the experimental group will carry out the rheopheresis in two stages:~Stage 1: induction treatment: 3 apheresis sessions during the first week (w0; i.e. between D1 and D7) and then 2 apheresis sessions each week for 3 weeks (from w1 to w3; i.e. between D8 and D28) ;~Step 2: maintenance treatment with 1 apheresis session per week until the 11th week (i.e. between D29 and D84)."
89000761|NCT04654000|Sham Comparator|Sham-apheresis group|In addition to the standards of care, the comparator group will carry out Sham-apheresis sessions according to the same scheme as the rheopheresis sessions of the experimental group.
89000762|NCT00205569||1|Individuals with traumatic brain injury requiring inpatient rehabilitation.
89000763|NCT03454789|Active Comparator|LB Group|Ultrasound-guided brachial plexus block for LB Group (15 ml lidocaine 1% + 15 ml bupivacaine 0.5%)
89000764|NCT03454789|Active Comparator|BS Group|Ultrasound-guided brachial plexus block for BS Group (20 ml bupivacaine 0.5% + 10 ml normal saline)
89000765|NCT03454789|Active Comparator|LS Group|Ultrasound-guided brachial plexus block for LS Group (20 ml lidocaine 1% + 10 ml normal saline)
89000766|NCT03454789|Active Comparator|BL Group|and Ultrasound-guided brachial plexus block for BL Group (20 ml bupivacaine 0.5% + 10 ml lidocaine 1%)
89000767|NCT04653727||Online survey with 3.000 participants using mobile website technology|
89000768|NCT04653532|Experimental|mHealth Technology|Participants in this group (Mobile health technology (mHealth)) will receive the same 6-month exercise and physical activity programme supported by an exercise specialist, but participants in this group will also receive a fitness watch that links to a mobile phone application (App).
89000769|NCT04653532|Active Comparator|Exercise Counselling|Participants in this group (Exercise Counselling) will complete a 6-month structured exercise and physical activity programme supported by regular contact with an exercise specialist.
89177803|NCT00847613|Placebo Comparator|Sequence 4|
89177804|NCT00821860|Experimental|Arm I|Patients undergo video-assisted thoracoscopic cytoreductive pleurectomy either at the time of biopsy or after confirmation of biopsy results.
89000770|NCT04653649|Experimental|HSP-CAR30 (anti-CD30 CAR T cells)|"Phase I:~Ten patients will be treated with HSP-CAR30 (anti-CD30 CAR T-cells) with an escalation approach to define maximum tolerated dose (MTD) from 3 x 106/kg to 10 x 106/kg.~Phase IIa:~Twenty patients will be treated with HSP-CAR30 at MTD to evaluate efficacy."
89000771|NCT04653493|Experimental|CD19 CAR-T cells|Pediatric or adolescent/young adult patients with CD19+ relapsed or refractory B cell acute lymphoblastic leukemia (R/R B-ALL)
89000772|NCT00557713|Experimental|A|"-Induction treatment. 4 cycles (every 3 weeks) of bevacizumab (7,5mg/kg day 1) + oxaliplatin (130mg/m2 day 1) + capecitabine (1000mg/m2/12h days 1-14)~-Concomitant (CT+RT) treatment (3 weeks later): bevacizumab (5mg/kg day 1 of 1st, 3th and 5th weeks) + capecitabine (825mg/m2/12h daily during radiotherapy treatment) + radiotherapy (45Gy (25fractions of 1,8Gy/day over 5weeks) followed by boost 5.4Gy (1,8Gy/day over 3days))~-Surgery (6-8 weeks after last bevacizumab dose)~-Adjuvant treatment: It will be individual decision of each investigator, but it's recommended 4 cycles of XELOX (equal dose at induction treatment)"
89000773|NCT00557752|Active Comparator|1|Addition to the standard therapy of non-invasive mechanical ventilation. Continuously for the first 24 hours, then trials to discontinuation every 24 hours. Interface adjusted for the associated injuries.
89000774|NCT00557752|No Intervention|2|Standard therapy for severe post-traumatic hypoxia: pain control with epidural anesthesia and oxygen.
89000775|NCT04653415|Active Comparator|Study Group|"The study group will receive as pre-emptive analgesia a single dose of 300 mg oral gabapentin and 125 mg intravenous methylprednisolone."
89000776|NCT04653415|Placebo Comparator|Controls group|The controls group will receive placebo orally - a tablet without any pharmacological properties, intravenously - saline solution.
89000777|NCT04653259|Experimental|Intervention Group|The INT group will meet with their health coach over the phone or video chat. The health coach will orient them to the LyfeMD, app and ensure the participant has received a nutrition plan in the app. They will be asked to complete the app assessment tools to design a personalized nutrition, physical activity and yoga and meditation program. They will set goals in each area they are interested in implementing. The health coach will then follow-up by phone, video or email 2 weeks after the initial meeting, then monthly with the patient for 2 more months (total of 4 meetings). The health coach will use the following schedule to discuss app related content: First visit nutrition content; second visit behaviour change tools; third visit Yoga, meditation and breathing plans, and; the fourth visit the physical activity plans. The health coach will also be available to answer questions when required using email. Goal attainment will be collected weekly within the app.
89000778|NCT04653259|No Intervention|Conventional Management Group|The CM group (n=22) will receive conventional care as well as a similar health coaching schedule as the intervention group. The health coach will meet the patient over the phone or video chat to outline their role over the next 3 months and to provide general nutrition guidelines using Canada's Food Guide and Alberta Health Services online resources. The health coach will then follow-up by phone, video chat or email 2 weeks after the initial meeting, then monthly with the patient for 2 more months (total of 4 meetings). The health coach session topics will be the same as the intervention group. For example, the second visit will provide online resources from Alberta Health Services focused on promoting behaviour change, the third visit will orient the patient to Alberta Health Services focused online stress management tools and the final visit will share online versions of the Canadian guidelines for physical activity and sedentary time.
89000779|NCT00557791|Active Comparator|A|Lucentis® (0.5 mg) every 4 weeks.
89000780|NCT00557791|Experimental|B|Bevasiranib (1.0 mg) every 8 weeks beginning at week 12, after pre-treatment with 3 injections of Lucentis® and initial priming doses of bevasiranib at weeks 2 & 6.
89000781|NCT00557791|Experimental|C|Bevasiranib (2.0 mg) every 8 weeks beginning at week 12, after pre-treatment with 3 injections of Lucentis® and initial priming doses of bevasiranib at weeks 2 & 6.
89000782|NCT00557791|Experimental|D|Bevasiranib (2.5 mg) every 8 weeks beginning at week 12, after pre-treatment with 3 injections of Lucentis® and initial priming doses of bevasiranib at weeks 2 & 6.
89000783|NCT04653376||Chronic tonsillitis|Patients with tonsil sizes grade 1 and 2, and tonsillectomy indications included frequently recurrent tonsillary infection, sore throat, and malodorous mouth problems were accepted as the chronic tonsillitis group.
89000784|NCT04653376||Tonsillar hypertrophy|Patients with tonsil size grades 3 and 4 and tonsillectomy indications included obstructive symptoms such as snoring, open mouth breathing, difficulty in breathing, and swallowing problems were accepted as the tonsillar hypertrophy group.
89000785|NCT00178217|Experimental|Music Therapy|The music therapy intervention will consist of approximately 30 minutes of active music making and/or improvisation. The session will begin at least 15 minutes prior to receiving the Botox injections, followed by the necessary time of the procedure and 10 minutes following. During this time the patient will be encouraged to actively engage in a musical activity of his/her choice. After the last injection has been administered, the monitoring and music therapy will continue for up to 10 minutes, and focus on soothing and relaxation rather than on distraction.
89000786|NCT00178217|No Intervention|Standard Care Control|Subjects will receive standard care at control condition sessions, which includes the use of television, books, CD's, a child life specialist (when available) or other activities to help cope with the procedure.
89000787|NCT04653025|Experimental|Test group|Test group patients received an immediate implant with provisional restoration, bone augmentation and soft tissue grafting
89000788|NCT04653025|Experimental|Control group|Patients in the control group received soft tissue grafting after tooth extraction and an implant with bone augmentation after 6 weeks of healing.
89000789|NCT04653103||Patients with obesity|Subjects with different classes of obesity
89000790|NCT04652635|Active Comparator|Nail plate removal, nail bed repair|Participants will undergo nail plate removal and nail bed repair, and follow up at clinic visits at 1 week, 3 months, and 6 months
89357798|NCT03164772|Experimental|Arm B: BI 1361849 mRNA Vaccine + durvalumab + tremelimumab|"The BI 1361849 mRNA vaccine comprises 6 drug product components (F2408 coding for MUC1, F2409 coding for survivin, F2410 coding for NY-ESO-1, F2624 coding for 5T4, F2625 coding for MAGE-C2, and F2626 coding for MAGE-C1), which were provided and administered separately; each component was administered twice, thus there were 12 intradermal administrations of 100 µL (80 µg) each for each dose. The PharmaJet Tropis® device was used for the administration of the BI 1361849 components.~Durvalumab 1500 mg was to be administered as an intravenous (IV) infusion every 4 weeks for 12 cycles; tremelimumab 75 mg was to be administered as an intravenous (IV) infusion every 4 weeks for the first 4 cycles (Arm B only); BI 1361849 was to be administered as 14 doses over the 12 cycles."
89357799|NCT02497690|Active Comparator|In-person ART|In-person approach to provide ART.
89357800|NCT02497690|Experimental|Telehealth ART|Telemedicine technology approach (e.g. interactive video) to provide ART.
89357801|NCT03801317|Experimental|BC/ egg|4.3 grams egg powder + 5.7 grams bovine colostrum
89357802|NCT03801317|Placebo Comparator|Control|15 grams corn-soya blend
89357803|NCT02497768|Experimental|Chewing of nuts|8 samples (4-5 g) of nuts (pistachios or Brazils) on two separate visit days.
89357804|NCT03795545|Active Comparator|Ultraslow shock wave lithotripsy (SWL)|"SWL at ultraslow rate of 30 SW/min. Power ramping at the first 100 SW from 6 to 18 kv followed by safety pause for two minutes then power ramping from 18 to 22kv during the second 100 SW followed by safety pause for another two minutes.~The rest of the session at 22kv (full power)."
89357805|NCT03795545|Active Comparator|Slow power-ramping SWL|SWL at a slow rate of 60 SW/min. Power ramping from 6 - 10 kv during the first 500 SW then from 11 - 14 kv during the second 500 SW then from 15 - 18 kv during the following 500 SW then from 19 - 22 kv during the remaining 1000 - 1500 SW.
89357806|NCT02493400||Exercise group|A follow up from 3 months detraining from the exercise group. Patients follows their earlier randomisation.
89534235|NCT03894462|Experimental|Zero Suicide Usual Care + ASSIP|"Patients in this treatment arm will receive ASSIP brief therapy in addition to being able to access any usual care as recommended by their provider.~ASSIP is a manualized, three-session intervention, delivered either in-person or via telehealth: In Session 1, the therapist guides the patient in telling the story of their attempt. The session is video recorded. In Session 2, the therapist and patient sit side-by-side to view selections of the video, working together to understand the feelings and events that preceded the attempt. The patient is assigned a homework task. In Session 3, the therapist and patient create a summary of the suicide attempt and what led up to it, along with creating a personal safety plan."
88829369|NCT02601833|Active Comparator|Conventional Caries Management|Restorative dental care according to American Academy of Pediatric Dentistry guidelines. This treatment typically includes administration of local anesthesia, placement of rubber dam, caries removal with rotary and hand instruments, and placement of a final restoration.
88829370|NCT02602223|Experimental|Amnion chorion membrane|Amnion chorion membrane will be placed over bone graft after socket preservation on randomly assigned side of the mouth i.e., contra-lateral to the active comparator.
89357807|NCT02493400||Active Comparator: PAP group|A follow up from 3 months detraining from the active comparator group. Patients follows their earlier randomisation.
89534236|NCT03884556|Experimental|Arm 1, Single Agent|TTX-030
89534237|NCT03884556|Experimental|Arm 2, Anti-PD-1 Combination|TTX-030 plus pembrolizumab
88829371|NCT02602223|Active Comparator|d-PTFE membrane|dense polytetrafluoroethylene membrane will be placed over bone graft after socket preservation on randomly assigned side of the mouth i.e., contra-lateral to the Experimental side
89357808|NCT01331070|Experimental|PATIENT|Patients, half with moderate (GOLD II) and half with severe (GOLD III) COPD
89357809|NCT01331070|Other|Accepts Healthy Volunteers|Control arm with the same intervention
89357810|NCT03337126|Active Comparator|Fasting Condition|Single dose of ATI-1501(oral suspension) administered under fasting conditions; BioAvailability and PK parameters will be measured and analyzed. These parameters will be compared to the BA and PK parameters measured after administration of a single Metronidazole Tablet
89357811|NCT03337126|Active Comparator|Fed Condition|Single dose of ATI-1501(oral suspension) administered under fed condition; BioAvailability and PK parameters will be measured and analyzed. These parameters will be compared to the BA and PK parameters measured after administration of a single Metronidazole Tablet
89357812|NCT01331226|Experimental|3 session telephone counseling|
89357813|NCT01331226|Experimental|1 session telephone counseling|
89357814|NCT01331226|Active Comparator|written materials|
89357815|NCT05016050|Experimental|Digital therapeutic|Use HPDT-DA-013 digital therapeutic for a period of 8-10 weeks.
89357816|NCT04710732|Active Comparator|Control|Peri-operative VTE prophylaxis with a standard once-daily dose of enoxaparin 40 mg and anti-embolic stockings
89357817|NCT04710732|Experimental|Experimental|Peri-operative VTE prophylaxis with an escalated twice-daily dose of enoxaparin 30 mg and anti-embolic stockings
89357818|NCT02497456|Experimental|Follow-up counselling|Participants in the experimental arm will receive home-based HIV counselling and testing and referral for HIV care if found to have HIV infection. Additionally, participants will receive home-based follow-up counselling at 1 and 2 months after HIV diagnosis.
88829372|NCT00364559|Experimental|B|A, Active B, Historical Register
88829373|NCT02271984|Experimental|Treatment A: MSC2499550A|MSC2499550A: 20 milligram per kilogram (mg/kg) under fed condition
88829374|NCT02271984|Experimental|Treatment B: Cysticide|Cysticide® 40 mg/kg under fed condition
88829375|NCT02271984|Experimental|Treatment C: MSC2499550A|C1:MSC2499550A :10 mg/kg under fed condition C2:MSC2499550A : 30 mg/kg under fed condition
88829376|NCT02271984|Experimental|Treatment D: MSC2499550A|MSC2499550A 20 mg/kg under fasting condition
89357819|NCT02497456|No Intervention|Standard of care|Participants in this arm will receive only home-based HIV counselling and testing and referral for HIV care if found to have HIV infection.
89357820|NCT05014334|Experimental|Berberine-containing triple therapy|vonoprazan 20 mg , amoxicillin 1000 mg , and berberine 500 mg by mouth,twice daily for 14 days.
88829377|NCT02271984|Experimental|Treatment E: MSC2499550A|MSC2499550A: 20 mg/kg directly disintegrated in mouth under fed condition
89357821|NCT05014334|Active Comparator|Bismuth-containing quadruple therapy|Bismuth potassium citrate 220 mg,rabeprazole 10 mg, amoxicillin 1000mg, and clarithromycin 500 mg by mouth,twice daily for 14 days.
89357822|NCT05014334|Active Comparator|vonoprazan-containing quadruple therapy|Bismuth potassium citrate 220 mg, vonoprazan 10 mg, amoxicillin 1000mg, and clarithromycin 500 mg by mouth,twice daily for 14 days.
88829378|NCT03833011|No Intervention|no intervention|
88829379|NCT03833011|Experimental|Osteopathic manipulation|
88829380|NCT00366041|Experimental|Cellularised LG002|Cellularised LG002
88829381|NCT00366041|Experimental|UnCellularised LG002|UnCellularised LG002
88829382|NCT05371535|Experimental|Experimental group|Those in the experimental group will receive MatrixOssTM Bone Graft plus Bio-Gide membrane.
89357823|NCT02497378|Experimental|JNJ-54767414 (Daratumumab) +Bortezomib+Dexamethasone|Participants will be administered JNJ-54767414 (daratumumab) intravenously at a dose of 16 milligram per kilogram (mg/kg) weekly for the first 3 cycles, then on Day 1 of Cycles 4-8 (every 3 weeks), and then on Day 1 of subsequent cycles (every 4 weeks), First 8 Cycles are 21-day cycles; Cycles 9 and onwards are 28-day cycles. Bortezomib at a dose of 1.3 milligram per meter square (mg/m^2) subcutaneously (SC) on Days 1, 4, 8 and 11 of each 21-day cycle for 8 treatment cycles and Dexamethasone orally at 20 mg on Day 1, 2, 4, 5, 8, 9, 11 and 12 of the first 8 bortezomib treatment cycles.
89534238|NCT03884556|Experimental|Arm 4, Chemotherapy Combination|TTX-030 plus gemcitabine plus nab-paclitaxel
89357824|NCT02497144|Active Comparator|NMES Group|"Intervention: NMES group will receive neuromuscular electrical stimulation using high frequency galvanic stimulation and breathing exercises.~Neuromuscular electrical stimulation will be applied bilaterally to quadriceps femoris muscle for 3days/6 weeks by a physiotherapist.~NMES group will also perform breathing exercises 120 times/day, 7 days/week, for 6 weeks."
89357825|NCT02497144|Sham Comparator|Control Group|"Sham: Control group will receive breathing exercises. Control group will perform breathing exercises 120 times/day, 7 days/week, for 6 weeks.~Control group will be followed-up by telephone once a week."
89357826|NCT02497222|Experimental|RNS60|RNS60 4 ml, inhaled twice daily by nebulization for 21 days.
89357827|NCT02497222|Placebo Comparator|Normal Saline|Normal Saline 4 ml, inhaled twice daily by nebulization for 21 days.
89357828|NCT02491606|Experimental|Load only|Loading with tafenoquine 400 mg base for three days followed by placebo weekly.
89357829|NCT02491606|Experimental|Low weekly dose|Loading with tafenoquine 200 mg base for 3 days followed by tafenoquine 200 mg weekly.
89357830|NCT02491606|Experimental|High weekly dose|Loading with tafenoquine to 400 mg base for 3 days followed by tafenoquine 400 mg base weekly.
89357831|NCT02491606|Experimental|Placebo|Loading with placebo for 3 days followed by placebo once weekly.
89357832|NCT05255354||Diffuse Large B Cell Lymphoma|For DLBCL patients, prospective blood samples will be collected, in provided collection kits, at: pre-lymphodepletion chemotherapy, Day+14, Day+28, Day+90, Day+180, and potentially at relapse following CAR infusion. For DLBCL, PET/CT scan images done prior to CAR19 therapy, Day 28 post-infusion, 3 months post-infusion, and 6 months post-infusion of CAR19 cells
88829383|NCT05371535|Active Comparator|Control group|Those in the control group will receive Bio-Oss Bone Graft plus Bio-Gide membrane
88829384|NCT02604173|Experimental|Budesonide|Budesonide inhaler as experimental treatment along with placebo pill.
88829385|NCT02604173|Active Comparator|Acetazolamide|Acetazolimide pill as active comparator along with sham inhaler.
88829386|NCT02604173|Sham Comparator|Control|Sham inhaler as control for budesonide inhaler along with placebo pill as control for acetazolamide comparator.
88829387|NCT01841281|Active Comparator|Low Exhaled Nitric Oxide (NO)|"Subjects with a baseline exhaled NO level less than or equal to 20 ppb will be enrolled in the Low Exhaled Nitric Oxide arm.~All subjects will receive L-arginine and placebo in this cross-over design study."
88829388|NCT01841281|Active Comparator|High Exhaled Nitric Oxide (NO)|"Subjects with a baseline exhaled NO level greater than or equal to 25 ppb will be enrolled in the High Exhaled Nitric Oxide arm.~All subjects will receive L-arginine and placebo in this cross-over design study."
89357833|NCT05255354||Follicular Lymphoma|For FL patients, prospective blood samples will be collected, in provided collection kits, at: pre-lymphodepletion chemotherapy, Day+14, Day+28, Day+90, Day+180, Day+365, and potentially D+547 and at relapse following CAR infusion. For FL patients, PET/CT scan images done prior to CAR19 therapy, Day 28 post-infusion, 3 months post-infusion, and 6 months post-infusion of CAR19 cells
89357834|NCT05255354||Mantle Cell Lymphoma|For MCL patients, prospective blood samples will be collected, in provided collection kits, at: pre-lymphodepletion chemotherapy, Day+14, Day+28, Day+90, Day+180, Day+365, and potentially D+547 and at relapse following CAR infusion. For MCL patients, PET/CT scan images done prior to CAR19 therapy, Day 28 post-infusion, 3 months post-infusion, and 6 months post-infusion of CAR19 cells
89357835|NCT03353753|Active Comparator|Arm 1|150 mg QD DCC-2618
89357836|NCT03353753|Placebo Comparator|Arm 2|Placebo
89357837|NCT03329638|Experimental|DE-127 Ophthalmic Solution low dose|
89357838|NCT03329638|Experimental|DE-127 Ophthalmic Solution medium dose|
89357839|NCT03329638|Experimental|DE-127 Ophthalmic Solution high dose|
89357840|NCT03329638|Placebo Comparator|Placebo Ophthalmic Solution|
88829389|NCT02287038|Active Comparator|Atomoxetine 80mg|Atomoxetine (fixed dose of 80mg), a non-stimulant medication, FDA approve for treatment of ADHD. The active drug will be applied in first phase in group one and in second phase in group two
88829390|NCT02287038|Placebo Comparator|Placebo|A pharmaceutically inert substance, which will be given to group one in their second phase and group tow in first phase.
88829391|NCT00365339|Active Comparator|A|
88829392|NCT00365339|Experimental|B|
88829393|NCT00365339|Experimental|C|
88829394|NCT00365339|Experimental|D|
89357841|NCT03050450|Experimental|dose level 1|25 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)
89357842|NCT03050450|Experimental|dose level 2|50 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)
89357843|NCT03050450|Experimental|dose level 3|100 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)
88829395|NCT00365339|Experimental|E|
88829396|NCT02815033|Other|Single arm|Experimental: Single arm Subjects will receive 1 dd 160 mg Enzalutamide orally continuously until progressive disease occurs. Serial PSA measurements, PET/CT scans, Whole Body MRI, bone scans will be performed to assess metastatic tumour load, progressive disease and response to treatment.
88829397|NCT04340687||IP group|All patients recevied pancreatic duct stent during ERCP and one single dose of 100mg rectal indomethacin after ERCP.
88829398|NCT04340687||IN group|All patients received one single dose of 100mg rectal indomethacin after ERCP.
88829399|NCT02286960|Active Comparator|Steroid|Prednizone pills. 4 day course 2 x 20mg per day.
89357844|NCT03050450|Experimental|dose level 4|150 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)
88829400|NCT02286960|Placebo Comparator|Placebo|Lactose Pills. 4 day course 2 x 20mg per day.
88829401|NCT01842061|Experimental|Active Living Program|Participants in the intervention group will receive a self-management program designed to reduce sedentary behaviour and increase physical activity. Specifically, they will be given an EASY Program Manual with strategies to break up sitting time during the day and increase utilitarian activity; this will include a section on how to set, monitor and maintain achievable goals. They will also be offered a pedometer program, group education sessions and encouraged to use public transport by providing free bus tickets.
89357845|NCT03050450|Experimental|dose level 5|150 mg/m2 Lenalidomide (Revlimid®) and 230 mg/m2 Vorinostat (Zolinza®)
89357846|NCT03329560|Experimental|Oral fecal microbiota transplantation|All subjects will receive one dose per week for 6 weeks (6 total doses) of PRIM-DJ2727 oral capsules containing lyophilized microbiota product derived from 150 grams of healthy donor stool.
89357847|NCT05463718|Experimental|children treated by the traditional physical therapy program based on Neurodevelopmental technique|Twenty-five cerebral palsied hemiplegic children will be treated by the traditional physical therapy program ( balance board, single limb support, standing with throwing ball ) based on Neurodevelopmental technique for 6 month
88829402|NCT01842061|Active Comparator|Education|Control group participants will be offered monthly drop-in sessions that target information on general health and well-being unrelated to physical activity.
88829403|NCT05371379|Experimental|CM338 75 mg, subcutaneous injection|Qquaque week
88829404|NCT05371379|Experimental|CM338 150 mg, subcutaneous injection|Qquaque week
88829405|NCT05371379|Experimental|CM338 300 mg, subcutaneous injection|Qquaque week
88829406|NCT05371379|Experimental|CM338 300 mg, intravenous infusion|Qquaque week
88829407|NCT05371379|Placebo Comparator|Placebo|placebo
88829408|NCT02286102|Experimental|OrthoPAT|Patients in the experimental group will receive OrthoPAT drains, which will be used to collect and retransfuse postoperative blood loss. Drains will be removed after 48 hours.
88829409|NCT02286102|Active Comparator|Constavac|Patients identified as active comparator will receive standard Constavac drains, which will be removed after 48 hours.
88829410|NCT05371301|Experimental|NACT-IDS|For patients whoes WB-DWI/MRI Suidan Standard Evaluation≥4 Neoadjuvant chemotherapy: platinum-based combination regimen 3 courses
88829411|NCT05371301|Active Comparator|PDS|For patients whoes WB-DWI/MRI Suidan Standard Evaluation<4
88829412|NCT02285166||Ever User of Omega-3 fatty acid ethyl esters 2 g|The usual adult dosage for oral use was 2 g of omega-3 fatty acid ethyl esters administered once daily or twice daily immediately after meals for treatment of hyperlipidemia. Participants received both interventions and standard antihyperlipidemic therapy as part of routine medical care.
88829413|NCT02285166||Never User of Omega-3 fatty acid ethyl esters 2 g|Participants received standard antihyperlipidemic therapy without omega-3 fatty acid ethyl esters 2 g as part of routine medical care.
88829414|NCT01842841|Experimental|velaglucerase alfa|15 to 60 U/kg, EOW via intravenous infusion
88829415|NCT02605187|Active Comparator|No choice|No choice given medium dose intrathecal morphine acetaminophen po q6h ibuprofen po q6h
88829416|NCT02605187|Experimental|Choice: low protocol|Choice given low dose intrathecal morphine acetaminophen po q6h ibuprofen po q6h
88829417|NCT02605187|Experimental|Choice: medium protocol|Choice given medium dose intrathecal morphine acetaminophen po q6h ibuprofen po q6h
89357848|NCT05463718|Experimental|children treated by Virtual Reality for 15 min. besides the traditional physical therapy program|twenty-five cerebral palsied hemiplegics will be included in this group; they will be receive the regular physical therapy program in addition to training by Virtual reality with use of the HMD helmet allows users to perceive a 3D stereoscopic images that enable participants to interact with different balance games as football Soccer, football heading (known as Soccer Heading), the tight rope walks and the Penguin slide game.
88829418|NCT02605187|Experimental|Choice: high protocol|Choice given high dose intrathecal morphine acetaminophen po q6h ibuprofen po q6h gabapentin po one time dose
88829419|NCT05371067|Other|Healthy volunteers|
88829420|NCT02606903|Experimental|BI 695501 prefilled syringe|
88829421|NCT02606903|Experimental|BI 695501 autoinjector|
88829422|NCT04350619||Genetic study in retrospective and prospective groups|Genetic screening using NGS technique in a retrospective and prospective groups. No therapeutic intervention
88829423|NCT05592197|Experimental|RT+TACE+Lenvatinib|Patients in RT+TACE+Lenvatinib group will take oral lenvatinib first and receive TACE one day after oral administration of lenvatinib. RT will begin within 4 weeks after the first TACE.
88829424|NCT05592197|Active Comparator|TACE+Lenvatinib|Patients in TACE+Lenvatinib group will take oral lenvatinib first and receive TACE one day after oral administration of lenvatinib.
88829425|NCT02989207|Active Comparator|Trabeculectomy with Mitomycin-C|The current standard surgical treatment for glaucoma remains trabeculectomy.
88829426|NCT02989207|Active Comparator|Baerveldt tube surgery with Mitomycin C|It consists of a tube, draining aqueous humour to a plate
88829427|NCT02989207|Active Comparator|Baerveldt tube surgery without Mitomycin C|It consists of a tube, draining aqueous humour to a plate
88829428|NCT05591729|Experimental|Pilates exercise|pilates exercise will be received twice a week for four weeks
88829429|NCT05591729|Active Comparator|postural correction exercise|postural correction exercises will be received twice a week for four weeks
88829430|NCT04340219||Cancer patients|Participants complete a survey consisting of sociodemographic information and self-administered questionnaires (CPDI, DASS-21, and WHOQOL-BREF).
88829431|NCT05442281||Vegan diet|Children fed vegan diet from 6 months of life
88829432|NCT05442281||Mixed diet|Children fed mixed diet from 6 months of life
88829433|NCT02409589|Experimental|ECG-guided PICC Tip Placement|New intracavitary ECG guiding method
88829434|NCT02409589|Active Comparator|Conventional|Surface prediction length method
89357849|NCT05463718|Experimental|children treated by Balance Beam for 15 min besides the traditional physical therapy program|Twenty-five cerebral palsied hemiplegics will be included in this group; they will be receive the regular physical therapy program in addition to training by standing and walking in balance beam by differentiate levels of walking balance proficiency as varying widths of beam and walking in different direction (forward or backward).
88829435|NCT01843465||Cryoablation of atrial fibrillation|
88829436|NCT01843621|Experimental|Total vaccinated|The total vaccinated cohort included all enrolled subjects who received the DEN vaccine F17 for whom data were available. These subjects were Thai children previously enrolled and vaccinated in study Dengue-003
88829437|NCT02608229|Experimental|Dose De-escalation: BVD-523/Nab-paclitaxel/Gemcitabine|"Treatment will be given in a 28-day cycle.~BVD-523 600 mg on a twice daily basis (at approximately 12-hour intervals).~BVD-523 at 600 mg twice daily on its own for two weeks before initiating Cycle 1 treatment with gemcitabine and nab-paclitaxel.~Nab-paclitaxel 125 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle over the course of 30-40 minutes.~Gemcitabine 1000 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle over the course of 30 minutes.~Mandatory biopsy at baseline and baseline at end of 2 week BVD-523 lead in."
88829438|NCT02608229|Experimental|Dose Expansion: BVD-523/Nab-paclitaxel/Gemcitabine|"Treatment will be given in a 28-day cycle.~First 2 patients enrolled: BVD-523 600 mg on a twice daily basis (at approximately 12-hour intervals), nab-paclitaxel 125 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle over the course of 30-40 minutes, and gemcitabine 1000 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle over the course of 30 minutes~Remaining 6 patients enrolled: BVD-523 450 mg on a twice daily basis (at approximately 12-hour intervals), nab-paclitaxel 100 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle over the course of 30-40 minutes, and gemcitabine 800 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle over the course of 30 minutes~Mandatory biopsy at baseline and at end of cycle 2 (if deemed safe for participant and feasible to obtain)"
88829439|NCT00555061|Experimental|Arm 1|Single Arm Retapamulin 1% Ointment
88829440|NCT01844479|Active Comparator|Standard innersole|"Per sequence cross over design. Order of testing innersoles was randomized and each testing condition lasted 15 minutes.~The industry standard diabetic innersole will be used as the active comparator"
88829441|NCT01844479|Experimental|Diabetic Foot Orthotic|The Dynamic Foot Orthosis (DFO) is designed with a rolling link mechanism at the distal 3rd to reduce sliding friction at the metatarsal heads in addition to decreasing compressive forces. The relative sliding motion of two compliant surfaces over each other allows some deformation horizontally and lowers frictional resistance. The DFO addresses the friction element by accommodating the normal sliding and rolling motion at the distal 3rd of the foot during gait. Additionally, the DFO has a silicone layer at the metatarsal head and the remainder of the anterior section made of 2 separated orthotic layers that slide over each other. This provides an articulating surface to provide a relative motion between the orthotic segments while transmitting load.
88829442|NCT01642212|Experimental|Oral Budesonide Suspension|Taken once or twice daily for up to 40 weeks
88829443|NCT01642212|Placebo Comparator|Matching Placebo|Taken once or twice daily for 20 weeks
88829444|NCT02608463|Other|Part A - Neuropathic Pain|Subjects with a score of ≥ 13 on the painDETECT Questionnaire (PDQ) will be assigned to the Neuropathic Pain group.
88829445|NCT02608463|Other|Part A - Non-Neuropathic Pain|Subjects with a score of ≥ 1 or ≤ 12 on the painDETECT Questionnaire (PDQ) will be assigned to the Non-Neuropathic Pain group.
88829446|NCT02608463|Other|Part A - Control|Subjects with a score of score = 0 on the painDETECT Questionnaire (PDQ) will be assigned to the Control group.
88829447|NCT02608463|Experimental|Part B - rTMS|Subjects from the Neuropathic Pain group will be invited to participate in the Part B rTMS group to receive repetitive transcranial magnetic stimulation (rTMS).
88829448|NCT05649618|Experimental|Tumor Infiltrating Lymphocytes|TIL cells (2.5×10^9-5×10^10) will be infused i.v. to patients with advanced solid tumors after non-myeloablative lymphocyte-depleting preparative regimen.
88829449|NCT00552175|Experimental|Duloxetine 60|duloxetine 60 milligram (mg) taken orally every day
88829450|NCT00552175|Experimental|Duloxetine 40|Duloxetine 40 mg taken orally every day
88829451|NCT00552175|Placebo Comparator|Placebo|placebo comparator taken orally every day
88829452|NCT05357183||PEG-IFN optimized treatment group|Patients received optimized treatment of NAs (ETV + TDF or ETV + TAF) combined with PEG-IFN ETV 0.5 mg, TDF 300 mg or TAF 25 mg, oral once a day, PEG-IFN 180 or 135 micrograms, subcutaneous injection once a week, with a personalized course of treatment of 24 weeks.
88829453|NCT05357183||NAs optimized treatment group|Patients received NAS (ETV + TDF or ETV + TAF) combination therapy and continued NAs maintenance therapy.
88829454|NCT05649462||supplementary group|take vitamin D supplementation (400 IU/day) during VDZ treatment
88829455|NCT05649462||non-supplementary group|
88829456|NCT05649384||0/1-hour algorithm|High-sensitivity cardiac troponin (hs-cTn) blood tests are performed at admission (0 h) and 1 hour later in the emergency department.
88829457|NCT05649384||0/3-hour algorithm|High-sensitivity cardiac troponin (hs-cTn) blood tests are performed at admission (0 h) and 3 hours later in the emergency department.
88829458|NCT04741763|Placebo Comparator|Placebo|Maltodextrin Placebo: Experimental is 1:2
88829459|NCT04741763|Experimental|Active|Eye Promise Visual Edge containing 8 mg zeaxanthin & 4 mg lutein Placebo: Experimental is 1:2
88829460|NCT04743089|Experimental|Spyglass arm|Patients who underwent IHD/EHD stone removal by ERCP with SpyGlass™ DS Direct Visualization System.
89357850|NCT03795077|No Intervention|Control group|Control group followed traditional lectures about professional ethics during 3 months as usual.
88829461|NCT04743089|Other|PTCS arm (historical cohort)|Patients who underwent IHD/EHD stone removal by PTCS
88829462|NCT02974205|Active Comparator|Rehabilitation with orthosis (Jack brace)|
88829463|NCT02974205|Active Comparator|Rehabilitation without orthosis|
88829464|NCT02974205|Active Comparator|Rehabilitation with orthosis (össur brace)|
88829465|NCT01644474|Active Comparator|Ezetimibe 10 mg|Oral ezetimibe 10 mg capsule daily and subcutaneous (SC) placebo injection for alirocumab every 2 weeks (Q2W) for 24 weeks.
89357851|NCT03795077|Experimental|Experimental group|Experimental group followed the programme based in professional ethics. A specific syllabus about Professional Ethics was developed. It consisted of 6 themes and included topics as moral values, ethics and moral, bioethics and professional ethics, ecc. Six related activities were created: to solve situations related to real clinical practices. Face to face group sessions based on cooperative learning were planned. Students were divided in small groups, and active participation techniques were used. Techniques used: concept maps, glossaries, brainstorming, four corners activity, aquarium, philip 6-6, kahoot, Realm Individual-Process Situation, reduced groups, guided debates, and discussion groups.
89357852|NCT03799679|Experimental|Chemotherapy|Nanoparticle Albumin-Bound Paclitaxel 125mg/m2, iv, d1* 12 cycles ( weekly), followed by epirubicin 90mg/m2, iv, d1 + cyclophosphamide 600mg/m2, iv, d1 * 4 cycles (14 days per cycle)
89357853|NCT03329482|Experimental|Pulse Ultrasound Group A|This is the Pulse Ultrasound group. Twenty five patients will be in this group.
89357854|NCT03329482|Experimental|Kneading Massage Group B|This is kneading massage group . Also 25 patients will be in this group.
89357855|NCT03505021|Experimental|Levosimendan|Levosimendan 1 mg capsules for oral administration, once to twice a day. The total duration of treatment 48 weeks
89357856|NCT03505021|Placebo Comparator|Placebo for levosimendan|Placebo capsule for oral administration, once to twice a day. The total duration of treatment 48 weeks.
89357857|NCT02497066|Placebo Comparator|Neuropathic Pain|Subjects with neuropathic pain will receive a neuropathic pain cream combined of Ketamine 10%/Gabapentin 6%/Clonidine 0.2% and Lidocaine 2% or placebo. They will be told to use the pain cream 3 times per day. Each will receive cream in identical dispensers. Cream is dispensed by rotating the base of the device and each rotation also produces a clicking sound. The number of clicks will be standardized so that all doctors utilize the same prescription depending on the size of the patient's pain location.
89357858|NCT02497066|Placebo Comparator|Nociceptive pain|Subjects with nociceptive pain will receive a nociceptive pain cream combined of Ketoprofen 10%/Baclofen 2%/Cyclobenzaprine 2% and Lidocaine 2% or placebo. They will be told to use the pain cream 3 times per day. Each will receive cream in identical dispensers. Cream is dispensed by rotating the base of the device and each rotation also produces a clicking sound. The number of clicks will be standardized so that all doctors utilize the same prescription depending on the size of the patient's pain location.
89357859|NCT02497066|Placebo Comparator|Mixed pain|Subjects who have a mixed (nociceptive and neuropathic) pain conditions will receive a mixed pain cream combined of Ketamine 10%/Gabapentin 6%/Diclofenac 3%/baclofen 2%/Cyclobenzaprine 2% and Lidocaine 2% or placebo. They will be told to use the pain cream 3 times per day. Each will receive cream in identical dispensers. Cream is dispensed by rotating the base of the device and each rotation also produces a clicking sound. The number of clicks will be standardized so that all doctors utilize the same prescription depending on the size of the patient's pain location.
89357860|NCT04217603|Experimental|Group 1|This group will perform a 6MWT with CPAP
89357861|NCT04217603|Sham Comparator|Group 2|This group will perform a 6MWT with a sham-CPAP
89357862|NCT05463640|Experimental|ADGRE2 CAR-T|"Dose Escalation:After enrollment ,Participants complete the PBMC apheresis,then complete the Lymphocyte clearance,and then receive the dose climning test: 3×10e6/kg，6 ×10e6/kg，9×10e6/kg.~Dose Expansion:Participants receive a single dose (at the MTD determined)."
89357863|NCT05155358||Control group|Healthy volunteers
89357864|NCT05155358||Patients within the acute phase of disease|Patients within 24 hours after onset
89357865|NCT05155358||Recovery stage of disease|Organ dysfunction was corrected, The patient had no obvious discomfort.
89357866|NCT03793283||Continous Subcutaneous Insulin Infusion|"All T1DM adult patients attended in Ciudad Real General University Hospital and treated with CSII.~Forty-five patients are actually treated with CSII in our hospital."
89357867|NCT03793283||Multiple dose insulin injections (MDI):|"Forty-five T1DM adult patients attended in Ciudad Real General University Hospital and treated with MDI.~MDI patients will be selected through simple random sampling (1:1) from our T1DM patient database."
89357868|NCT02496988|Other|Temozolomide|Capsules supplied in 5-mg, 20-mg, 100-mg, 140-mg, 180-mg, and 250-mg strengths; dosed at 200 mg/m2/day for 5 consecutive days, repeated every 28 days
89357869|NCT02496988|Other|Temozolomide+CIK|Autologous cytokine-induced killer cells were transfer via venous one week after Temozolomide treat
89357870|NCT03050372|Experimental|Active Low Field Magnetic Stimulation|LFMS - Active
88829466|NCT01644474|Experimental|Alirocumab 75/Up to 150 mg Q2W|SC injection of alirocumab 75 mg Q2W and oral placebo capsule for ezetimibe daily for 24 weeks. Alirocumab dose up-titrated to 150 mg from Week 12 when LDL-C levels ≥70 mg/dL (1.81 mmol/L) at Week 8.
88829467|NCT02614469|Experimental|Group 1, Inosine with Food|Group 1 subjects will take inosine with food on day 1 after an overnight fast and will take a second dose of inosine without food on day 8 after an overnight fast.
89357871|NCT03050372|Sham Comparator|Sham Low Field Magnetic Stimulation|LFMS - Sham
89357872|NCT01647971|Experimental|ublituximab|"Phase I:~4 cohorts with IV ublituximab starting with 450 mg followed by 600 mg, 900 mg or 1200 mg in each cohort (3 - 6 patients per cohort). Infusions will be on days 1, 8, 15 and 22 of cycle 1 followed by a planned maintenance with a single infusion monthly starting cycle 3. Patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) will have infusions on Days 1, 8 and 15 of cycle 1 & 2 followed by a planned maintenance with a single infusion monthly starting cycle 3. Expansion of patient enrollment in select cohorts will apply."
89357873|NCT03721315|No Intervention|Control|This group will receive the standard of care for this condition.
89357874|NCT03721315|Experimental|Intervention|This group will receive additional education along with their designated health support person prior to hospital discharge. This intervention does not include drugs/or devices.
89357875|NCT03793205|Experimental|Long-acting G-CSF group|Patients in long-acting G-CSF group accept long-acting with or without short-acting G-CSF.
89357876|NCT03793205|Experimental|Short-acting G-CSF group|Patients in long-acting G-CSF group only accept short-acting G-CSF.
89357877|NCT03324568|Other|Educational handout|
89357878|NCT03324568|Experimental|Video plus educational handout|
89357879|NCT03329248|Experimental|NANT Pancreatic Cancer Vaccine|A combination of agents will be administered to subjects in this study: ALT-803, ETBX-011, GI-4000, haNK, avelumab, bevacizumab, capecitabine, cyclophosphamide, fluorouracil, leucovorin, nab-paclitaxel, omega-3-acid ethyl esters, oxaliplatin, SBRT
89357880|NCT03792893|Experimental|Higher Blood Pressure|BOSO-TM-2430 blood pressure cuff is applied to the upper arm with the previously determined higher systolic blood pressure. Intervention: Ergometry H
89357881|NCT03792893|Experimental|Lower Blood Pressure|BOSO-TM-2430 blood pressure cuff is applied to the upper arm with the previously determined lower systolic blood pressure. Intervention: Ergometry L
89357882|NCT05482022|Experimental|speaking valve|Respiratory physical therapy treatments conducted using a speaking valve for 2 weeks (at least 8 treatments).
89357883|NCT05482022|Other|control|Respiratory physical therapy treatments conducted without using a speaking valve .
89357884|NCT05479682||EORTC QLQ-C30 first, EORTC QLQ-F17 second|Intervention relates to the order of questionnaires to be completed. In this cohort, the EORTC QLQ-C30 will be completed first and after a short interim task the QLQ-F17 second.
89357885|NCT05479682||EORTC QLQ-F17 first, EORTC QLQ-C30 second|Intervention relates to the order of questionnaires to be completed. In this cohort, the order of questionnaires is reversed: EORTC QLQ-F17 will be completed first and after a short interim task the QLQ-C30 second.
89357886|NCT03329014|Experimental|Intravenous Remimazolam|4 mg intravenous remimazolam as an intravenous control
89357887|NCT03329014|Experimental|10 mg Powder Remimazolam|Powder containing 10 mg remimazolam for intranasal administration
89357888|NCT03329014|Experimental|10 mg Solution Remimazolam|Solution containing 10 mg remimazolam for intranasal administration
89357889|NCT03329014|Experimental|20 mg Powder Remimazolam|Powder containing 20 mg remimazolam for intranasal administration
89357890|NCT03329014|Experimental|20 mg solution Remimazolam|Solution containing 20 mg remimazolam for intranasal administration
89357891|NCT03329014|Experimental|40 mg Powder Remimazolam|Powder containing 40 mg remimazolam for intranasal administration
89357892|NCT03329014|Experimental|40 mg Solution Remimazolam|Solution containing 40 mg remimazolam for intranasal administration
89357893|NCT03329014|Placebo Comparator|Placebo Powder|Powder containing 20 mg placebo for intranasal administration
89357894|NCT03329014|Placebo Comparator|Placebo solution|Solution containing 20 mg placebo for intranasal administration
89357895|NCT03792971|Experimental|Fixed Sequence|
89357896|NCT03470545|Experimental|mavacamten (MYK-461)|
89357897|NCT03470545|Placebo Comparator|Placebo|
89357898|NCT03163446|Experimental|CF-301|Patients will receive a single IV infusion of CF-301 in addition to standard of care (SOC) antibacterial therapy selected by the investigator.
89357899|NCT03163446|Placebo Comparator|Placebo|Patients will receive a single IV infusion of placebo in addition to standard of care (SOC) antibacterial therapy selected by the investigator.
89357900|NCT03799133|Experimental|Patients with Florence device|Patients with the Florence catheter placed and connected to the Florence monitor to measure XL trend.
89357901|NCT03328936|Experimental|Arm I (melphalan hydrochloride for 3-day severe neutropenia)|Patients receive personalized dose of melphalan hydrochloride IV on day -2 for for predicted 3-day duration of severe neutropenia and undergo standard of care autologous stem cell transplant on day 0.
89357902|NCT03328936|Experimental|Arm II (melphalan hydrochloride or 5-day severe neutropenia))|Patients receive personalized dose of melphalan hydrochloride IV on day -2 for predicted 5-day duration of severe neutropenia and undergo standard of care autologous stem cell transplant on day 0.
89357903|NCT01303757|Experimental|Low glycemic load diet|Low glycemic load diet
89357904|NCT01303757|Active Comparator|Low fat diet|Low fat diet
89357905|NCT02496754|Experimental|New protocol group|Use long term GnRH-a 3.75mg at day 2 of menstrual cycle. Around 30 days later, controlled ovarian hyperstimulation using gonadotropins is initiated.
89357906|NCT02496754|Active Comparator|Standard GnRH-a long protocol|Use short GnRH-a 0.1mg at luteal phase of last menstrual cycle for 10 days and 0.05mg for another 4 days. Once pituitary down regulation is achieved,controlled ovarian hyperstimulation using gonadotropins is initiated. During ovarian stimulation, short GnRH-a is used daily at the dose of 0.05mg until human chorionic gonadotrophin (HCG) trigger.
89357907|NCT03301337|Experimental|Hydrolyzed meat protein|D5-phenylalanine intrinsically labelled hydrolyzed meat protein (0.6 g per kg lean body mass), which will be consumed together with a full meal.
89357908|NCT03301337|Experimental|Minced Meat|D5-phenylalanine intrinsically labelled hydrolyzed meat protein (0.6 g per kg lean body mass), which will be consumed together with a full meal.
89357909|NCT03301337|Experimental|Beef|D5-phenylalanine intrinsically labelled hydrolyzed meat protein (0.6 g per kg lean body mass), which will be consumed together with a full meal.
88829468|NCT02614469|Experimental|Group 2, Inosine without Food|Group 2 subjects will take inosine without food on day 1 after an overnight fast and will take a second dose of inosine with food on day 8 after an overnight fast.
89357910|NCT02496910|Active Comparator|Group 1 - Period 1|Telmisartan/Amlodipine 80/5 mg (FDC) and Chlorthalidone 25mg
88829469|NCT02989129|Experimental|Chemotherapy Induced Neuropathic Pain (CINP) Treatment Group|"Questionnaires completed at Baseline and at End of Study Visit.~Participants take Quercetin tablets by mouth 2 times every day for 12 weeks."
89357911|NCT02496910|Experimental|Group 2 - Period 1|YH22162 FDC tablet of Yuhan Corporation
89357912|NCT02496910|Experimental|Group 1 - Period 2|YH22162 FDC tablet of Yuhan Corporation
89357913|NCT02496910|Active Comparator|Group 2 - Period 2|Telmisartan/Amlodipine 80/5 mg (FDC) and Chlorthalidone 25mg
89357914|NCT01304615|Active Comparator|Web-Based|Participants will receive a web-based behavioral intervention that decreases dietary energy density and increases physical activity combined with a life skills training program. Life skills training topics include stress management, coping with change, time management, and thoughts and emotions in weight control.
89357915|NCT01304615|Experimental|Web-Based plus Culinary Training|Participants will receive a web-based behavioral intervention that decreases dietary energy density and increases physical activity combined with a hands-on culinary skills training program designed to increase food purchasing and meal self-preparation and consumption of meals low in energy density.
88829470|NCT02989129|Experimental|Chemotherapy Induced Neuropathic Pain (CINP) Prevention Group|"Questionnaires completed at Baseline and at End of Study Visit.~Participants take Quercetin tablets by mouth 2 times every day for 12 weeks."
88829471|NCT02615717|Experimental|Attentional Bias Modification|In the ABM treatment condition, participants will have four 20-minute in-lab treatment conditions across two weeks. Within these Attention Bias Modification sessions, participants will be presented with a fixation cross for 500 ms. The fixation cross will then be replaced with a word pair consisting of either a threat/neutral pair or a neutral/neutral word for 500 ms, followed by a probe in the location of one of the two words (80% threat/neutral pairs, 20% neutral/neutral pairs; the target will always appear in the location of the neutral word).
88829472|NCT02615717|Active Comparator|Attentional Control Condition|Participants will have four 20-minute in-lab treatment conditions across two weeks. Within the Attention Bias Modification control sessions, participants will be presented with a fixation cross for 500 ms. The fixation cross will then be replaced with a word pair consisting of either a threat/neutral pair or a neutral/neutral word for 500 ms, followed by a probe in the location of one of the two words (80% threat/neutral pairs, 20% neutral/neutral pairs; the target appears in the location of the neutral word in 50% of the trials. Complete Stroop and 3-back task, etc.
88829473|NCT05302115||S-ICD|
88829474|NCT01847131|Active Comparator|oxymetazoline|0.05% oxymetazoline nasal sprays 2 sprays in each nostril twice daily
88829475|NCT01847131|Placebo Comparator|placebo|placebo nasal spray 2 sprays in each nostril twice daily
88829476|NCT02285010|Placebo Comparator|Placebo|Placebo in capsule is prescribed to the patient 60 min prior to the surgery.
88829477|NCT02285010|Active Comparator|Pregabalin|Pregabalin (150 mg) one capsule is prescribed to the patient 60 min prior to the surgery.
88829478|NCT02617667|Experimental|CyclASol Ophthalmic Solution 1|Cyclosporine A solution (dose-level 1) in vehicle
88829479|NCT02617667|Experimental|CyclASol Ophthalmic Solution 2|Cyclosporine A solution (dose-level 2) in vehicle
88829480|NCT02617667|Placebo Comparator|Placebo Ophthalmic Solution|Vehicle only
88829481|NCT02617667|Active Comparator|Restasis|Cyclosporine A 0.05% ophthalmic emulsion
88829482|NCT05154773|Experimental|KidneyTIME|KidneyTIME is a self-directed digital intervention. It contains 26 animated videos, each 1-3 minutes in length, designed to address knowledge gaps and concerns about kidney transplantation and living donation that were identified in literature reviews, formative research, and video development studies as critical for optimal prospective kidney recipient and donor participation in LDKT. We chose 6 videos from the entire series to be delivered sequentially for a total duration of 13 minutes. After completing the proscribed videos and an immediate-post exposure survey, everyone then received a link to access all 26 videos centralized on a website where the videos were activated for sharing through various modalities, including text, email, Facebook, and Twitter. The website could be accessed using this link from any electronic device throughout the study. Prompts to use the intervention were sent once a week for 3 weeks and then monthly for 12 months.
88829483|NCT05154773|No Intervention|Usual Care|Routine educational materials from non-study sources through usual Transplant Center protocols including booklets, nurse communications, and the usual care video, a nurse-narrated power-point presentation outlining recipient and donor evaluation, surgery, and recovery processes and outcomes.
88829484|NCT05533411|Experimental|Donanemab|Donanemab administered intravenously (IV).
88829485|NCT05533411|Placebo Comparator|Placebo|Placebo administered IV.
88829486|NCT04742855||Group A|It will consist of 10 adults and 5 children. They will get the yogurt strains
88829487|NCT04742855||Group B|It will consist of 10 adults and 5 children. They will get the Bifidobacterium strains.
88829488|NCT04742855||Group C|It will consist of 10 adults and 5 children. They will get the placebo.
88829489|NCT01848067|Experimental|Treatment (alisertib, abiraterone acetate, prednisone)|Patients receive alisertib PO BID on days 1-7, abiraterone acetate PO daily, and prednisone PO BID. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
88829490|NCT05068349|Experimental|A group of patients with ischemic stroke were treated with butylphthalide injection and capsules|Patients eligible for inclusion and exclusion are only divided into one group, no controls or other.
88829491|NCT05731739||RESPONDERS|The investigators will define responders as patients achieving Numerical Rating Score (NRS) reductions of 30% or greater based on literature defined criteria for meaningful reductions in pain scores
88829492|NCT05731739||NON RESPONDERS|When a patient failed to respond to the lidocaine infusion, they were given the option to have repeat infusion after four weeks. If no response was obtained, despite two infusions, this was considered as a failure of treatment and no further lidocaine infusions were conducted. Patient will be labelled as a non responder
88829493|NCT01848847|Experimental|Full Bladder|Hysteroscopy conducted under full bladder.
88829494|NCT01848847|Experimental|Empty Bladder|Hysteroscopy conducted under empty bladder.
88829495|NCT04591717|Experimental|Cohort 1: 0.5 mL of hAd5-S-Fusion+N-ETSD SC|0.5 mL of hAd5-S-Fusion+N-ETSD SC (5 × 10e10 VP/dose) on days 1 and 22
88829496|NCT04591717|Experimental|Cohort 2: 1.0 mL of hAd5-S-Fusion+N-ETSD SC|Cohort 2: 1.0 mL of hAd5-S-Fusion+N-ETSD SC (1 × 10e11 VP/dose) on days 1 and 22
88829497|NCT04591717|Experimental|Cohort 3a: 1.0 mL of hAd5-S-Fusion+N-ETSD SC and 0.5 mL of hAd5-S-Fusion+N-ETSD sublingually|Cohort 3a: 1.0 mL of hAd5-S-Fusion+N-ETSD SC (1 × 10e11 VP/dose) and 0.5 mL of hAd5-S-Fusion+N-ETSD sublingually (5 × 10e10 VP/dose) on day 1; 1.0 mL of hAd5-S-Fusion+N-ETSD SC (1 × 10e11 VP/dose) and 0.5 mL of hAd5-S-Fusion+N-ETSD sublingually (5 × 10e10 VP/dose) on day 22
88829498|NCT04591717|Experimental|Cohort 3b: 1.0 mL of hAd5-S-Fusion+N-ETSD SC and 0.5 mL of hAd5-S-Fusion+N-ETSD sublingually|Cohort 3b: 1.0 mL of hAd5-S-Fusion+N-ETSD SC (1 × 10e11 VP/dose) and 0.5 mL of hAd5-S-Fusion+N-ETSD sublingually (5 × 10e10 VP/dose) on day 1; no vaccine on day 22
88829499|NCT04591717|Experimental|Cohort 3c: 1.0 mL of hAd5-S-Fusion+N-ETSD SC and 0.5 mL of hAd5-S-Fusion+N-ETSD sublingually|Cohort 3c: 1.0 mL of hAd5-S-Fusion+N-ETSD SC (1 × 10e11 VP/dose) and 0.5 mL of hAd5-S-Fusion+N-ETSD sublingually (5 × 10e10 VP/dose) on day 1; 0.5 mL of hAd5-S-Fusion+N-ETSD sublingually (5 × 10e10 VP/dose) on day 22
89357916|NCT03342352|Experimental|Arm A|Nivolumab plus epacadostat in combination with platinum (carboplatin/cisplatin) plus 5-fluorouracil.
89357917|NCT03342352|Active Comparator|Arm B|EXTREME regimen.
88829500|NCT04591717|Experimental|Cohort 3d: 1.0 mL of hAd5-S-Fusion+N-ETSD SC and 0.5 mL of hAd5-S-Fusion+N-ETSD sublingually|Cohort 3d: 1.0 mL of hAd5-S-Fusion+N-ETSD SC (1 × 10e11 VP/dose) and 0.5 mL of hAd5-S-Fusion+N-ETSD sublingually (5 × 10e10 VP/dose) on day 1; 0.5 mL of hAd5-S-Fusion+N-ETSD sublingually (5 × 10e10 VP/dose) on days 15 and 29
89357918|NCT03342352|Experimental|Arm C|Nivolumab plus placebo for epacadostat in combination with platinum (carboplatin/cisplatin) plus 5-fluorouracil.
89357919|NCT03722563|Active Comparator|TLHS|total laparoscopic hysterectomy with sacrocolpopexy will be performed
89357920|NCT03722563|Experimental|TLHLS|total laparoscopic hysterectomy with lateral suspension will be performed
89357921|NCT03636360|Experimental|LED - Sunlike|LED lighting with spectral pattern similar to that of sunlight
89357922|NCT03636360|Active Comparator|Fluorescent|Fluorescent light at same illuminance (lux) as LED light
89357923|NCT03636360|Placebo Comparator|Dim|"Dim fluorescent light with same spectrum as Fluorescent condition"
89357924|NCT03636360|Active Comparator|LED|Standard LED lighting
89357925|NCT03795389|Experimental|3.0 µg/kg SC, single dose|n=8, study group of T1D or T2D with stage 3 CKD. separate n=8 of study group with T1D or T2D with CKD stage 4).
89357926|NCT03795389|Experimental|5.0 µg/kg SC, single dose|n=8, study group of T1D or T2D with stage 3 CKD.
89357927|NCT03795389|Experimental|8.0 µg/kg SC, single dose|n=8, study group of T1D or T2D with stage 3 CKD.
89357928|NCT03719443|Experimental|VIS649|A single dose of VIS649 will be administered IV over approximately 1 hour on Day 1, at doses ranging from 0.5 mg/kg up to but not to exceed 20 mg/kg. No other doses will be administered during the study.
88829501|NCT05731583||Recovering COVID|Subjects with hospitalization due to a confirmed diagnosis of Sars-CoV-2 infection, that were considered eligible for home monitoring.
89357929|NCT03719443|Placebo Comparator|Placebo|Single IV dose of placebo will be administered via IV over approximately 1 hour on Day 1. No other doses will be administered during the study.
88829502|NCT05731583||Ongoing COVID|Subjects with confirmed new diagnosis of Sars-CoV-2 infection, not requiring immediate hospitalization.
88829503|NCT05460793|Experimental|Surgical treatment|Minimally invasive endoscopy-guided surgery in addition to standard medical management for the treatment of spontaneous supratentorial intracerebral hemorrhage performed within 8 hours of symptom onset.
88829504|NCT05460793|No Intervention|Standard medical management|Standard medical treatment for the treatment of spontaneous supratentorial intracerebral hemorrhage (treatment of blood pressure, admission to stroke unit and supportive care, surgical treatment if necessary in case of deterioration).
89357930|NCT03636204|Experimental|AL001|Up to six single ascending doses of AL001
89357931|NCT03636204|Placebo Comparator|Saline Solution|Saline solution will be administered as a single infusion for each cohort in a ratio of 6 active and 2 placebo subjects
89357932|NCT03120442|Experimental|Propofol-fentanyl|Fentanyl 0.5 mcg/kg Propofol Target-controlled infusion to achieve MOAA/S 3-4 as end point of sedation Bispectral index (BIS) monitoring
89357933|NCT03120442|Experimental|Dexmedetomidine|Fentanyl 0.5 mcg/kg Dexmedetomidine in incremental titrated dose for moderate sedation to achieve MOAA/S 3-4 as end-point of titration Bispectral index (BIS) monitoring
88829505|NCT05731427||Pseudomonas aeruginosa colonization group|Colonization of Pseudomonas aeruginosa in the airways of patients with bronchiectasis
88829506|NCT05731427||Non-Pseudomonas aeruginosa colonization group|No colonization of Pseudomonas aeruginosa in the airways of patients with bronchiectasis
89357934|NCT03120442|Experimental|Fentanyl|Fentanyl 0.5 mcg/kg Supplemental dosage of fentanyl for intraoperative anxiolysis
89357935|NCT03722485|Experimental|Negative Pressure Therapy w/ instillation and dwell (NPWTi-d)|V.A.C. VeraFlo Cleanse Choice Dressing, V.A.C.Ulta Therapy Unit and saline solution
89357936|NCT03722485|Active Comparator|Collagenase Ointment|Collagenase Ointment
89357937|NCT00852696|Placebo Comparator|Placebo Group|Placebo Orally 9 weeks once daily.
89357938|NCT00852696|Experimental|Solifenacin Group|Solifenacin Orally 9 weeks once daily.
89357939|NCT02496832|Experimental|FAZA PET-CT scan|"FAZA PET-CT imaging within 14 days of treatment from the EMR200592-001 study.~FAZA PET-CT imaging about 5 weeks after start of treatment from the EMR200592-001 study."
89357940|NCT04640246|Experimental|TBX-3400|TBX-3400 by intravenous infusion
89357941|NCT03324490|Active Comparator|TSA group|Thoracic Spinal Anesthesia; Bupivacaine 0.5% (hyperbaric) 7.5mg, Fentanyl 25 µg & Dexmedetomidine 5 µg by intrathecal injection
89357942|NCT03324490|Active Comparator|TEA group|Thoracic Epidural Anesthesia; Bupivacaine 0.5% (isobaric) 25-50 mg & Fentanyl 10-20 µg by epidural injection
89357943|NCT04286412|Experimental|Treatment Arm|At least twenty five eligible male subjects will be enrolled in the treatment arm to receive Nonacog alfa until 16 exposure days (EDs) or a period of up to 8 weeks on treatment had occurred (whichever occurs first).
89357944|NCT03798899|Experimental|Penthrox® (Methoxyflurane)|"Patients will be asked to inhale Penthrox® intermittently or continuously to obtain adequate analgesia.~Penthrox® or placebo will be administered in combination with standard analgesic treatments usually used according to the emergency department protocol (SoC).~Duration of treatment: 1 administration (with a maximum of 2 inhalers) during passage to emergency."
89357945|NCT03798899|Placebo Comparator|Normal Saline|"Patients will be asked to inhale Penthrox® intermittently or continuously to obtain adequate analgesia.~Penthrox® or placebo will be administered in combination with standard analgesic treatments usually used according to the emergency department protocol (SoC).~Duration of treatment: 1 administration (with a maximum of 2 inhalers) during passage to emergency."
89357946|NCT03274661|Experimental|Pembrolizumab 200 mg Q3W|Pembrolizumab 200 mg Intravenous Infusion every 3 weeks administered on Day 1 of each 3 week cycle
89357947|NCT02496598|Experimental|In Vitro Follicle Activation (IVA)|Ovarian tissue will be removed and cultured in vitro with compounds to activate dormant follicles. Following activation, ovarian tissue will be auto-grafted and the patient monitored for follicular growth.
89357948|NCT03636126|Experimental|VR + TACS|"Complete one chapter of the virtual reality game Land's End while simultaneously using the tACS system (chapters range in length from approximately 5-20 minutes) after waking up each day (or prior to beginning a work shift).~Use the tACS system without the VR for 20 minutes just before sleep (or at the end of a work shift, whichever time point is most convenient). Table 1. Timeline of Study Treatment"
89357949|NCT03636126|No Intervention|No Intervention for 2 Weeks|For 2 weeks of the 4 week study, each group (Group A and Group B) will continue work shifts as usual with no intervention.
89357950|NCT01560455|Active Comparator|single stent|single stent
89357951|NCT01560455|Active Comparator|dual stent|dual stent (culotte)
88829507|NCT05731427||Before treatment with macrolides|Before treatment with macrolides in patients with bronchiectasis
88829508|NCT05731427||After treatment with macrolides|After 6 months of treatment with macrolides for patients with bronchiectasis
88829509|NCT01850485||normothermia, 36 degrees|microcirculation after cardiac arrest by SDF and NIRS, in patients treated with 36 degrees, difference is temperature, in this group 36
88829510|NCT01850485||33 degrees, therapeutic hypothermia|microcirculation after cardiac arrest by SDF and NIRS, in patients treated with 33 degrees, difference is temperature, in this group 33
88829511|NCT00364871|Experimental|1|Bupropion SR (400 mg/day) plus Naltrexone (48 mg/day)
88829512|NCT00364871|Experimental|2|Bupropion SR (400 mg/day) plus Naltrexone (16 mg/day)
88829513|NCT00364871|Active Comparator|3|Bupropion SR (400 mg/day)
88829514|NCT00364871|Active Comparator|4|Naltrexone (48 mg/day)
88829515|NCT00364871|Placebo Comparator|5|B-Placebo plus N-Placebo
88829516|NCT00364871|Placebo Comparator|6|B-Placebo plus N-Placebo
89357952|NCT02491372|Experimental|Intervention|Acceptance and commitment therapy group
88829517|NCT00364871|Experimental|7|Bupropion SR (400 mg/day) plus Naltrexone (32 mg/day)
88829518|NCT00551161|Experimental|single-arm|24-week observational lead-in period, wherein patients already on a stable dose of donepezil, rivastigmine, or galantamine continue on that dose, followed by a 24-week open-label memantine period, wherein patients receive open-label memantine treatment titrated to a dose of 20 mg per day, in addition to their ongoing stable cholinesterase inhibitor treatment
88829519|NCT04660019|Experimental|the scalp and ear acupuncture|CHIAN HUEI ACUPUNCTURE NEEDLE
88829520|NCT04660019|Placebo Comparator|sham acupuncture|Auricular points sticker
88829521|NCT05429177|Experimental|SAD Cohort 1(0.1% QY101 ointment or vehicle apply to 5%BSA)|3 subjects use 0.1% QY101 ointment，1 subject uses vehicle topical applied to 5% Body Surface Area，assessed until 72 hours postdose
88829522|NCT05429177|Experimental|SAD Cohort 2(0.1% QY101 ointment or vehicle apply to 20%BSA)|6 subjects use 0.1% QY101 ointment，2 subjects use vehicle topical applied to 20% Body Surface Area，assessed until 72 hours postdose
88829523|NCT05429177|Experimental|SAD Cohort 3(0.3% QY101 ointment or vehicle apply to 20%BSA)|6 subjects use 0.3% QY101 ointment，2 subjects use vehicle topical applied to 20% Body Surface Area，assessed until 72 hours postdose
88829524|NCT05429177|Experimental|SAD Cohort 4(0.5% QY101 ointment or vehicle apply to 20%BSA)|6 subjects use 0.5% QY101 ointment，2 subjects use vehicle topical applied to 20% Body Surface Area，assessed until 72 hours postdose
88829525|NCT05429177|Experimental|SAD Cohort 5(1.0% QY101 ointment or vehicle apply to 20%BSA)|6 subjects use 1.0% QY101 ointment，2 subjects use vehicle topical applied to 20% Body Surface Area，assessed until 72 hours postdose
88829526|NCT05429177|Experimental|SAD Cohort 6(1.0% QY101 ointment or vehicle apply to 40%BSA)|6 subjects use 1.0% QY101 ointment，2 subjects use vehicle topical applied to 40% Body Surface Area，assessed until 72 hours postdose
88829527|NCT05429177|Experimental|MAD Cohort 7(0.3% QY101 ointment or vehicle apply to 20%BSA)|6 subjects use 0.3% QY101 ointment，2 subjects use vehicle topical applied to 20% Body Surface Area，twice daily for 7 days and once in the morning on D8
88829528|NCT05429177|Experimental|MAD Cohort 8(0.5% QY101 ointment or vehicle apply to 20%BSA)|6 subjects use 0.5% QY101 ointment，2 subjects use vehicle topical applied to 20% Body Surface Area，twice daily for 7 days and once in the morning on D8
88829529|NCT05429177|Experimental|MAD Cohort 9(1.0% QY101 ointment or vehicle apply to 20%BSA)|6 subjects use 1.0% QY101 ointment，2 subjects use vehicle topical applied to 20% Body Surface Area，twice daily for 7 days and once in the morning on D8
88829530|NCT05429177|Experimental|MAD Cohort 10(1.0% QY101 ointment or vehicle apply to 40%BSA)|6 subjects use 1.0% QY101 ointment，2 subjects use vehicle topical applied to 40% Body Surface Area，twice daily for 7 days and once in the morning on D8
89357953|NCT02491372|No Intervention|Comparison|Treatment as usual
88829531|NCT02277925|Active Comparator|Gore-Tex permanent suture|Participants in this arm will receive Gore-Tex permanent suture
88829532|NCT02277925|Experimental|PDS delayed absorbable suture|Participants in this arm will receive 2-0 PDS delayed absorbable suture
88829533|NCT02988037|Experimental|A-DBT-A|Began Adapted Dialectical Behaviour Therapy for Adolescents
88829534|NCT01851655|Experimental|Plyometric Exercise - High intensity|The exercises should produce a higher peak vertical ground reaction force than those in the low group based on literature findings (e.g. single leg jumps, jumps from higher heights, higher percent effort).
89357954|NCT03324412|Active Comparator|Treatment of MTX|Patients were treated with methotrexate (MTX)and Tripterygium wilfordii Hook F（TwHF）placebo.
89357955|NCT03324412|Experimental|Treatment of MTX and TwHF|Patients were treated with methotrexate (MTX)and Tripterygium wilfordii Hook F（TwHF).
89357956|NCT03798821|Experimental|Experimental|One capsule a day will be consumed. At breakfast for the six weeks.
89357957|NCT03798821|Placebo Comparator|Comparator|One capsule a day will be consumed. At breakfast for the six weeks.
89357958|NCT03324334||Study group|Patients with ulcerative colitis Interventions to be administered: Thyroid antibodies and Thyroid sonography
89357959|NCT03324334||Control group|normal control subjects selected from general population at random Interventions to be administered: Thyroid antibodies and Thyroid sonography
89357960|NCT05434416|No Intervention|No Interventions|Given access to all interventions at the end of the 5 weeks of the trial.
89357961|NCT05434416|Experimental|Short-term interventions|Participants have access only to short-term interventions. Given access to all interventions at the end of the 5 weeks of the trial.
89357962|NCT05434416|Experimental|Short-term and long-term interventions|Short-term and long-term interventions Participants have access to short-term and all long-term interventions.
89357963|NCT05434416|Experimental|Long-term intervention: Meditations|Participants have access to short-term interventions. Participants have access to one long-term intervention: Meditations. Given access to all interventions at the end of the 5 weeks of the trial.
89357964|NCT05434416|Experimental|Long-term intervention: Mindfulness|Participants have access to short-term interventions. Participants have access to one long-term intervention: Mindfulness. Given access to all interventions at the end of the 5 weeks of the trial.
89357965|NCT05434416|Experimental|Long-term intervention: My beliefs|Participants have access to short-term interventions. Participants have access to one long-term intervention: My beliefs. Given access to all interventions at the end of the 5 weeks of the trial.
89357966|NCT05434416|Experimental|Long-term intervention: Success Diary|Participants have access to short-term interventions. Participants have access to one long-term intervention: Success Diary. Given access to all interventions at the end of the 5 weeks of the trial.
88829535|NCT01851655|Active Comparator|Plyometric Exercise - Low intensity|A lower peak vertical ground reaction force will be generated in the low intensity group compared to the high intensity group based on findings in the literature (e.g. lower box heights, only two-legged jumps, lower percent effort)
88829536|NCT05442151|Other|FAPI-PET/CT group|
88829537|NCT00365807|Active Comparator|Brief Family Intervention (Primarily education)|Behaviorally based family group intervention using standard education and nutrition counseling. Three hours of client contact
88829538|NCT00365807|Experimental|Positively Fit|12 week (90 minute per session) behavioral group intervention for children and their parents. Children and parent attend parallel group with identical (but developmentally appropriate) information presented.
88829539|NCT00365885|Experimental|1|electronic mail notifications to care managers about sentinel health events
88829540|NCT00365885|Experimental|2|feedback reports with notifications to clinic managers about sentinel health events
88829541|NCT00365885|Experimental|3|letters to patients with notifications about sentinel health events
88829542|NCT00365885|No Intervention|4|electronic mail notifications to care managers about sentinel health events -- generated but withheld
88829543|NCT00365885|No Intervention|5|feedback reports with notifications to clinic managers about sentinel health events -- generated but withheld
88829544|NCT00365885|No Intervention|6|letters to patients with notifications about sentinel health events -- generated but withheld
88829545|NCT04741373|Placebo Comparator|Group of health education|
89357967|NCT05434416|Experimental|Long-term intervention: Gratitude Journal|Participants have access to short-term interventions. Participants have access to one long-term intervention: Gratitude Journal. Given access to all interventions at the end of the 5 weeks of the trial.
89357968|NCT05434416|Experimental|Long-term intervention: Planner|Participants have access to short-term interventions. Participants have access to one long-term intervention: Planner. Given access to all interventions at the end of the 5 weeks of the trial.
89357969|NCT05434416|Experimental|Long-term intervention: Journey to Sobriety|Participants have access to short-term interventions. Participants have access to one long-term intervention: Journey to Sobriety. Given access to all interventions at the end of the 5 weeks of the trial.
89357970|NCT05434416|Experimental|Long-term intervention: Mood Journal|Participants have access to short-term interventions. Participants have access to one long-term intervention: Mood Journal. Given access to all interventions at the end of the 5 weeks of the trial.
88829546|NCT04741373|Active Comparator|Group of health education and rehabilitation exercise|
88829547|NCT04741373|Experimental|Group of health education,exercise and ONS|
88829548|NCT01852201|No Intervention|Best medical therapy|"Patients randomized to the control group will receive best conventional MT for acute ischemic stroke as determined by the attending stroke physician. Standardization of medical management in both arms will occur according to the following:~General medical management according to AHA/ASA guidelines~Admission to monitored or intensive care unit for at least 24 hours~Aggressive hypertensive-hypervolemic therapy should be used only in the case of symptomatic blood pressure fluctuations or if blood pressure drops below the normal range for the patient~Antithrombotics: ASA 325 mg PO qd for 7 days (clopidogrel may be used as adjunctive therapy if indicated for cardiac disease) then per discretion of treating physician~Close monitoring of BP and glucose with treatment according to AHA/ASA guidelines~Follow-up imaging study required in any patient with neurologic deterioration"
88829549|NCT01852201|Experimental|Endovascular treatment|Endovascular intervention can be performed under either general anesthesia or conscious sedation based on best practices as determined by treating physician. Attempt should be made to expedite the transition from imaging to treatment in as rapid a fashion as possible. The subject should be prepared for the planned interventional procedure according to standard hospital procedures. Mechanical revascularization should be performed with the operators standard thrombectomy technique using aspiration or a stent retriever, separately or in combination.
88829550|NCT04433195|Active Comparator|Immediate NAA by clinician|Nucleic acid amplification test requested by clinicians as the initial diagnostic test for the diagnosis of pulmonary TB
88829551|NCT04433195|Experimental|Immediate NAA as intervention|Nucleic acid amplification test not requested by clinicians as the initial diagnostic test for the diagnosis of pulmonary TB, but Xpert MTB/RIF is performed as intervention in this study (intervention group)
88829552|NCT04433195|No Intervention|No immediate NAA|Nucleic acid amplification test not requested by clinicians as the initial diagnostic test for the diagnosis of pulmonary TB, and Xpert MTB/RIF is not performed as the initial diagnostic test in this study (control group). Nucleic acid amplification test may be ordered at a later point in time by clinicians as an add-on test after sputum smear microscopy
88829553|NCT05730959|Other|malfunctioning IPAA|Patients with malfunctioning IPAA
88829554|NCT00550771|Active Comparator|Doxorubicin Based Regimen|
88829555|NCT00550771|Experimental|Pegylated Liposomal Doxorubicin (PLD) Based Regimen|
88829556|NCT04340765|Experimental|18F-fluorocholine PET/CT|18F-fluorocholine PET/CT
89357971|NCT05434416|Experimental|Long-term intervention: Dream Diary|Participants have access to short-term interventions. Participants have access to one long-term intervention: Dream Diary. Given access to all interventions at the end of the 5 weeks of the trial.
89357972|NCT05434416|Experimental|Long-term intervention: Thinking traps|Participants have access to short-term interventions. Participants have access to one long-term intervention: Thinking traps. Given access to all interventions at the end of the 5 weeks of the trial.
89357973|NCT03792815|Experimental|busulfan melphalan etoposide|busulfan 3.2 mg/kg/day i.v. on day -7, -6, and -5 etoposide 400 mg/m2 i.v. on day -5 and -4 melphalan 50mg/m2/day i.v. on day -3 and -2
89357974|NCT03328858|Other|Ketogenic Diet|Participants will be provided a consultation with a ketogenic dietitian, and test the tolerance to the diet in an inpatient mode
89357975|NCT04381364|Experimental|Medical treatment|Treatment with ciclesonide
89357976|NCT04381364|No Intervention|Standard of Care|Standard Medical Care
89357977|NCT01331382|Experimental|250mg trans- resveratrol|
89357978|NCT01331382|Experimental|250mg trans-resveratrol with 20mg piperine|
89357979|NCT01331382|Placebo Comparator|Placebo|
89357980|NCT03328780||Hemoglobin determination|In this study classical laboratory determination, determination with HemoCue® and Rad-67™ will be performed to compare precision of those three methods as well as their correlation.
89357981|NCT03794765|Experimental|Antibiotic|Standard of Care (steroids, prophylactic anticoagulation, oral nutrition) And Antibiotics (Inj Ceftriaxone 1 gram intravenous twice daily And Inj Metronidazole 500 mg intravenous thrice daily) for initial 48 hours
89357982|NCT03794765|Placebo Comparator|Placebo|Standard of care (steroids, prophylactic anticoagulation, oral nutrition) And Placebo infusions similar to the active drugs
89357983|NCT04280744|Experimental|Music therapy|Music listening intervention provided by a board certified music therapist.
89357984|NCT03723876|Active Comparator|Intervention group|Twelve occasions of Basic body awareness therapy, administered once a week, alongside treatment as usual (such as structured everyday support, medicine, contact with social worker).
89357985|NCT03723876|No Intervention|Control group|No extra intervention except treatment as usual.
89357986|NCT03324256|Active Comparator|Energy drink and placebo gum|Commercially-available energy drink (16oz) + 2 pieces of placebo gum
89357987|NCT03324256|Active Comparator|Caffeinated drink and placebo gum|Commercially-available caffeinated drink (16oz) + 2 pieces of placebo gum
89357988|NCT03324256|Active Comparator|Control drink and energy gum|Control drink (16oz) + 2 pieces of energy gum
89357989|NCT03324256|Placebo Comparator|Control drink and placebo gum|Control drink (16oz) + 2 pieces of placebo gum
89357990|NCT03324256|Active Comparator|Energy drink and total sleep deprivation|Commercially-available energy drink (16oz) + 2 pieces of placebo gum following total sleep deprivation
89357991|NCT03792581|Active Comparator|EV1000 monitor|MAP management will be done as usual ( adjustment by nurses) and fluid management will be managed using the EV1000 monitoring device with the automated decision support system
88829557|NCT02278237|Experimental|VME Group|Pre and post VME education group. The Intervention is the use of the virtual education module rather than the interpersonal educational strategy.
89000791|NCT04652635|No Intervention|Observation|Participants will follow up at clinic visits at 1 week, 3 months, and 6 months
89357992|NCT03792581|Experimental|EV1000 monitor + closed-loop system|fluid management will be done using the automated decision support system and MAP will be adjusted by the automated closed-loop system for vasopressor administration
89357993|NCT01622712|Experimental|Unilateral inguinal hernia|A Nitinol containing large pore polypropylene mesh will be placed in patients with unilateral inguinal hernia.
89357994|NCT03342118|Experimental|Phloroglucin group|patients taken Phloroglucin(Flospan®)
89357995|NCT03342118|Placebo Comparator|Normal saline placebo group|patients taken normal saline placebo
88829558|NCT01852513|Active Comparator|QNASL nasal spray|QNASL 320 mcg once-daily administered as two sprays in each nostril; 2 weeks of treatment
88829559|NCT01852513|Placebo Comparator|Placebo nasal spray|Placebo nasal spray once-daily administered as two sprays in each nostril; 2 weeks of treatment
88829560|NCT01852669|Experimental|Inversion, Hydration, ESWL|ESWL with hydration and inversion
88829561|NCT01852669|Active Comparator|ESWL, Hydration|ESWL with hydration
89000792|NCT04652791||Wangbi Capsule|Patients who are taking Wangbi Capsule for the treatment.
89000793|NCT04652791||Other drugs|Patients who are not taking Wangbi Capsule for the treatment.
89000794|NCT04652284|Active Comparator|Rifabutin full dose|oral amoxicillin 1000mg bd and rifabutin 150 mg bd and esomeprazole 40 mg bd 14 days
89000795|NCT04652284|Active Comparator|Rifabutin low dose|oral amoxicillin 1000mg bd and rifabutin 150 mg d and esomeprazole 40 mg bd 14 days
89177805|NCT00821860|Active Comparator|Arm II|Patients undergo talc pleurodesis via an indwelling intercostal chest drain or via thoracoscopy either at the time of biopsy or after confirmation of biopsy results.
89177806|NCT00794196|No Intervention|Usual Care|The control group will be receiving usual medical and pharmaceutical care.
89357996|NCT03798587||OS patients|"Patients with age ≥18 years that were/can be recruited within the IRCCS Istituto Ortopedico Galeazzi BioBanca (ethical committee approval n. 29/INT/2017).~Patients with age <18 years: will be additionally recruited besides the IRCCS Istituto Ortopedico Galeazzi BioBanca.~The target group corresponds to patients hospitalized at Istituto Ortopedico Galeazzi, undergoing surgical eradication of primary osteosarcoma.~Patients will be considered eligible for enrollment in the study if able to sign the consent to the procedure after appropriate information from the reference surgeon or signed by parents or legal guardian after appropriate information from the reference surgeon (if age <18).~Inclusion Criteria:~Indication for primary OS eradication surgery~Patients hospitalized in Istituto Ortopedico Galeazzi~Exclusion criteria:~-Patients not able to sign the Informed Consent."
89357997|NCT03324178|Experimental|Neurofeedback training|Sixteen 30-minute sessions of neurofeedback training performed once a day over the course of four weeks (four sessions each week)
89357998|NCT03324178|Active Comparator|Video game control group|Sixteen 30-minute sessions of playing video games once a day over the course of four weeks (four sessions each week)
89357999|NCT01331460|Experimental|RBT Experimental|
89358000|NCT01331460|Active Comparator|Case-Management: Treatment as Usual|
89358001|NCT03798509|Experimental|Human CD19 targeted T Cells Injection|
89358002|NCT02496364|Other|Observation|Clinical data analysis
89358003|NCT01605552|Experimental|Beating the Blues (BtB)|An 8-session, empirically supported, computerized, cognitive-behavioral intervention for depression (www.beatingthebluesus.com)
89358004|NCT01605552|Other|Usual Care|Patients and their primary care providers were informed of the positive depression screen, and follow-up was encouraged.
89358005|NCT02496442|Active Comparator|using Aqueduct|Patients passing procedures with Aqueduct
89358006|NCT02496442|No Intervention|Not using Aqueduct|Patients passing the standard procedures
89358007|NCT02496286|Experimental|Eligible patients requiring paracentesis for symptom control|
88829562|NCT05271383||Study group|Male and female, major or minor, who will be treated by orthognathic surgery (maxillary, mandibular, maxillomandibular or/with genioplasty). The bone maturity of the participants (assessed by investigators) need to be sufficient for the treatment.
88829563|NCT01853215|Experimental|Sternal intraosseous vascular access|Sternal intraosseous vascular access using T.A.L.O.N. Intraosseous System.
88829564|NCT04741295|No Intervention|Control Group|Adenomyosis patients in control group have normal luteal progesterone support.
88829565|NCT04741295|Experimental|Low molecular weight heparin Group|Adenomyosis patients in Low molecular weight heparin group have Low molecular weight heparin in addition to normal luteal progesterone support.
89358008|NCT01489176|Experimental|Regadenoson; Optison|Use of Regadenoson as the chemical stress agent using Optison as a contrast agent during stress echocardiography.
89358009|NCT03792503|Experimental|Apatinib，Pemetrexe|Pemetrexe 500 mg/m2 d1×q3w; Apatinib 500 mg Po qd
89358010|NCT03323788||Aim 1|Aim 1. To determine whether the transcription factor expression response to exercise is dysregulated in muscle from type 2 diabetic patients. We will test the hypothesis that MZF1, NFKB1, RELA, SP1/KLF and EGR1 responses to an acute exercise bout are reduced in insulin resistant patients with type 2 diabetes.
89358011|NCT03323788||Aim 2|"Aim 2. To determine how insulin resistance changes the response of post-translational modifications of SP1/KLF family and MZF1 transcription factors to acute exercise in muscle from type 2 diabetic patients. We will test the hypothesis that:~SP1/KLF2, 4, and 6 and phosphorylation/acetylation and MZF1 phosphorylation is altered in response to acute exercise.~The response of SP1/KLF2, 4, and 6 phosphorylation and acetylation and MZF1 phosphorylation to acute exercise is abnormal in patients with type 2 diabetes."
89358012|NCT03323788||Aim 3|"Aim 3. To define the response of miRNAs to acute exercise in healthy and insulin resistant muscle from obese and type 2 diabetic patients. We will test the hypotheses that:~The exercise-induced increases in expression of miR-378 members and miR-128 are lower in obese and type 2 diabetic muscle than in lean healthy controls.~FOXO1 expression, a target of miR-378 and miR-128, is higher in obese and type 2 diabetic muscle and this is accompanied by decreased FOXO1 phosphorylation.~The exercise-induced increases in expression of miR-30 family members, miR-10a, miR-422a, and miR-532 are lower in obese and type 2 diabetic muscle.~There are novel miRNAs that regulate the transcriptional program induced by acute exercise and are dysregulated in insulin resistance."
89358013|NCT03323788||Aim 4|Aim 4. To determine whether treatment with PPAR-Alpha agonist fibrate derivatives suppresses the normal gene expression response to acute exercise. We will test the hypothesis that Gemfibrozil treatment inhibits the normal transcriptional response to exercise.
89358014|NCT01331538||adolescents with TMD|adolescents with temporomandibular dysfunction
89358015|NCT01331538||No TMD|adolescents without temporomandibular dysfunction
89358016|NCT03047720|Other|One: Study Phases (S1 and S2)|The therapeutic phase of this study for the participant in Arm One will be: 6 weeks of behavioral modifications plus the Lully device (S1), followed by 6 weeks of behavioral modifications only without the device (S2)
89358017|NCT03047720|Other|Two: Study Phases (S2 and S1)|The therapeutic phase of this study for the participant in Arm Two will be: 6 weeks of behavioral modifications only without the device (S2), followed by 6 weeks of behavioral modifications plus use of the Lully device(S1)
89358018|NCT04494724|Experimental|Clazakizumab|Clazakizumab - 25mg in 50 milliliters (mL) of 0.9% saline, IV infusion over 30 minutes.
89358019|NCT04494724|Placebo Comparator|Placebo|Placebo - 50 mL 0.9% saline, IV infusion over 30 minutes.
88829566|NCT05729867|Experimental|fully covered self-expanable metal stent with HCC|This prospective cohort is comprised of patients with malignant biliary obstruction caused by hepatocellular carcinoma who were treated with endoscopic biliary drainage using fully covered self expandable metal stent.
88829567|NCT05729321||Epicutaneo-caval catheter removed electively|This is a pilot study designed to evaluate the patency of the Epicutaneo-caval catheter after its closure for 1 hour in order to assess the feasibility of possible Taurolidine lock-terapy in Epicutaneo-Caval Catheters.
88829568|NCT04828577|Experimental|Real Time Neurofeedback|Real time neurofeedback will be based on a classifier of increasing or decreasing delay discounting fMRI patterns. Participants will try to modulate their discounting rate based on neurofeedback via a visual dial, during an fMRI scan. Participants will be told they will be controlling the visual dial.
88829569|NCT04828577|Sham Comparator|"Idealized/Sham Neurofeedback"|"Rather than using the output of a classifier, the visual dial will display perfect modulation of increasing and decreasing delay discounting and participants will told that they will not be controlling the visual dial."
88829570|NCT00550537|Experimental|Treatment|Erlotinib followed by paclitaxel + carboplatin (+ bevacizumab in non-squamous) at the time disease progression.
88829571|NCT04801043|Experimental|Cohort 1: Healthy young females|Healthy young females participants, ≥ 18 to ≤ 45 years of age, randomized to receive a single dose of XNW4107 250mg IV co-administered with imipenem 500mg /cilastatin 500mg.
88829572|NCT04801043|Experimental|Cohort 2: Healthy elderly males|Healthy elderly male participants, ≥ 65 years of age, randomized to receive a single dose of XNW4107 250mg IV co-administered with imipenem 500mg /cilastatin 500mg.
89358020|NCT03794843|Experimental|Nimodipine Injection (II)|The specification of this injection is 5 ml: 4 mg , which is administered by constant infusion intravenously with an infusion pump. The injection and 0.9% sodium chloride injection is simultaneously infused at a ratio of 1:16 (injection: combined infusion). The rate of intravenous drip was started at 0.5 mg/h for 2 hours, and the rate of intravenous drip was 1.0 mg/h after 2 hours, and continuous infusion for 12 hours, for a total of 11 mg of nimodipine.
89358021|NCT03794843|Experimental|Nimodipine Injection|The specification of this injection is 50 ml: 10 mg ,which is administered by constant infusion intravenously with an infusion pump. The injection and 0.9% sodium chloride injection is simultaneously infused at a ratio of 1:4 (injection: combined infusion). The rate of intravenous drip was started at 0.5 mg/h for 2 hours, and the rate of intravenous drip was 1.0 mg/h after 2 hours, and continuous infusion for 12 hours, for a total of 11 mg of nimodipine.
89358022|NCT03635970|Placebo Comparator|conventional treatment|receive the best conventional therapy
89358023|NCT03635970|Active Comparator|experimental treatment|The best medical treatment possible plus celular therapy
89358024|NCT04220216|Experimental|H4H fitness program|"The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits.~Patients will attend the 16-week program of boxing conditioning.~This 16-week program will include supervised exercises designed to improve strength, flexibility, balance,and cardiopulmonary fitness.~There will be 4, 1-hour sessions each week per participant"
89358025|NCT04494802|Placebo Comparator|higher pressure|During the operation, cuff pressure of LMA flexible is maintained to 50cmH2O
89358026|NCT04494802|Experimental|lower pressure|During the operation, cuff pressure of LMA flexible is maintained to 30cmH2O
89358027|NCT01333800|Active Comparator|Ciclesonide|
89358028|NCT01333800|Placebo Comparator|Beclomethasone|
89358029|NCT04926077|Experimental|Validation Arm|Participants will wear the DreamKit device (test device) while instrumented with an esophageal manometry catheter (reference standard) to record respiratory effort.
89358030|NCT04494100|Active Comparator|CONTROL|Troncular blocks using a long-acting LA + Tourniquet
89358031|NCT04494100|Experimental|WALANT|Troncular blocks using a long-acting LA + WALANT technique using a short-term LA with epinephrine a vasoconstrictor agent
89358032|NCT01333878|Experimental|Open-Label Subcutaneous Abatacept|Open-Label Subcutaneous Abatacept
89358033|NCT03798431|Experimental|M-ROCC|Mindful Recovery OUD Care Continuum (M-ROCC) builds on other mindfulness interventions for addictive disorders, but is specifically designed with the clinical needs of OUD patients on buprenorphine and logistic needs of primary care OBOT clinicians in mind. It focuses on integration of mindfulness practice for living well through stress, anxiety, depression, pain and addiction recovery. M-ROCC curriculum has three primary components, including a low-dose mindfulness phase, an intensive mindfulness training phase and then ongoing mindful recovery support.
89358034|NCT03328390|Experimental|Quadratus lumborum block Group|ultrasound guided
89358035|NCT03328390|Active Comparator|Transversus abdominis plane block Group|ultrasound guided
88829573|NCT04801043|Experimental|Cohort 3: Healthy elderly females|Healthy elderly female participants, ≥ 65 years of age, randomized to receive a single dose of XNW4107 250mg IV co-administered with imipenem 500mg /cilastatin 500mg.
88829574|NCT04801043|Placebo Comparator|Placebo to XNW 4107 & imipenem/cilastatin|Matching placebo for XNW4107 and imipenem/cilastatin
89358036|NCT03167879|Experimental|SCC1--high intensity supervision|Integration of safer conception counseling into family planning services, with intensive training and supervision
88829575|NCT04425577|Other|Transabdominal Ultrasound|All patients enrolled will undergo a transabdominal ultrasound at a specified time point as outlined in the protocol.
89358037|NCT03167879|Experimental|SCC2-- low intensity supervision|Integration of safer conception counseling into family planning services, with less intensive training and supervision that mimics Ministry of Health approach
89358038|NCT03167879|No Intervention|Usual care family planning services|Family planning services that are currently available as part of usual care, which focus almost solely on contraception and pregnancy prevention
89358039|NCT03328312|Active Comparator|Sugammadex|For reversal of rocuronium neuromuscular- block we will use Sugammadex
89358040|NCT03328312|Placebo Comparator|neostigmine+atropine|For reversal of rocuronium neuromuscular- block we will use Neostigmine (Miostin®; Stigmosan®) 0.05 mg/kg and atropine 1 mg/ dose.
88829576|NCT04795505||Intervention group|A tertiary A-level hospital WeChat-based intervention
88829577|NCT04795505||Control group|Traditional community hospital intervention
88829578|NCT01853371|Experimental|Wet cupping and conventional treatment|"Wet cupping: Will be administered through 3 sessions, with 4 weeks interval between each session and the other.~Conventional treatment: Is the usual anti-HTN treatment taken by the patients at the King Abdulaziz university hospital outpatient department."
88829579|NCT01853371|Active Comparator|Conventional treatment|Conventional treatment: Is the usual anti-HTN treatment taken by the patients at the King Abdulaziz university hospital outpatient department.
88829580|NCT04734197|Experimental|SURF-100 (a combination of 0.3% Mycophenolic Acid and 0.01% Betamethasone Sodium Phosphate)|One drop in the study eye (and fellow eye, if applicable) twice daily for 84 days
88829581|NCT04734197|Experimental|Mycophenolic Acid 0.1%|One drop in the study eye (and fellow eye, if applicable) twice daily for 84 days.
88829582|NCT04734197|Experimental|Mycophenolic Acid 0.3%|One drop in the study eye (and fellow eye, if applicable) twice daily for 84 days.
89358041|NCT03328312|Experimental|neostigmine+atropine+sugammadex|For reversal of rocuronium neuromuscular- block we will use Neostigmine (Miostin®; Stigmosan®) 0.025 mg/kg and atropine 0.5 mg/dose followed within 3 min by Sugammadex 1 mg/kg.
89358042|NCT03328234|Experimental|SIB-IMRT combined chemotherapy with IFI|
89358043|NCT03328234|Experimental|SIB-IMRT with IFI|
89358044|NCT03626168|Active Comparator|Consumption of 100% watermelon juice|Consumption of two 12-ounce doses of pasteurized 100% watermelon juice for a four-week period
89358045|NCT03626168|Placebo Comparator|Consumption of a placebo beverage|Consumption of a placebo beverage with comparable sugar content, pH, taste, texture, and color for a four-week period
89358046|NCT03798275|Active Comparator|the study group|healthy pregnant women with borderline oligohydramnios who accept to drink a cup of coffee
89358047|NCT03798275|No Intervention|the control group|healthy pregnant women with normal amniotic volume
89358048|NCT03328156||patient with STEMI will treated by PPCI|Primary angioplasty procedure The procedure will be performed using a standard angioplasty technique. A bolus of100 IU kg of heparin will be administered intra-arterially after insertion of the vascular catheter. The target lesions will initially treated with appropriate balloon predilatation as necessary, followed by intracoronary stenting. After stent implantation, heparin will be routinely administered. The sheaths will be removed the same day.
89358049|NCT03328156||patient with STEMI will treated by Thrombolytic therapy|oral clopidogrel (300 mg), Low-flow nasal oxygen, oral acetylsalicylic acid (325 mg), Will be given to each patient. Streptokinase will be given intravenously at 1.5 million units over approximately 60 min. Reperfusion afterTT will be assessed according to clinical criteria .
89358050|NCT05625035|Experimental|Lianhua Qingwen plus conventional therapy|
89358051|NCT05625035|No Intervention|Conventional therapy|
89358052|NCT03323710|Experimental|Propranolol plus Sunitinib|
89358053|NCT04771676|Experimental|Oncorine (H101)|H101 diluted in 5ml 0.9% sodium chloride solution will be intraperitoneally injected through the drainage catheter. Each patient will receive a dose of 1.5×10^12 vp by i.p. administration on day 1 and 3.
89358054|NCT03792269|Experimental|Multi-channel chemotherapy|Patients will receive intraperitoneal irinotecan (50mg, d1, q2w).
89358055|NCT03792269|Active Comparator|Control Group|Patients will receive intravenous oxaliplatin (130mg/m^2, d1, q3w), and oral capecitabine (1.0g, d1-14, q3w).
89358056|NCT02488564|Experimental|Liposomal doxorubicin +Docetaxel+Trastuzumab+Metformin|"Day 1: Liposome-encapsulated doxorubicin, 50 mg/m2 IV 1 hour infusion; Day 2 and 9: Docetaxel, 30 mg/m2 IV 1 hour infusion; Day 2, 9 and 16: Trastuzumab 4 mg/kg for the first infusion loading dose, then 2 mg/kg/week for subsequent injections.~Day -13 to 0: Metformin is administered as single agent. From day -13 to day -11, Metformin 1000 mg will be administered once a day; from day -10 Metformin 1000 mg will be administered twice a day continuously until end of the study treatment."
89358057|NCT02966873|Experimental|N-Acetylcysteine (NAC) Treatment Group|"Participant will receive 12 weeks of Active Treatment NAC (2400 mg) daily, as well as weekly cognitive-behavioral therapy, medication management, and Adverse Event (AE) monitoring.~Participant will receive one week of study medication at a time from the study physician or the study coordinator. The study medication provided in blister packs in the form of 600 mg tablets. Each participant will be asked to take two (2) 600 mg tablets in the morning and two (2) 600 mg tablets in the evening."
89358058|NCT02966873|Placebo Comparator|Placebo Group|"Participant will receive 12 weeks of inactive placebo comparator daily, as well as weekly cognitive-behavioral therapy, medication management, and Adverse Event (AE) monitoring.~Participant will receive one week of study medication (placebo) at a time from the study physician or the study coordinator. The study medication (placebo) provided in blister packs in the form of 600 mg tablets. Each participant will be asked to take two (2) 600 mg tablets in the morning and two (2) 600 mg tablets in the evening."
89358059|NCT03626636|Active Comparator|Active Group|Treatment Group 1: 25 Non-Exudative AMD subjects with BCVA of 20/40 - 20/200 will be injected intravitreally with 1.0mg of Luminate®
89358060|NCT03626636|Placebo Comparator|Placebo Group|Treatment Group 2: 15 Non-Exudative AMD subjects with BCVA of 20/40 - 20/200 will be treated with a sham injection
88829583|NCT04734197|Experimental|Betamethasone Sodium Phosphate 0.01%|One drop in the study eye (and fellow eye, if applicable) twice daily for 84 days.
88829584|NCT04734197|Placebo Comparator|Vehicle|One drop in the study eye (and fellow eye, if applicable) twice daily for 84 days.
88829585|NCT04734197|Active Comparator|Cyclosporine 0.05% Ophthalmic Emulsion|One drop in the study eye (and fellow eye, if applicable) twice daily for 84 days
88829586|NCT04734197|Active Comparator|Lifitegrast 5% Ophthalmic Solution|One drop in the study eye (and fellow eye, if applicable) twice daily for 84 days
89358061|NCT03323632|Experimental|MyndMove|The MyndMove system is a neuromodulation device that delivers short electrical pulses to stimulate muscle contractions and enhance motor recovery following Stroke or Spinal Cord Injury. MyndMove delivers therapeutic stimulation sequences called protocols, which are coded therapeutic algorithms which assist muscle movement allowing the brain and central nervous system to be retrained restoring voluntary reaching and grasping functions lost following neurological injury. The MyndMove system comprises the hardware device, stimulation electrodes and cables, hand and foot switches, and integrated software.
89358062|NCT04697186|Experimental|berberine , amoxicillin and rabeprazole triple therapy|Berberine 300mg three time daily for 14days, amoxicillin 1000 mg and rabeprazole 10 mg by mouth, twice daily for 14 days.
89358063|NCT04697186|Active Comparator|Bismuth-containing Quadruple Therapy|amoxicillin 1000 mg，clarithromy 500mg，rabeprazole 10 mg, and Bismuth 220mg by mouth, twice daily for 14 days.
89358064|NCT02488642|Experimental|isosorbide dinitrate-oxytocin|"Preinduction with isosorbide dinitrate gel solution (80 mg/1.5 mL) were administered in the posterior fornix every 3 hours. Once a Bishop score of over 7 was reached, oxytocin was infused in a balanced electrolyte solution beginning with an infusion rate of 2 milli-International Units per minute (mIU/min) and doubling the dose every 15 minutes.~If the cervical conditions (<7 Bishop Score) did not change after the treatment application, a new dose, without exceeding 4 doses, to facilitate cervical ripening."
89000796|NCT04652284|Active Comparator|Standard of Care|Standard of care in previously untreated patients will consist of concomitant treatment (oral amoxicillin 1000mg, clarithromycin 500 mg, tinidazole 500 mg and esomeprazole 40 mg all given twice daily for 14 days). In previously treated patients standard of care will consist of bismuth quadruple therapy, quinolone based therapy, or other susceptibility guided treatment where available
89000797|NCT04652323||Control|Twenty-one empty polyethylene tubes remained empty to bewere used as in the control group.
89000798|NCT04652323||ProRoot MTA|ProRoot White MTA mixed according to the manufacturer's' instructions were filled placed into sterile p olyethylene tubules (internal diameter: 1.3 mm internal diameter, x external diameter: 1.6 mm external diameter, x length: 5.0 mm length) sterilized with ethylene oxide gas, as specified by ISO , with using a sterile Llentulo.
89000799|NCT04652323||Medcem MTA|Medcem MTA mixed according to the manufacturer's' instructions were filled placed into sterile p olyethylene tubules (internal diameter: 1.3 mm internal diameter, x external diameter: 1.6 mm external diameter, x length: 5.0 mm length) sterilized with ethylene oxide gas, as specified by ISO , with using a sterile Llentulo.
89000800|NCT04652323||Medcem Pure Portland Cement|Medcem Pure Portland Cement mixed according to the manufacturer's' instructions were filled placed into sterile p olyethylene tubules (internal diameter: 1.3 mm internal diameter, x external diameter: 1.6 mm external diameter, x length: 5.0 mm length) sterilized with ethylene oxide gas, as specified by ISO , with using a sterile Llentulo.
89000801|NCT04652011||Patients with chronic pelvic pain|Patients with chronic pelvic pain and a benign gynecologic disease associated, referring to our Unit, medically or surgically treated from 2010 to 2019
89000802|NCT04651933||Epithelial ovarian cancer patients sensitive to platinum based chemotherapy|
89000803|NCT04651933||Epithelial ovarian cancer patients resistant to platinum based chemotherapy|
89000804|NCT04652128|Experimental|zoledronate|Subject will receive a single infusion of zoledronic acid 5mg/100mL intravenously.
89000805|NCT04652128|Placebo Comparator|saline|Subject will receive a single infusion of physiological saline 100mL intravenously.
89000806|NCT04651738|Experimental|Study group|All eligible participants consenting to participate the study.
89000807|NCT04651426|Placebo Comparator|Placebo|The Placebo is a Patch identical to the F3 and F4 patches in aesthetics but without any biomineral, therefore with no reflectance ability.
89000808|NCT04651426|Active Comparator|F3 Patch|The F3 is a patch made of 100% polypropylene non-woven fabric, an acrylic adhesive mass and a mix of titanium dioxide printed on with a refringency spectrum 2 m x kg
89000809|NCT04651426|Active Comparator|F4 Patch|The F4 is a patch made of 100% polypropylene non-woven fabric, an acrylic adhesive mass and a mix of titanium dioxide printed on with a refringency spectrum of 4 m x kg
89000810|NCT00178373|Experimental|Modafinil|Modafinil 200 mg taken by mouth once a day. Subjects will take 2 100 mg tablets each morning.
89000811|NCT00178373|Placebo Comparator|placebo|Inactive sugar pill, 2 are taken once a day in the morning
89534239|NCT03861871|Experimental|Fenfluramine Hydrochloride|"Study medication will be administered as equal doses twice a day in the morning and in the evening approximately 12 hours apart.~Patients will first be titrated over 14 days to a dose of ZX008 0.8 mg/kg/day (maximum dose 30 mg/d).~After completion of the Titration Period, patients will continue to receive the ZX008 0.8 mg/kg/day dose and be treated for an additional 12 weeks (Maintenance Period). Study medication will continue to be administered twice a day in the morning and in the evening, approximately 12 hours apart.~After completion of the Maintenance Period, patients will enter the Taper Period, where they will decrease from 0.8 mg/kg twice a day to a dose of 0.4 mg/kg twice a day (maximum 30 mg/day). After 4 days at this dose level, patients will decrease their dose to 0.2 mg/kg/day. On day 9 of the Taper Period, all participants will stop taking study medication."
89000813|NCT04651231|Active Comparator|tight flap technique group (forty patients-group A)|in this arm forty patients did tight flap technique for punch trabeculectomy. At 12 o'clock 10/0 nylon monofilament stitch was used to close the apex of triangular scleral flap tightly and two releasable stitches were used at the sides of triangular scleral flap.
89000814|NCT04651231|Experimental|loose flap technique (securing sutures) group (forty patients-group B).|in this arm forty patients did loose flap technique for punch trabeculectomy. At 12 o'clock 10/0 nylon monofilament stitch was used to secure the edges of the flap at the apex of and two-four releasable stitches were used at the sides of triangular scleral flap in group B.
89000815|NCT04650958|Active Comparator|STN DBS stimulation group|In the STN DBS stimulation group, patients will receive a continuous DBS stimulation for 3 months and the first default parameters applied will be monopolar setting (0.5 V under threshold that causes side effects, 135 Hz, 90 µs, at one of the two dorsal contacts). If the default parameters are found not suitable for an individual patient due to unexpected reasons, an alternative method will be applied (e.g., decreased voltage) to try to maintain full compliance with the scheduled study.
89534240|NCT03859713|Experimental|PT followed by Switching to CBT in Phase II for nonresponders|Phase I treatment is 8 weekly sessions of evidence-based physical therapy (PT). At the 10-week follow-up participants who are non-responders to Phase I PT will switch to 8 weekly sessions of cognitive behavioral therapy (CBT) as Phase II treatment. If participant is a responder to Phase I PT, he or she will receive up to 2 more PT sessions in Phase II of treatment.
89534241|NCT03859713|Experimental|PT followed by Mindfulness in Phase II for nonresponders|Phase I treatment is 8 weekly sessions of evidence-based physical therapy (PT). At the 10-week follow-up participants who are non-responders to Phase I PT will receive 8 weekly sessions of mindfulness using a mindfulness-oriented recovery enhancement protocol as Phase II treatment. If participant is a responder to Phase I PT, he or she will receive up to 2 more PT sessions in Phase II of treatment.
89534242|NCT03859713|Experimental|CBT followed by Switching to PT in Phase II for nonresponders|Phase I treatment is 8 weekly sessions of cognitive behavioral therapy (CBT). At the 10-week follow-up participants who are non-responders to Phase I CBT will switch to 8 weekly sessions of evidence-based physical therapy (PT) as Phase II treatment. If participant is a responder to Phase I CBT, he or she will receive up to 2 more CBT sessions in Phase II of treatment.
89534243|NCT03859713|Experimental|CBT followed by Mindfulness in Phase II for nonresponders|Phase I treatment is 8 weekly sessions of cognitive behavioral therapy (CBT). At the 10-week follow-up participants who are non-responders to Phase I CBT will switch to 8 weekly sessions of mindfulness using a mindfulness-oriented recovery enhancement protocol as Phase II treatment. If participant is a responder to Phase I CBT, he or she will receive up to 2 more CBT sessions in Phase II of treatment.
89358065|NCT02488642|Placebo Comparator|misoprostol-oxytocin|"Preinduction with misoprostol gel solution (100 mcg/1.5 mL) were administered in the posterior fornix every 3 hours. Once a Bishop score of over 7 was reached, oxytocin was infused in a balanced electrolyte solution beginning with an infusion rate of 2 milli-International Units per minute (mIU/min) and doubling the dose every 15 minutes.~If the cervical conditions (<7 Bishop score) did not change after the treatment application, participants received a new dose, without exceeding 4 doses, to facilitate cervical ripening."
89358066|NCT03792425|Other|implant with immediate temporization|Immediate nonfunctional loading
89358067|NCT03792425|Other|Delayed implant without temporization|Conventional loading protocol
89358068|NCT03798197|Active Comparator|30 mg estetrol (E4) without food (fasted)|Treatment A (reference): One 30 mg E4 tablet administered orally following an overnight fast of at least 10 hours.
89358069|NCT03798197|Experimental|30 mg estetrol (E4) with food (fed)|Treatment B (test): One 30 mg E4 tablet administered orally 30 min after the start of an FDA prescribed high-fat breakfast preceded by at least a 10 hours overnight fast.
88829587|NCT00550147|Experimental|1|Oros Methylphenidate and Quetiapine
88829588|NCT01853605|Experimental|Augmentation|Women undergoing breast augmentation.
88829589|NCT01853605|Experimental|Reconstruction|Women undergoing breast reconstruction.
88829590|NCT01853605|Experimental|Revision-Augmentation|Women undergoing revision of previous breast augmentation.
88829591|NCT01853605|Experimental|Revision-Reconstruction|Women undergoing revision of previous breast reconstruction.
88829592|NCT04741685||SAP with LGS|Type 1 diabetes adults patients treated with sensor-augmented insulin pump with low glucose predictive suspension function
88829593|NCT04740983|Experimental|Heliotherapy|will receive 16-week heliotherapy regimen based on the predicted anti psoriasis effective irradiance values along with olive oil (in-house formulation)
88829594|NCT04740983|No Intervention|Control|only will receive olive oil (in-house formulation)
88829595|NCT01856491|Other|RELIANCE 4-FRONT™ Passive Fixation|Single arm, all patients will be implanted with the RELIANCE 4-FRONT™ Passive Fixation lead
88829596|NCT00366353|Other|1|Sedation suring a spontaneous breathing trial.
88829597|NCT00366353|Other|2|No sedation during spontaneous breathing trial
88829598|NCT00557401|Experimental|XP19986 SR3, 20 mg QD|XP19986, 20 mg QD for approximately 32 days
88829599|NCT00557401|Experimental|XP19986 SR3, 40 mg QD|XP19986, 40 mg QD for approximately 32 days
88829600|NCT00557401|Experimental|XP19986 SR3, 60 mg QD|XP19986, 60 mg QD for approximately 32 days
88829601|NCT00557401|Experimental|XP19986 SR3, 30 mg BID|XP19986, 30 mg BID for approximately 32 days
88829602|NCT00557401|Placebo Comparator|Placebo|Placebo for approximately 32 days
88829603|NCT02617901|Experimental|Recruited children|"Children aged below 16 years attending the Radiology Department for a left hand radiograph in order to assess bone age on the basis of clinical need. There will be one male and one female from each of five age groups (< 5 years; 5 to 7 years; 8 to 10 years; 11 to 13 years; 14 to 16 years).~Bone age will be assessed according to the Greulich & Pyle and TW3 methods by 3 observers on 2 separate occasions at least 4 weeks apart. Recruited children will have intervention in the form of a left hand DXA which will be anonymised and from which the same 3 observers will independently assess bone age according to Greulich and Pyle and TW3 methods on 2 separate occasions at least 4 weeks apart.~Radiographs and DXA will be read in random and varied order."
88829604|NCT04685213|Active Comparator|Active E-Stim|Subjects will receive an active electrical stimulation device to wear for 1 hour daily up to two weeks or until hospital discharge, whichever came first (phase I).
88829605|NCT04685213|Sham Comparator|sham E-Stim|Subjects will receive a sham electrical stimulation device to wear for 1 hour daily up to two weeks or until hospital discharge, whichever came first (phase I).
88829606|NCT03832777|Active Comparator|5 Hz Stimulation|This group will receive 5Hz (Hertz) Dorsomedial Prefrontal Cortex repetitive Transcranial Magnetic Stimulation with 1500 pulses per session, once per weekday, with a final result of 15 sessions in this modality.
88829607|NCT03832777|Placebo Comparator|Placebo Stimulation|This group will receive the Sham modality simulating 1500 pulses of 5Hz Transcranial Magnetic Stimulation for 15 sessions, one per weekday.
88829608|NCT02278783|Experimental|Regorafenib Treatment arm, all patients|
89358070|NCT02488486|Experimental|Automated postoperative sedation|Postoperative sedation is provided automatically using a closed-loop system. Bispectral index is used as the input signal and an algorithm defines the appropriate concentrations of propofol and remifentanil. Adequate postoperative sedation is defined by a bispectral index between 40 and 60.
89358071|NCT01389024|Experimental|Hydroxyurea|Treatment with hydroxyurea 20 mg/kg/day increased by 5 mg/kg every 8 weeks to maximum of 35 mg/kg/day or hematologic toxicity or Absolute Neutrophil Count (ANC) <4000
89358072|NCT01389024|Placebo Comparator|Placebo|Sucrose placebo 0.2 ml/kg/day increased to max of 0.35 ml/kg/day
88829609|NCT02618915|Experimental|DTX101, Cohort 1|a single peripheral intravenous (IV) infusion of 1.6 x 10^12 genome copies (GC)/kg DTX101
88829610|NCT02618915|Experimental|DTX101, Cohort 2|a single peripheral IV infusion of 5.0 x 10^12 GC/kg DTX101
88829611|NCT04768699|Experimental|TQG203(30µg/kg)|
88829612|NCT04768699|Experimental|TQG203(90µg/kg)|
89358073|NCT03327766||RPL group|history of unexplained recurrent pregnancy loss (defined as two or more consecutive missed miscarriage before 14 weeks of gestation).
89000816|NCT04650958|Sham Comparator|Sham stimulation group|In the sham stimulation group, the programming will also start within 1 week after the surgery, but at each follow-up the DBS system will be turned off after the parameter is adjusted to the threshold that causes side effects without continuous stimulation. After the 3-month double-blind period the patients can choose to set on the DBS system again and receive regular continuous stimulation treatment.
89000817|NCT00178412|Experimental|1|Treatment group
89358074|NCT03327766||Control group|womens coming for contraception after normal pregnancy outcome.
89358075|NCT03798119|Experimental|Switch to TAF|Subjects who meet the inclusion and exclusion criteria will switch prior NUCs to TAF 25 mg/day for 96 weeks
89000818|NCT00178412|Active Comparator|2|Comparison Group
89000819|NCT04651309|Other|Ultrasound group|Labor progress assessed by US, avoiding digital exams as much as possible;
89000820|NCT04651309|No Intervention|Control group|Labor progress assessed according to the regular protocol
89000821|NCT00557908||VWF/FVIII product infusions|One to three infusions of factor replacement as needed to control bleeding.
89000822|NCT00557986|No Intervention|A|Standard Systemic Therapy only group (no primary surgery)
89000823|NCT00557986|Other|B|Surgery group
89358076|NCT03323554|Experimental|Ustrap®|Ustrap is a new adjustable-pressure 4-arm device
89358077|NCT03323554|Active Comparator|AMS 800®|Artificial sphincter currently considered the gold standard device in this field
89358078|NCT03794219|Experimental|Kinesio tape plus NSAID|Kinesio tape is applied 3 times a week for 2 weeks with a total of 6 sessions in addition to 750 mg/day oral naproxen.
89358079|NCT03794219|Active Comparator|NSAID|750 mg/day oral naproxen is administered for 10 days.
89358080|NCT03327688|Active Comparator|POCUS group|Point-of-care ultrasound
89534244|NCT03852758|Experimental|Outdoor Exercise|2 sessions of outdoor exercise per week
89000824|NCT00558142|Active Comparator|1|Healthy volunteers will be randomised to receive either placebo capsules PO plus an infusion of normal saline, acetylcysteine capsules PO plus an infusion of normal saline or placebo capsules PO plus an IV infusion of acetylcysteine in normal saline
89000825|NCT00558142|Active Comparator|2|Volunteers with CKD III will be randomised to receive either placebo capsules PO plus an infusion of normal saline, acetylcysteine capsules PO plus an infusion of normal saline or placebo capsules PO plus an IV infusion of acetylcysteine in normal saline
89000826|NCT00558142|Active Comparator|3|Healthy volunteers will receive a single IV dose of 100mls Visipaque 320 (iodixanol, equivalent to 320 mg iodine/ml). They will then be randomised to receive either placebo capsules PO plus an infusion of normal saline, acetylcysteine capsules PO plus an infusion of normal saline or placebo capsules PO plus an IV infusion of acetylcysteine in normal saline
89358081|NCT03327688|No Intervention|Radiologist group|Traditional diagnostic way
89358082|NCT03327688|Active Comparator|DVT POCUS group|DVT group after POCUS education
89358083|NCT03327688|No Intervention|DVT traditional group|DVT group traditional diagnostic way before educational intervention
89358084|NCT01304771|Active Comparator|Synbiotic AKSB|Participants (healthy > 65 year old persons) will be randomized to take the synbiotic AKSB. All participants will also receive inactivated trivalent Influenza vaccine while being on the AKSB. We will assess safety of the AKSB in this setting. We will also assess the stool microbiology in relation to vancomycin-resistant enterococcus and probiotic strain enterococcus. We will also assess influenza vaccine response in patients on AKSB
89358085|NCT01304771|Placebo Comparator|Talc Placebo|Participants (healthy > 65 year old persons) will be randomized to take the placebo. All participants will also receive inactivated trivalent Influenza vaccine while being on the placebo. We will also assess the stool microbiology in relation to vancomycin-resistant enterococcus. We will also assess influenza vaccine response in patients on placebo.
89358086|NCT01334034|Experimental|Dose levels 1-7|
89358087|NCT03050060|Experimental|Treatment (nelfinavir, immunotherapy, radiation therapy)|Beginning 7-14 days prior to start of pembrolizumab, nivolumab, or atezolizumab, patients receive nelfinavir mesylate PO BID on days 1-7 or 1-14 (dependent upon when treatment is started) up to 11-12 weeks. Patients also receive pembrolizumab, nivolumab or atezolizumab IV over 30-60 minutes on day 1. Cycles repeat every 21-28 days in the absence of disease progression or unacceptable toxicity. Patients then undergo hypofractionated radiation therapy over 3-14 days starting after cycle 1 and before cycle 3 of pembrolizumab, nivolumab or atezolizumab. The study will exclude irradiation of liver metastases as an added precaution.
89358088|NCT01304849|Experimental|Primary|Patients with aHL will receive 2 cycles of ABVD and undergo interim PET-2 scan- those with positive scans will receive 4 additional cycles of Esc BEACOPP while those with negative scans will receive 4 additional cycles of ABVD.
89358089|NCT03327610|No Intervention|BASELINE|The subjects were kept in their current ventilatory mode.
89358090|NCT03327610|Experimental|VC-CMV20|Application of a ventilator hyperinflation intervention with Volume Control Continuous Mandatory Ventilation (VC-CMV) with an inspiratory flow of 20Lpm.
89534245|NCT03852758|Experimental|Indoor Exercise|2 sessions of indoor exercise per week
89000827|NCT00558142|Active Comparator|4|Volunteers with CKD III will receive Visipaque 320 during coronary angiography. They will have been randomised to receive either placebo capsules PO plus an infusion of normal saline, acetylcysteine capsules PO plus an infusion of normal saline or placebo capsules PO plus an IV infusion of acetylcysteine in normal saline
89000828|NCT04650997|Experimental|Combined|12 weeks eccentric exercise combined with 6 sessions of extracorporeal shockwave therapy in the initial 6 weeks
89000829|NCT04650997|Sham Comparator|Exercise|12 weeks eccentric exercise combined with 6 sessions of sham extracorporeal shockwave therapy in the initial 6 weeks
89000830|NCT04650724|Experimental|T cell infusion agent targeting BCMA chimeric antigen receptor|
89358091|NCT03327610|Experimental|VC-CMV50|Application of a ventilator hyperinflation intervention with Volume Control Continuous Mandatory Ventilation (VC-CMV) with an inspiratory flow of 50Lpm.
89358092|NCT03327610|Experimental|PC-CMV1|Application of a ventilator hyperinflation intervention with Pressure Control Continuous Mandatory Ventilation (PC-CMV1) with an inspiratory time of 1 second.
89534246|NCT03851835|Experimental|Ondansetron Oral Solution|Ondansetron Oral Solution (4mg/5mL solution) - Dose = 0.15mg/kg. One dose every 8 hours (q8h). Six doses over 48 hours.
89534247|NCT03851835|Placebo Comparator|Placebo Oral Solution|Compounded Placebo Oral Solution to match experimental arm
89358093|NCT03327610|Experimental|PC-CMV3|Application of a ventilator hyperinflation intervention with Pressure Control Continuous Mandatory Ventilation (PC-CMV1) with an inspiratory time of 3 seconds.
89358094|NCT03327610|Experimental|PSV10|Application of a ventilator hyperinflation intervention with Pressure Support Ventilation (PSV) with a cycling off of 10% of peak inspiratory flow.
89358095|NCT03327610|Experimental|PSV25|Application of a ventilator hyperinflation intervention with Pressure Support Ventilation (PSV) with a cycling off of 25% of peak inspiratory flow.
89358096|NCT01334112|Experimental|Axitinib|Oral Axitinib (5mg, twice daily) will be administered to all patients
89358097|NCT03791957||Group A - Healthy Periodontium|Absence of clinical signs of inflammation like bleeding on probing, erythema, edema, attachment loss, bone loss, patient symptoms, (bone levels at 1-3mm apical to CEJ) n=20
89358098|NCT03791957||Group B - Gingivitis|Presence of cardinal signs of inflammation along with, bleeding and discomfort on gentle probing, loss of knife-edged margin and blunting of papilla, n=20
89358099|NCT03791957||Group C - Periodontitis|Presence of cardinal signs of inflammation along with, bleeding and discomfort on gentle probing, loss of knife-edged margin and blunting of papilla,periodontal pocketing, clinical attachment loss, radiographically assessed bone loss n=20
89358100|NCT01315314|No Intervention|conventional PDF (Stay safe)|
89358101|NCT01315314|Active Comparator|low GDP PDF (Balance)|
89358102|NCT02491450|Experimental|A Test|Test drug (Heterosofir)1 tablet contains 400 mg Sofosbuvir
89358103|NCT02491450|Active Comparator|B Reference|Reference drug (Sovaldi)1 tablet contains 400 mg Sofosbuvir
89358104|NCT03626090|Experimental|Treatment Arm|A single dose of 0.5 to 1 x 10^6/kg autologous BM MSCs (Total volume: 30 - 50 ml) will be infused via peripheral venous access.
89358105|NCT05624645|Experimental|Pelex Upp|In this arm, all patients received the device for use in treatment of stress urinary incontinence.
89358106|NCT01274442|Active Comparator|CONTROL: no dental implants lost|Group of patients who received an implant during a dental implant surgery in the University Hospital in Ghent in 2004-2007, who did not lose their implants.
89358107|NCT01274442|Experimental|CASE: patients lost one or more implants|Group of patients who received an implant during a dental implant surgery in the University Hospital in Ghent in 2004-2007, but who lost one or more implants.
89358108|NCT03320590||Couple|Couple with female aged under 37 years
89358109|NCT03792113|Experimental|Autologous fibrin glue|The periodontal flap will be approximated on the test site using autologous fibrin glue on the under surface of the raised flap up to 2 mm from the coronal margin and repositioned back on to the root surface. Thereafter, the tissues will be kept in position with a gentle pressure using a wet gauze for 30 - 60 seconds.
89358110|NCT03792113|Active Comparator|4-0 silk suture|The periodontal flap will be approximated using 4-0 black silk suture.
89358111|NCT01304927|Active Comparator|Cholecalciferol + calcium|Group of intervention: Each man will receive 300,000 IU (7500 ug) Cholecalciferol (VD3) orally once after blood and semen sampling and performed DXA scan. Thereafter they will receive VD tablets of 1,400 IU (35 ug) + 500 mg calcium daily for 3 months. At 3 months a clinical control and blood sampling will be performed, followed by continued daily intake of 1400 IU VD3 + 500 mg calcium. At end of treatment at five months after inclusion the men deliver two semen samples, have a blood sample drawn and a DEXA scan performed.
89358112|NCT01304927|Placebo Comparator|placebo|Group receiving placebo: Each man will receive placebo oral mixture once after blood- and semen sampling and performed DXA scan. Thereafter they will receive placebo tablets daily for 3 months. At 3 months a clinical control and blood sampling will be performed, followed by continued daily intake of placebo. At end of treatment at five months after inclusion the men deliver two semen samples, have a blood sample drawn and a DEXA scan performed.
89358113|NCT05464940|Active Comparator|Group assigned to receive caffeine|
89358114|NCT05464940|Placebo Comparator|Group assigned to receive masked placebo|
89534248|NCT03849534|Active Comparator|Soft occlusal appliance|Individually casted appliances
88829613|NCT04768699|Active Comparator|NovoSeven®(90µg/kg)|NovoSeven®,manufactured by Novo Nordisk Inc.
88829614|NCT04768699|Experimental|TQG203(180µg/kg)|
89358115|NCT01305551|Experimental|Treatment A-Saxagliptin+Metformin XR|5mg Saxagliptin + 500 mg Metformin XR Tablets, once on Day 1 only, administered together in the fasted state.
89358116|NCT01305551|Experimental|Treatment B-Saxagliptin/Metformin XR FDC|5mg Saxagliptin / 500 mg Metformin XR FDC tablet, once on Day 1 only, administered in the fasted state.
89358117|NCT01305551|Experimental|Treatment C-Saxagliptin+Metformin XR|5mg Saxagliptin + 500 mg Metformin XR Tablets, once on Day 1 only, administered together in the fed state.
89358118|NCT01305551|Experimental|Treatment D-Saxagliptin/Metformin XR FDC|5mg Saxagliptin / 500 mg Metformin XR FDC tablet, once on Day 1 only, administered in the fed state.
89000831|NCT04650802|Experimental|Gait training|Participants receive five weeks individual robotic gait training in LOPES II, targeting paretic propulsion (60 minutes, two time a week). The robotic gait training is complemented with daily home exercises (15 minutes/day) focusing on increasing strength and practice of learned strategies in daily life.
89000832|NCT00205920|Experimental|single|BLVR Treatment
89358119|NCT03897296|Experimental|healthy subjects examined with water-perfused catheter|healthy subjects - subjects without signs of functional and organic anorectal pathology
89358120|NCT03791879|Active Comparator|• Group A will take Caudal Levob 0. 125%+ DEXM 0.5µg/k|
89358121|NCT03791879|Active Comparator|• Group B will take Caudal Levob 0.125%+ DEXM 1µg/kg.|
89358122|NCT03791879|Active Comparator|• Group C will take Caudal Levob 0. 125%+ DEXM 1.5 µg/|
89358123|NCT03791879|Active Comparator|• Group D will take Caudal Levob 0. 125%+ DEXM 2µg/kg.|
89358124|NCT03896360|Experimental|Food order behavioral intervention plus standard care|Subjects will receive standard nutrition counseling and additional carbohydrate-last food order behavioral counseling.
89358125|NCT03896360|Other|Standard care|Subjects will receive standard nutrition counseling.
89534249|NCT03849534|Active Comparator|Jaw exercises|Resistance exercises to do twice a day
89534250|NCT03849534|Active Comparator|Counseling|Just information at the first visit
89534251|NCT03824132|Experimental|Intervention Group|
89358126|NCT03799757|Active Comparator|Bupivacaine|The wound was installed by 40ml of 0.25% bupivacaine through axillary and chest wall drains (20ml in each drain). Then, the drains were clamped for 20 minutes.
89358127|NCT03799757|Placebo Comparator|Placebo|The wound was installed by 40ml of 0.9% normal saline through axillary and chest wall drains (20ml in each drain). Then, the drains were clamped for 20 minutes. (placebo group)
89358128|NCT03844646|Experimental|CGM plus dietitian|Intermittent use of a continuous glucose monitor (CGM) plus dietitian support
89358129|NCT03844646|Other|Dietitian only|Dietitian support only
89358130|NCT04025255|Experimental|Braini|28-day oral capsules of Braini
89358131|NCT04025255|Placebo Comparator|Placebo|28-day oral capsule of placebo comparator
89358132|NCT04660058||chronic gastritis|patients with chronic non-atrophic gastritis and chronic atrophic gastritis according to histopathological results
89358133|NCT04660058||precancerous lesion|patients with gastric intestinal metaplasia and intraepithelial neoplasia according to histopathological results
89358134|NCT04660058||gastric cancer|patients with gastric cancer according to histopathological results
89358135|NCT01303913||Walking desaturation group|COPD patients that at the end of 6MWT have SO2 nadir <88-90%
89358136|NCT01303913||Walking No-desaturation group|COPD patients that at the end of 6MWT have SO2 nadir >88-90%
89358137|NCT02960009|Experimental|Anode HD-tDCS|The center anode is fixed on the ipsilesional primary motor cortex and the 4 surrounding cathode electrodes will be placed about 6 cm to the center.
89358138|NCT02960009|Experimental|Cathode HD-tDCS|The center cathode is fixed on the contralesional primary motor cortex and the 4 surrounding anode electrodes will be placed about 6 cm to the center.
89358139|NCT02960009|Placebo Comparator|Sham HD-tDCS|The center anode is fixed on the ipsilesional primary motor cortex and the 4 surrounding cathode electrodes will be placed about 6 cm to the center.
89358140|NCT00706342|Experimental|1|
89358141|NCT01303991|Experimental|Hexvix PDT|
89358142|NCT03327454||Benepali|Treatment of participants with the Benepali pre-filled pen takes place in accordance with the prescribing information and standard medical practice.
89358143|NCT05624411||A|post-placental insertion of CU T380A IUD during CS
89358144|NCT05624411||B|post-placental insertion of multiload 375 IUD during CS
89358145|NCT03323242|No Intervention|Control group|Recipient hepatectomy using conventional bipolar coagulation devices, surgical suture ligatures, and surgical clips (or any dissecting / coagulating device other than LS)
89358146|NCT03323242|Experimental|LS group|Recipient hepatectomy applying LigaSure.
88829615|NCT04749277||Endoscopist characterization on WLI and BLI modes|Optical characterization of an identified polyp, first in WLI and then in BLI mode, with CAD EYE® OFF. This evaluation should be systematically performed by two independent endoscopists in the exam room, preferably (but not necessarily) an experienced endoscopist and a trainee. The presence of at least one experienced endoscopist is mandatory. An independent evaluation is guaranteed. First step - The 1st endoscopist (who performing colonoscopy) request the polyp evaluation and record written by the 2nd endoscopist (who not performing the colonoscopy) - blinded evaluation since 1st endoscopist doesn't verbalize his evaluation); 2nd step - when the 2nd endoscopist signals that he completed his record, the 1st endoscopist verbally explicit his classification, which is recorded by the 2nd endoscopist. This evaluation should include polyp histological type (hyperplastic, adenoma, sessile serrated lesion or other type) and the level of confidence of the evaluation performed (high or low).
89358147|NCT03323242|Experimental|USD group|Recipient hepatectomy applying Harmonic Ultrasonic dissector.
89358148|NCT01305629|Experimental|Intervention Condition|Twelve sessions of spiritual self schema counseling, adapted to target target medication adherence and substance use.
89358149|NCT01305629|Active Comparator|Education Condition|Eight sessions of education with content designed to mirror the information covered in the intervention condition.
89358150|NCT03049748|Active Comparator|Control Group|Participants in the control group (20 LVAD patients) will receive usual care over 6 months. Usual care consists of routine clinic visits/follow-up at 1, 3, and 6 months post hospital discharge. A customary LVAD self-management/discharge education and training will be provided to patients and caregiver before hospital discharge and as need throughout the duration of the study. The control group will NOT receive the VAD Care App.
89358151|NCT03049748|Experimental|Intervention Group|Participants in the experimental group (20 LVAD patients) will receive usual care plus VAD Care App. They will implement LVAD self-management as directed by VAD Care App. The app will be used daily by patients and/or caregivers for over 6 months. Their LVAD self-management competencies will be assessed at months 1 and 5 post hospital discharge with a review of LVAD self-management skills provided by the LVAD RN Coordinator.
89534252|NCT03824132|Active Comparator|Waitlist Control Group|
89534253|NCT03823885|Experimental|E-cig|One time exposure to e-cig
89534254|NCT03823885|Experimental|sham|One time exposure to empty e-cig
89534255|NCT03817229|Active Comparator|Control Group|mHealth education module and automated digital reminders
89534256|NCT03817229|Experimental|Treatment Group|mHealth education module, automated digital reminders, and individualized adherence feedback (stage 1 SMART). After three months of intervention, the treatment group will be evaluated for responsiveness (> 95%) based on the 30-day adherence outcome (stage 2 SMART). If participants in the treatment group demonstrate adherence > 95%, they will continue with the treatment arm of receiving automated digital reminders and individualized adherence feedback. If they are deemed to be non-responsive (adherence < 95%), they will be re-randomized to either: 1) continued automated digital reminders and individualized adherence feedback or 2) a mHealth problem solving module with three therapist-guided problem-solving sessions.
89358152|NCT02491216|Experimental|Acupressure Group|A 15 minutes structured acupressure protocol with specific acupoints and applications technique will be performed on the elderly participants twice a week by the research team in YCHSS Homes. Designated para-medical staffs working in the elderly home or informal care giver of the elderly will be trained and perform the same acupressure protocol on the elderly at 2 additional occasions during the week. The total trial period is 12 weeks.
89358153|NCT02491216|No Intervention|Control Group|No acupressure therapy will be provided during the study.
89534257|NCT03806933|Experimental|NT 201 Dose group 1|Stage 1 and 2. Intramuscular injection into the glabellar area.
89534258|NCT03806933|Experimental|NT 201 Dose group 2|Stage 1. Intramuscular injection into the glabellar area.
89358154|NCT03794063||Robson group 1|Nulliparous women, single cephalic, more than or equal to 37 weeks, in spontaneous labour
89358155|NCT03794063||Robson Group 2|Nulliparous women, single cephalic, more than or equal to 37 weeks, induced or Caesarean section before labour
89358156|NCT03794063||Robson Group 3|Multiparous women with out a previous Caesarean section , with a single cephalic pregnancy, more than or equal 37 weeks gestation in spontaneous labour
89358157|NCT03794063||Robson Group 4|Multiparous women with out a previous Caesarean section , with a single cephalic pregnancy, more or equal 37 weeks gestation who had labour induced or were delivered by Caesarean section before labour
89358158|NCT03794063||Robson Group 5|All Multiparous women with at least one CS with a single cephalic pregnancy, more or equal to 37 weeks gestation
89358159|NCT03794063||Robson Group 6|All nulliparous women with a single breech pregnancy
89358160|NCT03794063||Robson Group 7|Multiparous women with a single breech pregnancy including women with previous Caesarean section
89358161|NCT03794063||Robson Group 8|All women with multiple pregnancies including women with previous Caesarean sections
89358162|NCT03794063||Robson Group 9|All women with a single pregnancy with a transverse or oblique lie, including women with previous Caesarean Section (s)
89358163|NCT03794063||Robson Group 10|All women with a single cephalic pregnancy less than 37 weeks gestation, including women with previous Caesarean section (s)
89358164|NCT02491138|Placebo Comparator|Standard information|In this arm, participants will receive standard information pamphlets about the benefits of good sleeping habits.
89358165|NCT02491138|Experimental|Appearance-based information|In this arm, participants will receive information about how sleep modifies their physical appearance. This will involve a computer transformation that morphs their face according to hours of sleep obtained.
89358166|NCT03320356||shoulder pain|Patients presenting inflammatory, degenerative, or post-traumatic shoulder pain and consulting at Orthopaedic Department, Reims Teaching Hospital.
89358167|NCT03792035|Experimental|Experimental group|First time given 8 capsules of Tongxinluo, then given 4 capsules of Tongxinluo, tid, po.Dosage form: capsule;Dose: 0.26g/capsule;Duration:1 year
89358168|NCT03792035|Placebo Comparator|Control group|First time given 8 capsules of placebo, then given 4 capsules of placebo, tid, po.Dosage form: capsule;Dose: 0.26g/capsule;Duration:1 year
89358169|NCT02488252|Active Comparator|Standard medical care|Angiotensin converting enzyme inhibitor or angiotensin receptor blocker and oral hypoglycemic agents or insulin at stable dose
89358170|NCT02488252|Experimental|Chinese Medicine on top of standard medical care|"Semi-individualised Chinese Medicine treatment on top of standard medical care The treatment plan consists of 5 different formulas and will be prescribed to patients categorised to 5 subgroups according to clinical manifestation. Patients having multiple manifestations that fit more than 1 subgroup will not be included.~Minor adjustment of the medication will be allowed and determined by the Chinese Medicine practitioner to reflect actual clinical practice. Dosage will follow strictly the China Pharmacopeia.~A: spleen and kidney Qi deficiency, B: spleen and kidney Yang deficiency, C: spleen and kidney Qi and Ying deficiency, D: liver and kidney Ying deficiency, E: Ying and Yang deficiency~Rehmannia-6 decoction: Wolfiporia cocos, Rehmannia glutinosa, Common macrocarpium Fruit, Dioscorea opposita , Paeonia suffruticosa Andr., Oriental waterplantain rhizome~Rehmannia-8 decoction: Radix Aconiti Lateralis preparata, Cinnamomum cassia Presl, Rehmannia-6 decoction"
89000833|NCT04651036|Experimental|Pegfilgrastim biosimilar product|QL0605 subcutaneously at a dose of 6 mg/0.6 mL.
89358171|NCT03799913|Experimental|anti-MESO CAR-T cells|Administration with anti-MESO CAR-T cells in the MESO-positive ovarian cancer patients
89358172|NCT03323008|Experimental|Training Prototype|Testing of 3 modules
89358173|NCT03814382|Experimental|Acupuncture|All subjects will receive up to 10 needles for 20 minutes for 1 treatment using acupuncture needles.
89358174|NCT01304069|Placebo Comparator|Placebo|
89358175|NCT01304069|Active Comparator|Selecoxib|
88829616|NCT04749277||CAD EYE® characterization on BLI mode|Optical characterization mode of CAD EYE® (CAD EYE® ON) in BLI mode should be activated for the evaluation of CAD EYE® optical characterization, in hyperplastic or neoplastic polyps, as well as the level of characterization (graduated from 1 to 3). The evaluation of the CAD EYE® should also be recorded by the endoscopist in the exam room who is not performing the colonoscopy, on its own record sheet. The iconographic record of evaluated polyps in WLI and BLI modes and the evaluation video using CAD EYE® in BLI characterization mode should be done.
88829617|NCT04749199|Experimental|Enhanced mirror therapy group|Participants in this group will perform complex and randomized finger opposition and reposition movements based on the training protocol, along with enhanced complexity and altered clarity of the displayed image.
89358176|NCT01304069|Active Comparator|Etoricoxib|
89358177|NCT03320278||SPIDS,TMH|There will be two tests in this study for evaluation. Both of them will be measured in same group.
89358178|NCT03327298|Other|accuracy of pedicle screw insertion|postoperative CT lumbar spine axial and sagittal views.
89358179|NCT03799601|Experimental|combination of docetaxel, carboplatin and anlotinib|
89358180|NCT03793985|Experimental|A (R+T+R+T)|Period 1 : R Period 2 : T Period 3 : R Period 4 : T
89358181|NCT03793985|Active Comparator|B (T+R+T+R)|Period 1 : T Period 2 : R Period 3 : T Period 4 : R
88829618|NCT04749199|Sham Comparator|Standard mirror therapy group|Participants in this group will perform simple and sequential finger opposition and reposition movements, along with a clear image showing the exercising hand of the participants.
88829619|NCT04749121|Experimental|Fit test|All the participants had to pass the initial fit test.After decontamination with UVC irradiation for 60 minutes.The protocol was conducted in accordance with the protocol from the OSHA respiratory protection standard , including the number, type, and duration of the exercise, and the seal checks in accordance with the manufacturer's instructions[15] 60 minutes, fit testing was conducted using qualitative fit test (Bittrex Solution aerosol)
88829620|NCT02264353|Experimental|Donepezil|Sleep data with Donepezil given
88829621|NCT02264353|Placebo Comparator|Placebo|Sleep data with Placebo given
89358182|NCT03326908|Other|Normal conditions of light exposure|"Spectral Domain Optical Coherence Tomography (SD-OCT):~Five SD-OCTs will be produced under the same lighting conditions (photopic).~At baseline~20 minutes after baseline~25 minutes after baseline~45 minutes after baseline~60 minutes after baseline"
89358183|NCT03326908|Other|Light variations|"Spectral Domain Optical Coherence Tomography (SD-OCT):~Five SD-OCT will be performed:~at baseline, in a room with photopic artificial lighting (400 lux)~after a period of adaptation to the dark (20 minutes in the dark: 0 lux)~after 5 min of retinal glare, obtained by means of a projection of light of 1000 lux on the fundus of eye~15 minutes after this period of retinal glare, in photopic artificial lighting~30 minutes after the period of retinal glare, in photopic artificial lighting"
89358184|NCT03607526||Barriers to Vegetable Consumption|Four groups of participants will meet for NGT sessions, identifying barriers to meeting the DGA recommendation for vegetable consumption.
89358185|NCT03607526||Facilitators to Vegetable Consumption|Four groups of participants will meet for NGT sessions, identifying facilitators to meeting the DGA recommendation for vegetable consumption.
89358186|NCT01305005||patients with active-fluidics system|patients who underwent phacoemulsification surgery using active-fluidics system
89358187|NCT01305005||patients with gravity-fluidics system.|patients who underwent phacoemulsification surgery using gravity-fluidics system
89358188|NCT03791801|Active Comparator|Neostigmine|Will receive rocuronium and neostigmine (5-70microg/kg) + glycopyrrolate (10microg/kg) at train of four 1
89358189|NCT03791801|Active Comparator|Sugammadex|Will receive rocuronium and sugammadex (4mg/kg) after a successful intubation (ETT is in the trachea and secure).
89358190|NCT03319966||Oculomotor Dysfunction|This group consists of subjects with mTBI who have been diagnosed with OMD by objective OD measurements. These subjects will undergo neurovision rehabilitation used to treat oculomotor dysfunction following traumatic brain injury per usual clinical standard of care at the HCMC TBI Clinic.
89358191|NCT03494192|Experimental|scapula retraction exercise group|"Manual Therapy~Stretching Exercises~Exercise training focus on scapulothoracic muscles will be applied two times per week total 12 week After 12 week follow-up, patients will proceed to reduced exercise program until the 6-month follow-up."
89358192|NCT03494192|Experimental|Scapula Retraction +Glenohumeral Rotational Exercise Group|"Manual Therapy~Stretching Exercises~Exercise training focus on scapulothoracic muscles~Exercise training focus on rotator cuff muscles will be applied two times per week total 12 week After 12 week follow-up, patients will proceed to reduced exercise program until the 6-month follow-up."
89358193|NCT03494192|No Intervention|Control Group|Age-sex and hand-dominancy matched healthy controls will be included as a control group (CG) for acromiohumeral distance (AHD) normative data
89358194|NCT01305083|Active Comparator|Udenafil|Active Ingredient
89358195|NCT01305083|Placebo Comparator|Placebo|Placebo
89358196|NCT03319888|Experimental|cpap group|CPAP treatment plus conservative treatment with lifestyle modifications.
89358197|NCT03319888|Active Comparator|control group|Conservative treatment with lifestyle modifications.
89358198|NCT02490826|Active Comparator|Table-based T2T intervention|"A combined phonological awareness therapy, listening and discrimination and auditory bombardment activities intervention will be applied. This will be based in a table top material version.~The intervention will consist of 12 weekly sessions (individual) of 45 min in duration, divided into two blocks (6+6) without any breaks."
89358199|NCT02490826|Active Comparator|Tablet-based T2T intervention|"A combined phonological awareness therapy, listening and discrimination and auditory bombardment activities intervention will be applied. This will be based in a tablet (digital) material version.~The intervention will consist of 12 weekly sessions (individual) of 45 min in duration, divided into two blocks (6+6) without any breaks."
89358200|NCT03464396||Preterm infant study visits|"Preterm infants Study Visits~Bedside Physiology Study at 28, 32, 36, 40, and 52 weeks GA.~Respiratory tests:~Carotid Body Function Test will be completed at 32, 36, 40 and 52 weeks GA~Room Air Challenge (RAC) or Hypoxia Challenge Test (HCT) will be completed at 36 weeks GA~Effects of nasal cannula flow be completed at 28, 32, 36, 40 and 52 weeks GA~Magnetic Resonance Imaging (MRI): Completed on a subset of infants between 37-40 weeks GA or before discharge, whichever comes first.~Echocardiogram (Echo): Completed at 32, 36 and 52 weeks GA~Blood sample: Obtained at 32, 36 and 52 weeks GA"
89358201|NCT03791723|Experimental|Sacubitril/valsartan|After catheter ablation, during a single blind, run-in period, participants received placebo. Then started with 50 mg sacubitril/valsarta for 2-4 weeks, then uptitrated to 100 mg bid for 2-4 weeks, and thereafter, uptitrated to 200 mg bid or tolerable maximum dose ≥6 months.
89358202|NCT03791723|Active Comparator|Valsartan|After catheter ablation,during a single blind, run-in period, participants received placebo. Then started with 40mg Valsartan twice daily qd for 2-4 weeks, then were uptitrated to 80mg qd or tolerable maximum dose ≥6 months.
89358203|NCT03322696||Cirr-PVT|Cirrhotic patients developing over 1 yr period thrombosis of portal vein or collaterals
89358204|NCT05452070|Experimental|HArmonyCa Lidocaine Injectable Gel|Participants will receive HArmonyCa Lidocaine Injectable Gel on Day 1 and followed for up to 25 months. Participants will have the opportunity to receive optional touch-up and optional repeat treatment of HArmonyCa Lidocaine injectable gel during the follow-up duration period.
89534259|NCT03806933|Experimental|NT 201 Dose group 3|Stage 1. Intramuscular injection into the glabellar area.
89534260|NCT03806933|Experimental|NT 201 Dose group 4|Stage 2. Intramuscular injection into the glabellar area.
89000834|NCT04651036|Active Comparator|US Neulasta|US Neulasta subcutaneously at a dose of 6 mg/0.6 mL.
89358205|NCT05452070|Other|Control Group|Participants will be followed for 3 months. Participants can opt to receive HArmonyCa Lidocaine Injectable Gel after 3 months and followed for up to 25 months.
89534261|NCT03806933|Experimental|NT 201 Dose group 5|Open Label Extension Period. Intramuscular injection into the glabellar area.
89534262|NCT03784612|Experimental|App-technology group|"Participants in the App-technology group arm will use a newly developed smartphone application (app), containing a 12-week healthy eating program.~Intervention: App-technology for healthy eating habits."
89534263|NCT03784612|No Intervention|Control group|The control group will receive standard care.
89534264|NCT03784131|Experimental|Personalized Tissue Engineered Vein|P-TEV
89534265|NCT03768544|Experimental|Self-help guided by a lay provider|
89534266|NCT03768544|Other|Waiting list where participants wait for delayed treatment|
89358206|NCT03797885||Patients with type 2 diabetes mellitus (T2DM)|Patients with type 2 diabetes, at the hospital setting.
88829622|NCT02622191|Experimental|Open-angle glaucoma|Participants with primary open-angle glaucoma and an abnormal visual field defect in one eye. Spectral domain Optical Coherence Tomography will be obtained from the effected eye and fellow eye of each glaucoma patient.
88829623|NCT02622191|Experimental|Healthy Controls|Participants without glaucoma and no other eye diseases. Spectral domain Optical Coherence Tomography will be obtained from eyes of each healthy control.
89358207|NCT03797885||Patients with T2DM and established cardiovascular disease|Subgroup of patients with type 2 diabetes and established cardiovascular disease
89358208|NCT05410912||The younger group|Patients who were under the age of 40
89358209|NCT05410912||The older group|Patients who were more than 40 years old
89358210|NCT04442932||Interventions|Per test, a minimum of 40 atopic subjects for a given allergy and a total of at least 100 non-atopic subjects. To ensure that sufficient subjects with valid results are enrolled, the atopic enrollment goal per allergy is approximately 50 subjects. For each allergen, approximately 20% of the samples must be in the range of 0.70 to 3.5 IUA/mL and the remainder must cover a measuring range that is representative of the target population. Results from a single positive subject can be used in the analyses of more than one allergen if the subject is sensitized for more than one allergen.
88829624|NCT02265913|Experimental|Test Product|acyclovir cream
88829625|NCT02265913|Active Comparator|Reference Product|acyclovir cream
88829626|NCT02265913|Placebo Comparator|Placebo Product|Placebo cream
88829627|NCT02624375|Experimental|10 persons over 70 years of age that received Zostavax|10 persons over 70 years of age that received Zostavax (single 0.65-mL dose subcutaneously in the deltoid region of the upper arm)
88829628|NCT01858753|Experimental|Autologous fibroblasts|Autologous fibroblasts grown in culture from skin biopsy taken from patient. The cells will be injected into the scars to be treated.
88829629|NCT01858753|Placebo Comparator|Sterile saline|Sterile saline will be injected into the scar to be evaluated.
88829630|NCT02624843|Experimental|Benzyl Alcohol Lotion 5%|Day 1- Sufficient to saturate hair and scalp for 10 min and then washed out. Day 8 -Sufficient to saturate hair and scalp for 10 min and then washed out.
88829631|NCT02624843|Active Comparator|Ulesfia (Benzyl Alcohol Lotion 5%)|Day 1- Sufficient to saturate hair and scalp for 10 min and then washed out. Day 8 -Sufficient to saturate hair and scalp for 10 min and then washed out.
88829632|NCT02624843|Placebo Comparator|Vehicle Placebo Lotion 0%|Day 1- Sufficient to saturate hair and scalp for 10 min and then washed out. Day 8 -Sufficient to saturate hair and scalp for 10 min and then washed out.
88829633|NCT05106101|Experimental|L-glutamine|Participants received L-glutamine oral powder 15 grams twice daily for 48 weeks
88829634|NCT04600973|Active Comparator|Surveillance with Technical Assistance|Surveillance will be offered to 3 teams with Technical Assistance (TA) in block randomization. Surveillance tool will execute regularly updated reports (continually updated with laboratory data entry of ESKAPE pathogen isolation results), which generates a set of data that will populate series of tables and graphs for each site based on data collection form as previously reported.
88829635|NCT04600973|Active Comparator|Surveillance with EBIP Coaching|Surveillance will be offered to 3 teams with Evidence-Based Infection Prevention Bundle (EBIP) coaching in block randomization. Surveillance tool will execute regularly updated reports (continually updated with laboratory data entry of ESKAPE pathogen isolation results), which generates a set of data that will populate series of tables and graphs for each site based on data collection form as previously reported. EBIP involves evidence-based improvements in perioperative hand hygiene, environmental cleaning, vascular care, and patient decolonization. Each participating site will receive monthly team-based coaching to establish a multidisciplinary team charged with continuously improving transmission and infection prevention.
88829636|NCT04600973|Active Comparator|Technical Assistance No Surveillance|TA will be offered to 3 teams. TA will have monthly scheduled TA calls (60 minutes each) with each team individually to review and discuss the protocol interventions (as is done in the EBIP group) and allow for a consultation with experts on the peri-operative interventions. Surveillance toolkit will only be used for transmission data collection.
88829637|NCT04600973|Active Comparator|EBIP Coaching No Surveillance|EBIP will be offered to 3 teams. Each participating site will receive monthly team-based coaching to establish a multidisciplinary team charged with continuously improving transmission and infection prevention. EBIP involves evidence-based improvements in perioperative hand hygiene, environmental cleaning, vascular care, and patient decolonization. Surveillance toolkit will only be used for transmission data collection.
88829638|NCT02625545|Experimental|UroLift System procedure|All eligible,enrolled subjects will undergo a UroLift procedure
88829639|NCT02279641|Experimental|Sequence A|RDEA3170 qd (once daily), RDEA3170 + allopurinol qd, allopurinol qd
88829640|NCT02279641|Experimental|Sequence B|allopurinol qd, RDEA3170 + allopurinol qd, RDEA3170 qd
88829641|NCT04339985|Experimental|ATx201 OINTMENT 4%|ATx201 OINTMENT 4%
89358211|NCT03920657|Experimental|Deferasirox|patients will be assigned to a fixed dose of 3.5 mg/kg/day of DFX FCT.
89358212|NCT03420950|Other|Sedative first|Rapid sequence intubation: sedative first
89358213|NCT03420950|Other|Paralytic agent first|Rapid sequence intubation: paralytic first
89358214|NCT03319654|Experimental|Spontaneous cycle IUI|"DNA fragmentation by TUNEL assay~DNA fragmentation will be measured both at the time of the diagnostic work-up as at the time of insemination."
89358215|NCT03501277|Experimental|Sequence I: ABCD|SYR-322-4833 BL (alogliptin 25 [milligram] mg and pioglitazone 15 mg) FDC tablet, orally, once, on Day 1 of Period 1 (Regimen A), followed by a 7-day washout period, followed by alogliptin 25 mg tablet and pioglitazone 15 mg tablet, orally, once, on Day 1 of Period 2 (Regimen B), followed by a 7-day washout period, followed by SYR-322-4833 BL (alogliptin 25 mg and pioglitazone 30 mg) FDC tablet, orally, once, on Day 1 of Period 3 (Regimen C), followed by a 7-day washout period, followed by alogliptin 25 mg tablet and pioglitazone 30 mg tablet, orally, once, on Day 1 of Period 4 (Regimen D).
89534267|NCT03758989|Experimental|Baseline PET|R-CHOP
89534268|NCT03758274|Experimental|CBT Phone Intervention|Cognitive-Behavioral Therapy for Treatment Seeking, CBT-TS, a manualized behavioral intervention, administered by telephone in a single session.
89358216|NCT03501277|Experimental|Sequence II: BCDA|Alogliptin 25 mg tablet and pioglitazone 15 mg tablet, orally, once, on Day 1 of Period 1 (Regimen B), followed by a 7-day washout period, followed by SYR-322-4833 BL (alogliptin 25 mg and pioglitazone 30 mg) FDC tablet, orally, once, on Day 1 of Period 2 (Regimen C), followed by a 7-day washout period, followed by alogliptin 25 mg tablet and pioglitazone 30 mg tablet, orally, once, on Day 1 of Period 3 (Regimen D), followed by a 7-day washout period, followed by SYR-322-4833 BL (alogliptin 25 mg and pioglitazone 15 mg) FDC tablet, orally, once, on Day 1 of Period 4 (Regimen A).
89358217|NCT03501277|Experimental|Sequence III: CDAB|SYR-322-4833 BL (alogliptin 25 mg and pioglitazone 30 mg) FDC tablet, orally, once, on Day 1 of Period 1 (Regimen C), followed by a 7-day washout period, followed by alogliptin 25 mg tablet and pioglitazone 30 mg tablet, orally, once, on Day 1 of Period 2 (Regimen D), followed by a 7-day washout period, followed by SYR-322-4833 BL (alogliptin 25 mg and pioglitazone 15 mg) FDC tablet, orally, once, on Day 1 of Period 3 (Regimen A), followed by a 7-day washout period, followed by alogliptin 25 mg tablet and pioglitazone 15 mg tablet, orally, once, on Day 1 of Period 4 (Regimen B).
89358218|NCT03501277|Experimental|Sequence IV: DABC|Alogliptin 25 mg tablet and pioglitazone 30 mg tablet, orally, once, on Day 1 of Period 1 (Regimen D), followed by a 7-day washout period, followed by SYR-322-4833 BL (alogliptin 25 mg and pioglitazone 15 mg) FDC tablet, orally, once, on Day 1 of Period 2 (Regimen A), followed by a 7-day washout period, followed by alogliptin 25 mg tablet and pioglitazone 15 mg tablet, orally, once, on Day 1 of Period 3 (Regimen B), followed by a 7-day washout period, followed by SYR-322-4833 BL (alogliptin 25 mg and pioglitazone 30 mg) FDC tablet, orally, once, on Day 1 of Period 4 (Regimen C).
89358219|NCT01304225|Active Comparator|100ms single-shot|Panretinal photocoagulation utilizing 100ms pulse duration, moderate intensity burns, in a single-shot fashion
89358220|NCT01304225|Experimental|20ms multiple-shot|Panretinal photocoagulation utilizing 20ms pulse duration, moderate intensity burns, in a multiple-shot fashion
89358221|NCT01304225|Experimental|20ms multiple-shot, barely visible|Panretinal photocoagulation utilizing 20ms pulse duration, barely visible intensity burns, in a multiple-shot fashion
89358222|NCT03447626||Prospective Group- Robotic UKA Arm|Robotic UKA with the MAKO machine.
89358223|NCT03447626||Control- Fixed and Mobile UKA Arm|Patients who have received fixed or mobile bearing UKA
89358224|NCT03447626||Control-Total Knee Arthroplasty|Patients who have had cemented or cementless total knee arthroplasty
89358225|NCT02488174|Active Comparator|Standard Care|The pre-intervention control condition will be usual care: that is, clinicians practice as usual without clinician notification of risk and without prompting on care practices as recommended by PROOFcheck.
89358226|NCT02488174|Experimental|PROOFcheck|The intervention for this study will consist of 3 parts: 1) Education of clinicians on prevention of severe ARF and MOF in and out of the ICU, and best practice with regards to patients with severe ARF; 2) Clinicians will be notified that a patient they are taking care of has been identified as being at high risk for developing severe ARF requiring prolong MV; 3) Notified clinicians will be directed to PROOFcheck with a bundle of recommendations for best care for patients with ARF.
89358227|NCT03870425|Placebo Comparator|MINCED-SKEWED|Minced meat administered with a skewed protein distribution pattern
89358228|NCT03870425|Experimental|MINCED-EVEN|Minced meat administered with an even protein distribution pattern
89358229|NCT03322228|Experimental|Music Therapy|1 music therapy session, lasting approximately 45 min-1 hr
89358230|NCT03797729|Placebo Comparator|Normal saline|
89358231|NCT03797729|Experimental|Tirofiban|
89358232|NCT03500419|Active Comparator|Control|No treatment will be administered for the initial 6 months post-prostatectomy. This is necessary as a measure to review post-prostatectomy penile length changes.
89358233|NCT03500419|Experimental|Group AB - PTT 1-2x daily x 5-7 days/week x 5 months|Men will utilize penile traction therapy for 30 minutes 1-2 times daily, 5-7 times a week, beginning 4 weeks post-prostatectomy. Men will remain in this phase for a period of 5 months.
89358234|NCT02487940|Active Comparator|Intralipid|Women with RIF received intralipid 20% (at a dose of 9mg/mL of the total blood volume, corresponding to 2 mL intralipid diluted at 20% in 250 mL normal saline) given over 1-2 hours on the day of oocyte retrieval. Dose is repeated on/the following day of a positive pregnancy test, followed by a final dose 2-3 weeks later when attending for pregnancy scan.
88829642|NCT04339985|Experimental|ATx201 OINTMENT 7%|ATx201 OINTMENT 7%
89358235|NCT02487940|Placebo Comparator|Placebo|Women with RIF received intravenous infusion of 250 mL physiological saline solution over 1-2 hours on the day of oocyte retrieval. Dose is repeated on/the following day of a positive pregnancy test, followed by a final dose 2-3 weeks later when attending for pregnancy scan.
89358236|NCT03625934|Experimental|VVX001 (20 micrograms)|Subjects will receive 5 injections of 20 micrograms each over a period of 4 months
89358237|NCT03625934|Placebo Comparator|Placebo|Subjects will receive 5 s.c. injections of matching placebo over a period of 4 months
89358238|NCT03797573|Active Comparator|active tDCS|Patients will receive tDCS (bilateral fronto-central stimulation) during 20 minutes preceded and followed by a clinical assessment (Modified Ashworth Scale and Coma Recovery Scale-Revised) and neurophysiological assessment (8 channels EEG).
89358239|NCT03797573|Sham Comparator|sham tDCS|Patients will receive sham tDCS (5 seconds of stimulation) during 20 minutes preceded and followed by a clinical assessment (Modified Ashworth Scale and Coma Recovery Scale-Revised) and neurophysiological assessment (8 channels EEG).
89358240|NCT02488096|Active Comparator|TRUS-Guided Biopsy|Transrectal Ultrasound (TRUS)-guided biopsy systematic 12-core biopsy (standard care)
89358241|NCT02488096|Experimental|MRI + TRUS-Guided biopsy|Prostate MRI later followed by systematic 12-score TRUS-guided biopsy + targeted biopsy of additional MRI-detected scores.
89358242|NCT03500341|Experimental|Test Subject|All subjects who are enrolled into the test group and participate in data collection receive the noninvasive INVSENSOR00014 sensor
89358243|NCT03827759||septic arthritis (group A)|Patients with acute juvenile arthritis with suspicion of bacterial infection,confirmed on a bacteriological plan, either by culture of the articular liquid or by blood culture, or by molecular biology in the articular liquid;
88829643|NCT04339985|Experimental|ATx201 OINTMENT vehicle|ATx201 OINTMENT vehicle
89358244|NCT03827759||inflammatory arthritis (group B)|Patients with idiopathic juvenile arthritis
89358245|NCT03827759||control (group C)|Healthy children who are matched by the age and at the sex in the groups A and B, to analyze elements studied in the blood.
88829644|NCT01859611|Experimental|Radiofrequency|Radiofrequency (RF) treatment with the TriActive+ RF device on the peri-oral and/or peri-orbital areas of the face once a week for eight weeks.
88829645|NCT04135807|Experimental|Microdevice|"The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits.~Patients with newly found supratentorial lesions, or patients previously diagnosed with supratentorial gliomas at time of recurrence, whose treatment plan includes partial or total resection surgery as a component of standard-of-care treatment will be included.~- Placement of 1-3 microdevices (depending on the size of the tumor) before tumor resection is started.~-- The microdevices will dwell in the tumor tissue for a time window of 2-4 hours to allow time for tissue effects of the drugs microdoses for intratumor release of the following 8 approved drugs: Temozolomide, Lomustine, Irinotecan, Carboplatin, Lapatinib, Osimertinib, Abenaciclib, and Everolimus. The drugs used in this study will only include drugs already used systemically for the treatment of gliomas."
88829646|NCT05215093|Experimental|Direct physiotherapy pathway|People with acute low back pain will directly go to a physiotherapist, who will treat the patient without prescription of the general practitioner.
88829647|NCT05215093|Active Comparator|Usual care pathway|People with low back pain will receive usual care by the general practitioner (with or without referral to physiotherapy).
88829648|NCT01862419|Experimental|Alert|Text page sent to patient's covering provider and unit pharmacist informing them of the presence of AKI as detected by changes in serum creatinine.
88829649|NCT01862419|No Intervention|Usual Care|Usual care arm. No alert will be provided to the patient's covering provider or unit pharmacist.
88829650|NCT02629991|Experimental|Intranasal Oxytocin|Participants were instructed to take 16 IU/per day everyday (2 puffs per nostril, 4 IU each puff).
88829651|NCT02629991|Placebo Comparator|Matched Placebo|Participants were instructed to take 16 IU/per day everyday (2 puffs per nostril, 4 IU each puff).
88829652|NCT05157529|Experimental|Aquablation|The participant will undergo aquablation procedure for Benign Prostate Hypeplasia (BPH) treatment using the AQUABEAM Robotic System and Ultrasound Accessories
88829653|NCT02633735|Experimental|Appy CDS|The Appy-cds intervention is a point of care clinical decision support system designed to identify pediatric patients at risk for appendicitis using EHR and supplemental data. The intervention is administered to providers in this arm.
88829654|NCT02633735|No Intervention|Usual Care|
88829655|NCT05018663||Prospective enrollment|All subjects will be enrolled prospectively. Subjects will be included in the study after eligibility is assessed and informed consent is obtained. The slide scanner will scan the slides on site and the images will be securely saved and sent for interpretation by the AI software at a different location. The results of the AI interpretation of the slides will be blinded to the on-site procedure team including the endoscopist and cytopathologist until the final pathology report is complete.
88829656|NCT03949231|Experimental|PD1/PDL1 inhibitor hepatic artery infusion|Interventional technique to place microcatheter in hepatic artery to infuse PD1/PDL1 inhibitor in 30 minutes.
88829657|NCT03949231|Experimental|PD1/PDL1 inhibitor vein infusion|Regular IV infusion of PD1/PDL1 inhibitor in 30 minutes.
88829658|NCT04992143|Experimental|TACE combined Tilelizumab and Sorafenib|TACE first combined Tilelizumab(240mg/3wks ivgtt） and Sorafenib （800mg/day orally)
88829659|NCT01866163|Experimental|LEO 90100|LEO 90100 aerosol foam, containing calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate)
88829660|NCT01866163|Placebo Comparator|Vehicle|Aerosol foam vehicle
89358246|NCT03365102|Experimental|anodal tDCS over the rIFG,|anodal tDCS over the rIFG,
88829661|NCT04485065|Experimental|IBI188+azacitidine|
88829662|NCT04969289|Experimental|Dr. Eric Digital Health Intervention|"Participants will interact with an ED-based iPad and the Dr. Eric app for a recorded period of time. After completion, an animated video will explain the ERIC texting program and live office hours. The participant enters his phone number and then receives a welcome text. Weekly texts are sent directly to the participant phone via short message service (SMS)."
88829663|NCT04969289|No Intervention|Standard of Care|Participants randomized to the SC arm will receive standard medical care as determined by the ED provider, which is typically referral to a primary care or adolescent provider. Mobile telephone numbers will be collected for follow up purposes.
88829664|NCT03769129|Experimental|Microwave ablation|Firstly, microwave ablation performed at our department by interventional radiologist, then Pembrolizumab will be administered at a dose of 2 mg/kg every three weeks.
89177807|NCT00794196|Experimental|Intervention Group|Intervention group will be receiving usual medical and pharmaceutical care plus a pharmaceutical support program.
89358247|NCT03365102|Experimental|anodal tDCS over the lOFC|anodal tDCS over the lOFC
89358248|NCT03365102|Placebo Comparator|sham tDCS stimulation|sham tDCS stimulation
89358249|NCT02487862|No Intervention|Screening|Participants were screened for the inclusion and exclusion criteria to select the study group. No intervention has been done.
89358250|NCT02487862|Placebo Comparator|catagerizing the study population|The selected participants where assigned into respective groups
89358251|NCT02487862|No Intervention|Stress Reduction Protocol|Participants were evaluated for the outcome of the intervention.
89358252|NCT03721159||Group I|30 Generalized chronic periodontitis subjects diagnosed with Coronary heart disease.
89358253|NCT03721159||Group II|30 Generalized chronic periodontitis subjects without coronary heart disease.
89358254|NCT03721159||Group III|30 Systemically healthy patients with no chronic periodontitis or coronary heart disease.
89534269|NCT03758274|Active Comparator|Being Read A Pamphlet on Alcohol Treatment|Guided review of a National Institute on Alcohol Abuse and Alcoholism (NIAAA) pamphlet on AUD treatment, administered by telephone in a single session.
89358255|NCT03816293|Active Comparator|Negative Pressure Wound Therapy|NPWT use on closed incision for 7 days after c-section, abdominal hysterectomy, and colon surgery in patients with diabetes and/or obesity
89358256|NCT03816293|No Intervention|Control Dressing|Standard dressing on closed incisions after c-section, abdominal hysterectomy, and colon surgery in patients with diabetes and/or obesity
89358257|NCT02487628|Experimental|HQ® Matrix Soft Tissue Mesh|HQ® Matrix Soft Tissue Mesh is a warp-knitted, multifilament, bioengineered scaffold which is comprised of the silk fibroin protein of the Bombyx mori (B. mori) silkworm. The porous network structure makes it soft and pliable and convenient to implant. The mesh is mechanically strong, biocompatible, and long-term bioresorbable. The pore size is suitable for macrophage migration and recruitment, which hinders bacteria growth. The mesh is provided in single sheets of varying widths and lengths and may be cut to the shape or size desired for a specific application. It is sterile and for single-patient use only.
89358258|NCT02487628|Active Comparator|ULTRAPRO® Partially Absorbable Lightweight Mesh|ULTRAPRO® Partially Absorbable Lightweight Mesh (Ethicon, Inc.) is manufactured from approximately equal parts of absorbable poliglecaprone-25 monofilament fiber and non-absorbable polypropylene monofilament fiber. Designed for open and laparoscopic hernia repairs, it allows surgeons the versatility to perform various hernia repairs with a single technology. It offers excellent strength with minimal foreign body mass, to allow patients to heal more naturally with increased comfort and mobility.
89358259|NCT03719365|Experimental|NAVAPSV|Each patient enrolled in the study will be submitted to 3 ventilation trials during PSV and NAVA ventilation modes, assigned in a randomized order.
89358260|NCT02487706|Experimental|Dolutegravir 50mg/day per 5 days|Dolutegravir 50mg/day per 5 days
89358261|NCT03797417||Disease|patients with vitiligo
89358262|NCT03797417||Healthy Control|healthy control
89358263|NCT02487784|Experimental|Particulate allograft + autogenous bone.|In the test arm of the study the treatment will include a mix of MinerOss CorticoCancellous Particulate allograft + autogenous bone chips.
89358264|NCT02487784|Active Comparator|Block allograft|The positive control treatment will include a block allograft plus Mineross corticocancellous particulate allograft.
89358265|NCT03797339||Discovery cohort|1000 cases of coronary heart disease follow-up cohort was used for multi-omics target discovery.During the follow-up period, the information about the occurrence and risk factors of adverse cardiovascular events will be collected.
89358266|NCT03797339||Validation corhort|3000 coronary heart disease follow-up cohorts was used for validating the results from the discovery corhort. During the follow-up period, the occurrence and risk factors of adverse cardiovascular events.Predictive mathematical models based on multi-omics combination will be constructed finally.
88829665|NCT03769129|Other|Pembrolizumab|Firstly, pembrolizumab was administered intravenously at a dose of 2 mg/kg. Then microwave ablation will be performed if there is no immune-related adverse reactions. Pembrolizumab will also be continuously administered every three weeks until the imaging evaluation of the disease progress.
88829666|NCT00366509||1|Lung Disease
89358267|NCT03319576|Experimental|Early feeding|Patients randomized to early feeding will be fed 4 hours following gastrostomy tube placement
89358268|NCT03319576|No Intervention|Standard feeding|Patients randomized to standard feeding will be fed 24 hours following gastrostomy tube placement
89358269|NCT03326752|Experimental|Dose Escalation Cohort 1-5|"Cohort 1-4~DV281 - Dose Level 1-5~DV281 in combination with nivolumab~DV281 is administered via a breath actuated nebulizer"
89358270|NCT03326752|Experimental|Dose Expansion (RP2D)|"4 Cohorts~Preliminary Recommended Phase 2 dosing of DV281 in combination with nivolumab~Cohort 1: Non-squamous and non-EGFR/ ALK mutation and progressed on anti-PD-1/L1 therapy~Cohort 2: Non-squamous and EGFR/ ALK mutation and progressed on targeted therapy~Cohort 3: Squamous and anti-PD-1/ L1 therapy experienced~Cohort 4: Squamous and anti-PD-1/L1 therapy naive~DV281 is administered via a breath actuated nebulizer."
89358271|NCT01304303|Experimental|SPARC1023 I|
89534270|NCT03730337|Experimental|ONO-7475 monotherapy|
89534271|NCT03730337|Experimental|ONO-7475 in combination with ONO-4538|
89534272|NCT03693807|Experimental|Pump Therapy|All patients will undergo surgery to have the Medtronic pump and Codman catheter placed appropriately before HAI therapy can begin.
88829667|NCT00366509||2|Healthy volunteer
88829668|NCT04957589|Experimental|VLCD & HIIT|Very low calorie diet (standardised LighterLife meal replacement packages consisting of approximately 150kcal each, amounting to 600kcal/day, with 200kcal of a pre-determined free expenditure consisting of nuts and/or vegetables) High intensity interval training (3x sessions per week following intensity estimation using cardiorespiratory testing (VO2max), using an established training protocol within our department) No additional protein supplementation
89177808|NCT00821938|Active Comparator|CRT-ICD|
89177809|NCT00821938|Placebo Comparator|DDD-ICD|
89358272|NCT01304303|Experimental|SPARC1023 II|
89358273|NCT03326674|Experimental|Arm A: Tesetaxel (oral) and capecitabine (oral)|Tesetaxel (27 mg/m2) once every 21 days on Day 1 of each 21-day cycle; and capecitabine (825 mg/m2) twice daily (in the morning and evening after a meal, for a total daily dose of 1,650 mg/m2) beginning with the evening dose on Day 1 through the morning dose on Day 15 of each 21-day cycle
89358274|NCT03326674|Active Comparator|Arm B: Capecitabine (oral)|Capecitabine (1,250 mg/m2) twice daily (in the morning and evening after a meal, for a total daily dose of 2,500 mg/m2) beginning with the evening dose on Day 1 through the morning dose on Day 15 of each 21-day cycle
89358275|NCT02491060|Experimental|IDP-121 Lotion|IDP-121 Lotion, applied topically to the face, once daily for 12 weeks.
89358276|NCT02491060|Placebo Comparator|IDP-121 Lotion Vehicle|IDP-121 Vehicle Lotion, applied topically to the face, once daily for 12 weeks
89358277|NCT01316900|Experimental|GSK573719/GW642444 125/25|125/25 mcg once-daily
89358278|NCT01316900|Experimental|GSK573719/GW642444 62.5/25|62.5/25 mcg once-daily
89358279|NCT01316900|Experimental|GW642444|25 mcg once-daily
89358280|NCT01316900|Active Comparator|tiotropium bromide|18 mcg once-daily
89358281|NCT02490982||Teriflunomide|Patient-reported outcomes and clinical assessment
89358282|NCT03322150|Active Comparator|Atropine group|Patients that receive atropine 0.01 mg/kg (max 0.5mg) before spinal anesthesia
89358283|NCT03322150|Active Comparator|Glycopyrrolate group|Patients that receive glycopyrrolate 0.004mg/kg (max 0.2 mg) before spinal anesthesia
89358284|NCT03499873|Experimental|Nepafenac 0.3% Opthalmic Suspension|Test product manufactured by Indoco Remedies, Ltd for Actavis LLC.
89358285|NCT03499873|Active Comparator|Ilevro 0.3% Opthalmic Suspension|Reference product manufactured by Alcon Laboratories Inc.
89358286|NCT03499873|Placebo Comparator|Placebo (vehicle) Opthalmic Suspension|Placebo (vehicle) manufactured by Indoco Remedies, Ltd for Actavis LLC.
89358287|NCT01305707|Experimental|C-ECT and Pharmacotherapy|Consolidation treatment with ECT will be considered finished after 9 months of being started, at which time patients will stay only on the pharmacological treatment they already had. The study will be completed within 15 months of patient inclusion (six months after the end of C-ECT). Patient assessment and follow-up will be conducted by participant researchers. Blind rater will conduct clinical and adverse effects ratings. A neuropsychologist will conduct neuropsychological assessments.
89358288|NCT01305707|Active Comparator|Pharmacotherapy|Pharmacotherapy will remain unchanged since the acute episode to the end of the study. Psychotropics will be obtained as usually from the National Health System and will be prescribed according to data sheet.
89358289|NCT04051970|Experimental|Strategy TRI-BI|
89177810|NCT00807092|Experimental|BIAsp 30|BIAsp 30 (biphasic insulin aspart 30) administered subcutaneously (under the skin) twice daily (before breakfast and dinner) + metformin. Initial total daily dose of 0.3 U or IU/kg body weight followed by individual dose adjustment for BIAsp 30 was performed over the first 4 weeks (titration period) to achieve the pre-meal blood glucose target of 4.4-6.1 mmol/l. The achieved dose was maintained for the last 2 weeks of treatment unless hypoglycaemia occurred.
89358290|NCT04051970|Active Comparator|Strategy Immediate BI|
89358291|NCT04442854|Experimental|cognitive behavioral group therapy|A cognitive behavioral group prevention program An 8-session, cognitive behavioral group prevention program, featuring cultural appropriateness. One session per week, 3 hours for each session. The program contents include psychoeducation, cognitive skills training to identify and challenge maladaptive cognitions, and behavioral skills training. Each session contains mood check and homework. Participants' own examples are used in the group to demonstrate the CBT skills.
89358292|NCT04442854|No Intervention|Wait-list control group|No immediate intervention No intervention was provided when the experimental group was receiving services, but the same cognitive behavioral group prevention program was delivered to the wait-list control group after that.
89358293|NCT03722329|Experimental|SB12|SB12 (proposed eculizumab biosimilar)
89358294|NCT03722329|Active Comparator|EU Soliris|EU sourced Soliris (eculizumab)
89358295|NCT03722329|Active Comparator|US Soliris|US sourced Soliris (eculizumab)
89358296|NCT03791333||multi trauma patients group|
89358297|NCT03326440|Other|Study Arm|Patients with a histological diagnosis of prostate cancer are shown how Radiotherapy is planned and given using 3D images on the VERT (Virtual Environment Radiotherapy) system prior to the start of Radiotherapy.
89358298|NCT03326440|Other|Control Arm|Patients with a histological diagnosis of prostate cancer who are shown how Radiotherapy is planned and given using 3D images on the VERT (Virtual Environment Radiotherapy) system following completion of Radiotherapy.
89358299|NCT03791177|Experimental|Study Group|A total of 70 patients were included in the study. Using simple randomization method, the patients were acknowledged about the aim of the study and the cards with letters C (control) and S (study) were placed in closed envelopes and the patients were asked to draw a random envelope. After the draw, two groups were formed according to the letter as group I consisted of patients with C letter and group II consisted of patients with S letter.
89358300|NCT03791177|Sham Comparator|Control Group|A total of 70 patients were included in the study. Using simple randomization method, the patients were acknowledged about the aim of the study and the cards with letters C (control) and S (study) were placed in closed envelopes and the patients were asked to draw a random envelope. After the draw, two groups were formed according to the letter as group I consisted of patients with C letter and group II consisted of patients with S letter.
89358301|NCT05420896|Active Comparator|Manual therapy|Upper cervical spine mobilization Posterior-anterior mobilization of the fifth cervical vertebra Suboccipital inhibition Suboccipital mobilization Trigger point application to my masseter, temporal and sternocleidomastoid muscles Intraoral and extraoral myofascial release Intraoral sphenopalatine ganglion technique TMJ mobilization Massage for chewing muscles The 45-minute treatment program, which includes applications including the techniques above, will be applied to the patients randomly assigned to the study group once a week for a total of 4 weeks.The changes in muscle activity of the masseter and anterior temporalis bilaterally will be recorded with EMG.
89358302|NCT05420896|No Intervention|Control group|Patients assigned to the control group randomly will be re-evaluated 4 weeks after their initial evaluation. No intervention will be applied during this period. After 4 weeks, when the patients are re-evaluated, they will be directed to the appropriate treatment.
89358303|NCT03467971|Experimental|Metformin-Gliclazide (fasted), Then Metformin-Gliclazide (fed)|Participants received single dose of Metformin 1000 milligram (mg) and Gliclazide 30 mg fixed combination tablet in fasting state in treatment period 1 followed by single dose of Metformin 1000 mg and Gliclazide 30 mg fixed combination tablet in fed state in treatment period 2. Each treatment period was separated by a 14-day wash-out period.
89358304|NCT03467971|Experimental|Metformin-Gliclazide (fed), Then Metformin-Gliclazide (fasted)|Participants received single dose of Metformin 1000 mg and Gliclazide 30 mg fixed combination tablet in fed state in treatment period 1 followed by single dose of Metformin 1000 mg and Gliclazide 30 mg fixed combination tablet in fasting state in treatment period 2. Each treatment period will be separated by a 14-day wash-out period.
89358305|NCT03138590|Experimental|Active tDCS|Active transcranial Direct Current Stimulation targeting the trigeminal nerve
89358306|NCT03138590|Sham Comparator|Sham tDCS|Sham transcranial Direct Current Stimulation targeting the trigeminal nerve
89358307|NCT02487550|Experimental|DC-CIK|Patients receive autologous dendritic cells (DC) loaded with autologous tumor lysate (DC vaccine) by endermic injection and infusion of CIK cells.
89358308|NCT02487550|Other|IL-2/IFN-α|Patients receive treatment of IL-2 or IFN-α.
89358309|NCT04442776|Experimental|Intervention group|The intervention group will complete the Dual Integrated Attention Program (D-AIP) The D-AIP will consist on 6 individualized sessions with the psychiatric inpatients, and during follow-up up to one year after discharge in which 4 individual sessions and 3 telephone contacts will be made.
89358310|NCT04442776|No Intervention|Control group|The control group will complete the usual treatment. One session per day voluntary during admission and discharge, nursing consultations only to put injectable medication
89358311|NCT03791021||third trimester pregnant women|the group of participants in this research would include approximately 100 subjects in the third trimester of their pregnancy. the participants would be collected in the central area of Israel from various socioeconomic groups. each participant would be asked to make draw a person (DAP) test, and answer a number of questionnaires including Edinburgh Postnatal Depression Scale (EPDS), Beck Depression Inventory II (BDI-II), and Traumatic Events Questionnaire (TEQ).
89358312|NCT03049280|Experimental|Transoral robotic surgery|
89358313|NCT04442698||Diabetic MGB post op patients|Diabetic MGB post op patients
89358314|NCT03791099|Experimental|Metronidazole|19,8 mg of metronidazole in one polymer matrix
89358315|NCT03791099|No Intervention|Only SRP|standard non-surgical treatment- scaling/root planing
89358316|NCT03326362|Experimental|High intensity resistance training (HIRT)|"12 weeks of two weekly training sessions, with at least 48 hours of interval between sessions. The HIRT performed the squat, deadlift and lunge exercises, as these exercises induce high core muscles activity. HIRT started with two weeks of low intensity exercises emphasizing the activation of core muscles (pelvic elevation with feet on the floor, superman, static supine bridge on bosu), and the technique of the selected resistance exercises (e.g. squat, deadlift, and lunges). Participants performed 3 sets of 10 repetitions per exercise. In the third and forth weeks, participants performed the exercises from the previous weeks and also static unipedal forward flexion on bosu and dynamic unipedal forward flexion and the main exercises with a load corresponding to (50% of the 1 RM load (Brzycki, 1993).~From the 5th to the 12th week, participants performed only the selected resistance exercises with progressive higher intensities (from 12RM to 8RM)."
89358317|NCT03326362|Active Comparator|Low intensity resistance training (LIRT)|12 weeks of two weekly training sessions, with at least 48 hours of interval between sessions.The LIRT group performed very low intensity and volume exercises (i.e. 1 set per exercise). Exercises started with participants lying on a firm surface, with the back supported, knees bent and feet flat on the floor. Then, participants performed the following exercises: 1) inhaling and exhaling and then isometrically contract in gluteal and abdominal muscles for 20 seconds and relax; 2) raising the head, lifting the chin and shoulders toward the chest for 20 seconds and relax; 3) raising one knee towards the chest and raising the head and shoulders likewise in the second exercise for 20s, relaxing, and changing the leg.; 4) raising both knees towards the chest in the same time that raise the head and shoulder off the floor during 20 seconds and relax.
89358318|NCT03185000|Experimental|Immediate ATIMP (AP)|Patients will receive Treg immunotherapy (TR004) infusion at Week 0.
89358319|NCT02653313|Experimental|ParvOryx|ParvOryx given intravenously on four consecutive days (day 1 to 4) and intrametastatic six to thirteen days thereafter (day 7, 10 or 14).
89358320|NCT03791255|Experimental|Resin Modified Calcium Silicate|light-cured resin-modified calcium silicate-filled base/ liner material designed for direct and indirect pulp capping
89358321|NCT03791255|Active Comparator|Light Cured Calcium Hydroxide|gold standard for pulp capping, It allows for the formation of a reparative dentine bridge through cellular differentiation, extracellular matrix secretion and subsequent mineralization.
89358322|NCT03326284|Experimental|15g protein hypocaloric diet|Following a 5-day hypocaloric diet the subjects (n=10) will ingest 15g of protein and their mixed muscle protein synthesis response will be monitored using tracer kinetics.
89358323|NCT03326284|Experimental|35g protein hypocaloric diet|Following a 5-day hypocaloric diet the subjects (n=10) will ingest 35g of protein and their mixed muscle protein synthesis response will be monitored using tracer kinetics.
89358324|NCT03326284|Experimental|60g protein hypocaloric diet|Following a 5-day hypocaloric diet the subjects (n=10) will ingest 60g of protein and their mixed muscle protein synthesis response will be monitored using tracer kinetics.
89358325|NCT03326284|Experimental|35g protein energy balanced diet|Following a 5-day energy balanced diet the subjects (n=10) will ingest 35g of protein and their mixed muscle protein synthesis response will be monitored using tracer kinetics.
89358326|NCT03794141|Experimental|Tervas|Follow up group from an earlier study. Information on risk gene status. All test persons were given information on healthy diet and life style.
89358327|NCT03794141|Experimental|Informed|Information on risk gene status was given before intervention. All test persons were given information on healthy diet and life style.
89358328|NCT03794141|Active Comparator|non informed|Information on risk gene status was not given before intervention. All test persons were given information on healthy diet and life style.
89358329|NCT03326206||COPE participants|Individuals living with diabetes seen at a study site who were enrolled in the COPE programmatic intervention during the study period. Participation in COPE consists of receiving home visits by a Navajo Community Health Representative (CHR) once or twice a month for a period of at least 12 months. CHRs use structured patient coaching materials to support behavior change. CHRs also check vital signs, monitor blood glucose levels through finger sticks, and facilitate access to appointments and medical refills. CHRs communicate regularly with providers through electronic health record documentation and case management rounds. In-person or telephone communication is be used to address acute issues that may arise.
89358330|NCT03326206||Non-COPE participants|Individuals living with diabetes seen at a study site, did not participate in the COPE programmatic intervention, and had comparable baseline characteristics.
89358331|NCT03797105|No Intervention|Control, 0 days|control group, no intervention
89358332|NCT03797105|Experimental|1 day|received the intervention 1 day/week
89358333|NCT03797105|Experimental|3 days|received the intervention 3 days/week
89358334|NCT03797105|Experimental|5 days|received the intervention 5 days/week
89358335|NCT03319420|Experimental|LO2A|1 drop of sodium hyaluronate instilled into each eye 4 times daily
89358336|NCT03319420|Active Comparator|Systane Ultra UD|1 drop of Systane Ultra UD instilled into each eye 4 times daily
89358337|NCT03794297|Experimental|Treatment (dabrafenib mesylate, trametinib dimethyl sulfoxide)|Patients receive dabrafenib mesylate PO BID and trametinib dimethyl sulfoxide PO QD on days 1-28. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
89358338|NCT04531020||Patients at PACU|Patients undergoing elective surgical or diagnostic intervention admitted to PACU after postanaesthesia recovery
89358339|NCT03321994|Experimental|Stereotaxic unit, navigation|
89358340|NCT03321994|Active Comparator|Conventional biopsy technique|
89358341|NCT03048500|Experimental|Treatment (metformin hydrochloride, nivolumab)|Patients receive metformin hydrochloride PO once QD on days -7 to -1 and 1-28. Patients also receive nivolumab IV over 30 minutes on days 1 and 15 of courses 1-4, then over 60 minutes on day 1 beginning course 5. Courses repeat every 28 days in the absence of disease progression, unacceptable toxicity, or withdrawal of consent.
89358342|NCT01331772|Other|Control arm|Dietetic follow-up only
89358343|NCT01331772|Experimental|Intervention arm|Dietetic + adapted physical activity
89358344|NCT03319342|Experimental|Group I (acts of kindness to others)|Participants perform small acts of kindness or generosity for others 3 times per week for 4 weeks and complete weekly online questionnaires.
89358345|NCT03319342|Experimental|Group II (acts of kindness to self)|Participants perform small acts of kindness for themselves 3 times per week for 4 weeks and complete weekly online questionnaires.
88829669|NCT04957589|Active Comparator|VLCD only|Very low calorie diet (standardised LighterLife meal replacement packages consisting of approximately 150kcal each, amounting to 600kcal/day, with 200kcal of a pre-determined free expenditure consisting of nuts and/or vegetables) No additional exercise or protein supplementation
89358346|NCT03319342|Experimental|Group III (self-kindness meditation)|Participants direct kind, loving thoughts to themselves, via guided meditation, 3 times per week for 4 weeks and complete weekly online questionnaires.
89358347|NCT03319342|Active Comparator|Group IV (track daily activities)|Participants keep track of their daily activities, focusing on factual information rather than thoughts and feelings, on 3 separate days each week. At the end of the week, participants report on their activities and complete several online questionnaires.
89358348|NCT03790787|Experimental|Sequential arm ABC|A: Empagliflozin 25 mg QD in the morning on Days 1-5; B: Empagliflozin 25 mg in the morning and Dorzagliatin 75 mg BID (morning and evening) on Days 6-10, with only the morning dose on Day 10; C: Dorzagliatin 75 mg BID (morning and evening) on Days 11-15, with only the morning dose on Day 15.
89534273|NCT03680521|Experimental|Sitravatinib and nivolumab|Sitravatinib oral capsule administered daily 2 weeks alone then in combination with nivolumab administered as 240 mg IV every 2 weeks. Total treatment duration: 6-8 weeks prior to planned nephrectomy.
88829670|NCT04484051||Routine clinical care with Genotropin treatment|Data collection throughout routine clinical care with subcutaneous injections Genotropin, 0.6-0.8 mg/day. Participants start with 0.2 mg/day and the dose increases with 0.2 mg/day per month to a maximum dose of 0.6-0.8 mg/day.
88829671|NCT04482569|Experimental|Single Ascending Dose Study|Six XNW4107 doses ( 50-1250 mg ), each administered as a single dose with 60-minute IV infusion
88829672|NCT04482569|Experimental|Multiple Ascending Dose Study|Three XNW4107 doses (167-500 mg), each administered as 60-minute IV infusion every 6 hours for 7 days
88829673|NCT04482569|Experimental|Multiple Dose Study of XNW4107 +Imipenem/Cilastatin|500 mg XNW4107 co-administered with imipenem/cilastatin as 60-minute IV infusion every 6 hours for 14 days
88829674|NCT05075551|Experimental|Acupuncture|Before participants accept the treatment, they are acquired to finish the clinical scales (including NIH-CPSI scale, HADS, VAS, SSRS, SES, IPSS and QoL) and then get the fMRI scan. Hwato brand disposable acupuncture needles will be used. Sanyinjiao (SP6), Zhibian (BL54), Shenshu (BL23), and Huiyang (BL35) are selected as acupoints. The course of treatment is 2 times a week in three months (totally 24 times). At the ending of the treatment, all the volunteers will be asked to finish the clinical scales and get the fMRI scan again. As the step of following up, all the patients will be asked to finish the clinical scales and get the fMRI scan again to evaluate the efficacy of avoiding the recurrence of acupuncture.
88829675|NCT05075551|Sham Comparator|Sham Acupuncture|In the sham acupuncture group, these volunteers will receive relatively shallow needling at bilateral sham SP6, BL54, BL23, and BL35. This treatment gets involved in the same duration and frequency of sessions, but the treatment was delivered superficially at non-acupuncture points 10 mm to the lateral of corresponding acupuncture and not above a meridian line (10mm to SP6, BL54, BL23 and BL35). The Hwato brand disposable acupuncture needles will be inserted with a depth of 2-3 mm without any manipulation.The procedure of finishing scales and get fMRI scanning will be the same as the group of acupuncture.
88829676|NCT02988739|Experimental|Laser assisted epidermal application|"Laser pretreatment: 4 adjacent areas of 2 cm² each (14mm x 14 mm) will be pretreated with an Erbium Yttrium Aluminium Garnet laser (22,7 J/cm², 2 pulses, Density: 5%) generating micropores with a depth of approximately 91 µm.~0,1 ml of Intanza (15 µg, seasonal trivalent influenza vaccine) will be topically administered on the laser-treated area."
88829677|NCT02988739|Active Comparator|Intradermal application|0,1 ml of Intanza (15 µg, seasonal trivalent influenza vaccine) will be intradermally injected in the deltoid area.
88829678|NCT05044585|Experimental|Remote Automated Monitoring System|Two MultiSense® patches will be placed on each volunteer. The monitoring will last no more than 3 hours, during an induced and controlled hypoxia.
88829679|NCT01866943|Placebo Comparator|Group 1|Patients undergo primary total hip arthroplasty and have a wash of 100cc of normal saline applied to the tissues under the skin prior to skin closure. The wash sits in the wound for 5 minutes then is suctioned out and the skin is closed.
89000835|NCT04650685|Experimental|The novel Salvadora persica toothbrush|The novel toothbrush is under Al-Abyad Miswak brand that will be supplied by Insight Prestige Sdn Bhd. Participants are expected to use this oral hygiene tool for 3 weeks.
89358349|NCT01334268|Active Comparator|Taxus Liberte Paclitaxel-Eluting Coronary Stent System|Subjects will be randomized to be treated with Taxus Liberte Paclitaxel-Eluting Coronary Stent System by an interactive voice response system (IVRS).
89358350|NCT01334268|Experimental|Medtronic Resolute (Zotarolimus-eluting stent)|Subjects will be randomized to be treated with Medtronic Resolute (Zotarolimus-eluting stent) by an interactive voice response system (IVRS).
89358351|NCT04493398|Active Comparator|Titanium curette and ultrasonic.|Debridement of mandibular furcations with conventional ultrasonic/curette (control).
89358352|NCT04493398|Experimental|Erythritol air-polishing.|Treatment of mandibular furcations with erythritol powder/air-polishing system (test)
89358353|NCT01304381|Experimental|Integrated care|Multidisciplinary approach and collaboration between specialist palliative and heart failure (HF) caregivers in a shared structured person-centred and identity-promoting homecare
89358354|NCT01304381|No Intervention|control|Usual care is performed for the control group
89358355|NCT00908076|Active Comparator|amitiza|Amitiza
89358356|NCT00908076|Placebo Comparator|Placebo|Matching Placebo
89358357|NCT03319264|Experimental|Patients with SpA|"Patients included in this single group study will have 3 interventions to assess the severity of muscle loss :~dynamometry exam~walking test~Dual-energy X-ray Absorptiometry (DXA) measurement Quality of life will be assessed with Sarcopenia & Quality of Life (SARQOL) questionnaire. Patients will also fill a Life habits Questionnaire."
89358358|NCT02664740|Experimental|Phage therapy|"Patients randomized to this arm will have phage therapy.~Intervention: Topical anti-Staphylococcus bacteriophage therapy"
89358359|NCT02664740|Placebo Comparator|Placebo|"Patients randomized to this arm will have placebo therapy anologous to that of the experimental arm.~Intervention: Topical placebo corresponding to anti-Staphylococcus bacteriophage therapy"
88829680|NCT01866943|Experimental|Group 2|Patients undergo primary total hip arthroplasty and have a wash of 100cc of normal saline plus 1.5 g (100 mg/mL)Tranexamic Acid is applied to the tissues under the skin prior to skin closure. The wash sits in the wound for 5 minutes then is suctioned out and the skin is closed.
88829681|NCT04436081|Active Comparator|Hemp-based CBD oil Gelcaps|The intervention consists of 6 weeks oral administration of CBD oil Gelcaps, starting at a dosage of 15 mg twice per day with up titration to 45 mg twice per day. At any given dose, if participants develop side effects, the dosage will be reduced to the previous dose.
88829682|NCT04436081|Placebo Comparator|Oral placebo Gelcaps|Participants in the control group will receive oral placebo Gelcaps that are identical in appearance to the CBD oil Gelcaps. Dosing will be identical to the intervention arm.
88829683|NCT01868425|Experimental|multimodal:acetaminophen, gabapentin, ketamine, bupivacaine|aggressive multimodal plus standard care, which includes ketorolac, bupivacaine, fentanyl, ondansetron, dexamethasone, sevoflurane
88829684|NCT01868425|Placebo Comparator|placebo pills and injectables|standard care which includes ketorolac, bupivacaine, fentanyl, ondansetron, dexamethasone, sevoflurane
88829685|NCT01869439|Experimental|External wounds measured for length by width using a ruler|This is a single arm study of subjects who have an external wound that is currently measured for length and width using a ruler. A study subject may have up to 3 qualifying external wounds.
88829686|NCT00550459|Placebo Comparator|1|Placebo tablet given once a day for 21 days
89358360|NCT03721237|Experimental|EBC-assisted|A nasogastric tube, equipped with esophageal and gastric balloons, will be inserted in each patient enrolled in the study. After definitive catheter positioning has been obtained, Esophageal ballon calibration will be run in volume-controlled ventilation, pressure support ventilation and sigh + pressure support ventilation.
89358361|NCT03797027|Other|No cushion|Patients in no cushion group undergo prone percutaneous nephrolithotomy without an abdominal cushion
89358362|NCT03797027|Other|5 cm cushion|Patients in 5 cm cushion group undergo prone percutaneous nephrolithotomy with an 5 cm abdominal cushion
89358363|NCT03797027|Other|10 cm cushion|Patients in 10 cm cushion group undergo prone percutaneous nephrolithotomy with an 10 cm abdominal cushion
89358364|NCT03319186|Experimental|EDIT Management|
89358365|NCT03319186|Active Comparator|Standard Care|
89358366|NCT01305317|Experimental|lipitor|atorvastatin 20mg daily
88829687|NCT00550459|Active Comparator|2|Tolvaptan 15 mg-60 mg tablet given once a day for 21 days.
88829688|NCT04916587|Active Comparator|Multifaceted Implementation Strategy|The core implementation strategy components are: 1) short video-trainings for clinic personnel (care team staff and providers) on the administration of caregiver-reported screening tools; 2) technical implementation support using an approach comprised of external academic consultants, and internal FQHC personnel to increase inner context capacity, 3) use of a validated clinical screening tool - Pediatric Symptoms Checklist (PSC-17), used in pediatric primary care settings to assess behavioral and social/emotional development. For this study, we will use the PSC tools that are tailored to children ages 0 to 5 years old with the Baby Pediatric Symptomatology Checklist (BPSC) for ages 0 to 18 months, and the Preschool Pediatric Symptom Checklist (PPSC) for ages 18 to 60 months. This screening tools is needed as the PEARLS only assesses ACEs exposure and not mental health symptomatology; and 4) use of a technology based tailored ACEs algorithm that incorporates multiple data sources.
89358367|NCT02613416|Experimental|Denosumab|6 monthly subcutaneous injections of denosumab
89358368|NCT03326050|Placebo Comparator|gemifloxacin and Rifampicin|first group will be given a short course (four weeks) of oral Gemifloxacin 320 mg once dailygroup will be given the usual regimen given for free by the Ministry of Health in Egypt; Rifampicin 300 mg twice daily for three months..
89358369|NCT03326050|Placebo Comparator|gemifloxacin and ciprofloxacin|. group will be given a short course (four weeks) of oral Gemifloxacin 320 mg once daily group will be given a short course (four weeks) of oral Ciprofloxacin 750 mg twice daily
89358370|NCT03326050|Placebo Comparator|gemifloxacin and placipo|.group will be given a short course (four weeks) of oral Gemifloxacin 320 mg once daily
89358371|NCT03614585|Experimental|High-intensity interval training|Intensity will be determined using a combination of heart rate reserve (HRR, calculated as HRR= [max HR - resting HR] x [% training] + [resting HR]) and ratings of perceived exertion (RPE). The protocol will involve 10 60-second intervals of high intensity interspersed with 9 60-second low-intensity intervals. The initial high intensity intervals will start at 80% of the HRR (RPE=14-17) and progress by 10% every 4 weeks. Low intensity intervals will be performed at 30% of HRR (RPE=9-11). Three-minute warm-up and 2-minute cool-down periods will be performed at 30% of HRR. Total HIIT time including warm-up and cool-down is 24 minutes.
89534274|NCT03599648|Experimental|BPT-E|"Behavioral parent training (BPT) plus a psychoeducation program.~Includes a 10-week standard BPT, plus a 6-week psychoeducation program delivered prior to the standard BPT."
89358372|NCT03614585|Experimental|Moderate-intensity continuous training|Intensity will be determined using a combination of heart rate reserve (HRR, calculated as HRR= [max HR - resting HR] x [% training] + [resting HR]) and ratings of perceived exertion (RPE). The MICT protocol will be increased using a progression schedule previously used (initial intensity at 40% HRR (RPE=9-11), and progressed by 10% HRR every 4 weeks up to 60% HRR (RPE=13-14) will be maintained until the end of the intervention). A 3-minute warm-up and 2-minute cool-down will be performed at 30% HRR (RPE=9-11). The total duration of MICT, including warm-up and cool-down, will be 35 minutes.
89358373|NCT01334346|Active Comparator|Neutral Shoe|Conventional, non-minimalist, footwear.
89358374|NCT01334346|Experimental|Partial minimalist shoe|
89358375|NCT01334346|Experimental|Full minimalist|
89358376|NCT03467425|Experimental|TRELEGY ELLIPTA (FF/UMEC/VI: 100 mcg/62.5 mcg/25 mcg)|Eligible subjects will receive a blended combination of FF in the first strip (100 mcg per blister) and UMEC/VI in second strip (62.5 mcg UMEC per blister and 25 mcg VI per blister), a single inhalation once daily in the morning in the same TRELEGY ELLIPTA Dry Powder Inhaler (DPI) via inhalation route for a period of 24 weeks. Study treatment may be augmented with other prescribed COPD medications such as including rescue medications, which will be prescribed and obtained according to usual practice.
89358377|NCT03467425|Active Comparator|Non-ELLIPTA MITT|Eligible subjects will receive the ICS/LAMA/LABA products twice daily and dosing regimens as prescribed by their physician for a period of 24 weeks. Study treatment may be augmented with other prescribed COPD medications such as including rescue medications, which will be prescribed and obtained according to usual practice.
89358378|NCT04490850|Experimental|Participants|Blood sample
89358379|NCT03606941|Experimental|electroacupuncture treatment|"Participants in the treatment group received acupuncture (0.30mm×70mm) at bilaterally Shenmen (HT7) acupoints (0.3-0.5 inch), Neiguan (PC6) acupoints (0.5-1 inch), Baihui (DU20) acupoint (0.5-0.8 inch) and Yintang (EX-HN3) acupoint (0.3-0.5 inch) 30 minutes before anesthesia induction. After Deqi, electroacupuncture stimulation apparatus (HANS G6805-2, Huayi Co, Shanghai, China) is connected and maintained the end of operation."
89358380|NCT03606941|Sham Comparator|sham electroacupuncture treatment|"Participants in the control group received shallow needling (0.30mm×25mm) at bilateral sham HT7, PC6, DU20 and EX-HN3 (nonacupoints located 1 inch beside acupoints, about 20mm). Specifically, the depth of needle insertion into nonacupoints is 3-5mm and avoided manual stimulation and no Deqi without actual current output."
89358381|NCT05464108||Gastric intestinal metaplasia observed by IEE|Get pictures from gastric antrum body and angle by image-enhanced endoscopy in order to calculate the EGGIM score.
89358382|NCT01560611||High-risk cardiac surgery patient|
89358383|NCT01334424|Placebo Comparator|no propofol|induction anesthesia with midazolam 0.2 - 0.3 mg/kg
89358384|NCT01334424|Experimental|propofol induction|induction anesthesia with propofol 2 - 2.5 mg/kg
89358385|NCT01334424|Experimental|propofol maintenance|induction anesthesia with midazolam 0.2 - 0.3 mg/kg and maintain anesthesia with propofol 2 mg/kg.h (maintenance dose)
89358386|NCT01334424|Experimental|propofol induction and maintenance|induction anesthesia with propofol 2 - 2.5 mg/ kg and maintain anesthesia with propofol 2 mg/kg.h (maintenance dose)
89358387|NCT04493008|Other|MIU students and patents|Educational session
89358388|NCT03789227|Placebo Comparator|Group C|ganglion impar block :patients will receive a premixed solution of 3 ml lidocaine 2%, 5 ml absolute alcohol 95% and 4 ml saline in a total volume 12 ml.
89358389|NCT03789227|Active Comparator|Group D|ganglion impar block :patients will receive a premixed solution of 3 ml lidocaine 2%, 5 ml absolute alcohol 95% and 8 mg dexamethasone with 4 ml saline in a total volume 12 ml.
89358390|NCT03789227|Active Comparator|Group K|ganglion impar block :patients will receive a premixed solution of 3 ml lidocaine 2%, 5 ml absolute alcohol 95% and 15 mg ketorolac with 4 ml saline in total volume 12 ml.
89358391|NCT04492696|Active Comparator|Crashcourse|"CC uses an approach to providing concussion education informed by user-centered formative design research studies. The program features an interactive choose your own adventure approach to navigate the learner through the content, and is guided by near-peer Division I collegiate football athletes"
89358392|NCT04492696|Active Comparator|CDC Video|CDC-Vi is an online learning module developed by the CDC and the National Federation of State High School Associations Learning Center. Learners progress through the curriculum sequentially completing each unit before proceeding to the next. The primary narrator of CDC-Vi is Dr. Mick Koester, Chair of the NFHS Sports Medicine Advisory Committee
88829689|NCT04916587|Other|ACEs Screening|"Adverse Childhood Experiences (ACEs) are potentially traumatic events occurring before age 18, such as maltreatment, harsh migration experiences or exposure to violence. ACEs screening are increasingly recommended to prevent and address physical and mental health conditions associated with ACEs. To promote ACEs screening uptake, the state of California issued the ACEs Aware 2020 policy; a fee-for-service health policy that provides a financial incentive to Medicaid-serving clinics to promote yearly ACEs pediatric screenings in primary care settings. This study will focus on screening children ages 0-5, in line with the partnering FQHC's ACEs screening priorities."
89358393|NCT04492696|Active Comparator|CDC Written|"CDC-Wr consists of educational PDFs available for download from the CDC website, as part of the CDC's Heads Up brain injury awareness initiative. The PDFs used for the CDC-Wr condition were specific to high school athlete concussion education"
89358394|NCT02178072|Other|HPV positive|HPV positive patients
89358395|NCT02178072|Other|HPV negative|HPV negative patients
89358396|NCT03722251|Experimental|Glucose Beverage|50 g of glucose in solution
89358397|NCT03722251|Experimental|Control Beverage|Sucralose in solution
89358398|NCT03722251|Experimental|Glucose beverage and active video game playing|50 g of glucose in solution and 30 min of active video game playing
89358399|NCT03722251|Experimental|Control Beverage and active video game playing|Sucralose in solution and 30 min of active video game playing
89358400|NCT03319108|Other|Low Comorbidity Index Score|CCI; 1-3 as Group 1
89358401|NCT03319108|Other|High Comorbidity Index Score|CCI; 4 and above as Group 2
89358402|NCT01804998|Experimental|Laparoscopic Sentinel Node Biopsy|Laparoscopic Sentinel Node Biopsy or Stomach Preserving Surgery could be performed in this arm
89358403|NCT01804998|Active Comparator|Laparoscopy Assisted Gastrectomy|Conventional procedure is laparoscopy assisted gastrectomy in early gastric cancer patient.
89358404|NCT05664685|Experimental|Intervention|The intervention group will be treated with Esomeprazole 40 mg every 8 hours, Amoxicillin 1 gr every 8 hours, Metronidazole 500 mg every 8 hours, Bismuth subsalicylate 369 mg every 8 hours.
89358405|NCT05664685|Active Comparator|Control|The control group will be treated with Omeprazole 20mg every 12 hours, Amoxicillin 1 gr every 12 hours, Clarithromycin 500 mg every 12 hours, Placebo identical to Bismuth Subsalicylate, 3 times daily.
89358406|NCT03321838|Experimental|Accommodative/vergence therapy|Accommodative/vergence therapy (60 minutes per visit, one time per week, 12-14 weeks) and home reinforcement (15 minutes each time, five times per week, 12-14 weeks) will be provided to patients of treatment group. These therapy includes accommodative, vergence and anti-suppression technique. No drug is used during the whole therapy process.
89358407|NCT03793517|Experimental|Decitabine plus mBU/CY for HLA-mismatched HSCT|"Decitabine plus mBU/CY as precondition regimen for High Risk Acute Leukemia With MRD at the time of HLA-mismatched HSCT.~Details:~The conditioning therapy for human eukocyte antigen (HLA)-mismatched HSCT patients was decitabine plus modified BU/CY and ATG,consisting of decitabine 100mg·m-2·d-1 q12h on days-12 and -11,cytarabine (Ara-C 4 g·m-2·d-1) intravenously on days -10 to -9, busulfan (BU 3.2 mg·kg-1·d-1) intravenously on days -8 to -6, cyclophosphamide (CY 1.8 g·m-2·d-1), intravenously on days -5 to -4, simustine (Me-CCNU, 250 mg/m2), orally once on day -3, and ATG (2.5 mg·kg-1·d-1) intravenously on days -5 to -2."
89358408|NCT03793517|Experimental|Decitabine plus mBU/CY for matched sibling transplant|"Decitabine plus mBU/CY as precondition regimen for High Risk Acute Leukemia With MRD at the time of matched sibling transplant.~Details:~In matched sibling transplantations, patients received decitabine 100mg·m-2·d-1 q12h on days-12 and -11,hydroxycarbamide (80 mg/kg) orally on day -10 and a lower dose of Ara-C (2 g·m-2·d-1) on day -9, busulfan (BU 3.2 mg·kg-1·d-1) intravenously on days -8 to -6, cyclophosphamide (CY 1.8 g·m-2·d-1), intravenously on days -5 to -4, simustine (Me-CCNU, 250 mg/m2), orally once on day -3."
89358409|NCT03319030||Duchenne Muscular Dystrophy (DMD)|Enrolls boys with a genetically confirmed diagnosis of DMD.
89358410|NCT04493944|Experimental|Intervention group (with culinary workshop)|This group will be composed of participants that will answer online questionnaires before and after the study, and will participate in a culinary workshop with a chef (3 hours).
89358411|NCT04493944|No Intervention|Control group (without culinary workshop)|This group will be composed of participants that will answer online questionnaires before and after the study.
89358412|NCT03789071||Patient scheduled for general anesthesia with intubation|Patients in this group (only group) will have clinical airway assessment and external ultrasound assessment of the airway
89358413|NCT02490748|No Intervention|RFA alone|Patients undergo radiofrequency ablation alone.
89358414|NCT02490748|Experimental|RFA+CIK|Autologous cytokine-induced killer cells were transfer via venous one week after RFA Interventions
89358415|NCT02886702|Experimental|Test|Tazarotene Cream 0.05% (Fougera Pharmaceuticals Inc.)
89358416|NCT02886702|Active Comparator|Reference|TAZORAC® (tazarotene) Cream 0.05% (Allergan, Inc.)
89358417|NCT02886702|Placebo Comparator|Placebo|Placebo (Vehicle of test product) (Fougera Pharmaceuticals Inc.)
89358418|NCT03498313|Experimental|Transdermal Estradiol + Placebo|.1mg per 24 hours transdermal estradiol applied to the skin weekly, and sugar pill manufactured to mimic the progesterone pills taken twice daily by mouth, for 14 days.
89358419|NCT03498313|Experimental|Oral Micronized Progesterone + Placebo|100 mg oral micronized progesterone pill taken twice daily by mouth, and clear patch manufactured to mimic the E2 patch applied to the skin weekly, for 14 days.
89358420|NCT03498313|Placebo Comparator|Placebos|Sugar pill designed to mimic the P4 pills taken twice daily by mouth, and clear patch manufactured to mimic the E2 patch applied to the skin weekly, for 14 days.
89358421|NCT02569229||Patients with Cystic Fibrosis|Patients between 10-20 years of age with genetically determined cystic fibrosis followed at the university children's hospital Basel and university children's hospital Kinderklinik Bern, Switzerland. All patients will get the diagnostics for glucose tolerance with 3 different methods (CGMS, OGTT and optionally IVGTT).
89358422|NCT04494022|No Intervention|Cross-sectional image only|Image set which consists of a Cross-sectional image only.
89358423|NCT04494022|Active Comparator|Cross-sectional image with CEUS|The same participants with Arm1. But image set will consist of a Cross-sectional image and CEUS.
89358424|NCT03721081|Placebo Comparator|Na Cl 0.9%/Epi 1:200000|Subcutaneous infiltration of Na Cl 0.9%/Epi 1:200000
89534275|NCT03599648|Experimental|BPT-M|"Behavioral parent training (BPT) plus mindfulness-based stress reduction (MBSR).~Includes a 10-week standard BPT, plus a 6-week MBSR delivered prior to the standard BPT."
89534276|NCT03590613|Experimental|Sequence 1: Placebo TID then 60 TID then 120 TID then 240 TID|The eligible subjects in this arm will receive placebo TID in TP1, GSK2982772 60 mg TID in TP2, GSK2982772 120mg TID in TP3 and GSK2982772 240 mg TID in TP4. GSK2982772 or placebo will be administered at 0 hour (the first dosing), 7 hours (the second dosing) and 14 hours (the third dosing) on Day 1 in each TP. Subjects will fast overnight for 8 hours before first dose. Each TP will be followed by a washout period of at least 7 days, for each subject.
88829690|NCT04901611|Experimental|Parental touch (pre-procedural)|Parents will stroke their baby on the posterior lower limb of the leg where the heel lance will be administered, at a speed of 3cm/s for 10 seconds using the whole hand and in one direction down the limb towards the foot. This will happen just before the control procedure and clinical heel lance.
88829691|NCT04901611|Placebo Comparator|Parental touch (post-procedural)|Parents will stroke their baby on the posterior lower limb of the leg where the heel lance was administered, at a speed of 3cm/s for 10 seconds using the whole hand and in one direction down the limb towards the foot. This will happen just after the control procedure and clinical heel lance.
88829692|NCT03545971|Experimental|Ia Cohort A|Low-dose group:Participants will receive IBI310 0.3mg/kg intravenous every 3 weeks,after 4 cycle, if the patient benefits it will be continued until disease progression or unacceptable toxicity.
89358425|NCT03721081|Active Comparator|Lidocaine 1%/Epi 1:200000|Subcutaneous infiltration of Lidocaine 1%/Epi 1:200000
89358426|NCT04493554|Experimental|Vasopressin|Vasopressin (20 IU) intranasally
89358427|NCT04493554|Placebo Comparator|Placebo|Placebo intranasally
89358428|NCT02601014|Experimental|Nivolumab and ipilimumab|Patients receive nivolumab IV over 60 minutes and ipilimumab IV over 90 minutes every 3 weeks for 12 weeks. Patients then receive nivolumab IV over 60 minutes every 2 weeks for 36 weeks in the absence of disease progression or unacceptable toxicity.
89358429|NCT02601014|Experimental|Enzalutamide plus Nivolumab and Ipilimumab|Patients will continue on standard of care enzalutamide, with the addition of nivolumab IV over 60 minutes and ipilimumab IV over 90 minutes every 3 weeks for 12 weeks. Patients then receive nivolumab IV over 60 minutes every 2 weeks for 36 weeks in the absence of disease progression or unacceptable toxicity.
89358430|NCT01307046|Experimental|MK-0954A|Participants administered MK-0954A, Placebo for Losartan 50 mg , and Placebo for Losartan 100 mg orally, once daily for 8 weeks.
89534277|NCT03590613|Experimental|Sequence 2: 60 TID then Placebo TID then 120 TID then 240 TID|The eligible subjects in this arm will receive GSK2982772 60 mg TID in TP1, placebo TID in TP2, GSK2982772 120mg TID in TP3 and GSK2982772 240 mg TID in TP4. GSK2982772 or placebo will be administered at 0 hour (the first dosing), 7 hours (the second dosing) and 14 hours (the third dosing) on Day 1 in each TP. Subjects will fast overnight for 8 hours before first dose. Each TP will be followed by a washout period of at least 7 days, for each subject.
88829693|NCT03545971|Experimental|Ia Cohort B|Middle-dose group:Participants will receive IBI310 1.0mg/kg intravenous every 3 weeks,after 4 cycle, if the patient benefits it will be continued until disease progression or unacceptable toxicity
88829694|NCT03545971|Experimental|Ia Cohort C|Middle-dose group:Participants will receive IBI310 2.0mg/kg intravenous every 3 weeks,after 4 cycle, if the patient benefits it will be continued until disease progression or unacceptable toxicity
88829695|NCT03545971|Experimental|Ia Cohort D|High-dose group:Participants will receive IBI310 3.0mg/kg intravenous every 3 weeks,after 4 cycle, if the patient benefits it will be continued until disease progression or unacceptable toxicity
88829696|NCT03545971|Experimental|Ib Cohort A|3 subjects, low-dose group:Participants will receive IBI310 1.0mg/kg in Combination with Sintilimab 200mg intravenous every 3 weeks. After 4 cycles, Sintilimab alone 200mg intravenous every 3 weeks, until disease progression, lost follow-up visit, death , unacceptable toxicity, withdrawn of ICF, another other reason for end of treatment. Maximum treatment duration is 2 years.
88829697|NCT03545971|Experimental|Ib Cohort A2|low-dose group:Participants will receive IBI310 1.0mg/kg in Combination with Sintilimab 200mg intravenous every 3 weeks. After 4 cycles, Sintilimab alone 200mg intravenous every 3 weeks, until disease progression, lost follow-up visit, death , unacceptable toxicity, withdrawn of ICF, another other reason for end of treatment. Maximum treatment duration is 2 years.
88829698|NCT03545971|Experimental|Ib Cohort B|3 subjects, low-dose group:Participants will receive IBI310 2.0mg/kg in Combination with Sintilimab 200mg intravenous every 3 weeks. After 4 cycles, Sintilimab alone 200mg intravenous every 3 weeks, until disease progression, lost follow-up visit, death , unacceptable toxicity, withdrawn of ICF, another other reason for end of treatment. Maximum treatment duration is 2 years.
88829699|NCT03545971|Experimental|Ib Cohort B2|low-dose group:Participants will receive IBI310 2.0mg/kg in Combination with Sintilimab 200mg intravenous every 3 weeks. After 4 cycles, Sintilimab alone 200mg intravenous every 3 weeks, until disease progression, lost follow-up visit, death , unacceptable toxicity, withdrawn of ICF, another other reason for end of treatment. Maximum treatment duration is 2 years.
88829700|NCT01871077|Experimental|PRO-156|Drug: PRO-156 ophthalmic solution One drop of PRO-156 ophthalmic solution administered to each eye, four times a day for 10 days.
88829701|NCT03426709|Experimental|Low intensity Internet-delivered psychotherapy|improved Treatment-as-usual (TAU) + face to face (2 sessions of 90 minutes/session) + low intensity psychological intervention (6 sessions of 60 minutes/session) applied by ICTs (Information and communication technologies).
88829702|NCT03426709|No Intervention|Improved Treatment-as-usual (TAU)|In this group, the general practitioner (GP) will apply the usual but improved treatment. The GP will have a training meeting and will be provided with the recommendations of one of the Guidelines for the Treatment of Adult Depression in AP most used in our country.
88829703|NCT02988583|Experimental|low viscosity silicone oil|Retinal detachment surgery using low viscosity silicone oil
88829704|NCT02988583|Active Comparator|high viscosity silicone oil|Retinal detachment surgery using high viscosity silicone oil
88829705|NCT04894045|Other|Personalized management group|Intraoperative MAP will be maintained at least at the mean nighttime MAP (assessed using preoperative automated blood pressure monitoring). If the mean nighttime MAP is below 65 mmHg, intraoperative MAP will be maintained at least at 65 mmHg.
88829706|NCT04894045|No Intervention|Control group|Routine intraoperative blood pressure management with a lower intervention threshold of 65 mmHg. In contrast to the patients in the personalized management group, the individual mean nighttime MAP assessed using preoperative automated blood pressure monitoring is not taken into account and the treating anesthesiologists are blinded to the data of preoperative automated blood pressure monitoring.
88829707|NCT01872325||Training site|All emergency medical dispatchers at a central ambulance communication centre in Ontario will participate in an educational program designed to improve cardiac arrest diagnostic accuracy.
88829708|NCT01872325||Control site|All emergency medical dispatchers at a central ambulance communications centre geographically remote from the Training Site and has a similar rate to the Training Site for cardiac arrests, bystander CPR rate, and survival
88829709|NCT01874119|Experimental|Fosaprepitant|During treatment admission, intravenous fosaprepitant 150 mg every 48 hours during 6-day hospital admission
88829710|NCT01874119|Placebo Comparator|Placebo|During placebo admission, intravenous 0.9% saline every 48 hours during 6-day hospital admission
88829711|NCT02280655|Active Comparator|Storage-aged red blood cells (saRBCs)|Subjects with cardiovascular disease (CVD) received a transfusion with older stored red blood cells (RBCs) units. The units had been stored for greater than 21 days.
89358431|NCT01307046|Active Comparator|Losartan|Participants administered Losartan 100 mg, Placebo for MK-0954A, and Placebo for Losartan 50 mg orally, once daily for 8 weeks.
89358432|NCT03719209|Placebo Comparator|Standard Practice|Patients and families will be shown images of their endoscopic procedure per standard practice.
89358433|NCT03719209|Experimental|Virtual Reality|Patients and families will be showed the results of their endoscopic procedure via a virtual reality application called HealthVoyager, in addition to standard practice images.
89358434|NCT03318796|Other|Interventional|Coronary artery stenting of De novo bifurcation lesions MB & SB
89358435|NCT05419115|No Intervention|Usual Care|"Open label, 1:1 randomisation to usual care in hospital vs early supported discharge with SQIN-Furosemide administered via SQIN-Infusor.~Usual care: Usual care as per institutional practice (including IV diuretics)"
88829712|NCT02280655|Active Comparator|Fresh red blood cells (RBCs)|Subjects with cardiovascular disease (CVD) received a transfusion with fresh red blood cells (RBCs) units. The units had been stored for less than 14 days.
88829713|NCT02987881|Experimental|Adult women with early stage localized endometrial cancer|Adult women with early stage localized endometrial cancer at least 2 months following hysterectomy
89358436|NCT05419115|Experimental|Early supported discharge|"Open label, 1:1 randomisation to usual care in hospital vs early supported discharge with SQIN-Furosemide administered via SQIN-Infusor.~Early supported discharge: with SQIN-Furosemide and SQIN-Infusor. SQIN-Furosemide: 80mg of SQIN-Furosemide in each cartridge; 5 hours running time; up to 2 applications in 24h (maximum dose of 160mg of SQIN-Furosemide in 24h). SQIN-Infusor: patient/carer administered."
89358437|NCT05664607|No Intervention|control group|no multimodal rehabilitation
89358438|NCT05664607|Experimental|multimodal rehabilitation group|include excise, nutrition consultant, nutrition supplement and psychologic intervention.
89358439|NCT02490592|Experimental|G1|Thirty children aged seven to twelve years who had seventy one active white spots lesions in permanent anterior teeth randomly assigned to four or eight weekly intervals applications of fluoride foam, Flúor Care (NaF 1.23%), to verified the activity (visual scores) and the dimensional changes of whit spot lesions (with WHO probe and millimeter ruler), caries Management by Risk Assessment (CAMBRA) and OHI-S (Simplified Oral Hygiene Index) of children.
89358440|NCT02490592|Experimental|G2|Twenty-eight children aged seven to twelve years who had seventy five active white spots lesions in permanent anterior teeth randomly assigned to four or eight weekly intervals applications of fluoride gel, Flugel FFA (NaF 1.23%), to verified the activity (visual scores) and the dimensional changes of whit spot lesions (with WHO probe and millimeter ruler), caries Management by Risk Assessment (CAMBRA) and OHI-S (Simplified Oral Hygiene Index) of children.
89358441|NCT03790475|No Intervention|Current screening practice.|Subjects randomized into this group will receive named invitations for colonoscopy with pre-specified date, contact details of dedicated screening center. Invitations will be sent 6 weeks prior to suggested date of screening test. All subjects not responding to the invitation will receive a reminder letter 3 weeks prior to proposed appointment date. Additionally, a re-invitation for colonoscopy (screening test in 6 weeks) will be sent to participants not responding to the first invitation and the reminding letter.
89358442|NCT03790475|Experimental|Sequential screening strategy.|"Subjects randomized into this group will be initially invited to participate in a screening colonoscopy as per group 1. All subjects who will refuse colonoscopy or do not respond to invitation within 6 weeks since the first letter, will receive another invitation letter with FIT test enclosed.~The screening office will contact persons with a positive test result in order to determine the date of the colonoscopy appointment.~A negative test result will be sent together with a recommendation to have another screening test performed 2 years later and information about the possible delivery of the test in two years."
88829714|NCT02823145|Experimental|ZX008|ZX008 is supplied as an oral solution in a concentration of 2.5 mg/mL. Subjects will be titrated to an effective dose beginning with 0.2 mg/kg/day (maximum: 30 mg/day).
88829715|NCT02721589|Experimental|Injection SHR-1210 1mg/kg Cohort|
88829716|NCT02721589|Experimental|Injection SHR-1210 3mg/kg Cohort|
88829717|NCT02721589|Experimental|Injection SHR-1210 200mg Cohort|
88829718|NCT02721589|Experimental|Injection SHR-1210 10mg/kg Cohort|
88829719|NCT00366821||1|Examine the outcomes following cardiac surgery in those newborns with genetic abnormalities.
88829720|NCT00366821||2|Examine the outcomes following cardiac surgery in newborns without genetic abnormalities.
88829721|NCT02657707|Experimental|Single-arm, open label|To evaluate the safety and effectiveness of MicroVention, Inc. Roadsaver™ Carotid Stent System used in conjunction with the Nanoparasol® embolic protection system for the treatment of carotid artery stenosis in patients with elevated risk for adverse events following carotid endarterectomy.
88829722|NCT02280811|Experimental|T Cell Receptor Immunotherapy|patients will receive cyclophosphamide and fludarabine followed by infusion of the human papilloma virus (HPV) E6 T cell receptor (TCR), followed by high dose aldesleukin
88829723|NCT02263963|Experimental|TAP Block Experal|Patient who randomized to this arm, will be blinded, TAP block will be performed under ultrasound guidance, where 20-30 ml of Exparel will be injected in transversus abdominis plane, bilaterally.
88829724|NCT02263963|No Intervention|No TAP Block|
88829725|NCT03029923|Experimental|Smoking Cessation and Mood Management|Participants will receive standard smoking cessation plus Behavioral Activation based mood management. Will be offered the nicotine patch if medically cleared.
88829726|NCT03029923|Active Comparator|Smoking cessation and Health and Wellness|Participants will receive standard smoking cessation plus health and wellness education. Will be offered the nicotine patch if medically cleared.
88829727|NCT01930435|Experimental|Sterile Humidification Device, MyPurMist|Sterile Humidification Device Twice a day, 15 minutes each 12 weeks
88829728|NCT01930747|Experimental|deep neuromuscular block|deep neuromuscular block is given after first measurement of lap workspace one bolus dose of 1 mg/kg rocuronium is given
88829729|NCT01930747|Experimental|inhalation with 1 MAC Sevoflurane|1 MAC Sevoflurane inhalation is given after first measurement of lap workspace
88829730|NCT01930747|Experimental|remifentanyl|remifentanyl infusion is given after first measurement of lap workspace
89358443|NCT03790475|Experimental|Multiple options screening strategy.|"Subjects in this group will receive a letter with an offer to choose between colonoscopy or FIT screening.~The first letter will include an invitation with a scheduled date of colonoscopy (in 6 weeks) and a FIT kit.~Three weeks before a scheduled date of colonoscopy subjects randomized into this group will receive a reminder letter with an information about proposed screening methods. After the scheduled date of the colonoscopy examination, subjects who will not respond to the invitation for colonoscopy and will not send the FIT test back to the laboratory will receive another invitation for colonoscopy (in 6 weeks) and a FIT kit."
89358444|NCT04492930|Active Comparator|Comparator|Time restricted eating
89358445|NCT04492930|Experimental|Intervention|Time restricted eating
89358446|NCT03075462|Experimental|Fluzoparib + Apatinib|Fluzoparib and apatinib will be separately administered to patients on the 1st and 4th day, respectively. Then from the 7th day they are administered continuously and orally in combination, 28 days per cycle, until disease progression or unacceptable toxicity.
89358447|NCT03788915|Active Comparator|Online dietician lifestyle counseling|Online dietetic lifestyle counseling
89358448|NCT03788915|Placebo Comparator|Usual care|Usual care
89358449|NCT03325660|Active Comparator|study group|whole body vibration
89358450|NCT03325660|No Intervention|control group|No intervention
89358451|NCT01305395|Experimental|Early Intervention Arm|Initiate sirolimus within 6 months of heart transplant
89358452|NCT01305395|Experimental|Late Intervention Arm: Group 2A|Initiate sirolimus after CAV is diagnosed by angiogram
89358453|NCT01305395|Experimental|Retrospective Arm: Angiogram group|Start sirolimus after CAV diagnosed is by angiogram
89358454|NCT01305395|Experimental|Late Intervention Arm: Group 2B|Start sirolimus after CAV is diagnosed by IVUS
89358455|NCT01305395|Experimental|Retrospective Arm: Intravascular Ultrasound|Sirolimus after CAV is diagnosed by IVUS
89358456|NCT03495817|Experimental|ATI-50002 Topical Solution|"This is an open-label phase 2 study designed to evaluate the safety and efficacy of ATI- 50002 Topical Solution, 0.46% in male and female subjects with androgenetic alopecia.~Subjects will be required to apply ATI-50002 study medication to their scalp twice a day for a total of 26 weeks."
89358457|NCT02490514||Mircera|Patients with stage III-IV CKD received open-label Mircera for 12 months at a dose to be determined by the investigator.
89358458|NCT02886624|Experimental|Grazoprevir/Elbasvir|Once-daily, oral grazoprevir/elbasvir combination therapy at fixed-dose (100mg/50mg) for 8 weeks
89358459|NCT03790241|Experimental|Young males of normal corpulence|Insertion of a catheter to people ageg between 18 and 25; IBM between 18,5 and 25
89358460|NCT03790241|Experimental|Young females of normal corpulence|Insertion of a catheter to people ageg between 18 and 25; IBM between 18,5 and 25
89358461|NCT03790241|Experimental|Aged males of normal corpulence|Insertion of a catheter to people ageg between 60 and 75; IBM between 18,5 and 25
89358462|NCT03790241|Experimental|Aged females of normal corpulence|Insertion of a catheter to people ageg between 60 and 75; IBM between 18,5 and 25
89358463|NCT03790241|Experimental|Obese young males|Insertion of a catheter to people ageg between 18 and 25; superior or equal to 30
88829731|NCT01931527|No Intervention|Obese subjects with normal uric acid|Subjects with a body mass index = or > 30 kg/m² with normal uric acid (= or < 5 mg/dL)
88829732|NCT01931527|Experimental|Obese subjects with high uric acid|"Subjects with a body mass index = or > 30 kg/m² with high uric acid (>6 mg/dL)~Intervention: one single infusion of rasburicase (0.19 mg/kg FFM) infused over 30 min"
89358464|NCT03790241|Experimental|Obese young females|Insertion of a catheter to people ageg between 18 and 25; superior or equal to 30
89358465|NCT03790241|Experimental|Obese aged males|Insertion of a catheter to people ageg between 60 and 75; IBM superior or equal to 30
89358466|NCT03790241|Experimental|Obese aged females|Insertion of a catheter to people ageg between 60 and 75; IBM superior or equal to 30
89358467|NCT03717025|Active Comparator|Mini Punch Grafting|
89358468|NCT03717025|Active Comparator|Suction Blister Epidermal Grafting|
89358469|NCT03717025|Active Comparator|Non Cultured Epidermal Cell Suspension|
88829733|NCT01933243|Experimental|Fish oil|Fish oil for 12 weeks
88829734|NCT01933243|Placebo Comparator|Placebo pill|Placebo pills for 12 weeks
88829735|NCT01933399|Other|Standard of Care|Medication based on physician prescriptions or overcounter use not germane to the study. Subjects also receive physical therapy for 2 weeks.
88829736|NCT01933399|Experimental|Extensible lumbosacral orthoses plus standard of care|This group receives a flexible/extensible lumbosacral orthosis, one that is commonly available over the counter
89358470|NCT02487238|Experimental|Fecal Microbiota Enema|Live, healthy, human donor stool prepared as fecal enemas. Fecal enemas are prepared and collected by Rebiotix(®) (RBX2660), using extensively screened donor stool. Enemas will be administered on site at one of the participating trial sites by trained study investigators. Enemas are given: 2x per week for 6 weeks (total = 12 enemas over 6 weeks). Patients will be masked to enema contents.
89358471|NCT02487238|Placebo Comparator|Normal Saline Enema|Normal saline enemas will be administered on site at one of the participating trial sites by trained study investigators. Enemas are given: 2x per week for 6 weeks (total = 12 enemas over 6 weeks). Patients will be masked to enema contents.
89358472|NCT01305863|Active Comparator|Propaten graft|Untreated Propaten vascular graft
89358473|NCT01305863|Experimental|ASC-Coated ePTFE graft|ASC Coated BARD IMPRA® ePTFE Vascular Graft
89358474|NCT02280902||Patient with immunologic and inflammatory diseases|Patient treated with corticosteroids, immunosuppressive drugs or biotherapy for immunologic and inflammatory diseases
89358475|NCT02487316|Experimental|crizotinib combined with chemotherapy|crizotinib 250mg, bid from day 1 to 18 weeks. cyclophosphamide, 750mg/m2,d1, vincristine, 1.4mg/m2, maximal dose is 2mg d1, doxorubicin, 50mg/m2d1, prednison, 100 mg d1-5) every 3 weeks for up to six cycles.
89358476|NCT02490436|Experimental|A: active drug first|Cetuximab in treatment period 1, placebo in treatment period 2, and open-label cetuximab in treatment period 3.
89358477|NCT02490436|Experimental|B: placebo first|Placebo in treatment period 1, cetuximab in treatment period 2, and open-label cetuximab in treatment period 3.
89358478|NCT03793595|Experimental|Seated Battle Ropes Protocol|
89358479|NCT03793595|Active Comparator|Seated Upper Extremity Arm Bike|
89358480|NCT03318718|Experimental|TOF measurement|TOF and MEP measurement after Anesthesia with non-depolarizing NMBA Rocuronium
89358481|NCT03790319||Single Workshop 'The Emotional Backpack'|Subjects of this group are participating in one single workshop over three days.
88829737|NCT01933399|Experimental|Inextensible lumbosacral orthoses and standard of care|This group receives an inextensible lumbosacral orthoses which leads to 14% increase in trunk stiffness compared to the other conditions.
89358482|NCT03790319||Year Program 'The Power of Feelings'|Subjects of this group are participating in three workshops of over 3 days each in a continuing group over nine months. They are animated to deal with the content inbetween the workshops through biweekly e-mails and to exchange in couples.
89358483|NCT03325348|Experimental|Oral Nifedipine|Nifedipine 10mg oral tablet & 1ml 0.9%N/Saline will be given every 15 minutes up till one hour
89358484|NCT03325348|Active Comparator|IV Labetalol|IV labetalol 20 mg and mint tablet will be given every 15 minutes up till one hour
89358485|NCT03790163|Placebo Comparator|levobupivacaine at ( 23˚C)|Levobupivacine hydrochloride at ( 23˚C) will be received 3.5 ml levobupivacaine at the operating room temperature 23˚C will be administered
89358486|NCT03790163|Active Comparator|Warm levobupivacaine at (30˚C)|Drug:Warm levobupivacaine hydrochlorid (3.5 ml) will be warmed at (30˚C) for 24 hours. The empty syringes and needles ,in their packaging, will be held at the same temperature before the spinal anesthesia
89358487|NCT03790163|Active Comparator|Warm levobupivacaine at (37˚C)|Drug:Warm levobupivacaine hydrochlorid (3.5 ml) will be warmed at (37˚C) for 24 hours. The empty syringes and needles ,in their packaging, will be held at the same temperature before the spinal anesthesia
89358488|NCT01775657|Experimental|Air leak present - Analogue|Patients randomized to Pleur Evac (Analogue drainage) monitoring system, air leak present.
89358489|NCT01775657|Active Comparator|Air leak absent - Analogue (Pleur Evac)|Patients randomized to Pleur Evac (Analogue drainage) monitoring system, no air leak present
89358490|NCT01775657|Experimental|Air leak present - Digital (Thopaz)|Patients with an air leak present, randomized to Thopaz (digital drainage) monitoring system.
89358491|NCT01775657|Active Comparator|Air leak absent - Digital (Thopaz)|Patients randomized to digital system, no air leak present.
89358492|NCT03321448|Experimental|TMTP1|The TMTP1-ICG (WuXi AppTec, Shanghai, China) powder was diluted in 20 ml of aqueous sterile water to a concentration of 1.0 mg/mL. 0.4ml of this TMTP1-ICG solution was injected into the cervix, divided into 3 and 9 o'clock position, in the operating room. During the laparoscopy, the PinPoint S1 Novadaq (PinPoint Endoscopic Fluorescence Imaging System, NOVADAQ, Mississauga, ON, Canada), 30° laparoscopes were used for fluorescent detection.
89358493|NCT03321448|Active Comparator|ICG|The ICG powder was diluted in 20 ml of aqueous sterile water to a concentration of 1.0 mg/mL. 0.4ml of ICG solution was injected into the cervix, divided into 3 and 9 o'clock position, in the operating room. During the laparoscopy, the PinPoint S1 Novadaq (PinPoint Endoscopic Fluorescence Imaging System, NOVADAQ, Mississauga, ON, Canada), 30° laparoscopes were used for fluorescent detection.
88829738|NCT02639351|Experimental|LHD153R Formulation 1 Group|Healthy subjects aged 18 to 45 years who received a single dose of investigational MenC-CRM vaccine adjuvanted with 12.5 ug of LHD153R.
88829739|NCT02639351|Experimental|LHD153R Formulation 2 Group|Healthy subjects aged 18 to 45 years who received a single dose of investigational MenC-CRM vaccine adjuvanted with 25 ug of LHD153R.
88829740|NCT02639351|Experimental|LHD153R Formulation 3 Group|Healthy subjects aged 18 to 45 years who received a single dose of investigational MenC-CRM vaccine adjuvanted with 50 ug of LHD153R.
88829741|NCT02639351|Experimental|LHD153R Formulation 4 Group|Healthy subjects aged 18 to 45 years who received a single dose of investigational Meningococcal C-CRM conjugate vaccine (MenC-CRM) adjuvanted with 100 ug of LHD153R.
89358494|NCT03325270|Experimental|ferrous fumarate|labeled iron as Ferrous Fumarate
89358495|NCT03325270|Experimental|ferrous fumarate and GOS|labeled ferrous fumarate + prebiotics
89358496|NCT03325270|Experimental|ferrous sulfate and GOS|labeled ferrous sulfate + prebiotics
89358497|NCT04493788||PCOS group|
89358498|NCT04493788||Control group|
89358499|NCT03318562|Experimental|TNBC Cohort|female subjects who have pathologically documented, radiographically measurable, metastatic or locally advanced and unresectable TNBC and have received >=1 prior cancer therapy regimen for metastatic disease
89358500|NCT03318562|Experimental|HCC Cohort|male and female subjects who have histologically or cytologically confirmed advanced HCC not amenable to surgical resection and have failed >=1 systemic therapy, which must include sorafenib, or are intolerant to multikinase inhibitor therapies
89358501|NCT03318484|Active Comparator|Optimal Medical Care|Optimal medical care (OMC) only is administrated in this arm. OMC is established according to the standards established by the 2016 ACC-AHA Guidelines for the Management of Patients with Peripheral Artery Disease in order to promote best practices for risk factor management.
88829742|NCT02639351|Active Comparator|MenC Group|Healthy subjects aged 18 to 45 years who received a single dose of MenC-CRM vaccine.
88829743|NCT02639429|Experimental|Combined approach: Foley Balloon + Vaginal Misoprostol|These women will receive vaginal misoprostol per standard protocol at 25 micrograms every 4 hours. In addition, a 26 Fr-Foley balloon catheter will be inserted by routine clinical standards. The Foley will be inserted through the internal cervical os, filled with 60 mL of normal saline, and then pulled snugly against the internal os. The catheter of the Foley will be taped to the patient's inner thigh under gentle traction. If the Foley is unable to be placed, the patient will be reexamined in 1 hour and placement will be reattempted if Bishop's score is still 6 or less by the healthcare provider. When the Foley balloon had fallen out or had to be removed because 12 hours have passed since insertion as per protocol, further management of labor will be left at the discretion of the labor team.
89358502|NCT03318484|Experimental|Optimal Medical Care and SDT|OMC and sonodynamic therapy (SDT) are administrated in this arm.
89358503|NCT02963766|Experimental|Placebo/0.75 milligram (mg) Dulaglutide|Participants received placebo administered subcutaneously (SC) for 26 weeks during the double-blind period and open-label 0.75 mg/week dulaglutide for 26 weeks during the Open Label Extension (OLE).
89358504|NCT02963766|Experimental|0.75 mg Dulaglutide|Participants received 0.75 mg/week dulaglutide administered SC for 26 weeks during the double-blind period and open-label 0.75 mg/week for 26 weeks during the OLE.
88829744|NCT02639429|Active Comparator|Single approach: Vaginal Misoprostol only|These women will receive 25 micrograms of misoprostol per vagina every 4 hours. Once the cervix becomes favorable (Bishop score > 6), misoprostol administration will be discontinued. Further management will be left at the discretion of the labor team.
89358505|NCT02963766|Experimental|1.5 mg Dulaglutide|Participants received 1.5 mg/week dulaglutide administered SC for 26 weeks during the double-blind period and open-label 1.5 mg/week for 26 weeks during the OLE.
89358506|NCT02490280|Experimental|Trier Social Stress Test|Participants will be administered the Trier Social Stress Test (TSST). The TSST is the gold standard social stress test and involves speaking in front of confederate judges and completing arithmetic tasks. The task takes 10-15 minutes.
89358507|NCT02487004||chronic hemodialysis patients|
89358508|NCT04493476|Active Comparator|Chineese Herbal formula|The study group will be given capsules containing Chinese herbal formula extract - Traditional Chinese MedicinalSubstances
89358509|NCT04493476|Placebo Comparator|placebo|The control group tested will receive placebo capsules. Containing starch.
89358510|NCT03325192|Placebo Comparator|Standard of care|Subjects in this arm will receive placebo only (100mL of normal saline) into the pleural space delivered via the newly placed tunneled intrapleural catheter
89358511|NCT03325192|Experimental|Rapid pleurodesis protocol|Subjects in this arm will receive the chemical pleurodesing agent of 10% iodopovidone solution delivered to the pleural space via the newly placed tunneled intrapleural catheter
89358512|NCT01334502|Experimental|everolimus and RCHOP|Patients registered to the study will receive an assigned dose of everolimus by mouth and RCHOP for a maximum of six cycles. Each cycle is a total of 21 days. RCHOP consists of 375 mg/m2 IV rituximab, 750 mg/m2 IV cyclophosphamide, 50 mg/m2 IV doxorubicin, 1.4 mg/m2 IV vincristine and 100 mg/m2 by mouth QD prednisone. The study includes a Phase I component to determine the maximum tolerated dose of everolimus and the second component determines the feasibility of therapy administered to lymphoma patients.
89358513|NCT02490358||1|Healthy smoking subjects
89358514|NCT02490358||2|COPD smoking subjects
89358515|NCT02490358||3|COPD ex-smoker subjects
89358516|NCT02490124||Type 1 Diabetic|Type 1 Diabetic
89358517|NCT02490124||Control|normal healthy control
89358518|NCT04839965|Experimental|IV Ampion|Ampion administered via intravenous infusion
89358519|NCT04839965|Placebo Comparator|IV placebo|Placebo administered via intravenous infusion
89358520|NCT02490046|Experimental|MS and rec UTIs not using a catheter|people with multiple sclerosis and recurrent urinary tract infections with spontaneous voiding Intervention- will be given D-mannose
89358521|NCT02490046|Experimental|MS and rec UTIs using a catheter|people with multiple sclerosis and recurrent urinary tract infections using either urethral or suprapubic indwelling catheter or intermittent catheterisation Intervention- will be given D-mannose
89000836|NCT04650685|Experimental|The Salvadora persica (miswak) chewing sticks|The chewing sticks are under the brand of Al-Khair. They will be prepared into equal length of 15 cm with uniform diameter of 1.0-1.5 cm and are sealed in airtight plastic bags. Participants are expected to use this oral hygiene tool for 3 weeks.
89000837|NCT04650685|Other|Standard toothbrush and toothpaste (control)|Participants will be given straight-handle soft-bristle Oral-B™ standard toothbrush and Colgate® fluoride tooth. Participants are expected to use this oral hygiene tool for 3 weeks.
89000838|NCT04650334|Other|Perinatal Collaborative Care|Experimental: Perinatal Collaborative Care in Can Tho, Vietnam This is an active treatment arm consisting of 3 health centers receiving training in collaborative care and enrollment of a total of 100 perinatal patients into collaborative care.
89000839|NCT00178490|Experimental|1|Children with high blood pressure who will receive treatment for high blood pressure
89358522|NCT05390333|Other|Self-Care Sampler for Family Care Partners|The 6-week Self-Care Sampler for Family Caregivers program was created to provide a variety of evidence-based self-care practices that improve the mental and physical health of caregivers by relieving stress. Sessions will take place once a week for 90 minutes, each starting with a centering exercise and focusing on a new form of self-care. The first 30 minutes will be used for a support group and the last 60 minutes will be for a self-care practice. Self-care practices that will be offered throughout the 6 weeks include mindfulness, mindful drawing, exercise, and health prevention and promotion.
89358523|NCT02487082|Other|Group A|Melatonin and donepezil (melatonin 3mg and donepezil 1.25-5mg based on age/weight each night) or placebo for 15 weeks
89358524|NCT02487082|Other|Group B|Melatonin and donepezil (melatonin 3mg and donepezil 1.25-5mg based on age/weight each night) or placebo for 15 weeks
88829745|NCT01936363|Experimental|Pimasertib (once daily) plus SAR245409|
89358525|NCT03788681|Active Comparator|"oral estradiol  estradiol valerate"|"this group will include ( 85 ) poor responder women undergoing a trial of IVF/ICSI .This group will receive oral estradiol  estradiol valerate  (Cyclo-Progynova® , 2mg , Bayer Schering Pharma Ag , Germany ) from within 24 hours ovum pickup of the cycle."
89358526|NCT03788681|Placebo Comparator|placebo|this group will include ( 85 ) poor responder women undergoing a trial of IVF/ICSI . This group will receive oral placebo (tablets) from within 24 hours ovum pickup of the cycle
89358527|NCT03788603|Experimental|Rogaratinib (BAY1163877)|Eligible patients will be selected based on the confirmation of high fibroblast growth factor receptor (FGFR) 1, 2, 3 or 4 mRNA expression levels in archival or fresh tumor biopsy specimens collected before the start of screening
88829746|NCT01936363|Experimental|Pimasertib (twice daily) plus SAR245409 placebo|
89358528|NCT03789929||The Emotional Backpack|Healthy adults participating in the offered online-course on their own initiative.
89358529|NCT03789929||Feelings as Powers|Healthy adults participating in the offered online-course on their own initiative.
89358530|NCT03790085|Experimental|Risperidone|It can be used after schizophrenia is diagnosed. Risperidone affects prolactin and may affect menstruation in young women, so we will try not to use it in such patients. Patients were randomized to a single Risperidone control trial for 8 weeks to evaluate the clinical efficacy of the patients. Risperidone routine daily 2-6 mg, up to 8 mg, can be taken orally twice a day.
89000840|NCT00178490|No Intervention|2|Children with normal blood pressure who will undergo no treatment
89358531|NCT03790085|Experimental|Olanzapine|It can be used after schizophrenia is diagnosed. Olanzapine is not generally used in patients with diabetes and hyperlipidemia. Patients were randomized to a single Olanzapine control trial for 8 weeks to evaluate the clinical efficacy of the patients. Olanzapine is available once or twice a day, starting at 5 mg daily and up to 20 mg daily.
89358532|NCT03790085|Experimental|Aripiprazole|It can be used after schizophrenia is diagnosed. Aripiprazole has no specific contraindications. Patients were randomized to a single Aripiprazole control trial for 8 weeks to evaluate the clinical efficacy of the patients. Aripiprazole is taken orally once a day, starting at 10 mg daily and up to 30 mg daily.
89358533|NCT01306097|Experimental|Zinc sulfate|daily zinc supplementation for 3 months. (10mg daily for under 1 years old children and 20mg daily for above 1 years old children)
89358534|NCT03466099|Experimental|KVD001 Injection (high dose)|
89358535|NCT03466099|Experimental|KVD001 Injection (low dose)|
89358536|NCT03466099|Sham Comparator|Sham Procedure|
89358537|NCT01308281|Experimental|PCI with IVUS guidance|PCI(percutaneous coronary intervention) with IVUS(IntraVascular UltraSound) group
89358538|NCT01308281|Active Comparator|PCI without IVUS guidance|PCI(percutaneous coronary intervention) group
89358539|NCT03790007|Active Comparator|Transversus Abdominis Plane Block|Transversus abdominis plane block (10 cc / 10 cc, 0.5% bupivacaine to the right and left transversus abdominis muscle regions) will be applied.
89358540|NCT03790007|Active Comparator|TROCHAR SITES LOCAL ANESTHETIC INJECTION|local anesthetic injection (6 cc to subxiphoid and infraumbilical trocar sites, 4 cc instead of 2 cc, 0.5% bupivacaine solution to be applied)
89358541|NCT03790007|Active Comparator|INTRAPERİTONEAL LOCAL ANESTHETIC SPREADING METHOD|Intraperitoneal direct vision of the gallbladder excision area-periportal area under the direct injection of local anesthetic spraying process (percutaneous method injected into the periportal area 1: 1 diluted with 20 cc SF, 20 cc 0.5% bupivacaine solution total 40 cc spraying will be applied.
89358542|NCT03790007|No Intervention|CONTROL GROUP|group will be the control group and any of these methods will not be applied,
89358543|NCT03716947|Active Comparator|ORBIT Mechanical disc prosthesis|"Surgical procedure with total disc replacement using mechanical disc prosthesis device, ORBIT, Globus Medical"
89358544|NCT03716947|Experimental|ZACK viscoelastic disc prosthesis|"Surgical procedure with total disc replacement using viscoelastic disc prosthesis device, ZACK, FH Orthopaedics"
89358545|NCT03716947|Active Comparator|ORBIT SASCA|Surgical procedure with total disc replacement (TDR) using ORBIT disc prostheses device combined with adjacent level anterior intracorporal fusion (ALIF) with intracorporal device SASCA.
89358546|NCT03716947|Experimental|ZACK SASCA|Surgical procedure with total disc replacement (TDR) using ZACK disc prostheses device combined with adjacent level anterior intracorporal fusion (ALIF) with intracorporal device SASCA.
89358547|NCT03789695|Experimental|Dabigatran etexilate|Dabigatran etexilate (Pradaxa) 110 mg b.i.d. or 150 mg b.i.d. according SmPC during 2 years
89358548|NCT03789695|Active Comparator|Warfarin|Warfarin under the control of INR once a month (target range 2.0 - 3.0) during 2 years
89358549|NCT05693831||Singula|Patients with a diagnosis of cancer who have already received first line therapy
89358550|NCT05693831||Ventura|Patients with a diagnosis of relapsed or refractory cancer
88829747|NCT04894097|Active Comparator|study group|Patients will received 3,000 pulses, 1,500 pulses per site at a frequency of 12 Hz per session with the submaximal pressure between 0.39 and 1.95 mJ/mm2 (1.0 and 5.0 bar), depending on the level which the patient can tolerate without local anesthetics.
88829748|NCT04894097|Sham Comparator|control group|The patients in this group will be treated by sham radial extracorporeal shock wave therapy
88829749|NCT04893629|Experimental|intervention group|children diagnosed with dilated cardiomyopathy , will undergo trans endocardium injection of mono nuclear cells
88829750|NCT04893629|Active Comparator|control group|children diagnosed with dilated cardiomyopathy ,will continue the classic medical treatment
88829751|NCT04892849||Trial cohort|"The study cohort consist of patients suffering from HNSCC (palliative), NSCLC (separately palliative and adjuvant) and other solid tumors (including in particular esophageal carcinomas, urothelial and renal carcinomas, small cell bronchial carcinomas and squamous cell carcinomas of the skin [depending on the current drug approval]) which will be treated with ICI (PD-1/PD-L1) and potential radiation of metastases at Department of Radiation Oncology of Universitätsklinikum Erlangen."
89000841|NCT04650412|Experimental|Intervention|Bundle of comorbidities care
89358551|NCT03720769|Experimental|Step-by-Step|
89358552|NCT03720769|Active Comparator|Enhanced care as usual|
89358553|NCT03720691|Active Comparator|Real rTMS Supplementary motor area|Real rTMS will be applied over the supplementary motor area
89358554|NCT03720691|Sham Comparator|Sham rTMS Supplementary motor area|Sham rTMS will be applied over the supplementary motor area
89358555|NCT05663437|Active Comparator|Control group|Core stabilization exercises
89358556|NCT05663437|Experimental|Experimental group|Core stabilization exercises and Neural mobilization technique
89358557|NCT03789851|Experimental|core needle biopsy|All patients enrolled in this study received a ultrasound-guided multipoint core needle biopsy after surgery.
89358558|NCT00739674|Active Comparator|Losartan-Based Regimen Alone (L Group)|Losartan-based regimen, with sequential titration including HCTZ and CCB as needed to achieve target blood pressure.
89358559|NCT00739674|Experimental|Diet Management and Losartan-Based Regimen (DML Group)|Losartan with sequential titration including HCTZ and CCB as needed to achieve target blood pressure combined with low-salt intake diet.
89358560|NCT03639181|Experimental|GB226 3mg/kg every 2 weeks|Geptanolimab Injection, 3mg/kg every 2 weeks
89358561|NCT01306409|Experimental|A|Sequential application of different ESA
89358562|NCT01331928|Experimental|Capecitabine, Oxaliplatin, Docetaxel , Gastric cancer|
89358563|NCT03785795||Uncertain diagnosis of true labor|Patients who cannot be accurately classified as experiencing true labor or false labor based on standard clinical assessments.
89358564|NCT01329822|Experimental|Caloric restriction group|CR group were educated by a dietitian to reduce their usual energy intake to 1400 kcal/day (-500 kcal/day, -26% from baseline) for weight reduction and the recommended macronutrient composition was the 50-55% of energy intake as carbohydrate, 15-20% as protein and 20-25% as fat. Daily energy intake and nutrient composition were determined using a computer-aided nutritional analysis program (CAN-Pro 3.0; Korean Nutrition Society, Seoul, South Korea).
89358565|NCT01329822|No Intervention|Control group|Control group - ad libitum diet
89358566|NCT03494725|Active Comparator|Lpc-37|"Lacticaseibacillus paracasei Lpc-37 (Lpc-37), formerly Lactobacillus paracasei Lpc-37~1x 1 capsule in the morning for 5 weeks"
89358567|NCT03494725|Placebo Comparator|Placebo|"Placebo capsule manufactured to mimic Lpc-37 capsule~1x 1 capsule in the morning for 5 weeks"
89358568|NCT01306487||Macular hole patients|The patients who underwent vitreous surgery for idiopathic macular hole.
88829752|NCT01936519|Active Comparator|Calcineurin Inhibitor with Mycophenolic Acid|Calcineurin inhibitor immunosuppression with mycophenolic acid
89358569|NCT01334580|Active Comparator|Methadone Drug Counseling|Methadone Drug Counseling is provided by skilled drug counselors over a 12 week period and focuses on cessation of illicit drugs
89358570|NCT01334580|Experimental|Cognitive-Behavioral Therapy for Pain and Opioid Dependence|CBT is provided by skilled psychologists in weekly sessions for 12 weeks and focuses on reducing illicit drug use and increasing pain management.
88829753|NCT01936519|Experimental|Everolimus with Mycophenolic Acid|Conversion to Everolimus immunosuppression combined with mycophenolic acid (Myfortic: MPA), and complete discontinuation of Calcineurin inhibitor at 3 months post transplant.
88829754|NCT04509557|Experimental|50mCi|Using a drug product for which dose is determined (50±5 mCi dose), dilute with 0.9% NaCl 5 mL and slowly i.v. inject over 10 minutes, with 500 mL of 0.9% NaCl slowly administered for hydration over approximately 90 minutes from 30 minutes before treatment to 60 minutes after treatment.
88829755|NCT04509557|Experimental|75mCi|Using a drug product for which dose is determined (75±8 mCi dose), dilute with 0.9% NaCl 5 mL and slowly i.v. inject over 10 minutes, with 500 mL of 0.9% NaCl slowly administered for hydration over approximately 90 minutes from 30 minutes before treatment to 60 minutes after treatment.
88829756|NCT04509557|Experimental|100mCi|Using a drug product for which dose is determined (100±10 mCi dose), dilute with 0.9% NaCl 5 mL and slowly i.v. inject over 10 minutes, with 500 mL of 0.9% NaCl slowly administered for hydration over approximately 90 minutes from 30 minutes before treatment to 60 minutes after treatment.
88829757|NCT04509557|Experimental|125mCi|Using a drug product for which dose is determined (125±13 mCi dose), dilute with 0.9% NaCl 5 mL and slowly i.v. inject over 10 minutes, with 500 mL of 0.9% NaCl slowly administered for hydration over approximately 90 minutes from 30 minutes before treatment to 60 minutes after treatment.
88829758|NCT04509557|Experimental|150mCi|Using a drug product for which dose is determined (150±15 mCi dose), dilute with 0.9% NaCl 5 mL and slowly i.v. inject over 10 minutes, with 500 mL of 0.9% NaCl slowly administered for hydration over approximately 90 minutes from 30 minutes before treatment to 60 minutes after treatment.
88829759|NCT04507841|Experimental|Niraparib group|Niraparib was used in patients with newly diagnosed ovarian cancer before any treatment. The daily dose (e.g. 200 mg is 2 capsules of 100 mg) should be strictly controlled according to the experimental design.
88829760|NCT01936909|Experimental|Anakinra (short)|Anakinra 100 mg daily for 2 weeks, followed by placebo for 10 weeks
88829761|NCT01936909|Experimental|Anakinra (long)|Anakinra 100 mg daily for 12 weeks
88829762|NCT01936909|Placebo Comparator|Placebo|Placebo injections daily for 12 weeks
88829763|NCT01938079|Active Comparator|Sedative without Ketamine|Subjects will receive sedative drug regimen without Ketamine.
88829764|NCT01938079|Experimental|Sedative with Ketamine|Subjects will receive sedative drug regimen with Ketamine.
88829765|NCT02641067|Experimental|Severe Renal Impairment|Participants with severe renal impairment receive a single oral dose of 100 mg doravirine
89358571|NCT00705718|Experimental|Endurant Bifurcated arm|The Bifurcated arm includes subjects who have received a bifurcated device. The Endurant Stent Graft System Bifurcated device is administered to treat patients with an Abdominal Aortic Aneurysm.
88829766|NCT02641067|Experimental|Healthy Matched Control|Healthy participants matched for age and weight receive a single oral dose of 100 mg doravirine
88829767|NCT01939405|No Intervention|standard physical activity counseling|
89358572|NCT00705718|Experimental|Endurant AUI arm|The AUI arm includes subjects who have received an AUI device. The Endurant Stent Graft System AUI device is administered to treat patients with an Abdominal Aortic Aneurysm.
88829768|NCT01939405|Experimental|built environment use counseling|personalized counseling on active use of the built environment
88829769|NCT02329015|Experimental|Health and Wellness program|Behavioral intervention
89358573|NCT05523713|Other|Patients with major elective digestive surgery|"The size of the cohort is 240 patients~Population: Patients with major elective digestive surgery (eg, colon or colorectal resection, partial or total gastrectomy, pancreaticoduodenectomy, hepatectomy)."
89358574|NCT02694588|Active Comparator|Infliximab|5 mg/kg body weight, week 0/2/6, then every 8 weeks
89358575|NCT02694588|Active Comparator|Vedolizumab|300 mg, week 0/2/6, then every 8 weeks
89358576|NCT03789539|Active Comparator|LD Universal Influenza Vaccine Uniflu|low dose of Uniflu vaccine 0.5 ml (20 mkg of recombinant protein HBc-4M2eh) administrated intramuscularly 2 times at 21 days intervals
89358577|NCT03789539|Active Comparator|HD Universal Influenza Vaccine Uniflu|high dose of Uniflu vaccine 0.5 ml (40 mkg of recombinant protein HBc-4M2eh) administrated intramuscularly 2 times at 21 days intervals
89358578|NCT03789539|Placebo Comparator|Placebo|saline 0.5 ml
89358579|NCT01334658|Active Comparator|Balanced Salt Solution (BSS®)|Subjects who received Balanced Salt Solution.
89358580|NCT01334658|Active Comparator|Glucose-bicarbonate-Ringer Lactate (GBRL)|Subjects who received glucose-bicarbonate-Ringer Lactate.
89358581|NCT01308359|Experimental|glucose 5%|glucose 5%
89358582|NCT01308359|Active Comparator|saline|saline
89534278|NCT03590613|Experimental|Sequence 3: 60 TID then 120 TID then Placebo TID then 240 TID|The eligible subjects in this arm will receive GSK2982772 60 mg TID in TP1, GSK2982772 120mg TID in TP2, placebo TID in TP3 and GSK2982772 240 mg TID in TP4. GSK2982772 or placebo will be administered at 0 hour (the first dosing), 7 hours (the second dosing) and 14 hours (the third dosing) on Day 1 in each TP. Subjects will fast overnight for 8 hours before first dose. Each TP will be followed by a washout period of at least 7 days, for each subject.
88829770|NCT02329015|Active Comparator|Physical Education Class|Behavioral intervention
88829771|NCT02641691|Experimental|Arm 1: Radiation/Oxaliplatin/Leucovorin/5-FU|"Radiotherapy will consist of five fractions, delivered once daily, to a total dose of 25Gy at 5 Gy per fraction.~An optional concomitant boost may be delivered to the primary tumor of 1-2 Gy per day (30-35 Gy to tumor total). If a boost is given then the maximum allowed dose to small bowel is 25 Gy.~Chemotherapy should begin two weeks (9-12 working days) after completion of radiotherapy.~Oxaliplatin will be given intravenous (IV) over 2 hours on Day 1 every 14 days for a maximum of 8 cycles.~Leucovorin will be given IV over 2 hours on Day 1 every 14 days for a maximum of 8 cycles.~5-FU bolus will given IV push on Day 1 every 14 days for a maximum of 8 cycles.~5-FU infusion will be given continuous IV on Day 1 over 46 hours every 14 days for a maximum of 8 cycles~Alternatively, capecitabine/oxaliplatin (CAPE PO 1000 mg/m2 BID days 1-14 Q21 days, oxaliplatin IV 130 mg/m2 IV Q21 days on day 1) x 5 cycles over 15 weeks may be administered instead of FOLFOX"
88829772|NCT02642237|Experimental|LPS-Fluenz|Healthy volunteers administered intravenously with endotoxin, followed by an intranasal inoculation with Fluenz, a live-attenuated influenza vaccin
88829773|NCT02642237|Placebo Comparator|Placebo-Fluenz|Healthy volunteers administered intravenously with placebo, followed by an intranasal inoculation with Fluenz, a live-attenuated influenza vaccin
88829774|NCT01941745|Placebo Comparator|half normal saline|Single dose of half normal saline at 2 ml/kg given intratracheally times one dose
88829775|NCT01941745|Experimental|Low Dose rhCC10|1.5 mg/kg study drug (rhCC10)in 2 ml/kg given intratracheally times one dose
88829776|NCT01941745|Experimental|High dose rhCC10|5 mg/kg of rhCC10 given in 2 ml/kg and administered intratracheally times one dose
88829777|NCT01943227||6ml/kg|"Enthalpy measured in patients receiving controlled positive pressure ventilation 6ml/kg Tidal volume.~The VQm monitor samples the gas at a rate of 3 L/min, returning the analyzed gas to the circuit. As the exhaled gas passes through the analytical chamber, the temperature and humidity are measured essentially continuously (40Hz). These data are combined with pressure measurements to determine the exhaled gas volume and then the heat content (enthalpy) is calculated."
88829778|NCT01943227||9ml/kg|"Enthalpy measured in patients receiving controlled positive pressure ventilation 9ml/kg Tidal volume.~The VQm monitor samples the gas at a rate of 3 L/min, returning the analyzed gas to the circuit. As the exhaled gas passes through the analytical chamber, the temperature and humidity are measured essentially continuously (40Hz). These data are combined with pressure measurements to determine the exhaled gas volume and then the heat content (enthalpy) is calculated."
89358583|NCT02490202|Experimental|SANGUINATE|Two (2) infusions of SANGUINATE
89534279|NCT03590613|Experimental|Sequence 4: 60 TID then 120 TID then 240 TID then Placebo TID|The eligible subjects in this arm will receive GSK2982772 60 mg TID in TP1, GSK2982772 120mg TID in TP2, GSK2982772 240 mg TID in TP3 and placebo TID in TP4. GSK2982772 or placebo will be administered at 0 hour (the first dosing), 7 hours (the second dosing) and 14 hours (the third dosing) on Day 1 in each TP. Subjects will fast overnight for 8 hours before first dose. Each TP will be followed by a washout period of at least 7 days, for each subject.
88829779|NCT02642393|Experimental|Inosine|Inosine will be dosed by titrating the number of capsules taken daily to achieve an elevation of serum urate to trough levels of 7.1 to 8.0 mg/dL.
88829780|NCT02642393|Placebo Comparator|Placebo|Placebo will be dosed to match the capsule titrations of the inosine group.
89000842|NCT04650412|No Intervention|Control|Standard care
89000843|NCT04650373||Surgical management|Underwent bariatric surgery
89000844|NCT04650373||Non-surgical management|Patients treated medically
89000845|NCT04650763|No Intervention|Control Group|Dental implant was placed in these patients following full protocol of immediate implant placement.
89358584|NCT02490202|Placebo Comparator|Normal Saline|Two (2) infusions of Normal Saline
89358585|NCT01334736|Placebo Comparator|Usual care|
89358586|NCT01334736|Active Comparator|Lung Age|
89358587|NCT01334736|Active Comparator|Contingency Management|
89358588|NCT01334736|Active Comparator|Lung age + Contingency Management|
89358589|NCT05654389|Experimental|Application of teleconsultation using WhatsApp to refer patient with with myocardial infarction|Application of teleconsultation using WhatsApp for a patient with myocardial infarction with a provisional diagnosis of myocardial infarction during referral from a district hospital to a cardiac centre.
89358590|NCT05654389|No Intervention|Routine care and handling of a patient with mycardial infarction at peripheral hospital|Routine care and consultation received by a patient with a provisional diagnosis of myocardial infarction during referral from the district hospital to the cardiac centre
88829781|NCT02642627|Experimental|Bellafill Injections|Correctable acne scars will be individually identified and only scars that the Investigator determines to be correctable will receive study treatment. All eligible scars within the treatment area will be treated. Bellafill will be injected using a standard tunneling technique whereby the filler is injected in a retrograde manner utilizing several passes until the scar reaches a desired level of correction. A touch-up treatment is allowed if additional treatment is required to achieve optimal correction.
88829782|NCT04272593|Experimental|Simultaneous Control|Simultaneous pattern recognition style of control allows prosthetic users to actuate more than one hand/arm function on their device at the same time.
88829783|NCT04272593|Active Comparator|Conventional Control|Conventional, seamless sequential pattern recognition style of control allows prosthetic users to actuate a single hand or arm functions on their device at a time.
88829784|NCT04740749|Other|Prospective group|Patients who have to undergone the implant surgery
88829785|NCT04740749|Other|Retrospective group|Patients that have already undergone the implant surgery
88829786|NCT04741061|Active Comparator|Sputnik Light Vaccine|study group (4500 receiving the Sputnik-Light vector vaccine) against the SARS-СoV-2-induced coronavirus infection.
88829787|NCT04741061|Placebo Comparator|Placebo Group|control group (1500 subjects receiving placebo)
88829788|NCT04221737|Active Comparator|Conventional ventilation|Protective lung conventional strategy with volume-controlled ventilation (VCV) or pressure-controlled ventilation (PCV) mode, with low tidal volume and adequate positive end expiratory pressure (PEEP) level.
88829789|NCT04221737|Experimental|Time-controlled adaptive APRV|Airway Pressure Release Ventilation with Time-controlled adaptive ventilation method. Allowing for spontaneous breathing.
88829790|NCT00367757|Other|PVI group|Trigger-based ablation guided by pulmonary vein antrum isolation
88829791|NCT00367757|Other|CFAE group|Substrate-based ablation using an approach targeting CFAEs
88829792|NCT00367757|Other|Combined group|Combined trigger and substrate based approach
88829793|NCT05588999|Active Comparator|Group A (Cryotherapy Alone)|Patients in this Group were subjected to Cryotherapy Alone with liquid nitrogen and received maximum of four treatments given two to three weeks apart
88829794|NCT05588999|Active Comparator|Group B (Cryotherapy plus Salicylic Acid)|Patients in this Group were subjected to cryotherapy plus salicylic acid for a maximum of eight weeks
88829795|NCT04339283|Experimental|Standardized Hibiscus sabdariffa tea Arm|300 mL of freshly prepared standardized Hibiscus sabdariffa tea (containing 102.49 mg/L of total monomeric anthocyanin) is administered daily to the participants for 28 days
88829796|NCT04339283|No Intervention|Water Arm|300 mL of distilled water is administered to the participants daily for 28 days.
88829797|NCT01643928|Experimental|Rituximab-Pfizer|
88829798|NCT01643928|Active Comparator|Rituximab-EU+Rituximab-Pfizer|Subjects will receive Rituximab-EU x 1 course followed by Rituximab-Pfizer x 2 courses.
88829799|NCT01643928|Active Comparator|Rituximab-US+Rituximab-Pfizer|Subjects will receive Rituximab-US x 1 course followed by Rituximab-Pfizer x 2 courses.
88829800|NCT03750071|Experimental|VXM01/Avelumab|Combination of VXM01, Ty21a transformed with a eukaryotic expression cassette encoding VEGFR-2, and anti-PD-L1 Checkpoint Inhibitor Avelumab
88829801|NCT03631979|Experimental|Intervention group|Regular intestinal lavage with normal saline twice per day, starting after randomization and not later than 24 hours of age, and continued until full enteral nutrition of 170ml/kg/day is achieved or NEC diagnosis (Bell stage II or more) is established, which one comes first. The intervention will be applied at a maximum of 2 weeks from birth.
88829802|NCT03631979|No Intervention|Control group|Current routine for extremely preterm infants that do not defecate adequately will be applied.
88829803|NCT05588765|Experimental|Respiratory muscle endurance training|Volume oriented incentive spirometer improves respiratory muscle endurance and chest expansion.
88829804|NCT05588765|Active Comparator|Diaphragmatic breathing exercises|Improvement in diaphragm contraction, chest wall symmetry and reduce activity of accessory muscle due to diaphragmatic breathing technique causes respiratory muscle endurance to improve.
88829805|NCT04339829|Other|Dacomitinib 45mg PO ,QD|Single arm
89530294|NCT03254953|Experimental|Sequential Intervention|"in this Sequential eHealth intervention, participants are asked to self-monitor only their body weight for the first month, then for months 2 and 3 they will be asked to also self-monitor their diet~participants are asked to use the MyFitnessPal app for self-monitoring~given goal to lose 5% weight by end of intervention (3 months)~weekly personalized feedback via email~weekly skills training materials (behavioral modification lessons; tips on using different features of the app) via email~weekly action plans via email"
88829806|NCT04740281||Medical Doctors at Aarhus University Hospital, Denmark|Medical Doctors from different subspecialties at Aarhus University Hospital, Denmark. Blinded for the purpose of the trial, their footwear will be evaluated by trial responsible personal.
88829807|NCT05588531|Active Comparator|YK-1169 0.5g (containing cefepime 0.4g, avibactam 0.1g)|Four healthy subjects in group A1, two males and two females, without control, were administered the test drug
88829808|NCT05588531|Active Comparator|YK-1169 1.25 g (containing cefepime 1.0 g and avibactam 0.25 g)|12 healthy subjects, of whom 10 subjects were administered the investigational product and 2 subjects were administered placebo, half males and half females
88829809|NCT05588531|Active Comparator|YK-1169 2.5g (containing cefepime 2.0g and avibactam 0.5g)|12 healthy subjects, of whom 10 subjects were administered the investigational product and 2 subjects were administered placebo, half males and half females
88829810|NCT05588531|Placebo Comparator|YK-1169 3.75g (containing cefepime 3.0g and avibactam 0.75g)|12 healthy subjects, of whom 10 subjects were administered the investigational product and 2 subjects were administered placebo, half males and half females
88829811|NCT05588531|Active Comparator|YK-1169 5.0g (containing cefepime 4.0g and avibactam 1.0g)|8 healthy subjects, 6 of whom were administered the investigational product and 2 of whom were administered placebo, half males and half females
88829812|NCT05588531|Active Comparator|Drug Interaction Studies|18 subjects (single gender not less than 1/3) were randomly divided into D1, D2 and D3 groups, 6 subjects for each group
89358591|NCT02484586|Other|Presbyope group|"40 years and over with a reading add.~Control lens: Etafilcon A, Nelfilcon A, Nesofilcon A, Somofilcon A, 58% Poly-HEMA~Test lens: Etafilcon A~Up to 10 prototype contact lens designs and at least 1 commercially available contact lens designs will be worn by each participant for up to a week on a daily disposable modality. Participants will attend separate fitting and assessment visits for each lens type (Fitting Visit on Day 1, and Assessment Visit as late as Day 7, but may be as early as 6 hours after the Fitting Visit). There will be a minimum 1 night washout period between lens designs, i.e. after an assessment visit but before the next fitting visit."
89358592|NCT02484586|Other|Non-Presbyope group|"18-39 years with no reading add.~Control lens: Etafilcon A, Nelfilcon A, Omafilcon A~Test lens: Etafilcon A~Up to 10 prototype contact lens designs and at least 1 commercially available contact lens designs will be worn by participants for up to a week on a daily disposable modality. Participants will attend separate fitting and assessment visits for each lens type (Fitting Visit on Day 1, and Assessment Visit as late as Day 7, but may be as early as 6 hours after the Fitting Visit). There will be a minimum 1 night washout period between lens designs, i.e. after an assessment visit but before the next fitting visit."
89358593|NCT01332006|Experimental|Intra-bone injection|Intra-bone transplantation of hematopoietic stem cells from cord blood
89358594|NCT02486848|Placebo Comparator|5% Topical Minoxidil Solution|5% Topical Minoxidil Solution
89358595|NCT02486848|Active Comparator|15% Topical Minoxidil Solution|15% Topical Minoxidil Solution
89358596|NCT01306565|Active Comparator|High dose atorvastatin|Three 80mg daily doses of atorvastatin
89358597|NCT01306565|Experimental|Low dose Atorvastatin|80mg atorvastatin followed by two 20mg daily atorvastatin
89358598|NCT03716791|Placebo Comparator|Placebo Control Group|pill capsules containing white rice flour
89358599|NCT03716791|Active Comparator|Methylsulfonylmethane Group|pill capsules containing MSM
89358600|NCT05186610||FDG PET/CT guided metabolic core needle biopsy group|2- Fluorodeoxyglucose (FDG) PET-positive lesions at initial presentation or at the end of treatment were considered for PET/CT guided biopsy after discussion with the hemato oncologist.
89358601|NCT02486770|Experimental|Group 1|Aerucin 2.0mg/kg
89358602|NCT02486770|Experimental|Group 2|Aerucin 8.0mg/kg
89534280|NCT03568968|Experimental|Nicotinamide Riboside|nicotinamide riboside, 1000mg daily for the duration of the trial (52 weeks). Dosage form is capsules.
88829813|NCT04153097||pembrolizumab-treated advanced NSCLC|Patients with advanced non-small cell lung cancer treated with pembrolizumab
88829814|NCT05588375|Experimental|home-based physical activity telemonitoring program|The home telehealth physical activity training program is a telemedicine physical activity training that uses Google Meet software to communicate and supervise through webcams. The exercise process is supervised and guided by a trained critical care nurse. The experimental group participated in a telehealth physical activity training program. The telemedicine physical activity training program included a 3-month online intervention (exercise diary, exercise training education, and 24 exercise sessions for patients) and a 3-month follow-up after exercise.
88829815|NCT05588375|Active Comparator|walk 2-3 days a week|Maintain daily physical activity and lifestyle and walk for 30 minutes 2-3 days a week for three months
88829816|NCT05588297|Experimental|Nivolumab + Bevacizumab + CAPOX as neoadjuvant treatment for 4 cycles|"CapOx: Capecitabine is given orally at 1500mg / m² twice a day from day1-14 every 3 weeks for 4 cycles and Oxaliplatin is given by intravenous infusion at 200mg / m2 on Day 1 every 3 weeks for 4 cycles;~Bevacizumab：Bevacizumab is given intravenously at 10mg/kg on day 1 every 3 weeks for 4 cycles; Nivolumab：Nivolumab is given intravenously at 360 mg on day 1 every 3 weeks for 4 cycles;"
88829817|NCT05587985||Experimental Group|"After randomization, 34 patients will be included in the experimental group. This group is the group to be mobilized early after surgery.~During the data collection process, the pain level of the experimental group will be evaluated at the 8th hour after the operation, then the level of mobility will be evaluated by providing mobilization.~At the 20th hour after the surgery, pain assessment of both groups will be made, and then their mobility will be evaluated, and their mobility levels will be evaluated."
88829818|NCT05587985||Control Group|"After randomization, 34 patients will be included in the control group. This group is the group that did not undergo early mobilization.~The control group will only be evaluated for pain at the 8th hour after surgery, and they will not be mobilized.~At the 20th hour after the surgery, pain assessment of both groups will be made, and then their mobility will be evaluated, and their mobility levels will be evaluated."
88829819|NCT04339673|Active Comparator|MNB- masseteric nerve block|masseteric nerve block with local anesthesia lidocaine single app.
88829820|NCT04339673|Active Comparator|LA -trigger point injection with local anesthetic|local anesthetic injections on trigger points in masseter
88829821|NCT04339673|Placebo Comparator|DN-dry needling|dren needling to masseter
88829822|NCT02303405|Experimental|Hydroxychloroquine|Treatment with hydroxychloroquine 400 mg (2 x 200 mg tablets) po once daily x 4 months
88829823|NCT02303405|Active Comparator|Pioglitazone|Treatment with pioglitazone 45 mg po (1 tablet) once daily x 4 months
88829824|NCT02164955||Relapsed and Refractory Multiple Myeloma Patients|Single Cohort of Relapsed and Refractory Multiple Myeloma Patients treated with IMNOVID (pomalidomide)
88829825|NCT05587907|Experimental|Group 1|18 soccer players follow a 6-month exercise program with visual stimuli, 5 times a week and lasting 15 minutes each time, which precedes their regular soccer training program.
88829826|NCT05587907|No Intervention|Group 2|20 soccer players follow a regular soccer training program.
89358603|NCT02486770|Experimental|Group 3|Aerucin 20.0mg/kg
89534281|NCT03568968|Placebo Comparator|Placebo Comparator|Placebo capsules, no active ingredients.
88829827|NCT05587829|Experimental|Group A|Group A: will be treated with basic breathing technique.
88829828|NCT05587829|Experimental|Group B|Group B: will be treated by will be breathing technique along with diaphragm and abdominal training.
88829829|NCT04740203|Experimental|CAR-T therapy|Administration of CD19 and CD22 CAR T-cells
89358604|NCT03786029|Experimental|A (Acetaminophen)|22 children will receive 320mg (10ml) 30 minutes before the local anesthesia injection.
89358605|NCT03786029|Placebo Comparator|B (Placebo)|22 children will receive 10ml 30 minutes before the local anesthesia injection.
89534282|NCT03562221|Experimental|Gluten free diet|Gluten free diet
89358606|NCT03786029|Experimental|C (Ibuprofen)|22 children will receive 200mg (10ml) 30 minutes before the local anesthesia injection.
89358607|NCT01334892|Active Comparator|L-CsA|Twice daily inhalation of 2.5 ml/10 mg L-CsA for 96 weeks
89358608|NCT01334892|Placebo Comparator|L-CsA placebo|Twice daily inhalation of 2.5 ml aerosolised placebo (carrier) for 96 weeks (24 months)
89358609|NCT03435211|Experimental|INVSENSOR00006|All subjects consented are enrolled into the test group and received the INVSENSOR00006.
89358610|NCT02484508|Experimental|Guli capsule|Guli capsule, the tested drug of this study
89358611|NCT02484508|Active Comparator|Kangguzengsheng capsule|Kangguzengsheng capsule, a CFDA approved drug for articular genu osteoarthritis,is adopted as active comparator in this study
89358612|NCT05186532|Experimental|Dry heat group|infra red-light therapy that supplies radiant heat or infra-red rays to produce heat to the episiotomy wound.
89358613|NCT05186532|Active Comparator|Moist heat group|warm sitz bath in which a woman is asked to sit in a warm water tub up to the hip level.
89358614|NCT04730219|Experimental|Tislelizumab and Nab Paclitaxel|Tislelizumab 200mg IV on day 1 in combination with nab paclitaxel 200mg IV on day 2 every 3 weeks for 3 cycles followed by surgery.
89358615|NCT04492774|Experimental|GOLDIC serum|Epidural ultrasound guided injections
89358616|NCT04492774|Active Comparator|Steroid|Epidural ultrasound guided injections
89358617|NCT04492774|Active Comparator|Manual therapy|veno-lymphatic spinal drainage
89358618|NCT01332084|Experimental|hypoallergenic wheat cereals|HA wheat cereal used in a SOTI test
89358619|NCT01928732|Active Comparator|CPT|Cognitive Processing Therapy (CPT) - a type of cognitive therapy for treating PTSD.
89358620|NCT01928732|Active Comparator|PE|Prolonged Exposure (PE) - a type of exposure therapy for treating PTSD.
89358621|NCT03321292|Experimental|L-arginine and Acetylesalicylic acid|L-arginine 1000mg capsules( manufactured by Putriant Pride,INC Holbrook,NY 11741 U.S.A.) every 8 hours Acetylesalicylic acid 75 mg tablet(manufactured by Multi_Apex Pharma , Egypt) once daily will be given for patients of group A starting from diagnosis till birth
89358622|NCT03321292|Active Comparator|Acetylesalicylic acid75mg|acetylsalicylic acid 75 mg tablet(manufactured by Multi_Apex Pharma , Egypt) orally once daily will be given for patients of group B starting from diagnosis till birth
89358623|NCT01337388||Cohort|
89358624|NCT03785717|Active Comparator|ROG only|cancellous (1-2 mm) & cortical (250-1000 mm) bone allograft and pericardium membrane without extracorporeal shockwave therapy
89358625|NCT03785717|Active Comparator|ROG & ESWT|cancellous 1-2mm & cortical 250-1000mm Bonegrafts and membrane with extracorporeal shockwave therapy
89358626|NCT02484742|No Intervention|Sleep control condition|8 hours of sleep throughout the 18-day stay in the Clinical Research Center
89358627|NCT02484742|Experimental|Insomnia symptom induction condition|4 4-day cycles, each consisting of 3 nights with sleep disruption followed by one night of recovery sleep.
89358628|NCT01306721|Active Comparator|FEX 60 mg|"Study medications is administered one hour before or two hours after a meal twice a day.~Placebo lead-in period: 1 placebo tablet of fexofenadine 60 mg + 2 placebo tablets of fexofenadine 60 mg/pseudoephedrine 60 mg (fixe dose combination)~Double-blind treatment period:~1 tablet of fexofenadine 60 mg + 2 placebo tablets of fexofenadine 60 mg /pseudoephedrine 60 mg (fixe dose combination)"
89358629|NCT01306721|Experimental|FEX 60 mg/PSE 60 mg|"Study medications is administered one hour before or two hours after a meal twice a day.~Placebo lead-in period: 1 placebo tablet of fexofenadine 60 mg + 2 placebo tablets of fexofenadine 60 mg/pseudoephedrine 60 mg (fixe dose combination~Double-blind treatment period:~1 tablet of fexofenadine 60 mg/pseudoephedrine 60 mg (fixe dose combination) + 1 placebo tablet of fexofenadine 60 mg / pseudoephedrine 60 mg (fixe dose combination)"
88829830|NCT01943461|Experimental|Dose-escalation Cohort: Avelumab 3 mg/kg|
88829831|NCT01943461|Experimental|Dose-escalation Cohort: Avelumab 10 mg/kg|
89358630|NCT01306721|Experimental|FEX 60 mg/PSE 120 mg|"Study medications is administered one hour before or two hours after a meal twice a day.~Placebo lead-in period: 1 placebo tablet of fexofenadine 60 mg + 2 placebo tablets of fexofenadine 60 mg/pseudoephedrine 60 mg (fixe dose combination)~Double-blind treatment period:~2 tablets of fexofenadine 30 mg/pseudoephedrine 60 mg (fixe dose combination) + 1 placebo tablet of fexofenadine 30 mg"
89358631|NCT01337466|Experimental|[124I]FIAU|single dose study of [124I]FIAU in healthy volunteers or subjects with prosthetic joint infection who will undergo PET-CT scanning
89358632|NCT02486926|Placebo Comparator|Sevoflurane|Anesthesia was maintained with sevoflurane,and the incidence and severity of emergence agitation was investigated.
89358633|NCT02486926|Active Comparator|Remifentanil|Anesthesia was maintained with sevoflurane and remifentanil. The incidence and severity of emergence agitation was compared with sevoflurane group.
89358634|NCT02486926|Active Comparator|Alfentanil|"Anesthesia was maintained with sevoflurane and remifentanil, and alfentanil was administered 10 min before the end of surgery.~The incidence and severity of emergence agitation was compared with sevoflurane group."
89358635|NCT02486926|Other|Thiopental|General anesthesia was induced with thiopental 5 mg/kg, rocuronium 0.6 mg/kg and sevoflurane in all patients.
89358636|NCT02486926|Other|Rocuronium|General anesthesia was induced with thiopental 5 mg/kg, rocuronium 0.6 mg/kg and sevoflurane in all patients.
89358637|NCT01335048|Experimental|Atorvastatin-Clopidogrel group|Patients who receive Atorvastatin 80 mg/day and Clopidogrel 150 mg/day
89358638|NCT01335048|Active Comparator|Clopidogrel group|Patients who receive clopidogrel 150 mg daily
89358639|NCT03318250|Active Comparator|Burst3D|"This is a device progamme setting which is being compared against DR6-LF.~Intervention for this arm is the dorsal root ganglion neurostimulation device implant which will occur at trial implant. Once device is implanted participants are assigned progammes in a randomized manner."
89358640|NCT03318250|Active Comparator|DRG-LF|"This is a device progamme setting which is being compared against Burst3D.~Intervention for this arm is the dorsal root ganglion neurostimulation device implant which will occur at trial implant.Once device is implanted participants are assigned progammes in a randomized manner."
88829832|NCT01943461|Experimental|Dose-escalation Cohort: Avelumab 20 mg/kg|
88829833|NCT01943461|Experimental|Expansion Cohort: Avelumab 10 mg/kg|
88829834|NCT01397669|Other|HIV infection and non HIV infection|
89358641|NCT05693519||Children|Patients aged 0-17 years at primary gastrointestinal cancer diagnosis
89358642|NCT05693519||Young people aged 18-24 years|Patients aged 18-24 years at primary gastrointestinal cancer diagnosis
89358643|NCT01335126|Experimental|Test|
89358644|NCT03465709|Experimental|Pegcetacoplan Study Drug|
89358645|NCT02489812|Experimental|music|The Mozart Symphony No 40 in G minor K550 was played in headphones. While the child received restorative treatment in the teeth she heard music in a session and was subjected to other dental treatment session without listening to music. The cardiac and respiratory frequencies were measured with children's finger oximeter while the child listened to music and also in session in which she did not hear music. Changes in the measurements obtained by the oximeter showed levels of anxiety.
89358646|NCT01567475|Experimental|Everolimus and rituximab|
89358647|NCT01337544|Experimental|IL-15 STIMULATED NK CELLS|
89358648|NCT03716713|Experimental|CeraShield Endotracheal Tube|Subjects who are expected to require mechanical ventilation for 24 hours or longer will be intubated with the CeraShield ETT.
89358649|NCT03316144|Experimental|1 mg/kg Toripalimab|humanized anti-PD-1 monoclonal antibody is to be injected intravenously 1mg/kg Q2w until disease progresses or unacceptable tolerability occurs
89534283|NCT03562221|Active Comparator|Probiotics|Capsules with a combination of two probiotic bacteria with maize starch as excipient and at a total dose of 10(10) colony forming units (CFU)/capsule.
89534284|NCT03562221|Placebo Comparator|Placebo|Placebo capsules with maize starch and without any bacteria.
89534285|NCT03525418|Experimental|Cohort A - Phase 1 (Open Label)|10 consecutive HLHS patients will be enrolled and treated with Longeveron Mesenchymal Stem Cells (LMSCs). A single administration of LMSCs will be performed via intramyocardial injections during the Stage II (BDCPA) surgery. Dosing is based on body weight. Each LMSC-treated patient will be given 2.5 x 105 LMSCs per kg of body weight. The entire dose of the cells will be roughly 600 microliters.
88829835|NCT00422435|Experimental|Drug eluting stent|CoStar™ Paclitaxel-Eluting Coronary Stent with SRX catheter
88829836|NCT03679247|Experimental|Intervention|Intervention arm will receive guidance within electronic health record from clinical decision support system.
88829837|NCT03679247|Experimental|Control|The control arm will continue to provide usual care.
88829838|NCT00540371||Port wine stain Birthmark|Port wine stain Birthmark
88829839|NCT03029767|Experimental|Aerobic exercise|Aerobic exercise training will be carried out as an intervention activity
88829840|NCT03029767|Experimental|Resistance exercise|Resistance exercise training will be conducted as an intervention activity
88829841|NCT03029767|Experimental|Aerobic and resistance exercise|Aerobic and resistance training will be implemented
88829842|NCT03029767|No Intervention|Control group|standard or usual activity carried out.Additional intervention will not be given.
88829843|NCT03676283|Experimental|Web-based psycho-educational support for family caregivers|Gaining access to the website (närstående.se) with supportive films and texts
89358650|NCT03316144|Experimental|3 mg/kg Toripalimab|humanized anti-PD-1 monoclonal antibody is to be injected intravenously 3mg/kg Q2w until disease progresses or unacceptable tolerability occurs
89358651|NCT03316144|Experimental|10 mg/kg Toripalimab|humanized anti-PD-1 monoclonal antibody is to be injected intravenously 10mg/kg Q2w until disease progresses or unacceptable tolerability occurs
89358652|NCT05527028|Placebo Comparator|Control group|Both groups will receive the standard care provided at the long-term care home. The intervention group will receive the addition of directed occupational therapy intervention provided by student occupational therapists for up to 30 minutes, five days a week. At present, no decisive evidence exists that this intervention being tested will be superior to the standard of care.
89358653|NCT05527028|Experimental|Intervention Group|Both groups will receive the standard care provided at the long-term care home. The intervention group will receive the addition of directed occupational therapy intervention provided by student occupational therapists for up to 30 minutes, five days a week. At present, no decisive evidence exists that this intervention being tested will be superior to the standard of care.
89358654|NCT01306799||Barrett's Esophagus, Erosive Esophagitis, GERD|
89358655|NCT01332162|Experimental|Biventricular pacing|All patients will be pacing during two years
89358656|NCT01332162|Active Comparator|No Pacing during the first year|No Pacing during the first year. In the second year all patients will be pacing
89358657|NCT02484196||Couples|Women, with their partners, referred to the Obstetrics and Gynecological Department of the University Hospital for surgical treatment of endometriosis.
89358658|NCT02484196||Women|Women referred to the Obstetrics and Gynecological Department of the University Hospital for surgical treatment of endometriosis.
89358659|NCT03435055|Experimental|Nitrous Oxide - inhaled|Each volunteer will participate in one scanning visit in which simultaneous functional magnetic resonance imaging (fMRI) and electroencephalogram (EEG) data will be collected wherein they receive placebo (20 minutes) followed by inhaled nitrous oxide at subanalgesic levels (35% inhaled concentration) over 40 minutes.
89358660|NCT01337622|Experimental|No routine check for gastric residuals|
89358661|NCT01337622|Active Comparator|Routine check for gastric residuals|
89358662|NCT02489656|Experimental|Coloplast Hydrocoated silicone JJ stent|Double loop ureteral stent endoscopic placement
88829844|NCT00702481|Experimental|Nimotuzumab/CDDP/RT|Open label treatment arm of Nimotuzumab and cisplatin and radiation
88829845|NCT02643875|Sham Comparator|Ortho-k lens with normal compression factor|The eye wears ortho-k lens with normal compression factor to achieve plano (+/- 0.25D) correction.
88829846|NCT02643875|Active Comparator|Ortho-k lenses with increased compression factor|The eye wears ortho-k lenses with increased compression factor to achieve 1 diopter (+/- 0.25D) over correction.
89358663|NCT02489656|Active Comparator|Boston Percuflex Plus JJ stent|Double loop ureteral stent endoscopic placement
89358664|NCT03788447|Experimental|High CO2 group|end tidal CO2 : 40-45 mmHg
89358665|NCT03788447|Placebo Comparator|Low CO2 group|end tidal CO2 : 30-35 mmHg
89358666|NCT03316066|Experimental|Group 5|stellate ganglion block with ropivacaine 0.2% 5 mL
88829847|NCT02645123|Experimental|Spinal mobilization|The individuals of the group received 5 treatments in total for 10 minutes that included: posterior to anterior spinal accessory mobilization passive physiological inter vertebral rotation The above was applied to the level that the MRI showed disc degeneration
89358667|NCT03316066|Active Comparator|Group 2|stellate ganglion block wit ropivacaine 0.2% 2 mL
89358668|NCT03716635|Experimental|cryotherapy|2.5c cold saline as a final flush after chemicomechanical debridement
89358669|NCT03716635|Other|normal saline|room temperature saline is used as a final flush after chemicomechanical preparation
89358670|NCT03315988|Experimental|Vegan diet|"Intervention Description and Definition The participants will be asked to follow a diet that excludes foods hypothesised to support the syntheses of TMAO, particularly meat (any), eggs and fish (any). A number of studies suggest that dairy products may also have an effect in modulating TMAO production whereas other studies do not. Therefore, in order to avoid any potential contaminating or confounding effect, dairy products will also be avoided.~The diet employed in this study is broadly aligned to a vegan diet. The term vegan will be used to aid behaviour change and food choice. For example, an increasing array of products are now pack marked as vegan. The participants will be asked to keep their diet similar to their original and the Registered Dietitian involved in this study will plan their weekly menus accordingly."
89358671|NCT05186298|Experimental|AcrySof® IQ PanOptix® (Alcon Laboratories, Inc., Fort Worth, TX)|The subject will be implanted bilaterally during cataract surgery
89358672|NCT05186298|Experimental|Synergy® (Johnson & Johnson Surgical Vision, Santa Ana, CA)|The subject will be implanted bilaterally during cataract surgery
88829848|NCT02645123|Sham Comparator|Sham Treatment|The investigator touched the skin overlying the low back statically for 10 minutes
89358673|NCT05695157|Experimental|Single arm|Closure of the abdomen after laparotomy with Suture-TOOL.
89358674|NCT03318016|Experimental|Cyclophosphamide|"Cohort -1: Cyclophosphamide 500 mg/m2~Cohort 1: Cyclophosphamide 1000 mg/m2~Cohort 2: Cyclophosphamide 2000 mg/m2~Cohort 3: Cyclophosphamide 3000 mg/m2~Cohort 4: Cyclophosphamide 4000 mg/m2"
89358675|NCT03434977|Experimental|TAK-536 10 mg (fasted) + TAK-536 10 mg (fed)|TAK-536 10 milligram (mg) granule formulation (pediatric formulation), once daily on Day 1 of Period 1 (6 days) in the morning under fasted condition, followed by wash-out (6 days), followed by TAK-536 10 mg granule formulation (pediatric formulation), once daily on Day 1 of Period 2 (6 days) after starting breakfast.
89358676|NCT03434977|Experimental|TAK-536 10 mg (fed) + TAK-536 10 mg (fasted)|TAK-536 10 mg granule formulation (pediatric formulation), once daily on Day 1 of Period 1 (6 days) after starting breakfast, followed by wash-out (6 days), followed by TAK-536 10 mg granule formulation (pediatric formulation), once daily on Day 1 of Period 2 (6 days) in the morning under fasted condition.
89358677|NCT01308515|Other|Posterior Stabilized|Patients who received a PS (Posterior Stabilized) Tibial Bearing.
89358678|NCT01308515|Other|Anterior Stablized|Patients who received an AS (Anterior Stabilized) Tibial Bearing
88829849|NCT02645123|Active Comparator|Classic Physiotherapy|This group received static hamstring stretch for 5 minutes, TENS (2 channels biphasic pulse, 90Hz, 100μs pulse width) for 20 minutes and 15 minutes of Swedish type massage (effleurage, petrissage, kneading)
88829850|NCT02646371|Active Comparator|Flexyn2a|2 doses of 10 μg of Flexyn2a will be injected intramuscularly 4 weeks apart
88829851|NCT02646371|Placebo Comparator|Placebo|2 doses of TBS solution will be injected intramuscularly 4 weeks apart
89000846|NCT04650763|Experimental|PRP Group|In this group Platelet Rich Plasma (PRP) was injected in soft tissue over surgical site.
89358679|NCT01335360||Subjects >80kg|As above
89000847|NCT04650139||successful CTO|
89358680|NCT01335360||Subjects <70kg|As above
89358681|NCT01335360||Subjects 70-80kg|As above
89358682|NCT02489890|No Intervention|Non-CIK|After accepting chemotherapy, patients will regularly follow up.
89358683|NCT02489890|Experimental|CIK|After accepting chemotherapy, patients will receive at least 3 cycles of Cytokine-induced Killer Cells treatment per year.
89358684|NCT03788057|Other|stable asthma|"In patients with previously stable course of the asthma, every 3 months the symptoms are evaluated and the dose of ICS is customized - in accordance with the GINA guidelines. This decision is based solely on clinical data (control of symptoms) and is the same as in patients not participating in the study.~In patients participating in the study, inflammatory parameters are also measured (sputum eosinophilia, eNO, EBT, bronchial reactivity), but results are not known to clinician taking decision about possible ICS dose reduction."
89358685|NCT01332240|Experimental|Endosonography|Endoscopic ultrasonography (EBUS-TBNA +/- EUS-FNA) for invasive mediastinal nodal staging
89358686|NCT02489266|Experimental|Arm 1|Patients will receive cyclophosphamide and fludarabine followed by infusion of the AKTi-treated TIL, followed by high dose aldesleukin.
88829852|NCT02646449|Active Comparator|Mirtazapine|Gelatin capsules mirtazapine 15 mg, 1 capsule every a.m. Medication will be increased by one capsule, to a dose of 2 capsules barring side effects, at Week 2.
88829853|NCT02646449|Placebo Comparator|Placebo|Gelatin capsules Placebo capsules, identical to mirtazapine capsules, 1 capsule every a.m. Medication will be increased by one capsule to 2 capsules at Week 2, barring any side effects.
89358687|NCT03785483|Experimental|Motivation|Using implementation intention techniques such as action planning. Every week, participants state when, where, and what kind of prescribed exercises they will do.
89358688|NCT03785483|Active Comparator|Mindfulness|10 minutes of audio recordings daily. Recordings contain: awareness of the breath, acceptation of thoughts and emotions, awareness of postures, awareness during stretching, awareness of a single movement (moving legs up while standing).
89358689|NCT03785483|No Intervention|Treatment as usual|Physical activity prescribe 120 minutes per week.
89358690|NCT03317938|Experimental|Fecobionics studies|
89358691|NCT01337778|Active Comparator|Primary Care for DILs|Primary care for DILs will be offered based on national and international standards and include access to critical support services for women who have experienced gender-based violence. A comprehensive health examination for mothers-in-law will include a gynecological exam and screening for diabetes and hypertension, along with appropriate information, prescriptions, and/or referrals. We will routinely offer GBV-related resources, such as information, counseling, and referrals to all participants. Referrals will be documented using a Referral Care Form and reviewed on a routine basis to ensure that appropriate care is being provided and to detect any potential study-related risks.
89358692|NCT01337778|Experimental|Standard Care plus Dil Mil Intervention|The Dil Mil intervention will be implemented during the second and third trimesters of the daughter-in-law's (DILs) pregnancy. It consists of 2 half-day group sessions with DILs, 5 half-day group sessions with mothers-in-law (MILs), and one joint half-day session with DILs and MILs. The sessions are based on participatory learning and action principles and use stories, role-play, and discussion to enhance participants' knowledge, skills, and social support. The DIL-MIL joint session ends in a short celebration (based on a traditional ritual) in which MILs bless their DILs, and the MIL sessions culminate in a ceremony in which MILs' position in the family and community is recognized and celebrated. MILs draw up a family health action plan and take a pledge to reduce gender-based violence (GBV) and protect and promote their family's health.
89534286|NCT03525418|Experimental|Cohort B - Phase 2 Treatment Group|Double-blinded, in which 20 HLHS patients will be randomized to either receive treatment with Longeveron Mesenchymal Stem Cells (LMSCs) (Cohort B, 10 patients) performed via intramyocardial injections during the Stage II (BDCPA) surgery, or will receive no cells and no injection (Cohort C, 10 patients) during the Stage II (BDCPA) surgery. The second stage is to obtain preliminary safety and efficacy data the will enable and guide a subsequent larger Phase 2 trial.
89534287|NCT03525418|No Intervention|Cohort C - Phase 2 Control Group|Double-blinded, in which 20 HLHS patients will be randomized to either receive treatment with Longeveron Mesenchymal Stem Cells (LMSCs) (Cohort B, 10 patients) performed via intramyocardial injections during the Stage II (BDCPA) surgery, or will receive no cells and no injection (Cohort C, 10 patients) during the Stage II (BDCPA) surgery. The second stage is to obtain preliminary safety and efficacy data the will enable and guide a subsequent larger Phase 2 trial.
89534288|NCT03473873||SHIELD|Patients with anterior cruciate ligament injury
89534289|NCT03410277|Experimental|All Subjects|Experimental hypoglycemia
88829854|NCT02646761|Experimental|Rehabilitation with InterACTION|After total knee arthroplasty, subjects will undergo physical therapy 1 time per week supplemented by home exercise program with InterACTION device.
88829855|NCT02646761|Other|Standard Physical Therapy|After total knee arthroplasty, subjects will undergo standard of care physical therapy 2 times per week with standard home exercise program.
89177811|NCT00807092|Experimental|BHI 30|BHI 30 (biphasic human insulin 30) administered subcutaneously (under the skin) twice daily (30 minutes before breakfast and dinner) + metformin. Initial total daily dose of 0.3 U or IU/kg body weight followed by individual dose adjustment for BHI 30 was performed over the first 4 weeks (titration period) to achieve the pre-meal blood glucose target of 4.4-6.1 mmol/l. The achieved dose was maintained for the last 2 weeks of treatment unless hypoglycaemia occurred.
88829856|NCT02646917|Active Comparator|SkinPen II|Three treatments using SkinPen II aesthetic microneedling device to each patient, with each treatment spaced one month apart.
88829857|NCT02646917|Active Comparator|SkinPen Precision|Three treatments using SkinPen Precision aesthetic microneedling device to each patient, with each treatment spaced one month apart.
89000848|NCT04650139||non- successful CTO|
89000849|NCT04649827||COVID-19|Patients with confirmed COVID-19 by RT-PCR or serological test
89177812|NCT00794118||1.0|As per routinary clinical practice
89177813|NCT02549872||Dementia|Patients with a recorded diagnosis of dementia in primary or secondary care
89177814|NCT02549872||Non-dementia|Patients without a recorded diagnosis of dementia in primary or secondary care
89177815|NCT04112550|Active Comparator|Methadone|This cohort will receive oral methadone 15mg po tablet pre-operatively
89177816|NCT04112550|Active Comparator|Oxycodone|This cohort will receive oxycodone/acetaminophen 10/325 po tablet pre-operatively
89177817|NCT00640042|Experimental|1|
89177818|NCT00807014|Experimental|Duac Gel|Duac Gel
89177819|NCT00807014|Active Comparator|Differin gel|Differin gel
89177820|NCT04830566|Experimental|Myofascial release technique group|
89177821|NCT04830566|Sham Comparator|Simulated myofascial release technique group|
88829858|NCT02650193|Experimental|HSP-130|"Cycle 0:~Regimen A: HSP 130, 3 mg, single SC injection in the deltoid region (n = 6) Regimen B: HSP 130, 6 mg, single SC injection in the deltoid region (n = 6)~Cycles 1-4:~Regimen B (n = 12): HSP 130, 6 mg, single SC injection in the deltoid region, at least 24 hours after administration of chemotherapy in Cycle 1, Cycle 2, Cycle 3, and Cycle 4.~Potential Regimen A (n = 12): 3 mg with background chemotherapy: Inclusion of this cohort will be based on assessment of comparability between Regimens A and B in Cycle 0 for ANC and CD34+ as defined above. If performed, this regimen will be HSP 130, 3 mg, single SC injection in the deltoid region, at least 24 hours after administration of chemotherapy in Cycle 1, Cycle 2, Cycle 3, and Cycle 4, as appropriate.~Conditional Regimen C (12 mg):This cohort will not be initiated until data from cycle 0 for 3 mg and 6 mg and Cycles 1-4 for 6 mg has been reviewed and analyzed."
88829859|NCT04339361|Experimental|lidocaine spray|four puffs (50ml, 10 mg/puff) of lidocaine spray will be applied to the cervical canal and cervix before tenaculum placement plus vaginal placebo will be given 3 hours before IUD insertion
88829860|NCT04339361|Active Comparator|vaginal dinoprostone|vaginal dinoprostone 3 mg will be given 3 hours before IUD insertion plus four puffs of saline spray will be applied to the cervical canal and cervix before tenaculum placement
88829861|NCT04339361|Placebo Comparator|placebo|vaginal placebo will be given 3 hours before IUD insertion plus four puffs of saline spray will be applied to the cervical canal and cervix before tenaculum placement
88829862|NCT02652221|Experimental|Study cohort|Acoustic Radiation Force Imaging
88829863|NCT04340297|Experimental|Experimental group|Tongjiang granules are taken orally in liver-stomach depression-heat syndrome, Jianpi Qinghua granules are taken orally in spleen deficiency damp-heat syndrome, Wenpi Qingwei granules are taken orally in cold-heat complicated syndrome, one bag per time, 3 times a day and 1 hour after a meal. At the same time, it was combined with acid inhibitors to reduce the steps of withdrawal treatment: in the 1-2 weeks, acid inhibitor (PPI) was reduced from the dose before entering the group to half of the dose, once a day, before going to bed; in the 3-4 weeks, acid inhibitor was changed from PPI to famotidine tablets, 20mg each time, before going to bed; in the 5-6 weeks, all acid inhibitors were stopped.
88829864|NCT04340297|Placebo Comparator|Control group|Tongjiang placebo granules are taken orally by patients with liver-stomach depression-heat syndrome, Jianpi Qinghua placebo granules are taken orally by patients with spleen deficiency damp-heat syndrome, Wenpi Qingwei placebo granules are taken orally by patients with cold-heat complicated syndrome, 1 bag per time, 3 times a day and 1 hour after a meal. At the same time, it was combined with acid inhibitors to reduce the steps of withdrawal treatment: in the 1-2 weeks, acid inhibitor (PPI) was reduced from the dose before entering the group to half of the dose, once a day, before going to bed; in the 3-4 weeks, acid inhibitor was changed from PPI to famotidine tablets, 20mg each time, before going to bed; in the 5-6 weeks, all acid inhibitors were stopped.
88829865|NCT02653391|Experimental|Elamipretide 1.0% Ophthalmic Solution Part A (Cohort 1)|Part A Each subject will receive one drop of elamipretide 1.0% ophthalmic solution BID in the randomly selected study eye (Cohort 1).
88829866|NCT02653391|Experimental|Elamipretide 3.0% Ophthalmic Solution Part B (Cohort 2)|Part B Each subject will receive one drop of elamipretide 3.0% ophthalmic solution BID in both the right and left study eyes (Cohort 2).
88829867|NCT02653391|Placebo Comparator|Placebo A|Part A: Each subject will receive one drop of vehicle solution BID in the paired eye of the randomly selected study eye (Cohort 1).
88829868|NCT02653391|Placebo Comparator|Part B Placebo|Part B Each subject will receive one drop of vehicle solution BID in both the right and left study eyes (Cohort 2).
88829869|NCT05288309|Other|RAİNSTİCK|In the 1st experimental group, the sound of the rain stick was played to distract attention. The rainstick, used by traditional societies, is a rhythm instrument that makes the sound of rain by moving it up and down. The length of the rain stick made of bamboo is 40 cm. There are spiral-shaped spines inside the tool, which is closed at both ends. It makes the sound of drizzling rain by moving it up and down.
88829870|NCT05288309|Other|KALEİDOSCOPE|In the second experimental group, kaleidoscope was used to distract attention. A kaleidoscope, or kaleidoscope, is a device that sees colorful patterns when looked into. Inside, there are three mirrors adjacent to each other with an inclination of 60 degrees between them. There are pieces of colored glass between the mirrors. When viewed from one end of this binocular, shape-shifting polygons are seen, often with images that will never be the same again. These patterns are created by the reflection of light and change constantly as the binoculars are moved.
88829871|NCT02654483|Experimental|5 mg VPD-737|5 mg tablets of VPD-737 to be taken daily by mouth for 56 days
88829872|NCT02654483|Placebo Comparator|Placebo|Placebo tablets to be taken daily by mouth for 56 days
88829873|NCT03237845|Experimental|Rimegepant 75 mg|Participants were administered a single oral dose of 75 mg of rimegepant tablet on occurrence of migraine that reached moderate or severe intensity up to 45 days after randomization.
88829874|NCT03237845|Placebo Comparator|Placebo|Participants were administered a single oral dose of matching placebo tablet for rimegepant (75 mg) on occurrence of migraine that reached moderate or severe intensity up to 45 days after randomization.
88829875|NCT02655653|Experimental|Epsilon-aminocaproic acid (EACA)|Epsilon-aminocaproic acid administered following anesthetic induction: EACA was administered as a bolus loading dose of 150 mg/ kg followed by a maintenance infusion of 15 mg/ kg /hr.
88829876|NCT02655653|Experimental|Tranexamic acid (TA)|Tranexamic Acid administered following induction: TA was administered as a bolus dose of 30 mg /kg followed by a 16 mg/ kg/hour maintenance infusion.
88829877|NCT02656745|Experimental|Mobile Smoking Cessation Solution|Subjects download & use the mobile application.
88829878|NCT03081143|Experimental|FOLFIRI plus Ramucirumab|Ramucirumab 8 mg/kg i.v. infusion on day 1 and 15 of a 28-day cycle plus FOLFIRI (Irinotecan 180 mg/m2; i.v. bolus of 5-FU 400 mg/m2, i.v. infusion of leucovorin 400 mg/m2 , followed by a 46-hour continuous administration of 5-FU 2400 mg/m2 on day 1 and 15 of a 28-day cycle)
88829879|NCT03081143|Active Comparator|Paclitaxel plus Ramucirumab|Ramucirumab 8 mg/kg i.v. infusion on day 1 and 15 of a 28-day cycle plus Paclitaxel 80 mg/m2 on day 1, 8, 15
89000850|NCT04650022||TPCIV-ABAO|TPCIV-ABAO
89358693|NCT03787979|Experimental|Lumbopelvic stiffening technique|Hamstring muscle stretching with lumbopelvic stiffening technique.
89358694|NCT03787979|Active Comparator|Lumbopelvic relaxing technique|Hamstrings muscle stretching with lumbopelvic relaxing technique.
89358695|NCT03434119|Experimental|Soliqua 100/33|Soliqua 100/33 (Insulin glargine/lixisenatide) once daily in the morning within 1 hour before breakfast, on top of oral anti-diabetic drug (OAD) therapy for 26 weeks.
89358696|NCT03434119|Active Comparator|Lantus|Lantus (Insulin glargine) once daily at any time of the day but at about the same time every day on top of OAD therapy for 26 weeks.
89358697|NCT02484352|Other|0 mg/kg of oxycodone|Intervention: patients receive 10 ml of normal saline without oxycodone through intravenous route before intubation.
89358698|NCT02484352|Other|0.05 mg/kg of oxycodone|Intervention: patients receive 10 ml of fluid with 0.05 mg/kg of oxycodone in normal saline through intravenous route before intubation.
89358699|NCT02484352|Other|0.1 mg/kg of oxycodone|Intervention: patients receive 10 ml of fluid with 0.1 mg/kg of oxycodone in normal saline through intravenous route before intubation.
89358700|NCT02484352|Other|0.15 mg/kg of oxycodone|Intervention: patients receive 10 ml of fluid with 0.15 mg/kg of oxycodone in normal saline through intravenous route before intubation.
89358701|NCT02484352|Other|0.2 mg/kg of oxycodone|Intervention: patients receive 10 ml of fluid with 0.2 mg/kg of oxycodone in normal saline through intravenous route before intubation.
89358702|NCT05186220|Experimental|Cardioneuroablation|After 3D mapping of the surface of the left and right atrium and the superior vena cava (Ensite Navx or Carto system), localization of ganglion plexus (GP) will be performed either anatomically and/or by means of high frequency stimulation (HFS). The anterior and superior right sided GP will always be ablated per protocol. Other GP will be ablated according to interventional electrophysiologist judgement. The endpoint of the ablation procedure will be 1) absence of a vagal response after HFS from the right jugular vein and 2) an increase in at least 10 bpm as compared to baseline.
89358703|NCT05186220|Active Comparator|Permanent pacemaker implantation|A dual chamber pacemaker implantation will be performed. The device will be programmed in a AAI-DDDR mode to avoid unnecessary ventricular pacing.
89358704|NCT02484274|Other|infants followed by pediatrician|
89358705|NCT02489188||ankle osteoarthritis|patients with ankle osteoarthritis scheduled for arthroplasty
89358706|NCT02489188||knee osteoarthritis|patients with knee osteoarthritis scheduled for arthroplasty
89358707|NCT02489188||hip osteoarthritis|patients with hip osteoarthritis scheduled for arthroplasty
89358708|NCT02489188||lumbar spinal stenosis|patients with lumbar spinal stenosis scheduled for lumbar spinal stenosis decompression
88829880|NCT02657915|Placebo Comparator|Placebo|This was a follow-up study, investigational product was administered in the previous study. Participants in the placebo arm have received at least 1 dose of placebo.
88829881|NCT02657915|Experimental|BIIB033 100mg/Kg|This was a follow-up study, investigational product was administered in the previous study. Participants in the BIIB033 arm have received at least 1 dose of 100 mg/kg BIIB033.
88829882|NCT02658461||Trastuzumab IV Infusion|Participants with HER2-positive EBC will be evaluated for the costs and other factors associated with health care utilization with the administration of trastuzumab via IV infusion.
89358709|NCT02489188||muscle contracture|patients with functionally limited range of motion at the knee because of muscle contracture scheduled for manual therapy
89358710|NCT02489188||healthy subjects|healthy subjects
89358711|NCT01308593|Active Comparator|Juvederm XC|Juvederm XC
89358712|NCT01308593|Active Comparator|Botox|Medication used to block neuromuscular transmission
89358713|NCT03716557|Experimental|Spinal Cord Stimulation 4000Hz|Patients will trial Spinal Cord Stimulation 4000Hz for 4 weeks. PET/CT scan will be conducted at the end of this period.
89358714|NCT03716557|Experimental|Spinal Cord Stimulation 10000Hz|Patients will trial Spinal Cord Stimulation 10,000Hz for 4 weeks. PET/CT scan will be conducted at the end of this period.
88829883|NCT02658461||Trastuzumab SC Single-Use Injection Device|Participants with HER2-positive EBC will be evaluated for the costs and other factors associated with health care utilization with the administration of trastuzumab via SC single-use injection device.
88829884|NCT02658461||Trastuzumab SC Vial/Syringe|Participants with HER2-positive EBC will be evaluated for the costs and other factors associated with health care utilization with the administration of trastuzumab via SC vial/syringe.
88829885|NCT02658851|Experimental|J-Plasma|Enrolled participants will have their PLND performed using J-Plasma® for dissection and sealing of lymphatic channels.
88829886|NCT03069521|Other|EndoArt®|EndoArt® Artificial Endothelial Layer
88829887|NCT02653079||Study Cohort|Blood draw and Questionaire from patients suffering from chronic inflammatory diseases of the joints, namely painful shoulder syndrome (periarthritis humeroscapularis), painful elbow syndrome (Epicondylopathia humeri), benign achillodynia, and benign calcaneodynia, Arthrosis (finger- and Rhizarthrosis, Gonarthrosis, Anklearthrosis), and Arthritis with an planned local low dose radiation therapy (LDRT) at the Department of Radiation Oncology, Universitätsklinikum Erlangen.
88829888|NCT04739501||TACE in HCC group 1|the patient did undergo tace
89358715|NCT03716557|Active Comparator|Spinal Cord Stimulation 40Hz|Patients will trial Spinal Cord Stimulation 10,000Hz for 4 weeks. PET/CT scan will be conducted at the end of this period.
89358716|NCT01308671|Active Comparator|varenicline|On 3 day after received clopidogrel 75mg/day, Varenicline group will be administered with varenicline 0.5mg Qd,after 3 days, 0.5mg Bid,after 7days,1mg Bid .And received counseling and psychosocial support.
89358717|NCT01308671|Other|Blank|Blank group will be only administered with Counseling and psychosocial support,beside antiplatelet etc.conventional therapy for 14 days.
89358718|NCT02484118|Experimental|Targeted blood flow rate 320 ml/min|Hemodialysis blood flow will be targeted at 320 ml/min during hemodialysis for two weeks
89358719|NCT02484118|Experimental|Targeted blood flow rate 380 ml/min|Hemodialysis blood flow will be targeted at 380 ml/min during hemodialysis for two weeks
89358720|NCT00378378|Experimental|MFNS 100 mcg QD for subjects 6 to less than 12 years|Mometasone Furoate nasal Spray (MFNS) 100 mcg once per day (QD) for subjects 6 to less than 12 years of age
89358721|NCT00378378|Placebo Comparator|Placebo QD for subjects 6 to less than 12 years|
89358722|NCT00378378|Experimental|MFNS 200 mcg QD for subjects 12 to less than 18 years|
89358723|NCT00378378|Experimental|MFNS 200 mcg BID for subjects 12 to less than 18 years|
89358724|NCT00378378|Placebo Comparator|Placebo QD for subjects 12 to less than 18 years|
89358725|NCT00378378|Experimental|MFNS 100 mcg BID for subjects 6 to less than 12 years|
88829889|NCT02659709||Glaucoma Patients and Caregivers|Glaucoma patients and caregivers will complete a 20 item questionnaire providing demographic information, glaucoma eye drop compliance, interest in medication reminders, availability to smartphone, tablet and social media technology and interest in using a glaucoma application on social media.
88829890|NCT02659787|Active Comparator|Low dose buprenorphine|Subjects all receive placebo, 0.2 mg buprenorphine in crossover design
88829891|NCT02659787|Placebo Comparator|Placebo|Subjects all receive placebo, 0.2 mg buprenorphine in crossover design
88829892|NCT02660801|Experimental|Spinal manipulation|Twenty-six participants with chronic nonspecific back pain will participate in two experimental sessions. During the first session, each participant will received either a spinal manipulation of a spinal mobilization of their thoracic spine preceded and followed by the assessment of their thoracic spine stiffness. The second session (24 to 48h after) will be identical but with the other experimental condition (spinal manipulation or spinal mobilization).
88829893|NCT02660801|Experimental|Spinal mobilization|Twenty-six participants with chronic nonspecific back pain will participate in two experimental sessions. During the first session, each participant will received either a spinal manipulation of a spinal mobilization of their thoracic spine preceded and followed by the assessment of their thoracic spine stiffness. The second session (24 to 48h after) will be identical but with the other experimental condition (spinal manipulation or spinal mobilization).
88829894|NCT02661737||YVOIRE volume s|Treatment with YVOIRE volume s
88829895|NCT05044871|Experimental|Arm 1: Pamiparib+ Bevacizumab|Arm1 (Pathological classification: Serous, Endometrioid, and Clear cell Ovarian cancer; Biomarkers: BRCA 1/2 mutant): Pamiparib 40mg PO. bid. plus Bevacizumab 7.5mg/kg IV. D1 (q3w.).
88829896|NCT05044871|Experimental|Arm 2: Tislelizumab + Bevacizumab + Nab-paclitaxel|Arm2 (Pathological classification: Serous, Endometrioid, and Clear cell Ovarian cancer; Biomarkers: BRCA 1/2 wildtype and ≥3 CD8+ TILs count): Tislelizumab 200mg IV. D1 + Bevacizumab 7.5mg/kg IV. D1 + Nab-paclitaxel 125mg / m2 IV. D1, 8 (q3w).
88829897|NCT05044871|Experimental|Arm 3: Bevacizumab + Nab-paclitaxel|Arm3 (Pathological classification: Serous, Endometrioid, and Clear cell Ovarian cancer; Biomarkers: BRCA 1/2 wildtype and <3 CD8+ TILs count): Bevacizumab 7.5mg/kg IV D1, 15 + Nab-paclitaxel 100mg / m2 IV D1, 8, 15 (Q4w).
88829898|NCT05044871|Experimental|Arm 4: Tislelizumab + Bevacizumab + Nab-paclitaxel|Arm4 (Pathological classification: Mucinous Ovarian cancer, Ovarian carcinosarcoma; Biomarkers: ≥3 CD8+ TILs count): Tislelizumab 200mg IV D1 + Bevacizumab 7.5mg/kg IV D1 + Nab-paclitaxel 125mg / m2 IV D1, 8 (q3w).
88829899|NCT05044871|Experimental|Arm 5: Bevacizumab + Nab-paclitaxel|Arm5 (Pathological classification: Mucinous Ovarian cancer, Ovarian carcinosarcoma; Biomarkers: <3 CD8+ TILs count: Bevacizumab 7.5mg/kg IV. D1, 15 + Nab-paclitaxel 100mg / m2 IV. D1, 8, 15 (Q4w).
88829900|NCT05009849|Experimental|Exercise I|Yogic and Routine Exercises (referred to as exercise I) Phase I: 1-7 days (Minimum attendance 4 days), Phase II: 8 - 14 days (Minimum attendance 4 days), Phase III: at 6-9 months or 12-15 months 1 year up gradation of exercises at 6-9 month or 12-15 months 1 year (Depending upon compliance to phase II exercises) Objective assessment at baseline, 14 days, 6-9, 12-15, 18-21, 36-39 and 54-57 months Exercise evaluation will be done at 6-9, 12-15, 30-33, 48-51 and 66-69 months
88829901|NCT05009849|Active Comparator|Exercise II|Objective assessment at baseline, 14 days, 6-9, 12-15, 18-21, 36-39 and 54-57 months
88829902|NCT01643850|Experimental|MCS110|Participants will receive a single dose of 10mg/kg on day 1 administered by regular infusion.
88829903|NCT01643850|Placebo Comparator|Placebo|Part A: single-dose placebo to match MCS110 (10 mg/kg, 1 h i.v. infusion) Part B: single dose placebo to match MCS110 (10 mg/kg, 1 h i.v. infusion administered i.v. at Day 1, followed by 6 doses of placebo to match MCS110 (10 mg/kg)
88829904|NCT01643850|Experimental|MCS110 3 mg/kg|Part C: MCS110 3 mg/kg (i.v. infusion)
88829905|NCT01643850|Experimental|MCS110 5 mg/kg|Part C: MCS110 5 mg/kg (i.v. infusion)
88829906|NCT01643850|Experimental|MCS110 10 mg/kg|Part C: MCS110 10 mg/kg (i.v. infusion)
88829907|NCT01643850|Experimental|MCS110 3 mg/kg & MCS110 10mg/kg|Part C: MCS110 3 mg/kg (i.v. infusion) & MCS110 10 mg/kg (i.v. infusion)
88829908|NCT01643850|Experimental|MCS110 5 mg/kg & MCS110 10mg/kg|Part C: MCS110 5 mg/kg (i.v. infusion) & MCS110 10 mg/kg (i.v. infusion)
88829909|NCT04931693|Active Comparator|control|conventional control group(C) (n=20) where20 children will receive IV paracetamol 20 mg / kg and atracurium top ups at a dose of 0.1mg/kg. every 30 minutes.
88829910|NCT04931693|Active Comparator|PECs|Pectoral nerves blocks group (P) (n=20) where 20 children will have PECs Block and atracurium top ups upon request.
88829911|NCT03662633||Breast cancer group|Patients who have histologically confirmed new diagnosis of breast cancer are recruited.
89534290|NCT03374085|Experimental|Administration of CC-92480 in combination with dexamethasone|Part 1: Escalating doses of CC-92480 plus a fixed dose of dexamethasone Part 2: RP2D of CC-92480 in combination with dexamethasone
88829912|NCT03662633||Benign breast tumor group|Patients who have histologically confirmed new diagnosis of benign breast tumors are recruited.
88829913|NCT04340453|Active Comparator|Group 1 (Hip and Knee Exercise Program)|Standard exercise physiotherapy treatment of a Hip and Knee Exercise Program plus stretching.
88829914|NCT04340453|Experimental|Group 2 (BFR-training hip and knee exercise group)|BFR-training hip and knee exercise group plus stretching.
88829915|NCT04866641|Experimental|T-1201 Injection 100 mg Kit|T-1201 Injection 100 mg Kit will be administered via intravenous infusion once every 4 weeks. T-1201 Injection 100 mg Kit is required to be reconstituted with its specific Injection Diluent supplied in the kit, then further diluted with 5% Dextrose solution prior to the intravenous infusion in patients.
88829916|NCT02271594|Active Comparator|Intervention|Intensive education on injection technique
88829917|NCT02271594|Placebo Comparator|Control|Standard education on injection technique
88829918|NCT04879212|Experimental|PCIA +Acupuncture group|Acupuncturing bilateral Zusanli (ST36) and Sanyinjiao (SP6) to connect Huatuo brand electroacupuncture apparatus, but no electricity. Acupuncture was given once a day. PCIA（patient controlled intravenous analgesia）.
89358726|NCT00378378|Placebo Comparator|Placebo BID for subjects 6 to less than 12 years|
89358727|NCT00378378|Placebo Comparator|Placebo BID for subjects 12 to less than 18 years|
89358728|NCT03720457|Experimental|Human CD19 targeted T Cells Injection|
88829919|NCT04879212|Experimental|PCIA +2 Hz Electroacupuncture group|Acupuncture bilateral Zusanli (ST36) and Sanyinjiao (SP6) to connect Huatuo brand electroacupuncture apparatus, and the ipsilateral Zusanli, Sanyinjiao were respectively connected as a loop. The parameters of electroacupuncture were set as 2Hz, continuous wave, 25min, and current intensity was 0.1-5.0mA. Acupuncture was given once a day.
89358729|NCT01306955|Active Comparator|methylprednisolone|patients who received methylprednisolone
89358730|NCT01306955|Placebo Comparator|dextrose water 5%|patients who received dextrose water 5% as placebo
89358731|NCT03315676|Active Comparator|Oral Bonoprazan|Daily intake of Bonoprazan
89358732|NCT03315676|Active Comparator|Oral Esomeprazol|Daily intake of Esomeprazol
89358733|NCT01335438|Experimental|Cementless Nexgen CR|Cementless fixation of Nexgen CR TKR
89358734|NCT01335438|Active Comparator|Cemented Nexgen CR|Cemented fixation of Nexgen CR TKR
89358735|NCT01307189|Active Comparator|Tiotropium|
89358736|NCT01307189|Placebo Comparator|Placebo|
88829920|NCT04879212|Experimental|PCIA +20/100 Hz Electroacupuncture group|Acupuncture bilateral Zusanli (ST36) and Sanyinjiao (SP6) to connect Huatuo brand electroacupuncture apparatus, and the ipsilateral Zusanli, Sanyinjiao were respectively connected as a loop. The parameters of electroacupuncture were set as 20 / 100Hz, density wave, 25min, and current intensity was 0.1-5.0mA. Acupuncture was given once a day.
88829921|NCT02664311|Placebo Comparator|Conventional Ventilation|Patients receiving conventional ventilation for the duration of this study
89358737|NCT03720379|Active Comparator|Fluoride Varnish - Fluor PROTECTOR S|"Fluor Protector S - manufacturer: Ivoclar Vivadent Composition: ethanol, water, polymer, saccharin, mint flavor, 1.5% ammonium fluoride (7700 ppm fluoride), additional ingredients~APPLICATION OF Fluor Protector S will be performed AT BASELINE, after 3,6 months (control 1) and after 9 and 12 months (control 2). Preliminary(AT BASELINE) and control dental exams after 12 months will include an interview and a physical examination, radiological and Diagnodent examination, a 6 months follow-up -a physical examination, Diagnodent examination and interview."
89358738|NCT03720379|Placebo Comparator|PLACEBO|"- Placebo - manufacturer: Ivoclar Vivadent Composition: ethanol, water, polymer, saccharin, mint flavor.~APPLICATION OF PLACEBO will be performed AT BASELINE, after 3,6 months (control 1) and after 9 AND 12 months (control 2). Preliminary(AT BASELINE) and control dental exams after 12 months will include an interview and a physical examination, radiological and Diagnodent examination, a 6 months follow-up -a physical examination, Diagnodent examination and interview."
89358739|NCT02486458|No Intervention|Negative control|No treatment will be applied
89358740|NCT02486458|Experimental|Varnish 4 h|Fluoride varnish will be applied on teeth and removed after 4 hours
89358741|NCT02486458|Experimental|Varnish 24 h|Fluoride varnish will be applied on teeth and removed after 24 hours
89358742|NCT02486458|Experimental|Fluoride Gel|Fluoride gell will be applied on teeth and removed after 4 minutes
89358743|NCT01307345|No Intervention|Monitoring Alone|Research assistants will phone or text participants and request videorecordings of breathalyzer samples up to 21 times per week. Participants will receive compensation for each valid videorecording that occurs within the requested one-hour time frame, and bonus compensation each time all requested videorecordings are submitted within the timeframe over a 7-day period, and/or if >90% of prompts are returned over the study period.
89358744|NCT01307345|Experimental|Monitoring plus contingency management for abstinence|Participants assigned to this condition will receive the same monitoring schedule outlined above, plus the same payment for compliance. In addition, they will receive contingent reinforcement for submission of videorecordings that demonstrate negative breath alcohol samples. For each sample submitted that reads below the cut point, participants will receive vouchers for payment.
88829922|NCT02664311|Active Comparator|Jet Ventilation|Patients receiving Jet ventilation while under general anesthesia and during mapping and ablation in the left atrium
89000851|NCT04650061|Experimental|PIMA Group|"MEntA: Educational & Training Program~Stratification: Identification of Personal Variables (Age, Level of study, Work status, preference of care attention, digital behaviour)~Adherence evaluation: Evaluation of Perceived Competence, Quality of Life, Mood, Activities, Social relations and Social Support~Identification of Care plan and Schedule next visits~Follow-up D21-D90-D120-D180 depending of the care plan, through the channel that belong for each care plan"
89358745|NCT03720301|Experimental|Treatment|Study arm who will receive pre operative and intraoperative treatments intended to effect POST severity.
89358746|NCT03720301|Sham Comparator|Sham|Sham are who will receive a preoperative treatment not intended to effect POST outcomes.
89358747|NCT03317704|Active Comparator|speed endurance training (SET)|Training 6 weeks 3 times pr. week
89358748|NCT03317704|No Intervention|Controls|Asked to continue their usual life style
89358749|NCT03317704|Active Comparator|speed endurance training (SET) II|Training 6 weeks 3 times pr. week
88829923|NCT02535923|Experimental|Cognitive Behavioral Therapy-Insomnia|CBT-I addresses cognitive, arousal and behavioral factors related to sleep difficulties. Sessions combine assessment, conceptualization, psychoeducation, behavioral strategies and cognitive therapy, using a consistent structure including review of participants' sleep log and adherence to behavioral guidelines, modification of time in bed, cognitive therapy, and relaxation techniques. CBT-I also incorporates psychoeducation about biological and psychological elements that regulate sleep. Other strategies include stimulus control (i.e., getting out of bed when not sleepy) to extinguish the conditioned arousal common in insomnia, and relaxation techniques to reduce arousal associated with the bed, bedroom, or bedtime.
89000852|NCT04650061|Active Comparator|Control|"Training program~Schedule next visits~Follow-up D21-D90-D120-D180 using the same process: visit at home or phone."
89000853|NCT04649554|Experimental|Experimental: ExAblate 4000 System|Exablate treatment on Neuropathic Pain
89000854|NCT04649437|Other|Symptomatic patients|Subjects with symptoms of atrial fibrillation i.e. AF-6 sum score 30 points or more.
89358750|NCT05694923|No Intervention|life style modification and diet control|40 patient of non alcoholic fatty liver patients and non diabetic only receive life style modification and diet control
89358751|NCT05694923|Experimental|empaglifizon 10 mg plus life style and diet control|40 patient of non alcoholic fatty liver patients and non diabetic Will receive empaglifizon in minimum dose 10 mg in addition to life style modification and diet control
89358752|NCT03490981|Other|Treatment as usual (TAU) only|Primary care treatment as usual
89358753|NCT03490981|Experimental|Treatment as usual (TAU) plus Brief Cognitive Behavioral Therapy for Chronic Pain (Brief CBT-CP)|Primary care treatment as usual and Brief CBT-CP
89358754|NCT02483806|Experimental|PEEP 0 cmH2O|PEEP 0 cmH2O (zero end expiratory pressure, ZEEP)
89358755|NCT02483806|Experimental|PEEP 5 cmH2O|
89358756|NCT02483806|Experimental|EEP 10 cmH2O|
89358757|NCT01332396||Patients prescribed TYKERB|Patients with HER2 overexpressing inoperable or recurrent breast cancer
89358758|NCT03787667||Patients with pathologically diagnosed colorectal cancer|Patients with pathologically diagnosed colorectal cancer
88829924|NCT02535923|Active Comparator|Health and Wellness|Health and Wellness is a general self-management curriculum focused on providing education and support for managing physical and emotional well-being. Each session follows a basic structure including review of previous session material, new educational information and discussion on several topics over the course of single or multiple sessions. Each session will focus on the impact of the topic on overall health and wellness, identifying benefits and challenges to improving or maintaining health in that area, and strategies that clients may find helpful to address challenges in that area. Example topics include physical activity/exercise, nutrition/healthy eating, managing medications and side effects, and addictive behaviors (e.g., substance use, gambling, eating).
88829925|NCT04769921||All-on-4 TiUltra and Xeal|Patients rehabilitated in the edentulous maxilla or mandible with an implant supported prosthesis through the All-on-4 Concept (2 anterior implants in the axial position and 2 posterior implants inserted with distal tilting). The implants used will be NobelParallel Conical Connection, with TiUltra surface. The abutments used will be Multi-unit abutments of internal connection with Xeal surface. The immediate prosthesis will be a high-density acrylic and 4 titanium cylinders. The definitive prosthesis will be a Titanium infrastructure with acrylic resin artificial gingiva and either acrylic or ceramic crowns.
88829926|NCT02350517|Experimental|Paclitaxel+Nedaplatin+Endostar|Patients will receive chemotherapy every 3 weeks: Paclitaxel 175mg/m2 IV over 3 hours on Day 4; Nedaplatin 80mg/m2 IV over 1 hours on Day 4; Endostar 3mg/day for 14 days continuous infusion from Day 1 to Day 14.
88829927|NCT02270736|Experimental|Double-blind MP: Placebo (Age 6 to 17 Years)|Participants will receive placebo via bilateral intraglandular injection into the parotid and submandibular glands in one injection session on Day 1 (Visit 2) of the MP, followed by an observation period of 16 weeks. Volumes will be matched to the volumes of NT 201 (incobotulinumtoxinA; Xeomin) injected in the experimental arm.
88829928|NCT02270736|Experimental|Double-blind, MP: NT 201 (Age 6 to 17 Years)|Participants will receive NT 201 (up to 2.5 Units per kilogram [U/kg] body weight) via bilateral intraglandular injection into the parotid and submandibular glands in one injection session on Day 1 (Visit 2) of the MP, followed by an observation period of 16 weeks.
88829929|NCT02270736|Experimental|Open-label, MP: NT 201 (Age 2 to 5 Years)|Participants will receive NT 201 (about 1.5-2 U/kg body weight) via bilateral intraglandular injection into the parotid and submandibular glands in one injection session on Day 1 (Visit 2) of the MP, followed by an observation period of 16 weeks.
88829930|NCT02270736|Experimental|OLEX: NT 201 (Age 6 to 17 Years)|"Participants will receive NT 201 (up to 2.5 U/kg body weight) via bilateral intraglandular injection into the parotid and submandibular glands on Day 1 of second (Visit 6), third (Visit 10), and fourth (Visit 14) injection cycle of the OLEX, followed by an observation period of 16 weeks each (48 weeks in total). This arm will consist of participants who will participate in MP arms Double-blind, MP: placebo (age 6 to 17 years) and Double-blind, MP: NT 201 (age 6 to 17 years)."
89000855|NCT04649437|Other|Asymptomatic patients|Subjects with no symptoms of atrial fibrillation i.e. AF-6 sum score = 0.
89358759|NCT03321214|Experimental|Light use of Nima|Ten participants will be randomized to receive 12 capsules every other month (18 capsules for the 3 months which is considered light use).
89358760|NCT03321214|Experimental|Moderate use of Nima|Ten participants will be randomized to receive 12 capsules per month (36 capsules for the 3 months which is considered moderate use).
89358761|NCT03321214|Experimental|Heavy use of Nima|Ten participants will be randomized to receive 24 capsules per month (72 capsules for the 3 months which is considered heavy use).
89358762|NCT01332474||JCP|treatment of Equinus Foot due to Lower Limb Spasticity in Juvenile Cerebral Palsy Patients Aged 2-year or Older
89358763|NCT03787823|Other|Retzius-sparing RARP|Arm B randomizes men with an indication for radical robotic Prostatectomy (RARP) to retzius-sparing transdouglas RARP
89358764|NCT03787823|Other|anterior transperitoneal RARP|Arm A randomizes men with an indication for radical robotic Prostatectomy (RARP) to anterior transperitoneal RARP
89358765|NCT03719053|Experimental|Truvada|single oral dose of Truvada® (300 mg tenofovir disoproxil fumarate)
89358766|NCT03788135|Experimental|Quadriceps cooling|Participants in this group will receive a cold pack on anterior thigh muscles for 20 minutes.
89534291|NCT03374085|Experimental|Administration of CC-92480 monotherapy|Escalating doses of CC-92480 Monotherapy administered according to different dosing schedules
89534292|NCT03369223|Experimental|Part 1A: BMS-986249|
89534293|NCT03369223|Experimental|Part 1B: BMS-986249 + nivolumab (nivo)|
89000856|NCT04649281|Other|Accelerometry|Recording of sleep and physical activity by accelerometry during one week.
89000857|NCT04638556||Normal|A healthy, disease-free population.
89358767|NCT03788135|Experimental|Hamstring cooling|Participants in this group will receive a cold pack on posterior thigh muscles for 20 minutes.
89358768|NCT03788135|Experimental|Calf cooling|Participants in this group will receive a cold pack on posterior leg muscles for 20 minutes.
89358769|NCT03788135|Experimental|Back cooling|Participants in this group will receive a cold pack on posterior low back muscles for 20 minutes.
89358770|NCT03788135|No Intervention|Control|The participants in the control group will be rested for 20 minutes without any intervention.
89358771|NCT03526848|Experimental|Group 1|HIV infected participants on ART will undergo analytical treatment interruption 2 days after the first infusion of 3BNC117 and 10-1074, and will receive 6 additional infusions of both antibodies at weeks 2, 4, 8, 12, 16 and 20 (Part A). Participants will remain off ART until week 38, if viral suppression is maintained (Part B).
89534294|NCT03369223|Experimental|Part 2A Arm C: BMS-986249 + nivo|Previously untreated unresectable stage III-IV melanoma
89534295|NCT03369223|Experimental|Part 2A Arm D: ipilimumab + nivo then nivo|Previously untreated unresectable stage III-IV melanoma
89358772|NCT03526848|Experimental|Group 2|HIV infected participants on ART will remain on ART and will be administered seven infusions of 3BNC117 and 10-1074 at weeks 0, 2, 4, 8, 12, 16 and 20 (Part A). Analytical treatment interruption will begin at week 26 until week 38, if viral suppression is maintained (Part B).
89358773|NCT02486536|Active Comparator|Group A|Fast for 12h before the examination and take 8ml of Simethicone Emulsion (Berlin-Chemie, Germany, containing 40 mg simethicone in 1mL emulsion) with 250ml water 30min before capsule ingestion.CE are performed with the Pillcam SB2 capsule endoscopy system (Given Imaging Co. Ltd., Yoqnem, Israel).
88829931|NCT02270736|Experimental|OLEX: NT 201 (Age 2 to 5 Years)|Participants will receive NT 201 (about 1.5-2 U/kg body weight) via bilateral intraglandular injection into the parotid and submandibular glands on Day 1 of second (Visit 6), third (Visit 10), and fourth (Visit 14) injection cycle of the OLEX, followed by an observation period of 16 weeks each (48 weeks in total).
88829932|NCT04672031|No Intervention|Control Arm|Patients in the control arm will be instructed to check blood sugars seven times per day: fasting, pre-prandial, and 1 hour after each meal. The glycemic targets for the control arm will be defined as follows: fasting ≤95 mg/dL, pre-prandial ≤95 mg/dL, and 1-hour postprandial ≤140 mg/dL (i.e. conventional targets). Patients who do not achieve glycemic goals with diet and exercise will be started on medical therapy (metformin or insulin) at the discretion of a maternal-fetal medicine subspecialist and endocrinologist.
88829933|NCT04672031|Experimental|Interventional Arm|Patients in the experimental arm will be instructed to check blood sugars seven times per day: fasting, pre-prandial, and 1 hour after each meal. The glycemic targets for the intervention arm will be defined as follows: fasting ≤80 mg/dL, pre-prandial ≤80 mg/dL, and 1-hour postprandial ≤110 mg/dL. Patients who do not achieve glycemic goals with diet and exercise will be started on medical therapy (metformin or insulin) at the discretion of a maternal-fetal medicine subspecialist and endocrinologist.
88829934|NCT02269098|Experimental|Intervention|"Diabetes survival skills self-management education; plus diabetes medication management using medication algorithm by diabetes educator supervised by endocrinologist, plus health system naviagation.~Metformin, sulfonylureas and basal insulin were included in the algorithm. Survival skills DSME included: BG meter instruction if the patient did not already have a meter or confirmation of self-BG monitoring technique if they did; instructions on how to self-inject insulin if prescribed; and information on BG targets, signs and treatment of hypoglycemia and hyperglycemia, basic nutrition information and when to call the doctor or go to the ED."
88829935|NCT02269098|No Intervention|Control|Usual ED care was provided to controls. Hyperglycemia was treated with rapid acting insulin and with IV hydration, if indicated. DM medications were added and/or doses were adjusted at the discretion of the ED physician and prescriptions provided. Insulin, however, was not prescribed as a new medication due to staff concerns regarding post-discharge hypoglycemia and lack of certainty of timely medical follow-up. Follow-up with primary care was recommended.
88829936|NCT04651595|Experimental|Caudal|
88829937|NCT04651595|Active Comparator|Control|
88829938|NCT04645511|Experimental|Chronic sinusitis: Balloon sinuplasty|30 patients with chronic maxillary sinusitis that are randomized to be treated with the real Balloon sinuplasty procedure of maxillary sinuses.
88829939|NCT04645511|Sham Comparator|Chronic sinusitis: Placebo|30 patients with chronic maxillary sinusitis that are randomized to be treated with sham surgery.
88829940|NCT04645511|Experimental|Recurrent sinusitis: Balloon sinuplasty|30 patients with recurrent maxillary sinusitis that are randomized to be treated with the real Balloon sinuplasty procedure of maxillary sinuses.
88829941|NCT04645511|Sham Comparator|Recurrent sinusitis: Placebo|30 patients with recurrent maxillary sinusitis that are randomized to be treated with sham surgery.
88829942|NCT04630067|Experimental|AZD3427: Cohort 1a|Participants will receive single SC dose A of AZD3427 on Day 1.
88829943|NCT04630067|Experimental|AZD3427: Cohort 2a|Participants will receive single SC dose B of AZD3427 on Day 1.
89358774|NCT02486536|Active Comparator|Group B|the same as protocol A plus 1L Polyethylene glycol 11-12h before VCE. CE are performed with the Pillcam SB2 capsule endoscopy system.
89534296|NCT03369223|Experimental|Part 2A Arm F: BMS-986249 + nivo|Previously untreated unresectable stage III-IV melanoma
89534297|NCT03369223|Experimental|Part 2B Cohort 1: BMS-986249 + nivo|Advanced or intermediate hepatocellular carcinoma (HCC)
88829944|NCT04630067|Experimental|AZD3427: Cohort 3a|Participants will receive single SC dose C of AZD3427 on Day 1.
88829945|NCT04630067|Experimental|AZD3427: Cohort 4a|Participants will receive single SC dose D of AZD3427 on Day 1.
88829946|NCT04630067|Experimental|AZD3427: Cohort 5a|Participants will receive single IV dose E of AZD3427 on Day 1.
88829947|NCT04630067|Experimental|AZD3427: Cohort 6a|Participants of Japanese descent will receive single SC dose anticipated equal to the highest dose of AZD3427 in the global cohorts on Day 1.
88829948|NCT04630067|Experimental|AZD3427: Cohort 7a|Participants will receive single SC dose F of AZD3427 on Day 1
88829949|NCT04630067|Placebo Comparator|Part A: Placebo|Participants will receive single SC or IV dose of placebo matched to AZD3427 on Day 1.
89000858|NCT04638556||T2DM|T2DM group was simple type 2 diabetes mellitus.
89358775|NCT02486536|Active Comparator|Group C|the same as protocol A plus 2L Polyethylene glycol 10-12h before VCE. CE are performed with the Pillcam SB2 capsule endoscopy system.
89358776|NCT02486536|Active Comparator|Group D|Group D: the same as protocol A plus 1L Polyethylene glycol 3-4h before VCE. CE are performed with the Pillcam SB2 capsule endoscopy system.
89358777|NCT02486536|Active Comparator|Group E|Group E: the same as protocol A plus 2L Polyethylene glycol 2-4h before VCE. CE are performed with the Pillcam SB2 capsule endoscopy system.
89358778|NCT03718975|Experimental|Successor of Phonak Audéo B90|The successor of the Phonak Audéo B90 is a Receiver-in-the-canal Hearing aid with direct connectivity functionality from Phonak which will be fitted to the participants individual Hearing loss.
89358779|NCT03718975|Active Comparator|Phonak Audéo B90|The Phonak Audéo B90 is the most recent Receiver-in-the-canal Hearing aid from Phonak which will be fitted to the participants individual Hearing loss.
89358780|NCT03321136|Placebo Comparator|Placebo, LSD-25, LSD-50, LSD-100, LSD-200, LSD-200-Ketanserin|Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase
89358781|NCT03321136|Placebo Comparator|LSD-25, LSD-50, LSD-100, LSD-200, LSD-200-Ketanserin, Placebo|Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase
89358782|NCT03321136|Placebo Comparator|LSD-50, LSD-100, LSD-200, LSD-200-Ketanserin, Placebo, LSD-25|Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase
89358783|NCT03321136|Placebo Comparator|LSD-100, LSD-200, LSD-200-Ketanserin, Placebo, LSD-25, LSD-50|Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase
89358784|NCT03321136|Placebo Comparator|LSD-200, LSD-200-Ketanserin, Placebo, LSD-25, LSD-50, LSD-100|Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase
89358785|NCT03321136|Placebo Comparator|LSD-200-Ketanserin, Placebo, LSD-25, LSD-50, LSD-100, LSD-200|Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase
89358786|NCT01332552|Experimental|Part 1: Single dose escalation|GSK2485852 planned single doses are placebo, 70 mg, 420 mg, 70 mg with food
89358787|NCT01332552|Experimental|Part 2: Repeat dose escalation|GSK2485852 planned repeat doses are placebo, 420mg BID, 420mg TID, 630mg BID
89358788|NCT01332552|Experimental|Part 3: GSK2485852 + Ritonavir|GSK2485852 single dose 70mg, 210 mg +Ritonavir 100mg x 1 day; GSK2485852 210mg + Ritonavir 100mg single dose x 3 days;
88829950|NCT04630067|Experimental|AZD3427: Cohort 1b|Participants with HFrEF will receive SC dose A of AZD3427 on Days 1, 8, 15, 22, and 29.
89358789|NCT03720223|Experimental|Liposomal Bupivacaine|20ml Liposomal Bupivacaine 1.3% (13.3mg/mL), injected to the buccal mucosal graft harvest site.
89358790|NCT03720223|No Intervention|Control|No local anesthetics injected to the buccal mucosal graft harvest site
89358791|NCT02486380|Experimental|Full face/Nasal masks|Toffee Full face/Toffee nasal
89358792|NCT03160716|Other|Treatment|
89358793|NCT03720145|Experimental|Treatment Group|lifestyle medicine group
89358794|NCT03720145|No Intervention|CAU group|Care-As-Usual group
89358795|NCT03317626|Experimental|Cold Stimulus|The study procedure will beto use a coldstimulus (ice) to assess the subjects for hypesthesia the dermatomes of the lower abdomen at 15 minutes and if necessary at 30 minutes after the epidural is inserted
89358796|NCT01332708|Experimental|Obese and overweight subjects|The participants are overweight and obese people with and without metabolic syndrome that will participate in diet groups.
89358797|NCT02483962|Placebo Comparator|Gelatine capsule|Gelatine capsules containing no active ingredients, will be taken once per day, in the morning after breakfast, for 30 days. These capsules will be of identical appearance to the experimental comparator.
88829951|NCT04630067|Experimental|AZD3427: Cohort 2b|Participants with HF with EF ≥ 41% will receive SC dose A of AZD3427 on Days 1, 8, 15, 22, and 29.
88829952|NCT04630067|Experimental|AZD3427: Cohort 3b|Participants with HFrEF will receive SC dose B of AZD3427 on Days 1, 8, 15, 22, and 29.
88829953|NCT04630067|Experimental|AZD3427: Cohort 4b|Participants with HF with EF ≥ 41% will receive SC dose B of AZD3427 on Days 1, 8, 15, 22, and 29.
89358798|NCT02483962|Experimental|Venavine Intensive®|Gelatine capsules containing the active ingredients of: 360 mg red vine leaf extract, 60 mg of horse chestnut extract, 35 mg of butcher's broom extract and 3,2 mg of vitamin B6, will be taken once per day, in the morning after breakfast, for 30 days.
89358799|NCT02483884|Experimental|Low risk for recurrence|Diagnostic [68Ga]RM2 is administered to 10 primary prostate cancer patients with low risk of recurrence who undergo PET/CT 60 min post i.v. for at least 20 min.
89358800|NCT02483884|Experimental|Intermediate risk for recurrence|Diagnostic [68Ga]RM2 is administered to 10 primary prostate cancer patients with intermediate risk of recurrence who undergo PET/CT 60 min post i.v. for at least 20 min.
89358801|NCT02483884|Experimental|High risk for recurrence|Diagnostic [68Ga]RM2 is administered to 10 primary prostate cancer patients with high risk of recurrence who undergo PET/CT 60 min post i.v. for at least 20 min.
89358802|NCT01335672||GPRD patients|"All patients included in up to standard GPRD practices that agreed to the linkage with the MINAP database are included in this cohort."
88829954|NCT04630067|Experimental|AZD3427: Cohort 5b|Participants with HFrEF will receive SC dose C of AZD3427 on Days 1, 8, 15, 22, and 29.
88829955|NCT04630067|Experimental|AZD3427: Cohort 6b|Participants with HF with EF ≥ 41% will receive SC dose C of AZD3427 on Days 1, 8, 15, 22, and 29.
88829956|NCT04630067|Placebo Comparator|Part B: Placebo|Participants with HFrEF or HF with EF ≥ 41% will receive SC dose of placebo matched to AZD3427 on Days 1, 8, 15, 22, and 29.
88829957|NCT04586387|Experimental|Brain stimulation over bicep muscle than finger (FDI) muscle.|Brain stimulation will occur over two sessions. Both sessions will occur with sham stimulation then active stimulation. There will be a 3 day rest period between the two muscle groups.
89358803|NCT03713021|Experimental|TraceIT Tissue Marker|"Following successful tumor resection, TraceIT Tissue Marker will be applied in 0.2 to 0.5 mL injections at 5 locations to mark the tumor bed: superiorly, inferiorly, laterally, medially, and center of resection. The marginal injections will be within 3 mm of the resection edge and within 5 mm deep. The center of the resection bed will be injected within 5 mm deep if possible.~Within 6 weeks after surgery, a CT simulation scan will be performed per normal protocol for patients receiving surgery followed by adjuvant therapy. This scan will be used to generate the intensity-modulated radiation therapy (IMRT) treatment plan~Two treatment plans will be performed per patient using the simulation CT scan. One will be the standard of care treatment plan and will be the basis of the actual radiation treatment they receive. The second treatment plan will be based on utilizing the TraceIT hydrogel markers as a guide for the resection bed."
89358804|NCT02483494|Experimental|APN-led Telemedicine|Participants will receive APN-led Telemedicine in addition to usual care.
89358805|NCT02483494|No Intervention|Usual care|Participants will receive the standard of care which includes education by cardiac care nurses and face-to-face consultations.
89358806|NCT01335828|Other|echography/elastography|
89358807|NCT03317548||fresh embryo transfer|patients with fresh day 3 embryo transfer after oocyte pick up, the hormone including FSH, LH, E2 and progesterone was test before embryo transfer for analysis. The clinical outcomes including implantation and pregnancy were checked and recorded.
89358808|NCT03317548||frozen embryo transfer|"freeze-all embryo was performed after oocyte fertilization, the hormone including FSH, LH, E2 and progesterone was test before oocyte pick up and embryo transfer for analysis.~vitrification of pronuclear stage embryo (zygote) and frozen embryo transfer"
89358809|NCT03787199|Experimental|Andago|Application of walking over-ground with body-weight support in the Andago
89358810|NCT03787199|Active Comparator|Treadmill|Application of walking on a treadmill with body-weight support
89358811|NCT03320980||RALPPS|Patients with initial volume of FLR < 40% which underwent RALPPS and major liver resection (as the second stage of RALPPS) for hilar and intrahepatic cholangiocarcinoma
89358812|NCT03320980||Portal vein embolization (PVE)|Patients with initial volume of FLR < 40% undergoing PVE and major liver resection for hilar and intrahepatic cholangiocarcinoma
89358813|NCT01335906|Experimental|Evidence-based informed consent|
89358814|NCT01335906|No Intervention|Usual information|
89358815|NCT03787433||ARC - Assisted Rehabilitation Care|All study participants will be asked to use ARC during for their post-stroke home based rehabilitation for up to 6 months.
89000859|NCT04638556||DPN|The screening criteria for T2DM patients with DPN are as follows: 1. Clear history of type 2 diabetes mellitus. 2. Neuropathy at or after the diagnosis of diabetes. 3. The clinical symptoms and signs were consistent with those of DPN. Clinical symptoms include: numbness or sensation; tingling or tingling; pain; abnormal sensitivity or tenderness after touching. 4. Examination: A. abnormal temperature sense; B. 10 g nylon thread examination, foot sensation decreased or disappeared; C. abnormal vibration sense; D. ankle reflex disappeared; e. two or more items of nerve conduction velocity were slowed down (electromyography or sensory threshold measurement). 5. Nerve injury caused by other diseases or drugs was excluded. Two of the above five items were abnormal, or clinical symptoms + 1 item were abnormal.
89000860|NCT04638868|Experimental|Isolation of circulating tumor cells|Both portal venous and peripheral blood will be obtained from the patient and subjected to analysis for pancreatic cancer circulating tumor cells
89000861|NCT00178724||No Treatment Given|Any male or female 18 years or older admitted to a NACTN hospital, at the time of injury, with an initial (first time) spinal cord injury caused by trauma and has paralysis (muscle weakness) or loss of sensation (touch). The patient has not received medical or surgical care for this injury prior to admission to a NACTN hospital. Patient or family member must give consent to participate.
89000862|NCT04639063||Cesarean sectioned|All females who treated in our hospital by Cesarean section operation during two-years-period
89000863|NCT04639063||Complicated with Abdominal wall endometriosis|All the surgically excised endometrioma cases during the same time period
89000864|NCT00559702|Experimental|1|Natalizumab IV (Participants with secondary progressive multiple sclerosis)
89177822|NCT04809272|Experimental|ParentChat for parents of children ages 2-17|The ePLH parent support groups will be delivered over a 8 week period (i.e., 7-8 short online interactive group sessions, two per week). ePLH facilitators will moderate discussions around the parenting theme, support parents on an individual basis, and encourage them to apply the parenting skills at home. The facilitators will begin the next group engagement with a brief voice summary of the feedback and address possible solutions to 2-3 key challenges. Facilitators will also be provided with weekly supervision by an ePLH coach or trainer. A designated research assistant will provide parent support groups with needed technical support during the implementation - including IT-related support. Data bundles will be provided for internet access and to incentivise engagement.
89177823|NCT00592631|Experimental|CPAP|Subjects will use CPAP of 8-12 during days 2 through 6 of the study.
89177824|NCT00592631|Sham Comparator|SHAM|Subjects will use sham CPAP of 0-2 during days 2 through 6 of the study.
89358816|NCT01337856|Other|WHO alcohol handrub protocol|handrubbing with alcohol using the standard 7-step technique (WHO alcohol handrub protocol)
89358817|NCT01337856|Other|CDC alcohol handrub protocol|Handrubbing with alcohol covering all hand surfaces in no particular order (CDC alcohol handrub protocol)
89358818|NCT01337856|Other|Chlorhexidine handwashing|chlorhexidine handwashing using the standard 7-step technique (WHO handwashing protocol)
89358819|NCT01337934|Placebo Comparator|Lactated Ringer|Patients randomized for this group will receive 500 ml of lactated Ringer solution in early phase of sepsis or septic shock (less than six hour from sepsis onset) if mean arterial pressure was under 65mmHg, or blood lactate concentration higher than 4 mmol/L or base excess under - 4mmol/L until the target of central venous pressure of 8 mmHg or higher or recovery of hypotension.
89000865|NCT00559702|Experimental|2|Natalizumab IM (Participants with secondary progressive multiple sclerosis)
89177825|NCT05757674||Patients|Patients
89177826|NCT05757674||Control|Control
89177827|NCT04116125|Placebo Comparator|Sentinel lymph node biopsy|Perform conventional sentinel lymph biopsy
89177828|NCT04116125|Experimental|Adjuvant radiation without Sentinel lymph node biopsy|Perform radiotherapy instead of sentinel lymph node biopsy
89000866|NCT00559702|Experimental|3|Natalizumab SC (Participants with secondary progressive multiple sclerosis)
89000867|NCT00559702|Other|4|Standard of care as determined by the Investigator and Treating Neurologist (Participants with secondary progressive multiple sclerosis)
89534298|NCT03369223|Experimental|Part 2B Cohort 2: BMS-986249 + nivo|Metastatic castration-resistant prostate cancer (CRPC)
89534299|NCT03369223|Experimental|Part 2B Cohort 3: BMS-986249 + nivo|Unresectable locally advanced or metastatic triple-negative breast cancer (TNBC)
89358820|NCT01337934|Active Comparator|Albumin|Patients randomized for Albumin group will receive 500 ml of 4% Albumin solution in early phase of sepsis (less than six hour from sepsis onset) if mean arterial pressure was under 65mmHg or blood lactate concentration higher than 4 mmol/L or base excess under - 4mmol/L until the target of central venous pressure of 8 mmHg or higher or recovery of hypotension.
89358821|NCT03786887|Experimental|Nalbuphine|
89358822|NCT03787043|Experimental|Sequence Group A|"1st period: FDC(MP-513 10mg/Metformin XR 750mg) under fasted~2nd period: FDC(MP-513 10mg/Metformin XR 750mg) under fed"
89358823|NCT03787043|Experimental|Sequence Group B|"1st period: FDC(MP-513 10mg/Metformin XR 750mg) under fed~2nd period: FDC(MP-513 10mg/Metformin XR 750mg) under fasted"
89358824|NCT03786809|Experimental|Experimental|Women will use Cimifuga Racemosa for 28 days and will be submitted to measurement of the diameter of the brachial artery before and after treatment
89358825|NCT03786809|Placebo Comparator|Placebo|Women will use Placebo for 28 days and will be submitted to measurement of the diameter of the brachial artery before and after treatment
89358826|NCT01307735||Myocarditis negative on CMR|Patients with suspected myocarditis referred for CMR and not fulfilling at least 2 of the 3 CMR criteria (Lake Louise Criteria)for myocarditis.Lake Louise Criteria are edema, hyperaemia, and necrosis/fibrosis.
89358827|NCT01307735||Myocarditis positive on CMR|Patients with suspected myocarditis referred for CMR and fulfilling at least 2 of the 3 CMR criteria (Lake Louise Criteria)for myocarditis.Lake Louise Criteria are edema, hyperaemia, and necrosis/fibrosis.
89358828|NCT01332786|Experimental|Tigecycline|
89358829|NCT03786731|Experimental|TranS-C Group|Transdiagnostic Sleep and Circadian Treatment
89358830|NCT03786731|No Intervention|CAU group|Care-As-Usual group
89358831|NCT03160560|Active Comparator|Test-Unflavored Rinse|CloSYS Oral Rinse product containing 0.1% stabilized chlorine dioxide (sodium chlorite) in aqueous solution.
89358832|NCT03160560|Active Comparator|Test-Flavored Rinse|CloSYS Oral Rinse product containing 0.1% stabilized chlorine dioxide (sodium chlorite) in aqueous solution with mint flavoring.
89358833|NCT03160560|Placebo Comparator|Placebo|CloSYS Oral Rinse product (no chlorine dioxide)
89000868|NCT00559702|Experimental|5|Natalizumab SC (Participants with relapsing forms of multiple sclerosis)
89000869|NCT00559702|Experimental|6|Natalizumab IV (Participants with relapsing forms of multiple sclerosis)
89000870|NCT00559780|Experimental|1|12 weeks of resistance training
89358834|NCT05694377|Experimental|TR group|The training group (TR) will undergo 3 weeks of electroencephalography-based neurofeedback (EEG-NFB). EEG-NFB training.
89358835|NCT05694377|No Intervention|CO group|Control group (CO) will not undergo 3 weeks of EEG-NFB training.
89358836|NCT03786575|Experimental|NGS detection group|Before treatment, the patients in the study group underwent NGS detection of ctDNA and formulated endocrine treatment plan according to the test results. After 2 months of endocrine therapy, all patients underwent NGS detection of ctDNA, and the efficacy was evaluated according to RECIST v1.1 standard.
89358837|NCT03489343|Experimental|Sym023 0.03 mg/kg|Sym023 was administered at a dose of 0.03 mg/kg by intravenous infusion
89358838|NCT03489343|Experimental|Sym023 0.1 mg/kg|Sym023 was administered at a dose of 0.1 mg/kg by intravenous infusion
89358839|NCT03489343|Experimental|Sym023 0.3 mg/kg|Sym023 was administered at a dose of 0.3 mg/kg by intravenous infusion
89358840|NCT03489343|Experimental|Sym023 1.0 mg/kg|Sym023 was administered at a dose of 1.0 mg/kg by intravenous infusion
89358841|NCT03489343|Experimental|Sym023 3.0 mg/kg|Sym023 was administered at a dose of 3.0 mg/kg by intravenous infusion
89358842|NCT03489343|Experimental|Sym023 10.0 mg/kg|Sym023 was administered at a dose of 10.0 mg/kg by intravenous infusion
89358843|NCT03489343|Experimental|Sym023 20.0 mg/kg|Sym023 was administered at a dose of 20.0 mg/kg by intravenous infusion
89358844|NCT01338090||89Zr-bevacizumab|
89358845|NCT01307969|Experimental|Anesthetic efficacy|Local anesthetics were injected at the apex of the maxillary right canine.
89358846|NCT01332864|Active Comparator|OMT to the head and rest of body|OMT is the intervention that will be applied to areas of somatic dysfunction as well as to the head using a compression of the fourth ventricle (CV4) technique.
89358847|NCT01332864|Placebo Comparator|Light touch|Light touch will be applied to the head region for 10 minutes with the patient at rest in the supine position.
89358848|NCT01332864|Experimental|OMT with CV4 to head|OMT is the intervention using the CV4 technique to the head region for 10 minutes with patient at rest.
89358849|NCT01332864|Active Comparator|OMT to the body except the head region|OMT is the intervention that will be applied to areas of somatic dysfunction in any region except the head.
89358850|NCT03786419|Experimental|Atezolizumab|Participants with unresectable or advanced malignant pleural mesothelioma who have progressed after platinum-based chemotherapy will receive atezolizumab 1200 mg every 21 days, until Investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or participant's decision to withdraw from therapy, or death (whichever occurs first).
89358851|NCT03786263||Prospective Treatments for NS|"Observation of children (between the ages of 1 and 17) who are diagnosed with Nephrotic Syndrome at their initial presentation, first or second relapse.~Observation of children who receive Glucocorticoids to treat Nephrotic Syndrome.~Observation of children who receive other drugs (Second Line Agents) for Nephrotic Syndrome."
89358852|NCT01335984|Experimental|Telemonitoring group|The subjects who are assigned in the Telemonitoring group should perform body composition measurement with self blood pressure measurement, and shall transmit the results to the Smart Care Serve via Smart Care PC. Telemonitoring group require site visit once per 2 months (8weeks)
89358853|NCT01335984|Experimental|Telemonitoring & Telemedicine group|The subjects who are assigned in the Telemonitoring & Telemedicine group should perform body composition measurement with self blood pressure measurement, and shall transmit the results to the Smart Care Serve via Smart Care PC. Telemonitoring & Telemedicine group take remote medical treatment through video telephone instead of visiting study site.
89358854|NCT01335984|Other|Control group|The subjects who are assigned in the Control group require site visit once per 2 months (8weeks)
89534300|NCT03369223|Experimental|Part 2A Arm A: BMS-986249 + nivo then nivo|"Previously untreated unresectable stage III-IV melanoma~Enrollment is closed for this Arm"
89000871|NCT00559780|Experimental|2|12 weeks of neuromuscular electrical stimulation
89000872|NCT00559780|Other|3|12 weeks of standard rehabilitation
89534301|NCT03369223|Experimental|Part 2A Arm B: BMS-986249 + nivo|"Previously untreated unresectable stage III-IV melanoma~Enrollment is closed for this Arm"
89534302|NCT03369223|Experimental|Part 2A Arm E: Nivo|"Previously untreated unresectable stage III-IV melanoma~Enrollment is closed for this Arm"
89534303|NCT03327714|Experimental|Mindfulness and compassion|Children aged between 6-16 years old will perform 5-10 minutes daily mindfulness and compassion training in school. The intervention will last for 10 weeks.
89177829|NCT05757596|Active Comparator|VSA001 injection|A single dose of active drug (VSA001, low or high dose) will be administered by subcutaneous injection on Day 1.
88829958|NCT04586387|Experimental|Brain stimulation over than finger (FDI) muscle than bicep muscle.|Brain stimulation will occur over two sessions. Both sessions will occur with sham stimulation then active stimulation. There will be a 3 day rest period between the two muscle groups.
88829959|NCT02667821|Experimental|Intervention group|Participants included in the experimental arm will be adults aged 18 years and older with chronic/recurrent neck pain Grade II who have been prescribed cervical manipulation for treatment of their condition. Each participant will undergo three separate test maneuvers consistent with prior work completed at the St. Joseph's Healthcare Hamilton Brain Body Institute. Each participant will begin with neutral cervical spine as a standard natural control, followed by block randomization between maximum voluntary rotation of the cervical spine and one cervical manipulation. Please see Intervention section for a detailed description.
88829960|NCT02669615|Experimental|Melphalan HCl for injection (propylene glycol free)|Patients will receive 200 mg/m^2 of Melphalan HCl for injection (propylene glycol free) as a one-time infusion on day 2. Blood samples for the pharmacokinetic (PK) evaluation of melphalan will be collected after melphalan dosing (day -2). Following one day of rest after the myeloablative Melphalan conditioning (day -1), patients will receive an autologous graft with a minimum cell dose of 2 × 106 CD34+ cells/kg of patient body weight (day 0).
88829961|NCT04739579||Anastomotic Leak|
88829962|NCT04739579||Non-Anatomotic Leak|
88829963|NCT02670629|Active Comparator|Anatomic Closed Reduction + Short Cast|"Patients in this group were treated by performing a closed anatomic reduction under anesthesia by using sedatives and then placing the child in a short arm cast for 6 weeks. The follow up was done at week 1, 3, 6 and 10 with new X rays in each consult.~The intervention in this control group was performing a closed anatomic reduction under anesthesia."
89534304|NCT03327714|No Intervention|Control group|The control group consists of children who do not perform mindfulness in school.
89534305|NCT03315377|Active Comparator|Lunate-Capitate Fusion (LCF)|Operation with a Lunate-Capitate Fusion (LCF) for SLAC or SNAC arthritis.
89534306|NCT03315377|Active Comparator|Four Corner Fusion (4CF)|Operation with a Four Corner Fusion (4CF) for SLAC or SNAC arthritis
89534307|NCT03310892|No Intervention|Usual Care|Participants in this arm will Usual scheduling process without any intervention
88829964|NCT02670629|Experimental|Partial reduction overriding position|"Patients in this group were only given oral medications, the fracture was not reduced, instead it was left with a partial reduction with overriding position placed in a short arm cast for 6 weeks. The follow up was done at week 1, 3, 6 and 10 with new X rays in each consult.~The intervention in this control group was not performing a closed anatomic reduction under anesthesia."
88829965|NCT02672111|Experimental|CAM2038 q1w or q4w exposure to SL BPN/NX|"CAM2038 (buprenorphine FluidCrystal®)~Subjects previously exposed to SL BPN/NX who received CAM2038 q1w or q4w"
88829966|NCT02672111|Experimental|CAM2038 q1w or q4w new to BPN treatment|CAM2038 (buprenorphine FluidCrystal®) New to BPN Treatment who received CAM2038r q1w or q4w
88829967|NCT01456013|Active Comparator|Standard Therapy|Standard of care for patients at risk of CIN
88829968|NCT01456013|Experimental|RenalGuard Therapy|Induced Diuresis with Matched Replacement
88829969|NCT02675543|Experimental|Standard silicone oil|after vitreous removal, the vitreous chamber was filled with standard silicone oil (PDMS)
88829970|NCT02675543|Experimental|Heavy silicone oil|after vitreous removal, the vitreous chamber was filled with heavy silicone oil (Densiron 68)
88829971|NCT02684435|Experimental|Perflutren lipid microsphere|Activate by shaking for 45 seconds using VIALMIX. Use activated product within 5 minutes. Infusion: The recommended infusion dose for activated perflutren is via an IV infusion of 1.3 mL added to 50 mL of preservative-free saline. The rate of infusion should be initiated at 4.0 mL/minute, but titrated as necessary to achieve optimal image enhancement, not to exceed 10 mL/minute per P.I. approval
88829972|NCT02684591|Experimental|Aramchol 600 mg orally daily|"Total 600 mg Aramchol (200 mg/tablet and 400 mg/tablet) per day once a day orally for 12 weeks.~Intervention: Aramchol"
88829973|NCT02684591|Placebo Comparator|Placebo|Placebo in the form of a tablet; Two bottles will be given to patient and they will take two pills, once a day orally for 12 weeks.
89358855|NCT03489109|Experimental|Intermittent Fasting diet|HIV positive subjects with body mass index ≥30 kg/m2 (obese) consume approximately 25% of their daily calories for 2 non-consecutive days per week, normal diet for the other 5 days, and receive healthy lifestyle counseling for 12 weeks.
88829974|NCT02685293|Experimental|GFF MDI (PT003)|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI)
88829975|NCT02685293|Placebo Comparator|Placebo MDI|Placebo Metered Dose Inhaler (MDI) for Glycopyrronium and Formoterol Fumarate Inhalation Aerosol
88829976|NCT00782249|Experimental|1|Vagus nerve stimulation paradigm #1
88829977|NCT00782249|Experimental|2|Vagus nerve stimulation paradigm #2
88829978|NCT00782249|Experimental|3|Vagus nerve stimulation paradigm #3
88829979|NCT04339127||Cohort NMDARE-HSE|Patients developing clinical autoimmune encephalitis with anti-NMDA antibodies after a herpetic encephalitis, managed by the National Reference Center for Paraneoplastic Syndromes and Autoimmune Encephalitis at the Neurological Hospital of Bron.
88829980|NCT04340375|Experimental|AP green tea extracts|8 weeks
88829981|NCT05436275|Experimental|CM310|CM310 300mg is given subcutaneously (SC) every two weeks
88829982|NCT05436275|Placebo Comparator|Placebo|Placebo is given subcutaneously (SC) every two weeks
88829983|NCT04707755|Experimental|Motor imagery technique|Motor Imagery technique Plus Conventional Physical therapy
88829984|NCT04707755|Active Comparator|Conventional Physical therapy|passive stretching, ROM exercises, sitting to standing, anteroposterior step, climbing and descending stairs.
88829985|NCT05432843|Active Comparator|Pregabalin|Treatment with pregabalin in the treatment of globus sensation
88829986|NCT05432843|Placebo Comparator|Placebo|Treatment with placebo in the treatment of globus sensation
88829987|NCT02678039|Experimental|Fluoroscopy|"Real-time fluoroscopic X-ray guidance to confirm placement of an epidural catheter in the spinal epidural space at the desired location.~Following epidural catheter placement, 1/8% bupivacaine is infused at 4ml/hr into the epidural catheter during and after surgery for pain control."
88829988|NCT02678039|Active Comparator|Traditional|"The traditional approach for placement of an epidural catheter is used with indirect indicators of placement including palpation of spine and 'loss-of-resistance' to fluid injection.~Following epidural catheter placement, 1/8% bupivacaine is infused at 4ml/hr into the epidural catheter during and after surgery for pain control."
88829989|NCT02679911|Experimental|Loceryl NL|Amorolfine hydrochloride NL 5% to be applied once weekly for 12 weeks on all affected toenails of one foot
88829990|NCT02679911|Active Comparator|Ciclopirox NL|Ciclopirox NL 8% to be applied once daily for 12 weeks on all affected toenails of the opposite foot
88829991|NCT02680145|Experimental|Preoperative Pessary Use|All patients will use a pessary for 1-4 weeks preoperatively to reparative surgery for pelvic organ prolapse
88829992|NCT02680301|Other|Ointment Right/Cream Left|Pt. will use 0.1% triamcinolone OINTMENT with wet-wrap dressing on right side and 0.1% triamcinolone CREAM with wet-wrap dressing on left side of bilateral flare of atopic dermatitis twice daily as instructed.
88829993|NCT02680301|Other|Ointment Left/Cream Right|Pt. will use 0.1% triamcinolone OINTMENT with wet-wrap dressing on left side and 0.1% triamcinolone CREAM with wet-wrap dressing on right side of bilateral flare of atopic dermatitis twice daily as instructed.
88829994|NCT02680457|Active Comparator|Insulin Degludec - Insulin Glargine|Insulin Degludec 10 IU SC every 24 hours for 6 days Washout for 14 days Insulin Glargine 10 IU SC every 24 hours for 6 days
89177830|NCT05757596|Placebo Comparator|Placebo|The placebo is normal saline (0.9%) administered subcutaneously; volume matched to the corresponding VSA001 dose volume.
89358856|NCT03489109|Active Comparator|Standard of Care diet|HIV positive subjects with body mass index ≥30 kg/m2 (obese) receive nutritional and healthy lifestyle counseling for 12 weeks.
89358857|NCT01336062|Experimental|Nanoparticle Albumin-Bound Paclitaxel|The study evaluate 3 dose level of nab-paclitaxel:100 mg /m2;125 mg /m2;80 mg /m2;
89358858|NCT05694221|Experimental|Group A: Digoxin combined with Supaglutide group|"Subjects will receive a single oral dose of 0.25 mg digoxin tablets on Day 1. And will received subcutaneous injection of sulpalutide QW for five weeks（D5-D33）.~Then receive another single oral dose of 0.25 mg digoxin tablets on Day 35."
88829995|NCT02680457|Active Comparator|Insulin Glargine - Insulin Degludec|Insulin Glargine 10 IU SC every 24 hours for 6 days Washout for 14 days Insulin Degludec 10 IU SC every 24 hours for 6 days
88829996|NCT02689973|Experimental|Self-efficacy|The self-efficacy intervention protocol included following behavior change techniques (BCT; Michie et al., 2011): barrier identification, prompting focus on past success, and prompting self-talk. Applications of all BCT included references to self-efficacy beliefs. The intervention was integrated into health promotion-nutrition education program (8h). The intervention was applied twice (the baseline and 2-month follow-up).
88829997|NCT02689973|Experimental|Planning|"The following BCT were included in the planning intervention protocol: action planning, barrier identification, prompting self-talk, relapse prevention/coping planning. Applications of all BCT included references to planning.~The intervention was integrated into health promotion-nutrition education program (8h). The intervention was applied twice (the baseline and 2-month follow-up)."
88829998|NCT02689973|Experimental|Combined planning+self-efficacy|This condition included all BCT applied in the planning and self-efficacy arms. The intervention was integrated into health promotion-nutrition education program. The intervention was applied twice (the baseline and 2-month follow-up).
88829999|NCT02689973|Active Comparator|Education|The education group received extended physical activity education program. The physical activity education was integrated into health promotion-nutrition education program.The education program was applied twice (the baseline and 2-month follow-up).
88830000|NCT02691143|Experimental|Manipulation plus Tape|"The Tape Group will have TheraBand® Kinesiology Tape, an elastic therapeutic tape (ETT), applied immediately following cervical manipulation from a licensed chiropractor. The taping protocol will be applied by the investigator and consist of a Y strip applied at 25% tension running superior to inferior from the hair line to T1-2 and a horizontal I strip applied at 50% tension at the site of pain."
88830001|NCT02691143|No Intervention|Manipulation Only|The control group will receive manipulation from a licensed chiropractor only
88830002|NCT02283762|Experimental|Riociguat|Main treatment phase of 52 weeks: participants received increasing doses of riociguat by 0.5 mg every 2 weeks up to 2.5 mg 3 times a day (TID) in a-titration period of up to 10 weeks and a maintenance period of up to 42 weeks. Long-term extension phase: starting after the completion of the Main Treatment Phase in Week 52, participants received sham-titration in a dose-titration period of up to 10 weeks followed by a maintenance period.
88830003|NCT02283762|Placebo Comparator|Placebo|Main treatment phase of 52 weeks: participants received matching placebo tablets to riociguat as sham titration in a dose-titration period up to 10 weeks and a maintenance period of up to 42 weeks. Long-term extension phase: starting after the completion of the Main Treatment Phase in Week 52, participants received increasing doses of riociguat by 0.5 mg every 2 weeks up to 2.5 mg 3 times a day (TID) in a dose-titration period of up to 10 weeks followed by a maintenance period.
88830004|NCT02692391|Placebo Comparator|Placebo|6 doses, Q8hrs for a total period of 48 hours
88830005|NCT02692391|Active Comparator|Indomethacin suppository|Loading dose :100mg Maintenance dose: 50 mg, Q8hrs for a total period of 48 hours (5 doses)
88830006|NCT02692859|Experimental|Vaccine(Chengdu Olymvax Biopharmaceuticals Inc.)|Hib conjugate vaccine
88830007|NCT02692859|Active Comparator|Vaccine (Walvax Biotechnology Co., LTD.)|Hib conjugate vaccine
88830008|NCT04878120|Active Comparator|Standard Hybrid Closed Loop Control (USS Virginia)|Use of Standard Hybrid Closed Loop Control
88830009|NCT04878120|Experimental|Hybrid Closed Loop Control (USS Virginia) with Smart Bolus Calculator Informed by SI|Use of Hybrid Closed Loop Control with Enhanced Prandial Dosing
88830010|NCT02694029|Active Comparator|ABC (Active Breathing Coordinator ), Then VRT|Active Breathing Coordinator to assist radiation therapy. This group will be administered 14 fractions with ABC-assisted DIBH, followed by 14 fractions with VRT-assisted DIBH
88830011|NCT02694029|Active Comparator|VisionRT (VRT), Then ABC|VisionRT-based deep inspiration breath-hold to assist radiation therapy. This group will be administered 14 fractions with VRT-assisted DIBH, followed by 14 fractions with ABC-assisted DIBH
88830012|NCT04739033|Experimental|Experimental group|"This group will receive access to the web-based lifestyle intervention (exercise and nutritional education), supported by audiovisual instructions given by their hypertension specialist doctor.~The self-applied online program will comprise a three months behavioural intervention composed by 9 modules seeking to develop gradually achieving the goals of changing eating and physical activity habits, supported by audiovisual instructions. This group will receive access to the web-based lifestyle intervention (exercise and nutritional education), supported by audiovisual instructions given by their hypertension specialist doctor."
88830013|NCT04739033|Active Comparator|Control Group|The control group will receive the same webbased lifestyle intervention (exercise and nutritional education), but in this case supported by audiovisual instructions given by a doctor outside the patient.
88830014|NCT02696291|Experimental|Cohort 1 - 30 mg|Subjects receiving UV-4B 30 mg oral solution or placebo
88830015|NCT02696291|Experimental|Cohort 2 - 75 mg|Subjects receiving UV-4B 75 mg oral solution or placebo
88830016|NCT02696291|Experimental|Cohort 3 - 150 mg|Subjects receiving UV-4B 150 mg oral solution or placebo
88830017|NCT02696291|Experimental|Cohort 4 - X mg (dose to be determined)|Subjects receiving UV-4B X mg (dose to be determined) oral solution or placebo
88830018|NCT02696291|Experimental|Cohort 5 - Y mg (dose to be determined)|Subjects receiving UV-4B Y mg (dose to be determined) oral solution or placebo
88830019|NCT05406245||Group C|Patients drank carbohydrate fluid 2 hours prior to surgery.
88830020|NCT02682563|Experimental|Dapagliflozin 10mg once daily|Once daily treatment with oral dapagliflozin (forxiga) 10mg for 12 consecutive weeks.
88830021|NCT02682563|Active Comparator|Gliclazide modified release 30mg once daily|Once daily treatment with oral gliclazide MR 30mg for 12 consecutive weeks.
88830022|NCT02697071|Placebo Comparator|Placebo Control|Patients will receive an equivalent volume of normal saline intravenously.
88830023|NCT02697071|Experimental|Ketamine|Patients will receive 0.2mg/kg ketamine intravenously over one minute.
88830024|NCT02683421|Other|Cohort 1|Healthy Volunteers: 50 mcg tilmanocept with 2 millicuries (mCi) Tc 99m
88830025|NCT02683421|Other|Cohort 2|Healthy Volunteers: 200 mcg tilmanocept with 2 mCi Tc 99m
88830026|NCT02683421|Experimental|Cohort 3|RA Group: 50 mcg tilmanocept with 2 mCi Tc 99m
88830027|NCT02683421|Experimental|Cohort 4|RA group:200 mcg tilmanocept with 2 mCi Tc 99m
89000873|NCT00178763|Experimental|1|All protocol subjects are treated with fever-range whole-body thermal therapy combined in an optimized schedule with cisplatin + gemcitabine + metronomic low-dose interferon-alpha
89534308|NCT03310892|Experimental|Generic Message|"Participants in this arm will receive a telephone call from a study team member, and if no answer, up to two additional attempts will be made. During the telephone call, the study team member will ask the participant a series of 7 questions then receive a generic message encouraging colonoscopy scheduling."
89000874|NCT00559975|Active Comparator|1|
89000875|NCT00559975|Active Comparator|2|
89000876|NCT00559975|Experimental|3|
89000877|NCT00559975|Experimental|4|
89000878|NCT00559975|Experimental|5|
89000879|NCT04638439|Experimental|P1101 + Nivolumab + Entecavir|
89000880|NCT00178802|Other|1|thermochemotherapy using fever-range whole-body thermal therapy combined with continuous infusion 5-fluorouracil, Doxil, and low-dose interferon-alpha.
89000881|NCT00560014|Experimental|1|Arginine and Canola oil supplemented group
89000882|NCT00560014|Experimental|2|Arginine and Coromega
89000883|NCT00560014|No Intervention|3|Control
89000884|NCT04638010|Experimental|Cancer control navigation (CNN) plus General referral (usual care)|"Information Specialists at the 2-1-1 call center provide cancer control referrals specific to participant's screening or prevention needs.~Additionally, Cancer Control Navigators (CNNs) housed at 2-1-1 call centers aid callers. CNNs receive electronic summary profiles of participants assigned to navigation. Navigators call the participant, build a collaborative relationship with them, identify their needs, work with them to identify barriers to services and coordinate solutions, and provide logistic (e.g., making appointments) and emotional support. Navigation services are provided by telephone only."
89000885|NCT04638010|Active Comparator|General referral (usual care)|Information Specialists at the 2-1-1 call center provide cancer control referrals specific to participant's screening or prevention needs.
89000886|NCT00201045|Experimental|Intervention|Intervention patients receive care from a clinical pharmacist to improve blood pressure.
89000887|NCT00201045|No Intervention|Control|Control patients receive usual care and do not have a clinical pharmacist included in their care.
89000888|NCT04638166|Experimental|Mineral water group|The mineral water group were instructed to consume 1.25L of a commercially supplied bicarbonate rich mineral water per day at meal times, supplemented by other fluid intake up to 2.5 - 3L/day.
89000889|NCT04638166|Active Comparator|Plain water group|The plain water group consumed only plain water up to 2.5 - 3L/day.
89000890|NCT00178880||Healthy volunteers|
89000891|NCT00178880||Depressed patients|
89000892|NCT04637737|Experimental|Training group|
89000893|NCT04637737|Other|Control group|
89000894|NCT04637854|Experimental|Operating Microscope.|"Surgical technique is the same used for extraction of the lower third molar. Patients will be enrolled (baseline) whenever sign their written informed consent to participate to the study, after having read and understand the informative pamphlet.~The intervention will be performed under local anesthesia (mepivacaine 20 mg/ml with adrenaline 1:100000) and by the use of microscope.~At the end of the surgical procedure, all patients will receive a 100mg Nimesulide cpr and apply the ice pack on the cheek.~At the end of each procedure will give post-operative instructions for all patients and prescribe an antiseptic therapy with chlorhexidine coll. 0.2% 3 times/ day for 10 days from the day following the intervention and anti-inflammatory therapy Nimesulide 100 mg cpr to take up to 2 times / day for up to 4 days.~Each patients will be recalled for follow-up visits at 7 days."
89000895|NCT04637854|Active Comparator|Surgical Loupes with coaxial illumination.|The same as above but the intervention will be performed with the use of surgical loupes
89000896|NCT04637854|Active Comparator|Naked Eye.|The same as above but the intervention will be performed at naked eyes
89000897|NCT04637659||Healthy non-treated teeth|Healthy teeth being treated for restorative or prosthodontics reasons
89000898|NCT04637659||Healthy treated teeth|Teeth being retreated for restorative or prosthodontics reasons
89000899|NCT04637659||Irreversible pulpitis|Teeth being treated because of a poor pulpal status
89000900|NCT04637659||Post-treatment apical periodontitis|Teeth being retreated due to the presence of an apical lesion
89177831|NCT00791388|Placebo Comparator|placebo|placebo capsule
89000901|NCT04637659||Necrosis|Teeth being treated because of pulpal necrosis
89000902|NCT00201084|Active Comparator|1|Uncertainty reduction tools, at physician discretion, 24 hour ambulatory BP monitoring and/or electronic bottle cap monitoring and/or lifestyle counseling
89000903|NCT00201084|No Intervention|2|Usual primary care
89000904|NCT04637503|Experimental|effectiveness of CAR-T cells targeting GD2, PSMA and CD276|Gene-modified T cells are designed to kill tumor cells through specific recognition of GD2, PSMA and CD276. This study will evaluate the side effects and effective doses of GD2, PSMA and CD276 CAR-T cells in treating refractory and recurrent NB
89000905|NCT00408239|Experimental|1|Dose regimen 1
89000906|NCT00408239|Active Comparator|2|
89000907|NCT00408239|Experimental|3|Dose regimen 2
89000908|NCT04637308|Experimental|Succinylated gelatin|The patients received intravenous infusion of succinylated gelatin one day before and on the day of chemotherapy, 500ml each time, once per day.
89000909|NCT04637308|No Intervention|Control|Observation.
89000910|NCT04637542|Experimental|Control Group (Traditional)|"Application in the Control Group: After the theoretical lesson, the control group was taken to the Anatomy Laboratory. The laboratory consists of three application rooms, one control room and one analysis room. The Anatomy of the Organs Forming the Genital System was explained using an anatomical model of the genital system organs by a researcher responsible for the human anatomy course. Students were given time until the end of the lesson to work on the models. During this time, their questions were answered. At the end, all of the students were given a State Inventory by the researcher and asked to fill it in. Students were then asked to use textbooks and atlases to study for the Knowledge Test (post-test) which took place three days later."
89177832|NCT00791388|Experimental|50 mg PG 760564|50 mg PG 760564 active
89177833|NCT00791388|Experimental|100 mg PG 760564|100 mg PG 760564 active
89177834|NCT00791388|Experimental|200 mg PG 760564|200 mg PG 760564 active
88830028|NCT02683577|Experimental|Telotristat etiprate 500 mg|1 single oral dose (2 x 250-mg tablets)
89534309|NCT03310892|Experimental|Tailored Message|"Participants in this arm will receive a telephone call from a study team member, and if no answer, up to two additional attempts will be made. During the telephone call, the participant will answer a series of 7 questions then receive a tailored message encouraging colonoscopy scheduling, which will be determined by their responses to the preceding questions."
89534310|NCT03292510|Experimental|GO-OUT Group|Participants attend 1-day walking workshop followed by a 3-month outdoor walking group intervention, twice weekly for 60-minutes. The same activities are completed during both sessions within the same week. Each session includes a 10-minute warm-up, a distance walk, practice of a specific outdoor walking skill, a distance walk, and a 10-minute cool down. The warm up and cool down include stretching, functional strengthening exercises and balance exercises taught during the workshop. The program incorporates the principles of task-specific training by emphasizing repetitive practice of progressively more difficult outdoor walking tasks. The outdoor walking program is conducted in one or more large park settings given the mental health benefits of exercising in a natural environment.
89534311|NCT03292510|Active Comparator|Workshop Group|The 1-day workshop will be 5 hours with breaks. Participants will complete a series of stations learning information, strategies and skills related to safely walking outdoors. Stations include: pedometer use; walking pole use; footwear; footcare; fall prevention; balance exercises; proper use of walking aids; correct posture; self-management of exercise intensity; goal setting; and walking safely outdoors. Participants will receive a workbook with Canadian Physical Activity Guidelines, benefits of outdoor walking, information for each workshop station and a pedometer. Participants will use the workbook as an information resource and to record their community ambulation goals, planning routes, and walking time. All participants will be encouraged to walk outside with a partner, for safety.
88830029|NCT05369897|Experimental|VR training|VR training for at least 10 minutes at least three days per week, resulting in a total of at least 36 sessions (at least ~12 hours of training in total) for each participant, spread across three months. Each session will focus on cognitive training.
88830030|NCT05369897|Sham Comparator|VR activity|VR activity for at least 10 minutes at least three days per week, resulting in a total of at least 36 sessions (at least ~12 hours of training in total) for each participant, spread across three months, with 360º images and videos but without the interactive cognitive training.
88830031|NCT02283294|Experimental|Apixaban|Apixaban twice a day for 180 days with drug initiation day 0-3 (TIA), day 3-5(small stroke) or day 7- 9 (medium stroke) respectively
88830032|NCT02283294|Active Comparator|Warfarin|standard of care warfarin starting at day 7±5 (TIA) or day 14 ±5 (small to medium ischemic stroke).
88830033|NCT02700425|Active Comparator|His Bundle Pacing|Subjects will be randomized to the HB lead position with their cardiac resynchronization therapy (CRT) pacemaker. HB lead pacing will be performed with the Medtronic SelectSecure™, Model 3830 lead. Delivery of the lead utilizes a deflectable sheath, the Medtronic SelectSite™, Model C304. Both devices are FDA approved for the purpose of HB pacing. It is the only device available which is presently FDA approved for selective HB pacing.
88830034|NCT02700425|Active Comparator|Coronary Sinus Pacing|Subjects will be randomized to the CS lead position with their cardiac resynchronization therapy (CRT) pacemaker. CS lead and CRT device generator selected for implant will be left to the discretion of the operator. Only FDA approved CS leads and CRT generators will be utilized in the study. There are five present manufacturers of CS leads and CRT generators: Biotronik, Boston Scientific, Medtronic, Sorin, and St. Jude Medical.
88830035|NCT02282982||Infants at high-risk of serious RSV illness|Infants who received immunoprophylaxis during the RSV season
88830036|NCT02701049|Other|SO/GI Collection|Methods to collect SO/GI information in the ED
88830037|NCT05648994|Experimental|TCR-T cells|TCR-T cells will be infused to patients with advanced solid tumors after non-myeloablative lymphocyte-depleting preparative regimen.
88830038|NCT04869384|Experimental|Intervention|Subjects will receive reminders and feedback to improve their adherence via a sensor attached to Easyhaler inhaler and mobile application
88830039|NCT04869384|Active Comparator|Usual care|Subjects do not receive reminders and feedback, but receive treatment as usual.
88830040|NCT04869306|Active Comparator|Hyaluronic acid|hyaluronic acid gel application after lower third molar removal
88830041|NCT04869306|Active Comparator|Hyaluronic acid+carrier|hyaluronic acid gel application together with a carrier after lower third molar removal
88830042|NCT04869306|No Intervention|Standard treatment|standard treatment after lower third molar removal (i.e., blood clot only)
88830043|NCT02702921|Active Comparator|Surgeon's 'standard of care' stapler|Surgeon's current standard of care stapler
88830044|NCT02702921|Experimental|Ethicon Powered Vascular Stapler|Ethicon Powered Vascular Stapler
88830045|NCT05648760|Other|Usual training|Participants randomized to the control condition received a standard training of how to communicate bad news to patients
88830046|NCT05648760|Experimental|Simulation training|Participants randomized to the simulation training group received simulation training based on a standard training of how to communicate bad news to patients
88830047|NCT05648682|Experimental|Saline|The patients in the group gargling with saline were given in a 500 ml bottle at each visit for one week of use. Patients were told that they should gargle using approximately two tablespoons of the solution given for each usage.
88830048|NCT05648682|Experimental|Sodium Bicarbonate|The sodium bicarbonate solution prepared by the researcher by mixing one teaspoon of baking soda (4.5 grams) into 500 ml of distilled water by the researcher was given to the patients in the group gargling with sodium bicarbonate for a one-week use at each interview. Patients were told that they should gargle using approximately two tablespoons of the solution given for each usage.
88830049|NCT05648682|Experimental|Thyme Honey|20 ml of honey was diluted in 100 ml distilled water bottles by the researcher to the patients in the group gargling with thyme honey. For a week's use, the patient was given five honey solutions in 100 ml bottles at one time at each visit. Patients were told that they should gargle using approximately two tablespoons of the solution given for each use.
89177835|NCT00791388|Experimental|400 mg PG 760564|400 mg PG 760564 active
88830050|NCT05648682|Experimental|Control|No solution was given to the patients in the control group by the researcher.
88830051|NCT02702999|Active Comparator|Routine third trimester care|Routine third trimester care with clinically-indicated ultrasound (control)
88830052|NCT02702999|Experimental|Serial third trimester ultrasound|Ultrasound evaluation for fetal growth and amniotic fluid will be performed every 4 weeks starting at 30 weeks (intervention group). Thus, if they continue to term, there will be 3 additional ultrasounds exams (30, 34 and 38 weeks).
88830053|NCT02268864|Experimental|Simeprevir + Daclatasvir|Participants who have Hepatitis C virus (HCV) genotype 1b infection with advanced fibrosis or compensated cirrhosis (METAVIR F3/F4) will receive simeprevir 150 milligram (mg) capsule and daclatasvir 60 mg tablet orally once daily for 12 or 24 weeks.
88830054|NCT02703467||Healthy|Healthy subjects will have no significant medical history and no previous history of asthma or other serious illnesses. They should be non-smokers. The investigators willl measure spirometry and ensure that the values lie within the normal predicted range.
88830055|NCT02703467||Asthmatics|Patients diagnosed as having asthma will be recruited from Royal Brompton Hospital Asthma Clinics. These patients will have a range of severity of asthma ranging from mild-moderate to severe asthma patients. The diagnosis of asthma is ascertained as described in the inclusion criteria.
88830056|NCT02268786|Experimental|Group A|Intent to transfer single euploid embryo based on NGS testing (VeriSeq™ PGS) of biopsied blastocysts
88830057|NCT02268786|No Intervention|Group B|Intent to transfer single embryo based on morphological assessment according to the Gardner scoring system (no PGS)
88830058|NCT02703779|Active Comparator|Stem cell collection without in-vivo purging with Bortezomib|"Standard of Care Stem cell collection without in-vivo purging with Bortezomib. Standard of Care drugs Granulocyte colony-stimulating factor (G-CSF) +/- Mozobil (the latter if needed).~NOTE: Multiparametric Flow Cytometry to be performed on samples for BOTH groups A and B"
88830059|NCT02703779|Experimental|Stem cell collection with in-vivo purging with Bortezomib|"Bortezomib will be given subcutaneously (SQ) at 1.3 mg/m2 on day -11 and day -8 followed by Granulocyte colony-stimulating factor (G-CSF) given SQ on day -4 thru day -1 and continued until the collection is completed. Mozobil will be given if needed.~There must be at least 72 hours between each dose of bortezomib. NOTE: Multiparametric Flow Cytometry to be performed on samples for BOTH groups A and B"
88830060|NCT04738955|Experimental|High dose group|micafungin sodium ≥ 200, ≤ 300 mg/time, once a day, intravenous drip
88830061|NCT02268396|Experimental|Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler|Glycopyrronium and Formoterol Fumarate Metered-dose Inhaler (GFF MDI), PT003
88830062|NCT04859400|Experimental|Intervention|"standardized nutritional program including a nutritional supplement~standardized exercise program~app for monitoring."
88830063|NCT04859400|No Intervention|Control|"standard of care~limited version of the app (e.g. without the help function)."
88830064|NCT05648526|Experimental|ACTH4-10PRO8-GLY9-PRO10|The compound ACTH4-10Pro8-Gly9-Pro10 is a synthetic analog molecule of a short fragment of adrenocorticotropic hormone (ACTH). It is free from hormonal effects and has neuromodulatory effects.
88830065|NCT05648526|Active Comparator|ketamine 40 mg/kg BW subcutaneously|ketamine results in impaired brain function associated with neuroapoptosis injury in the immature brain.
88830066|NCT02268084|Sham Comparator|Sham Stimulation|Sham treatment will consist of 6 seconds a minute for 30 minutes a day, 5 days a week for 2 weeks (double blind phase only) using a sham device. Sham device mimics the same noise and sensation of active treatment.
88830067|NCT02268084|Active Comparator|Active sTMS|Active treatment will consist of 6 seconds a minute for 30 minutes a day, 5 days a week for 2 weeks (double blind phase) and 2 additional weeks for all subjects (open label) with Synchronized Transcranial Magnetic Stimulation (sTMS), using an active device.
88830068|NCT05320601|Experimental|Repetitive Peripheral Magnetic Stimulation|Repetitive Peripheral Magnetic Stimulation 1 session
88830069|NCT05320601|Experimental|Dry Needling|Dry Needling 1 session
88830070|NCT04420338|Experimental|Chronic hemodialysis patients|
88830071|NCT04420338|Experimental|Caregivers of chronic hemodialysis patients|
88830072|NCT04015817|Experimental|Etude longitudinale|Work on positions, ventilatory education, use of a fan, pulmonary rehabilitation, stress management, mindfulness meditation, psychosocial services, support from the mobile palliative care team
88830073|NCT05558748|Active Comparator|Pediatric patients undergoing inguinal surgeries with USG-guided Caudal block.|All pediatric patients (6 months to 12 year) posted for inguinal surgery under general anesthesia with USG-guided Caudal block for analgesia
88830074|NCT05558748|Active Comparator|Pediatric patients undergoing inguinal surgeries with USG-guided Ilioinguinal/Iliohypogastric block.|All pediatric patients (6 months to 12 year) posted for inguinal surgery under general anesthesia with USG-guided Ilioinguinal/Iliohypogastric block for analgesia
88830075|NCT05557968|Active Comparator|Conventional Therapy|"Active range of motion exercises.~Passive range of motion exercises~Balance exercises.~On-ground gait training without watching videos"
88830076|NCT05557968|Experimental|Action Observation Therapy (AO)|Conventional therapy in addition to observing images related to stair walking will be observed and physical training will performed to imitate tasks with a physical therapist. While observing the image, they will be instructed to think that their body was performing the movement of the image
88830077|NCT02705807|Experimental|FLOLAN arm|Subjects will receive the existing FLOLAN treatment (i.e., FLOLAN injection prepared with the currently marketed diluent) for a run-in period of a maximum of 4 weeks, the thermostable formulation of FLOLAN injection (i.e., FLOLAN injection prepared with the reformulated diluent) for a 4-week treatment period and there will be a one-week follow-up visit.
88830078|NCT05648370||oligometastatic disease|Dynamic blood samples before and after surgery and tissue samples from oligometastatic NSCLC undergone surgery will be obtained for exploratory analysis.
88830079|NCT02706041|Active Comparator|Definitive closure laparotomy|Subjects randomized to the definitive closure laparotomy arm will have the incision closed at the end of the exploratory laparotomy.
89358859|NCT05694221|Experimental|Group B: Metformin combined with Supaglutide Group|"Subjects will receive multiple oral dose of Metformin tablets on Day 1-3. And will received subcutaneous injection of sulpalutide QW for five weeks（D5-D33）.~Then receive another round of Metformin tablets on Day 32-34."
89358860|NCT03786341|Experimental|with auxiliary illuminator|the walking training was by conventional strategy with lase quad-cane.
89358861|NCT03786341|Placebo Comparator|control group|Ambulation training WITHOUT laser quad-cane.
89358862|NCT01338402|Other|AIR OPTIX® AQUA|Lotrafilcon B contact lenses worn in both eyes on a daily wear basis for one week in Phase 1.
88830080|NCT02706041|Other|Damage control laparotomy|Subjects randomized to the damage control laparotomy arm will have the incision left open at the end of the exploratory laparotomy. The trauma team will evaluate the patient's clinical course to determine when the incision can be closed.
88830081|NCT01643772|Experimental|Oxycodone Hydrochloride 5 mg Capsules|Group 1: single dose Oxycodone Hydrochloride 5 mg Capsules after 10 hours fasting
89358863|NCT01338402|Experimental|AIR OPTIX® COLORS|Lotrafilcon B contact lens with color randomly assigned to one eye, with phemfilcon A contact lens with color in the fellow eye for contralateral wear. Both products worn on a daily wear basis for 4 weeks in Phase 2. A replacement phemfilcon A lens was dispensed at the Week 2 visit.
89358864|NCT01338402|Active Comparator|FRESHLOOK® COLORBLENDS|Phemfilcon A contact lens with color randomly assigned to one eye, with lotrafilcon B contact lens with color in the fellow eye for contralateral wear. Both products worn on a daily wear basis for 4 weeks in Phase 2. A replacement phemfilcon A lens was dispensed at the Week 2 visit.
89358865|NCT01308047|Experimental|bupivacaine S75:R25|3 ml for subarachnoid block
89358866|NCT01308047|Active Comparator|bupivacaine (S50:R50)|3 ml subarachnoid block
89358867|NCT03716479|Experimental|0 fiber|0 grams fiber added to orange juice
88830082|NCT01643772|Experimental|Oxycodone Hydrochloride 10 mg Capsules|Group 2: single dose Oxycodone Hydrochloride 10 mg Capsules after 10 hours fasting
89358868|NCT03716479|Experimental|low fiber|20 grams of acacia gum added to orange juice
89358869|NCT03716479|Experimental|high fiber|40 grams of acacia gum added to orange juice
89358870|NCT05186142||Patients hospitalized for treatment of lymphoedema|Patients hospitalized for treatment of lymphoedema
89358871|NCT05694143|Other|Intervention group|Intervention group: Participants assigned to the intervention group will receive both will receive educational intervention including educational booklet will be distributed to the participants in the first session, and they will be asked to take it home and read it within one week. The booklet's content will include the risk factors of NCD and the benefits of adopting a healthy diet and physical activity in reducing overweight and obesity. Then, the educational classes will include six weekly teaching units. The general objective is to prevent obesity among students by delivering education and behavioural skills. The training units will be carried out in the schools. Each training unit will end with activities. The adolescents will learn more about their susceptibility to obesity and weight gain and how to make better decisions and feel better about themselves through these activities.
89358872|NCT05694143|Other|Control group: No Intervention|Participants randomized to the control group in this study will not receive any intervention (They will have their regular curriculums and normal physical activity routine).
89358873|NCT01332942|Placebo Comparator|Placebo|
89358874|NCT01332942|Experimental|Molidustat (BAY85-3934) 5 mg|
89358875|NCT01332942|Experimental|Molidustat (BAY85-3934) 10 mg|
88830083|NCT01643772|Experimental|Oxycodone Hydrochloride 20 mg Capsules|Group 3: single dose Oxycodone Hydrochloride 20 mg Capsules after 10 hours fasting
88830084|NCT01643772|Experimental|Oxycodone Hydrochloride 10 mg Capsules(multi-dose)|Group 4: multi-dose 4 times per day Oxycodone Hydrochloride 10mg Capsules for 3 days, and one dose on 4th day morning
88830085|NCT02707523|Placebo Comparator|Control|Placebo controlled (normal saline) daily for 3 days
88830086|NCT02707523|Active Comparator|Azithromycin (10 mg/kg)|10 mg/kg IV Azithromycin daily for 3 days
88830087|NCT02707523|Active Comparator|Azithromycin (20 mg/kg)|20 mg/kg IV Azithromycin daily for 3 days
88830088|NCT05299853|Experimental|Robotic Rehabilitation|
88830089|NCT05299853|Active Comparator|Conventional Rehabilitation|
88830090|NCT02712047|Experimental|Fluticasone furoate/vilanterol (FF/VI) 100/25 mcg|Subjects will receive FF/VI 100/25 mcg each morning (once daily) from Day 1 to Day 14, followed by a 21-day monitoring/washout period
88830091|NCT02712047|Placebo Comparator|Placebo|Subjects will receive placebo each morning (once daily) from Day 1 to Day 14, followed by a 21-day monitoring/washout period
89358876|NCT01332942|Experimental|Molidustat (BAY85-3934) 25 mg|
89358877|NCT01332942|Experimental|Molidustat (BAY85-3934) 50 mg|
89358878|NCT01332942|Experimental|Molidustat (BAY85-3934) 75 mg|
89358879|NCT05693987||stage I-II ovarian cancer|54 patients with stage I-II ovarian cancer
88830092|NCT02712359|Other|Havrix 1 dose_Year 8 Group|Subjects who received one dose of Havrix vaccine and with more than or equal to (≥) 7 years and less than (<) 10 years between the administration of the vaccine dose and the Persistence Visit at Year 8 and who participated in the Year 8 cross-sectional survey.
88830093|NCT02712359|Other|Havrix 2 doses_Year 8 Group|Subjects who received two doses of Havrix vaccine and with more than or equal to (≥) 7 years and less than (<) 10 years between the administration of the last vaccine dose and the Persistence Visit at Year 8 and who participated in the Year 8 cross-sectional survey.
88830094|NCT02712359|Other|Havrix 1 dose_Year 10 Group|Subjects who received one dose of Havrix vaccine and with more than or equal to (≥) 10 years and less than (<) 13 years between the administration of the vaccine dose and the Persistence Visit at Year 10 and who participated in the Year 10 cross-sectional survey.
89358880|NCT05693987||stage III-IV ovarian cancer|54 patients with stage III-IV ovarian cancer
89358881|NCT05693987||benign ovarian cancer|40 patients with benign ovarian cancer
89358882|NCT05693987||healthy people|100 healthy people
89358883|NCT03785951|Experimental|Whey Protein Isolate|Subjects are asked to supplement their habitual diet with 56 g of whey protein isolate a day for 8 weeks
89358884|NCT03785951|Experimental|Wheat Protein|Subjects are asked to supplement their habitual diet with 56 g of wheat protein a day for 8 weeks
89358885|NCT03785951|Experimental|Wheat protein with leucine|Subjects are asked to supplement their habitual diet with 56 g of wheat protein with leucine a day for 8 weeks
89358886|NCT03777449||Vertical bone loss|Infra-osseous defects
89358887|NCT03777449||Horizontal bone loss|Supra-osseous defects
89358888|NCT03777449||Combined bone loss|Combined supra-osseous and infra-osseous defects
89358889|NCT03777605|Experimental|"NTG1523, rapid absorbable capsule"|"Nitroglycerine 0.4 milligram taken as ordinary tablets or NTG1523 rapid absorbable capsule once in the morning, and subsequently blood samples and observations for 2 hours are performed"
89358890|NCT03777761|Experimental|Treatment Sequence ABC|tucatinib + placebo + moxifloxacin (administered in sequential treatment periods)
89358891|NCT03777761|Experimental|Treatment Sequence CAB|moxifloxacin + tucatinib + placebo (administered in sequential treatment periods)
89358892|NCT03777761|Experimental|Treatment Sequence BCA|placebo + moxifloxacin + tucatinib (administered in sequential treatment periods)
89358893|NCT03777761|Experimental|Treatment Sequence CBA|moxifloxacin + placebo + tucatinib (administered in sequential treatment periods)
89358894|NCT03777761|Experimental|Treatment Sequence ACB|tucatinib + moxifloxacin + placebo (administered in sequential treatment periods)
89358895|NCT03777761|Experimental|Treatment Sequence BAC|placebo + tucatinib + moxifloxacin (administered in sequential treatment periods)
89358896|NCT05185908||Group 1|The patients undergoing laparoscopic transperitoneal nephrectomy.
89358897|NCT01316861|Experimental|EMS Acarbose|
89358898|NCT01316861|Active Comparator|Bayer Acarbose|
89358899|NCT01338480|Experimental|video|Participants in the intervention group watched an educational video illustrating informed consent information
89358900|NCT01338480|No Intervention|control|Participants in the control group read an informed consent document.
89358901|NCT03777293|Experimental|training cohort|ultrasound viscoelasticity
89358902|NCT03777293|Other|testing cohort|ultrasound viscoelasticity
89358903|NCT01336218|Experimental|1|Fostamatinib
89358904|NCT01336218|Experimental|2|Rifampicin
89358905|NCT03776981|No Intervention|Baseline Gait Comparisons of Groups|Determine if kinetic (time to first peak ground reaction force [T1] and second peak ground reaction force [F2], both in the sagittal plane) and kinematic (peak stance knee flexion angle [KFA] and external knee adduction moment [KAM]) gait variables, and speed, differ between patients with KOA and age and gender matched controls during self-selected paced ambulation, and determine which ones have predictive relationships with Knee Injury and Osteoarthritis Outcome Score (KOOS) scores in the patients with KOA.
89358906|NCT03776981|Experimental|Gait with core activation|Determine if volitional core activation alters gait kinetics (T1 and F2), kinematics (KFA and KAM), and speed in patients with and without KOA during self-selected paced ambulation when compared to ambulating without volitional core activation, and whether the subjective pain complaints are significantly changed in the group with KOA. Determine whether there are baseline differences in core activation between those with and without KOA.
89358907|NCT03776981|Experimental|Knee OA Gait After core stabilization|Determine if a six-week core stabilization program alters KOOS score, and the kinetics (T1 and F2), kinematics (KFA and KAM), and speed of gait in patients with KOA during self-selected paced ambulation as compared to their pre-intervention baselines. Determine if there is a predictive relationship between the number of completed intervention sessions performed and these observed changes.
88830095|NCT02712359|Other|Havrix 2 doses_Year 10 Group|Subjects who received two doses of Havrix vaccine and with more than or equal to (≥) 10 years and less than (<) 13 years between the administration of the vaccine dose and the Persistence Visit at Year 10 and who participated in the Year 10 cross-sectional survey.
88830096|NCT02716727|Active Comparator|Aquasil Ultra Cordless, Dentsply|Gingival displacement procedure that uses a pneumatic hand piece to inject the light body impression material into the gingival sulcus.
88830097|NCT02716727|Active Comparator|Ultrapak, Ultradent cord|The knitted cord is used for physical displacement of gingival tissue. Cord is placed in the gingival sulcus and left in place for at least 4 minutes to achieve gingival displacement.
88830098|NCT02717273|Active Comparator|standard peri-operative antibiotics|The standard of care at the University of Virginia Medical Center for liver transplantation patients is a 3.375 gram dose of piperacillin / tazobactam (Zosyn®) at the time of induction of anesthesia, though this dose may be adjusted for renal insufficiency. This dose is repeated during the operation every six hours.
89358908|NCT03776903||endemic|Samples collected from areas endemic for zika. Subject specimens underwent testing with the study device and reference method.
89358909|NCT03776903||non-endemic|Samples collected from areas non-endemic for zika. Subject specimens underwent testing with the study device and reference method.
89358910|NCT01318031|Experimental|DDI|
89358911|NCT03776825||Perianal Crohn's Disease|Permacol Paste injection
89358912|NCT03776591|Experimental|Open D3|Right colectomy Open surgery Central lymphadenectomy and vascular ligation
89358913|NCT03776591|Active Comparator|Laparoscopic CME with CVL|Right colectomy Laparoscopic surgery Central lymphadenectomy and vascular ligation
89358914|NCT05097833|Experimental|Enhanced Treatment Group|Randomized group of participants receiving an enhanced Fatherhood FIRE program.
89358915|NCT05097833|Active Comparator|Control Group|Randomized group of participants receiving the 'services as usual' Fatherhood program.
89358916|NCT05029115||SGLT-2 inhibitor administration group|The group who administrated SGLT-2 inhibitor for hypoglycemic medication
89358917|NCT05029115||control|The group who are not administrated SGLT-2 inhibitor
88830099|NCT02717273|Experimental|extended three-day course of antibiotics|"For those patients randomized to the study group, antibiotics will be started as per the usual intra-operative dosing regimen, then continued to provide coverage for 72 hours.~This is typically provided as additional doses of 3.375 grams of piperacillin / tazobactam (Zosyn®) every 8 hours for 3 total days (giving a total of 72 hours of antibiotic coverage), though this may be altered based on kidney function."
88830100|NCT05215925|Experimental|A|
88830101|NCT05215925|Experimental|B|
88830102|NCT05215925|Experimental|C|
88830103|NCT03815357||Children with IPD|Children with IPD will be referred for immunological evaluation. The protocol for immune work up will be the same but between centres there is variation in the age criteria for referral i.e. >2 years in some, >6 months in others.
88830104|NCT02719535|Experimental|Corneal reshaping therapy|Subjects will be wearing corneal reshaping lenses for the correction of their myopia
89177836|NCT00794040|Active Comparator|Add-on citalopram following optimized methylphenidate|After optimized treatment with methylphenidate, those who meet threshold for chronic irritability are randomized to add-on citalopram or placebo
89177837|NCT00794040|Placebo Comparator|Add-on placebo after optimized methylphenidate|After optimized treatment with methylphenidate, those who meet threshold for chronic irritability are randomized to add-on citalopram or placebo
89177838|NCT02603796||Newborns requiring ncpap|3D scan of nares will be performed before and after administration of NCPAP for infants with Corrected Gestational Age greater than or equal to 24 weeks and less than or equal to 42 weeks.
89177839|NCT04109742|Active Comparator|Curcumin 500mg capsules|Dose will be 500mg daily phosphatidylcholine-curcumin complex supplement, orally for 24 weeks
88830105|NCT05159687|Active Comparator|Atomoxetine|Atomoxetine 40 mg PO BID (morning and late afternoon) Dosing will start at 40 mg daily for 3 days1 week, followed by a forced titration to 40 mg BID, as per the FDA label for atomoxetine.
88830106|NCT05159687|Placebo Comparator|Placebo|Matching placebo will be identical in appearance to the active treatment pill. BID (morning and late afternoon)
88830107|NCT02720627|Experimental|CB-03-01 cream, 1%|Topical CB-03-01 (cortexolone 17α-propionate) cream containing 1% active drug applied to the face and trunk twice daily for 14 days
88830108|NCT02721017|Experimental|Cryoanalgesia|Cryoanalgesia performed thoracoscopically under general anesthesia by the patient's surgeon at the time of the Nuss procedure
88830109|NCT02721017|Active Comparator|Thoracic Epidural|Thoracic epidural (ropivicaine, fentanyl).
88830110|NCT02721641|Experimental|Herceptin|Participants with stable disease and HER2-overexpressing metastatic or locally advanced cancer will receive expanded access to IV Herceptin until disease progression, unacceptable toxicity, death, or decision by the investigator or participant to discontinue treatment.
88830111|NCT02724449|Experimental|Cavilon Advanced Barrier Film|Cavilon Advanced Barrier Film applied to areas of IAD
88830112|NCT03754127|Experimental|Active group|tDCS
88830113|NCT03754127|Sham Comparator|Sham group|Sham tDCS
88830114|NCT03730883|Experimental|Central line removal at 100ml/kg/day.|"In this group central line will be removed at the time the infant reaches 100 ml/kg/day of enteral intake. Central lines will be removed after 3 well tolerated consecutive feedings (assessed by the physician) with no contraindications for central line removal present.~Assessment of feedings tolerance will be at discretion of the physician taking care for the infant. After central line removal, infants in this group may continue to receive parenteral nutrition via peripheral venous access, depending on the decision of the physician taking care for the infant.~Parenteral nutrition will be prescribed according to the local protocol. Enteral nutrition will be initiated during the first days of life and advanced gradually at the discretion of the neonatologist."
88830115|NCT03730883|Active Comparator|Central line removal at 140 ml/kg/day.|"In this group central line will be removed at the time the infant reaches 140 ml/kg/day of enteral intake (full enteral intake). In this group central line will be removed at the time the infant reaches 100 ml/kg/day of enteral intake. Central lines will be removed after 3 well tolerated consecutive feedings (assessed by the physician) with no contraindications for central line removal present.~Assessment of feedings tolerance will be at discretion of the physician taking care for the infant.~Parenteral nutrition will be prescribed according to the local protocol. Enteral nutrition will be initiated during the first days of life and advanced gradually at the discretion of the neonatologist."
88830116|NCT03649061|Active Comparator|standard COBRA-Slim induction|Leflunomide 10mg PO daily added to the COBRA-Slim scheme (Methotrexate 15 mg PO weekly, Step down scheme of GC: 30-20-12,5-10-7,5-5 mg prednisone PO daily, each for 7 days except for the lowest dose of 5 mg, this will be maintained until w28 and then tapered to 2.5 mg daily for two weeks before stopping completely.)
88830117|NCT03649061|Experimental|COBRA-Slim Bio-induction|Etanercept 50mg subcutaneous (SC) weekly added for 24 weeks to COBRA-Slim scheme (Methotrexate 15 mg PO weekly, Step down scheme of GC: 30-20-12,5-10-7,5-5 mg prednisone PO daily, each for 7 days except for the lowest dose of 5 mg, this will be maintained until w28 and then tapered to 2.5 mg daily for two weeks before stopping completely.)
88830118|NCT02265744|Experimental|Experimental:Arm A: BMS-931699|12.5mg subcutaneous (SC) injection Weekly dosing
88830119|NCT02265744|Experimental|Experimental:Arm B: BMS-931699|12.5mg SC injection Every other Week dosing
88830120|NCT02265744|Experimental|Experimental:Arm C: BMS-931699|5mg SC injection Every other Week dosing
88830121|NCT02265744|Experimental|Experimental:Arm D: BMS-931699|1.25mg SC injection Every other Week dosing
88830122|NCT02265744|Placebo Comparator|Placebo Comparator: Arm E: Placebo matching BMS-931699|0mg SC injection Weekly dosing
88830123|NCT03647891|Experimental|CPAP Intervention Pathway|"Patients will receive continuous positive airway pressure (CPAP) therapy in the hospital followed by home CPAP therapy. Their home CPAP therapy will include wireless connectivity, which includes adherence data. Furthermore, the patients will be entered into our usual automated platform (USleep; ResMed Corp) in which patients with suboptimal CPAP use will be sent messages (based on patient preference) in order to ensure adherence to therapy. This platform is already a standard part of our usual care.~The patients will receive CPAP in addition to contemporary standard of care pharmacotherapy for their underlying cardiac condition(s). They will follow up at the Fontana Sleep Center within 1 month after discharge for assessment of CPAP use and asked to complete a questionnaire packet. Patients will be followed during the 30-day period and assessed for readmission rates, time to readmission, adherence to CPAP therapy, and presence of symptoms."
88830124|NCT03647891|No Intervention|Usual Care Pathway|Patients will receive contemporary standard of care pharmacotherapy for their underlying cardiac condition(s) and will not receive CPAP therapy for the duration of the study. They will be asked to follow up at the Fontana Sleep Center within 1 month after discharge for a repeat outpatient portable sleep study and asked to complete a questionnaire packet. The results of the outpatient portable sleep studies will be compared with the in-patient portable sleep study. Patients will also be asked to follow up with the Fontana Sleep Center within 1 month after discharge for assessment of primary and secondary outcomes. Patients will be followed during the 30-day period and assessed for readmission rates, time to readmission, adherence to CPAP therapy, and presence of symptoms.
88830125|NCT03624725|Active Comparator|modified BII+Braun|The jejunum of the input segment is properly ligated with double line 7 at 3-5cm from the anastomotic site, and the jejunum of the output segment is extended to 30cm
88830126|NCT03624725|No Intervention|traditional BII+Braun|traditional BII+Braun digestive tract reconstruct
88830127|NCT05109143|Active Comparator|Group B|Standard Medical Treatment
88830128|NCT05109143|Experimental|Group A|Will be administered 100mg of Indomethacin Suppository sigle dose at the time of induction of anesthesia with Standard Medical Treatment
88830129|NCT03614663|Experimental|ZYN002 - Cannabidiol transdermal gel|"ZYN002 supplied as a transdermal gel. Patients weighing less than or equal to 35 kg will be randomized to receive either 125 mg cannabidiol Q12H or placebo.~Patients weighing greater than 35 kg will be randomized to receive 250 mg cannabidiol Q12H or placebo."
88830130|NCT03614663|Placebo Comparator|Placebo transdermal gel|Matching ZYN002 placebo supplied as a transdermal gel.
88830131|NCT05648136|Experimental|patients|"Women aged 18 to 39 years~with a history of RIF or unexplained RM~with a negative diagnostic work-up (including pelvic ultrasound and hysteroscopy, parental karyotype, thyroid function test, and anti-thyroid and anti-phospholipid antibodies)~with a basal FSH level <10IU/l and AMH level >1.5ng/ml~with a regular menstrual cycle of 30+/-5 days~receiving a new cycle of in vitro fertilization (IVF) +/- intracytoplasmic sperm injection (ICSI) for patients in the RIF group or a first cycle of IVF +/-ICSI for patients in the RM group~received written and oral information and signed an informed consent"
88830132|NCT05648136|Active Comparator|control|"Controls recruited in the Obstetrics and Gynecology Department with at least one live birth after a spontaneous pregnancy (with a time to conception of less than 12 months for each pregnancy) Voluntary oocyte donors recruited within the CECOS de Picardie (having presented at least one live birth with a delay necessary to conceive of less than 12 months)~Controls recruited in the Reproductive Medicine and Biology Department having presented at least one live birth (spontaneous with a delay to conceive of less than 12 months for each pregnancy or after one or two MPA procedures) and benefiting from an IVF+/-ICSI procedure for secondary infertility~Controls recruited in the department of Medicine and Reproductive Biology with a normal infertility assessment and benefiting from an IVF procedure with ICSI on male indication."
88830133|NCT00085735|Experimental|Arm I (3-7 years of age, LDCSI, IFRT)|See Detailed Description (Arm I)
88830134|NCT00085735|Experimental|Arm II (3-7 years of age, LDCSI, PFRT)|See Detailed Description (Arm II)
88830135|NCT00085735|Experimental|Arm III (3-7 years of age, SDCSI, IFRT)|See Detailed Description (Arm III)
88830136|NCT00085735|Active Comparator|Arm IV (3-7 years of age, SDCSI, PFRT)|See Detailed Description (Arm IV)
88830137|NCT00085735|Experimental|Arm V (8-21 years of age, SDCSI, IFRT)|See Detailed Description (Arm V)
88830138|NCT00085735|Active Comparator|Arm VI (8-21 years of age, SDCSI, PFRT)|See Detailed Description (Arm VI)
88830139|NCT03578783|Experimental|PSD502|PSD502 spray contains a eutectic-like mixture of lidocaine and prilocaine, and a propellant (norflurane) which also serves as a solvent. Each spray contains 7.5 mg lidocaine and 2.5 mg prilocaine. A single dose consists of 3 sprays applied to the glans penis.
88830140|NCT03578783|Placebo Comparator|Placebo|The placebo is a metered dose spray, identical in appearance to the active treatment and contains the same propellant (norflurane) but has no lidocaine or prilocaine (instead it contains PEG600 and Povidone).
88830141|NCT04338737|Active Comparator|fluid and soft food|It consists of 100 patients that will be allocated for early post-operative oral feeding receiving water and clear fluid approximately 2 hours after surgery, followed by soft food and regular diet 4 hours later irrespective to intestinal sounds, flatus or stool.
88830142|NCT04338737|Active Comparator|fluid only|It consists of 100 patients that will be allocated for early Postoperative oral feeding receiving water and clear fluid approximately 2 hours after surgery till the return of intestinal sounds, then soft food and regular diet later on.
88830143|NCT04338737|Active Comparator|Npo|It consists of 100 patients that will receive no oral feeding till passage of flatus instead 2 to 3 Litres of intravenous fluid will be used for feeding. Water and fluid will be then offered, followed by soft foods and then a regular diet.
88830144|NCT05544786|Active Comparator|Treatment A: Nirmatrelvir/ritonavir|Nirmatrelvir and ritonavir tablets
88830145|NCT05544786|Experimental|Treatment B: Nirmatrelvir/ ritonavir|Nirmatrelvir/ritonavir with water
88830146|NCT05544786|Experimental|Treatment C: Nirmatrelvir/ ritonavir|Nirmatrelvir/ ritonavir with infant formula
88830147|NCT05544786|Experimental|Treatment D: Nirmatrelvir/ ritonavir|Nirmatrelvir/ ritonavir with vanilla pudding
89177840|NCT04109742|Active Comparator|Curcumin 1000mg capsules|Dose will be1g daily of phosphatidylcholine-curcumin complex supplement, orally for 24 weeks
89177841|NCT04109742|Placebo Comparator|Placebo curcumin capsules|Dose will be matching placebo capsules daily, orally for 24 weeks
88830148|NCT05544786|Experimental|Treatment E: Nirmatrelvir/ ritonavir|Nirmatrelvir/ ritonavir with food and vanilla pudding
88830149|NCT02726789|Experimental|Experimental|Patients either treatment naive or with HBV DNA controlled with entecavir receive REP 2139-Ca in combination with pegylated interferon. Only patients receiving entecavir at enrollment continue to receive entecavir during treatment in the study.
89177842|NCT00813488|Experimental|Fentanyl buccal tablet first then immediate release oxycodone|This crossover study includes a screening period, two titration periods, two double-blind treatment periods during which subjects will be randomized to receive fentanyl buccal tablet (FBT) plus placebo during the first treatment period and then immediate release oxycodone plus placebo during the second treatment period or vice versa, then followed by a 12-week open-label treatment period with FBT or an alternative short acting opioid.
88830150|NCT04420104|Experimental|esp block group|
88830151|NCT04420104|Active Comparator|control group|
88830152|NCT02731313||Gastric and Gastro-Esophageal Junction (GEJ) Carcinoma|Tumor samples with histologically confirmed gastric or GEJ adenocarcinoma, any stage, were collected and analyzed. No study visits or interventions were planned.
88830153|NCT02281591|Experimental|eslicarbazepine acetate|900mg of eslicarbazepine acetate (ESL, BIA 2-093)
88830154|NCT02281591|Active Comparator|S-licarbazepine R-licarbazepine|450 mg of S-licarbazepine plus 450 mg of R-licarbazepine
88830155|NCT02281591|Active Comparator|S-licarbazepine|450 mg of S-licarbazepine
88830156|NCT02281591|Active Comparator|R-licarbazepine|450 mg of Rlicarbazepine
88830157|NCT02987101|Experimental|Autologous SVF + Standard of care|"local injection around and under wound with autologous stromal vascular fraction.~Standard wound care is given independent of this study."
88830158|NCT02987101|Other|Standard of care|Standard wound care is given independent of this study.
88830159|NCT01880047|Active Comparator|Eltrombopag|Subjects in the study will receive 75 mg eltrombopag and then be randomized to receive either an additional 25 mg of eltrombopag or matching placebo tablet dispensed by the research pharmacy. Subjects and investigators will be blinded to randomization. Randomization will be stratified according to splenectomy status. Randomization will be performed at the time of informed consent with a computer generated randomization table. Subjects and investigators will be blinded to assignment and treatment in this phase.
88830160|NCT01880047|Placebo Comparator|Placebo|Subjects will be randomly allocated in a two to one ratio to receive treatment or placebo. All subjects in the study will receive 75 mg eltrombopag and then be randomized to receive either an additional 25 mg of eltrombopag or matching placebo tablet dispensed by the research pharmacy. Subjects and investigators will be blinded to randomization. Randomization will be stratified according to splenectomy status.
88830161|NCT02731469|Experimental|BCD-131, 0.05 mcg/kg subcutaneously|Healthy volunteers will receive BCD-131 in a dose 0.05 mcg/kg subcutaneously
88830162|NCT02731469|Experimental|BCD-131, 0.15 mcg/kg subcutaneously|Healthy volunteers will receive BCD-131 in a dose 0.15 mcg/kg subcutaneously
88830163|NCT02731469|Experimental|BCD-131, 0.40 mcg/kg subcutaneously|Healthy volunteers will receive BCD-131 in a dose 0.40 mcg/kg subcutaneously
88830164|NCT02731469|Experimental|BCD-131, 1.05 mcg/kg subcutaneously|Healthy volunteers will receive BCD-131 in a dose 1.05 mcg/kg subcutaneously
88830165|NCT02731469|Experimental|BCD-131, 1.70 mcg/kg SC|Healthy volunteers will receive BCD-131 in a dose 1.70 mcg/kg subcutaneously
88830166|NCT02731469|Experimental|BCD-131, 2.25 mcg/kg SC|Healthy volunteers will receive BCD-131 in a dose 2.25 mcg/kg subcutaneously
88830167|NCT02731469|Experimental|BCD-131, 4.45 mcg/kg subcutaneously|Healthy volunteers will receive BCD-131 in a dose 4.45 mcg/kg subcutaneously
88830168|NCT02731469|Active Comparator|Mircera®, 1.20 mcg/kg subcutaneously|Healthy volunteers will receive Mircera in a dose 1.20 mcg/kg subcutaneously
88830169|NCT02731469|Active Comparator|Aranesp®, 0.45 mcg/kg subcutaneously|Healthy volunteers will receive BCD-131 in a dose 0.45 mcg/kg subcutaneously
88830170|NCT02731469|Experimental|BCD-131, optimal dose, intravenously|Healthy volunteers will receive BCD-131 in optimal dose determined on first stage of clinical trial intravenously
88830171|NCT02731469|Experimental|BCD-131, optimal dose, subcutaneously|Healthy volunteers will receive BCD-131 in optimal dose determined on first stage of clinical trial subcutaneously
88830172|NCT03493217|Experimental|ICP-022|Two regimens of ICP-022 (High and low dose QD) are designed for study Part I to determine RP2D. The RP2D determined will be used in Part II to further evaluate the preliminary efficacy of ICP-022 in Chinese subjects with R/R CLL/SLL.
88830173|NCT01882543|Experimental|AQX-1125|1 x AQX-1125 Capsule daily
88830174|NCT01882543|Placebo Comparator|Placebo|1 x placebo capsule daily
88830175|NCT01944319|Active Comparator|Control group|The participants in control group will accept routine meropenem therapy
88830176|NCT01944319|Experimental|Study group|The participants in study group will accept meropenem therapy based on a PPK and PD model.
88830177|NCT03424499|Active Comparator|Single-use catheter|"Participants will use a sterile single-use catheter of polyvinyl chloride (PVC) for intermittent urethral catheterization.~Intermittent Bladder Catheterization will be done using clean technique, each PVC catheter will be sterile and used only once for each catheterization.~A Urine culture will be performed at day 0, 7, 14, 28, 49 and 56 (a total of 8 cultures)"
89177843|NCT00813488|Experimental|Immediate Release Oxycodone first then FBT|This crossover study includes a screening period, two titration periods, two double-blind treatment periods during which subjects will be randomized to receive fentanyl buccal tablet (FBT) plus placebo during the first treatment period and then immediate release oxycodone plus placebo during the second treatment period or vice versa, then followed by a 12-week open-label treatment period with FBT or an alternative short acting opioid.
88830178|NCT03424499|Experimental|Reused catheter with 0.5% benzalkonium chloride|"Participants will use a clean reused catheter of polyvinyl chloride for intermittent urethral catheterization.~Intermittent Bladder Catheterization will be done using clean technique. The PVC catheter will be used for 1 week, cleaning the catheter with water and soap after each catheterization and stored in a container with 0.5% benzalkonium chloride.~A Urine culture will be performed at day 0, 7, 14, 28, 49 and 56 (a total of 8 cultures)"
89358918|NCT01319123|Other|wound dressing|The dressing is indicated for moderately to heavily exuding wounds such as venous leg ulcers.
88830179|NCT03424499|Experimental|Reused catheter with soap and water|"Participants will use a clean reused catheter of polyvinyl chloride for intermittent urethral catheterization.~Intermittent Bladder Catheterization will be done using clean technique. The PVC catheter will be used for 1 week, cleaning the catheter with water and soap after each catheterization.~A Urine culture will be performed at day 0, 7, 14, 28, 49 and 56 (a total of 8 cultures)"
88830180|NCT00368381|Active Comparator|Hydrocortision and fludrocortisone|Study is comparing hydrocortisone alone versus the combination of hydrocortisone and fludrocortisone in the treatment of adrenal insufficiency of septic patients.
88830181|NCT02733653|Experimental|Jetstream Atherectomy System|Adjunctive therapy with Jetstream Atherectomy System for percutaneous intervention
88830182|NCT02734355|Active Comparator|Therapy|Telmisartan 80 mg and amlodipine 5 mg tablet by mouth every 24 hours for 7 days
88830183|NCT02734355|Placebo Comparator|Placebo|Placebo (for telmisartan 80 mg and amlodipine 5 mg) tablet by mouth every 24 hours for 7 days
88830184|NCT00369395|Experimental|Volociximab|Volociximab 15 mg/kg
88830185|NCT04984109|Sham Comparator|Control group|Patients will receive preoperative US-guided will receive sham PENG with an injection of just 1mL saline.
88830186|NCT04984109|Experimental|PENG Group|Patients will receive preoperative US-guided will receive real PENG with an injection of 20mL of bupivacaine 0.25%+ 0.2mg/mL dexamethasone.
88830187|NCT01947907|Experimental|ACP-001, dose-level 1|Once weekly subcutaneous injection of ACP-001
88830188|NCT01947907|Experimental|ACP-001, dose-level 2|Once weekly subcutaneous injection of ACP-001
88830189|NCT01947907|Experimental|ACP-001, dose-level 3|Once weekly subcutaneous injection of ACP-001
88830190|NCT01947907|Active Comparator|Human Growth Hormone|Once daily subcutaneous injection of human Growth Hormone (rhGH)
88830191|NCT05735665|Experimental|study group: the bowel Ultrasound-based treat to target arm|"At W12 ± 4 and W24 ± 4, subjects will perform FC and bowel US and PRO will be recorded.~If rectal bleeding > 2 + stool frequency > 2 AND FC > 250 mcg/g AND/OR MUC > 6.2, treatment will be changed according to GCP and international guidelines."
88830192|NCT05735665|Other|control group: the routine Colonoscopy treat to target arm.|"At W12 ± 4 and W24 ± 4, subjects will perform FC and PRO will be recorded for all patients.~If rectal bleeding > 2 + stool frequency > 2 AND FC > 250 mcg/g, treatment will be changed according to GCP and international guidelines. If rectal bleeding > 0 + stool frequency > 2 AND FC will be ≥ 50 mcg/g and ≤ 250 mcg/g, a RSS will be done in order to decide any treatment switch."
88830193|NCT02737397|Experimental|pain medicine and antihistamine|JMI-001 (SJP-304 and SJP-223)
88830194|NCT02737397|Active Comparator|pain medicine|SJP-304 and placebo
89358919|NCT03776435||CT-exposed group|
88830195|NCT02737397|Active Comparator|antihistamine|SJP-223 and placebo
88830196|NCT02737397|Placebo Comparator|placebo|placebo and placebo
88830197|NCT02737631|Experimental|Healthy subject|"Healthy subjects exposed to Chameleon personal lubricant via occlusive patch"
88830198|NCT01948141|Experimental|Treatment (nintedanib)|Patients receive nintedanib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88830199|NCT04938323|Experimental|BCG Vaccine|Participants randomized to the BCG Vaccine Arm will receive the vaccine. The vaccination site is about halfway down the outer aspect of the upper arm.
88830200|NCT04938323|Placebo Comparator|Placebo Arm|Placebo will be administered in an intradermal route in the same location as the BCG vaccines': upper arm.
88830201|NCT05446493|Active Comparator|Tadalafil group|Each patient will be treated by tadalafil 5mg daily for 3months
88830202|NCT05446493|No Intervention|control group|Estimation of serum YKL-40, platelet indices and serum total testosterone in healthy individuals in camparing with tadalafil group
89358920|NCT03776435||CT-unexposed group|
89358921|NCT03776513|Experimental|experimental group|Thirty obese boys (12-17 years old) undergoing an MRI, a clinical and psychological examination and a series of cognitive tests
89358922|NCT03776513|Other|control group|Thirty healthy boys (12-17 years old) paired for pubertal stage, level of education and socio-economic level undergoing an MRI, a clinical and psychological examination and a series of cognitive tests
89358923|NCT03776279|Experimental|Mitoxantrone Hydrochloride Liposome Injection|4 weeks is a treatment cycle, and the first day of each cycle is administered.
89358924|NCT03776045|No Intervention|Standard care|This group did not receive any supervised exercise or were not given any specific exercise recommendations during the trial period. However, patients in this group were offered the exercise intervention after completing the study.
89358925|NCT03776045|Experimental|Standard care plus exercise|This group received standard care in addition to a 3-month exercise intervention upon initiating androgen deprivation therapy.
89358926|NCT03709823|Experimental|1.5 mg Cytisine, Commercial Schedule|1.5 mg cytisine dose using the commercial 25-day titration schedule + behavioral support
89358927|NCT03709823|Experimental|3.0 mg Cytisine, Commercial Schedule|3.0 mg cytisine dose using the commercial 25-day titration schedule + behavioral support
89358928|NCT03709823|Placebo Comparator|Placebo, Commercial Schedule|Placebo tablets using the commercial 25-day titration schedule + behavioral support
89358929|NCT03709823|Experimental|1.5 mg Cytisine, TID Schedule|1.5 mg cytisine dose for 25 days using a simplified 3 times daily (TID) schedule + behavioral support
89358930|NCT03709823|Experimental|3.0 mg Cytisine, TID Schedule|3.0 mg cytisine dose for 25 days using a simplified TID schedule + behavioral support
89177844|NCT02604030|Experimental|Upper limb function|Assessment of scapular kinematics during arm elevation, perceived function, quality of life, range of motion and muscle strength for shoulder complex after a rehabilitation program focused on upper limb.
88830203|NCT01948375|Experimental|real needle- placebo needle|Participants received acupuncture with real needle in the first period, and with pragmatic placebo acupuncture needle in the second period.
88830204|NCT01948375|Experimental|placebo needle - real needle|Participants received acupuncture with pragmatic placebo needle in the first period, and with real acupuncture needle in the second period.
88830205|NCT05446103|Experimental|BFR|20 healthy individuals will be assigned to perform elbow flexion exercises with low-load resistance BFR training (30% of 1 RM)
88830206|NCT05446103|Sham Comparator|Sham BFR|20 healthy individuals will be assigned to perform elbow flexion exercises with high-load resistance training with sham BFR (65% of 1 RM)
88830207|NCT04934033|Other|Healthy volunteers|The participants will constitue a cohort of healthy volunteers, they will have a MRI, and language and cognitive assessment.
88830208|NCT01885117|Experimental|TIVf (18 to ≤ 60 years)|Adult subjects aged 18 to ≤ 60 years received one dose of trivalent, surface antigen inactivated subunit influenza virus vaccine (TIVf), formulation 2013/2014 Northern Hemisphere
88830209|NCT01885117|Experimental|TIVf (≥ 61 years)|Adult subjects aged ≥ 61 years received one dose of trivalent, surface antigen inactivated subunit influenza virus vaccine (TIVf), formulation 2013/2014 Northern Hemisphere
88830210|NCT04895501|Active Comparator|running with stiff shoes|21 km of running with stiff shoes followed by a time-to-exhaustion run.
88830211|NCT04895501|Experimental|running flexible shoes|21 km of running flexible shoes followed by a time-to-exhaustion run.
88830212|NCT02905721|Experimental|Spectral cardiac CT scan|All patients will undergo cardiac CT scan with spectral mode acquisition
88830213|NCT04879355|Experimental|Spinal needle|Fine needle aspiration from thyroid nodules using af spinal needle.
88830214|NCT04879355|Active Comparator|Conventional fine needle|Fine needle aspiration from thyroid nodules using af conventional fine needle, which is traditionally used.
88830215|NCT00368771|Active Comparator|1|IBS Stress Management
88830216|NCT00368771|Active Comparator|2|IBS Symptom Management
88830217|NCT00368771|Active Comparator|3|IBS Educational Training
88830218|NCT02711735|Active Comparator|RUTI® vaccine|Intervention: Patients randomized to receive RUTI® vaccine will receive one injection of RUTI® vaccine in their right or left deltoid muscle.
88830219|NCT02711735|Placebo Comparator|Matching RUTI® Placebo|Intervention: Patients randomized to receive Placebo will receive one injection of Placebo in their right or left deltoid muscle.
88830220|NCT04738565|Experimental|Probiotic|The mixture of 3 probiotic strains in the following proportions: 50% Lactobacillus casei ŁOCK 0919, 25% Lactobacillus rhamnosus ŁOCK 0908, 25% Lactobacillus rhamnosus ŁOCK 0900 (Latopic® preparation, Biomed S.A., Cracow, Poland).
88830221|NCT04738565|Placebo Comparator|Maltodextrin|Maltodextrin - a substance in which probiotic strains have been suspended.
88830222|NCT05445011|Experimental|TAA05 Cell Injection|Fludarabine + Cyclophosphamide + TAA05 Cell Injection Patients will receive lymphodepletion with fludarabine (25 mg/kg) and cyclophosphamide (250 mg/kg) for 3 days on day -7~-2, followed by the infusion of TAA05 Cell with the dose of 1×10^8, 2×10^8 or 4×10^8 cells on day 0. If no dose-limited toxicity(DLT) emerges in the group, then the subsequent higher dose will be used in the next group. If DLT emerges in a single subject in any dose level, 3 more subjects will be enrolled to the same dose level. After the end of dose climbing, if the maximum dose group(MTD) is still not observed, the highest dose group is defined as MTD.
88830223|NCT02380781|No Intervention|Control|Patients will receive current standard postpartum contraceptive counseling.
88830224|NCT02380781|Experimental|Intervention|Patients will receive current standard postpartum contraceptive counseling and will be shown a 10 minute video from the CHOICE project which outlines the different contraceptive options
88830225|NCT04744181||cases|patients who fulfill the inclusion criteria
88830226|NCT04744181||controls|Patients who underwent cardiac surgery in 2019 and 2018
88830227|NCT05444387|Experimental|Upper Limb Loading Group|Partial body weight support treadmill training with upper limb external weights in addition to conventional treatment: balance, gait training, facilitation for normal development
88830228|NCT05444387|No Intervention|Control Group|Partial body weight support treadmill training without upper limb external weights in addition to conventional treatment: balance, gait training, facilitation for normal development
88830229|NCT01887041|Active Comparator|Stent|Arm B, after randomisation the biliary tract stents shall remain. The patients in study arm B will also receive chemotherapy and gemcitabine, according to the recommended palliative therapy for a pancreas carcinoma.
88830230|NCT01887041|Active Comparator|Biliodigestive anastomosis|"Study arm A will, after randomisation, have a biliodigestive anastomosis inserted. After the healing of the wound (al least 14 days postoperative) the treatment using gemcitabine, according to the plan mentioned below.~Gemcitabine shall be administered on days 1, 8 and 15 of each 4 week cycle. The cycle is defined as a weekly, over a period of 3 consecutive weeks, applied infusions, followed by 1 week pause. On the day of therapy a dosage of 1000 mg/ml body surface shall be administered, intravenous, over a period of 30 minutes."
88830231|NCT04717115||Genetic diagnosis|
88830232|NCT00619931|Experimental|1|APD791 or placebo
88830233|NCT00619931|Experimental|2|APD791 or placebo
88830234|NCT00619931|Experimental|3|APD791 or placebo
88830235|NCT00619931|Experimental|4|APD791 or placebo
88830236|NCT00619931|Experimental|5|APD791 or placebo
88830237|NCT05452655|Experimental|Intensive Outpatient Integrated Motor-Cognitive and Aerobic Exercises Rehabilitation Program|Intervention of highly challenging motor and cognitive training for 6 consecutive weeks.
88830238|NCT05452655|Active Comparator|Home-Based Stretching Exercises|Home-based self-treatment program for 40 '/ day for 6 consecutive weeks
88830239|NCT04739111|Experimental|Experimental Arms|All participants will receive treatment with LDP combined with CDP1. In the dose-escalation phase, a fixed dose of CDP1 will be given once a week, while LDP will be given every two weeks with dose climbing. Then, cohort studies (cohorts 1 to 5) will be conducted during the dose-expansion phase.
88830240|NCT05444075||subjects with preparatory education level|Ten subjects have a preparatory education level
88830241|NCT05444075||subjects with high school education|ten subjects with a high school education or its equivalent
88830242|NCT05444075||subjects with university education|ten subjects who have a university education, or are still in a university education stage
88830243|NCT05443997|Experimental|A&T- intensive|"Capacity building will involve offsite training conducted by Vitamin Angels and short capsule trainings delivered by government staff~Supportive supervision will involve training and handholding of supervisors on use of job aids and mobile application~Strategic use of data will involve setting up processes to review key data, review meetings and short trainings on gap areas.~Engagement of Panchayati Raj Institutions (PRI) around convergence where PRI members will be equipped with job aids, including an App~Improved food supplements where THR offering for pregnant and lactating women and children 6 months and older will be revisited and improved solutions will be explored."
88830244|NCT05443997|No Intervention|A&T-non intensive|Only receives standard government services
88830245|NCT01885897|Experimental|Study treatment|Weekly dose of ALT-803 at assigned dose, ranging from 1mcg/kg to 30 mcg/kg (based on phase 1 dose escalation schedule,) IV once a week for 4 weeks.
88830246|NCT04621331|Experimental|Roxadustat|Starting doses of 20, 50, 70 or 100 mg based on weight.
88830247|NCT04768231|Experimental|R35HZE|Participants treated with rifampicin at a dose of 35 mg per kilogram of body weight per day, added to the standard doses of isoniazid, pyrazinamide and ethambutol.
88830248|NCT02987725|Active Comparator|Attention Control|Participants will listen to a 30-minute historical story.
88830249|NCT02987725|Experimental|Hypnosis|Participants will receive a 30-minute hypnosis session
88830250|NCT05452421|Experimental|Group A|
88830251|NCT05452421|Experimental|Group B|
88830252|NCT01889563|Experimental|Physical exercise training program|Physical Exercise Training Program Exercise training was conducted in three times a week, during 12 weeks at high-intensity targets. Each session consisted of a five minute warm up (walking) at 2 km/h and 30 minutes with an intensity targets set at 70% of the peak speed rate. The increase of intensity was 0.5Km/h when the patient scored less than 4 point of Borg scale (moderate to intense effort) during each session. All evaluations were done at 6th week, in order to analyze the progression of outcomes and exactly adjust the intensity of training.
88830253|NCT01889563|No Intervention|No Physical Exercise Training Program|No Physical Exercise Training Program
88830254|NCT04608851|Experimental|Nissle group|Intervention will start on the day following the ending of the antimicrobial treatment of the UTI. Patients will receive 1 ml of oral suspension containing 10 E8 CFU/ml of E coli Nissle. Patients under one year of age will receive one daily dose and patients aged more than one year will receive a dose twice daily. Intervention will last for 30 days
88830255|NCT04608851|Placebo Comparator|Control group|Intervention will start on the day following the ending of the antimicrobial treatment of the UTI. Patients will receive 1 ml of oral syrup consisting of Saccharum 630 mg/g and Aqua purificata 370 mg/g. Patients under one year of age will receive one daily dose and patients aged more than one year will receive a dose twice daily. Intervention will last for 30 days
88830256|NCT04599491|Experimental|INTELLiVENT-ASV with sidestream capnography|Patients randomized into the 'Sidestream capnography'-arm will receive postoperative ventilation on the ICU with INTELLiVENT-ASV with sidestream etCO2 monitoring.
88830257|NCT04599491|Active Comparator|INTELLiVENT-ASV with mainstream capnography|Patients randomized into the 'Mainstream capnography'-arm will receive postoperative ventilation on the ICU with INTELLiVENT-ASV with mainstream etCO2 monitoring.
88830258|NCT05452343|Experimental|CM310|600 mg (first dosing) + 300 mg (subsequent dosing), once every two weeks
88830259|NCT05452343|Placebo Comparator|Placebo|once every two weeks
88830260|NCT05452265||endoscopic resection (ER)|ER with backup surgery was indicated for patients with endoscopic intent, and a small tumor size tolerated endoscopic retrieval.
89177845|NCT02603874|Experimental|Target Tape|Including target tape in the procedure
89177846|NCT02603874|No Intervention|Control|Without target tape in the procedure
89177847|NCT04109664||antral preservation|The patients were grouped according to the distance of gastric division as Antral preservation group (6cm from pylorus)
89358931|NCT03709823|Placebo Comparator|Placebo, TID Schedule|Placebo tablets for 25 days using a simplified TID schedule + behavioral support
89358932|NCT03488563|Experimental|B244 Dose 1|B244 1X suspension in 30ml/bottle Subjects will apply 1 pump per nostril twice-a-day
89358933|NCT03488563|Experimental|B244 Dose 2|B244 4X suspension in 30ml/bottle Subjects will apply 1 pump per nostril twice-a-day
89358934|NCT03488563|Placebo Comparator|Vehicle|Vehicle, 30ml/bottle Subjects will apply 1 pump per nostril twice-a-day
89358935|NCT03775889|Experimental|Behavioral|Behavioral Gardening Exposure
89358936|NCT03718741|Experimental|Adiuvant Radiotherapy +/- CT|"The radiation treatment will be delivered with two possible schedules, according to the presence of positive margins on the pathology specimen:~R0: PTVb + PTVn 50 Gy in 25 fractions~R1-2: PTVn 50 Gy in 25 fractions. PTVb (including cystectomy bed and residual tumor when present) 55 Gy in 25 fractions with simultaneous integrated boost (SIB).~Considering an alfa/beta of 10 for bladder tumor and 3 for healthy tissues the equivalent doses will be respectively:~BED10: 60/67.1; EQD2: 50/55.92 Gy BED3: 83.33/95.33; EQD2: 50/57.20 Gy~Patients with ECOG PS<2, good haematological, hepatic and renal function (haemoglobin, neutrophil count, platelets, creatinine, glycaemia, Bilirubin, AST, ALT values within the limits of normal), will be submitted to concurrent cisplatin based weekly chemotherapy, 20-30 mg/m2, if they have not received neoadjuvant chemotherapy before surgery."
89358937|NCT03775655|Active Comparator|LD-DEX|This group will receive 7mg hyperbaric bupivacaine (about 1.4 ml of hyperbaric bupivacaine 0.5%) and 10μg dexmedetomidine (10 unit by U-100 insulin syringe using a preservative free dexmedetomidine 100μg/ml).
89358938|NCT03775655|No Intervention|Control group|This group will receive 12 mg hyperbaric bupivacaine (about 2.2 ml of hyperbaric bupivacaine 0.5%).
89358939|NCT03775733|Experimental|Hydrolysed red ginseng extract|Hydrolysed red ginseng extract 2.4g/day for 12 weeks
89358940|NCT03775733|Placebo Comparator|Placebo|Placebo for 12 weeks
89358941|NCT01320059|Experimental|Imaging with 18F-PEG6-IPQA|Radioactive injection given by vein before multiple (3) PET scans.
89358942|NCT03775031|Active Comparator|Fraxel 1927nm|Treatment setting for Fraxel 1927 nm: 20 mJ, Treatment level 8, 6 passes
89358943|NCT03775031|Active Comparator|Fraxel 1550nm|Treatment setting for Fraxel 1550 nm: 70 mJ, Treatment level 6, 6 passes
89358944|NCT03775031|Active Comparator|25% TCA Peel|25% TCA on 5 x 5 cm of sun exposed back
89358945|NCT03775031|Placebo Comparator|Control|Patient serves as their own control
89358946|NCT03775499|Other|Period 1: Placebo - Period 2: BL NCC 2705|For the 2 populations (Celiac and Non-Celiac Gluten Sensitivity)
88830261|NCT05452265||laparoscopic resection (LR)|LR was indicated for patients with surgical intent, and those with the following conditions, which were not suitable for ER: (1) large tumor size with difficult endoscopic retrieval ; (2) symptoms of gastrointestinal tract bleeding with difficulty in endoscopic visualization; (3) suspicion of tumor rupture that required intra-abdominal exploration; and (4) histologic diagnosis of GIST with initial treatment of target therapy.
88830262|NCT04594031|Experimental|ECT-001-CB|"An Umbilical Cord Blood for transplant will undergo CD34+ selection and expansion. The CD34- fraction is infused on Day +1 post-transplant.~Patients will receive standard supportive care and GVHD prophylaxis"
88830263|NCT05452187||Patients with IBD and chronic HCV infection treated with DAAs and/or interferon.|Cohort patients with IBD and chronic HCV infection treated with DAAs and/or interferon collected from the ENEIDA database.
88830264|NCT05443373||experimental group (narcolepsy Type 1)|experimental group (narcolepsy Type 1, 300 subjects)
88830265|NCT05443373||experimental group (narcolepsy Type 2)|experimental group (narcolepsy Type 2, 100 subjects)
88830266|NCT05443373||experimental group (KLS)|experimental group (KLS, 100 subjects)
89358947|NCT03775499|Other|Period 1: BL NCC 2705 - Period 2: Placebo|For the 2 populations (Celiac and Non-Celiac Gluten Sensitivity)
89358948|NCT01310465|Experimental|Experimental group|Three days postoperatively, patients in this group are given one infusion of zoledronic acid intravenously.
89358949|NCT01310465|Placebo Comparator|Placebo Comparator|Three days postoperatively, patients in this group are given one infusion of sodium chloride intravenously.
89358950|NCT03782441|Experimental|RSP-19|Subjects will perform daily measurements on the IMD (Prototype 0.5) for 42 days.
89358951|NCT05457179|Experimental|Intervention|PARCS is a park-based physical activity intervention including aerobic and resistance training adapted for adults with serious mental illness and led by certified peer counselors as part of peer group mental health recovery services.
89358952|NCT05457179|Active Comparator|Active Control|"The active control group will receive information about the importance of park-based PA and a map of local park locations but will not participate in structured park-based PA sessions. Participants in the control group will be invited to participate in park PA sessions after they have completed posttest.~Participants in both groups will receive usual care outpatient peer group treatment services, including routine counseling and health and wellness information/activities given by CPSs."
89358953|NCT05456399||Patients with cranial MRI|Axial sections of 5 mm and 1 mm thickness will be imaged. The thickness of the temporal muscle will be measured from the posterior angle, where the temporal fossa loses its cavity. After the MRI measurements are completed, the thickness of the muscle will be measured by ultrasound at the same location by two clinicians (a radiologist and a physiatrist) who are expertise in musculoskeletal ultrasonography.
89358954|NCT05456399||Patients with cranial CT|Axial sections of 5 mm and 1 mm thickness will be imaged. The thickness of the temporal muscle will be measured from the posterior angle, where the temporal fossa loses its cavity. After the MRI measurements are completed, the thickness of the muscle will be measured by ultrasound at the same location by two clinicians (a radiologist and a physiatrist) who are expertise in musculoskeletal ultrasonography.
89358955|NCT03782129||Diabetic patients with DFU|Diabetic patients with DFU diagnosed in 2010
89358956|NCT03782051|Active Comparator|Phacovisco group|group had combined phacoemulsification and viscocanalostomy
89358957|NCT03782051|Active Comparator|OloPhacovisco group|group had combined phacoemulsification and viscocanalostomy and Ologen
89358958|NCT03781895|Placebo Comparator|A0|"A0- On day 0,before intervention placebo,~Microcrystalline Cellulose (303.8gm)~Butylated Hydroxy Toluene (0.2mg)~Magnesium Stearate (3mg)~Gelatin Capsule Shell (1mg)~weekly,orally,for 90days"
89358959|NCT03781895|Placebo Comparator|A90|"A90- On day 90,after intervention placebo,~Microcrystalline Cellulose (303.8gm)~Butylated Hydroxy Toluene (0.2mg)~Magnesium Stearate (3mg)~Gelatin Capsule Shell (1mg)~weekly,orally,for 90days"
89358960|NCT03781895|Active Comparator|B0|"B0- On day 0,before intervention cholecalciferol,~Cholecalciferol (40,000IU)~Microcrystalline Cellulose (58.1 gm)~Butylated Hydroxy Toluene ( 0.2mg)~Magnesium Stearate (3mg)~Gelatin Capsule Shell (1mg)~80.000IU/week,orally,for 90 days"
89358961|NCT03781895|Active Comparator|B90|"B90- On day 90,after intervention cholecalciferol,~Cholecalciferol (40,000IU)~Microcrystalline Cellulose (58.1 gm)~Butylated Hydroxy Toluene ( 0.2mg)~Magnesium Stearate (3mg)~Gelatin Capsule Shell (1mg)~80.000IU/week,orally,for 90 days"
89358962|NCT03781739|Experimental|MANP|subjects receiving MANP (2.5 micrograms/kg, single subcutaneous injection)
89000911|NCT04637542|Experimental|Experimental Group (Mobile)|"Application in Experimental Group: After the theoretical lesson, students in the experimental group were taken to an empty classroom. The mobile application was installed on the smartphones of the students in the experimental group by the researchers and they were told not to share it with anyone until the end of the study. At the end of the study, the mobile application was also installed on the phones of the students in the control group due to ethical sensitivity. Anatomy of Organs Forming the Genital System was explained on the mobile application containing the genital system organs. The students were allowed to ask questions and the questions were answered. Afterwards, all students in the experimental group were given a State Inventory by the researcher and asked to fill it in. Students were then asked to study using the genitalsystem.apk mobile application until the Knowledge Test (post-test) which took place three days later."
89358963|NCT03781739|Placebo Comparator|Placebo|subjects receiving placebo (saline solution, single subcutaneous injection)
89358964|NCT03781661|Experimental|Intervention Group|The participants in the intervention group will be provided with extended information of the advantages of the CT examination of the heart's arteries. This will be given to the participants both orally and written in form of a leaflet. In addition will they be given the opportunity for a visual go-through of their own calcium score images. After this they will be informed of the normal examination result.
89358965|NCT03781661|No Intervention|Control group|Control Group receives standard care.
89000912|NCT00201162|Experimental|Intervention|dietary supplement soy protein containing isoflavones
89000913|NCT00201162|Placebo Comparator|Placebo|dietary supplement casein placebo
89177848|NCT04109664||Antral resection|The patients were grouped according to the distance of gastric division as Antral preservation group (2 cm from pylorus)
89358966|NCT00706030|Experimental|neratinib 160 mg + vinorelbine|neratinib 160 mg tablets administered daily by mouth, vinorelbine 25 mg/m^2 administered IV on day 1 and day 8 of 21 day cycle
89358967|NCT00706030|Experimental|neratinib 240 mg + vinorelbine|neratinib 240 mg tablets administered daily by mouth, vinorelbine 25 mg/m^2 administered IV on day 1 and day 8 of 21 day cycle
89358968|NCT00706030|Experimental|neratinib 240 mg + vinorelbine, No Prior Lapatinib|neratinib 240 mg tablets administered daily by mouth, vinorelbine 25 mg/m^2 administered IV on day 1 and day 8 of 21 day cycle
89358969|NCT00706030|Experimental|neratinib 240 mg + vinorelbine, Prior Lapatinib|neratinib 240 mg tablets administered daily by mouth, vinorelbine 25 mg/m^2 administered IV on day 1 and day 8 of 21 day cycle
89358970|NCT05409599|Active Comparator|Vestibular Exercises|Cawthorne-Cooksey Exercises applied to 1st group for 3 days/week for 12 weeks
89358971|NCT05409599|Active Comparator|Cervical Stabilization Exercises|cervical stabilization Exercises applied to 1st group for 3 days/week for 12 weeks
89358972|NCT05409599|Active Comparator|Balance Exercises|classical balance Exercises applied to 1st group for 3 days/week for 12 weeks
89358973|NCT02484040|Experimental|Two-week course arm|"Experimental arm receive 33 Gy in 10 fractions of radiation for 2 weeks with oral capecitabine.~Two-week course of radiation, 33 Gy/10 fx and oral capecitabine, 825 mg/m2, bid"
89358974|NCT02484040|No Intervention|Conventional arm|conventionally fractionated radiation of 50.4 Gy/28 fx and 5-FU, 500 mg/m2 and leucovorin, 20 mg/m2 for 5 days, monthly or Capecitabine, 825 mg/m2, bid
89358975|NCT01312883|No Intervention|Treatment as usual|Participants will receive standard postpartum education and discharge materials provided by the hospital and a list of community and Internet resources by mail.
89358976|NCT01312883|Experimental|Behavioral education|Participants will receive behavioral education on postpartum depression and a list of community and Internet resources by mail.
89399132|NCT03031431|Experimental|Non-Electric Infant Warmer|In line with current recommended practice, mothers will be encouraged to provide Kangaroo Mother Care (KMC) whenever possible. If an infant's temp is not rising by ½ degree C per hour with KMC alone, the infant warmer will be offered as an addition by the study team. If the mother is not available for KMC at any time, the infant will be warmed exclusively with the warmer. Bundling in clothes will only be used in addition to the warmer per carer preference. Temp measurement of the infant, warmer, and ambient air will be measured every 15 mins for the first hr, then hrly and as needed for the remainder of use or until warmer endpoint is reached (warmer temp below 36 degrees or phase-change material hardens [soft, semisoft, or hardened]).
89358977|NCT03781505|Experimental|Intravenous paracetamol with Caudal Ropivacaine|"Paracetamol is widely accepted and most commonly used as an adjuvant for postoperative analgesia. It also improves the quality of recovery by attenuating the pain associated with the surgical position. Adverse effects associated with the paracetamol are rare <1/10000, which includes malaise, increased level of hepatic transaminases and hypersensitivity reaction. It has been studied in combination with caudal analgesia with bupivacaine through the rectal route 7,8 with variable results.~Caudal anaesthesia is effective in alleviating pain below the umbilicus. Also if the caudal block is administered at the beginning of surgery, the effect will start wearing off 2 to 3 hours post surgery. Administration of paracetamol towards end of surgery may help with both these issues. In this study we aim to investigate the effect of adding intravenous paracetamol in combination with caudal analgesia with ropivacaine, hoping that it may improve quality of postoperative analgesia and recovery."
89358978|NCT03781505|Placebo Comparator|Placebo|Intravenous Normal Saline with Caudal Ropivacaine
89358979|NCT02483728|Other|Metal Allergy Hx +, Metal Patch Test +|These are patients with a history of metal allergy who are patch test positive to metals (metal series, metal disc if available from manufacturer, bone cement components and topical antibiotics) prior to implantation of metal device.
89358980|NCT02483728|Other|Metal Allergy Hx +, Metal Patch Test -|These are patients with a history of metal allergy who are patch test negative to metals (metal series, metal disc if available from manufacturer, bone cement components and topical antibiotics) prior to implantation of metal device.
89358981|NCT03781271|Experimental|Fraction 1-Addition of EMN|During the fraction 1 insertion, the custom MRI-compatible vaginal cylinder will be placed in the patient, and will contain the 6 degree-of-freedom (DOF) sensor. The electromagnetic navigation system and computer will have been setup in the operating room (OR) prior to the procedure and will be used to actively insert up to 25 catheters into the target. The catheters will be inserted using a custom metallic stylet that has a custom 5-DOF sensor embedded in the tip for tracking its position in real-time. The physician may use ultrasound for assistance in target visualization as well. Catheter deflections will be detected and corrected for in real-time by the radiation oncologist as the catheter is inserted into the patient during the procedure, this will occur when the EM system is in use.
89358982|NCT03781271|Experimental|Fraction 3-Addition of EMN|For the second group of patients in the trial the same protocol will be followed as in the first group, the only difference will be that the electromagnetic navigation is used during the second implantation procedure immediately preceding fraction 3 as opposed to fraction 1, the time at which it was used for the first group of patients.
89358983|NCT05384327|Other|Interview|Content experts who will be interviewed in order to collect their opinion on theoretical knowledge.
89358984|NCT05384327|Other|Novices|Medical students who will complete the test
89358985|NCT05384327|Other|Intermediates|Junior residents (surgery, pneumology, emergency medicine) who will complete the test.
89358986|NCT05384327|Other|Experienced|Faculty members (surgery, pneumology, emergency medicine) who will complete the test.
88830267|NCT05443373||experimental group (IH)|experimental group (IH,50 subjects)
88830268|NCT05443373||healthy control group|healthy control group (age and gender matched healthy subjects,50 subjects)
88830269|NCT01889797|Active Comparator|Arm A: Rituximab|Rituximab 375 mg/m² IV weekly for 4 weeks.
88830270|NCT01889797|Experimental|Arm B: GA101|GA101 1,000 mg IV weekly for 4 weeks.
89399133|NCT03540056||Boys without varicocele|Boys thoroughly examined but without diagnose of varicocele
89399134|NCT03540056||Boys with a varicocoele|Boys with a diagnosed varicocele of any stage possible.
88830271|NCT00369551|Experimental|Treatment (paclitaxel, carboplatin, bevacizumab, radiation)|"Patients receive paclitaxel IV over 1 hour and carboplatin IV over 30-60 minutes on days 1, 8, 15, 22, 29, 36, and 43 and bevacizumab IV over 30-90 minutes on days 1, 15, 29, and 43. Patients also undergo chest radiotherapy 5 days a week for 7 weeks beginning on day 1.~Consolidation therapy: Beginning 4-5 weeks after completion chemoradiotherapy, patients receive paclitaxel IV over 1 hour followed by carboplatin IV over 1 hour followed by bevacizumab IV over 30 minutes. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity."
88830272|NCT01890031|No Intervention|Low Risk, No ICAT|Low risk, not randomized to use the Interactive Cholesterol Advisory Tool, no study physician visits
88830273|NCT01890031|Other|Low risk, ICAT|Low risk, randomized to use the Interactive Cholesterol Advisory Tool, no study physician visits
88830274|NCT01890031|Other|Low risk, ICAT, and study physician|Low risk, assigned to use the Interactive Cholesterol Advisory Tool, and study physician visits.
88830275|NCT01890031|Other|Moderate risk, no ICAT|Moderate risk, study physician visits, and not randomized to use the Interactive Cholesterol Advisory Tool
88830276|NCT01890031|Other|Moderate risk, ICAT|Moderate risk, study physician visits, and randomized to use the Interactive Cholesterol Advisory Tool
88830277|NCT04537793|Experimental|Part A: ELX/TEZ/IVA|Participants weighing greater than or equal to (>=)14 kilograms (kg) at screening received elexacaftor (ELX) 100 milligrams (mg) once daily (qd)/tezacaftor (TEZ) 50 mg qd/ivacaftor (IVA) 75 mg every 12 hours (q12h) in the treatment period for 15 days.
88830278|NCT04537793|Experimental|Part B: ELX/TEZ/IVA|Participants weighing (>=)14 kg at screening received ELX 100 mg qd/TEZ 50 mg qd/IVA 75 mg q12h. Participants weighing (>=)10 kg to less than (<)14 kg received ELX 80 mg qd/TEZ 40 mg qd/IVA 60 mg once every morning (qAM) and 59.5 mg once every evening (qPM) in the treatment period for 24 weeks.
88830279|NCT01949389|Experimental|Internet-based Cognitive Behavioral Therapy for Insomnia|This is an internet-based Cognitive Behavioral treatment for insomnia. It is accessed via a computer with an internet connection and consists of 7 modules, homework, and a daily sleep log. The intervention is self administered.
88830280|NCT04529291|Other|Group with walking disorder|This Group with walking disorder corresponds to patient reporting walking disorders due to his illness.
88830281|NCT04529291|Other|Group without walking disorder|This Group without walking disorder corresponds to patients not reporting walking disorders due to his illness.
88830282|NCT04480307|Experimental|temelimab 18 mg/kg|Monthly IV repeated dose
88830283|NCT04480307|Experimental|temelimab 36 mg/kg|Monthly IV repeated dose
88830284|NCT04480307|Experimental|temelimab 54 mg/kg|Monthly IV repeated dose
88830285|NCT04480307|Placebo Comparator|Placebo|Monthly IV repeated dose
88830286|NCT05450939||Ruptured group|Group of subarachnoid hemorrhage after rupture of intracranial aneurysm
88830287|NCT05450939||Unruptured group|Group of inexperience of aneurysmal rupture during specific period
88830288|NCT05450861|Experimental|SF DNA Treatment|the scalp conditioning solution with SF DNA extraction composition is applied daily and combination with hair loss medical treatment for eight weeks.
88830289|NCT05450861|Placebo Comparator|Placebo|the scalp conditioning solution without SF DNA extraction composition is applied daily and combination with hair loss medical treatment for eight weeks.
88830290|NCT05450783||Patients group|Patients and their relatives affected with left ventricular or biventricular AC and carrier of a pathogenic or likely pathogenic variant in one of the following genes : PKP2, DSG2, DSC2, JUP, DSP, DES, FLNC, PLN, LMNA, TMEM43, CDH2, BAG3, RYR2, RBM20
88830291|NCT05450627||Case|Adult patients diagnosed with pancreatic exocrine insufficiency of any etiology
88830292|NCT05450471|Experimental|L-lactide and trimethynele carbonate Terpolymers polymer implant|The polymer implant will be placed in the ethmoidal region, at the same time that the nasal endoscopic examination will be performed. The polymer in this study is biocompatible. The polymers will be made in the biomaterials laboratory located at the Pontifical Catholic University of São Paulo (PUC-SP), located in the city of Sorocaba-SP. Polymers will be provided free of charge for the study.
88830293|NCT05450471|Placebo Comparator|Placebo polymer implant|Placebo polymer implant
88830294|NCT05437601|Experimental|Astaxanthin|Patients will receive three capsules of astaxanthin (4mg) daily for 8 weeks.
88830295|NCT05437601|Placebo Comparator|Control|Patients will receive three capsules of placebo daily for 8 weeks.
88830296|NCT05437445||Cases Data|subjects having abnormal plasma amino acid profiles with either one or more amino acid concentrations beyond (high or low) the locally defined age-specific reference ranges
88830297|NCT04339907|Sham Comparator|Cataract surgery only|Participants needing cataract surgery, without glaucoma or any other corneal diseases.
88830298|NCT04339907|Sham Comparator|Glaucoma surgery only|Participants needing glaucoma filtration surgery, without any prior corneal transplantation.
88830299|NCT04339907|Experimental|Corneal transplantation|"Participants needing corneal transplantation (penetrating keratoplasty or Boston keratoprosthesis), with or without glaucoma.~This allows analyzing samples at baseline (time 0), at the time of the corneal transplantation procedure."
88830300|NCT04339907|Experimental|Intraocular surgery following corneal transplantation|"Participants needing intraocular surgery (cataract, retina or glaucoma), with prior corneal transplantation (penetrating keratoplasty or Boston keratoprosthesis).~This allows analyzing samples during the potential development or progression of glaucoma in participants who have previously undergone corneal transplantation."
88830301|NCT04339907|Experimental|Glaucoma surgery following corneal transplantation|"Participants needing glaucoma filtration surgery, with prior corneal transplantation (penetrating keratoplasty or Boston keratoprosthesis).~This allows analyzing samples once glaucoma is confirmed in participants who have previously undergone corneal transplantation."
88830302|NCT05447975|Experimental|Tai Chi group|
88830303|NCT05447975|No Intervention|Control|
88830304|NCT05450315|Experimental|TARG|Group will receive physical activity information targeted to young adult cancer survivors
88830305|NCT05450315|Active Comparator|CPAG|Group will receive the Canadian Public Health Guidelines
88830306|NCT05449925|Experimental|TEST GROUP|i-PRF and Microneedling Procedure in thin gingiva followed by orthodontic treatment
88830307|NCT05449925|No Intervention|CONTROL GROUP|no periodontal intervention
88830308|NCT05449847||Complicated HCV|
88830309|NCT05449847||Non Complicated HCV|
88830310|NCT04287101|Experimental|home PAC|A home PAC team will care for patients in his/her home within 3 weeks after acute hospitalization. The patient will get a physical therapy (PT) or occupational therapy (OT) 1 to 6 session(s) per week.
88830311|NCT04287101|Active Comparator|hospital PAC|A rehabilitation PAC team will care for patients in the hospital within 3 weeks after acute hospitalization. The patient will have 1 to 2 session(s) of PT or OT on weekdays, and a daily physician visit and nurse care.
88830312|NCT04287101|No Intervention|conventional care group|usual care
88830313|NCT05449613|Active Comparator|acupoint application|The acupoint application is applied each stick apply time 2h, once each day. Acupoints selected: Yanglingquan, Dubi, Neixiyan. The treatment lasted for 4 weeks.
88830314|NCT05449613|Placebo Comparator|placebo|The placebo is applied the same acupuncture points, each stick apply time 2h, once each day. Acupoints selected: Yanglingquan, Dubi, Neixiyan. The treatment lasted for 4 weeks.
88830315|NCT05447429|Experimental|TAP Block|In this group ,TAP block will be performed with 0.5% 15 ml bupivacaine + 5 ml .
88830316|NCT05447429|Placebo Comparator|Placebo|In this group , 20 ml saline solution will injected into the transversus abdominis plane.
88830317|NCT05447351||Treated|Counselling, personalized dietary strategy aimed at increasing the adherence to Mediterranean diet, personalized physical activity program with a personal trainer, use of digital tools (i.e., games, apps) aimed at improving the adherence to dietary/lifestyle indications.
88830318|NCT05447351||Control|generic dietary indications oriented to weight reduction; generic invitations to increase physical activity, routine monitoring
88830319|NCT04743557|Experimental|Cohort 1|Weekly infusions of DYN101 at the starting dose level
88830320|NCT05447039|Active Comparator|Montelukast treated|
88830321|NCT05447039|No Intervention|Standard treatment|
89177849|NCT04006626||PET group|the staging and management of newly diagnosed ER+ Breast Cancer Patients based on 18F-FDG PET/CT
89177850|NCT04006626||FES group|the staging and management of newly diagnosed ER+ Breast Cancer Patients based on 18F-FDG PET/CT and 18F-FES PET/CT
89358987|NCT03317470|Active Comparator|Phase I:|"In Phase 1 of the study (first five months), the investigators will enroll new patients when they call them to remind them of their first colposcopy appointment. If patients consent, the investigators also will assess their basic needs during the call. Those who screen positive for at least one unmet basic need, will be referred to the 2-1-1 helpline at their clinic visit (or this information will be sent to them if they miss their clinic visit).~All women enrolled in our study will be asked to complete our basic needs survey and take a follow-up survey at the time of their first colposcopy visit.~For patients in phase 1, the follow-up survey will only assess acceptability of the basic needs survey (five questions)"
89534312|NCT03246906|Experimental|Arm I (mycophenolate mofetil, cyclosporine, sirolimus)|Patients undergo allogeneic HCT at day 0. Patients with an HLA-matched unrelated donor receive mycophenolate mofetil PO on days 0 to 40, cyclosporine PO every 12 hours BID on days -3 to 96 then tapered to day 150, and sirolimus PO QD on days -3 to day 150 then tapered to day 180. Patients with an HLA-mismatched donor receive mycophenolate mofetil PO on days 0-100 then tapered to day 150, cyclosporine PO BID on days -3 to 150 then tapered to day 180, and sirolimus PO QD on days -3 to 180 then tapered to day 365.
88830322|NCT05446961|Active Comparator|covid 19 LCLT supplement|LCLT is made out of 68% elemental L-carnitine and 32 % Tartric acid and therefore the EFSA (European Food Safety Authority) stated that it is safety up to at least 3 g. Each 3 g of LCLT delivers 2 g of elemental L-carnitine L-carnitine and Tartric acid, 3g oral capsules daily use for 21 days
88830323|NCT05446961|Placebo Comparator|covid 19 placebo|The formulation will contain all salt ingredients v/v without LCLT (made out of 68% elemental L-carnitine and 32 % Tartric acid) and is replaced by Maltodextrin in the placebo capsules Placebo capsules daily for 21 days
88830324|NCT05446961|Active Comparator|Healthy LCLT supplement|LCLT is made out of 68% elemental L-carnitine and 32 % Tartric acid and therefore the EFSA (European Food Safety Authority) stated that it is safety up to at least 3 g. Each 3 g of LCLT delivers 2 g of elemental L-carnitine L-carnitine and Tartric acid, 3g oral capsules daily use for 21 days
88830325|NCT05446961|Placebo Comparator|Healthy Placebo|The formulation will contain all salt ingredients v/v without LCLT (made out of 68% elemental L-carnitine and 32 % Tartric acid) and is replaced by Maltodextrin in the placebo capsules Placebo capsules daily for 21 days
88830326|NCT05446805||depression|All participants will receive two one time PET scans with tracers AV1451 and PIB to detect tau and amyloid in the brain.
88830327|NCT05446805||control|All participants will receive two one time PET scans with tracers AV1451 and PIB to detect tau and amyloid in the brain.
88830328|NCT05446649|Experimental|dry needling|the patient will receive dry needling and conventional therapy three times per week for four weeks
88830329|NCT05446649|Experimental|instrumented assisted soft tissue mobilization|the patient will receive instrumented assisted soft tissue mobilization and conventional therapy three times per week for four weeks
89534313|NCT03246906|Experimental|Arm II (cyclosporine, sirolimus, cyclophosphamide)|Patients undergo HCT at day 0. Patients with an HLA-matched unrelated donor receive cyclosporine PO BID on days 5-96 then tapered to day 150, sirolimus PO QD on days 5-150 then tapered to day 180, and cyclophosphamide IV on days 3 and 4. Patients with an HLA-mismatched donor receive cyclosporine PO BID on days 5-150 then tapered to day 180, sirolimus PO QD on days 5-180 then tapered to day 365, and cyclophosphamide IV on days 3 and 4.
89534314|NCT03225872||Osteosarcoma patients and family members|Osteosarcoma patients and family members
88830330|NCT05446649|Active Comparator|conventional therapy|the patient will receive conventional therapy three times per week for four weeks
89534315|NCT03168737|Experimental|Group A (18F-fluoroazomycin arabinoside, PET-CT scans)|Patients receive 18F-fluoroazomycin arabinoside IV and after 60 minutes undergo 5 PET-CT scans at 60, 90, 120, 150, and 180 minutes on days 1 and 2.
89534316|NCT03168737|Experimental|Group B (18F-fluoroazomycin arabinoside, PET-CT scans)|Patients receive 18F-fluoroazomycin arabinoside IV and after 60 minutes undergo 5 or less PET-CT scans on day 1 and 5 or less PET-CT scans >= 24 hours later up to 10 days.
89534317|NCT03162627|Experimental|Selumetinib + Olaparib|"Dose Escalation Phase: Participants take both Selumetinib and Olaparib by mouth 2 times each day, about 12 hours apart at the Starting Dose Level. Treatment cycle is 28 days.~When maximum tolerated dose reached, Dose Expansion Phase begins."
89534318|NCT03162627|Experimental|Ovarian Cancer with RPA|Dose Expansion Phase: Selumetinib + Olaparib taken at the maximum tolerated dose from Dose Escalation Phase.
89534319|NCT03162627|Experimental|Endometrial Cancer with RPA|Dose Expansion Phase: Selumetinib + Olaparib taken at the maximum tolerated dose from Dose Escalation Phase.
89534320|NCT03162627|Experimental|Ovarian Cancer-Progression-prior PARP Treatment|Dose Expansion Phase: Selumetinib + Olaparib taken at the maximum tolerated dose from Dose Escalation Phase.
89534321|NCT03162627|Experimental|Solid Tumors that Harbor Somatic RPA|Dose Expansion Phase: Selumetinib + Olaparib taken at the maximum tolerated dose from Dose Escalation Phase.
89534322|NCT03081988||Responder|"Complete Remission after chemoradiotherapy in locally advanced or advanced esophageal cancer~evaluation of disease status: endoscopy, CT, and/or PET-CT"
89534323|NCT03081988||non-responder|"Progressive disease or stationary state after chemoradiotherapy in locally advanced or advanced esophageal cancer~evaluation of disease status: endoscopy, CT, and/or PET-CT"
89534324|NCT03072628|Experimental|Nicotine: use e-cig with nicotine|One time exposure to e-cig with nicotine
89534325|NCT03072628|Experimental|no nicotine: use e-cig without nicotine|One time exposure to e-cig without nicotine
89534326|NCT03072628|Experimental|Nicotine inhaler: use a nictoine inhaler|One time exposure to nicotine inhaler
89534327|NCT03072628|Sham Comparator|Sham control|Use an empty e-cigarette
89534328|NCT03041610|Experimental|Walking intervention|
89534329|NCT03041610|No Intervention|Control|
89534330|NCT03017833|Experimental|Treatment (metformin, sapanisertib)|Patients receive metformin PO 1-3 times daily on days 1-42 and sapanisertib PO daily on days 15-42 of cycle 1. Patients then receive metformin PO daily and sapanisertib PO daily on days 1-28 of cycle 2 and beyond. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89534331|NCT02979977|Experimental|All subjects|Advanced squamous cell carcinoma of the head and neck region, having previously been treated on a platinum based regimen or with an immune checkpoint inhibitor. Subjects will receive Afatinib dose 30 mg per day and weekly/bi-weekly intravenous cetuximab.
89358988|NCT03317470|Experimental|Phase 2:|"-In Phase 2 of the study (second five months), new colposcopy patients will be approached and consented in a similar fashion as in Phase 1 and asked to complete the basic needs survey. However, this time, patients who screen positive with at least one unmet basic need will be offered assistance by a life navigator (a trained case manager) who will contact the patients by phone within 2 business days of completing the survey.~The life navigator will connect patients with community resources in each area to help with their unmet basic needs.~All women enrolled in our study will be asked to complete our basic needs survey and take a follow-up survey at the time of their first colposcopy visit.~Patients enrolled in phase 2 will be asked the same five questions in addition to seven more assessing perceived effectiveness of the life navigator"
89358989|NCT02488954|Experimental|Probiotics|Oral daily take of probiotics in the form of cheese portion (50g) during 8 weeks
89358990|NCT05380349|Experimental|Personalized Combination Drug Therapy for Cancer Stem Cells|Administer combinations of up to 3 FDA approved drugs from a panel of compounds selected based on high throughput screening
89358991|NCT02489032|Experimental|SBIRT Training & Support Tool|The SBIRT Training & Support Tool has two components, both of which will be evaluated: (1) online SBIRT Training for EAP and behavioral health practitioners conducting alcohol SBIRT with their adult clients and (2) mobile/web interactive alcohol screening tools and brief intervention protocols to facilitate use of SBIRT by practitioners.
89358992|NCT02489032|Other|Waitlist control|Subjects randomized to the control condition will be placed on a wait-list and given access to the SBIRT Training & Support Tool after 3 months and completion of the 3-month follow-up assessment.
88830331|NCT05446415|Other|Prospective analisys|"Immunohistochemical assays : biopsy sampled from each site was immediately fixated and then embedded in paraffin, cut in thin slide sections and dewaxed. Subsequently, antigen retrieval was performed, with incubations with (1) specific primary antibodies, (2) a second layer of antibodies and (3) a third layer of an avidin-biotin complex. Finally, counterstaining was performed, generating biopsy slides with cells positive for peptide YY (PYY), GLP-1, respectively.~Quantitative real-time polymerase chain reaction (qPCR) : the mRNA expression of the genes of interest glp-1,PYY 3-36 genes as well as the genes used for normalisation 18S were investigated. One biopsy sample from each biopsy site was immediately incubated in RNAlater solution (to preserve mRNA quality) (dna/rna Shield, USA). Subsequently, standard RNA purification, cDNA synthesis and quantitative PCR (qPCR) analysis were performed ."
88830332|NCT05448521||Low lactate|Patients with a low lactate level defined by logistic regression analysis.
89358993|NCT03320746|Experimental|Activity trackers|The participants were requested to wear a commercial wrist-worn activity tracker (Polar Loop 2, Polar, Kempele, Finland) every day and night for 12 months.
89358994|NCT03320746|No Intervention|No activity trackers|Control group members were requested to abstain from the use of any type of activity trackers and they were informed that they will receive the activity trackers and guidance for using them after the follow-up.
89358995|NCT03781349|Active Comparator|MENS|MENS are applied through placement of six electrodes (size of 4x4cm), of which four were placed exactly like the TENS electrodes and the other two, one in the palm and the other at the height of the asteroid ganglion. Duration of the intervention was 24 min for a total of 15 sessions. The frequency was 50 Hz and the intensity was 100 μA.
88830333|NCT05448521||High lactate|Patients with a high lactate level defined by logistic regression analysis.
88830334|NCT05448053|Experimental|Ilizarov device|Ilizarov fixation in open type III pediatric tibial shaft fractures
88830335|NCT04728347|Experimental|ARCT-021|Participants will receive a single dose of ARCT-021 on Day 1
88830336|NCT04728347|No Intervention|Long-term follow up from ARCT-021-01|Participants will not receive intervention but will be followed for safety.
88830337|NCT03183791|Experimental|RELAX group|
88830338|NCT03183791|Active Comparator|Monitored Usual Care (MUC) group|
88830339|NCT04713995|Other|All Study Participants|"Enrolled with: AxSpA diagnosis, HLA-B27 positive, mASDAS > or = 1.3 and HLA-B27 positive. Will complete surveys online or on an app, about mental and physical health and how they are doing, submits and collection of samples (blood, stool, saliva, urine, fasting blood test at local lab). Receives results of some of the analysis of samples. Participants that qualify and complete the first set of samples can be eligible for the 3 and 6 month longitudinal follow-up collection kits.~All participants receive dietary recommendations based on samples collected and the analysis of the microbiome."
88830340|NCT03175523|Active Comparator|Imaging guided Bioresorbable scaffold|
88830341|NCT03175523|Experimental|QCA-guided Bioresorbable scaffold|quantitative coronary angiography guided Bioresorbable scaffold
88830342|NCT04687553|Experimental|Patients with vegetative state|Patients with vegetative state were assessed by the SECONDs and CRS-R for two days.
88830343|NCT04687553|Experimental|Patients with minimally conscious state|Patients with minimally conscious state were assessed by the SECONDs and CRS-R for two days.
88830344|NCT03034421|Active Comparator|Modified medical care|Patients will undergo 48-hours bed rest after endoscopic valve implantation.
88830345|NCT03034421|No Intervention|Standard medical care|Patients will be treated with standard medical care without restriction to bed rest after endoscopic valve implantation.
88830346|NCT02971787|Experimental|Probiotics and salt|Lactobacillus enrichment and salt increase
88830347|NCT00370799|Active Comparator|local anesthetic|Group 1. local anesthetics only
89358996|NCT03781349|Active Comparator|TENS|TENS are applied through the placement of four electrodes on either side of the deltoid muscle, on the front and back surfaces of the shoulder joint for 20 min and each patient received 15 sessions (five per week). A constant current of high frequency was used (100 HZ) and its intensity was initiated at 10mA and was then gradually increased to 15mA
89358997|NCT02483338|Other|Children surgery|
89358998|NCT03781115|Experimental|Ziprasidone|The investigators will conduct a pilot dose-response evaluation of a single dose of the anti-psychotic drug ziprasidone (Geodon). The investigators will start with a single 20mg pill given to (3) subjects and will increase the dosage in sequential subjects until the desired sedation effect is achieved (i.e. 40 and 60mg tablets). If Ziprasidone causes the desired sedation effect additional healthy subjects will be recruited to take the medication and have an electroencephalogram (EEG) taken.
89000914|NCT04637464|Experimental|Experimental group|"Discontinuation of empirical antibiotics, despite neutrophil count below 0.5x10⁹ cells/L, after 48 hours of apyrexia and clinical stability.~A child is considered clinically stable when there is resolution of all symptoms and signs of infection, and normalization of vital signs including heart rate, respiratory rate, oxygen saturation, blood pressure, and daily diuresis."
89358999|NCT03781115|Experimental|Olanzapine|The investigators will conduct a pilot dose-response evaluation of a single dose of the anti-psychotic drug olanzapine (Zyprexa). The investigators will start with a single 2.5 mg pill given to (3) subjects and will increase the dosage in sequential subjects until the desired sedation effect is achieved (i.e. 5, 7.5, and 10 mg tablets).If olanzapine causes the desired sedation effect additional healthy subjects will be recruited to take the medication and have an electroencephalogram (EEG).
89359000|NCT03781115|Placebo Comparator|Placebo Comparator|The investigators have prepared a placebo which duplicates the exact color and size of the study drug capsule to use as a non-drug control.
89359001|NCT03317236|Experimental|Reference - Test|A new extended release formulation containing quetiapine 50 mg (T) followed by a branded formulation (R).
88830348|NCT00370799|Active Comparator|Local anesthetic with generic Celestone|Group 2. local anesthetic with 6mg of non-particulate Celestone
88830349|NCT00370799|Active Comparator|Local anesthetic with Celestone|Group 3. local anesthetic with 6 mg of brand nameCelestone
89359002|NCT03317236|Experimental|Test - Reference|A branded formulation (R) followed by a new extended release formulation containing quetiapine 50 mg (T).
89359003|NCT02488798||postmenopausal bleeding group|"100 women with postmenopausal bleeding undergoing 2D greyscale vaginal ultrasound and 3D Endometrial power Doppler and the features were classified using six different vascular patterns described by IETA group including the following patterns; single dominant vessel without branching, with branching, multiple vessels with focal origin, with multifocal origin at the myometrium-endometrium junction, scattered vessels or circular flow (Kucur et al., 2013 ).~All patients then had Office hysteroscopy carried out in the outpatient clinic using vaginoscopic approach (Cooper et al., 2010). With endometrial samples from lesions or from the cavity for histopathological analysis."
88830350|NCT00370799|Active Comparator|Local anesthetic with DepoMedrol|Group 4. local anesthetic with 40 mg of alcohol-free DepoMedrol
89359004|NCT01313429|Experimental|1|tumor cell vaccine administered with chemotherapy
89359005|NCT03488251|Experimental|Part 1: Cohort 1: MT-3724 10 mcg/kg/ GEM/ OX|In original protocol and amendment 2, participants will be administered intravenous (IV) MT-3724 10 micrograms per kilograms (mcg/kg) over 1 hour on Days 1, 3, 5, 8, 10 and 12 in Cycles 1 and 2 (each 28-day cycle) and on Days 1, 8, 15, and 22 in Cycles 3 and 4 (each 28-day cycle). Participants will also be administered Gemcitabine 1000 milligrams per meter square (mg/m^2) as 30-minute IV infusion and Oxaliplatin 100 mg/m^2 as 2-hour IV infusion on Days 2 and 16 in Cycles 1, 2, 3 and 4 (each 28-day cycle). Per amendment 2, participants will be administered MT-3724 10 mcg/kg on Days 1, 3, 5, 8, 10, 12, 15, 22, 29, and 36 in Cycle 1 (42-day cycle). In Cycles 2, 3 and 4, MT-3724 10 mcg/kg will be administered weekly on Days 1, 8, 15, and 22 of each 28-day cycle. Gemcitabine and oxaliplatin will be administered on Days 16 and 30 of Cycle 1 and on Days 2 and 16 in Cycles 2, 3 and 4 (42-day cycle for Cycle 1 and 28-day cycle for Cycle 2, Cycle 3 and Cycle 4).
89399135|NCT03696615|Experimental|Tabata Kettlebell Swings|"Participants in this group performed:~A brief dynamic warm-up (10 clockwise and counterclockwise arm circles, 10 horizontal arm swings, and 15 air squats)~Receive instruction on the kettlebell swing~Performed a high-intensity workout in a Tabata Kettlebell Swings format, which involves 20 seconds of all out effort followed by 10 seconds of rest, repeated for a total of 8 times."
88830351|NCT04593953|No Intervention|CONTROL|Standard general anesthesia
88830352|NCT04593953|Experimental|TLIP|Standard general anesthesia + TLIP block
88830353|NCT04738253||Study group|Stroke patients with limitation of range of motion on the affected shoulder.
88830354|NCT05445089|Experimental|Isothymol or Carvacrol group|"Each ml contains 6mg of Isothymol or Carvacrol (2-Methyl-5-(1-methylethyl)-phenol modified) at 1% v/v. (GRAS lipophilic modified with isothymol).~Oral solution (dispersion L/L). Dilute lipophilic aqueous solution of light or medium yellow.~Excipients: Cis-9-octadecenoic acid with Squalene (99%)."
88830355|NCT05445089|Placebo Comparator|Control|•Placebo
89000915|NCT04637464|No Intervention|Control group|Discontinuation of antibiotics when neutrophil count is equal to or above 0.5x10⁹ cells/L, and the child is afebrile and clinical stable OR the child has received 10 days of antibiotics and have been afebrile and clinically stable for 7 days
88830356|NCT00370877|Active Comparator|Standard care for post-partum hemorrhage|The patients included in this arm of the study will recieve standard care for post-partum hemorrhage.
88830357|NCT00370877|Experimental|rFVIIa|The patients included in this arm of the study will recieve standard care for post-partum hemorrhage plus a slow intravenous injection (2ml/min) of rFVIIa (60µg/kg)
88830358|NCT04515953|Active Comparator|Control|Standard practice of pain management for post-TKA
88830359|NCT04515953|Experimental|ND-340|ND-340 90mg~320mg at dose escalations
88830360|NCT00370955|Active Comparator|High vacuum group|Those patients who underwent phacoemulsification using high hydrodynamic parameter: 400 mmHg vacuum and 40 ml/min flow rate.
88830361|NCT00370955|Active Comparator|Low vacuum group|Patients who underwent phacoemulsification using low hydrodynamic parameters: 200 mmHg vacuum and 20 ml/min flow rate.
88830362|NCT02665247|Experimental|C-SIP|Participants assigned to the C-SIP group will attend sessions where information about sleep is presented. In session I, information about sleep and the effects of lack of sleep will be presented. Participants will also be presented with advice and tips on how to improve sleep. Session II will focus on assisting participants overcome any barriers they faced in applying the advice they received in session I; participants will also receive additional information on sleep and sleep-related techniques.
88830363|NCT02665247|Other|Control Session|Participants assigned to the control group will attend sessions in which information on sleep is presented in the form of dream discussions.
88830364|NCT02661971|Active Comparator|FLOT alone|"Pre-operative therapy with FLOT followed by surgical resection followed by post-operative therapy with FLOT~Docetaxel 50 mg/m², d1~Oxaliplatin 85 mg/m², d1~Calciumfolinat 200 mg/m², d1~5-Fluorouracil 2600 mg/m², d1"
89000916|NCT00560092|Experimental|intrathecal magnesium sulfate|
88830365|NCT02661971|Experimental|FLOT + Ramucirumab|"Pre-operative therapy with FLOT + ramucirumab followed by surgical resection followed by post-operative therapy with FLOT + ramucirumab~Ramucirumab 8mg/kg, d1~Docetaxel 50 mg/m², d1~Oxaliplatin 85 mg/m², d1~Calciumfolinat 200 mg/m², d1~5-Fluorouracil 2600 mg/m², d1"
88830366|NCT01949545|Experimental|Normal Hepatic Function|Participants with normal hepatic function (bilirubin and aspartate aminotransferase (AST) ≤ the upper limit of normal (ULN)) received carfilzomib 20 mg/m² administered by intravenous (IV) infusion on days 1 and 2 of cycle 1, followed by a planned step-up to 27 mg/m² IV on days 8, 9, 15, and 16 of cycle 1. Participants who adequately tolerated dosing at 27 mg/m² in cycle 1 received carfilzomib 56 mg/m² IV on days 1, 2, 8, 9, 15, and 16 of cycle 2 and subsequent 28-day cycles until confirmed progressive disease (PD), unacceptable toxicity, withdrawal of consent, study closure, or death.
88830367|NCT01949545|Experimental|Mild Hepatic Impairment|Participants with mild hepatic impairment (bilirubin > 1-1.5 x ULN or AST > ULN, but bilirubin ≤ ULN) received carfilzomib 20 mg/m² administered by intravenous (IV) infusion on days 1 and 2 of cycle 1, followed by a planned step-up to 27 mg/m² IV on days 8, 9, 15, and 16 of cycle 1. Participants who adequately tolerated dosing at 27 mg/m² in cycle 1 received carfilzomib 56 mg/m² IV on days 1, 2, 8, 9, 15, and 16 of cycle 2 and subsequent 28-day cycles until confirmed progressive disease (PD), unacceptable toxicity, withdrawal of consent, study closure, or death.
88830368|NCT01949545|Experimental|Moderate Hepatic Impairment|Participants with moderate hepatic impairment (bilirubin > 1.5-3 x ULN, any AST) received carfilzomib 20 mg/m² administered by intravenous (IV) infusion on days 1 and 2 of cycle 1, followed by a planned step-up to 27 mg/m² IV on days 8, 9, 15, and 16 of cycle 1. Participants who adequately tolerated dosing at 27 mg/m² in cycle 1 received carfilzomib 56 mg/m² IV on days 1, 2, 8, 9, 15, and 16 of cycle 2 and subsequent 28-day cycles until confirmed progressive disease (PD), unacceptable toxicity, withdrawal of consent, study closure, or death.
88830369|NCT01949545|Experimental|Severe Hepatic Impairment|(Bilirubin > 3 × ULN; any AST) Participants with severe hepatic impairment (bilirubin > 3 x ULN; any AST) received carfilzomib 20 mg/m² administered by intravenous (IV) infusion on days 1 and 2 of cycle 1, followed by a planned step-up to 27 mg/m² IV on days 8, 9, 15, and 16 of cycle 1. Participants who adequately tolerated dosing at 27 mg/m² in cycle 1 received carfilzomib 56 mg/m² IV on days 1, 2, 8, 9, 15, and 16 of cycle 2 and subsequent 28-day cycles until confirmed progressive disease (PD), unacceptable toxicity, withdrawal of consent, study closure, or death.
88830370|NCT05442905|Active Comparator|Quadratus lumborum block group|will receive quadratus lumborum block the patient will be placed in lateral position, the probe will be placed on the crista iliaca anterior superior. After the external oblique, internal oblique, and transversus abdominis muscles will be seen, the probe will be moved to the posterior and the quadratus lumborum muscle will be observed. A 22-gauge, 80 mm insulated Quince-type needle (Uniplex; Pajunk, Geisingen, Germany) will be moved from the anterolateral plane to the posteromedial plane, and confirmation will be made using 0.5 mL/kg saline; after a negative aspiration, 0.7 mL/kg (0.25%) bupivacaine will be applied to the posterior of the quadratus lumborum muscle and the thoracolumbar fascia in between the quadratus lumborum and latissimus dorsi muscles.
88830371|NCT05442905|Active Comparator|Transversus abdominis block group|will receive TAP block with 0.7mL/kg of 0.25% bupivacaine under US guidance. A linear high frequency ultrasound probe (6-13 MHz) will be placed transversely in the mid axillary line between the iliac crest and the costal margin. The three layers of muscles, the external oblique, the internal oblique, and the transversus abdominis will be identified. Using the in-plane technique, needle will be inserted (from anterior to posterior direction) until the tip of the needle will reach between the internal oblique and the transversus abdominis. Hydro dissection with 1-2 mL saline will be done to separate the fascial layers. After the correct localization, 20 mL of the drug will beinjected with repeated aspiration to avoid the accidental intravascular injection.
88830372|NCT05442905|Active Comparator|Caudal block group|will receive caudal block with 1mL/kg of 0.25% bupivacaine, with children in left lateral position. with all aseptic measures caudal block will be performed using 25 G needle in left lateral decubitus position. Needle position will be confirmed by the pop felt during penetration of the sacrococcygeal ligament, further ensured by doing whoosh test using 0.5 mL of air injection 0.25% bupivacaine 1mL/kg will be administered after negative aspiration of blood and CSF. Intraoperative hemodynamic parameters will be recorded throughout the surgery at fixed intervals (at time of skin incision then after every 5 min till the end of surgery).
88830373|NCT04338425|No Intervention|No Communication group|Participants will not communicate with their surgeons until the post operative office visit.
88830374|NCT04338425|Active Comparator|Voice call group|Participants will receive voice call from the surgeon after being discharged and before their post operative office visit.
88830375|NCT04338425|Active Comparator|Video call group|Participants will receive video call from surgeon after being discharged and before their post operative office visit
88830376|NCT01949779||TransForm™ Occlusion Balloon Catheter|TransForm™ Occlusion Balloon Catheter
88830377|NCT01890343|Experimental|Frontotemporal Disorder|Subjects with frontotemporal disorder (FTD) received a one-time intravenous (IV) bolus injection of 300 megabecquerels (MBq) florbetapir 18F and a one-time IV bolus injection of 185 MBq of 18F-FDG.
88830378|NCT01890343|Experimental|Cognitively Normal|Cognitively normal (CN) subjects received a one-time intravenous (IV) bolus injection of 300 megabecquerels (MBq) florbetapir 18F.
88830379|NCT01890343|Experimental|Alzheimer's Disease|Subjects with Alzheimer's disease (AD) received a one-time intravenous (IV) bolus injection of 300 megabecquerels (MBq) florbetapir 18F.
88830380|NCT02588027|Active Comparator|Control|Ibuprofen 400mg by mouth three times daily. Patients will also receive the standard opiate medication (hydrocodone/acetaminophen 10mg/325mg) for the UCSF orthopaedic clinic for postoperative pain control.
88830381|NCT02588027|Placebo Comparator|Placebo|Placebo tablet by mouth three times daily. Patients will also received the standard opiate medication (hydrocodone/acetaminophen 10mg/325mg) for the UCSF orthopaedic clinic for postoperative pain control.
88830382|NCT05441189||training cohort|30 patients undergoing resection between March 2015 and December 2016 at Chinese PLA General Hospital in Beijing, China
88830383|NCT05441189||validation cohort|40 patients from The Cancer Genome Atlas (TCGA) database (https://www.cancer.gov/about-nci/organization/ccg/research/structural-genomics/tcga)
89399136|NCT03696615|Active Comparator|Control Group|"Participants in this group performed:~1. A brief dynamic warm-up (10 clockwise and counterclockwise arm circles, 10 horizontal arm swings, and 15 air squats)"
88830384|NCT01894087|Active Comparator|Therapist-led brief intervention (TBI) - Cohort 1|"Participants will receive a therapist-led, computer-assisted intervention session with a master's level therapist. The interventions are designed to address extramedical prescription opioid use and overdose risk behaviors. This includes a review of the participants' strengths, values, and goals; feedback regarding their opioid use and overdose risk behaviors; developing a discrepancy between their opioid and other drug use and ability to meet goals and values; and the formulation of a change plan for each participant."
88830385|NCT01894087|No Intervention|Enhanced usual care - Cohort 1|
88830386|NCT01894087|Active Comparator|Therapist-led brief intervention (TBI) - Cohort 2|"Participants will receive a therapist-led, computer-assisted intervention session with a master's level therapist. The interventions are designed to address extramedical prescription opioid use and overdose risk behaviors. This includes a review of the participants' strengths, values, and goals; feedback regarding their opioid use and overdose risk behaviors; developing a discrepancy between their opioid and other drug use and ability to meet goals and values; and the formulation of a change plan for each participant."
88830387|NCT01894087|No Intervention|Enhanced usual care - Cohort 2|
88830388|NCT05438069||Patients with elevated LDL-cholesterol (hypercholesterolemia)|Application of si RNA Inclisiran to reduce serum LDL-cholesterol levels.
88830389|NCT04449965|Experimental|PVP-I sinus rinses and throat gargles|Participants will dilute 7 mL of 10% PVP-I into 300 mL of saline for a final concentration of 0.23% available iodine. They will be instructed to rinse each nostril with 120ml (total 240mL) in a NeilMedTM sinus rinse bottle, and gargle with 60 mL of the solution.
88830390|NCT04449965|Placebo Comparator|Placebo sinus rinses and throat gargles|Participants will dilute 7 mL of PVP-I placebo into 300 mL of saline. They will be instructed to rinse each nostril with 120ml (total 240mL) in a NeilMedTM sinus rinse bottle, and gargle with 60 mL of the solution.
88830391|NCT04449965|Experimental|PVP-I gel forming nasal spray|0.6% PVP-I gel forming nasal spray will come prepared and ready for participants to use. They will be instructed to use two sprays to each nostril each time they administer the spray.
88830392|NCT05433389|Active Comparator|Breath Counting|
88830393|NCT05433389|Experimental|Body Scan|
88830394|NCT05433389|Experimental|Mindful Breathing|
88830395|NCT05433389|Experimental|Mindfulness of Pain|
88830396|NCT05433389|Experimental|Mindful Savoring|
88830397|NCT05431673|Active Comparator|Doxycycline|• Subjects in this group will be treated with Doxycycline (100mg/day for 8 weeks).[1]
88830398|NCT05431673|Active Comparator|Doxycycline & Ciprofloxacin|• Subjects in this group will be treated with combination of Doxycycline (100mg/day for 8 weeks) & Ciprofloxacin (250mg twice daily for 4 weeks).[1]
89534332|NCT02947802|Experimental|Consumer Support|Participants will be presented with three labels: a calorie label, a textual warning label and a textual warning label with corresponding graphic images and will be asked to rate their support for each label on a 1 (not at all) to 7 (a great deal) scale.
88830399|NCT05431673|Active Comparator|Rifampicin|• Subjects in this group will be treated with Rifampicin (600mg/day for 6 weeks)
88830400|NCT01951651|Experimental|Exenatide|Exenatide 10 micrograms injected subcutaneously twice daily for 6 months
88830401|NCT01951651|Experimental|Glipizide|Glipizide 5 mg (tablet), one tablet twice daily orally for 6 months
88830402|NCT02466581|Active Comparator|Arm 1|"Patients keep the intervention they had in the NORD-STAR-study (NCT01491815), i.e. one of the four below:~Sulphasalazine + Hydroxychloroquine OR Prednisolone plus Methotrexate and steroids~Cimzia plus Methotrexate and steroids~Orencia plus Methotrexate and steroids~RoActemra plus Methotrexate and steroids~This intervention is de-escalated starting at randomization."
88830403|NCT02466581|Active Comparator|Arm 2|"Patients keep the intervention they had in the NORD-STAR-study (NCT01491815), i.e. one of the four below:~Sulphasalazine + Hydroxychloroquine OR Prednisolone plus Methotrexate and steroids~Cimzia plus Methotrexate and steroids~Orencia plus Methotrexate and steroids~RoActemra plus Methotrexate and steroids~This intervention is de-escalated starting 24 weeks after randomization."
88830404|NCT01951963|Experimental|Ketamine|Ketamine, single dose, 0.3 mg/kg, IV
88830405|NCT01951963|Active Comparator|Morphine|Morphine, single dose, 0.05 mg/kg, IV
88830406|NCT02377271|Experimental|Bosentan|Bosentan at a dose of 125 mg two times daily, will be administered orally, twice a day, during eight weeks
88830407|NCT02377271|Placebo Comparator|Placebo|placebo drug , twice a day, during eight weeks
88830408|NCT01894555|Experimental|Aspirin|Participants treated with aspirin - there is no control group. Participant's baseline will act as their control.
88830409|NCT02330471|Experimental|Spray|cervical coagulation using a superficial electrical coagulation mode, ie spray coagulation
88830410|NCT02330471|Active Comparator|Forced|cervical coagulation using a deep tissue electrical coagulation mode, ie forced coagulation
88830411|NCT04421495|Experimental|delamanid containing regimen arm|the only one arm to be studied with delamid-containing regimen.
88830412|NCT01895647|Experimental|Biceps stimulation|EMS
88830413|NCT01895647|Experimental|Quadriceps stimulation|EMS
88830414|NCT01895647|No Intervention|Control|Control group without electric muscle stimulation
88830415|NCT02034461|Experimental|Acute surgical implantation|The investigators will conduct three acute surgeries where a Utah slanted Electrode Array (USEA) will be implanted in volunteers who are about to undergo limb amputations. These acute implantations will provide the PI with human surgical experience in implanting USEAs and evaluating the containment system the investigators will be using to immobilize the implanted USEA in the nerve.
88830416|NCT02034461|Experimental|Implantation of a Utah Electrode Array|The arm which has been amputated or has peripheral nerve trauma. Intervention include insertion of the Utah Slanted Electrode Arrays which will interact with nerve endings in order to gain knowledge about device feasibility and nerve stimulation.
88830417|NCT01896115|Experimental|Short PW|Patients with a Vercise DBS system programmed to 30 microseconds pulse width
88830418|NCT01896115|Experimental|Conventional PW|Patients with a Vercise DBS system programmed to 60 microseconds pulse width
88830419|NCT01896115|Experimental|Ventral current steering|Patients with a Vercise DBS system programmed to steer current ventrally
88830420|NCT01896115|Experimental|Dorsal current steering|Patients with a Vercise DBS system programmed to steer current dorsally.
88830421|NCT01953211||Healthy reproductive age women|These volunteers were previously taking the oral contraceptives of interest for a minimum of 3 months
88830422|NCT02028221|Placebo Comparator|Placebo|1 tablet daily by mouth X 4 weeks, then 1 tablet twice daily by mouth for the remaining duration of the trial (12 months)
88830423|NCT02028221|Experimental|Metformin|metformin 850 mg 1 tablet taken by mouth daily X 4 weeks, then metformin 850 mg 1 tablet taken twice daily for the remaining duration of he intervention period.
88830424|NCT02987569|Experimental|Group One|Intervention
88830425|NCT02987569|Active Comparator|Group Two|Control
88830426|NCT05735197|Active Comparator|Dapagliflozin group|Includes 50 patients, they will receive SGLT2i as add on drug, Dapagliflozin 10 mg will be used once daily with or without food.
88830427|NCT05735197|Placebo Comparator|Placebo group|Includes 50 patients, they will receive placebo plus their medication.
88830428|NCT00370097|Experimental|Subjects receiving HFA|Subjects in Session 1 will receive two inhalations of placebo HFA by meter-dose inhaler (MDI) twice daily and in Session 2 subjects will receive two inhalations of fluticasone propionate (FP) HFA MDI 44 mcg twice daily
88830429|NCT01897285|Experimental|All study participants: AQUACEL® foam adhesive dressings|Original adhesive + test adhesive
88830430|NCT00370253|Active Comparator|2|Terlipressin
88830431|NCT00370253|Experimental|1|Noradrenalin
88830432|NCT01800539|Experimental|Provider Education Model (PEM)|condition wherein providers will receive specially structured training during their typical home visits based by Kennedy Krieger Institute (KKI) staff
88830433|NCT01800539|No Intervention|Treatment-as-Usual (TAU)|condition wherein providers continue with their existing practices
88830434|NCT04412525|Active Comparator|27 gauge needle vitrectomy surgery|ultra-small gauge
88830435|NCT04412525|Active Comparator|larger than 27 gauge (23G or 25G) needle vitrectomy surgery|23-gauge and 25-gauge instruments are a little larger in size
88830436|NCT01618565|Experimental|Hands-On Training|30 minutes hands-on training of maneuvers to manage shoulder dystocia
88830437|NCT01618565|Active Comparator|Demonstration|30 minutes passive training by watching an expert instructor explain and perform maneuvers to manage shoulder dystocia
88830438|NCT01491815|Active Comparator|Active conventional therapy (ACT)|Non-biological DMARD's: Methotrexate plus steroids or Methotrexate plus Sulphasalazine and Hydroxychloroquine and steroids
88830439|NCT01491815|Active Comparator|Biologic agent 1|Cimzia: Certolizumab-pegol plus Methotrexate and steroids
88830440|NCT01491815|Active Comparator|Biologic agent 2|Orencia: Abatacept plus Methotrexate and steroids
88830441|NCT01491815|Active Comparator|Biologic agent 3|RoActemra: Tocilizumab plus Methotrexate and steroids
88830442|NCT04359953|Experimental|Hydroxychloroquine|Patient will take 200mg of Hydroxychloroquine twice a day during 14 days
88830443|NCT04359953|Experimental|Azithromycin|Patient will take 250mg of Azithromycin twice a day during 14 days
88830444|NCT04359953|Experimental|Telmisartan|Patient will take 40mg of Telmisartan twice a day during 14 days
88830445|NCT04359953|No Intervention|Usual Care|No intervention
88830446|NCT01470677|Experimental|application of Tachosil fibrin patches|A Tachosil® patch of 4.8x4.8cm will be attached to the obturator fossa and a Tachosil® patch of 4.8x4.8cm will be attached to the femoral canal of each side of surgery in the intervention group.
88830447|NCT01470677|No Intervention|Control group|In the control group, no Tachosil® patch will be used. No specific drainage of the retroperitoneum will be performed.
88830448|NCT05364515|Active Comparator|Conventional treatment|0.05% Clobetasol propionate
88830449|NCT05364515|Experimental|PRGF|"0.05% Clobetasol propionate + PRGF~PRGF: 4 infiltrations (first two months) + topical administration (from third month)"
88830450|NCT01438073|Experimental|kisspeptin, GnRH|24-hour continuous intravenous infusion of kisspeptin 112-121 (12.5-40 mcg/kg/h), single intravenous dose of kisspeptin 112-121 (0.313-13.19 mcg/kg), and single bolus of GnRH (gonadotropin-releasing hormone) (2.5-250 ng/kg)
88830451|NCT04334369|Sham Comparator|Single Vision Contact Lenses|
88830452|NCT04334369|Experimental|Multifocal Contact Lenses|
88830453|NCT05295095|No Intervention|control group|Classical extubation technique : ETT was removed with continuous endotracheal suction
88830454|NCT05295095|Experimental|VSPEP|ETT was removed with APL valve set to 20cmH2O
88830455|NCT05295095|Experimental|VSAIPEP|ETT removed with ventilator parameters were set for PSV mode (inspiratory pressure of 10cmH2O and PEEP identical to that administered in the operating room
88830456|NCT05454917||Patients undergoing surgery|Mechanical measures, VQ mismatch evaluation
88830457|NCT05454761|Experimental|Lifestyle medicine intervention with self-tracking tools|Lifestyle intervention including diet, sleep, exercise, relaxation, and mindfulness. Self-tracking tools including a smartphone application and an Actigraphy will be given.
88830458|NCT05454761|Experimental|Pure lifestyle medicine intervention|Lifestyle intervention including diet, sleep, exercise, relaxation, and mindfulness.
88830459|NCT05454761|No Intervention|Care-As-Usual|continue receiving the routine care as usual and be given a smartphone-based LM intervention after the completion of follow-up assessments
88830460|NCT00371033|Active Comparator|1|Pregabalin
88830461|NCT00371033|Placebo Comparator|2|Placebo
88830462|NCT00371111|Active Comparator|1|Intravitreal injection of Triamcinolone
88830463|NCT00371111|Active Comparator|2|Intravitreal injection of Avastin
88830464|NCT00371189|Experimental|Group C: Ad35.CS.01-10^10 vp/ml|15 subjects will receive dosage 10^10 vp/mL; 3 subjects will receive placebo.
88830465|NCT00371189|Experimental|Group D: Ad35.CS.01-10^11 vp/ml|15 subjects will receive dosage 10^11 vp/mL; 3 subjects will receive placebo.
88830466|NCT00371189|Experimental|Group A: Ad35.CS.01-10^8 vp/ml|15 subjects will receive dosage 10^8 vp/mL; 3 subjects will receive placebo.
88830467|NCT00371189|Experimental|Group B: Ad35.CS.01-10^9 vp/ml|15 subjects will receive dosage 10^9 vp/mL; 3 subjects will receive placebo.
88830468|NCT05286203|Active Comparator|Standard of Care|Patients enrolled in the trial and randomized to the standard of care (SOC) arm will undergo standard of care testing.
88830469|NCT05286203|Experimental|MDS|Patients enrolled in the trial and randomized to the MDS arm will undergo standard of care testing and MDS testing.
89177851|NCT00797316|Experimental|Aliskiren plus Hydrochlorothiazide|Aliskiren (150 mg) plus Hydrochlorothiazide (12.5 mg) for one week. Subsequently up-titrated to Aliskiren (300 mg) plus Hydrochlorothiazide (25 mg). Medication was taken once daily in oral form.
88830470|NCT05275361|Experimental|Patient: Scheduled for mammogram|"Will be asked to choose 2 social contacts (adult family member or friend identified by the participant as someone who could be engaged by the research team to encourage the participant to attend her mammogram appointment)~Will receive reminder(s) from social contact about the screening mammogram appointment~Will receive reminder from Breast Health Center about screening mammogram appointment~Will be contacted to provide experience with the study"
88830471|NCT05275361|No Intervention|Social Contact of Patient|"Facilitate enrolled patient to complete the screening mammogram.~Will receive information about screening mammograms and resources available at the Breast Imaging Center.~Will be contacted approximately 3 days prior to the patient's mammogram appointment.~Will be contacted to provide experience with the study"
88830472|NCT05242523|No Intervention|Control|No exposure to smells.
88830473|NCT05242523|Experimental|Olfactory Condition - 1|Participants in this condition will be exposed to the smell of natural wood scent continuously. A diffuser with essential oils will be turned on during that time to deliver the smell.
88830474|NCT05242523|Experimental|Olfactory Condition - 2|Participants in this condition will be exposed to the smell of Bergamot scent continuously. A diffuser with essential oils will be turned on during that time to deliver the smell.
88830475|NCT05233943||Parkinson's patients|"The cognitive function of Parkinson's patients will be assessed using the Standardized Mini Mental Test  .~The spinal posture will be evaluated using IDIAG M360 Spinal Mouse  .~Parkinson's patients' spinal position sense will be assessed using a repositioning error test with J-TECH medical, Salt Lake City, USA Dual Digital Inclinometer.~Dynamic and static components of the balance function will be evaluated with 'four square step tests' and 'stand on one leg' tests respectively"
88830476|NCT05233943||Healthy control group|"The cognitive function of Parkinson's patients will be assessed using the Standardized Mini Mental Test  .~The spinal posture will be evaluated using IDIAG M360 Spinal Mouse  .~Parkinson's patients' spinal position sense will be assessed using a repositioning error test with J-TECH medical, Salt Lake City, USA Dual Digital Inclinometer.~Dynamic and static components of the balance function will be evaluated with 'four square step tests' and 'stand on one leg' tests respectively"
88830477|NCT05229887|Active Comparator|Nostril-Tragus-Length|
88830478|NCT05229887|Experimental|Vocal cord markings|
88830479|NCT05454683|Experimental|Melatonin plus Zinc|"Dietary Supplement:~53 patients treated with melatonin 1 mg plus Zinc 10 mg"
88830480|NCT05454683|Placebo Comparator|Placebo|53 patients treated with isomaltose and magnesium stearate (excipients)
88830481|NCT04175249|Experimental|Pizza meal challenge|Vegetarian pizza containing 10 grams of salt
88830482|NCT04146857|Placebo Comparator|Normoxia|20.9% oxygen
88830483|NCT04146857|Active Comparator|Hypoxia 1|15.0% oxygen
88830484|NCT04146857|Active Comparator|Hypoxia 2|12.8% oxygen
88830485|NCT05186051|Experimental|ZYIL1 Capsule|subject will receive 50 mg twice daily (BD) dose for 7 days
88830486|NCT04707521|Experimental|3M tape ship-shaped combined with strap fixing method|"Cutting method of 3M adhesive tape of ship shape: cut a piece of 20cm×3cm elastic adhesive tape, fold it in half to form a rectangle of 10cm×3cm, cut 5cm straight line from the middle point of the crease, cut it at an Angle of 45°, fold and open the 3M elastic adhesive tape in half, which is the adhesive tape required for fixing. The final shape is similar to that of a ship, and it is named as 3M adhesive tape of ship shape.~Fixation method: The ship shape with 3M adhesive tape was pasted upward on the opposite cheek (near zygomatic), and the endotracheal intubation was wound around for two rounds and then glued to the near cheek (near zygomatic).Put the tooth pad next to the endotracheal intubation and wrap the tooth pad and catheter together for two turns with a short 3M adhesive tape of 12cm×1.5cm.Finally, fasten it with a lacing."
89177852|NCT00797316|Active Comparator|Aliskiren|Aliskiren (150 mg) for one week. Subsequently up-titrated to Aliskiren (300 mg). Medication was taken once daily in oral form.
89177853|NCT00587964|Experimental|Treatment|
89177854|NCT02608580|Other|Patients with sicke cell disease|"Adult sickle cell disease patients will fill in a survey about the quality of their hospital care, in the transition period between the pediatric to an adult hospital care system.~Since filling in this survey is not part of the standard of care, this study has been defined as interventional."
89177855|NCT05753696|Experimental|azilsartan group|the initial dose of azilsartan is 20mg/day, if not reached the goal of blood pressure, azilsartan was adjust to 40mg/day
88830487|NCT04707521|No Intervention|traditional X-shaped tape and string fixing|traditional X-shaped tape and string fixing
88830488|NCT04145453|Experimental|intervention group|Participants with PAV haplotype will receive personalised dietary recommendations regarding consumption of fruit and vegetables. The information about genotype will be given at the beginning of study.
89000917|NCT00560170|Experimental|high dose statin|40mg of Simvastatin (n=20)
89177856|NCT05753696|Active Comparator|losartan group|the initial dose of losartan is 40mg/day, if not reached the goal of blood pressure, losartan was adjust to 80mg/day
89177857|NCT04109898|No Intervention|standard I-gel insertion technique|Investigator will apply the recommended (standard) I-gel insertion technique in patients
89177858|NCT04109898|Experimental|Modified I-gel insertion technique|Investigator will apply the modified (interventional) I-gel insertion technique in patients
89177859|NCT04788992|Experimental|Intervention group|receive dementia care training
88830489|NCT04145453|Sham Comparator|control group 1|Participants with PAV haplotype will receive personalised dietary recommendations regarding consumption of fruit and vegetables, but the information about genotype will be given at the end of study.
88830490|NCT04145453|Active Comparator|Control group 2|Participants with AVI haplotype will receive general recommendations regarding consumption of fruit and vegetables.
88830491|NCT05454059|Active Comparator|Group 1 (HH)|17 systemically healthy + periodontally healthy (normoglycemic)
88830492|NCT05454059|Experimental|Group 2 (HP)|17 systemic healthy + grade A periodontitis
88830493|NCT05454059|Active Comparator|Group 3 (T2D+H)|17 T2DM (HbA1c<%7) + periodontally healthy
88830494|NCT05454059|Experimental|Group 4 (T2D+P)|17 T2DM (HbA1c<%7) + grade B periodontitis
88830495|NCT05454059|Active Comparator|Group 5 (T2D-H)|17 T2DM (HbA1c≥%7) + periodontally healthy
88830496|NCT05454059|Experimental|Group 6 (T2D-P)|17 T2DM (HbA1c≥%7) + grade C periodontitis
88830497|NCT05139095|Experimental|Cohort A|Population: ultra high-risk gestational trophoblastic neoplasia
88830498|NCT05139095|Experimental|Cohort B|Population: high-risk chemo-refractory or relapsed gestational trophoblastic neoplasia
88830499|NCT05453669|Experimental|CD19-CAR-DNT cells|9 patientsare planned to be enrolled in the dose-escalation trial (1×10^6 CD19-CAR-DNT cells/kg, 3×10^6 CD19-CAR-DNT cells/kg, 9×10^6 CD19-CAR-DNT cells/kg) and 3 patients in the dose-expansion trial.
88830500|NCT04108247|Experimental|Abiraterone+SHR3162|
88830501|NCT01955473|Experimental|Sym004|
88830502|NCT05453435|Experimental|Entecavir prophylaxis|0.5mg qd
88830503|NCT05453279|Active Comparator|Active (experimental)|Delcetravir inhalation via dry powder inhaler device administered up to 4 single ascending doses. According to tolerability of single ascending doses, delcetravir is then given as inhalation via dry powder device in multiple ascending doses, once daily for 7 days.
88830504|NCT05453279|Placebo Comparator|Placebo comparator|Placebo inhaler, identical in appearance to the active comparator, administered doses up to 4 single ascending doses. According to tolerability of single ascending doses, placebo doses are then given as inhalation via dry powder device in multiple ascending doses, once daily for 7 days.
88830505|NCT05453123|Active Comparator|paper-handout arm|the paper-handout arm is the control group taking the home exercise printed in the paper handout.
88830506|NCT05453123|Experimental|intervention arm|the intervention arm is the experimental group where they take home exercise and motivational text messages by WhatsUp
88830507|NCT03029845|Active Comparator|propranolol 1|20 mg propranolol twice a day
89399137|NCT02171780|Experimental|BI 1744 CL single rising doses|
88830508|NCT03029845|Active Comparator|propranolol 2|10 mg propranolol twice a day
88830509|NCT03029845|Placebo Comparator|Placebo|Placebo twice a day
88830510|NCT05451719|Experimental|Fruquintinib Plus Capecitabine|Maintenance therapy with Fruquintinib Plus Capecitabine
88830511|NCT05451719|Active Comparator|Capecitabine|Maintenance therapy with Capecitabine
88830512|NCT01955629|Experimental|Aflibercept + XELOX (Oxaliplatin and Capecitabine)|Aflibercept 6 mg/kg every 3 weeks (q3w) in combination with Oxaliplatin 100 mg/m^2 q3w and Capecitabine 850 mg/m^2 twice daily orally (from Day 1 to Day 14 of each cycle), up to 6 cycles as induction therapy, followed by aflibercept 6 mg/kg q3w as maintenance therapy up to disease progression or unacceptable toxicity or participant's refusal of further treatment.
88830513|NCT01898611|Active Comparator|Ghrelin plus resistance training|Ghrelin 7.5 mcg/kg as a once daily subcutaneous dose for 12 weeks plus resistance training
88830514|NCT01898611|Placebo Comparator|Placebo plus resistance training|Placebo as a once daily subcutaneous dose for 12 weeks plus resistance training
88830515|NCT05110703|Active Comparator|Dietary supplement: Prebiotic fiber meal replacement shake|Prebiotic fiber meal replacement shake
88830516|NCT05110703|Placebo Comparator|Dietary supplement: Placebo meal replacement shake|Placebo meal replacement shake
88830517|NCT05110703|Other|Dietary guidelines|Dietary guidelines
88830518|NCT01898689|Experimental|RIGHT side Ropivacaine 0.1% and LEFT side Ropivacaine 0.4%|Bilateral sciatic perineural catheters were inserted and ropivacaine administered as a basal infusion concurrently. For the right catheter, ropivacaine 0.1% was infused at 8 mL/h basal for 6 hours. For the left catheter, ropivacaine 0.4% was infused at 2 mL/h for 6 hours.
88830519|NCT01898689|Active Comparator|RIGHT side Ropivacaine 0.4% and LEFT side Ropivacaine 0.1%|Bilateral sciatic perineural catheters were inserted and ropivacaine administered as a basal infusion concurrently. For the right catheter, ropivacaine 0.4% was infused at 8 mL/h basal for 6 hours. For the left catheter, ropivacaine 0.1% was infused at 2 mL/h for 6 hours.
88830520|NCT05090267|Experimental|Dietary Supplement (e.g., vitamins, minerals)|Visbiome probiotic supplement
88830521|NCT05090267|Active Comparator|Device (including sham)|Transcutaneous Vagal Nerve Stimulation (tVNS)
88830522|NCT04350697||Mini-Sternotomy|Patients underwent aortic surgery by Mini-Sternotomy
88830523|NCT04350697||Mini-Thoracotomy|Patients underwent aortic surgery by Mini-Thoracotomy
88830524|NCT00370409|Experimental|1|Cryotherapy
88830525|NCT00370409|Placebo Comparator|2|
88830526|NCT05062577|Experimental|ASP8062 in combination with buprenorphine/naloxone|Participants will receive ASP8062 once daily at bedtime (QHS) and buprenorphine/naloxone once daily every morning (QAM) for 12 weeks.
88830527|NCT05062577|Placebo Comparator|Placebo ASP8062 in combination with buprenorphine/naloxone|Participants will receive matching placebo once daily at bedtime (QHS) and buprenorphine/naloxone once daily every morning (QAM) for 12 weeks.
88830528|NCT01956097|Experimental|HX106 590mg|HX106 590mg/day
88830529|NCT01956097|Experimental|HX106 1180mg|HX106 1180mg/day
88830530|NCT01956097|Placebo Comparator|Placebo|Placebo
89000918|NCT00560170|Active Comparator|combination arm|10mg/10mg of Ezetimibe/Simvastatin (n=20)
89000919|NCT04637152|No Intervention|Group A: Usual recommended therapy|Antihypertensive regimen based on the usual recommended (optimized) therapy.
89399138|NCT02171780|Placebo Comparator|Placebo|
89399139|NCT02171858||stroke|Patients admitted to hospital who are diagnosed with stroke will be treated as usually a our center by observation, venous or arterial thrombolysis depending on extension, condition, thrombolysis feasibility.
89359006|NCT03488251|Experimental|Part 1: Cohort 2: MT-3724 25 mcg/kg/ GEM/ OX|In original protocol and amendment 2, participants will be planned to administer IV MT-3724 25 mcg/kg over 1 hour on Days 1, 3, 5, 8, 10 and 12 in Cycles 1 and 2 (each 28-day cycle) and on Days 1, 8, 15, and 22 in Cycles 3 and 4 (each 28-day cycle). Participants will also be planned to administer Gemcitabine 1000 mg/m^2 as 30-minute IV infusion and Oxaliplatin 100 mg/m^2 as 2-hour IV infusion on Days 2 and 16 in Cycles 1, 2, 3 and 4 (each 28-day cycle). Per amendment 2, participants will be planned to administer MT-3724 25 mcg/kg on Days 1, 3, 5, 8, 10, 12, 15, 22, 29, and 36 in Cycle 1 (42-day cycle). In Cycles 2, 3 and 4, MT-3724 25 mcg/kg will be planned to administer weekly on Days 1, 8, 15, and 22 of each 28-day cycle. Gemcitabine and oxaliplatin will be planned to administer on Days 16 and 30 of Cycle 1 and on Days 2 and 16 in Cycles 2, 3 and 4 (42-day cycle for Cycle 1 and 28-day cycle for Cycle 2, Cycle 3 and Cycle 4).
89359007|NCT03488251|Experimental|Part 1: Cohort 3: MT-3724 50 mcg/kg/ GEM/ OX|In original protocol and amendment 2, participants will be planned to administer IV MT-3724 50 mcg/kg over 1 hour on Days 1, 3, 5, 8, 10 and 12 in Cycles 1 and 2 (each 28-day cycle) and on Days 1, 8, 15, and 22 in Cycles 3 and 4 (each 28-day cycle). Participants will also be planned to administer Gemcitabine 1000 mg/m^2 as 30-minute IV infusion and Oxaliplatin 100 mg/m^2 as 2-hour IV infusion on Days 2 and 16 in Cycles 1, 2, 3 and 4 (each 28-day cycle). Per amendment 2, participants will be planned to administer MT-3724 50 mcg/kg on Days 1, 3, 5, 8, 10, 12, 15, 22, 29, and 36 in Cycle 1 (42-day cycle). In Cycles 2, 3 and 4, MT-3724 50 mcg/kg will be planned to administer weekly on Days 1, 8, 15, and 22 of each 28-day cycle. Gemcitabine and oxaliplatin will be planned to administer on Days 16 and 30 of Cycle 1 and on Days 2 and 16 in Cycles 2, 3 and 4 (42-day cycle for Cycle 1 and 28-day cycle for Cycle 2, Cycle 3 and Cycle 4).
89359008|NCT03488251|Experimental|Part 2: MT-3724/ GEM/ OX|Participants will be planned to administer Maximum tolerated dose (MTD) of MT-3724 in combination with Gemcitabine and Oxaliplatin (GEMOX).
89359009|NCT02727322|Active Comparator|Nitrofurantoin|Receives once daily nitrofurantoin 100mg
89359010|NCT02727322|Placebo Comparator|Placebo|Receives matching placebo
89359011|NCT03716401||Bari: Biopsy Arm|"All study participants will undergo a baseline MRI and US and corresponding blood and urine sample collection. This will be followed up annually for additional blood and urine samples.~Additionally, participants at the Bari site will have an additional renal biopsy at baseline."
89359012|NCT03716401||Bordeaux: MRI Follow-up arm|"All study participants will undergo a baseline MRI and US and corresponding blood and urine sample collection. This will be followed up annually for additional blood and urine samples.~Additionally, participants at the Bordeaux site will have an additional ultrasound US and MRI in Follow-up year 2."
89359013|NCT03716401||Exeter: Microvascular arm|"All study participants will undergo a baseline MRI and US and corresponding blood and urine sample collection. This will be followed up annually for additional blood and urine samples.~Participants at the Exeter site will undergo microvascular measurements including estimating glycocalyx thickness at baseline and at 2 years follow-up."
88830531|NCT05449379|Experimental|Post COVID experimental group|Safe protocol of 6 week physical training (aerobic training, resistance training, general improvement training, stretching training and respiratory rehabilitation) adjusted to the clinical state of patients plus additional resistance respiratory training with the use of respiratory muscle trainer (Philips Respironics Threshold IMT).
88830532|NCT05449379|Placebo Comparator|Post COVID control group|Safe protocol of 6 week physical training (aerobic training, resistance training, general improvement training, stretching training and respiratory rehabilitation) adjusted to the clinical state of patients. No resistance set on respiratory muscle trainer (Philips Respironics Threshold IMT).
88830533|NCT05448989|Experimental|1% atropine 5+3|Put the 1% atropine eye drops into the conjunctival sac, then close the eyes and press the nasolacrimal duct used for 5 consecutive nights in the first week of each month, one night per week in the 2nd, 3rd, and 4th weeks; after 3 months of monocular application, change to the contralateral eye Total treatment time 1 year
88830534|NCT05448989|Placebo Comparator|1% atropine weekly|Put the 1% atropine eye drops into the conjunctival sac, then close the eyes and press the nasolacrimal duct once a week in both eyes Total treatment time 1 year
88830535|NCT05447195|Experimental|CAN008|CAN008 IV infusion weekly
88830536|NCT05447195|Placebo Comparator|placebo|Placebo IV infusion weekly
88830537|NCT05049161|Experimental|Temelimab 18 mg/kg|Monthly IV repeated dose
88830538|NCT05049161|Experimental|Temelimab 36 mg/kg|Monthly IV repeated dose
88830539|NCT05049161|Experimental|Temelimab 54 mg/kg|Monthly IV repeated dose
88830540|NCT05039723|Experimental|Treatment|Treatment with Xeomin, Radiesse, and/or Belotero
88830541|NCT05391191|Experimental|MitrAssist TRISKELE® transcatheter aortic valve system|Device: MitrAssist TRISKELE® transcatheter aortic valve system
88830542|NCT05370989|Experimental|Technology-Based Parent School Program.|Technology-Based Parent School Program. This program, developing parents' self-efficacy and parenting skills in child care with the Parent School Program
88830543|NCT05370989|Active Comparator|Control group|the control group will continue to receive routine check-ups.
88830544|NCT05356247|Experimental|LTP-B Intervention|Families will take part in an online semi-structured assessment and video feedback paradigm of family interactions, with an emphasis on co-parenting and parent-child relations.
88830546|NCT03904823|Experimental|famitinib, HS-10296|
88830547|NCT03888131|Experimental|CHF 1535 100/6 µg pMDI|2 inhalations BID Total Daily Dose = 400/24µg
88830548|NCT03888131|Active Comparator|Symbicort® Turbohaler®|2 inhalations BID Total Daily Dose = 640/18µg
88830549|NCT01900249|Active Comparator|R348 Ophthalmic Solution, 0.2%|R348 Ophthalmic Solution, 0.2%
88830550|NCT01900249|Active Comparator|R348 Ophthalmic Solution, 0.5%|R348 Ophthalmic Solution, 0.5%
88830551|NCT01900249|Placebo Comparator|Placebo|Placebo Ophthalmic Solution, 1 drop per eye twice a day for 12 weeks.
88830552|NCT02987647|Experimental|Hidrafemme|"The arm in question will have 14 patients who use the Hidrafemme product, encoded as group A.~Name: hidrafemme Dosage form: applicator Dosage: the applicator must be complete (full) Frequency: twice a week Duration: 28 days"
89177860|NCT04788992|Active Comparator|Control group|receive dementia care training without virtual reality activity
88830553|NCT02987647|Active Comparator|Vagidrat|"The arm in question will have 14 patients who use the Vagidrat product, encoded as group B.~Name: vagidrat Dosage form: applicator Dosage: the applicator must be complete (full) Frequency: twice a week Duration: 28 days"
88830554|NCT02987647|Active Comparator|Lubrinat|"The arm in question will have 14 patients who use the Lubrinat product, encoded as group C.~Name: lubrinat Dosage form: applicator Dosage: the applicator must be complete (full) Frequency: twice a week Duration: 28 days"
88830555|NCT02987647|Active Comparator|Antrofi|"The arm in question will have 14 patients who use the Antrofi product, encoded as group D.~Name: antrofi Dosage form: applicator Dosage: the applicator must be complete (full) Frequency: twice a week Duration: 28 days"
88830556|NCT05267171|Experimental|Intervention group|
88830557|NCT05267171|No Intervention|Control group|
88875473|NCT05214456|Experimental|Interventional group|The interventional group will comprise 28 participants with chronic non-specific low back pain. The treatments of this group will include dry needling plus sham mobilization for the lumbar spine and routine physiotherapy. The needles will be inserted to obtain local twitch responses, and this process will continue until no more local twitch response occurs in each session. Then the needles will be left in place for 20 minutes. Sham mobilization for the lumbar spine will be done in the same way as the real mobilization, with the difference that the mobilization will be applied only on the skin surface and less than the first degree of Maitland's mobilization. Routine physical therapy will include low-level laser therapy and motor control training. The treatment will last 4 weeks, 8 sessions, twice a week.
89177861|NCT04107480|Experimental|Intervention|Patients in the intervention groups will be referred to one of the participating neurosurgical centers, for surgical consultation. After this consultation, the patient may choose to continue with surgery or not.
89177862|NCT04107480|Active Comparator|Standard care|Patients in the standard care groups will receive treatment as usual as described by the US Endocrine Society.
89177863|NCT04024202||Patients|"Patients with a positive DAT, a positive eluate and signs of hemolysis~Patients with a positive DAT with complement only, negative eluate, but with hemolysis"
89177864|NCT04024202||Blood donors|Blood donors with a positive direct antiglobulin test and a positive eluate and/or clinically relevant cold auto-antibodies
89177865|NCT00915408|Experimental|CRD|
89177866|NCT00590954|Experimental|Treatment|Following a diagnosis of tumor recurrence or progression, all patients will receive perifosine monotherapy until toxicity, progression, or death.
89177867|NCT04030286||Control|Healthy patients
89177868|NCT04030286||Periodontitis|Patients with periodontal disease
89177869|NCT04030286||Cardiovascular|Patients with cardiovascular disease
89177870|NCT04030286||Periodontitis+Cardiovascular|Patients with both periodontal and cardiovascular disease
89177871|NCT05753540|Experimental|Laser therapy|Multiwave locked system laser therapy
89177872|NCT05753540|Placebo Comparator|Sham laser therapy|Sham laser therapy
89177873|NCT02602548||Open Shoulder Surgery|Culture
89177874|NCT02602548||Arthroscopic Shoulder Surgery|Culture
89177875|NCT00791076|Placebo Comparator|Saline Placebo|Saline
89177876|NCT00791076|Active Comparator|Pancreatic Polypeptide|Pancreatic Polypeptide
89177877|NCT05757518|Experimental|Experimental group|Cryo-stimulation using cryosauna after fatigue-induced exercise.
89177878|NCT05757518|No Intervention|Control group|Without any intervention after fatigue-induced exercise.
89177879|NCT04785560|Active Comparator|Shunt setting 4 (=110 mm H20)|Patients randomised to have the Certas Plus valve initial shunt setting post-operatively set to 4 (110 mm H20), our standard setting.
89177880|NCT04785560|Active Comparator|Shunt setting 8 (=400 mm H20)|Patients randomised to have the Certas Plus valve initial shunt setting post-operatively set to 8 (400 mm H20 a k a virtual off), in practice a closed non-functional shunt.
89177881|NCT05757440|Experimental|Icon resin|Low-viscosity Icon resin infiltration
89177882|NCT02609126|Experimental|EP-104IAR|15mg EP-104IAR in 4 mL carrier fluid
89177883|NCT02609126|Placebo Comparator|Vehicle|4 mL carrier fluid
89177884|NCT04107402|Experimental|Septic shock|Septic shock Patients admitted to the ICU
89177885|NCT04107402|Other|Control group|Patients recruited at the central lab of the hospital, with matched age, gender and comorbidities
89177886|NCT04107402|Experimental|Covid-19|Covid-19 patients admitted to the ICU for Acute Respiratory Distress Syndrom with PaO2/FiO2 < 200
89177887|NCT02603718|Experimental|Standard physical therapy treatment with feedback|Standard physical therapy rehabilitation is administered to stroke patients. Attention level of the patient gathered with an EEG tool is measured, and provided to both therapist and patient on-line during one of the two treatments.
89177888|NCT02603718|Experimental|Standard physical therapy treatment without feedback|Standard physical therapy rehabilitation is administered to stroke patients. Attention level of the patient gathered with an EEG tool is measured but feedback is not provided.
89177889|NCT02610062|Experimental|AGS67E 1.2 mg/kg Schedule 1|Participants will receive 1.2 mg/kg of AGS67E as an intravenous infusion once every three weeks (Q3).
89177890|NCT02610062|Experimental|AGS67E 1.8 mg/kg Schedule 1|Participants will receive 1.8 mg/kg of AGS67E as an intravenous infusion once every three weeks.
89177891|NCT02610062|Experimental|AGS67E 2.4 mg/kg Schedule 1|Participants will receive 2.4 mg/kg of AGS67E as an intravenous infusion once every three weeks.
89177892|NCT02610062|Experimental|AGS67E 0.6 mg/kg Schedule 2|Participants will receive 0.6 mg/kg of AGS67E once weekly for three weeks.
89177893|NCT02610062|Experimental|AGS67E 0.9 mg/kg Schedule 2|Participants will receive 0.9 mg/kg of AGS67E once weekly for three weeks.
89177894|NCT02610218||histo-HER2+ gastric cancer patients|Histologically HER2 positive gastric cancer patients treated with HER2 targeted therapy. Interventions: peripheral blood samples of 12.5 mL for CTC and cfDNA analysis will be collected before targeted therapy, at the time that they achieve the optimal response and when they suffer progressive disease.
89177895|NCT02610218||histo-HER2- gastric cancer patients|Histologically HER2 negative gastric cancer patients treated with chemotherapy. Interventions: peripheral blood samples of 12.5 mL for CTC and cfDNA analysis will be collected before targeted therapy, at the time that they achieve the optimal response and when they suffer progressive disease.
89534333|NCT02947802|Experimental|Consumer Support with Effectiveness Info|Participants will be presented with three labels: a calorie label, a textual warning label and a textual warning label with corresponding graphic images and will be asked to rate their support for each label on a 1 (not at all) to 7 (a great deal) scale. Participants will also receive effectiveness information- how each label influenced the purchasing of sugar sweetened beverages- from a recent field experiment.
88830558|NCT01900561|Experimental|IVR Intervention|The intervention will consist of two components, both with content design based on established theories for self-management support: 1) automated telephone monitoring of PC survivor symptoms and goals for symptom reduction, based on a patient empowerment approach, and 2) personally tailored newsletters that incorporate elements of CBT to improve survivors' identification with the material, confidence/self-efficacy in symptom management, and to reduce common cognitive distortions related to successful implementation of behavior change. Intervention-group participants will receive four automated assessment and self-management support calls over a 3-month period (at baseline, 1-month, 2-month, 3-months). Information collected during automated phone assessments will be used to construct tailored newsletters, which will be sent following each automated call.
88830559|NCT01900561|No Intervention|Enhanced Usual Care|Because of the strong evidence documenting symptom burden in PC survivors, the investigators believe that providing control subjects with some information about symptom self-management is warranted. The investigators further believe, based on the investigators' prior experience conducting RCTs, that offering some type of educational material for Veterans randomized to the control arm will increase their willingness to enroll in the study (as opposed to a pure usual care arm where they would not receive any such materials). Therefore, survivors randomized to the control condition will receive written material at the time of enrollment designed to educate them about PC symptoms and symptom management. Material will be approximately six pages in length, also written at or below an 8th grade reading level, and will include a summary of common symptoms experienced by prostate cancer survivors.
88830560|NCT03789617|Experimental|EBViNT Cell|
88830561|NCT05166473|Experimental|Telerehabilitation group (n=21)|"This group was conducted with a physiotherapist for video conference-based vestibular rehabilitation exercises, was called the telerehabilitation group (TR). In terms of ease of Use and applicability, the WhatsApp app was preferred. Patients were individually searched for two days a week, 25-30 minutes. The exercises were performed gradually from easy to difficult, initially in a sitting position in accordance with the levels of the patients."
88830562|NCT05166473|Active Comparator|Control Group (n=21)|"After the home exercise program, which should be applied twice a day for six weeks, was shown in practice, the home exercise program was given, in which the exercises were visual and written, this group was called the control group. All participants were given a phone number to consult when there were any problems, and were phoned to decry whether they were continuing the exercises."
88830563|NCT01957657|Experimental|Healthy volunteers group 1|Healthy volunteers with normal renal function
88830564|NCT01957657|Experimental|Renal function group 2|Patients with mild renal impairment
88830565|NCT01957657|Experimental|Renal function group 3|Patients with moderate renal impairment
88830566|NCT01957657|Experimental|Renal function group 4|Patients with severe renal impairment
88830567|NCT05734963||Group 1|"Patients with histologically confirmed cancer~Tissue, blood and saliva samples collected before and after surgery and before and after any adjuvant therapy. Molecular profiling, DNA sequencing, gene expression analysis"
88830568|NCT02987491|Experimental|Exercise Metabolic Study Day|"Participants will perform a single bout of moderate intensity exercise on a cycle ergometer for 60 minutes.~A total of 3 muscle biopsies will be collected throughout the study day. Insulin sensitivity will be measured using a hyperinsulinemic-euglycemic clamp with glucose tracers."
88830569|NCT02987491|No Intervention|Resting Metabolic Study Day|"Participants will rest quietly in bed for 60 minutes and resting energy metabolism will be measured with a ventilated hood.~A total of 3 muscle biopsies will be collected throughout the study day. Insulin sensitivity will be measured using a hyperinsulinemic-euglycemic clamp with glucose tracers."
88830570|NCT04969211|Experimental|Sequence A: VHX-896 then iloperidone|
88830571|NCT04969211|Experimental|Sequence B: Iloperidone then VHX-896|
88830572|NCT05734885|Experimental|Midwife Massage Experimental Group (1)|"Back and sacral massage will be applied to pregnant women in labor in the application group. Massage will be applied by the research midwife. Midwife massage will be performed when cervical dilation is 5-6 cm and 8-9 cm.~Massage application time will last 20 minutes."
88830573|NCT05734885|Experimental|Spouse Massage Experimental Group (2)|"Back and sacral massage will be applied to pregnant women in labor in the application group. Massage will be applied by the spouse of the pregnant woman. Massage will be performed when cervical dilation is 5-6 cm and 8-9 cm.~Massage application time will last 20 minutes."
88830574|NCT05734885|No Intervention|Control Group|It will be perform routine practice who the women in the control group.
88830575|NCT01901575|Experimental|Remifentanil IV PCA|patients with PVC's prior to administration of remifentanil
88830576|NCT05049005|Active Comparator|RED FOOD Intervention Group|Participants in the RED FOOD group will be taught a simplified way of identifying high-calorie foods (red foods) and reducing them using the Traffic Light Diet. Limiting the number of red foods consumed is a simple way to reduce calories without having to track calories. Participants in this group will use the study website to track their red foods and will be given a daily red food limit base on their baseline weight and will track their red foods on the study website daily. Participants will be recommended to enter their red foods at least once per day (at which time they would enter all red foods for the day), but ideally multiple times per day to reduce errors associated with recall.
88875173|NCT02500836|Experimental|Cocaine HCI 10% Topical Solution|Cocaine HCl 10% Topical Solution, up to 4 mL, is applied for 20 minutes via cotton or rayon pledget(s), then the nasal site is tested with a Von Frey (or equivalent) filament (Size 5.88, about 60 grams of force) to determine and record whether the subject has a pain score of 0 (zero) (0 = No Pain, 10 = Unbearable pain) after treatment application compared to the Von Frey filament test right before treatment application. If a pain score of 0 (zero) is recorded the application then proceed with the diagnostic procedure or surgery along with safety monitoring for at least 90 minutes post removal of pledgets, and, the subject will be followed for safety for at least seven days post solution application. The total number of pledgets used, and the amount of Cocaine HCl 10% topical solution used (1 mL per pledget) will be recorded.
89359014|NCT03716401||Leeds: Microstructure MRI arm|"All study participants will undergo a baseline MRI and US and corresponding blood and urine sample collection.~Participants at the Leeds' site will have an extended MRI scan at baseline including novel microstructure MRI measurements."
89359015|NCT03716401||Turku: PET arm|"All study participants will undergo a baseline MRI and US and corresponding blood and urine sample collection. This will be followed up annually for additional blood and urine samples.~Additionally, participants at the Turku site will undergo a renal Positron Emission Tomography (PET) scan at the baseline timepoint."
88830577|NCT05049005|Experimental|GREEN FOOD Intervention Group|Participants in the GREEN FOOD group will be taught a simplified way of identifying low-calorie foods (green foods) and maximizing them using the Traffic Light Diet. Maximizing the number of green foods consumed is a simple way to reduce dietary energy density while allowing for consumption of a satisfying amount (i.e. weight and volume) of food. Maximizing green food consumption may simultaneously reduce red food consumption, thereby reducing calorie intake and promoting greater diet quality than red food reduction alone. Participants in this group will also use the study website to track their green foods and will be given a daily green food goal based on their baseline weight and will track their green foods on the study website daily. Participants will be recommended to enter their green foods at least once per day (at which time they would enter all green foods for the day), but ideally multiple times per day to reduce errors associated with recall.
88830578|NCT01901809|Active Comparator|Bolus furosemide and no dopamine|"If the patient is not on a prior diuretic dose, a standard dose of furosemide 40mg IV every 12 hrs, with total dose of 80 mg IV over 24 hrs will be initiated.~If the patient is already on a prescribed diuretic dose, their outpatient dose will be doubled and administered as the equivalent IV dose every 12 hrs. (i.e if the prescribed dose is furosemide 80mg by mouth twice daily, the inpatient treatment dose will be furosemide 80mg IV twice daily)."
88830579|NCT01901809|Active Comparator|Continuous infusion furosemide and no dopamine|"If the patient is not on a prior diuretic dose, a standard dose of furosemide 80mg IV over 24 hrs, will be initiated.~If the patient is already on a prescribed diuretic dose, their outpatient dose will be doubled and administered as the equivalent IV dose continuously over 24 hrs. . (i.e. if the prescribed dose is furosemide 80mg by mouth twice daily, the inpatient treatment dose would be furosemide 160mg IV to be administered continuously over 24 hrs)."
88830580|NCT01901809|Active Comparator|Bolus furosemide plus dopamine|Intermittent furosemide diuretic therapy as outlined with the addition of dopamine at 3 µg/kg/min
88830581|NCT01901809|Active Comparator|Continuous furosemide plus dopamine|Continuous furosemide diuretic therapy as outlined with the addition of dopamine at 3 µg/kg/min
88830582|NCT01902901|Active Comparator|Usual care|Requested carrier status testing.
88830583|NCT01902901|Experimental|Whole Genome Sequencing|These participants will receive the carrier status testing they requested from their provider, plus whole genome sequencing.
88830584|NCT05740189|Experimental|C2 CryoBalloon 180 Ablation System|C2 CryoBalloon 180 Ablation System will be used to ablate visible Barrett's esophagus
88830585|NCT04929743|Experimental|5.5 mm implants|
88830586|NCT04929743|Active Comparator|>6.5 mm implants|
88830587|NCT02284399||IDTFK Group Post NIPT - (January 2012-June 2014)|Pregnant women who present to participating centers between January 2012-June 2014, after the release of non-invasive prenatal testing (NIPT), who are undergoing invasive prenatal diagnostic testing for fetal karyotype (IDTFK).
88830588|NCT02284399||IDTFK Group pre-NIPT (January 2010-July 2010)|A control group of pregnant women, prior to the release of non-invasive prenatal testing (NIPT), who present to participating centers between January 2010-June 2010 and are undergoing invasive prenatal diagnostic testing for fetal karyotype (IDTFK).
88830589|NCT05734651||Intervention|
88830590|NCT03029533|Experimental|DWJ108J (leuprolide acetate)|DWJ108J (leuprolide acetate)
88830591|NCT03029533|Active Comparator|Leuplin DPS Inj|Leuplin DPS Inj
88830592|NCT04921007|Active Comparator|Group (A) Sacral ESP block|Ultrasound guided sacral erector spinae plane (ESP) block will be performed in the lateral position under sterile conditions, and bupivacaine will be administered.
88830593|NCT04921007|Active Comparator|Group (B) Caudal block|Ultrasound guided caudal block will be performed in the lateral position under sterile conditions, and bupivacaine will be administered.
88830594|NCT01904071|Experimental|UFNB|Ultrasound guided 3 in 1 femoral nerve block: The UFNB was performed by first visualizing the femoral nerve in a transverse orientation just inferior to the inguinal ligament and lateral to the common femoral artery.
88830595|NCT01904071|Experimental|UFIB|Ultrasound Guided Fascia Iliaca Compartment Block: For the UFIB, the two fascial planes, the fascia lata and the fascia iliaca, were sonographically visualized with the probe transverse to the thigh just inferior to the inguinal ligament and one-third of the distance from the anterior superior iliac spine to the pubic tubercle.
88830596|NCT01904071|Active Comparator|IVMS|IV Morphine: IV Morphine patients were also monitored for a minimum of one hour after they were given a second dose of IV morphine, 0.1 mg/kg, once the radiographs demonstrated fracture. The control group was also eligible to receive rescue analgesia of an additional 0.1 mg/kg of IV morphine, followed by repeat doses of 0.05 mg/kg
88830597|NCT01905241|Experimental|Anatomic TSA using RTI|During Anatomic Total Shoulder Arthroplasty (TSA), the surgeon will have use of the SmartBone and the bone cement mold made from the SmartBone (the RTI) to transfer the preoperative plan for glenoid implant positioning to the patient's anatomy.
88830598|NCT01907113|Experimental|BI 10773 / Group 2|Single Dose Administration (type 2 diabetes and mild renal impairment)
88830599|NCT01907113|Experimental|BI 10773 / Group 3|Single Dose Administration (type 2 diabetes and moderate renal impairment)
88830600|NCT01907113|Experimental|BI 10773 / Group 4|Single Dose Administration (severe renal impairment 8)
88830601|NCT01907113|Experimental|BI 10773 / Group 5|Single Dose Administration (kidney failure)
88830602|NCT01907113|Experimental|BI 10773 / Group 1|Single Dose Administration (type 2 diabetes and normal renal function)
88830603|NCT03535337|Active Comparator|CPS-Rsp-T|After 3 months of intervention, this group of CPS Rsp will receive 3 months of CPS-T intervention followed by SC.
88830604|NCT03535337|Active Comparator|CPS-Rsp-SC|After 3 months of intervention, this group of CPS Rsp's intervention will discontinue and they'll receive SC only
89534334|NCT02944253|Experimental|Low energy diet 70 gram carbohydrates|isocaloric 4128 kilojoules/day (1000 kilocalories/day) for men and women, low energy diet containing 70 gram carbohydrates for 8 weeks.
89359016|NCT03315520|Experimental|Relapsed/refractory malignant lymphomas|Malignant Lymphoma Subjects With Indications to Autologous Hematopoietic Stem-cell Transplantation using BeEAC (Bendamustine, Cytarabine, Etoposide, Cyclophosphamide) conditioning regimen
89359017|NCT02483182|Experimental|ZEP-3 ointment 1.0%|Topical administration
89359018|NCT02483182|Active Comparator|Acyclovir cream 5%|Topical administration
89359019|NCT03780491|No Intervention|Control|The first 50 patients will have usual care with providers conducting the visit in their typical manner.
89359020|NCT03780491|Experimental|Cost Discussion|The second group of 50 patients will be the intervention group where the providers will have a discussion of cost emphasizing five points: 1) Cancer care is expensive and it is normal to be concerned about cost. 2) We will recommend treatments for your cancer based on what we think gives you the best chance of doing well, not based on the cost of the treatment. 3) Because of how complex our healthcare system is, it is very hard for your doctors to know what your costs will be, but we will do our best to give you some general information. 4) We have resources available to help you get more specific information so that you can plan appropriately. 5) Do you have any specific concerns about cost that you'd like to share with me?
89359021|NCT03431857||TESS V2 Prosthesis|Single study patient cohort, including 106 patients who meet the inclusion/exclusion criteria and who received the TESS V2 shoulder prosthesis.
89399140|NCT03540524|Experimental|Cohort A - F508del homozygous|Dual combination (GLPG2451 and GLPG2222) will be administered for 14 days, followed by the triple combination (GLPG2451, GLPG2222 and GLPG2737) for 14 days, without washout in between the sequential treatment periods.( Study Part I)
88830605|NCT03535337|Active Comparator|CPS-NRsp-I|After 3 months of intervention, this group of CPS NRsp will receive 3 months of CPS-I followed by 3 months of CPS-T and 3 months of SC.
88830606|NCT03535337|Active Comparator|CPS-NRsp-SMS-I|After 3 months of intervention, this group of CPS NRsp will receive 3 months of SMS-I followed by 3 months of SMS-T and 3 months of SC
88830607|NCT03535337|Active Comparator|SMS-Rsp-T|After 3 months of intervention, this group of SMS Rsp will receive 3 months of SMS tapered (SMS-T) intervention followed by SC.
88830608|NCT03535337|Active Comparator|SMS-Rsp-SC|After 3 months of intervention, this group of SMS Rsp, intervention will discontinue and they'll receive SC only
88830609|NCT03535337|Active Comparator|SMS-NRsp-CPS-I|After 3 months of intervention, this group of SMS NRsp will receive 3 months of CPS-I followed by 3 months CPS-T and 3 months SC
88830610|NCT03535337|Active Comparator|SMS-NRsp-I|After 3 months of intervention, this group of SMS NRsp will receive 3 months of SMS-I followed by 3 months of SMS-T and 3 months of SC
88830611|NCT01907269|Experimental|Video-based intervention|"Video-based intervention providing personalized feedback regarding patients' risk of subsequent fractures, customized information regarding osteoporosis care, and messaging to activate patients to become more engaged in improving osteoporosis treatment and doctor-patient communication. This novel content will use story-telling delivered via the Internet and DVDs. The content will be uniquely tailored to each person based on their reported barriers to care, age and race/ethnicity. The video-based intervention materials will be augmented by a personal phone call and interactive voice response messaging."
88830612|NCT01907269|No Intervention|Usual care|
88830613|NCT01908127|Active Comparator|tell- show- do procedure|"Group I (Tell- Show- Do Group): Tell-Show-Do, prophylaxis with paste and rubber cap and fluoride therapy was performed by the dentist for each participant in the operation room.~In the second session,injection of loal anesthesia solution including a mandibular alveolar nerve block technique and the occlusal cavity preparation was performed."
88830614|NCT01908127|Experimental|film modelling|"Group II (Filmed modelling Group): the children were directed to a quiet and comfort room to watch a film presented by a dental assistant. The film showed that the same procedure consisted of Tell-Show-Do, prophylaxis with paste and rubber cap and fluoride therapy was performed on a 5-years-old child model with a time of 20 minutes. The child in the film was cooperative and was reinforced by a reward at the end of the procedure.~In the second session, injection of loal anesthesia solution including a mandibular alveolar nerve block technique and the occlusal cavity preparation was performed."
88830615|NCT04679831|Experimental|Ujiplus® porridge|Arm receiving porridge fortified with dried papaya seeds (Ujiplus)
88830616|NCT04679831|Active Comparator|Praziquantel 400mg|Arm receiving the approved Praziquantel treatment of 400mg once with plain porridge daily (without papaya seeds)
88830617|NCT00371423|Experimental|Arm 1|
88830618|NCT00371423|Other|Arm 2|Control data derived from ATLAS Workhorse Trial
88830619|NCT04882397|Experimental|Instrument Assisted Soft Tissue Mobilization|In the application group, Instrument Assisted Soft Tissue Mobilization will be applied to the Trapezius and Sternocleideomastoideus muscles for 90 seconds.
88830620|NCT04882397|Sham Comparator|Sham Instrument Assisted Soft Tissue Mobilization|In the sham application group, 90 degrees to 90 seconds will be applied to the Trapezius and Sternocleideomastoideus muscles without applying pressure.
88830621|NCT04882397|No Intervention|Control|No application will be made to the control group.
89177896|NCT00590720|Experimental|MEDI528 50 mg|MEDI-528 at a dose of 50 mg administered as a subcutaneous injection twice weekly for 4 weeks
88830622|NCT01908751|Experimental|Sliding Hip Screw and Vitamin D supplementation|Participants allocated to the vitamin D Group will be given a six-month supply of vitamin D3 supplementation. Participants in the vitamin D Group will receive a bottle of 2,000 International Units (IU) vitamin D3 drops (Ddrops®, Ddrops Company). Participants will be instructed to take two drops daily for six months, for a total daily dose of 4,000 IU.
88830623|NCT01908751|Experimental|Sliding Hip Screw and Vitamin D placebo|Participants in the placebo group will receive an identical bottle of placebo drops with no active ingredient. Similarly, they will be instructed to take two drops daily for six months. The placebo supplement is also manufactured by the Ddrops Company.
88830624|NCT01908751|Experimental|Cancellous Screws and Vitamin D supplementation|Participants allocated to the vitamin D Group will be given a six-month supply of vitamin D3 supplementation. Participants in the vitamin D Group will receive a bottle of 2,000 International Units (IU) vitamin D3 drops (Ddrops®, Ddrops Company). Participants will be instructed to take two drops daily for six months, for a total daily dose of 4,000 IU.
88830625|NCT01908751|Experimental|Cancellous Screws and Vitamin D placebo|Participants in the placebo group will receive an identical bottle of placebo drops with no active ingredient. Similarly, they will be instructed to take two drops daily for six months. The placebo supplement is also manufactured by the Ddrops Company.
88830626|NCT04873115|Active Comparator|Sialanar|Sialanar administered as per the SmPC - titration over 4 weeks to reach a dose balancing efficacy with tolerability.
88830627|NCT04873115|Placebo Comparator|Placebo|Placebo administered as per the Sialanar SmPC - titration over 4 weeks to reach a dose balancing efficacy with tolerability.
88830628|NCT00370721|Experimental|I|
88830629|NCT03459521|Experimental|Fendrix HBV vaccine or HBVaxpro 40|"Drug: Fendrix Fendrix suspension for injection GlaxoSmithKline Route of administration, dose regimen: Intra-muscular Dose: 20mcg of Hepatitis B Surface Antigen per vaccination at baseline, 1, 2 and 6 months.~Drug: HBVaxpro 40 Sanofi Pasteur MSD Route of administration, dose regimen: Intra-muscular Dose: 40mcg of Hepatitis B Surface Antigen per vaccination at baseline, 1 and 6 months."
88830630|NCT01909141|Active Comparator|arm 1:letrozole-pioglitazone -metformin group|Arm 1 will receive letrozole 2.5 mg/day starting from the 3rd day of the cycle and for 5 days and (combined pioglitazone 15 mg+ metformin 850 mg) once daily from the first day of the cycle for 10 days.
88830631|NCT01909141|Active Comparator|arm 2: clomiphene citrate-pioglitazone-metformin|Arm 2 will receive clomiphene citrate 100 mg/day starting from the 3rd day of the cycle for 5 days and (combined pioglitazone 15 mg + metformin 850 mg) once daily from the first day of the cycle for 10 days.
89177897|NCT00590720|Placebo Comparator|PLACEBO|Placebo administered as a subcutaneous injection twice weekly for 4 weeks
89177898|NCT00625378|Experimental|Sorafenib (Nexavar, BAY43-9006)|Participants receive single-agent sorafenib at the same dose and schedule as in their original clinical trials.
89177899|NCT00822250|Other|1|cutting hair, skin phenotype description
89177900|NCT00819364|Experimental|1|Participants with autism will receive BCRI intervention program.
89177901|NCT00819364|Active Comparator|2|Participants with autism will receive standard care available in the community.
89177902|NCT00806624|Experimental|2|DU-176b tablets: high-dose
89177903|NCT00806624|Active Comparator|3|Warfarin tablets
89359022|NCT02480062|Experimental|mWELLCARE software arm|The doctor and nurse care coordinators (NCCs) in the mWELLCARE intervention arm will be trained on the use of mWELLCARE software loaded on a tablet computer. Patients diagnosed with hypertension and/or diabetes will be registered by the nurse using mWellcare application. The nurse will record patient parameters, medical history, medication etc and generate a management plan (including drug recommendation, lifestyle advise) using the mWellcare application based on standard treatment guidelines. The doctor will review the recommendation and agree or disagree giving reasons. Patient will be followed up using SMS.
88830632|NCT04486859|Other|mechanical prevention|patients were managed with IPC
88830633|NCT04486859|Other|mechanical plus anticoagulant drugs prevention|patients were managed with IPC, and LMWH was added 24h after surgery and followed by rivaroxaban 5 days after surgery
88830634|NCT01910311|Experimental|Baricitinib|Single oral dose of 10 milligrams (mg) baricitinib on Day 1.
88830635|NCT01910311|Experimental|Baricitinib + Rifampicin|Oral doses of 600 mg rifampicin once daily on Days 3 to 11, with a single oral dose of 10 mg baricitinib co-administered on Day 10.
89177904|NCT00806624|Experimental|1|DU-176b tablets: low-dose
89177905|NCT04022564||The subjects are diagnosed as MS patient|The study population is based on the 'National Health Insurance Research Database' (NHIRD) from 2001 to 2015 provided by Taiwan Ministry of Health and Welfare. The subjects are diagnosed as MS patients based on the 'Registry for Catastrophic Illness'.
89177906|NCT05753228|Active Comparator|COVID fatigue patients|MRI/ 3D Arterial Spin Labelling (ASL) and 1H magnetic resonance spectroscopy (MRS),Chalder fatigue scale, Health Questionnaire (EQ-5D-5L), Hamilton Depression Rating Scale
89177907|NCT05753228|Active Comparator|Cancer fatigue patients|MRI/ 3D Arterial Spin Labelling (ASL) and 1H magnetic resonance spectroscopy (MRS),Chalder fatigue scale, Health Questionnaire (EQ-5D-5L), Hamilton Depression Rating Scale
89177908|NCT05753228|Active Comparator|Healthy patients as controls|MRI/ 3D Arterial Spin Labelling (ASL) and 1H magnetic resonance spectroscopy (MRS),Chalder fatigue scale, Health Questionnaire (EQ-5D-5L), Hamilton Depression Rating Scale
89177909|NCT00806546|Experimental|NP101|sumatriptan iontophoretic transdermal patch
89177910|NCT00624832|Experimental|Xolair (Immunoglobulin E (IgE) = 30-300 IU/mL)|Patients with screening Immunoglobulin E (IgE) levels = 30-300 IU/mL. Participants received subcutaneous injections of Xolair (Omalizumab) every 2 weeks or every 4 weeks; dosage dependent on IgE level and body weight.
89177911|NCT00624832|Experimental|Xolair (Immunoglobulin E (IgE) = 700-2000 IU/mL)|Patients with screening Immunoglobulin E (IgE) levels = 700- 2000 IU/mL. Participants received subcutaneous injections of Xolair (Omalizumab) every 2 weeks; dosage dependent on IgE level and body weight.
89177912|NCT00624832|Experimental|Xolair (Immunoglobulin E (IgE) = 301-699 IU/mL)|Patients with screening Immunoglobulin E (IgE) levels = 301- 699 IU/mL. Participants received subcutaneous injections of Xolair (Omalizumab) every 2 weeks; dosage dependent on IgE level and body weight.
88830636|NCT04404959|Active Comparator|fascia iliaca compartment block with ropivacaine|in this arm, the fascia iliaca compartment block will be performed with 40 mL ropivacaine 0.25%
88830637|NCT04404959|Placebo Comparator|fascia iliaca compartment block with placebo|in this arm, the fascia iliaca compartment block will be performed with 40 mL normal saline
89399141|NCT03540524|Experimental|Cohort B - F508del heterozygous/potentiator nonresponsive|Dual combination (GLPG2451 and GLPG2222) will be administered for 14 days, followed by the triple combination (GLPG2451, GLPG2222 and GLPG2737) for 14 days, without washout in between the sequential treatment periods. (study Part II)
88830638|NCT05739877|Experimental|Sequence A(Before→ After)|
88830639|NCT05739877|Experimental|Sequence B(After→ Before)|
88830640|NCT04403711|Active Comparator|local anesthetic and dexmedetomidine|ultrasound-guided transversus abdominis plane block with 25 mL ropivacaine 0.5% and 2 mL dexmedetomidine
88830641|NCT04403711|Placebo Comparator|local anesthetic and placebo|ultrasound-guided transversus abdominis plane block with 25 mL ropivacaine 0.5% and 2 mL normal saline
88830642|NCT01911169|Experimental|Vitamin D 5000|5,000 IU vitamin D (cholecalciferol) given orally daily
88830643|NCT01911169|Active Comparator|Vitamin D 400|cholecalciferol 400 IU daily by mouth
88830644|NCT04403087|Experimental|Trimebutine add group|Addition of Trimebutine on the Bismuth-containing quadruple regimen
88830645|NCT04403087|No Intervention|Control group|Bismuth-containing quadruple regimen
88830646|NCT03374891|No Intervention|Participants will fill out surveys|These participants will fill out surveys in regard to their experiences, opinions, and knowledge of the defibrillator process.
88830647|NCT03374891|Active Comparator|Educational video and/or handout|These participants will receive an educational video and/or handout about the defibrillator process. Then they will fill out surveys in regard to their experiences, opinions, and knowledge of the defibrillator process.
88830648|NCT04399421||Conventional pedicle screw fixation|Patients undergoing conventional pedicle screw fixation without the use of bone cement.
88830649|NCT04399421||Cement-augmented pedicle screw fixation|Patients undergoing pedicle screw fixation augmented with bone cement.
88830650|NCT01911403|Active Comparator|Angio-Seal|Closure procedure by Angio-Seal
88830651|NCT01911403|Active Comparator|Manual compression|Closure procedure by manual compression
88830652|NCT04375241||Screening with Mobile ECG Device|Subjects with asymptomatic atrial fibrillation will be screened by using a Mobile ECG Device
88830653|NCT01912495|Experimental|Boceprevir, peginterferon ribavirin|All patients were intended to be treated in the 12 week peginterferon, ribavirin and boceprevir arm.
88830654|NCT05739799|Active Comparator|Group A Intense pulse light laser|IPL laser Patients in Group A received intense pulse light (IPL) frequency of 690. A total of three sessions were carried out one month apart, and hair reduction was assessed by seeing thickness of hair and by counting the number of hair follicles in a 1cm2 area on each side of the face before the first session and at the 4th month. A consultant dermatologist assessed the reduction in hair count on the affected side of face at the end of last session. Patients' response and any adverse effects experienced by patients' were recorded
88830655|NCT05739799|Active Comparator|Group B Diode laser|Diode laser patients in Group B received diode laser treatment system. Diode laser was employed using triple wavelength (1064, 810 and 755 mm). A total of three sessions were carried out one month apart, and hair reduction was assessed by seeing thickness of hair and by counting the number of hair follicles in a 1cm2 area on each side of the face before the first session and at the 4th month. A consultant dermatologist assessed the reduction in hair count on the affected side of face at the end of last session. Patients' response and any adverse effects experienced by the patients were recorded.
88830656|NCT04354727|Experimental|APG-1252|
88830657|NCT04354727|Experimental|APG-1252 + Ruxolitinib|
88830658|NCT05739721|Experimental|Zoom meeting (camera off)|participants will be randomly assigned to a Zoom (San Jose, CA, USA) video conference meeting with another participant of the opposite gender
88830659|NCT05739721|Experimental|In person meeting (blindfolded)|Once all subjects have been selected and enrolled in the study, participants will be randomly assigned for an in-person meeting.
88830660|NCT05739721|Experimental|Zoom meeting (camera on)|participants will be randomly assigned to a Zoom (San Jose, CA, USA) video conference meeting with another participant of the opposite gender
88830661|NCT05739721|Experimental|In person meeting (no blindfold)|Once all subjects have been selected and enrolled in the study, participants will be randomly assigned for an in-person meeting.
88830662|NCT03339089||Participants with Rheumatoid Arthritis (RA)|This group/ cohort includes participants with RA.
89534335|NCT02944253|Experimental|Low energy diet 100 gram carbohydrates|isocaloric (4128 kilojoules/day (1000 kilocalories/day) for men and women, low energy diet containing 100 gram carbohydrates for 8 weeks.
88830663|NCT03339089||Participants with Plaque Psoriasis (Ps)|This group/ cohort includes participants with Ps.
88830664|NCT03339089||Participants with Ankylosing spondylitis (AS)|This group/ cohort includes participants with AS.
88830665|NCT04330859|Experimental|Intervention|Parent-driven intervention bundle of 6 evidence-based elements: vocal soothing, scent exchange, comforting touch, kangaroo care, infant massage and physical therapy
88830666|NCT04330859|Placebo Comparator|Routine care|Routine care per unit guidelines
88830667|NCT04748887||nonsmokers copd cases ,|Fourty subjects of COPD who are non-smokers or stopped smoking for more than 6 months
88830668|NCT04748887||non smokers healthy control|Thirty subjects of non smokers healthy control
88830669|NCT04748575|Experimental|Acai smoothie consumption|Participants (n=5) in this arm were randomly allocated to consume the acai smoothie at the first intervention. After a 7 day wash-out period, the participants consumed the placebo smoothie.
88830670|NCT04748575|Experimental|Placebo smoothie consumption|Participants (n=5) in this arm were randomly allocated to consume the placebo smoothie at the first intervention. After a 7 day wash-out period, the participants consumed the acai smoothie.
89359023|NCT02480062|Active Comparator|Usual care arm|"In the control arm or the usual care arm CHCs, the doctor and Nurse will get refresher training in the detection, management and follow up of hypertension and diabetes patients based on standard guidelines. They will be provided with charts for quick reference to standard treatment guidelines. Patients diagnosed with hypertension and/or diabetes will be managed by the doctor at the CHC. The nurse will assist in recording blood pressure, height, weight etc, providing lifestyle advise and follow up advice to patients."
89359024|NCT03780647||Patients with suspicion of thoracic outlet syndrome|
88830671|NCT05739487||IAT therapy|patients with central retinal artery occlusion received selective intra-arterial thrombolysis
88830672|NCT01916629|Active Comparator|Photocil for Psoriasis|Active Drug - Photocil for Psoriasis
88830673|NCT01916629|Placebo Comparator|Placebo - Sunscreen (SPF 2)|Placebo - Sunscreen (SPF 2)
88830674|NCT01916941|Active Comparator|Prazosin|Prazosin titrated to 16 mg daily x 6 weeks
88830675|NCT01916941|Placebo Comparator|Placebo|Placebo X 6 weeks
88830676|NCT02987413|Experimental|Autologous Mesenchymal stem cells|Two escalated intrathecal infusions of autologous mesenchymal stem cell
88830677|NCT01918189|Experimental|10 week Pain EASE access|behavioral pain self-management intervention (Pain EASE) delivered via the Internet
88830678|NCT04780685|Experimental|hMSCs|hMSCs will be given via IV administration.
88830679|NCT04780685|Placebo Comparator|Lactated Ringer's Solution|Lactated Ringer's Solution will be given via IV administration.
88830680|NCT05739409|Experimental|LILRB4 STAR-T cells injection|"The study was divided into two phases: dose climbing and dose extension. Dose climbing stage: adopt the 3 + 3 dose climbing design principle, and the dose group is set as follows, in which, dose group-A is the backup dose reduction dose group, and dose group A is the starting dose:~Dose Group-A: 3×105STAR+T cells / kg； Dose group A: 1×106STAR+T cells / kg； Dose group B: 3×106STAR+T cells / kg； Dose group C: 6×106STAR+T cells / kg； Dose group D: 1×107STAR+T cells / kg。"
88830681|NCT04768985|Experimental|Treatment sequence 1: Treatment AB|Participants will be randomized to receive one of the two different treatment sequences. In each treatment sequence participant will receive fixed single doses of 100 mg acalabrutinib orally (Treatment A; Treatment B) in 2 treatment periods, under fasted conditions. Treatment A will include acalabrutinib tablet and Treatment B will include acalabrutinib capsule.
88830682|NCT04768985|Experimental|Treament sequence 2: Treatment BA|Participants will be randomized to receive one of the two different treatment sequences. In each treatment sequence participant will receive fixed single doses of 100 mg acalabrutinib orally (Treatment B; Treatment A) in 2 treatment periods, under fasted conditions. Treatment A will include acalabrutinib tablet and Treatment B will include acalabrutinib capsule.
88830683|NCT05739253||Transfemoral TAVR for AS|Patients undergoing transfemoral transcatheter aortic valve replacement for aortic stenosis
88830684|NCT04210037|Experimental|APG-1252 160 mg|intravenous infusion over 30 minutes on days 1, 8 and 15
88830685|NCT04210037|Experimental|APG-1252 240 mg|intravenous infusion over 30 minutes on days 1, 8 and 15
88830686|NCT04210037|Experimental|APG-1252 80 mg|intravenous infusion over 30 minutes on days 1, 8 and 15
88830687|NCT05739175|Experimental|Intervention group receiving interactive nurse support based on mobile application|Experimental: Intervention Group The mobile application containing an interactive nurse support program will be uploaded to the telephone of the intervention group patients. Patients will be informed on how to use the mobile application. Data will be collected face-to-face before chemotherapy begins and by telephone one week after every four chemotherapy. Demographic/Clinical Information Form, Eastern Cooperative Oncology Group Performance Scale, Multidimensional scale of perceived social support, Memorial Symptom Rating Scale, European Organization for Research and Treatment of Cancer- Quality of Life, QLQ-BR23, Beck Anxiety Scale and Mobile Application evaluation form will be used to collect data.
88830688|NCT05739175|No Intervention|Control group receiving standard care and no intervention|No Intervention: Control Group The patients received routine care and training in the polyclinic, and no additional intervention was applied. Data will be collected face-to-face before chemotherapy begins and by telephone one week after every four chemotherapy.Demographic/Clinical Information Form, Eastern Cooperative Oncology Group Performance Scale, Multidimensional scale of perceived social support, Memorial Symptom Rating Scale, European Organization for Research and Treatment of Cancer- Quality of Life, QLQ-BR23,Beck Anxiety will be used to collect data.
88830689|NCT05739097||non-anemic women|Pregnant women consecutively observed at Ob/Gyn Dept
88830690|NCT05739097||anemic women|Pregnant women at Ob/Gyn Dept
88830691|NCT05739097||bleeders|Pregnant women at Ob/Gyn Dept
88830692|NCT01923805|Experimental|Treatment Group|Vitagel
88830693|NCT01923805|No Intervention|Control|Standard of care for surgical hemostasis.
88830694|NCT01923961|Experimental|HDF NaCl, Then HD, Then Standard Pre-HDF|Participants first receive hemodiafiltration with infusion of 5 M NaCl for 4 hours. After a washout period of 1 week, they then receive 4 hours of bicarbonate hemodialysis. After another washout period of 1 week, they reveive 4 hours of standard predilution hemodiafiltration.
88830695|NCT01923961|Experimental|HD, Then Standard Pre-HDF, Then HDF NaCl|Participants first receive bicarbonate hemodialysis for 4 hours. After a washout period of 1 week, they then receive 4 hours of standard predilution hemodiafiltration. After another washout period of 1 week, they reveive 4 hours of hemodiafiltration with infusion of 5 M NaCl.
88830696|NCT01923961|Experimental|Standard Pre-HDF, Then HDF NaCl, Then HD|Participants first receive standard predilution hemodiafiltration for 4 hours. After a washout period of 1 week, they then receive hemodiafiltration with infusion of 5 M NaCl 4 hours of. After another washout period of 1 week, they reveive 4 hours of bicarbonate hemodialysis.
89359025|NCT01338558|Experimental|K-RAS mutated|
89359026|NCT01338558|Experimental|K-RAS native A|
88830697|NCT04116281|Experimental|Supervised group|Supervised group
88830698|NCT04116281|Other|No supervised group|Control group
88830699|NCT04750733||Multiple Sclerosis|Ambulatory MS patients
88830700|NCT01924975|Active Comparator|Landmark group|An operator is not allowed to use an ultrasound. A 22 or 24 G catheter will be advanced blindly toward the expected location of the saphenous vein at the level of the medial malleolus. Once blood appears in the hub, then the catheter will be advanced into the saphenous vein.
89359027|NCT01338558|Active Comparator|K-RAS native B|
89177913|NCT00624832|Placebo Comparator|Placebo|By subcutaneous injection of a solution with a concentration of 125 mg/mL placebo in a supine position: Patients in Xolair (Immunoglobulin E (IgE) = 30-300 IU/mL) group received doses of 150 mg to 375 mg of placebo every 2 or 4 weeks for 12 or 14 weeks. Patients in Xolair (Immunoglobulin E (IgE) = 700- 2000 IU/mL) group received doses of 450 mg, 525 mg, or 600 mg of placebo every 2 weeks for 14 weeks. Patients in Xolair (Immunoglobulin E (IgE) = 301- 699 IU/mL) group received doses of 225 mg to 375 mg of placebo every 2 weeks for 6 weeks.
89534336|NCT02944253|Experimental|Low energy diet 130 gram carbohydrates|isocaloric 4128 kilojoules/day (1000 kilocalories/day) for men and women, low energy diet containing 130 gram carbohydrates for 8 weeks.
89534337|NCT02926365|Experimental|ICBT|Therapist-supported internet-delivered CBT
88830701|NCT01924975|Active Comparator|Ultrasound group|An operator will identify the saphenous vein by using ultrasound with a linear transducer (L15-7io) in short axis view. A 22 or 24 G catheter will be advanced until the tip of the needle is seen on the ultrasound image. The needle is then advanced until blood appears in the hub. The catheter is then advanced into the saphenous vein.
88830702|NCT00371501|Active Comparator|treatment arm 1|
88830703|NCT00371501|Placebo Comparator|Treatment arm 2|
88830704|NCT00371501|Active Comparator|treatment arm 3|aspirin
88830705|NCT00371501|Placebo Comparator|treatment arm 4|placebo
88830706|NCT03251651|Experimental|PPF|Patient who received propofol during the operation
88830707|NCT03251651|Experimental|DEX|Patient who received dexmedetomidine during the operation
88830708|NCT01925677|Experimental|da Vinci® Single-Site™|Robotic-assisted single-incision laparoscopic nephrectomy.
88830709|NCT05349461|Active Comparator|Complete contact|
88830710|NCT05349461|Active Comparator|Incomplete contact|
88830711|NCT05738863|Experimental|Low Frequency rTMS Protocol|It was planned to apply 1 Hz low-frequency inhibition protocol to the primary motor cortex 5 days a week for 3 weeks, for a total of 15 sessions.
88830712|NCT05738863|Placebo Comparator|Sham rTMS Protocol|It was planned to apply the recorded beat sound to the primary motor cortex area daily 5 days a week for 3 weeks, for a total of 15 sessions by turning the TMS coil with the reverse side and in a 90-angle upright position.
88830713|NCT04023461|No Intervention|Clinical Treatment Group|
88830714|NCT04023461|Experimental|Interventional Ablation Group|
88830715|NCT02287675|Active Comparator|Lymphoseek|Lymphoseek (technetium Tc 99m tilmanocept) Injection is indicated for lymphatic mapping with a hand-held gamma counter to assist in the localization of lymph nodes draining a primary tumor site in patients with breast cancer or melanoma and guiding sentinel lymph node biopsy using a hand-held gamma counter in patients with clinically node negative squamous cell carcinoma of the oral cavity.
88830716|NCT02287675|Active Comparator|Sulfur Colloid|"Technetium Tc 99m Sulfur Colloid Injection is a radioactive diagnostic agent indicated for use as follows:~In adults, to assist in the:~localization of lymph nodes draining a primary tumor in patients with~breast cancer or malignant melanoma when used with a hand-held gamma counter.~evaluation of peritoneovenous (LeVeen) shunt patency in adults."
88830717|NCT02973893|Placebo Comparator|Placebo plus Standard Care|Placebo plus Standard Care
88830718|NCT02973893|Experimental|VF001-DP LD plus Standard Care|VF001-DP (14 micrograms per treatment) and Standard Care (low dose [LD])
88830719|NCT02973893|Experimental|VF001-DP HD plus Standard Care|VF001-DP (140 micrograms per treatment) and Standard Care (high dose [HD])
88830720|NCT05738707||Recombinant protein vaccine|
88830721|NCT05738707||Adenovirus vector vaccine|
88830722|NCT05738629|Experimental|PSC-MSC-Exo Eye Drops Treatment|Participants will receive artificial tears for 2 weeks to get the normalized baseline, followed by PSC-MSC-Exo eye drop intervention for 12 weeks.
88830723|NCT05349149|Experimental|Tocilizumab|Participants will receive one 30 min intravenous infusion of tocilizumab/Actemra® (Roche). The dose will be 8 mg/kg bodyweight or a maximum of 800mg. Tocilizumab is dissolved in 100 mL 0.9% saline.
88830724|NCT05349149|Placebo Comparator|Saline|As placebo, participants will receive one 30 min intravenous infusion of 100 mL 0.9% saline.
88830725|NCT04337645|Experimental|Test group|resective surgical treatment of peri-implantitis (decontamination performed with titanium brushes and sterile saline) combined with implantoplasty
88830726|NCT04337645|Active Comparator|Control group|resective surgical treatment of peri-implantitis (decontamination performed with titanium brushes and sterile saline)
88830727|NCT01928797|No Intervention|Control group|The care provider will use blood pressure and heart rate data to administer vasopressor use. In the control group, vasopressors (phenylephrine and ephedrine) will be used as considered appropriate to maintain BP within 20% of baseline. The CO data is measured and blinded to the anesthesiologists in the control group, therefore the anesthesiologist choice of ephedrine or phenylephrine is based on the individual anesthesiologist standard of care preference
88830728|NCT01928797|Experimental|Study group|The care provider will use the cardiac output monitor data (intervention) to guide vasopressors (Phenylephrine and ephedrine) in addition to blood pressure and heart rate data based on a standardized protocol in addition to the blood pressure and heart rate data available in the control group.
88830729|NCT03702413|No Intervention|Best medical treatment|Best medical treatment
88830730|NCT03702413|Experimental|Endovascular treatment|Best medical treatment plus endovascular treatment
88830731|NCT04338035||Patients with rectosigmoid endometriosis|
88830732|NCT05349071|Experimental|methylprednisolone group|a single preoperative dose of 500 mg of methylprednisolone diluted in 250 mL of physiological saline 2 hours before surgery as a 30-minute infusion.
89177914|NCT04029662|Experimental|Group Valsalva Maneuver|Patients who undergo spinal anesthesia and perform Valsalva maneuver to reduce the pain intensity
89177915|NCT04029662|No Intervention|Group Control|Patients who undergo spinal anesthesia and perform nothing to reduce the pain intensity
89177916|NCT00826774|Active Comparator|Ususal Care|
89177917|NCT00826774|Experimental|Breif Lifestyle Counseling|
88830733|NCT05349071|Active Comparator|physiological saline group|a single preoperative dose of 250 mL of physiological saline 2 hours before surgery as a 30-minute infusion.
88830734|NCT01929889|Experimental|Iloperidone|Patients currently taking an antipsychotic medication other than Fanapt® will switch from their current medicine to Fanapt® in a cross-titration at a rate that is determined by the study physician. Treatment with iloperidone will be initiated and dosage will increase until the subject has achieved clinical stability, or has achieved the maximum dose, or 8 weeks have elapsed. Subjects who do not achieve clinical stability (as defined in the inclusion criteria) for the final 2 weeks in this 8-week period at the maximum dose of iloperidone will be discontinued from the study. If patients achieve stabilization, the lowest effective dose will be maintained. Subjects who have achieved clinical stability will then enter the 12-week treatment phase of the study.
88830735|NCT05738473||pregnant women colonized by Group B Streptococcus (GBS) and undergoing IAP|vaginal microbiome of pregnant women colonized by Group B Streptococcus (GBS)、Pregnant women undergoing IAP
88830736|NCT05738473||pregnant women does not colonized by Group B Streptococcus (GBS) and not undergoing IAP|Group B streptococcus (GBS) does not colonize the vaginal microbiome of pregnant women、Pregnant wome
88830737|NCT03452033|Placebo Comparator|H-1337 Placebo|H-1337 Placebo
89177918|NCT00826774|Experimental|Enhanced Brief Lifestyle Counseling|
89177919|NCT02550730|Experimental|Birth Sisters|Half of the women who agree to participate in the evaluation will be randomized to the Birth Sisters Best beginnings for Babies Program, which includes community doula support and consultation with Medical Legal Partnership when indicated.
89177920|NCT02550730|Active Comparator|Routine care|Half of the women who agree to participate in the evaluation will be randomized to the usual maternity care group
89177921|NCT00826930|Experimental|1A|0.5 mg/kg TSC, anticonvulsants at Baseline - phenytoin only or none
89177922|NCT00826930|Experimental|2A|0.75 mg/kg TSC, anticonvulsants at Baseline - phenytoin only or none
88830738|NCT03452033|Experimental|H-1337 [1]|H-1337 [1]
88830739|NCT03452033|Experimental|H-1337 [2]|H-1337 [2]
88830740|NCT03452033|Experimental|H-1337 [3]|H-1337 [3]
89177923|NCT00826930|Experimental|3A|1.0 mg/kg TSC, anticonvulsants at Baseline - phenytoin only or none
89177924|NCT00826930|Experimental|4A|Dose of TSC either 0.5 mg/kg, 0.75 mg/kg, or 1.0 mg/kg based on the Data Monitoring Committee decision, anticonvulsants at Baseline - phenytoin only or none
88830743|NCT05718271|Experimental|Explicit instructions before + after extinction|
88830744|NCT05718271|Experimental|Explicit instructions before extinction|
88830745|NCT05718271|Experimental|Explicit instructions after extinction|
88830746|NCT05718271|No Intervention|No explicit instructions|
88830747|NCT05738317|Experimental|Adebrelimab Combined With Bevacizumab and Albumin Paclitaxel|"Adebrelimab: 20 mg/kg Adebrelimab is given on day 1 of each cycle, with 1 dosing cycle every 3 weeks. The dosing time window may be ±5 days, but within 72 hours before each dose, subjects must complete an examination including all clinically necessary tests to assess tolerability of continued dosing, in addition to imaging. Subjects are also advised to remain in the hospital for observation 72 hours after the first dose.~Bevacizumab: 7.5 mg/kg Bevacizumab administered intravenously on day 1 of each cycle, with 1 dosing cycle every 3 weeks.~Albumin Paclitaxel: 100 mg/m2 Albumin Paclitaxel is given on days 1, 8, and 15 of each cycle by intravenous infusion for 1 dosing cycle every 3 weeks."
88830748|NCT02284555|Experimental|Mupirocin 2% nasal Ointment|Mupirocin (Bactroban 2% nasal ointment) will be administered twice daily for 5 days in accordance with the Summary of Product Characteristics (SmPC).
88830749|NCT02987179||ESRD Patients|"The following inclusion criteria must be met for each subject.~Age ≥18 years and able to give written informed consent to the study~On chronic hemodialysis for ≥ 90 days at time of enrollment~Ability to read~Consent to have video recording taken during study visit"
88830750|NCT02753699|Experimental|From Study 2210|All participants enrolled from CDEB025A2210 (n=164) who had been treated with alisporivir during the feeder study. There was no investigational treatment given to participants while enrolled in this follow-up study.
88830751|NCT02753699|Experimental|From Study 2301|All participants enrolled from CDEB025A2301 (n=397) who had been treated with alisporivir during the feeder study. There was no investigational treatment given to participants while enrolled in this follow-up study.
88830752|NCT02753699|Experimental|From Study 2211|All participants enrolled from CDEB025A2211 (n=162) who had been treated with alisporivir during the feeder study. There was no investigational treatment given to participants while enrolled in this follow-up study.
88830753|NCT04335617|Experimental|Investigational|Patients receive MMPF 500mg for one year
88830754|NCT04335617|Placebo Comparator|Placebo|Patients receive Placebo for one year
88830755|NCT05717413||Patients after arthroplasty of the 1st metatarsophalangeal joint|
88830756|NCT05717413||Patients after arthrodesis of the 1st metatarsophalangeal joint|
88830757|NCT02973971||Healthy subjects|
88830758|NCT02973971||Alzheimer patients|
89177925|NCT00826930|Experimental|1B|0.5 mg/kg TSC, anticonvulsants at Baseline - any except phenytoin-only or none
89177926|NCT00826930|Experimental|2B|0.75 mg/kg TSC, anticonvulsants at Baseline - any except phenytoin-only or none
89177927|NCT00826930|Experimental|3B|1.0 mg/kg TSC, anticonvulsants at Baseline - any except phenytoin-only or none
89177928|NCT00826930|Experimental|4B|Dose of TSC either 0.5 mg/kg, 0.75 mg/kg, or 1.0 mg/kg based on the Data Monitoring Committee decision, anticonvulsants at Baseline - any except phenytoin-only or none
89177929|NCT00913796|Experimental|Postassium citrate|Aim: correction of metabolic acidosis
89177930|NCT00913796|Active Comparator|Potassium chloride|Potassium chloride is given to compensate for any possible effects of potassium in potassium citrate (primary treatment).
89177931|NCT00822406|Active Comparator|1|This arm received individualized homeopathic medicine during 6 months (initial phase), and completed three years (second phase)
89177932|NCT00822406|Placebo Comparator|2|This arm received placebo during 6 months. After this period, all patients received individualized homeopathic medicine for three years.
89177933|NCT02550574|Experimental|Wound closure with 2-octylcyanoacrylate|One side of the patient's wound defect will be assigned to wound closure with 2-octylcyanoacrylate liquid bonding agent).
88830759|NCT05736601||UKA MAKO|Prospective group- Patient Reported Outcomes (PROs) will be assessed using the FocusMotion app survey
88830760|NCT05736601||TKA MAKO|Control group-Already collected data on patient reported out comes using the FocusMotion app survey
88830761|NCT03133247|Experimental|SHR-1316 dose-escalation|SHR-1316 doses will be escalated sequentially in 5 cohorts.
88830762|NCT03029689|Experimental|Current ART + Raltegravir|Current ART + Raltegravir
88830763|NCT03029689|Placebo Comparator|Current ART + placebo|Current ART + placebo
88830764|NCT03085277|Active Comparator|Preterm Formula|MM is always the first priority, when available. When MM is not available, or the available amounts do not fulfill the needs, infants in this group will receive preterm formula, as the supplementary diets following the standard feeding guidelines in the participating hospitals.
88830765|NCT03085277|Experimental|Bovine Colostrum|MM is always the first priority, when available. When MM is not available, or the available amounts do not fulfill the needs, infants in this group will receive Bovine Colostrum (BC), as the supplementary diets. BC feeding follows the same guideline as the control group in terms of initiation time (within 24-48h of age) and volume (5-10 ml/kg) and advancing rate (5-20 ml/kg/d). BC intervention should not exceed postnatal day 14.
88830766|NCT02287909|Experimental|A) clopidogrel 600 mg LD 24 hours after last MD of ticagrelor|Patients will be randomized (1:1:1:1) into one of the four following groups: A) clopidogrel 600 mg LD 24 hours after last MD of ticagrelor, followed by 75mg daily MD; B) clopidogrel 600 mg LD 12 hours after last MD of ticagrelor, followed by 75mg daily MD; C) clopidogrel 75mg daily MD 24 hours after last MD of ticagrelor; D) continue ticagrelor MD 90mg twice daily
89359028|NCT05390866|Experimental|HIIT group|The HIIT session will be conducted on a bicycle ergometer and consist of a 3-minute warm-up, followed by 4x4-minute intervals performed at 85-95% of the individually determined maximum heart rate, interspersed with 3-minute active recovery phases at a light effort). The HIIT session will be followed by a 2-minute cool-down phase.
89359029|NCT05390866|No Intervention|Control group|The control group will follow the same procedure except for the HIIT session, which will be replaced by a 30-minute physical rest in a sitting position. The participants will be allowed to read a book or work on their computer/phone.
89359030|NCT03780569|Experimental|NovoTTF-200A/Radiotherapy/Temozolomide|Patients will receive multiple 1 month courses of continuous NovoTTF-200A treatment together with standard Radiotherapy/Temozolomide followed by maintenance Temozolomide.
89359031|NCT03316846|Experimental|Internet-delivered therapy|10 week, guided and individually tailored internet-delivered cognitive behavioral therapy.
89359032|NCT03316846|No Intervention|Wait list control group|Wait list control group, receives treatment at later point.
89359033|NCT05512559||remimazolam|general anesthesia induction with 6mg/kg/hr continuous infusion of remimazolam. general anesthesia maintenance with 1mg/kg/hr continuous infusion of remimazolam.
89359034|NCT01333020|Experimental|transglutaminase cross-linking of emulsion|The impact of enzyme cross linking of the protein stabilising the test emulsion on gastric emptying rate will be assessed. In this crossover study the subjects will also consume ( on a separate day)an emulsion of the same formulation but not cross-linked.
89359035|NCT03780413|Active Comparator|PR-ESSENCE treatment|The treatment group receives PR-ESSENCE for 10 weeks. Outcome measures are collected pre- and post-treatment, and after 6 months and one year.
89359036|NCT03780413|Active Comparator|Control (TAU)|"The control group receives 10 weeks of treatment as usual (TAU) (that is the standard psychoeducation, support and treatment given to all youth after neuropsychiatric assessment at our clinic), followed by 10 weeks of PR-ESSENCE. Outcome measures were collected pre- and post-treatment, and after 6 months and one year."
89359037|NCT01338714|Experimental|A foumula|Compound Herbal Formula (RHD-1)
89359038|NCT01338714|Placebo Comparator|B formula|dilute Compound Herbal Formula
89359039|NCT03487549|Experimental|VP-102|Open label of VP-102 cantharidin topical film forming solution, using the VP-102 applicator.
89359040|NCT02486068|Experimental|ABSORB scaffold|Patient will undergoes elective or emergent percutaneous coronary intervention and will be treated with ABSORB scaffold.
89359041|NCT02486068|Active Comparator|Xience|Patient will undergoes elective or emergent percutaneous coronary intervention and will be treated with Xience Prime.
89359042|NCT01313585||IPDA salbutamol MDI|receive a recorded increase in ICS therapy as BDP Easibreathe at the index date and also receive salbutamol MDI
89359043|NCT01313585||IPDA salbutamol EB|receive a recorded increase in ICS therapy as BDP Easibreathe at the index date and also receive salbutamol Easibreathe
89359044|NCT01313585||IPDI salbutamol EB|initiate ICS therapy as BDP Easibreathe at the index date and also receive salbutamol Easibreathe
89359045|NCT01313585||IPDI salbutamol MDI|initiate ICS therapy as BDP Easibreathe at the index date and also receive salbutamol MDI
89359046|NCT01572714|Active Comparator|Social Support Program|The social support program will consist of 6 weekly, 1.25-hours, teleconference calls with 4 biweekly, 15 minute, follow-up one-to-one phone calls. Topics will include information on MS, disease modifying medications, preventive screening, community organizations, nutrition, cognitive problems, and hiring an aide.
89359047|NCT01572714|Active Comparator|Physical Activity Program|The physical activity education program will consist of 3 weekly, 1.25-hours, teleconference calls with 4 biweekly, 15 minute, follow-up one-to-one phone calls. Subjects in this program will learn MS-specific benefits of physical activity, how to use a pedometer to self-monitor their progress for increasing physical activity levels, and learn strategies for maintaining their progress in the program.
88830767|NCT02287909|Experimental|B) clopidogrel 600 mg LD 12 hours after last MD of ticagrelor|Patients will be randomized (1:1:1:1) into one of the four following groups: A) clopidogrel 600 mg LD 24 hours after last MD of ticagrelor, followed by 75mg daily MD; B) clopidogrel 600 mg LD 12 hours after last MD of ticagrelor, followed by 75mg daily MD; C) clopidogrel 75mg daily MD 24 hours after last MD of ticagrelor; D) continue ticagrelor MD 90mg twice daily
88830768|NCT02287909|Experimental|C) clopidogrel 75mg MD 24 hours after last MD of ticagrelor|Patients will be randomized (1:1:1:1) into one of the four following groups: A) clopidogrel 600 mg LD 24 hours after last MD of ticagrelor, followed by 75mg daily MD; B) clopidogrel 600 mg LD 12 hours after last MD of ticagrelor, followed by 75mg daily MD; C) clopidogrel 75mg daily MD 24 hours after last MD of ticagrelor; D) continue ticagrelor MD 90mg twice daily
88830769|NCT02287909|Active Comparator|D) continue ticagrelor MD 90mg twice daily|Patients will be randomized (1:1:1:1) into one of the four following groups: A) clopidogrel 600 mg LD 24 hours after last MD of ticagrelor, followed by 75mg daily MD; B) clopidogrel 600 mg LD 12 hours after last MD of ticagrelor, followed by 75mg daily MD; C) clopidogrel 75mg daily MD 24 hours after last MD of ticagrelor; D) continue ticagrelor MD 90mg twice daily
88830770|NCT02935907|Experimental|APG-115|APG-115 to be explored sequentially during accelerated dose escalation. This will continue until either the occurrence in Cycle 1 of one DLT or two Grade 2 toxicities (graded as per the National Cancer Institute's Common Terminology Criteria for Adverse Events [NCI CTCAE] version 4.0) that are related or possibly related to APG-115. When either of these criteria is fulfilled, dose escalation will be converted to a standard 3+3 escalation scheme,
89359048|NCT01572714|Active Comparator|Physical Activity Plus Fatigue|The physical activity plus fatigue management education program will consist of 6 weekly, 1.25-hours, teleconference calls with 4 biweekly, 15 minute, follow-up one-to-one phone calls. Subjects in this program will learn MS-specific benefits of physical activity, how to use a pedometer to self-monitor their progress for increasing physical activity levels, and learn strategies for maintaining their progress in the program. In addition, subjects in this course will learn strategies to reduce fatigue, such as taking rest breaks and re-arranging workspace.
89359049|NCT03779945|Active Comparator|posteriolateral lumbar fusion +bone graft+ PRP|the addition of autologous platelet rich plasma to the bone graft
89359050|NCT03779945|Active Comparator|posteriolateral lumbar fusion+bone graft only|posteriolateral lumbar fusion with adding autologus bone graft alone posteriolateral lumbar fusion only
89359051|NCT01561235|Active Comparator|Normal Protein|"Energy content 3 or 4 MJ/meal, depending on the subject's individual daily energy requirements).~Macronutrient content: Protein: 14 E%, Fat: 30 E% and carbohydrate: 56E%. The fibre content was similar in all three test meals. The test meals were served as pork/rice/mushroom pâtés, flavoured with thyme in order to blind differences in taste."
88830771|NCT02284867||Preterm labor|Patients who has threatened preterm labor and will receive tocolysis and these patients will either not respond to tocolysis and delivered preterm or will respond to tocolysis and will deliver at term .
88830772|NCT02284867||Term labor|Patient delivered vaginally at term with no history of having tocolysis for preterm labor at the current pregnancy .
88830773|NCT02833805|Experimental|Bone marrow transplant|Non-myeloablative bone marrow transplant with a Thymoglobulin (ATG), fludarabine (Flu), cyclophosphamide (Cy), total body irradiation (TBI) preparative regimen and post-transplant Cy, mycophenolate mofetil (MMF), and tacrolimus as GVHD prophylaxis.
88830774|NCT02327195|Experimental|Methylphenidate|Quillivant XR - Methylphenidate HCL Extended Release oral suspension - (after reconstruction with water - 5mg/mL) 20 mg (PO) given 2 hours prior to surgery
88830775|NCT02327195|Placebo Comparator|Placebo|20 mg Placebo (PO) given 2 hours prior to surgery
88830776|NCT04768465||Combined Immunotherapy|"MG patients are treated with tacrolimus combined with low-dose prednisone (0.25mg/kg/d).~Symptomatic treatment like pyridostigmine bromide can be added to relieve symptoms (≤480mg/d)."
88830777|NCT04768465||Tacrolimus monotherapy|MG patients are treated with tacrolimus as initial immune monotherapy. Symptomatic treatment like pyridostigmine bromide can be added to relieve symptoms (≤480mg/d).
88830778|NCT02756351|Experimental|CytaCoat Nasal Prong|The CytaCoat Nasal Prong is composed of the reference device coated with CytaCoat technology.
88830779|NCT02756351|Active Comparator|Reference Nasal Prong|Inspiration Healthcare Inspire nCPAP Nasal Prong consists of silicone. Is a Conformité Européenne marked (CE-marked) commercially available medical device.
88830780|NCT01744223|Experimental|SCT, BPX-501 dose 1, Rimiducid if needed|"2x10E5 BPX-501 (rivogenlecleucel) cells per kg infused after TCR alpha beta depleted donor stem cell transplant.~Rimiducid: Dimerizer drug administered by intravenous infusion in those subjects with acute GVHD with no response to steroids and/or other aGVHD medications or worsening in stage or grade of aGVHD after 48 hours. Subjects with chronic GvHD who do not respond to steroids/systemic therapies within 7 days, or there is a worsening in cGVHD, patients may then receive rimiducid."
88830781|NCT01744223|Experimental|SCT, BPX-501 dose 2, Rimiducid if needed|"5x10E5 BPX-501 (rivogenlecleucel) cells per kg infused after TCR alpha beta depleted donor stem cell transplant.~Rimiducid: Dimerizer drug administered by intravenous infusion in those subjects with acute GVHD with no response to steroids and/or other aGVHD medications or worsening in stage or grade of aGVHD after 48 hours. Subjects with chronic GvHD who do not respond to steroids/systemic therapies within 7 days, or there is a worsening in cGVHD, patients may then receive rimiducid."
88830782|NCT01744223|Experimental|SCT, BPX-501 dose 3, Rimiducid if needed|"1x10E6 BPX-501 (rivogenlecleucel) cells per kg infused after TCR alpha beta depleted donor stem cell transplant.~Rimiducid: Dimerizer drug administered by intravenous infusion in those subjects with acute GVHD with no response to steroids and/or other aGVHD medications or worsening in stage or grade of aGVHD after 48 hours. Subjects with chronic GvHD who do not respond to steroids/systemic therapies within 7 days, or there is a worsening in cGVHD, patients may then receive rimiducid."
88830783|NCT01744223|Experimental|SCT, BPX-501 dose 4, Rimiducid if needed|"3x10E6 BPX-501 (rivogenlecleucel) cells per kg infused after TCR alpha beta depleted donor stem cell transplant .~Rimiducid: Dimerizer drug administered by intravenous infusion in those subjects with acute GVHD with no response to steroids and/or other aGVHD medications or worsening in stage or grade of aGVHD after 48 hours. Subjects with chronic GvHD who do not respond to steroids/systemic therapies within 7 days, or there is a worsening in cGVHD, patients may then receive rimiducid."
88830784|NCT01614665|Active Comparator|Tacrolimus|Participants receive tacrolimus twice daily starting from day 1 for 4 weeks for in Part A, and continue to receive tacrolimus twice daily up to end of Part B and C of the study.
88830785|NCT01614665|Experimental|Tacrolimus Prolonged Release|Participants receive tacrolimus prolonged release once daily starting from day 1 for 4 weeks for in Part A, and continue to receive tacrolimus prolonged release once daily up to end of Part B and of the study.
88830786|NCT02285023||CU-Q2oL|"Evaluation by the Urticaria Activity Score (UAS7)~Fill the DLQI and CU-Q2oL questionnaire"
88830787|NCT05348135|Active Comparator|Functional strength training|
88830788|NCT05348135|Active Comparator|Cognitive training|
88830789|NCT05348135|Active Comparator|Combined treatment|
89177934|NCT02550574|Active Comparator|Wound closure with 5-0 vicryl sutures|One side of the patient's wound defect will be assigned to wound closure with 5-0 vicryl sutures.
88830790|NCT05348135|Placebo Comparator|Conventional physical therapy|
88830791|NCT02330341|Experimental|Artemisia Dracunculus|Artemisia Dracunculus extract, 2 capsules of 500 mg, two times per day before breakfast and dinner during 90 days
88830792|NCT02330341|Placebo Comparator|Placebo|Calcined magnesia, 2 capsules of 500 mg, two times per day before breakfast and dinner during 90 days
88830793|NCT02740517||HUT1|First phase of the home user trial. 19 users, 12 who were part of a couple and 7 who were single.
88830794|NCT02740517||HUT2|"Second phase of home user trial, testing improvements to the device user interface as a result of the experience from HUT1. Total 11 users.~Main change to device was a simpler set of displays and button-sequence on a 24 hour period."
88830795|NCT02740517||HUT3|"Third phase of home user trial, testing the final improvements to the device. A total of 18 users, 16 of which who were part of a couple and 2 who were single.~Main change was the introduction of a scheduled recording option, making the device totally automatic in routine use."
89177935|NCT02550340||Acute alcohol intake|Visitors of the Munich Octoberfest or similar events who fulfil in- and exclusion criteria
88830796|NCT04337801|Experimental|Acupressure|The acupressure was carried out as two sessions, postpartum second (the first session of intervention) and fourth hours (the second session of intervention). The intervention was applied bilaterally and clockwise (left Pericardium 6, left Large Intestine 4, right Large Intestine 4 and right Pericardium 6) in this study. The acupressure was applied for three minutes in average, one minute for massage and two minutes for pressure per point; with an average of 12 minutes for the whole application. In addition, the pain score of the women was assessed by themselves through the VAS before the intervention (Time 1) and 15 minutes (Time 2) after the intervention at postpartum second hour. Also, it was assessed before the intervention (Time 3) and 15 minutes (Time 4) after the intervention at postpartum forth hour. Additionally, the analgesic substance and its amount applied during the application were recorded by the first researcher.
88830797|NCT04337801|Placebo Comparator|Placebo|The Pericardium 6 and Large Intestine 4 points were slightly touched without pressure to women in the placebo group. Touches were applied to each acupressure point for three minutes similar to the acupressure group, each session of placebo lasted approximately 15 minutes. Similar to the acupressure group, In parallel with the acupressure, the pain score of the women was recorded at the postpartum second hour (Time 1) before intervention and 15 minutes later after intervention (Time 2), and at the fourth hour (Time 3) before intervention and 15 minutes later after intervention (Time 4). Additionally, the analgesic substance and its amount applied during the application were recorded by the researcher.
88830798|NCT04337801|No Intervention|Control Group|No intervention was applied to the control group except for the routine nursing care. The data collection process in the control group was conducted in parallel with the acupressure and placebo groups. Pain score of women was recorded prior to intervention in the acupressure and placebo groups. The duration of intervention in the acupressure and placebo groups was 12 minutes and the measurements were repeated 15 minutes after the intervention. The average duration between the first and the second measurements is 30 minutes in the acupressure and placebo groups. In parallel with the acupressure and placebo groups, the current pain score of the women was recorded at the postpartum second hour (Time 1) and 30 minutes later (Time 2), and at the fourth hour (Time 3) and 30 minutes later (Time 4). Additionally, the analgesic substance and its amount applied during the application were recorded by the first researcher.
88830799|NCT02958839||Recurrence Group|In the case control trial, patients who have any episode of atrial fibrillation/atrial flutter/atrial tachycardia after a blanking period of 3 months from the catheter ablation procedure will be assign to the recurrence group
88830800|NCT02958839||Non-recurrence Group|In the case control trial, patients who do not have any episode of atrial fibrillation/atrial flutter/atrial tachycardia after a blanking period of 3 months from the catheter ablation procedure will be assign to the recurrence group
88830801|NCT05348057|Experimental|Ivabradine group|The starting dose is 5 mg twice a day. After 2 weeks of treatment, if the patient's resting heart rate continues to be higher than 70 beats per minute, increase the dose to 7.5 mg twice a day. If the patient's resting heart rate continues to be less than 50 beats per minute or symptoms related to bradycardia occur, reduce the dose to 2.5 mg
88830802|NCT05348057|No Intervention|The control group|
88830803|NCT05735977|Other|Indocyanine Green|Cohort study using one arm, no comparator group is possible or feasible
88830804|NCT00371735|Experimental|Arm 1|
88830805|NCT03833245|No Intervention|Control|The standard care condition includes brief case management and referral. The brief case management involves the participant speaking to a hospital social worker who conducts a patient needs assessment in the areas of behavioral health and social services. All patients will be referred to MAT and any identified behavioral health or social service needs.
88830806|NCT03833245|Experimental|Patient Navigation|The prenatal portion of the intervention includes 10 sessions delivered within approximately 14 weeks. The postnatal portion of the intervention will be delivered as 4 sessions over 8 weeks. Women who complete the intervention before delivery will receive regular calls/texts until delivery wherein the navigator will encourage and reinforce abstinence and treatment retention.
88830807|NCT04337411||Cohort 1|Non-ambulatory acute stroke survivors at admission (Functional Ambulation Categories (FAC) ≤ 2)
88830808|NCT04337411||Cohort 2|Ambulatory acute stroke survivors at admission (Functional Ambulation Categories (FAC) ≥ 3)
89177936|NCT05123768||Patients with cerebral palsy|In Slovenia, all children with cerebral palsy born in 1996 or later are included in the Slovenian National Registry of Cerebral Palsy. All patients from the Registry will be invited to participate in the study.
89177937|NCT00819442|Placebo Comparator|1|patients without heart failure, with cardiobiopsy
89177938|NCT00819442|Experimental|2|patients with heart failure in NYHA class I, II
89177939|NCT00819442|Experimental|3|Patients with heart failure in NYHA class III, IV
89177940|NCT00822484|Active Comparator|ILV-095|6 SC single dose injections
89177941|NCT00822484|Placebo Comparator|Placebo|Placebo
89177942|NCT00633880|Experimental|Droxidopa|Double-blind
89177943|NCT00633880|Placebo Comparator|Placebo|Double-blind
89359052|NCT01561235|Experimental|Medium-high protein|"Energy content 3 or 4 MJ/meal, depending on the subject's individual daily energy requirements).~Macronutrient content: Protein: 25E%, Fat: 30 E% and carbohydrate: 45E%. The fibre content was similar in all three test meals. The test meals were served as pork/rice/mushroom pâtés, flavoured with thyme in order to blind differences in taste."
89359053|NCT01561235|Experimental|High Protein|"Energy content 3 or 4 MJ/meal, depending on the subject's individual daily energy requirements).~Macronutrient content: Protein: 50 E%, Fat: 30 E% and carbohydrate: 20E%. The fibre content was similar in all three test meals. The test meals were served as pork/rice/mushroom pâtés, flavoured with thyme in order to blind differences in taste."
89359054|NCT02485990|Experimental|Arm A: Tremelimumab Alone|25 patients will receive tremelimumab alone at 10 mg/kg IV every 4 weeks for 7 doses then every 12 weeks until disease progression.
89359055|NCT02485990|Experimental|Arm B1: DESE Tremelimumab and Olaparib|18 patients will receive tremelimumab (3 or 10 mg/kg IV) every 4 weeks for 7 doses then every 12 weeks and olaparib (150 or 300 mg orally twice a day) until disease progression.
89359056|NCT02485990|Experimental|Arm B2: Tremelimumab and Olaparib|25 patients will receive tremelimumab (every 4 weeks for 7 doses then every 12 weeks) and olaparib (daily) until disease progression. Dose of tremelimumab and olaparib will be determined during the DESE (Arm B1).
88830809|NCT04337333|Other|Two-in-one stent|Endoscopic placement of a Two-in-one stent into the extrahepatic bile duct, considering the longitudinal location of the stricture segment and predicted safety margin
88830810|NCT04337567|Active Comparator|Patients over 75 years_RF ablation|Patients randomized to receive pulmonary vein isolation by means of radiofrequency ablation.
89359057|NCT01313819|Active Comparator|Group 1|Give IV amantadine first then IV placebo(normal saline) drug
88830811|NCT04337567|Active Comparator|Patients over 75 years_ballon cryoablation|Patients randomized to receive pulmonary vein isolation by means of ballon cryoablation.
88830812|NCT03029377|Experimental|Chronic Fatigue Patients|Patients between 18-60 years of age with fatigue symptoms who meet preliminary chronic fatigue phenotype criteria and complete preliminary screening surveys. Participants will undergo a Posture Study, Autonomic Function Tests, and a Stress Test. Participants' blood will be drawn to measure markers of sympathetic nervous system function.
89359058|NCT01313819|Active Comparator|Group 2|Give IV placebo drug first then IV amantadine
89359059|NCT03315442|Sham Comparator|Caffeine Group|Caffeine group consumed 200mg of caffeine one time.
89359060|NCT03315442|Experimental|Energy Drink Group|The energy drink group consumed 1 16 ounces energy drink one time.
89359061|NCT03464383|Experimental|Epileptologist-Driven Treatment|The intervention will consist of initiating a chronic care management plan in the epilepsy clinic and an initial prescription from the epileptologist for escitalopram 10mg daily. Escitalopram dose adjustment will be made based on biweekly repeated screening of anxiety and depression symptoms, as well as side effects identified on biweekly telephone calls or the 6-week advanced practice provider (APP) follow up visit. Escitalopram dose may be titrated up to a maximum of 20mg daily in 5-10mg increments every 2 weeks for treatment effect, or titrated down to 5mg if needed for adverse effects. If a participant is unable to tolerate escitalopram, then venlafaxine XR 37.5mg will be substituted, to be titrated in a similar manner biweekly based on side effects and anxiety and depression symptoms (with 37.5-75mg increment dose changes and maximum dose of 225mg daily).
89359062|NCT03464383|Active Comparator|Standard of Care|A psychiatry referral order placed by epileptologist under typical care circumstances (internal or external referral based on the participant's geographic preferences). Internal referrals will be processed by current clinic/institutional protocols. External referral orders will be printed and provided to the patient along with brief instructions on how to find a provider covered by the patient's insurance.
89359063|NCT03464383|Other|Survey Arm|This option will be offered to individuals who are found to have anxiety or depression symptoms on screening but who are found to be ineligible for intervention arms of the study, or those who are eligible for the intervention arm but decline to participate in the intervention.
89359064|NCT03780335||MVO group|CMR was performed in all the cases. According to the results of CMR, we divided the study population into MVO group and Non-MVO group.
89359065|NCT03780335||Non-MVO group|CMR was performed in all the cases. According to the results of CMR, we divided the study population into MVO group and Non-MVO group.
89359066|NCT03779633|Experimental|Linoladiol Estradiol|Linoladiol Estradiol cream 6 weeks before surgery of pelvic organ prolapse
88830813|NCT03029377|Active Comparator|Healthy Controls|Patients between 18-60 years of age with no known conditions or prescription medications who meet preliminary screening criteria. Participants will undergo a Posture Study, Autonomic Function Tests, and a Stress Test. Participants' blood will be drawn to measure markers of sympathetic nervous system function.
88830814|NCT00372125|Active Comparator|Norditropin SimpleXx|0.3 mg/day or 0.4 mg/day if bodyweight was below or above 100 kg,for 4 weeks, 0.6 mg/day or 0.8 mg/day, for 11 months.
88830815|NCT00372125|Placebo Comparator|Placebo|Placebo for 12 months
89359067|NCT03779633|Placebo Comparator|Placebo|Placebo cream 6 weeks before surgery of pelvic organ prolapse
89359068|NCT03720067|Active Comparator|Phase 1: Propranolol (PPL)|Hepatic venous pressure gradient (HVPG) will be measured before and after 120 minutes of a loading dose of Propranolol (PPL) 80 mg PO. Thereafter, patients will receive maintenance therapy with Propranolol (40 to 320 mg / day) adjusted according to blood pressure and heart rate. After 28 days of reaching the maximum tolerated dose, a new HVPG measurement will be performed.
88830816|NCT05028439|Experimental|RAF combined with gemcitabine and S-1 group|Patients will receive endobiliary radiofrequency ablation ( RFA) followed by plastic stent(s) placement, and be treated with gemcitabine and S-1 within 1 month after RFA.
88830817|NCT05028439|Placebo Comparator|RFA-only gruop|Patients will only receive endobiliary radiofrequency ablation ( RFA) followed by plastic stent(s) placement
89000920|NCT04637152|Experimental|Group B: Sacubitril/Valsartan|Suspension of ACE inhibitors - for at least 36h of the last dose - or ARB. Initial dosage: Sacubitril/valsartan 49mg/51mg, 1 tablet twice daily. Target dose (after two weeks): 97mg/103 mg, 1 tablet twice daily.
89000921|NCT02963909|Experimental|ZPIV in Flavivirus-naïve Subjects|Two doses of 5.0mcg ZPIV or placebo on Days 1 and 29. N=20 ZPIV, N=5 placebo. Subjects who consent to a third ZPIV dose will receive a 5.0 mcg of ZPIV or placebo on Day 224
89359069|NCT03720067|Active Comparator|Phase 1: Carvedilol (CVD)|HVPG will be measured before and after 120 minutes of a loading dose of Carvedilol (CVD) 12.5 mg PO. Thereafter, patients will receive maintenance therapy with Carvedilol (6.25 - 25 mg / day) adjusted according to blood pressure. After 28 days of reaching the maximum tolerated dose, a new HVPG measurement will be performed.
88816768|NCT05410548|Experimental|Standard-of-Care + Clinical Screening|In addition to routine, standardized prosthetic follow-up care, patient participants will receive comorbidity screening for contralateral limb peripheral arterial disease, peripheral neuropathy, major depression, and greater than low risk for persistent low back pain. Participants will be educated on clinical screening findings, provided a copy of their screening results to share with their medical providers, and their results will be securely sent to their primary care provider.
89359070|NCT03720067|Active Comparator|Phase 2: PPL non-responders/rosuvastatin|Patients treated with PROPRANOLOL (PPL) who do not reach HVPG fall below 12 mmHg will be randomized to receive the addition of ROSUVASTATIN 20 mg /day PO. HVPG will be measured again after 56 days.
88816769|NCT05388110||Healthy controls|
88816770|NCT05388110||Depressed adolescents|
88816771|NCT05379530|Experimental|TEG Arm|"All patients enrolled in the study will have up to four 0.5cc blood samples obtained specifically for TEG analysis at the following defined points (for a total of up to 2cc of blood) when other routine labs are drawn (via an existing intravenous line or arterial line placed for clinical care) :~Once at the beginning of the case~Once at the end of the case~Up to two times at the same time as arterial blood gas (ABG) samples (if drawn)~The research team will collect the following information from the electronic medical record and input it into the Internal REDCap database:~De-identified demographic data, including age, height, weight, and diagnosis~Preoperative, intraoperative, and postoperative laboratory values( including PT, PTT, INR and fibrinogen and platelets), as dictated by standard clinical practice~Time of TEG results printed and time delivered to anesthesiologist~Complications/Adverse events within the first 48 hours postoperatively"
88816772|NCT05377294|Experimental|MOL therapy|Participants with Psychosis and/or Suicidality receiving MOL therapy
88816773|NCT05373706|Experimental|Cue Reactivity Personalized Feedback Intervention (PFI)|Participants randomized to the Cue Reactivity PFI condition will receive personalized feedback at the end of completing 17 days of ecological momentary assessments (EMAs) four times a day. The personalized feedback will be delivered online and contains information summarizing participants' desire to drink as it varied as a function of several real-world factors across the 17-day EMA period.
88816774|NCT05373706|No Intervention|Assessment-only control|Participants randomized to the control group will not receive any intervention. They will be an assessment-only control group.
88816775|NCT05361135|Experimental|PET/CT|Enhanced imaging with PET/CT
88816776|NCT05361135|No Intervention|Routine Imaging|Standard of Care Imaging
88816777|NCT05359887|Experimental|Unsuccessful BS (Total Weight Loss (TWL) < 20%)|Fifteen who had unsuccessful BS (Total Weight Loss (TWL) < 20%)
88816778|NCT05359887|Experimental|Successful BS (TWL > 25%).|Fifteen who had successful BS (TWL > 25%).
88816779|NCT05330676||No shock|Patients who have no evidence of clinical malperfusion or require vasoactive agents after cardiac surgery.
88816780|NCT05330676||Shock|Patients who have evidence of clinical malperfusion or require vasoactive agents after cardiac surgery.
88816781|NCT05319782|Experimental|Experimental arm|
88816782|NCT05299216|Experimental|Group A|Group A will receive Manual Diaphragm Technique in addition to Conventional Physical Therapy. Treatment will be provided for a total of four weeks, thrice a week.
88816783|NCT05299216|Active Comparator|Group B|Group B will receive Conventional Physical Therapy and Sham Diaphragm Technique. Conventional Physical Therapy group comprises electrotherapeutic treatment and exercise plan. Treatment will be provided for a total of four weeks, thrice a week.
88816784|NCT05280392||People living with HIV|PLWH who were offered to participate in the EHVA T02/ANRS VRI07 clinical trial
88816785|NCT05272605|Experimental|Adjuvanted SARS-CoV-2 beta variant RBD recombinant protein vaccine (DoCo-Pro-RBD-1) 5mcg + MF59|DoCo-Pro-RBD-1 antigen 5mcg mixed with MF59 adjuvant in 0.5 mL suspension, administered intramuscularly in a one dose regimen, on Day 1
88816786|NCT05272605|Experimental|Adjuvanted SARS-CoV-2 beta variant RBD recombinant protein vaccine (DoCo-Pro-RBD-1)15mcg + MF59|DoCo-Pro-RBD-1 antigen 15mcg mixed with MF59 adjuvant in 0.5 mL suspension, administered intramuscularly in a one dose regimen, on Day 1
88816787|NCT05272605|Experimental|Adjuvanted SARS-CoV-2 beta variant RBD recombinant protein vaccine (DoCo-Pro-RBD-1) 45mcg + MF59|DoCo-Pro-RBD-1 antigen 45mcg mixed with MF59 adjuvant in 0.5 mL suspension, administered intramuscularly in a one dose regimen, on Day 1
88816788|NCT05272605|Experimental|SARS-CoV-2 beta variant RBD mRNA vaccine (MIPSCo-mRNA-RBD-1) 10mcg|MIPSCo-mRNA-RBD-1 antigen 10mcg administered intramuscularly as a 0.5 mL dose in a one dose regimen on Day 1
88816789|NCT05272605|Experimental|SARS-CoV-2 beta variant RBD mRNA vaccine (MIPSCo-mRNA-RBD-1) 20mcg|MIPSCo-mRNA-RBD-1 antigen 20mcg administered intramuscularly as a 0.5 mL dose in a one dose regimen on Day 1
88816790|NCT05272605|Experimental|SARS-CoV-2 beta variant RBD mRNA vaccine (MIPSCo-mRNA-RBD-1) 50mcg|MIPSCo-mRNA-RBD-1 antigen 50mcg administered intramuscularly as a 0.5 mL dose in a one dose regimen on Day 1
88816791|NCT05272605|Placebo Comparator|Normal saline (0.9%)|Normal saline (0.9%) administered intramuscularly as a 0.5 mL dose in a one dose regimen on Day 1
88816792|NCT05265286|Experimental|Arm 1 prophylaxis treatment|"Subjects of high dose group are being received four doses of FRSW117. dosing on day1(ED1), day8(ED2), day15(ED3), day22(ED4) respectively.~Subjects of low dose group are being received four doses of FRSW117. dosing on day1(ED1), day8(ED2), day15(ED3), day22(ED4) respectively.~All subjects are being received PK assessment in ED1 and ED4."
88816793|NCT05264376|Experimental|Diabetes Body Project|
88816794|NCT05264376|Active Comparator|Educational Control Group|
88816795|NCT05233202|Experimental|LEVOSIMEDAN|Levosimendan administered as a continuous infusion over a 24-hour period at the rate of 0.2μg/kg/min, with no bolus administration. The infusion will begin 24H to 48H before anesthetic induction.
88816796|NCT05233202|Placebo Comparator|PLACEBO|Placebo (isotonic sodium) administered as a continuous infusion over a 24-hour period at the rate of 0.2μg/kg/min, with no bolus administration. The infusion will begin <48H before anesthetic induction.
88830818|NCT02761967|Experimental|Physical activity|"The women in the EG (Exercise Group) performed moderate physical exercise in water, following the SWEP method (Study of Water-based Exercise during Pregnancy). It consists of performing moderate physical exercise in an aquatic environment from weeks 20 to 37 of gestation. The sessions take place three times weekly, with a duration of 60 minutes each (45 minutes of activity followed by 15 minutes of relaxation). The sessions are composed of three phases: a) warm-up; b) the main phase, divided into aerobic exercise and strength-endurance exercises, designed specifically for pregnant women; c) stretching and relaxation.~After the postpartum period, women begin a program based on postpartum recovery exercises Fitness Low Pressure method 12-week, 3 days a week, in sessions of 60 minutes."
88830819|NCT02761967|No Intervention|No exercise|"The CG (Control Group) received the standard recommendations during pregnancy, including guidelines from the midwife on the positive effects of physical exercise. These participants received the usual visits from healthcare providers (midwives, obstetricians and family doctor) during pregnancy, as did those in the EG.~After the postpartum period, the women in the control group did not perform regulated physical activity."
88830820|NCT03029299|No Intervention|Control|Subjects receive standard of care testing as determined by the clinician.
88830821|NCT03029299|Experimental|Intervention|Subjects are tested using the FilmArray RP EZ and the results are provided to the clinician for use in determination of patient care (along with any other clinician-ordered testing)
88830822|NCT05012605||SLEEPR cohort|Individuals within first 3 months following stroke who did not have obstructive sleep apnea within the first 15 days following stroke
88830823|NCT05009797||Patients undergoing atrial fibrillation catheter ablation|Patients undergoing scheduled atrial fibrillation catheter ablation.
88830824|NCT05417659|Placebo Comparator|Control|A placebo drink to be consumed 1 hour prior to exercise and every 15 minutes during exercise and placebo tablets to be consumed 30 minutes prior to exercise, at the onset of exercise and 30 minutes into exercise.
88830825|NCT05417659|Active Comparator|Exercise plus carbohydrate|A high carbohydrate drink (1.6g/kg) to be consumed 1 hour prior to exercise and further drinks (0.2g/kg) every 15 minutes during exercise.
88830826|NCT05417659|Experimental|Exercise plus niacin|A dose of niacin (10mg/kg) to be consumed 30 minutes prior to exercise and two further doses (5mg/kg) at the onset of exercise and 30 minutes into exercise.
88830827|NCT02762513|Experimental|Axitinib|Participants will receive 5 mg of Axitinib twice a day continuously, with subsequent dose escalation to 7 mg and then 10 mg twice a day in the absence of grade 2 or worse toxicities
88830828|NCT04996225|Experimental|Group (A): (study group)|Group (A): (study group) 15 patients received aerobics exercises and balancing exercises in addition to relaxation exercises for 4 weeks, 3sessions/week.
88830829|NCT04996225|Placebo Comparator|Group (B): (Control group)|2-Group (B): (Control group) 15 patients received relaxation exercises in the form of physical relaxation exercise for 4 weeks, 3 sessions/week. the participants who received aerobics exercises and balancing exercises in addition to relaxation exercises (experimental group A), showed significant decrease in anxiety and dizziness more than (placebo group B)
88830830|NCT02958761|Experimental|Platelet-rich plasma|Patients in the intervention group will receive three autologous PRP plus calcium gluconate (as activator) intraarticular injections at 4-week intervals. Briefly, at the Immunohaematology and Transfusion Service, on each scheduled visit 20 ml of autologous whole blood will be sampled from each patient, 2 ml ACD-A will be added directly the syringe as anticoagulant; finally the vial will be gently centrifuged at 900rpm for 7 minutes. Platelet-rich plasma was collected. The PRP vials plus activator will be immediately shipped to the rehabilitation unit, where intraarticular injection will be performed by an experienced physiatrist.
88830831|NCT02958761|Active Comparator|hyaluronic acid|Patients in the control group will receive three intraarticular hyaluronic acid (20 mg/2 mL; Hyalgan, Fidia, Abano Terme, Italy) injections at the same intervals, by the same study staff.
88830832|NCT02764385|Other|AAC only|This is a system-based intervention that involves changes in the EHR regarding documenting tobacco assessment and the capability to order an eReferral to the Quitline. This system-based intervention also changes the role of the medical technical assistant.
88830833|NCT02764385|Other|AAC + TMCP|The Teachable Moment Communication Process is a clinician-focused intervention designed to guide an approach to discussing smoking cessation during routine primary care visits.
88830834|NCT05215535|Experimental|MRI group|An abbreviated MRI of the liver/abdomen
88830835|NCT05215535|Active Comparator|CT group|A combined single venous and 3 min equilibrium phase CT of the abdomen/liver
88830836|NCT05649397|Experimental|cervical manipulation|in the cervical manipulation, provide a high velocity, low-amplitude manipulation to each subject's cervical spine.
88830837|NCT05649397|Active Comparator|conventional therapy|"15 mins moist hot pack~Neck Isometric exercise~hold for 5-8 seconds and repeat 10 times~Cervical range of motion~10 repetitions of movement in rotation within pain free range"
88830838|NCT04336709|Active Comparator|Calcipex II|Calcipex group Manufactures Nishika, Yamaguchi, Japan Color- White Formulation- Water based Duration- 7 days Form: Paste Frequency: Used once on 1st day only till canal fills. Composition- Water-based calcium hydroxide paste without radio contrast agent (Barium Sulfate) Packaging- (1 syringe of Calcipex Plain II (1.8g), 2 needles of Nishika Spin with 2 needle caps) Storage requirement- Room temperature (1-30℃).
88830839|NCT04336709|Active Comparator|Metapex|Metapex group Manufactures- Meta Biomed, Korea Color- Yellow Formulation- Oil based Duration- 7 days Form: Paste Frequency: Used once on 1st day only till canal fills. Composition- Premixed oil-based paste composed of Calcium Hydroxide with Iodoform and silicon oil Packaging-2.2g paste in 1 syringe. 20 disposable tips. 1 ring rotator for direction control of the tip Storage requirement- Room temperature (1-30℃).
88830840|NCT02767271|Experimental|Tinea Pedis|Participants with tinea pedis received luliconazole cream 1% topically once daily in the morning for 15 days (Day 1 through 15). The dose was approximately 3.0 grams per application and covered all affected and adjacent areas, including up to the ankles.
89359071|NCT03720067|Placebo Comparator|Phase 2: PPL non-responders/placebo|Patients treated with PROPRANOLOL (PPL) who do not reach HVPG fall below 12 mmHg will be randomized to receive the addition of PLACEBO 1 tablet PO. HVPG will be measured again after 56 days.
89359072|NCT03720067|Active Comparator|Phase 2: CVD non-responders/rosuvastatin|Patients treated with CARVEDILOL (CVD) who do not reach HVPG fall below 12 mmHg will be randomized to receive the addition of ROSUVASTATIN 20 mg /day PO. HVPG will be measured again after 56 days.
89359073|NCT03720067|Placebo Comparator|Phase 2: CVD non-responders/placebo|Patients treated with CARVEDILOL (CVD) who do not reach HVPG fall below 12 mmHg will be randomized to receive the addition of PLACEBO 1 tablet PO. HVPG will be measured again after 56 days.
89359074|NCT03779555||Patients taking lenalidomide for multiple myeloma|-Patients will be seen at baseline, 1 month (+/- 1 week), 2 months (3-5 weeks following 1-month assessment), and 3 months (3-5 weeks after 2-month follow-up)
89359075|NCT03718663||Knee OA patients (part 1)|Painful knee OA patients signed up for standardized exercise therapy
89359076|NCT03718663||Healthy subjects (part 2)|Healthy subjects (age 18-28) signed up military service in Defence Command Denmark
89359077|NCT03779399||Patient with benign ovarian tumor|25 patients with benign ovarian tumor (cystadenoma) were admitted to IInd Department of Gynecology, Lublin Medical University, Lublin, Poland.
89359078|NCT03779399||Patient with borderline tumor|11 women with borderline ovarian tumor were admitted to IInd Department of Gynecology
89359079|NCT03779399||Patient with ovarian cancer|24 women with ovarian cancer were admitted to IInd Department of Gynecology
89359080|NCT03779399||Patient without ovarian pathology|20 patient with unexpleined infertility were admitted to IInd Department of Gynecology
89359081|NCT01444092|Experimental|Entocort|Study Medication
89359082|NCT03719989|Experimental|Treatment arm|This study is sing-arm study. Therefore, all enrolled patients will be treated with azacitidine plus R-GDP regimen
89359083|NCT02480296|Experimental|MYK-461|Oral Tablet x 28 days
89359084|NCT02480296|Placebo Comparator|Placebo|Oral Tablet x 28 days
89359085|NCT03716323|Experimental|immediate premolar implant with xenograft and allograft|Immediate Implant Placement in Maxillary Premolar zone with grafting the jumping gap using xenograft and allograft
89359086|NCT05460442|Experimental|Caudal Block group|25 patients will receive ultrasound-guided caudal block with bupivacaine 0.25% (0.5 mL/kg) after induction of anesthesia.
89359087|NCT05460442|Experimental|Pericapsular nerve group block|25 patients will receive ipsilateral ultrasound-guided Pericapsular nerve group block with bupivacaine 0.25% (0.5 mL/kg) after induction of anesthesia.
89359088|NCT05460442|Experimental|Fascia iliaca group|25 patients will receive ipsilateral ultrasound-guided Fascia iliaca compartment block with bupivacaine 0.25% (0.5 m. L/kg) after induction of anesthesia.
89359089|NCT03779477|Experimental|Coping with Stress Course|The Coping with Stress Program that consists of 8 sessions will be implemented to the experimental group. 8-10 adolescents will be included in this program. The session frequency will be one session per week. After the completion of 8 sessions, two 90-minute sessions will be carried out each month in the following two months.
89359090|NCT03779477|No Intervention|Control|There will be no intervention in the control group. If the program will be effective, this group will also undergo the Coping with Stress Program after the termination of the study.
89359091|NCT05460208|Experimental|Enriched spread|Children between 20-40 kg will receive a dose of 15 g of the spread (1.2 g/d of plant sterols: 0.06-0.03 g/kg of weight/d) and those with a weight between 40-60 kg will receive two doses of 15 g of the spread (2.4 g/d of plant sterols: 0.06-0.04 g/kg of weight/d)
89359092|NCT05460208|Placebo Comparator|Control spread|Children between 20-40 kg will receive a dose of 15 g of the spread (1.2 g/d of plant sterols: 0.06-0.03 g/kg of weight/d) and those with a weight between 40-60 kg will receive two doses of 15 g of the spread (2.4 g/d of plant sterols: 0.06-0.04 g/kg of weight/d)
89359093|NCT05263115|Active Comparator|Resistance exercise|12-week progressive power-oriented resistance exercise program on leg press machine
89359094|NCT05263115|Experimental|Functional stair and stepping-based exercise|12-week progressive functional weight-bearing stair and stepping-based exercise program
89359095|NCT05463328|Experimental|Laparoscopic assisted pancreaticoduodenctomy|If inclusion criteria are met ,these group of patients will undergo Laparoscopic assisted pancreaticoduodenctomy.
89359096|NCT05463328|Active Comparator|Open pancreaticduodenctomy|criteria are met ,these group of patients will undergo open pancreaticoduodenctomy
89359097|NCT05462470||repeat liver surgery|repeat liver surgery for liver relapse lesions
89359098|NCT05462470||non-repeat liver surgery|non-repeat liver surgery, just only systemic palliative chemotherapy
89359099|NCT03774797||Pre-Implementation Patients|Enrolled patients will take online surveys following a prenatal or a postpartum visit.
89359100|NCT03774797||Post-Implementation Patients|All enrolled patients will take online surveys following a prenatal or a postpartum visit. A subset will be interviewed after the postpartum survey.
89359101|NCT03774797||Post-Implementation Providers|All enrolled providers will take online surveys at 6-12 months after program implementation, and a subset will be interviewed.
89359102|NCT02480218||Tamoxifen|Chemotherapy-naïve women 65 and older with a first diagnosis of early stage HR+ BC, post surgical resection prescribed tamoxifen.
89359103|NCT02480218||Aromatase Inhibitors|Chemotherapy-naïve women 65 and older with a first diagnosis of early stage HR+ BC, post surgical resection prescribed aromatase inhibitors.
89359104|NCT02479984|Experimental|Staging laparoscopy|"Resectable pancreatobiliary cancer confirmed by radiologic studies (CT scan, MRI, PET-CT) and no evidence of distant metastasis.~Staging laparoscopy will perform through 2 ports and a 30˚ laparoscope is inserted into the peritoneal cavity. Examining the whole abdominal wall, including the parietal and visceral peritonea, we will observe the liver surface from the dome area to the inferior surface and hepatoduodenal ligament in order to find metastatic nodules. Laparoscopic ultrasound (US) will be used to overcome in inspecting the posterior part of the liver. After complete laparoscopic examination, peritoneal lavage will be performed through the laparoscopic port."
89359105|NCT01265784|Experimental|TP-434, 1.5 mg/kg q24h|TP-434 was administered intravenously (IV) at a dose of 1.5 milligrams per kilogram of body weight (mg/kg) every 24 hours (q24h) for a minimum of 4 days and a maximum of 14 days (7 days for participants in India). TP-434 treatment was to be stopped when symptoms of complicated intra-abdominal infection (cIAI) resolved, there was treatment failure, or the maximum allowed number of infusion days was reached.
89359106|NCT01265784|Experimental|TP-434, 1.0 mg/kg q12h|TP-434 was administered IV at a dose of 1.0 mg/kg every 12 hours (q12h) for a minimum of 4 days and a maximum of 14 days (7 days for participants in India). TP-434 treatment was to be stopped when symptoms of cIAI resolved, there was treatment failure, or the maximum allowed number of infusion days was reached.
89359107|NCT01265784|Active Comparator|Ertapenem, 1 g q24h|Ertapenem was administered IV at a dose of 1 gram (g) q24h for a minimum of 4 days and a maximum of 14 days (7 days for participants in India). Ertapenem treatment was to be stopped when symptoms of cIAI resolved, there was treatment failure, or the maximum allowed number of infusion days was reached.
89359108|NCT02485756|Experimental|Educational handout|Participants in the intervention group will read an educational handout on hormonal contraceptives/antiepileptic interactions.
88830841|NCT02767271|Experimental|Tinea Cruris|Participants with tinea cruris received luliconazole cream 1% topically once daily in the morning for 8 days (Day 1 through 8). The dose was approximately 3.0 grams per application and covered all affected and adjacent areas, including up to the groin, thighs, and abdomen.
88830842|NCT04928677|Experimental|Codrituzumab|For Phase A of the study, we will use the 3+3 study design, with 2 planned dose levels, starting at 50% of the adult RP2D to confirm the pediatric RP2D/MTD. 6-9,43 Phase B will include an expansion cohort for patients with hepatoblastoma.
88830843|NCT02741297|Experimental|Spinal Cord Stimulation (SCS) System|Boston Scientific (BSC) PRECISION SCS System with MultiWave Technology
88830844|NCT05375071|Experimental|Conventional rehabilitation plus blood flow restriction (BFR) therapy|Following standard of care surgery, subjects will immediately be started in standard of care physical therapy. Additionally, a BFR Cuff will be applied during physical therapy.
88830845|NCT05375071|Active Comparator|Conventional rehabilitation|Following standard of care surgery, subjects will immediately be started in standard of care physical therapy.
88830846|NCT05647993|Placebo Comparator|Control group (Placebo)|Patient will receive standard antimicrobial prophylaxis(cefazolin intravenously weight dependent) and placebo(0.9% NaCl 100 ml intravenously) before the incision
88830847|NCT05647993|Experimental|azithromycin|Patient will receive standard antimicrobial prophylaxis(cefazolin intravenously weight dependent) and azithromycin 500 mg intravenously before the incision
89359109|NCT02485756|No Intervention|Control (no educational handout)|Those in the standard care group will not receive the educational handout.
88830848|NCT02741687|Experimental|Sitagliptin Arm|"Participants will receive sitagliptin beginning the day prior to surgery and continuing daily during hospitalization (up to 10 days post-surgery).~Point of care (POC) testing will be done four times daily, before meals and at bedtime, or every 6 hours for patients who are not eating (NPO). Patients developing hyperglycemia during or after surgery will be treated with insulin per standard of care.~Patients with fasting and/or premeal blood glucose levels >180 mg/dl will receive supplemental insulin provided on a sliding scale. Patients with two consecutive fasting and/or premeal blood glucose levels >180 mg/dl, or with average daily blood glucose levels >180 mg/dl will be started on rescue therapy with subcutaneous insulin once daily plus correction doses by a sliding scale."
88830849|NCT02741687|Placebo Comparator|Placebo Arm|"Participants will receive a placebo tablet beginning the day prior to surgery and continuing daily during hospitalization (up to 10 days post-surgery).~Point of care (POC) testing will be done four times daily, before meals and at bedtime, or every 6 hours for patients who are not eating (NPO). Patients developing hyperglycemia during or after surgery will be treated with insulin per standard of care.~Patients with fasting and/or premeal blood glucose levels >180 mg/dl will receive supplemental insulin provided on a sliding scale. Patients with two consecutive fasting and/or premeal blood glucose levels >180 mg/dl, or with average daily blood glucose levels >180 mg/dl will be started on rescue therapy with subcutaneous insulin once daily plus correction doses by a sliding scale."
88830850|NCT05361499|Experimental|Streptococcus pneumoniae 6B (Sp_6B) inoculated|
88830851|NCT02742077|Other|Robotic-assisted PVI|Robotic-assisted peripheral vascular intervention
88830852|NCT00372203|Experimental|Endobronchial ultrasound|
88830853|NCT02768129|Sham Comparator|sham tDCS|10 sessions sham transcranial direct current stimulation (tDCS)
88830854|NCT02768129|Experimental|active tDCS|10 sessions active transcranial direct current stimulation (tDCS)
88830855|NCT05637151|Other|ICC in pregnant women with ICP|Immediate cord clamping group in pregnant women with intrahepatic cholestasis of pregnancy
88830856|NCT05637151|Experimental|DCC in pregnant women with ICP|Delayed cord clamping group in pregnant women with intrahepatic cholestasis of pregnancy
88830857|NCT05637151|Other|ICC in normal pregnant women|Immediate cord clamping group in normal pregnant women
88830858|NCT05637151|Experimental|DCC in normal pregnant women|Delayed cord clamping group in normal pregnant women
88830859|NCT02768753|Experimental|The Axillary Bilateral-breast Approach (ABBA) group|All patients were told about the operative techniques involved in robotic thyroidectomy via the Axillary Bilateral-breast Approach (ABBA) and Bilateral Axillo-breast Approach (BABA), and patients subsequently chose their preferred surgical procedure, voluntarily agreed to participate in our study, and provided written informed consent.
88830860|NCT02768753|Experimental|The bilateral Axillo-breast Approach (BABA) group|All patients were told about the operative techniques involved in robotic thyroidectomy via the Axillary Bilateral-breast Approach (ABBA) and Bilateral Axillo-breast Approach (BABA), and patients subsequently chose their preferred surgical procedure, voluntarily agreed to participate in our study, and provided written informed consent.
88830861|NCT05162807|Experimental|Palliative Care Education|The intervention arm will view a psychoeducational video on palliative care.
88830862|NCT05162807|Placebo Comparator|Attention Control|The control arm will view an educational video on nutrition as an attention control.
88830863|NCT05129735|Experimental|Meal replacement shake|Teatis meal replacement shake
88830864|NCT05354323|Experimental|NECVAX-NEO1|Personalized patient-individual oral DNA vaccine
88830865|NCT02770625|Experimental|ISU302|60 U/kg (once every 2 weeks for 6 months)
88830866|NCT05350657|Experimental|Ketogenic Diet|Subjects will be provided with foods following a ketogenic diet for 15 consecutive days.
88830867|NCT05124041|Experimental|ROTEM-arm|Treatment of significant blood loss using point-of-care testing of whole blood viscoelasticity (ROTEM) monitoring coagulopathy or hyperfibrinolysis
89359110|NCT01315223|No Intervention|Conventional treatment CHF patients|One hundred and fifty patients with CHF will be treated according to current guidelines (conventional treatment).
89359111|NCT01315223|Experimental|Lung impedence-guided treatment|
88830868|NCT05124041|Active Comparator|Control-arm|Treatment of significant blood loss conventionally, ie. using clinical judgement and conventional coagulation tests, such as prothrombin time (as international normalized ratio, INR), activated partial thrombin time (APTT), fibrinogen in plasma
88830869|NCT04863859||Grandchildren|Granddaughter or Grandson of the person living with dementia who serves as the primary caregiver
88830870|NCT04863859||Siblings|Brother, sister, brother-in-law or sister-in-law of the person living with dementia who serves as the primary caregiver
88830871|NCT04863859||Nieces/Nephews|Niece or nephew of the person living with dementia who serves as the primary caregiver
88830872|NCT04863859||Step-Kin|Step-kin (step-daughter, step-son, step-sister, step-brother or other step-kin) of the person living with dementia who serves as the primary caregiver
88830873|NCT04863859||Adult Child|Adult child (son or daughter) of the person living with dementia who serves as the primary caregiver
88830874|NCT04863859||Spouse|Spouse (husband or wife) of the person living with dementia who serves as the primary caregiver
88830875|NCT05627791|Experimental|Oxytocin gel|Oxytocin gel 400IU per 1 ml (on HPMC 4,000 cps base gel), applied at vaginal canal 1 ml per day for 8 weeks
88830876|NCT05627791|Placebo Comparator|Placebo gel|Placebo gel (HPMC 4,000 cps base gel) , applied at vaginal canal 1 ml per day for 8 weeks
88830877|NCT00372281|Experimental|Cliavist|
88830878|NCT02986945|Experimental|Immediate|"Resiliency App: Study participants randomized to the Immediate group will receive the text-messaging app, B-RESILIENT-an adaptation of a Resiliency Course for improving mood in individuals with depressive symptoms--for 4 weeks.~Wk 1: BOOST - manage unhealthy thoughts. Wk 2: BREAK - doing pleasant activities. Wk 3: BUDDY - effective communication for social support. Wk 4: Review of first 3 weeks. Each day, users will receive a daily affirmation text message, a series of approximately 5-10 text messages on the topic of the day, and a daily goal corresponding to the day's content (e.g. do a pleasant activity). At the end of the day, users will receive text messages asking them to report whether they completed the daily goal, followed by a daily mood measure."
88830879|NCT02986945|Other|Delayed|Resiliency App: The Delayed arm will receive the intervention after the Immediate Arm completes its use of the intervention.
88830880|NCT04337879|Experimental|AL2846 + mFOLFOX6|AL2846 capsule administered orally,once daily in 28-day cycle; oxaliplatin 85mg/ ㎡ administered intravenously (IV) on day 1, day 15 in 28-day cycle；calcium folate 400mg/ ㎡ IV on day 1, day 15 in 28-day cycle；5-fu 2800mg/ ㎡ IV on day 1, 2, 15, 16 in 28-day cycle.
88830881|NCT04337879|Experimental|AL2846 + FOLFIRI|AL2846 capsule administered orally,once daily in 28-day cycle; irinotecan 180mg/㎡ administered intravenously (IV) on day 1,15 in 28-day cycle; calcium folate 400mg/ ㎡ IV on day 1,15 in 28-day cycle; 5-fu 2800mg/ ㎡ IV on day 1, 2, 15, 16 days in 28-day cycle.
88830882|NCT05613049||Observational group|Patients have 2 or more miscarriage or repeated implantation failure (RIF), or infertile women would be invited to do endometrial sampling (ES) procedure. The ES will be conducted randomly or when women undergo hysteroscopy or obtained precisely 7 days after LH surge. It will be obtained using a Pipelle sampler as an outpatient procedure.
88830883|NCT05294419|Other|cardiovascular integrated risk score (CVD-IRT)|The CVD IRT device will generate a result based on the polygenic risk score derived from participant genomic information
88830884|NCT04336631|Other|Routine Medical Follow Up, Counseling & Usual Care|Behavioral counseling was provided to the patients on each consecutive follow up after enrolling in this study. They were adequately followed on physical exercise, reduced salt intake, lifestyle modifications, and smoking cessation. All measurements of blood pressure and weight were maintained and recorded.
88830885|NCT04336631|No Intervention|Routine Medical Follow Up & Usual Care|Usual routine medical care was provided to the study participants only.
88830886|NCT05456945|Experimental|Acupressure|Before the injection, patients will be asked to lie in the prone position. The acupressure point (UB32) will be located on the side to be injected. The UB32 point is located in the sacrum region, below the medial and posterior superior iliac spine, in the second sacral foramen. The acupressure point UB32 will be pressed circularly with a stopwatch for 1 minute. Then the acupressure point will be pressed three times in sequence with the thumb directly (pressure equal to 4.5 kg/cm2). Diclofenac sodium (75mg/3ml) will be injected after acupressure.
88830887|NCT05456945|Experimental|Shotblocher|Before the injection, patients will be asked to lie in the prone position. The protruding surface of the Shotblocker will be placed in the area just before the injection so that the point of entry with the needle will not be contaminated. Pressure will be applied by keeping the Shotblocker constant throughout the process. The injector will be quickly inserted through the gap in the middle of the shortblocher. Shotblocker will be removed after drug administration.
88830888|NCT05456945|No Intervention|Control group|No intervention will be applied before the injection
88830889|NCT05456789|Experimental|Combined interventional treatment|Combined catheter-based fibrinolysis and thrombectomy plus conventional treatment
88830890|NCT05456789|Active Comparator|conventional treatment|Conventional treatment
88830891|NCT02745353|Active Comparator|A|Patients in Arm A will receive a single daily dose of 25mg naloxegol for the 2-week initial treatment period, followed by a 3-day washout period and 2-week crossover treatment period in which the patient will receive the treating physician's usual care for OIC using a stimulant laxative + rescue medication.
89359112|NCT02479906|Sham Comparator|Sham Treatment|In the sham treatment,the electrical field induced by the sham coil cannot invoke any action potentials and if no action potentials are induced, then the electric field is insignificant and there is no treatment effect on the brain.
89359113|NCT02479906|Experimental|Deep TMS System|Deep Transcranial Magnetic Stimulation (DTMS) is a new form of TMS which allows direct stimulation of deeper neuronal pathways than the standard TMS. The HAC Coil is designed to stimulate neuronal pathways in the medial prefrontal cortex or motor cortex, including the anterior cingulated cortex.
89359114|NCT03778853|Experimental|Anlotinib Hydrochloride|Anlotinib Hydrochloride p.o, qd and it should be continued until disease progress or toxicity cannot be tolerated or patients withdraw consent
89359115|NCT02479750|Experimental|ColdZyme|ColdZyme® mouth spray liquid. Treatment (6 doses per day) will be applied for 11 days from the day of inoculation.
88830892|NCT02745353|Active Comparator|B|Patients in Arm B will receive the treating physician's usual care for OIC using a stimulant laxative + rescue medication for the 2-week initial treatment period, followed by a 3-day washout period and 2-week crossover period in which the patient will receive a single daily dose of 25mg naloxegol.
88830893|NCT04778839|Experimental|Paclitaxel Micelles for Injection|In the First Period, Only three Participants in the first dose group were randomly assigned to 175 mg/m2 paclitaxel micelle for injection at a 1:1 rate.175 mg/m2, 260 mg/m2, 320 mg/m2, and 390 mg/m2 of paclitaxel micelle for Injection was intravenously administrated for three hours,three weeks constituted one course of treatment.
89177944|NCT04029428|Active Comparator|90Y DOTATATE|Therapy 90Y DOTATATE, total activity 4x3.7GBq (14.8 GBq), i.v. infusion of 90Y DOTATATE administered for 20 min. via infusion pump with co-infusion of amino-acids (AA) solution 1000ml for 1h before and then et least 6h after 90Y DOTATATE infusion. Therapy consists up to 4 cycles at 8 ± 2 weeks between each other.
88830894|NCT04778839|Active Comparator|Paclitaxel Injection|three Participants were randomly assigned to 175 mg/m2 paclitaxel Injection,175 mg/m2 of conventional Paclitaxel Injection was intravenously administrated for three hours, three weeks constituted one course of treatment.
88830895|NCT05456711||knee osteoarthritis|ultrasonographic measurement for femoral cartilage thickness VAS for pain severity WOMAC for functionality
88830896|NCT05456711||healthy control|ultrasonographic measurement for femoral cartilage thickness VAS for pain severity WOMAC for functionality
89177945|NCT04029428|Experimental|177Lu DOTATATE or mix 90Y and 177Lu DOTATATE (50% each)|Therapy 177Lu DOTATATE, total activity 4x5.55GBq (22.2 GBq), i.v. infusion of 177Lu DOTATATE administered for 20 min via infusion pump with co-infusion of amino-acids solution (AA) 1000ml for 1h before and then et least 6h after 177Lu DOTATATE infusion. Therapy consists up to 4 cycles at 8 ± 2 weeks between each other or therapy 90Y and 177Lu DOTATATE, 4x3.7GBq total activity 14.8 GBq, (mix 50% each 90Y and 177Lu), i.v. infusion of mix 90Y and 177Lu DOTATATE administered for 20 min via infusion pump with co-infusion of amino-acids (AA) solution 1000ml for 1h before and then et least 6h after 90Y and 177Lu DOTATATE infusion. Therapy consists up to 4 cycles at 8 ± 2 weeks between each other.
89177946|NCT02608424|Experimental|Foot Mechanical Stimulation|"Intervention: Foot Mechanical Stimulation (FMS) will be performed on enrolled patients every 72 hours (total 5 stimulation sessions) by a pressure-controlled mechanical stimulator (Gondola®, European Community (CE) marking n° 0476) .~The sites of the stimulation will be the tip of the hallux and the lower big toe first metatarsal joint plantar surface. The FMS procedure consists in the application of the patient's calibrated pressure for 6 seconds, over the selected sites. Each of the 2 cutaneous sites of both feet will be mechanically stimulated. The procedure will be automatically repeated for 4 times in every subject so that the overall time of stimulation will be approximately 2 minutes."
89177947|NCT00827086||1|Patients with non-infectious Uveitis
89177948|NCT00827086||2|Patients with scleritis
89177949|NCT00819520|Experimental|Ivermectin|ivermectin Stromectol®)
89177950|NCT00819520|Active Comparator|Malathion|malathion(Prioderm®)
89177951|NCT00590564|Experimental|1|All patients will receive treatment with 2.5grams of SST as granules in packet form by mouth three times a day every day for 52 weeks unless occurrence of unacceptable adverse events or patient withdrawal.
89177952|NCT00827164|Experimental|Resistance Training|Patient will meet with an exercise specialist once per week for the first 6 weeks. Patients will receive guidance in a safe and appropriate exercise regimen based on specific medical history and preference. An exercise specialist will telephone weekly for consultation and support once per week for the final 6 weeks.
89177953|NCT00827164|Other|Nutrition Counseling|Patients will meet once per week with dietitian for the first 6 weeks in 60 minute sessions. Dietitian will telephone each patient weekly for the final 6 weeks of counseling and support.
89177954|NCT04029740|Other|Healthy controls|40 Healthy controls matched on gender and age with no current psychopathology will have exosomal microRNAs measured twice over a 3 month period.
89177955|NCT04029740|Experimental|panic disorder receiving CBT|40 adult patients diagnosed with primary panic disorder will have their exosomal microRNAs measured 2x over 3 months.
89177956|NCT00631696|Experimental|1|
89177957|NCT00631696|Placebo Comparator|2|
89177958|NCT04430140||1|"CT Scan~Number of research exams: 1 Effective Dose (mSv) for 1 exam: 0.6 Total Effective Dose (mSv)*: 0.6"
89177959|NCT00822562|Active Comparator|Procedure/Surgery|surgery
89177960|NCT00822562|Experimental|Procedure|PRFA or PMCT
89177961|NCT00631540|Experimental|1|renal artery stenting
89177962|NCT02608112||Participants with Moderate to Severe RA|Participants with moderate or severe RA, naïve to TCZ treatment (IV or SC), and who have no contra-indication to TCZ SC therapy as per the local label are included.
89177963|NCT00630916|No Intervention|A|
89177964|NCT02549326|Placebo Comparator|Obese, placebo|Placebo daily for 12 weeks
89177965|NCT02549326|Active Comparator|Obese, vitamin D|Vitamin D3 50 µg / daily for 12 weeks
89177966|NCT02549326|Placebo Comparator|Control, placebo|Placebo daily for 12 weeks
89177967|NCT02549326|Active Comparator|Control, vitamin D|Vitamin D3 50 µg / daily for 12 weeks
89177968|NCT02549404|Experimental|KHK7580|
89177969|NCT00819598||SUSPECTED ARTERIAL DISEASE|
89177970|NCT02549248||Idiopathic interstitial diseases|" Test group : patients suffering from idiopathic interstitial lung diseases including sarcoidosis and idiopathic pulmonary fibrosis.~Nanoparticles (NP) loads will be measured on Bronchoalveolar lavages (BAL), bronchial washings (BW), exhaled air condensates (EAC), blood specimen and urine specimen."
89177971|NCT02549248||Non idiopathic intertitial diseases|" Control group : patients suffering from interstitial lung diseases of known aetiologies, such as hypersensibility pneumonitis, infectious or cancerous interstitial diseases and interstitial diseases caused by drug reactions.~Nanoparticles (NP) loads will be measured on Bronchoalveolar lavages (BAL), bronchial washings (BW), exhaled air condensates (EAC), blood specimen and urine specimen."
89177972|NCT00630292|Experimental|1|
89177973|NCT00822640|Experimental|1|Columbus Knee Prosthesis with rotating Platform
88830897|NCT02746991|Sham Comparator|Sham Injection|Sham Injection
88830898|NCT02746991|Experimental|FAI Insert|FAI Insert (0.18 mg fluocinolone acetonide)
88830899|NCT04738357|Experimental|HSK21542|
88830900|NCT04738357|Placebo Comparator|placebo|
88830901|NCT02289157|Experimental|Negative Pressure Wound Therapy|After standard cesarean section completed patients will have Prevena negative pressure wound therapy system placed.
88830902|NCT02289157|No Intervention|Standard dressing|After standard cesarean section completed patients will have standard dressing placed.
88830903|NCT02747615|Other|Control group (n=30)|The control group, which consisted of 30 patients who were transfused only allogeneic blood.
88830904|NCT02747615|Active Comparator|Preoperative blood donation (n=30)|the study group including 30patients who were transfused pre-operatively donated autologous blood, either during surgery or after it.
88830905|NCT04336319|Experimental|Patients with a confirmed diagnosis of UC who underwent IPAA|Patients who meet inclusion criteria will be enrolled and will sign an informed consent form. The study includes six visits to the IBD clinic and phone calls between visits.
88830906|NCT02775617|Other|Parallel Treatment|Site 1- Parallel Treatment Arm Single dose azithromycin (for yaws) and Ivermectin/Permethrin (for scabies) will be offered on D1. A second dose of Ivermectin/Permethrin will be offered 7-14 days later.
88830907|NCT02775617|Other|Sequential Treatment|"Site 2- Serial Treatment Arm Ivermectin/Permethrin (for scabies) will be offered on D1 with a second dose of Ivermectin/Permethrin offered 7-14 days later..~Single dose azithromycin (for yaws) will be offered at the twelve month follow-up visit."
88830908|NCT04336007|Experimental|Radio-frequency group|The equipment used, INDIBA® Activ Ct9, (448kHz), with the switch-mode on.
88830909|NCT04336007|Placebo Comparator|Placebo group|The equipment used, INDIBA® Activ Ct9, (448kHz), with the switch-mode off.
88830910|NCT04336007|Sham Comparator|Control Group|NO INTERVENTION athlete's usual pre-competition warming-up
88830911|NCT04719403|Experimental|VIDEO|Participants receive access to video recordings of their clinic visits
88830912|NCT04719403|No Intervention|Usual Care|Participants receive usual care (UC), which is their normal clinic visit and written after-visit summary
88830913|NCT05456633||Capri Cervical 3D Static|Subjects who have undergone or will undergo VBR in the cervical spine (C2 to T1 in the USA, C3 to C7 outside of the USA) to replace diseased or damaged vertebral bodies due to tumor, trauma (i.e., fracture), or osteomyelitis, or for reconstruction following corpectomy performed to achieve decompression of the spine cord and neural tissues in cervical degenerative disorders
88830914|NCT05456633||Capri Cervical 3D Expendable|Subjects who have undergone or will undergo VBR in the cervical spine (C2 to T1 in the USA, C3 to C7 outside of the USA) to replace diseased or damaged vertebral bodies due to tumor, trauma (i.e., fracture), or osteomyelitis, or for reconstruction following corpectomy performed to achieve decompression of the spine cord and neural tissues in cervical degenerative disorders
88830915|NCT05456633||Capri Thoracolumbar Expandable|Subjects who have undergone or will undergo VBR in the thoracolumbar spine (T1 to L5) with Capri Thoracolumbar Expandable to replace collapsed, damaged, or unstable vertebral bodies due to tumor or trauma (i.e., fracture)
88830916|NCT02777021||Early Discharge Patients|Patients receiving or having received chemotherapy for AML who are discharged to outpatient management within 3 days after chemotherapy completion. Subjects will complete a health related quality of life (HRQOL) survey at baseline and again at the start of the next treatment course. Survey questions will collect information such as patient race and educational level.
88830917|NCT02777021||Inpatient Management Patients|Patients receiving or having received chemotherapy for AML who remain in the hospital more than 3 days after chemotherapy completion. Subjects will complete a health related quality of life (HRQOL) survey at baseline and again at the start of the next treatment course. Survey questions will collect information such as patient race and educational level.
88830918|NCT02748785|Experimental|Group 1 (No MTX Hold before Vaccination)|Group 1 will continue MTX
88830919|NCT02748785|Experimental|Group 2 (MTX hold 4 Weeks before vaccination)|Group 2 will hold MTX 4 weeks before vaccination and resume MTX on the day of vaccination
88830920|NCT02748785|Experimental|Group 3 (MTX hold 2 Weeks before Vaccination)|Group 3 will hold MTX 2 weeks before vaccination and resume MTX 2 weeks after vaccination
89177974|NCT00822640|Active Comparator|2|Columbus Knee Prosthesis with fixed platform
89177975|NCT00819676||subjects with asthma|
89177976|NCT00819676||healthy subjects|
89177977|NCT00626548|Placebo Comparator|Placebo|Matching Placebo
89177978|NCT00626548|Experimental|ZD4054|ZD4054 (Zibotentan)
89177979|NCT00819754|Experimental|IXO regimen + bevacizumab|This is phase I/II safety and efficacy study. There is only one arm of Irinotecan, Xeloda and Oxaliplatin (IXO) regimen with Avastin (bevacizumab)
89177980|NCT00827476|Experimental|ovarian transplantation|tissue will be used for xenotransplantation or in vitro culture
89177981|NCT00819988|Placebo Comparator|Sugar pill|Single dose given 30-60 minutes preoperatively, then given every 8 hours for 3 days postoperatively
89177982|NCT00819988|Experimental|Pregabalin|Single dose of 75 mg given 30-60 minutes preoperatively, then 50 mg every 8 hours for 3 days postoperatively if creatinine clearance > 60 ml/min OR 25 mg every 8 hours for 3 days postoperatively if creatinine clearance 30-60 ml/min
89177983|NCT00827554|Experimental|LMWH plus TACE|50 HCC patients will be allocated to receive Nadroparin 4100 AXa iu twice daily 3 days after TACE which lasted for 6 weeks
89177984|NCT00827554|Active Comparator|TACE alone|50 HCC patients randomly assigned to receive TACE without LMWH
89177985|NCT00822796|Experimental|A|Burn patients with >20% TBSA burns scheduled to undergo debridement and grafting who will have placed the Thermogard™ central venous warming catheter by Alsius
89177986|NCT00822796|Active Comparator|B|Burn patients with >20% TBSA burns scheduled to undergo debridement and grafting who will have placed a central venous catheter as a part of their routine burn management
89177987|NCT00822874|Experimental|in-vitro maturation of oocytes|
89359116|NCT02479750|Placebo Comparator|Placebo|Sugar based mouth spray liquid manufactured to mimic ColdZyme® mouth spray. Treatment (6 doses per day) will be applied for 11 days from the day of inoculation.
89359117|NCT01315301|Active Comparator|Arm-A|Immediate Treatment Group
89359118|NCT01315301|Active Comparator|Arm-B|Deferred Treatment Group-1
89359119|NCT01315301|Active Comparator|Arm-C|Deferred Treatment Group-2
89359120|NCT03635814|Experimental|YD312 drug treatment|From the date when dispensed, investigational products will be dosed once a day at similar time to the first dosing time with meals and much water.
89359121|NCT03635814|Placebo Comparator|YD312 placebo drug treatment|From the date when dispensed, investigational products will be dosed once a day at similar time to the first dosing time with meals and much water.
89359122|NCT02485522||Fecal incontinence|Women age >18 years old with a diagnosis of fecal incontinence
89359123|NCT02485522||Controls|Women age >18 without a diangosis of fecal incontinence
89359124|NCT04492852|Experimental|Interventional Arm 1|After total knee replacement, the skin closure of the patients in this group will be done using polypropylene (PROLENE) sutures.
88830921|NCT02748785|Experimental|Group 4 (MTX hold on Day of Vaccination)|Group 4 will hold MTX on day of vaccination and resume MTX 4 weeks after vaccination.
88830922|NCT02750267|Experimental|Group A|In this randomized, cross-over study, the intervention involves blood glucose control using a Closed Loop system run by the Diabetes Assistant (DiAs) during a stay at a Research House/Hotel. All subjects will have blood glucose data compared between their usual diabetes care (at home, using home insulin pump) and this Closed-Loop care (at Research House/Hotel using the DiAs system). Subjects who are randomized to Group A will have home care evaluated before the Research House/Hotel admission. Subjects in this arm will participate in CGM training and data collection prior to the Research House/Hotel admission.
88830923|NCT02750267|Experimental|Group B|Group B is identical to Group A with the exception that usual diabetes care (at home, using home insulin pump) will be evaluated after the Research House/Hotel admission. Subjects who are randomized to Group B will participate in CGM training and data collection after the Research House/Hotel admission. As with Group A, all subjects will use Diabetes Assistant (DiAs) with Closed-Loop during the admission.
88830924|NCT02295553|Experimental|Ketamine 0 mg/kg|Ketamine dose will be 0 mg/kg. Propofol dose for the first patient will be 4 mg/kg. Doses for the subsequent patients will increase or decrease by 1.6 mg/kg using the Dixon Up and Down method.
88830925|NCT02295553|Experimental|Ketamine 0.25 mg/kg|Ketamine dose will be 0.25 mg/kg. Propofol dose for the first patient will be 3 mg/kg. Doses for the subsequent patients will increase or decrease by 1.2 mg/kg using the Dixon Up and Down method.
88830926|NCT02295553|Experimental|Ketamine 0.5 mg/kg|Ketamine dose will be 0.5 mg/kg. Propofol dose for the first patient will be 2.5 mg/kg. Doses for the subsequent patients will increase or decrease by 0.8 mg/kg using the Dixon Up and Down method.
88830927|NCT02295553|Experimental|Ketamine 1.0 mg/kg|Ketamine dose will be 1.0 mg/kg. Propofol dose for the first patient will be 2 mg/kg. Doses for the subsequent patients will increase or decrease by 0.4 mg/kg using the Dixon Up and Down method.
88830928|NCT05455151|Active Comparator|Conservative therapy|This is Group 1, whose patients received electrical impulse therapy using a BTL-4000 Premium G device (BTL Medical Technologies, Czech Republic) starting from day 5-7 of menstrual cycle for 10-12 days daily.
88830929|NCT05455151|Experimental|PRP injection|This is Group 2, whose patients received single intraendometrial injections of autologous PRP during proliferative phase (day 6-9) of menstrual cycle.
88830930|NCT05455151|Experimental|Injection of PRP after conservative therapy|This is Group 3, whose patients received electrical impulse therapy identically with Group 1 during the first menstrual cycle. In the second cycle, the patients received autologous PRP injections identically with Group 2.
88830931|NCT05455151|Experimental|Injection of PRP with endometrial cells|This is Group 4, whose patients received single intraendometrial injections of the minimally manipulated autologous endometrial cells suspended in autologous PRP during proliferative phase (day 6-9) of menstrual cycle.
88875474|NCT05214456|Active Comparator|Control group|The control group will comprise 28 participants with chronic non-specific low back pain. The treatments of this group will include anterior-posterior mobilization based on the Maitland technique for the lumbar spine plus sham dry needling and routine physiotherapy. Based on the findings of the patient evaluation, the severity, rhythm, time, the degree of mobilization and the place of force (spine or lamina) will be determined. For sham dry needling The needles will be inserted subcutaneously and there will be no local twitch response. Then the needles will be left in place for 20 minutes. Routine physical therapy will include low-level laser therapy and motor control training. The treatment will last 4 weeks, 8 sessions, twice a week.
89359125|NCT04492852|Active Comparator|Interventional Arm 2|After total knee replacement, the skin closure of the patients in this group will be done using staple sutures.
89359126|NCT01336374||Greened Vacant Lot|A cluster of vacant lots is greened. People living around this area make up this cohort.
89359127|NCT01336374||Control Site|The control site is a cluster of vacant lots that will not be greened. The people living around these lots make up the control group.
89359128|NCT03774953|Experimental|Intervention group|protein and vitamin supplementation
89534338|NCT02917798||Genetic Testing in Ovarian ,Prostate or Pancreas Cancer|This study is a prospective single-arm study to examine how an alternative clinical genetics cancer care delivery model affects ovarian, prostate or pancreas cancer patients' cognitions, emotions, and behaviors. Participants will be contacted 1 week (+/- 1 week) (Assessment #2; and 3 months (+/- 2 weeks) (Assessment #3;) following the telephone post-test counseling session to complete the follow-up assessments. These assessments will measure psychological and behavioral study constructs.
88830932|NCT02296099|Experimental|Liposomal Bupivacaine|The placement of the retropublic sling will be placed in routine fashion under general anesthesia. If randomized to liposomal bupivacaine, the standard 20 milliliter (ml) vial (266mg dose) will be diluted with 10ml of preservative-free, sterile normal saline (0.9%) for injection to a reconstituted volume of 30ml. At the completion of the procedure, and at least 20 minutes after the injection of 30ml lidocaine with epinephrine (routine for the surgical procedure), those subjects in the liposomal bupivacaine arm will have the 30ml dilutional volume injected. 10ml will be injected into the vaginal epithelium in the mid-urethral area and 10ml will be injected into each of the trocar paths through the suprapubic incisions bilaterally. An aspiration and moving needle technique will be employed.
88830933|NCT02296099|Placebo Comparator|Saline Placebo|The placement of the retropublic sling will be placed in routine fashion under general anesthesia. At the completion of the procedure, and at least 20 minutes after the injection of 30ml lidocaine with epinephrine (routine for the surgical procedure), those subjects in the saline placebo arm will receive 30ml normal saline injected. 10ml will be injected into the vaginal epithelium in the mid-urethral area and 10ml will be injected into each of the trocar paths through the suprapubic incisions bilaterally. An aspiration and moving needle technique will be employed.
88830934|NCT05455073|Experimental|Full package intervention arm|"Dietary Supplement of Weekly Iron and Folic Acid (WIFA) Supplementation (containing 60 mg of elemental iron and 2800 µg of folic acid) and;~Associated behavior change intervention (BCI) to change the knowledge, attitudes, and practices of nutrition (including dietary diversity), IFA, deworming~Water, sanitation and hygiene (WASH) intervention: ensure availability (or provision) of water, sanitation, and hygiene supplies~Menstrual hygiene management (MHM) intervention: support for menstrual hygiene, including sale of menstrual products in schools~Associated behavior change intervention (BCI) to change the knowledge, attitudes, and practices (KAP) of WASH and menstrual hygiene management (MHM)"
88830935|NCT05455073|Experimental|Limited package intervention arm|"Dietary Supplement of Weekly Iron and Folic Acid (WIFA) Supplementation (containing 60 mg of elemental iron and 2800 µg of folic acid; weekly school provision of WIFA tablets) and;~Associated behavior change intervention (BCI) to change the knowledge, attitudes, and practices of nutrition (including dietary diversity), IFA, deworming"
88830936|NCT05455073|No Intervention|Control|No intervention.
88830937|NCT04334993|Experimental|Blinatumomab pre-transplant to high risk Ph-negative ALL pts.|Patients designated high risk based on protocol will receive 2 cycles of therapy followed by allogeneic transplantation. Patients ≥45 kg (fixed dose): Cycles 1 and 2: 28 mcg daily administered as a continuous infusion on days 1 to 28 of a 6-week treatment cycle.
88830938|NCT04335071|Experimental|Actemra|Patients get one dose (= 8 mg/kg bodyweight, max. single dose 800 mg) Actemra® (active ingredient: TCZ) intravenously in 100 mL NaCl 0.9% after confirmation of progressive dyspnoea. Infusion time: 60 min. The procedure is repeated once if no improvement in the 8-point WHO scale is observed.
88830939|NCT04335071|Placebo Comparator|Placebo|The placebo-controlled intervention is one dose (100 mL) NaCl 0.9% intravenously administered after confirmation of progressive dyspnoea. Infusion time: 60 min. The procedure is repeated once if no improvement in the 8-point WHO scale is observed.
88830940|NCT05349929|Experimental|Ibuprofen|Ibuprofen(Gelofen) 400mg capsules, Dana pharma company, every 6hours
88830941|NCT05349929|Experimental|Anahil|Bromelain(Anahil) 200 mg capsules, Permon Amin Health Company,every 6hours
88830942|NCT04335227|Experimental|Yoga therapy group|Structured yoga therapy program for 60 minutes six days per week for 12 weeks and nutritional management uniquely prepared by dietitian
88830943|NCT04335227|Experimental|Aerobic exercise group|Aerobic training of moderate intensity for 30-60 minutes six days per week for 12 weeks and nutritional management uniquely prepared by dietitian
88830944|NCT04335227|Experimental|Combined yoga therapy and aerobic exercise group|Combined yoga therapy for three days and vigorous aerobic exercise program for three days with nutritional management uniquely prepared by dietitian
89534339|NCT02912507|Experimental|Investigational Enlighten Device|Tattoo removal treatments with the investigational Cutera enlighten laser
88830945|NCT04335227|Active Comparator|Control group|Nutritional management uniquely prepared by dietitian
88830946|NCT04737941|Experimental|Immediate foam sclerotherapy|Immediate foam sclerotherapy group patients are treated with immediate (first-visit) foam sclerotherapy and truncal vein endothermal ablation is scheduled when anatomy is suitable. Compression therapy is started immediately.
88830947|NCT04737941|Active Comparator|Scheduled treatment|Scheduled treatment group patients are treated with scheduled endovenous ablation including foam sclerotherapy and/or endothermal ablation depending on reflux anatomy. Compression therapy is started immediately.
88830948|NCT00371969|Active Comparator|1 - enhanced MI|Enhanced brief motivational interview (including an IVR component for alcohol self-monitoring purposes)
88830949|NCT00371969|Active Comparator|2- standard MI|The intervention consists of a standard motivational interview or viewing a DVD on HIV self-care.
88830950|NCT05455307|Experimental|single arm|single arm without placebo control
88830951|NCT04335851|Experimental|Physical Activity Group|"Individuals in this group will be given walk at home exercise video made by American Hearth Association. Videos for each week will be chosen by therapist. They will be asked to do exercise 3 days a week for 4 weeks by following the videos. The intensity and duration of the exercises will be gradually increased by therapists each week. Exercise follow-ups will be done over the phone and by asking individuals to keep an exercise diary."
88830952|NCT04335851|No Intervention|Control Group|Physically inactive individuals will be included to study as control. Individuals will be asked to continue their daily routines.
88830953|NCT04334447|Experimental|Intervention Group Patients|All HF patients that experience a HF education session
88830954|NCT04336085|Experimental|caudal group|Caudal block using ultrasound guidance. the sacral hiatus will be visualized at the level of the sacral cornus by employing the linear transducer of ultrasound machine and the depth and gain will be adjusted for optimal visual quality.the needle will be advanced toward the upper third of the sacrococcygeal ligament. The needle advancement will be terminated immediately after penetrating the sacrococcygeal ligament.
88830955|NCT04336085|Experimental|PENG group|The ilio-pubic eminence (IPE), the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle will be visualized using a linear ultrasound probe. the needle will be introduced in a lateral to medial fashion in an in-plane approach to place the tip of the needle in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly.
88830956|NCT04335695|Other|Vascular Rehabilitation and Follow Up|All subjects will be enrolled in a 6-12 Vascular Rehab Program (VRP) and then be followed for one year following discharge from the VRP.
88830957|NCT04822883|Experimental|Dose-escalation - RL-007|Each cohort will include a single dose-strength. Within each cohort, the sequence of active capsules and matching placebo capsules will be varied and unknown to the participant.
88830958|NCT04822883|Placebo Comparator|Dose-escalation - matching Placebo|Within each cohort, the sequence of active capsules and matching placebo capsules will be varied and unknown to the participant.
88830959|NCT02331589|Active Comparator|Korea Red Ginseng (KRG)|KRG capsule (3,000 mg/day) for 3 weeks
88830960|NCT02331589|Placebo Comparator|Placebo (for KRG)|placebo (for KRG) for 3 weeks
88830961|NCT05427227||Gastrointestinal cancer (GI) patients receiving immunotherapy|
88830962|NCT05427227||GI patients receiving anti-HER2 therapy|
88830963|NCT05427227||GI patients receiving anti-CLDN18.2 therapy|
88830964|NCT04100837||transportal group|swabs will be obtained from subcutaneous tissue at antromedial portal track in transportal technique (femoral tunnel drilling) , before and after the instrumentation and femoral screw insertion, a control sample will be taken at antrolateral track in both techniques, then samples will be sended to the lab to be studied.
88830965|NCT04100837||transtibial group|swabs will be obtained from subcutaneous tissue at antromedial portal track in transtibial technique (femoral tunnel drilling), before and after the instrumentation and femoral screw insertion, a control sample will be taken at antrolateral track in both techniques, then samples will be sended to the lab to be studied.
88830966|NCT05421455|Other|Biologic group|treat paticipants with up to 2 biologics
88830967|NCT05421455|Other|Surgery group|treat paticipants with surgery
88830968|NCT05414591|Experimental|Sequence group A|DWP16001 A mg 1T
88830969|NCT05414591|Experimental|Sequence group B|DWP16001 B mg 3T
88830970|NCT04814225|Experimental|Pea Protein Powder|Participants will be instructed to mix the IP with 250 mL room temperature water once/day for 12 weeks.
88830971|NCT04814225|Experimental|Pea & Oat Protein Powder|Participants will be instructed to mix the IP with 250 mL room temperature water once/day for 12 weeks.
88830972|NCT04814225|Experimental|Oat Protein Powder|Participants will be instructed to mix the IP with 250 mL room temperature water once/day for 12 weeks.
88830973|NCT04814225|Active Comparator|Whey Protein Isolate|Participants will be instructed to mix the IP with 250 mL room temperature water once/day for 12 weeks.
88830974|NCT02986867|Experimental|SAbR|SAbR treatment of lesions
88830975|NCT05146999|Active Comparator|Active arm - QM1114-DP|a Botulinum Toxin Type A (BoNT-A)
88830976|NCT05146999|Placebo Comparator|Inactive arm - Placebo|
88830977|NCT03029221||Marriage & Relationship Ed Skills-Couples|This group will receive the PREP 8.0 curriculum developed by PREP. In Years 2-5, 4 7-week class series will be held each year in Clearfield and Centre Counties (PA); 32 adults will be served each year. In Year 1, 8 adults will be served. Couples will receive 11 hours of curriculum instruction. This group will also receive two 30-minute presentations on available financial management, and job and career advancement services through two partnering organizations (CareerLink and Central PA Community Action, Inc.). Participants will also have access to optional parenting skills training provided by CAS (i.e., Triple P - Positive parenting Program). Referrals to community agencies based on individual/family needs will be provided by participant's case managers, as needed.
88875475|NCT05044182|Experimental|Decompression and drainage seton|Decompress the pressure in intersphincteric space,and drainage seton will be put around the external anal sphincter.
89359129|NCT03774953|No Intervention|Control group|No supplementations
89177988|NCT00847379|Experimental|Overall Participants: High-Dose Ataluren|All participants will receive ataluren suspension orally three times a day (TID), 20 mg/kg at morning, 20 mg/kg at midday, and 40 mg/kg at evening (total daily dose 80 mg/kg) for up to 96 weeks in this study. Any participant who was receiving a reduced dose of ataluren at the end of treatment visit in study PTC124-GD-007-DMD, will be initiated ataluren therapy in this extension study at the 5-, 5-, and 10-mg/kg dose level; dose will be increased to 10, 10, and 20 mg/kg at Week 6 and to 20, 20, and 40 mg/kg at Week 12, if the preceding dose level is well tolerated.
89177989|NCT00820144|Experimental|1|voie nasale 0.25 mg
89177990|NCT00820144|Experimental|2|0.5mg of CTB by oral way
89177991|NCT00820144|Experimental|3|1mg of dukoral by oral way
89177992|NCT00820144|Experimental|4|0.25mg of CTB by sublingual way
89177993|NCT00820144|Experimental|5|1mg of CTB by sublingual way
89177994|NCT00827710|Active Comparator|1|patients who received point-of-care report cards and were listed on provider performance report card
89177995|NCT00827710|Active Comparator|2|Patients who received point-of-care diabetes report cards but were not listed on provider performance report card
89177996|NCT00827710|Active Comparator|3|Patients who did not receive point-of-care report card but who were listed on provider performance report card
89177997|NCT00827710|No Intervention|4|Patients who did not receive point of care report card and who did were not listed on provider performance report card
89177998|NCT00847301||Renal Impairment|
89177999|NCT00698633||M2a- Taper™ Hip System|M2a- Taper™ Hip System
89178000|NCT00624520|Active Comparator|Cognitive Behavioral Stress Management|10 week program of Cognitive Behavioral Stress Management (CBSM) group sessions
89178001|NCT00624520|Active Comparator|Patient Education|10 week program of once weekly Patient Education group sessions
89178002|NCT04118075|Experimental|PT-CY-FK +/- ATG|GVHD prophylaxis: PT-CY followed by tacrolimus for all patients. low-dose ATG for patients with unrelated or haplo-identical transplantation.
89178003|NCT00698711|Experimental|1|"Three groups of 5 patients enrolled sequentially comprised from will receive MUC-2-KLH vaccines at the following g amounts of MUC-2-KLH per vaccination.~10 + 100 μg QS21 30 + 100 μg QS21 3 + 100 μg QS21"
89178004|NCT04122209|Experimental|HIIE-First|60-min of exercise split into; firstly 30-min HIIE (10 x 1min of PPO, followed by 2-min rest). Secondly 30-min of continuous exercise (50% peak maximal oxygen uptake).
89178005|NCT04122209|Experimental|Continuous-First|60-min of exercise split into; firstly 30-min of continuous exercise (50% peak maximal oxygen uptake). Secondly 30-min HIIE (10 x 1min of PPO, followed by 2-min rest)
89178006|NCT00847145|Experimental|12B12M (1a)|Previously in the parent study subjects had received three doses of rMenB+OMV NZ and routine vaccine at 2, 4 and 6 months of age,respectively. These subjects received a booster (fourth) dose at 12 months of age concomitantly with one dose of MMRV vaccine in the present study.
88830978|NCT03029221||Marriage & Relationship Ed Skills-Individuals|This group will receive the Within My Reach curriculum developed by PREP. In Years 2-5, 4 9-week class series will be held each year in Clearfield and Centre Counties (PA); 32 adults will be served each year. In Year 1, 8 adults will be served. Participants will receive 15 hours of curriculum instruction. This group will also receive two 30-minute presentations on available financial management, and job and career advancement services through two partnering organizations (CareerLink and Central PA Community Action, Inc.). Participants will also have access to optional parenting skills training provided by CAS (i.e., Triple P - Positive parenting Program). Referrals to community agencies based on individual/family needs will be provided by participant's case managers, as needed.
88830979|NCT03029221||Pre-Marital Ed and Marriage Skills|This group will receive healthy marriage and relationship education to pre-marital couples using Within Our Reach 8 Hours curriculum developed by PREP. In Years 2-5, 9 10-hour weekend workshops will be held each year in nine central PA counties; 72 adults will be served each year. In Year 1, 24 adults will be served.
88830980|NCT03029221||Marriage Enhancement and Marriage Skills|This group will receive healthy marriage and relationship education to married couples using Within Our Reach 8 Hours curriculum developed by PREP. In Years 2-5, 9 12-hour weekend workshops will be held each year in nine central PA counties; 174 adults will be served each year. In Year 1, 60 adults will be served.
88830981|NCT04787939|Experimental|Early Feeding Arm|Early Feeding Group
88830982|NCT04757675|Experimental|0.3 SK iv|0.3 μg/kg intravenous injection s-ketamin
89534340|NCT02912507|Active Comparator|Cynosure PicoSure 755 nm laser|Tattoo removal treatments with the Cynosure PicoSure 755 nm laser
89534341|NCT02911714|Experimental|CEUS and Delayed Graft Function|On the first post-operative day after kidney transplantation, recipients enrolled in the study will undergo CEUS using Lumason to quantify microvascular perfusion within the cortical and medullary zones of the kidney allograft for comparison to the concentration of neutrophil gelatinase-associated lipocalin (NGAL, an early biomarker of acute kidney injury) measured from recipient urine simultaneously collected on the first post-operative day.
89178007|NCT00847145|Experimental|12B13M (1b)|Previously in the parent study subjects had received three doses of rMenB+OMV NZ and routine vaccine at 2, 4 and 6 months of age, respectively. These subjects received a booster (fourth) dose at 12 months and one dose of MMRV vaccine at 13 months of age in the present study.
89178008|NCT00847145|Experimental|12M13B15B (2a)|Previously in the present study subjects had received routine vaccine at 2, 4 and 6 months of age respectively. These subjects received MMRV vaccine at 12 months of age and two catch-up doses of rMenB+OMV NZ vaccine at 13 and 15 months of age in the present study.
89534342|NCT02911714|Experimental|CEUS and Biopsy-Proven Acute Rejection|We will identify and enroll kidney transplant recipients in need of clinically-indicated duplex ultrasounds and possible biopsy to evaluate allograft dysfunction during hospital admissions and outpatient follow-up. Immediately after the duplex ultrasound, we will perform CEUS using Lumason for allograft perfusion measurements to determine its potential association with biopsy-proven acute rejection according to the most recent Banff criteria.
88830983|NCT04757675|Experimental|0.5 SK iv|0.5 μg/kg intravenous injection s-ketamin
88830984|NCT04757675|Experimental|2 SK in|2 μg/kg intranasal s-ketamin
88830985|NCT04757675|Experimental|1 SK in + 1 DEX in|1 μg/kg intranasal s-ketamin + 1 μg/kg intranasal dexmedetomidine
89178009|NCT00847145|Experimental|12M12B14B (2b)|Previously in the parent study subjects ahd received three doses of routine vaccine at 2, 4 and 6 months of age, respectively. These subjects received two catch-up doses of rMenB+OMV NZ at 12 and 14 months of age and one dose of MMRV vaccine given concomitantly at 12 months of age in the present study.
88830986|NCT04757675|Experimental|0.5 SK in + 2 DEX in|0.5 μg/kg intranasal s-ketamin + 2 μg/kg intranasal dexmedetomidine
88830987|NCT04731311|Other|Usability Evaluation of the BrightGo system|Participants with rate the device in each of 4 usability evaluation sessions.
88830988|NCT04726163|No Intervention|Tele-expertise|Basal-bolus insulin treatment with adaptation of insulin doses according to continuous glucose measurement
88830989|NCT04726163|Experimental|Standard|Standard treatment and adaptation of insulin doses according to the usual management of the unit
89178010|NCT00847145|Experimental|12B12M (3a)|Previously in the parent study subjects had received three doses of rMenB+OMV NZ at 2, 4 and 6 months of age respectively. These subjects had received one booster (fourth) dose of rMenB+OMV NZ at 12 months of age concomitantly with one dose of MMRV vaccine in the present study.
89178011|NCT00847145|Experimental|12B13M (3b)|Previously in the present study subjects had received three doses of rMenB+OMV NZ at 12 months of age respectively. These subjects one booster (fourth) dose of rMenB+OMV NZ at 12 months of age and one dose of MMRV vaccine at 13 months of age in the present study.
89534343|NCT02907502|Experimental|Experimental formula|Young-child formula with low protein content
89534344|NCT02907502|Active Comparator|Control formula|Young-child formula with protein content similar to that of cow's milk
89534345|NCT02851173|Experimental|LLLT|Six weekly sessions of LLLT. The treatment will consist of applying light of a specific wavelength (1064 nm) using a laser diode supplied by Cell Gen Therapeutics, LLC (CG-5000 laser, HD Laser Center, Dallas, TX, USA). Each laser stimulation session will consist of total 8 min, with eight 1 min/cycle treatments alternating between two locations on the right forehead.
89534346|NCT02851173|Active Comparator|Placebo|The control group will undergo the same procedure as the treatment group, but will receive brief (5-s) stimulation to the intended site on the forehead, followed by 55 s of no stimulation, for each 1-min cycle. Thus the control group will receive approximately 1/12th of the cumulative energy density as the treatment group. This is sufficient to provide a brief sensation of slight heat (as active placebo) at the onset of each one-minute cycle, using a fraction of the energy received by the experimental group.
89534347|NCT02829437||Retrospective Observational Group|Patients who received treatment for EST Patients with EST diagnosis prior August 2016
89534348|NCT02829437||Prospective Observational Group|Patients who will receive treatment for EST Patients with EST diagnosis after August 2016
89534349|NCT02803541|Experimental|12 day mainstream summer camp experience|The 12 day mainstream camp experience involves increased exercise from baseline at home. Can this exercise and peer contact improve physical endurance as measured by the 6 minute walk test and self concept as measured by a modified Harter scale
89534350|NCT02754856|Experimental|Treatment (tremelimumab, durvalumab)|Patients receive tremelimumab IV over 1 hour and durvalumab IV over 4 hours during week 11. Between weeks 15 and 17, patients undergo liver surgery. Patients then receive durvalumab IV over 1 hour during weeks 21, 25, 29, and 33.
88875476|NCT05044182|Experimental|Cutting seton|Cutting seton will be put around the internal and external anal sphincter.
89000922|NCT02963909|Experimental|ZPIV in JEV (IXIARO®)|Two 0.5mL doses of IXIARO® (Valneva) Days 1 and 29 followed by two ZPIV or placebo doses will be administered on Days 112 and 140. N=20 ZPIV, N=5 placebo. Subjects who consent to a third ZPIV dose will receive it on Day 336
89178012|NCT00847145|Experimental|12B12M_C (4a)|Previously in the parent study subjects had received three doses of Meningococcal C vaccine and routine vaccine at 2, 4 and 6 months of age respectively. These subjects had received one single dose of rMenB+OMV NZ at 12 months of age concomitantly with one dose of MMRV vaccine in the present study.
89178013|NCT00847145|Experimental|12B13M_C (4b)|Previously in the parent study subjects had received three doses of Meningococcal C vaccine and routine vaccine at 2, 4 and 6 months of age. These subjects received one single dose o rMenB+OMV NZ at 12 months of age and one dose of MMRV vaccine at 13 months of age in the present study.
89534351|NCT02734888|Other|Healthy control|"Will undergo PET scan as a negative control"
89534352|NCT02734888|Other|Tobacco cigarette smoker|"Will undergo PET scan as a positive control"
89534353|NCT02734888|Other|E-cigarette user|Will undergo PET scan
89534354|NCT02713269|Experimental|Treatment (thermal ablation, SSRS)|Patients undergo thermal ablation and CT-guided SSRS via intensity-modulated radiation therapy on different dates within a 1-14 day window. The order of treatment is at the doctor's discretion.
89534355|NCT02710097|Experimental|Active THC and Placebo Ethanol|
89534356|NCT02710097|Experimental|Active THC and Active Ethanol|
88816801|NCT05229055|Active Comparator|Intranasal ketamine|Ketamine solution 250 mg/5ml was used. It was applied intranasally using a nasal spray pump whereeach spray delivered approximately 0.4 ml of solution corresponding to 20 mg of ketamine. After initial evaluation, each patient having the inclusion criteria receives one pulverisation (0.4 ml) per nostril of ketamine corresponding to a total dose of 20 mg of ketamine. Ketamine dosing was based on previous reports of intranasal ketamine use in ED patients, doses ranged from 0.45mg/kg to 1.25mg/kg (9).
88816802|NCT05229055|Active Comparator|subcutanous ketamine|Ketamine dosing by subcutanous route was based on previous reports use for post operative pain management. . The results of these reports revealed that low-dose ketamine 20-60 mg (0.5mg/kg for patients weighing 40-120 kg) showed an over all decrease in either the amount of opioid used or the amount of pain experienced (10, 11).For our study, we decided to chose a dose of 20mg of ketamine for all patients administered via 1ml insulin syringe once subcutaneously.
88816803|NCT05222659||Urologic surgery patients|
88816804|NCT05198921|Experimental|rTMS + neurorehabilitation|
88816805|NCT05198921|Sham Comparator|sham rTMS + neurorehabilitation|
88816806|NCT05192707||Healthy Volunteers|TcPO2 measurement in the upper limb of healthy volunteers
88816807|NCT05192707||Patients with arterial disease in the upper limb and wound|Patients with arterial disease in the upper limb and wound (retrospective setting, research on data)
88816808|NCT05179109|Experimental|Robot-assisted laparoscopy|Surgery for deep endometriosis using robot-assisted laparoscopy.
88816809|NCT05179109|Active Comparator|Conventional laparoscopy|Surgery for deep endometriosis using conventional laparoscopy.
88816810|NCT05166057|Experimental|Telerehabilitation Group (TG)|TGr will be given online exercises, synchronized 2 days a week, and a home program for 1 day, accompanied by a physiotherapist, via videoconference on the group smartphone.
88816811|NCT05166057|Experimental|Video Group (VGr)|After 1 session of online simultaneous exercise training in the company of a physiotherapist via a smart phone videoconference to the VGr group, an exercise video including the exercises will be sent and the participants will be asked to do exercises 3 days a week. The cases will be asked to keep an exercise diary and the status of the diaries will be followed by calling once a week.
88816812|NCT05166057|Experimental|Standard pulmonary rehabilitation group (SGr)|The SGr group will be applied the pulmonary rehabilitation program with supervision in the hospital 2 days a week, and participants will be asked to do exercises at home for 1 day. The exercise period will be 8 weeks for both groups.
88816813|NCT05125497||In Vitro Fertilisation (IVF)-Patients|Patients aim to do In-Vitro-Fertilisation (IVF)
88816814|NCT05099445|Experimental|Group 1: Normal Renal Function|Participants with normal levels of renal function will receive a single oral dose of INCB000928 200 mg on Day 1.
88816815|NCT05099445|Experimental|Group 2: Mild Renal Impairment|Participants with mild levels of renal impairment will receive a single oral dose of INCB000928 200 mg on Day 1.
88816816|NCT05099445|Experimental|Group 3: Moderate Renal Impairment|Participants with moderate levels of renal impairment will receive a single oral dose of INCB000928 200 mg on Day 1.
88816817|NCT05099445|Experimental|Group 4: Severe Renal Impairment|Participants with severe levels of renal impairment will receive a single oral dose of INCB000928 200 mg on Day 1.
88816818|NCT05099445|Experimental|Group 5: Kidney Failure|Group 5 participants with ESRD maintained on HD will receive a single dose of INCB000928 on Day 1 of each of 2 treatment periods before (Period 1) and after (Period 2) an HD session in order to study the effects of HD on INCB000928.
88816819|NCT05097703|Experimental|Sleep Resource Intervention|"Half the participants in the study will be allocated to the intervention group. The resource will be sent to participants in this group, along with information about the research study and instructions for completing outcome measures. This will be followed up by a telephone call to ensure participants understand what is required of them and to answer any questions. All carers will be asked to complete questionnaires at baseline, immediately post intervention and at one-month post intervention; as well as sleep diaries for their child for the duration of the intervention period. Carers in the intervention group will also be asked to complete a diary of resource use as well as a feedback survey on their experience of using the resource.~Carers in the intervention group will be asked that they use the resource with their child at bedtime for a minimum of three-days a week over a one-month period."
88830990|NCT05288075|Experimental|Indacaterol/glycopyrronium Easyhaler® 85/43 µg/dose, inhalation powder, product variant A|Each subject will receive a single dose of 2 inhaled doses from Indacaterol/glycopyrronium Easyhaler product variant A in one of the four periods (cross-over) with concomitant charcoal administration (Carbomix granules). The total dose is 170 µg of indacaterol and 86 µg glycopyrronium (delivered doses).
88830991|NCT05288075|Experimental|Indacaterol/glycopyrronium Easyhaler® 85/43 µg/dose, inhalation powder, product variant B|Each subject will receive a single dose of 2 inhaled doses from Indacaterol/glycopyrronium Easyhaler product variant B in one of the four periods (cross-over) with concomitant charcoal administration (Carbomix granules). The total dose is 170 µg of indacaterol and 86 µg glycopyrronium (delivered doses).
88830992|NCT05288075|Experimental|Indacaterol/glycopyrronium Easyhaler® 85/43 µg/dose, inhalation powder, product variant C|Each subject will receive a single dose of 2 inhaled doses from Indacaterol/glycopyrronium Easyhaler product variant C in one of the four periods (cross-over) with concomitant charcoal administration (Carbomix granules). The total dose is 170 µg of indacaterol and 86 µg glycopyrronium (delivered doses).
88830993|NCT05288075|Active Comparator|Ultibro® Breezhaler® 85/43 µg inhalation powder, hard capsule|Each subject will receive 2 capsules of Ultibro® Breezhaler® (=Indacaterol/glycopyrronium) as a single dose in one of the four periods (cross-over) with concomitant charcoal administration (Carbomix granules). The total dose is 170 µg of indacaterol and 86 µg glycopyrronium (delivered doses).
88830994|NCT04424251|Experimental|stage I：HSK21542 0.4 μg/kg|Preoperative:0.4 μg/kg Postoperative:0.2 μg/kg； intravenous injection
88830995|NCT04424251|Experimental|stage I：HSK21542 1 μg/kg|Preoperative:1 μg/kg Postoperative:0.5 μg/kg；intravenous injection
88830996|NCT04424251|Experimental|stage I：HSK21542 0.5μg/kg|Postoperative: 0.5μg/kg；intravenous injection
88830997|NCT04424251|Experimental|stage I：HSK21542 1μg/kg|Postoperative: 1μg/kg；intravenous injection
88830998|NCT04424251|Experimental|stage II：HSK21542 0.5μg/kg|Postoperative: 0.5μg/kg；intravenous injection
89000923|NCT02963909|Experimental|ZPIV in YFV (YF-VAX®)|One 0.5mL dose of YF-VAX® (Sanofi Pasteur) on Day 1 followed by two ZPIV or placebo doses on Days 84 and 112. N=20 ZPIV, N=5 placebo. Subjects who consent to a third ZPIV dose will receive it on Day 308
88830999|NCT04424251|Experimental|stage II：HSK21542 1μg/kg|Postoperative: 1μg/kg；intravenous injection
88831000|NCT04424251|Placebo Comparator|Postoperative: Placebo|Placebo；intravenous injection
88831001|NCT05272787|Experimental|Left face TH Facial Moisturizer|All subjects will receive all the products. There will be a supervised application at the site on the baseline visit of the study. Then subjects will use all the products at home. The choice of the half face on which the product will be applied will be defined by a randomization list, prepared by the statistician in charge. If the TH Facial Moisturizer will be applied on the left side of the face, then the Facial Moisturizer B (Control) will be applied on the right side of the face. Lip moisturizer, facial wash and sunscreen will be applied in all arms of the study.
88831002|NCT05272787|Experimental|Right face TH Facial Moisturizer|All subjects will receive all the products. There will be a supervised application at the site on the baseline visit of the study. Then subjects will use all the products at home. The choice of the half face on which the product will be applied will be defined by a randomization list, prepared by the statistician in charge. If the TH Facial Moisturizer will be applied on the right side of the face, then the Facial Moisturizer B (Control) will be applied on the left side of the face. Lip moisturizer, facial wash and sunscreen will be applied in all arms of the study.
88831003|NCT05215145|Active Comparator|Baby Navigator Bundle|Parent and child measures, including a home observation video, will be collected at baseline, after which study staff will use Motivational Interviewing techniques to engage families to access resources and support (Baby Navigator Bundle) when parents first learn their child has social communication/language delay. Families may use the Baby Navigator Bundle as little or as much as desired. The Baby Navigator Bundle includes: Social Communication Growth Charts and the Baby Navigator webinar series.
88831004|NCT05215145|Active Comparator|Baby Navigator Bundle + Individual-ESI|At 18-21months of age, slow responders (communication delay still below the 10th percentile) will be randomized to continue the Baby Navigator Bundle with or without Individual-ESI, and responders (communication above the 10th percentile) will continue with Baby Navigator Bundle. For Individual ESI, trained coaches or family navigators will coach families using the Early Social Interaction (ESI) model. ESI teaches parents how to support their child's social communication, language, play and behaviors in everyday routines, activities, and places. Family navigators will also engage the family in the How-to Guide for Families online course. The family navigator will use zoom or other telehealth platform to meet with parents 1 time per week for 30-60 minutes per session for 6 months.
88831005|NCT04349683|Experimental|Experimental group|basic treatment combined with Jinshuibao
89534357|NCT02710097|Experimental|Placebo THC and Active Ethanol|
88831006|NCT04349683|Placebo Comparator|Control group|basic treatment and placebo
88831007|NCT05145569|Experimental|Carboplatin/paclitaxel + Bintrafusp alfa (M7824)|Bintrafusp alfa (M7824) (2400 mg flat dose IV), in combination with chemotherapy including carboplatin AUC 5 and paclitaxel 175 mg/m2 on Day 1 of the 21-day cycle
88831008|NCT05145569|Active Comparator|Carboplatin/paclitaxel|Carboplatin AUC 5 and paclitaxel 175 mg/m2 on Day 1 of the 21-day cycle
88831009|NCT05136833|Experimental|Group A (RUTI)|Subjets will receive one inoculation of the RUTI® vaccine at the same time as standard treatment is started. It will be administered subcutaneously in the deltoid region at a dose of 25 µg of fragmented, purified and liposomed heat-inactivated Mycobacterium tuberculosis bacilli (FCMtb) in an injection volume of 0.3 mL
89000924|NCT04637347|Other|IP-ISV|In plane infraclavicular subclavian vein catheterization
89178014|NCT02613143||Surgery|
89178015|NCT00700193|Other|Group A|Equal to or greater 6 months to less than 3 years old
89178016|NCT00700193|Other|Group B|Equal to or greater 3 years to less than 9 years old
89534358|NCT02710097|Placebo Comparator|Placebo THC and Placebo Ethanol|
89534359|NCT02709954|Experimental|Active THC and Placebo Ethanol|
89534360|NCT02709954|Experimental|Active THC and Active Ethanol|
89534361|NCT02709954|Experimental|Placebo THC and Active Ethanol|
89534362|NCT02709954|Placebo Comparator|Placebo THC and Placebo Ethanol|
89534363|NCT02689258|Experimental|Part A, Cohort A: HTX-011A|HTX- 011A (bupivacaine/meloxicam), 200 mg/6 mg via injection
89534364|NCT02689258|Placebo Comparator|Parts A and B, Cohort B: Saline Placebo|Saline placebo via injection
88831010|NCT05136833|Placebo Comparator|Group B (Placebo)|Subjets will receive one inoculation of normal saline at the same time as standard treatment is started. It will be administered subcutaneously in the deltoid region.
88831011|NCT04547725|Experimental|CRS-IP (Arm-A)|Stage IV gastric cancer with limited peritoneal carcinomatosis (peritoneal carcinomatosis index [PCI] ≤ 10)
88831012|NCT04547725|Experimental|CRS-IP (Arm-B)|Stage IV gastric cancer with positive peritoneal wash cytology (CY1/P0)
88831013|NCT04622345|Experimental|VSJ-110 Solution|
88831014|NCT04622345|Placebo Comparator|Placebo Solution|
88831015|NCT04608617||Pre-Viz|Pre-Viz LVO implementation patient data utilized as a control data set
88831016|NCT04608617||Post-Viz|Patient data collected post-Viz LVO implementation
88831017|NCT02292433|Experimental|PF-04937319|PF-04937319 Split dose
88831018|NCT02292433|Placebo Comparator|Placebo|Placebo split dose
88831019|NCT03907631||Acute Severe Ulcerative Colitis|Patients hospitalised for acute severe ulcerative colitis will be invited to participate. Participants will be treated at the discretion of their treating physicians as per standard of care. We expect some participants will undergo an endoscopic assessment, some participants will be treated with standard versus accelerated infliximab dosing, permitting comparisons, in addition to other treatment strategies.
88831020|NCT04939805|Experimental|Selective CRP apheresis as an adjunct to standard of care|Apheresis using the PentraSorb®-CRP system will be performed at day 1, 2 and 3 after PCI.
88831021|NCT04939805|No Intervention|Standard of care according to current guideline recommendations|
88831022|NCT04334213|Experimental|Sequence 1|"Period 1: CKD-501 - A single oral dose of 1 tablet under fasting conditions for 5 days.~Period 2: CKD-501, D745, D150 - A single oral dose of 4 tablets under fasting conditions for 5 days (CKD-501: 1 tablet, D745: 1 tablet, D150: 2 tablets)."
88831023|NCT04334213|Experimental|Sequence 2|Period 1: CKD-501, D745, D150 - A single oral dose of 4 tablets under fasting conditions for 5 days (CKD-501: 1 tablet, D745: 1 tablet, D150: 2 tablets). Period 2: CKD-501 - A single oral dose of 1 tablet under fasting conditions for 5 days
88831024|NCT04334213|Experimental|Sequence 3|Period 1: D745, D150 - A single oral dose of 3 tablets under fasting conditions for 5 days (D745: 1 tablet, D150: 2 tablets). Period 2: CKD-501, D745, D150 - A single oral dose of 4 tablets under fasting conditions for 5 days (CKD-501: 1 tablet, D745: 1 tablet, D150: 2 tablets).
88831025|NCT04334213|Experimental|Sequence 4|Period 1: CKD-501, D745, D150 - A single oral dose of 4 tablets under fasting conditions for 5 days (CKD-501: 1 tablet, D745: 1 tablet, D150: 2 tablets). Period 2: D745, D150 - A single oral dose of 3 tablets under fasting conditions for 5 days (D745: 1 tablet, D150: 2 tablets).
88831026|NCT05077579||metabolically abnormal overweight & obese|
88831027|NCT05077579||metabolically normal overweight|
88831028|NCT05077579||obese and metabolically normal lean|
88831029|NCT04885595|Active Comparator|Forceps-Cryo 1.1 mm|Forceps biopsy following cryobiopsy with a 1.1mm cryoprobe are obtained within the same session
88831030|NCT04885595|Active Comparator|Forceps-Cryo 1.7 mm|Forceps biopsy following cryobiopsy with a 1.7mm cryoprobe are obtained within the same session
89534365|NCT02689258|Experimental|Part A, Cohort C: HTX-011B|HTX- 011B (bupivacaine/meloxicam), 200 mg/6 mg via injection
88831031|NCT02986477|Other|Contrast Ultrasound|Patients with vesicoureteral reflux will receive contrast ultrasound via Foley catheter for study of vesicoureteral reflux.
88831032|NCT03812549|Experimental|Sintilimab Combined with SBRT and LDRT|"Part A-Dose escalation cohort. DOSE LEVEL: Stereotactic body radiation therapy (SBRT) dose at 30 Gy/3f + Low Dose Radiotherapy (LDRT) dose from 2 Gy to 10Gy + anti-PD-1 inhibitor 200mg.~Part-B - Expansion cohort. SBRT dose at 30 Gy/3f + LDRT + anti-PD-1 inhibitor 200mg, LDRT dose at MTD determined in Part A ."
88831033|NCT03763175|Active Comparator|SYN-010 21 mg|Enrolled subjects will be screened and randomized into the three study arms in a 1:1:1 ratio. 50 subjects with constipation-predominant irritable bowel syndrome (IBS-C) will be administered a 12-week course of lovastatin (21 mg PO QD). Study activities will be the same across all three arms.
89534366|NCT02689258|Experimental|Part A, Cohort D: HTX-011B|HTX- 011B (bupivacaine/meloxicam), 400 mg/12 mg via injection
89178017|NCT04117529|Experimental|Experimental Arm|Pemphigus or other autoimmune diseases.
89178018|NCT02612987|Experimental|iCBT|
89178019|NCT00912977||Group 1|Groups are defined by another study
89178020|NCT00912977||Group 2|Groups are defined by another study
89178021|NCT00912977||Group 3|Groups are defined by another study
89178022|NCT00701753||Olanzapine|Subjects treated with olanzapine as part of their routine clinical care
89178023|NCT00701753||Risperidone|Subjects treated with risperidone as part of their routine clinical care
89178024|NCT00701753||Quetiapine|Subjects treated with quetiapine as part of their routine clinical care
89178025|NCT00846521|Experimental|Acarbose|At baseline, subjects underwent an OGTT and 72 hr of out-patient continuous glucose monitoring. They were treated with acarbose (50 mg with meals three times daily) for 6 weeks and repeat 72 hr CGMS profiles were obtained at the end of the study.
89178026|NCT00698945|Active Comparator|2|Alphagan
89178027|NCT00698945|Active Comparator|1|Istalol and Optive
89178028|NCT00862823|Active Comparator|Atripla Tablet|Drug exposure after administration of Atripla Tablet
89178029|NCT00862823|Experimental|Atripla Liquid|Drug exposure after administration of an extemporaneously prepared liquid formulation of Atripla
89178030|NCT00790842|Experimental|Group A - CrCl 30-60 mL/min|Creatinine clearance 30 - 60 mL/min, lenalidomide dose determined in phase I, dexamethasone 40 mg orally days 1, 8, 15 and 22 of a 28 day cycle, and anticoagulants.
89178031|NCT00790842|Experimental|Group B, CrCl < 30 mL/min|Creatinine clearance < 30 mL/min, not on dialysis, lenalidomide dose determined in phase I, dexamethasone 40 mg orally days 1, 8, 15 and 22 of a 28 day cycle, and anticoagulants.
89178032|NCT00790842|Experimental|Group C, CrCl < 30 mL/min, on dialysis|Creatinine clearance < 30 mL/min and on dialysis, lenalidomide dose determined in phase I, dexamethasone 40 mg orally days 1, 8, 15 and 22 of a 28 day cycle, and anticoagulants.
89178033|NCT04107012|Experimental|Clear Aligner|Group 1 treated with clear aligners
89178034|NCT04107012|Active Comparator|Fixed appliance|Group 2 treated with conventional fixed appliances
89178035|NCT04104204|Sham Comparator|Intrathecal morphine|Intrathecal morphine 0.1 mg, A sham subcutaneous injection of 0.5 ml normal saline at inguinal area
89178036|NCT04104204|Experimental|Ultrasound guided supra-inguinal fascia iliaca block|0.25% bupivacaine 40 ml
89178037|NCT04107324|Other|PVE (Portal vein embolisation)|Standard of care when FLR is small.
89178038|NCT04107324|Experimental|ARAPS (Portal vein embolisation and associating RFA)|Experimental arm with PVE combined with RFA to induce accelerated liver hypertrophy.
89178039|NCT00915486|Experimental|Good Standard of Care (GSoC)|Twice per week
89178040|NCT00915486|Experimental|GSoC + vehicle|Twice per week
89178041|NCT00915486|Experimental|GSoC + I-020201 (33microg)|Twice per week
89178042|NCT00915486|Experimental|GSoC + I-020201 (100microg)|Twice per week
89178043|NCT00915486|Experimental|GSoC + I-020201 (300microg)|Twice per week
89178044|NCT02602392|Experimental|Lungtropolis|A game-based website for children with asthma aged 5-10 to teach basic self-management skills and a comprehensive adjunct informational website for parents
89178045|NCT02602392|Active Comparator|Asthma educational booklet|Text-based asthma education booklet for parents and children in PDF format
89178046|NCT00574288|Experimental|Dose Escalation: Daratumumab|
89178047|NCT00574288|Experimental|Dose Expansion: Daratumumab|
89178048|NCT05568654|Active Comparator|Rapid diagnostic testing (RDT)|Rapid diagnostic testing: Eligible patients at hospitals randomized to this arm will undergo testing for viral pathogens (from November-April) and pneumococcal UAT testing. If the patient is not being admitted to the ICU, and the patient has an admitting diagnosis of pneumonia, the form will append orders for viral testing and UAT testing to providers in hospitals randomized to receive it.
89178049|NCT05568654|Active Comparator|Pharmacist-led de-escalation|Pharmacist-led de-escalation: Another CDSS algorithm will identify CAP patients who meet study criteria and have negative culture results for > 48 hours and generate a list for the clinical pharmacist, who will be a member of the study team. The alerts will be audited by the pharmacist daily on weekdays at a centralized location. The pharmacist will attempt to determine whether each patient is clinically stable. The validated measures of clinical stability in patients with CAP are a) resolved vital sign abnormalities b) normal mental status c) ability to eat. If the patient appears stable, the pharmacist will communicate their recommendations for de-escalation to the clinical providers via a phone call or page.
89178050|NCT05568654|Active Comparator|Rapid diagnostic testing (RDT) and Pharmacist-led de-escalation|"Rapid diagnostic testing: Eligible patients at hospitals randomized to this arm will undergo testing for viral pathogens (from November-April) and pneumococcal UAT testing. If the patient is not being admitted to the ICU, and the patient has an admitting diagnosis of pneumonia, the form will append orders for viral testing and UAT testing to providers in hospitals randomized to receive it.~Pharmacist-led de-escalation: Another CDSS algorithm will identify CAP patients who meet study criteria and have negative culture results for >48-hours and generate a list for the clinical pharmacist, who will be a member of the study team. The alerts will be audited by the pharmacist daily on weekdays at a centralized location. The pharmacist will attempt to determine whether each patient is clinically stable. If the patient appears stable, the pharmacist will communicate their recommendations for de-escalation to the clinical providers via a phone call or page."
89178051|NCT05568654|No Intervention|Usual care (no intervention)|Usual care
89178052|NCT00827788|Active Comparator|iodixanol|Iso-osmolar contrast medium (Iodixanol) will be administered during PCI
89178053|NCT00827788|Active Comparator|iopromide|Low-osmolar contrast medium (Iopromide) will be administered during PCI
89178054|NCT00827866|Other|1|Counselor-Initiated Tobacco Quit Line Group QL where the counselor contacts the client with a standardized intervention protocol)
89178055|NCT00827866|Other|2|Self-Paced Tobacco Quit Line Group which leaves the calling up to participants
88831034|NCT03763175|Active Comparator|SYN-010 42 mg|Enrolled subjects will be screened and randomized into the three study arms in a 1:1:1 ratio. 50 subjects with constipation-predominant irritable bowel syndrome (IBS-C) will be administered a 12-week course of lovastatin (42 mg PO QD). Study activities will be the same across all three arms.
88831035|NCT03763175|Placebo Comparator|Placebo|Enrolled subjects will be screened and randomized into the three study arms in a 1:1:1 ratio. 50 subjects with constipation-predominant irritable bowel syndrome (IBS-C) will be administered a 12-week course of placebo. Study activities will be the same across all three arms.
88831036|NCT04737863|Experimental|selective root canal retreatment|retreatment process is performed to the affected root only
88831037|NCT04737863|Active Comparator|traditional root canal retreatment|retreatment process is performed to all roots
88831038|NCT04365049||Nab-Paclitaxel+Gemcitabine+Camrelizumab+Radiotherapy|Chemotherapy consisted of eight 21-day cycles of nab-paclitaxel plus gemcitabine (nab-paclitaxel 125 mg/m² by intravenous infusion for approximately 30-45 mins, followed by gemcitabine 1000mg/m² intravenous infusion for approximately 30 mins on days 1 and 8). Anti-PD-1 antibody (camrelizumab, Hengrui Medicine Co., Ltd) 200 mg was administered intravenously for 30 mins every three weeks. During the chemotherapy-treated period, camrelizumab was administered on day 1 of each 21-day cycle before the infusion of chemotherapy. Radiotherapy started after two cycles of chemotherapy. A total radiation dose greater than 50 Gy without damaging organ function was the essential requirement.
88831039|NCT04365049||Nab-Paclitaxel+Gemcitabine|Chemotherapy consisted of eight 21-day cycles of nab-paclitaxel plus gemcitabine (nab-paclitaxel 125 mg/m² by intravenous infusion for approximately 30-45 mins, followed by gemcitabine 1000mg/m² intravenous infusion for approximately 30 mins on days 1 and 8).
88831040|NCT03092011|Experimental|Clonidine|Clonidine at 0.38 mcg/kg/dose every 3 hours or 0.5 mcg/kg/dose every 4 hours
88831041|NCT03092011|Active Comparator|Morphine|Morphine Sulfate at 0.03 mg/kg/dose every 3 hours or 0.04 mg/kg/dose every 4 hours
88831042|NCT04589585|Experimental|DiVeRt treatment|DiVeRt device to be used in the single arm
89534367|NCT02689258|Experimental|Part A, Cohort E: HTX-011B|HTX- 011B (bupivacaine/meloxicam), 400 mg/12 mg via combination
89534368|NCT02689258|Experimental|Part A, Cohort F: HTX-011B|HTX- 011B (bupivacaine/meloxicam), 600 mg/18 mg via injection
88831043|NCT03088033|Experimental|Treatment|Patients randomized to the treatment arm will undergo a fluoroscopically and intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE) guided trans-septal puncture and IASD System II implant procedure.
88831044|NCT03088033|Sham Comparator|Control|Patients randomized to the control arm will undergo ICE from the femoral vein or TEE for examination of the atrial septum and left atrium.
88831045|NCT04572035|Experimental|Exercise only|Undergraduate peer-facilitators part of a curricular kinesiology program will facilitate a personalized group-based exercise program adapted to the participant's abilities, teach participants how to exercise, and gauge exercise intensity in a safe manner (26). The CANMAT guidelines will be implemented, with the program consisting of supervised group-based moderate-intensity exercise sessions lasting 30-minutes (plus 10-minutes for warm-up and cool-down), 3 times weekly, for a period of 10-weeks. Participants will start exercising at a low intensity and progressively increase until they are consistently exercising at a moderate intensity. As a result of the uncertainty surrounding the pandemic, the intervention will be conducted either via a virtual platform or in-person at the Exercise and Health Psychology Lab, depending on the health and safety restrictions applicable to when the student enrolls and begins their program.
88831046|NCT04572035|Experimental|Exercise + Self-compassion|Participants will undergo the same exercise program as described in the exercise only treatment arm. Participants will receive equal contact supplemental individual manualized strategies each session (+15-20 minutes) centered on self-compassion strategies (i.e., mindfulness, self-directed kindness meditations, and writing tasks).
88831047|NCT04572035|Experimental|Exercise + Behavioural Coaching|Participants will undergo the same exercise program as described in the exercise only treatment arm. Participants will receive equal contact supplemental individual manualized strategies each session (+15-20 minutes) centered on behaviour change strategies (i.e., action planning, implementation intentions, relapse prevention, and goal setting).
88831048|NCT04554173||surgical resection neurogenic tumors|
88831049|NCT02986165|Placebo Comparator|Placebo control|100 g of flavoured water
88831050|NCT02986165|Experimental|Low dose pomace extract|1 g pomace extract powder
88831051|NCT02986165|Experimental|High dose pomace extract|2.5 g pomace extract powder
89178056|NCT00790452|Active Comparator|Group 1 (Aspirin)|Aspirin 325 mg/day orally
88831052|NCT00372515|Experimental|High dose gefitinib|
88831053|NCT04333979|Experimental|Drain replacement|Effects of drainage
88831054|NCT04333979|No Intervention|Drain not placed|Effects of not using drain
88875477|NCT05016024|Other|Colilen IBS + Placebo|First Period: Colilen IBS Second Period: Placebo
88875478|NCT05016024|Other|Placebo + Colilen IBS|First Period: Placebo Second Period: Colilen IBS
89178057|NCT00790452|Placebo Comparator|Group 2 (Placebo)|Tablet/day orally
89178058|NCT00823030|Placebo Comparator|Placebo|Placebo instillation: 20 ml of normal saline instilled intravesically
89178059|NCT00823030|Experimental|experimental arm|The experimental instillation will include 8 ml of 2% lidocaine, 3 ml of sodium bicarbonate, and 9 ml of normal saline.
89178060|NCT00823186|Experimental|Phyxol,cancer,intra vascular flow|weekly cisplatin plus paclitaxel for 3 cycles as neoadjuvant chemotherapy (NAC) for FIGO IB2 and bulky IIA, squamous cell cervical cancer followed by radical hysterectomy and pelvic lymphedectomy
89178061|NCT00820378||atherosclerosis|Patients With Clinically Evident Arterial Disease or Cardiovascular Risk Factors
89178062|NCT02550496|Experimental|tinea capitis|
89178063|NCT00626392|Experimental|NER 500; ASA run-in, ASA coadmin|Aspirin (ASA) daily during run-in (1 week); ASA 30 min prior to niacin extended-release ([NER], 500 mg starting dose), daily during coadministration period (4 weeks)
89178064|NCT00626392|Experimental|NER 500; ASA Pbo run-in, ASA coadmin|Aspirin placebo (ASA Pbo) daily during run-in (1 week); ASA 30 min prior to niacin extended-release ([NER], 500 mg starting dose), daily during coadministration period (4 weeks)
89178065|NCT00626392|Experimental|NER 500; ASA Pbo run-in, ASA Pbo coadmin|Aspirin placebo (ASA Pbo) daily during run-in (1 week); ASA Pbo 30 min prior to niacin extended-release ([NER], 500 mg starting dose), daily during coadministration period (4 weeks)
89359130|NCT05185752|Active Comparator|Erector Spinae Plane Block (ESP block)|"The patient is positioned in the prone position, the probe is used to locate in cross-section the T4 spinous process. Next, using a lateral scan, approximately 3 cm away, the costotransverse joint is located, and then change to sagittal ultrasound vision. By locating the intertransverse line with the probe, the following anatomical structures can be identified: three longitudinal muscles (trapezius, rhomboid, erector spinae).~The needle enters in a single punction at an angle of 45º, in the cranio-caudal direction, until it touches the apex of the costotransverse image. Subsequently, 30 cc of 0.25% bupivacaine are administered in the depth of the erector spinae, which will remain elevated."
89359131|NCT05185752|Active Comparator|Pectoral Nerve type II Block (PECS II block)|"The patient is positioned supine, with the ipsilateral upper limb extended. The clavicular external third line is drawn. In parallel, the lower costal line and the infraclavicular space are highlighted. The probe obtains an image that allows the identification of the pectoralis major and pectoralis minor.~If colour Doppler is added, the acromiothoracic artery is identified and must be avoided.~The needle enters at an angle of 45º from medial to lateral, and 20 cc of 0.25% bupivacaine are administered. Next, needle advances in the interfascial space between the pectoral minor and serratus anterior and 10 cc of 0.25% bupivacaine are administered."
89359132|NCT05185752|Active Comparator|Serratus-Intercostal Fascial Plane Block (SIFP block)|"The patient is positioned supine, with the ipsilateral upper extremity at a 90º angle. The fourth, fifth, and sixth intercostal spaces are identified in the mid-axillary line. In coronal section, it is possible to appreciate the subcutaneous cellular tissue, the serratus anterior, and the intercostal muscles.~The needle is introduced at an angle of 30º. From caudal to cranial and resting the needle on the fourth rib, 30 cc of 0.25% bupivacaine are administered between the serratus anterior and lateral intercostal muscles."
89359133|NCT02483026|Experimental|Intensive supplements care pre-surgery|Multi vitamins pills vitamin D
89359134|NCT02483026|Other|Standard supplements care pre-surgery|vitamin D (Vitamin D will be given in a reduced doses compared to the intervention group)
89359135|NCT01320371||Barbed sutures|Barbed sutures are self-anchoring, requiring no knots for wound closure.
89359136|NCT01320371||Knotted sutures|Knotted sutures used for traditional surgical closures.
89359137|NCT02483104|Experimental|veliparib (ABT-888)|
89359138|NCT00116220|Active Comparator|Treatment 1|External beam radiation therapy + 6 months total androgen ablation
89359139|NCT00116220|Active Comparator|Treatment 2|External beam radiation therapy
89359140|NCT03785015|Experimental|Withold aspirin till after endoscopic haemostasis|Withhold the standard treatment of aspirin within 12 hours after endoscopic haemostasis.
89359141|NCT03785015|Active Comparator|Withold aspirin till 72 hours|Withhold the standard treatment of aspirin till 72 after endoscopic haemostasis.
89359142|NCT02485678|Experimental|Proactive Telephone Toxicity Management|Proactive Telephone Toxicity Management
89359143|NCT02485678|Active Comparator|Control Arm|Control
89359144|NCT05690555|Experimental|Postoperative Pelvic Floor Physical Therapy (PFPT)|If patients were randomized into the Postoperative PFPT arm, they were further randomized into the following sub-arms: Postoperative PFPT alone and Preoperative and Postoperative PFPT
89359145|NCT05690555|Active Comparator|No Postoperative Pelvic Floor Physical Therapy (PFPT)|Patients will present to see the physical therapist 3 weeks postoperatively. The following interventions will be performed: Subjective assessment of bowel and bladder function. Visual and external palpation and assessment of external pelvic floor region. Intravaginal pelvic floor assessment. Pelvic floor muscle dynamics and coordination assessment. Review of pelvic floor anatomy and function.
89359146|NCT01336452|Other|CCRTx|consecutive patients who plan to undertake CCRTx due to advanced hepatocellular carcinoma
89359147|NCT04492228|Experimental|Ketogenic diet group|patients with COVID-19 feeding with a ketogenic diet (4.1 formula)
89359148|NCT04492228|No Intervention|Standard diet group|patients with COVID-19 feeding with a standard diet
88831055|NCT04448119|Experimental|Chemoprophylaxis|Participants of LTCH units allocated to the chemoprophylaxis arm receive favipiravir for 25 days. Residents in the LTCH unit diagnosed with COVID- 19 at enrollment will be offered treatment with favipiravir for 14 days.
88831056|NCT04448119|Placebo Comparator|Placebo|Participants of LTCH units allocated to the control arm receive placebo for 25 days. Residents in the LTCH unit diagnosed with COVID-19 at enrollment will be offered treatment with placebo for 14 days.
89000925|NCT04637347|Other|IP-SSV|In plane supraclavicular subclavian vein catetherization
89000926|NCT04637269|Experimental|BCMA CAR-T|"The study will employ dose level cohorts of three patients that will be treated at each level described below, based on the number of T cells to be infused using the 3 + 3 dose-escalation strategy to find MTD followed by a dose-expansion phase at determined optimal dosage."
89359149|NCT01333176|Experimental|All volunteers have HbA1c test|All candidates receive same procedure
89359150|NCT03784859||All patients in study|5 consecutive patients with breast cancer or a breast cancer-causing gene that elect to undergo bilateral breast reconstruction will be Insertion of Tissue Expander with Fluid Reservoir as the first stage of reconstruction. Post-surgical care will be similar as patients with conventional expanders, except that during office visits, fluid will be transcutaneously aspirated from the fluid reservoir on each side.
89359151|NCT02485600||DUODOPA patients.|Patients starting DUODOPA treatment at time of enrollment.
89359152|NCT05185596|Experimental|Trans-esophageal echocardiography|Transesophageal Echocardiography during advanced life support for out of hospital cardiac arrest will be performed.
89359153|NCT05185518|Experimental|Use of novel insulin injection port|subjects inject insulin through a glucose sensing port
89359154|NCT05185518|No Intervention|use of standard SC injections|subjects inject insulin through standard rotating subcutaneous sites.
89359155|NCT03778775||Overall eligible participants|Eligible participants will receive standard esophagogastroduodenoscopy and liver stiffness measurement by FibroTouch.
89359156|NCT03316690|Experimental|Metformin treatment|
89359157|NCT03316690|Placebo Comparator|Placebo treatment|
89359158|NCT01333254|No Intervention|Indwelling urinary catheter|Patients in this group with hip fracture will get an indwelling catheter at arrival to the orthopaedic ward. The patients with arthrosis get the indwelling catheter in the morning at the day of surgery. In both cases the indwelling catheter is inserted after shower with skin disinfectant. The catheter system is kept close. The catheter will be removed in the morning on day 2 after surgery. The patients are bladder-scanned every four-hour until normal bladder function is recaptured. If the bladder volume exceeds 400ml and the patient is unable to urinate, the patient will be re-catheterised. The procedure of the patients in this arm is in accordance with common practice in the Orthopaedic clinic.
89359159|NCT01333254|Experimental|Intermittent urinary catheterisation|Patients randomised to this arm will urinate either in a toilet or in a bedpan or a diaper when needed. Bladder scan control will be performed on these patients at least every four hour. If the patient is unable to urinate and bladder scan indicates ≥ 400 ml urine in the bladder, the patient will be intermittent catheterised.
89359160|NCT03315052|Experimental|Budesonide treatment arm|Patients treated with budesonide in place of prednisone as part of immunosuppressive regimen
89359161|NCT03315052|Active Comparator|Standard immunosuppression arm|Patients treated with standard immunosuppression after liver transplant
89359162|NCT05187468|Experimental|ESWT 1|Extracorporeal Shockwave Therapy 1000 pulses, 60 mJ, 10 Hz
89359163|NCT05187468|Experimental|ESWT 2|Extracorporeal Shockwave Therapy 2000 pulses, 60 mJ, 10 Hz
89359164|NCT05187468|Active Comparator|Ultrasound therapy, Massage, Heat Pack|10 Min massage 5 min US therapy 10 min Heat pack
89534369|NCT02689258|Experimental|Part B, Cohort A: HTX-002|HTX-002, 400 mg via combination
88831058|NCT02986633||Patients with heart failure and CRT|Heart failure with left ventricular ejection fraction less than 35 % treated with CRT
88831059|NCT04502615|Experimental|Sand|Participants perform 5 single leg hops onto a Sand surface from a 30cm height
88831060|NCT04502615|Active Comparator|Artificial grass|Participants perform 5 single leg hops onto a grass surface from a 30cm height
88831061|NCT04502615|Active Comparator|Firm Ground|Participants perform 5 single leg hops onto a firm ground surface from a 30cm height
88831062|NCT02986555|Placebo Comparator|Stress relief with existing biofeedback|After distressing virtual reality video and full resting time to relieve this stress, the investigators are going to give cognitive distress with serial seven, accompanied with existing biofeedback approach to relieve stress.
88831063|NCT02986555|Active Comparator|Stress relief with biofeedback and VR|After distressing virtual reality video and full resting time to relieve this stress, the investigators are going to give cognitive distress with serial seven, accompanied with biofeedback combined to virtual reality relaxation.
88831064|NCT03047473|Experimental|Newly diagnosed GBM|single arm, open label Addition of Avelumab to standard treatment
88831065|NCT03043963|Active Comparator|Sleep Timing|Intervention will include basic education concerning sleep hygiene and regularity of sleep timing
88831066|NCT03043963|Experimental|Sleep Extension|Intervention will include basic education concerning sleep hygiene and an extension of the sleep period.
89359165|NCT03778697|Experimental|Adolescent Endosleeve|Patients who will undergo endoscopic sleeve gastroplasty
89359166|NCT02482948|Active Comparator|Collagenase|This is an enzymatic debridement agent to remove non-viable tissue from wounds to be applied daily
89359167|NCT02482948|Active Comparator|Active leptospermum honey|This is an active medicinal grade honey used to promote autolytic debridement and applied daily
89359168|NCT03779321|Other|Lean panelists|Lean panelists or normal weight panelists with a BMI between 18.5 and 24.9 Acceptability was assessed
89359169|NCT03779321|Other|Obese panelists|Obese panelists with a BMI between 25 and 29.9 Acceptability was assessed
89359170|NCT02482792|Experimental|Norwegian Psychomotor Physiotherapy|NPMP is a body-mind awareness approach, often given in a combination of massage, exercises and conversations. The NPMP is individualized, with duration of 45-60 minutes in each session. As the NPMP is a longitudinal and normally slow process to obtain change, treatment can last up till one year, in the beginning once a week, and after some time once a month.
89359171|NCT02482792|Active Comparator|Cognitive Patient Education and PT|The comparison group will receive a combination of education about how to manage pain (COPE) followed by active individual physiotherapy.They will receive one session weekly with COPE, given by a physiotherapist, maximum 4 times, followed by active individual Physiotherapy (PT).
89359172|NCT03778619|Experimental|single arm|"Phase 1~MG4101 (Allogeneic Natural Killer cell): i.v bi-weekly~Group 1: 1 x 10^7 cells/㎏~Group 2: 3 x 10^7 cells/㎏~Group 3: 9 x 10^7 cells/㎏~Interleukin-2 (IL-2): s.c bi-weekly with MG4101 at 1X10^6 IU/m2 per day.~Rituximab: 375mg/m2. i.v. weekly for the first 2 cycles only (8 doses). monthly (3-6 cycle)~Lymphodepletion: Fludarabine 20mg/m2 + Cyclophosphamide 250 mg/m2 i.v. D-3, D-2, D-1 of 1st, 3rd, and 5th cycle~Phase 2a Administration of recommended dosage of MG4101 determined from Phase 1 will be applied in Phase 2a. Dosage regimens for lymphodepletion, IL-2 and Rituximab will be the same as Phase 1."
89359173|NCT05714176|Experimental|Liposomal iron|30 pediatric patients who will receive oral liposomal iron (Novoferr) 30 mg/day for 12 weeks.
89359174|NCT05714176|Experimental|Iron supported Lactoferrin|30 pediatric patients who will receive oral iron supported Lactoferrin iron (Provan) 100 mg/day for 12 weeks.
89359175|NCT05714176|Experimental|Iv iron dextran|30 pediatric patients who will receive IV iron dextran 50 mg/3 times weekly for 12 weeks.
89359176|NCT03156504|Experimental|Ketamine|Subjects will receive three IV Ketamine Hydrochloride infusions (0.5 mg/kg, infused over 100 minutes) and measure their depressive symptom responses. Biomarkers will be developed using blood samples from study subjects, taken prior to (predictive biomarkers) and following ketamine treatment (change biomarkers).
89359177|NCT01315925||Newly disgnosed AML|Adult and pediatric patients with newly diagnosed acute myeloid leukemia, both eligible and not eligible for intensive chemotherapy. Since this is a non-interventional study, therapeutic strategies remains related to local guidelines. Will be treated as cases all patients with acute leukemia in first induction developing an Invasive Fungal Infection according to international EORTC criteria for possible/probable/proven infections. Patients who do not develop the infection will be used as a control group.
89359178|NCT03316612|Experimental|Intervention group|"Ingredients: Vaccinium Myrtillus L. extracts, and excipients (cellulose microcrystalline, mannitol, silica, magnesium stearate, coating agent)~Brown oval tablet, 650mg per tablet with 150mg Vaccinium Myrtillus L. extracts, twice a day, 2 tablets each time.~The intervention period is about 3 months."
89359179|NCT03316612|Placebo Comparator|Placebo group|"Ingredients: excipients (cellulose microcrystalline, mannitol, silica, magnesium stearate, coating agent)~Brown oval tablet without Vaccinium Myrtillus L. extracts, 650mg per tablet, twice a day, 2 tablets each time.~The intervention period is about 3 months."
89359180|NCT01333332|Experimental|Capecitabine, Radiation|
89534370|NCT02689258|Experimental|Part C, Cohort A: HTX-011B|HTX-011B (bupivacaine/meloxicam), 400 mg/12 mg via instillation
89359181|NCT01308827||Children with suspected pneumococcal invasive disease|
89534371|NCT02689258|Experimental|Part C, Cohort B: HTX-011B|HTX-011B (bupivacaine/meloxicam), 400 mg/12 mg via combination
88831067|NCT03020251|Active Comparator|control group (C group)|patient will receive preoperative chest physiotherapy (standard supportive care)
88831068|NCT03020251|Experimental|rehabilitation group (R group)|patient will receive preoperative chest physiotherapy and a preoperative rehabilitation program at home (exercise training)
89359182|NCT03316534|Placebo Comparator|Placebo|Placebo
88831069|NCT04707365|Experimental|digestive cancers|Colorectal and pancreatobiliary cancers
88831070|NCT02990845|Experimental|Pembrolizumab/ Exemestane/ Leuprolide|Dose level 1 (Pembrolizumab 150 mg IV Q2W); Dose level -1 (Pembrolizumab 100 mg IV Q2W); Dose level -2 (Pembrolizumab 50 mg IV Q2W) Combination with Exemestane 25 mg PO QD, and Leuprolide 3.75 mg SC Q4W
88831071|NCT04310449|Experimental|Dual zone concept and customized healing abutment|Immediate implant placement with bone grafts in the dual zone and customized healing abutment.
88831072|NCT04310449|Active Comparator|Connective tissue graft and customized healing abutment|immediate implant placement with CTG and customized healing abutment
88831073|NCT04480931|Experimental|mHealth Intervention Group|This group will be provided with the mobile health app (including introductory videos on how to use its features).
88831074|NCT04480931|Sham Comparator|Control Group|This group will receive an educational brochure about physical activity during pregnancy.
88831075|NCT01987219|Active Comparator|Albuterol-sulphate|Albuterol-sulphate (Proventil ®) Beta-2-adrenergic agonist 2.5 mg 3 cc inhalation Peak effect 15 - 30 mins. Mean duration of effect 3 hours
88875479|NCT04986540|Experimental|Cohort 1|A single subcutaneous injection of SHR-1906/placebo dose 1 in healthy subjects
89359183|NCT03316534|Active Comparator|Aspirin|Aspirin (100 mg/daily)
89359184|NCT05498051|Experimental|Sentinel lymph node detection after submucosal bevacizumab-800CW injection|Therefore this prospective study aims to assess the safety and feasibility of lymph node identification using bevacizumab-800CW in patients with cT1-3N0-2 tumours, using peritumoral submucosal injections.
89359185|NCT04476420|Active Comparator|Steroid group|Participants in group 1 will be given corticosteroid lotion (Betamethasone valerate 0.1%) and will be advised to apply it topically (0.5 ml) on the buccal mucosa thrice a day along with physiotherapy using ice cream sticks three times a day for the duration of 10 minutes (3-5minutes on each side).
89359186|NCT04476420|Experimental|Nigella Sativa oil group|Group 2 will be given commercially available, cold pressed N.sativa (Black seed) oil and will be advised to apply it topically over the buccal mucosa (1 ml) thrice a day along with physiotherapy using ice cream sticks three times a day for the duration of 10 minutes (3-5minutes on each side).
89359187|NCT03778463|Experimental|Synovectomy|
89359188|NCT03778463|No Intervention|No synovectomy|
89359189|NCT03314896|Experimental|Laparoscopic surgery for T4 colon tumor|Laparoscopic surgery for T4 colon cancers
89359190|NCT03314896|No Intervention|Open surgery for T4 colon tumor|Conventional open surgery for T4 colon cancers
89359191|NCT03778541|Experimental|CRT group|patients with brain metastases of more than 6 cc and treated with fractionated stereotactic radiotherapy plus concomitant Temozolomide.
89534372|NCT02689258|Experimental|Part C, Cohort C: HTX-011B|HTX-011B (bupivacaine/meloxicam), 300 mg/9 mg via combination
89359192|NCT03778541|Active Comparator|RT group|patients with brain metastases of more than 6 cc and treated with fractionated stereotactic radiotherapy alone.
89534373|NCT02689258|Active Comparator|Part C, Cohort D: Bupivacaine HCI|Bupivacaine HCl, 100 mg via injection
89534374|NCT02689258|Placebo Comparator|Part C, Cohort E: Saline Placebo|Saline placebo via injection
89534375|NCT02685735|Active Comparator|Gabapentin|Subjects will be randomized, stratifying for norepinephrine serotonin reuptake inhibitor (NSRI) use, to equal number to receive gabapentin or placebo pills. Drug treatment will begin 2 weeks prior to surgery and continue 3 weeks afterwards. Subjects randomized to gabapentin will receive 900 mg/day for the first week, 1800 mg/day for the next 3 weeks, and 900 mg/day for the last week.
89534376|NCT02685735|Placebo Comparator|Placebo|Subjects will be randomized, stratifying for norepinephrine serotonin reuptake inhibitor (NSRI) use, to equal number to receive gabapentin or placebo pills. Drug treatment will begin 2 weeks prior to surgery and continue 3 weeks afterwards.
89534377|NCT02673021|Experimental|Microwave Ablation|Microwave Ablation
89534378|NCT02649764|Experimental|Treatment (fludarabine phosphate, cytarabine, prexasertib)|Patients =/< 65 years of age: receive fludarabine IV over approximately 2 hours on days 1-4, cytarabine IV over 4 hours on days 1-4, and prexasertib (LY2606368) IV over approximately 2 hours on days 1, 3, and 4 or on days 1-4. Patients > 65 years of age: receive fludarabine IV over approximately 2 hours on days 1-3, cytarabine IV over 4 hours on days 1-3, and prexasertib (LY2606368) IV over approximately 2 hours on days 1, 3, and 4 or on days 1-4. Treatment for both age groups repeats every 28 days for up to 5 courses in the absence of disease progression or unacceptable toxicity.
89359193|NCT03159468|Experimental|Cognitive Restructuring & Alcohol Condition|Participants will receive a brief online training regarding the use of cognitive restructuring skills to cope with negative emotions. They will then consume an alcoholic beverage in the lab.
88831076|NCT01987219|Active Comparator|Ipratropium-bromide (Atrovent ®)|IpratroAnti-cholinergic(Atrovent ®) 500 mcg 3 cc inhalation Peak effect 30 - 90 mins. Duration of effect 2 - 4 hours.pium-bromide
89359194|NCT03159468|Experimental|Mindfulness & Alcohol Condition|Participants will receive a brief online training regarding the use of mindfulness skills to cope with negative emotions. They will then consume an alcoholic beverage in the lab.
89000927|NCT04636918|Other|Single arm|Ikervis (cyclosporine 0.1%), emulsion, one drop into both eyes, once at night.
89359195|NCT03159468|Experimental|Nutrition Information & Alcohol Condition|Participants will receive general information about nutrition. They will then consume an alcoholic beverage in the lab.
89359196|NCT03159468|Experimental|Cognitive Restructuring & No Alcohol Condition|Participants will receive a brief online training regarding the use of cognitive restructuring skills to cope with negative emotions. They will then consume a non-alcoholic beverage in the lab.
89359197|NCT03159468|Experimental|Mindfulness & No Alcohol Condition|Participants will receive a brief online training regarding the use of mindfulness skills to cope with negative emotions. They will then consume a non-alcoholic beverage in the lab.
89359198|NCT03159468|No Intervention|Nutrition Information & No Alcohol Condition|Participants will receive general information about nutrition. They will then consume a non-alcoholic beverage in the lab.
89359199|NCT02479828|Active Comparator|Fascia iliaca compartment block (FICB)|Under ultrasound guidance performing fascia iliaca compartment block, in which 40 ml ropivacaine 0,5% are injected under the fascia iliaca.
89359200|NCT02479828|Placebo Comparator|Placebo (not FICB)|Half of the patients will not receive FICB
89359201|NCT01320449|Placebo Comparator|No training + placebo|10 young men being investigated with 10 weeks apart. The will receive placebo injections twice a week. Blood samples, blood pressures as well as VO2-max tests will be obtained during the 10 weeks.
89359202|NCT01320449|Active Comparator|No training + EPO|10 young men being investigated with 10 weeks apart. During the 10 weeks participants will receive EPO injections twice a week. Blood samples, blood pressures as well as VO2-mas tests will be obtained during the 10 weeks.
88831077|NCT01987219|Placebo Comparator|Placebo|Placebo Saline solution 3 cc NA
89359203|NCT01320449|Active Comparator|Training + placebo|10 young men will be trained for 10 weeks and investigated before and after. They will receive placebo injections twice a week. Blood samples, blood pressures as well as VO2-max tests will be obtained during the 10 weeks.
89359204|NCT01320449|Active Comparator|Training + EPO|10 young men will be investigated with 10 weeks apart. During the ten weeks they will train 3 times a week and receive EPO injections twice a week. Blood samples, blood pressures as well as VO2-max tests will be obtained during the 10 weeks.
89359205|NCT02482714|Experimental|Rehab Institute|This group will do some physical activity in a specialized institute
89359206|NCT02482714|Active Comparator|Club structure|This group will do some physical activity in a club.
89359207|NCT02479672|Active Comparator|VividTrac video laryngoscope|VividTrac® Videolaryngoscope, A device for endotracheal intubation
89359208|NCT02479672|Active Comparator|Direct laryngoscopy|Direct laryngoscopy, A device for endotracheal intubation
89534379|NCT02643108|Experimental|Lateral episiotomy|Lateral episiotomy (left or right) is performed by the attending physician or assisting midwife at crowning of the fetal head in operative vaginal delivery by vacuum extraction. Regular manual perineal support is applied.
88831078|NCT03027245||Eribulin-treated participants|Participants treated with eribulin according to Fachinformation and managed according to clinical practice
88831079|NCT04768387|Experimental|Personalized microbiome diet|Six weeks of AI-based microbiome diet was introduced.
88831080|NCT04768387|Active Comparator|Standard IBS diet|Six weeks of standard IBS diet was introduced.
88831081|NCT02758223|Experimental|Treatment|Experimental: TCM allogeneic humane central memory T cells, cryopreserved Solution for injection (intravenous use) up to 65*10^4 TCM /kg body weight patient will receive investigational product 3 times (Day 30, Day 60, Day 90 after alloHSCT)
88831082|NCT04265053|Experimental|Male NOS|Males visit MRI twice. Once for hypercapnia visit (no drugs), and once for hypoxia visit (IV and drug infusion to inhibit NOS). CBF measured via MRI sequences, and hemodynamics monitored for safety/research.
88831083|NCT04265053|Experimental|Male COX|Males visit MRI twice. Once for hypercapnia visit (no drugs), and once for hypoxia visit (IV and drug infusion to inhibit COX). CBF measured via MRI sequences, and hemodynamics monitored for safety/research.
88831084|NCT04265053|Experimental|Female NOS|Females visit MRI twice. Once for hypercapnia visit (no drugs), and once for hypoxia visit (IV and drug infusion to inhibit NOS). CBF measured via MRI sequences, and hemodynamics monitored for safety/research.
89359209|NCT05187234|Experimental|Education|Experimental: intervention group The patients were interviewed 3 times, initially at the 1st month and at the 3rd month. All forms were initially administered to patients in the intervention group. Patients were randomly assigned to the intervention group and participated in a one-on-one Roy Adaptation Model-based training program consisting of an initial 30-45 minute session. Hemodialysis Patient Education Manual prepared by the researchers was applied to the patients in the intervention group during the training. All forms were re-administered to the patients in the intervention group in the 1st and 3rd months.
89359210|NCT05187234|No Intervention|Control|Education and training manual based on the Roy adaptation model was not given to the patients.
89359211|NCT03774251|Active Comparator|Greater Trochanter Pain Syndrome - PRP Arm|Individuals with Greater Trochanter Pain Syndrome with MRI evidence of gluteus medius or gluteus minimus tendinopathy, assigned to undergo platelet rich plasma injection
89359212|NCT03774251|Active Comparator|Greater Trochanter Pain Syndrome - ESWT Arm|Individuals with Greater Trochanter Pain Syndrome with MRI evidence of gluteus medius or gluteus minimus tendinopathy, assigned to extracorporeal shock wave therapy
89359213|NCT03314818||Ultrasound 3D Imaging|To investigate natural history of subclinical atherosclerosis as determined by 3D carotid ultrasound.
89359214|NCT03430063|Experimental|SDREGN2810|
89359215|NCT03430063|Experimental|SDREGN2810/ipi|
89359216|NCT03430063|Experimental|HDREGN2810|
89359217|NCT02485366|Experimental|Rejuvenated PRBCs|The investigators will restore important energy molecules in stored red blood cells before they are transfused, with a rejuvenating solution (Rejuvesol).
89359218|NCT01308905|Experimental|FLT-PET|"Patients will be managed per COG protocol ANBL00B1 (low risk, LR), ANBL0521 (intermediate risk, IR), ANBL0531 (high risk, HR) or other future neuroblastoma studies according to their risk group (risk assignment, treatment schema and protocols are available in COG website). The following is a brief description of the treatment.~Low risk patients: observation only.~Intermediate risk patients: chemotherapy stratified according to risk sub-groups followed by surgical resection.~High risk patients: 6 courses of induction chemotherapy, surgical resection and high dose chemotherapy with autologous stem cell transplant (SCT), involved field radiation and 6 months of Isotrenitoin.~PET scan will be conducted at diagnosis, at the end of the first cycle of treatment and prior to the surgical procedure (resection)."
89359219|NCT03158220|Experimental|Adult Women 27- to 45-years Old|Adult women 27- to 45-years old will receive V503 vaccination, 0.5 mL in a 3-dose regimen administered on Day 1, Month 2, and Month 6.
89359220|NCT03158220|Active Comparator|Young Adult Women 16- to 26-years Old|Young adult women 16- to 26-years old will receive V503 vaccination, 0.5 mL in a 3-dose regimen administered on Day 1, Month 2, and Month 6.
89359221|NCT04492462|Experimental|Formal Physical Therapy|
89359222|NCT04492462|Experimental|Self-directed Physical Therapy|
89359223|NCT01308983|Other|Amiloride|
89359224|NCT03718585||nocturnal group|Chronic kidney disease patients with nocturnal hypertension
89359225|NCT03718585||non-nocturnal group|Chronic kidney disease patients without nocturnal hypertension
89359226|NCT03718585||non-CKD group|patients without chronic kidney disease
89359227|NCT03316456||AL Patients Undergoing Induction Chemotherapy|Adults undergoing inpatient induction chemotherapy for newly diagnosed/relapsed acute leukemia.
89359228|NCT03774017|Other|Traditional microsurgery group|Patients receive only traditional microsurgical operations in traditional operating theaters or the one-staged hybrid operation theater. No endovascular intervention technique or intraoperative digital subtraction angiography(DSA) will be performed. The DSA will be performed in 3 days after the operation.
89359229|NCT03774017|Experimental|Hybrid operation group|Patients receive microsurgical operation under the assistance of intraoperative DSA, endovascular embolization and/or balloon occlusion in the one-staged hybrid operating theater.
89359230|NCT02484976|Experimental|Family Based Behavioral Treatment|Central satiety brain and hormonal responses will be compared pre-and post-Family Based Behavioral Treatment, as well, as to a non-obese sample.
89359231|NCT01336842|Experimental|Phase I dose-escalation|Drug: panobinostat Drug: cisplatin Drug: pemetrexed Other: Biomarker studies
89359232|NCT02485132||T2DM at SU initiation|T2DM newly prescribed a SU
89359233|NCT03785171||Moyamoya disease|The cohort includes patients with Moyamoya disease diagnosed by DSA examination who are treated by surgical revascularization.
89359234|NCT02485210|Active Comparator|Covencional treatment|"Convencional endodontic treatment for deciduous teeth, with Surgical chemical preparation with series of Kerr files appropriate for each case, using initial file and an additional two files of larger size, with irrigation and aspiration with 1% sodium hypochlorite (Milton's solution) and endo PTC (Fórmula & Ação) with each change of file.~Filling of root canals with calcium hydroxide (Ultra-cal, Ultradent, Brazil); base of thin gutta-percha and filling with glass ionomer cement; restorative treatment performed in subsequent session."
89359235|NCT02485210|Experimental|Photodynamic therapy|Endodontic Treatment with photodynamic terapy Irrigation of the root canal system Insertion of sterile paper cone immersed in Chimiolux® methylene blue for three minutes; administration of wireless Therapy XT EC laser device (DMC - São Carlos, Brazil) after removal of cone; energy density: 4 J/cm², power: 100 mw; wavelength: 660 nm; exposure time: 40 seconds Filling of root canals with calcium hydroxide (Ultra-cal, Ultradent, Brazil); base of thin gutta-percha and filling with glass ionomer cement; restorative treatment performed in subsequent session
89359236|NCT03156270|Experimental|Vivaer Stylus Treatment|Thermal treatment of the submucosal tissue including cartilage in the internal nasal valve area
89359237|NCT03773939||Derivation cohort|Prospective cohort study based on the 'Simple Intensive Care Studies' (SICS) registry (NCT02912624, NCT03577405, and NCT03553069)
89359238|NCT03773939||External validation cohort|We will create a multicenter cohort based on prospectively collected data derived from the Dutch National Intensive Care Evaluation (NICE) registry
89359239|NCT02485054||Eligible patients|Adults having had a transient visual disturbance during the last 8 days, except a diplopia
89359240|NCT01339026|Active Comparator|Prasugrel|Day 1 loading 60mg Day 2 to 7 10mg o.d. Day 8 to 30 days 10mg od
89359241|NCT01339026|Active Comparator|Clopidogrel|Day 1 Loading 600mg Day 2 to 7 day: 150mg o.d. Day 8 to 30 days: 75mg o.d.
89359242|NCT03429049|Placebo Comparator|Placebo|Matching placebo of 2.0 mL for IA injection
89359243|NCT03429049|Experimental|CNTX-4975-05|Pre-filled glass syringes administered as a single 2.0 mL IA injection
89359244|NCT03314740|Active Comparator|Arm A|Intravenous administration of weekly Paclitaxel (dosage: 80 mg/mq) for a maximum of 6 cycles. Cycle is defined as 4 weeks.
89359245|NCT03314740|Experimental|Arm B|"Oral administration of two experimental drugs:~Cediranib 20 mg/day given 7 days per week~Olaparib 600 mg / day (i.e. 300 mg twice a day) 7 days per week until progression, unacceptable toxicity, patient or physician decision to discontinue or death."
89534380|NCT02643108|No Intervention|No episiotomy|No episiotomy is performed during operative vaginal delivery, unless vitally indicated (for example severe fetal distress). The woman may tear spontaneously. Regular manual perineal support is applied.
89000928|NCT00560209|Placebo Comparator|P|
89359246|NCT03314740|Experimental|Arm C|"Oral administration of two experimental drugs:~Cediranib 20 mg/day given 5 days per week~Olaparib 600 mg / day (i.e. 300 mg twice a day) 7 days per week until progression, unacceptable toxicity, patient or physician decision to discontinue or death."
89359247|NCT02482558|Experimental|High GI diet|8 Healthy subjects will be assessed at the start and end of a 7 day high glycaemic in diet following the appropriate High/Low Glycaemic index test breakfast.
89359248|NCT02482558|Experimental|Low GI diet|8 Healthy subjects will be assessed at the start and end of a 7 day low glycaemic in diet following the appropriate High/Low Glycaemic index test breakfast.
89359249|NCT01339104|Experimental|Regorafenib|
89359250|NCT03778151|Active Comparator|TRANSCRANIAL MAGNETIC STIMULATION|repetitive TRANSCRANIAL MAGNETIC STIMULATION (rTMS) will be applied over the precuneus to modulate DMN activity. The rTMS treatment will consist of two phases: an intensive phase and a maintenance phase. The intensive phase will involve 2 weeks of treatment, 5 days per week (10 sessions, 1.600 pulses per day for a total of 16.000 pulses). The maintenance phase will consist of 1 session of treatment every week for 5 months (21 sessions, 100.800 pulses in total).
89359251|NCT03778151|Sham Comparator|SHAM TRANSCRANIAL MAGNETIC STIMULATION|SHAM TMS will be applied over the precuneus. The SHAM protocol will consist of two phases: an intensive phase and a maintenance phase. The intensive phase will involve 2 weeks of treatment, 5 days per week (10 sessions, 1.600 pulses per day for a total of 16.000 pulses). The maintenance phase will consist of 1 session of treatment every week for 5 months (21 sessions, 100.800 pulses in total).
89359252|NCT03428815|Experimental|PCM liner|Willowwood Smart Temp Liner
89359253|NCT03428815|Active Comparator|regular liner|User's regular prescribed liner
89359254|NCT02482480|Experimental|Interventional group|"Participants followed a 8-week intervention program with a total of 24 sessions (12 of those were supervised). The aim of the supervision was to increase the adherence to the treatment and to control the compliance of patients. General physical activity consisted in walking along previously standardized urban parks designed for the urban EPOC training project (Arbillaga-Etxarri et al, 2016). The duration of walking were 30 minutes. The physiotherapist supervised the accomplishment of other activities such as oropharyngeal exercises and diet control.~Oropharyngeal exercises:~Expiratory muscle strength training (EMST):~Masako Manoeuvre~Shaker Head Lift:~Facial exercise"
89534381|NCT02628275|No Intervention|Control|Continued inactivity
89534382|NCT02628275|Active Comparator|Moderate to vigorous physical activity|MVPA (55-90% of maximum heart rate) for 150 min/week (current recommendations)
88831085|NCT04265053|Experimental|Female COX|Females visit MRI twice. Once for hypercapnia visit (no drugs), and once for hypoxia visit (IV and drug infusion to inhibit COX). CBF measured via MRI sequences, and hemodynamics monitored for safety/research.
88831086|NCT04332497|Active Comparator|Group CPB = Clavipectoral fascia plane block group|In group CPB, CPB will be performed with patients in the supine position. The probe will be placed on the anterior border of the medial third of the clavicle. A 22-gauge block needle will be inserted in a caudal to cephalic direction, the periosteum of the clavicle and the surrounding fascia will be visualized, 20 ml of 0.25% bupivacaine will be injected between these two layers. The local anesthetic spread to medial and lateral third of the clavicle will be seen.
88831087|NCT04332497|No Intervention|Group C = Control group|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
88831088|NCT04332497|Active Comparator|Group ISCB = ISCB group|In group ISCB, ISCB will be performed with patients in the supin position. US probe will be placed in transverse plane at the level of cricoid cartilage. The prob will be moved laterally when the artery is visualized. The needle will be inserted in a medial-to-lateral direction after the brachial plexus between the scalen muscles is visualized. Then, 5 ml normal saline will be enjected for correction of the needle with in-plane technique. Following confirmation of the correct position of the needle 30 ml %0.25 bupivacaine will be administered for block.
88831089|NCT02840383|Active Comparator|Delayed Intervention|Schools not receiving intervention until two years after implementation.
88831090|NCT02840383|Experimental|Intervention|Schools receiving intervention at the beginning of study.
88831091|NCT04322981|Experimental|Community Pharmacist-Led|Patients in Arm 1 will receive care and treatment at their home pharmacy and be evaluated and treated by a community pharmacist under medical directives and with study oversight.
88831092|NCT04322981|Active Comparator|Academic hepatology|Patients in Arm 2 will be evaluated and treated by hepatologists at the Toronto Centre for Liver Disease.
88831093|NCT04307225||CABG|Patients whom has undergone CABG surgery for NSTEMI, stable or unstable angina, with no previous history of Atrial Fibrillation
88831094|NCT04307225||PCI|Patients whom has undergone PCI for NSTEMI, stable or unstable angina, with no previous history of Atrial Fibrillation
88831095|NCT02548715|Placebo Comparator|Control|Daily placebo
89359255|NCT02482480|Sham Comparator|Control Group|Control group participants only received general recommendations regarding general physical activity, diet and sleep hygiene. After 8-weeks of control, they were re-evaluated with the same evaluation test used in the beginning of the study period. Recommendations for general physical activity were walking during 30 minutes at least 3 times a week maintaining the greatest possible pace. Also, control group patients received the same diet control document as intervention group and verbal advice for sleep hygiene. Approximately 1 month after enrolment, a follow-up phone call was completed were we also informed about the new re-evaluation data.
89534383|NCT02628275|Active Comparator|Light physical activity|LPA (40-55% of maximum heart rate) for 150 min/week
89534384|NCT02628145|Experimental|Resistance Training Intervention|The RT intervention will take place three times per week for approximately 12 weeks on non-consecutive days using 8-10 exercises for major muscle groups utilizing free weights and machines follow American College of Sports Medicine and National Strength and Conditioning Association guidelines for RT in older adults.
88831096|NCT02548715|Experimental|Treatment|Participants administered daily levothyroxine at 1.6mcg/kg to a target normal TSH, measured at 6 weeks after the initiation of therapy
89359256|NCT05187078|Experimental|IUD placement with allis clamp|
89359257|NCT05187078|Active Comparator|IUD placement with single tooth tenaculum|
89359258|NCT05681507|Active Comparator|Control group|Patients will benefit of our institutional intensive-care unit analgesia protocol
89359259|NCT05681507|Experimental|Intervention group|Patients will benefit of a transversus thoracic muscle plane block and our institutional intensive-care unit analgesia protocol
89534385|NCT02628145|Active Comparator|Active Control Group|The CON group will meet three times weekly for approximately 12 weeks for light physical activity and stretching.
89359260|NCT02482636|Other|Group 1|"Group 1 will receive the following interventions:~DTaP/IPV/Hib vaccine IM 0.5ml at 2, 3 and 4 months~13 valent pneumococcal conjugate vaccine (PCV13) IM 0.5ml at 2, 4 and 12 months~Rotavirus vaccine oral 1.5ml at 2 and 3 months~4-component Meningococcal B (4CMenB) vaccine IM 0.5ml given at 2, 4 and 12 months~Meningococcal C/Hib vaccine IM 0.5ml at 12 months~Measles/Mumps/Rubella (MMR) vaccine IM 0.5ml at 13 months"
88831097|NCT02611687|Experimental|pitolisant|tablet, oral, once a day.
88831098|NCT02611687|Placebo Comparator|placebo|tablet, oral, once a day.
88831099|NCT04258397|Active Comparator|Experimental, pirfenidone|"Pirfenidone 267 mg capsules~Randomized participants will take 5 capsules (1335 mg pirfenidone): 2 pills in the morning, 1 mid-day, and 2 in the evening, with meals."
88831100|NCT04258397|Placebo Comparator|Placebo, pirfenidone|"Pirfenidone placebo capsules~Randomized participants will take 5 capsules (1335 mg pirfenidone): 2 pills in the morning, 1 mid-day, and 2 in the evening, with meals."
88831101|NCT01988857|Experimental|dTpa Group|
89000929|NCT00560209|Experimental|E2|
88831103|NCT04295213|Experimental|oligosaccharide group|intervention with oligosaccharides, total duration of study is 13 weeks
88831104|NCT04295213|Placebo Comparator|placebo group|Placebo comparator, total duration of study is 13 weeks
88831105|NCT01989793|Active Comparator|Losartan|For those subjects randomized to the losartan group, they will receive losartan 25mg by mouth daily for 8 weeks, then increase to 50mg by mouth daily for another 8 weeks, then increase to 100mg by mouth daily for a final 8 weeks.
88831106|NCT01989793|Placebo Comparator|Placebo|For those subjects randomized to placebo, they will receive a placebo to take for 24 weeks total.
88831107|NCT02422745|Active Comparator|Cocoa extract + multivitamin|
88831108|NCT02422745|Active Comparator|Cocoa extract + multivitamin placebo|
88831109|NCT02422745|Active Comparator|Cocoa extract placebo + multivitamin|
88831110|NCT02422745|Placebo Comparator|Cocoa extract placebo + multivitamin placebo|
88831111|NCT01991821|Experimental|APD421|IV APD421 single dose
88831112|NCT01991821|Placebo Comparator|Placebo|IV placebo single dose
88831113|NCT04197635|Active Comparator|Dapagliflozin 10 mg|After providing informed consent, patients will be randomly assigned to receive dapagliflozin 10 mg per day.
88831114|NCT04197635|Placebo Comparator|Placebo identical to dapagliflozin 10 mg|After providing informed consent, patients will be randomly assigned to receive placebo (one tablet a day orally).
89359261|NCT02482636|Other|Group 2|"Group 2 will receive the following interventions:~DTaP/IPV/Hib vaccine IM 0.5ml at 2, 3 and 4 months~13 valent pneumococcal conjugate vaccine (PCV13) IM 0.5ml at 3 and 12 months (instead of current routine schedule of 2,4 and 12 months)~Rotavirus vaccine oral 1.5ml at 2 and 3 months~4-component Meningococcal B (4CMenB) vaccine IM 0.5ml given at 2, 4 and 12 months~Meningococcal C/Hib vaccine IM 0.5ml at 12 months~Measles/Mumps/Rubella (MMR) vaccine IM 0.5ml at 13 months"
89359262|NCT03155724|Experimental|MultiPole Pacing|Traditional biventricular pacing CRT non-responders at the 3 or 6 month QP ExCELs study follow-up.
88831115|NCT01992523|Experimental|Ticagrelor mashed pills|Ticagrelor loading dose (LD) 180 mg as mashed pills
88831116|NCT01992523|Active Comparator|Ticagrelor integral pills|Ticagrelor loading dose (LD) 180 mg as integral pills
88831117|NCT04057391||QT Scanner in comparison to mammography|Women who have experience with both technologies (QT Scanner/Breast mammography
88831118|NCT00373373|Placebo Comparator|A|Chemotherapy + Placebo
88831119|NCT00373373|Active Comparator|B|Chemotherapy + Sorafenib
88831120|NCT00373451|Experimental|Abciximab+UFH|Abciximab and unfractionated heparin as bolus given during PCI and abciximab-perfusion for 12 hours after PCI
88831121|NCT00373451|Active Comparator|Bivalirudin|Bivalirudin given only during PCI
88831122|NCT01387763|Active Comparator|PegIntron <= 60 years|In patients <= 60 years PegIntron is started at low-dose 35 micrograms once weekly. Dose escalation to 50 micrograms weekly if lack of complete hematological response at 4 months or lack of at least partial molecular response at 8 months. If complete hematological response or lack of at least partial molecular response is not achieved at 50 micrograms weekly at 12 months and 18 months respectively, dose escalation to 96 micrograms weekly.
88831123|NCT01387763|Active Comparator|Pegasys <= 60 years|In patients <= 60 years Pegasys is started at low-dose 45 micrograms once weekly. Dose escalation to 90 micrograms weekly if lack of complete hematological response at 4 months or lack of at least partial molecular response at 8 months. If complete hematological response or lack of at least partial molecular response is not achieved at 90 micrograms weekly at 12 months and 18 months respectively, dose escalation to 135 micrograms weekly.
88831124|NCT01387763|Active Comparator|PegIntron > 60 years|In patients < 60 years PegIntron is started at low-dose 35 micrograms once weekly. Dose escalation to 50 micrograms weekly if lack of complete hematological response at 4 months or lack of at least partial molecular response at 8 months. If complete hematological response or lack of at least partial molecular response is not achieved at 50 micrograms weekly at 12 months and 18 months respectively, dose escalation to 96 micrograms weekly.
88831125|NCT01387763|Active Comparator|Pegasys > 60 years|In patients > 60 years Pegasys is started at low-dose 45 micrograms once weekly. Dose escalation to 90 micrograms weekly if lack of complete hematological response at 4 months or lack of at least partial molecular response at 8 months. If complete hematological response or lack of at least partial molecular response is not achieved at 90 micrograms weekly at 12 months and 18 months respectively, dose escalation to 135 micrograms weekly.
88831126|NCT01387763|Active Comparator|Hydroxyurea > 60 years|Capsule Hydrea 500-2000 mg orally QD or BID
88831127|NCT01719497||Alcohol|Subjects diagnosed with alcohol dependence
88831128|NCT01719497||Obese|Subjects diagnosed with obesity
88831129|NCT01719497||High Stress|Subjects diagnosed with high stress
88831130|NCT01719497||Healthy|Subjects deemed medically healthy
88831131|NCT02514187|Other|Evaluation of hyperthyroidism|For the evaluation of hyperthyroidism each research subject will undergo imaging using both cyclotron-produced 99mTc and the current standard method used at the site for thyroid imaging (either 123I or generator-produced 99mTc). Each study will be performed on a separate day, with flexibility to schedule either study first.
88875480|NCT04986540|Experimental|Cohort 2|A single subcutaneous injection of SHR-1906/placebo dose 2 in healthy subjects
89000930|NCT00560209|Experimental|E1|
89359263|NCT03784469|Experimental|Changing body position in bed|The first hour:Supine position. The second hour:lateral position (right or left). The third hour:Supine position. The fourth hour:lateral position (right or left).
89359264|NCT03784469|No Intervention|Control group|No changing body position in bed,remaining supine position in complete bed rest and immobilized for four hours.
89359265|NCT02482402|Experimental|Inhaled Iloprost|2 inhalations per day of 2.5 µg Iloprost [Ventavis®] per inhalation to a maximum of 6 inhalations per day of 5 µg Iloprost per inhalation (total daily dose 5 - 30 µg) will be performed according to each patient's health condition.
89359266|NCT02482402|Placebo Comparator|Placebo inhaled|2 to a maximum of 6 inhalations per day of placebo solution (PLA) will be performed. Study medication will be inhaled using the portable, hand-held I-Neb AAD vibrating mesh technology nebulizer system.
89359267|NCT03426787|Experimental|Decision Aid|A decision supports tool that guides patients with Hepatitis C and Chronic Kidney Disease through choices about whether, when, and how to treat each illness.
89359268|NCT03774173|Experimental|Aramchol 300 mg|Aramchol 300 mg twice daily (every 12 hours)
89359269|NCT03774173|Experimental|Aramchol 600 mg|Aramchol 600 mg once daily (every 24 hours)
89359270|NCT05713864|Experimental|BTL-899 Treatments|The BTL-899 will be applied over the abdomen, and the device will induce visible muscle contractions along with mild heating of the muscles. Four (4) treatments once a week will be delivered.
89359271|NCT05713864|Experimental|HPM-6000UF Treatments|The HPM-6000UF device will induce pelvic floor muscle contractions. Six (6) treatments 2-4 days apart will be delivered.
89359272|NCT03774095|No Intervention|No oil|6-hour oral glucose tolerance test
89359273|NCT03774095|Active Comparator|Hydrolyzed pine nut oil|6g hydrolyzed pine nut oil in delayed release capsules given 30 min prior to an 6-hour oral glucose tolerance test
89359274|NCT03774095|Active Comparator|Hydrolyzed pine nut oil and olive oil|3g hydrolyzed pine nut oil and 3g olive oil in delayed release capsules given 30 min prior to an 6-hour oral glucose tolerance test
89359275|NCT01333410|Active Comparator|0.1% tacrolimus ointment|
89359276|NCT01333410|Active Comparator|0.1% mometasone furoate cream|
89359277|NCT03426631|Placebo Comparator|Placebo|Placebo before sleep
89359278|NCT03426631|Experimental|DAW1033B2 oral capsule|DAW1033B2 before sleep
89359279|NCT02482012||Staff|Staff nurses and physicians in the NICU
89359280|NCT02482012||Parents|Parents of infants in the NICU and a smaller group of parents of infants in the well baby nursery.
89359281|NCT04604951|Experimental|Moderate|Group 1: Moderate 2 times per week transcutaneous spinal cord stimulation.
89359282|NCT04604951|Experimental|Intensive|Group 2: Intensive 5 times per week transcutaneous spinal cord stimulation.
89359283|NCT01315470|Experimental|neupogen|
88831132|NCT02514187|Other|Evaluation of altered osteogenesis by bone scintigraphy|For the evaluation of altered osteogenesis by bone scintigraphy each research subject will serve as his/her own control, and undergo imaging using both generator- and cyclotron-produced 99mTc. Each study will be performed on a separate day, with flexibility to schedule either study first.
88831133|NCT03996395||Infants|Infants, 4-4.5 months of age at enrollment
88831134|NCT00373061||Pregnant Women Exposed to Xolair®|Women who are exposed to at least one dose of Xolair® within 8 weeks prior to conception or at any time during their pregnancy will be followed to completion of their pregnancies.
88831135|NCT03936257|Placebo Comparator|Breast milk|group receiving breastfeeding
88831136|NCT03936257|Active Comparator|infant formula conventional BIO|infant formula with conventional whey BIO
88831137|NCT03936257|Active Comparator|infant formula BIO TrueGreen|infant formula with whey BIO TrueGreen
89359284|NCT01315470|No Intervention|no intervantion|
89359285|NCT02482090|Experimental|Patient group|"All patients receive the same treatment. Alle patients are hospitalized during treatment (approximately 3 weeks) and receive treatment only once.~Stem Cells are harvested a minimum of 3 weeks before treatment for potential later use if the patients are having difficulties recovering from the lymphodepleting chemotherapy.~The patients are admitted to hospital day -8 and receive lymphodepleting chemotherapy (cyclophosphamide and fludarabine= on day -7 to day -1.~The TILs are infused on day 0 and Interleukin-2 therapy is administered on day 0 to day 5.~Interleukin-2 is administered in an i.v. continous decrescendo regimen starting approximately 6 hours after TIL infusion with a duration of approximately 5 days.~Stem Cells can be administered after treatment if needed."
89359286|NCT05643313|Experimental|Treatment|Participants will then undergo a training programme with the ABLE Exoskeleton three to five times a week for up to 8 weeks for a total of 18 training sessions and 4 assessment sessions.
89359287|NCT03773861|Other|Participants|Active BLS- Instructors at the Bern Simulation and CPR- Center (BeSiC), at the Bern University Hospital, Bern, Switzerland. Participants have to oversee a BLS instructional session, where standardized errors are performed by trained volunteers.
89359288|NCT01337154|Experimental|Tamibarotene|Subjects will receive tamibarotene, 6 mg/m2, divided as twice daily orally starting 1 week before chemotherapy and continuing through all 6 cycles and through the duration of the study. Chemotherapy will include paclitaxel (IV; 200 mg/m2) and carboplatin (IV; AUC=6)administered once every 3 weeks for up to 6 cycles.
89359289|NCT01337154|Placebo Comparator|Placebo|Subjects will take an equal number of placebo tablets as the group receiving tamibarotene divided as twice daily orally, starting 1 week before chemotherapy and continuing through all 6 cycles and through the duration of the study. Paclitaxel (IV; 200 mg/m2) and carboplatin (IV; AUC=6) will be administered once every 3 weeks for up to 6 cycles.
89000931|NCT04636957|Experimental|ciprofloxacin 0.3% plus fluocinolone acetonide 0.025%|Warm the otic solution by holding the vial in the hands for 1 to 2 minutes. Twist off the vial cap. Tilt the subjects' head to one side to keep the affected ear up. Instill the content of 1 vial in the ear (0.25mL). Gently pull the outer ear lobe upward and outward to allow the solution to flow into the ear canal. Keep the subjects' head tilted sideways for approximately 5 minutes to allow the drug time to penetrate the ear. Use twice daily (every 12±1h , morning and evening) for 7 consecutive days.
89359290|NCT03719911|Experimental|Live diabetes coaching program|Live diabetes coaching program
89359291|NCT03777683|Experimental|Dietary Supplement (OLIGOPIN)|Intervention group will receive French maritime pine bark extract supplement (OLIGOPIN) in the form oral capsules containing 50 mg French maritime pine bark extract plus 130 mg Microcrystalline Cellulose. OLIGOPIN powder of each capsule are dissolved in 10 ml deionized water and given to patients via gavage (3 capsule per day) for 10 days
89359292|NCT03777683|Placebo Comparator|Placebo|Control group will receive oral capsules containing 130 mg Microcrystalline Cellulose with 10 ml of deionized water via gavage (3 capsule per day) for 10 days.
89359293|NCT02482324|Other|Treatment A-B|12 subjects will receive a single oral inhaled dose of ALZT-OP1a, via dry powder inhaler, and a single oral tablet dose of ALZT-OP1b on Day 1, and two doses of ALZT-OP1a and ALZT-OP1b on Day 2, within two minutes of each other. All subjects will have plasma collected for PK analysis and 6 of 12 consented subjects from this group will provide CSF samples for analysis. CSF collected on Day 1 only.
89000932|NCT04636957|Active Comparator|ciprofloxacin 0.3%|Warm the otic solution by holding the vial in the hands for 1 to 2 minutes. Twist off the vial cap. Tilt the subjects' head to one side to keep the affected ear up. Instill the content of 1 vial in the ear (0.25mL). Gently pull the outer ear lobe upward and outward to allow the solution to flow into the ear canal. Keep the subjects' head tilted sideways for approximately 5 minutes to allow the drug time to penetrate the ear. Use twice daily (every 12±1h, morning and evening) for 7 consecutive days
89000933|NCT04636996|Experimental|artificial intelligence assisted follow-up group|artificial intelligence assisted follow-up group
88831141|NCT03871907|Active Comparator|Digital technology|standard cardiac rehabilitation program + 4 personalized short messages about risk factors modification 4 times per week
88831142|NCT03871907|No Intervention|Control|standard cardiac rehabilitation program
88831143|NCT03865979|Active Comparator|Intervention Arm|"Subject CT images assessed by Viz RECRUIT software in real time analysis All subjects in which the Viz RECRUIT software is utilized will be identified per cohort described below per PI confirmation of ENRICH Trial status/Study ID.~Cohort A: Subjects with imaging data Cohort B: Subjects with imaging data and ultimately enrolled as part of the ENRICH Trial"
88831144|NCT03865979|No Intervention|Control Arm|Subjects enrolled as part of the ENRICH Trial prior to Viz RECRUIT software activation
88831145|NCT00707213|Experimental|All Participants|All Participants will be assessed by FDG-PET to identify possible sites of infection
89359294|NCT02482324|Other|Treatment B-A|12 subjects will receive two oral inhaled doses of ALZT-OP1a, via dry powder inhaler, and two oral tablet doses of ALZT-OPb, within two minutes of each other, on Day 1, and single doses of ALZT-OP1a and ALZT-OP1b on Day 2. All subjects will have plasma collected for PK analysis and 6 of 12 consented subjects from this group will provide CSF samples for analysis. CSF collected on Day 1 only.
88831146|NCT01993849|Active Comparator|N-Acetylcysteine (NAC)|Oral N-acetylcysteine 1200 mg twice daily dosing for 8 weeks
88831147|NCT01993849|Placebo Comparator|Placebo|Oral placebo (matched in appearance to active treatment) twice daily dosing for 8 weeks
88831148|NCT02308189|Active Comparator|Exercise|Low load resistance exercise training
88831149|NCT02308189|Experimental|Exercise with blood flow restriction|Low load resistance exercise training with blood flow restriction
89359295|NCT05676437||Satisfied|Patients that are satisfied with their knee replacement, defined by OKS above PASS.
89359296|NCT05676437||Unsatisfied|Patients that are unsatisfied with their knee replacement, defined by OKS below PASS.
89359297|NCT05185284|Experimental|Favipiravir (Areplivir)|Arm 1 (n=106) receives the study drug Areplivir for parenteral administration as follows: Day 1 1600 mg 2 times a day, Day 2-10 800 mg 2 times a day. Administration will be done intravenously by drip infusion for 2 hours. The course of treatment is 10 days. The test drug is administered in hospital setting under supervision of a clinical investigator. The test drug is not handed over to the patient.
89359298|NCT05185284|Active Comparator|Standard of care|"Arm 2 (n=108) patients receive standard therapy prescribed in accordance with the recommended treatment regimens included in the Interim Guidelines for the prevention, diagnosis and treatment of new coronavirus infection (COVID-19) approved by the Russian Ministry of Health by decision of the investigator and taking into account the availability of drugs at the study site. Might include Favipiravir tab, Remdesivir or other recommended schemes.~Standard therapy is administered in hospital setting. Discharge of patients from a hospital is carried out in accordance with the local practice of the study site in compliance with the current sanitary and epidemiological regime."
88831150|NCT02778113|Experimental|Nasal Glucagon (NG) - 0.5 mg|Ng dose at 0.5 milligram (mg) administered once in one of four study periods.
88831151|NCT02778113|Experimental|NG - 1.0 mg|Ng dose at 1.0 milligram (mg) administered once in one of four study periods.
88831152|NCT02778113|Experimental|NG - 2.0 mg|Ng dose at 2.0 milligram (mg) administered once in one of four study periods.
88831153|NCT02778113|Active Comparator|SC Glucagon 1 mg|Subcutaneous (SC) glucagon dose of 1 mg, in one of four study periods.
88831154|NCT01994785|Active Comparator|EGD capnography open|Capnographic monitoring during EGD - Data made available to study staff throughout procedure
88831155|NCT01994785|Active Comparator|EGD capnography blinded|Capnographic monitoring during EGD - Data made available to study staff only if necessary for safety reasons
88831156|NCT01994785|Active Comparator|Colonoscopy capnography open|Capnographic monitoring during Colonoscopy - Data made available to study staff throughout procedure
88831157|NCT01994785|Active Comparator|Colonoscopy capnography blinded|Capnographic monitoring during Colonoscopy - Data made available to study staff only if necessary for safety reasons
88831158|NCT04982237|Experimental|AK104+chemotherapy± bevacizumab|AK104 in combination with cisplatin or carboplatin and paclitaxel± bevacizumab
88831159|NCT04982237|Placebo Comparator|Placebo+chemotherapy± bevacizumab|Placebo in combination with cisplatin or carboplatin and paclitaxel± bevacizumab
89000934|NCT04636996|Placebo Comparator|Control group|Control group
89000935|NCT04636567|Experimental|Nerindocianine for injection|One Arm: Nerindocianine for Injection (0.055 mg/kg body weight); solution, intravenous, one time administration during surgery.
89000936|NCT04636606|Active Comparator|Home Exercise|Home Exercise program includes educational training program about parafunctional activities of patients having oral dysphagia with temporomandibular disorders. Program includes stretching and strengthening of masticatory and neck muscles and posture exercises as well as diaphragmatic breathing exercises.
89000937|NCT04636606|Active Comparator|Manual Therapy Combined with Home Exercise|"Manual Therapy includes deep friction massage and myofascial relaxation techniques to masticatory and neck muscles, active and resistant temporomandibular joint movements, temporomandibular joint distraction and mobilization, stretching techniques to the temporomandibular joint, mobilization of upper cervical joints.~Home Exercise program includes educational training program about parafunctional activities of patients having oral dysphagia with temporomandibular disorders. Program includes stretching and strengthening of masticatory and neck muscles and posture exercises as well as diaphragmatic breathing exercises."
89000938|NCT04636606|Active Comparator|Orofacial Myofunctional Therapy combined with Manual Therapy and Home Exercise|"Orofacial Myofunctional therapy includes stretching the tongue muscles, tongue rotation exercises, isometric and isotonic strengthening of the tongue, special maneuver, effortful swallow exercise, strengthening exercise of hyoidal muscles.~Manual Therapy includes deep friction massage and myofascial relaxation techniques to masticatory and neck muscles, active and resistant temporomandibular joint movements, temporomandibular joint distraction and mobilization, stretching techniques to the temporomandibular joint, mobilization of upper cervical joints.~Home Exercise program includes educational training program about parafunctional activities of patients having oral dysphagia with temporomandibular disorders. Program includes stretching and strengthening of masticatory and neck muscles and posture exercises as well as diaphragmatic breathing exercises."
89000939|NCT00178997||Good blood flow|Group without ischemia to the small intestine
89000940|NCT00178997||Poor blood flow|Groups that have partial ischemia to their small intestine
89000941|NCT04636645|Active Comparator|Normal Treadmill|After completion of the baseline evaluation, Group A participants will exercise for 25 minutes under low-load walking conditions three times a week for 8 consecutive weeks on the AGT treadmill at a set speed of 3.1 mph at a 0-degree incline. For each session, 20% support will be given to participants
89000942|NCT04636645|Experimental|Anti-gravity treadmill with lower limb positive pressure|Group B participants will be exercised for 25 minutes under normal-load walking conditions three times a week for 8 consecutive weeks on the AGT treadmill at a set speed of 3.1 mph at a 0-degree incline. Participants will be blinded to the study groups.
89000943|NCT04636645|Experimental|Anti-gravity treadmill with without lower limb positive pressure|Group C participants will be exercised for 25 minutes three times a week for 8 consecutive weeks on the normal treadmill at a set speed of 3.1 mph at a 0-degree incline. Participants will be blinded to the study groups.
89000944|NCT04636489|Experimental|Highland barley β-glucan group|Participants will be given oral liquids mainly containing highland barley β-glucan once daily for 8 weeks followed by comprehensive physical and clinical examinations.
89000945|NCT04636489|Placebo Comparator|Placebo group|Participants will be given oral liquids mainly containing Corn starch once daily for 8 weeks followed by comprehensive physical and clinical examinations.
89000946|NCT00179036||Good blood flow|Group without any ischemia to the small intestine
89359299|NCT03484429|Experimental|Group 1|Standard medical therapy and 30 to 60 days of peripheral nerve stimulation starting within 7 days after surgery
88875481|NCT04986540|Experimental|Cohort 3|A single subcutaneous injection of SHR-1906/placebo dose 3 in healthy subjects
89000947|NCT00179036||Poor blood flow|Group with partial ischemia to the small intestine
89000948|NCT00560248||I|Patients presenting to the Emergency Department with chest pain suspected to be of cardiac origin.
89000949|NCT00560287|Active Comparator|1|Volume assist non-invasive ventilation
89000950|NCT00560287|Active Comparator|2|Pressure Assist mode
89000951|NCT00560326|Experimental|1|
89000952|NCT00560443|Active Comparator|1|children 4-17 y. old with not compound bone fracture treated with ketorolac
89000953|NCT00560443|Experimental|2|children 4-17 y. old with not compound bone fracture treated with tramadol
89000954|NCT00560521|Active Comparator|1|
89359300|NCT03484429|Active Comparator|Group 2|Standard medical therapy only
88875482|NCT04986540|Experimental|Cohort 4|A single subcutaneous injection of SHR-1906/placebo dose 4 in healthy subjects
88875483|NCT04986540|Experimental|Cohort 5|A single subcutaneous injection of SHR-1906/placebo dose 5 in healthy subjects
88875484|NCT04986540|Experimental|Cohort 6|A single subcutaneous injection of SHR-1906/placebo dose 6 in healthy subjects
88875485|NCT04965714|Experimental|Treatment (nivolumab, pegargiminase)|Patients receive nivolumab IV over 30 minutes on day 1 and pegargiminase IM at 2 days before day 1 of cycle 1, day 8 of cycle 1, days 1 and 8 of cycle 2, and day 1 of cycle 3. Treatments repeat every 2 weeks for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgical resection at week 7. A cycle is 14 days.
88875486|NCT04787562|Experimental|Cohort 1: normal renal function|Participants with an eGFR ≥ 90 mL/min/1.73m2 receive a single dose of XNW4107 250mg IV co-administered with imipenem 500mg /cilastatin 500mg
88875487|NCT04787562|Experimental|Cohort 2: Mild renal insufficiency|Participants with an eGFR 60 to <90 mL/min/1.73m2 receive a single dose of XNW4107 250mg IV co-administered with imipenem 500mg /cilastatin 500mg
88875488|NCT04787562|Experimental|Cohort 3: Moderate renal insufficiency|Participants with an eGFR 30 to <60 mL/min/1.73m2 receive a single dose of XNW4107 250mg IV co-administered with imipenem 500mg /cilastatin 500mg
88875489|NCT04787562|Experimental|Cohort 4: Severe renal insufficiency|Participants with an eGFR 15 to <30 mL/min/1.73m2 receive a single dose of XNW4107 100mg IV co-administered with imipenem 200mg /cilastatin 200mg
88831160|NCT02780765|Experimental|Heated humidifier group|30 postoperative patients with overnight endotracheal intubation will be supplied humidified oxygen using Heated Humidifier (HH). Temperature of inspired gas at the Y piece will be measured as surrogate marker for quality of humidification. The suctioning of ETT will be done once every 2 hourly by nurse/ doctor/trained personnel.
88831161|NCT02780765|Active Comparator|Mist humidifier group|30 postoperative patients with overnight endotracheal intubation will be supplied humidified oxygen using mist nebuliser. Temperature of inspired gas at the Y piece will be measured as surrogate marker for quality of humidification. The suctioning of ETT will be done once every 2 hourly by nurse/ doctor/trained personnel.
88831162|NCT01995487|Experimental|BioNIR|"The BioNIR Ridaforolimus Eluting Coronary Stent System is a single use device/drug combination product comprising:~Stent - a mounted Cobalt Chromium (CoCr) alloy based stent~Delivery System - Rapid Exchange (RX) Coronary System~Polymer matrix coating - Poly n-butyl methacrylate (PBMA) and CarboSil®~Ridaforolimus drug - CAS Registry Number: 572924-54-0~The drug Ridaforolimus is utilized on the stent system at a dose of 1.1 μg/mm2 (with a drug load of 100 μg per 2.75/3.00 x 17 mm stent)."
88831163|NCT01995487|Active Comparator|Resolute|"The Endeavor Resolute Zotarolimus-Eluting Stent System consists of four subsystems:~Endeavor Resolute Stent- a pre-mounted cobalt alloy based stent~Delivery system (Rapid Exchange [RX] Coronary System)~Polymer system~Zotarolimus - drug The Resolute has a nominal drug dose of 1.6µg Zotarolimus per mm2 of the stent surface area."
88831164|NCT02783027|Experimental|SleepTrackTXT2|Participants will receive text-message based assessment during shift work (intra-shift) and between shifts (inter-shift). Participants in the experimental group that report high levels of fatigue, sleepiness, or difficulty with concentration during shift work (intra-shift) will receive tailored text-messages promoting adoption of behaviors that can improve alertness. Participants will also receive a summary of their sleep debt once a week and suggestions for paying back sleep debt. Participants will also have access to a graphic summary of their sleep hours over previous 30-days.
88831165|NCT02783027|No Intervention|Text-Message Assessments Only|Participants in the non-intervention group/arm will receive text-message based assessment during shift work (intra-shift) and between shifts (inter-shift). The inter-shift assessments will query the participant about his/her sleep hours, fatigue, sleepiness, and difficulty with concentration. No intervention messages sent to this group/arm.
88831166|NCT01996657||Standard intensity of anticoagulation|After mechanical valve replacement，patients should be gave oral anticoagulants，such as warfarin.and The intensity of anticoagulation for this group was standard intensity (INR:2.5-3.5).
88831167|NCT01996657||Low intensity and adjusted by elevated D-dimer|The intensity of anticoagulation maintained at low level initiatively, D-dimer testing were analyzed at 3 month later. In case of D-dimer level elevated, adjusted the intensity to standard level.
88831168|NCT01996657||Low intensity without adjustment|The intensity of anticoagulation for this group was kept at low intensity without adjustment (INR:1.8-2.6),
88831169|NCT02462629|Experimental|BLZ-100|
88831170|NCT01996813|Experimental|Prospective Case|Patients with a BMI of 30 kg/m^2 or greater who underwent shoulder arthroscopy in the beach chair position and were monitored intraoperatively using near-infrared spectroscopy while wearing thigh-high compression stockings.
88831171|NCT01996813|No Intervention|Historical Control|Patients with a BMI of 30 kg/m^2 or greater who underwent elective shoulder arthroscopy in the beach-chair position and were monitored intraoperatively using near-infrared spectroscopy but without wearing compression stockings.
88831172|NCT02784275|Experimental|Dose A|Cyclo-Z containing 23 mg zinc plus 3 mg CHP
88831173|NCT02784275|Experimental|Dose B|Cyclo-Z containing 23 mg zinc plus 9 mg CHP
88831174|NCT02784275|Experimental|Dose C|Cyclo-Z containing 23 mg zinc plus 15 mg CHP
88831175|NCT02784275|Placebo Comparator|Dose D|Placebo
88831176|NCT04229563||Study patients|Eligible PAD patients who are routinely treated with atherectomy by AURYON™ Atherectomy System.
88831177|NCT02784587|Experimental|Stellate Ganglion Block|All patients in the study will receive a stellate ganglion block in order to asses the feasibility and efficacy of this procedure performed by cardiac anesthesiologists in the operating room.
88831178|NCT01997125|Experimental|Open Label|Neural bridge system implant and external stimulator
88831179|NCT01997437|Other|Tissue-engineered airway transplantation|Stem-cell seeded bioartificial tracheal scaffold
88831180|NCT02316379|Experimental|Hyperpolarized 129 Xenon|Administration of up to 1 liter doses of Hyperpolarized Xenon gas during MRI to optimize acquisition of images for adults vs. proton MR imaging. These scans, utilizing volunteers for calibration, may be utilized through this study to optimize the scan details.
88831181|NCT03764501|Active Comparator|Image fusion group (Image fusion)|Use image fusion system during surgery (Image fusion, ZedTrauma, LEXI Co., Ltd.)
88831182|NCT03764501|No Intervention|Control group (ZedTrauma)|only use 3D preoperative planning (Zed Trauma, LEXI Co., Ltd.)
88831183|NCT03701165|Other|Snoring cohort.|Subjects will undergo two nights of polysomnography. The first night will be a baseline recording. The next night subjects will use the DryMouth Shield during the polysomnography.
88831184|NCT02303743|Active Comparator|Smart Phone Application (SPA) Group|Patients assigned to SPA group were instructed on how to free-download the application onto their smartphone. Each patient enters the date and time of his colonoscopy and timed alerts appeared on the phone to alert the patient of the next step in bowel preparation. In addition to the alerts, the app assists in bowel preparation by explaining the procedure, providing tips, examples of low fiber diet, and displaying pictures of preparation quality and educational video to explain how to prepare the purgative solution.Finally, the patient can obtain a checklist to confirm all steps.
88831185|NCT02303743|Active Comparator|Control Group|Written instructions with visual aids explaining the procedure and when to begin self-administration of the bowel solution
88875490|NCT04787562|Experimental|Cohort 5: End-stage renal disease (ESRD) receiving hemodialysis (HD) therapy|Participants with ESRD receiving HD therapy at least 3 times a week for at least 3 months prior to Screening visit receive a single dose of XNW4107 100mg IV co-administered with imipenem 200mg /cilastatin 200mg
88875491|NCT04780698|Experimental|Study Cohort|
89359301|NCT03784703|Experimental|Atrovastatin|atorvastatin (40 mg per day) for 6 months
89359302|NCT03784703|Experimental|Rosuvastatin|Rosuvastatin (10 mg per day) for 6 months
89359303|NCT05525260|Active Comparator|Limonene capsules(marketed product in China)|Limonene capsules(marketed product in China) donate by pharmaceutical company.
89359304|NCT05525260|Placebo Comparator|Limonene capsules(Placebo)|Same smell, color and shape as limonene capsules(marketed product in China), without limonene in capsules.
89359305|NCT01339182|Experimental|Pegylated-Somatropin, 10mcg/kg|
89359306|NCT01339182|Experimental|Pegylated-Somatropin, 30mcg/kg|
89359307|NCT01339182|Experimental|Pegylated-Somatropin, 60mcg/kg|
89359308|NCT01339182|Experimental|Pegylated-Somatropin, 120mcg/kg|
89359309|NCT01339182|Experimental|Pegylated-Somatropin, 200mcg/kg|
89359310|NCT01337232|Active Comparator|1 session per week|
89359311|NCT01337232|Experimental|2 sessions per week|
89359312|NCT01337310|Experimental|Tesetaxel|Tesetaxel administered orally once every 21 days for at least 2 cycles
89359313|NCT03484273|Experimental|Full Compression|The LifeWrap compression garment will be fully secured with all straps.
89359314|NCT03484273|Experimental|Abdominal and Pelvic Compression|The Lifewrap compression garment abdominal, pelvic and upper thigh straps only will be secured.
89359315|NCT03484273|Experimental|Lower Limb Compression|The Lifewrap compression garment calf and ankle straps only will be secured.
89359316|NCT03484273|No Intervention|No Compression|None of the LifeWrap compression garment straps will be secured.
89359317|NCT02724592|Experimental|intervention|intervention group, self assembling peptide P11-4 (Curodont™ Repair) and fluoride varnish (Duraphat®)
89359318|NCT02724592|Active Comparator|control|control group, only Fluoride varnish (Duraphat®)
89359319|NCT03773783|Active Comparator|Twin Block|Twin Block appliance
89359320|NCT03773783|Experimental|Button and Bead|Button and Bead appliance
89359321|NCT01333566|Experimental|Intervention Group|
89359322|NCT01333566|Placebo Comparator|Control Group|
89359323|NCT02476864|Experimental|Sequence AB|Subjects receive treatment A in Period 1 followed by treatment B in Period 2 with a washout phase of 10 to 14 days between the two treatment periods
89359324|NCT02476864|Experimental|Sequence BA|Subjects receive treatment B in Period 1 followed by treatment A in Period 2 with a washout phase of 10 to 14 days between the two treatment periods
89359325|NCT02761122|Experimental|Patients with lichen|"Patients with non-erosive lichen planus, erosive lichen planus or lichen sclerosus.~Human biological samples :~Blood sample~Skin or mucosal brushing~Skin or mucosal biopsy"
89359326|NCT01320527|Experimental|Nutriceutical formulation|Nutritional supplement
89359327|NCT01320527|Placebo Comparator|Placebo 1|
89359328|NCT01320527|Placebo Comparator|Placebo 2|
89359329|NCT01339338|Experimental|warm media|Subjects undergo HSG using a warm media heated with a 37℃ water-bathing
89359330|NCT01339338|No Intervention|cold media|the contrast media under room temperature without heat
89359331|NCT03314428|Experimental|Gait retraining|Runners will be taught how to modify their running gait through multiple laboratory sessions and in-field training.
89359332|NCT01333644||HIV-Infection|Treated HIV-infected individuals with an undetectable HIV RNA level (< 75 copies RNA/mL, untreated HIV-infected individuals, and HIV-uninfected individuals.
89359333|NCT03773549||Body dysmorphic disorder|Meet DSM-5 criteria for principal body dysmorphic disorder, assessed via the Structured Clinical Interview for the DSM-V Axis I Disorders (SCID)
89359334|NCT03773549||Healthy control|Individuals who do not have a current psychiatric diagnosis, assessed via the Mini-International Neuropsychiatric Interview (MINI)
89359335|NCT03635736||Severe brain injury|ICU-patients suspect to severe brain injury, measurement with multiple-spectral-sonography as acustocerebrography (ACG
89359336|NCT05451550|Experimental|General anesthesia group|Patients were maintained with propofol/remifentanil in general anesthesia
89359337|NCT05451550|Experimental|General anesthesia combined with brachial plexus block group|An additional ultrasound-guided brachial plexus block were performed
89359338|NCT05451550|Experimental|general anesthesia combined with suprascapular nerve block group|An additional ultrasound-guided suprascapular nerve block were performed
89359339|NCT01339494|Active Comparator|arginine supplementation|Oral L-arginine supplementation will be administered to subjects with MELAS for 48 hours at a dose of 10 grams per M2 per day. Arginine will be given every 4 hours.
89359340|NCT01339494|Active Comparator|citrulline supplementation|Oral L-citrulline supplementation will be administered to subjects with MELAS for 48 hours at a dose of 10 grams per M2 per day. Citrulline will be given every 4 hours
89359341|NCT02476708|Experimental|Curcumin 1800mg|curcumin capsule 600mg taken 3 times per day for 8 weeks
89359342|NCT02476708|Placebo Comparator|Placebo|placebo capsule taken 3 times per day for 8 weeks
89359343|NCT01341522|Active Comparator|Control|Control
89359344|NCT01341522|Experimental|MRI|experimental
89359345|NCT03769571|Other|parental coaching program at ESDM (P-ESDM)|
89359346|NCT03769571|No Intervention|CONTROL|
89359347|NCT02479204|Experimental|Part A ACT-334441 + atenolol|4 subjects will receive 50 mg of atenolol once daily for 6 days, and a concomitant single administration of ACT-334441 2 mg on Day 6
89359348|NCT02479204|Experimental|Part A ACT-334441 + diltiazem|4 subjects will receive 240 mg of diltiazem once daily for 6 days, and a concomitant single administration of ACT-334441 2 mg on Day 6
89359349|NCT02479204|Experimental|Part B ACT-334441 + atenolol|12 subjects will receive 50 mg of atenolol (once daily) from day 1 to day 15, placebo once on day 6, and ACT-334441 4 mg (once daily) from day 8 to day 15
89359350|NCT02479204|Experimental|Part B ACT-334441 + diltiazem|12 subjects will receive 240 mg of diltiazem (once daily) from day 1 to day 15, placebo once on day 6, and ACT-334441 4 mg (once daily) from day 8 to day 15
89359351|NCT03784547||multiple sclerosis patients|multiple sclerosis patients receiving ocrelizumab 600 mg endovenous every 6 months
89359352|NCT01339572|Experimental|Plerixafor|All subjects will receive filgrastim as part of their primary mobilization regimen. If a subject does not meet minimum peripheral blood CD34+ cell count levels or fails to adequately collect a threshold number of CD34+ cells, plerixafor will be added to the mobilization regimen.
89359353|NCT01339572|Active Comparator|Observation|All subjects will receive filgrastim as part of their primary mobilization regimen. If the subject meets minimum peripheral blood CD34+ cell count levels or adequately collects a threshold number of CD34+ cells, plerixafor will not be added to the mobilization regimen.
89359354|NCT03773705|Active Comparator|Electrocautery group|Electrocautery used to raise pediclued nasoseptal flaps to repair skull based defects following endoscopic transphenoidal surgery.
89359355|NCT03773705|Active Comparator|Scalpel group|Scalpel used to raise pediclued nasoseptal flaps to repair skull based defects following endoscopic transphenoidal surgery.
88831186|NCT04964375|Experimental|ABSK043|"Dose escalation of oral ABSK043 with a starting dose of 200mg once daily will be guided byBOIN escalation rules based on safety data until an MTD has been identified or a RDE. For each dose,In the escalation part, sequential cohorts of patients will receive an oral dose of ABSK043 in repeated 28-day cycles. Starting dose level will be 200 mg QD. Cohort 3 on 800mg will be switched to 400mg BID.Then, patients will continuously receive ABSK043 （total daily dose） in repeated 28-day cycles.For the Dose Expansion Phase, patients will each receive orally administered doses of ABSK043 at the RDE in repeated 28-day cycles."
89359356|NCT04382118||OWDFO: Open Wedge Distal Femoral Varus osteotomy|
89359357|NCT04382118||CWDFO: Closed Wedge Distal Femoral Varus osteotomy|
89359358|NCT01320605|Experimental|Weekly HP802247 treatment|
89359359|NCT01341678|Other|Normal Phosphorus Diet|Diet containing 1500mg of phosphorus per day
88831187|NCT02303977|Experimental|Gemcitabine + Paciltaxel|All patients were treated intravenously with albumin-bound paclitaxel at 100 mg/m2 plus gemcitabine at 1000 mg/m2 on days 1 and 8 of each three-week cycle.
89359360|NCT01341678|Other|Restricted Phosphorus Diet|Diet containing 750mg of phosphorus per day and administration of a phosphate binder (lanthanum carbonate)
89359361|NCT01341678|Other|High Phosphorus Diet|Diet containing 3000mg of phosphorus per day and phosphorus supplementation (NeutraPhos)
89359362|NCT02481856|Experimental|12 DU SQ tree SLIT-tablet|Betula verrucosa, allergen extract, Oral lyophilisate
89359363|NCT02481856|Experimental|7 DU SQ tree SLIT-tablet|Betula verrucosa, allergen extract, Oral lyophilisate
88831188|NCT01997515|Active Comparator|Group K (Ketamine)|Group K (ketamine) will receive 0.5mg /kg of ketamine bolus followed by an infusion of 0.5 mg/kg/hour of ketamine throughout the intraoperative period (Adjusted body weight).
88831189|NCT01997515|Placebo Comparator|Group P (Placebo)|Group P (placebo) will receive the same amount of saline.
88831190|NCT02786771|Experimental|Spire device without & with feedback|Participants will receive a Spire device with user-feedback switched off within 4 days of enrollment in the study (shipped within 2 business days after they finish enrollment survey). Participants will be given 4 days, after enrollment, to set up their device before the 2 weeks of baseline. The 2 week baseline will start 4 days after enrollment. After two weeks of baseline with user-feedback off (and a 3 day transition period), participants will turn on the user-feedback for the Spire device which would provide a relaxation aid for the participant for the 6 remaining weeks.
88875492|NCT04669236|Experimental|Intervention group|Intervention promoting healthy sleep behaviour in adolescents based on a participatory health research approach. Based on participatory session, the pupils of the action group will develop the intervention. They will participate in every step of the development to maximize their input.
88875493|NCT04669236|No Intervention|Control group|Participants in the control group will receive no intervention.
88875494|NCT04293198||control arm|Cryoballoon PVI procedure where the freeze was initiated based on the occlusion assessed using fluoroscopy
88875495|NCT04293198||Kodex arm|Cryoballoon PVI where the freeze was initiated based on the outcome of the KODEX occlusion Viewer
88875496|NCT04199832||Nasogastric tube|The patient had difficulty swallowing before chemoradiotherapy and placed a nasogastric tube.
89000955|NCT04636450|Active Comparator|Adult manual instrumentation|Primary mandibular molars who are treated with a manual pulpectomy and a K-file system.
89359364|NCT02481856|Experimental|2 DU SQ tree SLIT-tablet|Betula verrucosa, allergen extract, Oral lyophilisate
89359365|NCT02481856|Placebo Comparator|Placebo|No active ingredient, Oral lyophilisate
89359366|NCT05185206|Active Comparator|Analysis of post-operative sensitivity after caries removal using conventional steel bur|Caries will be excavated using a carbide on one side of the arch and restoration will be done with Cention-N(commercially available restorative material) as per manufacturer's instructions.Thermal stimulation (refrigerant spray Endo-Ice) will be used to evaluate the type of sensitivity. The pain intensity will be recorded with the Visual Analog Scale.
89359367|NCT05185206|Experimental|Analysis of post-operative sensitivity after caries removal using polymer bur|Caries will be excavated using a polymer on one side of the arch and restoration will be done with Cention-N(commercially available restorative material) as per manufacturer's instructions.Thermal stimulation (refrigerant spray Endo-Ice) will be used to evaluate the type of sensitivity. The pain intensity will be recorded with the Visual Analog Scale.
89359368|NCT02479282|Other|group A|natural cesarean section
89359369|NCT02479282|Other|group B|traditional cesarean section
89359370|NCT01309139|Experimental|Treatment A: Tiotropium medium dose|Oral inhalation daily for 21 days
89359371|NCT01309139|Experimental|Treatment A: BI 54903 high dose|Oral inhalation daily for 21 days
89359372|NCT01309139|Experimental|Treatment B: Tiotropium medium dose|Oral inhalation daily for 21 days
89359373|NCT01309139|Experimental|Treatment C: BI 54903 high dose|Oral inhalation daily for 21 days
89359374|NCT03154476|Experimental|Sildenafil|Subjects randomized to this arm will receive sildenafil 5 mg 3 times per day for the first week, and titrated to 10 mg 3 times per day for the second week, and 20 mg 3 times per day from the third week to the end of the study period, 12 months.
89359375|NCT03154476|Placebo Comparator|Placebo|Subjects will receive placebo times per day for 12 months.
89359376|NCT02479594|Experimental|competence-feedback|Therapists assigned to this group will receive standardized feedback on their psychotherapeutic competency after every fourth treatment session with a patient for a period of 20 therapy sessions. The feedback will be given by two experienced raters who are licensed as psychological psychotherapists.
89359377|NCT02479594|Placebo Comparator|control|Therapists assigned to this group will receive no competence-feedback.
89359378|NCT03769337||Infected|Serum biomarkers in patients with diagnosis of prosthetic joint infection
88831191|NCT02786771|Experimental|Muse device & spire device no feedback|Participants in this group will also receive Spire device to assess two weeks of baseline stress levels (with user-feedback off). Participants will be given 4 days, after enrollment, to set up their device before the 2 weeks of baseline. The 2 week baseline will start 4 days after enrollment. After these two weeks, participants will continue to use the Spire device with user feedback off for the remaining 6 weeks while they use the Muse device to manage stress through meditation. They will receive the Muse device 3 days before the end of baseline period with set up instructions and will utilize the three last days of baseline to set up their Muse device, Meditation will begin at the end of baseline (week three) and will continue for the remaining 6 weeks.
88831192|NCT01997905|Experimental|AtriClip LAA Exclusion Device|AtriClip delivered via minimally invasive surgical procedure
88831193|NCT04938089||ICS|Irregular compliant smoker
88831194|NCT04938089||RCS|Regular compliant smoker
88831195|NCT04938089||ICN|Irregular compliant non-smoker
88831196|NCT04938089||RCN|Regular compliant non-smoker
88831197|NCT02788019|Experimental|Mid-Thigh Adductor Block|Subject will receive a mid-thigh adductor block method using ropivacaine (0.5%, 15 mL).
88831198|NCT02788019|Active Comparator|Distal-Thigh Adductor Block|Subject will receive a distal-thigh adductor block method using ropivacaine (0.5%, 15 mL).
88831199|NCT02788097|Experimental|Progesterone + 4|the transfer of day 5 blastocyst on the 5th day of progesterone supplementation
88831200|NCT02788097|Active Comparator|Progesterone + 5|the transfer of day 5 blastocysts on the 6th day of progesterone supplementation
88831201|NCT01999231|Experimental|1μg/ml ESAT6-CFP10|The 1μg/ml ESAT6-CFP10 is given 0.1ml alone to volunteers in the RIGHT or LEFT forearm according to a randomisation scheme.
88831202|NCT01999231|Experimental|5μg/ml ESAT6-CFP10|The 5μg/ml ESAT6-CFP10 is given 0.1ml alone to volunteers in the RIGHT or LEFT forearm according to a randomisation scheme.
88831203|NCT01999231|Experimental|10μg/ml ESAT6-CFP10|The 10μg/ml ESAT6-CFP10 is given 0.1ml alone to volunteers in the RIGHT or LEFT forearm according to a randomisation scheme.
88831204|NCT01999231|Experimental|20μg/ml ESAT6-CFP10|The 20μg/ml ESAT6-CFP10 is given 0.1ml alone to volunteers in the RIGHT or LEFT forearm according to a randomisation scheme.
88831205|NCT02789033|Active Comparator|Chitosan|Chitosan chemically is a high-molecular-weight linear polycationic heteropolysaccharide comprising copolymers of 1,4-linked D-glucosamine and N-acetyl-D-glucosamine
88831206|NCT02789033|Active Comparator|Isosorbide dinitrate spray|Isosorbide dinitrate spray (2.5 mg) is an organic nitrate, is a vasodilator with effects on both arteries and veins. The chemical name of ISDN is 1,4:3,6-dianhydro-D-glucitol 2,5-dinitrate.
88831207|NCT02789033|Placebo Comparator|Placebo|Placebo in the same pharmacological presentation
88831208|NCT01999777|Experimental|USL261|5 mg intranasal midazolam
88831209|NCT01999777|Placebo Comparator|Placebo|intranasal placebo
88831210|NCT04913519|Experimental|SAD Cohorts 1 -3 TDM-105795 topical solution|Single dose administration of TDM-105795 Topical Solution, 0.0025% or 0.005% or 0.01%
88831211|NCT04913519|Placebo Comparator|Placebo for TDM-105795 topical solution|Single dose administration of Placebo forTDM-105795 Topical Solution
88831212|NCT02278315|Experimental|Single|I-131-CLR1404 with or without concurrent dexamethasone
88831213|NCT02188147|Experimental|SWD 1000|Short Term Wearable Defibrillator
88831214|NCT02794727|Sham Comparator|Blinded Fitbit|Subjects will wear the physical activity monitor (fitbit) for 12 weeks but will be blinded to the monitor display.
88831215|NCT02794727|Active Comparator|Unblinded Fitbit|Subjects will wear the physical activity monitor (fitbit) for 12 weeks. They will have access to the monitor display and will have consults with study physician to set goals for the duration of the study.
88831216|NCT02794727|No Intervention|No Fitbit|Subjects will not wear any activity monitor for 12 weeks.
88831217|NCT02795117|Experimental|Test product|
88831218|NCT02795117|Active Comparator|Reference product|
88831219|NCT02795117|Placebo Comparator|Placebo product|
88831220|NCT02333071|Experimental|Bremelanotide (BMT/BMT)|"(Main Study) Subjects will self-administer a fixed dose (1.75 mg) of bremelanotide (BMT) subcutaneously (SC) via auto-injector on an as needed basis with no more than 1 dose taken every 24 hours for 24 weeks~(OLE Study) Subjects will self-administer a fixed dose (1.75 mg) of bremelanotide (BMT) subcutaneously (SC) via auto-injector on an as needed basis with no more than 1 dose taken every 24 hours for 52 weeks"
88831221|NCT02333071|Placebo Comparator|Placebo (PBO/BMT)|"(Main Study) PBO administered SC on an as-desired basis for 24 weeks~(OLE Study) subjects will self-administer a fixed dose (1.75 mg) of bremelanotide (BMT) subcutaneously (SC) via auto-injector on an as needed basis with no more than 1 dose taken every 24 hours for 52 weeks"
88831222|NCT02795819|Experimental|Cohort minus 1 (-1)|Participants take 10 mg AR-42 orally per day on 3 non-consecutive days during the 1st 3 weeks of each 4-week cycle and pazopanib 600mg orally daily continuously
88831223|NCT02795819|Experimental|Cohort 1|Participants take 20 mg AR-42 orally per day on 3 non-consecutive days during the 1st 3 weeks of each 4-week cycle and pazopanib 600mg orally daily continuously
88831224|NCT02795819|Experimental|Cohort 2|Participants take 20 mg AR-42 orally per day on 3 non-consecutive days during the 1st 3 weeks of each 4-week cycle and pazopanib 800mg orally daily continuously
88831225|NCT02795819|Experimental|Cohort 3A|Participants take 30 mg AR-42 orally per day on 3 non-consecutive days during the 1st 3 weeks of each 4-week cycle and pazopanib 800mg orally daily continuously
88831226|NCT02795819|Experimental|Cohort 3B|Participants take 30 mg AR-42 orally per day on 3 non-consecutive days during the 1st 3 weeks of each 4-week cycle and pazopanib 600mg orally daily continuously
88831227|NCT02795819|Experimental|Cohort 4A|Participants take 40 mg AR-42 orally per day on 3 non-consecutive days during the 1st 3 weeks of each 4-week cycle and pazopanib 800mg orally daily continuously
88831228|NCT02795819|Experimental|Cohort 4B|Participants take 40 mg AR-42 orally per day on 3 non-consecutive days during the 1st 3 weeks of each 4-week cycle and pazopanib 600mg orally daily continuously
88831229|NCT02882633|Active Comparator|Lumbar Plexus Block|Subjects will receive single shot local anesthetic, 30 ml bolus of bupivacaine, given preoperatively to help with postoperative pain
89359379|NCT03769337||Not Infected|Serum biomarkers in patients with implant failure not caused by infection
89359380|NCT02476630||Study subjects|All participants will have a measurement of the tissue oxygen concentration (StO2) level after applying the noninvasive probe to the thenar eminence. This measurement is done at the same time as blood gases(ScvO2) from the central venous catheter is obtained. The StO2 measurement is documented once for the subject in the study.
89359381|NCT01339650|Experimental|ABT-767|ABT-767 monotherapy
89359382|NCT03784391||Treatment|Patients diagnosed with acute and chronic Chagas' disease, respectively, who were treated with nifurtimox
89359383|NCT03784391||Reference|Patients diagnosed with acute and chronic Chagas' disease, respectively, who did not receive antitrypanosomal treatment
89359384|NCT05338918|Experimental|Mental Imagery with Virtual Reality Group|Mental Imagery with Virtual Reality
88831230|NCT02882633|Active Comparator|Fascia Iliac Block|Subjects will receive single shot local anesthetic, 30 ml bolus of bupivacaine, given preoperatively to help with postoperative pain
89359385|NCT05338918|Active Comparator|Virtual Reality Alone Group|Virtual Reality Alone
88831231|NCT00373607|Experimental|Dihydroartemisin-piperaquine|Dihydroartemisin-piperaquine (Artekin, Hualijian Pharmaceutical Co. Ltd., Guangzhou, China). Each tablet contains 40mg of dihydroartemisinin and 320mg piperaquine
88831232|NCT00373607|Active Comparator|Mefloquine + Artesunate (MAS3)|The MAS3 regimen is artesunate 4 mg/kg/day once daily for 3 days plus mefloquine 24 mg/kg given as a three day regimen of 8mg/kg/day
88831233|NCT02797613|Experimental|Restricted Reporting|"Microbiology laboratory will report Positive urine cultures may represent asymptomatic bacteriuria or urinary tract infection. If urinary tract infection is suspected clinically, please call 777-xxxx (researcher mobile phone) for identification and susceptibility results"
88831234|NCT02797613|No Intervention|Standard Reporting|Microbiology laboratory will report identification and susceptibility results
88831235|NCT02882711|Experimental|ketamine|
88831236|NCT02884427|Experimental|Cathode Stimulation|Group that is involved with the (black) negative electrode seeking the polar effect of nervous increased excitability and conductivity with the current application.
88831237|NCT02884427|Experimental|Anode Stimulation|Group that is involved with the (red) positive electrode seeking the polar effect of nervous excitability and conductivity decreased with the current application.
88831238|NCT02884427|Placebo Comparator|Control|Group that will be placed electrotherapy without operation, but only installation. Patients in this group will see the team work but it will not be delivering current.
88831239|NCT02798627|Experimental|NS2359|The initial dose of the NS2359 will be two mg once daily. Patients with difficult adverse events at the 2 mg dose will be allowed to reduce to 1 mg once daily. Subjects will participate in weekly cognitive behavioral relapse prevention psychotherapy from week 2 through week 9.
88831240|NCT02798627|Placebo Comparator|placebo|Placebo pills matched to NS2359 pills will be given once daily. Patients with difficult adverse events at the 2 mg placebo will be allowed to reduce to 1 mg placebo once daily. Subjects will participate in weekly cognitive behavioral relapse prevention psychotherapy from week 2 through week 9.
88831241|NCT02794337|Active Comparator|DEB TACE Arm|Patients randomized to drug eluting beads(DEB) TACE arm will undergo 3 cycles of DEB-TACE (100 mg of doxorubicin drug eluting beads which will be repeated after 4-6 weeks. CT/MRI will be repeated prior to each cycle. Sorafenib will be omitted on the day of TACE and will be reinitiated after the TACE procedure. After completing all TACE cycles patients will continue to be on sorafenib till progression, or 12 months whichever is later, or in patients who fail to tolerate it after dose modifications. Hepatobiliary CTCAE will be completed at baseline, at each TACE cycle and subsequently at each follow up. QOL will be evaluated at the same time and also at two months after completing all sessions of TACE (matched time point with completion of SBRT in interventional arm)
88831242|NCT02794337|Experimental|DEB-TACE+SBRT arm|Patients randomized to DEB TACE/SBRT arm will undergo DEB-TACE as in standard arm. SBRT will be initiated 4-6 weeks after last TACE procedure. During this period patients will stop Sorafenib. SBRT once initiated will continue for 2-2.5 weeks. Sorafenib will be reinitiated 4 weeks after SBRT completion and will continue to be administered till progression or 12 months whichever is earlier, or in patients who fail to tolerate it after dose modifications. QOL will be evaluated at baseline, before each cycle of TACE, 1 month after SBRT and three monthly thereafter. Hepatobiliary CTCAE will be completed at baseline, after each TACE, before SBRT and after completion of SBRT and subsequently at each follow up.
88831243|NCT02886923|Experimental|Test/Control Sequence|Subjects will wear the Hioxifilcon A Test contact lens and then the Hioxifilcon A with Cosmetic Ring Control contact lens for approximately three to four hours at each of the two measurement visits.
88831244|NCT02886923|Active Comparator|Control/Test Sequence|Subjects will wear the Hioxifilcon A with Cosmetic Ring Control contact lens and then the Hioxifilcon A Test contact lens for approximately three to four hours at each of the two measurement visits.
88831245|NCT02888093|Experimental|Absorbable|Absorbable suture (polydioxanone) for uterosacral ligament suspension (USLS)
89359386|NCT03635580|Experimental|rhGH/Jintropin AQ|Jintropin AQ, injection, 30IU/10mg/3ml/cartridge, 0.05mg /kg/d in phase 1 and 0.05-0.07mg/kg/d in phase 2.
89359387|NCT02479516|Experimental|CHAPP intervention communities|"CHAPP intervention: The proposed CHAPP intervention will include:~Diabetes risk assessment (modified FINRISK and assessment of lifestyle risk behaviours) sessions be at least every 2 weeks in accessible community locations, manned by trained volunteers of LLO~Volunteers educate CHAPP participants regarding their diabetes risk factors and ways to practice healthy lifestyle (including referral to local resources/activities) using diabetes education materials adapted for local context~Use of an accepted process have participant data transmitted to a central web database system through a combination of cell-phone and computer-based technology~Have participant assessment result forwarded to the Municipal Health Officer (doctor) for follow-up and screening"
89359388|NCT02479516|No Intervention|Delayed Intervention communities|
89359389|NCT01320761|Experimental|Group 1A|"Left side injected first:~Left submental - ATX-101-BA Right submental - ATX-101-BA-free"
89359390|NCT01320761|Experimental|Group 1B|"Right side injected first:~Left submental - ATX-101-BA Right submental - ATX-101-BA-free"
89359391|NCT01320761|Experimental|Group 2A|"Left side injected first:~Left submental - ATX-101-BA-free Right submental - ATX-101-BA"
89359392|NCT01320761|Experimental|Group 2B|"Right side injected first:~Left submental - ATX-101-BA-free Right submental - ATX-101-BA"
88831246|NCT02888093|Experimental|Permanent|Permanent suture (Gore-Tex CV2) for uterosacral ligament suspension (USLS)
88831247|NCT02590523|Experimental|A: Vancomycin|Intracameral vancomycin injection given at conclusion of cataract case
88831248|NCT02590523|Experimental|B: Moxifloxacin|Intracameral moxifloxacin injection given at conclusion of cataract case
88831249|NCT02590523|Placebo Comparator|C: Placebo|Intracameral placebo injection with BSS given at conclusion of cataract case
88831250|NCT02519309|Experimental|onsite|Education (the virta program) for the onsite group will be delivered in person, with 26 classes over 12 months including group and individual sessions. Sessions will be scheduled weekly for the first 3 months, biweekly during months 4-6, and monthly thereafter. Each session will last approximately 90 minutes.
88831251|NCT02519309|Experimental|web-based|Education (the virta program) for the web-based educational group will be the same content as the onsite group, but delivered via the web and completed at the participant's own pace.
88831252|NCT02519309|No Intervention|Control (usual care)|The study will make no intervention to this group. Participants in this group will be recent referrals to a local diabetes education program and care for their condition will continue to be managed by their own medical providers.
88831253|NCT02895035|Active Comparator|Epinephrine|Epinephrine is the intracameral additive during cataract surgery.
88831254|NCT02895035|Active Comparator|Omidria|Omidria is the intracameral additive during cataract surgery.
88831255|NCT02802449|Placebo Comparator|Placebo|The participant will be randomized to receive two tablets of Placebo (microcrystalline cellulose) to take under direct observation at the baseline and week 2 visit.
88831256|NCT02802449|Active Comparator|25 hydroxy-Vitamin D3 or [25 (OH) D3]|The participant will be randomized to receive two 50,000 IU tablets of oral Vitamin D3 [also known as cholecalciferol or 25 hydroxy-Vitamin D3 or 25 (OH) D3] to take under direct observation at the baseline and week 2 visit.
88831257|NCT02803229|Placebo Comparator|Placebo|matched Placebo arm
88831258|NCT02803229|Experimental|Adderall-XR|Adderall-XR (MAS-XR) 80 mg/day maximum maintenance dose
88831259|NCT01938001|Experimental|Rituximab and Lenalidomide|Participants received rituximab 375 mg/m^2 intravenously (IV) every week in Cycle 1 (Days 1, 8, 15 and 22) and on Day 1 of every 28-day cycle from Cycles 2 to 5 plus lenalidomide 20 mg by mouth (PO) once daily on Days 1 to 21 every 28 days, up to 12 cycles (21-day treatment and 7-day rest period); if creatinine clearance (CrCl) was ≥ 30 mL/min but < 60 mL/min, participants received lenalidomide 10 mg capsules on days 1 to 21 every 28 days.
88831260|NCT01938001|Active Comparator|Rituximab and Placebo|Participants received riituximab 375 mg/m^2 IV every week in Cycle 1 (Days 1, 8, 15 and 22) and on Day 1 of every 28-day cycle from cycle 2 to 5 plus placebo (identically matched capsule) once daily on Days 1 to 21 of every 28-day cycle up, to 12 cycles.
88831261|NCT04349293|Experimental|Patients with cancer|
88831262|NCT02805179|Experimental|High Dose Chemoradiation|Patients will receive high dose radiation based in part on advanced imaging, and concurrent temozolomide. Four weeks after the completion of chemoradiation, patients will receive adjuvant temozolomide.
88831263|NCT02003053|Experimental|IMT|In the IMT group, inspiratory muscle training will start with 30% of MIP, for five minutes twice a day with increments of 10 % (absolute) everyday. Supplemental oxygen will be given as needed. The exercise will be done seven days a week until patient achieves liberation from mechanical ventilation or ICU/CCU discharge.
88831264|NCT02003053|Sham Comparator|Sham|In the SHAM group, sham device will be used to train subjects 5 minutes twice a day, seven days a week until patient achieves liberation from mechanical ventilation or ICU/CCU discharge.
88831265|NCT02896595|Active Comparator|General Anesthesia with endotracheal tube|Patients assigned to the ETT tube group will have ETT placed in the safest manner deemed appropriate by attending anesthesiologist. Possible ways to have ETT placed will be using direct laryngoscopy, glidescope or fiberoptic intubations. Size of ETT will be decided based on patient characteristics and discretion of attending anesthesiologist. Once placed, auscultation and capnography will be used to ensure correct placement of ETT.
88831266|NCT02896595|Active Comparator|General Anesthesia with laryngeal mask airway|Patients assigned to the LMA group will have LMA placed in a standard fashion by anesthesia provider. LMA size will be decided based on patient characteristics and at the discretion of attending anesthesiologist. LMA used will be LMA Supreme (Teleflex Medicals, Ireland). Once placed auscultation will be used to ensure correct placement of LMA.
88831267|NCT02003911|Experimental|Azithromycin suspension|"Azithromycin suspension at 10mg/kg/dose (max 500mg)~Once daily for 3 days"
88831268|NCT02003911|Placebo Comparator|Placebo suspension|"Same volume as active drug~Once daily for 3 days"
88831269|NCT04147351|Experimental|Atezolizumab+bevacizumab+pemetrexed+carboplatin or cisplatin|
88831270|NCT02805647||Fracture/study group|The study group consisted of 100 children aged 3 to 18 years (78% boys) hospitalized in the Department of Pediatric Orthopedics in 2011-2013 due to low-energy fractures
88831271|NCT02805647||Control group|The control group (122 children, 68% boys) consisted of children aged 3 to 17 years, hospitalized for other reasons (injuries, diagnosis of knee ligament injuries and others) without fractures
88831272|NCT02004613|Active Comparator|Dexmedetomidine|Dexmedetomidine infusion, without a bolus dose, (or a comparable volume of placebo) will be initiated before the surgical incision at a rate of 0.1 mcg/kg/hr at the end of bypass, the dose will be increased to 0.2 mcg/kg/hr. Postoperatively patients will continue to receive the study medication at a rate of 0.4mcg/kg/hr. The study medication infusion will be continued for a total of 24 hours from the initial administration time intra-operatively.
88831273|NCT02004613|Placebo Comparator|Placebo|normal saline administration matching dexmedetomidine rate of infusion.
88831274|NCT02806895|Placebo Comparator|Placebo|Once daily dosing
88831275|NCT02806895|Active Comparator|JZP-110|150 mg/day for first 3 days and 300 mg/day for next 4 days
88831276|NCT01754779|Placebo Comparator|Placebo|Placebo tablets twice daily
89359393|NCT01341756|Experimental|Radiotherapy for gastric cancer|Single arm study
89359394|NCT02476552|Experimental|Niraparib Oral and IV|Single Oral dose of Niraparib capsules (unlabeled active pharmaceutical ingredient) orally and a 15-minute IV infusion of Niraparib (labeled active pharmaceutical ingredient)
89359395|NCT02476552|Experimental|Niraparib Oral|Single Oral dose of Niraparib capsules (labeled active pharmaceutical ingredient)
88831277|NCT01754779|Active Comparator|Citric Acid|Citric acid tablets twice daily
89359396|NCT01316484||No Treatment|Adult subjects with diabetes mellitus and a diagnosis of gastroparesis
89359397|NCT01316562||Group 1|Healthy controls
89359398|NCT01316562||Group 2|Patients with an Alzheimer's disease or related disorders
89359399|NCT03773315|Experimental|UMH group|This group takes UMH extract for 12 weeks
89359400|NCT03773315|Placebo Comparator|Placebo group|This group takes placebo for 12 weeks
89359401|NCT01316718|Experimental|Mesalazine Granules|2g oral granules, once a day for 1 week, then 2g oral granules, twice a day for 11 weeks
89359402|NCT01316718|Placebo Comparator|Placebo Granules|2g oral granules, once a day for 1 week, then 2g oral granules, twice a day for 11 weeks
88831278|NCT01754779|Active Comparator|Potassium Citrate|Potassium Citrate tablets twice daily
88831279|NCT02298361||Intervention patients|Community Health Centers that implemented health insurance outreach IT tools: active patients on whom tools were used
88831280|NCT02298361||Within-clinic comparison patients|Community Health Centers that implemented health insurance outreach IT tools: active patients on whom tools were not used
88831281|NCT02298361||Control clinic comparison patients|Matched Community Health Centers that did not implement health insurance outreach IT tools: active patients
88831282|NCT02149277|Active Comparator|Filgrastim|Injection Filgrastim 300 ug intravaginally during an IVF cycle or during an embryo transfer
88831283|NCT02149277|Placebo Comparator|Sodium Chloride|Injection of 1 ml of Sodium Chloride intravaginally during an IVF cycle or during an embryo transfer cycle.
88831284|NCT02005393|Other|FICE Imaging System followed by NBI|Images Captured with FICE Image Acquisition System (experimental) followed by NBI Image Acquisition System (standard of care); always in that order. Imaging took place in esophagus, gastric, duodenum and/or colon.
88831285|NCT02896907|Experimental|Treatment (FOLFIRINOX, ascorbic acid)|Patients receive oxaliplatin IV over 2 hours, irinotecan hydrochloride IV over 90 minutes, leucovorin calcium IV over 2 hours, and fluorouracil IV continuously over 46 hours on day 1. Patients then receive ascorbic acid IV over 2 hours on days 3, 5, 8, 10 and 12. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
88831286|NCT02005549|Experimental|Neoadjuvant Therapy|
88831287|NCT02897141|Experimental|mVIP group|This group will receive targeted symptom strategies via a Health Management App developed from the UCSF symptom management manual based on the symptoms that they report. This is the intervention app group.
89359403|NCT01320839||Stroke|People who have had a stroke and have an ankle-foot orthosis.
89359404|NCT01339806|Other|Standard of Care for mTBI Provider Arm|Arm 1: Psychoeducational Control Group. Individuals assigned to arm 1 will receive psychoeducational materials specifically adapted for persistent management of symptoms and routine follow-up with medical providers (every three weeks). Additionally, subjects assigned to this group will receive medical care (e.g., psychopharmacological management of depression) and/or referral for symptom management (e.g., vestibular rehabilitation) of non-cognitive complaints, consistent with the current standard of care treatment model for managing post-concussive symptoms (see Figure below adapted with permission from authors; Brenner et al., 2009).
88831288|NCT02897141|Placebo Comparator|Attention Control Group|This group will received an app without symptom strategies, pre-loaded on their smartphones. This is the control app group.
89359405|NCT01339806|Experimental|Computer Based Therapy Group|"Arm 2: Non-therapist directed computerized cognitive rehabilitation. Individuals assigned to treatment arm 2 will receive ten hours of in-clinic, computerized treatment per week throughout the 6-week treatment trial. Participants will be scheduled for 2 hours per day, proctored by clinic staff (certified recreation therapist or neuropsychology technician) who will be responsible for recording daily performance, providing positive reinforcement of participation, and effort. Computer programs selected for this treatment trial include both skill-specific training (e.g., attention processes) and general cognitive activation. These computer programs are commercially available and advertised as brain fitness or brain training."
89359406|NCT01339806|Experimental|Cognitive Rehab Group|"Arm 3: Therapist-directed individualized cognitive rehabilitation. Individuals assigned to treatment arm 3 will receive 10 hours of individual and group cognitive rehabilitation treatment (including homework assignments) per week conducted by credentialed speech therapists and occupational therapists. The treatment components will include five hours of weekly individual therapy (one-hour sessions; two hours focused on compensatory strategies and three hours focused on restorative strategies), two hours of weekly group therapy (one hour sessions focused on compensatory strategies), and three hours of weekly computer-based homework proctored by clinic staff who will be responsible for recording performance, and providing positive reinforcement of participation and effort."
89399142|NCT03540524|Experimental|Cohort C - F508del homozygous|Dual combination (GLPG2451 and GLPG2222) will be administered for 14 days, followed by the triple combination (GLPG2451, GLPG2222 and GLPG2737) for 14 days, without washout in between the sequential treatment periods. (Study Part II)
88831289|NCT03645356|Active Comparator|fixed appliances|patients will be treated using fixed appliances in order to align their teeth after extraction of four premolars
88831290|NCT03645356|Experimental|clear aligners|patients will be treated using clear aligners in order to align their teeth after extraction of four premolars
88831291|NCT04349696|Active Comparator|T2DM with Child-Pugh A|"All subjects with T2DM with normal hepatic function received a Mitiglinide Tablets 10 mg.~Intervention: Drug: Mitiglinide Tablets 10 mg"
88831292|NCT04349696|Experimental|T2DM with Child-Pugh B|"All subjects with T2DM with moderate impaired hepatic function received a MitiglinideTablets 10 mg.~Intervention:Drug: Mitiglinide Tablets 10 mg"
88831293|NCT03028675||Multiple Sclerosis|
88831294|NCT03028675||Healthy Volunteer|10 age-matched control volunteers
88875497|NCT04199832||gastrostomy feeding|Patients with dysphagia before chemoradiotherapy began to voluntarily choose gastrostomy feeding.
88831295|NCT03582020|Placebo Comparator|Traditional Western Diet|Intervention: Menu plans and recommendations for persons who consume a traditional Western diet (daily consumption of meat and sausage)
88831296|NCT03582020|Active Comparator|Flexitarians|Intervention: Menu plans and recommendations for persons, who rarely consume meat and meat products (predominantly high-quality products; ≤ 2 times / week) = flexitarians
88831297|NCT03582020|Active Comparator|Vegetarians|Intervention: Menu plans and recommendations for persons who do not eat meat and sausage (vegetarians)
88831298|NCT03582020|Active Comparator|Vegans|Intervention: Menu plans and recommendations for persons who do not eat products from animal origin (vegans)
88831299|NCT01529983|Experimental|Fractional photothermolysis|Fractional photothermolysis (FP) for treatment of photo- damaged skin is an FDA-approved method for treating facial rhytids. Fractionated treatment with 1550-nm laser is a safe, nonsurgical method for improvement of periorbital rhytides, photodamage, and scarring
88831300|NCT01529983|Active Comparator|High-intensity focused ultrasound|High-intensity focused ultrasound (HIFUS) is an FDA-approved method for periorbital treatment and nonablative tissue tightening. Ultrasound waves induce a vibration in the tissue, generating heat and increasing the tissue temperature within a focal area. The tissue changes depend on amount of heat and exposure duration. These findings are similar to the thermally induced changes within the skin after CO2 laser fractional ablative treatments.
88831301|NCT01808183||supracondylar humerus fractures|All members of the study will have near Infrared spectroscopy pads placed on their injured and uninjured arms as a part of this study.
88831302|NCT02809859|Experimental|Investigational CPAP device|Fisher & Paykel Healthcare CPAP Device
88831303|NCT04116619||Individuals with Cannabis Use Disorder|Participants who meet criteria for Cannabis Use Disorder will complete three guided imagery conditions (stress, cannabis, neutral) in an inpatient research unit. During the guided imagery, repeated measurements of subjective (i.e., craving, negative affect), neuroendocrine (i.e., cortisol), and physiological variables (i.e., heart rate variability [HRV]) will be collected.
88831304|NCT04116619||Light Cannabis Users|Participants who are light cannabis users (<1 joint/week) will complete three guided imagery conditions (stress, cannabis, neutral) in an inpatient research unit. During the guided imagery, repeated measurements of subjective (i.e., craving, negative affect), neuroendocrine (i.e., cortisol), and physiological variables (i.e., heart rate variability [HRV]) will be collected.
88831305|NCT02810327||MZ heterozygote with symptoms of COPD|Individuals who have previously had testing for Alpha-1 antitrypsin deficiency with genotype MZ (PiMZ) results. Individuals in this cohort have symptoms or clinical diagnosis of COPD.
88831306|NCT02810327||MZ heterozygote without symptoms of COPD|Individuals who have previously had testing for Alpha-1 antitrypsin deficiency with genotype MZ (PiMZ) results. Individuals in this cohort do not have symptoms or clinical diagnosis of COPD.
88831307|NCT04349462|Other|VFSS and Water Sip Test|Enrolled patients will undergo a water sip test and Videofluroscopy Swallow Test (VFSS)
89359407|NCT01339806|Experimental|Cognitive and Psychological Based Rehab|"Arm 4: Integrated interdisciplinary cognitive rehabilitation combined with cognitive-behavioral psychotherapy. Individuals assigned to treatment arm 4 will receive 10 hours of individual and group treatment per week conducted by credentialed therapists and doctoral-level psychologists. The treatment components will include four hours of weekly 1 hr individual therapy sessions; 2 hrs of cognitive rehabilitation, 1 hr of cognitive rehab & 1 hr of individual psychotherapy targeting anxiety/combat stress symptoms including relaxation training & exposure therapy and cognitive-behavioral principles, 3 hrs of weekly group therapy & three hours of weekly homework including 30-mins relaxation training, 30-mins cognitive-behavioral psychotherapy homework, and 2 hrs of computerized cognitive rehabilitation exercises proctored by clinic staff."
89359408|NCT01316952||LabRx database Oct. 1st 2004 to Sep. 30th 2009|The study cohort from which cases and controls are drawn is all subjects in the LabRx database between Oct. 1st 2004 to Sep. 30th 2009.
89399143|NCT03539978||SM-THINk Unit|Two of the three inpatient floors will use the SM-THINk enhanced discharge method. This is part of a clinical practice change and not for research. Parents will complete a questionnaire at the time of the patient's discharge from the hospital.
88831308|NCT02810873|Experimental|F-18-FDG Whole body Scan|STAGE I: Patients with a positive biopsy and abnormal (positive) fludeoxyglucose F18-labeled PET whole-body scan undergo a whole-body copper Cu 64 TP3805-labeled PET scan.
88831309|NCT02810873|Experimental|No F-18-FDG Scan|STAGE II: Patients with a positive biopsy, but no fludeoxyglucose F18 scan undergo a breast fludeoxyglucose F18-labeled PEM Positron Emission Mammography scan followed by a breast copper Cu 64 TP3805-labeled PEM scan.
88831310|NCT04492358|Experimental|colchicine + prednisone|Prednisone should be administered for 3 consecutive days (60 mg/d) together with colchicine (at doses of 0.5 to 1.5 mg/d, adjusted for weight and renal function) for 3 days and maintained for 14 days in total (0.5 mg/d).
88831311|NCT04492358|Active Comparator|Standard treatment|The standard treatment used in each site will be administered to the patients assigned to the control group.
88831312|NCT04480970|Experimental|Nasogastric tube placement|
88831313|NCT04470128|Experimental|Stage I: HSK21542 0.5 μg/kg|intravenous injection
88831314|NCT04470128|Experimental|Stage I: HSK21542 1 μg/kg|intravenous injection
88831315|NCT04470128|Experimental|Stage II : HSK21542 0.5 μg/kg|intravenous injection
88831316|NCT04470128|Experimental|Stage II : HSK21542 1 μg/kg|intravenous injection
88831317|NCT04470128|Experimental|Stage II : HSK21542 2 μg/kg|intravenous injection
88831318|NCT04470128|Placebo Comparator|Stage II : placebo|intravenous injection
88831319|NCT03447704|Experimental|BCD-085 (netakimab)|
88831320|NCT03447704|Placebo Comparator|Placebo|
88831321|NCT01661426|Active Comparator|Low-Carbohydrate Diet first, then Low-Fat Diet (IR)|Participants who were more insulin resistant based on the median AUC for insulin concentrations measured from OGTT prior to randomization.
88831322|NCT01661426|Active Comparator|Low-Fat Diet first, then Low-Carbohydrate Diet (IS)|Participants who were more insulin sensitive based on the median AUC for insulin concentrations measured from OGTT prior to randomization.
88831323|NCT02811419|Active Comparator|i-scan|Inspection with i-scan surface enhancement
88831324|NCT02811419|Active Comparator|Standard high-definition white light|Inspection with standard high-definition white light (usual care)
89359409|NCT02726074|Experimental|Perampanel 12 mg|During the Titration Period, participants will receive perampanel 2 milligrams per day (mg/day) and be up-titrated in no less than 2-week intervals in increments of 2 mg up to 12 mg according to the investigator's judgment. Upon entering the Maintenance Period, participants will receive the last dose they achieved at the end of the Titration Period and will continue receiving this dose once daily for the remainder of the study.
88831325|NCT02811965|No Intervention|Control|Pressure mapping is performed without a heel offloading intervention applied.
88831326|NCT02811965|Experimental|Pillow Condition 1|Pressure mapping is performed with the Pillow condition 1 intervention applied to the heel.
88831327|NCT02811965|Experimental|Pillow Condition 2|Pressure mapping is performed with the Pillow condition 2 applied to the heel.
88831328|NCT02811965|Experimental|Heel Foam Pillow|Pressure mapping is performed with the heel foam pillow device applied to the heel.
88831329|NCT02811965|Experimental|Offloading Device A|Pressure mapping is performed with Offloading Device A applied to the heel.
88831330|NCT02811965|Experimental|Offloading Device B|Pressure mapping is performed with Offloading Device B applied to the heel.
88831331|NCT02811965|Experimental|Offloading Device C|Pressure mapping is performed with Offloading Device C applied to the heel.
88831332|NCT01637051|Other|Zimmer NexGen®, Trabecular Metal Technology (TMT) Monoblock|The tibial component has a monoblock design
88831333|NCT01637051|Other|Zimmer NexGen® Trabecular Metal Technology (TMT), Modular|The tibial component has a modular design
88831334|NCT01066663|Experimental|DL1: Pyrimethamine 12.5 mg|Pyrimethamine single daily oral 12.5 mg dose.
88831335|NCT01066663|Experimental|DL2: Pyrimethamine 25 mg|Pyrimethamine single daily oral 25 mg dose.
88831336|NCT01066663|Experimental|DL3: Pyrimethamine 50 mg|Pyrimethamine single daily oral 50 mg dose.
88831337|NCT00804427|Experimental|Fish oil (90% triglycerides)|Fish oil (4 grams/day of combined EPA and DHA) as 90% triglyceride formulation, taken in two divided doses with main meals.
88831338|NCT00804427|Experimental|Fish oil (60% triglycerides)|Fish oil (4 grams/day of combined EPA and DHA) as 60% triglyceride formulation, taken in two divided doses with main meals.
88831339|NCT00804427|Experimental|Fish oil (ethyl esters)|Fish oil (4 grams/day of combined EPA and DHA) as ethyl esters formulation (0% triglycerides), taken in two divided doses with main meals.
88831340|NCT00804427|Placebo Comparator|Soy oil|Soy oil supplement with identical total fat content, taken in two divided doses with main meals.
88831341|NCT01508078||Asthmatics|Otherwise healthy asthmatic subjects
89178066|NCT00626392|Experimental|NER 1000; ASA run-in, ASA coadmin|Aspirin (ASA) daily during run-in (1 week); ASA 30 min prior to niacin extended-release ([NER], 1000 mg starting dose), daily during coadministration period (4 weeks)
88831342|NCT01508078||Healthy controls|Healthy individuals without evidence of pulmonary disease.
88831343|NCT04349527||RB Group|In this Group Patients receive round-block oncoplastic breast coserving surgery
89178067|NCT00626392|Experimental|NER 1000; ASA Pbo run-in, ASA coadmin|Aspirin placebo (ASA Pbo) daily during run-in (1 week); ASA 30 min prior to niacin extended-release ([NER], 1000 mg starting dose), daily during coadministration period (4 weeks)
88831344|NCT04349527||RG Group|In this Group Patients receive retrogladular oncoplastic breast coserving surgery
88831345|NCT02986724||Vedolizumab|Bio-naïve participants with UC or CD will be treated with vedolizumab as per local prescriptions from physician in routine medical practice for up to 52 Week. Participants who fail on vedolizumab may be switched during the study to another biologic treatment as prescribed by the physician during routine medical practice for up to 52 Weeks.
88831346|NCT01959685|Experimental|Dose escalting|Placebo, 125 mg Androxal, 250 mg Androxal each given as a single dose
88831347|NCT02986646||physical therapy (PT) and rest|This group of subjects will be prescribed a physical therapy home exercise program and rest (of the injured elbow).
88831348|NCT02986646||PT and intra-tendinous steroid injection|This group of subjects will be prescribed a physical therapy home exercise program and will received an intra-tendinous corticosteroid injection into the area of the ECRB origin (of the injured elbow).
88831349|NCT02986646||PT and intra-articular steroid injection|This group of subjects will be prescribed a physical therapy home exercise program and will received an intra-articular corticosteroid injection into the elbow joint (of the injured elbow).
88831350|NCT04333589|Experimental|Favipiravir group|On the 1st day, 1600mg each time, twice a day; from the 2nd to the 7th day, 600mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 14 days.
88831351|NCT04333589|No Intervention|Regular treatment group|Treatments other than lopinavir and ritonavir, chloroquine phosphate, hydroxychloroquine sulfate, arbidol, and colomycin can be given.
88831352|NCT02902913|Experimental|Oleocanthal-rich, D2i2|Oleocanthal-rich, D2i2 (Extra virgin olive oil containing oleocanthal to oleacein in a 2:1 ratio)
88831353|NCT02902913|Experimental|Oleacein-rich, D2i0.5|Oleacein-rich, D2i0.5 (Extra virgin olive oil containing oleocanthal to oleacein in a 1:2 ratio)
88831354|NCT02902913|Placebo Comparator|Oleocanthal and Oleacein-low, D2i0|Oleocanthal and Oleacein-low, D2i0 (Extra virgin olive oil containing low amounts of oleocanthal to oleacein, but with a similar total phenolic content as the other two oils)
89359410|NCT02479438||Diagnosed with GERD|Collect data on GERD patients
88831355|NCT02902913|Active Comparator|Ibuprofen|Ibuprofen, 400 mg
88831356|NCT04737161|Experimental|T regulatory cell infusion|Infusion will be administered to the patient within 72 hours of collection from donor.
88831357|NCT03002753|Experimental|DM|Group of patients receiving detached mindfulness (for details, see detailed description of the study)
88831358|NCT03002753|Active Comparator|CR|Group of patients receiving cognitive restructuring (for details, see detailed description of the study)
88831359|NCT03002753|No Intervention|WL|Waitlist control group, which, however, is again randomized after the waiting time in order to receive one of the two interventions (DM or CR).
88831360|NCT03417986|Experimental|Group 1a: TEP 26 mg daily for 4d|
88831361|NCT03417986|Experimental|Group 1b: TEP 52 mg daily for 4d|
88831362|NCT03417986|Experimental|Group 2: TEP 26 mg daily for 54d|
88875498|NCT04199832||Oral intake|Patients with normal swallowing or not receiving tube feeding.
89359411|NCT02481388||Weakness Group (WG)|Patients with heart failure and a maximum inspiratory pressure (MIP) <70% of predicted MIP to age, considered as inspiratory muscle weakness. Following the recruitment process, these volunteers will be evaluated by spirometry and manovacuometry. Afterwards, volunteers will be also assessed in a maximal exercise ramp test. Before and after the ramp test, the optoelectronic pletysmography will be performed to analyse the chest wall tricompartmental distribution and the shortening velocities of rib cages muscles. Also a high-definition ultrasonography will be performed to measure the right diaphragmatic cupule thickness
89399144|NCT03539978||Control Unit|One of the three inpatient floors will use the usual discharge method. Parents will also complete a questionnaire at the time of the patient's discharge from the hospital.
89399145|NCT02255864|Experimental|Coronary Scaffold Implantation|AmM FORTITUDE Bioresorbable Drug-Eluting Coronary Scaffold
89530295|NCT03254953|Experimental|Simultaneous Intervention|"in this Simultaneous eHealth intervention, participants are asked to self-monitor both their body weight and diet for 3 months~participants are asked to use the MyFitnessPal app for self-monitoring~given goal to lose 5% weight by end of intervention (3 months)~weekly personalized feedback via email~weekly skills training materials (behavioral modification lessons; tips on using different features of the app) via email~weekly action plans via email"
88831363|NCT02906813|Experimental|TAK-935 300 mg (Tablets Fed+Tablets Fasted+Solution Fasted)|TAK-935 300 mg, tablets, orally, 30 minutes after a high-fat meal on Day 1 of Intervention Period 1, followed by a washout period of at least 3 days, further followed by TAK-935 300 mg, tablets, orally, under fasted state on Day 1 of Intervention Period 2, followed by a washout period of at least 3 days, further followed by TAK-935 300 mg, solution, orally, in fasted state on Day 1 of Intervention Period 3.
88831364|NCT02906813|Experimental|TAK-935 300 mg (Tablets Fasted+Solution Fasted+Tablets Fed|TAK-935 300 mg, tablets, orally under fasted state on Day 1 of Intervention Period 1, followed by a washout period of at least 3 days, further followed by TAK-935 300 mg, solution, orally, in fasted state on Day 1 of Intervention Period 2, followed by a washout period of at least 3 days, further followed by TAK-935 300 mg tablets, orally, 30 minutes after high-fat meal on Day 1 of Intervention Period 3.
88831365|NCT02906813|Experimental|TAK-935 300 mg (Solution Fasted+Tablets Fed+Tablets Fasted)|TAK-935 300 mg, solution, orally, in fasted state on Day 1 of Intervention Period 1, followed by washout period of at least 3 days, further followed by TAK-935 300 mg, tablets, orally, 30 minutes after a high-fat meal on Day 1 of Intervention Period 2, followed by washout period of at least 3 days, further followed by TAK-935 300 mg, tablets, orally, under fasted state on Day 1 of Intervention Period 3.
88831366|NCT04349228|Experimental|Hydroxychloroquine (HCQ)|Exposed health care professionals working in the intensive care unit
88831367|NCT04349228|Placebo Comparator|Placebo|Exposed health care professionals working in the intensive care unit
88831368|NCT02301416|Experimental|Phentermine/topiramate|All subjects enrolled in the study will be placed on the study medication.
88831369|NCT02301416|No Intervention|Historical Control|Historical controls who had sleeve gastrectomy during the same time frame without phentermine/topiramate treatment
88831370|NCT02815709|Experimental|Treatment 1 Oliceridine|
88831371|NCT02815709|Experimental|Treatment 2 Oliceridine|
88831372|NCT02815709|Experimental|Treatment 3 Oliceridine|
88831373|NCT02815709|Placebo Comparator|Placebo|
88831374|NCT02815709|Active Comparator|Morphine|
88831375|NCT02816723|Experimental|Mindfulness|mindfulness/meditation/movement training
88831376|NCT02816723|Active Comparator|Brain Health|Brain Health education class
88831377|NCT02912195|Experimental|Intravenous lidocaine|"Participants will receive IV lidocaine (75 mg if <50kg, 100 mg if 50 - 100 kg, and 150 mg if >100 kg) over 10 minutes in a 100 mL normal saline minibag followed by a 50 minute IV lidocaine drip (75 mg if <50kg, 100 mg if 50 - 100 kg, and 150 mg if >100 kg) in a 100 mL normal saline minibag.~At 20 and 40 minutes, participants can elect to receive morphine 4mg IV as a rescue analgesic."
88831378|NCT02912195|Active Comparator|Morphine|"ED provider will choose an appropriate dose of intravenous morphine for the patient.~At 20 and 40 minutes, participants can elect to receive morphine 4mg IV as a rescue analgesic."
88831379|NCT01960075|Active Comparator|Fosphenytoin (FOS)|Administer 20 mg/Kg fosphenytoin intravenously up to a maximum dose of 1500 mg ( 75 Kg) over 10 minutes. Those weighing more than 75 Kg receive a fixed dose of 1500 fosphenytoin over 10 minutes.
88831380|NCT01960075|Active Comparator|Valproic acid|Administer 40 mg/Kg valproic acid intravenously up to a maximum dose of 3000 mg (75 Kg) over 10 minutes. Those weighing more than 75 Kg receive a fixed dose of 3000 valproic acidover 10 minutes.
88831381|NCT01960075|Active Comparator|Levetiracetam|Administer 60 mg/Kg levetiracetam intravenously up to a maximum dose of 4500 mg ( 75 Kg) over 10 minutes. Those weighing more than 75 Kg receive a fixed dose of 4500 levetiracetam over 10 minutes.
88831382|NCT01988246|Sham Comparator|Sham Injection|"Patients will be sequentially randomized to treatment with a sham injection at the time of surgery. The sham injection is accomplished by pressing an empty syringe against the eye wall without penetration. This will be administered post cataract excision by the Prinicipal Investigator. The patient will be masked as to which Arm they are assigned."
88831383|NCT01988246|Active Comparator|Intravitreal Aflibercept Injection|Patients will be sequentially randomized to treatment with Aflibercept 2 mg via intravitreal injection (0.05 mL or 50 microliters) at the time of surgery. This will be administered post cataract excision by the Principal Investigator. The patient will be masked as to which Arm they are assigned.
88831384|NCT02821403|Experimental|Young adults|adults without presbyopia who aged 18-35 years
88831385|NCT02821403|Experimental|Middle-aged adults|adults with presbyopia who aged over 40 years
89359412|NCT02481388||Control group (CG)|Patients with heart failure and do not have a maximum inspiratory pressure (MIP) > 70% of predicted MIP to age, considered as inspiratory muscle weakness. Following the recruitment process, these volunteers will be evaluated by spirometry and manovacuometry. Afterwards, volunteers will be also assessed in a maximal exercise ramp test. Before and after the ramp test, the optoelectronic pletysmography will be performed to analyse the chest wall tricompartmental distribution and the shortening velocities of rib cages muscles. Also a high-definition ultrasonography will be performed to measure the right diaphragmatic cupule thickness
89359413|NCT02479360||Outcome measurement|Each participant will be asked to complete each standardised outcome measure (SOM) three times and each trial will be videotaped by the researcher. The selected SOM's are the 10 metre walk test, the timed up and go test, the functional reach test and the nine-hole peg test. A physiotherapist will watch the video on 2 separate occasions to evaluate intra-rater reliability. Inter-rater reliability will be assessed through asking three other neurofibromatosis specialist professionals (two NF1 consultants and one NF1 specialist nurse) to review the video and to score each measure completed. Once the filmed sessions have been analysed by the relevant clinician's the data will be destroyed in line with Trust policy.
89359414|NCT02476318|Experimental|ArterX Vascular Sealant|
89359415|NCT02476240|Active Comparator|Internally Focused PD-SAFEx|While performing the exercises in PD-SAFEx™, participants will be instructed to focus their attention on sensory feedback. This will include focusing participants' attention on the stretch in their limbs while walking, on the straightness of their backs while sitting, on limb and body orientation in space while coordinating their movements, and on chest movements during breathing exercises. Throughout each exercise session, the instructor and volunteers will constantly provide attention-directing instructions.
89359416|NCT02476240|Experimental|Externally Focused PD-SAFEx|While performing the exercises from the PD-SAFEx™ program, participants will be instructed to focus their attention externally on the movement of coloured labels attached to their feet, knees, elbows and hands. Participants will be reminded and encouraged by the exercise instructor and volunteers to perform all exercises while focusing attention on the labels.
88831386|NCT01990820|Active Comparator|Adenoidectomy without balloon dilation|Subjects will have Adenoidectomy + maxillary sinus irrigation, without balloon dilation.
89359417|NCT02476240|No Intervention|Control Group|This group will be asked to refrain from changing activities of their daily lives throughout the 20-week duration of the experiment (from pre-assessment to washout).
89359418|NCT02478814|Experimental|Active, Young Adult Males|Subjects will receive different levels of amino acid intakes varying from 0.2 to 2.6 g/kg/day.
89359419|NCT05449444|Experimental|Masitinib (4.5) & BSC|Masitinib 4.5 mg/kg/day administered as an add-on to optimal concomitant symptomatic treatment (i.e. best supportive care, BSC). Participants receive masitinib (3.0 mg/kg/day) for 4 weeks, given orally twice daily, with a dose escalation to 4.5 mg/kg/day for the remainder of the treatment period. Each ascending dose titration is subjected to a safety control.
89359420|NCT05449444|Experimental|Masitinib (6.0) & BSC|Masitinib 6.0 mg/kg/day administered as an add-on to optimal concomitant symptomatic treatment (i.e. best supportive care, BSC). Participants receive masitinib (3.0 mg/kg/day) for 4 weeks, given orally twice daily, with a dose escalation to 4.5 mg/kg/day for4 weeks of treatment, then a second dose escalation to 6 mg/kg/day for the remainder of the treatment period. Each ascending dose titration is subjected to a safety control.
89359421|NCT05449444|Placebo Comparator|Placebo & BSC|Placebo administered as an add-on to optimal concomitant symptomatic treatment (i.e. best supportive care, BSC). Participants receive a matched dose placebo, given orally twice daily.
89359422|NCT02481544|Experimental|Gratitude Journaling Plus Standard of Care|"The most often used gratitude intervention consists of journaling, writing lists of things for which the individual is grateful. This technique was first employed and found to be effectual for enhancing wellbeing by Emmons and McCullough and has been suggested to be as effective as methods frequently used in clinical therapy. We are proposing an 8-week intervention in which the participant records 3-5 things for which they are grateful most days of the week. A longer intervention was chosen because Emmons and McCullough (2003) suggest that healthy behavior changes only occurred in a prolonged multi-week intervention. To ensure some conformity in the intervention, instructions that will be used will be similar to Emmons and McCullough (2003): There are many things in our lives, both large and small, that we might be grateful about. Think back over your day (week) and write down on the lines below up to five things in your life that you are grateful or thankful for."
88831387|NCT01990820|Experimental|Adenoidectomy with balloon dilation|Adenoidectomy + balloon dilation of maxillary sinus ostia using Acclarent Relieva Balloon Sinuplasty + irrigation
88831388|NCT01990898|Experimental|Cyclosporine|Drug: Cyclosporine, Pill form, dosage calculated upon patient study visit, frequency - twice daily, duration - 3 months.
88831389|NCT02822885|Experimental|ultrasonography|Ultrasonographic assessment of the thickness of the endometrium of the uterus and transvaginal color Doppler ultrasonography for measurements of Pulsatility index and resistance indices of uterine arteries and spiral arteries
88831390|NCT01960387|Experimental|Clofarabine and Cytarabine|Clofarabine will be administered as a 1-hour (range: 1 hour minimum to 2 hours maximum) intravenous infusion at a dose of 40mg/m2 daily on days 1 through 5. Cytarabine at a dose of 1g/m2 daily will then be given as a 2-hour intravenous infusion, starting 3 hours after the completion of clofarabine administration on days 1 through 5.
88831391|NCT01991522|Experimental|Curriculum Group|The curriculum group will undergo a comprehensive curriculum in colonoscopy utilizing a virtual reality (VR) colonoscopic simulator. This curriculum involves 6 hours of interactive, small-group didactic teaching on colonoscopy interlaced with 8 hours of supervised one-on-one endoscopy VR simulation training with experienced endoscopists.
88831392|NCT01991522|Active Comparator|Self-directed learning group|The self-directed group will receive 8 hours of colonoscopic virtual reality (VR) simulation practice with an experienced endoscopist present, but without structured training.
88875499|NCT04116996|Experimental|Adults with Parkinson's disease and severe insomnia|1 arm study
89000956|NCT04636450|Experimental|Pediatric manual instrumentation|Primary mandibular molars treated with a manual pulpectomy and a Kedo-SH system.
88831393|NCT02823431|Active Comparator|Analgesia Arm|Participants randomized to this arm will undergo uroflow studies then be given a 2-hour rest. Urodynamics with the use of Urojet (lidocaine hydrochloride 2%) will then be performed. The lidocaine gel will be placed in and around the urethra. It will be allowed to set for 3 minutes, then the remainder of the standard urodynamic evaluation will be performed. We are using Urojet (lidocaine gel) in an FDA approved manner (for analgesia).
88831394|NCT02823431|Placebo Comparator|Placebo Arm|Participants randomized to this arm will first undergo uroflow studies then be given a 2-hour rest. Urodynamic testing without analgesia (standard of care) will then be performed.
88831395|NCT01960465|Experimental|African Americans|138 Self identified African American
88831396|NCT01960465|Active Comparator|non African Americans|53 Caucasians and 29 Other race (non African-Americans) Veterans.
88831397|NCT01991990|Placebo Comparator|Placebo|
88831398|NCT01991990|Experimental|RoActemra/Actemra|
88831399|NCT02824913|Experimental|P-321 Ophthalmic Solution|0.017% P-321 Ophthalmic Solution will be administered to approximately 8 patients in Phase I and either 0.05% P-321 Ophthalmic Solution or 0.01% P-321 Ophthalmic Solution or additional 0.017% P-321 Ophthalmic Solution will be administered to approximately 16 patients in Phase II
88831400|NCT02824913|Placebo Comparator|Drug: P-321 Ophthalmic Solution placebo|Placebo treatment administered to approximately 8 patients in Phase I and approximately 16 patients in Phase II
88831401|NCT01961089|Experimental|Normal|Arm: Normal eyes Interventions: Galilei Lens Professional, IOLMaster, Lenstar
88831402|NCT01961089|Active Comparator|Mild Cataract|Arm: Eyes with mild cataract Interventions: Galilei Lens Professional, IOLMaster, Lenstar
88831403|NCT01961089|Experimental|Severe cataract|Arm: Eyes with severe cataract Interventions: Galilei Lens Professional, IOLMaster, Lenstar
88831404|NCT02825849|Experimental|PRP intrauterine infusion|Intrauterine infusion of platelet rich plasma in combination with standard treatment, in patients with Asherman's Syndrome or thin uterine lining in frozen embryo transfer cycles
88831405|NCT02825849|No Intervention|Control group with standard treatment only|Patients with Asherman's Syndrome or thin uterine lining in frozen embryo transfer cycles undergoing standard treatment protocols
88831406|NCT02057042|Experimental|PS-cCBT|peer-assisted computerized CBT
88831407|NCT02057042|Active Comparator|EUC|Enhanced usual care
88831408|NCT01961167|Experimental|Gore VIABAHN BX|Balloon expandable stenting of iliac occlusive disease
88831409|NCT03008213|Experimental|Netupitant and Palonosetron|Subjects will be allowed to participate only once in the study. Study Day 1 will be the day of Akynzeo® dosing. Subjects will receive a single capsule of Akynzeo® (300 mg of netupitant and 0.5 mg of palonosetron) on Study 1.
88831410|NCT01959542|Experimental|MRIs and PSA Blood Test|"Visit 1 (8 weeks after starting ADT): PSA blood test and prostate MRI~Visit 2 (6 weeks after starting EBRT): PSA blood test and prostate MRI~Visit 3 (on last day of EBRT): PSA blood test~Visit 4 (6 months after starting ADT): PSA blood test and prostate MRI"
89000957|NCT04636450|Active Comparator|Adult rotatory instrumentation|Primary mandibular molars treated with a rotatory technique pulpectomy and a K3 system.
88875500|NCT04107168||Cohort 1|"Disease: Unresectable AJCC (American Joint Committee on Cancer) stage 3 or 4 melanoma.~Anti-PD-1 monotherapy (Nivolumab or Pembrolizumab). Dosage form, dosage, frequency and duration will be either standard of care and accessed via normal commissioning arrangements, or will be part of an ethics-approved clinical trial, where co-enrollment into an observational study is permitted."
89359423|NCT02481544|Sham Comparator|Memorable Events Journaling Plus Standard of Care|"In the sham control condition, individuals will record memorable events with methods identical to the gratitude journaling condition: Patients will be asked to record 3-5 memorable events in a given day, on most days of the week. Patients will be contacted once per week to remind them to continue with the memorable events journal. Patients will be given 2 journals during their first testing session (one journal is for the first four weeks and the second is for the second four weeks of journaling). Patients will be contacted once per week to remind them to continue with gratitude journal writing. Patients will be instructed to record the date of each journal entry next to each new day of journaling Patients will be provided with materials to return their first journal by mail and will and return their second journal at the T2 laboratory testing session."
89534386|NCT02610855|Active Comparator|Spinal Fusion Surgery|The surgical participants recruited from the pediatric orthopaedic clinic and have severe scoliosis curves requiring posterior spinal fusion. Physical activity measured using Tri-axial accelerometers and paraspinal muscle stiffness measured by Shear Wave Elastography (SWUE) ultrasound will be quantified before and one year after spinal fusion surgery.
89534387|NCT02610855|Active Comparator|Brace Treatment|The bracing participants have scoliosis curves that require treatment with a spinal brace for at least the next year. All braces will have monitors to record hours of brace wear, as is current standard of care. Physical activity measured using Tri-axial accelerometers and paraspinal muscle stiffness measured by Shear Wave Elastography (SWUE) ultrasound will be quantified before bracing and after one year.
89534388|NCT02610855|Other|Control Arm|The control group are participants who do not have scoliosis. Physical activity measured using Tri-axial accelerometers and paraspinal muscle stiffness measured by Shear Wave Elastography (SWUE) ultrasound will be quantified at baseline and one year after enrollment.
88831411|NCT03008837|Experimental|PENFS|Veterans with fibromyalgia who meet study criteria and are randomized to the experimental group will receive standard therapy in addition to percutaneous electrical neural field stimulation (PENFS), which involves placement of small electrodes through a similar process to ear acupuncture to the ear. These electrodes are attached to a battery pack that is taped behind the ear and worn for 5-day intervals. The intention of this FDA-approved device is to relieve pain, though data on its effectiveness is still limited. Device placement (series of 4, weekly) will be performed by an Anesthesiology Pain Clinic provider. fMRI evaluation of neural changes, assessment of function and quality of life improvements will be performed at the beginning and end of the study.
88831412|NCT03008837|Active Comparator|Standard Therapy|Veterans with fibromyalgia who meet study criteria and are randomized to standard therapy will receive physical therapy, medication management through the Anesthesiology Pain Clinic, and referral to a pain psychologist. fMRI evaluation of neural changes, assessment of function and quality of life improvements will be performed at the beginning and end of the study.
88831413|NCT01962025|Active Comparator|Buttonhole needling technique|the intervention is the Buttonhole needling technique for home hemodialysis
88831414|NCT01962025|No Intervention|Step Ladder Group|Patients will use step ladder needling technique
88831415|NCT01992380|Experimental|Healthy Volunteer Subjects|Healthy males or females 50 years or older with no evidence of cognitive impairment
88831416|NCT01992380|Experimental|MCI subjects|Subjects 50 years or older with mild cognitive impairment (MCI)
88831417|NCT01992380|Experimental|Probable AD Subjects|Subjects 50 years or older with probable Alzheimer's Disease (AD)
88831418|NCT02059070|Experimental|0.125% Bupivacaine|Group 1) Post-operative 0.125% Bupivacaine Interscalene brachial plexus block, 6ml/hr, continuous.
88831419|NCT02059070|Experimental|0.2% Ropivacaine|Group 2) Post-operative 0.2% Ropivacaine Interscalene brachial plexus block, 6ml/hr, continuous.
88831420|NCT04348994|Experimental|Laser therapy|Non-ablative thermal-only Er:YAG laser treatment using IncontiLase® protocol.
88831421|NCT01962961|Experimental|PharmaNAC 1800 mg|PharmaNAC 900 mg orally twice daily for 8 weeks
88831422|NCT01962961|Experimental|PharmaNAC 3600 mg|PharmaNAC 1800 mg orally twice daily for 8 weeks
88831423|NCT01962961|Placebo Comparator|Placebo|Matching placebo pills given twice daily for 8 weeks
88831424|NCT03010631|Active Comparator|Cohort 1 (Treatment Sequence AB)|Cohort 1: Treatment A. Capsule Fasted (7-day Washout) then Treatment B. Sprinkle Formulation, Fasted
88831425|NCT03010631|Experimental|Cohort 1 (Treatment Sequence BA)|Cohort 1: Treatment B. Sprinkle Formulation, Fasted (7-day Washout) then Treatment A. Capsule Fasted
89178068|NCT00626392|Experimental|NER 1000; ASA Pbo run-in, ASA Pbo coadmin|Aspirin placebo (ASA Pbo) daily during run-in (1 week); ASA Pbo 30 min prior to niacin extended-release ([NER], 1000 mg starting dose), daily during coadministration period (4 weeks)
89534389|NCT02609685|Other|Active Surveillance|Active surveillance instead of standard of care immediate surgery. Patients will be closely monitored every six months until disease is stable for a two-year period and then annually thereafter.
88831426|NCT03010631|Experimental|Cohort 2 (Treatment Sequence CD)|Cohort 2: Treatment C: Sprinkle Formulation, Fed (7-day Washout) then Treatment D: Sprinkle Formulation, Fasted
89534390|NCT02609685|No Intervention|Immediate Surgery|"Patients who choose to get surgery immediately after diagnosis may choose to enroll in a questionnaire sub-study that will compare quality of life and anxiety scores to patients who enroll in the active surveillance study. This is considered no intervention because the protocol is not directing treatment. Surgery is the standard treatment for papillary thyroid microcarcinoma."
88831427|NCT03010631|Experimental|Cohort 2 (Treatment Sequence DC)|Cohort 2: Treatment D: Sprinkle Formulation, Fasted (7-day Washout) then Treatment C. Sprinkle Formulation, Fed
88831428|NCT01993238|Experimental|Liposonix with pre-treatment analgesia|Liposonix System (Model 2) treatment of subcutaneous adipose tissue with pre-treatment analgesia (combination of ondansetron, ketorolac, and hydromorphone)
88831429|NCT01965067|Active Comparator|C group|normal thermal condition with core temperatures between 36.5°C and 37°C
88831430|NCT01965067|Experimental|H group|mild hypothermia with core temperatures between 34.5°C and 35°C
88831431|NCT00374621|Active Comparator|Misoprostol|
89178069|NCT00820690||Clinical stage III|Women with invasive breast cancer; clinical stage III, condition to receive neoadjuvant chemotherapy based in doxorubicin/ cyclophosphamide and paclitaxel followed by surgery (mastectomy and axillary lymph node dissection)
88831432|NCT00374621|Active Comparator|Misoprostol with Isosorbide Mononitrate|
88831433|NCT01960400|Active Comparator|GMI + tDCS|Graded motor imagery (GMI) + tDCS
88831434|NCT01960400|Placebo Comparator|GMI + sham TDCS|Graded motor imagery (GMI) + sham tDCS
88831435|NCT03012191|Experimental|Gentamicin|Topical gentamicin; Topical gentamicin with microneedle roller assistance; IV gentamicin. While the intervention is the same drug, the topical gentamicin is compounded into a 0.5% ointment and the IV gentamicin is prepared to 7.5 mg/kg body weight and administered over a 30 minutes.
88831436|NCT01994486|Experimental|Telaprevir and Sofosbuvir|All subjects will receive Telaprevir twice a day, 1125mg capsule and Sofosbuvir 400 mg capsule once daily. Both will be given for 12 weeks.
88831437|NCT01997216|Other|Delefilcon A MF, then AOAMF|Delefilcon A multifocal contact lenses, followed by lotrafilcon B multifocal contact lenses, as randomized. Each product was worn bilaterally (in both eyes) for 9 hours. The wear periods were separated by 2 ± 1 days.
88831438|NCT01997216|Other|AOAMF, then Delefilcon A MF|Lotrafilcon B multifocal contact lenses, followed by delefilcon A multifocal contact lenses, as randomized. Each product was worn bilaterally (in both eyes) for 9 hours. The wear periods were separated by 2 ± 1 days.
88831439|NCT02059928|Experimental|Intraosseous device placement|Intraosseous device
88831440|NCT01967641|Experimental|buprenorphine/naloxone combination|Buprenorphine/naloxone (Bup/Nx; Suboxone sublingual tablets, Reckitt Benckiser) will be administered sublingually at daily doses of 2/0.5, 8/2 mg, and 16/4 mg, which are within the recommended dose range for treating both pain and opioid abuse. The total daily dose will be divided and administered on a QID dosing regimen (0.5/0.125, 2/0.5, and 4/1 mg QID at 0830, 1230, 1730, 2130). Each participant will be tested with all three doses in random order for two weeks at each dose (one week of stabilization followed by one week of testing). Following completion of the 7-week inpatient phase, participants will be followed at the Substance Use Research Center (SURC) and maintained on 16/4 mg Bup/Nx.
88831441|NCT03017261|Experimental|TSolution One®|This group will undergo total knee arthroplasty with the TSolution One® System for the preparation of the femoral and tibial cuts.
88831442|NCT01968421|Experimental|OM-85|The subjects will be randomly received two courses of 7mg of OM-85 to take one oral capsule per day for 10 days a month for 3 consecutive months at the beginning of the study, then 3 months later with the same schedule for 1 year.
88831443|NCT01968421|Placebo Comparator|Placebo|The subjects will be randomly received two courses of 7mg of matching placebo to take one oral capsule per day for 10 days a month for 3 consecutive months at the beginning of the study, then 3 months later with the same schedule for 1 year.
88831444|NCT02314520|Active Comparator|PICC|Patients randomly assigned to receive a peripherally inserted central catheter and they will be monitored for either having a complication or no complication.
88831445|NCT02314520|Active Comparator|CVC|Patients randomly assigned to receive a centrally inserted central catheter and they will be monitored for either having a complication or no complication.
88831446|NCT02913521|Experimental|Diclofenac Sodium Gel 1%|Apply 4 g of gel to the knee four times a day
88831447|NCT02913521|Active Comparator|Voltaren Gel|Apply 4 g of gel to the knee four times a day
88831448|NCT02913521|Placebo Comparator|Placebo|Apply 4 g of gel to the knee four times a day
88831449|NCT01969201|Experimental|Fostimon®|75 IU/vial, powder and solvent for solution for subcutaneous injection (Follicle Stimulating Hormone,IBSA Institut Biochimique SA)
88831450|NCT01969201|Active Comparator|Gonal-F®|75 IU/vial powder and solvent for solution for subcutaneous injection (Follicle Stimulating Hormone; Merck Serono)
88831451|NCT02062502|Experimental|VARIVAX™ NSP + M-M-R II™|VARIVAX™ New Seed Process 0.5 mL administered in the left arm and M-M-R II™ vaccine 0.5 mL administered in the right arm by subcutaneous injection on Day 1 and Day 91
88831452|NCT02062502|Active Comparator|VARIVAX™ 2007 Process + M-M-R II™|VARIVAX™ 2007 Process 0.5 mL administered in the left arm and M-M-R II™ vaccine 0.5 mL administered in the right arm by subcutaneous injection on Day 1 and Day 91
88831453|NCT01962428|Experimental|high loading dose of ticagrelor|Patients will receive ticagrelor 360mg loading dose, then 90mg bid maintenance dose starting 12 hours after loading dose.
88831454|NCT01962428|Active Comparator|conventional loading dose of ticagrelor|Patients will receive ticagrelor 180mg loading dose, then 90mg bid maintenance dose starting 12 hours after loading dose.
88831455|NCT01999400|Experimental|Arm 1: Pentasa then Delzicol then Apriso then Lialda|"Pentasa 500 mg capsule x 2 with 240 mL water, single dose.~Washout period of 10 days.~Delzicol 100 mg mesalamine x 1 with 245 mL water, single dose.~Washout period of 10 days.~Apriso 375 mg capsule x 3 with 240 mL water, single dose.~Washout period of 10 days.~Lialda 1200 mg tablet x 1 with 240 mL water, single dose."
88831456|NCT01999400|Experimental|Arm 2: Pentasa then Delzicol then Lialda then Apriso|"Pentasa 500 mg capsule x 2 with 240 mL water, single dose.~Washout period of 10 days.~Delzicol 100 mg mesalamine x 1 with 245 mL water, single dose.~Washout period of 10 days.~Lialda 1200 mg tablet x 1 with 240 mL water, single dose.~Washout period of 10 days.~Apriso 375 mg capsule x 3 with 240 mL water, single dose."
89178070|NCT00828334|Experimental|Transcatheter PDA Coil|Transcatheter occlusion of Patent Ductus Arteriosus (PDA) with the flex and medium Nit-Occlud PDA.
88831457|NCT01999400|Experimental|Arm 3: Apriso then Delzicol then Pentasa then Lialda|"Apriso 375 mg capsule x 3 with 240 mL water, single dose.~Washout period of 10 days.~Delzicol 100 mg mesalamine x 1 with 245 mL water, single dose.~Washout period of 10 days.~Pentasa 500 mg capsule x 2 with 240 mL water, single dose.~Washout period of 10 days.~Lialda 1200 mg tablet x 1 with 240 mL water, single dose."
88831458|NCT01999400|Experimental|Arm 4: Apriso then Delzicol then Lialda then Pentasa|"Apriso 375 mg capsule x 3 with 240 mL water, single dose.~Washout period of 10 days.~Delzicol 100 mg mesalamine x 1 with 245 mL water, single dose.~Washout period of 10 days.~Lialda 1200 mg tablet x 1 with 240 mL water, single dose.~Washout period of 10 days.~Pentasa 500 mg capsule x 2 with 240 mL water, single dose."
88875501|NCT04107168||Cohort 2|Disease: Unresectable AJCC stage 3 or 4 melanoma. Nivolumab + Ipilimumab. Dosage form, dosage, frequency and duration will be either standard of care and accessed via normal commissioning arrangements, or will be part of an ethics-approved clinical trial, where co-enrollment into an observational study is permitted.
89530296|NCT03254953|Experimental|Control (diet-tracking only)|"participants are asked to self-monitor their diet for 3 months~participants are asked to use the MyFitnessPal app for self-monitoring~given goal to lose 5% weight by end of intervention (3 months)"
88831459|NCT01999400|Experimental|Arm 5: Lialda then Delzicol then Pentasa then Apriso|"Lialda 1200 mg tablet x 1 with 240 mL water, single dose.~Washout period of 10 days.~Delzicol 100 mg mesalamine x 1 with 245 mL water, single dose.~Washout period of 10 days.~Pentasa 500 mg capsule x 2 with 240 mL water, single dose.~Washout period of 10 days.~Apriso 375 mg capsule x 3 with 240 mL water, single dose."
88831460|NCT01999400|Experimental|Arm 6: Lialda then Delzicol then Apriso then Pentasa|"Lialda 1200 mg tablet x 1 with 240 mL water, single dose.~Washout period of 10 days.~Delzicol 100 mg mesalamine x 1 with 245 mL water, single dose.~Washout period of 10 days.~Apriso 375 mg capsule x 3 with 240 mL water, single dose.~Washout period of 10 days.~Pentasa 500 mg capsule x 2 with 240 mL water, single dose."
89359424|NCT02481544|No Intervention|Standard of Care|SOC consists of medical care that is included in post-MI treatment, such as physician visits and medication adjustments and cardiac rehabilitation. These patients will not have any active intervention, but will undergo the same testing routine as the gratitude intervention group. These patients will be given the opportunity to participate in the gratitude journaling intervention after they have completed the study. Patient records will be evaluated at each timepoint for changes in medications and medical treatment.
89359425|NCT02478970|Experimental|Corneal endotheliopathy|Patients with primary corneal endotheliopathies, such as posterior polymorphous dystrophy, congenital hereditary endothelial dystrophy, Fuchs' dystrophy, iridocorneal endothelial syndrome will be evaluated with the NIDEK CEM-350 and Konan SP4000
88831461|NCT02000180|Experimental|Progressive Group|The progressive learning group will undertake 6 hours of interactive small-group didactic sessions, interlaced with up to 6 hours of self-directed instruction initially on the low-fidelity box simulator, with feedback provided one-on-one by an expert academic endoscopist. Participants in the progressive learning group can switch to the high-fidelity simulator at their discretion, but cannot return to the low-fidelity simulator. On the high fidelity VR simulator they can progress through six modules each in colonoscopy and endoscopic polypectomy in a self-directed fashion, with one-on-one feedback by an expert academic endoscopist. The endoscopy instructor will demonstrate techniques, answer questions and provide feedback. The entirety of this will be delivered over two days.
88831462|NCT02000180|No Intervention|High-Fidelity Group|The high-fidelity group will undertake 6 hours of interactive small-group didactic and hands-on sessions on the theory of colonoscopy, led by an expert academic gastroenterologist. The sessions will be interlaced with up to six hours of self-directed instruction on the high-fidelity VR simulator. Six task-specific modules of increasing difficulty in colonoscopy and colonoscopic polypectomy will be taught solely on the VR simulator with one-on-one feedback from an expert academic endoscopist. The endoscopy instructor will demonstrate techniques, answer questions and provide feedback as necessary. The entirety of this will be delivered over two days.
89359426|NCT02478970|Placebo Comparator|Normal|Patients without corneal endotheliopathies will be evaluated with the NIDEK CEM-350 and Konan SP4000
89359427|NCT03482635|Experimental|Group 1- Placebo Group|
89359428|NCT03482635|Experimental|Group 2- Small Dose Group|
89359429|NCT03482635|Experimental|Group 3- Medium Dose Group|
88831463|NCT01969435|Experimental|Melphalan, carmustine, etoposide, cytarabine (BEAM)|"Day -7, carmustine intravenous (IV) infusion~Days -6, -5, -4, and -3, etoposide and cytarabine (IV) infusions twice a day~Day -2, melphalan HCl (propylene glycol-free)(IV) infusion~Day 0, stem cell transplant."
89359430|NCT03482635|Experimental|Group 4 - High Dose Group|
88875502|NCT04107168||Cohort 3|Disease: Advanced renal cell carcinoma. Anti-PD-(L)1 + kinase inhibitor. Dosage form, dosage, frequency and duration will be either standard of care and accessed via normal commissioning arrangements, or will be part of an ethics-approved clinical trial, where co-enrollment into an observational study is permitted.
89359431|NCT05428852|Active Comparator|Standard of Care|Patients receive standard of care therapy with SRS and AICR Diet education.
89000958|NCT04636450|Experimental|Pediatric rotatory instrumentation|Primary mandibular molars treated with a rotatory technique pulpectomy and a Kedo-S system
89359432|NCT05428852|Experimental|Standard of Care + Ketogenic Diet|(standard of care, ketogenic diet) Patients receive standard of care with SRS. Patients undergo a controlled feeding period ketogenic diet comprising of meals for the first week and then transition into a free living with guided support type of intervention.
89359433|NCT01309217|Active Comparator|Usual Care|The comparison group will receive usual care in accordance to how the hospital responds to current Joint Commission on Accreditation of Healthcare Organization's (JC) standards. See below for a complete description.
89359434|NCT01309217|Experimental|Tobacco Tactics Intervention|"At the intervention sites the research nurse will teach the Tobacco Tactics Intervention to nurses. For nurses, the Cessation Toolkit includes: 1) 1 CEU contact hour for training; 2) PowerPoint presentation on behavioral and pharmaceutical interventions; 3) pocket card Helping Smokers Quit: A Guide for Clinicians developed by U.S. Department of Health and Human Services, Public Health Service; 4) behavioral and pharmaceutical protocols; and 5) computerized template for nurse documentation. For patients, the Cessation Toolkit includes: 1) brochure; 2) videotape; 3); and 4) pharmaceuticals."
89000959|NCT04636372|Experimental|Intense pulsed light therapy group|
89359435|NCT02476162||Group 1: Daily for 3 Months|Participants randomly assigned to this group will be instructed to measure their blood pressure (BP) every day during the 3-month study period. BP reading will be taken using an iHealth Wireless Blood Pressure Monitor.
89359436|NCT02476162||Group 2: Daily for 1 Week/Month|Participants randomly assigned to this group will be instructed to measure their BP for seven consecutive days once each month during the 3-month study period. BP reading will be taken using an iHealth Wireless Blood Pressure Monitor.
89359437|NCT02476162||Group 3: 3 Consecutive Days Once/Month|Participants randomly assigned to this group will be instructed to measure their BP for seven consecutive days once each month during the 3-month study period. BP reading will be taken using an iHealth Wireless Blood Pressure Monitor.
89530297|NCT04502069|Experimental|Open label opaganib|opaganib dosed at 500 mg Q12 hours
89530298|NCT03246139|Experimental|Action observation, imagery & execution|
89530299|NCT03246139|Active Comparator|Action observation|
89530300|NCT03246139|Active Comparator|Control treatment|
89530301|NCT02517359|Experimental|Single dose, healthy volunteers|
89530302|NCT02517359|Experimental|14 day repeat dose, healthy volunteers|
89530303|NCT02517359|Experimental|28 day repeat dose, healthy volunteers|
89530304|NCT02517359|Experimental|14 day repeat dose, asthma patients|
89359438|NCT03768869|Experimental|Low Risk: Oupatient Management|Patients will be categorized according to risk of serious bacterial infection per risk stratification system, which is based on demographic, clinical history and physical findings that have been shown to be predictive of risk.
89359439|NCT03768869|Active Comparator|Low Risk: Inpatient Management|Patients will be categorized according to risk of serious bacterial infection per risk stratification system, which is based on demographic, clinical history and physical findings that have been shown to be predictive of risk.
89359440|NCT03768869|Active Comparator|High Risk: Inpatient Management|Patients will be categorized according to risk of serious bacterial infection per risk stratification system, which is based on demographic, clinical history and physical findings that have been shown to be predictive of risk.
89359441|NCT03768791|Experimental|SCS off|
89359442|NCT03768791|Experimental|SCS on|
89359443|NCT02479048|Active Comparator|Test meal 1 (TM1)|High fat meal (HF) with ½ avocado (~68g)
88831464|NCT01965002|Experimental|MRgHIFU|The InSightec ExAblate 2000 magnetic resonance-guided high-intensity focused ultrasound (MRgHIFU) system is a non-invasive device that is fully integrated with an MR imaging system and used for the ablation of soft tissue. The treatment process begins with the physician acquiring a set of MR images, identifying 1+ target volume(s) of fibroid tissue to be ablated, and drawing the treatment contours. The therapy planning software computes the type and number of sonications required to treat the defined volume while minimizing total treatment time. MR images taken during the sonication provide a diagnostic quality image of the target tissue and a quantitative, real-time temperature map overlay to confirm the therapeutic effect of the treatment. The transducer is then automatically moved to the succeeding treatment point and the process is repeated until the entire volume has been treated. About 100 individual sonications can be delivered over a 3-hour period to complete a treatment.
89359444|NCT02479048|Active Comparator|Test meal 2 (TM2)|High fat meal (HF) with 1 avocado (~136g)
89359445|NCT02479048|Placebo Comparator|Control meal (CM)|High carbohydrate, high saturated fat control meal (CM) without avocado.
88831465|NCT02304757|Experimental|99Tc-MDP|15mg 99Tc-MDP were intravenously administered twice a week for 10 weeks, then once a week for 8 weeks, every two weeks for 22 weeks and monthly for another 3m.
88831466|NCT02304757|Active Comparator|Fosamax|70mg po every week for 12 months.
89359446|NCT01309295||Cohort|
88831467|NCT02002208|Experimental|OC000459 Tablets|50 mg orally once a day
88831468|NCT02002208|Placebo Comparator|Placebo Tablets|Orally once a day
88831469|NCT01969747|Experimental|Empagliflozin low|Empagliflozin low once daily
88831470|NCT01969747|Experimental|Empagliflozin medium|Empagliflozin medium once daily
88831471|NCT01969747|Experimental|Empagliflozin high|Empagliflozin high once daily
88831472|NCT01969747|Placebo Comparator|Placebo|Placebo once daily
88831473|NCT02002832|Experimental|Lurasidone group|
88831474|NCT02002832|Active Comparator|Risperidone group|
88831475|NCT02010151|Experimental|NAD-CPR|When dispatcher detects a patient with OHCA, the dispatcher activates trained neighborhoods by informing events nearby using short message service via cellular phone. The neighborhood within geographically accessible area who could perform effective CPR and defibrillation would be alerted with event of OHCA and the nearest AED.
88831476|NCT02010151|No Intervention|Conventional dispatcher assisted CPR|When dispatcher detects OHCA, they instruct the caller with CPR instructions. This is conventional dispatcher assisted CPR performed in Seoul.
88831477|NCT01966718|Experimental|Repository corticotropin injection|Repository corticotropin injection, 80 United States Pharmacopeia (USP) Units per mL, dosed as 1 mL (80 Units) subcutaneous injection every 72 hours for 12 weeks
88831478|NCT02010697|Experimental|Messages targeting nonsmokers|Messages targeting nonsmokers include 10 mailings for nonsmokers sent over 10 weeks. The mailed materials include postcards, informational materials, CDs, DVDs, coupons for cessation-related incentives such as nicotine patches, and links to secured websites. The mail campaign is augmented with brief phone calls to ensure receipt of mailings and to reinforce targeted messages.
88875503|NCT04107168||Cohort 4|Disease: Advanced renal cell carcinoma Nivolumab + Ipilimumab. Dosage form, dosage, frequency and duration will be either standard of care and accessed via normal commissioning arrangements, or will be part of an ethics-approved clinical trial, where co-enrollment into an observational study is permitted.
89359447|NCT02475928|Placebo Comparator|100 mg placebo|100 mg Placebo plus nutritional education
89359448|NCT02475928|Experimental|100 mg zinc supplement|Nutritional education plus 100 mg of zinc gluconate
89359449|NCT01320917|Active Comparator|LNG-IUS|Insertion of a LNG-IUS device
89359450|NCT01320917|Placebo Comparator|Cu-IUD|Insertion of a Cu-IUD
89359451|NCT02478658|Experimental|Intervention|"The acute intervention will consist of 1 session of training following the program:~Resistance Training Exercises. Each participant in the intervention group will perform resistance-training exercises in the form of a circuit. The circuit will consist of 10 repetitions per exercise of 7 exercises: leg press, bent-over row, bench press, squats, dumbbell jump squats with raises, dead-lifts and weighted abdominal crunches, with approximately 30 sec of rest in between each exercise (based on the estimated time needed to move from one position to the next). Initial intensity 6-7 of RPE and ending the set at 9-10. Each participant will move through the circuit 3 times, with 2 to 3 minutes of rest between each round."
89359452|NCT02478658|No Intervention|Control|No intervention
89359453|NCT02475616|Experimental|PCO371|Single oral dose of PCO371
89359454|NCT02475616|Placebo Comparator|Placebo Comparator|Single oral dose of placebo
89359455|NCT01320995|Experimental|Experimental arm|In this arm, perineal ultrasound is used directly after delivery in order to hypothetically better detect anal lesions.
89530305|NCT02517359|Experimental|14 day repeat dose, smokers|
89530306|NCT02454673||Group A|"3-4 cycles of preoperative chemotherapy~Surgery"
89530307|NCT02454673||Group B|"3-4 cycles of induction chemotherapy~Radiotherapy with concurrent chemotherapy for 5 weeks~Surgery"
89530308|NCT02517281|Experimental|Patients having received targeted therapies|Patients treated using targeted therapies
89530309|NCT02517437|Active Comparator|Suprascapular & axillary blocks|Suprascapular and axillary blocks.
89530310|NCT02517437|Active Comparator|Interscalene block|Interscalene block.
89530311|NCT00700999|Other|Arm 1|Intervention-Paroxetine
88831479|NCT02010697|Experimental|Messages targeting smokers|Messages targeting smokers include 10 mailings for smokers sent over 10 weeks. The mailed materials include postcards, informational materials, CDs, DVDs, coupons for cessation-related incentives such as nicotine patches, and links to secured websites. The mail campaign is augmented with brief phone calls to ensure receipt of mailings and to reinforce targeted messages.
88831480|NCT02010697|No Intervention|Usual care|one time mailing with a self-help quit kit
88831481|NCT02004158|Experimental|Positive psychology|Positive psychology intervention
89359456|NCT01320995|No Intervention|Standard arm|No perineal ultrasound immediately after delivery.
89534391|NCT02606136|Experimental|Pamrevlumab|Participants will receive pamrevlumab 35 milligrams (mg)/kilogram (kg) by intravenous (IV) infusion every 2 weeks for a minimum of 104 weeks.
89534392|NCT02577302|Experimental|CAN-Stim Group - CAN-Stim System|"Intervention: tibial medical device~Subjects randomized to this group will have the Protect CAN-Stim System tibial medical device implanted for the duration of the study."
88831482|NCT02308501|Active Comparator|Lastacaft ®|One drop Lastacaft ® in right eye or left eye based on randomization list once on Day 1 and once on Day 2
88831483|NCT02308501|Placebo Comparator|Tears Naturale ®|One drop Tears Naturale ® in right eye or left eye based on randomization list once on Day 1 and once on Day 2
88831484|NCT02005016|Experimental|Intervention|All study participants will be assigned to this arm of this single-arm study. Participants will receive intensive behavioral therapy intended to improve their naming (word production) ability.
88831485|NCT02311309||control|Patients with either transfusion with pre ordered packed red blood cells or hemoglobin concentration > 8 g/dL.
88831486|NCT02311309||unanticipated bleeding|Unanticipated bleeding was defined as either transfusion above the pre ordered packed red blood cells or hemoglobin concentration < 8 g/dL.
88831487|NCT01966796||PSI II|PSI less than 70 or equal to 70
88831488|NCT01966796||PSI III|PSI 70-90
88831489|NCT01966796||PSI IV|PSI 90-130
88831490|NCT01966796||PSI V|PSI more than 130
88831491|NCT01967342|Experimental|Pain Ed|Pain Education: A psychosocial treatment group focusing on providing core pain education to low-income patients who may not have received this information due to existing barriers that often includes limited health literacy. This condition also included medical treatment as usual.
88831492|NCT01967342|Experimental|CBT for Pain|Cognitive-Behavioral Therapy for Pain: A psychosocial treatment group focusing on providing core pain education and cognitive-behavior skills to low-income patients who may not have received this information due to existing barriers that often includes limited health literacy. This condition also included medical treatment as usual.
88831493|NCT01967342|Active Comparator|Usual Care|Usual Care (Medical Treatment-as-Usual: A control/comparison condition in which patients receive on-going standard care at the federally qualified health center partnering in this research. Facets of care may include medication, surgery, chiropractic, and physical therapy, among others, which are available to all patients in all arms.
88831494|NCT02006108|Experimental|Feraheme|"Intravenous injection of Feraheme, 5 mg Fe/kg~Interventions:~Drug: Feraheme Procedure: MR Scan"
88831495|NCT02006264|Active Comparator|TDF Intravaginal Ring|Tenofovir Disoproxil Fumarate intravaginal ring (TDF-IVR) is a white (with clear segment), flexible torus-shaped device with an inner core compartment comprised of TDF (86 wt% of formulation) and Sodium Chloride (NaCl) (14 wt% of formulation). The intravaginal ring will be worn continuously for 14 days. It will be inserted into the vagina following cessation of participant's menses at Visit 3 and removed at Visit 7.
88831496|NCT02006264|Placebo Comparator|Placebo Intravaginal Ring|The placebo intravaginal ring (IVR) is a clear, flexible torus-shaped device with an inner core which contains sodium chloride (NaCl). The intravaginal ring will be worn continuously for 14 days. It will be inserted into the vagina following cessation of participant's menses at Visit 3 and removed at Visit 7.
88831497|NCT02006342|Experimental|Insulin Glargine plus Regular Insulin|Patient's with Diabetic Ketoacidosis receiving standard of care treatment with regular insulin drip, IV fluids and close monitoring, with the addition of subcutaneous Insulin Glargine within 2 hours of diagnosis.
88831498|NCT02006342|Active Comparator|Control - Regular Insulin|Patient's with Diabetic Ketoacidosis receiving standard of care treatment with regular insulin drip, IV fluids and close monitoring.
88831499|NCT02006420||ARFI-SVI Ultrasound|Ultrasound imaging of forearm and thigh, lasting approximately 5-10 minutes.
89359457|NCT02481232|Experimental|freeze-dried group ACYW135 MCV 4μg|4μg group: vaccines serial number is A0001-A0100（18-55 years-old group A0001-A0020，7-17 years-old group A0021-A0040，1-6 years-old group A0041-A0060，7-10 months-old group A0061-A0080，2 months-old group A0081-A0100）
89534393|NCT02577302|Active Comparator|SNS Group - Interstim® System|"Intervention: SNS Medical device~Subjects randomized to SNS will have their Stage I device implanted and tested during a 2-week period. Stage I will have a tined, quadripolar lead placed in the S3 (preferred) or S4 (alternate) foramen in the standard fashion using fluoroscopic guidance and motor response. Motor responses can include a contraction of the levators (bellows response) with or without plantar flexion of the great toe. Subjects who are not demonstrating an appropriate motor response will not have the device implanted and will be exited from the study."
88831500|NCT02006420||Healthy Volunteers: ARFI/SVI Ultrasound|Ultrasound imaging of forearm and thigh, lasting approximately 5-10 minutes.
88831501|NCT02062580|Active Comparator|Delayed BCG|BCG delayed to 8 weeks of age
88831502|NCT02062580|Other|Early BCG|BCG at birth; standard of care
88831503|NCT01968356|Experimental|3M CHG/IPA Prep Colorless|Applied topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
88831504|NCT01968356|Experimental|3M CHG/IPA Prep Tint|Applied topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
88831505|NCT01968356|Active Comparator|ChloraPrep Hi-Lite Orange|Applied topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
88831506|NCT01968356|Placebo Comparator|Normal Saline|Applied topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
88831507|NCT02063516|Experimental|Guardian|Device: Guardian Laryngeal Mask
88831508|NCT02063516|Experimental|Proseal|Device:Proseal Laryngeal Mask Airway
89359458|NCT02481232|Experimental|freeze-dried group ACYW135 MCV 8μg|8μg group: vaccines serial number is B0001-B0100（18-55 years-old group B0001-B0020，7-17 years-old group B0021-B0040，1-6 years-old group B0041-B0060，7-10 months-old group B0061-B0080，2 months-old group B0081-B0100）
88831509|NCT02006888|Experimental|IBI-10090 low dose|IBI-10090 low dose
88831510|NCT02006888|Experimental|IBI-10090 med dose|IBI-10090 med dose
89359459|NCT03768713|Experimental|Drug (Suvorexant)|20 mg of Suvorexant daily (taken orally ~1 hour before bedtime)
89359460|NCT03768713|Placebo Comparator|Placebo|20 mg of Placebo daily (taken orally ~1 hour before bedtime)
89359461|NCT02481076|Experimental|compression therapy|"Intervention arm: administration of~Flowtron Hydroven boot in the Emergency Department~Coban2 Lite after surgery~Flowtron Hydroven boot after surger, before discharge"
89359462|NCT02481076|Other|controle|"The leg is elevated on a Braun frame. This is the old fashioned conservative treatment to prevent swelling."
89359463|NCT03768635||Necrotizing external otitis|description of necrotizing external otitis
89359464|NCT02478736||delirium group|the patients with delirum after on-pump cardiac surgery
88831511|NCT02006888|Placebo Comparator|Placebo|Placebo
88831512|NCT02007200|Experimental|Treatment (soy isoflavones)|Patients receive soy isoflavones PO for approximately 14 days before undergoing surgery.
88831513|NCT01969214|Experimental|IQP-MM-101|"Dissolve the effervescent tablets in half a glass of water,to be taken orally~1 tablet, 3 times a day"
88831514|NCT02008682|Experimental|Liraglutide 1.8 mg + metformin|2-week screening period, 26-week treatment duration, and a 1-week follow-up period
88831515|NCT02008682|Active Comparator|Sitagliptin 100 mg + metformin|2-week screening period, 26-week treatment duration, and a 1-week follow-up period
88831516|NCT01969448|Active Comparator|Inframammary Fold Incision Cohort|"Inframammary fold incision which is in the crease under the breast.~Perfusion of the involved breast will be monitored at three separate time points using laser-assisted fluorescence angiography (Spy Elite, LifeCell)~Intraoperatively prior to mastectomy~At the conclusion of NASSM (following completion of mastectomy procedure and prior to implant insertion during reconstruction) - (ie. Mastectomy done, implant not in yet)~Following the conclusion of reconstruction with an immediate implant and skin closure with either temporary staples or final suture placement (ie. Mastectomy done and implant in)"
88831517|NCT01969448|Active Comparator|Lateral Radial Incision Cohort|"Lateral radial incision~Perfusion of the involved breast will be monitored at three separate time points using laser-assisted fluorescence angiography (Spy Elite, LifeCell)~Intraoperatively prior to mastectomy~At the conclusion of NASSM (following completion of mastectomy procedure and prior to implant insertion during reconstruction) - (ie. Mastectomy done, implant not in yet)~Following the conclusion of reconstruction with an immediate implant and skin closure with either temporary staples or final suture placement (ie. Mastectomy done and implant in)"
88831518|NCT01969448|Other|Non-Randomized Cohort|"Patients in which the surgeon feels that for oncologic reasons must have a specific incision (either inframammary fold or lateral radial incision) and cannot be randomized due to concerns of compromising clinical care but otherwise meet the inclusion and exclusion criteria will be offered participation as part of a non-randomized cohort.~Perfusion of the involved breast will be monitored at three separate time points using laser-assisted fluorescence angiography (Spy Elite, LifeCell)~Intraoperatively prior to mastectomy~At the conclusion of NASSM (following completion of mastectomy procedure and prior to implant insertion during reconstruction) - (ie. Mastectomy done, implant not in yet)~Following the conclusion of reconstruction with an immediate implant and skin closure with either temporary staples or final suture placement (ie. Mastectomy done and implant in)"
89359465|NCT02478736||no delirium group|the patients without delirum after on-pump cardiac surgery
89359466|NCT05713474||Healthy controls|
88831519|NCT01969916|Other|Regadenoson|
88831520|NCT02011490|Experimental|Severe Renal Insufficiency Participants: Part 1|Participants with severe renal insufficiency will receive a single dose of 4 mg/kg sugammadex administered as an IV bolus over 10 seconds. Dose will be administered by direct injection into a peripheral vein.
88831521|NCT02011490|Experimental|Moderate Renal Insufficiency Participants: Part 1|Participants with moderate renal insufficiency will receive a single dose of 4 mg/kg sugammadex administered as an IV bolus over 10 seconds. Dose will be administered by direct injection into a peripheral vein.
88831522|NCT02011490|Experimental|Healthy Control Participants: Part 1|Healthy control participants will receive a single dose of 4 mg/kg sugammadex administered as an IV bolus over 10 seconds. Dose will be administered by direct injection into a peripheral vein.
89000960|NCT04636372|Experimental|Hot compress massage group|
89000961|NCT04636372|Experimental|Intense pulsed light therapy and hot compress massage group|
89359467|NCT05713474||Patients previously diagnosed with motor neurone disease|
89359468|NCT05713474||Patients previously diagnosed with sarcopenia|
89359469|NCT05713474||Patients previously diagnosed with post-polio syndrome|
89359470|NCT05713474||Patients previously diagnosed with myasthenia gravis|
89359471|NCT02480842|Experimental|Alloplastic group A|"After randomization (15 days after surgery):~- Patients will start to perform exercises with free shoulder ROM. Patients will be told only to limit the movement if they feel pain."
89359472|NCT02480842|Experimental|Alloplastic group B|"After randomization (15 days after surgery):~- Patients will keep shoulder exercises limited to 90° up to 30 days after surgery. At that moment (one month after surgery), then patients will also be allowed to move the shoulder with no restriction"
89530312|NCT00700999|No Intervention|Arm 2|No Intervention
89530313|NCT03347669|Experimental|FM patients|50 fibromyalgia patients/50 healthy subjects
89530314|NCT03347669|Active Comparator|Healthy subjects|50 fibromyalgia patients/50 healthy subjects
89530315|NCT03121937|Experimental|Mobile App|Participants will receive a mobile app to be used during psychotherapy that syncs information with the participant's therapist from sessions.
89530316|NCT03121937|No Intervention|Treatment as Usual|Participants will receive treatment as usual with aspects of the mobile app available through paper-based worksheets.
89530317|NCT03248869|Active Comparator|Current Daily Survey|need description
89530318|NCT03248869|Experimental|Mobile Health App (MHA)|Participants download the mobile health app via the Apple App Store
89530319|NCT03121859|Active Comparator|Neck stabilization exercise|The patients who had only neck stabilization exercise
88831523|NCT02011490|Experimental|Severe Renal Insufficiency Participants: Part 2|Participants with severe renal insufficiency will receive a single dose of 4 mg/kg sugammadex administered as an IV bolus over 10 seconds. Dose will be administered into a peripheral vein through an IV catheter connected to an IV tubing with injection port. The IV tubing is connected to a saline bag. Free-flowing access to the vein will be confirmed immediately prior to dose administration, and dose will be followed by saline flush.
88831524|NCT02011490|Experimental|Moderate Renal Insufficiency Participants: Part 2|Participants with moderate renal insufficiency will receive a single dose of 4 mg/kg sugammadex administered as an IV bolus over 10 seconds. Dose will be administered into a peripheral vein through an IV catheter connected to an IV tubing with injection port. The IV tubing is connected to a saline bag. Free-flowing access to the vein will be confirmed immediately prior to dose administration, and dose will be followed by saline flush.
88831525|NCT02011490|Experimental|Healthy Control Participants: Part 2|Healthy control participants will receive a single dose of 4 mg/kg sugammadex administered as an IV bolus over 10 seconds. Dose will be administered into a peripheral vein through an IV catheter connected to an IV tubing with injection port. The IV tubing is connected to a saline bag. Free-flowing access to the vein will be confirmed immediately prior to dose administration, and dose will be followed by saline flush.
88831526|NCT02916407|Active Comparator|Sevoflurane Group|The patients will maintained general anesthesia with sevoflurane.
88831527|NCT02916407|Experimental|Desflurane Group|The patients will maintained general anesthesia with desflurane.
88831528|NCT02916563|Experimental|Altitude|Single arm study Blood Glucose Monitoring System Altitude Performance
88831529|NCT02828267|No Intervention|Usual Care|In the Usual Care arm, patients will have standard discharge information and instructions without any further health or wellness instruction
88831530|NCT02828267|Experimental|BNI|In the BNI arm, patients will receive a 5-30 minute brief negotiational intervention about their alcohol use as well as the standard discharge information and instructions.
88831531|NCT02828267|Active Comparator|BNI plus standard booster|In the BNI plus standard booster arm, patients will receive the 5-30 minute brief negotiational intervention about their alcohol use as well as the standard discharge information and instructions. Then after discharge patients will receive a test focused on reducing alcohol use to a SMS capable cell phone weekly for a total of 6 months of follow up. The messages will be standard messages for all those in this arm.
88831532|NCT02828267|Active Comparator|BNI plus personalized booster|In the BNI plus personalized booster arm, patients will receive a 5-30 minute brief negotiational intervention about their alcohol use as well as the standard discharge information and instructions. Then after discharge patients will receive a text focused on reducing alcohol use to a SMS capable cell phone weekly for a total of 6 months of follow up. In the personalized arm, the text sent will be personalized based on information obtained about the patient's reasons for reducing their drinking found in the BNI.
88831533|NCT02918357|Experimental|Ga-68 labeled PSMA-11 PET|PSMA PET imaging: Patients will receive Ga-68 labeled PSMA-11 PET and then undergo PET/CT or PET/MRI approximately 55-70 minutes later.
88831534|NCT02829983|Active Comparator|clarithromycin group|20 subjects that received one-stage full-mouth ultrasonic debridement (FMUD) associated with clarithromycin (500 mg - 12/12 hours) for 3 days.
88831535|NCT02829983|Placebo Comparator|placebo group|20 subjects that received FMUD associated with placebo (members took with placebo 500 mg b.i.d. for 3 days).
88831536|NCT02014129|Experimental|Cohort 1 - 100 mg Abemaciclib|100 milligram (mg) abemaciclib administered orally every 12 hours (Q12H) in 28 day cycles. (Cycle 1 = 32 days.) Participants remained on treatment until discontinuation criteria were met.
88831537|NCT02014129|Experimental|Cohort 2 - 150 mg Abemaciclib|150 mg abemaciclib administered orally Q12H in 28 day cycles. (Cycle 1 = 32 days.) Participants remained on treatment until discontinuation criteria were met.
88831538|NCT02014129|Experimental|Cohort 3 - 200 mg Abemaciclib|200 mg abemaciclib administered orally Q12H in 28 day cycles. (Cycle 1 = 32 days.) Participants remained on treatment until discontinuation criteria were met.
88831539|NCT02918669|Experimental|coflex|Patients who received the coflex Device in the IDE Study and presented with a spinous process fracture at 24 months (identified by independent radiographic review lab). Patients will undergo a CT Scan.
88831540|NCT04333355|Experimental|COVID-19 patients receiving Convalescent Plasma|Convalescent Plasma from patients who recently recover from COVID-19
88831541|NCT02012192|Experimental|Ganetespib + Paclitaxel|Drug: ganetespib, dose will depend on phase I results, given iv once weekly for 3 out of 4 weeks (days 1, 8, 15 of each 4-weeks/28-days cycle); Drug: paclitaxel, 80 mg/m2, given iv once weekly for 3 out of 4 weeks (days 1, 8, 15 of each 4-weeks/28-days cycle), until progression.
88831542|NCT02012192|Active Comparator|Paclitaxel|Drug: paclitaxel: 80 mg/m2, given iv once weekly for 3 out of 4 weeks (days 1, 8, 15 of each 4-weeks/28-days cycle), until progression
88831543|NCT02066792|Experimental|Tailored Post-Session DCS|Individuals in this condition will receive 5 weeks of CBT for social anxiety disorder and two pills (i.e. one placebo before and one dcs/placebo after the session). The type of pill (i.e. dcs vs. placebo) will be determined after the session.
88831544|NCT02066792|Active Comparator|Pre-Session DCS|Individuals in this condition will receive 5 weeks of CBT for social anxiety disorder and two pills (i.e. one dcs before and one placebo after the session).
88831545|NCT02066792|Placebo Comparator|Placebo|Individuals in this condition will receive 5 weeks of CBT for social anxiety disorder and two pills (i.e. one placebo before and one placebo after the session).
88831546|NCT02066792|Active Comparator|Non-Tailored Post-Session DCS|Individuals in this condition will receive 5 weeks of CBT for social anxiety disorder and two pills (i.e. one placebo before and one dcs after the session).
88831547|NCT02922959|Active Comparator|PTOEND|"PTOEND: Personally-tailored opioid overdose prevention education and naloxone distribution.~Participants in this arm will be given a NARCAN (naloxone) nasal spray kit and personally-tailored information packet about opioid overdose and treatment."
89000962|NCT00179153|Active Comparator|1|
89000963|NCT04636099|Experimental|CTA Group|The CTA group was peformed upper abdomen enhenced and CT Angiography before surgery
89534394|NCT02546232|Active Comparator|Control|Paclitaxel 80 mg/m2 weekly for 12 weeks, thereafter current standard chemotherapy for 12 weeks
89000964|NCT04636099|No Intervention|Non-CTA Group|The CTA group was routinely peformed upper abdomen enhenced without CT Angiography before surgery
89359473|NCT02480842|Experimental|Oncoplastic group A|"After randomization (15 days after surgery):~- Patients will start to perform exercises with free shoulder ROM. Patients will be told only to limit the movement if they feel pain."
89359474|NCT02480842|Experimental|Oncoplastic group B|"After randomization (15 days after surgery):~- Patients will keep shoulder exercises limited to 90° up to 30 days after surgery. At that moment (one month after surgery), then patients will also be allowed to move the shoulder with no restriction"
89359475|NCT05713396|Experimental|Quinapril (Q)|Patients receiving Quinapril
89359476|NCT05713396|Experimental|Losartan (L)|Patients receiving Losartan
89359477|NCT05713396|Experimental|Quinapril + Losartan (Q+L)|Patients receiving both Quinapril and Losartan
89534395|NCT02546232|Experimental|Additional therapy|"Carboplatin AUC 6 (area under curve; mg/ml/min) once every 3 weeks, for 12 weeks.~Paclitaxel 80 mg/m2 weekly for 12 weeks, thereafter current standard chemotherapy for 12 weeks"
88831548|NCT02922959|Experimental|PTOEND+PI|"PTOEND+PI: Personally-tailored opioid overdose prevention education and naloxone distribution, plus Peer Intervention.~In addition to a NARCAN (naloxone) nasal spray kit and personally-tailored information packet about opioid overdose and treatment, participants randomized to this arm will also receive the experimental Peer Intervention."
88831549|NCT02014363|Experimental|ETS6103 (low dose)|ETS6103 (low dose) extended release tablets (encapsulated) taken once daily orally for the duration of randomised phase of the study (8 weeks).
88831550|NCT02014363|Experimental|ETS6103 (high dose)|ETS6103 (high dose) extended release tablets (encapsulated) taken once daily orally for the duration of randomised phase of the study (8 weeks).
88831551|NCT02014363|Active Comparator|Amitriptyline|Amitriptyline tablets (encapsulated) Standard dosing regime
88831552|NCT02014363|No Intervention|Lead-in phase|"Citalopram tablets:~Standard dosing regime"
88831553|NCT02833415|Experimental|Empagliflozin|Empagliflozin 10 mg by mouth daily for 3 months.
88831554|NCT02833415|Placebo Comparator|Placebo|Placebo one tablet daily for 3 months
88831555|NCT02014519|Other|Study Group|Subjects, male and female, aged 18 years and above who had agreed to collection of blood sample.
88831556|NCT01971086||acute rhinitis|
88831557|NCT04737551||No adjuvant treatment|Pancreatic cancer patients who received surgery without subsequent adjuvant treatment.
88831558|NCT04737551||Adjuvant chemotherapy|Pancreatic cancer patients who received surgery and only adjuvant chemotherapy.
88831559|NCT04737551||Adjuvant chemoradiotherapy|Pancreatic cancer patients who received surgery and only adjuvant chemoradiotherapy.
88831560|NCT04737551||Adjuvant chemoradiotherapy + adjuvant chemotherapy|Pancreatic cancer patients who received surgery and both adjuvant chemoradiotherapy and chemotherapy.
88831561|NCT04737395|Experimental|"Device-assisted therapy (Meditouch,MSQUARE)"|40 hours of therapy with the the Hand Tutor (MediTouch) device and a wearable vest (MSQUARE) for arm rehabilitation
88831562|NCT02012348|Placebo Comparator|Control soap|Forearms of subjects in this arm will be washed with control (non-antibacterial) soap
88831563|NCT02012348|Experimental|Antibacterial soap with triclocarban|The forearms of subjects in this group will be washed with antibacterial soap containing triclocarban
88831564|NCT02012348|Active Comparator|Antibacterial soap + benzalkonium chloride|The forearms of subjects in this group will be washed with antibacterial soap containing benzalkonium chloride
88831565|NCT02016235|Experimental|Dent Disease Intervention|Dent Disease subjects will receive 2 week supplementation with phosphorus
88831566|NCT02016235|Experimental|Kidney Stone subjects|Kidney stone with or without phosphate leak subjects will receive 2 week supplementation with phosphorus
88831567|NCT02016235|Placebo Comparator|Dent Disease Observation|Dent disease subjects will not get phosphorus
88831568|NCT02834663|Experimental|Lucentis|Patients were administered 0.5-mg IVR injections monthly for 6 months.
88831569|NCT01973036|Active Comparator|Oxytocin|This arm will receive oxytocin at a rate of 2 milliunits/milliliter. If the fetal status is reassuring, this can be increased by 2 milliunits/milliliter every 30 minutes to achieve an adequate contraction pattern as per the institution's definition to a maximum of 30 milliunits/milliliter. This infusion may be continued until delivery.
88831570|NCT01973036|Experimental|Foley Catheter and Oxytocin|A 30cc/16 French (16F) foley catheter will be inserted by the provider under direct visualization or by palpation, ensuring that the catheter is appropriately and adequately positioned. Oxytocin will be administered concurrently at a rate of 2 milliunits/milliliter (as noted under oxytocin active comparator). If the catheter remains in place after 12 hours, it will be deflated and removed and oxytocin infusion will continue.
89359478|NCT02480530|No Intervention|Control|Patients will be given educational material on the importance of adherence to statin medications. The GlowCaps device will be set to only record adherence.
89359479|NCT02480530|Experimental|Individual Feedback|In addition to educational material on adherence to statin medications, the research coordinator will review set-up of personal reminders for the GlowCaps device which will be set to glow and buzz when the medication is missed. In addition, patients will receive information on the weekly adherence feedback report.
89530320|NCT03121859|Active Comparator|TENS+ neck stabilization exercise|The patients who had both TENS and neck stabilization exercise
89530321|NCT03121859|Active Comparator|IFC+ neck stabilization exercise|The patients who had both interferential current therapy and neck stabilization exercise
89530322|NCT04502771||Antifungal treatment|Patients receiving antifungal treatment during their stay in Intensive Care Unit
89530323|NCT02454361|Experimental|KBP-7072 cohort 1|KBP-7072 by mouth once
89530324|NCT02454361|Experimental|KBP-7072 cohort 2|KBP-7072 by mouth once
89530325|NCT02454361|Experimental|KBP-7072 cohort 3|KBP-7072 by mouth once
89530326|NCT02454361|Experimental|KBP-7072 cohort 4|KBP-7072 by mouth once
89530327|NCT02454361|Experimental|KBP-7072 cohort 5|KBP-7072 by mouth once
89530328|NCT02454361|Experimental|KBP-7072 Fed Group|KBP-7072 by mouth once to the fed group
88831571|NCT02017093|Experimental|Error Enhancement|Training of the upper extremity, using a robotic devise with error enhanced forces and traditional therapy.
89359480|NCT02480530|Experimental|Feedback Friend|The patient will be given educational material on the importance of adhering to statin medications. The research coordinator will review set-up of alarm features of GlowCaps device. Similar to Arm 2, patients will be given information on interpretation of weekly adherence feedback report. If the patient chooses a family/friend, they will be called and provided information on the interpretation of weekly adherence feedback report. If the patient chooses a reciprocal partner, they will be assigned to another patient who has made a similar choice
89359481|NCT02480608|Experimental|combination Imatinib + Hydroxyurea|Patients who meet the inclusion criteria will be started on 400 mg Imatinib daily. In part 1 of the protocol, the dose of HU will be increased by 500 mg at 3-weekly intervals until the maximal tolerated dose has been reached. In part 2 of the study, patients will be randomized to receive either the combination or Imatinib monotherapy.
88831572|NCT02017093|Experimental|Control treatment|Training of the upper extremity, using a robotic devise without forces applied and traditional therapy.
88831573|NCT02835677|Experimental|Intervention|Behavioral intervention with caregivers to reduce stress and management of patient concerns, particularly ambulation
88831574|NCT02310776|Other|Automated & Handheld breast US exams|"Automated breast ultrasound exam: 3D supine automated breast ultrasound scanner.~Handheld breast ultrasound exam: High-resolution handheld breast ultrasound."
89359482|NCT02480608|Active Comparator|monotherapy Imatinib|Imatinib monotherapy
88831575|NCT02017327|Experimental|Monoprost|1 drop in each eye once daily at 9.00 pm (± 1 hour) for 3 months.
88831576|NCT02017327|Active Comparator|Lumigan 0.01%|1 drop in each eye once daily at 9.00 pm (± 1 hour) for 3 months.
88831577|NCT02017327|Active Comparator|Lumigan 0.03% Unit Dose|1 drop in each eye once daily at 9.00 pm (± 1 hour) for 3 months.
88831578|NCT02923271|Experimental|Teen-Parent Monitoring Group|"Cellcontrol DriveID device will automatically turn on when the teen or parent begins driving and will be pre-set to block all calls and text messages when the car is in motion but participants will have the ability to override the blocking. The teen-parent monitoring group involves will send email notifications to the teen when their parent unlocks their phone while driving and vice versa.~Participants (parents and teens) will self-report information on their individual driving behaviors for the three weeks prior to study enrollment, including how often they report texting while driving and self-report cellphone use. At the end of the study participants will be asked to report feedback about the use the cellphone blocking technology and their perceptions for whether their safety improved using the technology."
88831579|NCT02923271|Experimental|Teen Only Monitoring Group|"Cellcontrol DriveID device will automatically turn on when the teen or parent begins driving and will be pre-set to block all calls and text messages when the car is in motion but participants will have the ability to override the blocking. The teen only group involves parental monitoring of the teen's cellphone use while driving only. The parent will receive an email notification when their teen unlocks their phone while driving. Both parents and teens will drive under the same restrictions, but only the parent is notified of teen cellphone use.~Participants (parents and teens) will self-report information on their individual driving behaviors for the three weeks prior to study enrollment, including how often they report texting while driving and self-report cellphone use. At the end of the study participants will be asked to report feedback about the use the cellphone blocking technology and their perceptions for whether their safety improved using the technology."
88831580|NCT02018107|Experimental|N-13 ammonia to image liver PET perfusion|This single-arm study involves the non-therapeutic administration of a radiopharmaceutical, N-13 ammonia or F-18 fluorodeoxyglucose, one to two doses, during the tumor ablation procedure. The N-13 ammonia perfusion PET scan is a diagnostic imaging test. The tumor ablation procedure is performed according to our standard clinical practice and is not itself a research activity. The use of N-13 ammonia to image liver perfusion with a PET scanner is the research portion of the procedure. The participant will receive one or two IV doses of N-13 ammonia (10 mCi/dose) for intraprocedural assessment of ablation results. Not more than two doses will be administered and one or both doses will be administered on the day of the tumor ablation procedure only
88831581|NCT02314598||No treatment|
88831582|NCT02018653|Experimental|Calcium Alumina-Silicate (CASAD)|CASAD 1 gram orally every 6 hours for up to 6 days. Questionnaire completion at baseline about diarrhea and other symptoms.
88831583|NCT02018653|Placebo Comparator|Placebo|Placebo orally every 6 hours for up to 6 days. Questionnaire completion at baseline about diarrhea and other symptoms.
88831584|NCT02923895|Experimental|Test dentifrice|Participants will be instructed to dose a dry toothbrush with a full strip of toothpaste. Participants will then first brush each of the qualifying test teeth for 30 seconds each followed by the whole mouth thoroughly for at least 1 timed minute twice daily.
88831585|NCT02923895|Active Comparator|Control dentifrice|Participants will be instructed to dose a dry toothbrush with a full strip of toothpaste. Participants will brush the whole mouth thoroughly for at least 1 minute twice daily.
88831586|NCT01973348|Experimental|4-hour AmblyZ glasses|4-hour AmblyZ glasses for moderate amblyopia
88831587|NCT01973348|Active Comparator|2-hour eye patching|2-hour eye patching for moderate amblyopia
88831588|NCT01973348|Experimental|12-hour AmblyZ glasses|12-hour AmblyZ glasses for severe amblyopia
88831589|NCT01973348|Active Comparator|6-hour eye patching|6-hour eye patching for severe amblyopia
89534396|NCT02520154|Experimental|Treatment (carboplatin, paclitaxel, and pembrolizumab)|"NACT: Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15, and carboplatin IV over 1 hour on day 1. Treatment repeats every 21 days for 3 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery.~ADJUVANT THERAPY: Beginning 3-6 weeks after surgery, paclitaxel IV over 1 hour on days 1, 8, and 15, patients receive carboplatin IV over 1 hour on day 1, and pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for 3 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 20 cycles in the absence of disease progression or unacceptable toxicity."
88831590|NCT02925143|Experimental|E-learning course|
88831591|NCT02018809|Experimental|MAP Daily Notification|The subject's MAP receives daily notification about whether subject took statin.
89359483|NCT02480686|Experimental|SOF+PEG+RBV|Participants with HCV genotype 1b infection will receive Sofosbuvir (SOF) 400 mg +PEG+RBV for 12 weeks.
89359484|NCT02475538|Experimental|Electroacupuncture|"Subjects in this group will be treated with electroacupuncture along with a gradual tapering schedule.~Benzodiazepines will be tapered off over four weeks. The expected reduction rate of benzodiazepines should be 25% in the first two weeks and 12.5% in 3-4 days in week 3 and week 4. If the participants cannot tolerate the effects after tapering according to our suggested plan, the dose can be kept unchanged or they can reduce the dose at a slower pace.~Subjects will receive electroacupuncture 2 times per week for 4 consecutive weeks. Electroacupuncture involves acupuncture needling at traditionally used acupoints according to Chinese medicine theory."
89359485|NCT02475538|Placebo Comparator|Placebo acupuncture|"Subjects in this group will be treated with placebo acupuncture along with a gradual tapering schedule.~Benzodiazepines will be tapered off over four weeks. The expected reduction rate of benzodiazepines should be 25% in the first two weeks and 12.5% in 3-4 days in week 3 and week 4. If the participants cannot tolerate the effects after tapering according to our suggested plan, the dose can be kept unchanged or they can reduce the dose at a slower pace.~The subjects will be receive placebo acupuncture 2 times per week for 4 consecutive weeks. Placebo acupuncture is a treatment that simulates the procedure of acupuncture treatment but may not have the effects of acupuncture."
89534397|NCT02477358|Experimental|PRF Treated|Subjects will be randomized to either receive either left tooth platelet rich fibrin; right tooth implant alone, OR right tooth platelet rich fibrin; left tooth implant alone. Following treatment each tooth is replaced and splinted to the adjacent teeth. Teeth are followed for 3 months and then tested for vitality before extracting and examining histologically.
89359486|NCT02475460|Experimental|HM 3 LIS|All patients implanted with the HM 3 LVAD via less invasive surgical technique
89359487|NCT02475304|Experimental|Experimental FP187|Treatment with a daily dose of 500mg FP187 (twice daily). Other names: Dimethyl fumarate
89359488|NCT02475304|Placebo Comparator|Placebo Comparator|Patients will receive the same number of tablets as patients randomized to FP187 arm in order to maintain the blind. The colour and shape of the FP187 and placebo tablets will be the same so that no visible difference is detectable
89359489|NCT02478346|Experimental|All Patients|All patients enrolled in the study will prepare for surgery as per standard neurosurgical indications, procedures and institution protocols. At the time of the anesthesia induction, with the patient under general anesthesia, Fluorescein Sodium 10% (100mg/1mL) at a dose of 500mg (100mg/ml) will be administered intravenously (the optimal dosage will be determined within the study as the most minimal dose for adequate visualization will be used).
89359490|NCT02478424|Experimental|Cannabidiol arm|Patients undergoing an allogeneic hematopoietic cell transplantation will be given standard GVHD prophylaxis comprising cyclosporine and a short course of methotrexate plus CBD 150 mg BID starting 7 days before transplantation until day 100.
89359491|NCT02475148|Experimental|Part 1: Cohort 1|Participants will receive either JNJ-54175446 0.5 milligram (mg) or placebo on Day 1.
89359492|NCT02475148|Experimental|Part 1: Cohort 2|Participants will receive either JNJ-54175446 2.5 mg or placebo on Day 1.
88831592|NCT02018809|Experimental|MAP Weekly Notification|The subject's MAP receives weekly about how often the subject took statin during previous week.
88831593|NCT02018809|Experimental|MAP Missed Doses|The subject's MAP receives notification if the subject missed >2 consecutive daily doses of statin.
89359493|NCT02475148|Experimental|Part 1: Cohort 3|Participants will receive either JNJ-54175446 10 mg or placebo on Day 1.
89359494|NCT02475148|Experimental|Part 1: Cohort 4|Participants will receive either JNJ-54175446 30 mg or placebo on Day 1.
89359495|NCT02475148|Experimental|Part 1: Cohort 5|Participants will receive either JNJ-54175446 100 mg or placebo on Day 1.
89359496|NCT02475148|Experimental|Part 1: Cohort 6|Participants will receive either JNJ-54175446 200 mg or placebo on Day 1.
89359497|NCT02475148|Experimental|Part 2: Cohort 7|Participants will receive JNJ-54175446 on Day 1. The dose of JNJ-54175446 will be determined in part 1 as suitable dose.
89359498|NCT02475148|Experimental|Part 3: Cohort 8|Participants will receive JNJ-54175446 on Day 1 along with high fat/high calorie breakfast. The dose of JNJ-54175446 will be determined in part 1 as suitable dose.
88831594|NCT02018809|Other|Usual Care|Usual care with GlowCap.
88831595|NCT02838407|Other|Total group|All enrolled subjects, male or female aged between 6 months included and less than 6 years at the time of enrollment, who visited the hospital with suspected chronic lower respiratory tract infections (LRTIs) and who had an indication for bronchoalveolar lavage (BAL).
89359499|NCT03712787|Experimental|300 mg/1000 mg Tilavonemab|Participants who received 300 mg tilavonemab in Study M15-566 receive 1000 mg tilavonemab in Study M15-570 via intravenous (IV) infusion every 4 weeks for up to 5.5 years.
89359500|NCT03712787|Experimental|1000 mg/1000 mg Tilavonemab|Participants who received 1000 mg tilavonemab in Study M15-566 continue on the same dose in Study M15-570 via IV infusion every 4 weeks for up to 5.5 years.
89359501|NCT03712787|Experimental|2000 mg/2000 mg Tilavonemab|Participants who received 2000 mg tilavonemab in Study M15-566 continue on the same dose in Study M15-570 via IV infusion every 4 weeks for up to 5.5 years.
89359502|NCT03712787|Experimental|PBO/2000 mg Tilavonemab|Participants who received placebo (PBO) in Study M15-566 receive 2000 mg tilavonemab in Study M15-570 via IV infusion every 4 weeks for up to 5.5 years.
88831596|NCT02020135|Experimental|Arm 1: PSMA ADC|Subjects started the extension study at the same dose received upon completion of the core PSMA ADC 2301 study. Each Prostate Specific Membrane Antigen Antibody Drug Conjugate (PSMA ADC) dose was administered as an IV infusion over approximately 60 minutes once every three weeks (Q3W) for up to eight doses, unless a dose delay or dose reduction was required.
89359503|NCT04492150|Experimental|study group|women who will receive 250 mL/hour of dextrose 5% with normal saline in a 1:1 ratio.
89359504|NCT04492150|Active Comparator|control group|women who will receive 250 mL/hour of normal saline for the whole duration of induction
89359505|NCT02475226||Patients with body and head trauma|type of the brain injury in patients with brain damage associated both general body and head trauma
89359506|NCT02475226||Patients with pure head trauma|type of the brain injury in patients with brain damage associated pure head trauma
89359507|NCT02475226||Patients with spontaneous hemorrhage|type of the brain injury in Patients with brain damage associated spontaneous hemorrhage
88831597|NCT02020369|Experimental|FVIIa: 75 µg/kg first, then 225 µg/kg|Coagulation Factor VIIa (Recombinant): First Intervention (3 months), Second Intervention (3 months), repeat cycle until study completion.
88831598|NCT02020369|Experimental|FVIIa: 225 µg/kg first, then 75 µg/kg|Coagulation Factor VIIa (Recombinant): First Intervention (3 months), Second Intervention (3 months), repeat cycle until study completion.
88831599|NCT02839889|Placebo Comparator|Placebo|Placebo once daily for two weeks
88831600|NCT02839889|Active Comparator|Naloxegol|Naloxegol 25mg tablets once daily for two weeks
88831601|NCT02012582|Experimental|VAS203 15 mg/kg|Three 5 mg/kg/12-hours infusion with 12 hours break after each infusion. Total dose: 15 mg/kg
88831602|NCT02012582|Experimental|VAS203 20 mg/kg|10 mg/kg/24 hours, 48 hour continuous infusion. Total dose: 20 mg/kg
88831603|NCT02012582|Experimental|VAS203 30 mg/kg|10 mg/kg/24 hours, 72 hour continuous infusion. Total dose: 30 mg/kg
88831604|NCT02012582|Placebo Comparator|Saline|0.9 % Sodium chloride infusion
88831605|NCT01971385|Active Comparator|2% Squaric Acid Sensitization|2% Squaric Acid solution will be applied for sensitization to the inner arm.
88831606|NCT01971385|Placebo Comparator|Placebo Solution|Patients in placebo group will be given dimethyl sulfoxide.
88831607|NCT01971463|Experimental|Normal Saline|intravenous administration of 500cc of 0.9% NaCl over 30 minutes
88831608|NCT02925611|Active Comparator|Isoflurane|Isoflurane as an inhalational anaesthetic ,titrated with BIS ( bispectral index) /entropy monitoring,from start to end of surgery.
88831609|NCT02925611|Active Comparator|Desflurane|Desflurane as an inhalational anaesthetic ,titrated with BIS ( bispectral index) /entropy monitoring,from start to end of surgery.
88831610|NCT00374153|Experimental|1|Online personal feedback report.
88831611|NCT00374153|Experimental|2|In-person Motivational Interview with personal feedback report
88831612|NCT00374153|Experimental|3|In-person Motivational Interview only (without a personal feedback report)
88831613|NCT00374153|No Intervention|4|Assessment only
88831614|NCT00374153|No Intervention|5|Delayed Assessment
88831615|NCT02841449|Experimental|Hypohydrated|After being dehydrated in the heat tent, participants in this trial arm will be given 3 mL/kg lean body mass to consume over the rest of the day (e.g. a 75 kg participant with a body composition of 85 % fat free mass would consume 191 mL water [63.75 kg * 3 mL])
88831616|NCT02841449|Experimental|Rehydrated|After being dehydrated in the heat tent, participants in this trial arm will be given 40 mL/kg lean body mass plus 150 % of their water losses (from the heat tent procedure) over the rest of the day (e.g. a 75 kg participant with a body composition of 85 % fat free mass and lost 1 % of their body mass in the heat tent (0.75 kg) would consume 2550 mL [63.75 kg * 40 mL] + 1125 mL [750 g * 1.5], totalling 3675 mL).
88831617|NCT01973335|Experimental|Acetazolamide/low-dose loop diuretics, upfront spironolactone|"2x2 factorial design: This group is the experimental group for both study interventions (acetazolamide and upfront spironolactone).~See interventions for more details."
88831618|NCT01973335|Experimental|High-dose loop diuretics, upfront spironolactone|"2x2 factorial design: This group is the experimental group for the study intervention with upfront spironolactone. This group receives high-dose loop diuretics as an active comparator to the study intervention with acetazolamide.~See interventions for more details."
89359508|NCT02478268|Active Comparator|Patients with idiopathic pulmonary fibrosis|
88831619|NCT01973335|Experimental|Acetazolamide/low-dose loop diuretics, no spironolactone|"2x2 factorial design: This group is the experimental group for the study intervention with acetazolamide. This group receives no intervention with regards to the spironolactone arm.~See interventions for more details."
88831620|NCT01973335|Active Comparator|High-dose loop diuretics, no spironolactone|"2x2 factorial design: This group receives high-dose loop diuretics as an active comparator to the study intervention with acetazolamide. This group receives no intervention with regards to the spironolactone arm.~See interventions for more details."
88831621|NCT02844569|Experimental|Test|Extraction treated with xenograft bone substitute (BioOss Collagen®) + 3D-collagen matrix (Mucograft Seal®).
88831622|NCT02844569|Active Comparator|Control|Extraction treated with xenograft bone substitute (BioOss Collagen®) + collagen dressing (HeliPlug®).
88831623|NCT01973413|Experimental|Closed-Loop Control with DiAs System|Subjects will use the Diabetes Assistant (DiAs) and will wear a Tandem t:slim insulin pump and a Dexcom G4 Platinum sensor with active low and high sensor glucose alarms. Subjects will be remotely monitored throughout the night in real time.
89000965|NCT04636294||COVID-19 suspected by symptoms, after high-risk contact or after a borderline PCR result.|
89359509|NCT02478268|Active Comparator|Healthy volunteers|
89359510|NCT04053881||Certolizumab pegol|Plaque psoriasis patients who have been newly prescribed certolizumab pegol (CZP).
88831624|NCT01973413|Placebo Comparator|Control Group, Sensor-Augmented Pump Therapy|Subjects will wear a Tandem t:slim insulin pump and a Dexcom G4 Platinum sensor with active low and high sensor glucose alarms. They will not use the Diabetes Assistant (DiAs) nor have remote monitoring.
88831625|NCT02927327|Experimental|PET/MR ZTE MRAC|"PET/MR zero echo time (ZTE) scan for head attenuation and Q.Static . PET/MR ZTE MRAC images to be acquired for post-processing and reader assessment.~Zero Echo Time (ZTE) scan for head attenuation"
88831626|NCT02927327|Experimental|PET/MR Q Static (Q. MRAC)|"Q.Static (Q. MRAC) for respiratory motion correction. PET/MR Q Static (Q. MRAC) images to be acquired for post-processing and reader assessment.~PET/MR Q Static (Q. MRAC)"
88831627|NCT02021461|Experimental|ESL Banana taste|Subjects were to be enrolled until there were at least 30 evaluable subjects (of whom at least 60% were <7 years of age). Evaluable subjects were those who completed 3 Visual analogue scale (VAS), 1 for each of the 3 tasting steps with the 3 flavoured oral suspensions.
88831628|NCT02021461|Experimental|ESL Grape taste|Subjects were to be enrolled until there were at least 30 evaluable subjects (of whom at least 60% were <7 years of age). Evaluable subjects were those who completed 3 Visual analogue scale (VAS), 1 for each of the 3 tasting steps with the 3 flavoured oral suspensions.
88831629|NCT02021461|Experimental|ESL Tutti-Frutti taste|Subjects were to be enrolled until there were at least 30 evaluable subjects (of whom at least 60% were <7 years of age). Evaluable subjects were those who completed 3 Visual analogue scale (VAS), 1 for each of the 3 tasting steps with the 3 flavoured oral suspensions.
88831630|NCT02927639|Experimental|Intervention|This group will receive the intervention for 6 months. The intervention will consist of daily text messages sent to the subject's personal mobile device in addition to the usual standard care. Subjects will be incentivized to respond to text messages via a financial reward lottery system. Previously developed text messages based on the ADA behavior goals will be used for this intervention.
88831631|NCT02927639|No Intervention|Control|This group will receive the usual standard of care for 6 months.
88831632|NCT02929667|Active Comparator|Treatment|Subjects randomized to treatment arm will receive fluoxetine with titration schedule consisting of 10 mg per day for 1 week, 20 mg per day for 1 week, 40 mg per day for 2 weeks, 20 mg per day for 1 week and 10 mg per day for 1 week. Then stop.
88831633|NCT02929667|Placebo Comparator|Control|Subjects randomized to control arm will receive placebo with titration schedule consisting of 10 mg per day for 1 week, 20 mg per day for 1 week, 40 mg per day for 2 weeks, 20 mg per day for 1 week and 10 mg per day for 1 week. Then stop.
88831634|NCT02021929|Experimental|Sorafenib|400 mg (2 capsules) taken by mouth once a day
88831635|NCT02021929|Placebo Comparator|Placebo|2 capsules taken by mouth once a day
88831636|NCT02848079|Experimental|combined TAS-102 and oxaliplatin|"Combination treatment with TAS-102 and oxaliplatin. Combination treatment with TAS-102 and oxaliplatin. TAS-102 is an oral medication; oxaliplatin (TAS-OX) is given by infusion. In Part 1 treatments were started at level 1 doses, which were based on prior clinical experience with the medications studied. Dose escalation followed a traditional 3+3 design. The subjects in Part 2 were treated with dose level 3.~Oxaliplatin infusion was given on day 1 of each cycle. TAS-102 was taken twice daily on days 1-5 of each cycle."
88831637|NCT02022085|Experimental|Baha Attract System|"This transcutaneous solution is based on a magnet coupling using magnets on both side of the skin;~One implant magnet~One external magnet on which a sound processor is attached, i.e. the Sound Processor magnet (SP magnet)"
88831638|NCT02929823|Experimental|Low Dose SJP-0035 Ophthalmic solution|Patients will administer 1 drop of 0.0002% SJP-0035 ophthalmic solution in the affected eye(s) 4 times daily for 4 weeks.
88831639|NCT02929823|Experimental|High Dose SJP-0035 Ophthalmic solution|Patients will administer 1 drop of 0.001% SJP-0035 ophthalmic solution in the affected eye(s) 4 times daily for 4 weeks.
88831640|NCT02929823|Placebo Comparator|Vehicle of SJP-0035 Ophthalmic solution|Patients will administer 1 drop of 0% SJP-0035 ophthalmic solution (consisting of the vehicle for the solution) in the affected eye(s) 4 times daily for 4 weeks
88831641|NCT02929979|Experimental|Cognitive Training|Participants will complete 22.5 hours of cognitive training exercises over 6-weeks (training 5 times a week) using an app-based program, BrainHQ. BrainHQ is based on a previous neuroscience-based cognitive training program shown to improve cognition in several different randomized controlled studies with other clinical populations. The investigators will use a suite of BrainHQ exercises designed to target and ameliorate cognitive disruptions in 4 cognitive domains (see main outcome). The investigators will employ basic exercises that focus on increasing processing efficiency in the auditory and visual perceptual and working memory domains, as well as exercises that target impulsivity and cognitive biases. Exercises will be packaged into 4 modules (attention skills, memory skills, executive functioning skills, cognitive control skills) comprised of 4 exercises each. All participants will progress through the same fixed schedule of modules.
88875504|NCT04107168||Cohort 5|Disease: Advanced NSCLC Anti-PD-(L)1 (Nivolumab, Pembrolizumab or Atezolizumab) monotherapy in the first line setting. Dosage form, dosage, frequency and duration will be either standard of care and accessed via normal commissioning arrangements, or will be part of an ethics-approved clinical trial, where co-enrollment into an observational study is permitted.
89359511|NCT05713162|Experimental|Children experimental group|Children who receive 10 sessions of the social skills training program
89359512|NCT05713162|Experimental|Adolescent experimental group|Adolescents who receive 10 sessions of the social skills training program
89359513|NCT05713162|No Intervention|Children control group|Children in waiting list (do not receive 10 sessions of the social skills training program)
89359514|NCT05713162|No Intervention|Adolescent control group|Adolescents in waiting list (do not receive 10 sessions of the social skills training program)
89359515|NCT02480452||CVI|All children consulting at the CVI clinic (with suspicion of CVI) receiving a diagnosis of CVI
89359516|NCT02480452||no CVI|All children consulting at the CVI clinic (with suspicion of CVI) not receiving a diagnosis of CVI
89359517|NCT05713084|Experimental|mandibular setback using low medial cut ostetomy|mandibular setback using low medial cut ostetomy by keeping the cut ''low'' or close to the mandibular occlusal plane and ''short'' or terminating anterior to the lingula.
89359518|NCT05713084|Active Comparator|mandibular setback using high medial cut ostetomy|mandibular setback by placement of the medial ramus osteotomy cut 'high', just a few millimeters above the lingula, superior and lateral to the entrance point of the inferior alveolar nerve (IAN) into the mandibular foramen ,
89359519|NCT01567553||Control group|Only unenhanced MR scanning will be performed in a control group of normal, age-matched subjects and after acceptance of the protocol by an independent ethical committee for the implication of a normal population in such an MRI research project.
89359520|NCT01567553||Experimental group|CIS at presentation (clinically isolated syndromes) will be recruited with MRI evidence of at least two asymptomatic brain MRI lesions. The group will compromise 50 CIS patients. These CIS patients will be included within three months after first clinical presentation.
89359521|NCT03768557|Experimental|Minocycline|single dose of minocycline (200mg)
89359522|NCT03768557|Placebo Comparator|Placebo|lactose pills (400mg)
89359523|NCT02478190|Experimental|Tight control|Patients in this arm will have a treatment glucose value at ED discharge of 350 mg/dL or lower.
89359524|NCT02478190|Experimental|Loose control|Patients in this arm will have a treatment glucose value at ED discharge of 600 mg/dL or lower.
89359525|NCT05712928|Experimental|Dance/movement therapy|Ten weekly 60-minute individual dance/movement therapy telehealth sessions (eMove).
89359526|NCT01309373||001|Patient assessment 2 scales will be used to assesss the remission of schizophrenia (APA scale and PSRS scale). The BPRS scale will be used to assess the clinical integration of patients.
89359527|NCT02480140|Experimental|Self-regulated constraint-induced movement therapy|Self-regulated constraint-induced movement therapy (SR-CIMT) - participants' non-hemiplegic arm was restrained in a mitt for 4 hours every day, 2 weeks, 5 days a week (therapy days) (CIMT) (the same CIMT protocol as in the CIMT group described under 'comparator/control treatment'); participants were taught using the self-regulation (SR) strategy to relearn the tasks; SR strategy involved participants self reflecting on their abilities and deficits in performing the tasks, identifying problems and solutions in achieving the most independence in the tasks, and then actually carrying out the tasks.
89359528|NCT02480140|Active Comparator|Constraint-induced movement therapy|In the constraint-induced movement therapy group (CIMT), participants' non-hemiplegic arm was restrained in a mitt for 4 hours every day, 2 weeks, 5 days a week (therapy days); therapist provided demonstration on the adapted task performance with one arm (the side of participants' hemiplegic arm), and participants to practice the tasks with the unrestrained hemiplegic arm under supervision.
89359529|NCT02480140|Active Comparator|Conventional occupational therapy|It involved therapist to demonstrate the adapted task performance followed by patient's practice under supervision.
89359530|NCT04034381||Port-au-Prince metropolitan area|
89534398|NCT02477358|No Intervention|Control|Subjects will be randomized to either receive either left tooth platelet rich fibrin; right tooth implant alone, OR right tooth platelet rich fibrin; left tooth implant alone. Following treatment each tooth is replaced and splinted to the adjacent teeth. Teeth are followed for 3 months and then tested for vitality before extracting and examining histologically.
89000966|NCT01580566||Group 1 - Control|"Non-Q wave MI subjects with normal cardiac and renal function (defined as eGFR >60ml/min) not undergoing a cardiac procedure involving contrast will serve as control for renal injury subjects."
89359531|NCT04034381||Other urban areas|
89359532|NCT04034381||Rural areas|
89359533|NCT03783845|Experimental|test group|"Metronidazole 400mg,three times daily for two weeks~Amoxicillin 500mg,three times daily for two weeks."
89359534|NCT03783845|No Intervention|control group|no intervention during study period
89359535|NCT05349370|Experimental|All patients|All patients receive the same intervention/sampling protocol
89359536|NCT03768479|Experimental|FES-Fulvestrant|Patients with ER positive breast cancer receive Fulvestrant as the first line treatment enrolled in the study would receive 18F-FES-PET/CT imaging before and after cycle 1 treatment with the first line Fulvestrant.
89359537|NCT01560689|Active Comparator|BUDESONIDE/FORMOTEROL|
89359538|NCT01560689|Placebo Comparator|control|
89359539|NCT02474914|Active Comparator|Octreotide|Enrolled patients will be randomized to either the octreotide (sandostatin ) or the placebo group. The randomization process will be done using closed envelop method and will be withdrawn by a nurse after pancreaticoduodenectomy . Patients in the octreotide group will receive sandostatin 100ug SC every 8 hours daily staring from the day of operation to the postoperative day 7. Patients in the placebo group will receive saline administered in a similar manner.
89359540|NCT02474914|Placebo Comparator|Placebo|pancreaticoduodenectomy without octreotide postoperative
89359541|NCT03768401|Experimental|Educational Seminars and Wellness Clinics|"I. Community outreach educational seminars about wellness and exercise while living with a neurological physical disability and measurement of the effects of these seminars for training individuals with neurological physical disabilities and their care givers (family, therapists, community personal trainers and community funders such as Lions or Rotary Clubs) about how to create a safe cost-effective exercise program .~II. Creation and measurement of the effects of a wellness clinic for those with a neurological physical disability."
89359542|NCT03768323|No Intervention|Control|No airtime incentive was given for completing the survey
89359543|NCT03768323|Experimental|1X incentive|1X airtime incentive
88831642|NCT02929979|Placebo Comparator|Placebo control|Participants will play a rotating set of commercial computer games at the same dose and frequency as the cognitive training. The investigators selected this control activity because it mirrors the game-like properties of the cognitive training and it will be used to control for contact with research personnel and for the non-specific effects of participant motivation and engagement with daily computerized activities. It also allows for a double blind study design. Games from the website Sporcle will be used and an online account can be created for each participant.
88831643|NCT04026529|Experimental|walking at incline|Subjects will walk on treadmill at slope and speed to equal 60% of their peak work rate as determined on baseline cardiopulmonary exercise test.
88831644|NCT02932787|Experimental|Height-adjustable workstation|Participants received a height-adjustable workstation for four weeks
88831645|NCT02932787|No Intervention|Control|
88831646|NCT02023411|Active Comparator|teriparatide|10 diabetic patients with inactive Charcot's foot who are calcium and Vit.D sufficient will receive 20 microgram of teriparatide , subcutaneous between 8-9 p.m., daily.
88831647|NCT02023411|Placebo Comparator|placebo|10 diabetic patients with inactive Charcot's foot who are calcium and Vit.D sufficient will receive placebo , subcutaneous between 8-9 p.m. , daily.
88831648|NCT02851823|Active Comparator|Control Group|Mechanical periodontal treatment: Scaling and root planing were performed with periodontal curettes until the operator feels that root surface is clean, hard and smooth.
88831649|NCT02851823|Experimental|Test Group|Combined laser therapy: An Er:YAG laser (160 mj/pulse, 10 Hz) (AT Fidelis Fotona, Ljubljana, Slovenia) with water irrigation was first used to remove subgingival calculus and infected cementum.The Er:YAG laser beam was delivered into the periodontal pockets using a chisel-shaped quartz tip in contact mode under water irrigation, from a coronal to an apical direction with the tip inclined at 10o to 15o to the root surfaces. After Er:YAG laser application, Nd:YAG laser treatment (AT Fidelis Fotona, Ljubljana, Slovenia) was performed at an energy level of 100 mJ/pulse, and 20 Hz for removing pocket epithelium and detoxiﬁcation purpose. Irradiation was accomplished with a 320 μm fiber optic delivery system. The fiber was inserted into the periodontal pocket base in parallel alignment with the root surface, and the fiber was slowly moved from apical to coronal in a sweeping motion during the laser light emission.
88831650|NCT02023801|Experimental|Aurora Treatment Arm|Endometrial Ablation
88831651|NCT02933879|Experimental|NVXT topical|daily dosing for one 8-week treatment period (Treatment Group A) and two 8-week treatment periods separated by a 32-week rest period (Treatment Group B),
88831652|NCT02933879|Placebo Comparator|Placebo (Vehicle) Topical|two 8-week treatment periods separated by a 32-week rest period (Treatment Group C),
88831653|NCT02068820|Active Comparator|ISB dye, standard white light|SLN mapping utilizing da Vinci surgical system with Isosulfan Blue (ISB) dye and standard white light imaging.
88831654|NCT02068820|Experimental|ICG dye, FireFly fluorescence imaging|SLN mapping utilizing da Vinci surgical system with ISB dye and standard white light first, and then additionally, Indocyanine Green (ICG) dye and FireFly fluorescence imaging.
88831655|NCT02855567|Active Comparator|Acupuncture|Receives acupuncture during gynecological surgery at 5 known points for pain control. Needles will be placed prior to the start of surgery by an anesthesiologist trained in acupuncture after induction of anesthesia and while the patient is prepped for surgery. They will be in place for 15 minutes.
88831656|NCT02855567|Sham Comparator|Sham acupuncture|Receives acupuncture during gynecological surgery at sham points not associated with pain control. Needles will be placed by the gynecologic surgeon who is not trained in acupuncture after induction of anesthesia and prior to the start of the surgery. The needles will be removed immediately after placement.
88831657|NCT02856035|Experimental|Stroke Group|"Intervention: Stroke subjects will receive neural feedback plus FES and motor learning intervention that spans 3 phases and up to a total of 60 sessions.~Phase I: real-time fMRI neural feedback training; Phase II: rtfNIRS-based neural feedback learning (built upon self-regulation strategies learned in Phase I and also assisted by neurally-triggered, peripherally-directed FES motor practice of wrist and finger extension); Phase III: motor learning minus neural feedback for an additional sessions up to 60 total; Phase IV: follow-up testing at 3 months after-treatment ends"
88831658|NCT01975519|Experimental|TRC105 and Pazopanib|Weekly TRC105 in combination with standard dose pazopanib or every two week administration during cycle 1, and starting on cycle 2 day 1 and beyond, TRC105 may be administered every two weeks. This is also in combination with standard dose pazopanib.
88831659|NCT02934191|Experimental|Acetaminophen/Oxycodone + Celecoxib|Subjects will take acetaminophen orally (dose 15mg/kg/dose) in scheduled doses every 4 hours for the first 5 days. Subjects will also take celecoxib orally (dose is 6mg/kg twice a day with a maximum dose of 300mg twice a day). The first dose of celecoxib will be given preoperatively, within 1 hour prior to entering the operating room. The second dose will be given at bedtime on the night of surgery and subsequent doses will be given 12 hours apart. Supplemental standard of care oxycodone may be used to control breakthrough pain.
89359544|NCT03768323|Experimental|2X incentive|2X airtime incentive
89359545|NCT03768245|Experimental|Behaviour|Physical activity and the Health Education programs are applied.
89359546|NCT03768245|Active Comparator|Nutrition|In this Arm, the the Physical activity, the Health education and Nutrition program are applied.
89359547|NCT03769103|Active Comparator|SRS + Osimertinib|Stereotactic radiotherapy will be delivered in 1-5 fractions to each brain metastases according to the volume and location of the metastases and clinician discretion. Osimertinib will start 1-7 days post radiotherapy.
89359548|NCT03769103|Experimental|Osimertinib alone|Osimertinib 80mg PO daily
89359549|NCT03768167|Other|patients with metastatic spinal lesions|corpectomy
89359550|NCT03773081|Other|Magmaris implantation|Subjects will undergo a PCI for the implantation of the Magmaris scaffold in accordance with the standard of care and standard hospital practice.
89359551|NCT01561547|Experimental|Kangaroo Mother Care|Infant is held in skin-to-skin contact with mother at least 15 minutes prior to painful procedure, remains in that position throughout the procedure and after the procedure at least until heart rate returns to baseline. Infant is given sterile water by mouth. This is for every heel lance and venipuncture, and if possible for tape removal.
88831660|NCT02934191|Active Comparator|Acetaminophen/Oxycodone + Placebo|Subjects will take acetaminophen orally (dose 15mg/kg/dose) in scheduled doses every 4 hours for the first 5 days. Subjects will also take the placebo orally twice a day. The first dose of placebo will be given preoperatively, within 1 hour prior to entering the operating room. The second dose will be given at bedtime on the night of surgery and subsequent doses will be given 12 hours apart. Supplemental standard of care oxycodone may be used to control breakthrough pain.
88831661|NCT02934347||Supine|A baseline group of adult patients who required intubation as part of their routine anaesthesia who were intubated in the standard horizontal sniffing position.
88831662|NCT02934347||Back-up|A subsequent group of similar the patients who had their anaesthesia induced and tracheas intubated in a 25 degree back-up position achieved by flexion of the operating table at the hips
88831663|NCT01975909|Active Comparator|Transcranial Magnetic Stimulation (TMS)|A Magstim 200 (Magstim, UK) and 14cm circular coil positioned tangential to the head will be used to deliver stimuli at 100% of maximum stimulator output. Transcranial Magnetic Stimulation will be applied to three regions: 1) 4cm lateral to the right of the inion, 2) centered on the inion, 3) 4cm lateral to the left of the inion. Five pulses separated by 6 seconds will be delivered with a counter-clockwise current, followed by the same five pulses delivered with a clockwise current, for a total of 10 pulses per region, and 30 pulses per session.
88831664|NCT01975909|Sham Comparator|Sham Transcranial Magnetic Stimulation|A sham condition of Transcranial Magnetic Stimulation will be used and follow the same protocol as the active stimulation; however no magnetic pulses will be delivered through the scalp.
88831665|NCT02937623|Experimental|Test Product: Dissolvable polymer strip containing Novamin|In this arm, participants received an experimental dissolvable polymer strip containing 15 % weight/weight (w/w) calcium sodium phosphosilicate (Novamin). One strip was applied per test tooth topically by a suitably qualified member of the site staff. Each participant received 2 strips in total (as two test tooth were assessed per participant).
88831666|NCT02937623|No Intervention|Reference Product: No treatment/product|In this arm, participants did not receive any treatment/product.
88831667|NCT01977547|Active Comparator|Short storage|Red blood cells storage duration of equal to or less than 7 days.
88831668|NCT01977547|Active Comparator|Standard issue|Red blood cells storage duration of 2 to 42 days with an expected average length of storage of about 17-21 days.
88831669|NCT02863289||Children with proximal humerus fractures|Children aged from 10 to 18-year-old in NHS Tayside whom sustained proximal humerus fractures during year 2008 to 2015.
88831670|NCT02864069|Experimental|Walking Intervention|
88831671|NCT02864069|Experimental|Cognitive Training Intervention|
88831672|NCT02864069|Experimental|Combined Intervention|
88831673|NCT02013050|Placebo Comparator|Placebo|Control
88831674|NCT02013050|Experimental|SGX942|Investigational Drug i) 1.5 mg/kg ii) 3.0 mg/kg iii) 6.0 mg/kg
88831675|NCT01977781|Experimental|Tacrolimus|Topical tacrolimus suspension will be formulated and aseptically prepared from commercially available intravenous tacrolimus, PROGRAF® (Astellas Pharma US, Inc), and transferred into a sterile dropper container by the MEEI pharmacy. A formulation of 0.05% (5mg/10ml) concentration of tacrolimus with diluting solvent, LiquiTears Ophthalmic Solution (Major Pharmaceuticals, Inc.) will be used. Patients will be instructed to keep refrigerated each bottle after opening for 9 days and keep frozen the unopened bottles up to 45 days. They will also be instructed to shake the bottles at least 20 times before using it.
88831676|NCT01977781|Active Comparator|Methylprednisolone Sodium Succinate|Topical methylprednisolone sodium succinate suspension will be formulated and aseptically prepared from commercially available sterile dry powder vial preservative-free for intravenous use, SOLU-MEDROL® (Pfizer, Inc.). A formulation of 0.5% (5mg/1ml) concentration of methylprednisolone with diluting solvents, LiquiTears Ophthalmic Solution (Major Pharmaceuticals, Inc.) will be used. Patients will be instructed to keep refrigerated each bottle after opening for 9 days and keep frozen the unopened bottles up to 45 days. They will also be instructed to shake the bottles at least 20 times before using it.
88831677|NCT02938169|Experimental|walking exercise group|"**walking exercise with bracing exercise~walking exercise: treadmill gait with tolerable gait speed~bracing exercise: patient is instructed as follows: Draw your navel up towards your head and in toward your spine without moving your pelvis. Continue to breathe normally as you do this."
88831678|NCT02938169|Experimental|stabilization exercise group|"** stabilization exercise with bracing exercise~stabilization exercise: Lumbar stabilization is a multi-component program and involves education/training, strength, flexibility, and endurance. It is generally used during all phases of a back pain episode and may be prescribed after a thorough evaluation of the patient's specific condition.~bracing exercise: patient is instructed as follows: Draw your navel up towards your head and in toward your spine without moving your pelvis. Continue to breathe normally as you do this."
88831679|NCT02938169|Experimental|walking and stabilization exercise group|"**walking exercise, bracing exercise with stabilization exercise~stabilization exercise: Lumbar stabilization is a multi-component program and involves education/training, strength, flexibility, and endurance. It is generally used during all phases of a back pain episode and may be prescribed after a thorough evaluation of the patient's specific condition.~bracing exercise: patient is instructed as follows: Draw your navel up towards your head and in toward your spine without moving your pelvis. Continue to breathe normally as you do this.~walking exercise:treadmill gait with tolerable gait speed"
88831680|NCT02938169|Sham Comparator|flexibility exercise group|"**Stretching exercise(control)~Only educate the flexibility exercise(stretching exercise)~Don't educate the walking exercise method and stabilization exercise method"
88831681|NCT04012411|Active Comparator|Patient with LP|Huntington's disease patients who agreed to have LP
88831682|NCT04012411|Active Comparator|Patient without LP|Huntington's disease patient with contraindication to LP or refusal to have LP
88831683|NCT04012411|No Intervention|Control Group|Retrospective study with biologic samples of patients without Huntington's disease
88831684|NCT02070302|Active Comparator|Botulinum Toxin Type A|After appropriate consent, each patient will receive 40 units of BOTOX® (onabotulinumtoxin A) divided into two injection sites of 20 units each into Opponens Pollicis (OP) and the Abductor Pollicis Brevis (APB)
89534399|NCT02455804|Other|Single Arm|This is a prospective, post-marketing, non-randomized, multi-center, single-arm clinical study that will be conducted at up to 15 sites in the United States (US). All subjects will be treated with the NIRxcell Stent System and followed at 30 days, 9 months and 1, 2 and 3 years post-index stenting procedure. An unscheduled follow up may be conducted as clinically warranted.
88831685|NCT02070302|Placebo Comparator|Placebo|.4cc/muscle of Normal saline will be injected into two injection sites each into Opponens Pollicis (OP) and the Abductor Pollicis Brevis (APB)
88831686|NCT02938949|Active Comparator|Alirocumab|Alirocumab (150 mg) will be administered by subcutaneous injection once, within the first day of the patient's diagnosis of NSTEMI. Patients will also receive an 80 mg dose of atorvastatin.
88831687|NCT02938949|Placebo Comparator|placebo|Placebo (sterile saline) will be administered by subcutaneous injection once, within the first day of the patient's diagnosis of NSTEMI. Patients will also receive an 80 mg dose of atorvastatin.
88831688|NCT01979029|Experimental|preserving the left colic artery|We preserve the left colic artery and resect the No. 253 lymph node during the rectal surgery.
88831689|NCT01979029|Experimental|not preserving the left colic artery|We preserve the high ligation of the inferior mesenteric artery during the rectal surgery.
88831690|NCT02939105|Experimental|CoolSculpting Treatment in the Upper Arm|"Subjects in the study were treated with the CoolSculpting System with one of two vacuum applicator types for bilateral fat reduction in the upper arms. Applicators were used concurrently, with an applicator on each arm. Each subject received 1 or 2 cooling cycles on each arm for 35 minutes at protocol-defined temperatures.~The Investigator selected the applicator for each subject based on the intended fat volume of the treatment area."
88831691|NCT02025439|Experimental|rTMS Alone followed by rTMS+AMA|Subjects assigned to rTMS Alone will receive 30 sessions of rTMS. Two rTMS sessions will be provided per day, four days per week.After first completing rTMS Alone, subjects will receive rTMS plus Amantadine. A total of 30 rTMS sessions are provided, 2 rTMS sessions per day, four days per week, while receiving 200mg of Amantadine daily.
88831692|NCT02025439|Experimental|AMA Alone followed by rTMS+AMA|Subjects who are assigned to the Amantadine Alone group will receive 28 doses of Amantadine (100mg BID) every day for 28 days. After first completing Amantadine Alone subjects will receive rTMS plus Amantadine. A total of 30 rTMS sessions are provided, 2 rTMS sessions per day, four days per week, while receiving 200mg of Amantadine daily.
88831693|NCT02939651|Experimental|Pembrolizumab|Monotherapy with PD-1 antibody pembrolizumab
88831694|NCT02025829||Clinically Stable|Patients with cystic fibrosis and are clinically stable, 10 subjects with one copy of F508del and 4 subjects with at least one copy of G551D
88831695|NCT02025829||Exacerbation|Patients with cystic fibrosis admitted for treatment of a pulmonary exacerbation with IV antibiotics, 10 subjects with one copy of F508del
88831696|NCT02943941|Other|All participants|All participants enrolled in a single arm to evaluate effect of variables (posture, respiration, exertion) on pulmonary artery pressure (PAP)
88831697|NCT02026297|Placebo Comparator|Control, low risk PPH|Patients at lower risk for postpartum hemorrhage during cesarean delivery, to receive standard of care NOT including tranexamic acid.
88831698|NCT02026297|Experimental|Treated, low risk PPH|Patients at lower risk for postpartum hemorrhage during cesarean delivery, to receive standard of care AND tranexamic acid.
89534400|NCT02404688|Experimental|Active THC and Placebo Ethanol|
88831699|NCT02070692|Experimental|Tamoxifen|Participants will be randomized to receive either tamoxifen 10mg twice daily for seven days, or placebo twice daily for seven days, to be started on the third day of an episode of bleeding.
88831700|NCT02070692|Placebo Comparator|Placebo|Placebo tablets twice daily for seven days, to be started on the third day of a bleeding episode.
88831701|NCT02026453|No Intervention|Usual care|Physicians and nurses obtain admission medication history.
88831702|NCT02026453|Experimental|Pharmacist obtains home med hx|Pharmacist obtains admission medication history, although usual care practices may also continue.
88831703|NCT02026453|Experimental|Pharm tech obtains home med hx|Pharmacy technician obtains admission medication history, although usual care practices may also continue.
88831704|NCT02026687|Active Comparator|Epidural analgesia|The epidural anesthesia is applied at a low thoracic level, primarily Th10-Th11. A bolus dose of fentanyl together with a continuous infusion of bupivacain 2.5 mg/ml, fentanyl 1.8 µg/ml and epinephrine 2.5 µg/ml is used during surgery. Infusion rate is chosen by the attending anesthetist. Postoperatively the epidural anesthesia is continued until the morning of the third postoperative day using bupivacain 1 mg/ml, fentanyl 2 µg/ml and epinephrine 2µg/ml. Infusion rate is set by the responsible physician, maximum rate is 10 ml/hour.
88831705|NCT02026687|Experimental|Intrathecal analgesia|The patient is given one intrathecal dose of plain bupivacaine (Marcain® spinal) 5 mg/ml, 15 mg together with morphine (Morphine Special®) 0,4 mg/ml, 0.2 mg and clonidine (Catapresan®) 150 µg/ml, 75 µg. The intrathecal mixture is given through a lumbal puncture at level L2/3, L3/4 or L4/5 before the induction of general anesthesia.
88831706|NCT02015234|Experimental|TNX-102 SL|1x TNX-102 SL 2.8 mg sublingual tablet taken daily at bedtime for 12 months
88831707|NCT01974050|Other|Text message monitoring|Use of text messaging to monitor post-vaccination
89534401|NCT02404688|Experimental|Active THC and Active Ethanol|
89534402|NCT02404688|Experimental|Placebo THC and Active Ethanol|
89534403|NCT02404688|Placebo Comparator|Placebo THC and Placebo Ethanol|
89534404|NCT02392572|Experimental|Arm A (Akt/ERK inhibitor ONC201)|Patients receive Akt/ERK inhibitor ONC201 PO once every 3 weeks. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89534405|NCT02392572|Experimental|Arm B (Akt/ERK inhibitor ONC201)|Patients receive Akt/ERK inhibitor ONC201 PO once every week. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89359552|NCT01561547|Active Comparator|Sucrose|Two minutes before the painful procedure and at the moment of the procedure, the infant will be given 24% sucrose by mouth. The volume is determined by body weight and is not important in terms of efficacy, it is the percentage of sweetness that is important.
89359553|NCT01561547|Experimental|Combination Kangaroo Mother Care and Sucrose|Infant is held in skin-to-skin contact with mother at least 15 minutes prior to painful procedure, remains in that position throughout the procedure and after the procedure at least until heart rate returns to baseline. Infant is given sucrose water by mouth. This is for every heel lance and venipuncture, and if possible for tape removal.
89359554|NCT04998214||control group non cirrhotic|compare liver function 1m after COVID-19 and that at beginning of infection
89359555|NCT04998214||cirrhotic patients|compare liver function 1m after COVID-19 and that at beginning of infection
89359556|NCT03772769|Experimental|Subjects with advanced deep space odontogenic infection|Subjects will be diagnosed via two methods: 1. Target Enriched Multiplex PCR (TEM- PCR) and 2. Standard microbial culture.
89359557|NCT01309529||thoracic surg, epidural, urine retention|
89000967|NCT01580566||Group 2 - stable CAD or non-Q wave MI|Patients undergoing coronary angiography +/- PCI for stable CAD or non-Q wave MI with normal cardiac and renal function (defined as eGFR >60ml/min) will control for the contrast STEMI patients are likely to receive as part of their post-MI management
89359558|NCT05710354||The Study Group|Patients in the study group (N=57), in addition to the usual diet, received nutritional support with the Oral Nutrition Supplement (ONS) Nutridrink Compact Protein in the amount of 2 bottles per day for 14 days prior to surgery and 14 days following surgery. During the hospital stay, additional nutritional support was added to the patient's standard hospital diet. On an outpatient basis, the patient received the required amount of ONS at his/her disposal and took it as a supplement to his/her usual and habitual diet. The ONS was recommended to be taken between main meals
89359559|NCT05710354||The Control Group|Patients in the control group (N=57) followed the standard hospital diet, and at outpatient basis - their usual habitual diet
89359560|NCT02474680||Care Coordination Group|Patients participating in the Avera Care Coordination Program for Intervention 'Pharmacogenetic testing'
89359561|NCT04636151|Experimental|Individual Treatment|Participants will have up to three individual sessions with a study therapist. One or more treatment modules will be presented in each session.
89359562|NCT04636151|Experimental|Group Treatment|Participants will have up to three group sessions with a study therapist. One or more treatment modules will be presented in each session.
89359563|NCT04636151|Experimental|Workshops|Participants will have one workshop with a study therapist. All three treatment modules will be presented in one session.
89359564|NCT01309607|Experimental|Pre-operative Therapy|Neoadjuvant paclitaxel/carboplatin/lapatinib x 12 weeks
89000968|NCT01580566||Group 3 - Acute STEMI without chronic kidney disease|Acute STEMI patients (n=40), without chronic kidney disease (defined as eGFR ≥60ml/min).
89000969|NCT01580566||Group 4 - Acute STEMI with kidney disease|Acute STEMI patients (n=40), with evidence of background chronic kidney disease (eGFR <60ml/min).
89534406|NCT02392572|Experimental|Arm C (Akt/ERK inhibitor ONC201)|Patients receive Akt/ERK inhibitor ONC201 PO on the first two consecutive days of every week. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89534407|NCT02392572|Experimental|Arm D (Akt/ERK inhibitor ONC201)|Patients receive Akt/ERK inhibitor ONC201 PO QD. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89000970|NCT00179192|No Intervention|1|control group
89000971|NCT00179192|Active Comparator|2|angioplasty intervention
89359565|NCT04001933|Experimental|Intervention Arm|CPOP Intervention (see below).
89359566|NCT04001933|No Intervention|Control Arm|Usual care.
89359567|NCT03767855|Experimental|CK-3773274 for SAD Cohorts|Subjects will be assigned to one of 8 planned dose cohorts and receive single doses of CK-3773274
89359568|NCT03767855|Placebo Comparator|Placebo for SAD Cohorts|Subjects will be assigned to one of 8 planned dose cohorts and receive single doses of placebo
89359569|NCT03767855|Experimental|CK-3773274 for MAD Cohorts|Subjects will be assigned to one of 3 planned dose cohorts and receive multiple doses of CK-3773274
89359570|NCT03767855|Placebo Comparator|Placebo for MAD Cohorts|Subjects will be assigned to one of 3 planned dose cohorts and receive multiple doses of placebo
89359571|NCT03767855|Experimental|CK-3773274 for CYP2D6 Cohort|Subjects with CYP2D6 poor metabolizer phenotype will be assigned to receive a single dose of CK-3773274
89359572|NCT03767855|Placebo Comparator|Placebo for CYP2D6 Cohort|Subjects with CYP2D6 poor metabolizer phenotype will be assigned to receive a single dose of placebo
89359573|NCT03767855|Experimental|Food Effect|Subjects will be administered CK-3773274 with and without food in a randomized cross-over fashion
89359574|NCT03767855|Experimental|Relative Bioavailability|Subjects will be administered CK-3773274 as granules in a capsule and as a tablet in a randomized cross-over fashion.
89359575|NCT03783455|Active Comparator|Non arthroscopic joint lavage (NAJL)|Establishment of sterile areas and cleaning of the skin around the knee with a povidone-iodine solution, followed by an injection of local anesthetic (5 mL of 2% mepivacaine hydrochloride) into the outer mediopatellar zone. The anesthetic was allowed to act, and an access way was then opened with a No. 16 abocat. Any effusion in the joint was drained. Then, approximately 100 mL of cold saline was instilled through the outer access way. Once the knee was distended, a further 5 mL of local anesthetic was injected into the inner mediopatellar zone, and a new abocat guide was used to establish the inner drainage way. The lavage proper involved instillation of 4 L of cold (8ºC) saline at a constant flow-rate using a dropper line connected to the entry way; the inner zone was also connected to another, free-fall dropper.
89399146|NCT02168894|Experimental|Group 1 - Acupuncture With Electrical Stimulation|Participants in Group 1 have acupuncture sessions with electrical stimulation 3 times a week for 4 weeks, for a total of 12 sessions. Then, take a 2 week break. After that, participant randomly assigned to receive 12 sessions of acupuncture with electrical stimulation as before or not have anymore sessions in this study. Nerve function tests performed at visit before acupuncture and at end of study visit. These tests consist of hand tasks and balance tests. Questionnaires completed at baseline, visit before acupuncture, after 6 and 12 acupuncture visits, and at end of study visit.
89359576|NCT03783455|Active Comparator|Non arthroscopic joint lavage plus corticosteroid|Establishment of sterile areas and cleaning of the skin around the knee with a povidone-iodine solution, followed by an injection of local anesthetic (5 mL of 2% mepivacaine hydrochloride) into the outer mediopatellar zone. The anesthetic was allowed to act, and an access way was then opened with a No. 16 abocat. Any effusion in the joint was drained. Then, approximately 100 mL of cold saline was instilled through the outer access way. Once the knee was distended, a further 5 mL of local anesthetic was injected into the inner mediopatellar zone, and a new abocat guide was used to establish the inner drainage way. The lavage proper involved instillation of 4 L of cold (8ºC) saline at a constant flow-rate using a dropper line connected to the entry way; the inner zone was also connected to another, free-fall dropper. Following administration of the joint lavage, the NAJL plus corticosteroid group was given an intra-articular injection containing 40 mg of triamcinolone acetonide.
89359577|NCT03783455|Active Comparator|Non arthroscopic joint lavage plus hyaluronic acid|Establishment of sterile areas and cleaning of the skin around the knee with a povidone-iodine solution, followed by an injection of local anesthetic (5 mL of 2% mepivacaine hydrochloride) into the outer mediopatellar zone. The anesthetic was allowed to act, and an access way was then opened with a No. 16 abocat. Any effusion in the joint was drained. Then, approximately 100 mL of cold saline was instilled through the outer access way. Once the knee was distended, a further 5 mL of local anesthetic was injected into the inner mediopatellar zone, and a new abocat guide was used to establish the inner drainage way. The lavage proper involved instillation of 4 L of cold (8ºC) saline at a constant flow-rate using a dropper line connected to the entry way; the inner zone was also connected to another, free-fall dropper. Following administration of the joint lavage, the patients were given an intra-articular injection containing 4 ml of a bioengineered hyaluronic acid.
89359578|NCT03783455|Active Comparator|Intraarticular injection of hyaluronic acid|Establishment of sterile areas and cleaning of the skin around the knee with a povidone-iodine solution. This was followed by an intraarticular injection containing 4 mL of a bioengineered hyaluronic acid.
89359579|NCT03783455|Active Comparator|Intraarticular injection of corticosteroid|Establishment of sterile areas and cleaning of the skin around the knee with a povidone-iodine solution. This was followed by an intraarticular injection containing 40 mg of triamcinolone acetonide.
89359580|NCT03783611|Experimental|Intervention group|The intervention group has access to the MyPlan 2.0. eHealth intervention. MyPlan is a eHealth intervention designed to increase physical activity. The intervention is based on the self-regulation theory and focuses on pre- and post-intentional processes to increase physical activity.
89359581|NCT03783611|No Intervention|control group|The control group receives no intervention
89359582|NCT05305066|Active Comparator|Sub-study 1 TNFi|TNFi - any sub-cutaneous (sc) formulation, namely etanercept (receptor fusion protein), adalimumab (monoclonal antibody), golimumab (monoclonal antibody), or certolizumab (pegylated fragment of a monoclonal antibody)
89359583|NCT05305066|Active Comparator|Sub-study 1 Anti-IL6|Anti-IL6 receptor monoclonal antibodies - tocilizumab or sarilumab
89359584|NCT05305066|Active Comparator|Sub-study 2 Anti-IL6|Anti-IL6 receptor monoclonal antibodies - tocilizumab or sarilumab
89359585|NCT05305066|Active Comparator|Sub-study 2 JAKi|JAKi - tofacitinib (JAK1/3 inhibitor), baricitinib (JAK 1/2 inhibitor) or upadacitinib (JAK1 inhibitor)
89359586|NCT03767777|Experimental|Intervention arm|Participants will be treated with Artery Stent Graft System Intervention: Device: Artery Stent Graft System
89359587|NCT02474836|Active Comparator|Atopic subjects|Patients sensitized to other allergenic sources but the allergen extracts under investigation.
89359588|NCT02474836|Active Comparator|Non atopic subjects|Healthy volunteers
89359589|NCT02474836|Other|Allergic Subjects|
89359590|NCT03772535|No Intervention|Control Group|Subjects in this arm will receive the standard postoperative pain prescription protocol.
89359591|NCT03772535|Active Comparator|Pharmacogenomics Guided Group|Subjects in this group will receive postoperative pain prescriptions based on the results of pharmacogenomic testing.
89359592|NCT02478112|Experimental|Biodegradable Balloon Implant|Biodegradable balloon implanted before radiotherapy
88831708|NCT02028247|Experimental|Personalized Cognitive-behavioral therapy|Personalized Cognitive-behavioral therapy involves 16 weekly individual therapy sessions, up to 90 minutes each, based on a treatment protocol that has been designed specifically for youth with high-functioning autism spectrum disorders.
88831709|NCT02028247|Active Comparator|Standard Practice Cognitive-behavioral therapy|Standard Practice Cognitive-behavioral therapy involves 16 weekly individual therapy sessions, up to 60 minutes each, based on a treatment protocol that represent the standard practice psychotherapy for anxiety that has been found to be effective in multiple trials in youngsters without autism spectrum disorders.
89359593|NCT02478034|Experimental|fludrocortisone|effects of fludrocortisone on cognition compared to placebo
89359594|NCT02478034|Placebo Comparator|Placebo|effects of fludrocortisone on cognition compared to placebo
89359595|NCT02477956|Experimental|vitamin D3|subjects taking the standard vitamin D protocol with added monthly high dose cholecalciferol of 100,000 IU cholecalciferol
89359596|NCT02477956|Active Comparator|Control|group of subjects taking the standard vitamin D
89359597|NCT02472574|Experimental|0.3 mg|Subjects randomized to the 0.3 mg arm will undergo minimally invasive surgery with YL-1 type of intracranial hematoma puncture needle, followed by up to 4 doses of 0.3 mg of rt-PA (Activase/Alteplase/CathFlo) for intracerebral hemorrhage clot resolution.
88831710|NCT02028247|Other|Treatment as Usual|Participants randomized to the TAU condition will be instructed to continue receiving their prior interventions as recommended by their providers (e.g., psychotherapy, social skills training, behavioral interventions, family participation in family therapy or a parenting class, or pharmacological interventions) for a 16-week period. Treatment changes (e.g., medication increase, starting psychotherapy in community) are not prohibited and will be monitored. Thus, treatment will continue as it would in standard practice; and will be monitored through periodic study assessment.
89000972|NCT00179192|Active Comparator|3|surgery intervention
89359598|NCT02472574|Experimental|0.5 mg|Subjects randomized to the 0.5 mg arm will undergo minimally invasive surgery with YL-1 type of intracranial hematoma puncture needle,followed by up to 4 doses of 0.5 mg of rt-PA (Activase/Alteplase/CathFlo) for intracerebral hemorrhage clot resolution.
89359599|NCT02472574|Experimental|1.0 mg|Subjects randomized to the 1.0 mg arm will undergo minimally invasive surgery with YL-1 type of intracranial hematoma puncture needle,followed by up to 4 doses of 1.0 mg of rt-PA (Activase/Alteplase/CathFlo) for intracerebral hemorrhage clot resolution.
89359600|NCT05708248|Experimental|Group I|
89359601|NCT05708248|No Intervention|Group II|
89359602|NCT04600505|Experimental|Treatment Sequence ABC|Participants will be randomized to one of the 6 different treatment sequences. Each participant will receive 3 single-dose treatments of BGF MDI (Treatment A; Treatment B; Treatment C) in 3 treatment periods, with first dose on Day -1 for all treatment periods.
89359603|NCT04600505|Experimental|Treatment Sequence BCA|Participants will be randomized to one of the 6 different treatment sequences. Each participant will receive 3 single-dose treatments of BGF MDI (Treatment B; Treatment C; Treatment A) in 3 treatment periods, with first dose on Day -1 for all treatment periods.
89359604|NCT04600505|Experimental|Treatment Sequence CAB|Participants will be randomized to one of the 6 different treatment sequences. Each participant will receive 3 single-dose treatments of BGF MDI (Treatment C; Treatment A; Treatment B) in 3 treatment periods, with first dose on Day -1 for all treatment periods.
89359605|NCT04600505|Experimental|Treatment Sequence ACB|Participants will be randomized to one of the 6 different treatment sequences. Each participant will receive 3 single-dose treatments of BGF MDI (Treatment A; Treatment C; Treatment B) in 3 treatment periods, with first dose on Day -1 for all treatment periods.
89359606|NCT04600505|Experimental|Treatment Sequence BAC|Participants will be randomized to one of the 6 different treatment sequences. Each participant will receive 3 single-dose treatments of BGF MDI (Treatment B; Treatment A; Treatment C) in 3 treatment periods, with first dose on Day -1 for all treatment periods.
89359607|NCT04600505|Experimental|Treatment Sequence CBA|Participants will be randomized to one of the 6 different treatment sequences. Each participant will receive 3 single-dose treatments of BGF MDI (Treatment C; Treatment B; Treatment A) in 3 treatment periods, with first dose on Day -1 for all treatment periods.
89359608|NCT03772379|Experimental|tooth borne hyrax expander group|patients of this group will receive a tooth borne hyrax expander anchored to the first premolars and first permanent molars .
89359609|NCT03772379|Experimental|tooth borne hyrax expander with microosteoperforation|patients of this group will receive a tooth borne hyrax expander anchored to the first premolars and first permanent molars and microosteoperforation .
89359610|NCT02474992|Experimental|Intervention|This arm is eligible for participation in the Microclinic intervention, a social network-based educational program.
89359611|NCT02474992|No Intervention|Comparison|This arm is not eligible for participation in the intervention during the first twelve months of the study. Following collection of the primary study endpoints, this arm will also be invited to participate in a Microclinic group. Participants in this arm will still have access to standard HIV care at the facility of their choice. At time of recruitment into the study, prior to randomization, all eligible participants will be counseled on the importance of returning to their clinic for ongoing HIV care.
89359612|NCT03772223|Experimental|Treatment sequence 1 (ABC)|Participants will be randomized to each of the 6 different treatment sequences. Each treatment sequence consist of Treatment A (Budesonide/Albuterol Sulfate metered dose inhaler [BDA MDI] - PT027) , Treatment B (Budesonide metered dose inhaler [BD MDI] - PT008), and Treatment C (Albuterol Sulfate metered dose inhaler [AS MDI] - PT007). Each randomized participant will receive a single-dose (2 inhalations) on Day 1 of this Treatment Period.
89359613|NCT03772223|Experimental|Treatment sequence 2 (BCA)|Participants will be randomized to each of the 6 different treatment sequences. Each treatment sequence consist of Treatment B (Budesonide metered dose inhaler [BD MDI] - PT008), Treatment C (Albuterol Sulfate metered dose inhaler [AS MDI] - PT007), and Treatment A (Budesonide/Albuterol Sulfate metered dose inhaler [BDA MDI] - PT027). Each randomized participant will receive a single-dose (2 inhalations) on Day 1 of this Treatment Period.
89359614|NCT03772223|Experimental|Treatment sequence 3 (CBA)|Participants will be randomized to each of the 6 different treatment sequences. Each treatment sequence consist of Treatment C (Albuterol Sulfate metered dose inhaler [AS MDI] - PT007), Treatment B (Budesonide metered dose inhaler [BD MDI] - PT008), and Treatment A (Budesonide/Albuterol Sulfate metered dose inhaler [BDA MDI] - PT027). Each randomized participant will receive a single-dose (2 inhalations) on Day 1 of this Treatment Period.
89359615|NCT03772223|Experimental|Treatment sequence 4 (ACB)|Participants will be randomized to each of the 6 different treatment sequences. Each treatment sequence consist of Treatment A (Budesonide/Albuterol Sulfate metered dose inhaler [BDA MDI] - PT027), Treatment C (Albuterol Sulfate metered dose inhaler [AS MDI] - PT007), and Treatment B (Budesonide metered dose inhaler [BD MDI] - PT008). Each randomized participant will receive a single-dose (2 inhalations) on Day 1 of this Treatment Period.
89359616|NCT03772223|Experimental|Treatment sequence 5 (BAC)|Participants will be randomized to each of the 6 different treatment sequences. Each treatment sequence consist of Treatment B (Budesonide metered dose inhaler [BD MDI] - PT008), Treatment A (Budesonide/Albuterol Sulfate metered dose inhaler [BDA MDI] - PT027), and Treatment C (Albuterol Sulfate metered dose inhaler [AS MDI] - PT007). Each randomized participant will receive a single-dose (2 inhalations) on Day 1 of this Treatment Period.
89359617|NCT03772223|Experimental|Treatment sequence 6 (CAB)|Participants will be randomized to each of the 6 different treatment sequences. Each treatment sequence consist of Treatment C (Albuterol Sulfate metered dose inhaler [AS MDI] - PT007), Treatment A (Budesonide/Albuterol Sulfate metered dose inhaler [BDA MDI] - PT027), and Treatment B (Budesonide metered dose inhaler [BD MDI] - PT008). Each randomized participant will receive a single-dose (2 inhalations) on Day 1 of this Treatment Period.
89359618|NCT03783377|Experimental|ARO-APOC3|
89359619|NCT03783377|Placebo Comparator|Placebo|
89359620|NCT02472340||Sedentary, Pre-frail|10 sedentary, pre-frail elderly, >61 year of age
89359621|NCT02472340||Active, Healthy|10 Active, healthy elderly, >61 years of age
89359622|NCT02474602|Experimental|Group A - Active or Placebo Phototherapy|"The phototherapy was divided in program 1 and program 2. One of these programs consisted in active phototherapy and the other placebo.~The subjects allocated in group A, received program 1 before strength training, and the same program 1 after training."
89534408|NCT02392572|Experimental|Arm E (Akt/ERK inhibitor ONC201)|Patients receive Akt/ERK inhibitor ONC201 PO twice weekly. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89359623|NCT02474602|Experimental|Group B - Active or Placebo Phototherapy|"The phototherapy was divided in program 1 and program 2. One of these programs consisted in active phototherapy and the other placebo.~The subjects allocated in group B, received program 1 before strength training, and program 2 after training."
89359624|NCT02474602|Experimental|Group C - Active or Placebo Phototherapy|"The phototherapy was divided in program 1 and program 2. One of these programs consisted in active phototherapy and the other placebo.~The subjects allocated in group C, received program 2 before strength training, and program 1 after training."
89359625|NCT02474602|Experimental|Group D - Active or Placebo Phototherapy'|"The phototherapy was divided in program 1 and program 2. One of these programs consisted in active phototherapy and the other placebo.~The subjects allocated in group B, received program 2 before strength training, and the same program 2 after training."
89359626|NCT03783299|Experimental|Village-based MTAT|"Intervention: For all households in intervention villages, after obtaining informed consent, MTAT will be conducted with all household members aged 18 months and older.~The MTAT team will test each individual using both a standard RDT and HS-RDTs. Positive cases will be treated with age-appropriate doses of Artemether-lumefantrine (AL) and Primaquine Phosphate (SLD-PQ)"
89000973|NCT04635982|Placebo Comparator|Placebo Group|With regard to the Kinesiotape technique, 2 I-shaped tapes were placed at the quadriceps, following the same direction of the muscle fibres and with no tension. At the gluteus, 2 I-shaped tapes were applied following the same direction of the muscle fibres and with no tension.
89000974|NCT04635982|Experimental|Experimental Group|In rectus femoris, origin was under the anterosuperior iliac spines, and taping finished with a Y-shape pattern under the patella. After that, an I-shaped KT was applied over vastus medialis and vastus lateralis muscles in both quadriceps. Finally, subjects were taped with a Y-shaped KT at the gluteus maximus muscles. Tape tension was between 25% and 50%.
89000975|NCT04635982|No Intervention|Control Group|It has not done any intervention in this group.
89000976|NCT00201396|Active Comparator|A arm|CCRT
89000977|NCT00201396|Experimental|B arm|Induction/CCRT
89000978|NCT04635709|Experimental|behavioral therapy|applying biofeedback training on the pelvic floor muscles
89000979|NCT04635709|Experimental|interferential therapy (IF)|Interferential current was applied to the body using four surface electrodes placed on the lower abdomen and lower buttocks.
89000980|NCT04635475|No Intervention|Control Group|Consented parents of a concussed high school student who will receive CDC Head's UP Concussion Guidelines during a five week program. 75 Participants.
89000981|NCT04635475|Experimental|Intervention Group|Consented parents of a concussed high school student who will receive the CDC Head's Up Concussion Guidelines and intervention RTL Student Protocol during a five week program. 75 Participants.
89000982|NCT04635514||Study group of 32 subjects|"Thirty-two women who presented with symptomatic lateral vaginal prolapse (deep dyspareunia, sensation of vaginal fulness, and heaviness) composed the study's group.~The surgical lateral vaginal reconstruction (lateral colporrhaphy) of the lateral vaginal wall was administered."
89000983|NCT00560599|No Intervention|1: Standard of care|Standard of care (no body decolonization regimen) and Standard of care (no environmental decolonization regimen)
89359627|NCT03783299|Experimental|Peer navigator-led FTAT|"Intervention: Peer navigators will actively seek non-village based HRPs in forested areas, rice fields and plantations, and any other non-permanent settlements within target health center catchment areas, and conduct FTAT among all consenting individuals.~The Peer Navigators will test each individual using both a standard RDT and HS-RDT. Positive cases will be treated with age-appropriate doses of Artemether-lumefantrine (AL) and Primaquine Phosphate (SLD-PQ)"
89000984|NCT00560599|Experimental|2: Body decolonization regimen|Body decolonization regimen and Standard of care (no environmental decolonization regimen)
89534409|NCT02292706||SOF+RBV|Participants who were previously treated with sofosbuvir (SOF) along with ribavirin (RBV) will be followed up to 5 years.
89534410|NCT02292706||LDV/SOF|Participants who were previously treated with ledipasvir/sofosbuvir (LDV/SOF) will be followed up to 5 years.
89000985|NCT00560599|Experimental|3 Environmental decolonization regimen|Standard of care (no body decolonization regimen) and Environmental decolonization regimen
89000986|NCT00560599|Experimental|4 Body and Environmental decolonization regimens|Body decolonization regimen and Environmental decolonization regimen
89000987|NCT04635202|Experimental|group A|patients (n=30) in this group will receive 16 weeks of elliptical training on elliptical trainer, 3 times per week. the training will start with 5 minutes warming up at 50 % of maximal heart rate (MHR), 20-minute continuous ET at 70% of MHR, 12 minutes (4×3) intervals at 90% of MHR with a 3-minute active recovery at 70% of MHR between intervals, and finally 5-minute cool-down period at 50% of MHR
89000988|NCT04635202|Other|Group B (control group)|patients (n=30) in this group will receive general advises on maintaining physical activities
89000989|NCT04635319||18-40 years old of both sexes|patient from 18 to 40 years old seeking orthodontic treatment
89000990|NCT00201474||brief depressive periods|brief depressive periods together with other fluctuating psychiatric symptoms
89000991|NCT00201474||major depressive disorder|
89534411|NCT02292706||LDV/SOF+RBV|Participants who were previously treated with LDV/SOF along with ribavirin will be followed up to 5 years.
89534412|NCT02292706||SOF/VEL|Participants who were previously treated with sofosbuvir/velpatasvir (SOF/VEL) will be followed up to 5 years.
89534413|NCT02292706||SOF/VEL+RBV|Participants who were previously treated with SOF/VEL along with RBV will be followed up to 5 years.
89534414|NCT02292706||SOF/VEL/VOX|Participants who were previously treated with sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) with or without RBV will be followed up to 5 years.
89534415|NCT02292706||Other SOF-Based|Participants who previously received other SOF based regimen will be followed up to 5 years.
89534416|NCT02292706||Enrolled From Ineligible Parent Treatment Group|Participants were enrolled from ineligible parent treatment group.
89534417|NCT02278601|Experimental|MPIB modified programmed intermittent bolus|Modified programmed intermittent bolus (MPIB) up-down frequency of 5mls ropivacaine/fentanyl solution in bolus with epidural delivery system
89534418|NCT02278601|Experimental|CIPCEA|computer integrated patient controlled epidural analgesia (CIPCEA) up-down variable basal infusion of ropivacaine/fentanyl solution with epidural delivery system
89359628|NCT03771833|Other|Main MARIA scan visit|For Arm 1, participants will be identified in clinic as having a suitable symptomatic breast and approached about the study. They will have the study design explained to them and will be informed that they are under no obligation to participate. Arm 1 participants will receive study information that they will be sent home with and informed that they will be approached via a telephone call in 2-3 days (or the closest working day to that date) to enquire if they would like to schedule an appointment for the study visit. If so, this will be scheduled to occur around 7 days from the date of the phone call.
89359629|NCT03771833|Other|Same-day MARIA scan visit|"For Arm 2, participants will be identified in clinic as having a suitable symptomatic breast and approached about the study. They will have the study design explained to them and will be informed that they are under no obligation to participate. Arm 2 participants will receive study information and as much time as possible to consider their involvement with the study (at least 1 hour). If the patient agrees to participate, they will be scheduled to have their MARIA scans at a time that suits their commitments that day.~This arm also includes the 2b group, who can optionally consent to a dielectric constant reading of their routinely-aspirated cyst fluid before this is disposed of as per usual site process."
89359630|NCT04491838|Experimental|Process A|Randomized 1:1
89359631|NCT04491838|Experimental|Process B|Randomized 1:1
89359632|NCT03771911|Other|AED guided|"Laypeople will be guided by an Automatic External Defibrillator's (AED) voice instructions during the cardiopulmonary resuscitation.~No other help is available."
89359633|NCT03771911|Other|Telephone guided|"Laypeople will be guided by telephone assistance (from an Emergency Call Center) during the cardiopulmonary resuscitation.~AED voice instructions are also available."
89359634|NCT03109054||Low Anxiety Level|The patients had low anxiety levels. Anxiety levels will determine with S-Anxiety TX-1 (State-Trait Anxiety Inventory Test:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3879951/)
89359635|NCT03109054||High Anxiety Level|The patients had high anxiety levels. Anxiety levels will determine with S-Anxiety (State-Trait Anxiety Inventory Test: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3879951/)
89359636|NCT03767387|Active Comparator|Prehabilitation + standard care|Trimodal Prehabilitation consisting on motivation, personalisation and supervision of physical activity before major surgery
89359637|NCT03767387|No Intervention|Standard care|Standard care before major surgery
89359638|NCT02474524|Experimental|Health intervention|+ treatment as usual
89359639|NCT02474524|Active Comparator|Social intervention|+ treatment as usual
89359640|NCT03771755|Active Comparator|Ibuprofen group|800 mg IV - Ibuprofen every 6 hours. In case required - followed with Morphine (PCA) 1-2 mg every 5 minutes
89359641|NCT03771755|Placebo Comparator|Acetaminophen group|1000mg IV Acetaminophen every 6 hours. In case required - followed with Morphine (PCA) 1-2 mg every 5 minutes
89359642|NCT02472184|Active Comparator|Office Hysteroscopy|Group of patients in which office hysteroscopy will be performed prior to endometrial biopsy
89359643|NCT02472184|Active Comparator|Endometrial biopsy|Group of patients in which endometrial biopsy will be performed prior to office hysteroscopy
89359644|NCT03783221|Experimental|High-fat diet|
89359645|NCT03783221|Active Comparator|High-residue diet|
89359646|NCT01321229||With sleep APNEA|Sleeping Apnea Syndrome (SAS) screening usin an APNEA LINK device within the 10 first days following the admission Diagnosis and medical care by a sleeping disorder qualified specialist
88831711|NCT01975922|Experimental|Enhanced Milieu Teaching|"Parents receive 28 intervention sessions in which they learn to use language support strategies with their children.~Children are assessed at baseline, 4 months after baseline, 10 months after baseline, and 16 months after baseline."
89359647|NCT01321229||Without sleep APNEA|Sleeping Apnea Syndrome (SAS) screening usin an APNEA LINK device within the 10 first days following the admission
88831712|NCT01975922|No Intervention|Community Services|Children receive speech-language services in the community. Children are assessed at baseline, 4 months after baseline, 10 months after baseline, and 16 months after baseline.
88831713|NCT02028325|Experimental|Fluorescein Sodium|All patients enrolled in the study will prepare for surgery as per standard neurosurgical indications, procedures and institution protocols. At the time of the anesthesia induction, with the patient under general anesthesia, Fluorescein Sodium 10% (100mg/1mL) at a dose of 3-20 mg/kg will be administered intravenously (the optimal dosage will be determined within the study as the most minimal dose for adequate visualization will be used). For vascular lesions, fluorescein sodium 10% (100mg/1mL) will be injected and used to assess its application after the conventional methods have confirmed the exclusion of the aneurysm. No patient's care will be affected by the results of the Fluorescein angiography.
89359648|NCT03767309|Experimental|Test group|SCTG will be harvested from the palate in the intervention group (coronally advanced flap and abrasively de-epithelialized free gingival graft)
89359649|NCT03767309|Active Comparator|Control group|SCTG will be harvested from the palate using Zucchilli's technique (zucchelli, 2010) in the control group (coronally advanced flap and conventionally de-epithelialized free gingival graft)
89359650|NCT02477566|Experimental|Long-acting Triptorelin|Pituitary down-regulation with Long-acting Triptorelin 1.875mg during the luteal
89359651|NCT02477566|Active Comparator|Short-acting Triptorelin|Pituitary down-regulation with Short-acting Triptorelin 0.1mg/d,x10d, then 0.05mg/d until E2<40pg/ml in serum, was initiated during the luteal phase
89359652|NCT05432531|Experimental|Baracetinib|oral tablet 4 mg baricitinib and placebo IV infusion/ month
89359653|NCT05432531|Active Comparator|Cyclophosphamide|IV cyclophosphamide 0.7mg/m2 every month and placebo tablet daily
89359654|NCT03772067|Experimental|MBdiet|This arm consist on 3 month on Bdiet with high energy and protein breakfast (660 +/-20 kcal), medium sized lunch (580+/-20 kcal) and dinner reduced in energy (300+/-20 kcal), with distribution of calories: breakfast 44%, lunch 37% and dinner 19%. The breakfast will contain 38 g protein mostly from milk and dairy products.
89534419|NCT02278601|Active Comparator|patient controlled epidural analgesia with basal infusion|patient controlled epidural analgesia (PCEA) with fixed basal infusion of ropivacaine/fentanyl solution with epidural delivery system
89534420|NCT02276937|Placebo Comparator|Placebo (0 ciu/limb)|Placebo control
89534421|NCT02276937|Active Comparator|DVC1-0101 low dose (1x10^9 ciu/limb)|Low dose cohort
89534422|NCT02276937|Active Comparator|DVC1-0101 high dose (5x10^9 ciu/limb)|High dose cohort
88831714|NCT02016560|Experimental|Exploratory Cognitively Healthy Subjects|Subjects will receive an IV injection, 370 megabecquerel (MBq) (10 millicurie [mCi]), single dose of florbetapir F 18 at baseline. Subjects will receive an IV injection, 370 MBq (10 mCi), single dose of flortaucipir at baseline.
88831715|NCT02016560|Experimental|Exploratory MCI Subjects|Subjects will receive an IV injection, 370 MBq (10 mCi), single dose of florbetapir F 18 at baseline. Subjects will receive an IV injection, 370 MBq (10 mCi), single dose of flortaucipir at baseline, 9 months and 18 months.
89359655|NCT03772067|Active Comparator|OBdiet|This arm consist on 3 month on Bdiet with high energy and protein breakfast (660 +/-20 kcal), medium sized lunch (580+/-20 kcal) and dinner reduced in energy (300+/-20 kcal), with distribution of calories: breakfast 44%, lunch 37% and dinner 19%. The breakfast will 38 g protein without milk or dairy products mostly from other proteins, i.e. eggs, tuna, soy, oatmeal. Milk product will be avoided in this diet also in other meals along the day.
89359656|NCT03783065|Experimental|Experimental group|Procedure: Laparoscopic splenectomy and pericardial devascularization Drug: Propranolol
89359657|NCT03783065|Active Comparator|Control group|Procedure: Endoscopic therapy Drug: Propranolol
88831716|NCT02016560|Experimental|Exploratory AD Subjects|Subjects will receive an IV injection, 370 MBq (10 mCi), single dose of florbetapir F 18 at baseline. Subjects will receive an IV injection, 370 MBq (10 mCi), single dose of flortaucipir at baseline, 9 months and 18 months.
89359658|NCT01309763|Active Comparator|AFFITOPE AD03|s.c. injection
89359659|NCT01309763|Experimental|AFFITOPE AD03 + Alum|s.c. injection
89359660|NCT03771599|Active Comparator|Control group|"Routine physical therapy~[Time Frame: Twelve weeks]"
88831717|NCT02016560|Experimental|Confirmatory Subjects|Subjects will receive an IV injection, 370 MBq (10 mCi), single dose of florbetapir F 18 and flortaucipir at baseline.
88831718|NCT02017574|Experimental|Implicit Group|Receives little feedback about task performance during learning
88831719|NCT02017574|Active Comparator|Control|Receives detailed feedback about task performance during learning
88831720|NCT02869295|Experimental|NKTR-214 Dose Escalation|This is a first in human, open-label, sequential dose escalation and expansion Phase 1 study of NKTR--214 in adult patients with locally advanced and metastatic solid tumors. The Phase 1 stage of the study is designed as an open-label dose escalation trial of NKTR--214 in participants with locally advanced or metastatic solid tumors. The goal of the dose escalation stage of the study is to find the recommended phase 2 dose, to evaluate the efficacy of NKTR--214 by assessing the objective response rate and to evaluate the safety of NKTR-214. Immunological biomarkers in plasma and tumor samples will also be measured.
88831721|NCT02340104|Experimental|Baricitinib|Single oral dose of baricitinib and single intravenous (IV) infusion of [^13C4D3^15N]-baricitinib over 1.5 hours.
88831722|NCT02869451|Experimental|Treatment|Cognitive-behavioral counseling for marijuana and smoking cessation, mobile contingency management for marijuana and smoking cessation, transdermal nicotine patch (7-21 mg over six weeks), nicotine polacrilex or nicotine lozenge (4 mg administered as needed over six weeks), bupropion (150 mg once per day for 7 days, then 150 mg twice per day for about six months.
88831723|NCT02340338|Experimental|Dose Group 1|Treatment: rTSST-1 Variant Candidate Vaccine 100 ng
88831724|NCT02340338|Experimental|Dose Group 2|Treatment: rTSST-1 Variant Candidate Vaccine 300 ng
88831725|NCT02340338|Experimental|Dose Group 3|Treatment: rTSST-1 Variant Candidate Vaccine 1 µg
88831726|NCT02340338|Experimental|Dose Group 4|Treatment: rTSST-1 Variant Candidate Vaccine 3 µg
88831727|NCT02340338|Experimental|Dose Group 5|Treatment: rTSST-1 Variant Candidate Vaccine 10 µg
88831728|NCT02340338|Experimental|Dose Group 6|Treatment: rTSST-1 Variant Candidate Vaccine 30 µg
88831729|NCT02340338|Placebo Comparator|Dose Group 0|Control: Al(OH)3 Adjuvant
88831730|NCT02305316|Experimental|BIA 9-1067 non-micronized - micronized|Each subject was orally administered with 50 mg OPC non-micronized followed by a washout period of 14 days. After washout period each subject was orally administered with 50 mg OPC micronized
88831731|NCT02305316|Experimental|BIA 9-1067 micronized - non-micronized|Each subject was orally administered 50 mg OPC micronized followed by a washout period of 14 days. After washout period each subject was orally administered with 50 mg OPC non-micronized
88831732|NCT02944565|Experimental|Treatment (daratumumab)|Patients receive daratumumab IV over 1.5 hours. Treatment continues in the absence of disease progression or unacceptable toxicity.
88831733|NCT02870309|Experimental|Alpha-1 MP|Participants received 8 IV infusions of 60 mg/kg Alpha-1 MP administered weekly at an infusion rate not exceeding 0.08 mL/kg/min over approximately 15 minutes, up to Week 8.
88831734|NCT01979276|Experimental|Pomalidomide, Romidepsin, Dexamethasone|Pomalidomide, 4 mg by mouth daily on days 1-21 of 28 day cycle Dexamethasone, 40 mg by mouth on days 1, 8, 15, and 22 of 28 day cycle Romidepsin, IV on days 1 and 15 of 28 day cycle, dose level to be determined Dexamethasone
89359661|NCT03771599|Experimental|Intervention group|"Traditional massage + Routine physical therapy~[Time Frame: Twelve weeks]"
89359662|NCT04586933|Active Comparator|Omega-3|"0,9 gram omega-3/capsule x 4 = 3,6 gram omega-3 daily~It will be investigated whether diet optimization followed with supplementation of omega-3s can reduce disease activity in patients with inflammatory arthritis. A new omega-3 high concentrate from GC Rieber Oils will be used"
89534423|NCT01931033|Experimental|Oxytocin|Intranasal Oxytocin (brand name Syntocinon) will be administered daily (for a total daily dose of 48 IU) for 8 weeks.
89534424|NCT01930539|Experimental|Ultraviolet B lamp|Intervention arm: Patients in the Ultraviolet B lamp group will continue vitamin D2/D3 daily and will receive 3 treatment sessions of Ultraviolet B light once a week for 12 weeks. Patients will receive Ultraviolet B light from Ultraviolet B lamp at a distance of 14 inches for duration of 5 minutes each area while wearing an Ultraviolet eye shield. Areas of skin exposure will include 3 different areas amounting to 27% of body surface area. 9% body surface area will include front of abdomen, lower back, each arm, each leg is 18%, each thigh. Ultraviolet B light sessions will be supervised and conducted by study personnel or Center for Clinical and Translational Research staff. A food questionnaire will be reviewed at each visit to assess dietary intake of calcium. Skin exam will be conducted at the beginning and end of the session.
89359663|NCT04586933|Placebo Comparator|Placebo capsules|Soya oil
89359664|NCT03771443|Experimental|gluten free toothpaste|experimental gluten free toothpaste with natural ingredients prepared for the study to be used 3 times per day for six months
88831735|NCT02871011|Placebo Comparator|Control|Water, delivered as a footbath for 30 minutes, daily for 3 consecutive days.
89359665|NCT03766997|Experimental|local injection|Compound betamethasone injection (Each injection contains betamethasone dipropionate at 5 mg for betamethasone and betamethasone sodium phosphate at 2 mg for betamethasone) was local injected to the breast by the patient once a week for one to four times followed by Hydrocortisone butyrate cream(0.1%) topical use twice a day until the termination of treatment.
89359666|NCT03766997|Active Comparator|topical|Hydrocortisone butyrate 0.1% cream was applied to the breast by the patient twice a day until the termination of treatment.
89359667|NCT03766919|Experimental|INVICTA lead|All patients eligible for enrolment in whom the INVICTA lead is attempted (Implant of the INVICTA lead)
89359668|NCT03782831|Experimental|TACE plus PD-1 antibody|Patients received hepatic intra-arterial infusion with lipiodol mixed with chemotherapy drugs (EADM, lobaplatin, and MMC), and embolization with polyvinyl alcohol particles (PVA) on demand. In addition, patients received 3mg/kg PD-1 antibody intravenously every 2 weeks up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
89359669|NCT03782831|Active Comparator|TACE alone|Patients received hepatic intra-arterial infusion with lipiodol mixed with hemotherapy drugs (EADM, lobaplatin, and MMC), and embolization with polyvinyl alcohol particles (PVA) on demand. In addition, patients received placebos intravenously every 2 weeks
89359670|NCT03782909|Experimental|Behaviour change intervention|Intensive behaviour change for 6 weeks, followed by a maintenance phase for 6 weeks
89359671|NCT03766841|Experimental|Facilitated Enrollment|Patients will be aided in the account creation and usage of a consumer informatics tool to collect and report patient-contextual data within the electronic health record
89359672|NCT03766841|No Intervention|Usual Care|Patients will be invited to use the patient contextual data tool as per usual care, but will not receive additional assistance in account creation and usage.
89359673|NCT03771365||Standard-PCNL|Perform PCNL with ≥24 Fr access tract for the treatment of ≥2 renal stones
89359674|NCT03771365||Mini-PCNL|Perform PCNL with 12-20 Fr access tract for the treatment of ≥2 renal stones
89359675|NCT03771365||Super-mini PCNL|Perform SMP for the treatment of ≥2 renal stones
89359676|NCT03771287|Experimental|OpenSound Navigator (OSN) Hearing Aid|Participants will be fit with Oticon OPN™ behind-the-ear hearing aids with the OpenSound Navigator algorithm enabled. Participants are to use the hearing aids at least an average of 8 hours per day over the course of 6-8 months.
89359677|NCT03771287|Active Comparator|omni-directional Hearing Aid|Participants will be fit with Oticon OPN™ behind-the-ear hearing aids with the Omni-directional microphone system enabled. Participants are to use the hearing aids at least an average of 8 hours per day over the course of 6-8 months.
89359678|NCT01560767|Active Comparator|Femoral Nerve Block|levobupivacaine
89359679|NCT01560767|Active Comparator|peri-articular infiltration|The peri-articular infiltration of multimodal agents will consist of 150 mg of levobupivacaine, 10 mg morphine and 30mg ketorolac diluted in 0.9% saline to make a volume 100 ml. (0.5ml 1:1000 adrenaline will be added to the mixture to reduce blood loss after the operation) Fifty ml of the mixture will be injected into the posterior, medial and lateral soft-tissues just prior to implantation of the TKA components. Care will be taken to avoid excessive infiltration in the area of the common peroneal nerve. Then, while the cement is curing, the anterior soft-tissues including the quadriceps mechanism, the retinacular tissues and the subcuticular tissues will be infiltrated with the remaining 50 ml of peri-articular injection.
89359680|NCT03770897|Experimental|3D laparoscopic appendectomy.|Laparoscopic appendectomy will be performed with 3d technology device by young surgeons, tutored by an expert assistant.
89359681|NCT03770897|Active Comparator|2D laparoscopic appendectomy.|Laparoscopic appendectomy will be performed by young surgeons (tutored by an expert assistant) with the standard 2D viewing method.
89359682|NCT03782675|Sham Comparator|Control|In the control arm, the ABS device will be placed as usual on the patient, but the airflow will NOT be activated. Only the technician in the room will be aware whether the device the device is turned on or not.
89359683|NCT03782675|Experimental|Air Barrier System|In the experimental (interventional) arm, the ABS device will be placed as usual on the patient, and the airflow will be activated. Only the technician in the room will be aware whether the device is turned on or not.
89359684|NCT03771131|Experimental|Experimental group|Group receiving the multi-domain cognitive training
89359685|NCT03771131|No Intervention|Control group|Passive control group
88816820|NCT05097703|No Intervention|Control|Participants randomised to the wait-list control group will be asked to complete pre, post and follow-up measures, as well as keep a sleep diary for the duration of the intervention period. They will then be sent the resource after the final outcome measures have been collected to use as they wish.
88816821|NCT05084209|Experimental|Parkinson's medical decision making support intervention group|All participants will complete an online medical decision making intervention, lasting about 30 minutes, and complete pre and post surveys.
88816822|NCT05077150||PCP cases|"Any allogeneic HSCT recipient who, during the 1-year study period, underwent a BAL from the day of transplant, and whose BAL fluid was positive for PcP: either by qPCR alone, or positive cytology or IF, irrespectively of clinical presentation, imaging, co-infection and PcP treatment. Only first episode of PcP will be included (incident cases).~Due to the lack of standardization, qPCR on sputum only will not be taken in account for the diagnosis of PcP."
88816823|NCT05077150||Controls|Controls are matched to case on Centre and HSCT date and if possible on gender and date of birth.
88816824|NCT05069285|Experimental|Self-help book|A self-help book for insomnia (written in Norwegian)
88816825|NCT05069285|Active Comparator|Sleep hygiene advice|A sheet of paper with standard sleep hygiene advice
88816826|NCT05063877|Placebo Comparator|Placebo|"Matched placebo control 10 mg capsule or 20 mg capsules totaling to 10 mg, 20 mg, 40mg or 60 mg will be administered once daily orally for 12 weeks with the option for open-label extension.~Intervention: Drug: Placebo"
89359686|NCT03766607|Experimental|Trastuzumab with Ramucirumab and Paclitaxel|Single arm study of trastuzumab (8 mg/kg loading dose; 6 mg/kg maintenance) every 21 days + ramucirumab (8 mg/kg) on days 1 & 15 every 28 days + paclitaxel (80 mg/m2) on days 1, 8, and 15 every 28 days
89359687|NCT03782753||Group A|25 LRRK2-PD patients
89359688|NCT03782753||Group B|25 idiopathic PD patients
89359689|NCT03782753||Group C|25 HC subjects
89359690|NCT05515835||rocuronium|The patient will be given 50mg of rocuronium intravenously for induction.
89359691|NCT03771209|Experimental|ultrasound assessment|The aim of this study is the creation of a five-step ultrasound examination to evaluate and monitor HF patients during hospitalization and short follow-up.
89359692|NCT03770819|Placebo Comparator|Placebo group|Application of placebo gel followed by sham Photodynamic therapy
89359693|NCT03770819|Active Comparator|Zinc oxide gel group|Application of Zinc oxide gel followed by sham Photodynamic therapy.
89359694|NCT03770819|Experimental|PDT group|Application of placebo gel followed by Photodynamic therapy.
89359695|NCT03770819|Experimental|Zinc oxide and PDT group|Application of Zinc oxide gel followed by Photodynamic therapy.
89359696|NCT03770975|Active Comparator|Delayed implant placement with immediate provisionalization|Single delayed implant placement in the esthetic zone with placing an immediate temporary crown placed within 48 hours after the surgery
89359697|NCT03770975|Experimental|Implant with immediate temporization and soft tissue graft|Single delayed implant placement in the esthetic zone with placing a subepithelial connective tissue graft buccal to the implant and immediate temporary crown within 48 hours after the surgery
88831736|NCT02871011|Experimental|Nitric oxide|Nitric oxide delivered as a footbath for 30 minutes, daily for 3 consecutive days.
88831737|NCT02343380|Experimental|morning-first|calorimetric exam after a standard meal
89534425|NCT01930539|No Intervention|Control|Patients in control group will continue with their current dose of Vitamin D2/D3 for 12 weeks.Patients will remain on the same steady dose for the duration of the study.These patients will not receive Ultraviolet B light sessions.
88831738|NCT02343380|Experimental|evening-first|calorimetric exam after a standard meal
88831739|NCT02871479|Experimental|SAN007 5% cream|A cream containing 5% East Indian sandalwood oil (EISO).
88831740|NCT02871479|Placebo Comparator|Placebo cream|The vehicle cream
88831741|NCT02871479|Experimental|SAN007 10% cream|A cream containing 10% East Indian Sandalwood Oil (EISO).
89359698|NCT04518683|Experimental|Groupe 1 - Study group|"The home program (outside of the sessions with the physiotherapist) will be done with a mobile application equipped with a vaginal probe. The exercises should be done 3x/week for 10 minutes (time corresponding to 1 programe). The correct use of the prob will have been checked during the sessions with the physiotherapist. This training will work on the strength, relaxation and endurance of the pelvic floor.~The program includes 3 levels of difficulty. Once the user has successfully completed one level, she can move on to the next."
89359699|NCT04518683|Active Comparator|Groupe 2 - Control group|"The home program (outside of the sessions with the physiotherapist) will be done without a mobile application. The exercises will have been explained during the sessions with the physiotherapist by oral instructions. The exercises will be done 3x/week for 10 minutes. The correct realization of the exercises will have been verified during the sessions with the physiotherapist.~This training will work on pelvic floor strength, relaxation and endurance. The program includes 3 levels of difficulty"
89359700|NCT01321307||Sorend|Group no. 1 shall receive Sorend following diagnosis of aphtostomatitis or mucositis.
89359701|NCT01321307||Sorend placebo|Group no. 2 shall receive Sorend placebo following diagnosis of aphtostomatitis or mucositis.
89359702|NCT01567709|Experimental|Treatment (alisertib, vorinostat)|Patients receive alisertib PO BID on days 1-7 or days 1-3 and 8-10, and vorinostat PO BID on days 1-14 or days 1-5 and 8-12. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89359703|NCT01321619|Experimental|Varicell|Drug A(Varicell) : Administered one tablet three times a day,(oral), the main meals (breakfast, lunch and dinner)for 30 days.
89359704|NCT01321619|Experimental|Placebo daflon (Drug D)|Drug D (Placebo Daflon): Administered one tablet two times daily (oral), the main meals (breakfast and dinner)for 30 days.
88831742|NCT02344238|Other|Standard Capsules|Receive standard capsules (no ID cap technology) with compliance measured by self-report, pill count, and riboflavin measurement.
88831743|NCT02344238|Other|ID Capsules without Prompts|Receive ID capsules, with compliance measured by self-report, pill count, riboflavin measurement, and data collected by the ID Cap.
88831744|NCT02344238|Other|ID Capsules with Prompts|Receive ID capsules, with compliance measured by self-report, pill count, riboflavin measurement, and data collected by the ID Cap. This arm will also receive prompts (reminder calls and/or text messages) to ingest the study medication if a signal is not sent to the study team within one hour of the scheduled medication administration time.
88831745|NCT02344316|Active Comparator|Melatonin|Group randomized to melatonin 3 mg orally nightly
88831746|NCT02344316|Placebo Comparator|Placebo|Group randomized to placebo orally nightly
88831747|NCT02872103|Experimental|F-627|F-627, 20 mg fixed dose pre-filled syringe, dosed Day 2 of each of 4 chemotherapy cycles.
88831748|NCT02872103|Placebo Comparator|Placebo|Placebo, pre-filled syringe administered Day 2 of the first chemotherapy cycle; and F-627, 20 mg fixed dose pre-filled syringe administered Day 2 of each of the following 3 chemotherapy cycles.
88831749|NCT02344628|Active Comparator|AZT30|Single dose of azithromycin at a dose of 30mg/kg - max 2 Grams
88831750|NCT02344628|Experimental|AZT20|Single dose of azithromycin at a dose of 20mg/kg - max 1 Grams
88831751|NCT02345486|Active Comparator|0.9% sodium chloride|Participants in the '0.9% sodium chloride' arm will receive 0.9% sodium chloride ('normal saline') any time an isotonic crystalloid is ordered by a provider during the intensive care unit admission.
89359705|NCT03766217|Experimental|Mesenchymal stem cells associated with biomaterials|Mesenchymal stem cells obtained from autogenous deciduous dental pulp associated with biomaterials. The stem cells will be obtained by enzimatic digestion in GMP laboratory and will be seed into the biomaterial (hydroxyapatite/collagen).
89359706|NCT03766217|Active Comparator|Iliac crest autogenous bone graft|Autogenous bone will be obtained from iliac crest. The prepare of the receptor area will be the same in both arms and will follow current recommendations.
89359707|NCT03766139|Experimental|SUPERCELL GLUE(STEM CELLS AND PRFM)|Following optimum anaesthesia, reflection of full thickness mucoperiosteal flaps for defect access and thorough debridement will be done. Subsequently the defect will be filled with supercell glue in test sites .
89359708|NCT03766139|Active Comparator|PRFM ALONE|Following optimum anaesthesia, reflection of full thickness mucoperiosteal flaps for defect access and thorough debridement will be done. Subsequently the defect will be filled with PRFM in control sites
89359709|NCT03766061|Active Comparator|Onlay Mesh Hernioplasty|In this group patients with paraumbilical hernia are treated with onlay mesh hernioplasty in which we placed mesh on the anterior rectus sheath
89359710|NCT03766061|Active Comparator|Sublay Mesh Hernioplasty|In this group patients with paraumbilical hernia are treated with sublay mesh hernioplasty in which we placed mesh in the retromuscular space
89359711|NCT03765905||PCOS diagnosis area|The study group consisted of 40 reproductive age women between 18th and 35th years old women who were PCOS diagnosis (according to the 2003 Rotherdam criteria)
89359712|NCT03765905||PCOS is not diagnosed|Forty patients who did not have any complaints between the ages of 18-35 who applied to the gynecology policlinic as a control group but who had no PCOS orany other systemic problems and were similar in terms of age group and body mass index were included in the study after being approved for participation in the study
89359713|NCT03765827|Experimental|Vitamin E acetate|Vitamin E acetate ointment will be applied over the staple lines and anastomoses in Roux-en-Y gastric bypass
89359714|NCT03765827|Sham Comparator|Control group|No ointment will be applied
89359715|NCT03765671|Experimental|Mild Child-Pugh A|Single oral dose of elafibranor 120mg
89359716|NCT03765671|Experimental|Moderate Child-Pugh B|Single oral dose of elafibranor 120mg
89359717|NCT03765671|Experimental|Severe Child-Pugh C|Single oral dose of elafibranor 120mg
89359718|NCT03765671|Experimental|Healthy|Single oral dose of elafibranor 120mg
89359719|NCT03765593||Study group 1|Immunopositive primary SS (Anti-SSA +/anti-Ro+) will receive salivary gland biopsy.
89359720|NCT03765593||Study group 2|Immunonegative primary SS (Anti-SSA -/anti Ro-, biopsy Chisholm-Mason 3-4) will receive salivary gland biopsy.
89359721|NCT03765593||Study group 3|Non-autoimmune sicca syndrome (Anti-SSA/anti Ro-, biopsy Chisholm-Mason 2 o less) will receive salivary gland biopsy.
89359722|NCT03765593||Control group|Patients who have sicca syndrome but do not meet the classification criteria of Sjögren's syndrome, therefore, at the time of evaluating these patients to determine whether or not they have the disease are what will serve as controls since according to the usual diagnostic process, the same studies will be carried out as for patients with the proposed disease. Will receive salivary gland biopsy.
89359723|NCT03765515|Experimental|Q-Fix|"Q-Fix has the advantages of all-suture implant and has the same or better performance than the traditional anchor.~Consistent activation effect~Excellent performance~Streamlined technique Q-fix is an experimental Arm."
89359724|NCT03765515|Active Comparator|Twinfix Ti|The Smith & Nephew's marketed Twinfix Suture Anchor is selected as the control product. This product is composed of anchor, suture, suture needle and inserter. The anchor is made of Ti6Al4V titanium alloy conforming to ISO5832-3. The Durabraid suture is made of polyester (Polyethylene terephthalate) conforming to YY 0167. Ultrabraid suture is made of two materials of UHMWPE and polypropylene monofilaments conforming to GB/T 19701.1. The suture needle is made of Type 420B stainless steel conforming to YY/T 0726. The stem portion of inserter that comes into contact with the body is made of Type 630B stainless steel conforming to YY/T 0726.
89359725|NCT03765203|Active Comparator|Control|Control participants will care for the same set of CPV patients as the intervention arm, but will not have knowledge of or access to Natera's dd-cfDNA test results. Investigators will compare control participants' clinical recommendations to those in the intervention arm.
89359726|NCT03765203|Experimental|Intervention|Intervention participants will care for the same set of CPV patients as the control arm, but will be educated on and given access to Natera's dd-cfDNA test results. Investigators will compare intervention participants' clinical recommendations to those in the control arm.
89359727|NCT03765047|Experimental|Intervention Arm|"This study arm includes the schools where the School Team (school teachers, coordinator) receives the physical activity intervention. The intervention consists of four parts:~School Engagement and Assessment~Training~Physical Activity Equipment and Resources~Ongoing Assessment and Technical Assistance"
89359728|NCT03765047|No Intervention|Control Arm|The control arm includes the schools where the School Team does not receive any intervention but all the necessary data will be collected.
89359729|NCT03771053|Experimental|Ezetimibe with simvastatin group|ezetimibe 10mg with simvastatin 40mg everyday for 12 months after PCI
89359730|NCT03771053|Active Comparator|Simvastatin group|simvastatin 40mg everyday for 12 months after PCI
89534426|NCT01781689|Experimental|Functional Electric Stimulation|perform arm cranking with functional electrical stimulation
89359731|NCT03770585|Active Comparator|Group 1(Fluoroscopy guided group)|IN Fluoroscopy guided group, with x-ray beam, after cleaning and drapping and administration of local anesthesia, a22-g spinal needle is inserted in line till bony contact is felt under sterile conditions. Each facet joint is infiltrated with a mixture containing 0.5 ml of 0.25 % bupivacaine and 0.5 ml (20mg) methylprednisolone acetate injected into the joint.
89359732|NCT03770585|Active Comparator|Group2 (Ultrasound guided group)|In Ultrasound guided group, with Ultrasound guidance, , a mixture containing 0.5 ml of 0.25 % bupivacaine and 0.5 ml(20mg) methylprednisolone acetate is administered intra-articular (until resistance was encountered) and injected around the posterior facet joint capsule.
89359733|NCT03770663|Experimental|European strategy|"3 IV pulses of Methylprednisolone (7.5 mg/kg/day followed by tapering doses of oral Prednisone, started at 1 mg/kg/day from D4 to M12~In association with:~6 IV pulses of Cyclophosphamide (1000mg) followed from M5 to M12 by oral Azathioprine (2mg/kg/day), with a maximum of 150mg/day"
89359734|NCT03770663|Experimental|American strategy|"3 IV pulses of Methylprednisolone (7.5 mg/kg/day followed by tapering doses of oral Prednisone, started at 1 mg/kg/day from D4 to M12~In association with:~Tacrolimus given orally from M0 to M12 (started at the initial dose of 2x2mg/day). Tacrolimus doses are regularly adapted to its serum concentration to reach 5-15ng/mL."
88831752|NCT02345486|Active Comparator|Physiologically balanced fluid|Participants in the 'physiologically balanced fluid' arm will receive physiologically balanced fluid (Lactated ringers or Plasmalyte-A) any time an isotonic crystalloid is ordered by a provider during the intensive care unit admission.
88831753|NCT02950025|Active Comparator|Online non-adaptive MRI-guided SBRT|"All patients will be initially planned for stereotactic body radiation therapy to a minimum dose of 50Gy in five fractions to the planning target volume (PTV)~Radiotherapy will consist of stereotactic body therapy, to be given over five fractions, delivered once daily or once every other day for a period of one to two weeks, for a total of five treatments~All patients will undergo both CT and MRI simulation in positioning appropriate for the specific treatment site~Quality of life questionnaire baseline, 6 weeks after treatment conclusion, and 6 months after treatment conclusion"
89359735|NCT03770507|Experimental|Treadmill Exercise in Adolescents and Adults|Comparison of gas exchange kinetics between treadmill and cyclo ergometer exercises
89359736|NCT03770507|Experimental|Cyclo Ergometer Exercise in Adolescents and Adults|Comparison of gas exchange kinetics between treadmill and cyclo ergometer exercises
89359737|NCT03048422|Experimental|Arm 1: Maternal DTG+FTC/TAF|Mothers randomized to receive dolutegravir (DTG) plus emtricitabine/tenofovir alafenamide (FTC/TAF) during pregnancy, through delivery, and for 50 weeks postpartum.
88831754|NCT02950025|Experimental|Arm B: Online-Adaptive MRI-guided SBRT|"All patients will be initially planned for stereotactic body radiation therapy to a minimum dose of 50Gy in five fractions to the planning target volume (PTV)~Radiotherapy will consist of stereotactic body therapy, to be given over five fractions, delivered once daily or once every other day for a period of one to two weeks, for a total of five treatments~All patients will undergo both CT and MRI simulation in positioning appropriate for the specific treatment site~When patients present for their first SBRT treatment session, the treating physician will evaluate their individual anatomy to determine if adaptive planning is indicated. Patients randomized to the online-adaptive treatment planning arm will have all tumor volumes and critical structures within 3 axial slices of the PTV re-contoured on the MR-localization image of the day~Quality of life questionnaire baseline, 6 weeks after treatment conclusion, and 6 months after treatment conclusion"
88831755|NCT02873585|Experimental|Stationary intraoral tomosynthesis|Stationary intraoral tomosynthesis after standard conventional bitewing radiography
88831756|NCT02019758|Active Comparator|Oral Viscous Budesonide (OVB)|Subjects will be treated with OVB at a dose of 1 mg twice daily, and they will also be instructed to use a placebo inhaler identical to the fluticasone MDI, with instructions to swallow 4 puffs twice daily.
88831757|NCT02019758|Active Comparator|Active Fluticasone MDI|Subjects will be treated with fluticasone MDI at a dose of 880 mcg twice daily (4 puffs of a 220 mcg inhaler twice daily), and they will also be instructed to take 4 mL twice daily of a placebo slurry of sucralose identical in consistency and taste to the OVB.
88831758|NCT02876159|Experimental|Vaccination Naïve|Participants who have received an influenza vaccine in 2 or less of the past 5 years will receive the FDA-approved 2016-2017 influenza vaccine.
89359738|NCT03048422|Experimental|Arm 2: Maternal DTG+FTC/TDF|Mothers randomized to receive DTG plus emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) during pregnancy, through delivery, and for 50 weeks postpartum.
89359739|NCT03048422|Active Comparator|Arm 3: Maternal EFV/FTC/TDF|Mothers randomized to receive efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) during pregnancy, through delivery, and for 50 weeks postpartum.
89359740|NCT03048422|No Intervention|Arm 1 Infants|Infants born to women in Arm 1. Infants did not directly receive study intervention, but may have been exposed to the randomized treatment through placental or breastmilk transfer.
89359741|NCT03048422|No Intervention|Arm 2 Infants|Infants born to women in Arm 2. Infants did not directly receive study intervention, but may have been exposed to the randomized treatment through placental or breastmilk transfer.
89359742|NCT03048422|No Intervention|Arm 3 Infants|Infants born to women in Arm 3. Infants did not directly receive study intervention, but may have been exposed to the randomized treatment through placental or breastmilk transfer.
89359743|NCT03770195||Abdominoplasty Patients|Patients undergoing full abdominoplasty procedures in which the surgeon elects to use HEMOBLAST Bellows to control minimal, mild, or moderate bleeding for which conventional means of hemostasis are ineffective or impractical
89359744|NCT03770117||Prehabilitation|"In this arm of the study, participants will undergo prehabilitation prior to surgery. This is intended to increase the participants overall health prior to surgery to try and increase their general well-being during and after surgery.~Prehabilitation is multimodal therapy comprising:~Assessment for malnutrition and nutritional support dependent on the outcome~Optimisation of management of pancreatic exocrine insufficiency~Assessment of muscle mass and strength~Individually tailored, goal directed exercise regimen under the care of physiotherapy"
89359745|NCT03770117||Standard Procedure|In this arm, participants will not receive any Rehabilitation prior to the surgery. This is the current standard care and will act as the control data for this study.
89359746|NCT01561781|Experimental|digoxin then digoxin + vandetanib|Digoxin alone followed by digoxin in combination with vandetanib
89359747|NCT03770039|Experimental|2-period, fixed sequence|fixed sequence with 2 treatment period
89359748|NCT03782363|Experimental|Autologous CIK Dose level 1|autologous CIK at dose level 1
89359749|NCT03782363|Experimental|Autologous CIK Dose level 2|autologous CIK at dose level 2
88831759|NCT02876159|Experimental|Vaccination Experienced|Participants who have received an influenza vaccine at least 3 of the past 5 years will receive the FDA-approved 2016-2017 influenza vaccine.
89359750|NCT03782363|Experimental|Autologous CIK Dose level 3|autologous CIK at dose level 3
89359751|NCT03782363|Experimental|Autologous CIK Dose level 4|autologous CIK at dose level 4
89359752|NCT05693168|Experimental|Comparison of ANNE Limb Sensor pulse oximetry measurements to blood gas analysis|
89359753|NCT01321775|Experimental|Bevacizumab,Trastuzumab,Paclitaxel,Cyclophosphamide,Myocet|
89359754|NCT03764657||"16 patients, named Hot group"|"We considered 16 sinus excision by diathermy as a case group (named Hot group)"
89359755|NCT03764657||"13 patients, named Cold group"|"13 procedures performed by knife as control group (named Cold group)."
89534427|NCT01781689|Sham Comparator|traditional rehabilitation program|Receive traditional rehabilitation programs
88831760|NCT02020304|Experimental|Room temperature|room temperature combined spinal epidural dose (60-75 degrees F)
89359756|NCT03764579|Active Comparator|sleep and diet intervention|
89359757|NCT03764579|Active Comparator|diet intervention|
89359758|NCT03764423|Experimental|Salmon fishmeal|7,5 g fishmeal and 7,5 g microcrytalline cellulose per day in capsules by mounth for 8 weeks
89359759|NCT03764423|Placebo Comparator|Microcrystalline cellulose|7,5 g microcrystalline cellulose per day in capsules by mounth for 8 weeks
89359760|NCT03764345|Experimental|Sofosbovir/Ledipasvir Daily|Patients receive oral daily dose of Sofosbovir/Ledipasvir (200/45mg) daily for 8 weeks
89359761|NCT03769961||ET (DBS-, Ataxia+)|Essential Tremor without DBS with Ataxia on examination
89359762|NCT03769961||ET (DBS-, Ataxia-)|Essential Tremor without DBS and without Ataxia on examination
89359763|NCT03769961||ET (DBS+, Ataxia+)|Essential Tremor with DBS with Ataxia on examination
89359764|NCT03769961||ET (DBS+, Ataxia-)|Essential Tremor with DBS without Ataxia
89359765|NCT03769883|Experimental|Dietary control (DCON)|The macro-nutrient distributions are in line with the current guidelines from the national Diabetes Association and Canadian guidelines, where individualization in macronutrient distribution should lie within the range of 45-60E% carbohydrate, 15-20E% protein and 20-35E% fat. The dietary plan will aim at reducing saturated fat intake <7E% aiming at a caloric deficit of 500 kilo calories/day
89534428|NCT01781689|No Intervention|Health|with no motor function impairment
89534429|NCT01678638|Active Comparator|Early inguinal hernia (IH) repair|IH repair before NICU discharge
89534430|NCT01678638|Active Comparator|Late inguinal hernia (IH) repair|IH repair as outpatient at approximately 55-60 weeks post-menstrual age
89534431|NCT01643564||Group 1|Heart Transplant Recipients with Unexplained Graft Dysfunction
89359766|NCT03769883|Experimental|Moderate Exercise Dose (MED)|Two aerobic training sessions per week of 45-60 min duration and one session per week with combined aerobic (30-35 min) and resistance (30 min) training and a dietary intervention (as above)
89359767|NCT03769883|Experimental|High Exercise Dose (HED)|Four aerobic training sessions per week of 45-60 min duration and two sessions per week with combined aerobic (30-35 min) and resistance (30 min) training and a dietary intervention (as above)
89359768|NCT03769883|No Intervention|Control|No intervention
89359769|NCT04223531|Other|Saline|Each participant will receive a saline infusion of normal saline 0.9%NaCl
89359770|NCT03769805|Experimental|Anlotinib Arm|Anlotinib hydrochloride capsule 12 mg, orally, once a day, oral before breakfast, according to the research program for 2 weeks, discontinued for 1 week. Patients with complete remission (CR), partial remission (PR) and stable disease (SD) continued to administer drugs until the disease progressed, intolerable toxicity or withdrawal was required. Patients with progression of illness (PD) discontinued their medication.
89359771|NCT03764267|Active Comparator|remifentanil|MAC group
89359772|NCT03764267|Active Comparator|general anesthetic|TIVA group
89359773|NCT03758885|Experimental|Nolasiban 900 mg|Nolasiban dispersible tablets for single oral administration
89359774|NCT03758885|Placebo Comparator|Placebo|Placebo dispersible tablets for single oral administration
89359775|NCT01321931|Experimental|NRT 60|A 6 mg dose of an experimental Nicotine Replacement Therapy (NRT) given every hour for 11 hours, with a 36-hour washout between visits
89359776|NCT01321931|Active Comparator|NFG 60|A 4 mg dose of a marketed Nicotine Fruit Gum (NFG) given every hour for 11 hours, with a 36-hour washout between visits
89359777|NCT01321931|Experimental|NRT 90|A 6 mg dose of NRT given every 90 minutes for 10.5 hours, with a 36-hour washout between visits
89359778|NCT01321931|Active Comparator|NFG 90|A 4 mg dose of NFG given every 90 minutes for 10.5 hours, with a 36-hour washout between visits
89359779|NCT01321931|Active Comparator|NIQ 60|A 4 mg dose of marketed nicotine mint lozenge (NIQ), given every hour for 11 hours, with a 36-hour washout between visits
89359780|NCT03764189|No Intervention|en masse retraction only|anterior segment retraction on miniscrews without microosteoperforation
89359781|NCT03764189|Active Comparator|en masse retraction with alveocentesis|anterior segment retraction on miniscrews with microosteoperforation
89359782|NCT02400203|Active Comparator|Control|54 grams of hulled sesame seeds, consumed in 2 daily 27 gram portions, and 30 grams of soybean oil per day
89359783|NCT02400203|Experimental|Hemp foods|60 grams of hulled hemp seeds,consumed in 2 daily 30 gram portions, and 30 grams of hemp oil per day
89359784|NCT03764111||large mobile ultrasound system|the ultrasound transducer is based on piezoelectric technology.
89359785|NCT03764111||handheld ultrasound machine|The handheld device utilizes Capacitive micro-machined ultrasound transducers (CMUTs) instead of piezoelectric technology
89359786|NCT04305197|Experimental|Lower Dose|
89359787|NCT04305197|Experimental|Medium Dose|
89534432|NCT01643564||Group 2|Normal Control
89534433|NCT01643564||Group 3|Class III-IV Heart Failure
89534434|NCT01643564||Group 4|Heart Transplant Recipients with Normal Graft Function
89534435|NCT01459484|Experimental|Mifamurtide arm|Chemotherapy for patients who over express ABCB1/P-glycoprotein (methotrexate, cisplatinum, doxorubicine, ifosfamide + mifamurtide)
89534436|NCT01459484|Other|3 drugs arm|High grade osteosarcoma treatment for patients who do not over express ABCB1/P-glycoprotein
89534437|NCT01459068|No Intervention|Waitlist-Control|Eligible study subjects were assigned to the waitlist-control arm on a rolling admissions basis. The waitlist-controls waited for a period equivalent to the duration of the intervention and then were re-interviewed.
88831761|NCT02020304|Active Comparator|refrigerated temperature|refrigerated temperature combined spinal epidural dose (~<43 degrees F)
88831762|NCT04349384||Colon adenocarcinoma|Patient who underwent surgical resection for colon adenocarcinoma
88831763|NCT04349384||Rectal adenocarcinoma|Patient who underwent surgical resection for rectal adenocarcinoma
88831764|NCT01980589|Experimental|Carfilzomib, Cyclophosphamide and Dexamethasone (CCd)|Participants received carfilzomib, cyclophosphamide and dexamethasone for up to eight 28-day cycles, or until progressive disease (PD), unacceptable toxicity, withdrawal of consent, or death.
88831765|NCT02021942|Experimental|SOM230 LAR|SOM230 LAR in a dosage of 60 mg i.m. once every 4 weeks
88831766|NCT01981057||Numeta|parenteral receipt prescribed with Numeta
88831767|NCT01981057||Individual|individually prescribed parenteral receipt
88831768|NCT02022020||Group 1|
88831769|NCT02345642|Active Comparator|10 Healthy Patients without THA|The 10 test subjects of this study arm will be healthy volunteers of various ages that are willing to have the efficacy of pneumatic compression tested on them.
88831770|NCT02345642|Experimental|10 Patients with THA on Post-Op Day 2|The 10 test subjects of this study arm will be primary THR patients of Dr. Westrich that have undergone uncomplicated THR surgery in which they are allowed to be full weight bearing by or before post-op day 2.
88831771|NCT02345720|Experimental|etafilcon - PVP (multi-focal)|The investigational soft contact lenses will be worn in a daily wear modality for 30 days over the course of the study.
88831772|NCT01981759|Placebo Comparator|Placebo|Participants receive a weekly dose of placebo by mouth one hour before Cognitive Behavioral Therapy (CBT) sessions from week 1-12 (12 visits).
88831773|NCT01981759|Experimental|D-Cycloserine|Participants will receive a weekly dose of placebo by mouth one hour before Cognitive Behavioral Therapy (CBT) sessions from weeks 1-2 (2 visits), then a weekly 50 mg dose of D-Cycloserine by mouth one hour before CBT sessions from weeks 3-12 (10 visits).
88831774|NCT01980524|Experimental|acipimox+|250 mg at 0 and 180 minutes (one day)
88831775|NCT01980524|Placebo Comparator|Placebo|1 Tablet at 0 and 180 minutes (one day)
88831776|NCT01982539|Experimental|Zipsor® (Liquid filled capsules)|25mg/every 6hrs/up to 4 days treatment
88831777|NCT01980914|Experimental|Type 2 diabetes group|Patients over age 70 who have had type 2 diabetes for at least 5 years and are being treated with insulin. All patients will have a BMI of between 20 and 35 Kg/M2, and an A1C between 7 and 8.5 %.
88831778|NCT01982695|Active Comparator|Lisinopril|
88831779|NCT01982695|Active Comparator|Losartan|
88831780|NCT02347124|Active Comparator|Usual Care Control|Standard tobacco quitline counseling program and materials + attention-matched text messaging.
88831781|NCT02347124|Experimental|Enhanced Intervention|Standard tobacco quitline counseling program and materials + multi-modal oral health promotion program .
88831782|NCT01983787||Pharmacokinetics Piperacillin|Patients with cystic fibrosis , treated with Piperacillin/Tazobactam, given as continuous infusion for a period of two weeks.
88831783|NCT01981772|Experimental|buffered lidocaine|administration of 4% buffered lidocaine with 1:100,000 epinephrine
88831784|NCT01981772|Active Comparator|nonbuffered lidocaine|administration of 4% lidocaine with 1:100,000 epinephrine
88831785|NCT01982240|Active Comparator|Plecanatide 3.0 mg|Plecanatide tablets 3.0 mg QD for 12 weeks
88831786|NCT01982240|Active Comparator|Plecanatide 6.0 mg|Plecanatide tablets 6.0 mg QD for 12 weeks
88831787|NCT01982240|Placebo Comparator|Placebo|Matching placebo tablets QD for 12 weeks
88831788|NCT01982240|Other|Bisacodyl|Rescue medication
88831789|NCT02029495|Experimental|210 mg brodalumab|Administered via subcutaneous injections
88831790|NCT02029495|Experimental|140 mg brodalumab|Administered via subcutaneous injection
88831791|NCT02029495|Placebo Comparator|Placebo|Administered via subcutaneous injection until week 24.
88831792|NCT02348606|Active Comparator|37.5 mg of JZP-110|Once Daily Dosing
88831793|NCT02348606|Active Comparator|75 mg of JZP-110|Once Daily Dosing
88831794|NCT02348606|Active Comparator|150 mg of JZP-110|Once Daily Dosing
88831795|NCT02348606|Active Comparator|300 mg of JZP-110|Once Daily Dosing
88831796|NCT02348606|Active Comparator|Placebo|Once Daily Dosing
88831797|NCT02348684||Radiation therapy groups|Risk groups based on dosimetric radiation parameters.
88831798|NCT02312713|Active Comparator|Standard Physical Therapy|"Participants assigned to the PT arm will receive 3-8 individual visits with a physical therapist. The content of these visits will be semi-standardized, meaning that they will include some common core components (e.g., evaluation, prescription of home exercise program), but the therapists will have flexibility in terms of how many visits are appropriate and the details of the visit content."
88831799|NCT02312713|Experimental|Internet Based Exercise Training|Participants assigned to the internet-based exercise training arm will be given access to a program that aims to tailor exercises based on individuals' functional levels. The program assigns specific exercises, progresses these exercises as appropriate over time, and shows individual video clips to demonstrate appropriate performance of exercises.
88831800|NCT02312713|No Intervention|Wait list control|no intervention
88831801|NCT02033083|Active Comparator|Laminaria|Patients in this arm will receive laminaria cervical dilators one day before D&E procedure.
88831802|NCT02033083|Active Comparator|Dilapan-S|Patients in this arm will receive Dilapan-S cervical dilators one day before D&E procedure.
88831803|NCT01985425|Experimental|Active Colchicine|On the day of surgery, the intervention group will receive 2 doses of colchicine 0.6 mg orally. The first dose will be administered within 4 hours before surgery. The second dose will be given between 6:00PM and 11:59PM after surgery. All patients will receive colchicine 0.6 mg or placebo twice daily orally for 10 days.
89359788|NCT04305197|Experimental|Higher Dose|
89359789|NCT04305197|Placebo Comparator|Placebo|
89359790|NCT03763409|Experimental|losartan|50 mg single-dose oral losartan
89359791|NCT03763409|Placebo Comparator|placebo|microcellulose placebo in identical capsule
89359792|NCT01322477||Hepatocellular Carcinoma|Patients with advanced HCC
89359793|NCT03763097||participants|Patients who are scheduled for single-incision needleless (Contasure-needleless®) mini-sling for their stress urinary incontinence. They will be assessed by Pelvic floor ultrasound
89359794|NCT01321853|Experimental|Machine and NCC|Medications dispensed to subject via MD2 machine and nurse care coordination used to coordinate care among providers and fill machine at least every 2 weeks.
88831804|NCT01985425|Placebo Comparator|Placebo Colchicine|On the day of surgery, the intervention group will receive 2 doses of colchicine placebo 0.6 mg orally. The first dose will be administered within 4 hours before surgery. The second dose will be given between 6:00PM and 11:59PM after surgery. All patients will receive colchicine 0.6 mg or placebo twice daily orally for 10 days.
89359795|NCT01321853|Experimental|Medplanner and NCC|Medications loaded in medplanner by nurse care coordinator who coordinates care among providers and visits subject at least every 2 weeks
89359796|NCT01321853|No Intervention|Usual Care Group|Admitted post home health care with no intervention.
89359797|NCT03763955||PD patients|PD patients at 1-5 H&Y stage undergoes 4week Multidisciplinary Intensive Rehabilitation Treatment
89359798|NCT03763019|Active Comparator|Respiratory rehabilitation|"Conventional rehabilitation program aiming to normalize movement patterns and minimize spasticity. Including static and dynamic control of position, balance skills, weight shift, and activities of daily living. 45 minutes, once daily.~Respiratory exercises 30 minutes, once daily, (incentive spirometric trainer, forced expiration, percussion, postural drainage etc.)"
89359799|NCT03763019|Placebo Comparator|Conventional rehabilitation|Conventional rehabilitation program aiming to normalize movement patterns and minimize spasticity. Including static and dynamic control of position, balance skills, weight shift, and activities of daily living. 45 minutes, once daily.
89359800|NCT03762863|Experimental|Appropriate application of a CAT tourniquet|All study subjects attended an American College of Surgeons Stop the Bleed Basic course with live training by approved instructors. 6 months after participation in the Stop the Bleed class volunteers study subjects are randomly solicited to return for a refresher session. During this refresher session the volunteer study subjects are observed to determine if they have retained tourniquet application skills and to what degree they have retained them. A 10 point check list will be used to evaluated tourniquet application skill retention.
89359801|NCT03758807|Sham Comparator|Passive treatment|Passive treatment will consist of Manual Therapy with biomechanical explanation of the technique.
89359802|NCT03758807|Experimental|Active Treatment|Active treatment will consist of Manual Therapy with a neuroplasticity explanation of the technique.
89359803|NCT03762785|Active Comparator|nebulized dexmedetomidine 2ug/kg|inhalation of dexmedetomidine in the dose of 2ug/kg by nebulization
89359804|NCT03762785|Active Comparator|nebulized dexmedetomidine 3ug/kg|inhalation of dexmedetomidine in the dose of 3ug/kg by nebulization
89359805|NCT03763487|Experimental|Patients|Ultrasound examination: scaled to spleen size (spleen volumetry) Methodology of laboratory tests: venous blood sampling
89359806|NCT03763487|No Intervention|healthy blood donors|No intervention in this group.
89359807|NCT03756701|Experimental|Group 1|Initial participants in the 10 mind body sessions
89359808|NCT03756701|Active Comparator|Group 2|10 week no intervention groups - receives the mind body interventions after group 1 has completed.
89359809|NCT03762629|Experimental|Obese intervention group|Obese children were received exercise and diet intervention for 6 weeks.
89359810|NCT03762629|No Intervention|Normal weight control group|Normal weight children were recruited as a control group without any intervention.
89359811|NCT03762551|Experimental|vitiligo|assess the level of JAK1 in vitiligo patients before and after treatment with NB-UVB
89359812|NCT03762551|Active Comparator|psoriasis|assess the level of JAK1 in psoriasis patients before and after treatment with NB-UVB
89359813|NCT03762551|Other|controls|assess the level of JAK1 in controls
89359814|NCT04664855|Experimental|Experimental Yoga Group|35 freshman students enrolled in a health and wellness/physical education class at a rural Montana high school
89359815|NCT04664855|No Intervention|Control Group (No Yoga Intervention)|20 freshman students enrolled in a health and wellness/physical education class at a rural Montana high school
89359816|NCT03758729|Experimental|Nivolumab|Nivolumab 3mg/kg + NS 100mL MIV over 1hr every 2 weeks
89359817|NCT03756623|Experimental|Drug: Metformin powder|0.5g of Metformin powder administered three times a day orally before meal
89359818|NCT03756623|Experimental|Drug: Probiotics powder|0.5g of Probiotics powder administered three times a day orally before meal
89359819|NCT03756623|Placebo Comparator|Drug: Placebo powder|0.5g of Placebo powder administered three times a day orally before meal
89359820|NCT04664153|Experimental|atopic dermatitis - PF-07038124 ointment|
89359821|NCT04664153|Placebo Comparator|atopic dermatitis - vehicle ointment|
89359822|NCT04664153|Experimental|plaque psoriasis - PF-07038124 ointment|
89359823|NCT04664153|Experimental|plaque psoriasis - vehicle ointment|
89359824|NCT03756467|No Intervention|Arm 1|1) the Girl Empower life skills curriculum, facilitated by local mentors; 2) caregiver discussion group, facilitated by IRC staff
89359825|NCT03756467|Experimental|Arm 2|1) the Girl Empower life skills curriculum, facilitated by local mentors; 2) caregiver discussion group, facilitated by IRC staff; and 3) savings account start-up
89359826|NCT03756467|Active Comparator|Arm 3|1) the Girl Empower life skills curriculum, facilitated by local mentors; 2) caregiver discussion group, facilitated by IRC staff; and 3) savings account start-up.
89000992|NCT04635124|Active Comparator|1: Dog visit with a dog, no additional activity (D)|The nursing home resident receives 12 10-minute visits in their own room. The visitor is accompanied with a dog, and the resident can touch the dog. Apart from the visitor, an observer is present.
89000993|NCT04635124|Experimental|2: Dog visit with an additional activity (DA)|"The nursing home resident receives 12 10-minute visits in their own room. The visitor is accompanied with a dog, and the resident can touch the dog. During the visit, the visitor offers the resident to participate in an activity that involves interacting with the dog.~Apart from the visitor, an observer is present."
89000994|NCT04635124|Active Comparator|3: Visit without dog, with an additional activity (A)|"The nursing home resident receives 12 10-minute visits in their own room. During the visit, the visitor offers the resident to participate in an activity.~Apart from the visitor, an observer is present, but no dog is present.."
89359827|NCT04663295|Experimental|Subjects with Type 1 diabetes wearing HCL pump system|Subjects 14-75 years of age who have been diagnosed with Type 1 diabetes.
89359828|NCT03758495||Patients with Schizophrenia|Individuals who have been previously diagnosed with schizophrenia and meet our research criteria for symptoms indicative of schizophrenia within their lifetime.
89359829|NCT03758495||Patients with Major Depressive Disorder|Individuals who have been previously diagnosed with major depressive disorder and meet our research criteria for symptoms indicative of major depressive disorder within their lifetime.
89359830|NCT03758495||Healthy Controls|Individuals who have not met criteria for a psychiatric disorder within their lifetime according to our research criteria for symptoms indicative of a psychiatric disorder.
89359831|NCT03762239|Active Comparator|Purified air|Purifying the air with a Pure Airbox device (Zonair 3D). Use of air purifier (Pure Airbox, Zonair 3D) in the classroom 30 minutes before the participants enter the room and during the 2 hours of the experiment.
89000995|NCT00201513|Experimental|TrA exercise|Isolated Transversus abdominis (TrA) exercises (low load)
89000996|NCT00201513|Experimental|sling exercise|Sling exercises (high load)
89000997|NCT00201513|Active Comparator|group exercise|Non-specific group exercises
89000998|NCT00560638|Experimental|Loteprednol Etabonate TID|loteprednol etabonate ophthalmic suspension, 0.5%, TID
89000999|NCT00560638|Experimental|Loteprednol Etabonate QID|loteprednol etabonate ophthalmic suspension, 0.5%, QID
89001000|NCT00560638|Placebo Comparator|Vehicle|vehicle of loteprednol etabonate
89001001|NCT04634656|Active Comparator|Group L|Patients will receive lidocaine in a loading dose of 1 mg/ kg diluted in 10 ml of normal saline that will be infused over 5 minutes after induction of anesthesia then followed by a continuous infusion at 1.5 mg/ kg/ h diluted in normal saline to a volume of 50 ml until the end of surgery.
89001002|NCT04634656|Placebo Comparator|Group C|Patients will receive normal saline after induction of anesthesia with the same volume and rate changes as lidocaine group until the end of surgery.
89001003|NCT04634500|Experimental|Study group|DWP16001 A mg, Dapagliflozin placebo
89001004|NCT04634500|Active Comparator|Control group|DWP16001 A mg placebo, Dapagliflozin
89001005|NCT04634422|Experimental|Plasma Exchange and convalescent Plasma|2 plasma exchange procedures within 24 hours and in addition 2 bags of CCP (equalling 600 ml CCP) infused at the end of the 2nd procedure.
89001006|NCT04634422|No Intervention|Control without intervention|Standard care without the use of PLEX or convalescent plasma.
89001007|NCT04633954|Experimental|Brimonidine Group|Patients in this arm receive an extra drop of brimonidine in addition to routine eye drops prior to femtosecond laser assisted cataract surgery (FLACS)
89001008|NCT04633954|No Intervention|Control Group|Patients in this arm only receive routine eye drops prior to femtosecond laser assisted cataract surgery (FLACS)
89001009|NCT04633915||Dialysis|Patients with CKD stage 5, treated with maintenance hemodialysis
89001010|NCT04633915||Healthy|Volunteers who are not dialysis-dependent
89001011|NCT04634032||Hernia|Patients planned to undergo routine indirect inguinal hernia repair procedure
89359832|NCT03762239|Sham Comparator|Normal air|Using a sham air purifier (same device without filters). Use of the same air purifier but without filters, so that it only recirculates the air without purifying it. Used for the same time period than the other arm.
89359833|NCT03762083|Experimental|pHyph, Gedea Pessary|Clinical performance, tolerability, safety and user experience of Gedea Pessary, a slow-release vaginal tablet for the treatment of BV.
89359834|NCT03762005|Experimental|CRT guided resuscitation|Fluid resuscitation will be aimed at normalizing capillary refill time (CRT) during the intervention period. Fluid challenges will be administered at a rate of 500 ml of crystalloids over 30 minutes, with reassessment of CRT until achieving normal values, or the patient becomes fluid unresponsive, or a safety issue develops.
89359835|NCT03762005|Active Comparator|Lactate guided resuscitation|Fluid resuscitation will be aimed at normalizing or decreasing lactate levels by more than 20% every 2 hours during the intervention during the intervention period. Fluid challenges will be administered at a rate of 500 ml of crystalloids over 30 minutes, with reassessment of lactate every 2 hours until reaching target, or the patient becomes fluid unresponsive, or a safety issue develops.
89359836|NCT03761927|Active Comparator|Hearing Aid without NR enabled.|Hearing Aid without Noise Reduction (NR) enabled serves as reference condition.
89359837|NCT03761927|Experimental|Hearing Aid with NR(1)|Hearing Aid with Noise Reduction I (NR) enabled.
89359838|NCT03761927|Experimental|Hearing Aid with NR(2)|Hearing Aid with Noise Reduction II (NR) enabled.
89001012|NCT04634032||Control|Patients planned to undergo routine circumcision procedure
89001013|NCT00560872|Other|1|conventional ablation with manual catheter navigation
89001014|NCT00560872|Active Comparator|2|ablation with remote magnetic catheter navigation
89001015|NCT04634188||Meningioma Group|"This group is based on the type of histopathology and MRI images that lead to a meningioma type brain tumor.~After grouping, blood serum samples was collected to check the value of CRP, procalcitonin and NLR. The data were entered in a table and then compared with values from other types of brain tumors."
89359839|NCT04228445|Experimental|HIGH DOSE|48 subjects randomly treated with 5 mL of drug
89359840|NCT04228445|Experimental|LOW DOSE|48 subjects randomly treated with 2.5 mL of drug
89359841|NCT04228445|Placebo Comparator|Saline|96 subjects treated with 5 ml of saline than crossover to treatment arm
89359842|NCT03761771||colonoscopy withdrawal with the ADS monitoring|The ADS automatically initiated once the ileocecal valve was pictured by the colonoscopist or the colonoscopist recorded any image of colon during the insertion. When colonoscopists withdrew the colonoscopies and inspect the colons, the video streaming of colonoscopies was real-time switched to the ADS, which made it feasible to identify and classify lesions in real time.
89359843|NCT05460923|Experimental|Swiss Ball Exercises|Swiss ball exercises along with baseline treatment trunk twists,
89359844|NCT05460923|Experimental|Proprioceptive Neuromuscular Facilitation|pelvic neuromuscular facilitation techniques including various PNF movement patterns along with the baseline treatment
89359845|NCT03756233|Active Comparator|Remifentanil gradually withdrawal group|20 minutes before the end of the operation, remifentanil was gradually decreased by 25% every 5 minutes.
89359846|NCT03756233|Active Comparator|Remifentanil immediately stop group|The control group stopped remifentanil 10 minutes before the end of the operation.
89359847|NCT04641299|Placebo Comparator|Placebo|Placebo solution for subcutaneous injection.
89359848|NCT04641299|Experimental|AZD8233 high dose|AZD8233 high dose for subcutaneous injection.
89359849|NCT04641299|Experimental|AZD8233 medium dose|AZD8233 medium dose for subcutaneous injection.
89359850|NCT04641299|Experimental|AZD8233 low dose|AZD8233 low does for subcutaneous injection.
89359851|NCT05280899|Active Comparator|Partial Weight-bearing (PWB)|Patients will PWB for 3 weeks following surgery, followed by a gradual return to FWB.
89359852|NCT05280899|Experimental|Weight-bearing As Tolerated (WBAT)|Patients will WBAT immediately following surgery.
89359853|NCT03703817||tofacitinib citrate users|patients who have been using tofacitinib citrate for 6 months or more and less than 2 year in RA patients
89359854|NCT03703817||adalimumab users|patients who have been using adalimumab for 6 months or more and less than 2 year in RA patients
89359855|NCT03761693|Experimental|Severe/classical MCADD|"Severe MCADD will be defined by ACADM mutations associated with clinical ascertainment or residual MCAD enzyme activity < 10 %, as defined previously (Touw et al., 2012).~Interventions include fasting challenges at two and six months of age."
89359856|NCT03761693|Experimental|Mild MCADD|"Mild MCADD will be defined by the remaining ACADM genotype variants and residual MCAD enzyme activity ≥ 10%.~Interventions include fasting challenges at two and six months of age."
89359857|NCT03758339|Experimental|Tucatinib|
89359858|NCT03698591|Experimental|Transcranial magnetic stimulation (TMS), then Sham TMS.|Experimenters will employ a continuous theta-burst stimulation (cTBS) sequence using a figure-8 coil positioned tangentially to the scalp over the target coordinates. Experimenters have defined the target coordinates for stimulation (Montreal Neuroscience Institute coordinates -53, -53, 23) based on peak objective distancing activation in the left temporal parietal junction (TPJ) in previous fMRI studies using the same task. Thirty minutes after stimulation, experimenters will employ a sham version of the TMS intervention where subjects will receive a small electrical stimulation on the scalp via two small electrodes in conjunction with a TMS coil activation. The TMS coil will be reoriented to stimulate into the air away from the scalp, simulating traditional TMS, without inducing any current to the subject.
89359859|NCT03698591|Sham Comparator|Sham TMS, then Transcranial magnetic stimulation (TMS)|Experimenters will employ a sham version of the TMS intervention where subjects will receive a small electrical stimulation on the scalp via two small electrodes in conjunction with a TMS coil activation. The TMS coil will be reoriented to stimulate into the air away from the scalp, simulating traditional TMS, without inducing any current to the subject. Experimenters have defined the target coordinates for the stimulation (Montreal Neuroscience Institute coordinates -53, -53, 23) based on peak objective distancing activation in the left temporal parietal junction (TPJ) in previous fMRI studies using the same task. Thirty minutes post sham stimulation, experimenters will employ a continuous theta-burst stimulation (cTBS) sequence using a figure-8 coil positioned tangentially to the scalp over the target coordinates.
89359860|NCT03755921|Experimental|Brief and intensive therapy|exercises for swallowing (strength and mobility of oral and pharyngeal muscles) controlling the number of series according to each participant, daily
89359861|NCT03755921|Active Comparator|Therapy Weekly|exercises for swallowing (strength and mobility of oral and pharyngeal muscles) controlling the number of series according to each participant, weekly
89359862|NCT03761303|Active Comparator|active rTMS|Patients in the intervetion group (active rTMS stimulation) receive active 10 Hz rTMS stimulation over the left dorsolateral prefrontal cortex (DLPFC) over a period of 20 days, seven days a week (20 sessions).
89359863|NCT03761303|Sham Comparator|sham rTMS|Patients in the control group receive sham rTMS stimulation over the left dorsolateral prefrontal cortex (DLPFC) over a period of 20 days, seven days a week (20 sessions).
89359864|NCT05089799||Patients|"Older adults 60 years old or older They are referred to the day care hospital for memory problems or frailty and may present with various cognitive, behavioural, mental and physical disorders.~Persons in this group are diverse in socio-cultural levels. The investigators expect to include 100 patients (N = 100). Each patient will test 1 out of the 5 use cases, so 20 patients will test the same use case (n = 20)."
89359865|NCT05089799||Informal carers or family caregivers|"This group includes persons who accompany patients during the hospital visit, such as family members (spouses or children) and friends.~They provide support to the patient with various frequency and intensity (occasional / regular / continuous).~Persons in this group are diverse in age and socio-cultural levels. They may also suffer from physical and/or psychological disorders.~The investigators expect to include 100 informal or family caregivers (N = 100). Each one will test 1 out of the 5 use cases, so 20 informal or family caregivers will test the same use case (n= 20)."
89359866|NCT05089799||Professionals|"All categories of professionals working in the day care hospital. Persons in this group belong to different professional categories (administrative, health, technical). They have different levels of proximity with the public and have various positions in the hospital.~The investigators expect to include 50 professionals."
89359867|NCT04606199|Experimental|Mindfulness-based intervention|Participants will be randomly assigned to an app-based intervention that includes brief (<5 min) audio-guided mindfulness and compassion-based practices.
89359868|NCT04606199|No Intervention|No intervention|Participants will continue their normal activities and not practice any form of mindfulness mediation at the time of app-notification.
89359869|NCT05085665|Experimental|Ivermectin|All eligible participants received a single dose (150 ug/kg) ivermectin by mouth
89359870|NCT05017493|Experimental|Treatment arm|Patients in the Treatment arm received Xagrotin in combination to the standard of care for Covid19.
89359871|NCT05017493|No Intervention|Control arm|Patients in the Control arm received the standard of care for Covid19.
89359872|NCT04599803|Experimental|Arm 1|Participants told they may have Obstructive Sleep Apnea (OSA) and provided a home sleep test (HST)
89359873|NCT01322087|Experimental|Nutritional intervention|
89359874|NCT05002985|Experimental|Walking Group|Subjects will participate in a walking group led by a community organizer as a means to get to a local farmer's market.
89359875|NCT03758183||two-stage algorithm|Prolotherapy injections (PrT) combined with rehabilitation protocol (RP) prior to total knee arthroplasty (TKA)
89359876|NCT03758183||one-stage algorithm|total knee arthroplasty (TKA)
89359877|NCT03760757|Experimental|PCSO-524® (no krill oil)|Four total capsules per day (2 in the morning; 2 at night) for 29 days. Amounts per day equal to 800 mg olive oil, 400 mg lipid extract (~58 mg EPA and 44 mg DHA) and 1.8 mg vitamin E (d-alpha-tocopherol).
88831805|NCT02348918|Active Comparator|Luminate 1.0mg group|Stage 1- Luminate 1.0 mg intravitreal injection administered at baseline (Day 0), 4 weeks and 8 weeks with prn Luminate injection at week 20 for a total of at least 3 and no more than 4 Luminate injections. Sham injections will be performed at weeks 12 and 16 and may also be performed at week 20 if prn Luminate is not required; sham laser treatment will be administered at baseline and at 16 weeks.
88831806|NCT02348918|Active Comparator|Luminate 2.0mg group|Stage 1 -Luminate 2.0 mg intravitreal injection administered at baseline (Day 0), 4 weeks and 8 weeks with prn Luminate injection at week 20 for a total of at least 3 and no more than 4 Luminate injections. Sham injections will be performed at weeks 12 and 16 and may also be performed at week 20 if prn Luminate is not required; sham laser treatment will be administered at baseline and at 16 weeks.
89359878|NCT03760757|Experimental|ESPO-572® (75% PCSO-524®, 25% krill oil)|Four total capsules per day (2 in the morning; 2 at night) for 29 days. ESPO-572®, a 75/25% PCSO-24®/Krill oil blend. Each capsule of the ESPO-572® contains green lipped mussel oil, krill oil, olive oil and vitamin E.
89359879|NCT03755609|Active Comparator|patients with oxycodone|
88831807|NCT02348918|Active Comparator|Luminate 3.0mg group|Stage 1- Luminate 3.0 mg intravitreal injection administered at baseline (Day 0), 4 weeks and 8 weeks with prn Luminate injection at week20 for a total of at least 3 and no more than 4 Luminate injections. Sham injections will be performed at weeks 12 and 16 and may also be performed at week 20 if prn Luminate is not required; sham laser treatment will be administered at baseline and at 16 weeks.
88831808|NCT02348918|Active Comparator|Avastin® group|Stage 1- Avastin 1.25 mg intravitreal injection administered at baseline (Day 0), 4 weeks and 8 weeks with prn Avastin injection at weeks 12, 16, or 20 for a total of at least 3 and up to 6 Avastin injections. Sham injections may be performed at weeks 12, 16, and 20 if prn Avastin is not required.
89359880|NCT03755609|Sham Comparator|patients with fentanyl|
89359881|NCT04580303|Active Comparator|Uniform 0.1-milliliters (mL) 1-Aliquot Grid Injection Technique (Buttock)|Dose per participant per treatment visit = up to 1.68 milligrams (mg) of CCH (0.84 mg in each treatment area)
89359882|NCT04580303|Active Comparator|Uniform 0.3-mL 2-Aliquot Grid Injection Technique (Buttock)|Dose per participant per treatment visit = up to 1.68 mg of CCH (0.84 mg in each treatment area)
89359883|NCT04580303|Active Comparator|Uniform 0.1-mL 1-Aliquot Grid Injection Technique (Thigh)|Dose per participant per treatment visit = up to 1.68 mg of CCH (0.84 mg in each treatment area)
89359884|NCT04580303|Active Comparator|Uniform 0.3-mL 2-Aliquot Grid Injection Technique (Thigh)|Dose per participant per treatment visit = up to 1.68 mg of CCH (0.84 mg in each treatment area)
89359885|NCT04577183|Experimental|RD1 System|The RD1 is created by drawing the patient's blood with the use of citrate anticoagulant. The anticoagulant allows the clot to form later in a controlled fashion-citrate is a widely used anticoagulant. The blood is then placed in the clotting tray (within few minutes) and the coagulation is facilitated by adding calcium and kaolin (insoluble aluminum silicate). The forming clot assumes the shape of the tray containing it, and can then be applied to the wound, and then covered with primary and secondary dressings.
89359886|NCT03760445|Experimental|Part 1 - first line (1L) AML|1L acute myeloid leukemia (AML) subjects receiving HDM201 in various doses/schedules in combination with cytarabine/anthracyclines
89359887|NCT03760445|Experimental|Part 1 - relapsed/refractory (R/R) AML|R/R AML subjects receiving HDM201 in various doses/schedules in combination with cytarabine
89359888|NCT03760445|Experimental|Part 2 - Expansion Cohort 1|1L de novo AML subjects without documented FLT3 mutation receiving HDM201 at the recommended dose of expansion (RDE) in combination with cytarabine/anthracyclines
89359889|NCT03760445|Experimental|Part 2 - Expansion Cohort 2|1L de novo AML subjects with documented FLT3 mutation status receiving HDM201 at RDE in combination with cytarabine/anthracyclines and midostaurin
89359890|NCT03760445|Experimental|Part 2 - Expansion Cohort 3|1L secondary AML subjects receiving HDM201 at RDE in combination with liposomal cytarabine/daunorubicin
89359891|NCT03760445|Experimental|Part 2 - Expansion Cohort 4|R/R AML subjects receiving HDM201 at RDE in combination with cytarabine
89359892|NCT03760445|Experimental|Part 3 - DDI Cohort 1|R/R AML subjects receiving HDM201 at adjusted recommended Phase 3 dose (RP3D) determined in Part 2 in combination with cytarabine and posaconazole added in Cycle 1
89359893|NCT03760445|Experimental|Part 3 - DDI Cohort 2|R/R AML subjects receiving HDM201 at RP3D in combination with cytarabine and midazolam
89359894|NCT05460377|Active Comparator|IMBCAMS Sabin IPV full dose at 14 weeks and 9 months|Participants will receive two full doses of Sabin IPV intramuscularly at 14 weeks and 9 months produced by Institute of Medical Biology Chinese Academy of Medical Sciences, Kunming (IMBCAMS).
89359895|NCT05460377|Active Comparator|IMBCAMS Sabin IPV fractional dose at 14 weeks and 9 months|Participants will receive two fractional (1/5) doses of Sabin IPV intradermally at 14 weeks and 9 months produced by Institute of Medical Biology Chinese Academy of Medical Sciences, Kunming (IMBCAMS).
89359896|NCT05460377|Active Comparator|BIBP Sabin IPV full dose at 14 weeks and 9 months|Participants will receive two full doses of Sabin IPV intramuscularly at 14 weeks and 9 months produced by Beijing Bio Institute Biological Products (BIBP).
89359897|NCT05460377|Active Comparator|BIBP Sabin IPV fractional dose at 14 weeks and 9 months|Participants will receive two fractional (1/5) doses of Sabin IPV intradermally at 14 weeks and 9 months produced by Beijing Bio Institute Biological Products (BIBP).
89359898|NCT05693012||Cancer Arm|participants with newly diagnosed multiple myeloma, from whom blood samples will be collected.
89359899|NCT05693012||Benign Arm|Participants with newly diagnosed benign hematologic disorders, from whom blood samples will be collected.
89359900|NCT05693012||Healthy arm|Participants without known presence of malignancies or certain benign diseases, from whom blood samples will be collected.
89359901|NCT03626558|Experimental|Distroke patients|"For every patient include in the study, ultrasound measures at the admission/discharge of hospitalization will be realized.~All the patients will see each other suggested participating in a new collection of remote ultrasound measures of the stroke (around 2-3 months). These measures will be made during the usual consultation proposed by the department of neurology. This medical consultation is a part of the follow-up post--stroke recommended by the High Authority of Health. These measures will allow us to highlight the kinetics of recovery of the diaphragmatic function except any intervention of reeducation of muscles inspirers."
89359902|NCT04345562|Active Comparator|Back and forth pattern|Abdominal skin prep using ChloraPrep 2 x 26 mL single use applicators. The first applicator will be applied to the skin prep over the suspected skin incision site for 30 sec - the first applicator will then be used in a back and forth pattern work up towards the upper edge of the surgical field. The first applicator will then be discarded. The second applicator will then again start at the expected site of the incision and again working inferiority until the lower edge of the surgical field is reached.
88831809|NCT02348918|Active Comparator|Avastin then Luminate 1.0 mg IVT + sham injection|Stage 2 - Week 0 (Baseline): Avastin 1.25 mg IVT Weeks 1, 4 and 8: Luminate 1.0 mg IVT + sham injection Weeks 12 and 16: Sham IVT
88831810|NCT02348918|Active Comparator|Avastin then Luminate 0.5 mg IVT + sham injection|Stage 2- Week 0 (Baseline); Avastin 1.25 mg IVT Weeks 1, 4 and 8: Luminate 0.5 mg IVT + sham injection Weeks 12 and 16: Sham IVT
88831811|NCT02348918|Active Comparator|Sham then Luminate 1.0 mg + Avastin 1.25 mg IVT|Stage 2 : Week 0 (Baseline): Sham IVT Weeks 1, 4 and 8: Luminate 1.0 mg + Avastin 1.25 mg IVT Weeks 12 and 16: Sham IVT
88831812|NCT02348918|Active Comparator|Sham then Luminate 0.5 mg IVT + Avastin 1.25 mg IVT|Stage 2 : Week 0: Sham IVT Weeks 1, 4 and 8: Luminate 0.5 mg IVT + Avastin 1.25 mg IVT Weeks 12 and 16: Sham IVT
88831813|NCT02348918|Active Comparator|Avastin 1.25 mg + Sham IVT|Stage 2 : Week 0 (Baseline): Sham IVT Weeks 1, 4 and 8: Avastin 1.25 mg + Sham IVT Weeks 12 and 16: Avastin PRN
89359903|NCT04345562|Active Comparator|Circular pattern|Abdominal skin prep using ChloraPrep 2 x 26 mL single use applicators. The first applicator will be applied to the skin over the suspected skin incision site for 30 sec - the applicator will then be moved in a circular pattern moving outwards form the incision site until approximately half of thee surgical field is cleaned. The second applicator will then be used to complete the surgical prep until the entire surgical field is prepped in accordance with the package instructions.
89359904|NCT03626324|Experimental|C2P Study|Clinical Evaluation of Connected Catheter 2P Urinary Prosthesis for Management of Neurogenic Lower Urinary Tract Dysfunction
89359905|NCT04339634||Program of All-Inclusive Care for the Elderly|The Program of All-Inclusive Care for the Elderly (PACE) provides comprehensive medical and supportive services for community-dwelling persons, mostly older adults (>55 years), as an alternative to institutionalization. Medical services are provided by an interdisciplinary team of healthcare professionals, Tabula Rasa HealthCare being the pharmacy care provider for several PACE organizations.
89359906|NCT05692856|Experimental|Clenbuterol|Participants are randomized to daily ingestion of clenbuterol for a period of 8 weeks, with or without supervised resistance training.
89359907|NCT05692856|Placebo Comparator|Placebo|Participants are randomized to daily ingestion of placebo for a period of 8 weeks, with or without supervised resistance training.
89359908|NCT02827214||Surgical treatment|"Several surgical treatments exist to treat the fractures included in the study. The following section describes the different surgical treatment modalities in more detail~Approaches:~Open short segment surgical fixation (1 level above and below the fracture level) with or without posterior decompression~Open long segment posterior fixation (2 or more levels above, 2 or more levels below) with or without posterior decompression~Posterior short or long fixation with posterolateral corpectomy and reconstruction~Anterior alone instrumentation~Combined Anterior Posterior (AP) instrumentation~Percutaneous posterior fixation combined with anterior instrumentation~Percutaneous posterior fixation with or without vertebroplasty"
88831814|NCT01985581|Experimental|Placebo first then GXR|patient will continue to take stable dosage of usual stimulant therapy (Ritalin, Ritalin SR, Biphentin, Concerta, Vyvanse, Adderall or Dexedrine). In the first intervention period subject took placebo and second intervention period subject took GXR. GXR dose was optimized to between 1 and 4mg.
88831815|NCT01985581|Placebo Comparator|GXR first then Placebo|patient will continue to take stable dosage of usual stimulant(Ritalin, Ritalin SR, Biphentin, Concerta, Vyvanse, Adderall or Dexedrine). In the first intervention period subject took GXR and second intervention period subject took placebo. GXR dose was optimized to between 1 and 4mg.
88831816|NCT02024204|Active Comparator|Uncontrolled LRS|Patients who have uncontrolled lower respiratory symptoms (ACT < 20) at time of Visit 1 will be provided with study Advair (Fluticasone propionate 230mcg/salmeterol 21mcg) for a total of 3 months and receive medication adherence counseling Patients who have uncontrolled LRS at V1, but do not fit criteria for Step 3,4 or 5 asthma therapy according to NIH EPR III asthma guidelines will be deferred from the study until they have been seen by their physician and tried on ICS therapy.
88831817|NCT02024204|Other|Controlled LRS|Patients who had symptoms at monitoring visit but are now controlled at V1 will be asked to continue their current treatment (or no treatment) and will continue with the study. They will not be provided with any medications.
89359909|NCT02827214||Non-surgical treatment|"Non-surgical treatment is defined as bed rest followed by immobilization with:~Custom-molded or prefabricated total body contact thoracolumbosacral orthosis (TLSO)~Thermoplastic removable brace~Jewett hyperextension braces~Anterior hyperextension brace (ASH)~Taylor-Knight brace~Plaster of Paris (POP)"
89359910|NCT04574999|Experimental|0.005% Estriol group|0.005% Estriol (50 μg/g) gel for vaginal administration. Route: Vaginal by a cannula inserted deep inside the vagina Single dose: 1 g of gel Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: single application 2 times per week.
89359911|NCT04574999|Placebo Comparator|Placebo group|Placebo gel for vaginal administration. Route: Vaginal by a cannula inserted deep inside the vagina Single dose: 1 g of gel Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: single application 2 times per week.
89359912|NCT03758027|Experimental|CARESS|"The proposed intervention for this study has three stages: communicate alternatively (CA), release endorphins (RE), and self-soothe (SS) (CARESS)~CARESS is a combined skill of three activities. Each section is timed and has specific activities:~CA - will last eight (8) minutes, and will be expression of emotion with drawing with crayons.~RE - will last six (6) minutes, and will be a butterfly hug with a blanket. SS - will last six (6) minutes, and will be a pre-recorded music selection."
89359913|NCT03758027|Active Comparator|ISOMETRIC|This is a one time five-minute isometric circuit involving contracting muscles in different parts of the body. In order to be equivalent in time spent with the experimental intervention, this circuit will be performed three times with a five-minute break between each instance
89359914|NCT04565249|Experimental|PLN-74809 Dose Level1|Dose Level 1 of PLN-74809
89359915|NCT04565249|Experimental|PLN-74809 Dose Level 2|Dose Level 2 of PLN-74809
89359916|NCT04565249|Experimental|PLN74809 Dose Level 3|Dose Level 3 of PLN-74809
89359917|NCT03760367|Experimental|Blue Covarine Toothpaste|After a short video introduction to the bass technique, participants brush their teeth once with a silica toothpaste containing blue covarine (Pepsodent White Now Gold, 1 g) for 2 min, starting with the upper front teeth. Thereafter, participants rinse their mouth with of tap water.
89359918|NCT03760367|Active Comparator|Control Toothpaste|After a short video introduction to the bass technique, participants brush their teeth once with a silica toothpaste (Colgate Advanced Whitening, 1 g) for 2 min, starting with the upper front teeth. Thereafter, participants rinse their mouth with of tap water.
89359919|NCT04942925|Other|Precision1, then Infuse|Verofilcon A contact lenses worn first, with kalifilcon A contact lenses worn second, as randomized. Each study lens type will be worn bilaterally (in both eyes) for 8 -0/+3 days in a daily disposable modality.
89359920|NCT04942925|Other|Infuse, then Precision1|Kalifilcon A contact lenses worn first, with verofilcon A contact lenses worn second, as randomized. Each study lens type will be worn bilaterally (in both eyes) for 8 -0/+3 days in a daily disposable modality.
89359921|NCT01322243|Other|Dietary Intervention: Fasted State|Participants will be randomized to a dietary intervention of a fasted or fed group upon admission.
89359922|NCT01322243|Other|Dietary Intervention: Fed State|Participants will be randomized to a dietary intervention of a fasted or fed group upon admission
89359923|NCT03755531|Experimental|Carbetocin|One ml of Carbitocin (100 mcg), was given as a bolus intravenous injection after labor of the baby at once.
89359924|NCT03755531|Active Comparator|Oxytocin|One ml of Oxytocin (10 IU), was given as a bolus intravenous injection after labor of the baby at once.
89359925|NCT04917653||Atrial fibrillation|"Patients with recent-onset atrial fibrillation treated by cardioversion intervention.~Intervention:~Device: Heart rhythm monitoring with portable device. Biomarkers: Biomarker kinetics based on blood samples."
89359926|NCT03755453|Active Comparator|Audéo B-Direct fitted with fitting method A|Traditional standard fitting method which do not include adjustments from the participants.
88831818|NCT04349137|Experimental|In-phase 6Hz tACS|Transcranial alternating current stimulation (tACS) will be administered over the right PPC and the right DLPFC in a synchronized (in-phase) manner at a frequency of 6Hz
89359927|NCT03755453|Experimental|Audéo B-Direct fitted with fitting method B|Alternative fitting method which includes additional adjustments from the participants.
89359928|NCT04913363|Experimental|Walking|This contemplative activity will see users taken to a local green space area near their center and encouraged to walk around the space. It is anticipated walks will last around 15-20 minutes.
89359929|NCT04913363|Experimental|Citizen Science|This cerebral activity sees users engage with local green spaces, under the instruction of a citizen scientist, to learn about the intricacies of the space. This may include lichen counts (or similar) where the main outcome is learning based.
89359930|NCT04913363|Experimental|Planting|This physical activity will see users, lead by a local Master Gardener, engage with planting vegetables/fruit in raised beds. Not only will this allow users a chance to engage physically with nature, but it is anticipated that the grown produce will be used for center users.
88831819|NCT04349137|Active Comparator|Anti-phase 6Hz tACS|Transcranial alternating current stimulation (tACS) will be administered over the right PPC and the right DLPFC in a desynchronized (anti-phase, i.e. with a difference of 180deg) manner at a frequency of 6Hz
89359931|NCT04897061||Participants undergoing major pelvic organ prolapse surgery|
89359932|NCT03760133|Active Comparator|with Probiotics|Participants included in this group will be taken probiotics for 1 month after bowel preparation for colonoscopy.
88831820|NCT04349137|Sham Comparator|Sham tACS|A sham transcranial alternating current stimulation (tACS) will be administered over the right PPC and the right DLPFC at a frequency of 6Hz using physical vibrations instead of electrical current
89359933|NCT03760133|No Intervention|without Probiotics|Participants included in this group will not be taken probiotics for 1 month after bowel preparation for colonoscopy.
89359934|NCT03760055||Glaucoma and glaucoma suspects|Patients with at least two consecutive and reliable standard automated perimetry (SAP) examinations with either a pattern standard deviation (PSD) outside the 95% normal limits or a glaucoma hemifield test (GHT) result outside the 99% normal limits. Patients considered suspects for glaucoma must have an intraocular pressure (IOP) greater than 21 millimeters of mercury (mmHg) or suspicious appearance of the optic nerve head but with reliable normal visual fields, defined as a PSD within 95% confidence limits and a GHT result within normal limits.
89359935|NCT03760055||Age-related macular degeneration|"Patients will be considered as having AMD if one or more of the following are present on posterior biomicroscopy (fundoscopy), indirect ophthalmoscopy or Optical Coherence Tomography (OCT) exams:~Presence of at least intermediate-size drusen (63µm or larger in diameter)~Retinal pigment epithelium (RPE) abnormalities such as hypopigmentation or hyperpigmentation~Reticular pseudodrusen (also called sub retinal drusenoid deposit)~Presence of any of the following features: geographic atrophy of the RPE, choroidal neovascularization (exudative, wet), polypoidal choroidal vasculopathy, or retinal angiomatous proliferation."
89359936|NCT03760055||Other eye diseases|Patients with other retinal degenerations such as retinitis pigmentosa or with other diseases affecting the visual pathways such as tumors, ischemic neuropathy or optic neuritis may also be included. Their diagnosis will be extracted from their clinical visits.
89359937|NCT03760055||Healthy subjects|To be considered healthy, subjects have to have IOP < 22 mmHg with no history of elevated IOP and with at least two reliable normal visual fields, defined as a PSD within 95% confidence limits and a GHT result within normal limits.
89359938|NCT03759977|Experimental|Adapted Physical Activity group|This group will receive 3 sessions per week of specific physical activity.
88831821|NCT03019055|Experimental|CAR-20/19-T cells (1.0 x10^5 CAR-20/19-T cells/kg)|Dose Escalation Phase: CAR-20/19-T transduced with a lentiviral vector to express an anti CD19 and anti CD20 tandem receptor coupled to CD3ζ and 4-1BB signaling domains will be administered by IV injection. Patients will receive one of four dose levels based the study protocol. Cells will be given over 2 days, 30% of cells infused on Day 0 and 70% of cells infused on Day 1 in the Phase 1 portion and as a single infusion in the Phase 1b portion.
88831822|NCT03019055|Experimental|CAR-20/19-T cells (2.5 x10^5 CAR-20/19-T cells/kg)|Dose Escalation Phase: CAR-20/19-T transduced with a lentiviral vector to express an anti CD19 and anti CD20 tandem receptor coupled to CD3ζ and 4-1BB signaling domains will be administered by IV injection. Patients will receive one of four dose levels based the study protocol. Cells will be given over 2 days, 30% of cells infused on Day 0 and 70% of cells infused on Day 1 in the Phase 1 portion and as a single infusion in the Phase 1b portion.
88831823|NCT03019055|Experimental|CAR-20/19-T cells (7.5 x10^5 CAR-20/19-T cells/kg)|Dose Escalation Phase: CAR-20/19-T transduced with a lentiviral vector to express an anti CD19 and anti CD20 tandem receptor coupled to CD3ζ and 4-1BB signaling domains will be administered by IV injection. Patients will receive one of four dose levels based the study protocol. Cells will be given over 2 days, 30% of cells infused on Day 0 and 70% of cells infused on Day 1 in the Phase 1 portion and as a single infusion in the Phase 1b portion.
88831824|NCT03019055|Experimental|CAR-20/19-T cells (2.5 x10^6 CAR-20/19-T cells/kg)|Dose Escalation Phase: CAR-20/19-T transduced with a lentiviral vector to express an anti CD19 and anti CD20 tandem receptor coupled to CD3ζ and 4-1BB signaling domains will be administered by IV injection. Patients will receive one of four dose levels based the study protocol. Cells will be given over 2 days, 30% of cells infused on Day 0 and 70% of cells infused on Day 1 in the Phase 1 portion and as a single infusion in the Phase 1b portion.
88831825|NCT03930745|Experimental|Arm 1|TOL-463 insert administered vaginally twice a week for twelve weeks. N=125
88831826|NCT03930745|Placebo Comparator|Arm 2|Matching placebo insert administered vaginally twice a week for twelve weeks. N=125
88831827|NCT02033317|Experimental|patiromer|
88831828|NCT02034019|Active Comparator|OTX-DP (Dexamethasone Punctum Plug)|Resorbable hydrogel drug delivery vehicle containing dexamethasone
88831829|NCT02034019|Placebo Comparator|PVPP (Placebo Punctum Plug)|Resorbable hydrogel drug delivery vehicle containing no drug
88831830|NCT02349152|Experimental|Remifentanil group|Half of subjects enrolled will be randomized to the remifentanil group
88831831|NCT02349152|Active Comparator|Fentanyl group|Half of subjects enrolled will be randomized to the fentanyl group
88831832|NCT02034175|Experimental|SomnaPatch|SomnaPatch is a standalone flexible diagnostic skin-adhesive patch with electronics inside. The patch is placed on the patient's face.
88831833|NCT02034175|Active Comparator|Polysomnography|Polysomnography performed in a sleep lab is considered a gold standard in diagnosing the sleep breathing disorders.
88831834|NCT02035345|Experimental|Carboplatin|"Carboplatin will be prepared as a single 500ml infusion. Potentially 6 cycles Carboplatin (Amount of total dose) will be administered intravenously by the treating nurse according to the following schedule:~First hour - Administer 1 percent of total dose (5ml with tubing primed)~Second hour - Administer 9 percent (45 mL)~Third hour - Administer 90 percent (450 mL)"
88831835|NCT01985971|Experimental|EF5|
88831836|NCT01986361|Experimental|flurbiprofen 8.75 mg lozenge|A single flurbiprofen lozenge is sucked until fully dissolved.
88831837|NCT01986361|Placebo Comparator|Placebo lozenge|A single placebo lozenge is sucked until fully dissolved.
88831838|NCT01983020|Experimental|Ketamine|Ketamine infused at 0.25 mg/kg/hour.
89359939|NCT03759977|No Intervention|Usual accompaniment group|This group will continue to follow the usual accompaniment of the nursing home.
88831839|NCT01983020|Experimental|Lidocaine|Lidocaine infused at 0.5 mg/kg/hour.
89359940|NCT04854707||Monoprotocols: follitropin alpha biosimilar only and antagonists/agonists of GnRH|The ovarian stimulation (OS) protocols included monotherapy protocols with using follitropin alpha biosimilar only and antagonists/agonists of of gonadotropin-releasing hormone (GnRH): ganirelix, cetrorelix, triptorelin, buserelin.
89359941|NCT04854707||Mixed protocols: recombinant and urinary-derived gonadotropins and antagonists/agonists of GnRH|The OS protocols included: mixed protocols (recombinant with addition of urinary-derived gonadotropins) and antagonists/agonists of GnRH (ganirelix, cetrorelix, triptorelin, buserelin), where follitropin alpha biosimilar used for at least 5 days during OS.
88831840|NCT01983020|Experimental|Ketamine and Lidocaine|Ketamine infused at 0.25 mg/kg/hour along with lidocaine at 0.5 mg/kg/hour
88831841|NCT01983020|Placebo Comparator|Placebo|Placebo (saline) given to compare usual treatment against active agents in post operative pain management.
88831842|NCT02058511|Experimental|Intervention Group|"all enrolled patients undergo the same protocol/ treatment:~Anesthesia Premedication, Induction and Maintenance Pupillometry after administration of anesthetic drugs"
88831843|NCT01983566|Active Comparator|BI 207127 fasted|patient to receive BI 207127 as a single dose in fasted state
88831844|NCT01983566|Experimental|BI 207127 high fat|patient to receive BI 207127 as a single dose after a high fat breakfast
89359942|NCT04854707||Monoprotocols: follitropin alpha biosimilar only and antagonists of GnRH|The OS protocols included: monotherapy protocols with using only follitropin alpha biosimilar and antagonists of GnRH.
89359943|NCT04854707||Monoprotocols: follitropin alpha biosimilar only and agonist of GnRH|The OS protocol included: monotherapy protocols with using only follitropin alpha biosimilar and agonists of GnRH.
89359944|NCT04854707||The overall protocols|The OS protocols included: (1) Monoprotocols: follitropin alpha biosimilar only and antagonists/agonists of GnRH, (2) Mixed protocols: recombinant and urinary-derived gonadotropins and antagonists/agonists of GnRH
89359945|NCT03215069|Experimental|Empagliflozin|Empagliflozin 10 mg PO daily
89359946|NCT03215069|Placebo Comparator|Placebo|Matched placebo PO daily
89359947|NCT03759821|Experimental|Nutrition, mothers|Community health workers (CHWs) will facilitate peer group sessions with mothers of children aged 0-18 months at enrollment. The CHWs will deliver key messages and facilitate problem-solving and skill-building activities to promote nutrition-related behavior change. Group sessions will last between 1.5-2 hours and groups will meet biweekly for a period of 12 months. Due to the COVID pandemic, group sessions were paused for three months (March-June 2020). The intervention resumed in July 2020 with delivery via home visits rather than peer groups, and concluded in September 2020.
89359948|NCT03759821|Experimental|Nutrition, mothers and fathers|Community health workers (CHWs) will facilitate peer group sessions with mothers and fathers of children aged 0-18 months at enrollment. The CHWs will deliver key messages and facilitate problem-solving and skill-building activities to promote nutrition-related behavior change. Group sessions will last between 1.5-2 hours and the groups will meet biweekly for a period of 12 months. Due to the COVID pandemic, group sessions were paused for three months (March-June 2020). The intervention resumed in July 2020 with delivery via home visits rather than peer groups, and concluded in September 2020.
89359949|NCT03759821|Experimental|Nutrition+parenting, mothers|Community health workers (CHWs) will facilitate peer group sessions with mothers of children aged 0-18 months at enrollment. CHWs will deliver key messages and facilitate problem-solving and skill-building activities to promote nutrition and parenting-related behavior change. The group sessions will last between 1.5-2 hours and groups will meet biweekly for a period of 12 months. Due to the COVID pandemic, group sessions were paused for three months (March-June 2020). The intervention resumed in July 2020 with delivery via home visits rather than peer groups, and concluded in September 2020.
89359950|NCT03759821|Experimental|Nutrition+parenting, mothers and fathers|Community health workers (CHWs) will facilitate peer group sessions with mothers and fathers of children aged 0-18 months at enrollment. CHWs will deliver key messages and facilitate problem-solving and skill-building activities to promote nutrition and parenting-related behavior change. The group sessions will last between 1.5-2 hours and groups will meet biweekly for a period of 12 months. Due to the COVID pandemic, group sessions were paused for three months (March-June 2020). The intervention resumed in July 2020 with delivery via home visits rather than peer groups, and concluded in September 2020.
89359951|NCT03759821|No Intervention|Standard of care control|Local standard of care
89359952|NCT03759743|Experimental|Probiotics|
89359953|NCT03759743|Placebo Comparator|Placebo|
89359954|NCT01322321|Experimental|ACZ885|
89359955|NCT01322321|Placebo Comparator|Placebo|
89359956|NCT04557371|Experimental|Developmental Serum|The participants will apply a developmental serum topically to the face twice daily (morning and evening) to freshly cleansed with normal moisturizing routine for 21 days.
89359957|NCT04557371|Experimental|Developmental Lotion|The participants will apply a developmental lotion topically to the face twice daily (morning and evening) to freshly cleansed skin for 21 days.
89359958|NCT04557371|Experimental|Developmental Cream|The participants will apply a developmental cream topically to the face twice daily (morning and evening) to freshly cleansed skin for 21 days.
88831845|NCT01983566|Experimental|BI 207127 low fat|patient to receive BI 207127 as a single dose after a low fat breakfast
88831846|NCT01983566|Experimental|BI 207127 with Omeprazole|patient to receive BI 207127 as a single dose after 4 days treatment with Omeprazole 40 mg once a day
88831847|NCT02059057|Experimental|LVRC System|
89534438|NCT01459068|Experimental|Common Elements Treatment Approach|Eligible study subjects randomized into the CETA intervention were offered ten weeks of counseling sessions, consisting of nine elements designed to treat symptoms of common mental health disorders including depression, PTS, and anxiety and to provide skills to deal with life stressors.
89534439|NCT01409863|No Intervention|laser and standard diamond fraise dermabrasion|laser and standard diamond fraise dermabrasion
88831848|NCT01983878|Experimental|Ramucirumab|Ramucirumab 8 milligrams per kilogram (mg/kg) administered intravenously (IV) once every 2 weeks. Treatment will continue until there is evidence of progressive disease (PD), the development of unacceptable toxicity, protocol noncompliance or withdrawal of consent.
88831849|NCT01986686|No Intervention|Observational|The observation group will be followed clinically with no further intervention until the primary endpoint is reached.
88831850|NCT01986686|Active Comparator|Surgery|The surgery group will be offered colon resection.
88831851|NCT02351258|Experimental|Usual Care only, then Usual Care + 70% Isopropyl Alcohol|Usual care for central line while patients are at home and then switch to usual care plus 70% isopropyl alcohol after washout.
89359959|NCT03755141|Experimental|Herzuma|Herzuma + TPC
89534440|NCT01216202||Preoperative RT|Men with rectal cancer treated with preoperative radiotherapy (RT) and surgery.
89534441|NCT01216202||No preoperative RT|Men with rectal cancer or prostate cancer treated with surgery alone (no RT).
89534442|NCT01186016|Experimental|Genetic Education Session (GES)|The objectives are to: discuss the impact of the human genome project; define basic genetic concepts and terminology; distinguish between single-gene and multifactorial genetic diseases/conditions; describe genetic counseling/testing; identify uses of pharmacogenetics; discuss psychological and legal/ethical implications of genetic discoveries; smoking as a multifactorial behavior; findings of epidemiological studies about smoking heritability; research about candidate genotypes DRD2 and CYP2A6; and potential use of genotyping to tailor smoking cessation treatment. All participants also receive a 5-week standard cognitive-behavioral smoking cessation intervention with 6 weeks of OTC transdermal nicotine replacement therapy.
88831852|NCT02351258|Experimental|Usual Care + 70% Isopropyl Alcohol, then Usual Care only|Use of 70% isopropyl alcohol embedded caps on central lines in addition to usual care of central line in the home setting and then switch to usual care only after washout.
88831853|NCT02029040|Experimental|3% hypertonic saline group|Once consented, the study drug (in this arm: 3% Hypertonic Saline) will be ordered by a physician at the request of a study team member. Once the drug order set is received by a pharmacist, he/she will obtain the study drug from an Omnicell and prepare the medication to a volume of 3 mL in a syringe with a blinded study label prepared in advance by the IDS pharmacy. The pharmacist will then give the study drug to the patient's respiratory therapist or the bedside nurse. The respiratory therapist or the nurse will pour the drug from a syringe to an inhaler cup and the study drug will be given by the standard nebulizer over the course of 15 minutes.
88831854|NCT02029040|Placebo Comparator|0.9% normal saline group|Once consented, the study drug (in this arm: 0.9% normal saline) will be ordered by a physician at the request of a study team member. Once the drug order set is received by a pharmacist, he/she will obtain the study drug from an Omnicell and prepare the medication to a volume of 3 mL in a syringe with a blinded study label prepared in advance by the IDS pharmacy. The pharmacist will then give the study drug to the patient's respiratory therapist or the bedside nurse. The respiratory therapist or the nurse will pour the drug from a syringe to an inhaler cup and the study drug will be given by the standard nebulizer over the course of 15 minutes.
88831855|NCT02029196|Experimental|e-vapour product (EVP)|Subjects who switch from using conventional cigarettes to using an e-vapour product (EVP).
88831856|NCT02029196|Active Comparator|Conventional cigarette (CC)|Subjects who continue smoking their usual conventional cigarette (CC) brand.
88831857|NCT02396732|Experimental|Low Molecular Weight Heparin (LMWH) + Aspirin (ASA)|Group will get both enoxaparin (standard of care) and aspirin (intervention) after consent up to Intensive Care Unit (ICU) discharge.
88831858|NCT02396732|Active Comparator|Low Molecular Weight Heparin (LMWH) Alone|Group will get only enoxaparin (standard of care) after consent up to Intensive Care Unit (ICU) discharge.
88831859|NCT02030288|Experimental|Relational Agent plus Treatment as Usual|"Relational Agents are onscreen characters that speak to the patient and establish a relationship with them. They have been used to improve several health behaviors including diet and exercise, and can overcome communication barriers related to low levels of computer literacy. The Relational Agent can be placed on a desktop or tablet computer with a touch screen, on which patients indicate their responses. Using Motivational Interviewing and behavior change principles, the Relational Agent guides patients to consider change."
88831860|NCT02030288|No Intervention|Treatment as Usual|Patients are routinely screened yearly for unhealthy alcohol use. Providers are prompted to provide elements of a brief intervention if the patient scores 5 or above on the AUDIT-C. Providers are also prompted to refer patients if they meet certain criteria for specialty alcohol treatment.
88831861|NCT02031770|Other|A: Treatment/Control|Patients will start with sodium bicarbonate treatment then switch to control (no treatment)
88831862|NCT02031770|Other|B: Control/Treatment|Patients will start with control (no treatment) then switch to sodium bicarbonate treatment
88831863|NCT02032550|Experimental|Preference Based Decision Aid|The experimental arm of preference based decision aid intervention will complete a web-based conjoint analysis instrument for preference assessment.
88831864|NCT02032550|No Intervention|Usual Care|Participants randomized into this group will have usual care from their doctors without any intervention
88831865|NCT02352974|Experimental|GAD-Alum+Vitamin D|"GAD-Alum (Diamyd) injected into Lymph Nodes Dosage and interval: One injection of 4 µg Diamyd will be administered into the lymph nodes at three occasions, with one month intervals~Vitamin D (Calciferol) in oral solution. Dosage and interval: 2000 IU daily for 120 days"
88831866|NCT02353754|Active Comparator|Standard of Care|Subjects in Group 1 (Standard of Care) will receive intrathecal morphine injection (e.g., Duramorph®) 0.2 mg in conjunction with the single-shot spinal anesthesia. No TAP block will be administered.
88831867|NCT02353754|Experimental|EXPAREL/TAP|Subjects in Group 2 will receive a bilateral TAP infiltration with a single 20 mL dose of EXPAREL 266 mg expanded in volume with 20 mL of normal saline for a total volume of 40 mL (20 mL infiltrated on each side of the abdomen).
88831868|NCT02354144|Experimental|Carrageenan-based gel|"The intervention to be administered is:~a commercially available gel that contains carrageenan.~water-based, latex-condom compatible, clear, odourless, tasteless, and have similar viscosity as the placebo gel.~also packaged in a similar plastic bottle with a disk cap that can be operated with one finger, and must be applied prior to anal intercourse during the entire study period. Around 15 ml of the personal lubricant will be dispensed into the hand and applied directly to the genital, anal, and condom surfaces prior to and as needed during anal sex. When sexual activity ceases, the water-based formulation of the gel allows it to be easily removed with lukewarm water."
88831869|NCT02354144|Placebo Comparator|Control gel|"The intervention to be administered is:~a commercially available gel that does not contain carrageenan.~water-based, latex-condom compatible, clear, odourless, tasteless, and have similar viscosity as the carrageenan-containing gel.~also packaged in a similar plastic bottle with a disk cap that can be operated with one finger, and must be applied prior to anal intercourse during the entire study period. Around 15 ml of the personal lubricant will be dispensed into the hand and applied directly to the genital, anal, and condom surfaces prior to and as needed during anal sex. When sexual activity ceases, the water-based formulation of the gel allows it to be easily removed with lukewarm water."
88831870|NCT02397122|Experimental|PRF+CAF+CTG|platelet-rich fibrin + coronally advanced flap + connective tissue graft
88831871|NCT02397122|Active Comparator|CAF+CTG|coronally advanced flap + connective tissue graft
88831872|NCT02354378||Children undergoing sedation with Dexmedetomidine|Children who will undergo sedation for MRI will be given a memory encoding task during dexmedetomidine bolus induction to measure the effects of sedation. The mere task of naming a picture will encode that picture into memory. When the anesthesia has worn off (at approximately 1 hour later), children will be given a memory recognition task to measure the amnesic effects of dexmedetomidine.
89534443|NCT01186016|Active Comparator|Nutrition Education Session (NES)|The objective is to provide a control group that will received comparable attention as the experimental group by providing USDA approved nutritional information (MyPyramid) dietary and food safety guidelines. All participants also receive a 5-week standard cognitive-behavioral smoking cessation intervention with 6 weeks of OTC transdermal nicotine replacement therapy.
88831873|NCT02354378||Children not undergoing sedation|A control group of children of similar age scheduled for MRI will be recruited to perform memory recognition testing.
89359960|NCT04555655|Experimental|Chicken extract supplement|
89359961|NCT04555655|Experimental|Peptides supplement|
89359962|NCT04555655|Placebo Comparator|Placebo|
89359963|NCT03757871|Experimental|Laser Stimulation|laser pen acupuncture projecting an infrared beam with a wavelength of 905nm bilaterally for 30 seconds on each point.
89359964|NCT03757871|Placebo Comparator|Placebo|The placebo group will have an application of the pen according to the same extinguished laser criteria.
89359965|NCT04848233|Other|Drink intervention|Placebo and two drinks containing a blend of five amino acids and chromium picolinate, are included with every main meal and served in a standardized, non-randomised order.
89359966|NCT05460065|Experimental|Cohort A|
89534444|NCT01113749|Experimental|Decision support|Structured decision aid with prompting to share information in discussion with primary treating health care providers.
88831874|NCT02312726||Epidural group|Participants who elect to have an epidural anesthesia during labor, delivery and postplacental IUD insertion
88831875|NCT02312726||Non Epidural group|Participants who elect not to have epidural anesthesia during labor, delivery and postplacental IUD insertion
88831876|NCT02399228|Experimental|0.25% EISO Mouth Rinse|"A mouth rinse containing 0.25% East Indian sandalwood oil (EISO), a candidate botanical drug substance. The rinse will be used three times a day for up to ten weeks. The material will not be ingested but used to swish, gargle and spit."
88831877|NCT02033174|Other|Sugar water first, then alcohol|8 participants have received oral fat diet plus water with sugar (equivalent caloric intakes as sugar with water in the control group). Then they receive the same oral fat-enriched diet (1486 kcal/m2) with 654 kcal/m2 (44%) as fat and a daily total amount of 16 g/m2 of alcohol, of different beverages (red wine, vodka, brandy or rum)
88831878|NCT02033174|Other|Alcohol first then sugar water|8 participants have received oral fat diet plus alcoholic beverages (a daily total amount of 16 g/m2 of alcohol, of different beverages : red wine, vodka, brandy or rum). Then they receive the same oral fat-enriched diet (1486 kcal/m2) with 654 kcal/m2 (44%) as fat and water with sugar (equivalent caloric intakes as sugar with water in the control group).
88831879|NCT02059213|Active Comparator|ADT Alone|Androgen Deprivation Therapy (ADT): Bicalutamide (an active non-steroidal antiandrogen; 50mg taken daily by mouth) and Zoladex (LHRH agonist administered by injection), or Lupron Depot (LHRH agonist, administered by injection).
88831880|NCT02059213|Experimental|ADT + Ibrance®|Ibrance® (125mg taken daily by mouth days 1-21 of a 28 day cycle) in addition to Androgen Deprivation Therapy (ADT): Bicalutamide (an active non-steroidal antiandrogen; 50mg taken daily by mouth) and Zoladex (LHRH agonist administered by injection), or Lupron Depot (LHRH agonist, administered by injection).
88831881|NCT02037061|Placebo Comparator|normal saline|Intraoperatively the patient will receive 10ml of normal saline injected into the sacrospinous ligament.
88831882|NCT02037061|Active Comparator|bupivacaine|Intraoperatively the patient will receive 10 ml of bupivacaine injected into the sacrospinous ligament.
88831883|NCT02354534|Experimental|50 mg Artesunate suppositories, 1 cycle|Subjects enrolled in this cohort will receive 1 five day cycle of Artesunate suppositories prior to therapeutic resection of their lesion (if clinically indicated).
88831884|NCT02354534|Experimental|200 mg Artesunate suppositories, 1 cycle|Subjects enrolled in this cohort will receive 1 five day cycle of Artesunate suppositories prior to therapeutic resection of their lesion (if clinically indicated).
88831885|NCT02354534|Experimental|200 mg Artesunate suppositories,2 cycles|Subjects enrolled in this cohort will receive 2 five day cycles of Artesunate suppositories prior to therapeutic resection of their lesion (if clinically indicated).
88831886|NCT02354534|Experimental|200 mg Artesunate suppositories,3 cycles|Subjects enrolled in this cohort will receive 3 five day cycles of Artesunate suppositories prior to therapeutic resection of their lesion (if clinically indicated).
89534445|NCT01113749|No Intervention|Control|Usual care
89359967|NCT05460065|Experimental|Cohort B|
89359968|NCT05460065|Experimental|Cohort C|
89359969|NCT05460065|Placebo Comparator|Placebo|
89359970|NCT03759509|Experimental|aerobic exercise training|three times a week, a total of twenty-four times in eight weeks
89359971|NCT03759509|No Intervention|control|routine activity
89359972|NCT04834271|Active Comparator|Exercise without blood flow restriction|Side-lying external rotation exercise with a dumbbell (20-30% 1RM) without blood flow restriction.
89359973|NCT04834271|Experimental|Exercise with 40% of arterial occlusion pressure blood flow restriction|Side-lying external rotation exercise with a dumbbell (20-30% 1RM) with 40% of arterial occlusion pressure blood flow restriction.
89359974|NCT04834271|Experimental|Exercise with 80% of arterial occlusion pressure blood flow restriction|Side-lying external rotation exercise with a dumbbell (20-30% 1RM) with 80% of arterial occlusion pressure blood flow restriction.
89359975|NCT03759353|Active Comparator|Lactoferrin Group|Includes 49 pregnant women receiving lactoferrin 100 mg one sachet twice daily for 30 days to be dissolved in 1/4 glass of water before meals (Pravotin (R) , Hygint pharmaceuticals). Baseline ferritin level will be obtained and compared to follow up ferritin level after 30 days of treatment.
89534446|NCT01060384|Experimental|Phase 1/Phase II|All participants will receive the same dose of Ofatumumab. There will be three planned dose cohorts for the Lenalidomide in the Phase 1 portion of this trial. A maximum of 18 patients will be enrolled in to Phase 1. Three evaluable patients will be enrolled in to each of the dose cohorts with an additional 3 patients to be enrolled in the maximum tolerated dose (MTD). An additional 29 evaluable patients will be enrolled in to Phase II using the MTD for Lenalidomide that was determined in Phase 1.
89534447|NCT00876525|Other|Freedom SOLO stentless valve|Prospective data collection on the outcomes in patients treated with the CE Marked Freedom Solo Valve within the approved indication.
89534448|NCT00733161|Active Comparator|1|Passive leg cycle exercise with stretching and resistance training
89534449|NCT00733161|Active Comparator|2|Stretching and resistance training
89534450|NCT00580047|Active Comparator|1 Zoledronic Acid|Zoledronic Acid 4mg intravenously once a year for 2 years
89534451|NCT00580047|Active Comparator|2 Alendronate|Alendronate 70mg orally once a week for 2 years
89359976|NCT03759353|Active Comparator|Ferrous Sulfate Group|Includes 49 pregnant women receiving 200 mg of dried ferrous sulfate tablet once daily for 30 days on empty stomach but may be taken with meals to avoid stomach upset (Feosol (R) , Meda pharmaceuticals). Baseline ferritin level will be obtained and compared to follow up ferritin level after 30 days of treatment.
89359977|NCT05393375||Group 1 Amyoplasia|Patients with diagnosis of Amyoplasia
89001016|NCT04634188||Glioma Group|"This group is based on the type of histopathology and MRI images that lead to a glioma type brain tumor.~After grouping, blood serum samples was collected to check the value of CRP, procalcitonin and NLR. The data were entered in a table and then compared with values from other types of brain tumors."
89359978|NCT05393375||Group 2 Distal Arthrogryposis|Patients with diagnosis of Distal Arthrogryposis
89359979|NCT05393375||Group 3 Other|Patients with diagnosis of other form of AMC
89359980|NCT03754985||Hyperbaric Oxygen Therapy|The study included participants 18 years or older, scheduled for 60 HBOT sessions for any indication.
89359981|NCT04825379|Experimental|bioactive composite|Cention N, Ivoclar Vivadent, Schaan, Liechtenstein (CN)
89359982|NCT04825379|Experimental|posterior resin composite|G-ænial Posterior (GC, Tokyo, Japan) (GP)
89359983|NCT05280977|Experimental|POST ISOMETRIC RELAXATION|
89359984|NCT05280977|Experimental|POST FACILITATION STRETCHING|
89359985|NCT03757559|Experimental|Cebranopadol 200 micrograms (Treatment A)|"Cebranopadol 200 micrograms (low dose): Participants took 2 tablets (cebranopadol 100 micrograms) as a single dose.~In addition, participants took 4 placebo capsules matching hydromorphone capsules as a single dose."
89359986|NCT03757559|Experimental|Cebranopadol 400 micrograms (Treatment B)|"Cebranopadol 400 micrograms (medium dose): Participants took 2 tablets (cebranopadol 400 micrograms plus matching placebo) as a single dose.~In addition, participants took 4 placebo capsules matching hydromorphone capsules as a single dose."
89359987|NCT03757559|Experimental|Cebranopadol 800 micrograms (Treatment C)|"Cebranopadol 800 micrograms (high dose): Participants took 2 tablets containing cebranopadol 400 micrograms as a single dose.~In addition, participants took 4 placebo capsules matching hydromorphone capsules as a single dose."
89359988|NCT03757559|Active Comparator|Hydromorphone IR 8 milligrams (Treatment D)|"Hydromorphone immediate-release (IR) 8 milligrams: Participants took 4 capsules (2 capsules of hydromorphone hydrochloride 4 mg plus 2 placebo capsules) as a single dose.~In addition, participants took 2 placebo tablets matching cebranopadol tablets as a single dose."
89359989|NCT03757559|Active Comparator|Hydromorphone IR 16 milligrams (Treatment E)|"Hydromorphone immediate-release (IR) 16 milligrams: Participants took 4 capsules of hydromorphone hydrochloride 4 mg as a single dose.~In addition, participants took 2 placebo tablets matching cebranopadol tablets as a single dose."
89359990|NCT03757559|Placebo Comparator|Placebo (Treatment F)|"Placebo: Participants took 4 placebo capsules matching hydromorphone capsules as a single dose.~In addition, participants took 2 placebo tablets matching cebranopadol tablets as a single dose."
89359991|NCT03757559|Placebo Comparator|Placebo (Treatment G)|"Placebo (following Treatment C): Participants took 2 placebo tablets matching cebranopadol tablets as a single dose.~In addition, participants took 4 placebo capsules matching hydromorphone capsules as a single dose."
89359992|NCT03754907|Experimental|stapled anastomosis group|Following the first side-to-side anastomosis at the antimesenteric border in both intestinal limbs, the staple lines are oversewn to reinforce the crotch. Thereafter, the stapler is again fired across the joined intestinal limbs to close the enterotomies. The suture line of the side-to-side anastomosis should not overlap, and the staple lines are oversewn to reinforce the double-stapled areas.
89359993|NCT03754907|Active Comparator|hand-sewn anastomosis group|Patients chose HA group will performed in an end-to-end manner using absorbable suture material.
89359994|NCT03759119|Experimental|Tummy Time and Parent Education|This group will receive tummy time and parent education and be encouraged to perform tummy time on their own. They will utilize the PT Pal application to record their tummy time adherence. The primary investigator performs the intervention to the participants two times a day for 10 minutes for 4 weeks.
89359995|NCT03759119|No Intervention|Parent education|This group will receive parent education only and utilize the PT Pal application to record their adherence. The primary caregiver will be encouraged to perform the same dosage of tummy time (2x/day, 10 minutes each, 4 weeks) and record their adherence on the PT Pal application.
89359996|NCT01322399|Experimental|Structural Integration plus usual care|Each subject in this arm will receive ten Structural Integration treatments at intervals of between one and three weeks, and will also receive usual care for chronic low back pain as standard practice at Spaulding Medford Rehabilitation Clinic, which may include pain medication, exercise and physical therapy. Usual care will be provided on average twice weekly for between 3 and 7 weeks, at the discretion of the clinic's medical director
89359997|NCT01322399|Active Comparator|Usual care|Each subject in this arm will receive care for chronic low back pain as standard practice at Spaulding Medford Rehabilitation Clinic, which may include pain medication, exercise and physical therapy. Usual care will be provided on average twice weekly for between 3 and 7 weeks, at the discretion of the clinic's medical director
89359998|NCT02658929|Experimental|bb2121|bb2121 autologous CAR T cells will be infused at a dose ranging from 150 - 450 x 10^6 CAR+ T cells after receiving lymphodepleting chemotherapy
89359999|NCT02652923|Experimental|Part 1 - volunteers|Subdermal low (1.0 ml) or high (2.0 ml) dose injection of the ultrasound contrast agent Sonazoid divided into four individual aliquots at four locations (12, 3, 6, and 9 o'clock) around a 2 cm in diameter region in the mid-upper outer quadrant of the left breast, followed a week later by the other dose injected in the same fashion into the right breast.
89001017|NCT04634188||Brain Metastasis Group|This group is based on the type of histopathology and MRI images that lead to a metastasis brain tumor type After grouping, blood serum samples was collected to check the value of CRP, procalcitonin and NLR. The data were entered in a table and then compared with values from other types of brain tumors.
89360000|NCT02652923|Experimental|Part 2 - patients|Subdermal injection of the ultrasound contrast agent of Sonazoid divided into four individual aliquots at four locations (12, 3, 6, and 9 o'clock) around the breast cancer. Subjects will receive an injection of either a low (1.0 ml) or a high (2.0 ml) dose of Sonazoid depending on the outcome of the Part 1 safety and tolerability study.
89360001|NCT03754829|Experimental|HSKA - Web Group|The first experimental group will receive direct access to the web version of HSKA.
89360002|NCT03754829|Experimental|HSKA - Mobile Group|The second experimental group will receive direct access to the mobile app of HSKA as well as automated supportive text messages based on PST.
89360003|NCT03754829|No Intervention|Control Group|The control group consists of a wait-list and for ethical reasons, participants in this group will gain access to the intervention (either web or mobile application) four months after the baseline.
89360004|NCT03754751|Experimental|Modified ERAS program group|Laparoscopic cholecystectomy with the implementation of modified ERAS program
89360005|NCT03754751|Active Comparator|Conventional care group|Laparoscopic cholecystectomy with standard perioperative treatment
89360006|NCT04539275|Experimental|Convalescent Plasma|The study intervention consists of intravenous administration of 200-500 mL of convalescent plasma administered in two equally divided doses, less than 12 hours apart.
88831887|NCT02059993|Other|continuous positive airway pressure|mean continuous positive airway pressure use was at least 4 hours per night; continuous positive airway pressure group received fixed-level continuous positive airway pressure titration using an automated pressure
89360007|NCT04539275|Placebo Comparator|Masked Saline Placebo|The study intervention consists of intravenous administration of 200-500 mL of 0.9% saline administered in two equally divided doses, less than 12 hours apart.
89360008|NCT04784897|Experimental|Brilacidin + SoC|Brilacidin IV infusion, 3 days and up to 5 days, in addition to Standard of Care
89360009|NCT04784897|Placebo Comparator|Placebo + SoC|Placebo IV infusion, 3 days and up to 5 days, in addition to Standard of Care
89360010|NCT02651597|Experimental|Low Viscous|Low Viscous Beta Glucan Oatmeal
89360011|NCT02651597|Experimental|Medium Viscous|Medium Viscous Beta Glucan Oatmeal
88831888|NCT02059993|No Intervention|Control|The control subjects received standardised anti-hypertension medications according to the current guildline.
88831889|NCT02060461|Experimental|FS200 femtosecond laser LASIK|LASIK flap created with an FS200 femtosecond laser system
88831890|NCT02060461|Experimental|IntraLase femtosecond laser LASIK|LASIK flap created with an IntraLase femtosecond laser system
88831891|NCT02354924|Experimental|Visco soft contact lens|Olifilcon A, Daily wear, monthly disposable soft contact lens
88831892|NCT02354924|Active Comparator|Biofinity soft contact lens|Comfilcon A, Daily wear, monthly disposable soft contact lens
88831893|NCT02060539|Experimental|Biofinity XR|Participants dispensed Biofinity XR lenses over two weeks of lens wear
88831894|NCT02355158|Experimental|Active|Clonidine hydrochloride topical gel, 0.1%
88831895|NCT02033876|Experimental|Ursodiol|Ursodeoxycholic acid (UDCA) 600mg in delayed (ileocolonic)-release to be taken twice daily
88831896|NCT02033876|Placebo Comparator|Placebo|matching placebo capsules to be taken twice daily
88831897|NCT02061397|Experimental|simvastatin treatment arm|Eligible patients on sirolimus or everolimus will be assigned to receive 20 mg of simvastatin once daily for a period of two months. If tolerated, the dosage of simvastatin will be advanced to 40 mg once daily in months 3 and 4.
88831898|NCT02400710|Experimental|Clinician-Supported PTSD Coach|Four 20-minute sessions (2 in-person, 2 by phone) focused on instructions for use, setting symptom reductions goals, and assigning specific PTSD Coach activities (i.e., assessments, management strategies, psycho-educational readings) for the participant to complete on their own.
88831899|NCT02400710|Active Comparator|Self-Managed PTSD Coach|One in-person 10-minute session that provides instructions on how to use the PTSD Coach app.
88831900|NCT04349761|Experimental|Cohort 1 - 5mg MyMD1|8 subjects randomized to receive either 5mg MyMD1 (6 subjects) or Placebo (2 subjects)
89360012|NCT02651597|Experimental|High Viscous|High Viscous Beta Glucan Oatmeal
89360013|NCT03757325|Experimental|DNL747 First, Placebo Second|Subjects will receive DNL747 for 29 days for the first period and then will switch to placebo for 29 days for the second period. There will be a 14-day washout period between the 2 treatment periods.
89360014|NCT03757325|Experimental|Placebo First, DNL747 Second|Subjects will receive placebo for 29 days for the first period and then will switch to DNL747 for 29 days for the second period. There will be a 14-day washout period between the 2 treatment periods.
89534452|NCT00580047|Placebo Comparator|3 Placebo|Combination drug entity: calcium 1200 mg with vitamin D 800 International Units daily
89534453|NCT00561340|Experimental|1 Can of Pediasure Supplement Plus Nutritional Counseling|Pediasure and nutritional counseling
89534454|NCT00561340|Active Comparator|Counseling by the Provider on Ways to Encourage Caloric Intake|Behavioral intervention - Nutritional Counseling
88831901|NCT04349761|Experimental|Cohort 2 - 10mg MyMD1|8 subjects randomized to receive either 10mg MyMD1 (6 subjects) or Placebo (2 subjects)
88831902|NCT04349761|Experimental|Cohort 3 - 15mg MyMD1|8 subjects randomized to receive either 15mg MyMD1 (6 subjects) or Placebo (2 subjects)
88831903|NCT04349761|Experimental|Cohort 4 - 20mg MyMD1|8 subjects randomized to receive either 20mg MyMD1 (6 subjects) or Placebo (2 subjects)
88831904|NCT04349761|Experimental|Cohort 5 - 25mg MyMD1 or Placebo|8 subjects randomized to receive either 25mg MyMD1 (6 subjects) or Placebo (2 subjects)
88831905|NCT02401022|Active Comparator|AZD8529 low dose|1.5 mg
88831906|NCT02401022|Active Comparator|AZD8529 high dose|40mg
88831907|NCT02062177|Experimental|propofol group|70 patients (35 upper endoscopy - 35 colonoscopy)
88831908|NCT02062177|Active Comparator|midazolam group|70 patients (35 upper endoscopy - 35 colonoscopy)
88831909|NCT02034578|Experimental|Arm A: Apixaban|Single dose Apixaban 5 mg (0.4 mg/mL x 12.5 mL) oral solution via oral syringe
88831910|NCT02034578|Experimental|Arm B: Apixaban|Single dose Apixaban 5 mg (0.4 mg/mL x 12.5 mL) oral solution via nasogastric tube (NGT) immediately followed by 60 mL of D5W via NGT
89001018|NCT04634305||Total elbow arthroplasty|Total elbow arthroplasty, all indications combined
89360015|NCT03758963|Experimental|Active Laser|"Once the energy to be applied for the treatment is determined through the laser irradiation testing, conduct laser therapy after selecting T corresponding to treatment laser on GUI.~At irradiation, excluding the circle area with a 100 μm radius (200 μm diameter) from the center of the fovea, irradiate laser in the form of surrounding the leakage site with an interval of 0.5-1 spot diameter (fovea = 1 spot size). As for the test spots, the serial number needs to be given for each treatment spot with the order of irradiation, as described above.~If pigment epithelial detachment (PED) occurs at the leakage site, irradiate laser around the PED (excluding the circle area with a 100 μm radius (200 μm diameter) from the center), not to the leakage site.~Within 2 hours after therapy, perform tests for efficacy evaluation (color fundus photography and fluorescein angiography)."
89360016|NCT03758963|Sham Comparator|Sham Laser procedure|"Select C corresponding to Sham Therapy on GUI of the laser device, and then perform Sham therapy.~During Sham therapy, for patient's blinding, both light from the slit lamp and sound from laser oscillation are same as laser irradiation, and no laser oscillation will occur for treatment.~Perform subsequent procedures in the same manner as the procedure of study group."
89360017|NCT05692778||1: Patients being foot examined by using an eHealth tool|Patients being foot examined by using an eHealth tool
89360018|NCT05692778||2: Patients being foot examined in traditional manner|Patients being foot examined in traditional manner
89360019|NCT05692700|Experimental|Aromatherapy lavender group|Stage 1: Patient information form, follow-up form, State Continuity Anxiety Scale, Richard-Campbell Sleep Scale were filled.Stage 2: On the second day of the surgery, at 20:00 in the evening, they were asked to inhale 2-3 drops of lavender essential oil, which was dripped onto the pillow pouches, at 21:00, and these bags were placed 10 cm away from the patient after 20 minutes. These bags were taken from the bedside of the patient at 08:00 in the morning.. Stage 3: Before the evening application, the patient follow-up form, State-Continuity Anxiety Scale, Richard Campbell Sleep Scale were filled and they were asked to inhale 2-3 drops of lavender essential oil, which was dropped on the pillow bags prepared at 20:00, and inhaled at 21:00. Afterwards, these sacs were placed 10 cm away from the patient. These sacs were taken from the bedside of the patient at 08:00 in the morning and the patient follow-up Form, State-Trait Anxiety Scale, Richards-Campbell Sleep Scale were filled
89360020|NCT05692700|Experimental|Aromatherapy bergamot group|Stage1:Patient information form, follow-up form, State Continuity Anxiety Scale, Richard Campbell Sleep Scale were filled. Stage 2:On the second day of the surgery, at 20:00 in the evening, they were asked to inhale 2-3 drops of bergamot essential oil, which was dripped onto the pillow pouches,at 21:00, and these bags were placed 10 cm away from the patient after 20 minutes. These bags were taken from the bedside of the patient at 08:00 in the morning.Stage 3:Before the evening application, the patient follow-up form, State-Continuity Anxiety Scale, Richard Campbell Sleep Scale were filled and they were asked to inhale 2-3 drops of bergamot essential oil, which was dropped on the pillow bags prepared at 20:00, and inhaled at 21:00. Afterwards, these sacs were placed 10 cm away from the patient.These sacs were taken from the bedside of the patient at 08:00 in the morning and the patient follow-up Form, State-Trait Anxiety Scale, Richards-Campbell Sleep Scale were filled.
89360021|NCT05692700|Placebo Comparator|Plasebo group|Stage 1:Patient identification form, follow-up form, State Continuity Anxiety Scale, Richard Campbell Sleep Scale were filled in.Stage2: 2-3 drops of distilled water dripped onto the prepared pillow bags at 21:00 on the second and third days of the surgery by inhalation. They were asked to breathe and after 20 minutes, these sacs were taken and placed 10 cm away from the patient.Stage 3:These sacs were taken from the bedside of the patient at 08:00 in the morning and the patient follow-up form, State-Trait Anxiety Scale, Richards Campbell Sleep Scale were filled again.
89360022|NCT01322711|Active Comparator|Atorvastatin|"Each day accordingly to randomization patients allocated to Atorvastatin received a pill of 40 mg of atorvastatin. In diabetic patients the concomitant aspirin treatment include a previous 30 days treatment with 100 mg daily of aspirin.~All patients followed the diet used in the placebo group."
89360023|NCT01322711|Placebo Comparator|Diet|Low-fat diet with mean macronutrient profiles that were close to the present Adult Treatment Panel III guidelines (7% energy from saturated fat and, 200 mg dietary cholesterol per day)
89360024|NCT04532099|Other|LID018869, then AOHP (Part A)|Lehfilcon A contact lenses worn first, followed by senofilcon A contact lenses, as randomized. Each product will be worn bilaterally (in both eyes) for approximately 30 days, with a scheduled visit at approximately Day 15 of each wear period. Lenses will be removed nightly for cleaning and disinfection with CLEAR CARE contact lens solution.
89534455|NCT00292045|Experimental|NY-ESO-1 protein + CpG 7909|Patients received immunization with intradermal injections of the NY-ESO-1 protein combined with CpG 7909.
89534456|NCT00242944|Active Comparator|1|Pitavastatin
89534457|NCT00242944|Active Comparator|2|Atorvastatin
89534458|NCT00204919|Placebo Comparator|1|
89534459|NCT00204919|Active Comparator|2|
89534460|NCT00143910||Renal transplant recipient|Recipients of successful renal transplant
88831911|NCT02034578|Experimental|Arm C: Apixaban|Single dose Apixaban 5 mg (0.4 mg/mL x 12.5 mL) oral solution via NGT immediately followed by 60 mL of infant formula via NGT
88831912|NCT02403830|Experimental|Methylnaltrexone|Patients will be randomly assigned in a 1:1 fashion to receive either i.v methylnaltrexone or placebo (0.9% sodium chloride iv injection). Methylnaltrexone, at a dose of 0.3 mg/Kg, will be administered diluted with 5 ml of normal saline as a single i.v. bolus over 1 minute followed by morphine (5-mg intravenous bolus). Then patients will receive iv morphine and a loading dose of ticagrelor.
88831913|NCT02403830|Placebo Comparator|Placebo|Patients will be randomly assigned in a 1:1 fashion to receive either i.v methylnaltrexone or placebo (0.9% sodium chloride iv injection). Methylnaltrexone, at a dose of 0.3 mg/Kg, will be administered diluted with 5 ml of normal saline as a single i.v. bolus over 1 minute followed by morphine (5-mg intravenous bolus). Then patients will receive iv morphine and a loading dose of ticagrelor.
88831914|NCT02036840||Penicillin allergy|
88831915|NCT02951195|Placebo Comparator|Part 1: Placebo|
88831916|NCT02951195|Experimental|Part 1 Cohort 1A: TC|
88831917|NCT02951195|Experimental|Part 1 Cohort 1B: TC|
88831918|NCT02951195|Experimental|Part 1 Cohort 1C: TC|
88831919|NCT02951195|Active Comparator|Part 2 Cohort 2A: TEZ/IVA|
88831920|NCT02951195|Experimental|Part 2 Cohort 2A: TC|
89360025|NCT04532099|Other|AOHP, then LID018869 (Part A)|Senofilcon A contact lenses worn first, followed by lehfilcon A contact lenses, as randomized. Each product will be worn bilaterally (in both eyes) for approximately 30 days, with a scheduled visit at approximately Day 15 of each wear period. Lenses will be removed nightly for cleaning and disinfection with CLEAR CARE contact lens solution.
89360026|NCT04532099|Active Comparator|Biofinity (Part B)|Comfilcon A contact lenses worn bilaterally (in both eyes) for approximately 30 days, with a scheduled visit at approximately Day 15 of the wear period. Lenses will be removed nightly for cleaning and disinfection with CLEAR CARE contact lens solution.
89360027|NCT03041792|Experimental|Active|Liraglutide
89360028|NCT03041792|Placebo Comparator|Placebo|Placebo comparator
89360029|NCT05384093|Active Comparator|Adhesive Capsulitis Study|The purpose of this study is to compare treatment efficacy of patients with symptoms of primary and secondary adhesive capsulitis between three groups: 1) Patients treated with Physical Therapy alone; 2) Patients treated with the ERMI Shoulder Flexionater® alone; 3) Patients treated with PT + Device in the treatment.
89360030|NCT05384093|Active Comparator|Post operative Shoulder Stiffness Study|The purpose of this study is to compare treatment efficacy of patients with post-operative stiffness indicative of secondary adhesive capsulitis between three groups: I) Patients treated with Physical Therapy alone; II) Patients treated with the ERMI Shoulder Flexionater® alone; III) Patients treated with PT + Device in the treatment.
89360031|NCT05384093|Active Comparator|Secondary Surgery Study|The purpose of this study is to compare recovery of patients who have undergone a manipulation under anesthesia or a lysis of adhesions between three groups: 1) Patients treated with Physical Therapy alone; 2) Patients treated with the ERMI Shoulder Flexionater® alone; 3) Patients treated with PT + Device in the treatment.
89360032|NCT03753581|Experimental|Care protocol plus microcurrents|"Standardized protocol of nursing care: postural treatment plus standardized cure.~Intervention with microcurrents: application of 2 electrodes (Mc Patch, Newmark USA) around the ulcer."
89360033|NCT03753581|Placebo Comparator|Care protocol plus placebo microcurrents|"Standardized protocol of nursing care: postural treatment plus standardized cure.~Placebo microcurrents: application of 2 electrodes (Mc Patch, Newmark USA) around the ulcer previously handled that do not emit current."
89360034|NCT04051424|Active Comparator|ConMed bite block|Standard bite block (Conmed Bite Block; Conmed Corp., Utica NY, USA)
89360035|NCT04051424|Active Comparator|Williams Airway|Williams Airway Intubator (Williams Airway Intubator Ltd, Calgary, Canada)
88831921|NCT02951195|Active Comparator|Part 2 Cohort 2B: TEZ/IVA|
88831922|NCT02951195|Experimental|Part 2 Cohort 2B: TC|
88831923|NCT02037230|Experimental|MK-1775/ Gemcitabine/ Radiation Therapy|
88831924|NCT02312882|Experimental|Tofacitinib|Participants will receive tofacitinib for 3 months.
88831925|NCT03020537|Other|Group A: 1-2 years old|Group A: 1-2 years old, seasonal influenza vaccine-naive. Given intramuscular,inactivated influenza vaccine-trivalent (IM IIV3) - Fluzone (pediatric formulation).
88831926|NCT03020537|Other|Group B: 18-30 years old|Group B: 18-30 years old, who did not receive the 20l2-2013 seasonal influenza vaccine. Given intramuscular,inactivated influenza vaccine-trivalent (IM IIV3) - Fluzone.
88831927|NCT02037776|Placebo Comparator|Rikkunshito Placebo|
88831928|NCT02037776|Active Comparator|Rikkunshito|
88831929|NCT02877095|Experimental|Active|All subjects in the pilot study will receive the subcutaneous pump to administer a special formulation of furosemide to be delivered subcutaneously.
89360036|NCT04051424|Experimental|McKay airway|A new device that enables maintenance of jaw thrust. (US patent application 16/098,530)
89360037|NCT03753503|Experimental|PD-TR|"Intervention:~exercise, dose: 8-week HIIT program (three times a week) & conventional physical therapy"
89360038|NCT03753503|Active Comparator|PD-NTR|conventional physical therapy
89360039|NCT03753503|No Intervention|Healthy controls|healthy controls without any kind of therapy
89360040|NCT03625856|Experimental|Intervention|1500 mg Chlorella Vulgaris capsule
89360041|NCT03625856|Placebo Comparator|Control|1500 mg placebo (starch)
89360042|NCT05375123||Trial group|A total of 660 singleton pregnant women in the first trimester (gestational age of 6-13 weeks + 6 days), who had normal results in various examinations and experienced regular obstetric examinations throughout the pregnancy, were selected from the obstetric outpatients in 33 centers, with 20 cases in each center.
89360043|NCT03757169|Active Comparator|Control group|Verbal informations about the disease, and exercise behavior, and nutrition.
89360044|NCT03757169|Active Comparator|Hand grip group|Three supervised sessions por week: 4 series (2 at each arm) of two minutes of isometric hand grip contraction at 30% of maximal voluntary contraction. Between series there will be two minutes to rest.
89360045|NCT05366270|Experimental|Whole Body Hyperthermia (WBH)|A single treatment of Whole Body Hyperthermia will be administered using the Heckel Hyperthermia device. During this procedure, participants' core body temperature will be elevated to 38.5 degrees Celsius.
88831930|NCT02356484||Major abdominal surgery cohort|In this surgical cohort, 4 inflammatory markers were measured: albumin, procalcitonin, CRP and lactate levels
88831931|NCT02951273||Study of cerebral blood flow|Patients undergoing oesophageal- or ventricular resection (n=30)
88831932|NCT02357264||pre-eclampsia|Ultrasound of Pregnant Females 18+ with pre-Eclampsia
88831933|NCT02357264||No pre-eclampsia.|Ultrasound of Pregnant Females 18+ with no pre-eclampsia
89360046|NCT05366270|Sham Comparator|Sham|Under the sham condition, participants will enter the Heckel Hyperthermia device as in the active treatment condition, but will not receive the whole body hyperthermia treatment, and will instead only receive mild heating.
89360047|NCT04507763||Patients with ankylosing spondylitis|Iraqi patients diagnosed with ankylosing spondylitis that received Etanercept as treatment for disease
89360048|NCT03045302|Experimental|BIM23B065|
89360049|NCT05365100|Experimental|Phase1dose escalation|Phase1 Dose Escalation Multiple dose levels of BN102 to be evaluated; determination of MTD/Phase 2 recommended dose(RP2D)
89360050|NCT05365100|Experimental|Phase2 expansion in R/R MCL with BTK inhibitor treatment history|patients must have received at least one systemic treatment and failed or relapsed, patients previous treatment should with BTK inhibitor, approximate 12-23 patients this group
89360051|NCT05365100|Experimental|Phase2 expansion in R/R MCL without BTK inhibitor treatment history|patients must have received at least one systemic treatment and failed or relapsed, patients previous treatment should without BTK inhibitor, approximate 12-23 patients this group
89360052|NCT05365100|Experimental|Phase2 expansion in R/R CLL/SLL with BTK inhibitor treatment history|patients must have received at least one systemic treatment and failed or relapsed, patients previous treatment should with BTK inhibitor, approximate 12-23 patients this group
89360053|NCT05365100|Experimental|Phase2 Expansion in R/R CLL/SLL without BTK inhibitor treatment history|patients must have received at least one systemic treatment and failed or relapsed, patents previous treatment should without BTK inhibitor, approximate 12-23 patients this group
88831934|NCT02877485|Active Comparator|Triamcinolone acetonide then Ayr spray|This study arm will start with 6 weeks of therapy with the intranasal steroid, followed by 6 weeks of therapy with a placebo, with a two week washout period in between treatments.
89360054|NCT05365100|Experimental|Phase2 Expansion in other R/R B-NHL with BTK inhibitor treatment history|patients must have received at least one systemic treatment and failed or relapsed, patents previous treatment should with BTK inhibitor, approximate 12-23 patients this group
89360055|NCT05365100|Experimental|Phase2 Expansion in other R/R B-NHL without BTK inhibitor treatment history|patients must have received at least one systemic treatment and failed or relapsed, patents previous treatment should without BTK inhibitor, approximate 12-23 patients this group
88831935|NCT02877485|Active Comparator|Ayr spray then triamcinolone acetonide|This study arm will start with 6 weeks of placebo, followed by 6 weeks of therapy with the intranasal steroid, with a two week washout period in between treatments.
88831936|NCT02404532|Experimental|1|
88831937|NCT02879747|Active Comparator|Interventional|Unchanged dose Genotropin
88831938|NCT02879747|Active Comparator|Interventional 2|reduced dose 50% Genotropin
88831939|NCT02880137|Experimental|RTMPE|RTMPE with Perflutren Lipid Microsphere (DEFINITY) is a safe and feasible non-invasive technique commonly used to diagnose coronary disease, and offers an attractive alternative for CAV detection.
88831940|NCT03023891|Experimental|Prednisone|"Each participant will received a single dose of oral 60 mg of prednisone~Visit 1: Baseline Oral Glucose Tolerance Test (OGTT) and White Blood Count (WBC) count Visit 2: Prednisone 60mg oral at 7am, OGGT and WBC count at 4 to 8 hours post drug"
88831941|NCT03026777|Experimental|Fluid Loading|(1) 500 milliliters of an intravenous crystalloid solution of the operator's choosing will be (2) infused at any time after randomization and prior to the administration of procedural medications from (3) above the level of the central or peripheral intravenous or intraosseus access used and allowed to infuse by gravity and (4) stopped after 500 mL have infused. All intravenous infusions preceding the decision to perform endotracheal intubation will not be altered.
88831942|NCT03026777|No Intervention|Usual Care|No intravenous fluids are started after the decision is made to perform endotracheal intubation. All intravenous infusions preceding the decision to perform endotracheal intubation will not be altered.
88831943|NCT03028025|Active Comparator|TR Band Only|TR Band: Patients randomly assigned to the control group will have a TR band applied over the arteriotomy site and inflated with 15-18ml of air. After aspirating and clearing the contents of the sheath, the radial sheath will be removed. The TR band will be deflated until bleeding occurs, and 2 ml of air will be reintroduced to provide hemostasis. Patent hemostasis will be documented with plethysmography and oximetry as described below within 5 minutes after band application and removal, and within 30 min of discharge or after 24 hours. The TR band will be left inflated and in place for 2 hours following the procedure for all patients (regardless of diagnostic or PCI procedure), after which deflation attempts will commence.
88831944|NCT03028025|Experimental|Statseal with TR Band|StatSeal: Patients randomly assigned to the experimental group will have a Statseal Advance (SSA) disc applied after withdrawing the radial sheath 2-4 cm. A Tegaderm dressing will be applied to secure the disc position. The TR band will be applied over the SSA disc with the center of the balloon (the green dot) over the center of the SSA disc. The TR band will be inflated with 8cc of air (which is typically occlusive pressure), and the sheath removed. No deflation will occur immediately. After 20 minutes of pressure, 3 cc of air will be removed from the TR band. After an additional 20 minutes (40 minutes after procedure), the TR band will be completely deflated, and the TR band left in place. After an additional 20 minutes (60 minutes after procedure) the TR band will be removed.
88831945|NCT02955329|Experimental|Tobacco Arm|Participants will vape tobacco leaves with nicotine out of the PAX device.
88831946|NCT02955329|Experimental|Cannabis Arm|Participants will vape marijuana leaves with THC (Tetrahydrocannabinol) out of the PAX device.
88831947|NCT02955329|Experimental|Combined Cannabis and Tobacco Arm|Participants will vape flavorless 6% nicotine e-liquid, followed by THC (Tetrahydrocannabinol) out of the PAX device.
89360056|NCT04676945||untreated control group|NO MDS disease modifying therapy
88831948|NCT02359058|Other|Ramucirumab + Capecitabine + Cisplatin|Ramucirumab (8 milligram per kilogram (mg/kg) given intravenously (IV) on days 1 and 8 in combination with 1000 mg/square meter (m^2) capecitabine given orally twice a day on days 1 through 14 and 80 mg/m^2 cisplatin given IV on day 1 of each 21 day cycle (up to 6 cycles). Participants may continue to receive treatment until discontinuation criteria are met.
88831949|NCT02359058|Other|Ramucirumab + S-1 + Cisplatin|Ramucirumab 8 mg/kg given IV on days 1 and 8 of 21 day in combination with 40 mg/m^2 tegafur/gimeracil/oteracil (S-1) given orally twice a day on days 1 through 21 and 60 mg/m^2 cisplatin given IV on day 8 of each 35 day cycle (up to 8 cycles). Participants may continue to receive treatment until discontinuation criteria are met.
89360057|NCT04676945||treated patients|ANY MDS disease modifying therapy
89360058|NCT03754595|Active Comparator|2D Laparoscopic pancreatoduodenectomy|Patients with pancreatic cancer treated by 2D Laparoscopic pancreatoduodenectomy
89360059|NCT03754595|Experimental|3D Laparoscopic pancreatoduodenectomy|Patients with pancreatic cancer treated by 3D Laparoscopic pancreatoduodenectomy
89534461|NCT00084799|Experimental|hu3S193 10 mg/m2|Patients with small cell lung cancer tumors confirmed to have Lewis Y expression were enrolled to receive 4 weekly injections of hu3S193 at a dose of 10 mg/m2. The dose of hu3S193 given on Weeks 1 and 4 was trace-labeled with 6-8 millicurie (mCi) of indium-111 (111In).
89360060|NCT00705484||Remicade Group|Participants with no prior exposure to Remicade or who have been treated with Remicade in the past, who at the time of enrollment are scheduled to receive Remicade within 30 days of the Baseline Visit. Participants who have been treated in the past with Remicade must have a Remicade-free interval of no less than 90 days from the date of the next expected infusion.
89360061|NCT00705484||Standard Therapy Group|Participants who are scheduled to receive standard therapy (defined as initiation or dose-increase of corticosteroids and/or immunosuppressants) that does not include Remicade. Standard therapy participants must not have previously received Remicade for UC or any other condition.
89360062|NCT03754517||Serofast status|The syphilitic patients who remain in a serologically positive state after therapy
89360063|NCT03754517||Untreated|untreated syphilis cases
89360064|NCT03754517||Serological cure|"In the early syphilis patients, at 6 months following treatment, a serological cure was defined as either a negative RPR or ≥2 dilution (4-fold) decrease in the RPR titer.~In the late syphilis patients, at 12 months following treatment, a serological cure was defined as either a negative RPR or ≥2 dilution (4-fold) decrease in the RPR titer."
89360065|NCT03754439||Inborn|"Infants born within Nottingham University hospitals~< 32 weeks gestational age~< 72 hours old"
89360066|NCT03754439||Transported|- Infants born outside of Nottingham University Hospitals or transferred between units Phase 1 < 32 weeks gestational age and <72 hours old Phase 2 any gestation and age
89360067|NCT03754361|Experimental|APD group|Subjects will receive PD catheter placement and subsequent automated peritoneal dialysis treatment
89360068|NCT03754361|Active Comparator|IHD group|Subjects will receive un-tunneled hemodialysis catheter placement and subsequent hemodialysis treatment 3-4 times per week,2-4 hours each time.
89360069|NCT02471872|Experimental|Air Pollution Education|Students are presented with a one-hour interactive information session about air pollution and the environment.
89360070|NCT02471872|Placebo Comparator|Non-Air Pollution Education|Students are presented with a one-hour interactive information session about vaccines.
88831950|NCT02359058|Other|Ramucirumab + S-1 + Oxaliplatin|Ramucirumab 8 mg/kg given IV on days 1 and 8 in combination with 40 mg/m^2 S-1 given orally twice a day on days 1 through 14 and 100 mg/m^2 oxaliplatin given IV on day 1 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
88831951|NCT02404610|Experimental|Moderate Procedural Sedation|Subjects will undergo procedural sedation for an indicated urgent medical procedure with a target sedation level of moderate sedation. Moderate procedural sedation is a specific term referring to procedural sedation with a target depth of moderate.
88831952|NCT02404610|Experimental|Deep Procedural Sedation|Subjects will undergo procedural sedation for an indicated urgent medical procedure with a target sedation level of deep sedation. Deep procedural sedation is a specific term referring to procedural sedation with a target depth of deep.
88831953|NCT02359916||A|Snacks sold under equal pricing, no delays
89360071|NCT05459597||Treatment|The use of antiepileptic drugs depends on the clinical practice.
89360072|NCT03754283|Experimental|Silicone|Indirect bonding performed with the silicone trays
89360073|NCT03754283|Active Comparator|Vacuum formed|Indirect bonding performed with the vacuum formed trays
89360074|NCT03753425||PEG4L, four liters polyethylene glycol|PEG4L, four liters polyethylene glycol
88831954|NCT02359916||B|Healthier snacks sold at 25% or $0.25 discount, no delays
88831955|NCT02359916||C|Less healthy snacks sold at equal pricing with delays
89360075|NCT03753425||PEG2L, two liters polyethylene glycol with ascorbic acid|PEG2L, two liters polyethylene glycol with ascorbic acid
89360076|NCT03753425||Pico, sodium picosulfate|Pico, sodium picosulfate
89360077|NCT03753425||NaP, sodium phosphate|NaP, sodium phosphate
89360078|NCT03753425||MPS, sodium, magnesium and potassium sulphates|MPS, sodium, magnesium and potassium sulphates
89360079|NCT05692310|Experimental|Patients will have a central venous line placed using an ultraportable ultrasound device.|
89360080|NCT05692310|Sham Comparator|Patients will benefit from the technique of central venous line placement by conventional ultrasound|
89360081|NCT03753269|Experimental|Fasudil Hydrochloride|Fasudil Hydrochoride will be delivered into culprit vessel right after the first wire passage
89360082|NCT03753269|Placebo Comparator|Placebo saline|Same volume of 0.9% saline will be delivered into culprit vessel right after the first wire passage
89360083|NCT03753191|Experimental|People with Dementia|Twenty subjects each group will be randomized to receive either anodal tDCS or shame tDCS over the Right iFG or Left DLPFC. A 2mA direct current for active tDCS (current density : .057 mA/cm2) with a 20 mins stimulation period
89360084|NCT03753191|Sham Comparator|Health Control|Twenty subjects each group will be randomized to receive either anodal tDCS or shame tDCS over the Right iFG or Left DLPFC. After a fade in period of 10s to mimic initial tDCS peripheral skin sensations, the stimulator will be turned off in order to prevent the induction of any neuromodulatory effect.
89360085|NCT03753035||epileptic children|Completion of questionnaire, during medical consultation, on compliance and quality of life
89360086|NCT05692076|Experimental|HVNI group|Patients will receive high velocity nasal insufflation therapy
89360087|NCT05692076|Other|Control group|Patient will receive conventional oxygen therapy via nasal prongs , normal oxygen mask or venturi mask
89360088|NCT01322789|Experimental|Intravenous mesenchymal stem cell|This group wil receive 8 intravenous infusions of mesenchymal stem cells. Four infusions 1 week apart and 4 infusions a month apart
89360089|NCT05691998||Patients|the previous prosthesis experience
89360090|NCT03754205|Experimental|Laser Group|"Microablative Fractional CO2 laser therapy at monthly intervals.~The laser parameters that will be used are the following: (1) Power: 30 ή 40 watts, 2) Dwell time:1000μs, 3) Spacing 1000 μm, 4) Depth: SmartStak parameter from 1-3 depending on the treatment status, 5) D-pulse mode."
88831956|NCT02359916||D|Healthy snacks sold at 25% or $0.25 discount, plus delays on less healthy snacks
88831957|NCT02359916||E|Less healthy snacks sold at 25% or $0.25 higher price, no delays
88831958|NCT02359916||F|Less healthy snacks sold at 25% or $0.25 higher price, plus delays
88831959|NCT02359916||G|Snacks sold under equal pricing, no delays
89360091|NCT03754205|Placebo Comparator|Placebo Group|"Placebo CO2 laser therapies at monthly intervals.~The laser parameters that will be used are the following: 1) Power: 0.5 watts, 2) Dwell time:1000μs, 3) Spacing 1000 μm, 4) Depth: SmartStak parameter 1, 5) Smart-pulse mode."
89360092|NCT05459441|Experimental|Treatment of glioma|For patients with glioma, after the patient's general condition was stable, contraindications were excluded and RAK cells were injected into Ommaya sac.
89360093|NCT05459441|Experimental|Treatment of brain metastases|For patients with brain/meninges metastasis, Ommaya capsule was placed subcutaneously after puncture under local anesthesia. Two days after surgery, chemotherapy was started when the intracranial pressure was stable and the condition was stable, and the conjunctivitis was eliminated. Intracapsular injection of autoimmune cells was started in the second week after chemotherapy.
89001019|NCT04633876|Active Comparator|Control group|The subjects allocated to this group receive some results from baseline measurements (as do subjects in the intervention) but do not receive lifestyle counselling
89360094|NCT05691842|Experimental|HIIT intervention|Patients in this group (n=22) will undergo a HIIT training protocol for 12 weeks
89360095|NCT05691842|Experimental|Dual task intervention (DT)|Patients in this group (n=22) will undergo a DT training protocol for 12 weeks
89360096|NCT05691842|No Intervention|Control group (CG)|Patients in this group (n=22) will not perform any exercise during the intervention period (12 weeks)
89360097|NCT04523831|Active Comparator|Ivermectin and Doxycycline|Ivermactin 6 mg 2 tab stat, cap Doxycycline 100 mg 1 cap BD 5 days
89360098|NCT04523831|Placebo Comparator|Placebo|Standard treatment
89001020|NCT04633876|Experimental|Individual coaching|These subjects receive individual counselling during the study.
89001021|NCT04633876|Experimental|Group coaching|These subjects receive individual counselling during the study.
89360099|NCT05691764|Experimental|Cyclosporin + RIPC|This group received cyclosporin intravenously 2 hours pre-induction of anesthesia, with the dose of 3 mg/ kg body weight. RIPC was performed preoperatively after induction of anesthesia by inflating pressure cuff on the extremity 30 mmHg higher than systolic blood pressure of the patient for 5x5 minutes with 5 minutes reperfusion interval.
89360100|NCT05691764|Placebo Comparator|Control|This group received placebo intravenously 2 hours pre-induction of anesthesia.
89360101|NCT05367167||Case group|Patients who meet the 2010 American College of Rheumatology diagnostic criteria and were diagnosed with OSAS in the sleep laboratory will be considered as the case group.
89360102|NCT05367167||Control group|Patients who did not meet the 2010 American College of Rheumatology diagnostic criteria and were diagnosed with OSAS in the sleep laboratory will be considered as the control group.
89360103|NCT04707664|Experimental|Sargramostim Arm|Day 1 - 5: Sargramostim treatment in addition to standard of care for COVID-19
89360104|NCT04707664|Placebo Comparator|Placebo Arm|Day 1 - 5: Placebo treatment in addition to standard of care for COVID-19
89360105|NCT03752879||Case (Kristaller Group)|Group of kristeller maneuver applied in the second stage of labor due to clinical necessity.
89360106|NCT03752879||Control (no Kristaller Group)|The control group not required to kristeller maneuver
89360107|NCT01316276|Experimental|LAI|590 mg LAI QD via a PARI Investigational eFlow® Nebulizer System (eFlow®) for 28 days followed by a 28-day off-treatment period. This cycle (28 days on treatment, 28 days off treatment) was to be repeated for up to 12 cycles, divided into 2 periods of 6 cycles each (approximately 12 months each).
89360108|NCT03756857|Experimental|Afterload transfer|First, an empty catheter passes to the level of the lower uterine segment under ultrasound guidance to a point where the inner catheter enters the endometrial cavity. The inner sheath is removed slowly, leaving the outer sheath just beyond the internal os. After verifying the catheter's position on the TA ultrasound scan, the physician gives the signal to the embryologist to start the embryo loading. The embryologist brings the loaded inner catheter and inserts it into the outer sheath, which is maintained in its position by the physician.
89360109|NCT03756857|Experimental|Trial Followed by Transfer|First a trial transfer is performed using both the inner catheter and outer sheath connected together in standard configuration, just before the actual embryo transfer. It is passed up to and just through the the internal os. When it appears that the actual transfer will be possible without great difficulty ,the trial catheter is withdrawn. An embryo transfer catheter is loaded and the actual transfer is performed
89001022|NCT04633720|Experimental|Evaluation of intratidal compliance|"When the patient is in the supine position 10 minutes after induction of anesthesia, the following 4 mechanical ventilator settings are applied to the patients in order.~Positive end-expiratory pressure 8 cmH2O, tidal volume 8 ml/kg~Positive end-expiratory pressure 10 cmH2O, tidal volume 5 ml/kg~Positive end-expiratory pressure 10 cmH2O, tidal volume 8 ml/kg~Positive end-expiratory pressure 12 cmH2O, tidal volume 5 ml/kg"
89360110|NCT04700566|Experimental|Injection of Renuva Allograft adipose matrix in vocal fold|Injection of Renuva Allograft Adipose matrix in the vocal fold for vocal fold medialization and treatment of glottal insufficiency
89360111|NCT02474290|Experimental|Sorafenib group|Sorafenib will be used from day 30 to 180 post-transplantation.
89360112|NCT02474290|No Intervention|non-Sorafenib group|
89360113|NCT05691608|Experimental|Patient with solid tumor or leukemia (no treatment)|Patient with solid tumor or leukemia (no treatment)
89360114|NCT03753971|Experimental|Apneas with and without intervention|Each patient will be his own control.
89360115|NCT02474212|Active Comparator|Enoxaparin 40 mg s.c.|Subcutaneous enoxaparin (Klexane®, Sanofi-Aventis) 40 mg thromboprophylaxis every 24 hours for three days (72 hours)
89360116|NCT02474212|Active Comparator|Enoxaparin 40 mg i.v.|Enoxaparin thromboprophylaxis (40 mg) daily as continuous intravenous infusion for three days (72 hours)
89360117|NCT02474212|Active Comparator|Enoxaparin 0.5 mg/kg s.c.|Subcutaneous enoxaparin (Klexane®, Sanofi-Aventis) 0.5 mg/kg thromboprophylaxis twice a day for three days (72 hours)
89360118|NCT02474212|Active Comparator|Enoxaparin 1 mg/kg i.v.|Enoxaparin thromboprophylaxis 1 mg/kg daily as continuous intravenous infusion for three days (72 hours)
89001023|NCT00201669|Experimental|Arm I|
89001024|NCT04633798|Experimental|IPL/Lipiflow|the group in which patients treated with IPL combined with lipiflow
89360119|NCT05227118|Experimental|MK-8189|Participants will be assigned to one of the following regimens: Titration 1: 4 mg x 2 tablets Days 1-3; 4 mg x 1 tablet & 12 mg x 1 tablet Days 4-28 OR Titration 2: 4 mg x 2 tablets Days 1-3; 4 mg x 1 tablet & 12 mg x 1 tablet Days 4-6; 12 mg x 2 tablets Days 7-28 OR Titration 3: 4 mg x 1 tablet Days 1-3; 4 mg x 2 tablets Days 4-6; 4 mg x 1 tablet & 12 mg x 1 tablet Days 7-9; 12 mg x 2 tablets Days 10-28.
89360120|NCT05227118|Placebo Comparator|Placebo|Participants will be assigned to one of the following regimens: Titration 1: 2 tablets Days 1-28 OR Titration 2: 2 tablets Days 1-28 OR Titration 3: 1 tablet Days 1-3; 2 tablets Days 4-28.
89360121|NCT03756779|Experimental|Low Saturated Fat Diet|Goal will be to attain <7% of daily calories from saturated fat. Replace it with energy from monounsaturated fat.
89360122|NCT03756779|Active Comparator|High Saturated Fat Diet|Goal will be to attain 15% of daily calories from saturated fat. Decrease intake of monounsaturated fat.
89360123|NCT05200286|Experimental|Severe renal impairment|120 mg olorofim
89360124|NCT05200286|Active Comparator|Normal renal function|120 mg olorofim
89360125|NCT03753815|Active Comparator|19G FNA needle|Patients referred for EUS-guided tissue acquisition of AIP
89360126|NCT03753815|Active Comparator|20G FNB needle|Patients referred for EUS-guided tissue acquisition of AIP
89360127|NCT02474446|Experimental|1|"Anthropometry measurement, Skin colour grading using Fitzpatrick scale, Dietary intake of calcium and vitamin D using food frequency questionnaire (FFQ), Baseline fasting blood samples for vitamin D, VDBP, VDBP genotype, Calcium, Phosphorus, Albumin, Parathyroid Hormone(PTH), Alkaline Phosphatase, Bone turnover markers(P1NP, CTX).~Fasting urine for Calcium Creatinine ratio. Saliva for bio-available Free Vitamin D measurement.~Vitamin D administration under direct supervision. Spot Urine sample for calcium : creatinine ratio after a week. Repeat all measurements done at baseline except VDBP genotype 4 weeks from baseline."
89360128|NCT05199818|Experimental|Palonosetron HCl Buccal Film|Palonosetron HCl Buccal Film 0.5 mg 1 hr before administration of moderately emetogenic chemotherapy and normal saline injection 30 minutes before administration of moderately emetogenic chemotherapy
89360129|NCT05199818|Active Comparator|Palonosetron IV Injection|Placebo buccal film 1 har before administration of moderately emetogenic chemotherapy and Palonosetron HCl Injection 0.25 mg 30 min before administration of moderately emetogenic chemotherapy
89360130|NCT03753737||Chemsex|Men who have Sex with Men (MSM) attending an addiction care center for past or present mild, moderate or severe substance-related disorder(s) according to DSM-V criteria, occurring in a sexual context and concerning cathinones, GHB/GBL, methamphetamine, cocaine and/or ketamine.
89360131|NCT03753737||Control|Men who have Sex with Men (MSM) consulting for a PrEP (HIV Pre-Exposure Prophylaxis) prescription who have never used cathinones, GHB/GBL, methamphetamine, cocaine or ketamine before or during sex.
89360132|NCT03752645|Experimental|intervention|Transverse Many Channels Laser Instrument
89360133|NCT03752645|No Intervention|control|
89360134|NCT02474134|Other|PF530/Betaferon|Single subcutaneous injection of two interferon beta-1b products (PF530 and Betaferon) 0.25 mg
89360135|NCT02474134|Other|Betaferon/PF530|Single subcutaneous injection of two interferon beta-1b products (Betaferon and PF530) 0.25 mg
89360136|NCT04668989|Experimental|stenfilcon A - (Test lens)|Subjects will be randomized to wear test lenses for one week then cross-over to the control lenses for one week.
89360137|NCT04668989|Active Comparator|kalifilcon A - (Control Lens)|Subjects will be randomized to wear control lenses for one week then cross-over to the test lenses for one week.
89360138|NCT03752489|Experimental|Fluid treatment-specific algorithm|The experimental arm will involve patients monitored by the fluid treatment-customized version of InSight.
89360139|NCT03752489|Active Comparator|Standard InSight|The control arm will involve patients monitored with the standard, non-treatment specific version of InSight.
89360140|NCT02473900|Experimental|Sequence 1|HIP1403→HGP0919
89360141|NCT02473900|Experimental|Sequence 2|HGP0919→HIP1403
89360142|NCT04513691||Sample|Asymptomatic newborns 35 weeks or greater GA born at Banner - University Medical Center Phoenix whose mothers were determined or suspected to have CAM.
89360143|NCT02471638|Experimental|Single arm study|PQ Bypass System for Femoropopliteal Bypass to complete percutaneous fem-pop bypass
89360144|NCT04689178|Experimental|Invitation letter + GP reminder (Arm 1)|
89360145|NCT04689178|Active Comparator|Invitation letter (Arm 2)|
89360146|NCT04689178|No Intervention|Usual care (Arm 3)|
89360147|NCT03700385|Experimental|IOWA Approach Endocardial Ablation|Subjects who are treated with the IOWA Approach Endocardial Ablation System for paroxysmal atrial fibrillation.
89360148|NCT02471950||Elective Cardiac surgery|Those patients scheduled for elective heart surgery requiring cardiopulmonary bypass who will be given 2.5% isoflurane while on bypass.
89360149|NCT02471794|No Intervention|Standard Shared Medical Appointment|The SMA group will be a standard shared diabetes medical appointment group consisting of up to 10 patients that utilizes the design and curriculum of the SMAs that are currently being held at the Duke Family Medicine Center.
89360150|NCT02471794|Experimental|Personalized Health Planning Shared Medical Appointment|The PHP SMA group will combine personalized health planning with a modified version of the standard shared diabetes medical appointment. Modifications include: a self-assessment of health status, greater emphasis on a collaborative patient-provider health goal-setting process, a plan to meet goals, a mindfulness practice included in each session, and the creation of a 'personalized health plan' participant notebook for each individual to document health goals and track progress to review at each session. The participant notebook also includes educational handouts and worksheets to complement the educational curriculum.
89360151|NCT02471794|No Intervention|Retrospective|A retrospective chart review will be conducted once all participants (both SMA group and PHP SMA group) complete the intervention. The retrospective chart review will collect healthcare utilization data six months prior, during, and after each subject's participation in the SMA.
89360152|NCT01322867|Active Comparator|Reference Drug|
89360153|NCT01322867|Active Comparator|Test Drug|
89534462|NCT00084799|Experimental|hu3S193 20 mg/m2|Patients with small cell lung cancer tumors confirmed to have Lewis Y expression were enrolled to receive 4 weekly injections of hu3S193 at a dose of 20 mg/m2. The dose of hu3S193 given on Weeks 1 and 4 was trace-labeled with 6-8 millicurie (mCi) of indium-111 (111In).
89360154|NCT04624828|Experimental|Stereotactic body radiation treatment (SBRT)|"RT treatment Schedule as for clinical practice: Stereotactic body radiation treatment (SBRT) will be delivered with image guidance (image-guided radiation therapy or IGRT) and in the form of volumetric modulated arc therapy (VMAT).~RT treatment Schedule: SBRT will be delivered in 1 to 6 fractions on bone or lymph node metastases. The dose and fractionation schedule will depend on the size and location of the lesion and the surrounding normal tissue constraints."
89360155|NCT02474056||trauma patients|patients with decreased blood volume
89360156|NCT02474056||surgical patients|patients with decreased blood volume
89360157|NCT02474056||non surgical patients|patients with decreased blood voloume
89360158|NCT02473978||Participants undergoing cesarean sections|The participants preoperative data will be compared to intraoperative data and analyzed in order to evaluate the dynamic cerebral oxygen and blood perfusion changes in participants undergoing cesarean sections.
89360159|NCT02473978||Participants throughout cesarean sections|The participants intraoperative data will be compared to preoperative data and analyzed in order to evaluate the dynamic cerebral oxygen and blood perfusion changes in participants undergoing cesarean sections.
89360160|NCT02477722|Experimental|EFP-NF|Subjects are asked to change their brain activity in response to feedback they receive from the brain itself, mediated via various visual or auditory stimuli.
89360161|NCT02477722|Sham Comparator|Sham-NF|Placebo
89360162|NCT04491760|Experimental|Inspiratory muscle training|Inspiratory muscle training (IMT) will be perform for 15 minutes each time, twice a day, training every day from 12h to 24h after primary percutaneous coronary intervention (PCI) to 30 days since randomized.
89360163|NCT04491760|No Intervention|Control group|Participants will receive standard care according to the current guideline and clinical practice after primary PCI.
89360164|NCT03750929|No Intervention|Non physical exercises|Patients will not be submmitted to combined acute physical exercises (strength and aerobic)
89360165|NCT03750929|Experimental|Physical exercises|Patients will be submmitted to combined acute physical exercises (strength and aerobic) that consist on: supine, paddling, leg press 45º, knee extensor, flexor knee (two sets of 15 to 20 repetitions, with loads between 30% and 40% of a maximum repetition, with 30 seconds of interval). We will perform in the first exercise for upper and lower limbs, for heating, after starting the training where 4 series of 8 to 12 maximum repetitions will be performed, using the load between 70% and 80% of 1 maximum repetitions, already evaluated. The recovery between sets will be 90 seconds and between exercises will be 120 seconds.
89360166|NCT04585594|Experimental|Mi Propio Camino (MPC; My Own Way)|Participants will complete the MPC intervention alongside usual care for hypertension
89360167|NCT04585594|Active Comparator|Habilidades para Controlar la Presion (HCP; Skills for Blood Pressure Control)|Participants will complete the HCP intervention alongside usual care for hypertension.
89360168|NCT04498403|Experimental|Crisaborole 2%|Crisaborole 2% ointment applied twice daily (BID)
89360169|NCT02471560|Experimental|dimethyl fumarate|As prescribed by the Investigator according to the local Summary of Product Characteristics.
89360170|NCT02471560|Active Comparator|injectable MS DMT|As prescribed by the Investigator according to the local Summary of Product Characteristics.
89001025|NCT04633798|Active Comparator|IPL/MGX|the group in which patients treated with IPL combined with meibomian gland massage
89360171|NCT02477488|Experimental|Allopurinol HS|Allopurinol at bedtime compared to AM administration
89360172|NCT03750851|Placebo Comparator|GPlacebo|In this group, a water soluble gel without addition any desensitizing agent (K-Y®, Johnson & Johnson, Brazil) was applied to hypersensitive dentin. The GPlacebo volunteers were submitted to the application of placebo dentifrice on the vestibular surfaces of hypersensitive teeth with the aid of a microbrush applicator (Microbrush, 3M ESPE, Brazil) and left undisturbed on the surface during 05 minutes. Then, a rubber cup (Unid Microdont, Brazil) mounted on a low speed handpiece (500, Kavo, Germany) was used to scrub the placebo gel for 20 seconds on each tooth.
89360173|NCT03750851|Experimental|GCPPACPF|In this group, a toothpaste MI Paste Plus™ (Recaldent™, GC América, USA) was applied to hypersensitive dentin. The GCPPACPF volunteers were submitted to the application of the paste dentifrice on the vestibular surfaces of hypersensitive teeth with the aid of a microbrush applicator (Microbrush, 3M ESPE, Brazil) and left undisturbed on the surface during 05 minutes. Then, a rubber cup (Unid Microdont, Brazil) mounted on a low speed handpiece (500, Kavo, Germany) were used to scrub the desensitizing gel for 20 seconds on each tooth.
89360174|NCT03750851|Experimental|GLaser|In this group, the diode laser with an active medium of Asauxa bauxite (Photon Lase III, DMC Equipamentos Ltda, Brazil) was applied in hypersensitive dentin. GLaser received the laser application using the infrared light spectrum with wavelength of 808 nm with its active AsGaAl medium in two points of the vestibular face of the hypersensitive teeth. It was applied at each point 60 J / cm², for 16 seconds. The laser was applied in 3 sessions with a time interval of 24 hours between them.
89534463|NCT00072410|Experimental|Cohort 1|Patients received a single intraperitoneal (IP) dose of 10 mg of hu3S193 radiolabeled with 10 millicuries (mCi) 90Y and 5mCi 111In-hu3S193 to enable imaging after dosing.
88831960|NCT02405390|Experimental|Video Laryngoscopy|Some patients will be intubated with a video laryngoscope 'Storz C-Mac® laryngoscope'
88831961|NCT02405390|Active Comparator|Direct Laryngoscopy|Some patients will be intubated with a direct (conventional) laryngoscope
88831962|NCT02881775|Experimental|rTMS and exercise, then Sham rTMS and exercise|At lab visit, subjects receive repetitive transcranial magnetic stimulation (rTMS) at 10 Hz, 5 sec on, 55 sec off and quadriceps isometric exercise (5% MVIC) for 15 minutes. This is followed by a wash out period of 1 week. At the next lab visit, subjects receive sham rTMS and exercise using the same parameters.
88831963|NCT02881775|Sham Comparator|Sham rTMS and exercise, then rTMS and exercise|"At lab visit, subjects receive sham repetitive transcranial magnetic stimulation (rTMS) at 10 Hz, 5 sec on, 55 sec off and quadriceps isometric exercise (5% MVIC) for 15 minutes. This is followed by a wash out period of 1 week. At the next lab visit, subjects receive the true rTMS and exercise using the same parameters."
88831964|NCT03109769|Experimental|Mobile phone application|Subjects in this group received a mobile phone application that sends active reminder notifications of oral hygiene 3 times a day.
89360175|NCT03750851|Experimental|GLaserCPPACPF|In this group the laser + CPP-ACPF was applied. The laser was used with light intensity medium Asauxa (Photon Lase III, DMC Equipamentos Ltda, Brazil) and a toothpaste containing CPP-ACPF MI Paste Plus™ (Recaldent™, GC América, USA) was applied in hypersensitive dentin. GLaserCPPacpf first named a toothpaste application and them the laser application, according to the manufacturer's recommendations.
89360176|NCT05163106|Experimental|Ribociclib and Letrozole Arm|Patients entered into this study will be given letrozole (FemarTM) in combination with ribociclib (KisqaliTM) for at least 6 months. Premenopausal women will also receive treatment with goserelin 3.6 mg s.c. every 4 weeks.
89360177|NCT02477410|Experimental|Hydrolysed porcine protein from blood|Dietary intervention with hydrolysed porcine protein from blood
89360178|NCT02477410|Experimental|Hydrolysed porcine protein from muscle|Dietary intervention with hydrolysed porcine protein from muscle
89360179|NCT02477410|Experimental|Hydrolysed whey protein|Dietary intervention with hydrolysed whey protein
89360180|NCT02473666||All Health Conditions.|All Health Conditions. Area of Focus: Transfusions of blood products.
89360181|NCT05594524|Experimental|Body Confident Athletes|Participants in the intervention condition will take part in an in-person program consisting of three sessions over three weeks.
89360182|NCT05594524|No Intervention|Waitlist control|Participants will not be explicitly told their study condition, although they will be made aware of the assessment time points and whether they will receive access to the intervention after the first survey (intervention group) or after follow-up assessments (waitlist control group). Following completion of follow-up assessments, the control condition will get access to the intervention, but they will not be monitored or assessed.
89360183|NCT02471248|Experimental|Ankle Robot with Power Assistance|In this experimental group, the Ankle Robot assists the ankle dorsiflexion when the stroke patients voluntarily perform the swing phase gait movement.
89360184|NCT02471248|Placebo Comparator|Sham group|In this sham group, the Ankle Robot provides very low assistance to generate tactile feedback to the stroke patients indicating they are performing the swing phase gait movement, but no assistance will be given to support their ankle dorsiflexion.
89360185|NCT02477254||SLE patients|SLE patients who received HPV vaccination
89360186|NCT02477254||Control subjects|Healthy subjects who received HPV vaccination
89360187|NCT04362137|Experimental|Ruxolitinib 5 mg|Ruxolitinib 5 mg tablets twice daily (b.i.d.) for 14 days with possible extension of treatment to 28 days
89360188|NCT04362137|Placebo Comparator|Placebo|Matching-image placebo for 14 days with possible extension of treatment to 28 days
88831965|NCT03109769|Active Comparator|Verbal oral hygiene instructions|Subjects in this group received verbal oral hygiene instructions during their regular orthodontic visits every 4 weeks.
89360189|NCT04491916|Experimental|Iron Treatment|Treatment with iron sucrose with orginal guideline from ferritin>500ng/ml, or TSAT>20% to ferritin>800ng/ml, or TSAT>50%.
89360190|NCT02473588|Other|LTIA Group|Patients in the LTIA Group (all patients) will have blood pressure recorded continuously. LTIA will be used to measure stroke volume and cardiac output after the completion of data collection
89360191|NCT02477098|Experimental|Pre RSB|patients who receive preoperative rectus sheath block of ropivacaine hydrochloride and receive postoperative rectus sheath block of saline
88831966|NCT02957123|Experimental|Intranasal auto-M2-BFs|"Intranasally-Administered Bioactive Factors, Produced by Autologous M2 Macrophage (auto-M2-BFs). M2 macrophages were generated in vitro from peripheral blood of patients during 7 days.Cell-free culture medium, containing auto-M2-BFs, was collected and aliquots of 2 mL/vial were cryopreserved.~30 patients with organic brain syndrome will receive auto-M2-BFs with the aerosol inhaler device (nebulizer), 2.0 mL once a day up to 30 days."
88831967|NCT03110003|Active Comparator|10 mg Bupivacaine|Subjects will receive 10 mg of preservative-free isobaric bupivacaine with 12.5mcg of fentanyl.
88831968|NCT03110003|Active Comparator|5 mg Bupivacaine|Subjects will receive 5 mg of preservative-free isobaric bupivacaine with 12.5mcg of fentanyl in combination with 10 mL of sterile saline injected into the epidural space.
88831969|NCT03110471||Glangarnant Care Home|This is a 'before and after' observational study involving 10 care homes, listed below as groups. The investigators will observe the changes in detection and management of adverse drug reactions between usual care and with administration of the West Wales ADR Profile. Usual care will be provided before and during the intervention period.
88831970|NCT03110471||Fieldbay Care Homes|All groups are having identical intervention, so the above text applies to all.
88831971|NCT03110471||Neuadd Drymmau Care Home|As above
89360192|NCT02477098|Experimental|Post RSB|patients who receive preoperative rectus sheath block of saline and receive postoperative rectus sheath block of Ropivacaine hydrochloride
89360193|NCT03752255|Experimental|Anxiety measurement method|Before the operation, patients in the experimental group will fill the anxiety scales (DAS and STAI). Then patients will watch a video about impacted tooth. This video will include the complications that patients may face and what should be done after the procedure. After the watching the video, patients will fill the both DAS and STAI.
89360194|NCT03752255|Placebo Comparator|Control|Before the operation, patients in the experimental group will fill the anxiety scales (DAS and STAI). The verbal information in detail will be given to the patients by the surgeon.This verbal information will include the complications that patients may face and what should be done after the procedure.
89360195|NCT05099380|Experimental|TEST lens|Eligible subjects that are habitual wearers of silicone hydrogel spherical contact lenses will be randomized to the TEST Lens for the duration of the study.
89360196|NCT05099380|Active Comparator|CONTROL lens|Eligible subjects that are habitual wearers of silicone hydrogel spherical contact lenses will be randomized to the CONTROL Lens for the duration of the study.
88831972|NCT03110471||Monkstone House,|As above
89360197|NCT03108742|Experimental|dermal stapler|
89360198|NCT03108742|Active Comparator|classic intradermal suture|
88831973|NCT03110471||Danygraig House|As above
88831974|NCT03110471||Ty Coch|As above
88831975|NCT03110471||Swn y mor|As above
88831976|NCT03110471||Hengoed court|As above
88831977|NCT03110471||Hengoed park|As above
88831978|NCT03110471||Cefn Lodge care home|As above
88831979|NCT02957357||National Cancer Data Base|Patients within the National Cancer Database with newly diagnosed prostate cancer between 2004 and 2010. Participating institutions each provided a random of sample of 10 patients to be included in the final cohort.
89178071|NCT00624286|Experimental|Indacaterol 150 μg|Patients inhaled indacaterol 150 μg once daily in the morning between 8:00 AM and 11:00 AM via a single-dose dry-powder inhaler (SDDPI) for 12 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
88831980|NCT02957357||NC ProCESS|The North Carolina Prostate cancer Comparative Effectiveness & Survivorship Study (NC ProCESS) is a prospective population-based cohort of >1,000 patients with newly diagnosed prostate cancer, enrolled from January 2011 through June 2013.
88831981|NCT03111407|Other|iAssist group|patients will have primary total knee arthroplasty with the iAssist. The iAssist Knee System is a computer assisted stereotaxic surgical instrument system to assist the surgeon in the positioning of orthopedic implant system components intra-operatively. It involves surgical instruments and position sensors to determine alignment axes in relation to anatomical landmarks and to precisely position alignment instruments and implant components relative to these axes.
88831982|NCT03111407|Other|conventional instrumentation|patients will have primary total knee arthroplasty with the conventional instrumentation.
88831983|NCT02958995||Full KPNC Cohort|Participants who were members of the KPNC registry (with or without diabetes) were followed up to 15 years (1997-2011) in this epidemiological study.
88831984|NCT02958995||Survey Responders|A subset of KPNC members who completed the Kaiser Diabetes Registry Survey in 1994-1996 and among a random sample of KPNC members who completed the Member Health Survey (MHS), in 1996, 1999, 2002, or 2005 were followed up to 15 years (1997-2011) in this epidemiological study.
88831985|NCT03032393|Experimental|Dominant|Subjects in the experimental group were instructed to stand with hands on their hips, elbows pointing out and feet approximately one foot apart for 20 seconds.
88831986|NCT03032393|Active Comparator|Submissive|Subjects in the control group were instructed to stand with hands and arms wrapping around the torso and feet together for 20 seconds.
88831987|NCT03114683|Experimental|IBI308|
88831988|NCT02959307|Experimental|Transcranial Light Therapy|Transcranial light therapy penetrates the skin and brain using light energy and, the light energy may activate under-stimulated brain regions.
88831989|NCT02959307|Sham Comparator|Sham Transcranial Light Therapy|For the sham group, The transcranial light therapy device uses nonpenetrating light emitting diode light energy. The sham controls for which participants improve from the actual transcranial light therapy treatment and which participants improve during the study for reasons other than the therapy
88831990|NCT03114995|Experimental|Group A (high platelet reactivity - tirofiban)|Patients with high platelet reactivity unit (230 or higher) Tirofiban administered dose: 0.4 μg/kg/min continuous infusion for 30 min and then 0.10 μg/kg/min continuous infusion for 12 h
88831991|NCT03114995|No Intervention|Control C1 (high platelet reactivity - no tirofiban)|Patients with high platelet reactivity unit (230 or higher) Tirofiban was not administered
88831992|NCT03114995|No Intervention|Control C2 (low platelet reactivity - no tirofiban)|Patients with low platelet reactivity unit (less than 230) Tirofiban was not administered
88831993|NCT02959853|Placebo Comparator|weight loss|Patients given counseling on diet and exercise in order to achieve a goal weight loss of 10 percent
88831994|NCT02959853|Experimental|aromatase inhibitor (anastrazole) plus weight loss|Patient placed on an aromatase inhibitor anastrazole 1 mg daily plus given counseling on diet and exercise in order to achieve a goal weight loss of 10 percent
88831995|NCT03036215|No Intervention|Traditional Self-Care Control Arm|Traditional self-care includes focusing on rest and healing through changes in chewing, diet, heat/cold, over the counter analgesics, and reducing strain from oral and sleeping habits. Participants will also participate in usual care from the dentist such as a splint or anti-inflammatory medications. Participants will complete follow-up measures at 8-weeks (post-intervention) and at 16-weeks (2 months after program end). .
88831996|NCT03036215|Experimental|PACT Experimental Arm|If selected for the PACT care arm, participant will be prompted to complete a self-management program, entitled Personalized Activated Care and Training (PACT) that is a tailored 8-week progressive web-based training program supported by a health coach to enhance understanding, compliance, and success in improving TMD pain. Participant will also participate in usual care from the dentist such as a splint or anti- inflammatory medications.Participant will complete follow-up measures at 8-weeks (post-intervention) and at 16-weeks (2 months after program end).
89001026|NCT04633525|Experimental|Optimum Cup Orientation|
89001027|NCT00201708|Active Comparator|Arm A (Docetaxel before doxorubicin/cyclophosphamide)|"Docetaxel 75 mg/m2 every 2 weeks for 4 cycles followed by A (doxorubicin) 60 mg/m2 & C (cyclophosphamide) 600 mg/m2 every 2 weeks for 4 cycles."
89360199|NCT02473744|Experimental|Oedematous lower limb subcutaneous drainage|In case of lymphoedema in palliative situation, a subcutaneous drainage can be performed. It is a simple method, easy to use. After topic analgesia, three subcutaneous channels are created and an absorbent pad collects the lymphatic fluid.
89360200|NCT02476942||Cohort A: Adults and Adolescents with FVIII Inhibitors|Adults and adolescents with hemophilia A of any severity with the presence of FVIII inhibitors will be observed.
89360201|NCT02476942||Cohort B: Children with FVIII Inhibitors|Children with hemophilia A of any severity with the presence of FVIII inhibitors will be observed.
89360202|NCT02476942||Cohort C: Adults and Adolescents without FVIII Inhibitors|Adults and adolescents with severe hemophilia A without the presence of FVIII inhibitors will be observed.
89360203|NCT04447456||Surgery|
89360204|NCT04447456||Radiotherapy|
89360205|NCT02473432|Experimental|RMT + usual care|Device: Orygen-Dual® valve trainer Intensity: 30% of maximal respiratory pressures (increasing intervals: 10 cmH2O per week) Training schedule: 5 sets of 10 repetitions followed by 1-2 minutes of unloaded recovery breathing off the device, two sessions per day, 5 days per week, for 3 weeks.
89360206|NCT02473432|Experimental|NMES + usual care|Device: Vital Stim (Chattanooga Group, Hixson, TN, USA) Administration of 80 Hz transcutaneous electrical biphasic stimulus Schedule: 40 minutes per day, 5 sessions per week during hospitalization in the Neurorehabilitation ward (3 weeks approx).
89360207|NCT02473432|Active Comparator|Usual care|Usual care (standard multidisciplinary inpatient rehabilitation program) consisting of physical, occupational and speech therapy sessions to improve activities of daily life, mobility and communication skills (minimum 3 hours per day, 5 days a week, during 3 weeks), Standard swallow therapy (usual care of dysphagia in stroke patients) consists of physiotherapy, occupational therapy and speech therapy targeting specific swallow impairments. In the case of dysphagia, the standard pattern includes measures to protect the airway and compensatory techniques.
89360208|NCT02473354|Other|Resp Depression Sequence 1 - 3|"Sequence #1: breathe 21% through the facemask and increase ventilation to achieve a target hypocapnic ET CO2 of 25 - 30 mmHg. Subject will then breathe a gas mixture containing 6% CO2 / 30% O2 to achieve a target hypercapnic ET CO2 up to 60 mmHg or HCVR is terminated at the discretion of the PI.~Sequence #2: breathe 21% O2 (normoxia) before remifentanil administration Sequence #3: breathe 50% O2 (hyperoxia) before remifentanil administration"
89360209|NCT04382638|Experimental|RCO group|Patients in the experimental group will receive RCO fabrication with standard level of care for bracing, which consists of education on general exercises for spinal movement, strengthening, and balancing. These patients will attend study assessments at baseline, 3 months, 6 months, 12 months and every year until they reach skeletal maturity or if surgical intervention is required.
89360210|NCT04382638|Active Comparator|TLSO group|Patients in the experimental group will receive TLSO fabrication with standard level of care for bracing, which consists of education on general exercises for spinal movement, strengthening, and balancing. These patients will attend study assessments at baseline, 3 months, 6 months, 12 months and every year until they reach skeletal maturity or if surgical intervention is required.
89360211|NCT02470936|Experimental|Group 1- Lifestyle Intervention|Men will receive a web-based, personalized lifestyle program. They will receive personalized prostate cancer-specific lifestyle recommendations on specific habits based on their eligibility survey responses. They will have access to the website composed of four topic areas (get active, eat well, stop smoking, and find support), receive a Fitbit and access to a Fitbit account and community group, and receive text messages and refrigerator magnet to reinforce behaviors. The website will be updated frequently with new tips and material and two weekly blogs will be maintained. Final content is reviewed by study investigators and patient advocates. Men will complete an intervention acceptability survey (acceptability of the website and intervention components) at 3 months.
89360212|NCT02470936|No Intervention|Group 2 - Control|Men randomized to the control group will receive standard of care. They will receive access to the website and personalized lifestyle recommendations on the 8 healthy habits targeted in the study after the 3 month trial.
89360213|NCT03628612|Experimental|AUTO CAR T cell therapy|Patients who received previous treatment with AUTO CAR T Cell Therapy
89360214|NCT02470858|Experimental|LDV/SOF+ASV|Participants with genotype 1b HCV infection will receive LDV/SOF FDC + ASV 3 weeks.
89360215|NCT02470858|Experimental|SOF+DCV+SMV|Participants with genotype 1b HCV infection will receive SOF + DCV + SMV for 3 weeks.
89360216|NCT02470858|Experimental|SOF+DCV+ASV|Participants with genotype 1b HCV infection will receive SOF + DCV + ASV for 3 weeks
89360217|NCT02473198|Active Comparator|Femoral Nerve Block (Group 1)|"In group1 (standard group) all patients receive the standard current perioperative pain management protocol for TKR.~The patient will then undergo an ultrasound guided femoral nerve block with bupivacaine 0.25% 20 cc. Intraoperatively prior to cementing of the TKR, patients will also receive a local anesthetic injection of a mixture of 30cc 0.25% bupivicaine with epinephrine, 30mg of toradol and 10 mg of morphine sulfate into the posterior capsule of the knee joint. Postoperatively patients will receive narcotic pain medication on a PRN basis."
89360218|NCT02473198|Experimental|Exparel (Group 2)|Group 2 will receive standard perioperative pain management for TKR; will undergo placebo femoral nerve block under ultrasound guidance with normal saline (NS) 20 cc. Following femoral bone cuts they will receive local anesthetic injection mixture of 30cc 0.25% bupivicaine with epinephrine 20 cc of preservative free normal saline, 30mg of toradol and 10 mg of morphine sulfate into the periarticular tissues including periosteum, joint capsule and posterior capsule of the knee joint and collateral ligaments and subcutaneous tissues. Prior to cementing prosthesis, a second injection with mixture of 20mL 1.3% Exparel and 40mL normal saline solution will be injected into the same tissues, joint capsules and collateral ligaments.
89360219|NCT03614728|Experimental|Part 1: Participants receiving GSK3326595|
89360220|NCT03614728|Experimental|Part 2 Dose escalation : Participants receiving GSK3326595+5-Azacitidine|
89360221|NCT03614728|Experimental|Part 2 Dose expansion: Participants receiving GSK3326595+5-Azacitidine|
89360222|NCT03154086|Experimental|Part A: Cohort 1: Placebo/GSK3352589 5mg/15mg/50mg|Subjects will receive single oral dose of placebo tablet in Period 1 followed by GSK3352589 5 milligrams (mg) tablet in Period 2 followed by GSK3352589 15 mg tablet in Period 3 followed by GSK3352589 50 mg tablet in Period 4 of Cohort 1 in Part A of the study. Subjects will return for their next scheduled dosing period approximately 14 days (wash out period) after administration of the study drug during the prior dosing period.
89534464|NCT00072410|Experimental|Cohort 2|Patients received a single intraperitoneal (IP) dose of 10 mg of hu3S193 radiolabeled with 15 millicuries (mCi) 90Y and 5mCi 111In-hu3S193 to enable imaging after dosing.
89360223|NCT03154086|Experimental|Part A:Cohort 1:GSK3352589 2mg/ Placebo/GSK3352589 15mg/50mg|Subjects will receive single oral dose of GSK3352589 2 mg tablet in Period 1 followed by Placebo tablet in Period 2 followed by GSK3352589 15 mg tablet in Period 3 followed by GSK3352589 50 mg tablet in Period 4 of Cohort 1 in Part A of the study. Subjects will return for their next scheduled dosing period approximately 14 days (wash out period) after administration of the study drug during the prior dosing period.
89360224|NCT03154086|Experimental|Part A:Cohort 1: GSK3352589 2mg/5mg/Placebo/GSK3352589 50mg|Subjects will receive single oral dose of GSK3352589 2 mg tablet in Period 1 followed by GSK3352589 5 mg tablet in Period 2 followed by Placebo tablet in Period 3 followed by GSK3352589 50 mg tablet in Period 4 of Cohort 1 in Part A of the study. Subjects will return for their next scheduled dosing period approximately 14 days (wash out period) after administration of the study drug during the prior dosing period.
89360225|NCT03154086|Experimental|Part A:Cohort 1: GSK3352589 2mg/5mg/15mg/Placebo|Subjects will receive single oral dose of GSK3352589 2 mg tablet in Period 1 followed by GSK3352589 5 mg tablet in Period 2 followed by GSK3352589 15 mg tablet in Period 3 followed by Placebo tablet in Period 4 of Cohort 1 in Part A of the study. Subjects will return for their next scheduled dosing period approximately 14 days (wash out period) after administration of the study drug during the prior dosing period.
89360226|NCT03154086|Experimental|Part A:Cohort 2: GSK3352589 25mg Fasted/GSK3352589 25mg Fed|Subjects will receive single oral dose of GSK3352589 25 mg tablet in Period 1 (fasted state) and Period 2 (fed state). Subjects will return for their next scheduled dosing Period approximately 14 days (wash out period) after administration of the study drug during the prior dosing period.
89360227|NCT03154086|Experimental|Part A: Cohort 2: Placebo Fasted/Placebo Fed|Subjects will receive single oral dose of placebo tablet matching GSK3352589 25 mg in Period 1 (fasted state) and Period 2 (fed state). Subjects will return for their next scheduled dosing period approximately 14 days (wash out period) after administration of the study drug during the prior dosing period.
89360228|NCT03154086|Experimental|Part A:Cohort 3: GSK3352589 150 mg/Placebo|Subjects will receive single oral dose of GSK3352589 150 mg tablet in Period 1 followed by placebo tablet matching GSK3352589 150 mg in Period 2 in Cohort 3 of Part A. Subjects will return for their next scheduled dosing period approximately 14 days (wash out period) after administration of the study drug during the prior dosing period.
89360229|NCT03154086|Experimental|Part A:Cohort 3: Placebo/GSK3352589 400 mg|Subjects will receive single oral dose of placebo tablet matching GSK3352589 400 mg in Period 1 followed by single oral dose of GSK3352589 400 mg tablet in Period 2 in Cohort 3 of Part A. Subjects will return for their next scheduled dosing period approximately 14 days (wash out period) after administration of the study drug during the prior dosing period.
89360230|NCT03154086|Experimental|Part A:Cohort 3: GSK3352589 150mg/GSK3352589 400mg|Subjects will receive single oral dose of GSK3352589 150 mg tablet in Period 1 followed by GSK3352589 400 mg tablet in Period 2 in Cohort 3 of Part A. Subjects will return for their next scheduled dosing period approximately 14 days (wash out period) after administration of the study drug during the prior dosing period.
89360231|NCT03154086|Experimental|Part B: GSK3352589|Subjects will receive repeat oral doses of GSK3352589 of 5 mg, 15 mg, 50 mg, 100 mg or 200 mg twice daily administered for 14 days.
89360232|NCT03154086|Placebo Comparator|Part B: Placebo|Subjects will receive repeat oral doses of placebo twice a day tablet administered for 14 days.
89360233|NCT02471482|Experimental|Music First group|"Mozart music lullaby for 30 minutes with recording of cerebral oxygenation (by using Near infrared spectroscopy) and vital signs (respiratory rate, heart rate, oxygen saturations and frequency of apneic episodes continuously) followed by 10 minutes of washout period and then period of no music for next 30 minutes (with same variables recorded as outlined for music session).~This cycle is repeated every 6 hours for 24 hours. In addition, the behavioral response of baby is observed during the study period by video recording which will be in 'Mute' video mode and then reviewed by our developmental staff"
89360234|NCT02471482|Experimental|No Music First group|"No music in first 30 minutes of study followed by 10 minutes of washout period and then 30 minutes of Mozart music lullaby while recording same variables. This cycle was repeated every 6 hours for 24 hours."
89360235|NCT01953458||hepatitis C and/or B|
89360236|NCT05691296|Experimental|Home-school training group|There was a Letter Chart Accomodative Rock Training for accommodation facility at home and school everyday. This training usually lasted 2 minutes each time.
89360237|NCT05691296|Experimental|School training group|There was a Letter Chart Accomodative Rock Training for accommodation facility only at school everyday. This training usually lasted 2 minutes each time.
89360238|NCT05691296|No Intervention|No training group|There was no such treatment for students.
89360239|NCT02473120|Experimental|Determination of ESR1 mutations|Blood sample will be collected every 3 months during two years to determine ESR1 mutations
89360240|NCT02472808|Other|cTBNA without ROSE|Patients who will undergo conventional TBNA without ROSE + Endobronchial biopsy + Transbronchial Lung Biopsy
89360241|NCT02472808|Other|cTBNA with ROSE|Patients who will undergo conventional TBNA with ROSE + Endobronchial biopsy + Transbronchial Lung Biopsy
89360242|NCT02472808|Other|EBUS-TBNA without ROSE|Patients who will undergo EBUS-TBNA without ROSE + Endobronchial biopsy + Transbronchial Lung Biopsy
89360243|NCT02472808|Other|EBUS-TBNA with ROSE|Patients who will undergo EBUS-TBNA with ROSE + Endobronchial biopsy + Transbronchial Lung Biopsy
89360244|NCT05687942|Experimental|REBUILD|REBUILD is an investigational medical device (bioabsorbable anchor and deployment instruments) used with third party suture to close the abdominal wall. As the suture and Anchor absorb, abdominal wall forces gradually transfer to the organizing scar, one of the tenets of successful wound tensile strength acquisition. After full absorption, no permanent material remains that would otherwise alter normal anatomy, anisotropic properties, or compliance of the abdominal wall (Deeken, 2017).
89360245|NCT05180292|Experimental|Acute on Chronic Liver failure|
89360246|NCT01315938|Other|Active treatment|Abatacept will be administered intravenously at a dose based on body weight at the screening visit (baseline): participants weighing <60 kg received 500 mg, 60-100 kg received 750 mg and those >100 kg received 1000 mg.
89360247|NCT01315938|Other|Delayed-onset treatment|Abatacept will be administered intravenously at a dose based on body weight at 3 months: participants weighing <60 kg received 500 mg, 60-100 kg received 750 mg and those >100 kg received 1000 mg.
89360248|NCT03108430||Inhalation pneumonia|
89360249|NCT03108430||Proven inhalations|
89360250|NCT03108430||Suspected inhalations (coma + anamnesis)|
89360251|NCT04800354|Experimental|Nurse-led Mindfulness Based Intervention|
89360252|NCT04800354|Active Comparator|Nurse-led Pain Psychoeducation|
89360253|NCT05684432||Prostate and rectal cancer patients|Curative EBRT
89360254|NCT02470624||treatment following current guideline|
89360255|NCT01339884|Active Comparator|Resveratrol, 1g daily|15 participants will receive resveratrol 1g daily
89360256|NCT01339884|Active Comparator|Resveratrol, 5g daily|15 participants will receive resveratrol, 5g daily
89360257|NCT05112614||Observational (biospecimen collection, medical record review)|Patients undergo collection of blood and stool samples and have their medical records reviewed.
89360258|NCT04736394|Active Comparator|Epirubicin hydrochloride group|intravesical instillation of Epirubicin hydrochloride
89360259|NCT04736394|Experimental|APL-1202 group|receive APL-1202 single-agent oral treatment
89360260|NCT04257370|Experimental|Kerecis™ Omega3 Wound|
89360261|NCT04257370|Active Comparator|Standard of care|
88831997|NCT02962427|Experimental|Sphenopalatine Ganglion Block|Sphenopalatine Ganglion Block: The patient is placed in the supine position. Four cc of 2% viscous lidocaine is placed to the level of the sphenopalatine ganglion with a 20 gauge angiocatheter along sterile swabs which were placed carefully into the patients nostrils bilaterally and lateral to the middle turbinate. It will be documented that the patient has no pain or paresthesia during or after the procedure. The swabs are withdrawn after 30 minutes.
89360262|NCT01339962||Non-Interventional Study|Outcomes Research Study
88831998|NCT02962427|Active Comparator|Epidural blood patch|Epidural Blood Patch: The patient is positioned in the sitting or lateral positon. Using aseptic technique, 20mL of autologous blood is drawn by a trained practitioner. The epidural placement is performed by a trained practitioner using aseptic technique and the vertebral space accessed is at or immediately below the original neuraxial placement. After entrance into the epidural space is confirmed with loss of resistance technique to either air or saline, 15-20 milliliters of sterile autologous venous blood is injected. After the procedure the patient rests supine for at least 1 hour. Patients are instructed to avoid heavy lifting, abdominal straining, or coughing for at least 48 hours.
88831999|NCT02039726|Experimental|Quizartinib|Participants who were randomized to receive 20 or 30 mg quizartinib tablets administered orally once daily.
88832000|NCT02039726|Active Comparator|Salvage chemotherapy|Participants who were randomized to receive salvage chemotherapy, such as low dose cytarabine (LoDAC); mitoxantrone, etoposide, and intermediate-dose cytarabine (MEC); or fludarabine, cytarabine, and granulocyte colony stimulating factor (G-CSF) with idarubicin (FLAG-IDA), were administered during 28-day cycles.
89360263|NCT01341834|Experimental|LBH589-RAD001|LBH589-RAD001, single arm dose finding study
89360264|NCT01340040|Experimental|MEDI-573|MEDI-573
89360265|NCT02723344|Experimental|L. reuteri|Commercially available L. reuteri (deposited in the Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ) and referenced as DSM 17938; Gerber Soothe Colic Drops, 100 million CFU/5 drops; formerly known as L. reuteri ATCC 55730) will be used in the proposed study. L. reuteri (phylum Firmicutes) is a gram-positive anaerobic commensal bacteria found in the gut microbiome of humans. Independent testing of the viability of the commercial product will be conducted in our laboratories by diluting drops, plating on agar in triplicate, and anaerobic culturing at 37 oC. The commercial strain (DSM 17938) has been used to improve intestinal functions in infants and reduce symptoms of infantile colic.
89360266|NCT02723344|Placebo Comparator|Sunflower and medium chain triglyceride oils|Sunflower and medium chain triglyceride oils
89360267|NCT01340118|Experimental|Budesonide|Patients with FeNO level greater than 25 ppb were randomly allocated to one of two groups. Randomisation was stratified by baseline FeNO. In one group (treatment group), participants were assigned to once daily treatment with 400 µg budesonide. In the other group (non-treatment group), participants did not receive any medication.
89360268|NCT01340118|No Intervention|remain untreated|
89360269|NCT03401398|Active Comparator|Treatment|Approximately half of the subjects randomized into SHIPSS will be randomized into the Treatment Group and will receive hydrocortisone sodium succinate according to a predetermined dosing schedule.
89360270|NCT03401398|Placebo Comparator|Placebo|Approximately half of the subjects randomized into SHIPSS will be randomized into the Placebo Group and will receive equivalent study drug volumes of normal saline.
89360271|NCT01340274|Active Comparator|Treatment as Usual|"Clients will receive 12 sessions of Treatment as usual , delivered 1 session per week for 12 consecutive weeks."
89360272|NCT01340274|Experimental|CRAFT Treatment|"Clients will receive 12 sessions of CRAFT, delivered 1 session per week for 12 consecutive weeks."
89360273|NCT02469766|Active Comparator|Extracorporeal Shockwaves|Patients in this arm will undergo SWL
89360274|NCT02469766|Active Comparator|Semirigid URS|Patients in this arm will undergo Semirigid Ureteroscopy
89360275|NCT02469766|Active Comparator|Flexible URS|Patients in this arm will undergo Flexible Ureteroscopy
89360276|NCT03635658|Active Comparator|titanium mesh|using non resorbable titanium mesh to fix and cover the onlay bone graft mixture to the atrophic maxillary ridge.
89360277|NCT03635658|Experimental|collagen membrane(Sausage technique)|using resorbable collagen membrane with the sausage technique to fix the onlay bone graft mixture to the resorbed atrophic maxillary ridge
89360278|NCT02723188|Sham Comparator|Sham|Sham electrical stimulation
89360279|NCT02723188|Experimental|DC: Direct current|Direct current electrical stimulation
89360280|NCT02723188|Experimental|AC: Alternating current|Alternating current electrical stimulation
89360281|NCT04422366|Experimental|9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52|Participants in this arm would receive 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha)
89360282|NCT04422366|Active Comparator|GARDASIL®|Participants in this arm would receive GARDASIL®
89360283|NCT01375582|Experimental|Drop Administration|
89360284|NCT01340352||study group: previous preterm labor|
89360285|NCT01340352||control group:previous term delivery|
89360286|NCT04409964|Experimental|opioid-free anesthesia|The study group receives the dexmedetomidine and lidocaine infusion with general anesthesia for gynecological laparoscopy.
89360287|NCT04409964|Active Comparator|opioid anesthesia|The control group receives the remifentanil infusion with general anesthesia for gynecological laparoscopy.
89360288|NCT03220282|Active Comparator|Donor milk|Pasteurized donor breast milk
89360289|NCT03220282|Placebo Comparator|Preterm infant formula|Preterm formula determined by clinical practice
89360290|NCT04328376|Experimental|Prospective FEMQT Group|Propositus patients with genetically proven LQTS and their relatives
89360291|NCT03310996|Experimental|tDCS Active arm|The experimental arm will have the tDCS stimulation electrodes placed on the scalp and the current will be delivered over 20 minutes
89360292|NCT03310996|Placebo Comparator|tDCS Sham arm|The sham arm will have electrodes placed over the scalp and will be given the current for 10 seconds after which it will be ramped down and stopped.
88832001|NCT03036293|Experimental|Tenoten, 2 tablets twice daily (4 tablets/day)|Tablet for oral use. Dose per administration: 2 tablets. 2 tablets twice daily (4 tablets/day). The tablets should be held in the mouth until dissolution, without meal.
88832002|NCT03036293|Placebo Comparator|Placebo, 2 tablets twice daily (4 tablets/day)|Tablet for oral use. Dose per administration: 2 tablets. 2 tablets twice daily (4 tablets/day). The tablets should be held in the mouth until dissolution, without meal.
88832003|NCT03036293|Experimental|Tenoten, 2 tablets 4 times daily (8 tablets/day)|Tablet for oral use. Dose per administration: 2 tablets. 2 tablets 4 times daily (8 tablets/days). The tablets should be held in the mouth until dissolution, without meal.
88832004|NCT03036293|Placebo Comparator|Placebo, 2 tablets 4 times daily (8 tablets/day)|Tablet for oral use. Dose per administration: 2 tablets. 2 tablets 4 times daily (8 tablets/days). The tablets should be held in the mouth until dissolution, without meal.
89360293|NCT02471092|Placebo Comparator|Water Control|Skim milk products. Water and permeate control; 250mL serving.
89360294|NCT02471092|Active Comparator|Skim Milk|Skim milk products. Skim milk (regular 80:20 protein ratio); 250mL serving.
88832005|NCT02408198|Experimental|Immediate therapy|Therapy will be delivered for a period of 6 weeks immediately after randomisation
88832006|NCT02408198|No Intervention|Delayed therapy|Therapy will be delayed until 10 weeks following randomisation, and then delivered over a 6 week period
88832007|NCT02040116|Other|rituximab infusion|Every patient is getting the same therapy of rituximab. If day 1 is tolerated at standard infusion then day 14 and beyond will be given as rapid infusion over 90 minutes
88832008|NCT03037541|Experimental|Group 1 Carac (fluorouracil) 0.5% cream|Carac cream (fluorouracil) 0.5% applied daily on the face for one week
88832009|NCT03037541|Placebo Comparator|Group 2 Placebo|Placebo Cetaphil cream applied daily on the face for one week
88832010|NCT02986256|No Intervention|Conventionnal Group|No intervention for this group. Patients will be followed by a usual care.
88832011|NCT02986256|Experimental|"Telepied Group"|Patients will be followed by a nurse referring to ulcers of the diabetic foot.
88832012|NCT02360774|Experimental|Canagliflozin|Subjects will be randomized (1:1) to treatment with canagliflozin 300mg or placebo once daily for 18 weeks.
88832013|NCT02360774|Placebo Comparator|Placebo|Subjects will be randomized (1:1) to treatment with canagliflozin 300mg or placebo once daily for 18 weeks.
89360295|NCT02471092|Experimental|High Protein Milk|Skim milk products. High protein milk (regular 80:20 protein ratio); 250mL serving.
89360296|NCT02471092|Experimental|High Protein Milk (Modified Ratio)|Skim milk products. High protein milk with modified protein ratio (40:60 ratio); 250 mL serving.
89360297|NCT02471092|Experimental|Skim Milk (Modified Ratio)|Skim milk products. Skim milk with modified protein ratio (40:60 ratio); 250 mL serving.
89360298|NCT03212716|Experimental|diltiazem|oseltamivir + diltiazem
88832014|NCT02361476|Experimental|Intervention|Clonidine : injection og 3 micg/kg IV during the operation.
89360299|NCT03212716|Placebo Comparator|oseltamivir + placebo|oseltamivir + placebo of diltiazem
89360300|NCT05184114|Active Comparator|Recovered COVID-19 patients|Recovered COVID-19 Patients will undergo three CMR examinations. The scans will take place at (i) within 2 weeks of confirmed recovery, (ii) 3 months after recovery and (iii) 1 year after recovery. At time of CMR examinations, patients will have blood tests.
89360301|NCT05184114|Experimental|non-COVID-19 patients with viral respiratory infections|non-COVID-19 Patients will undergo three CMR examinations. The scans will take place at (i) within 2 weeks of confirmed recovery, (ii) 3 months after recovery and (iii) 1 year after recovery. At time of CMR examinations, patients will have blood tests.
89360302|NCT05184114|Experimental|Volunteers as age and gender matched controls.|Volunteer controls will undergo one CMR examination. At time of CMR examinations, patients will have blood tests.
89360303|NCT05184114|Experimental|Volunteers who planning to receive a 2-dose COVID-19 vaccine as vaccination controls|Vaccination controls will undergo two CMR examinations. The scans will take place (i) within 2 weeks before received 1st dose of COVID-19 vaccine and (ii) within 2 weeks (preferably 5-7 days) after receiving the 2nd dose of COVID-19 vaccine. At time of CMR examinations, patients will have blood tests.
89360304|NCT02469922|Experimental|Positron emission tomography|Two additional PET Scan will be performed at 2 and 4 weeks for the first 30 patients. Then for the other patients only one additional PET-Scan will be performed
88832015|NCT02361476|Placebo Comparator|Placebo|Placebo : injection og equal amount of NaCl IV during the operation.
88832016|NCT02363270|Active Comparator|IV Push Group|Ketamine medication given via IV Push. IV Push is the intervention.
88832017|NCT02363270|Active Comparator|IV Drip Group|Ketamine medication given via IV Drip. IV Drip is the intervention.
88832018|NCT02042534|Experimental|Rivaroxaban|Rivaroxaban group for 1 month : initial 5 days after randomization rivaroxaban 10mg QD will be administered. Rivaroxaban 20mg QD, but 15mg in case of Cr CL will be administered for remaining 25 days.
88832019|NCT02042534|Active Comparator|Warfarin|Patients allocated to warfarin receive warfarin plus aspirin 100mg until INR value exceed 1.7 followed by warfarin monotherapy with target INR value of 2.5 [2.0 - 3.0].
88832020|NCT02409914||POLYCYSTIC OVARY SYNDROME (PCOS)|FDG PET scan,T1-weight MRI and blood were obtained for each participant
88832021|NCT03038399|Experimental|Dose Level Group 1|Participants enrolled in Dose Level Group 1 will receive vamorolone 0.25 mg/kg/day.
88832022|NCT03038399|Experimental|Dose Level Group 2|Participants enrolled in Dose Level Group 2 will receive vamorolone 0.75 mg/kg/day.
88832023|NCT03038399|Experimental|Dose Level Group 3|Participants enrolled in Dose Level Group 3 will receive vamorolone 2.0 mg/kg/day.
88832024|NCT03038399|Experimental|Dose Level Group 4|Participants enrolled in Dose Level Group 4 will receive vamorolone 6.0 mg/kg/day.
89360305|NCT04762836|Experimental|Augmented learning|Conditioning and extinction of a nocebo response to the activation of a sham electrode, controlled within subjects. All participants in this arm receive a double-blind oral dose of DCS two hours prior to conditioning and fMRI
88832025|NCT02043704|Experimental|IV Acetaminophen|Subjects will receive a 1000mg dose of IV acetaminophen in 100mL solution every 6 hours for 24 hours. The first dose will be administered prior to anesthesia induction, approximately 30 minutes before skin incision. A total of 4 doses will be given.
88832026|NCT02043704|Placebo Comparator|Saline|Subjects will receive a 100mL dose of IV saline every 6 hours for 24 hours. The first dose will be administered prior to anesthesia induction, approximately 30 minutes before skin incision. A total of 4 doses will be given.
88832027|NCT03117569|Other|Standard monitoring schedule|Participants will have on-treatment clinic visits at weeks 4 and 8. Participants have also phone contact-based visits at weeks 4 and 8 (1-2 days prior to scheduled clinic visits).
88832028|NCT03117569|Experimental|Simplified monitoring schedule|Participants will have no on-treatment clinic visits at weeks 4 and 8. Participants have phone contact-based visits at weeks 4 and 8.
88832029|NCT02363972|Experimental|Ellipsys Vascular Access Catheter|ESRD patients who require and qualify for creation of a surgical AV fistula will be offered the opportunity to participate in this study for a less invasive way of creating an AV fistula.
89360306|NCT04762836|Placebo Comparator|Baseline learning|Conditioning and extinction of a nocebo response to the activation of a sham electrode, controlled within subjects. All participants in this arm receive a double-blind oral dose of placebo two hours prior to conditioning and fMRI
88832030|NCT02963597|Active Comparator|Group A|Standard medical therapy plus AirSense™ 10 AutoSet for 48hrs.
88832031|NCT02963597|Placebo Comparator|Group B|Standard medical therapy only.
88832032|NCT02410382|Placebo Comparator|Arm 1 Placebo|Subjects receiving radiation therapy or radiation and chemotherapy randomly assigned to placebo bid for 14 days
88832033|NCT02410382|Active Comparator|Arm 2 Dexamethasone|Subjects receiving radiation therapy or radiation and chemotherapy randomly assigned to dexamethasone 4 mg bid for 14 days
88832034|NCT04737005|Other|Nano-ceramic hybrid (Grandio Blocs) Endo-crown.|Nano-ceramic hybrid ( intervention)
88832035|NCT04737005|Active Comparator|Lithium di-silicate Ceramic (E.max CAD blocks) Endo-crown|Lithium di-silicate Ceramic ( Control)
88832036|NCT03038867|Experimental|Duloxetine|Duloxetine orally 60mg daily for 5 weeks, then taper to 30mg daily for 1 week
88832037|NCT03038867|Placebo Comparator|Placebo|Placebo
89360307|NCT04755660|Experimental|Exercise behavior change group (EBCG)|Behavior Change Theory-based intervention + Resistance Exercise
89360308|NCT04755660|Active Comparator|Elastic band resistance exercise group( EBRG)|Elastic Band Resistance Exercise
89360309|NCT04755660|Sham Comparator|Usual care (UC)|usual care: exercise education
88832038|NCT03039179|Experimental|Polyurethane foam|
88832039|NCT03039179|No Intervention|standard care|Only application of the Walker in the immediate postoperative period.
88832040|NCT02963987|Experimental|100% Portion Size|100% Food and Beverage Portion Size
88832041|NCT02963987|Experimental|150% Portion Size|150% Food and Beverage Portion Size
88832042|NCT02964767||HIV mono infection|HIV Patients do not have active Mycobacterium Tuberculosis infection
88832043|NCT02964767||HIV-Tb. co infection|Patients with HIV and MycobacteriumTuberculosis co infections
89360310|NCT00705406|Experimental|Peramivir 600 mg|600 mg peramivir administered as bilateral 2-mL intramuscular injection.
89360311|NCT00705406|Placebo Comparator|Placebo|Placebo (buffered diluent) administered as bilateral 2-mL intramuscular injection.
88832044|NCT03040427|Experimental|AL or TTR type amyloidosis|The participants will undergo F-18 florbetapir PET scan.
88832045|NCT03119831|Experimental|C31G (Group A)|C31G
88832046|NCT03119831|Experimental|Alcohol-free Chlorhexidine (Group B)|Alcohol-free Chlorhexidine Gluconate 0.12%
88832047|NCT03119831|Experimental|Alcohol-based Chlorhexidine (Group C)|Alcohol-based Chlorhexidine Gluconate 0.12%
88832048|NCT02965781|Active Comparator|One SADBE application|Patient will receive a topical 2% SADBE sensitization dose applied to the patient's upper arm. Three weeks after topical sensitization dose patient will receive topical placebo applied to the patient's upper arm.
88832049|NCT02965781|Active Comparator|Two SADBE applications|Patient will receive a topical 2% SADBE sensitization dose applied to the patient's upper arm. A 0.5% SADBE intensification dose will be applied to the patient's upper arm 3 weeks after sensitization dose.
89360312|NCT04318314||Healthy and asymptomatic healthcare workers|Healthy and asymptomatic healthcare workers
89360313|NCT01342224|Experimental|tadalafil and vaccination|Participants receive a 4-week course of vaccination with telomerase vaccine and GM-CSF by injection, along with a cycle of gemcitabine chemotherapy (IV). This is followed by radiation and gemcitabine given twice weekly then by another dose of vaccine.
89360314|NCT01342302|Other|Couples Intervention|Single arm study design
89360315|NCT03155178|Experimental|3M CHG/IPA Prep|Apply topically for 30 seconds (abdominal site) or 2 minutes (inguinal site), and allow to dry for 3 minutes.
89360316|NCT03155178|Active Comparator|ChloraPrep|Apply topically for 30 seconds (abdominal site) or 2 minutes (inguinal site), and allow to dry for 3 minutes.
89360317|NCT02470546|Active Comparator|Metformin|Patients receiving metformin
89360318|NCT02470546|Placebo Comparator|Placebo|Patients receiving placebo
89360319|NCT01315626||Immediately preceding intervention|3 months immediately before the education event. Charts of patients with a primary respiratory complaint will be reviewed so evaluate if they 1) have experienced 3 or more suppurative respiratory infections and 2) have required 3 or more courses of antibiotic therapy for respiratory infection over the period of one year. 4) Whether or not they underwent a HRCT, and if so, and 5) Were the patients diagnosed with BE.
89360320|NCT01315626||3 months after educational event|3 months immediately after the education event. An active assessment will be preformed as per the proposed diagnostic algorithm (attachment B) Patients that meet all criteria in the algorithm are considered at risk for bronchiectasis and based on these criteria, physicians will be encouraged to order HRCT, and the number/ proportion of patients identified with BE will be noted and compared to the other time periods.
89360321|NCT01315626||Seasonal prior year|As respiratory illnesses are commonly seasonal, an assessment of rate of Bronchiectasis diagnosis during the months of Period 2 in the year prior to the educational intervention will also be assessed as described in Period 1
89360322|NCT03310762|Experimental|Alma Sana Bracelet Arm|Subjects in this arm will receive a vaccine reminder and tracker bracelet developed by Alma Sana Inc. This bracelet uses a combination of symbols and numbers to denote the entire vaccine schedule a child is supposed to receive before the age of 2 years. Shapes indicate vaccines, and numbers signify the child's age.
88832050|NCT02965781|Placebo Comparator|Placebo application (DMSO only-No SADBE)|Patient will receive a topical placebo (vehicle-DMSO) dose applied to the patient's upper arm. A topical placebo (vehicle-DMSO) follow up dose will be applied to the patient's upper arm 3 weeks after the first placebo dose dose.
88832051|NCT02968277|Experimental|Started with Forearm Support Walker (LW Upright)|Data collection began with participants using the LifeWalker Upright Walker then using the two remaining walkers in a randomized order
88832052|NCT02968277|Experimental|Standard Rollator Walker (Control)|Data collection began with participants using a conventional standard rollator (SR) walker then using the two remaining walkers in a randomized order
88832053|NCT02968277|Experimental|Predicate Device (PD)|Data collection began with participants using their own rollator walkers then using the two remaining walkers in a randomized order
88832054|NCT03124121|Other|Induction cohort|Golimumab induction therapy
89360323|NCT03310762|Experimental|Simple Silicon Bracelet Arm|Subjects in this arm will receive a simple silicon bracelet. This bracelet has six symbols to remind parents that their child needs to get at least six vaccination visits before he reaches 2 years of age. The first five symbols are represented by a crescent shape and the sixth symbol is represented by a star shape to denote that the child is fully immunized.
89360324|NCT03310762|No Intervention|Control Arm|Subjects in this arm will not receive any bracelet/intervention.
89360325|NCT05158920|Experimental|Intervention Group|Participants in the intervention group received Mindfulness-Based Cognitive Therapy in addition to their treatment as usual.
89360326|NCT05158920|No Intervention|Control Group|Participants in the control group received their treatment as usual.
89360327|NCT03310606|Other|Peritonitis|"Patient received for antibiotic treatment a B lactam according to French recommendation :~type of antibiotic : cefotaxime or ceftriaxone or piperacilline/tazobactam or imipenem~dose : cefotaxime 2g / cetriaxone 2g / piperacilline 4g / imipenem 1g"
89360328|NCT01315704||Group 1|Patients with Mild Cognitive Impairment
88832055|NCT03124121|Other|Maintenance cohort|Golimumab maintenance therapy
88832056|NCT04333277|Experimental|Probiotic|Patients with major depression (both sexes) will receive capsules with 1 × 10^9 CFUs of Lactobacillus helveticus in addition to a conventional antidepressant treatment for 8 weeks.
89360329|NCT01315704||Group 2|Patients with Mild Alzheimer's disease or related disorders
89360330|NCT01315704||Group 3|Patients with Moderate Alzheimer's disease or related disorders
89360331|NCT05158608|Active Comparator|Cyclophosphamide on day +3,+4 at dose 50 mg/kg/day|Post-transplantation Cyclophosphamide will be apply for GVHD prophylaxis on day +3,+4 at dose 50 mg/kg/day in combination with cyclosporine A at 3 mg/kg/day from day +5 and mycophenolate mofetil at dose 30-45mg/kg/day from day +5.
89360332|NCT05158608|Experimental|Cyclophosphamide on day +3,+4 at dose 25 mg/kg/day|Post-transplantation Cyclophosphamide will be apply for GVHD prophylaxis on day +3,+4 at dose 25 mg/kg/day in combination with cyclosporine A at 3 mg/kg/day from day +5 and mycophenolate mofetil at dose 30-45mg/kg/day from day +5.
89360333|NCT01342536|Experimental|lifestyle counseling (OHDC)|Oh Happy Day Class (OHDC) is a culturally-specific, 12-week cognitive behavioral group counseling intervention designed for African American adults experiencing depression
88832057|NCT04333277|Placebo Comparator|Maltodextrin|Patients with major depression (both sexes) will receive capsules of placebo (maltodextrin) in addition to a conventional antidepressant treatment for 8 weeks
88832058|NCT03041441|Experimental|MRICP method|MRI sequences have been developed that may be able to estimate ICP in a non-invasive fashion.6-10 The MRI-based method for measurement of ICP (MRICP method) is based on basic principles of the cranio-spinal CSF physiology: The mono-exponential relationship between intracranial volume and pressure leads to a linear relationship between elastance (i.e., the derivative of pressure with respect to volume) and pressure.
88832059|NCT03041909|Experimental|Single Arm|Single Arm / open label
88832060|NCT03042299|Experimental|TAK-536 Granules + TAK-536 Tablet|TAK-536 10 milligram (mg), granules (pediatric formulation), under fasted condition, orally, once on Day 1 of Intervention Period 1, followed by a Washout Period of at least 6 days, further followed by TAK-536 10 mg, tablet (commercial formulation), under fasted condition, orally, once on Day 1 of Intervention Period 2.
89360334|NCT01342536|Active Comparator|lifestyle counseling (CWD)|Coping with Depression Course (CWD) is a 8-week cognitive behavioral group counseling depression intervention
89360335|NCT03310372|Experimental|ultrafractionated brain irradiation - temozolomide|
89360336|NCT01340508|Experimental|Intensity modulated Radiotherapy|Intensity modulated radiotherapy, dose escalation, rectal cancer, volumetric modulated arc therapy
88832061|NCT03042299|Experimental|TAK-536 Tablet + TAK-536 Granules|TAK-536 10 mg, tablet (commercial formulation), under fasted condition, orally, once on Day 1 of Intervention Period 1, followed by a Washout Period of at least 6 days, further followed by TAK-536 10 mg, granules (pediatric formulation), under fasted condition, orally, once on Day 1 of Intervention Period 2.
88832062|NCT03043079|Experimental|Ventral Hernia|Twenty-five patients diagnosed with ventral hernia
89360337|NCT03635502||Stroke Group|
89360338|NCT03635502||Healthy Group|
89360339|NCT05183958|Experimental|Combined radiotherapy group|"Chemotherapy :TP program (paclitaxel 175mg/m 2 d1, carboplatin AUC=5 d1 IV Q3W; or paclitaxel 175mg/m 2 d1, cisplatin 75mg/m 2 d1, or paclitaxel 175mg/m 2 d1, cis Platinum 25mg/m 2 d1-3 IV (Q3W, up to 4 cycles). Fluorouracil + cisplatin, cisplatin 80 mg/m 2 d1 IV and 5-Fu 800 mg/m 2 continuous IV d1-5 Q3W (up to 4 cycles).Or cisplatin 50mg/m 2 IV d1; LV 200mg/m 2 IV d1; 5-Fu 2000mg/m 2 24 hours continuous IV d1; or cisplatin 80mg/m 2 IV d1, capecitabine 1000mg/m 2 PO BID d1-14.~Camrelizumab :200mg every 3 weeks,maximum 6 cycles.~The experimental group received radiotherapy of the lesion within 8 weeks after the end of chemotherapy and immunotherapy. Immunotherapy shall be started within 8 weeks after the end of all radiotherapy.~The maintenance immunotherapy of the two groups was: Camrelizumab 200mg Q3W, until PD or toxicity is intolerable or up to 24 months."
89534465|NCT00066729|Experimental|NY-ESO-1b peptide with Montanide® ISA-51|Patients received NY-ESO-1b peptide mixed with Montanide® ISA-51 by subcutaneous injections, once every 3 weeks (weeks 1, 4, 7, 10, and 13) for a total of 13 weeks.
89534466|NCT00014131|Experimental|Biological/Vaccine|Biological/Vaccine: therapeutic autologous dendritic cells. Apheresis procedure collects peripheral blood mononuclear cells (PBMC) for the production of dendritic cell, which are admixed with irradiated tumor cells from autologous tumor cell line for vaccine product.
88832063|NCT03043079|Other|Healthy Volunteers|Twenty-five volunteers without ventral hernia
88832064|NCT03043079|Other|Active Health Volunteers|Ten healthy volunteers with an International Physical Activity Questionnaire (IPAQ) with the scoring result of High or Vigorous Intensity
88832065|NCT02971631|Placebo Comparator|Placebo|Infusion of 1% human albumin in normal saline.
88832066|NCT02971631|Experimental|Exendin|Infusion of Exendin 9-39 in 1% human albumin in normal saline
88832067|NCT00374777|Experimental|1|
88832068|NCT00374777|Experimental|2|
88832069|NCT00374777|Active Comparator|3|
88832070|NCT00374777|Placebo Comparator|4|
88832071|NCT03045809||Women at risk of urogenital infections|Adult women living in the city of Kigali who are at high risk of HIV/urogenital infections (defined as having had more than one sexual partner in the last 12 months OR having been treated for a sexually transmitted infection (STI) in the last 12 months) regardless of the presence of current urogenital symptoms. Women who are known to be HIV-positive and/or pregnant are not excluded. All eligible women will be offered urogenital infection point-of-care tests.
88832072|NCT02044796|Experimental|Treatment (filgrastim, mitoxantrone, cladribine, cytarabine)|"INDUCTION CHEMOTHERAPY (G-CLAM): Patients receive G-CLAM chemotherapy comprising filgrastim SC daily on days 0-5, mitoxantrone hydrochloride IV over 60 minutes on days 1-3, cladribine IV over 2 hours daily on days 1-5, and cytarabine IV over 2 hours daily on days 1-5. Patients achieving CRi, partial remission, or persistent disease may receive a second course of induction chemotherapy. Patients achieving CR or CRp may continue on to Consolidation Chemotherapy.~CONSOLIDATION CHEMOTHERAPY (G-CLA): Beginning within 6 weeks of achieving CR/CRp/CRi, patients receive G-CLA comprising filgrastim SC on days 0-5, cladribine IV over 2 hours daily on days 1-5, and cytarabine IV over 2 hours daily on days 1-5. Treatment continues for up to 4 courses in the absence of disease progression or unacceptable toxicity."
88832073|NCT03124823|Experimental|Test Subject|All subjects are enrolled into the test group and all subjects received the Rainbow DCI Sensor
88832074|NCT03124901|Experimental|Test Group|All subjects are enrolled into the test group and all subjects receive DCI pulse oximeter sensor.
88832075|NCT03124979|Other|Test Subject|All subjects are enrolled into the test group and all subjects received the LNCS DBI Sensor.
88832076|NCT02045108|Experimental|Active TDCS + Active Retraining|2.0 milliamps (mA) of TDCS applied during active alcohol avoidance retraining
88832077|NCT02045108|Experimental|Sham TDCS + Active Retraining|.1 mA of TDCS applied during active alcohol avoidance retraining
88832078|NCT02045108|Experimental|Active TDCS + Sham retraining|2.0 mA of TDCS applied during sham alcohol avoidance retraining
88832079|NCT02045108|Sham Comparator|Sham TDCS + Sham Retraining|0.1 mA of TDCS applied during sham alcohol avoidance retraining
88832080|NCT02973503|Experimental|Elbasvir/Grazoprevir|evaluate the efficacy of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Naïve, HCV GT1b-Infected Patients, with non- severe fibrosis as measured by the proportion of subjects with sustained viral response 12 weeks after cessation of treatment (SVR 12).
88832081|NCT03127943|Active Comparator|Buffered 1% lidocaine|"In week One, Each subject would be injected intraorally with either anesthetic (Buffered 1% lidocaine with 1/100,00 epinephrine) or (Non-buffered 1% lidocaine with 1/100,00 epinephrine to block the Inferior alveolar, Lingual and Buccal nerves.~At least a week later injections for the same nerves would involve the alternate anesthetic. Mandibular molar and canine tested for pulpal anesthesia."
88832082|NCT03127943|Active Comparator|Non-buffered 1% lidocaine|"In week Two, Each subject would be injected intraorally with the alternate anesthetic (Buffered 1% lidocaine with 1/100,00 epinephrine) or (Non-buffered 1% lidocaine with 1/100,00 epinephrine to block the Inferior alveolar, Lingual and Buccal nerves.~At least a week later injections for the same nerves would involve the alternate anesthetic. Mandibular molar and canine tested for pulpal anesthesia."
88832083|NCT03047447|Experimental|Ketogenic group|10-week diet with controlled glycemic indices provided for ketogenic group. Baseline triglyceride, HgA1c, VO2 max, body mass index (BMI), resting metabolic rate (RMR), blood ketone levels and body fat mass measurements were assessed at week 0 and week 3, 6 and 10.
89360340|NCT05183958|Placebo Comparator|Non-radiotherapy group|"Chemotherapy :TP program (paclitaxel 175mg/m 2 d1, carboplatin AUC=5 d1 IV Q3W; or paclitaxel 175mg/m 2 d1, cisplatin 75mg/m 2 d1, or paclitaxel 175mg/m 2 d1, cis Platinum 25mg/m 2 d1-3 IV (Q3W, up to 4 cycles). Fluorouracil + cisplatin, cisplatin 80 mg/m 2 d1 IV and 5-Fu 800 mg/m 2 continuous IV d1-5 Q3W (up to 4 cycles).Or cisplatin 50mg/m 2 IV d1; LV 200mg/m 2 IV d1; 5-Fu 2000mg/m 2 24 hours continuous IV d1; or cisplatin 80mg/m 2 IV d1, capecitabine 1000mg/m 2 PO BID d1-14.~Camrelizumab :200mg every 3 weeks,maximum 6 cycles.~The control group continued Camrelizumab after 3 weeks of the 4 cycles of chemotherapy combined with immunotherapy.~The maintenance immunotherapy of the two groups was: Camrelizumab 200mg Q3W, until PD or toxicity is intolerable or up to 24 months."
89360341|NCT03108664|Experimental|11.25 mg/mL SYL1001 ophthalmic solution|1 drop of 11.25 mg/mL SYL1001 ophthalmic solution in the affected eye(s) q.d
89360342|NCT03108664|Experimental|Vehicle ophthalmic solution|1 drop of vehicle ophthalmic solution in the affected eye(s) q.d
89360343|NCT04848012|No Intervention|Usual non-invasive ventilation|The usual therapy the participant is receiving via non-invasive ventilator.
89360344|NCT04848012|Experimental|Auto-titrating non-invasive ventilation|A novel auto-titrating non-invasive ventilator
89360345|NCT01342614|Active Comparator|Fosinopril group|Fosinopril group received fosinopril, 10mg, once per day.
89360346|NCT01342614|Experimental|Metformin group|Metformin group was treated with metformin hydrochloride, 500mg, three times per day
89360347|NCT03310294|Placebo Comparator|placebo|one bottle of placebo (minidrink fermented with low-fat milk but without Lactobacillus rhamnosus and without FOS, and without viable bacteria 90 grams)
89360348|NCT03310294|Active Comparator|Prebiotics and Probiotics|one bottle of the study product (minidrink with fermented low-fat milk added with Lactobacillus rhamnosus (Lactobacillus rhamnosus) and fructooligosaccharides (FOS), 90 grams)
89360349|NCT04408248||COVID-19 patients with acute respiratory disease|Adult patients with COVID-19 and moderate or severe respiratory disease
89360350|NCT03108508|Experimental|Prod1|G5 Siliplant
89360351|NCT03108508|Experimental|Prod2|Orgono Powder®
89360352|NCT03108508|Experimental|Prod3|G7 ALOE
89360353|NCT01342692|Active Comparator|Azacitidine alone|
89534467|NCT00006099|Experimental|Intraperitoneal (IP) Infusion of 111In-hu3S193|"Hu3S193 was administered intraperitoneally at a dose of 5 mg radiolabeled with 5 millicurie (mCi) of 111In.~Patients received 10 mCi 99mTc-sulphur colloid IP administered in 500 ml of normal saline to assure the absence of any loculation or heterogeneous distribution of radioactivity in the peritoneal cavity. A paracentesis catheter was inserted and the hu3S193 was diluted in 100 mL of 5% human serum albumin and administered as a continuous intraperitoneal infusion over 30 minutes. This was followed immediately by 900 mL of normal saline."
89360354|NCT01342692|Experimental|Azacitidine +Valproic acid|
89360355|NCT01342692|Experimental|Azacitidine +Lenalidomide|
89360356|NCT01342692|Experimental|Azacitidine + Idarubicine|
89360357|NCT04043208|Experimental|Biofeedback|
89360358|NCT04043208|Placebo Comparator|Placebo|
89360359|NCT05155488||Participants With MPS II|Retrospective data of participants diagnosed with MPS II will be collected from the database (DATASUS) from January 1st, 2008 to September 30th, 2020 in this observational study.
89360360|NCT03310216|Experimental|Order I of visual inspection|Participants in group I are provided AI visual inspection system first and EDTRS later.
89360361|NCT03310216|Active Comparator|Order II of visual inspection|Participants in group II are provided EDTRS first and AI visual inspection system later.
89360362|NCT02469688|Experimental|Part1 ASP4070 intramuscular vaccination group|ASP4070 high dose x 4 times
89360363|NCT02469688|Experimental|Part1 ASP4070 intradermal vaccination group|ASP4070 high dose x 4 times
89360364|NCT02469688|Experimental|Part2 ASP4070 intramuscular vaccination group 1|ASP4070 high dose x 4 times
89360365|NCT02469688|Experimental|Part2 ASP4070 intramuscular vaccination group 2|ASP4070 high dose x 1 time, Placebo x 3 times
89360366|NCT02469688|Placebo Comparator|Part2 Placebo intramuscular vaccination group|Placebo x 4 times
89360367|NCT02469688|Experimental|Part2 ASP4070 intradermal vaccination group 1|ASP4070 high dose x 4 times
89360368|NCT02469688|Experimental|Part2 ASP4070 intradermal vaccination group 2|ASP4070 low dose x 4 times
89360369|NCT02469688|Experimental|Part2 ASP4070 intradermal vaccination group 3|ASP4070 high dose x 1 time, Placebo x 3 times
89360370|NCT02469688|Experimental|Part2 ASP4070 intradermal vaccination group 4|ASP4070 low dose x 1 time, Placebo x 3 times
89360371|NCT02469688|Placebo Comparator|Part2 Placebo intradermal vaccination group|Placebo x 4 times
89360372|NCT03310138|Active Comparator|Dorsolateral Prefrontal Cortex|"Intervention: Real Transcranial Magnetic Stimulation~Real Transcranial Magnetic Stimulation will be delivered to the left dorsolateral prefrontal cortex (10Hz, 110% of resting motor threshold) using a MagVenture MagPro B60 coil."
89360373|NCT03310138|Active Comparator|Motor Cortex|"Intervention: Real Transcranial Magnetic Stimulation~Real Transcranial Magnetic Stimulation will be delivered to the left primary motor cortex (10Hz, 80% of resting motor threshold) using a MagVenture MagPro B60 coil."
89360374|NCT03310138|Placebo Comparator|Sham stimulation|"Intervention: Sham Transcranial Magnetic Stimulation~Sham Transcranial Magnetic Stimulation will be delivered to the prefrontal cortex (10Hz, 110% of resting motor threshold) using the integrated sham system on the MagVenture MagPro B60 coil."
89360375|NCT03998046|Active Comparator|Basic Resources and Services|Patients will receive outreach engagement in goal setting via MyChart, an electronic scale, telemonitoring of self weighing, and information about linkages to extant intensive lifestyle interventions in the community
89360376|NCT03998046|Experimental|Coordinated Primary Care Population Management (C3PO)|Patients will receive outreach engagement in goal setting via MyChart, an electronic scale, telemonitoring of self weighing, information about linkages to extant intensive lifestyle interventions, and outreach MyChart messages that are tailored to each individual's pattern of self-weighing and progress towards their weight goal, and more intensive support from a primary care nurse based on self-weighing behavior and weight loss success.
89360377|NCT03310060|Active Comparator|Tisseel combined Tranexamic acid|"Drug: Tisseel® Applied on potential bleeding sites. The entire content was 4 mL.~Drug: Tranexamic acid Intravenous application of tranexamic acid 15mg/kg before surgical incision and 3 hours after surgery"
89360378|NCT03310060|Placebo Comparator|Tranexamic acid|Drug: Tranexamic acid Intravenous application of tranexamic acid 15mg/kg before surgical incision and 3 hours after surgery
89360379|NCT02470000|Experimental|Experimental Group|Intravascular laser irradiation of blood (ILIB, output power 0.3mW), Transcutaneous electrical nerve stimulation (TENS), stretching exercise.
89360380|NCT02470000|Sham Comparator|Control Group|Intravascular laser irradiation of blood (ILIB, output power 0mW), Transcutaneous electrical nerve stimulation (TENS), stretching exercise.
89360381|NCT03740958|Experimental|Argatroban combined with rt-PA|Drug: Argatroban combined with rt-PA Argatroban as a 100 ug/kg bolus over 3 to 5 minutes was administered intravenously within 1 hour of the tPA bolus followed by a continuous Argatroban infusion of 1.0 ug/kg per minute for 48 hours adjusted to a target activated partial thromboplastin time of 1.75 X baseline (about 10%)
89360382|NCT03740958|Active Comparator|rt-PA|Drug: rt-PA Intravenous throbolysis with 0.9mg/kg rtPA.
89360383|NCT01340820|Experimental|AERAS-422 Low dose|>=10^5 to < 10^6 CFU
88832084|NCT03047447|Active Comparator|Exercise group|Exercise group maintained normal diet for 10-weeks and exercised 3-5 days per week. Baseline triglyceride, HgA1c, VO2 max, body mass index (BMI), resting metabolic rate (RMR), blood ketone levels and body fat mass measurements were assessed at week 0 and week 3, 6 and 10.
89360384|NCT01340820|Experimental|AERAS-422 High Dose|>=10^6 CFU
89360385|NCT01340820|Active Comparator|BCG Tice|BCG Tice 1-8 x 10^5 CFU
88832085|NCT03047447|Active Comparator|Non-exercise|Non-exercise group maintained normal diet for 10-weeks with no exercise. Baseline triglyceride, HgA1c, VO2 max, body mass index (BMI), resting metabolic rate (RMR), blood ketone levels and body fat mass measurements were assessed at week 0 and week 3, 6 and 10.
89360386|NCT05290246|Experimental|Time restricted eating|daily 8 hour eating window
88832086|NCT02412098|Experimental|Moderate Hepatic Impairment (Cohort 1)|Participants with moderate hepatic impairment and matched healthy controls will receive a single dose of eleclazine 30 mg (5 x 6 mg tablets).
89360387|NCT05290246|Active Comparator|Caloric Restriction|reduction of caloric intake by 15%
88832087|NCT02412098|Experimental|Severe Hepatic Impairment (Cohort 2)|Participants with severe hepatic impairment and matched healthy controls will receive a single dose of eleclazine 30 mg (5 x 6 mg tablets).
88832088|NCT02412098|Experimental|Mild Hepatic Impairment (Cohort 3)|Participants with mild hepatic impairment and matched healthy controls will receive a single dose of eleclazine 30 mg (5 x 6 mg tablets).
88832089|NCT03048383|Active Comparator|OnabotulinumtoxinA Injectable Product|onabotulinumtoxinA (Botox®, Allergan) administered for n=15 total treatments. Each patient in this arm was administered the Synkinesis Assessment Questionnaire (SAQ) to assess severity of synkinesis pre-treatment. SAQ was administered again at 1, 2, and 4 weeks post-treatment and improvements were compared to the other arms of the study.
88832090|NCT03048383|Active Comparator|AbobotulinumtoxinA Injectable Product|abobotulinumtoxinA (Dysport®, Medicis) administered for n=13 total treatments. Each patient in this arm was administered the Synkinesis Assessment Questionnaire (SAQ) to assess severity of synkinesis pre-treatment. SAQ was administered again at 1, 2, and 4 weeks post-treatment and improvements were compared to the other arms of the study.
88832091|NCT03048383|Active Comparator|Incobotulinumtoxin A Injectable Product|incobotulinumtoxinA (Xeomin®, Merz) administered for n=10 total treatments. Each patient in this arm was administered the Synkinesis Assessment Questionnaire (SAQ) to assess severity of synkinesis pre-treatment. SAQ was administered again at 1, 2, and 4 weeks post-treatment and improvements were compared to the other arms of the study.
89360388|NCT05251584|Experimental|Mupirocin and Gentamicin|2% mupirocin ointments apply at exit-site once daily after wound cleaning before recruit in the study then use 0.1% gentamicin cream apply at exit-site once daily after wound cleaning after entry to the study.
89360389|NCT05251506|Experimental|laser lancing device (LMT-1000) first user|Subjects measure blood glucose using laser lancing device (LMT-1000) for first 2 months, then take a month for wash out period, after that do using lancet for following 2 months.
89360390|NCT05251506|Active Comparator|lancet first user|Subjects measure blood glucose using lancet for first 2 months, , then take a month for wash out period, after that do using laser lancing device (LMT-1000) for following 2 months.
89360391|NCT03309982|Experimental|Plant polyphenol blend|The study product (4 g) consists of 3 g of a mix a maltodextrins, and 1 g of anthocyanin-rich plant polyphenol blend containing: 1) 100 mg bilberry extract; 2) 300 mg black currant extract; and 3) 600 mg black rice extract.
89360392|NCT03309982|Placebo Comparator|Placebo|The placebo (4 g) consists of a mix of maltodextrins (3.85 g) and Red Dye No. 40 (0.125 g) and Blue Dye No. 1 (0.025 g).
89360393|NCT05183568|Experimental|Mindful Self-Compassion|"Participants will undergo an 8-week self-help program consisting of assigned weekly chapters in the workbook entitled The Mindful Self-Compassion Workbook: A Proven Way to Accept Yourself, Build Inner Strength, and Thrive (Neff & Germer, 2018), paired with daily guided meditations provided through a free smartphone app that was developed by the Centre for Mindfulness Studies, a Canadian-based mental health charity."
89360394|NCT03309904|Experimental|Knee Control training program|The Knee Control program is a neuromuscular training program that consists of 6 different exercises, with 4 levels of progression and one pair-exercise, for each exercise. The Knee Control program takes about 10 minute to complete after familiarization. In addition, a 5-minute running warm-up is instructed to coaches. Coaches are to perform the Knee Control program + the 5 minute warm-up at all training sessions during the season, and the 5 minute warm-up before all matches.
89360395|NCT03309904|No Intervention|Control group - usual training|The control group teams receive no intervention, and coaches are instructed to carry out their normal training and warm-up practice throughout the season.
89534468|NCT00006099|Experimental|Intravenous Infusion of 111In-hu3S193|Hu3S193 was to be administered intravenously at a dose of 5 mg radiolabeled with 5 millicurie (mCi) of 111In, diluted in 100 mL of 5% human serum albumin and administered over a 30 minute period.
89360396|NCT04406142|Experimental|treatment feasibility|feasibility, safety and effectiveness assessment
89360397|NCT02470078|Experimental|Pharyngeal electrical stimulation|Pharyngeal electrical stimulation once daily for 10 minutes on three consecutive days.
89360398|NCT02470078|Sham Comparator|Sham stimulation|Sham stimulation once daily for 10 minutes on three consecutive days.
89360399|NCT02470156|Experimental|High Intensity Arm (Intervention)|"Women in the High Intensity (intervention) arm are counseled by a wellness coach and have a group meeting each month. They are also interviewed four times (at baseline, 4 months, 8 months, and 12 months). Women in the high intensity group must have monthly contact with coaches during at least 9 of 12 months via participation in a group activity and/or monthly coaching to receive a full dose of the intervention."
89360400|NCT02470156|Active Comparator|Low Intensity Arm (Comparison)|Women in the Low Intensity (comparison) arm are interviewed and coached four times during the study (at baseline, 4 months, 8 months, and 12 months).
89360401|NCT05251350||An incarcerated right inguinal hernia containing sigmoid colon|
89360402|NCT03309748|Active Comparator|Dental Prophylaxis|Standard dental prophylaxis
89360403|NCT03309748|Active Comparator|Dental prophylaxis + antimicrobial photodynamic therapy|Dental prophylaxis + aPDT
89360404|NCT03309670||Formers young patients|all patients hospitalized between 2006 and 2010 in the Pass'Aje unit
89360405|NCT01316016|Experimental|Rose hip|
89360406|NCT03152682|Experimental|Consume GoodIdea at Visit 2 and Placebo at Visit 3|
89360407|NCT03152682|Experimental|Consume Placebo at Visit 2 and GoodIdea at Visit 3|
89360408|NCT03169998||GDFT group|The fluid infusion is to be performed, in accordance with GDFT protocol, on the basis of cardiac index (CI), stroke volume index(SVI) and stroke volume (SV) in addition to invasively measured arterial pressure by Vigilio / FloTrac Monitor.
89360409|NCT03169998||Control group|Patients in whom the surgery was conducted without the use of EV1000/ FloTrac monitoring among those who had undergone laparoscopic hepatobiliary or pancreatic surgery in the past.
89360410|NCT01341132||Suspected Liver Disease|"Alpha-feto protein > 400 ng / mL or~prior ultrasound with mass suspicious for hepatic malignancy or.~clinical risk of hepatocellular carcinoma or~prior multi-detector CT with mass suspicious for possible hepatocellular carcinoma"
89360411|NCT00705250|Experimental|1|bendamustine hcl 120mg/m^2
89360412|NCT03309592|Other|Combination Therapy|Qualifying participants will begin combination therapy with ambrisentan pill 5 mg daily and tadalafil pill 20 mg. After one week of therapy, patients will increase tadalafil pill to 40 mg daily and continue ambrisentan pill 5 mg daily. On day 15, patients will increase ambrisentan pill to 10 mg daily and continue at 40 mg of tadalafil pill daily.
89360413|NCT04641312|Experimental|LY3457263 - Part A|Escalating single doses of LY3457263 administered subcutaneously (SC) to healthy participants
89360414|NCT04641312|Placebo Comparator|Placebo - Part A|Placebo administered SC to healthy participants
89360415|NCT04641312|Experimental|LY3457263 - Part B|Escalating single doses of LY3457263 administered SC in combination with Dulaglutide administered SC to participants with type 2 diabetes
89360416|NCT04641312|Placebo Comparator|Placebo - Part B|Placebo administered SC in combination with Dulaglutide administered SC to participants with type 2 diabetes
89360417|NCT04640220|Experimental|Adhesive capsulitis in breast cancer survivors|Intra-articular steroid injection
89360418|NCT06209775||Split liver transplantation group|Between January 1, 2015 and December 31, 2022, all recipients who underwent split liver transplantation at the First Affiliated Hospital of the Zhejiang University School of Medicine, Shulan (Hangzhou) Hospital and the Affiliated Hospital of Qingdao University were considered for inclusion. After exluding pediatric cases, multiorgan transplantations, liver cancer patients with macrovascular invasion or distant metastasis and recipients without computed tomography (CT) scan within three months before split liver transplantation, 240 patients were included. The procedures of organ donation and transplantation were strictly implemented under the regulation of the China Organ Donation Committee (CODC), Organ Transplant Committee (OTC) and the Declaration of Helsinki (as revised in 2013). All donor livers came from donation after citizens' death and there was no procurement from prisoners.
89360419|NCT06209775||Whole liver transplantation group|2991 patients received deceased donor liver transplantation (DDLT) for liver cancers in the First Affiliated Hospital of Zhejiang University School of Medicine (Hangzhou, China) between January 2015 and January 2021, Shulan (Hangzhou) Hospital (Hangzhou, China) between July 2017 and January 2021, and the Affiliated Hospital of Qingdao University between January 2015 and January 2022. The subject selection process is shown in Figure 1. After excluding transplants for benign disease (N=1667), pediatric transplants (N=141), re-transplants (N=219), multi-organ transplants (N=23), transplants for neoplasms other than HCC (N=62), patients with macrovascular invasion (N=159), patients who died within 30 days after transplantation (N=55), patients with incomplete clinical data (N=45), and patients without pre-LT CT scans (N=208), 756 patients were studied.
89360420|NCT06209762|Active Comparator|Control Group|
89360421|NCT06209762|Experimental|Inspiratuar Muscle Education Group|Patients in this group will have 10 repetitions of slow diaphragmatic deep breathing exercises followed by core stabilization exercises. Then, IMT will be applied with a respiratory muscle training device. In this training, the difficulty of the exercise will be increased by starting from 40% of the MIP value measured during the evaluation and following the values of 60% and 80% according to tolerance. In addition to physical therapy sessions three days a week for eight weeks, patients will be asked to do this exercise five days a week in the morning and evening.
89360422|NCT06209736|Experimental|Study Drug OMS906|Repeat-dose OMS906 5 mg/kg IV administration at 4-week intervals
89360423|NCT06209723|Experimental|Vegetarian diet|Vegetarian diet during five weeks
89360424|NCT06209723|No Intervention|No change diet|The 'habitual' diet during five weeks. There are no specific restrictions to their diet.
89360425|NCT06209710|Experimental|Intervention Arm: BPA + PADN + Standard Drug Therapy|Participants in this arm will undergo the combination of Balloon Pulmonary Angioplasty (BPA) and Pulmonary Artery Denervation (PADN) procedures.
89360426|NCT06209710|Sham Comparator|Control Arm: BPA + Sham PADN + Standard Drug Therapy|Participants in this arm will receive the combination of Balloon Pulmonary Angioplasty (BPA) and standard drug therapy as the control group. Similar to the intervention arm, a denervation catheter will be placed in the same anatomical position, but no further denervation intervention will be performed.
89360427|NCT06209697|Active Comparator|red clover|Red clover (Promensil, PharmaCare Europe Ltd., UK) and placebo (starch capsules) were administered orally twice a day with an interval of 12 hours for a total period of 6 months. Red clover capsules contained 40 mg of standardized red clover isoflavones in each capsule [genistein (1 mg), daidzein (1 mg), biochanin A (23 mg) and biochanin B (formononetin, 15 mg)].
89360428|NCT06209697|Placebo Comparator|placebo|Placebo capsules were ordered to be prepared with the same color, taste and smell as the red cover capsules. Placebo capsules were administered orally twice a day with an interval of 12 hours for a total period of 6 months.
89360429|NCT06209684|Experimental|Experimental|CarboFix implant for spinal surgery
89360430|NCT06209684|Active Comparator|Traditional|Titanium implant for spinal surgery
89360431|NCT06209671|Experimental|INS19 CAR-T Cells|After preconditioning with chemotherapy, INS19 CAR-T Cells will be evaluated
89360432|NCT06209658|Experimental|experimental group|breastfeeding education with Teach Back
89360433|NCT06209658|Other|Control Group|breastfeeding education simple explanation
89360434|NCT06209645|Experimental|tDCS then tACS|This group is made up of adult patients with drug-resistant neuropathic pain, who started with tDCS stimulation, followed by tACS stimulation, in accordance with randomization. Each series of each modality comprises 6 sessions spaced 2 weeks apart, the first session being in placebo mode and the following 5 in active mode. Each session lasts 20 minutes. In placebo mode, a 2 miliampere (mA) current is delivered for 30 seconds at the start and at the end of the session, to prevent the patient noticing the difference between placebo and active stimulation. In active mode, the 2mA current is delivered for the duration of the session.
89360435|NCT06209645|Experimental|tACS then tDCS|This group is made up of adult patients with drug-resistant neuropathic pain, who started with tACS stimulation, followed by tDCS stimulation, in accordance with randomization. Each series of each modality comprises 6 sessions spaced 2 weeks apart, the first session being in placebo mode and the following 5 in active mode. Each session lasts 20 minutes. In placebo mode, a 2mA current is delivered for 30 seconds at the start and at the end of the session, to prevent the patient noticing the difference between placebo and active stimulation. In active mode, the 2mA current is delivered for the duration of the session.
89360436|NCT06209593||Patients well established on tube feeds will act as their own control|Each participant will receive the new trial feed a nutritionally complete standard enteral tube feed for a period of 7 days. The new trial feed is a food for special medical purposes for use under medical supervision. The Health Care Professional/ dietitian will determine the feeding regimen on an individual basis and the enteral formula will be provided via a feeding tube.
89360437|NCT06209567|Experimental|Participants with high-grade glioma|Participants with newly diagnosed or recurrent high-grade glioma/HGG or brain metastases
89360438|NCT06209502||Population A|Parkinson's disease patients between H&Y stages 1.5 and 3
89360439|NCT06209502||Population B|Early Parkinson's disease patients of H&Y stage 1
89360440|NCT06209502||Population C|Healthy controls
89360441|NCT06209489|Experimental|İntervention group|"White fabric will be covered over the incubator for term newborns during phototherapy.~During phototherapy, term newborns will receive a baby massage, including facial massage, chest massage, arm massage, abdominal massage and leg massage, twice a day for 15 minutes."
89360442|NCT06209489|No Intervention|Control group|The hospital's clinical routine will be applied to the newborns in the control group.
89360443|NCT06209463||Study group|The inclusion of 40 children diagnosed with Autism Spectrum Disorder (ASD) and their parents/caregivers is planned. Parents/caregivers of children diagnosed with ASD will undergo assessments including a demographic information form; sensory processing (Dunn Sensory Profile); nutrition (Screening Tool for Eating Problems (STEP), Brief Autism Mealtime Behavior Inventory (BAMBI)); quality of life (Pediatric Quality of Life Inventory (PedsQL 4.0)); assessments for children, including balance (Pediatric Berg Balance Scale); head posture (Craniovertebral angle method), hand functions (Jebsen Taylor Hand Function Test); grip strength (Jamar Hand Dynamometer); and evaluations for parents, including depression, anxiety, and stress levels (Beck Depression Inventory, Beck Anxiety Inventory, Spielberger State-Trait Anxiety Inventory).
89360444|NCT06209463||Control group|The inclusion of 40 typically developing children and their parents/caregivers is planned. Parents/caregivers of typically developing children will undergo assessments including a demographic information form; sensory processing (Dunn Sensory Profile); nutrition (Screening Tool for Eating Problems (STEP), Brief Autism Mealtime Behavior Inventory (BAMBI)); quality of life (Pediatric Quality of Life Inventory (PedsQL 4.0)); assessments for children, including balance (Pediatric Berg Balance Scale); head posture (Craniovertebral angle method), hand functions (Jebsen Taylor Hand Function Test); grip strength (Jamar Hand Dynamometer); and evaluations for parents, including depression, anxiety, and stress levels (Beck Depression Inventory, Beck Anxiety Inventory, Spielberger State-Trait Anxiety Inventory).
89360445|NCT06209450|Experimental|Ventral hernia repair|
89360446|NCT06209424|Active Comparator|In-Person Phase|Habitual Activity + Resistance Exercise Metabolic Trials
89360447|NCT06209424|Active Comparator|At-Home Phase|Habitual Activity + Step-Reduction Metabolic Trials
88832092|NCT02045264|Experimental|Icatibant (30 mg)|30mg dose of icatibant is administered as a single subcutaneous injection in the abdominal area
88832093|NCT02975297|Experimental|Exenatide plus NRT plus counseling|Once weekly exenatide Injectable Product, Nicotine Replacement Therapy (NRT) Patch, smoking cessation counseling
89360448|NCT06209411|Active Comparator|Referral Arm|CHW will contact participants with GDM from communities in the referral arm beginning at 6 weeks postpartum to arrange a convenient time for a home visit within the first postpartum year. During the home visit, CHW will provide 1) T2DM education and 2) referral to the postnatal clinic at a government hospital for T2DM screening.
89360449|NCT06209411|Experimental|Home Testing Arm|CHW will contact participants with GDM from communities in the home-based testing arm beginning at 6 weeks postpartum to arrange a convenient time for a home visit within the first postpartum year. During the home visit, CHW will provide 1) T2DM education, and 2) offer home-based OGTT.
89360450|NCT06209398|Experimental|Combined immunization Group|The first dose of inactivated EV71 vaccine and the third dose of hepatitis B vaccine were combined administered on day 0, and the second dose of EV71 vaccine and Group A meningococcal polysaccharide vaccine were jointly administered on day 30.
89360451|NCT06209398|Active Comparator|Single immunization Group|On the 0th and 30th day, receive two doses of inactivated EV71 vaccine respectively. On the 60th day, both hepatitis B vaccine and Group A meningococcal polysaccharide vaccine were administrated.
89360452|NCT06209398|Active Comparator|hepatitis B and Group A meningococcal polysaccharide vaccine Group|Administrate hepatitis B vaccine on day 0, and Group A meningococcal polysaccharide vaccine on day 30.
89360453|NCT06209385|Experimental|YZJ-5053 tablets|YZJ-5053 tablets will be administrated orally quaque die (QD) for 21 days
89360454|NCT06209372||Group PENG (P)|Group PENG (P) received the PENG block with 20 mL of 0.25% bupivacaine under ultrasound guidance at preoperative care unit (PCU). The linear ultrasound probe for the PENG block was placed parallel to the imaginary line passing between the spina iliaca anterior inferior and the iliopubic eminence (IPE). The 80mm peripheral block needle was advanced with the in-plane technique, and the block was completed by injecting 20 mL of 0.25% bupivacaine.
89360455|NCT06209372||Group Control (C)|Group Control (C), patients who did not prefer the block were given 10 mg of IV bolus tramadol, followed by 10 mg/hr infusion at preoperative care unit (PCU).
89360456|NCT06209346|Experimental|TeleRehab Group|"The duration of treatment for the TeleRehab Group will be 8 weeks and will consist of a total of 20 sessions, with between 2 and 3 sessions per week depending on the week they are in.~Weeks 2, 4, 6 and 8 will have 2 sessions per week and weeks 1, 3, 5 and 7 will have 3 sessions per week.~These sessions will consist of videos that will make up the educational material, videos that will guide the TE program and respiratory control practices. All the sessions mentioned above will be in online format, through the TRAK platform."
89360457|NCT06209346|Active Comparator|Advices Group|They will receive informative material in weeks 1, 3, 5 and 7 about their pathology and with recommendations for them to achieve healthy lifestyle habits that do not further damage their disease. o Participants in the Advices Group will have the same follow-up assessments as the TeleRehab Group and will receive informative material. They will not have access to the audiovisual material generated for the TeleRehabGroup.
89360458|NCT06209333|Experimental|pelvic physiotherapy|
89360459|NCT06209333|Active Comparator|standard patient education|
89360460|NCT06209320|Active Comparator|Experimental group 1|Lower dose atropine sulfate eye drops
89360461|NCT06209320|Active Comparator|Experimental group 2|Low dose atropine sulfate eye drops
89360462|NCT06209320|Placebo Comparator|control group|placebo
89360463|NCT06209294|Experimental|Experimental: AK104 combined with nab-paclitaxel and carboplatin|Carboplatin, nab-paclitaxel and AK104 as neoadjuvant treatment before fertility-sparing surgery
89360464|NCT06209281|Experimental|Experimental group 1|1 drop each time, once every night at bedtime
89360465|NCT06209281|Experimental|Experimental group 2|1 drop each time, once every night at bedtime
89360466|NCT06209281|Experimental|control group|1 drop each time, once every night at bedtime
89360467|NCT06209268|Active Comparator|paricalcitol group|
89360468|NCT06209268|Placebo Comparator|placebo group|
89360469|NCT06209242|Experimental|Cast immobilization|Using cast immobilization with sugar tong and short arm splinting
89360470|NCT06209242|Experimental|Percutaneous pinning|Using k-wire percutaneous pinning
89360471|NCT06209229|Experimental|natirium nucleonate|"Calcitriol- 5000 units in the morning before meals every other day 21 days and the next 3 weeks after the end of therapy.~Magnesium (in the form of lactate dihydrate) 470 mg + pyridoxine (in the form of hydrochloride) 5 mg - take orally 3 tablets per meter square of body surface area, in the evening 2 hours before bedtime, 21 days and the next 3 weeks after the end of therapy.~Quercetin from onion juice - take orally 1000 mg in the morning before meals, 21 days, as well as the next 3 weeks after the end of therapy.~sodium oligodinucleatide orally at the rate of 2 tablets under the tongue per meter square of body surface, in the morning 15 minutes before meals every other day, a total of 5 times (1, 3, 5, 7 , 9 day from the beginning of therapy), then after 21 days to repeat the course for 3 months.~Spray natirium nucleonate 4 doses in the morning on the hyoid, suck, do not swallow for 3-5 minutes, once every 4 days for 21 days."
89360472|NCT06209216||Total Hip Replacement|No intervention
89360473|NCT06209203|Experimental|lowe-dose ZKY001 eye drops|The drug was given once immediately after surgery on D0, and 1 drop was given 4 times a day from D0 to D6
89360474|NCT06209203|Experimental|Medium-dose ZKY001 eye drops|The drug was given once immediately after surgery on D0, and 1 drop was given 4 times a day from D0 to D6
89360475|NCT06209203|Placebo Comparator|placebo|The drug was given once immediately after surgery on D0, and 1 drop was given 4 times a day from D0 to D6
89360476|NCT06209190|Experimental|Total marrow and lymphoid irradiation (TMLI)|TMLI will be added in doses of 12 Gy on days -3 to -1 divided into 6 fractions of 2 Gy every 12 hours for 3 days, which will be administered through a computed tomography tomotherapy system.
89360477|NCT06209177|Experimental|ARO-CFB (Healthy Volunteers)|1 or 2 doses of ARO-CFB by subcutaneous (sc) injection
89360478|NCT06209177|Experimental|Placebo (Healthy Volunteers)|placebo calculated volume to match active treatment by sc injection
89360479|NCT06209177|Experimental|ARO-CFB (Adult Patients with IgAN)|3 doses of ARO-CFB by sc injection
89360480|NCT06209099|Experimental|Group A: Nonoperative Management|Patients who achieve Clinical complete response (cCR) or near-cCR when restaged at 16 weeks following IMRT plus consolidation CapeOX.
89360481|NCT06209099|Experimental|Group B: Local Excision|Patients with near-cCR or residual tumor ≤ycT2N0 when reassessed at 16 weeks following IMRT plus consolidation CapeOX; or Patients with regrowth ≤ycT2N0 when reassessed during surveillance in NOM;
89360482|NCT06209099|Experimental|Group C: Total Mesorectal Excision|"Patients with residual tumor &gt;ycT2N0 when restaged at 16 weeks following IMRT plus consolidation CapeOX.~or Patients with regrowth &gt;ycT2N0 when reassessed during surveillance in NOM; or Patients with any high-risk pathological factors following local excision (LE)"
89360483|NCT06209073|Experimental|virtual reality exercise|the patients will receive virtual reality and conventional therapy three times a week for six weeks
89360484|NCT06209073|Experimental|conventional treatment|the patients will receive conventional treatment three times a week for six weeks
89360485|NCT06209047|Experimental|drug group|this arm will include half number of cases(which will be 35 cases) selected in a randomized manner and will undergo bronchoscopic airway clearance followed by local instillation of gentamicin(80 mg once) and dexamethasone(5 mg) once.
89360486|NCT06209047|No Intervention|control group|his arm will include the other half number of cases(35 cases) selected in a randomized manner and will receive only conventional treatment without intervention.
89360487|NCT06209008|Experimental|Intravesical PRP injection|Patients will receive 20 submucosal injections of PRP solution, each injection site receives 0.5 mL PRP. The injection needle will be inserted about 1 mm into the at the posterior and lateral walls of the bladder, using a 23 gauge needle and 22 F rigid cystoscope.
89360488|NCT06208995||Arm 1|Polycystic Ovary Syndrome (PCOS)
89360489|NCT06208995||Arm 2|Hypothalamic-Pituitary-Ovarian Axis Dysfunction
89360490|NCT06208982||Colorectal ulcers|Colonoscopy images and videos of colorectal ulcers.
89360491|NCT06208969|Experimental|intensive nutrition counseling|Five-stage nutrition counseling vith educational materials was carried out during hospitalization in the intensive nutrition counseling. Telephone interviews were conducted at the 2nd week and 2nd month after discharge.
89360492|NCT06208969|Active Comparator|standard nutrition counseling|Routine nutritional counseling was applied. Interviewed only at admission and at discharge if patient is consulted.
89360493|NCT06208956|Experimental|Dexmedetomidine group|Dexmedetomidine is infusion intravenously with a loading dose of 0.5 μg kg-1 for 10 min, then infusion at 0.3 μg kg-1 h-1 according to the ideal body weight of the patient until the end of colonoscopy. If Ramsay sedation scale score reach 3, colonoscope will be inserted. During the whole process, maintenance Ramsay score of 3 to 4. Propofol 10 mg will be administrated as the rescue dose if body movement occur during colonoscopy.
89001028|NCT00201708|Active Comparator|Arm B (Docetaxel after doxorubicin/cyclophosphamide)|"A (doxorubicin) 60 mg/m2 & C (cyclophosphamide) 600 mg/m2 every 2 weeks for 4 cycles followed by Docetaxel 75 mg/m2 every 2 weeks for 4 cycles."
89360494|NCT06208956|Other|Propofol group|Propofol is administrated 1 mg kg-1 intravenously, then titrated given by 0.5 mg kg-1 until Ramsay score reach 3. During the whole process, propofol is given intermittently to maintain Ramsay score 3 to 4. If body movement happen, propofol 10mg will be administrated every time.
89001029|NCT04632901||Testing of Visual Acuity (VA) Group|The same participants will undergo VA and CVA test with two different Landolt C charts under the same lighting conditions.
89001030|NCT04632901||Testing of Critical Visual Acuity (CVA) Group|The same participants will undergo VA and CVA test with two different Landolt C charts under the same lighting conditions.
89360495|NCT06208943||NeuroCOVID Group|Individuals (ages 18-70 years) who endorse a reported change in concentration, memory, feelings anxiety or depression since initial COVID infection.
89360496|NCT06208943||COVID Control Group|Individuals (ages 18-70 years) who do not feel any different since recovering from initial COVID infection.
89001031|NCT00410358|Experimental|LBQ707|
89001032|NCT04632979|Experimental|Backward runners|Training protocol patients
89360497|NCT06208917|Experimental|oral soluble film of ondansetron combined with dexamethasone|"Participants received the first dose of ondansetron oral soluble film (age-based adjustment) 30 minutes before chemotherapy and equal doses were given 4 hours and 8 hours after the first dose for whom younger than 12 years old while the others should be given 8h hours after the first dose.~Ondansetron oral soluble film was administered continuously for two days after chemotherapy according to the administration regimen on the day of chemotherapy. Dexamethasone (based on body surface area) iv/po twice daily from day 1 of chemotherapy until 2 days after completion of chemotherapy."
89360498|NCT06208917|Active Comparator|ondansetron intravenously combined with dexamethasone|"Participants received the first dose of ondansetron intravenously (weight-based adjustment) 30 minutes before chemotherapy and equal doses were given 4 hours and 8 hours after the first dose.~Ondansetron (po) was given for next continuously two days in the same dose and frequency of administration. Dexamethasone (based on body surface area) iv/po twice daily from day 1 of chemotherapy until 2 days after completion of chemotherapy."
89001033|NCT04632862|Experimental|DWP16001 Amg|DWP16001 Amg, Tablets, Orally, Once daily
89001034|NCT04632862|Placebo Comparator|DWP16001 Amg Placebo|DWP16001 Amg Placebo, Tablets, Orally, Once daily
89001035|NCT04633174|Experimental|Sous vide device|The intervention will be the use of a sous vide device to heat the water bath to 38oC, rather than the traditional methods of manual water exchanges or placing the frostbitten tissue under running water.
89001036|NCT04633135|No Intervention|Control|Households enrolled in the control arm of the study did not receive either improved cookstove
89001037|NCT04633135|Experimental|Gyapa/Gyapa|Households enrolled in the Gyapa/Gyapa arm of the study received two Gyapa stoves for free
89001038|NCT04633135|Experimental|Gyapa/Philips|Households enrolled in the Gyapa/Philips arm of the study received one Gyapa stove and one Philips stove for free
89001039|NCT04633135|Experimental|Philips/Philips|Households enrolled in the Philips/Philips arm of the study received two Philips stoves for free
89001040|NCT00410397|Experimental|A|Osteopathic Manipulative Medicine
89001041|NCT00410397|Placebo Comparator|B|
89001042|NCT04632745|Other|Cast Group|participant with distal radius fracture will be treated with short arm fiberglass cast
89360499|NCT06208891||Robotic myomectomy|Women who received robotic myomectomy
89360500|NCT06208852|No Intervention|Qualitative phase|The qualitative phase of the sub-study will consist of semi-structured interviews. During the semi-structured interviews, 10 eligible women will be recruited to identify barriers and facilitators to accessing virtual mental health services during the pandemic. This information will be used to adapt an evidence-based patient navigation intervention for virtual use. Investigators will also use information from this qualitative study to adapt a measure of engagement in early intervention services for use among women with postpartum depression to measure engagement with mental health services.
89360501|NCT06208852|Experimental|Intervention Phase|For the intervention phase of the sub-study, 30 women with persistent postpartum depression symptoms will be recruited to participate in the adapted virtual navigator program using rapid cycle testing over a 2-month period.
89360502|NCT06208839|Active Comparator|SBIRT/TAU for those with moderate risk drug or alcohol use|This moderate risk group will receive the standard Screening and Brief Intervention Treatment (SBIRT) along with Treatment as Usual (TAU) at the clinic.
89360503|NCT06208839|Experimental|SBIRT/eIntervention for those with moderate risk drug or alcohol use|Subjects assigned to this condition will be instructed by the research assistant in how to download and use the eIntervention app, which they will be free to use as they like for the duration of the study. The app will contain a personalized suite of programs and activities. Unlike the TAU condition, the patient's referral to treatment would be managed through eIntervention. For example, the app will show the patient their referral details (if a referral to treatment was made), including details on the provider, referred services, and contact information, and will offer them videos of peers and professionals educating them on addiction, treatment, and sharing personal stories of recovery.
89360504|NCT06208839|Active Comparator|SBIRT/TAU for those assessed with high risk.|This high risk group will receive the standard Screening and Brief Intervention Treatment (SBIRT) along with Treatment as Usual (TAU) at the clinic.
89360505|NCT06208839|Experimental|SBIRT/eIntervention those assessed with high risk.|Subjects assigned to this condition will be instructed by the research assistant in how to download and use the eIntervention app, which they will be free to use as they like for the duration of the study. The app will contain a personalized suite of programs and activities. Unlike the TAU condition, the patient's referral to treatment would be managed through eIntervention. For example, the app will show the patient their referral details (if a referral to treatment was made), including details on the provider, referred services, and contact information, and will offer them videos of peers and professionals educating them on addiction, treatment, and sharing personal stories of recovery.
89360506|NCT06208826|Experimental|Toripalimab|toripalimab, IV, 240mg, q3w, for 15 cycles
89360507|NCT06208826|Active Comparator|SOC CCRT or radiotherapy|Standard concurrent radiochemotherapy or postoperative radiotherapy
89360508|NCT06208813|No Intervention|Control Group|Participants will consume their normal daily diet.
89360509|NCT06208813|Experimental|Creatine supplementation|The intervention group will consume their usual diet plus 5 grams of creatine for the first four days following the initial meeting, and then 3 grams of creatine once per day thereafter until asymptomatic.
89360510|NCT06208800|Experimental|Experimental group to which the essential oil mixture will be applied|Thirty elderly individuals will be included in the experimental group. The elderly individuals in the intervention group were given essential oil mixtures in 5 ml bottles prepared by the expert aromatherapist and the researcher, and it was decided to inhale these essential oils by dropping 5 drops on cotton wool for 10 minutes each for 4 weeks.
89360511|NCT06208800|No Intervention|Experimental group without essential oil mixture.Control group|Thirty elderly individuals will be included in the control group. This group will not be intervened, only questionnaires will be administered.
89360512|NCT06208774|Experimental|LV-ISBP block Group (n=40): US-guided low volume interscalene brachial plexus block|Patient in a semi-sitting position with the head tilted to the opposite side of the injection site. A linear US probe (4-12 MHz) will be placed parallel to the clavicle in the supraclavicular fossa, and the subclavian artery will be seen beating above the first rib.Then the probe will be moved cranially to identify the transverse process of the C7 vertebra at the level of the brachial plexus roots between the scalenus anterior and medius muscles.The needle will be inserted in a plane approach from lateral to medial to scalenus medius and C5-C6 brachial plexus roots. After negative aspiration, a total of 5 mL of bupivacaine 0.5% will be injected incrementally.
89360513|NCT06208774|Active Comparator|PENG block Group (n=40): US-guided pericapsular nerve group block for shoulder|The patient's arm was placed in external rotation and abducted at 45 degrees. A linear US probe (4-12 MHz) will be placed longitudinally between the coracoid and the humeral head, visualizing the deltoid muscle and subscapularis tendon. 22-gauge needle will be advanced in-plane into the fascial plane between the deltoid muscle and subscapularis tendon. The location of the needle tip will be confirmed by hydrodissection of inter-fascial planes with 3 ml of normal saline. After negative aspiration, a total of 20 mL of bupivacaine 0.5% will be injected in the fascial plane incrementally, aspirating every 5 ml.
89360514|NCT06208761|Placebo Comparator|Placebo capsule supplementation|Participants were randomized to receive an arm. In this arm, participants consumed placebo capsule for 2 capsules daily consisting of 1 capsule (500 mg) before breakfast and 1 capsule (500 mg) before dinner, 5 days/week - separated by a couple of days, for 8 weeks. Consumption was taken at participants' dwelling.
89360515|NCT06208761|Experimental|Triphala capsule supplementation|Participants were randomized to receive an arm. In this arm, participants consumed Triphala capsule for 2 capsules daily consisting of 1 capsule (500 mg) before breakfast and 1 capsule (500 mg) before dinner, 5 days/week - separated by a couple of days, for 8 weeks. Consumption was taken at participants' dwelling.
89360516|NCT06208761|Experimental|High-intensity interval training|Participants were randomized to receive an arm. In this arm, participants received leg cycling exercise program in the form of high-intensity interval training for 28 min/day, 3 days/week for 8 weeks. Exercise training was performed at Burapha University.
88832094|NCT02975297|Placebo Comparator|Placebo plus NRT plus counseling|Once weekly placebo, Nicotine Replacement Therapy (NRT) Patch, smoking cessation counseling
88832095|NCT02046200|Experimental|Ivermectin|Ivermectin 30 mg single dose
88832096|NCT02046200|Placebo Comparator|Sugar pill|Matched placebo, single dose
89360517|NCT06208761|Experimental|Triphala capsule supplementation and high-intensity interval training|Participants were randomized to receive an arm. In this arm, participants received both Triphala capsule and high-intensity interval training in the similar extent to the Triphala capsule supplementation and high-intensity interval training arms. Consumption was taken at participants' dwelling and exercise training was performed at Burapha University.
89360518|NCT06208748|Experimental|bezuclastinib in combination with sunitinib|"Bezuclastinib 600 mg (tablet) administered orally daily Sunitinib 37.5 mg administered orally daily~Patients will begin bezuclastinib and add sunitinib 2 weeks later. Each cycle is 28 days."
89360519|NCT06208735|Experimental|CLIC-2201|A single Intravenous infusion of CLIC-2201 will be given.
89360520|NCT06208722|Experimental|Experimental|Children in the experimental arm will receive the same health education module as in the control arm. They will also receive a brief tutorial on additional app components in the form of a digital social story, which is an effective way to convey information to children with autism. Participants will be completing 26-item Behavioral Survey at 2 weeks, 1 month, 2 month, and 3 month. Participants will be using the app during toothbrushing 2x a day for 3 months under direct supervision of the caregiver.
89360521|NCT06208722|Other|Control|The control arm will consist of a 20-second health education module delivered through the control app that consists of a digital selfie mirror and a timer that matches the length of brushing time in the experimental app. Participants will be completing all the survey activities similar to that of the participants in the experimental arm.
89360522|NCT06208709|Experimental|CASA Arm|Arm that will be given the test intervention device.
89360523|NCT06208709|Active Comparator|SOC Arm|Arm that is given a standard brace used for treating Carpal Tunnel Syndrome pain.
89360524|NCT06208696|Experimental|Intervention group (TCS)|"Participants with Long-COVID and chronic diseases that agree to participate in the intervention will participate in the Tomando Control de su Salud (TCS) workshops. TCS is an evidenced based intervention in Spanish and a culturally appropriate version similar to the Chronic Disease Self-Management program of the Centers for Disease Control and Prevention (CDC) aimed to improve disease management skills, including decision making, problem solving, and action planning among patients with at least one chronic condition."
89360525|NCT06208696|No Intervention|Non-Intervention Group (Regular care)|Those not interested in participating in the intervention will receive general information about chronic disease management available at the CDC website in Spanish, by email or in person.
89360526|NCT06208683|Experimental|1MCV: MV|100 students with a history of 1 dose of MCV will receive 1 dose of MV.
89360527|NCT06208683|Experimental|1MCV: QIV|100 students with a history of 1 dose of MCV will receive 1 dose of QIV.
89360528|NCT06208683|Experimental|1MCV: MV +QIV|100 students with a history of 1 dose of MCV will receive 1 dose of MV and 1 dose of QIV simultaneously.
89360529|NCT06208683|Experimental|2MCV: MV|100 students with a history of 2 dose of MCV will receive 1 dose of MV.
89360530|NCT06208657|Experimental|Arm A Paxalisib|Drug: Irinotecan Drug: Temozolomide Drug: Paxalisib Irinotecan 50mg/m2/day, intravenous, on days 1-5, 28 day cycle, 13 cycles Temozolomide 150mg/m2/day, oral, on days 1-5, 28 day cycle, 13 cycles Paxalisib 21mg/m2 oral, daily, 28 day cycle, 13 cycles
89360531|NCT06208657|Experimental|Arm B Pimasertib|Drug: Pimasertib Pimasertib 28mg/m2 oral, twice daily, 28 day cycle, 26 cycles
89360532|NCT06208631|Experimental|Gait modification|Participants will learn to change muscle coordination while walking through real-time haptic biofeedback based on the activation of the gastrocnemius muscle
89360533|NCT06208605|Experimental|Transdiagnostic Network Informed Personalized Treatment|Participants will receive 1 session of education about the treatment after completing Phase I of the study (two weeks of ecological momentary assessment). Participants will then complete 10 sessions of personalized treatment for eating disorders based on their ecological momentary assessment surveys. Participants will complete one session of relapse prevention at the end.
89360534|NCT06208605|Active Comparator|Cognitive Behavioral Therapy for Eating Disorders|Participants will receive 1 session of education about the treatment after completing Phase I of the study (two weeks of ecological momentary assessment). Participants will then complete 10 sessions of Enhanced Cognitive Behavioral Therapy for Eating Disorders (CBT-E. Participants will complete one session of relapse prevention at the end.
89360535|NCT06208566|Experimental|Conversational Agent Zenny|Participants received access to a self-help program delivered via an automated conversational agent on WhatsApp.
89360536|NCT06208566|Active Comparator|Web-based Wellness Resources|Participants received a list of three freely accessible wellness resources available on the web.
89360537|NCT06208540|Active Comparator|Patients group (with interventional treatment)|Patients with persistent smell and taste disorders and treated with cerebrolysin
89360538|NCT06208540|Placebo Comparator|Control|Patients with persistent smell and taste disorders but untreated with cerebrolycin (no intervention)
89360539|NCT06208527|Placebo Comparator|Placebo group|Placebo, no active ingredients. Administered in tablet form twice daily for the duration of the trial (1 year).
89360540|NCT06208527|Experimental|NR group|Nicotinamide Riboside (NR) administered in doses of 1000 mg twice daily for the duration of the trial (1 year).
89360541|NCT06208475|Experimental|The exercise in the follicular phase (EF)|Resistance exercise during the early-follicular phase (approximately during days 1-7 of the menstrual cycle).
89360542|NCT06208475|Experimental|The exercise in the luteal phase (EL)|Resistance exercise during the mid-luteal phase (approximately during days 18-25 of the menstrual cycle).
89360543|NCT06208475|No Intervention|The control in the follicular phase (CF)|Sit and rest during the early-follicular phase (approximately during days 1-7 of the menstrual cycle).
89360544|NCT06208475|No Intervention|The control in the luteal phase (CL)|Sit and rest during the mid-luteal phase (approximately during days 18-25 of the menstrual cycle).
89399147|NCT02168894|Experimental|Group 2 - Acupuncture Sessions Without Electrical Stimulation|Participants in Group 2 have acupuncture sessions without electrical stimulation 3 times a week for 4 weeks, for a total of 12 sessions. Then, will take a 2 week break. After that, participant randomly assigned to receive 12 extra sessions of acupuncture without electrical stimulation or not have anymore sessions in this study. Nerve function tests performed at visit before acupuncture and at end of study visit. These tests consist of hand tasks and balance tests. Questionnaires completed at baseline, visit before acupuncture, after 6 and 12 acupuncture visits, and at end of study visit.
89360545|NCT06208449|Experimental|Robotic repair group|"the patients were lying in a left decubitus position (45° prone).~An 8-mm trocar was inserted into the thoracic cavity at the fifth intercostal space of the right midaxillary line and used as a camera port, Another two 8-mm trocars were placed at the third intercostal space of the right midaxillary line and the eighth intercostal space of the posterior axillary line. Insufflation of the CO2 was at a flow rate of 1 L/min and a pressure of 6 mm Hg.~The fistula was ligated and sutured by figure-of-eight suture ligation. The proximal blind end was fully mobilized and the distal blind end was properly mobilized to prepare for anastomosis.~Next, the 5-0 absorbable sutures were used to perform the anastomosis posteriorly and anteriorly in an interrupted way.. Thereafter, the nasogastric tube was inserted into the stomach. followed by another 6 sutures to complete the anterior wall anastomosis.~A chest drain was placed alongside the anastomosis."
89360546|NCT06208449|Experimental|Thoracoscopic repair group|"All procedures were performed through three ports~Insufflation of the CO2 was at a flow rate of 1 L/min and a pressure of 4-6 mm Hg.~The azygos vein was ligated and cut, or divided by electrocoagulation.~The fistula was then dissociated, ligated with 4-0 absorbable sutures, and divided.~After identifying the proximal esophageal pouch with a nasogastatic tube, the proximal and distal blind ends were mobilized to prepare for anastomosis.~Next, the tip of the blind ends was excised, and the anastomosis was completed with 5-0 absorbable sutures in an interrupted manner.~A chest drain was placed alongside the anastomosis."
89360547|NCT06208449|Active Comparator|Thoracotomy repair|Usually, the fifth intercostal space was applied using the muscular-sparing technique. Fistula ligation, proximal pouch isolation and anastomosis were performed in turn.The fistula was then dissociated, ligated with 4-0 absorbable sutures, and divided. After identifying the proximal esophageal pouch with a nasogastatic tube, the proximal and distal blind ends were mobilized to prepare for anastomosis. Next, the tip of the blind ends was excised, and the anastomosis was completed with 5-0 absorbable sutures in an interrupted manner. A chest drain was placed alongside the anastomosis.
89360548|NCT06208436||TMUCIH-PDAC|Between 2010 and 2021, the data of patients who underwent surgical resection and were pathologically diagnosed as PDAC from Tianjin Medical University Cancer Institute and Hospital (TMUCIH) were collected retrospectively.
89360549|NCT06208397||Experimental: Diagnostic (MRE)|Patients undergo a preoperative routine MRI scan and MRE the day before their scheduled surgery to assess OSS and NOSS. After surgery, the HGP of tumor will be assessed by H&E-stained sections.
89360550|NCT06208384|Experimental|Statin eye drop|Use of topical atorvastatin eye drop 8 times a day; in addition to eyelid hygiene and artificial tear drops (8 weeks)
89360551|NCT06208384|Placebo Comparator|Control|Use of topical eye drops as a placebo same as intervention group but without active ingredient of atorvastatin 8 times a day; in addition to eyelid hygiene and artificial tear drops (8 weeks)
89360552|NCT06208358|Active Comparator|real tACS|Device: Transcranial Alternating Current Stimulation In recent years, transcranial alternating current stimulation (tACS) has been widely used to regulate brain neural activity and improve cognitive function because of its non-invasive, portable, and easy-to-operate characteristics. tACS can effectively improve 9 cognitive functions, including visual attention, working memory, long-term memory, executive control, fluid intelligence, learning, decision-making, motor learning, and motor memory
88832097|NCT02978339|Experimental|Curcumin|Subjects will receive one 750 mg softgel by mouth twice a day for 12 weeks. Each each 750 mg CuraMed® softgel supplies 500 mg of highly bioavailable BCM-95 curcumin.
88832098|NCT02367014|Experimental|Low Dose|elamipretide 0.01 mg/kg/hr infused for 2 hours for 5 days
88832099|NCT02367014|Experimental|Intermediate dose|elamipretide 0.10 mg/kg/hr infused for 2 hours for 5 days
88832100|NCT02367014|Experimental|High dose|elamipretide 0.25 mg/kg/hr infused for 2 hours for 5 days
88832101|NCT02367014|Placebo Comparator|Placebo|In each cohort, subjects received either IV elamipretide given once daily for 2 hours for 5 days or matching placebo.
88832102|NCT02367872|Active Comparator|Participants with normal renal function: TAK-272 40 mg|Fasted single oral administration of TAK-272 40 milligram (mg)
88832103|NCT02367872|Experimental|Participants with mild renal impairment: TAK-272 40 mg|Fasted single oral administration of TAK-272 40 mg
88832104|NCT02367872|Experimental|Participants with moderate renal impairment: TAK-272 40 mg|Fasted single oral administration of TAK-272 40 mg
88832105|NCT02367872|Experimental|Participants with severe renal impairment: TAK-272 40 mg|Fasted single oral administration of TAK-272 40 mg
88832106|NCT02367872|Experimental|Hemodialysis participants: TAK-272 40 mg|Fasted single oral administration of TAK-272 40 mg
88832107|NCT02367872|Active Comparator|Participants with normal hepatic function: TAK-272 40 mg|Fasted single oral administration of TAK-272 40 mg
88832108|NCT02367872|Experimental|Participants with mild hepatic impairment: TAK-272 40 mg|Fasted single oral administration of TAK-272 40 mg
88832109|NCT02367872|Experimental|Participants with moderate hepatic impairment: TAK-272 40 mg|Fasted single oral administration of TAK-272 40 mg
88832110|NCT02979899|Experimental|TRC105 plus votrient|weekly TRC105 i.v. in combination with standard dose votrient by mouth, once daily
88832111|NCT02979899|Active Comparator|votrient|standard dose votrient by mouth, once daily
88832112|NCT02412644|Active Comparator|Apremilast + apremilast|apremilast 30mg bid for 12 weeks.followed by apremilast 30 mg bid for 24 weeks
88832113|NCT02412644|Placebo Comparator|apremilast + placebo|apremilast 30mg bid for 12 weeks followed by placebo bid for 24 weeks
88875505|NCT04107168||Cohort 6|Disease: Advanced NSCLC Anti-PD-(L)1 (Nivolumab, Pembrolizumab or Atezolizumab) + chemotherapy +/- antiangiogenic (Bevacizumab) in the first line setting. Dosage form, dosage, frequency and duration will be either standard of care and accessed via normal commissioning arrangements, or will be part of an ethics-approved clinical trial, where co-enrollment into an observational study is permitted.
89360553|NCT06208358|Sham Comparator|sham tACS|Device: Transcranial Alternating Current Stimulation In recent years, transcranial alternating current stimulation (tACS) has been widely used to regulate brain neural activity and improve cognitive function because of its non-invasive, portable, and easy-to-operate characteristics. tACS can effectively improve 9 cognitive functions, including visual attention, working memory, long-term memory, executive control, fluid intelligence, learning, decision-making, motor learning, and motor memory
88832114|NCT03134963||Mild cognitive impairment|"MCI Patient-specific Inclusion Criteria~Clinical diagnosis of MCI made by a specialist* in a patient who fulfils the established clinical consensus criteria for MCI [NIA/AA 2011] specifically:~Concern regarding a change in cognition compared to the person's previous level, by the patient and/or informant~Objective evidence of impairment of one or more cognitive domains, greater than expected for age, and educational background, over time if repeated measures are available.~Preserved independence of functional abilities and minimal to no impairment on complex instrumental functions~Not demented"
89360554|NCT06208332|Experimental|Photo-Narrative|
89360555|NCT06208332|No Intervention|Usual Care|
89360556|NCT06208280|Experimental|Assigned Interventions|
88832115|NCT03134963||Alzheimer disease|"NIA/AA criteria~Meets the criteria for dementia~o The memory impairment and cognitive deficits cause significant impairment functioning, a significant decline from a previous level of functioning, Impairment of at least two cognitive domains~Insidious or gradual onset~Clear history of worsening cognition by report or observation~The initial and most prominent cognitive deficits are evident on history and examination in one of the following domains:~Amnestic: impaired learning and recall of recently learned information~Non amnestic: language/visuospatial/executive dysfunction"
88832116|NCT03134963||Vascular dementia|"NINDS-AIREN criteria for VascD, specifically:~Cerebrovascular disease defined by the presence of focal signs on neurological examination consistent with stroke and evidence of cerebrovascular disease on brain imaging.~One or more of:~Onset of dementia within 3 months of a diagnosed stroke~Abrupt deterioration in cognitive function~Fluctuating, stepwise progression of cognitive deficits"
89360557|NCT06208267|Active Comparator|1)Standard care: 1G TXA IV|1 gm TA IV given prior to incision and 1G TXA IV during cementation
88832117|NCT03134963||Healthy controls|"Healthy Controls-specific Inclusion Criteria~No evidence of subjective or objective memory impairment on cognitive testing~No major medical co-morbidity (outlined in detail in the exclusion criteria) or medication use that could adversely affect cognition"
88832118|NCT02046902||Heart disease|Adults with a diagnosis of coronary artery disease and may have had a percutaneous coronary intervention.
88832119|NCT02046902||Healthy adults|Adults without a diagnosis of coronary artery disease. Focus groups will be held.
89001043|NCT04632745|Other|Splint Group|participant with distal radius fracture will be treated with short arm velcro wrist splint
89360558|NCT06208267|Active Comparator|2) Standard + 1G oral TXA - 0 and 8 hours post-operatively|Standard + 1G oral TXA given at 0 and 8 hours post-operatively
89360559|NCT06208267|Active Comparator|3) Standard + 1G oral TXA - 0, 8 and 16 hours post-operatively|Standard + 1G oral TXA given at 0, 8 and 16 hours post-operatively
89360560|NCT06208267|Active Comparator|4) Standard + 1G oral TXA given at 0, 8, 16 and 24 hours post-operatively|Standard + 1G oral TXA given at 0, 8, 16 and 24 hours post-operatively
89360561|NCT06208254||Patients|Patients having at least one rough surface titanium implant in function for more than 5 years.
89360562|NCT06208228|Experimental|kinesiotape|Kinesiotape application to masseter and hyoid muscles of late preterm infants for improving sucking and swallowing.
89360563|NCT06208228|No Intervention|Control|In this group the late preterm infants won't be applied kinesiotaping to suck and swallow muscles.
89360564|NCT06208202|Active Comparator|Fruit flavored e-cigarette with synthetic cooling agents added|Synthetic cooling agents will be added to fruit flavored e-liquid for this condition.
89360565|NCT06208202|Active Comparator|Fruit flavored e-cigarette|Fruit flavored e-liquid will be for this condition.
89360566|NCT06208202|Active Comparator|Tobacco flavored e-cigarette with synthetic cooling agents added|Synthetic cooling agents will be added to tobacco flavored e-liquid for this condition.
89360567|NCT06208202|Active Comparator|Tobacco flavored e-cigarette|Tobacco flavored e-liquid for this condition.
89360568|NCT06208176|Active Comparator|active stimulation group|23 patients will receive 20 sessions of active HD-tDCS
89360569|NCT06208176|Placebo Comparator|placebo stimulation group|High-definition transcranial direct current (HD-tDCS), sham condition
89360570|NCT06208163|Experimental|Chiropractic care|6 weeks of chiropractic care
89360571|NCT06208137|Experimental|Intervention group|Remind patients to test their immune status among 120-180 days post-transplantation. Physicians assessed the risk level of patients in the intervention group based on their immune status on days 91-180 using the CIRS.
89360572|NCT06208137|No Intervention|Control group|Only remind patients to test their immune status among 120-180 days post-transplantation.
89360573|NCT06208111|Experimental|Treatment group|"Experimental Group:~participants in the experimental group would receive 8-10 Cognitive Behaviour Therapy-based therapeutic sessions."
89360574|NCT06208111|No Intervention|control group|Participants in the control group did not receive the said Cognative Behaviour Therapy intervention
89360575|NCT06208098|Experimental|Salivary cortisol dosage|saliva sample (1 ml) at 8 & 9 h & at T30
89360576|NCT06208085|Experimental|Avocado|Participants will be provided avocados and asked to consume an avocado a day for 12 weeks.
89360577|NCT06208085|No Intervention|No Avocado|Comparison arm in which no intervention occurs.
89360578|NCT06208072|Active Comparator|Irbesartan group|Randomized obese hypertensive patients will receive treatment with oral Irbesartan 150mg once daily for 8 weeks. Blood pressure response will be assessed at that time.
89360579|NCT06208072|Active Comparator|Eplerenone group|Randomized obese hypertensive patients will receive treatment with oral Eplerenone twice daily for 8 weeks. Blood pressure response will be assessed at that time.
88832120|NCT02980211|Experimental|Tooth Extraction and Graft Dehisced Socket|Treatment of dehiscence defects at the time of tooth extraction using a minimally-invasive GBR technique that involves the application of a particulate bone allograft and a non-resorbable PTFE membrane.
88832121|NCT02412956|No Intervention|Control|pamphlet
89360580|NCT06208059|Active Comparator|manual acupuncture group|In the manual acupuncture group, participants will be needled in the scalp motor area on the lesion side and left in place for 30 minutes after obtaining qi. During needle retention, the needles will be intermittently twisted for 2min twice, with a frequency of about 200 r/min. Participants will receive treatment once daily, with six consecutive days of treatment followed by one day of rest each week, for three weeks.
89360581|NCT06208059|Experimental|electroacupuncture group|The same acupoint was selected as the manual acupuncture group in the electroacupuncture group. After obtaining qi, electroacupuncture stimulation will be applied using a continuous wave at a frequency of 2 Hz. The stimulation intensity will be adjusted based on the patient's tolerance, and each treatment will be lasted for 30 minutes. Participants will receive treatment once daily, with six consecutive days of treatment followed by one day of rest each week, for three weeks.
89360582|NCT06208033|Experimental|Treatment-naïve subjects with EGFR positive advanced Lung Adenocarcinoma|toripalimab：3mg/kg， Q2W； SMET12：60μg，Q2W； Pemetrexed Disodium 500mg/m2 d+Carboplatin AUV＝5 d1 Q3W，administered for 2~4 cycles
89360583|NCT06208033|Experimental|Treatment-naïve subjects with EGFR positive advanced Lung Squamous Cell Carcinoma|toripalimab：3mg/kg， Q2W； SMET12：60μg，Q2W； paclitaxel 100mg/m2 d1，d8，d15+cisplatin 75mg/m2 d1 Q3W， administered for 2~4 cycles
88832122|NCT02412956|Experimental|Intervention (text)|SmokefreeMOM text messaging program
88832123|NCT02412956|Experimental|Intervention Plus (text+quitline)|SmokefreeMOM text messaging program + state quitline
88832124|NCT03054077|No Intervention|Control or Group 1|This group receives standard of care for the child receiving a sedated procedure. There is no intervention for this group.
88832125|NCT03054077|Experimental|Intervention group or Group 2|This group receives an iPad with downloaded games to play while waiting for the sedation/procedure and then resume play upon return to the recovery area and awakening.
88832126|NCT02046980|Experimental|Gufoni|Gufoni maneuver for apogeotropic horizontal BPPV at the first day
88832127|NCT02046980|Experimental|Vibration|Vibration maneuver for apogeotropic horizontal BPPV at the first day
88832128|NCT02046980|Sham Comparator|Sham|Sham maneuver for apogeotropic horizontal BPPV at the first day
88832129|NCT02983877|Experimental|iTAB-CV|"In the Individualized Texting for Adherence Building-CV (iTAB-CV) Stage 1, participants will receive alternating daily texts with educational and motivational content on treatment for high blood pressure and bipolar disorder, and a daily mood rating request to both monitor their mood and to determine adherence to iTAB-CV intervention. Stage 1 will last one month.~In the Individualized Texting for Adherence Building-CV (iTAB-CV) Stage 2, participants will receive daily texts which will include medication reminders, contextual cues, and immediate reinforcement for medication taking behavior in addition to the content from Stage 1. Stage 2 will last one month."
88832130|NCT02413034|Placebo Comparator|Control group|no antibiotic prophylaxis group
88832131|NCT02413034|Active Comparator|Study group cefazolin|Classical antibiotic prophylaxis
89360584|NCT06208033|Experimental|Subjects resistant to first-line treatment contain immune checkpoint inhibitors|toripalimab：3mg/kg， Q2W； SMET12：60μg，Q2W； Docetaxel 60-75 mg/m2 d1Q3W，administered for 2~4 cycles
89360585|NCT06207994|No Intervention|Standard Target Range|The SpO2 TR width is set to 5% SpO2, as is routine in the department. The actual TR will vary depending on the GA, as is standard practice in the department.
89360586|NCT06207994|Experimental|Narrow Target Range|The SpO2 TR width is set narrower than the Standard TR. The actual TR will vary depending on the GA, as is standard practice in the department.
89360587|NCT06207994|Experimental|Shifted Target Range|The SpO2 TR width is set as the Standard TR. The median of the TR is shifted up compared to the Standard TR. The actual TR will vary depending on the GA, as is standard practice in the department.
89360588|NCT06207968||Arthroplasty|"Knee prostheses are intended for patients suffering from functionally serious diseases of the knee causing daily disability that is insufficiently improved by medical treatment.~The functional diseases are among:~Knee osteoarthrosis~Osteonecrosis of the knee~Inflammatory disease~Patellofemoral arthritis~The patients having benefited from an arthroplasty will be followed for at least 15 years (until 20 years)."
89360589|NCT06207968||Ligament reconstruction|"Ligament reconstruction surgery should be considered for patient who have undergone a rupture of the anterior and/or posterior cruciate ligaments requiring partial or total reconstruction.~The patients having benefited from a ligament reconstruction will be followed for at least 5 years."
89360590|NCT06207955|Active Comparator|TMJ arthrocentesis + (I-PRF) injection & injection of Botox to lateral pterygoid muscle|
89360591|NCT06207955|Active Comparator|TMJ arthrocentesis followed by intra-articular injection of liquid platelet rich fibrin ( I-PRF )|
89360592|NCT06207955|Active Comparator|TMJ arthrocentesis|
89360593|NCT06207838|No Intervention|Actual therapy|The patient continues Multiple Daily Injection/Insulin Pump Therapy with or without CGM use as per routine procedures
89360594|NCT06207838|Experimental|Advanced Hybrid Cloosed Loop System|The patients will be switched to MiniMed 780G advanced hybrid cloosed loop system/ AHCL system
88832132|NCT04737473|Experimental|Opiod Free Anesthesia (OFA) group|The OFA protocol will entailed induction of anesthesia intravenously by the administration of the following drugs: magnesium sulfate 40mg/kg (without exceeding 2.5g), lidocaine 1.5mg/kg, ketamine 25mg, propofol 1.5-2mg/kg, dexamethasone 8mg and rocuronium 0.6mg/kg. Anesthesia will be maintained using isofluorane through volume controlled ventilation, and a mixture of magnesium sulfate 40mg/kg (without exceeding 2.5g/24h), lidocaine 1.5mg/kg, ketamine 25mg, and clonidine 1ug/kg in an electric pump syringe at 10 - 15 ml/h.
89360595|NCT06207825||Test cohort|A set of test images and videos will be collected prospectively from other subjects, according to the eligibility criteria, followed by random allocation of computer-generated sequence.Two expert endoscopists (with more than 5 years of experience in colonoscopy and a total number of procedures more than 1,000) and two junior endoscopists (with less than 3 years of experience in colonoscopy and a total number of procedures less than 500), who are blinded to the final diagnostic result, will be invited to classify the test set images and videos according to the pre-defined subtypes. All endoscopists will assess the test set data independently in a real-time basis. On the other hand, the CADx system will scan the test set images and videos independently. The prediction of ulcer subtypes will be recorded. The formal diagnostic report after evaluation by independent pathologists and gastroenterologists will be regarded as the ground truth.
88832133|NCT04737473|Active Comparator|General anesthesia (GA) group|The GA protocol described in the intervention arm
89360596|NCT06207773|Experimental|Educator verbal feedback|During the study, the educator will hold one-on-one meetings with the students regarding their clinical internship for at least 20 minutes every week for a total of 6 weeks
89360597|NCT06207760|Experimental|Minocycline|All subjects will receive Minocycline over 8 weeks in addition to their current antidepressant treatment.
89360598|NCT06207747|Experimental|This study will prospectively collect data from metastatic or stage III.D unresectable melanoma pts|"Timing of PET/CT scans:~Baseline PET/CT less than 4 weeks before first ICI infusion~Follow-up: 4 weeks (+/- 5 days) after first infusion, 16 weeks (+/- 7 days) after first infusion, then after every 16 weeks (+/- 7 days) or before in case of PD suspicion"
89534469|NCT00006046|Experimental|Hu3S193 10 mg/m2|Hu3S193 was administered weekly for 8 consecutive weeks. The antibody was diluted in physiologic saline containing 5% human serum albumin and infused intravenously at a maximum rate of 100 mg/hour. If patients were stable or responding, they were eligible to receive 8-week maintenance cycles of hu3S193 at 10 mg/m2 starting in week 10 and continuing until progression.
89534470|NCT00006046|Experimental|Hu3S193 25 mg/m2|Hu3S193 was administered weekly for 8 consecutive weeks. The antibody was diluted in physiologic saline containing 5% human serum albumin and infused intravenously at a maximum rate of 100 mg/hour. If patients were stable or responding, they were eligible to receive 8-week maintenance cycles of hu3S193 at 10 mg/m2 starting in week 10 and continuing until progression.
89360601|NCT06207695|Experimental|Brief Psychosocial Intervention|The group was leaded by two psychologists trained on trauma and disaster psychology, and group intervention. Each groups lasted 2.50 hours.
89360602|NCT06207682|Experimental|Arm 1: Avacopan and Simvastatin|A single dose of 40 mg simvastatin will be given orally in the morning on Day 1 and Day 10. The Day 10 dose of simvastatin will be co-administered with the morning dose of avacopan. On Days 3 through 11, avacopan will be given orally at 30 mg BID.
89360603|NCT06207682|Experimental|Arm 2: Avacopan and Simvastatin|A single dose of 40 mg simvastatin will be given orally in the morning on Day 1 and Day 10. The Day 10 dose of simvastatin will be co-administered with the morning dose of avacopan. On Days 3 through 11, avacopan will be given orally at 60 mg BID.
89360604|NCT06207669|Experimental|Music therapy group|A musical concert will be held for the participants in the Hicaz makam.
89360605|NCT06207656|Experimental|cetuximab in combination with encorafenib plus binimetinib (EBC)|"Patients will receive the following per 28-day cycle:~Encorafenib: 300 mg (4 × 75 mg oral capsule) daily (QD)~Binimetinib: 45 mg (3 × 15 mg oral tablet) twice daily (BID)~Cetuximab: 500 mg/m2 every 2 weeks as per standard institutional practice."
89360606|NCT06207643|Active Comparator|group (A) conventional CEA|this group of patients will be subjected to carotid endarterectomy using the conventional technique of this procedure
89360607|NCT06207643|Active Comparator|group (B) Eversion CEA|this group of patients will be subjected to carotid endarterectomy using the Eversion technique of this procedure
88832134|NCT03136913|Active Comparator|Closed Flap Technique|Healing by primary intention: Extraction and ridge preservation, utilizing non-resorbable membrane (Cytoplast® TXT-200 ) and freeze dried bone allograft (MinerOss® Cortical and Cancellous Chips (FDBA)), with flaps in primary coverage.
88832135|NCT03136913|Active Comparator|Open Flap Technique|Healing by secondary intention: Extraction and ridge preservation, utilizing non-resorbable membrane (Cytoplast® TXT-200) and freeze dried bone allograft (MinerOss® Cortical and Cancellous Chips (FDBA)), with flaps in position for healing by secondary intention.
88832136|NCT02413580|Experimental|IGIV-C Treatment|In this arm, subjects with myasthenia gravis exacerbations were treated with an IV dose of 2 g/kg of IGIV-C, which was administered over 2 consecutive days at a dose of 1 g/kg per day.
89360608|NCT06207617|Experimental|Immediate implant placement + customized healing abutment|After atraumatic extraction, flapless immediate implant of a suitable size will be placed using sequential drills of the Straumann implant system for osteotomy preparation. According to the prosthetically driven planned position, implant will be placed. Primary stability of the implant will be measured by rotational insertion torque, to be more than or equal 30 Ncm. All patients will receive an immediate anatomical customized healing abutment fabricated by adding flowable composite to the temporary cylindrical abutment mimicking the shape of the socket at the marginal gingiva, then it will be screwed to the implant.
89360609|NCT06207617|Active Comparator|Immediate implant placement + xenogeneic bone graft material + customized healing abutment|After atraumatic extraction, immediate implant will be placed as mentioned-above, then particulate xenogeneic bone graft will be packed into the gap between the implant and the buccal plate mesially and distally. bone grafting will be up to the level of the buccal bone crest, followed by screwing the customized healing abutment.
89360610|NCT06207604|Experimental|Open sinus lifting without bone grafting and simultaneous implant placement|When adequate release of the membrane is achieved and deemed enough by the operator, an osteotomy is created in the edentulous area following the drilling sequence provided by the implant system used. the implant placement is done directly with the implant motor and the use of a hand driver if needed to adjust the implant platform relation to the crestal bone, followed by cover screw placement.
89360611|NCT06207604|Active Comparator|Open sinus lifting with bone grafting and simultaneous implant placement|When adequate release of the membrane is achieved and deemed enough by the operator, an osteotomy is created in the edentulous area following the drilling sequence provided by the implant system used. the palatal packing of bone is made before the implant placement, as the palatal aspect of the sinus will be inaccessible after placement of the implant, the implant placement is done directly with the implant motor and the use of a hand driver if needed to adjust the implant platform relation to the crestal bone, followed by cover screw placement.
89360612|NCT06207591|Experimental|ECoG (electrocorticography) sensing|Use implantable ECoG-based Brain Computer interface to control assistive technology
89001044|NCT04632823|Experimental|Comprehensive non-pharmacological program intervention|The experimental group receives usual diabetes care plus 24 weeks of the comprehensive non-pharmacological program intervention.
89360613|NCT06207578|Experimental|Implant placement using crestal sinus approach|Drilling will be done gently till reaching 0-1mm from the sinus floor, then implant placement will take place and the implant itself will be used to gently elevate the sinus up to 3-5mm.
89360614|NCT06207578|Active Comparator|Implant placement using osseodensification|Using Densah bur kit foe osteotomy preparation followed by implant placement
89360615|NCT06207565|Experimental|Vestibular Flap Group|Vestibular Flap with immediate implant placement, bone graft and customized healing abutment.
89360616|NCT06207565|Active Comparator|Single Flap Approach group|Single Flap approach with immediate implant placement, bone graft and customized healing abutment.
89360617|NCT06207539|Other|Group 1|"Intramuscular administration of 20 milligrams hyoscine N-butyl bromide under the generic name of buscopan ampoule produced by Sanofi company, plus misoprostol under the generic name of misotac tablets, each of wich is 200 micrograms produced by Sigma company, approximately 400 micrograms (2 tablets) given by a member of the study team according to FIGO guidelines for use of misoprostol 2019 and to have a halved dose to 200 micrograms if patient with history of one or two cesarean section.~Misoprostol only will be repeated every 4 hours for maximum 5 doses."
89360618|NCT06207539|Other|Group 2|"Administration of misoprostol under generic name of misotac tablets each one is 200 micrograms produced by Sigma company, about 400 micrograms (2 tablets) given by a member of the study team according to FIGO guidelines use of misoprostol 2019 and to have a halved dose if patient with history of one or two cesarean sections.~Misoprostol only will be repeated every 4 hours for maximum 5 doses."
89360619|NCT06207526|Experimental|Blended face-to-face and smartphone intervention for delusional thoughts and experiences|"The blended face-to-face and smartphone intervention is implemented as a four-session intervention that is primarily based on an intervention from Bell et al. (2018/2020) which focused on hallucinations and is now being tailored to delusions. The intervention itself builds on the Coping Strategy Enhancement - program by Tarrier and colleagues (CSE; (Tarrier et al., 1990) by systematically build upon already applied coping strategies and therefore improve coping with psychotic symptoms. Participants receive four therapy sessions in person, while the app is used to collect data between sessions to be used in therapy and to record and train coping strategies between sessions.~All participants are allowed to continue parallel implemented standard scheduled treatment."
89360620|NCT06207500|Active Comparator|Intervention Group|Patients were offered pharmacist- led medication reconciliation on admission and discharge coupled with patient counselling.
89360621|NCT06207500|No Intervention|Control Group|Patients received standard care - only written instructions on discharge medications in the discharge letter, according to the standard practice.
89360622|NCT06207474|Other|Video + Chatbot|
89360623|NCT06207474|Other|Video + Paper|
89360624|NCT06207474|Other|Paper + Chatbot|
89360625|NCT06207474|Other|Paper + Paper|
89360626|NCT06207422|Experimental|Moderate intensity training program|
89360627|NCT06207422|Experimental|High intensity training program|
89360628|NCT06207383|Other|Atrial fibrillation ablation|Catheter ablation of atrial fibrillation using technique at the investigator's discretion but including pulmonary vein isolation as an endpoint.
89360629|NCT06207383|Active Comparator|Conduction system pacing + atrioventricular nodal ablation|Conduction system pacing (either His bundle pacing or left bundle branch area pacing) with catheter ablation of the atrioventricular node.
88832137|NCT02985827|Active Comparator|Rohto (r) Hydra|Menthol containing over the counter eyedrop
89001045|NCT04632823|No Intervention|Usual diabetes care|This group is control, the patients receive usual diabetes care routines.
89001046|NCT04632277|Placebo Comparator|Placebo|"A tap water,"
89001047|NCT04632277|Experimental|Expermental recieve low MG|Low Mg bottle water (50mg/l)
89001048|NCT04632277|Experimental|Expermental recieve high MG|high Mg bottle water (100 mg/l)
89001049|NCT04632472|Active Comparator|Active fixation bipolar lead|Left ventricular bipolar pacemaker lead, fixated by a side helix
89360630|NCT06207318|Experimental|ACT Intervention group|Participants in the ACT Intervention condition will receive a two-session intervention, with each session lasting 60-90 minutes. Intervention content will center around personal values and behaviors that align with participant goals and utilize the 'triflex' model of ACT, which indicates three core processes of psychological flexibility: be present, open up, and do what matters. Sessions will be facilitated by the PI, an advanced graduate student in the Clinical Science Ph.D. program at the University of Iowa trained in ACT psychotherapy and supervised by a licensed and highly experienced psychologist. Patients will receive a patient workbook and audio recordings of mindfulness exercises that mirror those completed during the session. The intervention will also focus on patients' health-related goals and objectives surrounding their surgery, and expectations for positive post-surgical functioning.
89360631|NCT06207318|No Intervention|Control treatment as usual (TAU) group|The control condition will consist of treatment as usual. This includes a 1.5-hour preoperative appointment with the case-assigned cardiothoracic surgeon and a nurse practitioner. Patients are provided with workbooks that include orientation to the hospital and lifestyle factors information, which includes diet, physical activity, and stress management recommendations.
89360632|NCT06207292|Experimental|SABR in oligo-M NSCLC|Synchronous and Metachronous oligo-M NSCLC patients will be enrolled to stereotactic ablative radiotherapy (SABR) of primary tumour (T) and/or regional node(s) (N) and oligo-metastatic site (M) with the aim of maintaining ongoing therapy or delaying delaying the start of systemic therapy
89360633|NCT06207279||Major Depressive Disorder|Patients meeting the diagnostic criteria for Major Depressive Disorder (MDD) according to DSM-5.
89360634|NCT06207279||Chronic Insomnia Disorder|Patients meeting the diagnostic criteria for Chronic Insomnia Disorder according to ICSD-3.
89360635|NCT06207279||Health Control|Healthy population.
89360636|NCT06207279||Attention Deficit and hyperactivity Disorder|Patients meeting the diagnostic criteria for Attention Deficit and hyperactivity Disorder (ADHD) according to DSM-5.
89360637|NCT06207266|Experimental|Participants with opioid use disorder group with emotion intelligence program (n=20)|Participants with opioid use disorder group who had emotion intelligence program to increase aware about definition, component, how to deal with EI to reduce relapse rate.
89360638|NCT06207266|No Intervention|Participants with opioid use disorder group without intelligence program (n=20).|Participants with opioid use disorder group who had traditional medical treatment only
89360639|NCT06207266|No Intervention|A healthy group (n=20) served as a control group.|A healthy group who did not have history of psychiatric illness or substance use.
89360640|NCT06207253|Experimental|High concentration of diclofenac sodium|High concentration of diclofenac sodium mixed with saline
89360641|NCT06207253|Active Comparator|Low concentration of diclofenac sodium|Low concentration of diclofenac sodium mixed with saline
89360642|NCT06207253|Active Comparator|Calcium hydroxide|Calcium hydroxide paste form
89360643|NCT06207240|Experimental|FES Therapy|Intention-driven assistive functional electrical stimulation provided during approximately 1 hour of task-oriented therapy. Sessions will be scheduled 3 days per week for 8 weeks.
89360644|NCT06207227|Experimental|VITA AV Clinical System|VITA AV Clinical System
89360645|NCT06207188||Observational|Patients undergo ultrasound imaging on study.
89360646|NCT06207136|Experimental|Intervention healthy diet|Participants in the active intervention group will have specific diet advice delivered with motivational and behaviour-change techniques and will learn relevant cooking skills in remotely-delivered group cooking classes (via Zoom).
89360647|NCT06207136|Active Comparator|Standard diet|The active control group will focus on an energy-adequate diet considered standard-of-care but similar to the participant's baseline diet. The control dietary intervention group will receive general diet advice and standard care and will receive instruction in cooking skills delivered in remote group cooking classes (via Zoom).
89360648|NCT06207123|Experimental|All Participants (Single Arm)|"All study participants will receive LP-118 and ponatinib. The initial dose of LP-118 to be tested is 100 mg, and initial dose of ponatinib to be tested is 30 mg. Higher doses of LP-118 will only be tested if the study doctor feels it is safe to do so. A member of the study team will let study participants know which doses they are assigned.~Study drugs will be given in 21-day cycles. There will be 7 study visits in cycle 1 (on Days 1, 5, 6, 7, 15, 22, and 28). LP-118 and ponatinib will be taken at home every day. Dexamethasone will be taken between days 1-7 and days 15-22. For Cycles 2-12, study participants will have 5 study visits per cycle (on Days 1, 8, 15, 22, and 28). On all days, study participants will take LP-118 and ponatinib at home.~Participants in this group will also receive standard of care vincristine, dexamethasone, and methotrexate during study cycles."
89360649|NCT06207097|Experimental|Dry needling plus exercise program.|
89360650|NCT06207097|Experimental|Elastic taping plus exercise program.|
89360651|NCT06207045|Experimental|limb elevation group|limb elevation plus standard medication
89360652|NCT06207045|No Intervention|control group|standard medication only
89360653|NCT06207019|Active Comparator|Hyflex EDM|Hyflex EDM One File (25/) with variable taper was used in continuous rotation at 500 rpm and 2.5 Ncm in a circumferential brushing action in the coronal and middle thirds, then in a pecking action for three to five cycles until the WL was reached.
89360654|NCT06207019|Active Comparator|The XP-endo Shaper|The XP-endo Shaper (30/0.01) was used in rotation mode at 800 rpm and 1.0 Ncm torque. Long, gentle strokes with amplitudes of 3-4 mm were used to go down to adjusted WL in three to five cycles. After it reached the WL over the adjusted WL, it was subjected to five more up-and-down motions.
89360655|NCT06207019|Active Comparator|Primary WaveOne Gold|Primary WaveOne Gold (25/07) was applied three times in a reciprocating motion; a gradual in-and-out pecking movement was utilized as directed by the manufacturer till the WL was reached.
89360656|NCT06207006|Experimental|eConquerFear-HK|Participants in the eConquerFear-HK intervention group will receive six online modules with each containing educational text, illustrative graphics, interactive exercises, and brief videos. Every module will teach a specific topic, such as self-examination and medical surveillance, values-based goal setting, attention training, detached mindfulness, worry management and treatment summary and relapse prevention.
89360657|NCT06207006|Active Comparator|Basic Cancer Care|Participants in the control group will receive six videos, which were designed to provide comprehensive lifestyle guidance (e.g., relaxation techniques, diet and physical activity advices) to help with survivors' maintenance of health in long-term.
89360658|NCT06206993|Experimental|Resistance training on the Kieser A5 pelvic floor trainer|"Participants will receive a supervised full body resistance exercise program with 10-12 machines twice weekly.~The resistance training for the experimental group includes an intervention program on the Kieser A5 pelvic floor trainer. The training is a predetermined program of the Kieser Training AG. A standardized instruction protocol and custom settings of the seat minimize training or measurement variations. The exercise on the Kieser A5 pelvic floor muscle trainer is standardized and will take 120 s in total which is based on current training theories."
89360659|NCT06206993|Active Comparator|Resistance training without pelvic floor biofeedback Kieser A5 pelvic floor trainer|"Participants will receive a supervised full body resistance exercise program with 10-12 machines twice weekly.~Participants in the active comparator group perform the resistance training unit without the pelvic floor biofeedback device A5 and undergo conventional pelvic floor muscle training with a physiotherapist once a week before the resistance training unit starts. Participants are individually informed about the anatomy and function of the pelvic floor muscles and how to correctly contract them. The methodical structure for the movement therapy after prostatectomy suggests that the participants first lay down, then go in the seat, then above the all fours position stand in the upright position tt be treated. Each exercise lasts 3 to 5 min and the session lasts around 20 - 30 min."
89360660|NCT06206980|Experimental|Physical Activity Promotion Group|"The rehabilitation program has the purpose of motivating patients to be more physically active. The treatment protocol had a total duration of 12 weeks.~During hospitalization, an education of patients is conducted and physical activity is initiated. A diary is provided to patients to record the activities that they perform during each week until completing the 12 weeks.~Additionally, phone calls are performed at 15 days, 1 and 2 months to motivate patients and answer any questions they may have."
89360661|NCT06206980|Active Comparator|Control group|Patients received an informational brochure in a consultation with a health professional. The brochure explained the importance of physical activity to improve the health condition of these patients. Patients had the opportunity to ask any questions to the healthcare professional.
89360662|NCT06206967|Experimental|Physical Activity Promotion Group|"The rehabilitation program has the purpose of motivating patients to be more physically active. The treatment protocol had a total duration of 12 weeks.~Three sessions are conducted during hospitalization for the education of patients and to start physical activity. A diary is provided to patients to record the activities that they perform during each week until completing the 12 weeks.~Additionally, phone calls are performed at 15 days, 1 and 2 months to motivate patients and answer any questions they may have."
89360663|NCT06206967|Active Comparator|Control group|Patients received an informational brochure in a consultation with a health professional. The brochure explained the importance of physical activity to improve the health condition of these patients. Patients had the opportunity to ask any questions to the healthcare professional.
89360664|NCT06206954|Experimental|MyHealthPath Tool|Receive MyHealthPath Tool intervention.
89360665|NCT06206954|Active Comparator|MyHealthPath Guide|Receive MyHealthPath Guide intervention
89360666|NCT06206915|Experimental|XZ120 monotherapy|
89360667|NCT06206889||Nurse|Nurses working in tertiary intensive care
89360668|NCT06206798|Experimental|experimental group|"Subjects were randomly assigned to the experimental or the control group.~There were 20 members in the experimental group who received 6-week intervention activities.~Each subject was asked to fill out the questionnaires three times in total. The first time was before the intervention; the second time was right after the intervention; and the last time was four weeks later of the intervention."
89001050|NCT04632472|Placebo Comparator|Passive fixation quadripolar lead|Left ventricular quadripolar passive fixation pacemaker lead
89360669|NCT06206798|No Intervention|control group|"There were 20 members in the control group who accepted chronic nursing care as usual without any nursing intervention.~Each subject was asked to fill out the questionnaires three times in total. The first time was the same time as the experimental group; the second time was 6 weeks after the first test; and the last time was four weeks after the second test."
89360670|NCT06206772||Healthy subjects|
89360671|NCT06206772||Episodic cluster headache, active|
89360672|NCT06206772||Episodic cluster headache, remission|
89360673|NCT06206772||Chronic cluster headache|
89001051|NCT00410436|Experimental|Resistance Training Group|Resistance Training (R) 3X/week progressing to 3 sets, 8 repetitions of 8 exercises at the maximum load that can be lifted 8 times in a controlled manner, maintaining proper form (8RM).
89001052|NCT00410436|Active Comparator|Control Group|Subjects will not be performing resistance exercise but will continue performing aerobic exercise at the same volume, duration and intensity as they did at baseline.
89360674|NCT06206720|Experimental|Deuremidevir Hydrobromide for Suspension|Deuremidevir Hydrobromide for Suspension will be orally administered at the twice-daily dosing levels of 15 mg/kg, 30 mg/kg, or 50 mg/kg for five days according to the weight of patients.
89360675|NCT06206720|Experimental|Placebo|Placebo will be orally administered at the twice-daily dosing levels of 15 mg/kg, 30 mg/kg, or 50 mg/kg for five days according to the weight of patients.
89360676|NCT06206668|No Intervention|Control Group|Participants will watch a video of landscapes without human or animal movement.
89360677|NCT06206668|Experimental|Intervention Group with Referent (GIR)|Participants will observe actions whose referent has been selected by themselves based on perceived similarity. A total of 16 different videos will be used, with 4 new videos each week. The videos will gradually increase in difficulty as the study progresses. All exercises are exercises used to improve balance.
89360678|NCT06206668|Active Comparator|Standard Intervention Group (GIE)|Participants will observe actions with a standard reference. In this case, a basic digitally designed faceless doll will be used. A total of 16 different videos will be used, with 4 new videos each week. The videos will gradually increase in difficulty as the study progresses. All exercises are exercises used to improve balance.
89360679|NCT06206642|Experimental|18F-FAPI-04|18F-FAPI-04 PET-CT is injected through the patient's elbow vein without special preparation at a dose of 2.96-5.55 megabecquerels (MBq) /kg (0.08-0.15 millicurie/kg).
89360680|NCT06206642|Experimental|18F-FDG|Before the 18F-FDG PET/CT examination, all patients should fast for at least 4-6 hours, and the fasting blood glucose should be controlled to less than 9.0mmol/L to avoid difficulties in image analysis due to poor blood glucose in patients. 18F-FDG is administered via the patient's elbow vein at a dose of 2.96-5.55 megabecquerels (MBq) /kg (0.08-0.15 millicurie/kg).
89360681|NCT06206590||exposed group|Contains differential proteins
89360682|NCT06206590||non-exposed group|No differential protein
89360683|NCT06206577|Experimental|Group A|Seven horizontal anterior maxillary ridge augmentation was done with symphyseal autogenous bone block, which was placed buccally as onlay graft.
89360684|NCT06206577|Experimental|Group B|Seven horizontal anterior maxillary ridge augmentation was done with symphyseal autogenous bone block, which was interpositioned in space created between buccal and lingual cortex as inlay graft.
89360685|NCT06206564|Experimental|Artesunate|
89360686|NCT06206564|Placebo Comparator|Placebo ointment|
89360687|NCT06206551||Prospective patients|Patients who are on the palliative care ward or who are being treated by the palliative consultation service at the University Hospital Muenster.
88832138|NCT02985827|Placebo Comparator|Systane (r) Ultra|Non-Menthol containing over the counter eyedrop
88832139|NCT04707287||Breast Cancer Patients|All the patients irrespective of age, ethnicity and stage of disease will be including once the disease is confirmed after triple assessment
89360688|NCT06206551||Restrospective patients|Patients who were on the palliative care ward or were treated by the palliative consultation service at University Hospital Muenster during the same period in the previous year.
89360689|NCT06206499|Experimental|Laterally Rotated Flap|LRF, Moreno and Caffesse, 2016
89360690|NCT06206499|Active Comparator|Free gingival graft|FGG, Sullivan and Atkins, 1968, Langer and Sullivan, 1989
88832140|NCT02369900|Active Comparator|Esmolol infusion|"Esmolol infusion for 24 hours. Esmolol will be titrated to a heart rate of 80 - 94 per minute, starting at 10mcg/kg/min and subsequently increasing every 20 minutes in increments of 10 mcg/kg/min (or slower at the discretion of the team) until target is achieved. The maximum allowed dose will be 300mcg/kg/min.~Patients, irrespective of treatment group, will be managed at the discretion of the clinical team. BIDMC has internal guidelines for the management of septic shock which reflect the most recent 2012 Surviving Sepsis Campaign guidelines and are incorporated into the care of patients with septic shock in the ICUs"
89360691|NCT06206447||Tunnel-cuffed Catheter Group|Hemodialysis patient with Tunnel-cuffed Catheter in right internal jugular vein
89360692|NCT06206447||Non-ccuffed Catheter Group|Hemodialysis patient with Non-cuffed Catheter in right internal jugular vein
89360693|NCT06206395||Cancer patients receiving chemotherapeutic drugs|Cancer patients ≥ 18 years of age, and scheduled to receive chemotherapy will be included.
88832141|NCT02369900|Placebo Comparator|Standard care, Saline|Standard care (no esmolol). Patients, irrespective of treatment group, will be managed at the discretion of the clinical team. BIDMC has internal guidelines for the management of septic shock which reflect the most recent 2012 Surviving Sepsis Campaign guidelines and are incorporated into the care of patients with septic shock in the ICUs
88832142|NCT03054857|Experimental|Dex group|After skin incision, the Dexmedetomidine group received a loading dose of 0.5 mcg/kg of Dexmedetomidine in 20 minutes followed by a continuous IV infusion at 0.4 mcg/kg/hr until the end of operation.
88832143|NCT03054857|Placebo Comparator|Placebo group|The control group received a loading dose and continuous IV infusion of normal saline at the same rate.
89360694|NCT06206382||Upfront surgery for locally advanced pancreatic cancers|
89360695|NCT06206382||Surgery after neoadjuvant chemotherapy for locally advanced pancreatic cancers|
89360696|NCT06206369||Abdominal Aortic Aneurysm patients|
89360697|NCT06206369||Peripheral Arterial Disease patients|
89360698|NCT06206330|Active Comparator|Platelet rich plasma group|In this group we applied Platelet rich plasma after the surgery. The surgery was fistulotomy and curettage.
89360699|NCT06206330|No Intervention|Control group|In this group, we did the surgery as fistulotomy and curettage but we did not apply a Platelet rich plasma.
89360700|NCT06206317||Study Group|Comprising children diagnosed with Type 1 Diabetes Mellitus (T1DM). This group constitutes the focal point of the study, assessing the motor and sensory functions of the hand. These children undergo various tests and measurements aimed at evaluating the motor skills, sensory perception, and functionality of the hand. The study solely involves evaluation and will not include any treatment or intervention.
89360701|NCT06206317||Control Group|Consisting of children without any health issues. This group comprises healthy individuals and serves as a comparative reference against the study group. Similar tests and measurements are applied to assess the motor and sensory functions of the hand in healthy individuals for comparison with the study group. The study solely involves evaluation and will not include any treatment or intervention.
89360702|NCT06206304||Light-eyed females|Blue-green colors were categorized as light
89360703|NCT06206304||Dark-eyed females|All shades of brown were categorized as dark.
89360704|NCT06206278|Experimental|Infigratinib|Infigratinib 125 mg orally daily, 3 weeks on, 1 week off. . In patients with mild liver function abnormalities or mild renal impairment, the starting dose is 100 mg.
89360705|NCT06206252||Medical Cannabis Group|Participants will use designated medical cannabis products for the study duration.
89360706|NCT06206252||Control Group|Participants will not use any cannabis for the study duration.
89360707|NCT06206213||Healthy Young University Students|This study involves just one group which will be consist of 40 healthy young adults (university students). It will include both males and females and all of them will be exposed to the same protocol.
89534471|NCT00006046|Experimental|Hu3S193 50 mg/m2|Hu3S193 was administered weekly for 8 consecutive weeks. The antibody was diluted in physiologic saline containing 5% human serum albumin and infused intravenously at a maximum rate of 100 mg/hour. If patients were stable or responding, they were eligible to receive 8-week maintenance cycles of hu3S193 at 10 mg/m2 starting in week 10 and continuing until progression.
89360708|NCT06206200|Experimental|Dual task training|Patients will recieve 12 sessions (2x/week) of standard of care exercise-based physiotherapy with implementation of cognitive dual task training. This implies that the patients will perform cognitive tasks simultaneously during at least 50% of their physical rehabilitative exercises.
89360709|NCT06206200|Active Comparator|Standard of care physiotherapy|Patients will recieve 12 sessions (2x/week) of standard of care exercise-based physiotherapy without implementation of cognitive dual task training.
89360710|NCT06206187|Active Comparator|Electrophysiologist judgment|
89360711|NCT06206187|Experimental|Artificial Intelligence Detection|
89360712|NCT06206174|Experimental|TGRX-814|TGRX-814 monotherapy for Dose escalation study; oral, once daily administration.
89360713|NCT06206161|Active Comparator|IPO, CLIN|Standard brief intervention eligibility criteria involving indicated prevention (i.e., brief interventions delivered to high-risk drinkers only). BIs delivered by standard SBIRT workforce involving school nursing or clinical staff.
89360714|NCT06206161|Experimental|IPO, CLIN+PARA|Standard brief intervention eligibility criteria involving indicated prevention (i.e., brief interventions delivered to high-risk drinkers only). BIs delivered by expanded SBIRT workforce involving school nursing or clinical staff and trained paraprofessionals.
89534472|NCT00006046|Experimental|Hu3S193 100 mg/m2|Hu3S193 was administered weekly for 8 consecutive weeks. The antibody was diluted in physiologic saline containing 5% human serum albumin and infused intravenously at a maximum rate of 100 mg/hour. If patients were stable or responding, they were eligible to receive 8-week maintenance cycles of hu3S193 at 10 mg/m2 starting in week 10 and continuing until progression.
89360715|NCT06206161|Experimental|SIP, CLIN|Expanded brief intervention eligibility criteria involving selective prevention in addition to indicated prevention (i.e., brief interventions delivered to current drinkers with and without risky alcohol use). BIs delivered by standard SBIRT workforce involving school nursing or clinical staff.
89360716|NCT06206161|Experimental|SIP, CLIN+PARA|Expanded brief intervention eligibility criteria involving selective prevention in addition to indicated prevention (i.e., brief interventions delivered to current drinkers with and without risky alcohol use). BIs delivered by expanded SBIRT workforce involving school nursing or clinical staff and trained paraprofessionals.
89360717|NCT06206135||low-dose group|initial dose 1.5 g/day
89360718|NCT06206135||standard-dose group|initial dose 4 g/day
89360719|NCT06206096|Experimental|CAPOX+BEV+PD-1|
89360720|NCT06206083||Patients with EC endometroid|Patients with EC endometroid subtype and peripheral blood, treated during 2015-2019 at the INCan.
89360721|NCT06206018|Experimental|PROM_R Knee|"Completed a rehabilitation program based on the updated Journal of Orthopaedic and Sports Physical Therapy (JOSPT) guidelines for knee injuries. These guidelines essentially refer to lower limb massage, mobilization, neuromuscular strengthening and rehabilitation, exercise literacy, neuromuscular electrical stimulation and cryotherapy.~The intervention group will complete the four-week rehabilitation program, with five sessions per week, performed and supervised by the physiotherapist."
89360722|NCT06206018|No Intervention|Crontrol Group|The control group will follow a standard six-week rehabilitation program.
89360723|NCT06205992||Experimental group|Experimental group was set to develop the novel non-invasive model for virtual HVPG using 3d-MRE
89360724|NCT06205992||Control group|Control group was set to develop the novel non-invasive model for virtual HVPG using 2d-MRE
89360725|NCT06205966|Active Comparator|Probiotics|Study product containing L. reuteri (PTA5289 and DSM 17938) taken orally once in the morning and once in the evening, each time 5 drops.
88832144|NCT02370056|Experimental|3D Visualization|"3-dimensional visualization: In this group, total laparoscopic abdominal colectomy will be performed for patients diagnosed with ulcerative colitis by using 3D Laparoscopic Surgical Video System.~This group will be consisted of 27 patients, 9 colectomies performed by 3 surgeons.Effect of using 3D Laparoscopic Surgical Video System on operative outcomes will be evaluated."
88832145|NCT02370056|Active Comparator|2D Visualization|"2-dimensional visualization: In this group, total laparoscopic abdominal colectomy will be performed for patients diagnosed with ulcerative colitis by using conventional Laparoscopic Surgical Video System.~This group will be consisted of 27 patients, 9 colectomies performed by 3 surgeons and outcomes will be evaluated."
88832146|NCT02987231|Sham Comparator|CAF + SHAM|CAF treatment was performed by starting with two divergent releasing incisions lateral to the recessed area. A sulcular incision was made to unite the releasing incisions and the flap was raised beyond the mucogingival junction (MGJ) in split-full-split thickness. Sling sutures were placed to stabilize the flap in a coronal position 2 mm above the CEJ, followed by interrupted sutures to close the releasing incisions. Patients randomized to the SHAM Group will receive the simulation of the electrical stimulation process.
88875506|NCT04107168||Cohort 7|Disease: Resected AJCC stage 3 or 4 melanoma. Anti-PD-1 monotherapy (Nivolumab or Pembrolizumab). Dosage form, dosage, frequency and duration will be either standard of care and accessed via normal commissioning arrangements, or will be part of an ethics-approved clinical trial, where co-enrollment into an observational study is permitted.
88875507|NCT04107168||Cohort 8|Disease: Resected renal cancer Anti-PD-(L)1 monotherapy (Durvalumab or Pembrolizumab). Dosage form, dosage, frequency and duration will be either standard of care and accessed via normal commissioning arrangements, or will be part of an ethics-approved clinical trial, where co-enrollment into an observational study is permitted.
89360726|NCT06205966|Placebo Comparator|Placebo|Placebo taken orally once in the morning and once in the evening, each time 5 drops.
89360727|NCT06205940|Experimental|Audio guided nature tour|Listening to audio instructions by an app while visiting nature. The instructions emphasize the connection between self and nature and direct attention to the present moment experience by guiding focus towards sensory experiences and specific natural elements.
89360728|NCT06205940|Active Comparator|Non audio guided nature tour|Visiting nature without listening to audio instructions.
89360729|NCT06205927|Active Comparator|Standard treatment arm|The standard treatment arm will receive carbon ion beam radiotherapy of 77Gy (RBE equivalent) per 22 fractions for gross tumor volume.
89360730|NCT06205927|Experimental|Boost arm|Boost arm will receive 77Gy (RBE equivalent) per 22 fractions for gross tumor volume and a simultaneously dose boost of 83.6Gy (RBE equivalent) per 22 fractions for hypoxic lesions detected by 18F-Misonidazole PET/CT
89360731|NCT06205914|Experimental|patient group|patients more than 16 years old with patella frature
89360732|NCT06205888||Compare 18F-LNC1007 injection (18F-FAPI-RGD) PET/CT and 18F-FDG PET/CT imaging|This is a prospective, controlled, open-label (with blind members), single-center clinical trial to evaluate the diagnostic efficacy and safety of 18F-LNC1007 injection PET/CT for suspected tumor or tumor initial staging, recurrence monitoring, etc.
89360733|NCT06205849|Experimental|IRE + CD40 Antibody|
89360734|NCT06205836|Experimental|Cohort A - Cemiplimab|
89360735|NCT06205836|Experimental|Cohort B - Cemiplimab with Fianlimab|
89360736|NCT06205823||T cell engager|
89360737|NCT06205823||Standard-of-care|
89360738|NCT06205797|Experimental|HU-045 group|"HU-045 Injection group will receive intramuscular injection of HU-045 to a total of 5 glabellar line sites 4 U/0.1ml each.~HU-045 will be reconstituted from a powder into liquid form by adding 2.5cc of 0.9% sterile saline to the vial, and appropriate volumes will be administered."
89360739|NCT06205797|Active Comparator|Xeomin® group|"Xeomin® Injection group will receive intramuscular injection of Xeomin® to a total of 5 glabellar line sites 4 U/0.1ml each.~Xeomin® will be reconstituted from a powder into liquid form by adding 2.5cc of 0.9% sterile saline to the vial, and appropriate volumes will be administered."
89360740|NCT06205784|Experimental|Prehab|
89360741|NCT06205784|No Intervention|NoTrain|
89360742|NCT06205771|No Intervention|NP|normal pregnancy and preeclampsia pregnancy
89360743|NCT06205771|Experimental|PE|preeclampsia
89360744|NCT06205732||TACE+PD-(L)1+TKI|Application of TACE, TKI, and immunotherapy in patients with intermediate and advanced liver cancer.
89360745|NCT06205732||TACE alone|Application of TACE in patients with intermediate and advanced liver cancer.
89360746|NCT06205719|Experimental|Remazolam combined with Remifentanil anesthesia|0.2mg/kg Remazolam and 2ug/kg Remifentanil for induction of anesthesia, remifentanil 0.1 μg/kg/min and 0.2mg/kg Remazolam were continuously pumped intravenously.
89360747|NCT06205719|Active Comparator|ciprofol combined with Remifentanil anesthesia|0.4mg/kg ciprpfol and 2ug/kg Remifentanil for induction of anesthesia,remifentanil 0.1 μg/kg/min and 0.4-2.4mg/kg/h ciprpfol were continuously pumped intravenously.
89360748|NCT06205719|Active Comparator|The flumazenil was injected at the end of the surgery|0.2mg/kg Remazolam and 2ug/kg Remifentanil for induction of anesthesia, remifentanil 0.1 μg/kg/min and 0.2mg/kg Remazolam were continuously pumped intravenously. The 0.5mg flumazenil was injected at the end of the surgery
89360749|NCT06205706|Experimental|Phase I, Part A - Dose escalation and safety of BI-1910 as single agent|Dose escalation of BI-1910 administered as a single agent.
89360750|NCT06205706|Experimental|Phase I, Part B - Dose escalation and safety of BI-1910 in combination with pembrolizumab|Dose escalation of BI-1910 in combination with pembrolizumab.
89360751|NCT06205706|Experimental|Phase 2a, Part A - Dose expansion of BI-1910 as single agent|BI-1910 administered as a single agent at the hypothesized recommended phase 2 dose determined in Phase 1.
88832147|NCT02987231|Experimental|CAF + ES|CAF treatment was performed by starting with two divergent releasing incisions lateral to the recessed area. A sulcular incision was made to unite the releasing incisions and the flap was raised beyond the mucogingival junction (MGJ) in split-full-split thickness. Sling sutures were placed to stabilize the flap in a coronal position 2 mm above the CEJ, followed by interrupted sutures to close the releasing incisions. For electrical stimulation, a unit consisting of a signal generator, a power supply, and circuit board will be used. Conductive electrodes for electrical current application will be applied to the vestibular gingival surface on each side of the flap, at a distance of 3 mm from the relaxing incisions and an alternating current of 100 μA at 9 kHz, will be distributed in order to traverse the operated area. A single application of electrical stimulation will be given for 120 seconds, once a day for five days after surgery.
88832148|NCT02414204|Active Comparator|Sildenafil|20 mg twice a day orally
88832149|NCT02414204|Placebo Comparator|Placebo|Placebo twice a day orally
88832150|NCT02987621|Experimental|Sham first, wash out 7 days, then tDCS|"Separated by a minimum of 7 days from the sham treatment in a counterbalance order, all participants will perform leg muscle strength and fatigue testing once with tDCS stimulation.~Leg muscle strength testing will be measured by performing a series of maximal effort knee extension, knee flexion, plantar/dorsi-flexion trials.~Sham: Less than 0V of Transcranial Direct Current Stimulation tDCS: Less than 10V of Transcranial Direct Current Stimulation"
88832151|NCT02987621|Experimental|tDCS first, wash out 7 days, then Sham|"Separated by a minimum of 7 days from the sham treatment in a counterbalance order, all participants will perform leg muscle strength and fatigue testing once with tDCS stimulation.~Leg muscle strength testing will be measured by performing a series of maximal effort knee extension, knee flexion, plantar/dorsi-flexion trials.~Sham: Less than 0V of Transcranial Direct Current Stimulation tDCS: Less than 10V of Transcranial Direct Current Stimulation"
88832152|NCT02989493|Experimental|Doxazosin|Participants receive 8 weeks of doxazosin (8mg target dose).
88832153|NCT02989493|Placebo Comparator|Placebo|Participants will receive 8 weeks of matched placebo.
88832154|NCT02050334|Experimental|CC100 (3 single doses)|CC100 (3 single increasing doses by mouth). Dosing will occur every 2 to 7 days for a study duration of 5 to 15 days from the 1st dose.
89360752|NCT06205706|Experimental|Phase 2a, Part B - Dose expansion of BI-1910|BI-1910 administered in combination with pembrolizumab at the respective hypothesized recommended phase 2 doses determined in Phase 1
89360753|NCT06205693|Active Comparator|Stent|Placement of biodegradable stent intraoperatively.
89360754|NCT06205693|No Intervention|No stent|Control group. No placement of stent.
89360755|NCT06205680|Experimental|NAA with Lidocaine|One 1 ml syringes with lidocaine 2 % will be prepared and connected to the NAA device. The device will be placed in front of a nostril and the subject is asked not to breath until 0,5 ml of lidocaine has been administered. The lidocaine will be sprayed by the attending anaesthesiologist. After a waiting period of 2 minutes another 0,5 ml of lidocaine will be administered (= total of 1 ml lidocaine 2%).
89360756|NCT06205680|Experimental|NAA with NaCl 0,9%|"One 1 ml syringes with NaCl 0,9 % will be prepared and connected to the NAA device.~The device will be placed in front of the other nostril and the subject is asked not to breath until 0,5 ml of NaCl has been administered. The NaCl will be sprayed by the attending anaesthesiologist. After a waiting period of 2 minutes another 0,5 ml of NaCl will be administered (= total of 1 ml NaCl 0,9%)."
89360757|NCT06205667|Experimental|Computer Guided Arthrocentesis|a study group injected intra-articularly through TMJ using a computer-guided template.
89360758|NCT06205667|Active Comparator|Conventional Arthrocentesis|a control group which injected intra-articular through TMJ using conventional method based on anatomical landmark determination
89360759|NCT06205641|Placebo Comparator|Xuanfei Baidu Granule Placebo group|
89360760|NCT06205641|Experimental|Xuanfei Baidu Granule group|
89360761|NCT06205641|Active Comparator|Baloxavir Marboxil Tablet group|
88832155|NCT02050334|Experimental|CC100 (2 single doses) & placebo(1 dose)|CC100 (2 single increasing doses by mouth) and placebo (1 single dose by mouth). Dosing will occur every 2 to 7 days for a study duration of 5 to 15 days from the 1st dose.
88832156|NCT03062267|No Intervention|Treatment as Usual|Treatment as usual for 3 months.
89360762|NCT06205641|Active Comparator|Combination group|
89360763|NCT06205589|Active Comparator|Group 1/Phase 2a: ID93+GLA-SE 4 months and 6 months after start of TB treatment|Participants will be enrolled at approximately 4 months after the start of TB treatment, entering the study directly into Step 2, and will be randomized to receive ID93 + GLA-SE immediately. They have no Step 1 observation period from the start of SOC TB treatment to randomization.
89360764|NCT06205589|Active Comparator|Group 2/Phase 2a: ID93+GLA-SE 3 months and 5 months after start of TB treatment|Participants will be enrolled at approximately 3 months after the start of TB treatment, entering the study directly into Step 2, and will be randomized to receive ID93 + GLA-SE or placebo immediately. They have no Step 1 observation period from the start of SOC TB treatment to randomization.
89360765|NCT06205589|Active Comparator|Group 3/Phase 2a: ID93+GLA-SE 2 months and 4 months after start of TB treatment|Participants will enter the study within approximately 7 days after starting TB treatment in Step 1, which is an observation period between the start of SOC TB treatment until entering Step 2. In Step 2 they will be randomized to ID93 + GLA-SE at 2 months after study entry/start of TB treatment.
89360766|NCT06205589|Active Comparator|Group 4/Phase 2a: ID93+GLA-SE 1 month and 3 months after start of TB treatment|Participants will enter the study within approximately 7 days after starting TB treatment in Step 1, which is an observation period between the start of SOC TB treatment until entering Step 2. In Step 2 they will be randomized to ID93 + GLA-SE 1 month after study entry/start of TB treatment.
89360767|NCT06205589|Active Comparator|Group 5/Phase 2b: ID93+GLA-SE schedule based on Group 3 and 4 safety and immunogenicity data|Participants will enter the study within approximately 7 days after starting TB treatment in Step 1, which is an observation period between the start of SOC TB treatment until entering Step 2. The vaccination schedule will be selected from either the Group 3 or Group 4 schedule, following a review of the safety and immunogenicity data after the last participant in Group 4 receives the second vaccination. If both the safety and immunogenicity criteria are met, the Group 4 schedule will be selected and Group 5 will include Group 4 participants. If Group 4 fails to meet both the safety and immunogenicity criteria, the Group 3 vaccination schedule will be selected and Group 5 will include Group 3 participants. If safety and immunogenicity criteria are not met in either Group 3 or 4, then enrollment to Group 5 will not proceed and the phase 2b component of the study will not be undertaken.
89360768|NCT06205589|Placebo Comparator|Group 1/Phase 2a: Placebo vaccine 4 months and 6 months after start of TB treatment|Participants will be enrolled at approximately 4 months after the start of TB treatment, entering the study directly into Step 2, and will be randomized to receive placebo immediately. They have no Step 1 observation period from the start of SOC TB treatment to randomization.
89360769|NCT06205589|Placebo Comparator|Group 2/Phase 2a: Placebo vaccine 3 months and 5 months after start of TB treatment|Participants will be enrolled at approximately 3 months after the start of TB treatment, entering the study directly into Step 2, and will be randomized to receive placebo immediately. They have no Step 1 observation period from the start of SOC TB treatment to randomization.
89360770|NCT06205589|Placebo Comparator|Group 3/Phase 2a: Placebo vaccine 2 months and 4 months after start of TB treatment|Participants will enter the study within approximately 7 days after starting TB treatment in Step 1, which is an observation period between the start of SOC TB treatment until entering Step 2. In Step 2 they will be randomized to placebo at 2 months after study entry/start of TB treatment.
88832157|NCT03062267|Experimental|Mobile Interventionist|Participants will exchange text messages with a mobile interventionist throughout the day for 3 months.
89360771|NCT06205589|Placebo Comparator|Group 4/Phase 2a: Placebo vaccine 1 month and 3 months after start of TB treatment|Participants will enter the study within approximately 7 days after starting TB treatment in Step 1, which is an observation period between the start of SOC TB treatment until entering Step 2. In Step 2 they will be randomized to ID93 + GLA-SE or placebo 1 month after study entry/start of TB treatment.
89360772|NCT06205589|Placebo Comparator|Group 5/Phase 2b: Placebo vaccine schedule based on Group 3 and 4 safety and immunogenicity data|Participants will enter the study within approximately 7 days after starting TB treatment in Step 1, which is an observation period between the start of SOC TB treatment until entering Step 2. The vaccination schedule will be selected from either the Group 3 or Group 4 schedule, following a review of the safety and immunogenicity data after the last participant in Group 4 receives the second vaccination. If both the safety and immunogenicity criteria are met, the Group 4 schedule will be selected and Group 5 will include Group 4 participants. If Group 4 fails to meet both the safety and immunogenicity criteria, the Group 3 vaccination schedule will be selected and Group 5 will include Group 3 participants. If safety and immunogenicity criteria are not met in either Group 3 or 4, then enrollment to Group 5 will not proceed and the phase 2b component of the study will not be undertaken.
89360773|NCT06205576|Experimental|DCB catheter|Using DCB catheter for the treatment of subjects with a de novo or non-stented restenotic obstructive lesion located in the native arteriovenous dialysis fistulae.
89360774|NCT06205563|Experimental|Arm A|
89360775|NCT06205563|Active Comparator|Arm B|
89360776|NCT06205550|Active Comparator|Flecainide + beta-blocker|
89360777|NCT06205550|Experimental|Flecainide monotherapy|
88832158|NCT03063125||Bladder Cancer Patients|Patients with bladder cancer scheduled to undergo radical cystectomy (RC).
88832159|NCT02371850|Experimental|Nicoderm patch first, then Aveva patch|Each subject gets two procedure days with heating applied for one hour at hours 4 and hour 8 after the application of the Nicoderm CQ nicotine patch, then followed by two procedure days with heating applied for one hour at hours 4 and hour 8, after the application of the Aveva nicotine patch (total of four Procedure days)
89360778|NCT06205537|Placebo Comparator|Oral Liquid Supplement (ONS) Group A|One 8 oz. serving
89360779|NCT06205537|Experimental|Oral Liquid Supplement (ONS) Group B|One 8 oz. serving
89360780|NCT06205511||Main Group|Single group, observational cross-sectional cohort.
88832160|NCT03141281|Experimental|BrainHQ|Participants will be provided with a laptop computer and enrolled in a commercial web-based cognitive training program, BrainHQ, trained on how to access it, and instructed to complete a fixed number of sessions in 20 hours.
88832161|NCT03141281|Experimental|Rise of Nations|Participants will be provided with a laptop computer with the Rise of Nations video game, be trained in game play, and instructed to play the game for 20 hours
89360781|NCT06205472|Experimental|Adjuvant SIB radiotherapy|Adjuvant integrated boost radiotherapy following narrow-margin hepatectomy in patients with HCC.
89360782|NCT06205459|Experimental|intervention|deep marginal acquisition using thermacut bur from dentsply
89360783|NCT06205459|Active Comparator|control|functional crown lengthening
89360784|NCT06205446|Experimental|abdominal breathing|The relationship between respiration and the autonomic nervous system (ANS) is closely intertwined, as the phrenic nerve, responsible for controlling the movement of the diaphragm, is connected to the vagus nerve of the parasympathetic nervous system.The respiratory cycle reflects the balance between the parasympathetic and sympathetic nervous systems in the Autonomic Nervous System (ANS), which can be observed through Heart Rate Variability (HRV). The ANS state shifts from the parasympathetic nervous system to the sympathetic nervous system during inhalation, while it transitions from the sympathetic nervous system to the parasympathetic nervous system during exhalation. In HRV, an increase in heart rate indicates enhanced sympathetic nervous system activity during inhalation, whereas a decrease in heart rate signifies increased parasympathetic nervous system activity during exhalation.
89360785|NCT06205420|Experimental|Injectable composite resin restoration|The use of injectable GC Gaenial restoration in restoring hypoplastic permanent anterior teeth and the evaluation of its clinical performance using FDI criteria.
89360786|NCT06205420|Experimental|Injectable Giomer restoration|The use injectable beautiful flow giomer restoration in restoring hypoplastic permanent anterior teeth and the evaluation of its clinical performance using FDI criteria.
89360787|NCT06205394||GROUP 1 (focus group)|Cancer survivors participate in a focus group on study.
89360788|NCT06205394||GROUP 2 (interview)|Breast cancer clinicians undergo a semi-structured interview on study.
89360789|NCT06205355|Experimental|goal-directed analgesia using ANI monitoring|
89360790|NCT06205355|Active Comparator|Standard monitoring|
89360791|NCT06205342|Experimental|Experimental Cohort|MSC
88832162|NCT03141281|Experimental|IADL training|Participants will be enrolled in American Association of Retired Persons' web-based driver training course, trained on how to access it, and asked to complete the course, estimated to take approximately 6-8 hours. They will also be provided with web-based access to a finance and fraud avoidance training tutorial, instructed on how to access it, and be asked to complete the course, estimated to take approximately 5-7 hours. The two courses combined are estimated to take about 15 hours.
88832163|NCT03141281|Active Comparator|Active Control|Participants will be provided with a laptop computer and asked to complete 20 hr of training with Sudoku, crossword puzzles, and word search
88832164|NCT02415608|Experimental|Ibrutinib 420 mg/day|Participants receive ibrutinib daily on days 1 to 28, at 420 mg/day in 28-day cycles
88832165|NCT02415608|Experimental|Ibrutinib 560 mg/day|Participants receive ibrutinib daily on days 1 to 28, at 560 mg/day in 28-day cycles
88832166|NCT03144089|Active Comparator|Guedel oral airway|Each participant in the study will have both devices (GOA or AOA). The participants reported in this arm were randomized to receive the Guedel oral airway first and measurements were taken during breaths 6 through 10. After its removal the Articulated Oral Airway was inserted and measurements were repeated again during breaths 6 through 10.
89360792|NCT06205342|Placebo Comparator|Validation Cohort|Placebo
89360793|NCT06205329|Experimental|WPV01 Dose 1-4|WPV01 Dose 1-4 or Placebo
89360794|NCT06205329|Experimental|WPV01 Dose 5-8|WPV01 Dose 5-8 co-administrated with ritonavir or Placebo
89360795|NCT06205329|Experimental|WPV01 Dose 9-12|WPV01 Dose 9-12 or Placebo
89360796|NCT06205329|Experimental|WPV01 Dose 13-15|WPV01 Dose 13-15 or Placebo
89360797|NCT06205329|Experimental|WPV01 Dose 16|WPV01 Dose 16(with high fat meal) or WPV01 Dose 16 (fed)
89360798|NCT06205303|Experimental|intervention arm using PDA|The intervention arm participants will watch the PDA which is estimated to take 10 minutes, after their consultation with the physician. The participants will be directed to a private room to watch the PDA.
89360799|NCT06205303|No Intervention|Control arm|The control arm participants will receive a thyroxine replacement pamphlet at their routine clinic appointment but will not attend the health education session using the PDA.
89360800|NCT06205030|Active Comparator|NOSHIN SHAHD drug|All the volunteers directed to the laboratory so that biochemical tests can be performed on them before taking the drug. Volunteers are asked to take the received NOSHIN SHAHD drug 20 ml three times per day after food. at the end of the six week. then, the sample collection will be done to review all the tests of the end stage of receiving the drug.
89360801|NCT06205030|Placebo Comparator|placebo|The placebo with the same appearance as the herbal syrup will be drinking nectar. All the volunteers directed to the laboratory so that biochemical tests can be performed on them before taking the drug. Volunteers are asked to take the received placebo 20 ml three times per day after food. at the end of the six week. then, the sample collection will be done to review all the tests of the end stage of receiving the drug.
89360802|NCT06204978|Other|scFOS Dose 1|scFOS 10g
89360803|NCT06204978|Other|scFOS Dose 2|scFOS 20g
89360804|NCT06204965|Experimental|Time-restricted eating group (TRE group)|Participants assigned to the TRE group will be instructed to continue eating their usual diet during the experiment (without any qualitative or quantitative restrictions), but to eat it within a limited time frame - from 9:00 a.m. to 5:00 p.m., and then fast until the next day ( protocol 8/16).
89360805|NCT06204965|No Intervention|Non-fasting group|Participants assigned to the control group will receive only dietary recommendations consistent with the healthy eating plate. Additionally, the recommended energy intake will be individually determined for each patient using the PPM (calculated using the Harris-Benedict formula) multiplied by the physical activity factor.
89360806|NCT06204887|Experimental|Manual dynamic activation|
89360807|NCT06204887|Experimental|Passive ultrasonic activation|
89360808|NCT06204887|Experimental|Laser activation|
89360809|NCT06204887|No Intervention|Non-activated Control|
88832167|NCT03144089|Experimental|Articulated Oral Airway|Each participant in the study will have both devices (GOA or AOA). The participants reported in this arm were randomized to receive the Articulated oral airway first and measurements were taken during breaths 6 through 10. After its removal the Guedel Oral Airway was inserted and measurements were repeated again during breaths 6 through 10.
88832168|NCT02051426|Experimental|D-serine|single P.O. administration of D-serine (2.1g)
89360810|NCT06203821|Experimental|Treatment|Patient receive two doses of the study drug, NP137, approximately two weeks apart. This will be followed by surgery. After the surgery if feasible, patients will begin post-surgical treatment with a standard-of-care chemotherapy regimen called FOLFIRINOX, combined with the study drug, NP137, for a total duration of about 6 months. Upon completing this phase, patients will receive an additional 6 months of treatment with only the study drug NP137.
89360811|NCT06203730|No Intervention|Routine care|The Blood purification Center provides routine care for MHD patients
88832169|NCT02051426|Placebo Comparator|Placebo|single P.O. administration of corn starch
88832170|NCT03144635|Experimental|Grazoprevir plus Elbasvir|Grazoprevir 100 mg plus Elbasvir 50 mg per day for 12 weeks.
88832171|NCT02313506|Active Comparator|Immediate Intervention Group|Education session, Fitbit Flex, and remote coaching by a PT. These three components of the intervention will be delivered to the participants in Month 1. At the end of the education session, the PT will help participants set personal activity goals. In Month 1, participants will use the Fitbit Flex. The PT will review the progress with participants via 20-minute weekly phone calls and progressively modify their activities. In Month 2, they will continue using the Fitbit and have access to a PT via email as needed, but no weekly phone calls.
88832172|NCT02313506|Placebo Comparator|Delayed Intervention Group|Same intervention with a 1 month delay: The full intervention will be initiated in Month 2 with a brief education session, use of Fitbit Flex, and counselling by a physiotherapist. The trial will conclude at the end of Month 2.
88832173|NCT05719298|Experimental|Respiratory interface|Use of the new respiratory interface and accessories to deliver non-invasive therapy
88832174|NCT03145259|Other|Diclofenac patch|Study Session 1: diclofenac epolamine patches (PK) [51 h study duration]
88832175|NCT03145259|Other|Diclofenac solution|Study Session 2: diclofenac sodium solution (PK) [47 h study duration]
88832176|NCT03145259|Other|Diclofenac patch and solution|Study Session 3: diclofenac epolamine patch pieces and diclofenac sodium solution (no PK, for skin tape stripping) [51 h study duration]
88832177|NCT05719220||Group preoperative pelvic floor training|Patients will receive group preoperative PFT, 4 weeks prior to HoLEP.
88832178|NCT05719220||No preoperative pelvic floor training|The control group will receive standard care, which may include patient education about postoperative care and pelvic floor muscle exercises, but will not receive structured group PFT.
88832179|NCT00354692|Experimental|Experimental|
88832180|NCT03146585||Patients on artificial ventilation|
89360812|NCT06203730|Experimental|dyadic psychological intervention strategy|an intervention strategy for both patients and caregivers that combines psychotherapy techniques and health management
88832181|NCT03146585||Patients on renal replacement therapy|
88832182|NCT03146585||Patients with targeted temperature management|
88832183|NCT05719142|Experimental|Sweet Food (SW)|Exposure to pictures of sweet food.
88832184|NCT05719142|Experimental|Savoury Food (SA)|Exposure to pictures of savoury food.
89360813|NCT06203522||MRI with Dexmedetomidin|"Mean age is compared between the pass and fail groups using a Student's t-test accounting for inequality of variances. MRI success rates are compared between subgroups using Fischer's exact tests. Finally, factors related to MRI success rates are investigated using multivariate logistic regression, including all the factors described above."
88832185|NCT05719142|Experimental|Non-Food (NF)|Exposure to pictures of non-food items.
89360814|NCT06203327||OLGA 0-I|
89360815|NCT06203327||OLGA II|
89360816|NCT06203327||OLGA III-IV|
89360817|NCT06203288|Experimental|MBSEL program for educators|"Teachers randomized to this arm will receive a mindfulness-based social and emotional learning (MBSEL) program for educators training outside the classroom. These teachers will continue to teach their regular business as usual social and emotional learning (SEL) curriculum in the classroom.~Note: In the school district where this research study is being conducted, every teacher is required to allot at least one 50-min class period to implementing SEL programs and/or practices, and to embed SEL activities and practices throughout the school day."
89360818|NCT06203288|Experimental|MBSEL program for educators and MBSEL program for students|Teachers randomized to this arm will first receive training in a mindfulness-based social and emotional learning (MBSEL) program designed specifically for educators and will complete the program on their own outside the classroom. Following, they will receive training for implementing an MBSEL program for their students, and then they implement weekly lessons of this program in their classroom to their students.
88832186|NCT02375984|Experimental|Tumor Infiltrating Lymphocytes (TIL)|Patients will have a melanoma metastasis resected and cultured in IL-2 in vitro either as part of this treatment protocol or the JWCI procurement protocol. TIL from these cultures will be assessed for tumor-reactivity and those with such activity will be further expanded and adoptively transferred. Patients will receive a non-myeloablative lymphocyte-depleting preparative regimen consisting of cyclophosphamide (60 mg/kg/day X 2 days IV) and fludarabine (25 mg/m2/day IV X 5 days). Following this regimen, patients will receive an intravenous adoptive transfer of at least 109 tumor-reactive lymphocytes (TIL) followed by high-dose intravenous IL-2 (600-720,000 IU/kg/dose every 8 hours for up to 12 doses).
88832187|NCT02989727|Experimental|Lamotrigine - melancholic depression|Participants with melancholic depression who were randomly assigned to receive lamotrigine tablets escalated to a target dose of 200mg/day.
88832188|NCT02989727|Placebo Comparator|Placebo - melancholic depression|Participants with melancholic depression who were randomly assigned to receive a placebo comparator.
88832189|NCT02989727|Experimental|Lamotrigine - nonmelancholic depression|Participants not meeting DSM-IV-TR diagnostic criteria for melancholic depression who were randomly assigned to receive lamotrigine tablets escalated to a target dose of 200mg/day.
88832190|NCT02989727|Placebo Comparator|Placebo - nonmelancholic depression|Participants not meeting DSM-IV-TR diagnostic criteria for melancholic depression who were randomly assigned to receive a placebo comparator.
88832191|NCT02051816|Active Comparator|VL and AO|Video laryngoscopy and apneic oxygenation
89534473|NCT00006046|Experimental|Hu3S193 200 mg/m2|Hu3S193 was administered weekly for 8 consecutive weeks. The antibody was diluted in physiologic saline containing 5% human serum albumin and infused intravenously at a maximum rate of 100 mg/hour. If patients were stable or responding, they were eligible to receive 8-week maintenance cycles of hu3S193 at 10 mg/m2 starting in week 10 and continuing until progression.
88832192|NCT02051816|Active Comparator|DL and AO|Direct Laryngoscopy and apneic oxygenation
88832193|NCT02051816|Active Comparator|VL and no AO|Video Laryngoscopy and no apneic oxygenation
88832194|NCT02051816|Active Comparator|DL and no AO|Direct Laryngoscopy and no apneic oxygenation
88832195|NCT02039947|Experimental|Cohort A|Subjects will receive dabrafenib 150 milligram (mg) twice daily and trametinib 2 mg once daily until evidence of disease progression, death, or unacceptable toxicity.
88832196|NCT02039947|Experimental|Cohort B|Subjects will receive dabrafenib 150 mg twice daily and trametinib 2 mg once daily until evidence of disease progression, death, or unacceptable toxicity
88832197|NCT02039947|Experimental|Cohort C|Subjects will receive dabrafenib 150 mg twice daily and trametinib 2 mg once daily until evidence of disease progression, death, or unacceptable toxicity
88832198|NCT02039947|Experimental|Cohort D|Subjects will receive dabrafenib 150 mg twice daily and trametinib 2 mg once daily until evidence of disease progression, death, or unacceptable toxicity
88832199|NCT02052752|Experimental|Test Product|Test product contained 3% benzoyl peroxide in the form of a gel. It was applied on participant's face once-daily at approximately the same time on Days 0, 1, 2 and 3.
88832200|NCT02052752|Active Comparator|Vehicle gel|The vehicle gel was similar to the test product except that it did not contain 3% benzoyl peroxide. The vehicle gel served as the negative control and was applied on participant's face once-daily at approximately the same time on Days 0, 1, 2 and 3.
88832201|NCT02052752|Placebo Comparator|Positive control|A commercial product containing 2% salicylic acid that reportedly improves acne lesions was applied on participant's face once-daily at approximately the same time on Days 0, 1, 2 and 3.
88832202|NCT02992067||Operable breast cancer|clinical stage: cTis, cI, cII, cT3N1M0
88832203|NCT03063437|Experimental|Active: Encapsulated Fecal Microbiota Preparation|Single dose of oral, encapsulated fecal microbiota preparation (30 capsules per dose) with follow-up at 3 days, 10 days, 28 days, and 6 months.
88832204|NCT03063437|Placebo Comparator|Placebo: Encapsulated Placebo|Single dose of oral, placebo capsule (30 capsules per dose) with follow-up at 3 days, 10 days, and 28 days, and 6 months.
88832205|NCT02042131|Active Comparator|Treatment As Usual (TAU)|"TAU includes the following intervention components:~suicide risk assessment~supportive listening~provision of professional and crisis contact information~referral to mental health treatment and community resources~verbal contract for safety"
88832206|NCT02042131|Experimental|Standard Crisis Response Plan (S-CRP)|"CRP includes the following intervention components:~suicide risk assessment~supportive listening~identify personal warning signs~identify self-management skills~identify social support contacts~provision of professional and crisis contact information~referral to mental health treatment and community resources"
88832207|NCT02042131|Experimental|Enhanced Crisis Response Plan (E-CRP)|"The E-CRP includes the following intervention components:~suicide risk assessment~supportive listening~identify personal warning signs~identify self-management skills~identify reasons for living~identify social support contacts~provision of professional and crisis contact information~referral to mental health treatment and community resources"
88832208|NCT02996591|Active Comparator|Spinal anesthesia with popliteal and adductor canal blocks.|Ultrasound (US) guided sciatic nerve blocks in the popliteal fossa and adductor canal block with 25 mL and 10 mL, respectively, of 0.25% bupivacaine (plus 2 mg preservative-free (PF) dexamethasone / 30 ml), performed under procedural IV sedation protocol. IV sedation protocol: midazolam, 2-5 mg IV + Glycopyrrolate, 0.1 mg IV + Ketamine, 10-20 mg, + propofol as needed. Spinal protocol: 45-60 mg 1.5% mepivacaine, depending on the expected case duration (45 mg for cases with projected duration 1-2 hours, 60 mg for cases with projected duration 2-3 hours). Intraoperative sedation maintained with propofol infusion and ketamine, 10 mg/hr.
88832209|NCT02996591|Active Comparator|General anesthesia with popliteal and adductor canal blocks.|Ultrasound (US) guided sciatic nerve blocks in the popliteal fossa and adductor canal block with 25 mL and 10 mL, respectively, of 0.25% bupivacaine (plus 2 mg preservative-free (PF) dexamethasone / 30 ml), performed under procedural IV sedation protocol. IV sedation protocol: midazolam, 2-5 mg IV + Glycopyrrolate, 0.1 mg IV + Ketamine, 10-20 mg, + propofol as needed. General anesthesia protocol: After induction with propofol and insertion of the LMA, anesthesia maintained with titrated propofol infusion, sevoflurane, ketamine 10 mg/hr.
88832210|NCT02053376|Experimental|regorafenib|Patients with advanced and metastatic biliary tract adenocarcinoma (cholangiocarcinoma) who had been treated with and failed first-line chemotherapy will be treated with regorafenib (120 mg) (160 mg for second and subsequent treatment cycles) orally once daily 21 days (3 weeks) on and 7 days (1 week) off in the 28-day (4-week) cycle
88832211|NCT03065075|Experimental|Phenazopyridine|Participant is given Phenazopyridine 200mg on postoperative day 1
88832212|NCT03065075|No Intervention|No Phenazopyridine|Participant is not given Phenazopyridine on postoperative day 1
88832213|NCT03066947|Experimental|SV-BR-1-GM Monotherapy|Pretreatment with low dose cyclophosphamide 2-3 days prior to SV-BR-1-GM inoculation; SV-BR-1-GM inoculation intradermally in 4 sites on the upper back (x2) and thighs (x2); Post-inoculation low dose Interferon-alpha-2b into the vaccination sites ~2 and ~4 days after SV-BR-1-GM inoculation
88832214|NCT02042911|Experimental|SyB L-0501|
88832215|NCT02043145||Axillary Hyperhidrosis|Patients with Axillary Hyperhidrosis who are treated with BOTOX® (botulinum toxin Type A) as prescribed according to standard of care in clinical practice.
88832216|NCT02043145||Focal Spasticity|Patients with Focal Spasticity who are treated with BOTOX® (botulinum toxin Type A) as prescribed according to standard of care in clinical practice.
88832217|NCT02043145||Glabellar Lines|Patients with moderate or severe Glabellar Lines who are treated with BOTOX® (botulinum toxin Type A) as prescribed according to standard of care in clinical practice.
88832218|NCT02062801|Active Comparator|Prophylactic ephedrine|Ephedrine 10mg iv once at time of combined spinal epidural insertion
88832219|NCT02062801|Placebo Comparator|Normal saline (placebo) control group|1ml normal saline intravenously once at time of combined spinal epidural insertion
88832220|NCT03152591|Experimental|LIK066|LIK066 tablets received three times daily; before breakfast, lunch and dinner for 14 days and once on day 15 morning before meal test
88832221|NCT03152591|Placebo Comparator|Placebo|Placebo tablets received three times daily; before breakfast, lunch and dinner for 14 days and once on day 15 morning before meal test
88832222|NCT02063035|Experimental|Tranexamic acid|Participants undergoing spinal surgery will receive a single, topical dose of tranexamic acid. The surgeon will irrigate the study medication in the wound prior to closure, and aspirate it after five minutes. Drains will be placed after the study drug has been aspirated.
89360819|NCT06203288|No Intervention|"Comparison Business as Usual"|"Teachers randomized to this arm will teach their regular business as usual social and emotional learning (SEL) curriculum to their student in the classroom.~Note: In the school district where this research study is being conducted, every teacher is required to allot at least one 50-min class period to implementing SEL programs and/or practices, and to embed SEL activities and practices throughout the school day."
89360820|NCT06203067|Experimental|Type 1 Together|In Type 1 Together, families will work with other families who have experience using CGM (Peer Mentors) to overcome common barriers to CGM use. Families in the Type 1 Together program will also have access to CGM-specific educational materials, a digital journal to facilitate patient-provider communication around issues with CGM, and social determinant of health screening and intervention with a diabetes community health worker.
89360821|NCT06203067|Active Comparator|Standard of Care|Quarterly clinic visits with endocrinology provider.
89360822|NCT06202794|Experimental|Experimental group|TENS will be initiated one hour after surgery. A portable device with two channels will be used (Neurodyn Portable TENS, Ibramed, Amparo, São Paulo, Brazil). This device will deliver a biphasic, asymmetrical, balanced current, with a frequency of 100 Hz and pulse duration of 100 μs. Four electrodes (5x5 cm) will be positioned on the left and right sides of the spine according to the indicated instructions. The assessor will increase the intensity to promote a strong tingling sensation, reaching the patient's maximum tolerance level without causing discomfort. Emission will be applied in a single session of one continuous hour and the patients will be informed that the sensation may decrease over time. Every 10 minutes, the assessor will ask the patient if there is habituation to the current and will increase the intensity if necessary. TENS will be administered only once for one hour.
89360823|NCT06202794|Sham Comparator|Control group|Sham TENS will be performed using equipment identical in appearance to active TENS (Neurodyn Portable TENS, Ibramed, Amparo, São Paulo, Brazil) specifically designed for this study. The device will emit an electrical current gradually increased during the first 30 seconds, followed by a gradual decrease over the subsequent 15 seconds reaching an intensity of 0 mA. The device will remain inactive during the rest of the application, but will have a flashing light, giving the patient the appearance that it is active. The assessor will inform the patient that it is possible to feel the sensation of the current or not depending on individual characteristics. This type of equipment is validated and has been used in other studies to facilitate the blinding of participants. Both systems will be calibrated using a digital oscilloscope (DPO 7000, Tektronix Inc., Beaverton, OR, USA).
89360824|NCT06202599||Study group|Fruquintinib treatment group
89360825|NCT06202378|Experimental|SHPL-49 Injection，3 ampoules|1mL/ampoule
89360826|NCT06202378|Experimental|SHPL-49 Injection，6 ampoules|1mL/ampoule
89360827|NCT06202378|Placebo Comparator|Placebo|1mL/ampoule
89360828|NCT06202235||CKD Patients|Participants with diagnosed Chronic Kidney Disease will undergo the same MRI protocol as the Healthy Volunteers, including T1-weighted, T2-weighted imaging, and Magnetic Resonance Elastography (MRE). In addition to the imaging, these participants will have their blood creatinine, cystatin C, and blood pressure measured within 3 days before and after the MRE. A renal biopsy will be performed as part of their clinical assessment to evaluate the extent of kidney fibrosis.
89360829|NCT06202235||Healthy Volunteers|Age-matched healthy individuals with no known kidney disease will be recruited. They will undergo the same MRI protocols as the CKD patient group, including T1-weighted, T2-weighted imaging, and MRE, to establish baseline viscoelasticity parameters for comparison with the CKD patients.
89360830|NCT06202222|No Intervention|standard rehabilitation|
89360831|NCT06202222|Experimental|standard rehabilitation and cycloergometer|
89360832|NCT06202144|Experimental|Personalized Noninvasive support|Helmet noninvasive support, with positive end-expiratory pressure (PEEP)=12 cmH2O and the minimal pressure-support level capable of generating inspiratory effort between 5 and 10 cmH2O
89360833|NCT06202144|Active Comparator|Continuous positive airway pressure|Helmet CPAP will be delivered through a high-flow generator and PEEP valve set at 12 cmH2O
89360834|NCT06202144|Active Comparator|Noninvasive ventilation|Helmet NIV will be delivered in the pressure-support mode, with PEEP=12 cmH2O and pressure support=12 cmH2O
88832223|NCT02063035|Placebo Comparator|Placebo|Participants undergoing spinal surgery will receive a single, topical dose of matching placebo. The surgeon will irrigate the study medication in the wound prior to closure, and aspirate it after five minutes. Drains will be placed after the study drug has been aspirated.
88832224|NCT00375245|Experimental|Rapamycin + Grapefruit juice|
88832225|NCT05405933|Experimental|Propioceptive Neuromuscular Facilitation|Propioceptive Neuromuscular Facilitation With Conventional Therapy for Balance and Gait
88832226|NCT05405933|Experimental|Balance Exercise|Balance Exercise Along With Conventional Therapy for Balance and Gait
88832227|NCT02043379|Experimental|IVIG|Those randomized to the study arm will receive a dose of IVIG 1 gram/kg at 12 hours post-cardiopulmonary bypass. This is a one time only dose and will be administered per hospital standards for IVIG administration.
88832228|NCT02043379|Placebo Comparator|Normal Saline|Subject's randomized into the placebo arm of the study will receive a volume of normal saline that is comparative to that if they were to receive IVIG. This will be at 12 hours post-cardiopulmonary bypass. This volume is to ensure blinding of study drug. This infusion will be administered as if the subject is receiving IVIG according to hospital policy.
89360835|NCT06201806|Experimental|Test food breakfast with NCS|"Experimental: Participants with type 1 diabetes will consume Breakfast I with a mixed sweetener of stevia and sucralose, equivalent to 30 drops (36 mg stevia + 34.8 mg sucralose). Total non-nutritive sweeteners (NNS) amount to 70.8 mg.~Intervention: Breakfast I includes whole wheat pita bread (43 g), turkey ham (40 g), gouda cheese (18 g), semi-skimmed milk 200 cc (enhanced with 15 drops of sweetener), and natural orange juice 200 cc (with an additional 15 drops of sweetener). 15 drops for each preparation, making a total of 30 drops, providing 50 grams of available carbohydrates. Subjects administer rapid-acting insulin before breakfast based on their ratio and sensitivity."
89360836|NCT06201806|Experimental|Test food breakfast without NCS|"Experimental: Intervention involves the consumption of a breakfast without non-nutritive sweeteners (NNS).~Intervention: Subjects with type 1 diabetes who ingest Breakfast II (without sweetener): Whole wheat pita bread (43 g), turkey ham (40 g), gouda cheese (18 g), semi-skimmed milk 200 cc, and natural orange juice 200 cc.~Intervention includes the ingestion of 50 grams of available carbohydrates in the breakfast without NNS. Subjects will administer rapid-acting insulin before breakfast based on their ratio and sensitivity."
89360837|NCT06201806|Active Comparator|Reference food|Intervention involves the consumption of White Bread (standard food): 86g of crustless white sandwich bread as the standard food to reach the 50g of available CHO. Subjects administer rapid-acting insulin before consumption based on their ratio and sensitivity.
89360838|NCT06201715|Experimental|tofacitinib|
88832229|NCT02054156|Active Comparator|azithromycin and TIS|azithromycin and tobramycin solution for inhalation (TIS) Azithromycin 3 times weekly, oral suspension, 10 mg/kg/dose up to 500 mg, for 18 months Tobramycin solution for inhalation (TIS), 300 mg, twice daily for 28 days when respiratory cultures are found positive for Pa at study visits for 18 months
89360839|NCT06201598||Patients treated with p64MW HPC and p48MW HPC|Patients with intracranial aneurysms or dissections undergoing endovascular treatment with p64MW HPC and p48MW HPC flow-diverting devices.
88832230|NCT02054156|Placebo Comparator|placebo and TIS|placebo and tobramycin solution for inhalation (TIS) Placebo 3 times weekly, oral suspension, volume-matched to azithromycin, for 18 months Tobramycin solution for inhalation (TIS), 300 mg, twice daily for 28 days when respiratory cultures are found positive for Pa at study visits for 18 months
89360840|NCT06200701|Experimental|Intervention Program application of a Job Crafting|job crafting training program designed for this study was implemented through twelve sessions, from which three theory and nine practical sessions were held in a room at the worksite. The sessions were conducted outside of working hours in the hospital These sessions lasted 21 hours; 3 theory hours (one hour for each theoretical session); and 9 practical sessions (two hours for each practical session). Having the whole number of nurses at the same time was difficult, so the nurses were classified into five groups each group consisting of about 16 nurses. All sessions were repeated to the five main groups until 80 nurses completed the entire 21-hours instruction period
89360841|NCT06200701|No Intervention|non Intervention Program application|non Intervention Program application
89360842|NCT06200649|Experimental|Intervention Group|"Massage will be applied to the intervention group by the researcher who has received training in classical massage techniques and has a certificate. The massage will start with effusion (stroking) and will end with effleurage (stroking).~Baby oil will be used during the massage in order to provide slipperiness and to prevent mothers and babies from being affected by the smell. The oil used will be spread on the back by patting. The massage will last 20 minutes. Post-test data will be obtained by re-filling the forms after 3 hours (6 hours after Normal Birth) for the intervention group to whom massage is applied."
89360843|NCT06200649|No Intervention|Control group|No intervention will be made to the control group, and the routine nursing practices of the clinic will continue. Pre-test and post-test will be applied.
89360844|NCT06200415|Experimental|Glucosamine sulphate gel|injecting about 2 mm of glucosamine sulphate gel in the affected periodontal pocket only once
89360845|NCT06200415|Experimental|ginger gel|injecting about 2 mm of ginger gel in the affected periodontal pocket only once
89360846|NCT06200350|Experimental|Experimental group|This group will carry out the tailored training proposed by de recommender system, and followed and encouraged by the blockchain dApp.
89360847|NCT06200350|Active Comparator|Control group|This group will continue with the traditional training planned.
89360848|NCT06200155|Experimental|Arm A|Participants will receive psilocybin (25 mg).
89360849|NCT06200155|Placebo Comparator|Arm B|Participants will receive the placebo (100 mg of Niacin).
89360850|NCT06199765|Experimental|Lecture, demonstration, and role play on NSI|this arm will receive intervention regarding needlestick prevention using needlestick prevention educational module. this intervention only involve educational intervention which consist of lecture, demonstration, and role play. This intervention will be done for 1 week duration.
89360851|NCT06199765|Sham Comparator|Patient Safety Materials|This arm will receive material regarding patient safety. this material will have some element of needlestick and injury prevention. this intervention will done for 1 week.
89360852|NCT06198517|Experimental|Moxibustion|
89360853|NCT06198517|Active Comparator|Control|
89360854|NCT06197815|Experimental|Off-site assistance group|The trainer supervised the trainee's cannulation operation outside the procedure room through a high-definition screen displaying the endoscopic view. Trainees wear headphones, and trainers use intercom to provide the unlimited verbal instructions. The trainer was not allowed into the procedure room and touched the endoscope or accessories until the trainee ask for help or failed to achieve deep biliary cannulation. Then the trainer would then take over and continue with the cannulation. The trainer would halt and correct the trainee's inappropriate maneuvers immediately to avoid unnecessary papillary trauma and potential complications.
88832231|NCT03159143|Experimental|Docetaxel and Oxaliplatin|Docetaxel administered at a dose of 60mg/m^2 IV infusion, followed by oxaliplatin at a dose of 110mg/m^2 as a 2 hour IV infusion.
88832232|NCT03159299|Experimental|Yo Puedo|This group will receive the modified Yo Puedo + mHealth program.
89360855|NCT06197815|Active Comparator|Hands-on assistance group|During trainees' attempted cannulation, the trainer gave unlimited verbal instructions with hands-on assistance limited to only adjustment of scope position if necessary. To avoid unintended cannulation, the trainer was not allowed to touch the control section of the scope or the sphincterotome used for cannulation. However, the trainer would correct any inappropriate maneuvers immediately to avoid unnecessary papillary trauma and potential complications. The trainees could ask for help or stop cannulation at any time if they were not comfortable continuing the procedure. The trainer would then take over and continue with the cannulation.
89360856|NCT06196450|Experimental|Intervention arm|Vivomixx also known as VSL#3, Powder (in sachets), weight 4.4g, 450 X 10^9 cfu of probiotic bacteria per sachet, dose 1 sachet daily for 56 days
88832233|NCT03159299|No Intervention|Wait-list Control|This group will not receive the Yo Puedo + mHealth program during the 6 month data collection period, but will be invited to participate in it after data collection has finished.
89360857|NCT06196450|Placebo Comparator|Placebo arm|Microcrystalline maltose, Powder (in sachets), weight 4.4g, dose 1 sachet daily for 56 days
89360858|NCT06196320|Experimental|Tenecteplase|Intravenous tenecteplase (0.25mg/kg, maximum 25mg) within 24 hours ± thrombectomy at treating clinician's discretion
89360859|NCT06196320|Active Comparator|Best Practice (which may include intravenous Alteplase)|Intravenous alteplase (0.9mg/kg) within 4.5 hours from stroke onset or standard care (no lysis) ± thrombectomy at treating clinician's discretion
89360860|NCT06195228|Experimental|Radioiodine-refractory differentiated thyroid cancer|advanced or metastatic thyroid cancer patients who are refractory to radioiodine treatment
89360861|NCT06195228|Experimental|Differentiated thyroid carcinoma not suitable for radioiodine therapy|advanced or metastatic differentiated thyroid cancer patients who are not suitable for radio iodine therapy, for example, DTC patients with huge neck tumor but cannot receive the thyroid ectomy
89360862|NCT06195228|Experimental|Medullary thyroid cancer|patients with advanced or metastatic medullary thyroid cancer
89360863|NCT06195228|Experimental|High-grade or poorly differentiated thyroid cancer|patients with advanced or metastatic High-grade or poorly differentiated thyroid cancer
89360864|NCT06195228|Experimental|Anaplastic thyroid cancer|patients with anaplastic thyroid cancer
89360865|NCT06194162|Experimental|Weighted blanket|The intervention group will receive a weighted blanket classified as a medical device class 1 as an add on to usual treatment.
89360866|NCT06194162|Sham Comparator|Non-weighted blanket|The control comparator group will receive a sham intervention in the form of a non-weighted blanket. as an add on to usual treatment.
89360867|NCT06192485|Active Comparator|Proactive balance training group|
89360868|NCT06192485|Active Comparator|Reactive balance training group|
89360869|NCT06191848|Experimental|Tirzepatide|"Drug: Tirzepatide is a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1receptor (GLP1R) agonist Dose: Tirzepatide will be initiated at 2.5mg once weekly, with the dose increasing by a further 2.5mg every four weeks until the target weekly dose of 15mg is achieved (or participants reach a lower maximum tolerated dose of 5mg or 10mg).~Duration: 72-weeks Mode: subcutaneous"
89360870|NCT06191848|Placebo Comparator|Placebo|Drug: Placebo Dose: once-weekly Duration: 72 weeks Mode: subcutaneous
89360871|NCT06190795|Experimental|Smartphone Application|AMPLIFY Programme delivered via smartphone application with 2 levels. Level 1 is catered for people with stroke with ARAT score <34, while Level 2 is catered for people with stroke with ARAT score >=34. Five to 6 exercises will be prescribed to the stroke participants for each session to be performed independently or with the help of caregiver. Stroke participants are to performed exercises 3 sessions per day for 6 days per week. Stroke participants are to use paretic UL to perform functional activities prescribed whenever needed throughout the day. AMPLIFY programme will last for 4 weeks. If the stroke participants are discharged before 4 weeks, the participants will continue at home with the reviews being performed by the therapists via tele-rehabilitation. Frequency of reviews for the experimental group will be: Week1 (2x); Week2 (1x); Week3 (x0); Week4 (x1).
89360872|NCT06190795|Active Comparator|Hardcopy Manual|AMPLIFY Programme will be delivered via hardcopy manual. AMPLIFY Programme consists of two booklets (Booklet 1 and Booklet 2). Booklet 1 is catered for people with stroke with ARAT score <34, while Booklet 2 is catered for people with stroke with ARAT score >=34. Five to 6 exercises will be prescribed to the stroke participants for each session to be performed independently or with the help of caregiver. Stroke participants are to performed the exercises 3 sessions per day for 6 days per week. Stroke participants are to use paretic UL to perform functional activities prescribed whenever needed throughout the day. AMPLIFY programme will last for 4 weeks. If stroke participants are discharged before AMPLIFY programme ends, the participants will continue at home with the reviews being performed by the therapists via tele-rehabilitation. Frequency of reviews for the control group will be as follows: Week1 (3x); Week2 (2x); Week3 (x1); Week4 (x1).
88832234|NCT02376530|No Intervention|Usual shopping|No change in condition.
88832235|NCT02376530|Experimental|Nutrient profiling|Nutrient profiling system will be present during shopping session.
88832236|NCT02376530|Experimental|Price change|Price changes will be present during shopping session.
88832237|NCT02376530|Experimental|Nutrient profiling and price change|Nutrient profiling system and price changes will be present during shopping session.
88832238|NCT02376998|Experimental|Valiant™ endoluminal procedure|Data from early and long term complications following endoluminal stent-graft placement for thoracic endovascular aortic repair (TEVAR) procedure (Valiant™ endoluminal procedure) will be collected.
88832239|NCT03161327|Other|ABI|ABI will be performed in patient
88832240|NCT02377700|Experimental|Xeltis Vascular Patch, Model COR-VP-001|Patients implanted with the vascular patch during staged bidirectional cava-pulmonary anastomosis.
89360873|NCT06190080|Other|Management of eosinophilic esophagitis|Follow-up visits are always organized in the same way. A consultation with a gastropediatrician will take place, with assessment of symptoms (PEESS score) and quality of life (PedsQL module for eosinophilic esophagitis and PedsQL 4.0 Generic Core Scales). Then, if treatment needs to be introduced or changed, a digestive endoscopy with biopsies will be carried out at 3 months to determine whether the patient is in remission or not. Depending on the results, the patient may be advised to adapt or maintain the current treatment.
89360874|NCT06190054|Experimental|MERAMIRT|Patients with diagnosis of moderate to severe dry eye disease with asthenopia and accommodative effort will receive MERAMIRT®, 1-2 drop per eye 3 times a day for 90 days.
89360875|NCT06190028|Experimental|IRIDIUM A gel|Patients will receive IRIDIUM® A gel (four boxes to be used and one spare box) and they will be instructed to bilaterally apply 1 drop per eye onto the conjunctival sac 2 times a day for 60 days (one application during the day and one before going to sleep).
89360876|NCT06189625|Experimental|No-bandaging group|Only general measures will be recommended without the use of external support devices.
89360877|NCT06189625|Active Comparator|Bandaging group|functional bandage for 5 days and general measure.
89360878|NCT06188286|Active Comparator|TEAS|transcutaneous acupoint electrical stimulation was performed at the bilateral Hegu and Waiguan acupoints for 30 minutes, and then transcutaneous acupoint electrical stimulation was performed at the Sanyinjiao and Zusanli acupoints of the bilateral lower limbs for 30 minutes.
89360879|NCT06188286|Placebo Comparator|sham TEAS|Except for the transcutaneous acupoint electrical stimulator, which has no current output, the other operations are the same as TEAS group
89360880|NCT06185452|Active Comparator|Hospital Group|Administration of long-acting Vocabria (cabotegravir) 600 mg and long-acting Rekambys (rilpivirine) 900 mg in the hospital (standard of care)
89360881|NCT06185452|Experimental|Outpatient Group|Out-of-hospital administration of long-acting Vocabria (cabotegravir) 600 mg and long -acting Rekambys (rilpivirine) 900 mg
89360882|NCT06184945|No Intervention|Usual care|Usual ICU care
89360883|NCT06184945|Experimental|Audit and Feedback|ICUs receive electronic dashboard that display realtime ABCDEF bundle performance data
89360884|NCT06184945|Experimental|RN Implementation Facilitator|ICUs receive a extra RN who help facilitate ABCDEF bundle implementation
89360885|NCT06183983|Other|Extended MRI group|In this group, patients with a glioblastoma undergo an extended MRI-scan prior to radiotherapy.
89360886|NCT06183320|Active Comparator|Incremental Composite in Proximal Wall|38 teeth will receive class II restorations using flowable bulk fill composite to fill the cavities, leaving the proximal wall and the occlusal surface to be restored with traditional incremental composite.
89360887|NCT06183320|Experimental|Bulk Fill Composite in Proximal Wall|38 teeth will receive class II restorations using flowable bulk fill composite to fill the cavities, leaving the occlusal surface to be restored with traditional incremental composite.
89360888|NCT06182332|Experimental|Screening (AI algorithm)|Patients' medical records are reviewed for consideration of palliative care consult using AI algorithm QW for 6 months.
89360889|NCT06180902|Experimental|Fluid responsiveness testing|In our clinical study to evaluate infusion therapy responsiveness, we'll start by measuring the inferior vena cava diameter. Two minutes later, we'll assess central venous pressure. After another two-minute pause, the passive leg raise test begins, followed by a 15-minute wait. Then, we conduct the fluid challenge. Post-evaluation, we administer balanced crystalloid solutions at 1000 ml, infused at 15 ml/kg/h, adjusting for any previous infusions during the fluid challenge.
89360890|NCT06179446|Experimental|PF-07985819 pdmFlu vaccine dose A|
89360891|NCT06179446|Experimental|PF-07985819 pdmFlu vaccine dose B|
89360892|NCT06179446|Experimental|PF-07985819 pdmFlu Vaccine dose C|
89360893|NCT06179446|Placebo Comparator|Placebo|
89360894|NCT06179446|Active Comparator|Quadrivalent influenza vaccine (QIV)|
89360895|NCT06179368||Hypothroid group|throid fuction will be evaluated on admission of hepatic failure patients, and the hypothroid patients will be enroled in this group.
89360896|NCT06179368||Euthroid group|throid fuction will be evaluated on admission of hepatic failure patients, and the euothroid patients will be enroled in this group.
89360897|NCT06179225|Experimental|HMD AR|Pairs of older adults with their designated family members who geographically apart will perform collaborative activities using HMD AR in 8 sessions over 4 weeks.
89360898|NCT06179225|Active Comparator|2-D Audio-Visual|Pairs of older adults with their designated family members who geographically apart will perform collaborative activities using 2-D Audio-Visual in 8 sessions over 4 weeks.
89360899|NCT06178341|Experimental|Intervention|"Kata Inhalations-App with the following functions:~Inhalation reminder~Inhalation trainer~Health parameter documentation~Diary~Audio and video recording of user's inhalation maneuvers~Provision of study-specific questionnaires~Reminder to fill out study-specific questionnaires"
89360900|NCT06178341|No Intervention|Control|"Messinstrument (Measurement)-App. Smartphone application with the following functions:~Audio and video recording of user's inhalation maneuvers~Provision of study-specific questionnaires~Reminder to fill out study-specific questionnaires~Note: the Messinstrument-App does not provide any inhalation training, inhalation reminders, or feedback."
89360901|NCT06177665|Experimental|Erector Spinae Plane Block|Ultrasound(US)-guided erector spinae plan block(ESP) with 20 ml 0,25% bupivacaine at T4 vertebra level will performe preoperatively to all patients in the ESP group.
89360902|NCT06177665|Experimental|Rhomboid Intercostal Block|Ultrasound(US)-guided rhomboid intercostal block(RIB) with 20 ml 0,25% bupivacaine at T5-T6 vertebra level will performe preoperatively to all patients in the RIB group.
89360903|NCT06177457|Experimental|PF-07293893 and Placebo (Cohort 1)|Dose level 1: Multiple dose administration of PF-07293893 and placebo over 14 days in healthy participants; 6 participants will receive PF-07293893 and 2 will receive placebo.
89360904|NCT06177457|Experimental|PF-07293893 and Placebo (Cohort 2)|Dose level 2: Multiple dose administration of PF-07293893 and placebo over 14 days in healthy participants; 6 participants will receive PF-07293893 and 2 will receive placebo.
89360905|NCT06177457|Experimental|PF-07293893 and Placebo (Cohort 3)|Dose level 3: Multiple dose administration of PF-07293893 and placebo over 14 days in healthy participants; 6 participants will receive PF-07293893 and 2 will receive placebo.
89360906|NCT06177457|Experimental|PF-07293893 and Placebo (Cohort 4)|Dose level 4: Multiple dose administration of PF-07293893 and placebo over 14 days in healthy participants; 6 participants will receive PF-07293893 and 2 will receive placebo.
89360907|NCT06177457|Experimental|PF-07293893 and Placebo (Cohort 5)|Dose level 5: Multiple dose administration of PF-07293893 and placebo over 14 days in healthy participants; 6 participants will receive PF-07293893 and 2 will receive placebo.
89360908|NCT06177457|Experimental|PF-07293893 and Placebo (Cohort 6, Optional)|Dose level 6: Multiple dose administration of PF-07293893 and placebo over 14 days in healthy participants; 6 participants will receive PF-07293893 and 2 will receive placebo.
88832241|NCT03028753|Experimental|All subjects|All subjects enrolled in the study will have a back-fill voiding trial performed at the time of catheter removal after urogynecologic surgery.
89360909|NCT06177457|Experimental|Midazolam drug-drug interaction (Cohort 7, Optional)|Drug-drug interaction assessment of pharmacokinetics interaction in PF-07293893 and midazolam
89360910|NCT06177457|Experimental|Metabolism and elimination of PF-07293893 (Cohort 8, Optional)|Determination of excretion routes and metabolite profiling of PF-07293893.
89360911|NCT06177457|Experimental|Skeletal muscle imaging (Cohort 8, optional)|Evaluation of the effect of 14-days of daily PF-07293893 on skeletal muscle glycogen in healthy adult participants
89360912|NCT06177301|Experimental|Tislelizumab combined with GX|"Patients will receive tislelizumab combined with GX regimen： Tislelizumab：200mg vgtt，q3w；treatment until disease progression, patients withdrawal of informed, or intolerable toxicity.~Gemcitabine：1000mg/m2, vgtt, d1,8, q3w, repeat 4-6 cycles. Capecitabine: 1000mg/m2, bid，po, d1-14, q3; treatment until disease progression, patients withdrawal of informed, or intolerable toxicity."
88832242|NCT03068897|Active Comparator|Metaxalone|"Ibuprofen 600mg mg + metaxalone 400-800mg every 8 hours, as needed for low back pain, x 7 days.~All participants receive a brief educational intervention."
88832243|NCT03068897|Active Comparator|Tizanidine|"Ibuprofen 600mg mg + tizanidine 2-4mg every 8 hours, as needed for low back pain, x 7 days.~All participants receive a brief educational intervention."
88832244|NCT03068897|Active Comparator|Baclofen|"Ibuprofen 600mg mg + baclofen 10-20 mg every 8 hours, as needed for low back pain, x 7 days.~All participants receive a brief educational intervention."
88832245|NCT03068897|Placebo Comparator|Placebo|"Ibuprofen 600mg mg + placebo, 1 or 2 capsules, every 8 hours, as needed for low back pain, x 7 days.~All participants receive a brief educational intervention."
88832246|NCT05718986||Bnai Zion Medical Center|Bnai Zion Medical Center
88832247|NCT05718986||Tel Aviv Sourasky Medical Center - Ichilov Hospital|Tel Aviv Sourasky Medical Center - Ichilov Hospital
88832248|NCT05718986||Galil Medical Center|Galil Medical Center
88832249|NCT05718986||Ziv Medical Center|Ziv Medical Center
88832250|NCT05718986||Emek Medical Center|Emek Medical Center
88832251|NCT05718986||Beilinson Hospital|Beilinson Hospital
88832252|NCT05718986||Meir Medical Center|Meir Medical Center
88832253|NCT05718986||Kaplan Medical Center|Kaplan Medical Center
88832254|NCT05718986||Sheba Medical Center|Sheba Medical Center
88832255|NCT05718986||Rambam Medical Center|Rambam Medical Center
88832256|NCT05718986||Shaare Zdek Medical Center|Shaare Zdek Medical Center
88832257|NCT05718986||Hadassah Medical Center|Hadassah Medical Center
88832258|NCT05718986||Shamir Medical Center (Assaf Harofeh)|Shamir Medical Center (Assaf Harofeh)
88832259|NCT05718986||Soroka Medical Center|Soroka Medical Center
88832260|NCT05718986||Assuta Ashdod Hospital|Assuta Ashdod Hospital
88832261|NCT02049476|Experimental|Dexamethasone Pellet|This is a proof of concept study; therefore all enrolled patients will receive the intervention according to its FDA-approved indication.
88832262|NCT02299297|Experimental|Tofacitinib|Tofacitinib will be self-administered for 6 months, with the option to extend treatment up to an additional 6 months at the discretion of the principal investigator. Patients will then be followed for 6 months off the drug to assess the incidence and timing of recurrence of disease or documentation of delayed response to treatment.
88832263|NCT02055404|Experimental|Delefilcon A|Delefilcon A spherical contact lens with molded marks randomly assigned to one eye, with etafilcon A toric contact lens in the fellow eye for contralateral wear approximately 2 hours in duration
88832264|NCT02055404|Other|Etafilcon A|Etafilcon A toric contact lens randomly assigned to one eye, with delefilcon A spherical contact lens with molded marks in the fellow eye for contralateral wear approximately 2 hours in duration
88832265|NCT03069677|Active Comparator|Music group|research-selected music
88832266|NCT03069677|Active Comparator|Midazolam group|IV midazolam (1mg to 2mg max)
89360913|NCT06177301|Experimental|Tislelizumab combined with GP|"Patients will receive tislelizumab combined with GX regimen： Tislelizumab: 200mg vgtt，q3w；treatment until disease progression, patients withdrawal of informed, or intolerable toxicity.~Gemcitabine: 1000mg/m2, vgtt, d1,8, q3w, repeat 4-6 cycles； Cisplatin: 80mg/m2, ivgtt, d1 (high-dose cisplatin antiemetic and hydration regimen), q3w，repeat 4 ~ 6 cycles."
89360914|NCT06176430|Active Comparator|Daily Group|one group will receive ferrous sulphate 3mg/kg in the form of syrup daily
89360915|NCT06176430|Sham Comparator|Twice Weekly Group|other group will receive ferrous sulphate 3mg/kg in the form of syrup twice weekly.
89360916|NCT06176131||cardio-share|"Patients with successful cardio-share model fulfill at least one of the following:~A plan for follow-up after discharge established, based on communication with Primary Care (home-care and/or General Practice) before discharge~The patient has accessed MinSP-Ass. and received information on heart failure~The patient has sent vital measurements and symptoms through MinSP-Ass. to the hospital cardiologist"
89360917|NCT06176131||Others|"All others who fulfill the inclusion criteria but none of the three elements have been successful are the comparative group Others"
89360918|NCT06175832|Experimental|CFA/PPOS cycle|Interventional stimulation
89360919|NCT06175832|Active Comparator|rFSH / GnRH antagonist cycle|Conventional stimulation
89360920|NCT06173505|Experimental|Vudalimab + Carboplatin + Pemetrexed|
89360921|NCT06173505|Active Comparator|Pembrolizumab + Carboplatin + Pemetrexed|
88832267|NCT03820063|Experimental|PTC-Pz|"Paclitaxel 80mg/m2 administered intravenously on day 1 and day 8~Herceptin® 6mg/kg administered intravenously on day 1 (loading dose 8mg/kg) or Herceptin® administered subcutaneously 600mg on day 1~Carboplatin AUC 6mg•ml/min administered intravenously on day 1~Pertuzumab 420mg administered intravenously on day 1 (loading dose 840mg)~Treatment cycles are repeated on day 22~Patients who do not achieve pCR will complete a total of nine cycles taxane-containing chemotherapy followed by 14 cycles of treatment with adjuvant T-DM1."
88832268|NCT03072953|Other|APD334|APD334 active treatment for 12 weeks.
88832269|NCT02044393|Experimental|Reference|single dose BI 691751
88832270|NCT02044393|Experimental|Test|multiple doses of itraconazole + single dose BI 691751
88832271|NCT05718830||patients with traumatic lung injury (TLI)|
88832272|NCT05718830||patients with inhalation injury (ILI)|
88832273|NCT05718830||health controls(HCs)|
88832274|NCT05405465||UC patients with exposure to golimumab|The investigators retrospectively analyzed all ulcerative colitis patients from the Swiss IBD cohort study treated with golimumab.
88832275|NCT02378402||Unstable HF group|Patients with acute HF episode with hospitalization treatment within 12 months, currently LVEF<50%. Proton (1H-) magnetic resonance (MR) spectroscopy.
88832276|NCT02378402||Stable HF group|Patients with acute HF episode with hospitalization treatment within 12 months, LVEF>=50%. Proton (1H-) magnetic resonance (MR) spectroscopy.
88832277|NCT02378402||Control group|Age- and gender-matched healthy volunteers recruited as normal control group. Proton (1H-) magnetic resonance (MR) spectroscopy.
88832278|NCT00374933|Experimental|1|"Prophylactic delayed activated donor lymphocyte infusion (ADLI) after non-myeloablative conditioning and allogeneic peripheral blood cell stem cell transplantation"
88832279|NCT02046265|Experimental|Step Up to Prevention: knowledge|Participant receives an individual computer-delivered information session and participant is offered the HPV vaccine only by their nurse practitioner in clinic.
88832280|NCT02046265|Experimental|Step Up to Prevention:belief|Participant receives a one-on-one tailored educational session with a trained study team member and participant is offered the HPV vaccine only by their nurse practitioner in clinic.
88832281|NCT02046265|Experimental|Step up to Prevention|Participant receives both the knowledge session and the tailored belief sessions and the participant is offered the HPV vaccine only by their nurse practitioner in clinic. This combined intervention is call Step Up to Prevention.
88832282|NCT02046265|Active Comparator|Offered HPV vaccine only|Participant is offered the HPV vaccine only by their nurse practitioner in clinic.
88832283|NCT02064907|Experimental|Dexlansoprazole OD Tablets + Dexlansoprazole Capsules|Two Dexlansoprazole 30 mg, delayed-release orally disintegrating tablets, orally, once daily for 5 days in Period 1, followed by a 7 day washout period, followed by one dexlansoprazole 60 mg, capsule, orally, once daily for 5 days in Period 2.
88832284|NCT02064907|Experimental|Dexlansoprazole Capsules + Dexlansoprazole OD|Dexlansoprazole 60 mg, capsules, orally, once daily for 5 days in Period 1, followed by a 7 day washout period, followed by two dexlansoprazole 30 mg, delayed-release orally disintegrating tablets, orally, once daily for 5 days in Period 2.
88832285|NCT03165617|Experimental|QIVc (≥2 years to <18 Years of Age)|Cell-derived Seasonal Quadrivalent Influenza Vaccine
88832286|NCT03165617|Active Comparator|Non-Influenza Comparator Vaccine|Non-Influenza Comparator Vaccine
88832287|NCT02064985|Experimental|Ticagrelor 45mg|A single dose of ticagrelor 45 mg on Day 1 followed by 45 mg twice daily (bid) on Days 3-6 and a 45mg single dose on Day 7.
88832288|NCT02064985|Experimental|Ticagrelor 60mg|A single dose of ticagrelor 60 mg on Day 1 followed by 60 mg twice daily (bid) on Days 3-6 and a 60mg single dose on Day 7.
88832289|NCT02064985|Experimental|Ticagrelor 90mg|A single dose of ticagrelor 90 mg on Day 1 followed by 90 mg twice daily (bid) on Days 3-6 and a 90mg single dose on Day 7.
88832290|NCT00375089||Group 1|Individuals with Prader-Willi syndrome.
88832291|NCT00375089||Group 2|Individuals with Early-onset Morbid Obesity
88832292|NCT05396027|No Intervention|Control Group|Participants (healthy or physically disabled) in the control group do not require to perform audio-guided deep breathing for 14 days continuously
88832293|NCT05396027|Experimental|Experimental Group with Audio-guided deep breathing|Participants (healthy or physically disabled) in the interventional group need to perform 5 mins audio-guided deep breathing with 6 deep breaths per minute for 14 days continuously
88832294|NCT02065453|Other|Disposable Device - Left & Reusable Devices - Right|One side of the uterine attachments would be transected using the disposable device (Ligasure, Covidien).
88832295|NCT02065453|Other|Disposable Device - Right & Reusable Devices - Left|One side of the uterine attachments would be transected using the reusable Robi bipolar and Storz laparoscopic
88832296|NCT03077165|Experimental|Group A|S42909 dose 100 mg p.o., 50 mg bid
88832297|NCT03077165|Experimental|Group B|S42909 dose 200 mg p.o., 100 mg bid
89360922|NCT06172855|Experimental|Premature ejaculation|Adult male with primary premature ejaculation. They will receive electroacupuncture at ST36 to treat premature ejaculation.
89360923|NCT06169852|Experimental|Aim 1 -|Elicit and measure interactions between DBS and target neuronal populations
89360924|NCT06168604|Experimental|Pain Identification and Communication Toolkit|The Pain Identification and Communication Toolkit (PICT) components include: a) training using an observational assessment tool to detect pain in persons with Alzheimer's disease and related dementias (ADRD), b) coaching and feedback by a trained interventionist in effective strategies for communicating with providers about pain, c) future planning for what steps to take when a pain symptom is detected, and d) updating the caregiver's skill set through routine practice and homework exercises. A trained interventionist will deliver the PICT intervention following a manualized protocol to the caregiver participants. Patient participants will not receive any intervention.
89360925|NCT06168604|Sham Comparator|Attention Control|The Attention Control (AC) condition, also known as the Health Promotion Program (HPP), focuses on caregiver health promotion topics, such as nutrition, exercise, and sleep. A trained interventionist will provide education on these topics using scripted material, use active listening and open questioning techniques, and provide the HPP participants with worksheets (e.g., meal plans) to complete between sessions to mirror the homework activities in the PICT condition for the caregiver participants. Patient participants will not receive any intervention.
89360926|NCT06167811|Experimental|whole-body electrical stimulation, Protocol 1|A whole body electrical stimulation session. Symmetrical biphasic current will be used, pulse width of 400µs, frequency of 75Hz, contraction time of five seconds, rest time of 10 seconds, for eight minutes, totaling 32 muscle contractions. During the first two minutes of stimulation, the patient will remain in isometry to become familiar with the electrical current. Then with the use of a stick (for proprioception), a series of biceps exercises and a series of triceps exercises, a series of sit-ups and a squat, a series of step ups and downs, and a series of plantings.
88832298|NCT03077165|Experimental|Group C|S42909 dose 400 mg p.o., 200 mg bid
88832299|NCT03077165|Experimental|Group D|S42909 dose 800 mg p.o., 400 mg bid
88832300|NCT03077165|Experimental|Group E|S42909 dose 1200 mg p.o., 600 mg bid
88832301|NCT03077165|Placebo Comparator|Group F|Placebo p.o. bid
88832302|NCT03170219|Experimental|Subcutaneous Furosemide and sc2wear device|Subjects will receive device training and study materials (SQ pump device and up to a 7 day supply of SQ furosemide vials) on the day of randomization (study day 0) and discharged within 24 hours. Subjects will be discharged with planned treatment of 80 mg subcutaneous furosemide injection over 5-hours either QD or BID, depending on anticipated diuretic requirements.
88832303|NCT03170219|No Intervention|Usual Care|Subjects randomized to usual care will continue to receive inpatient therapy, eventual transition to oral diuretics, and discharge and post discharge care as per the discretion of the treating clinician and standard treatment guidelines.
88832304|NCT00375557|Active Comparator|1|Quetiapine
88832305|NCT00375557|Active Comparator|2|Divalproex ER
88832306|NCT03177395|No Intervention|Acetylcysteine (N-acetylcysteine; NAC)|NAC infusion 100mg/kg in 200ml 'loading dose' at timepoint '0'. 12 hour NAC regime will be continued with the second dose: 200mg/kg NAC in 1000ml i.v. over 10hr as per standard care protocol in NHS Lothian.
88832307|NCT03177395|Experimental|PP100-01 (Calmangafodipir)+ NAC|"In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:~Group A: PP100-01 (2 umol/kg calmangafodipir) after the loading dose of NAC~Group B: PP100-01 (5 umol/kg calmangafodipir) after the loading dose of NAC~Group C: PP100-01 (10 umol/kg calmangafodipir) after the loading dose of NAC~PP100-01 treatment is administered intravenously over 5 minutes."
88832308|NCT03078647|Experimental|Profound treatment to small areas|Single Profound treatment with the Dermal and/or SubQ cartridges to bra bulge, above the knees or upper arms
88832309|NCT03083093||CTEPH patients|the initial CTPA scan will be reviewed in patients diagnosed with CTEPH after an episode of an acute PE
88832310|NCT03083093||non CTEPH patients|the initial CTPA scan will be reviewed in patients after an episode of an acute PE in whom CTEPH was excluded
88832311|NCT03179345|Active Comparator|Gralise® (gabapentin)|Gralise® 3 x 600 mg tablets (1800 mg total dose) administered once daily at 7:00 pm on Day 1 and Day 2 with one placebo capsule matching the over-encapsulation of doses of Neurontin® and Lyrica®. At other dosing times, treatment consisted of 3 placebo tablets matching the appearance of Gralise® and 1 placebo capsule.
88832312|NCT03179345|Active Comparator|Neurontin® (gabapentin)|Neurontin® 1 x 600 mg film-coated tablet administered 3 times daily at 7:00 pm on Day 1, at 8:00 am, 2:00 pm and 8:00 pm on Day 2 and at 8:00 a.m. on Day 3. Each dose of Neurontin® was over-encapsulated and administered with 3 placebo tablets matching the appearance of Gralise®.
88832313|NCT03179345|Active Comparator|Lyrica® (pregabalin)|Lyrica® 1 x 150 mg capsule administered 2 times daily at 7:00 pm on Day 1, at 8:00 am and 8:00 pm on Day 2 and at 8:00 a.m. on Day 3. Each dose of Lyrica® was over-encapsulated and administered with 3 placebo tablets matching the appearance of Gralise®.
88832314|NCT03179345|Placebo Comparator|Placebo (sugar pill)|Each dose consisted of 3 placebo tablets matching the appearance of Gralise® and 1 placebo capsule matching the over-encapsulation of doses of Neurontin® and Lyrica®.
88832315|NCT03180515|Experimental|Activa PC+S Neurostimulator|All patients will complete motor testing on both continuous DBS and adaptive DBS during a study visit. The UPDRS rater and the patient will be blind to which type of stimulation they are on.
88832316|NCT03086213|Experimental|paravertebral nerve block group|non-intubated thoracic paravertebral nerve block of regional anesthesia Thoracic paravertebral nerve block of regional anesthesia at the T4 thoracic interspace
88832317|NCT03086213|Active Comparator|intercostals nerve block group|non-intubated intercostal nerve block of regional anesthesia Thoracic intercostal nerve block of regional anesthesia at the T3/4/5 thoracic interspace
88832318|NCT04737083||clubfoot fetuses|
88832319|NCT03089879|Experimental|Shigella Group|Healthy male and female subjects, aged 22 to 50 years, previously primed with 3 doses of the GVGH Shigella sonnei 1790GAHB vaccine in the H03_01TP parent study and who had undetectable antibody titers at baseline, received one intramuscular booster dose of the same vaccine in the current study, at Day 1.
88832320|NCT03089879|Experimental|Placebo Group|Healthy male and female subjects, aged 22 to 50 years, who previously received placebo in the H03_01TP parent study and who had undetectable antibodies at baseline, received one intramuscular GVGH Shigella sonnei 1790GAHB vaccine dose in the current study, at Day 1.
88832321|NCT03089879|Experimental|Naïve Group|Healthy male and female subjects, aged 22 to 50 years, who were not part of H03_01TP parent study, received one intramuscular GVGH Shigella sonnei 1790GAHB vaccine dose in the current study, at Day 1.
88832322|NCT02378714|Placebo Comparator|Standard treatment + placebo varenicline|Standard behavioral smoking cessation treatment plus placebo varenicline
88832323|NCT02378714|Experimental|BASC + placebo varenicline|Behavioral activation for smoking cessation plus placebo varenicline
88832324|NCT02378714|Active Comparator|Standard treatment + active varenicline|Standard behavioral smoking cessation treatment plus active varenicline
88832325|NCT02378714|Experimental|BASC + active varenicline|Behavioral activation for smoking cessation plus active varenicline
88832326|NCT03091361||All patients (imaging/no intervention)|There is only one group in this study, the imaging/no intervention group. These patients will meet all enrollment criteria and bacterial (red or cyan) fluorescence will be visualized within or around their wound with the MolecuLight i:X imaging device. A targeted curettage sample will be taken from the site of fluorescence and sent for microbiological analysis. There will be no intervention or followup.
88832327|NCT05091047|Experimental|Erchonia EVRL|635 nanometers (nm) and 405 nm laser application
88832328|NCT03091673|Experimental|G-Pen (glucagon injection) 0.5 mg|A single 0.5 mg subcutaneous (SC) injection of G-Pen (glucagon injection)
88832329|NCT03091673|Experimental|G-Pen (glucagon injection) 1.0 mg|A single 1.0 mg subcutaneous (SC) injection of G-Pen (glucagon injection)
88832330|NCT03091751|Experimental|BeneFIX|BeneFIX is a recombinant FIX provided in a vial containing 100 IU/mL lyophilized nonacog alfa accompanied with solvent for reconstitution and injection.
88832331|NCT02381288|Experimental|TAK-448 0.1 mcg|TAK-448 0.1 mcg, injection, subcutaneously, once daily on Days 1 through 42.
88832332|NCT02381288|Experimental|TAK-448 0.3 mcg|TAK-448 0.3 mcg, injection, subcutaneously, twice-weekly on Days 1 through 39.
88832333|NCT02381288|Experimental|TAK-448 1.0 mcg|TAK-448 1.0 mcg, injection, subcutaneously, once-weekly on Days 1 through 36.
88832334|NCT02381288|Placebo Comparator|Placebo|TAK-448 placebo matching injection, subcutaneously, either once daily on Days 1 through 42, or twice weekly on Days 1 through 39 or once weekly on Days 1 through 36.
88832335|NCT05364359|Active Comparator|Intervention group|The patients will receive a individual dietary counseling based on the taste-test
88832336|NCT05364359|Placebo Comparator|Standard dietary counseling|The patients will receive a individual standard dietary counseling not based on the taste-test
88832337|NCT02381678||Subjects implanted with Perimount Heart Valve|Only one group was set for this study, including all enrolled subjects who implanted with Perimount Heart Valve during 2001 to 2007
88832338|NCT05363735||Ultrasound Elastography|Patients will be examined by ultrasound elastography.
88832339|NCT00355316|Experimental|Stage IV Breast Cancer|Blood draws at baseline before systemic therapy. Blood draw then every 6 weeks for approximately 12 weeks.
88832340|NCT00355316|Other|Healthy Volunteers|Baseline blood draw.
88832341|NCT05363657||Renal tumor patiens|Patients with any renal tumor diagnosed with conventional imaging (computed tomography or magnetic resonance imaging) and undergoing to a clinical management in a hugh-volume center.
88832342|NCT02382848|Active Comparator|Prazosin, Then Placebo|Participants first received Prazosin. A starting dose of Prazosin (1mg capsule) will be given at Week # 1 of this arm. Symptoms will be reassessed and medication will be adjusted by 1-2 mg increments every 7 days for 3 weeks based on clinical response and severity of night mares, to achieve maximum therapeutic benefit while monitoring adverse effects using side effects scale on weekly basis (psychiatrist will be using the scale at every visit). The end point for capping the Prazosin dose will be 6 mg daily. After a washout period, they then receive Placebo
88832343|NCT02382848|Placebo Comparator|Placebo, Then Prazosin|Participants first received Placebo (matching Prazosin) for a 3 consecutive week period during the 7 week study period. After a washout period, they then received Prazosin. The starting dose of Prazosin (1mg capsule) will be given at Week # 5 of this arm. Symptoms will be reassessed and medication will be adjusted by 1-2 mg increments every 7 days for 3 weeks based on clinical response and severity of night mares, to achieve maximum therapeutic benefit while monitoring adverse effects using side effects scale on weekly basis (psychiatrist will be using the scale at every visit). The end point for capping the Prazosin dose will be 6 mg daily.
89399148|NCT02168894|Active Comparator|Group 3 - Waitlist Group|Participants in Group 3 have acupuncture sessions 3 times per week over 4 weeks for a total of 12 sessions. Participant may or may not have electrical stimulation at these sessions. These sessions will begin 14 weeks after enrollment. Nerve function tests performed at visit before acupuncture and at end of study visit. These tests consist of hand tasks and balance tests. Questionnaires completed at baseline, visit before acupuncture, after 6 and 12 acupuncture visits, and at end of study visit.
88832344|NCT03094325|Experimental|Septal myectomy|
89399149|NCT02171936||chronic pain|
88832345|NCT05718440||patient with spinal dysraphism|
89360927|NCT06167811|Experimental|whole-body electrical stimulation, Protocol 2|A whole body electrical stimulation session. Symmetrical biphasic current will be used, pulse width of 400µs, frequency of 75Hz, contraction time of five seconds, rest time of 10 seconds, for 16 minutes, totaling 64 muscle contractions. During the first two minutes of stimulation, the patient will remain in isometry to become familiar with the electrical current. Then with the use of a stick (for proprioception), a series of biceps exercises and a series of triceps exercises, a series of sit-ups and a squat, a series of step ups and downs, and a series of plantings.
89360928|NCT06166888|Experimental|AK131|Subjects will receive AK131 via intravenously (IV) Q2W or Q3W, up to 2 years
88832346|NCT02065687|Experimental|Arm I (paclitaxel, carboplatin, metformin hydrochloride)|"Patients receive paclitaxel IV over 3 hours on day 1, carboplatin IV over 30 minutes on day 1, and metformin hydrochloride PO BID (approximately every 10-12 hours apart) on days 1-21 (QD in course 1). Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive maintenance therapy comprising metformin hydrochloride PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~In both arms, patients who achieve SD or PR and still have measurable disease at the completion of course 6 may continue to receive paclitaxel IV and carboplatin IV (with metformin hydrochloride or placebo) for an additional 4 courses at the discretion of the treating investigator."
89360929|NCT06166381|Active Comparator|control|This group will receive parenteral antibiotics to prevent infection in the surgery.
88832347|NCT02065687|Active Comparator|Arm II (paclitaxel, carboplatin, placebo)|"Patients receive paclitaxel IV and carboplatin IV as in Arm I. Patients also receive placebo PO BID (approximately every 10-12 hours apart) on days 1-21 (QD in course 1). Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive maintenance therapy comprising placebo PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~In both arms, patients who achieve SD or PR and still have measurable disease at the completion of course 6 may continue to receive paclitaxel IV and carboplatin IV (with metformin hydrochloride or placebo) for an additional 4 courses at the discretion of the treating investigator."
88832348|NCT03095885|Other|Test Meal|controlled oxalate-rich test meal
88832349|NCT02383706||Subjects|Pregnant women, BMI greater than or equal to 40 undergo questionnaires, physical exam, and ApneaLink Air, at home, overnight polysomnography study.
88832350|NCT03096353|Experimental|Naloxone, then Placebo|"Day one - During MRI session participant underwent sensory stimulus testing followed by bolus and infusion doses of naloxone (0.05 mg/kg bodyweight). When infusion levels reached stability, sensory testing was performed again.~Day two - During MRI session participant underwent sensory stimulus testing followed by bolus and infusion doses of normal saline. When infusion levels reached stability, sensory testing was performed again."
88832351|NCT03096353|Experimental|Placebo, then Naloxone|"Day one - During MRI session participant underwent sensory stimulus testing followed by bolus and infusion doses of normal saline. When infusion levels reached stability, sensory testing was performed again.~Day two - During MRI session participant underwent sensory stimulus testing followed by bolus and infusion doses of naloxone (0.05 mg/kg bodyweight). When infusion levels reached stability, sensory testing was performed again."
88832352|NCT02384096|Active Comparator|Conventional Programming, then Advanced Programming|Precision Spectra SCS System with CoverEdge Surgical Lead or more than 2 percutaneous leads. Subjects first received conventional single source programming followed by Precision Spectra SCS System advanced programming.
88832353|NCT02384096|Active Comparator|Advanced Programming, then Conventional Programming|Precision Spectra SCS System with CoverEdge Surgical Lead or more than 2 percutaneous leads. Subjects first received Precision Spectra SCS System advanced programming followed by conventional single source programming.
88832354|NCT03098615|Other|Jublia (Efinaconazole 10% Topical Solution) + nail polish|Subjects with distal lateral subungual onychomycosis (DLSO) with dermatophytoma.
88832355|NCT05363579|Other|Physiotherapy|It is a form of therapy.
88832356|NCT05363579|Other|Tuina Therapy|It is a form of therapy.
88832357|NCT05363579|Other|Physiotherapy mixed with Tuina|It is a form of therapy.
88832358|NCT05504798|Active Comparator|Group (A)|will receive a selected physical therapy program.
88832359|NCT05504798|Active Comparator|Group (B)|will receive interrupted progressive serial casting in addition to a modified selected physical therapy program during casting.
88832360|NCT05504798|Active Comparator|Group (C)|will receive interrupted progressive serial casting and the modified selected physical therapy as group (B) in addition to neuromuscular electrical stimulation for ankle dorsiflexors and knee extensors muscles through cast windows
89360930|NCT06166381|Experimental|clinical trial|This group will include patients who will receive parenteral antibiotics combined with vancomycin presoaked solution for the graft.
88832361|NCT05363501|Active Comparator|Naloxone IM Injection|Single 0.4 mg IM naloxone injection will be administered (1 mL of 0.4 mg/mL injection, into the gluteus maximus muscle using a 23-gauge needle).
88832362|NCT05363501|Active Comparator|Intranasal Naloxone Spray|Single 4 mg intranasal naloxone spray will be administered in one nostril (0.1 mL of 4 mg/0.1 mL spray, based on the prescribing information and approved Instructions for Use).
88832363|NCT05363501|Experimental|Single 8 mg naloxone nasal swab-Swirl method|Single 8 mg naloxone nasal swab administered as one swab in one nostril, swirled 3 times around the inside of the nasal mucosa.
88832364|NCT05363501|Experimental|Single 4 mg naloxone nasal swab-Swirl method|Single 4 mg naloxone nasal swab administered as one swab in one nostril, swirled 3 times around the inside of the nasal mucosa.
88832365|NCT05363501|Experimental|Single 12 mg naloxone nasal swab-Swirl method|Single 12 mg naloxone nasal swab administered as one swab in one nostril, swirled 3 times around the inside of the nasal mucosa.
88832366|NCT05363501|Experimental|Single 12 mg naloxone nasal swab-Squeeze method|Single 12 mg naloxone nasal swab administered into the nasal cavity - administered in one nostril and using two fingers to squeeze outside of both nostrils.
88832367|NCT05363501|Experimental|Single 12 mg naloxone nasal swab in each nostril-Squeeze method|Two 12 mg naloxone nasal swabs in both nostrils- administered one per nostril and using two fingers to squeeze outside of both nostrils (two doses given sequentially)
88832368|NCT05363501|Experimental|Single 8 mg naloxone nasal swab in each nostril-Squeeze method|Two 8 mg naloxone nasal swab in both nostrils - administered one per nostril and using two fingers to squeeze outside of both nostrils (two doses given sequentially)
88832369|NCT05363501|Experimental|Single 12.5 mg naloxone nasal swab-Squeeze method|Single target naloxone nasal swab dose identified in Phase 1(12.5 mg) administered as one swab in one nostril, using the insert into nostril and squeeze method of administration
88832370|NCT05363501|Experimental|Single 12.5 mg naloxone nasal swab in each nostril-Squeeze method|Single target naloxone nasal swab dose identified in Phase 1 (12.5 mg) using the insert into each nostril and squeeze method of administration (two doses given in total).
88832371|NCT04736927|Experimental|GLPG3667 + Midazolam|
89534474|NCT00003102|Experimental|Cohort 1 50cGy radiation|"On day 1, patients received a single dose of 131I-cG250 (5 mCi/5 mg) administered as an intravenous infusion over 10 minutes.~Therapeutic doses of 131I-cG250 were administered the following week as fractionated outpatient doses, starting with 30 millicurie (mCi)/5 mg 131I-cG250. Subsequent doses of 131I-cG250 were administered at 2-3 day intervals with the total amount of 131I-cG250 administered based on the calculated clearance of the initial dose administered on day 1. Whole body activity was maintained at no more than 30 mCi iodine-131.~In the absence of disease progression and after recovery from toxicity, patients could be re-treated beginning 8 weeks after the last treatment of the initial series, for a total of not more than 3 treatments."
88832372|NCT02387294|Experimental|Age group 1: children (3-11 years)|"Intervention: Vaccination with Fluval AB Novo suspension for injection.~Dosage: Half dose of a single dose (0.25 ml) vaccine, administered intramuscularly."
88832373|NCT02387294|Experimental|Age group 2: adolescents (12-18 years)|"Intervention: Vaccination with Fluval AB Novo suspension for injection.~Dosage: A single dose (0.5 ml) vaccine, administered intramuscularly."
88832374|NCT05352269|Experimental|Cohort 1 XBI-302|40 XBI-302 capsules in 1 day
88832375|NCT05352269|Placebo Comparator|Cohort 1 Placebo|40 placebo capsules in 1 day
88832376|NCT05352269|Experimental|Cohort 2 XBI-302|80 XBI-302 capsules over 2 days
88832377|NCT05352269|Placebo Comparator|Cohort 2 Placebo|80 placebo capsules over 2 days
88832378|NCT05352269|Experimental|Cohort 3 XBI-302|40 XBI-302 capsules per day, once a week for 4 weeks.
88832379|NCT05352269|Placebo Comparator|Cohort 3 Placebo|40 placebo capsules per day, once a week for 4 weeks.
88832380|NCT05352269|Experimental|Cohort 4 XBI-302|80 XBI-302 capsules over 2 days, once a week for 4 weeks.
88832381|NCT05352269|Placebo Comparator|Cohort 4 Placebo|80 placebo capsules over 2 days, once a week for 4 weeks.
88832382|NCT05718206|Experimental|Coronary stenosis|
88832383|NCT05718206|Other|Control|
88832384|NCT02066857|Active Comparator|Generic plaster or fiberglass cast group|Patients will be randomized to receive a generic plaster or fiberglass cast for treatment of non-displaced distal radius fracture for 6 weeks.
88832385|NCT02066857|Active Comparator|"Generic off the shelf removable splint group"|"Subjects will be randomized and receive a generic off the shelf removable splint for treatment of non-displaced distal radius fracture for 6 weeks."
88832386|NCT04940585|Experimental|Rose Program Group|ROSE is a 7-session intervention. Participants will attend 6 weekly group sessions virtually, through a program on the computer called WebEx or at the clinic, and then one individual session after delivery. Participants will complete a few questionnaires at three different timepoints, including demographics, stress, social support, physical and mental health, and trauma.
88832387|NCT04940585|No Intervention|Comparison Group|Participants will complete three sets of questionnaires including demographics, stress, social support, physical and mental health, and trauma.
88832388|NCT02388386|Experimental|PROTEUS-SENSOR|The current study is a prospective interventional design with a single experimental arm. The intervention consists of two components: an edible sensor and a wearable receiver health monitor.
88832389|NCT03810703|Placebo Comparator|placebo arm|Participant will receive placebo oral capsule during this four hour session.
88832390|NCT03810703|Experimental|amphetamine 10 mg arm|Participant will receive d-amphetamine 10 mg oral capsule during this four hour session.
88832391|NCT03810703|Experimental|amphetamine 20 mg arm|Participant will receive d-amphetamine 20 mg oral capsule during this four hour session.
88832392|NCT05718050|Experimental|Flexure|Dentate patients, 18 years of age or older, in good health and, in need of implant treatment
88832393|NCT04332965|Experimental|Patients with chronic periodontitis|Patients with CP (n=30) had teeth with 30% periodontal bone loss and ≥ 2 non-adjacent sites per quadrant with probing depth (PD) ≥ 5 mm and bleeding on probing.
88832394|NCT04332965|Experimental|Patients with gingivitis|Participants with G (n=30) had gingival index ≥ 2 and other inflammation signs.
88832395|NCT04332965|No Intervention|Participants with periodontal healthy|The H group (n=30) consisted of individuals with no attachment loss, no history of periodontal disease, PD ≤3 mm, and whole-mouth bleeding scores <10%.
89360931|NCT06164314|Experimental|Dex group|Subjects assigned to Dex group will receive a continuous dexmedetomidine infusion (0.4 ug/kg/h) after anesthesia induction until dural closure, and then received an intravenous analgesia pump with dexmedetomidine(0.08ug/kg/h), sufentanil and antiemetic until 48 hours postoperatively
89360932|NCT06164314|Placebo Comparator|Placebo group|Subjects in the Placebo group were given comparable volumes of normal saline during the surgery, and intravenous analgesia pump also contains sufentanil and antiemetic, but no dexmedetomidine used until 48 hours postoperatively.
89360933|NCT06163482||Healthy controls|No cystic fibrosis (CF)
89360934|NCT06163482||Pancreatic sufficient CF|cystic fibrosis, but not pancreatic insufficient
89360935|NCT06163482||Pancreatic insufficient CF|cystic fibrosis and pancreatic insufficient
89360936|NCT06161974|Experimental|Stratum A|Patients with localized, intracranial, non-pontine, and non-thalamic IDH 1 mutant Astrocytoma, CNS WHO Grade 3.
89360937|NCT06161974|Experimental|Stratum B|Patients with localized, intracranial, non-pontine, and non-thalamic IDH 1 mutant Astrocytoma, CNS WHO Grade 4.
89360938|NCT06161974|Experimental|Stratum C|Patients with IDH-1 mutant DIPG, primary thalamic and spinal cord IDH-1 mutant HGG.
89360939|NCT06158568|Experimental|Percutaneous Electrical Nerve Stimulation|Participants assigned to this group will received four sessions (once per week) of ultrasound guided percutaneous electrical nerve stimulation targeting the axillar and suprascapular nerves for 30 minutes. We will apply a biphasic compensated electrical current at a frequency of 2 Hz, a pulse width of 250 μs and intensity allowed over a pain-free motor threshold (muscle contraction). In addition, they will receive a program of exercises for the shoulder musculature for 3 weeks.
89360940|NCT06158568|Placebo Comparator|Placebo Percutaneous Nerve Stimulation|Participants assigned to this group will received four sessions (once per week) of placebo ultrasound guided percutaneous electrical nerve stimulation targeting the axillar and suprascapular nerve. The electrical current will be off and no electrical current will be provided to the patient. In addition, they will receive the same program of exercises for the shoulder than the experimental group for three weeks.
89360941|NCT06158568|Active Comparator|Exercise|Participants assigned to this group will receive the same program of exercises for the shoulder than the remaining groups for three weeks.
88832396|NCT02389088|No Intervention|Phase I|"9 PCOS women will be studied. On study day one, r-FSH will be administered I.V. at a dose of 150 IU (FSH stimulation test). Blood samples will be obtained before and after FSH administration. After the FSH stimulation test, each subject will receive an I.M. injection of Lupron 3.75 mg. This dose has a duration effect of one month.~The FSH stimulation test will be repeated, as described above, at 5 weeks (early resumption of ovarian function) and 6 weeks (moderate resumption of ovarian function)."
88832397|NCT02389088|Active Comparator|Phase II|"Women that participated in Phase I will be studied again after a washout of 2 months. On study day one, an FSH stimulation test will be performed as described above.~After the FSH stimulation test, each subject will receive an I.M. injection of Lupron 3.75 mg. This dose has a duration effect of one month. Four weeks after administration of Lupron, each subject will receive Letrozole 5mg for 14 days. The FSH stimulation test will be repeated at 5 weeks (early resumption of ovarian function) and 6 weeks (moderate resumption of ovarian function)."
88832398|NCT04747691||Patients assessed with postoperative bedside gastric ultrasound|This patient population will include postoperative patients who received a gastrointestinal surgery and are being assessed with the bedside gastric ultrasound.
88832399|NCT02068027|Experimental|Clonidine Gel 0.1%|Clonidine hydrochloride topical gel, 0.1%
89360942|NCT06156982||Evusheld administered group|
89360943|NCT06156410|Experimental|Treatment|Cabozantinib
89360944|NCT06155123||HFEM or CM treated with mAbs|Patients with high frequency episodic or chronic migraine undergoing treatment with monoclonal antibodies directed against calcitonin gene related peptide pathway
89360945|NCT06155123||Healthy Controls|Group of healthy controls comparable for demographic features
89360946|NCT06152588|Experimental|Time-restricted eating|TRE group for 1 year: The intervention consists of a 3-month (12 weeks) strict TRE period, where participants follow the same eating window each day with minimal support, followed by a 9-month (40 weeks) period of individually adjusted TRE according to their experiences.
88832400|NCT02068027|Placebo Comparator|Placebo|Placebo gel of identical appearance as active treatment
88832401|NCT05242055||Integrated group|Patients in the integrated group should be the patients getting integrated diagnosis and treatment during following up period. Integrated diagnosis and treatment includes control of hypertension, hyperglycemia, hyperlipidemia, anemia, CKD-MBD, and malnutrition by regular follow-up according to the guidelines of Kidney Disease- Improving Global Outcomes and of Chinese Medical Association in 2021.
88832402|NCT05242055||Unintegrated group|Patients in the unintegrated group are those who do not follow the contents of guidelines in some items of the integrated diagnosis and treatment during follow-up.
88832403|NCT05717972|Experimental|A Group|
88832404|NCT05717972|Other|B Group|Waiting list
88832405|NCT05717894|Experimental|Treatment ( primary )|
88832406|NCT05717894|No Intervention|Control|
89360947|NCT06152588|No Intervention|Control|Control group for 1 year: Participants will be instructed to continue their habitual lifestyle during the study and they will follow standard care with regular visits at the SDCC clinic 3-4 times/year.
89360948|NCT06151184|Experimental|Post-concussion syndrome participants|Post-concussion syndrome participants will all receive manual chiropractic adjustment interventions.
89360949|NCT06145581|Experimental|Supportive Care (home-based physical activity)|Patients participate in remote monitored home-based physical activity sessions including flexibility practice, slow walking and breathing exercises daily on 6 out of 7 days a week and receive telephone health coaching over 5-20 minutes once a week for 12 weeks. Patients also participate in a brief telephone interview at the end of 12 weeks. Additionally, patients wear a monitor on the wrist to monitor physical activity for 7 days during enrollment and at 3 months.
89399150|NCT05142488|Experimental|8 week interval|Third dose Covid-19 (recombinante) vaccine 6 months after the second dose of a two dose vaccine schedule with a 8 week interval between the first two doses.
88832407|NCT05231681|Experimental|Eye Concealer|Saie Beauty's Hydrabeam Sheer Brightening Under Eye Concealer
88832408|NCT04661657||COVID-19|Non-prisoner and non-pregnant subjects, without prior cardiac disease, who have tested positive or have been hospitalized due to COVID-19 infection. Subjects will be undergo a physical exam, blood draw to asses serological biomarkers. Subjects will also undergo an transthoracic echocardiogram (TTE) and a clariscan-enhanced cardiovascular magnetic resonance imaging (CMR) using a gadolinium based contrast agent (GBCA).
88832409|NCT04661657||Control|Non-prisoner and non-pregnant subjects, without prior cardiac disease, who have never tested positive and/or has never been hospitalized due to COVID-19 infection. Subjects will be undergo a physical exam, blood draw to asses serological biomarkers. Subjects will also undergo an transthoracic echocardiogram (TTE) and a clariscan-enhanced cardiovascular magnetic resonance imaging (CMR) using a gadolinium based contrast agent (GBCA).
88832410|NCT02391350|Active Comparator|Usual Care|Patients will be managed by primary care provider with a stepped care approach supported by current practice guidelines. Initial management will include education and re-assurance for the first 4 weeks following the primary care visit. Patients in will be recommended to follow-up with their primary care provider if unsatisfied with their progress after 4 weeks. At that time decisions on further treatments and/or referrals will be made by the primary care provider in consultation with the patient consistent with usual care.
88832411|NCT02391350|Experimental|Early Intervention|Patients will receive education and re-assurance in the same manner as the usual care group and will receive physical therapy during the initial 4 weeks following enrollment. Physical therapy will be based on evidence and prior research evaluating a centralizing treatment program for patients with LBP and sciatica. The first physical therapy session will be scheduled within 3 days after enrollment and 6-8 sessions will be administered in the first 4 weeks. Each session will include a brief assessment, treatment with centralizing exercises and spinal mobilizations. Mechanical traction is an optional component. Patients will be provided handouts and instructed to perform assigned exercises at home every 4-5 hours on days between sessions.
88832412|NCT02392208|Other|Telavancin Before Hemodialysis|Stage 5 Chronic Kidney Disease patients receive a single dose of telavancin before their normally scheduled hemodialysis session.
88832413|NCT02392208|Other|Telavancin After Hemodialysis|Stage 5 Chronic Kidney Disease patients receive a single dose of telavancin immediately after their normally scheduled hemodialysis session.
88832414|NCT05185583|Experimental|Sequence A: Methylphenidate, Placebo|Participants will first receive methylphenidate capsules twice daily for four weeks. Doses will be administered four hours apart. The maximum dose is determined based on the participant's weight. After a 2-day washout, participants then receive Placebo (matching methylphenidate capsules) twice daily for four weeks.
88832415|NCT05185583|Experimental|Sequence B: Placebo, Methylphenidate|Participants will first receive Placebo capsules twice daily for four weeks. Doses will be administered four hours apart. After a 2-day washout, participants then receive methylphenidate capsules (matching Placebo capsules) twice daily for four weeks. The maximum dose is determined based on the participant's weight.
88832416|NCT04645121||Hemodialysis group|Subjects receiving maintenance hemodialysis for at least three months
88832417|NCT04645121||Case group|Healthy subjects with eGFR above 60 ml/min/1.73m2
88832418|NCT05470712||Plasma from women with preeclampsia|Plasma collected from women who developed preeclampsia during pregnancy will be analyzed for mechanism of NETs formation.
88832419|NCT05470712||Plasma from women with normal pregnancies|Plasma collected from women with normal pregnancies will be analyzed for mechanism of NETs formation.
88832420|NCT05462444||Children with food allergy|
88832421|NCT05462444||Children with food intolerance|
88832422|NCT05462444||Children with other allergies (reference group)|
88832423|NCT02392286|Active Comparator|Weight-based|Corticosteroid dose weight-based at equivalent to 1mg/kg prednisone daily.
88832424|NCT02392286|Active Comparator|Fixed dose|Corticosteroid dose fixed at equivalent to 40mg prednisone daily.
88832425|NCT04586153|Experimental|Meplzaumb|This arm is combined with 3 groups, low dose, middle dose, and high dose. Low dose group: First dose: 0.12 mg/kg - Day 1; second dose: control - Day 8 Middle dose group: First dose: 0.2 mg/kg - Day 1; second dose: 0.2 mg/kg - Day 8 High dose group: First dose: 0.3 mg/kg - Day 1; second dose: 0.3 mg/kg - Day 8
88832426|NCT04586153|Placebo Comparator|Placebo|First dose: control - Day 1; second dose: control - Day 8
88832427|NCT02393378|Experimental|Adalimumab 40 mg|Adalimumab 40 mg, subcutaneous (SC) injection at Weeks 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 22 as an add-on to weekly existing stable MTX and folic acid as per prescribed medication.
88832428|NCT02393378|Active Comparator|Namilumab 150 mg|Namilumab 150*2 mg, SC injection at Week 0 followed by 150 mg, SC injections at Weeks 2, 6, 10, 14, 18, and 22 as an add-on to weekly existing stable MTX and folic acid as per prescribed medication.
88832431|NCT04949477|Active Comparator|Group (D)|The patient will receive intranasal dexmedetomidine.
88832432|NCT04949477|Active Comparator|Group (P)|The patient will receive paracetamol orally.
88832433|NCT00354926|Experimental|AME 133v|All subjects will receive weekly intravenous infusions of AME-133v. Each subject will receive a total of 4 infusions administered once a week for 3 consecutive weeks.
88832434|NCT05717660|Active Comparator|Control|Androgen Deprivation therapy and Apalutamide
88832435|NCT05717660|Experimental|Treatment|Androgen Deprivation therapy and Apalutamide and SBRT on all sites of metastatic disease
89399151|NCT05142488|Active Comparator|12 week interval|Third dose Covid-19 (recombinante) vaccine 6 months after the second dose of a two dose vaccine schedule with a 12 week interval between the first two doses.
89399152|NCT02172014|Experimental|Fentanyl|midazolam and fentanyl citrate infusion
89399153|NCT02172014|Placebo Comparator|Control|midazolam and normal saline infusion
89360950|NCT06145464|Active Comparator|Control|Adolescents will be recommended to use the sun protection interventions implemented on Foz do Lizandro beach (collective shadow, sun protector, and information about healthy behaviors of sun protection disposed in an infographic installed near the collective shadow), without a previous health literacy session about skin cancer prevention provided 15 days before the beginning of the use of the interventions on the beach.
88832436|NCT05717582|Experimental|maximal-cytoreductive therapy|Patients with de novo mCSPC who achieve ≤10 oligopersistent metastases on PSMA PET CT after initial 3-month systemic treatment with apalutamide plus ADT will receive cytoreductive radical prostatectomy with/without PLND and metastasis-directed therapy with radiation.
89360951|NCT06145464|Experimental|Interventional EST SUP|Adolescents will be recommended to use the sun protection interventions implemented on Foz do Lizandro beach (collective shadow, sun protector, and information about healthy behaviors of sun protection disposed in an infographic installed near the collective shadow), with a previous health literacy session about skin cancer prevention provided 15 days before the beginning of the use of the interventions on the beach by students on ongoing graduation at the University of Lisbon.
89360952|NCT06145464|Experimental|Interventional FARMA|Adolescents will be recommended to use the sun protection interventions implemented on Foz do Lizandro beach (collective shadow, sun protector, and information about healthy behaviors of sun protection disposed in an infographic installed near the collective shadow), with a previous health literacy session about skin cancer prevention provided 15 days before the beginning of the use of the interventions on the beach by community pharmacists who will be working on pharmacies located in Mafra.
88832437|NCT03101033|Experimental|Epidural neuroplasty group|This group will be given epidural neuroplasty once enrolled.
88832438|NCT03101033|Active Comparator|Transforaminal steroid injection group|This group will be given transforaminal betamethasone injection once enrolled, if no obvious pain relief was reported, another epidural injection will be given one week later.
88832439|NCT02069041|Experimental|Ramucirumab + FOLFOX4|"8 milligram/kilogram (mg/kg) ramucirumab given intravenously (IV) on Day 1 followed by FOLFOX4 (folinic acid + fluorouracil + oxaliplatin chemotherapy regimen) given IV on Day 1 of 2 week cycles:~FOLFOX4 every 2 weeks:~85 milligram per square meter (mg/m²) oxaliplatin IV on Day 1 200 mg/m² folinic acid(FA) IV on days 1 and 2 400 mg/m² 5-FU bolus on days 1 and 2 600 mg/m2 5-FU 22-h continuous infusion on Days 1 and 2~Participants may continue to receive treatment until discontinuation criteria are met."
88832440|NCT03101111|Experimental|MV-CHIK and Placebo|"Subjects will receive two injections on study day 0 and one injection on day 28.~On both days they will receive a 5E+05 (+/- 0.5 log) TCID50 intramuscularly in the deltoid muscle of one arm.~On day 0 they will receive a dummy injection of placebo (physiological saline) subcutaneously in the contralateral arm."
88832441|NCT03101111|Active Comparator|MMR-vaccine and Placebo|"Subjects will receive two injections on study day 0 and one injection on day 28.~On both days they will receive dummy injections of placebo (physiological saline) in the deltoid muscle of one arm.~On day 0 they will receive MMR-vaccine subcutaneously in the contralateral arm."
88832442|NCT05423834||TAF-treated Chronic hepatitis B patients|Chronic hepatitis B patients that treated with Tenofovir alafenamide
88832443|NCT05423834||ETV-treated Chronic hepatitis B patients|Chronic hepatitis B patients that treated with Entecavir
88832444|NCT03102437|Experimental|Optimizer Smart System|All eligible subjects will have the Optimizer Smart System implanted and receive cardiac contractility modulation therapy (CCM).
88832445|NCT05717426|Active Comparator|Open chain exercises group|Group A(Open chain exercises group) received open kinetic exercises 3 times a week for 3-4 weeks.
88832446|NCT05717426|Active Comparator|Closed kinetic chain exercises group|Group B(Closed kinetic chain exercises group) received close kinetic exercises 3 times a week for 3-4 weeks.
88832447|NCT02069119|Experimental|OPC-108459|OPC-108459 solution will be intravenously administered by 30-minute infusion in the forearm.
88832448|NCT02069119|Placebo Comparator|Placebo|placebo solution will be intravenously administered by 30-minute infusion in the forearm.
88832449|NCT04139135|Experimental|HLX10|HLX10 combined with chemotherapy will be adopted in the neoadjuvant treatment phase, and HLX10 monotherapy will be administered in the adjuvant treatment phase
88832450|NCT04139135|Placebo Comparator|Placebo|Placebo combined with chemotherapy will be given in the neoadjuvant treatment phase, and chemotherapy alone will be administered during the adjuvant treatment phase.
89360953|NCT06142929||Primary Dupuytren disease|50 patients with primary Dupuytren disease that are selected for surgery and will undergo the resection of Dupuytren tissue with the microfasciectomy technique
89360954|NCT06142929||Recurrence Dupuytren disease|30 patients with recurrence Dupuytren disease that are selected for surgery and will undergo the resection of Dupuytren tissue with the microfasciectomy technique
89360955|NCT06141499|Experimental|Providers|Dialysis providers will receive educational material about the kidney transplantation and waitlisting process.
88832451|NCT05406557|Active Comparator|Partial pulpotomy|Removal of superficial 2-3 mm of pulp tissue from entire pulp chamber
88832452|NCT05406557|Active Comparator|Miniature pulpotomy|Removal of superficial 2-3 mm of pulp tissue from only affected pulp horn
88832453|NCT02069353|Experimental|Cardiac arrest|Survivors of cardiac arrest at high risk of neurological deterioration. Participants will undergo placement of a Spencer Probe Depth Electrode and QFlow 500™ Perfusion Probe in addition to the institutional standard multimodal neurological monitoring.
88832454|NCT04899830|Experimental|Installation of a telepresence robot in the home of a disabled person hospitalized in a PRM center|From the application installed on a tablet, the patient hospitalized in a center for a period of at least 2 months can start from the center where he is hospitalized the mobile robotic telepresence assistance device installed at home to communicate with his family, his friends, his neighbors,…)
89360956|NCT06141499|Experimental|Patients|Dialysis patients will receive letters with information about their status within the kidney transplantation and waitlisting process.
89360957|NCT06139575|Experimental|Lutetium Lu 177 JH020002 Injection|
89399154|NCT02168972|Experimental|Global mapping and ablation device|
88832455|NCT04011527||Patients with Coronary Artery Disease|Patients with Coronary Artery Disease undergoing a Rotational Atherectomy in Coronary Lesion/s
89360958|NCT06134505|Experimental|Experimental: Experimental Group1|Barrier cream group 1 consists of a mixture of propolis, beeswax, queen bee larva and plant oil
89360959|NCT06134505|Experimental|Experimental: Experimental Group2|Olive oil group
89360960|NCT06134505|Active Comparator|Control Group|Barrier cream group 2 consists of zinc oxide
89360961|NCT06132087|Experimental|Treatment (surgical resection)|Patients undergo laparoscopy followed by surgical resection with pancreaticoduodenectomy, distal pancreatectomy, or total pancreatectomy at the discretion of the surgeon within 2-8 weeks following completion of standard of care neoadjuvant chemotherapy regimen. Patients undergo CT and blood sample collection throughout the study and/or MRI during screening. Patients also undergo tissue collection at time of surgical resection on study.
88832456|NCT05440877|Experimental|Intervention group|Provided with a tutorial guide, and VR-based teaching materials in the tutorial session
89360962|NCT06131671|Experimental|Intervention|This group will receive whole-body electrical stimulation associated with exercises for upper, lower limbs and trunk for twice a week, for eight weeks, totaling 16 sessions.
89360963|NCT06131671|No Intervention|Control|This group will not receive any type of electrical stimulation or exercise.
89360964|NCT06124521|Experimental|Eye concern|Those with a diagnosis of glaucoma or glaucoma suspect (or other concerning eye disease, such as diabetic retinopathy or macular degeneration) will be invited to participate in the ComBaT Glaucoma.
89360965|NCT06123494|Experimental|SHR-A1811|
89360966|NCT06123494|Active Comparator|The investigators' choice|
88832457|NCT05440877|Experimental|Control group|Provided with the tutorial guide in the tutorial session.
88832458|NCT03103061|Experimental|Myocardial Stress CT Perfusion|Low-radiation, dynamic perfusion CT of the heart in patients with suspected ischemic chest pain and a moderate or severe stenosis seen on coronary CTA. Lexiscan(TM) will be used as the pharmacological stress agent (coronary vasodilator).
88832459|NCT03105479|Experimental|Part A / Cohort A|Subjects from 12 years to 18 years old (exclusive) will receive cadazolid 500 mg per day for 10 days. The dose may be adjusted based on the pharmacokinetic (PK) and safety data reviewed for the first 3 subjects.
88832460|NCT03105479|Experimental|Part A / Cohort B|Subjects from 6 years to 12 years old (exclusive) will receive cadazolid for 10 days. The dose will depend on the PK and safety data from cohort A reviewed by the Independent Data Monitoring Committee (IDMC).
88832461|NCT03105479|Experimental|Part A / Cohort C|Subjects from 2 years to 6 years old (exclusive) will receive cadazolid for 10 days. The dose will depend on the PK and safety data from cohort B reviewed by the IDMC.
88832462|NCT03105479|Experimental|Part A/ Cohort D|Subjects from 3 months to 2 years old (exclusive) will receive cadazolid for 10 days. The dose will depend on the PK and safety data from cohort C reviewed by the IDMC.
89360969|NCT06120231|Experimental|Pedicle Screw Stimulation Arm|
89360970|NCT06116110||Long-term Follow-Up|No intervention
89360971|NCT06114056|Experimental|JWK007 injection|AAVrh74 was used as the vector for JWK007 injection. Because the Dystrophin gene is too large to be used for conventional rAAV loading (AAV packaging capacity < 5.0kb), we independently designed a new micro-dystrophin (μDystrophin) for each functional domain of the gene. The protein includes structures essential for promoting neuronal nitric oxide synthase (nNOS) activity and membrane-binding domains.
89360972|NCT06112561|Active Comparator|Cardiac output/index/SVR|Record of CO/CI/SVR before and after weaning form ECC from radial and femoral artery cannula.
89360973|NCT06112561|Active Comparator|Hypotension event|Prevent of hypotension event calculated from radial/femoral artery cannula
89360974|NCT06110962||Patients|Sleep clinic patients undergoing polysomnography sleep studies for diagnosis of sleep apnea
89360975|NCT06107543||Intravenous lidocaine|Patients who received lidocaine intravenously before induction of anesthesia will be considered in this group.
89360976|NCT06107543||Nebulized lidocaine|Patients who received lidocaine by inhalation with a nebulizer before induction of anesthesia will be considered in this group.
89360977|NCT06107153|Active Comparator|basal insulin plus glucose lowering drugs|"New diagnosed T2DM with an age of 18 years and above. HbA1c of equal to or more than 9% and or random serum glucose equal to or more than 300 mg/dl.~Agree to start basal insulin for two weeks"
89360978|NCT06107153|Active Comparator|glucose lowering drugs only|"New diagnosed T2DM with an age of 18 years and above. HbA1c of equal to or more than 9% and or random serum glucose equal to or more than 300 mg/dl.~Refuse to start basal insulin."
89360979|NCT06106893|Experimental|Experimental Arm|Participants will receive CD19 Universal CAR-γδ T Cells intravenous infusion
89360980|NCT06106880|Placebo Comparator|Group A: Placebo Throat Spray and Placebo Tablet|"The placebo spray contained vehicle buffer, a sub-therapeutic dose of menthol, and a sweetener.~Placebo Tablet: Looked like the treatment aspirin tablet but contained no drug and only inactive excipients."
89360981|NCT06106880|Active Comparator|Group B: Wintergreen Throat Spray and Aspirin Tablet|"The liquid spray contained wintergreen oil, menthol, lactoferrin, lysozyme, aloe, and glycerin.~Aspirin in a 325mg tablet"
89399155|NCT02169050||No intervention|There is no intervention to subjects in this study. All subjects are morbidly women seeking bariatric surgeries.
88832463|NCT03105479|Experimental|Part A/ Cohort E|Subjects from birth to 3 months old (exclusive) will receive cadazolid for 10 days. The dose will depend on the PK and safety data from cohort D reviewed by the IDMC.
88832464|NCT03105479|Experimental|Part B / Cadazolid|Subjects from birth to 18 years old (exclusive) will receive cadazolid for 10 days, at the dose defined in the corresponding age cohort in Part A.
88832465|NCT03105479|Active Comparator|Part B / Vancomycin|Subjects from birth to 18 years old (exclusive) will receive vancomycin capsule (for subjects able to swallow) or vancomycin solution (for the others) during 10 days .
88832466|NCT00355862|Active Comparator|1|Center specific immunosuppressive regimen (mTOR inhibitor free)
88832467|NCT00355862|Experimental|2|Sirolimus containing regimen
88832468|NCT03106337|Experimental|Shear-Wave Elastography|Shear-Wave Elastography was performed on patients scheduled for partial/total thyroidectomy. Results were compared with pathology from surgical excision.
88832469|NCT03772847|Experimental|ginkgolide group|ginkgolide plus alteplase
88832470|NCT03772847|No Intervention|control|alteplase
88832471|NCT05345834|No Intervention|Usual Care|Participants will participate in usual prenatal care throughout the duration of study.
88832472|NCT05345834|Experimental|Patient Navigation and treatment|"In the patient navigation arm, women who do not meet diagnostic criteria (Group 2a) can participate in: (1) group-based CBT preventative intervention; (2) peer support group (virtual); or (3) both. Women in the threshold risk group, meeting diagnostic criteria for depression/anxiety (Group 2b) at baseline can participate in: (1) individual CBT treatment (2) peer support group (virtual) (3) both~Prevention group includes 8 sessions based on culturally adapted CBT for Black/ of African descent populations facilitated by mental health professionals. Individual treatment includes 12 sessions based on culturally adapted CBT for Black/ of African descent populations."
88832473|NCT02049151|Experimental|Tecemotide|
88832474|NCT02049151|Placebo Comparator|Placebo|
88832475|NCT03844295|Experimental|Activated Inspire® Upper Airway Stimulation System|INSPIRE® device will be active a month
89360982|NCT06106880|Active Comparator|Group C: Aspirin Throat Spray and Placebo Tablet|"The liquid spray contained 6mg dissolved acetyl salicylic acid per dose, menthol, lactoferrin, lysozyme, aloe, and glycerin.~Placebo Tablet: Looked like the treatment aspirin tablet but contained no drug and only inactive excipients."
89399156|NCT02165150|Experimental|Wheelchair-bound Senior Elastic Band|WSEB interventions three times per week, 40 minutes per practice
88832476|NCT03844295|Placebo Comparator|Inactivated Inspire® Upper Airway Stimulation System|"After a period 15 days of wash-out the INSPIRE® device will be inactivated for a second period of one month."
88832477|NCT00355550|Active Comparator|AC-1202|Tricaprilin formulation, once daily. Administered orally
88832478|NCT00355550|Placebo Comparator|Matching Placebo to AC-1202|Placebo formulation, once daily. Administered orally
88832479|NCT03726359|Experimental|Fractionated Stereotactic Radiation Therapy|This study is unique in that it employs a continuous reassessment methodology (CRM) to determine the Maximum Tolerated Dose. Information for the proper dose level for each subsequent patient enrolled will be determined based on DLTs from previous patients enrolled in the trial.
88832480|NCT02049307|Active Comparator|Treatment|Losartan 100mg daily
88832481|NCT02049307|Placebo Comparator|Placebo|Matching placebo
88832482|NCT05314556|Experimental|Intervention|Group psychotherapy
88832483|NCT00355628|Experimental|1|KW-2246 (fentanyl citrate)
88832484|NCT02049385|Experimental|Diazoxide|Subjects received 200-400 mg daily of diazoxide orally for three weeks; the dose was, adjusted depending on side effects and response.
88832485|NCT02049385|Experimental|Placebo|Subjects received a matched placebo for three weeks
88832486|NCT03717155|Experimental|Avelumab and Cetuximab|Participants received 800 milligrams Avelumab, 1250 milligrams per square meter (mg/m^2) gemcitabine on Day 1 and Day 8, cisplatin at a dose of 75 mg/m^2 on Day 1 along with 250 mg/m2 body surface area Cetuximab on Day 1 and 500 mg/m2 body surface area on Day 8 of each cycle as intravenous (IV) infusions up to maximum of 4 cycles (each cycle is of 3 weeks) until disease progression or unacceptable toxicities. In case of cisplatin toxicities, participants were switched to carboplatin at a dose of target area under the serum concentration-time curve of 5 (AUC 5) on Day 1 for the remainder of cycles. Subsequently participants were administered with avelumab and cetuximab as IV infusion at the dose of 800 mg and 500 mg/m^2 respectively, every 2 weeks in the Maintenance phase until disease progression or unacceptable toxicities.
88832487|NCT05311046||Retrospective EHR-data only group|"Members of this group are pediatric patients between the ages of 3 months to 17 years inclusive, that presented to one of the six participating institution's emergency department between the years 2016-2021 and screened positive for suspicion of sepsis using the institution's existing pediatric sepsis screening protocol and receive a blood culture order. Current pediatric screening/alerting tools are known to be highly sensitive but poorly specific. Cases in this cohort will be comprised of those that are ultimately diagnosed with sepsis and/or receive protocolized sepsis treatment. Controls in this cohort will be those with a false positive alert, i.e., are not diagnosed with sepsis and do not receive protocolized sepsis treatment."
88875508|NCT04107168||Cohort 9|Disease: Resected renal cancer Durvalumab + Tremelimumab. Dosage form, dosage, frequency and duration will be either standard of care and accessed via normal commissioning arrangements, or will be part of an ethics-approved clinical trial, where co-enrollment into an observational study is permitted.
89360983|NCT06106880|Active Comparator|Group D: Wintergreen Throat Spray and Placebo Tablet|"The liquid spray contained wintergreen oil, menthol, lactoferrin, lysozyme, aloe, and glycerin.~Placebo Tablet: Looked like the treatment aspirin tablet but contained no drug and only inactive excipients."
89360984|NCT06106295|Experimental|Mild Autonomous Cortisol Secretion (MACS) Open Label Phase and Optional Extension Phase|Subjects diagnosed with Mild Autonomous Cortisol Secretion (MACS) will receive metyrapone for a 6 month treatment period (Open Label Phase) with the option to continue for an additional 30 months of metyrapone therapy. If a patient chooses to participate in the Optional Extension Phase they will continue to receive metyrapone therapy until Month 36. This is an additional 30 months of therapy after completion of the Open Label Phase.
89360985|NCT06103734|Active Comparator|Zavegepant 10 mg|This is the active arm where the participant will receive 4 doses of the zavegepant 10mg intranasal
89360986|NCT06103734|Placebo Comparator|Placebo - Control 1|This is one of the two placebo arms where the participant will receive 3 doses of placebo and 1 dose of zavegepant 10mg intranasal. Participant will not know which dose will be zavegepant.
89360987|NCT06103734|Placebo Comparator|Placebo - Control 2|This is one of the two placebo arms where the participant will receive 3 doses of placebo and 1 dose of zavegepant 10mg intranasal. Participant will not know which dose will be zavegepant.
89360988|NCT06103474|Active Comparator|Standard of Care Report|The subject will receive standard of care imaging report.
89360989|NCT06103474|Active Comparator|Clinical Report|The subject will receive a technical report that avoids language that may cause catastrophizing or evoke the nocebo effect.
89360990|NCT06100705|Experimental|Testosterone Cypionate + Sipuleucel-T|Participants will start with testosterone injection every 4 weeks. The first dose of standard of care Sipuleucel-T will be prepared and infused after two doses of testosterone and will continue every 2 weeks for a total of 3 infusions at a standard schedule. The testosterone injection will continue once every 4 weeks until treatment discontinuation criteria are met.
89360991|NCT06100172|Active Comparator|Active tAN + standard of care (SOC) for post-operative pain management for lumbar fusion patients.|"Subjects will be randomized to receive the active device on the day of surgery.~Subjects will receive treatment according to the following time points:~Pre-operative: 30 minutes in the hour prior to surgery~Intra-operative: 30 minutes before the end of surgery~Post-operative: 30 minutes at 3 and 6 hours after surgery~Inpatient: Four 30-minute sessions on Day 2"
89360992|NCT06100172|Placebo Comparator|Sham tAN + standard of care (SOC) for post-operative pain management for lumbar fusion patients.|"Subjects will be randomized to receive the sham device on the day of surgery.~Subjects will receive treatment according to the following time points:~Pre-operative: 30 minutes in the hour prior to surgery~Intra-operative: 30 minutes before the end of surgery~Post-operative: 30 minutes at 3 and 6 hours after surgery~Inpatient: Four 30-minute sessions on Day 2"
89360993|NCT06099730|Other|Pulsed Field Ablation|This is a non-randomized one arm study.
89360994|NCT06091189|Experimental|Relevant Stressor Condition with No Ethanol|Participants complete the Relevant Trier Social Stress Test (TSST), which asks participants to prepare a 5-minute speech on how their sexuality has developed over time. Participants are then assigned to receive a placebo priming beverage (with no ethanol) to consume over 10 minutes. Participants will consume the initial placebo drink, which is intended as a priming cue. Next, participants will be given a free period of an additional 20 minutes in which participants can consume up to three additional placebo cocktails, which do not contain ethanol.
89360995|NCT06091189|Active Comparator|Irrelevant Stressor Condition with No Ethanol|Participants complete the Irrelevant Trier Social Stress Test (TSST), which asks participants to prepare a 5-minute speech on how their gender identity has developed over time. Participants are then assigned to receive a placebo priming beverage (with no ethanol) to consume over 10 minutes. Participants will consume the initial placebo drink, which is intended as a priming cue. Next, participants will be given a free period of an additional 20 minutes in which participants can consume up to three additional placebo cocktails, which do not contain ethanol.
89360996|NCT06091189|Placebo Comparator|Control Stressor Condition with No Ethanol|Participants complete the Control Trier Social Stress Test (TSST), which asks participants to prepare a 5-minute speech on a recent book participants read, or a recent movie participants saw. Participants are then assigned to receive a placebo priming beverage (with no ethanol) to consume over 10 minutes. Participants will consume the initial placebo drink, which is intended as a priming cue. Next, participants will be given a free period of an additional 20 minutes in which participants can consume up to three additional placebo cocktails, which do not contain ethanol.
89399157|NCT02165150|No Intervention|Control|routine care
89399158|NCT02165228|Experimental|Mindfulness-based stress reduction|Stress reduction class and behavioral intervention
89399159|NCT02165228|Active Comparator|Nutrition Enhancement|Nutrition education class and behavioral intervention
89399160|NCT02165228|No Intervention|Control|No class or behavioral intervention
89399161|NCT02172092|Experimental|Ketoacidosis|Patients treated for diabetic ketoacidosis at the Intensive care unit, Vrinnevi Hospital, Norrköping.
88832488|NCT05311046||Prospective EHR and Biomarker data group|"Members of this group are pediatric patients between the ages of 3 months to 17 years inclusive, that presented to one of the six participating institution's emergency department during the study enrollment period, screen positive for suspicion of sepsis using the institution's existing pediatric sepsis screening protocol, receive a blood culture order and provide informed consent/assent for the collection of a 1-5 mL blood sample to be used to measure PERSEVERE biomarkers. Members of this cohort will have also consented to the reuse of their medical record data for the research. Current pediatric screening/alerting tools are known to be highly sensitive but poorly specific. Cases in this cohort will be comprised of those that are ultimately diagnosed with sepsis and/or receive protocolized sepsis treatment. Controls in this cohort will be those with a false positive alert, i.e., are not diagnosed with sepsis and do not receive protocolized sepsis treatment."
88832489|NCT02049931|Experimental|No brace group|Patients in the no brace treatment group were allowed to ambulate without any braces as long as it would be tolerable.
88832490|NCT02049931|Active Comparator|Rigid brace group|Patients in the rigid brace immobilization group were strictly maintained on bed rest until fitted a thoraco-lumbo-sacral orthosis. Brace is required to be worn at all times except when lying. All patients were instructed to wear the rigid brace for a total of 8 weeks.
88832491|NCT02049931|Active Comparator|Soft brace group|Because soft back brace was a custom-made, it began to be worn when enrollment for the study. Brace is required to be worn at all times except when lying. All patients were instructed to wear the soft brace for a total of 8 weeks.
88832492|NCT03655613|Experimental|Arm A: Hepatocellular Carcinoma|PD-1 inhibitor (APL-501) 3 mg/kg intravenously every 2 weeks + c-Met inhibitor (APL-101) 150 mg or 200 mg administered twice daily continuously until documented disease progression, discontinuation due to toxicity withdrawal of consent or the study ends
88832493|NCT03655613|Experimental|Arm B: Renal Cell Carcinoma|PD-1 inhibitor (nivolumab) 3 mg/kg or 240 mg intravenously every 2 weeks + c-Met inhibitor (APL-101) 300 mg or 400 mg administered twice daily continuously until documented disease progression, discontinuation due to toxicity withdrawal of consent or the study ends
88832494|NCT00422747|Experimental|beclomethasondipropionate|2 x 100 ug dd for two months, via aerochamber
88832495|NCT03766009|Active Comparator|Arm I (surgical consultation)|Prior to institutional crossover, participants receive care as per usual care.
88832496|NCT03766009|Experimental|Arm II (web-based breast cancer surgery decision aid)|Following a 10 week implementation period, at the time of institutional crossover, participants will receive a web-based decision aid prior to the surgical consultation..
88832497|NCT00355940|Experimental|1|
88832498|NCT00355940|Active Comparator|2|
88832499|NCT03286829|Experimental|"Tesomet High dose in fasted condition"|"A Tesomet FDC tablet (20 mg immediate release [IR] metoprolol, 1 mg tesofensine, 80 mg extended release [ER] metoprolol) in fasted condition (High dose)"
88832500|NCT03286829|Experimental|"Tesomet Low dose in fasted condition"|"Treatment B (Test 2): A Tesomet FDC tablet (5 mg immediate IR metoprolol, 0.2 mg tesofensine, 20 mg ER metoprolol) in fasted condition. (Low dose)"
88832501|NCT03286829|Active Comparator|Comperator|1 mg tesofensine (2 tablets of 0.5 mg), 25 mg commercial IR metoprolol (1 tablet of 25 mg), 75 mg commercial ER metoprolol (1 tablet of 25 mg ER metoprolol and 1 tablet of 50 mg ER metoprolol), fasted condition
88832502|NCT03286829|Experimental|"Tesomet High dose in fed condition"|"A Tesomet FDC tablet (20 mg immediate IR metoprolol, 1 mg tesofensine, 80 mg ER metoprolol in fed condition (High dose)"
88832503|NCT02051335|Experimental|Sequence 1 (ABDC)|Roflumilast placebo-matching tablets, orally, donepezil placebo-matching overencapsulated tablets, orally, and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 1, followed by roflumilast placebo-matching tablets, orally, donepezil 10 mg, overencapsulated tablets, orally and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 2, followed by roflumilast Dose A tablets, orally, donepezil 10 mg, overencapsulated tablets, orally and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 3, followed by roflumilast Dose A tablets, orally, donepezil placebo-matching overencapsulated tablets, orally, and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 4. Each treatment period is separated by a 14-day washout period.
88832504|NCT02051335|Experimental|Sequence 2 (BCAD)|Roflumilast placebo-matching tablets, orally, donepezil 10 mg, overencapsulated tablets, orally and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 1, followed by roflumilast Dose A tablets, orally, donepezil placebo-matching overencapsulated tablets, orally, and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 2, followed by roflumilast placebo-matching tablets, orally, donepezil placebo-matching overencapsulated tablets, orally, and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 3, followed by roflumilast Dose A tablets, orally, donepezil 10 mg, overencapsulated tablets, orally and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 4. Each treatment period is separated by a 14-day washout period.
88832505|NCT02051335|Experimental|Sequence 3 (CDBA)|Roflumilast Dose A tablets, orally, donepezil placebo-matching overencapsulated tablets, orally, and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 1, followed by roflumilast Dose A tablets, orally, donepezil 10 mg, overencapsulated tablets, orally and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 2, followed by roflumilast placebo-matching tablets, orally, donepezil 10 mg, overencapsulated tablets, orally and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 3, followed by roflumilast placebo-matching tablets, orally, donepezil placebo-matching overencapsulated tablets, orally, and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 4. Each treatment period is separated by a 14-day washout period.
88832506|NCT02051335|Experimental|Sequence 4 (DACB)|Roflumilast Dose A tablets, orally, donepezil 10 mg, overencapsulated tablets, orally and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 1, followed by roflumilast placebo-matching tablets, orally, donepezil placebo-matching overencapsulated tablets, orally, and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 2, followed by roflumilast Dose A tablets, orally, donepezil placebo-matching overencapsulated tablets, orally, and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 3, followed by roflumilast placebo-matching tablets, orally, donepezil 10 mg, overencapsulated tablets, orally and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 4. Each treatment period is separated by a 14-day washout period.
88832507|NCT03289481|Active Comparator|Active lozenge first|Subject will take active lozenge (Vitamin C, Vitamin B12, Nitric Oxide Blend, L-citrulline, Sodium Nitrite) for one week, perform cardiac testing then take placebo lozenge for one week and perform cardiac testing.
88832508|NCT03289481|Active Comparator|Placebo lozenge first|Subject will take placebo lozenge for one week, perform cardiac testing then take active lozenge (Vitamin C, Vitamin B12, Nitric Oxide Blend, L-citrulline, Sodium Nitrite) for one week and perform cardiac testing.
88832509|NCT04791254||A - main study cohort|"This is the main study cohort. All patients with upper gastrointestinal (gastric, oesophageal and gastro-oesophageal) cancers attending the medical oncology clinic and commencing systemic therapy will be invited to participate.~They will receive dietician support as part of their standard treatment. They will undergo assessments of body composition as part of this assessment"
88832510|NCT04791254||Sub-cohort B|This sub-cohort will be invited to undergo more detailed fitness testing in the form of cardio-pulmonary exercise testing in addition to their routine care in the main cohort
88832511|NCT04791254||sub-cohort C|This sub-cohort will be invited to undergo an assessment of gut hormone and cytokine levels in addition to their routine care in the main cohort
88832512|NCT04791254||Cohort D|This is a cohort of healthy volunteers invited to act as a control to cohort C and undergo the gut hormone assessment
88832513|NCT03290027|Experimental|Active|DFD-03 (0.1% tazarotene) Lotion
88832514|NCT03290027|Placebo Comparator|Vehicle|Vehicle (0% tazarotene) Lotion
88832515|NCT02979158|Experimental|CPB Low Dose|Conduct of cardiopulmonary bypass using a low heparin dose verified by the activated clotting time at 250 s
88832516|NCT02979158|Experimental|CPB High Dose|Conduct of cardiopulmonary bypass using a high heparin dose verified by the activated clotting time at 480 s
88832517|NCT02979236||STEMI treated with STENTYS Xposition S|Patients 18 years of age and older presenting with symptoms consistent with a ST-Elevation Myocardial Infarction (STEMI) lasting ≤12 hrs in duration, with ≥2 mm of ST-segment elevation in ≥2 contiguous leads, treated with primary stent implantation (Xposition S planned per operator's assessment).
88832518|NCT02300077|Active Comparator|Control|Control (Intra-operative administration of opioids, other than methadone)
88832519|NCT02300077|Active Comparator|Treatment methadone 0.1 mg/kg|methadone 0.1 mg/kg
88832520|NCT02300077|Active Comparator|Treatment methadone 0.15 mg/kg|
88832521|NCT04745546|Experimental|WeFlow-JAAA Stent Graft System|Participants will be treated with WeFlow-JAAA Stent Graft System
89360997|NCT06091189|Experimental|Relevant Stressor Condition with Ethanol|Participants complete the Relevant Trier Social Stress Test (TSST), which asks participants to prepare a 5-minute speech on how their sexuality has developed over time. Participants are then assigned to receive a priming beverage containing ethanol to consume over 10 minutes. Participants will consume the initial drink containing ethanol, which is intended as a priming dose. Next, participants will be given a free period of an additional 20 minutes in which participants can consume up to three additional cocktails, which contain ethanol. The initial drink in the alcohol condition will contain 0.3 g/kg (males) or 0.2 g/kg (females) of 80-proof ethanol, adjusted for body weight, and subsequent drinks will contain 0.1 g/kg of ethanol.
88832522|NCT03291041|Experimental|tasimelteon|tasimelteon, administered as oral capsule(s)
88832523|NCT03291041|Placebo Comparator|Placebo|Placebo, administered as oral capsule(s)
88832524|NCT02052661|Experimental|Engerix-B Kinder Group|Subjects who were previously primed and boosted with four doses of Infanrix™ hexa in the first two years of life, received a single dose of Engerix™-B Kinder vaccine. The vaccine was administered intramuscularly into the deltoid of the non-dominant arm.
88832525|NCT02052895||Sepsis/SIRS|Patients with sepsis or SIRS
88832526|NCT02052895||Control|Patients without SIRS, sepsis, or end stage renal disease
88832527|NCT02052895||End Stage Renal Disease|Patients with end stage renal disease, without SIRS or sepsis
88832528|NCT03291197|Experimental|Open label treatment|These patients will receive suprascapular and median nerve blocks for shoulder hand syndrome. Investigators will assess the tolerability of his procedure using pre-defined criteria (outlined elsewhere).
88832529|NCT03411707||Mutiple screening test group|
88832530|NCT03275675||Patients with cancer chemotherapy|This study project is designed to evaluate the satisfaction of patients undergoing oral chemotherapy treated for a cancer and whose treatment is provided by their community pharmacies.
88832531|NCT03294629|No Intervention|APAP begins without SensAwake|Patients will receive CPAP treatment without SensAwake™ activation for two weeks, then crossed-over to CPAP treatment with SensAwake™ activation for additional two weeks.
88832532|NCT03294629|Experimental|APAP begins with SensAwake|"Patients will receive CPAP treatment with SensAwake™ activation for two weeks, then crossed-over to CPAP treatment without SensAwake™ activation for additional two weeks.~SensAwake™ modification: SensAwake™ is a new design based on the research of Doctor Ayappa 5 years ago. The SensAwake™ modification to the Fisher and Paykel automatically titrating positive airway pressure (APAP) device aims to sense whether the patient is awake via respiratory patterns that differentiate between sleep and wake. Upon sensing that the patient is awake the device is able to reduce positive airway pressure PAP aiming to improve patient comfort which should result in more consolidated sleep."
88832533|NCT04737044|No Intervention|Study 1: Normal sugar|Control group will be required to continue consuming normal sugar intake for 8 weeks.
88832534|NCT04737044|Experimental|Study 1:Minimally refined brown sugar (MRBS)|Intervention group will be required to consume MRBS as added sugar based on their habitual diet for 8 weeks intervention.
88832535|NCT04737044|No Intervention|Study 2: Normal sugar intake|- The control group will have no intervention and will continue with their normal daily intake for six months.
88832536|NCT04737044|Experimental|Study 2: White sugar|"Intervention group I will be advised to reduce sugar intake to no more than 10% from total energy intake.~Intervention group I will be given white sugar for daily usage.~Participants in this group will be exposed to the nutrition education module (45 minutes per session, once a week) for six months, attend lecture classes and communicate with health educators through communication applications.~For the first three months, one-to-one diet counseling will be conducted.~Participants' intake of free sugar, as well as other nutrients (carbohydrate, protein, fats, fibre and others) will be closely monitored to ensure compliance to dietary recommendations."
88832537|NCT04737044|Experimental|Study 2: MRBS|"Intervention group II will be advised to reduce sugar intake to no more than 10% from total energy intake.~Intervention group II will be given MRBS for daily usage.~Participants in this group will be exposed to the nutrition education module (45 minutes per session, once a week) for six months, attend lecture classes and communicate with health educators through communication applications.~For the first three months, one-to-one diet counseling will be conducted.~Participants' intake of free sugar, as well as other nutrients (carbohydrate, protein, fats, fibre and others) will be closely monitored to ensure compliance to dietary recommendations."
88832538|NCT05230394|Experimental|Level 1 In Lab Polysomnography|
88832539|NCT05230394|Experimental|Level 2 In Home Polysomnography|
89001053|NCT04632394||Cases|Patients with scar-dependent ventricular tachycardia, requiring ablation. These patients will have satisfied the inclusion/exclusion criteria and be put forward for VT ablation. They will undergo the previously described study protocol, including generation of a computational model of the heart from their cardiac MRI and a VT ablation where we will study the points of interest generated from the MRI model in detail.
88832540|NCT03243461|Experimental|Temozolomide + Valproic acid|E.g. Valproat-neuraxpharm®, Valproat-neuraxpharm® Lösung, Ergenyl®, Ergenyl®-Lösung oder Orfiril® Saft (Valproic acid), [10 mg/kg/d] tablet oder juice, p.o., every day in parallel to simultaneous radiochemotherapy with cytostatic drug Temodal (Temozolomid): [75 mg/m2/d] during simultaneous radiochemotherapy (7 days a week, max. 49 days); [150-200 mg/m2/d] during consolidation therapy (for 5 days every 28 days, 12 cycles), tablets, p.o. (or powder for preparation of an intravenously applicable solution).
88832541|NCT03296345|Active Comparator|Intervention|"Prior to the second dose of IV opiates, the experiment was to give patients a single IV bolus of ketamine at the dose of 0.2 mg/kg. Pain scores were collected using the FACES scale currently in place. In consenting patients, chart review was performed with the following data collected: mg/kg/hour of morphine equivalents, pain scores on admission, during the encounter, and at discharge, the time to 50% pain reduction, and whether or not the patient was discharged.~In addition, a survey, which is attached, was given to patients/families at the time of drug administration to determine if they experienced a subjective improvement in their pain and if they suffered any undue side effects due to drug administration."
88832542|NCT03296345|No Intervention|Historical Control|"Patient data from at least one but up three patient encounters within the prior year were compared to their visit in which they were given adjuvant ketamine, using the outcome measures in the Intervention arm. Since this a historical control study, patients acted as their own controls in the above manner. Patients were allowed to re-enroll 4 weeks after presentation, which is typically considered a separate vaso-occlusive episode in the literature."
88832543|NCT00376181|Experimental|Pioglitazone 45 mg/Azilsartan 20 mg QD|
88832544|NCT00376181|Experimental|Pioglitazone 45 mg/Azilsartan 40 mg QD|
88832545|NCT00376181|Active Comparator|Pioglitazone 45 mg QD|
88832546|NCT05607134|Sham Comparator|Physical and occupational therapy group|The group will receive a Physical and occupational therapy program
88832547|NCT05607134|Active Comparator|Shock Wave group|The group will receive a radial Extracorporeal Shock Wave sessions
88832548|NCT05607134|Active Comparator|Peripheral Magnetic Stimulation group|The group will receive a Peripheral Magnetic Stimulation sessions
88832549|NCT04736693||Raloxifene|Reference Group
88832550|NCT04736693||Zoledronic Acid|Exposure Group
88832551|NCT04655378||Acute Rheumatoid Purpura|
88832552|NCT04655378||Rheumatoid Purpura in Remission|
88832553|NCT04655378||Controls|Without infection, inflammatory or auto-immune pathology
88832554|NCT04652414|Experimental|Prednisone|Patients randomized to the intervention arm will receive prednisone 50mg PO daily for 7 days.
88832555|NCT04652414|Placebo Comparator|Placebo|Patients will receive matching placebo PO daily for 7 days.
88832556|NCT04736069|Active Comparator|Inpatient physical therapy program|The group received 21 sessions of physical therapy program including electrotherapy, superficial- deep heat applications and basic knee exercise program at inpatient clinic.
88832557|NCT04736069|Active Comparator|Outpatient physical therapy program|The group received the same physical therapy program including electrotherapy, superficial-deep heat applications and basic knee exercise program at outpatient clinic.
88832558|NCT04736459|Experimental|Washed Catheter|Washed catheter arm: will be washed with culture medium before insemination
88832559|NCT04736459|Sham Comparator|Unwashed Catheter|Unwashed catheter arm: will not be washed with culture medium.
88832560|NCT05605886|Placebo Comparator|first group: (Control group)|"EMG will be performed for masseter & temporalis muscles at the diagnosis appointment.~Patients will recieve a daily placebo tablet in the morning after breakfast for 4 days prior to injections.~Patients will receive a one-time treatment of 50 units of BoNT-A, the dose will be injected into the bilateral masseter muscles (16.7 units each masseter) and 1/3 into the bilateral temporalis (8.3 units each temporalis).~Follow up will be performed using EMG for the masseter and temporalis muscles 4 months after the BoNT-A injection."
88832561|NCT05605886|Active Comparator|second group. (intervention group)|"EMG will be performed for masseter & temporalis muscles at the diagnosis appointment.~Patients will receive a daily zinc supplement tablets of 50 mg in the morning after breakfast for 4 days prior to injections.~Patients will receive a one-time treatment of 50 units of BoNT-A, the dose will be injected into the bilateral masseter muscles (16.7 units each masseter) and 1/3 into the bilateral temporalis (8.3 units each temporalis).~Follow up will be performed using EMG for the masseter and temporalis muscles 4 months after the BoNT-A injection."
88832562|NCT05169242|Experimental|Intervention group|In the intervention arm, one or more endoclips will be used to completely close the mucosal defect after polypectomy. Prophylactic clipping will be applied to all post-polypectomy sites. The total number of endoclips used will be recorded.
88832563|NCT05169242|No Intervention|Control group|In the control arm, no endoclip will be applied to all post-polypectomy sites, with the exceptions of uncontrolled immediate PPB or pre-treatment in very large pedunculated polyps as specified above. The subjects with endoclips applied due to safety reasons will be included in the subsequent intention-to-treat analysis, but not the per-protocol analysis.
88832564|NCT04736381||Kidney transplanted patients treated with Nulojix|Patients treated with Simulect as induction, and with Nulojix®, mycophenolic acid and steroids as maintenance therapy during the first year of kidney transplant.
88832565|NCT02906657|Experimental|Medication reconciliation|Medication reconciliation involving a pharmacist using electronic pharmaceutical records
88832566|NCT02906657|No Intervention|Control|Usual Care
89001054|NCT04632550|Active Comparator|Circumferential pulmonary vein isolation(CPVI) group|
89360998|NCT06091189|Active Comparator|Irrelevant Stressor Condition with Ethanol|Participants complete the Irrelevant Trier Social Stress Test (TSST), which asks participants to prepare a 5-minute speech on how their gender identity has developed over time. Participants are then assigned to receive a priming beverage containing ethanol to consume over 10 minutes. Participants will consume the initial drink containing ethanol, which is intended as a priming dose. Next, participants will be given a free period of an additional 20 minutes in which participants can consume up to three additional cocktails, which contain ethanol. The initial drink in the alcohol condition will contain 0.3 g/kg (males) or 0.2 g/kg (females) of 80-proof ethanol, adjusted for body weight, and subsequent drinks will contain 0.1 g/kg of ethanol.
89399162|NCT02261246|Experimental|Immediate treatment|This arm receives spinal manipulation treatment shortly after enrollment
89360999|NCT06091189|Placebo Comparator|Control Stressor Condition with Ethanol|Participants complete the Control Trier Social Stress Test (TSST), which asks participants to prepare a 5-minute speech on a recent book participants read, or a recent movie participants saw. Participants are then assigned to receive a priming beverage containing ethanol to consume over 10 minutes. Participants will consume the initial drink containing ethanol, which is intended as a priming dose. Next, participants will be given a free period of an additional 20 minutes in which participants can consume up to three additional cocktails, which contain ethanol. The initial drink in the alcohol condition will contain 0.3 g/kg (males) or 0.2 g/kg (females) of 80-proof ethanol, adjusted for body weight, and subsequent drinks will contain 0.1 g/kg of ethanol.
88832567|NCT03302741|Active Comparator|Standard BTX injection (ultrasound guided)|For standard injection procedures, target muscles will be visualized under ultrasound imaging which is operated by an experienced and dedicated technician. Position of needle tip within the target muscle is visualized prior to injection. Ultrasound guidance can help ensure depth of needle tip location, i.e., to make sure the needle tip is within the muscle, but it is not able to tell where it is located with reference to the IZs of the entire muscle.
89361000|NCT06089863|Experimental|PAMPERO program group|This program is an intensive multidisciplinary program rehabilitation including Physical, Occupational, Speech, Psychomotor therapy and Adapted Physical Activity.
89361001|NCT06089863|No Intervention|Usual Care intervention group|"Usual Rehabilitation of the patient after the inclusion. 0 to 2 physical therapy sessions and 0 to 2 Speech therapy sessions each week usually constitute this program.~This rehabilitation highly depends on the patients usual preferences. Some patients have no rehabilitation in the daily care while some have more."
89361002|NCT06089486|Other|Invasive Coronary Angiography|Patients in this arm will undergo annual CAV surveillance with ICA
89361003|NCT06089486|Other|Positron Emission Tomography|Patients in this arm will undergo annual CAV surveillance with PET
89361004|NCT06089434|Experimental|Transesophageal Echocardiography (TEE) with limited number of TEE clips|The intervention group would limit the number of TEE clips per case.
89361005|NCT06089434|Other|Transesophageal Echocardiography (TEE) with number of TEE clips per attending anesthesiologist|The control group would leave the number of TEE clips to the discretion of the attending anesthesiologist.
89361006|NCT06087627||PN treatment|Participants ≥ 18 years suffering from moderate-to-severe PN who receive long-term dupilumab treatment for PN in a real-world setting in Germany.
89361007|NCT06080282||Sepsis|No intervention
89361008|NCT06080178|Active Comparator|Static group|"When during surgery systolic blood pressure (SBP) is below 100mmHg:~give a fluid bolus (Plasmalyte A) until 5ml/kg/h crystalloid (without maintenance infusion) is reached or until SBP is above 100mmHg~if the 5ml/kg/h crystalloid limit is already reached: start or increase norepinephrine infusion until SBP is above 100mmHg (with a maximum dose of 0.2mcg/kg/min).~When SBP is above 120mmHg: decrease the norepinephrine infusion rate until SBP is below 120mmHg.~When SBP remains below 100mmHg after reaching a vasopressor dose of 0.2mcg/kg/min: the anaesthetist can decide to give a bolus of 6mg ephedrine intravenous (IV) (with a maximum dose of 12mg ephedrine iv per hour)."
89361009|NCT06080178|Experimental|Dynamic group|"After insertion of an arterial line, a pulse contour analysis system will be installed (Acumen IQ sensor, Edwards) for measuring PPV and cardiac index (CI).~When during surgery SBP is below 100mmHg and PPV is above 12%:~• give a fluid bolus (Plasmalyte A) until PPV is below or equal to 12% or SBP is above 100mmHg~When during surgery SBP is below 100mmHg and PPV is below or equal to 12%:~• start or increase norepinephrine infusion until SBP is above 100mmHg (with a maximum dose of 0.2mcg/kg/min) When SBP is above 120mmHg: decrease the norepinephrine infusion rate until SBP is below 120mmHg.~When SBP remains below 100mmHg after reaching a vasopressor dose of 0.2mcg/kg/min, and CI is < 2.2 L/min/m², a bolus of 6mg ephedrine iv will be given (with a maximum dose of 12mg ephedrine iv per hour)."
89399163|NCT02261246|Experimental|Delayed treatment|This arm receives spinal manipulation treatment approximately 4 weeks after enrollment
89399164|NCT02261246|No Intervention|Healthy control (no low back pain)|In this arm, healthy controls are tested at baseline.
88832568|NCT03302741|Experimental|3-dimensional innervation zone (3DIZ) guided injection|In the IZ-guided injection technique, IZ location obtained using the 3DIZ will be first marked over the skin surface of the muscle and the depth of the IZ will be also provided. The 3DIZ will be applied to the IZ-guided injection group 1 day prior to scheduled injection. The surface location and depth information of the IZ will be used to guide where the needle tip needs to go. Currently, patients commonly receive 1 to 2 injection sites, occasionally 3 sites for biceps muscles. To standardize the procedure, we will choose 2 sites for all patients.
88832569|NCT02803307|Experimental|6 mg TLC599|6 mg DSP with 50 μmol PL
88832570|NCT02803307|Experimental|12 mg TLC599|12 mg DSP with 100 μmol PL
88832571|NCT02669537|Experimental|GOPRO resident|Residents will use the gopro during a vaginal procedure, review the case with the attending after, and perform a 2nd case of the same type. The VVSI and GRS will be used to assess any changes in surgical skill
88832572|NCT02669537|No Intervention|Control Resident|Residents will use standard surgical education practices, direct instruction from attending, surgical atlas, online videos. They will perform 2 cases of the same type and the difference in VVSI and GRS will be assessed
88832573|NCT02669537|Experimental|GOPRO medical student|Medical students will be allowed to watch the surgery on an iPad with the GoPro app. Their assessment of the educational value of the surgery will be assessed at the end of the procedure. They will also take a pre and post-test focusing on surgical instruments and steps used in the procedure.
88832574|NCT02669537|No Intervention|Control Medical Student|Medical students will be taught using standard practices, i.e instruction by residents/attendings. Their assessment of the educational value of the surgery will be assessed at the end of the procedure. They will also take a pre and post-test focusing on surgical instruments and steps used in the procedure.
88832575|NCT05573828|Experimental|Angiography group|Patients undergoing initially ICG angiography guided thyroidectomy to identify the vessels feeding the parathyroid glands and then, post-thyroidectomy ICG angiography to predict immediate parathyroid function.
89001055|NCT04632550|Experimental|Posterior box isolation(POBI) group|
88832576|NCT05573828|No Intervention|Control group|Patients who underwent post-thyroidectomy ICG angiography to predict immediate parathyroid gland function by scoring the degree of fluorescence of the parathyroid glands
89001056|NCT04632550|Experimental|POBI+Anterior linear ablation(AL) group|
89399165|NCT02169128||Patients and their significant others|Patients affected by necrotizing fasciitis and their significant others
89399166|NCT02165306|Experimental|Intervention|Patients enrolled in the intervention arm will receive two educational sessions on the importance of medication and barriers to adherence
88832577|NCT02769611|Experimental|Ruboxistaurin 64 mg|ruboxistaurin, 64 mg as 1 capsule by mouth with water, 1 time administration
88832578|NCT02769611|Experimental|Ruboxistaurin 128 mg|ruboxistaurin, 128 mg as 2 capsules by mouth with water, 1 time administration
88832579|NCT02769611|Experimental|Ruboxistaurin 256 mg|ruboxistaurin, 256 mg as 4 capsules by mouth with water, 1 time administration
88832580|NCT00356174||Children with food allergy|340 longitudinally followed children with egg and/or milk allergy without elevated peanut specific Immunoglobulin E (IgE), less than 5 kUA/L
88832581|NCT00356174||Full sibling controls for genetic studies|Approximately 250 not age matched full siblings (i.e., non-step siblings, non-half siblings) will be recruited as an additional control group for genetic studies.
88832582|NCT00356174||Full sibling controls for mechanistic studies|Approximately 50 not age matched full siblings (i.e., non-step siblings, non-half siblings) will be recruited as an additional control group for mechanistic studies. A subset of this cohort will be without food allergy,
88832583|NCT02512445|Experimental|Trauma Informed Guilt Reduction Therapy|6-session psychotherapy intervention
88832584|NCT02512445|Active Comparator|Supportive Care Therapy|6-session psychotherapy intervention
88832585|NCT04525820|Experimental|High Dose Vitamin D|"Patient will receive a single high dose of vitamin D (140'000) in addition to daily 800 IU of vitamin D.~The medication be administered orally"
88832586|NCT04525820|Placebo Comparator|Placebo|Patient will receive a single dose of placebo, orally administered and then treatment as usual (daily 800 IU of vitamin D, orally administered)
88832587|NCT03303911|Experimental|Cytisine 1.5 mg|"Multiple doses of 1.5 mg cytisine administered per 25-day schedule:~Days 1-3 (6 times daily)~Days 4-12 (5 times daily)~Days 13-16 (4 times daily)~Days 17-20 (3 times daily)~Days 21-24 (2 times daily)~Day 25 (Once daily)"
88832588|NCT03303911|Experimental|Cytisine 3.0 mg|"Multiple doses of 3.0 mg cytisine administered per 25-day schedule:~Days 1-3 (6 times daily)~Days 4-12 (5 times daily)~Days 13-16 (4 times daily)~Days 17-20 (3 times daily)~Days 21-24 (2 times daily)~Day 25 (Once daily)"
88832589|NCT03305159|Active Comparator|Control (Povidone Iodine)|Patients to receive povidone iodine for the surgical preparation of the vagina.
88832590|NCT03305159|Experimental|Intervention (4% Chlorhexidine gluconate)|Patients to receive 4% chlorhexidine gluconate for the surgical preparation of the vagina.
88832591|NCT05552690|Other|Thalassemia screening positive|In this study only 1 group of participants. No comparative. Only description
88832592|NCT03306641|Active Comparator|Test Contact Lens|Per randomized schedule, subject will wear a pair of the test lens or control lens for one week and then cross-over with the control pair for 1 week.
88832593|NCT03306641|Active Comparator|nelfilcon A lens (control)|Per randomized schedule, subject will wear a pair of the control lens for one week and then cross-over with the test pair for 1 week.
88832594|NCT04473326|Experimental|Reinforcement Learning Intervention Arm|Up to daily, tailored text messages.
88832595|NCT04473326|No Intervention|Control Arm|Up to daily, untailored text messages.
88832596|NCT02163317|Experimental|Treatment (MRI-guided focal SRS)|Patients undergo 3 fractions of MRI-guided focal SRS every other day for 1 week. Patients undergo additional MRI scans between the 2nd and 3rd fractionated treatments, at 6 months following the end of radiation therapy, and at 12 and 24 months.
88832597|NCT03308669|Experimental|Lasmiditan Alone|Lasmiditan administered orally, alone
88832598|NCT03308669|Placebo Comparator|Placebo Alone|Placebo administered orally, alone
88832599|NCT03308669|Experimental|Topiramate + Lasmiditan|Topiramate administered orally, alone, and co-administered with oral lasmiditan
88832600|NCT03308669|Experimental|Topiramate + Placebo|Topiramate administered orally, alone, and co-administered with oral placebo
88832601|NCT01386359||Adult de novo EBV-seropositive kidney-transplant recipients|Adult de novo EBV-seropositive kidney-transplant recipients treated with Nulojix (belatacept)
88832602|NCT05099042|Experimental|Group intervention - questionnaire and recommendations|The intervention group will take the ESOGER questionnaire at month 0 and month 3 ( beginning and end) and receive recommendations following their needs.
88832603|NCT05099042|No Intervention|Group control - questionnaire without recommendations|The participants will only take the ESOGER questionnaire at month 0 and month 3 without recommendations.
88832604|NCT02055781|Experimental|Pacritinib, Once Daily|Pacritinib 400 mg QD
88832605|NCT02055781|Experimental|Pacritinib, Twice Daily|Pacritinib 200 mg BID
89361010|NCT06079177||Male patients with age ≥ 60 years undergoing TURP surgery|"All patients will receive spinal anesthesia Under complete aseptic technique at level of L 4-L5 or L3-L4 using 12.5-15 mg of 0.5 % hyperbaric bupivacaine and 25 ug fentanyl.~Lung ultrasound score:~A curvilinear (5-2 MHz) probe will be used. The sliding multiple B-lines will be evaluated in eight antero-lateral lung examination zones.~Inferior vena cava (IVC) measurement using ultrasound:~A curvilinear (5-2 MHz) probe with B-mode scan will be used. Caval-Aorta index will be calculated by taking the ratio of the two respective diameters measured.~Other vital parameter as ,heart rate (HR), Mean arterial pressure (MAP), oxygen saturation (SpO2), arterial blood gases (ABG), serum Na and K levels will be measured and recorded at same time as the following:~(T0) ,(T1) ,(T2),(T3) ,(T30, T60, T90) intraoperative ,(T PACU),(T critical)"
89361011|NCT06078033|Experimental|Intervention: Mobilization with movement (MWM)|The MWM technique was performed by asking patients to perform their painful movement (flexion, extension…). If pain was not reproduced, a combination of movements (flexion + rotation…) was performed. The most painful vertebral level was also evaluated with passive accessory vertebral movements. Then, with the patient in a seated position on a stretcher with the feet supported and a belt around the waist, the therapist performed a sustained glide over the targeted vertebra (spinous process) with the force and direction that relieved pain to the lowest level and asked the patient to perform his previous painful movement, as described by Mulligan. Three sets of 10 repetitions were performed, with 1-2 minutes rest between sets.
89361012|NCT06078033|Sham Comparator|Control: Sham mobilization with movement|Patients allocated to sham group received same evaluation and treatment process. However, only manual contact was performed over the spinous process of the targeted vertebra, without the sustained glide and without applying any force. Three sets of 10 repetitions were performed, with 1-2 minutes rest between sets.
89361013|NCT06076395|Experimental|Group A pressure control ventilation|Inspiratory pressure was adjusted to achieve an expired tidal volume of 7 ml/Kg, respiratory rate was adjusted to achieve an end ETCO2 at 32-35 mmHg, inspiratory to expiratory ratio at 1:2, PEEP at 4 cm H2O and FiO2 at 0.5 providing that the maximum airway pressure was limited to 25 cmH2O.
89361014|NCT06076395|Experimental|Group B volume control ventilation|VT adjacent to 7 ml/Kg, respiratory rate was adjusted to achieve an end ETCO2 at 32-35 mmHg and I/E at: 1:2 and PEEP at 4 cm H2O and FiO2 at 0.5.
89361015|NCT06075758||ribociclib ambispective|Ambispective patients should have initiated Ribociclib, in combination with hormonal therapy, for at least 12 months before the patient's recruitment date and are still on Ribociclib in combination with hormonal therapy at recruitment. These patients will be followed up till progression, death, Ribociclib discontinuation due to adverse events, or till a maximum period of 6 months, whichever comes first.
89361016|NCT06075758||ribociclib retrospective|Retrospective patients should have been on Ribociclib in combination with hormonal therapy for at least 18 months and stopped the medication before the patient's recruitment
89361017|NCT06074120|Experimental|Women with genitourinary symptoms of menopause|Receive low-level laser therapy
89361018|NCT06073379|Experimental|Korean manupuncture|
89361019|NCT06073379|Placebo Comparator|Placebo/control|
89361020|NCT06068530|Active Comparator|MDA + Vaccine|The participants in MVDA villages will receive R21/Matrix M at M0, M1, M2, and a booster M12 plus DHA/piperaquine and a SLD-PQ at M0, M1, and M2
89001057|NCT00410475||U.S. radiologic technologists|Radiologic technologists certified by the American Registry of Radiologic Technologists (ARRT) during 1923-1980 and residing in any U.S. state or territory.
89361021|NCT06068530|Active Comparator|MDA only|The participants in MDA only villages will receive DHA/piperaquine and a SLD-PQ at M0, M1, and M2
89361022|NCT06068530|Active Comparator|Vaccine only|The participants in vaccine only villages will receive R21/Matrix M at M0, M1, M2, and a booster M12
89361023|NCT06068530|No Intervention|Control|The participants in control will receive MVDA at the end of the 24th month assuming that MVDA is found to be safe and effective. During M0 to M24, the comparison villages will receive the standard of care as per national malaria treatment guidelines.
89361024|NCT06064929|Experimental|Felzartamab|
89361025|NCT06064877|Experimental|Arm 1 (Investigational Arm: ficlatuzumab plus cetuximab)|Intravenous (IV) ficlatuzumab dose A on Day 1 (D1) and D15 of each 28-day cycle IV cetuximab on D1 and D15 of each 28-day cycle
89361026|NCT06064877|Experimental|Arm 2 (Investigational Arm: ficlatuzumab plus cetuximab)|IV ficlatuzumab dose B on D1 and D15 of each 28-day cycle IV cetuximab on D1 and D15 of each 28-day cycle
89361027|NCT06064877|Placebo Comparator|Arm 3 (Comparator Arm: placebo plus cetuximab)|IV placebo (saline, ficlatuzumab-matched) on D1 and D15 of each 28-day cycle IV cetuximab on D1 and D15 of each 28-day cycle
89361028|NCT06061562||DS group|A cohort of participants (child, teenager, or adult), with or without sleep disorders
89361029|NCT06057766|Experimental|Physical activity tele coaching group|Patients in the experimental group will undertake a 12-week (semi)automated telecoaching program with the aim of enhancing their physical activity. The program uses a Fitbit wearable and a smartphone application that is developed for and tested to be effective for patients with COPD.
89361030|NCT06057766|No Intervention|Control group|
89361031|NCT06056141|Active Comparator|Group A|Drug: Misoprostol 25mcg (200 mcg dissolved with 200 ml water and divided to 8 doses) every 2 hours
89361032|NCT06056141|Active Comparator|Group B|Device: Foley Catheter Transcervical Foley catheter (silicone, size 20F with 30ml balloon)
89361033|NCT06056063|Experimental|Evaluate the Halcyon 4.0 obtained CBCT in comparison to a CT SIM for radiotherapy dose planning|To evaluate the Halcyon 4.0 as a machine that will obtain CBCT that will be comparable to a CT simulator for radiotherapy treatment planning dose calculation. The novel CBCT images of subjects with malignancies from six disease sites obtained during the course of treatment for evaluation in place of the standard evaluation CBCT will be compared to their initial standard conventional CT simulation images used for treatment planning.
89361034|NCT06054750|Experimental|cACB active|Periarticular joint injection (medication) + single shot adductor canal block (medication) + adductor canal catheter infusion (medication)
89361035|NCT06054750|Placebo Comparator|cACB sham|Periarticular joint injection (medication) + single shot adductor canal block (medication) + adductor canal catheter infusion (normal saline)
89361036|NCT06053398|Active Comparator|Phenylephrine|Patients receiving phenylephrine for intraoperative hypotension
89361037|NCT06053398|Active Comparator|Norepinephrine|Patients receiving norepinephrine for intraoperative hypotension
89361038|NCT06051227|Active Comparator|Fentanyl IV|Opioid analgesic Form: fentanyl solution for injection/infusion Administration: intravenous Initial dose: 1 ug/kg Second dose (if required): 0.6ug/kg
89361039|NCT06051227|Experimental|Fentanyl IN|Opioid analgesic Form: fentanyl solution for injection/infusion Administration: intranasal using nasal atomizer Initial dose: 1.25 ug/kg to a maximum of 100ug Second dose (if required): 1ug/kg to a maximum total dose of 2ug/kg
89361040|NCT06051227|Experimental|Esketamine IV|Anesthetic, in lower doses the analgesic effect is dominant Form: esketamine solution for injection/infusion Administration: intravenous Initial dose: 0.2mg/kg Second dose (if required): 0.12mg/kg
89361041|NCT06051227|Experimental|Esketamine IN|Anesthetic, in lower doses the analgesic effect is dominant Form: esketamine solution for injection/infusion Administration: intranasal using a nasal atomizer Initial dose: 0.625mg/kg to a maximum of 50mg Second dose (if required): 0.5mg/kg to a maximum total dose of 1mg/kg
89361042|NCT06048783|Experimental|Program of systematic and periodic spiritual accompaniment and care|A minimum of 3 sessions of spiritual accompaniment by trained volunteers, considering a 1:1 ratio (patient:companion). The topics that will be proposed during the sessions are: sense of suffering, uncertainty, death, life after life, ideas about healing, forgiveness and guilt, etc. In addition, the spiritual needs of the participants will be explored through an instrument specially designed for this purpose and culturally adapted in Chile (FICA). The spiritual accompaniment sessions will be implemented preferably at a distance, using zoom or video call.
89361043|NCT06048783|No Intervention|Standard Care|It correspond to spiritual care currently offered by the hospital. This consists of the possibility of being assisted by a Catholic priest or being contacted by pastors from Protestant churches.
89361044|NCT06047496|Experimental|Time restricted eating|Caloric intake restricted to a self-defined 8-10 hour window in each 24-hour period, for 12 weeks.
89361045|NCT06047496|No Intervention|Standard eating|Normal eating schedule. Participants are expected to maintain their normal eating and dietary habits.
89361046|NCT06045455||Patients with neurological deficits (stroke or SM)|"All patients with acute neurological deficits (stroke or SM) will undergo neuroimaging diagnostic procedures initial multimodal brain CT (NCCT, CTP, CTA); then the follow-up NCCT within 24-36 hours.~All patients without a confirmed concordant hypoperfusion or cerebral ischemia on their previous CT scans will undergo a magnetic resonance imaging (MRI) examination between the 3rd and 7th day after the admission to the hospital in order to confirm the diagnosis of SM."
89361047|NCT06044168|Experimental|Intervention group|Receive leucine on a daily basis for 10 weeks.
89361048|NCT06042517|Experimental|Cohort 1: Ultrasound during a hyperinsulinemic euglycemic clamp (HEC).|Hepatic ultrasound during a hyperinsulinemic euglycemic clamp (HEC).
89361049|NCT06042517|Experimental|Cohort 2: Ultrasound then NMR with unlabeled glucose.|Hepatic ultrasound and subsequent NMR measurement of glycogen with unlabeled glucose.
89361050|NCT06042517|Experimental|Cohort 3: Ultrasound then NMR with carbon13 labeled glucose.|Hepatic ultrasound and subsequent NMR measurement of glycogen with carbon13 labeled glucose.
89361051|NCT06042517|Experimental|Cohort 4: Dual site ultrasound stimulation followed by CGM glucose recording alone.|Hepatoportal plexus + superior mesenteric plexus dual site ultrasound stimulation followed by CGM glucose recording alone.
88832606|NCT02055781|Active Comparator|Best Available Therapy|BAT includes any physician-selected treatment for myelofibrosis, such as approved JAK2 inhibitors administered according to package insert for patients with thrombocytopenia, and may include any treatment received before study entry.
89001058|NCT04632082|Experimental|Intervention: Telepsychoeducation with personalized videos|One psychoeducation session administered by a therapist by video call, with interventions focused on promoting protective factors and reducing common risk factors for psychopathology. The intervention is complemented by the sending of 4 videos of 2 to 3 minutes, with psychoeducational content, sent each week by the therapist.
89361052|NCT06041217|Experimental|Semaglutide 2.4 milligram (mg)|Participants will receive once-weekly subcutaneous (s.c) injection of semaglutide for 44 weeks.
89361053|NCT06041217|Placebo Comparator|Placebo|Participants will receive once-weekly subcutaneous (s.c) injection of placebo for 44 weeks.
89361054|NCT06040320|Experimental|Polatuzumab vedotin + Rituximab (Safety Lead-in Low Risk/Interim Complete Remission)|"Cycle 1 (21 days)~Day 1: polatuzumab vedotin + rituximab~Day 8: rituximab~Day 15: rituximab~Cycle 2 (21 days)~Day 1: polatuzumab vedotin + rituximab~After Cycle 2, a response assessment will be performed. Patients who show a complete response (and are therefore determined to be low risk) will continue to receive polatuzumab vedotin + rituximab on Day 1 of each 21-day cycle for 4 additional cycles (6 cycles of treatment total)."
89361055|NCT06040320|Experimental|Polatuzumab vedotin + Rituximab (Expansion Low Risk/Interim Complete Remission)|"Cycle 1 (21 days)~Day 1: polatuzumab vedotin + rituximab~Day 8: rituximab~Day 15: rituximab~Cycle 2 (21 days)~Day 1: polatuzumab vedotin + rituximab~After Cycle 2, a response assessment will be performed. Patients who show a complete response (and are therefore determined to be low risk) will continue to receive polatuzumab vedotin + rituximab on Day 1 of each 21-day cycle for 4 additional cycles (6 cycles of treatment total)."
89399167|NCT02165306|Active Comparator|Active Comparator|Usual Care The usual care group received routine counseling performed by the neurologist/neurosurgeon and nurses.
88832607|NCT03309449|Other|Intramuscular administration|Participants in this arm will be provided with the training and supplies to administer intramuscular simulated naloxone using a syringe and needle to a simulated flesh pad on a mannequin.
88832608|NCT03309449|Other|Intranasal (Atomizer)|Participants in this arm will be provided with the training and supplies to administer atomized intranasal simulated naloxone to a mannequin via a syringe using an intranasal mucosal atomization device.
88832609|NCT03309449|Other|Intranasal (Spray)|Participants in this arm will be provided with the training and supplies to administer an intranasal spray simulated naloxone to a mannequin.
88832610|NCT05094440|Experimental|Immediate Treatment|Pocket Skills is a dialectical behavior therapy skills training (DBT-ST) webapp that includes video lessons, an interactive chatbot AI coach, and in-app exercises to practice DBT skills. The delivery of the app intervention will be primarily monitored for one month, but followed for up to 3 months, and will be supplemented with a walk through manual and links to DBT worksheets. The intervention will be delivered in conjunction with treatment as usual which includes standard psychosocial care (e.g., assessments, group, and individual programming) as part of the Addictions Program or greater community.
88832611|NCT05094440|Active Comparator|Waitlist and Delayed Treatment|Waitlist control whereby outpatients or members of the community will wait 1 month (4 weeks) to receive the intervention and then receive the Pocket Skills webapp for the subsequent 2 months (8 weeks). The waitlist period and subsequent intervention will be delivered in conjunction with treatment as usual which includes standard psychosocial care (e.g., assessments, group, and individual programming) as part of the Addictions Program.
89361056|NCT06040320|Experimental|Polatuzumab vedotin + Rituximab + CHP (Safety Lead-in High Risk/Lack of Interim Complete Remission))|"Cycle 1 (21 days)~Day 1: polatuzumab vedotin + rituximab~Day 8: rituximab~Day 15: rituximab~Cycle 2 (21 days)~Day 1: polatuzumab vedotin + rituximab~After Cycle 2, a response assessment will be performed. Patients who show anything other than a complete response (and are therefore determined to be high risk) will receive polatuzumab vedotin + rituximab + CHP (cyclophosphamide + doxorubicin + prednisone) on Day 1 of each 21-day cycle for 4 additional cycles, followed by 2 final cycles of CHP alone on Day 1 (8 cycles of treatment total)."
89361057|NCT06040320|Experimental|Polatuzumab vedotin + Rituximab + CHP (Expansion High Risk/Lack of Interim Complete Remission)|"Cycle 1 (21 days)~Day 1: polatuzumab vedotin + rituximab~Day 8: rituximab~Day 15: rituximab~Cycle 2 (21 days)~Day 1: polatuzumab vedotin + rituximab~After Cycle 2, a response assessment will be performed. Patients who show anything other than a complete response (and are therefore determined to be high risk) will receive polatuzumab vedotin + rituximab + CHP (cyclophosphamide + doxorubicin + prednisone) on Day 1 of each 21-day cycle for 4 additional cycles, followed by 2 final cycles of CHP alone on Day 1 (8 cycles of treatment total)."
89361058|NCT06038578|Experimental|Arm A: TRK-950(5 mg/kg)+Ramucirumab+Paclitaxel|Participants who will be randomized to receive a 5 mg/kg intravenous(IV) dose of TRK-950 on days 1, 8, 15 and 22 in combination with 8 mg/kg IV dose of ramucirumab on days 1 and 15 and 80 mg/m^2 IV dose of paclitaxel on Days 1, 8, and 15 of a 28-day cycle.
89361059|NCT06038578|Experimental|Arm B: TRK-950(10 mg/kg)+Ramucirumab+Paclitaxel|Participants who will be randomized to receive a 10 mg/kg intravenous(IV) dose of TRK-950 on days 1, 8, 15 and 22 in combination with 8 mg/kg IV dose of ramucirumab on days 1 and 15 and 80 mg/m^2 IV dose of paclitaxel on Days 1, 8, and 15 of a 28-day cycle.
89361060|NCT06038578|Active Comparator|Arm C: Ramucirumab+Paclitaxel|Participants who will be randomized to receive a 8 mg/kg IV dose of ramucirumab on Days 1 and 15 in combination with 80 mg/m^2 IV dose of paclitaxel on Days 1, 8, and 15 of a 28-day cycle.
89361061|NCT06036017|No Intervention|Control groups|"T1: TBF, GCS, GKS, RCUOS, RASS, CAM-ICU forms will be filled out from the patients and blood samples will be taken.~T2: GCS, GKS, RCUOS, RASS, CAM-ICU forms will be filled out from the patients and blood samples will be taken. Additionally, durations of anesthesia, intubation and sedation as well as the amount of medication used for sedation will be recorded. The care package prepared will be applied to this group by the nurses working at the ward.~T3: GCS, GKS, RCUOS, RASS, CAM-ICU forms will be filled out from the patients and blood samples will be taken. Their length of stay in the intensive care unit will be noted."
89361062|NCT06036017|Experimental|Study groups|"T1: TBF, GCS, GKS, RCUOS, RASS, CAM-ICU forms will be filled out from the patients and blood samples will be taken.~T2: GCS, GKS, RCUOS, RASS, CAM-ICU forms will be filled out from the patients and blood samples will be taken. Additionally, durations of anesthesia, intubation and sedation as well as the amount of medication used for sedation will be recorded.~T3: GCS, GKS, RCUOS, RASS, CAM-ICU forms will be filled out from the patients and blood samples will be taken. Their length of stay in the intensive care unit will be noted."
89361063|NCT06031701|Experimental|Intervention|Neuro-psychosocial intervention with 12 grupal sessions is offered
89361064|NCT06031701|Experimental|Control|Waiting list control group
89361065|NCT06029894|Experimental|Treatment Group|Participants with MCI will receive dietary citicoline supplements.
89361066|NCT06029894|Placebo Comparator|Placebo|Participants with MCI will receive a placebo supplement.
88832612|NCT04429100||liver fibrosis stage F0|
89534475|NCT00003102|Experimental|Cohort 2 75cGy radiation|"On day 1, patients received a single dose of 131I-cG250 (5 mCi/5 mg) administered as an intravenous infusion over 10 minutes.~Therapeutic doses of 131I-cG250 were administered the following week as fractionated outpatient doses, starting with 30 millicurie (mCi)/5 mg 131I-cG250. Subsequent doses of 131I-cG250 were administered at 2-3 day intervals with the total amount of 131I-cG250 administered based on the calculated clearance of the initial dose administered on day 1. Whole body activity was maintained at no more than 30 mCi iodine-131.~In the absence of disease progression and after recovery from toxicity, patients could be re-treated beginning 8 weeks after the last treatment of the initial series, for a total of not more than 3 treatments."
88832613|NCT04429100||early-stage liver fibrosis (F1-2)|
88832614|NCT04429100||late-stage liver fibrosis (F3-4)|
88832615|NCT02056171|Experimental|Quetiapine|A randomized group will receive quetiapine as treatment for delirium.
88832616|NCT02056171|Placebo Comparator|Placebo|A randomized group will receive placebo, and not quetiapine.
88832617|NCT03312023|Experimental|Group A (LDV/SOF for low replicative HBV)|12 week treatment with ledipasvir/sofosbuvir (Harvoni) for chronic hepatitis B in low replicative state.
88832618|NCT03312023|Experimental|Group B (LDV/SOF for viral suppressed HBV)|12 week treatment with ledipasvir/sofosbuvir (Harvoni) for chronic hepatitis B, virally suppressed.
88832619|NCT03312023|Experimental|Group C (SOF for low replicative HBV)|"12 weeks treatment with sofosbuvir (Sovaldi) for chronic hepatitis B in low replicative state.~Randomized 1:1 with Group D."
88832620|NCT03312023|Experimental|Group D (LDV for low replicative HBV)|"12 weeks treatment with ledipasvir for chronic hepatitis B in low replicative state.~Randomized 1:1 with Group C."
89361067|NCT06029673|Experimental|Cabergoline|After the completion of the surgical procedure or medical induction for the early second-trimester abortion or fetal loss, the participant will be administered cabergoline 1mg orally with juice or water by the clinician or study investigator.
89361068|NCT06029673|Placebo Comparator|Placebo|After the completion of the surgical procedure or medical induction for the early second-trimester abortion or fetal loss, the participant will be administered a placebo pill orally with juice or water by the clinician or study investigator.
89361069|NCT06027918|Active Comparator|Group V (1726 meter altitude)|"In the application of infraclavicular brachial plexus blocks (coracoid approach); 1.5mg/kg dose of bupivacaine and 1mg/kg lidocaine mixture will be applied around the axillary artery in the 6 o'clock position under US guidance.~The block will be applied only once, approximately 15-20 minutes before surgery."
89361070|NCT06027918|Active Comparator|Group D (675 meter altitude)|"In the application of infraclavicular brachial plexus blocks (coracoid approach); 1.5mg/kg dose of bupivacaine and 1mg/kg lidocaine mixture will be applied around the axillary artery in the 6 o'clock position under US guidance.~The block will be applied only once, approximately 15-20 minutes before surgery."
88832621|NCT04425122||Esophageal cancer|Patients with esophageal cancer (SCC)
89361071|NCT06027918|Active Comparator|Group H( 100 meter altitude)|"In the application of infraclavicular brachial plexus blocks (coracoid approach); 1.5mg/kg dose of bupivacaine and 1mg/kg lidocaine mixture will be applied around the axillary artery in the 6 o'clock position under US guidance.~The block will be applied only once, approximately 15-20 minutes before surgery."
89361072|NCT06025942|Experimental|Intervention|The Purrble intervention takes the form of an interactive plush toy, designed to be handed over to the young person and support in-the-moment soothing.
89361073|NCT06025942|No Intervention|Control|Wait-list control (access to services as usual)
89361074|NCT06025747|Experimental|Treatment (abemaciclib, radiation therapy, surgery)|Prior to surgery, patients receive abemaciclib orally PO BID on days 1-28. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo radiation therapy over 28 fractions starting on cycle 1 day 15 in the absence of disease progression or unacceptable toxicity. After completion of radiation therapy, patients may undergo surgery. Patients also undergo CT or MRI during screening and on study.
89361075|NCT06025396|Experimental|Active TMP-301|"Cohort 1= 50mg, capsules form, one capsule - two times per day - total 100mg/day;~Cohort 2= 50mg, capsule form, 1 capsules - one time per day- total 50mg/day~Cohort 3= 50mg, capsule form, 2 capsules - one time per day- total 100mg/day;~Cohort 4 = Dose Titration: 50mg, capsule form, 1 capsules - one time per day - total 50 mg/day - on Days 1-7; and 50 mg, capsule form, 2 capsules - one time per day - total 100mg/day - on Days 8-14;~Each cohort duration is 14 days of dosing"
89361076|NCT06025396|Placebo Comparator|Placebo|"Cohort 1= Placebo, capsules form, one capsule - two times per day;~Cohort 2= Placebo, capsule form, 1 capsules - one time per day;~Cohort 3= Placebo, capsule form, 2 capsules - one time per day;~Cohort 4 = Dose Titration: Placebo, capsule form, 1 capsules - one time per day - on Days 1-7; and Placebo, capsule form, 2 capsules - one time per day - on Days 8-14;~Each cohort duration is 14 days of dosing"
89361077|NCT06025370|Experimental|Swimmer Position|
89361078|NCT06025370|Active Comparator|Arms at side|
89361079|NCT06024070|Experimental|study group|this study group assessed by 3 functional tests (Figure of 8 hopping , single leg stance test and y balance test) pre and post receiving rigid ankle tapping
88832622|NCT04425122||Non-cancer group|Non-cancer patients scheduled for upper endoscopy
88832623|NCT02056639|Experimental|Pessary|Use of the Bioteque cup pessary. Pessary will be placed between 18 and 27 6/7 weeks gestation, and will be removed during the 36th week of pregnancy (or earlier if indicated)
88832624|NCT02056639|No Intervention|No pessary|No pessary will be used. Subjects will receive standard obstetrical management
88832625|NCT01123499||Healthy Volunteers|Any healthy volunteers that are eligible to donate blood.
89361080|NCT06020664|Experimental|NOX1416+SOC|NOX1416 is a foam based gaseous nitric oxide (NO) product that will be topically applied directly onto the wound bed and left on the wound bed for a 5-minute period. Subjects randomized to the NOX1416 treatment group will receive once a day application, for a total of 12 weeks with a double treatment, 10 minutes apart, on the first day. Standard of care will include evaluation to document, off-loading adequate arterial flow, wound cleaning, removal of necrotic, infected and/or nonviable tissue by debridement, maintenance of moist wound environment, and management of infection.
89361081|NCT06020664|Placebo Comparator|Placebo+SOC|Placebo is topically applied directly onto the wound bed and left on the wound bed for a 5-minute period. Subjects randomized to the control group will receive once a day application, for a total of 12 weeks with a double treatment, 10 minutes apart, on the first day. Standard of care will include evaluation to document, off-loading adequate arterial flow, wound cleaning, removal of necrotic, infected and/or nonviable tissue by debridement, maintenance of moist wound environment, and management of infection.
89361082|NCT06017245|Active Comparator|Control|Healthy young-adult groups
89361083|NCT06017245|Experimental|Senile osteoporosis|Patients with senile osteoporosis
89361084|NCT06017245|Experimental|Postmenopausal osteoporosis|Patients with postmenopausal osteoporosis
88832626|NCT03839420|Experimental|CZM IOL|
88832627|NCT03839420|Active Comparator|Competitor IOL|
88832628|NCT04368806|Experimental|JointStem|Autologous Adipose tissue derived Mesenchymal Stem Cells(AdMSC)
88832629|NCT04368806|Placebo Comparator|Placebo|Normal Saline with Autologous Serum
88832630|NCT02340091|Experimental|HA IDF plus|cross-linked HA filler with lidocaine
88832631|NCT02340091|Active Comparator|HA IDF|cross-linked HA filler without lidocaine
88832632|NCT02340715||MRI for treatment planning or follow up|MRI for treatment planning for radiation therapy or those who have completed treatment and are receiving follow up care.
88832633|NCT02342197|Active Comparator|Minidose long protocol|Half dose of GnRH agonist (Decapeptyl 0.05) was started in the midluteal phase and Gn's was started from the second day of the cycle.
89399168|NCT02169206|Other|shoulder radiography|Bilateral shoulder AP standard plain x-ray in 0 and 90 degrees of arm abduction. Non-affected shoulder is used to be compared with the affected shoulder.
89361085|NCT06016725|Experimental|Arm 1 (nutritional counseling, resistance training)|Patients participate in online nutritional counseling over 30 minutes in weeks 1, 3, 5, 7, 9, and 11, and participate in online resistance training sessions weekly over 30 minutes in weeks 1-6 and biweekly at weeks 8, 10, and 12. Patients also receive educational materials at baseline.
89361086|NCT06016725|Active Comparator|Arm 2 (educational materials)|Patients receive educational materials at baseline.
89361087|NCT06016387|Experimental|Tucatinib, Transtuzumab, Capecitabine|Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+ Metastatic Breast Cancer and Leptomeningeal Disease.
89361088|NCT06013878||Informal Caregivers|Informal caregivers who provide transfer assistance to an individual with a disability
89361089|NCT06013878||Individuals who use transfer assistance|Individuals who require assistance with transfers moving from one surface to the other
89361090|NCT06011850||Kidney Donor QLB Group|Quadratus lumborum block (QLB) will be applied to the kidney donor in kidney transplant surgery immediately after induction of general anesthesia before the surgical incision is started.
88832634|NCT02342197|Active Comparator|Microdose flare protocol|Half the dose of GnRH agonist (Decapeptyl 0.05) was started on the second day of the cycle together with Gn's
88832635|NCT03182933|Experimental|Liposomal bupivacaine group|20ml 1.33% liposomal bupivacaine administered in adductor canal (a type of peripheral nerve block)
88832636|NCT03182933|Active Comparator|Standard bupivacaine group|20ml 0.5% standard bupivacaine in adductor canal (a type of peripheral nerve block)
88832637|NCT04324034|Experimental|vNOTES|vaginal Natural Orifice Transluminal Endoscopic Surgery (vNOTES) is vaginal surgery with a natural approach. The GelPOINT V-path transvaginal access platform is used. It is a device designed to be placed transvaginally to establish a pathway for the insertion of minimally invasive instruments while maintaining insufflation to perform diagnostic or operative procedures. This device also allows a passage for the extraction of operating parts.
88832638|NCT04324034|Active Comparator|laparoscopy|conventional laparoscopy
88832639|NCT03183869|Active Comparator|Early Intervention|Fecal microbiota via enema at Month 1, 2, 3. 4, 5 and month 6 along with stool, urine and blood collection. At months 7, 8, 9, 10, 11 and 12 only stool, urine and blood collection.
88832640|NCT03183869|Active Comparator|Late Intervention|At months 1, 2, 3, 4, 5 and 6, stool, urine and blood collection. Fecal microbiota via enema at month 6, 7, 8, 9, 10, 11and 12 months along with stool, urine and blood collection.
88832641|NCT02344225|Active Comparator|Caffeine+Saline IV+Saline drops|Caffeine citrate IV (20 mg/kg loading dose, 5 mg/kg/day maintenance dose) plus placebo saline IV (1 ml/kg followed by 0.25 ml/kg) for 5 days plus sterile normal saline (one drop two times a day) for 14 days (n=40); Caffeine is the intervention
88832642|NCT02344225|Experimental|Caffeine+Ibp IV+Saline drops|Caffeine citrate as described in group 1, plus Ibuprofen (10 mg/kg loading dose followed by low dose ibuprofen 2.5 mg/kg/day) for 5 days plus sterile normal saline (one drop two times a day) for 14 days (n=40); Ibuprofen is the intervention
88832643|NCT02344225|Experimental|Caffeine+Saline+Ketorolac drops|Caffeine citrate plus saline IV placebo as described in group 1, and Ketorolac (Acuvail) eye drops (one drop two times a day) for 14 days (n=40); Ketorolac is the intervention
88832644|NCT04319588|Experimental|Parasternal Group|"The parasternal group of patients will receive the pre-operative parasternal block (20 ml of 0.5% Ropivacaine per side) in association with infiltration with local anesthetic of access to thoracic drainage (drainage infiltration with 20 ml of 0.25% Ropivacaine) at the end of the intervention combined to General Anesthesia."
88832645|NCT04319588|Active Comparator|Case control group|"The case control group will only receive drainage infiltration with local anesthetic and standard intraoperative management with opioids."
88832646|NCT05078528|Experimental|Experimental group - MMC|Imaging of study participants will be performed during the colposcopy examination. The mobile colposcope and the confocal imaging probe, together referred to as the Multimodal Mobile Colposcope (MMC), will be used to image and/or record videos the cervix. Cervical biopsies will be performed using biopsy forceps per standard protocols.
88832647|NCT03314753||Cryoballoon Arm from FIRE AND ICE Trial|"No new/additional patients will be enrolled within this project. Only retrospective data will be collected on performed re-ablation procedures within the FIRE AND ICE Trial.~The FIRE AND ICE Trial collected data to compare efficacy and safety of isolation of the pulmonary veins (PV) using a Cryoballoon catheter versus (Cryoballoon Arm) a radiofrequency ablation (RF Arm) with a ThermoCool catheter in patients with drug refractory symptomatic paroxysmal atrial fibrillation (AF).~Products Used within the FIRE AND ICE Trial: Arctic Front® & Arctic Front Advance® Cardiac CryoAblation Catheter System.~The purpose of this retrospective data collection on re-ablations performed in both treatment arms (Cryo arm and Radiofrequency arm) of the FIRE AND ICE Trial."
89361091|NCT06011850||Kidney Donor Paracetamol Group|In kidney transplantation surgery, 1000 milligrams of Paracetamol will be administered intravenously to the kidney donor before the surgical incision is started, immediately after induction of general anesthesia.
89361092|NCT06011850||Kidney Recipient QLB Group|Quadratus lumborum block (QLB) will be applied to the kidney recipient in kidney transplant surgery immediately after induction of general anesthesia before the surgical incision is started.
89361093|NCT06011850||Kidney Recipient Paracetamol Group|In kidney transplantation surgery, 1000 milligrams of Paracetamol will be administered intravenously to the kidney recipient before the surgical incision is started, immediately after induction of general anesthesia.
89361094|NCT06005688|Experimental|Vepdegestrant with and without Carbamazepine|Vepdegestrant administered as a single dose in Period 1 and Period 2. Carbamazepine administered once a day for 19 days in Period 2.
89399169|NCT02169362|Experimental|Platelet Rich Plasma - Bio-Bandage™|Autologous Platelet Rich Plasma (PRP) Gel (Magellan® Bio-Bandage™)
89399170|NCT02169362|Sham Comparator|Saline Spray, Standard of Care|
89399171|NCT02172170|Experimental|BI 10773 single rising dose|
89399172|NCT02172170|Placebo Comparator|Placebo|
89399173|NCT02255942|Experimental|Iron fortified rice|Administration of iron fortified rice to all subjects; subjects will act as their own controls and each subject will receive all foreseen treatments/interventions.
88816827|NCT05063877|Experimental|Study drug EQU-001|"10mg capsules or 20 mg EQU-001 capsules totally 10 mg, 20 mg, 40 mg, 60 mg will be administered once orally daily to active-treatment subjects for 12-weeks with the option for open-label extension. During the open-label extension, subjects taking 60 mg dose for 4 weeks or longer may increase to 80 mg per day dose, at the discretion of the PI.~Intervention: Drug : EQU-001"
88816828|NCT05059691||Observational (transbronchial cryobiopsy)|Patients undergo transbronchial cryobiopsy guided by three-dimensional fluoroscopy. Patients' medical records are also reviewed.
88816829|NCT04999982|Experimental|Intervention group- PRE-CARE|Participants will receive the 1:1 PRE-CARE social needs navigation intervention with specific content and delivery strategy which was developed based on 1) quantitative analyses of the association between unmet social needs and ADHD symptoms in a large-scale nationally representative sample of children age 3-5, and 2) in-depth qualitative interviews with parents/guardians of preschoolers with inattention and/or hyperactivity symptoms to identify mechanisms by which unmet social needs exacerbate ADHD symptoms and functioning.
88816830|NCT04999982|Active Comparator|Control group- Care as Usual|Families randomly assigned to the control condition will continue to receive care as usual, which includes screening for social needs annually at well-child visits as recommended by the American Academy of Pediatrics (AAP), followed by provision of information as needed by the family. Families will also be offered the opportunity to make research assessments available to their primary care physician for best continuity of care.
88816831|NCT04986072|Experimental|Sodium Nitroprusside Arm|Sodium Nitroprusside (0.5 μg/kg/min) for 4 hours
88816832|NCT04986072|Placebo Comparator|Placebo Arm|5% Dextrose (0.5 μg/kg/min) for 4 hours
88816833|NCT04977765||Transgender Males|Individuals assigned female gender at birth but considering gender-affirming testosterone therapy. May self-identify as transgender or nonbinary etc.
88816834|NCT04977765||Cisgender Controls|Individuals assigned male or female at birth. May identify as cisgender or nonbinary etc. These individuals should not be undergoing or considering any form of hormone therapy.
88816835|NCT04964869|Experimental|Epinephrine solution injection group|In injected group, The saline epinephrine solution (1mg in 10ml N/S) is injected to 2 sites of cutted papilla (1 o'clock and 11 o'clock) by injected needle, at least 0.5ml per injected site, and must be protruded from submucosal layer.
88816836|NCT04964869|No Intervention|non-injection group|In non injection group, the saline epinephrine solution is not given
88816837|NCT04943731|Other|Provox Life™|"Phase 1: Provox Life™. Like-for-like transition from Provox (or other brand) to Provox Life™ under guidance from Speech Pathologist who will assess when the participant is ready to commence the 6 week study observation period.~Phase 2: Provox Life™ with Day/Night regimen. Establishment of optimal day/night routine under guidance of Speech Pathologist who will assess when the participant is ready to commence the 6 week observation period."
88816838|NCT04939922||Migraine|Patients with migraine (including vestibular migraine), including all types of migraine as defined by ICHD-3
88816839|NCT04939922||Other Primary Headache Disorders|Patients with other primary headache disorders (excluding migraine), including all types of other primary headache disorders (such as Tension-Type Headache, Cluster Headache) as defined by ICHD-3.
88816840|NCT04939922||Vertigo|Patients with other vertigo disorders (excluding vestibular migraine).
88816841|NCT04939922||Secondary Headache Disorders|Patients with secondary headache disorders as defined by ICHD-3.
88816842|NCT04939922||Normal control|Normal people do not have headache and vertigo.
88832648|NCT03314753||Radiofrequency Arm from FIRE AND ICE Trial|"No new/additional patients will be enrolled within this project. Only retrospective data will be collected on performed re-ablation procedures within the FIRE AND ICE Trial.~The FIRE AND ICE Trial collected data to compare efficacy and safety of isolation of the pulmonary veins (PV) using a Cryoballoon catheter versus (Cryoballoon Arm) a radiofrequency ablation (RF Arm) with a ThermoCool catheter in patients with drug refractory symptomatic paroxysmal atrial fibrillation (AF).~Products Used within the FIRE AND ICE Trial: NaviStar® ThermoCool® Ablation Catheter (Radiofrequency Arm; Manufacturer Biosense Webster, Inc.).~The purpose of this retrospective data collection on re-ablations performed in both treatment arms (Cryo arm and Radiofrequency arm) of the FIRE AND ICE Trial."
88832649|NCT05068622||patients with nasogastric tube before surgery|
88832650|NCT05068622||patients without nasogastric tube before surgery|
88832651|NCT05060354||MS Kesimpta (ofatumumab)|MS patients treated with Kesimpta (ofatumumab) for at least 3 months prior to SARS-CoV2 vaccination (completed regimen) Drug administration n/a, following routine clinical care Blood draws at 2-3 months, 5-6 months, and 11-12 months after enrollment
88832652|NCT05060354||MS Ocrevus (ocrelizumab)|MS patients treated with Ocrevus (ocrelizumab) for at least 3 months prior to SARS-CoV2 vaccination (completed regimen) Drug administration n/a, following routine clinical care Blood draws at 2-3 months, 5-6 months, and 11-12 months after enrollment
88832653|NCT05060354||MS Gilenya (fingolimod) and Mayzent (siponimod)|MS patients treated with Gilenya (fingolimod) or Mayzent (siponimod) for at least 3 months prior to SARS-CoV2 vaccination (completed regimen) Drug administration n/a, following routine clinical care Blood draws at 2-3 months, 5-6 months, and 11-12 months after enrollment
88832654|NCT05060354||Healthy Control|Individuals with major autoimmune disorders or current treatment with immunosuppressive or immunomodulatory drugs Received SARS-CoV2 vaccination (completed regimen) within 2-6 months of enrollment Blood draws at 2-3 months, 5-6 months, and 11-12 months after enrollment
88832655|NCT03318341|Other|Real then Sham|Participants are instructed to wear the TheraBracelet device on the affected wrist every day for at least 8 hours/day during their daily activity for 1 month. After 2-week washout, participants are again instructed to wear the device on the affected wrist every day for at least 8 hours/day during their daily activity for 1 month. The device applies real stimulation in the first month. The device applies sham stimulation in the second month. The stimulation is imperceptible. Thus, participants do not perceive stimulation in either month.
88832656|NCT03318341|Other|Sham then Real|Participants are instructed to wear the TheraBracelet device on the affected wrist every day for at least 8 hours/day during their daily activity for 1 month. After 2-week washout, participants are again instructed to wear the device on the affected wrist every day for at least 8 hours/day during their daily activity for 1 month. The device applies sham stimulation in the first month. The device applies real stimulation in the second month. The stimulation is imperceptible. Thus, participants do not perceive stimulation in either month.
88832657|NCT02300545|Experimental|Pazopanib|Pazopanib will be started at a dose of 200 mg BID for four days, then escalated to a dose of 400 mg BID for four days, then escalated once more to a dose of 800 mg QD for the duration of participation (or until dose reduction, if necessary). Pazopanib should be taken orally without food at least one hour before or two hours after a meal. One cycle of pazopanib is 28 days.
88832658|NCT05040464|Experimental|AZA group|Combination of sub-cutaneous administration of adalimumab at a dose of 160mg(W0)-80mg(W2)-40mg(W6) and then 40mg EOW and oral AZA capsules at a daily dose of 2.5 mg/kg
88832659|NCT05040464|Experimental|MTX group|Combination of sub-cutaneous administration of adalimumab at a dose of 160mg (week (W) 0)-80mg(W2)-40mg(W6) and then 40mg EOW and sub-cutaneous MTX 25mg once a week
88832660|NCT02979080|Experimental|Oral Iron Supplementation|Eisensulfat LOMAPHARM 50 mg administration for 120 days
88832661|NCT02346643||Treated Subjects|All subjects recruited and treated with the Axium neurostimulator
88832662|NCT05032664|Experimental|Intervention Group|Home-based aromatherapy programme
88832663|NCT05032664|Other|Control Group|Wait-list control
88832664|NCT03589651|Experimental|Group A|INCMGA00012 with epacadostat.
89361095|NCT06003621|Experimental|Tiragolumab and atezolizumab|"96 patients will be treated with tiragolumab for one cycle (600mg IV over 60-90 minutes). At Cycle 2 Day 1, participants receive IV tiragolumab (600mg) and atezolizumab (1,200mg) over 60-90 minutes. Cycles of tiragolumab and atezolizumab repeat every 21 days, with infusion time decreased (if tolerable) until treatment discontinuation, with or without disease progression.~Because of the heterogeneity of eligible cancer types, and lack of knowledge about relevant cut-offs for this combination, analysis will be performed prospectively to allocate patients into 4 subgroups based on the following tumour characteristics;~Group 1: TMB ≥ 10, assessed using NGS panel screening. n=24~Group 2:Tumour and immune cell PD-L1 expression (TAP score) > 20% high or PD-L1 (CD274) amplification, defined as gene copy number > 6 on the panel. n=24~Group 3: Tumour and immune cell PD-L1 expression (TAP score) 5% - 20% int. n=24~Group 4: Tumour infiltrating lymphocytes CD3+CD8+ ≥ 5%. n=24"
89361096|NCT06003361|Experimental|Digital CBT|digitally-delivered CBT for depression accessed via mobile app
88832665|NCT03589651|Experimental|Group B|INCMGA00012 with INCB050465.
88832666|NCT03186677|Experimental|Cohort 1|Single intravenous administration of BeneFIX (75 IU/kg) with 72 hours of observation, followed by single intravenous administration of ISU304/CB2679d/Dalcinonacog alfa (75 IU/kg) with 72 hours of observation
88832667|NCT03186677|Experimental|Cohort 2|Single intravenous administration of ISU304/CB2679d/Dalcinonacog alfa (75 IU/kg) with 72 hours of observation, followed by single subcutaneous administration of ISU304/CB2679d/Dalcinonacog alfa (75 IU/kg) with 72 hours of observation
88832668|NCT03186677|Experimental|Cohort 3|Single intravenous administration of ISU304/CB2679d/Dalcinonacog alfa (75 IU/kg) with 72 hours of observation, followed by single subcutaneous administration of ISU304/CB2679d/Dalcinonacog alfa (150 IU/kg) with 120 hours of observation
88832669|NCT03186677|Experimental|Cohort 4|One subcutaneous administration of ISU304/CB2679d/Dalcinonacog alfa (150 IU/kg) per day for 6 days with 240 hours of observation
88832670|NCT03186677|Experimental|Cohort 5|One intravenous administration of ISU304/CB2679d/Dalcinonacog alfa (75 IU/kg) followed by subcutaneous administration of ISU304/CB2679d/Dalcinonacog alfa (150 IU/kg) once daily for 9 days with 312 hours of observation
89361097|NCT06003361|Other|Waitlist|Participants will wait for 5 weeks prior to receiving the intervention
89361098|NCT06001645||Acute Respiratory Distress Syndrome|Patients with ARDS requiring or not requiring invasive ventilation
89361099|NCT06000683|Experimental|Empower LCS|Patient will be given education material(addressing knowledge barriers); patients' referral to financial navigation resources (addressing health-related social risks); and patients' reminder to discuss LCS during PCP visit. Providers will also be notified of eligibility of their patients to receive LCS.
89361100|NCT05998889|Experimental|Intervention group: GPE+GMI|Pain Education program based on Neuroscience of pain and the Fear-Avoidance model + Graded Pain Exposure Exercises + Graded Motor Imagery
89361101|NCT05998889|Active Comparator|Control group: GMI|Graded Motor Imagery
89361102|NCT05997186|Other|Surgery|Oral cavity and oropharyngeal defect reconstruction
89361103|NCT05996419|Experimental|DSB-Intervention|Active intervention group receives text message intervention via ANNIE for 30 days
89361104|NCT05988398|Experimental|RTS Intervention|RTS intervention will include a total of one 120-minute session of programming delivered to school personnel, and six, 45-minute sessions (total = 4.5 hours) for students. There are five components in this intervention that both students and school personnels will receive: 1) Psychoeducation on CSEC, 2) Healthy relationship skills training, 3) Programming components to enhance valuing of self and others, 4) Bystander intervention skills, and 5) Social norms for both students and school personnel. Students will additionally receive programming on Identification of safe people and resources, while school personnel will receive programming on Responding to Student Disclosures, and Cultural Humility.
89361105|NCT05987072|Experimental|Arm 1|This only arm will be given as a single dose on Day 1 in a fasted state followed by repeated twice daily doses (200 mg BID, Q12 hours) from Days 4-7 plus 1 morning dose on Day 8 in a fed state
89361106|NCT05985681|Experimental|Arm I (RG1-VLP, Gardasil-9)|Patients receive RG1-VLP IM for 3 doses at months 0, 2, and 6 in the absence of disease progression or unacceptable toxicity. Patients may also receive Gardasil-9 via injection for 3 doses at 6 months after the 3rd study vaccination (month 12), then at months 14 and 18 in the absence of disease progression or unacceptable toxicity. Patients also undergo blood sample collection on study and may undergo vaginal swab collection on study.
89361107|NCT05985681|Placebo Comparator|Arm II (saline placebo, Gardasil-9)|Patients receive saline placebo IM for 3 doses at months 0, 2, and 6 in the absence of disease progression or unacceptable toxicity. Patients may also receive Gardasil-9 via injection for 3 doses at 6 months after the 3rd saline injection (month 12), then at months 14 and 18 in the absence of disease progression or unacceptable toxicity. Patients also undergo blood sample collection on study and may undergo vaginal swab collection on study.
89361108|NCT05980403||Lymph node metastasis negative|Superficial esophageal squamous cell carcinoma with negative lymph node metastasis
89361109|NCT05980403||Lymph node metastasis positive|Superficial esophageal squamous cell carcinoma with positive lymph node metastasis
89361110|NCT05979207|Experimental|MMV367|IBSM challenge and MMV367
89361111|NCT05976555|Experimental|BCMA-TGFβ CAR-T cells (0.50 x 10^6 cells/kg)|BCMA-TGFβ CAR-T cells will be administered either fresh or thawed after cryopreservation by IV injection. Subjects will receive one of four dose levels of BCMA-TGFβ CAR-T cells based on the dose escalation design.
89361112|NCT05976555|Experimental|BCMA-TGFβ CAR-T cells (0.75 x10^6 cells/kg)|BCMA-TGFβ CAR-T cells will be administered either fresh or thawed after cryopreservation by IV injection. Subjects will receive one of four dose levels of BCMA-TGFβ CAR-T cells based on the dose escalation design.
89361113|NCT05976555|Experimental|BCMA-TGFβ CAR-T cells (1 x 10^6 cells/kg)|BCMA-TGFβ CAR-T cells will be administered either fresh or thawed after cryopreservation by IV injection. Subjects will receive one of four dose levels of BCMA-TGFβ CAR-T cells based on the dose escalation design.
89361114|NCT05976555|Experimental|BCMA-TGFβ CAR-T cells (2.5 x 10^6 cells/kg)|BCMA-TGFβ CAR-T cells will be administered either fresh or thawed after cryopreservation by IV injection. Subjects will receive one of four dose levels of BCMA-TGFβ CAR-T cells based on the dose escalation design.
89361115|NCT05976555|Experimental|BCMA-TGFβ CAR-T cells (Maximum tolerated dose)|After the maximal tolerated dose (MTD) is determined, an additional dose-expansion cohort of up to 9 patients (3 BCMA-naïve and 6 BCMA exposed) may be enrolled at that dose.
89361116|NCT05975983|Experimental|INS018_055|"Group 1: INS018_055 once daily up to 12 weeks, low dose~Group 2: INS018_055 twice daily up to 12 weeks, low dose~Group 3: INS018_055 once daily up to 12 weeks, high dose"
89361117|NCT05975983|Placebo Comparator|Placebo|Group 4: Placebo once or twice daily up to 12 weeks
89361118|NCT05972681|Experimental|Local Anesthesia arm|Bupivicaine and Epinephrine
89361119|NCT05972681|Sham Comparator|Normal saline sham arm|
89361120|NCT05969236|Experimental|Experimental Group|Including 2 single dose groups (Part A) and 2 multiple dose groups (Part B). Participants in experimental groups will receive MDI-1228_mesylate Ophthalmic Solution.
89361121|NCT05969236|Placebo Comparator|Comparator Group|One comparator group will be set for each of the 4 experimental groups, to a total of 4 comparator groups. Participants in comparator groups will receive placebo.
88816843|NCT04936841|Experimental|NKTR-214, anti-PD therapy plus Palliative Radiation|"Cycle 1 consists of anti-PD-1 therapy (200mg) and NKTR-214 (0.006 mg/kg3 administered intravenously), followed by palliative radiation (8 Gy x 3 or 4 Gy x 5 fractions) combined with anti-PD-1 therapy and NKTR-214 in cycle 2.~In subsequent cycles participants will receive NKTR-214 and anti-PD-1."
88816844|NCT04930536|Experimental|Acalabrutinib Capsule|Single-arm study
88816845|NCT04893291|Active Comparator|Everolimus Eluting Stent|
88816846|NCT04893291|Experimental|Magic Touch Sirolimus Coated Balloon|
88818004|NCT03556293|Active Comparator|Virtual Learning Collaborative (No ASR)|Virtual Learning Collaborative (VLC). Intervention: The VLC will be offered to 4 teams without automated surveillance reportingand will receive the AKI Prevention Toolkit plus monthly virtual training calls with the other VLC sites. Each participating site will be supported to establish a multidisciplinary team charged with continuously improving AKI, which will include interventional cardiologists, cardiac catheterization lab manager and technicians, nursing representatives from the intensive care unit and/or holding areas, cardiology administration, nephrology, and representation from the quality improvement department (VA Clinical Application Coordinator [CAC] and Systems Redesign).
89361122|NCT05968820|Experimental|Sleep Health Enhancement Intervention|The sleep health enhancement intervention is a 4-week, 1x/week one-one-one program with a graduate research assistant who will be trained and supervised by the PI in provision of the sleep health enhancement intervention.
89361123|NCT05968820|No Intervention|Wait-List Control Group|The wait-list control group will be encouraged to continue with their usual activities and sleep habits during the wait period between baseline and reassessment and will undergo the sleep health enhancement intervention following the initial reassessment.
89361124|NCT05968768|Experimental|Experimental - Naxitamab Arm|Treatment with naxitamab will be continued no longer than 6 cycles a year or until disease progression, patient consent, unacceptable toxicities, or study closure
89361125|NCT05968768|No Intervention|Control Group - standard treatment|The control group - will receive only standard treatment.
89361126|NCT05962450|Experimental|RPI group|Regorafenib + PD-1 + iNKT cells
89361127|NCT05962450|Other|RP group|Regorafenib + PD-1
89361128|NCT05962372|Experimental|Intervention|Intervention group will receive culturally-tailored portion-control Mediterranean-like advice through monthly individual counseling for 6 months, reinforced with daily text messages for 12 months, and a monthly household supply of legumes (i.e., beans and peanuts), vegetable oils (i.e., olive oil + a blend of canola and soybean), and locally sourced assorted fruit and vegetables for 18 months. From months 18 to 24, we will monitor maintenance of behavior (no food or counseling) with support from the nutritionist available.
89361129|NCT05962372|Active Comparator|Control|Control group will receive portion-control standard non-tailored nutritional counseling in monthly individual sessions for 6 months, reinforced with daily text messages for 12 months, and monthly supermarket vouchers (no foods) for 18 months. From months 18 to 24, we will monitor maintenance of behavior (no voucher or counseling), with support from the nutritionist available.
89361130|NCT05960747||Control group|Medical students with standard training: theoretical teaching, associated with a real-life demonstration of at least one thoracentesis by a senior doctor from our department
89361131|NCT05960747||Simulation group|Medical students with standard training + training using an augmented virtual reality simulator specially developed for thoracentesis.
89361132|NCT05956158|Experimental|Behavioral Treatment|
89361133|NCT05956158|Placebo Comparator|Sleep Education Treatment|
89361134|NCT05954442|Experimental|Arm A|Everolimus plus Investigator's Choice of Chemotherapy
89361135|NCT05954442|Active Comparator|Arm B|Investigator's Choice of Chemotherapy
89361136|NCT05951972|Experimental|Nutritional intervention|The trial will consist of two short periods in which increased intake of a pair of food items will be implemented. The first pair of food items is apples and bananas (pair A), and the second pair of food items is peanuts and cucumbers (pair B).
89361137|NCT05950139|Experimental|Advanced ALK+ NSCLC|All patients will receive the intervention
89361138|NCT05944458|Active Comparator|Acetylcysteine group|"Generic name: N-acetylcysteine.~Trade name: Fluimucil.~Company: Zambon.~Dosage form: ampoules for intravenous administration.~Dose: 600mg taken every 12 hours daily with a fixed dose as there is no need for renal or hepatic adjustment, starting with the inception of linezolid therapy.~Duration: at least one day or more"
89361139|NCT05944458|Placebo Comparator|Placebo|They will receive placebo drug.
88832671|NCT03769844|Experimental|IV GM-CSF 125 mcg/m2/dose|Subjects in this arm who demonstrate immunoparalysis will receive GM-CSF by the intravenous (IV) route at a dose of 125 mcg/m2/day for 7 consecutive days.
88832672|NCT03769844|Experimental|SQ GM-CSF 125 mcg/m2/dose|Subjects in this arm who demonstrate immunoparalysis will receive GM-CSF by the subcutaneous (SQ) route at a dose of 125 mcg/m2/day for 7 consecutive days.
88832673|NCT03769844|Experimental|IV GM-CSF 250 mcg/m2/dose|If the IV 125 mcg/m2/dose arm is not successful in the first cohort of subjects, we will transition to 250 mcg/m2/day via the IV route for 7 consecutive days in a subsequent cohort.
89361140|NCT05942690|Experimental|experimental|"The intervention evaluated is a technique of prolonged abdominal manual pressure centered on the zone of restriction of mobility called trigger point with diaphragmatic aim."
89361141|NCT05939791|Experimental|Exercise training|Children previously diagnosed and treated for acute lymphoblastic leukemia in remission between 1 and 3 years with physical exercise intervention
89361142|NCT05939791|No Intervention|Passive|Children previously diagnosed and treated for acute lymphoblastic leukemia in remission between 1 and 3 years without physical exercise intervention
89361143|NCT05938127|Experimental|Lymphoma Survivors IMST|Participants will undergo a version of the BfitBwell Cancer Exercise Program physical assessment, which assesses physical fitness and function.
89361144|NCT05938127|Experimental|Lymphoma Survivors sham IMST|Participants will undergo a version of the BfitBwell Cancer Exercise Program physical assessment, which assesses physical fitness and function.
89361145|NCT05936099|No Intervention|Control|Participants will complete the baseline survey and receive an informational brochure
89361146|NCT05936099|Experimental|Intervention|Participants will complete the baseline survey, receive a behavioral health intervention supported by computerized decision support, and take an exit survey
89361147|NCT05935826|Active Comparator|Amino Acid Supplement|Treatment
89361148|NCT05935826|Placebo Comparator|Placebo|Placebo
89361149|NCT05934851|Experimental|Frozen-Section Directed Excision Vulvectomy|The surgeon(s) will identify the lesion and make a 1 mm excision around the lesion site.
89361150|NCT05934851|Active Comparator|Wide Local Excision Vulvectomy|The surgeon(s) will visually identify the abnormal lesion. A Wide Local Excision with 5 mm margins will be made through the dermis per standard of care.
89361151|NCT05932199|Experimental|Induction dual immunotherapy with durvalumab / tremelimumab|3 cycles of durvalumab (1500 mg intravenously) + tremelimumab (75 mg intravenously) starting Cycle1 Day (Cohort A).
88832674|NCT03769844|Experimental|SQ GM-CSF 250 mcg/m2/dose|If the SQ 125 mcg/m2/dose arm is not successful in a cohort of subjects (or if the IV dose had to be escalated to 250 mcg/m2/dose), we will transition to 250 mcg/m2/day via the SQ route for 7 consecutive days in a subsequent cohort.
88832675|NCT02347345|Active Comparator|Active injection drug use (IDU)|In active IDU, Harvoni (Fixed dose combination ledipasvir/sofosbuvir), one pill orally daily x 12 weeks
89361152|NCT05932199|Experimental|Platinum cisplatin or carboplatin and pemetrexed chemotherapy plus durvalumab/tremelimumab|3 cycles of durvalumab (1500 mg intravenously) + tremelimumab (75 mg intravenously) with cisplatin 75mg/ m2 (or carboplatin AUC 5-6) + pemetrexed 500 mg/m2 (Cohort B).
89361153|NCT05930782|Active Comparator|Part 1 (fasted) : Group 1 PQP hard tablet, 320mg (N=12)|Group 1: Piperaquine hard tablet, 320mg (administered in fasting condition of at least 10 hours) (N=12)
89361154|NCT05930782|Experimental|Part 1 (Fasted): Group 2: PQP dispersible granules 320mg (N=12)|Group 2: Piperaquine dispersible granules 320mg administered in fasting condition of at least 10 hours (N=12)
89361155|NCT05930782|Experimental|Part 2 (Fed): Group 3 - high fat: PQP dispersible granule (planned as 320 mg) (N=12)|Group 3: Piperaquine dispersible granules 320mg administered in fed conditions - High-fat meal (N=12)
89361156|NCT05930782|Experimental|Part 2 Fed): Group 4 - low fat: PQP dispersible granule (planned as 320 mg) (N=12)|Group 4: Piperaquine dispersible granules 320mg administered in fed conditions - Low-fat meal representative of African diet (N=12)
88832676|NCT02347345|Active Comparator|Former injection drug use (former IDU)|In former IDU, Harvoni (Fixed dose combination ledipasvir/sofosbuvir), one pill orally daily x 12 weeks
88832677|NCT02347345|No Intervention|Healthy volunteers|HIV, HCV and HBV negative, never injected drugs, no recreational drugs for at least 2 years (does not include marijuana) and negative urine screen for opiates at the screening visit.
89361157|NCT05930782|Experimental|Part 2 (Fed): Group 5 - whole milk: PQP dispersible granule (planned as 320 mg) (N=12)|Group 5: Piperaquine dispersible granules 320mg administered in fed conditions - Whole milk 250 ml (N=12)
89361158|NCT05929742|Experimental|experimental group|received early rehabilitation combined with VR training
88832678|NCT03319277|Active Comparator|Routine opiate prescription|This arm will receive the standard post-discharge prescriptions of ibuprofen, docusate, acetaminophen, and polyethylene glycol. In addition, they will receive the standard amount of post-discharge opiate medications - 28 tablets of oxycodone 5mg.
88832679|NCT03319277|Experimental|Decreased opiate prescription|This arm will receive the standard post-discharge prescriptions of ibuprofen, docusate, acetaminophen, and polyethylene glycol. In addition, they will receive the decreased amount of post-discharge opiate medications - 5 tablets of oxycodone 5mg with a paper prescription for an additional 10 tablets of oxycodone 5mg as a backup for uncontrolled pain.
88832680|NCT03767426|No Intervention|Overnight sleep|Subjects are permitted a night of polysomnograph-recorded sleep before participating in training and testing sessions the next day
88832681|NCT03767426|Active Comparator|Sleep deprivation|Subjects sleep deprived before participating in training and testing sessions the next day
88832682|NCT03767426|Experimental|Daytime Nap|Subjects are trained and then retested after a daytime nap
88832683|NCT03323723|Other|RS-2 SUI Device|Comparing use of device to non-treatment phase
88832684|NCT04624295|Active Comparator|Early Antiplatelet Therapy|
88832685|NCT04624295|Placebo Comparator|Non-Early Antiplatelet Therapy|
88832686|NCT02348593|Active Comparator|75 mg of JZP-110|Once Daily Dosing
88832687|NCT02348593|Active Comparator|150 mg JZP-110|Once Daily Dosing
88832688|NCT02348593|Active Comparator|300 mg of JZP-110|Once Daily Dosing
89361159|NCT05929742|Active Comparator|comparison group|received only early rehabilitation
89361160|NCT05928351|Experimental|PNE Group|Pain Neuroscience Education + Standard Physiotherapy Program
89361161|NCT05928351|Active Comparator|Control Group|Standard Physiotherapy Program
89361162|NCT05924516|No Intervention|Control Group|Control Group: Standard Treatment
89361163|NCT05924516|Experimental|Experimental Group|Experimental Group: Standard Treatment + Adhera® Fatigue Digital Program
89534476|NCT00003102|Experimental|Cohort 3 100cGy radiation|"On day 1, patients received a single dose of 131I-cG250 (5 mCi/5 mg) administered as an intravenous infusion over 10 minutes.~Therapeutic doses of 131I-cG250 were administered the following week as fractionated outpatient doses, starting with 30 millicurie (mCi)/5 mg 131I-cG250. Subsequent doses of 131I-cG250 were administered at 2-3 day intervals with the total amount of 131I-cG250 administered based on the calculated clearance of the initial dose administered on day 1. Whole body activity was maintained at no more than 30 mCi iodine-131.~In the absence of disease progression and after recovery from toxicity, patients could be re-treated beginning 8 weeks after the last treatment of the initial series, for a total of not more than 3 treatments."
89534477|NCT03337217|Experimental|Prone Position|Position during colonoscopy
89534478|NCT03337217|Active Comparator|Left lateral decubitus position|Position during colonoscopy
88832689|NCT02348593|Placebo Comparator|Placebo|Once Daily Dosing
88832690|NCT03323801|Experimental|13-cis retinoic acid|20 mg 13-cis retinoic acid twice daily (BID) with means for 32 weeks
88832691|NCT04197908|Experimental|EUS-guided gallbladder drainage (EGBD)|The procedure would be performed with a linear echoendoscope using a 10mm x 10mm or a 15 x 10mm stent. The distal flange of the stent would be deployed under EUS guidance, followed by deployment of the proximal flange under endoscopic guidance. Once deployed, the gallbladder would be completely emptied by suction and irrigation until the effluent through the stent is clean.
88832692|NCT04450355|Experimental|Nefopam group|At the end of induction, the nefopam group will receive intravenous nefopam 20mg mixed with 50ml of normal saline, and at the end of surgery, this group will receive intravenous nefopam 60mg mixed with 50ml of normal saline at a rate of 2ml/hr.
88832693|NCT04450355|Placebo Comparator|Control group|The control group will receive intravenous normal saline 50ml at the end of induction and receive intravenous normal saline 50ml at a rate of 2ml/hr at the end of surgery.
88832694|NCT02349685|Experimental|14 day bismuth based quadruple therapy (PBMT) group|Proton pump inhibitor (PPI) regular dose b.i.d., tripotassium dicitrate bismuthate 300 mg q.i.d. (three tablets at 30 min before meals and one tablet at 2 hours after dinner), metronidazole 500 mg t.i.d., and tetracycline 500 mg q.i.d
89361164|NCT05920772|Experimental|Intervention group|A smoking initiation prevention intervention (called KickAsh! intervention) will be implemented in 12 youth social work organisations offering sport and/or recreational activities, during a period of three months (October 2023 to December 2023).Youth workers will act as implementers of the intervention. Approximately 5 youth workers per organisation will participate in the study. Adolescents participating in the youth social work organisations will receive the intervention. Approximately 25 adolescents per organisation will participate in the study.
89361165|NCT05920772|No Intervention|Control group|12 other youth social work organisations offering sport and/or recreational activities will be allocated to the control group. This group will not receive the KickAsh! intervention. Approximately 5 youth workers per organisation will participate in the study. Approximately 25 adolescents per organisation will participate in the study.
89361166|NCT05920148||Elderly|
89361167|NCT05920135|Experimental|Phase 1a; Dose escalation at various dose levels in patients with EGFR TKI sensitizing mutation|
89361168|NCT05920135|Experimental|Phase 1b; At 2 recommended dose levels of BBT-207 in patients with EGFR C797S mutation|
89361169|NCT05920135|Experimental|Phase 2; At the recommended phase 2 dose of BBT-207 in patients with EGFR C797S mutation|
89361170|NCT05918549||Popolation|
89361171|NCT05910346|Experimental|Experimental Group|At the beginning of the study, the pregnant women who applied to the obstetrics clinics and met the sample selection criteria will be divided into the experimental and control groups by randomization method by filling out the Personal Information Form. Motherhood Theory-Based Education Program will be applied to the pregnant women who are allocated to the experimental group.
89361172|NCT05910346|No Intervention|Control Group|"First stage: Pregnant women in the control group will receive routine care. Second stage: Data Collection Form for the follow-up and Birth Process and Results will be filled within the first 24 hours after the birth.~Third stage: Follow-up will be done by phone within 4 weeks after birth. Maternal Attachment Scale (MBI), Barkin Maternal Function Inventory will be applied.~Fourth stage: At the end of the fourth month postpartum, follow-up counseling will be made by telephone and the Maternal Attachment Scale and the Barkin Maternal Function scale will be filled.~Fifth stage: When the study is completed, a training booklet will be given to the mothers in the control group."
89361173|NCT05909228||Children with intestinal failure|Children with intestinal failure on parenteral nutrition
89361174|NCT05909228||Healthy controls|Healthy controls without parenteral nutrition
89361175|NCT05907967|Active Comparator|Active VeNS|The active device utilizes a technology termed vestibular nerve stimulation (VeNS). The device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 30 minutes per day.
89361176|NCT05907967|Sham Comparator|Sham VeNS|The sham device looks identical to the active device and interacts with the app in a similar manner to the active device. It will apply some stimulation to a user for a limited period of time (30 seconds), before tapering down to zero over a further 20 seconds, thus creating the impression of an active device. The device will be placed on the head in a manner analogous to headphones with hydrogel electrodes placed over the mastoid processes. Participants will be advised to use the device at home for 30 minutes per day.
89361177|NCT05907564|Experimental|Single Arm|Device: Aventus Thrombectomy System
88832695|NCT02349685|Experimental|14 day Moxifloxacin containing triple therapy (MEA) group|PPI regular dose b.i.d., moxifloxacin 400 mg q.d., and amoxicillin 1g b.i.d.
88832696|NCT02349685|Active Comparator|14 day tailored therapy group|based on H. pylori culture and antimicrobial sensitivity, select the 2nd rescue regimen between 14 days of bismuth-based quadruple therapy or 14 days moxifloxacin-containing triple therapy according to antibiotics susceptibility.
89361178|NCT05905367|Experimental|Symptom-inhibited IV fentanyl induction|Symptom-inhibited IV fentanyl induction followed by opioid agonist therapy (OAT) with either oral methadone or slow-release oral morphine (SROM)
88832697|NCT03676010||Sarcoma and GIST|Experts involved in the consensus process for providing recommandations for the definitions of time to event outcomes to be used in randomized trials for patients with Sarcoma and GIST
88832698|NCT03676010||Breast cancer|Experts involved in the consensus process for providing recommandations for the definitions of time to event outcomes to be used in randomized trials for patients with Breast cancer
88832699|NCT03676010||Pancreatic cancer|Experts involved in the consensus process for providing recommandations for the definitions of time to event outcomes to be used in randomized trials for patients with Pancreatic cancer
89361179|NCT05905172|Experimental|Hydronidone group|Patients were given three capsules of hydronidone three times a day for 5 years.
89361180|NCT05905172|Placebo Comparator|The placebo group|Patients were given three capsules of placebo three times a day for 5 years.
89361181|NCT05902949|Active Comparator|Stretching Group|The pattern will be performed 3 times per day (10 repetitions, 30 seconds each repetition). A daily control diary will be filled in when performing the exercise.
88832700|NCT03676010||Renal cell carcinoma|Experts involved in the consensus process for providing recommandations for the definitions of time to event outcomes to be used in randomized trials for patients with Renal cell carcinoma
89361182|NCT05902949|Active Comparator|Heel Cup Group|The heel cup will be 5mm high (Eva Shore 65)
89361183|NCT05902364|Experimental|Systane Ultra Preservative-Free|1-2 drops in each eye four times a day for 30 days
89361184|NCT05901155|Experimental|MedAL-mentor|"In health facilities allocated to the medAL-mentor arm, the intervention will consist in :~Providing tablets with ePOCT+ and initial training for use by healthcare workers~Access to medAL-mentor for healthcare workers and the monitoring team~Regular (at least every 2 weeks) supportive messages sent by the monitoring team to healthcare workers providing feedback from medAL-mentor~Targeted phone calls and health facilities visits by the monitoring team based on medAL-mentor review Monitoring will be performed by the study team."
89361185|NCT05901155|No Intervention|Routine mentoring|"In health facilities allocated to the control arm, tablets with ePOCT+ will also be provided to healthcare workers with initial training, but subsequent mentoring will be conducted routinely:~No access to medAL-mentor for healthcare workers or the monitoring team~At least one message sent by the monitoring team to healthcare workers every two weeks, to inquire about any issues and trigger a site visit if needed~At least one visit from the monitoring team in each health facility every two months Monitoring will be performed by the study team."
89361186|NCT05898646|Experimental|Arm I (6 cycles of daratumumab)|Patients receive daratumumab subcutaneously (SC) on day 1 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity for up to 6 cycles on study. Patients also undergo x-ray imaging at screening and bone marrow biopsy and blood sample collection throughout the study. Patients with cardiac involvement also undergo echocardiography throughout the trial.
88832701|NCT03676010||Colon Cancer (adjuvant setting)|Experts involved in the consensus process for providing recommandations for the definitions of time to event outcomes to be used in randomized trials for patients with Colon Cancer (adjuvant setting)
88832702|NCT03676010||Solid tumours undergoing image-guided tumor ablation|Experts involved in the consensus process for providing recommandations for the definitions of time to event outcomes to be used in randomized trials for patients with Solid tumours undergoing image-guided tumor ablation
88832703|NCT03326843|Experimental|Avatrombopag 60 mg|Open-label: oral avatrombopag
88832704|NCT02352259|Experimental|Electrochemotherapy|
88832705|NCT04155866||Healthy participants|Measurement of lower-limb muscle activation from healthy participants.
88832706|NCT04155866||Chronic Stroke Survivors|Measurement of lower-limb muscle activation from chronic stroke survivors
88832707|NCT02354443|Experimental|ProHema-CB|ProHema-CB represents Ex Vivo Modulated Human Cord Blood Cells. Each subject will receive one administration of ProHema-CB unit transplant.
88832708|NCT03326999|Experimental|Investigational arm|Patients in this arm will receive adductor canal regional block with bupivacaine and obturator nerve regional block with bupivacaine
88832709|NCT03326999|Sham Comparator|Control arm|Patients in this arm will receive adductor canal regional block with bupivacaine and obturator nerve regional block with saline
88832710|NCT04952870||COVID-19 group|Perinatal COVID-19 infection group, including newborns born from COVID-19 infected mothers and newborns with postnatal COVID-19 infections;
88832711|NCT04952870||NO group|Newborns admitted in NICU and receiving inhaled NO for respiratory failure
88832712|NCT04952870||Control group|Newborns admitted in NICU for respiratory failure not receiving iNO and not infected with COVID-19;
88832713|NCT02397265|Experimental|Bihormonal closed loop|Bi-hormonal closed loop pump will be used in the exercise and mixed meal substudies
88832714|NCT02397265|Active Comparator|Standard opened loop pump|Standard opened loop pump will be used in the exercise and mixed meal substudies
88832715|NCT02397265|Placebo Comparator|Insulin only|Insulin only closed loop
88832716|NCT04948580|Experimental|ICC-T|5.5 days with 8 hours of training for teachers aiming at changing attitudes towards violence and equipping teachers with non-violent discipline strategies
88832717|NCT04948580|No Intervention|Monitoring condition|No intervention
88832718|NCT02959489|Active Comparator|Amyloid Brain Imaging Non-Disclosure|Subjects will receive their Alzheimer's disease (AD) risk assessment based on age, gender, family history and ancestry.
88832719|NCT02959489|Experimental|Amyloid Brain Imaging Disclosure|"Subjects will receive both their elevated or not elevated amyloid neuroimaging results based on their brain scan interpretation and Alzheimer's disease (AD) risk disclosure. The AD risk assessment is based on age, gender, family history and ancestry."
88832720|NCT02979314|Experimental|Galvanic Vestibular Stimulation|A standard placement of the electrodes will be used for GVS and sham, placed on the mastoids. Weak currents up to maximally 3 mA will be used (tested before in each participant individually, and expected mean current will be around 1.5 mA). Previous studies have used Magnetic Resonance (MR) compatible GVS without reporting any discomfort for the participants, however weak sensations of nausea could be possible and in case that they are disturbing for the participants the experiment will be aborted. Continuous stimulation for up to 30min with intensities of 1-1.5 mA is generally considered as safe and free of any considerable side effects.
88832721|NCT03328949|Experimental|IVL Coronary Lithotripsy System|All enrolled patients will receive treatment from the IVL coronary lithotripsy system prior to coronary stent placement.
88832722|NCT00356642|Experimental|Single dose 1 cohort|Subjects with body surface area (BSA) disease involvement between 10 and 15% will be included. Subjects will receive either 100 milligrams (mg) GW842470X or placebo in a ratio of 2:1.
88832723|NCT00356642|Experimental|Repeat dose 1 cohort|Subjects with BSA disease involvement between 10 and 15% will be included. Subjects will receive either 100-150 mg GW842470X or placebo in a ratio of 3:1
88832724|NCT00356642|Experimental|Repeat dose 2 cohort|Subjects with BSA disease involvement between 30 and 40% will be included. Subjects will receive either 300-400 mg GW842470X or placebo in a ratio of 3:1
88832725|NCT00356642|Experimental|Repeat dose 3 cohort|Subjects with BSA disease involvement >=50% will be included. Subjects will receive either 500-1000 mg GW842470X or placebo in a ratio of 2:1
88832726|NCT03330041|Experimental|Fast absorbing gut suture placed 2 mm apart|Wound closed with sutures spaced 2 millimeters apart will be treated in a simple, interrupted cutaneous suture pattern
88832727|NCT03330041|Experimental|Fast absorbing gut suture placed 5 mm apart|Wound closed with sutures spaced 5 millimeters apart will be treated in a simple, interrupted cutaneous suture pattern
88832728|NCT04121780|Experimental|Growth Hormone|Norditropin® (somatropin [rDNA origin] injection) via FlexPro® 30 mg / 3ml strength auto-injector pens (Novo Nordisk Inc).
88832729|NCT04121780|Placebo Comparator|Saline|Saline-placebo via auto-injector pens (Haselmeier Inc).
88832730|NCT00375869|Active Comparator|Darbopoeitin|The treatment group, comprised of ten patients, will receive an intravenous dose of 200 mcg (1 ml) of darbepoetin (Aranesp®). Patients will be randomly assigned to either the treatment group, or the control group in a 2:1 ratio. The treatment group will be given 200 mcg of darbepoetin intravenously. The control group will be given a matching placebo of 1 mL of normal saline.
89361187|NCT05898646|Active Comparator|Arm II (18 cycles of daratumumab)|Patients receive daratumumab SC on day 1 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity for up to 18 cycles on study. Patients also undergo x-ray imaging at screening and bone marrow biopsy and blood sample collection throughout the study. Patients with cardiac involvement also undergo echocardiography throughout the trial.
89361188|NCT05898126|Experimental|Renin-guided hemodynamic management|We will measure serum renin values every six hours. If the measured renin concentration increases by more that 20% compared with the last value, the target mean arterial pressure (MAP) will be elevated to 75-80 mmHg. If the subsequent renin level is still rising, the target MAP will be further raised to 85-90 mmHg and the addition of inotropes will be considered. If the first subsequent renin level decreases or increases by ≤20%, the target MAP will be kept at 75-80 mmHg. If the renin level at the subsequent measurement after reaching the highest step of management protocol is still increasing, a failure of the intervention will be declared, the target MAP will return to 65-70 mmHg. If renin level further decreases or increases ≤20% for two consecutive measurements, we will downgrade the target MAP to the previous step.
89361189|NCT05898126|Sham Comparator|Usual care|Patients in the usual care group will be managed according to standard of practice at each participating center.
89361190|NCT05895968|No Intervention|Preoperative|
89361191|NCT05895968|Experimental|postoperative (2 weeks)|
89361192|NCT05895968|Experimental|postoperative (4 weeks)|
89361193|NCT05895968|Experimental|postoperative (3 months)|
89361194|NCT05895578|Active Comparator|Probiotic|2 Capsule daily containing approximately 1*10E9 colony forming unit (CFU) of Lactobacillus CECT 9422 +1*10E9 colony forming unit (CFU) of Bifidobacterium CECT 30257.
89361195|NCT05895578|Active Comparator|Probiotic + placebo|One capsule daily containing approximately 1*10E9 colony forming unit (CFU) of Lactobacillus CECT 9422 +1*10E9 colony forming unit (CFU) of Bifidobacterium CECT 30257 and 1 capsule of placebo supplement.
89361196|NCT05895578|Placebo Comparator|Placebo|Two capsules daily of Placebo supplement.
89361197|NCT05893498|Experimental|FFRangio|FFRangio guided revascularization
89361198|NCT05893498|Active Comparator|Pressure wire|Pressure wire-based guided revascularization (FFR or NHPR)
89361199|NCT05892302|Active Comparator|Access to Asma Guardian website/app|Participants who are randomized to the Asma Guardian website at their baseline visit will have access to the website for 6 months starting at baseline. Access will be turned off at 6 months.
89361200|NCT05892302|Other|No Access to Asma Guardian website/app for 6 months|Note: Participants who are randomized to no access will not receive access during the 6 months of the study; however they will receive 1 month of access after their 6 month study visit but any information gained during this time will not be part of analysis.
89361201|NCT05892250|Active Comparator|Control group|Intervention will consist of a conventional physical therapy treatment program that includes manual therapy techniques and exercise
89361202|NCT05892250|Experimental|Experimental group|Intervention will consist of a conventional physical therapy treatment program that includes manual therapy techniques and exercise plus Dynamic Humeral Centering exercises
89361203|NCT05888103|Experimental|Inclisiran|Inclisiran s.c
89361204|NCT05888103|Placebo Comparator|Placebo|Placebo s.c.
89361205|NCT05887713|Experimental|Group 1: Active CES|Active CES treatment at home 40 minutes daily for 6 weeks
89361206|NCT05887713|Sham Comparator|Group 2: Sham CES|Sham CES treatment at home 40 minutes daily for 6 weeks
89361207|NCT05884437|Experimental|Chiropractic|Chiropractic adjustment
89361208|NCT05882981||Study group|22 young adults aged 17-26 years with high femoral anteversion.
89361209|NCT05882981||Control group|22 young adults aged 17-26 years with normal femoral anteversion
89361210|NCT05879718|Experimental|Group 1|PF-06823859
89361211|NCT05879718|Placebo Comparator|Group 2|Placebo
89361212|NCT05875727|Experimental|20-valent pneumococcal conjugate vaccine|Pneumococcal conjugate vaccine (20vPnC)
89361213|NCT05872685|Experimental|Group A (Chemotherapy+Serplulimab )|"Drug: Oxaliplatin，S-1，Serplulimab~Chemotherapy (SOX): Oxaliplatin, administered as a 2-hour intravenous infusion (130 mg/m2) S-1, orally twice daily for 2 weeks followed by a 7-day rest period. The dose of S-1 was 80 mg/day for body surface area less than 1.25 m2, 100 mg/day for body surface area greater than or equal to 1.25 to less than 1.5 m2, and 120 mg/day for body surface area greater than or equal to 1.5 m2 Chemotherapy will be repeated each 21 day for 3 cycles prior to surgery and 3 cycles after surgery.~Serplulimab: 300 mg IV infusion on Day 1 of each 21 day cycle for 3 cycles prior to surgery and 3 cycles after surgery."
89361214|NCT05872685|Active Comparator|Group B (Chemotherapy+Placebo )|"Drug: Oxaliplatin，S-1，Placebo~Chemotherapy (SOX): Oxaliplatin, administered as a 2-hour intravenous infusion (130 mg/m2) S-1, orally twice daily for 2 weeks followed by a 7-day rest period. The dose of S-1 was 80 mg/day for body surface area less than 1.25 m2, 100 mg/day for body surface area greater than or equal to 1.25 to less than 1.5 m2, and 120 mg/day for body surface area greater than or equal to 1.5 m2 Chemotherapy will be repeated each 21 day for 3 cycles prior to surgery and 3 cycles after surgery.~Placebo: 300 mg IV infusion on Day 1 of each 21 day cycle for 3 cycles prior to surgery and 3 cycles after surgery."
89361215|NCT05869461|Experimental|Intervention|This group will receive access to the wellness sessions that have specific content geared towards our key populations and they will also receive peer navigation for 6 months.
89361216|NCT05869461|No Intervention|Control|Control arm participants will receive standard HIV care through the Mumbai Districts AIDS Control Society (MDACS)-run ART clinics. In addition, participants will have access to an abbreviated version of the wellness groups to help them remain engaged with the study team and to control for attention.
89361217|NCT05867992||Case group|This group enrolls patients with acute severe traumatic brain injury.
89361218|NCT05867992||Control group|This group enrolls patients with acute traumatic bone fracture but without traumatic brain injury.
89361219|NCT05867654||Osteomyelitis Treated with Oral Antibiotics|"Patients that are receiving oral antibiotics for the treatment of their osteomyelitis.~Based on the indication, patients will receive one the following medications orally for 6-8weeks: Amoxicillin-clavulanate 875mg/125mg q12hrs, clindamycin 300mg q6hrs, Levofloxacin 750mg QID, Penicillin 500mg q6hrs"
89534479|NCT03336047|Active Comparator|10,000 steps daily|Subjects will be encouraged to obtain 10 000 steps a day, monitored by a step counter (fit bit zip)
89361220|NCT05865249|No Intervention|Control|In participants randomised to the control group, the primary care referrer will receive the spirometry report plus any additional information as per local spirometry pathway. The primary care referrer will not receive an interpretation and quality assessment report generated by ArtiQ.Spiro.
89361221|NCT05865249|Other|Intervention|In participants randomised to the intervention group, the primary care referrer will receive the spirometry report plus any additional information as per local spirometry pathway plus an interpretation and quality assessment report generated by ArtiQ.Spiro.
89361222|NCT05865197||Passive monitoring|No intervention
89361223|NCT05861375||Non applicable (NA)|Patients with Anorexia Nervosa hospitalized for malnutrition
89361224|NCT05858957|Experimental|Magnesium|Magnesium sulfate 30 mg/kg with 100 ml saline will apply in 10 min before induction of general anesthesia (maximum magnesium dose 2g) (Group M) . When the magnesium infusion completed, general anesthesia induction will start.
89361225|NCT05858957|Active Comparator|Saline|saline 100 ml will apply in 10 min before induction of general anesthesia (Group S) . When the saline infusion completed, general anesthesia induction will start.
89361226|NCT05853705|Experimental|Exercise Group|Participants will participate in a remote, app-enabled exercise program consisting of strength and aerobic exercises for four to twelve weeks. They will perform the exercises 3-5 times a week at home guided by exercise videos in the app. The exercise sessions will increase in frequency throughout the training regimen. The videos will include athletes demonstrating how to perform each exercise safely, and provide tips for optimal form and breathing. Participants will wear wearable fitness trackers and monitor their heart rates during exercise sessions.
89361227|NCT05852002|Experimental|35 kDa hyaluronan fragment injection|35kDa hyaluronan fragment was produced by using hyaluronidase PH20 to cleave 1600kDa hyaluronan ( HA1600 ). Batch number of 35 kDa hyaluronan fragment injection is L20200708MP07707,and the injection was approved by Ministry of Health, Mongolia.
89361228|NCT05849896|Experimental|Static contractions in healthy volunteers|Acquisition of HD SEMG signals of an upper limb muscle and a lower limb muscle while the participant executes simple static exercises.
89361229|NCT05849896|Experimental|Dynamic contractions in healthy volunteers|Acquisition of HD SEMG signals of a leg muscle while the participant executes simple dynamic exercises.This arm will recruited recreationally active or athletic volunteers, preferably between 18 and 20 years
89361230|NCT05849896|Experimental|Static contractions in post-stroke patients|Acquisition of HD SEMG signals of a lower limb muscle while the participant executes simple static exercises.
88818005|NCT03556293|Active Comparator|Technical Assistance with ASR|Technical Assistance (TA). Intervention: TA will be offered to the 4 teams randomized to the TA condition with automated surveillance reporting (ASR) and will receive the AKI Prevention Toolkit plus monthly technical calls independently and monthly ASR dashboard.
88818006|NCT03556293|Active Comparator|Virtual Learning Collaborative with ASR|Virtual Learning Collaborative (VLC). Intervention: The VLC will be offered to 4 teams with automated surveillance reporting (ASR) and will receive the AKI Prevention Toolkit plus monthly virtual training calls with the other VLC sites with the and monthly ASR dashboard. Each participating site will be supported to establish a multidisciplinary team charged with continuously improving AKI, which will include interventional cardiologists, cardiac catheterization lab manager and technicians, nursing representatives from the intensive care unit and/or holding areas, cardiology administration, nephrology, and representation from the quality improvement department (VA Clinical Application Coordinator [CAC] and Systems Redesign).
88818007|NCT01262846|Active Comparator|Fluzone SD|Fluzone® Standard dose
88818008|NCT01262846|Experimental|Fluzone® High dose|Fluzone® High dose in a blinded manner as single-0.5mL injection intramuscularly into one of the subject's deltoid muscles.
88818009|NCT04769297|Experimental|Sublingual Micro-Dose Ketamine|Ketamine micro-dose 37.5mg compounded sublingual daily administration
88818010|NCT03461757|Experimental|Arm 1: Rimegepant 75 mg|Participants were administered a single sublingual dose of 75 mg of rimegepant ODT on occurrence of migraine that reached moderate or severe intensity up to 45 days after randomization.
88818011|NCT03461757|Placebo Comparator|Arm 2: Placebo|Participants were administered a single sublingual dose of matching placebo for rimegepant (75 mg) ODT on occurrence of migraine that reached moderate or severe intensity up to 45 days after randomization.
88818012|NCT01325714|Experimental|Arm 1: PAVeD Intervention|In the experimental arm, the caregiver will receive six to eight 45-minute visits to teach caregiver about pain and memory problems. The person with dementia will also be able to learn from these visits. These visits will take place over three months.
88818013|NCT01325714|Active Comparator|Arm 2: Enhanced Usual Care|In the comparison arm, the caregiver will receive information in the mail about memory problems and pain; and the caregiver will receive eight short telephone calls to check on how the person with dementia is doing.
88818014|NCT03234569|Experimental|sonoHSG|This is the research procedure and it will be added onto the standard of care procedure for all subjects.
88818015|NCT01325792||GORE® BIO-A® Tissue Reinforcement|Single-staged open complex ventral incisional repair of primary or recurrent anterior abdominal wall hernia.
88818016|NCT02989961|Experimental|A-Resticutis|Autologous, Activated-Platelets type of preparation.
88818017|NCT02989961|Placebo Comparator|C-Platelet-Poor Plasma PPP|Platelet-Poor Plasma type of preparation achieved by centrifugation of blood samples at high speed conditions. Resticutis is administered instead if the patient doesn't achieve full healing after 6 injections.
88818018|NCT02631057||Non-Valvular Atrial Fibrillation|
88818019|NCT02631057||acute ischemic stroke|
88818020|NCT01325870|Experimental|ACD-CPR +ITD|Active Compression Decompression CPR with the ResQPRO device and ResQPOD ITD device.
88818021|NCT01325870|Experimental|S-CPR + ITPR|
88818022|NCT01325870|Active Comparator|S-CPR|
88818023|NCT01775735|Experimental|Treatment|The treatment is continuous stimulation with an occipital nerve stimulator, specifically the BSC Precision™ ONS System for 6 months post-randomization
88818024|NCT01775735|Active Comparator|Control|The control is intermittent stimulation for 20 seconds every 90 minutes with an occipital nerve stimulator, specifically the BSC Precision™ ONS System for 6 months post-randomization
88832731|NCT00375869|Placebo Comparator|Normal Saline (Placebo)|The treatment group, comprised of ten patients, will receive an intravenous dose of 200 mcg (1 ml) of darbepoetin (Aranesp®). Patients will be randomly assigned to either the treatment group, or the control group in a 2:1 ratio. The treatment group will be given 200 mcg of darbepoetin intravenously. The control group will be given a matching placebo of 1 mL of normal saline.
88832732|NCT03198221|Active Comparator|Group A|Participants in Group A will begin drinking the bowel preparation Golytely (4 liter Polyethylene glycol based preparation) at 4:00 PM on the day before colonoscopy - an 8-ounce glass of the bowel preparation every 10 minutes. Participants must finish drinking the bowel preparation by 7:00 PM, and may continue to drink clear liquids until midnight.
88832733|NCT03198221|Active Comparator|Group B|Participants in Group B will begin drinking the bowel preparation Golytely (4 liter Polyethylene glycol based preparation) at 4:00 PM on the day before colonoscopy - an 8-ounce glass of the bowel preparation every 10 minutes for a total of 8 glasses, and must complete drinking the bowel preparation by 5:30 PM. Participants may continue to drink clear liquids until midnight. The next day, 4 hours before the scheduled time of colonoscopy, participants will be asked to drink an 8 ounce glass of bowel preparation every ten minutes for a total of 8 glasses over no more than 1.5 hours. Participants may continue to drink clear liquids until 2 hours before the scheduled time of colonoscopy.
88832734|NCT03198221|Active Comparator|Group C|Participants in Group C will begin drinking the bowel preparation Clenpiq (sodium picosulfate, magnesium oxide, and citric acid) at 4:00 PM on the day before colonoscopy. Participants will be asked to drink 5 ounces of the bowel preparation and at least five (5) additional 8-ounce glasses of clear liquids by 9:00 PM. At 10:00 PM, participants will drink another 5 ounces of the bowel preparation, and will then be asked to drink at least three (3) additional glasses of clear liquids by midnight.
88832735|NCT03198221|Active Comparator|Group D|Participants in Group D will begin drinking the bowel preparation Clenpiq (sodium picosulfate, magnesium oxide, and citric acid) at 4:00 PM on the day before colonoscopy. Participants will be asked to drink 5 ounces of the bowel preparation and at least five (5) additional 8-ounce glasses of clear liquids by 9:00 PM, and may continue drinking clear liquids until midnight. The next day, 4 hours before the scheduled time of colonoscopy, participants will drink another 5 ounces of the bowel preparation and at least three (3) 8 ounce glasses of clear liquids within the next 2 hours. Participants may continue to drink clear liquids until 2 hours before the scheduled time of colonoscopy.
88832736|NCT05723120|Experimental|Neuromuscular Score|"Patients undergoing spontaneous ventilation, noninvasive mechanical ventilation, or invasive mechanical ventilation were assessed by two physical therapists with a minimum interval of 15 minutes between them. There was no communication between the physical therapists before, during, or after the assessments. Patients were also evaluated by the EuroSCORE16, SAPS 317, and ARISCAT18 scales. They were evaluated three times during hospitalization: at protocol admission, after five and ten days, or at hospital discharge, whichever occurred first. The surgical patients were also evaluated three times: immediately postoperative, at ICU discharge, and seven days later or at hospital discharge, whichever occurred first.~In addition, patients' characteristics at hospital admission were also analyzed, including demographic characteristics, clinical signs and symptoms, imaging, laboratory findings, and medical history"
88832737|NCT05723120|Experimental|Respiratory Score|"Patients undergoing spontaneous ventilation, noninvasive mechanical ventilation, or invasive mechanical ventilation were assessed by two physical therapists with a minimum interval of 15 minutes between them. There was no communication between the physical therapists before, during, or after the assessments. Patients were also evaluated by the EuroSCORE16, SAPS 317, and ARISCAT18 scales. They were evaluated three times during hospitalization: at protocol admission, after five and ten days, or at hospital discharge, whichever occurred first. The surgical patients were also evaluated three times: immediately postoperative, at ICU discharge, and seven days later or at hospital discharge, whichever occurred first.~In addition, patients' characteristics at hospital admission were also analyzed, including demographic characteristics, clinical signs and symptoms, imaging, laboratory findings, and medical history"
88832738|NCT03674996|Experimental|Same day discharge|Patients submitted to minimally invasive radical prostatectomy, and discharged 12 hours after the surgery.
88832739|NCT03674996|Experimental|Next-day discharge|Patients submitted to minimally invasive radical prostatectomy, and discharged 24 hours after the surgery.
88832740|NCT03674996|Other|2-days discharge|Patients submitted to minimally invasive radical prostatectomy, and discharged 48 hours after the surgery.
88832741|NCT03203681|Other|Natesto|Participants in this group will receive Natesto for a 24 consecutive weeks treatment course.
88832742|NCT03207035|Active Comparator|20 ml of lidocaine 2% with epinephrine|Patients will receive axillary brachial plexus block with 20 ml of lidocaine 2% with epinephrine.
88832743|NCT03207035|Experimental|40 ml 0f lidocaine 1% with epinephrine|Patients will receive axillary brachial plexus block with 20 ml of lidocaine 1% with epinephrine diluted with 20 ml of nacl 0.9% ( total 40 ml)
88832744|NCT05993962|Placebo Comparator|Control group|Participants received one daily serving (provided in one cup of 150grams) of unfortified yoghurt for 8 weeks
88832745|NCT05993962|Experimental|Fortified group|Participants received one daily serving (provided in one cup of 150grams) of yoghurt fortified with vitamin B12 for 8 weeks
88832746|NCT05993923||Control group|Classical management in the digestive surgery department
88832747|NCT05993923||GPOU group|Treatment is carried out in Peri-Operative Geriatrics Unit to optimize specific geriatric care
88832748|NCT05993910||Hyperthermie Register|Hyperthermia simultaneous with Radiotherapy alone, Hyperthermia simultaneous with Chemotherapy alone, Hyperthermia simultaneous with Radiochemotherapy alone
88832749|NCT05993897|Active Comparator|Dapagliflozin|patients who will receive SGLT2 inhibitors
88832750|NCT05993897|Placebo Comparator|Placebo|Patients who will receive Rhythm control +/- oral anticoagulation
88832751|NCT05993884|Experimental|Treatment (clinical standard treatment, iEPCs)|Patients receive clinical standard treatment and iEPCs IV with a single dose
89361231|NCT05847114|Experimental|Stress Ball Group|VAS-A, VAS, Spielberg Trait Anxiety Inventory was applied. Vital signs were evaluated before, during and after surgery. Stress balls were given to the patients in addition to the standard care protocol. Stress balls were used for 15 minutes during the operation, by placing the patient in both hands, counting from one to five, and tightening and loosening twice.
89361232|NCT05847114|No Intervention|Control Group|Patients in the control group will not undergo any intervention other than the standard care protocol.
88832752|NCT05993884|Placebo Comparator|Placebo (clinical standard treatment, Placebo)|Patients receive clinical standard treatment and placebo IV 150 mL with a single dose
88818025|NCT02631525|Active Comparator|REM-PRO|Total intravenous anesthesia with remifentanil and propofol, target controlled infusion based on Minto's and Marsh's pharmacokinetic models.
88818026|NCT02631525|Active Comparator|REM-DES|Balanced anesthesia with remifentanil target controlled infusion based on Minto's pharmacokinetic model and desflurane.
88818027|NCT03162497|Experimental|Azithromycin|Preservative-free azithromycin 15mg/g (Azyter® Augentropfen im Einzeldosisbehältnis, Thea, Clermont-Ferrand, France) one drop twice daily for two days then once daily for 26 days
88818028|NCT03162497|Active Comparator|Doxycycline|"Doxycycline 100mg (Doxycycline Genericon, Genericon Pharma GmbH, Graz, Austria) twice daily for 6 weeks"
88818029|NCT01327274|Experimental|Treatment Arm|This is a non-randomized study in which otherwise healthy patients, ages 8-14, with severe pectus excavatum (PSI > 3.5) will undergo the interventional treatment arm by having outpatient surgery and the Magnetic MIni-Mover Magnimplant procedure is performed during which the magnetic implant is surgically placed. After 2 years of treatment with the implanted magnet and brace treatment, the Magnetic Mini-Mover Magnimplant will be explanted. After surgery and recovery, all subjects will be fitted for an orthotic brace, which houses the external magnet and records brace-wear compliance. They will undergo 3MP treatment for 18-24 months, enough to attempt to improve their PSI (< 3.25).
88818030|NCT05167643|Experimental|Trastuzumab injection+Piperacillil tablets+Letrozole tablets|Trastuzumab injection:Once in 21 days IVD；Piperacillil tablets:125mg qd (d1-21) PO；Letrozole tablets:2.5mg POqd；According to the current clinical guidelines combined with clinical practice, the treating physicians recommended the treatment plan to the subjects, and decided to enroll HR+/HER2+ advanced breast cancer patients treated with H combined with CDK4/6 inhibitor + AI±OFS into this study
88818031|NCT03162341|Experimental|UltraSonography and DECT|"UltraSonography and DECT will be used in patient monitoring after 6, 12 and 24 months of treatment in order to evaluate the correlation between the 2 explorations for the measurement in tophus volume change.~Those are interventions that are not part of the standard care of the patients."
88818032|NCT00367029|Active Comparator|1|Print-based, individually tailored motivational program
88818033|NCT00367029|Experimental|2|Enhanced version of the print-based, individually tailored motivational program
88818034|NCT05152199|Other|Cystoscopy with use of obturator sheath|This intervention arm will include the use of the obturator sheath upon entry into the urethra during rigid cystoscopy.
88818035|NCT05152199|Active Comparator|Cystoscopy without use of obturator sheath|This intervention arm will not include the use of the obturator sheath upon entry into the urethra during rigid cystoscopy, but will consist of using the telescope under direct visualization.
88818036|NCT01366196|Placebo Comparator|Control Group (C)|Patients in the control group will receive a placebo tablet with a sip of water one hour prior to surgery and a placebo tablet twice a day for a total of two weeks.
88818037|NCT01366196|Experimental|Pregabalin Group (P)|Patients in the treatment group will receive 150 mg of pregabalin with a sip of water one hour prior to surgery, and then 150 mg daily (75 mg BID) for a total of two weeks.
88818038|NCT03155321||Polish General Surgeons|The group is formed by active polish general surgeons, both specialists and in training
88818039|NCT01366976|Placebo Comparator|Placebo|
88818040|NCT01366976|Active Comparator|Acetaminophen|Acetaminophen will ge given as 1g every 6 hours for 4 doses over a 24 hours study period
88818041|NCT01777217|Active Comparator|solifenacin succinate|Solifenacin succinate, 5mg or 10 mg once daily
88818042|NCT01777217|Placebo Comparator|Placebo|Drug: Placebo oral
88818043|NCT03021707|Experimental|UV-FS laser|WaveLight® Ultraviolet Femtosecond Laser System during UV-Femto, single session (one treatment per eye per participant)
88818044|NCT02251379|Experimental|ECS + Medication Group|"The Environmental Control Strategy (Home Environmental Intervention) plus inhaled corticosteroids or inhaled corticosteroids plus long-acting beta agonist. (Flovent Diskus or Advair diskus)"
88818045|NCT02251379|Active Comparator|Medication Group Alone|inhaled corticosteroids or inhaled corticosteroids plus long-acting beta agonist. (Flovent Diskus or Advair diskus)
88818046|NCT02948231|Experimental|Mistral|
88818047|NCT02936219||Early complementary breast feeding|The EARLY complementary feeding group is defined as the introduction of complementary food <17th week of life corrected for term. In addition, infants are stratified to the milk regime, like human milk feeding, at the study enrollment.
88818048|NCT02936219||Early complementary combined feeding|The EARLY complementary feeding group is defined as the introduction of complementary food <17th week of life corrected for term. In addition, infants are stratified to the milk regime, like combined milk feeding, at the study enrollment.
88818049|NCT02936219||Early complementary formula feeding|The EARLY complementary feeding group is defined as the introduction of complementary food <17th week of life corrected for term. In addition, infants are stratified to the milk regime, like formula feeding, at the study enrollment.
88818050|NCT02936219||Late complementary breast feeding|The LATE complementary feeding group is defined as the introduction of complementary food ≥17th week of life corrected for term. In addition, infants are stratified to the milk regime, like human milk feeding, at the study enrollment.
88818051|NCT02936219||Late complementary combined feeding|The LATE complementary feeding group is defined as the introduction of complementary food ≥17th week of life corrected for term. In addition, infants are stratified to the milk regime, like combined milk feeding, at the study enrollment.
88818052|NCT02936219||Late complementary formula feeding|The LATE complementary feeding group is defined as the introduction of complementary food ≥17th week of life corrected for term. In addition, infants are stratified to the milk regime, like formula feeding, at the study enrollment.
88818053|NCT02255513|Experimental|HLD200|"HLD200 (methylphenidate hydrochloride) 20, 40, 60, 80, or 100 mg capsules~Subjects were allowed to titrate to their optimal HLD200 dose during a 6 week open-label, treatment optimization phase before being randomized to continue their HLD200 treatment over an one week double-blind, placebo-controlled phase. HLD200 was administered orally, once daily each evening."
89361233|NCT05845099|Active Comparator|Polymethyl Methacrylate-Based Complete Removable Dentures.|The patient will be provided by a CRD to restore his missing teeth which will be manufactured by heat curing processing technique
89361234|NCT05845099|Experimental|Photopolymerized Methacrylate- Based Complete Removable Dentures.|The patient will be provided by a CRD to restore his missing teeth which will be manufactured by 3D-printed (Digital Light Processing).
89361235|NCT05841940|Experimental|[14C]HLX208|Single oral dose of 450mg [14C]HLX208 suspension.
89361236|NCT05840770|Experimental|Treatment (Cemiplimab)|Patients receive cemiplimab IV and undergo blood sample collection while on study. Patients undergo MRI, CT scan and PET scan throughout the study.
89361237|NCT05837221||Oral Squamous Cell Carcinoma Saliva Sample Group|"Saliva will be collected at least 30 minutes after subjects stop eating, drinking, chewing gum, and smoking. Subjects will be instructed to spit saliva into a collection tube. The saliva will be split into two aliquots, one that is immediately frozen at~-80C and one that is mixed 1:1 with pre-reduced tryptic soy broth, L-cysteine, and glycerol then frozen at -80C to preserve the viability of microorganisms."
89361238|NCT05837221||Non Oral Squamous Cell Carcinoma Saliva Sample Group|"Saliva will be collected at least 30 minutes after subjects stop eating, drinking, chewing gum, and smoking. Subjects will be instructed to spit saliva into a collection tube. The saliva will be split into two aliquots, one that is immediately frozen at~-80C and one that is mixed 1:1 with pre-reduced tryptic soy broth, L-cysteine, and glycerol then frozen at -80C to preserve the viability of microorganisms."
89361239|NCT05837221||Oral Squamous Cell Carcinoma Stool Sample Group|Stool collection methods may differ depending on the patient. The aim is to collect fresh stool samples, those that are available will be collected during the study visit. If a patient is unable to give a sample at the visit, samples may be collected at home using the OMNIgene-GUT and OMNImet-GUT kits (DNA Genotek, Inc.).
88832753|NCT05993871||Patients with diabetic small fiber neuropathy|Diabetic Patients presented with pure small fiber neuropathy.
89361240|NCT05837221||Non Oral Squamous Cell Carcinoma Stool Sample Group|Stool collection methods may differ depending on the patient. The aim is to collect fresh stool samples, those that are available will be collected during the study visit. If a patient is unable to give a sample at the visit, samples may be collected at home using the OMNIgene-GUT and OMNImet-GUT kits (DNA Genotek, Inc.).
89361241|NCT05834023|Active Comparator|Bupivacaine 0.25% plus Lidocaine 1%|Infraclavicular block with Bupivacaine and Lidocaine
89361242|NCT05834023|Experimental|Bupivacaine 0.5%|Infraclavicular block with Bupivacaine
89361243|NCT05832437|Experimental|BREATHE-Peds intervention|The patient's primary care provider (PCP) will deliver a brief intervention using motivational interviewing and shared decision making, in a one time 9-minute intervention integrated into an office visit for asthma. PCPs will follow a 4-step script tailored to erroneous asthma and inhaled corticosteroid (ICS) beliefs, as well as ACQ score, measured just prior to the office visit. PCPs will follow a 4-step script tailored to erroneous asthma and inhaled corticosteroid (ICS) beliefs, as well as ACQ score, measured just prior to the office visit.
89361244|NCT05832437|Active Comparator|Control Intervention|The patient's primary care provider (PCP) will deliver a 9-minute scripted intervention on credible nutrition and lifestyle information. The control intervention is designed to not be specific enough to change strategies related to asthma control.
89361245|NCT05826015|Experimental|Paclitaxel + AVB-500|Patients will receive up to 9 21-day cycles of paclitaxel + AVB-500. Patients will receive AVB-500 via intravenous (IV) infusion at the assigned dose level on days 1, 8, and 15 of each cycle. Patients will receive IV paclitaxel at a dose of 175 mg/m^2 on day 1 of each cycle. After 3 cycles, patients will be assessed for disease response. Patients who have progression will not continue on treatment. Patients who have a partial response or stable disease will continue on treatment for another 3 cycles of paclitaxel + AVB-500 at the assigned dose. Patients will be assessed for response again at the end of 6 cycles and may continue on treatment if they have partial response (PR) or stable disease (SD). Up to 9 cycles of treatment with paclitaxel + AVB-500 may be given. At the end of the 9 cycles, patients with a SD or PR can continue on maintenance AVB-500 until progression. Patients with complete response will continue single agent AVB-500 as maintenance therapy until progression.
89361246|NCT05821231|Experimental|Patients with metastatic soft tissue sarcoma with lung metastases|
89361247|NCT05819892|Experimental|Adjuvant Therapy During Radiation|Participants will receive an active treatment for 6 cycles. Participants will be on maintenance for 14 cycles, as long as the disease does not get worse. Follow-up will then occur every 6 months for 5 years (from your enrollment date).
88832754|NCT05993871||Patients with diabetic mixed small and large fiber neuropathy|Diabetic Patients presented with mixed small and large fiber neuropathy
88832755|NCT05993871||Subjects without neuropathy|Healthy subjects without any symptoms and/or signs suggesting neuropathy, and within average IENFD on skin biopsy.
88832756|NCT05993858|Other|Neoadjuvant therapy+Surgery+Adjuvant therapy+Consolidation therapy|Participants receive totally 3 cycles of neoadjuvant therapy (Toripalimab+cetuximab), then radical treatment(surgery). After surgery, Participants receive radiotherapy or chemoradiotherapy according to the pathological results of the operation. Then, participants receive consolidation therapy of Toripalimab.
88832757|NCT05993819|Experimental|pilates based core stability training and congnitive therapy|the patients will receive pilates and cognitive therapy three times a week for eight weeks
88832758|NCT05993819|Active Comparator|Pilates based core stability training|the patients will receive pilates three times a week for eight weeks
88832759|NCT05993806|Experimental|A (L04RD1 -> L04TD3)|Administration of 1 tablet of L04RD1, and taking 7-day wash-out period, and then administration of 1 tablet of L04TD3
88832760|NCT05993806|Experimental|B (L04TD3 -> L04RD1)|Administration of 1 tablet of L04TD3, and taking 7-day wash-out period, and then administration of 1 tablet of L04RD1
88832761|NCT05993793|Experimental|Fototherapy|
88832762|NCT05993780|Other|ARDS patient|14 patients with ARDS were included in the study. It was planned as a single group.
88832763|NCT05993767|Experimental|dolutegravir (DTG)/emtricitabine (FTC)/tenofovir alafenamide (TAF) regimen|Switch or start dolutegravir (DTG)/emtricitabine (FTC)/tenofovir alafenamide (TAF) regimen with a novel dose ratio for HIV treatment
88832764|NCT05993741|Experimental|AR group (EG-AR)|Behavioral: AR intervention For the EG-AR, the AR dental care training system will give to patients that 2 to 3 times tooth clean skill learning course (including Bass method of brushing and inter-dental toothbrush brushing technique) during non-surgical periodontal treatment period.
89361248|NCT05819892|Experimental|Adjuvant Therapy After Radiation|Participants will receive an active treatment for 6 cycles. Participants will be on maintenance for 14 cycles, as long as the disease does not get worse. Follow-up will then occur every 6 months for 5 years (from your enrollment date).
89361249|NCT05819892|Experimental|Immunotherapy after Radiation and Chemo|Participants will receive an active treatment for 6 cycles. Participants will be on maintenance for 14 cycles, as long as the disease does not get worse. Follow-up will then occur every 6 months for 5 years (from your enrollment date).
89361250|NCT05816889||Patients|"Upper extremity exercise capacity (6 minutes pegboard and ring test), muscle oxygenation (moxy monitor), functional exercise capacity(6 minutes walk test), respiratory functions (spirometer), respiratory muscle strength (mouth pressure measurement), respiratory muscle endurance (incremental threshold loading test), peripheral muscle strength (dynamometer), physical activity level (multi-sensor activity monitor) and fatigue (Parkinson's fatigue scale) will be evaluated."
89361251|NCT05816889||Healthy Controls|"Upper extremity exercise capacity (6 minutes pegboard and ring test), muscle oxygenation (moxy monitor), functional exercise capacity(6 minutes walk test), respiratory functions (spirometer), respiratory muscle strength (mouth pressure measurement), respiratory muscle endurance (incremental threshold loading test), peripheral muscle strength (dynamometer), physical activity level (multi-sensor activity monitor) and fatigue (Parkinson's fatigue scale) will be evaluated."
89361252|NCT05812131|Experimental|COPEWEb|online COPEWeb training
89361253|NCT05812131|Active Comparator|COPE In person|COPE training delivered in person
89361254|NCT05808153|Experimental|Symptomatic (MH) and pre-symptomatic (preMH) patients|"Number of GAC ≥ 40~GAP score ≥ 250~10 ≤ TFC ≤ 13~TMS >5 if TFC=13~Diagnostic confidence level =4~Age onset of the disease > 20 years~Patients in physical capacity to sign the consent"
89361255|NCT05808153|Active Comparator|Age-matched controls (healthy volunteers)|"TFC functional UHDRS score = 13~TMS engine UHDRS rating < 6"
89361256|NCT05803564|Experimental|Intervention arm|
89361257|NCT05802719|Experimental|rheumatoid arthritis patient|patient with an active Rheumatoid arthritis and an indication to start an anti-TNFa treatment
89361258|NCT05801978|Experimental|YF-17D Vaccination|Yellow Fever Vaccine (YF-17D) vaccination: Eligible participants will be asked to read the Vaccine Information Sheet for YF-17D per the Centers for Disease Control and Prevention (CDC) guidelines. Participants will then receive the YF-17D vaccine. They will be observed for a minimum of 20 minutes for any immediate hypersensitivity reactions. They will also be given the International Certificate of Vaccination documenting receipt of YF-17D.
89361259|NCT05801978|Experimental|QIV Vaccination|Quadrivalent seasonal influenza vaccine (QIV) vaccination: Eligible participants will be asked to read the Vaccine Information Sheet for QIV per the CDC guidelines. Participants will then receive QIV. They will be observed for a minimum of 20 minutes for any immediate hypersensitivity reactions.
89361260|NCT05801146|Experimental|Botulinum toxin type A(HG102)|
89361261|NCT05801146|Active Comparator|Botulinum toxin type A(Botox®)|
89361262|NCT05796765|Experimental|Micronized DHACM 40 mg|Injection of 40 mg allogeneic micronized dehydrated human amnion chorion membrane (DHACM) suspended in 2.5 mL, 0.9% Sodium Chloride, USP
89361263|NCT05796765|Experimental|Micronized DHACM 100 mg|Injection of 100 mg allogeneic micronized dehydrated human amnion chorion membrane (DHACM) suspended in 2.5 mL, 0.9% Sodium Chloride, USP
89361264|NCT05796765|Placebo Comparator|Saline|Injection of 2.5 ml, 0.9% Sodium Chloride, USP
89361265|NCT05795166||People with obesity|Patients with obesity coming into the clinic as part of routine visit to their treating physician/general practitioner
89361266|NCT05791981|Experimental|Harmony & Health Intervention (Group 1)|Participants randomized to the Harmony and Health intervention group will attend group-based in-person intervention sessions at FOP or COGIC. on.
89361267|NCT05791981|Experimental|Attention Control (Group 2)|Participants randomized to the attention control condition will participate in in-person group-based health education sessions twice a week for 8 weeks with a trained interventionist and will receive 4 monthly newsletters (20 total contacts).
89361268|NCT05791591|Experimental|NUV001 - IR|Sickle cell disease patients receiving NUV001 Immediate release gel capsule formulation
89361269|NCT05791591|Experimental|NUV001 - GR|Sickle cell disease patients receiving NUV001 Gastro resistant gel capsule formulation
89361270|NCT05791591|Placebo Comparator|Placebo|Sickle cell disease patients receiving Placebo
89361271|NCT05789355|Experimental|NUV001|Daily supplementation with NUV001 1000 mg
89361272|NCT05786417|Experimental|Beta-Blockers (BB) Therapy|Participants randomized to this arm will be given a beta-blocker. Specific and appropriate drug selection from the class of beta blockers (i.e. type of BB, dosing, and escalation of dose) will be left to the site clinician in accordance with clinical guidelines. All BB will be administered orally (i.e. pills).
89361273|NCT05786417|Experimental|Calcium Channel Blockers (CCB) Therapy|Participants randomized to this arm will be given a calcium channel blocker. Specific and appropriate drug selection from the class of calcium channel blockers (i.e. type of CCB, dosing, and escalation of dose) will be left to the site clinician in accordance with clinical guidelines. All CCB will be administered orally (i.e. pills).
89361274|NCT05784415||Observational|Clinical information on participants, who carry a diagnosis of HIV disease AND received CAR19 therapy outside of a clinical trial between August 30, 2017 and August 31, 2021 will be captured
89361275|NCT05780801|Experimental|Live microbiome therapeutic|Live microbiome therapeutic prepared as Allogeneic Microbiota in Glycerol (10%) (AMG)
89361276|NCT05779969||Chest CT scan Patient|Identification of structural damage to the manubriosternal joint (MST) in a population of patients with radiographic axSpA
89361277|NCT05779969||Chest CT scan Control|Identification of structural damage to the manubriosternal joint (MST) in a control population free of chronic inflammatory rheumatism on chest CT.
89361278|NCT05775939|Experimental|Diagnostic (sarcoidosis FDG PET-CT)|Patients undergo sarcoidosis FDG PET-CT of the heart before, during and, after radiotherapy.
89361279|NCT05773105|Experimental|Cadonilimab+regorafenib|
89001059|NCT04632082|Active Comparator|Comparator: Telepsychoeducation without personalized videos|One psychoeducation session administered by a therapist by video call, with interventions focused on promoting protective factors and reducing common risk factors for psychopathology.
89361280|NCT05766657|Experimental|Intervention group|Children with obesity or T1D will be randomized into this group. An individualized dietary approach will be used in this group of children.
89361281|NCT05766657|Placebo Comparator|Control Group|children assigned to the control group will receive generic advice based on European dietary guidelines for obesity or follow their usual diet in the case of children with T1D.
89361282|NCT05763342|Experimental|Adult Cochlear Implant|Adult cochlear implant recipients receiving different focused multipolar maps that are programmed using either behavioural or objective methods
89361283|NCT05757193|Experimental|Ketone ester|All patients will receive ketone ester as (R)-3-hydroxybutyl (R)-3-hydroxybutyrate. This will begin at 250 mg/kg for 10 participants (5 who are on SGLT2i and 5 who are not on SGLT2i) and then dose escalation to 500 mg/kg in 10 subsequent participants (5 who are on SGLT2i and 5 who are not on SGLT2i).
89361284|NCT05757037|Experimental|Laser acupuncture group|The participants in this group will receive low level laser therapy 3 times weekly for 4 weeks. A diode laser emitter with a 650 nm wavelength, an average power of 30 mW, and a 0.15 cm2 spot size, with continuous wave, and exposure of 90 s per acupuncture point had been used in the current study at each of the following acupoints: : ST25, ST37 , LI11 , BL60 , and BL25 Also, participants will recieve received behavioral therapy advice: Sitting on the toilet for 10-15 min after breakfast and after dinner and maintaining the same bathroom schedule every day, sitting in the correct position on the toilet (leaning forward while resting forearms on thighs, raising both feet on a small block (like a step stool) with feet apart, relax and lower the shoulders, and do not suppress urges to defecate and relax stomach muscles). Dietary modifications include a high-fiber diet, fruits, vegetables, whole grain, dairy, and wheat
89361285|NCT05757037|Sham Comparator|Sham laser acupuncture|"The participants in the control group will receive sham laser acupuncture treatment, without any laser output. The participants are unable to recognize whether they are being treated or not because laser acupuncture is a low-intensity and non-thermal laser irradiation.~Also, participants will receive behavioral therapy advice."
89361286|NCT05756491|Experimental|Experimental: Group1|In group 1: 5 centers will be randomized for the inclusion of unaccompanied patients for 24 months
89361287|NCT05756491|Experimental|Experimental: Group2|In group 2: 5 other centers will be randomized for the inclusion of unaccompanied patients for 18 months
89361288|NCT05756491|Experimental|Experimental: Group3|In group 3: 5 other centers will be randomized for the inclusion of unaccompanied patients for 12 months
89361289|NCT05756491|Experimental|Experimental: Group4|In group 4: 5 other centers will be randomized for the inclusion of unaccompanied patients for 6 months
89361290|NCT05748990|Experimental|Schizophrenia Group|Insulin (160IU) or placebo is administered intranasally 15 minutes prior to the PET scan.
89361291|NCT05748990|Experimental|Healthy Control Group|Insulin (160 IU) or placebo is administered intranasally 15 minutes prior to the PET scan.
89361292|NCT05746624|Experimental|Arm 1 Long COVID left handed|Long COVID left handed
89361293|NCT05746624|Experimental|Arm 1 Long COVID right handed|Long COVID right handed
88832765|NCT05993741|Experimental|AR-health consulting group (EG-ARHC)|"AR intervention For the EG-B, the ARHC dental care training system will give to patients that 2 to 3 times tooth clean skill learning course (including Bass method of brushing and inter-dental toothbrush brushing technique) during non-surgical periodontal treatment period.~The health counseling will also provide professional oral health related courses (including oral care for diabetes and periodontal disease, etc.)"
88832766|NCT05993741|No Intervention|Control group (CG)|the control group(CG) only have standard oral hygiene education
88832767|NCT05993715|Experimental|Nitrate supplementation|2 × 70 mL/day shots of concentrate nitrae-rich (~12.8 mmol/day NO3-) beetroot juice. Two shots were supplemented for 5 days; one each morning (~9 am) and one each evening (~9 pm) except for the day of the experimental trial when both shots were taken together 2.5 h before the experimental trial.
88832768|NCT05993715|Placebo Comparator|Placebo supplementation|2 × 70 mL/day shots of concentrate nitrate-depleted (~0.08 mmol/day NO3-) beetroot juice. Two shots were supplemented for 5 days; one each morning (~9 am) and one each evening (~9 pm) except for the day of the experimental trial when both shots were taken together 2.5 h before the experimental trial.
88832769|NCT05993702||TAS-102 in combination with regorafenib|(TAS102): Trifluridine tepipiridine tablets 35 mg/m2 twice a day, D1-5, D15-D19, 28 days as a cycle; (TKI: regorafenib: regorafenib capsules administered at a dose of 80 mg (2 tablets, each containing 40 mg regorafenib) once daily for a 28-day cycle)
89361294|NCT05746624|Experimental|Arm 2 Healthy Controls left handed|healthy left handed
89361295|NCT05746624|Experimental|Arm 2 Healthy Controls right handed|healthy right handed
89361296|NCT05746091|Experimental|Arthroscopic partial Trapezictomy With Hematoma Distraction|
89361297|NCT05744479|Experimental|Metformin (Oral)|50 participants will be administered oral metformin titrated to a maximum dose of 2000mg/day for 24 weeks.
89361298|NCT05744479|Placebo Comparator|Placebo|50 participants will be administered an identical oral placebo for 24 weeks.
89361299|NCT05743621|Experimental|TVB-2640 in combination with Enzalutamide|
89361300|NCT05740462|Experimental|Dietary app 1|Dietary app recommends high iron or iron-focused recipes
89361301|NCT05740462|Sham Comparator|Dietary app 2|Dietary app recommends standard iron recipes
89361302|NCT05740462|Experimental|Hydroponic unit 1|Growing vitamin B12 biofortified plants in a hydroponic unit and will be randomised to dietary app 1 or 2
89361303|NCT05740462|No Intervention|Hydroponic unit 2|No hydroponic unit be given to participants and will be randomised to dietary app 1 or 2
89361304|NCT05739032|Experimental|Exercise group|Exercise group received aerobic exercise (30-min walking) and upper and lower extremity strength training for 12 weeks for 3 days/week.
89361305|NCT05739032|No Intervention|Control group|Control group continued only routine follow-up.
89361306|NCT05731882|Experimental|Catheter ablation+E-SeaLATM|
89361307|NCT05729568|Experimental|Randomized Phase: Lenacapavir (LEN) + Teropavimab Dose A + Zinlirvimab Dose B|Participants will receive oral LEN 600mg, subcutaneous (SC) LEN 927 mg, teropavimab Dose A, and zinlirvimab Dose B on Day 1. Participants will self-administer oral LEN 600 mg on Day 2. The last treatment regimen will include SC LEN + teropavimab Dose A + zinlirvimab Dose B.
89361308|NCT05729568|Experimental|Randomized Phase: Antiretroviral Therapy (ART)|Participants will continue their baseline oral ART through Week 52.
88832770|NCT05993702||TAS-102 in combination with fruquintinib|TAS102: Trifluridine tepipiridine tablets 35 mg/m2 twice a day, D1-5, D15-D19, 28 days as a cycle; Fruquintinib: a dose of 3mg/dose administered orally once daily, continuously for 28 days as a cycle.
88832771|NCT05993676|Sham Comparator|Control|The control group received an app containing only signposting information about a range of statutory and third sector organisations that focused on veterans' mental health.
89534480|NCT03336047|Experimental|using personal activity intelligence|Subjects will be encouraged to obtain 100 PAI points per week, monitored by Mio Slice and the Mio Pai 2.0 smart phone application
88832772|NCT05993676|Active Comparator|Intervention|"The intervention group will receive a 'full' version of the app over the 1month trial period. The app consists of five core elements:~Personas developed as an aide to the provision of psycho-education on how mental health difficulties might look in real life and to help participants identify symptoms of mental health difficulties in themselves.~Daily life goals employing behavioural activation principles to encourage users to set a series of small tasks to help them achieve larger goals in different areas of their life e.g. work, family, physical health.~Self-help tools to provide participants with a range of resources that they can use independently to help them manage symptoms of mental ill-health they may be experiencing.~Tracking tools to allow users to monitor their own mental health and to see their progress across the elements of the app.~A schedule of daily notifications to encourage participants to continue to engage with the app."
88832773|NCT05993663|Experimental|Intervention group|Intervention groups that will receive 12 Arts in Health session. There will be four groups of 15 individuals for reaching the needed sample size.
88832774|NCT05993663|No Intervention|Control group|Control groups. Participants in these groups won't receive any group intervention, just regular health care.
88832775|NCT05993650|Experimental|Training Group|The individuals in the training group will be performed inspiratory muscle training using an inspiratory muscle training device (PowerBreathe®) at 30-50% of the maximal inspiratory pressure.
88832776|NCT05993650|Sham Comparator|Control Group|Individuals in this group will be given thoracic expansion exercises and patient education.
88832777|NCT05993637||High Tibial Osteotomy|patients who were diagnosed with medial gonarthrosis and underwent HTO surgery
88832778|NCT05993637||Unicompartmantal Knee Arthroplasty|patients who were diagnosed with medial gonarthrosis and underwent UKA surgery
88832779|NCT05993624|Other|Rehabilitation Group|Participants in the study played 30-minute exergame games once a week for 8 weeks and rehabilitation was applied. Before starting the application, the participants were given a demographic information form, Tampa kinesiophobia scale for kinesiophobia, BeCure balance assessment system for balance measurement, geriatric depression scale-short form for depression, mini-mental state test for cognitive functions, and lower extremity functional strength. and 5 times the risk of falling. lifting test was performed. These tests were repeated at the end of 8 sessions and before and after values were measured.
88832780|NCT05993598|Experimental|Group 1 (Saddled)|Each group did a 30-minute hippotherapy session in the manege area. Before the application, the sitting balance of the children was evaluated by playing the Nintendo Wii Balance Platform and the Basic Balance Game. In addition, 10 m walking test was applied for walking speed. These assessments were repeated after the 30-minute session.
88832781|NCT05993598|Experimental|Group 2 (Saddleless, direct contact with horse)|Each group did a 30-minute hippotherapy session in the manege area. Before the application, the sitting balance of the children was evaluated by playing the Nintendo Wii Balance Platform and the Basic Balance Game. In addition, 10 m walking test was applied for walking speed. These assessments were repeated after the 30-minute session.
88832782|NCT05993598|Experimental|Group 3 (Different tissue to be put on the saddle)|Bubbled nylon (pat-to-pat) was used as a different texture. Each group did a 30-minute hippotherapy session in the manege area. Before the application, the sitting balance of the children was evaluated by playing the Nintendo Wii Balance Platform and the Basic Balance Game. In addition, 10 m walking test was applied for walking speed. These assessments were repeated after the 30-minute session.
89178072|NCT00624286|Placebo Comparator|Placebo to indacaterol|Patients inhaled placebo to indacaterol once daily in the morning between 8:00 AM and 11:00 AM via a single-dose dry-powder inhaler (SDDPI) for 12 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
89178073|NCT00823420|Experimental|in-vitro maturation of oocytes|
88832785|NCT05993455|Experimental|Oral sotorasib + IV Panitumumab|Oral sotorasib at a dose of 960 mg once daily with Panitumumab is administered intravenously (IV) at a dose of 6 mg/kg every 14 days, infused over 60 minutes (≤ 1,000 mg) or 90 minutes (> 1,000 mg).
88832786|NCT05993403|Experimental|Intercultural Sensitivity Education|Data collection tools were applied to this group before the research. A training program consisting of three sessions was applied to the intervention group. Each training session lasted an average of 90-100 minutes. Various methods and techniques were used in the trainings.
88832787|NCT05993403|No Intervention|Control|Data collection tools were applied to this group before the research. No intervention was applied to this group.
88832788|NCT05993312||A bras actif|
88832789|NCT05993299|Experimental|Letetresgene autoleucel|
88832790|NCT05993286|Other|Psychoeducation|This was an active control group and included information on the proposed mechanism of the development of misophonia, how symptoms are reinforced, and basic coping skills.
88832791|NCT05993286|Experimental|Exposure Therapy and Psychoeducation|Exposure has been successfully used in the treatment of anxiety disorders, phobias, and obsessions. There are also case reports showing its effectiveness in the treatment of misophonia. The proposed procedure is to expose the misophonic person to the triggering sound in a controlled and gradual manner until habituation/desensitization to the trigger occurs. In the current research setting, each participant was asked to choose the two misophonic sounds that are most disturbing.
88832792|NCT05993286|Active Comparator|Sound Therapy and Psychoeducation|The music used in the current study was adapted from the protocol used by Jastreboff and Jastreboff (2013) for the treatment of misophonia. It includes noises such as white (noise with equal volume in all octaves) or pink noise (noise that decreases by 3 dB per octave towards high frequencies) or relaxing instrumental music
89178074|NCT00820768|Experimental|ABI-010|
89178075|NCT00821080|Experimental|Vandetanib and Sirolimus|Single arm study
89178076|NCT00828490||Pediatric Asthmatics|Medicaid beneficiaries ≤21 years of age who meet the HEDIS criteria for persistent asthma
89178077|NCT00828490||Antipsychotic Therapy|Medicaid beneficiaries ≥18 years of age and enrolled ≥6 months of the past 12 months with enrollment in at least one of the past 3 months and ≥3 antipsychotic Rx within past 12 months
88816867|NCT04741984|Experimental|MT-201-GBM monocyte vaccine|pp65 monocyte vaccines (MT-201-GBM) - cohorts of patients will receive increasing doses (dose escalation) of MT-201-GBM followed by a dose expansion cohort at the maximum tolerated dose. Patients will receive a total of 3 intravenous vaccines every 4 weeks after completing standard radiation therapy (XRT) and temozolomide (TMZ) and a single course of dose-intensified TMZ.
88816868|NCT04739722|Experimental|Colosense Test|All participants will be evaluated with the Colosense Test system and a colonoscopy.
88816869|NCT04736550|Experimental|Assisted Exercise and I-STOP|Participant will receive Assisted Exercise (stationary cycling) and psychotherapy for pain (I-STOP). Exercise (supervised) will be offered 3 days/week. I-STOP will be offered 1 day/week.
89178078|NCT00828490||Bipolar Therapy|Medicaid beneficiaries ≥18 years of age and enrolled ≥6 months of the past 12 months with enrollment in at least one of the past 3 months and a diagnosis of Bipolar in past 3 years, and ≥ 1 antidepressant Rx in past 6 months, and no mood stabilizer in past 6 months.
88816870|NCT04736550|Experimental|Voluntary Exercise and I-STOP|Participant will receive Voluntary Rate Exercise (stationary cycling) and psychotherapy for pain (I-STOP). Exercise (supervised) will be offered 3 days/week. I-STOP will be offered 1 day/week.
88816871|NCT04736550|Experimental|No Exercise (TAU) and I-STOP|Participant will receive psychotherapy for pain (I-STOP). I-STOP will be offered 1 day/week.
88816872|NCT04736550|Experimental|Assisted Exercise and No I-STOP (TAU)|Participant will receive Assisted Exercise (stationary cycling). Exercise (supervised) will be offered 3 days/week.
88816873|NCT04736550|Experimental|Voluntary Exercise and No I-STOP (TAU)|Participant will receive Voluntary Rate Exercise (stationary cycling). Exercise (supervised) will be offered 3 days/week.
88816874|NCT04736550|No Intervention|No Exercise (TAU) and No I-STOP (TAU)|Participant will receive their usual behavioral treatment offered at the residential drug treatment center and their medicated assisted treatment (MAT) as applicable.
88816875|NCT04731779|Placebo Comparator|Placebo|Participants will ingest 3ml of non-CBD containing MCT (medium-chain triglycerides) oil.
88816876|NCT04731779|Experimental|25 mg|Participants will ingest 3ml of MCT (medium-chain triglycerides) oil containing 25 mg of CBD.
88816877|NCT04731779|Experimental|50 mg|Participants will ingest 3ml of MCT (medium-chain triglycerides) oil containing 50 mg of CBD.
88816878|NCT04731779|Experimental|200 mg|Participants will ingest 3ml of MCT (medium-chain triglycerides) oil containing 200 mg of CBD.
88816879|NCT04719000|Experimental|rhFSH+rhLH|Ovarian Stimulation with rhFSH+rhLH
88816880|NCT04719000|Active Comparator|rhFSH|Ovarian Stimulation with rhFSH
88816881|NCT04715568|Experimental|Placebo then Losartan|Placebo tablets will be administered for the first 4 weeks followed by a washout period of 2 weeks. After the washout period has been completed, losartan tablets will be administered for the next 4 weeks.
88816882|NCT04715568|Experimental|Losartan then Placebo|Losartan tablets will be administered for the first 4 weeks followed by a washout period of 2 weeks. After the washout period has been completed, placebo tablets will be administered for the next 4 weeks.
88816883|NCT04708548||Oligodendroglioma (Grade II and III) Patients|Patients diagnosed with a WHO Grade II or III Oligodendroglioma
88816884|NCT04702035|Experimental|iNPH patients|20 patients with completed diagnostics concerning NPH, in which the indication for implantation of a VP shunt for NPH treatment was found by the responsible surgeon independently from the study.
88816885|NCT04702035|Active Comparator|Healthy volunteers|20 volunteers, matched with group 1 concerning sex and age.
88816886|NCT04702035|Active Comparator|Young healthy volunteers|20 volunteers, matched with group 1 concerning sex only and between 18 and 40 years old.
88816887|NCT04676711|Experimental|GFH312|
88816888|NCT04676711|Placebo Comparator|Placebo|
88816889|NCT04675216||Posterior fossa lesion|This group will be integrated by patients with posterior fossa lesion that likely to rise the posterior fossa intracranial pressure
88816890|NCT04675216||Post-operative posterior fosa surgical patients|This group will be integrated by patients operated for posterior fossa lesions in which we will try to find out what range of posterior fossa pressure is to be expected in this situation
88816891|NCT04671732||Fenestrated endovascular aortic aneurysm repair (FEVAR)|
88816892|NCT04671732||Open repair (OR)|
88816893|NCT04667221|Experimental|Anodal transcranial direct current stimulation|Patients will be bilaterally stimulated with anodal tDCS at the parietal cortex (Brodmann Area 7).
88816894|NCT04667221|Experimental|Cathodal transcranial direct current stimulation|Patients will be bilaterally stimulated with cathodal tDCS at the parietal cortex (Brodmann Area 7).
88816895|NCT04667221|Sham Comparator|Sham transcranial direct current stimulation for anodal group|Patients will be bilaterally stimulated with sham tDCS at the parietal cortex (Brodmann Area 7). As a consequence of the crossover design, both experimental arms receive sham stimulation.
88816896|NCT04667221|Sham Comparator|Sham transcranial direct current stimulation for cathodal group|Patients will be bilaterally stimulated with sham tDCS at the parietal cortex (Brodmann Area 7). As a consequence of the crossover design, both experimental arms receive sham stimulation.
88816897|NCT04660175|Experimental|Non-resistance therapy|From the 2nd to 5th day of hospitalization, once a day, 4 times of non-resistance therapy is administered. And non-resistance therapy group is also treated with other Korean integrative medicine treatment everyday: acupuncture, chuna, pharmacoacupuncture and Korean herbal medicine.
89361309|NCT05729568|Experimental|Extension Phase: LEN + Teropavimab Dose A + Zinlirvimab Dose B|At Week 52, participants who receive the study drug of LEN, teropavimab, zinlirvimab, and complete study through Week 52 with human immunodeficiency virus type 1 (HIV-1) ribonucleic acid (RNA) < 50 copies/mL will be given the option to participate in the study extension phase, where they will continue to receive their randomized study drugs treatment regimen until after completion of the primary analysis (unless modified based on the data monitoring committee (DMC) analysis), up to approximately 5 years.
89001060|NCT04632160|Experimental|Treatment|Treatment arm will undergo a fluoroscopically and intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE) guided trans-septal puncture and IASD System II implant procedure.
89361310|NCT05729568|Experimental|Extension Phase: ART|Participants who complete study through Week 52 with HIV-1 RNA < 50 copies/mL and in the absence of confirmed virologic rebound (VR) throughout the randomized phase of the study will be given the option to participate in the extension phase and receive the study drugs of LEN, teropavimab, and zinlirvimab at the dose specified for randomized phase until after completion of the primary analysis (unless modified based on the data monitoring committee (DMC) analysis), up to approximately 5 years. Treatment with study drug will begin at Week 52 and at that time the baseline oral ART will be discontinued.
89361311|NCT05727761|Experimental|oral leukoplakia patients|36 total high risk oral leukoplakia patients.
89361312|NCT05724901||Adults with MS|Participants will complete an in-clinic visit (self-reported outcome of MS disability, a standard walking clinical evaluation, and a sensor-based gait evaluation) and 3 remote supervised self-administered gait assessments using the MS-GRCA system.
88816898|NCT04660175|Active Comparator|Oriental medicine integrated treatment|The control group is received Korean integrative medicine treatment everyday; acupuncture, chuna, pharmacoacupuncture and Korean herbal medicine.
88816899|NCT04658849|Experimental|Pioglitazone Arm|"Subjects will self-administer a 30 mg pioglitazone oral tablet daily for 6 months.~For patient taking a diabetic regimen of gemfibrozil, the dose will be 15 mg daily."
88816900|NCT04658849|Placebo Comparator|Placebo Arm|Subjects will self-administer an oral placebo tablet containing cellulose daily for 6 months.
88816901|NCT04656795|Experimental|Subjects with severe renal impairment|
88816902|NCT04656795|Experimental|Subjects with normal renal function|
88816903|NCT04656795|Experimental|Subjects with moderate renal impairment|
88816904|NCT04656795|Experimental|Subjects with mild renal impairment|
88816905|NCT04616313||c-cigarette never users|Includes 70 participants who are e-cigarette users who have never smoked combustible cigarettes.
88816906|NCT04616313||former or current c-cigarette users|Includes 70 participants who are e-cigarette users who are also former or current combustible cigarette smokers.
88816907|NCT04616313||never smokers|Includes 10 participants who have never smoked e-cigarettes or combustible cigarettes.
88816908|NCT04604834|Experimental|PFAT first|1 eyedrop of PFAT every 2 hours in study eye.
88816909|NCT04604834|Experimental|APRP first|1 eyedrop of APRP every 2 hours in study eye.
88816910|NCT04604834|Experimental|APRP+PFAT first|1 eyedrop of PFAT and APRP every 2 hours in study eye.
88816911|NCT04601974|Experimental|lentiviral gene therapy treatment (Intervention Arm)|Patients will receive a single dose of lentiviral gene therapy treatment administered once intracranially
88816912|NCT04599309||PRE-MERIDIAN|Patients with a histological or cytological diagnosis of LA-HNSCC of the oral cavity, oropharynx, hypopharynx, and larynx (stage III HPV positive or stage III-IV HPV negative). Patients who are candidates for standard definitive treatment such as surgery followed by radiotherapy +/- chemotherapy, or definite radiotherapy, or definite chemoradiotherapy.
88816913|NCT04577404|Experimental|MT-1186|Oral Edaravone administered once daily for 10 days out of 14, followed by a 14-day drug- free period
88816914|NCT04565054|Experimental|Abemaciclib plus ET|Abemaciclib 150 mg, 2 x daily, resulting in 300 mg/day, oral, 24 months plus endocrine treatment of physician´s choice
88816915|NCT04565054|No Intervention|Standard-of-care ET|"Standard-of-care ET according to clinical guidelines.~Pre-/perimenopausal patients:~Either aromatase inhibitor + GnRH agonist~or Tamoxifen +/- GnRH-agonist (as per investigator´s decision) or~Postmenopausal patients:~Either Aromatase inhibitor~or Tamoxifen OR"
88816916|NCT04560036|Other|FAZA PET/MRI scan|FAZA PET/MRI scan before and after the standard of care chemotherapy
88816917|NCT04552899|Experimental|PRM-151|Participants will receive intravenous (IV) infusions of PRM-151 over 50-70 minutes on Days 1, 3 and 5, then followed by infusions every 4 weeks (Q4W) to Week 48.
88816918|NCT04552899|Placebo Comparator|Placebo|Participants will receive IV infusions of placebo over 50-70 minutes on Days 1, 3 and 5, followed by infusions Q4W to Week 48.
88816919|NCT04479358|Active Comparator|Sub-study A, Tocilizumab-Free Standard of Care|Patient assigned to Sub-study A by primary treating physicians. Patient enrolled on trial sub-study A and randomized to receive no tocilizumab.
88816920|NCT04479358|Experimental|Sub-study A, Tocilizumab 40mg|Patient assigned to Sub-study A by primary treating physicians. Patient enrolled on trial sub-study A and randomized to receive tocilizumab 40mg.
88816921|NCT04479358|Experimental|Sub-study A, Tocilizumab 120mg|Patient assigned to Sub-study A by primary treating physicians. Patient enrolled on trial sub-study A and randomized to receive tocilizumab 120mg.
88816922|NCT04479358|Active Comparator|Sub-study B, Tocilizumab 400mg or 8mg/kg Standard of Care|Patient assigned to Sub-study B by primary treating physicians. Patient enrolled on trial sub-study B and randomized to receive standard of care tocilizumab dose (400mg or 8mgkg).
88816923|NCT04479358|Experimental|Sub-study B, Tocilizumab 40mg|Patient assigned to Sub-study B by primary treating physicians. Patient enrolled on trial sub-study B and randomized to receive standard of care tocilizumab 40mg.
88816924|NCT04479358|Experimental|Sub-study B, Tocilizumab 120mg|Patient assigned to Sub-study B by primary treating physicians. Patient enrolled on trial sub-study B and randomized to receive standard of care tocilizumab 120mg.
88816925|NCT04472728|Experimental|BIO101|BIO101 350 mg bid
88816926|NCT04472728|Placebo Comparator|Placebo|Placebo
89361313|NCT05724563|Experimental|Zimberelimab and Domvanalimab|Individual will be given Zimberelimab (AB122) 360 mg IV in a 1 hour infusion + 30 minute rest + Domvanalimab (AB154) 1200 mg IV in a 1 hour infusion every three weeks. Study treatment will continue until disease progression, unacceptable toxicity, death, or discontinuation from the study treatment for any other reason
89361314|NCT05715229|Active Comparator|Arm A|"Arm A - Intervention arm (Immunotherapy and Chemotherapy)~Nivolumab 360 mg/kg every 3 weeks Ipilimumab 1 mg/kg every 6 weeks~Platinum- doublet Chemotherapy (Histology-based) 4 cycles depending on the investigator's discretion.~Carboplatin dosed at AUC 5, and either Paclitaxel 175 mg/m2 for squamous or Pemetrexed 500 mg/m2 for non-squamous"
89361315|NCT05715229|Other|Arm B|"Arm B - control arm (Immunotherapy only)~Nivolumab 360 mg/kg every 3 weeks Ipilimumab 1 mg/kg every 6 weeks"
89361316|NCT05704049|Experimental|Cohort 1: manual administration|Isatuximab will be administered manually for 8 minutes on Day 1 of Cycle 1 followed by 6 minutes from Day 8 of Cycle 1 and thereafter.
88816927|NCT04458883|Experimental|Myocardial Infarction Group|Patients diagnosed with a myocardial infarction
89361317|NCT05704049|Experimental|Part 1 Cohort 2: manual administration|Isatuximab will be administered manually for 6 minutes on Day 1 of Cycle 1 and thereafter.
89361318|NCT05704049|Experimental|Part 2 Randomized Cohort: OBDS to manual|Isatuximab will be administered via OBDS from Cycle 1 to 3. For Cycle 4 to 6, the method of administration will be switched for each participant from OBDS to manual administration.
88816928|NCT04458883|Experimental|Healthy Volunteers|Healthy Volunteers
88816929|NCT04458649||No increased risk of hypoglycemia|Infants born with no obvious risk factors for hypoglycemia in the neonatal period.
88816930|NCT04458649||Increased risk of hypoglycemia|"Infants considered at increased risk for hypoglycemia after birth including the following criteria:~Infant born to a diabetic mother~Very large for gestational age (VLGA) infant with weight >97%"
88816931|NCT04453774|Experimental|Covi19 patients receiving intervention|We will collect self-reported symptoms via a questionnaire, temperature and oxygen saturation will be entered by the patient and passive near continuous sensing of heart rate, audio for cough detection, respiratory rate, cough and physical activity from a smart watch. The smart watch then transmits this sensor data to the paired smartphone.
88816932|NCT04452747|Active Comparator|Dino-first|Labour will be induced by the use of the vaginal Dinoprostone system (Propess®) first.
88816933|NCT04452747|Active Comparator|Balloon-first|Labour will be induced by the use of a cervix dilatation balloon first.
88816934|NCT04446845|Experimental|Double Stimulation (Elonva+rFSH) in luteal /follicular phase|"A first stimulation Stimulation will initiate in the luteal phase of the menstrual cycle On day 21 of the previous cycle150mcg of corifollitropin alfa (Elonva, Merck Sharp & Dohme (MSD), Spain) will be administrated and from day 8 of the stimulation when necessary, r-FSH of 250 IU per day will start until the day of ovulation trigger in a flexible gonadotropin-releasing hormone (GnRH) antagonist protocol. The first ovulation triggering will be induced with GnRH-agonist (triptorelin 0.2 ml). The embryos obtained from the first stimulation will be cryopreserved in a freeze-all approach.~A second stimulation will start on day 2 of bleeding after the first oocyte retrieval.~This time will correspond to a conventional COS where corifollitropin alfa will be administered on the beginning of the follicular phase, in a flexible antagonist protocol, and the second ovulation will be triggered with 250μg of Recombinant Human Chorionic Gonadotropin (rhCG)"
88816935|NCT04446845|Active Comparator|Conventional Stimulation (Elonva+rFSH) in follicular phase|A conventional COS where Corifollitropin alfa will be administered on the beginning of the follicular phase, in a flexible antagonist protocol, and the second ovulation will be triggered with 250μg of rhCG
88816936|NCT04421339|Experimental|Melatonin|
88816937|NCT04421339|Placebo Comparator|Placebo|
88816938|NCT04418076|Experimental|No feedback|For participants in the control group (Group A), no feedback from the TowerView Health® smart pill box or clinical nurse will be given.
88816939|NCT04418076|Experimental|Automated feedback|For participants in Group B (automated feedback), automated feedback will be generated from the TowerView Health® smart pill box and sent to participants' smartphone as text messages.
88816940|NCT04418076|Experimental|Automated feedback + Clinician feedback|For participants in Group C, automated feedback will be generated from the TowerView Health® smart pill box and sent to participants' smartphone as text messages. In addition, clinical nurse will also send personalized feedback and suggestions to the participants in this group.
88816941|NCT04418076|Experimental|Automated feedback + Social Network feedback|For participants in Group D, automated feedback will be generated from the TowerView Health® smart pill box and sent to participants' smartphone as text messages. In addition, a weekly text reminder will be sent to each participant from a social network designee chosen by the participant.
88816942|NCT04381208||Sacroiliac joint pain|Patients diagnosed with sacroiliac joint pain on the basis of history, physical examination and diagnostic sacroiliac joint block
88816943|NCT04381208||Lumbar pain|Patients diagnosed with other chronic lumbar pathologies on the basis of history, physical examination and radiographic studies
88816944|NCT04342572|Experimental|Intra-arterial injections of melphalan|-Participants will receive intra-arterial injections of melphalan Q4W for 3 cycles.
88816945|NCT04327544|Experimental|Frailty Intervention group|A multi-domain intervention program that includes nutrition education and low to moderate multi-component exercise intervention.
88816946|NCT04327544|No Intervention|Control group|Respondents in the control group will not receive any nutritional education or exercise intervention activities.
88816947|NCT04285892|Experimental|CAPA IVM|CAPA IVM is a 2-step In vitro Maturation system in which an additional culture step, in which the oocytes are kept in meiotic arrest by the presence of the C-type Natriuretic peptide (CNP) for 22-24 hours, is preceding the in vitro maturation step in which maturation medium is supplemented with amphiregulin (AREG). The 'IVM System' of Medicult-Origio is used as a base medium.
88816948|NCT04285892|No Intervention|Standard IVM|The IVM is performed as a single step protocol in which oocytes are immediately exposed to in vitro maturation medium for 30 hours. This is the current standard procedure in the clinical practice using the commercially available 'IVM System' of Medicult-Origio. Standard IVM medium: 10% HSA + 75mIU/ml FSH + 100mIU/ml hCG
89361319|NCT05704049|Experimental|Part 2 Randomized Cohort: Manual to OBDS|Isatuximab will be administered manually from Cycle 1 to 3. For Cycle 4 to 6, the method of administration will be switched for each participant from manual to OBDS administration.
89361320|NCT05702814||Group A: GD1 with Low-normal Bone Disease|Participants with GD1 with low-normal bone disease whose samples are available for analysis in BSSA will be collected retrospectively up to approximately 5 years from diagnosis.
89361321|NCT05702814||Group B: GD1 with Mild Bone Disease|Participants with GD1 with mild bone disease whose samples are available for analysis in BSSA will be collected retrospectively up to approximately 5 years from diagnosis.
89361322|NCT05702814||Group C: GD1 with Severe Bone Disease|Participants with GD1 with severe bone disease whose samples are available for analysis in BSSA will be collected retrospectively up to approximately 5 years from diagnosis.
89361323|NCT05702814||Group D: Healthy Participants|Healthy Participants whose samples are available for analysis in BSSA will be collected retrospectively up to approximately 5 years.
89361324|NCT05700929|Experimental|Communication skills training|The intervention is a one-day face-to-face training to foster patient-centered communication skills of nursing professionals at the University Medical Center Hamburg-Eppendorf, Germany. The training is developed based on results of a previously conducted needs assessment with nurses, medical assistants and nursing service managers as well as literature research and will be rolled out after baseline assessment and randomization.
89361325|NCT05700929|No Intervention|Waitlist-control group|Participants of the waitlist-control group receive no specific study related intervention. Participants of this group will be offered a communication skills training after complete data collection of all participants of the RCT has been finished.
89361326|NCT05700006||Age 65+, AI therapy|Postmenopausal women age 65 and older who are starting treatment with standard of care aromatase inhibitor therapy
89361327|NCT05700006||Age 65+, no endocrine therapy|Postmenopausal women age 65 and older who are not starting treatment with any endocrine therapy
89361328|NCT05700006||Age under 65, AI therapy|Postmenopausal women age less than 65 who are starting treatment with standard of care aromatase inhibitor therapy
89361329|NCT05698537||People living with epilepsy (PwE)|Study participants with epilepsy
89361330|NCT05698537||Control subjects|Study participants without epilepsy
89361331|NCT05697146||ribociclib + ET|Women prescribed ribociclib + Endocrine Therapy (ET)
89361332|NCT05695716|Experimental|CSI pVAD System|clinical use of the CSI pVAD System during high risk percutaneous coronary interventions (HR-PCI)
89361333|NCT05686668||AASP|
89361334|NCT05684341|Experimental|Device Intervention arm|Connected Solution with H2S app which connects with blood glucose meter (BGM) to support glycemic control in T2DM participants
89361335|NCT05684341|No Intervention|No Device Control arm|Physician-recommended routine management (usual care) to support glycemic control in T2DM participants
89361336|NCT05683418|Experimental|TOS-358 Single Agent Arm|Multiple doses of TOS-358 for oral administration.
89361337|NCT05682937|Experimental|HFOV-sigh mode|HFOV-sigh setting both SLE6000 and Drager Babylog VN500: setting (Hz, MAP, delta pressure) same as HFOV, set sigh RR 3 breath/min, Sigh Ti = 1 sec, Sigh PIP = (MAP+5, maximum 30) cm H2O, Slope sigh 0.5. No change in Hz, MAP, delta pressure, and increased FiO2 less than 0.1 occurred between intervention.
89361338|NCT05680623||study population|"Subgroups based on the ISGPS diagnostic criteria and the grading system of PPAP:~Without PPAP or POH: Patients without POH nor imaging consistent with AP.~POH: sustained postoperative serum hyperamylasemia neither clinically relevant nor consistent imaging~PPAP: requiring the fulfilment of three criteria:~POH: sustained serum hyperamylasemia greater than the institutional upper limit of normal persisting on postoperative days 1 and 2;~macroscopic radiologic features of AP~clinically relevant complications. PPAP severity will be classified into grades B and C, with progressive clinical deterioration."
89361339|NCT05679635|Other|Study participants|"In intubated patients during CPAP ventilation, a conventional tube adapter (CTA, Ventinova Medical B.V., Eindhoven, The Netherlands) will be connected to the tracheal tube for tracheal pressure measurement. Tracheal pressure measurements will be recorded directly from the respirator Evone (Ventinova Medical B.V., Eindhoven, The Netherlands) three times, as well as the corresponding airway pressure values from the Evita Infinity V500 respirator (Dräger Medical, Lübeck, Germany).~Study related time points:~T1: 10 minutes after insertion of the conventional tube adapter during CPAP without ventilator support T2: 10 minutes after T1 during CPAP with activated automatic tube compensation (ATC) T3: 10 minutes after T2 during CPAP with assisted spontaneous breathing (ASB) of 4 cmH2O"
89361340|NCT05679232|Experimental|Hydrogel coating|cementless revision hip arthroplasty with hydrogel coating applied on orthopaedic implants' surfaces
89361341|NCT05679232|Sham Comparator|Control|cementless revision hip arthroplasty
89361342|NCT05677906|Active Comparator|Walking only (Step It Up!)|A group-based, weekly walking program (Step It Up) where participants walk for up to 45 minutes.
89361343|NCT05677906|Experimental|Combined (Step It Up! plus Change Club)|A group-based, weekly walking program (Step It Up) where participants walk for up to 45 minutes. Participants also spend 30 minutes each week in a civic engagement program (the Change Club) improving walkability in the community
88832793|NCT05993273|Experimental|Epidural|In patients randomized to this Arm, before the induction of general anesthesia, the epidural catheter is placed in the intervertebral space (T4-T5, T5-6 or T6-T7) and used intra and post-operatively for administration of local anesthetics.
88832794|NCT05993273|Experimental|ESP block|In patients randomized to this Arm, after induction of general anesthesia the Erector spinae plane (ESP) block is performed with a catheter introduced and left in place for continuous postoperative infusion of local anesthetics.
88832795|NCT05993273|Experimental|Cryoanalgesia|In patients randomized to this Arm, after induction of general anesthesia and single lung ventilation the first thoracoscopic surgical access is performed. A cryoanesthesia device with a dedicated atraumatic angled-tip cryoprobe is inserted through the thoracoscopic access and the active tip of the probe is positioned in contact with the intercostal nerves from T3 to T8.
88832796|NCT05993260|Active Comparator|Control|"Received the text message You are now eligible for your free NHS Covid-19 vaccine. Please book yours now at [LINK] or by calling 119."
89361344|NCT05675735|Experimental|Cohort 1|6 of the 36 recruited opioid treatment programs (OTPs) will be enrolled in group 1. Group 1 will start the six-month intervention at Baseline and end at Month 6.
88832797|NCT05993260|Experimental|Simple|"Received the text message You can now book your free NHS Covid-19 vaccine. Please book yours now at [LINK] or by calling 119."
88832798|NCT05993260|Experimental|Reserved|"Received the text message Your free NHS Covid-19 vaccine is waiting for you. Please book yours now at [LINK] or by calling 119."
88832799|NCT05993260|Experimental|Top of queue|"Received the text message You've reached the top of the queue and are a priority for getting a free NHS Covid-19 vaccine. Please book yours now at [LINK] or by calling 119."
88832800|NCT05993260|Experimental|Join the millions|"Received the text message You are now eligible for your free NHS Covid-19 vaccine. Join the millions who have already had theirs. Please book yours now at [LINK] or by calling 119."
88832801|NCT05993260|Experimental|Convenience|"Received the text message You are now eligible for your free NHS Covid-19 vaccine. Choose a time and place that suits you. Please book yours now at [LINK] or by calling 119."
88832802|NCT05993260|Experimental|Protection against virus|"Received the text message You are now eligible for your free NHS Covid-19 vaccine. Getting vaccinated is the best protection against coronavirus. Please book yours now at [LINK] or by calling 119."
88832803|NCT05993260|Experimental|Protect you and those close to you|"Received the text message You are now eligible for your free NHS Covid-19 vaccine. Getting the vaccine is the best way to protect yourself and those close to you against coronavirus. Please book yours now at [LINK] or by calling 119."
88832804|NCT05993247|Active Comparator|Probiotics arm|Probiotics combination capsule (Bacillus Subtilis 150 mg /Clostridium Burtyricum Toa 150 mg /Saccharomyces Boulardii 113 mg) per oral, three times a day, for 8 weeks
88832805|NCT05993247|Placebo Comparator|Placebo arm|Placebo capsule in the same form as probiotics, per oral, three times a day, for 8 weeks
88832806|NCT05993195||Conduit Interbody device|The Conduit Titanium Interbody Graft will be compared to the Concorde Bullet Device group for PLIF and TLIF.
88832807|NCT05993195||Concorde Bullet Device|The control group is patients with degenerative spondylotic disease undergoing either one level or two level fusions with Concorde Bullet Device interbody device.
88832808|NCT05993156|Active Comparator|Removable twin block group|participants would receive conventional removable twin block for correction of class II malocclusion for 9 months
88832809|NCT05993156|Experimental|Fixed twin block group|participants would receive a modified fixed twin block for correction of class II malocclusion for 9 months
88832810|NCT05993143|Experimental|Ivermectin (test product)|Ivermectin 9 mg and 18 mg immediate-released tablets to be taken orally once daily during 3 days at 600 µg/kg/day ± 120 µg/kg/day depending on their body weight.
88832811|NCT05993143|Placebo Comparator|Placebo (reference product)|Placebo tablets to be taken orally once daily during 3 days.
88832812|NCT05993065||polycythemia vera|All patients aged 18 years and older who were newly diagnosed to have polycythemia vera between September 2014 and November 2022 at Sohag university hospital, department of internal medicine, hematology unit and hematology outpatient clinic.
88832813|NCT05993065||secondary erythrocytosis|Patients with secondary erythrocytosis will be included as controls and will be recruited from Sohag university hospital especially internal medicine department and chest department. Patients of chronic respiratory failure, congenital heart diseases, polycystic kidney and other causes recruited in this study to be compared to PV group as regards Hematocrit to Hemoglobin Ratio and Red Blood Cell Distribution Width
88832814|NCT05992987||CSU group|Adult patients complaining of chronic spontaneous urticaria (CSU)
88832815|NCT05992987||Control group|A group of age and sex-matched healthy controls (blood donors).
88832816|NCT05992883|Experimental|Non-steroidal anti-inflammatory drug (NSAID)|Patients will proceed to their injection appointment within 4 weeks of their initial evaluation. At the injection appointment, patients will receive an injection containing 1.0 mL of ketorolac 15 mg/mL (15 mg total of ketorolac).
88832817|NCT05992883|Active Comparator|Corticosteroid|Patients will proceed to their injection appointment within 4 weeks of their initial evaluation. At the injection appointment, patients will receive an injection containing 0.5 mL of triamcinolone 40 mg/mL (20 mg total of triamcinolone).
88832818|NCT05992870|Experimental|Neoadjuvant radiotherapy group|Radiotherapy followed by skin-sparing mastectomy and immediate implant-based reconstruction in HBCH
88832820|NCT05992792|Experimental|App Salud Responde|"Subjects register in the Salud Responde (SR) app services de platform"
88832821|NCT05992792|Experimental|SMS Salud Responde|Subjects register in SR SMS services platform
88832822|NCT05992792|Experimental|Internet|Subjects users with internet in their mobile phone
89361345|NCT05675735|Experimental|Cohort 2|6 of the 36 recruited opioid treatment programs (OTPs) will be enrolled in Cohort 2. Cohort 2 will start the six-month intervention at Month 6 and end at Month 12.
89361346|NCT05675735|Experimental|Cohort 3|6 of the 36 recruited opioid treatment programs (OTPs) will be enrolled in Cohort 3. Cohort 3 will start the six-month intervention at Month 12 and end at Month 18.
89361347|NCT05675735|Experimental|Cohort 4|6 of the 36 recruited opioid treatment programs (OTPs) will be enrolled in Cohort 4. Cohort 4 will start the six-month intervention at Month 18 and end at Month 24.
89361348|NCT05675735|Experimental|Cohort 5|6 of the 36 recruited opioid treatment programs (OTPs) will be enrolled in Cohort 5. Cohort 5 will start the six-month intervention at Month 24 and end at Month 30.
89361349|NCT05675735|Experimental|Cohort 6|6 of the 36 recruited opioid treatment programs (OTPs) will be enrolled in Cohort 5. Cohort 5 will start the six-month intervention at Month 30 and end at Month 36.
89361350|NCT05671588|Experimental|Controlled combined program (aerobic-resistant)|Patients randomized into the Experimental arm will undergo controlled exercise on a cycling ergometer in combination with strength training on a multifunctional fitness device for 1-hour duration, twice a week for one month, and once a week for the next month (12 therapies in total).
89361351|NCT05671588|Active Comparator|Conventional rehabilitation|Patients randomized into this study arm will undergo conventional rehabilitation.
89361352|NCT05671588|No Intervention|No intervention|Patients randomized into this study arm will undergo no intervention and will serve as the control group.
89361353|NCT05669599|Experimental|Cohort A: AMG 133|Part 1: Cohort A will consist of participants without a diagnosis of type 1 or type 2 diabetes mellitus. Participants will be randomized to receive AMG 133 or placebo in 1 of 7 dose cohorts. Participants will then have the option to begin part 2 if they meet the entry criteria. Part 2: Participants that continue into part 2 will be re-randomized to receive AMG 133 or Placebo in 1 of 4 dose cohorts.
89361354|NCT05669599|Placebo Comparator|Cohort A: Placebo|Part 1: Cohort A will consist of participants without a diagnosis of type 1 or type 2 diabetes mellitus. Participants will be randomized to receive AMG 133 or placebo in 1 of 7 dose cohorts . Participants will then have the option to begin part 2 if they meet the entry criteria. Part 2: Participants that continue into part 2 will be re-randomized to receive AMG 133 or Placebo in 1 of 4 dose cohorts.
89361355|NCT05669599|Experimental|Cohort B: AMG 133|Part 1: Cohort B will consist of participants with a diagnosis of type 2 diabetes mellitus. Participants will be randomized to receive AMG 133 or placebo in 1 of 4 dose cohorts. Participants will then have the option to begin part 2 if they meet the entry criteria. Part 2: Participants that continue into part 2 will be re-randomized to receive AMG 133 or Placebo in 1 of 4 dose cohorts.
89361356|NCT05669599|Placebo Comparator|Cohort B: Placebo|Part 1: Cohort B will consist of participants with a diagnosis of type 2 diabetes mellitus. Participants will be randomized to receive AMG 133 or placebo in 1 of 4 dose cohorts. Participants will then have the option to begin part 2 if they meet the entry criteria. Part 2: Participants that continue into part 2 will be re-randomized to receive AMG 133 or Placebo in 1 of 4 dose cohorts.
89361357|NCT05667753|Active Comparator|Basic|The MINISTOP app will be offered to all parents of children at the 2.5/3-year routine visit at primary child healthcare. The child healthcare centers randomly allocated to the basic group will receive the basic implementation strategy package.
89361358|NCT05667753|Experimental|Enhanced|The MINISTOP app will be offered to all parents of children at the 2.5/3-year routine visit at primary child healthcare. The child healthcare centers randomly allocated to the enhanced group will receive the enhanced implementation strategy package.
89361359|NCT05666336|Experimental|Experimental Group|"The treatment regimen consists of four drugs, a glucocorticoid plus Telitacicept plus hydroxychloroquine plus an immunosuppressor.~Prednisone(30mg, Qd) or Methylprednisolone(24mg, Qd) plus Telitacicept(160mg, Qw) plus Hydroxychloroquine (0.2g, Qd) plus cyclophosphamide(0.8g, Qm) or Mycophenolate Mofetil (0.5g, Bid) or Tacrolimus (1mg, Bid) The above treatment will continue for 24 weeks."
89361360|NCT05665244||Upper airway cough syndrome|
89534481|NCT05029323|Active Comparator|Conventional HUTT|"All patients with unexplained syncope at initial evaluation with indication to perform a Head up tilt test (HUTT) randomized to conventional HUTT protocol characterized by a stabilization phase of 5 min in the supine position; a passive phase of 10 min at a tilt angle of 60 degrees; aprovocation phase of further 10 min after 300 micrograms NTG sublingual spray."
89534482|NCT05029323|Experimental|Fast HUTT|"All patients with unexplained syncope at initial evaluation with indication to perform a Head up tilt test (HUTT) randomized to fast HUTT protocol characterized by a stabilization phase of 5 min in the supine position; a passive phase of 10 min at a tilt angle of 60 degrees; a provocation phase of further 10 min after 300 micrograms NTG sublingual spray."
89361363|NCT05660772|Active Comparator|Corticosteroid Injection|The cases assigned to this group will be injected intra-articularly in the knee with a corticosteroid. It will be administered once at the baseline visit of the study.
89361364|NCT05660772|Experimental|Microfragmented Adipose Tissue (Mfat)|"Injection of Microfragmented Adipose Tissue derived using Lipogems® Kit~The cases assigned to this group will be injected intra-articularly with Lipogems®. The patients will undergo lipoaspiration of their own adipose tissue for Mfat then this Mfat will be injected intra-articularly in the knee. It will be administered once at the baseline visit of the study."
89361365|NCT05660382|Active Comparator|Active group|Miconazole (2%) oil, administered as 5 drops per ear at ~30 mg per drop instilled into the external ear canal of the ear(s) affected by otomycosis, twice daily for 14 days.
89361366|NCT05660382|Placebo Comparator|Placebo group|Mineral oil, administered as 5 drops per ear instilled into the external ear canal of the ear(s) affected by otomycosis, twice daily for 14 days.
89361367|NCT05658263|Active Comparator|Standard Diet|Participants receiving only standard of care (SOC) nutrition advice, which is SOC Dietary Instructions, as provided by routine surgical consults and one protein shake per day for 4 weeks prior to surgery (SOC).
88832823|NCT05992792|Experimental|Whitout internet|Subjects whitout internet to recibe message by SMS
88832824|NCT05992779||Patient elderly implanted|Patients over 80 years old, primo implanted between 2011 and 2021
88832825|NCT05992766|Experimental|Reformer Pilates|Reformer Pilates were performed, 2 days a week, for 4 weeks, in a total of 8 sessions (45 minutes each). The exercises of the Reformer Pilates were given as individual sessions by the physiotherapist. Reformer Exercises were explained by the physiotherapist in detail to understand the movement and starting position correctly, and the participants were then asked to perform the movements.
88832826|NCT05992766|Experimental|Hammach Yoga|Hammock Yoga were performed, 2 days a week, for 4 weeks, in a total of 8 sessions (45 minutes each). Hammock Yoga were given as individual sessions by the physiotherapist.
89001061|NCT04632121||Group A|will receive standard treatment + 20 mg nicorandil prior to PPCI, and then maintained on 20 mg b.i.d for 3 months .
89361368|NCT05658263|Experimental|BIG MACS Diet|Participants will be instructed to consume the study diet, referred to as the 'BIG MACS Diet' and one protein shake per day for 4 weeks prior to surgery (SOC). Following surgery, participants will continue to follow the BIG MACS Diet for an additional four weeks, with solid food reintroduction after surgery as early as tolerated.
89361369|NCT05656235|Experimental|Enfortumab vedotin with Pembrolizumab|"The study population will include male and female patients over the age of 18 with high grade UTUC (cN0/xM0) and is ineligible for or refuses definitive radical nephroureterectomy (RNU).~Enfortumab vedotin will be administered on Days 1 and 8 at 1.25mg/kg of every 3-week cycle by intravenous (IV) infusion given over approximately 30 minutes. Pembrolizumab will be administered on Day 1 at 200mg of every 3-week cycle by IV infusion over approximately 30 minutes. Enfortumab vedotin and Pembrolizumab may be administered for up to total of 35 cycles (approximately 2 years)."
89361370|NCT05654922|Experimental|ARINA-1 plus standard of care|ARINA-1 (88 mg/mL ascorbic acid, ASC; 150 mg/mL reduced glutathione, GSH); fixed dose, 4 mL solution inhaled twice daily via nebulization plus standard 3-therapy immunosuppression regimen and azithromycin
89361371|NCT05654922|Other|Standard of care only|Standard 3-therapy immunosuppression regimen and azithromycin
89361372|NCT05653258|Other|Younger Lean Group|Participants will be aged 18-30 years and have a BMI of 18.5 - 24.9 kg/m2
89361373|NCT05653258|Other|Older Lean Group|Participants will be over 65 years of age with a BMI of 18.5 to 24.9 kg/m2
89361374|NCT05653258|Experimental|Older Obese Group|Participants will be over 65 years of age with a BMI of 30-39.9 kg/m2.
89361375|NCT05653011||Control group|Patients who are not diagnosed with inflammatory bowel disease and have colitis.
89361376|NCT05653011||TNF-alpha Inhibitor-naive IBD group|Patients who are diagnosed with inflammatory bowel disease but do not have a history of TNF-a inhibitor treatment.
89361377|NCT05653011||TNF-alpha Inhibitor-treated IBD group|Patients who are diagnosed with inflammatory bowel disease and have a history of TNF-a inhibitor treatment.
89361378|NCT05652699|Active Comparator|High Flow Nasal Oxygen|60L/minute. FiO2 according to clinical protocol. Temperature highest tolerated by patient, starting with 37 degrees Celcius.
89361379|NCT05652699|Active Comparator|Conventional Oxygen therapy|
89361380|NCT05650255|Experimental|A Digital Twin for Exoskeleton Pilot|This project is expected to use different machine learning models to make accurate predictions of human intent when healthy people drive different actions or action transitions of common human actions. Drivers will wear sensors such as inertial measurement unit (IMU) and electromyography (EMG) in the lower limbs to measure body signals of participants during actions in a non-invasive way, and let the system calculate the joint angle, angular velocity and angular acceleration of each joint of the driving lower limb related human signals.
89534483|NCT03335969|Experimental|pre colon irrigation diaries followed by post diaries|4 week bowel movement and rescue medication diaries will be compared to same diaries used 4 weeks after the colon irrigation procedure
89534484|NCT02493413||Group A|observational time of three months in the obese group with distressed (type D) personality (high DS 14 score) with moderate aerobic exercise
89534485|NCT02493413||Group B|observational time of three months in obese group without distressed personality (low DS 14 score) with moderate aerobic exercise
89361384|NCT05645757|Experimental|Cohort 1|WCK 6777 (Ertapenem 1 g combined with Zidebactam 1 g) or placebo administered by 100 ml of intravenous infusion (IV) for 30 (±5) minutes once daily for 7 days. N= 8
89361385|NCT05645757|Experimental|Cohort 2|Ertapenem 2 g or placebo administered by 250 ml of intravenous infusion (IV) for 1 hour once daily for 7 days. N=8
89361386|NCT05645757|Experimental|Cohort 3|Zidebactam 2 g administered by 250 ml of intravenous infusion (IV) for 1 hour,once daily,for 7 days. N=6
89361387|NCT05645757|Experimental|Cohort 4|WCK 6777 (Ertapenem 2 g combined with Zidebactam 2 g) or placebo administered by 250 ml of intravenous infusion (IV) for 1 hour, once daily, for 7 days. N=8
89361388|NCT05645757|Experimental|Cohort 5|Ertapenem 3 g or placebo administered by 250 ml of intravenous infusion (IV) for 2 hours, once daily, for 7 days. N=8
88832827|NCT05992766|Active Comparator|Mat|Traditional mat exercises were performed, 2 days a week, for 4 weeks, in a total of 8 sessions (45 minutes each). The mat exercises were applied as a home program. The exercises were visually given with detailed explanations on a piece of paper, and they were checked by telephone every week.
89361389|NCT05645757|Experimental|Cohort 6|Zidebactam 3 g administered by 250 ml of intravenous infusion (IV) for 2 hours, once daily, for 7 days. N=6
88832828|NCT05992727||Group 1( cases)|Galectin 3 will be measured in 30 Patients who are with active stage of pemphigus either newly diagnosed or in a relapse. The diagnosis of each patient is based on clinical examination and histopathological examination.
88832829|NCT05992727||Group 2( controls)|Galectin 3 will be measured in30 age and sex matched healthy controls
88832830|NCT05992714|Experimental|Virtual Reality Glasses|Except for the preparation of the patient for the procedure, since the arthroscopy procedure takes approximately 60 minutes, 60-minute 360-degree VR video scenes will be watched using VR head device
89361390|NCT05645757|Experimental|Cohort 7|WCK 6777 (Ertapenem 3 g combined with Zidebactam 3 g) or placebo administered by 250 ml of intravenous infusion (IV) for 2 hours, once daily, for 7 days. N=8
89361391|NCT05638867|Experimental|Experimental Group|Triple Antithrombotic Therapy: Aspirin (12 months) + Clopidogrel (12 months) + Rivaroxaban (3 months)
89361392|NCT05638867|Other|Control Group|Dual Antiplatelet Therapy: Aspirin (12 months) + Clopidogrel (12 months)
89361393|NCT05638087|Experimental|Dexamethasone Treatment|Oral Dexamethasone treatment
89361394|NCT05638087|Placebo Comparator|Placebo Treatment|Placebo control
89361395|NCT05637476|Active Comparator|Group A (Active control group)|Group A (number=20): which is the control group with medial tibial stress syndrome, they will receive a selected physical therapy exercise program.
89534486|NCT03094455|Experimental|Experimental group|AOT is based on the observation of meaningful actions followed by their execution
89534487|NCT03094455|Other|Control group|Children will continue standard care for 3 weeks and then will receive the AOT as the Experimental group
89534488|NCT03335891|Experimental|Training Group|Asthma Education Program Breathing Exercises Core Stabilization Exercises
89534489|NCT03335891|Active Comparator|Control Group|Asthma Education Program Breathing Exercises
89361396|NCT05637476|Experimental|Group B (Experimental group)|Group B (number=20): which is the experimental group with Medial tibial stress syndrome, they will receive the same physical therapy exercise program as group A in addition to, functional strength training of hip abductors.
89361397|NCT05635084|Experimental|YN001|YN001 (with a strength of 5 mL:10 mg). Subjects will be administered 250 to 500 mL of YN001 diluted in 5% dextrose injection up to 120 min(which allows a +/-5 min infusion window) intravenous infusion.
89361398|NCT05635084|Placebo Comparator|Matching placebo for YN001|Matching placebo for YN001 is 5% dextrose injection. Subjects will be administered 250 to 500mL of 5% dextrose injection up to 120 min (which allows a +/-5 min infusion window) intravenous infusion.
89361399|NCT05634343|Experimental|Laughter Group|The laughter therapy program consists of 16 sessions, twice a week for eight weeks. Each session; It is planned to last 30-45 minutes with a maximum of 25 nurses.
89361400|NCT05634343|Experimental|Mindfulness Group|The mindfulness practice program consists of 16 sessions, twice a week for eight weeks. Each session is planned to last 45-60 minutes with a maximum of 25 nurses.
89361401|NCT05634343|No Intervention|Control Group|No intervention was made in the control group.
89361402|NCT05630144|Experimental|All Participants|
89361403|NCT05630001|Experimental|Iptacopan treatment in adult PNH patients|Subjects will receive iptacopan at a dose of 200 mg b.i.d. orally
89361404|NCT05629429|Experimental|Arm 1: olaparib treatment|Olaparib 300mg BID PO
89361405|NCT05629429|Active Comparator|Arm2: continuation of the chemotherapy|continuation of the current platinum based chemotherapy
89361406|NCT05626777|Experimental|Pre-filled syringe, mepolizumab 100 mg/month|Pre-filled syringe, mepolizumab, 100 mg/month, 6 first months of treatment administered by nurse, 6 last months of treatment administered by patient
89361407|NCT05626777|Experimental|Auto-injector pen, mepolizumab 100 mg/month|Auto-injector pen, mepolizumab, 100 mg/month 12 months of treatment administered by patient
89361408|NCT05621304||Foreign Born subjects w/Chronic HBV|foreign born (FB) chronic hepatitis B subjects
89361409|NCT05613751|Experimental|Pregnant women-COVID-19 vaccine RCT - intervention group|Women randomized to the intervention group will receive the nudge (three text messages four weeks apart) to remind them to get the COVID-19 booster vaccine
89361410|NCT05613751|No Intervention|Pregnant women-COVID-19 vaccine RCT - standard care group|Women randomized to the standard care group will not receive the nudge (three text messages four weeks apart) to remind them to get the COVID-19 booster vaccine. They will receive normal care at the hospital.
89361411|NCT05613751|Experimental|Pregnant women-influenza vaccine RCT - intervention group|Women randomized to the intervention group will receive the nudge (three text messages four weeks apart) to remind them to get the annual influenza vaccine
88832831|NCT05992714|Experimental|White Noise|Except for the preparation of the patient for the procedure, since the arthroscopy procedure takes approximately 60 minutes, 60-minute 360-degree VR video scenes will be listened using phone
88832832|NCT05992714|No Intervention|control group|Patients of the control group, will not receive any intervention except for applied routine hospital arthroscopy surgery procedures
88832833|NCT05992636||low insufflation flow (10 lt/min)|Patiens who perform pneumoperitoneum with low insufflation flow (10 lt/min)
88832834|NCT05992636||high insufflation flow (40 lt/min)|Patiens who perform pneumoperitoneum with high insufflation flow (40 lt/min)
88832835|NCT05992623|Active Comparator|Output synchronized to 200J using Zoll Rectilinear Biphasic Waveform (RBW) defibrillator|Participants receiving Direct Current Cardioversion (DCCV) using full output Rectilinear Biphasic Waveform (RBW) shocks from a Zoll defibrillator (200 Joules) up to 2 shocks.
88832836|NCT05992623|Active Comparator|Output synchronized to 360J Lifepak Biphasic Truncated Exponential Waveform (BTE) defibrillator|Participants receiving Direct Current Cardioversion (DCCV) using full output Biphasic Truncated Exponential Waveform (BTE) shocks from a Physiocontrol/Medtronic Lifepak defibrillator (360 Joules) up to 2 shocks.
88832837|NCT05992623|Active Comparator|Zoll defibrillator waveform used after unsuccessful second full output shock.|Participants who received first shock via Zoll that do not have success after a second full output shock will be crossed over to the Lifepak defibrillator waveform and receive up to 2 full output shocks with a minimum of 1 minute between each shock to ascertain the outcome of the immediately prior shock.
89001062|NCT04632121||Group B|will be given standard treatment, without nicorandil loading or maintainance.
89361412|NCT05613751|No Intervention|Pregnant women-influenza vaccine RCT - standard care group|Women randomized to the standard care group will not receive the nudge (three text messages four weeks apart) to remind them to get the annual influenza vaccine. They will receive normal care at the hospital.
89361413|NCT05613751|Experimental|Medically at risk children-COVID-19 vaccine RCT - intervention group|Parents of medically at risk children randomized to the intervention group will receive the nudge (three text messages four weeks apart) to remind them to get their child the COVID-19 vaccine
89361414|NCT05613751|No Intervention|Medically at risk children-COVID-19 vaccine RCT - standard care group|Parents of medically at risk children randomized to the standard care group will not receive the nudge (three text messages four weeks apart) to remind them to get their child the COVID-19 vaccine. They will receive normal care at the hospital.
89361415|NCT05613751|Experimental|Medically at risk children-influenza vaccine RCT - intervention group|Parents of medically at risk children randomized to the intervention group will receive the nudge (three text messages four weeks apart) to remind them to get their child the annual influenza vaccine
89361416|NCT05613751|No Intervention|Medically at risk children-influenza vaccine RCT - standard care group|Parents of medically at risk children randomized to the standard care group will not receive the nudge (three text messages four weeks apart) to remind them to get their child the annual influenza vaccine. They will receive normal care at the hospital.
89361417|NCT05613452|Experimental|Study arm|patients received carbon ion radiotherapy
89399174|NCT03029247|Active Comparator|Participants receiving Epoetin alfa|On Day 1, participants will undergo 24-hour Acute Challenge 1, in which participants will receive a single dose of 100 U/kg epoetin alfa IV. After completing Acute Challenge 1, participants will enter in an 8-week Hgb maintenance period. At the end of Hgb maintenance period, on Day 57, Acute Challenge 2 will be performed utilizing the same treatment dose administered in Acute Challenge 1.
88832838|NCT05992623|Active Comparator|Lifepak defibrillator waveform used after unsuccessful second full output shock.|Participants who received first shock via Lifepak that do not have success after a second full output shock will be crossed over to the Zoll defibrillator waveform and receive up to 2 full output shocks with a minimum of 1 minute between each shock to ascertain the outcome of the immediately prior shock.
88832839|NCT05992610|Experimental|Chemotherapy (Ch)+ Radiotherapy (RT)|"Induction phase:~Chemotherapy based on carboplatin 6 AUC (area under the curve) + paclitaxel 75 mg/m2 carboplatin 6 AUC 30-minute infusion on D: 1 (maximum carboplatin dose is 700 mg) paclitaxel 75 mg/m2 1-hour infusion on D: 1, 8, 15~Radiotherapy:~D:1 - 2 x 0,5 Gy (first dose up to one hour after the end of the carboplatin infusion, second dose 3 to 6 hours later), D:2 - 2 x 0,5 Gy (interval between doses not less than 3 hours), D:8 and D:15 - 2 x 0,5 Gy (first dose up to one hour after the end of the chemotherapeutic infusion, second dose 3 to 6 hours later)."
88832840|NCT05992493||Breast-milk feeding|Exclusive breastfeeding for 4 months or more
88832841|NCT05992493||Control Formula milk feeding|Exclusive formula milk for 4 months or more
88832842|NCT05992493||HMO-Formula-milk feeding|Exclusive HMO-formula milk for 4 months or more
88832843|NCT05992480|Experimental|Ebola Virus Disease (EVD) survivors|Participants with a history of admission and discharge from an Ebola Treatment Unit as registered by the Sierra Leone Association of Ebola Survivors (SLAES), and Anti-EBOV GP IgG positive by ELISA at the time of screening.
89361418|NCT05607992|Experimental|Brief exposure-based CBT|"Patient education: Common reactions following ACS. The role of PTS, cardiac anxiety and avoidance behavior on quality of life and physical health and health behaviors.~Labeling i.e., describe cardiac-related symptoms, thoughts, and feelings.~Imaginal exposure to reduce PTSS: Imaginal processing and revisiting of the memory of the ACS~Interoceptive exposure to physical sensations (e.g., palpitations due to physical activity) to reduce fear of these symptoms.~Gradual exposure in-vivo to avoided situations, activities and physical activity. Continuously use labeling while conducting exposure exercises.~Relapse prevention: Prevention of relapse into avoidance behaviors by identifying risk situations and encouragement of maintaining a healthy physically active lifestyle."
89361419|NCT05607992|No Intervention|Waitlist control|The waitlist control will be offered an opportunity to participate in the intervention after the 2-month intervention evaluation period.
89361420|NCT05606991|No Intervention|CPAP on|Participants will continue with their usual continuous positive airway pressure (CPAP) therapy as advised by their treating physician.
88832844|NCT05992480|Active Comparator|Community control|Age- and sex-matched controls who are Anti-EBOV GP IgG negative by ELISA at the time of screening.
88832845|NCT05992441||breast cancer|This group will consist of women who have received breast cancer and will be based on participant volunteerism.
88832846|NCT05992415|Active Comparator|Arm 1: Intervention Using Patient Navigators|Consented participants referred to ophthalmology from the 9 developments randomized to the Intervention Arm will receive ongoing support from patient navigators to assist with all aspects of follow-up eye care and ocular surgery at either Harkness Eye Institute or Harlem Hospital, specifically eye exam appointment scheduling and arranging transportation over a 1-year period.
88832847|NCT05992415|Placebo Comparator|Arm 2: Usual Care Without Patient Navigators|Consented participants referred from the 5 developments randomized to the Usual Care Arm 2 who are referred to an ophthalmologist for a follow-up eye exam will only be scheduled for their initial appointment at either Harkness Eye Institute or Harlem Hospital. They will not receive enhanced support. Scheduling this initial appointment will allow tracking of adherence. Arm 2 represents a realistic choice available for participants following screening over a 1-year period.
88832848|NCT05992363|Active Comparator|single silicone stent|patients with malignant ureteral obstruction that was treated by single large-caliber 8-12Fr silicone stent
88832849|NCT05992363|Active Comparator|Tandem polyurethane stents|patients with malignant ureteral obstruction that was treated by tandem 6 Fr Percuflex™ stents
88832850|NCT05992324|Experimental|Patients presenting with clinical suspicion of B-Lines|Patients will undergo two 8-zone protocol lung ultrasound exams. One exam will be conducted by an expert lung ultrasound user without Caption LungAI and will last approximately 5-10 minutes. The second exam will be conducted by a healthcare professional with Caption LungAI and will last approximately 15-20 minutes.
88832851|NCT05992298|Experimental|7 T MRI|
88832852|NCT05992285|Experimental|cTBS group|the intensity of stimulus was 80% Resting motor threshold (RMT); the frequency of trains was 50 Hz and the number of pulses was three; and the frequency of intertrain intervals was 5 Hz and pulses number was 200. Two groups were repeatedly stimulated in the dentate nucleus of bilateral cerebellum, the interval of each group was 5min, and the number of stimulation pulses at each site was 1200.
88832853|NCT05992285|Sham Comparator|sham group|The treatment of the sham group was the same as active group. The only difference was that the coil was flipped 180° in the sham group. The device also made the same sound but could not stimulate the brain.
88832854|NCT05992272||alcohol use disorder (AUD)|"Participants with alcohol use disorder (mild to moderate or severe if no withdrawal symptoms) including:~daily smokers (at least 1 cigarette per day in last 3 months)~non-daily (min 1x/last 3months)~non-smokers"
88832855|NCT05992272||non-AUD|"Participants with a maximum of 1 AUD criteria according to DSM-5, including:~daily smokers (at least 1 cigarette per day in last 3 months)~non-daily (min 1x/last 3months)~non-smokers"
88832856|NCT05992259|Active Comparator|Active TENS|It will be performed attached to the tragus of the left ear.
88832857|NCT05992259|Sham Comparator|Sham TENS|It will be performed attached to the earlobe of the left ear.
88832858|NCT05992233|Experimental|Dual wavelength low dose laser|Immediately after suturing the patient, a low-dose laser application was performed on the laser group using the square probe (16 J/min) of the locally produced GRR laser device (Ankara, Turkey) for 5 minutes. The device combines a 22 mW GaAlAs infrared laser with a wavelength of 904 nm and a 10 mW red laser with a wavelength of 650 nm. The square probe contains 5 red lasers and 4 infrared lasers, covering an area of 30mm X 30mm.
88832859|NCT05992233|Placebo Comparator|Plasebo|Laser probe will be applied to the control group patients, but the device was not operated.
88832860|NCT05992220|Experimental|Radiotherapy combination|"Atezolizumab+Bevacizumab, combined EBRT to vascular invasion~Atezolizumab will be administered by IV, 1200 mg on day 1 of each 21day cycle.~Bevacizumab will be administered by IV, 15 mg/kg on day 1 of each 21day cycle.~The external beam radiotherapy will commence after day 2 of the first cycle of A+B, and will be delivered in accordance with institutional protocol."
89361421|NCT05606991|Experimental|CPAP off|Participants will be weaned off their usual continuous positive airway pressure (CPAP) therapy and enter a 2-week period of non-treatment.
89361422|NCT05605535|Experimental|Combination of Oregovomab and chemotherapy|Six (6) cycles of chemotherapy with oregovomab given only at specific cycles (Cycle 1, Cycle 3, Cycle 4, Cycle 6 and Cycle 6 plus 12 weeks).
89361423|NCT05605535|Placebo Comparator|Combination of Placebo and chemotherapy|Six (6) cycles of chemotherapy with placebo given only at specific cycles (Cycle 1, Cycle 3, Cycle 4, Cycle 6 and Cycle 6 plus 12 weeks).
89361424|NCT05605522|Experimental|Phase 1 Dose Escalation|
89361425|NCT05605522|Experimental|Phase 1 Dose Expansion|
89361426|NCT05603052|Experimental|Test group(EuCorVac-19) - Cohort A|Cohort A - Immunogenicity cohort
89361427|NCT05603052|Active Comparator|Comparator group(ChAdOx1) - Cohort A|Cohort A - Immunogenicity cohort
89361428|NCT05603052|Experimental|Test group(EuCorVac-19) - Cohort B|Cohort B - Safety cohort
89361429|NCT05603052|Active Comparator|Comparator group(ChAdOx1) - Cohort B|Cohort B - Safety cohort
89361430|NCT05602142|Experimental|[11C]CPPC|All participants will receive [11C]CPPC which is a radiotracer ligand that specifically binds to CSF1R.
88832861|NCT05992220|Active Comparator|Atezolizumab+Bevacizumab|"Atezolizumab will be administered by IV, 1200 mg on day 1 of each 21day cycle.~Bevacizumab will be administered by IV, 15 mg/kg on day 1 of each 21day cycle."
89361431|NCT05598515|Experimental|Time-Restricted Feeding|
89361432|NCT05595850|Experimental|Mindfulness|Three-week online mindfulness course followed by one-month social community online interaction.
89361433|NCT05595850|Active Comparator|Mindful Learning|Three-week online mindful learning course followed by one-month social community online interaction
89361434|NCT05595200||Study Group|All subjects diagnosed with pulmonary hypertension by right heart catheterization agreeing to participate and meeting inclusion criteria but not meeting exclusion criteria
89361435|NCT05593926|Experimental|Intervention|The functional food, Myota Metabolic Regulator, consisting of 20g of a powdered fibre mix, to be taken daily alongside usual diet for 24 weeks.
89361436|NCT05593926|No Intervention|Placebo|Placebo will be 2g of powdered cellulose, to be taken daily alongside usual diet for 24 weeks. Placebo will be 2g of powdered cellulose, to be taken daily alongside usual diet for 24 weeks.
89361437|NCT05593328|Experimental|Onvansertib 20 mg + Standard of Care (SOC)|Participants will receive 20 mg of onvansertib on Days 1 to 5 and 15 to 19 of a 28-day treatment cycle and SOC (FOLFIRI + bevacizumab) on Days 1 and 15 of each 28-day cycle.
89361438|NCT05593328|Experimental|Onvansertib 30 mg + Standard of Care (SOC)|Participants will receive 30 mg of onvansertib on Days 1 to 5 and 15 to 19 of a 28-day treatment cycle and SOC (FOLFIRI + bevacizumab) on Days 1 and 15 of each 28-day cycle.
89361439|NCT05593328|Active Comparator|Standard of Care (SOC)|Participants will receive SOC (FOLFIRI + bevacizumab) on Days 1 and 15 of each 28-day cycle.
88832862|NCT05992207|Active Comparator|physical thertapy training|The Control group received the selected physical therapy program for one hour, three times weekly for three successive months including facilitation of balance and protective reactions from standing position, standing on one leg, weight shifting from standing, squat to standing, strengthening exercises for trunk muscles and for upper and lower extremities musculatures, gait training activities for correction of gait pattern
89178079|NCT00828490||Opioid Therapy|"Medicaid beneficiaries ≥18 years and enrolled ≥6 of prior 12 months with enrollment in ≥1 of prior 3 months and ≥1 opioid fill in prior 3 months and none of the following in prior 12 months:~Hospice CPT code or Primary diagnosis of cancer or Oncology CPT code"
89361440|NCT05590208|Experimental|sleeve gastrectomy+ cruroplasty + omental rape|sleeve gastrectomy+ cruroplasty + omental rape
89361441|NCT05584540|Experimental|UNTIRE App|"At baseline meeting participants will answer questionnaires and be introduced and instructed on self-managed use of Untire app treatment program.~Participants will then have check in meetings assessing app usage and progress on weeks 4, 8 and 12 post baseline, then a final check-in 6 months post baseline."
89361442|NCT05582590|Experimental|Cohort 1|2 x 10^8 NEXI-003 T cells (derived from peripheral blood mononuclear cells [PBMCs] of the patient) administered by intravenous infusion on Day 1 of each cycle
89361443|NCT05582590|Experimental|Cohort 2|2 x 10^8 NEXI-003 T cells (derived from peripheral blood mononuclear cells [PBMCs] of the patient) administered by intravenous infusion on Days 1 and 8 of each cycle
89361444|NCT05582590|Experimental|Cohort 3|2 x 10^8 NEXI-003 T cells (derived from peripheral blood mononuclear cells [PBMCs] of the patient) administered by intravenous infusion on Days 1, 8, and 15 of each cycle
89361445|NCT05582590|Experimental|Cohort 4|4 x 10^8 NEXI-003 T cells (derived from peripheral blood mononuclear cells [PBMCs] of the patient) administered by intravenous infusion on Day 1, and 2 x 10^8 NEXI-003 T cells administered by intravenous infusion on Days 8 and 15 of each cycle
89361446|NCT05582590|Experimental|Dose Expansion Stage|Dose Expansion Stage to further define the safety and clinical activity, and to confirm the recommended Phase 2 dose of the NEXI- 003 T cell product at the dose established from the Dose Escalation Stage.
89361447|NCT05581745|Experimental|A2 donor transplant to O recipient|
89361448|NCT05581043|Placebo Comparator|0 gram 3-OHB 30 minutes before an OGTT|0 gram 3-OHB 30 minutes before an OGTT
89361449|NCT05581043|Experimental|10 gram 3-OHB 30 minutes before an OGTT|10 gram 3-OHB 30 minutes before an OGTT
89361450|NCT05581043|Experimental|20 gram 3-OHB 30 minutes before an OGTT|20 gram 3-OHB 30 minutes before an OGTT
89361451|NCT05581043|Experimental|40 gram 3-OHB 30 minutes before an OGTT|40 gram 3-OHB 30 minutes before an OGTT
89361452|NCT05581043|Experimental|20 gram 3-OHB 0 minutes before an OGTT|20 gram 3-OHB 0 minutes before an OGTT
89361453|NCT05581043|Experimental|20 gram 3-OHB 60 minutes before an OGTT|20 gram 3-OHB 60 minutes before an OGTT
89361454|NCT05580718|Experimental|Online CBT targeting cardiac anxiety|CBT for MI primarily targets two processes of MI-related disability: fear of cardiac-related symptoms avoidance behavior and physical inactivity. The CBT is therapist-guided and lasts for 8 weeks.
89399175|NCT03029247|Experimental|Participants receiving Daprodustat|On Day 1, participants will undergo 24-hour Acute Challenge 1, in which participants will receive 24 mg daprodustat. After completing Acute Challenge 1, participants will enter an 8-week Hgb maintenance period. At the end of Hgb maintenance period, on Day 57, Acute Challenge 2 will be performed utilizing the same treatment dose administered in Acute Challenge 1.
88832863|NCT05992207|Active Comparator|motor imaginary training|The study group received the selected physical therapy program for one hour, three times weekly for three successive months in addition to motor imagery program for 30 minutes as the following. Each child shown a video of 5 minutes of illustrating normal movements while the child resting in semireclined sitting in quiet room in front the screen. Children then asked to close their eyes and imagine practicing the task like the illustrative video. Repetition of the exercises depend on the children ranging from 5 to 10 repetitions per exercise
88832864|NCT05992129|Other|structural foot types and their influence on core in collegiate athletes|Athletes do 12 weeks of exercises and then evaluate how they influenced core stability
88832865|NCT05992129|Other|structural foot types and their influence on performance in collgiate athletes|Athletes do 12 weeks of exercises and then evaluate how they influenced on sport performance
89001063|NCT04631887|Experimental|Intervention Arm: Doing What Matters in Times of Stress: An Illustrated Guide|The intervention arm will receive the assigned intervention for five weeks. They will receive the intervention materials and will be called by psychologists three times (at the beginning, middle and end) during the intervention.
89178080|NCT00828490||Fraud and Abuse|Medicaid beneficiaries who filled at least 3 opioid Rx in the last 12 months
89178081|NCT00828490||Pediatric Antipsychtotic Therapy|Medicaid beneficiaries <18 years of age with at least 3 antipsychotic Rx's in the past year.
89178082|NCT00823498||African American Parents|
89178083|NCT00823498||African American Youth|African American Youth between ages of 12-15 Years Old
89178084|NCT04044430|Experimental|Treatment (encorafenib, binimetinib, nivolumab)|"Participants in Phase 1 receive encorafenib PO QD on days 1-28, binimetinib PO BID on days 1-28, and nivolumab IV on day 1. Cycles repeat every 28 days for a maximum of 24 cycles of treatment in the absence of disease progression or unacceptable toxicity.~The study was terminated before Phase II was initiated. The study did not open Phase II for enrollment."
89178085|NCT00821158|Placebo Comparator|1|Placebo tablet and iv
89178086|NCT00821158|Experimental|2|Placebo tablet and intervention iv
89178087|NCT00821158|Experimental|3|Intervention tablet and placebo iv
89178088|NCT00830674|Experimental|KRN23|Single IV or SC administration on day 1
89178089|NCT00830674|Placebo Comparator|Placebo|Single IV or SC administration on day 1
89178090|NCT00823732|Active Comparator|Phase 2 Intervention|GROUP II (palliative care intervention): Patients receive an individualized interdisciplinary palliative care intervention comprising learner-centered, knowledge-centered, assessment-centered, and community-centered concepts. Patients undergo 4 teaching sessions, focused on physical, psychological, social, and spiritual well-being, once weekly in weeks 3-6. Patients then receive 4 follow-up phone calls in weeks 9, 13, 17, and 21.
89178091|NCT00823732|No Intervention|Phase I Usual Care|GROUP I (usual care): Patients receive standard care.
89178092|NCT00828646|Experimental|BMS-708163 - Panel 1|(Age 20-45 years)
89178093|NCT00828646|Experimental|BMS-708163 - Panel 2|(Age 20-45 years)
89178094|NCT00828646|Experimental|BMS-708163 - Panel 3|(age 65 or above)
89178095|NCT00828646|Experimental|BMS-708163 - Panel 4|(age 65 or above)
89178096|NCT02548936|Experimental|Lipid-lowering treatment|The Lipid-lowering treatment is Ezetimibe+Simvastatin Drug Combination by oral administration. The patients in intervention group received simvastatin (10mg/day) + ezetimibe (20 mg/day) combined therapy for 12 month.
89399176|NCT03696459|Experimental|Part 1 (Dose Escalation): Panel 1|Participants will receive single oral dose of JNJ-53718678, 2000 milligram (mg) suspension or matching placebo on Day 1, under fasted conditions.
89178097|NCT02548936|No Intervention|No lipid-lowering treatment|Without any Lipid-lowering treatment for 12 month.
89178098|NCT02548858|Active Comparator|Perineorrhaphy|Patients who are randomized to receive a perineorrhaphy as part of their vaginal or abdominal reconstructive procedure
89178099|NCT02548858|Active Comparator|No Perineorrhaphy|Patients who are randomized not to receive a perineorrhaphy as part of their vaginal or abdominal reconstructive procedure
89178100|NCT00828724|Experimental|Lorcaserin 10mg|
89178101|NCT00828802|Experimental|Cohort 1|Lenalidomide (5mg) and Decitabine
89178102|NCT00828802|Experimental|Cohort 2|Lenalidomide (10 mg) and Decitabine
89178103|NCT00828802|Experimental|Cohort 3|Lenalidomide (15 mg) and Decitabine
89178104|NCT00828802|Experimental|Cohort 4|Lenalidomide (20 mg) and Decitabine
89178105|NCT00828802|Experimental|Cohort 5|Lenalidomide (25 mg) and Decitabine
89178106|NCT00823810|Experimental|Colorectal cancer|
89178107|NCT00785577|Placebo Comparator|Placebo|LY545694 placebo twice daily (BID) oral (po) for 5 weeks and pregabalin placebo capsules thrice daily (TID) po for 6 weeks
89178108|NCT00785577|Active Comparator|Pregabalin|"Pregabalin thrice daily (TID) oral for 6 weeks: 50 mg TID po for Week 1, 100 mg TID po for Weeks 2 - 5, and 50 mg TID po taper for Week 6~LY545694 placebo BID po for 5 weeks"
89178109|NCT00785577|Experimental|LY545694 21 mg|"LY545694 21 milligrams (mg) BID po for 1 week~Pregabalin placebo TID po for 6 weeks"
89178110|NCT00785577|Experimental|LY545694 49 mg|"LY545694 escalated to 49 mg BID po during Week 2; possible titration down to 21 mg BID po within 1 week of escalation for remainder of study treatment.~Pregabalin placebo TID po for 6 weeks"
89178111|NCT00785577|Experimental|LY545694 105 mg|"LY545694 escalated to 105 mg BID po during Week 3 through Week 5; possible titration down to 49 mg BID po within 1 week of escalation for the remainder of study treatment.~Pregabalin placebo TID po for 6 weeks"
89178112|NCT00828880||DRX9000|
89178113|NCT02548390|Experimental|RXDX-107|
89178114|NCT00830908|Experimental|LaserComb|Patients aged 18 years and older with a diagnosis of seborrheic dermatitis of the scalp
89178115|NCT04105101|Experimental|Prototype exoskeleon|The experimental trial will be performed with the prototype exoskeleton
89178116|NCT04105101|Experimental|Skel-Ex|The experimental protocol will be performed with the commercially available Skel-Ex 360 (Skel-Ex, Rotterdam, The Netherlands)
89178117|NCT04105101|Experimental|No exoskeleton|The experimental protocol will be performed without exoskeleton.
89178118|NCT00830986||1|Computer Assisted Total Knee Arthroplasty
89178119|NCT00830986||2|Conventional Instrumented Total Knee Arthroplasty
89178120|NCT02548780|Experimental|Chemoembolization + Pharmacokinetics|"First cohort: Chemoembolization with Doxorubicin-loaded LifePearl™ microspheres (TACE): Escalation of dose loaded in microspheres from 75 mg to 150 mg. Pharmacokinetic testing in all patients.~Second cohort: Chemoembolization with doxorubicin-loaded LifePearl™microspheres: microspheres loaded with maximum tolerated dose as established with dose escalation arm. Pharmacokinetic testing in all patients."
89178121|NCT04105023|Experimental|genistein|Genistein capsules of 25 mg each, 50mg/day
89178122|NCT04105023|Placebo Comparator|placebo|Maltodextrin capsules, administered orally once every 12 hours
89361455|NCT05580718|No Intervention|Waitlist control|Participants randomised to waitlist can have no other concurrent psychological treatment but are free to use any medical treatment as usual. Participants on the waitlist also complete pre- and post-treatment, the follow-up measurement as well as weekly instruments (with exception of the treatment process measures Credibility scale and WAI). After the 3-month follow-up assessments, participants will receive internet-CBT for MI over 8 weeks
89361456|NCT05580614|Active Comparator|Active tVNS paired with 12 sessions of ERP|
89178123|NCT00831064|Active Comparator|1. 4L PEG only|4L PEG PO
89178124|NCT00831064|Active Comparator|2. 2L PEG plus bisacodyl|2L PEG PO + 4 tablets bisacodyl PO
89361457|NCT05580614|Sham Comparator|Sham tVNS paired with 12 sessions of ERP|
89361458|NCT05579366|Experimental|PRO1184|PRO1184 monotherapy in escalating doses in Part A and at the recommended dose in Part B.
89178125|NCT00831064|Active Comparator|3. NaP|90 cc NaP PO
89178126|NCT00831064|Active Comparator|4. PSMC plus Mg-citrate|PSMC plus 300 cc Mg-citrate PO
89178127|NCT04104867|Active Comparator|Colonoscopy preparation by PEG-EL with Itopride|Regular protocol for colonoscopy preparation, no solid foods are allowed except low residue diet during three days before the procedure. On the next day, only liquid diet consumption is allowed.On the day prior to colonoscopy, the patients can have only clear liquid and ad libitum throughout the day until midnight. They are also informed to begin consuming the 3 liters of PEG-EL at 5.00 PM and complete it within 3 hours one day befor colonoscopy.
89178128|NCT04104867|Placebo Comparator|Colonoscopy preparation by PEG-EL with Placebo|Regular protocol for colonoscopy preparation, no solid foods are allowed except low residue diet during three days before the procedure. On the next day, only liquid diet consumption is allowed.On the day prior to colonoscopy, the patients can have only clear liquid and ad libitum throughout the day until midnight. They are also informed to begin consuming the 3 liters of PEG-EL at 5.00 PM and complete it within 3 hours one day befor colonoscopy.
89178129|NCT04104867|Active Comparator|Colonoscopy preparation by PEG-EL with Domperidone|Regular protocol for colonoscopy preparation, no solid foods are allowed except low residue diet during three days before the procedure. On the next day, only liquid diet consumption is allowed.On the day prior to colonoscopy, the patients can have only clear liquid and ad libitum throughout the day until midnight. They are also informed to begin consuming the 3 liters of PEG-EL at 5.00 PM and complete it within 3 hours one day befor colonoscopy.
89178130|NCT04024605|Experimental|Sunflower|Biscuits containing sunflower isolate intrinsically labelled with 15N and 2H
89178131|NCT04024605|Experimental|Rapeseed|Biscuits containing rapeseed isolate intrinsically labelled with 15N and 2H
89361459|NCT05578885|Placebo Comparator|Group A|will receive Lidocaine
89361460|NCT05578885|Active Comparator|Group B|will receive Lidocaine Plus fentanyl
89178132|NCT04024605|Experimental|Flaxseed|Biscuits containing flaxseed isolate intrinsically labelled with 15N and 2H
89178133|NCT04024605|Experimental|Lupin|Biscuits containing lupin flour intrinsically labelled with 15N and 2H
89178134|NCT00789828|Experimental|Everolimus|Everolimus was administered orally at a starting dose of 4.5mg/m^2 daily and subsequently titrated to attain whole blood trough concentration of 5 to 15 ng/mL. Dose adjustments were permitted based on safety and whole blood trough concentrations.
89361461|NCT05578885|Active Comparator|Group C|will receive lidocaine Plus dexamethasone
89361462|NCT05578417||HAE nC1-INH|Participants with HAE nC1-INH will be observed retrospectively for the treatments they receive and their outcomes in the real-world setting from January 1, 2012, to January 1, 2022.
89361463|NCT05578417||NHAE nC1-INH|Participants with NHAE nC1-INH will be observed retrospectively for the treatments they receive and their outcomes in the real-world setting from January 1, 2012, to January 1, 2022.
89399177|NCT03696459|Experimental|Part 1 (Dose Escalation): Panel 2|Participants will receive single oral dose of JNJ-53718678, of maximum 3000 mg suspension or matching placebo on Day 1, under fasted conditions.
89178135|NCT00789828|Placebo Comparator|Placebo|Matching Placebo administered orally.
89178136|NCT04044118|Experimental|Caloric Restriction|3-week low calorie diet
89178137|NCT04024839|Active Comparator|Post Isometric Relaxation|Post Isometric Relaxation was applied three times a week for the duration of three weeks.
89178138|NCT04024839|Experimental|Active Isolated stretch|Active Isolated stretch was was applied three times a week for the duration of three weeks.
89178139|NCT02550262|Experimental|60 minutes|The infusion pump will deliver programmed intermittent epidural boluses at a 60-minute interval. The bolus will consist of 10mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml will also be available.
89178140|NCT02550262|Experimental|50 minutes|The infusion pump will deliver programmed intermittent epidural boluses at a 50-minute interval. The bolus will consist of 10mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml will also be available.
89399178|NCT03696459|Experimental|Part 1 (Dose escalation): Panel 3|Participants will receive single oral dose of JNJ-53718678 4500 mg suspension (this dose may be used in Part 2, Treatment F) or matching placebo on Day 1, under fasted condition.
89178141|NCT02550262|Experimental|40 minutes|The infusion pump will deliver programmed intermittent epidural boluses at a 40-minute interval. The bolus will consist of 10mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml will also be available.
89178142|NCT02550262|Experimental|30 minutes|The infusion pump will deliver programmed intermittent epidural boluses at a 30-minute interval. The bolus will consist of 10mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml will also be available.
89178143|NCT04024449||Celiac Disease|"Celiac disease with the following criteria;~13 ≤ Age ≤20~At least one year after menarche~Non-obesity or malnutrition, Non-Hyperandogenism symptoms, and blood tests, Non-Hyper or hypothyroidism, Non-Hyperprolactinemia."
89178144|NCT04024449||Control|"The adolescent with the following criteria;~13 ≤ Age ≤20~At least one year after menarche~Non-obesity or malnutrition, Non-Hyperandogenism symptoms, and blood tests, Non-Hyper or hypothyroidism, Non-Hyperprolactinemia.~Control group; with normal menstrual period, Non-chronic diseases"
88832867|NCT05992051|Experimental|online exercise therapy|"The participants had weekly online exercise meetings with the physiotherapist in a group of 3-5 participants using online meeting app. Then the participants performed the remaining two sessions of exercises themselves weekly. All the participants of the experimental group received a package of exercise pamphlet and a video disc containing 17-minute exercise demonstrations by the physiotherapist.~At baseline, the suitable elastic bands (Thera-band®) for performing the exercises were selected by testing the 15 repetitions maximum (15RM) of the Modified Brügger's Exercise (MBE) and the Modified Proprioceptive Neuromuscular Facilitation Diagonal Flexion Exercise (MPNFDFE) for the participants of both the experimental group and control group.~Participants performed the following exercises three times a week for six weeks at home:~A. Warm-up exercises B. Cranio-cervical flexion exercises C. Strength-endurance exercises D. Scapular stabilization exercises E. Stretching exercises"
88832868|NCT05992051|Active Comparator|conventional exercise therapy|"Participants in the control group completed the same exercise program three times a week for six weeks with face-to-face mode delivery by physiotherapists.~At baseline, the suitable elastic bands (Thera-band®) for performing the exercises were selected by testing the 15 repetitions maximum (15RM) of the Modified Brügger's Exercise (MBE) and the Modified Proprioceptive Neuromuscular Facilitation Diagonal Flexion Exercise (MPNFDFE) for the participants of both the experimental group and control group.~Participants performed the following exercises three times a week for six weeks in a group of 3-5 participants in the laboratory of the Sport Medicine and Rehabilitation School of the Beijing Sport University:~A. Warm-up exercises B. Cranio-cervical flexion exercises C. Strength-endurance exercises D. Scapular stabilization exercises E. Stretching exercises"
88832869|NCT05992025|No Intervention|Observation|Observation with the OURA ring and no digital meetings. The participants are offered delayed randomization after the study period. This group's outcome from the delayed randomization will be for the exploratory analysis, i.e., not in the primary analysis.
88832870|NCT05992025|Experimental|Physical activity|12 weeks of physical activity guidance with short discussions via online group meetings according to a schedule. The participants in this arm will conduct moderate-intensity exercises for at least 150 minutes per week. Brisk walks are the primary choice of activity; alternatively, swimming, cycling, or dancing to the physical exertion according to the Borg scale can be performed.
88832871|NCT05992025|Active Comparator|Sleep hygiene intervention|12 weeks of sleep exercises. The lifestyle intervention of sleep will be delivered via an online group, with recommended home practices between sessions. Topics covered will include sleep education, sleep hygiene, and practices to improve sleep quality.
88832872|NCT05991973|Experimental|low-dose chidamide maintenance therapy after allo-HSCT|
88832873|NCT05991947||gastric cancer patients|
88832874|NCT05991947||healthy individuals|
88832875|NCT05991869|Experimental|Intervention|
88832876|NCT05991869|No Intervention|Usual Care|
88832877|NCT05991856||radiofrequency ablation|Patients with aldosterone-producing adenoma undergoing ultrasound-guided radiofrequency ablation
88832878|NCT05991856||laparoscopic adrenalectomy|Patients with aldosterone-producing adenoma undergoing laparoscopic adrenalectomy
88832879|NCT05991830||Older adults > 60 years|
88832880|NCT05991778||Group of Patients who Survived (S)|The group is defined by the number of patients who survived.
88832881|NCT05991778||Group of Patients who Died (D)|The group is defined by the number of patients who died.
88832882|NCT05991765||Digit Tip Wound|Experimental Wound Exudate from Digit Tip Wounds
88832883|NCT05991765||Split Skin Donor Site Wound|Active Comparator Wound Exudate from Split Skin Donor Site Wound
88832884|NCT05991752|Experimental|ROMA Score|Experimental group: CA125 and HE4 assays every 4 months for 3 years to assess the ROMA score, in addition to the recommended conventional follow-up.
88832885|NCT05991752|No Intervention|CA125 alone|Control group: CA125 assay alone every 4 months for 3 years, as part of the recommended standard follow-up.
88832886|NCT05991726||Cohort 1: Professional Expert|This includes Healthcare professionals (HCPs) who look after people with CKD in the UK, anyone involved in designing, developing, managing and commissioning of CKD healthcare in the UK and researchers interested in self-management or CKD
89001064|NCT04631887|No Intervention|Control Arm: Wait List|The control arm has no intervention. The participants in the control arm will receive the intervention after the post-assessments are completed.
89001065|NCT00560911|Other|1Self-management|
89001066|NCT00560911|Other|2 Routine control|
89178145|NCT02550418|Experimental|Budesonide|
89178146|NCT00829114|Active Comparator|1|ART/COC group
89178147|NCT00829114|Active Comparator|2|COC group
89178148|NCT00790296|Experimental|Thyrotropin releasing hormone (TRH)|TRH
89178149|NCT00790296|Placebo Comparator|Saline|Placebo
89178150|NCT02548702|Experimental|Community-based sport|Patients with type 2 diabetes will receive motivational counselling and will be allocated to a low intensity community-based sporting activity (Fit4Life programme) depending on their interests and perceived barriers to taking part.
89178151|NCT02548702|No Intervention|Control|One in 10 participants will be allocated to a control group who do not receive the intervention
89178152|NCT00829192|Experimental|1|Afamelanotide (CUV1647) implant administered subcutaneously every 60 days for 24 months
89534490|NCT03094377|Experimental|Multisensory therapy group|The Multisensory therapy (MT) group received a 12-weeks (two sessions/ week; 90 minutes/session) training conducted by an occupational therapist. Each session began with 15 minutes of sensory stimulation (cold and vibration), 45 minutes of motor training and 30 minutes of self-care training.
88832887|NCT05991726||Cohort 2: Non-Professional Expert|People living with a diagnosis of CKD. This survey focusses on people with non-dialysis CKD, typically stages 3-4. However, this study does not exclude participation by those at a more advanced stage or receiving renal replacement therapy (dialysis or transplant) as these people also have lived experience of earlier stages to draw on. This will also include 'significant others' whom are supporters or carers of people with CKD such as a family member or a partner of a person with CKD.
89178153|NCT00829192|Placebo Comparator|2|Placebo implant administered subcutaneously every 60 days for 24 months
88832888|NCT05991167||EndeavorRx Users|All participants with an active EndeavorRx prescription. Treatment regimen is as directed by their prescribing healthcare provider.
89178154|NCT00829270||mitochondrial diseases diagnosis|
89178155|NCT00824122||1|Children greater than 6 months receiving at least one dose of Vancomycin and Red Man Syndrome
89178156|NCT00824122||2|Children greater than 6 months receiving at least one dose of Vancomycin and has not had Red Man Syndrome
89178157|NCT00623194|Experimental|insulin detemir|Insulin detemir up to twice daily plus insulin aspart at larger meals, doses are adjusted individually (treatment up to 104 weeks)
89178158|NCT00829348|No Intervention|Statins, counseling|60 patients post ACS receiving the study medication + doctor/pharmacist explanation at discharge - control group
89178159|NCT00829348|Experimental|Statins, Counselling, SMS|60 patients post ACS receiving the study medication + doctor/pharmacist explanation at discharge + daily SMS reminder service (8 PM) - study group
89178160|NCT02548000|Experimental|Resistance training|Resistance training will be performed three times a week, for 12 weeks, composed by 12 resistance exercises for all body muscles with 2-3 series and 12-8 repetitions in each exercise.
89178161|NCT02548000|Active Comparator|Stretching control|The control group will perform one stretching session a week.
89178162|NCT00829582|Experimental|ETI-204|ETI-204, Anthim
89178163|NCT00829582|Sham Comparator|placebo|
89178164|NCT00831220||1|Patients with a COPD exacerbation
89399179|NCT03696459|Experimental|Part 1 (Dose Escalation): Panel 4 (Optional)|Participants will receive single oral dose of JNJ-53718678 (dose to be decided [this dose may be used in Part 2, Treatment F]) suspension or matching placebo on Day 1, under fasted condition, if 4500 mg dose in Panel 3 is considered safe and tolerable and if pharmacokinetic data require further dose escalation to reach the target exposure.
89534491|NCT03094377|Active Comparator|Conventional training group|The conventional training (CT) group included 12 weeks (two sessions/ week; 90 minutes/session) training conducted by an occupational therapist. Each session included 60 minutes of upper extremity motor practice (same as in MT group) and 30 minutes of self-care training (same as in MT group).
89178165|NCT00831220||2|Patients with stable COPD
89178166|NCT00831220||3|Smokers or former smokers
89178167|NCT00831220||4|Never smokers
89178168|NCT00831298|Other|1|Behavioral Questionnaire Sleep Recordings Genetic analysis
89178169|NCT00784368|Experimental|SFI (ITCZ Oral Solution Monotherapy)|Participants with deep-seated mycosis (Systemic Fungal Infection [SFI]) received itraconazole (ITCZ) oral solution in the dose range of 20 milliliter (ml) per day to 40 ml per day for 12 weeks as per Investigator's discretion.
89178170|NCT00784368|Experimental|SFI (Switched Treatment)|Participants with SFI received 200 milligram (mg) twice daily itraconazole intravenous (into the vein) infusion (ITCZ-IV) for first 2 days followed by 200 mg per day ITCZ-IV up to 14 days. Participants then received ITCZ oral solution in the dose range of 20 ml per day to 40 ml per day for 12 weeks as per Investigator's discretion.
89178171|NCT00784368|Experimental|FN (Switched treatment)|Participants with febrile neutropenia (FN) with suspected fungal infection received 200 mg twice daily ITCZ-IV for first 2 days followed by 200 mg per day ITCZ-IV up to 14 days. Participants then received ITCZ oral solution in the dose range of 20 ml per day to 40 ml per day for 12 weeks as per Investigator's discretion.
89178172|NCT02548468|Experimental|Reduced Intensity Conditioning, DLI, PBSCT|"REDUCED INTENSITY CONDITIONING: Patients receive fludarabine phosphate IV over 30 minutes on days -11 to -8 and undergo total body irradiation BID on day -7. Patients also receive donor CD3+ enriched T lymphocyte infusion on day -6 and high-dose cyclophosphamide IV over 2 hours on days -3 to -2.~TRANSPLANT: Patients undergo allogeneic PBSCT on day 0.~GVHD PROPHYLAXIS: Beginning on day -1, patients receive tacrolimus IV with taper (drug wean) by day 60 and mycophenolate mofetil IV BID on days -1 to 28 in the absence of GVHD."
89178173|NCT00829660|Active Comparator|Acarbose|The participants were given one tablet (50mg) of acarbose per day, taken with a meal during their first week (7 days). During the second week, the dose was increased to two tablets/day (50mg twice a day i.e. 100mg/day) and then three tablets/day (50mg three times a day i.e. 150mg/day) thereafter. The maximum tolerated dose is being taken for the duration of the trial (maximum dose is 150mg/day).
89178174|NCT00829660|Placebo Comparator|Matching Placebo|The participants were given one tablet of matching placebo per day, taken with a meal during their first week (7 days). During the second week, the dose was increased to two tablets/day and then three tablets/day thereafter. The maximum tolerated dose is being taken for the duration of the trial (maximum dose is 3 tablets/day).
89178175|NCT00915564|Experimental|TMC435 + methadone|Supervised intake of individualized methadone dose (range, 30 to 150 mg once daily) from Day -14 to Day -1; followed by addition of 150 mg dose of TMC435 once daily from Day 1 to Day 7 along with methadone; and later followed by continued intake of individualized methadone 30 to 32 days follow-up.
89178176|NCT02603406|Experimental|Group A|mechanical barrier disruption procedure + hrEPO manufactured by Dong-A pharmaceutics Multiple burrholes with local anesthesia after medication Drug: Erythropoietin 33,000u daily for 3 day via intravenous
89178177|NCT02603406|No Intervention|Group B|mechanical barrier disruption procedure Drug: no-specific intervention
89178178|NCT04106700|Experimental|Apixaban (single arm)|
89178179|NCT04107090|Experimental|US guided lung recruitment|Group A: it included 22 patients on whom the recruitment manoeuvre was applied guided by lung ultrasonography.
89178180|NCT04107090|Other|Non US guided lung recruitment|Group B: it included 22 patients on whom the recruitment maneuver was not ultrasound guided. This is considered the control group.
89361464|NCT05576883|Other|Emotion Regulation Intervention and Control Intervention|"Participants will be asked in the morning and in the evening at their self-selected time to evaluate their emotional state through ecological momentary assessment (EMA) and will be prompted to engage in an ER intervention (60% likelihood) or to read health information (40% likelihood). Upon completion they will evaluate the likability and helpfulness of the exercise or the article and re-evaluate their emotional state (post-EMA).~The intervention consists of 20 ER exercises and 20 health facts. The ER intervention is based on different therapeutic approaches targeting various underlying transdiagnostic factors such as rumination, self-referential thoughts etc. The 20 health facts will act as a placebo intervention with no effect on emotion regulation and keep participants engaged in the post-EMA evaluation when they are not randomized to an exercise.~The interventions and the control intervention materials were developed by the research team for the purposes of this study."
89361465|NCT05573724|Experimental|Treatment Arm|"Part A:~The participants will receive a single oral dose of AZD5305 on Day 1, followed by a 2-day washout. Then Itraconazole will be dosed for 3 days [BD] on Day 4 and [OD] on Days 5 and 6, then a single oral dose of AZD5305 administered concurrently with Itraconazole on Day 7 and only Itraconazole on Days 8 to 12.~Part B:~Patients proceeding to Part B after completing Part A of the study will receive AZD5305 OD as monotherapy."
89361466|NCT05573490|Experimental|Experimental Cognitive Training and Tai Chi- Qi Gong Arm|Participants receiving 14 weeks of Cognitive Training (BrainHQ) and Tai Chi- Qi Gong exercise training
89361467|NCT05573490|Active Comparator|Active Control Arm|Participants receiving 14 weeks of Brain Games (BrainHQ) and stretching
89361468|NCT05565144||cerebral amyloid angiopathy (CAA)|Patients with CAA treated with intravenous thrombolysis
89361469|NCT05562141||With lidocaine|Patient with injection of a 1.5 mg/kg bolus of lidocaine at induction of anaesthesia
89361470|NCT05562141||Without lidocaine|Patient without injection of a 1.5 mg/kg bolus of lidocaine at induction of anaesthesia
89361471|NCT05560399|Experimental|Iberdomide, Elotuzumab and Dexamethasone|Dose-Finding: Patients will be enrolled in a 3+3 dose escalation cohort. Dose-Expansion: additionally enrolled patients at the recommended maximum tolerated dose of Iberdomide as was determined in Part 1 (Dose-Finding Phase).
89361472|NCT05559736|Experimental|Artemis Proximal Femoral Nail (PFN) implant|All participants will receive the Artemis Proximal Femoral Nail (PFN) implant.
89361473|NCT05558384|Experimental|Aerobic exercise|15-week standardized aerobic exercise intervention
89361474|NCT05557331|No Intervention|Pre-intervention (no app)|Participants before (12-month retrospective period) the implementation of the app in the emergency department.
89361475|NCT05557331|Active Comparator|Post-intervention (PIMPmyHospital app)|Participants that will use the mobile heath PIMPmyHospital app during the prospective 6-month period after the implementation of the app in the emergency department.
89178181|NCT00831376|Experimental|levosalbutamol|Patients will be asked to take two puffs four times a day for 2 weeks
89361476|NCT05556967|Experimental|Immulina Dietary Supplementation|Immulina Dietary Supplementation (200 mg per capsule) 4-200 mg capsules given by mouth once on the only study visit day.
89361477|NCT05555121|Active Comparator|Endometrin 100 mg three times per day (TID)|Women with progesterone levels ≥ 8.8 ng/ml during frozen embryo transfer cycle will take Endometrin 100 mg TID until 10th week of pregnancy
89361478|NCT05555121|Active Comparator|Endometrin 200 mg three times per day (TID)|Women with progesterone levels < 8.8 ng/ml during frozen embryo transfer cycle will take Endometrin 200 mg TID until 10th week of pregnancy
89361479|NCT05553600|Other|Regular Absorbency|Modified regular absorbency tampon versus regular absorbency reference tampon
89361480|NCT05553600|Other|Super Absorbency|Modified super absorbency tampon versus super absorbency reference tampon
89361481|NCT05553015||PH Patients receiving treprostinil sodium treatment|Patients with pulmonary hypertension receiving treprostinil sodium treatment
89361482|NCT05550480|Experimental|Continuous glucose monitoring|"Participants will monitor their glucose levels using CGM with access to interstitial glucose levels continuously throughout the day.~Each study period is preceded by 20 days of masked CGM assessment."
89361483|NCT05550480|No Intervention|Self-monitoring of blood glucose|"Participants will monitor their blood glucose levels using a glucometer and a capillary blood sample from finger-pricking. Participants will in addition use masked CGM for the last 20 days of the study period to monitor glucose levels for comparison.~Each study period is preceded by 20 days of masked CGM assessment."
89178182|NCT00831376|Active Comparator|2: racemic salbutamol|Patients will be asked to take two puffs four times a day for 2 weeks
89178183|NCT00831376|Placebo Comparator|3: Placebo|Patients will be asked to take two puffs four times a day for 2 weeks
89178184|NCT02602470||Rosacea treated patients|Patients using topical rosacea treatment
89361484|NCT05547386|Experimental|Observational (68Ga-PSMA-11 PET/CT)|Patients receive 68Ga-PSMA-11 IV and then undergo a PSMA PET/CT scan throughout the trial.
89361485|NCT05541016|Active Comparator|Group 1 (observation)|Patients undergo observation following standard of care surgery. Patients undergo modified barium swallow study (MBSS) at pre-op, 2 weeks post-op, and 3 months follow-up. Patients also undergo CT, PET/CT, or magnetic MRI at baseline and 3 months and 1, 2 and 5 years post treatment. Patients undergo blood specimen collection for NavDx testing at pre-op, 1-2 days post-op, 2 weeks post-op, and 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 48, and 60 months.
89361486|NCT05541016|Experimental|Group 2 (DART, docetaxel)|Patients undergo DART with/without mucosal sparing BID on days 1-12 Monday-Friday for a total of 20 fractions within 8 weeks of standard of care surgery. Patients receive concurrent docetaxel IV over 1 hour on days 1 and 8 (Mondays preferred). Treatment continues in the absence of disease progression or unacceptable toxicity. Patients undergo MBSS at pre-op, 2 weeks post-op, and 3 and 12 months post-treatment. Patients also undergo CT, PET/CT, or MRI at baseline and 3 months and 1, 2 and 5 years post treatment. Patients undergo blood specimen collection for NavDx testing at pre-op, 1-2 days post-op, 2 weeks post-op, end of RT, and 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 48, and 60 months.
89361487|NCT05541016|Experimental|Group 3 (IMRT/IMPT, with/without cisplatin)|Patients undergo IMRT or IMPT QD on days 1-40 Monday-Friday for a total of 30 fractions within 6 weeks of standard of care surgery. Depending on risk status, patients may also receive concurrent cisplatin IV over 1-2 hours once a week QW on Monday, Tuesday, or Wednesday or once every 3 weeks for 6 doses (or accepted alternate regimen when drug shortage applies per physician discretion). Treatment continues in the absence of disease progression or unacceptable toxicity. Patients undergo MBSS at pre-op, 2 weeks post-op, and 3 and 12 months post-treatment. Patients also undergo CT, PET/CT, or MRI at baseline and 3 months and 1, 2 and 5 years post treatment. Patients undergo blood specimen collection for NavDx testing at pre-op, 1-2 days post-op, 2 weeks post-op, end of RT, and 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 48, and 60 months.
89361488|NCT05541016|Experimental|Group 4 (IMRT/IMPT, cisplatin)|Patients undergo IMRT or IMPT therapy QD on days 1-40 Monday-Friday for 28 or 35 fractions based on biomarker response along with concurrent cisplatin IV over 1-2 hours QW on Monday, Tuesday, or Wednesday or once every 3 weeks for 6 doses (or accepted alternate regimen when drug shortage applies per physician discretion). Treatment continues in the absence of disease progression or unacceptable toxicity. Patients undergo MBSS prior to RT and at 3 and 12 months post RT. Patients undergo CT, PET/CT, or MRI at baseline and 3 months and 1, 2 and 5 years post treatment. Patients undergo blood specimen collection for NavDx testing pre-RT, 4 weeks into RT, anticipated fraction 20, end of RT, 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 48, and 60 months.
89361489|NCT05540860|Experimental|Cohort 1|Drug: EDG-5506 Drug: Placebo
88832889|NCT05990894||Standard treatment group|Each patient received subcutaneous low-molecular-weight heparin in adjusted doses for 10 to 14 days, followed by oral anticoagulants (warfarin or dabigatran or rivaroxaban, if warfarin was used, PT-INR was maintained between 2.0 and 3.0) for 6 months or more. The use of endovascular treatment (local thrombectomy/thrombolysis) was reserved for patients who are still progressing with adequate anticoagulant therapy.
88832890|NCT05990894||Steroid therapy group|Patients in the steroid therapy group received short-term steroids in addition to standard anticoagulant therapy.
88832891|NCT05990335|Experimental|Cognition exercises group I|Subjects enrolled in this arm are exposed to an active task intervention designed for higher cognitive effort training functions
88832892|NCT05990335|Active Comparator|Cognition exercises group C|Subjects enrolled in this arm are exposed to an active task intervention designed for lower cognitive effort training functions
89361490|NCT05540860|Experimental|Cohort 2|Drug: EDG-5506 Drug: Placebo
89361491|NCT05540860|Experimental|Cohort 3|Drug: EDG-5506 Drug: Placebo
89361492|NCT05540860|Experimental|Cohort 4|Drug: EDG-5506 Drug: Placebo
88832893|NCT05990257|Experimental|HHB+TAPB+and LA|Group A: patients who received a HHB, TAPB, and LA
88832894|NCT05990257|Experimental|HHB+LA|Group B: patients who received HHB and LA
88832895|NCT05990257|Experimental|TAPB+LA|Group C: patients who received TAPB and LA
88832896|NCT05989477|No Intervention|Control Arm|The control arm will receive standard treatment.
88832897|NCT05989477|Experimental|Interventional Arm|Individuals within the intervention will receive standard care and access to the Breast Cancer Treatment Application (BCTA) for 13 months.
88832898|NCT05989438|Active Comparator|Premature that the family receives only orientation.|The orientations will happen once a month via telephone, and once a week a reminder will be sent. Follow-up will occur from 4 to 12 corrected months.
88832899|NCT05989438|Active Comparator|Premature who receive intervention by a specialized professional more orientation for the family|The frequency of stimulation by a specialized professional will vary according to the degree of prematurity, from approximately 1 to 8 times per month. The guidelines will take place on the days of the calls. Follow-up will occur from 4 to 12 corrected months.
88832900|NCT05989425|Experimental|surufatinib|Surufatinib 300mg will be taken orally once daily continuously through a 28-day cycle of study treatment. After treatment, the patients will receive operation treatment if the tumor is evaluated as resectable cases by clinical examination. Patients with high risk of postoperative recurrence will receive 131I treatment. After 131I treatment, maintenance treatment with surufatinib will be determined according to the recurrence risk stratification.
88832901|NCT05989386|Experimental|Group A|Intra-operative wound irrigation of 0.9% solution saline solution
89361493|NCT05540860|Experimental|Cohort 5|Drug: EDG-5506 Drug: Placebo
89361494|NCT05540860|Experimental|Cohort 2NS|Drug: EDG-5506 Drug: Placebo
89361495|NCT05538572|Experimental|PRT3645|PRT3645 capsules will be self-administered once daily, continuously, at the dose-level assigned
89361496|NCT05526651|Experimental|True electroacupuncture group|the investigators use stainless steel acupuncture needle, disposable : Huanqiu® 0.25 x 0.40 mm Electroacupuncture device : Hwato-SDZ V®, continuous wave, 2 Hz, for 30 minutes
89534492|NCT03331211||Chmotherapy combined with TKIs|Patients with ALL were treated by chmotherapy and TKIs(PDT-NFH-2016)
88832902|NCT05989386|Active Comparator|Group B|No intra-operative wound lavage done
88832903|NCT05989360|Experimental|observational|
88832904|NCT05989321||PVI alone group|Patients who undergo PVI alone using ThermoCool SmartTouch catheter.
88832905|NCT05989321||PVI + SPs ablation group|Patients who undergo PVI + SPs ablation using ThermoCool SmartTouch catheter.
88832906|NCT05989295|Placebo Comparator|Placebo group|2.0 g maltodextrin /sachet； Take one sachet a day before meals. Dilute in water； Store in a cool, dry place without sun exposure.
88832907|NCT05989295|Active Comparator|Probiotic group|(2B CFU/sachet) Lactobacillus rhamnosus LRa05 and maltodextrin Take one sachet a day before meals. Dilute in water； Store in a cool, dry place without sun exposure.
88832908|NCT05989243||Veterans with a transtibial amputation|20 Veterans with a transtibial amputation, 10 females and 10 males
88832909|NCT05989243||Veterans with a transfemoral amputation|20 Veterans with a transfemoral amputation, 10 females and 10 males
88832910|NCT05989230|Experimental|Emotional Awareness and Expression Therapy|Emotional Awareness and Expression Therapy (EAET) is a non-pharmacological intervention designed to address persistent pain.
88832911|NCT05989061|Experimental|PEEK customized healing abutment.|"Group I (Customized PEEK Healing Abutment):~13 patients will receive guided delayed implant and a customized PEEK healing abutment placed simultaneously with implant surgery"
88832912|NCT05989061|Active Comparator|Titanium customized healing abutment.|"Group II (Customized Titanium Healing Abutment):~13 patients will receive guided delayed implant and a customized titanium healing abutment placed simultaneously with implant surgery."
88832913|NCT05989009||Women < 32 weeks of gestational age|Women that delivered before 32 weeks of gestational age
88832914|NCT05989009||Women between 32 and 36,6 weeks of gestational age|Women that delivered between 32 and 36,6 weeks of gestational age
88832915|NCT05989009||Women > 37 weeks of gestational age|Women that delivered after 37 weeks of gestational age
88832916|NCT05988840||The hardware group (on-board camera)|A physical device equipped with a camera and embedding the acquisition/monitoring software. Positioned in the living space, it will be possible to capture the facial expressions of the person in ecology, for example when watching a TV program or reading.
88832917|NCT05988840||The software-only group (running on a PC or tablet and using the available webcam)|Software running on a computer, connected to the computer's camera (webcam). If the person is teleworking on a PC, it is expected that images will be captured during videoconferencing-type interactions.
88832918|NCT05988801|Experimental|Glass ionomer sealant|glass ionomer based sealant material
88832919|NCT05988801|Active Comparator|Resin sealant|resin-based sealant material
88832920|NCT05988788|Experimental|Epigallocatechin-3-Gallate|20% Epigallocatechin-3-Gallate solution
88832921|NCT05988788|Active Comparator|sodium hypochlorite|2.5% sodium hypochlorite
88832922|NCT05988775|Experimental|Leg training|Participants sat on a chair with their left heel resting on the table with the push button switches. participants performed 10 blocks of the aforementioned sequence with their leg, with a 30s break between each block.
88832923|NCT05988775|Active Comparator|Sequence observation|Participants observed 10 blocks of the sequence with the lights alternating automatically, with a 30s break between each block.
88832924|NCT05988775|Other|Nature movie watching|"Participants watched a scenic relaxation film, for 10 minutes, with a 30s break after every minute."
88832925|NCT05988736|Experimental|Group A|
88832926|NCT05988736|Active Comparator|Group B|
88832927|NCT05988723||Study Group (obese patient)|Leptin, IL-6, OPG, RANKL levels were measured in samples taken from the distal gingival groove of the canine teeth of obese individuals. Roth metal brackets and tubes with 0.022 inch slots were used for the fixed orthodontic treatment of the patients. After leveling the teeth of the patients with arch wires, it was waited for 2 months in 19x25 stainless steel arch wire and then 150 gr distalization force was applied. DOS samples were taken from the distal gingival groove of teeth on day 7 (T2), day 14 (T3) and day 21 (T4), just before distalization force was applied (T0), 24 hours after force was applied (T1). In order to determine the speed of tooth movement, the patient's mouth was scanned on the days when DOS was taken (T0,T1,T2,T3,T4) and in addition to these days, on the 28th day (T5) and at the end of the 3rd month (T6), and the amount of movement of the canine tooth was measured in mm. Leptin, IL-6, OPG, RANKL levels were examined with Elisa kits from the samples obtained.
88832928|NCT05988723||Control Group (normal patient)|Leptin, IL-6, OPG, RANKL levels were measured in samples taken from the distal gingival groove of the canine teeth of normal weight individuals.Roth metal brackets and tubes with 0.022 inch slots were used for the fixed orthodontic treatment of the patients.After leveling the teeth of the patients with arch wires, it was waited for 2 months in 19x25 stainless steel arch wire and then 150 gr distalization force was applied.DOS samples were taken from the distal gingival groove of teeth on day 7 (T2), day 14 (T3) and day 21 (T4), just before distalization force was applied (T0), 24 hours after force was applied (T1). In order to determine the speed of tooth movement, the patient's mouth was scanned on the days when DOS was taken (T0,T1,T2,T3,T4) and in addition to these days, on the 28th day (T5) and at the end of the 3rd month (T6), and the amount of movement of the canine tooth was measured in mm. Leptin, IL-6, OPG, RANKL levels were examined with Elisa kits from the samples obtained.
88832929|NCT05988619|Active Comparator|iCBT and TMS|All participants complete six weeks of TMS treatment (five days per week) within the UCLA TMS Clinic. Participants in this condition additionally access iCBT materials and attend a weekly session for 30 minutes with a trained mental health coach to discuss iCBT content.
88832930|NCT05988619|Placebo Comparator|Psychoeducation and TMS|All participants complete six weeks of TMS treatment (five days per week) within the UCLA TMS Clinic. Participants in this condition additionally access educational materials about mental health and attend a weekly session for 30 minutes with a trained mental health coach to discuss educational content.
89361497|NCT05526651|Sham Comparator|sham electroacupuncture group|"the investigators use the same device like true electroacupuncture group, but the acupuncture needle not puncture on the skin and only attached.~electroacupuncture device, with no electrical stimulation"
89361498|NCT05524246|Experimental|Pravastatin Prophylactic Treatment|
89361499|NCT05520307||HF|Patients with heart failure.
89361500|NCT05520307||IHD|Patients with ischemic heart disease.
89001067|NCT04631614|Experimental|Manual therapy plus muscle strengthening exercises|The procedures to be performed with participants in the experimental group are as follows: (1) warm up with a walk or exercise bike for 5 minutes; (2) two ankle manual therapy techniques - [a] passive calf muscle stretching and [b] ankle joint mobilization; (3) five muscle strengthening exercises focusing on quadriceps and posterolateral hip complex - [a] clam exercise, [b] hip abduction exercise in side lying, [c] knee extension exercise in a sitting position, [d] squat exercise and [e] forward lunge exercise.
89178185|NCT00829816|Experimental|Dimebon|20 mg dimebon by mouth 3 times per day
89178186|NCT00829816|Placebo Comparator|Placebo|20 mg placebo by mouth 3 times per day
89178187|NCT00824200|Experimental|Behavioral and Exercise Therapy (M-BET)|Multicomponent behavior and exercise therapy program (M-BET) - pelvic floor muscle exercises, urge suppression strategies, fluid strategies, sleep hygiene & non-pharmacological management of peripheral edema. M-BET alone will be given with placebo capsules.
89178188|NCT00824200|Active Comparator|Drug Therapy w/ Behavioral Placebo|alpha-adrenergic antagonist medication with a placebo behavioral intervention
89178189|NCT00824200|Active Comparator|Combination Therapy|Combination therapy: MBET and alpha-adrenergic antagonist medication
89178190|NCT04043884|Experimental|sEmg Biofeedback training|8-week exercise program, twice a week, with emg biofeedback training.
89178191|NCT04043884|Active Comparator|Exercises|8-week exercise program, twice a week.
89178192|NCT04103736|Experimental|Beet Juice Supplement|A single, acute dose of Beet It Sport Shot containing ~12.6mmol naturally occurring dietary nitrates.
89178193|NCT04103736|Placebo Comparator|Placebo juice|A single, acute dose of nitrate-depleted Beet It Sport Shot
89178194|NCT00829894|Experimental|1|Risperidone 1 mg Tablet
89178195|NCT00829894|Active Comparator|2|Risperdal® 1 mg Tablet
89178196|NCT00622726|Experimental|Bevacizumab for ROP|Intravitreal Bevacizumab Therapy is the Experimental Arm of this Study
89178197|NCT00622726|Active Comparator|Conventional Laser for ROP|Conventional Laser to the Peripheral Retina is the Control Arm of this Study
89178198|NCT00831610|Other|STUDY|"Female healthy volunteers (25 to 55 years old) with normal weight.~Morbid Obese women waiting for bariatric surgery.~Post-bariatric female patients, 25 to 55 years old, MORE than 12 months of weight stability, pendular abdominal wall, clinical conditions to anchor-line abdominoplasty without flap undermining. Skin Evaluation before the abdominoplasty.~Group 3, submitted to anchor-line abdominoplasty without flap undermining."
89178199|NCT00831610|Other|CONTROL|Group 3: Post-bariatric female patients, 25 to 55 years old, LESS than 12 months of weight stability, pendular abdominal wall, clinical conditions to anchor-line abdominoplasty without flap undermining. Who will be submitted to abdominoplasty after the study period.
89178200|NCT00830050|Experimental|Arm 1|
89178201|NCT00830050|Placebo Comparator|Arm 2|
89178202|NCT00623428|Experimental|PEG-IFN alfa-2a + Ribavirin for 24 weeks|After 24 weeks of treatment with pegylated interferon alfa-2a (PEG-IFN alfa-2a) 180 μg/week plus ribavirin 800-1200 mg/day participants who achieved at least a 2-log10 drop of hepatitis C virus (HCV) ribonucleic acid (RNA) at Week 12 (as compared to HCV RNA levels prior to treatment initiation) or had HCV RNA <15 IU/mL, and who were still taking study medication at treatment Week 24 were randomized into the study, at which time treatment was stopped. Participants were followed for an additional 48 weeks during the treatment-free follow-up period.
89178203|NCT00623428|Active Comparator|PEG-IFN alfa-2a + Ribavirin for 48 weeks|After 24 weeks of treatment with PEG-IFN alfa-2a 180 μg/week plus ribavirin 800-1200 mg/day participants who achieved at least a 2-log10 drop of HCV RNA at Week 12 (as compared to HCV RNA levels prior to treatment initiation) or had HCV RNA <15 IU/mL, and who were still taking study medication at treatment Week 24 were randomized into the study, and continued treatment for another 24 weeks (for a total of 48 weeks of treatment). Participants were followed for an additional 24 weeks during the treatment-free follow-up period.
89178204|NCT00831688|Active Comparator|1|Local overpressure treatment
89178205|NCT00831688|Placebo Comparator|2|Placebo treatment
89178206|NCT00824356|Active Comparator|GSK1004726 (1000mg)|1000mg aqueous suspension
89178207|NCT00824356|Placebo Comparator|Placebo|Intranasal spray
89178208|NCT00824356|Active Comparator|GSK1004723 (200mg)|200 mg aqueous suspension
89001068|NCT04631614|Active Comparator|Muscle strengthening exercises|The procedures to be performed with participants in the control group are as follows: (1) warm up with a walk or exercise bike for 5 minutes; (2) five muscle strengthening exercises focusing on quadriceps and posterolateral hip complex - [a] clam exercise, [b] hip abduction exercise in side lying, [c] knee extension exercise in a sitting position, [d] squat exercise and [e] forward lunge exercise.
89178209|NCT00831922|Experimental|1|masitinib (AB1010) 3 mg/kg/day
89178210|NCT00831922|Experimental|2|masitinib (AB1010) 6 mg/kg/day
89178211|NCT00824590|Experimental|Severe renal impairment group|Subjects with severe renal impairment defined by creatinine clearance of less than 30 mL/min but not yet on dialysis
89361501|NCT05516199|Experimental|Antenatal breastmilk expression|Breastfeeding consultation with trained midwife in week 33 + antenatal breastmilk expression from week 34
89361502|NCT05516199|Other|Control|Breastfeeding consultation with trained midwife in week 33
89178212|NCT00824590|Experimental|normal renal function|Subjects with normal renal function defined by creatinine clearance of greater than 80 mL/min and demographically comparable to subjects with impaired renal function
89178213|NCT00837304||UC|Patients with known ulcerative colitis
89178214|NCT00832156|Experimental|1|wound 1: the placement of keratinocytes onto a collagen/elastin support after the application of the meshed split skin autograft.
89178215|NCT00832156|Other|2|control wound site; application of mesh graft alone
89178216|NCT00837382|Experimental|1|MEDVAMC Nightmare Treatment
89178217|NCT00837382|Experimental|2|Videoconferencing nightmare Treatment
89361503|NCT05514574|Experimental|Music|Patients (listening to music group) who are taken to the intervention table and placed on their backs by the team that will perform the intervention will be monitored. The hemodynamic parameters on the monitor screen will be recorded on the data collection form before and after percutaneous coronary intervention by the researcher KY. Anxiety levels of patients will be evaluated by the researcher KY with the State Anxiety Scale before being taken to the intervention room for percutaneous coronary intervention (while in a bed or stretcher or wheelchair). Anxiety levels of patients will be evaluated by the researcher KY with the State Anxiety Scale after leaving the intervention room (while on the bed or stretcher). During percutaneous coronary intervention; Except for routine treatment and care interventions, the patient will listen to music during the procedure.
89361504|NCT05514574|Experimental|Stress ball|Patients (stress ball group) who are taken to the intervention table and placed on their backs by the team that will perform the intervention will be monitored. The hemodynamic parameters on the monitor screen will be recorded on the data collection form before and after percutaneous coronary intervention by the researcher KY. Anxiety levels of patients will be evaluated by the researcher KY with the State Anxiety Scale before being taken to the intervention room for percutaneous coronary intervention (while in a bed or stretcher or wheelchair). Anxiety levels of patients will be evaluated by the researcher KY with the State Anxiety Scale after leaving the intervention room (while on the bed or stretcher). During percutaneous coronary intervention; Except for routine treatment and care interventions, the patient will stress ball will be applied during the procedure.
89361505|NCT05514574|No Intervention|Control|Patients (control group) who are taken to the intervention table and placed on their backs by the team that will perform the intervention will be monitored. The hemodynamic parameters on the monitor screen will be recorded on the data collection form before and after percutaneous coronary intervention by the researcher KY. Anxiety levels of patients will be evaluated by the researcher KY with the State Anxiety Scale before being taken to the intervention room for percutaneous coronary intervention (while in a bed or stretcher or wheelchair). Anxiety levels of patients will be evaluated by the researcher KY with the State Anxiety Scale after leaving the intervention room (while on the bed or stretcher). During percutaneous coronary intervention; No intervention will be performed except for routine treatment and care interventions.
89361506|NCT05514327|Experimental|treatment group|ultra-fraction radiotherapy + CAR-T
89361507|NCT05513053|Experimental|Group 9 to 17 years old|Participants of 9 to 17 years old who will receive RIV4 single intramuscular (IM) injection at D01
89361508|NCT05513053|Experimental|Group 18 to 49 years old|Participants of 18 to 49 years old who will receive RIV4 single intramuscular (IM) injection at D01
89361509|NCT05509049|Experimental|Treatment|Behavioral science and reinforcement learning-driven hyper-personalized messages
89361510|NCT05509049|Active Comparator|Control|Standard of care message
89361511|NCT05508750|Experimental|New Infant Formula|New infant formula for healthy term infants
89361512|NCT05508750|Active Comparator|Commercial Infant Formula|Standard, commercially available infant formula for healthy term infants
89361513|NCT05508750|No Intervention|Human Milk|Breastfed infants serve as a reference group
89361514|NCT05505968|Experimental|virtual reality - Day1|Use of the virtual reality headset during the first epidural infiltration (Day 1). The second infiltration (Day 3) will be performed without the virtual reality headset.
88832931|NCT05988606|Experimental|15TEMP|Participants cycled at 70% heart rate max for 8 min as a warm-up and then completed one round of HIIT, i.e., 4 min at 90% heart rate max followed by 3 min at 70% heart rate max for a total of 15 minutes in a temperate environment, followed by a graded exercise test to measure maximal aerobic capacity.
89361515|NCT05505968|Experimental|virtual reality - Day3|First epidural infiltration without the virtual reality headset (day 1). The second infiltration will be performed with the virtual reality headset (Day 3).
89361516|NCT05503771|Experimental|Intervention Group: ISA-MI|"The ISA-MI study condition involves, in addition to the standard of care described for the SOC group, a clinician training activity related to using the ISA (Infant Sleep Assessment) tool. Clinicians assigned to the ISA-MI Group will view a 20-30-minute recorded video training session on infant safe sleep (including its epidemiology, risk factors and recommendations), use of the ISA tool, and use of motivational interviewing-inspired (MI) communication skills to respond to ISA parent responses. The ISA tool builds on the 2022 AAP infant sleep recommendations and will be implemented at the 2-month WBV.~Parents/patients of physicians in the ISA-MI study condition will also be given several infant safe sleep related products that facilitate compliance with safe sleep recommendations, namely, a portable crib, a sleep sack and a pacifier."
88832932|NCT05988606|Experimental|15HEAT|Participants cycled at 70% heart rate max for 8 min as a warm-up and then completed one round of HIIT, i.e., 4 min at 90% heart rate max followed by 3 min at 70% heart rate max for a total of 15 minutes in a hot environment, followed by a graded exercise test to measure maximal aerobic capacity.
88832933|NCT05988606|Experimental|43TEMP|Participants cycled at 70% heart rate max for 8 min as a warm-up and then performed the HIIT protocol (4 min at 90% heart rate max and 3 min at 70% heart rate max, repeated 4 times for a total of 43 minutes) in a temperate environment followed by a graded exercise test to measure maximal aerobic capacity.
88832934|NCT05988606|Experimental|43HEAT|Participants cycled at 70% heart rate max for 8 min as a warm-up and then performed the HIIT protocol (4 min at 90% heart rate max and 3 min at 70% heart rate max, repeated 4 times for a total of 43 minutes) in a hot environment followed by a graded exercise test to measure maximal aerobic capacity.
88832935|NCT05988606|No Intervention|Control|Participants completed a graded exercise test on a stationary bicycle in a temperate environment (~ 22 °C (72 °F), ~40% RH) to measure maximal aerobic capacity and maximal heart rate.
88832936|NCT05988476|No Intervention|Control|
88832937|NCT05988476|Experimental|Stretching Exercise|
88832938|NCT05988476|Experimental|Pulsed Electromagnetic Field|
88832939|NCT05988476|Experimental|Pulsed Electromagnetic Field and Stretching Exercise|
88832940|NCT05988450|Experimental|SQ-Kyrin TMVr System|Transcatheter edge-to-edge mitral valve repair using SQ-Kyrin TMVr System.
88832941|NCT05988424|Active Comparator|Pentaray|Initial map collected with Pentaray
89361517|NCT05503771|Other|Control Group: Standard of Care (SOC)|The SOC study condition consists of WBVs that follow the usual practice of American Academy of Pediatrics (AAP) Bright Futures Health Supervision Guidelines and includes age- and developmentally based anticipatory guidance. As part of their training, pediatric residents receive formal teaching on core aspects of providing primary care to infants, including the AAP recommendations on safe sleep. This includes the recommended ABCS: babies should sleep Alone (no objects or people), on their Back (supine), in a Crib (or safe alternative including portable crib or bassinet), and in a Smoke-free environment.
89361518|NCT05500040||Patients with IBD - Crohn's Disease|
89361519|NCT05500040||Patients with IBD - Ulcerative Colitis|
89361520|NCT05499455|Active Comparator|Control|Active Control
89361521|NCT05499455|Experimental|Positional Sleep Belt|Rematee Positional Sleep Belt
89361522|NCT05499286|Active Comparator|Mindfulness Program|Participants will attend an online mindfulness program known as the Mindful Awareness and Resilience Skills for Adolescents (MARS-A) program.
89361523|NCT05499286|No Intervention|Online Peer Support Program|Participants will attend an online peer support program where they will engage with each other by sharing experiences while providing advice and emotional support.
89361524|NCT05495243|Experimental|ARINA-1|ARINA-1 (88 mg/mL ascorbic acid, ASC; 150 mg/mL reduced glutathione, GSH); fixed dose, 4 mL solution inhaled twice daily via nebulization for 28 days
89361525|NCT05495243|Placebo Comparator|Placebo|Isotonic saline (0.9%); 4 mL solution inhaled twice daily via nebulization for 28 days
89361526|NCT05491213|Experimental|TELESCOPE intervention|Participants will be surveyed at baseline and at one-week after the scheduled primary care office visit. If a participant is a current smoker then they are offered and navigated to evidence-based smoking cessation. If the participant is interested in screening, an LDCT is ordered. Support for screening, diagnostic testing and oncology care will be provided as needed from the Nurse Navigators.
89361527|NCT05491213|No Intervention|Enhanced usual care (EUC)|Participants will be surveyed at baseline and at one-week after the scheduled primary care office visit. Primary and secondary outcome data related to the office visit will be collected.
89361528|NCT05487859|Experimental|Arm 1|"Ipilimumab (1 mg/kg) IV q3wks + Nivolumab (3mg/kg) IV q3wks + Acarbose (upto 100 mg PO TID) followed by Nivolumab 480 mg IV q4 wks + Acarbose (upto 100 mg PO TID)~OR~Pembrolizumab 200 mg IV q3 wks or 400 mg IV q6 wks + Lenvatinib (up to 20 mg PO Daily) + Acarbose (upto 100 mg PO TID) [ Frontline/Refractory pts]~OR~Lenvatinib (upto 18 mg PO daily) + Everolimus (upto 5 mg PO Daily) + Acarbose (upto 100 mg PO TID) [ Refractory pts]~OR~Cabozantinib (upto 60 mg PO Daily) + Acarbose (upto 100 mg PO TID) [Refractory pts]"
89361529|NCT05487677|Experimental|BioBrace Augmentation|During the shoulder replacement surgery (arthroplasty) in order to access the shoulder, the subscapularis is removed from its insertion in your upper arm bone. It is repaired in reverse total shoulder arthroplasty, but is sometimes not as robust as we would like based on tissue quality and other factors. A shoulder arthroplasty is when the ball and socket are replaced with prosthetic components. If randomized to the BioBrace, patient will receive BioBrace augmentation of the standard subscapularis repair.
89361530|NCT05487677|Active Comparator|Standard Repair with Sutures|During the shoulder replacement surgery (arthroplasty) in order to access the shoulder, the subscapularis is removed from its insertion in your upper arm bone. It is repaired in reverse total shoulder arthroplasty, but is sometimes not as robust as we would like based on tissue quality and other factors. A shoulder arthroplasty is when the ball and socket are replaced with prosthetic components. If randomized to standard repair, patient will receive the standard repair with sutures.
89361531|NCT05486897||cerebral amyloid angiopathy|Patient with cerebral amyloid angiopathy
89361532|NCT05486897||Hypertensive arteriopathy|Patients with hypertensive arteriopathy
89361533|NCT05486481|Experimental|Phase I (venetoclax, dexamethasone, daratumumab)|All participants receive 400 mg venetoclax once a day (QD) on days 1-28 of each cycle. Depending on the number of DLTs reported for this dose-level, participants may also receive dexamethasone on days 1, 8, 15, and 22 of each cycle with or without daratumumab on days 1, 8, 15, and 22 of cycles 1-2, days 1 and 15 of cycles 3-6, then on day 1 of cycles thereafter. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
89361534|NCT05486481|Experimental|Phase II (venetoclax, dexamethasone, daratumumab)|Participants will receive the RP2D of venetoclax QD on days 1-28 of each cycle, dexamethasone on days 1, 8, 15, and 22 of each cycle, and daratumumab on days 1, 8, 15, and 22 of cycles 1-2, days 1 and 15 of cycles 3-6, then on day 1 of cycles thereafter. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity
89361535|NCT05482945|Experimental|Intervention|Patients will be ventilated with a mixture of Ar 70%/O2 30% for 4 hours
89178218|NCT00837460|Experimental|rehabilitation|Bilateral and unilateral prehension oriented rehabilitation to enhance prehension.
89361536|NCT05482945|No Intervention|Control-standard|Ventilation with a FiO2 of 30% in room air is continued for 4 hours.
89534493|NCT05040165|Experimental|Failure time analysis|"The primary objective is to evaluate the durability of the investigational device over its intended use lifetime (i.e. warranty period), specifically relating to any defect in the TPE material. Additionally, to gather information on the rate of side-effects, i.e. skin rashes, sores, etc.~Secondary objectives relate to gather information on how amputees use the liner, specifically:~Intensity of use (days/week and hours/day)~Alternation; i.e. switching every other day between liners~Use of personal hygiene or cosmetic products~The following performance and safety aspects are to be verified:~• The ICEFORM line of devices are durable over their intended use lifetime."
88832942|NCT05988424|Active Comparator|Octaray|Initial map collected with Octaray
88832943|NCT05988385|Active Comparator|3-month OSA treatment|"A 3-month OSA treatment by any combination of PAP, OAT, and positional therapy that results in an effective AHI3a<15 (rapid multi-modal treatment RMMT)."
88832944|NCT05988385|Other|Waitlist control group|A waitlist control group to receive treatment at the conclusion of the 3-month intervention period.
88832945|NCT05988359|Active Comparator|Dental turbine|In the first group, G1 (n=30) a conventional high-volume evacuator (Monoart® Euronda, Vicenza, Italy) was used to remove aerosols during caries treatment by a dental turbine.
88832946|NCT05988359|Experimental|Laser|In the second G2 (test, n=30) group, a conventional high-volume evacuator (Monoart® Euronda, Vicenza, Italy) was used to remove aerosols during caries treatment by an Er:YAG laser.
88832947|NCT05988333|Experimental|Psychoeducational Family Intervention|The experimental intervention will be administered individually to each recruited family. Sessions will take place three times a month for a period ranging from 4 to 6 months (about 18 sessions in total). The number of sessions, as well as the frequency, may vary depending on the patient's clinical situation. Sessions will have an average duration of 60-90 minutes.
88832948|NCT05988333|Active Comparator|Informative intervention|The informative intervention consists of five sessions, administered every 7-10 days.
88832949|NCT05988307|Experimental|receive percussion massage gun and conventional physical therapy program|
89361537|NCT05478837|Experimental|Treatment (KIND T cells, cyclophosphamide, fludarabine)|Patients receive fludarabine IV on days -4, -3, and -2 and cyclophosphamide IV on day -2 in the absence of disease progression or unacceptable toxicity for the conditioning regimen. Patients also receive KIND T cells IV at dose level 1 (2 x 106 dextramer®+ CD8+ cells/kg) on day 0. If no DLTs are reported, newly enrolling participants may receive dose level 2 of KIND T cells on day 0.
89361538|NCT05469321||Patients|patients presenting to the CHU of Nîmes for an acute or subacute neurological picture after having consumed N2O.
89361539|NCT05454995|Experimental|Alucent VRS for Treatment of Atherosclerotic Lesions|Combination Product: VRS
89361540|NCT05451329|Active Comparator|VVN539 Ophthalmic Solution 0.02%|VVN539 Ophthalmic Solution 0.02%
89361541|NCT05451329|Active Comparator|VVN539 Ophthalmic Solution 0.04%|VVN539 Ophthalmic Solution 0.04%
88832950|NCT05988307|Other|receive conventional physical therapy program only for knee osteoarthrities|
89361542|NCT05451329|Placebo Comparator|VVN539 Ophthalmic Solution Vehicle|VVN539 Ophthalmic Solution Vehicle
89361543|NCT05450978||Lamotrigine (LTG)|Participants will include women with epilepsy planning pregnancy within the next 6 months and treated with lamotrigine (LTG)
89361544|NCT05450978||Levetiracetam (LEV)|Participants will include women with epilepsy planning pregnancy within the next 6 months and treated with Levetiracetam (LEV)
89361545|NCT05450562|Experimental|SAR444200 - Dose Escalation Phase (Part 1A)|SAR444200 will be administered as intravenous injection as monotherapy in participants with GPC3+ solid tumors over a 21-day cycle
89361546|NCT05450562|Experimental|SAR444200 - Dose Expansion Phase (Part 2A)|SAR444200 will be administered as intravenous injection in participants with GPC3+ NSCLC over a 21-day cycle
89361547|NCT05450562|Experimental|SAR444200 and Atezolizumab combination therapy - Dose Escalation Phase (Part 1B)|SAR444200 in combination with atezolizumab will be administered as intravenous injection in participants with GPC3+ solid tumors over a 21-day cycle
89361548|NCT05444192|Active Comparator|insoles manufactured from foam-box cast|Both arms are currently standard treatment within the NHS GGC Orthotic Department. There are no experimental interventions in the study.
89361549|NCT05444192|Active Comparator|insoles manufactured from direct 3D scan|Both arms are currently standard treatment within the NHS GGC Orthotic Department. There are no experimental interventions in the study.
89361550|NCT05441813|Experimental|Standard of care + virgin coconut oil|Arm A: Standard of care + virgin coconut oil
89361551|NCT05441813|No Intervention|Standard of Care|Arm B: Standard of care
89534494|NCT03335735|Experimental|Loss-Framed Text Messages|Loss-framed text message
89534495|NCT03335735|No Intervention|Control|Participants in this arm will not receive any intervention.
89534496|NCT03335735|Experimental|Gain-Framed Messaging Group|Gain-framed text message
88832951|NCT05988281|Experimental|Type I dental implant placement.|Type I dental implant placement (immediately after extraction)
88832952|NCT05988281|Experimental|Type II dental implant placement.|Type II dental implant placement (6-8 weeks after extraction)
88832953|NCT05988281|Experimental|Type III/IV placement.|Type III/IV placement in socket preserved sites after 3-6 months.
89534497|NCT01929915|Active Comparator|Epidural patient controlled analgesia|Epidural patient controlled analgesia
89361556|NCT05440097|Other|single-arm|GINA guideline education and implementation
89361557|NCT05434949||Effect of food intake on C4|Blood tests to analyse serum C4 pre, and 2 and 4 hours post a standardised meal, and the same 10 patients to analyse serum C4 at 0, 2 and 4 hours, all fasting.
89361558|NCT05434949||Effect of Lipid-lowering therapy on C4|Spare sample collected from patients before and after starting on lipid-lowering therapy will be used to measure C4 before and after lipid-lowering therapy.
88832954|NCT05988268|Active Comparator|Vibration Foam Rolling Group|The vibration foam rolling method will be applied to the gluteal, tensor fascia latae, hamstring, quadriceps femoris, and gastrocnemius muscles of both lower extremities of the participants in the Vibration Foam Rolling Group, in addition to the routine warm-up protocol, 3 days a week for a total of 15 minutes a day for 6 weeks.
88832955|NCT05988268|Active Comparator|Non-Vibration Foam Rolling Group|The non-vibration foam rolling method will be applied to the gluteal, tensor fascia latae, hamstring, quadriceps femoris, and gastrocnemius muscles of both lower extremities of the participants in the Non-Vibration Foam Rolling Group, in addition to the routine warm-up protocol, 3 days a week for a total of 15 minutes a day for 6 weeks.
88832956|NCT05988268|No Intervention|Control Group|No intervention will be applied to the control group. This group will continue the routine warm-up protocol.
88832957|NCT05988255|Experimental|Static progressive stretch|
88832958|NCT05988255|Active Comparator|Cyclic manual stretch|
88832959|NCT05988255|No Intervention|No treatment|
88832960|NCT05988242|Experimental|primrose oil|primrose oil
89361559|NCT05430412|Experimental|Adacolumn|"Adacolumn is a non-pharmacological treatment which reduces the inflammation by removing specifically targeted white blood cells from the blood circulation. The Adacolumn is designed to be used in combination with the Adamonitor and its Adastand, and the Adacircuit. The column has a capacity of 335 mL and is filled with cellulose acetate beads of 2 mm in diameter as the column adsorptive leukocytapheresis carriers. The carriers are bathed in 130 mL of sterile saline until use when the column is primed with additional sterile saline and then with heparinized saline prior to use.~Patients will receive 10 sessions with Adacolumn. It would be reduced between 5 - 10, according to the patient´s response and following PI valuation. Patients will receive Adacolumn with IFX for that period of time.~Patients will have received previously IFX for 12-16 weeks. visits will be conducted every week, for the application of Adacolumn."
89534498|NCT01929915|Sham Comparator|Intravenous patient controlled analgesia|Intravenous patient controlled analgesia for post operative pain control
89361560|NCT05428969|Experimental|Phase 1 - Intermediate/high risk MDS, CMML 10-19%, MDS/CMML failure to HMA, r/r AML|Standard of care azacitidine as per label; bexmarilimab 4 dose levels at once every week (Q1W) followed by once every 2 weeks (Q2W); 28-day cycle
89361561|NCT05428969|Experimental|Phase 1 - Newly diagnosed AML patients non-fit for induction therapy|Standard of care azacitidine and venetoclax as per label; bexmarilimab 4 dose levels Q1W followed by Q2W; 28-day cycle
89361562|NCT05428969|Experimental|Phase 2 - Intermediate/high risk MDS, CMML, MDS/CMML failure to HMA, r/r AML & newly diagnosed AML|Standard of care venetoclax and/or azacitidine as per label plus bexmarilmab
89361563|NCT05425420|Experimental|Single arm, Open label Methadone IV|All participants will be treated with Methadone Hydrochloride IV (over 10 minutes) and monitored overnight.
89361564|NCT05422430|Sham Comparator|Spontaneous breathing|Participants will be spontaneously breathing during an oral glucose tolerance test.
89361565|NCT05422430|Experimental|Rebreathing-induced hypoxia|Participants will rebreathe room air from a low-volume closed-circuit system for a period of 2 minutes.
89361566|NCT05417516|Active Comparator|Whole Breast Irradiation (WBI)|26 Gy in 5 fractions to the whole breast
89361567|NCT05417516|Experimental|Partial Breast Irradiation (PBI)|26 Gy in 5 fractions to the tumour bed with a margin of normal tissue
89361568|NCT05417217|Active Comparator|Control group|"Ventilation is discontinued after going on CPB and lungs are exposed to atmospheric pressure.~Blood will be drawn:~At baseline: before general anaesthesia, after start of CPB, after clamping the aorta, before unclamping the aorta, after the operation, 5 h after clamping the aorta, 12 hours after clamping the aorta, and 24 hours after aortic clamping"
89361569|NCT05417217|Experimental|Ventilation group|"Ventilation is continued from going on CPB until clamping of the ascending aorta.~Blood will be drawn:~At baseline: before general anaesthesia, after start of CPB, after clamping the aorta, before unclamping the aorta, after the operation, 5 h after clamping the aorta, 12 hours after clamping the aorta, and 24 hours after aortic clamping"
89361570|NCT05415124|Experimental|HemoPIll group|Participants who have scheduled endoscopies will be given the HemoPill acute capsule and the HemoPill Receiver will be activated (connected to the HemPill). Approximately 20 to 60 minutes after HemoPill acute capsule ingestion, the endoscopy will start. The attending physician will proceed with the endoscopic intervention in accordance with clinical practice and NYU protocols, which is a standard procedure. In the case bleeding pathologies are found, these will be endoscopically treated as per clinical standard.For later evaluation of the HemoPill acute measurement, a statistical correlation of the obtained data from the HemoPill Acute measurement with the endoscopic findings will be performed. The HemoPill acute capsule travels through and leaves the body naturally
89361571|NCT05406115|Experimental|Part A: Single Ascending Dose Cohorts|Participants in 4 cohorts will receive either AMG 786 or placebo in Single Ascending Doses.
89361572|NCT05406115|Experimental|Part A: Food Effect Cohort|Participants in the food effect cohort (FEC) will receive 1 of 2 AMG 786 in 1 of two sequences. Participants in Sequence 1 will receive a dose of AMG 786 on day 1 under fed conditions followed by a 10-day washout period and another dose of AMG 786 on day 11 under fasted conditions. Participants in Sequence 2 in the FEC cohort will receive the first dose on day 1 under fasted conditions and the second dose on day 11 under fed conditions.
89361573|NCT05406115|Experimental|Part B: Multiple Ascending Dose Cohorts|Participants in 4 cohorts will receive either AMG 786 or placebo in Multiple Ascending Doses.
89361574|NCT05397639|Experimental|Low Dose Masupirdine Arm|Tablet
89361575|NCT05397639|Experimental|High Dose Masupirdine Arm|Tablet
89361576|NCT05397639|Placebo Comparator|Placebo|Tablet
89361577|NCT05396820|Experimental|Experimental pain|Experimental pain will be induced at the level of the dominant delto-pectoral groove of the participant (between the shoulder stump and the pectoral).
89361578|NCT05395741|Experimental|R1 - Regorafenib Arm|R1 - the experimental group. Standard oncological treatment will be started. Additionally, patients will receive regorafenib orally at doses adjusted for age, body surface area and pharmacokinetics. Treatment with regorafenib will be continued for up to 1 year or until disease progression, patient death, unacceptable toxicity, or study closure. Pharmacokinetics and safety profile of the investigational product (IP) will be determined throughout the course therapy.
89361579|NCT05395741|No Intervention|R2 - Control Group|R2 - the control group - will receive only standard treatment. In the event of progression or relapse, patients in the control group will have the option to receive the IP along with the standard treatment of the next line.
89361580|NCT05394792||Participants Receiving Upadacitinib|Participants receiving upadacitinib for moderate to severe atopic dermatitis.
89361581|NCT05394675|Experimental|Dose Escalation: DS-9606a|Participants who will receive an intravenous (IV) dose of DS9606a starting at 0.016 mg/kg every 3 weeks.
89361582|NCT05394675|Experimental|Dose Expansion: Cohort B-1|Participants with ovarian cancer who will receive an intravenous (IV) dose of DS9606a at the recommended dose for expansion (RDE) every 3 weeks.
89361583|NCT05394675|Experimental|Dose Expansion: Cohort B-2|Participants with refractory germ cell tumors who will receive an intravenous (IV) dose of DS9606a at the recommended dose for expansion (RDE) every 3 weeks.
89361584|NCT05392751|Experimental|EA-2353|EA-2353 Ophthalmic Suspension will be administered via unilateral intravitreal injection into the Study Eye weekly for one month (4 injections)
89361585|NCT05392452|Experimental|Closed-loop insulin therapy|"Intervention:~Use of a fully-automated closed-loop insulin delivery system from day of admission until hospital discharge (or maximum 20 days)."
89001069|NCT04632004|Other|Questionnaire survey|Patients, visitors, and staff members of the University Medical Center Goettingen are invited to participate within our survey study. Study participation has no effect on any medical treatment.
89361586|NCT05392452|Active Comparator|Standard insulin therapy|The control group will receive insulin therapy in accordance with local practice. The insulin regimen during the study period may involve subcutaneous and/or insulin intravenous insulin administration. The modality of insulin treatment, dose adjustment and frequency of glucose monitoring will be at the discretion of the clinical team. No active treatment optimisation will be undertaken by the study team. Participants in the control group will be fitted with the identical study CGM system. The CGM system will be blinded upon hospital admission.
89361587|NCT05389046|Experimental|Escitalopram|Escitalopram monotherapy (10-20 mg/day）
88832961|NCT05988242|Experimental|lavender oil|lavender oil
89001070|NCT00560989||1|CBD cases
89361588|NCT05389046|Experimental|Escitalopram + omega-3 PUFAs|Escitalopram (10-20 mg/day）combined with omega-3 PUFAs （EPA 900mg，DHA 300 mg）
89361589|NCT05389046|Experimental|Escitalopram + Aripiprazole|Escitalopram (10-20 mg/day）combined with Aripiprazole （2.5-10 mg/day)
89361590|NCT05389046|Experimental|Escitalopram + omega-3 PUFAs + Aripiprazole|Escitalopram (10-20 mg/day）combined with omega-3 PUFAs （EPA 900mg，DHA 300 mg）and Aripiprazole （2.5-10 mg/day)
89361591|NCT05388487|Experimental|Dose escalation cohort 1: HF1K16 given QOD at 45 mg/m²|The first dosing group (45 mg/m²) will include a sentinel subject receiving one dose followed by a 7-day safety evaluation interval. Three or more subjects will receive 7 doses of HF1K16 QOD at 45 mg/m2 per cycle of 21 days.
89361592|NCT05388487|Experimental|Dose escalation cohort 2: Oral ATRA followed by HF1K16 QOD at 90 mg/m²|The second dosing group will receive oral ATRA at 45mg/m², and three days later HF1K16 QOD at 90 mg/m2 for 7 times per cycle of 21 days.
89361593|NCT05388487|Experimental|Dose escalation cohort 3: HF1K16 QOD at 120 mg/m²|The cohort 3 will receive 7 doses of HF1K16 QOD at 120 mg/m² per cycle of 21 days.
89361594|NCT05388487|Experimental|Dose escalation cohort 4: HF1K16 QOD at 160 mg/m²|The cohort 4 will receive 7 doses of HF1K16 QOD at 160 mg/m² per cycle of 21 days.
89361595|NCT05388487|Experimental|Dose escalation cohort 5: HF1K16 QOD at 120mg or180 mg|The cohort 5 will receive 7 doses of HF1K16 QOD at 120 mg or 180mg per cycle of 21 days.
89361596|NCT05385042|Other|Non-anaemic pregnant women|50 pregnant women who have normal haematocrit (not anaemic) at 12 weeks.
89361597|NCT05385042|Other|Anaemic pregnant women|100 pregnant women who have haematocrit below 33% (equates to Hb 11g/dL) in first trimester (<14 weeks gestation) and below 30% (equates to Hb 10g/dL).
89361598|NCT05375539|Experimental|AGN-CognI.Q|Dose level +1 (800 mg, 4 CognI.Q capsules, Fast at least 2 h before dose and 1 h after) Dose level +2 (1,200 mg, 6 CognI.Q capsules, Fast at least 2 h before dose and 1 h after) Dose level +3 (1,600 mg, 8 CognI.Q capsules, Fast at least 2 h before dose and 1 h after)
89361599|NCT05373953|Experimental|mild impairment subjects|Administration of a single dose of CHF6001 800 µg in mild impairment subjects
89361600|NCT05373953|Experimental|moderate impairment subjects|Administration of a single dose of CHF6001 800 µg in moderate impairment subjects
89361601|NCT05373953|Experimental|severe impairment subjects|Administration of a single dose of CHF6001 800 µg in severe impairment subjects
88832962|NCT05988242|Placebo Comparator|the placebo group|took the same bottle of oil which didn't contain the active substances but have the same shape, same oder, same color.
89361602|NCT05373953|Active Comparator|healthy volunteers|Administration of a single dose of CHF6001 800 µg in healthy volunteers
88832963|NCT05988190|Experimental|Contextual Word Learning Intervention|Intervention will consist of a metalinguistic intervention with novel words (n=9), based on Cain (2007), administered across three sessions, and spaced one week apart. Semantic diversity will vary across items.
89361603|NCT05371041|Experimental|Medtronic Percept Neurostimulator|This is a deep brain stimulator that can also record brain signals and deliver stimulation through a control algorithm based on brain activity.
89361604|NCT05365412||Colorectal cancer group|Patients treated after being diagnosed with colorectal cancer
89361605|NCT05365035|Experimental|cladribine, cytarabine, venetoclax, and azacitidine|Participants will receive cladribine, cytarabine, and venetoclax for 2 cycles and then azacitidine and venetoclax for 2 cycles. Participants will repeat this pattern of 2 cycles each for up to a total of 18
89361606|NCT05364775||Focus Groups with International Nurses|It is anticipated that there will be four focus groups, each comprised of 6-8 participants
89361607|NCT05364775||Interviews with Nursing Staff|Interviews with qualified and unqualified staff who work with international nurses
89361608|NCT05362773|Experimental|Dose Escalation|Escalating doses of MGD024 will be assigned based on safety and tolerability of the previous dose level.
89361609|NCT05361811|Experimental|1/Internal Pilot|Participants will begin their 1-week baseline EMA data collection period and then take part in intervention procedures immediately after enrollment to assess feasibility and acceptability.
89361610|NCT05361811|Active Comparator|2/Immediate Intervention|Participants will begin their 1-week baseline EMA data collection period immediately after randomization and will begin receiving the 8-week intervention at the end of this week/beginning of the next week (depending on participant schedule).
89361611|NCT05361811|Active Comparator|3/Waitlist Control|After an initial 1-week baseline period for EMA data collection and 8 weeks of maintaining their usual routine (wait list period), participants will begin receiving the 8-week intervention.
89361612|NCT05360511|Experimental|Group A (Test group)|Group A (Test group): Twelve patients will be subjected to open flap debridement and application of particulate xenograft + erythropoietin gel.
89361613|NCT05360511|Active Comparator|Group B (Control group)|Group B (Control group): Twelve patients will be subjected to open flap debridement and application of particulate xenograft.
89361614|NCT05358613|Experimental|Immediate treatment|"The My Choices program will be offered immediately (maximum 10 working days from their first research interview) to the participants of this group.~The treatment will be dispensed as usual, wich means there are no special conditions that need to be respected specifically for the study."
89361615|NCT05358613|Active Comparator|Waiting list|"The My Choices program will be offered 3 months after the first research interview to the participants in this group.~The treatment will be dispensed as usual, wich means there are no special conditions that need to be respected specifically for the study."
88832964|NCT05988177|Experimental|Carrimycin tablets|Carrimycin tablets
88832965|NCT05988060|Experimental|Patients who were randomized in the PEI group and accepted the invitation|The experimental intervention consist of a PEI for 10 weeks. The PEI will be executed 6 to 7 weeks during and 3 to 4 weeks after (C/B)RT.
88832966|NCT05988060|No Intervention|Patients who were not randomized in the PEI group|Patients will receive usual care.
89001071|NCT00560989||2|Beryllium-exposed, non-diseased control subjects
89001072|NCT00560989||3|Sarcoidosis cases
89001073|NCT00560989||4|Sarcoidosis control subjects
89361616|NCT05357846|Experimental|NCRT+IO group|"• NCRT+IO group consists of the PD-1 inhibitor combined with concurrent chemoradiotherapy prior to surgery. The patient will receive 4 weeks of radiation therapy. The radiation will generally commence on the 1st day of treatment and will run for 4 weeks.PD-1 inhibitor is given by intravenous infusion on days 1 and 22. Chemotherapy is given by intravenous infusion on days 1, 8, 15, and 22.~Interventions:~Radiation: (40 or 45 Gy/20 fractions)~Drug: Sintilimab~Drug: Paclitaxel~Drug: Cisplatin"
89361617|NCT05357846|Active Comparator|NCRT group|"• NCRT group consists of the concurrent chemoradiotherapy prior to surgery. The patient will receive 4 weeks of radiation therapy. The radiation will generally commence on the 1st day of treatment and will run for 4 weeks. Chemotherapy is given by intravenous infusion on days 1, 8, 15, and 22.~Interventions:~Radiation: (40 or 45 Gy/20 fractions)~Drug: Paclitaxel~Drug: Cisplatin"
89361618|NCT05357469|Experimental|Immediate St (Scrambler Therapy)|Participant will start ST (Scrambler Therapy) treatment right away.
89361619|NCT05357469|Experimental|Waitlist ST (Scrambler Therapy)|Participant will start ST (Scrambler Therapy) treatment about 4 weeks after your Baseline Visit.
89361620|NCT05354349|Experimental|PRA023 SC/Placebo IV|Participants randomized to receive active subcutaneous injection/placebo intravenous infusion
89361621|NCT05354349|Active Comparator|Placebo SC/PRA023 IV Low Dose|Participants randomized to receive placebo subcutaneous injection/active intravenous infusion
89361622|NCT05354349|Placebo Comparator|Placebo SC/Placebo IV|Participants randomized to receive placebo subcutaneous injection/placebo intravenous infusion
89361623|NCT05354349|Experimental|Placebo SC/PRA023 IV High Dose|
89361624|NCT05353244|Active Comparator|Active PrTMS|Participants will receive PrTMS five days a week for six weeks.
89361625|NCT05353244|Sham Comparator|Sham|Participants will receive sham treatment five days a week for six weeks.
89361626|NCT05344417|No Intervention|Arm 1: Standard of Care|25 patients undergoing laparoscopic right hemi-colectomies or sigmoid resections using high pneumoperitoneum pressure with conventional insufflation under moderate neuromuscular blockade with rocuronium and neuromuscular blockade reversal with neostigmine. In addition, clinical data on postoperative ileus will be correlated with experimental outcomes from in vitro exploratory studies done using human samples of peritoneal lavage fluid, serum, and a small portion of the surgically removed bowel from each patient (that is otherwise discarded). A panel of inflammatory markers will be analyzed and biochemical, imaging, histological, immunochemical, molecular signaling, and glial activation studies will be done to evaluate the potential mechanisms of dysfunction associated with postoperative ileus.
89361627|NCT05344417|Experimental|Arm 2A: Conventional Pneumoperitoneum and Moderate Blockade|25 patients undergoing laparoscopic right hemi-colectomies or sigmoid resections using high pneumoperitoneum pressure with conventional insufflation under moderate neuromuscular blockade with rocuronium and neuromuscular blockade reversal with sugammadex. In addition, clinical data on postoperative ileus will be correlated with experimental outcomes from in vitro exploratory studies done using human samples of peritoneal lavage fluid, serum, and a small portion of the surgically removed bowel from each patient (that is otherwise discarded). A panel of inflammatory markers will be analyzed and biochemical, imaging, histological, immunochemical, molecular signaling, and glial activation studies will be done to evaluate the potential mechanisms of dysfunction associated with postoperative ileus.
89361628|NCT05344417|Experimental|Arm 2B: AirSeal® Pneumoperitoneum and Moderate Blockade|25 patients undergoing laparoscopic right hemi-colectomies or sigmoid resections using high pneumoperitoneum pressure with AirSeal® trademark (TM) system under moderate neuromuscular blockade with rocuronium and neuromuscular blockade reversal with sugammadex. In addition, clinical data on postoperative ileus will be correlated with experimental outcomes from in vitro exploratory studies done using human samples of peritoneal lavage fluid, serum, and a small portion of the surgically removed bowel from each patient (that is otherwise discarded). A panel of inflammatory markers will be analyzed and biochemical, imaging, histological, immunochemical, molecular signaling, and glial activation studies will be done to evaluate the potential mechanisms of dysfunction associated with postoperative ileus.
89361629|NCT05344417|Experimental|Arm 3A: Conventional Pneumoperitoneum and Deep Blockade|25 patients undergoing laparoscopic right hemi-colectomies or sigmoid resections using low pneumoperitoneum pressure with conventional insufflation under deep neuromuscular blockade with rocuronium and neuromuscular blockade reversal with sugammadex. In addition, clinical data on postoperative ileus will be correlated with experimental outcomes from in vitro exploratory studies done using human samples of peritoneal lavage fluid, serum, and a small portion of the surgically removed bowel from each patient (that is otherwise discarded). A panel of inflammatory markers will be analyzed and biochemical, imaging, histological, immunochemical, molecular signaling, and glial activation studies will be done to evaluate the potential mechanisms of dysfunction associated with postoperative ileus.
89361630|NCT05344417|Experimental|Arm 3B: AirSeal® Pneumoperitoneum and Deep Blockade|25 patients undergoing laparoscopic right hemi-colectomies or sigmoid resections using low pneumoperitoneum pressure with AirSeal® TM system under deep neuromuscular blockade with rocuronium and neuromuscular blockade reversal with sugammadex. In addition, clinical data on postoperative ileus will be correlated with experimental outcomes from in vitro exploratory studies done using human samples of peritoneal lavage fluid, serum, and a small portion of the surgically removed bowel from each patient (that is otherwise discarded). A panel of inflammatory markers will be analyzed and biochemical, imaging, histological, immunochemical, molecular signaling, and glial activation studies will be done to evaluate the potential mechanisms of dysfunction associated with postoperative ileus.
89001074|NCT04631653|Experimental|Verisee|Screening diabetic retinopathy using Verisee software
89361631|NCT05336955|Experimental|Telemental health START|Telemental health START will deliver two components via telephonic or other communication technology (e.g., Zoom). This includes component #2 (consultation and coping skills coaching) and component #4 (service linkages, referrals, outreach, & training). START components #1 (intake and quarterly assessment) and #3 (24-hour urgent crisis response and intervention) will continue to be provided in-person.
89361632|NCT05336955|Active Comparator|In-person START|In-person START will deliver all model components in-person. This is the established model.
89178219|NCT00837538||Back pain|Persons with back pain and supposed instability of lumbar spine
89534499|NCT05039697|Experimental|NBO group Normobaric Hyperoxia combined with endovascular mechanical thrombectomy|Within 6 hours after stroke onset, patients were randomized into the NBO group and immediately given 100% oxygen inhalation (no more than 30minutes after admission) at a ventilation rate of 10L/min using a sealed non-ventilating oxygen storagemask and keep giving oxygen for 4 hours. If the patient needs to be intubated with a ventilator to maintain ventilation, the FiO2 should be set to 1.0.
88832967|NCT05988034|Experimental|Cohort 1: Avacopan|Participants will be randomized to receive multiple doses of avacopan orally twice daily (BID): 30 mg for 7 days and 100 mg for 7 days, for a total of 14 dosing days, and placebo for moxifloxacin on Days 1 and 15.
88832968|NCT05988034|Active Comparator|Cohort 2A: Moxifloxacin/Placebo|Participants will be randomized to receive moxifloxacin 400 mg orally on Day 1, placebo for avacopan BID on Days 1 to 14, and placebo for moxifloxacin on Day 15.
88832969|NCT05988034|Active Comparator|Cohort 2B: Placebo/Moxifloxacin|Participants will be randomized to receive placebo for moxifloxacin orally on Day 1, placebo for avacopan BID on Days 1 to 14, and moxifloxacin 400 mg orally on Day 15.
88832970|NCT05988021|Experimental|Cohort 1: Sequence ABCD|"Participants assigned to sequence ABCD will receive the following treatments:~Period 1: Single dose of 30 mg CCX168 after a high-fat, high-calorie meal (Treatment A).~Period 2: After a washout period of ≥ 10 days, single dose of 30 mg CCX168 in the fasted state (Treatment B).~Period 3: After a washout period of ≥ 10 days, single dose of 3 mg CCX168 in the fasted state (Treatment C).~Period 4: 24 hours after the 3 mg CCX168 dose in Period 3, single dose of 100 mg CCX168 on Day 1, and then 100 mg CCX168 twice daily from Day 2 through Day 6. On Day 7, only a morning dose of 100 mg CCX168 (Treatment D)."
88832971|NCT05988021|Experimental|Cohort 2: Sequence BACD|"Participants assigned to sequence BACD will receive the following treatments:~Period 1: Single dose of 30 mg CCX168 in the fasted state (Treatment B).~Period 2: After a washout period of ≥ 10 days, single dose of 30 mg CCX168 after a high-fat, high-calorie meal (Treatment A).~Period 3: After a washout period of ≥ 10 days, single dose of 3 mg CCX168 in the fasted state (Treatment C).~Period 4: 24 hours after the 3 mg CCX168 dose in Period 3, single dose of 100 mg CCX168 on Day 1, and then 100 mg CCX168 twice daily from Day 2 through Day 6. On Day 7, only a morning dose of 100 mg CCX168 (Treatment D)."
88832972|NCT05988008|Experimental|Cohort A: Single Oral Dosing of CCX168 in Japanese Adult Males|Healthy Japanese adult males will receive 1 of 3 single oral doses of CCX168 (10 mg, 30 mg or 100 mg) or placebo. Each dose level will be administered under fasted conditions. Single doses of CCX168 30 mg will be administered under fasted and fed conditions.
88832973|NCT05988008|Experimental|Cohort B: Multiple Oral Dosing of CCX168 in Japanese Adult Males|Healthy Japanese adult males will receive 1 of 2 oral doses of CCX168 (30 mg or 50 mg) or placebo twice-daily for 7 days under fed conditions.
88832974|NCT05988008|Experimental|Cohort C: Single Oral Dosing of CCX168 in Caucasian Adult Males|Healthy Caucasian adult males will receive 1 of 2 single oral doses of CCX168 (10 mg or 30 mg) or placebo under fasted conditions.
88832975|NCT05988008|Experimental|Cohort D: Multiple Oral Dosing of CCX168 in Caucasian Adult Males|Healthy Caucasian adult males will receive an oral dose of CCX168 30 mg or placebo twice-daily for 7 days under fed conditions.
88832976|NCT05987995|Experimental|Endometrial injury group|Endometrial injury was done on day 3-5 of stimulation, just after the cessation of menstruation. After the insertion of a vaginal speculum, the cervix was cleaned using a sterile saline solution. A pipelle endometrial sampler was introduced gently into the uterine cavity. The inner piston of the catheter was withdrawn to create suction, and injury (scratching) of the endometrium was done by moving the pipelle catheter up and down within the uterine cavity. The obtained tissues were seen in a transparent tube. If no tissues were seen in the tube, the procedure was repeated.
88832977|NCT05987995|No Intervention|Control group|no thing is done for this group
88832978|NCT05987982|Experimental|Group with oral management|The investigators taught and monitored patients or caregivers to oral health care plus oral exercises such as salivary glands massage methods after meals and before sleep.
88832979|NCT05987982|Experimental|Group with oral care|The investigators taught and monitored patients or caregivers to do oral care after meals and before sleep.
88832980|NCT05987982|No Intervention|Group with standard of care|Only provided oral care education.
88832981|NCT05987969|Experimental|Intervention|"Access to the Alena CBT-based mobile application intervention for 8 weeks. Instructed to complete one of the 4 main modules every 2 weeks. Also asked to complete one additional short exercise per week and engage with one forum post per week."
88832982|NCT05987969|No Intervention|No intervention|Wait list control - Given access to the intervention at the end of the 10-week trial period.
88832983|NCT05987839|Active Comparator|intervention group|Total knee arthroplasty assisted by knee navigation and positioning system. Specification Model: OP-RKL22
88832984|NCT05987839|No Intervention|control group|Total knee arthroplasty without knee navigation and positioning system
88832985|NCT05987800|Other|Preterm infants on non-invasive respiratory support|All infants on non-invasive respiratory support will be studied. Only infants on NIV-NAVA, will undergo an intervention.
88832986|NCT05987787||Obese patients underwent laparoscopic sleeve gastrectomy with suture reinforcement|Laparoscopic sleeve gastrectomy running seromuscular stitches at the proximal third of the stapled line using unidirectional 2/0 barbed sutures to invaginate the staple line completely.
88832987|NCT05987787||Obese patients underwent laparoscopic sleeve gastrectomy without suture reinforcement|Laparoscopic sleeve gastrectomy without staple line reinforcement.
88832988|NCT05987774|Experimental|Intervention Group|This group will receive the treatment (AI conversation modules) available through the application.
88832989|NCT05987774|No Intervention|Control Group|This waitlist control group will not receive treatment until the experimental group completes their intervention.
89001075|NCT00186771|Active Comparator|True Transcranial Magnetic Stimulation|True treatment with TMS over the temporoparietal cortex.
89001076|NCT00186771|Sham Comparator|Sham Transcranial Magnetic Stimulation|Sham treatment with rTMS over the temporoparietal cortex.
89001077|NCT04631341|Experimental|Melatonin Group|Take melatonin supplements
89534500|NCT05039697|Placebo Comparator|Control group Inhale air placebo plus endovascular mechanical thrombectomy|For Sham NBO group, Patients were immediately given oxygen inhalation (no more than 30 minutes after admission) at a ventilation rate of 1l/min using the same mask and keep giving oxygen for 4 hours. If the patient needs to be intubated with a ventilator to maintain, the FiO2 should be set to 0.3 and gradualy incerased if spO2≤94%
89534501|NCT05029245|Experimental|Sinovac 2 dosage followed by Comirnaty® 6 microgram Intradermal|Patients who had history of Coronavac vaccine 2 dosage at least 1 month before enrollment will received Intradermal Comirnaty® vaccine 6 microgram 2 dosage by 28 days interval
89534502|NCT05029245|Active Comparator|Sinovac 2 dosage followed by Comirnaty® 30 microgram Intramuscular|Patients who had history of Coronavac vaccine 2 dosage at least 1 month before enrollment will received Intramuscular Comirnaty® vaccine 30 microgram 2 dosage by 28 days interval
88832992|NCT05987748|Experimental|Morning exercise|Individuals will exercise train at 8 AM three times per week for 12 weeks.
88832993|NCT05987748|Experimental|Evening exercise|Individuals will exercise train at 8 PM three times per week for 12 weeks.
88832994|NCT05987735|Experimental|BLAME-LESS Program|If allocated to the intervention group, participants will have direct access to the online intervention for two weeks after allocation.
88832995|NCT05987735|No Intervention|Waiting-list control group|When a participant is assigned to the waiting-list control group, he or she has a two-week waiting period, after which the participant will have access to the intervention.
88832996|NCT05987722|Experimental|Enoxolone|The experimental group (N=15) returned home after the operation and used BGA toothpaste (Enoxolone) three times a day for oral cleaning for 12 weeks.
88832997|NCT05987722|Active Comparator|Sensodyne|The control group (N=12) used BGA-free toothpaste (Sensodyne) for oral cleaning for 12 weeks.
88832998|NCT05987709|Other|Guardant Shield Blood Test|Patients will have the Guardant Shield blood test for colorectal cancer screening.
88832999|NCT05987709|No Intervention|Standard of Care|Patients will have standard of care, which is a reminder to do their FIT test for colorectal cancer screening
88833000|NCT05987696|Experimental|CD33/CLL1 dual CAR-NK cell|CLL1/CD33 dual CAR-NK cell therapy in Adult subjects with r/r AML
88833001|NCT05987696|Experimental|CD33 CAR-NK cell|CD33 CAR-NK cell therapy in Adult subjects with r/r AML
88833002|NCT05987696|Experimental|super NK cell|super NK cell therapy in Adult subjects with AML MRD
88833003|NCT05987618|Experimental|Oral appliance with elastic bands|Oral appliance therapy with elastic bands.
88833004|NCT05987618|Active Comparator|Oral appliance without elastic bands|Oral appliance therapy without elastic bands.
88833005|NCT05987553||General practitioners|All participants were general practitioners (in training).
88833006|NCT05987540|Experimental|Investigational Treatment|Investigational treatment mode (stimulation pattern)
88833007|NCT05987514|Experimental|Patients|Patients affected by hepatocellular carcinoma needing to undergo loco-regional treatment
88833008|NCT05987501|Experimental|Patients|patients with Crohn's disease or Ulcerative Colitis needing to begin biologic treatment
88833009|NCT05987462|Experimental|Green Walk group|Patients who were admitted to the Cardiology Outpatient Clinic of Y State Hospital and passed the 6MWT conducted by the cardiology physician were eligible for participation in the green walk group. Following the physician's examination at the Cardiology Outpatient Clinic, the researcher conducted face-to-face interviews with the patients in a private room. During these interviews, the patients were administered the Structured Patient Information Form, Blood Lipids and BMI Monitoring Form, the Brief IPQ, and the MIDAS, and the collected data were recorded on the respective forms. Then, the researcher provided detailed information to the patients about green walking. For the randomized MI patients, two groups were formed, and they engaged in a 50-minute green walking three days a week for 12 weeks, under the guidance of the researcher. The green walk group's walks were scheduled differently for the two subgroups.
88833010|NCT05987462|No Intervention|Control group|"Patients who were admitted to the Cardiology Outpatient Clinic of X State Hospital and passed the 6MWT conducted by the cardiology physician were enrolled in the control group. Upon their visit to the outpatient clinic, the patients in this group underwent a face-to-face interview, during which they were administered the Structured Patient Information Form, the Blood Lipids and BMI Monitoring Form, the Brief-IPQ, and the MIDAS as pretests. . The patients in the control group continued with their routine daily activities. No specific intervention or additional measures were implemented by the investigator in this group. Furthermore, a follow-up Blood Lipids and BMI Monitoring Form was administered to the patients during their visit to the Cardiology Outpatient Clinic in the middle of the study (6th week). At the end of the 12-week period, the patients in the control group underwent a posttest."
88833011|NCT05987436||Group 1|Group 1 exercised for six weeks, involving once per day, five sessions per week under the supervision of a medical doctor, and a nurse in the aerobic exercise laboratory. The aerobic exercise training program lasted six weeks, and patients lived in the hospital for the whole period. Aerobic exercise training was performed on cycle ergometers (Ergoline, ergoselect II 100/200/Reha, Germany) equipped with a computed ergometer and developed to monitor electrocardiography (ECG), heart rhythm, and BP. Each session consisted of a 5-minute warm-up, followed by 50 minutes of aerobic exercise with an intensity of 50% to 70% of heart rate reserve, calculated by Karvonen formula, and ended with a 5-min cool-down period.
88833012|NCT05987436||Group 2|The subjects assigned to the control group (Group 2) were advised to maintain dietary habits and physical activity levels and the aerobic exercise program was provided to them after completing the study.
88833013|NCT05987397|Experimental|Group A: Idebenone short-term treatment group|The patient received oral idebenone 30 mg three times a day after stroke for a total course of 14 days (acute phase).
88833014|NCT05987397|Experimental|Group B: Idebenone long-term treatment group|The patient will be treated with oral idebenone 30 mg three times a day after stroke for a total course of 3 months.
88833015|NCT05987384|Placebo Comparator|Placebo group|Sunflower oil capsules
88833016|NCT05987384|Experimental|D3 ARA group|ARA capsules
88833017|NCT05987384|Experimental|D6 ARA group|Sunflower oil capsules and ARA capsules
88833018|NCT05987358|Experimental|TQB3454 tablets|TQB3454 tablets orally administered, 21 days as a treatment cycle.
89361633|NCT05336240|Active Comparator|PCOM Standard Arm|"Providers in participating in the PCOM-standard intervention will be trained on optimizing an in-person provider communication technique about HPV vaccination by training primary care providers in a 2-step verbal communication process: 1) to start the HPV vaccine discussion using a presumptive format, and 2) to use motivational interviewing (MI) techniques to address parental vaccine hesitancy."
89361634|NCT05336240|Experimental|PCOM2 Virtual Arm|"Providers participating in the PCOM2-virtual arm will receive training on this communication method through an adapted virtual model of PCOM-standard.~PCOM2-Virtual intervention will result in a shelf ready intervention and associated User Manual that can be easily incorporated into practices broadly to improve the practice's adolescent HPV vaccination rates. PCOM-Virtual arm will then be compared to that of the original PCOM-standard intervention in its efficacy for increasing HPV vaccination among adolescents."
89361635|NCT05335993|Experimental|Combination of Oregovomab and Niraparib|"Niraparib (300/200 mg) will be administered orally once daily.~Oregovomab (2 mg) will be administered via IV infusion on Day 1 of Week 1, Week 4, Week 7, Week 12, and Week 20."
89001078|NCT04631341|No Intervention|Normal Control Group|Don't take melatonin supplements
89361636|NCT05335941|Experimental|Pemetrexed Plus AB928 (Etrumadenant) Plus AB122 (Zimberelimab)|All patients will receive combination therapy of pemetrexed and ZIMBERELIMAB (AB122) intravenously every 3 weeks as well as ETRUMADENANT (AB928) orally daily.
89361637|NCT05333393|Experimental|Experimental group|Children in the experimental group will be informed about the diabot application and how they will use the application to manage their disease processes. Children/adolescents in the study group and their parents will be evaluated 5 times, once every 3 months, through data collection tools. Data will be collected from the children/adolescents in the control group and their parents by means of pre-test and data collection tools 5 times, once every 3 months.
89361638|NCT05333393|No Intervention|Control group|The control group will recieve standard diabetes treatment without any training intervention
89361639|NCT05333185|Experimental|Experimental group|Children in the experimental group will be informed about the diabot application and how they will use the application to manage their disease processes. Children/adolescents in the study group and their parents will be evaluated 5 times, once every 3 months, through data collection tools. Data will be collected from the children/adolescents in the control group and their parents by means of pre-test and data collection tools 5 times, once every 3 months.
89361640|NCT05333185|No Intervention|Control group|The control group will recieve standard diabetes treatment without any training intervention
89361641|NCT05329493|Experimental|Cooling digit device application|Device: Cooling digit device. The cooling finger device will be applied in the subjects on their right hand. Subjects will serve as their own control.
89361642|NCT05326243|Experimental|CD19-targeted chimeric antigen receptor T-cell|Patients will receive a lymphodepletion chemotherapy with fludarabine plus cyclophosphamide for three consecutive days(Day -5 to Day -3) before infusion of CD19-targeted chimeric antigen receptor T-cell (CD19 CAR-T). Patients will receive the CD19 CAR-T(also known as PL001) infusion on Day 0.
89361643|NCT05325151|Experimental|Arm I (GCPP intervention)|Patients receive GCPP intervention consisting of a series of educational videos on pre-genetic test information.
89361644|NCT05325151|Active Comparator|Arm II (conventional genetic counseling)|Patients receive conventional genetic counseling.
89361645|NCT05321979|Experimental|MBA-P01|MBA-P01 will be injected into GL:
89361646|NCT05319834|Active Comparator|Progesterone with asprin|The included women will be randomly allocated to prophylactically receive either vaginal progesterone at a dose of 200 mg (prontogest 200mg every 12 hr) combined with oral aspirin at a dose of 100mg once daily both at the same time (group1),
89361647|NCT05319834|Placebo Comparator|Progesterone and placebo|vaginal progesterone (prontogest 200mg every 12 hr) and oral placebo (manufactured in a standard way to have the same size and shape of asprin tablet) also at the same time (group 2).
89361648|NCT05319574|Experimental|Neoadjuvant SBRT plus immunochemotherapy|Stereotactic body radiation therapy (8Gy*3d) followed by Tislelizumab (200mg) with platinum-based doublet chemotherapy administered pre-operatively every 3 weeks for 2 cycles before surgical resection
89361649|NCT05318183|Experimental|Whole Wheat Bread|Participants consuming 128 g of whole wheat bread (4 slices of bread) daily for two weeks
89361650|NCT05318183|Placebo Comparator|White Bread (control)|Participants consuming 128 g of white bread (4 slices of bread) daily for two weeks
89361651|NCT05317975|Experimental|Add-on telerehabilitation combined with usual home-based rehabilitation|Add-on telerehabilitation combined with usual home-based rehabilitation
89361652|NCT05317975|Experimental|Stand-alone usual home-based rehabilitation|Stand-alone usual home-based rehabilitation
89361653|NCT05317975|No Intervention|Usual care|Usual care
89361654|NCT05316194||Participation in digital OA treatment|All participants that have participated in a digitally delivered first-line treatment program (Joint Academy) for hip or knee OA until May 2022.
89001079|NCT04723238|Experimental|Duloxetine Test Product|Participants will receive one capsule of the test formulation containing Duloxetine 60 mg. The capsules will be taken with water and in a fasting condition.
89001080|NCT04723238|Active Comparator|Duloxetine Referent Product|Participants will receive one capsule of the marketed reference formulation containing Duloxetine 60 mg. The capsules will be taken with water and in a fasting condition.
89361655|NCT05315011|Experimental|Whole-body cryotherapy|
89361656|NCT05315011|Placebo Comparator|Placebo cryotherapy|
89534503|NCT05029245|Experimental|Aztrazeneca 1 dosage followed by Comirnaty® 6 microgram Intradermal|Patients who had history of ChAdOX1 Cov-19 vaccine 1 dosage at least 1 month before enrollment will received Intradermal Comirnaty® vaccine 6 microgram 2 dosage by 28 days interval
89001081|NCT04631575|Experimental|Healthy participants|Intervention: Drug: SHR6390 single dose
89534504|NCT05029245|Active Comparator|Aztrazeneca 1 dosage followed by Comirnaty® 30 microgram Intramuscular|Patients who had history of ChAdOX1 Cov-19 vaccine 1 dosage at least 1 month before enrollment will received intramuscular Comirnaty® vaccine 30 microgram 2 dosage by 28 days interval
89001082|NCT04631575|Experimental|Mild liver impairment|Intervention: Drug: SHR6390 single dose
89001083|NCT04631575|Experimental|Moderate liver impairment|Intervention: Drug: SHR6390 single dose
89361657|NCT05303701|Placebo Comparator|GV1001 Placebo|"GV1001 placebo (0.9% saline) subcutaneous injection will be administered once a week for 4 weeks and then administered every 2 weeks for 20 weeks in a double-blind phase.~During the open-label extension phase, patients assigned to the GV1001 Placebo arm in the double-blind phase will receive a placebo in the first week, followed by 1.12 mg of GV1001 weekly for 4 weeks and then every 2 weeks until EOT (End of Treatment)."
89361658|NCT05303701|Experimental|GV1001 1.12 mg|"GV1001 1.12 mg subcutaneous injection will be administered once a week for 4 weeks and then administered every 2 weeks for 20 weeks in a double blind phase.~During the open-label extension phase, patients will alternate between 1.12 mg of GV1001 and placebo weekly for the first 5 weeks to maintain double blindness, and then 1.12mg of GV1001 every 2 weeks until EOT."
89361659|NCT05301816|Experimental|IPG Activated|The group of participants who have had a successful trial (>50% pain relief) during the trial phase
89361660|NCT05300607||questionnaire|rotator cuff diseases patients will self report the items of the Arabic version of The Western Ontario Rotator Cuff Index questionnaire
89361661|NCT05297760|Active Comparator|Polvac|Polvac Grass+Rye
89361662|NCT05297760|Placebo Comparator|Placebo|Saline
89361663|NCT05295953|Active Comparator|TBS (Theta burst stimulation)|Four sessions of TBS in one day
89361664|NCT05295953|Placebo Comparator|Sham TMS|Four sessions of sham TMS
89361665|NCT05291325|Experimental|3L PEG + Linaclotide|Bowel preparation for colonoscopy was performed with 3L polyethylene glycol solution combined with 3-day linaclotide.
89361666|NCT05291325|Active Comparator|3L PEG alone|Bowel preparation for colonoscopy was performed with 3L polyethylene glycol solution without linaclotide.
89361667|NCT05291325|Experimental|2L PEG + Linaclotide|Bowel preparation for colonoscopy was performed with 2L polyethylene glycol solution combined with 3-day linaclotide.
89361668|NCT05289180||Participants undergoing Heart Catherization|Participants undergoing Heart Catherization and will complete a research survey focusing on the comfort and anxiety during procedure. Participants will be followed for 18 months after enrollment. For each clinically indicated Brachial RV-EMB Biopsy during the 18-month follow up period, data from biopsy and pre and post-procedure echocardiograms will be reviewed and recorded for research purposes. A post-procedure questionnaire and post-discharge phone call will also take place after each procedure.
89361669|NCT05279976|Experimental|Children receiving education-Intervention group 1 (35 children)|Children in the intervention group 1 will be told by the researchers the operation preparation room and the pre-anesthesia process with a picture booklet. It will be ensured that the child and parent are together during the training. The booklet, which is printed separately for each child, will be given to the child and the parent after an average of 15-20 minutes of narration is completed. Simultaneous visual presentation will be made with the content of the picture booklet being explained to the child. While one of the researchers will explain the pre-operative process from the picture booklet, the other will explain the pre-operative preparation process simultaneously with the picture booklet by putting on the bonnet, mask and glove, and with the balloon inflated by the child. In this way, the pictures shown in the picture booklet will be matched with the real environment.
89361670|NCT05279976|Experimental|Children who are distracted-Intervention group 2 (35 children)|"Children included in intervention group 2 will be given a kaleidoscope. Each child will be given a separate kaleidoscope. It will be ensured that the child is with the parent while the child is looking at the kaleidoscope for an average of 15-20 minutes. After the attempt is over, the kaleidoscope will be presented to the child.~Usage of Kaleidoscope: It is a game tool that reproduces the outside image when viewed from inside the kaleidoscope. This image is obtained thanks to the glasses placed inside the kaleidoscope at different angles, and the images change as the kaleidoscope is rotated. Inside the kaleidoscope, there are mirrors or glasses placed with an inclination of 60 degrees. When viewed from one side of the kaleidoscope, images are often seen that are not the same."
89534505|NCT05029245|Experimental|Naive vaccine followed by Comirnaty® 6 microgram Intradermal|Patients who had no history SAR-CoV vaccine before enrollment will received intradermal Comirnaty® vaccine 6 microgram 2 dosage by 28 days interval
88833019|NCT05987358|Placebo Comparator|Placebo|Placebo tablets orally administered, 21 days as a treatment cycle.
88833020|NCT05987345|Experimental|PEF treatment|All of participants who signed the Informed Consent Form(ICF) and meet all of inclusion and exclusion criterial will be enrolled to experimental arm. PEF treatment on Day 1, followed by anti PD-1 on Day 7 and then routinely.
88833021|NCT05987280||Phase 1|We aim to use an online survey to collect data from participants. It is estimated that this survey will take 10 minutes to complete. The first part of the survey asks questions about the participant including what stakeholder group best describes them. The second part asks them about what outcomes are important in pharmacy research and in the management of kidney disease.
88833022|NCT05987280||Phase 2|"The outcomes generated in this survey will be supplemented by outcomes identified in an ongoing systematic review being performed by our group. We will take this long list of outcomes and aim to reach consensus on a COS using a 2-round Delphi process. The Delphi process is a structured process used for forming a consensus, where stakeholder groups provide their opinions in an iterative approach for answering questions over several rounds.~This will also take place using surveys online and we will submit an ethical amendment for each round with the questions and outcomes we will be seeking consensus on. In each Delphi round, participants will be asked to rate the importance of outcomes for inclusion or exclusion. Between each round, excluded outcomes will be removed. Included outcomes (those reaching consensus, defined as a minimum of 75% of participants who scored outcomes as agree or strongly agree or disagree or strongly disagree) will go into the COS."
88833023|NCT05987267|Experimental|multidisciplinary precision care group|Give the intervention of nurse-led multidisciplinary precision care
88833024|NCT05987267|No Intervention|control group|standard care according to guidelines
88833025|NCT05987228|Experimental|Thymus vulgaris group|500 mg of Thymus vulgaris (capsules) was given orally twice daily
88833026|NCT05987228|Placebo Comparator|control group|500 mg starch (capsules) was given orally twice daily
88833027|NCT05987215||CASE|Patients with surgically confirmed otosclerosis who initially consulted for conductive hearing loss with normal otoscopy, and with a high resolution computed tomography of temporal bone available
88833028|NCT05987215||CONTROL|Random patients with a high resolution computed tomography scan of temporal bone performed without suspicion of otosclerosis and considered normal
89178220|NCT04043338|Experimental|XC130-A10H|XC130-A10H (single dose)
89361671|NCT05279976|No Intervention|Control group of children (35 children)|After obtaining informed consent from the children and parents included in the control group after randomization, the pre-test (first measurement) will be applied. The final test (Second Measurement) will be applied immediately after the child wears the surgical gown.
89361672|NCT05279976|Experimental|Parents of children receiving education-Intervention group 1 (35 parents)|The parents of children included in intervention group 1 will also be in intervention group 1.It will be ensured that the child and parent are together during the training. The booklet, which is printed separately for each child, will be given to the child and the parent after an average of 15-20 minutes of narration is completed.
89361673|NCT05279976|Experimental|Parents of distracted children-Intervention group 2 (35 parents)|The parents of children included in intervention group 2 will also be in intervention group 2. Children included in intervention group 2 will be given a kaleidoscope. Each child will be given a separate kaleidoscope. It will be ensured that the child is with the parent while the child is looking at the kaleidoscope for an average of 15-20 minutes.
89361674|NCT05279976|No Intervention|Control group of parents (35 parents)|The parents of children included in control group will also be in control group.
89361675|NCT05277636|Experimental|125 mg MDMA|MDMA (125 mg)
89361676|NCT05277636|Experimental|125 mg S-MDMA|S-MDMA (125 mg)
89361677|NCT05277636|Experimental|125 mg R-MDMA|R-MDMA (125 mg)
88833029|NCT05987176|No Intervention|Standard of Care|Control arm as per standard of care patients go on routine follow up post surgery.
88833030|NCT05987176|Experimental|Treatment|Treatment with Lutathera post surgery.
89361678|NCT05277636|Experimental|250 mg R-MDMA|R-MDMA (250 mg)
89361679|NCT05277636|Placebo Comparator|Placebo|Placebo
89361680|NCT05277272||Patients with clinically suspected or confirmed Hemophagocytic Lymphohistiocytosis|Multi-institutional cohort registry of patients with clinically suspected or confirmed Hemophagocytic Lymphohistiocytosis
89361681|NCT05274906|Experimental|Controlled HEI-2015 diet with red and processed meat|
88833031|NCT05987163|Experimental|GP0116|
88833032|NCT05987163|Active Comparator|FDA Approved Device|
88833033|NCT05987150||Type A|Type A was defined as a round/oval spinal cord shape with visible cerebrospinal fluid (CSF) between the cord and the apical vertebrae.
88833034|NCT05987150||Type B|Type B was defined as a round/oval spinal cord shape with no CSF between the apical vertebrae and spinal cord.
88833035|NCT05987150||Type C|Type C cord was defined as a spinal cord that is fattened/deformed by the vertebral body, with no visible CSF between the apex and the cord.
88833036|NCT05987111|Active Comparator|Mat Pilates|Mat Pilates Exercises
88833037|NCT05987111|Experimental|Reformer Pilates|Reformer Pilates Exercises
88833038|NCT05987098|Experimental|Malignant Tumors|BBPA in suspected malignant tumors. This arm investigates the metabolic characteristics of BBPA in suspected malignant tumor patients who consider for surgical operations. A single dose of 0.10 mCi/kg BBPA will be intravenously injected and PET examination will carry out 30 minutes later. Surgical operations, if recommended after multiple examination, will be carried out within 1 week after BBPA PET scan.
88833039|NCT05987059|Experimental|Standard Structured Follow-Up|Mailed informational flyer(s) on prioritized cardiovascular risks
88833040|NCT05987059|Experimental|Enhanced Structured Follow-Up|text or phone message(s) focused on the same prioritized risks + mailed informational flyer(s). These will be in addition to the SBIRT intervention delivered by Healthy Start and other similar community organization staff that all participants will receive.
89361682|NCT05274906|Experimental|Controlled HEI-2015 diet without red and processed meat|
89361683|NCT05274815|Experimental|Tezepelumab|Tezepelumab subcutaneous injection
89361684|NCT05270668|Experimental|Tulisokibart|Tulisokibart IV administered by IV infusion
89361685|NCT05270668|Placebo Comparator|Placebo|Placebo administered by IV infusion
89361686|NCT05267600|Experimental|efgartigimod PH20 SC|participants receiving efgartigimod PH20 SC on top of Prednisone
89361687|NCT05267600|Placebo Comparator|placebo PH20 SC|participants receiving placebo PH20 SC on top of Prednisone
89361688|NCT05262270|Experimental|Drug intervention (XR-NTX+XR-BUP)|"The study intervention is three doses of 380mg XR-NTX (Weeks 0, 3 and 6) and two doses of 300mg XR-BUP (Weeks 0, 4).~Drug: XR-NTX XR-NTX: 3 intramuscular injections administered Week 0, 3, 6. Other Names: Extended Release Injectable Naltrexone Arm: Experimental~Drug: XR-BUP XR-BUP: 2 subcutaneous injections administered Week 0, 4. Other Names: Extended Release Injectable Buprenorphine Arm: Experimental"
88833041|NCT05986994||Group A|15 healthy newborns with umbilical cord arterial pH between 7.26 and 7.35
88833042|NCT05986994||Group B|15 newborns with metabolic acidosis at birth with umbilical cord arterial pH at birth < 7.12 and who do not practice therapeutic hypothermia due to lack of enrollment criteria
88833043|NCT05986994||Group C|15 newborns with metabolic acidosis at birth with umbilical cord arterial pH at birth < 7.12 and practicing therapeutic hypothermia in accordance with current guidelines
88833044|NCT05986981|Experimental|MUC1 Vaccine|"Enrollment by cohort from the starting dose of the trial and proceed to the next higher dose level if no one of the first 3 subjects develops DLT. If 1 of the 3 subjects develops DLT, then 3 additional subjects will be added to that dose level for a total of 6 subjects.~If only 1 of 6 subjects develops DLT, proceed to the next higher dose level. If no fewer than 2 of the 6 subjects develop DLT, no more subjects will be added to that dose level and dose escalation will cease. The Safety Monitoring Committee (SMC) decides whether to use the intermediate dose as the next dose level for the study. Until the maximum sample size specified in the protocol or the SMC decides to terminate the dose increment.each subject receives only one dose group of study drug (during the incremental period, subjects may receive a reduced dose to continue treatment after the investigator has assessed the risk-benefit for safety reasons; dose increments are not permitted for the same subject)."
88833045|NCT05986968|Experimental|Treatment arm|Ticagrelor monotherapy instead of dual antiplatelet therapy (aspirin plus ticagrelor)
88833046|NCT05986968|Active Comparator|Control arm|Dual antiplatelet therapy (aspirin plus ticagrelor) for 12 months.
89178221|NCT04043338|Placebo Comparator|Placebo|placebo (single dose)
89178222|NCT00832234|Experimental|BDR|
89361689|NCT05262270|Placebo Comparator|Placebo|"Matched placebo injections (PBO-Inj) for the treatment of cocaine use disorder (CUD).~Drug: Placebo (PLB) Injectable Placebo: 3 intramuscular injections administered Week 0, 3, 6. Other Names: Injectable matching (to XR-NTX) placebo Arm: Placebo Comparator - matched Placebo (PLB)~Drug: Placebo (PLB) Injectable Placebo: 2 subcutaneous injections administered Week 0, 4. Other Names: Injectable matching (to XR-BUP) placebo Arm: Placebo Comparator - matched Placebo (PLB)"
89361690|NCT05261204||Transcatheter Aortic Valve Implantation|Patients with aortic-valve stenosis at risk to severe valve obstruction who received TAVI with or without CABG or PCI. Individuals were adequately treated per applicable standards, including for coronary artery disease, LV dysfunction, aortic valve stenosis, and heart failure. Patients enrolled in the studies were NYHA functional class II, III, or outpatient NYHA IV.
89361691|NCT05261204||Bioprosthesis|Patients with aortic-valve stenosis at risk to severe valve obstruction who undervent SAVR with the use of bioprosthesis with or without CABG or PCI. Individuals were adequately treated per applicable standards, including for coronary artery disease, LV dysfunction, aortic valve stenosis, and heart failure. Patients enrolled in the studies were NYHA functional class II, III, or outpatient NYHA IV.
89361692|NCT05261204||Sutureless|Patients with aortic-valve stenosis at risk to severe valve obstruction who were managed by mean of SAVR with the use of sutureless with or without CABG or PCI. Individuals were adequately treated per applicable standards, including for coronary artery disease, LV dysfunction, aortic valve stenosis, and heart failure. Patients enrolled in the studies were NYHA functional class II, III, or outpatient NYHA IV.
89361693|NCT05254080|Experimental|Active taVNS then Sham taVNS|Participants will receive active then sham (placebo) ear stimulation.
89361694|NCT05254080|Experimental|Sham taVNS then Active taVNS|Participants will receive sham (placebo) then active ear stimulation.
89361695|NCT05253469||Cryopreserved Aortic Homograft|"Include patients who received CAH for native (NVE) or prosthetic valve endocarditis (PVE).~The CAH are implanted using miniroot procedure. For extended aortic valve infection, aortic root replacement and reconstruction of regional contiguity is the recommended approach. Complicated aortic IE may present with destruction of a large portion of the aortic annulus, annular abscess and colonization of infected foci in contiguous cardiac structures (eg. Aortic root and intervalvular fibrosa).~Use of homograft in first time aortic valve replacement for IE decreased over time (9,4% to 5,6%) and in reoperation (37,5% to 28,5%) in a report from STS database between 2005-2011 (6). Nevertheless, the homograft was used more often in reoperations than in primary interventions (32.2% vs 7.0%, p < 0.0001) in both valve replacements (14,6%) and for root replacements (53,2%) (6)."
89361696|NCT05253469||Stented/Non stented xenograft|Stented/Non stented xenograft may be inserted using separate or continuos stich with or without teflon pledget. The use of biological valves increased from 57% to 67% for primary the operation during which the use of mechanical valves decreased from 30% to 24%. For reoperations, the use of biologic valves increased from 38% to 52% compared to the warning use of mechanical valves from 20% to 17%. A homograft was used in only 2.5% of valve replacements, while a biological valve was used in 68.7% of the cases. This trend is reversed both in NVE and PVE the aortic root was involved (6). In the presence of peri-annular abscess formation and mitro-aortic discontinuity, conventional stented /non stented xenograft are used in combination with synthetic patch for both NVE and PVE.
89361697|NCT05253469||Mechanical valve prostheses|Mechanical prostheses may be inserted using separate or continuos stich with or without teflon pledget. Prior to 2000, mechanical valves were used in 50% of patients compared to 14% since 2009. Analysis of the STS Database (6) showed that from 2005 to 2011 a progressive shift in favour of biological valves both as the primary operation (NVE) (73%) and in the reoperation (PVE) (27%) compared to mechanical prosthesis. For extended aortic valve infection, aortic root replacement and reconstruction of regional contiguity is the recommended approach. Complicated aortic IE may present with destruction of a large portion of the aortic annulus, annular abscess and colonization of infected foci in contiguous cardiac structures (eg. aortic root and intervalvular fibrosa). In the presence of peri-annular abscess formation and mitro-aortic discontinuity, conventional mechanical prostheses are used in combination with synthetic patch for both NVE and PVE
89361698|NCT05252754|Experimental|Oral Tacrolimus + Indomethacin|"Tacrolimus Capsule 1-2 hours prior to the endoscopy~Rectal Indomethacin immediately after ERCP, in high-risk patients"
89361699|NCT05252754|Placebo Comparator|Oral Placebo + Indomethacin|"Placebo Capsule 1-2 hours prior to the endoscopy~Rectal Indomethacin immediately after ERCP, in high-risk patients"
89361700|NCT05249101|Experimental|Ivaltinostat plus Capecitabine|Ivaltinostat plus Capecitabine
89361701|NCT05249101|Active Comparator|Capecitabine Monotherapy|Capecitabine Monotherapy
89361702|NCT05248126|Active Comparator|Comparator arm|All patients randomized to this arm will participate in a standard patient education program.
89534506|NCT05029245|Active Comparator|Naive vaccine followed by Comirnaty® 30 microgram Intramuscular|Patients who had no history SAR-CoV vaccine before enrollment will received intramuscular Comirnaty® vaccine 30 microgram 2 dosage by 28 days interval
89534507|NCT05029245|Experimental|Any history of vaccination with Anti-RBD< 650AU/ml followed by Comirnaty® 6 microgram Intradermal|Patients who had history of any SAR-CoV vaccine at least 1 month before enrollment will received intradermal Comirnaty® vaccine 6 microgram 2 dosage by 28 days interval
88833047|NCT05986955|Experimental|Specified Diet 1 - Microbial Diet|Participants provided with a typical Australian diet including all food groups as described by the Australian Guide to Healthy Eating without any dietary exclusions. Meals have been designed by researchers and dietitians and prepared by professional chefs.
89178223|NCT05036980|Experimental|0.5 mg/kg Trans Sodium Crocetinate|Subjects will receive a single IV bolus dose of 0.5 mg/kg TSC. Subjects will also receive a single IV dose of normal saline as placebo, thereby serving as their own control.
89534508|NCT05029245|Active Comparator|Any history of vaccination with Anti-RBD <650AU/ml followed by Comirnaty® 30 microgram Intramuscular|Patients who had history of any SAR-CoV vaccine at least 1 month before enrollment will received intramuscular Comirnaty® vaccine 30 microgram 2 dosage by 28 days interval
89534509|NCT05050461|Active Comparator|Cases|Patients with a history of B-NHL
89534510|NCT05050461|Other|Controls|Spouses of cases
89534511|NCT05039853|Experimental|A brief cognitive task-based based intervention|Participants will engage in a brief cognitive task including: a memory reminder procedure, playing the computer game, Tetris, on a smart-device using mental rotation.
89361703|NCT05248126|Experimental|Experimental arm|All patients randomised to this arm have the opportunity to participate in a patient education programme via a chatbot.
89361704|NCT05244239|Experimental|Treatment (lurbinectedin and palliative radiation therapy)|Patients undergo palliative RT over 5 or 10 treatment fractions at the discretion of the treating physician daily for 21 days. Patients also receive lurbinectedin IV over 1 hour on day 1 of each cycle. Cycles of lurbinectedin repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89361705|NCT05242367|Active Comparator|Active VeNS|The active device utilizes a technology termed vestibular nerve stimulation (VeNS). The device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 30 minutes per day.
89361706|NCT05242367|Sham Comparator|Sham VeNS|The sham device looks identical to the active device and interacts with the app in a similar manner to the active device. It will apply some stimulation to a user for a limited period of time (30 seconds), before tapering down to zero over a further 20 seconds, thus creating the impression of an active device. The device will be placed on the head in a manner analogous to headphones with hydrogel electrodes placed over the mastoid processes. Participants will be advised to use the device at home for 30 minutes per day.
89361707|NCT05241873|Experimental|Phase I - Part 1A Dose Escalation|BLU-451 monotherapy with dose escalation in participants with metastatic cancer with EGFR Ex20ins or other selected EGFR mutations that have progressed after prior systemic therapies.
89361708|NCT05241873|Experimental|Phase I - Part 1B Dose Escalation (US only)|BLU-451 with dose escalation in combination with carboplatin and pemetrexed in participants with metastatic NSCLC with common EGFR mutations. This arm will enroll participants only in the United States.
88833048|NCT05986955|Active Comparator|Specified Diet 2 - Non-microbial Diet|Diet provided to participants is identical to Specified Diet 1 however after cooking and packaging, food for this arm will be sterilised by irradiation in line with International Organisation for Standardisation (ISO) standards and Australian code of good manufacturing practice.
88833049|NCT05986903||HLA-DQA1*05 variant carriers|
88833050|NCT05986903||HLA-DQA1*05 non-carriers|
88833051|NCT05986877|Experimental|lowest dose group|8 subjects will be randomized to receive lowest dose of STSA-1201 or dose-matched placebo.
88833052|NCT05986877|Experimental|low dose group|12 subjects will be randomized to receive low dose of STSA-1201 or dose-matched placebo.
88833053|NCT05986877|Experimental|middle dose group|12 subjects will be randomized to receive middle dose of STSA-1201 or dose-matched placebo.
88833054|NCT05986877|Experimental|high dose group|12 subjects will be randomized to receive high dose of STSA-1201 or dose-matched placebo.
88833055|NCT05986812||Normal subjects|
88833056|NCT05986812||Diseased subjects|
88833057|NCT05986799|Active Comparator|Amway Herbal Drink|"Amway Herbal Drink: 5g/sachet, containing the following active ingredients:~Extract of Phyllanthus emblica~Sophora flower extract~Wild cherry extract~Flower extract of Dendrobium candidum~Pomegranate extract~Resistant dextrin~γ-cyclodextrin"
88833058|NCT05986799|Placebo Comparator|Placebo Drink|"Placebo Drink: 5g/sachet, containing the following active ingredients:~Maltodextrin~Sugar~Honey"
88833059|NCT05986760|Experimental|SPARK|The SPARK is an evidence based plan designed to improve health-related well-being and to maintain the positive socialization and enjoyment of physical activities or academic achievements.(4) The SPARK discipline is in line with NASPE (National Association of Sport and PE) guidelines. A standard SPARK lesson will be delivered in two parts: a health fitness activity and a skill-fitness activity. In the health fitness activity part, there will be 13 activities that include aerobic dance, running games and jump ropes. In this part, the main focus will be on developing cardiovascular endurance and promotion by modifying the intensity, duration and complexity of the activities. The activities will be mostly aimed to develop abdominal and upper body strength.
88833060|NCT05986760|Experimental|Fundamental Motor training|In terms of motor development, fundamental motor skills (FMS, e.g., locomotor and object manipulation)-such as running, jumping, throwing, and kicking-are considered the essential building blocks for further, more complex gross motor movement. (24) There will be 13 FMS activities including; running, jumping, Gallop, hopping, side gliding, skipping, leaping, catching, stationary dribbles, kicking, striking a stationary ball, overarm throw and underarm throw. FMS group will receive 30 sessions for 10 weeks (3 sessions per week, 60 min per session including CPT).
88833061|NCT05986721|Placebo Comparator|Placebo Oral Tablet|Matching placebo to AGB101 tablet once daily, taken orally, for 78 weeks
88833062|NCT05986721|Experimental|AGB101 220 mg tablet|Single 220 mg AGB101 tablet once daily, taken orally, for 78 weeks.
88833063|NCT05986708|Experimental|intervention|The intervention group conducted 6 sessions of interviews with the researcher using the worksheets within the scope of the guided self-determination method.
88833064|NCT05986708|No Intervention|control|No intervention was made to the individuals in the control group.
88833065|NCT05986695|Active Comparator|Peer Comparison Report|Clinicians assigned to peer comparison, will receive messages by secure email every two weeks regarding their SGLT2i and MRA prescribing performance.
88833066|NCT05986695|Active Comparator|Alert|Clinicians in the alert arm will receive an alert two business days prior to a patient's upcoming appointment. Clinicians will receive approximately two alerts per week.
88833067|NCT05986695|Active Comparator|Alert and Peer Comparison|The combined alert and peer comparison arm will receive both interventions.
88833068|NCT05986695|No Intervention|Control|No alert or peer comparison
88833069|NCT05986578|Experimental|dlPFC then dmPFC then Sham iTBS|
88833070|NCT05986578|Experimental|dmPFC then dlPFC then sham iTBS|
89361709|NCT05241873|Experimental|Phase I - Part 2 BLU-451 Monotherapy Enrichment|BLU-451 enrichment at select doses.
89361710|NCT05241873|Experimental|Phase II - Cohort 2A|EGFR Ex20ins participants who have previously received platinum-based chemotherapy and either amivantamab or mobocertinib will receive BLU-451.
89534512|NCT05039853|Placebo Comparator|Placebo activity|Participants will engage with a placebo activity: listening to a pod-cast for approximately 15 minutes on a smart-device.
89534513|NCT02491385|Experimental|TEA|thoracic epidural analgesia group
89534514|NCT02491385|Active Comparator|iv-PCA|intravenous patient controlled analgesia group
88833071|NCT05986578|Experimental|dmPFC then sham iTBS then dlPFC|
89361711|NCT05241873|Experimental|Phase II - Cohort 2B|EGFR Ex20ins participants who have previously received platinum-based chemotherapy but have not received a prior EGFR Ex20ins-targeted agent will receive BLU-451.
89361712|NCT05241873|Experimental|Phase II - Cohort 2C|EGFR Ex20ins participants with at least one measurable lesion in brain per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 who have previously received platinum-based chemotherapy will receive BLU-451. Previous treatment with EGFR Ex20Ins-targeted therapies is allowed but not required.
89361713|NCT05241873|Experimental|Phase II - Cohort 2D|Participants with EGFR Ex20ins who have previously received platinum-based chemotherapy and both amivantamab AND mobocertinib, OR received any investigational Ex20Ins targeted agent(s) will receive BLU-451. Participants with Ex20ins or atypical mutations enrolled in other cohorts and who have other oncogenic drivers by central testing at baseline will be moved to this arm.
89361714|NCT05241873|Experimental|Phase II - Cohort 2E|Participants with EGFR Ex20ins who have not received prior systemic therapy in metastatic setting will receive BLU-451.
89361715|NCT05241873|Experimental|Phase II - Cohort 2F|Participants with EGFR atypical mutations (e.g., G719X, L861Q) who have previously received at least one EGFR tyrosine kinase inhibitor (TKI) will receive BLU-451. Participants with with other atypical EGFR mutations, such as S768I, may be enrolled if approved by Sponsor Medical Monitor.
89361716|NCT05241873|Experimental|Phase II - Cohort 2G|Participants with EGFR atypical mutations (e.g., G719X, L861Q) who have not received prior systemic therapy in metastatic setting will receive BLU-451. Participants with with other atypical EGFR mutations, such as S768I, may be enrolled if approved by Sponsor Medical Monitor.
89361717|NCT05241275|Experimental|Progressive Pulmonary Fibrosis|Whether magnetic resonance imaging (MRI) using inhaled hyper-polarized 129 Xenon gas can help visualize impaired lung function to detect changes over time in Progressive Pulmonary Fibrosis patients receiving approved treatments.
89361718|NCT05230667|Active Comparator|PRP injection (PRP group) and physical therapy|Patients in the PRP group will receive both shoulder joint (GHJ) and SASD bursa injection for 2 times in 2-week interval. PRP will be prepared by taking 10ml venous blood which is then mixed with 2ml of thrombin and centrifuged in a specially designed tube at 3400 rotations per minute (rpm) for 15 minutes. About 2ml PRP and 3ml platelet poor plasma (PPP) will be extracted, then 4ml 1% xylocaine will be added to make 9ml injectate. 6ml injectate will be injected into the posterior GHJ with a 7 cm 23-gauge needle under ultrasound (US) guidance. Another 3ml injectate will be injected into the SASD bursa of the affected shoulder with a 3.8 cm 22-gauge needle under US guidance. Physical therapy will be conducted for 8 weeks.
89361719|NCT05230667|Active Comparator|Corticosteroid injection (CS group) and physical therapy|Three ml triamcinolone (1ml= 10mg), 4ml 1% xylocain, and 2ml normal saline to make a 9ml injectate is injected into the affected shoulder (6ml to posterior GHJ and 3 ml to SASD bursa) for 2 times in 2-week interval. The techniques of injection are the same as those used in the PRP injection. Physical therapy will be conducted for 8 weeks.
89361720|NCT05230667|Active Comparator|Normal saline injection (NS group) and physical therapy|Four 4ml 1% xylocaine mixed with 5ml normal saline will be injected into the affected GHJ (6ml) and SASD bursa (3ml) for 2 times in 2-week interval . The techniques of injection are the same as those used in the PRP injection. Physical therapy will be conducted for 8 weeks.
89361721|NCT05228067|Active Comparator|Anodal stimulation|Anodal tDCS of the hypothalamus network
89361722|NCT05228067|Active Comparator|Cathodal stimulation|Cathodal tDCS of the hypothalamus network
89361723|NCT05228067|Sham Comparator|Sham stimulation|Sham tDCS of the hypothalamus network
89361724|NCT05226364|Experimental|Rubber tourniquet|The blood sample is taken with a rubber tourniquet,
89361725|NCT05226364|Experimental|Fabric tourniquet|The blood sample is taken with a a fabric tourniquet
89361726|NCT05226364|Experimental|No tourniquet|The blood sample is taken without tourniquet
89361727|NCT05222971|Experimental|Olaparib plus durvalumab|"Olaparib 300 mg twice daily Durvalumab 1,500 mg IV on Day 1~Every 4 weeks"
89361728|NCT05222971|Active Comparator|Olaparib|"Olaparib 300 mg twice daily~Every 4 weeks"
89361729|NCT05218993||Development of the new dual task test|the new two different method of dual task measurement and a traditional dual task measurement method and also, cognitive and performance measurement test will be conducted.
89361730|NCT05218993||Collecting the normative values|Better dual task measurement method (from the two methods) will be conducted at different football levels.
89361731|NCT05218993||Measurement of the athletes in return to sport stage|new dual task measurement method and other return to sport measurements will be conducted on athletes who wish to return to sport.
89361732|NCT05210790|Experimental|Rusfertide|Rusfertide (32 Weeks) - Rusfertide (124 Weeks Open-label)
89361733|NCT05210790|Experimental|Placebo|Placebo (32 Weeks) - Rusfertide (124 Weeks Open-label)
89361734|NCT05209815||Group 1|continuation of NTZ throughout pregnancy and postpartum
89361735|NCT05209815||Group 2|exposure during the first trimester
89361736|NCT05209815||Group 3|exposure during the first and the second trimester
89361737|NCT05209568|Experimental|Celiac Disease|Individuals with a confirmed diagnosis of celiac disease based on serology and/or histology
89361738|NCT05209568|Experimental|Healthy Controls|Individuals without a diagnosis of celiac disease
89361739|NCT05208294|Experimental|High expectation with sulpiride group|Prior to the experimental procedure, participants are told by the study clinicians that an antidepressant sulpiride capsule is administrated, while participants actually receive a sulpiride 400mg-capsule (note that the dose is presumably too high to produce antidepressant effects).
89361740|NCT05208294|Experimental|High expectation with placebo group|Prior to the experimental procedure, participants are told by the study clinicians that an antidepressant sulpiride capsule is administrated, while participants actually receive a placebo capsule.
89534515|NCT03331055|Experimental|percutaneous stimulation|PENS in 2/100HZ, 30 min for each time, twice a day, for 3 days. With conventional analgesic medication if necessary.
89534516|NCT03331055|Experimental|trancutaneous stimulation|TENS in 2/100HZ, 30 min for each time, twice a day, for 3 days. With conventional analgesic medication if necessary.
89534517|NCT03331055|No Intervention|Control|Conventional analgesic medication is offered.
89534518|NCT05028543|Placebo Comparator|conventional TLH|women that will be subjected to conventional Total laparoscopic hysterectomy
89361741|NCT05208294|Experimental|Low expectation with sulpiride group|Prior to the experimental procedure, participants are told by the study clinicians that an inactive placebo capsule is administrated, while participants actually receive a sulpiride capsule (400 mg).
89361742|NCT05208294|Experimental|Low expectation with placebo group|Prior to the experimental procedure, participants are told by the study clinicians that an inactive placebo capsule is administrated, and participants actually receive a placebo capsule.
89361743|NCT05201014||1 year follow-up|patients who were treated in the year before and are now returning for their 1-year follow-up.
89361744|NCT05201014||Prior to anthracycline-based therapy|patients presenting before the start of anthracycline-based therapy, then to be followed thereafter for 1 year and thereby contributing to the pool of patients with 1-year post-anthracycline assessment.
89361745|NCT05200936|Placebo Comparator|Arm 1- Placebo|A total of 26 patients will receive a placebo identical in appearance to the investigational medicinal product (IMP) administered orally twice weekly (e.g., Tuesday/Friday) for 6 weeks.
89361746|NCT05200936|Experimental|Arm 2- MM-120|A total of 26 patients will receive 20 μg of MM-120 administered orally twice weekly for 6 weeks.
89361747|NCT05196035|Experimental|Finerenone (Kerendia, BAY94-8862)|Participants will receive finerenone treatment.
89361748|NCT05196035|Placebo Comparator|Placebo|Participants will receive placebo to finerenone.
89361749|NCT05193877|Active Comparator|treatment with autologous bone marrow aspirate concentrate|autologous bone marrow aspirate is taken under local anesthesia to be centrifuged and the concentrate given intra articularly in knee joint
89361750|NCT05193877|Sham Comparator|control|control group given analgesics only
89361751|NCT05191641|Experimental|İntervention group|"PVQ and PedsQL will be used to collect research data. The same measurement tools will be used in the collection of pre-test, mid-term and post-test data. After obtaining the necessary written and verbal permissions from the parents in the intervention group included in the research, 12-week individualized nursing care will be applied. It is planned to make three measurements, namely pre-test, interim evaluation and post-test, from the parents in the intervention groups.~12 Weeks of Individualized Nursing Care~5 individual interviews~A interview after 2 weeks~Telephone consultation"
89361752|NCT05191641|No Intervention|Control group|Pre-test (PVQ and PedsQL) will be applied after obtaining informed consent from the parents included in the control group after randomization. In the pre-test application, an interim evaluation (PVQ and PedsQL) will be applied to the control group 1 week after and the post-test (PVQ and PedsQL) will be applied 4 weeks later. After the post-test application is completed, a five-day individual interview will be applied to the parents included in the control group.
89361753|NCT05187897|No Intervention|Standard Care Control|CHVs based at facilities in the control arm will continue to implement the standard of care.
89361754|NCT05187897|Experimental|CHV-NEO Intervention|CHVs based at facilities in the Intervention arm will implement the integrated CHV-NEO two-way SMS messaging intervention with their clients.
89361755|NCT05180812|Experimental|Experimental Group: Gravity Compensation|The participants will be wearing the ExoNet device tuned to gravity support.
89361756|NCT05180812|Sham Comparator|Control Group: No Gravity Compensation|The participants will be wearing the ExoNet device, but it will not be tuned to gravity support.
89361757|NCT05170503|Experimental|Neoadjuvant chemo-immunotherapy|Neoadjuvant Immunotherapy (Sintilimab, PD-1 inhibitor) Combined With Chemotherapy (Tegafur+Oxaliplatin) Each patient will complete 3 cycles of neoadjuvant therapy. After evaluating the radiographical response, operation with curative extent (Ivor-lewis or Mckeown procedure with two-field lymph node dissection) will be performed after 6 to 8 weeks from the last cycle of neoadjuvant treatment. Patients with and without surgery enter the survival follow-up period.
89361758|NCT05166304|Placebo Comparator|placebo|patients will receive the standard therapy (methotrexate) plus placebo tablets
89361759|NCT05166304|Experimental|rebamipide|100 mg rebamipide taken orally daily plus Methotrexate 7.5 mg weekly
89361760|NCT05164172|Experimental|Eptinezumab 300 mg|Participants will receive 3 intravenous (IV) infusions of eptinezumab 300 mg (weight adjusted) at Weeks 0, 12, and 24.
89361761|NCT05164172|Experimental|Eptinezumab 100 mg|Participants will receive 3 IV infusions of eptinezumab 100 mg (weight adjusted) at Weeks 0, 12, and 24.
89361762|NCT05153889|Other|Intensive care unit|systematic intensive care unit (ICU) monitoring
89361763|NCT05153889|Experimental|General cardiology ward|Group without ECG monitoring
89361764|NCT05151991|Active Comparator|Groups MET|Patients from this group will undergo orthodontic fixed treatment with stainless steel brackets.
89361765|NCT05151991|Active Comparator|Group CER|Patients from this group will undergo orthodontic fixed treatment with ceramic brackets.
88833072|NCT05986578|Experimental|dlPFC then sham iTBS then dmPFC|
89361766|NCT05140317||Group 1|The direct stargegy group included patients with implanation of the THV without predilatation The reference group included patients with direct implanation of tne THV withour predilaation
89361767|NCT05140317||Group 2|the echographists were blinded regarding the groups of the patients
89361768|NCT05127044||Qualified Preterm Infants|Preterm infants will receive non-invasive optical spectroscopy and transcutaneous bilirubin testing for baseline comparison
89361769|NCT05126446|Experimental|aortic dissection involving the aortic arch|Aortic dissection involving the aortic arch was diagnosed in patients requiring revascularization of the aortic arch and its branches
88833073|NCT05986578|Experimental|sham iTBS then dlPFC then dmPFC|
89361770|NCT05126147|Experimental|Hydroxychloroquine|Hydroxychloroquine 200mg twice daily for 6 months.
89361771|NCT05126147|No Intervention|Control|Observation and active surveillance.
89361772|NCT05124795|Experimental|IMU-935 - low dose, administered twice daily|main treatment phase of 3 cycles of 28 days; followed by extended treatment cycles for patients that show clinical benefit from treatment
88833074|NCT05986578|Experimental|shami iTBS then dmPFC then dl PFC|
88833075|NCT05986448|Experimental|Tai-chi group|Basic care measures and Tai-chi exercise
88833076|NCT05986448|No Intervention|control group|Basic care measures
88833077|NCT05986409|Experimental|opaque black tape covering part of the light source|10 wards were randomly selected as the intervention group (opaque black tape covering part of the light source).
89534519|NCT05028543|Experimental|TLH with prior uterine artery clipping at its origin|women that will be subjected to TLH with prior uterine artery clipping at its origin
88833078|NCT05986409|No Intervention|no intervention|another 10 wards were selected as the control group (no intervention)
88833079|NCT05986396||All Subjects|Subjects that have received the INSPIRIS Resilia device.
88833080|NCT05986383||Guoup 1|Liver function is Child Pugh A：If ICG-R15<10%, the standardized residual functional liver volume ratio (RRS) ≥ 40%
88833081|NCT05986383||Guoup 2|Liver function is Child Pugh A：If ICG-R15 is 10% - 20%, RRS ≥ 60%
88833082|NCT05986383||Guoup 3|Liver function is Child Pugh A：If ICG-R15 is 21% - 30%, RRS ≥ 80%
88833083|NCT05986383||Guoup 4|Liver function is Child Pugh A：If ICG-R15 is 31%~40%, only minimal hepatectomy with hepatectomy rate less than 5% can be performed
88833084|NCT05986383||Guoup 5|Liver function is Child Pugh A：If ICG-R15>40%, only tumor resection is feasible
88833085|NCT05986383||Guoup 6|Liver function is Child Pugh B: only tumor resection is allowed
88833086|NCT05986357||Study group|120 healthy women presenting with threatened miscarriage.
88833087|NCT05986357||Control group|120 healthy women with an uncomplicated single pregnancy.
88833088|NCT05986344||Copper intrauterine contraceptive device|Women will have the copper T-380 IUD (silverline, imported by DKT Egypt LLC-Egypt) ® IUD.
88833089|NCT05986344||Levonorgestrel Intrauterine System|Women will recieve the LNG-IUS (Mirena, Bayer HealthCare, Berlin, Germany)® IUD .
88833090|NCT05986305|Active Comparator|GOACT|GOACT is structured as a small group intervention for parents, consisting of four 60-minute sessions occurring over a 4-week period.
88833091|NCT05986305|Active Comparator|PEER|PEER is structured as a small group intervention for parents, consisting of four 60-minute sessions occurring over a 4-week period.
88833092|NCT05986227|Experimental|FOLFOX(D1)was combined with toripalimab(D3)|
88833093|NCT05986227|Experimental|FOLFOX(D1)was combined with toripalimab(D1)|
88833094|NCT05986227|Experimental|FOLFOX(D3) was combined with toripalimab(D1)|
88833095|NCT05986227|Active Comparator|FOLFOX(D1)|
88833096|NCT05986214|Experimental|VC-OPTIONS|Participants will be enrolled in the Annie texting VC-OPTIONS protocol
88833097|NCT05986201||40 patients|There were 33 (82.5%) males and 7 (17.5%) females aged 32-87 years, with a mean age of 67.8 years.
88833098|NCT05986175|Experimental|Motor Imagery Training Group|The Motor Imagery Training Group will receive motor imagery training in addition to Jeffreys' core (body) stabilization training protocol.
88833099|NCT05986175|Active Comparator|Core Stabilization Exercises Group|The Core Stabilization Exercises Group will receive only Jeffreys' core (body) stabilization training protocol.
88833100|NCT05986162|Experimental|Itolizumab Dose Level 1|Itolizumab of 25 mg administered by intravenous infusion every 2 weeks for a total of 7 doses.
88833101|NCT05986162|Experimental|Itolizumab Dose Level 2|Itolizumab of 50 mg administered by intravenous infusion every 2 weeks for a total of 7 doses.
88833102|NCT05986162|Experimental|Itolizumab Dose Level 3|Itolizumab of 100 mg administered by intravenous infusion every 2 weeks for a total of 7 doses.
88833103|NCT05986123|Other|Topical cream for PIH|The topical cream contain combination of niacinamide, arbutin, Scutellaria Baicalensis Root Extract, Centella Asiatica Extract and Camellia Sinensis Leaf Extract.
88833104|NCT05986110|Experimental|Intervention Group|
88833105|NCT05986110|No Intervention|Control Group|
88833106|NCT05986097|Experimental|Very low-carbohydrate breakfast|Materials will encourage eating a very low-carbohydrate breakfast (or first meal of the day), with no more than about 5-10 non-fiber (net) grams of carbohydrates each.
89534520|NCT05464745|Experimental|PERINDOPRES® DUO (Test)|A single oral dose of the test product PERINDOPRES® DUO 8 mg perindopril tert-butylamine / 2.5 mg indapamide tablets.
88833108|NCT05986058|Experimental|Hybrid PA intervention|The PA intervention implemented 1-hour sessions for 12 weeks focusing on improving (1) body muscle, (2) body flexibility, (3) muscle endurance, and (4) body balance. The 12-week hybrid PA intervention was concurrently deployed in-person at a senior center and at-home through a web-based modality.
88833109|NCT05986045||Cohort 1|Newborn infants diagnosed with Cystic Fibrosis at newborn screening
88833110|NCT05986045||Cohort 2|Children with previous diagnosis of Cystic Fibrosis up to 5 years of age
88833111|NCT05986045||Control|Newborn infants without cystic fibrosis
88833112|NCT05986019|Experimental|Active tFUS|tFUS will be administered within the MRI scanner. Participants receive two, 10-min sessions of active tFUS spread 10 min apart targeting the nucleus accumbens.
88833113|NCT05986019|Sham Comparator|Sham tFUS|The sham sessions will include a transducer that is connected in a similar fashion to that of active tFUS, however the cable will not be plugged into the system, thus no ultrasound will be delivered to the participant. Participants will not know or be told whether they are receiving active- or sham- tFUS.
88833114|NCT05986006|Active Comparator|Anterior Cervical Discectomy and Fusion (ACDF) w/Machined Allograft|Participant will undergo primary, elective one-level to four-level ACDF and will be randomized to machined bone allograft
88833115|NCT05986006|Active Comparator|Anterior Cervical Discectomy and Fusion (ACDF) w/Iliac Crest Allograft|Participant will undergo primary, elective one-level to four-level ACDF and will be randomized to iliac crest bone allograft
88833116|NCT05985980||Exercise test results will be grouped based on the menstrual cycle.|Positive exercise treadmill tests will be repeated at a different phase of menstrual cycle in premenopausal women (early versus late follicular phase).
88833117|NCT05985967|Other|Control|Passive recovery for 30 minutes
88833118|NCT05985967|Experimental|PBMT-sMF|Photobiomodulation therapy combined with static magnetic field, with a total treatment duration lasting for around 30 minutes.
88833119|NCT05985967|Active Comparator|Shock wave|Shock wave therapy applied for 30 minutes.
88833120|NCT05985967|Active Comparator|Pneumatic compression|Pneumatic compression applied for 30 minutes.
88833121|NCT05985902|Active Comparator|Control Group|Core stabilization exercise training will be given to the control group for 12 weeks, 7 days a week, for 60 minutes. Core stabilization exercises will be applied to this group under the supervision of a physiotherapist for 2 days in our unit, while home-based core stabilization exercise training will be given on other days of the week.
89178224|NCT05036980|Experimental|1.5 mg/kg Trans Sodium Crocetinate|Subjects will receive a single IV bolus dose of 1.5 mg/kg TSC. Subjects will also receive a single IV dose of normal saline as placebo, thereby serving as their own control.
88833122|NCT05985902|Experimental|Training Group|After the first evaluation, the training group will be given Schroth exercise training for 12 weeks, 7 days a week, for 60 minutes. This group will be given Schroth exercises under the supervision of a physiotherapist for 2 days in our unit, while home-based Schroth exercise training will be given on other days of the week.
88833123|NCT05985889|Experimental|Robotic|They performed training with a robot 15 times over 3 weeks.
88833124|NCT05985889|Experimental|Fizio|They receive physiotherapy treatment.
88833125|NCT05985889|Experimental|EXE1|Virtual reality treatment is performed once a day.
88833126|NCT05985889|Experimental|EXE2|Virtual reality treatment is performed twice a day.
88833127|NCT05985889|Experimental|EXE+ROB|Virtual and robotic treatments are performed once a day.
88833128|NCT05985876|Experimental|KULEA-NET application|Participants using the KULEA-NET application in addition to the usual care
88833129|NCT05985876|Experimental|Control Group: Usual Care|Control participants will receive usual care i.e. standard obstetrical care at MWHC and Mamatoto Village and will receive the standard Babyscripts app only without the KULEA-NET tile.
88833130|NCT05985837||Adolescents and adults|Adolescents from 12 years old and adults with sore throat and/or pharyngitis, who have bought the product.
88833131|NCT05985837||Children 1-6 years|Children from 1 to 6 years old with sore throat and/or pharyngitis, whose parents/caregivers have bought the product.
88833132|NCT05985837||Children 6-12 years|Children from 6 to 12 years old with sore throat and/or pharyngitis, whose parents/caregivers have bought the product.
88833133|NCT05985798|Experimental|Sin-Bev-TACE|Sintilimab, bevacizumab plus TACE
88833134|NCT05985798|Active Comparator|Len-TACE|Lenvatinib plus TACE
88833135|NCT05985785|Experimental|Autologous (from subject to self) bone marrow aspirate concentrate (BMAC) injections|"Autologous bone marrow aspirate concentrate (BMAC) will be removed from the subject knee body with a needle, processed and concentrated by an FDA-approved centrifuge (separator) system. The concentrated cells will be injected into the subject knee. Autologous means that the subject is receiving back their own cells that were collected."
88833136|NCT05985785|Active Comparator|Corticosteroid injection|Corticosteroid injection group (ARM 2) will receive a sham incision.
88833137|NCT05985785|Other|Crossover Group|Any patient in the corticosteroid injection group that shows no improvement in pain after 24 weeks (12 month follow-up if crossover), per physician discretion, will be allowed crossover to the BMAC injection group (ARM 3).
88833138|NCT05985772|Active Comparator|Non-operative Control (ARM 1)|Subjects randomized to the non-operative treatment arm will receive analgesics, physical therapy and will remain non-weight bearing. This will consist in anti-inflammatory drugs daily for 8-12 weeks and supervised physical therapy at least twice a week over a period of 8 weeks. Subjects in the non-operative arm will be offered the opportunity to crossover to the operative arm (ARM 2) of the study if the subjects do not report symptomatic improvement within 3 months after entry in this study.
88833139|NCT05985772|Experimental|Operative Intervention (ARM 2)|Subjects randomized to the operative treatment arm will undergo transtibial medial meniscus root repair within 3 weeks of enrollment. All surgically treated subjects, regardless if repairs were performed acutely or after cross over, will receive identical postoperative rehabilitation.
88833140|NCT05985759|No Intervention|970nm diode laser|
88833141|NCT05985759|Experimental|N acetyle cystiene|
88833142|NCT05985759|No Intervention|calcium hydroxide|
88833143|NCT05985746|Experimental|Augmented Reality (AR) group.|- The experimental group will consist of approximately 20 undergraduate medical students. Participants will use the TEACHANATOMY learning application with the HoloLens 2.
88833144|NCT05985746|Active Comparator|Traditional learning (TL) group.|- The control group will consist of approximately 20 undergraduate medical students. Participants will use traditional learning methods with textbooks, atlases, videos, and online learning programs,
88833145|NCT05985733||Study group|patients who applied to our clinic with complaint of pain in TMJ region subjects who had RDC/TMD type II disorder
88833146|NCT05985733||Control group|age and sex matched healthy volunteers
88833147|NCT05985629|Experimental|IPACK|After the adductor canal block, the anesthesiologist will reposition, visualize the anatomy of the IPACK block with ultrasound, and place 1% lidocaine for skin infiltration. Once adequate needle visualization is achieved within the correct anatomic position and plane, 20mL of 0.5% bupivacaine will be injected.
88833148|NCT05985629|Placebo Comparator|Placebo|After the adductor canal block, the anesthesiologist will reposition, visualize the anatomy of the IPACK block with ultrasound, and place 1% lidocaine for skin infiltration. Once adequate needle visualization is achieved within the correct anatomic position and plane, 20mL of normal saline will be injected.
88833149|NCT05985577||Cancer tissues|Cancer tissues
88833150|NCT05985577||Normal adjacent tissues|Normal adjacent tissues
88833151|NCT05985564||The Bochdalek hernia group|
88833152|NCT05985564||the congenital diaphragmatic eventration group|
88833153|NCT05985525||Observational|All patients
88833154|NCT05985512|Other|Insomnia Disorder|Patients with insomnia disorder
88833155|NCT05985460|Experimental|Intervention: motion-sensor video game|The experimental arm is a 1-2 mins motion-sensoring video game, which can accommodate 1-4 individuals, engaging their entire bodies in the physical motions involved. It aims to increase PA intention by increasing their motivation, as well as personal and family well-being by increasing the interaction with family members. Assessments will be conducted at two different time points, immediately following the intervention (T2) and after 1-month follow-up (T3).
88833156|NCT05985460|Placebo Comparator|Placebo: mobile APP game (without motion-sensoring)|The placebo arm is a 1-2 mins mobile app game, which allows 1-4 participants to play together with a duration of 1-2 minutes. It aims to increase participants' family and personal well-being by increasing the interaction of family members. Assessments will be conducted at two different time points, immediately following the intervention (T2) and after 1-month follow-up (T3).
88833157|NCT05985408|Experimental|LVSP-CRT|Patients received LVSP based CRT implantation; LVSP, left ventricular septal pacing; CRT, cardiac resynchronization therapy.
88833158|NCT05985408|Active Comparator|RVAP-CRT|Patients received RVAP based CRT implantation; RVAP, right ventricular apical pacing; CRT, cardiac resynchronization therapy.
88833159|NCT05985369|Experimental|Vegan diet|Participants will be allocated to a fully controlled 1-week vegan diet containing 0.8 g/kg BW/day of protein where all protein provided will be derived from non-animal-derived protein sources.
88833160|NCT05985369|Experimental|Omnivorous diet|Participants will be allocated to a fully controlled 1-week omnivorous diet containing 0.8 g/kg BW/day of protein where the majority of protein will be derived from animal-derived protein sources.
89361773|NCT05124795|Experimental|IMU-935 - medium dose, administered twice daily|main treatment phase of 3 cycles of 28 days; followed by extended treatment cycles for patients that show clinical benefit from treatment
89361774|NCT05124795|Experimental|IMU-935 - high dose, administered twice daily|main treatment phase of 3 cycles of 28 days; followed by extended treatment cycles for patients that show clinical benefit from treatment
89361775|NCT05121142|No Intervention|Arm 1: Existing patients with chronic GVHD|Participants with established diagnosis of chronic GVHD and currently on treatment with ruxolitinib for chronic GVHD for at least 3 weeks. Participants in this arm are receiving ruxolitinib clinically and will not receive ruxolitinib as part of this research study.
89361776|NCT05121142|Experimental|Arm 2: Acute GVHD ages 0-<12 years|Participants with acute GVHD will receive ruxolitinib on this arm.
89534521|NCT05464745|Active Comparator|Noliterax® 10 mg/2.5 mg (Reference)|A single oral dose of the reference product Noliterax® 10 mg/2.5 mg 10 mg perindopril arginine / 2.5 mg indapamide film-coated tablets.
88833161|NCT05985317|Active Comparator|Collagen membrane covering BMAC loaded on bovine graft|Collagen membrane will be used to BMAC loaded on bovine graft . Variables include assessment of the osteogenic potential In terms of bone density measurements of graft immediate and 4 months Postoperative
88833162|NCT05985317|Active Comparator|PRF membrane covering BMAC loaded on bovine graft|Platelet rich fibrin membrane will be used to BMAC loaded on bovine graft . Variables include assessment of the osteogenic potential In terms of bone density measurements of graft immediate and 4 months Postoperative
88833163|NCT05985291||PDN treated with SCS and CMM|Painful diabetic neuropathy patients treated with burst stimulation along with conservative medical management as part of regular medical care.
88833164|NCT05985278|Experimental|[ Lu-177]-Catalase|Participants received [ Lu-177]-Catalase intratumoral injection
88833165|NCT05985265|Experimental|Nano fat grafting and fractional carbon dioxide laser resurfacing|treating of atrophic acne scars with nano fat and fractional carbon dioxide laser
88833166|NCT05985252|Experimental|Virtual ileostomy|Laparoscopic or robotic surgery with virtual ileostomy
88833167|NCT05985252|Active Comparator|Diverting ileostomy|Laparoscopic or robotic surgery with diverting ileostomy
88833168|NCT05985226|Experimental|scanning strategies|"6 experimental groups will be created based on the strategy-scan body used (1.- zigzag with conventional scan body (ZZ-SBL), 2.- circumferential with conventional scan body (C-SBL), 3.- surface blocking with scan conventional body (B-SBL), 4.- zigzag with low profile scan body (ZZ-SBL), 5.- a standard strategy with low profile scan body (STD-SBL), 6.- single pass with low profile scan body ( OP-SBL) These experimental groups will be scanned directly in the patient's mouth, to later be compared with the reference model, called the master model."
88833169|NCT05985213||CSVD patients|The neuroimaging diagnosis will follow the Standards for Reporting Vascular Changes on Neuroimaging (STRIVE) criteria established by the neuroimaging experts in 2013. The interpretation and assessment will be conducted jointly by one experienced radiologist and one experienced neurologist.
88833170|NCT05985187|Experimental|TQB2440 injection + Trastuzumab + docetaxel|"Neoadjuvant phase (cycle 1-4):~TQB2440 injection + Trastuzumab + Docetaxel, intravenous infusion on the first day of each cycle, each cycle is 21 days.~Adjuvant chemotherapy phase (cycle 5-7):~Fluorouracil (600 mg/m2)+Epirubicin (90 mg/m2)+Cyclophosphamide (600mg/m2), intravenous injection once a day, on the first day of each cycle, each cycle is 21 days.~Double targeted maintenance phase (cycle 8-20):~TQB2440 injection+Trastuzumab, intravenous infusion on the first day of each cycle, each cycle is 21 days."
88833171|NCT05985187|Active Comparator|Perjeta® + Trastuzumab + docetaxel|"Neoadjuvant phase (cycle 1-4):~Perjeta® (Pertuzumab injection) + Trastuzumab + Docetaxel, intravenous infusion on the first day of each cycle, each cycle is 21 days.~Adjuvant chemotherapy phase (cycle 5-7):~Fluorouracil (600 mg/m2)+Epirubicin (90 mg/m2)+Cyclophosphamide (600mg/m2), intravenous injection once a day, on the first day of each cycle, each cycle is 21 days.~Double targeted maintenance phase (cycle 8-20):~TQB2440 injection+Trastuzumab, intravenous infusion on the first day of each cycle, each cycle is 21 days."
88833172|NCT05985174|Experimental|cases|"Neonates of both sexes included in this study with any suspected case of neonatal sepsis with maternal risk factors , e.g., prolonged labor , premature rupture of membrane (PROM) , maternal intrapartum fever and chorioamnionitis , and neonates with sepsis-related clinical signs :temparature instability , apnea , need for supplemental oxygen , bradycardia , tachycardia , hypotension , hypo~perfusion , feeding intolerance , and abdominal distension ."
88833173|NCT05985161|Experimental|Cohort A.1 Wilms Tumor|Participants will have any type of Wilms tumor or nephroblastoma
88833174|NCT05985161|Experimental|Cohort B.1 Rhabdoid Tumor|Participants will have any Rhabdoid tumor
88833175|NCT05985161|Experimental|Cohort C.1 MPNST|Participants will have progressive, relapsed, unresectable or metastatic MPNST
88833176|NCT05985161|Experimental|Cohort D.1 Other Solid Tumor|Participants must not qualify for Cohorts A, B, or C but have a solid tumor (no hematologic malignancies including lymphoma) for which there is specific evidence that this particular patient's tumor may benefit from selinexor.
88833177|NCT05985096|Experimental|Virtual Reality Group|"Adequate physical activity not only reduces depression, but also prevents the neural dysfunction that can occur as a result of depression. However, the level of physical activity among young people is not sufficient. Based on this fact, we believe that it is necessary to use 3D virtual reality applications to increase physical activity levels and exercise motivation.~The aim of our study is to investigate the effect of virtual reality training on balance, depression, anxiety and stress parameters in healthy young people."
88833178|NCT05985096|No Intervention|Control Group|The control group will perform individual exercise. The physical activity will be monitored with video recordings.
88833179|NCT05985070|Experimental|Intervention Arm B|Subjects in this arm will receive a daily single dose of oral 30mg elemental iron supplement as Ferrous Sulphate for 6 weeks
88833180|NCT05985070|Experimental|Intervention Arm C|Subjects in this arm will receive a daily single dose of oral 30mg elemental iron supplement as Ferric Pyrophosphate for 6 weeks
89361777|NCT05121142|Experimental|Arm 3: New onset chronic GVHD ages 0-≤18 years|Participants with new onset chronic GVHD will receive ruxolitinib on this arm.
89361778|NCT05118399|Active Comparator|To receive supraclavicular BPB using standard ropivacaine only.|20ml of plain bupivacaine will be injected using 2 syringes, so 10ml of 0.5% plain bupivacaine will be injected, and immediately followed by another 10ml of 0.5% plain bupivacaine.
89361779|NCT05118399|Experimental|To receive supraclavicular BPB using liposomal bupivacaine together with ropivacaine.|10ml of 0.5% plain bupivacaine will be injected, and immediately followed by 10ml of 1.33% liposomal bupivacaine.
89361780|NCT05115903|Experimental|Tapered doses of TNFi|Tapering of TNFi through standardized increases in the dosing interval between drug administration. The tapering dose intervals for each TNFi are designed to decrease the dose from baseline by 75% for 12 weeks, 50% for 24 weeks, and 25% for 12 weeks
89361781|NCT05115903|Active Comparator|Standard dose of TNFi|Stable doses of TNFi according to the approved summary of product characteristics for biologic agents used in axial spondyloarthritis
89361782|NCT05114421|Experimental|Cohort A (pembrolizumab, lenvatinib)|Beginning cycle 0, patients receive pembrolizumab IV over 30 minutes on day 1. Beginning cycle 1, patients also receive lenvatinib PO QD on days 1-21. Treatment repeats every 21 days for up to 35 cycles in the absence of disease progression or unacceptable toxicity.
89361783|NCT05114421|Experimental|Cohort B (pembrolizumab, lenvatinib)|Beginning cycle 0, patients receive lenvatinib PO QD on days 1-21. Beginning cycle 1, patients also receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 35 cycles in the absence of disease progression or unacceptable toxicity.
89361784|NCT05113381|Experimental|Intraventricular Hemorrhage Subjects|Intervention: Cerebrospinal Fluid (CSF) reduction Extra Ventricular Drainage (EVD) catheters will be used for cerebrospinal fluid drainage
89361785|NCT05107128|Experimental|SAGE-718|Participants will receive SAGE-718, once daily for 84 days.
89001084|NCT04631068|Active Comparator|Santen xact Mono-EDoF ME4 Intraocular Lens (IOL)|"The Monofocal Extended Depth of Focus (Mono-EDoF) posterior chamber foldable intraocular lens is ultraviolet and blue-light absorbing designed to be positioned in the lens capsule to replace the optical function of the natural crystalline lens. The diffractive technology of the IOL allows most of the light to converge in one focal point thereby providing high quality of distance vision and continuous focus to intermediate vision while minimizing the effects of unwanted visual disturbances. The visual quality is expected to be similar to monofocal IOLs.~Surgery to implant the Mono-EDoF ME4 Intraocular Lens (IOL) will be performed on Day 0 of the study, using standard microsurgical techniques. All instruments and procedures used will be identical to those routinely used for small incision phacoemulsification."
89001085|NCT04631068|Placebo Comparator|J&J TECNIS ZCB00 Intraocular Lens (IOL)|"The TECNIS 1-Piece Intraocular Lens (IOL), Model ZCB00, is a standard monofocal ultraviolet light absorbing posterior chamber IOL, which is designed to be positioned in the lens capsule to replace the optical function of the natural crystalline lens.~Surgery to implant the TECNIS ZCB00 Intraocular Lens (IOL) will be performed on Day 0 of the study, using standard microsurgical techniques. All instruments and procedures used will be identical to those routinely used for small incision phacoemulsification."
89361786|NCT05107128|Placebo Comparator|Placebo|Participants will receive placebo, once daily for 84 days.
89361787|NCT05106478||Moderate lateral Group|Patients will be anesthetized using ® AuraGain airway that will be inserted lubricated with partially deflated cuff. After insertion, the cuff will be inflated with the recommended volume of air and operation will undergo while patient's neck in moderate lateral position.
89361788|NCT05106478||Extreme lateral Group|Patients will be anesthetized using ® AuraGain airway that will be inserted lubricated with partially deflated cuff. After insertion, the cuff will be inflated with the recommended volume of air and operation will undergo while patient's neck in extreme lateral position.
89361789|NCT05088967|Experimental|IBI110+sintilimab|IBI110 and sintilimab will be administered as intravenous (IV) infusion on Day 1 of each 21-day cycle (every 3 weeks) for 3 cycles during the neoadjuvant treatment phase. IBI110 and sintilimab will be administered as IV infusion 3 weeks during the post-operative adjuvant phase up to 1 year.
89361790|NCT05088967|Active Comparator|sintilimab|Sintilimab will be administered as intravenous (IV) infusion on Day 1 of each 21-day cycle (every 3 weeks) for 3 cycles during the neoadjuvant treatment phase. Sintilimab will be administered as IV infusion 3 weeks during the post-operative adjuvant phase up to 1 year.
89001086|NCT00201786|Experimental|Pentostatin|Pentostatin is given at a dose of 1.5 mg/m2/day IV x 3 consecutive days. Each IV infusion of pentostatin will be administered over 20-30 minutes in 100-250 ml of D5W or NS.
89001087|NCT04631146||Camrelizumab-treated advanced NSCLC|Patients with advanced non-small cell lung cancer treated with camrelizumab. Dosage form, dosage, frequency and duration of camrelizumab is determined according to the investigator's actual clinical practice.
89001088|NCT04723433|Experimental|"Conservative O2 Supplementation"|Oxygen administration will titrated to a oxyhemoglobin saturation (SpO2) between 90 and 94%.
89001089|NCT04723433|Active Comparator|"Liberal O2 Supplementation"|Oxygen administration will titrated to an SpO2 > 96%.
89361791|NCT05084430|Experimental|Recurrent MG|To determine the safety and tolerability of M032 at the doses examined when given in combinations with pembrolizumab in patients with recurrent MG.
89361792|NCT05084430|Experimental|Newly Diagnosed MG|To determine Overall Survival at 12 and 24 months, and Progression Free Survival at 6 months (PFS-6) in patients with newly diagnosed glioblastoma multiforme of M032 when given in combinations with pembrolizumab (while maintaining safety).
89361793|NCT05078034|Active Comparator|HFNO|High Flow Nasal Oxygen alone
89361794|NCT05078034|Active Comparator|H-NIV|Helmet Non-Invasive ventilation for a minimum of 12 hours per day with HFNO between sessions
89361795|NCT05075486|Experimental|Intervention group|Group who recieve collaborative quality improvement during study period.
89534522|NCT03094533|Active Comparator|Total intravenous anesthesia|In the total intravenous anesthesia(TIVA) group, target controlled infusion (TCI) I was performed with propofol 4 mcg / ml. When the consciousness of the patient is lost, Remifentanil is administered as TCI with a target concentration of 1 ng / ml as an analgesic agent, and rocuronium 0.5 mg / kg is administered intravenously for intubation.
89361796|NCT05075213|Experimental|QuitBet|"QuitBet is a quit smoking game delivered via a smartphone application that lasts 28 days and includes contingency management in the form of a deposit contract, integrated exhaled breath carbon monoxide (CO) testing, a social feed on which players can post and respond to messages, and a leaderboard that displays players' status (i.e., whether they are still eligible to win). A game host will post educational information about smoking cessation and serve as a discussion moderator. Participants will deposit (bet) $30 of their own money at the start of the game. Participants who submit a CO test that is 6ppm or lower (indicating no smoking) on at least 24 of the 26 days between day 3-28 will be declared winners and will split the pot of money that was deposited. All participants who submit at least 21 CO tests during the 28 day game, regardless of the CO test result, will be entered into a lottery to win a prize worth $75."
89361797|NCT05075213|Active Comparator|QuitBet-NS (no social elements)|QuitBet-NS will include the deposit contract and integrated CO testing with identical rules to QuitBet for being a winner, the $75 raffle for submitting at least 21 CO tests, a display of the participant's daily CO test results that is updated in real time, and a game feed on which only the game host has the ability to post. Players will not be able to post on this feed or respond to the host's posts. At the beginning of the game, the host will post limited information, including a list of smoking cessation resources. QuitBet-NS will NOT include the social feed, leaderboard, or any other social features.
89361798|NCT05072236|Placebo Comparator|normal saline|intravenous normal saline 5 mL 1 minute before bronchoscope insertion
89361799|NCT05072236|Active Comparator|lidocaine|intravenous lidocaine 1.5 mg/kg 1 minute before bronchoscope insertion
89361800|NCT05072236|Experimental|alfentanil|intravenous alfentanil 10 ug/kg 1 minute before bronchoscope insertion
89361801|NCT05070845|Experimental|Open Label PF-06835375 dose 1 Treatment|subcutaneous injection once monthly for 3 months
89361802|NCT05070845|Experimental|Open Label PF-06835375 dose 2 Treatment|subcutaneous injection once monthly for 4 months
89361803|NCT05068713|Experimental|Hihg Target Mean Arterial Pressure|Target of mean arterial pressure of 85-90 mmHg in ther first 24h after liver transplant.
89361804|NCT05068713|Active Comparator|Low Target Mean Arterial Pressure|Target of mean arterial pressure of 65-70 mmHg in ther first 24h after liver transplant.
89361805|NCT05065021|Experimental|Initial/Cohort C|Niraparib by mouth (orally), once a day, every day. Bevacizumab, by vein (intravenously), once every 3 weeks for up to 1 year, then every 6 weeks.
89361806|NCT05065021|Experimental|Cohort A|"Niraparib by mouth (orally), once a day, every day. Bevacizumab, by vein (intravenously), once every 3 weeks for up to 1 year, then every 6 weeks.~Dostarlimab, by vein (intravenously), once every 3 weeks for 4 doses, then every 6 weeks afterwards."
89361807|NCT05065021|Experimental|Cohort B|"Paclitaxel, by vein (intravenously), once a week. Bevacizumab, by vein (intravenously), once every 3 weeks for up to 1 year, then every 6 weeks.~Dostarlimab, by vein (intravenously), once every 3 weeks for 4 doses, then every 6 weeks afterwards."
89361808|NCT05064735|Experimental|semaglutide 2.4 mg|Participants will receive semaglutide subcutaneous (s.c) 2.4 mg once-weekly as adjunct to a reduced-calorie diet and increased physical activity
89361809|NCT05064735|Placebo Comparator|semaglutide 2.4 mg (placebo)|Participants will receive semaglutide subcutaneous (s.c) placebo once-weekly as adjunct to a reduced-calorie diet and increased physical activity
89361810|NCT05063721|Experimental|Intra-arterial delivery of autologous MABs|Autologous mesoangioblasts (MABs) will be intra-arterially delivered to lower leg of participant
89361811|NCT05063721|No Intervention|No intervention|intra-subject control
88833181|NCT05985070|Experimental|Interventional Arm D|Subjects in this arm will receive a daily single dose of oral 30mg elemental iron supplement as Ferric Sodium Pyrophosphate for 6 weeks
88833182|NCT05985070|Active Comparator|Control Arm|Subjects in this arm will receive a daily single dose of oral Vitamin D (200 IU) supplement for 6 weeks
88833183|NCT05985031|Experimental|Spinal cord injuries|This was the patient group. Achilles tendon hits were performed for eliciting the soleus T reflex while the ankle was in neutral, dorsiflexion, and plantar flexion. Surface and multi-unit EMG recordings were taken from the anterior and soles muscles of the tibialis during the tendon tapping.
88833184|NCT05985031|Active Comparator|Healthy Control|This was the healthy control group. Achilles tendon hits were performed for eliciting the soleus T reflex while the ankle was in neutral, dorsiflexion, and plantar flexion. Surface and multi-unit EMG recordings were taken from the anterior and soles muscles of the tibialis during the tendon tapping.
88833185|NCT05984511|Experimental|TACE plus Atezolizumab/Bevacizumab and I-125 Seeds Brachytherapy (TACE-AB-I)|"TACE will be performed for the patients after randomization. Iodion-125 seeds will be implanted into the PVTT under CT guidance within 3-7 days after the first TACE.~Atezolizumab/bevacizumab (1,200 mg atezolizumab plus 15 mg/kg bevacizumab intravenously every 3 weeks) will be started at 3-7 days after the first TACE and I-125 Seeds Brachytherapy.~TACE and iodion-125 seeds implantation can be repeated on demand during follow-up based on the evaluation of laboratory and imaging examination."
88833186|NCT05984511|Active Comparator|TACE and Atezolizumab/Bevacizumab (TACE-AB)|"TACE will be performed for the patients after randomization. Atezolizumab/bevacizumab (1,200 mg atezolizumab plus 15 mg/kg bevacizumab intravenously every 3 weeks) will be started at 3-7 days after the first TACE.~TACE can be repeated on demand during follow-up based on the evaluation of laboratory and imaging examination."
88833187|NCT05983952|Experimental|Intervention（Anti-CD38 antibody）|10 enrolled subjects: once a week x 8 doses
88833188|NCT05983926|Experimental|Differences in conditions before and after surgical treatment of constipation|
88833189|NCT05983237|Experimental|Camre+Fluzo+TMZ|This arm will enroll patients who has advanced melanoma with a genetic HR mutation/ alteration .
88833190|NCT05982769|Experimental|Endurance Arm|
88833191|NCT05982769|Experimental|Resistance|
88833192|NCT05982769|Active Comparator|Standard of Care|
88833193|NCT05982496|Experimental|Cohort A|"Candidates to surgery as first treatment regardless of cN~ER+ Her2 negative BC with ki67>10%"
88833194|NCT05982496|Experimental|Cohort B|• ER positive BC treated with induction ET
88833195|NCT05982496|Experimental|Cohort C|• Candidates to neoadjuvant chemotherapy
88833196|NCT05982496|Experimental|Cohort D|• Metastatic LumA or ER-positive Lob BC, at first diagnosis or in progression
89361812|NCT05051982|Experimental|Study Group|Prior to the induction of anesthesia, the Sedline monitor will be placed on the patient's head to ensure the monitor is working properly. For those in the study group, the monitor will be in full view of the anesthesiologist administering the anesthetic.
89361813|NCT05051982|No Intervention|Control Group|Prior to the induction of anesthesia, the Sedline monitor will be placed on the patient's head to ensure the monitor is working properly. For those in the control group, an apparatus will be placed over the monitor will not be in view of the anesthesiologist. The
89361814|NCT05050929|Active Comparator|20 Gy in 5 Fractions Volumetric Modulated Arc Therapy to Brain Metastases|Five treatments of 4 Gy will be delivered using volumetric modulated arc therapy on a conventional linear accelerator in a conventional head shell without the use of stereotactic radiosurgery technique.
89361815|NCT05050929|Experimental|8 Gy in 1 Fraction Volumetric Modulated Arc Therapy to Brain Metastases|A single treatment of 8 Gy will be delivered using volumetric modulated arc therapy on a conventional linear accelerator in a conventional head shell without the use of stereotactic radiosurgery technique.
89361816|NCT05049460|Active Comparator|Active intervention|Four sessions of theta burst stimulation, amounting to 7200 pulses at 120% resting motor threshold. Targeting will be done using neuronavigation and processed resting state brain scan.
89361817|NCT05049460|Placebo Comparator|Sham TMS|Four sessions of sham TMS. Targeting will be done using neuronavigation and processed resting state brain scan.
89361818|NCT05045612|Experimental|Intervention|Stop antibiotic therapy as instituted by admitting physician
88833197|NCT05981937||Indocyanine Green|Indocyanine green infusion in left-side colorectal surgery (elective segmentary colic resection)
89361819|NCT05045612|No Intervention|Control|Continue antibiotic therapy at the discretion of the treating physician (no change in ongoing treatment)
89361820|NCT05044793||Cohort A|Pre-operative washout of ocular hypotensive medications with post-washout DIOP of 21-36mmHg
89361821|NCT05044793||Cohort B|Pre-operative washout of ocular hypotensive medications with pre-operative medicated IOP ≥18 mmHg and on 1 to 5 hypotensive medications
89361822|NCT05038332|Active Comparator|Moderately Hypo-fractionated Radiation Therapy|20 fractions of moderately hypofractionated radiation therapy over no more than 5-6 weeks.
89361823|NCT05038332|Experimental|Ultra-Hypofractionated Radiation Therapy|5 fractions of ultra-hypofractionated radiation therapy with at least one day between each treatment over the course of no more than 3-4 weeks
89361824|NCT05035342|Experimental|Fecal microbiota Transplant (FMT)|Fecal microbiota Transplant (FMT) prepared from the stools of healthy donors diluted in 80% glycerol used as bacterial cryoprotectant, blenderized, sieved and centrifuged (4°C, 4000 tr/min, 20 min) and manufactured in capsules (n=50 capsules corresponding to approximately 50 grams of stool; 25 two days in a row).
89361825|NCT05035342|Placebo Comparator|Placebo of FMT|FMT vehicle (solution of saline (NaCl 0.9%)) with 80% glycerol (storage in the same conditions as preparation for FMT experimental group) administered at the same volume and same time point as the experimental group.
89361826|NCT05035316|Placebo Comparator|Placebo|125 BD participants will receive placebo. Patients, clinicians and researchers will be blinded for the intervention
89361827|NCT05035316|Active Comparator|Active|125 BD participants will receive active treatment. Patients, clinicians and researchers will be blinded for the intervention
89361828|NCT05028816|Other|Group 1|"Side 1: Final layer dermal closure with poliglecaprone 25 suture (Monocryl ®, Ethicon, Inc. Bridgewater, NJ)~Side 2: Final layer closure with force modulating tissue bridges (FMTB) (Brijjit BP100-6, Brijjit Medical Inc., Marietta, GA)"
89361829|NCT05028816|Other|Group 2|"Side 1: Final layer closure with force modulating tissue bridges (FMTB) (Brijjit BP100-6, Brijjit Medical Inc., Marietta, GA)~Side 2: Final layer dermal closure with poliglecaprone 25 suture (Monocryl ®, Ethicon, Inc. Bridgewater, NJ)"
89361830|NCT05027438|Experimental|COAST + Deprescribing|CBT-I with simultaneous sedative-hypnotic deprescribing delivered through a digital platform
89361831|NCT05025852||Metformin exposed in utero|Offspring of mothers who were exposed to metformin during pregnancy in the MiTy trial.
89361832|NCT05025852||Placebo exposed in utero|Offspring of mothers who were not exposed to metformin during pregnancy in the MiTy trial.
89361833|NCT05020860|Active Comparator|Triple Negative Breast Cancer (for tumors > 5 cm)|Paclitaxel IV plus carboplatin IV (+/- pembrolizumab IV) (4 cycles total), followed by doxorubicin IV plus cyclophosphamide IV (+/- pembrolizumab IV) (4 cycles total)
89361834|NCT05020860|Active Comparator|Triple Negative Breast Cancer (for tumors < 5 cm)|Paclitaxel IV (4 cycles total), followed by doxorubicin IV plus cyclophosphamide IV (4 cycles total)
89361835|NCT05020860|Active Comparator|HER2-Positive Breast Cancer|Paclitaxel IV plus Trastuzumab IV plus Pertuzumab IV (or PHESGO) (4 cycles total), followed by doxorubicin IV plus cyclophosphamide IV administered (4 cycles total)
89361836|NCT05020860|Active Comparator|Hormone Receptor Positive Breast Cancer|Paclitaxel IV plus Carboplatin IV (4 cycles total), followed by doxorubicin IV plus cyclophosphamide IV (4 cycles total)
89361837|NCT05013905|Experimental|PRA023|Participants to receive PRA023 administered by intravenous (IV) infusion.
89361838|NCT05011487|Experimental|osimertinib plus chemotherapy|Osimertinib (80mg/qd) po. for 60 days with two cycles of Pemetrexed (500 mg/m2) to be administered with cisplatin (75mg/m2) on Day 1 of every 3-week cycle for 2 cycles
89361839|NCT05007925|Experimental|Single-arm|
89361840|NCT05005962||Acute ischemic patients suffering with stroke|Acute ischemic patients treated with commercially available neurothrombectomy devices in India. The device can be either a stent retriever or aspiration catheter to treat the stroke as per the labeling indications of the products.
89361841|NCT05003817|Experimental|LV-unloading|Participants in the elective unloading (intervention) group will have a percutaneous left ventricular unloading device (pLVAD) inserted at the start of the procedure, before the coronary intervention. Maximal support will be provided throughout the procedure, following which support will be weaned and the device removed should the patient remain haemodynamically stable.
88833198|NCT05981937||non-Indocyanine Green|No infusion of Indocyanine green in left-side colorectal surgery (elective segmentary colic resection )
89361842|NCT05003817|No Intervention|Standard of Care|Participants in the control arm will receive the planned high-risk percutaneous coronary intervention as is the current standard of care without elective left ventricular unloading. Alternative mechanical circulatory support devices (such as the intra-aortic balloon pump (IABP) or extracorporeal membrane oxygenation (ECMO) will only be permitted in case of complications.
88833199|NCT05981716||Young Breast Cancer Survivors|The investigators will enroll approximately 384 female breast cancer patients. Only non-institutionalized, English literate, female breast cancer patients diagnosed within the previous ten years and younger than 50 years old at the time of diagnosis will be eligible.
88833200|NCT05979883|Other|Arm A: Standard of care (SOC) treatment planning|Patients randomized to the SOC treatment planning arm will receive a treatment planning computed tomography (CT) scan followed by dosimetric planning with a medical dosimetrist; and the plan will be reviewed by a medical physicist and radiation oncologist. This is the current standard practice for all radiation oncology patients.
88833201|NCT05979883|Active Comparator|Arm B: Machine Learning Assisted Planning (MLAP)|Patients randomized to the MLAP arm will receive a treatment planning scan followed by MLAP through the RapidPlan module produced by Varian. Of note, RapidPlan is an FDA cleared module with treatment planning being the approved usage for the program. The RapidPlan module has site specific treatment packages for different disease sites. These separate disease specific packages have different capabilities. For example, the Head and Neck package currently audits dosimetrist-generated plans for possible improvements. The MLAP arm of the trial will leverage the RapidPlan module's full capabilities upwards to the FDA-approved usage.
88833202|NCT05979350|Active Comparator|Standard care group|Endotracheal aspirates, blood samples, urine samples, and nasopharyngeal swabs were obtained from the patients as soon as possible after ICU admission. Bacterial culture was performed, with the use of standard techniques, on blood samples and endotracheal aspirates. Urine antigen detection was performed for detection of L. pneumophila and S. pneumoniae. A PCR assay was performed on nasopharyngeal swabs for the detection of influenza A and B viruses and SARS-CoV-2 viruses. Fungal or mycobacterial detections, and whether to use multiplex PCR for pathogen detection, such as the FilmArray system, were determined at the discretion of the physicians.
88833203|NCT05979350|Experimental|mNGS group|Subjects assigned to the mNGS group will receive etiology work-up followed the protocol used in the standard care group and additional mNGS testing for two specimen of mini-bronchoalveolar lavage and one specimen of blood samples retrieved at the same time of standard work-up.
88833204|NCT05976945|Experimental|Baseline-Preparation-Imagery Rescripting-Post Treatment|Each participant follows this sequence: (1) 6-10 weeks waitlist during which no treatment is offered; (2) 5 weekly preparatory sessions. During these sessions the rationale of ImRs will be explained in more detail and a list of painful (childhood) memories to be addressed with ImRs is to be compiled, based on any further input from the patient; and a case conceptualization is made; (3) 8 to 12 sessions (45-60 minutes) of ImRs will be offered to participating patients. The stand-alone ImRs treatment will be based upon the protocol described by Arntz & Weertman (1999). (This protocol can be modified to tailor the needs of this study more specifically. Possible adaptations shall be based upon the manual developed by Brewin and colleagues (2009) for their study of applying ImRs to depression.); (4) After end of active treatment (ImRs) 5 weeks follow during which only weekly assessments are done.
88833205|NCT05976594||HE group|Subjects who has been diagnosed as HE.
88833206|NCT05976594||Control group|Subjects who didn't meet the diagnosis criteria of HE.
88833207|NCT05973929||Multiple sclerosis patients with movement disorders.|"A randomized cross-sectional study will be conducted on diagnosed multiple sclerosis patients who were diagnosed according to McDonald criteria of MS 2017 (Thompson et al. 2018).~We will study the prevalence of movement disorders in M.S patients, clinical type of movement disorder and the MRI findings. Data collected from patients admitted or following at Al-Azhar university hospitals at Al-Hussein and El-Sayed Galal hospitals. The included eligible patients should fulfil the following inclusion criteria:~i. Full clinical history and neurological assessment. ii. Detailed multiple sclerosis history according to MS unit history sheet. iii. Detailed history of movement disorder which include clinical type of movement disorder and medication taken (or not).~iv. MRI Brain and spine of the included patient will be photographed."
88833208|NCT05971732|Experimental|Ferric derisomaltose|"Iron to be administered as ferric derisomaltose.~The treatment dose (mL) to be administered will be determined by the patient's body weight and hemoglobin (Hb) value.~Where Hb ≥10 g/dL, dosage according to body weight is as follows:~Body weight <50 kg: 20 mg/kg; Body weight 50 to <70 kg: 1000 mg; Body weight ≥70 kg: 20 mg/kg up to a maximum of 1500 mg.~Where Hb <10 g/dL, dosage according to body weight is as follows:~Body weight <50 kg: 20 mg/kg; Body weight 50 to <70 kg: 20 mg/kg; Body weight ≥70 kg: 20 mg/kg up to a maximum of 2000 mg.~Infused over a minimum of 15mins for doses up to and including 1000mg, and a minimum of 30 mins for doses >1000mg"
88833209|NCT05971732|Placebo Comparator|Placebo|Participants in this arm will receive normal saline 0.9% in analogy to treatment arm.
88833210|NCT05970744|Experimental|RSV/Flu-01E low dose 18-59|Participants aged 18 to 59 years will receive single injection of low dose RSV/Flu-01E Vaccine
88833211|NCT05970744|Experimental|RSV/Flu-01E high dose 18-59|Participants aged 18 to 59 years will receive single injection of high dose RSV/Flu-01E Vaccine
88833212|NCT05970744|Placebo Comparator|Placebo 18-59|Participants aged 18 to 59 years will receive single injection of Placebo
88833213|NCT05970744|Experimental|RSV/Flu-01E high dose over 60|Participants aged over 60 years will receive single injection of high dose RSV/Flu-01E Vaccine
88833214|NCT05970744|Placebo Comparator|Placebo over 60|Participants aged over 60 years will receive single injection of Placebo
88833215|NCT05970380||Local anesthesia|Local anesthesia with 0.25% 20 mL bupivacaine will be given extrapedicular part of the fractured vertebra by the surgeon. At the same time, intravenous 0.1 mg/kg midazolam, 0.3 mg/kg ketamine and 25-100 mcg/kg/min propofol will be administered to achieve sedation and analgesia.
88833216|NCT05970380||ESP Block|Bilateral erector spinae plane block will be performed at the level of fractured vertebra with totally 40 mL 0.25% bupivacaine under ultrasound imaging by the anesthesiologist. Intravenous 0.1 mg/kg midazolam will be administered for sedation.
88833217|NCT05969756|Experimental|Fluoride varnish group|5% sodium fluoride varnish, 3M, USA
89361843|NCT05003440|Experimental|NNC0385-0434 15 mg|15 mg oral NNC0385-0434 will be administered once-daily over 10 consecutive days
89361844|NCT05003440|Placebo Comparator|Placebo (NNC0385-0434 15 mg)|Oral placebo will be administered once-daily over 10 consecutive days
89361845|NCT05003440|Experimental|NNC0385-0434 40 mg|40 mg oral NNC0385-0434 will be administered once-daily over 10 consecutive days
89361846|NCT05003440|Placebo Comparator|Placebo (NNC0385-0434 40 mg)|Oral placebo will be administered once-daily over 10 consecutive days
89361847|NCT05003440|Experimental|NNC0385-0434 100 mg|100 mg oral NNC0385-0434 will be administered once-daily over 10 consecutive days
89361848|NCT05003440|Placebo Comparator|Placebo (NNC0385-0434 100 mg)|Oral placebo will be administered once-daily over 10 consecutive days
89361849|NCT05003388|Experimental|Treatment Group|Single intravenous infusion of 100 million cells
89361850|NCT04999709|Active Comparator|Active|The active device utilizes a technology termed vestibular nerve stimulation (VeNS). The device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 1 hour per day.
89361851|NCT04999709|Sham Comparator|Sham|The sham device looks identical to the active device and interacts with the app in a similar manner to the active device. It will apply some stimulation to a user for a limited period of time (30 seconds), before tapering down to zero over a further 20 seconds, thus creating the impression of an active device. The device will be placed on the head in a manner analogous to headphones with hydrogel electrodes placed over the mastoid processes. Participants will be advised to use the device at home for 1 hour per day.
89361852|NCT04996797|Experimental|Cohort 1 PRA023|Participants randomized to receive PRA023 administered by intravenous (IV) infusion.
89361853|NCT04996797|Placebo Comparator|Cohort 1 Placebo|Participant randomized to receive placebo administered by intravenous (IV) infusion.
89361854|NCT04996797|Experimental|CDx+ Expansion Cohort PRA023|Participants randomized to receive PRA023 administered by intravenous (IV) infusion.
89361855|NCT04996797|Placebo Comparator|CDx+ Expansion Cohort Placebo|Participant randomized to receive placebo administered by intravenous (IV) infusion.
89361856|NCT04987203|Experimental|Tivozanib in Combination with Nivolumab|Subjects with advanced RCC will receive 0.89 mg of tivozanib once daily (QD) for 3 weeks followed by 1 week off study drug and nivolumab every 4 weeks on Day 1 of each Cycle, until disease progression or unacceptable toxicities occur, other withdrawal criteria are met, or completion of 2 years of treatment [for nivolumab] whichever occurs first.
89361857|NCT04987203|Experimental|Tivozanib|Subjects with advanced RCC will receive 1.34 mg of tivozanib once daily (QD) for 3 weeks followed by 1 week off study drug until disease progression or unacceptable toxicities occur, or other withdrawal criteria are met.
89361858|NCT04987034||Direct and indirect PPG measurements|Measuring the portalsystemic pressure gradient in patients directly using the EchoTip® Insight™ and indirectly through the HVPG procedure.
89361859|NCT04975724|Experimental|Group A Liposom Forte + Citalopram|Liposom Forte (2 ampoules of 28mg/2 ml) for 30 days + citalopram (10mg) for 90 days
89361860|NCT04975724|Experimental|Group B Placebo + Citalopram|Placebo (2 ampoules of 2 ml) for 30 days + citalopram (10mg) for 90 days
89361861|NCT04967989|Experimental|First Randomization: Low Energy SLT|"Low energy SLT will consist of 100 treatment spots delivered at 0.4mJ per spot throughout the full 360° treatment, with the exception that energy can be reduced to 0.3mJ if bubbles are seen with 5 consecutive spots and can be increased back to a maximum of 0.4mJ is no bubbles are seen with 5 consecutive spots.~Regardless of energy level randomization, energy may be adjusted downward in 0.1mJ increments throughout the procedure in response to factors such as heavy focal pigmentation or patient discomfort."
89361862|NCT04967989|Active Comparator|First Randomization: Standard Energy SLT|"Standard SLT will be performed as follows: beginning at 0.8 mJ, energy will be titrated up or down within the first 5-10 spots until champagne bubbles are visualized with every 2nd or 3rd spot. Energy can be titrated throughout the procedure, in response to variations in pigmentation, to ensure the appearance of champagne bubbles with every 2nd or 3rd spot throughout the full 360° treatment. Energy should be increased if no bubbles are seen with 5 consecutive spots and decreased if bubbles are seen with 5 consecutive spots.~Regardless of energy level randomization, energy may be adjusted downward in 0.1mJ increments throughout the procedure in response to factors such as heavy focal pigmentation or patient discomfort."
89361863|NCT04967989|Experimental|Second Randomization: Annual Low Energy Repeat SLT|At month 12, subjects remaining medication-free will be re-randomized to undergo repeat SLT either annually at low energy or as needed at initially assigned energy (from first randomization). The method of SLT delivery is as described in the sections above.
89361864|NCT04967989|Active Comparator|Second Randomization: As-Needed Repeat SLT at Initial Energy|At month 12, subjects remaining medication-free will be re-randomized to undergo repeat SLT either annually at low energy or as needed at initially assigned energy (from first randomization). The method of SLT delivery is as described in the sections above.
89361865|NCT04958941|Experimental|Intervention group|The group will receive the ecological momentary intervention (CUIDA-TE APP). This intervention will allow the individual to learn and practice adaptive ways to regulate their emotions. The protocol contains the following components: Distraction, acceptation skills, re-appraisal and problem-solving skills.
89361866|NCT04958941|No Intervention|Control group|This condition is a waiting list control group with no intervention. The participants will wait for a period of 3 months. They will be offered the possibility of receiving the intervention APP (CUIDA-TE) after the waiting list period.
89361867|NCT04949191|Experimental|Study Treatment 1: Pemigatinib (INCB054828)|Pemigatinib will be taken orally once daily
89361868|NCT04949191|Experimental|Study Treatment 2: Pemigatininb+ Retifanlimab|Participants rolling over from study INCB 54828-101 only will receive pemigatinib once daily and retifanlimab will be administered once every 4 weeks
89361869|NCT04949191|Experimental|Study Treatment 3: Pemigatininb + Pembrolizumab|Participants rolling over from study INCB 54828-101 only will receive pemigatinib once daily and pembroluzimab as per dosage instructions.
89361870|NCT04947904|Experimental|Optimised Restrictive Strategy|The volume of non-resuscitative fluids infused to the patient will be reduced by the doctor in charge of the patient for the first 7 days of the patient's stay in ICU according to a special protocol.
89361871|NCT04947904|No Intervention|Control|Resuscitation fluids, maintenance fluids, nutrition and drugs will be administered as usually performed and following most recent guidelines.
89361872|NCT04943224|Experimental|R1 time of trametinib treatment|Patients with negative status of any mutation in ctDNA or 0-1 Disease Activity Score (DAS) in three consecutive tests in three month intervals.
89361873|NCT04943224|Experimental|R2 time of trametinib treatment|Patients with negative status of any mutation in ctDNA or 0-1 Disease Activity Score (DAS) in in five consecutive tests in three month intervals.
89361874|NCT04943211|Other|R1 low intervention arm|Children of both sexes who meet all inclusion criteria and do not meet any exclusion criteria will be eligible for the study.
89361875|NCT04943198|Experimental|R1 time of vemurafenib treatment|vemurafenib will be given to 6 months after BRAF negativization
89361876|NCT04943198|Experimental|R2 time of vemurafenib treatment|vemurafenib will be given to 12 months after BRAF negativization
89361877|NCT04941651|Experimental|OBE-COACH program|The OBE-COACH experimental group: access to the complete OBE-COACH program
89361878|NCT04941651|Active Comparator|e-learning program|The control group: access to an e-learning program with free access via the web to advice sheets, a menu generator and a catalog of physical activity (resources made available by the site www.mangerbouger.fr ; Public Health France, Ministry of Health) and provision of connected devices (auto-tensiometer and balance).
89361879|NCT04930562|Experimental|200mg qd|200mg qd po.
89361880|NCT04929899|Other|Bright Ideas- CIN Training|"The PSST will be delivered by a trainer in a minimum of three 30-minute to 1-hour sessions with a parent and patient (if developmentally appropriate).~During the first session, the study team member will build rapport by understanding relevant personal background and medical information; introduce PSST and the Bright IDEAS paradigm; review the patients experience with nausea as reported in Phase 1 and at other times during treatment; promote problem-solving strategies and skills; and develop an anti-nausea action plan. During the second session, the trainer will discuss how well the prior action plan worked and reinforce successful outcomes or, if unsuccessful, return to the problem-solving steps to generate a new action plan. The third session will review progress on CINV control, assist in problem-solving as needed, and discuss how to continue to use the Bright IDEAS framework to resolve future issues with CINV or symptom management more broadly."
89361881|NCT04927741|Experimental|Method 1: Sweet Marjoram Essential Oil + Grapeseed Oil with Massage|Subjects randomized will receive dilution of sweet marjoram essential oil (mixed with grapeseed oil), which will be applied topically with massage after IUD insertion.
89361882|NCT04927741|Active Comparator|Method 2: Grapeseed Oil with Massage|Subjects randomized will grapeseed oil applied topically with massage after IUD insertion.
89361883|NCT04927741|No Intervention|Method 3: Control Group (no oil or massage)|Subjects will serve as control and no essential oils or massage will be applied.
89361884|NCT04920175||NICU Cohort|Participants will undergo a standard polysomnogram
89361885|NCT04917068||Bulimia Nervosa|Participants with diagnosed bulimia nervosa (BN) who will complete all tasks during Visits 1 and 2 in addition to ecological momentary assessment (EMA) procedures following Visit 2.
89361886|NCT04917068||Healthy Control|Participants without diagnosed BN or other current or past eating disorders who will complete all tasks during Visits 1 and 2 and will not complete EMA procedures following Visit 2.
89361887|NCT04908787|Experimental|BD0801+chemotherapy|BD0801 is in combination with one of three chemotherapies: Paclitaxel, Topotecan or Doxorubicin liposomes.
89361888|NCT04908787|Placebo Comparator|Placebo+chemotherapy|Placebo is in combination with one of three chemotherapies: Paclitaxel, Topotecan or Doxorubicin liposomes.
89361889|NCT04908735|Experimental|Ruxolitinib Treatment|
89361890|NCT04902872|Experimental|Phase 1 Schedule B Dose Escalation (Daily Dosing x 3)|CBX-12 administered on a daily x 3, 3 week schedule
89361891|NCT04902872|Experimental|Phase 1 Schedule C Dose Escalation (Once Weekly Dosing )|CBX-12 administered once weekly, 4 week schedule
89361892|NCT04902872|Experimental|Phase 2 Ovarian Cancer Expansion Cohort|CBX-12 administered TBD
89361893|NCT04902872|Experimental|Phase 2 Metastatic Breast Expansion Cohort|CBX-12 administered TBD
89361894|NCT04902872|Experimental|Phase 1 Schedule A Dose Escalation (Daily Dosing x 5)|CBX-12 administered on a daily x 5, 3 week schedule
89361895|NCT04902872|Experimental|Phase 1 Modified Schedule B Dose Escalation (Once Every 3 weeks)|CBX-12 administered once every 3 weeks
89361896|NCT04896580|Experimental|Active|Participants will be asked to complete a 12 week exercise program
89361897|NCT04891822||E (ERAS protocol)|receive ERAS protocol 8 hours of fasting and ingestion of oral carbohydrate 2 hour before surgery TIVA(Total intra-venous anesthesia) TAP(transversus abdominis plane) block IV-PCA using NSAIDs after surgery Resuming oral intake 2 hours after surgery.
89361898|NCT04891822||C (Control)|receive standard perioperative care 8 hours of fasting before surgery Inhalation anesthesia IV-PCA using NSAIDs Resuming oral intake 6 hours after surgery.
89361899|NCT04891289|Experimental|HAI FUDR plus GemOx (Arm 1)|Surgical HAI pump placement. 2. HAI FUDR [(0.12 mg/kg/day) x wt (kg) x (30ml) / pump flow rate ] and dexamethasone [1 mg/day * 30] / pump flow rate ] on Day 1 of each cycle. Chemotherapy with HAI FUDR/Dex will commence no sooner than 14 days postsurgical placement of HAI pump. 3. Gemcitabine (800 mg/m2 IV over 30 minutes) and oxaliplatin (85 mg/ m2 IV over 120 minutes on Days 1 and 15 of each cycle; however, for patients in Arm 1, initiation of systemic chemotherapy will not take place until 4 weeks post-surgery for pump placement, so the first dose of systemic chemotherapy will be given on Cycle 1, Day 15, and then every 2 weeks thereafter.
89361900|NCT04891289|Active Comparator|GemOx alone (Arm 2)|Gemcitabine (800 mg/m2 IV over 30 minutes) and oxaliplatin (85 mg/m2 IV over approximately 120 minutes) on Days 1 and 15 of each 28-day cycle.For patients in Arm 2, systemic therapy will be administered on Days 1 and Day 15 of each Cycle on a 28-day cycle basis, compromised of Gemcitabine and Oxaliplatin. If a patient randomized to Arm 2 has intrahepatic progression on any follow-up scan during study treatment, that patient will be eligible to crossover to Arm 1 and commence to pump placement surgery and HAI FUDR treatment. Patients with any extrahepatic progression will not be eligible to utilize the crossover arm. Arm 2 patients will have 28 days from date of the scan showing intrahepatic progression to proceed to the crossover arm.
89361901|NCT04887506|Experimental|TAVT-45|TAVT-45 administered twice daily as a 1 x sachet containing TAVT-45 (250 mg abiraterone acetate) + Prednisone (5mg once or twice daily, depending on prostate cancer population). TAVT-45 administered approximately every 12 hours without respect to food. Patients treated for 84 days.
88833218|NCT05969756|Experimental|Conventional etch and rinse sealant group|Resin-based composite sealant, 3M, USA
88833219|NCT05969756|Active Comparator|Self-etch sealant group|Self-etch primed sealant, Shofu, Japan
89178225|NCT05036980|Experimental|2.5 mg/kg Trans Sodium Crocetinate|Subjects will receive a single IV bolus dose of 2.5 mg/kg TSC. Subjects will also receive a single IV dose of normal saline as placebo, thereby serving as their own control.
89178226|NCT00837772|Active Comparator|Arm 1|Usual standard cutting guide for TKA (Total Knee Arthroscopy)
89178227|NCT00837772|Experimental|Arm 2|Otismed MRI generated cutting guide for TKA
88833220|NCT05966870|Experimental|Replacement of SSB with Unsweetened Sparkling Beverage|To encourage participants to substitute sparkling water flavored water for SSB intake, we will provide enough supplies of the drinks to adolescents (and their families) each month. We will also provide iPhones with the TADA app to the adolescent participants. Study staff will remind participants to consume the sparkling water through iMessages sent through the TADA app.
88833221|NCT05966324|Experimental|Cohort 1|Oral tablet dose of baxdrostat 1 mg or placebo, administered as a single dose (Day 1) and multiple doses (once daily [QD] for 5 days, Days 6 - 10) to Japanese subjects
89361902|NCT04887506|Active Comparator|Reference abiraterone acetate (Zytiga®) - R-AA|Zytiga (reference abiraterone acetate formulation, hereafter referred to as R-AA) administered once daily as (2 x 500mg Zytiga tablets) + Prednisone (5mg once or twice daily, depending on prostate cancer population). R-AA administered once daily either ≥ 1 hour before or ≥ 2 hours after a meal. Patients treated for 84 days.
89534523|NCT03094533|Active Comparator|volatileinduction maintenance anesthesia|In the volatile induction and maintenance anesthesia(VIMA) group, when 8% sevoflurane is inhaled with 100% oxygen at 6 L / min and the consciousness is lost, the concentration of sevoflurane is reduced to 2-3% and then the mask is ventilated.Remifentanil is administered as TCI with a target concentration of 1 ng / ml as an analgesic agent, and rocuronium 0.5 mg / kg is administered intravenously for intubation.
89534524|NCT03330977|Other|Before and after use of compression garments|"At inclusion, patients will only have medication prescription as usual but without compression garments, and thus, for 4 months.~4 months after inclusion, patients will continue medication but will also be prescribed compression garments Then every 6 months, until 26 months, patients will come back to have new compression garments (as usual practice)"
89534525|NCT05028231||Neoadjuvant Immunotherapy (PD-1 / PD-L1) Combined With Chemotherapy|
88833222|NCT05966324|Experimental|Cohort 2|Oral tablet dose of baxdrostat 3 mg or placebo, administered as a single dose (Day 1) and multiple doses (QD for 5 days, Days 6 - 10) to Japanese subjects
88833223|NCT05966324|Experimental|Cohort 3|Oral tablet dose of baxdrostat 3 mg or placebo, administered as a single dose (Day 1) and multiple doses (QD for 5 days, Days 6 - 10) to Caucasian subjects
88833224|NCT05966324|Experimental|Cohort 4|Oral tablet dose of baxdrostat 10 mg or placebo, administered as a single dose (Day 1) and multiple doses (QD for 5 days, Days 6 - 10) to Japanese subjects
89178228|NCT00832312|Experimental|ozone-oxygen mixture|10 cc of an ozone-oxygen mixture with ozone concentration 10000 mcg/L (10 mcg/ml) injected into the knee joint
89178229|NCT00832312|Placebo Comparator|Saline|Injection of 1cc of saline into the knee joint
89534526|NCT03335579||non-MACE|patients without major postoperative cardiac or cerebral complications
88833225|NCT05965466|Experimental|Distal gastrectomy|Distal subtotal gastrectomy was performed after exclusion of contraindications to surgery. Gastrointestinal reconstruction was performed by residual gastrojejunal Roux-en-Y anastomosis. Anastomosis was performed ex vivo or in vivo.
88833226|NCT05965466|Sham Comparator|Total gastrectomy|Total gastrectomy was performed after the exclusion of contraindications to surgery. Gastrointestinal reconstruction was performed by oesophageal jejunum Roux-en-Y anastomosis. Anastomosis was performed ex vivo or in vivo.
88833227|NCT05963009|Experimental|Baxdrostat oral solution|5 mg CIN-107 oral solution in a fasted state
88833228|NCT05963009|Experimental|Baxdrostat tablet (fasted state)|5 mg CIN-107 tablet(s) in a fasted state
89178230|NCT02547532||usual COPD|Patients meeting the diagnostic criteria for COPD and without AATD
89178231|NCT02547532||normal smokers|subjects with a history of smoking, without symptoms, without AATD and with normal lung function
89178232|NCT02547532||normal non smokers|subjects without a history of smoking, without symptoms, without AATD and with normal lung function
89178233|NCT02547532||AATD not treated|patients with COPD, with AATD and not on augmentation therapy for AATD
89178234|NCT02547532||AATD treated|patients with COPD, with AATD on augmentation therapy for AATD
89178235|NCT00837850|Active Comparator|1|
89178236|NCT00837850|Active Comparator|2|
89178237|NCT00784134|Experimental|Alteplase|administration of alteplase via the intraventricular catheter
89178238|NCT00784134|Placebo Comparator|Saline Placebo|1 ml of normal saline administered via the intraventricular catheter
89534527|NCT03335579||MACE|patients with major postoperative cardiac or cerebral complications
89534528|NCT05050071|Active Comparator|Calcium hydroxide (7 days)|is also known as slaked lime or calcium hydrate. It is produced by the hydration of lime
89534529|NCT05050071|Experimental|Allium sativum (7 days)|is a species of bulbous flowering plant in the onion genus Allium
89534530|NCT05050071|Experimental|Combination (7 days)|combination between Calcium hydroxide and Allium sativum
89534531|NCT05050071|Active Comparator|Calcium hydroxide (14 days)|is also known as slaked lime or calcium hydrate. It is produced by the hydration of lime
89534532|NCT05050071|Experimental|Allium sativum (14 days)|is a species of bulbous flowering plant in the onion genus Allium
89534533|NCT05050071|Experimental|Combination (14 days)|combination between Calcium hydroxide and Allium sativum
89534534|NCT03330899|Active Comparator|15 mcg H7N9 + adjuvant IB160|"Participants in this arm will receive one dose of the combination (15 mcg H7N9 antigen + adjuvant IB160) at Day 0 and another dose at Day 28.~Each dose after combination = 0,5 ml 15 mcg of the monovalent H7N9 antigen per dose"
89178239|NCT00832468|Placebo Comparator|sham ear acupressure|
89178240|NCT00832468|Experimental|ear acupressure|
89178241|NCT00832546|Placebo Comparator|1|Placebo
89178242|NCT00832546|Experimental|2|Powder in solution
89361903|NCT04884308|Experimental|Cystic Fibrosis|Participants with Cystic Fibrosis.
89361904|NCT04884308|Experimental|Non Cystic Fibrosis Bronchiectasis|Participants with Non Cystic Fibrosis Bronchiectasis.
89361905|NCT04884308|Active Comparator|Healthy Volunteer|Participants with no condition (healthy volunteers).
89361906|NCT04883775|Experimental|89Zr-DFO-HuMab-5B1 (MVT-2163) Imaging|All subjects will receive a single, fixed, intravenous dose of MVT-2163, consisting of 3 mg (nominal mass - actual mass administered will likely vary between 2.0 and 2.5 mg) of MVT-2163 radiolabeled from 5 mCi to no less than 1.0 mCi (adjusted as of 16-Mar 2017) of 89Zr.Cohort 1 subjects will receive MVT-2163, with no MVT-5873 pre-dosing. Subjects in subsequent cohorts 2 and 3 will receive a dose of MVT-5873 15 minutes, ~ 2 hours, and ~4 hours prior to administration of MVT-2163. Future cohorts 4 and 5 may evaluate alternate time frames. Other cohorts may evaluate administration of MVT-5873 one week prior (D-7) to the day of MVT-2163 administration and a second administration of MVT-5873 the day of (D0) MVT-2163 administration. The re-entry (RE) and pre-surgery (PS) cohorts will administer MVT-2163 3 ± 1 hour after administration of MVT-5873.
89361907|NCT04883450||Risk of pancreatic cancer|Subjects with an increased predicted 18-month risk of pancreatic cancer
89361908|NCT04872595|Experimental|P-rATG with total body irradiation, thiotepa, cyclophosphamide|"P-rATG days (always starting on Day -12 to -10)~Hyper fractionated total body irradiation (1375 - 1500cGy*) Day -9 to -6~Thiotepa (5mg/kg/day x 2 day) Day -5 to -4~Cyclophosphamide (60mg/kg/day x 2 days) Day -3 to -2~GCSF Day +7 *TBI dose in 125cGy fractions (with lung shielding) and total dose to be determined by treating physician/radiation oncology and is based off age, stage of disease, and anesthesia requirements."
89361909|NCT04872595|Experimental|P-rATG with busulfan, melphalan and fludarabine|"P-rATG days (Appendix A - always starting on Day -12 to -10)~Busulfan -Day -9 to -7~Initial dose per table in Appendix B; doses 2-3 to be adjusted per PK for target cumulative exposure of 65 mg*h/L Melphalan (70mg/m2/day x 2 days) Day -6 to -5~Fludarabine (25mg/m2/day x 5 days) Day -6 to -2~GCSF Day +7"
89361910|NCT04872569|Experimental|Decision-making tool|Women will receive the decision making tool and use for a 3 month period.
89361911|NCT04871776|Experimental|"Why messaging"|In this arm, patients will be sent an electronic patient portal message a few days in advance of their office visit. Messages will focus on reasons to get the COVID booster vaccine, including protecting self and loved ones or the idea of herd immunity.
89361912|NCT04871776|Experimental|"How messaging"|"In this arm, patients will be sent an electronic patient portal message a few days in advance of their office visit. How messages will focus on the details of obtaining a vaccination at MGB, what to expect, and how to prepare for the visit."
89361913|NCT04871776|Active Comparator|Usual Care|In this arm, patients will not receive any additional message about their upcoming visit, beyond what they already receive by the health system.
88833229|NCT05963009|Experimental|Baxdrostat tablet (fed state)|5 mg CIN-107 tablet(s) in a fed state (standard high fat meal)
88833230|NCT05962762|Experimental|Human Umbilical Cord Mesenchymal Stem Cell Injection|The trial was divided into three dose groups： Low-dose group: 1000000 cells/kg Medium-dose group: 3000000 cells/kg High-does group: 5000000 cells/kg
88833231|NCT05962476|Experimental|Parkinson's Disease|"Participants will use the vibro-acoustic device 90-120 days for 6 hours at night on the Apollo Neuro setting Sleep and Renew."
89178243|NCT00832546|Experimental|3|
89178244|NCT00837928|Experimental|Bendamustine and Fractionated stereotactic radiotherapy|Bendamustine 40 mg/m2 and will be administered IV on days 1,2,and 3 prior to surgery on each day of SRT (Sterotactic radiation therapy). Laboratory biomarker analysis will be obtained on day 1 or 2 only from patients undergoing surgery on day 3 (i.e. Pharmacokinetic samples will not be collected from patients who begin SRT on day 1). Surgical Resection of Brain Metastases Day 3 (immediately after Bendamustine) Stereotactic fractionated radiation therapy starting at least 4 weeks after surgery (Day 1 if no surgery ); 30 Gy in 5 daily fractions(Mon-Fri). Concurrent Bendamustine is administered on Days of Stereotactic Radiotherapy (Arm 1: 40 mg/m2/ Day; Arm 2: 50 mg/m2/day).
88833232|NCT05961397|Experimental|Normal hepatic function group|Subjects with normal hepatic function
88833233|NCT05961397|Experimental|Moderate hepatic impairment group|Subjects with a Child-Pugh score of 7 to 9 (Category B) at screening
88833234|NCT05961384|Experimental|10 mg [14C]-bexdrostat|single oral dose of 10 mg baxdrostat containing 100 μCi of [14C] baxdrostat
88833235|NCT05961020|Experimental|20 women was treated by moderate restricted diet for 3 months.|
88833236|NCT05961020|Experimental|20 women treated by whole body vibration.|
88833237|NCT05960552|Experimental|The PReTEE group|Prior to clinical application of PReTEE, all participants designated must receive professional training. Within the given 120 seconds participants in the PreTEE group need to provide the leading cause with regard to difficult separation from cardiopulmonary bypass among high-risk cardiac surgical procedures.
88833238|NCT05960552|Active Comparator|The conventional TEE group|The routine intra-operative TEE examinations are performed within the given 120 seconds before patients are separated from the cardiopulmonary bypass.
88833239|NCT05960448|Experimental|Transcutaneous Spinal Cord Stimulation|The transcutaneous spinal cord stimulation used in this experiment is specific to each participant as determined in a previous study. Possible parameters include biphasic or monophasic, Russian or Nonrussian, a variety of pulse widths, and location of stimulation (T7-8, T9-10,- T11-12, L1-2). The amplitude of the stimulation also depends on the results of the mapping study. This stimulation will be delivered 30 minutes at a time.
88833240|NCT05960448|Sham Comparator|Sham Transcutaneous Spinal Cord Stimulation|The sham stimulation will follow the above parameters but will only be delivered for a minute rather than the full 30 minutes.
88833241|NCT05955222|Experimental|PEEK splint group|Patients received splints produced from PEEK blocks
89178245|NCT02550184|Experimental|Ultrasonography findings unblinded|"Intervention group: Patients in this group will receive a focused ultrasonography examination of the heart and the lungs which will be performed by the investigator.~Intervention: The treating physician receives the results from the ultrasonographic examination (=unblinding of ultrasonography examination results)."
89361914|NCT04854811|Placebo Comparator|Placebo|Placebo oral capsule, once daily for 12 weeks
89361915|NCT04854811|Experimental|Roflumilast (100 microgram)|once daily for 12 weeks
89534535|NCT03330899|Active Comparator|7.5 mcg H7N9 + adjuvant IB160|"Participants in this arm will receive one dose of the combination (7.5 mcg H7N9 antigen + adjuvant IB160) at Day 0 and another dose at Day 28.~Each dose after combination = 0,5 ml 7.5 mcg of the monovalent H7N9 antigen per dose"
89534536|NCT03330899|Active Comparator|3.75 mcg H7N9 + adjuvant IB160|"Participants in this arm will receive one dose of the combination (3.75 mcg H7N9 antigen + adjuvant IB160) at Day 0 and another dose at Day 28.~Each dose after combination = 0,5 ml 3.75 mcg of the monovalent H7N9 antigen per dose"
89361916|NCT04854642|Experimental|T - R (fed then fasting condition)|Subjects were assigned to the sequence of treatments TR to receive Ladarixin in fed conditions (T treatment) during period 1 and in fasting conditions (R treatment) in period 2.
89361917|NCT04854642|Experimental|R - T (fasting then fed condition)|Subjects were assigned to the sequence of treatments RT to receive Ladarixin ini fasting conditions (R treatment) in period 1 and in fed conditions (T treatment) during period 2.
89361918|NCT04853732||Chronic Low Back Pain Cases|
89361919|NCT04853732||Chronic Pain-Free Controls|
89361920|NCT04852523|Experimental|18F fluciclovine Administration|"Initial normal standardized uptake values (SUV) of the pancreas, liver, and blood pool will be obtained from 50archived previous 18F-Fluciclovine studies, as there are no normal ranges in the literature. This will be done by retrospective medical record review after a waiver of consent/authorization is obtained from the local IRB.~Informed consent will be obtained from 10 patients with pancreatic allografts, and each will undergo an 18F-Fluciclovine study. These patients will not be suspected of having current rejection or allograft dysfunction. Timing of 18F-Fluciclovine PET/CT scans will be planned to coincide with standard-of-care imaging studies and laboratory tests.~The 18F-Fluciclovine study will be compared with the patients' standard-standard-of-care US and/or CT with the assessment of ease of visualization of the pancreatic allograft."
89361921|NCT04848337|Experimental|Study Treatment Arm|Lenvatinib 20 mg Orally Day1-21 with Pembrolizumab 200 mg Intravenously (IV) over 30 minutes Day 1. Each cycle = 21 days
89361922|NCT04844606|Experimental|Mirikizumab Dose 1 for UC|"Dose 1 of Mirikizumab is administered subcutaneously (SC)~Dosing is based on the participant's weight."
89361923|NCT04844606|Experimental|Mirikizumab Dose 2 for UC|"Dose 2 of Mirikizumab is administered SC~Dosing is based on the participant's weight."
89361924|NCT04844606|Experimental|Mirikizumab Dose 3 for UC|"Dose 3 of Mirikizumab is administered SC~Dosing is based on the participant's weight."
89361925|NCT04844606|Experimental|Mirikizumab Dose 4 for CD|"Dose 4 of Mirikizumab is administered SC~Dosing is based on the participant's weight."
88833242|NCT05955222|Experimental|PMMA splint group|Patients received splints produced from PMMA blocks
88833243|NCT05955222|Active Comparator|Traditional splint group|Patients received splints produced fabricated traditional methods (vacuum forming )
88833244|NCT05952011|Active Comparator|The first group (A)(Left internal mammary artery diameter before left stellate ganglion block ).|control group
88833245|NCT05952011|Active Comparator|The second Group (B)(Left internal mammary artery diameter after left stellate ganglion block )|same group but after intervention
88833246|NCT05947409|Experimental|SMARTO ONE|
88833247|NCT05947396|Experimental|SMARTO ONE|
88833248|NCT05947396|Placebo Comparator|placebo|
88833249|NCT05942612|Experimental|Cohort 1|A single subcutaneous injection of SHR-2001/placebo dose 1 in healthy subjects
88833250|NCT05942612|Experimental|Cohort 2|A single subcutaneous injection of SHR-2001/placebo dose 2 in healthy subjects
89361926|NCT04844606|Experimental|Mirikizumab Dose 5 for CD|"Dose 5 of Mirikizumab is administered SC~Dosing is based on the participant's weight."
89361927|NCT04844606|Experimental|Mirikizumab Dose 6 for CD|"Dose 6 of Mirikizumab is administered SC~Dosing is based on the participant's weight."
89361928|NCT04844606|Experimental|Mirikizumab Dose 7 for UC or CD|Intravenous (IV) rescue dosing, if response is lost.
89361929|NCT04839328|Experimental|60mg Hemay005|Patients with chronic plaque psoriasis will be treated BID for 16 weeks with 60mg Hemay005 in first phase. Then will be treated BID for 36-week extension followed with 60mg of Hemay005.
89361930|NCT04839328|Placebo Comparator|Placebo|Patients with chronic plaque psoriasis will be treated BID for 16 weeks with placebo in first phase. Then will be treated BID for 36-week extension followed with 60mg of Hemay005.
88833251|NCT05942612|Experimental|Cohort 3|A single subcutaneous injection of SHR-2001/placebo dose 3 in healthy subjects
88833252|NCT05942612|Experimental|Cohort 4|A single subcutaneous injection of SHR-2001/placebo dose 4 in healthy subjects
88833253|NCT05942612|Experimental|Cohort 5|A single subcutaneous injection of SHR-2001/placebo dose 5 in healthy subjects
88833254|NCT05942612|Experimental|Cohort 6|A single subcutaneous injection of SHR-2001/placebo dose 6 in healthy subjects
88833255|NCT05942612|Experimental|Experimental: Cohort 7|A single subcutaneous injection of SHR-2001/placebo dose 7 in healthy subjects
88833256|NCT05939349|Active Comparator|Intervention Group|The PPR intervention will span 6 months and will include 2 main components: produce vouchers and nutrition education.
88833257|NCT05939349|No Intervention|Delayed Intervention Group|For participants enrolled in the delayed control group they will complete all the biometric measurements and surveys during the 9-month period while the intervention group received the 6-month intervention and completes the 3-month post intervention assessments.
88833258|NCT05939323||Investigation Team|"Questionnaires assessed adolescents and their parents ①Adolescents aged 14-25 years old (including 14,25 years old) and their parents, who agreed to participate in the study~②Investigate whether they have family communication difficulties and whether they have negative internet use behaviors"
89178246|NCT02550184|Active Comparator|Ultrasonography findings blinded|"Control group: Patients in this group will receive a focused ultrasonography examination of the heart and the lungs which will be performed by the investigator.~Active Comparator: The ultrasonographic examination results will remain blinded for the treating physician."
89178247|NCT04043572||Participants with Epilepsy|This group comprises pregnant patients with epilepsy who are actively using anti-epileptic drugs
88833259|NCT05938790|Active Comparator|Continuous Fetal Monitoring|A nurse will turn on the Obix cEFM machine which will automatically register the patient in the Obix system and begin the timer which will be used to measure time to fetal monitoring. The patient will lay on the triage stretcher and the continuous external fetal monitor doppler probe will be placed on the abdomen over the fetus, identified via Leopold maneuvers. Nurses will adjust the cEFM as needed until a full fetal heart rate signal is obtained. At this point the timer will be counted as the time to monitor. Once the fetal heart rate signal is obtained via cEFM, the patient's participation in the study ends.
88833260|NCT05938790|Experimental|Point of Care Handheld Ultrasound|A nurse will turn on the Obix cEFM machine which will automatically register the patient in the Obix system and begin the timer which will be used to measure time to fetal monitoring. The patient will lay on the triage stretcher and a Butterfly ultrasound (Figure 1) probe will be used with a secure institutional Ipad by the triage nurse to identify the fetal position and location of the fetal heart. All images are deidentified and not stored since it will be a live real time aid to obtain a fetal heart tracing via cEFM. The cEFM will be placed on the maternal abdomen according to the imaging obtained by the ultrasound. Once fetal heart rate signal is obtained via cEFM, the patient's participation in the study ends.
88833261|NCT05938088|Experimental|mirogabalin group|perioperative mirogabalin
88833262|NCT05938088|Sham Comparator|placebo group|placebo
88833263|NCT05933967|Experimental|orelabrutinib+R-CHOP|
88833264|NCT05929781||Young healthy adults|1. 20-39 years old
88833265|NCT05929781||Middle to older healthy adults|"40-80 years old~age-matched with People with Parkinson's disease group"
88833266|NCT05929781||People with Parkinson's disease|"40-80 years old~Diagnosis of idiopathic Parkinson's disease~Hoehn and Yahr stage 1-2"
88833267|NCT05929352|Experimental|Musical Intervention|Participants will work together in a group with other voice hearers, making music with a trained facilitator for 4 weekly sessions
88833268|NCT05928832|Experimental|Intervention group|Patients in the intervention group will receive an information letter on their discharge presenting the follow-up from which they will benefit: call from the case-manager and access to the internet platform.
88833269|NCT05928832|No Intervention|Control group|Patients randomized to the control group will receive the usual practices
88833270|NCT05927935|Experimental|Supervised strength exercise intervention|Group 1
88833271|NCT05927935|Active Comparator|Usual care|Group 2
89178248|NCT04043572||Healthy Controls|Healthy volunteers
89188927|NCT00781937|Experimental|Lira 3.0 mg|A 12-week run-in period where screened subjects were treated with a low calorie diet. Randomised subjects (those who lost more than or equal to 5% of screening body weight) were treated with liraglutide 3.0 mg, once daily, injected subcutaneously and instructed to follow a standard energy-restricted diet in the 56-week main trial period. Subjects discontinued treatment in the 12-week follow-up period. The starting dose of liraglutide was 0.6 mg, with weekly increments of 0.6 mg every 7 days until the target dose of 3.0 mg was reached
89188928|NCT00781937|Placebo Comparator|Placebo|A 12-week run-in period where screened subjects were treated with a low calorie diet. Randomised subjects (those who lost more than or equal to 5% of screening body weight) were treated with liraglutide placebo, once daily, injected subcutaneously for 56 weeks and instructed to follow a standard energy-restricted diet in the 56-week main trial period. Subjects discontinued treatment in the 12-week follow-up period
88833272|NCT05916287|Experimental|Healthy volonteer|
88833273|NCT05911698|Other|Patients with all types of melasma|"Fractional ablative CO2 laser : For each patient, Right side of the face : Fractional ablative CO2 laser will be followed by immediate topical application of vitamin c 3% .~Left side of the face: Fractional ablative CO2 laser will be followed by immediate topical application of tranexamic acid.~Fractional ablative CO2 laser sessions will be performed using the following parameters: power 8-10 W(according to the skin type), spacing 1000 μm (5.3% density), dwell time 400 μs, and stack .~During the session, protective goggles will be used both by the patient and by the physician."
88833274|NCT05911594|Experimental|Solifenacin group|Patients in this group will receive medical treatment (Solifenacin 5 mg once or twice daily) without any second line of treatment
88833275|NCT05911594|Experimental|Percutaneous tibial nerve stimulation group|Patients in this group will receive Percutaneous tibial nerve stimulation after failure of medical therapy
89188929|NCT00802581|Experimental|1|Ensuring circumferential spread of local anesthetic around the sciatic nerve.
89188930|NCT00802581|Active Comparator|2|Single shot injection of local anesthetic near the sciatic nerve will be performed, without ensuring circumferential spread.
89188931|NCT00842062|Experimental|MyoScience Tissue Remodeling Device|
89188932|NCT00806091||COPD subjects|healthy subjects
89188933|NCT00836836|Experimental|1|Modified Atkins diet arm-In this arm, the children will start the modified Atkins diet after a 4-week baseline period, during which daily seizure log will be maintained. Anti-epileptic medications will remain unchanged during the 3 month trial period, unless the change in AED regimen is medically indicated; e.g. drug side effects or status epilepticus; in which case standard therapy will be provided.
89188934|NCT00836836|No Intervention|2|"No Intervention arm- After the 4-week baseline period, this group will receive their normal diet with no dietetic input, and remain on the same on-going antiepileptic medication for the 3 months. Anti-epileptic medications will remain unchanged during the 3 month trial period, unless the change in AED regimen is medically indicated; e.g. drug side effects or status epilepticus; in which case standard therapy will be provided.~At the end of three months, patients in this arm will be offered the option of the modified Atkins diet treatment.~This group will not receive any dietetic input"
89188935|NCT00797589|Experimental|Ringer lactate|Crystalloid solution
89188936|NCT00797589|Experimental|HES solution (Tetraspan®)|Balanced colloid solution
89188937|NCT00719108|Experimental|Wosulin R|Wosulin R, Regular insulin for injection (Recombinant Human Insulin) (100 IU/mL)in vials 10.0 ml
89188938|NCT00719108|Active Comparator|Actrapid|Actrapid, Regular insulin for injection (Recombinant Human Insulin) (100 IU/mL)in vials 10.0 ml
89188939|NCT00842140|Active Comparator|1|This group will receive an oral contraceptive containing 0,03mg ethynylestradiol and 2mg chlormadinone acetate
89188940|NCT00842140|Experimental|2|The patient will receive an oral contraceptive (0,03mg ethynylestradiol and 2mg chlormadinone acetate) plus 100 mg spironolactone. One pill each once a day for twelve months.
88833276|NCT05911594|Experimental|Intradetrusor BOTOX group|Patients in this group will receive Intradetrusor BOTOX after the failure of medical therapy
89361931|NCT04832971|Experimental|ARO-ANG3|Two doses of ARO-ANG3 by subcutaneous (sc) injection at Day 1 and Week 12 during double-blind treatment period. Up to 8 doses of ARO-ANG3 by sc injection during the open-label extension period.
89361932|NCT04832971|Placebo Comparator|Placebo|Calculated volume to match active treatment by sc injection at Day 1 and Week 12 during the double-blind treatment period. Up to 8 doses of ARO-ANG3 by sc injection during the open-label extension period.
89361933|NCT04828733|Experimental|OAGB + SCP + FundoRing|laparoscopic one anastomosis gastric bypass with excluded stomach fundoplication: FundoRingOAGB and suture cruroplasty
89361934|NCT04828733|Active Comparator|OAGB + SCP + NF|laparoscopic one anastomosis gastric bypass with excluded stomach Nissen fundoplication and suture cruroplasty
89361935|NCT04828733|Active Comparator|OAGB + SCP|laparoscopic one anastomosis gastric bypass without excluded stomach fundoplication and only suture cruroplasty
89361936|NCT04824521|Experimental|Mindfulness-Oriented Recovery Enhancement via tele-health|Participants will be assigned to 8 weeks of Mindfulness-Oriented Recovery Enhancement delivered via tele-health.
88833277|NCT05911594|Experimental|Intradetrusor BOTOX combined with Percutaneous tibial nerve stimulation group|Patients in this group will receive Intradetrusor BOTOX combined with Percutaneous tibial nerve stimulation after the failure of medical therapy
88833278|NCT05910879|Active Comparator|Promotores Health Education only condition|"The Promotores de Salud Health Education intervention includes: (1) a culturally tailored health education to increase knowledge about COVID-19 and the benefits of testing; (2) motivational interviewing (MI) strategies to explore personal, social, and behavioral barriers to testing and to discuss available resources to resolve these barriers; (3) emotional support to address testing-related concerns and anxieties that may dissuade Latinx individuals from getting tested; and (4) service navigation.~When promotores (community health advocates) are on-site at Mexican Consulate events, they will provide information about COVID-19 and preventive behaviors using in-person instruction on effective mask wearing, hand washing, and physical distancing, as well as the importance of repeated testing and vaccines."
88833279|NCT05910879|Experimental|Self-Affirmation Implementation Intentions (SAII) intervention (plus Promotores Health Education)|"The SAII is designed to reduce stigma and enhance uptake of health messaging. SAII couples; (a) self-affirming interventions that focus on restoring self-integrity in the face of identity threats, with (b) implementation intention interventions focus on whether realization of goal intentions for health behaviors is facilitated by forming an implementation intention that spells out when, where, and how of goal striving in advance."
88833280|NCT05908396|Experimental|IGM-2644 Dose Escalation|Participants will receive IGM-2644 via intravenous (IV) infusion weekly.
88833281|NCT05908396|Experimental|IGM-2644 Dose Expansion|Participants will receive IGM-2644 via IV infusion at a dose and schedule to be determined after reviewing all available response and safety data.
88833282|NCT05900882|Experimental|study group|SVRd induction treatment
88833283|NCT05899738|Experimental|Iberdomide Powder (Fasted), followed by Iberdomide Capsule (Fasted)|
88833284|NCT05899738|Experimental|Iberdomide Capsule (Fasted), followed by Iberdomide Powder (Fasted)|
88833285|NCT05899738|Experimental|Iberdomide Powder (Fasted), followed by Iberdomide Powder (Fed)|
89361937|NCT04822337|Experimental|Phase I|Carfilzomib, Lenalidomide, Dexamethasone, Belantamab Mafodotin
89361938|NCT04822337|Experimental|Phase II|Carfilzomib, Lenalidomide, Dexamethasone, Belantamab Mafodotin
89361939|NCT04818684||Physician|at least 3 years of seniority in palliative care unit will be required, including 1 year in the participating palliative care unit.
88833286|NCT05899738|Experimental|Iberdomide Powder (Fed), followed by Iberdomide Powder (Fasted)|
88833287|NCT05878301|Other|standard mixed meal (SMM)|standard mixed meal (SMM) consumed within 15 min to compared to the vegetable protein first followed 10 min later by carbohydrates it with the effect on postprandial glucose ,insulin and hunger rating
88833288|NCT05875857|No Intervention|Control|Control group will receive current standard of care education and surveys at 6-8 weeks post discharge.
88833289|NCT05875857|Experimental|Intervention|Intervention group will receive a specialized handout and patient education on the safe storage of opioid medications, importance of opioid destruction, opioid destruction options and medication destruction (Deterra) bag before discharge. Surveys will be sent to group at 6-8 weeks post discharge.
88833290|NCT05873452|Experimental|Kaitoh Atherectomy System|Eligible participants will undergo atherectomy using the Kaitoh Atherectomy System.
88833291|NCT05870943|Experimental|Hybrid Argon Plasma Coagulation and Endoscopic Sleeve Gastroplasty|Hybrid APC will be utilized to first ablate the gastric mucosa along the greater curve of the stomach, followed immediately by endoscopic full-thickness tissue acquisition and plication using 2-0 Prolene synthetic sutures via the Apollo ESG platform.
88833292|NCT05870943|Active Comparator|Endoscopic Sleeve Gastroplasty|Endoscopic full-thickness tissue acquisition and plication using 2-0 Prolene synthetic sutures via the Apollo ESG platform.
89361940|NCT04818684||Psychologists|at least 3 years of seniority in palliative care unit will be required, including 1 year in the participating palliative care unit.
89361941|NCT04818684||Caregivers|at least 3 years of seniority in palliative care unit will be required, including 1 year in the participating palliative care unit.
89361942|NCT04818684||Nurses|at least 3 years of seniority in palliative care unit will be required, including 1 year in the participating palliative care unit.
89361943|NCT04818684||Social and Educational Assistants|at least 3 years of seniority in palliative care unit will be required, including 1 year in the participating palliative care unit.
89361944|NCT04818684||Volunteers|at least 3 years of seniority in palliative care unit will be required, including 1 year in the participating palliative care unit. The representative participating in the study will preferably be the volunteer coordinator.
89534537|NCT03330899|Active Comparator|15 mcg H7N9 + adjuvant SE|"Participants in this arm will receive one dose of the combination (15 mcg H7N9 antigen + adjuvant SE) at Day 0 and another dose at Day 28.~Each dose after combination = 0,5 ml 15 mcg of the monovalent H7N9 antigen per dose"
89361945|NCT04818684||Relatives|"Relative of a patient who died in the palliative care unit at least 6 months ago Person to trust or to prevent if not designated Relative understanding and speaking sufficient French Relative not a health professional~Relative who visited the palliative care unit during the last 3 days of the patient's life and who met the care team:~Traceability of the arrival of the loved one in the last 2/3 days of the patient's hospitalization~Traceability of a meeting of the loved one with a member of the team over the last 3 days of his hospitalization or verification during telephone contact with the loved one after drawing lots Relative with an email address (to be verified during telephone contact with the loved one after drawing lots)"
89361946|NCT04818112|Experimental|Behavioral ATVV intervention|A multi-sensory behavioral intervention that includes auditory, tactile, visual and vestibular (ATVV) stimulation contingent upon infant cues.
89361947|NCT04818112|Active Comparator|Attention control|An attention control group that receives education on safe infant care and the same amount of attention as the intervention group.
89361948|NCT04817618|Experimental|iptacopan 200mg|iptacopan 200 mg b.i.d.
89361949|NCT04817618|Placebo Comparator|Placebo to iptacopan 200mg|Placebo to iptacopan 200mg b.i.d.
89361950|NCT04812483|Other|Standard Arm|"HD-DXM will be administered orally (40 mg) from day 1-4, followed by Arm 1:~No planed further treatment. = standard therapy (without eltrombopag)"
89361951|NCT04812483|Experimental|Study Arm|"HD-DXM will be administered orally (40 mg) from day 1-4, followed by Arm 2:~The subjects in the experimental arm will be treated with eltrombopag:~Eltrombopag (Revolade®), 50 mg PO, from day 5-140. Tapering over 1 week (week 21) from day 141-148 with 50 mg every second day. Eltrombopag will be administered on a starting dose of 50mg. After the end of treatment a clinical and laboratory observation follow-up period until week 30 follows."
89361952|NCT04809077|Other|Reverse total shoulder replacement|Patients who underwent a total shoulder replacement using a reverse type implant (Delta Xtend or Zimmer TM)
89361953|NCT04804137||Group|adult patients with adenocarcinoma type non-small cell lung cancer
88833293|NCT05865119|Experimental|endovascular|Transcatheter correction of a SVD with an OPTIMUS covered stent
88833294|NCT05865119|Active Comparator|surgery|Surgical correction of a SVD
88833295|NCT05862857|Active Comparator|Aim 1: HIV-focused mobilization|Patrons and workers at drinking venues will be given a recruitment card for free HIV testing at the local clinic.
88833296|NCT05862857|Experimental|Aim 1: Multi-disease-focused mobilization|Patrons and workers at drinking venues will be given a recruitment card for free multi-disease testing at the local clinic, including: diabetes, hypertension, HIV, malaria, TB, pregnancy.
88833297|NCT05862233|Experimental|MIL62|
89361954|NCT04800497||Patients resected for hepatocellular carcinoma|Surgical resection, peripheral blood sampling
89361955|NCT04800497||Patients who underwent surgery for benign diseases|Surgical resection, peripheral blood sampling
89361956|NCT04800133|Experimental|BNT162b2 (adult/adolescent)|BNT162b2, tozinameran by Fosun/BioNTech Intramuscular injection (or intradermal for immunocompromised patients; or by graded challenge with history of non-severe allergy to PEG-containing drugs) 30ug/0.3ml per dose 3 doses, or 4 for immunocompromised patients; or 1/2 dose for patients with prior COVID-19
88833298|NCT05862233|Active Comparator|Cyclosporine|
88833299|NCT05859815||Directional preference responder|This group is comprised of participants who responded to repeated movements in a direction (e.g., neck flexion) that significantly improved their symptoms and/or their ability to move their head/neck.
89361957|NCT04800133|Experimental|CoronaVac (intramuscular)|CoronaVac by SinoVac Intramuscular injection 3ug/0.5ml per dose 3 doses, or 4 for immunocompromised patients; or 1/2 dose for patients with prior COVID-19
88833300|NCT05859815||Directional preference non-responder|This group is comprised of participants who did not respond to repeated movements in any specific direction that significantly improved their symptoms and/or their ability to move their head/neck.
88833301|NCT05856851|Experimental|Intra-arterial alteplase|Participants in the experimental group will receive a 15-minute continuous infusion of intra-arterial alteplase at a drug concentration of 1.0 mg/ml. 15 minutes after the start of intra-arterial thrombolysis, the infusion will be stopped and an angiogram will be performed to assess the eTICI score. If the angiographic eTICI score improves from the baseline score, the procedure will be terminated, otherwise, a new angiogram will be repeated 5-10 minutes after the end of drug administration.
88833302|NCT05856851|No Intervention|Standard medical treatment|Participants allocated to the control group will receive standard medical treatment without intra-arterial alteplase after mechanical thrombectomy.
88833303|NCT05856617|Experimental|Remimazolam|Anesthesia induction with remimazolam
88833304|NCT05856617|No Intervention|Propofol|Anesthesia induction with propofol
89361958|NCT04800133|Experimental|CoronaVac (intradermal)|CoronaVac by SinoVac Intradermal injection 3ug/0.5ml per dose 3 doses, or 4 for immunocompromised patients; or 1/2 dose for patients with prior COVID-19
89361959|NCT04800133|Experimental|BNT162b2 (paediatric)|BNT162b2, tozinameran by Fosun/BioNTech Intramuscular injection (for immunocompromised patients only) 10ug/0.1ml per dose 4 doses for immunocompromised patients
89361960|NCT04799249|Experimental|Trilaciclib + gemcitabine + carboplatin|Trilaciclib (240mg/m2) + gemcitabine (1000 mg/m2) and carboplatin (AUC 2)
89534538|NCT03330899|Active Comparator|7.5 mcg H7N9 + adjuvant SE|"Participants in this arm will receive one dose of the combination (7.5 mcg H7N9 antigen + adjuvant SE) at Day 0 and another dose at Day 28.~Each dose after combination = 0,5 ml 7.5 mcg of the monovalent H7N9 antigen per dose"
88833305|NCT05851469|Experimental|RSP-26-01|
88833306|NCT05851469|Experimental|RSP-26-02|
88833307|NCT05848973|Active Comparator|Healthy diet|The study participants randomized to this arm will be given advice about consuming a healthy diet, i.e. a diet rich in vegetables/fruits and wholegrain/fibre, fish, olive oil; and moderate in red meat and dairy products. The participants will receive 8 weekly, one hour group sessions delivered by trained nutritionists.
88833308|NCT05848973|Active Comparator|Mindfulness-based cognitive therapy (MBCT)|The study participants randomized to this arm will be taught the purpose and application of MBCT, namely to modify cognitive and effective processes in the management of depressive symptoms as well as relapse prevention among those with residual depressive symptoms. It is a structured 8-weeks' intervention program delivered in groups, with an all-day practice session around week six and regular reunion sessions thereafter.
89361961|NCT04799249|Placebo Comparator|Placebo + gemcitabine + carboplatin|The subjects in the placebo arm will follow the same schedule as the trilaciclib arm, but will receive placebo instead of trilaciclib.
89361962|NCT04797429|Experimental|intervention group|The intervention group will receive antidiabetic therapy according to the current guidelines but with the additional opportunity to use the peer support IMS tool. Peer support and moderation of the intervention group will be provided by moderators. Moderators will be supervised by a dietitian.
89361963|NCT04797429|Active Comparator|control group|The control group receives the antidiabetic therapy according to the current guidelines, but without having access to the IMS tool. This means that participants receive medical treatment by their practitioner according to the Austrian recommendations.
89361964|NCT04795856|Active Comparator|chronic compensated moderate-severe primary mitral regurgitation (PMR)|
89361965|NCT04795856|Active Comparator|Healthy Volunteers|
89361966|NCT04795765||Patients treated with SpineJack system|SpineJack system procedure
89361967|NCT04795765||Patients treated with vertebral augmentation|Vertebral augmentation procedures may include either balloon kyphoplasty (BKP) or vertebroplasty (VP).
89361968|NCT04792489|Experimental|Single, open label|
89361969|NCT04791761|Experimental|Opioid pain control|Patients in this group will be receiving triple therapy for pain control with oxycodone, acetaminophen, and ibuprofen. They will be asked to complete a pain diary which will be used to determine the level of pain control achieved with this regimen. The diary will be completed by post-operative day 14. A post-operative appointment between 4-8 weeks will be scheduled and the patient and caregiver will return the pain diary or by email/mail if no appointment was scheduled. Families will receive an opioid disposal education document.
89361970|NCT04791761|Experimental|Opioid pain control + Disposal Pouch|Patients in this group will be receiving triple therapy for pain control with oxycodone, acetaminophen, and ibuprofen. They will be asked to complete a pain diary which will be used to determine the level of pain control achieved with this regimen. The diary will be completed by post-operative day 14. A post-operative appointment between 4-8 weeks will be scheduled and the patient and caregiver will return the pain diary or by email/mail if no appointment was scheduled. Half of the families randomized to the opioid group will be further randomized to receive an opioid disposal bag + an opioid disposal education document. The pouch is a drug deactivation disposal pouch to dispose the opioid at home.
89361971|NCT04791761|Active Comparator|Non-opioid pain control|Patients in this group will be receiving therapy for pain control with acetaminophen and ibuprofen only. They will be asked to complete a pain diary which will be used to determine the level of pain control achieved with this regimen. The diary will be completed by post-operative day 14. A post-operative appointment between 4-8 weeks will be scheduled and the patient and caregiver will return the diary or by email/mail if no appointment was scheduled.
89361972|NCT04787991|Experimental|Cohort A: Nivolumab + Ipilimumab + nP/gem|
89361973|NCT04787991|Experimental|Cohort B: Hydroxychloroquine + Ipilimumab + nP/gem|
89361974|NCT04787991|Experimental|Cohort C: NG-350A + Ipilimumab + nP/gem|
89361975|NCT04785547|Experimental|Blincyto|Blincyto is given over a 28-day cycle. Starting day for patients, who are MRD-positive before HSCT is between day +60 and day +100 and for patients, who become MRD-positive post HSCT it is between day +60 and day +360 post HSCT.
89361976|NCT04785508|Experimental|treated group|neuromuscolar tape application
89361977|NCT04785508|Active Comparator|control group|antigravity position
88833309|NCT05848973|Active Comparator|Healthy diet and MBCT combined|The study participants randomized to this arm will receive both the healthy diet intervention and the MBCT intervention
88833310|NCT05848973|No Intervention|Control|No particular intervention will be provided to the control group.
89361978|NCT04781322|Experimental|Intervention|Heavy drinking healthy volunteers
89361979|NCT04781322|Placebo Comparator|Placebo|Heavy drinking healthy volunteers
88833311|NCT05842460|Active Comparator|Nutrient warnings|Individuals in this trial arm will see images of products carrying nutrient warnings that are currently included in Brazil's front-of-package labeling scheme.
88833312|NCT05842460|Experimental|Nutrient and ultraprocessed warnings|Individuals in this trial arm will see images of products carrying nutrient warnings that are currently included in Brazil's front-of-package labeling scheme and an experimental warning stating that the product is ultraprocessed.
88833313|NCT05842070|Experimental|Low-Intensity Protocol|Participants choose the low-cost, low-intensity egg-freezing protocol
89361980|NCT04780893|Active Comparator|Active VeNS|
89361981|NCT04780893|Sham Comparator|Sham VeNS|
88833314|NCT05842070|Active Comparator|High-intensity protocol|Participants choose a routine high-intensity egg-freezing protocol
88833315|NCT05840887|Experimental|Knee Ostetomy combined with meniscal allograft transplantation|The treatment group will perform osteotomy and meniscal allograft transplantation to restore the meniscal deficiency.
89361982|NCT04774523|Active Comparator|Control group|This group will be made up of patients implanted with CRT-D devices without the CRT AutoAdapt feature, or with the CRT AutoAdapt feature deactivated.
89534539|NCT03330899|Active Comparator|3.75 mcg H7N9 + adjuvant SE|"Participants in this arm will receive one dose of the combination (3.75 mcg H7N9 antigen + adjuvant SE) at Day 0 and another dose at Day 28.~Each dose after combination = 0,5 ml 3.75 mcg of the monovalent H7N9 antigen per dose"
89534540|NCT03330899|Active Comparator|15 mcg H7N9 without adjuvant|"Participants in this arm will receive one dose of the 15 mcg H7N9 antigen without adjuvant at Day 0 and another dose at Day 28.~Each dose = 0,5 ml"
88833316|NCT05840887|Active Comparator|Knee Osteotomy|The control group will consist of patients who will perform an isolated osteotomy.
88833317|NCT05840861||MDD|Participants with major depressive disorder (MDD), unmedicated and currently depressed to participate in MRI and [18F]FPEB PET scans
88833318|NCT05840861||Bipolar|Participants with bipolar disorder, unmedicated and currently depressed to participate in MRI and [18F]FPEB PET scans
88833319|NCT05840861||Healthy Control|Healthy participant with no MDD or other psychiatric condition to participate in MRI and [18F]FPEB PET scans
88833320|NCT05839431|Experimental|Virtual Reality Therapy for Youth Phobias|Participants will undergo up to 10 weeks of virtual reality-assisted exposure therapy.
88833321|NCT05837715|Experimental|stabilization group|cervical stabilization exercises
88833322|NCT05837715|Experimental|vibration group|vibration application to the cervical region
88833323|NCT05837715|Experimental|telerehabilitation group|online exercise method
88833324|NCT05830344|Placebo Comparator|Placebo|Placebo treatment will be irradiated using a Multi Radiance Medical Super Pulsed Laser, manufactured by Multi Radiance Medical® (Solon,Ohio, USA), at 5 sites in the knee area, without any emission of therapeutic dose. The treatment will be performed 3 times a week, for four consecutive weeks, yielding 12 treatments. The sounds and signals emitted from the device as well as the information displayed on the screen will be identical, regardless of the type of treatment (active or placebo).
88833325|NCT05830344|Experimental|Active|Active treatment will be irradiated using a Multi Radiance Medical Super Pulsed Laser, manufactured by Multi Radiance Medical® (Solon,Ohio, USA), at 5 sites in the knee area, with a dose of 8.02 J per site. The treatment will be performed 3 times a week, for four consecutive weeks, yielding 12 treatments.
88833326|NCT05829642||ECM intervention arm|The Enhanced Care Management (ECM) intervention consists of training and coaching family physicians and their teams to develop holistic care and pro-active outreach plans for chronically ill patients or those vulnerable to developing chronically illnesses, as identified and agreed between the enrolled providers and the Estonian Health Insurance Fund (EHIF). The core goal of ECM is to improve the quality of care provided to complex patients, including by increasing the use of preventive care, improving coordination of care across health system levels, and increasing patient involvement in care. These elements can improve patient health and quality of life, and may reduce the need for curative medical services.
89534541|NCT03330899|Placebo Comparator|Placebo (PBS)|"Participants in this arm will receive one dose of Placebo (PBS) at Day 0 and another dose at Day 28.~Each dose = 0,5 ml"
88833327|NCT05829642||Control|The control group will not receive any intervention.
88833328|NCT05825625|Experimental|Platinum-based chemotherapy in combination with atezolizumab and tiragolumab|"Patients will receive 2 cycles of SOC platinum-based chemotherapy as per investigator's choice in combination with atezolizumab and tiragolumab administrated by IV infusion.~Curative intended surgery will follow after last dose of neoadjuvant treatment. After surgery, patients will receive adjuvant treatment including 2 cycles of platinum-based chemotherapy and atezolizumab plus tiragolumab for up to 1 year. Patients who achieved pCR will receive only atezolizumab plus tiragolumab for up to one year as maintenance therapy."
88833329|NCT05823558||Ostoporotic Patients Group|T value of -2.5 and below in DEXA measurement
88833330|NCT05823558||Osteopenic Patients Group|T value between -2.5 and -1 in DEXA measurement
88833331|NCT05823558||Healthy Group|T value of -1 and above in DEXA measurement
88833332|NCT05822843|Experimental|ESG206 dose level 1|ESG206 will be administered intravenously at dose level 1 every two weeks in a 28-day cycle
88833333|NCT05822843|Experimental|ESG206 dose level 2|ESG206 will be administered intravenously at dose level 1 every two weeks in a 28-day cycle
88833334|NCT05822843|Experimental|ESG206 dose level 3|ESG206 will be administered intravenously at dose level 1 every two weeks in a 28-day cycle
88833335|NCT05822843|Experimental|ESG206 dose level 4|ESG206 will be administered intravenously at dose level 1 every two weeks in a 28-day cycle
89188941|NCT00842140|Experimental|3|The patient will receive an oral contraceptive (0,03mg ethynylestradiol and 2mg chlormadinone acetate) plus 850 mg metformin.
88833336|NCT05819515|Active Comparator|Connective Tissue Graft|A connective tissue graft from the patient's palate will be used
88833337|NCT05819515|Experimental|Allogenic Dermal Matrix with Platelet-Rich Fibrin|An allogenic dermal matrix with the patient's platelet-rich fibrin will be used
89188942|NCT00806169|Experimental|1|group I (n=17) nonproliferative DR and ischemic maculopathy
89188943|NCT00806169|Experimental|2|group II (n=38) nonproliferative DR without ischemic maculopathy
89188944|NCT00806169|Experimental|3|group III (n=18) proliferative DR with or without ischemic maculopathy
89188945|NCT02572232|Experimental|Combitube, Easytube, Laryngeal masks|Combitube, Easytube, Laryngeal mask airway are intubated in pediatric airway manikins by probands in randomized order.
89188946|NCT00844324|Experimental|A|Candesartan cilexetil 1mg/mL
89188947|NCT00844324|Experimental|B|Candesartan cilexetil 1.6mg/mL
89188948|NCT02572154|Other|Cases|men from couples with RPL after natural pregnancies, had blood and sperm samples for sperm DNA fragmentation exploration
89188949|NCT02572154|Other|Controls|men from couples who have a child consequently to a natural pregnancy, had blood and sperm samples for sperm DNA fragmentation exploration
89188950|NCT00802815|Experimental|Etanercept|
89188951|NCT04100759|Experimental|Non-Smokers|Subjects administer one tablet of sildenafil 50 mg
89188952|NCT04100759|Experimental|Cigarette Smokers|Subjects administer one tablet of sildenafil 50mg
89188953|NCT04100759|Experimental|Cannabis Smokers|Subjects administer one tablet of sildenafil 50mg
89188954|NCT00836914|Active Comparator|CAL-101|
89188955|NCT00836914|Placebo Comparator|Placebo|
89188956|NCT04124042|Experimental|Stage A: 0.15 mg/mL XT-150, Stage B: 0.15 mg/mL XT-150|Low dose active in Stage A and Stage B
89188957|NCT04124042|Experimental|Stage A: 0.15 mg/mL XT-150, Stage B: 0.45 mg/mL XT-150|Low dose active in Stage A, high dose active in Stage B
89188958|NCT04124042|Experimental|Stage A: 0.45 mg/mL XT-150, Stage B: 0.15 mg/mL XT-150|High dose active in Stage A, low dose active in Stage B
89188959|NCT04124042|Experimental|Stage A: 0.45 mg/mL XT-150, Stage B: 0.45 mg/mL XT-150|High dose active in Stage A and Stage B
89188960|NCT04124042|Placebo Comparator|Stage A: Placebo, Stage B: 0.15 mg/mL XT-150|Inactive comparator in Stage A, low dose active in Stage B
89188961|NCT04124042|Placebo Comparator|Stage A: Placebo, Stage B: 0.45 mg/mL XT-150|Inactive comparator in Stage A, high dose active in Stage B
89188962|NCT05180175|Experimental|Access to protein profile|
89188963|NCT05180175|No Intervention|No access to protein profile|
89188964|NCT00844402|Experimental|Atorvastatin|Atorvastatin 10 mg per day for 48 weeks
89188965|NCT04117412|Other|Patients with COPD|Patients with COPD will undergo two different one bout of exercise training after maximal exercise test.
89188966|NCT00802971|Experimental|1: FOS|Oligofructose (FOS, BioCare Ltd, Birmingham, England) powder will be distributed in sachets of 10 g. Two sachets are to be included in daily nutrition, preferentially 10 g diluted in water at breakfast and before supper.
89188967|NCT00802971|No Intervention|2: Control|
89188968|NCT02546908||High-risk localized Prostate Cancer (PC)|No intervention will be administered in this study. Participants with High-risk localized PC will be enrolled. High-risk localized PC involves clinical T stage greater than or equal to (>=) cT3a and one of the following high risk features: Gleason score 8-10 or prostate specific antigen (PSA) level above 20 nanogram per milliliter (ng/mL).
89188969|NCT02546908||Non-metastatic Biochemically Recurrent PC|No intervention will be administered in this study. Participants with Non-metastatic biochemically recurrent PC will be enrolled. A non-metastatic biochemically recurrent PC involves a confirmed PSA value of >0.2 ng/mL following prostatectomy (European Association of Urology (EAU) guidelines), a PSA value of 2 ng/mL or more above the nadir following radiation therapy (American Society for Radiation Oncology (ASTRO) guidelines).
89188970|NCT02546908||Metastatic PC|No intervention will be administered in this study. Participants with Metastatic PC will be enrolled.
89188971|NCT04115852||CON|Healthy Controls
89188972|NCT04115852||BED|Patients with Binge-Eating-Disorder
89188973|NCT00716222||1|Obese adolescent and young adult with sleep disorder
89188974|NCT00716222||2|Obese adolescent and young adult without sleep disorder
89188975|NCT00716222||3|Lean adolescent and young adult with sleep disorder
89188976|NCT00803127||no treament|
89188977|NCT00797745|Active Comparator|Standard of Care|"PegIntron 1.5 mcg/kg SC weekly plus ribavirin 600 to 1400 mg daily (weight-based) by mouth twice daily for 48 weeks.~Subjects with >= 1 log decrease from baseline in HCV-RNA levels after 12 weeks, but still above the lower limit of quantitation, have the option of crossing over to PegIntron, ribavirin plus SCH 900518 400 mg and ritonavir 100 mg daily for 12 weeks. This is followed by standard of care, PegIntron and ribavirin, for a total treatment duration of up to 48 weeks."
89188978|NCT00797745|Experimental|2|PegIntron 1.5 mcg/kg SC weekly plus ribavirin 600 to 1400 mg daily (weight-based) by mouth twice daily plus SCH 900518 200 mg daily plus ritonavir 100 mg daily for 12 weeks. Depending on HCV-RNA levels after 4 weeks of SCH 900518, patients will receive an additional 12 or 36 weeks of PegIntron/ribavirin. Total treatment duration will be 24 or 48 weeks.
89188979|NCT00797745|Experimental|3|PegIntron 1.5 mcg/kg SC weekly plus ribavirin 600 to 1400 mg daily (weight-based) by mouth twice daily plus SCH 900518 400 mg daily plus ritonavir 100 mg daily for 12 weeks. Depending on HCV-RNA levels after 4 weeks of SCH 900518, patients will receive an additional 12 or 36 weeks of PegIntron/ribavirin. Total treatment duration will be 24 or 48 weeks.
89188980|NCT00797745|Experimental|4|4 week lead-in with PegIntron 1.5 mcg/kg SC weekly plus ribavirin 600 to 1400 mg daily (weight-based) by mouth twice daily followed by PegIntron plus ribavirin plus SCH 900518 200 mg daily plus ritonavir 100 mg daily for 12 weeks. Depending on HCV-RNA levels after 4 weeks of SCH 900518, patients will receive an additional 8 or 32 weeks of PegIntron/ribavirin. Total treatment duration will be 24 or 48 weeks.
89188981|NCT00797745|Experimental|5|4 week lead-in with PegIntron 1.5 mcg/kg SC weekly plus ribavirin 600 to 1400 mg daily (weight-based) by mouth twice daily followed by PegIntron plus ribavirin plus SCH 900518 400 mg daily plus ritonavir 100 mg daily for 12 weeks. Depending on HCV-RNA levels after 4 weeks of SCH 900518, patients will receive an additional 8 or 32 weeks of PegIntron/ribavirin. Total treatment duration will be 24 or 48 weeks.
89188982|NCT00797745|Experimental|6|PegIntron 1.5 mcg/kg SC weekly plus ribavirin 600 to 1400 mg daily (weight-based) by mouth twice daily plus SCH 900518 100 mg twice daily plus ritonavir 100 mg twice daily for 12 weeks. Depending on HCV-RNA levels after 4 weeks of SCH 900518, patients will receive an additional 12 or 36 weeks of PegIntron/ribavirin. Total treatment duration will be 24 or 48 weeks.
89188983|NCT00797745|Experimental|7|4 week lead-in with PegIntron 1.5 mcg/kg SC weekly plus ribavirin 600 to 1400 mg daily (weight-based) by mouth twice daily followed by PegIntron plus ribavirin plus SCH 900518 600 mg daily plus ritonavir 100 mg daily for 12 weeks. Depending on HCV-RNA levels after 4 weeks of SCH 900518, patients will receive an additional 8 or 32 weeks of PegIntron/ribavirin. Total treatment duration will be 24 or 48 weeks.
89188984|NCT00842374||Non-STEMI ACS|
89188985|NCT04070846|Experimental|[14C] LC350189|Single oral dose
89188986|NCT00836992||Control|Patient's QOL assessments data is not shared with the physician, nurse, and/or nurse practitioner and the patient
89188987|NCT00836992||Active|Patient's QOL assessments data is shared with the physician, nurse, and/or nurse practitioner and the patient immediately prior to the on-treatment visit.
89188988|NCT00716300||1|obese and insulin resistant subjects
89188989|NCT00716300||2|lean and normolipidaemic subjects
89188990|NCT00659373|Active Comparator|Tamoxifen|Tamoxifen 20mg orally daily for 5 years
89188991|NCT00659373|Experimental|T+OFS|Tamoxifen 20mg orally daily for 5 years plus ovarian function suppression (OFS; triptorelin (GnRH analogue) 3.75 mg by im injection q28 days for 5 years; or surgical oophorectomy; or ovarian irradiation)
89188992|NCT00659373|Experimental|E+OFS|Exemestane 25mg orally daily for 5 years plus ovarian function suppression (OFS; triptorelin (GnRH analogue) 3.75 mg by im injection q28 days for 5 years; or surgical oophorectomy; or ovarian irradiation)
89188993|NCT00837070|Experimental|1|Percutaneous zygapophyseal cyst rupture
89188994|NCT00842452|Experimental|Oral Topotecan|
89188995|NCT02552745||study group|parecoxib sodium was administered postoperatively
89188996|NCT02552745||control group|parecoxib sodium was not administered postoperatively
89188997|NCT02547844|Active Comparator|efavirenz + emtricitabina + tenofovir|Patients assigned to the control group will continue receiving the same medication than before to be included in the study: Atripla (efavirenz + emtricitabina + tenofovir)
89188998|NCT02547844|Experimental|rilpivirina + emtricitabina + tenofovir|Patients assigned to the experimental group will change the medication that are taking before to enter in the study ( atripla) for eviplera (rilpivirina + emtricitabina + tenofovir)
89188999|NCT00806325||AML|Adult patients with AML admitted for treatment of the same
89189000|NCT00439777|Experimental|Rivaroxaban (Xarelto, BAY59-7939)|Participants received 15 mg rivaroxaban (oral) twice daily (b.i.d.) for 3 weeks, followed by 20 mg once daily (o.d.)
89361983|NCT04774523|Experimental|AutoAdapt group|This group will be made up of patients implanted with CRT-D devices that have the CRT AutoAdapt feature available. It is mandatory that all patients within this group have the feature activated, independently of other characteristics.
89361984|NCT04773184||Healthy adults|132 individuals with no history of swallowing impairment or any health conditions known to impact swallowing function will be included in this study to serve as a comparative control group or reference standard group here and in future studies.
89361985|NCT04773184||Adults at risk for swallowing impairment.|132 individuals with an underlying condition documented to lead to dysphagia will be enrolled in this study. 2) Confirmed medical diagnosis associated with an increased risk of dysphagia including but are not limited to: head and neck cancer, neurologic (e.g., stroke, traumatic brain impairment), neurodegenerative (e.g., Parkinson's disease, amyotrophic lateral sclerosis), neuromuscular disorders (e.g., myotonic dystrophy, Pompe disease, inclusion body myositis) rheumatologic diseases (e.g., dermatomyositis, inclusion body myositis, scleroderma), chronic respiratory illnesses (e.g., chronic obstructive pulmonary disease), structural (e.g., mass or trauma to the upper aerodigestive tract) and iatrogenic conditions (e.g., post-surgical such as anterior cervical discectomy/fusion or cardiac, post-radiation treatment to the upper aerodigestive tract).
89361986|NCT04771338|Experimental|Treatment group|Job interview training protocol for 12 sessions
89361987|NCT04771338|No Intervention|Control group|No participation in any intervention protocol
89361988|NCT04764942|Experimental|Arm A (selinexor, dexamethasone, carfilzomib, carfilzomib)|Patients receive selinexor PO and dexamethasone PO on days 1, 8 15, and 22, carfilzomib IV on days 1, 8, and 15, and pomalidomide PO on days 1-21. Treatment repeats every 28 days for up to 18 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo PET/CT or CT and bone marrow biopsy and aspiration during screening and on the trial. Patients may optionally undergo blood sample collection during screening and on the trial.
89361989|NCT04764942|Experimental|Arm B (selinexor, dexamethasone, pomalidomide)|Patients receive selinexor PO and dexamethasone PO on days 1, 8, 15, and 22, and pomalidomide PO on days 1-21. Treatment repeats every 28 days for up to 18 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo PET/CT or CT and bone marrow biopsy and aspiration during screening and on the trial. Patients may optionally undergo blood sample collection during screening and on the trial.
89361990|NCT04754984|Experimental|Intervention|One-time in-person workshop with pelvic floor physiotherapist
89361991|NCT04754984|No Intervention|Control|Standard care
89361992|NCT04754061|Experimental|Psilocybin Microdosing|Participants will receive a 4-week psilocybin microdosing intervention (1-3mg/day, Monday-Friday for up to 4 weeks; start at 1mg with opportunity to increase dose each week)
89361993|NCT04742387||1|Medical records of subjects enrolled on various studies conducted by HAMB/CCR from 1/1/2005 to 12/1/2020
89361994|NCT04739436|Other|Bilateral hearing aid fitting group|
89361995|NCT04739436|Active Comparator|Unilateral hearing aid fitting group|
89361996|NCT04729322|Experimental|Arm I (FMT, pembrolizumab)|"Patients receive metronidazole PO Q8H on days -14 to -8 and then vancomycin PO Q6H and neomycin PO Q6H on days -8 to -6. Patients then undergo colonoscopic FMT on day -5.~POST-COLONOSCOPIC FMT: Patients receive standard of care pembrolizumab IV over 30 minutes on day 1. Patients also receive fecal microbiota transplantation capsule PO on days 1, 8, and 15 of cycle 1. Beginning in cycle 2, patients receive fecal microbiota transplantation capsule PO on day 1. Cycles repeat every 21 days for up to 6 months in the absence of disease progression or unacceptable toxicity."
89361997|NCT04729322|Experimental|Arm II (FMT, nivolumab)|"Patients receive metronidazole PO Q8H on days -14 to -8 and then vancomycin PO Q6H and neomycin PO Q6H on days -8 to -6. Patients then undergo colonoscopic FMT on day -5.~POST-COLONOSCOPIC FMT: Patients receive standard of care nivolumab IV over 30 minutes on day 1. Patients also receive fecal microbiota transplantation capsule PO on days 1 and 8 of cycles 1-2. Beginning in cycle 4, patients receive fecal microbiota transplantation capsule PO on day 1 of every other cycle. Cycles repeat every 14 days for up to 6 months in the absence of disease progression or unacceptable toxicity."
89361998|NCT04727866|Experimental|Rostral tsDCS|DCS cathode over ~C3-C5 posteriorly, anode over ~C5-T1 anteriorly
89361999|NCT04727866|Experimental|Caudal tsDCS|DCS cathode over ~T1-T4 posteriorly, anode over ~C5-T1 anteriorly
89362000|NCT04727866|Experimental|Coronal tsDCS|DCS cathode over C5-C7 transverse process on target side, anode over C5-C7 transverse process on non-target side.
89362001|NCT04724616|No Intervention|Control Group|Participants received no specific educational program
89362002|NCT04724616|Experimental|Intervention Group|Participants received our educational program for five days, with one teaching session per day. Every teaching session will be conducted for 60 minutes in a group of up to 6 children by a trained member of our staff.
89362003|NCT04722887|Experimental|Cohort 1: Treatment Period 1 (Alpha-1 15%, 72 mg/kg)|Participants will receive Alpha-1 15% 72 mg/kg, single weekly subcutaneous (SC) infusion in treatment-period 1 (Single-Dose) at Week 1.
89362004|NCT04722887|Experimental|Cohort 1: Single-Dose Data Evaluation Period (Liquid Alpha 1-Proteinase Inhibitor 60 mg/kg)|Following treatment period 1, participants in Cohort 1 will enter 21 days of washout/serial pharmacokinetic (PK) phase and then the single-dose data evaluation period. During the single-dose data evaluation phase, Liquid Alpha1- Proteinase Inhibitor (PI) 60 mg/kg, weekly intravenous (IV) Infusions will be administered from intravenous-dose Week 1 (single-dose Week 5) for up to Week 78, with the last IV dose given 1 week prior to the first repeat Alpha-1 15% SC dose.
89362005|NCT04722887|Experimental|Cohort 1: Treatment Period 2 (Alpha-1 15%, 72 mg/kg)|Following treatment period 1 and single-dose data evaluation period, participants in Cohort 1 will enter treatment period 2 (Repeat-Dose) and will receive Alpha-1 15% 72 mg/kg, for 8 weekly SC infusions.
89362006|NCT04722887|Experimental|Cohort 2: Treatment Period 1 (Alpha-1 15%, 180 mg/kg)|Participants will receive Alpha-1 15% 180 mg/kg, single weekly SC infusion in treatment-period 1 (Single-Dose) at Week 1.
89534542|NCT03335501|Active Comparator|Rapid-acting Aspart|Rapid-acting Aspart will be used to regulate glucose levels
89534543|NCT03335501|Active Comparator|Faster insulin Aspart|Faster insulin Aspart will be used to regulate glucose levels
88833339|NCT05814640|Experimental|Fluoxetine|"Dosage form: po Dosage: 10-60mg Frequency: qn Course of treatment: 8 weeks. At week 8, patients will be evaluated as in remission or not in remission. Patients who are not in remission will be randomized to phase II treatment based on the patient's wishes."
89362007|NCT04722887|Experimental|Cohort 2: Single-Dose Data Evaluation Period (Liquid Alpha1-Proteinase Inhibitor 120 mg/kg)|Following treatment period 1, participants in Cohort 2 will enter 21 days of washout/serial pharmacokinetic (PK) phase and then the single-dose data evaluation phase. During the single-dose data evaluation phase, Liquid Alpha1-PI 120 mg/kg, weekly IV Infusions will be administered from intravenous-dose Week 1 (single-dose Week 5) for up to Week 78, with the last IV dose given 1 week prior to the first repeat Alpha-1 15% SC dose.
89362008|NCT04722887|Experimental|Cohort 2: Treatment Period 2 (Alpha-1 15%, 180 mg/kg)|Following treatment period 1 and single-dose data evaluation phase, participants in Cohort 2 will enter treatment period 2 (Repeat-Dose) and will receive Alpha-1 15% 180 mg/kg, for 8 weekly SC infusions.
89362009|NCT04713475|Experimental|Part 1: Dose I of Dose Escalation Cohorts designed to identify the optimal dose of PBGM01|"Assigned Intervention:~PBGM01 Dose I: 3.3 x 10^10 GC/g estimated brain weight, single dose of PBGM01 via intra cisterna magna in Late Onset Infantile GM1 Gangliosidosis (Type 2a) and Early Onset Infantile GM1 Gangliosidosis (Type 1)"
89362010|NCT04713475|Experimental|Part 1: Dose II of Dose Escalation Cohorts designed to identify the optimal dose of PBGM01|"Assigned Intervention:~PBGM01 Dose II: 1.1 x 10^11 GC/g estimated brain weight, single dose of PBGM01 via intra cisterna magna in Late Onset Infantile GM1 Gangliosidosis (Type 2a) and Early Onset Infantile GM1 Gangliosidosis (Type 1)"
89362011|NCT04713475|Experimental|Part 1: Dose III of Dose Escalation Cohorts designed to identify the optimal dose of PBGM01|"Assigned Intervention:~PBGM01 Dose III: 2.2 x 10^11 GC/g estimated brain weight, single dose of PBGM01 via intra cisterna magna in Late Onset Infantile GM1 Gangliosidosis (Type 2a) and Early Onset Infantile GM1 Gangliosidosis (Type 1)"
89362012|NCT04713475|Experimental|Part 2: Expansion Cohort designed to confirm the safety and efficacy of PBGM01|"Confirmatory Cohorts: Late Onset Infantile GM1 Gangliosidosis (Type 2a) and Early Onset Infantile GM1 Gangliosidosis (Type 1)~Assigned Intervention:~PBGM01 Single dose of PBGM01, via intra cisterna magna Dose to be determined"
89362013|NCT04706091|Experimental|Treatment --> Placebo|This group will receive suvorexant during the first 4-week phase, and placebo during the second 4-week phase.
89362014|NCT04706091|Experimental|Placebo --> Treatment|This group will receive placebo during the first 4-week phase, and suvorexant during the second 4-week phase.
89362015|NCT04704219|Experimental|Pembrolizumab + Lenvatinib|Pembrolizumab 400 mg, every 6 weeks (Q6W) intravenous (IV) up to 18 infusions or up to progressive disease or discontinuation PLUS Lenvatinib 20 mg, daily (QD), oral, until progressive disease or discontinuation.
89362016|NCT04703920|Experimental|Talozoparib in combination with Belinostat|Patients will receive Talozoparib in combination with Belinostat
89362017|NCT04702607||contrast enhanced 4DCT|
89362018|NCT04699942|Active Comparator|Conventional|Conventional low-flow Oxygen Delivery
89362019|NCT04699942|Experimental|Revoxa|Oxygen Delivery via Revoxa Oxygen Rebreather Device
89362020|NCT04689594|Experimental|CLS2702C/CLS2702D|
89362021|NCT04685473|Experimental|T-1101 (Tosylate)|
89362022|NCT04685356|Experimental|IBAIP Group|Children benefiting from assessment and intervention providing by a healthcare professional (physiotherapist or psychomotor therapist) trained and certified for IBAIP. This care will take place upon discharge from the hospital at the rate of one session per month for 6 months. The sessions will take place in the presence of at least one of the parents and at home. These children will also benefit from standard follow-up (medical follow-up, paramedical or specialized medical support depending on the development and needs).
89362023|NCT04685356|Active Comparator|Control group|Children benefiting from standard care upon discharge from hospital with 1 medical consultation per month and, medical sepcialist and / or paramedical(physiotherapy, speech therapy, psychomotricity, etc.). consultations if indicated by the physician providing follow-up
89362024|NCT04676477|Experimental|Dose Escalation: HER3-DXd + osimertinib|Participants in the Dose Escalation phase will receive HER3-DXd IV Q3W + osimertinib PO once daily. The dose of HER3-DXd in the first cohort will be 3.2 mg/kg Q3W. The dose of osimertinib in the first cohort will be 80 mg PO once daily.
89362025|NCT04676477|Experimental|Second-line Dose Expansion: HER3-DXd + osimertinib (RCD)|Participants in the Second-line Dose Expansion phase will be randomized to receive HER3-DXd + osimertinib at the RCD
89362026|NCT04676477|Experimental|Second-line Dose Expansion: HER3-DXd|Participants in the Second-line Dose Expansion phase will be randomized to receive HER3-DXd 5.6 mg/kg IV Q3W
89362027|NCT04676477|Experimental|First-line Dose Expansion: HER3-DXd + osimertinib (Cohort 3; RCD)|If the RCD includes an osimertinib dose of 80 mg PO once daily, then participants will receive treatment with HER3-DXd and osimertinib at the RCD
88833340|NCT05814640|Experimental|group cognitive behavioral therapy（GCBT）|"GCBT was administered in addition to fluoxetine and consisted of 11 sessions for 8 weeks. It lasts 90 to 120 minutes, once or twice a week. At week 8, patients will be evaluated as in remission or not in remission. Patients who are not in remission will be randomized to phase II treatment based on the patient's wishes."
88833341|NCT05814640|Experimental|Sertraline|dosage form: po dosage:25-200mg frequency:qn duration: At Week 8, patients assessed as 'non-remission' will be given Sertraline as a switching treatment to fluoxetine.
88833342|NCT05814640|Experimental|Votioxetine|dosage form: po dosage: 10-20mg frequency:qn duration: At Week 8, patients assessed as 'non-remission' will be given votioxetine as a switching treatment to fluoxetine.
88833343|NCT05814640|Experimental|Duloxetine|dosage form: po dosage: 60-120mg frequency: qn duration: At Week 8, patients assessed as 'non-remission' will be given duloxetine as an add-on treatment to fluoxetine.
88833344|NCT05814640|Experimental|Aripiprazole|dosage form: po dosage: 2.5-15mg frequency:qn duration: At Week 8, patients assessed as 'non-remission' will be given aripiprazole as an add-on treatment to fluoxetine.
89362028|NCT04676477|Experimental|First-line Dose Expansion: HER3-DXd + osimertinib (Cohort 4a)|Participants in the First-line Dose Expansion phase will be randomized to receive HER3-DXd 5.6 mg/kg IV Q3W and osimertinib dose of 80 mg PO once daily.
89362029|NCT04676477|Experimental|First-line Dose Expansion: HER3-DXd + osimertinib (Cohort 4b)|Participants in the First-line Dose Expansion phase will be randomized to receive HER3-DXd 4.8 mg/kg IV Q3W and osimertinib dose of 80 mg PO once daily.
89362030|NCT04676178|Experimental|SAD Cohorts 1-6 Experimental Arm|Subjects will receive single intravenous doses of PRA023 in a dose escalation format
89362031|NCT04676178|Placebo Comparator|SAD Cohorts 1-6 Placebo Arm|Subjects will receive intravenous doses of placebo
89362032|NCT04676178|Experimental|MAD Cohorts 1-5 Experimental Arm|Subjects will receive three intravenous doses of PRA023, one dose every 2 weeks, in a dose escalation format
89362033|NCT04676178|Placebo Comparator|MAD Cohorts 1-5 Placebo Arm|Subjects will receive three intravenous doses of placebo, one dose every 2 weeks,
89362034|NCT04672434|Experimental|Sym024 Dose Level 1|Part I, Sym024 monotherapy dose level 1
89362035|NCT04672434|Experimental|Sym024 Dose Level 2|Part I, Sym024 monotherapy dose level 2
89362036|NCT04672434|Experimental|Sym024 Dose Level 3|Part I, Sym024 monotherapy dose level 3
89362037|NCT04672434|Experimental|Sym024 Dose Level 4|Part I, Sym024 monotherapy dose level 4
89362038|NCT04672434|Experimental|Sym024 Dose Level -1|Part I, Sym024 monotherapy dose level -1. Evaluate only if needed based on tolerability
88833345|NCT05814640|Experimental|Lithium carbonate|dosage form:po dosage: 125-500mg frequency: qn duration: At Week 8, patients assessed as 'non-remission' will be given lithium carbonate as an add-on treatment to fluoxetine.
88833346|NCT05814640|Experimental|Olanzapine|dosage form:po dosage: 1.25-10mg frequency:qn duration: At Week 8, patients assessed as 'non-rremission' will be given olanzapine as an add-on treatment to fluoxetine.
88833347|NCT05810597|Experimental|Tirzepatide - Test|A single dose of tirzepatide administered by subcutaneous (SC) injection via a test device (test formulation)
89362039|NCT04672434|Experimental|Sym021+Sym024 Dose Level 2|Part II, Sym021 in combination with dose level 2 of Sym024
88833348|NCT05810597|Active Comparator|Tirzepatide - Reference|A single dose of tirzepatide administered by SC injection via a reference device (reference formulation)
88833349|NCT05806099|Experimental|MBS303|
88833350|NCT05804240||Surgical aortic valve replacement|Patients who have surgical aortic valve replacement
88833351|NCT05804240||Mini-sternotomy aortic valve replacement|Patients who have mini-sternotomy aortic valve replacement
88833352|NCT05804240||Transcatheter aortic valve replacement|Patients who have transcatheter aortic valve replacement
88833353|NCT05804084|Experimental|Acetazolamide, then Placebo|"Subjects will start with a 4-week ACETAZOLAMIDE regimen~Day 1-27: Acetazolamide 500mg at bedtime at home Day 28: Acetazolamide 500mg at bedtime in the sleep laboratory~After a wash-out period, subjects will then cross-over to a 4-week PLACEBO regimen:~Day 1-27: Placebo (matching Acetazolamide 500mg) at bedtime at home Day 28: Placebo (matching Acetazolamide 500mg) at bedtime in the sleep laboratory"
88833354|NCT05804084|Experimental|Placebo, then Acetazolamide|"Subjects will start with a 4-week PLACEBO regimen~Day 1-27: Placebo (matching Acetazolamide 500mg) at bedtime at home Day 28: Placebo (matching Acetazolamide 500mg) at bedtime in the sleep laboratory~After a wash-out period, subjects will then cross-over to a 4-week ACETAZOLAMIDE regimen:~Day 1-27: Acetazolamide 500mg at bedtime at home Day 28: Acetazolamide 500mg at bedtime in the sleep laboratory"
88833355|NCT05798507|Experimental|Arm I (Defactinib)|Patients receive 1 dose of defactinib PO while on study, prior to planned tumor resection. Patients undergo blood collection and donate resected tumor tissue while on study.
88833356|NCT05798507|Experimental|Arm II (Avutometinib)|Patients receive 1 dose of avutometinib PO while on study, prior to planned tumor resection. Patients undergo blood collection and donate resected tumor tissue while on study.
88833357|NCT05796206|Experimental|MIL62(Part A and B)|
88833358|NCT05796206|Placebo Comparator|Placebo (Part A and B)|
89362040|NCT04672434|Experimental|Sym021+Sym024 Dose Level 3|Part II, Sym021 in combination with dose level 3 of Sym024
89362041|NCT04672434|Experimental|Sym021+Sym024 Dose Level 4|Part II, Sym021 in combination with dose level 4 of Sym024
89362042|NCT04672434|Experimental|Sym021+Sym024 Dose Level 5|Part IIa, Sym024 monotherapy and in combination with Sym021
89362043|NCT04672434|Experimental|Sym021+Sym024 Dose Level 1|Part II, Sym021 in combination with dose level 1 of Sym024. Evaluate only if needed based on tolerability
89534544|NCT05038995||Cow milk elimination group|The CME children will be eligible for the study if they (1) had a diagnosis of CMA by OFC, except children with known anaphylaxis (2) those on a CME diet or a specialized infant formula for at least three months (3) had reintroduced cow's milk for at least three months ago. Children who excluded other foods in addition to cows' milk in the first four years of life for ≥ three months and who currently introduced these foods for at least ≥ three months will be also enrolled in the CME group.
88833359|NCT05794243|Experimental|LY3493269 (Part A)|LY3493269 administered orally as test or reference formulations in participants who are in a fasted state.
88833360|NCT05794243|Experimental|LY3493269 (Part B)|LY3493269 administered orally as test or reference formulations in participants who are either in a fasted or fed state.
88833361|NCT05792306|Experimental|The electrolyzed water spray group|Study staff will use the novel electrolyzed water spray device and spray for approximately 2-4 minutes on the participant's diseased area until half a bottle (20-40ml) of water is used.
88833362|NCT05792306|Placebo Comparator|Control group of water spray|Study staff will use the saline and spray for approximately 2-4 minutes on the participant's diseased area until half a bottle (20-40ml) of water is used.
88833363|NCT05789004|Experimental|Hydrogen Peroxide 35%|In the participants of this group, the tooth whitening process will be performed with 35% hydrogen peroxide.
89362044|NCT04672434|Experimental|Dose Expansion Sym021 (+Sym024)|Part III, dose expansion Sym024 and/or Sym021+Sym024
89362045|NCT04664361|Experimental|NMN 250|NMN tablet (250 mg)
89362046|NCT04664361|Experimental|NMN 500|NMN tablet (500 mg)
89362047|NCT04664361|Placebo Comparator|Placebo|NMN-free placebo tablet.
89362048|NCT04656652|Experimental|DS-1062a 6.0 mg/kg|Participants will be randomized to receive 6.0 mg/kg of DS-1062a.
89362049|NCT04656652|Active Comparator|Docetaxel 75 mg/m^2|Participants will be randomized to receive 75 mg/m^2 docetaxel.
89534545|NCT05038995||Healthy group|Healthy children will ve eligible for the study if they (1) did not have CMA and other allergic diseases (2) who had never been on a diet throughout their lives.
89362050|NCT04650568|Experimental|Mesenchymal Stem Cell Recipient|Patients in this group will receive between 1-4 ml of bone marrow aspirate concentrate (BMAC) containing mesenchymal stem cells (MSCs) obtained from their iliac crest. A small incision will be made on the anterior superior iliac spine in order to withdraw the aspirate. The aspirate will be ran through a centrifuge in order to isolate the BMAC containing MSCs. The BMAC will be injected into the ACL allograft prior to implanting into the patient.
89362051|NCT04650568|Placebo Comparator|Control Sham Incision|Patients will receive a sham incision on the anterior superior iliac spine where the bone marrow aspirate is obtained in the the experimental group. This ensures proper blinding. The patient will receive the normal standard of care.
88833364|NCT05789004|Experimental|Hydrogen Peroxide 6%|In the participants of this group, the tooth whitening process will be performed with 6% hydrogen peroxide.
88833365|NCT05779449|Experimental|Pre-Pro group|"Patients with RRMS under dimethyl fumarate or Ocrelizumab treatment according to the good clinical practice, who will recieve the following dietary supplementation with pre- and probiotics:~1st-15th days: One capsule containg 6 billions of Saccharomyces boulardii and 8,5 billions of probiotics including Bifidobacterium lactis Bi-07®, Bifidobacterium lactis Bl-04, Lacticaseibacillus paracasei Lpc-37, Lactobacillus acidophilus NCFM® (Probactiol Duo cps, Metagenics) One packet with 4 g of prebiotics including inulin enriched with oligofructose (Probactiol Stips bustine Metagenics).~16th-365th days:~Two capsules, each containg 7,5 billions of Lactobacillus acidophilus NCFM®, 7,5 billions of Bifidobacterium lactis Bi-07®, 2,5 ug Vitamine D3, 320 ug Vitamine A, 100 mg Threonine, 250 mg 2'-Fucosyllactose (Probactiol HMO Combi cps, Metagenics)."
88833366|NCT05779449|Placebo Comparator|Placebo group|"Patients with RRMS under dimethyl fumarate or Ocrelizumab treatment according to the good clinical practice, who will receive only starch, the probiotic bacteria carrier:~1st-15th days: One capsule and one packet only with starch.~16th-365th days: Two capsules containg starch."
88833367|NCT05773521||SILAP patients|This cohort is composed by all pediatric patients operated on for SILAP between January 1st, 2012 and August 31, 2022.
88833368|NCT05770271|Experimental|The mild senile groin eczema, neurodermatitis and psoriasis and one treatment|Participants with itching of mild senile groin eczema, neurodermatitis and psoriasis will receive one treatment with the device and complete the questionnaire.
88833369|NCT05770258|Experimental|The mild periodontitis and one treatment|Participants with mild periodontitis accompanied by gingival discomfort will receive one treatment with the device and complete the questionnaire.
88833370|NCT05770245|Experimental|Mild dermatophytosis and one treatment|Study staff will use the novel electrolyzed water spray device and spray for approximately 10 minutes on the participant's diseased area until half a bottle (200ml) of water is used.
88833371|NCT05766930|Experimental|The genital itching and one treatment|Participants with itching genitalia will receive one treatment with the device and complete the questionnaire.
88833372|NCT05765526|Experimental|The scalp of discomfort or itching and one treatment|Participants with discomfort or itching scalp who will receive one treatment with the device and complete the questionnaire.
88833373|NCT05764070|Experimental|Non Invasive Vagus Stimulation|Aerobic exercise + Non Invasive- Vagus Stimulation
89362052|NCT04649151|Experimental|mRNA-1273|"Part 1A (Blinded Phase): Participants will receive 2 intramuscular (IM) injections of mRNA-1273 (100 microgram [ug] each), 28 days apart, on Day 1 and Day 29.~Part 1B (Open-Label Phase): Participants who cross over from placebo in Part 1A to Part 1B will receive 2 IM injections of mRNA-1273 (100 ug each), 28 days apart on Open Label Day 1 and Open Label Day 29.~Part 2 (Open-Label): Participants will receive 2 IM injections of mRNA-1273 (50 ug each), 28 days apart, on Day 1 and Day 29 and may receive a booster dose on Day 149."
88833374|NCT05764070|Placebo Comparator|Placebo Non Invasive Vagus Stimulation|Aerobic exercise + Placebo Non Invasive Vagus Stimulation
88833375|NCT05759780|Experimental|Healthy cornea|Optical imaging of the cornea in healthy subjects
88833376|NCT05759780|Experimental|Healthy skin|Optical imaging of the skin in healthy subjects
88833377|NCT05759780|Experimental|Healthy gingiva|Optical imaging of the gingiva in healthy subjects
88833378|NCT05759780|Experimental|Keratoconus cornea|Optical imaging of the cornea in mild and moderate keratoconus
88833379|NCT05758831|Active Comparator|Ocrelizumab|Day 0 (300mg), Day 15(300mg), and then 300 mg every 6 months (M6, M12, M18 and M24)
88833380|NCT05758831|Experimental|Rituximab|Day 0 (1000mg), Day 15 (1000 mg), and then 500 mg every 6 months (M6, M12, M18 and M24)
88833381|NCT05756426||Healthy Volunteers|Healthy Volunteers >/= 18yrs of age without acute or chronic illness.
88833382|NCT05755971|Experimental|study group|Receive combination taping in addition to conventional physiotherapy
88833383|NCT05755971|Other|control group|Receive conventional physiotherapy
88833384|NCT05754580|Experimental|High Dose Rate (HDR) Brachytherapy and Stereoscopic Body Radiation (SBRT) treatment|High dose rate Brachytherapy in combination with stereoscopic body radiation therapy.
88833385|NCT05754151|Experimental|MAYA Mobile App|Participants receive treatment with the MAYA application for 6 weeks
88833386|NCT05752916|Experimental|Intravenous rhTNK-tPA|rhTNK-tPA(0.25mg/kg) given as a single, intravenous bolus immediately upon randomization. Experimental treatment will be administered as a single intravenous bolus over 5-10 seconds as per the standard manufacturers' instructions for use.
89362053|NCT04649151|Placebo Comparator|Placebo|Part 1A (Blinded Phase): Participants will receive 2 IM injections of mRNA-1273 matching placebo, 28 days apart, on Day 1 and Day 29.
89362054|NCT04649151|Experimental|mRNA-1273 BD|"Part 1C-1 (BD Phase): Participants will receive 1 IM injection of mRNA-1273 (50 ug) on BD-Day 1, 5 months after the last dose of Part 1A and 1B.~Part 1C-2 (BD Phase): Participants will receive 1 IM injection of mRNA-1273 (50 ug) on BD-Day 1, at least 3 months post-last dose."
89362055|NCT04649151|Experimental|mRNA-1273.222|Part 3 (Open-Label): Participants will receive up to 2 IM injections of mRNA-1273.222 (50 ug each), 6 months apart, on Day 1 and Day 181.
89362056|NCT04631744|Experimental|Cabozantinib Arm|
89362057|NCT04629053||Patients with an acute febrile illness|Patients with acute febrile illness, 4,800 children and 2,400 adults, divided equally across four countries (Laos, Myanmar,Thailand (including the Thai-Myanmar border region), and Bangladesh) and three age groups: >28 days to <5 years; ≥5 years to <15 years, and ≥15 years of age.
89362058|NCT04611529|Experimental|Oral ibuprofen + topical diclofenac|Oral ibuprofen 400mg Topical diclofenac 2gm
88833387|NCT05752916|Active Comparator|Antiplatelet agents|Patients will be treated with standard guideline-directed antiplatelet treatment-choice at the discretion of the clinician. Aspirin will be the choice of most physicians; some will choose to use the clopidogrel. Standard of care medication(s) should be given immediately upon randomization.
89362059|NCT04611529|Active Comparator|Oral ibuprofen + topical placebo|Oral ibuprofen 400mg Topical placebo
89362060|NCT04611529|Active Comparator|Oral placebo + topical diclofenac|Oral placebo Topical diclofenac 2gm
89362061|NCT04610580|Experimental|Crossover ALXN1840 Sequence 1|Participants will first receive a single dose of ALXN1840 test formulation on Day 1 of Period 1. After a washout period of 14 days, they will then receive a single dose of ALXN1840 reference formulation on Day 1 of Period 2.
89362062|NCT04610580|Experimental|Crossover ALXN1840 Sequence 2|Participants will first receive a single dose of ALXN1840 reference formulation on Day 1 of Period 1. After a washout period of 14 days, they will then receive a single dose of ALXN1840 test formulation on Day 1 of Period 2.
89362063|NCT04610580|Experimental|Parallel Dose-proportionality Extension: ALXN1840 Dose 1|Participants will receive a single dose of ALXN1840.
89362064|NCT04610580|Experimental|Parallel Dose-proportionality Extension: ALXN1840 Dose 2|Participants will receive a single dose of ALXN1840.
89362065|NCT04610580|Experimental|Parallel Dose-proportionality Extension: ALXN1840 Dose 3|Participants will receive a single dose of ALXN1840.
89362066|NCT04610580|Experimental|Parallel Dose-proportionality Extension: ALXN1840 Dose 4|Participants will receive a single dose of ALXN1840.
89362067|NCT04609592|Experimental|Lutathera|2 cycles of 177Lu Dotatate, followed by cytoreductive surgery, followed by additional 177Lu Dotatate (up to 2 cycles) for residual disease as determined by 68Ga DOTA TATE PET/CT
89362068|NCT04608604|Active Comparator|Physiotherapy 1|
89362069|NCT04608604|Active Comparator|Physiotherapy 2|
88833388|NCT05752409|Experimental|Propofol + esketamin 0.5|1mg•kg-1propofol, 0.5 mg•kg-1esketamin, 1 μg•kg-1 fentanyl and 0.15 mg•kg-1 cis-atracurium was administered intravenously in one minute.
88833389|NCT05752409|Experimental|Propofol+ esketamin 0.75|1mg•kg-1propofol, 0.75 mg•kg-1esketamin, 1 μg•kg-1 fentanyl and 0.15 mg•kg-1 cis-atracurium was administered intravenously in one minute.
88833390|NCT05752409|Active Comparator|Propofol|2 mg•kg-1propofol, 1 μg•kg-1 fentanyl and 0.15 mg•kg-1 cis-atracurium was administered intravenously in one minute.
89362070|NCT04605783|Experimental|Travelan®|Product will be started 2 days prior to arrival in overseas destination and maintained for a maximum duration of 20 days (minimum of 10 days) during travel or deployment.
89362071|NCT04605783|Placebo Comparator|Placebo|Placebo will be started 2 days prior to arrival in overseas destination and maintained for a maximum duration of 20 days (minimum of 10 days) during travel or deployment.
89362072|NCT04604210|Experimental|Dysphoric target|"The dysphoric target is a region in the dorsolateral prefrontal cortex. TMS targeted to this region has been shown to be more effective for depression than anxiety."
89362073|NCT04604210|Experimental|Anxiosomatic target|"The anxiosomatic target is a region in the dorsomedial prefrontal cortex. TMS targeted to this region has been shown to be more effective for anxiety than depression."
89362074|NCT04601350|Experimental|Remimazolam 1|
89362075|NCT04601350|Other|Control|
89362076|NCT04597125|Experimental|Arm A|Participants with bone dominant metastatic castration resistant prostate cancer (mCRPC) progressing on/after one line of NAH will be randomized to receive radium-223 dichloride
89362077|NCT04597125|Active Comparator|Arm B|Participants with bone dominant metastatic castration resistant prostate cancer (mCRPC) progressing on/after one line of NAH will be randomized to receive second novel anti-hormonal therapy (NAH)
88833391|NCT05749172|Experimental|Group A|This group was provided with Strength training along with parkour routine training.
88833392|NCT05749172|Active Comparator|Group B|The control group was provided with parkour routine training
89362078|NCT04595435||Cohort A- Preoperative Prospective|Subjects are eligible to receive IORT and have agreed to participate in the study prior to any intervention.
89362079|NCT04595435||Cohort B- Postoperative Prospective|Subjects who have had IORT performed within the previous 6 month who agree to participate.
89362080|NCT04592250||Observational (survey)|Participants will complete a survey packet that is estimated to take about 30 minutes. The survey packet will be collected at baseline and at 6 months.
89362081|NCT04584853|Active Comparator|Endocrine Therapy only|Endocrine therapy prescribed as per standard of care, for an expected duration of at least 5 years, or until evidence of disease recurrence or other discontinuation criteria are met. Choice of endocrine therapy may include non-steroidal aromatase inhibitor (letrozole or anastrozole), steroidal aromatase inhibitor (exemestane), or tamoxifen
88833393|NCT05748457||2015-2017|Patients treated for anorexia nervosa in the years 2015-2017 at Nedre Romerike outpatient clinic, Department of child and adolescent mental health services, Akershus university hospital.
88833394|NCT05748457||2018-2020|Patients treated for anorexia nervosa in the years 2018-2020 at Nedre Romerike outpatient clinic, Department of child and adolescent mental health services, Akershus university hospital.
88833395|NCT05746481|Experimental|Single Treatment Arm|Tiragolumab in combination with atezolizumab, pemetrexed, and carboplatin.
88833396|NCT05738187|Experimental|local cryotherapy treatment|
88833397|NCT05728723|Experimental|Intervention group|Pharmacy Education with Android Application as a Tool Conducted for Three Months in Hypertensive Patients to Improve Knowledge, Adherence, Outcome Therapy and Quality of Life
88833398|NCT05728723|Active Comparator|Pharmacy education|Pharmacy education in hypertensive patients
88833399|NCT05726487|Experimental|ACTION Intervention|Orientation (week 0): 1 group session Induction phase (weeks 1-12): 8 weekly then 2 bi-weekly goal setting via text with health coach + 2 group sessions (week 5, 9) Adoptive phase (weeks 13-24): 2 monthly goal setting with remote health coach + 3 group sessions (week 13, 17, 21) Maintenance phase (weeks 25-48): 1 group session Outcome assessment (12-, 24-, and 48-weeks)
88833400|NCT05726487|Other|Education Control|Orientation (week 0): 1 individual asthma education session Education texts: weekly (weeks 1-8), then bi-weekly (week 9-12), then monthly (weeks 13-24) Outcome assessments (12-, 24-, 48-weeks)
88833401|NCT05725395|Experimental|Virtual Reality then Standard of Care|Participants will be randomized to receive the virtual reality intervention on the first day and receive standard of care on the second day of in-patient care.
88833402|NCT05725395|Experimental|Standard of Care then Virtual Reality|Participants will be randomized to receive the standard of care on the first day and receive virtual reality intervention on the second day of in-patient care.
88833403|NCT05721937||Exposed to CIBINQO during pregnancy|Received at least one dose of CIBINQO at any time during pregnancy or prior to pregnancy (within 1 day prior to the date of conception).
88833404|NCT05721937||Unexposed to CIBINQO during pregnancy|Diagnosed with moderate-to-severe atopic dermatitis, but not exposed to CIBINQO during pregnancy.
88833405|NCT05715411|Placebo Comparator|Control|
88833406|NCT05715411|Experimental|Light therapy|
88833407|NCT05714436||Work Package 1a|Longitudinal interviews with patients and family carers to generate thematic framework for co-design workshops
88833408|NCT05714436||Work Package 1b|On-line focus groups with healthcare professionals to generate thematic framework for co-design workshops
88833409|NCT05714436||Work Package 2|Co-design workshops to generate decisions about priority areas for intervention development
88833410|NCT05711238|Experimental|Robot Assisted Therapy Group|"Investigators planned to apply robotic rehabilitation therapy with a hand-finger robot [Amadeo (Tyromotion, Graz, Austria)] for 40 minutes, accompanied by a physiotherapist who is trained in the field of robotic rehabilitation and has at least 5 years of experience for the hands on the affected side of the children in the Robot Assisted Therapy Group group.~Amadeo (Tyromotion, Graz, Austria) is an end-effector device designed for the hand. It is a groove-shaped device attached to the forearm using magnets using bandages on the fingers."
88833411|NCT05711238|Active Comparator|Conventional Therapy Group|"Conventional therapy group In the pediatric rehabilitation of the children's hands on the affected side, an exercise program consisting of 40 minutes of hand finger joint range of motion exercises (passive, active assistive), strengthening exercises, and coarse and fine dexterity exercises was planned, accompanied by a physiotherapist experienced for at least 5 years.~A total of 30 sessions of treatment were planned for both groups, 5 days a week. It will be recommended that they continue with the same dose of the medical treatment they have been using during the treatment program. Children will be evaluated by a physiatrist blinded to groups before and after treatment."
88833412|NCT05707247|Experimental|prototype software|
88833413|NCT05706766|Experimental|Exercise Group (PARE)|"Participants will be randomly assigned to the Exercise Group (PARE) and will complete study procedures as outlined:~8 weeks of 3x weekly sessions of virtually supervised aerobic and resistance exercise performed at home using study-provided stationary bike, resistance equipment, heart-rate monitor, and a wi-fi enabled tablet.~Clinic visits at week 1, week 10, and 30 days post Autologous Stem Cell Transplantation (ASCT).~Questionnaires and surveys."
88833414|NCT05706766|Active Comparator|Waitlist Control Group|"Participants will be randomly assigned to the Waitlist Control Group and will complete study procedures as outlined:~8 weeks of continuing with normal daily activities.~Option to participate in PARE exercise program after study completion.~3 clinic visits with option of 5 visits. The two additional visits are for evaluation and testing for those who choose to participate in exercise program after study completion."
88833415|NCT05701644|Experimental|C1K 150mg|Subcutaneous Administration C1K 150mg single or multi dose
88833416|NCT05701644|Experimental|C1K 300mg or placebo|Subcutaneous Administration C1K 300mg or placebo single or multi dose
88833417|NCT05701644|Experimental|C1K 600mg or placebo|Subcutaneous Administration C1K 600mg or placebo single or multi dose
88833418|NCT05701644|Experimental|C1K 900mg or placebo|Subcutaneous Administration C1K 900mg or placebo single or multi dose
88833419|NCT05701644|Experimental|C1K 1200mg or placebo|Subcutaneous Administration C1K 1200mg or placebo single or multi dose
88833420|NCT05694403||Neurologists|
88833421|NCT05694403||General practitioners|
88833422|NCT05692960|Experimental|Hypnotic Relaxation Intervention (HRI)|"The hypnotic relaxation intervention consists of three different audio files, each about 20 minutes in length. These three hypnotic inductions build upon each other. The first hypnotic induction audio focuses on relaxation, feelings of wellness, wholeness, strength, and confidence. The second hypnotic induction audio focuses more specifically on body image related to sexuality and being a sexual being. The third hypnotic induction audio focuses on sexual desire, passion, and energy. Each hypnotic induction will be used for two weeks, three times per week for a total of six weeks of hypnosis.~The vaginal moisturizer component of this arm is the same as that described for the VVA study arm."
89189001|NCT00439777|Active Comparator|Enoxaparin/VKA|Participants received enoxaparin (subcutaneous) 1.0 mg/kg b.i.d. for minimal 5 days, plus vitamin K antagonist (VKA) at individually titrated doses to achieve a target international normalized ratio (INR) of 2.5 (range: 2.0 - 3.0)
89189002|NCT04045821|Placebo Comparator|Control|Patients in this arm will not receive the study drug. A placebo of normal saline will be injected subcutaneously and the D&C procedure will be completed.
89189003|NCT04045821|Experimental|Intervention|Patients in this arm will receive a dose of the study drug, AMD3100, injected subcutaneously and the D&C procedure will be completed.
89001090|NCT04630678|Experimental|Virtual Reality Group|"The first group was received conventional physiotherapy and virtual reality therapy for 60 minutes.~The conventional physiotherapy interventions, including joint and muscle mobilization, strengthening, and stretching exercises by neurodevelopmental treatment principles and special for the needs of the child, was applied to both groups. The virtual reality group received that simulate daily life and contain individual scenarios by using the USE-IT system for thirty minutes. USE-IT (Most Rehabilitation, Ankara, Turkey) is a 2D non-immersive virtual reality system that plays games on a 50-inches touchscreen. The children played the matching, plumber, plumber, math, and car wash games in accordance with their reaching map results. The treatment were given three times a week for eight weeks."
89189004|NCT04068584|Experimental|Complete Smart Angel|Smat Angel application with artificial intelligence
89189005|NCT04068584|Experimental|Basic Smart Angel|Smat Angel application without artificial intelligence
89189006|NCT04068584|No Intervention|Control|
89189007|NCT00842842|Active Comparator|1: tacks|mesh fixation with tacks
89189008|NCT00842842|Experimental|2: glue|mesh fixation with glue
89189009|NCT00803439||Cohort Group 1|Subjects number 1 to 20
89189010|NCT00803439||Cohort Group 2|Subjects number 21 to 40
89189011|NCT00803439||Cohort Group 3|Subjects number 41 to 60
89189012|NCT00803439||Cohort Group 4|Subjects number 61 to 80
89189013|NCT00844636|Active Comparator|Sharp Needles|Sharp needles to close uterus, fascia and skin during cesarean section
89189014|NCT00844636|Active Comparator|Blunt Needles|Assignment to blunt needles to close uterus, fascia and skin during cesarean section
89189015|NCT02575196||Cardiac arrest|Consecutive adult cardiac arrest patients with sustained ROSC in an academic medical center
89189016|NCT00806481|Active Comparator|1|Treatment group: treatment with 1600mg tablets of sevelamer carbonate three times daily for 36 weeks
89189017|NCT00806481|Placebo Comparator|2|Treatment group: treatment with tablets of placebo three times daily for 36 weeks
89189018|NCT02546596|Experimental|Electro-hyperthermia plus radiation|External beam radiation 40 Gy with 20 fractions (4 weeks) Electro-hyperthermia twice a week, one hour for each session
89189019|NCT00709436|Experimental|1|PMI-150 (intranasal ketamine) at time 0 and specified time points thereafter.
89189020|NCT00709436|Placebo Comparator|2|Placebo at time 0 and specified time points thereafter.
89189021|NCT00803673|Experimental|Active|100mcg 719
89189022|NCT00803673|Experimental|Active 2|500mcg '719
89189023|NCT00803673|Experimental|Active 3|1000mcg '719
89189024|NCT00803673|Placebo Comparator|Placebo|Placebo '719
89189025|NCT00844792|Experimental|1|This group of men will be on active treatment (antioxidants)for 6-8 weeks prior to their radical prostatectomy.
89189026|NCT00844792|Placebo Comparator|2|This group of men will be on placebo for 6-8 weeks prior to their radical prostatectomy.
89189027|NCT04017195|Experimental|Group 1: Sequence AB (Right/Left)|A single patch of currently marketed EVRA patch using the adhesive component at the beginning of shelf life (BOSL) (Treatment A) will be applied to the right buttock of participants on Day 1 of Treatment Period 1, followed by application of a single patch of transdermal contraceptive using newly sourced adhesive component HMW PIB at the end of shelf life (EOSL) (Treatment B) to left buttock of participants on Day 1 of Treatment Period 2. The Treatment periods will be separated by a washout period of 21 days.
89189028|NCT04017195|Experimental|Group 2: Sequence BA (Right/Left)|Treatment B will be applied to the right buttock of participants on Day 1 in Period 1, followed by Treatment A to the left buttock on Day 1 in Period 2. The Treatment periods will be separated by a washout period of 21 days.
89189029|NCT04017195|Experimental|Group 3: Sequence AB (Left/Right)|Treatment A will be applied to the left buttock of participants on Day 1 in Period 1, followed by Treatment B to the right buttock on Day 1 in Period 2. The Treatment periods will be separated by a washout period of 21 days.
89189030|NCT04017195|Experimental|Group 4: Sequence BA (Left/Right)|Treatment B will be applied to the left buttock of participants on Day 1 in Period 1, followed by Treatment A to the right buttock on Day 1 in Period 2. The Treatment periods will be separated by a washout period of 21 days.
89189031|NCT00719420|Experimental|1|Clarithromycin 500 mg bid, metronidazole 500 mg tid, and amoxicillin 500mg tid for 14 days (with or without omeprazole 20 mg bid)
89189032|NCT00719420|Active Comparator|2|Clarithromycin 500 mg bid, amoxicillin 1 g bid, and omeprazole 20 mg bid for 10 days
89189033|NCT00837226||Study group-Bariatric procedure performed|
89189034|NCT00837226||Control group: No bariatric procedures|
89189035|NCT00797901|Experimental|Collaborative Care, Treatment as Usual|
89189036|NCT00844870|Active Comparator|1|stabilization training group
89189037|NCT00844870|Experimental|2|auditory response training group
89189038|NCT00716612|Placebo Comparator|2|PO Placebo QD
89189039|NCT00716612|Experimental|1|PO Coenzyme Q 10 QD
89189040|NCT00842920|Placebo Comparator|Placebo|Placebo or 20 mg Simvastatin (stratified by prior use of statins)
89189041|NCT00842920|Experimental|Simvastatin 60 mg|Simvastatin 60 mg once daily
89189042|NCT00842920|Experimental|Simvastatin 20 mg|Simvastatin 20 mg once daily
89189043|NCT00806559|Active Comparator|Usual room|Patients in this arm will see their clinician in the usual clinical exam room
89189044|NCT00806559|Experimental|Re-designed room|Patients assigned to this arm will see the physician in a redesigned clinical exam room
89189045|NCT00716690|Experimental|treatment|
89189046|NCT00722774|Experimental|1|Participants will receive 2 doses of vaccine 4 to 8 weeks (28-62 days) apart
89189047|NCT03118063|Experimental|Active trigger point|Evaluation of the dynamometry of the maximum and medium gluteus muscles and correlate with the presence or not of trigger point
89362082|NCT04584853|Experimental|Endocrine Therapy with abemaciclib|"Abemaciclib administered at dose of 150mg twice daily (provided as 50mg tablets), for 2 years or until evidence of disease recurrence or other discontinuation criteria are met.~Endocrine therapy prescribed as per standard of care, for an expected duration of at least 5 years, or until evidence of disease recurrence or other discontinuation criteria are met. Choice of endocrine therapy may include non-steroidal aromatase inhibitor (letrozole or anastrozole), steroidal aromatase inhibitor (exemestane), or tamoxifen"
89362083|NCT04582227||The ETT group|Oral endotracheal intubation via direct laryngoscopy will be performed. The ETT cuff will be inflated to 25 cmH2O using a manometer.
88833423|NCT05692960|Other|Vulvovaginal Atrophy (VVA)|This study arm might best be described as standard of care. Vulvovaginal dryness will be treated with a daily moisturizer for two weeks, then every other day for the remaining six weeks. Vaginal moisturizer will be applied at night, before sleep and after all sexual activity. Several moisturizers are available, including vaginal DHEA (IntraRosa®). Due to the need for reproducibility, we have decided to use one non-hormonal vaginal moisturizer, Replens™ moisture, which is a vaginal moisturizer consisting primarily of a purified water, glycerin, and mineral oil. Other ingredients included in the formulation are polycarbophyl, carbomer, homopolymer type B, hydrogenated palm oil glyceride, sorbic acid, sodium hydroxide. The moisturizing gel was determined to be a medical device for marketing by the FDA in 2010. It is non-hormonal (unlike vaginal DHEA) and therefore will be more likely to be acceptable by a broader range of oncology providers.
88833424|NCT05683678||Cohort 1|"Participants who started selumetinib and discontinued selumetinib before enrollment (the discontinued cohort)."
88833425|NCT05683678||Cohort 2|"Participants who started selumetinib before enrollment and are continuing to receive selumetinib at the time of enrollment (the continuing cohort)."
88833426|NCT05683678||Cohort 3|"Participants who intend to initiate selumetinib within approximately 3 months after enrollment (the initiating cohort)."
88833427|NCT05678010|Experimental|Arm A, Dose Level 1|Participants have peripheral metastases only, without bowel and lung in SBRT treatment planning target. Once 2 dosing cohorts of safety data are available from concomitant dosing of AZD1390 with SBRT in Arm A, and provided that Arm A is advancing to Cohort 3, Arm B (with bowel and lung in SBRT treatment planning target [PTV]) may be triggered at the initial dose level).
88833428|NCT05678010|Experimental|Arm A, Dose Level 2|Participants have peripheral metastases only, without bowel and lung in SBRT treatment planning target. Once 2 dosing cohorts of safety data are available from concomitant dosing of AZD1390 with SBRT in Arm A, and provided that Arm A is advancing to Cohort 3, Arm B (with bowel and lung in SBRT treatment planning target [PTV]) may be triggered at the initial dose level).
88833429|NCT05678010|Experimental|Arm A, Dose Level 3|Participants have peripheral metastases only, without bowel and lung in SBRT treatment planning target. Once 2 dosing cohorts of safety data are available from concomitant dosing of AZD1390 with SBRT in Arm A, and provided that Arm A is advancing to Cohort 3, Arm B (with bowel and lung in SBRT treatment planning target [PTV]) may be triggered at the initial dose level).
89362084|NCT04582227||The LMA group|The Ambu aura-i LMA size will be chosen and inserted using the recommended single-handed rotational technique. Subsequently, a manometer was used to inflate the cuff to 60 cm H2O.
88833430|NCT05678010|Experimental|Arm A, Dose Level 4|Participants have peripheral metastases only, without bowel and lung in SBRT treatment planning target. Once 2 dosing cohorts of safety data are available from concomitant dosing of AZD1390 with SBRT in Arm A, and provided that Arm A is advancing to Cohort 3, Arm B (with bowel and lung in SBRT treatment planning target [PTV]) may be triggered at the initial dose level).
88833431|NCT05678010|Experimental|Arm B, Dose Level 1|Participants have peripheral metastasis with bowel and lung in SBRT treatment planning target
88833432|NCT05678010|Experimental|Arm B, Dose Level 2|Participants have peripheral metastasis with bowel and lung in SBRT treatment planning target
88833433|NCT05678010|Experimental|Arm B, Dose Level 3|Participants have peripheral metastasis with bowel and lung in SBRT treatment planning target
88833434|NCT05678010|Experimental|Arm B, Dose Level 4|Participants have peripheral metastasis with bowel and lung in SBRT treatment planning target
89362086|NCT04574856|Experimental|Patients with Newly Diagnosed Glioblastoma|Patients will receive dose-intensified, adaptive photon radiation therapy
89362087|NCT04574219|Other|Feasibility/Acceptability|This arm will be used to assess the feasibility and acceptability of using FaceTime during induction.
89362088|NCT04574219|Other|Coaching prior to surgery|
88833435|NCT05669521|Experimental|TK112690|TK112690 treatment
88833436|NCT05669521|Placebo Comparator|Placebo|TK112690 formulation
89362089|NCT04574219|Other|Coaching day of surgery|
89362090|NCT04573881|Experimental|HistoSonics System|
89362091|NCT04573478|Experimental|Atrasentan|Once daily oral administration of 0.75 mg atrasentan for 132 weeks
89362092|NCT04573478|Placebo Comparator|Placebo|Once daily oral administration of placebo for 132 weeks
89362093|NCT04569461|Experimental|Single Arm|Subjects with unfavorable localized prostate cancer will be enrolled.This is a single arm, phase II study of pembrolizumab (Keytruda), SBRT, and Short-term Androgen Deprivation Therapy (STADT), known together as trimodality therapy, followed by radical prostatectomy 8 weeks after SBRT.
89362094|NCT04566263|Other|Successful embolization of intracranial aneurysms|Successful embolization of intracranial aneurysms defined by angiographic occlusion of greater than or equal to 90% at 6 months.
89362095|NCT04565236|Experimental|Part A: PTPs <12 years of age|Previously treated severe hemophilia A patients (PTPs) <12 years of age
89362096|NCT04565236|Experimental|Part A: PTPs ≥12 to 65 years of age|Previously treated severe hemophilia A patients (PTPs) ≥12 to 65 years of age
89362097|NCT04565236|Experimental|Part B: PUPs/MTPs <6 years of age|Previously untreated/minimally treated severe hemophilia A patients (PUPs/MTPs) <6 years of age
89362098|NCT04564833|Experimental|Low Dose RBT-1|Single IV infusion prior to cardiac surgery
89362099|NCT04564833|Experimental|High Dose RBT-1|Single IV infusion prior to cardiac surgery
89362100|NCT04564833|Placebo Comparator|Placebo|Single IV infusion prior to cardiac surgery
89362101|NCT04561232|Other|Locomotor Learning|"This study has three phases. The first phase of the study will be the observation of early spontaneous leg movements which will be measured monthly from 1-4 months of age.~The prone locomotor intervention phase using the Self-Initiated Prone Progression Crawler (SIPPC) will occur from 5-9 months of post-term age, or end earlier if the child achieves the ability to crawl six feet. Treatment will occur at an intensity of 3 times per week for 15-30 minutes. Infants will use the SIPPC for the duration of each therapy session~The upright locomotor intervention phase using DWS will occur from 9-18 months of age, or begin earlier if the child achieves the ability to crawl six feet before 9 months of age, and end earlier if the child achieves independent walking before 18 months of age. Treatment will occur at an intensity of 3 times per week for 30 minutes. Infants will receive dynamic weight support (DWS) for the duration of the 30-minute therapy session."
89362102|NCT04557540|Experimental|Arm I (Fasting WORD)|Participants receive the Fasting WORD intermittent fasting weight loss intervention consisting of 16 small-group lessons over 1.5 hours each QW for 2 months and then Q2W for 4 months.
89362103|NCT04557540|Experimental|Arm II (The WORD)|Participants receive The WORD CER weight loss intervention consisting of 16 small-group lessons over 1.5 hours each QW for 2 months and then Q2W for 4 months.
89362104|NCT04556305|Experimental|Mind - BrainHQ cognitive training intervention|The Mind intervention uses the evidence-based BrainHQ computerized cognitive training program. BrainHQ focuses on improving memory, attention, sensory function, and working memory, and has demonstrated efficacy in improving memory among healthy older adults and adults with heart failure. BrainHQ is tailored to the individual, and program difficulty automatically progresses based on performance. Training occurs during three 30-minute sessions per week, for a total of 36 hours. Participants will complete the BrainHQ program on an iPad tablet, which will be provided to them.
89362105|NCT04556305|Experimental|Move - lifestyle physical activity intervention|"The Move intervention is a 24-week evidence-based program based on social cognitive theory. It was originally developed for midlife women and successfully maintained increased physical activity. It has since been tailored for older women with CVD to prevent or delay cognitive decline, and includes: (1) education on the importance of lifestyle physical activity for brain health, (2) increasing lifestyle physical activity while considering CVD, and (3) including a goal for increasing Fitbit active minutes (≥ 3 METs or moderate-intensity physical activity) to ensure participants are obtaining the beneficial aerobic fitness effects during periods of lifestyle physical activity. Core elements include a personal lifestyle physical activity goal and five group meetings."
89362106|NCT04556305|Experimental|MindMoves - cognitive training and lifestyle physical activity|Participants who are assigned to this condition will complete both the Move lifestyle physical activity program and the Mind BrainHQ cognitive training intervention simultaneously for 24 weeks (see Move and Mind descriptions). Participants will receive both a Fitbit and iPad tablet to complete the combined MindMoves intervention.
89362107|NCT04556305|No Intervention|Usual Care|Participants in the usual care group do not receive any Mind- or Move-related intervention, and will receive their usual care from their cardiology provider.
89362108|NCT04554459|Experimental|ponatinib plus reduced-intensity chemotherapy|ponatinib plus reduced-intensity chemotherapy in first-line treatment of Adult Ph+ ALL
89362109|NCT04552613|Experimental|Standard programme group|EGFR-TKI targeted therapy
89362110|NCT04552613|Active Comparator|controlled programme group|EGFR-TKI targeted therapy combined chemotherapy(pemetrexed plus carboplatin for 4 cycles )
89362111|NCT04531839|Experimental|Intervention period|The 1.5-year period during which all six participating centers receive evidence-based collaborative quality improvement interventions including benchmarking, potential better practice list, PDSA implementation, and collaborative learning
89362112|NCT04531839|No Intervention|Baseline period|The 2-year period before the collaborative quality improvement intervention
89362113|NCT04528199|Experimental|[18F]FLOR (FC303)|[18F]FLOR (FC303) PET/CT imaging.
89362114|NCT04524195|Experimental|[18F]F-AraG|A one-time nominal injection dose of 5 millicurie (mCi) +/- will be administered at each PET/CT imaging time point.
88833437|NCT05667233|Active Comparator|Train to failure|Training regime will be highly uncomfortable since it will be both physically and psychologically challenging to push to momentary muscular fatigue (MMF; i.e., failure).
88817039|NCT03248908|Experimental|Intervention 1|Pupillary dilation reflex based perioperative intravenous remifentanil administration. Starting dose 5 ng/ml by continous infusion, dosage adjustments are made after pupillary dilation reflex assessment every 10 minutes. When PPI score is 1, the dosage is decreased with 0.2 ng/ml. When PPI score is greater than 1, the dosage is increased with 0.2 ng/ml.
88817040|NCT03248908|Active Comparator|Intervention 2|Anesthesiologist based perioperative intravenous remifentanil administration (daily practice, standard of care). Starting dose 5 ng/ml, dosage adjustments are made when deemed necessary by attending anesthesiologist.
88833438|NCT05667233|Active Comparator|Train to non-failure|Training regime will be moderately uncomfortable as participants will be training at a close proximity to failure (4-0 repetitions in reserve; i.e., non-failure).
88833439|NCT05661955|Experimental|Previously Treated UC Cohort A|BGB-A445 Monotherapy
88833440|NCT05661955|Experimental|Previously Treated UC Cohort B|BGB-A445 and Tislelizumab
88833441|NCT05661955|Experimental|Previously Treated RCC Cohort C|BGB-A445 Monotherapy
89189048|NCT03118063|Active Comparator|Latent trigger point|Assessment of the level of pain and function of asymptomatic individuals, compared with the time that they evolve with acute and chronic low back pain
89189049|NCT03118063|Active Comparator|No trigger point|Assessment of the level of pain and function of asymptomatic individuals, compared with the time that they evolve with acute and chronic low back pain
89189050|NCT00842998|Experimental|1 - Trastuzumab|Day1 Week1: 8 mg/kg iv in 90 min. Following 1st week: 2 mg/kg once/weekly for 8 weeks
89189051|NCT00842998|Experimental|2 - Lapatinib|1500 mg/die orally
89189052|NCT00806637|Experimental|1|Vessel sealing system uvulopalatoplasty (VSSU) is a new technique for uvulopalatoplasty using a special biclamp forceps for better hemostasis control. Vessel sealing system (VSS) is a bipolar vascular sealing system, with integrated active feedback control. The tissue is grasped and compressed by the handpiece. After the instrument is removed, the seal is visible as a semitransparent window, which can safely be divided. Uvular tip is grasped with an Allis clamp and retracted back toward the soft palate. Excision of the uvula and the redundant part of soft palate is performed by the VSS handpiece. VSS is also used for hemostasis.
89189053|NCT00806637|Active Comparator|2|Uvulopalatal flap (UPF) is a standard uvulopalatoplasty technique. Uvulopalatal flap is usually performed as described originally by Powell et al. The soft palate was injected with 5 to 10 milliliters of 1% lidocaine with epinephrine solution. The mucosa, submucosa with glands, and fat on the lingual surface of the uvula and soft palate were removed with a scalpel. Bleeding was controlled with bipolar electrocoagulation. The uvular tip was amputated, and reflected back toward the soft palate, and fixated into its new position with multiple sutures of 3-0 chromic catgut.
89189054|NCT00716768|Active Comparator|Laparoscopic Inguinal Hernia Repair|
89189055|NCT00716768|Active Comparator|Open Inguinal Hernia Repair|
89189056|NCT00716846|Active Comparator|statin-1|simvastatin
89189057|NCT00716846|Active Comparator|statin-2|atorvastatin
89189058|NCT00716846|Active Comparator|statin-3|pitavastatin
89189059|NCT00797979|Experimental|1|Skull Grip bone fixation
89189060|NCT00797979|Active Comparator|2|Standard skull bon flap fixation, sutures
89189061|NCT00620854|Experimental|rsCTA|Oral Tablet
89189062|NCT00620854|Experimental|rsCTB|Oral Tablet
89189063|NCT00620854|Active Comparator|Fortical|Nasal Spray
89189064|NCT05672966|Experimental|1-BV601DP(Low dose HPV vaccine with adjuvant)|Subjects received low dose of BV601DP
89189065|NCT05672966|Experimental|1-BV601DPP(Low dose HPV vaccine without adjuvant)|Subjects received low dose of BV601DPP
89189066|NCT05672966|Placebo Comparator|1-Placebo|Subjects received placebo
89189067|NCT05672966|Experimental|2-BV601DP(High dose HPV vaccine with adjuvant)|Subjects received high dose of BV601DP
89189068|NCT05672966|Experimental|2-BV601DPP(High dose HPV vaccine without adjuvant)|Subjects received high dose of BV601DPP
89189069|NCT05672966|Placebo Comparator|2-Placebo|Subjects received placebo
89189070|NCT00716924|Experimental|1|300-mg loading dose of clopidogrel given ≥ 6 and ≤ 24 hours before PCI
89189071|NCT00716924|Experimental|2|600-mg loading dose of clopidogrel given ≥ 6 hours and ≤ 24 before PCI.
89189072|NCT00716924|Experimental|3|600-mg loading dose of clopidogrel given immediately (≤ 45 minutes) before PCI.
89189073|NCT00798057||Proton Radiation|
89189074|NCT00430027|Experimental|Capecitabine, oxaliplatin, cetuximab, and radiation therapy|Patients enrolled on the trial will receive neoadjuvant combined capecitabine, oxaliplatin, cetuximab, and radiation therapy. This will be followed by surgical resection and adjuvant capecitabine, oxaliplatin, and cetuximab
89189075|NCT04043182|No Intervention|group control|You will not receive any type of intervention
89189076|NCT04043182|Experimental|treatment group (ultrasound)|Will perform protocols of 10 sessions of ultrasound in the region of abdomen
89189077|NCT04043182|Placebo Comparator|placebo group|It will perform protocols of 10 sessions of ultrasound in the region of abdomen, but the apparatus will be with zero intensities
89189078|NCT00717002||1|Patients from Group 1 will undergo thoracoscopy as part of their routine clinical management to drain off excess pleural fluid. Even though taking a sample of the tumour tissue present on the pleural/ lining of the lung may not routinely form part of a routine thoracoscopy, it will be obtained for the study and sent to the laboratory for testing.
89189079|NCT00717002||2|Patients from Group 2 should have tumour samples obtained previously for diagnosis, and these will be obtained from the Department of Pathology. If they are undergoing thoracoscopy as part of their routine clinical management, a sample of the tumour tissue present on the pleural/ lining of the lung will also be obtained during the procedure and sent to the laboratory for testing.
89189080|NCT04043260|Experimental|Intervention|Subject's glucose and insulin data will be transferred to the DreaMed Advisor Pro system. Optimization of insulin treatment plan will be done using the DreaMed Advisor Pro algorithm. After approval by the study physician (may override the suggestions for safety reasons), the treatment plan will be sent to the subject to be followed for the following 3 weeks. The study team will follow-up with a phone call to the subject to verify the subject received the updated treatment plan.
89189081|NCT00717080|Experimental|Arm 1|IOL surgery with Capsular Tension Ring
89362115|NCT04520048|Experimental|Women with gestational hypertension and/or preeclampsia|Pregnant patients from the 20th week of amenorrhea with the initial diagnosis of gestational hypertension and/or preeclampsia. Patients in a stable state undergoing follow-up consultation (day hospital and week hospitalization)
89362116|NCT04518072||Biopsy prostatic group|positive biopsy (100) negative biopsy (100)
89362117|NCT04518072||Control group|No prostate cancer (50)
89362118|NCT04517656|Experimental|patients with hematologic malignancy|Adult patient, over 18 years old, suffering from a malignant hemopathy (without exception) for whom an allogeneic hematopoietic stem cell transplant from a related or unrelated donor is indicated
89362119|NCT04517552||Experimental: [11C] CS1P1|
89362120|NCT04505813|Experimental|Safety Evaluation Phase|Treatment with NEXI-002 T cells, derived from PBMCs of the patient
89362121|NCT04505813|Experimental|Dose Expansion Phase|Dose Expansion Phase to further define the safety, tolerability and initial anti-tumor efficacy of the NEXI- 002 T cell product at the dose established from the Safety Evaluation Phase.
89362122|NCT04497220|Placebo Comparator|Nocebo Group|Participants in this group will receive the control treatment
89362123|NCT04497220|Experimental|Positive Connotation Group|Participants in this group will receive the experimental treatment.
89362124|NCT04483947|Experimental|Cohort 1|15 participants will receive AZD2693 dose 1 and 5 participants will receive placebo
89362125|NCT04483947|Experimental|Cohort 2|15 participants will receive AZD2693 dose 2 and 5 participants will receive placebo
89362126|NCT04483947|Experimental|Cohort 3|15 participants will receive AZD2693 dose 1 and 5 participants will receive placebo
88833442|NCT05661955|Experimental|Previously Treated RCC Cohort D|BGB-A445 and Tislelizumab
88833443|NCT05661955|Experimental|Previously Treated Melanoma Cohort E|BGB-A445 Monotherapy
89362127|NCT04483947|Experimental|Cohort 4|15 participants will receive AZD2693 dose 3 and 5 participants will receive placebo
89362128|NCT04482478|Experimental|EDL(Extract of Dolichos lablab Linne)|The randomly assigned target was given a Extract of Dolichos lablab Linne (EDL) 715 mg/day for 12 weeks.
89362129|NCT04482478|Placebo Comparator|Placebo comparator|The randomly assigned target was given a placebo for 12 weeks.
88833444|NCT05661955|Experimental|Previously Treated Melanoma Cohort F|BGB-A445 and Tislelizumab
88833445|NCT05658016|Experimental|TK112690|TK112690 treatment
88833446|NCT05658016|Placebo Comparator|Placebo|TK112690 formulation
89362130|NCT04482062|Experimental|Edwards EVOQUE System & OMT|Transcatheter tricuspid valve replacement with the Edwards EVOQUE System in conjunction with optimal medical therapy (OMT) in patients with tricuspid regurgitation
89362131|NCT04482062|Active Comparator|Optimal Medical Therapy (OMT)|Optimal medical therapy (OMT) alone in patients with tricuspid regurgitation
89362132|NCT04482062|Experimental|Single-Arm Registry|Transcatheter tricuspid valve replacement with the Edwards EVOQUE System in conjunction with optimal medical therapy (OMT) in patients with tricuspid regurgitation who are not eligible for randomization
88833447|NCT05657938||DMD Patients|Ambulatory males aged 4 to <13 years with Duchenne Muscular Dystrophy
88833448|NCT05657938||Age Matched Controls|Normal male age-matched controls
89362133|NCT04482062|Experimental|Continued Access Study|Provides continued access to transcatheter tricuspid valve replacement with the Edwards EVOQUE System in conjunction with optimal medical therapy (OMT) in patients with tricuspid regurgitation.
89362134|NCT04480008|Experimental|Resilient Living Program|All participants will be in the Resilient Living Program arm. Study participation involves participating in a 12-week stress management and resilience training program. This will involve four virtual sessions (video or phone) and answering questions about their health, well-being, and quality of life. There will also be online modules to watch and an accompanying journal (with prompts) to keep.
89362135|NCT04479475|Experimental|Supportive care through social support persons|MMT participants will attend seven sessions over the course of six weeks to build social support systems and make progress toward drinking and drug use goals. Social support persons identified by participating MMT clients will jointly attend up to five sessions over the course of six weeks.
89362136|NCT04474600|Experimental|TIVA group|Patients receiving the total intravenous anesthesia using propofol
89362137|NCT04474600|Active Comparator|Inhalation group|Patients receiving inhalation anesthesia using desflurane
89362138|NCT04469218|No Intervention|Control Group|Subjects in the control group will receive the standard of care intervention for peripheral IVs at the study hospital.
89362139|NCT04469218|Experimental|SafeBreak Vascular Group|Subjects in the SafeBreak Vascular group will have as near to identical treatment as possible to the control group with the exception that a SafeBreak Vascular device will be placed in the peripheral IV line.
89362140|NCT04468321|Experimental|Apple Watch|Patients will be provided with the Apple Watch Series 6 with Irregular Rhythm Detection and ECG capabilities.
88833449|NCT05648773|Experimental|Message Only|Email or SMS Booster Vaccination Reminder
88833450|NCT05648773|Experimental|Message + Financial Incentive|Email or SMS Booster Vaccination Reminder + Offer of a financial incentive for getting boosted in the next 2 weeks.
88833451|NCT05648773|Placebo Comparator|Control|No message or financial incentive
88833452|NCT05648630|Experimental|Exercise Rehabilitation+PB125|Participants will be assigned to the Exercise+Placebo or Exercise+PB125 rehabilitation interventions using block randomization.
89362141|NCT04468321|Placebo Comparator|Withings Move|Patients will be provided with the Withings Move with activity tracking.
88833453|NCT05648630|Placebo Comparator|Exercise Rehabilitation with Placebo|Participants will be assigned to the Exercise+Placebo rehabilitation interventions using block randomization.
88833454|NCT05646446|Experimental|REACH Program|The REACH program addresses alcohol use, sexual assault risk, and experiences relating to experiences of harm among bisexual women.
88833455|NCT05646446|No Intervention|Wait List Control Group|The Wait List Control Group will have the opportunity to complete the REACH program after completing study assessments at the 4-month follow-up.
88833456|NCT05646082|Experimental|Open Label|
88833457|NCT05645016|Experimental|Adapted Comprehensive Overdose Education and Skills Training (COEST)|
89362142|NCT04467515|Experimental|Dose Escalation and Expansion|"The dose escalation phase of the study will be an open label 3 + 3 design, where at least 3 patients are treated at each dose level. Dose escalation will be done via increases of the nominal activity of CAM-H2 in cohorts of 3 to 6 patients.~In the dose expansion phase of the study, the patients will be given the RDP2 determined in the dose escalation phase. Similar to the dose escalation phase, all patients will receive at least 1 cycle of CAM-H2."
89362143|NCT04464603|Experimental|Arm A (InterFACE)|"Participants that will use the mHeath InterFACE tool during the simulation-based pediatric scenario.~Each participant will have to do 2 consecutive scenarios (PALS, ATLS)."
89362144|NCT04464603|Active Comparator|Arm B (Conventional methods)|"Participants that will use conventional methods during the simulation-based pediatric scenario.~Each participant will have to do 2 consecutive scenarios (PALS, ATLS)."
89362145|NCT04458051|Experimental|SAR442168|Dose 1 of oral SAR442168 once daily
88833458|NCT05640271|Experimental|Early Tocilizumab|This arm will receive tocilizumab 80 mg at the time of acute chest syndrome diagnosis and subsequent randomization. Then, two days later, they will receive 50 mL of normal saline.
89362146|NCT04458051|Placebo Comparator|Placebo|Placebo to match the SAR442168 once daily
89362147|NCT04454515|Experimental|dexmedetomidine|patient recieving dexmedetomidine
89362148|NCT04454515|Placebo Comparator|placebo|patients receiving placebo
89362149|NCT04452981|Active Comparator|Active|The active device utilizes a technology termed vestibular nerve stimulation (VeNS). The device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 1 hour per day.
89362150|NCT04452981|Sham Comparator|Sham|The sham device looks identical to the active device and interacts with the app in a similar manner to the active device. It will apply some stimulation to a user for a limited period of time (30 seconds), before tapering down to zero over a further 20 seconds, thus creating the impression of an active device. The device will be placed on the head in a manner analogous to headphones with hydrogel electrodes placed over the mastoid processes. Participants will be advised to use the device at home for 1 hour per day.
89362151|NCT04450771|Experimental|Family-based Treatment for ARFID(FBT-ARFID)|FBT-ARFID is a manualized treatment based on the model of FBT that employs the same interventions as standard FBT for AN and BN: externalization, agnosticism, parental empowerment, a behavioral focus on changing eating behavior. Early sessions focus on inciting parents to make changes and include a family meal that allows therapists to observe & consult directly to mealtime behaviors. FBT-ARFID for children 12 and under is manualized and consists of 2 phases. The first phase is focused on parents taking charge & changing the eating behaviors of their child that are maintaining ARFID. The second phase focuses on the child taking up in an age-appropriate way managing their eating consistent with the changes the parents have employed in phase 1. Fourteen 1-hour sessions will be conducted approximately weekly over 4 months. Throughout medical monitoring and weekly dietary consultation are available to the family.
88833459|NCT05640271|Active Comparator|Delayed Tocilizumab|This arm will receive 50 mL of normal saline at the time of acute chest syndrome diagnosis and subsequent randomization. Then, two days later, they will receive tocilizumab 80 mg. Thus, this delayed arm will serve as a placebo comparator for the first 48 hours and then as an active comparator for the remaining duration on study.
89362152|NCT04450771|Active Comparator|Manualized Non-Specific Usual Care for ARFID(NSC)|A manualized non-specific psycho-educational and motivational enhancement approach that is based on a supportive non-directive psychotherapy model that has been used in other RCTs with eating disorders as a comparison. NSC consists of sessions with the child alone and 5 parent-only meetings. Sessions are 1-hour. NSC matches FBT-ARFID for time and therapist attention. The focus of the NSC intervention is psychoeducation about health & social impacts of restrictive eating and supporting parent & child exploration of motivation to change eating patterns & choices they make about changes to eating. The therapist does not initiate behavioral or cognitive interventions. Feelings about eating and making changes are explored in both the child and parent sessions. Medical and dietary advice are provided weekly.
89362153|NCT04444102|No Intervention|Control group (CG)|Those subjects randomized to the CG will be offered reading options that do not evoke high emotional distress. They will spend an hour reading.
89362154|NCT04444102|Experimental|Stretching protocol 1, Mild Stretching Group (MSG)|The protocol starts with 5 minutes of instruction about finding a range of stretching representing approximately 50% of the range of motion and pain-free. The instructor will also wear wrist and ankle reflective bands as body-marks to show a posture with 100% stretch and then corrected to 50%. Once the participant grasps the concept the routine will begin with 5 minutes of warm-up, followed by stretching exercises targeting 10 anatomical groups. Each posture will last 1 minute divided in 30 seconds of settling into each posture and 30 seconds of holding. Each session will be video recorded to analyze the stretching range, only if the participant agrees at the informed consent visit. Participants will be encouraged to find their own 50% with some feedback from the instructor.
88833460|NCT05633862|Experimental|BI 1015550 low dose|
88833461|NCT05633862|Experimental|BI 1015550 high dose|
88833462|NCT05632861|Experimental|Experimental group|HuHuangLianzonggan capsule, 4 pills, take orally after meals, 2 times a day
88833463|NCT05632861|Placebo Comparator|Placebo group|HuHuangLianzonggan capsule placebo, 4 pills, take orally after meals, 2 times a day
88833464|NCT05628597|Active Comparator|Fos Biomedical patch product|Participants will be randomized to 1 of 2 sequence permutations of the Fos Biomedical patch product and a placebo patch product, which will begin after randomization.
88833465|NCT05628597|Placebo Comparator|Fos Biomedical product: placebo|Participants will be randomized to 1 of 2 sequence permutations of the Fos Biomedical patch product and a placebo patch product, which will begin after randomization.
88833466|NCT05624047|Experimental|Experimental Group|Breastfeeding education using the hybrid simulation method
88833467|NCT05624047|Other|Control Group|Routine verbal breastfeeding education
88833468|NCT05621811|Experimental|Naronapride 10 mg|
88833469|NCT05621811|Experimental|Naronapride 20 mg|
88833470|NCT05621811|Experimental|Naronapride 40 mg|
88833471|NCT05621811|Placebo Comparator|Placebo|
88833472|NCT05616858|Experimental|Intervention group|Group with exercise program
88833473|NCT05616858|No Intervention|Control group|Group without exercise program
88833474|NCT05615597|Other|Para-discal infiltration|Single arm study
88833475|NCT05606380|Experimental|HLX60 Group|The initial dose of HLX60 is 0.5mg/kg, and 5 dose levels are designed: 2mg/kg, 5mg/kg, 15mg/kg and 25mg/kg (Q3W). Patients will receive the treatment until without any clinical benefit, death, intolerable toxicity, or withdraw the informed consent (whichever occurs first)
89189082|NCT00717080|Placebo Comparator|Arm 2|IOL surgery without Capsular Tension Ring
88833476|NCT05605340|Experimental|Intervention|Meal delivery intervention with brief behavioral support.
88833477|NCT05603429||CABG with cold blood cardioplegia|Subjects undergo Elective Coronary Artery Bypass Grafting with the use of cold blood cardioplegia solution for myocardial protection
88833478|NCT05603429||CABG with Del Nido|Subjects undergo Elective Coronary Artery Bypass Grafting with the use of Del Nido cardioplegia solution as myocardial protection
88833479|NCT05603429||AVR with cold blood cardioplegia|Subjects undergo Aortic Valve Replacement with the use of cold blood cardioplegia solution as myocardial protection
89189083|NCT04766229|Experimental|Single Arm|All participants in single arm study
89189084|NCT00844948||Young adults (18-25 years old)|Young adults (18-25 years old). Major Depressive - eligible subjects will meet a baseline depression severity score of 10 or greater on the QIDS-C & QIDS-IVR, will have recently started treatment or about to start receiving treatment for MDD. Exclusion: subjects with suicidal ideation; subjects who have a history or current diagnosis of the following DSM-IV psychiatric illness: organic mental disorder, schizophrenia, schizoaffective disorder, delusional disorder, psychotic disorders not otherwise specified, bipolar disorder, patients with mood congruent or mood incongruent psychotic features, patients with substance dependence disorders, other than alcohol, active within the last 12 months; subjects with a history or current diagnosis of dementia or diagnosis or history of hypothyroidism.
89189085|NCT00844948||Elderly (60-80 years old)|Elderly (60-80 years old). Major Depressive - eligible subjects will meet a baseline depression severity score of 10 or greater on the QIDS-C & QIDS-IVR, will have recently started treatment or about to start receiving treatment for MDD. Exclusion: subjects with suicidal ideation; subjects who have a history or current diagnosis of the following DSM-IV psychiatric illness: organic mental disorder, schizophrenia, schizoaffective disorder, delusional disorder, psychotic disorders not otherwise specified, bipolar disorder, patients with mood congruent or mood incongruent psychotic features, patients with substance dependence disorders, other than alcohol, active within the last 12 months; subjects with a history or current diagnosis of dementia or diagnosis or history of hypothyroidism.
89189086|NCT00844948||Chinese speakers|Chinese speakers (Mandarin or Cantonese). Major Depressive - eligible subjects will meet a baseline depression severity score of 10 or greater on the QIDS-C & QIDS-IVR, will have recently started or about to start receiving treatment for MDD. Exclusion: subjects with suicidal ideation; subjects who have a history or current diagnosis of the following DSM-IV psychiatric illness: organic mental disorder, schizophrenia, schizoaffective disorder, delusional disorder, psychotic disorders not otherwise specified, bipolar disorder, patients with mood congruent or mood incongruent psychotic features, patients with substance dependence disorders, other than alcohol, active within the last 12 months; subjects with a history or current diagnosis of dementia or diagnosis or history of hypothyroidism.
89189087|NCT04068506|Experimental|Group A|Gabapentin 600 mg Tab
89189088|NCT04068506|Active Comparator|Group B|Paracetamol 1000 mg Tab
89189089|NCT00851188|Experimental|internet CBT self-help|CBT via the internet
89189090|NCT00851188|Experimental|CBT self-help booklet|
89189091|NCT00851188|Active Comparator|Waiting list|
89189092|NCT04068740||Mitral valve disease|
89189093|NCT04068740||Aortic valve disease|
89189094|NCT00803907|Experimental|nodular BCC of the eyelid|Patients with nodular BCC of the eyelid
89189095|NCT00843154|Experimental|Candesartan QD|
89189096|NCT00843154|Active Comparator|Standard chronic heart disease therapy|
89189097|NCT00719654||EOS-Preeclampsia|Women with symptoms of early-onset preeclampsia
89189098|NCT00719654||Normal|Women who do not have symptoms of early-onset preeclampsia
89189099|NCT00803985|Active Comparator|Lichtenstein|Open operation with onlay light weight polypropylene mesh
89189100|NCT00803985|Active Comparator|Total Extraperitoneal repair (TEP)|Laparoscopic operation with preperitoneal nonfixated mesh
89189101|NCT00429793|Experimental|Treatment (temsirolimus)|Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89189102|NCT00851266|Experimental|1|V512
89189103|NCT00851266|Placebo Comparator|2|Placebo to V512
89189104|NCT04067570|Experimental|SBRT post operative|"Stereotactic Body Radiotherapy (SBRT) 30 Gy in 5 fractions, once weekly to prostate bed~/ - 25 Gy in 5 fractions, once weekly simultaneously to pelvic lymph nodes~/ - 6-24 months of androgen deprivation therapy (ADT)"
89189105|NCT00806871|Active Comparator|A|
89189106|NCT00806871|Active Comparator|B|
89189107|NCT00806871|Placebo Comparator|C|
89189108|NCT00843232||Elderly T2DM|Elderly T2DM subjects 65 to 80 years old
89189109|NCT00843232||Middle-age T2DM|Middle-age T2DM subjects 35 to 50 years old
89189110|NCT00717158|No Intervention|I|Usual medical care. They received written healthy lifestyle information
89189111|NCT00717158|Active Comparator|2|Intervention participants were assigned to one registered dietitian who they met with over a one year period for 6 session (four hours) of individual care, 6- one-hour group classes, and had monthly email contact for follow up and checking in
89189112|NCT00855400|Experimental|Transplant|T3-T4 laminectomy and bone marrow ficoll separated mononuclear autologous cells intraspinal transplantation
89189113|NCT00798213|Experimental|Participants with AML randomized to SCH 727965|
89189114|NCT00798213|Active Comparator|Participants with AML randomized to gemtuzumab ozogamicin|
89189115|NCT00798213|Experimental|AML treated w/ SCH 727965 after prog. on gemtuzumab ozogamicin|
89189116|NCT00798213|Experimental|Participants with ALL treated with SCH 727965|
88833480|NCT05603429||AVR with Del Nido|Subjects undergo Aortic Valve Replacement with the use of Del Nido cardioplegia solution as myocardial protection
88833481|NCT05602961|Experimental|Cohort 1 (includes GLB-COV2-043 15 μg)|12 eligible adult participants will be randomized to 15 ug of GLB-COV2-043 or to 30 ug of BNT162b2/COMIRNATY®, active control with a 5:1 allocation ratio.
88833482|NCT05602961|Experimental|Cohort 2 (includes GLB-COV2-043 30 μg)|12 eligible adult participants will be randomized to 30 ug of GLB-COV2-043 or to 30 ug of BNT162b2/COMIRNATY®, active control with a 5:1 allocation ratio.
88833483|NCT05602961|Experimental|Cohort 3 (includes GLB-COV2-043 60 μg)|12 eligible adult participants will be randomized to 60 ug of GLB-COV2-043 or to 30 ug of BNT162b2/COMIRNATY®, active control with a 5:1 allocation ratio.
88833484|NCT05602961|Experimental|Cohort 4 (includes GLB-COV2-043 90 μg)|12 eligible adult participants will be randomized to 90 ug of GLB-COV2-043 or to 30 ug of BNT162b2/COMIRNATY®, active control with a 5:1 allocation ratio.
88833485|NCT05594238|Active Comparator|Arm A|First stage intervention: Telephone engagement Second stage intervention: Telehealth Motivational Interviewing-Cognitive Behavioral Therapy (MI-CBT program)
88833486|NCT05594238|Active Comparator|Arm B|First stage intervention: Telephone engagement Second stage intervention: Enhanced Telephone engagement
88833487|NCT05594238|Active Comparator|Arm C|First stage intervention: Telephone engagement Second stage intervention: Not Applicable (NA), proceed directly to follow up
88833488|NCT05594238|Active Comparator|Arm D|First stage intervention: Portal Engagement Second stage intervention: NA, proceed directly to follow up
88833489|NCT05594238|Active Comparator|Arm E|First stage intervention: Portal Engagement Second stage intervention: Enhanced Portal Engagement
88833490|NCT05594238|Active Comparator|Arm F|First stage intervention: Portal Engagement Second stage intervention: Telehealth MI-CBT program
88833491|NCT05593796|Active Comparator|treatment-as-usual (TAU)|
88833492|NCT05593796|Active Comparator|Clinician-delivered CBT with tratment as usual|
88833493|NCT05586776|Active Comparator|Decolonization|Participants randomized into this arm will perform decolonization using topical antiseptic soap (chlorhexidine body wash) and an antibiotic ointment (nasal mupirocin).
88833494|NCT05586776|Placebo Comparator|Routine Care|Participants randomized into this arm will perform routine care using soap without antiseptic properties (placebo) and placebo nasal ointment.
88833495|NCT05584800|Experimental|Dose Escalation|
88833496|NCT05584800|Experimental|Dose Expansion|Tumor type: colorectal cancer，pancreatic cancer
89189117|NCT04069208|Experimental|IA14|Idarubicin 14mg/m2 for 3 days cytarabine 100mg/m2 every 12 hour for 7 days
89189118|NCT04042246|No Intervention|Control|No intervention is implemented among Control
89189119|NCT04042246|Experimental|Treatment (Educational Information on Vaccination)|Provide general and tailored information on vaccination and vaccination schedule at the end of the baseline survey
89189120|NCT04067258||Beta-Thalassemia group|Patients suffering from beta thalassemia major or intermedia will be included in this group
89189121|NCT04067258||Control group|Healthy age and sex matched volunteers will be included in this group
89189122|NCT00807027|No Intervention|Control Group|The study subjects randomly assigned to the control group is given Temozolomide chemotherapy and radiation therapy for 6 weeks according to the clinical test plans, and then administers Temozolomide only for 6 weeks.
89189123|NCT00807027|Experimental|Test Group|The study subjects assigned to the test group blood is drawn before minimum 2 weeks in order to manufacture the test drug. Test group is compared its progression free survival rate after surgery by administering Temozolomide chemotherapy and radiation therapy same as control group with Immuncell-LC (14 times).
89189124|NCT00424645|Experimental|Voraxaze|Voraxaze administered 50 units/kg intravenously (IV) repeated a maximum of 2 times in a given cycle of chemotherapy.
89189125|NCT00424645|Placebo Comparator|Placebo|Placebo administered IV following Voraxaze arm.
89189126|NCT00717392||Hippotherapy_ADHD|10 children with ADHD who receive hippotherapy
89189127|NCT00717392||Hippotherapy_ASD|10 children with ASD who receive hippotherapy
89189128|NCT00717392||Control_ADHD|10 children with ADHD who DO NOT receive hippotherapy
89189129|NCT00717392||Control_ASD|10 children with ASD who DO NOT receive hippotherapy
89189130|NCT00845104|Experimental|Arm I|See Detailed Description
89189131|NCT00804063||1|glaucoma patients
89189132|NCT00804063||2|non-glaucoma controls
89189133|NCT02553681|Experimental|HPT treated|Hydra-PEG Treatment (HPT) treated RGP contact lenses made from roflufocon D
89189134|NCT02553681|Active Comparator|untreated|untreated RGP contact lenses made from roflufocon D
89189135|NCT01034605|Experimental|inulin|oligofructose
89189136|NCT03994939|Experimental|Intervention|Received Families Talking Together (FTT) intervention, an evidence-based program designed to increase parent-adolescent communication about sex in order to delay sexual debut and prevent negative sexual and reproductive health outcomes in adolescents age 10-14. The FTT intervention consisted of two components. Component 1 was comprised of 2 FTT intervention sessions between a parent and bilingual/bicultural promotor trained to deliver FTT in English or Spanish. These sessions highlighted adverse health consequences of sex to motivate parents to communicate with their adolescent and provided guidance to parents on communication strategies. Component 2 was comprised of written supplemental materials that promotores used to guide each intervention session. Experimental condition families will complete all measurement assessments.
89189137|NCT03994939|No Intervention|Control|Parents randomized to the control group did not receive any intervention sessions and only completed assessment questionnaires.
89189138|NCT00763451|Experimental|Lixisenatide (Two-Step Titration)|2-step initiation regimen of lixisenatide: 10 microgram (mcg) once daily (QD) for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment.
89189139|NCT00763451|Experimental|Lixisenatide (One-Step Titration)|1-step initiation regimen of lixisenatide: 10 mcg QD for 2 weeks, then 20 mcg QD up to the end of treatment.
89189140|NCT00763451|Placebo Comparator|Placebo (Two-Step Titration)|2-step initiation regimen of volume matching placebo: 10 mcg QD for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment.
89362155|NCT04444102|Experimental|Stretching protocol 2, Intense Stretching Group (ISG):|The protocol starts with 5 minutes of instruction about finding a range of stretching representing approximately 100% of the range of motion and pain-free. The instructor will also wear wrist and ankle reflective bands as body-marks to show a posture with 100% stretch. Once the participant grasps the concept the routine will begin with 5 minutes of warm-up, followed by stretching exercises targeting 10 anatomical groups. Each posture will last 1 minute divided in 30 seconds of settling into each posture and 30 seconds of holding. Each session will be video recorded to analyze the stretching range, only if the participant agrees at the informed consent visit. Participants will be encouraged to find their own 100% with some feedback from the instructor.
89362156|NCT04442373||Patients undergoing THR with no known bone neoplasm|Pre- and postoperative blood sampling for ROTEM assessment in THR patients
89362157|NCT04442373||Patients undergoing THR with known bone neoplasm|Pre- and postoperative blood sampling for ROTEM assessment before and after THR in patients with bone neoplasm
89362158|NCT04411849|Experimental|Group I (intervention)|Participants receive the HPV self-testing intervention consisting of mailed HPV self-test devices. Participants also receive an information about cervical cancer. Participants who do not return their self-test within a few weeks receive telephone-based patient navigation.
89362159|NCT04411849|Active Comparator|Group II (usual care continued)|Participants receive usual care consisting of a reminder letter to get a clinic-based cervical cancer screening test and information about cervical cancer.
89362160|NCT04409782|Experimental|Arm 1|Our study will be largely advertised to DCC's patients and caregivers via electronic provider portal BPA. Providers will provide prospective participants with a link to an online survey where they can consent, complete eligibility screening, the pretest, and contact information.
89362161|NCT04409782|Experimental|Arm 2|People with social medial accounts (e.g. Facebook) will receive a message about the study (e.g. via a geospatially targeted Facebook ad) and have the option to enroll in the study if meeting eligibility criteria, with some participating in online follow-up.
89362162|NCT04408625|Experimental|Initial Cohort - Low dose|
89362163|NCT04408625|Experimental|Initial Cohort - Medium dose|
89362164|NCT04408625|Experimental|Bridging Cohort - Low dose|Participants enrolled in the Bridging Cohort will be assigned to either low or medium dose in an alternating manner
89362165|NCT04408625|Experimental|Bridging Cohort - Medium dose|Participants enrolled in the Bridging Cohort will be assigned to either low or medium dose in an alternating manner
89362166|NCT04408105||Primary Care Providers|400 eligible primary care providers (PCPs) will be recruited across the 7 participating sites to complete an anonymous survey. The survey will be distributed to eligible PCPs by the study site research coordinator via anonymous REDCap internet survey with 2 additional automated electronic reminders. There will also be opportunities for providers to complete a paper survey at PCP clinic meetings which will be collected by only the site research coordinator to maintain response anonymity.
89362167|NCT04408105||Gastroenterologists|100 eligible gastroenterologists (GIs) will be recruited across the 7 participating sites to complete an anonymous survey. The survey will be distributed to eligible GIs by the study site research coordinator via anonymous REDCap internet survey with 2 additional automated electronic reminders. There will also be opportunities for GIs to complete a paper survey at provider clinic meetings which will be collected by only the site research coordinator to maintain response anonymity.
89362168|NCT04408105||Patients|500 eligible patients will be recruited across the 7 participating sites to complete a survey. The survey will be distributed to eligible patients at the time of a clinic appointment, via telephone, or via a REDCap internet survey that will allow for 2 additional electronic phone call reminders and 1 email reminder.
89362169|NCT04398524|Experimental|single arm|ISA101b 4 times plus cemiplimab every 3 weeks for up to 24 months
89362170|NCT04398316|Experimental|Intravenous Lidocaine|Administered at a dose of 2 mg/kg over 5 minutes
89362171|NCT04398316|Active Comparator|Intravenous Hydromorphone|Administered at a dose of 1 mg over 5 minutes
88817041|NCT03248908|Experimental|Intervention 3|Pupillary dilation reflex based perioperative intravenous sufentanil administration. Starting dose 0.1 mcg/kg bolus, dosage adjustments are made after pupillary dilation reflex assessment every 10 minutes. When PPI score is 1, no supplementary administration is executed. When PPI score is greater than 1, a supplementary bolus of 0.1 mcg/kg is given.
88817042|NCT03248908|Active Comparator|Intervention 4|Anesthesiologist based perioperative intravenous sufentanil administration (daily practice, standard of care). Starting dose 0.1 mcg/kg bolus, dosage adjustments are made when deemed necessary by attending anesthesiologist.
88817043|NCT03184233|Other|Cerebral aneurysm surgery with RVP|Subjects receive a Magnetic Resonance Imaging of the brain pre-and postoperatively as standard of care. To screen for rapid ventricular pacing induced micro-infarcts, the contralateral hemisphere (contralateral to the hemisphere operated on) and fossa posterior will be evaluated. Troponin levels will be determinated preoperatively, peroperative and at 6, 12 and 24 hours postoperative by blood sample. Maximum cTnl level and cTnl level 24 hours will be compared. Brain oxygenation (Sct O₂) by near-infrared spectroscopy will be monitored. During surgery subjects allocated in this study arm will undergo RVP.
88818054|NCT02255513|Placebo Comparator|Placebo|"Placebo capsules (dose matched to HLD200 capsules)~Subjects were allowed to titrate to their optimal HLD200 dose during a 6 week open-label, treatment optimization phase before being randomized to receive placebo treatment over a one week double-blind, placebo-controlled phase. Treatments were administered orally, once daily each evening."
88818055|NCT01778465|Experimental|Low salicylate diet, then Normal Diet|Patients followed a low salicylate diet for one week, then they followed a Normal diet for another week.
89362172|NCT04396808|Active Comparator|Standard of care (no pre-treatment genomics testing)|Provider will discuss askMUSIC results with patient prior to deciding on a management strategy (standard of care).
89362173|NCT04396808|Active Comparator|Standard of care + pre-treatment genomics testing|Provider will discuss askMUSIC and Gene Expression Classifier (GEC) results with patient prior to deciding on a cancer management strategy. Patients' biopsy tissue will be analyzed using one of the following GECs: Decipher, Prolaris or Oncotype Dx.
89362174|NCT04359758|Experimental|Proactive Streamlined Genetic Education and Testing|Participants randomized to this arm will proactively receive genetic education print materials and the option to proceed directly with genetic testing.
89362175|NCT04359758|Active Comparator|Usual Care|Participants in this arm will be sent a referral letter recommending that they schedule a genetic counseling session and providing them with contact information to do so.
88818056|NCT01778465|Experimental|Normal diet, then Low Salicylate diet|Patients followed a Normal diet for one week, then they followed a Low Salicylate diet for another week.
89362176|NCT04358107||1|Medical records of subjects enrolled on various ACC studies conducted by CCR
88818057|NCT01779167|Experimental|All Patients|Daily alternating thalidomide and lenalidomide plus rituximab (ThRiL) in patients with previously treated WM
88818058|NCT01780337|Active Comparator|Oxytocin|Patients will be administered an intranasal dose of the study drug, 20 IU oxytocin. Repeat electrophysiologic measurements will be assessed at 15 minutes and 30 minutes after administration of the study medication/placebo. During the waiting periods in between the electrophysiologic measurements, we will continue with the standard protocol for an AF ablation, including transseptal puncture and left atrial mapping, performed prior to initiation of general anesthesia and actual delivery of ablation lesions. This 'preablation' period normally takes 45 minutes to one hour.
89362177|NCT04353973|Experimental|ARM A|"Visit 1/Pre-Test Session - Standard-of-Care Pre-Test Counseling with a genetic counselor either in-person or by remote services (Telephone or Video Conferencing).~Visit 2/Disclosure Session - Standard-of-Care Post-Test Counseling with a genetic counselor either in-person or by remote services (Telephone or Video Conferencing)."
89362178|NCT04353973|Experimental|ARM B|"Visit 1/Pre-Test Session - Standard-of-Care Pre-Test Counseling with a genetic counselor either in-person or by remote services (Telephone or Video Conferencing).~Visit 2/Disclosure Session - Self-directed web-based eHealth result disclosure intervention."
89362179|NCT04353973|Experimental|ARM C|"Visit 1/Pre-Test Session - Self-directed web-based eHealth pre-test session intervention.~Visit 2/Disclosure Session - Standard-of-Care Post-Test Counseling with a genetic counselor either in-person or by remote services (Telephone or Video Conferencing)."
89362180|NCT04353973|Experimental|ARM D|"Visit 1/Pre-Test Session - Self-directed web-based eHealth pre-test session intervention.~Visit 2/Disclosure Session - Self-directed web-based eHealth result disclosure intervention."
89534546|NCT03330431|Experimental|Experimental group 1 (personal expert)|Participants watch a video of an expert describing the positive effects of Progressive Muscle Relaxation (PMR) with personalized examples and stories before undergoing a PMR session.
89534547|NCT03330431|Experimental|Experimental group 2 (factual expert)|Participants watch a video of an expert describing the positive effects of Progressive Muscle Relaxation (PMR) with factual information (not personal) before undergoing a PMR session.
88818059|NCT01780337|Placebo Comparator|Saline|Patients will be administered an intranasal dose of saline. Repeat electrophysiologic measurements will be assessed at 15 minutes and 30 minutes after administration of the study medication/placebo. During the waiting periods in between the electrophysiologic measurements, we will continue with the standard protocol for an AF ablation, including transseptal puncture and left atrial mapping, performed prior to initiation of general anesthesia and actual delivery of ablation lesions. This 'preablation' period normally takes 45 minutes to one hour.
88818060|NCT02251613|Experimental|Olopatadine (right or left, randomized)|Olopatadine HCl ophthalmic solution, 0.1%, 1 drop in the right or left eye as randomized
88818061|NCT02251613|Active Comparator|Epinastine (fellow eye)|Epinastine HCl ophthalmic solution, 0.05%, 1 drop in the in the fellow eye
88818062|NCT02865473|No Intervention|primary open angle glaucoma patients|
88818063|NCT02865473|No Intervention|patients with primary angle closure|
88818064|NCT02865473|No Intervention|patients with neovascular glaucoma|
88818065|NCT02865473|No Intervention|PEX glaucoma patients|
88818066|NCT02865473|No Intervention|glaucoma patients with filtering bleb|
88818067|NCT02865473|Experimental|healthy volunteers|instillation of antiglaucoma treatment in the study eye
88818068|NCT02850419|Experimental|ThermoDox (40mg/m2)+hyperthermia+RT|Treatment will consist of up to six cycles of LTLD combined with hyperthermia every 21 days with the first day of each cycle being Day 1. ThermoDox will be administered at a dose of 40 mg/m2. Thermal dose is a one-hour treatment at a temperature between 40 and 43°C at the target site. At Cycle 1, radiotherapy will begin and will be combined with hyperthermia. A total of 40 Gy in 20 fractions of 2 Gy per fraction will be administered. Up to 66 Gy of radiation therapy can be administered however institutional guidelines should be followed.
88818069|NCT04769063|Experimental|Hip|
88818070|NCT04769063|Experimental|Knee|
88818071|NCT04769063|No Intervention|Control|
88818072|NCT01783847|Experimental|Recombinant human erythropoietin (EPO)|Intravenous EPO 10,000 IU for 5-13 years of age and 20,000 IU for >13 years/ day for 3 days
88818073|NCT01783847|Active Comparator|Methylprednisolone|Just Intravenous Methyl prednisolone 250 mg every 6 hours for 3 days.
88818074|NCT01783847|Other|Observation|Observation
88818075|NCT02663531|Experimental|Mild cognitive impairment|Patients with mild cognitive impairment
88818076|NCT02663531|Experimental|Alzheimer Disease|Patients with Alzheimer Disease
88818077|NCT02663531|Experimental|Healthy|Healthy volunteers
88818078|NCT02585375|Experimental|Patients with glaucoma or ocular hypertension 1|35 patients with glaucoma or ocular hypertension
88818079|NCT02585375|Active Comparator|Patients with glaucoma or ocular hypertension 2|35 patients with glaucoma or ocular hypertension
88818080|NCT02516813|Experimental|Phase Ia Arm A: MSC2490484A +Fractionated RT|Subjects will receive MSC2490484A tablet once daily up to 10 times, for two consecutive weeks in concomitance with fractionated radiotherapy (RT) (5 fractions /week).
89362181|NCT04347291|Experimental|FAMS 2.0|"Patient participants will receive FAMS 2.0 components (monthly phone coaching and text message support for goals and medication adherence) for nine months. Linked support persons will receive text message support tailored to the goal set by the patient participant.~All patient participants will receive text messages advising how to access their study A1c test results, and receive high-quality print materials including a book upon enrollment and quarterly newsletters on healthy living with diabetes. All support person participants will receive high-quality print materials including a book and information about providing quality social support upon enrollment and quarterly newsletters on healthy living with diabetes."
89362182|NCT04347291|Placebo Comparator|Print Materials|All patient participants will receive text messages advising how to access their study A1c test results, and receive high-quality print materials including a book upon enrollment and quarterly newsletters on healthy living with diabetes. All support person participants will receive high-quality print materials including a book and information about providing quality social support upon enrollment and quarterly newsletters on healthy living with diabetes.
89362183|NCT04336293|Experimental|active|active sTMS
89362184|NCT04336293|Sham Comparator|sham|sham sTMS
89362185|NCT04331353|Active Comparator|Comparator 1 (tailored approach)|Multi-component intervention tailored to the participant's allergic profile.
89362186|NCT04331353|Active Comparator|Comparator 2 (insecticidal bait)|Insecticidal bait for cockroach reduction.
89362187|NCT04331275|Experimental|Viral Specific T-cells (VSTs)|
89362188|NCT04328584|Experimental|SNS|Intraoperative imaging/surgical navigation system (SNS)
89362189|NCT04325152|Experimental|FCSEMS+Clip|After successful cannulation, a 10mm FCSEMS with the length of 6cm or 8cm were inserted into CBD. One to two centimeters of distal end of FCSEMS was left outside of the papilla and the stent was released. Then a metal clip was used to fix the distal end of FCSEMS with the duodenal mucosa adjacent to papilla.
89362190|NCT04325152|Sham Comparator|FCSEMS|FCSEMS was released as the same as mentioned above. No fixating method was used.
89362191|NCT04311086|Experimental|Renal Denervation|Renal angiography and Renal Denervation (Symplicity Spyral™ multi-electrode renal denervation system)
89362192|NCT04308174|Experimental|Durvalumab + Gem/Cis|"<Investigational arm: preoperative phase (up to 4 cycles)> Durvalumab 1,500 mg IV on Day 1, every 3 weeks (preop period) 1,500 mg IV Day 1, every 4 weeks (postop period) Gemcitabine 1,000 mg IV on Day 1 and 8, every 3 weeks Cisplatin 25 mg IV on Day 1 and 8, every 3 weeks~<Postoperative therapy for all patients (up to 6 cycles)> Durvalumab 1,500 mg IV Day 1, every 4 weeks (postop period)"
89362193|NCT04308174|Active Comparator|Gem/Cis|"<Control arm: preoperative phase (up to 4 cycles)> Gemcitabine 1,000 mg IV on Day 1 and 8, every 3 weeks Cisplatin 25 mg IV on Day 1 and 8, every 3 weeks~<Postoperative therapy for all patients (up to 6 cycles)> Durvalumab 1,500 mg IV Day 1, every 4 weeks (postop period)"
88833497|NCT05584137|Experimental|Dose cohort 1 of the first stage (escalation stage)|"In this cohort, HLX26 500 mg in combination with HLX10 300 mg will be intravenously administered every 3 weeks. 3 to 6 subjects will be enrolled in this cohort. Patients will be treated with investigational products until 2 years, disease progression, death, receiving new antitumor treatment, intolerable toxicity or withdrawal of informed consent (whichever occurs first).~Interventions:~Drug: HLX26 Drug: HLX10"
88833498|NCT05584137|Experimental|Dose cohort 2 of the first stage (escalation stage)|"In this cohort, HLX26 800 mg in combination with HLX10 300 mg will be intravenously administered every 3 weeks. 3 to 6 subjects will be enrolled in this cohort. 3 to 6 subjects will be enrolled in this cohort. Patients will be treated with investigational products until 2 years, disease progression, death, receiving new antitumor treatment, intolerable toxicity or withdrawal of informed consent (whichever occurs first).~Interventions:~Drug: HLX26 Drug: HLX10"
88833499|NCT05584137|Experimental|Dose cohort 3 of the first stage (escalation stage)|"In this cohort, HLX26 1600 mg in combination with HLX10 300 mg will be intravenously administered every 3 weeks. 3 to 6 subjects will be enrolled in this cohort. 3 to 6 subjects will be enrolled in this cohort. Patients will be treated with investigational products until 2 years, disease progression, death, receiving new antitumor treatment, intolerable toxicity or withdrawal of informed consent (whichever occurs first).~Interventions:~Drug: HLX26 Drug: HLX10"
88833500|NCT05584137|Experimental|Dose cohort 1 of the second stage (expansion stage)|"In this cohort, HLX26 800 mg in combination with HLX10 300 mg will be intravenously administered every 3 weeks. 20 subjects will be enrolled in this cohort. Patients will be treated with investigational products until 2 years, disease progression, death, receiving new antitumor treatment, intolerable toxicity or withdrawal of informed consent (whichever occurs first).~Interventions:~Drug: HLX26 Drug: HLX10"
88833501|NCT05584137|Experimental|Dose cohort 2 of the second stage (expansion stage)|"In this cohort, HLX26 1600 mg in combination with HLX10 300 mg will be intravenously administered every 3 weeks. 20 subjects will be enrolled in this cohort. Patients will be treated with investigational products until 2 years, disease progression, death, receiving new antitumor treatment, intolerable toxicity or withdrawal of informed consent (whichever occurs first).~Interventions:~Drug: HLX26 Drug: HLX10"
89362194|NCT04290546|Experimental|Cohort I without Ipilimumab Lead in|"Haploidentical donor derived CIML NK cell infusion with subcutaneous N-803 for eligible patients with platinum-refractory and immune checkpoint blockade-refractory, advanced head and neck squamous cell carcinoma (Cohort 1)~CIML NK cell infusion (Dose 0 or -1) infused on Day 0.~Interleukin-15 Superagonist dosed at 15 mcg/kg subcutaneously every 21 days for 4 total doses (a cycle being every 21-days, so 4 cycles)."
89362195|NCT04290546|Experimental|Cohort 2 with Ipilimumab Lead In|"Cohort 2 treated with an ipilimumab lead-in prior to CIML NK cell infusion after safety is established with the NK cell and N-803 treatments alone.~Participants in the ipilimumab subgroup (Cohort 2) will receive a single dose of lead-in ipilimumab via iv per protocol determined dose followed by lymphodepleting chemotherapy on Day -6 for a total of 5-days, prior to receiving CIML NK cell infusion.~CIML NK cell infusion-Highest Dosed per cohort 1, infused on day 0~Interleukin-15 Superagonist (N-803) Administration~-- dosed at 15 mcg/kg subcutaneously every 21 days for 4 total doses (a cycle being every 21-days, so 4 cycles).~Cohort 2 will receive the highest number of CIML NK cells that is still considered safe and ipilimumab."
89534548|NCT03330431|Active Comparator|Control group|Participants read a neutral text before undergoing a Progressive Muscle Relaxation (PMR) session.
89534549|NCT02493101||Chronic kidney disease|Patients with lupus nephritis and IgA nephropathy
89534550|NCT02493101||Control|Healthy controls
89534551|NCT05049915|Experimental|Masquelet technique: bioactive glass|
89534552|NCT05049915|Active Comparator|Masquelet technique: RIA + TCP|
88818081|NCT02516813|Experimental|Phase Ia Arm B: MSC2490484A +Fractionated RT|Subjects will receive MSC2490484A capsule once daily up to 35 times, for 7 consecutive weeks in concomitance with fractionated RT and Cisplatin (5 fractions/week).
89189141|NCT00763451|Placebo Comparator|Placebo (One-Step Titration)|1-step initiation regimen of volume matching placebo: 10 mcg QD for 2 weeks, then 20 mcg QD up to the end of treatment.
89189142|NCT00762762|Active Comparator|Total toothpaste|Brush whole mouth 2x/day for 12 months with triclosan/copolymer/fluoride toothpaste.
89189143|NCT00762762|Placebo Comparator|Fluoride mouthrinse|Swish whole mouth 2x/day for 12 months with fluoride mouthrinse.
88818082|NCT02516813|Experimental|Phase Ib Arm A Expansion: MSC2490484A+Fractionated RT|Subjects will receive MSC2490484A tablet once daily up to 35 times in concomitance with fractionated RT (5 fractions /week).
89189144|NCT00424489|Experimental|Hematopoietic Stem Cell Transplantation|Autologous Hematopoietic Stem Cell Transplantation will be performed after conditioning
89189145|NCT00578864|Experimental|Protracted Oral Etoposide|"Protracted oral etoposide for cycles 1, 2 and 4 of induction. Etoposide will be given in combination with IV cisplatin (a standard of care agent). If a subject does not respond after cycle 2, cycle 4 will be bolus etoposide in combination with IV cisplatin.~All patients will receive Adriamycin and cyclophosphamide for cycle 3 and 5 as a standard of care."
89189146|NCT00578864|Active Comparator|IV Bolus Etoposide|"IV bolus etoposide in combination with IV cisplatin will be given for cycles 1,2, and 4 of induction chemotherapy for patients who are not eligible for the experimental arm (e.g.require emergent treatment)~All patients will receive Adriamycin and cyclophosphamide for cycle 3 and 5 as a standard of care."
89189147|NCT01034683|Experimental|Esophageal Carcinoma|
89189148|NCT02579070|Experimental|DFUPS (visual and thermal images)|Visual and thermal imaging with DFUPS and standard foot care. The study investigator will have access to the thermal and visual images captured with DFUPS.
89189149|NCT02579070|Placebo Comparator|DFUPS ( visual images)|Visual and blinded thermal imaging with DFUPS and standard foot care. The study investigator will have access only to the visual images and will be blinded to the thermal images which will be captured at each visit but accessed only at the end of the study.
89189150|NCT00717470|Active Comparator|Prograf + MMF + Steroids|oral
89189151|NCT00717470|Active Comparator|Advagraf (dose 1) + MMF + steroids|oral
89189152|NCT00717470|Active Comparator|Advagraf (dose 2) + MMF + steroids|oral
89189153|NCT00717470|Active Comparator|Advagraf + MMF + Basilixmab + steroids|oral
89189154|NCT02577198|Experimental|Intervention|Electronic Health Records with computerised decision support system activated Medilogy Decision Support System (MediDSS)
89189155|NCT02577198|Other|Control|Electronic Health Records with computerised decision support system silenced Medilogy Decision Support System (MediDSS) silenced
89189156|NCT00631566|Experimental|1|
89189157|NCT00631566|Placebo Comparator|2|
89189158|NCT00631566|No Intervention|No MRSA colonization|
89189159|NCT04067414|Experimental|BZ019 treatment|Subjects will receive lymphodepleting chemotherapy of fludarabine and cyclophosphamide (flu/cy) followed by single-dose of BZ019 infusion. A 3×3 dose escalation design of BZ019 will be adopted.
89189160|NCT00717548|Experimental|A|
89189161|NCT00722852|Experimental|1|
89189162|NCT00722852|Placebo Comparator|2|
89189163|NCT00770315|Experimental|SCH 39641 1.5 Amb a 1-U|Participants receive Ambrosia artemisiifolia allergan extract (SCH 39641 1.5 Amb a 1-U) rapidly dissolving sublingual tablets, administered once daily for approximately 52 weeks
89189164|NCT00770315|Experimental|SCH 39641 6 Amb a 1-U|Participants receive Ambrosia artemisiifolia allergan extract (SCH 39641 6 Amb a 1-U) rapidly dissolving sublingual tablets, administered once daily for approximately 52 weeks
89189165|NCT00770315|Experimental|SCH 39641 12 Amb a 1-U|Participants receive Ambrosia artemisiifolia allergan extract (SCH 39641 12 Amb a 1-U) rapidly dissolving sublingual tablets, administered once daily for approximately 52 weeks
89189166|NCT00770315|Placebo Comparator|Placebo|Participants receive matching placebo rapidly dissolving sublingual tablets, administered once daily for approximately 52 weeks
89189167|NCT04071600|Placebo Comparator|Placebo|Type two trauma patients randomly assigned to be administered the vehicle (water) with Kurve intranasal device once and followed for up to 60 days afterwards for development of Acute Stress Disorder and Posttraumatic Stress Disorder.
89189168|NCT04071600|Active Comparator|Neuropeptide Y|The individuals in this arm will be randomly assigned to be administered intranasal NPY with Kurve intranasal device once and will be followed for at least 60 days afterwards for development of Acute Stress Disorder and Posttraumatic Stress Disorder.
89189169|NCT04071600|No Intervention|Control|The individuals in this arm will be randomly assigned and treated the same as the other arms but with no intervention.
89189170|NCT05657444|Experimental|TNK group|
89189171|NCT05657444|No Intervention|control group|
89189172|NCT04072302|Experimental|KAF156 800 mg pre-challenge|Single dose 800 mg KAF156 oral administration in healthy subjects, prior to exposure to P. falciparum sporozoite-infected mosquitos
89189173|NCT04072302|Placebo Comparator|Placebo 800 mg pre-challenge|Single dose 800 mg placebo oral administration in healthy subjects, prior to exposure to P. falciiparum sporozoite-infected mosquitos
89189174|NCT04072302|Experimental|KAF156 800 mg post-challenge|Single dose 800 mg KAF156 oral administration in heatlhy subjects, after exposure to P. falciparum sporozoite-infected mosquitos
89189175|NCT04072302|Placebo Comparator|Placebo 800 mg post-challenge|Single dose 800 mg placebo oral administration in heatlhy subjects, after exposure to P. falciparum sporozoite-infected mosquitos
89189176|NCT04072302|Experimental|KAF156 300 mg post-challenge|Single dose 300 mg KAF156 oral administration in heatlhy subjects, after exposure to P. falciparum sporozoite-infected mosquitos
89189177|NCT04072302|Placebo Comparator|Placebo 300 mg post-challenge|Single dose 300 mg placebo oral administration in heatlhy subjects, after exposure to P. falciparum sporozoite-infected mosquitos
89189178|NCT04072302|Experimental|KAF156 100 mg post-challenge|Single dose 100 mg KAF156 oral administration in heatlhy subjects, after exposure to P. falciparum sporozoite-infected mosquitos
88833502|NCT05583019||Healthy Control|Those who do not have a diagnosis of Atopic Dermatitis (AD) or eczema and score a Clear (0) or Almost Clear (1) on the Investigator's Static Global Assessment (ISGA) at intake.
88833503|NCT05583019||Mild Atopic Dermatitis (AD)|Those who have a diagnosis of Atopic Dermatitis (AD) or eczema and score a Mild (2) on the Investigator's Static Global Assessment (ISGA) at intake.
88833504|NCT05583019||Moderate Atopic Dermatitis (AD)|Those who have a diagnosis of Atopic Dermatitis (AD) or eczema and score a Moderate (3) on the Investigator's Static Global Assessment (ISGA) at intake.
88833505|NCT05583019||Severe Atopic Dermatitis (AD)|Those who have a diagnosis of Atopic Dermatitis (AD) or eczema and score a Severe (4) on the Investigator's Static Global Assessment (ISGA) at intake.
88833506|NCT05576831|No Intervention|HPV-A VSCC|Patients with HPV-A VSCC and margins that are negative for cancer but <8mm (regardless of in-situ (HSIL) margin status) will be eligible for the de-escalation prospective study.
88833507|NCT05576831|Experimental|HPV-I VSCC|If the margins are negative for cancer but <8mm, or positive for Differentiated vulvar intraepithelial neoplasia (dVIN), and/or positive for p53 abnormality on IHC, these patients will be randomized (2:1) to further re-excision vs observation only.
88833508|NCT05576207|Active Comparator|Arm 1|Multiple Micronutrient Supplement for Pregnant women (UNIMMAP formulation) containing 15 nutrients all at a recommended daily allowance (RDA) for pregnancy to be consumed one-per-day during pregnancy
88833509|NCT05576207|Experimental|Arm 2|Balanced energy and protein (BEP) food supplement (ready-to-use) for pregnant women containing 15 nutrients all at an RDA for pregnancy, and Ca and P. to be consumed one-per-day during pregnancy. BEP is recommended by the World Health Organization (WHO) for pregnancy use in undernourished contexts. Bangladesh is one such place. In this arm all pregnant women will receive this intervention
89189179|NCT04072302|Placebo Comparator|Placebo 100 mg post-challenge|Single dose 100 mg placebo oral administration in heatlhy subjects, after exposure to P. falciparum sporozoite-infected mosquitos
88833510|NCT05576207|Experimental|Arm 3|Balanced energy and protein food supplement (ready-to-use) for pregnant women containing 15 nutrients all at an RDA for pregnancy, and Ca and P. to be consumed one-per-day during pregnancy. BEP is recommended by the WHO for pregnancy use in undernourished contexts. Bangladesh is one such place. In this arm, only low pre-pregnancy BMI women (<18.5) will receive the BEP, the rest will receive the MMS.
88833511|NCT05576207|Experimental|Arm 4|Balanced energy and protein food supplement (ready-to-use) for pregnant women containing 15 nutrients all at an RDA for pregnancy, and Ca and P. to be consumed one-per-day during pregnancy. BEP is recommended by the WHO for pregnancy use in undernourished contexts. Bangladesh is one such place. In this arm, only low pre-pregnancy BMI women (<18.5) and those who have inadequate gestational weight gain during pregnancy will receive the BEP, the rest will receive the MMS.
88833512|NCT05568420||Colorectal Cancer Cohort|"Stool collection prior to starting treatment (i.e. chemotherapy, chemoradiotherapy, etc.)~Blood sample to be collected either prior to starting treatment (i.e. chemotherapy, chemoradiotherapy, etc.) or during surveillance.~Prospective tissue collection will be utilized from clinically indicated diagnostic colonoscopies/biopsies/resections s, including surveillance colonoscopies. Non-diagnostically indicated tissue collections will not be performed. Some EOCRC patients will have already undergone prior surgical resection, with tissue (including normal colonic mucosae distant from the malignant tumor). The pathology FFPE blocks may be used as a source of normal colon tissue for genomic analysis."
88833513|NCT05568420||Healthy Control Cohort|"Tissue collection of normal colon mucosa will be utilized from clinically indicated colonoscopies or from tissue obtained from a prior colonoscopy, non-diagnostically indicated tissue collections will not be performed. Colonoscopies for indications of IBD, anemia, and/or genetic predisposition will be excluded.~Stool samples will be collected at time of colonoscopy. Samples to be collected either within 3-14 days before or at least 14 days after colonoscopy, to avoid changes in microbiome caused by colonoscopy prep.~Blood samples will be collected at time of colonoscopy.~Risk factor questionnaire will be completed at time of colonoscopy. Will also try to collect stool from healthy control patients; however, if accrual is low after 3-6 months, remainder of cohort will be filled with specimen data from the Human Microbiome Project Data Portal."
88833514|NCT05567159|Experimental|Donanemab|Donanemab administered intravenously (IV).
88833515|NCT05565807|Experimental|STI-6129|Nine dosing cohorts will be evaluated: 0.25 mg/kg，0.50 mg/kg，0.67 mg/kg, 0.88 mg/kg, 1.18 mg/kg, 1.56 mg/kg, 2.08 mg/kg, 2.77 mg/kg, 3.68 mg/kg where STI-6129 will be intravenously administered once as part of a 4-week treatment cycle.
88833516|NCT05555953||Phase-1|The draft CORONATE questionnaire will be administered to participants to create the final version of the questionnaire.
88833517|NCT05555953||Phase-2|The questionnaire created in Phase 1 will be administered to a new group of participants for validation. All partners who are in a relationship with the participants since at least 3 years will be asked to participate in the study for the comparison between participants' and partners' perspectives on the impact of long-term psoriasis on participants' life.
88833518|NCT05554601|No Intervention|attention control|participants receive a FitBit and set goals but do no other intervention
88833519|NCT05554601|Experimental|gamification with collaboration|participants receive a FitBit and set goals, then are assigned to a group of other participants who will play a game to gain points based on collaboration with each other
88833520|NCT05554601|Experimental|gamification with competition|participants receive a FitBit and set goals, then are assigned to a group of other participants who will play a game to gain points based on competition with each other
88833521|NCT05553041|Experimental|18F-Fluciclovine PET-MRI in pediatric HGG or DMG participants|Single intravenous administration of 18F fluciclovine for PET-MRI Scan
88833522|NCT05549934|Experimental|PF-06651600 (Ritlecitinib)|200 mg once-daily for 8 weeks and then 100 mg once daily for the remaining 40 weeks
88833523|NCT05549687|Experimental|Group I (Pack Health Program)|Patients participate in the Pack Health Program which includes up to 60 scheduled touch points via phone, text, email and a mobile application and weekly interaction with a health coach over 3 months. They also have access to standard of care support services at MD Anderson including a telephone triage line 5 days a week between 8 a.m. and 5 p.m.
88833524|NCT05549687|Active Comparator|Group II (standard of care support services)|Patients receive standard of care support services with a telephone triage line available 5 days a week between 8 a.m. and 5 p.m.
89362196|NCT04290546|Experimental|Cohort 3 with Cetuximab Infusions|"Cohort 3 treated with CIML NK cell infusion after safety is established with the NK cell and N-803 treatments alone, followed by cetuximab infusions.~- Participants in cetuximab subgroup (Cohort 3) will receive lymphodepleting chemotherapy on Day -6 for a total of 5-days, prior to receiving CIML NK cell infusion.~CIML NK cell infusion-Highest Dosed per cohort 1, infused on day 0~Interleukin-15 Superagonist (N-803) Administration~-- dosed at 15 mcg/kg subcutaneously every 21 days for 4 total doses (a cycle being every 21-days, so 4 cycles).~Cetuximab Administration~--dosed at 500mg/m2 IV over 120 minutes for the first dose, then over 60 minutes for subsequent doses. This will be infused every 14 days for 8 doses started on day +15.~Cohort 3 will receive the highest number of CIML NK cells that is still considered safe and ipilimumab."
89362197|NCT04284228|Experimental|Safety Evaluation Phase|Treatment with NEXI-001 T cells, derived from PBMCs of original HLA- matched HCT donor.
89362198|NCT04284228|Experimental|Dose Expansion Phase|Dose Expansion Phase to further define the safety, tolerability and initial anti-tumor efficacy of the NEXI-001 T cell product at the dose established from the Safety Evaluation Phase.
89362199|NCT04283864||Group A|
88818083|NCT02516813|Experimental|Phase Ib Arm B Expansion: MSC2490484A+Fractionated RT|Subjects will receive MSC2490484A tablet once daily up to 35 times in concomitance with fractionated RT (5 fractions /week) and cisplatin.
89362200|NCT04283864||Group B|
89362201|NCT04283864||Group C|
89362202|NCT04276142|Experimental|Migraine - ceprica|online program: ceprica in addition to treatment as usual
89362203|NCT04276142|Other|Migraine - active control intervention|active control intervention: psychoeducation in addition to treatment as usual
89362204|NCT04275167|Experimental|Feasibility of TCE|Feasibility is measured by the number of participants that we have successfully deployed the Tethered capsule device in.
89362205|NCT04275167|Experimental|Feasibility of TNE and Microbiome Brushing|Feasibility is measured by the number of participants that we have successfully deployed the TNE device and collected brush samples in.
89362206|NCT04274426|Active Comparator|Control arm with Platinum-based chemotherapy|"Carboplatin (AUC5, d1) combined with pegylated liposomal doxorubicin (PLD) (30 mg/m², d1) q28d~Carboplatin (AUC4, d1) combined with gemcitabine (1000 mg/m2, d1 & d8) q21d~Carboplatin (AUC5, d1) combined with paclitaxel (175 mg/m², d1) q21d"
89362207|NCT04274426|Experimental|Carboplatin + Mirvetuximab soravtansine (IMGN853)|Carboplatin (AUC5, d1) + Mirvetuximab soravtansine (IMGN853) 6 mg/kg IV d1 x 6 cycles q21d, followed by subsequent monotherapy of Mirvetuximab soravtansine (IMGN853) 6 mg/kg IV q3w until disease progression.
89362208|NCT04272801|Experimental|Pre-operative endocrine therapy|All participants enrolled to the study will receive 3 months of pre-operative endocrine therapy (e.g. tamoxifen or aromatase inhibitors (AIs) such as letrozole, anastrozole, or exemestane). The choice and dose of endocrine therapy will be at the discretion of the treating medical oncologist.
89362209|NCT04265261|Placebo Comparator|Group A|Participants will receive an oral dose of placebo matched to RG7774 once daily (QD)
88818084|NCT02516813|Experimental|Ancillary cPoP: MSC2490484A+Fractionated RT|Ancillary Clinical proof-of-principle (cPOP) study, subjects will receive first dose of RT on Day 1, and will receive MSC2490484A capsule or Tablet formulation within 1.5 hour before the second dose of RT on Day 2.
89362210|NCT04265261|Experimental|Group B|Participants will receive a low oral dose of RG7774 QD
89362211|NCT04265261|Experimental|Group C|Participants will receive a high oral dose of RG7774 QD
89362212|NCT04262180|Experimental|Base intervention- Fitbit with EHR integration|All participants will receive a first-line intervention (i.e., Fitbit activity tracker with EHR integration including messages delivered via the EHR's patient portal) and will be evaluated for response/non-response every 4 weeks until week 20.
89362213|NCT04262180|Experimental|Nonresponders -Stepped up to Online gym|"Non-responders to 'fitbit with EHR integration' will be randomized to be stepped up to one of two augmentation strategies(either Online gym or coaching calls). This arm will be stepped up to Online gym."
89362214|NCT04262180|Experimental|Nonresponders -Stepped up to Coaching calls|"Non-responders to 'fitbit with EHR integration' will be randomized to be stepped up to one of two augmentation strategies(either Online gym or coaching calls). This arm will be stepped up to Coaching calls."
89362215|NCT04261439|Experimental|Arm 1|Single agent arm. NIZ985 is administered as a single agent (subjects may be treated with the NIZ985-Spartalizumab combination after their first disease re-evaluation)
89362216|NCT04261439|Experimental|Arm 2|Combination arm. NIZ985 and Spartalizumab combination is administered starting at Cycle 1 Day 1 in dose escalation. NIZ985 and tislelizumab combination is administered starting at Cycle 1 Day 1 in dose expansion.
89362217|NCT04257318|Experimental|Vibrating Relaxation Tool|Use of a Vibrating Relaxation Tool in case of pain during pregn
88818085|NCT05009147|Experimental|experimental group|receive whole body manual massage
88818086|NCT05009147|No Intervention|control group|After experiment, receive whole body manual massage
88818087|NCT01785095|Experimental|FSH|FSH (Follicle stimulation hormone, 75 IU/vial) will be administered to women according to their need and response assessed by the Investigator.
88818088|NCT02990429|Experimental|Forced Air warmer (bair hugger)|".~In groups: A = 45, receiving intraoperative forced air warming( bair hugger). The forced air was delivered at the high setting of 43ºC"
88818089|NCT02990429|Experimental|Intravenous Fluid Warmer(ranger warmer)|In groups:B =45, having intraoperative intravenous fluid via a fluid warmer patients received intravenous fluid via a fluid warmer after induction anesthesia. The device automatically heated fluid up to 41ºC as set point.
88818090|NCT01786187|Active Comparator|Symptom Experience Group|Conventional treatment for cancer as prescribed by the participant's health care providers and will receive planned, structured, weekly telephone visits to report the experience of symptoms and health-related quality of life information.
88818091|NCT01786187|Experimental|Light Physical Activity Group|Conventional treatment for cancer as prescribed by the participant's health care providers and will receive a home-based light physical activity program to help manage a specific symptom related to cancer and cancer treatment.
88818092|NCT01367444|Experimental|SAR422459 (Dose 1)|Starting dose of SAR422459 given through subretinal injection
88818093|NCT01367444|Experimental|SAR422459 (Dose 2)|Escalating dose of SAR422459 given through subretinal injection
88833525|NCT05548231|Experimental|LY3437943|LY3437943 administered subcutaneously (SC)
89189180|NCT04072302|Experimental|KAF156 20 mg post-challenge|Single dose 20 mg KAF156 oral administration in heatlhy subjects, after exposure to P. falciparum sporozoite-infected mosquitos
89189181|NCT04072302|Placebo Comparator|Placebo 20 mg post-challenge|Single dose 20 mg Placebo oral administration in heatlhy subjects, after exposure to P. falciparum sporozoite-infected mosquitos
88818094|NCT01367444|Experimental|SAR422459 (Dose 3)|Maximum tolerated dose (MTD) of SAR422459 given through subretinal injection
89189182|NCT04072302|Experimental|KAF156 50 mg post-challenge|Single dose 50 mg KAF156 oral administration in heatlhy subjects, after exposure to P. falciparum sporozoite-infected mosquitos
88818095|NCT01786343|Experimental|Decitabine - 5 Day Regimen|Decitabine 20 mg/m2 by vein daily for 5 days.
89189183|NCT04072302|Placebo Comparator|Placebo 50 mg post-challenge|Single dose 50 mg Placebo oral administration in heatlhy subjects, after exposure to P. falciparum sporozoite-infected mosquitos
89189184|NCT04103411|Experimental|High Intensity Interval Training (HIIT)|For the twelve weeks of intervention, participants will have three training sessions per week. Each session will be done on a cycle ergometer and will last approximately 40 minutes. Participants will be supervised by certified kinesiologists and their training programs will be revised every four weeks.
89189185|NCT04103411|Active Comparator|HydroChloroThiazide|For this group, participants have to take a diuretic (12,5 mg of Hydrochlorothiazide) daily prescribed by the doctor of this study, for twelve weeks. Participants should also maintain the same lifestyle habits that they had before the study.
88818096|NCT01786343|Experimental|Decitabine - 10 Day Regimen|Decitabine 20 mg/m2 by vein daily for 10 days.
88818097|NCT02327429|Experimental|A Chinese menu plan for type 2 diabetes|All participants will be in the intervention arm for this pilot study
88818098|NCT03362775|Other|All subjects|EEG will be recorded in all subjects before (0.0 µL/mL) and during a target controlled infusion of propofol (0.5 µL/mL and 1.0 µL/mL).
88818099|NCT01786967|Experimental|Fesoterodine Fumarate|Participants will receive 4 mg of study drug for first 2 weeks, and then 8 mg of study drugs for 2 weeks.
88818100|NCT02392871|Experimental|Radiotherapy|"Palliative radiotherapy in combination with dabrafenib and trametinib Eligible subjects are patients who have been on dabrafenib and trametinib for more than 2 weeks, as the current standard management for advanced stage melanoma.~Palliative RT will be delivered to symptomatic or bulky (>2cm) soft tissue, nodal or bony metastases concurrently with dabrafenib and trametinib. Up to 3 areas of disease can be irradiated at the same time.~Following RT, dabrafenib and trametinib alone will be continued until disease progression according to RECIST 1.1 criteria."
89189186|NCT00587171|Active Comparator|Active|2 hours of daily patching combined with 1 hour daily of near activities (that includes 30 minutes of at-home active vision therapy) and weekly in-office active vision therapy
89189187|NCT00587171|Sham Comparator|Control|2 hours of daily patching combined with 1 hour of daily near activities (that includes 30 minutes of at-home control vision therapy) and weekly in-office control vision therapy
89189188|NCT04833426|Active Comparator|Testosterone therapy|Daily application of two pump auctions of 16.2mg/ml testosterone gel. Dosage may be altered depending on clinical response
89189189|NCT04833426|Placebo Comparator|Placebo therapy|Daily application of two pump auctions of placebo gel.
89189190|NCT02576964|Experimental|Capecitabine + Peginterferon alfa-2a|Treatment-naive participants with advanced liver cancer will receive combination treatment with capecitabine (1000 milligrams per meter-squared [mg/m^2] twice daily orally on Days 1 to 14 of each 21-day cycle) and peginterferon alfa-2a (180 micrograms (mcg) subcutaneous [SC] every week during each 21-day cycle) until at least 6 cycles (18 weeks) or disease progression, intolerable toxicity, or consent withdrawal.
89189191|NCT00763139|Experimental|Placebo First|Placebo for first 8 weeks, then washout period for 4 weeks, and finally pioglitazone for 8 weeks.
89189192|NCT00763139|Experimental|Pioglitazone First|Pioglitazone for first 8 weeks, then washout period for 4 weeks, and finally placebo for 8 weeks.
89189193|NCT04074408|Experimental|Cohort 1|low dose hUMSCs or high dose hUMSCs
89189194|NCT04074408|Experimental|Cohort 2|best dose of hUMSCs (from cohort 1) or placebo
89189195|NCT00781859|Experimental|125µg Ocriplasmin|125µg intravitreal injection of ocriplasmin
89189196|NCT00781859|Placebo Comparator|Placebo|placebo intravitreal injection
89189197|NCT03915210||Candidates of HSCT|Physical activity level using a metabolic holter device, dynamic lung volumes (FEV1, FVC, FEV1/FVC, PEF, FEF25-75%) using a spirometer and quality of life using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 version 3.0 were objectively evaluated.
89189198|NCT03915210||Healthy individuals|Physical activity level using a metabolic holter device, dynamic lung volumes (FEV1, FVC, FEV1/FVC, PEF, FEF25-75%) using a spirometer and quality of life using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 version 3.0 were objectively evaluated.
89189199|NCT02576886|Experimental|Supine/Prone Imaging|The patient will be imaged in the standard supine position and then an additional image will be acquired of the patient in the prone position.
89189200|NCT04100915||Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)|Patients diagnosed with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).
89189201|NCT01344252|Experimental|Topical|
89189202|NCT01344252|Active Comparator|subtenon|
89189203|NCT04101383|Experimental|RinGlar®|Single subcutaneous administration of RinGlar® in dose 0.6 Units/kg
89189204|NCT04101383|Active Comparator|Lantus®|Single subcutaneous administration of Lantus® in dose 0.6 Units/kg
89189205|NCT02576808|Experimental|Ginger extract|Drug
89189206|NCT02576808|Active Comparator|Loratadine|Drug
89189207|NCT04100681|Active Comparator|Active FlowOx™|The application of pulsating negative pressure will be up to 120 minutes long per day. The pulsating negative pressure used will be approximately 40 mm Hg alternating with ambient air pressure, the pulse consisting of 10 seconds of negative pressure followed by 7 seconds of atmospheric pressure.
89362218|NCT04256993||Ra-223 initiators|"Patients diagnosed with mCRPC (Metastatic Castration-Resistant Prostate Cancer) who start treatment with Ra-223. Patients will be identified from the Patient-overview Prostate Cancer (PPC), a sub-registry of the Prostate Cancer data Base Sweden (PCBaSe) data set."
89362219|NCT04256993||Initiators of other standard of care|The comparator cohort will be patients using standard of care other than Ra-223.
89362220|NCT04251624|Experimental|Goal Management Therapy|"Goal Management Therapy is a structured, short-term, present-oriented cognitive remediation program with emphasis on mindfulness and practice in planning and completion of goal-oriented behaviors.~The primary objective of GMT is to train patients to interrupt ongoing behavior through the resumption of executive control in order to define goal hierarchies and monitor performance in achieving goals. Sessions include instructional material, interactive tasks, discussion of patients' real-life deficits, and homework assignments.~Phase 1: Inpatients will attend group sessions twice per week for 3 weeks, each session being 2 hours in length.~Phase 2: Outpatients from the community will attend 1 session per week for 9 weeks, each session being 2 hours in length.~Phase 3: Outpatients from the community will attend 1 session per week for 9 weeks, each session being 2 hours in length."
89362221|NCT04251624|Active Comparator|Psychosocial Education|"Psychosocial education will provide participants with educational materials (e.g., brain function, neuroplasticity) and lifestyle interventions (e.g., sleep hygiene, stress, exercise).~They will be matched for length and for amount of facilitator contact with the Goal Management Therapy sessions.~Phase 1: Inpatients will attend group sessions twice per week for 3 weeks, each session being 2 hours in length.~Phase 2: Outpatients from the community will attend 1 session per week for 9 weeks, each session being 2 hours in length.~Phase 3: Outpatients from the community will attend 1 session per week for 9 weeks, each session being 2 hours in length."
89362222|NCT04251052|Experimental|Group I (bilateral salpingectomy)|Patients undergo bilateral salpingectomy. Patients may then undergo oophorectomy after initial surgery. Patients also undergo a transvaginal ultrasound during screening and blood sample collection throughout the trial.
89362223|NCT04251052|Active Comparator|Group II (bilateral salpingo-oophorectomy)|Patients undergo bilateral salpingo-oophorectomy. Patients also undergo a transvaginal ultrasound during screening and blood sample collection throughout the trial.
89362224|NCT04230668|Experimental|CPT + SRM|Participants will be randomized to teletherapy sessions of Cognitive Processing Therapy + Suicide Risk Management for PTSD-BPD which will be administered twice weekly over 6 weeks, for a total of 12 sessions.
89362225|NCT04230668|Experimental|TAU + SRM|Participants will be randomized to teletherapy sessions with only Suicide Risk Management for PTSD-BPD which will be administered once a week for 6 weeks, for a total of 6 sessions.
89362226|NCT04226547|Experimental|Device Group|Randomized to Amplatzer Amulet LAA occluder
89362227|NCT04226547|Active Comparator|Control Group|Randomized to NOAC
89362228|NCT04225715|Active Comparator|Nucleos(t)ide (NUC) Control Arm|Participants will continue their background NUC therapy for the 48-week treatment period. At the end of the treatment period, in line with current CHB treatment guidelines, participants will continue NUC treatment during the follow-up unless the NUC discontinuation criteria have been met.
89362229|NCT04225715|Experimental|Core Protein Allosteric Modulator (CpAM; RO7049389) + Toll-like Receptor 7 (TLR7;RO7020531) + NUC|Participants will receive RO7049389 (600 mg once daily [QD]) in addition to their background NUC therapy for the 48-week treatment period. RO7020531 (150 mg once every other day [QOD]) will be administered during Weeks 1-12 and Weeks 25-36. At the end of the treatment period, participants will continue NUC treatment during the follow-up unless the NUC discontinuation criteria have been met.
89362230|NCT04225715|Experimental|Short Interfering Ribonucleic acid (siRNA; RO7445482) (Dose1) + NUC|Participants will receive RO7445482 (Dose 1) in addition to their background NUC therapy for the 48-week treatment period. At the end of the treatment period, participants will continue NUC treatment during the follow-up unless the NUC discontinuation criteria have been met.
89362231|NCT04225715|Experimental|siRNA (RO7445482) (Dose 2) + NUC|Participants will receive RO7445482 (Dose 2) in addition to their background NUC therapy for the 48-week treatment period. At the end of the treatment period, participants will continue NUC treatment during the follow-up unless the NUC discontinuation criteria have been met.
89362232|NCT04225715|Experimental|siRNA (RO7445482) + Pegylated Interferon (PEG-IFN) + NUC|Participants will receive RO7445482 (Dose 2) in addition to their background NUC therapy for the 48-week treatment period. PEG-IFN will be administered at a dose of 180 μg once weekly (QW) for 48 weeks. At the end of the treatment period, participants will continue NUC treatment during the follow-up unless the NUC discontinuation criteria have been met.
89362233|NCT04225715|Experimental|siRNA (RO7445482) + CpAM (RO7049389) + NUC|Participants will receive RO7445482 (Dose 2) and RO7049389 (600 mg QD) in addition to their background NUC therapy for the 48-week treatment period. At the end of the treatment period, participants will continue NUC treatment during the follow-up unless the NUC discontinuation criteria have been met.
89362234|NCT04225715|Experimental|siRNA (RO7445482) + TLR7 (RO7020531) + NUC|Participants will receive RO7445482 (Dose 2) in addition to their background NUC therapy for the 48-week treatment period. RO7020531 (150 mg QOD) will be administered during Weeks 13-24 and Weeks 37-48 (i.e., 2 treatment cycles of 12 weeks' duration each and 42 doses of RO7020531 for each cycle). At the end of the treatment period, participants will continue NUC treatment during the follow-up unless the NUC discontinuation criteria have been met.
89534553|NCT02492789|Experimental|INCSHR01210|"3 dose levels are designed in this study.3 to 6 patients (traditional 3+3 design) will be enrolled in each dose cohort. INCSHR01210 injection at each dose level is administered every 2 weeks (q2w, except in the first cycle)."
89534554|NCT02492945|Experimental|PDRN group|They take the three times of the ultrasonography-guided injections for four weeks(0,2,4 weeks) under double-blind. PDRN group take ultrasonography-guided 3ml-Rejuvinex injection for the lesion( tear or tendinosis about extensor carpi radialis brevis, extensor digitorum communis, radial collateral ligament ) of lateral epicondylitis for 4 weeks.
88818101|NCT02382575|Active Comparator|Tacrolimus|Tacrolimus: Standard dose with oral Tacrolimus 0.2 mg/kg/day in two divided doses till 6 month of relapse free survival.
89001091|NCT04630678|Active Comparator|Activity Training (Control) Group|The second group was received conventional physiotherapy and, activity training which the same movement patterns with virtual reality games for 60 minutes. The children in the activity training group received unilateral, bilateral, and bimanual activity training that supported manual skills for thirty minutes. Similar activity patterns were presented to the virtual reality group and activity training (control) group. The treatment were given three times a week for eight weeks.
89001092|NCT04630444|Experimental|Intervention Group|30 PTSD patients receiving riluzole 100 mg daily (50 mg bid).
89001093|NCT04630405|Active Comparator|Wright jet nebulizer|Will employ the Wright jet nebulizer for use in an allergen challenge triad
89001094|NCT04630405|Active Comparator|Solo vibrating mesh nebulizer|Will employ the Aerogen Solo vibrating mesh device for use in an allergen challenge triad
89001095|NCT00186810|Other|1|
89001096|NCT04630600|Other|Control|Normal waiting room
89001097|NCT04630600|Experimental|Intervention#1|Waiting room with partially-equipped aquarium (without fish)
89001098|NCT04630600|Experimental|Intervention#2|Waiting room with fully-equipped aquarium (with fish)
89001099|NCT04630288||Clopidogrel|Clopidogrel is a prodrug that requires metabolic activation in two stepsby hepatic CYP450 enzymes to produce the active metabolite that inhibits platelet aggregation. The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation. Consequently, due to the irreversible binding to the P2Y12 receptor,platelets exposed to clopidogrel's active metabolite are affected for the remainder of their lifespan (about 7 to 10 days) and recovery of normal platelet function occurs at a rate consistent with the normal platelet turnover. Clopidogrel was approved by the European Commission on 15 July 1998 for the secondary prevention of atherothrombotic events in adult patients with ACS.
89001100|NCT04630288||Ticagrelor|Ticagrelor is a nucleoside analogue member of the chemical class cyclopentyltriazolopyrimidines (CPTP), which is a selective and reversible ADP- receptor antagonist acting on the platelet P2Y12 receptor. This prevents the binding of ADP to the receptor which attenuates plateletactivation and aggregation.The drug was approved by the European Commission on December 3, 2010, for the prevention of thrombotic events (cardiovascular death, myocardial infarction and stroke) in patients with ACS (unstable angina, non ST elevation Myocardial Infarction [NSTEMI] or ST elevation Myocardial Infarction [STEMI]) including patients managed medically, and those who are managed with percutaneous coronary intervention (PCI) or coronary artery by-pass grafting (CABG).
89001101|NCT00561028||1|ST-elevation acute myocardial infarction.
89001102|NCT00561028||2|high-risk unstable angina or non-ST-elevation myocardial infarction.
89001103|NCT00561028||3|known coronary artery disease, either asymptomatic or with stable angina.
89001104|NCT00561028||4|blood donors without known coronary artery disease.
89001105|NCT00561067|Active Comparator|1|Methylprednisolone
89001106|NCT00561067|Experimental|2|Erythropoietin
89001107|NCT00561106|Active Comparator|1|
89362235|NCT04225715|Experimental|siRNA(RO7445482)+ Programmed Death Ligand-1 Locked Nucleic Acid (PD-L1 LNA; RO7191863) + NUC [1]|Participants will receive RO7445482 (Dose 2) during Weeks 1-24 and RO7191863 (Dose 1) will be administered during Weeks 13-24, in addition to their background NUC therapy for the 24-week treatment period. At the end of the treatment period, participants will continue NUC treatment during the follow-up unless the NUC discontinuation criteria have been met.
89001108|NCT00561106|Placebo Comparator|2|
89001109|NCT00179894|Experimental|1 Physician training|Physician participants will receive training in guidelines and medication monitoring
89001110|NCT00179894|No Intervention|2|Physician participants will provide usual care and no special intervention
89001111|NCT04630639|Experimental|Validation Arm|Participants will wear the Sparkle device (test device) while instrumented with an esophageal manometry catheter (reference standard) to record respiratory effort.
89001112|NCT00561184|Experimental|1|
89001113|NCT00561184|Experimental|2|
89001114|NCT00186849|Other|1|
89001115|NCT04630132||Frailty Group|"The 'phenotype' of frailty (cases) is defined as follows: presence of three or more of the following features:~Decreased grip strength~Self-reported exhaustion~Unintentional weight loss of more than 4.5 kg over the past year~Slow walking speed~Low physical activity"
89001116|NCT04630132||Non-Frailty Group|"The 'phenotype' of non-frailty (control) is defined as follows: presence of less than three of the following features:~Decreased grip strength~Self-reported exhaustion~Unintentional weight loss of more than 4.5 kg over the past year~Slow walking speed~Low physical activity"
89001117|NCT00201981|Active Comparator|1|rebamipide 1%
89362236|NCT04225715|Experimental|siRNA (RO7445482) + PD-L1 LNA (RO7191863) + NUC [2]|Participants will receive RO7445482 (Dose 2) during Weeks 1-24 and RO7191863 (Dose 1) will be administered during Weeks 25-36, in addition to their background NUC therapy for the 36-week treatment period. At the end of the treatment period, participants will continue NUC treatment during the follow-up unless the NUC discontinuation criteria have been met.
89001118|NCT00201981|Active Comparator|2|Rebamipide 2%
89001119|NCT00201981|No Intervention|3|placebo
89001120|NCT04629742|Experimental|Seawater Pizza|Administration of a seawater pizza
89001121|NCT04629742|Active Comparator|Standard Pizza|Administration of a Standard pizza
89001122|NCT04629391|Active Comparator|Anatomic TSA|The control group will receive through a deltopectoral approach an anatomic total shoulder arthroplasty (TSA) for a primary glenohumeral arthritis
89001123|NCT04629391|Experimental|RTSA|The experimental group will receive through a deltopectoral approach a reverse total shoulder arthroplasty RTSA for a primary glenohumeral arthritis
89362237|NCT04221490|Experimental|Treatment|Treatment with the Edwards EVOQUE Tricuspid Transcatheter Valve Replacement System
89001124|NCT04629235|Active Comparator|24 hours of bedrest|- 24 hours of bedrest
89001125|NCT04629235|Experimental|Intervention group|- Wonder around after 8 hours of bedrest
89001126|NCT00180011|Experimental|omaluzimab|
89001127|NCT00186966|Other|FLAG|
89001128|NCT00186966|Other|FLAG and LP Dox|
89001129|NCT04629001||with Covid-19 infection|
89362238|NCT04219969|Experimental|Diagnostic (18F-FDG PET-MRI)|Patients receive fludeoxyglucose F-18 IV over 1 minutes and then undergo PET-MRI over 15-60 minutes at 60, 300, and 480 minutes after fludeoxyglucose F-18 injection in the absence of unacceptable toxicity.
89362239|NCT04213209||Brentuximab Vedotin 1.8 mg/kg (body weight)|The usual dosage for intravenous administration is 1.8 milligrams per kilograms (mg/kg) (body weight) as Brentuximab Vedotin (genetic recombination) once every three weeks (up to 12 months). The dose may be reduced appropriately according to the participant's condition. Participants receive interventions as part of routine medical care.
89362240|NCT04211610||Group 1 - Healthy subjects without any evidence of cardiac o|"Inclusion criteria:~Normal serum troponin (below the 99th percentile)~GFR 60ml/min~Proteinuria <1gr/gr creatinine~Blood and urine samples will be collected for troponin and other measures."
89362241|NCT04211610||Group 2 - Subjects with acute myocardial infarction and norm|"Inclusion criteria:~At least one measurements of serum troponin above the 99th percentile, with either a rise or fall in cardiac troponin levels.~GFR 60ml/min/1.73m2~Blood and urine samples will be collected for troponin and other measures."
89362242|NCT04211610||Group 3 - Subjects with acute myocardial infarction and decr|"Inclusion criteria - Group 3a:~At least one measurements of serum troponin above the 99th percentile, with either a rise or fall in cardiac troponin levels.~30 GFR <60ml/min/1.73m2~Inclusion criteria - Group 3b:~At least one measurements of serum troponin above the 99th percentile, with either a rise or fall in cardiac troponin levels.~GFR <30ml/min/1.73m2~Blood and urine samples will be collected for troponin and other measures."
89362243|NCT04211610||Group 4 - Subjects with decreased GFR but without any eviden|"Inclusion criteria - Group 4a:~Normal serum troponin (below the 99th percentile)~No known past medical history of any cardiac disease and/or procedure.~30 GFR <60ml/min/1.73m2~Inclusion criteria - Group 4b:~Normal serum troponin (below the 99th percentile)~No known past medical history of any cardiac disease and/or procedure.~GFR <30ml/min/1.73m2~Blood and urine samples will be collected for troponin and other measures."
89362244|NCT04211610||Group 5 - Subjects with chronic myocardial injury and normal|"Inclusion criteria:~At least one measurements of serum troponin above the 99th percentile, with neither a rise nor fall in cardiac troponin levels.~GFR 60ml/min/1.73m2~Blood and urine samples will be collected for troponin and other measures."
89362245|NCT04211610||Group 6 - patients on RRT|"Inclusion criteria:~a. Patients who are dependent on renal replacement therapy, including hemodialysis, peritoneal or hemodiafiltration.~Blood and urine samples will be collected for troponin and other measures."
89362246|NCT04203303||Observational|Observational
89362247|NCT04189679||First line|20 patients in first line of treatment
89362248|NCT04189679||Second or third line|40 patients in second and third line of treatment
89362249|NCT04186871|Experimental|Systemic Lupus Erythematosus (SLE): branebrutinib|
89362250|NCT04186871|Placebo Comparator|SLE: placebo|
89362251|NCT04186871|Experimental|Primary Sjögren's Syndrome (pSS): branebrutinib|
89362252|NCT04186871|Placebo Comparator|pSS: placebo|
89362253|NCT04186871|Experimental|Rheumatoid Arthritis (RA): branebrutinib followed by abatacept|
89362254|NCT04186871|Placebo Comparator|RA: placebo followed by abatacept|
89362255|NCT04186546||Cases|Zephyr Valve Procedure
89362256|NCT04182087||Focal Brain Injury|Patients with focal brain injury (post-stroke or post-cortical resection)
89362257|NCT04180176|Experimental|All-Comer Cohort|Participants with mNSCLC or ES-SCLC will give blood samples at three separate timepoints for ctDNA profiling.
89362258|NCT04180176|Experimental|Front-line Immunotherapy Re-enrollment Cohort|Participants with mNSCLC or ES-SCLC that have received front-line treatment as defined by the protocol will give blood samples at three separate timepoints for ctDNA profiling.
89362259|NCT04163081|Experimental|Quit Card Intervention (QCI)|Study intervention group.
89362260|NCT04163081|No Intervention|Usual Care (UC)|Study control group.
89362261|NCT04158154|Experimental|Primary Health Care Centers|Selected primary health care centers in Abuja will implement a culturally- and contextually-adapted intervention package based on the Kaiser Permanente Northern California and World Health Organization HEARTS programs for hypertension diagnosis and treatment.
89362262|NCT04150783||Unilateral Cleft Lip Nasal Deformity (uCLND)|uCLND patients who are scheduled to undergo surgical treatment for nasal obstruction as standard of care.
89362263|NCT04150783||Healthy Subjects|Existing data from healthy subjects with no prior symptoms of nasal obstruction used to create normative ranges for comparison to uCLND cohort.
89362264|NCT04149951|Experimental|Active|Randomized to active device use plus lifestyle modification (500kcal deficit hypocaloric diet and 150 min of exercise per week for each subject).
89362265|NCT04149951|Placebo Comparator|Control|Randomized to sham device use plus lifestyle modification (500kcal deficit hypocaloric diet and 150 min of exercise per week for each subject).
89362266|NCT04145622|Experimental|Dose escalation|All participants enrolled in the dose escalation part
89362267|NCT04145622|Experimental|Dose expansion|All participants enrolled in the dose expansion part
89362268|NCT04140526|Experimental|ONC-392 Treatment as single agent|"The Part A study will test ONC-392 intravenous (IV) infusion up to five predefined dose levels from 0.1 mg/kg to 10 mg/kg ONC-392 as monotherapy every 21 days (Q3W). The Part A study will determine the maximal tolerable dose (MTD) and the recommended Phase 2 dose in monotherapy (RP2D-M).~In Part C, Arms A-C, I-N monotherapy expansion cohorts will further assess the safety and efficacy of ONC-392 in different dose levels as monotherapy in pancreatic cancer, triple negative breast cancer, non small cell lung cancer with driver mutations, PD-1 resistant non small cell lung cancer, PD-1 resistant melanoma, head and neck cancer, ovarian cancer, renal cell carcinoma and other solid tumors.~Part D is a Phase II study on recurrent and/or metastatic adenoid cystic carcinoma."
89362269|NCT04140526|Experimental|ONC-392 in combination with pembrolizumab|"The Part B1 study will test ONC-392 intravenous (IV) infusion, Q3W, in combination with fixed dose of pembrolizumab. The dose for pembrolizumab will be fixed at 200mg/cycle dosed every 21 days (Q3W).~The Part B1 will start at one level below RP2D-M dose for ONC-392 and 200mg of pembrolizumab. When 2 DLTs occur before 6 patients are enrolled, the ONC-392 dose will be decreased to the next dose level until ≤ 1/6 patients treated at that dose develops a DLT. This dose level will be designated RP2D-C.~In Part C, the expansion cohorts Arm D to G will assess the safety and efficacy of ONC-392 in different dose levels and Pembrolizumab combination therapy in non small cell lung cancer, and metastatic melanoma."
88833526|NCT05548231|Placebo Comparator|Placebo|Placebo administered SC
88833527|NCT05546931|Experimental|Intervention|A smartphone-based, interactive coaching application designed to enhance adherence to home-based blood pressure monitoring, provided guidance on blood pressure management, patient-facing education, and assistance with modifying behaviors associated with poor blood pressure control; connected to a wireless blood pressure cuff for accurate blood pressure measurement and automated storage on a digital platform. All participants in the experimental arm receive a smartphone for the 6-month intervention duration and the home-based blood pressure cuff.
88833528|NCT05546931|Active Comparator|Enhanced usual care|WebMD, a smartphone-based tool for learning about blood pressure and other health conditions. Enhanced usual care participants receive a wireless blood pressure cuff for accurate blood pressure measurement and automated storage on a digital platform. All participants in the experimental arm receive a smartphone for the 6-month intervention duration and the home-based blood pressure cuff.
88833529|NCT05543850|Active Comparator|Open loop control|In this arm, the patients will use their usual diabetes therapy. Additionally, patients will wear a blinded DexcomG6 for data collection during the open loop period.
88833530|NCT05543850|Experimental|Bi-hormonal closed-loop control|In this arm, treatment consists of the bi-hormonal closed-loop system. A short acting insulin analogue (Humalog, 3 ml pre-filled cartridge, Eli Lilly) and glucagon (Glucagen, Novo Nordisk; 3.15 ml cartridge Accu-Chek Spirit, Roche) will be administered according to the closed-loop algorithm. Additionally, patients will wear a blinded DexcomG6 for data collection during the closed loop period.
89189208|NCT04100681|Sham Comparator|Sham FlowOx™ (Placebo)|The application of a mild pulsating negative pressure will be up to 120 minutes long. The pulsating negative pressure used will be approximately 10 mm Hg alternating with ambient air pressure, the pulse consisting of 10 seconds of negative pressure followed by 7 seconds of atmospheric pressure.
89189209|NCT04098965|Experimental|Experimental|Physical Therapy Techniques
89189210|NCT04098965|Other|Control|physician treatment
88833534|NCT05538325||Group A|40 females who experienced cesarean birth
89189211|NCT02576730||Fratures|patient with foot and ankle fractures and surgery with ORIF
89189212|NCT02576730||healthy subjects|patients without foot and ankle fracture s
89189213|NCT04098887|Experimental|Lattice stereotactic body radiation therapy|Patients with up to 10 chondrosarcoma lesions will undergo radiotherapy to all sites of disease. For lesions less than 4.5 cm, traditional SBRT will be used. For sites 4.5 cm or greater, Lattice SBRT will be used. For Lattice SBRT, radiotherapy will be prescribed to 20 Gy in 5 fractions delivered every other day with a LATTICE simultaneous integrated boost (SIB) to 66.7 Gy in 5 fractions.
89189214|NCT04100603||Patients with CDI|Patients who are infected with C. diff
89189215|NCT00580788|Experimental|PTHrP(1-36) 2 pmol/kg/hr|PTHrP(1-36) at 2 picomoles/kg/hr for one week.
89189216|NCT00580788|Experimental|PTHrP (1-36) 4 pmol/kg/hr|PTHrP(1-36) at 4 picomoles/kg/hr for one week.
89189217|NCT00580788|Experimental|PTHrP(1-36) 5 pmol/kg/hr|PTHrP(1-36) at 5 picomoles/kg/hr for one week.
89189218|NCT00580788|Experimental|PTHrP(1-36) 6 pmol/kg/hr|PTHrP(1-36) at 6 picomoles/kg/hr for one week.
89189219|NCT02576106|Experimental|Cryoablation|Cryoablation of the tumor followed by a lumpectomy as practiced in standard care
89189220|NCT02575872|Experimental|Exercise Intervention|Participants partake in 30 minutes of group discussions regarding physical activity behavior followed by 60 minutes of moderate-intensity exercise comprised of 5 minutes warm-up, 25 minutes cardiovascular training, 20 minutes of resistance training exercises using body weight and exercise band, and 10 minutes of cool-down and stretching once weekly for 12 weeks. Participants also complete a brisk walk for 90 minutes per week outside of class for 12 weeks.
89189221|NCT02575872|No Intervention|wait-list for intervention|Participants receive a handout indicating the importance of physical activity and improved nutrition for health outcomes. After 12 weeks, patients are invited to participate in the physical behavior intervention as in Group I.
89189222|NCT04071678||A: Model A|Mode A was silent mode, back-to-back with endoscopic physicians to simultaneously display endoscopic images and record video, but did not interfere with the operation of endoscopic physicians.After the operation, the AI model automatically generates an endoscopy report, which is compared with the official report given by the endoscopy doctor in the endoscopy system. If the difference is large, video verification shall be played back immediately or endoscopic examination shall be performed again before the patient wakes up
89189223|NCT04071678||B: Model B|Mode B is a delayed reminder mode. If the lesion is found during the operation, it is required to be moved to the middle of the visual field within 5 seconds. If the lesion has been detected by the AI model (the lesion has been circled in the picture), but the doctor does not move the lesion to the middle of the visual field within 5 seconds, the AI system will give an alarm prompt
89189224|NCT04071678||C: Model C|Mode C is a real-time reminder mode, which is an alarm prompt when the focus is captured in the visual field.
89189225|NCT04073160|Experimental|Decipher Bladder test subtype non-basal|Subjects with localized muscle invasive urothelial carcinoma of the bladder, whose tumor is Decipher Bladder test subtype non-basal
89189226|NCT04073160|Experimental|Decipher Bladder test subtype basal and cisplatin-ineligible|Subjects with localized muscle invasive urothelial carcinoma of the bladder, whose tumor is Decipher Bladder test subtype basal and the subject is cisplatin-ineligible
89189227|NCT00417079|Active Comparator|Mitoxantrone + Prednisone|Mitoxantrone + Prednisone
89189228|NCT00417079|Experimental|Cabazitaxel + Prednisone|Cabazitaxel + Prednisone
89189229|NCT00429169|Active Comparator|Paroxetine|Participants will receive paroxetine for 8 weeks
89189230|NCT00429169|Active Comparator|Bupropion|Participants will receive bupropion for 8 weeks
89189231|NCT02575716|Experimental|Muscle relaxant|Intubation with McGrath video laryngoscope after fentanyl 1.5 mcg/kg, xylocaine 1.5 mg/kg and propofol 3 mg/kg muscle relaxant use rocuronium 0.6 mg/kg
89189232|NCT02575716|Placebo Comparator|Placebo|Intubation with McGrath video laryngoscope after fentanyl 1.5 mcg/kg, xylocaine 1.5 mg/kg and propofol 3 mg/kg placebo use NSS 0.6 mg/kg
89189233|NCT01034761|Experimental|Pop-up alerts|Providers will receive pop-up alerts in the electronic medical record when prescribing one of the specified medications from the Beers list.
89189234|NCT01034761|No Intervention|Usual care|
89362270|NCT04134923||[11C] Pittsburgh Compound-B (PIB)|Using [11C] Pittsburgh Compound-B (PIB) to look for biomarkers in preclinical and symptomatic AD.
89362271|NCT04128839|Experimental|Aronia juice (ARO)|A juice blend of three different cultivars was used: Viking, MacKenzie and Autumn Magic. Raw juice was heat pasteurized before provided to participants. Participants consumed 100 mL of juice per day for duration of intervention period (28-30 days)
89362272|NCT04128839|Sham Comparator|Placebo juice (PLA)|The placebo juice was flavor, color, and carbohydrate-matched to experimental Aronia juice. PLA consisted of 28.8 g black cherry Koolaid mix (no sugar added), 128.5 g sorbitol, 74.5 g glucose, 77.9 g fructose, 4 oz lemon juice, 16 drops of blue food coloring, and enough water to create 1 L of solution. Participants consumed 100 mL of juice per day for duration of intervention period (28-30 days)
89362273|NCT04128761|Experimental|Scarcity Narrative|Participants assigned to the scarcity group will be asked to listen and consider a hypothetical narrative about a sudden loss of resources.
89362274|NCT04128761|Sham Comparator|Neutral Narrative|Participants assigned to the neutral group will be asked to listen and consider a hypothetical narrative about a neutral change in resources.
89362275|NCT04122742||Patients with RSTS|
89001130|NCT04629001||without Covid-19 infection|
89362276|NCT04121312|Experimental|Facilitation Intervention|"A brief, web-based facilitation guide (called Weight Loss Your Way Kickoff Materials) that encourages initial and sustained engagement in online tracking and social network tools for weight loss.The intervention also includes 8 emails sent over 12 weeks to further motivate use of the online tools and weight loss."
89362277|NCT04116853|Experimental|ADAPTIVE Extended-Care Group|"Participants randomized to the ADAPTIVE extended-care program will receive extended-care intervention phone delivered only if either 1) an algorithm developed by our study team detects that a participant is at high risk for weight regain or 2) the participant self-initiates a request for a session."
89362278|NCT04116853|Active Comparator|STATIC Extended-Care Group|Participants randomized to the STATIC extended-care program will receive the extended-care intervention phone calls on a fixed, once-per-month schedule (the schedule currently used in gold-standard weight maintenance programs).
89362279|NCT04113811|Experimental|Microwave needle thermoablation of prostate cancer|The treatment will be performed under general anaesthesia or monitored anaesthetic care using the Biomedical TATO3® Microwave needle thermoablation device (Koelis, Grenoble, France) under Organ-based Tracking® (OBT) mechanism of the Koelis Trinity® machine. Both Koelis Trinity and TATO3 are CE (European Conformity) marked in Europe. A transrectal sideview ultrasound probe is used for real-time imaging and OBT of the prostate. The TATO3® needle is inserted transperineally to the tumor under MRI-Ultrasound fusion OBT guidance with the treatment zone covering the whole tumor. The dominant MRI-visible lesion and up to 1-2 more MRI-visible or invisible lesion will be treated.
89362280|NCT04111939|Experimental|Wave 1 - Intervention|Communities in Wave 1 will receive the CTH intervention during the first 30 months of the trial. The intervention will include 3 components: community engagement to assist key stakeholders in applying evidence-based practices to addressing their opioid crisis, a menu of evidence-based practices for communities to select and implement, and a communications campaign to build demand for evidence-based practices to address overdose and opioid use disorder.
89362281|NCT04111939|Other|Wave 2 - Wait-list comparison|Communities in Wave 2 will continue usual care during the first 30 months of the trial. At month 31, Wave 2 communities will begin receiving the CTH intervention.
89001131|NCT04629313||periodontal disease group|"Gingivitis: BOP score of 10% or greater and PD≤3mm with no attachment or radiographic bone loss.~SI Periodontitis: interdental AL of 1-2 mm, PD≤4 mm and no tooth loss SII Periodontitis: interdental AL of 3-4 mm, PD≤5 mm and no tooth loss SIII Periodontitis: interdental AL ≥5 mm, PD≥6 mm SIV Periodontitis: interdental AL ≥5 mm teeth, radiographic bone lose extending to middle or apical third of the root,"
89362282|NCT04104659||MK 6240|
89362283|NCT04100018|Experimental|Arm A: Nivolumab + docetaxel + prednisone|
89362284|NCT04100018|Placebo Comparator|Arm B: Placebo + docetaxel + prednisone|
89362285|NCT04098445||Pediatric and young adult HSCT recipients|Prospective multi-institutional cohort study in pediatric patients undergoing allogeneic (alloHSCT) or autologous hematopoietic stem cell transplantation (autoHSCT).
88818102|NCT02382575|Experimental|Rituximab|Two to four rituximab infusions (over 2-4 weeks) will be administered once every week at standard dose (Intravenous infusion of rituximab 375mg/mt2)depending on circulating B cells level.
89001132|NCT04629313||periodontal healthy group|consisted of individuals with clinically healthy gingiva
89001133|NCT04629040|Experimental|Intervention|
89001134|NCT04629040|Placebo Comparator|Control|
89001135|NCT00575302|Active Comparator|300|administration of 300 IU Gonal-f® in a short agonist protocol.
89001136|NCT00575302|Experimental|450|administration of 450 IU Gonal-f® in a short agonist protocol.
89001137|NCT00575341|Active Comparator|1|substitution of DHEA-hormone, oral, once daily
89001138|NCT00575341|Placebo Comparator|2|substitution of placebo, oral, once daily
89001139|NCT04579471||Transplanted patients|All patients who underwent solid organ or hematopoietic cell transplantation at UZ Leuven
89362286|NCT04094844|Active Comparator|Roadmap 2.0|"Roadmap 2.0 mobile app + wearable sensor to track activity and sleep + usual care (informational or educational resources provided through verbal communication or written hand-out materials).~Includes caregivers of adult patients and caregivers of pediatric patients"
89362287|NCT04094844|Experimental|Roadmap 2.0 with Positive Activities|"Roadmap 2.0 mobile app (patients), Roadmap 2.0 with mobile Positive Activities app (caregivers) + wearable sensor to track activity and sleep + usual care (informational or educational resources provided through verbal communication or written hand-out materials).~Includes caregivers of adult patients and caregivers of pediatric patients"
88833535|NCT05538325||Group B|15 females who experienced vaginal birth
88833536|NCT05538325||Group C|40 females who were the controls, did not experience any pregnancy
88833537|NCT05526690|Active Comparator|Treatment A: Immediate-release metformin|"Treatment A: single 1000 mg dose of immediate-release metformin~Subjects will be randomly assigned to 1 of 2 sequences: AB or BA.~Treatment A: a single 1000 mg dose of immediate-release metformin; and~Treatment B: a single 1000 mg dose of immediate-release metformin coadministered with a 10 mg dose of CIN-107.~All study medication will be administered at 8:00 AM (±2 hours). There will be a minimum 10-day washout between administration of study drug in each treatment period."
89362288|NCT04094428||Intensive care unit patient|All intensive care unit patients staying for at least 72 hours on the ICU and patients dying within 72 hours
89362289|NCT04084574|Experimental|Behavioral Diet Counseling|Groups of 4-6 participants will attend 12 weekly dietitian-led counseling sessions and receive coaching on practical strategies to enhance DASH diet adherence and reduce daily sodium intake.
89001140|NCT04579471||Transplanted patients with past SARS-CoV-2 infection|Transplanted patients with past SARS-CoV-2 infection will be followed for one year (at month 3, 6 and 12 after the initial study visit) to assess durability of IgG positivity
89362290|NCT04084574|Other|Standard of Care|Participants will meet one-on-one with the study dietitian for a single 30- minute encounter and be advised to limit daily sodium intake per current clinical practice guidelines for hypertension in patients with CKD. Educational handouts and tip sheets about practical strategies to reduce dietary sodium will be distributed.
89362291|NCT04067713||PARADIGM-D|Newly diagnosed metastatic prostate cancer patients starting long term therapy with Docetaxel with androgen deprivation therapy (ADT).
89362292|NCT04067713||PARADIGM-A|Newly diagnosed metastatic prostate cancer patients starting long term therapy with Androgen Receptor Signalling Inhibitor (ARSI) drugs with androgen deprivation therapy (ADT).
89362293|NCT04067713||PARADIGM-E|Newly diagnosed metastatic prostate cancer patients starting long term therapy with Enzalutamide with androgen deprivation therapy (ADT).
89362294|NCT04058366|Experimental|ELX/TEZ/IVA|"Part A: Participants received ELX (elexacaftor) 200 milligram (mg) once daily (qd)/TEZ 100 mg qd/IVA 150 mg every 12 hours (q12h) in the treatment period for 96 weeks.~Part B: Participants from certain countries participated in Part B and continued to receive ELX 200 mg qd /TEZ 100 mg qd/IVA 150 mg q12h in the treatment period for 48 weeks."
89362295|NCT04050007|Experimental|1|Preventive initiation of fluid removal
89362296|NCT04050007|Other|2|Curative initiation of fluid removal
89362297|NCT04049760|Experimental|migalastat HCl 150 mg|One migalastat 123 mg capsule equivalent to 150 mg migalastat HCl will be administered every other day (QOD) during the treatment period.
89362298|NCT04046913|Active Comparator|Low food additive diet|Dietary advice, given by a dietitian, will be discussed at trial baseline.
89362299|NCT04046913|Placebo Comparator|Habitual food additive diet|Dietary advice, given by a dietitian, will be discussed at trial baseline.
89362300|NCT04044937|Experimental|Population 1: Intracranial neoplasms (glial or metastatic disease)|Participants with intracranial neoplasms (glial or metastatic disease) with concern for recurrence or progression on conventional imaging (e.g., MRI) will receive F-18 fluoroethyltyrosine (FET) injected intravenously over approximately 1 minute and receive a single PET image lasting up to 40 minutes. Repeat FET PET will be offered to adult patients.
89362301|NCT04044937|Experimental|Population 2: Suspected glial neoplasms|Participants with suspected glial neoplasms (Grade 2-4) planning to undergo a non-investigational biopsy or surgery prior to non-investigational, primary treatment (radiation therapy and/or surgery) will receive F-18 fluoroethyltyrosine (FET) injected intravenously over approximately 1 minute and receive a single PET image lasting up to 40 minutes. Repeat FET PET will be offered to adult patients.
89362302|NCT04036058|Experimental|Intervention|Enact universal gloving practices
89362303|NCT04036058|No Intervention|Control|Continue standard of care gloving practices
89362304|NCT04031716|No Intervention|Control|Participants in the control group will receive present standard of care, which includes an assessment of participant/family needs by integrative care after surgery, as well as standard holistic health care by a licensed/certified holistic health specialist. They will not receive the MUSETM focused-attention meditation training or intervention protocol.
89362305|NCT04031716|Experimental|Meditation|Participants randomized to receive focused-attention meditation training will attend a preoperative training session, provided by a licensed/certified Holistic Health Specialist. The content will include an age appropriate explanation of focused-attention meditation, using breath as the focus; set-up and utilization of the MUSETM headband; and experiential practices. The goal of the intervention is to increase mindfulness (i.e., moment-to-moment, non-judgmental and non-reactive awareness of sensations, emotions, and thoughts), provide self-regulation strategies, and promote healthy and adaptive responses to stress.
89001141|NCT04579471||Transplanted patients without past SARS-CoV-2 infection|100 transplanted patients without past SARS-CoV-2 infection will be followed for one year (at month 3, 6 and 12 after the initial study visit) to assess durability of IgG positivity and as control for the transplanted patients with WITH past SARS-CoV-2 infection
89001142|NCT00575419|Experimental|1, IV NAC|N-acetylcysteine administered intravenously
89362306|NCT04030455|Experimental|Treatment (cisplatin, docetaxel, pembrolizumab)|Patients receive cisplatin IV over 1 hour, docetaxel IV over 1 hour (patients who develop significant adverse events to cisplatin treatment may receive carboplatin IV over 1 hour instead), and pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients who completely respond to the study drugs (the disease appears to go away) then receive pembrolizumab IV over 30 minutes on day 1 for 4 additional cycles in the absence of disease progression or unacceptable toxicity.
89362307|NCT04022980|Experimental|Stage 1|Safety Run-In
89362308|NCT04022980|Experimental|Stage 2|Expansion Cohort
89362309|NCT04021108|Other|Cohort 1|"Subjects will receive standard dose FOLFOX plus nivolumab 240mg IV every 2 weeks for 2 months. If you are responding to treatment, you will receive FOLFOX plus nivolumab for one additional month and then you will be randomized to Cohort 1 or Cohort 2.~Subjects in Cohort 1 will receive Nivolumab alone (every 2 weeks for two doses, and then every 4 weeks)"
89001143|NCT00575419|Experimental|2, IA NAC|N-acetylcysteine administered intra-arterial
89001144|NCT00575458||1|Static Splint
89001145|NCT00575458||2|Dynamic Splint
89001146|NCT00575497|Experimental|A|Six Day per week short daily hemodialysis
89001147|NCT00575497|Experimental|B|Six nights per week nocturnal hemodialysis
89001148|NCT00575497|Experimental|C|Every other day short daily hemodialysis
89001149|NCT00575497|Experimental|D|Every other night hemodialysis
89001150|NCT00575497|Experimental|E|5 days per week short daily hemodialysis
89001151|NCT00575497|Experimental|F|5 nights per week hemodialysis
89001152|NCT00575497|Active Comparator|G|Conventional three time per week short daily hemodialysis
89534555|NCT02492945|Active Comparator|Dextrose group|They take the three times of the ultrasonography-guided injections for four weeks(0,2,4 weeks) under double-blind. Dextrose group as active control group takes the 3ml-15%-dextrose solution for same procedure: the lesion( tear or tendinosis about extensor carpi radialis brevis, extensor digitorum communis, radial collateral ligament ) of lateral epicondylitis for 4 weeks. This dextrose solution for common extensor tendons are used as prolotherapy.
89189235|NCT01037491|Active Comparator|aspirin|Patients who have taken aspirin for more than 1 month and are found to have PUD by upper endoscopy will receive PPI (rabeprazole 20 mg once daily) to treat their PUD.patients will be randomly assigned rabeprazole (20 mg/day) plus aspirin (100 mg/day) or rabeprazole (20 mg/day) plus clopidogrel (75 mg/day) for 12 weeks.
89189236|NCT01037491|Active Comparator|clopidogrel|Patients who have taken aspirin for more than 1 month and are found to have PUD by upper endoscopy will receive PPI (rabeprazole 20 mg once daily) to treat their PUD.patients will be randomly assigned rabeprazole (20 mg/day) plus aspirin (100 mg/day) or rabeprazole (20 mg/day) plus clopidogrel (75 mg/day) for 12 weeks.
89534556|NCT03335423|Experimental|Oral Metformin|Oral metformin 1000mg will be given as a single dosis
89534557|NCT03335423|Experimental|Intravenous metformin|Intravenous metformin 500mg will be injected as a single dosis
89534558|NCT03335423|Experimental|Oral codeine and oral metformin|Codeine 25 mg will be given at 5 occasions with approximately 6 hours between each dosing. The fifth and last dose will be given together with 1000 mg oral metformin
89362310|NCT04021108|Experimental|Cohort 2|"Subjects will receive standard dose FOLFOX plus nivolumab 240mg IV every 2 weeks for 2 months. If you are responding to treatment, you will receive FOLFOX plus nivolumab for one additional month and then you will be randomized to Cohort 1 or Cohort 2.~Subjects in Cohort 2 will receive Nivolumab (every 2 weeks for two doses, and then every 4 weeks) plus radiation therapy (total 5 sessions)"
89362311|NCT04008706|Experimental|Acalabrutinib|Participants will be enrolled into 3 cohorts. In the treatment-naive cohort, a minimum of 300 participants with treatment-naïve chronic lymphocytic leukemia will be enrolled. In the relapsed/refractory cohort, approximately 200 participants with relapsed/refractory chronic lymphocytic leukemia will be enrolled. In the prior ibrutinib cohort, approximately 40 participants with Prior ibrutinib therapy will be enrolled.
89362312|NCT03997123|Experimental|Capivasertib + Paclitaxel|"Paclitaxel: Intravenous infusion. 3 consecutive weekly infusions of 80 mg/m2 (given on Day 1 of Weeks 1, 2, and 3), followed by 1 week off-treatment within each 28-day treatment cycle.~Capivasertib: Oral tablets. 400 mg of Capivasertib (2 tablets) BD given on an intermittent weekly dosing schedule. Dosed on Days 2 to 5 of Weeks 1, 2, and 3 followed by 1 week off-treatment within each 28-day treatment cycle."
89362313|NCT03997123|Placebo Comparator|Placebo + Paclitaxel|"Paclitaxel: Intravenous infusion. 3 consecutive weekly infusions of 80 mg/m2 (given on Day 1 of Weeks 1, 2, and 3), followed by 1 week off-treatment within each 28-day treatment cycle.~Placebo: Oral tablets. 400 mg of Placebo (2 tablets) BD given on an intermittent weekly dosing schedule. Dosed on Days 2 to 5 of Weeks 1, 2, and 3 followed by 1 week off-treatment within each 28-day treatment cycle."
89362314|NCT03995953|No Intervention|Control|2 control zones with no intervention at the clinic or community level
89362315|NCT03995953|Experimental|SHIELD: Community-based behavioral intervention|2 clinic zones where participants attend modules designed to educate and empower adolescent girls and young women (AGYWs) and their families, along with attendance at community-based youth clubs to foster peer support.
89362316|NCT03995953|Experimental|SHIELD: Community- based behavioral intervention & IWC Clinic|2 clinic zones where participants receive the Support for HIV Integrated Education, Linkages to care, and Destigmatization (SHIELD) intervention along with the coupled benefits of having an integrated wellness care (IWC) clinic within health facilities where adolescent girls and young women (AGYWs) can receive sexual and reproductive health services, including HIV testing and treatment, family planning, sexually transmitted disease screening and treatment, and human papilloma virus (HPV) vaccination.
89362317|NCT03992131|Experimental|Arm A: Rucaparib and Lucitanib|Participants will receive oral rucaparib twice daily (BID) and oral lucitanib once daily (QD) continuously in 28-day cycles.
89362318|NCT03992131|Experimental|Arm B: Rucaparib BID and Sacituzumab Govitecan|Participants will receive oral rucaparib BID, administered continuously, in combination with intravenous (IV) sacituzumab govitecan administration on Day 1 and Day 8 of a 21-day cycle.
89001153|NCT00575536||Rhizotomy for children with spasticity|Children with spasticity needing Rhizotomy surgery
89001154|NCT00575575|Experimental|A,2|
89362319|NCT03992131|Experimental|Arm B: Rucaparib QD and Sacituzumab Govitecan|Participants will receive oral rucaparib QD, administered continuously, in combination with IV sacituzumab govitecan administration on Day 1 and Day 8 of a 21-day cycle.
89362320|NCT03962166||Cohort|consecutive adult patients undergoing first-time elective open-heart surgery
89362321|NCT03955445|Experimental|Cohort A: participants with native kidneys from CLNP023X2202|C3G participants from study CLNP023X2202 with native kidneys receiving LNP023 capsules 200 mg b.i.d
89362322|NCT03955445|Experimental|Cohort B: participants with transplanted kidneys from CLNP023X2202|C3G participants from study CLNP023X2202 who have undergone kidney transplant and have recurrence of C3G receiving LNP023 capsules 200 mg b.i.d
89362323|NCT03955445|Experimental|Cohort C: Participants with native C3G from CLNP023B12301|Participants from CLNP023B12301 study receiving LNP023 capsules 200 mg b.i.d
89362324|NCT03955029|Experimental|Conventional Interval training|It is a split-type workout that alternates periods of intensity between 60% -95% of the maximum effort (depending on the modality) and periods of passive or active rest between 20-30% of the maximum effort. The experimental group will follow conventional Interval Training
89362325|NCT03955029|Experimental|Progressive Interval training|It is a split-type workout that alternates periods of intensity between 60% -95% of the maximum effort (depending on the modality) and periods of passive or active rest between 20-30% of the maximum effort. The experimental group will follow progressive Interval Training
89362326|NCT03953612|Experimental|patients receiving PREG|Eligible participants will be randomly assigned to 2 doses of PREG (300/500 mg/day) over 8 weeks with a) an inpatient-outpatient option where they will be admitted to the Clinical Neuroscience Research Unit (CNRU) at the Connecticut Mental Health Center (CMHC) for first two weeks and then outpatient at Yale Stress Center (YSC) for the remaining 6 weeks, or b) an outpatient option where they will participate in the entire study outpatient at YSC.
89362327|NCT03953612|Placebo Comparator|patients receiving placebo|Eligible participants will be randomly assigned to a placebo (PLA) treatment over 8 weeks with a) an inpatient-outpatient option where they will be admitted to the Clinical Neuroscience Research Unit (CNRU) at the Connecticut Mental Health Center (CMHC) for the first two weeks and then transition to outpatient at Yale Stress Center (YSC) for the remaining 6 weeks, or b) an outpatient only option where they will participate in the entire study outpatient at YSC.
89362328|NCT03946878|Experimental|Treatment (acalabrutinib, venetoclax)|Patients receive acalabrutinib PO BID on days 1-28. Starting cycle 2 day 1, patients also receive venetoclax PO daily. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89362329|NCT03943004|Experimental|DFP-14927|DFP-14927: weekly IV infusion, 28 day treatment cycle
89362330|NCT03921905||Patients with CAD|In this study will be included patients with stable CAD
89362331|NCT03914664||Tourette Syndrome|Adults (>18 years of age) with diagnosis of Tourette syndrome
89362332|NCT03914664||Healthy Control|Adults who are generally healthy with no known neurologic or psychiatric diagnoses
89001155|NCT00575614|Active Comparator|1|
89001156|NCT00575614|Placebo Comparator|2|
89001157|NCT00575653||11-18 (Primary)|Enrolled members of one of the participating health plans who are ages 11-18 at any time during the study period, March 1, 2005 through August 31, 2008.
89178249|NCT04106622||Wolff Parkinson White patients|"The investigators will decide the location of the AP by:~- Invasively: if the patient is subjected to (EPS)~• There are different locations of AP To assess whether the AP is of high risk or not, for all patients the Antegrade refractory period of the APAERP of the AP will be determined by one of the following ways: ( AERP) is measured during EPS as the shortest cycle length with one-to-one conduction over the AP by incremental atrial stimulation after which the QRS becomes narrow or no conduction occurs due to block of the impulse in the AP. The shortest pre-excited R-R interval (SPERRI) during spontaneous or induced AF.~The AERP and the risk category of the AP according to its value, will be recorded in relation to the site of the AP determined in every case and compared between different accessory Locations to see whether some of these positions are more liable to be of higher risk or there is no differerence between different positions."
89362333|NCT03907397|Active Comparator|Treatment|Ingests peanut - . Depending upon reaction threshold, participants may begin with different starting amounts of store bought peanut butter measured with study-supplied kitchen measuring spoons.
89362334|NCT03907397|No Intervention|Avoidance|Avoids peanut, standard care
89362335|NCT03903835|Active Comparator|Control: Standard Care|Randomization between assignment to the control arm or the biomarker driven arm will be stratified on biomarker signatures, previous treatment, and fraction of ctDNA and will therefore occur after the results from the ctDNA profiling is obtained. Patients in the control arm will receive standard of care following national guidelines.
89362336|NCT03903835|Experimental|Treatment 1 in mHSPC: AR signalling inhibitors (ARSi)|Assignments to therapy in the biomarker driven arms will be done on the basis of the biomarker signature using the current information about the efficacy of the various regimens for that signature. Information from previous studies may be incorporated in the randomization at study onset if such reliable data exists. Specifically, patients with an intact androgen receptor (AR) and without TP53 mutations will have increased chance of being randomized to treatment with ARSi.
89362337|NCT03903835|Experimental|Treatment 2 in mHSPC: taxane-based chemotherapy in combination with ARSi|Patients with TP53 mutations and TMPRSS2-ERG gene fusions will have an increased chance of being randomised to treatment with chemotherapy plus an ARSi.
89362338|NCT03903835|Experimental|Treatment 3 in mHSPC: Poly ADP Ribose Polymerase (PARP) inhibitor|DNA-repair deficient patients will have an increased chance of receiving PARP inhibitors at study onset.
89362339|NCT03903835|Experimental|Treatment 1 in mCRPC: AR signalling inhibitors (ARSi)|Specifically, patients with an intact androgen receptor (AR) and without TP53 mutations will have increased chance of being randomized to treatment with ARSi.
89362340|NCT03903835|Experimental|Treatment 2 in mCRPC: Poly ADP Ribose Polymerase (PARP) inhibitor|DNA-repair deficient patients will have an increased chance of receiving PARP inhibitors at study onset.
89362341|NCT03903835|Experimental|Treatment 3 in mCRPC: selective AKT Inhibitor|Patients with alterations in the PI3K pathway will have an increased chance of receiving the combination treatment with Capivasertib plus Docetaxel.
88833538|NCT05526690|Experimental|Treatment B: Immediate-release metformin coadministered with a CIN-107|"Treatment B: a single 1000 mg dose of immediate-release metformin coadministered with a 10 mg dose of CIN-107~Subjects will be randomly assigned to 1 of 2 sequences: AB or BA.~Treatment A: a single 1000 mg dose of immediate-release metformin; and~Treatment B: a single 1000 mg dose of immediate-release metformin coadministered with a 10 mg dose of CIN-107.~All study medication will be administered at 8:00 AM (±2 hours). For Treatment B, the dose of CIN-107 will be administered 2 hours prior to the dose of metformin.~There will be a minimum 10-day washout between administration of study drug in each treatment period."
88833539|NCT05526430|Experimental|Harmine Dose|There will be a total of seven possible doses that include 100 mg, 200 mg, 300 mg, 500 mg, 700 mg, 900 mg and 1200 mg. Each study subject will receive a single oral dose of harmine in this single ascending dose design.
88833540|NCT05523739|Experimental|Part 1: Cohort 1|Participants will receive a single 300 mg dose of STI-1558 or placebo. Cohort 1 will dose 6 subjects to STI-1558 and 2 subjects to placebo.
88833541|NCT05523739|Experimental|Part 1: Cohort 2|Participants will receive a single 600 mg dose of STI-1558 or placebo. Cohort 2 will dose 6 subjects to STI-1558 and 2 subjects to placebo.
88833542|NCT05523739|Experimental|Part 1: Cohort 3|Participants will receive a single 1200 mg dose of STI-1558 or placebo. Cohort 3 will dose 6 subjects to STI-1558 and 2 subjects to placebo.
88833543|NCT05523739|Experimental|Part 1: Cohort 4|Participants will receive a single 2000 mg dose of STI-1558 or placebo. Cohort 4 will dose 6 subjects to STI-1558 and 2 subjects to placebo.
88833544|NCT05523739|Experimental|Part 2: Cohort 1|"Participants will receive a 300 mg dose of STI-1558 or placebo q12h on Day1 to Day7 and once in the morning on Day8 for a total of 15 doses.~Cohort 1 will dose 6 subjects to STI-1558 and 2 subjects to placebo."
88833545|NCT05523739|Experimental|Part 2: Cohort 2|"Participants will receive a 600 mg dose of STI-1558 or placebo q12h on Day1 to Day7 and once in the morning on Day8 for a total of 15 doses.~Cohort 2 will dose 16 subjects to STI-1558 and 8 subjects to placebo."
88833546|NCT05523739|Experimental|Part 2: Cohort 3|"Participants will receive a 800 mg dose of STI-1558 or placebo q12h on Day1 to Day7 and once in the morning on Day8 for a total of 15 doses.~Cohort 3 will dose 16 subjects to STI-1558 and 8 subjects to placebo."
88833547|NCT05520528|Experimental|Reading Group|All participants in this group will receive language intervention within weekly group sessions and independent tasks with emphasis on improving reading and writing skills among persons with aphasia.
88833548|NCT05520138||Enzalutamide cohort|Patients with mCRPC initiating enzalutamide
88833549|NCT05520138||Abiraterone cohort|Patients with mCRPC initiating abiraterone
88833550|NCT05517980|Experimental|IgAN Cohort Stage 1 Dose 1|Participants will be randomized to receive weekly or biweekly maintenance doses of KP104 at Dose 1. Participants in Stage 1 will also have the opportunity to be switched to the OBD if they are still in the treatment period.
88833551|NCT05517980|Experimental|C3G Cohort Stage 1 Dose 1|Participants will be randomized to receive weekly or biweekly maintenance doses of KP104 at Dose 1. Participants in Stage 1 will also have the opportunity to be switched to the OBD if they are still in the treatment period.
88833552|NCT05517980|Experimental|IgAN Cohort Stage 1 Dose 2|Participants will be randomized to receive weekly or biweekly maintenance doses of KP104 at Dose 2. Participants in Stage 1 will also have the opportunity to be switched to the OBD if they are still in the treatment period.
88833553|NCT05517980|Experimental|C3G Cohort Stage 1 Dose 2|Participants will be randomized to receive weekly or biweekly maintenance doses of KP104 at Dose 2. Participants in Stage 1 will also have the opportunity to be switched to the OBD if they are still in the treatment period.
88833554|NCT05517980|Experimental|IgAN Cohort Stage 2|Participants will receive weekly or biweekly maintenance doses of KP104 at the OBD.
88833555|NCT05517980|Experimental|C3G Cohort Stage 2|Participants will receive weekly or biweekly maintenance doses of KP104 at the OBD.
88833556|NCT05516849|Experimental|Oxandrolone|Participants will be randomly assigned in a 1:1 fashion to one of the two treatment arms using the REDCap database randomization procedure.
88833557|NCT05516849|Placebo Comparator|Placebo|Participants will be randomly assigned in a 1:1 fashion to one of the two treatment arms using the REDCap database randomization procedure.
88833558|NCT05514834|Experimental|combined HA with PRP|Hyaluronic acid and PRP combination treatment
88833559|NCT05514834|Placebo Comparator|Placebo|saline solution
88833560|NCT05514834|Active Comparator|PRP|Platelet rich plasma without hyaluronic acid
88833561|NCT05510427|Experimental|Part A (Dose Escalation)|The first group of participants will receive the lowest dose level of infigratinib.
88833562|NCT05510427|Experimental|Part B (Dose Expansion)|Participants will receive infigratinib at the recommended dose that was found in Part A.
88833563|NCT05509985|Experimental|ASKG315|Single or multiple ascending dose of ASKG315
88833564|NCT05505292|Placebo Comparator|Lifitegrast Ophthalmic Solution Vehicle|
88833565|NCT05505292|Experimental|Lifitegrast Ophthalmic Solution 5%|
88833566|NCT05503238|Experimental|Skin-to-skin contact group|Provide maternal-infant skin-to-skin contact for preterm infants in the neonatal intensive care unit.
88833567|NCT05503238|Other|Routine care group|Perform routine nursing care for preterm infants in the neonatal intensive care unit.
88833568|NCT05503212||AIS and isolated VAO|Patients with acute ischemic stroke (AIS) and concomitant isolated intracranial and/or extracranial vertebral artery occlusion (VAO)
88833569|NCT05500820|Experimental|Cohort 1: 2.5 mg CIN-107|Subjects on a low salt diet
88833570|NCT05500820|Experimental|Cohort 2: 5.0 mg CIN-107|Subjects on a low salt diet
88833571|NCT05500820|Experimental|Cohort 3: 1.5 mg CIN-107|Subjects on a normal salt diet
88833572|NCT05500820|Experimental|Cohort 4: 2.5 mg CIN-107|Subjects on a normal salt diet
88833573|NCT05500820|Experimental|Cohort 5: 0.5 mg CIN-107|Subjects on a normal salt diet
88833574|NCT05500820|Placebo Comparator|Cohort 1: 2.5 mg matching placebo|Subjects on a low salt diet
88833575|NCT05500820|Placebo Comparator|Cohort 2: 5.0 mg matching placebo|Subjects on a low salt diet
88833576|NCT05500820|Placebo Comparator|Cohort 3: 1.5 mg matching placebo|Subjects on a normal salt diet
88833577|NCT05500820|Placebo Comparator|Cohort 4: 2.5 mg matching placebo|Subjects on a normal salt diet
88833578|NCT05500820|Placebo Comparator|Cohort 5: 0.5 mg matching placebo|Subjects on a normal salt diet
88833579|NCT05497180|Experimental|Passive Myofunctional Appliance|provision of passive myofunctional appliance
89362342|NCT03903835|Experimental|Treatment 4 in mCRPC: Carboplatin|Only patients with DNA-repair deficiency will be treated with Carboplatin as second line treatment in the castration-resistant phase of ProBio.
88833580|NCT05497180|Active Comparator|Oral Appliance Therapy|provision of mandibular advancement device
88833581|NCT05495997|Experimental|Mental Imagery|
88833582|NCT05495997|Active Comparator|Psychoeducation|
88833583|NCT05493891||Group A|40 participants have been exposed to cesarean delivery
88833584|NCT05493891||Group B|15 participants have been exposed to vaginal delivery
88833585|NCT05493891||Group C|40 participants who were in the control negative group (no previous pregnancy),
88833586|NCT05493501|Experimental|Aumolertinib monotherapy|
88833587|NCT05493501|Experimental|Aumolertinib + platinum-based doublet chemotherapy|"For adenocarcinoma, either:~Aumolertinib + cisplatin with pemetrexed, or~Aumolertinib + carboplatin with pemetrexed~For squamous cell carcinoma, one of the following:~Aumolertinib + cisplatin or carboplatin with paclitaxel;~Aumolertinib + cisplatin or carboplatin with albumin-bound paclitaxel; or~Aumolertinib + cisplatin or carboplatin with gemcitabine"
88833588|NCT05493501|Active Comparator|Osimertinib monotherapy|
88833589|NCT05492721|Active Comparator|Dermabond|Dermabond over incisions
88833590|NCT05492721|Active Comparator|Swiftset|Swiftset over incisions
88833591|NCT05492474|Experimental|Cranial Point of Care Ultrasound|Cranial ultrasound involves 2-dimensional B mode imaging of the brain parenchyma in the axial plane
88833592|NCT05492240|Experimental|i-STRONGER|The high-intensity rehabilitation intervention, termed i-STRONGER, relies on principles of physiologic overload using an 8-repetition max (8RM) to promote muscle strengthening and emphasizes functional carryover for independence.
88833593|NCT05492240|Active Comparator|Usual Care|The Usual Care SNFs will continue clinical practice as normal, and sites will not have any overlap of personnel or training with i-STRONGER SNFs.
88833594|NCT05488964|Experimental|Exercise|Regular endurance training for 8 weeks
88833595|NCT05488964|No Intervention|Control|Habitual living for 8 weeks
88833596|NCT05483530|Experimental|HLX60 combined with HLX10|
88833597|NCT05483231|Experimental|Family integrated care intervention group|Provide Family integrated care for very low birth weight infants in the NICU.
88833598|NCT05483231|Other|Routine nursing care group|Perform routine nursing care for very low birth weight infants in the NICU.
88833599|NCT05483153|Experimental|Infant-Directed Singing Coaching Group|At-risk mothers and infants will receive four, 30-minute sessions of an infant-directed singing coaching intervention.
88833600|NCT05478278|Experimental|Part 1: Treatment A (IP at Therapeutic Dose)|A single therapeutic dose of psilocybin.
88833601|NCT05478278|Experimental|Part 1: Treatment B (IP at Supratherapeutic Dose)|A single supratherapeutic dose of psilocybin.
88833602|NCT05478278|Placebo Comparator|Part 1: Treatment C (Placebo - Negative Control)|A single dose of placebo-to-match psilocybin MCC capsules.
88833603|NCT05478278|Active Comparator|Part 1: Treatment D (Placebo - Positive Control)|A single 400 mg dose of moxifloxacin.
88833604|NCT05478278|Experimental|Part 2: IP at Therapeutic Dose (Fasted Conditions)|A single therapeutic dose of psilocybin administered under fasted conditions.
89362343|NCT03884543|Experimental|Individualized high PEEP strategy|Recruitment maneuver (performed after induction of anesthesia, after any disconnection from the mechanical ventilator, and before extubation) followed by the decremental PEEP trial to determine the highest level of PEEP resulting in the lowest driving pressure. This is again followed by a recruitment maneuver, after which PEEP is set at the level indicated by the decremental PEEP trial.
88833605|NCT05478278|Experimental|Part 2: IP at Therapeutic Dose (Fed Conditions)|A single therapeutic dose of psilocybin under fed conditions.
88833606|NCT05478239|Experimental|Prostate cancer patients|Men with biochemical recurrence of prostate cancer after initial local therapy.
89362344|NCT03884543|No Intervention|Standard low PEEP strategy|PEEP at maximum 5cm H2O. No recruitment maneuvers. Patients are randomized and intraoperatively ventilated with conventional strategy. (PEEP at maximum 5cm H2O without recruitment maneuvers)
89362345|NCT03881098|Other|Squamous Cell Carcinoma Pre-Malignant Lesions|The prospective SCC-PML cohort is envisioned to provide a well-matched group of high-risk subjects that will provide clinically comparable subjects with lesional sites representing progressive and non-progressive disease.
89362346|NCT03875144|Experimental|association of PIPAC and systemic chemotherapy|4 PIPAC of Cisplatin 10.5mg/m² + Doxorubicin 2.1 mg/m² every 6 weeks alternating with standard intravenous chemotherapy for mesothelioma (Cisplatin 75mg/m² + Pemetrexed 500mg/m²)
89362347|NCT03875144|Active Comparator|systemic chemotherapy alone|6 cycles of Cisplatin 75mg/m² + Pemetrexed 500mg/m²
89362348|NCT03873870|Experimental|68Ga -DOTATATE PET scan|Single arm study.
88833607|NCT05475782|Active Comparator|Spyglass group|lithotripsy through Spyglass and ERCP
88833608|NCT05475782|Experimental|ESWL group|Lithotripsy through ESWL and ERCP
88833609|NCT05475210|Experimental|Peptide Receptor Radionucleotide Therapy (PRRT)|The treatment regimen will consist of a single-dose intravenous administration of 177Lu-DOTA-EB-TATE per 6-week cycle, for a total of 2 cycles. The dose per cycle will be fixed for each patient and will be escalated in 3 different dose levels, from 50 mCi to 150 mCi (1.85 -5.55 GBq). Each dose of 177Lu-DOTA-EB-TATE will be administered in association with intravenous renal protective amino acid solutions.
88833610|NCT05471908|Experimental|As-needed (PRN) post-hospitalization follow-up|At hospital discharge, participant receives a recommendation for PRN follow-up. Recommendation informs participant that scheduling a follow-up visit is not needed at discharge and suggests that participant follow symptoms after discharge to decide if a visit is ultimately needed or not.
88833611|NCT05471908|Active Comparator|Automatic post-hospitalization follow-up|At hospital discharge, participant receives a recommendation for automatic follow-up. Recommendation instructs participant to schedule a follow-up visit and attend the visit even if symptoms get better.
88833612|NCT05470725|Experimental|Control (normal renal function or mild renal impairment)|Estimated glomerular filtration rate (eGFR) ≥60 mL/min
88833613|NCT05470725|Experimental|Moderate to severe renal impairment|eGFR 15 to 59 mL/min
88833614|NCT05470725|Experimental|Kidney failure|"eGFR <15 mL/min, including:~Subjects not on dialysis; and~Subjects on dialysis, with study drug administration on a non-dialysis day"
88833615|NCT05469789||Prevalent Cohort A|Prevalent Cohort A will comprise eligible participants with HAE type I or II who have initiated treatment with lanadelumab at any point in time (i.e., all prevalent cases of exposure to lanadelumab). The total follow-up encompasses a 12-month pre-treatment period, and an up-to 24-month post-treatment period.
88833616|NCT05469789||Prevalent Cohort B|Prevalent Cohort B will comprise eligible participants with HAE type I or II who have been treated with lanadelumab for <12 months (i.e., the subset of participants from Prevalent Cohort A who initiated treatment with lanadelumab within <12 months). The total follow-up encompasses a 12-month pre-treatment and an up to 24-month post-treatment period, as well as a prospective data collection period of participant-specific duration.
88833617|NCT05469789||Incident Cohort A|Incident Cohort A will comprise eligible participants with HAE type I or II initiating treatment with lanadelumab at any time within the prospective data collection time period. The total follow-up encompasses a 12-month pre-treatment and an up-to 24-month post-treatment period, as well as a prospective data collection period of participant-specific duration.
88833618|NCT05468151|Experimental|Cold acclimation protocol|Participants with obesity (n = 20) will undergo weekly cold water immersions (water temperature 18ºC, two to three times a week, 30 minutes per day) for, at least, 12 weeks. Before and after the cold acclimation period, the participants will undergo PET/CT scans at room temperature and after controlled cold exposure to investigate BAT perfusion, BAT glucose and NEFA uptakes.
88833619|NCT05468151|Other|Acute cold exposure - control volunteers with obesity|"PET/CT scans will be carried out after 2 hours of cold exposure The participants in this group (n = 10) will undergo PET/CT scans at baseline and 12 weeks after the first scan.~The participants will undergo PET/CT scans at room temperature and after 2 hours of controlled cold exposure to investigate BAT perfusion, BAT glucose and NEFA uptakes."
88833620|NCT05468151|Other|Acute cold exposure - lean controls|PET/CT scans will be carried out after 2 hours of cold exposure The participants in this group (lean, n = 15) will undergo PET/CT scans at room temperature and after 2 hours of controlled cold exposure to investigate BAT perfusion, BAT glucose and NEFA uptakes.
88833621|NCT05466929|Experimental|TeACH System Resources|Patients who screen positive for anxiety will receive stakeholder-informed feedback and resources (i.e., psychoeducation and mental health recommendations).
88833622|NCT05466929|No Intervention|Evidence-based Resources|Patients who screen positive for anxiety will receive a link to a webpage providing psychoeducation about anxiety and possible treatment options.
88833623|NCT05465109|Experimental|TACSI|
88833624|NCT05465109|No Intervention|Usual care control group|The usual care control group would have continued receipt of standard services at either the Mayo Clinic or the MVAHCS. In addition, staff will offer participants the opportunity to request supportive/educational resources as needed after randomization.
89362349|NCT03858530|Experimental|All Patients Enrolled|All patients will undergo limited abdominal US with Doppler and SWE once a week upon admission for conditioning until the patient day +30 BMT or discharge, whichever comes first. Additional ultrasounds will also be performed if SOS is suspected.
89362350|NCT03857256|Placebo Comparator|Placebo|matching placebo for 12 weeks.
89362351|NCT03857256|Active Comparator|Oat beta-glucan 1.5g|CP105F (Oat beta-glucan) 1.5g (1 tablet of 0.5g TID) for 12 weeks.
88833625|NCT05461755|Experimental|Combination therapy: Fractional radiofrequency and topical tretinoin|3 study treatments: at baseline, 1-month, 2-month with subsequent application of topical tretinoin. Home application of tretinoin between study visits
88833626|NCT05461755|Active Comparator|Fractional radiofrequency|3 study treatments: at baseline, 1-month, 2-month
88833627|NCT05461755|Active Comparator|Topical tretinoin|Application at study visits and home application between study visits
88833628|NCT05461755|No Intervention|Untreated control|No study treatments
88833629|NCT05450965|Experimental|Single Treatment Arm|Onvansertib
88833630|NCT05448833|Experimental|V-LAP™ System|Heart failure subjects - Percutaneous implantation of the V-LAP™ implant by right heart catheterization (RHC) approach and daily LAP measurements at home and will be trained on the use of the device for self-management.
88833631|NCT05446909|Experimental|IBMT mindfulness|An evidence-based preventive intervention - integrative body-mind training (IBMT) has shown positive effects in reducing stress, and improving self-control and brain plasticity related to cognitive performance. It has bodifulness and mindfulness components.
88833632|NCT05446909|Active Comparator|health education|Health education includes health-related topics - exercise, sleep, stress management, nutrition, lifestyle
88833633|NCT05444582|Other|52 mg LNG IUD Same Day Start or EC|"Week 1: Text daily for seven days. Report occurrences of the following in the last day: presence or absence of bleeding, spotting, pain, sexual intercourse, use of other methods of contraception, IUD expulsion or removal, and report any additional medical care received.~Weeks 2 & 3: Weekly text survey assessing on which days of the previous week participants experienced bleeding and spotting, sexual intercourse, use of other methods of contraception, IUD expulsion or removal, or experienced adverse events.~Week 4 Survey: At 28 days, participants will be asked about pregnancy symptoms, concern about pregnancy, and the result of their urine pregnancy test including a prompt to upload a photo of the test."
88833634|NCT05442034|Experimental|recombinant human platelet derived growth factor (rh-PDGF) in combination with bone allograft|recombinant human platelet derived growth factor is a protein that is found in blood serum. It helps to recruit stem cells into the area to aid in cell differentiation and proliferation. When added to mineralized bone allograft, it stimulates the angiogenesis in the area, and this in turn may increase the outcomes of regeneration.
88833635|NCT05442034|Active Comparator|Enamel matrix derivatives (EMD) in combination with bone allograft.|Enamel matrix derivatives are natural proteins that are produced in the developing dental follicle. It has been available for decades and has been proved to help in regeneration of intrabony defects when applied into the root surface. When combined with bone allograft, it results in regeneration of intrabony defects.
88833636|NCT05440799|Experimental|BI 1819479|
88833637|NCT05440799|Placebo Comparator|Placebo|
88833638|NCT05437900|Experimental|Pressure Microcatheter guided strategy - PIOS-MC|Patients will be treated with the Pressure Microcatheter during PCI. After completing an angiographically successful PCI, patients will be randomized to FFR-guided stent optimization (PIOS).
89362352|NCT03857256|Active Comparator|Oat beta-glucan 3g.|CP105F (Oat beta-glucan) 3g (2 tablets of 0.5g TID) for 12 weeks.
89362353|NCT03857256|Active Comparator|Oat beta-glucan 6g.|CP105F (Oat beta-glucan) 6g (4 tablets of 0.5g TID) for 12 weeks.
89362354|NCT03850691|Experimental|Cohort 1: Nivolumab|
89362355|NCT03850691|Experimental|Cohort 2: Nivolumab & Ipilimumab|
89362356|NCT03847857|Experimental|Surgery+PFS|Arm A consists of the concurrent application of Porcine Fibrin Sealant (PFS) on the gastroesophageal anastomosis during McKeown esophagectomy.
89362357|NCT03847857|Placebo Comparator|Surgery|Arm B underwent conventional anastomosis during McKeown esophagectomy.
89362358|NCT03840902|Experimental|cCRT plus M7824 followed by M7824|Participants received cCRT: Cisplatin/Etoposide or Carboplatin/Paclitaxel or Cisplatin/Pemetrexed concomitant with Intensity Modulated Radiation Therapy (IMRT) along with M7824 followed by M7824.
89362359|NCT03840902|Active Comparator|cCRT plus placebo followed by durvalumab|Participants received cCRT: Cisplatin/Etoposide or Carboplatin/Paclitaxel or Cisplatin/Pemetrexed concomitant with Intensity Modulated Radiation Therapy (IMRT) along with placebo matched to M7824 followed by durvalumab.
89362360|NCT03839446|Experimental|mitoxantrone + etoposide + gemtuzumab ozogamicin|10 mg/m2 mitoxantrone days 1-5 + 100mg/m2 etoposide days 1-5 + 3mg/m2 gemtuzumab ozogamicin on day 6
89362361|NCT03837821|Experimental|All Subjects|Abemaciclib 200 mg oral, every 12 hours
89362362|NCT03832595|Active Comparator|Usual care|Patients in the usual care arm will continue to receive CKD care guided by their PCPs as per usual care practices (i.e., specialty consultation, pharmacotherapy, nurse education, etc. may be ordered by the PCP according to their usual practice).
89362363|NCT03832595|Experimental|Intervention Arm|Patients will receive a care bundle
89362364|NCT03819088|Experimental|Group I (zinc months 1 and 2)|Patients receive zinc PO TID for months 1 and 2 only of the first 4 months on therapy.
89362365|NCT03819088|Experimental|Group II (zinc months 3 and 4)|Patients receive zinc PO TID for months 3 and 4 only of the first 4 months on therapy.
89362366|NCT03813407|Experimental|Active Arm ( Sodium Zirconium Cyclosilicate SZC)|Dosage formulation: 5 g sachets 2.5 g sachets 0.25 g sprinkle capsules 0.125 g sprinkle capsules (can be manufactured to support participants <2 years of age) Route of administration: Oral Dosing instructions: SZC is provided as a powder. At the time of dosing SZC is mixed with a quantity of water or sprinkled onto semi-solid food (eg, milk, baby food, yogurt, or ice cream) within an hour of drug administration. Packaging and labelling: Study treatment will be provided in sachets packed in cartons or sprinkle capsules in high density polyethylene bottles, as appropriate for the dose. Each carton of sachets, individual sachets, and bottle of capsules will be labelled in accordance with Good Manufacturing Practice Annex 13 and per country regulatory requirement. Participant-specific dosing cards (diary) will be provided.
89362367|NCT03807804|Experimental|HLCM051 group【ARDS caused by pneumonia cohort】|"Patients will receive the standard therapy~A single, one-time dose of HLCM051 9.0×108 (±20%) cells are intravenously infused as a naturally dropped single dose over 30 to 60 minutes at the maximum infusion speed of 10 mL/minute"
89362368|NCT03807804|No Intervention|Standard treatment group【ARDS caused by pneumonia cohort】|•Patients will receive the standard therapy
89362369|NCT03807804|Experimental|HLCM051 group【ARDS caused by COVID-19 cohort 】|"Patients will receive the standard therapy~A single, one-time dose of HLCM051 9.0×108 (±20%) cells are intravenously infused as a naturally dropped single dose over 30 to 60 minutes at the maximum infusion speed of 10 mL/minute"
89362370|NCT03805269|Experimental|TAP block|USG guided TAP block
89362371|NCT03805269|Active Comparator|wound infiltration|local anesthetics infiltration at surgical incision site
89362372|NCT03778957|Experimental|Arm A|Transarterial Chemoembolization (TACE) in combination with Durvalumab
89362373|NCT03778957|Experimental|Arm B|Transarterial Chemoembolization (TACE) in combination with Durvalumab and Bevacizumab
89362374|NCT03778957|Placebo Comparator|Arm C|Transarterial Chemoembolization (TACE) in combination with Placebos
89362375|NCT03775486|Experimental|Durvalumab/Olaparib Combination Therapy|"Durvalumab/Olaparib Combination Therapy:~Durvalumab/SoC chemotherapy (initial therapy phase) followed by Durvalumab/Olaparib (maintenance phase)"
89362376|NCT03775486|Experimental|Durvalumab Monotherapy|Durvalumab Monotherapy: Durvalumab/SoC chemotherapy (initial therapy phase) followed by Durvalumab/placebo (maintenance phase)
89362377|NCT03773965|Experimental|Baricitinib|Baricitinib given orally.
89362378|NCT03763136|Experimental|hPSC-CM Therapy|Procedure: Injection of allogenic human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) during coronary artery bypass grafting surgery. 200 million hPSC-CMs in 2.5-5 mL medium suspension will be injected into the myocardium.
89362379|NCT03763136|Sham Comparator|Control|Procedure: Coronary artery bypass grafting surgery only.
89362380|NCT03762655|Experimental|Neuro-Spinal Scaffold Arm|Subjects in the Scaffold Arm will have the Scaffold implantation immediately following standard of care open spine surgery.
89362381|NCT03762655|No Intervention|Comparator Arm|Subjects in the Comparator Arm will have standard of care open spine surgery and will not receive the Scaffold.
89362382|NCT03742102|Experimental|Arm 1|durvalumab + paclitaxel
89362383|NCT03742102|Experimental|Arm 2|durvalumab + paclitaxel + capivasertib
89362384|NCT03742102|Experimental|Arm 5|durvalumab + paclitaxel + oleclumab
89362385|NCT03742102|Experimental|Arm 6|durvalumab + trastuzumab deruxtecan
88833639|NCT05437900|Active Comparator|Pressure Wire guided strategy - PIOS-PW|Patients will be treated with the Pressure Wire during PCI. After completing an angiographically successful PCI, patients will be randomized to FFR-guided stent optimization (PIOS).
88833640|NCT05437900|Experimental|Pressure Microcatheter guided strategy - Standard of care|Patients will be treated with the Pressure Microcatheter during PCI. After completing an angiographically successful PCI, patients will receive the standard of care treatment.
89362386|NCT03742102|Experimental|Arm 7|durvalumab + datopotamab deruxtecan
89362387|NCT03742102|Experimental|Arm 8|durvalumab + datopotomab deruxtecan (patients with PD-L1 positive status)
89362388|NCT03729609||Brentuximab vedotin 1.2 mg/kg (body weight)|Brentuximab vedotin 1.2 milligrams per kilograms (mg/kg) (body weight), intravenous infusion, once every two weeks (up to 12 times). The dose should be adjusted depend on the participant's condition. Participants received interventions as part of routine medical care.
88833641|NCT05437900|Active Comparator|Pressure Wire guided strategy - Standard of care|Patients will be treated with the Pressure Wire during PCI. After completing an angiographically successful PCI, patients will receive the standard of care treatment.
89362389|NCT03729401|Active Comparator|DAPT - Aspirin and Ticagrelor|As per results of the PEGASUS trial, patients will be treated with aspirin 81mg daily and ticagrelor 60mg twice daily
89362390|NCT03729401|Experimental|Ticagrelor Monotherapy|Patients will only receive ticagrelor 60mg twice daily.
89362391|NCT03729401|Experimental|Personalized Therapy Arm|Patients allocated to the personalized arm (PA) will have a DAPT score calculated. For those with a score of < 2, only aspirin at 81 mg daily will be prescribed. For those with a score of ≥ 2, P2Y12 inhibitor choice will be dependent on carrier status of CYP2C19 LOF alleles. Heterozygous or homozygous carriers will receive be prescribed ticagrelor 60mg twice daily and non-carriers with will be prescribed clopidogrel 75mg daily.
89362392|NCT03729011|Active Comparator|Volatile anesthesia group|
89362393|NCT03729011|Active Comparator|TIVA group|
89362394|NCT03721497|Active Comparator|Testosterone Undecanoate|Inj. Testosterone undecanoat (Nebido®), 1000 mg im preoperative (baseline, weeks 6, 18 and 30 depending on time to surgery) and postoperative (weeks 4, 16, 28, 40)
89362395|NCT03721497|Placebo Comparator|Placebo|Inj. placebo preoperative (baseline, weeks 6, 18 and 30 depending on time to surgery) and postoperative (weeks 4, 16, 28, 40)
89362396|NCT03717896|Experimental|Thiamine|200mg IV thiamine in 50mL 0.9% saline twice daily for 2 days
89362397|NCT03717896|Placebo Comparator|Placebo|100mL 0.9% saline twice daily for two days
89362398|NCT03715790||EP Referred Group|Subjects with EF ≤ 40% or meeting one of the referral criteria
89362399|NCT03715790||Non-Referred Group|Subjects with 40%< EF <50%.
89534559|NCT03335423|Experimental|Oral codeine and intravenous metformin|Codeine 25 mg will be given at 5 occasions with approximately 6 hours between each dosing. The fifth and last dose will be given together with 500 mg metformin administrated as an injection.
89534560|NCT03330353||Neurodegenerative Diseases|Individuals with neurodegenerative diseases
88833642|NCT05434754|Experimental|eHealth Tool|The Intervention is a text messaging algorithm that will operate like a chatbot, querying adolescents with T1D about their confidence with different aspects of T1D self-management as they are preparing to transition to adult diabetes care. The intervention has 4 components of messaging: personalized Educational Content, Standard Educational Curriculum, Provide participant compensation for filling out the questionnaires, Question & Answer feature.
89001158|NCT00575653||19-21 (Secondary)|Enrolled members of one of the participating health plans who are ages 19-21 at any time during the study period, March 1, 2005 through August 31, 2008.
89001159|NCT00575692||PulmoHypertension|Patients with suspected, latent or manifest pulmonary hypertension
89362400|NCT03697577||ER+/HER2- metastatic breast cancer|Subjects have metastatic ER+/HER2- breast cancer, and their doctor is offering treatment with CDK 4/6 inhibitors as standard of care treatment.We hypothesize that cyclin-dependent kinase (CDK) 4/6 inhibitors decrease fat mass among women with ER+/HER2- metastatic breast cancer without significant effect in the skeletal mass. Body composition will be obtained from CT scans (CT or PETCT) as part of their standard of care, and body fat mass will be obtained from DEXA scan(as part of proposed study)
89362401|NCT03691610|Experimental|Group 1|MenACYW conjugate vaccine + routine pediatric vaccines at 6 to 7 months of age and 12 to 13 months of age
89362402|NCT03691610|Active Comparator|Group 2|MENVEO® + routine pediatric vaccines at 6 to 7 months of age and 12 to 13 months of age
89362403|NCT03691610|Experimental|Group 3|MenACYW conjugate vaccine at 17 to 19 months of age and 20 to 23 months of age
89362404|NCT03691610|Active Comparator|Group 4|Menactra® at 17 to 19 months of age and 20 to 23 months of age
89362405|NCT03677076||Ancillary/Correlative|Patients will complete questionnaires and have research blood drawn.
89362406|NCT03675737|Experimental|Pembrolizumab + Chemotherapy (FP or CAPOX regimen)|"Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (approximately 2 years) + physicians' choice of either cisplatin 80 mg/m^2 IV on Day 1 Q3W and 5-fluorouracil (5FU) 800 mg/m^2/day via continuous IV infusion on Days 1 to 5 Q3W (FP regimen) OR oxaliplatin 130 mg/m^2 IV on Day 1 Q3W + capecitabine 1000 mg/m^2 orally twice a day (BID) on Days 1 to 14 Q3W (CAPOX regimen).~Participants who complete up to 35 administrations of pembrolizumab (approximately 2 years) or achieve a complete response (CR) but experience progression of disease (PD), can initiate a second course of pembrolizumab for up to 17 cycles (approximately 1 additional year)."
89362407|NCT03675737|Active Comparator|Placebo + Chemotherapy (FP or CAPOX regimen)|Participants receive placebo on Day 1 Q3W for up to 35 cycles (approximately 2 years) + physicians' choice of either cisplatin 80 mg/m^2 IV on Day 1 Q3W and 5FU 800 mg/m^2/day via continuous IV infusion on Days 1 to 5 Q3W (FP regimen) OR oxaliplatin 130 mg/m^2 IV on Day 1 Q3W + capecitabine 1000 mg/m^2 orally BID on Days 1 to 14 Q3W (CAPOX regimen).
89362408|NCT03662386||Patients with suspicion of hereditary retinal dystrophy|
89362409|NCT03656562|Experimental|Cohort 1 VAY736|multiple doses of VAY736, s.c.
89362410|NCT03656562|Placebo Comparator|Cohort 1 VAY736 Placebo|multiple doses of matching placebo s.c. until week 29. Multiple doses of VAY736, s.c from week 29 until week 53.
89362411|NCT03656562|Experimental|Cohort 2 CFZ533|multiple doses of CFZ533, i.v.
89534561|NCT02491307|Experimental|Ginger.io Application Users|This cohort is comprised of individuals that 1) are English-speaking; 2) possess an Android or iOS smartphone; 3) have a diagnosis for anxiety, depression, and/or bipolar disorder; and 4) are active behavioral health patients at any of the four CHCI clinic sites (New London, New Britain, Middletown, or Meriden) where behavioral health providers are using the Ginger.io app with their patients. These patients receive the Ginger.io smartphone application for daily use.
88833643|NCT05434754|No Intervention|Control|Participants randomized to the control arm will also be offered the same incentives to complete questionnaires (outcome measures) but will not receive any other components of the intervention - no personalized/customized support or diabetes resource messages and no reminders. Control arm participants will continue with their usual T1D transition care.
88833644|NCT05431881|Placebo Comparator|Control|A silent state (a wave file made without sound) is applied for at least 20 minutes from 20 minutes before arrival to the operating room. The sound generator is a smartphone device, set the volume (at a volume corresponding to 60 dB in the experimental group), and hang it on the transport bed. Upon arrival in the operating room, before anesthesia, the volume is adjusted to 0.
88833645|NCT05431881|Experimental|Binaural beat|In the experimental group, the binaural sound, which was produced by the beat of 2Hz difference, is applied for 20 minutes from 20 minutes before arrival to the operating room. The sound generator is a smartphone device, set the volume corresponding to 60 dB, and hang it on the transport bed. Upon arrival in the operating room, before anesthesia, the volume is adjusted to 0.
89001160|NCT00575692||Controls|Controls without history of cardiac or pulmonary diseases
89001161|NCT00575731|Experimental|Fine-Tuning|2-month intervention (8 lifestyle counseling classes)
89362412|NCT03656562|Placebo Comparator|Cohort 2 CFZ533 Placebo|multiple doses of matching placebo i.v. until week 29. Multiple doses of CFZ533, i.v. from week 29 until week 53.
89362413|NCT03654053|Experimental|Simvastatin|Simvastatin 40mg PO once at bedtime for up to 24 months. Note: all enrolled subjects will trial 20mg once at bedtime for two weeks as lead-in to determine tolerability prior to randomization.
89362414|NCT03654053|Placebo Comparator|Placebo|Placebo 40mg PO once at bedtime for up to 24 months. Note: all enrolled subjects will trial 20mg once at bedtime for two weeks as lead-in to determine tolerability prior to randomization.
89362415|NCT03653156||Mild cognitive impairment (MCI) and its subtypes|MCI cohort consists of mild cognitive impairment subjects with memory loss as predominant symptom, including amnestic mild cognitive impairment and vascular cognitive impairment no dementia, which recruit from community population and hospital population.
89362416|NCT03653156||Sporadic Alzheimer's disease (SAD)|SAD cohort consists of mild to moderate sporadic Alzheimer's disease subjects, which recruit from community population and hospital population.
89362417|NCT03653156||Familial Alzheimer's disease (FAD)|FAD cohort consists of familial Alzheimer disease subjects with known or unknown mutations, which recruit from community population and hospital population.
89362418|NCT03653156||Vascular dementia(VaD）|VaD cohort consists of cognitive impairment subjects caused by cerebral vessel disease, including vascular dementia and mixes dementia, which recruit from community population and hospital population.
89362419|NCT03653156||Normal control|Normal control cohort consists of cognitive normal subjects with ApoE ε4 positive or negative, which recruit from community population and hospital population.
89362420|NCT03653156||Non-Alzheimer degenerative dementia|Frontotemporal dementia (FTD); or Parkinson's disease dementia (PDD); or dementia with Lewy bodies (DLB); or corticobasal degeneration (CBD); or dementia not otherwise specified.
89178250|NCT04102566|No Intervention|Standard of care arm|"The standard of care group will group will receive the following regimen while inpatient:~2% topical lidocaine gel applied to catheter tip as needed for pain, maximum dose of 600mg in 12 hours~Acetaminophen 1000mg every 8 hours standing~Oxycodone 5mg PO every 4 hours as needed pain~Phenazopyridine 100mg TID as needed for urinary burning~Senna 1 tab every 12 hours~Miralax 17g powder once daily as needed for constipation~The standard of care group will get the following prescriptions on discharge:~Oxycodone 5mg every 4 hours as needed pain - 15 tabs~Acetaminophen 1000mg every 8 hours standing for two days then as needed~Phenazopyridine 100mg TID as needed for urinary burning - 9 tabs~Senna 1 tab every 12 hours - 10 tabs"
89362421|NCT03651973|Experimental|With learning workshops|Patients in experimental arm will attend learning workshops, one before breast cancer surgey and one after surgery. Patients will be educated by physiologist to self massages and self stretching. Each workshop will last around 2 hours.
89362422|NCT03651973|Other|Without learning workshops|Standard follow-up. Patients randomized in this arm won't attend Learning workshops and will be followed in a standard way.
89362423|NCT03646045||Transpyloric feed|Preterm infant receiving transpyloric feeding.
89362424|NCT03646045||Control|Preterm infants receiving gastric feeding
89362425|NCT03643562|Experimental|Adrabetadex|Participants will receive prescribed adrabetadex by intra-thecal (IT) injection every 2 weeks.
89362426|NCT03635567|Experimental|Pembrolizumab+Chemotherapy|On Day 1 of each 21-day cycle, participants receive an intravenous (IV) infusion of pembrolizumab 200 mg for up to 35 cycles (up to approximately 2 years) PLUS Investigator choice of chemotherapy for up to 6 cycles (paclitaxel 175 mg/m^2 PLUS cisplatin 50 mg/m^2 WITH or WITHOUT bevacizumab 15 mg/kg per local label OR paclitaxel 175 mg/m^2 PLUS carboplatin Area Under the Curve (AUC) 5 for up to 6 cycles, WITH or WITHOUT bevacizumab 15 mg/kg per local label). All treatments are administered until disease progression or toxicity.
89362427|NCT03635567|Placebo Comparator|Placebo+Chemotherapy|On Day 1 of each 21-day cycle, participants receive an IV infusion of placebo (Normal Saline or Dextrose solution) for up to 35 cycles (up to approximately 2 years) PLUS Investigator choice of chemotherapy for up to 6 cycles (paclitaxel 175 mg/m^2 PLUS cisplatin 50 mg/m^2 WITH or WITHOUT bevacizumab 15 mg/kg per local label OR paclitaxel 175 mg/m^2 PLUS carboplatin AUC 5 for up to 6 cycles, WITH or WITHOUT bevacizumab 15 mg/kg per local label). All treatments are administered until disease progression or toxicity.
89362428|NCT03620669|Experimental|Durvalumab|Durvalumab until progression or unacceptable toxicity
89362429|NCT03610711|Experimental|Arm A Nivolumab Only|stereotactic body radiation (SBRT) 8G x 3 followed by Nivolumab 240mg administered IV over 30 minutes every 2 weeks for one year or until evidence of disease progression or unresolved toxicity.
89362430|NCT03610711|Experimental|Arm B Nivolumab + Relatlimab|stereotactic body radiation (SBRT) 8G x 3 followed by Nivolumab 240mg administered IV over 30 minutes every 2 weeks and Relatlimab (anti-LAG3) every 2 weeks for one year or until evidence of disease progression or unresolved toxicity.
89362431|NCT03606486|Experimental|Diagnostic (pap smear, uterine lavage, tumor sample)|Participants undergo pap smear, uterine lavage, and collection of tumor sample during a planned surgery. DNA is then extracted from the samples and sequenced for TP53 mutations using Crispr-Duplex sequencing.
89362432|NCT03578536|Experimental|CIT with Recovery Rapids|"This project will develop a therapeutic model that promotes use of the impaired arm and hand. Researchers often call this type of therapy constraint induced therapy. In this study, participants focus on using the impaired limb rather than the unaffected limb. Study participants will only be able to play the game using the impaired limb.~A small group of patients will participate in a question and answer session about preferences for activities which make up transfer tasks. Patients will also receive automated reminders to use the impaired arm throughout the day. Twelve (12) Veterans will be recruited annually from the inpatient Stroke Specialty Program. Six (6) patients will be assigned to the Treatment group and receive the intervention. The remaining six (6) will receive the current standard of care. Outcome measures will include motor function tests that evaluate upper extremity function."
89362433|NCT03576547|Experimental|Treatment (ponatinib, venetoclax, dexamethasone, rituximab)|See Detailed Description
89362434|NCT03574493||Open laparotomy|A surgical procedure involving a large incision through the abdominal wall to gain access into the abdominal cavity.
89362435|NCT03574493||Laparoscopic surgery|A minimally-invasive technique in which operations are performed via small incisions (usually 0.5-1.5 cm) at a location distant to the site of interest.
88833646|NCT05430451|Experimental|Brief cessation advice (AWARD) + simple physical exercise with Instant Messaging (IM) support|The integrated intervention of brief cessation advice (AWARD), and simple physical exercise practices with Instant Messaging (IM) support for craving management
88833647|NCT05430451|Active Comparator|Brief cessation advice (AWARD)|Brief cessation advice (AWARD)
88833648|NCT05428449|Experimental|GT20029|
88833649|NCT05428449|Placebo Comparator|GT20029 Placebo|
88833650|NCT05425875|Experimental|Manual suction|A 50-mL syringe will be used to apply the suction.
88833651|NCT05425875|Experimental|Manual suction with tubing|A 50-mL syringe with a 15-cm rubber tubing.
88833652|NCT05425875|Active Comparator|Wall mount suction|A negative pressure of <100 mmHg will be applied using continuous wall suction.
88875509|NCT03958344|Experimental|Intraorbital injection of steroid|"2 mL of steroid will be ready for each injection session:~1 mL Triamcinolone (40 mg) + 1 mL Betamethasone (6 mg) = 2 mL~For Dacryoadenitis without myositis , 1 mL of this compound will be injected at lacrimal gland through 1 site of injection.~For Dacryoadenitis plus 1 rectus muscles myositis 1 mL of this compound will be injected at lacrimal gland and 0.5 mL of this compound will be injected at the rectus muscle through 2 separate sites of injection.~For Dacryoadenitis plus 2 rectus muscles myositis 1 mL of this compound will be injected at lacrimal gland and 0.5 mL of this compound will be injected at either recti muscles through 3 separate sites of injection."
89001162|NCT00575731|Active Comparator|Record-Keeping|2-month intervention (8 lifestyle counseling classes)
89362436|NCT03574493||Robot-assisted surgery using the da Vinci® Surgical System|A minimally-invasive approach that allows good precision, flexibility, and control.
89362437|NCT03574493||Transanal surgery through the anus|Where the protectomy is performed down to up until the Douglas pouch
89189237|NCT02578836|Experimental|Fogel Gastroplasty|The subject will be placed under general anesthesia. The procedure will last approximately 1-2 hours. CO2 will be used rather than air for the insufflation that is required during the procedure to minimize abdominal distention. The physician will place an interrupted suture pattern in a manner which partitions the greater curvature of the stomach from the Angle of His to the level of the incisura, creating a tube-like passage for gastric volume reduction. Afterwards, the remaining gastric volume will be reduced using a circumferential running stitch.The device that will be used to place the stitches is the OverStitch system FDA approved for tissue apposition
88833653|NCT05417490||Group with PRADO|"All patients seen in hospital and for whom the doctor will choose whether or not to offer one of the 2 solutions, alone or in combination, will be considered as included in the study, and their non-objection will be collected.~Subsequently, patients will benefit from follow-up for 6 months: V0 inclusion visit- V1 telephone contact at 1 month only for patients participating in one of the 2 programs and V2 consultation at 6 months. The 0 and 6M (6 months) visits are part of the usual follow-up of patients hospitalized for heart failure.~Administration of questionnaires:~Girerd's questionnaire : The objective is to measure the medication compliance of patients during treatment~SSQ6 (Social Support Questionnaire 6) : which measures two dimensions of social support (satisfaction and availability). SSQ6 is an abbreviated form of SSQ (Social Support Questionnaire). A high SSQ score indicates more optimism about life than a low score."
88833654|NCT05417490||Group with PRADO + remote monitoring|"All patients seen in hospital and for whom the doctor will choose whether or not to offer one of the 2 solutions, alone or in combination, will be considered as included in the study, and their non-objection will be collected.~Subsequently, patients will benefit from follow-up for 6 months: V0 inclusion visit- V1 telephone contact at 1 month optional only for patients participating in one of the 2 programs and V2 consultation at 6 months. The 0 and 6M visits are part of the usual follow-up of patients hospitalized for heart failure.~Administration of questionnaires:~Girerd's questionnaire~SUTAQ (Service User Technology Acceptability Questionnaire) : only for patients with remote monitoring.~the questionnaire has 22 items, measured on a Likert scale from 1 to 6, reflecting respectively more or less agreement with the statements of the items. The questionnaire has 5 subscales, each containing between 3 and 9 items.~SSQ6"
88833655|NCT05417490||Group with remote monitoring|"All patients seen in hospital and for whom the doctor will choose whether or not to offer one of the 2 solutions, alone or in combination, will be considered as included in the study, and their non-objection will be collected.~Subsequently, patients will benefit from follow-up for 6 months: V0 inclusion visit- V1 telephone contact at 1 month optional only for patients participating in one of the 2 programs and V2 consultation at 6 months. The 0 and 6M visits are part of the usual follow-up of patients hospitalized for heart failure.~Administration of questionnaires:~Girerd's questionnaire on therapeutic compliance~SUTAQ inspired digital tools acceptability questionnaire: only for patients with remote monitoring~SSQ6 social support questionnaire"
88833656|NCT05417490||Group without intervention|"All patients seen in hospital and for whom the doctor will choose whether or not to offer one of the 2 solutions, alone or in combination, will be considered as included in the study, and their non-objection will be collected.~Subsequently, patients will benefit from follow-up for 6 months: V0 inclusion visit- V1 telephone contact at 1 month optional only for patients participating in one of the 2 programs and V2 consultation at 6 months. The 0 and 6M visits are part of the usual follow-up of patients hospitalized for heart failure.~Administration of questionnaires:~Girerd's questionnaire on therapeutic compliance~SSQ6 social support questionnaire"
89001163|NCT00180167|Active Comparator|Daunorubicin + Ara-C|
89189238|NCT03994237||ALZHEIMER CAREGIVER|Caregiver available to accompany the patient to the consultation, helping calling for the first time the memory center, aidant who noticed a cognitive disorder help, having a family link identified with the patient
89189239|NCT01033201||Lung transplant|All lung transplant patients presenting for screening/surveillance and diagnostic bronchoscopies at Mayo Clinic Florida are eligible for participation.
89189240|NCT01034839||acute myeloid leukemia, adults|Adults treated for acute myeloid leukemia in our hospital between 1978 and 2007
89189241|NCT01033279|No Intervention|Usual care|Patients followed by usual care at the hospital's anticoagulation clinic
89189242|NCT01033279|Experimental|Self-management|Self-monitoring and self-adjustment of oral anticoagulation according to predefined algorithms
89189243|NCT02046330|Experimental|Deep Brain Stimulation|Device implantation (Deep Brain Stimulation Model 3387 Model 3389)
89189244|NCT04071522||LBP|110 literate Turkish speaking patients suffering from low back pain (LBP) for over 3 months, within the age range 18-65 were included in the study.
89189245|NCT02576418|Experimental|Partosure TTD Test|PartoSure TTD test will be performed on all patients and the test-to-spontaneous-delivery interval will be calculated.
89189246|NCT02576340|Active Comparator|study|drug was administered
89189247|NCT02576340|No Intervention|control|no drug administered
89189248|NCT02578602|Experimental|Diagnostic (gadoxetate disodium MRI)|Patients receive gadoxetate disodium IV and then undergo enhanced liver MRI.
89189249|NCT02574702|No Intervention|Control Group|Patients with primary loop ileostomy closure without drainage of the surgical wound
89189250|NCT02574702|Experimental|Drainage Group|"Patients with the application of a contralateral drainage (Penrose ®) in surgical wound of primary loop ileostomy closure.~Intervention: application of a contralateral drainage in surgical wound closure."
88833657|NCT05416203|Experimental|BEAST Condition|A one-session intervention that can be delivered effectively by a clinician via telehealth and supplemented with a mobile app to provide opportunities to practice the skills learned in the face-to-face session.
88833658|NCT05414240|Active Comparator|Ibudilast|IBUD at a dosage of 20 mg twice daily for 2 days, with an increase to 50 mg twice daily on day 3. The dosage will remain at 50 mg twice daily through most of the rest of the 6-week treatment period. However, for the last three days of week 6, participants will reduce the dosage gradually to 20 mg twice daily prior to discontinuing it at the end of the treatment period.
88833659|NCT05414240|Placebo Comparator|Inactive placebo|Placebo twice daily for 6-week treatment period. Placebo will match active medication in appearance and size.
88833660|NCT05413434|Experimental|HIIT with a supervisor|These individuals will be given HIIT training on the treadmill, accompanied by a physiotherapist, 3 days a week for 8 weeks.
88833661|NCT05413434|Experimental|Hiit and respiratory muscle training with a supervisor|HIIT program and respiratory muscle training will be applied to these individuals 3 days a week for 8 weeks.
88833662|NCT05413434|No Intervention|control group|The importance of physical activity will be explained and appropriate physical activity recommendations will be made.
88833663|NCT05412615|Experimental|Meniscal Allograft with PRC|These patients will receive a tissue allograft with their wrist reconstruction procedure.
88833664|NCT05412615|Placebo Comparator|PRC only|These patients will receive the standard proximal row carpectomy procedure.
88833665|NCT05411211||Pediatric Participants receiving adalimumab|Pediatric Participants receiving adalimumab for polyarticular juvenile idiopathic arthritis (pJIA)
88833666|NCT05411146|Experimental|[14C]-etrumadenant|Participants will receive a single dose of [14C]-etrumadenant.
88833667|NCT05405920|Experimental|Team-based Care Strategy for Hypertension Control|The core component of the intervention is a stepped-care protocol, based on the 2017 American College of Cardiology (ACC)/American Heart Association (AHA) Clinical Practice Guideline for High Blood Pressure and the 2021 World Health Organization (WHO) Hypertension Guideline. Using a team-based care model, a physician-nurse-CHW team will work with patients to implement clinical guideline-based treatment in all intervention clinics. Team-based care components will include task sharing and shifting, health care team training, home BP monitoring, BP audit and feedback, and CHW-led health coaching on lifestyle modification and medication adherence.
88833668|NCT05405920|Active Comparator|Enhanced Usual Care|We will train the primary care physicians, nurses, and other clinic staff in performing standardized BP measurements. We will offer physician education on clinical guidelines for hypertension management and issue continuing medical education credits. Patient educational materials will be distributed. We will not conduct any other interventions in the enhanced usual care clinics.
88833669|NCT05404542|Experimental|Severe Renal Impairment|Participants with severe renal impairment will receive a single dose of tavapadon, 0.25 milligrams (mg) tablet, on Day 1.
88833670|NCT05404542|Experimental|Normal Renal Function|Participants with normal renal function will receive a single dose of tavapadon, 0.25 mg tablet, on Day 1.
88833671|NCT05401227|Experimental|High Ketamine, TS-134|Two administrations of ketamine 0.23 mg/kg pre post 4 days of TS-134 20 mg
88833672|NCT05401227|Placebo Comparator|High ketamine, placebo|Two administrations of ketamine 0.23 mg/kg pre post 4 days of placebo
88833673|NCT05401227|Experimental|Medium Ketamine, TS-134|Two administrations of ketamine 0.125 mg/kg pre post 4 days of TS-134 20 mg
88833674|NCT05401227|Placebo Comparator|Medium Ketamine, placebo|Two administrations of ketamine 0.125 mg/kg pre post 4 days of placebo
88833675|NCT05401227|Experimental|Low Ketamine, TS-134|Two administrations of ketamine 0.06 mg/kg pre post 4 days of TS-134 20 mg
88833676|NCT05401227|Placebo Comparator|Low Ketamine, placebo|Two administrations of ketamine 0.06 mg/kg pre post 4 days of placebo
89362438|NCT03564938|Experimental|Regorafenib (Stivarga, BAY 73-4506)|Patients with metastatic colorectal cancer
89362439|NCT03564496|Active Comparator|Healthy Controls|Healthy Controls will be given approximately 15 minutes of active tDCS during MRI during the initial visit.
88833679|NCT05398653|Experimental|MIL62|
88833680|NCT05398653|Active Comparator|Ciclosporin|
88833681|NCT05396287||Controls|Healthy controls
88833682|NCT05396287||Vertebral Artery Hypoplasia|Healthy individuals with vertebral artery hypoplasia
88833683|NCT05386329|Experimental|Therapist-guided smartphone-delivered CBT|Participants will complete app-based cognitive-behavioral therapy (CBT) treatment for major depressive disorder (MDD) through their personal mobile smartphone. They will also be assigned a therapist, who will provide brief virtual treatment sessions (up to 25 minutes via a video platform) over the course of the same treatment period.
88833684|NCT05378802|Experimental|NAVA mode|"st select a NAVA level that gives peak pressure about 9-10 cm H2O assist keep NAVA level for 15 minutes, do ZAM breaths every 3 minutes (make sure not to disturb the patient). Insp Hold after every ZAM~nd increase NAVA level by 50% and repeat the protocol when patient's breathing has stabilized (only one increase) Do ZAM breaths every 3 minutes (make sure not to disturb the patient). Insp Hold after every ZAM"
88833685|NCT05378802|Experimental|N- PSV mode|"st PS level of 8-10 cmH2O, keep PS level for 15 minutes, do ZAM every 3 minutes (make sure not to disturb patient). Insp Hold after every ZAM At the end of protocol (minute 15) do one end-inspiratory hold-maneuver and one end-expiratory occlusion.~nd increase PS by 50% and repeat protocol when patient's breathing has stabilized (only 1 increase). Do ZAM every 3 minutes (make sure not to disturb patient). Insp Hold after every ZAM"
89001164|NCT00180167|Experimental|Mitoxantrone + Ara-C|
88833686|NCT05378802|Active Comparator|VCV mode|"no spontaneous breathing Set Vt, Ti and RR to match the breathing pattern observed during NAVA. Make sure each change in level does not increase the pressure by more than 1 cmH2O.~Mode PCV no spontaneous breathing-do ZAM after each PS level Increase PSV level from 8 to 20 in steps of 1 cmH2O every 2 minutes. Be careful at the higher pressures."
88833687|NCT05378802|Active Comparator|PCV mode|"Increase PSV level from 8 to 20 in steps of 1 cmH2O every 2 minutes. Be careful at the higher pressures The idea is not to have pressures as high as 20 cmH2O, it is important to have high enough VCV & PCV flow rates so we can match the flow rates during spontaneous breathing. You might find that 15 or 16 cmH2O is enough to generate flow rates that match the maximum flow rate you saw during spontaneous breathing."
88833688|NCT05378555|Experimental|Ketamine|
88833689|NCT05374317|Active Comparator|Standard Dose (Group 1)|Yellow Fever vaccine standard dose, 0.5mL.
88833690|NCT05374317|Experimental|Fractional dose (Group 2)|Yellow Fever vaccine 1/5th standard dose, 0.1mL.
88833691|NCT05374317|Experimental|Fractional dose (Group 3)|Yellow Fever vaccine 1/10th standard dose, 0.05mL.
88833692|NCT05374109|Active Comparator|SYV: Sauti ya Vijana (The Voice of Youth intervention)|"Sessions 1 to 3 - youth name their worries, discuss coping strategies, practice relaxation and breathing exercises, and learn components of cognitive behavioral therapy. Sessions 4 to 6 are dedicated to reflection and processing trauma. Caregivers (supportive adults) are invited at the discretion of enrolled youth to participate in Sessions 1 and 6. Session 7 - youth name their support network and any changes. Sessions 8 and 9 - youth consider stigma, disclosure, reproductive health, condom use, and gender-based violence. Sessions 9 and 10 expand the overall client-centered approach to emphasizing autonomy rather than imposing ideas about what the youth should do. In a final individual meeting, youth revisit their personal values, goals, and strategies for the next 6 months and review their support networks. A final gathering is used to review all session content, to celebrate all that has been shared and learned together, and to distribute certificates of completion."
88833693|NCT05374109|No Intervention|SOC - Standard of Care|"Participants in the SOC will not meet in study groups, thus are more at risk for attrition. They will be contacted by the study team on a monthly basis to check in and ensure their documented contact information remains accurate. SOC may vary by site depending on clinic structure, referral systems, and group activities. These differences could potentially dilute the SYV intervention effect and introduce content spillover whereby participants randomized to the intervention discuss intervention content with participants randomized to SOC. As part of the study survey, participants will be asked if they had friends who attended the SYV intervention and if they discussed content. Additionally, as part of the implementation science outcomes (Aim 3), the SOC group structure, adherence counseling, and any mental health referrals offered as part of SOC will be documented."
88833694|NCT05373771|Active Comparator|Post-intervention|
88833695|NCT05373771|No Intervention|Delayed intervention|
88833696|NCT05365243|Experimental|Interventional|All patients will use AMMA
89362440|NCT03564496|Experimental|MS Patients|MS patients will be given approximately 15 minutes of active tDCS during MRI during the initial visit. After the first MRI visit, MS patients will receive remotely-supervised home tDCS treatment for a month to test the cumulative effects of tDCS. Participants will complete 20 x 2.0mA x 20 minute tDCS sessions paired with cognitive training over 4-week period (20 mins per day and weekend off) with electrodes placed to target the bilateral DLPFC. Around 3 months after the 20-session treatment, MS patients only will be asked to come to the clinic for neuropsychological assessments.
89362441|NCT03564496|Active Comparator|Healthy Control subgroup|The Healthy Control subgroup will be given approximately 15 minutes of active tDCS during MRI during the initial visit. Participants in the healthy control subgroup will be given the option to have an additional 15 minutes of brain imaging, which will include 10 minutes of simultaneous tDCS at up to 4.0mA, added to the end of their baseline scan. After the first MRI visit, HC subgroup patients will receive remotely-supervised home tDCS treatment for a month to test the cumulative effects of tDCS. Participants will complete 20 x 2.0mA x 20 minute tDCS sessions paired with cognitive training over 4-week period (20 mins per day and weekend off) with electrodes placed to target the bilateral DLPFC.
89362442|NCT03564340|Experimental|Monotherapy|REGN4018 administration
89362443|NCT03564340|Experimental|Combination Therapy|REGN4018 and cemiplimab administration
88833697|NCT05364203|No Intervention|no intervention|Injections were done as usual without mask.
88833698|NCT05364203|Active Comparator|Comparator|Injections are made as in standard practice. The virtual reality headset is added to the patient. In this case, there is no image or sound. The mask is off.
89362444|NCT03562247|Active Comparator|Usual Care of IPF|Newly diagnosed patients will continue to receive excellent healthcare as currently given in management of the lung disease
88833699|NCT05364203|Experimental|Intervention|Injections are made as in standard practice. We add the virtual reality mask with the image and the sound.
88833700|NCT05360017|Experimental|Robot in lower limb motor function training of stroke patients with hemiplegia|"Test equipment: litestepper single lower limb rehabilitation training robot~Device type: Class II medical device"
88833701|NCT05359666|Experimental|Irrisept|Irrisept® was used for surgical irrigation in subjects with abdominal trauma or acute surgical abdomen for study protocol IRR-CT-901-2013-01.
88833702|NCT05359666|Active Comparator|Standard of Care (SoC)|Institution determined the type of SoC used for surgical irrigation in subjects with abdominal trauma or acute surgical abdomen for study protocol IRR-CT-901-2013-01.
88833703|NCT05356377||PKU Palynziq Group|Individuals with PKU who have previously completed baseline (pre-Palnyziq) neurocognitive and neuroimaging evaluations and have since demonstrated a significant and prolonged Phe response to Palynziq (as reflected by at least 3 consecutive months of Phe levels below 360 μmol/L).
88833704|NCT05356130|No Intervention|Treatment as Usual (TAU)|"Usual care services control group"
88833705|NCT05356130|Active Comparator|Minimal BLT Encouragement|Two minimal written communications promoting BLT as a promising treatment and outlining steps for patients to self-initiate. Arm 2 will not include any phone coaching or adherence promotion.
88833706|NCT05356130|Active Comparator|Enhanced BLT Encouragement + Adherence Promotion|2-4 brief calls to encourage BLT use, advise on purchase of a light box (LB), assist with obtaining compensation for LB purchase, educate for correct LB use, and provide motivational interviewing (MI) as needed to promote adherence. Arm 3 participants will also receive the written educational material on BLT.
88833707|NCT05338385|Experimental|Intervention|Participants will receive mental skills training in addition to receiving standard-of-care ACL reconstruction and follow-up care. The goal of mental skills training is to help athletes maximize performance, reach self-determined goals, and build confidence in their fields of play. Many of the same tools that benefit athletes in sport performance also translate to their injury experience. Mental conditioning helps athletes navigate the many ups and downs that accompany ACL injury and recovery. Athletes are taught techniques to maintain their sport mindset by capitalizing on motivation, consistency, and resilience. One-on-one sessions are athlete-centered, and are designed to encourage exploration and growth through tangible mental skills strategies.
88833708|NCT05334966|No Intervention|Historical LHH Controls|Previous women with a dx of fetal LHH and whose care was continued at Texas Children's Hospital.
88833709|NCT05334966|Placebo Comparator|Healthy Fetal Controls|Healthy mothers with healthy fetuses that will come in monthly for fetal echcos starting at 20 wks.
88833710|NCT05334966|Experimental|Chonic Maternal Hyperoxygenation w/ LHH|Mothers who have a fetus diagnosed with LHH and elect daily maternal hyperoxygenation therapy.
88833711|NCT05334966|Experimental|Acute Maternal Hyperoxygenation with LHH|Mothers who have a fetus diagnosed with LHH and elect acute maternal hyperoxygenation challenge testing.
88833712|NCT05319756|Experimental|gabapentin 600 mg single dose|
88833713|NCT05319756|Experimental|gabapentin 1200 mg single dose|
88833714|NCT05319756|Experimental|gabapentin 600 mg and oxycodone HCl 20 mg|
88833715|NCT05319756|Experimental|gabapentin 1200 mg and oxycodone HCl 20 mg|
88833716|NCT05319756|Active Comparator|oxycodone HCl 20 mg single dose|
88833717|NCT05319756|Placebo Comparator|placebo single dose|
88833718|NCT05319080|Experimental|Individualized magnetic resonance imaging (MRI) guided rTMS|Participants will receive a type of TMS called repetitive TMS (rTMS) wherein the magnetic pulses delivered will be close together in a rapid sequence. They will receive a 20-min once-daily rTMS sessions over a period of 2 weeks (weekends off), and therefore accrue a total of 10 rTMS stimulation sessions. The rTMS parameters that will be used are a frequency of 1 Hz (1 pulse per second) at an intensity of 90% of the motor threshold (MT). Therefore, the investigators will deliver 1200 continuous pulses per session/day which adds up to 12,000 pulses in total for the whole treatment.
88833719|NCT05317494||Venetoclax Participants|Participants treated with Venetoclax in accordance with approved local label.
88833720|NCT05314985|Experimental|Prehab Group / Intervention Group|4 to 8 weeks of preoperative physical therapy training and education intervention before total knee replacement surgery.
88833721|NCT05314985|No Intervention|Control Group|Usual care / no treatment before total knee replacement surgery.
88833722|NCT05314010|Experimental|MIL62|
88833723|NCT05314010|Placebo Comparator|Placebo|
88833724|NCT05313945|Experimental|Passive indwelling urinary catheter removal|The passive indwelling urinary catheter removal takes place due to gravity.
88833725|NCT05313945|Active Comparator|Manual indwelling urinary catheter removal|The manual indwelling urinary catheter removal takes place by manual traction by a nurse.
88833726|NCT05308901|Experimental|Pembrolizumab + Lenvatinib|Lenvatinib 20 mg daily plus pembrolizumab 200 mg IV every 3 weeks.
88833727|NCT05307224|Experimental|intervention group|In the experimental group, patients will receive both routine care and mandala painting. Experimental group will paint mandala for 30 minutes/day in the evening for six consecutive days.
88833728|NCT05307224|No Intervention|control group|The control group will receive the usual care.
88833729|NCT05306665|Experimental|ACT intervention|Participants assigned to this arm will complete a 1-day ACT workshop followed by a telephone booster after surgery
88833730|NCT05306665|No Intervention|Treatment As Usual|Participants assigned to this arm will receive treatment as usual.
88833731|NCT05305105|Experimental|Psilocybin|Participants will complete an 8-week course of study treatment including two doses of psilocybin with psychological support administered approximately 2 weeks apart.
88833732|NCT05301361|Active Comparator|Methylphenidate|
88833733|NCT05301361|Placebo Comparator|Placebo|
88833734|NCT05301257|Experimental|Experimental Group SOSteniamoci|Trans-diagnostic, 8 module, 8 week long internet intervention for reducing informal caregiver burden
88833735|NCT05301257|No Intervention|Control Group SOSteniamoci|Participants in the control group will be instructed to wait. Once intervention group will be finished, participants in control group will be able to access the same intervention
88875510|NCT03958344|Active Comparator|Oral Steroid|"Each patient will receive oral Prednisolone, 1 mg/kg, for 5-7 days, followed by tapered dose in 12 weeks (according to a pre-defined table of oral administration dose).~Daily Omeprazole 40mg p.o and daily Calcium Supplement will also be recommended to avoid complications."
88875511|NCT03901950|Experimental|XNW7201|
89362445|NCT03562247|Experimental|Telenursing|Patients will receive usual care with structured phone calls from the nurse practitioner and/or case manager occuring more frequently earlier in the diagnosis to help the patient and care giver understand all aspects of the disease and it time will evolve to managing symptoms outside of out-patient clinic visits.
88833736|NCT05280340|Experimental|Anakinra|"First 6 enrolled infants given 1.0mg/kg anakinra alternate daily IV for first 3 weeks of life.~Remaining 18 enrolled infants given 0.8mg/kg anakinra daily IV for the first 3 weeks of life, if infant is ≥ 26 weeks gestation.~If infant is < 26 weeks gestation, dosing of 1.0mg/kg anakinra alternate daily IV for the first 3 weeks of life, will continue (3 infants only)."
88833737|NCT05279027|Experimental|PET imaging|This is a single institution, prospective cohort study of 89Zr-Df-IAB22M2C PET/CT as an early measure of response in patients with melanoma.
88833738|NCT05277012|Experimental|Treatment sequence ABC|Participants will be sequentially administered with Treatment A, B then C (Treatment A: etrumadenant capsule in fasted state; Treatment B: etrumadenant tablet in fasted state; Treatment C: etrumadenant tablet in fed state). Each treatment will be separated by a washout period of 7 days.
88833739|NCT05277012|Experimental|Treatment sequence BCA|Participants will be sequentially administered with Treatment B, C then A. Each treatment will be separated by a washout period of 7 days.
88833740|NCT05277012|Experimental|Treatment sequence CAB|Participants will be sequentially administered with Treatment C, A then B. Each treatment will be separated by a washout period of 7 days.
88833741|NCT05273567|Experimental|Guanfacine-ER|Participants will start on guanfacine-ER 1mg nightly for 1-week (week 1) and slowly increase by 1mg/per week to a max dose of 4mg per day or maximum dose as tolerated. Medication taper to discontinuation will begin in week 11 and continue into week 12 until complete by end of study, decreasing the dose by 1mg every 4 days until stopped.
88833742|NCT05273567|Placebo Comparator|Placebo|Placebo will be taken nightly and titrated and tapered similar to the active arm.
88833743|NCT05272176|Experimental|Coping Long Term with Active Suicide Program (CLASP)|"The CLASP intervention is an adjunctive, telehealth-based behavioral intervention designed to reduce suicidal behavior among individuals at high risk for suicide going through periods of transition. CLASP is designed to intervene on four risk factor targets: ongoing treatment engagement, problem-solving, social and family support, and hopelessness. In addition to these general factors, the CLASP provider also has the flexibility to identify and target certain patient-specific risk factors (e.g., substance misuse) for intervention.~CLASP will begin after completion of the baseline assessment, and will continue for 6 months post-discharge. CLASP will be comprised of: a) 3 initial sessions while participants are still inpatients (can occur post-discharge if needed); b) 12 brief telehealth sessions over 6-months post-discharge; c) 6 brief SO telehealth sessions."
88833744|NCT05272176|No Intervention|Treatment As Usual (TAU)|Treatment As Usual (TAU) consists of unrestricted treatment provided as part of routine care in the Veterans Health Administration (VHA) following inpatient hospitalization. Study staff will provide no additional treatment in this arm.
88833745|NCT05269225|Experimental|Organic diet|Consuming organic food from the start of 2nd trimester and until gestational week 37.
88833746|NCT05269225|Placebo Comparator|Conventional diet|Consuming conventional food throughout the whole pregnancy.
88833747|NCT05266729|Experimental|AYP-101 1|0.2 mL injections, 1.0 cm apart, up to 10.0 ml per treatment session at intervals of approximately 2 weeks for up to a maximum of 6 treatments.
88833748|NCT05266729|Experimental|AYP-101 2|0.2 mL injections, 1.0 cm apart, up to 10.0 ml per treatment session at intervals of approximately 2 weeks for up to a maximum of 6 treatments.
88833749|NCT05266729|Placebo Comparator|Placebo|0.2 mL injections, 1.0 cm apart, up to 10.0 ml per treatment session at intervals of approximately 2 weeks for up to a maximum of 6 treatments.
88833750|NCT05266339|Experimental|Cross-education group|Each subject in the cross-education group will receive a treatment protocol consisting of cross-education (training of the contralateral limb) and standard exercise program applied after arthroscopic rotator cuff repair.
88833751|NCT05266339|Active Comparator|Standard exercise group|Each subject in the standard exercise group will receive a treatment protocol consisting of standard exercise program applied after arthroscopic rotator cuff repair.
88833752|NCT05263232|Experimental|Natural office light|Over 4.5 days, participants will stay inside in an office room from 8:00 to 17:00h with wide transparent windows under natural daylight.
88833753|NCT05263232|Experimental|Artificial office light|Over 4.5 days, participants will stay inside in an office room from 8:00 to 17:00h with shielded windows under artificial light.
88833754|NCT05258981|Other|Brain MRI|Obtain Brain MRI in adults with congenital heart disease and age/sex matched controls
88833755|NCT05257018|Experimental|R-CDOP+intrathecal MTX|"R-CDOP+intrathecal MTX：~Rituximab 375 mg / m^2，D1~Cyclophosphamide 750 mg / m^2，D2~Doxorubicin Hydrochloride Liposome Injection 35mg / m^2，D2~Vincristine 1.4mg/m^2 (dose capped at 2 mg)，D2~Prednisone 50 mg， bid D2-6~Cycle1-5：Intrathecal MTX 12 mg + DXM 5 mg after chemotherapy （PK patients will be given 24h after chemotherapy）"
88833756|NCT05255445||Sickle cell disease (SCD)|Patients with SCD who are chronically transfused (in the U.S. and Brazil)
88833757|NCT05255445||Thalassemia|Patients with thalassemia who are chronically transfused in the U.S.
88833758|NCT05255445||Pediatric Hematology-Oncology|Patients in U.S. with pediatric oncologic diagnoses with hypo-proliferative bone marrow requiring single unit red blood cell transfusion
88833759|NCT05255445||Blood Donors|Allogenic blood donors in the US (estimated: 10,200) and allogenic blood donors in Brazil (estimated: 2,100) with extended donation genotyping using an investigational hematology array.
88833760|NCT05254210|Experimental|Treatment with RF Device|Subjects may receive up to 3 treatments with the RF device if they are willing to receive treatment for brow lifting and/or present with conditions such as, but not limited to; wrinkles, fine lines, crepey skin, acne scars, active acne, enlarged pores, loose skin on the face, neck and/or body
89362446|NCT03562247|Experimental|Telenursing and Remote Monitoring|Patients will receive usual care with telenursing and will be given a hand held spirometer and puse oximeter and be asked to take daily measurements and report these via an electronic HIPAA approved secured platform for evaluation by the telenursing team.
89362447|NCT03554720|Active Comparator|Standard implants|ATTUNE PS Knee
89362448|NCT03554720|Active Comparator|Enhanced-Fixation|ATTUNE S+ PS Knee
88833761|NCT05243862|Experimental|PolyPEPI1018 plus Atezolizumab|Participants receive every 3 weeks PolyPEPI1018 CRC Vaccine (Emulsified solution, 0.2 mg/peptide, 6 peptides total, and Montanide™ ISA51VG adjuvant), by SC injection in combination with Atezolizumab (Injectable solution,1200mg/20mL) by IV injection.
88833762|NCT05242406|Experimental|H-EMST|"In 60% of the maximum expiratory pressure (MEP), 25 breaths a day, 7 days / week, a total of 12 weeks will be trained with a 1-minute rest cycle in 5 breaths.~Patients will be invited to control every 2 weeks. MEP measurements will be repeated and the training value will be adjusted in 60% of the new measurement."
88833763|NCT05242406|Experimental|L-EMST|"At 30% of the maximum expiratory pressure (MEP), 25 breaths, 7 days / week, a total of 12 weeks will be trained once a day with a 1-minute rest cycle in 5 breaths.~Patients will be invited to control every 2 weeks. MEP measurements will be repeated and the training value will be adjusted in 30% of the new measurement."
88833764|NCT05239767|Active Comparator|Ketorolac|Ketorolac 20mg orally x 1
88833765|NCT05239767|Active Comparator|Ibuprofen|Ibuprofen 800mg orally x 1
88833766|NCT05239598|Experimental|Povidone-iodine 0.5% antiseptic mouth rinse|Subjects will be asked to rinse/gargle one time with 10 mL of Povidone-iodine 0.5% antiseptic mouth rinse for 30 seconds.
88833767|NCT05239598|Placebo Comparator|Placebo|Subjects will be asked to rinse/gargle one time with 10 mL of placebo mouth rinse for 30 seconds.
88833768|NCT05232383|Active Comparator|Wp|
88833769|NCT05232383|Active Comparator|Wn|
88833770|NCT05232383|Active Comparator|Gn|
88833771|NCT05232383|Active Comparator|Gp|
88833772|NCT05232383|Active Comparator|Rp|
88833773|NCT05232383|Active Comparator|Rn|
88833774|NCT05227196|Experimental|Group 1 Sequence 1|Crossover arm
88833775|NCT05227196|Experimental|Group 1 Sequence 2|Crossover arm
88833776|NCT05227196|Experimental|Group 2 Sequence 1|Crossover arm
88833777|NCT05227196|Experimental|Group 2 Sequence 2|Crossover arm
88833778|NCT05227196|Experimental|Group 3 Sequence 1|Crossover arm
88833779|NCT05227196|Experimental|Group 3 Sequence 2|Crossover arm
88833780|NCT05218525|Experimental|Intervention group|The specialized COPD community nurses, who are responsible for patients in the intervention group, will experience an extra alarm option in the telehealth system. The COPD prediction algorithm has been implemented by the Danish Company, OpenTeleHealth, into their commercially available telehealth system, Telekit, and thus, the COPD prediction algorithm is approved for clinical use as a part of the existing telehealth system´s CE marking (class I and IIa).
88833781|NCT05218525|No Intervention|Control group|"The specialized COPD community nurses responsible for patients in the control group will only experience the usual alarms that are activated in the telehealth system, named Telekit, and are based on low or high values of vital signs. The specialized COPD community nurses are not instructed to act differently compared to how they act normally. This involves that the specialized COPD community nurses monitor as usual and respond to divergent data as usual.~The participants in the control group receive the usual practice, which includes the general offer of the telehealth intervention. The participants in the control group are instructed to do exactly the same procedures as the participants in the intervention group.~The specialized COPD community nurses, who are responsible for patients in the control group continue to monitor the participants as usual, but are informed that more oxygen saturation measurements will be present for the included participants."
88833782|NCT05216380|Experimental|ActivityLink|ActivityLink will be a clinic implementation program delivered to clinic staff.
88833783|NCT05212753|Active Comparator|Conventional Physical Therapy Group|The conventional physical therapy group will receive Transcutaneous Electrical Nerve Stimulation (TENS) and hot pack application.
88833784|NCT05212753|Active Comparator|Stabilization Group|The stabilization group will receive lumbar stabilization exercises and the conventional physical therapy program. That program includes lumbar stabilization exercises including activation of the transverses abdominals (TA) and multifidi muscles.
88833785|NCT05212753|Active Comparator|Breathing Exercise Group|The breathing exercise group will receive breathing exercises including sleep hygiene, and the stabilization group program. Breathing exercises include diaphragmatic breathing and pursed-lip.
88833786|NCT05211414|Experimental|Yoga Based Daily Excercise|Subjects will be trained to perform 30 minutes of moderate level yoga daily, with instruction on breathing, self-awareness, and ways to modify poses to avoid pain. Subjects will be instructed in use of the email links to access the 30-minute instructive video. Subjects will attend weekly Zoom classes to learn additional postures and techniques, which will be reflected in their 30 minutes video (i.e. a new video for each week). At these weekly remote yoga classes, they will be asked about difficulties encountered and given advice about their personal home practice.
88833787|NCT05211414|No Intervention|Usual Care|
88833788|NCT05208437|Experimental|Complete oral feeding intervention group|Premature infants will be assessed 12 times a day before feedings using the Feeding Preparation Scale. Feeding of premature infants using different interventions based on the results of the Feeding Preparation Scale.
88833789|NCT05208437|Active Comparator|Routine nursing care group|Pre-feeding assessments will be performed from premature infants corrected for gestational age at 34 weeks. If the baby's vital signs are stable, the method of oral feeding and then nasal feeding is used, and feeding 8 to 12 times a day until the baby reaches complete oral feeding. Routine nursing care is identical to the control group.
88833790|NCT05205031|Active Comparator|Intravenous|The intervention will consist of attempts to successfully establish a peripheral intravenous access during the cardiac arrest. The prehospital clinician will be required to attempt the intervention a minimum of two times.
88833791|NCT05205031|Experimental|Intraosseous|The intervention will consist of attempts to successfully establish an intraosseous access during the cardiac arrest. The prehospital clinician will be required to attempt the intervention a minimum of two times.
88833792|NCT05203679|Experimental|Arm of BBM-H901|1×10^13 vg/kg, Single-dose treatment
88833793|NCT05186779||Cohort A|Early Pregnancy Bleeding/Recurrent Pregnancy loss
88833794|NCT05186779||Cohort B|IVF/ART
88833795|NCT05177146|Experimental|Intravenous Ketamine (IV)|
88875512|NCT03805230||Cohort A|all patients admitted to participating hospitals during 7 consecutive days
88875513|NCT03805230||Cohort B|30 sequential patients with a single additional inclusion criterion
89534562|NCT02491307|No Intervention|Non-application users|This cohort is comprised of individuals that 1) are English-speaking; 2) possess an Android or iOS smartphone; 3) have anxiety, depression, and/or bipolar disorder; and 4) are patient of a behavioral health clinician that is providing paper surveys to patients in clinic. They do not receive the Ginger.io smartphone application.
88833796|NCT05171712|Experimental|Analysis Population|The analysis population will include patients considered at high or extreme surgical risk, who have met all inclusion criteria, have not met any exclusion criteria, have signed an Ethics Committee (EC) approved Informed Consent, and, at the minimum, the FlexNav delivery system entered his/her vasculature for an attempted Portico or Navitor Valve implant
88833797|NCT05169502||Patients with diabetes and newly diagnosed proliferative diabetic retinopathy, level 4. (n=10)|"Inclusion criteria: Type I or II diabetes, habile and age>18 years. Exclusion criteria: Incapacitated or age< 18 years.~One 20mL blood sample from each patient will be analysed by flow cytometry and single cell RNA sequencing.~A questionnaire describing the patients general health (gender, age, duration of diabetes, smoking status, blood pressure, BMI and hip/waist ratio) will be made."
88833798|NCT05169502||Patients with diabetes and newly diagnosed diabetic maculopathy. (n=10)|"These patients will be matched 1:1 to the patients with proliferative diabetic retinopathy, regarding gender, age, duration of diabetes, smoking status, and blood pressure.~One 20mL blood sample from each patient will be analysed by flow cytometry and single cell RNA sequencing.A questionnaire describing the patients general health (gender, age, duration of diabetes, smoking status, blood pressure, BMI and hip/waist ratio) will be made."
88833799|NCT05169502||Patients with diabetes without retinopathy, level 0. (n=10)|"These patients will be matched 1:1 to the patients with proliferative diabetic retinopathy, regarding gender, age, duration of diabetes, smoking status, and blood pressure.~One 20mL blood sample from each patient will be analysed by flow cytometry and single cell RNA sequencing.A questionnaire describing the patients general health (gender, age, duration of diabetes, smoking status, blood pressure, BMI and hip/waist ratio) will be made."
88833800|NCT05169502||Individuals without diabetes and known eye diseases (n=10)|"These patients will be matched 1:1 to the patients with proliferative diabetic retinopathy, regarding gender, age, smoking status, and blood pressure.~One 20mL blood sample from each patient will be analysed by flow cytometry and single cell RNA sequencing.A questionnaire describing the patients general health (gender, age, smoking status, blood pressure, BMI and hip/waist ratio) will be made."
88833801|NCT05168800|Experimental|Dialogue-Based Webinar|
88833802|NCT05168800|Experimental|Social Media Website|
88833803|NCT05168800|Active Comparator|Enhanced Usual Practice|
88833804|NCT05168774|Experimental|Low Dose (20-30mg)|Subjects will receive daily subcutaneous (SC) dosing of Elamipretide (20-30 mg) for 52 weeks
88833805|NCT05168774|Experimental|High Dose (40-60 mg)|Subjects will receive daily subcutaneous (SC) dosing of Elamipretide (40-60 mg) for 52 weeks
88833806|NCT05168124|Active Comparator|Acceptance Commitment Therapy for chronic fatigue|ACT for chronic fatigue involves psychoeducation on the clinical picture of CFS/ME and teaching coping strategies for dealing with symptoms, most notably fatigue, postexertional malaise, unrestful sleep, cognitive decline, and orthostatic dysregulation. For this purpose, the therapy manual designed for generalized anxiety disorders is adapted to the needs of patients with CFS, i.e., the exercises and worksheets that teach the acceptance- and mindfulness-based techniques are adapted to the symptoms (fatigue, powerlessness, unrestful sleep, among others). In addition, value goals and scopes of action are defined, in which the individual stress limits of each participant are identified and taken into account. In addition, it is recommended that the participants move within their respective energy limits under the regular evaluation of activity and rest phases using a diary, as well as regularly apply study-specific interventions between the appointments of group therapy.
89534563|NCT01673373|Experimental|iCAST RX™ Stent Systen|All enrolled subjects will receive the iCAST RX™ Stent System
89534564|NCT03335189|Experimental|ASyMS-Can|TParticipants assigned to the experimental group will be provided with the encrypted, secure, pre-programmed ASyMS-Can android phone, and instructed of its use; how to report their symptomatology on a twice daily basis using the CTAQ for the first 14 days of each treatment cycle until end of the final cycle of treatment (or up to 16 weeks).
88833807|NCT05168124|Active Comparator|Micro breaks in everyday life for chronic fatigue|Micro breaks in everyday life (MBEL) includes restructuring the patients' daily routine in terms of how they organize their breaks. A therapy manual is developed for this purpose, which is divided into three phases. In the first phase, patients learn to allow or integrate regular MB of one to five minutes in their daily routine. Appropriate examples are used to show when and where MB can be incorporated and this is practiced at home over the first few weeks until a routine has been established. Patients are encouraged to keep a break diary. In the second phase, the MBs are filled in with content. MB can be designed differently, e.g., with physical activity of moderate or high intensity, with short breathing or relaxation exercises, with nutrition or even with doing nothing. In the third phase, an individual optimization of the design of breaks in everyday life follows and an expansion towards meaningful mental time-out, a combination of relaxation break and mental activation.
88833808|NCT05168124|No Intervention|Waiting Group|
88833809|NCT05166421|Experimental|AZD7442 (co-formulation)|Participants will receive single dose of AZD7442 (co-formulation of AZD8895 + AZD1061) on Day 1.
88833810|NCT05166421|Active Comparator|AZD8895 and AZD1061 (clonal cell line material)|Participants will receive two separate doses of the individual mAbs (AZD8895 and then AZD1061) on Day 1.
88833811|NCT05166421|Active Comparator|AZD8895 and AZD1061 (cell pool material)|Participants will receive two separate doses of the individual mAbs (AZD8895 and then AZD1061) on Day 1.
88833812|NCT05156788|Experimental|PD-1 antibody +Lenvatinib+Gemox|Tilelizumab 200mg, d1 Q3W Lenvatinib 8mg, po, qd, Gemox chemotherapy Gemcitabine 1000mg/m2, d1, 8, Q3W, + oxaliplatin 85mg/m2 d1, Q3W
88833813|NCT05154513||Cohort 1|Children living with perinatally-acquired HIV who received early treatment in IMPAACT network studies or other research studies sponsored by the United States National Institutes of Health.
88833814|NCT05154136|Experimental|Etrumadenant then Etrumadenant + Itraconazole|"Participants will receive the Treatment A (etrumadenant) followed by Treatment B (etrumadenant + itraconazole).~A washout period of 5 days will be maintained between the two treatments."
88833815|NCT05153746|Experimental|3D colonoscopy|"Colonoscopy insertion under regular method. After reaching cecum, the subjects will be randomized into 3D or conventional colonoscopy.~Subjects in 3D colonoscopy arm:~Colonoscopist will switch the image to 3D imaging form and wearing special glasses to enhance the 3D imaging. The 3D mode will be maintained during the whole colonoscopy withdrawal. When encountering suspicious neoplasm, the colonoscopist can use any image-enhancing technique (such as NBI or indigo carmine dye) to assist the diagnosis and use standard resection procedure (such as polypectomy) to complete lesion resection if necessary. The procedure time, withdrawal time, adenoma detection rate will be recorded during the colonoscopy. The pathology specimen will be sent for histology examination and any adverse event after colonoscopy (such as bleeding or perforation) will be recorded after routine surveillance."
88833816|NCT05153746|Active Comparator|Conventional colonoscopy|"Colonoscopy insertion under regular method. After reaching cecum, the subjects will be randomized into 3D or conventional colonoscopy.~Subjects in conventional colonoscopy arm:~Colonoscopist will use regular colonoscopy imaging form during the whole colonoscopy withdrawal. When encountering suspicious neoplasm, the colonoscopist can use any image-enhancing technique (such as NBI or indigo carmine dye) to assist the diagnosis and use standard resection procedure (such as polypectomy) to complete lesion resection if necessary. The procedure time, withdrawal time, adenoma detection rate will be recorded during the colonoscopy. The pathology specimen will be sent for histology examination and any adverse event after colonoscopy (such as bleeding or perforation) will be recorded after routine surveillance."
88833817|NCT05152576|Placebo Comparator|Placebo|Placebo will be injected into the forehead on Day 1.
88833818|NCT05152576|Experimental|OnabotulinumtoxinA X Dose A|OnabotulinumtoxinA X will be injected into the forehead on Day 1.
88833819|NCT05152576|Experimental|OnabotulinumtoxinA X Dose B|OnabotulinumtoxinA X will be injected into the forehead on Day 1.
88833820|NCT05152576|Experimental|OnabotulinumtoxinA X Dose C|OnabotulinumtoxinA X will be injected into the forehead on Day 1.
88833821|NCT05148247|Experimental|PRPP Intervention|This baseline phase will be 3, 5 or 7 days, and intervention phase starts immediately after baseline with 45-60 minutes PRPP Intervention 3 times a week for 3 weeks.
88833822|NCT05138588|Experimental|VERUM|"In the verum experimental condition, participants will receive the experimental rTMS stimulation sessions, meaning the rTMS sessions targeting the insular cortex, taking into account the insular hypoperfusion (through MRI images) of each patient."
88833823|NCT05138588|Sham Comparator|CONTROL|"In the control experimental condition, participants will receive the control rTMS stimulation sessions, meaning the rTMS sessions will target the occipital cortex."
88833824|NCT05137938|Experimental|Intranasal Ketamine (IN)|Ketamine will be administered intranasally (IN) using an atomizer (MAD300 by Teleflex, North Carolina, USA).
88833825|NCT05134662|Experimental|ALT-801 Dose Level 1|
88833826|NCT05134662|Experimental|ALT-801 Dose Level 2|
88833827|NCT05134662|Experimental|ALT-801 Dose Level 3|
88833828|NCT05134662|Placebo Comparator|Placebo|
88833829|NCT05134454|Experimental|Extended ECG investigation|Participants will undergo 0-48 hours of continuous ECG recording and at least two long-term continuous ambulatory ECG recordings with a duration of 14 days each.
88833830|NCT05134454|No Intervention|Standard of care|Participants will undergo 24-48 hours of continuous ECG recording.
88833831|NCT05132335|Experimental|Experimental: Imaging Biomarkers|Each study subject is is studied in four session: twice after overnight fast and twice after liquid meal injestion using PETMRI imaging. Adipose and skeletal muscle pefusion and fatty adic uptake are measured and and the repeability of results tested for these two situations. In PEt studies PET/MRI Scan with radioactive water ([15O]-H2O) and [18F]-FTHA are used as tracers. In this experimental study number of subjects studied is rather small. Therefore volunteers with and without T2 diabetes are analysed together and not on different arms.
88833832|NCT05130606|Experimental|Video Arm|"Culturally Targeted Narrative Video: Is My Cancer Hereditary? Rosa Visits a Genetic Counselor. Participants in the video arm will be asked to watch an 18-minute video that the research team developed and tested previously about HBOC and genetic services. The video is recorded with Spanish audio and is available with English subtitles."
88833833|NCT05130606|Active Comparator|Fact Sheet Arm|Participants in the Fact Sheet arm will receive a Fact sheet about HBOC and genetic services and will be asked to read it in their own time. The Fact Sheet is available in English and Spanish.
88833834|NCT05121064|Experimental|Arm A- Alcohol Brief Intervention|Following enrollment and randomization, participants will receive a single session of alcohol brief intervention (BI). Further, standard of care antiretroviral therapy (ART) adherence counseling will be provided as per local guidelines.
88833835|NCT05121064|Experimental|Arm B- Alcohol Brief Intervention plus Common Elements Treatment Approach|Following enrollment and randomization, participants will receive a single session of alcohol brief intervention (BI) and then will be referred to receive Common Elements Treatment Approach (CETA). Further, standard of care antiretroviral therapy (ART) adherence counseling will be provided as per local guidelines. For CETA, a specially trained counselor will contact the participant within 2 weeks of enrollment to arrange for CETA sessions, which occur approximately weekly. Participants will receive 6 to 12 sessions of CETA with the number of sessions based on symptoms and response to therapy.
88833836|NCT05121064|Active Comparator|Arm C- Standard of Care|Following enrollment and randomization, participants will receive ART adherence counseling, which is the standard of care at the clinics.
88833837|NCT05120063|Experimental|3D anatomical stem|3-D-Planing with anatomical stem (SPS monoblock stem, Symbios)
88833838|NCT05120063|Experimental|3D non-anatomical stem|3-D-Planing with non anatomical stem (Quadra-H, Medacta)
88833839|NCT05120063|Experimental|2D anatomical stem|2-D-Planing with anatomical stem (SPS monoblock stem, Symbios)
88833840|NCT05120063|Experimental|2D non anatomical stem|2-D-Planning with non anatomical Stem (Quadra-H, Medacta)
88833841|NCT05119036|No Intervention|Observation|If patients have negative margins and have all negative nodes or only a single positive node, patients will be placed in the observation arm and will not receive further adjuvant treatment, only postoperative follow-up visits and a surveillance visit 3 months after surgery with a CT or PET-CT.
88833842|NCT05119036|Experimental|Adjuvant Radiation 44 Gray|If patients have 4 or fewer positive nodes and 2 mm or less of cancer spread extending outside the lymph nodes, patients will receive 44 gray fractions (the full dose of radiation divided into smaller doses) of adjuvant radiation.
88833843|NCT05119036|Experimental|Adjuvant Radiation 54 Gray|If patients have 4 or fewer positive nodes with greater than 2 mm of cancer spread extending outside the lymph nodes or 5 or more positive nodes with 2 mm or less of cancer spread extending outside the lymph nodes, patients will receive 54 gray fractions (the full dose of radiation divided into smaller doses) of adjuvant radiation.
88833844|NCT05117463||Healthy Younger Adults|Healthy younger adults without any neurological and orthopedic disorders.
88833845|NCT05117463||Healthy Older Adults|Healthy older adults without any neurological and orthopedic disorders.
88833846|NCT05117463||Older Adults with higher risk of falls|Older adults with a history of falls or poor balance based on the clinical balance and gait assessment.
88833847|NCT05117125||VAP|Enrolled participants that fully meet the criteria of VAP.
88833848|NCT05117125||Suspect VAP|Enrolled participants that develop signs of VAP but lack some variable, for instace new radiographic infiltrate or microbiological finding compatible with VAP.
88833849|NCT05117125||No VAP|Enrolled participants that do not develop VAP.
88833850|NCT05117060|Experimental|LEO 152020 tablet - Dose regimen 1|Participants will be asked to take tablets from Week 0 to Week 16 (end of treatment).
88833851|NCT05117060|Experimental|LEO 152020 tablet - Dose regimen 2|Participants will be asked to take tablets from Week 0 to Week 16 (end of treatment).
88833852|NCT05117060|Experimental|LEO 152020 tablet - Dose regimen 3|Participants will be asked to take tablets from Week 0 to Week 16 (end of treatment).
88833853|NCT05117060|Placebo Comparator|LEO 152020 placebo tablet|Participants will be asked to take tablets from Week 0 to Week 16 (end of treatment).
88833854|NCT05116384|Active Comparator|Pulmonary vein isolation|Electrical isolation by cryoballoon of all pulmonary veins
88833855|NCT05116384|Experimental|Pulmonary vein isolation + renal artery denervation|After completion of the standard PVI, radiofrequency ablation of bilateral renal arteries
88833856|NCT05114512|Experimental|RAPTOR Physical Therapy Intervention|RAPTOR intervention: hybrid in-person + telehealth physical therapy care for rural-dwelling individuals with knee osteoarthritis
88833857|NCT05114460|Placebo Comparator|Naloxone 0 mg + MJ 0.0 mg|Intranasal naloxone in combination with vaped marijuana
88833858|NCT05114460|Active Comparator|Naloxone 0 mg + MJ 12.5 mg|Intranasal naloxone in combination with vaped marijuana
88833859|NCT05114460|Active Comparator|Naloxone 0 mg + MJ 25 mg|Intranasal naloxone in combination with vaped marijuana (MJ)
88833860|NCT05114460|Active Comparator|Naloxone 4 mg + MJ 0.0 mg|Intranasal naloxone in combination with vaped marijuana (MJ)
88833861|NCT05114460|Experimental|Naloxone 4 mg + MJ 12.5 mg|Intranasal naloxone in combination with vaped marijuana (MJ)
88833862|NCT05114460|Experimental|Naloxone 4 mg + MJ 25 mg|Intranasal naloxone in combination with vaped marijuana (MJ)
88833863|NCT05113264|Experimental|Penny, a SMS Text-based chatbot intervention|This is a single arm study. All recruited patients will be entered on the Penny SMS Text-based chatbot intervention.
88833864|NCT05107453|Active Comparator|SAPB|"The IMP is levobupivacaine 0,25%, 2,5 mg/ml, solution for injection. The dosage scheme is as following:1.25 mg/kg levobupivacaine 0,25%, with a maximum of 100 mg, As the standard anaesthetic management already contains levobupivacaine, a maximum dosage of 100 mg (40 ml) levobupivacaine will be administered during the SAPB.~The IMP is given via ultrasound-guided infiltration, in plane, midaxillary, 4-5th rib, between the latissimus dorsi and serratus anterior muscle, at the end of surgery."
88833865|NCT05107453|No Intervention|Control|
88833866|NCT05105841|Experimental|Venetoclax + Obinutuzumab (V+G)|Participants will receive venetoclax + obinutuzumab for twelve 28-day cycles.
88833867|NCT05105841|Experimental|Venetoclax + Ibrutinib (V+I)|Participants will receive venetoclax + ibrutinib for fifteen 28-day cycles.
88833868|NCT05103826|Experimental|SHR6390+famitinib|Participants will receive SHR6390 in combination with famitinib.
88833869|NCT05102812|Experimental|Breakfast Group Intervention|The intervention will be piloted at Sheffield Teaching Hospitals for 1-2 weeks. Then will be refined and piloted at tow further stroke wards (Rotherham Hospitals NHS Foundation Trust and Doncaster and Bassetlaw Teaching Hospitals NHS Foundation Trust)
88833870|NCT05099848|Experimental|CAHAIC group|Hepatic Arterial Infusion Chemotherapy combined with Camrelizumab and Apatinib
88833871|NCT05099029|Experimental|EV71 Vaccine|
88833872|NCT05099029|Placebo Comparator|Placebo|
88833873|NCT05098860|Active Comparator|Home Exercise Program|"The home exercise program includes a general educational training program. The program includes active stretching, strengthening, and stabilization exercises of neck muscles, head and neck posture exercises as well as relaxation and diaphragmatic breathing exercises.~Patients will be asked to do home exercises for 30-45 minutes once a day, 5 days a week for 8 weeks."
88833874|NCT05098860|Active Comparator|Manual Therapy Combined with Home Exercise Program|"Manual Therapy includes soft tissue and joint mobilizations of the cervical vertebrae, scapula and thoracic vertebrae. MT will be applied to the patients 2 days a week for 8 weeks.~The home exercise program includes active stretching, strengthening, and stabilization exercises of neck muscles, head and neck posture exercises as well as relaxation and diaphragmatic breathing exercises."
88875514|NCT03780816||Pilot Site: Norris Cotton Cancer Center|Observation and interview protocols will be piloted at this site. The content of these observations and interviews will not be analyzed for content.
88875515|NCT03780816||Karmanos Cancer Institute|Observations and interviews will be analyzed to identify any emergent concepts, categories, and relationships in the data.
89362449|NCT03539094|Experimental|Intermittent fasting|The subjects randomized to this group will do IF by restricting their diet and consuming few calories two days per week. During the days of fasting, subjects will be allowed to drink water, calorie-free beverages, and eat fresh, steamed or roasted non-starchy vegetables.
89362450|NCT03539094|No Intervention|Western diet|The subjects randomized to this group will eat a standard western style diet.
88833875|NCT05098860|Active Comparator|Tele-rehabilitation Assisted Program|Tele-rehabilitation assisted program will be given in the on-line environment. During 8 weeks, regularly planned exercises will be done via online applications for 30-45 minutes 2 days a week, accompanied by a physiotherapist. These patients will apply active cervical and thoracic region mobilizations called self-mobilization. Patients will be taught active mobilization applications with the help of a towel for the cervical region, with the assistance of a foam-roller for active mobilization of the thoracic region.
89362451|NCT03532581|Experimental|Treatment (ICG lymphangiography)|Participants receive indocyanine green solution SC and undergo near-infrared imaging over 1-2 minutes during their standard of care neck surgery.
88833876|NCT05098327|Active Comparator|Prostate cancer on ADT receiving pioglitazone|Subjects will receive a 12-week supply of pioglitazone 30 mg dose 1 tab daily
89362452|NCT03515837|Experimental|Pembro+Pemetrexed+Chemo|Participants receive pembrolizumab (pembro) 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle (Q3W) for up to 35 cycles PLUS pemetrexed 500 mg/m^2 via IV infusion Q3W with no restrictions on the number of cycles PLUS platinum chemotherapy (chemo) (either carboplatin Area Under the Curve [AUC] 5 via IV infusion Q3W for 4 cycles [Cycles 1-4] or cisplatin 75 mg/m^2 via IV infusion Q3W for 4 cycles [Cycles 1-4]).
88833877|NCT05098327|Placebo Comparator|Prostate cancer on ADT receiving placebo|Subjects will receive a 12 week supply of placebo pills containing cellulose
88833878|NCT05098327|No Intervention|Prostate cancer not on ADT|No intervention will be done in this group
88833879|NCT05095246|Experimental|Cohort 1 (KB407)|A single dose of KB407 administered on Day 0
88833880|NCT05095246|Experimental|Cohort 2 (KB407)|Two (2) doses of KB407 administered at Day 0 and Day 14
88833881|NCT05095246|Experimental|Cohort 3 (KB407)|Four (4) doses of KB407 administered at Day 0, Day 7, Day 14, and Day 21
88833882|NCT05085795||All participants|
88833883|NCT05084937|Active Comparator|Structured transition|With the help of CeliCAT form
88833884|NCT05084937|No Intervention|Routine practices|
88833885|NCT05082610|Experimental|Part 1 - Dose Escalation Phase (Monotherapy)|HMBD-002 administered as a 60-minute IV infusion as a monotherapy. HMBD-002 will be administered on Days 1, 8, and 15 of a 21-day cycle.
88833886|NCT05082610|Experimental|Part 1 - Dose Escalation Phase (Combination Therapy)|"HMBD-002 administered as a 60-minute IV infusion at escalating doses in combination with pembrolizumab. HMBD-002 will be administered on Days 1, 8, and 15 of a 21-day cycle.~Pembrolizumab will be administered as a 30-minute IV infusion at a dose of 200 mg on Day 1 of every 21-day cycle."
88833887|NCT05082610|Experimental|Part 2 - Dose Expansion (Monotherapy)|HMBD-002 administered at the MTD/RP2D as a 60-minute IV infusion as a monotherapy in patients with TNBC or NSCLC.
88833888|NCT05082610|Experimental|Part 2 - Dose Expansion (Combination Therapy)|HMBD-002 administered at the MTD/RP2D as a 60-minute IV infusion in combination with pembrolizumab at the standard labeled dose in patients with TNBC or NSCLC.
88833889|NCT05080673|Experimental|Arm 1|5-Year and 10-Year Surveillance Colonoscopy after Qualifying Colonoscopy
88833890|NCT05080673|Experimental|Arm 2|10-Year Surveillance Colonoscopy after Qualifying Colonoscopy
88833891|NCT05080231||COVID-19 Vaccinated Individuals|Males and females, 13years old and above, vaccinated for COVID-19
88833892|NCT05080231||Previously positive for COVID-19 and unvaccinated individuals|Males and females, 13years old and above, unvaccinated for COVID-19 and previously tested positive for COVID-19.
88833893|NCT05080231||No previous COVID infection or vaccination|Males and females, 13years old and above, unvaccinated for COVID-19 and previously not tested positive for COVID-19.
88833894|NCT05079971|Active Comparator|Group A is a control group with aEEG monitoring only, and with retrospective cEEG review|
88833895|NCT05079971|Experimental|Group B is undergoing aEEG monitoring with concurrent full EEG review|
88833896|NCT05074589|Experimental|Treatment group A|Irinotecan liposome plus 5-fluorouracil, Leucovorin
88833897|NCT05074589|Active Comparator|Treatment group B|Placebo plus 5-fluorouracil, Leucovorin
88833898|NCT05069623|Experimental|VB10.2129 Part 1 Dose escalaton|0.3 mg, 1 mg or 3 mg will be administered by two IM injections 21 days apart.
88833899|NCT05069623|Experimental|VB10.2210 Part 1 Dose escalation|0.3 mg, 1 mg or 3 mg will be administered by two IM injections 21 days apart.
88833900|NCT05069623|Experimental|VB10.2129 Part 2 Dose expansion|The seleceted dose from Part 1 will be administered IM in a two-dose schedule.
88833901|NCT05069623|Experimental|VB10.2210 Part 2 Dose expansion|The seleceted dose from Part 1 will be administed IM in a two-dose schedule.
88833902|NCT05064241|Experimental|Virtual Advisory Board|Participants have access to a genetic counselor to answer their questions on accessing genetic medicine.
89362453|NCT03515837|Active Comparator|Placebo+Pemetrexed+Chemo|Participants receive normal saline solution via IV infusion on Day 1 of each 3-week cycle (Q3W) for up to 35 cycles PLUS pemetrexed 500 mg/m^2 via IV infusion Q3W with no restrictions on the number of cycles PLUS platinum chemotherapy (chemo)(either carboplatin AUC 5 via IV infusion Q3W for 4 cycles [Cycles 1-4] or cisplatin 75 mg/m^2 via IV infusion Q3W for 4 cycles [Cycles 1-4]).
89362454|NCT03495713|Experimental|Single Arm|Subjects will receive initial treatment with the immunomodulatory agent, nivolumab, followed by low-dose (4 Gy x 2) involved-site radiotherapy in subjects with less than an anatomic CR after the first restaging scan. Patients with anatomic CR will continue nivolumab alone without radiotherapy. Eligible patients will have r/r disease with at least 2 sites of measurable disease, and must be eligible for treatment with nivolumab.
88833903|NCT05064241|No Intervention|Virtual Peer-to-Peer Discussion Board|Participants answer each others' questions on the topic of accessing genetic medicine.
88833904|NCT05061654|Experimental|Treatment arm|Eligible patients will be started on empiric ceftolozane-tazobactam in addition to standard care.
89362455|NCT03485469|Other|Usual Care|The control group will benefit from a standard care dietary consultation in the service and 9 dietary consultations by phone every 15 days.
89362456|NCT03485469|Other|Hypnosis|The experimental group will benefit from a dietary consultation in the service, 9 dietary consultations by telephone every 15 days to which will be associated 7 individual sessions of hypnosis and 3 individual sessions of learning to autohypnosis. A recording containing the induction of a self-hypnosis session will be given to the subject at the end of the 10 sessions, in order to promote the continuation of home-made autohypnosis.
88833905|NCT05060965|Experimental|Cessation intervention|"All participants will receive nicotine replacement therapy and a referral to both Maryland Quitline and Johns Hopkins Tobacco Treatment Clinic for continued cessation care.~Nicotine replacement therapy: Nicoderm patches, gum, lozenges~Low nicotine dependence: Lozenge (2 mg) or Gum (2 mg) or Patch (7 mg)~Moderate nicotine dependence: Patch (14 mg) and Lozenge (2 mg) or Gum (2 mg)~High nicotine dependence: Patch (21 mg) and Lozenge (4 mg) or Gum (4 mg)~Regardless of the level of nicotine addiction and subsequent dose of nicotine replacement therapy (NRT), participants of this trials are described as recipients of NRT products."
88833906|NCT05053126|Experimental|Lyrica 300 mg|Single Dose
89362457|NCT03482245|Experimental|Pneumonia: Blue Light|a 12 hours:12 hours light:dark photoperiod cycle of bright (1700 lux) blue (peak 442 nm) light for a total of 3 days after the initial diagnosis and informed consent.
89362458|NCT03482245|Experimental|Diverticulitis: Blue Light|a 12 hours:12 hours light:dark photoperiod cycle of bright (1700 lux) blue (peak 442 nm) light for a total of 3 days after the initial diagnosis and informed consent.
89362459|NCT03482245|Experimental|Necrotizing Soft Tissue Infection: Blue Light|a 12 hours:12 hours light:dark photoperiod cycle of bright (1700 lux) blue (peak 442 nm) light for a total of 3 days after the initial diagnosis and informed consent.
88833907|NCT05053126|Experimental|Lyrica 450 mg|Single Dose
89362460|NCT03482245|No Intervention|Pneumonia: Ambient Light|a 12 hours:12 hours light:dark photoperiod cycle of the standard white fluorescent ambient light of the hospital for a total of 3 days after the initial diagnosis and informed consent.
88833908|NCT05053126|Experimental|Lyrica 300mg with Oxycodone 20 mg|Single Dose
88833909|NCT05053126|Experimental|Lyrica 450 mg with Oxycodone 20 mg|Single Dose
88833910|NCT05053126|Active Comparator|Oxycodone 20 mg|Single Dose
88833911|NCT05053126|Placebo Comparator|Placebo|Single Dose
88833912|NCT05050123|Active Comparator|First episode of anxiety: standard relaxation training|During a subject's first episode of anxiety the subject will be offered a session of standard relaxation training.
89362461|NCT03482245|No Intervention|Diverticulitis: Ambient Light|a 12 hours:12 hours light:dark photoperiod cycle of the standard white fluorescent ambient light of the hospital for a total of 3 days after the initial diagnosis and informed consent.
89362462|NCT03482245|No Intervention|Necrotizing Soft Tissue Infection: Ambient Light|a 12 hours:12 hours light:dark photoperiod cycle of the standard white fluorescent ambient light of the hospital for a total of 3 days after the initial diagnosis and informed consent.
89362463|NCT03482245|Experimental|Infected Joint: Blue Light|a 12 hours:12 hours light:dark photoperiod cycle of bright (1700 lux) blue (peak 442 nm) light for a total of 3 days after the initial diagnosis and informed consent.
89362464|NCT03482245|No Intervention|Infected Joint: Ambient Light|a 12 hours:12 hours light:dark photoperiod cycle of the standard white fluorescent ambient light of the hospital for a total of 3 days after the initial diagnosis and informed consent.
88833913|NCT05050123|Experimental|Second episode of anxiety: virtual reality relaxation|During a subject's second episode of anxiety the subject will be offered a session of virtual reality exposure available through the iPhone Google Cardboard virtual reality meditation/relaxation app.
88833914|NCT05049616|Experimental|Hctz/Lisinopril|Hctz/Lisinopril for postpartum management of hypertension. either a combined pill of ACE inhibitors and diuretics (Hydrochlorothiazide/Lisinopril)
88833915|NCT05049616|Active Comparator|Extended release nifedipine|calcium channel blocker (Nifedipine
88833916|NCT05049213|Experimental|Topical medical treatment|Intranasal spray and oral gargling
88833917|NCT05041075|Active Comparator|WB:UC|Weighted Blanket 2nd infusion Usual Care 3rd infusion
88833918|NCT05041075|Active Comparator|UC:WB|Usual Care 2nd infusion Weighted Blanket 3rd infusion
88833919|NCT05039346||Brain Tumor|Patients who are diagnosed with a high grade glioma that is progressive and therapy resistance. Patients will have a KPS of 60 or less.
88833920|NCT05039346||Care Giver|"Should a patient be unable to answer, the care giver will step in and provide surrogate answers.~Additionally, at four weeks following the patient's death, the patient's care giver will be interviewed by utilizing a validated questionnaire."
88833921|NCT05036538|Experimental|Relaxation intervention with natural sounds|The preoperative intervention includes a stress-reducing relaxation phase lasting approximately 30 minutes, during which the patients are presented with nature sounds.
88833922|NCT05036538|Experimental|Relaxation intervention with natural sounds and binaural beats|The preoperative intervention includes a stress-reducing relaxation phase lasting approximately 30 minutes, during which the patients are presented with nature sounds and binaural beats.
88833923|NCT05036538|Experimental|Relaxation intervention with natural sounds and virtual reality|The preoperative intervention includes a stress-reducing relaxation phase lasting approximately 30 minutes, during which the patients are presented with a nature scene in a spherical 360° environment with associated nature sounds.
88833924|NCT05036538|Experimental|Relaxation intervention with natural sounds, binaural beats and virtual reality|The preoperative intervention includes a stress-reducing relaxation phase lasting approximately 30 minutes, during which the patients are presented with a nature scene in a spherical 360° environment with associated nature sounds and binaural beats.
88833925|NCT05036538|No Intervention|Control without Intervention|
88833926|NCT05030467|Experimental|Intervention Arm|Providers within the clinics randomized to the intervention arm will receive a variety of EHR-based tools for eligible patients with uncontrolled hypertension.
88833927|NCT05030467|No Intervention|Control Arm|Providers within the clinics randomized to usual care will receive no EHR tools, except those currently available in clinical practice.
88833928|NCT05026502||Participants Being Treated With Elagolix + E2/NETA|Participants will receive Elagolix with Estradiol/Norethindrone Acetate per Standard of Care, as prescribed by their physicians.
88833929|NCT05025605|Experimental|80 Micrograms|Sublingual film containing 80 micrograms Dexmedetomidine
88833930|NCT05025605|Experimental|120 Micrograms|Sublingual film containing 120 micrograms Dexmedetomidine
88833931|NCT05025605|Placebo Comparator|Placebo|Sublingual Placebo film
88833932|NCT05025605|Experimental|60 Micrograms|Sublingual film containing 60 micrograms Dexmedetomidine Europe Only
88833933|NCT05025241|Experimental|NNZ-2591|NNZ-2591 oral solution (50mg/mL) to be administered twice daily dose for 13 weeks.
88833934|NCT05020600||Patients with fibromyalgia|Patients diagnosed with fibromyalgia according to American College of Rheumatology 2016 criteria
88833935|NCT05017480|Experimental|CBP-201 Dose|CBP-201 Dose subcutaneous (SC) injection
88833936|NCT05017480|Placebo Comparator|Placebo|subcutaneous (SC) injection
88833937|NCT05011266|Experimental|Buprenorphine-naloxone|Buprenorphine/naloxone 5.7 mg /1.4 mg/day sub-lingual tablets
88833938|NCT05011266|Placebo Comparator|Placebo|placebo sub-lingual tablet
88833939|NCT05010070|Experimental|diet and lifestyle program|Participants will be taught how to follow a very low carbohydrate, ketogenic diet, become more physically active, and get adequate sleep. They will also be taught about positive affect skills (such as gratitude, positive reappraisal, and personal strengths) and mindful eating.
88833940|NCT05008198||Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation is delivered as part of routine care and is not managed by this observational study.
88833941|NCT05000450|Experimental|ALLO-605, ALLO-647|
88833942|NCT04999917|Experimental|intraoperative high-resolution PET-CT imaging of resected breast tumor.|
88833943|NCT04998279||Intervention group|
88833944|NCT04998279||Control group|
88833945|NCT04991753|Placebo Comparator|Group 1: Placebo|Participants will receive placebo intravenously (IV) every 2 weeks (q2w) through Week 10 along with standard-of-care background therapy.
88833946|NCT04991753|Experimental|Group 2: Nipocalimab|Participants will receive nipocalimab IV q2w through Week 10 along with standard-of-care background therapy.
88833947|NCT04989907||Participants With Inflammatory Bowel Disease (IBD)|Participants diagnosed with moderately to severely active IBD (UC or CD) who are currently ongoing vedolizumab intravenous (IV) induction treatment in line with local prescribing information with the option to switch to vedolizumab subcutaneous (SC) treatment, will be observed prospectively for 12 months.
88833948|NCT04983420|Experimental|non-alcoholic Pilsner|1 L non-alcoholic Pilsner per day for 2 weeks
88833949|NCT04983420|Experimental|non-alcoholic wheat beer|1 L non-alcoholic wheat beer per day for 2 weeks
88833950|NCT04983420|Active Comparator|apple spritzer|1 L apple spritzer per day for 2 weeks
88833951|NCT04983420|Placebo Comparator|lemonade|1 L lemonade per day for 2 weeks
88833952|NCT04979169|No Intervention|Non-adherent control|Subjects who are determined to be non-adherent to screening guidelines and are assigned to usual treatment via randomization in REDCap.
88833953|NCT04979169|Experimental|Non-adherent intervention|Subjects who are determined to be non-adherent to screening guidelines and are assigned to intervention treatment (text messaging) via randomization in REDCap.
88833954|NCT04971148|Active Comparator|HFNC flow set at patient peak tidal inspiratory flow|HFNC flow will be set at the level that matches patient peak tidal inspiratory flow
88833955|NCT04971148|Experimental|HFNC flow set at 1.33 times of patient peak tidal inspiratory flow|HFNC flow will be set at the level that is 1.33 times of patient peak tidal inspiratory flow
88833956|NCT04971148|Experimental|HFNC flow set at 1.67 times of patient peak tidal inspiratory flow|HFNC flow will be set at the level that is 1.67 times of patient peak tidal inspiratory flow
88833957|NCT04971148|Experimental|HFNC flow set at 2 times of patient peak tidal inspiratory flow|HFNC flow will be set at the level that is 2 times of patient peak tidal inspiratory flow
88833958|NCT04965077|Experimental|MIL97|
88833959|NCT04960813|Experimental|Kidpower - Structured Games|Structured Games Camp.
88833960|NCT04960813|Active Comparator|Kidpower - Playgroup|Playgroup camp
88833961|NCT04958057|No Intervention|Routine prenatal care|Routine prenatal care: All women participating in the study will receive routine prenatal care by their obstetric provider, consisting of 1 prenatal visit a month up to 28 weeks of gestation, 1 prenatal visit every 2 weeks during 28-36 weeks and weekly visits during 36-40 weeks.
88833962|NCT04958057|Experimental|SAIL intervention|6 monthly group sessions with the study nurse with a background in prenatal care and the PI that will include each group will include preeclampsia education, coaching on stress management, resource navigation, and training in problem solving.
89362465|NCT03481933|Experimental|1:left-excitatory tDCS|20 SD patients who receive left-excitatory trans cranial stimulation
88833963|NCT04956120|Experimental|Citrate Dialysate then Standard Dialysate|Participants receiving hemodialysis using a citrate acid concentrate dialysate for the first year of the study, then receiving hemodialysis using a non-citrate acid concentrate dialysate (standard dialysate) for the second year of the study.
88833964|NCT04956120|Active Comparator|Standard Dialysate|Participants receiving hemodialysis using a non-citrate acid concentrate dialysate for the first year of the study, then receiving hemodialysis using a citrate acid concentrate dialysate for the second year of the study.
88833965|NCT04955795|Active Comparator|Alcohol Brief Intervention (BI)|At the time of trial enrollment, participants will receive a session of alcohol brief intervention (BI) via telephone.
89362466|NCT03481933|Active Comparator|2:right-inhibitory tDCS|20 SD patients who receive right-inhibotory trans cranial stimulation
89362467|NCT03481933|Sham Comparator|3:sham tDCS|20 SD patients who receive sham stimulation
89362468|NCT03474991|Active Comparator|Celestamine® N 0.5|oral betamethasone solution, once daily for two consecutive days at 0.1-0.2 mg/kg
89362469|NCT03474991|Placebo Comparator|Placebo|oral placebo matched to the product described above
89362470|NCT03443973|Experimental|Gantenerumab|Gantenerumab will be administered as SC injections with gradual uptitration.
88833966|NCT04955795|Experimental|Common Elements Treatment Approach (CETA) via Telemedicine|Participants will be provided with 6 to 12 weekly CETA sessions via telephone.
89362471|NCT03443973|Placebo Comparator|Placebo|Placebo will be administered as SC injections with gradual uptitration.
89362472|NCT03422679|Experimental|CB-103|CB-103 capsules will be administered orally in treatment cycles of 28-days each.
89362473|NCT03409809|Experimental|Training Alone|This condition involves an intensive 2-day initial train-the-trainer workshop that simultaneously trains peer educators to deliver the intervention and campus supervisors to train and support future peer educators, plus the facilitator guide and facilitator support website.
89362474|NCT03409809|Experimental|Training and Technical Assistance|This condition involves an intensive 2-day initial train-the-trainer workshop that simultaneously trains peer educators to deliver the intervention and campus supervisors to train and support future peer educators, plus the facilitator guide and facilitator support website. This condition additionally contains a 1/2 day implementation training to articulate goals, needs, leadership structure, adoption options, recruitment strategies, and communication.
89362475|NCT03409809|Experimental|Training, Tech. Assist., Qual. Assurance|This condition involves an intensive 2-day initial train-the-trainer workshop that simultaneously trains peer educators to deliver the intervention and campus supervisors to train and support future peer educators, plus the facilitator guide and facilitator support website. This condition additionally contains a 1/2 day implementation training to articulate goals, needs, leadership structure, adoption options, recruitment strategies and communication. Furthermore, this condition will have 1 year of technical assistance, coaching, and quality assurance to enhance implementation skills and sustainability.
89362476|NCT03406611|Active Comparator|Pegtibatinase|
88833967|NCT04953962|Experimental|Arm 1: CBP501 (25) + Cisplatin + Nivolumab|CBP501 25mg/m2 and Cisplatin 60mg/m2 will be administered simultaneously. Nivolumab 240mg will be administered following the completion of CBP501 and cisplatin infusions.
88833968|NCT04953962|Experimental|Arm 2: CBP501 (16) + Cisplatin + Nivolumab|CBP501 16mg/m2 and Cisplatin 60mg/m2 will be administered simultaneously. Nivolumab 240mg will be administered following the completion of CBP501 and cisplatin infusions.
88833969|NCT04953962|Experimental|Arm 3: CBP501 (25) + Cisplatin|CBP501 25mg/m2 and Cisplatin 60mg/m2 will be administered simultaneously.
89362477|NCT03406611|Placebo Comparator|Placebo|
89362478|NCT03400826|Experimental|Treatment Group|The 30 participants randomized in this group will intake Simvastatin 40mg / day of orally at the same time in the evening, every day for the study duration of 12 weeks prior to undergoing hysterectomy/ myomectomy. The fibroid samples will be collected after the surgery to evaluate the effects of the study medication on the fibroid tissue.
89362479|NCT03400826|Placebo Comparator|Placebo Group|The 30 participants randomized in this group will intake Placebo 40mg / day orally at the same time in the evening every day for the study duration of 12 weeks prior to undergoing hysterectomy/ myomectomy. The fibroid samples will be collected after the surgery to evaluate the effects of the study medication on the fibroid tissue.
89362480|NCT03389828||1|The study population will consist of approximately 340 focus groups participants.
88833970|NCT04953962|Experimental|Arm 4: Cisplatin + Nivolumab|Cisplatin 60mg/m2 will be administered as infusion and then Nivolumab 240mg will be administered.
88833971|NCT04947709|Experimental|Physical activity intervention group|The physical activity intervention will be structured to increase moderate-to-vigorous intensity aerobic physical activity, to achieve the 60-minute goal, five days per week. The intervention will also include weekly support calls from research staff to improve compliance to physical activity intervention.
88833972|NCT04947709|Other|Delayed-intervention control group|Participants randomized to the delayed-intervention control group will serve as the control group for 12 weeks, and will not receive physical activity intervention during this time and will not receive weekly support calls. After completion of the control group, participants will be offered physical activity advice according to the Children's Oncology Group Guidelines for Diet and Physical Activity recommendations. This delayed-intervention control group design is used not only to boost recruitment, but to eventually confer the benefits of physical activity to all those who enter the trial.
88833973|NCT04939480|Experimental|Atezolizumab|Pre-operative administration of atezolizumab 1200 mg followed by definitive resection of the tumor, followed by standard of care radiotherapy or radio-chemotherapy.
88833974|NCT04938960||Biological Heart Valve|Participants receiving a biological heart valve
88833975|NCT04938960||Mechanical Heart Valve|Participants receiving a mechanical heart valve
88833976|NCT04938492|Experimental|Cognitive Behavioral Therapy (CBT)|CBT delivered over the course of 6, ~45 minute sessions delivered via telehealth.
88833977|NCT04938492|Active Comparator|Health Education|Health education sessions delivered over the course of 6, ~45 minute sessions delivered via telehealth.
88833978|NCT04938349|Experimental|Single session dual task perturbation training-OAwMCI|Participants will receive single session training of dual task. Six cognitive games that target working memory, executive functioning, visuomotor reactions, and language fluency will be provided in standing to get themselves familiarized. Following the cognitive tasks, participants will receive 12 slips without performing cognitive task (Single task training) at the highest intensity. Subsequently, 12 slips during standing while performing a cognitive task (dual task) will be administered. Similarly, they will then undergo 12 dual task walking trials (at self-selected speed) followed by 12 walking slips.
88833979|NCT04938349|Experimental|Multiple session dual task perturbation training-OAwMCI|All participants will undergo stance and walking perturbation training for 4 weeks. Six cognitive games that target working memory, executive functioning, visuomotor reactions, and language fluency will be provided in standing to get themselves familiarized. Following the cognitive tasks, participants will receive 12 slips without performing cognitive task (Single task training) at the highest intensity. Subsequently, 12 slips during standing while performing a cognitive task (dual task) will be administered. Similarly, they will then undergo 12 dual task walking trials (at self-selected speed) followed by 12 walking slips.
88833980|NCT04938349|Active Comparator|Single session dual task perturbation training-CIOA|All participants will receive only one training session of dual task. Six cognitive games that target working memory, executive functioning, visuomotor reactions, and language fluency will be provided in standing to get themselves familiarized. Following the cognitive tasks, participants will receive 12 slips without performing cognitive task (Single task training) at the highest intensity. Subsequently, 12 slips during standing while performing a cognitive task (dual task) will be administered. Similarly, they will then undergo 12 dual task walking trials (at self-selected speed) followed by 12 walking slips.
88833981|NCT04931849|Experimental|Experimental: Avatrombopag|Avatrombopag 40 mg daily by mouth (PO)
88833982|NCT04927780|Experimental|Arm 1: Perioperative mFOLFIRINOX|Patients in the intervention arm (arm 1) start with neoadjuvant mFOLFIRINOX (consisting of oxaliplatin 85 mg/m², irinotecan 150 mg/m², leucovorin 400 mg/m², all at day 1, and fluorouracil continuous IV infusion 2.4 g/m² over 46 hours). Cycles are repeated every 14 days. After eight cycles, surgical resection is performed in the absence of unresectable or metastatic disease. After resection, four cycles of adjuvant mFOLFIRINOX are scheduled.
88833983|NCT04927780|Active Comparator|Arm 2: Adjuvant mFOLFIRINOX|Patients in the comparator arm (arm 2) start with surgery. After resection, 12 cycles of adjuvant mFOLFIRINOX (consisting of oxaliplatin 85 mg/m², irinotecan 150 mg/m², leucovorin 400 mg/m², all at day 1, and fluorouracil continuous IV infusion 2.4 g/m² over 46 hours) are scheduled.
88833984|NCT04927559||Observational (survey)|Patients complete a survey over 5-10 minutes about their understanding of radiation therapy.
88833985|NCT04925557|Active Comparator|Ocrevus|Patients diagnosed with secondary-progressive multiple sclerosis who have been prescribed Ocrevus by their neurologist.
88833986|NCT04925557|Active Comparator|Mayzent|Patients diagnosed with secondary-progressive multiple sclerosis who have been prescribed Mayzent by their neurologist.
89001165|NCT04579627||Hospital Doctors|Hospital doctors working at Royal Cornwall Hospital during the COVID-19 pandemic
88833988|NCT04903015|Experimental|professional Soccer players|
88833989|NCT04903015|Active Comparator|athletes not exposed to head injuries.|
88833990|NCT04899063|Other|ELIOS Procedure|ELIOS Procedure
88833991|NCT04897711|Experimental|Perceptual training with a speaker with dysarthria|To examine the effect of perceptual training with speakers with dysarthria, we use a standard three-phase perceptual training protocol involving pretest, training, and posttest phases, in which speech samples from a single speaker with dysarthria are utilized for all three phases.
88833992|NCT04897074|Experimental|AKL-T01|Digital Treatment
88833993|NCT04888585|Experimental|Dose A of ABBV-154|Participants in this group will receive dose A of ABBV-154 subcutaneously (SC) every other week (eow) for 12 weeks in the placebo-controlled period, 66 weeks in the long term extension (LTE) period 1 and 104 weeks in LTE period 2.
88833994|NCT04888585|Experimental|Dose B of ABBV-154|Participants in this group will receive dose B of ABBV-154 SC eow for 12 weeks in the placebo-controlled period, 66 weeks in the LTE period 1 and 104 weeks in LTE period 2.
88833995|NCT04888585|Experimental|Dose C of ABBV-154 EOW|Participants in this group will receive dose C of ABBV-154 SC eow for 12 weeks in the placebo-controlled period, 66 weeks in the LTE period 1 and 104 weeks in LTE period 2.
88833996|NCT04888585|Experimental|Dose C of ABBV-154 E4W|Participants in this group will receive dose C of ABBV-154 SC every 4 weeks (e4w) for 12 weeks in the placebo-controlled period, 66 weeks in the LTE period 1 and 104 weeks in LTE period 2.
89362481|NCT03384238|Experimental|Cohort 1a|A test/loading dose of 100 mg of unlabeled Panitumumab (fixed dose) will be administered via a 60 minute IV infusion prior to infusion of the Panitumumab IRDye800. Cohort 1a will receive 25 mg of Panitumumab IRDye800 with a 100 mg unlabeled test/loading dose of Panitumumab. The surgical resection will then occur 2 to 5 days after infusion. Intraoperative imaging will be performed using the intraoperative optical imaging devices
88833997|NCT04888585|Experimental|Placebo|Participants in this group will receive placebo SC eow for 12 weeks in the placebo-controlled period and will be re-randomized in 1:1 ratio to receive ABBV-154 dose B or C respectively SC eow for 66 weeks in the LTE period 1 and 104 weeks in LTE period 2.
88833998|NCT04888169|Experimental|Attention Bias Modification - Word Stimuli|Attention bias modification training involves a probe detection task as follows: (1) a fixation cross appears on the screen for 500ms; (2) the fixation cross is replaced by two target stimuli (one threat word and one neutral word) that are displayed at the top and the bottom of the screen for 500ms; (2) the stimuli disappear and a visual probe appears (the letter E or F), in the location of one of the two stimuli until the participant responds to indicate whether the letter was an E or an F using response buttons at the bottom of the phone screen. In the active ABM condition, the probe replaces the neutral stimulus 100% of the time.
89362482|NCT03384238|Experimental|Cohort 1b|Cohort 1b will receive 50 mg of Panitumumab IRDye800 with a 100 mg unlabeled test/loading dose of Panitumumab. A test/loading dose of 100 mg of unlabeled Panitumumab (fixed dose) will be administered via a 60 minute IV infusion prior to infusion of the Panitumumab IRDye800. The surgical resection will then occur 2 to 5 days after infusion. Intraoperative imaging will be performed using the intraoperative optical imaging devices
88833999|NCT04888169|Active Comparator|Attention Bias Modification - Face Stimuli|Attention bias modification training involves a probe detection task as follows: (1) a fixation cross appears on the screen for 500ms; (2) the fixation cross is replaced by two target stimuli (one threatening face and one neutral face) that are displayed at the top and the bottom of the screen for 500ms; (2) the stimuli disappear and a visual probe appears (the letter E or F), in the location of one of the two stimuli until the participant responds to indicate whether the letter was an E or an F using response buttons at the bottom of the phone screen. In the active ABM condition, the probe replaces the neutral stimulus 100% of the time.
88834000|NCT04888169|Experimental|Attention Control Training - Word Stimuli|Attention control training involves a probe detection task as follows: (1) a fixation cross appears on the screen for 500ms; (2) the fixation cross is replaced by two target stimuli (i.e. one threat word and one neutral word) that are displayed at the top and the bottom of the screen for 500ms; (2) the stimuli disappear and a visual probe appears (the letter E or F), in the location of one of the two stimuli until the participant responds to indicate whether the letter was an E or an F using response buttons at the bottom of the phone screen. In the active ACT condition, the probe replaces the neutral stimulus 50% of the time, and replaces the threat stimulus the other 50%.
89362483|NCT03384238|Experimental|Cohort 1c|Cohort 1c will receive 75 mg of Panitumumab IRDye800 with a 100 mg unlabeled test/loading dose of Panitumumab.A test/loading dose of 100 mg of unlabeled Panitumumab (fixed dose) will be administered via a 60 minute IV infusion prior to infusion of the Panitumumab IRDye800. The surgical resection will then occur 2 to 5 days after infusion. Intraoperative imaging will be performed using the intraoperative optical imaging devices
89362484|NCT03384238|Experimental|Cohort 1d|Cohort 1d will receive a 50 mg dose of Panitumumab IRDye800 and no test/loading dose. A test/loading dose of 100 mg of unlabeled Panitumumab (fixed dose) will be administered via a 60 minute IV infusion prior to infusion of the Panitumumab IRDye800. The surgical resection will then occur 2 to 5 days after infusion. Intraoperative imaging will be performed using the intraoperative optical imaging devices
89362485|NCT03384238|Experimental|Cohort 2- Dose Expansion|Cohort 2 will receive the optimal dose of Panitumumab-IRDye800 as determined in Cohort 1
89362486|NCT03379532|Active Comparator|BCI-NMES|Electrical stimulation of paretic upper limb is triggered contigent to voluntary motor cortex activation of the patient, as detected by the brain-computer interface.
89362487|NCT03379532|Sham Comparator|Sham-NMES|Electrical stimulation of paretic upper limb is applied independently of motor cortex activation of the patient by using a prerecorded session of another patient.
88875516|NCT03780816||UNC Lineberger Comprehensive Cancer Center|Observations and interviews will be analyzed to identify any emergent concepts, categories, and relationships in the data.
89362488|NCT03375242||crizotinib|
89362489|NCT03368963|Experimental|Treatment (Nal-IRI, TAS-102)|Patients receive nanoliposomal irinotecan IV over 90 minutes on day 1 and combination of trifluridine/tipiracil hydrochloride combination agent TAS-102 PO BID on days 1-5. Cycles repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.
89362490|NCT03365622|Active Comparator|IV acetaminophen and placebo pills|
89362491|NCT03365622|Placebo Comparator|placebo IV (normal saline) + oral acetaminophen|
89362492|NCT03361306|Experimental|KRd-Elotuzumab|"Induction (4 28-day cycles):~Carfilzomib (IV) @ 20 mg/m^2, Day 1 of Cycle 1; @ 56 mg/m^2, Day 8,15 of Cycle 1; @ 56 mg/m^2, Day 1,8,15 of Cycles 2-4~Lenalidomide (Oral) @ 25 mg, once daily at bedtime on Days 1-21 of each cycle (Cycles 1-4)~Dexamethasone @ 28 mg orally OR 8 mg IV, once weekly on Day 1,8,15,22 of Cycles 1-2; @28 mg orally OR 8 mg IV on Day 1 of Cycles 3-4~Elotuzumab (IV) @ 10 mg/kg, once weekly on Day 1,8,15,22 of Cycles 1-2; @ 20 mg/kg on Day 1 of Cycles 3-4~Maintenance (28-day cycles):~Elotuzumab (IV) @ 20 mg/kg, Day 1 of each cycle (Cycles 1-n)~Lenalidomide (Oral) @ 15 mg (or last tolerated dose if <15 mg), once daily at bedtime on Days 1-21 of each cycle (Cycles 1-n)"
89362493|NCT03355781||Schizophrenic patients|Patients will have clinical psychiatric evaluation, brain imaging and blood sample
88875517|NCT03780816||UAB O'Neal Comprehensive Cancer Center|Observations and interviews will be analyzed to identify any emergent concepts, categories, and relationships in the data.
88875518|NCT03734952|Experimental|Group A|Neoadjuvant Radiotherapy Program+Neoadjuvant chemotherapy Program+ Esophagectomy program+Postoperative radiotherapy program
89362494|NCT03355781||Related volunteers (first degree relative of patient)|Related volunteers will have clinical psychiatric evaluation, brain imaging and blood sample
89178251|NCT04102566|Experimental|Multi-modal group|"The multi-modal group will receive the following regimen while inpatient:~2% topical lidocaine gel applied to catheter tip as needed for pain, maximum dose of 600mg in 12 hours~Acetaminophen 1000mg every 8 hours standing~Ibuprofen 600mg every 6 hours standing~Oxycodone 5mg PO every 4 hours as needed pain~Phenazopyridine 100mg TID as needed for urinary burning~Senna 1 tab every 12 hours~Miralax 17g powder once daily as needed for constipation~Patient Education (Figures 2 & 3)~The multi-modal group will receive the following prescriptions on discharge:~Acetaminophen 1000mg every 8 hours standing for two days then as needed - 30 tabs~Ibuprofen 600mg every 8 hours standing for two days then as needed - 30 tabs~Phenazopyridine 100mg TID as needed for urinary burning - 9 tabs~Senna 1 tab every 12 hours - 10 tabs"
89178252|NCT04106778|Experimental|Study Treatment 1|DMT310 Powder mixed with Hydrogen Peroxide
89362495|NCT03355781||Healthy volunteers|Healthy volunteers will have clinical psychiatric evaluation, brain imaging and blood sample
89362496|NCT03325439|Experimental|Brivaracetam (BRV)|Exploratory Cohort and Confirmatory Cohorts
89362497|NCT03324425|Experimental|Simvastatin|Simvastatin 80 mg in combination with anti-HER2 therapy regimen
89362498|NCT03301532|Experimental|Patients on a ketogenic diet|This is a one arm study were patients will be receiving an oil called triheptanoin. Patients will be consuming triheptanoin 4 times over the course of one day. The triheptanoin oil will take up 45% of their daily calories on the day the day they are taking the oil.
89362499|NCT03291899|Experimental|Experimental single arm|"Chemotherapy using the FOLFIRINOX regimen will be given every 2 weeks for a total of 12 cycles. FOLFIRINOX consist of:~Oxaliplatin-85 mg/m2 IV Day 1~Leucovorin-400 mg/m2 IV Day 1~Irinotecan-180 mg/m2 IV Day 1~Fluorouracil (FU)-400 mg/m2 IV bolus Day 1~Fluorouracil 2400 mg/m2 infused over 46 hours starting day 1"
89362500|NCT03261089||Unresponsive patients post-cardiac arrest|As early as possible post-resuscitation, patients should undergo a detailed neurologic examination, comprised of a thorough assessment for consciousness and detailed cranial nerve function and motor response assessments. Neurologic assessment scores such as the Full Outline of Unresponsiveness, Glasgow Coma Scale (GCS), and Pittsburgh Cardiac Arrest Category Score will be also be used. On the first assessment (day of cardiac arrest), the PCAC score should be assigned only on the basis of the best neurologic exam in the first 6 hours after ROSC. Patients that are sedated or intubated will have the verbal score of GCS be estimated by a derivation of motor and eye scores. The presence of potential confounders, including core body temperature, medications, and/or intoxicants, as well as metabolic derangements should be noted.
88834001|NCT04888169|Active Comparator|Attention Control Training - Face Stimuli|Attention control training involves a probe detection task as follows: (1) a fixation cross appears on the screen for 500ms; (2) the fixation cross is replaced by two target stimuli (one threatening face and one neutral face) that are displayed at the top and the bottom of the screen for 500ms; (2) the stimuli disappear and a visual probe appears (the letter E or F), in the location of one of the two stimuli until the participant responds to indicate whether the letter was an E or an F using response buttons at the bottom of the phone screen. In the active ACT condition, the probe replaces the neutral stimulus 50% of the time, and replaces the threat stimulus the other 50%.
88834002|NCT04888169|Placebo Comparator|Placebo Attention Training - Word Stimuli|Placebo attention training involves a probe detection task as follows: (1) a fixation cross appears on the screen for 500ms; (2) the fixation cross is replaced by two target stimuli (two neutral words) that are displayed at the top and the bottom of the screen for 500ms; (2) the stimuli disappear and a visual probe appears (the letter E or F), in the location of one of the two stimuli until the participant responds to indicate whether the letter was an E or an F using response buttons at the bottom of the phone screen.
88875519|NCT03734952|Other|Group B|Neoadjuvant Radiotherapy Program+Neoadjuvant chemotherapy Program+ Esophagectomy program
89178253|NCT04106778|Experimental|Study Treatment 2|Placebo powder mixed with Hydrogen Peroxide
89178254|NCT00916110|Experimental|1.5mgSC|ATN-103
89362501|NCT03260465|Experimental|seleXys PC|seleXys PC cup combined with the optimys stem
89362502|NCT03260465|Active Comparator|RM|RM Pressfit vitamys cup combined with the optimys stem
89362503|NCT03247634|Experimental|Getting Ahead Program|12 staggered cohorts will be given the Getting Ahead program, using the established Getting Ahead in a Just-Gettin'-By World program. Six practices will be used. Each participant will come in for 16 session over an eight week period and will be followed up six months post intervention
89362504|NCT03246347|Experimental|Single Arm|Docetaxel + Enzalutamide + Androgen Deprivation Therapy
89362505|NCT03209713|Active Comparator|Parental Education|Participants will receive parental education on HPV vaccine and the vaccine's benefits.
89362506|NCT03209713|Experimental|Parental Education + Text Messaging|Participants will receive parental education on HPV vaccine and the vaccine's benefits plus text messaging reminder.
88834003|NCT04888169|Placebo Comparator|Placebo Attention Training - Face Stimuli|Placebo attention training involves a probe detection task as follows: (1) a fixation cross appears on the screen for 500ms; (2) the fixation cross is replaced by two target stimuli (two neutral faces) that are displayed at the top and the bottom of the screen for 500ms; (2) the stimuli disappear and a visual probe appears (the letter E or F), in the location of one of the two stimuli until the participant responds to indicate whether the letter was an E or an F using response buttons at the bottom of the phone screen.
88834004|NCT04888169|Sham Comparator|Control - Questions|The Control - Questions condition will only deliver a set of daily questions for participants to answer. Questions will ask about a variety of psychological factors such as mood, stress experiences, daily exercise and more.
88834005|NCT04885179||Individuals with SPLIS|Individuals diagnosed with SPLIS based on genetic testing that confirms bi-allelic pathogenic variants in SGPL1
88834006|NCT04885179||Parents of individuals with SPLIS|Parents of individuals diagnosed with SPLIS based on genetic testing that confirms bi-allelic pathogenic variants in SGPL1
88834007|NCT04885179||age and gender-matched controls|The investigators will attempt to collect biological specimens from individuals closely matched to SPLIS patient cohort by age and gender. This group may include siblings, cousins, and unrelated healthy children and adults.
88834008|NCT04878029|Experimental|Treatment (cabozantinib, enfortumab vedotin)|Patients receive cabozantinib PO QD on days 1-28 and enfortumab vedotin IV on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88834009|NCT04871529|Experimental|Arm A (avelumab, gemcitabine, carboplatin, surgery)|Patients receive avelumab IV over 60 minutes on day 1. Treatment repeats every 14 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up 4 in the absence of disease progression or unacceptable toxicity. Within 4-8 weeks after final systemic therapy, patients undergo standard of care surgery.
88834010|NCT04871529|Experimental|Arm B (surgery)|Patients undergo standard of care surgery.
88834011|NCT04865887|Experimental|Pembrolizumab with Lenvatinib|
88834012|NCT04864444|Experimental|MDA with DHA-PPQ + SLD-PQ|Participants in intervention villages will be given three rounds of MDA with DHA-PPQ and SLD-PQ. Prior to the intervention, participants will have received piperonyl butoxide (PBO) treated LLINs and proactive community case management. Unlike control villages, MDA-randomized villages will not receive SMC.
88834013|NCT04864444|No Intervention|Standard malaria control interventions|Participants in the control villages will receive standard malaria control interventions as implemented by the Senegal PNLP. This will include the distribution of PBO LLINs, proactive case management, and SMC.
88834014|NCT04854070|Experimental|IVUS-guided PCI|Method is already used in standard care, but in this trial compared to another method also already used in standard care
88834015|NCT04854070|Active Comparator|Angio-guided PCI|Method is standard care
89362507|NCT03207594||Arm 1|Current smokers with cancer who are planning to get radiation therapy at MUSC.
88834016|NCT04854018|Experimental|Single Arm|Injection of Indocyanine Green at doses detailed on summary of product characteristics for each age range
88834017|NCT04853043|Experimental|Cetuximab|
88834018|NCT04843501|Experimental|CATCH My Breath (CMB) program for E-cigarette prevention among adolescents|The CMB curriculum is divided into four developmentally appropriate e-cigarette lessons (approximately 20-30 minutes each) for middle school aged youth (6th - 8th grade). A variety of educational strategies are used and include cooperative learning groups, large group discussions, interviews, role-play, media, reports, and goal setting. CMB will provide study materials to teachers and schools through a state-of-the art online delivery portal. A site-based management team will oversee program implementation. Teachers will be trained via webinar. Project staff will visit all participating schools to assemble and train the CATCH site-based management team, and answer questions about the study. Teachers in CMB intervention schools will be provided with CMB-specific training for implementing the lessons with fidelity through a one-hour live webinar with Dr. Kelder, which will be offered at multiple times to accommodate teaching schedules.
89362508|NCT03207555|Experimental|Ibrutinib|Participants take Ibrutinib by mouth 1 time every day for up to 2 years (24 cycles).
89362509|NCT03203330|Active Comparator|Active Treatment (TG-C)|TG-C at 3 x 10e7 cells per single 2 mL intraarticular injection
88834019|NCT04843501|Active Comparator|Texas Education Agency required tobacco prevention program|The TEA tobacco prevention program is a state-supported program that meets the mandates of the state. It includes online lessons and support materials.
88834020|NCT04837222||Participants with CD30-positive Lymphoma|All participants diagnosed with CD30-positive lymphoma who are receiving or will recieve brentuximab vedotin will be observed prospectively over 24-month period, unless withdrawal of informed consent, lost or death, whichever comes first.
88834021|NCT04826133|Active Comparator|Acute Pretreatment with Calcitriol|To explore the effects of acute pre-treatment with Calcitriol on attempts to self-administer and ultimate number of infusions/boluses of cocaine, in experienced, non treatment-seeking users of the drug
88834022|NCT04826133|Placebo Comparator|Acute Pretreatment with Placebo|To explore the effects of acute pre-treatment with placebo on attempts to self-administer and ultimate number of infusions/boluses of cocaine, in experienced, non treatment-seeking users of the drug
88834023|NCT04810624|Experimental|Do, Accept, Motivation Through Values, Sessions, Long-Term Food Logs,|"Behavior Do: Including in-session eating experiments.~Thought Accept: Mindfully accepting of unhelpful thoughts as passing mental phenomena that need not guide behavior.~Motivation Through Values: Identifying individual motivators for recovery and opportunities to expand upon non-eating disorder aspects of identity.~Sessions for Skills Consolidation: Consolidation of skills introduced to patient and monitoring of continued progress using 45-min, face-to-face (via video) sessions.~Food Monitoring - Long-Term: Use of food logs for duration of treatment."
89001166|NCT04579354|No Intervention|Standardized Anaesthesia briefing|standardised anaesthesia information sessions, consisting of a detailed explanation of the anaesthesia procedure by the anaesthetist A specific information sheet is used to explain the procedure and the form of anaesthesia. This corresponds to the current procedure before an operation.
89362510|NCT03203330|Placebo Comparator|Placebo Control (Normal Saline)|Normal saline, single 2 mL intraarticular injection
88834024|NCT04810624|Experimental|Do, Accept, Motivation through Values, Sessions, Short-Term Food Logs|"Behavior Do: Including in-session eating experiments.~Thought Accept: Mindfully accepting of unhelpful thoughts as passing mental phenomena that need not guide behavior.~Motivation Through Values: Identifying individual motivators for recovery and opportunities to expand upon non-eating disorder aspects of identity.~Sessions for Skills Consolidation: Consolidation of skills introduced to patient and monitoring of continued progress using 45-min, face-to-face (via video) sessions.~Food-Monitoring - Short-Term: Use of food logs for first 5 weeks of treatment."
88834025|NCT04810624|Experimental|Do, Accept, Motivation through Values, Check-Ins, Short-Term Food Logs|"Behavior Do: Including in-session eating experiments.~Thought Accept: Mindfully accepting of unhelpful thoughts as passing mental phenomena that need not guide behavior.~Motivation Through Values: Identifying individual motivators for recovery and opportunities to expand upon non-eating disorder aspects of identity.~Check-Ins for Skills Consolidation: Consolidation of skills introduced to patient and monitoring of continued progress conducted independently by participant, with only brief (~20-min) check-ins during this period.~Food-Monitoring - Short-Term: Use of food logs for first 5 weeks of treatment."
88834026|NCT04810624|Experimental|Do, Accept, Motivation through Values, Check-Ins, No Food Logs|"Behavior Do: Including in-session eating experiments.~Thought Accept: Mindfully accepting of unhelpful thoughts as passing mental phenomena that need not guide behavior.~Motivation Through Values: Identifying individual motivators for recovery and opportunities to expand upon non-eating disorder aspects of identity.~Check-Ins for Skills Consolidation: Consolidation of skills introduced to patient and monitoring of continued progress conducted independently by participant, with only brief (~20-min) check-ins during this period.~No Food-Monitoring: No recommendation for food records or logs during treatment."
88834027|NCT04810624|Experimental|Do, Accept, Motivation through Narratives, Sessions, Short-Term Food Logs|"Behavior Do: Including in-session eating experiments.~Thought Accept: Mindfully accepting of unhelpful thoughts as passing mental phenomena that need not guide behavior.~Motivation Through Narratives: Using stories of others with lived experience (e.g., writings, podcasts) to appreciate long-term dangers of AN and the opportunity for symptom resolution with sustained recovery, without discussion of individualized motivators.~Sessions for Skills Consolidation: Consolidation of skills introduced to patient and monitoring of continued progress using 45-min, face-to-face (via video) sessions.~Food-Monitoring - Short-Term: Use of food logs for first 5 weeks of treatment."
88834028|NCT04810624|Experimental|Do, Accept, Motivation through Narratives, Sessions, No Food Logs|"Behavior Do: Including in-session eating experiments.~Thought Accept: Mindfully accepting of unhelpful thoughts as passing mental phenomena that need not guide behavior.~Motivation Through Narratives: Using stories of others with lived experience (e.g., writings, podcasts) to appreciate long-term dangers of AN and the opportunity for symptom resolution with sustained recovery, without discussion of individualized motivators.~Sessions for Skills Consolidation: Consolidation of skills introduced to patient and monitoring of continued progress using 45-min, face-to-face (via video) sessions.~No Food-Monitoring: No recommendation for food records or logs during treatment."
88834029|NCT04810624|Experimental|Do, Accept, Motivation through Narratives, Check-Ins, Long-Term Food Logs|"Behavior Do: Including in-session eating experiments.~Thought Accept: Mindfully accepting of unhelpful thoughts as passing mental phenomena that need not guide behavior.~Motivation Through Narratives: Using stories of others with lived experience (e.g., writings, podcasts) to appreciate long-term dangers of AN and the opportunity for symptom resolution with sustained recovery, without discussion of individualized motivators.~Check-Ins for Skills Consolidation: Consolidation of skills introduced to patient and monitoring of continued progress conducted independently by participant, with only brief (~20-min) check-ins during this period.~Food Monitoring - Long-Term: Use of food logs for duration of treatment."
88834030|NCT04810624|Experimental|Do, Change, Motivation Through Values, Sessions, Short-Term Food Logs|"Behavior Do: Including in-session eating experiments.~Thought Change: Monitoring and actively challenging distorted thoughts.~Motivation Through Values: Identifying individual motivators for recovery and opportunities to expand upon non-eating disorder aspects of identity.~Sessions for Skills Consolidation: Consolidation of skills introduced to patient and monitoring of continued progress using 45-min, face-to-face (via video) sessions.~Food-Monitoring - Short-Term: Use of food logs for first 5 weeks of treatment."
88834031|NCT04810624|Experimental|Do, Change, Motivation Through Values, Sessions, No Food Logs|"Behavior Do: Including in-session eating experiments.~Thought Change: Monitoring and actively challenging distorted thoughts.~Motivation Through Values: Identifying individual motivators for recovery and opportunities to expand upon non-eating disorder aspects of identity.~Sessions for Skills Consolidation: Consolidation of skills introduced to patient and monitoring of continued progress using 45-min, face-to-face (via video) sessions.~No Food-Monitoring: No recommendation for food records or logs during treatment."
88834032|NCT04810624|Experimental|Do, Change, Motivation through Values, Check-Ins, Long-Term Food Logs|"Behavior Do: Including in-session eating experiments.~Thought Change: Monitoring and actively challenging distorted thoughts.~Motivation Through Values: Identifying individual motivators for recovery and opportunities to expand upon non-eating disorder aspects of identity.~Check-Ins for Skills Consolidation: Consolidation of skills introduced to patient and monitoring of continued progress conducted independently by participant, with only brief (~20-min) check-ins during this period.~Food Monitoring - Long-Term: Use of food logs for duration of treatment."
88834033|NCT04810624|Experimental|Do, Change, Motivation Through Narratives, Sessions, Long-term Food Logs|"Behavior Do: Including in-session eating experiments.~Thought Change: Monitoring and actively challenging distorted thoughts.~Motivation Through Narratives: Using stories of others with lived experience (e.g., writings, podcasts) to appreciate long-term dangers of AN and the opportunity for symptom resolution with sustained recovery, without discussion of individualized motivators.~Sessions for Skills Consolidation: Consolidation of skills introduced to patient and monitoring of continued progress using 45-min, face-to-face (via video) sessions.~Food Monitoring - Long-Term: Use of food logs for duration of treatment."
89001167|NCT04579354|Experimental|Virtual reality (VR) tour|standardised anaesthesia information sessions, consisting of a detailed explanation of the anaesthesia procedure by the anaesthetist A specific information sheet is used to explain the procedure and the form of anaesthesia.Subsequently, the patients are shown a virtual tour of the operation using VR glasses. This includes the way through the clinic to the operating theatre: Admission -> inpatient preparation for the operation -> administration of premedication -> way to the operating theater -> OP preparation (holding) -> safe surgery
89362511|NCT03187288|Experimental|CFI-400945|CFI-400945 will be given by mouth at 64,96,128,160,192 or 224 mg/day, everyday until intolerable side effects or disease progression.
89362512|NCT03141177|Experimental|Doublet|Nivolumab and Cabozantinib
89362513|NCT03141177|Active Comparator|Monotherapy|Sunitinib
89362514|NCT03141177|Experimental|Triplet|"Nivolumab, Ipilimumab, Cabozantinib~*Enrollment to the triplet arm was discontinued by protocol amendment"
88834034|NCT04810624|Experimental|Talk, Accept, Motivation through Values, Sessions, Short-Term Food Logs|"Behavior Talk: Discussion of recent eating and plans for upcoming eating; absence of in-session eating experiments.~Thought Accept: Mindfully accepting of unhelpful thoughts as passing mental phenomena that need not guide behavior.~Motivation Through Values: Identifying individual motivators for recovery and opportunities to expand upon non-eating disorder aspects of identity.~Sessions for Skills Consolidation: Consolidation of skills introduced to patient and monitoring of continued progress using 45-min, face-to-face (via video) sessions.~Food-Monitoring - Short-Term: Use of food logs for first 5 weeks of treatment."
88834035|NCT04810624|Experimental|Talk, Accept, Motivation through Values, Sessions, No Food Logs|"Behavior Talk: Discussion of recent eating and plans for upcoming eating; absence of in-session eating experiments.~Thought Accept: Mindfully accepting of unhelpful thoughts as passing mental phenomena that need not guide behavior.~Motivation Through Values: Identifying individual motivators for recovery and opportunities to expand upon non-eating disorder aspects of identity.~Sessions for Skills Consolidation: Consolidation of skills introduced to patient and monitoring of continued progress using 45-min, face-to-face (via video) sessions.~No Food-Monitoring: No recommendation for food records or logs during treatment."
89001168|NCT04579705|Experimental|Group I (Brushed-1 minute)|Surgical hand scrubbing will be performed in 1 minute using a brush.
89001169|NCT04579705|No Intervention|Group II (Brushless-1 minute)|Surgical hand scrubbing will be performed in 1 minute without using a brush.
89001170|NCT04579705|Experimental|Group III (Brushed-2 minutes)|Surgical hand scrubbing will be performed in 2 minute using a brush.
89001171|NCT04579705|No Intervention|Group IV (Brushless-2 minutes)|Surgical hand scrubbing will be performed in 2 minute without using a brush.
89362515|NCT03135691||Patients at High Risk for OSA|Patients at High Risk for Obstructive Sleep Apnea Undergoing Laparoscopic Bariatric Surgery; retrospective study, no intervention administered.
89362516|NCT03099499|Experimental|ONC201 treatment Arm|
89362517|NCT03098836|Experimental|Caucasian|
89362518|NCT03098836|Experimental|African American|
88834036|NCT04810624|Experimental|Talk, Accept, Motivation through Narratives, Check-Ins, Short-Term Food Logs|"Behavior Talk: Discussion of recent eating and plans for upcoming eating; absence of in-session eating experiments.~Thought Accept: Mindfully accepting of unhelpful thoughts as passing mental phenomena that need not guide behavior.~Motivation Through Narratives: Using stories of others with lived experience (e.g., writings, podcasts) to appreciate long-term dangers of AN and the opportunity for symptom resolution with sustained recovery, without discussion of individualized motivators.~Check-Ins for Skills Consolidation: Consolidation of skills introduced to patient and monitoring of continued progress conducted independently by participant, with only brief (~20-min) check-ins during this period.~Food-Monitoring - Short-Term: Use of food logs for first 5 weeks of treatment."
88834037|NCT04810624|Experimental|Talk, Accept, Motivation through Narratives, Check-Ins, No Food Logs|"Behavior Talk: Discussion of recent eating and plans for upcoming eating; absence of in-session eating experiments.~Thought Accept: Mindfully accepting of unhelpful thoughts as passing mental phenomena that need not guide behavior.~Motivation Through Narratives: Using stories of others with lived experience (e.g., writings, podcasts) to appreciate long-term dangers of AN and the opportunity for symptom resolution with sustained recovery, without discussion of individualized motivators.~Check-Ins for Skills Consolidation: Consolidation of skills introduced to patient and monitoring of continued progress conducted independently by participant, with only brief (~20-min) check-ins during this period.~No Food-Monitoring: No recommendation for food records or logs during treatment."
88834038|NCT04810624|Experimental|Talk, Change, Motivation Through Values, Sessions, Long-Term Food Logs|"Behavior Talk: Discussion of recent eating and plans for upcoming eating; absence of in-session eating experiments.~Thought Change: Monitoring and actively challenging distorted thoughts.~Motivation Through Values: Identifying individual motivators for recovery and opportunities to expand upon non-eating disorder aspects of identity.~Sessions for Skills Consolidation: Consolidation of skills introduced to patient and monitoring of continued progress using 45-min, face-to-face (via video) sessions.~Food Monitoring - Long-Term: Use of food logs for duration of treatment."
88834039|NCT04810624|Experimental|Talk, Change, Motivation Through Values, Sessions, No Food Logs|"Behavior Talk: Discussion of recent eating and plans for upcoming eating; absence of in-session eating experiments.~Thought Change: Monitoring and actively challenging distorted thoughts.~Motivation Through Values: Identifying individual motivators for recovery and opportunities to expand upon non-eating disorder aspects of identity.~Sessions for Skills Consolidation: Consolidation of skills introduced to patient and monitoring of continued progress using 45-min, face-to-face (via video) sessions.~No Food-Monitoring: No recommendation for food records or logs during treatment."
88834040|NCT04810624|Experimental|Talk, Change, Motivation through Values, Check-Ins, Short-Term Food Logs|"Behavior Talk: Discussion of recent eating and plans for upcoming eating; absence of in-session eating experiments.~Thought Change: Monitoring and actively challenging distorted thoughts.~Motivation Through Values: Identifying individual motivators for recovery and opportunities to expand upon non-eating disorder aspects of identity.~Check-Ins for Skills Consolidation: Consolidation of skills introduced to patient and monitoring of continued progress conducted independently by participant, with only brief (~20-min) check-ins during this period.~Food-Monitoring - Short-Term: Use of food logs for first 5 weeks of treatment."
88834041|NCT04810624|Experimental|Talk, Change, Motivation through Values, Check-Ins, No Food Logs|"Behavior Talk: Discussion of recent eating and plans for upcoming eating; absence of in-session eating experiments.~Thought Change: Monitoring and actively challenging distorted thoughts.~Motivation Through Values: Identifying individual motivators for recovery and opportunities to expand upon non-eating disorder aspects of identity.~Check-Ins for Skills Consolidation: Consolidation of skills introduced to patient and monitoring of continued progress conducted independently by participant, with only brief (~20-min) check-ins during this period.~No Food-Monitoring: No recommendation for food records or logs during treatment."
88834042|NCT04810624|Experimental|Talk, Change, Motivation through Narratives, Sessions, Short-Term Food Logs|"Behavior Talk: Discussion of recent eating and plans for upcoming eating; absence of in-session eating experiments.~Thought Change: Monitoring and actively challenging distorted thoughts.~Motivation Through Narratives: Using stories of others with lived experience (e.g., writings, podcasts) to appreciate long-term dangers of AN and the opportunity for symptom resolution with sustained recovery, without discussion of individualized motivators.~Sessions for Skills Consolidation: Consolidation of skills introduced to patient and monitoring of continued progress using 45-min, face-to-face (via video) sessions.~Food-Monitoring - Short-Term: Use of food logs for first 5 weeks of treatment."
89001172|NCT00575809||Obsevational|
89001173|NCT00575848|Active Comparator|1|
89001174|NCT00575848|Placebo Comparator|2|
89001175|NCT00575926|Active Comparator|A: Lingzhi extract|Oral 300mg capsules containing Lingzhi extract (4 to 6 capsules per day as dosed by patients' age)
89001176|NCT00575926|Placebo Comparator|B: Placebo|Starch with same appearance and taste as LingZhi
89001177|NCT00576004|Active Comparator|group A|Pelvic organ prolapse repair plus concomitant Burch Colposuspension
89001178|NCT00576004|Active Comparator|group B|Pelvic organ prolapse without Burch colposuspension
89001179|NCT00576043|Active Comparator|1: Training|3 weeks/2 hours per day of structured training for a total of 20 hours on the virtual endoscopy simulator
89001180|NCT00576043|No Intervention|2: No Training|No simulator training before starting endoscopy training on real patients
89178255|NCT00916110|Experimental|4mgSC|ATN-103
89178256|NCT00916110|Experimental|10mgSC|ATN-103
89178257|NCT00916110|Experimental|25mgSC|ATN-103
89178258|NCT00916110|Experimental|25mgIV|ATN-103
89178259|NCT00916110|Experimental|50mgSC|ATN-103
89178260|NCT00916110|Experimental|100mgSC|ATN-103
89178261|NCT00916110|Experimental|200mgSC|ATN-103
89362519|NCT03083691|Other|Cohort 1, NSCLC|During Treatment Part A nivolumab 240 mg IV q2w as monotherapy is administered. At the time of disease progression a re-biopsy is performed before initiation of combination therapy (Treatment Part B). Within Treatment Part B, nivolumab is given in a dose of 3 mg/kg q2w together with ipilimumab 1 mg/kg IV q6w.
89362520|NCT03083691|Other|Cohort 2, SCLC|Within Treatment Part A, nivolumab 1 mg/kg q3w together with ipilimumab 3 mg/kg q3w for a total of four doses is administered. After the four combined doses have been administered, a re-biopsy is performed before initiation of Treatment Part B. In Treatment Part B, nivolumab 240 mg q2w monotherapy is administered until disease progression or unacceptable toxicity
89362521|NCT03071536|Experimental|Furosemide|"Single dose of furosemide 1.5 mg/kg intravenously will be given to all participants at 3 hours post-reperfusion of kidney allograft.~Urine output will be recorded hourly for 6 hours."
89362522|NCT03069937|Experimental|Docetaxel + Degarelix|Docetaxel (TAXOTERE) will be given for up to 6 cycles every 21 days. During the 5th and 6th cycles, degarelix (Firmagon) will be administered on Cycle 5 day 1 and cycle 6 day 8. After cycle 6, degarelix will continue to be given every 28 days for a 5 more doses, for a total of 7 doses.
89362523|NCT03065387|Experimental|Arm I (neratinib, everolimus)|Participants receive neratinib PO daily and everolimus PO daily. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88834043|NCT04810624|Experimental|Talk, Change, Motivation through Narratives, Sessions, No Food Logs|"Behavior Talk: Discussion of recent eating and plans for upcoming eating; absence of in-session eating experiments.~Thought Change: Monitoring and actively challenging distorted thoughts.~Motivation Through Narratives: Using stories of others with lived experience (e.g., writings, podcasts) to appreciate long-term dangers of AN and the opportunity for symptom resolution with sustained recovery, without discussion of individualized motivators.~Sessions for Skills Consolidation: Consolidation of skills introduced to patient and monitoring of continued progress using 45-min, face-to-face (via video) sessions.~No Food-Monitoring: No recommendation for food records or logs during treatment."
88834044|NCT04810624|Experimental|Talk, Change, Motivation through Narratives, Check-Ins, Long-Term Food Logs|"Behavior Talk: Discussion of recent eating and plans for upcoming eating; absence of in-session eating experiments.~Thought Change: Monitoring and actively challenging distorted thoughts.~Motivation Through Narratives: Using stories of others with lived experience (e.g., writings, podcasts) to appreciate long-term dangers of AN and the opportunity for symptom resolution with sustained recovery, without discussion of individualized motivators.~Check-Ins for Skills Consolidation: Consolidation of skills introduced to patient and monitoring of continued progress conducted independently by participant, with only brief (~20-min) check-ins during this period.~Food Monitoring - Long-Term: Use of food logs for duration of treatment."
88834045|NCT04810624|Experimental|Do, Change, Motivation through Narratives, Check-Ins, Short-Term Food Logs|"Behavior Do: Including in-session eating experiments.~Thought Change: Monitoring and actively challenging distorted thoughts.~Motivation Through Narratives: Using stories of others with lived experience (e.g., writings, podcasts) to appreciate long-term dangers of AN and the opportunity for symptom resolution with sustained recovery, without discussion of individualized motivators.~Check-Ins for Skills Consolidation: Consolidation of skills introduced to patient and monitoring of continued progress conducted independently by participant, with only brief (~20-min) check-ins during this period.~Food-Monitoring - Short-Term: Use of food logs for first 5 weeks of treatment."
88834046|NCT04810624|Experimental|Do, Change, Motivation through Narratives, Check-Ins, No Food Logs|"Behavior Do: Including in-session eating experiments.~Thought Change: Monitoring and actively challenging distorted thoughts.~Motivation Through Narratives: Using stories of others with lived experience (e.g., writings, podcasts) to appreciate long-term dangers of AN and the opportunity for symptom resolution with sustained recovery, without discussion of individualized motivators.~Check-Ins for Skills Consolidation: Consolidation of skills introduced to patient and monitoring of continued progress conducted independently by participant, with only brief (~20-min) check-ins during this period.~No Food-Monitoring: No recommendation for food records or logs during treatment."
88834047|NCT04810624|Experimental|Talk, Accept, Motivation through Values, Check-Ins, Long-Term Food Logs|"Behavior Talk: Discussion of recent eating and plans for upcoming eating; absence of in-session eating experiments.~Thought Accept: Mindfully accepting of unhelpful thoughts as passing mental phenomena that need not guide behavior.~Motivation Through Values: Identifying individual motivators for recovery and opportunities to expand upon non-eating disorder aspects of identity.~Check-Ins for Skills Consolidation: Consolidation of skills introduced to patient and monitoring of continued progress conducted independently by participant, with only brief (~20-min) check-ins during this period.~Food Monitoring - Long-Term: Use of food logs for duration of treatment."
88834048|NCT04810624|Experimental|Talk, Accept, Motivation through Narratives, Sessions, Long-Term Food Logs|"Behavior Talk: Discussion of recent eating and plans for upcoming eating; absence of in-session eating experiments.~Thought Accept: Mindfully accepting of unhelpful thoughts as passing mental phenomena that need not guide behavior.~Motivation Through Narratives: Using stories of others with lived experience (e.g., writings, podcasts) to appreciate long-term dangers of AN and the opportunity for symptom resolution with sustained recovery, without discussion of individualized motivators.~Sessions for Skills Consolidation: Consolidation of skills introduced to patient and monitoring of continued progress using 45-min, face-to-face (via video) sessions.~Food Monitoring - Long-Term: Use of food logs for duration of treatment."
88834049|NCT04797559|Experimental|SZMN Treatment Group|Patients randomized into the SZMN-treatment group will receive a bilateral single injection SZMN block under general anesthesia in the operating room. The injection will occur through the pterygomaxillary fissure into the pterygomaxillary fossa. Patients will receive 5 ml of local anesthestic per side.
88834050|NCT04797559|No Intervention|Control Group|Patients in this group will receive the standard of care for T&A procedures within the pediatric population.
88834051|NCT04796961|Other|Implementation Intervention|All participants will receive the implementation intervention.
88834052|NCT04792645|Placebo Comparator|Placebo|10mg once daily of placebo for two weeks, then 20mg for the remaining six weeks
88834053|NCT04792645|Experimental|Memantine|10mg once daily of memantine for two weeks, then 20mg for the remaining six weeks
89001181|NCT00576121||1|Left ventricular ejection fraction (LVEF) patients will be compared at two time-points, 2-5 days and 4 weeks after acute MI.
88834054|NCT04791228|Experimental|All Patients|LTLD 50 mg/m2 will be administered intravenously over 30 minutes on day 1 of every 21-day cycle. MR-HIFU hyperthermia will follow infusion (+/- 30 minutes) for one hour to a target area with a target temperature of 40-45°C followed by ablation therapy (>55°C). The HIFU hyperthermia regimen will have a duration of at least 60 minutes and will then be followed by ablation therapy. Patients may receive up to a total of 6 cycles. Subsequent treatment cycles may treat alternative target lesions. Disease status will be evaluated using standard imaging techniques (CT/MR) post each cycle.
88834055|NCT04790968|Experimental|PSMA-PET/MRI and PET/CT for detection of lymph node metastases.|"Each patients will undergo an MRI-, PET/MRI- and PET/CT-examination (on the same day) prior to treatment.~Patients in the radiotherapy cohort will additionally undergo an MRI examination after hormonal treatment, before radiotherapy."
88834056|NCT04786028|Experimental|Isatuximab with CyBorD and Lenalidomide Maintenance|This is a single arm study of Isatuximab administered intravenously in combination with cyclophosphamide, bortezomib and dexamethasone (CyBorD), and Lenalidomide maintenance treatment
89534565|NCT03335189|No Intervention|Control|Control group will be asked to complete the study questionnaires at your clinic visits. Also, research staff will contact participants at 1 to 14 days following each chemotherapy, mid and end of each chemotherapy appointment and again within week 8 and 16 of your participation to collect information about participants' symptoms.
88834057|NCT04782167|Experimental|Proprioception training|Researcher give proprioception protocol to one group
88834058|NCT04782167|Experimental|Brace|Researcher give BRace training to one group
88834059|NCT04772469|Experimental|Promoter training, multiple self-test kits, and incentives|Promoters in the intervention group will receive HIVST training, multiple HIVST for distribution to other men, and a small amount of remuneration (transport voucher) for themselves and to distribute to men in their networks.
88834060|NCT04772469|No Intervention|Short training and referral for testing|Promoters in the control group will a short training on the basics of HIV prevention and treatment and will be encouraged to refer men in their networks for standard of care testing at the local health facilities- this may include HIV testing with a counselor or HIV self-test from the local health clinic, depending on what is available.
88834061|NCT04768296|Experimental|Berzosertib + Topotecan|In Japan, a Safety Run-in Part will be conducted. In case safety and tolerability is confirmed in the Safety Run-in part, Japanese participants will enroll in the Main Part of the Phase 2. Both in the Safety Run-in and Main Part of the Phase 2, participants will receive berzosertib and topotecan until disease progression or other criteria for study intervention discontinuation are met.
88834062|NCT04762706|Experimental|CRUTCH Pathway|A novel behavioral health program.
88834063|NCT04760626|Experimental|Insulin icodec with DoseGuide|Participants randomised to insulin icodec will use insulin icodec with the DoseGuide App to guide their titration.
88834064|NCT04760626|Active Comparator|Once daily basal insulin analogues|Participants randomised to basal insulin analogue injections once daily
88834065|NCT04753307||Patients at least 45 years at-risk for cardiovascular complications|
88834066|NCT04751500|Experimental|Outpatient Hysteroscopy|Outpatient hysteroscopic morcellation of retained products of conception
88834067|NCT04751500|Active Comparator|Standard Treatment|Standard treatment of retained products of conception in the form of expectant management, medical management, antibiotic therapy and/or surgical management (manual vacuum aspiration/suction curettage/dilatation and curettage)
88834068|NCT04750486|No Intervention|Control|No intervention, the patient will be provided routine care at time of epidural placement without use of sequential compression devices.
88834069|NCT04750486|Experimental|Lower Extremity Compression|Patients will have sequential compression devices prior to epidural placement, and maintained for at least one hour following procedure.
88834070|NCT04750265|Experimental|Robotic assisted early mobilization|Early mobilization therapy assisted with robotics
88834071|NCT04750265|No Intervention|Standard Care|Mobilization according to standard care by staff
88834072|NCT04742049|Experimental|Telerehabilitation|Telerehabilitation based exercise training will be given to the study group.
88834073|NCT04742049|Experimental|Exercise brochure|Exercise training will be provided by sending a document to the control group
88834074|NCT04735874||Children ages 10.0 to 18.0|
88834075|NCT04732728||Safety Cohort|No intervention will be administered to subjects that comprise the safety cohort.
88834076|NCT04732728||Holter Cohort|No intervention will be administered to subjects that comprise the safety cohort.
88834077|NCT04729725|Experimental|Treatment (SAR439459, cemiplimab)|Patients receive SAR439459 IV over 30 minutes on day 1 and cemiplimab IV over 30 minutes on day 1 starting cycle 2. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
88834078|NCT04726449||psychiatric diagnosis|psychiatric diagnosis : patients who were given a psychiatric diagnosis at the end of the follow up
88834079|NCT04726449||somatic diagnosis|somatic diagnosis: patients who were given a somatic diagnosis at the end of the follow up
88834080|NCT04723004|Active Comparator|Experimental group|Toripalimab combined with Bevacizumab
89001182|NCT00576121||2|End-diastolic volume (LVEDV) patients will be compared at two time-points, 2-5 days and 4 weeks after acute MI.
89001183|NCT00576121||3|End-systolic volume (LVESV) patients will be compared at two time-points, 2-5 days and 4 weeks after acute MI.
89178262|NCT00916110|Experimental|200mgIV|ATN-103
89178263|NCT00776100|Other|Arm I|Patients undergo observation for 6 weeks.
88834081|NCT04723004|Active Comparator|Control group|Sorafenib
88834082|NCT04719130|Experimental|Experimental Group|Will received multimodal circuit exercise group.
88834083|NCT04719130|Active Comparator|Control Group|Will received multidisciplinary lectures on pain and usual care provided by the Basic Health Units.
88834084|NCT04708535||Bariatric Cohort|For consenting subjects who are undergoing bariatric surgery, a visceral fat sample will be taken during surgery. In addition to the fat sample, insulin resistance will be measured and determined by a modification of the insulin suppression test.
88834085|NCT04698603|Experimental|Phase 1 (Part A): GH001 dose A|
88834086|NCT04698603|Experimental|Phase 1 (Part A): GH001 dose B|
88834087|NCT04698603|Experimental|Phase 2 (Part B): GH001 Individualized Dosing Regimen|
89178264|NCT00776100|Experimental|Arm II|Patients undergo radiotherapy 5 days a week for 6 weeks to all sites of gross disease.
89362524|NCT03065387|Experimental|Arm II (neratinib, palbociclib)|Participants receive Neratinib PO daily for 28 days and Palbociclib PO daily for 21 days. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89362525|NCT03065387|Experimental|Arm III (neratinib, trametinib)|Participants receive neratinib PO daily and trametinib PO daily as directed. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89362526|NCT03055325||Surgical patients|Cognitive testing, testing of heart rate variability and collection of blood samples
89362527|NCT03044613|Experimental|Arm A|Nivolumab 240mg administered IV over 30 minutes every 2 weeks for 2 cycles and then standard of care chemoradiation (weekly carboplatin/paclitaxel and concurrent radiation
89362528|NCT03044613|Experimental|Arm B|Nivolumab 240mg administered IV over 30 minutes followed by relatlimab 80mg administered IV over 60 minutes on Day 1 every 2 weeks for 2 cycles and then standard of care chemoradiation (weekly carboplatin/paclitaxel and concurrent radiation).
89362529|NCT03035864|Experimental|rhNGF 20 µg/ml|Recombinant Human Nerve Growth Factor (rhNGF) at 20 μg/mL eye drops six times daily
89362530|NCT03035864|Placebo Comparator|Vehicle|Vehicle eye drops six times daily
89362531|NCT03021525|Experimental|Individualized Goal Directed Therapy (iGDT)|Patients receive fluids and catecholamines following a protocol of individualized parameters achieved by extended hemodynamic monitoring.
89362532|NCT03021525|Active Comparator|Control|Patients in the control group will be treated according to established basic treatment goals.
89362533|NCT02993068|Experimental|Arm A (online education)|Patients watch genetic testing online educational video and receive genetic testing online test results report.
89362534|NCT02993068|Experimental|Arm B (online education, post telephone counseling)|Patients watch genetic testing online educational video, receive genetic testing online test results report, and post-telephone genetic counseling.
89362535|NCT02993068|Active Comparator|Arm C (online education, pre- and post-telephone counselling)|Patients watch genetic testing online educational video, receive pre-telephone genetic counseling, genetic testing online test results report, and post-telephone genetic counseling.
89362536|NCT02993068|Experimental|Arm D (online education, pre-telephone counseling)|Patients watch genetic testing online educational video, receive pre-telephone genetic counseling, and genetic testing online test results report.
89362537|NCT02974595||Affected Participants|Individuals with undifferentiated autoinflammatory diseases or genetically defined conditions, such as NOMID/CAPS, DIRA, CANDLE, SAVI, and NLRC4 MAS.
89362538|NCT02974595||Healthy Volunteer|Volunteers without known autoinflammatory disease who consent to providing blood specimen for genetic testing.
89362539|NCT02974595||Unaffected Relatives|Blood relatives of the affected patients without known autoinflammatory disease who consent to providing specimen for genetic testing.
89362540|NCT02961504|Experimental|HLCM051 (MultiStem)|single dose of 1.2 billion HLCM051 cells
89362541|NCT02961504|Placebo Comparator|Placebo|a single dose of placebo
89178265|NCT00915642||Normal volunteers|Volunteers, body mass index 17 to 25
89178266|NCT00915642||Obese volunteers|Volunteers body mass index higher than 30
89178267|NCT04103658|No Intervention|Standard of care (control)|This will be the standard of care group. The excision of the non-melanoma skin cancer will be based on standard visual inspection with 4-6mm margins.
89178268|NCT04103658|Experimental|NIR heating|This will be the NIR heating group, where the excision of the non-melanoma skin cancer will be based on the lesion margins based on the application of near-infrared radiation (with 4-6mm margins).
89362542|NCT02942355|Experimental|Cohort A: First-line therapy|Anastrozole by mouth daily and palbociclib by mouth Days 1-21 on a 28 day cycle
89362543|NCT02942355|Experimental|Cohort B: Maintenance therapy|Anastrozole by mouth daily and palbociclib by mouth Days 1-21 on a 28 day cycle
89362544|NCT02922751||All Subjects|All subjects will be recruited from the Children parent studies: LOGIC (NCT00571272), BASIC (NCT00345553) and PROBE (NCT00061828) and will undergo Liver Stiffness Measurement (LSM). Subjects in these studies have one or more of the following conditions: biliary atresia (BA), Alpha1 Anti-trypsin Deficiency (A1AT) or Alagille Syndrome (ALGS).
89362545|NCT02902055|Active Comparator|Rocuronium 1 mg/kg i.v.|Neuromuscular blocking agent
89362546|NCT02902055|Active Comparator|Isotonic saline|
89362547|NCT02889809|Experimental|Fluticasone furoate 50 mcg|During run-in period, subjects will receive inhaled placebo for 16 weeks using ELLIPTA inhaler. Followed by treatment period where subjects will receive inhaled FF 50 mcg administered once daily in the morning for 52 weeks using ELLIPTA inhaler. Subjects will also receive open-label montelukast (4 milligrams [mg] for subjects who are 5 years old and 5 mg for subjects who are >= 6 years old) to be administered as one tablet of montelukast each evening for the duration of the study. Each subject will receive a SABA (albuterol/salbutamol [inhalation aerosol or nebuliser]) to be used as needed throughout the entire study period as rescue medication for symptomatic relief of asthma symptoms.
89362548|NCT02889809|Placebo Comparator|Placebo|During run-in period, subjects will receive inhaled placebo for 16 weeks using ELLIPTA inhaler. Followed by treatment period where subjects will receive inhaled placebo administered once daily in the morning for 52 weeks using ELLIPTA inhaler. Subjects will also receive open-label montelukast (4 milligrams [mg] for subjects who are 5 years old and 5 mg for subjects who are >=6 years old) to be administered as one tablet of montelukast each evening for the duration of the study. Each subject will receive a SABA (albuterol/salbutamol [inhalation aerosol or nebuliser]) to be used as needed throughout the entire study period as rescue medication for symptomatic relief of asthma symptoms.
89362549|NCT02884648|Experimental|Bevacizumab|Participants receive Bevacizumab by vein on Day 1 of every 21-day study cycle, for as long as study doctor thinks it is in participant's best interest.
89362550|NCT02862353||patients with thrombocytopenia drug|
89362551|NCT02860741|Experimental|Intervention|Churches in the REJOICE intervention arm will provide the REJOICE intervention over an 8 week period
89534566|NCT02493023|Experimental|navigated bronchoscopy|
88834088|NCT04697524|Experimental|Phase 1: Supportive care (GMV)|Participants will take a baseline assessment to collect socio-demographic information and complete a series of patient-reported outcome assessments (PROs) prior to their first group medical visit (GMV). The GMV intervention will take place over four weekly sessions conducted virtually. At the completion of all four weekly GMV sessions, participants will be asked to complete an exit survey. Participants in phase one will not be contacted or followed after the exit survey.
89534567|NCT03335111|Experimental|ACI with BAIPC|Beside of routine treatment for Anterior circulation infarction(ACI) patients, BAIPC group patients are admistrated by 5 cycles extremities ischemia (5-minute blood-pressure cuff inflation up to 50 mmHg higher than baseline, followed by 5-minute cuff deflation). All subjects will take BAIPC for 1 week using 'Remote Ischemic Conditioning Equipment' .Intravenous blood collection with anticoagulant and 5ml total blood will be administered at 0d, 1d and 7-10d respectively. The blood samples will be stored for laboratory assay. The blood samples only use in this trial.
88834089|NCT04697524|Experimental|Phase 2: Refined GMV|Up to three new cohorts of participants are recruited to assess the acceptability and feasibility of the refined intervention based on the results from the Phase 1 group
88834090|NCT04691154|Experimental|L606|
88834091|NCT04687475|Experimental|Clinical Tool (Mobile Spirometry and Survey)|All subjects enrolled will be placed into the clinical tool arm. The clinical tool is comprised of a mobile application based assessment of home spirometry and a survey measuring patient reported outcomes.
88834092|NCT04685798|Experimental|DWI MRI|-The patients will undergo an optimized research neck DWI MRI, up to 3 weeks post-treatment and then a standard-of-care 3-month post-treatment FDG PET/CT examination.
88834093|NCT04679909|Experimental|Single Low Dose AdCOVID|
88834094|NCT04679909|Experimental|Single Medium Dose AdCOVID|
88834095|NCT04679909|Experimental|Single High Dose AdCOVID|
88834096|NCT04679909|Experimental|Two Low Doses AdCOVID|
88834097|NCT04679909|Experimental|Two Medium Doses AdCOVID|
88834098|NCT04679909|Experimental|Two High Doses AdCOVID|
88834099|NCT04679909|Placebo Comparator|Single Dose Placebo|
88834100|NCT04679909|Placebo Comparator|Two Dose Placebo|
88834101|NCT04678440|Experimental|Healthy Volunteers|Study participants will undergo a single dynamic [18F]F-AraG PET/CT scan (of duration up to 90-minutes) on the uEXPLORER PET/CT scanner. There will be a follow-up visit or call 7 days after the scan to assess any adverse events that could be attributed to either the scan or the administration of [18F]F-AraG.
88834102|NCT04678440|Experimental|Non-Small Cell Lung Cancer Patients (NSCLC)|Study participants with NSCLC who are planned to receive PD-1/PD-L1 immunotherapy will undergo a pre-therapy dynamic [18F]F-AraG PET/CT scan, and an optional post-therapy (first dose only) dynamic [18F]F-AraG PET/CT scan on the uEXPLORER total-body scanner.
88834103|NCT04676334|Experimental|Rucaparib|Rucaparib administered at dose and schedule last taken in parent study, or per investigator decision
88834104|NCT04676022|Experimental|Spinal Cord Stimulation|To receive Spinal Cord Stimulation programming
88834105|NCT04676022|Other|Conventional Medical Management|To receive conventional medical management
88834106|NCT04674267|Experimental|Intervention Phase - Geriatric Co-Management|"Eligible older adults age 70 and older who score Pre-Frail or Frail will be randomized 2:1 to be offered to meet with a study geriatrician for geriatric co-management in addition to their standard oncology care. Study geriatrician will assist with management of symptoms, additional comorbidities, polypharmacy, and social/emotional concerns in addition to physical care. Geriatrician can make referrals and recommendations for additional supportive services that may be beneficial for more vulnerable older adult patients."
88834107|NCT04674267|No Intervention|Intervention Phase - Standard Oncology Care|"This arm is for those older adult patients (age 70+) who score as Pre-Frail or Frail in the fitness assessment questionnaire and are NOT randomized to meet with the study geriatrician. These patients will be followed for the duration of the study as they proceed with their usual oncology care. Study team will evaluate a number of different measures and outcomes, the primary one being unplanned emergency and hospital visits during the course of the study."
88834108|NCT04673292|Experimental|Fixed site SOC testing|Fixed site Standard of Care (SOC) testing
88834109|NCT04673292|Experimental|Community-based testing|Community-based, mobile van testing
88834110|NCT04673292|Experimental|Self-collected testing|Self-collected, home-based testing
88834111|NCT04669197|Other|Treatment|Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydrochloroquine
88834112|NCT04660812|Experimental|Etrumadenant + Zimberelimab + mFOLFOX-6 +/- Bevacizumab|Participants will receive oral etrumadenant in combination with zimberelimab +mFOLFOX-6 +/-bevacizumab by IV infusion.
88834113|NCT04660812|Active Comparator|mFOLFOX-6 +/- Bevacizumab|Participants will receive mFOLFOX-6 +/- bevacizumab by IV infusion.
88834114|NCT04660812|Active Comparator|Regorafenib|Participants will receive oral regorafenib
88834115|NCT04660812|Experimental|AB680 + Etrumadent+ Zimberelimab|Participants will receive oral etrmadenant in combination with AB680 + zimberelimab by IV infusion.
88834116|NCT04641325|Experimental|Exercise Intervention Group|Group of up to 20 patients will receive all of the preliminary outcome measure testing (cardiovascular, musculoskeletal, and psychological screening) in addition to exercise intervention education, demonstration, and follow up to ensure compliance and safety.
88834117|NCT04640831|Experimental|GH001 dose A|
88834118|NCT04640831|Experimental|GH001 dose B|
88834119|NCT04640831|Experimental|GH001 dose C|
88834120|NCT04640831|Experimental|GH001 dose D|
88834121|NCT04640831|Experimental|GH001 Individualized Dosing|
88834122|NCT04634851|Experimental|Intervention|These participants will get virtual home visits with the urologist and dietitian
88834123|NCT04634851|No Intervention|Control|These participants will get standard urologist and dietitian counseling
88834124|NCT04621734|Active Comparator|Nasal bridle to secure feeding tube|The nasal bridle will be used to secure the nasoenteric feeding tube.
88834125|NCT04621734|Placebo Comparator|Adhesive Tape use to secure feeding tube|Adhesive tape will be used as standard of care to secure the nasoenteric feeding tube.
88834126|NCT04617834||Quality Surveillance Data|For this quality surveillance study, data will be collected retrospectively through electronic health record (EHR) queries for all eligible patients treated for acute cardiovascular symptoms by one of the study sites.
89362552|NCT02860741|Other|Control|Churches in the control arm will receive an educational materials about both identifying depressive symptoms and managing depressive symptoms. This is consistent with self-management interventions commonly utilized for individuals experiencing subclinical levels of depressive symptoms.
89362553|NCT02860364|Experimental|Mild Hypothermic Circulatory Arrest|During aortic hemiarch surgery, mild hypothermia (32°C) will be used during circulatory arrest.
89362554|NCT02860364|Active Comparator|Moderate Hypothermic Circulatory Arrest|During aortic hemiarch surgery, moderate hypothermia (26°C) will be used during circulatory arrest.
89362555|NCT02835911||Lymphoma|Suspected lymphoma with confirmed hematologic malignancies treated under local conditions
89362556|NCT02830204|Experimental|Mitral Valve Replacement with Sapien3|subjects with surgical MVR with Sapien3
89362557|NCT02815592|Experimental|Experimental Arm 1|BMS-986012/Cisplatin/Etoposide
89362558|NCT02815592|Experimental|Experimental Arm 2|BMS-986012/Carboplatin/Etoposide
89362559|NCT02815592|Experimental|Experimental Arm 3A|BMS-986012/Platinum/Etoposide
89362560|NCT02815592|Active Comparator|Active Comparator Arm 3B|Platinum/Etoposide
89362561|NCT02807766|Experimental|Sensory Integration Training|Behavior modification and Sensory Integration Training
89362562|NCT02807766|Experimental|applied behavioral analysis|Behavior modification and applied behavioral analysis.
89362563|NCT02807766|Experimental|TEACCH|Behavior modification and TEACCH.
89362564|NCT02807766|Other|Behavior modification|Behavior modification.
89362565|NCT02807766|No Intervention|healthy control group|No intervention.
89362566|NCT02792465|Experimental|Cohort A|CFI-402257 capsules will be taken orally, once a day, every day.
89362567|NCT02792465|Experimental|Cohort B|CFI-402257 capsules will be taken orally, once a day, every day.
89362568|NCT02792465|Experimental|Cohort C|CFI-402257 capsules will be taken orally, once a day, every day + Fulvestrant injection on day 1 and day 15 of every 28 day cycle
89362569|NCT02785224||Vasopressin Steroids Epinephrine (VSE)|Patients with in-hospital cardiac arrest treated with vasopressin, methylprednisolone, and epinephrine during cardiopulmonary resuscitation, and also with stress-dose hydrocortisone for postresuscitation shock.
89362570|NCT02785224||Control|Patients with in-hospital cardiac arrest treated with normal saline placebo, normal saline placebo, and epinephrine during cardiopulmonary resuscitation, and also with normal saline placebo for postresuscitation shock.
88834127|NCT04616287|Experimental|dementia with Lewy bodies|
88834128|NCT04616287|Active Comparator|Alzheimer disease|
88834129|NCT04616287|Sham Comparator|healthy elderly subjects|
88834130|NCT04611568|Experimental|Prevention (health educational campaign)|"MEDIA CAMPAIGN: Participants view digital media strategies.~PRIMARY CARE PROVIDERS AND PROFESSIONALS: Primary care providers and professionals who see skin and potential melanomas receive online based curriculum on melanoma. Participants also complete a survey to assess knowledge and confidence before and after receiving the curriculum.~MELANOMA COMMUNITY REGISTRY VOLUNTEERS: Melanoma Community Registry volunteers in Oregon receive educational and training materials on melanoma. Participants also complete a survey before and after receiving educational material.~HIGH SCHOOL STUDENTS: High school students receive an educational lecture over 1 hour on sun-safety and early detection of melanoma practices. Participants also complete a survey before and after the educational lecture."
89362571|NCT02784171|Active Comparator|Arm A - Cisplatin/Pemetrexed|Pemetrexed 500 mg/m2 IV Day 1 every 21 days for 6 cycles Cisplatin 75 mg/m2 IV Day 1 every 21 days for 6 cycles
89362572|NCT02784171|Active Comparator|Arm B - Cisplatin/Pemetrexed/Pembrolizumab|Pembrolizumab 200 mg* IV Day 1 over 30 min every 21 days for a total of 2 years Pemetrexed 500 mg/m2 IV Day 1 every 21 days for 6 cycles Cisplatin 75 mg/m2 IV Day 1 every 21 days for 6 cycles
89362573|NCT02784171|Active Comparator|Arm C - Pembrolizumab (Phase II only)|Pembrolizumab 200 mg* IV 30 min Day 1 every 21 days for a total of 2 years
89362574|NCT02769949||Family members|Family members (adult and pediatric; affected and unaffected) may be enrolled for the purpose of determining the molecular lesion(s) responsible for genetic disorders.
89362575|NCT02769949||Genetic disorders|subjects with genetic disorders
89362576|NCT02759107|Experimental|Tirzepatide (Part A)|Participants received escalating single doses of either 0.25 milligram (mg) or 0.5mg or 1mg, or 2.5mg or 5mg or 8mg Tirzepatide by subcutaneous injection.
89362577|NCT02759107|Placebo Comparator|Placebo (Part A)|Participants received single dose of placebo by subcutaneous injection.
89362578|NCT02759107|Experimental|Tirzepatide (Part B)|Participants received fixed doses of either 0.5mg or 1.5mg or 4.5mg Tirzepatide once weekly for four weeks or titrated doses of 5mg, 5mg, 8mg and 10mg Tirzepatide once weekly for four weeks by subcutaneous injection.
89362579|NCT02759107|Placebo Comparator|Placebo (Part B)|Participants received placebo once weekly for four weeks by subcutaneous injection.
89362580|NCT02759107|Active Comparator|Dulaglutide (Part B)|Participants received 1.5mg Dulaglutide once weekly for four weeks by subcutaneous injection.
89362581|NCT02759107|Experimental|Tirzepatide (Part C)|Participants received fixed doses of either 0.5mg or 5mg Tirzepatide once weekly for four weeks or titrated doses of 5mg,5mg,10mg,10mg or 5mg,5mg,10mg,15mg Tirzepatide once weekly for four weeks by subcutaneous injection
89362582|NCT02759107|Placebo Comparator|Placebo (Part C)|Participants received placebo once weekly for four weeks by subcutaneous injection.
89362583|NCT02733133|Experimental|Uncovered|Half of the male partners in each cohort will apply the Testagen® TDS Testosterone 5% HypoSpray® and cover the area before engaging in contact with the female partner.
89362584|NCT02733133|Experimental|Covered|Half of the male partners in each cohort will apply the Testagen® TDS Testosterone 5% HypoSpray® and will not cover the area before engaging in contact with the female partner.
89362585|NCT02729519|Other|Group A|standard procedure TAVI performed with systematic pre dilatation (With prior balloon dilatation)
89362586|NCT02729519|Experimental|Groupe B|standard procedure TAVI performed without pre dilatation (Without prior balloon dilatation)
89362587|NCT02712086|No Intervention|usual dietary management|Control group: usual dietary management Following the intervention, the stomach of patients underwent many changes
89362588|NCT02712086|Experimental|care of with usual dietary protein supplementation|Intervention group: Usual dietary management with protein supplementation (30g) in addition to the usual inputs
89362589|NCT02697227|Active Comparator|Group I (NRT, SC)|Patients receive NRT patch daily for 8 weeks. Patients receive individual behavioral treatment sessions consisting of behavioral treatment strategies for smoking cessation and health education information over 45 minutes for 8 sessions.
88834131|NCT04610398|Active Comparator|Dexamethasone group|The patients in the dexamethasone group will receive 12mg dexamethasone (Fortecortin ®) intravenously 15-60 minutes prior to surgery while in general anasthesia as well as 12mg dexamethasone intravenously (Fortecortin®) on the first postoperative day at approx. 8.00a.m. by the investigators.
88834132|NCT04610398|Placebo Comparator|Placebo/ Control group|The patients will not receive any additional drugs preoperatively. A 0.9% NaCl Solution (NaCl B. Braun Inf Lös 0.9 % 250ml Ecoflac plus®) will be administered at approx. 8.00 a.m. on the first postoperative day by the investigators.
89362590|NCT02697227|Active Comparator|Group II (NRT, BATS)|Patients receive NRT patch daily for 8 weeks. Patients complete individual treatment sessions consisting of SC strategies and BA strategies over 45 minutes for 8 sessions.
89362591|NCT02694094||Adults on Chronic ketogenic diets|Adults who have been on Modified Atkins or ketogenic diets for over 1 year
89362592|NCT02694094||Adults naive to ketogenic diets|Adults who have never been on Modified Atkins or ketogenic diets
89362593|NCT02658968|Experimental|Betalutin|10 MBq/kg b.w., in escalated doses with lilotomab pre-dosing
89362594|NCT02651831||1A: Content Validation|"Up to 4 focus groups of 6-10 cancer patients each will be conducted each lasting approximately 90 mins. An additional 10 to 15 patients will undergo individual semi-structured interviews each lasting around 60 minutes.~10-12 expert clinicians experienced in treating patients with ICMs or managing ICM toxicities will participate in a survey, and group or individual interviews."
89362595|NCT02651831||1B: Face Validity|Patients who have been and are being treated with ICMs to complete draft questionnaire (FACT-ICM). Some patients who were involved in the first round of interviews will be re-interviewed, and interview naïve patients will also be included.
89362596|NCT02651831||2A: To measure test-retest reliability|Patients to complete FACT-ICM at at two time points separated by 5 to 14 days.
89362597|NCT02651831||2B: To confirm construct validity|To evaluate discriminative properties of FACT-ICM, scores will be compared between pre-defined groups of patients where differences are expected.
88834133|NCT04607460|Experimental|EMG-Biofeedback for Lower Back Pain|Participants will receive a JOGO Digital Therapeutics EMG Biofeedback device and a software installed on a tablet or smart phone. During the 8 weekly sessions participants will be instructed on how to use the device by a trained biofeedback instructor.
88834134|NCT04607460|No Intervention|Treatment as usual (Lower Back Pain)|Participants in this group will receive no active treatment.
88834135|NCT04607460|Experimental|EMG-Biofeedback for Persistent Post-Mastectomy Pain|Participants will receive a JOGO Digital Therapeutics EMG Biofeedback device and a software installed on a tablet or smart phone. During the 4 weekly sessions participants will be instructed on how to use the device by a trained biofeedback instructor ahead of their mastectomy.
88834136|NCT04607460|No Intervention|Treatment as usual (Persistent Post-Mastectomy Pain)|Participants in this group will receive no active treatment.
88834137|NCT04607460|Experimental|EMG-Biofeedback for Migraine|Participants will receive a JOGO Digital Therapeutics EMG Biofeedback device and a software installed on a tablet or smart phone. During the 6 weekly sessions participants will be instructed on how to use the device by a trained biofeedback instructor.
88834138|NCT04607460|No Intervention|Treatment as usual (Migraine)|Participants in this group will receive no active treatment.
88834139|NCT04606069|Experimental|Active Arm|Regadenoson will be given intravenously as 5 ug/kg loading dose (up to 400 mg/patient) over 30 mins (to avoid unpleasant side effects sometimes associated with the rapid bolus injection of Regadenoson), followed by a continuous slow infusion (1.44micrograms/kg/hour) with the use of a pediatric infusion pump for 6 hours.
88834140|NCT04606069|Placebo Comparator|Control Arm|The same volume of saline will be given intravenously for 30 mins followed by a continuous infusion for 6 hours.
89362598|NCT02651831||2C: To determine responsiveness and MCID|"Responsiveness testing: Patients will complete FACT-ICM within a week of starting treatment, then while on treatment and within 30 days after end of treatment (EOT) with ICMs.~MCID testing: In addition to the FACT-ICM score, patients undergoing serial assessment for responsiveness will also indicate how much better or worse they are using a 5-point rating scale."
89362599|NCT02604940|Experimental|dexmedetomidine|Experimental group will receive 1mcg/kg IV dexmedetomidine over 10 minutes intraoperatively at the beginning of surgical closure
89362600|NCT02604940|Active Comparator|Normal Saline|Control group will receive Normal saline over 15 minutes at the beginning of surgical closure
89362601|NCT02581137|Experimental|Prevention (extended-release metformin hydrochloride)|Patients receive extended-release metformin hydrochloride PO QD for 2 weeks and then BID for 10-12 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
89362602|NCT02530697|Active Comparator|Group 1 - Mucosal Antimoniate and Pentoxifylline|20mgSb+5/kg/day meglumine antimoniate intravenous for 28 days. Pentoxifylline 400mg 3x/daily for 28 days.
89362603|NCT02530697|Experimental|Group 2 - Mucosal Miltefosine and Pentoxifylline|Oral Miltefosine 2,5mg/kg/day up to 50mg 2x/daily. Oral Pentoxifylline 400mg 3x/daily for 28 days.
89362604|NCT02530697|Experimental|Group 3 - Cutaneous Antimoniate and Pentoxifylline|20mgSb+5/kg/day meglumine antimoniate intravenous for 20 days Oral Pentoxifylline 400mg 3x/daily for 20 days.
89362605|NCT02530697|Experimental|Group 4 - Cutaneous Miltefosine and Pentoxifylline|Oral Miltefosine 2,5mg/kg/day up to 50mg 2x/daily Oral Pentoxifylline 400mg 3x/daily for 20 days.
89362606|NCT02523066||Mitral Valve or Aortic Valve Replancement|One-arm group
89362607|NCT02489006|Experimental|Olaparib Prior to Surgery, Chemotherapy/Olaparib Post Surgery|"Olaparib, orally, at 300 mg twice per day, for 6 weeks (+/- 2 weeks) prior to surgery.~Platinum-based chemotherapy chosen by the study doctor and per standard of care after surgery.~Olaparib, orally, at 300 mg twice per day, continuously, after chemotherapy."
89362608|NCT02489006|Experimental|Olaparib Prior to Surgery and Post Surgery|Olaparib, orally, at 300 mg twice per day, for 6 weeks (+/- 2 weeks) prior to surgery and after surgery.
89362609|NCT02482467|Other|Cases|Prenatal diagnosis of ovarian cyst
89362610|NCT02482467|Other|controls|No prenatal diagnosis of cyst
89362611|NCT02467582|Experimental|Aspirin 100 mg|Asprin 100 mg daily for maximum 3 years standard chemo if indicated
88834141|NCT04601506|No Intervention|Care as Usual|Clinics assigned to this arm will continue to care for the patients as usual in regards to opioid prescribing.
89362612|NCT02467582|Active Comparator|Placebo|Placebo daily for maximum 3 years standard chemo if indicated
89362613|NCT02465736|Experimental|A (DP-RT)|"• Arm A consists of the concurrent chemoradiotherapy prior to surgery. The patient will receive 4 weeks of radiation therapy and 4 weekly cycles of chemotherapy. The radiation will generally commence on the 1st day of treatment and will run for 4 weeks. Chemotherapy is given by intravenous infusion on days 1, 8, 15, and 22.~Interventions:~Radiation: (44 Gy/20 fractions)~Drug: Docetaxel~Drug: Cisplatin"
89362614|NCT02465736|Experimental|B (NP-RT)|"• Arm B consists of the concurrent chemoradiotherapy followed by surgery. The patient will receive 4 weeks of radiation therapy and 2 cycles of chemotherapy. The radiation will generally commence on the 1st day of treatment and will run for 4 weeks. Each cycle of chemotherapy lasts 21 days/3 weeks. The drugs include Vinorelbine and Cisplatin.~Interventions:~Radiation: (44 Gy/20 fractions)~Drug: Vinorelbine~Drug: Cisplatin"
89362615|NCT02453594|Experimental|Cohort 1|Participants with RRcHL who failed to achieve a response or progressed after auto-SCT and have relapsed after treatment with or failed to respond to BV post auto-SCT received pembrolizumab, 200 mg, intravenously (IV) every 3 weeks (Q3W) on Day 1 of each 21-day cycle for up to 24 months.
89362616|NCT02453594|Experimental|Cohort 2|Participants with RRcHL who were unable to achieve CR or PR to salvage chemotherapy and did not receive auto-SCT, but have relapsed after treatment with or failed to respond to BV received pembrolizumab, 200 mg, IV Q3W on Day 1 of each 21-day cycle for up to 24 months.
89362617|NCT02453594|Experimental|Cohort 3|Participants with RRcHL who failed to achieve a response to or progressed after auto-SCT and have not received BV post auto-SCT received pembrolizumab, 200 mg, IV Q3W on Day 1 of each 21-day cycle for up to 24 months. These participants may or may not have received BV as part of primary treatment or salvage treatment.
89362618|NCT02449421|Experimental|Fidelity-oriented Learning Community|The Fidelity-oriented Learning Community arm will receive fidelity consultation (adherence and competence) feedback by a CPT expert via online meetings.
89362619|NCT02449421|Experimental|Quality Improvement Learning Community|The Quality Improvement Learning Community arm will include clinicians who set goals related to CPT delivery, execute a plan, study results, refine plan, and continue each cycle until goals are met.
89362620|NCT02423031||Caregivers|caregivers of pediatric patients with cancer and other serious illnesses
89362621|NCT02423031||pediatric patients|pediatric patients with cancer and other serious illnesses
89362622|NCT02418026|No Intervention|Control|women who attended the obstetrics department for a scheduled or unplanned cesarean section and who benefited from general care
89362623|NCT02418026|Experimental|Hypnosis|women who attended the obstetrics department for a scheduled or unplanned cesarean section and who benefited from a hypnosis session during the surgery in addition to general care
89362624|NCT02414178||Experimental F 18 T807|
89362625|NCT02408939||Intervention|Patients resuscitated from in-hospital cardiac arrest and treated with stress-dose hydrocortisone for postresuscitation shock
88834142|NCT04601506|Experimental|Choice Architecture Nudge|Clinics in this arm will receive the choice architecture nudge intervention.
88834143|NCT04601506|Experimental|PMP Integration & Nudge|Clinics in this arm will receive the Prescription Drug Monitoring (PMP) Integration & Nudge intervention.
88834144|NCT04601506|Experimental|Choice Architecture Nudge + PMP Integration & Nudge|Clinics in this arm will receive both the choice architecture nudge and prescription drug monitoring (PMP) integration & nudge interventions.
88834145|NCT04601493|No Intervention|Care as Usual|Clinics assigned to this arm will continue to care for the patients as usual in regards to opioid prescribing.
88834146|NCT04601493|Experimental|Choice Architecture Nudge|Clinics in this arm will receive the choice architecture nudge intervention.
88834147|NCT04601493|Experimental|PMP Integration & Nudge|Clinics in this arm will receive the Prescription Drug Monitoring (PMP) Integration & Nudge intervention.
88834148|NCT04601493|Experimental|Choice Architecture Nudge + PMP Integration & Nudge|Clinics in this arm will receive both the choice architecture nudge and prescription drug monitoring (PMP) integration & nudge interventions.
88834149|NCT04600206||Patients|Adult patients across all phases of advanced disease (UICC stage IV solid tumor or stage III lung or ovarian tumor) from diagnosis to terminal stages
88834150|NCT04600206||Caregivers|Adult informal caregivers of patients who are diagnosed with stage IV solid tumors or stage III lung or ovarian tumors
89362626|NCT02408939||Control|Patients resuscitated from in-hospital cardiac arrest and treated according to contemporary standards that did not include stress-dose steroids for postresuscitation shock
89534568|NCT03335111|Sham Comparator|ACI without BAIPC|ACI patients in this group only recieve routine treatment for ischemic stroke and are admistrated by 5 cycles extremities ischemia (5-minute blood-pressure cuff inflation using pressure 0 mmHg , followed by 5-minute cuff deflation). All subjects will take BAIPC for 1 week using 'Remote Ischemic Conditioning Equipment' .Intravenous blood collection with anticoagulant and 5ml total blood will be administered at 0d, 1d and 7-10d respectively. The blood samples will be stored for laboratory assay. The blood samples only use in this trial.
89534569|NCT05038605|Active Comparator|Topical metronidazole|Topical application of metronidazole cream on the anal verge after surgery
88834151|NCT04596644|Experimental|Dose A, followed by Dose B|On the first full inpatient day (Day 1), participants will smoke one specified strength (Dose A) of cannabis. Days 2-8 will comprise Phase 1, in which a second strength (Dose B) of cannabis will be administered 3x/day. The next 7 days (Day 9-15) will be Phase 2, in which cannabis Dose A will be administered once again, at the same 3 daily time points.
88834152|NCT04595981|Experimental|Chemo-embolization|Intra-arterial Cisplatin suspension 150-300 mg is infused into the tumor pedicle(s)
88818103|NCT01807637|Experimental|transcranial direct current stim|tDCS will be applied using a Soterix constant current stimulator with 5 x 5 cm (25cm2) carbon rubber electrodes (Covidien 664 REFX 2x2) applied to the scalp with 10-20 conductive paste. The anodal electrode will be placed over the lower extremity representation of primary motor cortex of the lesioned hemisphere [established during TMS motor threshold testing (Baseline Testing) and the functional MRI assessment]. The cathodal electrode will be placed over the contralateral motor cortex.
88834153|NCT04583644|Experimental|Device - FETO|Fetoscopic Endoluminal Tracheal Occlusion (FETO) surgery and removal of balloon using the BALT GOLDBAL2 balloon and BALTACCIBDPE100 catheter.
89362627|NCT02385110|Experimental|Group 1: Alemtuzumab + Etoposide + Dexamethasone|"Induction Phase: Participants receive Alemtuzumab daily on Days 1 - 4 with weekly Etoposide, and Dexamethasone by vein on Days 1-7 during the 8-weeks. Participants with central nervous system involvement receive intrathecal methotrexate 12 mg once a week for 5 weeks.~Dexamethasone by vein on Days 1-7 of the induction phase.~Maintenance Phase: Starts Post Induction Phase for16 weeks. Participants receive Alemtuzumab once every 4 weeks and Dexamethasone three times per week. Participants who have evidence of budding relapse may revert back to receiving Etoposide.~If participant responds to study drugs, they will receive a phone call by study staff every 3 - 6 months for up to 5 years after completion of treatment. Each call will last about 5-10 minutes."
89362628|NCT02385110|Experimental|Group 2: Etoposide + Dexamethasone + Tocilizumab|"Induction Phase: Participants receive Tocilizumab by vein over 60 minutes on Day 1 or Day 2. Participants receive Alemtuzumab daily on Days 1 - 4 with weekly Etoposide and Dexamethasone by vein on Days 1-7 during the 8-weeks. Participants with central nervous system involvement receive intrathecal methotrexate 12 mg once a week for 5 weeks.~Maintenance Phase: Starts Post Induction Phase and will last 16 weeks. Tocilizumab not given in the Maintenance Phase. Dexamethasone three times per week.~If participant responds to study drugs, they will receive a phone call by study staff every 3 - 6 months for up to 5 years after completion of treatment. Each call will last about 5-10 minutes"
89362629|NCT02363296|Experimental|EEG phase-triggered PAS|TMS triggered to a specific phase of the EEG mu rhythm
89362630|NCT02157493|Experimental|Arrowhead Business Group Curriculum|The Arrowhead Business Group (ABG) Curriculum is a 22-session youth entrepreneurship/life-skills intervention delivered by trained American Indian paraprofessionals from the community to mixed-gender groups of approximately 25 youth. The intervention is delivered over a 3 night/4 day camp along with weekend workshops once a month for 6 months during the academic year. Depending on the time of enrollment, subjects will receive follow-up assessments at 6-month intervals for up to 36-months post-intervention. (Subjects in this cohort will also receive the activities associated with the control condition.)
89362631|NCT02157493|Active Comparator|Recreational League Control Condition|The Recreational League Control Condition will be led by local American Indian study staff who are experienced with Johns Hopkins camps and community-based Apache sports programs. Sports and recreational activities will be conducted on 3 Saturdays during the academic year to mixed gender groups of approximately 50 participants.
89362632|NCT02143830|Experimental|Arm A: Good Risk Patients|Patients 18 years old or younger with marrow aplasia or single lineage cytopenias will be receive intravenous busulfan (4 doses x 2 days), cyclophosphamide (4 doses x 4 days) and fludarabine (4 doses x 4 days), as used in our most current study that led to > 90% survival rates . Busulfan pharmacokinetics will not be used. All patients will receive rabbit ATG (4 doses x 4 days) prior to and granulocyte-colony stimulating factor (G-CSF) after transplant to promote engraftment. Cyclosporine will not be used for GVHD prophylaxis. The source of the stem cells for all patients will be peripheral blood stem cells mobilized by treatment of the donor with G-CSF. T-cell depletion will be performed by positive CD34 selection with the use of the Miltenyi system (CliniMACS device). Enrollment on this arm will include up to 50 patients.
89362633|NCT02143830|Experimental|Arm B: Intermediate Risk Patients|"Patients 18 years old or younger with MDS or AML will receive intravenous busulfan (4 doses x 2 days), cyclophosphamide (4 doses x 4 days) and fludarabine (4 doses x 4 days). Busulfan pharmacokinetics will be used in this arm, as the dose of busulfan is higher. All patients will receive rabbit ATG (thymoglobulin) (4 doses x 4 days) prior to and G-CSF post transplant to promote engraftment. Cyclosporine will not be used for prophylaxis against GVHD. The source of the stem cells for all patients will be peripheral blood stem cells induced and mobilized by treatment of the donor. T-cell will be performed by positive CD34 selection with the use of the Miltenyi system (CliniMACS device).~The maximum number of patients enrolled in this arm will be 10."
89362634|NCT02143830|Experimental|Arm C: High Risk Patients|Patients 19 years old or older with marrow aplasia or MDS or AML will receive intravenous busulfan (4 doses x 2 days), cyclophosphamide (4 doses x 4 days) and fludarabine (4 doses x 4 days). In this study, we will test whether outcomes can be improved, yet engraftment maintained, with a slightly reduced dose of busulfan. Patients will receive rabbit ATG (4 doses x 4 days) prior to and G-CSF post transplant to promote engraftment. Cyclosporine will not be used for GVHD prophylaxis. The source of the stem cells will be peripheral blood stem cells collected from donors treated with G-CSF. T-cell depletion will be performed by positive CD34 selection with the use of the Miltenyi system (CliniMACS device). The maximum number of patients enrolled will be 10.
88834154|NCT04583215|Active Comparator|Active PAS|After completing the N-back and PAS-EEG at Visit 4, MCI participants randomized to the active condition will receive a 10-session course of PAS (Visits 5-14), followed by the three follow-up assessments at 0 days, 7 days, and 28 days post intervention.
88834155|NCT04583215|Sham Comparator|PAS-Control (PAS-C)|After completing the N-back and PAS-EEG at Visit 4, MCI participants randomized to the sham condition will receive a 10-session course of PAS-C (Visits 5-14), followed by the three follow-up assessments at 0 days, 7 days, and 28 days post intervention.
88818104|NCT01807637|Placebo Comparator|sham tDCS|Sham stimulation will be performed by turning the stimulator off after the initial sensory experience (30 seconds).
88818105|NCT01263314|Experimental|Panel A MK-8266 0.3 mg (Elderly Males with Mild/Mod. HTN)|MK-8266 single dose 0.3 mg
88818106|NCT01263314|Experimental|Panel A MK-8266 0.6 mg (Elderly Males with Mild/Mod. HTN)|MK-8266 single dose 0.6 mg
88818107|NCT01263314|Experimental|Panel A MK-8266 0.7/0.3 mg (Elderly Males with Mild/Mod. HTN)|MK-8266 single dose 0.7 mg and then 0.3 mg after 10 hours
88818108|NCT01263314|Placebo Comparator|Panel A Placebo to MK-8266 (Elderly Males with Mild/Mod. HTN)|Placebo to MK-8266 single dose
88818109|NCT01263314|Experimental|Panel B MK-8266 0.3 mg (Elderly Females with Mild/Mod. HTN)|MK-8266 single dose 0.3 mg
88834156|NCT04583215|No Intervention|Healthy Control|Healthy Controls will complete screening and baseline N-Back and PAS-EEG. They will not complete the 10-session course of PAS or follow-up assessments.
89362635|NCT02138110|Experimental|Neuro-Spinal Scaffold|Implantation of a Neuro-Spinal Scaffold into the epicenter of the post-irrigation contusion cavity during open spine surgery
89362636|NCT02108028||Cohort 1A / Initial Young Adults with Children|Young adults who have a child(ren) and are 18-39 years diagnosed with cancer or other chronic illness and enrolled on an NIH protocol or treated at a participating site. COMPLETE
89362637|NCT02108028||Cohort 1B / Comparison Young Adults with Children|Young adults who have children and are 18- 39 years diagnosed with cancer or other chronic illness and enrolled on an NIH protocol or treated at a participating site.
89362638|NCT02108028||Cohort 2A / Initial Independent Young Adults|Young adults who live independently and are 18-39 years diagnosed with cancer or other chronic illness and enrolled on an NIH protocol or treated at a participating site. COMPLETE
89362639|NCT02108028||Cohort 2B / Comparison Independent Young Adults|Young adults who live independently and are 18-39 years diagnosed with cancer or other chronic illness and enrolled on an NIH protocol or treated at a participating site.
89362640|NCT02108028||Cohort 3A / Initial Young Adults No Children, Not Independent|Young adults with no children, not living independently who are 18-39 diagnosed with cancer or other chronic illness and enrolled on an NIH protocol or treated at a participating site. COMPLETE
88834157|NCT04577482||Participants treated with Glecaprevir/Pibrentasvir|Participants will receive glecaprevir/pibrentasvir (GLE/PIB) as prescribed by physician in accordance with local clinical practice.
88834158|NCT04575805|Experimental|Internet-delivered Combined Cognitive Bias Modification|CBM Version 1 is the combination of internet-delivered Cognitive Bias Modification-Interpretation and internet-delivered Cognitive Bias Modification-Attention interventions taking place over 4 weeks (eight sessions, twice per week).
89362641|NCT02108028||Cohort 3B / Comparison Young Adults No Children, Not Independent|Young adults with no children, not living independently who are 18-39 diagnosed with cancer or other chronic illness and enrolled on an NIH protocol or treated at a participating site.
89362642|NCT02108028||Cohort 4 / Non-patient participants|Family members, friends, or health care providers of patient participant. COMPLETE
89362643|NCT02099617|Experimental|Drug Eluting Stent|Synergy II
89362644|NCT02099617|Active Comparator|Bare Metal Stent|Omega or Rebel
89362645|NCT02089217|Active Comparator|Carotid Endarterectomy (CEA)|Carotid Endarterectomy
88834159|NCT04575805|Experimental|Internet-delivered Cognitive Bias Modification-Interpretation|CBM Version 2 is an internet-delivered Cognitive Bias Modification-Interpretation intervention taking place over 4 weeks (eight sessions, twice per week).
89362646|NCT02089217|Active Comparator|Carotid Stenting (CAS)|Carotid Stenting
89362647|NCT02089217|Experimental|Intensive Medical Management - no CEA|Intensive Medical Management alone - no CEA
89362648|NCT02089217|Experimental|Intensive Medical Management - no CAS|Intensive Medical Management alone - no CAS
88834160|NCT04575805|Experimental|Internet-delivered Cognitive Bias Modification-Attention|CBM Version 3 is an internet-delivered Cognitive Bias Modification-Attention intervention taking place over 4 weeks (eight sessions, twice per week).
88834161|NCT04575805|No Intervention|Wait-List Control|This arm is wait-list control group which will also receive internet-delivered Combined Cognitive Bias Modification intervention after the follow-up assessment
88834162|NCT04575311|Active Comparator|Active: Dose Escalation|Participants will receive a single oral dose of AB680 at one of two ascending dose levels. Assignment to receive AB680 will be random.
88834163|NCT04575311|Placebo Comparator|Placebo: Dose Escalation|Participants will receive matching placebo as a single oral dose. Assignment to receive matching placebo will be random.
88834164|NCT04566562||Study Group|Brain scans, cognitive tests, blood biomarkers
89001184|NCT00576160|No Intervention|A|"Participants will complete Baseline and 30-day assessment visit. At both visits BDI II, Self-Efficacy Questions, AEs Assessment, and Treatment Satisfaction will be assessed. A MEMS cap will be used during the 30-day period to asses medication adherence to their prescribed aspirin.~Usual Care: Participants assigned to UCC will only receive the pre- and post-assessment session, and any adherence education or encouragement that is regularly provided by their treating physicians."
89362649|NCT02088775|Experimental|Diagnostic: PET scan - CT scan|Patients undergo PET-CT scan before and after standard radioembolization on day 0. A subset of patients undergo PET-CT scan on day 1, 24 hours after the day 0 post-treatment PET-CT.
89362650|NCT02015078||African Americans|Targets are family members attending African American family reunions.
89362651|NCT01973179||Radiation therapy|Radiotherapy with protons in patients with head and neck carcinoma
89362652|NCT01954316|Experimental|CFI-400945 fumarate Schedule A|CFI-400945 fumarate tablets daily dosing expansion at 64mg
89362653|NCT01954316|Experimental|CFI-400945 fumarate Schedule B|CFI-400945 fumarate tablets intermittent dosing schedule, 2 days on/5 days off. Escalation at following levels: 96mg, 128mg
89362654|NCT01954316|Experimental|CFI-400945 fumarate Schedule C|CFI-400945 fumarate tablets intermittent dosing schedule, 1 day on/6 days off. Escalation will start at MTD of Schedule B
89362655|NCT01949129|Experimental|Flu/Thio/Treo|"Fludarabine/Thiotepa/Treosulfan is used as conditioning regimen for haematopoietic stem cell transplantation (HSCT) in patients with:~MSD (matched sibling donors) or MD (matched related or unrelated donors). In addition, patients undergoing MD HSCT will receive ATG Thymo- or Grafalon.~MMD (mismatched donors) with CB (Cord blood) or TCD (T-Cell depletion) or CD34+ selection. In addition, these patients will receive ATG Thymo- or Grafalon.~MMD (mismatched donors) patients receiving Post TX-Cyclophosphamide"
89362656|NCT01949129|Active Comparator|TBI/VP16|"TBI (Total Body Irradiation) / VP16 is used as conditioning regimen for haematopoietic stem cell transplantation (HSCT) in patients older than 48 months with:~MSD (matched sibling donors) or MD (matched related or unrelated donors). In addition, patients undergoing MD HSCT will receive ATG Thymo- or Grafalon.~MMD (mismatched donors) with CB (Cord blood) or TCD (T-Cell depletion) or CD34+ selection. In addition, these patients will receive ATG Thymo- or Grafalon.~MMD (mismatched donors) patients receiving Post TX-Cyclophosphamide.~Patients aged 24-48 months may optionally receive Total Body Irradiation (TBI)."
89534570|NCT05038605|Active Comparator|Oral metronidazole|oral metronidazole 500 mg tablets after surgery
89534571|NCT05038605|No Intervention|Control|No metronidazole was received
88834165|NCT04565730|Active Comparator|Grup I= General anesthesia group|After applying standard ASA monitoring; 2-2,5 mg/kg propofol, and 0,6 mg/kg rocuronium IV will be performed for general anesthesia induction, and then orotracheal intubation will be performed. The patients will be placed in the supine position. General anesthesia will be maintained with sevoflurane in the mixture of oxygen-fresh air. Controlled mechanical ventilation will be initiated with a tidal volume of 8-10 ml/kg at 12 breaths per minute (I:E ratio 1:2), a fresh gas flow rate of 2 L per min, end tidal CO2 value at 30-35 mmHg, and peak airway pressure of maximally 30 cm H2O. All patients will undergo cesarean delivery surgery with the same technique by the same surgical team.
88834166|NCT04565730|Active Comparator|Grup II= Spinal anesthesia group|A standardized spinal anesthesia will administrated to the patients. After skin disinfection, 25G needle will used for puncture at the level of L2-L3 or L3-L4. After observing the cerebrospinal fluid, 15 mg bupivacaine (marcain spinal heavy) will be administered into the subarachnoid space. The level of anesthesia below T6 will be controlled.
88834167|NCT04554316|Active Comparator|Parallel placement|Steri-strips will be placed in-line (parallel) with the surgical incision.
88834168|NCT04554316|Active Comparator|Perpendicular placement|Steri-strips will be placed perpendicular to the surgical incision.
89362657|NCT01949129|Experimental|Flu/Thio/ivBu|"Fludarabine/Thiotepa/iV Busulfan is used as conditioning regimen for haematopoietic stem cell transplantation (HSCT) in patients with:~MSD (matched sibling donors) or MD (matched related or unrelated donors). In addition, patients undergoing MD HSCT will receive ATG Thymo- or Grafalon.~MMD (mismatched donors) with CB (Cord blood) or TCD (T-Cell depletion) or CD34+ selection. In addition, these patients will receive ATG Thymo- or Grafalon.~MMD (mismatched donors) patients receiving Post TX-Cyclophosphamide"
89362658|NCT01949129|Experimental|Bu/VP16/Cy|Busulfan/VP16/Cyclophosphamide is an alternative conditioning arm that may optionally be used for HSCT with MSD/MD and MMD graft in patients aged 0-24 months. Patients undergoing MD HSCT will also receive ATG Thymo- or Grafalon.
89362659|NCT01918683|Other|A -Tace alone|A - TACE alone (control group, current practice and treatment)
89362660|NCT01918683|Experimental|B - Tace combined with SBRT|B- TACE combined with SBRT (experimental group).
88834169|NCT04554121|Experimental|Brain Basics|Brain Basics is a cognitive remediation intervention that emphasizes training in early auditory processing.
88834170|NCT04554121|Active Comparator|Brain Training|Brain Training is a cognitive remediation intervention that targets a range of cognitive abilities
89362661|NCT01917929|Other|Secur-Fit Advanced|Secur-Fit Advanced Hip Stem
89362662|NCT01913938||patients with cytopenias|Patients with sepsis and concomitant cytopenias (leukopenia with thrombocytopenia and anemia) who are routinely treated with rhG-CSF will be followed for reconstitution of peripheral blood cell counts. In cooperation with the Department of Hematology, patients are examined for bone marrow cellularity and hemophagocytosis if G-CSF treatment does not result in leukocyte increase.
89362663|NCT01898793|Experimental|Phase I Dose Level 1: 0.5 x 10^6/kg CIML NK cells|"Lymphodepleting Preparative Regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.~Donor Leukapheresis: Peripheral blood cells are collected from haploidentical related donors over 5 hours on day -1.~CIML NK Cells: Patients undergo CIML NK cell infusion over 15-60 minutes on day 0.~Interleukin-2: Patients receive aldesleukin SC every other day for 2 weeks starting on day 1 (total of 7 doses)"
89362664|NCT01898793|Experimental|Phase I Dose Level 2: 1.0 x 10^6/kg CIML NK cells|"Lymphodepleting Preparative Regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.~Donor Leukapheresis: Peripheral blood cells are collected from haploidentical related donors over 5 hours on day -1.~CIML NK Cells: Patients undergo CIML NK cell infusion over 15-60 minutes on day 0.~Interleukin-2: Patients receive aldesleukin SC every other day for 2 weeks starting on day 1 (total of 7 doses)"
89362665|NCT01898793|Experimental|Phase I Dose Level 3: Maximum NK cell/number kg|"Lymphodepleting Preparative Regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.~Donor Leukapheresis: Peripheral blood cells are collected from haploidentical related donors over 5 hours on day -1.~CIML NK Cells: Patients undergo CIML NK cell infusion over 15-60 minutes on day 0.~Interleukin-2: Patients receive aldesleukin SC every other day for 2 weeks starting on day 1 (total of 7 doses)"
88834171|NCT04554004|Experimental|Study group|All consecutive patients undergoing outine CT angiography and dynamic CT-myocardial perfusion imaging(MPI) will be potentially eligible for inclusion in the trial. Assessment of coronary stenosis severity using invasive fractional flow reserve (FFR) and the status of myocardial microcirculation perfusion including coronary flow reserve (CFR) and index of microvascular resistance (IMR) will be performed as part of invasive coronary angiography(CAG).
88834172|NCT04544280|Experimental|Intervention|
88834173|NCT04533386|Experimental|BSMM|Intervention arm will include motivational interview-consistent discussion with a peer change agent and use of a mobile application to record and review sexual risk behaviors with participants.
88834174|NCT04532151|Other|Early SSc group|"Patients with SSc according to the criteria ACR / EULAR 2013, without scleroderma Normal routine clinical examinations and routine biology tests will be performed. For non-invasive imaging specific to the study, various parameters will be measured on the finger and forearm by LC-OCT, LC-OCT-Doppler, HD ultrasound as well as fluid silicone molding in a dimly lit room. The mRSS will be evaluated by an experienced clinician, blinded from imaging measurements.~Patients will be reassessed at M24. The participation of each subject will be 24 months, with two visits of one hour.~The clinical data corresponding to the current practice will be collected in a study specific case report form."
88834175|NCT04532151|Other|Established SSc group|"Patients with SSc according to criteria ACR / EULAR 2013 with scleroderma Normal routine clinical examinations and routine biology tests will be performed. For non-invasive imaging specific to the study, various parameters will be measured on the finger and forearm by LC-OCT, LC-OCT-Doppler, HD ultrasound as well as fluid silicone molding in a dimly lit room. The mRSS will be evaluated by an experienced clinician, blinded from imaging measurements. The participation of each subject will be one hour.~The clinical data corresponding to the current practice will be collected in a study specific case report form."
89362666|NCT01898793|Experimental|Phase II (IL-2): Maximum NK cell/number kg|The recipient will begin a lymphodepleting preparative regimen of fludarabine and cyclophosphamide on Day -6. The haploidentical donor identified by HLA matching of the immediate family members will undergo non-mobilized large volume (20-L) leukapheresis on Day -1, and the NK cell product will be infused into the recipient on Day 0. Subcutaneous IL-2 will begin approximately 2-4 hours after infusion and will continue every other day through Day 12 for a total of 7 doses.
89362667|NCT01898793|Experimental|Lead-in Cohort & Phase II (ALT-803): Maximum NK cell/number kg|"Lymphodepleting Preparative Regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.~Donor Leukapheresis: Peripheral blood cells are collected from haploidentical related donors on Day -1.~CIML NK Cells: Patients undergo CIML NK cell infusion on Day 0.~Subcutaneous ALT-803 will begin approximately 4 hours after the infusion and will continue for a total of 2 doses (Days 0 and 5)."
89362668|NCT01898793|Experimental|Pediatric Cohort: Maximum NK cell/number kg|"Lymphodepleting Preparative Regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.~Donor Leukapheresis: Peripheral blood cells are collected from haploidentical related donors on Day -1~CIML NK Cells: Patients undergo CIML NK cell infusion on Day 0~Subcutaneous IL-2 will begin approximately 2-4 hours after infusion and will continue every other day through Day 12 for a total of 7 doses"
89362669|NCT01898793|No Intervention|Donors|-The haploidentical donor identified by HLA matching of the immediate family members (parents, siblings, and children) will undergo non-mobilized leukapheresis on Day -1. Peripheral blood mononuclear cells (PBMCs) will be collected using standard collection techniques.
89362670|NCT01898637|Active Comparator|Proven pulmonary embolism.|Augmented pulse oximetry using incentive spirometer. Emergency Department patients with pulmonary embolism.
89362671|NCT01898637|Other|Control patients|Augmented pulse oximetry using incentive spirometer. Emergency Department patients who do not have pulmonary embolism.
89362672|NCT01858285||BCH Children's Rare Disease Cohort (CRDC)|Individuals with epilepsy, onset at any age. Must be followed clinically at Boston Children's Hospital. Research trio-based exome and/or whole genome with CLIA confirmation of diagnostic findings. Exclusions include presence of existing genetic diagnosis or known cause for epilepsy, presence of structural brain malformation.
89362673|NCT01858285||Gene-STEPS (Shortening Time of Evaluation in Paediatric Epilepsy Services)|"Collaborative effort of consortium including BCH, Great Ormond Street Hospital, Royal Children's Hospital Melbourne and Murdoch Children's Research Institute, and The Hospital for Sick Children.~For BCH cohort, eligibility limited to individuals presenting clinically at BCH with seizure onset at less than 12 months of age. Must be enrolled within six weeks of first seizure-related presentation to BCH. Clinical trio-based rapid whole genome sequencing in a CLIA laboratory.~Exclusions include:~Simple febrile seizures, provoked seizures, genetic or acquired cause already identified, MRI findings consistent with specific genetic etiology."
89362674|NCT01858285||Epilepsy Core|Individuals with epilepsy, onset at any age. Research trio-based exome and/or whole genome. Exclusions include presence of existing genetic diagnosis or known cause for epilepsy, presence of structural brain malformation.
89362675|NCT01858285||Phenotyping Cohort|Individuals with diagnosed genetic epilepsies, including but not limited to PRRT2, SCN1A, SCN2A, SCN8A, PCDH19, SYNGAP1, DEPDC5, KCNQ2, CACNA1A.
88834176|NCT04532151|Other|Control group:|"Patient without systemic sclerosis Normal routine clinical examinations and routine biology tests will be performed. For non-invasive imaging specific to the study, various parameters will be measured on the finger and forearm by LC-OCT, LC-OCT-Doppler, HD ultrasound as well as fluid silicone molding in a dimly lit room. The participation of each subject will be one hour.~The clinical data corresponding to the current practice will be collected in a study specific case report form."
88834177|NCT04523480|Experimental|Testopel 75mg Group|Participants in this group will receive a one-time subcutaneous testosterone insertion of 10 x 75 mg pellets of Testopel for a total of 750 mg Testopel.
89362676|NCT01858012||HCV infection|patients with hepatitis C infection
89362677|NCT01858012||non-HCV infection|healthy controls
89362678|NCT01857934|Experimental|Treatment|"Participants receive IV hu14.18K322A with each course of chemotherapy (cyclophosphamide, topotecan, cyclophosphamide, doxorubicin, vincristine, cisplatin, and etoposide). Mesna will be given prior to and after cyclophosphamide infusion. Peripheral blood stem cell harvest (PBSC) and surgical resection of primary tumor will be performed, if feasible. Intensification therapy includes busulfan, melphalan, and levetiracetam with peripheral blood stem cell transplantation. A course of hu14.18K322A with natural killer cell infusion will be given to consenting participants. Radiation therapy will follow PBSC transplant with the exception of any patient requiring emergent radiotherapy. MRD treatment includes hu14.18K322A, G-CSF, GM-CSF, interleukin-2 and isotretinoin.~Cells for infusion are prepared using the CliniMACS System."
89362679|NCT01849575|Active Comparator|Intervention|The intervention: Giving communication about risk of cardiovascular disease in the form of written and graphical information about silent atheroscslerosis measured by carotid ultrasound examination as carotid intima-media thickness, highlighted as vascular age, and plaque formation, visualized as a traffic light (green - no plaque, red - plaque).The ultrasound results are given to the study person and his/her physician, in addition to information about conventional risk factors for cardiovascular disease
89362680|NCT01849575|No Intervention|Control|The comaparator is that the study person and his/her physician do not get any information about carotid ultrasound results on silent atherosclerosis. They are only informed about results of measured conventional CVD risk factors
88834178|NCT04523480|Active Comparator|Compounded testosterone pellets 100mg Group|Participants in this group will receive a one-time subcutaneous testosterone insertion of 8 x 100 mg compounded testosterone for a total of 800 mg compounded testosterone.
89362681|NCT01842282|Experimental|Amlexanox|
88834179|NCT04523480|Active Comparator|Compounded Testosterone pellets 200mg Group|Participants in this group will receive a one-time subcutaneous testosterone insertion of 4 x 200 mg compounded testosterone for a total of 800 mg compounded testosterone.
89362682|NCT01759550||LigaSure Device|In this prospective observational study, 60 patients scheduled to undergo a Roux-en-Y or gastric reduction procedure (sleeve gastrectomy or plication) will have hemostasis controlled with LigaSure Advance ™ Pistol Grip or LigaSure™ Blunt Tip, respectively. Both devices are regularly used at Duke in the Bariatric Surgery division. The surgeon will select which device is used. There will be no randomization. The device decision tree will be based upon the procedure. Cases that require enterotomy will utilize the AdvanceTM pistol grip. Cases which don't need enterotomy will utilize the 5 Blunt Tip. The LigaSure AdvanceTM pistol grip and LigaSureTM Blunt Tip are used exclusively with the Force TriadTM Energy platform. There is no simultaneous use.
89362683|NCT01757665|Experimental|Bioprosthesis: Aortic Model 11000A/ Mitral Model 11000M|Aortic/Mitral valve replacement therapy
89362684|NCT01748149|Experimental|Vemurafenib|"Vemurafenib should be swallowed whole with 8 oz (1 cup) of water. Pharmacokinetic studies will determine if vemurafenib can be crushed. If patients receiving crushed tablets are felt to receive adequate exposure, then they will be allowed to participate in the expansion cohort. [Patients approved to take crushed tablets should use a pill crusher and mix pill with 3-5 ml apple sauce]. If not, then only patients able to swallow whole pills will be eligible.~The patient will be requested to maintain a medication diary of each dose of medication. The medication diary will be returned to clinic staff at the end of each cycle."
89362685|NCT01727284|Other|MR-guided cryoablation (freezing of tissue and/or tumors)|
89362686|NCT01689584|Other|Covar|
89362687|NCT01653535|Experimental|Fast Track Eligible|"Participants in the Experimental group received the Fast Track intervention. Intervention included school-based curriculum attended by high-risk children, parents, program staff, and occasionally teachers, home visiting, the the in-class PATHS prevention program."
89362688|NCT01653535|No Intervention|Control Group|Participants in the Control group were not eligible to receive the Fast Track intervention. These children received other services as usual, and served as the randomized comparison group for examining Fast Track program impacts
89362689|NCT01589081|Active Comparator|Female Smokers (Luteal Phase)|
89362690|NCT01589081|Active Comparator|Female Smokers (Follicular Phase)|
89362691|NCT01589068|Active Comparator|Male Smokers|
89362692|NCT01589068|Active Comparator|Female Smokers (Follicular Phase)|
89362693|NCT01589068|Active Comparator|Female Smokers (Luteal Phase)|
89362694|NCT01589055|Active Comparator|Male Smokers|
89362695|NCT01589055|Active Comparator|Female Smokers (Mid-Luteal Phase; cycle days 18-22)|
89362696|NCT01589055|Active Comparator|Female Smokers (Early Follicular Phase; cycle days 4-8)|
89362697|NCT01572337|Experimental|NIV|Non-invasive ventilation
89362698|NCT01572337|Other|Best available treatment|
89362699|NCT01515527|Experimental|Cladribine + Cytarabine Alt. with Decitabine|"Induction cycle: Cladribine intravenous (IV) over approximately 1 to 2 hours, daily on days 1-5 combined with Cytarabine subcutaneous (SQ) twice daily on days 1-10. Cytarabine should be administered approximately 3-6 hours following the start of the cladribine infusion.~Consolidation cycle: Cladribine IV over 1 to 2 hours, daily on days 1-3 combined with Cytarabine SQ twice daily on days 1-10. Cytarabine should be administered 3-6 hours following the start of the cladribine infusion.~Alternating with: Decitabine IV over 1 to 2 hours, daily on days 1-5."
89362700|NCT01501513|Experimental|BLI800 approved preparation regimen|BLI800 approved preparation regimen
89362701|NCT01501513|Experimental|BLI800 investigational preparation regimen|BLI800 investigational preparation regimen
89362702|NCT01501513|Active Comparator|PEG-3350 based bowel preparation|PEG-3350 based bowel preparation
89362703|NCT01481532|Experimental|Cohort 3|The third cohort will include up to 24 patients with Crotoxin doses of 0.2 to 1.32 mg per m2 in which the dose escalation speed will be faster. Drug is administered over 3 + 4 day intervals using ambulatory infusion pumps; treating on an outpatient basis. Subjects will receive increasing doses over the course of 28 treatment days (8 dose levels). Dose escalation will continue if DLT is not established
89362704|NCT01459497|Active Comparator|Radiation Therapy|Arm A:Image-Guided Radiation Therapy (IGRT), 60 Gy in 15 fractions in 3 weeks
89362705|NCT01459497|Active Comparator|Conventional Radiation|Arm B: Conventional radiation 60-66 Gy in 30-33 fractions in 6-7 weeks
89362706|NCT01410942|Placebo Comparator|Placebo + Sham Exercise|Placebo capsules by mouth twice daily. Participants in sham exercise intervention meet with exercise physiologist in person on first visit to learn stretching exercises and receive written instructions same as those receiving exercise therapy.
89362707|NCT01410942|Experimental|Methylphenidate + Sham Exercise|Methylphenidate starting dose 5 mg by mouth twice daily. Participants in sham exercise intervention meet with exercise physiologist in person on first visit to learn stretching exercises and receive written instructions same as those receiving exercise therapy.
89362708|NCT01410942|Placebo Comparator|Exercise + Placebo|Resistance exercise sessions completed 3 days a week allowing at least 48 hours between each session, and walk minimum of 5 days a week at intensity and duration established by exercise physiologist. Placebo capsules by mouth twice daily.
89362709|NCT01410942|Placebo Comparator|Cognitive Therapy + Placebo|Cognitive Therapy - 8 weekly sessions (1 in person and 7 by telephone) lasting 45 minutes each, during which review learned relaxation skills and taught new cognitive and/or behavioral skill. Placebo capsules by mouth twice daily.
89362710|NCT01410942|Experimental|Methylphenidate + Exercise|Methylphenidate starting dose 5 mg by mouth twice daily. Resistance exercise sessions completed 3 days a week allowing at least 48 hours between each session, and walk minimum of 5 days a week at intensity and duration established by exercise physiologist.
89362711|NCT01410942|Experimental|Methylphenidate + Cognitive Therapy|Methylphenidate starting dose 5 mg by mouth twice daily. Cognitive Therapy - 8 weekly sessions (1 in person and 7 by telephone) lasting 45 minutes each, during which review learned relaxation skills and taught new cognitive and/or behavioral skill.
89362712|NCT01410942|Placebo Comparator|Exercise + Cognitive Therapy + Placebo|Resistance exercise sessions completed 3 days a week allowing at least 48 hours between each session, and walk minimum of 5 days a week at intensity and duration established by exercise physiologist. Cognitive Therapy - 8 weekly sessions (1 in person and 7 by telephone) lasting 45 minutes each, during which review learned relaxation skills and taught new cognitive and/or behavioral skill. Placebo capsules by mouth twice daily
88818110|NCT01263314|Experimental|Panel B MK-8266 0.6 mg (Elderly Females with Mild/Mod. HTN)|MK-8266 single dose 0.6 mg
89362713|NCT01410942|Experimental|Methylphenidate + Exercise + Cognitive Therapy|Methylphenidate starting dose 5 mg by mouth twice daily. Resistance exercise sessions completed 3 days a week allowing at least 48 hours between each session, and walk minimum of 5 days a week at intensity and duration established by exercise physiologist. Cognitive Therapy - 8 weekly sessions (1 in person and 7 by telephone) lasting 45 minutes each, during which review learned relaxation skills and taught new cognitive and/or behavioral skill.
89362714|NCT01269593|Experimental|PET Imaging Using 124 IPUH71|Patients will receive an injection of up to 11.0 mCi (range: 4.0-11.0 mCi) of 124I-PUH71, followed by serial PET scanning and blood draws, over a period of 3 days. Optional with a fourth day of PET scanning is to be pursued, in willing patients.
89178269|NCT02602236|Experimental|AOS-C2000-B|A new 2-piece appliance composed with 2 parts : a base plate and an ostomy collection special pouch (1 base plate for 2 or 3 days and 1 to 4 collection special pouch per day)
89178270|NCT04102176|Active Comparator|Continue nucleos(t)ide analogue|patients will be given open label tenofovir alafenamide
89362715|NCT01238250||Copy Number Variants|Individuals with documented pathogenic or likely pathogenic copy number variants related to neurodevelopmental disorders.
88834180|NCT04521569|Experimental|EVLP with Regadenoson|Following the routine retrieval procedure of the lungs, they will be placed on the EVLP circuit (XVIVO Perfusion System) and infused with the study drug, Regadenoson.
88834181|NCT04521569|Placebo Comparator|EVLP with Steen solution|Following the routine retrieval procedure of the lungs, they will be placed on the EVLP circuit (XVIVO Perfusion System) and infused with the same volume of Steen solution.
88834182|NCT04519853|Experimental|Low Glycemic Load Diet|Feeding study with dietary composition (approximately) 50% fat, 30% carbohydrate, 20% protein.
89362716|NCT01238250||Gene Variants|Individuals with documented pathogenic or likely pathogenic variants in a gene related to neurodevelopmental disorders.
89362717|NCT01217931|Experimental|Group 1|Pazopanib + possible Bevacizumab
89362718|NCT01217931|Experimental|Group 2|Pazopanib + possible Everolimus
89362719|NCT01217931|Experimental|Group 3|Everolimus + possible Bevacizumab
89362720|NCT01217931|Experimental|Group 4|Everolimus + possible Pazopanib
89362721|NCT01217931|Experimental|Group 5|Bevacizumab + possible Pazopanib
89362722|NCT01217931|Experimental|Group 6|Bevacizumab + possible Everolimus
89362723|NCT01192568|Experimental|Oxybutynin Chloride|
89362724|NCT01063751|Other|Tritanium® Primary Acetabular Shell|Tritanium® Primary Acetabular Shell
89362725|NCT00809588|Experimental|Melanoma Vaccine|GM-CSF Vaccine
89362726|NCT00762580||Prospective|Patients with full thickness rotator cuff tears being treated with physical therapy
89362727|NCT00680901|Experimental|CapeOx plus Lapatinib|CapeOx plus Lapatinib
89362728|NCT00680901|Placebo Comparator|CapeOx plus Placebo|CapeOx plus Placebo
89362729|NCT00580476||1|150 patients will be women with breast cancer (75 early stage and 75 late stage)
89362730|NCT00580476||2|150 will be men with prostate cancer (75 early stage and 75 late stage)
89362731|NCT00557193|Experimental|Arm A (standard risk MLL-G)|Population Description: Eligible patients with MLL-G (germline, or non-rearranged)
89362732|NCT00557193|Active Comparator|Arm B (IR/HR MLL-R chemotherapy)|Population Description: Eligible patients with MLL-R (rearranged). Considered Intermediate Risk (IR) if age >= 90 days at diagnosis and High Risk (HR) if age < 90 days at diagnosis.
89362733|NCT00557193|Experimental|Arm C (IR/HR MLL-R chemotherapy and lestaurtinib)|Population Description: Eligible patients with MLL-R (rearranged). Considered Intermediate Risk (IR) if age >= 90 days at diagnosis and High Risk (HR) if age < 90 days at diagnosis.
89362734|NCT00516724|Experimental|1|Carboplatin + KU-0059436
89362735|NCT00516724|Experimental|2.|Paclitaxel + KU-0059436
89362736|NCT00516724|Experimental|3.|Paclitaxel, Carboplatin + KU-0059436
89362737|NCT00408590|Experimental|Experimental Arm|
89178271|NCT04102176|Experimental|Stopping nucleos(t)ide analogue|patients will stop nucleos(t)ide therapy (such as entecavir, tenofovir, lamivudine or adefovir)
89178272|NCT04101864|Experimental|Electromagnetic navigation|In the study group acetabular components in total hip arthroplasty will be placed with the help of electromagnetic image-less navigation system. Reference plane will be anterior pelvic plane.
89178273|NCT04101864|Active Comparator|Freehand|In the control group acetabular components in total hip arthroplasty will be placed with the help of the freehand technique.
89178274|NCT00783432|Experimental|1|Astepro Nasal Spray (0.1% azelastine hydrochloride)
89178275|NCT00783432|Active Comparator|2|Astelin Nasal Spray (0.1% azelastine hydrochloride)
89178276|NCT00783198|Experimental|SCH 39641 6 Amb a 1-U|Participants receive Ambrosia artemisiifolia allergen extract (SCH 39641 6 Amb a 1-U) rapidly dissolving tablets, administered once daily sublingually for approximately 52 weeks
89362738|NCT00408291||1|Winsta PH osteosynthesis device (Fischer Medical)for treatment of humeral fracture
89362739|NCT00364637|Active Comparator|Total intravenous anesthesia|
89362740|NCT00364637|Experimental|sevoflurane|
89362741|NCT00186888|Other|Stratum A|Patients with early bilateral or unilateral, or patients with bilateral that have already had the advanced eye enucleated. Treatment included vincristine and carboplatin for 8 courses, given at 3-4 week intervals. Focal therapies any time after second course can include cryotherapy, laser photocoagulation, thermotherapy, and plaque radiotherapy
89362742|NCT00186888|Other|Stratum B|"Patients with bilateral disease (at least one advanced stage eye), candidate for conservative management.~Treatment included window treatment with vincristine and topotecan, Followed by 3 more courses of vincristine-topotecan if they had a response to the window+ 6 courses of vincristine and carboplatin. If they do not respond to the window, they receive 6 courses of vincristine, carboplatin, and etoposide. Periocular carboplatin is also given three times, depending on whether they respond to window. External Beam Radiation 44-46 Gy administered using standard practices."
89362743|NCT00186888|Other|Stratum C|"Patients with advanced unilateral advanced intraocular disease. First intervention is enucleation.~If enucleated eye does not have disease outside the retina (low risk), no additional treatment is given.~For patients whose enucleated eye shows tumor outside the retina (intermediate risk), they will receive 4 courses of vincristine, cyclophosphamide, and doxorubicin followed by G-CSF.~For patients with high risk disease (involvement of the sclera, optic nerve at the level of the cut-end), treatment after enucleation is 6 courses of alternating chemotherapy with vincristine, carboplatin, etoposide (VCE) to alternate with vincristine, cyclophosphamide, and doxorubicin (VCD). High risk patients also receive external-beam radiation therapy."
89362744|NCT00183482|Experimental|Family Group Cognitive Behavioral|The intervention is a family group cognitive behavioral program for families of parents with a history of depression to teach parenting skills to parents and coping skills to children.
89362745|NCT00183482|Active Comparator|Written Information|The comparison arm involves providing written information about depression and stress to parents with a history of depression and their children.
89362746|NCT00030771|Active Comparator|Arm A|Neoadjuvant Chemoradiotherapy + Chemotherapy + Surgery
89362747|NCT00030771|Active Comparator|Arm B|Neoadjuvant Chemotherapy + Surgery
89362748|NCT03078192|Experimental|Training Set - PVD, Isolated Left Heart Failure, Isolated Lung Disease|Patients with Pulmonary Vascular Disease (10 subjects), isolated left sided heart failure (10 subjects), and isolated lung disease(10 subjects) will undergo Xe MRI scans with GE-141, Hyperpolarized 129Xenon gas to develop diagnostic criteria for optimizing the sensitivity and specificity of XeMRI for the diagnosis of PVD
89362749|NCT03078192|Experimental|Test Set - Pulmonary Vascular Disease|92 subjects being evaluated for undergoing right heart catheterization for evaluation of PAH or other cardiac or pulmonary disease for testing of diagnostic accuracy of XeMRI for diagnosis of PVD
89362750|NCT00703846|Other|KETOCONAZOLE|
89362751|NCT03309514|Experimental|Treatment|
89362752|NCT01341288|Experimental|Implant|Robotic implantation of brachytherapy seeds to treat prostate cancer
89362753|NCT03309436|Experimental|Use Clomiphene Citrate protocol|Ovulation induction: regular Clomiphene Citrate protocol. Start use rFSH or HMG from day 2/3 of the menstrual cycle, the initial dosage is determined by patients' age, BMI, antral follicle number, FSH, E2, AMH and past ovarian response, usually 150-225IU/d, until hCG injection. At the same time, take CC 100mg/d until hCG injection. The dosage of Gn will be adjust by serum E2, P, LH and the development of follicular.
89362754|NCT03309436|Active Comparator|Procedure|Ovulation induction: regular GnRH antagonist protocol. Start use rFSH or HMG from day 2/3 of the menstrual cycle, the initial dosage is determined by patients' age, BMI, antral follicle number, FSH, E2, AMH and past ovarian response, usually 150-225IU/d, until hCG injection. When a dominant follicle diameter over 14mm or serum E2 over 350pg/ml, use GnRH-ant 0.25mg/d, until hCG injection. The dosage of Gn will be adjust by serum E2, P, LH and the development of follicular.
89362755|NCT05183334|Placebo Comparator|group 1|patients with PE
89362756|NCT05183334|Experimental|group2|patients with PE
89362757|NCT05183334|Experimental|group 3|patients with PE
89362758|NCT05183334|Experimental|group 4|patients with PE
89362759|NCT05232526|Experimental|Mental imagery (MI) and exercise program|MI will start immediately when the sample is going to start the exercise program. The intervention group will undergo 24 sessions of imagery, starting from the 1st exercise program session. Participants of the intervention group will undergo a 45-minute imagery session sitting in a quiet place after the end of every exercise program session. The content of every imagery session is alike with the content of the exercise program session. That means that every session includes imagery of the same exercises of the exercise program performed earlier by the subject in the Day Center. Sessions are identical for all subjects of the intervention group. The total duration of the physiotherapy exercise program will be 24 sessions, 2 times/week, duration of 45 minutes each session, 3 months (12 weeks).
88818111|NCT01263314|Experimental|Panel B MK-8266 0.7/0.3 mg (Elderly Fem. with Mild/Mod. HTN)|MK-8266 single dose 0.7 mg and then 0.3 mg after 10 hours
89362760|NCT05232526|Placebo Comparator|Exercise program|The total duration of the physiotherapy exercise program will be 24 sessions, 2 times/week, duration of 45 minutes each session, 3 months (12 weeks).
89362761|NCT05250882|Experimental|Double Check enhanced perioperative care protocol|Perioperative care according to a best practice protocol focussing on optimizing the intraoperative condition of the patient and thereby minimalize exposure to 6 known modifiable independent intraoperative risk factors: anemia, hypothermia, epidural anesthesia, vasopressor drug administration, incorrect antibiotic prophylaxis and hyperglycemia.
89362762|NCT05250882|No Intervention|Current practice|Perioperative care according to usual practice. Historical controls from the previously conducted LekCheck study will be used as replacement of a control arm.
89362763|NCT03304990||Family History of CA|Hereditary cancer genetic screening based on risk factors
88818112|NCT01263314|Placebo Comparator|Panel B Placebo to MK-8266 (Elderly Fem. with Mild/Mod. HTN)|Placebo to MK-8266 single dose
88818113|NCT02261597||Insomnia Disorder|Testing reactivity of stress-related systems to repeated exposure to the cold pressor test (hand immersion into ice-cold water) among participants with a clinical diagnosis of insomnia disorder.
88818114|NCT02261597||Healthy Control|Testing reactivity of stress-related systems to repeated exposure to the cold pressor test (hand immersion into ice-cold water) among healthy participants without a diagnosis of insomnia disorder.
88818115|NCT01327508|Experimental|TRIGEN SURESHOT Distal Targeting|TRIGEN SURESHOT Distal Targeting Instrumentation is utilized to find screw holes.
88818116|NCT01327508|Active Comparator|Standard Nailing Instrumentation.|Free-hand technique utilizes x-rays to find screw holes
88818117|NCT01807871|Experimental|nicotine patch, experimental use|Participants will continue to use nicotine patch after they lapse and resume smoking as long as smoking is less than 75% of pre study levels.
88818118|NCT01807871|Active Comparator|nicotine patch, labeled use|Participants will discontinue using the nicotine patch when they resume smoking. This is the current FDA approved use of the nicotine patches.
88818119|NCT01327976|Active Comparator|vBloc (Active Device)|The treatment group will receive a functional device that will deliver charge to the vagus nerve during the study period
88818120|NCT01327976|Sham Comparator|Sham (Non-active Device)|The control group will receive a functional, but non-active device that will deliver no charge to the vagus nerve during the study period
89362764|NCT03304990||Risk Factors for CA|No dx of CA
89362765|NCT03304990||Suspected or Confirmed Diagnosis of CA|Suspected or confirmed diagnosis of cancer
89362766|NCT03304834|Experimental|ECHOPULSE|Arm of patient treated by HIFU
89362767|NCT01341366|Experimental|Fast-track perioperative program|
89362768|NCT01341366|Active Comparator|Traditional perioperative program|
88818121|NCT00507299|Experimental|Model Care (SEEK)|Residents in this group received special training on addressing pyschosocial problems. They then used a parent screening questionnaire, and addressed identified problems. A study social worker was also part of this intervention. Thus, this group provided enhanced pediatric primary care.
89362769|NCT03304756|Experimental|CAP|Cisplatin (50 mg/m2) in combination with doxorubicin (50 mg/m2) and cyclophosphamide (500 mg/m2) every 21 days and for a total of 6 cycles
89362770|NCT06065423|Experimental|Telerehabilitation Group|patients received exercises and massages through TR three times a week, conducted by a physiotherapist and a clinician. They were encouraged to perform their exercises and wear compression garments on the remaining days. Prior to the program, patients or their relatives received training from physiotherapists regarding exercises and Manual Lymphatic Drainage (MLD). Patients or their relatives were informed about the Zoom program and were instructed to acquire the application online. Two physiotherapists and groups of five patients each were organized based on rehabilitation days and hours, and access to the Zoom link was provided.
89362771|NCT06065423|Active Comparator|Home- Exercise Group|patients were provided with a brochure explaining the massages and exercises they needed to perform. Additionally, they were contacted three times a week by a physiotherapist and a clinician to remind them of the treatments, assess the continuity and accuracy of the treatments, encourage them to perform the treatments correctly and consistently, and promote the wearing of compression garments.
89362772|NCT06065410|Experimental|Patients with knee osteoarthritis|
89362773|NCT06065397|Experimental|People after a stroke event|Implementation of improvement program
88818122|NCT00507299|Active Comparator|Standard pediatric primary care|This arm involved residents receiving the regular education through the program. They did not use the screening questionnaire to identify psychosocial problems, and did not have a dedicated social worker to assist them. Instead, residents in this group provided standard pediatric primary care
88818123|NCT01263938|Other|Atorvastatin|
88818124|NCT01789775|Placebo Comparator|CD07805/47 gel Placebo|Placebo
88818125|NCT01789775|Experimental|CD07805/47 gel|Intervention: Drug: CD07805/47 gel
88818126|NCT02327741|Experimental|plavix long term|taking plavix more than 12 months
88818127|NCT02327741|Active Comparator|plavix short term|taking plavix less than 12 months
88818128|NCT01810289|Experimental|MJAP Clinics Intervention|START intervention. This is a stepped wedge design so each clinic will experience both conditions.
88818129|NCT01810289|No Intervention|MJAP Clinics Pre-Intervention|Standard of care. This is a stepped wedge design so each clinic will experience both conditions.
88818130|NCT01265966||Moderate Sedation|Children undergoing moderate sedation for procedures.
88818131|NCT01265966||Deep Sedation|Children undergoing deep sedation for procedures.
88818132|NCT01733069||No treatment|
88818133|NCT02634177|Active Comparator|Assay-guided treatment (AGT)|Assay results will be provided to the treating investigator, who will use the results to guide pharmacotherapy of the subject's MDD treatment.
88818134|NCT02634177|Placebo Comparator|Treatment-as-usual (TAU)|The treating investigator will treat subjects of the TAU group without the knowledge of the pharmacogenetic testing results.
88818135|NCT01329380||Adalimumab|Participants with ankylosing spondylitis (AS) receiving treatment with adalimumab (Humira) as prescribed by their physician.
88818136|NCT02635035|Experimental|Lisdexamfetamine First|In this crossover study design, participants assigned to this group will receive Lisdexamfetamine first, then placebo second
88818137|NCT02635035|Experimental|Lisdexamfetamine Second|In this crossover study design, participants assigned to this group will receive placebo first, then Lisdexamfetamine second
88818138|NCT01369706|Other|Hand-held metal detector|Exposure to two hand-held metal detectors
88818139|NCT02635425|Experimental|7 eggs collection|Aspiration of 7 eggs only
88818140|NCT02635425|Active Comparator|Full eggs collection|Aspiration of all eggs
88818141|NCT02636049|Experimental|Treatment Period: 6 mg Triferic IV over 3 hours|Each subject will receive a single 6 mg dose of Triferic administered as a continuous intravenous infusion over 3 hours on Day 2. The Triferic IV dosing solution will have been prepared by diluting Triferic from ampules (5.44 mg/mL) in an appropriate amount of D5W to a concentration of 0.020 mg/mL. Administration of 300 mL IV at 100 mL/hr for 3 hours results in delivery of 6 mg of Triferic iron.
88818142|NCT02636049|Experimental|Treatment Period: 35 micrograms/kg IV push|Each subject will receive Triferic as 35 µg/kg body weight IV push over 30-60 seconds on Day 3. The Triferic IV push dosing solution will have been prepared by diluting Triferic from ampules (5.44 mg/mL) in an appropriate amount of D5W to a concentration of 35 µg Triferic iron/kg body weight per subject in 4.5 mL.
88818143|NCT01370174|Active Comparator|Induced Step Training (IST)|The IST group will receive waist-pulls in both the left and right lateral directions by a motorized pulling system to produce stepping.
88818144|NCT01370174|Active Comparator|Hip Strength Training (HST)|The HST group will have muscle strength training, to include hip abduction (AB) and adduction (AD) resistance exercises.
88818145|NCT01370174|Active Comparator|Combined Induced Step and Hip Strength Training|This training group consists of combined induced step training (IST) and hip AB-AD strength training (HST).
88818146|NCT01370174|Placebo Comparator|Standard Flexibility and Relaxation (SFR)|The SFR group will perform a flexibility and relaxation program involving minimal-intensity exercises.
88818147|NCT01329848||discomfort symptoms|level of discomfort symptoms while performing near work
88818148|NCT01267136|Experimental|Capital® with Codeine Suspension|
88818149|NCT01267136|Active Comparator|Tramadol suspension|
88818150|NCT05139771|Other|EndoArt® Artificial Endothelial Layer|EndoArt® is intended to be used as an endothelial prosthesis in patients with chronic corneal edema. One arm - all subjects will be implanted with EndoArt®.
88818151|NCT01370564|Other|Daily diuretic adjustment|Daily adjustments of diuretics and associated supplements based on cardiac filling pressures.
88834183|NCT04518007|Active Comparator|hyperbaric oxygen therapy (HBOT) active treatment|The HBOT protocol consists of 60 daily sessions, five times per week, each session lasting 90 minutes, of 100% oxygen at 2 ATA and 5-minute air breaks every 20 minutes.
88834184|NCT04518007|Sham Comparator|sham|All the conditions provided in the HBOT intervention will be provided in the sham intervention. However, in contrast to the HBOT, where the pressure will go up to 2 ATA, in the sham condition the pressure will go up to 1.1 ATA during the first five minutes of the session with noise of circulating air, and then decrease slowly during the next half hour to 1.0 ATA and the oxygen level will be 21% The initial 1.1 ATA level will provide a minimal pressure sensation in the ears, with the same nurse advice on pumping the ears. In the last five minutes of the session, the air will be circulated again with its related noises. Sham and HBOT sessions will never be adjacent, so subjects from the two groups cannot meet and discuss the session and its effects.
89362774|NCT06065397|Experimental|Healthcare professionals|Implementation of improvement program
89362775|NCT06065397|Experimental|Close relatives of people after a stroke|Implementation of improvement program
89362776|NCT06065384|Experimental|intensive upper limb training|The intervention group receives 12 hours of motor training each week upon usual care during 10 weeks. This involves active and targeted motor training of all affected muscles below the injury level in the context of functional activities.
89362777|NCT06065384|Other|usual care|The control group receives only standard rehabilitation and care
89362778|NCT06065371|Experimental|Sacituzumab govitecan and capecitabine|The trial has three dose levels. Dose level -1 has capecitabine at 500mg/m2 twice daily taken orally for two weeks on and one week off, plus sacituzumab govitecan at 7.5mg/kg given intravenously on Days 1 and 8. Each cycle is 21 days. Dose level 0 has capecitabine at 500mg/m2 and sacituzumab govitecan at 10mg/kg. Dose level 1 has capecitabine at 825mg/m2 and sacituzumab govitecan at 10mg/kg.
89362779|NCT06065358|Experimental|Interventional, prospective, monocentric|
89362780|NCT06065345|Experimental|BRight DCB|Single arm study. All subjects will be treated with the BRight DCB
89362781|NCT06065332|Experimental|Velez Intense Hydration Mask® (biotech cellulose face mask) Right Side|For 30 minutes after an aesthetic procedure, a Velez Intense Hydration Mask® (biotech cellulose face mask) was applied to the right side of the face
89362782|NCT06065332|Experimental|Velez Intense Hydration Mask® (biotech cellulose face mask) Left Side|For 30 minutes after an aesthetic procedure, a Velez Intense Hydration Mask® (biotech cellulose face mask) was applied to the left side of the face
88834185|NCT04506203|Experimental|Air test|
88834186|NCT04501419|Experimental|Trained radiologists|Trainers will successfully train Nigerian radiologists
88834187|NCT04501419|Experimental|Patients with a suspicious breast mass|Women that present to the hospital with a suspicious breast mass
89362783|NCT06065319||All Comers to Cardiac Rehabilitation|Any participant that is enrolled in cardiac rehabilitation is eligible for this study.
89362784|NCT06065306||AD|Patient aged greater than 18, presented to the ED with first 24 hours of symptoms suggesting AD, including chest pain, upper back pain, syncope of unknown cause, symptoms of any acute perfusion deficit and confirmed AD.
89362785|NCT06065306||Healthy|Patients attending ED who do not have coronary disease, hypertension or aortic disease would be identified as healthy control.
89362786|NCT06065267|Experimental|sequential|Measure eradication rate of Helicobacter pylori infection with Levofloxacien sequential based regimen
89362787|NCT06065267|Active Comparator|concomitant|Measure eradication rate of Helicobacter pylori infection with Livofloxacine concomitant based regimen
89362788|NCT06065254|Experimental|Free gingival graft|Free gingival graft will be applied and and followed for 3 months
89362789|NCT06065254|Experimental|Connective tissue graft|Connective tissue graft will be applied and and followed for 3 months
89362790|NCT06065254|Other|No grafts will be applied.|No grafts of any types will be applied.
89362791|NCT06065150|Active Comparator|Standard support|"Initial medical treatment: placement of a nasogastric tube associated with hydration and vascular filling for hypovolaemic patients. Other medical treatments for occlusive small bowel syndrome on adhesion or flange can be performed but are not systematically recommended. Their use is left to the discretion of the surgeon. Medical treatment is carried out over 72 hours from admission.~In case of resumption of a transit by gas and/or stools associated with a tolerance to the food, the exit is authorized without resorting to surgery. In the absence of a resumption of transit by gas and/or stools associated with tolerance to food, semi-urgent surgical management is proposed 72 hours from the start of management. In the event of deterioration of the clinical condition during hospitalization, urgent surgery will be proposed, according to the recommendations for use."
89362792|NCT06065150|Experimental|Early surgery proposed according to the radiological score|Patients included in the experimental arm have treatment adapted to the radiological score. The radiological score described by Berge et al. (Berge et al. Eur J Trauma Emerg Surg 2021) is calculated after patient inclusion.
89362793|NCT06065137|Experimental|POH patients|incremental administration of investigated anesthetics up to full therapeutic dose in POH patients.
89362794|NCT06065124|Active Comparator|Bariatric surgery strategy|The intervention group will receive bariatric surgery including an intensive pre- and postoperative treatment scheme
89362795|NCT06065124|No Intervention|Standard of Care|The control group will receive standard of care
89362796|NCT06065111||study tendon damage in osteogenesis imperfecta patients|The study will be conducted in three centers: Brussels (30 patients, clinique Saint-Luc, Lille (30 patients) and Paris (50 patients). Patients will be recruited regardless of their form of osteogenesis imperfecta.
89362797|NCT06065085|Experimental|Mobile Education|An education application was installed on the mobile phones of the experimental group. Individuals with hypertension were provided with a training for three months through the mobile application. Data collection forms were filled in by the individuals with hypertension in the experimental and controlled groups at the beginning and at the 3rd month via the mobile application.
89362798|NCT06065072||Normal|
89362799|NCT06065072||Cataract|
89362800|NCT06065072||Special eye|
89362801|NCT06065046|Sham Comparator|Control group|Participants will receive standard treatment and care according to the current management guidelines for traumatic brain injury, e.g. the guideline made by U.S. Brain Trauma Foundation (BTF)
88834188|NCT04497142|Experimental|Perampanel|"Participants will take a predetermined first dose of perampanel on the day before their tumor surgery~During surgery, an approximately 4x6cm recording grid will be placed on the surface of the brain over the tumor, and brain activity around the tumor will be recorded for 10 minutes during surgery (Electrocorticography).~After surgery participants will take perampanel at a predetermined dose once a day for as long as they do not have serious side effects and their disease does not get worse, up to a maximum of 12 months. Participants will be provided a drug and seizure diary to document drug and seizure information and have monthly study visits either in clinic or by phone."
88834189|NCT04497142|Active Comparator|Standard of Care|"Participants will receive standard of care medication before surgery.~During surgery, an approximately 4x6cm recording grid will be placed on the surface of the brain over the tumor, and brain activity around the tumor will be recorded for 10 minutes during surgery (Electrocorticography).~After surgery participants will take standard of care medications as predetermined by their doctor. Participants will be provided a drug and seizure diary to document drug and seizure information and have monthly study visits either in clinic or by phone.~Participants will be followed up to 12 months after completing surgery."
88834190|NCT04495257|Experimental|Dose Level 1 (DL1)|DL1 will include ipilimumab at 1mg/kg and nivolumab at 3 mg/kg with APX005M of 0.1mg/kg for the induction phase. After 4 cycles, participants will be treated with 360mg of nivolumab and APX005M every 3 weeks.
89362802|NCT06065046|Experimental|Baricitinib group|Besides receiving standard treatment and care, baricitinib will be administrated orally (or crushed for nasogastric tube delivery) and given daily at the dosage of 4mg, for consecutive 14 days after patients' brain injury.
89362803|NCT06064994|Experimental|Experimental Group|Patients with ESRD receiving mindfulness meditation
88834191|NCT04495257|Experimental|Dose Level 2 (DL2)|DL2 will include ipilimumab at 1mg/kg and nivolumab at 3 mg/kg with APX005M of 0.3mg/kg for the induction phase. After 4 cycles we will treat with 360mg of nivolumab and APX005M every 3 weeks.
88834192|NCT04485767|Experimental|Progressive Resistance Training Exercise|Men with prostate cancer who are about to begin androgen-deprivation therapy (ADT) will attend structured progressive resistance exercise training sessions 2 times/week for six months.
88834193|NCT04485767|Active Comparator|Flexibility and Balance Exercise|Men with prostate cancer who are about to begin androgen-deprivation therapy (ADT) will attend flexibility and balance exercises training sessions 2 times/week for six months.
88834194|NCT04477759|Experimental|50 Gray (Gy) Radiation Therapy|50 Gy of ionizing radiation therapy will be administered in 15 fractions.
88834195|NCT04477759|Experimental|55 Gray (Gy) Radiation Therapy|55 Gy of ionizing radiation therapy will be administered in 15 fractions.
88834196|NCT04477759|Experimental|60 Gray (Gy) Radiation Therapy|60 Gy of ionizing radiation therapy will be administered in 15 fractions.
88834197|NCT04469712||SASI Bipartition|Subjects submitted to SASI Bipartition
88834198|NCT04469712||Roux-en-Y gastric bypass|Subjects submitted to gastric bypass
88834199|NCT04467853|Experimental|LCAR-C18S Cells|Each subject will receive LCAR-C18S Cells
88834200|NCT04466358|Experimental|Modified CLOSE protocol|Width antral circumferential pulmonary vein isolation guided according to CLOSE protocol, confirmed with multipolar circular mapping catheter.
88834201|NCT04466358|Active Comparator|High density mapping guided pulmonary vein isolation|Width antral circumferential pulmonary vein isolation guided according to CLOSE protocol and confirmed with high density mapping of each pulmonary vein antrum, with additional ablation lesions at sites of gap or dormant conduction.
88834202|NCT04454125|Active Comparator|Routine Care|
88834203|NCT04454125|Experimental|AQI Intervention|
89362804|NCT06064994|No Intervention|Control group|Patients with ESRD receiving traditional care.
89362805|NCT06064942|Experimental|MFNT Intervention (Treatment Group)|Parents of children with ADHD who are randomized in Treatment Group will first take part in a pre-tested 4-session MFNT intervention programme. The parents will participate in lectures, group discussions, video demonstrations, and in-group exercises offered in these four mentored sessions, while their children will attend the second and fourth sessions.
88834204|NCT04440891|Experimental|TMS-Stimulation with X-Torp task|TMS with VR 1 experimental arm
88834205|NCT04440891|Experimental|TMS-Stimulation with MindMotion Go|TMS with VR 2 experimental arm
88834206|NCT04440891|Sham Comparator|TMS-Sham with X-Torp task|TMS sham control with VR 1
88834207|NCT04440891|Sham Comparator|TMS-Sham with MindMotion Go|TMS sham control with sham VR 2
88834208|NCT04433949|Active Comparator|Arm I (physician choice)|Patients get best supportive care + physician choice of treatment
88834209|NCT04433949|Experimental|Arm II (LDRT)|Patients receive best supportive care + low dose RT (whole lung)
89362806|NCT06064942|Experimental|MFNT Intervention (Wait Listing Control Group)|Families of children with ADHD who are randomized in Wait Listing Control Group receive services as usual by the school social personnel during the intervention period. The 4-session MFNT intervention program will be delivered to them after the intervention period.
88834210|NCT04433299||low back pain patients|no intervention
88834211|NCT04433299||controls|no intervention
88834212|NCT04424199||LBD patients R-PA|"A group of 10 left brain damaged (LBD) patients will attend two sessions:~First session - before prismatic adaptation (pre-PA): they will perform a computerized test battery to measure time abilities (Mental Time Travel and Time Estimation) and a neuropsychological test battery to assess cognitive abilities.~Second session - after prismatic adaptation (post-PA): they will perform the Mental Time Travel and Time Estimation tasks immediately after a single session of pointing with prismatic goggles inducing rightward attentional shift (R-PA)."
88834213|NCT04424199||LBD patients L-PA|"A group of 10 left brain damaged (LBD) patients will attend two sessions:~First session - before prismatic adaptation (pre-PA): they will perform a computerized test battery to measure time abilities (Mental Time Travel and Time Estimation) and a neuropsychological test battery to assess cognitive abilities.~Second session - after prismatic adaptation (post-PA): they will perform the Mental Time Travel and Time Estimation tasks immediately after a single session of pointing with prismatic goggles inducing leftward attentional shift (L-PA)."
89178277|NCT00783198|Experimental|SCH 39641 12 Amb a 1-U|Participants receive Ambrosia artemisiifolia allergen extract (SCH 39641 12 Amb a 1-U) rapidly dissolving tablets, administered once daily sublingually for approximately 52 weeks
89362807|NCT06064838|Experimental|Flavonoids|Capsules with 500mg of cacao flavonoids, twice a day for 90 days
89362808|NCT06064838|Placebo Comparator|Placebo|Capsules with 500mg of excipients, twice a day for 90 days
89362809|NCT06064799||Group I|14 healthy volunteers
89362810|NCT06064799||Group II|14 periodontitis participants with stage III grade B Periodontitis
89362811|NCT06064799||Group III|14 periodontitis participants with stage III grade C Periodontitis
89362812|NCT06064786||Group I|15 healthy patients with generalized periodontitis stage III.
89362813|NCT06064786||Group II|15 patients suffering from type 2 diabetes mellitus with generalized periodontitis stage III
89362814|NCT06064786||Group III|15 systemically healthy patients without periodontitis
88834214|NCT04424199||RBD patients R-PA|"A group of 10 right brain damaged (RBD) patients will attend two sessions:~First session - before prismatic adaptation (pre-PA): they will perform a computerized test battery to measure time abilities (Mental Time Travel and Time Estimation) and a neuropsychological test battery to assess cognitive abilities.~Second session - after prismatic adaptation (post-PA): they will perform the Mental Time Travel and Time Estimation tasks immediately after a single session of pointing with prismatic goggles inducing rightward attentional shift (R-PA)."
88834215|NCT04424199||RBD patients L-PA|"A group of 10 right brain damaged (RBD) patients will attend two sessions:~First session - before prismatic adaptation (pre-PA): they will perform a computerized test battery to measure time abilities (Mental Time Travel and Time Estimation) and a neuropsychological test battery to assess cognitive abilities.~Second session - after prismatic adaptation (post-PA): they will perform the Mental Time Travel and Time Estimation tasks immediately after a single session of pointing with prismatic goggles inducing leftward attentional shift (L-PA)."
88834216|NCT04424199||HC R-PA|"A group of 10 healthy controls (HC) will attend two sessions:~First session - before prismatic adaptation (pre-PA): they will perform a computerized test battery to measure time abilities (Mental Time Travel and Time Estimation) and a neuropsychological screening (Mini Mental State Examination) to assess inclusion/exclusion criteria.~Second session - after prismatic adaptation (post-PA): they will perform the Mental Time Travel and Time Estimation tasks immediately after a single session of pointing with prismatic goggles inducing rightward attentional shift (R-PA)."
88834217|NCT04424199||HC L-PA|"A group of 10 healthy controls (HC) will attend two sessions:~First session - before prismatic adaptation (pre-PA): they will perform a computerized test battery to measure time abilities (Mental Time Travel and Time Estimation) and a neuropsychological screening (Mini Mental State Examination) to assess inclusion/exclusion criteria.~Second session - after prismatic adaptation (post-PA): they will perform the Mental Time Travel and Time Estimation tasks immediately after a single session of pointing with prismatic goggles inducing leftward attentional shift (L-PA)."
88834218|NCT04418440|No Intervention|Control|Routine NHS care following traumatic brain injury
88834219|NCT04418440|Experimental|Treatment|Routine NHS care following traumatic brain injury plus daily dose of test compound (oral nutritional supplement)
88834220|NCT04411719||EEG and Microexpression Analysis|Participants will be acutely unresponsive ICU patients. They will undergo non-invasive observational procedures, including EEG monitoring during exposure to emotional auditory stimuli, and concurrent video recording for microexpression analysis. Patient outcomes will be assessed at three, six, and twelve-month intervals post-initial observation.
88834221|NCT04410419|No Intervention|Standard Care|Standard care for patients with diabetes pre-operatively .
88834222|NCT04410419|Experimental|Carbohydrate drink|Carbohydrate drink containing 40g of carbohydrate to be consumed three hours prior to surgery
88834223|NCT04390048|Experimental|Anodal tDCS and Balance Training (BT) Group|Participants will undergo 4 weeks of BT under anodal tDCS treatment.
88834224|NCT04390048|Sham Comparator|Sham tDCS and BT Group|Participants will undergo 4 weeks of BT under sham tDCS.
88834225|NCT04386005|Experimental|Continuous Glucose Monitoring|All participants will have the continuous glucose monitoring device placed.
88834226|NCT04369820|Experimental|COVID-19 PATIENTS|"Two blood samples (40mL) at 2 different points in time:~Within the first 72 hours of medical care in resuscitation unit or department.~Between the 5th and the 10th day of medical care (ideally at the end of the first week) or on the day of discharge of patient if it is earlier, or of death if it takes place earlier."
89362815|NCT06064760|Experimental|Experimental group|The experimental group is given the Workshop on Strengths and Competences to Improve Psychological Wellbeing and Quality of Life of Grandparents.
89362816|NCT06064760|No Intervention|Control group|The control group is not given the Workshop on Strengths and Competences to Improve Psychological Wellbeing and Quality of Life of Grandparents.
89362817|NCT06064747|Experimental|LF-rTMS|"Using 8 coil,1-Hz rTMS to stimulate the M1 region of the ipsilateral hemisphere, the stimulation intensity was RMT 100%, 1200pulses/session, two sessions (2400 pulses)/day (interval ≥ 2 hours), lasting 3 days (total 6 sessions, 7200pulses)"
89362818|NCT06064747|Sham Comparator|Sham coil stimulation|The sham stimulation coil was used to stimulate the same site, duration and sound as the LF-rTMS group, ensuring no effective stimulation, twice a day for 3 days
89362819|NCT06064734|Experimental|LF-rTMS|H 4 Coil (stimulation site: prefrontal cortex, insular lobe),1-Hz rTMS, stimulation intensity RMT 100%,1200 pulses/session, two sessions (2400 pulses)/day (interval ≥2 hours), lasting about half an hour each time, the total duration of treatment was 3 days (6 sessions,7200 pulses).
89362820|NCT06064734|No Intervention|Control|Routine treatment.
89362821|NCT06064708|Experimental|Patients with ESRD receiving mindfulness-based intervention|Patients with ESRD who received mindfulness-based intervention: underwent hemodialysis thrice weekly, were at least 18 years old, were capable of reading and writing in Arabic, and agreed to participate. Patients under total parenteral nutrition (TPN), undergoing psychotherapy, taking psychopharmacological or anti-inflammatory drugs, and having immunocompromised and infectious illnesses were excluded from the research.
89362822|NCT06064708|No Intervention|Control group|The control group including patients with ESRD with the inclusion criteria similar to the experimental group received usual care, comprising biomedical normative dialysis treatment (the participants in this group did not receive any kind of additional treatment or holistic components). However, upon completion of the study, audio recordings of the intervention protocol were provided and explained to participants in the control group.
89362823|NCT06064669|Experimental|Metformin-Metformin Group|Metformin pretreatment before ovarian stimulation till oocyte retrieval and cryopreservation of all embryos, and followed by metformin pretreatment before endometrial preparation for frozen embryo transfer and till the establishment of clinical pregnancy (7-8 weeks gestation) after the first frozen embryo transfer.
89362824|NCT06064669|Experimental|Metformin-Placebo Group|Metformin pretreatment before ovarian stimulation till oocyte retrieval and cryopreservation of all embryos, and followed by placebo pretreatment before endometrial preparation for frozen embryo transfer and till the establishment of clinical pregnancy (7-8 weeks gestation) after the first frozen embryo transfer.
89362825|NCT06064669|Experimental|Placebo-Metformin Group|Placebo pretreatment before ovarian stimulation till oocyte retrieval and cryopreservation of all embryos, and followed by metformin pretreatment before endometrial preparation for frozen embryo transfer and till the establishment of clinical pregnancy (7-8 weeks gestation) after the first frozen embryo transfer.
89362826|NCT06064669|Experimental|Placebo-Placebo Group|Placebo pretreatment before ovarian stimulation till oocyte retrieval and cryopreservation of all embryos, and followed by placebo pretreatment before endometrial preparation for frozen embryo transfer and till the establishment of clinical pregnancy (7-8 weeks gestation) after the first frozen embryo transfer.
89362827|NCT06064630|Other|Telemedicine treatment group|Telemedicine group need to complete sleep-related questionnaires on the Redcap website. Participants in the telemedicine group will learn Home sleep apnea testing(HSAT) online and then complete overnight monitoring at home. Patients diagnosed with OSA after HSAT monitoring will receive standardized APAP treatment. At 1 month of APAP treatment, participants in the telemedicine group will be followed up by phone/video to check their APAP treatment compliance and prompted to complete the corresponding follow-up questionnaire on the Redcap website. After 3 months of APAP treatment, the telemedicine group will be followed up by phone/video to check their APAP treatment compliance at 3 month, and they will finish corresponding follow-up questionnaires on Redcap website. 24-hour ambulatory blood pressure monitoring, and physical measurements will be conducted in sleep center at 1 month and 3 month.
89362828|NCT06064630|Other|Outpatient treatment group|Outpatient group need to complete sleep-related paper questionnaires at sleep center. The sleep technicians will explain to the patients how to use the Home sleep apnea testing (HSAT) and then they will complete overnight monitoring at home. Patients diagnosed with OSA after HSAT monitoring will receive standardized APAP treatment. At 1 month of APAP treatment, participants in the outpatient group will be followed up at sleep center to check their APAP treatment compliance and prompted to complete the corresponding follow-up paper questionnaires at sleep center. After 3 months of APAP treatment, the outpatient group will be followed up to check their APAP treatment compliance at 3 month, and they will finish corresponding follow-up paper questionnaires at sleep center. 24-hour ambulatory blood pressure monitoring, and physical measurements will be conducted in sleep center at 1 month and 3 month.
89362829|NCT06064552||high risk pregnancy|Pregnant women with history of gestational diabetes in previous pregnancies, Polycystic ovaries syndrome, history of Macrosomic baby in previous pregnancies, Past history of late third trimester fetal demise, Past history of polyhydramnios, Overweight /Obese women, Women diagnosed to have other endocrinopathies like suprarenal, thyroid or pituitary disorders, multi fetal pregnancies, Past history of shoulder dystocia, Past history of preeclampsia
89362830|NCT06064552||low risk pregnancy|average risk population like primigravida healthy women or those with normal obstetric history.
89362831|NCT06064539|Experimental|Cohort 1|SAR442168 administered alone and together with gemfibrozil. 1 day washout for each administration of SAR442168.
88818152|NCT02637999|Experimental|MXB then PEG IFN|Myrcludex B 2mg daily for 24 weeks, followed by PEG IFN alfa-2a 180 µg/0.5 mL weekly for 48 weeks
88818153|NCT02637999|Experimental|MXB + PEG IFN then PEG IFN|Myrcludex B 2mg daily and PEG IFN alfa-2a 180 µg/0.5 mL weekly for 24 weeks, followed by PEG IFN alfa-2a 180 µg/0.5 mL weekly for 24 weeks
88818154|NCT02637999|Active Comparator|PEG IFN|PEG IFN alfa-2a 180 µg/0.5 mL once weekly for 48 weeks
88818155|NCT01790243|Experimental|Lutonix Drug Coated Balloon|Formerly called the Moxy Drug Coated Balloon, the Lutonix Drug Coated Balloon (Lutonix DCB) is a paclitaxel coated balloon catheter
88818156|NCT01790243|Active Comparator|Standard Uncoated Angioplasty Balloon|PTA Catheter
88818157|NCT03235479|Experimental|Rimegepant 75 mg|Participants were administered a single oral dose of 75 mg of rimegepant tablet on occurrence of migraine that reached moderate or severe intensity up to 45 days after randomization.
88818158|NCT03235479|Placebo Comparator|Placebo|Participants were administered a single oral dose of matching placebo tablet for rimegepant (75 mg) on occurrence of migraine that reached moderate or severe intensity up to 45 days after randomization.
88818159|NCT01371110|Active Comparator|Ketamine|Study participants will receive a one-time intravenous infusion of 0.5 mg/kg racemic ketamine hydrochloride
88818160|NCT01371110|Sham Comparator|Midazolam|Study participants will receive a one-time intravenous infusion of 0.045 mg/kg midazolam
88818161|NCT01791491|Experimental|Belatacept|
88818162|NCT01810991|Experimental|Nd:YAG Laser|Nd:YAG 1440nm Laser
88818163|NCT01372202|Active Comparator|Arm A|Paclitaxel with Cisplatin along with Radiotherapy and followed by Esophagectomy
88818164|NCT01372202|Active Comparator|Arm B|Cisplatin or Oxaliplatin with 5-Fluorouracil along with Radiotherapy and followed by Esophagectomy
88818165|NCT01372202|Active Comparator|Arm C|Cisplatin with 5-Fluorouracil along with Radiotherapy and followed by Esophagectomy
88818166|NCT05098899|Experimental|MyGeneMyDiet® Recommendations for Weight Management|A set of nutrition and lifestyle advice for weight management derived from genetic information
88818167|NCT05098899|Active Comparator|Usual Standard of Care for Weight Management|A set of standard nutrition and lifestyle advice for weight management without genetic information
89362832|NCT06064539|Experimental|Cohort 2|SAR442168 administered alone and together with rifampicin. 1 day washout for each administration of SAR442168.
89362833|NCT06064513|Experimental|control group|It consists of nurses working in Intensive Care, Emergency Service, Internal - Surgical Services and Polyclinic units in the public hospital in Kayseri. Individuals who volunteer to participate in the research will be included.
89362834|NCT06064513|Experimental|Video group|It consists of nurses working in Intensive Care, Emergency Service, Internal - Surgical Services and Polyclinic units in the public hospital in Kayseri. Individuals who volunteer to participate in the research will be included.
89362835|NCT06064409||Acute hypoxemic respiratory failure group|Patients with hypoxemic respiratory failure, defined as decreased PaO2.
89362836|NCT06064409||Acute hypercapneic respiratory failure group|Patients with hypercapneic respiratory failure, defined as increased PaCO2.
89362837|NCT06064357|Experimental|Transverese friction massage + Conventional Physio Therapy|"Transverse friction massage: Transverse friction massage at Rectus femoris, hip adductors, hamstring, and calf muscle on both lower limbs. TFM on each group of muscle for 30 seconds, 3 sets with 10 seconds rest interval after that massage will be performed on next group of muscle.4 session per week lasting for 6 weeks.~Conventional Therapy:~Conventional physical therapy program included application hot pack for 15 minutes, and Bobath treatment followed by stretching of calf muscles (10 repetitions with at least 8 seconds hold) 4 times a week lasting for 6 weeks"
89362838|NCT06064357|Experimental|Tissue flossing technique + Conventional Physio Therapy|"Tissue floss bands: These band will be applied on Rectus femoris, hip adductors, calf muscle and hamstring muscle of both lower limbs. Floss band will be wrap around the particular group of muscle from distal to proximal direction with 25 % stretch and 50% overlap a few inches below and few inches above the area and then 10 Reps of rom will be actively performed by the participants and then after 10 Reps remove the band and the rest interval is 2 mint after that next group of muscle will be wrap. 4 sessions per week lasting for 6 weeks.~Conventional Therapy: Conventional physical therapy program included application hot pack for 15 minutes, and Bobath treatment followed by stretching of calf muscles (10 repetitions with at least 8 seconds hold) 4 times a week lasting for 6 weeks."
89362839|NCT06064344|Experimental|Intralesional Rituximab Injection|
89362840|NCT06064344|Active Comparator|Involved Site Radiation Therapy|
89362841|NCT06064331|Experimental|Group Lignocaine|Group Lignocaine will receive an IV bolus dose of 1.5 mg/kg of 2% lignocaine HCL diluted up to 10 ml with normal saline in a 10 ml syringe which will be delivered via a syringe pump over a period of 3 min. This is then followed by an IV infusion at the rate of 1 mg/kg/h of 2% lignocaine HCL in a 20 ml syringe which will be administered by another syringe pump.
89362842|NCT06064331|Placebo Comparator|Group Placebo|Patients in Placebo Group will receive an IV bolus of 10 ml of normal saline over a period of 3 min followed by an IV infusion of an equal volume of normal saline, both of which will be delivered by separate syringe pumps.
89362843|NCT06064318||Primary cohort|All patients with a primary knee arthroplasty performed in Denmark between Jan 1st 1998 and 31st December 2021.
89001185|NCT00576160|Experimental|B|Participants will complete Baseline and 30-day assessment visit. At both visits BDI II, Self-Efficacy Questions, AEs Assessment, and Treatment Satisfaction will be assessed. A MEMS cap will be used during the 30-day period to asses medication adherence to their prescribed aspirin. After Baseline, there is an initial session telephone session with PST therapist. Subsequent treatment sessions provide a context for the patient to discuss the problems and difficulties they face and that give rise to medication non-adherence.
89001186|NCT00576238|Experimental|1:1|Part 1 - eczema treatment
89001187|NCT00576238|Active Comparator|1:2|Part 1 - eczema treatment
89001188|NCT00576238|Experimental|2:1|Part 2 - maintenance treatment
89001189|NCT00576238|No Intervention|2:2|Part 2 - maintenance treatment
89362844|NCT06064318||Revision cohort|All patients with a revision knee arthroplasty performed in Denmark between Jan 1st 1998 and 31st December 2021
89001190|NCT00576355|Active Comparator|2|Participants will receive treatment as usual
89001191|NCT00576355|Experimental|1|Participants will receive interpersonal and social rhythm therapy for adolescents
89001192|NCT00576394|Active Comparator|1Moderate Glycemic Control|Patients will receive an insulin drip to keep blood glucose levels between 120-180mg/dl
89362845|NCT06064305||Septic AKI patients|Septic AKI patients
89362846|NCT06064305||Non-septic post-cardiothoracic AKI patients|Non-septic post-cardiothoracic surgery AKI patients
89362847|NCT06064305||non-AKI patients undergoing routine nephrectomy|non-AKI patients undergoing routine nephrectomy
89362848|NCT06064292|Experimental|The High Intensity Training Group (HIT)|The High Intensity Training Group (HIT) received IMT at 40% of Maximum Inspiratory Pressure (MIP), the training load was set each 2 weeks to keep 40% of MIP.
89362849|NCT06064292|Experimental|The Low Intensity Training Group (LIT)|The Low Intensity Training Group (LIT) received IMT at 20% of MIP, following the same rules as HIT.
89362850|NCT06064240||Before operation, 1 month after operation, 3 months after operation and 6 months after operation.|Patients who underwent bariatric surgery were followed up regularly before and after surgery.
89362851|NCT06064227|Experimental|intervention group.|"Multi-module training intervention.~The intervention group, patients identified as pre-frail or frail, will be included in a multi-module educational program created specifically for this study."
89362852|NCT06064227|No Intervention|control group|The control group will be selected by single-blind, stratified randomization (coin-flip) from among patients identified as pre-frail or frail and will not receive any intervention.
89362853|NCT06064201|Experimental|Short-chain fatty acids (SCFAs)|SCFAs will be delivered directly to the colon using pH-dependent colon delivery capsules (CDCs).
89362854|NCT06064201|Placebo Comparator|Microcrystalline cellulose|Placebo capsules
88818168|NCT01792817|Sham Comparator|Sham GammaCore device|The Sham GammaCore device looks and operates like the Active GammaCore device, but does not deliver a therapeutic stimulation treatment.
89001193|NCT00576394|Active Comparator|2Aggressive Glycemic Control|Patients will receive an insulin drip designed to maintain serum glucose between 80-120mg/dl
89001194|NCT00576433|Experimental|1|
89001195|NCT00576511|Active Comparator|1|Prucalopride
89001196|NCT00576511|Placebo Comparator|2|
89362855|NCT06064175|Experimental|Ibuprofen 400 mg-group 1|Patients will receive ibuprofen 400 mg/4 ml via the parenteral route as a rapid 10-minute infusion in 150 ml of saline solution (0.09% NaCl).
89362856|NCT06064175|Experimental|Ibuprofen 800 mg-group 2|Patients will receive ibuprofen 800 mg/8 ml via the parenteral route as a rapid 10-minute infusion in 150 ml of saline solution (0.09% NaCl).
89362857|NCT06064162|Active Comparator|Ketamine (active treatment)|dose of 0.5 mg/kg intravenously over 40 minutes on day 1
89362858|NCT06064162|Placebo Comparator|Saline (placebo treatment)|Placebo (saline solution) over 40 minutes on day 1
89362859|NCT06064149|Other|Men With Prostate Cancer Planned for Receiving ADT|Men with prostate cancer > 18 years of age who are currently receiving or will be receiving treatment with ≥ 6 months of systemic androgen deprivation therapy (ADT).
89362860|NCT06064123||Cardiac transplant recipients|The group consist of all recruited cardiac transplant recipients operated in Helsinki University Hospital
89362861|NCT06064084||Psoriasis|
89362862|NCT06064084||Control|Age, Sex and BMI matched
89362863|NCT06064045|Experimental|Intervention arm|The intervention entails boosting the quantity and frequency of simulation-based team training within the intervention group. Additionally, measures to enhance and support simulation will be introduced within the intervention group.
89362864|NCT06064045|No Intervention|Control arm|Performing simulation as usual
89362865|NCT06064019|Other|Nevisense|"This will be a prospective investigator-initiated study to evaluate the accuracy of Nevisense for KC. First evaluation steps include dermatologist's clinical examination (visual inspection) and videodermoscopy. In those cases where the routine diagnostic procedures given above identify any suspicion of a KC, a Nevisense measurement is to be conducted after examination of inclusion and exclusion criteria. Thereafter, surgical excision and histopathologic examination follow.~All skin lesions with a suspicion of BCC, iSCC, BD or AK and destined for excision or biopsy for further histopathological analysis will be considered for inclusion in the study. A maximum of three lesions per patient will be allowed for the study. The study aims to enrol 250 lesions in total."
89362866|NCT06063980|Other|Conventional sinus lift procedure|Participants assigned to conventional sinus augmentation
89362867|NCT06063980|Other|Two-stage-sinus-lift procedure|Participants assigned to two-stage - sinus - lift procedure
89362868|NCT06063928||Observational (blood, tissue, genetic testing, questionnaires)|Patients undergo blood sample collection, collection of archival tumor tissue and genetic testing, and complete questionnaires on study. Patients also have their medical records reviewed on study.
89362869|NCT06063915|Active Comparator|Gold Rehab + Strength Training|Gold standard rehabilitation plus traditional strength training with overloads
89362870|NCT06063915|Experimental|Gold Rehab + Isoinertial|Gold standard rehabilitation with the inclusion of isoinertial training
89362871|NCT06063889||Knee OA Patients|This group consists of patients who have been diagnosed with knee osteoarthritis. They will be subjected to a series of tests to assess the maximal rate of force development of ankle muscles and their functional abilities.
89362872|NCT06063889||Healthy Control|This group will include healthy individuals without knee osteoarthritis. They will undergo the same series of tests to serve as a control group, enabling the comparison of results with the Knee OA Patients group.
89362873|NCT06063863|Experimental|Nurse led screening for ROP with OPTOS camera|Screening completed by nurse trained in the use of an OPTOS camera to obtain images, at the same time as screening via standard procedure by a trained ophthalmologist using binocular indirect ophthalmoscopy (BIO).
89362874|NCT06063824|Experimental|Intervention Arm|
89362875|NCT06063811||LVAD patients|Patients with end-stage heart failure with an LVAD implanted undergoing VT ablation.
89362876|NCT06063798|Experimental|Flow Controlled Ventilation Group|Ventilation by Flow Controlled Ventilation mode Patient is scheduled for elective laryngotracheal surgery under general anesthesia. The ventilation mode for this group is Flow Controlled Ventilation mode.
89362877|NCT06063798|Active Comparator|High Frequency Jet ventilation Group|Ventilation by High Frequency Jet ventilation mode Patient is scheduled for elective laryngotracheal surgery under general anesthesia. The ventilation mode for this group is High Frequency Jet ventilation mode.
89362878|NCT06063772|Experimental|Clevidipine|"Once consented, patients will be randomized into one of two groups using a block randomization table. The treatment arm will receive clevidipine. Clevidipine comes from the manufacturer in a ready to use formulation. It requires no preparation by pharmacy, nursing or physician staff. All patients randomized to receive clevidipine will be in the experimental cohort."
89362879|NCT06063772|Placebo Comparator|Placebo (Lactated Ringers)|The Control arm will receive Lactate Ringers as placebo. All patients randomized to receive lactated ringers will be in the control cohort. Lactated Ringers is stored at room temperature (25°C)
88818169|NCT01792817|Experimental|GammaCore Device|Non-Invasive Vagus Nerve Stimulator
88818170|NCT03193437|Experimental|Selinexor|Open Label Selinexor 40 mg
88818171|NCT01811147|Experimental|High Risk Depression|Interventions will include the prescribing of Selective serotonin reuptake inhibitor or Serotonin-norepinephrine reuptake inhibitor antidepressants, bupropion or other antidepressant.
88818172|NCT01811147|Experimental|Low Risk Depression|Interventions will include the prescribing of Selective serotonin reuptake inhibitor or Serotonin-norepinephrine reuptake inhibitor antidepressants, bupropion or other antidepressant..
88818173|NCT01811147|No Intervention|Healthy Control|There is no intervention, but rather phone follow ups conducted as check ins to determine the continued eligibility of the healthy control participant.
89362880|NCT06063759|Other|VitalDetectTM|Determination of microcirculating blood flow, glucose, SpO2, and heart rate.
89362881|NCT06063707||Survivors|Sepsis induced ARDS patients who survived
89362882|NCT06063707||Nonsurvivors|Sepsis induced ARDS patients who not survived
89362883|NCT06063668||patients|SLE patients
89362884|NCT06063668||controls|healthy controls
89362885|NCT06062134|Experimental|Pericapsular nerve group block group|All subjects enrolled in the study received a pericapsular nerve group block using a local anesthetic mixed with a contrast agent. After injection, subjects were transferred to the CT scan to obtain a 3D reconstruction to determine the spread of the injectate.
89362886|NCT06061458|No Intervention|control group|normal hearing
88834227|NCT04369326|Experimental|Community-Based TPT Initiation|All TB index patients who agree to participate will have a home visit by clinic staff who will perform: (1) contact enumeration (2) TB symptom screening of all children <15 years (3) Initiation of TPT for all asymptomatic children and (4) Referral of all symptomatic children less than 15 years, including those living with HIV. HIV testing will be offered to all child contacts 12 months of age and older. Those children less than 12 months will be referred to the clinic for HIV testing, if indicated by local guidelines. In South Africa, these home visits will occur by a combination of community health workers and professional nurses. In Ethiopia, home visits will occur by health extension workers supported by nurses.
88834228|NCT04369326|No Intervention|Facility-Based TPT Initiation|Children less than 15 years living in the home of TB index patients who agree to participate in the study will be referred to clinic for TB symptom screening and initiation of TPT for all asymptomatic child contacts. Symptomatic child contacts will be referred to a physician for evaluation, as is currently the standard of care. Additionally, child contacts identified in any maternal and child health program will be referred to the TB clinic for TB symptom screening. HIV testing will be offered at the clinic for all child contacts and will be performed according to local guideline.
88834229|NCT04348240||Group 1|asymptomatic or mildly symptomatic high-risk subjects with unknown SARS-CoV-2 status but with known history of close personal contact with a COVID-19 positive person.
88834230|NCT04348240||Group 2|asymptomatic or mildly symptomatic (e.g., low grade fever, mild malaise, minor sore throat, runny nose, or sneezing) subjects who are COVID-19 positive.
88834231|NCT04348240||Group 3|COVID-19 positive individuals retesting negative can be enrolled to complete the electronic questionnaire(s) and allow evaluation of history of symptoms.
88834232|NCT04348240||Group 4|COVID-19 positive individuals enrolled and admitted to the NIH Clinical Center for other protocols.
89001197|NCT00576550|Experimental|1:1|Part 1 of the study (maintenance part)
89001198|NCT00576550|No Intervention|1:2|Part 1 of the study (maintenance part)
89001199|NCT00576550|Experimental|2:1|Part 2 of the study (eczema part)
89001200|NCT00576550|Active Comparator|2:2|Part 2 of the study (eczema part)
89362887|NCT06061458|Experimental|the group with hearing aids|children with hearing aids
89362888|NCT06061458|Experimental|the group with cochlear implant|children with cochlear implant
89362889|NCT06061458|Experimental|the group with bimodal hearing|children with bimodal hearing
89362890|NCT06061237|Experimental|Aerobic Thai dance exercise intervention|Aerobic Thai dance exercise 60 minute per times, 3 times per weeks of 12 weeks.
89362891|NCT06061237|No Intervention|Control|Give advice on exercise.
89001201|NCT00576589|Experimental|CE-326,597|
89362892|NCT06059911|Experimental|Multi-ingredient dietary supplement|20 g of a multi-ingredient dietary supplement. Composition: 200 mg caffeine, 3.3 g creatine monohydrate, 3.2 g β-alanine, 6 g citrulline malate and 5 g BCAA
89362893|NCT06059911|Placebo Comparator|Placebo dietary supplement (97% maltodextrin)|20 g of isoenergetic placebo dietary supplement. Composition: 97% flavored maltodextrin, similar in color, flavor, taste and energy to the experimental multi-ingredient supplement
89362894|NCT06059664|Experimental|Finerenone|"Participants in this study arm will receive the study drug Finerenone.~Initial Dosing: Dosing regimen of 10 mg or 20 mg once daily (QD), based upon screening eGFR. For eGFR < 60 mL/min/1.73m^2, participants will start at 10 mg QD. For eGFR ≥ 60 mL/min/1.73m^2, participants will start at 20 mg QD.~Dose Titration: Dose will be titrated according to potassium levels. For participants initiated at 10mg, the dose will be up titrated to 20 mg if the potassium level measured after 2 weeks is ≤4.8 meq/L and eGFR has not decreased by >30 percent of the screening visit value. Study drug dosing may be titrated up or down per the below.~Potassium level: ≤ 4.8~If on lower dose, up-titrate to higher dose~If on higher dose, continue on the same dose~Potassium level: 4.9-5.5 = continue same dose~Potassium level: >5.5 = withhold study drug and recheck potassium within 3 days. Re-initiate study drug at the 10 mg dose once potassium is ≤4.8 meq/L."
89534572|NCT03329807|Experimental|Experimental rTMS and conventional sensory therapy|"Device: Repetitive Transcranial Magnetic Stimulation (rTMS) The subjects were seated in a comfortable chair with head and arm rests. Focal TMS of the somatosensory cortex was performed with a 70-mm figure-8 coil attached to magnetic stimulator stimulation parameters : frequency of 10Hz on the injured hemisphere by stroke; 1500 pulses with an intensity of 120% of MT 10 sessions of rTMS, one per day, always before conventional sensory therapy. rTMS it will be applied for about 20 minutes, five days per week.~Behavioral: conventional sensory therapy All patients will receive the same protocol of Sensory Therapy that will consist of the behavioral methods of Active Sensory Reeducation, Mirror Therapy and passive method that will consist in the administration of electric current by TENS (sensitive threshold). Participants will be instructed not to perform active muscular contraction during Interventions. The protocol it will be applied for about 60 minutes, five days per week."
89534573|NCT03329807|Sham Comparator|Sham Comparator|"control The control group received rTMS sham stimulation (same area as the experimental group) in 10 sessions, 5 days per week, and Sham conventional sensory therapy in the paretic upper limb The sham stimulation will be applied so that it is perceived by the patient as real. Thus during the rTMS sessions the same procedures of the active rTMS sessions will be applied, however the stimulation will be performed with two coils: a coil coupled to the stimulator positioned away from the patient's scalp, yet not visible to the patient so that the patient Perceive only the characteristic sound of the stimulation, and the other coil, disconnected from the stimulator positioned on the volunteer's head.~For the SHAM group, all sensory therapy activities will be performed, however only with the non-affected member. Patients will be convinced that a transfer of skills from one member to another can occur through the connections between the hemispheres."
89534574|NCT04467411||Breast Cancer Group|Breast Cancer Group
89534575|NCT04467411||Healthy Volunteer|Healthy Volunteer Group
89362895|NCT06059664|Placebo Comparator|Placebo|"Participants in this study arm will receive the placebo comparator.~Initial Dosing: Dosing regimen of 10 mg or 20 mg once daily (QD), based upon screening eGFR. For eGFR < 60 ml/min/1.73m^2, participants will start at 10mg QD. For eGFR ≥ 60ml/min/1.73m^2, participants will start at 20 mg QD.~Dose Titration: Dose will be titrated according to potassium levels. For participants initiated at 10 mg, the dose will be up titrated to 20 mg if the potassium level measured after 2 weeks is ≤4.8 meq/L and eGFR has not decreased by >30 percent of the screening visit value. Study drug dosing may be titrated up or down per the table below.~Potassium level: ≤ 4.8~If on lower dose, up-titrate to higher dose~If on higher dose, continue on the same dose~Potassium level: 4.9-5.5 = continue same dose~Potassium level: >5.5 = withhold study drug and recheck potassium within 3 days. Re-initiate study drug at the 10 mg dose once potassium is ≤4.8 meq/L."
89362896|NCT06059339||PENG Block and Spinal Anesthesia|The patients receive PENG block for postoperative pain management at the beginning of the surgery. TheLESP block will be provided with 20 ml 0,025% bupivacain under ultrasonography.
89362897|NCT06059339||Lumbar Erector Spinae Plain Block and Spinal Anesthesia|The patients receive LESP block for postoperative pain management at the beginning of the surgery. TheLESP block will be provided with 20 ml 0,025% bupivacain under ultrasonography.
89362898|NCT06059339||PENG Block and Lumbar Erector Spinae Plain Block and Spinal Anesthesia|The patients receive LESP block and PENG block for postoperative pain management at the beginning of the surgery. The LESP block and PENG block will be provided with 20 ml 0,025% bupivacain each under ultrasonography.
89362899|NCT06059313||Behavioral variant of frontotemporal disorder (bvFTD)|A group of participants who fulfill Rascovsky criteria (2011) for behavioural variant Frontotemporal Dementia
89362900|NCT06059313||Phenocopy frontotemporal dementia (phFTD)|A group of participants who fulfill who fulfill Rascovsky criteria (2011) for possible behavioural variant Frontotemporal Dementia and have no imaging abnormalities.
89362901|NCT06059313||Frontal variant of Alzheimer disease|A group of participants who fulfill Ossenkopele criteria (2022)
89362902|NCT06059313||Bipolar disorder|A group of participants who fulfill CIM 10 criteria
89362903|NCT06056232|Experimental|MIED group|Mindfulness Intervention for Emotional Distress (MIED) program provides standard audio instructions for mindfulness exercises, introduces the nature and law of anxiety, depression, and other emotions, the source of anxiety, depression, and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge, and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression, and other emotional problems.
89362904|NCT06056232|Experimental|MIED+DT group|The increase in distress tolerance dosage involves incorporating additional psychoeducational content related to distress tolerance and corresponding exercises to enhance distress tolerance within the MIED (Mindfulness Intervention for Emotional Distress) program.
88834233|NCT04337515|Experimental|Patients receiving allogeneic hematopoietic cell transplant|"The test product is a stem cell product which has been alpha-beta T- cell depleted using the CliniMACS system. Alpha-beta T-cell depleted cells are given intravenously over a period of time as dictated by the final volume of the infused product (5 ml/kg/hour).~The target dose of CD34+ cells is ≥20x10^6/kg, but a minimum of~≥2.5x10^6/kg is required. The target dose of T-cell receptor (TCR) alpha-beta CD3+ cells is ≤1x10^5/kg."
88834234|NCT04334135|Experimental|MitoQ|Participants will have sympathetic nerve activity, vascular function, blood pressure and blood samples (from intravenous catheters) assessed before and after acute MitoQ supplementation (80 - 160mg).
88834235|NCT04334135|Placebo Comparator|Placebo|Participants will have sympathetic nerve activity, vascular function, blood pressure and blood samples (from intravenous catheters) assessed before and after a placebo matched in appearance to the MitoQ.
88834236|NCT04333303|Experimental|Advance Care Planning Program|Implementation of a complex regional Advance Care Planning program.
88834237|NCT04333303|No Intervention|Care as usual|
88834238|NCT04318028|Experimental|Diagnostic (7 Tesla MRI)|Patients undergo 7 Tesla MRI over 30-90 minutes at baseline and 6-9 months.
88834239|NCT04316715|Experimental|Life-Steps for PreP|Participants in this group will receive standard of care treatment plus daily text message reminders. A subset of participants who demonstrate continued adherence challenges will also receive 4-6 weekly sessions of the Lifesteps for PrEP intervention.
88834240|NCT04316715|No Intervention|Standard of Care|Participants in this group will not receive an intervention outside the standard of care.
88834241|NCT04316702|Active Comparator|Hyperbaric Oxygen|60 daily hyperbaric oxygen treatment sessions will be administrated 5 days per week. Each session will include exposure of 90 minutes to 100% at 2 ATA, with 5 minutes air breaks every 20 minutes
89362905|NCT06056232|Experimental|MIED-DT group|The decrease in distress tolerance dosage entails reducing exercises related to distress tolerance within the MIED, such as interoceptive exposure exercises and challenging tasks.
88834242|NCT04316702|Active Comparator|Pharmacotherapy|Two medications currently licensed for the treatment of FM in Israel, i.e. Cymbalta and Lyrica. Treatment with Lyrica will start at a dose of 75 mg twice a day, at morning and at bedtime, while treatment with Cymbalta will start at a dose of 30 mg a day (in the morning). After a period of 2 weeks, patients will be evaluated and dose will be adjusted as necessary and tolerated, up to the maximum dosage recommended for FM. Patients may also be switched from one medication to the other according to clinical judgment of the physician.
88834243|NCT04315506|Experimental|SGR|Scheduled gradual reduction. Participants are asked to gradually reduce smokeless tobacco usage.
88834244|NCT04315506|Active Comparator|Control group|Participants in this arm will be given the Enuff Snuff cessation manual.
88834245|NCT04313751|Experimental|Education, Physical Activity, and Stress Management Program|Classes for the intervention group will be run by a bilingual interventionist and will last 120 minutes weekly for 12 weeks and then monthly for 3 months.
88834246|NCT04313751|Active Comparator|Wait-list Control|Data in the wait-list control group will be collected at the same time intervals as the intervention group. After Time 3 data collection, they will be offered the Phase I intervention (12 weekly sessions).
88834247|NCT04313296|Experimental|Patients identified at PBMC with a documented diagnosis of AF|Patients identified at PBMC with a documented diagnosis of AF (at any point in time) and who have undergone any cardioversion.
88834248|NCT04307446|Experimental|10 Minutes/20 Minutes|Subject takes part in 10 minute VR experience first and 20 minute VR experience second
88834249|NCT04307446|Experimental|20 Minutes/10 Minutes|Subject takes part in 20 minute VR experience first and 10 minute VR experience second
88834250|NCT04292457|Experimental|Propofol|Anesthesia is maintained with Propofol
88834251|NCT04292457|Experimental|Sevoflurane|Anesthesia is maintained with Sevoflurane
88834252|NCT04274179|Experimental|Diet therapy|Modified Atkins Diet - high fat, low carbohydrate, outpatient initiated approach. Parents will check urine ketones twice weekly and follow by email, phone and clinic. Labs at baseline and 3 months. Dietitian support.
88834253|NCT04274179|Active Comparator|Drug therapy|Families will have the usual care for absence epilepsy at the discretion of the family's neurologist and the family choice. Typically ethosuximide bis in die (BID), however, if convulsions have occurred or other factors are involved, the child may be started on valproate or lamotrigine. The child will continue medications with dose adjustment and antiseizure drug levels checked as usual. **OF NOTE, THIS ARM IS COMPLETED
88834254|NCT04273932|Experimental|Lithium aspartate 15mg a day|15mg of elemental lithium administered every morning by mouth.
88834255|NCT04273932|Experimental|Lithium aspartate 45mg a day|20mg every morning and 25mg every evening of elemental lithium administered by mouth.
88834256|NCT04273932|Experimental|Lithium carbonate|The dose will be titrated based on weekly blood tests to achieve a target serum level of 0.40-0.50mmol/L, which represents an elemental lithium dose of about 85-170mg a day.
88834257|NCT04273932|No Intervention|No lithium treatment|Control arm
88834258|NCT04273594|Experimental|FemBloc|Investigational device and procedure
88834259|NCT04272086|Placebo Comparator|Bupivacaine TAP|TAP block with 30 mL 0.25% bupivacaine mixed with 10 mL normal saline for a total of 40 mL per side
88834260|NCT04272086|Experimental|Liposomal bupivacaine TAP|TAP block with 10mL liposomal bupivacaine, 20mL 0.25% bupivacaine, and 10mL normal saline for a total of 40 mL per side
88834261|NCT04267705|Active Comparator|Black bean|A cup of black bean 7 days/week over a 12-week period
88834262|NCT04267705|Active Comparator|Chickpea|A cup of chickpea 7 days/week over a 12-week period
88834263|NCT04267705|Placebo Comparator|Control|A cup of white rice 7 days/week over a 12-week period
88834264|NCT04264572|Experimental|Medically Tailored Meals (MTM)|Participants in this arm will receive MTM for 12 weeks. Meals will be prepared and delivered by MANNA, a non-profit organization that has provided MTM for patients with chronic illnesses in Philadelphia and Southern New Jersey since 1990. MANNA will deliver 21 complete meals to the patient's home each week, providing 45-60 grams of carbohydrates per meal for optimal glucose control based on ADA guidelines and 100% of overall nutritional requirements based on USDA guidelines. In addition, children and any senior dependents for whom the participant is the primary caregiver will receive meals for the entire 12 weeks for no additional cost, as this is standard of care of MANNA services. MANNA registered dieticians will cater the program to meet the specific needs (e.g., dietary restrictions, cultural preferences). Investigators will provide information on community resources in the area, including food resources, for all patients.
89001202|NCT00576589|Placebo Comparator|Placebo|
89001203|NCT00576706|Experimental|1|
89001204|NCT00576706|Active Comparator|2|
89001205|NCT00576745|Active Comparator|1 Vicryl Suture|Patients will have their incision closed with vicryl suture
89001206|NCT00576745|Experimental|2 Steri-Strips|Patients will have their incisions closed with 3M Surgical-Strips
89362906|NCT06055205|Experimental|PAC-plan|"The patients receive a Pain- and Coordination plan (PAC-plan) at discharge from the hospital. The PAC-plan includes:~Upon discharge, patients have a patient-centered conversation and receive written information covering patient education on opioids, a tapering plan, and a plan for contact and follow-up with the general practitioner. The information is based on the Norwegian National Guide for Addictive Medications.~Before discharge, patients are scheduled an appointment with the GP, preferably within the first 2 weeks (2-4 weeks), for a follow-up regarding the injury and pain management.~The GP is invited to maintain contact with the study nurse at the hospital for one year. The general practitioner can call for consultation with the study nurse, and if necessary, be connected with relevant medical specialists for advice and eventually further follow-up."
89362907|NCT06055205|No Intervention|Control|Treatment and follow-up as usual.
89362908|NCT06054997||lower dose UFH/kg group|UFH below or equal to 60 IU/kg/surgery
89362909|NCT06054997||higher dose UFH/kg group|UFH above 60 IU/kg/surgery
89362910|NCT06051656||Case group|Any adult patient with severe hand and wrist spasticity or contracture who suffers from a refractory pain, and is already candidate for cryoneurolysis.
89362911|NCT06051149|Active Comparator|Epidural Catheter|procedure Will be performed under sterile precautions utilizing fluoroscopy, RK needle.patient will be placed prone with a pillow under the abdomen.The sacral area draped from the top of the iliac crest to the bottom of the buttocks.The sacral Corns and the sacral hiatus will be palpated,is in the gluteal fold opposite the affected side will be infiltrated with lidocaine16gauge RK needle will be passed through the described entry point advanced to a point below the S3foramen to prevent S3nerve root damage.Placement will be confirmed by lateral and anteroposterior fluoroscopic views and after aspiration is negative for blood and CSF10mL of iohexol will be injected under fluoroscopy.Once the needle placement is confirmed to be in the epidural space, a lumbar epidurogram will be carried out utilizing approximately2to5 mL of contrast. then the bevel of the needle should face the ventrolateral aspect of the caudal canal.
89362912|NCT06051149|Active Comparator|RACZ Catheter|same as procedure described above but using RACZ Catheter set
89362913|NCT06051149|Active Comparator|NAVI catheter|same as procedure described above but using NAVI Catheter set
89362914|NCT06044298||Gastrointestinal procedural sedation|Investigators will include in our study patients aged 60 and over who have been evaluated in the pre-anesthesia clinic for procedures such as endoscopy, colonoscopy, ERCP, PEG, EUS, and ESD, and who have received sedation by an anesthesiologist. Patients will be assessed for frailty prior to the procedure; during and after the procedure, respiratory monitoring (SpO2, capnography) will be closely observed, and they will be contacted by phone three days later.
89362915|NCT06041932|Experimental|Pentoxiphylline plus Carvedilol|Pentoxiphylline plus Carvedilol
89362916|NCT06041932|Active Comparator|Carvedilol|PCarvedilol
89362917|NCT06040424|Experimental|Ipratropium / Levosalbutamol Fixed Dose Combination|"In this one-day study, patients will be administered 2 inhalation of İPRALEV 20 mcg/50 mcg aerosol inhalasyonu, süspansiyon at morning."
89362918|NCT06040424|Active Comparator|Ipratropium + Levosalbutamol Free Dose Combination|"In this one-day study, patients will be administered 2 inhalations of VENTOLİN İnhaler 100 mcg and then 2 inhalations of ATROVENT MDI 0,02 mg/dose at morning."
89001207|NCT00576784|Active Comparator|A|pioglitazone/glimepiride
89001208|NCT00576862|Experimental|1|
89362919|NCT06038825|Active Comparator|topical vibration|For all patients one half of the scalp was injected with vibration device.
88818174|NCT01811147|No Intervention|Bipolar|Bipolar participants are checked in with via phone conversations every three months, and have the opportunity to be scheduled for non-study visits to manage their symptoms.
89362920|NCT06038825|No Intervention|control|Same patient's other side of the scalp was injected without vibration device.
89362921|NCT06037187||Immune-mediated condition|Participants with an immune-mediated condition
89001209|NCT00576940|Experimental|IMEN: 1|Enteral nutrition with immunostimulating diet (IMEN group: formula supplemented with arginine, glutamine, omega-3 fatty acids)
89362922|NCT06037187||Without immune-mediated dermatologic condition|Participants without an immune-mediated dermatologic condition
89362923|NCT06036823|Active Comparator|5 units of intravenous R insulin|"Will receive:~IV Insulin Regular 5 units with Dextrose 50 % 50 ml over 30 minutes. Salbutamol 10 mg Nebulization over 15 minutes."
89362924|NCT06036823|Active Comparator|10 units of intravenous R insulin|"Will Receive:~IV Insulin Regular 10 units with Dextrose 50 % 50 ml over 30 minutes. Salbutamol 10 mg nebulization over 15 minutes."
89362925|NCT06023836|Active Comparator|group 1: ESWT treatment|Participants in this group will only receive ESWT treatment
89362926|NCT06023836|Active Comparator|Dry needling|Participants in this group will only receive Dry needling treatment
89362927|NCT06023823|Active Comparator|Toe spread out treatment|
89362928|NCT06023823|Active Comparator|Dry needling|
89362929|NCT06023264|No Intervention|Control|
89001210|NCT00576940|Active Comparator|SEN|postoperative enteral nutrition - standard oligopeptic diet
89362930|NCT06023264|Experimental|dry needle|
88818175|NCT01373450|Experimental|OXM → Lg-0.6 → Pbo → Lg-1.2|Participants received Oxyntomodulin 3.0 pmol/kg/min in the first, Liraglutide 0.6 mg in the second, Placebo in the third, and Liraglutide 1.2 mg in the fourth period
88818176|NCT01373450|Experimental|Lg-0.6 → Pbo → OXM → Pbo|Participants received Liraglutide 0.6 mg in the first, Placebo in the second, Oxyntomodulin 3.0 pmol/kg/min in the third, and Placebo in the fourth period
88818177|NCT01373450|Experimental|Pbo → OXM → Lg-0.6 → Pbo|Participants received Placebo in the first, Oxyntomodulin 3.0 pmol/kg/min in the second, Liraglutide 0.6 mg in the third, and Placebo in the fourth period
88818178|NCT01373450|Experimental|Lg-0.6 → OXM → Pbo → Lg-1.2|Participants received Liraglutide 0.6 mg in the first, Oxyntomodulin 3.0 pmol/kg/min in the second, Placebo in the third and Liraglutide 1.2 mg in the fourth period
88818179|NCT01373450|Experimental|OXM → Pbo → Lg-0.6 → Pbo|Participants received Oxyntomodulin 3.0 pmol/kg/min in the first; Placebo in the second, Liraglutide 0.6 mg in the third, and Placebo in the fourth period
89001211|NCT00577018|Active Comparator|1|
89001212|NCT00577018|Active Comparator|2|
89362931|NCT06021990|Experimental|Clopidogrel group|The clopidogrel group will receive the intervention under study (clopidogrel 75mg once daily post-meal) for the study period along with the standard of care treatment as approved by the hospital based on national and international guidelines.
89362932|NCT06021990|No Intervention|Standard of Care|The standard of care will receive treatment as approved by the hospital based on national and international guidelines.
89362933|NCT06007755||Delirium is determined by 3D-CAM score|
88834265|NCT04264572|Experimental|MTM + tele-Medical Nutrition Therapy (MNT)|Patients in this arm will receive MTM services as well as tele-MNT over 12 months. The tele-MNT intervention will be delivered by a registered dietician within the Jefferson endocrine clinic, with assistance by other endocrine dieticians and fellows. In the first months, video visits focus on supporting individuals who are not selecting, preparing or purchasing their own meals. As the end of MTM services approaches, the intervention shifts to focus on the transition from MTM to self-directed eating. Based on Academy of Nutrition and Dietetics recommendations, each participant's MNT will include the following core features: nutrition assessment, intervention, care coordination, monitoring and evaluation. The following will also be addressed: nutrition prescriptions, nutrient intake, energy intake, glycemic index and load, alcohol consumption and physical activity. The schedule includes individual visits in the first 6 months and monthly group session in months 7-12.
89001213|NCT00577018|Placebo Comparator|3|
89001214|NCT04578847|Experimental|The TKI dose reduction|Imatinib, nilotinib, dasatinib or bosutinib; the two stage of TKI dose reduction phase for 12 months (6 months and 6 months, respectively).
89362934|NCT06007755||No delirium is determined by 3D-CAM score|
89362935|NCT06007378|Other|Bupivacaine and ketamine|
89362936|NCT06007378|Other|Bupivacaine and transdermal fentanyl patch|
89362937|NCT06007378|Other|Bupivacaine|
89362938|NCT05999279||Patient|Convenient sampling of patients who took at least one medication in the past month
89362939|NCT05996302|Active Comparator|6-minute walk distance at 2840m|Participants will have 6-minute walk distance (6MWD) assessment near their resident altitude at 2840m
89362940|NCT05996302|Experimental|6-minute walk distance at sea level|Participants will have 6-minute walk distance (6MWD) assessment at sea level (0-30m)
89362941|NCT05983679||Adults|
89362942|NCT05967819|No Intervention|Control|Participants will be asked to maintain their usual physical activity and lifestyle habits.
89362943|NCT05967819|Experimental|Exercise Stress|The duration of participant's weekly running or cycling mileage will be increased by 30% while intensity is maintained.
89362944|NCT05967819|Experimental|Psychosocial Stress|Participants will be asked to complete cognitive function tasks designed to be stressful while maintaining their usual physical activity habits.
89362945|NCT05967819|Experimental|Exercise + Psychosocial Stress|Participants will be asked to complete cognitive function tasks designed to be stressful while the duration of their weekly running or cycling mileage is increased by 30% and intensity maintained.
89001215|NCT00577174||1. Controls|Healthy children ages 8 to 18 years
89001216|NCT00577174||2. Obese childrens|Obese children, ages 8 to 18 years
89001217|NCT00187005|Other|1|
89001218|NCT00180401||QRS 120-150 ms|Subjects with a QRS width between 120-150 ms
89362946|NCT05946018|Other|Education only|This arm only includes a 6-8 minute educational video on ergonomics.
89362947|NCT05946018|Other|Education and coaching sessions|This arm includes a 6-8 minute education video on ergonomics and 1:1 15 minute coach sessions at 0, 2, 4, and 6 weeks.
89362948|NCT05910294|Active Comparator|standard of care|Standard of care arm will receive treatment at the time symptoms develop. Patients will be provided a list of recommended moisturizers by the female sexual medicine and women's health program (FSMWHP), but will purchase the moisturizers themselves at their local pharmacy.
89362949|NCT05910294|Experimental|intervention|Patients who are randomized to the upfront arm will receive sexual health counseling and be initiated on non-hormonal moisturizers 3-5 times per week (based on data regarding need in our patient population) at the time ovarian suppression. The upfront intervention group will also be educated about dilators and have a consultation with a pelvic floor physical therapist. Some potential vaginal moisturizers include Hyalogyn, Replens, Liquibeads, or Vitamin E capsules.
89362950|NCT05909020||Patients|Approximately 150 adults referred for suspected HNC will be recruited.
89001219|NCT00180401||QRS >150 ms|Subjects with a QRS width >150 ms
89001220|NCT00577252||1|Adolescents with CF.
89362951|NCT05909020||Staff|Approximately 15 ENT and Maxillofacial) clinicians will be recruited.
89362952|NCT05907993|No Intervention|Group (A):|30mg ketorolac in 200cc normal saline intravenously every 6hours for 24hours postoperatively.
89362953|NCT05907993|Active Comparator|Group (B):|800mg ibuprofen in 200cc normal saline intravenously every 6 hours for 24hours postoperatively.
89362954|NCT05897619|Experimental|Maya Perinatal Cognitive Behavioral Skills App|Participants receive the Maya Perinatal Cognitive Behavioral Skills App for 6 weeks.
89362955|NCT05890898|Experimental|Control: Nitrous Oxide, then Virtual Reality Goggles|Control group will receive the standard of care dental treatment with under nitrous sedation (N2O) and will have a second visit where Virtual Reality(VR) goggles will be used instead of N2O.
89362956|NCT05890898|Experimental|Treatment: Virtual Reality Goggles, then Nitrous Oxide|The treatment group will receive the standard of care dental treatment with VR googles first and will have a second visit under N2O will be used instead of VR.
89362957|NCT05875948|Experimental|An Open-Label Safety Run-In Part|"Three initial cohorts (Cohort 1, N=3 patients, Cohorts 2 and 3, N=6 patients, each) will be treated with an open-label combination of terlipressin and R2R01 to ascertain the safety of the combination therapy.~A Safety Review Committee (SRC) will review the safety of Cohort 1 patients based on the adverse events and laboratory abnormalities up until Day 14, prior to the start of recruitment of Cohort 2 patients, as well as the safety of Cohorts 1 and 2 patients up until Day 14 prior to the start of recruitment of Cohort 3 patients.~Data from all Cohorts 1, 2, and 3 patients up until Day 14 will be reviewed by the SRC before starting the randomized part of the study (Cohorts 4 and 5), so that the SRC can decide and confirm the most appropriate R2R01 dose schedule for patients in Cohorts 4 and 5. Patients enrolled in Cohorts 1, 2, or 3 will remain in their Cohort until study completion (Day 90) or study discontinuation."
89362958|NCT05875948|Placebo Comparator|Single-blind Placebo-controlled Randomized period|"After conclusion of the open-label safety run-in part, and after the SRC has determined the appropriate R2R01 dose schedule, approximately 80 patients will receive terlipressin and be randomized 1:1 to either R2R01 (Cohort 4) or placebo (Cohort 5).~At randomization, patients will be stratified by the presence of systemic inflammatory response syndrome (SIRS), since patients with SIRS have shown a better response to terlipressin than patients without SIRS."
89362959|NCT05875948|Experimental|An Open-Label Terlipressin Non-Responder Cohort|In Cohort 5, if patients do not respond to terlipressin, they must discontinue Cohort 5. After discontinuation, they will be allowed to enter Cohort 6 (Terlipressin Non-Responder Part) to receive R2R01 with the same dosing and schedule as that for Cohort 4. No patient from any Cohort other than Cohort 5 will be allowed to enter Cohort 6.
89362960|NCT05864521|Active Comparator|Active Beetroot Juice Supplement (aBRJ) then Placebo Beetroot Juice Supplement (pBRJ)|Subjects randomized to this arm of the study will have aBRJ administered during Visit 2 and then pBRJ administered during Visit 3.
89362961|NCT05864521|Active Comparator|Placebo Beetroot Juice Supplement (pBRJ) then Active Beetroot Juice Supplement (aBRJ)|Subjects randomized to this arm of the study will have pBRJ administered during Visit 2 and then aBRJ administered during Visit 3.
89362962|NCT05852041|Experimental|Treatment (rhPSMA, PET-MRI, mpMRI)|Patients receive rhPSMA-7.3 IV then undergo PET-MRI and mpMRI of the prostate on study. Patients also undergo Decipher test at screening and MRI-PET prostate biopsy or radical prostatectomy within 90 days per standard of care.
89362963|NCT05802602|Experimental|Porcine Collagen Membrane|Atraumatic tooth extraction with porcine collagen membrane placement
89362964|NCT05802602|Active Comparator|Bovine Collagen Dressing|Atraumatic tooth extraction with bovine collagen dressing placement
89362965|NCT05788367|Active Comparator|The pericapsular nerve group|patients received Ultrasound guided The pericapsular nerve group block using 20 ml of bupivacaine 0.5%
89362966|NCT05788367|Active Comparator|Interscalene group|patients will receive interscalene brachial plexus block using 15 ml of bupivacaine 0.5% before induction of general anesthesia.
89362967|NCT05777187|Experimental|Clinical Decision Support|Clinical decision support alerts in the electronic health record directed towards anesthesiologists caring for patients with preexisting cognitive impairment.
89362968|NCT05777187|No Intervention|Standard of Care|No clinical decision support will appear, and standard of care procedures will take place.
89362969|NCT05758181|No Intervention|Linear Wound Closure|A cutaneous layer of sutures will be placed on one side, as is standard of care.
89362970|NCT05758181|Experimental|Linear Wound Closure with Apical Undermining|The other side of the wound will have a cutaneous layer of sutures, as is standard of care, and will receive apical undermining.
89362971|NCT05749952|Active Comparator|Standard of Care - Non-Weight Bearing (Socket A)|A non-digital weight-bearing socket will be used to create the check socket (temporary socket), which will be used to create a laminated final socket for home use and research outcomes. The check socket is temporarily used; whereas, the final socket is for long-term use.
89362972|NCT05749952|Experimental|Symphonie Aqua System - Non-Digital (Socket B)|We will digitally capture (via computer) the shape of your limb, which will create a digital file (computer file) of what the internal shape of your socket should be. This file will then be used with a computer software program to optimize the fit of your prosthesis. This image will be used to create a check socket (temporary socket) to confirm a correct anatomical and comfortable socket. Then the check socket (temporary socket) will be used to create a laminated final socket for home use and research outcomes. The check socket is temporarily used; whereas, the final socket is for long-term use.
89362973|NCT05735717|Experimental|Fludarabine (flu), Total Body Irradiation (TBI), Flu/TBI Regimen|Patients will be treated on the most medically appropriate regimen with a preference for Flu/TBI Arm followed by an infusion at Day 0 of Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells.
89362974|NCT05735717|Experimental|Fludarabine (flu), Busulfan (bu), Flu/Bu Regimen|Patients will be treated on the most medically appropriate regimen with a preference for Flu/TBI Arm followed by an infusion at Day 0 of Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells.
89362975|NCT05735717|Experimental|Fludarabine (flu), Busulfan (bu), Melphalan (Mel) Regimen for Pediatric Patients Only|Flu/Bu/Mel will the preference for patients with JMML or infants with leukemia.
89362976|NCT05734937|Experimental|gastric assessment of gastric volume|ultrasound assessment of gastric volume in Preoperative and postoperative period in right lateral decubitus position in pediatric patients
89362977|NCT05723276|Experimental|Study arm|Psilocybin with therapeutic support
89534576|NCT02491229|Other|"Hepafast"|"This group consumes three portions of Hepafast and additionally 200 kcal of vegetables for two weeks. In the following ten weeks, they consume two portions of Hepafast and one meal which follows the instructions of the Low Glycemic and Insulinemic Diet (LOGI)."
89001221|NCT00577330|Experimental|Myalgesin|Subjects receive Myalgesin twice daily
89001222|NCT00577330|Active Comparator|Acetaminophen|Subjects receive acetaminophen 1000 mg three times a day
89534577|NCT02491229|Other|Control|This group follows the instruction of the LOGI diet for the entire 12 weeks
89534578|NCT03329729||Hyperlipidemic patients|
89534579|NCT05038683|Experimental|HOT|Holbæk Obesity Treatment
89534580|NCT05038683|Active Comparator|COT|Conventional Obesity Treatment
89001223|NCT04579003|Experimental|Mobilization|Mobilization, heat application, ultrasound, TENS
89001224|NCT04579003|Active Comparator|Mobilization with movement|Mobilization with movement, heat application, ultrasound, TENS
89362978|NCT05711524|Active Comparator|Patients given Traditional Cryo|These are the liver transplant and cardiothoracic (LT and CT) patients that will be given traditional cryo based on the randomization protocol. The blood bank will alternate use of PR cryo and regular cryo each month for all patients with a cryo order. All patients will receive either traditional cryo or PR cryo in a given month.
89362979|NCT05711524|Experimental|Patients given PR Cryo|These are the liver transplant and cardiothoracic (LT and CT) patients that will be given PR cryo based on the randomization protocol. The blood bank will alternate use of PR cryo and regular cryo each month for all patients with a cryo order. All patients will receive either traditional cryo or PR cryo in a given month.
89362980|NCT05709912|Experimental|CARE App|"Participants randomized to the CARE app + usual care will complete the following:~Questionnaires at baseline, Day 10, Day 60, and Day 100 post-HCT~use the CARE app from enrollment up to 60 days post-HCT: the CARE app includes 5 contains 5 modules and a 6th optional module~receive usual care as per HCT practice which entails meeting with a transplant social worker prior to HCT and as needed for extra visits"
89362981|NCT05709912|Active Comparator|Usual Care|"Participants randomized to usual care will complete the following:~Questionnaires at baseline, Day 10, Day 60, and Day 100.~receive usual care as per HCT practice, which entails meeting with a transplant social worker prior to HCT and as needed for extra visits."
89362982|NCT05706857|Experimental|Ultra fast-track|Patients are extubated in the operating room after the procedure
89362983|NCT05706857|Active Comparator|Conventional extubation|Patients are extubated in the intensive unit care
89178278|NCT00783198|Placebo Comparator|Placebo|Participants receive placebo matching ambrosia artemisiifolia allergen extract, rapidly dissolving tablets, administered once daily sublingually for approximately 52 weeks
89362984|NCT05697705||Population A|For evaluating second booster doses
89362985|NCT05697705||Population B|For evaluating first booster doses
89362986|NCT05690971|Experimental|Horizons mobile app|"Participants randomly assigned to the Horizons group, will use the Horizons app over an eight-week period in addition to receiving usual care from transplant team.~Participants will complete study questionnaires at the time of enrollment (baseline) and at eight and sixteen weeks after enrollment"
89362987|NCT05690971|Active Comparator|Usual Care|"Participant in the usual care group will receive usual care from the transplant oncology team including all the supportive care measures implemented by the transplant oncology team.~Participants will complete study questionnaires at the time of enrollment (baseline) nad at eight and sixteen weeks after enrollment"
89178279|NCT00789360|Experimental|Inhaled Placebo crossed over to Inhaled Loxapine|Inhaled Staccato Placebo, 2 inhalations, 8 hours apart; washout of at least 4 days; Inhaled Staccato Loxapine, 10 mg oses x 2, 8 hours apart
89362988|NCT05681195|Experimental|Induction Therapy + SOC Treatment|"Participants will receive the induction therapy (oral zanubrutinib + IV pemetrexed) and be placed into one of the cohorts according to standard of care (SOC) treatment:~Cohort 1: Induction Therapy + Autologous Stem Cell Transplant (ASCT) After completion of the induction therapy, ASCT candidates will undergo transplant as per SOC. If the transplant is delayed and 8 induction cycles have been completed, oral zanubrutinib maintenance will proceed until transplant, but will not occur after transplant.~Cohort 2: Induction Therapy + Whole Brain Radiation Therapy (WBRT) After completion of the induction therapy, WBRT candidates will undergo WBRT as per SOC. Oral zanubrutinib maintenance will start 7-10 days after the completion of WBRT. 28-d maintenance cycles will continue until disease progression.~Cohort 3: Induction Therapy Alone After completion of the induction therapy, 28-day oral zanubrutinib maintenance cycles will begin and continue until disease progression"
89362989|NCT05658107|Experimental|BI 765423 treatment group|BI 765423
89178280|NCT00789360|Experimental|Inhaled Loxapine crossed over to Inhaled Placebo|Inhaled Staccato Loxapine, 10 mg doses x 2, 8 hours apart; washout of at least 4 days; Inhaled Staccato Placebo, 2 inhalations, 8 hours apart;
89362990|NCT05658107|Placebo Comparator|Placebo group|Placebo
89362991|NCT05653986||Ubrogepant + Atogepant|Participants will receive ubrogepant in combination with atogepant as prescribed by their physician in routine clinical practice.
89362992|NCT05641623|Active Comparator|OSU6162|White, circular, coated tablets. Flexible dosage: the starting dose will be 15 mg TID and the maximal dose 45 mg TID.
89178281|NCT04022538|Experimental|Sandwich osteotomy with simultaneous implant placement|This group will undergo Sandwich osteotomy procedure and segment will be fixed using the dental implants placed simultaneously during the same surgical procedure. The remaining gap will be filled using xenograft.
89362993|NCT05641623|Placebo Comparator|Placebo|Coated tablets, flexible dosage, TID
89362994|NCT05635201|Active Comparator|Propofol group|Receives propofol for anesthesia induction
89362995|NCT05635201|Experimental|Remimazolam group|Receives remimazolam for anesthesia induction
89362996|NCT05631119||Diabetic Kidney Disease|"Sample Collection:~Whole blood will be collected in 3 x 5 mL SST tubes. The samples will be centrifuged into 5 x 1 mL serum aliquots. The aliquots will be shipped frozen (with dry ice) overnight to Novo Nordisk via FedEx Priority Overnight by 10:30 am.~Whole blood will be collected in 4 x 10 mL and 1 x 4 mL sodium heparin tubes. The samples will be shipped ambient overnight to Sanguine Labs via FedEx Priority Overnight by 10:30 am. Sanguine Labs will process the samples for PBMC isolations at 10 million cells per aliquot. Samples will be stored for batch shipment at the end of the study. The PBMC aliquot(s) will be shipped overnight using liquid nitrogen (LN2) to Novo Nordisk via FedEx Priority Overnight by 10:30 am.~Urine will be collected using a Vacuette collection device. The sample will be shipped frozen (with dry ice) overnight to Novo Nordisk via FedEx Priority Overnight by 10:30"
89362997|NCT05631119||Chronic Kidney Disease|"Sample Collection:~Whole blood will be collected in 3 x 5 mL SST tubes. The samples will be centrifuged into 5 x 1 mL serum aliquots. The aliquots will be shipped frozen (with dry ice) overnight to Novo Nordisk via FedEx Priority Overnight by 10:30 am.~Whole blood will be collected in 4 x 10 mL and 1 x 4 mL sodium heparin tubes. The samples will be shipped ambient overnight to Sanguine Labs via FedEx Priority Overnight by 10:30 am. Sanguine Labs will process the samples for PBMC isolations at 10 million cells per aliquot. Samples will be stored for batch shipment at the end of the study. The PBMC aliquot(s) will be shipped overnight using liquid nitrogen (LN2) to Novo Nordisk via FedEx Priority Overnight by 10:30 am.~Urine will be collected using a Vacuette collection device. The sample will be shipped frozen (with dry ice) overnight to Novo Nordisk via FedEx Priority Overnight by 10:30 am"
89534581|NCT02492477|Experimental|6 months|evaluation of PORT-A-CATH®, blocking with Medunasal®-Heparinblock, restoration of PORT-A-CATH® with Alteplase
89534582|NCT02492477|Experimental|12 months|evaluation of PORT-A-CATH®, blocking with Medunasal®-Heparinblock, restoration of PORT-A-CATH® with Alteplase
89534583|NCT03095547|Experimental|F901318 & cyclosporine A & tacrolimus|Interaction between cyclosporine A and tacrolimus with F901318
89534584|NCT03095547|Experimental|F901318 & posaconazole|Interaction between posaconazole and F901318
88818180|NCT01373450|Experimental|Pbo → Lg-0.6 → OXM → Lg-1.2|Participants received Placebo in the first, Liraglutide 0.6 mg in the second, Oxyntomodulin 3.0 pmol/kg/min in the third, and Liraglutide 1.2 mg in the fourth period
88818181|NCT04749719|Experimental|DLPFC stimulation|F3-SO montage or OLE optimized with 2 mA stimulation for up to 30 min during memory and metamemory task.
88818182|NCT04749719|Sham Comparator|Sham tDCS|F3-SO montage or OLE optimized with sham stimulation for up to 30 min during memory and metamemory task.
89362998|NCT05631119||Type 2 Diabetes|"Sample Collection:~Whole blood will be collected in 3 x 5 mL SST tubes. The samples will be centrifuged into 5 x 1 mL serum aliquots. The aliquots will be shipped frozen (with dry ice) overnight to Novo Nordisk via FedEx Priority Overnight by 10:30 am.~Whole blood will be collected in 8 x 10 mL and 1 x 4 mL sodium heparin tubes. The samples will be shipped ambient overnight to Sanguine Labs via FedEx Priority Overnight by 10:30 am. Sanguine Labs will process the samples for PBMC isolations at 10 mL cells per aliquot. Samples will be stored for batch shipment at the end of the study. The PBMC aliquot(s) will be shipped overnight using liquid nitrogen (LN2) to Novo Nordisk via FedEx Priority Overnight by 10:30 am.~Urine will be collected using a Vacuette collection device. The sample will be shipped frozen (with dry ice) overnight to Novo Nordisk via FedEx Priority Overnight by 10:30 am."
89362999|NCT05631119||Healthy Matched Controls|"Sample Collection:~Whole blood will be collected in 3 x 5 mL SST tubes. The samples will be centrifuged into 5 x 1 mL serum aliquots. The aliquots will be shipped frozen (with dry ice) overnight to Novo Nordisk via FedEx Priority Overnight by 10:30 am.~Whole blood will be collected in 16 x 10 mL and 1 x 4 mL sodium heparin tubes. The samples will be shipped ambient overnight to Sanguine Labs via FedEx Priority Overnight by 10:30 am. Sanguine Labs will process the samples for PBMC isolations at 10 mL cells per aliquot. Samples will be stored for batch shipment at the end of the study. The PBMC aliquot(s) will be shipped overnight using liquid nitrogen (LN2) to Novo Nordisk via FedEx Priority Overnight by 10:30 am.~Urine will be collected using a Vacuette collection device. The sample will be shipped frozen (with dry ice) overnight to Novo Nordisk via FedEx Priority Overnight by 10:30 am."
89363000|NCT05613777|Experimental|Microgynon®(Run-in)/Microgynon® (treatment reference, R)/ Microgynon®+BI 425809 (treatment test, T)|
89363001|NCT05602896|Experimental|Sepsis Education|The patient will receive a daily notification via their mobile phone and conduct the daily activity for 30 days. The program is interactive and aimed at measures that prevent exposure to infection sources in the environment, as well as recognition of early signs of infection and possible sepsis. Each session takes approximately 2 minutes or less. Each scenario or session has the user identify where germs may be present and then asks the user to perform a simple action to remove the germs (e.g. with an antiseptic wipe). The range of activities include cleaning of surfaces, proper mask use, and hand sanitizing. This includes areas of their home such as the kitchen, bathroom, living room/family room. The program also addresses common community areas such as public transit, grocery stores, and restaurants
89363002|NCT05574569|Experimental|Group 1: Play Therapy|Play therapy will be given to the participants.
89363003|NCT05574569|Experimental|Group 2: Mindful Parenting|Mindful parenting worksheets will be given to the parents.
89178282|NCT04022538|Active Comparator|Sandwich osteotomy using micro-plates fixation|This group will undergo Sandwich osteotomy procedure and segment will be fixed using micro-plates and screws, and the gap will be filled using xenograft.
89178283|NCT00782496|Experimental|Level1 Basic Meter Features|Adults with type 1 and type 2 diabetes use only basic features (Level 1) to test their blood. The CONTOUR meter has the basic features such as small meter size, easy to use , No Coding™ technology, 5-second test time, small sample size (0.6 µL), automatic control solution marking, 480 reading memory capacity.
89363004|NCT05574569|Experimental|Group 3: (Combined Interventions of both Group 1 & 2)|Play therapy will be given to children and in addition, culturally adapted mindful parenting worksheets will be given to the parents of children having emotional and behavioral problems.
89363005|NCT05574569|No Intervention|Group 4: Treatment as usual|No intervention will be given to the participants
89363006|NCT05569252|Experimental|DS-1211b low dose|Participants who will be randomized to receive a DS-1211 tablet once daily for 12 weeks.
89363007|NCT05569252|Experimental|DS-1211b middle dose|Participants who will be randomized to receive a DS-1211b tablet once daily for 12 weeks.
89363008|NCT05569252|Experimental|DS-1211b high dose|Participants who will be randomized to receive a DS-1211b tablet once daily for 12 weeks.
89363009|NCT05569252|Placebo Comparator|Placebo|Participants who will be randomized to receive a placebo tablet once daily for 12 weeks.
89363010|NCT05562778|Experimental|Chatbot|Subjects will receive a text message initiating a chatbot conversation that relies on natural language processing to gather personal and family cancer. Subjects are identified by the chatbot as meeting National Comprehensive Cancer Network (NCCN) high-risk criteria. Next, subjects undergo pre-test genetic counseling via the chatbot and then clinicians are notified (via the chatbot portal) that the subject meets high-risk criteria. For subjects meeting high-risk criteria (based on the chatbot evaluation), the clinician will complete genetic counseling and recommend genetic testing during the visit. For subjects interested in genetic testing, the clinician will order genetic testing.
89363011|NCT05562778|No Intervention|Usual Care|Personal and family cancer history will be collected by the clinician during the subject's visit. Clinicians will evaluate the patient's personal/family history according to National Comprehensive Cancer Network (NCCN) high-risk criteria. For subjects recognized by the clinician as meeting NCCN criteria, the clinician will complete genetic counseling and recommend genetic testing. For subjects interested in genetic testing, the clinician will order genetic testing.
89363012|NCT05562180|Experimental|Intervention arm|These participants will use the app to customize their weekly meal plan and grocery delivery
89363013|NCT05562180|No Intervention|comparison|These participants will not receive a weekly meal plan and will not get grocery delivery
89534585|NCT03095547|Experimental|F901318 & pantoprazole|Interaction between pantoprazole and F901318
89534586|NCT03095547|Experimental|F901318|F901318 alone
89534587|NCT03329651|Experimental|Metformin treatment|
89534588|NCT03329651|Placebo Comparator|Placebo treatment|
89534589|NCT03334955|Experimental|polycystic ovary syndrome patients|patients with polycystic ovary syndrome performed laparoscopic ovarian drilling to induce ovulation
89534590|NCT05049447|Active Comparator|Verum arm|Intervention: Drug: Verum (Pascoflair)
89534591|NCT05049447|Placebo Comparator|Placebo arm|Intervention: Drug: Placebo
89534592|NCT03334877||β -human chorionic gonadotropin|Cervico vaginal fluid sampling was undertaken for qualitative assessment of β -human chorionic gonadotropin (β-hCG) and fetal fibronectin(fFN) at 24 weeks of gestation to predict preterm labour in asymptomatic high risk patients
89534593|NCT03334799|Other|Sacroiliac belt on and off|Belt on and belt off
88834266|NCT04264572|No Intervention|Usual Care|Patients in this arm will receive usual services offered at Jefferson for patients with DM, which includes regular visits with a diabetes provider (primary care or endocrine), standard ADA information pamphlets and referral to 1) diabetes education classes and 2) nutrition counseling by dieticians and nurse practitioners. During routine office visits, providers reinforce messages about self-management and provide lists of local and national resources related to nutrition and diabetes self-management (e.g., diabetes.org). The standard of care at Jefferson for patients with DM is to begin with a single group MNT visit lasting from 60-90 minutes. Each participant's need for additional sessions and general time-frame for follow-up is individually determined following the group session, based on patient preference. Historically, only about 2% of the Jefferson population engages in these services, thus minimizing dilution of the effect of the tele-MNT.
89363014|NCT05561725|Active Comparator|Standard of Care: Control|"Patients will be screened for participation following indication for surgery by the treating surgeon and/or research assistant. Patients who elect to participate will then be randomized into either the dexamethasone or control groups.~Patients in the control group will receive one 8mg dose of dexamethasone intraoperatively as per standard of care anesthesia protocols. No sham medication will be utilized for control subjects."
89363015|NCT05561725|Experimental|Dexamethasone|"Patients will be screened for participation following indication for surgery by the treating surgeon and/or research assistant. Patients who elect to participate will then be randomized into either the dexamethasone or control groups.~Patients randomized to the dexamethasone cohort will be administered 8 mg of dexamethasone with 3 additional (8mg doses) administered at 8-hour intervals following surgery for a total of 4 doses."
89363016|NCT05556772|Experimental|Screening (biospecimen collection, cytology, interview)|Participants participate in an interview and clinical exam, lasting approximately 2 hours. Participants undergo vaginal self-sampling, cervical provider-sampling, and collection of blood and urine samples. Participants also undergo a pelvic exam. After first interview and clinical exam at enrollment, participants have two subsequent study visits over a 2 year period.
89363017|NCT05554991|Experimental|Liquid oral supplement comprising HMO|2 ampules/day for 21 days
89363018|NCT05554991|Placebo Comparator|Placebo|2 ampules/day for 21 days
89363019|NCT05548738|Active Comparator|Steroid group (Group S)|This group will receive ultrasound and fluoroscopy-guided caudal epidural steroid injection
89363020|NCT05548738|Experimental|Prolotherapy group (Group P)|This group will receive ultrasound and fluoroscopy-guided caudal epidural prolotherapy injection
89363021|NCT05537545|Active Comparator|Immediate soft tissue grafting|A connective tissue graft is immediately harvested and inserted in the buccal mucosa at the moment of implant placement
89363022|NCT05537545|Experimental|Delayed soft tissue grafting|Three months after implant placement, a connective tissue graft is harvested and inserted in the buccal mucosa
89363023|NCT05512143|Experimental|TMS|Participants will receive 30 sessions (5 days/week, 6 consecutive weeks) of active TMS to the left dorsolateral prefrontal cortex (DLPFC). Right DLPFC will be targeted using a modification of the Beam method. TMS will be administered at 10Hz, 120% of motor threshold, 3000 pulses per session
89363024|NCT05506969|Experimental|Part 1 Group 1:rF1V vaccine and CpG 1018® adjuvant co-administered|rF1V vaccine and CpG 1018® adjuvant will be administered on Days 1 and 29, and 2 injections of placebo will be administered on Day 183
89363025|NCT05506969|Experimental|Part 1 Group 2:rF1V vaccine and CpG 1018® adjuvant bedside mix|Bedside mix of rF1V vaccine and CpG 1018® adjuvant and placebo will be administered on Days 1 and 29, and 2 injections of placebo will be administered on Day 183
89363026|NCT05506969|Active Comparator|Part 1 Group 3: rF1V vaccine and placebo|rF1V vaccine and placebo will be administered on Days 1, 29, and 183
89363027|NCT05506969|Experimental|Part 2 Group 1 & 3, OR Group 2 & 3|"Group 1 & 3 (if selected): Group 1: rF1V vaccine and CpG 1018® adjuvant will be administered on Days 1 and 29, and 2 injections of placebo will be administered on Day 183. Group 3: rF1V vaccine and placebo will be administered on Days 1, 29, and 183~OR~Group 2 & 3 (if selected): Group 2: Bedside mix of rF1V vaccine and CpG 1018® adjuvant will be administered on Days 1 and 29; placebo will be administered on Day 183. Group 3: rF1V vaccine will be administered on Days 1, 29, and 183"
89363028|NCT05504343|Other|Single Arm|This study is a prospective, single arm single center, open label study.
89001225|NCT04578418|Active Comparator|Collagen + heavy slow resistance group|Daily collagen supplementation + heavy slow resistance training three times weekly for 12 weeks.
89363029|NCT05501483|Active Comparator|Pioglitazone|Pioglitazone is known to affect fat cells and is used as an active comparator. It reduces HbA1c but increase fat mass slightly. We hypothesize that pioglitazone may have particular benefits in individuals with a specific adipose cellularity.
89363030|NCT05501483|Experimental|Empagliflozin|Empagliflozin reduces HbA1c and increase lipolysis possibly due to increased glucagon secretion. It also reduces fat mass weight to a minor degree.
89363031|NCT05501483|Experimental|Semaglutide|Semaglutide reduces body weight, including fat mass, to a more significant degree than empagliflozin but has no known direct effects on adipose tissue.
89363032|NCT05500599|No Intervention|midazolam (Group M)|receive 0.5 mg/kg midazolam orally approximately 30 min before the induction of anaesthesia
89363033|NCT05500599|Active Comparator|fentanyl (Group F)|receive 10 μg/kg fentanyl orally approximately 30 min before the induction of anaesthesia
89001226|NCT04578418|Experimental|Placebo + heavy slow resistance group|Daily placebo supplementation + heavy slow resistance training three times weekly for 12 weeks.
89001227|NCT00577369|Active Comparator|1|The subject's participation will take place over one surgical procedure. It will begin with the first blood collection and end with either the second blood draw or the end of the procedure.
89363034|NCT05498870|Active Comparator|Adductor Canal Block (ACB) Only|Participants randomized to the ACB only group will receive an adductor canal block alone.
89363035|NCT05498870|Active Comparator|ACB + iPACK|Participants randomized to the ACB + iPACK group will receive both the ACB and iPACK block.
89363036|NCT05495698|Other|Control group|multi-inhaler triple therapy (Qvar and Bevespi)
89363037|NCT05495698|Other|Intervention group 1|single-inhaler triple therapy (Trimbow)
89363038|NCT05495698|Other|Intervention group 2|single-inhaler triple therapy (Trimbow) + e-health applications
89363039|NCT05482971|Experimental|Ropeginterferon alfa-2b (P1101)|Pre-filled Syringe, Q2W, SC injection
89363040|NCT05482737||Reference group|Transfused RBC stored 8-35 days
89363041|NCT05482737||less than or equal 7 days|Transfused RBC stored =<7 days
89363042|NCT05482737||more than 7 days|Transfused RBC stored <7 days
89363043|NCT05482737||less that or equal 10 days|Transfused RBC stored =<10 days
89363044|NCT05482737||more that 10 days|Transfused RBC stored >10 days
89363045|NCT05482737||more than 35 days|Transfused RBC stored >35 days
89363046|NCT05482737||less than or equal 35 days|Transfused RBC stored =<35 days
89363047|NCT05482737||less than 18 days|Transfused RBC stored <18 days
89363048|NCT05482737||more than or equal 18 days|Transfused RBC stored =>18 days
89363049|NCT05481541|Experimental|written education group|Experimental: The Effect of E-Mobile and Written Education on Quality of Life and Sleep in Patients with Transurethral Prostate Resection According to the randomization, preoperative training will be applied to the patients in the e-mobile training/written training group. The training will be administered by the principal researcher using the face-to-face interview technique.
89363050|NCT05481541|Active Comparator|Mobile education application group|Experimental: The Effect of E-Mobile and Written Education on Quality of Life and Sleep in Patients with Transurethral Prostate Resection According to the randomization, preoperative written/mobile education will be applied to the patients in the e-mobile education/written education group. The training will be given by the principal researcher using the face-to-face interview technique.
89363051|NCT05481541|No Intervention|Control (standard care) group|Experimental: The Effect of E-Mobile and Written Education on Quality of Life and Sleep in Patients with Transurethral Prostate Resection Routine post-operative care will be given to the control group without any intervention and data collection tools will be applied at the same time as the experimental group, twice at 30-minute intervals.
89363052|NCT05475431||The Charlson scores >= 2|Patients who are >= 20 years and diagnosed with H. pylori infection either by rapid urease test or by histology from January 1, 2012 to December 31, 2019 are reviewed retrospectively. Patients are excluded if they ever received H. pylori eradication before. Patient characteristics, including age, sex, and the parameters of the Charlson scores, are recorded and analyzed. Moreover, the tablet number and varieties of medications patients took for underlying diseases are also recorded. If the patients' Charlson scores >= 2, they are divided into the Charlson scores >= 2 group.
89363053|NCT05475431||The Charlson scores < 2|Patients who are >= 20 years and diagnosed with H. pylori infection either by rapid urease test or by histology from January 1, 2012 to December 31, 2019 are reviewed retrospectively. Patients are excluded if they ever received H. pylori eradication before. Patient characteristics, including age, sex, and the parameters of the Charlson scores, are recorded and analyzed. Moreover, the tablet number and varieties of medications patients took for underlying diseases are also recorded. If the patients' Charlson scores < 2, they are divided into the Charlson scores < 2 group.
89363054|NCT05469477|Other|Control|Participants are asked to buckle up and not engage in handheld phone use while driving. No further messaging will be provided about their behavior, and participants will not receive financial incentives for avoiding risky driving behavior.
89363055|NCT05469477|Experimental|Behavioral Engagement|Participants will receive a multicomponent safer driving intervention based on behavioral science. This will include persuasive education, WOOP (mental contrasting with implementation intentions) and customized habit tips.
89363056|NCT05469477|Experimental|Raffle incentive + behavioral engagement|Participants will receive the entire multicomponent safer driving behavioral intervention from arm 2. Participants will also be eligible for the Raffle Financial incentive, where participants can earn prize money for seat belt adherence and/or no phone use while driving.
88818183|NCT02906787|Experimental|BAS+|Participants will attend 8 counseling sessions and receive a behavioral activation intervention to smoking cessation and to post-cessation weight gain (BAS+).
89001228|NCT00577447|Active Comparator|1|DHA supplemented group
89363057|NCT05469477|Experimental|Shared pot incentive + behavioral engagement|Participants will receive the entire multicomponent safer driving behavioral intervention from arm 2. This arm will be identical to Arm 3, except there will be a shared pot financial incentive instead of a raffle. Participants that abstain from phone use while driving and seat belt adherence earn an equal share of prize money allocated for the entire group.
88818184|NCT02906787|Placebo Comparator|SC|Participants will attend 8 counseling sessions and receive standard smoking cessation counseling (SC).
88818185|NCT01330394|Sham Comparator|sham-tDCS control|simulate control for transcranial Direct Current Stimulation
88818186|NCT01330394|Active Comparator|active tDCS|active transcranial Direct Current Stimulation
88818187|NCT04340271|Experimental|Extracorporeal shock wave therapy group|Patients in the ESWT group were explained to select the most hypertrophic and retracting area for the treatment on dominant hand. ESWT was conducted using the Duolith SD-1® device (StorzMedical, Tägerwilen, Switzerland) with an electromagnetic cylindrical coil source for the focused shock wave (Fig. 2). ESWT was performed around the primary treatment site at 100 impulses/cm2, an energy flux density(EFD) of 0.05 to 0.30 mJ/mm2, frequency of 4Hz, and 1000 to 2000 impulses were administered at 1-week intervals for 4 sessions.
88818188|NCT04340271|Sham Comparator|sham stimulation group|The same shock wave equipment used in the experimental group was used with a sham adapter that had the same shape but emitted no energy
89363058|NCT05465551|No Intervention|Stress Management Toolkit Prototype Development|3-4 qualitative focus groups (n=3-4 dyads/group) will be held to explore experiences, perceptions, preferences, and recommendations of dementia-caring dyads regarding stress, stress management, and key components and features of a stress management toolkit. Eligible tools for the toolkit include low burden, high safety tools (e.g., weighted blankets, robotic pets and baby dolls, guided journals, aromatherapy, bright light therapy devices, massage and acupressure tools).
89363059|NCT05465551|Experimental|Stress Management Toolkit Prototype User Testing|10 dyads will use the toolkit for 2 weeks in their own homes. Feedback on usability, feasibility, and acceptability will be collected through questionnaires and focus groups. Stress-related, participant-reported outcomes (e.g., neuropsychiatric symptoms of dementia, caregiver stress, dyadic relationship strain), and salivary cortisol biospecimens will be collected at baseline and end of week 2, to explore their utility as endpoints in a future pilot study to examine efficacy.
89363060|NCT05464095|Active Comparator|mHealth Intervention|Patients will be randomized to the mHealth texting platform, which are messages designed to facilitate self-awareness, reinforce step targets, and link physical activity with a reward or memorable cue.
89363061|NCT05464095|Other|Usual Care|Routine medical care
89363062|NCT05456269|Experimental|Stratum 1|"Bisantrene infused daily for 7 days of induction cycle 1; followed by bisantrene infusion on Days 1 and 2 and cytarabine arabinoside continuous infusion on Days 1 to 5 of each consolidation cycle for up to 3 cycles.~Each cycle is 28 days, with a potential to expand to 42 days to allow for full hematologic recovery."
89363063|NCT05456269|Experimental|Stratum 2|"Decitabine/cedazuridine daily on Days 1-5, Bisantrene infusion on Days 3 and 5 in 28 day cycle. Treatment repeats every 28 days up to 12 cycles in the absence of disease progression or unacceptable toxicity.~Each has potential to expand to 42 days to allow for full hematologic recovery."
89363064|NCT05454813|Other|All|Each participant will be provided with the FitRight ® System for the duration of the study. The study products will be used to collect real-life measurement data in order to assess the FitRight® System.
89363065|NCT05454670|Experimental|Test group|The intervention will be primary cleft palate repair using resorbable collagen matrix graft as superpositional graft during approximation of the nasal mucosa and muscular layer in cleft palate repair. The collagen graft with be inserted between the nasal mucosa/ muscular layer and the oral mucosa layer during two-flap palatoplasty.
89363066|NCT05454670|Active Comparator|Control group|The intervention will be primary cleft palate repair using two-flap palatoplasty technique without collagen graft
89363067|NCT05451173|Experimental|Cohort A|SBRT to be delivered with concurrent and adjuvant anti-PD-(L)1 immune checkpoint inhibitor.
89363068|NCT05451173|Experimental|Cohort B|Hypo-fractionated radiotherapy to be delivered with concurrent and adjuvant anti-PD-(L)1 immune checkpoint inhibitor.
89363069|NCT05449392|Experimental|Neosporin|Neosporin will be distributed by the Yale Investigational Pharmacy. Subjects are to use Neosporin twice a day for 7 days.
88818189|NCT01811693|Experimental|Dose Tier 1|Glycerly Trinitrate (Nitroglycerine) 5mg/24hour (0.2mg/hour) transdermal
88818190|NCT01811693|Experimental|Dose Tier 2|Glycerly Trinitrate (Nitroglycerine) 10mg/24hour (0.4mg/hour) transdermal
89001229|NCT00577447|Placebo Comparator|2|Placebo group
89001230|NCT00577525||1|Case : Patients with steroid sensitive nephrotic syndrome
89363070|NCT05449392|Placebo Comparator|Vaseline or equivalent|Vaseline or equivalent will be distributed by the Yale Investigational Pharmacy. Subjects are to use Vaseline twice a day for 7 days.
89363071|NCT05449327|Experimental|Rivaroxaban|The participants are provided with Rivaroxaban 10mg
89363072|NCT05449327|No Intervention|Control|The participants are provided without antithrombotics
89363073|NCT05448846|Active Comparator|Control|Usual care (i.e., 'Enhanced Recovery After Surgery' (ERAS) protocol)
89363074|NCT05448846|Experimental|Home-based multicomponent exercise program|Complete a home-based multicomponent exercise program from diagnosis to 3 months after surgery in addition to ERAS protocol.
89363075|NCT05443685|Experimental|ADX-629 treatment|Open label treatment with ADX-629
89363076|NCT05431296|Experimental|Real time CGM post acute myocardial infarct|Real time Dexcom ONE CGM system to be applied for 26 weeks post acute myocardial infarct.
88818191|NCT01811693|Experimental|Dose Tier 3|Glycerly Trinitrate (GTN, Nitroglycerine) 5mg/24hour (0.2mg/hour) transdermal plus a single metered dose 0.4mg of sublingual GTN
88818192|NCT02639637|Other|Sitagliptin then Placebo|Subjects in this arm will receive sitagliptin 100 mg daily. After one week of treatment, subjects will report for study day #1. During the study day subjects will be given intra-aterial neuropeptide Y and enalaprilat. A four week washout of medications will occur after the study day. Subjects will then receive placebo for one week followed by study day #2.
88818193|NCT02639637|Other|Placebo then Sitagliptin|Subjects in this arm will receive placebo for one week. After this, subjects will report for study day #1. During the study day subjects will be given intra-aterial neuropeptide Y and enalaprilat. A four week washout of medications will occur after the study day. Subjects will then receive 100 mg of sitagliptin daily for one week followed by study day #2.
88818194|NCT02639637|Placebo Comparator|Sitagliptin then Placebo: Valsartan|Subjects in this arm will receive sitagliptin 100 mg/d for one week as well as valsartan 160 mg/d for one week. After this subjects will report for study day #1. During the study day, subjects will be given intra-arterial neuropeptide Y. A four week washout of medication will occur after the study day. Subjects will then receive placebo/d and valsartan 160 mg/d for one week followed by study day #2.
89363077|NCT05431296|No Intervention|Blinded CGM post acute myocardial infarct|Blinded Dexcom ONE CGM system to be applied for 10 days at recruitment, and then at days 17-23, week 10 and week 24. This will be for the purposes of monitoring glucose only and is not an intervention and is blinded to the participants and the study investigators. CGM measurements will be blinded until the end of the study. Management of diabetes in this cohort as per usual standards of care.
88834267|NCT04263181||Cohort 0|"-A technical run-in of 5 patients with any of the following:~Standard cytarabine/idarubicin induction, includes cytarabine 200 mg/m2 CIVI in 0.9% normal saline over 24 hours for 7 consecutive days (Days 1-7) & idarubicin 12 mg/m2 per day for 3 consecutive days (Days 1-3). Other standard cytarabine-based induction protocols are allowed~Decitabine 20 mg/m2/day as a 1-hour infusion on consecutive Days 1-5 or 1-10 of each 28-day cycle.~Azacitidine 75 mg/m2/day as a subcutaneous injection on Days 1-7 or on day 1-5 and 8-9 of each 28-day cycle~Decitabine 20 mg/m2/day as a 1-hour infusion on consecutive Days 1-5 or 1-10 of each 28-day cycle. Patients will receive venetoclax PO 100 mg on Day 1, 200 mg on Day 2, and 400 mg daily thereafter.~Azacitidine 75 mg/m2/day as a 1-hour infusion or by subcutaneous injection on consecutive Days 1-7 or on day 1-5 and 8-9 of each 28-day cycle. Patients will receive venetoclax PO 100 mg on Day 1, 200 mg on Day 2, and 400 mg daily thereafter."
89001231|NCT00577525||2|Controls (matched for age and sexe with the first group)
89363078|NCT05431296|No Intervention|Blinded CGM historical acute myocardial infarct (>6 months and <10 years ago)|Blinded Dexcom ONE CGM system to be applied for 10 days at recruitment. This will be for the purposes of monitoring glucose only and is not an intervention and is blinded to the participants and the study investigators. Management of diabetes in this cohort as per usual standards of care.
89363079|NCT05431296|No Intervention|Cardiovascular outcomes control group|Age and sex-matched controls from the NIHR Cardiovascular Health Informatics Collaborative.
89363080|NCT05411237|Active Comparator|Pegylated Liposomal Doxorubicin|Participants will receive a single intravenous dose of PLD 20 mg/m2 once every 3 weeks for a total of 18 weeks.
89363081|NCT05411237|Active Comparator|Paclitaxel|Participants will receive a single intravenous dose of PTX 100 mg/m2 once every 3 weeks for a total of 18 weeks.
89363082|NCT05402150|Experimental|Behavioral Activation|14 days of daily excercises
89363083|NCT05402150|Experimental|Mindfulness and Gratitude|14 days of daily excercises
89363084|NCT05402150|Experimental|Combination: Behavioral Activation and Mindfulness and Gratitude|14 days of daily excercises
89363085|NCT05402150|No Intervention|Waitlist control group|Will receive the intervention (combination) after two weeks of intervention time of the other groups.
89363086|NCT05387447|Experimental|Conversational Voice Assistant-Standard|Participants will complete a standard interactive routine with the voice assistant.
89363087|NCT05387447|Experimental|Conversational Voice Assistant-Enhanced|Participants will complete a personalized and tailored interactive routine with the voice assistant.
89363088|NCT05376449|Experimental|Immediate start|Intervention to start immediately after first visits.
89178284|NCT00782496|Experimental|Level 2 Advanced Meter Features|Adults with type 1 and type 2 diabetes additionally access and use more advanced meter features(Level 2)during blood glucose testing. The advanced features include ability to mark blood glucose values as obtained before or after meals or to set an audible reminder to test.
89178285|NCT00782418|Active Comparator|1|exenatide 5mcg
89363089|NCT05376449|Active Comparator|Delayed start|Intervention to start after 12 weeks delay.
89363090|NCT05374408|Other|BBN pilot|Deployment of BBN for patient use, self-paced
89363091|NCT05374291|Experimental|Dapagliflozin|Dapagliflozin 10 mg/day (oral)
89363092|NCT05374291|Placebo Comparator|Placebo|Placebo 10 mg/day (oral)
89363093|NCT05372575|Other|PCV13 group and non PCV13 group|This study plan to recruit those young patients who have or not have got PCV13 vaccine before study start
89363094|NCT05365659|Experimental|Dose Escalation Cohort (Part 1)|Each patient will receive repeat doses (by intravenous (IV) infusions) on Day 1 of each 21-day cycle. Participants may continue on study until disease progression, unacceptable toxicity, or other withdrawal criteria is met.
89363095|NCT05365659|Experimental|Dose Expansion: Diffuse-Large B-Cell Lymphoma Participants|Each patient will receive IKS03 at the recommended dose for expansion (RDE) defined in Part 1 on Day 1 of each 21-day cycle. Participants may continue on study until disease progression, unacceptable toxicity, or other withdrawal criteria is met.
89363096|NCT05365659|Experimental|Dose Expansion: Follicular Cell Lymphoma Participants|Each patient will receive IKS03 at the recommended dose for expansion (RDE) defined in Part 1 on Day 1 of each 21-day cycle. Participants may continue on study until disease progression, unacceptable toxicity, or other withdrawal criteria is met.
89363097|NCT05365659|Experimental|Dose Expansion: Mantle Cell Lymphoma Participants|Each patient will receive IKS03 at the recommended dose for expansion (RDE) defined in Part 1 on Day 1 of each 21-day cycle. Participants may continue on study until disease progression, unacceptable toxicity, or other withdrawal criteria is met.
89363098|NCT05365659|Experimental|Dose Expansion: Other B cell lymphoma (B-NHL not otherwise specified [NOS])|Each patient will receive IKS03 at the recommended dose for expansion (RDE) defined in Part 1 on Day 1 of each 21-day cycle. Participants may continue on study until disease progression, unacceptable toxicity, or other withdrawal criteria is met.
89363099|NCT05360732|Experimental|Experimental: FOLFIRINOX|FOLFIRINOX: Oxaliplatin, Leucovorin and 5-Fluorouracl, Irinotecan,
89363100|NCT05353998|Experimental|Sleep Navigation group|Caregiver-child dyads in this study arm (intervention condition) will participate in the Sleep Navigation program.
89363101|NCT05353998|Other|CDS-only group|Caregiver-child dyads in this study arm (control group) will not participate in the Sleep Navigation program, but will be directed to follow up with their primary care clinician as needed.
89363102|NCT05349487|Experimental|SpeakFree Hands Free Heat Moisture Exchanger (HEM) Valve Group|Participants will be fitted to use a hand free HME device over their stoma in order to communicate with a voice prosthesis for one month. The participants will also serve as their own control performing voicing and speech tasks using digital occlusion and digital depression HME.
89363103|NCT05343949|Experimental|HIIT protocol ABC|"HIIT protocol A, then HIIT protocol B, then HiIT protocol C. Patients first received HIIT A -High-intensity duration and intensity: 5 seconds, Rest duration: 40 seconds, Number of Repetitions: 54, Total duration of HIIT protocol: 2,430 seconds (40 minutes, 30 seconds).~After a rest of at least 2 days they received HIIT B: High-intensity duration and intensity: 10 seconds, Rest duration: 80 seconds, Number of Repetitions: 27, Total duration of HIIT protocol: 2,430 seconds (40 minutes, 30 seconds).~After a further rest of at least 2 days they received HIIT C-High-intensity duration and intensity: 30 seconds, Rest duration: 240 seconds, Number of Repetitions: 9 Total duration of HIIT protocol: 2,430 seconds (40 minutes, 30 seconds)."
89363104|NCT05343949|Experimental|HIIT protocol CAB|"HIIT protocol C, then HIIT protocol A, and lastly HIIT protocol B. Patients first received HIIT C:-High-intensity duration and intensity: 10 seconds, Rest duration: 80 seconds, Number of Repetitions: 27, Total duration of HIIT protocol: 2,430 seconds (40 minutes, 30 seconds). After a rest of at least 2 days they received HIIT A:-High-intensity duration and intensity: 5 seconds, Rest duration: 40 seconds, Number of Repetitions: 54, Total duration of HIIT protocol: 2,430 seconds (40 minutes, 30 seconds).~After a further rest of at least 2 day they performed HIIT protocol B:-High-intensity duration and intensity: 10 seconds, Rest duration: 80 seconds, Number of Repetitions: 27 Total duration of HIIT protocol: 2,430 seconds (40 minutes, 30 seconds)."
89363105|NCT05343949|Active Comparator|HIIT protocol BCA|"HIIT protocol B, then HIIT protocol C, and lastly HIIT protocol A. Patients firstly received HIIT protocol B:-High-intensity duration and intensity: 10 seconds, Rest duration: 80 seconds, Number of Repetitions: 27, Total duration of HIIT protocol: 2,430 seconds (40 minutes, 30 seconds).~Following at least 2 days rest the patient will receive HIIT protocol C:-High-intensity duration and intensity: 10 seconds, Rest duration: 80 seconds, Number of Repetitions: 27, Total duration of HIIT protocol: 2,430 seconds (40 minutes, 30 seconds). After at least another 2 days rest they will lastly receive Protocol A:-High-intensity duration and intensity: 5 seconds, Rest duration: 40 seconds, Number of Repetitions: 54, Total duration of HIIT protocol: 2,430 seconds (40 minutes, 30 seconds)."
88834268|NCT04263181||Cohort 1|"Patients treated with cytarabine/idarubicin induction therapy~Patients will receive a standard cytarabine/idarubicin induction, which includes cytarabine 200 mg/m2 CIVI in 0.9% normal saline over 24 hours for 7 consecutive days (Days 1-7) and idarubicin 12 mg/m2 per day in 0.9% normal saline over 15-30 minutes for 3 consecutive days (Days 1-3). Other standard cytarabine-based induction protocols are allowed (e.g. cytarabine/daunorubicin or Vyxeos)."
88834269|NCT04263181||Cohort 2|"Patients treated with decitabine~Patients will receive decitabine 20 mg/m2/day as a 1-hour infusion on consecutive Days 1-5 or 1-10 (per treating physician discretion) of each 28-day cycle."
88834270|NCT04263181||Cohort 3|"Patients treated with azacitidine~Patients will receive azacitidine 75 mg/m2/day as a subcutaneous injection on Days 1-7 or on day 1-5 and 8-9 (per treating physician discretion) of each 28-day cycle"
88834271|NCT04263181||Cohort 4|"Patients treated with decitabine + venetoclax~Patients will receive decitabine 20 mg/m2/day as a 1-hour infusion on consecutive Days 1-5 or 1-10 (per treating physician discretion) of each 28-day cycle. Patients will receive venetoclax PO 100 mg on Day 1, 200 mg on Day 2, and 400 mg daily thereafter."
88834272|NCT04263181||Cohort 5|"Patients treated with azacitidine + venetoclax~Patients will receive azacitidine 75 mg/m2/day as a 1-hour infusion or by subcutaneous injection on consecutive Days 1-7 or on day 1-5 and 8-9 (per treating physician discretion) of each 28-day cycle. Patients will receive venetoclax PO 100 mg on Day 1, 200 mg on Day 2, and 400 mg daily thereafter."
88834273|NCT04261504|Experimental|Integrative Body Mind Training (IBMT)|mindfulness
88834274|NCT04261504|Active Comparator|Relaxation Training (RT)|relaxation
88834275|NCT04259125||Acute symptomatic seizures|This is a cohort of 72 participants who will be enrolled into this study from the neonatal intensive care unit (NICU) after being diagnosed with seizures. They will be asked to contribute a blood specimen obtained ideally 48-96 hours (though blood collection allowed 24-120 hours) after seizures are diagnosed, to participate in an optional blood draw at 2-4 months of age, and to complete surveys at 12 & 24 months of age.
88834276|NCT04259125||Control|This is a cohort of 15 participants who will be enrolled into this study from the neonatal intensive care unit (NICU) after having an EEG for possible seizures, but found to have a normal EEG. They will be asked to contribute a blood specimen obtained ideally 48-96 hours (though blood collection allowed 24-120 hours) after birth.
88834277|NCT04258514|Experimental|Virtual Reality Vasectomy|This group of men will undergo vasectomy while wearing VR goggles.
88834278|NCT04258514|Experimental|Standard Vasectomy|This group of men will undergo a standard vasectomy without using VR goggles.
89363106|NCT05335967|Experimental|Self-management group|The experimental group will receive the self-management program for 12 weeks.
89363107|NCT05335967|Other|Information group|The control group will receive an information package on a healthy diet.
89363108|NCT05331261|Experimental|Patients who have had knee replacement surgery|
89363109|NCT05329103|Experimental|PEEL-224 Dose Escalation|PEEL-224 is administered intravenously (IV) on Days 1, 8, and 15 of a 28-day cycle. The study will begin at a low starting dose and will increase between cohorts according to mTPI-2 until a recommended phase 2 dose is determined. Approximately 10 dose levels are anticipated to be studied.
89363110|NCT05329103|Experimental|PEEL-224 Dose Confirmation|An additional arm of patients will be enrolled after dose escalation is completed to confirm the recommended phase 2 dose.
89363111|NCT05328349||Education Program|All participants will have to present shoulder symptoms related to rotator cuff related shoulder pain, which is defined as pain over the deltoid and/or upper arm region, pain associated with arm movement, and familiar pain reproduced with loading or resisted testing during abduction and/or external rotation of the arm.
89363112|NCT05320757|Experimental|Olaparib|Olaparib: 300mg BID orally for 10 - 28 days (stop 3 - 4 days before definitive treatment)
89363113|NCT05318612|Other|Control group (biopsy group)|Standard of care: biopsy + adjuvant treatment
89363114|NCT05318612|Experimental|Intervention group (LITT group)|Biopsy + LITT + adjuvant treatment
89363115|NCT05296356|Experimental|OSU6162|Coated tablet, flexible dosing
89363116|NCT05293067||carotid endarterectomy|High-sensitive troponin would be measured in patients undergoing carotid endarterectomy (CEA). Patients would be followed during the immediate postoperative period (until discharge from hospital), one month after, one and two years following the surgery, when researchers will gather information regarding the study outcomes during a regular postoperative control, or through telephone interviews.
89363117|NCT05293067||carotid artery stenting|High-sensitive troponin would be measured in patients undergoing carotid artery stenting (CAS). Patients would be followed in the immediate postoperative period (until discharge from hospital), one month after, one and two years following the surgery, when researchers will gather information regarding the study outcomes during a regular postoperative control, or through telephone interviews.
89363118|NCT05267470|Experimental|Part 1: Combination Dose Exploration|Participants with SqNSCLC will receive escalating doses of bemarituzumab in combination with docetaxel.
89363119|NCT05267470|Experimental|Part 2: Combination Dose Expansion|Participants with SqNSCLC and FGFR2b overexpression will receive the dose of bemarituzumab in combination with docetaxel identified as safe during Part 1.
89363120|NCT05267470|Experimental|Part 3: Bemarituzumab Monotherapy|Participants with SqNSCLC and FGFR2b overexpression will receive bemarituzumab monotherapy.
89363121|NCT05267470|Experimental|Part 4: Combination Immuno-chemotherapy|Participants with FGFR2b overexpression will receive the dose of bemarituzumab identified as safe during Part 1 in combination with pembrolizumab, carboplatin and either paclitaxel or nab-paclitaxel.
89363122|NCT05257655|Other|Intervention|MRI after Ganglionic Local Opioid Analgesia at the Ganglion Cervicale Superius;
89363123|NCT05250609|Experimental|"Intervention: Endocrown composite."|Composite Endocrown will be used as an extra-coronal restoration in endodontically treated mutilated first permanent molar
89363124|NCT05250609|No Intervention|Comparator / Control: Stainless steel crown.|Stainless steel crown will be used as an extra-coronal restoration in endodontically treated mutilated first permanent molar
89363125|NCT05247164|Experimental|PDAC Patients|Patients undergoing EUS for characterization of a PDAC lesion will receive EUS-guided portal blood sampling.
89363126|NCT05238181||The autoimmune gastritis group|Autoimmune gastritis is diagnosed if the anti-parietal cell antibody titer is positive and higher than 1:10 (ImmuGloTM COMVI mouse kidney/stomach IFA kit, Immco Diagnostics, Inc. Buffalo NY, USA).
89363127|NCT05238181||The controls|The patients who are enrolled to validate pathogenesis after H. pylori infection. H. pylori infection is diagnosed by histological assessment. The matched controls are needed to be confirmed to have negative anti-parietal cell antibody.
88834279|NCT04256707|Experimental|Monotherapy: Normal Hepatic Function (Selinexor)|"(Closed for Enrollment)~Cohort 1:~Week 1: selinexor 5 x 20-mg tablet daily;~Week 2: selinexor 1 x 100-mg tablet daily~Cohort 2:~Week 1: selinexor 1 x 100-mg tablet daily;~Week 2: selinexor 5 x 20-mg tablet daily."
88834280|NCT04256707|Experimental|Monotherapy: Impaired Hepatic Function (Selinexor)|"Cohort 3:~Patients with Moderate Hepatic Impairment with any Solid Tumors;~- Selinexor 2 x 20-mg tablet once weekly (QW).~Cohort 4:~Patients with Severe Hepatic Impairment with any Solid Tumors;~- Selinexor 2 x 20-mg tablet QW."
88834281|NCT04256707|Experimental|Combination Therapy: NSCLC Arm A: (Selinexor + Docetaxel)|"(Closed for Enrollment)~Selinexor 60 mg oral dose QW and docetaxel 75 mg/m^2 intravenously (IV) once every 3 weeks (Non-small cell lung cancer [NSCLC] patients)."
88834282|NCT04256707|Experimental|Combination Therapy: CRC Arm B: (Selinexor + Pembrolizumab)|"(Closed for Enrollment)~Selinexor 80 mg oral does QW and pembrolizumab 200 mg IV every 3 weeks (Colorectal cancer [CRC] Patients)."
89363128|NCT05237401|Active Comparator|Non-Surgical Periodontal treatment (NSPT)|Half of the study participants (controls) will be randomised to receive continued non-surgical periodontal treatment (NSPT). All treatment will be carried out by the same therapist in each centre, including oral hygiene.
89363129|NCT05237401|Experimental|Surgical Periodontal treatment/ Open Flap Debridement (OFD)|"The other half of the study participants (test) will be randomised to receive surgical periodontal treatment in the form of open flap debridement (OFD). The aim of the surgery will be to achieve thorough debridement of the furcation area and (if possible) improve accessibility for patient-performed hygiene in the furcation area.~Some of the included maxillary molars may have additional FI on the same tooth (for example, grade III FI buccal to mesial and grade I, II or III distal). In this occurrence, the other furcation will be treated according to judgment by the treating clinician. We anticipate that, based on inclusion criteria, the majority of cases will have multiple grade III FI."
89178286|NCT00782418|Active Comparator|2|exenatide 1.5mcg
89178287|NCT00782418|Placebo Comparator|3|Placebo
89363130|NCT05231707|Experimental|Intervention|For couples who are prevalent sero-discordant, this will be a CHTC session. For couples who are prevalent concordant HIV-positive, the first visit will be the first Partner Steps session. For couples in which one or both do not know their sero-status or have not tested for HIV in the past 12 months, the first session will be a CHTC session.
89363131|NCT05231707|Active Comparator|Attention Matched Control|Participants in the control group will receive an intervention, with the same number of sessions as couples of the same sero-status in the intervention condition, delivered via one-on-one couples counseling sessions (i.e., one couple with one counselor).
89363132|NCT05226052|Experimental|S. boulardii|treatment arm group (3 capsules of Floratil 200mg®/day)
89001232|NCT00180518|Experimental|1|"To evaluate the safety and efficacy of the over-the-wire (OTW) ACCULINK (tm) System in patients deemed to be either at high risk or unsuitable for carotid endarterectomy (CEA) To evaluate the efficacy of the OTW ACCUNET System in patients deemed to be either at high risk or unsuitable for carotid endarterectomy (CEA).~To demonstrate equivalence in the safety and performance of the RX ACCULINK Carotid Stent System and RX ACCUNET Embolic Protection System and the corresponding OTW devices."
89001233|NCT00187044|Other|1|
89363133|NCT05226052|Placebo Comparator|Placebo|control group (3 capsules of placebo/day)
89363134|NCT05218733|Active Comparator|G1 Group: (Erector Spinae Plane Block (ESPB) Group)|
89363135|NCT05218733|Active Comparator|G2 Group: (Intra thecal morphine (ITM) Group)|
89363136|NCT05218733|Other|G3 Group: (Control Group)|
89363137|NCT05173389|Other|Group 1|TechnoBody
89363138|NCT05173389|Other|Group 2|Thera Trainer
89363139|NCT05147220|Experimental|Remibrutinib - Core|Remibrutinib tablet and matching placebo of teriflunomide capsule
89363140|NCT05147220|Active Comparator|Teriflunomide - Core|Teriflunomide capsule and matching placebo remibrutinib tablet
89363141|NCT05147220|Experimental|Remibrutinib - Extension|Participants on remibrutinib in Core will continue on remibrutinib tablet
89363142|NCT05147220|Experimental|Remibrutinib - Extension (on teriflunomide in Core)|Participants on teriflunomide in Core will switch to remibrutinib tablet
89363143|NCT05136144|Experimental|SM-020|Topical Akt Inhibitor SM-020 Gel
89363144|NCT05132127|Experimental|Sutimlimab|Participants with body weight greater than or equal to (>=) 39 kilograms (kg) to less than (<) 75 kg and who had completed Part B of CARDINAL or CADENZA study were enrolled in the current study and received sutimlimab (BIVV009) 6.5 grams as intravenous (IV) infusion on Day 0, Day 7, Day 21 and thereafter every 2 weeks (maximum duration: 49 weeks) in the current study.
89363145|NCT05129436||Establishment of method|healthy volunteers who are asked to donate peripheral blood for the establishment of the method
89363146|NCT05129436||Influenza vaccination|Subjects receiving the influenza vaccine Vaxigrip Tetra 2020/2021 by Sanofi Pasteur Europe.
89363147|NCT05118529|Active Comparator|Sitting in bed|Sitting in bed with 60 degrees elevated back-rest during 20 minutes
89363148|NCT05118529|Experimental|Sitting in chair|Sitting in chair during 20 minutes
89001234|NCT00577603|Active Comparator|2|mesh reinforcement at stoma
89001235|NCT00577603|Active Comparator|Arm 1|standard stoma
89001236|NCT00577681||1|Participants from the SMART study who were randomly assigned to episodic or continuous ART and who have no history of CVD
89001237|NCT00577681||2|Participants from the SMART study who were randomly assigned to episodic or continuous ART and who experienced a major CVD event during the study, analyzed along with 2 matched controls
89001238|NCT00577681||3|Participants from the SMART study who have no previous use of ART or have taken ART but not done so within 6 months prior to study entry; allows for a comparison of immediate ART versus deferred ART
89363149|NCT05109741|Experimental|Internet-based Psychodynamic Therapy|"This is a 10-week treatment based on the psychodynamic SUBGAP model (Seeing, Understanding, Breaking, and Guarding Against Patterns) by Farrell Silverberg (2005). The treatment has been evaluated in two previous randomized controlled trials.~Silverberg, F. (2005). Make the leap: A practical guide to breaking the patterns that hold you back. Da Capo Press.~Andersson, G., Paxling, B., Roch-Norlund, P., Östman, G., Norgren, A., Almlöv, J., ... & Silverberg, F. (2012). Internet-based psychodynamic versus cognitive behavioral guided self-help for generalized anxiety disorder: a randomized controlled trial. Psychotherapy and psychosomatics, 81(6), 344-355.~Johansson, R., Ekbladh, S., Hebert, A., Lindström, M., Möller, S., Petitt, E., ... & Andersson, G. (2012). Psychodynamic guided self-help for adult depression through the internet: a randomised controlled trial. PloS one, 7(5), e38021."
89363150|NCT05109741|Active Comparator|Internet-based Behavioral Activation|"This 10-week treatment is based on the BATD-R (Behavioral Activation Treatment for Depression - Revised) treatment by Lejuez and others (2011).~Lejuez, C. W., Hopko, D. R., Acierno, R., Daughters, S. B., & Pagoto, S. L. (2011). Ten year revision of the brief behavioral activation treatment for depression: revised treatment manual. Behavior modification, 35(2), 111-161."
89363151|NCT05109741|No Intervention|Waiting-list|Participants will be in a 10-week waiting period.
89363152|NCT05078853||Formal/standard evaluation of a suspected cervical lymph node|"Patient with cervical lymph node suspected as differentiated thyroid carcinoma metastasis will be evaluated according to the current accepted American Thyroid Association Guidelines.~Two clinical scenarios, for each one of them the formal evaluation is described below:~Fine needle aspiration Clinic (a patient with known or suspected differentiated thyroid carcinoma is evaluation for suspicious cervical lymph node): the formal evaluation will include cytology and formal thyroglobulin measurement from the needle washout.~Operating room (evaluation of suspicious cervical lymph node found during partial or complete thyroidectomy in patient with known or suspected differentiated thyroid carcinoma): the formal evaluation will include frozen section and/or final histology."
88834283|NCT04256707|Experimental|Combination Therapy: CRC Arm C: (Selinexor + FOLFIRI)|"(Closed for Enrollment)~Cohort 1:~Selinexor 40 mg oral dose Days 1, 3, 15 and 18 in a 28-day cycle and FOLFIRI (irinotecan 180 mg/m^2; leucovorin 400 mg/m^2; 5- fluorouracil (5-FU) 400 mg/m^2 bolus then 5-FU 2400 mg/m^2 continuous over 46-48 hours; IV on Day 1 and 15 in a 28-day cycle) (CRC Patients).~Cohort 2:~Selinexor 80 mg oral dose Days 1 and 15 in a 28-day cycle and FOLFIRI (irinotecan 180 mg/m^2; leucovorin 400 mg/m^2; 5-FU 400 mg/m^2 bolus then 5-FU 2400 mg/m^2 continuous over 46-48 hours; IV on Day 1 and 15 in a 28-day cycle) (CRC Patients)."
88834284|NCT04249427|Active Comparator|Erenumab|140mg Erenumab administered by subcutaneous injection (in the abdomen, thigh, or upper arm), once monthly for six months.
89363153|NCT05078853||Point of care assay for thyroglobulin (POC-Tg) evaluation of a suspected cervical lymph node|"Patient with cervical lymph node suspected as differentiated thyroid carcinoma metastasis will be evaluated using the study kit: Novel rapid POC-Tg.~Two clinical scenarios, for each one of them the performance of the study kit (POC-Tg) will be valuated in parallel to the formal evaluation:~Fine needle aspiration Clinic (a patient with known or suspected differentiated thyroid carcinoma is evaluation for suspicious cervical lymph node): the suspected cervical lymph node will be evaluated using the POC-Tg in parallel to the formal evaluation.~Operating room (evaluation of suspicious cervical lymph node found during partial or complete thyroidectomy in patient with known or suspected differentiated thyroid carcinoma): the suspected cervical lymph node will be evaluated using the POC-Tg in parallel to the formal evaluation."
89363154|NCT05068479|Experimental|Natural Emmetropic Presbyopes|Patients that did not undergo any vision correcting surgery or implantation of an intraocular lens but suffering from presbyopia will receive bilateral Laser Scleral Microporation procedure.
89363155|NCT05068479|Experimental|Post Laser Vision Correction (LVC) Emmetropic Presbyopes|Patients that underwent laser vision correction procedure (e.g. LASIK) in the past and suffering from presbyopia will receive bilateral Laser Scleral Microporation procedure.
89363156|NCT05066087|Experimental|DAHLIA treatment|6 weeks of online behavioural treatment; mainly self-guided and weekly contact with their therapist
89363157|NCT05066087|Other|Treatment as usual|receive usual treatment at their rehabilitation centre; detailed information will be collected to define what treatment as usual means in clinical settings.
89363158|NCT05064449|Experimental|Part 1: Soticlestat 300 mg + Itraconazole 200 mg|Soticlestat 300 milligram (mg), tablets, orally, once on Day 1 in Period 1, followed by 4 days washout period, followed by itraconazole 200 mg solution, orally, once daily from Day 1 up to Day 11, further followed by soticlestat 300 mg tablet, orally along with itraconazole 200 mg solution, orally on the morning of Day in Period 2.
88834285|NCT04249427|Placebo Comparator|Placebo|Placebo administered by subcutaneous injection (in the abdomen, thigh, or upper arm), once monthly for six months.
88834286|NCT04241588||3D prostheses users|Children with unilateral congenital upper-limb reductions
88834287|NCT04241588||Typically Developing Children|Age- and sex-matched control group of typically developing children.
88834288|NCT04233229|Experimental|closed-loop and home care services|automated insulin delivery system (Closed-loop) with tailored Home Healthcare Provider (HHP) services
88834289|NCT04233229|Active Comparator|usual care|multiple daily injection insulin regimen with family nurse's daily assistance at home for performing insulin injections and/or glucose monitoring
88834290|NCT04230304|Experimental|Treatment (daratumumab, ibrutinib)|Patients receive daratumumab IV on days 1, 8, 15, and 22 of cycles 1-2, on days 1 and 15 of cycles 3-6, and then on day 1 of subsequent cycles. Beginning in cycle 2, patients also receive ibrutinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88834291|NCT04219215|Experimental|Hyperbaric oxygenation|Patients with T2D receive an 2 hour treatment with 100 % oxygen in a hyperbaric chamber
88834292|NCT04219215|Experimental|Ambient Air|Patients with T2D receive an 2 hour treatment with 21% oxygen in a hyperbaric chamber
88834293|NCT04210375|Active Comparator|JK07|Single dose of JK07 administered by intravenous infusion over 60 minutes
88834294|NCT04210375|Placebo Comparator|Matching Placebo|Single dose of placebo administered by intravenous infusion over 60 minutes
88834295|NCT04209673||Transcutaneous nerve stimulation (TENS) patients|Patients who received a TENS unit after surgery
89001239|NCT02963675||Group 1|Prostate cancer patients with bone metastases (mPC)
88834296|NCT04209673||No TENS|Historic controls- Patients who did not receive a TENS unit after surgery
88834297|NCT04207801|Experimental|Arm-1 400 mg BID|400 mg AUR101 twice daily
88834298|NCT04207801|Experimental|Arm-2 600 mg BID|600 mg AUR101 twice daily
88834299|NCT04207801|Placebo Comparator|Arm-3 - Matching Placebo BID|Matching Placebo twice daily
88834300|NCT04206215|Experimental|Active tDCS + Active TUS|Subjects in the experimental group will undergo 20 minutes of active transcranial direct current stimulation (tDCS) and active transcranial ultrasound (TUS).
89363159|NCT05064449|Experimental|Part 2: Soticlestat 300 mg + Mefenamic Acid 500 mg|Soticlestat 300 mg, tablets, orally, once on Day 1 in Period 1, followed by 4 days washout period, followed by single dose of mefenamic acid 500 mg capsule (first dose only), orally on the morning of Day 1 and 250 mg subsequent doses at every six hours up to Day 7 in Period 2, further followed by soticlestat 300 mg tablet, orally, followed by mefenamic acid 250 mg capsule, orally in morning of Day 2 in Period 2.
89363160|NCT05059470|Experimental|Pembrolizumab|The infusions are given every 6 weeks
89363161|NCT05054413||Observational (questionnaire)|Participants complete 3-4 rounds of questionnaires over 20-30 minutes each over 2 weeks.
88834301|NCT04206215|Sham Comparator|Sham tDCS + Sham TUS|Subjects in the sham group will undergo 20 minutes of sham transcranial direct current stimulation (tDCS) and sham transcranial ultrasound (TUS).
88834302|NCT04205552|Experimental|Nivolumab|"Nivolumab 2 cycles, every two weeks (q2w)~o Nivolumab 240 mg i.v. over 30 min"
88834303|NCT04205552|Experimental|Nivolumab/Relatlimab (80 mg)|"Nivolumab/Relatlimab (80 mg) 2 cycles, every two weeks (q2w)~Nivolumab 240 mg i.v. over 30 min~Relatlimab 80 mg i.v. over 30 min (within 30 min of nivolumab)"
88834304|NCT04205552|Experimental|Nivolumab/Relatlimab (240 mg)|"Nivolumab/Relatlimab (240 mg) 2 cycles, every two weeks (q2w)~Nivolumab 240 mg i.v. over 30 min~Relatlimab 240 mg i.v. over 30 min (within 30 min of nivolumab)"
89363162|NCT05033314|Experimental|Rivaroxaban thromboprophylaxis|
89363163|NCT05033314|Placebo Comparator|Placebo|
89363164|NCT05020522|Other|MRI scan|Mp-MRI, LI-MRI, plasma DNA methylation signature (optional)
89363165|NCT05015257|Active Comparator|Standard F100|If the test of appetite at the end of the stabilization phase is negative (the child does not accept the Plumpynut)
89363166|NCT05015257|Experimental|Standard F75+Plumpynut|If the test of appetite at the end of the stabilization phase is positive (the child accepts the Plumpynut) and the child received Standard F75 during the stabilization phase
89363167|NCT05015257|Experimental|Alternative F75 with CMV +Plumpynut|If the test of appetite at the end of the stabilization phase is positive (the child accepts the Plumpynut) and the child received Alternative F75 with CMV during the stabilization phase
89363168|NCT05015257|Experimental|Alternative F75 without CMV +Plumpynut|If the test of appetite at the end of the stabilization phase is positive (the child accepts the Plumpynut) and the child received Alternative F75 without CMV during the stabilization phase
88834309|NCT04191057|Experimental|Healthy twin|Free light chains of twins compared to non-twin siblings
88834310|NCT04181996|Placebo Comparator|Placebo|Placebo: Sugar pill manufactured to mimic colchicine 0.6 mg capsule. Placebo to be taken once a day.
88834311|NCT04181996|Experimental|Colchicine|Colchicine: 0.6 mg colchicine capsule to be taken once a day.
89001240|NCT02963675||Group 2|Castration-resistant prostate cancer patients with bone metastases (mCRPC)
89363169|NCT05008432||HFpEF Patients Diagnosed with Obstructive Sleep Apnea|Right heart cath patients who are diagnosed with HFpEF will undergo a home sleep apnea test (for patients hospitalized with HFpEF, the initial home sleep test will be performed in hospital overnight)
89363170|NCT04999592|Active Comparator|No prophylaxis (placebo)|"Standard care without antibiotic prophylaxis and treatment of infection if clinically warranted.~Administer antibiotics in response to infection."
89363171|NCT04999592|Experimental|Prophylaxis|Antibiotic prophylaxis for 3 days. Antibiotic prophylaxis with Ceftriaxone 2 gm IV q12h for 3 days.
89363172|NCT04997811|Experimental|VBaP|Combination of sodium valproate, bezafibrate, medroxyprogesterone
89363173|NCT04997811|Experimental|Danzol|Single agent
89363174|NCT04972578|Active Comparator|Screw Fixation|Traditional fixation method of placing one or two screws across the syndesmosis.
89363175|NCT04972578|Active Comparator|Suture Button|Suture button implants which use a suture and anchor to repair the syndesmosis
89363176|NCT04970069|Active Comparator|Analgesic education|
89363177|NCT04970069|Placebo Comparator|General perioperative education|
89363178|NCT04969276|Experimental|Group 1: Fluzone High-Dose (HD) Quadrivalent Influenza Vaccine and COVID-19 Vaccine|Participants received an injection of 0.7 milliliters (mL), fluzone HD quadrivalent influenza vaccine, co-administered with 0.5 mL COVID-19 vaccine, intramuscularly (IM) on Day 1.
89363179|NCT04969276|Active Comparator|Group 2: Fluzone HD Quadrivalent Influenza Vaccine|Participants received a single injection of 0.7 mL fluzone HD quadrivalent influenza vaccine, IM on Day 1.
89363180|NCT04969276|Active Comparator|Group 3: COVID-19 Vaccine|Participants received a single injection of 0.5 mL COVID-19 mRNA Vaccine, IM on Day 1.
89363181|NCT04969224|Experimental|ELX/TEZ/IVA|Participants received ELX 200 milligram (mg) once daily (qd)/TEZ 100 mg qd/IVA 150 mg every 12 hours (q12h) in the treatment period approximately 13 weeks.
89363182|NCT04967560|Active Comparator|DBS true-stimulation group|The electrical stimulation will be 'turned-on' immediately after programming in true-stimulation group.
89363183|NCT04967560|Sham Comparator|DBS sham-stimulation group|The electrical stimulation will be 'turned-off' after programming in sham-stimulation group. The stimulation will begin until after completing three months of Y-BOCS and CGI assessments
89363184|NCT04966117|Experimental|Risk-Guided DMP|The intervention is a 12 month disease management program after hospital discharge for coronary artery disease that is overseen by a cardiac nurse.
89363185|NCT04966117|Active Comparator|Usual Care|Usual care patients will receive standard cardiology care.
89363186|NCT04954313|Experimental|Treatment Group|The Treatment Group will receive the same periodontal treatment in addition to having subgingival chlorhexidine irrigation. All subjects will also complete a set of questionnaires (PANAS & PMT) using an online form. A subset of 50 subjects from each group will be randomly selected to have oral images captured using an intra-oral scanner at Baseline and a subset of follow-up visits. Additionally, subjects in the Treatment Group will also receive brief behavioral advice from dental professionals focusing mainly on motivation and acknowledgement.
89363187|NCT04954313|Active Comparator|Control Group|"The Control Group will receive an initial periodontal treatment consisting of a pre-procedural rinse and scaling & root planning (SRP).~Subjects in the Control Group will receive no products during the course of the study. They will receive a commercial connected toothbrush, toothpaste, mouthwash, proxabrush, and floss at the end of the study. Subjects will be scheduled to receive flow mediated dilation (FMD) and carotid intima media thickness (IMT) measurements prior to Baseline and approximately 4 weeks after their Baseline visit."
89363188|NCT04922307|Experimental|Blood Sparing Protocol|The intervention group (120 patients) will undergo radical nephrectomy with blood-sparing techniques. Acute Normovolemic Hemodilution (ANH) collects patients own blood prior to the start of surgical procedure; Cell saver is the collection of blood lost during surgery with subsequent auto-transfusion of the patients own cells; Veno-venous bypass will be used for patients with anticipated large loss of blood during surgery (>1L). The patients in the interventional group will be blinded to which blood sparing techniques utilized.
89363189|NCT04922307|Active Comparator|Standard Blood Replacement|The control group of one hundred and twenty (120) patients will undergo radical nephrectomy without blood sparing techniques (ie. Standard of care). Patients who need blood transfusion will receive cross-matched allogenic blood products.
89363190|NCT04908228|Experimental|Ibrutinib + obinutuzumab|Ibrutinib 420 mg QD for 24 months (Cycles 1-24) Obinutuzumab starting from Cycle 13 Day 1 (100 mg Cycle 13 Day 1, 900 mg Cycle 13 Day 2, 1000 mg Cycle 13 Days 8 and 15, 1000 mg Cycles 14-18 Day 1).
89363191|NCT04908163|Active Comparator|Nutritional education group (NEG)|"Participants in the nutritional education group will be given a leaflet with written nutrition educational information to follow a Mediterranean diet. Participants will be encouraged to adhere to this diet for one month. Four visits will be scheduled for participants assigned to this group:~(1) before randomization (T1); (2) after randomization and before the the beginning of the intervention (T2); and (3) (4) after the intervention (T3)(T4). In all time-points, questionnaires will be registered and at T2 and T4 blood samples will be collected and advanced glycation end-products will be measured."
89363192|NCT04908163|Experimental|Culinary intervention group (CIG)|"Participants assigned to the culinary intervention group will receive a written nutrition educational information as well as eight online nutritional and cooking classes during the one-month intervention period. Four visits will be scheduled for participants assigned to this group:~(1) before randomization (T1); (2) after randomization and before the the beginning of the intervention (T2); and (3) (4) after the intervention (T3)(T4). In all time-points, questionnaires will be registered and at T2 and T4 blood samples will be collected and advanced glycation end-products will be measured.~Participants will receive 8 culinary workshops between visit 2 and visit 3. In all time-points, questionnaires will be registered and at T2 and T4 blood samples will be collected and advanced glycation end-products will be measured.~Volunteers will be also contacted by phone after 6 months of the end of the intervention to collect information about food and culinary habits."
89363193|NCT04904679|Active Comparator|Amniotic Membrane group|Patients who will be treated with a amniotic membrane plug
89363194|NCT04904679|Active Comparator|Internal Limiting Membrane group|patients who will be treated with a internal limiting membrane flap
89363195|NCT04898790|No Intervention|Feedback for Preliminary Adaptation|Participants in Aim 1 will participate in qualitative interviews to obtain feedback on the CHAMPS-II intervention and survivorship education active control condition materials. Interviews will be with 1)adult participants 60+ years who have recently undergone HCT, 2)participants' care-partner, and 3)HCT team members.
89363196|NCT04898790|Experimental|Adapted CHAMPS-II intervention|"All participants in Aim 2 (preliminary testing) and Aim 3 (RCT) will participate in the CHAMPS-II physical activity program adapted to the HCT setting. Testing for outcome measures will be completed, and feedback on the intervention will be obtained via qualitative interviews from 1)adult participants 60+ years receiving HCT, 2)participants' care-partner, and 3)HCT team members.~Aim 3 participants will be randomized to either the immediate intervention (intervention then follow-up) or delayed intervention (wait period and then intervention)."
89363197|NCT04881799|Placebo Comparator|Placebo-Controlled Period|Participants in this phase of the study will be randomized 1:1 to receive either phentermine/topiramate or placebo.
89178288|NCT00782340|Active Comparator|Droxidopa|100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
88834312|NCT04180709|Experimental|Sleepio Intervention + Treatment As Usual (TAU)|Participants will receive the online Sleepio intervention to be completed approximately once per week, at least 6 sessions during the 8-week period, and complete daily sleep diaries. In addition they will continue their treatment as usual (TAU) with the CAMEO Early Intervention in Psychosis CPFT or Early Intervention in Psychosis Services NSFT care team.
88834313|NCT04180709|No Intervention|Treatment As Usual (TAU) alone|Participants will continue their treatment as usual (TAU) with their Early Intervention in Psychosis care team. They will however be offered access to the Sleepio intervention during the follow-up period of the study.
88834314|NCT04174365|Experimental|Brexpiprazole|"Participants received flexible doses of brexpiprazole 0.25 to 3 milligram per day (mg/day), orally, once daily (QD) up to Week 8. For participants with body weight < 50 kilograms (kg) the dose was titrated up from 0.25 mg/day on Days 1 to 3, followed by 0.5 mg on Days 4 to 7, and to 1 mg on Days 8 to 14. Based on the investigator's judgment the dose was increased to 1.5 mg/day after Day 15. The dose was fixed after Week 6 and administration continued for another 2 weeks until Week 8.~For participants with body weight ≥ 50 kg the dose was titrated up from 0.5 mg/day on Days 1 to 3, followed by 1.5 mg on Days 4 to 7, and to 2 mg on Days 8 to 14. Based on the investigator's judgment the dose was increased to 3 mg/day after Day 15. The dose was fixed after Week 6 and administration continued for another 2 weeks until Week 8."
88834315|NCT04174365|Placebo Comparator|Placebo|Participants received brexpiprazole matching placebo orally, QD, in the same way as brexpiprazole up to Week 8.
88834316|NCT04173780|Experimental|Atropine 0.01%|
88834317|NCT04173780|Placebo Comparator|Placebo|
88834318|NCT04167111|Active Comparator|Vitamin D 4000|At baseline, if subjects 25(OH)D levels are 12-19.9, they will be started on 4000 IU per day.
88834319|NCT04167111|Active Comparator|Vitamin D 2400|At baseline, if subjects 25(OH)D levels are 20-30, they will be started on 2400 IU per day.
88834320|NCT04144608|Experimental|Toripalimab Combined With Platinum-containing Dual-agent|Toripalimab combined with platinum-containing dual-agent as a neoadjuvant Therapy for Non-small Cell Lung Cancer
88834321|NCT04143009|Experimental|Enhanced Friendship Bench (EFB)|Women seeking ANC services at 2 public health centers in Lilongwe, Malawi will be enrolled into this study arm during study recruitment. Individuals enrolled in this arm will be administered the Enhanced Friendship Bench intervention from date of enrollment through 6 months post-partum.
88834322|NCT04143009|Active Comparator|Enhanced Standard Care (ESC)|Women seeking ANC services at 2 public health centers in Lilongwe, Malawi will be enrolled into this study arm during study recruitment. Individuals enrolled in this arm will received the Enhanced Standard Care intervention from date of enrollment through 6 months post-partum.
88834323|NCT04143009|Experimental|Adapted Friendship Bench (AFB)|Women seeking ANC services at 2 public health centers in Lilongwe, Malawi will be enrolled into this study arm during study recruitment. Individuals enrolled in this arm will be administered the Adapted Friendship Bench intervention from date of enrollment through 6 months post-partum.
88834324|NCT04139304|Experimental|Treatment (daratumumab, DA-EPOCH)|Patients receive daratumumab IV on days 1 (± 3 days), 8 (± 2 days), and 15 (± 2 days), of cycles 1-3, and on day 1 of cycles 4-6. Patients also receive etoposide, doxorubicin hydrochloride, and vincristine sulfate IV continuous over 96 hours on days 1-4, prednisone PO on days 1-5, and cyclophosphamide IV over 1 hour on day 5. Treatment repeats every 21 days for up to 6 cycles in absence of disease progression or unacceptable toxicity.
88834325|NCT04136288|Experimental|Males with erectile dysfunction (ED)|Males diagnosed with erectile dysfunction (ED) for over a year, but less than 5 years, will receive shock wave therapy via MoreNova device
88834326|NCT04135690|Experimental|HAIC plus toripalimab|Hepatic arterial infusion of oxaliplatin , fluorouracil, and leucovorin every 3 weeks. Toripalimab 240mg intravenously every 3 weeks.
88834327|NCT04135690|Active Comparator|HAIC plus sorafenib|Hepatic arterial infusion of oxaliplatin , fluorouracil, and leucovorin every 3 weeks. Sorafenib 400mg twice daily (Bid) oral dosing.
88834328|NCT04135690|Other|Patients receiving TKI plus ICI|Patients, who meet the inclusion criteria but withdraw consent or reject this study, receive systemic treatment according to the doctor. Systemic treatment include atezolizumab+bevacizumab, camrelizumab+apatinib, sintilimab+bevacizumab and so on.
88834329|NCT04132830||HIV-Exposed Uninfected Dyads|Mothers who had HIV during pregnancy and their HIV-negative young adult offspring
88834330|NCT04132830||HIV-Unexposed Uninfected Dyads|Mothers and young adults without HIV
88834331|NCT04131426|Experimental|Remune dosed twice daily|A nutritional supplement taken twice per day each day and standard care for your cancer as prescribed by your oncologist
88834332|NCT04131426|Experimental|Remune dosed twice daily and daily exercise with EXCAP|A nutritional supplement taken twice by day each day and a home-based exercise intervention as well as standard care for your cancer as prescribed by your oncologist
88834333|NCT04131426|No Intervention|Usual Care|Usual standard care as prescribed by your oncologist
89178289|NCT00782340|Placebo Comparator|Placebo|100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
88834334|NCT04130646|Active Comparator|Active taVNS, Active TMS|
88834335|NCT04130646|Sham Comparator|Sham taVNS, Active TMS|
88834336|NCT04130646|Sham Comparator|Active taVNS, Sham TMS|
88834337|NCT04130646|Sham Comparator|Sham taVNS, Sham TMS|
88834338|NCT04128215|Active Comparator|Older Men|
88834339|NCT04128215|Active Comparator|Postmenopausal Women|
88834340|NCT04126317|Experimental|intravitreal aflibercept injection (IAI)|"Treatment-naïve patients with neovascular wet age-related macular degeneration (nAMD) randomized in a 1:1 ratio"
88834341|NCT04126317|Experimental|High-dose aflibercept (HD)|Treatment-naïve patients with nAMD randomized in a 1:1 ratio
88834342|NCT04123314|Experimental|Psilocybin|Participants will complete an 8-week course of study treatment including weekly psychological support and two moderate to high dose psilocybin administrations in weeks 4 and 6.
88834343|NCT04122703|Experimental|Percutaneous tibial nerve stimulation (PTNS)|The patients in the PTNS group will receive 1 PTNS treatments per week for 12 weeks.
88834344|NCT04122703|Sham Comparator|Transcutaneous electrical nerve stimulation (TENS)|The patients in the Sham group will receive one sham (TENS) treatment per week for 12 weeks
88834345|NCT04109924|Experimental|Treatment (irinotecan, bevacizumab, TAS-102)|Patients receive irinotecan IV over 90 minutes and bevacizumab IV over 10 minutes on days 1 and 15. Patients also receive trifluridine and tipiracil hydrochloride PO BID on days 2-6 and 16-20. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89363198|NCT04881799|Experimental|Open Label Extension|Participants in this phase of the study will receive open label phentermine/topiramate.
89363199|NCT04869631||Aortic valve stenosis undergoing aortic valve replacement|Aortic valve stenosis undergoing aortic valve replacement.
88834346|NCT04100564|Active Comparator|Standard airway method arm|Standard airway management strategy
88834347|NCT04100564|Experimental|Supraglottic airway method arm|Supraglottic first airway management strategy
88834348|NCT04093596|Experimental|ALLO-647, ALLO-715, Nirogacestat|
88834349|NCT04091750|Experimental|Single Arm|"Induction phase:~Nivolumab 3mg/kg IV plus Ipilimumab 1mg/kg IV every 3 weeks x 4 cycles (12 week period)~Cabozantinib 40mg PO daily for 12 weeks~Maintenance phase:~Nivolumab 480mg IV every 4 weeks for up to 92 weeks~Cabozantinib 40mg PO daily for up to 92 weeks~Maintenance therapy will continue for up to 92 weeks to complete 2 years total of treatment if tolerating therapy well and disease is controlled."
88834350|NCT04074720|Other|Standard of Care|patients will have tissue procured after a standard of care procedure, a one time blood draw performed, and optional rectal swab
88834351|NCT04073498|Experimental|Part 1a - Cohort 1|A single IV infusion of 0.0003 mg/kg SerpinPC in healthy subjects.
88834352|NCT04073498|Experimental|Part 1a - Cohort 2|A single IV infusion of 0.001 mg/kg SerpinPC in healthy subjects.
88834353|NCT04073498|Experimental|Part 1a - Cohort 3|A single IV infusion of 0.003 mg/kg SerpinPC in healthy subjects.
88834354|NCT04073498|Experimental|Part 1a - Cohort 4|A single IV infusion of 0.01 mg/kg SerpinPC in healthy subjects.
88834355|NCT04073498|Experimental|Part 1a - Cohort 5|A single SC dose of 0.03 mg/kg SerpinPC and a single SC dose of placebo in healthy subjects.
88834356|NCT04073498|Experimental|Part 1b - Cohort 6|A single SC dose of 0.1 mg/kg SerpinPC and a single SC dose of placebo in patients.
88834357|NCT04073498|Experimental|Part 1b - Cohort 7|A single SC dose of 0.3 mg/kg SerpinPC and a single SC dose of placebo in patients.
88834358|NCT04073498|Experimental|Part 1b - Cohort 8|A single SC dose of 0.6 mg/kg SerpinPC and a single SC dose of placebo in patients.
88834359|NCT04073498|Experimental|Part 1b - Cohort 9|Two single SC doses of 0.6 mg/kg SerpinPC in patients.
88834360|NCT04073498|Experimental|Part 2|Up to 3 SC doses may be selected for Part 2 and each patient will be assigned a single SerpinPC dose level (and placebo). The dose for Part 2 will be determined from ongoing review of the Part 1 data. The dose in Part will not exceed 1.2 mg/kg, or the highest dose deemed safe from Part 1b.
88834361|NCT04073498|Experimental|Part 3|A single flat SC dose of SerpinPC will be administered every 4 weeks for 48 weeks for patients who have completed Week 24 of Part 2. The dose level will be chosen after reviewing Part 2 data and will not exceed maximum dose level in Part 2.
88834362|NCT04073498|Experimental|Part 4|SC doses of 1.2 mg/kg SerpinPC will be administered every 2 weeks for 24 weeks for patients who have completed Week 48 of Part 3.
88834363|NCT04073498|Experimental|Part 5|SC doses of 1.2 mg/kg SerpinPC will be administered every 2 weeks for 52 weeks for patients who have completed Week 24 of Part 4.
88834364|NCT04073498|Experimental|Part 6|A single flat SC dose of 60mg SerpinPC will be administered every 2 weeks for 52 weeks for patients who have completed Week 52 of Part 5.
88834365|NCT04066894|Experimental|Supportive Care (sacral nerve stimulator)|Patients undergo scheduled, elective surgery for placement of the sacral nerve stimulator with external battery pack. After 2 weeks, patients undergo implantation of a subcutaneous internal battery or removal of the leads if the sacral nerve stimulator is working but does not improve symptoms. If the sacral nerve stimulator is not working, it is repositioned and patients return 2 weeks later for implantation of external battery or removal of leads.
88834366|NCT04049695|Experimental|Exercise Intervention|This arm will receive a 12-month individually tailored phone and email-based exercise program.
88834367|NCT04049695|Active Comparator|Health & Wellness Intervention|This arm will receive a 12-month health and wellness program.
88834368|NCT04046536|Active Comparator|Active rTMS at the LDLPFC|Subjects will receive the repetitive Transcranial Magnetic Stimulation (rTMS) study procedure at the left dorsolateral prefrontal cortex (LDLPFC).
88834369|NCT04046536|Sham Comparator|Sham rTMS at the LDLPFC|Sham rTMS will appear the same as the active, with the same parameters, but will not receive the actual magnetic stimulation to the LDLPFC.
88834370|NCT04046536|Active Comparator|Active rTMS at the LMC|Subjects will receive the repetitive Transcranial Magnetic Stimulation (rTMS) study procedure at the left motor cortex (LMC)
88834371|NCT04046536|Sham Comparator|Sham rTMS at the LMC|Sham rTMS will appear the same as the active, with the same parameters, but will not receive the actual magnetic stimulation to the LMC.
88834372|NCT04043195|Experimental|Nivolumab + Oxaliplatin + Ipilimumab|Cohort 1
88834373|NCT04038255|Active Comparator|Usual Care|Participants in this group will receive a brief advice to quit smoking, 6-week supplies of nicotine replacement therapy (NRT), and self-help materials to quit smoking.
88834374|NCT04038255|Experimental|Craving-to-Quit app|"Participants in this group will receive one in-person orientation session, 6-week supply of NRT, the Craving-to-Quit app, and two brief follow-up phone calls."
88834375|NCT04038255|Experimental|In-person Mindfulness Training|Participants in this group will receive twice weekly group sessions (eight total during 4 weeks) that were manualized and delivered by instructors experienced in Mindfulness Training (MT) (a single therapist with >4 years of training in MT).
88834376|NCT04031729|Experimental|Aspirin|Low-dose (81mg) aspirin tablets
88834377|NCT04031729|Placebo Comparator|Placebo|Placebo tablets
88834378|NCT04024163|Experimental|Benznidazole|Benznidazole 100 mg Tablets or Benznidazole 12.5 mg Tablets by mouth, every 12 hours for 60 days
88834379|NCT04023019||Group 1: ITI with Nuwiq, octanate, or wilate|Participants receiving immune tolerance induction with either Nuwiq, octanate, or wilate. As needed, aPCC/rFVIIa will be administered to treat bleeding episodes or during surgery and for prophylaxis.
88834380|NCT04023019||Group 2: ITI with Nuwiq, octanate, or wilate with emicizumab|Participants receiving immune tolerance induction with either Nuwiq, octanate, or wilate, in combination with emicizumab prophylaxis. As needed, aPCC/rFVIIa will be administered to treat bleeding episodes or during surgery.
88834381|NCT04023019||Group 3: Prophylaxis with emicizumab, aPCC, or rFVIIa|Participants receiving routine prophylaxis with emicizumab, aPCC, or rFVIIa without immune tolerance induction. On-demand aPCC/rFVIIa can be used as needed to treat bleeding episodes or during surgery.
88834382|NCT04016402||Study Group|All participants enrolled in the study
88834383|NCT04014387|Active Comparator|Zolpidem Arm|Participants will be given one week of Zolpidem.
88834384|NCT04014387|Active Comparator|Suvorexant Arm|Participants will be given one week of Suvorexant.
88834385|NCT04014387|Placebo Comparator|Placebo Arm|Participants will be given one week of a placebo pill.
88834386|NCT04005053|Experimental|Low-Dose NAC|3600 NAC mg/day
88834387|NCT04005053|Experimental|High-Dose NAC|5400 NAC mg/day
88834388|NCT04005053|Placebo Comparator|Placebo|Placebo
88834389|NCT04001179||Presence of pulmonary embolism|≥ 1 noninfused and normoventilated segment(s) by pulmonary tomoscintigraphy
88834390|NCT04001179||No pulmonary embolism|Pulmonary perfusion without anomaly (segmental or sub-segmental) by pulmonary tomoscintigraphy
88834391|NCT03982225|Experimental|2.5% Polyene Phosphatidylcholine Injection 0.2 mL/1.0 cm|Participants receive 2.5% polyene phosphatidylcholine administered in 0.2 mL injections, 1.0 cm apart, up to 10.0 ml per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
88834392|NCT03982225|Experimental|5.0% Polyene Phosphatidylcholine Injection 0.2 mL/1.0 cm|Participants receive 5.0% polyene phosphatidylcholine administered in 0.2 mL injections, 1.0 cm apart, up to 10.0 ml per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
88834393|NCT03982225|Experimental|5.0% Polyene Phosphatidylcholine Injection 0.4 mL/1.0 cm|Participants receive 5.0% polyene phosphatidylcholine administered in 0.4 mL injections, 1.0 cm apart, up to 20.0 ml per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
88834394|NCT03982225|Placebo Comparator|Placebo 0.2 mL/1.0 cm|Participants receive placebo administered in 0.2 mL injections, 1.0 cm apart, up to 10.0 ml per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
88834395|NCT03981796|Active Comparator|Arm 1: Participants receiving dostarlimab + Carboplatin-paclitaxel followed by dostarlimab|
88834396|NCT03981796|Placebo Comparator|Arm 2: Participants receiving placebo + carboplatin-paclitaxel followed by placebo|
88834397|NCT03981796|Active Comparator|Arm 3: Participants receiving dostarlimab + carboplatin-paclitaxel followed by dostarlimab+niraparib|
88834398|NCT03981796|Placebo Comparator|Arm 4: Participants receiving placebo + carboplatin-paclitaxel followed by placebo|
88834399|NCT03979040|Experimental|Group Transdiagnostic Behavior Therapy|TBT was developed to address transdiagnostic avoidance via the use of four different types of exposure techniques (situational/in-vivo, physical/interoceptive, thought/imaginal, and [positive] emotional/behavioral activation). From the transdiagnostic avoidance perspective, the four exposure practices are matched to the type(s) of avoidance experienced by patients based upon their cluster of symptoms/disorders. Per protocol, the first six sessions of TBT are designed to educate on, prepare for, and practice the four different types of exposure techniques. The next five sessions are focused on practicing and refining exposure practices as participants work through their lists of avoided situations/sensation/thoughts. The final session reviews treatment progress and relapse prevention strategies.
88834400|NCT03979040|Active Comparator|Group Disorder-Specific Therapy (G-DSTs)|To provide an evidence-based comparison for the G-TBT condition, G-DSTs will be used that are matched to the participant?s principal diagnosis. G-DSTs will include groups for the most common principal diagnoses that have VA-approved protocols and training programs, including PTSD (Cognitive Processing Therapy for PTSD) and MDD (CBT-Depression). Each of these G-DSTs have published manuals for administration and have received extensive support in the literature.
88834401|NCT03971578||Autism Spectrum Disorders Group|Children identified as having Autism Spectrum Disorder Age: 3.5 to 4.5 years old
88834402|NCT03971578||Normal Control Group|Normal children without Autism Spectrum Disorder or other identified developmental disability Age: 3.5 to 4.5 years old
89178290|NCT00916188|Experimental|Black Tea-Four Doses|One, 2, 3 and 4 cups (150 ml/cup) of Black tea/day for week 1, 2, 3, and 4, respectively.
89001241|NCT00577759|Experimental|Active Intervention|Direct referral to community organizations, with support for practices to do so. These include the North Carolina Tobacco Quitline, public health department dietitians, and the YMCA.
89001242|NCT00577759|Experimental|Passive Intervention|Provision of information about community organizations to patients as above.
89001243|NCT00577759|Placebo Comparator|Usual Care|Usual care
89001244|NCT00577798||Observational|Only had observational arm
89178291|NCT00916188|Active Comparator|Black Tea-One Dose|One cup (150 ml) of Black tea/day during study.
89178292|NCT00774852|Experimental|Treatment|Abatacept plus Euro-lupus regimen
89178293|NCT00774852|Placebo Comparator|Control|Abatacept placebo plus Euro-lupus regimen
89178294|NCT02602158|Active Comparator|Octanoic acid (1-13C, 99%)|100 µL 13C Octanoic acid (Cambridge isotope laboratories)
89178295|NCT02602158|Active Comparator|TRIOCTANOIN (1,1,1-13C3, 99%)|100 µL 13C Trioctanoin (Cambridge isotope laboratories)
89178296|NCT02603016|Experimental|GLSE compound group|GLSE compound 2g each time by mouth,twice a day for 42 days.
89178297|NCT02603016|Experimental|Maitake mushroom extract compound group|Maitake mushroom extract compound 2 tables each time by mouth,twice a day for 42 days.
89178298|NCT02603016|Experimental|Ginseng compound group|Ginseng compound 2 tables each time by mouth,twice a day for 42 days.
89178299|NCT02603016|No Intervention|blank control group|Take nothing.
89178300|NCT04101942|Experimental|Internet-based CBT|The experimental group will go through active internet-based treatment which is delivered on a safe internet platform. Treatment is divided into four modules, each containing homework assignments. Participants in the experimental group will be assigned a therapist that they can contact through a message system in the platform and expect answer within 36 hours on weekdays
89363200|NCT04856215|Experimental|90-Yttrium-labelled anti-CD66 monoclonal antibody|"The medicinal product consists of the murine IgG1 anti-CD66 monoclonal antibody radio-labelled with 111In for imaging and dosimetry and with 90Y for therapy.~Dosage indications The [111In]-labeled anti-CD66 monoclonal antibody (MAb) will be given at an infused activity of 100MBq/sqm between 1-4 weeks before the therapeutic dose of radiolabelled antibody.~[90Y]-yttrium-labeled anti-CD66 MAb will be given as a single infusion on day - 14 prior to transplant. [90Y]-yttrium labelled anti-CD66 MAb will be given to target an absorbed dose to the bone marrow of 45 Gy +/- 10%. The maximum dose to be delivered to the liver and the kidneys is 15 Gy and 10 Gy, respectively."
89363201|NCT04826770||BNT/BNT/BNT|Subjects receiving two doses of BNT162b2 (Comirnaty®, tozinameran (INN), BioNTech/Pfizer) as homologous basic immunization and one dose of BNT162b2 as booster vaccination
89178301|NCT04101942|No Intervention|Control condition (assessment only)|Waitlist control, i.e. no active active intervention during waiting list period. Will be offered treatment after 7 weeks.
89178302|NCT04106310|Active Comparator|Theranova|Patients will be receiving hemodialysis using Theranova dialyzer. The other hemodialysis parameters are kept the same.
89178303|NCT04106310|Active Comparator|High-flux|Patients will be receiving hemodialysis using a high-flux dialyzer. The other hemodialysis parameters are kept the same
89178304|NCT04106076|Experimental|Dose escalation|Several tested doses of UCART123 until the Maximum Tolerated Dose (MTD) is identified.
89178305|NCT03998358||High Fatigue|TBI patients with significant fatigue as calculated by a score of >= 5.5 on the Fatigue Severity Scale
89178306|NCT03998358||Low Fatigue|TBI patients without significant fatigue as calculated by a score of < 5.5 on the Fatigue Severity Scale
89363202|NCT04826770||AZD/BNT/BNT|Subjects receiving one dose of AZD 1222 (Vaxzevria®, Covishield®, ChadOx1 nCoV-19, Oxford University/Astra-Zeneca) followed by one dose of BNT162b2 (Comirnaty®, tozinameran (INN), BioNTech/Pfizer) as heterologous basic immunization and one dose of BNT162b2 (Comirnaty®, tozinameran (INN), BioNTech/Pfizer) as booster vaccination
89363203|NCT04826770||AZD/AZD/BNT|Subjects receiving two doses of AZD 1222 (Vaxzevria®, Covishield®, ChadOx1 nCoV-19, Oxford University/Astra-Zeneca) as homologous basic immunization and one dose of BNT162b2 (Comirnaty®, tozinameran (INN), BioNTech/Pfizer) as booster vaccination
89363204|NCT04826770||AZD/MOD/BNT|Subject receiving one dose of AZD 1222 (Vaxzevria®, Covishield®, ChadOx1 nCoV-19, Oxford University/Astra-Zeneca) followed by one dose of mRNA-1273 (Spikevax®, elasomeran (INN), Moderna) as heterologous basic immunization and one dose of BNT162b2 (Comirnaty®, tozinameran (INN), BioNTech/Pfizer) as booster vaccination
89178307|NCT00774306|Active Comparator|1|Participants randomized to Group 1 will receive phenytoin (PHT) at 5 mg/kg/day in 2 divided doses.
89178308|NCT00774306|Active Comparator|2|Participants randomized to Group 2 will receive valproate (VPA) at 15 mg/kg/day in 3 divided doses or in a once-daily extended release formulation.
89178309|NCT00774306|Active Comparator|3|Participants randomized to Group 3 will receive levetiracetam (LEV) 1000-1500 mg/day in 2 divided doses.
89178310|NCT00774306|No Intervention|4|Participants randomized to Group 4 will receive no drug intervention.
89178311|NCT04105764|Active Comparator|DEEP BLOCK|In the deep NMB-group, a PTC of 1 to 2 twitches was maintained, and NMB was reversed with sugammadex at the end of surgery.
89178312|NCT04105764|Active Comparator|Moderate block|In the moderate NMB group, a TOF count of 1 to 2 was maintained and NMB was reversed with a combination of neostigmine and glycopyrolate at the end of surgery.
89178313|NCT04105608|Experimental|HFV meal|A vegetarian meal high in dietary carbohydrate and fiber
89178314|NCT04105608|Active Comparator|MED meal|A Mediterranean-like meal
89001245|NCT00187083|Experimental|1|Native asparaginase
89001246|NCT00187083|Experimental|2|PEG-asparaginase
89001247|NCT00577837|Active Comparator|1|5 mg risedronate, once daily for 6 months
89178315|NCT04105686|Active Comparator|Control Infant Formula|Milk-based study product
89178316|NCT04105686|Experimental|Experimental Infant Formula|Milk-based study product with oligosaccharides
89178317|NCT04105686|No Intervention|Reference Group|Human milk-fed group
89001248|NCT00577837|Experimental|2|100 mg risedronate, once a month for 6 months
89001249|NCT00577837|Experimental|3|150 mg risedronate, once a month for 6 months
89001250|NCT00577837|Experimental|4|200 mg risedronate, once a month for 6 months
89001251|NCT00180557|Experimental|Active fixation lead|Active fixation lead was implanted
88834403|NCT03961698|Experimental|Cohort A (TNBC)|"IPI-549 in combination with front-line treatment. Cohort A will include two sub-cohorts: Cohorts A1 and A2.~Cohort A1: Approximately 30 patients with locally advanced and/or metastatic TNBC with programmed death-ligand 1 (PDL1) positive disease based on immunohistochemistry (IHC) defined as IC1/2/3.~Cohort A2: Approximately 30 patients with locally advanced and/or metastatic TNBC with PDL1 negative disease based on IHC defined as IC0."
88834404|NCT03961698|Experimental|Cohort B (RCC)|"IPI-549 in combination with front-line treatment. Cohort B will include two sub-cohorts: Cohorts B1 and B2.~Cohort B1: Approximately 15 patients with locally advanced and/or metastatic RCC, with PDL1 positive disease based on IHC defined as IC1/2/3.~Cohort B2: Approximately 15 patients with locally advanced and/or metastatic RCC, with PDL1 negative disease based on IHC defined as IC0."
88834405|NCT03947749||Patients with HICMP|Patients with PROMIS Pain Interference-6b scores one standard deviation above the national average will be categorized into this group.
88834406|NCT03947749||Patients without HICMP|Patients without PROMIS Pain Interference-6b scores one standard deviation above the national average will be categorized will be categorized into this group.
88834407|NCT03947749||Patients at risk for opioid abuse or misuse|The Opioid Risk Tool and PROMIS Short Form v1.0-Prescription Pain Medication Misuse will be used to categorize patients at risk.
88834408|NCT03947749||Patients not at risk for opioid abuse or misuse|The Opioid Risk Tool and PROMIS Short Form v1.0-Prescription Pain Medication Misuse will be used to categorize patients at risk.
88834409|NCT03945643|Active Comparator|Sildenafil administration|Administration of 50mg sildenafil one time, one hour prior to measurements
88834410|NCT03945643|Placebo Comparator|Placebo administration|Administration of 50mg placebo one time, one hour prior to measurements
88834411|NCT03938389|Active Comparator|Valsartan|Valsartan 160 mg twice daily for 26 weeks
88834412|NCT03938389|Experimental|Sacubitril/Valsartan|Sacubitril/Valsartan (97/103 mg) twice daily for 26 weeks
88834413|NCT03938389|Placebo Comparator|Placebo|placebo (+/- amlodipine 2.5-5 mg twice daily if high blood pressure)
89178318|NCT00781326|Other|Open Label Antidepressant|In Phase 1, all participants will be placed on antidepressant medication. In Phase 2, participants will continue with their antidepressant medication and also receive receive either nimodipine or placebo.
89178319|NCT02603094|Experimental|clear fluids until premedication|allowed to drink until premedication, aprox 30 minutes before anaesthesia induction. Fasting for solids and non-clear fluids is six hours.
89178320|NCT02603094|Active Comparator|2 hours fluid fasting|allowed to drink until 2 hour before scheduled anaesthesia induction clear fluid Ingestion. Fasting for solids and non-clear fluids is six hours.
89178321|NCT00916266|Experimental|stem cell transplantation|Patients with refractory temporal lobe epilepsy that are transplanted with autologous bone marrow stem cells in order to provide seizure control.
89178322|NCT00787800|Active Comparator|Dual Chamber ICD|Dual chamber Implantable Cardioverter-Defibrillator (ICD): Atrial therapies and minimized ventricular pacing will be programmed on along with Ventricular Tachycardia/Ventricular Fibrillation (VT/VF) detection and therapies with detection enhancements; remote monitoring set to alert for sustained atrial fibrillation.
89178323|NCT00787800|Active Comparator|Single Chamber ICD|Single chamber Implantable Cardioverter-Defibrillator: Optimally programmed Ventricular Tachycardia/Ventricular Fibrillation (VT/VF) detection and therapies will be programmed on including use of detection enhancements.
89178324|NCT00773838|Experimental|Vorinostat + Bortezomib|Participants receive vorinostat 400 mg, orally, once daily (QD) on Days 1-14 of each 21-day treatment cycle and bortezomib 1.3mg/m^2 intravenous (IV) injection QD on Days 1, 4, 8 and 11 of each 21-day treatment cycle for up to 26 cycles. Participants with progressive disease (PD) after 2 cycles of treatment or no change (NC) after 4 cycles of treatment receive additional treatment of Dexamethasone, 20 mg of total daily dose, orally on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each 21-day treatment cycle for up to 26 cycles. Eligible participants could receive additional treatment on an extension.
89178325|NCT00787644|Active Comparator|1|
89178326|NCT00787644|Placebo Comparator|2|
89363205|NCT04826770||AZD/BNT/MOD|Subject receiving one dose of AZD 1222 (Vaxzevria®, Covishield®, ChadOx1 nCoV-19, Oxford University/Astra-Zeneca) followed by one dose of BNT162b2 (Comirnaty®, tozinameran (INN), BioNTech/Pfizer) as heterologous basic immunization and one dose of mRNA-1273 (Spikevax®, elasomeran (INN), Moderna) as booster vaccination
88834414|NCT03937973|Experimental|Social rejection by in-group|One hour prior to bed, participants will be exposed to a social rejection paradigm that includes a computerized ball-tossing game (Cyberball) and a speech task. Participants are made to believe that they are being rejected by someone of their own race/ethnicity (e.g., African American rejected by another African American).
88834415|NCT03937973|Experimental|Social rejection by out-group|One hour prior to bed, participants will be exposed to a social rejection paradigm that includes a computerized ball-tossing game (Cyberball) and a speech task. Participants are made to believe that they are being rejected by someone not of their own race/ethnicity (e.g., Caucasian American rejected by another African American).
88834416|NCT03929913|Experimental|Transcatheter Mitral Valve Cerclage Annuloplasty|"To evaluate the feasibility and safety of Transcatheter Mitral Cerclage Annuloplasty (TMCA) to treat symptomatic heart failure accompanied by mitral valve regurgitation despite optimal medical therapy.~The TMCA implant is attached to a guidewire and pulled through the internal jugular sheath, along the coronary sinus, through the basal septum, through the tricuspid valve, and back out of the internal jugular sheath. The position of the TMCA implant is adjusted so that the coronary protection element lies directly over any underlying branch of the left coronary artery."
88834417|NCT03927820||Patients Using Inhalers|Adult patient admitted to Vanderbilt University Medical Center (excluding surgery services) on a long acting inhaler or prescribed a long acting inhaler during admission.
89001252|NCT00180557|Active Comparator|Passive fixation lead|Passive fixation lead was implanted
89178327|NCT02602002|Experimental|Active|Remifentanil 0.1 ug/kg/min to 0.10 ug/kg/min
89178328|NCT02602002|Placebo Comparator|Placebo|Saline (0.9%)
89178329|NCT00787566|Experimental|0.5 mg of TRG (intranasal granisetron)|0.5 mg dose, intranasal powder, single spray, administered once
89363206|NCT04826770||Control/validation group|"Control samples for the validation of the used methods from the pre-SARS-CoV-2 era were transferred from the study Blood Donations from Healthy Blood Donors to Investigate Circannual Variations in Tryptophan Metabolism and Adaptive Immune Response to Bacterial Infectious Agents (in short TRP study). Subjects had not received any SARS-CoV-2 vaccination at that time. Remaining plasma samples were transferred to the AICOVI study."
89363207|NCT04818632|Experimental|AZD9833 monotherapy dose escalation|
88834418|NCT03908736|Other|Single-arm cohort|Baseline experimental measurements will be collected for each individual participant twice prior to zinc supplementation (0 month and 3 month time points). After zinc supplementation, experimental measurements will be collected for each individual participant at the 6 month and 9 month time points. The zinc intervention is zinc picolinate 15 mg once per day for 6 months.
88834419|NCT03905928|Experimental|18mg/ml Tobacco Flavor ECIG|Participants will be provided with an ECIG containing 15mg/ml nicotine concentration and a tobacco flavor.
88834420|NCT03905928|Placebo Comparator|0mg/ml Tobacco Flavor ECIG|Participants will be provided with an ECIG containing 0mg/ml nicotine concentration and a tobacco flavor.
88834421|NCT03905928|Experimental|18mg/ml Strawberry Vanilla Flavor ECIG|Participants will be provided with an ECIG containing 15mg/ml nicotine concentration and a strawberry vanilla flavor.
88834422|NCT03905928|Placebo Comparator|0mg/ml Strawberry Vanilla Flavor ECIG|Participants will be provided with an ECIG containing 0mg/ml nicotine concentration and a strawberry vanilla flavor.
88834423|NCT03882203|Experimental|treatment|Patients receive the study protocol: CLAGE sequential with Flu-Bu as conditioning regimen followed by low-dose decitabine maintenance
88834424|NCT03880500|Sham Comparator|Patient|25 Patients will receive a spinal manipulative therapy Intervention, the other 25 Patients receive a sham Intervention.
88834425|NCT03880500|No Intervention|Control|No intervention
88834426|NCT03872700|Experimental|Intranasal fentanyl|2 mcg/kg INF, administered via intranasal route by atomizer syringe
88834427|NCT03872700|Experimental|Placebo|0.04ml/kg of sterile water, administered via intranasal route by atomizer syringe
88834428|NCT03870386|Experimental|EUS-BD with LAMS|A curvilinear endoscope is inserted orally and advanced to the duodenal bulb. Biliary accessibility is confirmed via EUS and with Doppler to rule out any intervening vessels. For common bile ducts < 15 mm in diameter, the biliary access is established via needle puncture with a 19-gauge needle followed by advancement of a 0.035 or 0.025 inch guidewire. A LAMS (AxiosTM) will then be inserted with cautery assistance without tract dilation and deployed. For common bile ducts > 15 mm, the need for initial needle puncture and wire insertion is at the discretion of the endoscopist. A cholangiogram is then performed through the LAMS with contrast injection. The choice of stent size will be at the discretion of the endoscopist (8 x 8 mm or 6 x 8 mm).
88834429|NCT03870386|Active Comparator|Traditional transpapillary metal stent via ERCP|A duodenoscope is advanced orally to the papilla. The bile duct is then cannulated with a sphincterotome using the guidewire-assisted technique. A cholangiogram is then performed followed by insertion of a self-expanding metal biliary stent. The performance of a biliary sphincterotomy prior to stent insertion and the choice of stent size (10x 40 mm, 10 x 60 mm, 10x 80 mm) will be at the discretion of the endoscopist.
88834430|NCT03858153|Experimental|Exercise|Exercise for Cancer Patients (EXCAP©®) involves face-to-face instruction and a prescription for an at-home progressive walking and resistance exercise program.
88834431|NCT03858153|Active Comparator|Nutrition Education|Nutrition education involves equal time and attention as the exercise arm, but the content covers nutrition for cancer patients and lacks an exercise prescription.
88834432|NCT03852108|Experimental|Group comfort care|Socio-aesthetic care
89363208|NCT04818632|Experimental|AZD9833 monotherapy dose expansion|
89363209|NCT04818632|Experimental|AZD9833 with palbociclib dose expansion|
89363210|NCT04818632|Experimental|AZD9833 with everolimus dose expansion|
89363211|NCT04807283|Experimental|Treatment|
89363212|NCT04803565|Experimental|Custom-Made Insole|"This Group will receive a custom-made shoe insole designed on the foot shape of the subjects.~The group will also receive Physiotherapy and Occupational Therapy according to current guidelines"
89363213|NCT04803565|Sham Comparator|Sham Insole|"This group will receive a Sham shoe insole without any specific custom-made design.~The group will also receive Physiotherapy and Occupational Therapy according to current guidelines"
89363214|NCT04790045|Other|Venetoclax-based treatment|Single-arm study Patients enrolled will be receiving venetoclax-based regimens according to the standard of care
88834433|NCT03852108|No Intervention|Group control|Conventional care
88834434|NCT03846310|Experimental|Dose Escalation Arm A|Dose escalation is a 3+3 design, including a Dose Limiting Toxicity (DLT) evaluation period. The RDE of etrumadenant will be determined in this part with escalating doses of etrumadenant in combination with standard doses of carboplatin/pemetrexed chemotherapy regimen in participants with Non-Small Cell Lung Cancer.
88834435|NCT03846310|Experimental|Dose Escalation Arm B|Dose escalation is a 3+3 design, including a Dose Limiting Toxicity (DLT) evaluation period. The RDE of etrumadenant will be determined in this part with escalating doses of etrumadenant in combination with standard doses of carboplatin/pemetrexed chemotherapy regimen and pembrolizumab in participants with Non-Small Cell Lung Cancer.
88834436|NCT03846310|Experimental|Dose Expansion Arm 1|Zimberelimab will be administered in combination with standard carboplatin and pemetrexed chemotherapy regimen in participants with Non-Small Cell Lung Cancer harboring a sensitizing EGFR mutation.
89178330|NCT00787566|Experimental|1.0 mg of TRG (intranasal granisetron)|1.0 mg dose, intranasal powder, songle spray, administered once
88834437|NCT03846310|Experimental|Dose Expansion Arm 2|The etrumadenant at RDE determined from the dose escalation phase will be administered in combination with standard carboplatin and pemetrexed chemotherapy regimen and zimberelimab in participants with Non-Small Cell Lung Cancer harboring a sensitizing EGFR mutation.
88834438|NCT03844347|Experimental|C-Bien|
88834439|NCT03844347|No Intervention|Control|
89363215|NCT04789733|Experimental|Tight pressure management|"Patients assigned to tight blood pressure control angiotensin converting enzyme inhibitors and angiotensin receptor blockers will not be given the morning of surgery. Other chronic antihypertensives will only be given as necessary to treat hypertension. Norepinephrine or phenylephrine infusion will be infused at a rate sufficient to maintain intraoperative MAP ≥ 85 mmHg.~Resumption of chronic anti-hypertensive medications will be delayed until the third postoperative day unless deemed necessary to treat hypertension or for some other clear indication.~The target for postoperative systolic arterial pressures ≥110 mmHg during the initial three postoperative days."
89363216|NCT04789733|Other|Routine pressure management|ACEIs, ARBs, and/or calcium channel blockers can be given the morning of surgery if deemed appropriate by the attending anesthesiologist. Intraoperative blood pressure will be managed per clinical routine. As usual, chronic anti-hypertensive medications will be restarted shortly after surgery unless contraindicated by hypotension.
89363217|NCT04779216|Experimental|Active Romosozumab 210mg Injection|Romosozumab 210mg injection monthly for 12 months. Alendronate 70mg PO weekly starting at Month 12 through 24 months.
89363218|NCT04779216|Placebo Comparator|Placebo|Placebo injection monthly for 12 months. Alendronate 70mg PO weekly starting at Month 12 through 24 months.
88834440|NCT03832192|Experimental|care.coach Avatar|
88834441|NCT03832192|No Intervention|Control|
88834442|NCT03811964|Other|primary sleep-wake disorder|Subjects with primary sleep-wake disorder
88834443|NCT03811964|Other|neurological pathology|subjects presenting a neurological pathology with disorder of the controls of the wake and the sleep
88834444|NCT03811964|Other|psychiatric pathology|subject presenting a psychiatric pathology with disorder of the controls of the wake and the sleep
88834445|NCT03811964|Other|ophthalmological pathology|subject presenting an ophthalmological pathology with possible alteration of the photoreception and / or phototransduction
88834446|NCT03811964|Other|photosensitivity|subjects with photosensitivity with regulation disorder of sleep and wake
88834447|NCT03811964|Other|group control|healthy subject
88834448|NCT03808870|Experimental|NBM-BMX|
88834449|NCT03776461|Experimental|80-pin applicator|3 treatments with the 80-pin tip applicator at 0, 4, and 8 weeks.
88834450|NCT03776461|Active Comparator|160 pin applicator|3 treatments with the 160-pin tip applicator at 0, 4, and 8 weeks.
88834451|NCT03766971|Experimental|Early-onset Cigarette Smokers|Participants who began smoking cigarettes earlier in life (<16 years old) will be randomized to 7 or 21 days of tobacco cessation.
88834452|NCT03766971|Experimental|Late-onset Cigarette Smokers|Participants who began smoking cigarettes later in life (>16 years old) will be randomized to 7 or 21 days of tobacco cessation.
88834453|NCT03764696|No Intervention|air, the first and second stage of labor|"Patients randomized to the group will receive room air.~The therapy will continue until after delivery"
88834454|NCT03764696|Experimental|oxygen, the first and second stage of labor|"Patients randomized to the group will receive oxygen administered by high flow facemask oxygen at 10 L/min oxygen.~The therapy will continue until after delivery"
88834455|NCT03753347|Experimental|influenza vaccine recipients|Participants of an earlier clinical trial (TITRE I) to receive one dose of the 2018-19 quadrivalent inactivated influenza vaccine
88834456|NCT03749967|Experimental|Dose 1|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 1 is five sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
88834457|NCT03749967|Experimental|Dose 2|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 2 is ten sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
89001253|NCT00577876|Experimental|1|Day of Surgery:Patient is admitted through the Preoperative Surgical Center (PSC). If a large APA is identified, then subject will continue on study Dissect APA (without any changes from what is routinely done) with a penile injection of Trimix. Once the initial Doppler Ultrasound is completed, the accessory pudendal artery will be temporarily clamped to stop blood flow. After the artery is clamped, the Doppler Ultrasound will be repeated. We estimate an extension of the surgery no longer than 5 or 10 minutes in comparison to the usual operating time. Once the Doppler Ultrasound is completed, the clamp will be removed and the surgery continued in its usual fashion.
89363219|NCT04778761|No Intervention|Usual Care|Usual care entails receiving usual medical care by the home-based care team.
89363220|NCT04778761|Experimental|Video intervention|In addition to usual care, the intervention will entail having a visit by a trained study clinician to provide access to the ACP video. The study clinician will discuss the content of the video and answer any questions.
88834458|NCT03749967|Experimental|Dose 3|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 1 is fifteen sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
88834459|NCT03749967|Experimental|Dose 4|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 1 is twenty sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
88834460|NCT03749967|Experimental|Dose 5|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 1 is twenty-five sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
88834461|NCT03749967|Experimental|Dose 6|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 1 is thirty sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
88834462|NCT03749967|Experimental|Dose 7|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 1 is thirty-five sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
88834463|NCT03749967|Experimental|Dose 8|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 1 is forty sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
88834464|NCT03749967|Experimental|Dose 9|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 1 is forty-five sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
88834465|NCT03749967|Experimental|Dose 10|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 1 is fifty sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
88834466|NCT03749434||Adults with HAIs after VAD therapy|Adult patients who have received a ventricular assist device implant.
88834467|NCT03740230||Hepatitis C|Participants with Hepatitis C Genotypes 1 to 6 receiving Maviret (glecaprevir/pibrentasvir) for 8, 12, or 16 weeks.
88834468|NCT03738800|Experimental|CD5789 Cream 200 µg/g|CD5789 200 µg/g, topical, 50g
88834469|NCT03738800|Experimental|CD5789 Cream 100 µg/g|CD5789 100 µg/g, topical, 50g
88834470|NCT03738800|Placebo Comparator|CD5789 Cream Vehicle|CD5789 Cream Vehicle, topical, 50g
88834471|NCT03738670|Experimental|RFA|Single-arm prospective observational study
88834472|NCT03734640|Placebo Comparator|Guideline recommended standard monitoring|vital signs (HR, BP) and neurological assessment (GCS and NIHSS) 15-30mins x 2 hours, 30mins x 6 hours, 1hourly x 16 hours in usual care monitoring environment
88834473|NCT03734640|Active Comparator|Low-intensity monitoring strategy|vital signs (HR, BP) and neurological assessment (GCS and/or NIHSS) 15-30mins x 2 hours, 2hourly x 8 hours, 4hourly x 14 hours in a non-ICU ward
88834474|NCT03734055|Experimental|Peer Mentoring|The program will consist of 12 sessions of peer mentoring that will include one standard educational session by telephone or video for approximately 60 minutes every 2 weeks. Additional interaction will be discouraged, but mentees and mentors will be asked to report any additional social interaction should it occur. The bi-weekly educational session will be generally structured in three parts: introduction, structured education, and problem solving. 60-minute calls are necessary for the delivery of educational content and mentors and mentees to be able to discuss their own experiences and potential solutions.
88834475|NCT03734055|Active Comparator|Social Support Group|Mentees randomized to the social support control group will be enrolled in a lupus support group designed specifically for this project.
88834476|NCT03729752|Active Comparator|Healthy Volunteer|Four serial PET-MR scans over 120 hours following a single, bolus injection of [89]Zr-DFO-VRC-HIVMAB060-00-AB (89Zr-DFO-VRC01).
88834477|NCT03729752|Experimental|Viremic HIV-infected|Four serial PET-MR scans over 120 hours following a single, bolus injection of [89]Zr-DFO-VRC-HIVMAB060-00-AB (89Zr-DFO-VRC01).
88834478|NCT03729752|Experimental|Suppressed HIV-infected|A PET-MR scan following a single, bolus injection of [89]Zr-DFO-VRC-HIVMAB060-00-AB (89Zr-DFO-VRC01).
88834479|NCT03725345|Active Comparator|Alcohol Group|Participants who have recently consumed alcohol.
88834480|NCT03725345|Sham Comparator|No Alcohol Group|Participants who have not recently consumed alcohol.
88834481|NCT03720678|Experimental|Dose Escalation|Dose escalation is a 3+3 design, including a Dose Limiting Toxicity (DLT) evaluation period. The RDE of etrumadenant will be determined in this part with escalating doses of etrumadenant in combination with the standard mFOLFOX chemotherapy regimen in participants with gastroesophageal or colorectal cancer.
88834482|NCT03720678|Experimental|Dose Expansion-GE|The RDE of etrumadenant will be determined from the dose escalation part. Etrumadenant will be given in combination with the standard mFOLFOX chemotherapy regimen in participants with gastroesophageal cancer
89178331|NCT00787566|Experimental|2.0 mg of TRG (intranasal granisetron)|2.0 mg dose, intranasal powder, single spray, administered once
89178332|NCT04101552|Experimental|grafted versus graft less socket shield technique|
89178333|NCT04017234|Experimental|PMP group|children received health education for eye and the intervention(which included frequency following response, eye exercise, and transcutaneous electrical nerve stimulation) a 30 minute three times per week for four weeks.
89363221|NCT04778449||Observational (questionnaire, medical chart review)|Patients complete a maximum of 3 paper or electronic questionnaires over 30 minutes within 2 weeks of presentation to MD Anderson, new diagnosis of melanoma, and/or initiating a new treatment, within 2 weeks of first restaging, and within 2 weeks of the end of treatment. Patients may complete an additional paper or electronic dietary questionnaire over 10 minutes for 3 days (30 minutes total) or a phone-based dietary recall. Patients who start a new treatment of interest may repeat the questionnaires at the same time points. Patients' medical records are also reviewed.
88834483|NCT03720678|Experimental|Dose Expansion-CRC|The RDE of etrumadenant will be determined from the dose escalation part. Etrumadenant will be given in combination with the standard mFOLFOX chemotherapy regimen in participants with colorectal cancer
88834484|NCT03719326|Experimental|Dose Escalation-Arm A|Dose escalation is a 3+3 design, including a Dose Limiting Toxicity (DLT) evaluation period.
89363222|NCT04767282|Other|Fruit and Vegetable Prescription|Each program participant will receive a fruit and vegetable prescription that is written by pediatricians to exchange for $15 of fresh produce. Prescriptions will be distributed during pediatric office visits and are redeemable at a local farmers' market and mobile market.
89363223|NCT04760392|Experimental|GDM|Goal-directed mobilization
89363224|NCT04760392|No Intervention|Control|Standard of care
89363225|NCT04754035|Experimental|venetoclax + ibrutinib|
89363226|NCT04748419|Experimental|Hypofractionated radiation therapy (hfRT) with Durvalumab|Combining consolidative radiation therapy (RT) using a hypofractionated regimen (hfRT) of 10Gy x 2 fractions for boosting the residual primary lung cancer with adjuvant anti-PD-L1 therapy (durvalumab), dose of 10 mg/kg infusion every two weeks concurrently for up to 12 months or disease progression.
89363227|NCT04744350|Active Comparator|Surgical|Surgical treatment using a minimal invasive surgical method. At our hospital we perform a percutaneous sacroiliac osteosynthesis using cannulated, perforated and fenestrated screws. This procedure is preferably performed in our hybrid operation theatre, which allows for correct placement using an intraoperative CT-scan.
89363228|NCT04744350|Active Comparator|Conservative|Patients will receive individually tailored physiotherapy and analgesics if necessary.
89363229|NCT04738279|Experimental|Phase I: Soft Launch (120 days)|The study will conduct a soft launch on the first five HF patients enrolled to finetune process and protocol.
89363230|NCT04738279|Experimental|Phase II: Calibration (210 days)|After learning from the soft launch and updating the protocol, the study will continue to enroll 15 HF patients for calibration purposes
88834485|NCT03719326|Experimental|Dose Escalation-Arm B|Dose escalation is a 3+3 design, including a Dose Limiting Toxicity (DLT) evaluation period.
88834486|NCT03719326|Experimental|Dose Escalation-Arm C|Dose escalation is a 3+3 design, including a Dose Limiting Toxicity (DLT) evaluation period.
88834487|NCT03719326|Experimental|Dose Expansion-TNBC-Arm 1|The dose given will be determined from the dose escalation part (Arm A).
88834488|NCT03719326|Experimental|Dose Expansion-Ovarian Cancer-Arm 2|The dose given will be determined from the dose escalation part (Arm A).
88834489|NCT03719326|Experimental|Dose Expansion-TNBC-Arm 3|The dose given will be determined from the dose escalation part (Arm B). .
88834490|NCT03719326|Experimental|Dose Expansion-TNBC-Arm 4|The dose expansion will be determined from the dose escalation part (Arm C).
88834491|NCT03717909|Experimental|Experimental Group|Sodium Valproate 200Mg E/C Tablet (active treatment)
88834492|NCT03717909|Placebo Comparator|Control Group|Sodium Valproate matched placebo (inactive treatment)
89363231|NCT04731506|Experimental|Family Connection|2 in-person sessions spaced one week apart & 10 IVR calls/6 months; delivers intervention to parents only
88834493|NCT03715478|Experimental|GSK2857916 with Pomalidomide and Dexamethasone|This will be a single arm study of GSK2857916 administered with pomalidomide and dexamethasone. GSK2857916 will be administered intravenously either on Day 1 of each 28 day cycle (Single Dose) or on Days 1 and 8 (Split Dose) and up to 4 dose levels will be evaluated during the phase I portion. Pomalidomide will be administered orally on Days 1-21 at 4 mg. Dexamethasone will be administered orally at 40 mg for patients ≤ 75 years old or 20 mg for patients older than 75 on days 1, 8, 15, 22.
88834494|NCT03711097|No Intervention|Control|Upper left or right central and lateral incisor
88834495|NCT03711097|Experimental|Varnish Intervention|Upper central and lateral incisor contralateral to control upper central and lateral incisor
88834496|NCT03709043|Experimental|Kudzu|Standardized kudzu
88834497|NCT03709043|Placebo Comparator|Control|Placebo
88834498|NCT03700138|Experimental|Privigen|TThe treatment (IV Ig, 100mg/ml at the dose of 2g/kg of body weight) will be administered by perfusion every 6 weeks, with a total of 3 perfusions administered (W0, W4, W8).
88834499|NCT03700138|Placebo Comparator|Placebo|The treatment (NaCl 0,9% 20 ml/kg) will be administered by perfusion every 4 weeks, with a total of 3 perfusions administered (W0, W4, W8).
88834500|NCT03688464|Active Comparator|Melatonin Treatment|Subjects to receive melatonin 0.1 mg/kg (minimum dose of 1 mg, maximum dose of 5 mg) 30 minutes prior to bedtime (1 mg/ml oral compound suspension) for 4 weeks.
88834501|NCT03688464|Active Comparator|Diphenhydramine Treatment|Subject to receive diphenhydramine 2.5 mg/ml oral liquid, dosed at 1 mg/kg at bedtime for 4 weeks.
88834502|NCT03688464|Placebo Comparator|Placebo|Subjects will receive cherry flavored placebo at bedtime for 4 weeks.
88834503|NCT03682055|Experimental|Phase 1 Dose Escalation (Accelerated Titration)|VK-2019 QD in Accelerated Titration dose escalation cohorts enrolling EBV+ NPC
88834504|NCT03682055|Experimental|Phase 1 Dose Escalation (Rolling Six)|VK-2019 QD in Rolling Six dose escalation cohorts enrolling EBV+ NPC.
88834505|NCT03682055|Experimental|Phase 1 Dose Expansion(s)|VK-2019 QD in expansion cohorts that may be opened at doses that meet pre-specified criteria for clinical and/or biological activity.
88834506|NCT03682055|Experimental|Phase 2a Dose Expansion(s)|VK-2019 QD in expansion cohorts that may be opened at doses that meet pre-specified efficacy criteria in Phase 1 Dose Escalation cohorts.
88834507|NCT03677999||Brain tumor patients with Glioma|"Men and women scheduled who are diagnosed with glioma who is seeking clinical care for their conditions at the UMN Masonic cancer center.~Passed the safety screen for MRI~Age 18 or older Participants will receive MEGA-PRESS sequence Magnetic Resonance Spectroscopy during their routined schedule standard of care MRI."
88834508|NCT03677973|Active Comparator|Active: Dose Escalation|Healthy volunteers will receive AB680 as a single intravenous (IV) infusion at 7 dose levels and as multiple IV infusions at 1 dose level. Assignment to receive AB680 or matching placebo will be random.
88834509|NCT03677973|Placebo Comparator|Placebo: Dose Escalation|Healthy volunteers will receive matching placebo as a single IV infusion and as multiple IV infusions. Assignment to receive AB680 or matching placebo will be random.
88834510|NCT03668002|Placebo Comparator|Arteriovenous Fistula (AVF)|If the participant is randomized to the AVF arm of the trial, the surgeon will connect an artery to a vein in the upper extremity, without using artificial material as conduit.
88834511|NCT03668002|Active Comparator|Arteriovenous Graft (AVG)|If the participant is randomized to the AVG arm of the trial, the surgeon will place a synthetic graft connecting an artery and vein under the skin in an upper extremity.
88834512|NCT03666065|Active Comparator|Aspart-U100 Insulin|Standard Concentration Rapid Acting Insulin
88834513|NCT03666065|Experimental|Aspart-U25 Insulin|Diluted Concentration of Rapid Acting Insulin
88834514|NCT03664518|Experimental|Eltrombopag|58 enrolled patients are picked up to take eltrombopag at the indicated dose.
88834515|NCT03654716|Experimental|ALRN-6924 -- Cohort A|"Participants will receive ALRN-6924 monotherapy on days 1, 4 (± 1 day), 8 (± 1 day), and 11 (± 1 day) of a 21-day cycle.~ALRN-6924 will be administered intravenously.~Participants with otherwise unselected TP53 wild type solid tumors and lymphoma will participate in this cohort."
88834516|NCT03654716|Experimental|ALRN-6924 -- Cohort B|"Participants will receive ALRN-6924 monotherapy on days 1, 4 (± 1 day), 8 (± 1 day), and 11 (± 1 day) of a 21-day cycle.~ALRN-6924 will be administered intravenously.~Participants with solid and CNS tumors and lymphoma with specific diagnoses or molecular features will participate in this cohort."
88834517|NCT03654716|Experimental|ALRN-6924 -- Cohort C|"Patients will receive ALRN-6924 in combination with cytarabine on days 1, 8 (± 1 day), and 15 (± 1 day) of a 28-day cycle.~Cytarabine is administered intravenously.~ALRN-6924 will be administered intravenously.~Participants with TP53 wild type acute leukemia will participate in this cohort."
88834518|NCT03650101||Hydrocephalus group|"Inclusion criteria:~Age less than six months~Symptomatic hydrocephalus characterized by abnormal rate of head growth, full anterior fontanel, ventriculomegaly~A parent or a guardian qualified by Ugandan law to give informed consent~Patients from Eastern, Central and Northern districts of Uganda, and in geographic proximity to CURE hospital will be eligible~Exclusion criteria:~Age greater than six months~No evidence of progressive hydrocephalus~Patients outside of the districts specified in the inclusion criteria"
88834519|NCT03650101||Control group|"Inclusion criteria:~Born at GA ≥ 37 weeks~Age less than six months at the time of enrollment~No known medical conditions~With a parent or a guardian qualified by Ugandan law to give informed consent~Parents live in one of the villages in the Mbale or Budaka District, in geographic proximity to CCHU.~Exclusion criteria:~Born at GA < 37 weeks~Age greater than six months~Evidence of one or more medical conditions~Living outside of the districts specified in the inclusion criteria."
88834520|NCT03649958|Active Comparator|HIRREM-SOP or Cereset|HIRREM-SOP is a novel, noninvasive, closed-loop, BrainEcho, acoustic stimulation neurotechnology to support relaxation and auto-calibration of neural oscillations, using auditory tones to reflect brain frequencies in near real time. This group will have 10 sessions.
88834521|NCT03649958|Active Comparator|Cereset 2x|Participants randomized to the Cereset 2x group will be seated in a comfortable zero-gravity chair identical to those in the HIRREM-SOP arm. They will listen to a pattern of musical notes linked to their brain activity patterns, but also receive intermittent very low level electrical stimulation of the scalp linked to brain activity. This group will only have 5 sessions,
88834522|NCT03644342|Experimental|Niraparib Arm|For the purposes of this study, two dose levels of Niraparib (100 mg and 200 mg) will be evaluated concomitant with the concurrent administration of pelvic radiotherapy.
88834523|NCT03629756|Experimental|Dose Escalation|3+3 design, including a DLT evaluation period. Etrumadenant RP2D will be determined in this part with escalating doses of oral etrumadenant in combination with a fixed dose of IV zimberelimab.
88834524|NCT03629756|Experimental|Dose Expansion-advanced clear-cell RCC|Etrumadenant at RP2D + zimberelimab
88834525|NCT03629756|Experimental|Dose Expansion-mCRPC|Etrumadenant at RP2D + zimberelimab
88834526|NCT03629743||ECOG and EEG Sensor|Study subjects are neurosurgical patients with medically refractory epilepsy who will have implanted with intracranial ECoG electrodes. The electrodes will be used during a period of inpatient monitoring to identify resectable seizure foci.
88834527|NCT03629613|Sham Comparator|Baseline|"Subjects will be tested on one day. Baseline testing will take place and will be followed by oral antioxidant cocktail intake. Oral antioxidant cocktail testing will take place ~2 hours after antioxidant intake.~During baseline testing, no supplement or placebo intake will be used."
88834528|NCT03629613|Experimental|Oral antioxidant cocktail|"Subjects will be tested on one day. Baseline testing will take place and will be followed by oral antioxidant cocktail intake. Oral antioxidant cocktail testing will take place ~2 hours after antioxidant intake.~Dose 1:(immediately after baseline) 300 mg alpha-lipoic acid, 500 mg vitamin C, 200 IU vitamin E Dose 2: (30 minutes after dose 1) 300 mg alpha-lipoic acid, 500 mg vitamin C, 400 IU vitamin E"
89178334|NCT04017234|No Intervention|control group|children just received health education for eye
88834529|NCT03628677|Experimental|Domvanalimab Monotherapy|Varying Doses of domvanalimab Monotherapy
88834530|NCT03628677|Experimental|Domvanalimab + zimberelimab Q2W Combination Therapy|Varying Doses of domvanalimab in Combination With Varying Doses of zimberelimab
88834531|NCT03628677|Experimental|Domvanalimab + zimberelimab Q3W Combination Therapy|Varying Doses of domvanalimab in Combination With Varying Doses of zimberelimab
88834532|NCT03628677|Experimental|Domvanalimab + zimberelimab Q4W Combination Therapy|Varying Doses of domvanalimab in Combination With Varying Doses of zimberelimab
88834533|NCT03628677|Experimental|Domvanalimab and Zimberelimab Q6W combination therapy|Varying Doses of domvanalimab in Combination With Varying Doses of zimberelimab
88834534|NCT03628677|Experimental|Fixed dose Domvanalimab Q3W or Q4W and Zimberelimab Q3W, Q4W|Varying Doses of domvanalimab in Combination With Varying Doses of zimberelimab
88834535|NCT03619083||Breast cancer patients treated with chemotherapy|
88834536|NCT03619083||patients not exposed to chemotherapy|
88834537|NCT03619083||healthy controls|
88834538|NCT03617952|Experimental|S1 (Peer) group|"S1 group households located in 25 clusters that were included in a prior cookstove study: selected households are nearest neighbors (peers) of households who received free stoves in that prior study. This group is used to represent a potentially high peer influence on the adoption of improved cookstoves.~The P3 Bio Intervention is implemented in this group."
88834539|NCT03617952|Experimental|S2 (Non-Peer) Group|"S2 group households are located in 25 clusters randomly selected from the area of the K-N Districts more than 1 km from the S1 clusters. This group will have minimal prior knowledge of the cookstoves through peers.~The P3 Bio Intervention is implemented in this group."
88834540|NCT03594448||Ancillary-correlative (Specimen collection)|Participants undergo collection of blood samples in addition to the usual amount collected when they come in for their regular cancer treatments or doctor?s appointment every 6-8 weeks until disease progression or stopping at 9 months.
88834541|NCT03586895|Experimental|e-Connect|County receives training and materials and subsequently begins the e-Connect intervention
88834542|NCT03586895|No Intervention|Standard of care|Counties use the standard of care and there is no intervention in practices.
88834543|NCT03584217|Other|Clinical Investigation|All participants will undergo GFR (Iohexol Inj 300 MG/ML), ERPF (Aminohippurate Sodium Inj 20%) in addition to renal BOLD and ASL MRI.
88834544|NCT03568292|Experimental|Arm I: Virtual Reality|Participants receive the VR intervention during bone marrow biopsy or lumbar puncture lasting until completion of the procedure. Participants will be trained to use VR equipment prior to the bone marrow biopsy or lumbar puncture. The headset will cover both eyes with a strap along the back to hold the headset in place. The headset will be attached by a wire to a laptop which will power the headset and provide content. A remote control will be available for assistance in setting up or stopping the content in the case of an event. The VR content will consist of meditation and relaxing techniques through visual and auditory input which can last up to one hour. There will be minimal stimulatory effort to decrease excess movement for the procedure.
88834545|NCT03568292|Active Comparator|Arm II: No Virtual Reality|Participants receive standard of care during bone marrow biopsy or lumbar puncture.
88834546|NCT03557710|Experimental|Behavioral Response Training|In Arm 1 of Devaluing energy-dense foods for cancer-control, participants will complete computer delivered versions of the stop-signal, go/no-go, and dot-probe training tasks in 8 30-min biweekly visits to the lab, with breaks between training blocks in which participants sit with their eyes closed to allow consolidation of learning. Participants will also complete a weekly 15-min training task online from home. Total training time = 345 min. Training will involve 100 images of cancer risk foods that participants regularly eat, including red and processed meats; high-sugar foods; heavily salted, smoked, and pickled foods; fries, chips, and snacks with trans-fats, and 100 images of healthy foods that participants rate as palatable, including vegetables, fruits, nuts, and whole grains.
88834547|NCT03557710|Experimental|Cognitive Reappraisal Training|Arm 2 of the Devaluing energy-dense foods for cancer-control intervention will be delivered via computer-assisted in-person training. Between baseline and endpoint sessions, participants will practice reappraisal on a computer, under close supervision of a facilitator, in 8 30-min twice-weekly individual sessions. During sessions, participants will practice cognitive reappraisal to reduce the value of cancer risk foods. Participants will also practice reappraisal of cancer risk foods on a computer at home, twice weekly for 15 minutes, for a total intervention time of contact of 345 minutes. The facilitator will review homework completed by participants and offer corrective feedback. The home practice is intended to promote generalization of use of this skill in the natural environment.
88834548|NCT03557710|Active Comparator|Generic Response Training|In Arm 3 (active control) of the Devaluing energy-dense foods for cancer-control intervention will be identical in duration and contact time to the behavioral response training described above (345 min total), but will involve nonfood images (birds and flowers), as described in the pilot trial. Participants will be informed that this intervention is designed to improve response inhibition, which should lead to eating change and weight loss given that impulsivity increases the risk for overeating, ensuring the credibility of the control arm.
88834549|NCT03549520|Experimental|Contrast-enhanced Ultrasonography|Intravenous administration of contrast agent Sulfur hexafluoride lipid-type A microspheres before performing contrast-enhanced ultrasound (CEUS). In pediatric patients, after reconstitution 0.03 mL per kg is administered intravenously. The weight-based dose of 0.03 mL per kg will be repeated one time during a single examination. Following each injection, an intravenous flush of 0.9% Sodium Chloride is injected. The study duration per subject will be approximately 15 minutes including the time to prepare the contrast agent and perform the CEUS, as well as the 60 minute monitoring period after the first and second injection of the contrast agent.
88834550|NCT03547518|Experimental|Active PTNS treatment|One-week induction consisting of three active PTNS treatments, each 2 hours long
88834551|NCT03547518|Sham Comparator|Sham treatment|One-week induction consisting of three sham treatments, each 2 hours long
89178335|NCT02602938|Experimental|aspirin|"The included patients will be administered with aspirin (100mg) orally once a day in 28-day cycles.~The CTC was evaluated at baseline, and every 28 days for 2 months."
88834552|NCT03543098|Experimental|Early Surgery & Early Rehab|Individuals with a MLKI that present within 6 weeks of injury will be randomized to early surgery and early rehabilitation.
88834553|NCT03543098|Experimental|Early Surgery & Delayed Rehab|Individuals with a MLKI that present within 6 weeks of injury will be randomized to early surgery and delayed rehabilitation.
88834554|NCT03543098|Experimental|Delayed Surgery & Early Rehab|Individuals with a MLKI that present within 6 weeks of injury will be randomized to delayed surgery and early rehabilitation.
88834555|NCT03543098|Experimental|Delayed Surgery & Delayed Rehab|Individuals with a MLKI that present within 6 weeks of injury will be randomized to delayed surgery and delayed rehabilitation.
88834556|NCT03543098|Experimental|Early Rehab Only|Individuals not eligible for randomization to timing of surgery will be randomized to only early rehabilitation.
88834557|NCT03543098|Experimental|Delayed Rehab Only|Individuals not eligible for randomization to timing of surgery will be randomized to only delayed rehabilitation.
88834558|NCT03524742|Experimental|Avocado-Mediterranean Diet|Avocado based Mediterranean diet with intake of ½ portion of a Hass avocado per day, during 3 months.
88834559|NCT03524742|Active Comparator|Control-Group Diet|Control-Group Diet consists of a low fat-high complex carbohydrate diet, during 3 months.
88834560|NCT03519347|Experimental|Potassium Removal Maximization Strategy|Dialysate potassium will be adjusted according to the results of point of care testing in order to maximize potassium removal and avoid hyperkalemia.
88834561|NCT03519347|Experimental|Potassium Gradient Minimization Strategy|Dialysate potassium will be adjusted according to the results of point of care testing in order to minimize the flux of potassium.
89178336|NCT00787254|Experimental|Lansoprazole 15 mg QD|
89178337|NCT00787254|Active Comparator|Gefarnate 50 mg BID|
89178338|NCT00625846|Experimental|Cohort 1 (DTC)|Patients with differentiated thyroid cancer (DTC) receive 800 mg pazopanib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89178339|NCT00625846|Experimental|Cohort 2 (MTC)|Patients with medullary thyroid cancer (MTC) receive 800 mg pazopanib hydrochloride PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89178340|NCT00625846|Experimental|Cohort 3 (ATC)|Patients with anaplastic thyroid cancer (ATC) receive 800 mg pazopanib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89178341|NCT00625846|Experimental|Expansion Cohort (DTC)|Patients with confirmed, differentiated thyroid cancer (DTC) who are thyroglobulin antibody negative receive 800 mg pazopanib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89178342|NCT00824902|Experimental|Tissue Elastography Imaging|Using special elastography software, probe pressed gently against prostate during routine ultrasound before prostate surgery, 10-15 minutes process.
89178343|NCT00922402|Experimental|Treatment|All patients will be submitted to a shared intensive protocol of insulin infusion supported by continuous glucose monitoring
89178344|NCT00824980|Experimental|IP10.C8 Gel|
89178345|NCT00824980|Placebo Comparator|Placebo Gel|
89178346|NCT02603250||Wicking|50% of the 132 children enrolled in the study will have their Hb measured using the wicking method of HemoCue® 201+ blood collection.
89178347|NCT02603250||Gravity|50% of the 132 children enrolled in the study will have their Hb measured using the gravity method of HemoCue® 201+ blood collection.
89178348|NCT04105374|Active Comparator|Arm I (surgery, radiation therapy, temozolomide)|Beginning on week 5 following standard of care surgery, patients undergo radiation therapy over 30 fractions 5 days per week for up to 6 weeks, and receive temozolomide PO QD for up to 49 days. At the discretion of treating physician, patients may also receive novoTTF-100A (Optune) device 0-7 weeks following radiation and temozolomide treatment. One month following completion of radiation therapy, patients continue to receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
89178349|NCT04105374|Experimental|Arm II (Toca 511, Toca FC, radiation therapy, temozolomide)|Patients receive vocimagene amiretrorepvec via intracranial injection during surgery on day 1. Beginning on week 5 following surgery, patients receive extended release flucytosine PO TID for 7 consecutive days every 7 weeks. Patients also undergo radiation therapy and receive temozolomide as in arm I. After completion of radiation therapy and at the discretion of the treating physician, patients may continue to receive extended release flucytosine PO TID for 7 consecutive days every 8 weeks in the absence of disease progression or unacceptable toxicity.
89178350|NCT03856840||Bullous Pemphigoid Patients|Bullae and blood serum, which are obtained before and under treatment, will be compared in each other regardless of any condition.
89178351|NCT04102722|Experimental|Single Arm|All enrolled subjects will undergo breast cancer screening with mammography and the MUST device
89178352|NCT03856138||diarrhea with probiotics supplement|The children suffered from diarrhea, gastroenteritis oral probiotics during the clinical course
88834562|NCT03519347|Experimental|Alkalosis Avoidance Strategy|Dialysate bicarbonate concentration will be adjusted according to the results of point of care testing in order to prioritize avoiding alkalosis.
88834563|NCT03519347|Experimental|Acidosis Avoidance Strategy|Dialysate bicarbonate concentration will be adjusted according to the results of point of care testing in order to prioritize avoiding acidosis.
89178353|NCT03856138||diarrhea without probiotics supplement|The children suffered from diarrhea, gastroenteritis no oral probiotics during the clinical course
89178354|NCT03856138||healthy control|The children without diarrhea/ gastroenteritis
89178355|NCT04102878|Active Comparator|Transcutaneous anaesthetic|
89178356|NCT04102878|Active Comparator|Transconjunctival anaesthetic|
89178357|NCT00825136|Active Comparator|relaxation|The patients of this arm practice on-line muscle relaxation for 8 weeks.
89178358|NCT00825136|Experimental|relaxation & biofeedback|The patients of this arm practice on-line muscle relaxation plus finger temperature biofeedback for 8 weeks.
89178359|NCT00838084|Experimental|LY2811376 Part 1|LY2811376 (5 mg up to 500 mg); once a day or twice a day for 1 day in up to 3 periods.
88834564|NCT03493412|Experimental|BH4-Placebo|Subjects will be tested on two different days, first day will be baseline and Sapropterin Dihydrochloride (BH4, tetrahydrobiopterin) and second day will be Placebo. Testing will take place one-hour after BH4/placebo intake. There will be a 2-week washout between testing days.
88834565|NCT03493412|Experimental|Placebo-BH4|Subjects will be tested on two different days, first day will be baseline and placebo and second day will be Sapropterin Dihydrochloride (BH4, tetrahydrobiopterin). Testing will take place one-hour after BH4/placebo intake. There will be a 2-week washout between testing days.
88834566|NCT03484364|Experimental|Intervention Group|The ENACTS intervention is four peer-facilitated educational classes delivered over 8 weeks focused on hypertension self-management.
88834567|NCT03484364|No Intervention|Waitlist Group|Usual care and $50 in groceries every other week for 8 weeks.
88834568|NCT03474198|Active Comparator|Standard TB Management Strategy|Standard combination treatment for pulmonary TB of 8 weeks rifampicin, isoniazid, pyrazinamide, ethambutol, then 16 weeks rifampicin, isoniazid only
88834569|NCT03474198|Experimental|TRUNCATE-TB Management Strategy using Regimen B|"TRUNCATE-TB Management Strategy: 8 weeks* of initial treatment using Regimen B; close monitoring after treatment completion; treatment of relapse with 24 weeks of standard treatment.~*If persistent symptoms and positive smear at week 8, extend to 12 weeks of treatment using Regimen B; if persistent symptoms and positive smear at week 12, switch to standard treatment regimen and extend to 24 weeks of treatment.~Regimen B: Rifampicin (35mg/kg), isoniazid, pyrazinamide, ethambutol, linezolid"
88834570|NCT03474198|Experimental|TRUNCATE-TB Management Strategy using Regimen C|"TRUNCATE-TB Management Strategy as described above, using Regimen C in place of B.~Regimen C: Rifampicin (35mg/kg), isoniazid, pyrazinamide, ethambutol, clofazimine"
88834571|NCT03474198|Experimental|TRUNCATE-TB Management Strategy using Regimen D|"TRUNCATE-TB Management Strategy as described above, using Regimen D in place of B.~Regimen D: Rifapentine, isoniazid, pyrazinamide, linezolid, levofloxacin"
88834572|NCT03474198|Experimental|TRUNCATE-TB Management Strategy using Regimen E|"TRUNCATE-TB Management Strategy as described above, using Regimen E in place of B.~Regimen E: Isoniazid, pyrazinamide, ethambutol, linezolid, bedaquiline"
88834573|NCT03457129|Active Comparator|Fycompa 2 week titration intervals|Perampanel oral tablet: 2mg by mouth every 24 hours for two weeks, then up-titrated by 2 mg every two weeks to a target dose of 6 mg/day. Minimum total daily dose = 2 mg/day. Maximum daily dose is 12 mg/day. Total daily dose will be determined by the Investigator based on tolerability and seizure control.
88834574|NCT03457129|Experimental|Fycompa 3 week titration intervals|Perampanel oral tablet: 2mg by mouth every 24 hours for three weeks, then up-titrated by 2 mg every three weeks to a target dose of 6 mg/day. Minimum total daily dose = 2 mg/day. Maximum daily dose is 12 mg/day. Total daily dose will be determined by the Investigator based on tolerability and seizure control.
88834575|NCT03449511|Active Comparator|Ginger aromatherapy|Ginger essential oil (GIN-106) in an aromatherapy inhaler. Subject will take 3 sniffs of the inhaler four times daily (morning, noon, evening, bedtime) for 7 consecutive days during two chemotherapy cycles.
88834576|NCT03449511|Active Comparator|Orange aromatherpy|Orange essential oil (ORG-114) in an aromatherapy inhaler. Subject will take 3 sniffs of the inhaler four times daily (morning, noon, evening, bedtime) for 7 consecutive days during two chemotherapy cycles.
88834577|NCT03449511|Active Comparator|Lavender aromatherapy|Lavender essential oil (LAV-110) in an aromatherapy inhaler. Subject will take 3 sniffs of the inhaler four times daily (morning, noon, evening, bedtime) for 7 consecutive days during two chemotherapy cycles.
88834578|NCT03449511|Placebo Comparator|Jojoba aromatherapy|"Jojoba oil in an aromatherapy inhaler. Subject will take 3 sniffs of the inhaler four times daily (morning, noon, evening, bedtime) for 7 consecutive days during two chemotherapy cycles. One drop of jojoba oil is on the other three aromatherapy inhalers. Jojoba oil is a carreir oil for essential oils which will be used as a comparator and placebo in this study."
88834579|NCT03421288|Experimental|Arm A: FLOT with Atezolizumab|Patients randomized to treatment Arm A will receive atezolizumab (840 mg IV over 1 hour) + FLOT in four 2-week treatment cycles prior to undergoing surgery. Following surgery, patients will receive four further 2-week cycles of atezolizumab + FLOT followed by 8 additional 3-week treatment cycles with atezolizumab alone (maintenance setting: 1,200 mg q3w). FLOT can be deescalated to FLO, FLT or FL in case of chemorelated toxicity at any time and at the discretion of investigator.
88834580|NCT03421288|Active Comparator|Arm B: FLOT alone|Patients randomized to Arm B will receive FLOT alone for four 2-week treatment cycles prior to surgery. Following surgery, patients will receive four further 2-week cycles of chemotherapy alone. FLOT can be deescalated to FLO, FLT or FL in case of chemo-related toxicity at any time and at the discretion of investigator. Docetaxel 50 mg/m², d1 Oxaliplatin 85 mg/m², d1 Calciumfolinat 200 mg/m², d1 5-Fluorouracil 2600 mg/m², d1
88834581|NCT03418922|Experimental|Part 1: Lenvatinib Plus Nivolumab|Participants will receive specified doses of lenvatinib (oral) and nivolumab (intravenous) on specified days.
88834582|NCT03418922|Experimental|Part 2: Lenvatinib Plus Nivolumab|If tolerable in Part 1, participants will receive specified doses of lenvatinib and nivolumab on specified days until criteria for discontinuation are met.
88834583|NCT03385993|Experimental|Mediation and Relaxation Intervention|Patients will undergo a technology based guided meditation and relaxation exercise through use of an application on a tablet or virtual reality headset.
88834584|NCT03376971|Experimental|Diagnostic (lung biopsy)|Patients undergo extraction of up to 3 additional lung biopsies from target lesions that are at least 2-3 cm in diameter using the 19 gauge SuperCore biopsy needle or the 20 gauge Rotax needle. The extracted tissue is imaged via confocal fluorescence microscopy using a variety of fluorescent contrast agents, such as fluorescein sodium, methylene blue, indocyanine green and then undergo hematoxylin and eosin processing.
89178360|NCT00838084|Placebo Comparator|Placebo Part 1|once a day or twice a day for 1 day in up to 3 periods.
89178361|NCT00838084|Experimental|LY2811376 - Part 2 low dose|Single dose of LY2811376, dose determined by part 1
88834585|NCT03368092|Experimental|Dornase alfa|Dornase alfa (Pulmozyme®, Roche 2500U, 2,5mL) given by aerosol in the respiratory circuit (Aerogen solo®) within 6h at day 1 and 24 hours after on day 2.
88834586|NCT03368092|Placebo Comparator|Placebo|NaCl 0,9%, given by aerosol in the respiratory circuit within 6h at day 1 and 24 hours after on day 2.
88834587|NCT03360513||general group|Comprised 70 caucasian Brazilian individuals with normal occlusion and at least four of Andrew's six keys.
88834588|NCT03342027|Experimental|Bupropion + Positively Smoke Free|Positively smoke free-- an 8 session tailored behavioral treatment for smoking cessation bupropion--used for smoking cessation
88834589|NCT03342027|Experimental|Bupropion + Standard of Care|Standard of Care--brief advice to quit provided in a standardized format bupropion--used for smoking cessation
88834590|NCT03342027|Experimental|Placebo + Positively Smoke Free|Placebo--matched to bupropion Positively smoke free-- an 8 session tailored behavioral treatment for smoking cessation
88834591|NCT03342027|Placebo Comparator|Placebo + Standard of Care.|Placebo--matched to bupropion Standard of Care--brief advice to quit provided in a standardized format
88834592|NCT03336606|Active Comparator|Cohort I|MEDI0562 administration (90mg on day 1) followed by surgical resection (day 15)
88834593|NCT03336606|Active Comparator|Cohort II|MEDI0562 administration (30mg on days 1, 3, 5) followed by surgical resection (day 15)
88834594|NCT03329716|Other|Immediate Brace Weaning|Immediate weaning of brace
88834595|NCT03329716|Other|Gradual Brace Weaning|Nocturnal brace wearing for 6 months prior to stopping brace
88834596|NCT03314922|Experimental|Parsaclisib|
89178362|NCT00838084|Experimental|LY2811376 - Part 2 high dose|Single dose of LY2811376, dose determined by part 1
88834597|NCT03309098||Ankle Injury|Person who injures their ankle
88834598|NCT03302910|Experimental|Short Stay Unit|Subjects are assigned to the short stay unit (SSU) for approximately 23 hours treatment and observation period. In the SSU, patients will receive usual care for AHF, which includes loop diuretics and nitroglycerin, as needed.
88834599|NCT03302910|Active Comparator|Standard of Care|Subjects are assigned to inpatient hospitalization. During hospitalization, patients will receive usual care for AHF, which includes loop diuretics and nitroglycerin, as needed.
89178363|NCT00838084|Placebo Comparator|Placebo Part 2|single dose
88834600|NCT03297203|Experimental|groupe1|patients in septic shock (group 1) in the medical intensive care unit of the Timone Hospital.
88834601|NCT03297203|Active Comparator|groupe 2|patients with a bacterial sepsis alone, during a 6 months period.
88834602|NCT03286010|Experimental|Intervention|Participants in the W@H group will be assembled in small groups of 6-12 participants and attend 12-biweekly sessions over a 24-week intervention period. The sessions will be led by a trained peer leader and will be held in a variety of convenient locations in close geographic proximity to participants' home postal codes. Participants will receive a manual containing copies of learning exercises and educational material. Session content is focused on: emotional support (sharing your story, road to recovery, exploration of feelings, coping with changes, emotional management, coping with distress, effective communication, empowerment); informational support (self care behaviours, risk factor education and management, health care system and community resource navigation); and appraisal support (goal setting, action planning, problem solving, relapse prevention).
88834603|NCT03286010|No Intervention|Control|Participants in the control group will be eligible to participate in the study, but cannot participate because there are no groups within their geographical region. They will be offered the W@H program after their 26-week follow up.
88834604|NCT03282656|Experimental|Treatment arm|open-label, non-randomized, single center, pilot and feasibility, single arm cohort study of a single infusion of autologous bone marrow derived CD34+ HSC cells transduced with lentiviral vector containing a short-hairpin RNA targeting BC11A.
88834605|NCT03245541|Experimental|Durvalumab + SABR|Durvalumab + Stereotactic Ablative Body Radiotherapy
88834606|NCT03244644|Placebo Comparator|Placebo|Placebo is an suspension of normal saline. Packaging and labeling are identical to the packaging and labeling for RBX2660 to support the study blinding
88834607|NCT03244644|Experimental|RBX2660|RBX2660 is a rectally administered microbiota suspension in a 0.9% sodium chloride irrigation United States Pharmacopeia (USP) solution and cryoprotectant
88834608|NCT03240809|Experimental|Cohort 1|(ages 12 to <18 years): 140 mg SC dose of brodalumab
88834609|NCT03240809|Experimental|Cohort 2|(ages 6 to <12 years): 70 mg SC dose of brodalumab
88834610|NCT03207854||Ancillary-correlative (biospecimen collection)|Patients and healthy normal volunteers undergo collection of peripheral blood samples for analysis via flow cytometry, RNASeq, immunohistochemistry, CyTOF experiments, cell cultures, and functional studies of immune cell subsets obtained by FACS. Patients also undergo collection of bone marrow and leukopheresis/leukoreduction specimens, and single cell suspensions and bulk excised tumor biopsies are obtained from routine testing for analysis via immunohistochemistry or CyTOF.
88834611|NCT03201549|Experimental|healthy|healthy volunteers will ingest fructose and have FGF21 levels measured
88834612|NCT03200301|Experimental|Intact Umbilical Cord Milking|Umbilical Cord Milking involves pinching of the cord close to the placenta and milking about 20 cm segment of the cord proximal to the umbilicus, towards the infant over a 2-second duration. The cord will be then released, allowing for a brief 2-second pause between each milking motion. This will be repeated for a total of 3 times over a duration less than 20 seconds.
88834613|NCT03200301|No Intervention|Early Cord Clamping|Umbilical cord will be clamped immediately after delivery and baby will be handed over to the neonatal team.
88834614|NCT03199638|Experimental|an exercise group|in which subjects will perform daily 'exercise snacks' within 30 min before breakfast, lunch, and/or dinner or bedtime snack, along with a placebo drink which will be given before breakfast and dinner (twice daily);
88834615|NCT03199638|Experimental|an exercise + glutamine group|in which subjects will receive a glutamine drink (0.25 g/kg per dose) before breakfast and dinner (twice daily), and perform 'exercise snacks' before each meal
88834616|NCT03192995|Active Comparator|Experimental|lorcaserin, extended release, Substance use counseling, ACASI behavioral questionnaire, BART, and ecological momentary assessment
88834617|NCT03192995|Placebo Comparator|Control|Placebo, Substance use counseling, ACASI behavioral questionnaire, BART, and ecological momentary assessment
88834618|NCT03174977|Experimental|18F-Raltegravir|
88834619|NCT03150511|Experimental|Tesamorelin treatment|
88834620|NCT03150511|Placebo Comparator|Placebo|
88834621|NCT03121677|Experimental|Nivolumab/Poly-ICLC/Vaccine/+/- Rituximab|"All cycles are 4 weeks (wks), with nivolumab every 2 wks during Cycles 1-6 & every 4 wks during Cycles 7-12 & vaccine on Cycle 1 Days 1, 4, 8, 15; Cycle 2 Day 1; and then on Day 1 of Cycles 4, 6, 8, 10, 12~After 2 cycles, restaging will be performed, & patients with CR, PR, or SD will continue on nivolumab + vaccine. Patients with evidence of PD may initiate anti-CD20 mAb therapy (drug to be determined by the treating physician) weekly for 4 wks during Cycle 3, followed by a dose on Day 1 of every other cycle (Cycles 6, 8, 10, and 12).~After 6 cycles, restaging will be performed again, and patients with CR, PR, or SD will continue nivolumab + vaccine. Patients with PD at that time point (but not treated with anti-CD20 mAb therapy thus far on this protocol) will initiate anti-CD20 mAb (drug to be determined by the treating physician) therapy weekly for 4 wks during Cycle 7, followed by a dose Day 1 of Cycles 10 & 12 & 2 additional doses 8 wks apart."
88834622|NCT03110926|Experimental|Induction Chemotherapy /Chemoradiation|mFOLFOX6 for 3 cycles - Oxaliplatin 85 mg/m2, 5-fluorouracil 2400mg/m2/46 hours, 5-fluorouracil bolus 400mg/m2 and leucovorin 400 mg/m2, then chemoradiation for 5 cycles - Carboplatin AUC 2mg/mL/min, Paclitaxel 50 mg/m2 and radiation therapy.
88834623|NCT03104595|Experimental|Cohort 1|EC-18 500 mg
88834624|NCT03104595|Experimental|Cohort 2|EC-18 1000 mg
88834625|NCT03104595|Experimental|Cohort 3|EC-18 1500 mg
88834626|NCT03104595|Experimental|Cohort 4|EC-18 2000 mg
88834627|NCT03104595|Experimental|Cohort 5|EC-18 3000 mg
88834628|NCT03104595|Experimental|Cohort 6|EC-18 4000 mg
89178364|NCT00838240|Experimental|Arm I|Patients receive idarubicin IV over 5 minutes on days 1, 3, and 5, cytarabine IV continuously on days 1-10, and clofarabine IV over 1 hour on days 2, 4, 6, 8, and 10.
89178365|NCT00838240|Experimental|Arm II|Patients receive idarubicin IV and cytarabine IV as in arm I. Patients also receive clofarabine IV by push injection over 10 minutes on days 2, 4, 6, 8, and 10.
89178366|NCT00773292|Experimental|ciclosporin|48 weeks treatment with ciclosporin
88834629|NCT03098277|Experimental|Observational (physical activity, accelerometer, PROs)|Patients perform 2 physical activities in an exam room that are recorded using a Microsoft Kinect 2 stationary movement tracking device on days 1 and 21. The first activity is rising from a chair, walking 10 feet, and returning to the chair. The second activity is moving from the chair to the step-up examination table. Patients also wear a movement tracking wristband, Microsoft Band 2, around their wrist, complete a smartphone application based PRO questionnaire, and weigh themselves daily for 60 days.
88834630|NCT03092856|Experimental|Arm I (axitinib, anti-OX40 antibody PF-04518600)|Patients receive axitinib PO BID on days 1-14 and anti-OX40 antibody PF-04518600 IV over 60 minutes on day 1 beginning with course 2. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
88834631|NCT03092856|Active Comparator|Arm II (axitinib, placebo)|Patients receive axitinib as in Arm I and placebo IV on day 1 beginning with course 2. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
88834632|NCT03091816|Experimental|Diagnostic (DPCT)|Patients undergo DPCT at baseline, during SBRT (after 2 of 3 fractions or 3 of 5 fractions), and then at 1 and 3 months post stereotactic body radiation therapy.
88834633|NCT03043950||low risk|Low risk according to metastatic Colorectal Cancer Prognostic Score (mCCS)
88834634|NCT03043950||medium risk|Medium risk according to metastatic Colorectal Cancer Prognostic Score (mCCS)
88834635|NCT03043950||high risk|High risk according to metastatic Colorectal Cancer Prognostic Score (mCCS)
88834636|NCT03035331|Experimental|Treatment (pembrolizumab, dendritic cell therapy, cryosurgery)|Patients receive pembrolizumab IV on day 1. Treatment repeats every 21 days for up to 18 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive dendritic cell therapy IT on days 2, 8, and 15 of cycles 2 and 3, and day 2 of cycles 4 and 5. Patients undergo cryosurgery on day 2 of cycle 2 and receive pneumococcal 13-valent conjugate vaccine by injection on day 2 of cycles 2-5. Treatment repeats every 21 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity. Patients who are CR, PR, or SD after completion of therapy, may receive pembrolizumab for an additional 18 cycles in the absence of disease progression or unacceptable toxicity.
88834637|NCT03015194|Experimental|Laceration of Anterior Mitral Leaflet in Mitral Valve Failure Participants With no Surgical Option|The LAMPOON procedure has three steps: (1) leaflet traversal with a guidewire, followed by (2) leaflet laceration, immediately followed by (3) TMVR. These are all guided by fluoroscopy combined with transesophageal echocardiogram (TEE) or intracardiac echocardiography.
88834638|NCT03003338|Experimental|OBV/PTV/r with DSV followed by placebo|OBV/PTV/r in combination with DSV for 12 weeks followed by 12 weeks matching placebo.
88834639|NCT03003338|Experimental|Placebo followed by OBV/PTV/r with DSV|Matching placebo for 12 weeks followed by 12 weeks OBV/PTV/r in combination with DSV.
88834640|NCT02965638|Active Comparator|Oxygen Group|The mothers will be asked to be on 4 liter of oxygen through nasal cannula up to 24 hours a day. The subjects will be blinded to their treatment.
88834641|NCT02965638|No Intervention|Control Group|These mothers will not undergo CMH therapy
88834642|NCT02960308||Diagnostic (WNCTP scan)|Patients undergo WNCTP scan over 2-3 minutes during standard of care CT.
88834643|NCT02953977|Experimental|Diabetes Intervention|Diabetes Prevention Program
88834644|NCT02953977|Other|Delayed Intervention|Diabetes Prevention Program
88834645|NCT02946879||Low dose AAV OPTIRPE65|subretinal administration of a single low dose of AAV RPE65
88834646|NCT02946879||Intermediate dose AAV OPTIRPE65|subretinal administration of a single intermediate dose of AAV RPE65
88834647|NCT02946879||High dose AAV OPTIRPE65|subretinal administration of a single highdose of AAV RPE65
88834648|NCT02944500|Experimental|Liraglutide followed by placebo|Participants will receive liraglutide with dose titration over 5 weeks (0.6mg for 1 week, 1.2mg for 1 week, 1.8mg for 1 week, 2.4mg for 1 week, and 3.0mg for 1 week) followed by a minimum of 3 weeks wash-out and then return for the same dose of placebo for the same amount of time.
88834649|NCT02944500|Experimental|Placebo followed by liraglutide|Participants will receive placebo with dose titration (0.6mg for 1 week, 1.2mg for 1 week, 1.8mg for 1 week, 2.4mg for 1 week, and 3.0mg for 1 week) followed by a minimum of 3 weeks wash-out and then return for the same dose of liraglutide for the same amount of time.
88834650|NCT02944058|Active Comparator|Philos plate|Intervention is surgery with Philos plate
88834651|NCT02944058|Active Comparator|Multiloc nail|Intervention is surgery with Multiloc nail
88834652|NCT02923934|Experimental|Ipilimumab and Nivolumab|All Subjects will be treated with: Nivolumab at 3 mg/kg and ipilimumab at 1 mg/kg concurrently every 3 weeks for 4 doses followed by nivolumab only at 3mg/kg every 2 weeks until progression (up to 48 total doses of nivolumab)
88834653|NCT02913313|Experimental|Part 1A: Dose Escalation Monotherapy|
88834654|NCT02913313|Experimental|Part 1B: Dose Escalation Combination Therapy|
88834655|NCT02913313|Experimental|Part 2A: Expansion Monotherapy|
88834656|NCT02913313|Experimental|Part 2B: Expansion Combination Therapy|
88834657|NCT02913313|Experimental|Part 1C: Triplet Cohort|
88834658|NCT02913313|Experimental|Part 2C: Triplet Expansion|
88834659|NCT02908477|Experimental|De-escalated Adjuvant Radiation Therapy|Docetaxel 15 mg/m2 days 1, 8 + Radiation Therapy (RT) 30 Gy/1.5 Gy fractions twice daily (b.i.d.) days 1-12 only (intermediate risk) or 36 Gy/1.8 Gy b.i.d. fractions (high risk)
88834660|NCT02908477|Active Comparator|Standard of Care Treatment|RT 60 Gy/2 Gy fractions daily (qday) days 1-40. For high risk, add weekly Cisplatin 40 mg/m2 (Around days 1, 8, 15, 22, 29, 36)
88834661|NCT02904967|Experimental|patients with recurrent VTE|
88834662|NCT02904967|Active Comparator|patients with only one episode of VTE|
88834663|NCT02900014|Experimental|Children with cleft|
88834664|NCT02888626|Experimental|Treatment with Microlens Array|Treatment with Cutera Microlens Array Device used with the enlighten™ 532nm /1064nm/670nm laser
88834665|NCT02884791|Experimental|Fasting (Healthy)|Participation in this study involves fasting overnight, drinking a sweet beverage, and several blood draws through an IV line. Each subject may drink up to10 different sweet beverages, separated by 2 weeks.
88834666|NCT02884791|Experimental|Fasting (metabolic syndrome)|Participation in this study involves fasting overnight, drinking a sweet beverage, and several blood draws through an IV line. Each subject may drink up to10 different sweet beverages, separated by 2 weeks.
89363232|NCT04731506|No Intervention|Waitlist Standard-Care|6-month delayed start (waitlist) in the FC program; receive post-randomization standard health promotion materials available at the local health department; delivers intervention to parents only
89363233|NCT04728633|Experimental|Treatment (carmustine, ethiodized oil, gelatin sponge)|Patients undergo TACE by receiving an infusion of carmustine dissolved in ethiodized oil and an injection of gelatin sponge. Treatment repeats Q4W for bilobar disease or Q7W for unilobar disease in the absence of disease progression or unacceptable toxicity or until maximum clinical benefit is obtained.
89363234|NCT04721418||Cocaine Use Disorder|
89363235|NCT04721418||Healthy Control|
89534594|NCT05465447||Toric IOL|This study included the patients who underwent cataract surgery with the toric IOL(SN6ATX) implantation. Preoperative and postoperative corneal astigmatism, short-term and long-term postoperative total astigmatism were the main outcome indicators. Preoperative corneal astigmatism (Pentacam and IOLMaster) would be obtained from outpatient and inpatient medical records, and the IOL axis should be calculated before surgery. Short-term postoperative (1-3 months) subjective optometry results; Long-term postoperative (3-5 years) corneal astigmatism (Pentacam and IOLMaster), subjective optometry results, and axial lens would be observed using SSOCT after pupil dilation.
89534595|NCT03334643|Experimental|Non-Diabetes|Participants without clinical diagnosis of impaired glucose tolerance or type 2 diabetes and with fasting blood glucose less than 100 mg/dL. They will consume white bread or fiber mix for multiple times over a span of 2 weeks. Changes in blood glucose levels will be monitored.
89363236|NCT04717674|Experimental|Drug: [18F]Fluoropivalate ([18F]Fluoro-2,2-Dimethylpropionic Acid) (FPIA)|Participants will undergo two PET/CT scans with the tracer [18F]Fluoropivalate ([18F]Fluoro-2,2-Dimethylpropionic Acid) (FPIA), referred to as [18F]FPIA, on 2 separate visits.
89363237|NCT04716452|Experimental|Open Label Administration of Ceramide NanoLiposome|Ceramide NanoLiposome will be administered by Intravenous Dosing twice per week in accordance with the protocol relative to dose escalation. There is no placebo group or arm of the study.
88834669|NCT02860013|Active Comparator|Telemedicine|A tablet (a Samsung GALAXY TAB 2 (10.1)) that holds information on handling heart failure in general. The device can also collect and transmit relevant disease-specific data, which are indicative of their current state of health, via a Digital Blood Pressure Monitor (Model UA-767, plus BT-C) and a scale. The device can measure four vital signs, which are transferred wirelessly: blood pressure, pulse, and weight. The tablet can be activated and give a sound, when it is time for taking measurements again.
88834670|NCT02860013|No Intervention|Usual care|In Denmark, usual practice for treating, monitoring and caring for patients with heart failure are the responsibility of the patient's general practitioner (treatment and monitoring) and the municipalities (practical help and nursing care). Heart failure patients can make appointments with their general practitioner or practice nurse free of charge in order to get help in managing heart failure. Community based care and practical help varies. As a rule community care comes at regular intervals based on a clinically based estimate of the patients' needs, but the personnel are not necessarily certified nurses and often not fully educated in heart failure and definitely not on call
89363238|NCT04712864|Experimental|Experimental LB1901|Drug: anti-CD4 CAR T cells anti-CD4 CAR T cells transduced with a lentiviral vector to express CD4 chimeric receptor domain on T cells.
89363239|NCT04690205|Experimental|End of Life (EOL) Care at at Home|End of Life (EOL) Care at at Home intervention entails the following: patient-reported symptoms and home monitored vital signs and body weight with appropriate triggers for phone calls and home visits, and regular communication with oncology clinicians regarding care delivered at home to ensure continuity of care.
89363240|NCT04680923|Experimental|CPPLAI|Group-1 (CPPLAI) (n= 59) will receive intraoperative combined periportal and preperitoneal bupivacaine 0.25% 2-3 mg/kg diluted in 40 ml normal saline in patients scheduled for laparoscopic sleeve gastrectomy.
89363241|NCT04680923|Placebo Comparator|Placebo|Group 2 (placebo) (n= 58) will receive intraoperative combined periportal and preperitoneal sterile water 40 ml in patients scheduled for laparoscopic sleeve gastrectomy.
89363242|NCT04669535|Experimental|AXO-AAV-GM2|AXO-AAV-GM2 infusion
89363243|NCT04667949|Experimental|Fingolimod|Fingolimod 0.5 mg capsule taken orally once daily
89363244|NCT04646005|Experimental|Cemiplimab+ISA101b|
89363245|NCT04636801|Experimental|CHF6001 1600µg|
89363246|NCT04636801|Experimental|CHF6001 3200µg|
89363247|NCT04636801|Placebo Comparator|CHF6001 Placebo|
88834671|NCT02809716||Ancillary-Correlative (blood and tumor tissue collection)|Patients undergo collection of blood collection 1 week prior surgery, before and after surgery on the same day, and 1 week and 3 months after surgery. Patients also undergo and tissue collection during the surgery. Blood and tissue samples are processed for high definition single cell analysis including, whole-genome CNV profiles, protein expression, and cell morphology.
88834672|NCT02772770||Non Operative: Rehabilitation, Bracing, Activity Restriction|
88834673|NCT02772770||Operative: Transphyseal|
88834674|NCT02772770||Operative: Partial Transphyseal|
88834675|NCT02772770||Operative: Physeal sparing by Anderson Technique|
88834676|NCT02772770||Operative: Physeal sparing by Micheli/Kocher Technique|
88834677|NCT02754726|Other|single arm|open label using combination therapy
88875174|NCT02500836|Placebo Comparator|Placebo Topical Solution|Placebo Topical Solution, up to 4 mL, is applied for 20 minutes via cotton or rayon pledget(s), then the nasal site is tested with a Von Frey (or equivalent) filament (Size 5.88, about 60 grams of force) to determine and record whether the subject has a pain score of 0 (zero) (0 = No Pain, 10 = Unbearable pain) after treatment application compared to the Von Frey filament test right before treatment application. The subject will then exit the treatment portion of the trial and be followed for safety for seven days . The total number of pledgets used, and the amount of placebo solution used (1 mL per pledget) will be recorded. After a minimum of 90 minutes from the time of study drug pledget removal, the subjects may have their surgery or diagnostic procedure, and the treatment reverts to standard anesthetic management (e.g. application of lidocaine, tetracaine, bupivicaine or other suitable products at the discretion of the investigator).
89363248|NCT04626245|Experimental|Mindfulness training|Phone-delivered mindfulness training
89363249|NCT04626245|Other|Treatment as usual|Prenatal care
89363250|NCT04622722|Active Comparator|Group A|Group A: Drinking Nutren Diabetes provides energy at 360 kcal per 360 ml
89363251|NCT04622722|Placebo Comparator|Group B|Group B: Having Isocaloric diet provide 360 kcal.
89363252|NCT04614753|Active Comparator|Dealcoholized Muscadine Wine|Participants in this arm will receive 300ml of dealcoholized muscadine wine daily for six weeks. After a 7- day run-in period, participants will receive dealcoholized muscadine wine daily for six weeks
89363253|NCT04614753|Active Comparator|Control Beverage|Participants in this arm will receive 300 ml of sugar water and acid content for six weeks. After a 7-day run in period, participants will receive sugar water for six weeks.
89178367|NCT00838318||Arm 1 Hispanic CRC Patients|
89178368|NCT00838318||Arm 2 FDRs of Hispancic CRC Patients|First-Degree Relatives (FDRs) of Hispanic CRC Patients
88834678|NCT02733185|Active Comparator|Active/Active|Active disodium EDTA (chelation) + Active Oral Multi Vitamins/Minerals (OMVM)
89363254|NCT04610294|Experimental|Aerus air sterilization|Aerus air sterilization system will be used in an operating room, in addition to routine room air filtration
89363255|NCT04610294|Active Comparator|Conventional air handling|Only routine room air filtration will be used in an operation room.
89363256|NCT04607408|Experimental|Part A, Group 1: CH505TF gp120 + GLA-SE|Participants will receive 20 mcg Stable CH505TF gp120 admixed with 2.5 mcg GLA-SE, to be administered as a 0.25 mL intramuscular (IM) injection into either thigh at Weeks 0, 8, 16, 32, and 54.
89363257|NCT04607408|Placebo Comparator|Part A, Group 2: Placebo|Participants will receive Placebo to be administered as a 0.25 mL IM injection, into either thigh at Weeks 0, 8, 16, 32, and 54.
89363258|NCT04607408|Experimental|Part B, Group 3: CH505TF gp120 + GLA-SE|Participants will receive 20 mcg Stable CH505TF gp120 admixed with 5 mcg GLA-SE, to be administered as a 0.5 mL IM injection into either thigh at Weeks 0, 8, 16, 32, and 54.
88834679|NCT02733185|Active Comparator|Active/Placebo|Active disodium EDTA (chelation) + Placebo Oral Multi Vitamins/Minerals (OMVM)
88834680|NCT02733185|Active Comparator|Placebo/ Active|Placebo disodium EDTA (chelation) + Active Oral Multi Vitamins/Minerals (OMVM)
88834681|NCT02733185|Placebo Comparator|Placebo/Placebo|Placebo disodium EDTA (chelation) + Placebo Oral Multi Vitamins/Minerals (OMVM)
88834682|NCT02713997|No Intervention|Standard Care|Patients in the standard care arm will undergo the usual procedure of TPIAT with no ancillary therapies provided.
88834683|NCT02713997|Experimental|etanercept|Patients in the etanercept arm will undergo the usual procedure of TPIAT with additional therapy of etanercept.
89363259|NCT04607408|Placebo Comparator|Part B, Group 4: Placebo|Participants will receive Placebo to be administered as a 0.5 mL IM injection, into either thigh at Weeks 0, 8, 16, 32, and 54.
89363260|NCT04607408|Experimental|Part C, Group 5: CH505TF gp120 + GLA-SE|Participants will receive 20 mcg Stable CH505TF gp120 admixed with 5 mcg GLA-SE, to be administered as a 0.5 mL IM injection into either thigh at Weeks 0, 8, 16, 32, and 54.
89363261|NCT04607408|Placebo Comparator|Part C, Group 6: Placebo|Participants will receive Placebo to be administered as a 0.5 mL IM injection, into either thigh at Weeks 0, 8, 16, 32, and 54.
88834684|NCT02713997|Experimental|alpha-1 antitrypsin|Patients in the alpha-1 antitrypsin arm will undergo the usual procedure of TPIAT with additional therapy of alpha-1 antitrypsin (Aralast NP)
88834685|NCT02692300|No Intervention|Control Group|Patients will undergo standard anesthesia and will be blinded to EEG-based data, as per standard of care in this patient population.
89363262|NCT04607408|Experimental|Part C, Group 7: CH505TF gp120 + GLA-SE|Participants will receive 5 mcg Stable CH505TF gp120 admixed with 5 mcg GLA-SE, to be administered as a 0.5 mL IM injection into either thigh at Weeks 0, 8, 16, 32, and 54.
89363263|NCT04607408|Placebo Comparator|Part C, Group 8: Placebo|Participants will receive Placebo to be administered as a 0.5 mL IM injection, into either thigh at Weeks 0, 8, 16, 32, and 54.
89363264|NCT04606602|Experimental|30 mg|
89363265|NCT04606602|Placebo Comparator|Placebo|
89363266|NCT04606602|Experimental|100 mg|
89363267|NCT04606602|Experimental|300 mg|
89363268|NCT04606602|Experimental|600 mg|
89363269|NCT04606602|Experimental|900 mg|
89363270|NCT04606602|Experimental|100 mg multi dose|
89363271|NCT04606602|Experimental|200 mg multi dose|
89363272|NCT04606602|Experimental|300 mg multi dose|
89363273|NCT04606602|Experimental|600 mg multi dose|
88834686|NCT02692300|Experimental|EEG-Guided Group|Practitioners will follow the EEG-Guided protocol to limit the incidence of EEG burst suppression by decreasing administration of anesthesia. The EEG-guided protocol is suggestive rather than prescriptive, and practitioners will exercise judgment depending on the clinical situation.
88834687|NCT02684227|Experimental|Treatment (enzalutamide, paclitaxel, carboplatin)|Patients receive enzalutamide PO QD alone on days 1-28. Patients then receive enzalutamide PO QD on days 1-21, paclitaxel IV over 3 hours on day 1, and carboplatin IV over 1 hour on day 1. Treatment repeats every 21 days for 6-9 cycles in the absence of disease progression or unacceptable toxicity.
88834688|NCT02637024|Experimental|APBI: 30 Gy|Radiotherapy of 3 Dimensional Conformal Radiation Therapy (3DCRT) Accelerated Partial Breast Irradiation (APBI) 30 Gy in 5 daily fractions of 6 Gy
88834689|NCT02637024|Experimental|APBI: 27.5 Gy|Radiotherapy of 3 Dimensional Conformal Radiation Therapy (3DCRT) Accelerated Partial Breast Irradiation (APBI) 27.5 Gy in 5 daily fractions of 5.5 Gy
88834690|NCT02623972|Experimental|Arm A: Eribulin > AC|"Eribulin-Administered via iv, at predetermined dosage and schedule per cycle~Two research breast biopsies~Adriamycin (doxorubicin) via iv a predetermined dosage and schedule per cycle~Cyclophosphamide (AC) via iv a predetermined dosage and schedule per cycle~Surgical Removal of the breasts (Mastectomy) and axillary lymph node dissection~Radiation Therapy~Endocrine Therapy (if applicable)~Optional 5 Patient-Optional DCE-MRI (Dynamic Contrast Enhanced-Magnetic Resonance Imaging) scans"
88834691|NCT02623972|Experimental|Arm B: AC > Eribulin|"Adriamycin (doxorubicin) via iv a predetermined dosage and schedule per cycle~Cyclophosphamide (AC) via iv a predetermined dosage and schedule per cycle~Two research breast biopsies~Eribulin-Administered via iv, at predetermined dosage and schedule per cycle~Surgical Removal of the breasts (Mastectomy) and axillary lymph node dissection~Radiation Therapy~Endocrine Therapy (if applicable)~Optional 5 Patient-Optional DCE-MRI (Dynamic Contrast Enhanced-Magnetic Resonance Imaging) scans"
88834692|NCT02601495||Women in a court diversion program|Women enrolled in the court diversion program in Tulsa, Oklahoma called Women in Recovery who report symptoms related to anxiety or depressive symptoms (Patient Health Questionnaire score ≥ 10 and/or Overall Anxiety Severity and Impairment Scale ≥ 8), problematic eating behavior(Eating Disorder Screen score ≥ 2), problems related to substance use (Drug Abuse Screening Test score > 2), or post traumatic stress disorder symptoms (PTSD Checklist score ≥ 30).
88834693|NCT02601339||GM-IVH|Premature infants who developed germinal matrix-intraventricular hemorrhage. FDNIRS-DCS measures will be performed up to once a day if clinically feasible.
88834694|NCT02601339||Posthemorrhagic hydrocephalus (PHH)|"Premature infants with complications of hydrocephalus secondary to intraventricular hemorrhage and have the potential to receive endoscopic third ventriculostomy (ETV) with choroid plexus cauterization (CPC) and/or ventriculoperitoneal (VP) shunting for clinical treatment.~FDNIRS-DCS measures will be performed up to once a day if clinically feasible. Additional FDNIRS-DCS measures will be performed on the day of hydrocephalus treatment to monitor the treatment response if clinically feasible. These additional measures are limited to up to four times a day."
88834695|NCT02601339||Healthy Control (HC)|Premature infants without diagnosed brain injuries. FDNIRS-DCS measures will be performed up to once a day if clinically feasible.
88834696|NCT02601339||Ventriculomegaly Control (VC)|"Infants who have symptomatic hydrocephalus of any etiology except post-hemorrhagic etiology and have the potential to receive ETV/CPC and/or VP shunting for clinical treatment.~FDNIRS-DCS measures will be performed up to once a day if clinically feasible. Additional FDNIRS-DCS measures will be performed on the day of hydrocephalus treatment to monitor the treatment response if clinically feasible. These additional measures are limited to up to four times a day."
88834697|NCT02568618|Other|Immediate|Subjects will receive the results of the Pain Medication DNA Insight (TM) test at Visit 1.
88834698|NCT02568618|Other|Delayed|Subjects will receive the results of the Pain Medication DNA Insight (TM) test at Visit 4. After 3 months of standard treatment.
88834699|NCT02536300|Experimental|Idelalisib 150 mg BID|"Participants will receive idelalisib 150 mg twice daily continuously.~For participants enrolled prior to protocol amendment 5: Based on the independent review committee (IRC) response assessment, participants may be discontinued from the study or may receive blinded or open-label idelalisib 150 mg twice daily."
88834700|NCT02536300|Experimental|Idelalisib 100 mg BID|"Participants will receive idelalisib 100 mg twice daily continuously. Based on the IRC response assessment, participants may either be dose escalated to open-label 150 mg twice daily or maintain blind and continue on idelalisib 100 mg twice daily.~As of protocol amendment 5, enrollment to this arm has been closed."
88834701|NCT02536300|Experimental|Idelalisib 150 mg BID INT|Participants will receive idelalisib 150 mg twice daily in 28-day cycles with 21 days on-treatment and 7 days off-treatment.
88834702|NCT02534948|Experimental|Mindfulness and acceptance group therapy|The intervention group will consist of female participants who will be provided MABT in a group.The intervention will consist of 10 group therapy sessions. Each session will be conducted for 120 minutes.
88834703|NCT02534948|No Intervention|wait list control group|The control group will be the waiting list control group will receive no interventions in the first stage.
88834704|NCT02525692|Experimental|A: GBM ONC201 Q3W|
88834705|NCT02525692|Experimental|B: GBM ONC201 Q1W|
88834706|NCT02525692|Experimental|C: GBM Surgical Cohort ONC201 Q1W|
88834707|NCT02525692|Experimental|D: H3 K27M Glioma ONC201 Q1W|
88834708|NCT02525692|Experimental|E: Diffuse Midline Glioma Surgical Cohort ONC201 Q1W|
88834709|NCT02525692|Experimental|F: Non-H3 K27M Diffuse Midline Glioma ONC201 Q1W|
88834710|NCT02514382|Experimental|Treatment (dexamethasone, bortezomib, wild-type reovirus)|Patients receive dexamethasone PO, IV, or IM and bortezomib SC (preferably) or IV over 3-5 seconds on days 1, 8, and 15. Patients also receive wild-type reovirus IV over 60 minutes on days 1, 2, 8, 9, 15, and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88834711|NCT02511067|Active Comparator|Ranibizumab 0.3 mg|Mandatory monthly treatments with Intravitreal (IVT) ranibizumab (0.3 mg) starting at Baseline (BL) until Month 6. Starting at Month 6, treatments will be administered on as-needed basis, based on retreatment criteria.
88834712|NCT02511067|Experimental|Tocilizumab (8.0 mg/kg)|Mandatory monthly Intravenous (IV) infusions with tocilizumab (8.0 mg/kg) starting at Baseline (BL) until Month 6. Starting at Month 6, treatments will be administered on as-needed basis with IVT ranibizumab (0.3 mg), based on the retreatment criteria.
88834713|NCT02511067|Experimental|Tocilizumab (8.0 mg /kg) plus Ranibizumab 0.3 mg|Mandatory Intravitreal (IVT) ranibizumab 0.3 mg at Baseline (BL) followed with an IV infusion of tocilizumab (8.0 mg/kg) on same day starting at Baseline (BL) until Month 6. Combination treatments (IVT ranibizumab 0.3 mg followed by IV tocilizumab 8.0 mg/kg infusion administered at same visit) will be given every month until Month 6. Starting at Month 6, treatments will continue to be administered on as-needed basis with IVT ranibizumab (0.3 mg), based on retreatment criteria.
88834714|NCT02501733|Other|Medacta GMK Sphere® Knee Prosthesis|All subjects enrolled will receive the Medacta GMK Sphere® Medial Knee Prosthesis
88834715|NCT02491840|Experimental|Gastric and cardia adenocarcinomas|Biopsy of Gastric and cardia adenocarcinomas
89178369|NCT00838318||Arm 3 Key Informants|Key informants from Houston Hispanic Health Coalition.
89178370|NCT00786864|Experimental|1. Experimental Group|Exercise Intervention Group
89178371|NCT00786864|No Intervention|2. Control Group|Control group - no intervention
89363274|NCT04606602|Placebo Comparator|Placebo multi dose|
89534596|NCT03334643|Experimental|Prediabetes/Diabetes|Participants who are clinically diagnosed with impaired glucose tolerance or type 2 diabetes, and those without the above diagnosis but with fasting blood glucose equal to or greater than 100 mg/dL. They will consume white bread or fiber mix for multiple times over a span of 2 weeks. Changes in blood glucose levels will be monitored.
88834716|NCT02462239|Experimental|Whole-body FDG PET-CT|Whole-body FDG PET-CT (Experimental arm)
88834717|NCT02462239|No Intervention|No PET-CT|No PET-CT (Control arm)
89363275|NCT04591431|Experimental|Tailored Therapy|"Experimental (TT) Patients will be treated with target therapy and/or immunotherapy according to their genomic profile evidenced by Foundation One test and independently from their type of cancer with one or more drugs of the following list (administered according to the SmPCs or IBs if under development):~TARGET THERAPY: ERLOTINIB (EGFR mutation) TRASTUZUMAB, PERTUZUMAB, TDM1, LAPATINIB (ERBB2 amplifications/mut) EVEROLIMUS (mTOR mutations, AKT mut) VEMURAFENIB, COBIMETINIB (BRAFV600E mutations) ALECTINIB, BRIGATINIB (ALK, RET) PALBOCICLIB (CDK4/6, CDKN2A/p16) PONATINIB (Bcr-abl) VISMODEGIB (SMO/PTCH1) ITACITINIB (JAK mutation) INCB054828 (FGFR1/2/3) IPATASERTIB (PI3K, AKT, PTEN) ENTRECTINIB (NTRK1/2/3 -TRK fusion proteins-, ROS1) ALPELISIB (PI3K, AKT) TEPOTINIB (MET amplification/exon14 skipping mutations) PRALSETINIB (RET) TALAZOPARIB (BRCA1/2, ATM, other HRD status) SELPERCATINIB (RET) IMMUNOTHERAPY: ATEZOLIZUMAB, NIVOLUMAB, IPILIMUMAB (MSI, HIGH TUMOR MUTATIONAL BURDEN, OTHER)"
89363276|NCT04591431|Active Comparator|Standard of Care|Patients will be treated according the current version of the AIOM (Italian Association of Medical Oncology) guidelines for their type of cancer. As an example, patients could be treated with standard chemotherapy and/or targeted therapy according to the histological results.
89363277|NCT04588311|Active Comparator|Erythropoietin (EPO)|Epoetin alfa 40,000 IU (1mL pre-filled syringe) will be given by subcutaneous injection to eligible patients on Study Days 1 and 8 during the intensive care unit stay.
89363278|NCT04588311|Placebo Comparator|Placebo|Sodium Chloride 0.9% (1mL in volume) will be given by subcutaneous injection to eligible patients allocated to the placebo arm on Study Days 1 and 8 during the intensive care unit stay.
89363279|NCT04563143|Other|Novel stimulation|All subjects will undergo periods of stimulation using novel stimulation patterns
89363280|NCT04551677|Experimental|Group 1: Fluzone Quadrivalent Influenza Vaccine: 6 to <36 Months|Participants aged 6 to <36 months received a 0.5-milliliters (mL) dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 1. Participants for whom 2 doses of influenza vaccine were recommended per Advisory Committee on Immunization Practices (ACIP), a second dose was administered at Day 28.
89363281|NCT04551677|Experimental|Group 2: Fluzone Quadrivalent Influenza Vaccine: 3 to <9 Years|Participants aged 3 to <9 years received a 0.5-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 1. Participants for whom 2 doses of influenza vaccine were recommended per ACIP, a second dose was administered at Day 28.
89363282|NCT04551677|Experimental|Group 3: Fluzone High-Dose Quadrivalent Influenza Vaccine: >=65 Years|Participants aged >=65 years received a 0.7-mL dose of Fluzone High-Dose Quadrivalent vaccine intramuscularly at Day 1.
89363283|NCT04551378||Observational (survey)|Patients and survivors complete a survey online over 20-30 minutes at baseline about COVID-19 specific psychological distress, health care utilization, health behavior, social and financial disruptions, HRQoL, their social support, perceived benefits under times of stress, and the ability to manage stress. Patients and survivors may be contacted again at 6 months and 1 year for COVID-19 research.
89363284|NCT04546074|Experimental|Treatment|
89363285|NCT04510740||Hepatocellular Carcinoma (HCC)|Patients with Hepatocellular Carcinoma (HCC)
89363286|NCT04510740||Cholangiocarcinoma (CCC)|Patients with Cholangiocarcinoma (CCC)
88834718|NCT02458274||Patient without bronchiolitis obliterans syndrome|Lung transplanted patient without bronchiolitis obliterans syndrome
88834719|NCT02458274||Patient with bronchiolitis obliterans syndrome|Patient with bronchiolitis obliterans syndrome three years after lung transplantation.
88834720|NCT02409147|Experimental|Patients|Healthy female volunteers wishing to have a childbirth via uterine transplantation
88834721|NCT02402439|Experimental|Islet Transplant|Islet transplantation into the gastrointestinal submucosa
88834722|NCT02392026|Experimental|Metronidazole Gel|Metronidazole Vaginal Gel
88834723|NCT02389036|No Intervention|Control group- standard care|Standard care- In Australia there are no national guidelines so local policy is determined by each ICU. We are recommending (but not mandating) that control and SDD group management be in line with these national guidelines. We will recommend control and SDD group management is in line with current national standards of practice that may or may not include a VAP bundle. We will monitor record data regarding the nature and delivery of the control and SDD group co-interventions.
89178372|NCT00838396|Experimental|XP19986 CR|On either study Day 1 or study Day 5 (after completion of the minimum 3-day washout period), participants received a single dose of XP19986 10, 20, 40 or 60 mg.
89363287|NCT04507126|Experimental|BCG Immunization|All participants will receive two Bacillus Calmette-Guérin (Japan BCG) vaccine injections spaced four week apart. Each injection will have 1.8-3.9 x 10^6 colony forming units (CFU) reconstituted in 0.1 mL saline.
89363288|NCT04500600||Observational (questionnaire)|Patients complete an online questionnaire over 10 minutes regarding the COVID-19 pandemic including testing, risks of exposure, whether people they know have acquired COVID-19, as well as questions on how the pandemic has impacted their quality of life.
89363289|NCT04498832|Experimental|Group 1: QIV-HD|Participants received a single injection of 0.7 milliliters (mL) high dose quadrivalent influenza vaccine (QIV-HD), intramuscularly (IM) at Day 0.
89363290|NCT04498832|Active Comparator|Group 2: QIV-SD|Participants received a single injection of 0.5 mL standard-dose quadrivalent influenza vaccine (QIV-SD), subcutaneously (SC) at Day 0.
89363291|NCT04491539|No Intervention|Adaptation|Site will inform the adaptation of the FRESH intervention.
89363292|NCT04491539|Experimental|First Receipt|Site will received the adapted FRESH intervention first.
89363293|NCT04491539|Experimental|Second Receipt|Site will received the adapted FRESH intervention second.
89363294|NCT04490018|Experimental|Group 1: MenACYW Conjugate Vaccine + 9vHPV + Tdap-IPV Vaccines (Sequential Administration)|Participants received 0.5-milliliter (mL) intramuscular injection of MenACYW Conjugate vaccine on Day 01 and 0.5-mL intramuscular injection of 9vHPV + Tdap-IPV vaccines (sequentially after MenACYW vaccine) at Day 31.
89363295|NCT04490018|Active Comparator|Group 2: Nimenrix® + 9vHPV + Tdap-IPV Vaccines (Sequential Administration)|Participants received 0.5-mL intramuscular injection of Nimenrix® vaccine on Day 01 and 0.5-mL intramuscular injection of 9vHPV + Tdap-IPV vaccines (sequentially after Nimenrix® vaccine) at Day 31.
89363296|NCT04490018|Experimental|Group 3: MenACYW Conjugate Vaccine + 9vHPV + Tdap-IPV Vaccines (Concomitant Administration)|Participants received 0.5-mL intramuscular injection of MenACYW Conjugate vaccine concomitantly with 9vHPV + Tdap-IPV vaccines on Day 01.
89363297|NCT04488536||Frail patients|Clinical Frailty Scale level 5-9
89363298|NCT04488536||Nonfrail patients|Clinical Frailty Scale level 1-4
89363299|NCT04484909|Experimental|Treatment (NBTXR3, radiation therapy)|Patients receive NBTXR3 IT on day 1. Patients then undergo 15 fractions of radiation therapy between days 15-43 in the absence of disease progression or unacceptable toxicity.
89534597|NCT03334565|Sham Comparator|Sham|Participants were exposed to unfiltered ambient air (sham) filtered air using air filtration systems in the bedroom and main living space of each residence.
88834724|NCT02389036|Experimental|SDD intervention group|"The intervention will entail:~A six-hourly topical application of 0.5g paste, containing colistin 10mg, tobramycin 10mg and nystatin 125,000 IU, to the buccal mucosa and oropharynx~A six-hourly administration of 10 mL of a suspension containing 100 mg colistin, 80 mg tobramycin and 2 x 10^6 IU nystatin, to the gastrointestinal tract via a gastric/post-pyloric tube~A four-day course of an IV antibiotic. Patients not already receiving a therapeutic antibiotic will be prescribed cefotaxime 1g six-hourly or ceftriaxone 1g daily, with dose adjusted as appropriate for organ dysfunction. Ciprofloxacin (400mg 12-hourly) may be used as an alternative if there is a contraindication to cephalosporins (e.g. allergy). Patients already receiving an alternative IV antibiotic to treat infection will not receive this additional IV antibiotic, but will continue the prescribed antibiotic for the usual duration of therapy."
88834725|NCT02375854||Preterm infants|Less than 32 weeks' gestation
88834726|NCT02369523|Active Comparator|liposomal bupivacaine (LB) (Exparel)|Mixture of 50 milliliters (mL) of 0.25% Bupivacaine with epinephrine, 40 mL of sterile saline and 20 mL of Exparel®.
88834727|NCT02369523|Active Comparator|Ropivacaine cocktail (PIC)|400 milligrams (mg) Ropivacaine, 5 mg morphine, and 0.4 mg epinephrine in 100 cc solution
88834728|NCT02369523|Active Comparator|continuous femoral nerve blocks (cFNB)|"Continuous Femoral Nerve Block- 0.25% Bupivacaine at a rate of 5 ml/hour for 48 Hours.~Sciatic nerve block - 0.125% bupivacaine"
88834729|NCT02355340||DXA and pQCT Scan|"Dual energy x-ray absorptiometry (DXA): Assessment of bone mineral density~Peripheral quantitative computed tomography (pQCT): Assessment of bone mineral density"
88834730|NCT02339064|Experimental|Apomorphine infusion|Continuous subcutaneous apomorphine infusion
88834731|NCT02311192|Experimental|Ultrasonography B-scan|Patients of uveitis who are included in the study will be imaged using ultrasound B-scan
88834732|NCT02298777||Scleroderma (SSc) patients (beginners and established forms).|"Patients with the ACR / EULAR (2012) and / or criteria of Leroy and Medsger (2001)~Biological samples (skin, urine and blood):~1st point at patient's inclusion visit~2nd point (optional) at SSc patient's visceral complication (assessed during 3 years)"
88834733|NCT02298777||Undifferentiated Connective Tissue Disease (UCDT) patients|"Patients with criteria proposed by Mosca et al. (1998)~Biological samples (skin, urine and blood):~- 1single point at patient's inclusion visit"
88834734|NCT02298777||Raynaud disease patients|"Patients with primary and isolated Raynaud disease~Biological samples (skin, urine and blood):~- 1single point at patient's inclusion visit"
88834735|NCT02298777||Vascular disease patients|"Patients with vascular disease (type 2 diabetes, occlusive vascular disease, history of myocardial infarction or ischemic stroke)~Biological samples (skin, urine and blood):~- 1single point at patient's inclusion visit"
89363300|NCT04481204|Active Comparator|Control arm GroupI(mFOLFIRINOX)|Patients receive mFOLFIRINOX for 3 months before and after surgery in the absence of disease progression or unacceptable toxicity.
89363301|NCT04481204|Active Comparator|Control arm GroupII(chemotherapy, FOLFIRINOX)|Patients receive gemcitabine, gemcitabine and nab-paclitaxel, gemcitabine and cisplatin, or FOLFIRINOX for up to 4 months in the absence of disease progression or unacceptable toxicity.
89363302|NCT04481204|Active Comparator|Control arm GroupIII(FOLFIRINOX, radiation therapy)|Patients receive FOLFIRINOX for 4-6 months in the absence of disease progression or unacceptable toxicity. Patients may then undergo radiation therapy at the discretion of medical doctors.
89363303|NCT04481204|Active Comparator|Control arm GroupIV(chemotherapy,FOLFIRINOX,radiation therapy)|Patients receive gemcitabine, gemcitabine and nab-paclitaxel, gemcitabine and cisplatin, or FOLFIRINOX for 6 months in the absence of disease progression or unacceptable toxicity. Patients may then undergo radiation therapy at the discretion of medical doctors.
89363304|NCT04481204|Active Comparator|Control arm GroupV(FOLFIRINOX, radiation therapy)|Patients receive FOLFIRINOX for 4-6 months in the absence of disease progression or unacceptable toxicity. Patients may then undergo radiation therapy at the discretion of medical doctors
89363305|NCT04481204|Active Comparator|Control arm GroupVI(chemotherapy,FOLFIRINOX,radiation therapy)|Patients receive gemcitabine, gemcitabine and nab-paclitaxel, gemcitabine and cisplatin, or FOLFIRINOX for 6 months in the absence of disease progression or unacceptable toxicity. Patients may then undergo radiation therapy at the discretion of medical doctors
88834736|NCT02298777||Healthy control subjects|"Healthy subjects (no sign of connective tissue disease, no Raynaud, no vascular disease)~Biological samples (skin, urine and blood):~- 1single point at patient's inclusion visit"
89363306|NCT04473690|Experimental|Low Dose KBP-COVID-19 and adjuvant|"Two age groups.~Part A (18-49 years).~Part B (50-85 years).~All subjects in these groups will receive the low dose of KBP-COVID-19"
89363307|NCT04473690|Experimental|High Dose KBP-COVID-19 and adjuvant|"Two age groups.~Part A (18-49 years).~Part B (50-85 years).~All subjects in these groups will receive the high dose of KBP-COVID-19"
89363308|NCT04473690|Placebo Comparator|Placebo|"Two age groups.~Part A (18-49 years).~Part B (50-85 years).~All subjects in these groups will receive placebo"
89363309|NCT04466007|Placebo Comparator|Control arm|0.9% physiological saline
89363310|NCT04466007|Experimental|Low dose treatment arm|Low dose allogeneic mesenchymal stem cells derived from adipose tissue
89363311|NCT04466007|Experimental|High dose treatment arm|High dose allogeneic mesenchymal stem cells derived from adipose tissue
89363312|NCT04455139|Active Comparator|Treatment 1a|IVitC melphalan (randomized) in case of vitreous relapse only
89363313|NCT04455139|Experimental|Treatment 1b|IVitC topotecan (randomized) in case of vitreous relapse only
89363314|NCT04455139|Active Comparator|Treatment 2a|IAC melphalan (randomized) in case of retinal/diffuse subretinal relapse with no prior intra-arterial treatment
89363315|NCT04455139|Experimental|Treatment 2b|IAC melphalan and topotecan (randomized) in case of retinal/diffuse subretinal relapse with no prior intra-arterial treatment
89363316|NCT04455139|No Intervention|Treatment 2c|IAC melphalan and topotecan (randomized) in case of retinal/diffuse subretinal relapse with prior intra-arterial treatment
89363317|NCT04455139|No Intervention|Treatment 3a|sequential administration of IVitC melphalan and IAC melphalan in case of combined vitreous and retinal/diffuse subretinal relapse, if no pretreatment with intra-arterial treatment
89363318|NCT04455139|No Intervention|Treatment 3b|sequential administration of IVitC melphalan and IAC melphalan and topotecan, in case of combined vitreous and retinal/diffuse subretinal relapse, if prior pretreatment with intra-arterial treatment
89363319|NCT04439994|Active Comparator|Hypertonic saline|Each participant will be given i.d. in 0.1 mL volumes of a hypertonic saline solution. The subject will be blinded to the hypertonic/isotonic administration.
89363320|NCT04439994|Placebo Comparator|Isotonic Saline|Each participant will be given i.d. in 0.1 mL volumes of a isotonic saline solution. The subject will be blinded to the hypertonic/isotonic administration.
89363321|NCT04404569|Experimental|Continued Treatment|"Subjects who have completed the required study observation period or are still on treatment upon the closure of their respective BXQ-350 clinical study, and who are judged by the Investigator to benefit from continued treatment with BXQ-350. Treatment will begin after completion of the End of Study visit of the prior BXQ-350 clinical study.~The established safe dose of BXQ-350 from previous adult and pediatric phase 1 studies is 2.4 mg/kg and 3.2 mg/kg respectively once every 28 days (± 3 days). BXQ-350 will be administered intravenously at the same dose level and frequency the subject was receiving at the end of the prior BXQ-350 clinical study. Subjects receiving a reduced dose at the end of the prior BXQ-350 clinical study due to toxicity may continue to receive a reduced dose."
88834737|NCT02277717|Experimental|SYD985 (trastuzumab vc-seco-DUBA)|HER2-targeting Antibody-Drug Conjugate
88834738|NCT02273219|Experimental|Dose 1: AEB071 and BYL719|AEB071, oral, 100 mg twice daily BYL719, oral, 200 mg daily
88834739|NCT02273219|Experimental|Dose 2: AEB071 and BYL719|AEB071, oral, 200 mg twice daily BYL719, oral, 250 mg daily
88834740|NCT02273219|Experimental|Dose 3: AEB071 and BYL719|AEB071, oral, 200 mg twice daily BYL719, oral, 300 mg daily
88834741|NCT02273219|Experimental|Dose 4: AEB071 and BYL719|AEB071, oral, 200 mg twice daily BYL719, oral, 350 mg daily
88834742|NCT02273219|Experimental|Dose 5: AEB071 and BYL719|AEB071, oral, 300 mg twice daily BYL719, oral, 350 mg daily
88834743|NCT02246140|Experimental|Cannabis users|Cerebral MRI and MRA
88834744|NCT02246140|Active Comparator|healthy volunteers|Cerebral MRI and MRA
88834745|NCT02207712|Active Comparator|Standard Arm|Those receiving only their prescribed ranibizumab treatment only
89363322|NCT04387422|Experimental|150 mg/dL|Hyperglycemia target of 150 mg/dL
89363323|NCT04387422|Experimental|225 mg/dL|Hyperglycemia target of 225 mg/dL
88834746|NCT02207712|Experimental|Intervention Arm|Noctura 400 Eye Mask in conjunction with their prescribed ranibizumab treatment.
89363324|NCT04387422|Experimental|300 mg/dL|Hyperglycemia target of 300 mg/dL
88834747|NCT02207127||MRI, DISE, and Surgery|All participants will undergo MRI and DISE prior to undergoing surgical treatment of obstructive sleep apnea.
88834748|NCT02188095||Excia T®|
88834749|NCT02187991|Active Comparator|ER+/HER2- Paclitaxel Alone|Paclitaxel 90 mg/m2 IV on days 1, 8 and 15 of a 28-day cycle
88834750|NCT02187991|Experimental|ER+/HER2- Paclitaxel plus Alisertib|Paclitaxel 60 mg/m2 intravenously (IV) on days 1, 8 and 15 of a 28-day cycle; Alisertib 40 mg BID on days 1-3, 8-10, and 15-17 of a 28-day cycle
88834751|NCT02187991|Active Comparator|Triple Negative Paclitaxel Alone|Paclitaxel 90 mg/m2 IV on days 1, 8 and 15 of a 28-day cycle
88834752|NCT02187991|Experimental|Triple Negative Paclitaxel plus Alisertib|Paclitaxel 60 mg/m2 intravenously (IV) on days 1, 8 and 15 of a 28-day cycle; Alisertib 40 mg BID on days 1-3, 8-10, and 15-17 of a 28-day cycle
88834753|NCT02152046||Spring loaded retractor|The Alfonso Eyelid Speculum, newborn size
88834754|NCT02152046||Screw retractor|Cook Eyelid Speculum, infant size
88834755|NCT02118922||Healthy volunteers|Volunteers with normal corneas
88834756|NCT02118922||Patients with keratoconus|Patients diagnosed with keratoconus
88834757|NCT02118922||post-LASIK no complications|Subjects who underwent LASIK refractive surgery with no complications
89363325|NCT04338815|Experimental|Optimal assistance pattern|An optimization algorithm will change the assistance pattern on the hip exoskeleton during walking sessions and the optimal assistance pattern will be determined when gait variability is minimized.
89363326|NCT04338815|Experimental|Effects on endurance|Determine effects on endurance of participants using ground reaction force (Bertec treadmill), walking speed (Bertec treadmill), indirect calorimetry (Cosmed), and motion capture (Vicon).
89363327|NCT04330833|Active Comparator|Enhanced Usual Care Parent Education|Parent(s) and patients receiving care from clinicians whose practice has been randomized to the enhanced usual care parent education group.
89363328|NCT04330833|Experimental|Novel Communication Intervention|Parent(s) and patients receiving care from clinicians whose practice has been randomized to the novel communication intervention group.
89001254|NCT00577915|Experimental|Breast MR Spectroscopy|Conventional images will be taken with standard pulse sequences. These images will be used for the diagnostic examination for which the patient will have been scheduled. Following the diagnostic study, a pulse sequence designed to obtain spectroscopy data will be used.This will be used on the existing magnets 1.5T and 3T. Memorial Sloan-Kettering Cancer Center has 1.5T and 3T magnets. The patient will have only one injection of contrast (gadolinium-DTPA) for the initial diagnostic study. No additional contrast will be administered. The additional sequence should take about 10 minutes, depending on breast size.
89363329|NCT04312113|Experimental|Autologous mesenchymal stem cells|Adipose derived, autologous mesenchymal stem cells (AD-MSCs) at a dose of 15 million or 30 million cells will be administered via intra-arterial delivery with interventional radiology to the inferior mesenteric artery in subjects with medically refractory ulcerative colitis.
89363330|NCT04311099|Experimental|Ultrasound-guided TAP|Ultrasound-guided TAP with 20 ml ropivacaine 2 mg/ml solution bilaterally and laparoscopic assisted injection of 20 ml saline (placebo) bilaterally at the beginning of surgery
89363331|NCT04311099|Experimental|Laparoscopic assisted TAP|Laparoscopic assisted TAP with 20 ml ropivacaine 2 mg/ml solution bilaterally and ultrasound-guided injection of 20 ml saline (placebo) bilaterally at the beginning of surgery
89363332|NCT04311099|Placebo Comparator|Placebo|Laparoscopic assisted injection of 20 ml saline (placebo) bilaterally and ultrasound-guided injection of 20 ml saline (placebo) bilaterally at the beginning of surgery
89363333|NCT04296396|Experimental|Individualized Opioid Prescription|Individualized opioid prescription protocol and shared decision making
89363334|NCT04296396|Other|Fixed Opioid Prescription|Fixed opioid prescription of 20 tablets of oxycodone 5mg
89363335|NCT04291352|Experimental|Taurine|675mg taurine four times daily
89363336|NCT04291352|Placebo Comparator|Placebo|placebo four times daily
89363337|NCT04261335|Experimental|CL2020 cells|Intravenous injection of CL2020 cells
89363338|NCT04259658|Experimental|Calcium electroporation treatment|Experimental treatment with calcium electroporation for cutaneous metastases.
89363339|NCT04257526|Active Comparator|Intervention|Colorectal cancer free participants receive evidence-based diet and lifestyle advice in addition to the 'usual care' following a positive FIT test and diagnostic colonoscopy
89363340|NCT04257526|No Intervention|Control|Colorectal cancer free participants receive the 'usual care' following a positive FIT test and diagnostic colonoscopy
89363341|NCT04246515|Experimental|Blood Flow Restriction Training|As from week 2 in the rehabilitation proces, this experimental group will receive exercises in combination with blood flow restriction. While occluding the vascular flow of the limb (startpoint = above the injury site), participants will perform 3 exercises: wall squat, leg press and bridge (3 sets of 30 repetitions). These blood flow restricted exercises are always on top of the classic rehabilitation.
89363342|NCT04246515|Sham Comparator|Sham Blood Flow Restriction Training|The same description as the experimental arm is applicable here. However, The Blood Flow restriction material will be attached to the injured limb without occluding the vascular blood flow.
89363343|NCT04246515|Active Comparator|Classic rehabilitation|This group will undergo the classic rehabilitation program.
89363344|NCT04235764||1/ Cohort 1|Bladder Cancer Patients
89363345|NCT04220021|Experimental|C9orf72 positive ALS|"Subjects with C9orf72 positive ALS will be instructed in the use of Metformin and receive the first dose of Metformin under supervision of the investigator during Visit 1, Day 2.~Subjects will then continue on Metformin per the dose escalation schedule twice daily for 24 weeks."
89363346|NCT04214873|Experimental|POH|Treatment of POH Using PiQo4 Laser System
89363347|NCT04202393|Experimental|Integrated Treatment Adherence Program (ITAP)|A combination of in-person and phone sessions along with significant other involvement over 6 months post-hospitalization.
89363348|NCT04202393|Active Comparator|Safety Assessment and Follow-up Evaluation (SAFE)|Enhanced symptom monitoring and safety evaluation over 6 months post-hospitalization.
89001255|NCT00577954||1|Patients in a coma condition after a traumatic brain injury (250), stroke, cerebral anoxia or subarachnoid hemorrhage (150), for at least 7 days.
89001256|NCT00202098|Experimental|1|ALI/ARDS patients
89363349|NCT04193306|Experimental|Alirocumab|alirocumab 150 mg s.c. every 2 weeks, for 48 weeks
89363350|NCT04193306|Placebo Comparator|Placebo|placebo s.c. every 2 weeks, for 48 weeks
89363351|NCT04180241|Active Comparator|total division of the muscle layer|POEM- total division of the circular muscle layer into the gastroesophageal junction
89363352|NCT04180241|Active Comparator|partial division of the muscle layer|POEM - partial division of the circular muscle layer into the gastroesophageal junction
89363353|NCT04155099|Experimental|High dose|Capsules of active drug will be supplied in 8-capsule blister packets to be taken twice per week for four weeks. Blood and stool samples and cognitive assessments will be collected before treatment and at 1, 3, 6, and 12 months after treatment.
88834758|NCT02118922||post-LASIK who developed ectasia|patients who underwent LASIK refractive surgery and developed ectasia as a complications
89363354|NCT04155099|Experimental|Low dose|Capsules of active drug will be supplied in 4-capsule blister packets to be taken twice per week for four weeks. Blood and stool samples and cognitive assessments will be collected before treatment and at 1, 3, 6, and 12 months after treatment.
89363355|NCT04155099|Placebo Comparator|pill quantity-matched Placebo|Capsules of inactive compound will be supplied in 8- or 4-capsule blister packets to be taken twice per week for four weeks. Blood and stool samples and cognitive assessments will be collected before treatment and at 1, 3, 6, and 12 months after treatment.
89363356|NCT04148352|Experimental|Dupilumab|24-week treatment period, which includes a 4-week run-in period with dupilumab followed by 12 weeks of treatment with dupilumab in combination with a gradual up-dosing of milk protein OIT, then followed by 8 weeks of milk OIT dosing with no dupilumab
89363357|NCT04148352|Placebo Comparator|Placebo|24-week treatment period, which includes a 4-week run-in period with placebo for dupilumab followed by 12 weeks of treatment with placebo for dupilumab in combination with a gradual up-dosing of milk protein OIT, then followed by 8 weeks of milk OIT dosing with no placebo
89363358|NCT04141995|Experimental|Treatment|Participants start FOLFIRINOX. They will also begin digoxin and take it up to 4-5 months time period in patients with resectable pancreatic cancer. Digoxin is taken at the time of neo-adjuvant chemotherapy treatment, prior to surgery. After surgery, participants will continue with post-adjuvant chemotherapy.
89363359|NCT04134559|Experimental|Pembrolizumab|Pembrolizumab will be administered every 3 weeks at a dose of 2mg/kg/dose (max: 200mg) with 21 consecutive days defined as a treatment cycle.
89363360|NCT04130529|Experimental|Adjusted group CBT-i for Bipolar disorder|"The experimental group receives group-CBT-i adjusted for Bipolar disorder. This is a version of CBT for insomnia (CBT-i) developed during the pilot phase of this Project. Traditional CBT-i is adjusted for use in the population with Bipolar Disorder. This behavioral intervention adresses not only traditional aspects of insomnia, but also sleep phase problems and other aspects of sleep specifically relevant to the Bipolar population.~Treatment is given as 8 weekly group sessions."
89363361|NCT04130529|Active Comparator|Sleep lectures|The control group is offered a series of 3 lectures on sleep during the same time-period.
89363362|NCT04107675|Experimental|L-CsA 10 mg plus Standard of Care|"Liposomal Cyclosporine A 10 mg (10 mg/2.5 mL) bid, once in the morning and once in the evening, for up to 12 weeks.~The inhalations were scheduled to be taken approximately 12 hours (but not less than 6 hours) apart, eg, at 08:00 and 20:00 each day. Nebulization time per inhalation dose was approximately 8 to 13 minutes for the 0- and 10-mg doses.~Standard of care included prophylaxis against common opportunistic infections, immunosuppression, and any other chronic medication"
89363363|NCT04107675|Experimental|L-CsA 5 mg plus Standard of Care|"Liposomal Cyclosporine A 5 mg (5 mg/1.25 mL) bid, once in the morning and once in the evening, for up to 12 weeks. The inhalations were scheduled to be taken approximately 12 hours (but not less than 6 hours) apart, eg, at 08:00 and 20:00 each day. Nebulization time per inhalation dose was approximately 5 to 10 minutes for the 5-mg dose.~Standard of care included prophylaxis against common opportunistic infections, immunosuppression, and any other chronic medication"
89363364|NCT04107675|Placebo Comparator|Liposomal Placebo plus Standard of Care|"Liposomal Placebo 2.5 mL (0 mg L-CsA/2.5 mL) bid, once in the morning and once in the evening, for up to 12 weeks.~The inhalations were scheduled to be taken approximately 12 hours (but not less than 6 hours) apart, eg, at 08:00 and 20:00 each day. Nebulization time per inhalation dose was approximately 8 to 13 minutes for the 0- and 10-mg doses. Standard of care included prophylaxis against common opportunistic infections, immunosuppression, and any other chronic medication"
89363365|NCT04031209||G7 G7 Acetabular System|All patients will receive G7 G7 Acetabular System
89363366|NCT04021459|Other|women with endometrial cancer|
89363367|NCT04003038|Active Comparator|Group I (wound care with a standard dressing)|Patients receive wound care with a standard dressing (bandage) after surgery for 7 days.
89363368|NCT04003038|Experimental|Group II (NPWT)|Patients receive NPWT after surgery for 7 days.
88834759|NCT02118922||Volunteers to receive PRK surgery|This group includes patients who have been diagnosed with myopia and have been scheduled to undergo PRK surgery. Patients with high astigmatism > 2 diopter, prior ocular surgeries, and those patients taking any ocular medications except seasonal allergy medicine such as ketotifen or artificial tears will be excluded.
89363369|NCT03999320|Experimental|Sophrology group|8 sophrology sessions, approximately 60 minutes each, spread over 12 months
89363370|NCT03999320|Other|Control group|usual care
89363371|NCT03982082|Experimental|Device feasibility (MuscleSound technology)|Patients undergo ultrasound via MuscleSound technology over 3 minutes at baseline and immediately after each of 2 physical therapy sessions comprising cycling or walking over 10 minutes.
88834760|NCT02118922||Volunteers to receive LASIK Surgery|This group includes myopic patients who are scheduled to receive LASIK surgery. Patients with high astigmatism > 2 diopter, prior ocular surgeries, and those patients taking any ocular medications except seasonal allergy medicine such as ketotifen and artificial tears will be excluded.
89001257|NCT00578032||1|Patients with head and neck malignancies that require simultaneous surgical resection and reconstruction of the ablative defect will be eligible to participate.
89001258|NCT00578110|Experimental|Group 1|Glaucoma Patients
89001259|NCT00578110|Experimental|Group 2|Glaucoma suspects
88834761|NCT02118922||Patients with Fuch's Endothelial Corneal Dystrophy|This group includes subjects who are diagnosed with Fuch's corneal dystrophy, at early, mild and advanced stages. The inclusion also extends to subjects with, and without keratoconus. But this exclude patients with any other corneal disorders other than keratoconus, and/or history of ophthalmological surgeries that may affect endothelium cell status, e.g. cataract surgeries.
88834762|NCT02111382|Experimental|CV4 (4th ventricle technique) technique|Will be conduced a real cranial osteopathic medicine technique.
88834763|NCT02111382|Sham Comparator|CV4 sham|This group will received only a sham manual therapy technique.
88834764|NCT02111382|No Intervention|Control|The participants will be in supine position for 5 minutes without any visual or verbal contact.
89363372|NCT03959215|Experimental|Usual care + Back in the Game|Smartphone-delivered cognitive behavioural therapy to support confidence to return to sport + usual post-operative physiotherapy rehabilitation
89363373|NCT03959215|Active Comparator|Usual care|Usual post-operative physiotherapy rehabilitation
89363374|NCT03915405|Experimental|KHK2455 in Combination with Avelumab|
89363375|NCT03851003|Experimental|Endometrial suturing|Uterine incision repair including suturing of the endometrium
89363376|NCT03851003|Experimental|Non - Endometrial suturing|Uterine incision repair without suturing of the endometrium
89363377|NCT03829254|Experimental|NUC-7738|NUC-7738 administered by intravenous infusion on a weekly or fortnightly schedule. In the weekly dosing schedule, NUC-7738 is administered on Days 1 and 8 of a 14-day cycle. In the fortnightly dosing schedule, NUC-7738 is administered on Day 1 of a 14-day cycle.
89363378|NCT03829254|Experimental|NUC-7738 + pembrolizumab|NUC-7738 administered by intravenous infusion on a weekly schedule on Days 1, 8 and 15 of a 21-day cycle. Pembrolizumab administered by intravenous infusion every 3 weeks on Day 1 of a 21-day cycle.
89363379|NCT03826589|Experimental|Avelumab and Axitinib|"Avelumab: IV treatment; administered at 10 mg/kg IV every two weeks in a 4-weekly cycle up to 12 cycles or until disease progression or intolerable side effects (whichever occurs first)~Axitinib: Oral treatment; administered at 5 mg PO BID in a 4-weekly cycle up to 12 cycles or until disease progression or intolerable side effects (whichever occurs first)"
89363380|NCT03823573|Experimental|Rapid recovery protocol|They will start walking the day of surgery. Levobupivacain 5mg/ml will be placed in the knee tissues. Tranexamic acid inside the knee. No drains.
89363381|NCT03823573|Active Comparator|Classic protocol|They will start walking 3 days after surgery. Levobupivacain 5 mg/ml will be placed in the femoral nerve. Tranexamic acid inside the knee. A Redon drain will be used.
89363382|NCT03788980||carotid endarterectomy group|patients undergoing carotid endarterectomy
89363383|NCT03781414|Active Comparator|Arm 1|Control/Standard of Care: TAC + MMF + Corticosteroids
89363384|NCT03781414|Experimental|Arm 2|CFZ533 600mg dose + MMF + Corticosteroids
89363385|NCT03781414|Experimental|Arm 3|CFZ533 300mg dose + MMF + Corticosteroids
88834765|NCT02108860|Experimental|Blinded abatacept|Participants will receive blinded abatacept 125 mg administered by subcutaneous injection once a week for at least 12 months. Subjects may be removed from treatment earlier due to a disease relapse, disease worsening, or if they have not achieved remission by treatment month 6.
88834766|NCT02108860|Placebo Comparator|blinded placebo|Participants will receive blinded placebo. Placebo will be administered by subcutaneous injection once a week for at least 12 months. Subjects may be removed from treatment earlier due to a disease relapse, disease worsening, or if they have not achieved remission by treatment month 6.
89363386|NCT03757481|Other|no intervention|patients with history of PE (pulmonary embolism) with acute DVT (deep veinous thrombosis) treated with heparin plus edoxaban or heparin plus warfarin
89363387|NCT03724331|Experimental|Light Physical Activity 1|Conventional treatment for cancer as prescribed by the participant's health care providers and will receive a home-based light (mild) physical activity program that begins approximately within one week after discharge from the hospital with the physical activity program starting approximately within the first week post-discharge from the hospital.
89363388|NCT03724331|Experimental|Light Physical Activity 2|Conventional treatment for cancer as prescribed by the participant's health care providers and will receive a home-based light (mild) physical activity program that begins approximately within one week after discharge from the hospital with the physical activity program starting approximately 7 weeks post-discharge from the hospital.
89363389|NCT03724331|Active Comparator|Support Education Activity|Conventional treatment for cancer as prescribed by the participant's health care providers and will participate in a supportive cancer-related education activity each week for 6-weeks after returning home from the hospital.
88834767|NCT02079181|Experimental|Diagnostic (fluorine F 18 d-FMAU PET/CT scan)|Patients receive fluorine F 18 d-FMAU IV followed by PET/CT prior to start of cancer treatment. Patients may undergo 2 additional scans at one week prior to second course of chemotherapy and after completion of cancer treatment depending on cancer type.
88834768|NCT02076906|Experimental|MR-HIFU|Magnetic Resonance High Intensity Focused Ultrasound (MR-HIFU) ablative therapy for children with recurrent or relapsed solid tumors.
88834769|NCT02072642|Active Comparator|Active light therapy (10,000 lux)|Light therapy: DayVia lamp 10000 lux
88834770|NCT02072642|Placebo Comparator|Placebo light therapy (70 lux)|Placebo light therapy
89363390|NCT03717753|No Intervention|Before Group|We plan to have 70 patients studied prior to initiation of a pathway.
89363391|NCT03717753|Experimental|After Group|We plan to have 70 patients studied after initiation of a pathway.
89363392|NCT03701334|Experimental|Ribociclib + Endocrine Therapy|Participants will receive ribociclib 400 mg once daily on days 1-21 of a 28-day cycle and endocrine therapy once daily continuously
88875175|NCT02503410|Active Comparator|Usual care|Subjects receive physical therapy for low back pain as typically prescribed in the clinic.
88875176|NCT02503410|Experimental|Interactive gaming|Subjects participate in an intervention combining usual care and home-based exercises using the Valedo system.
89363393|NCT03701334|Active Comparator|Endocrine Therapy|Participants will receive endocrine therapy only once daily continuously
89363394|NCT03689179|Experimental|Treatment with Follow-up (Group A)|"Group A received access to the full Time for Living & Caring (TLC) intervention for 8 weeks (calendar + coaching + resources), followed by an 8-week maintenance period where they could continue to use the TLC intervention. The TLC intervention turned off after 16 weeks of exposure for all participants."
89363395|NCT03689179|Experimental|Wait-List Control w/Treatment (Group B)|"Group B received 8 weeks of waitlist control (minimal treatment - calendar only) , followed by access to the full Time for Living & Caring (TLC) intervention for an additional 8 weeks (calendar + coaching + resources). The TLC intervention turned off after 16 weeks of exposure for all participants."
89363396|NCT03681483|Experimental|RO5126766 (CH5126766)|The study will begin with a standard 3+3 design. The study will enroll 3 patients at the previously identified MTD15 (4mg two times per week on days 1 and 4). The period of evaluation for dose limiting toxicity will be through completion of cycle 1. If ≤1 of the 3 initial patients at the proposed dose experience a DLT, then 3 additional patients will be enrolled for a total of 6 planned patients at that dose level. Otherwise, 3 patients will be enrolled at dose level -1. If ≤ 1 of these patients experience a DLT, then 3 additional patients will be enrolled at the same dose level. If more than 1 patient experiences a DLT in dose level -1, the study will be terminated.
89363397|NCT03672461|Experimental|Yoga Practice Program|The 3-month yoga intervention will provide instruction and practice in a variety of yoga postures and techniques that have been selected by the study yoga expert consultants for their potential to improve bladder control and safety and feasibility for the target population. The study will feature a therapeutic program based primarily on Iyengar yoga, a form of Hatha yoga that is known for its potential therapeutic applications.
89363398|NCT03672461|Active Comparator|Physical Conditioning Program|"The 3-month muscle stretching/strengthening intervention program (also referred to as the physical conditioning program) has been designed by the study physical therapist consultants. Similar to postures in the yoga intervention program, the exercises in the stretching/strengthening program have been selected for their potential to be performed safely by women across a range of ages and flexibility levels."
89363399|NCT03620617|Experimental|Experimental: Raspberry supplementation|Dietary Supplement: 280g of frozen raspberries, taken daily for 8 weeks. Subjects will consume frozen raspberry to test if there is a significant difference on the impact on gut microbiota composition and metabolic syndrome parameters between this treatment and control group (without raspberry).
89363400|NCT03620617|No Intervention|Control|Control: follow their usual diet (control group). Subjects will follow their usual diet and not consume raspberry to test if there is a significant difference on the impact on gut microbiota composition and metabolic syndrome parameters between this treatment and the experimental group (with raspberry).
89363401|NCT03617003|Experimental|phototherapy with WST11|Patients with urothelial cancer that includes involvement of the upper urinary tract and have failed prior endoscopic treatment, refuse standard treatment, or are ineligible for curative surgical resection of the kidney or ureter will be offered WST11 VTP treatment to be provided at the time of scheduled endoscopic procedure. At the time of endoscopy, patients will be treated with VTP therapy applied to the site of the tumor.
89363402|NCT03612531|Experimental|Supportive Care (manual therapy)|Participants receive 10 manual therapy sessions performed by a speech pathologist during weeks 1-6. After completion of 6 weeks of therapy, participants perform manual therapy at home daily for 6 weeks.
89363403|NCT03611556|Experimental|Dose-escalation, Oleclumab 1500 mg + Durvalumab + Gemcitabine + nab-paclitaxel|Participants with 1L metastatic disease will receive intravenous (IV) infusions of oleclumab 1500 mg every 2 weeks for 4 doses, then every 4 weeks (Q4W) in combination with durvalumab 1500 mg Q4W plus chemotherapy of gemcitabine 1000 mg/m^2 and nab-paclitaxel 125 mg/m^2, both on Days 1, 8, and 15 and then repeated on Q4W schedule until disease progression, intolerable toxicity, withdrawal of participant consent, or another discontinuation criterion is met.
89363404|NCT03611556|Experimental|Dose-escalation, Oleclumab 3000 mg + Durvalumab + Gemcitabine + nab-paclitaxel|Participants with 1L metastatic disease will receive IV infusions of oleclumab 3000 mg every 2 weeks for 4 doses, then Q4W in combination with durvalumab 1500 mg Q4W plus chemotherapy of gemcitabine 1000 mg/m^2 and nab-paclitaxel 125 mg/m^2, both on Days 1, 8, and 15 and then repeated on Q4W schedule until disease progression, intolerable toxicity, withdrawal of participant consent, or another discontinuation criterion is met.
89534598|NCT03334565|Active Comparator|Low efficiency|"Participants were exposed to low-efficiency (LE) HEPA-type filtered air using air filtration systems in the bedroom and main living space of each residence."
89534599|NCT03334565|Active Comparator|High efficiency|"Participants were exposed to high-efficiency (HE) true-HEPA filtered air using air filtration systems in the bedroom and main living space of each residence."
88875177|NCT02507388|Experimental|Brolucizumab 3 mg|Brolucizumab 3 mg/50 μL administered as an intravitreal injection 3 times at 4-week intervals with follow-up for 84 days from the initial injection
89001260|NCT00578110|Active Comparator|Group 3|Controls
88875178|NCT02507388|Experimental|Brolucizumab 6 mg|Brolucizumab 6 mg/50 μL administered as an intravitreal injection 3 times at 4-week intervals with follow-up for 84 days from the initial injection
88875179|NCT02508480|Experimental|Photovoice|Participants in this arm will attend a 10-week peer-led Photovoice program conducted in group format.
89363405|NCT03611556|Experimental|Dose-escalation, Oleclumab 1500 mg + Durvalumab + mFOLFOX|Participants with 2L metastatic disease will receive IV infusions of oleclumab 1500 mg every 2 weeks for 4 doses, then Q4W in combination with durvalumab 1500 mg Q4W plus chemotherapy of mFOLFOX (oxaliplatin 85 mg/m^2 IV; folinic acid 400 mg/m^2 IV; 5-FU 400 mg/m^2 IV bolus followed by 2400 mg/m^2 continuous IV infusion over 46 to 48 hours) on Days 1 and 15 and then repeated on a Q4W schedule, until disease progression, intolerable toxicity, withdrawal of participant consent, or another discontinuation criterion is met.
89363406|NCT03611556|Experimental|Dose-escalation, Oleclumab 3000 mg + Durvalumab + mFOLFOX|Participants with 2L metastatic disease will receive IV infusions of oleclumab 3000 mg every 2 weeks for 4 doses, then Q4W in combination with durvalumab 1500 mg Q4W plus chemotherapy of mFOLFOX (oxaliplatin 85 mg/m^2 IV; folinic acid 400 mg/m^2 IV; 5-FU 400 mg/m^2 IV bolus followed by 2400 mg/m^2 continuous IV infusion over 46 to 48 hours) on Days 1 and 15 and then repeated on a Q4W schedule, until disease progression, intolerable toxicity, withdrawal of participant consent, or another discontinuation criterion is met.
89363407|NCT03611556|Active Comparator|Dose-expansion, Gemcitabine + nab-paclitaxel|Participants with 1L metastatic disease will receive IV infusions of chemotherapy of gemcitabine 1000 mg/m^2 and nab-paclitaxel 125 mg/m^2, both on Days 1, 8, and 15 and then repeated on Q4W schedule until disease progression, intolerable toxicity, withdrawal of participant consent, or another discontinuation criterion is met.
89363408|NCT03611556|Experimental|Dose-expansion, Oleclumab 3000 mg + Gemcitabine + nab-paclitaxel|Participants with 1L metastatic disease will receive IV infusions of oleclumab 3000 mg every 2 weeks for 4 doses, then Q4W in combination with chemotherapy of gemcitabine 1000 mg/m^2 and nab-paclitaxel 125 mg/m^2, both on Days 1, 8, and 15 and then repeated on Q4W schedule until disease progression, intolerable toxicity, withdrawal of participant consent, or another discontinuation criterion is met.
89363409|NCT03611556|Experimental|Dose-expansion, Oleclumab 3000 mg + Durvalumab + Gemcitabine + nab-paclitaxel|Participants with 1L metastatic disease will receive IV infusions of oleclumab 3000 mg every 2 weeks for 4 doses, then Q4W in combination with durvalumab 1500 mg Q4W plus chemotherapy of gemcitabine 1000 mg/m^2 and nab-paclitaxel 125 mg/m^2, both on Days 1, 8, and 15 and then repeated on Q4W schedule until disease progression, intolerable toxicity, withdrawal of participant consent, or another discontinuation criterion is met.
89363410|NCT03608657||Psoriatic Arthritis patients treated with Apremilast|Active PsA as per the CASPAR criteria, based on the investigator's clinical judgement with access to commercially available Otezla
89363411|NCT03600857|Experimental|Home administration|Home administration of 0.8 mg misoprostol pv
88834771|NCT02043457||Lifestyle intervention|Opt-in intervention to include the following procedures, called 'phenotyping' performed at baseline, after 10-15% weight loss from baseline weight or 6 months (whichever comes first) and at end of 2 years while in weight maintenance: oral glucose tolerance test, mixed meal tolerance test, with fasting leptin, biased and unbiased metabolomic profiling, DNA, RNA, muscle and adipose tissue biopsies: measurement of resting energy expenditure by indirect calorimetry; oxidative capacity (V02 peak/max); body composition by Dual Energy X-ray Absorptiometry (DEXA) or air displacement plethysmograph (Bod Pod); inventories of depression and health related quality of life instruments, measures of impulsivity, measures of hunger and appetite, work performance (including presenteeism and absenteeism) and pain survey.
88834772|NCT02039934|Experimental|high intensity interval training|30 minute sessions of high-intensity interval training on a bicycle ergometer three times per week
88834773|NCT01947218|Experimental|smoking COPD|
88834774|NCT01947218|Experimental|smoking without COPD|
88834775|NCT01947218|Other|No Smoking Control|
88834776|NCT01947218|Experimental|severe asthma|
88834777|NCT01860937|Experimental|Cohort 1 (MRD)|Patients with no morphologic evidence of disease at the time of T cell infusion, (<5% blasts in the bone marrow) as assessed by morphology or flow cytometry. Participating site PI to determine cohort stratification in the event of morphology/flow cytometry blast count discrepancy. Cohort 1 patients will receive conditioning chemotherapy followed by 1x10^6 19-28z+ T cells/kg over 1 to 2 days. During formulation of End of Production (EOP) T cells, under or over estimation of CAR modified T-cells may occur. Patients may receive an altered fractionation of the total doses (e.g. ½ on Day 0 and ½ on Day +1) or up to 35% over total cell dose with approval by the participating site PI. In both cohorts, patients will be allowed to receive a 2nd treatment of 19-28z+ T cells if they benefited from the first infusion and did not experience any non-hematologic grade 4 toxicities.
88834778|NCT01860937|Experimental|Cohort 2 (Morphologic Disease)|Pts with morphologic evidence of disease at the time of T cell infusion, (≥5% blasts in the bone marrow) as assessed by morphology or flow cytometry. Participating site PI to determine cohort stratification in the event of morphology/flow cytometry blast count discrepancy. Pts with increased blasts (5-10% blasts) that are immunophenotypically consistent with recovering marrow from prior re-induction chemo may be treated under Cohort 1 with approval of the participating site PI. Cohort 2 pts will get conditioning chemo followed by 1x10^6 19-28z+ T cells/kg over 1 to 2 days. During formulation of EOP T cells, under or over estimation of CAR modified T-cells may occur. Pts may get up to 35% over total cell dose with approval by the participating site PI. Both cohorts, pts will be allowed to receive a 2nd treatment of 19-28z+ T cells if they benefited from the first infusion & did not experience any non-hematologic grade 4 toxicities.
88834779|NCT01856686|Experimental|BP22042013|This group of patients receive 2.000 kilocalories diet(60 g. carbohydrates, 144 gr of fat and 107 gr of proteins), including 2 protein shakes.
89001261|NCT00187122|Other|1|See Detailed Description section for description of treatment plan.
89363412|NCT03600857|No Intervention|Hospital administration|Hospital administration of 0.8 mg misoprostol pv
89534600|NCT05049681|Experimental|SHR-1210（Camrelizumab）+Apatinib|Apatinib 250mg, q.d.po; SHR-1210（Camrelizumab） 200 mg，Intravenous injection,q2W ,A course of treatment need 28 days.
89534601|NCT05049681|Active Comparator|SHR-1210（Camrelizumab）|SHR-1210（Camrelizumab） 200 mg，Intravenous injection. q2W ,A course of treatment need 28 days.
89534602|NCT03334487|Experimental|Rovalpituzumab tesirine + dexamethasone|Rovalpituzumab tesirine 0.3 mg/kg administered intravenously on Day 1 of each 6-week cycle plus oral dexamethasone 8 mg twice daily on Day -1, Day 1, and Day 2 of 6-week each cycle.
89363413|NCT03586518||Haemodialysis patients|"The plans for patient recruitment were developed in partnership with our local haemodialysis patient participation and involvement group. Patients will be identified from the supportive care register established for haemodialysis patients in Leicester in 2008.~Inclusion:~Prevalent haemodialysis patient (more than 3 months)~Active on the supportive care register with anticipated death in the subsequent 12 months~Able to give informed consent~Consent to donation of heart for research following death~Able to understand written and verbal explanations in English~Exclusion:~Contraindication to MRI scan (e.g. pacemaker, incompatible metallic implants, claustrophobia)~Patients with expected or potential infiltrative cardiomyopathy (e.g. amyloidosis)~Unable to give informed consent~Unable to understand written and verbal explanations in English"
89363414|NCT03573583|Experimental|Resistance Training group (RT)|"The resistance training intervention will include a full body, resistance training performed three days per week.~The intensity, volume, tempo, and progression will be based on the Federal Physical Activity guidelines"
88834780|NCT01856686|Experimental|Low carbohydrate Diet|the second group of patients receive diet of 2.000 Kilo calories without rapidly absorbed carbohydrates and without proteins supplements
88834781|NCT01852448||Patients with Cystic Fibrosis|Blood or saliva sample collection and medical record review.
88834782|NCT01833689|Placebo Comparator|food consumption: control|The control product will be 50g glucose powder dissolved in 250ml of water
88834783|NCT01833689|Active Comparator|food consumption: product|The test food will provide 50g of available carbohydrate
88834784|NCT01796834|Experimental|Mindfulness-Based Stress Reduction|Subjects attend a community based Mindfulness-Based Stress Reduction course.
88834785|NCT01791829||Luminal A with other Clinical Criteria|BCS postulated to be at low risk for IBTR following Endocrine Therapy
88834786|NCT01770145|Experimental|APOKYN|"APOKYN (apomorphine hydrochloride injection) is used as needed to treat off-episode motor symptoms, such as muscle stiffness, slow movements, and difficulty starting movements, in people with advanced Parkinson's disease (PD).~In the study, subjects will complete an L-Dopa Baseline Period in which they record daily time to on following their regularly scheduled L-Dopa morning dose for 7 days. At the end of the baseline period, patients will start trimethobenzamide therapy during a minimum 3-Day Anti-Emetic Pretreatment Period. Patients determined to remain eligible at the end of the required Anti-Emetic Pretreatment Period will be initiated on APOKYN therapy by an investigator. Once the appropriate dose is identified by a study investigator, patients will inject APOKYN at their regularly scheduled levodopa morning dose time (levodopa will be delayed by 40 minutes) daily during a 7-day APOKYN Treatment Period and record time to on following the APOKYN injection."
88834787|NCT01758081|Active Comparator|vitamin D + fish oil|vitamin D3 + Omacor
89363415|NCT03573583|Active Comparator|Successful Aging|The comparator group will meet for stretching and health education classes every 2-5 weeks up to 7 total visits.
88834788|NCT01758081|Active Comparator|vitamin D + fish oil placebo|vitamin D3 + fish oil placebo
88834789|NCT01758081|Active Comparator|vitamin D placebo + fish oil|vitamin D placebo + Omacor
89363416|NCT03560700|Experimental|lactobacillus probiotic strain|60 billion CFU/day
89363417|NCT03560700|Placebo Comparator|placebo|
89363418|NCT03515720|Experimental|Study group|Painful points will be located in the path of the sensory nerves of the knee in which asepsis and antisepsis will be performed, and then 0.5-1 ml of 5% dextrose solution will be applied subcutaneously at a 45º angle along the way. of the nerve with a 27 gauge needle of ½ inch. The number of injections will vary according to the symptoms to be treated. The application will be made once a week for 6 weeks. After the first application of neuroprolotherapy, the patient will be trained to perform a rehabilitation therapy program based on thermotherapy, kinesitherapy and knee strengthening exercises. At the end of the 6 sessions, a new assessment will be made with the WOMAC, EVA and measurement of movement arcs to assess the evolution after treatment.
89363419|NCT03515720|No Intervention|Control group|Physical therapy consisting of 10 sessions based on thermotherapy, kinesitherapy and muscle strengthening exercises to the knee. Subsequently, the patient will perform this therapy home until completing 6 weeks. At the end a new assessment will be made with measurement of movement arcs, WOMAC scale and EVA to assess the evolution after treatment.
89534603|NCT05038215|Experimental|multifactor intervention|The experimental group will receive adherence promotion techniques in addition to routine care.
88834790|NCT01758081|Placebo Comparator|vitamin D placebo + fish oil placebo|vitamin D placebo + fish oil placebo
88834791|NCT01749137|Experimental|Setmelanotide|Participants received 1 milligram (mg) setmelanotide every day by continuous subcutaneous infusion using the Omnipod insulin pump for a duration of 90 days.
88834792|NCT01749137|Placebo Comparator|Placebo|Participants received placebo matching setmelanotide every day by continuous subcutaneous infusion using the Omnipod insulin pump for a duration of 90 days.
88834793|NCT01726582|Experimental|Milestones related to therapy|"Milestone 1: Targeted chemotherapy prior to surgery: 8 weeks targeted chemotherapy; restaging.~Milestone 2: Before surgery: Chemoradiotherapy (cRXT); restaging Milestone 3: Before surgery: 8 weeks targeted chemotherapy; restaging; chemoradiotherapy (cXRT); restaging.~Milestone 4: standard FOLFIRINOX chemotherapy prior to surgery: 8 weeks FOLFIRINOX (standard chemotherapy); restaging; standard chemoradiotherapy (cXRT); restaging.~Milestone 5: After surgery: 8 weeks targeted chemotherapy; restaging; chemoradiotherapy (cXRT); restaging.~Milestone 6: Gemcitabine after surgery: 8 weeks standard Gemcitabine (chemotherapy); restaging; chemoradiotherapy (cXRT); restaging.~Milestone 7: After surgery: chemoradiotherapy (cXRT); restaging. Milestone 8: Gemcitabine after surgery: 8 weeks Gemcitabine (chemotherapy); restaging; 8 weeks Gemcitabine (chemotherapy); restaging.~Milestone 9: No additional therapy after surgery. Milestone 10: After surgery no additional treatment."
88834794|NCT01693965|Other|sputum samples|
89534604|NCT05038215|Active Comparator|Control|The control group will receive routine care
88834795|NCT01687127|Experimental|Folic acid supplementation|Folic acid will be given orally in form of tablets. A supplement of 1 mg will be taken daily for 12 weeks. Thereafter, a supplement of 5 mg will be taken daily for 12 weeks (i.e., until Week 24). At baseline, Week 12, and Week 24, subjects will receive a 9-hour primed constant infusion of amino acids in saline solution for quantification of kinetics of one-carbon metabolism.
88875180|NCT02508480|Active Comparator|Enhanced Control|Participants in this arm will attend a 60-minute peer-led group discussion on stigma and discrimination, and be eligible to participate in the 10-week Photovoice program after completing all study assessments.
89001262|NCT00578188||RP100-400|Subjects with Chlamydia. The control group will also be identified with these numbers.
89363420|NCT03501992|Other|Practice A|Practice A will consist of the eligible patients empaneled to one of the six participating practices. In the first step, Practice A will be assigned to receive the current care intervention. in the second step, Practice A will be assigned to receive the current care intervention. In the third step, Practice A will receive the reminder-recall intervention. In the fourth step, Practice A will receive the combined reminder-recall and audit-and-feedback intervention.
89363421|NCT03501992|Other|Practice B|Practice B will consist of the eligible patients empaneled to one of the six participating practices. In the first step, Practice B will be assigned to receive the current care intervention. In the second step, Practice B will be assigned to receive the reminder-recall intervention. In the third step, Practice B will receive the combined reminder-recall and audit-and-feedback intervention. In the fourth step, Practice A will receive the combined reminder-recall and audit-and-feedback intervention.
89363422|NCT03501992|Other|Practice C|Practice C will consist of the eligible patients empaneled to one of the six participating practices. In the first step, Practice C will be assigned to receive the current care intervention. In the second step, Practice C will be assigned to receive the audit-and-feedback intervention. In the third step, Practice C will receive the audit-and-feedback intervention. In the fourth step, Practice C will receive the combined reminder-recall and audit-and-feedback intervention.
89363423|NCT03501992|Other|Practice D|Practice D will consist of the eligible patients empaneled to one of the six participating practices. In the first step, Practice D will be assigned to receive the current care intervention. In the second step, Practice D will be assigned to receive the current care intervention. In the third step, Practice D will receive the audit-and-feedback intervention. In the fourth step, Practice D will receive the combined reminder-recall and audit-and-feedback intervention.
89363424|NCT03501992|Other|Practice E|Practice E will consist of the eligible patients empaneled to one of the six participating practices. In the first step, Practice E will be assigned to receive the current care intervention. In the second step, Practice E will be assigned to receive the reminder-recall intervention. In the third step, Practice E will receive the reminder-recall intervention. In the fourth step, Practice E will receive the combined reminder-recall and audit-and-feedback intervention.
89363425|NCT03501992|Other|Practice F|Practice F will consist of the eligible patients empaneled to one of the six participating practices. In the first step, Practice F will be assigned to receive the current care intervention. In the second step, Practice F will be assigned to receive the audit-and-feedback intervention. In the third step, Practice F will receive the combined reminder-recall and audit-and-feedback intervention. In the fourth step, Practice F will receive the combined reminder-recall and audit-and-feedback intervention.
89363426|NCT03477162|Experimental|Metformin|Patients enrolled will be treated with metformin (administered orally; 750 mg QD for 4 days, then 750 mg BID for 3-6 days; or clinically indicated metformin) for a total of 7-10 days prior to surgery, up until the night before surgery.
89363427|NCT03426761|Experimental|Dalbavancin|Dalbavancin 1,500mg intravenously every fourteen days for two to four infusions
89363428|NCT03426761|Active Comparator|Standard of Care|Standard of care intravenous antibiotic based on microbiology susceptibility testing. Infusions may be one to three times daily for three to eight weeks. Examples of standard of care include vancomycin, daptomycin, nafcillin, cefazolin.
89363429|NCT03397667|Other|Control|Primary Care
89363430|NCT03397667|Experimental|Intervention|Primary Care plus ABC ANSWERS intervention
89363431|NCT03392974|Experimental|Valoctocogene Roxaparvovec Open Label|Single administration of valoctocogene roxaparvovec at a dose of 4E13 vg/kg
89363432|NCT03364283||Sitting Position|Sitting and semi-sitting
89001263|NCT00180635|Experimental|Healthy volunteers non smoker|Control group
89001264|NCT00180635|Experimental|Healthy volunteers smoker|More than 10 pack-years
89001265|NCT00180635|Experimental|Chronic Obstructive Pulmonary Disease COPD|COPD diagnosed according to the Global Initiative for Chronic Obstructive Lung Disease guidelines
89001266|NCT00578266|Other|No Arms|
89363433|NCT03364283||Horizontal Position|Prone, lateral and park bench.
89363434|NCT03332667|Experimental|131I-MIBG with Dinutuximab|Patients will receive 131I-MIBG on day 1. Dinutuximab is given intravenously on days 8-11 and 29-32 of therapy. Dinutuximab and 131I-MIBG dose will be based on the dose level assigned at the time of patient registration. Patient will receive GM-CSF on days 8-17 and 29-38 at 250 mcg/m2. All patients will receive autologous hematopoietic stem cell infusion on day 15 (+/- 2) of therapy
89363435|NCT03332667|Experimental|131I-MIBG with Dinutuximab and Vorinostat|Patients will receive vorinostat on days 0-13. 131I-MIBG will be received on day 1. Dinutuximab is given intravenously on days 8-11 and 29-32 of therapy. Dinutuximab and 131I-MIBG dose will be based on the dose level assigned at the time of patient registration. Patient will receive GM-CSF on days 8-17 and 29-38 at 250 mcg/m2. All patients will receive autologous hematopoietic stem cell infusion on day 15 (+/- 2) of therapy
89363436|NCT03309813|Experimental|Transcranial ExAblate|ExAblate Transcranial MR Guided Focused Ultrasound (MRgFUS)
89001267|NCT00578422||Arm I: In Vitro IVUS Plaque studies|IVUS of Amputation Specimens
89363437|NCT03309813|Sham Comparator|Sham Transcranial ExAblate|ExAblate MRgFUS Sham Procedure
89363438|NCT03304847|Other|Ablation|Radio-frequency catheter ablation
89363439|NCT03299205|Experimental|Exercise|Aerobic exercise program using treadmill.
89001268|NCT00578422||Arm 2: Obserational Study|IVUS for patients undergoing standard lower extremity angiography for PAD.
89001269|NCT04578496|Experimental|Afamelanotide|
89001270|NCT00202137|Active Comparator|1|home blood pressure monitoring with automatic blood pressure device
89001271|NCT00202137|Active Comparator|2|physician monitoring of blood pressure by 3 monthly office visits
89001272|NCT00578500|Active Comparator|OCCT|Patients referred to ovarian cryopreservation.
89001273|NCT00578578|Active Comparator|1|"Active Arm:~1000 mg Lemon flavored Capsules. Three capsules every morning."
89363440|NCT03287492|Experimental|Group I (QPS)|Participants receive QPS and answer questions from physician. At follow up visit, participants receive both QPS and GIS.
89363441|NCT03287492|Active Comparator|Group II (GIS)|Participants receive GIS and answer questions from physician. At follow up visit, participants receive both QPS and GIS.
88834796|NCT01687127|Experimental|5-MTHF supplementation|"The calcium salt of 5-methyltetrahydrofolate (5-MTHF; Brand name Metafolin) will be given orally in form of tablets. A supplement of 1 mg will be taken daily for 12 weeks. Thereafter, a supplement of 5 mg will be taken daily for 12 weeks (i.e., until Week 24). At baseline, Week 12, and Week 24, subjects will receive a 9-hour primed constant infusion of amino acids in saline solution for quantification of kinetics of one-carbon metabolism."
89363442|NCT03274830||aneXys|cases with aneXys cup and Mathys hip stem
89363443|NCT03271580||Diabetic patients infected ulcers|"Diabetic patients with HbA1c<9 with who have wound 4weeks or longer with infection with following interventions:~Finger prick test for HbA1c measurement~Punch biopsy~VAC sponge collection~Ankle brachial index"
89363444|NCT03271580||Diabetic patients non infected Ulcers|"Diabetic patients with HbA1c<9 who have wound 4 weeks or longer without infection with following interventions:~Finger prick test for HbA1c measurement~Punch biopsy~VAC sponge collection~Ankle brachial index"
89363445|NCT03268837|Experimental|Programmed Intermittent Bolus (PIB)|For the experimental group, patients will receive 5 mL of the study solution as a bolus every hour via a PIB-capable infusion pump.
89363446|NCT03268837|Active Comparator|Continuous Infusion|The control (standard care) group will receive the study solution at a rate of 5mL/h continuously via the current infusion pump.
89363447|NCT03266055|Experimental|Blueberry powder|
89363448|NCT03266055|Placebo Comparator|Blueberry placebo powder|
89363449|NCT03260491|Experimental|Dose Escalation: Cohort 1, 3.2 mg/kg|Participants in the Dose Escalation Cohort 1 will receive U3-1402 intravenously (IV) once every three weeks at 3.2 mg/kg.
89363450|NCT03260491|Experimental|Dose Escalation: Cohort 2, 4.8 mg/kg|Participants in Dose Escalation Cohort 2 will receive U3-1402 intravenously (IV) once every three weeks at 4.8 mg/kg.
89363451|NCT03260491|Experimental|Dose Escalation: Cohort 3, 5.6 mg/kg|Participants in Dose Escalation Cohort 3 will receive U3-1402 intravenously (IV) once every three weeks at 5.6 mg/kg.
89363452|NCT03260491|Experimental|Dose Escalation: Cohort 4, 6.4 mg/kg|Participants in Dose Escalation Cohort 3 will receive U3-1402 intravenously (IV) once every three weeks at 6.4 mg/kg.
89363453|NCT03260491|Experimental|Dose Expansion: Cohort 1, EGFR mutant|Participants with adenocarcinoma NSCLC with EGFR mutations in the Dose Expansion Cohort 1 will receive U3-1402 IV once every three weeks at the established recommended dose for expansion (RDE).
89363454|NCT03260491|Experimental|Dose Expansion: Cohort 2, EGFR wild-type|Participants with squamous or non-squamous NSCLC without EGFR-activating mutations in the Dose Expansion Cohort 2 will receive U3-1402 IV once every three weeks at the established recommended dose for expansion (RDE).
89363455|NCT03260491|Experimental|Dose Expansion: Cohort 3a, EGFR mutant|Randomized participants with NSCLC and EGFR mutations in the Dose Expansion Cohort 3a will receive U3-1402 IV once every three weeks at the established recommended dose for expansion (RDE) or, if applicable, adjusted RDE (aRDE).
89363456|NCT03260491|Experimental|Dose Expansion: Cohort 3b, EGFR mutant|Randomized participants with NSCLC and EGFR mutations in the Dose Expansion Cohort 3b will receive U3-1402 IV once every three weeks following an up-titration regimen (Cycle 1, Day 1: 57% of RDE or aRDE; Cycle 2, Day 1: 86% of RDE or, if applicable aRDE; Cycle 3 and subsequent cycles, Day 1: 114% of RDE or aRDE).
89363457|NCT03260491|Experimental|Dose Expansion: Cohort 4, EGFR mutant|Participants with NSCLC (including any histology other than small-cell or combined small-cell and non-small cell) with an EGFR-activating mutation will receive U3-1402 IV at 5.6 mg/kg every 3 weeks.
89363458|NCT03259685|Active Comparator|Regular beverages|Sugar sweetened soft drinks
89363459|NCT03259685|Experimental|Diet beverages|Soft drinks sweetened with artificial non-nutritive sweeteners (i.e. aspartame, acesulfame-K)
89363460|NCT03259685|Experimental|Stevia beverages|Soft drinks sweetened with natural non-nutritive sweeteners (i.e. steviol glycosides)
89363461|NCT03248479|Experimental|R/R Safety Cohort|Participants will receive 1 mg/kg magrolimab twice weekly for Cycle 1 Week 1 (Day 1 and 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11 and 15; and 30 mg/kg weekly thereafter starting Cycle 3 up to end of the study.
88834797|NCT01658787||Endovascular aortic repair|Patients treated with Gore Endovascular Aortic Products.
89001274|NCT00578578|Placebo Comparator|2|"Placebo Arm:~Cornstarch Capsules provided by Clinical Encapsulation services. Three capsules every morning."
89001275|NCT00578656|Experimental|1|Baked milk and at least 4 oral food challenges as clinically indicated
89363462|NCT03248479|Experimental|R/R Expansion Cohort:|Participants will receive 1 mg/kg magrolimab twice weekly for Cycle 1 Week 1 (Day 1 and Day 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11 and 15; 30 mg/kg weekly on Cycle 1 Day 22 through end of Cycle 2, then 30 mg/kg every 2 weeks starting Cycle 3 up to end of the study + azacitidine 75 mg/m^2 on Days 1 to 7 of each cycle.
89363463|NCT03248479|Experimental|R/R MDS Magrolimab Monotherapy Cohort|Participants will receive 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Day 11, 15, 22, weekly on Cycle 2, and then biweekly starting Cycle 3 up to end of the study.
89363464|NCT03248479|Experimental|Treatment-naive Unfit (TNU) Dose Evaluation Cohort|Participants will receive 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Day 11, 15, 22, and then weekly starting Cycle 2 up to end of the study + azacitidine 75 mg/m^2 on Days 1 to 7 of each cycle.
89363465|NCT03248479|Experimental|Treatment-naive Unfit (TNU) Dose Expansion Cohort|Participants will receive 1 mg/kg magrolimab twice weekly for Cycle 1; 15 mg/kg weekly for Cycle 1 Day 8; 30 mg/kg weekly through end of cycle 2; and then 30 mg/kg every 2 weeks starting Cycle 3 up to end of the study + azacitidine 75 mg/m^2 on Days 1 to 7 of each cycle.
89363466|NCT03248479|Experimental|RBC transfusion-dependent low-risk MDS, Safety Run-in Phase|Participants will receive 1 mg/kg magrolimab on Cycle 1 Day 1; 30 mg/kg on Cycle 1 Days 8, 15, and 22; and 60 mg/kg every 4 weeks starting on Cycle 2 Day 1 and thereafter up to end of the study. For participants who do not respond after Cycle 2, azacitidine 75 mg/m^2 may be added on subsequent cycles (ie starting at Cycle 3) on Days 1 to 5 of each cycle.
88834798|NCT01579552|Experimental|Intervention Group|The EMPOWER intervention trial is a 12-month study of 360 women from the Childhood Cancer Survivor Study who have previously been treated with chest radiation, are 25 to 49 years of age at the time of enrollment, are 8 years or more since their chest radiation, and have not had a mammogram or other breast imaging study in the preceding two years. Following a baseline questionnaire, participants will be randomized to the attention control group (N=120) or the intervention group (N=240).
88834799|NCT01579552|Active Comparator|attention control group|The EMPOWER intervention trial is a 12-month study of 360 women from the Childhood Cancer Survivor Study who have previously been treated with chest radiation, are 25 to 49 years of age at the time of enrollment, are 8 years or more since their chest radiation, and have not had a mammogram or other breast imaging study in the preceding two years. Following a baseline questionnaire, participants will be randomized to the attention control group (N=120) or the intervention group (N=240).
89363467|NCT03248479|Experimental|RBC transfusion-dependent low-risk MDS, Expansion Phase|Participants will receive 1 mg/kg magrolimab on Cycle 1 Day 1; at 30 mg/kg on Cycle 1 Days 8, 15, and 22; and 60 mg/kg every 4 starting on Cycle 2 Day 1 and thereafter up to end of the study + azacitidine 75 mg/m^2 on Days 1 to 5 of each cycle.
89363468|NCT03248479|Experimental|Rollover|Participants on a previous AML Phase 1 trial (SCI-CD47-002; NCT02678338) with clinical benefit on magrolimab treatment will receive the same dose level (0.1 mg/kg up to 30.0mg/kg based on the cohort to which the participant was assigned) twice weekly or may transition to once weekly dosing at the discretion of the Investigator and approval from Gilead.
89363469|NCT03243955|Active Comparator|TEAS|True acupoint locations for placement of TENS unit pads
89363470|NCT03243955|Sham Comparator|Placebo|non-acupoint locations for placement of TENS unit pads
89363471|NCT03194126|Experimental|Mifepristone + Misoprostol OR oxytocine + laminaria|
89363472|NCT03194126|Other|Mifepristone + Misoprostol OR oxytocine|
89363473|NCT03193970||Bladder Cancer Patients Undergoing Radical Cystectomy|Prospective registry of bladder cancer patients undergoing radical cystectomy at MD Anderson Cancer Center and the collaborating centers.
89363474|NCT03192267||No treatment|No treatment
88834800|NCT01565200|Other|T-DM1|After an imaging phase, the patient will receive T-DM1 iv every 3 weeks until progression or toxicity
88834801|NCT01476787|Experimental|Lenalidomide + Rituximab|"Lenalidomide dose 20-mg on days 2-22 every 28 days for 6 cycles, if CR then 10-mg on days 2-22 every 28 days for 12 cycles. PR after 6 cycles, continue 20 mg for 3~6 cycles and then 10 mg on days 2-22 every 28-day cycles for up to 18 cycles.~Rituximab, 375 mg/m2 on days 1, 8, 15 and 22 of cycle 1, day 1 of cycles 2 to 6; 8 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles."
88834802|NCT01476787|Active Comparator|Control|• ONE of the following: Rituximab-CHOP, Rituximab-CVP, Rituximab-Bendamustine. 7 to 8 weeks later responding patients will continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.
88834803|NCT01410825|Experimental|Gene transfer|Open label single arm study
88834804|NCT01398332||Aortic pathologies|Indication for aortic endovascular stent graft repair
88834805|NCT01373489|No Intervention|Usual Care|The usual care group received the current standards of care at the study clinics.
89363475|NCT03180151|No Intervention|Orthodontic tooth movement group|This is the control group in which pateints will be treated by conventional orthodontic treatment and extraction of premolars without piezotome
89363476|NCT03180151|Experimental|Corticotomy assisted orthodontic group|This is the study group in which patients will be treated by conventional orthodontic treatment aided by corticotomy procedure perfumed by using a piezotome.(piezotome assisted orthodontic tooth movement)
89363477|NCT03116139|No Intervention|Low risk for kidney injury with use of CT|No randomization due to low risk for kidney injury. 100 patients undergoing CTPA with an estimated risk of CIN <10% (CINRisk Score <2)
89363478|NCT03116139|Active Comparator|Randomized to V/Q|300 patients with > 25% estimated risk of CIN (CINRisk Score ≥ 2), randomized to VQ imaging (unexposed control)
89363479|NCT03116139|Active Comparator|Randomized to CT|300 patients with > 25% estimated risk of CIN (CINRisk Score ≥ 2), randomized to CT (exposure to iodinated contrast media)
88834806|NCT01373489|Experimental|Technology Assisted Case Management|The TACM group used the FORA 2-in-1 Telehealth system for diabetes management intervention to link a case manager to patients with poorly controlled type 2 diabetes in real time.
88834807|NCT01289834|Active Comparator|Hi-Fatigue Bone Cement|CPT femoral stems fixed with Hi-Fatigue Bone Cement
88834808|NCT01289834|Active Comparator|Palacos Bone Cement|CPT femoral stems fixed with Palacos Bone Cement
88834809|NCT01229059||lipid infusion in untrained humans|healthy lean humans before and after lipid infusion
89363480|NCT03108677||metastatic|For osteosarcoma patients with metastasis, collecting blood samples.
89363481|NCT03108677||non-metastatic|For osteosarcoma patients without metastasis, collecting blood samples.
89363482|NCT03061565||Erythropoietin|Patients were treated with EPO during the EPO-TBI study in 2010-2014.
89363483|NCT03061565||Placebo|Patients were treated with placebo during the EPO-TBI study in 2010-2014.
89363484|NCT03055481|Active Comparator|High level irradiation|High level irradiation: the target irradiance level is 30-35uW per square centimeter per nano-meter of wavelength.
89363485|NCT03055481|Experimental|Low level irradiation|Low level irradiation: the target irradiance level is 12-15uW per square centimeter per nano-meter of wavelength.
89363486|NCT02968992|Experimental|rhLactoferrin|rH lactoferrin will be provided by Ventria Biosciences. Each capsule will contain 250 mg of rH lactoferrin as active ingredient. Subjects will receive 1500 mg of lactoferrin in capsule form twice a day. Dosing will be six 250 mg capsules twice a day for six months.
89363487|NCT02968992|Placebo Comparator|Placebo|Matching placebo capsule will be provided by Ventria Biosciences and six capsules twice a day will be provided to the subjects in this arm.
88834810|NCT01229059||lipid infusion in athletes|endurance trained atheletes
88834811|NCT01222351|Experimental|BAY 94-9172|BAY 94-9172 PET/CT
88834812|NCT01176370|Experimental|Implantable Counterpulsation Therapy|The study is a single arm study with up to 20 patients enrolled and implanted with implantable counterpulsation. Patients that meet eligibility will be enrolled and implanted into the treatment arm of the study. There is not a control arm in this feasibility study.
88834813|NCT01132053||PML|These are subjects who have confirmed PML.
89363488|NCT02950493|Other|Single group, one arm study group|Compare echocardiograph imaging efficacy of active Definity or Lumason (perflutren lipid microsphere) with compressed Definity or Lumason.
89363489|NCT02928185||HSCT patients|Individual/dyadic semi-structured interviews between Day +100 to +130
89363490|NCT02928185||HSCT care givers|Individual/dyadic semi-structured interviews between Day +100 to +130
89363491|NCT02928185||HSCT dyads|Individual/dyadic semi-structured interviews between Day +100 to +130
89363492|NCT02928185||HSCT Clinicians|Can include: MD, RN, SW, PharmD and Nutritionist. Individual semi-structured interviews after 14 days to review the Coping Together manuals
89363493|NCT02910414|Experimental|Treated with Peregrine System Kit|The experimental group will receive an infusion of Dehydrated Alcohol Injection, USP into the perivascular space of the renal arteries with the Peregrine Catheter. A total of 0.6mL of the alcohol will be delivered to the perivascular space of each renal artery. The drug will only be delivered once to each renal artery during the treatment procedure.
89363494|NCT02910414|Sham Comparator|Renal Angiography Only (Sham Procedure)|The sham control group will only have diagnostic renal angiography performed. There will be no insertion of the Peregrine Catheter and no alcohol infusion (i.e. no renal denervation).
89363495|NCT02909036|Experimental|Melphalan|Test Dose CE Melphalan 10mg/m2 with PK studies Day -12 to Day-3, CE Melphalan Dose of Target AUC 13 mg/L/h infused with PK studies Day -2, 3-10 x 10^6 CD 34+ cells/kg reinfused Day 0, Pegfilgrastim 6mg injection Day +1
89363496|NCT02899221|Experimental|Treatment (high dose rate brachytherapy, hyperthermia)|Patients undergo high dose rate brachytherapy for 15-30 minutes. Immediately after radiation therapy (no longer than 90 minutes), patients undergo interstitial hyperthermia treatment for up to 60 minutes.
88834814|NCT01132053||Control|These are subjects who do not have PML. They may be healthy or immune compromised due to Cancer, Transplant, or HIV.
88834815|NCT01059786|Experimental|Arm 1|Rituximab + bendamustine at 70 mg/m2 for initial tolerability study (closed)
89363497|NCT02879604|Experimental|Compensatory cognitive training|Compensatory cognitive training
89363498|NCT02879604|Placebo Comparator|usual treatment|usual treatment for shizophrenai
89363499|NCT02863926|Experimental|Day 7|BKA performed at 7 days post autologous cBMA injection. Injection of cBMA aspirate into the index leg
89363500|NCT02863926|Experimental|Day 14|BKA performed at 14 days post autologous cBMA injection. Injection of cBMA aspirate into the index leg
89363501|NCT02863926|Experimental|Day 21|BKA performed at 21 days post autologous cBMA injection. Injection of cBMA aspirate into the index leg
89363502|NCT02756793|Active Comparator|Standard of Care Treatment|"Patient treatment may include the following 3 options, at the discretion of the treating physicians:~Continue with current systemic agent(s)~Observation~Switch to next-line treatment"
89363503|NCT02756793|Experimental|Stereotactic Ablative Radiotherapy (SABR)|SABR is delivered to all sites of progressive disease with continuation of current systemic agents. Further oligo-progressive lesions may be treated with SABR if possible. Upon progression at sites not amenable to SABR, the patient may receive any of the options in Arm 1.
89363504|NCT02744092|Active Comparator|Randomized Arm 1 (DOACs)|Randomized Arm 1 will get anticoagulation therapy with a Direct Oral AntiCoagulant (DOAC). There are four FDA-approved DOAC drugs that may be used for this study: Rivaroxaban, Apixaban, Edoxaban, or Dabigatran. The treatment (including dosage form, dosage, frequency and duration) should be administered in accordance with the drug's FDA package insert, and all modifications are at the discretion of the treating investigator.
89363505|NCT02744092|Active Comparator|Randomized Arm 2 (LMWH)|Randomized Arm 2 will get anticoagulation therapy with low molecular weight heparin (LMWH) with or without a transition to warfarin. There are three FDA-approved LMWH drugs that may be used for this study: Dalteparin, Enoxaparin, or Fondaparinux. The treatment (including dosage form, dosage, frequency and duration) should be administered in accordance with the drug's FDA package insert, and all modifications are at the discretion of the treating investigator.
89363506|NCT02744092|Active Comparator|Preference Cohort 1 (DOACs)|"If an eligible participant is offered randomization and declines randomization, then a limited number of participants (up to N=190) will be allowed to enroll in the Preference Cohort. In this case, the treating physician and patient choose Arm 1 or Arm 2 (non-randomized).~Preference cohort: Non-randomized Arm 1 will get anticoagulation therapy with a Direct Oral AntiCoagulant (DOAC)."
88834816|NCT01059786|Experimental|Arm 2|Rituximab +bendamustine at 90 mg/m2 for initial tolerability study (closed)
88834817|NCT01059786|Experimental|Arm 3|Rituximab + Bendamustine (at the tolerated dose)
88834818|NCT01059786|Active Comparator|Arm 4|Rituximab + Pentostatin
88834819|NCT01046123|Experimental|Whole brain radiotherapy|whole brain radiotherapy (WBRT) and a simultaneous integrated boost (SIB) using volumetric modulated arc therapy
88834820|NCT00993408|Experimental|ACT-293987 (NS-304) and matching placebo|"Subjects will be randomized to the study following screening.~Each subject will then undergo an acute hemodynamic study with right heart catheterization after a single oral administration of ACT-293987 (NS-304)on Day 0. The objectives are to collect data about the drug effect on the right heart hemodynamic parameters (PVR, calculated SVR and PVR/SVR) measured by right heart catheterization after single oral dose administration of NS-304 and to assess the safety and tolerability of a single oral dose of NS-304."
88834821|NCT00968747|Experimental|Fasting (Healthy).|Participants will fast for 72 hours during an inpatient stay at the Beth Israel Deaconess Medical Center in Boston, MA. Blood samples will be collected daily and two fat samples will be obtained by a trained surgeon. (We are no longer recruiting for Study Arm A).
89001276|NCT00578851||C2a Taper recipients|Patients who receive a THA with the C2a - Taper™ Acetabular System
89363507|NCT02744092|Active Comparator|Preference Cohort 2 (LMWH)|"If an eligible participant is offered randomization and declines randomization, then a limited number of participants (up to N=190) will be allowed to enroll in the Preference Cohort. In this case, the treating physician and patient choose Arm 1 or Arm 2 (non-randomized).~Preference cohort: Non-randomized Arm 2 will get anticoagulation therapy with Low Molecular Weight Heparin (LMWH) with or without a transition to warfarin."
89363508|NCT02729402|Experimental|Older Cochlear Implant Subjects|We will assign the study participants to a diagnostic intervention (cognitive testing) before and after their cochlear implant.
89001277|NCT00578890|Experimental|1|
89001278|NCT00579007||1|Women with a strong family history of breast cancer.
88834822|NCT00968747|Experimental|Fasting (NAFLD)|Participants with liver-biopsy diagnosed non-alcoholic fatty liver disease (NAFLD) will fast for 72 hours during an inpatient stay at the Beth Israel Deaconess Medical Center in Boston, MA. Blood samples will be collected daily, and participants will have an MRI before and after the fast.
88834823|NCT00968747|Experimental|Hypocaloric diet (NAFLD)|Participants will follow a low-calorie diet until they lose 3-5% of their body weight. Participants will have weekly outpatient visits at Beth Israel Deaconess Medical Center in Boston, MA for weight measurements. Participants will have blood drawn before and after the diet. Participants will also have an MRI before and after the diet.
88834824|NCT00968747|Experimental|Oral carbohydrate challenge|Participants will fast for 16 hours overnight then ingest drinks containing fructose, glucose or a mixture of fructose and glucose. Blood will be drawn postprandially at specified timepoints for up to 5 hours
88834825|NCT00951366||Bronchopulmonary Dysplasia (BPD)|
89363509|NCT02704117|Experimental|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation applied over the pre-supplementary motor area (pSMA), for ten sessions, Monday through Friday, over the course of two weeks.
88834826|NCT00934999|Active Comparator|Burch|Patients will receive a Burch urethropexy at the time of an abdominal sacral colpopexy.
88834827|NCT00934999|Experimental|Mid-urethral sling|Patients will receive a mid-urethral sling at the time of an abdominal sacral colpopexy.
88834828|NCT00923819|Experimental|Group A|Laparoscopic Gastric Bypass
88834829|NCT00923819|Active Comparator|Group B|Standard conservative treatment. Patients from Child Obesity Registry of Vestfold.
88834830|NCT00903890||A|Individuals who have previously received radiation therapy and anthracycline chemotherapy for their Hodgkin's or non-Hodgkin's lymphoma.
88834831|NCT00871065|Experimental|Sildenafil Treatment of Cerebral Aneurysm Vasospasm|Trial Arm (single arm study)
88834832|NCT00794339|Experimental|Copper ATSM|pre-therapy pelvic 64Cu-ATSM-PET/CT with Pre- and post- therapy FDG PET/CT
88834833|NCT00792662|Experimental|Methylphenidate|Subject will receive 5mg BID for the first two weeks then 10mg BID until week 16 of the study.
88834834|NCT00792662|Placebo Comparator|Placebo|Standard inactive pill.
88834835|NCT00786682|Experimental|Docetaxel and Hydroxychloroquine|"Drug: Docetaxel 75 mg/m2 intravenously every 21 days on Day 1 of the treatment cycle~Drug: hydroxychloroquine 200 mg twice daily~A cycle is defined as an interval of 21 days."
88834836|NCT00675844|Experimental|Elvucitabine|Participants currently receiving elvucitabine will continue elvucitabine as part of their antiretroviral therapy (ART) regimen for an additional 48 months.
88834837|NCT00672672|Experimental|Platelet Gel|Participants receive platlet gel.
88834838|NCT00672672|Placebo Comparator|Control (No platelet gel)|Participants do not receive platlet gel.
88834839|NCT00575081||Stereotactic Brain Procedures|Patients who have consented to undergo or have undergone a stereotactic brain procedure for any reason including those who need Deep Brain Stimulation, SEEG or other brain neurmodulation device implant.
88834840|NCT00571714|Active Comparator|1 Standard Peginterferon alpha-2a plus Rivavirin Therapy|Peginterferon alpha-2a once a week plus weight based ribavirin (800-1400mg/day)in 2 divided daily doses
88834841|NCT00571714|Active Comparator|2 Peginterferon alpha-2a plus Rivavirin Therapy with Betaine for First 12 Weeks|Peginterferon alpha-2a once a week plus weight based ribavirin (800-1400mg/day) in 2 divided daily doses plus betaine (20gm/day) in 2 divided doses for 12 weeks followed by Peginterferon alpha-2a q week plus weight based ribavirin (800-1400mg/day) in 2 divided daily doses for 36 weeks
88834842|NCT00514254||case|Participants complete questionnaires about lifestyle factors and their usual diet and measure their waist and hips. Saliva or buccal specimens are collected for future research.
88834843|NCT00514254||control|Participants complete questionnaires about lifestyle factors and their usual diet and measure their waist and hips. Saliva or buccal specimens are collected for future research.
88834844|NCT00506662|Experimental|Insulin detemir|Individually adjusted dose of insulin detemir once daily
88834845|NCT00506662|Active Comparator|Insulin NPH|Individually adjusted dose of insulin NPH once daily
88834846|NCT00494910|Experimental|1|Meaning Centered Group Psychotherapy (MCGP)
88834847|NCT00494910|Active Comparator|2|standardized Supportive Group Psychotherapy
88834848|NCT00476125|Experimental|3 day ketogenic diet|
88834849|NCT00476125|Experimental|12 day ketogenic diet|
88834850|NCT00476125|Experimental|16 hour fast|
88834851|NCT00455039|Experimental|GW572016 1500mg|patients received GW572016 1500mg daily
88834852|NCT00410956|Experimental|UNRESECTABLE PRIMARY HEPATIC MALIGNANCY|All patients enrolled in the study will receive HAI FUDR (0.16 mg/kg X pump volume / pump flow rate), Dexamethasone (1 mg/m2/day) and IV Bevacizumab at 5mg/kg. Chemotherapy with HAI FUDR/Dex will commence no sooner than 14 days post surgical placement of HAI pump; patients will receive their first treatment with Bevacizumab no sooner than 28 days post surgical placement of HAI pump.
88834853|NCT00325741|Experimental|Hematopoietc Stem Cell Transplant|Hematopoietic Cell Transplantation. Total body irradiation and Stem cell infusion in life threating lupus patients
88834854|NCT00161213|Experimental|Gemcitabine and Imatinib|
88834855|NCT00118131|Experimental|Docetaxel and Cisplatin|"A cycle is defined as an interval of 28 days.~Docetaxel, 35 mg/m2 per day on Days 1, 8 and 15 (total dose for this cycle = 105 mg/m2).~Cisplatin, 25 mg/m2 per day on Days 1, 8 and 15 (total dose for this cycle = 75 mg/m2).~Docetaxel is always to be given prior to cisplatin on Days 1, 8 and 15."
88834856|NCT00006436|Experimental|Arm 1-Combination Chemo and Biological Therapy|Combination chemo and biological therapy
89001279|NCT04578223||Study group|Patients with pulmonary arterial hypertension treated with prostacyclin analogues on top of ERA or PDE-5i.
89001280|NCT04578223||Control group|Patients with pulmonary arterial hypertension treated with ERA or PDE-5i only.
89001281|NCT00579046|Experimental|1|
89363510|NCT02700386|Experimental|Adjuvant Hypofractionated Radiation|"Adjuvant Hypofractionated Radiation (4005 cGy) will last 3-4 weeks with 15 treatments, +/- 4 additional fractions as a boost. Radiation should commence within 180 days of the date of primary surgery. Four additional fractions (a boost or conedown) to areas deemed to be at particularly high risk of recurrence may be added at the end of the radiation course. Fraction size for the boost treatment will continue at 267 cGy for an additional 1068 cGy in four fractions."
89363511|NCT02685098|Experimental|Active/Treatment Group|Amputation performed at 7 days post allogeneic bone marrow derived mesenchymal stem cell injections.
89363512|NCT02685098|No Intervention|Observation Group 1|Amputation performed with no MSC administration. Subjects will be followed for incidence of infection and wound healing status to week 24 as a comparator to the Active/Treatment group.
89363513|NCT02685098|No Intervention|Observation Group 2|"Tissue Collection Group:~Amputation performed with no MSC administration. Subjects will not be followed after amputation is performed. Tissue collection will occur at time of amputation."
89363514|NCT02685098|No Intervention|Observation Group 3|Patients undergoing lower extremity bypass grafting procedure. Skeletal muscle samples of the sartorius and anterior tibial muscle will be collected for comparison to treatment group. No study testing, nor follow up visits will occur.
89363515|NCT02685098|No Intervention|Control Group 4|Patients undergoing a standard of care surgical procedure under anesthesia. Core needle biopsies will be collected from the anterior tibial muscle at the time of surgical procedure. No study testing, nor follow up visits will occur.
89363516|NCT02649959|Experimental|Open Label|CM-AT
89363517|NCT02647827|Active Comparator|Lifestyle management|All women will receive lifestyle management instructions at the baseline visit, before randomization.
89363518|NCT02647827|Active Comparator|Acupuncture + lifestyle management|Three treatment per week (4 weeks) and thereafter 2 times per week during 12 weeks.
89363519|NCT02647827|Active Comparator|Metformin + lifestyle management|Oral metformin 500 mg three times daily, in total 1500 mg per day.
89363520|NCT02605421|Experimental|Patients Treated for Neuroblastoma|Consolidation course #1 consists of thiotepa and cyclophosphamide followed by a PBSC rescue. Consolidation course #2 consists of melphalan, etoposide and carboplatin followed by a second PBSC rescue. Post infusion, patients will receive Granulocyte-Colony Stimulating Factor beginning on Day 0 of each consolidation course.
89363521|NCT02582905|Placebo Comparator|Placebo|Matching placebo given beginning at 1 capsule BID increasing to 2 capsules BID at week 1, 3 capsules BID at week 2, and 4 capsules BID at weeks 3-12.
89363522|NCT02582905|Experimental|Citicoline|Citicoline will be given beginning at 250 mg BID with an increase to 500 mg BID at week 1, 750 mg BID at week 2, and 1000 mg BID at weeks 3-12.
89363523|NCT02582905|Experimental|Pregnenolone|Pregnenolone will be given beginning at 50 mg BID with an increase to 100 mg BID at week 1, 150 mg BID at week 2, and 250 mg BID at weeks 3-12.
88834857|NCT03632798|Active Comparator|Physician Choice treatment|"Participants will be treated with control chemotherapy treatment (Bevacizumab plus standard-of-care chemotherapy chosen by the Physician from the provided list).~Control chemotherapy treatment will be chosen from any of the following standard-of-care chemotherapy drugs or combinations:~Liposomal Doxorubicin;~Docetaxel;~Paclitaxel;~Carboplatin;~Cisplatin;~Gemcitabine;~Topotecan;~Carboplatin, Gemcitabine;~Cisplatin, Gemcitabine;~Carboplatin, Liposomal Doxorubicin;~Carboplatin, Paclitaxel;~Carboplatin, Docetaxel.~The treating physician will NOT receive the ChemoID assay results from the ChemoID lab."
88834858|NCT03632798|Experimental|ChemoID-guided treatment|"Participants will be treated with Bevacizumab plus ChemoID-guided standard-of-care chemotherapy drugs from the provided list.~ChemoID-guided treatment will be chosen from the following standard-of-care chemotherapy drugs or combinations:~Liposomal Doxorubicin;~Docetaxel;~Paclitaxel;~Carboplatin;~Cisplatin;~Gemcitabine;~Topotecan;~Carboplatin, Gemcitabine;~Cisplatin, Gemcitabine;~Carboplatin, Liposomal Doxorubicin;~Carboplatin, Paclitaxel;~Carboplatin, Docetaxel.~The treating physician will receive the ChemoID assay results from the ChemoID lab."
88834859|NCT03208673|Experimental|Optive® Fusion + Optive® Gel Drop|Optive® Fusion eyedrop will be used as needed up to four times a day but at least twice a day. The eyedrop will be used once in the evening; the gel drop being instilled any time during the last hour prior to sleep. The treatment regimen will be used for one month.
89001282|NCT00579085|Placebo Comparator|1|
89363524|NCT02548364|Experimental|Calcifediol|One capsule with 15,690 IU p.o. every two weeks
89363525|NCT02548364|Placebo Comparator|Placebo|One capsule with placebo p.o. every two weeks
89363526|NCT02546375||Chronic Myeloid Leukaemia|Patients diagnosed with chronic myeloid leukaemia treated with Bosutinib
89363527|NCT02504333|Active Comparator|AG|nab-Paclitaxel followed by Gemcitabine
89363528|NCT02504333|Experimental|AG-mFOLFOX|nab-Paclitaxel followed by Gemcitabine and FOLFOXm at dose levels selected from the phase I trial
89363529|NCT02491931|Active Comparator|GLN group|All patients in the GLN group received an oral GLN supplement. The total GLN dose given to patients was standardized to 0.5 g/kg/day during 3 days prior to CPB, and one final dose of 0.25 g/kg/day of GLN/maltodextrin in the morning of surgery 4 hours prior to initiation of anesthesia.
89363530|NCT02491931|Placebo Comparator|CONT group|All patients in the GLN group received an oral maltodextrin supplement, similar in shape and texture as GLN supplement. The total placebo given to patients was standardized to 0.5 g/kg/day during 3 days prior to CPB, and one final dose of 0.25 g/kg/day of maltodextrin in the morning of surgery 4 hours prior to initiation of anesthesia.
89363531|NCT02473042|Experimental|Electrical Stimulation + Standard of Care Antiemetics|"Participants receive light electrical stimulation to the wrist area during surgery. Participants also receive standard of care drugs to reduce post-operative nausea and vomiting (PONV).~Questionnaire completed about participant's pre-treatment expectations and their nausea about 15 minutes after they wake up after surgery, then every 30 minutes until they leave the clinic."
89363532|NCT02473042|Active Comparator|Standard of Care Antiemetics|"Participants receive standard of care drugs to reduce post-operative nausea and vomiting (PONV).~Questionnaire completed about participant's pre-treatment expectations and their nausea about 15 minutes after they wake up after surgery, then every 30 minutes until they leave the clinic."
89363533|NCT02328235|Experimental|High Saturated Fat Diet|Subjects will receive a high fat diet for 5 day following a 2 week lead in diet. Measurements will be made pre-post high fat diet
89363534|NCT02305173|Active Comparator|dexamethasone group|patients receive one single dose of intravenous dexamethasone 8 mg.
89363535|NCT02305173|Placebo Comparator|placebo group|patients receive one single dose of intravenous placebo.
89363536|NCT02285439|Experimental|Phase 1|Patients with non-hematologic malignancies that are recurrent, progressive, or refractory after standard up-front therapy receiving MEK162 will define the MTD, DLT, and toxicity profile.
89363537|NCT02285439|Experimental|Phase 2|Children with recurrent tumors signaling through the Ras/Raf pathway will be treated in 3 strata to define the activity of MEK162. S1: Children with LGG characterized by a BRAF truncated fusion (KIAA1549 and similar translocations). S2: Children with NF1 and LGG. S 3: Children with tumors involving the Ras/Raf pathway not included in strata 1 or 2.
89363538|NCT02285439|Experimental|Target Validation|Patients eligible for phase 2 (any stratum) for whom tumor biopsy or resection is clinically indicated may be enrolled on the target validation arm. Patients will receive MEK162 for 7 to 21 days prior to their surgery. Tumor sample will be analyzed for drug concentration and target inhibition.
89363539|NCT02273388|Experimental|12 mg BI 6727|
89363540|NCT02273388|Experimental|24 mg BI 6727|
89363541|NCT02273388|Experimental|48 mg BI 6727|
89363542|NCT02273388|Experimental|75 mg BI 6727|
89363543|NCT02273388|Experimental|125 mg BI 6727|
89363544|NCT02273388|Experimental|200 mg BI 6727|
89363545|NCT02273388|Experimental|300 mg BI 6727|
89178373|NCT00838396|Placebo Comparator|Placebo for XP19986 CR|On either study Day 1 or study Day 5 (after completion of the minimum 3-day washout period), participants received a single dose of placebo.
89363546|NCT02273388|Experimental|300 mg BI 6727 1h2h|Infusion over 1 hour (1h) in course 1 and over 2 hours (2h) in course 2.
89363547|NCT02273388|Experimental|300 mg BI 6727 2h1h|Infusion over 2 hours (2h) in course 1 and over 1 hours (1h) in course 2.
89363548|NCT02273388|Experimental|350 mg BI 6727|
89363549|NCT02273388|Experimental|400 mg BI 6727|
89363550|NCT02273388|Experimental|450 mg BI 6727|
89363551|NCT02272790|Experimental|Arm A (adavosertib + gemcitabine)|Adavosertib (175 mg PO) will be taken on Days 1-2, 8-9, and 15-16. Gemcitabine 800 mg/m² will be administered IV on days 1, 8, and 15 of each 28 day cycle.
89363552|NCT02272790|Experimental|Arm B (adavosertib + paclitaxel)|Five doses of adavosertib (225 mg PO BID) will be taken in approximate 12 hour intervals over 2.5 days weekly (Days 1-3, 8-10, and 15-17). Weekly paclitaxel 80 mg/m² IV will be administered according to institutional standards on Day 1, 8, and 15 of each 28 day cycle.
89363553|NCT02272790|Experimental|Arm C/C2 (adavosertib + carboplatin)|"Arm C: Five doses of adavosertib (225 mg PO BID) will be taken in approximate 12 hour intervals over 2.5 days (Days 1-3). Carboplatin AUC 5 IV will be administered according to institutional standards on Day 1 of each 21-Day cycle.~Arm C2: Five doses of adavosertib (225 mg PO BID) 2.5 days per dosing week (QW), on Weeks 1 (D1-3), 2 (D8-10) and 3 (D15-17), or on Weeks 1 (D1-3) and 2 (D8-10) ( 2 weeks on followed by 1 week off.) Carboplatin AUC 5 IV will be administered according to institutional standards on Day 1 of each 21 day cycle."
89363554|NCT02272790|Experimental|Arm D (adavosertib + PLD)|Five doses of adavosertib (175 mg or 225 mg) will be taken in approximate 12 hour intervals over 2.5 days (Days 1, 2, and 3) of each 28-day cycle. PLD will administered IV on Day 1 of each cycle.
89363555|NCT02190253||Organ transplant recipients|Recipients of either liver, kidney, liver and kidney, and small bowel transplants
89363556|NCT02190253||Waitlist patients|Patients on waitlist for liver, kidney or intestinal transplantation
89363557|NCT02172885|Experimental|Mesenchymal stem cells|Five Mesenchymal Stem Cell infusions
89363558|NCT02115191|Experimental|2-octylcyanoacrylate|Application of 2-octylcyanoacrylate
89363559|NCT02115191|Active Comparator|Surgical reintervention|Surgical reintervention for urethrocutaneous fistula repair
89363560|NCT02100956|Experimental|Oxytocin, then Placebo|The subject first received oxytocin 100 micrograms administered intrathecally (IT). After at least one week, they received normal saline placebo IT.
89363561|NCT02100956|Experimental|Placebo, then Oxytocin|The subject first received normal saline placebo intrathecally (IT). After at least one week, they then received oxytocin 100 micrograms administered IT.
89363562|NCT02081885|Experimental|Tricalcium Phosphate / Chitosan|
89363563|NCT02081885|Active Comparator|Autologous Graft|
89363564|NCT02009644|Experimental|Treovance|Subjects who receive the Treovance stent-graft
89363565|NCT01784601||Control Group|We will be including all patients undergoing shoulder surgery not scheduled for a nerve block.
89363566|NCT01784601||Study Group|We will be including all patients undergoing shoulder surgery scheduled for a nerve block.
89363567|NCT01757418|Experimental|Immune Globulin Intravenous|IVIG used in the trial is the GAMUNEX brand, at doses up through 800 mg/kg in Phase 1 and at 400mg/kg in Phase 2.
89363568|NCT01757418|Placebo Comparator|Normal saline|An equivalent volume (weight-based)of normal saline
89363569|NCT01535430||Eloquent area tumor|Standard of care with brain mapping, pre-, intra-, and post-operative.
89363570|NCT01438411|Other|Cholic Acid|Active drug
89363571|NCT01393483||patients endoscopically resected|In patients with endoscopically resected T1 disease (40 patients in 2 years) if available, we will stain the initial endoscopic tumor specimen, as well as any subsequent specimen obtained at each routine 3(+/- 2) month interval endoscopy.
89363572|NCT01393483||patients treated primarily with surgery|In patients who undergo surgery as their primary therapy, serum will be obtained at the time of surgical resection, and at each subsequent long-term disease status follow-up visit every 4 (+/- 2) months.
89363573|NCT01393483||patients who undergo chemo-radiation prior to surgery|a serum sample will be obtained : 1) prior to initiation of therapy, 2) following the completion of induction chemotherapy, 3) at the time of surgical resection, and 4) at each subsequent long-term disease status follow-up visit every 4 (+/- 2) months. The availability of tissue for staining will determine whether or not patients are evaluable for Group 3.
89363574|NCT01343342|Experimental|capsules omega-3|Omega-3 supplementation (3g EPA+DHA/d)
89363575|NCT01302834|Active Comparator|IMRT + Cisplatin|Intensity-modulated radiotherapy (IMRT) with concurrent cisplatin
89363576|NCT01302834|Active Comparator|IMRT + Cetuximab|Intensity-modulated radiotherapy (IMRT) with concurrent cetuximab
89363577|NCT01203839|Experimental|Radiation treatment|This is a Phase II single-arm study of PBI with external-beam radiation therapy in which a group of select women with early-stage invasive and noninvasive breast cancer will be given radiation to the partial breast.
89363578|NCT01153698||patients after hip or knee replacement|
89363579|NCT01142427||Ancillary-Correlative (classification)|Patients undergo blood sample collection and bone marrow biopsies at baseline and during and after induction therapy for immunophenotyping for ALL confirmation and classification, DNA ploidy, genomic variation, and cytogenetic (BCR-ABL, trisomies 4+10, and molecular testing for translocations) analysis by flow cytometry and FISH. Immunophenotype results obtained on this study are used to determine patient's assignment to specific clinical-trial treatments. Some samples (leukemic and germline) may be banked for current and/or future analyses.
89363580|NCT01115582|Experimental|Cholic Acid Capsule|Manufactured cholic acid capsules
89363581|NCT01048853|Experimental|Treatment (conservative surgery)|Patients undergo a complete lymphatic mapping with sentinel lymph node biopsy and/or pelvic lymph node dissection. If future fertility is no longer desired, patients also undergo hysterectomy with or without bilateral salpingo-oophorectomy.
89363582|NCT01040624|Experimental|High-risk arm A (HR-A)|< 15% risk of + lymph nodes (LN)
89363583|NCT01040624|Experimental|HR-B|> 15% risk of + LN
89363584|NCT01000753||Observational (specimen collection)|See Detailed Description
89363585|NCT00959283||Ancillary-correlative|Patients undergo peripheral blood collection periodically for biomarker analysis. Samples are analyzed for GATA1 mutations by real-time PCR, polymorphisms, cytogenetics, and K-RAS mutations, gene expression, drug sensitivity patterns, and minimal residual disease by flow cytometry.
88834860|NCT02399917|Experimental|Phase 1b Lead-in Cohort 1|"Patients receive azacitidine SC or IV over 1 hour as determined by the treating physician on days 1-7 and lirilumab IV over 60 minutes on day 8. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~5-Azacitidine 75mg/m^2 Lirilumab 1.0 mg/kg"
89363586|NCT00919269||Ancillary-Correlative (specimen collection)|Surgical tissue, bone marrow, and blood specimens are collected at diagnosis (initial or relapse) and, if applicable, at the development of a second primary tumor. Specimens are used for research purposes. A certificate of confidentiality protecting the identity of research participants in this project has been issued by the National Cancer Institute.
89363587|NCT00899990||Observational (biomarker sampling)|Patients undergo collection of tumor specimens, bone marrow, and peripheral blood at diagnosis. Associated demographic and clinical data are collected and archived. Patients who are not enrolled on a therapeutic clinical trial are followed annually.
89363588|NCT00899275||Ancillary-correlative|After the initial submission of blood samples, patients may undergo open or closed biopsy in order to obtain fresh and frozen tissue samples as well as paraffin embedded material. Patients who are enrolled at the time of initial diagnosis but then have a definitive surgery or develop recurrent disease may submit additional samples (paraffin block, frozen and fresh tumor tissue, or slides together with blood samples). Autopsy tumor samples may also be submitted.
89363589|NCT00804856|Experimental|Phase I Schedule A. Volasertib 150 mg+LDAC|Volasertib 150 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.
89363590|NCT00804856|Experimental|Phase I Schedule A. Volasertib 200 mg+LDAC|Volasertib 200 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.
89363591|NCT00804856|Experimental|Phase I Schedule A. Volasertib 250 mg+LDAC|Volasertib 250 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.
89363592|NCT00804856|Experimental|Phase I Schedule A. Volasertib 300 mg+LDAC|Volasertib 300 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.
89363593|NCT00804856|Experimental|Phase I Schedule A. Volasertib 350 mg+LDAC|Volasertib 350 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.
88834861|NCT02399917|Experimental|Phase 1b Lead-in Cohort 2|"Patients receive azacitidine SC or IV over 1 hour as determined by the treating physician on days 1-7 and lirilumab IV over 60 minutes on day 8. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~5-Azacitidine 75mg/m^2 Lirilumab 3.0 mg/kg"
89363594|NCT00804856|Experimental|Phase I Schedule A. Volasertib 400 mg+LDAC|Volasertib 400 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.
89363595|NCT00804856|Experimental|Phase I Schedule B. Volasertib 150 mg|Volasertib 150 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).
88834862|NCT02399917|Experimental|Phase 2|"Patients receive azacitidine SC or IV over 1 hour as determined by the treating physician on days 1-7 and lirilumab IV over 60 minutes on day 8. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~5-Azacitidine 75mg/m^2 Lirilumab 3.0 mg/kg"
88834863|NCT02400073|Experimental|AutoSet for Her PAP device|Patients in this study will use the AutoSet for Her: A new AutoSetting Positive Airway Pressure (PAP) device designed specifically to treat female OSA
89178374|NCT00838474|Other|music therapy|Each infant was randomized to receive music therapy or no music over 2 consecutive days
89363596|NCT00804856|Experimental|Phase I Schedule B. Volasertib 200 mg|Volasertib 200 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).
89363597|NCT00804856|Experimental|Phase I Schedule B. Volasertib 350 mg|Volasertib 350 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).
89363598|NCT00804856|Experimental|Phase I Schedule B. Volasertib 400 mg|Volasertib 400 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).
89363599|NCT00804856|Experimental|Phase I Schedule B. Volasertib 450 mg|Volasertib 450 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).
89363600|NCT00804856|Experimental|Phase I Schedule B. Volasertib 500 mg|Volasertib 500 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).
89363601|NCT00804856|Experimental|Phase I Schedule B. Volasertib 550 mg|Volasertib 550 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).
89363602|NCT00804856|Active Comparator|Phase II Schedule C. LDAC|Low-dose cytarabine (LDAC) monotherapy 2x20 milligram (mg) per day administered by subcutaneous injection on days 1-10 of each 28 days treatment cycle.
89363603|NCT00804856|Experimental|Phase II Schedule A. Volasertib 350 mg+LDAC|Volasertib 350 milligram (mg) on Days 1 and 15 (28-day cycle) administered by Intravenous Infusion (IV) over 60 minutes and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 days treatment cycle.
89363604|NCT00769652|Experimental|Medical nutrition therapy|Medical nutrition therapy
89363605|NCT00769652|Active Comparator|Standard care|Standard care
89363606|NCT00491842||At-risk|Individuals at-risk for HD
89363607|NCT00491842||Presymptomatic|Presymptomatic carriers of HD
89363608|NCT01315860||Pregnant Females|Pregnant females in their second or third trimester that meet the inclusion and exclusion criteria.
89363609|NCT03309358|Experimental|Inhaled SNSP113|
89363610|NCT03309358|Placebo Comparator|Inhaled Placebo|
89363611|NCT03309280||Patient at risk for OSA scheduled for Cardiac surgery|Patients with a positive STOP-Bang and DES-OSA score (that means patients at risk for OSA)
89363612|NCT03309280||Patient not at risk for OSA scheduled for Cardiac surgery|Patients with a negative STOP-Bang and DES-OSA score (that means patients not at risk for OSA)
89363613|NCT04391556|Experimental|Firmagon|120 mg Firmagon subcutaneous injection after a TEP-PSMA
89363614|NCT03314194|Experimental|Plant Based Diet Group|Study aims for two cohorts of 20 females each, being tested over 6 days in two conditions: habitual diet versus plant based diet.
89363615|NCT05066490|Experimental|endurance exercise|This group received endurance exercises only.
89363616|NCT05066490|Experimental|resistance exersise plus endurance exersise|This group received resistance exercises followed by endurance exercises.
89363617|NCT03304444|Active Comparator|Bupivacaine HCl in TAP block|"When performing a bilateral TAP with Bupivicaine 0.25% and the incision is below the umbilicus: 30 ml of 0.25% bupivacaine is drawn up and given on each side after identification of planes by the anesthesiologist (need 2 vials).~When performing a bilateral TAP with Bupivicaine 0.25% and the incision extends above the umbilicus: 30 ml of 0.25% bupivacaine is drawn up and given on each side after identification of planes by the anesthesiologist (need 2 vials). A 3rd vial of 30 ml 0.25% bupivacaine will be drawn up and is directly infiltrated into the surgical site (above and below the fascia prior to closure of fascia) extending above the umbilicus by the surgeon."
89363618|NCT03304444|Experimental|Liposomal Bupivicaine in TAP block|When performing a bilateral TAP with liposomal bupivacaine and the incision is below the umbilicus: the 20 ml vial of liposomal bupivacaine containing 266 mg, will be diluted with 20 ml of 0.25% bupivacaine (containing 50 mg of bupivacaine) and 20 ml saline (60 ml total). That total volume will be divided into two 30 ml syringes, and each will be used (per side) for the TAP blocks.
89363619|NCT03314116|Experimental|video group|guided by a 7-minute video that explains the importance of using ear plugs and correct installation.
89363620|NCT03314116|No Intervention|control group|instructed to use earplugs properly, including practical exercises by a medic
89363621|NCT04623138||Garmin Study Device Group|Individuals who are randomly assigned to receive the Garmin vívosmart® 4
89363622|NCT04623138||Empatica Study Device Group|Individuals who are randomly assigned to receive the Empatica E4
89363623|NCT03304366||Patients with primary pterygium|"All eyes have primary pterygium and seeking for surgery due to Cosmetic problems, ocular irritation, and, or visual impairment.~All selected patients will undergo complete ophthalmological examination including refraction, best corrected visual acuity, keratometry, and pentacam (scheimpflug imaging) preoperatively then will be followed up 2 and 6 months post pterygium excision."
89363624|NCT03304288|Experimental|low-dose rituximab & ATRA|rituximab 100mg once weekly for 6 weeks and oral all-trance retinoid acid 20mg/m^2 qd for 12 weeks.
89363625|NCT03304288|Active Comparator|low-dose rituximab|rituximab 100mg once weekly for 6 weeks
88834864|NCT00356486|Experimental|A|Peginterferon alfa-2a (40 KD) (270 µg/week) + Ribavirin (1600 mg/day) + epoetin-β (450 UI/kg/week) for 4 weeks. Peginterferon alfa-2a (40 KD) (180 µg/week) + Ribavirin (1000-1200 mg/day) for 8 weeks
88834865|NCT00356486|Experimental|B|Peginterferon alfa-2a (40 KD) (180 µg/week) subcutaneous + Ribavirin(1000-1200 mg/day) oral/day for 12 weeks
88834866|NCT02978846||Observational (side effects evaluation using cards)|Patients are shown two groups of cards on the last day of radiation treatment. Group A lists 48 physical side effects and group B lists 27 psychosocial side effects. The cards are shuffled and patients view one card at a time and select the side effects they attribute to their current treatment. Patients rank the selected cards from each group by order of severity. The top 5 cards from each group are then shuffled together and patients rank the remaining 10 cards in order of severity.
88834867|NCT02400463|Experimental|Ruxolitinib|"Ruxolitinib 15 mg by mouth twice daily.~For patients unable to ingest tablets, ruxolitinib suspended in water may be administered through a nasogastric (NG) or percutaneous endoscopy gastrostomy (PEG) tube."
89363626|NCT03309124|Experimental|White bread|Matched for energy content and available carbohydrate content of potato treatments
89363627|NCT03309124|Experimental|Baked potato with skin|Baked russet potato
89363628|NCT03309124|Experimental|Mashed potatoes|Mashed potatoes prepared from frozen, matched for available carbohydrate content of baked potato
89363629|NCT03309124|Experimental|Fried French fries|Matched for available carbohydrate content of baked potato
89363630|NCT03309124|Experimental|Meal skipping|No food given
88834868|NCT03331835|Experimental|Brodalumab|Kyntheum® (brodalumab)> pre-filled syringe 210 mg/1.5 mL solution for subcutaneous injections.> First 3 injections are administered weekly, and hereafter every two weeks (Q2W).
89363631|NCT02469454|Experimental|early insertion|Postpartum women into whom the etonogestrel-releasing contraceptive implant (Implanon®, N.V. Organon, Oss, Netherlands) will be inserted in the first 48 h postpartum. The ENG implant will be inserted subdermally in the non-dominant arm of volunteers upon local anesthesia with 2% lidocaine with vasoconstrictor, according to the manufacturer's instructions.
89363632|NCT02469454|Active Comparator|conventional insertion|Postpartum women into whom the etonogestrel-releasing contraceptive implant (Implanon®, N.V. Organon, Oss, Netherlands) will be inserted after 6 week of the delivery. The ENG implant will be inserted subdermally in the non-dominant arm of volunteers upon local anesthesia with 2% lidocaine with vasoconstrictor, according to the manufacturer's instructions.
89363633|NCT03313960|Active Comparator|"One Drop | Premium with Afrezza"|
89363634|NCT03313960|Other|"One Drop | Premium without Afrezza"|
89363635|NCT03308890|Active Comparator|Arm 1|0.5mg Entecavir QD for 6 months after cessation of TDF and clinical observation for up to 6 months after the end of study follow-up.
89363636|NCT03308890|Active Comparator|Arm 2|0.5mg Entecavir QD for 12 months after cessation of TDF and clinical observation for up to 6 months after the end of study follow-up.
89363637|NCT03308890|No Intervention|Arm 3|No consolidation arm and observation only and clinical observation for up to 6 months after the end of study follow-up.
89363638|NCT03313726|Experimental|GnRh-antagonist A|
89363639|NCT03313726|Experimental|GnRh-antagonist B|
89363640|NCT03308812|Active Comparator|Health360x|Participants will use the Health360x application for 6 months.
89363641|NCT03308812|Experimental|Health360x plus health coach|Participants will use the Health360x application and received personalized health coaching for 6 months.
89363642|NCT03308734|Experimental|Exercise Intervention Group|Reduced-Exertion High-Intensity Interval Training Following baseline testing, participants will start a 6-week training protocol involving reduced-exertion high-intensity training on a cycle ergometer based in a gym in Gloucestershire used by the Macmillan Cancer Support's Next Steps project.
89363643|NCT03308734|No Intervention|Control Group|Following baseline testing, participants will receive usual care only.
89363644|NCT03308656||Induced labor in term pregnancies|100 singleton nulliparous patients are planning to complete the study period. Study group constitute of third trimester pregnancies between 37-40 weeks of gestation. All participants were nulliparous and had no systemic illnesses. The uterocervical angle will be measured in all participants before the induction of labor.
89363645|NCT03304132||Upper aerodigestive squamous cell cancers (UADSCC) cases|From PLCO and ACS CPS II, identified 140 UADSCC cases. These cases are frequency matched 3:1 (420 controls) by incidence density sampling for study (ACS. PLCO),
89363646|NCT03304132||Controls|From PLCO and ACS CPS II, we have identified 140 UADSCC cases. These cases are frequency matched 3:1 (420 controls) by incidence density sampling for study (ACS. PLCO),
89363647|NCT03303976|Experimental|Pneumo1-low dose|Arm A: intramuscular injection monovalent bioconjugate pneumococcal vaccine
89363648|NCT03303976|Experimental|Pneumo1-mid dose|Arm B: intramuscular injection monovalent bioconjugate pneumococcal vaccine
89363649|NCT03303976|Experimental|Pneumo1-target dose|Arm C: intramuscular injection monovalent bioconjugate pneumococcal vaccine
89363650|NCT03303976|Active Comparator|Pneumovax23|Arm D: intramuscular injection multivalent plain polysaccharide vaccine
89363651|NCT03313648|Experimental|Laparoscopic Hepatectomy|Improvements in laparoscopic technology mean that LH now has superior short-term efficacy and similar long-term efficacy to open surgery , and LH has shown significant advantages in applications involving recurrent HCC.
89363652|NCT03313648|Active Comparator|Radiofrequency Ablation|With recent technological advances, RFA has become the most widely investigated new first-line therapeutic option for recurrent HCCs . Numerous large studies have demonstrated the advantages of RFA, which include its ease of use, safety, effectiveness, minimal invasiveness, and minimal morbidity and mortality .
89363653|NCT04490668||Human albumin support|Patients who received intravenous human albumin after gastric cancer surgery
89363654|NCT04490668||No human albumin support|Patients who did not receive intravenous human albumin after gastric cancer surgery
89363655|NCT03313414|Experimental|Treatment with Sofosbuvir/Velpatasvir|14 days of treatment with Sofosbuvir/Velpatasvir tablet
89178375|NCT00838552||1 Asthma subjects|Children with asthma undergoing clinically indicated bronchoscopy at National Jewish Health.
89363656|NCT04441684|Experimental|PCR+ group|This group includes any symptomatic person with a positive COVID result, with a RT-PCR test carried out at least 10 days before inclusion.
89178376|NCT00838552||2 Non-asthma subjects|Children with other respiratory diseases than asthma undergoing clinically indicated bronchoscopy at National Jewish Health.
89363657|NCT04441684|Experimental|PCR- group|This group includes any symptomatic person with a negative RT-PCR COVID 19 test carried out at least 10 days before inclusion.
89363658|NCT04441684|Experimental|No PCR|This group includes any person, for which no COVID 19 RT- PCR testing was performed.
89363659|NCT02468518|Experimental|Patients|Vitamin E capsule 200 IU bd x 12 weeks
89363660|NCT02468518|Active Comparator|Arsenic exposed controls|Vitamin E capsule 200 IU bd x 12 weeks
89363661|NCT02468518|Active Comparator|Healthy volunteers|Vitamin E capsule 200 IU bd x 12 weeks
89363662|NCT03308500|Experimental|High-intensity intermittent games HIIG|High-intensity intermittent games (HIIG): complete a supervised 12-weeks. Twice per week child-specific games program, intensity HRmax 75% ≤ - RPE 6-8.
89363663|NCT03308500|Active Comparator|Moderate-intensity games (MIG)|Moderate intensity games (MIG): complete a supervised 12-weeks. Twice per week child-specific games program, intensity HRmax 60-74% ≤ - RPE 4-5.
89363664|NCT03308422||Parents of 2-6-years-old children|Parents of preschool children in Nancy agglomeration
89363665|NCT03308344|Experimental|Spouse Trainers (MT-ST)|Participants will engage in a short-form mindfulness training delivered by their peers who underwent an extensive training practicum.
89363666|NCT03308344|No Intervention|Wait-list control|Participants will be tested before and after a no-training interval and may receive training at a later time.
89363667|NCT03308344|Experimental|Mindfulness Expert (MT-ME)|Participants will engage in a short-form mindfulness training delivered by an expert mindfulness trainer.
89178377|NCT02547376||Eligible patients with Soft Tissue Sarcoma|Primary Soft Tissue Sarcoma group
89178378|NCT00838708|Placebo Comparator|Vehicle cream|
89363668|NCT03313336|Active Comparator|Cohort 1|EMLA Test Patch.
89363669|NCT03313336|Active Comparator|Cohort 2|EMLA Reference Patch.
89363670|NCT03313336|Placebo Comparator|Cohort 3|Placebo patch.
89363671|NCT03308266||CLP children with pain-related TMD|
89363672|NCT03308266||CLP children with no TMD|
89363673|NCT03308266||CLP children with painfree TMD|
89363674|NCT05285332|Experimental|1 Primary and metastatic lesions PCR|surgery 1 Mastectomy OR Breast conserving surgery
89363675|NCT05285332|Experimental|2 Primary lesions NPCR and metastatic lesions PCR|surgery 1 Mastectomy OR Breast conserving surgery
89363676|NCT05285332|Experimental|3 Primary lesions PCR and metastatic lesions NPCR|surgery 2 Resection of metastasis
89363677|NCT05285332|Experimental|4 Primary lesions NPCR and metastatic lesions NPCR|Systemic therapy Endocrine therapy or chemotherapy or targeted therapy
89363678|NCT05262322||All Participants (Group 1; Retrospective)|All participants' data will be collected retrospectively from medical records 12 months prior to the date of diagnosis of a first ischaemic stroke attributable to nonvalvular AF
89363679|NCT05262322||Subset of All Participants (Group 2; Prospective)|A subset of participants from Group 1 who were initiated on apixaban, edoxaban or rivaroxaban for secondary prophylaxis of stroke will take part in this prospective component of the study, whereby data on their management pathway (treatments and follow-up appointments) and patient-reported outcomes will be collected for 6 months from the date of first dose of DOAC treatment.
89363680|NCT03313258|Active Comparator|Standard of Care Group|ZHF temperature monitor cable will be placed appropriately on the forehead by the care team under the direction of the research personnel. The research personnel will then connect this cable to a screen that is blinded to the care team but not to the research personnel.
89363681|NCT03313258|Experimental|Active Warming Group|ZHF temperature monitor cable will be placed appropriately on the forehead by the care team under the direction of the research personnel. The research personnel will then connect this cable to a screen that is un-blinded to everyone so healthcare practitioners will be able to visually detect continuous temperature readings from the ZHF monitor.
89363682|NCT03308110|Other|Relative Bioavailability Cohort|Relative Bioavailability cohort
89363683|NCT03308032|Experimental|Intervention|Participants assigned to the intervention arm will be invited to connect to a webpage, through either computer or tablet / iPad, where they can login to receive the SDL course. Immediately after the login, and weekly thereafter, participants will receive emails to remind them of the login passwords, to provide them with tracking data on their progress in going through the training lessons. For those who login but do not proceed to take baseline assessment for longer than two days, study staff will contact participants, via the email address or telephone number that was entered during initial registration for login, to answer any questions they might have and to provide assistance to those who have not been able to log onto the site. Those who sign up without taking any courses for 10 days will receive a reminder call by study staff. Intervention arm participants will be invited back via both
89363684|NCT03308032|Active Comparator|Control|"Participants assigned to the intervention arm will be invited to connect to a webpage, through either computer or tablet / iPad, where they can login to receive the SDL course.~Immediately after the login, and weekly thereafter, participants will receive emails to remind them of the login passwords, to provide them with tracking data on their progress in going through the training lessons (see below). For those who login but do not proceed to take baseline assessment for longer than two days, study staff will contact participants, via the email address or telephone number that was entered during initial registration for login, to answer any questions they might have and to provide assistance to those who have not been able to log onto the site. Those who sign up without taking any courses for 10 days will receive a reminder call by study staff. Intervention arm participants will be invited back via both"
89363685|NCT03303586|Active Comparator|Asthma group|Participants will be randomized to wear compression stockings or to control group for two weeks and cross over in the end of the period. When assigned to wear compression stockings, they will be instructed to put the stockings on as soon as they get up in the morning and to remove them just prior to bedtime for two weeks. If they have become loose, a new pair will be fitted. They will be given a diary to record the time they put on and remove the compression stockings each day. They will be telephoned after one week to check the fit of the compression stockings.
88834869|NCT03331835|Active Comparator|Fumaric acid esters|"Fumaderm® initial dose tablets (30 mg dimethyl fumarate, 67 mg ethyl hydrogen fumarate calcium salt, 5 mg ethyl hydrogen fumarate magnesium salt, 3 mg ethyl hydrogen fumarate zinc salt)> Fumaderm® tablets (120 mg dimethyl fumarate, 87 mg ethyl hydrogen fumarate calcium salt, 5 mg ethyl hydrogen fumarate magnesium salt, 3 mg ethyl hydrogen fumarate zinc salt)>~> Fumaderm® tablets are administered orally up to 3 times daily in accordance with the dosing scheme in the label."
88834870|NCT03523286|Experimental|RAPID-VT Software guided ablation|The induced VT(s) 12-lead ECG will be acquired by the RAPID-VT software which will provide real time localization of the VT(s) exits from the scar margin. These exits will be targeted by ablation
88834871|NCT02401555||Known HIV1 positives|Individuals known to the HIV1 positive tested with Geenius HIV1/2 Supplemental Assay
89178379|NCT00838708|Experimental|SRD174 Cream|
89363686|NCT03303586|Active Comparator|Healthy group|Participants will be randomized to wear compression stockings or to control group for two weeks and cross over in the end of the period. When assigned to wear compression stockings, they will be instructed to put the stockings on as soon as they get up in the morning and to remove them just prior to bedtime for two weeks. If they have become loose, a new pair will be fitted. They will be given a diary to record the time they put on and remove the compression stockings each day. They will be telephoned after one week to check the fit of the compression stockings.
88834872|NCT02401555||Known AIDS|Individuals known to meet diagnostic criteria for AIDS tested with Geenius HIV1/2 Supplemental Assay
88834873|NCT02401555||Low risk (negatives)|Individuals at low risk for HIV infection tested with Geenius HIV1/2 Supplemental Assay
88834874|NCT05723042|Experimental|EMS with CIMT group|
88834875|NCT05723042|Active Comparator|EMS Group|
88834876|NCT02402881|Experimental|Intervention|A patient-centered education bundle that will be delivered as an in-person, 1-on-1 discussion session with a nurse educator. Supporting education materials include a 2-page patient education sheet and a patient education video.
88834877|NCT02402881|No Intervention|Control|Patients will receive only the standard practices of care
88834878|NCT03435848|Experimental|BST-236|BST-236 Intravenous, 4.5 g/m2/d or 2.5 g/m2/d, for 6 days
88834879|NCT03332459|Experimental|Lumicitabine|Participants who completed the last planned study-related visit in a feeding Phase 2 study (64041575RSV2004), in which they received a regimen containing lumicitabine for the treatment of RSV infection, and who agree to participate in this follow-up study will be assessed for the incidence of the clinical diagnosis of asthma, frequency of wheezing, long-term safety of lumicitabine, frequency and type of respiratory infections and medical resource usage.
88834880|NCT03332459|Placebo Comparator|Placebo|Participants who completed the last planned study-related visit in a feeding Phase 2 study (64041575RSV2004), in which they received a regimen containing placebo for the treatment of RSV infection, and who agree to participate in this follow-up study will be assessed for the incidence of the clinical diagnosis of asthma, frequency of wheezing, long-term safety of placebo, frequency and type of respiratory infections and medical resource usage.
88834881|NCT02403895|Experimental|Open-label AZD2014|Open-label AZD2014 given twice daily 3 days on, 4 days off during weekly paclitaxel
88834882|NCT03987776|Experimental|Anti-inflammatory diet|energy-reduced diet with the use of low glycemic foods, wholegrain products, legumes, colorful vegetables and fruit, nuts, seeds, marine fish, olive oil, green/black tea, and multiple spices and herbs
88834883|NCT03987776|Experimental|Control energy-resticted diet|isocaloric to anti-inflammatory diet, energy restricted diet (55-60% carbohydrates, 25% fat, 15-20% protein) used in a standard obesity management
88834884|NCT03333317|Experimental|Regimen A (Low-Dose Lumicitabine)|Participants will receive a single 40 milligram per kilogram (mg/kg) loading dose (LD) (Dose 1) followed by nine 20 mg/kg maintenance doses (MDs) (Doses 2 to 10) of lumicitabine twice daily up to Day 5/6.
88834885|NCT03333317|Experimental|Regimen B (High-Dose Lumicitabine)|Participants will receive a single 60 mg/kg LD (Dose 1) followed by nine 40 mg/kg MDs (Doses 2 to 10) of lumicitabine twice daily up to Day 5/6.
88834886|NCT03333317|Placebo Comparator|Regimen C (Placebo)|Participants will receive either a single 40 mg/kg placebo LD (Dose 1) followed by nine 20 mg/kg maintenance dose (MDs) (Doses 2 to 10) of placebo twice daily or single 60 mg/kg placebo LD (Dose 1) followed by nine 40 mg/kg placebo MDs (Doses 2 to 10), twice daily up to Day 5/6.
88834887|NCT02406859|Experimental|Anorectal Manometry|Part 1 [Anorectal Manometry]: Fifty SCI subjects and 15 AB subjects will undergo anorectal manometry and a baseline assessment of level of constipation or frequency of fecal incontinence (FI). Additional 10 able-bodied subjects will be enrolled to serve as controls. The 10 Question Bowel Survey and Incontinence Scale will be administered.
88834888|NCT02406859|Experimental|Bowel Biofeedback Training|Part 2 [Bowel Biofeedback]: A subgroup of 20 subjects who participated in the first arm of the study (Anorectal Motility) and report either constipation or fecal incontinence will be asked to participate in 12 weeks of twice weekly, biofeedback training. The biofeedback training will consist of in-lab exercises that are paired with a visual feedback. Anorectal manometry and bowel surveys will be repeated after the training session to assess the effects of bowel biofeedback on anorectal function.
88834889|NCT05722730|Experimental|Pilates|The Pilates exercise protocol was designed based on protocols contained in previously published clinical trials whose objective had been muscle strengthening or improvement of muscle fatigue. Thus, the protocol will perform exercises from the classic repertoire of the Pilates Method, using equipment exclusive to the Method - such as Cadillac, Lader Barrel, Chair and Reformer. The sessions will take place twice a week, in a group of up to 3 participants, always in the morning lasting 60 minutes, with 10 minutes of warm-up, 40 minutes of load exercises and 10 minutes of relaxation exercises and calm down. All sessions were carried out by a physiotherapist specialized in the method, in a specific outpatient clinic. The professional who conducted the Pilates sessions, performed the proposed protocol, is unaware of the outcomes studied by the project.
88834890|NCT05722730|No Intervention|Control|Only follow-up of the clinical evolution will be carried out
88834891|NCT02406937|Experimental|Feihe New Formula|Oral intake of Feihe new formula with hydrolyzed protein supplied by Arla Foods Ingredients.
88834892|NCT02406937|Active Comparator|Feihe Stage 1 Formula|Oral intake of Feihe stage 1 formula
88834893|NCT02406937|Placebo Comparator|Breast Feeding|Oral intake of breast milk
88834894|NCT03210155|Active Comparator|Active Comparator|About the size of a smart phone, the Alpha-Stim® AID CES device delivers a mild electrical current (100-500 µA) to the brain via ear clips electrodes. The active intervention is one daily 60 minutes Alpha-Stim® CES treatment using ear clip electrodes for 6 weeks at 0.5 Hz. 50% duty cycle with a fixed current of 100 µA (subsensory level).
89178380|NCT00833014|Experimental|I|
89178381|NCT00838864|Active Comparator|1|ceftrioxone 500mg q12h for 3 days
89178382|NCT00838864|Active Comparator|2|ceftrioxone 500 mg q12h for 7 days
88834895|NCT03210155|Sham Comparator|Sham Comparator|The Alpha-Stim® AID CES sham device is identical in appearance to the active device but is inactive and does not emit electrical current to the brain via ear clip electrodes. The sham intervention is one daily 60 minutes Alpha-Stim® CES treatment using ear clip electrodes for 6 weeks.
88834896|NCT02408263||Total Hip Replacement (THR) and Total Knee Replacement (TKR)|25 patients receiving a THR and 25 patients receiving aTKR. The investigators are using Skin Conductance Algesimeter (SCA) to measure pain by analyzing changes in skin conductance.
88834897|NCT03210701|Other|Patients requesting a HIV screening test|
89363687|NCT03303508|Other|anti-ds DNA|anti-ds DNA
89363688|NCT02469376|Experimental|Diagnosis with GP1|Injection and scanning of [18F]-GP1
89363689|NCT02469532||Atherectomy|"Up to 20 atherectomy procedures at up to 5 sites in the United States. Change in inflammatory biomarkers (hs-CRP, MCP-1 and MMP-9) from baseline to 24 hours post-procedure and 30-days post-revascularization procedure.~This registry will also observe outcomes (target lesion revascularization rates, 6 and 12 month duplex ultrasound-detected binary restenosis with PSVR>2.4) post-atherectomy revascularization procedures."
88834898|NCT04345016|Experimental|All Participants|Eligible participants were provided a once-daily remote foot temperature monitoring mat (Podimetrics SmartMat; Podimetrics Inc., Somerville MA) during the intervention/treatment phase. Each was followed for one year or until study disenrollment, health plan disenrollment, death, or end of the study and follow-up period. Outcomes data from eligible participants from the two years prior to the intervention/treatment phase and the period of time after the intervention ended through the analysis date (2020-01-01) were evaluated. For this period, these participants received standard medical and diabetic foot care.
89363690|NCT02469532||Angioplasty|"Up to 20 angioplasty procedures at up to 5 sites in the United States. Change in inflammatory biomarkers (hs-CRP, MCP-1 and MMP-9) from baseline to 24 hours post-procedure and 30-days post-revascularization procedure.~This registry will also observe outcomes (target lesion revascularization rates, 6 and 12 month duplex ultrasound-detected binary restenosis with PSVR>2.4) post-angioplasty revascularization procedures."
89363691|NCT03303430||Surgery group|This patient's group will benefit from a endarteriectomy in order to treat their carotid stenosis.
88834899|NCT02354833|Experimental|Phenylephrine|A continuous phenylephrine infusion at 0.1 mcg/kg/min
89363692|NCT03303430||Stenting group|This patient's group will benefit from a stenting of their carotid in order to treat their stenosis.
89363693|NCT02469142|Experimental|ADM tension-free hernia reparation|Use ADM to repair incarcerated inguinal hernia by tension-free
89363694|NCT02469142|Placebo Comparator|traditional tension hernia reparation|Just repair incarcerated inguinal hernia by nothing in tension condition
89363695|NCT03303352|Experimental|Fast Pass First, Slow Pass Second|"Each patient will receive 2 EUS FNA passes, 1 fast and 1 slow, with a 22 gauge EUS needle, with suction syringe, employing the fanning technique, 10 jabs for each pass.~A fast pass has an advancing mean acceleration jab (to movement) higher than 1 g, while a slow pass has an advancing mean acceleration jab of less than 1 g (where 1 g equals 9.8 m/s2). Both movements will have a slow fro withdrawal movement, from the point of maximum advance into the lesion to the lesion entry site.~For each patient, the passes order with be either done as fast pass first, slow pass second."
89363696|NCT03303352|Experimental|Slow Pass First - Fast Pass Second|"Each patient will receive 2 EUS FNA passes, 1 fast and 1 slow, with a 22 gauge EUS needle, with suction syringe, employing the fanning technique, 10 jabs for each pass.~A fast pass has an advancing mean acceleration jab (to movement) higher than 1 g, while a slow pass has an advancing mean acceleration jab of less than 1 g (where 1 g equals 9.8 m/s2). Both movements will have a slow fro withdrawal movement, from the point of maximum advance into the lesion to the lesion entry site.~For each patient, the passes order with be either done as slow pass first, fast pass second."
89363697|NCT04490980|Experimental|Observed group|
88834900|NCT02354833|Experimental|Norepinephrine|A continuous norepinephrine infusion at 0.05 mcg/kg/min
88834901|NCT04295447|Other|Standard of care|"Observation only or~An optional adjuvant radiation of the prostate bed in case of positive surgical margin"
88834902|NCT04295447|Experimental|Apalutamide|30 cycles apalutamide 240 mg (4 x 60 mg) once daily on days 1-28 of a 28-day cycle in addition to standard of care
88834903|NCT04190147||Moderate-to-late preterm group|
88834904|NCT04190147||Full-term group|
88834905|NCT02355067|Experimental|Social Media Format|Social Media Intervention for women with postpartum depression (PPD) symptoms
89363698|NCT04490980|No Intervention|Control group|
89363699|NCT03303274|Experimental|Ipsilateral tilt|The operation table will be tilted 20 degrees right laterally before subclavian venous catheterization.
89363700|NCT03303274|No Intervention|Supine|Catheterization of right subclavian vein in supine position.
89363701|NCT03307954|Experimental|Ekso Therapy|Up to 12 weeks of Ekso Therapy. Three sessions per week. One hour per session
89363702|NCT03307954|Active Comparator|Control|Up to 12 weeks of usual physiotherapy care. Three sessions per week. One hour per session.
89363703|NCT03307876||groups that are fac + and -|autologous PPP injection is given to all patients. Prior to injection, a lavage of the disc space is taken to test for FAC.
89363704|NCT02468284|Experimental|Degarelix|
89363705|NCT03313102|Experimental|Horton disease|
89363706|NCT03313102|Experimental|control|
89363707|NCT03307720|Active Comparator|Poor responders. Classical trigger|"Intervention: HCG trigger (Administration of recombinant HCG 250 UI subcutaneously 36 prior to oocyte retrieval.~Women scheduled for IVF treatment with 4 or less antral follicles in ultrasound assessment."
89363708|NCT03307720|Experimental|Poor responders. Agonist trigger|"Intervention: Agonist trigger (administration of 0,2 mg of Triptoreline subcutaneously 36 hours prior to oocyte retrieval)~Women scheduled for IVF treatment with 4 or less antral follicles in ultrasound assessment."
89363709|NCT03307720|Active Comparator|Normo responders. Classical trigger|"Intervention: HCG trigger (Administration of recombinant HCG 250 UI subcutaneously 36 prior to oocyte retrieval.~Women scheduled for IVF treatment with more than 4 and less than 16 antral follicles in ultrasound assessment."
88834906|NCT02355067|Active Comparator|In-Person Format|Traditional In-Person Intervention for Women with postpartum depression (PPD)
89534605|NCT05038449|Experimental|Colchicine group|"The colchicine treatment includes an initial dose of 1 mg (1 mg and 0.5 mg two hours after), followed by 0.5 mg every 12 hours during the next 6 days and 0.5 mg every 24 hours until the completion of 10 days of total treatment.~+ standard therapy for COVID-19 according to the Novel Coronavirus Pneumonia Diagnosis and Treatment Plan (Trial 8th Edition)."
89534606|NCT05038449|Placebo Comparator|Standard therapy group|Standard therapy for COVID-19 according to the Novel Coronavirus Pneumonia Diagnosis and Treatment Plan (Trial 8th Edition).
88834907|NCT03340337|Experimental|Neo-Russian Electrical Stimulation|"MVIC will be measured for data normalization. The subjects will receive Neo-Russian electrical stimulation. The Maximal Elicited Induced Contraction (MEIC) will be measured.~One week later, after a washout period, the fatigue will be measured with this type of current."
88834908|NCT03340337|Experimental|Aussie Electrical Stimulation|"MVIC will be measured for data normalization. The subjects will receive Aussie electrical stimulation. The Maximal Elicited Induced Contraction (MEIC) will be measured.~One week later, after a washout period, the fatigue will be measured with this type of current."
88834909|NCT03340337|Experimental|RBS Electrical Stimulation|"MVIC will be measured for data normalization. The subjects will receive RBS electrical stimulation. The Maximal Elicited Induced Contraction (MEIC) will be measured.~One week later, after a washout period, the fatigue will be measured with this type of current."
88834910|NCT05722106|Experimental|Control - Info only|"Participants read a flyer containing the following message:~The virus spreads mainly between people who are in close contact with one another. You can help prevent the spread of COVID-19. We can all do our part:~Avoid social gatherings.~Wear a mask when you go out.~Stay at least six feet away from people outside your household.~Wash your hands often with soap and water. These actions prevent the spread of COVID-19."
88834911|NCT05722106|Experimental|Deontological|"Participants read a flyer containing the following message:~The virus spreads mainly between people who are in close contact with one another. You can help prevent the spread of COVID-19. We can all do our part:~Avoid social gatherings.~Wear a mask when you go out.~Stay at least six feet away from people outside your household.~Wash your hands often with soap and water. We all need to do this, however difficult, because it is the right thing to do: it is our duty and responsibility to protect our families, friends, and fellow citizens."
88834912|NCT05722106|Experimental|Empathy|"Participants read a flyer containing the following message:~The sick, elderly, and immunocompromised need our help. We all have a choice. If we don't take the right actions, we risk the lives of others. But we can protect those most likely to be harmed. We can protect those who are vulnerable by taking simple steps:~Avoid social gatherings.~Wear a mask when you go out.~Stay at least six feet away from people outside your household.~Wash your hands often with soap and water. Take action to protect those who are vulnerable!"
88834913|NCT05722106|Experimental|Identifiable victim|"Participants read a flyer containing the following message:~A few weeks ago, Sam was a healthy 26-year-old with no medical complications. The he suddenly came down with a bad cough and a feeling like he could not breath. He tested positive for COVID-19, and is now hospitalized, receiving oxygen from a ventilator, and fighting for his life. This could be any of us. Reduce the risk to yourself and other:~Avoid social gatherings.~Wear a mask when you go out.~Stay at least six feet away from people outside your household.~Wash your hands often with soap and water. If we take these actions, we can prevent more people from suffering the way Sam has."
88834914|NCT05722106|Experimental|Goal proximity|"Participants read a flyer containing the following message:~The recent development of safe and effective vaccines gives us great hope. We see the light at the end of the tunnel, but we are not quite there yet. Until a large proportion of the population is immunized, we must remain vigilant and double our efforts to prevent the spread of COVID-19.~Avoid social gatherings.~Wear a mask when you go out.~Stay at least six feet away from people outside your household.~Wash your hands often with soap and water. These actions prevent the spread of COVID-19."
88834915|NCT05722106|Experimental|Reciprocity|"Participants read a flyer containing the following message:~Doctors, nurses, and other healthcare workers are working around the clock, often risking their lives to care for patients with the coronavirus. Working long hours in highly infectious environments, many of them are falling ill. As our healthcare workers put their lives on the line, we can do our part:~Avoid social gatherings.~Wear a mask when you go out.~Stay at least six feet away from people outside your household.~Wash your hands often with soap and water. Our brave healthcare workers have sacrificed to help others. We should take action too."
88834916|NCT03340415|No Intervention|Control Rehab|Follow existing rehabilitation protocol of Non-weight bearing walking for 6 weeks followed by heel walking for 6 weeks; then the resumption of normal full weight-bearing walking in normal shoes at 12 weeks post-operation
88834917|NCT03340415|Experimental|Accelerated Rehab|Accelerated rehabilitation protocol of non-weight bearing walking for 2 weeks followed by heel walking for 10 weeks; then the resumption of normal full weight-bearing walking in normal shoes at 12 weeks post-operation
88834918|NCT05722028||Patients with benign uterine findings (polyp / retained products of conception)|Female patients undergoing diagnostic hysteroscopy with a diagnosis of uterine polyp or retained products of conception. These patients are then invited to a surgical office procedure without anaesthesia to remove these findings.
88834919|NCT02356003|Experimental|Low frequency rTMS|Eleven children (7-12 years of age) with Tourette syndrome will be undergo low frequency repetitive transcranial magnetic stimulation (5 times a week for three weeks).
88834920|NCT02356471|Experimental|Supportive care (consumer-based activity monitor)|Patients wear Fitbit Zip (portable pedometer device) to track physical activity for 7 days before undergoing surgery and for 21 more days after undergoing surgery.
88834921|NCT03340805|Experimental|Lactated Ringer's fluid (LR)|Lactated Ringer's (LR) fluid will be administered to patients randomized to the experimental arm. LR will be used for all fluid boluses and maintenance fluids (supplemental electrolytes are allowed) from time immediately after randomization through 11:59 pm of the next calender day. The determination of when to give fluid, how much fluid to give, how fast to give fluid, and what access to use to administer fluid will remain at the discretion of the treating team.
89178383|NCT00838942||1|Patients suffering from both Alzheimer's disease and low vision due to a bilateral impeding cataract.
89178384|NCT00825214|Active Comparator|1|Use of zapperclick on mosquito bite
89178385|NCT00825214|Placebo Comparator|2|use of inactivated zapperclick on mosquito bite
89001283|NCT00579085|Experimental|2|"INFUSION PLAN:~All patients will be infused intravenously with 100 ml of normal saline with or without ketamine for four hours (25 ml/hr) daily for 10 days. The maximum intravenous ketamine infusion dose for this study will be 0.35 mg/kg/hr, not to exceed 25 mg/hr (100 mg of ketamine over a 4 hour period). On the first day, the intravenous ketamine infusion will be set to 50% of the maximum rate. On the second day, the intravenous ketamine infusion will be increased to 75% of the maximum rate. On the third day, the intravenous ketamine infusion will be increased to the maximum rate. The daily ketamine infusion rate is maintained at this level for the duration of the ten day study."
89363710|NCT03307720|Experimental|Normo responders. Agonist trigger|"Intervention: Agonist trigger (administration of 0,2 mg of Triptoreline subcutaneously 36 hours prior to oocyte retrieval)~Women scheduled for IVF treatment with more than 4 and less than 16 antral follicles in ultrasound assessment."
89363711|NCT03307720|Active Comparator|High responders. Classical trigger|"Intervention: HCG trigger (Administration of recombinant HCG 250 UI subcutaneously 36 prior to oocyte retrieval.~Women scheduled for IVF treatment with more than 15 antral follicles in ultrasound assessment."
89363712|NCT03307720|Experimental|High responders. Agonist trigger|"Intervention: Agonist trigger (administration of 0,2 mg of Triptoreline subcutaneously 36 hours prior to oocyte retrieval)~Women scheduled for IVF treatment with more than 15 antral follicles in ultrasound assessment."
89001284|NCT04578262|Experimental|Epley Manoeuvre|Epley manoeuvre in participants with Multiple Sclerosis who suffer from benign paroxysmal positional vertigo. Only one administration.
89363713|NCT03303118|Other|Left|No product administration will be done in this study.
89363714|NCT03312946|Experimental|Treatment oscillating vibro|treatment such as the Modellata electromedical device (Ibramed), in the abdomen, flanks, thigh posterior, inner thigh and buttocks. Being performed twice a week, with a total duration of 50 minutes to the session, being 10 sessions total to end the treatment.
89363715|NCT03302962|Experimental|Intensive Asthma Education|"One half (54) of the identified cases were randomized to receive the previously established BREATHE study educational program, emphasizing patient-centered, self management of asthma. Periodic follow-up through personal contact and surveillance of IHS RPMS or other medical provider records was conducted."
89363716|NCT03302962|No Intervention|Routine Asthma Education Literature|"The remaining 54 cases were randomized to the control arm and received written materials related to patient-centered asthma control."
89363717|NCT03312790|Experimental|augmented reality device|Tasks realized using augmented reality device
89363718|NCT03312790|Other|Real condition|Same tasks than augmented reality realized in normal/real condition
89363719|NCT03302884|Experimental|Biological sampling in ovarian carcinoma|Blood and tumor samples
89363720|NCT03307642|No Intervention|SLIV + usual communication|Parents receive usual communication from school (paper consent packets & automated voice mails) about SLIV
89363721|NCT03307642|Active Comparator|SLIV + usual communication + text|Parents receive usual communication from school (paper consent packets & automated voice mails) about SLIV plus a series of text messages informing them about the usual communication for SLIV
89363722|NCT03312712||Participants with sarcoidosis|"Bronchoscopy, BAL collection, and PFTs* [SoC] *if required~Screening, research and safety bloods~Dynamic 18F-FDG PET/CT scan"
89363723|NCT03312712||Healthy volunteers|"Part A:~PFTs~Screening, research and safety bloods~Dynamic 18F-FDG PET/CT scan~Part B:~PFTs~Screening, research and safety bloods~Baseline and post challenge Dynamic 18F-FDG PET/CT scans~LPS/saline challenge"
89363724|NCT04608786|Experimental|Combined the therapy using Capecitabine and PD-L1|PD-L1 antibody ZKAB001 D1 5mg/kg every three weeks,up to 16 cycles or 1 year of treatment or the patient has tumor recurrence or metastasis Capecitabine 1000mg / m2/time, 2 times/d for 2 weeks, followed by 1 week of stopping ,three weeks is a course of treatment with a total of 8 courses, or the patient has tumor recurrence or metastasis
89363725|NCT01314872|Placebo Comparator|Part 1: placebo|Participants received two placebo matching vibegron tablets and one placebo matching tolterodine extended release (ER) capsule, taken orally each morning, for 8 weeks.
89001285|NCT04578262|Sham Comparator|Sham Manoeuvre|The second group will received a sham manoeuvre. However after the experimental intervention ends, this groups will also receive Epley manoeuvre.
89178386|NCT00839020|Active Comparator|1|Navigated total knee arthroplasty with a minimally invasive approach
89178387|NCT00839020|Active Comparator|2|Navigated total knee arthroplasty with a conventional approach
89363726|NCT01314872|Experimental|Part 1: vibegron 3 mg|Participants received one vibegron 3 mg tablet, one placebo matching vibegron tablet, and one placebo matching tolterodine ER capsule, taken orally each morning, for 8 weeks.
89363727|NCT01314872|Experimental|Part 1: vibegron 15 mg|Participants received one vibegron 15 mg tablet, one placebo matching vibegron tablet, and one placebo matching tolterodine ER capsule, taken orally each morning, for 8 weeks.
89363728|NCT01314872|Experimental|Part 1: vibegron 50 mg|Participants received one vibegron 50 mg tablet, one placebo matching vibegron tablet, and one placebo matching tolterodine ER capsule, taken orally each morning, for 8 weeks.
89363729|NCT01314872|Experimental|Part 1: vibegron 100 mg|Participants received two vibegron 50 mg tablets and one placebo matching tolterodine ER capsule, taken orally each morning, for 8 weeks.
89363730|NCT01314872|Active Comparator|Part 1: tolterodine ER 4 mg|Participants received one tolterodine ER 4 mg capsule and two placebo matching vibegron tablets, taken orally each morning, for 8 weeks.
89363731|NCT01314872|Experimental|Part 1: vibegron 50 mg + tolterodine ER 4 mg/vibegron 50 mg|Participants received one vibegron 50 mg tablet and one placebo matching vibegron tablet, taken orally each morning, for 8 weeks. They also received one tolterodine ER 4 mg capsule for the first 4 weeks and one placebo matching tolterodine ER capsule for the second 4 weeks, both taken orally each morning.
89363732|NCT01314872|Placebo Comparator|Part 2: placebo|Participants received two placebo matching vibegron tablets and one placebo matching tolterodine ER capsule, taken orally each morning, for 4 weeks.
89363733|NCT01314872|Experimental|Part 2: vibegron 100 mg|Participants received two vibegron 50 mg tablets and one placebo matching tolterodine ER capsule, taken orally each morning, for 4 weeks.
89363734|NCT01314872|Active Comparator|Part 2: tolterodine ER 4 mg|Participants received one tolterodine ER 4 mg capsule and two placebo matching vibegron tablets, taken orally each morning, for 4 weeks.
89363735|NCT01314872|Experimental|Part 2: vibegron 100 mg + tolterodine ER 4 mg|Participants received two vibegron 50 mg tablets and one tolterodine ER 4 mg capsule, taken orally each morning, for 4 weeks.
89001286|NCT04577950|Experimental|Arm with procedure: identification of lymphatic drainage of the uterus following 3 sites injections|A radiocolloid (Nanocoll® marked with Technetium 99), a fluorochrome (ICG) and a blue dye (Bleu Patenté®) will be injected in submucosal tissue to see the differences in lymphatic drainage between three different injection sites. Indeed, ICG will be injected under the endometrium, whereas Nanocoll® will be injected in the cervix and Bleu Patenté® in the uterine isthmus, at the transition between the cervix and the uterine corpus.
89363736|NCT01314872|Experimental|Extension Study: vibegron 50 mg|Participants in Base Study/Part 1 who received vibegron 50 mg continued their treatment in the Extension Study. In addition, participants in Base Study/Part 1 who received vibegron 3 mg received vibegron 50 mg in the Extension Study. Also, participants in Base Study/Part 1 who received vibegron 50 mg + tolterodine ER for 4 weeks, followed by vibegron 50 mg alone for 4 weeks, remained on vibegron 50 mg in the Extension Study. In the extension, participants received one vibegron 50 mg tablet, one placebo matching vibegron tablet, and one placebo matching tolterodine ER capsule, taken orally each morning, for 52 weeks.
89363737|NCT01314872|Experimental|Extension Study: vibegron 100 mg|Participants in Base Study/Part 1 or Part 2 who received vibegron 100 mg continued their treatment in the Extension Study. In addition, participants in Base Study/Part 1 who received vibegron 15 mg received vibegron 100 mg in the Extension Study. In the extension, participants received two vibegron 50 mg tablets and one placebo matching tolterodine ER capsule, taken orally each morning, for 52 weeks.
89363738|NCT01314872|Experimental|Extension Study: tolterodine ER 4 mg|Participants in Base Study/Part 1 or Part 2 who received tolterodine ER 4 mg continued their treatment in the Extension Study. In addition, participants in Base Study/Part 1 who received placebo also received tolterodine ER 4 mg in the Extension Study. In the extension, participants received one tolterodine ER 4 mg capsule and two placebo matching vibegron tablets, taken orally each morning, for 52 weeks.
89363739|NCT01314872|Experimental|Extension Study: vibegron 100 mg + tolterodine ER 4 mg|Participants in Base Study/Part 1 who received vibegron 100 mg + tolterodine ER 4 mg continued their treatment in the Extension Study. In addition, participants in Base Study/Part 2 who received placebo were assigned to the vibegron 100 mg + tolterodine ER 4 mg arm in the Extension Study. In the extension, participants received two vibegron 50 mg tablets and one tolterodine ER 4 mg capsule, taken orally each morning, for 52 weeks.
89363740|NCT04602312|Experimental|Mindfulness meditation|"focussed attention mindfulness meditation technique taught as means to reduce coronavirus-related catastrophizing."
89363741|NCT04602312|Sham Comparator|Specific sham mindfulness meditation|a training session designed to specifically match the real mindfulness training while lacking the proposed active elements of mindfulness training. Delivered as a means to elicit expectancy-mediated (but not mindfulness-mediated) reductions in coronavirus-related catastrophizing.
89363742|NCT04602312|Sham Comparator|General sham mindfulness meditation|a training session designed to generally match focussed-attention mindfulness meditation while maintaining greater distance from proposed mindfulness mechanisms. Delivered as a means to elicit expectancy-mediated (but not mindfulness-mediated) reductions in coronavirus-related catastrophizing.
89363743|NCT04602312|No Intervention|Book listening control|"this group completes no meditation training. They listen to a spoken excerpt from the audiobook The Natural History and Antiquities of Selborne"
89363744|NCT01343628|Placebo Comparator|Placebo, Atomoxetine|
89363745|NCT01343628|Active Comparator|Atomoxetine, Placebo|
89363746|NCT00703924|Experimental|WR 279,396|WR 279,396 is a topical antibiotic cream containing paromomycin and gentamicin
89363747|NCT00703924|Placebo Comparator|Placebo|Topical cream vehicle containing all of the components in WR 279,396 except the active ingredients.
89363748|NCT03152526|Other|Single-arm trial|Multi-center, open-label, single-arm, phase I/II clinical trial
89363749|NCT03302650|Experimental|Angiotensin group|Patients will receive Angiotensin II at a starting dose of 20 ng/Kg/min. During the first 30 minutes after randomization, the angiotensin II infusion will be titrated to achieve a mean arterial pressure of 65-75 mmHg while the norepinephrine infusion will be withdrawn and stopped. Following a stabilization of 60 minutes, the angiotensin II infusion is titrated to achieve a mean arterial pressure of 85-95 mmHg. Following a 30 minutes wash-in period and a 60 minutes stabilization period, a third set of measurements will be taken. Then, the angiotensin II infusion will be withdrawn in small steps and replaced by a norepinephrine infusion which will then be titrated to achieve a mean arterial pressure of 65-75 mmHg. Then, the final set of measurements will be taken.
89363750|NCT03302650|Placebo Comparator|Normal saline group|Patients will receive normal saline infusion in addition to norepinephrine infusion. The same mean arterial pressure levels (65-75 mmHg > 85-95 mmHg > 65-75 mmHg) will be achieved by titration of the norepinephrine infusion. Identical wash-in and stabilization periods will be kept as in the study group. Measurements will be taken at the same time points as in the study group. The maximum dose of norepinephrine applied will be 0.7 mcg/kg/min.
89363751|NCT03307486||Gestational diabetes|Women diagnosed with GDM according to the IADPSG criteria, either by abnormal fasting plasma glucose or by abnormal oral glucose tolerance test.
89363752|NCT03312478|Other|Case|Known cases of type 1 diabetes mellitus as described in the inclusion criteria for cases
89363753|NCT03312478|Other|Control|Age-matched non-diabetic controls as described in the inclusion criteria for controls
89363754|NCT02468986||Uncontrolled Rheumatoid Arthritis|"18-75 years old; Rheumatoid arthritis, defined by 1987 American College Rheumatology criteria; Attending clinic at Aston Center for Rheumatology or Parkland Rheumatology Clinic; Uncontrolled: Patients will be labeled as uncontrolled RA if Disease Activity Score (DAS) score is >3.2 and C-reactive protein (mg/dL) elevated above normal range.~Excluding: Insulin dependent diabetes; Cardiovascular or Cerebrovascular disease (history of myocardial infarction, stroke, peripheral vascular disease); Tobacco use in the past 24 months; Uncontrolled hypertension (BP > 150/90) in the past 3 months; Uncontrolled hyperlipidemia (LDL>160) in the past 6 months; Pregnant or nursing."
89534607|NCT05038059|Active Comparator|1. Ethylene diammine tetra acetic acid group|samples will be rinsed with ethylene diamine tetra acetic acid group, which is the gold standard for final rinse and compares with the experimental group.
89534608|NCT05038059|No Intervention|2. Control group|no final irrigant will be used and evaluate the outcomes
89001287|NCT00579397||1|"For Objective #1:~Healthy adult volunteers"
89001288|NCT00579397||2|"For Objectives #2 & #3:~Recipients undergoing an allogeneic stem cell transplant"
89001289|NCT04578067|Experimental|Intervention|culturally tailored intervention package on changes in lifestyle-habits
89001290|NCT04578067|No Intervention|Control|
89001291|NCT00187161|Experimental|A|"Group A: Resected Stage I and resected abdominal Stage II~Subjects will receive two courses (3 weeks apart) of COPAD."
89001292|NCT00187161|Experimental|B|"Group B: Other Stage II, Stage III, Stage IV or B-ALL M blast <70%; no CNS involvement.~Subjects in Group B will receive one week of treatment of COP."
89001293|NCT00187161|Experimental|C|"Group C: B-ALL with >70% BM blasts; CNS involvement, Group B COP failures i.e., <20% reduction Treatment Pre-Induction~Subjects will receive one week of treatment of COP."
89001294|NCT04578184|Other|Epithelial thickness map evaluation in keratoconus patients|Patients included in the study will be measured with the corneal acquisition mode, also allowing for epithelium thickness data, on each device without pupil dilatation Each patient will be measured three times with both devices. The corneal epithelial thickness will be measured as the distance between the air-tear and the epithelium-Bowman interfaces.
89001295|NCT04578184|Other|Epithelial thickness map evaluation in healthy cornea patients|Patients included in the study will be measured with the corneal acquisition mode, also allowing for epithelium thickness data, on each device without pupil dilatation Each patient will be measured three times with both devices. The corneal epithelial thickness will be measured as the distance between the air-tear and the epithelium-Bowman interfaces.
89001296|NCT00579475|Placebo Comparator|Placebo|
89001297|NCT00579475|Active Comparator|I|Mifepristone (Mifegyne) 50 mg every other day for 3 months
89001298|NCT00579592|Experimental|1|Campath, Rituximab, Myfortic, and 10-20 days of cyclosporine
89001299|NCT00579631||1|Questionnaire or Interview
89001300|NCT01054248|Experimental|MAS3|Standard three day regimen of artesunate-mefloquine (12/24 mg/kg) given as artesunate 4mg/kg/day and mefloquine 8mg/kg/day on Days 0, 1 and 2.
89001301|NCT01054248|Active Comparator|ALN+|Augmented 4 day regimen of artemether lumefantrine 2 doses per day for 4 days. Each dose consists of 5 tablets (20/120 mg of artemether/lumefantrine per tablet)
89001302|NCT01054248|Experimental|DP|Standard 3 days regimen DHA-piperaquine: (DHA/PPQ 40 mg/320 mg) 2.4 mg/kg DHA and 20 mg/kg PPQ once daily for 3 days
89001303|NCT00579748||1|
89001304|NCT00579787||1|Women with early stage cervical cancer undergoing radical trachelectomy
89001305|NCT00579787||2|Women with early stage cervical cancer undergoing radical hysterectomy
89001306|NCT00579865||Group A|Patients scheduled for percutaneous drainage
89001307|NCT00579865||Group B|Patients scheduled for a surgical bypass or resection of a high bile duct tumor.
89001308|NCT00579904|Active Comparator|walnuts|Patients will be randomized to receive walnuts
89534609|NCT05038059|Experimental|3. Experimental group|final irrigation of root canal will be done with ethanolic extract of sapindus mukorossi
89001309|NCT00579904|Active Comparator|almonds|Patients will be randomized to receive almonds
89001310|NCT00579943||premature infants|Inpatient very low birth weight infants who are ventilated and have an umbilical arterial catheter in place
89001311|NCT00580021||1|Patients with breast and pancreas cancer.
89001312|NCT00202176|Experimental|1|Ipratropium Bromide
89001313|NCT00202176|Placebo Comparator|2|Saline Solution (0.9% NaCl)
89001314|NCT00580099|Experimental|1|4 weeks of assisted exercise using passive range of motion on all major joints
89001315|NCT00580099|Active Comparator|2|cuddle for 20 minutes
89001316|NCT00580177|Active Comparator|L|The Lichtenstein procedure for repair of inguinal hernia (Single On-lay patch)
89001317|NCT00580177|Active Comparator|P|The well-konown PerFixPlug technique for inguinal hernia repair.
89001318|NCT00580177|Active Comparator|PHS|The well-known Prolene Hernia System method for inguinal hernia repair.
89001319|NCT00187239|Active Comparator|AICS On|Patients in this arm have Autointrinsic conduction search programmed ON.
89001320|NCT00187239|No Intervention|AICS Off|Patients assigned to this arm do not have Autointrinsic Conduction Search programmed on.
89001321|NCT04578145|Other|Female sex workers (FSW)|Female sex workers (FSWs) community is the only group which has implemented the study intervention. This group has been underlined as the one of key affected populations (KAPs) that hold an increasing number of HIV incidence and prevalence recently in Indonesia even though it is approximately 226,791 FSWs by 2016 and around 5,254,065 clients access their services per year (MoH, 2017). The condition will be worst because the transmission definitely will continue to clients' sexual partner and moreover, their babies if their HIV status has not been known earlier. It means that lowering the transmission of HIV infection for FSWs, it will simultaneously lower its transmission to their sexual partners and furthermore their babies.
89001322|NCT00580411||Alcohol Problem First|Alcohol Problem precedes Insomnia
89001323|NCT00580411||Insomnia First|Insomnia Precedes Alcohol Problem
89001324|NCT00580450|No Intervention|2|
89001325|NCT00580450|Experimental|1|
89001326|NCT00580528|Experimental|1 Tailored internet newsletters|Tailored newsletters delivered via the Internet with content for improving eating and activity to reduce blood pressure.
89001327|NCT00580528|Experimental|2 Tailored print newsletters|Tailored print newsletters delivered via the mail with content for improving eating and activity to reduce blood pressure.
89001328|NCT00580528|No Intervention|3 No newsletters|Participants receive no newsletters
89001329|NCT00580567||1|Pathological Gamblers
89001330|NCT00580567||2|Non-Pathological Gamblers
89001331|NCT04577872|Experimental|Supine group (n=22)|The 22 participants with lower muscle strength (under 60 microvolt) comprised the supine group.
89001332|NCT04577872|Experimental|Sitting group (n=19)|The 19 participants with higher muscle strength (over 60 microvolt) formed the sitting group.
89001333|NCT04577872|No Intervention|Control group (n=14)|The control group comprised 7 individuals with lower muscle strength (under 60 microvolt) and 7 with higher muscle strength (over 60 microvolt)
89001334|NCT00580684|Active Comparator|G1|G1: prevenar
89001335|NCT00580684|Active Comparator|G2|G2: pneumo 23
89363755|NCT02468986||Controlled Rheumatoid Arthritis|18-75 years old; Rheumatoid arthritis, defined by 1987 American College Rheumatology criteria; Attending clinic at Aston Center for Rheumatology or Parkland Rheumatology Clinic; Controlled: Disease activity score (DAS) <3.2, normal C-reactive protein. Excluding: Insulin dependent diabetes; Cardiovascular or Cerebrovascular disease (history of myocardial infarction, stroke, peripheral vascular disease); Tobacco use in the past 24 months; Uncontrolled hypertension (BP > 150/90) in the past 3 months; Uncontrolled hyperlipidemia (LDL>160) in the past 6 months; Pregnant or nursing.
89363756|NCT02468986||Healthy Controls|18-75 years old. Excluding: Insulin dependent diabetes; Cardiovascular or Cerebrovascular disease (history of myocardial infarction, stroke, peripheral vascular disease); Tobacco use in the past 24 months; Uncontrolled hypertension (BP > 150/90) in the past 3 months; Uncontrolled hyperlipidemia (LDL>160) in the past 6 months; Pregnant or nursing.
89363757|NCT05058222|Active Comparator|Deep breathing ex (10 reps) Group|The control program will consist of Deep Breathing Exercises (from Morning to night every three hours; each session consisting of 10 deep breaths with a few seconds pause between each set, for 3 days) in addition with progressive Exercises.
89363758|NCT05058222|Experimental|Deep breathing ex (30 reps) Group|The intervention group will perform additional Deep breathing Exercises (from Morning to night every three hours; each session consisting of 30 deep breaths with a few seconds pause between each set, for 3 days).
89363759|NCT03302572|Experimental|Brief information group|Patients will be given brief information about the existence of advance directives after resolving the reason for the visit for which they had come. This information will not last more than 3 minutes and will not be repeated on successive visits within the recruitment period. Also, an informative triptych will be given to the patient so that he can read it at home. These leaflets have been made by the regional Department of Health. They will be advised that we can extend the information or help them to do the document in the near future if they want, we will inform that we would wait for the answer 3 months. In case of interest, they can leave their information in the User Service by specifying name, telephone number and reference doctor or ask for an appointment again.
89363760|NCT03302572|No Intervention|Control group|"Patients who fall into a control group will only be attended to their reason for visiting and will be asked for the necessary data to obtain the independent variables if they do not appear in their history. If the patient in this group wants the information, he will be excluded from the study because he refuses to participate."
89363761|NCT02467972|Experimental|UBF group|Ready-to-eat frozen soups added unripe banana flour (18 portions; 3 times/week)
89363762|NCT02467972|Placebo Comparator|Control|Ready-to-eat frozen soups added maltodextrin (18 portions; 3 times/week)
89363763|NCT02467972|Experimental|Inulin group|Ready-to-eat frozen soups added inulin (18 portions; 3 times/week)
89363764|NCT02467972|Experimental|Nisin group|Ready-to-eat frozen soups added nisin (18 portions; 3 times/week)
89363765|NCT03312322|Experimental|CWT with high-frequency electrical nerve stimulation|This study has a cross-over design. Patients will achieve CWT with either sham, high-frequency or low-frequency lumbar transcutaneous electrical nerve stimulation in a randomised order.
89363766|NCT03312322|Experimental|CWT with low-frequency electrical nerve stimulation|This study has a cross-over design. Patients will achieve CWT with either sham, high-frequency or low-frequency lumbar transcutaneous electrical nerve stimulation in a randomised order.
89363767|NCT03312322|Experimental|CWT with sham electrical nerve stimulation|This study has a cross-over design. Patients will achieve CWT with either sham, high-frequency or low-frequency lumbar transcutaneous electrical nerve stimulation in a randomised order.
89363768|NCT04543344|Experimental|Low Dose|Repeated multiple doses
89363769|NCT04543344|Placebo Comparator|placebo|Repeated multiple doses
89363770|NCT04543344|Experimental|High Dose|Repeated multiple doses
89363771|NCT03302338|Experimental|SAFE group|SAFE group: simulated amniotic fluid 20cc/kg/day enterally divided according to number of feds (syringe for every fed). This amount provides enteral 4.5μg rhG-CSF / kg/day and enteral 88IU rhEPO / kg/day.
89001336|NCT00580762|Experimental|ESRD|End-Stage Renal Disease (ESRD) patients on dialysis who meet the NIH guidelines and preoperative requirements for RYGB will undergo laparoscopic RYGB
89178388|NCT00833326|Experimental|ARRY-334543 + docetaxel + prophylactic growth factors|
89363772|NCT03302338|Placebo Comparator|Placebo|Placebo group: distilled water 2.5 ml/kg every 3 hours enterally given.
89363773|NCT01343784|Active Comparator|Standard Voiding Trial|Subjects in this group will undergo backfill-assisted voiding trial that involves infusing 300ml of fluid in the bladder, removing the catheter and allowing the patient to void. All subjects will be asked to use visual analog scale (VAS) to assess their force of stream (FOS) and the voided amount as well as post-void residual (PVR) (measured by the bladder ultrasound) will be measured and recorded. Subjects will be discharged without a catheter if the voided amount is more than 200ml, or 2/3rds of the infused volume (300ml).
89363774|NCT01343784|Experimental|Force of Stream Voiding Trial|Subjects in this group will undergo backfill-assisted voiding trial that involves infusing 300ml of fluid in the bladder, removing the catheter and allowing the patient to void. All subjects will be asked to use visual analog scale (VAS) to assess their force of stream (FOS) and the voided amount as well as post-void residual (PVR) (measured by the bladder ultrasound) will be measured and recorded. Subjects in the FOS group will be discharged home without a catheter if they are able to void any amount and report an FOS of at least 50% their typical FOS based on a visual analog scale
89363775|NCT03307096|Experimental|Microperc surgery|Patient is turned into prone position and the desired calyx is punctured by 4.8F microperc under fluoroscopic or sonographic guidance. No tract dilation is needed. A 200um holmium laser fiber will be used to break stone into less than 2mm. Pull out microperc without drainage tube left.
89363776|NCT03307096|Active Comparator|FURS|Patient is placed in the lithotomy position, pull out the pre-inserted double J, and place guidewire into the renal pelvis. A 12/14 Fr ureteral access sheath (UAS) is advanced into the proximal ureter over the guidewire, and flexible ureteroscope is passed through the UAS. The stones are fragmented smeller than 2mm using a 200um holmium laser fiber. Fragments are removed using a stone basket for stone analysis if necessary, a double J stent is placed at the conclusion of the procedure and removed post-operative 4 weeks.
89001337|NCT00580762|Active Comparator|Non-ESRD|Non-ESRD patients who meet the NIH guidelines and preoperative requirements for RYGB will undergo laparoscopic RYGB
89001338|NCT00209040|Experimental|1|Subjects with posttraumatic stress disorder
89001339|NCT00209040|Active Comparator|2|Healthy controls
89001340|NCT00209040|Active Comparator|3|Combat controls
89001341|NCT00580918||1|Mild Traumatic Brain Injury group
89001342|NCT00580918||2|Normal healthy control group
89001343|NCT00581035|Experimental|1|Prevenar and Meningitec
89001344|NCT00581035|Experimental|2|Prevenar
89001345|NCT00581035|Experimental|3|Meningitec
89001346|NCT00187317|Experimental|PERT|Perturbation-based balance training.
89001347|NCT00187317|Placebo Comparator|CON|Flexibility and relaxation training.
89001348|NCT04577560|Experimental|MII with PB biopsy|Five selected MII will undergo sequential polar biopsy; on day 0 [PB1] (36-42 hours post trigger injection) and if fertilization occurred on day 1 [PB2] (17-20 hours post ICSI). On day 5, 6 or 7, the resulting blastocyst will be biopsied.
89001349|NCT04577560|Experimental|MII with no PB biopsy|MII will not go under polar body biopsy. On day 5, 6 or 7, the resulting blastocyst will be biopsied.
89001350|NCT00581074|Active Comparator|G|grapefruit
89001351|NCT00581074|Active Comparator|J|Juice
89001352|NCT00581074|Placebo Comparator|W|placebo
89001353|NCT00581191|Experimental|1|0.5 mg SLV-351 (fasted)
89001354|NCT00581191|Experimental|2|1 mg SLV-351 (fasted)
89001355|NCT00581191|Experimental|3|2.5 mg SLV-351 (fasted)
89363777|NCT05250492|Experimental|Patients with PENG block|
89363778|NCT05250492|Active Comparator|Patients with intra-articular infiltration|
89363779|NCT04355364|Experimental|Experimental group|Dornase alfa will be administered by nebulization, at a dose of 2500 IU twice daily, 12 hours apart, for 7 consecutive days, using a vibrating mesh nebulizer. The remainder of the management will be performed in accordance with good practice, including mechanical ventilation (protective ventilation, PEEP > 5 cmH2O, tracheal balloon pressure checking every 4 hours or automatic device, 30° head of the bed elevation, tidal volume 6-8mL/kg, plateau pressure < 30cmH2O), neuromuscular blockers if necessary, prone position if PaO2/FiO2<150, early enteral nutrition, glycemic control, a sedation protocol based on the RASS score.
89363780|NCT04355364|Active Comparator|Control group|Patients will receive the usual care in accordance with good practice.
89001356|NCT00581191|Experimental|4|5 mg SLV-351 (fasted)
89001357|NCT00581191|Experimental|5|10 mg SLV-351 (fasted)
89001358|NCT00581191|Experimental|6|15 mg SLV-351 (fasted)
89001359|NCT00581191|Experimental|7|20 mg SLV-351 (fasted)
89001360|NCT00581191|Experimental|8|30 mg SLV-351 (fasted)
89001361|NCT00581191|Experimental|9|xx mg SLV-351 (fasted and fed)
89001362|NCT00187356|Experimental|Surgical Conduit|The surgical arm will be composed of the experimental arm (the use of the radial artery) versus an active comparator (the use of the saphenous vein graft).
89001363|NCT00581269|Active Comparator|1|low-impact aerobic exercise group
89001364|NCT00581269|Active Comparator|2|dietary restriction group
89001365|NCT00581269|No Intervention|3|control group
89001366|NCT00581425|Experimental|Treated|
89001367|NCT04577092|Active Comparator|Motor-Cognitive|"In 10-minute warm up period; neck flexion/extension/side flexion/circumflexion (clockwise and counterclockwise), rounding shoulder back and forth, circumflexion of arm back and forth, side flexion of trunk and rising on the fingertips. After warm up period; participants had been asked to count back from the two-digit number while performing; in standing position, straight walk, side walk, abduction/flexion/extension of hip and hip and knee flexion; in sitting position, hip flexion, knee extension, ankle dorsi - plantar flexion.~In 10-minute cool down period, stretching of quadriceps femoris muscle, hamstring muscle, achill tendon and cervical muscles were performed."
89001368|NCT04577092|Active Comparator|Motor-Motor|In 10-minute warm up period; neck flexion/extension/side flexion/circumflexion (clockwise and counterclockwise), rounding shoulder back and forth, circumflexion of arm back and forth, side flexion of trunk and rising on the fingertips. After warm up period; participants had been asked to hold with both hand half-filled glasses with 90 degree of flexion elbow and near the trunk while performing; in standing position, straight walk, side walk, abduction/flexion/extension of hip and hip and knee flexion; in sitting position, hip flexion, knee extension, ankle dorsi - plantar flexion. In cool down period, stretching of quadriceps femoris muscle, hamstring muscle, achill tendon and cervical muscles were performed.
89001369|NCT04577053|Experimental|PEMF Therapy|Pulsed ElectroMagnetic Field Therapy using square wave forms. In addition to set, pre-defined frequencies to aid the body's own immune system, the Artificial Intelligence incorporated into the software used will suggest a variety of frequencies to be administered during treatment. Due to the software's selection, these recommendations or selections from the software will likely be different in each treatment session.
89001370|NCT04577053|No Intervention|Control|Control group will not receive treatment.
89001371|NCT00581464|Active Comparator|1|
89001372|NCT00581464|Active Comparator|2|
89001373|NCT04577131|Experimental|With check-ins|Daily blood pressure monitoring with weekly check-ins
89001374|NCT04577131|No Intervention|Without check-ins|Daily blood pressure monitoring without weekly check-ins
89001375|NCT00209079|Active Comparator|1|
89178389|NCT00839176|Placebo Comparator|Placebo|Placebo (w/o API)
89178390|NCT00839176|Experimental|2|5mg dose of RX-10100
89178391|NCT00839176|Experimental|3|10mg dose of RX-10100
89363781|NCT03312244|Experimental|Pyridostigmine|Pyridostigmine 180mg/d slow-release formulation
89363782|NCT03312244|Placebo Comparator|Placebo|Placebo
89363783|NCT05250336||Patients with Primary Breast Cancer|"The pretherapeutic cores or specimen from patients who meet the following criteria were subjected for analysis~INCLUSION CRITERIA Primary Breast cancer Completed scheduled treatment at SGPGI Adequate quality histopathology material available in Department of Pathology archives With minimum 6 months follow up~EXCLUSION CRITERIA Insufficient data Incomplete treatment Insufficient follow up information Insufficient histological material for review"
89363784|NCT03306940|Placebo Comparator|unilateral injection group|Patients of unilateral group were injected botulinum toxin type A to the affected hemiface.
89363785|NCT03306940|Experimental|bilateral injection group|Patients of bilateral group were injected botulinum toxin type A to the affected hemiface and normal hemiface. The intervention of the bilateral group was that the normal side was injected.
89001376|NCT04576975|Experimental|Ketamine|This group will receive a bolus dose of Ketamine [Ketamine HCL - Sterop, Belgium] (0.3 mg/kg) by the ideal body weight diluted with 0.9% Normal Saline over 10 minutes by 20 ml syringe infused before induction. After which Ketamine infusion (500 mg vial diluted over 50 cc infusion syringe, concentration 10 mg/ml) will start with rate of 0.3 mg/kg/hr till 10 Minutes before the end of the surgery
89001377|NCT04576975|Experimental|Dexmedetomidine|This group will receive a bolus dose of Dexmedetomidine [Precedex® -Hospira, USA] (0.5 µcg/kg) by the ideal body weight diluted with 0.9% Normal Saline over 10 minutes by 20 ml syringe infused before induction. After which, the Dexmedetomidine infusion (200 µcg vial diluted over 50 cc infusion syringe, concentration 4 µcg/ml) will start with rate of 0.5 µcg/kg/hr till 10 Minutes before the end of the surgery
89001378|NCT04576975|Placebo Comparator|Normal Saline 0.9%|This group will receive a bolus dose of NS 0.9% over 10 minutes by 20 ml syringe infused before induction. After which, NS 0.9% (50 ml over 50 cc syringe) will be infused.
89001379|NCT03453073||chocolate consumption level referent|women who ate 1 oz. (28.35 g) of chocolate <1 time/month
89363786|NCT03302260|No Intervention|Control|Participants in the control arm will receive standard postpartum clinical care through the participants' usual healthcare providers. No intervention will be administered. Participants in both arms will receive educational material about the risk of CVD, and CVD prevention for women with HDP from the Preeclampsia Foundation.
89363787|NCT03302260|Experimental|CardioPrevent® Program|In addition to standard care, participants randomized to the intervention arm will also receive the CardioPrevent® Program. This is a 1-year, evidence-based behaviour change lifestyle program that consists of 25 contacts (in person, by phone and in groups) with a trained lifestyle counsellor to facilitate desired lifestyle behaviours within the participants' own social context. Participants in both arms will receive educational material about the risk of CVD, and CVD prevention for women with HDP from the Preeclampsia Foundation.
89001380|NCT03453073||chocolate consumption level 2|women who ate 1 oz. (28.35 g) of chocolate between 1 and <1.5 times/month
89001381|NCT03453073||chocolate consumption level 3|women who ate 1 oz. (28.35 g) of chocolate between 1.5 and <3.5 times/month,
89001382|NCT03453073||chocolate consumption level 4|women who ate 1 oz. (28.35 g) of chocolate between 3.5 times/month and <3 times/week
89001383|NCT03453073||chocolate consumption level 5|women who ate 1 oz. (28.35 g) of chocolate >3 times/week
89001384|NCT03453073||No physician diagnosis|No incidence of serious chronic disease prior to visit 3
89534610|NCT05232695||metabolically healthy obese individuals|Individuals who have a body mass index equal or higher than 30 kg/m2, no medication usage, who have only high waist circumference without any other metabolic syndrome criteria.
89001385|NCT03453073||Physician diagnosis|Incidence of serious chronic disease prior to visit 3
89001386|NCT03453073||Younger|Age<65 years at follow-up baseline
89001387|NCT03453073||Older|Age>=65 years at follow-up baseline
89001388|NCT00581620|Active Comparator|G1|G1: HIV+
89001389|NCT00581620|Active Comparator|G2|G2: Sicle Cell disease
89001390|NCT00581620|Active Comparator|G3|G3: neprotic symdrome
89001391|NCT00581620|Active Comparator|G4|G4: Chronic pulmonary disease
89001392|NCT00581659||Lens A, Lens B|The first independent variable is the contact lens. Each subject will wear both PureVision (TM0 aspheric contact lenses and conventional spherical contact lenses on separate visits. The second independent variable is visibility condition. Subjects will complete the study drive both in clear nighttime conditions and at night under glare conditions. In both cases, the driver will experience oncoming traffic; however, in the glare condition, the simulator will be equipped with a point light source sufficient to provide glare similar to that provided by oncoming traffic in the real world.
89001393|NCT00581698||Surgical|Patients with primary melanomas Clark III and Breslow thickness > 1 mm, or Clark IV-V and any Breslow thickness, and clinically negative regional nodes
89001394|NCT00581815|Experimental|1|
89001395|NCT00581932||A|One group, all subjects with DSM-IV diagnosis of Schizophrenia, age 18-65 who are initiating clozapine therapy.
89001396|NCT00582049||1|Cases: retinoblastoma patients
89001397|NCT00582049||2|Controls: first cousins or other blood relatives of the retinoblastoma patients (relative controls) or friends of the retinoblastoma patients or children of friends of the parents (friend controls).
89001398|NCT00582088|Experimental|Vaccine|VEE C-84 - Venezuelan Equine Encephalomyelitis Vaccine, Inactivated, Dried, C-84, TSI-GSD 205
89001399|NCT00209196||pediatric solid organ transplants|Adherence to medical regimens refers to what degree a patient chooses to follow the advice given by his/her healthcare provider.More recently, researchers have started to look at adherence with children who have undergone solid organ transplantation. This is because about 50% of these children are to some degree non-adherent with their medical regimen. This comes at a costly price as ongoing non-adherence in pediatric transplant can lead to the child's body rejecting the new organ and even death. This study has been designed to look at the reasons that pediatric patients may choose to be non-adherent.
89001400|NCT00582127||1|Mild-moderate Alzheimer's Disease
89001401|NCT00582127||2|Age-matched Controls
89001402|NCT00582244|Experimental|1|CBT and relaxation.
89001403|NCT00582244|Experimental|2|Physical activity
89001404|NCT00582244|Experimental|3|CBT and physical activity
89001405|NCT00582244|No Intervention|4|Control group
89363788|NCT03149328|Experimental|Northern Alberta Renal Program (NARP)|Provide in NARP (intervention group), 1) an electronic tool (ePRO) that facilitates real time PRO data collection and feedback in clinical practice, and 2) educational support to multidisciplinary home dialysis clinicians about how to use PROs routinely in their practice.
89363789|NCT03149328|No Intervention|Southern Alberta Renal Program (SARP)|In SARP (comparator group), clinicians will not receive PRO feedback or education sessions.
89363790|NCT03312166|Experimental|Compression device|
89363791|NCT00739050|Experimental|1|Arm 1: Drug
89363792|NCT00739050|Placebo Comparator|2|Arm 2: Placebo
89363793|NCT03302182|Experimental|fasting group|"During the study session, healthy subjects will be administered a single dose of Ritonavir Tablet 100mg or NORVIR tablet 100mg under fasting condition.~For group1:~cycle 1:Ritonavir Tablet 100mg cycle 2:NORVIR tablet 100mg~For group2:~cycle 1:NORVIR tablet 100mg cycle 2:Ritonavir Tablet 100mg"
89363794|NCT03302182|Experimental|Fed group|"During the study session, healthy subjects will be administered a single dose of Ritonavir Tablet 100mg or NORVIR tablet 100mg under fed condition.~For group3:~cycle 1:Ritonavir Tablet 100mg cycle 2:NORVIR tablet 100mg~For group4:~cycle 1:NORVIR tablet 100mg cycle 2:Ritonavir Tablet 100mg"
89363795|NCT01343862|Experimental|D- Cycloserine|
89363796|NCT01343862|Placebo Comparator|sugar pill|
89363797|NCT03311932|Active Comparator|Cortef® Tablets - fasted|Single dose of 20mg Cortef® Tablets - fasted arm
88834922|NCT03340805|Active Comparator|"0.9% normal saline fluid (NS)"|"0.9% normal saline (NS) fluid will be administered to patients randomized to the active comparator (control) arm. NS will be used for all fluid boluses and maintenance fluids (supplemental electrolytes are allowed) from time immediately after randomization through 11:59 pm of the next calender day. The determination of when to give fluid, how much fluid to give, how fast to give fluid, and what access to use to administer fluid will remain at the discretion of the treating team."
88834923|NCT03838484|Experimental|Healthy: placebo first, nicotine last|Healthy controls will apply placebo skin patch for up to two hours prior to behavioral and EEG task during the first visit in week 1. After a washout period, they will return and apply a nicotine patch (7 mg/24 hour dose) for up to two hours prior to behavioral and EEG task during the second visit in week 2.
88834924|NCT03838484|Experimental|Healthy: nicotine first, placebo last|Healthy controls will apply nicotine skin patch (7 mg/24 hour dose) for up to two hours prior to behavioral and EEG task during the first visit in week 1. After a washout period, they will return and apply a placebo patch for up to two hours prior to behavioral and EEG task during the second visit in week 2.
88834925|NCT03838484|Experimental|SCZ: placebo first, nicotine last|Subjects with schizophrenia (SCZ) will apply placebo skin patch for up to two hours prior to behavioral and EEG task during the first visit in week 1. After a washout period, they will return and apply a nicotine patch (7 mg/24 hour dose) for up to two hours prior to behavioral and EEG task during the second visit in week 2.
88834926|NCT03838484|Experimental|SCZ: nicotine first, placebo last|Subjects with schizophrenia (SCZ) will apply nicotine skin patch (7 mg/24 hour dose) for up to two hours prior to behavioral and EEG task during the first visit in week 1. After a washout period, they will return and apply a placebo patch for up to two hours prior to behavioral and EEG task during the second visit in week 2.
88834927|NCT02357173|Active Comparator|cigarette group|This group (1/3 of the sample) will not receive electronic cigarettes to sample and will continue smoking their regular cigarettes as much or as little as they would like.
88834928|NCT02357173|Experimental|electronic cigarette|This group (2/3 of the sample) will be given electronic cigarettes for a 3-week period, to use as much or as little as they would like.
88834929|NCT02357485|Experimental|Treatment arm|Single injection of ADSC
88834930|NCT05721872|Experimental|Combination of D-isoascorbic acid (D-VC) with arsenic trioxide (ATO)-Phase 1|"Participants will receive single intravenous administration as monotherapy of D-isoascorbic acid (D-VC) with dose escalation (0.05, 0.1, 0.2 g/kg/day) and with arsenic trioxide (ATO).~Patients who have satisfactorily tolerated the study drug in combination with arsenic trioxide (ATO) in a phase I study are transferred to a phase II clinical trial."
88834931|NCT05721872|Experimental|Combination of D-isoascorbic acid (D-VC) with arsenic trioxide (ATO)-Phase 2|After 2 hours of intravenous administration of arsenic trioxide (ATO) (at a dose of 0.15 mg / kg / day) participants will further receive D-isoascorbic acid (D-VC) intravenously once a day at the maximum tolerated dose, determined at the end of phase I.
89001406|NCT00582283|Other|Diagnostic: iodine I-124 NM404 CT/PET scan|Patients undergo iodine I-124 NM404 CT/PET scan at 1-2, 4-6, 24, and 48 hours and at 5-10 days.
89001407|NCT00209313|Other|1|Acyclovir 800 mg twice daily for 8 weeks, two week washout, 8 weeks placebo
89001408|NCT00209313|Other|2|8 weeks placebo, 2 week washout, 8 weeks 800 mg acyclovir twice daily
89363798|NCT03311932|Experimental|Infacort® - fasted|Single dose of 20mg Infacort® - fasted arm
89363799|NCT03311932|Active Comparator|Cortef® Tablets - fed|Single dose of 20mg Cortef® Tablets - fed arm
89363800|NCT03311932|Experimental|Infacort® - fed|Single dose of 20mg Infacort® - fed arm
89363801|NCT03311698|Experimental|Intervention|Households receiving the intervention will receive (1) Interventions to promote homestead food production, increase agricultural production and food diversity, (2) nutritional counselling, including locally adapted instructions on the mix and quantity of food suitable for children of ages 6-24 months, and (3) a health-focused intervention, including information on micronutrient supplementation, integrated management of child illnesses, and prevention and management of child malnutrition with a focus on the first 1,000 days.
89363802|NCT03311698|No Intervention|Control|Households receive the standard of care in the area for agricultural and health services.
89363803|NCT00604812|Experimental|Panel A Rizatriptan|"Subjects allocated to Panel A and randomized to receive a single dose of rizatriptan 5 mg orally disintegrating tablet (ODT) on Day 1.~Subjects weighing 20-39 kg were allocated to Panel A."
89363804|NCT00604812|Placebo Comparator|Panel A Placebo|"Subjects allocated to Panel A and randomized to receive a single dose of rizatriptan 5 mg orally disintegrating tablet (ODT) placebo on Day 1.~Subjects weighing 20-39 kg were allocated to Panel A."
89363805|NCT00604812|Experimental|Panel B Rizatriptan|"Subjects allocated to Panel B and randomized to receive a single dose of rizatriptan 10 mg orally disintegrating tablet (ODT) on Day 1.~Subjects weighing 40 kg and above were allocated to Panel B."
88834932|NCT05721872|Active Comparator|Standard therapy (FOLFOX/FOLFIRI)-Phase 2|"Drug: FOLFOX/FOLFIRI regimen FOLFOX - oxaliplatin 85mg/m2 1 day, Leucovorin 200mg/m2 IV 2h, 1, 2 days, 5 - Fluorouracil 400mg/m2 IV bolus, 1, 2 days, 5 - Fluorouracil 600mg/m2 IV 22h, 1, 2 days~FOLFIRI - Irinotecan 180 mg/m2 IV, Leucovorin 400 mg/m2 IV, Fluorouracil bolus 400 mg/m2 IV, Fluorouracil infusional 2400 mg/m2 IV. Courses are held every 2 weeks"
88834933|NCT02408965|Experimental|methergine|Methergine group 0.2 mg of methylergonovine maleate single injection when manual cervical dilation begins the day before the procedure
88834934|NCT02408965|Placebo Comparator|saline placebo|Placebo group saline single injection when manual cervical dilation begins the day before the procedure
88834935|NCT02409277|Experimental|Standard e-AT Intervention|Patients in Standard e-AT or standard intervention group will receive a daily (if a participant forgets to complete his/her weekly assessment) email and text reminders with a link to the e-AT website to help patient/parent participants to comply with their weekly assessment of patient's level of asthma control. Note: patient/parent participants are required to complete their asthma control assessment 1x/week. The e-AT is now set up to send a weekly reminder to participants with a link to the website. If a participant does not complete an assessment within a week of the last assessment, the reminder will be sent daily until the patient/parent complies and the system resets to weekly.
88834936|NCT02409277|Experimental|Intensive e-AT Intervention|Participants in the intensive e-AT or adherence support intervention will receive everything as those in Standard Intervention. In addition, they will see a progress bar display, which adds 25 points each time they complete an assessment. When this bar reaches 100 points, a pop-up message with fireworks will appear to congratulate them about the milestone. The progress bar resets to zero after it reaches 100 points. Participants will also see a leader board allowing them to compare themselves with the 5 best users to increase compliance.
88834937|NCT02409277|No Intervention|Usual Care (Non-Randomized Cohort)|Both arms (Intensive and standard e-AT interventions) will be compared to each other as well as to a non-randomized cohort who did not receive the e-AT interventions. These non-randomized cohort will be matched 2:1 to each randomized individuals.
88834938|NCT02410291|Experimental|Experimental group|Patients will receive the standard are to prepare them for their planning CT scan. They will be presented with the flyer that will be developed based on information about the importance of rectal and bladder preparation that is currently provided to patients and will also watch a youtube video on how to prepare for their CT simulation appointment. A few days before the CT planning appointment, patients in this group will be called by the radiation therapist or RA, reminding them about the rectal preparation for the appointment. Each patient will also be reminded to watch the instructional video on YouTube. Patients will be asked not to share the video link with other patients during the study.
88834939|NCT02410291|No Intervention|Control group|Patients in this group will receive the standard care to prepare them for their planning CT scan. They will be presented with the flyer at the consultation. A few days before the CT appointment, patients in this group will also be called and reminded about the required preparations, but will not be told about the video. In addition to the statistics about patient preparedness collected by the radiation therapist conducting the CT scan and stored and secured in an OCC Pinnacle planning system, we will also evaluate: patients' satisfaction with the preparation instructions, their knowledge (knowledge questionnaire) about the video content and importance of understanding the rectal emptying procedures, and radiation therapists' satisfaction with patients' rectal preparation.
88834940|NCT02411461||Pseudohypoparathyroidism type 1a|Study group
88834941|NCT02411461||Healthy siblings|Control group
88834942|NCT02411461||Obese patients|Control group
88834943|NCT03216356|Experimental|CBT + ImRs + DCS pill|The experimental arm involves cognitive-behavioral therapy, imagery rescripting techniques and d-cycloserine medication (pill).
88834944|NCT03216356|Active Comparator|CBT + ImRs + placebo|The active comparator arm involves cognitive behavioral therapy, imagery rescripting techniques and placebo medication (pill).
88834945|NCT03216356|Active Comparator|CBT + I.E. + study pill|The placebo comparator involves cognitive behavioral therapy, imaginal exposure and study pill (DCS or placebo)
88834946|NCT03330275|Experimental|Test/Control 1/Control 2|Subjects will be randomized to 1 of 3 lenses (Test/Control 1/Control 2). Subjects will also be randomized to (1) Sequence of driving time (Day and Night) and (2) Driving Route (A, B, C). Hazard and pedestrian locations will be randomized for each driving route.
88834947|NCT03330275|Experimental|Test/Control 2/Control 1|Subjects will be randomized to 1 of 3 lenses (Test/Control 2/Control 1). Subjects will also be randomized to (1) Sequence of driving time (Day and Night) and (2) Driving Route (A, B, C). Hazard and pedestrian locations will be randomized for each driving route.
88834948|NCT03330275|Experimental|Control 1/Test/Control 2|Subjects will be randomized to 1 of 3 lenses (Control 1/Test/Control 2). Subjects will also be randomized to (1) Sequence of driving time (Day and Night) and (2) Driving Route (A, B, C). Hazard and pedestrian locations will be randomized for each driving route.
89363806|NCT00604812|Placebo Comparator|Panel B Placebo|"Subjects allocated to Panel B and randomized to receive a single dose of rizatriptan 10 mg orally disintegrating tablet (ODT) placebo on Day 1.~Subjects weighing 40 kg and above were allocated to Panel B."
88834949|NCT03330275|Experimental|Control 1/Control 2/Test|Subjects will be randomized to 1 of 3 lenses (Control 1/Control 2/Test). Subjects will also be randomized to (1) Sequence of driving time (Day and Night) and (2) Driving Route (A, B, C). Hazard and pedestrian locations will be randomized for each driving route.
89001409|NCT00582439|Other|1|Repair of Orthopaedic Trauma Fractures and Non-Unions
89178392|NCT00839176|Experimental|4|15 mg dose of RX-10100
89363807|NCT00604812|Experimental|Panel C Rizatriptan|"Subjects allocated to Panel C and randomized to receive a single dose of rizatriptan ODT on Day 1. Subjects in Panel C weighing 20-39 kg received a 5 mg dose and subjects weighing 40 kg and above received a 10 mg dose.~Panel C was added to the study by amendment to increase the number of male subjects in the 12-17 year old age group."
89363808|NCT00604812|Placebo Comparator|Panel C Placebo|"Subjects allocated to Panel C and randomized to receive a single dose of rizatriptan ODT placebo on Day 1. Subjects in Panel C weighing 20-39 kg received a 5 mg placebo dose and subjects weighing 40 kg and above received a 10 mg placebo dose.~Panel C was added to the study by amendment to increase the number of male subjects in the 12-17 year old age group."
89363809|NCT03302026|Experimental|Real-time neurofeedback training group|We propose to use rt-fMRI neurofeedback training to help smokers consciously modulate activation in areas related to cravings and self-control in order to improve control smoking urges. In this arm, participants will complete four sessions: an intake session and 3 neurofeedback scanning visits. The primary outcome is the ability to resist smoking during a validated smoking lapse paradigm. Secondary outcomes include changes in brain activity in areas related to craving and self-control, and self-reported craving for cigarettes.
88834950|NCT03330275|Experimental|Control 2/Test/Control 1|Subjects will be randomized to 1 of 3 lenses (Control 2/Test/Control 1). Subjects will also be randomized to (1) Sequence of driving time (Day and Night) and (2) Driving Route (A, B, C). Hazard and pedestrian locations will be randomized for each driving route.
89363810|NCT03302026|No Intervention|No-feedback control group|We propose to use rt-fMRI neurofeedback training to help smokers consciously modulate activation in areas related to cravings and self-control in order to improve control smoking urges. In the control group arm, participants will complete four sessions: an intake session and 3 scanning visits with no neurofeeback. The primary outcome is the ability to resist smoking during a validated smoking lapse paradigm. Secondary outcomes include changes in brain activity in areas related to craving and self-control, and self-reported craving for cigarettes.
89363811|NCT03301948|Experimental|Overfeed|Experimental trial where participants are provided with 50% higher energy intake than their estimated requirements on the first day of the trial.
89363812|NCT03301948|Experimental|Energy Balance|Experimental trial where participants are provided with an energy intake equal to their estimated requirements on the first day of the trial.
89363813|NCT04347408||Healthy Children|Healthy children of healthcare workers between 2 and 15 years of age
88834951|NCT03330275|Experimental|Control 2/Control 1/Test|Subjects will be randomized to 1 of 3 lenses (Control 2/Control 1/Test). Subjects will also be randomized to (1) Sequence of driving time (Day and Night) and (2) Driving Route (A, B, C). Hazard and pedestrian locations will be randomized for each driving route.
89363814|NCT04347408||Paediatric Multisystem Inflammatory Syndrome|Children admitted to hospital with Paediatric Multisystem Inflammatory Syndrome
88834952|NCT02411929|Experimental|Ertugliflozin|Period 1: Oral dose of 15 mg unlabeled ertugliflozin + intravenous (IV) dose of 100 µg 14^C-labeled ertugliflozin containing approximately 400 nCi 14^C. The 14^C IV dose will be administered as an infusion over approximately 5 minutes starting at 55 minutes after the unlabeled oral dose. → Period 2: Oral dose 15 mg unlabeled ertugliflozin + oral dose of 100 µg 14^C-labeled ertugliflozin containing approximately 400 nCi 14^C. Both the unlabeled and 14^C-ertugliflozin will be administered at the same time (no more than 5 minutes apart). Dosing in Periods 1 and 2 will be separated by a washout of at least 11 days.
88834953|NCT05715554|Experimental|Homeopathy Group|Individualized Homeopathy Treatment provided by homeopathic physicians
88834954|NCT05715554|No Intervention|Standard Group|Usual care provided by primary care physicians were followed by patients in the standard group
88834955|NCT02358889|Experimental|hI-con1|Patients will receive monthly intravitreal hI-con1 as monotherapy (plus sham injection) for the first 2 months followed by monthly treatment for 3 months, as needed, according to protocol criteria.
88834956|NCT02358889|Experimental|hI-con1 + ranibizumab|Patients will receive monthly intravitreal hI-con1 in combination with intravitreal ranibizumab for the first 2 months followed by monthly treatment for 3 months, as needed, according to protocol criteria.
88834957|NCT02358889|Active Comparator|ranibizumab|Patients will receive monthly intravitreal ranibizumab as monotherapy (plus sham injection) for the first 2 months followed by monthly treatment for 3 months, as needed, according to protocol criteria.
88834958|NCT02978924|Active Comparator|Cathodal tsDCS|20 min of active treatment
88834959|NCT02978924|Sham Comparator|Sham tsDCS|20 min of sham treatment
88834960|NCT03524365|Active Comparator|RYGB plus LM counselling|96 subjects with NASH
88834961|NCT03524365|Active Comparator|SG plus LM counselling|96 subjects with NASH
88834962|NCT03524365|Sham Comparator|ILM|96 subjects with NASH
88834963|NCT05715476|Active Comparator|sea levelaltitude|Pregnant women living in Giresun(sea levelaltitude),Turkey and undergoing cesarean section under elective conditions.
88834964|NCT05715476|Active Comparator|moderate altitude|Pregnant women living in Çorum(moderate altitude),Turkey and undergoing cesarean section under elective conditions.
89363815|NCT04347408||Serious Infection|Children admitted to hospital with serious infections
89363816|NCT03301870|Experimental|ATx201 GEL, 2% - intact skin|ATx201 GEL, 2% applied intact skin
89363817|NCT03301870|Experimental|ATx201 GEL, 4% - intact skin|ATx201 GEL, 4% applied to intact skin
88834965|NCT05715476|Active Comparator|high altitude|Pregnant women living in Van(high altitude),Turkey and undergoing cesarean section under elective conditions.
88834966|NCT03499327|Active Comparator|Wheat germ oil (UV treated)|Wheat germ oil (UV treated)
88834967|NCT03499327|Placebo Comparator|Wheat germ oil (untreated)|Wheat germ oil (untreated)
88834968|NCT03499327|No Intervention|Control|no study products
88834969|NCT05715398|Experimental|BR790+anlotinib|BR790 will be administered orally, variable dose on Day 1 of each 21-day cycle, Anlotinib will be administered as PO fixed dose on Day1-14 of each 21-day cycle
89363818|NCT03301870|Experimental|ATx201 GEL, 2% - abraded skin|ATx201 GEL, 2% applied to abraded skin
89363819|NCT03301870|Experimental|ATx201 GEL, 4% - abraded skin|ATx201 GEL, 4% applied to abraded skin
89363820|NCT03301870|Placebo Comparator|ATx201 GEL Placebo - intact skin|ATx201 GEL Placebo applied to intact skin
89363821|NCT03301870|Placebo Comparator|ATx201 GEL Placebo - abraded skin|ATx201 GEL Placebo applied to abraded skin
89363822|NCT03301870|Active Comparator|Negative Irritant Control - intact skin|Negative (low) Irritant Control applied to intact skin
88834970|NCT03134690|Experimental|delayed start antagonist|60 women with poor ovarian responses undergo ovarian stimulation with delayed start antagonist.
88834971|NCT03134690|Experimental|conventional antagonist|60 women with diagnose of poor ovarian response will have undergone ovarian stimulation with conventional antagonist protocol.
88834972|NCT05721014|Experimental|OsteoStrong|Training following the OsteoStrong-method.
89178393|NCT00825292|Active Comparator|2|HDNBI colonoscopy followed by standard white light colonoscopy
89001410|NCT04576624|Experimental|Lifestyle Intervention|Subjects in the Lifestyle Intervention group will, in six months, receive sixteen group sessions and six individualized treatment sessions.
89363823|NCT03301870|Active Comparator|Negative Irritant Control - abraded skin|Negative (low) Irritant Control applied to abraded skin
89363824|NCT03301870|Active Comparator|Positive Irritant Control - intact skin|Positive (high) Irritant Control applied to intact skin
89363825|NCT03306628|Experimental|Early Laser Therapy|a group which will receive laser therapy to one breast incision at the first post-operative visit
89363826|NCT03306628|Experimental|Late Laser Therapy|a group which will receive laser therapy to one breast incision 6 weeks after surgery
89001411|NCT04576624|Sham Comparator|Social Activities|Social Activities Group will receive twenty-two group sessions
89001412|NCT04576624|No Intervention|Passive Control|Control group will receive patient education materials with each assessment
89001413|NCT00582634|Experimental|Docetaxel followed by cisplatin|Docetaxel (75mg/m2) given IV followed by cisplatin (75mg/m2) given IV on day 1 of a 21 day cycle. Both drugs will be administered intravenously over 1 hour each for 4 cycles.
89001414|NCT04723407||Exposed patients|Those who had the management strategy implemented by the service during confinement
89001415|NCT04723407||Unexposed patients|Those who could not benefit from this strategy
89001416|NCT00582673|Experimental|1|
89001417|NCT00582673|Placebo Comparator|2|
89001418|NCT04576780||Referred Patients with Large, Complex Colorectal Polyps|Patients referred from outside community care hospitals or ambulatory endoscopy centers to the therapeutic endoscopy group at St. Michaels Hospital via the new integrated management pathway for endoscopic resection of a large or complex colorectal polyp.
89001419|NCT04576858||Cohort 1: Surgical resection + perioperative chemotherapy|
89001420|NCT04576858||Cohort 2: Neoadjuvant chemoradiotherapy followed by surgery|
89001421|NCT04576858||Cohort 3: Definitive chemoradiotherapy|
89001422|NCT04576858||Cohort 4: Chemotherapy with the aim to prolong life expectancy|
89001423|NCT04576858||Cohort 5: Non-chemotherapeutic palliation|E.g. Palliative radiotherapy
89001424|NCT00582829||1|"Generic Print Intervention: The generic print intervention will consist of the pamphlet, Colorectal Cancer Screening Saves Lives published by the Center for Disease Control that will be mailed to the participant."
89178394|NCT00825292|Active Comparator|1|standard white light colonoscopy followed by HDNBI colonoscopy
89363827|NCT01343940|Experimental|Dulce family partner intervention|"Participating families are assigned to a legal/developmental specialist who joins health care team during well-child visits and home visits. The specialist (a Dulce family partner) supports parent around child development issues, addresses unmet basic needs (e.g., housing, utilities, food, etc.), and makes referral to existing agencies and services."
89534611|NCT05232695||metabolically unhealthy obese individuals|Individuals who have a body mass index equal or higher than 30 kg/m2, no medication usage, who have more than one metabolic syndrome criteria (as defined below) including high waist circumference.
88834973|NCT05721014|Active Comparator|Individually Adapted and Combined Physical Training|Training based on current recommendations on exercise for people with osteoporosis.
88834974|NCT05720858|Experimental|Hospital group|A total of 36 sessions (3 days a week) will be applied. Training intensity will be performed at the level of 4-6 according to the modified Borg scale, and rest will be allowed between exercises according to the tolerance of the patients. In the hospital-based group, a supervised aerobic exercise program will be applied in the hospital. There will be warm-up exercises before the exercise and cool-down exercises after. At the beginning of the session, warm-up exercises will begin. Flexibility exercises will be applied during the warm-up period. Warm-up and cool-down exercises will be performed for 10 minutes with 3 repetitions, including the upper and lower extremities and distal joints. Exercises will be performed for 3 months, with 10 repetitions in the first 6 weeks and 15 repetitions in the next 6 weeks.
88834975|NCT05720858|Experimental|Telerehabilitation group|"A total of 36 sessions (3 days a week) will be applied. Training intensity will be performed at the level of 4-6 according to the modified Borg scale, and rest will be allowed between exercises according to the tolerance of the patients. Supervised sessions will be held with the telerehabilitation group via phone or computer video conference (For patients who agree to participate, the physiotherapist will initially conduct the first session face-to-face).~There will be warm-up exercises before the exercise and cool-down exercises after. At the beginning of the session, warm-up exercises will begin. Flexibility exercises will be applied during the warm-up period. Warm-up and cool-down exercises will be performed for 10 minutes with 3 repetitions, including the upper and lower extremities and distal joints. Exercises will be performed for 3 months, with 10 repetitions in the first 6 weeks and 15 repetitions in the next 6 weeks."
88834976|NCT05720858|No Intervention|Control group|They will continue their routine activities. After the study, those who wish will be included in the exercise program.
88834977|NCT02839070|Experimental|Regular Schedule|Participant will be on a regular sleep/wake schedule
88834978|NCT02839070|Experimental|Irregular Schedule|Participant will be on an irregular sleep/wake schedule
88834979|NCT00358202|Active Comparator|1 cefepime|
88834980|NCT00358202|Active Comparator|2 ceftriaxone|
88834981|NCT02818400|Experimental|Composite tissue allotransplantation|
88834982|NCT05720234|Experimental|Treatment group|53 subjects will be enrolled with the indicated treatment dose of avatrombopag.
88834983|NCT02802566|Experimental|Investigative|This arm receives a standard prenatal (provided by the study) and a micronutrient supplement.
88834984|NCT02802566|Active Comparator|Control|Standard prenatal vitamin provided by the study
88834985|NCT03340883|Experimental|BION-1301|BION-1301 will be administered once every 2 weeks as an intravenous (IV) infusion.
88834986|NCT04142489|Other|UV and biopsy|"Minimum erythematous dose (DEM) will be calculated using a solar irradiator on the scalp (study area) and on a forearm (control area). On D2 (D1+24h) a solar irradiation corresponding to 2 DEM will be performed on a region of the scalp (studied area), as well as on a forearm (control area). A 3mm biopsy will be performed 15mn after irradiation in these 2 regions to study DNA damage. At D4 (D2+48h) a 2nd biopsy of 3 mm will be performed to study the repair of induced DNA damage. The study of DNA damage induced by UV will be done by immunohistochemical analysis of markers validated in previous studies: CPD=pyridine dimers, 6.4 PP= 6.4 photoproducts, and p53. Immunolabeling will be performed on skin biopsies collected 15 minutes after UV exposure and 48 hours after UV exposure."
88834987|NCT04736225|Experimental|ISTE Group|This program includes a 60-min small-group lesson, a 20-min individual instruction. The education program's goal is to teach patients to self-titrate their insulin doses every six days to maintain their six-day average blood glucose levels < 120 mg/dl
88834988|NCT04736225|Placebo Comparator|Non-ISTE Group|The usual care (a 15-min individual education) was giving at the Diabetes Health Education Center. They were taught how to self-inject insulin and test and record their before-breakfast and before-dinner blood glucose levels daily at home.
88834989|NCT04345172|Active Comparator|a lacrimal dilator group (Group LD)|The patients allocated to receive STB performed with a lacrimal dilator
88834990|NCT04345172|Active Comparator|a Wescott scissors (Group WS)|The patients allocated to receive STB performed with a Wescott scissors
88834991|NCT03341975|Experimental|Intervention|They will receive the same pamphlet as controls and the enhanced ED SexHealth intervention with the educator. Based on behaviors, CDS system recommendations (generated from screening survey responses only for intervention participants), and discussions, participants may be offered testing (for pregnancy, gonorrhea/chlamydia, and /or HIV), hormonal birth control, condoms, emergency contraception (for immediate or future use), treatment for previously diagnosed (yet untreated) infection with gonorrhea/chlamydia, and a scheduled appointment at Adolescent Clinic (for ongoing care, including repeat STI/HIV testing if needed). All services will be provided at point of care, costs will be covered by the study.
88834992|NCT03341975|No Intervention|Control|They will receive a printed health pamphlet and a list of local resources with the phone number for Adolescent Clinic. Participants will then be referred back to their ED provider, who will provide their standard care.
88834993|NCT04344704||DX devices with SMART headset detection enabled|The SMART detection algorithm is designed to, with the aid of atrial rhythm assessment, discriminate between ventricular tachycardias and a variety of supraventricular tachyarrhythmias for which device intervention is not required or desired
88834994|NCT04344704||DX device programmed in single chamber mode|"with the activation of one of the available discrimination criteria:~Onset: distinguishes slow onset or onset tachycardias from sudden onset~Stability: distinguishes between irregularly transmitted supraventricular tachycardias and ventricular tachycardias requiring therapy by continuous interval monitoring.~Morphmatch: helps to distinguish between supra and ventricular signals through analysis of episode QRS width"
88834995|NCT03344861|Experimental|Photodynamic therapy-Photofrin|Photodynamic therapy (PDT) involves the i.v. injection of porfimer sodium (Photofrin®) followed by illumination of the tumor using a fiber optic device during navigational bronchoscopy. Two days after the injection, the laser light will be applied to the tumor.
88834996|NCT05719922|Experimental|Low-load blood flow restriction training (LL-BFR)|Twice daily LL-BFR for 3 weeks
88834997|NCT05719922|Active Comparator|Heavier load resistance training (HL-RT)|Three sessions per week for 3 weeks
89363828|NCT01343940|Active Comparator|Safety intervention|Participating family is assigned a safety specialist who will provide the parent with guidance, equipment and instruction to reduce risk of newborn injury during transport (car seat) and while sleeping (Pack-and-Play).
89363829|NCT03306550|Active Comparator|aspirin arm|only take aspirin (100mg,qd) orally for 10 days treatment course
89363830|NCT03306550|Active Comparator|salvianolate injection arm|only inject salvianolate(200mg+5%Glucose Injection 250ml，iv) for 10 days treatment course
89363831|NCT03306550|Experimental|aspirin and salvianolate injection arm|take aspirin (100mg,qd) orally and inject salvianolate(200mg+5%Glucose Injection 250ml，iv) for 10 days treatment course
89363832|NCT03311620|Other|Endobronchial ultrasound transbronchial needle aspirate|
89363833|NCT02468362|Active Comparator|Laparoscopic group|
89363834|NCT02468362|Active Comparator|Open group|
89363835|NCT04507152|Experimental|Blood flow restriction resistance training|
89363836|NCT04507152|Active Comparator|Resistance training|
89363837|NCT02467660|Experimental|Online Mindfulness Meditation Training|Weekly 1-hr online training and daily meditation for 30-45 min for 6 wks
89363838|NCT02467660|Experimental|Online Health & Wellness Education|6-week training entails completing weekly 1-hour online training and listening to educational podcasts for 30-45 minutes per day
89363839|NCT02467660|No Intervention|Wait List Control|No training
88835000|NCT02978768|Experimental|Exercise|First year, the investigators investigate the effect of 12-week Tai Chi 6-Form accompanied with music rhythm for patients with mild and moderate AD in behavioral and general health, functional and cognitive decline.
88835001|NCT02978768|Experimental|Cognitive training|Second year, the investigators investigate the effect of 12-week computer-based cognitive training games for patients with mild and moderate AD in behavioral and general health, functional and cognitive decline.
88835002|NCT02978768|Experimental|Physico-Mental training|Third year, the investigators investigate the effect of 12-week Physico-Mental rehabilitation Wii (PM Wii) for patients with mild and moderate AD in behavioral and general health, functional and cognitive decline.
88835003|NCT03348683|Experimental|Propranolol|2mg of IV push
88835004|NCT03348683|Placebo Comparator|Placebo|an equivalent quantity in milliliters of normal saline
88835005|NCT04344782|Experimental|Bevacizumab|
88835006|NCT04344782|No Intervention|Standard of Care|
88835007|NCT05693480|Experimental|Intervention Group|Older adults with zero time of falls in the past twelve months will be treated as the reference group. Older adults with at least one time of falls in the past twelve months will use the device to assess their balance ability by attending three rounds of the tests.
88835008|NCT03946241||Pre-reform study populations|Children from 1st to 9th grade (n ~ 2,600) from four different school-based studies collecting objective physical activity data. The four studies are 1) The European Youth Heart Study (EYHS) conducted in 1997-98, 2003-04 and 2009-10, 2) When Cities Move Children (WCMC) conducted in 2010 and 2012, 3) Childhood Health, Activity, and Motor Performance School Study Denmark (CHAMPS-DK) conducted in 2009, 2010 and 2012, and 4) School site, Play Spot, Active transport, Club fitness and Environment (SPACE) conducted in 2010 and 2012. A total of 44 schools where included in the studies.
89001425|NCT00582829||2|Tailored Print Intervention: The tailored print intervention will consist of a cover letter detailing the participant's stage of readiness along with a color pamphlet with information personally tailored for the individual participant.
89178395|NCT00833404|Experimental|Smoking Cessation|8-week nicotine patch regimen
89178396|NCT00833404|No Intervention|Wait List Control|Smoking as usual
89178397|NCT00833716|Experimental|A|
89363840|NCT03311464|Experimental|Arm A|Participants receiving adalimumab for Pyoderma Gangrenosum active ulcer(s).
89363841|NCT05013840||Physicians using neuromodulation|
89363842|NCT03301480||No contraception/18-19 years old|
89363843|NCT03301480||Use of ENG-I/18 - 19 years old|
89363844|NCT03301480||LNG-IUS/18-19 years old|
89363845|NCT03301480||No Contraception/ 25 - 45 years old|
89363846|NCT03301480||Use of ENG-I/25 - 45 years old|
89363847|NCT03301480||LNG-IUS/25-45 years old|
89363848|NCT02468440|Experimental|ESPAIR|Patients with an educational therapy's program since registration in transplant list.
89363849|NCT02468440|No Intervention|normal care|Patients without educational therapy
89363850|NCT01317186||Group I|Stage 2 Non-diabetic Chronic Kidney Disease
89363851|NCT01317186||Group II|Stage 3 Non-diabetic Chronic Kidney Disease
89363852|NCT01317186||Group III|Stage 4 Non-diabetic Chronic Kidney Disease
89363853|NCT03306238|Active Comparator|Open/Hasson|This group will undergo initial laparoscopic port insertion by the open or Hasson approach and then undergo the remaining laparoscopic surgery as usual
89363854|NCT03306238|Active Comparator|Closed/ Veress|This group will undergo initial laparoscopic port insertion by the closed or Veress approach and then undergo the remaining laparoscopic surgery as usual
89363855|NCT05217030|Experimental|Animal Assisted Therapy|This group of patients with traumatic brain injury received AAT throughout the acute care hospitalization
89363856|NCT05217030|No Intervention|Control|This group of patients with traumatic brain injury did not receive AAT throughout the acute care hospitalization
89363857|NCT05214066|Experimental|4-day ATG combined regimen|ATG combined regimen for prophylaxis of GVHD, includes ATG, MMF (Mycophenolate mofetil), CsA (cyclosporin A) and MTX (methotrexate). All recipients in this arm received ATG, CsA, mycophenolate mofetil, and short-term methotrexate for GVHD prophylaxis. ATG (Thymoglobuline, rabbit) was used as 1 mg/kg/d from day -5 to day -3 and 2 mg/kg/d on day -2. CsA (3 mg/kg, q12h, i.v.) was used from day -9, and the concentration was adjusted to 180-200 ng/mL. CsA was switched to oral administration when the patient's bowel function recovered. From day -9, 0.5 g of mycophenolate mofetil was administered orally from every 12 h, which was withdrawn on day +30. After graft infusion, MTX was given for all patients at 15 mg/m2 on day +1 and 10 mg/m2 on days +3, +6 and +11.
89363858|NCT03306004||Health Care Providers|Providers answer questionaires
89363859|NCT03306004||Mothers|Mothers answer questionaires
89363860|NCT02468206|Active Comparator|BRTO|Balloon-occluded retrograde transvenous obliteration
89363861|NCT02468206|Active Comparator|NBCA|Endoscopic Cyanoacrylate injection in the gastric varix
89363862|NCT04502472|Experimental|Recipient of COVID-19 Convalescent Plasma (CCP) Transfusion|Patients hospitalized with COVID-19 infection with severe or life-threatening clinical syndrome and meet eligibility criteria
89363863|NCT03301402|Active Comparator|Filter|
89363864|NCT03301402|No Intervention|No filter|
89363865|NCT04969068|Experimental|The median effective dose of remimazolam for duodenoscopy insertion with alfentanil 10µg/kg|The first patient was tested at 0.2mg/kg remimazolam (0.025mg/kg as a step size).The response of the patients to the duodenoscopy insertion during ERCP was categorized as either 'success (no movement)' or 'failure (movement)'
89363866|NCT01344174|Other|glucocorticoids treatment|
89363867|NCT03301246|Experimental|Artimes Pro Low Profile Dilatation Catheter|Subjects who require initial pre-dilatation using the study device, and then undergo definitive therapy using additional PTCA catheters and stents, according to standard of care will be enrolled in this study.
89363868|NCT05162274|Experimental|Group 1|Participants first received lazertinib(G001) 240mg tablet morning in a fasting state for 1 day. After a washout period of 14~21days, they then received lazertinib(G002) 240mg in a fasting state morning for 1 day.
89363869|NCT05162274|Experimental|Group 2|Participants first received lazertinib(G002) 240mg tablet morning in a fasting state for 1 day. After a washout period of 14~21days, they then received lazertinib(G001) 240mg in a fasting state morning for 1 day.
89363870|NCT03023566||Dotarem Enhanced MRI|All pediatric patients (< 18 years) scheduled for clinically indicated contrast enhanced MRI (Brain MRI with/without contrast) will receive a single IV bolus injection of Dotarem at a dose of 0.1 mmol/kg bw at a flow rate of 1-2 mL/sec followed by saline flush (routine/ standard of care).
89363871|NCT04345302|Experimental|Brief motivational treatment|"Participants in the intervention group will receive the Brief Motivational Treatment, which is a primary care-adaptation of the Motivational Enhancement Therapy as manualized in the Project MATCH [19]. This treatment consists of four 45-minute sessions, provided by a psychologist at weeks one, two, six, and twelve. The first three sessions, occurring during the first six weeks, are more active regarding the behavioural change, while the last session functions as closure and review of the process. If a participant asks for more support, they will be able to attend up to two extra sessions before the last one.~The main adaptations are:~The translation into Chilean Spanish.~Update of Motivational Interview concepts.~Companion training material that includes a demonstrative video and practical exercises.~An adapted personalized feedback procedure.~Information on additional resources available in the primary care centre and the community."
89363872|NCT04345302|Active Comparator|Enhanced usual care|"All participants will receive an educational brochure on alcohol use disorder, with self-help materials and guides on how to get additional support.~The physicians within the PC centre will also receive information on how to diagnose alcohol use disorders, prescription guides for the medications that are available for treating these disorders in the PC centre (mainly Disulfiram and any other if available), and directions on when and where to refer clients for treatment."
89363873|NCT03301090|Experimental|Cohort A|REGN3048+REGN3051 3 mg/kg (1.5 mg/kg of each mAb) single infusion IV, n=6; placebo IV, n=2
89363874|NCT03301090|Experimental|Cohort B|REGN3048+REGN3051 10 mg/kg (5 mg/kg of each mAb) single infusion IV, n=6; placebo IV, n=2
89363875|NCT03301090|Experimental|Cohort C|REGN3048+REGN3051 30 mg/kg (15 mg/kg of each mAb) single infusion IV, n=6; placebo IV, n=2
89363876|NCT03301090|Experimental|Cohort D|REGN3048+REGN3051 50 mg/kg (25 mg/kg of each mAb) single infusion IV, n=6; placebo IV, n=2
89363877|NCT03301090|Experimental|Cohort E|REGN3048+REGN3051 100 mg/kg (50 mg/kg of each mAb) single infusion IV, n=6; placebo IV, n=2
89363878|NCT03301090|Experimental|Cohort F|REGN3048+REGN3051 150 mg/kg (75 mg/kg of each mAb) single infusion IV, n=6; placebo IV, n=2
89363879|NCT04342962|Experimental|Experimental arm|"12 mcg/kg/day of tagraxofusp for 5 days, for at least 4 cycles of therapy; each cycle is 21 days.~Patients will receive the study drug until disease progression or in case of toxicity."
89363880|NCT03300934|Experimental|closed loop glucose control system|Closed loop glucose control system
88835009|NCT03946241||Post-reform study population|Children from 1st to 9th grade in 2017-18 from the same schools as included in the pre-reform research studies (n ~ 2,600). Two of the pre-reform research studies (CHAMPS-DK and SPACE) introduced PA promoting initiatives as part of the study. To minimize any influence from participation in these interventions we chose only to include and recruit participants from control schools from these studies. A total of 36 schools where invited and 31 subsequently accepted to participate. Parents and teachers of the children were included as well.
88835010|NCT03835910|Experimental|Social Incentives and Gamification, Corticosteroid AB|"Participants will receive a support person and be able to interact with a web-based platform to progress through levels based on their achievement of step goals.~The participants will receive injections in A-B order (corticosteroids, then lidocaine only)"
88835011|NCT03835910|Active Comparator|No Incentive, Corticosteroid AB|"Participants will only receive reminders to sync their activity monitor.~The participants will receive injections in A-B order (corticosteroids, then lidocaine only)"
88835012|NCT03835910|Experimental|Social Incentives and Gamification, Corticosteroid BA|"Participants will receive a support person and be able to interact with a web-based platform to progress through levels based on their achievement of step goals.~The participants will receive injections in B-A order (lidocaine only, then corticosteroids)"
88835013|NCT03835910|Active Comparator|No Incentive, Corticosteroid BA|"Participants will only receive reminders to sync their activity monitor.~The participants will receive injections in B-A order (lidocaine only, then corticosteroids)"
88835014|NCT03351101|Experimental|Senofilcon C|Senofilcon C Contact Lens
88835015|NCT03351101|Experimental|Samfilcon A|Samfilcon A Contact Lens
88835016|NCT00357188|Active Comparator|A|
88835017|NCT00357188|Active Comparator|B|
89001426|NCT00582829||3|Tailored print plus tailored phone intervention: The tailored print plus tailored telephone intervention will consist of a phone counseling session and the tailored print information described above. The tailored print material will serve as a guide during the telephone counseling contact and a reinforcement of the information.
89363881|NCT03300934|No Intervention|CSII Pump treatment|CSII Pump treatment without the integrated algorithm and glucose sensor
89363882|NCT04321044|Other|Renal Denervation|We attempt to identify predictors of blood pressure response to renal denervation by using a GWAS (Genome wide association study) approch
88835018|NCT03223337|Experimental|Subjects with moderate hepatic impairment: Part 1|Approximately 8 subjects with moderate hepatic impairment will receive 6 mg of daprodustat as a single oral dose in the fasted state. This group will include at least one subject with a Child-Pugh score of 7, one with a score of 8 and one with a score of 9. The group will also include at least one female and at least one male subject.
89363883|NCT03300856||Chart Review|Existing records of patients within the NINDS database who have had TMS performed to measure central motor conduction time (CMCT).
89363884|NCT01344330||Screening colonoscopy patients|Men and women age 50 to 75 scheduled for screening colonoscopy
89363885|NCT03300778|Experimental|aerobic exercise|Running at the intensity of 50%-70% of maximum heart rate (220-age) for 30 mins per day, 4 days per week, last for 3 months
89363886|NCT03300778|Placebo Comparator|Placebo controlled group|6 sections of group activities: 3 sections of general psychological education; one section of group game, one section of group poetry reading activity, group singing entertainment.
89363887|NCT05117190|Other|Facial Deformity|Face not the normal shape because of injury or illness.
89363888|NCT04490746||active|patients with active tuberculosis
89363889|NCT04490746||latent|patients with latent tuberculosis infection
89363890|NCT04490746||negtive control|healthy volunteers
88835019|NCT03223337|Active Comparator|Matched Healthy controls: Part 1|Approximately 8 healthy controls, matched in gender, age and BMI to subjects with moderate hepatic impairment, will receive 6 mg of daprodustat as a single oral dose in the fasted state. The group will include at least one female and at least one male subject.
88835020|NCT03223337|Experimental|Subjects with either mild or severe hepatic impairment: Part 2|Approximately 8 subjects with mild or severe hepatic impairment will receive 6 mg of daprodustat as a single oral dose in the fasted state. This group will include at least one subject with a Child-Pugh score of 5 and one with a score of 6 for mild hepatic impairment and at least one subject with a Child-Pugh score of 10 or 11 and one with a score of 12 or 13 for severe hepatic impairment. The group will also include at least one female and at least one male subject.
89363891|NCT03311386||Patients in AIS receiving actilyse|the patients will receive actilyse intaravenously in a dose of 0.9mg/kg once
89363892|NCT03620448|Experimental|bCPAP Arm.|"Babies randomized to receive bCPAP were started (by principle investigator assisted by a clinician) on bCPAP (Rice 360◦c low cost bCPAP device) consisting of 3 components:~(i) An oxygen concentrator with a gas flow fate of 3-4L/min, (ii) A nasal interface (short nasal prongs) connecting the baby's airway to a two limb circuit i.e the inspiratory limb connected to the bCPAP machine and the expiratory limb connected to the water bottle and (iii) An expiratory limb with the distal end submerged 6cm in water to generate an end expiratory pressure as seen in appendix 7. adopted from suppliers of the pumani bCPAP machine in Kenya."
89363893|NCT03620448|Other|Oxygen Arm|Preterms on the control arm and those whose parents didn't consent received the standard treatment for RDS i.e pure oxygen via nasal prongs from the oxygen cylinders.
89363894|NCT01343238|Experimental|Diet|12 week diet modification intervention by dietician
89363895|NCT01343238|Experimental|Exercise|12 week physical exercise modification intervention by physical therapist
89363896|NCT01343238|Experimental|Diet and Exercise|12 week diet and exercise behavioral modification by dietician and physical therapist
89363897|NCT01343238|No Intervention|Control|Standard procedure
89363898|NCT04343040|Experimental|perioperative glucose intake|glucose intolerant patients with perioperative glucose (carbohydrate supplement (Preload™) intake before Gastric By-Pass or Sleeve Gastrectomy.
89363899|NCT04343040|Sham Comparator|6 hours of preoperative fasting|glucose intolerant patients receiving 6 hours of preoperative fasting before Gastric By-Pass or Sleeve Gastrectomy.
89363900|NCT03305692|Experimental|ECG Belt|Use ECG Belt body surface mapping system to optimize CRT programming.
88835021|NCT03223337|Active Comparator|Matched healthy controls: Part 2|Approximately 8 healthy controls, matched in gender, age and BMI to subjects with mild or severe hepatic impairment, will receive 6 mg of daprodustat as a single oral dose in the fasted state. The group will include at least one female and at least one male subject.
88835022|NCT03834974|Experimental|Sun Safety Social Media Challenge|During this 4-week intervention, participants will be incentivized to create sun safety social media messages that will be distributed on our sun safety Twitter and Facebook feeds.
88835023|NCT03834974|Active Comparator|Digital Health Social Media Challenge|During this 4-week intervention, participants will be incentivized to create posts that promote the use of technology to engage in healthy lifestyle behaviors (diet, exercise) on our digital health Twitter and Facebook feeds.
88835024|NCT03223649|Experimental|Sedentary|(Control intervention) Six daily 3 hour sessions with no physical activity (i.e. subject remains sedentary in seated or recumbent position) throughout the 3 hour duration.
89363901|NCT03305692|Experimental|Echocardiography|Use mitral inflow echocardiography to optimize CRT programming.
89363902|NCT01343316||Transgastric tube|Nasogastric (NG tube)
89363903|NCT01343316||Transpyloric tube - Tiger2|Self-propelled by paristaltic waves of the stomach
89363904|NCT01343316||Transpyloric tube - Syncro BlueTube|Magnetically placed
89363905|NCT02468908|Experimental|Molgramostim nebuliser solution, inhaled|Single dose 150, 300 and 600 ug, multiple dose 300 and 600 ug for 6 days
89363906|NCT02468908|Placebo Comparator|Nebuliser solution, inhaled|Inhaled nebuliser solution
89363907|NCT01344408|Experimental|Computer-training|The computer-training program, Move it to improve it was installed in the participants homes using an internet-connected computer with a web camera connected to a cloud-based specifically adapted interactive training program.
89363908|NCT01344408|Experimental|Printed instructions|A training program delivered as printed instructions
89363909|NCT02468128|Experimental|SDE 150mg|Single dose, intramuscular, Sebacoyl Dinalbuphine Ester injection 150 mg (2 ml)
89363910|NCT02468128|Placebo Comparator|placebo|Single dose, intramuscular , Sebacoyl Dinalbuphine Ester placebo injection (2mL)
89363911|NCT03305536|Active Comparator|Interventional|1000 mcg/day of Vitamin K2 + 5000 IU/day Vitamin D3 as a treatment to decalcifiy the valve
89363912|NCT03305536|Active Comparator|interventional|5000 IU/day of Vitamin D3 will be given to measure the progression of the disease along the time of the study
89363913|NCT01344486|Experimental|Full conditioing|Intervention by alteration of laparoscopic gas with addition of oxygen and nitrous oxide, regulation of humidification and temperature (32°C), injection of 5mg Dexamethasone and application of Hyalobarrier Gel Endo (Nordic Pharma) at the surgical wound
89363914|NCT01344486|Active Comparator|carbon dioxide|induction pneumoperitoneum with carbon dioxide 100%
89363915|NCT01343472|Experimental|WISP supervision|Parolee supervised under WISP parole model.
89363916|NCT01343472|Active Comparator|Parole-as-usual|Parolees supervised under Washington State's parole-as-usual
89363917|NCT02467816|Experimental|School lunch intervention|Intervention schools (6 middle and 6 high) will receive the complete school lunch intervention for two school years.
89363918|NCT02467816|No Intervention|School lunch control|Control schools (6 middle and 6 high) will not receive the school lunch intervention for two school years. Lunch delivery will proceed as normal.
89363919|NCT01316406|Experimental|ATH008 cream 3%|ATH008 cream 3%
89363920|NCT01316406|Experimental|ATH008 cream 8%|ATH008 cream 8%
89363921|NCT01316406|Placebo Comparator|ATH008 cream placebo|ATH008 cream placebo
89363922|NCT02467426||Chemotherapy|intraarterial chemotherapy with cisplatin and mitoxantrone
89363923|NCT03300388|Placebo Comparator|Control|Dietary advice for a healthy diet supplemented with placebo (olive oil).
89363924|NCT03300388|Experimental|Omega-3|Dietary advice for a healthy diet supplemented with DHA-rich dietary supplement (providing 1.650 mg/day of DHA).
89363925|NCT03300388|Experimental|Resistance Training|Dietary advice for a healthy diet supplemented with placebo (olive oil) and moderate resistance training program.
89363926|NCT03300388|Experimental|Omega-3 + Resistance Training|Dietary advice for a healthy diet supplemented with a DHA-rich dietary supplement (providing 1.650 mg/day of DHA) and moderate resistance training program.
89363927|NCT02467348|Experimental|Albumin|MVP (Modest Volume Paracentesis) of less than 5 litres with intravenous albumin at a dose 8 gms/l of ascitic fluid.
89363928|NCT02467348|Active Comparator|No Albumin|MVP (Modest Volume Paracentesis) of less than 5 litres without albumin.
89363929|NCT04296942|Experimental|1/M7824 (Bintrafusp alfa) + Bavarian Nordic (BN)-Brachyury|"Arm 1 - Triple Negative Breast Cancer.~Bifunctional fusion molecule involving programmed death-ligand 1 (PD-L1) with transforming growth factor beta (TGF-b) sequestering agent added to a vaccine for the tumor associated antigen called brachyury."
89363930|NCT04296942|Experimental|2/M7824 + BN-Brachyury + Ado-trastuzumab emtansine (T-DM1)|"Arm 2 - Estrogen receptor (ER)-/progesterone receptor (PR)-/Human Epidermal Growth Factor Receptor 2 (HER2) + Breast Cancer.~Bifunctional fusion molecule involving programmed death-ligand 1 (PD-L1) with transforming growth factor beta (TGF-b) sequestering agent added to a vaccine for the tumor associated antigen called brachyury. These investigational agents will be added to standard of care treatment called Ado-trastuzumab emtansine (T-DM1)."
89363931|NCT04296942|Experimental|3/M7824 + BN-Brachyury + T-DM1 + Entinostat|"Estrogen receptor (ER)-/progesterone receptor (PR)-/Human Epidermal Growth Factor Receptor 2 (HER2)+ Breast Cancer.~Bifunctional fusion molecule involving programmed death-ligand 1 (PD-L1) with transforming growth factor beta (TGF-b) sequestering agent added to a vaccine for the tumor associated antigen called brachyury as well as to an oral histone deacetylase (HDAC) inhibitor called entinostat. These investigational agents will be added to standard of care treatment called Ado-trastuzumab emtansine (T-DM1). (T-DM1)."
89363932|NCT02468050|Experimental|Self Management|In addition to the weekly supervised exercise session, participants in this arm will view an instructional video. The video will deliver theory driven training of cognitive behavioural strategies for self management of exercise. It is expected that this will improve adherence to the exercise program.
89363933|NCT02468050|Experimental|Exercise|Personalized 6 week moderate intensity (50 - 75% of heart rate reserve) facility and home based exercise program including cardiovascular and muscular conditioning.
89363934|NCT02468050|No Intervention|Prospective Cohort Control|Eligible, consented participants who are unable to attend the weekly exercise sessions will serve as a cohort control group. Participants will be asked to complete patient reported measures of anxiety, depression, and exercise behaviour within 3 days of biopsy, and 6 weeks post biopsy.
89363935|NCT04442620|Experimental|1st group: Physical Activity and Mediterranean Diet (PA-MD)|"A first group of participants will be advised to reduce their caloric intake by 25-30% with a macronutrients distribution of 35-40% fat, 20% proteins, and 40-45% carbohydrates. Healthy fats (a maximum of 8-10% from saturated fats, >20% from monounsaturated fats, >10% from polyunsaturated fats and <300 mg/day of cholesterol) and low glycaemic index foods rich in fibre (not less than 30-35g /day) are strongly advised, together with foods rich in antioxidants, namely fruits and vegetables. Such diet reflects the traditional Mediterranean Diet described in the PREDIMED (Primary Prevention of Cardiovascular Disease with a Mediterranean Diet)-Plus study.~As for physical activity, patients the participants will be recommended a 35 minutes interval training session three times a week. Physical activity sessions of 35 minutes will consist of 5 minutes warm-up, 20 minutes interval training, and 10 minutes breathing and stretching."
89363936|NCT04442620|Experimental|2nd group: High Meal Frequency of Mediterranean Diet (HMF-MD)|A second group of participants will be advised to reduce their caloric intake by 25-30% with a macronutrients distribution of 30-35% fat, 25% proteins, and 40-45% carbohydrates. Healthy fats and low glycaemic index foods will be strongly advised, together with foods rich in antioxidants, namely fruits and vegetables. Participants will be advised to consume 7 meals a day, gradually reducing the caloric content at each main meal, and to walk 10.000 steps a day.
89363937|NCT04442620|Active Comparator|3rd group: Control diet (CD)|A third group of participants will be advised to reduce their caloric intake by 25-30% with a macronutrients distribution of 30% fat, 15% proteins, and 55% carbohydrates, and maintain an adequate fibre (25g/day) and cholesterol (<250mg/day) intake. Meal frequency will be of 3-5 meals a day. Moreover, the participants will be advised to walk 10.000 steps a day.
89363938|NCT01343550|Experimental|Creativity group for persons diagnosed with BPD|
89363939|NCT03305380||Patients with a pulmonary event|(under anti-PD1 or anti-PD-L1) This is the first group of the retrospective part of the study.
89363940|NCT03305380||Patients without a pulmonary event|(under anti-PD1 or anti-PD-L1) This is the second group of the retrospective part of the study.
89001427|NCT00582868||Hemorrhage|Patients having experienced subarachnoid hemorrhage and have in place a ventriculostomy
89001428|NCT00187551|Experimental|interruption of enfuvirtide|enfuvirtide interruption
89363941|NCT01344564|Other|ADT|All subjects receive ADT, degarelix acetate for 3 months followed by one 3 month leuprolide depot.
89363942|NCT04894812|Active Comparator|Group A|Neurodevelopmental Treatment. Total duration of treatment will be 20 minutes, 3 sessions per for 3 months
89363943|NCT04894812|Experimental|Group B|Neurodevelopmental Technique and Vestibular stimulation. Total duration of treatment will be 50 minutes (20 min NDT+ 30 MIN VS) 3 sessions per week for 3 months.
89363944|NCT01344720|Active Comparator|etoricoxib|etoricoxib up to 60mg/day as monotherapy
89363945|NCT01344720|Active Comparator|etoricoxib plus controlled-release oxycodone|combination treatment of etoricoxib (30 mg/day) plus controlled-release oxycodone (10 mg/day)
89363946|NCT04442230|Experimental|NasoVAX|Participants will receive a single intranasal dose of NasoVAX on Day 1 (enrollment).
89363947|NCT04442230|Placebo Comparator|Placebo|Participants will receive a single intranasal dose of placebo on Day 1 (enrollment).
89363948|NCT04921098|Experimental|Refractory glaucoma|
89363949|NCT04442542|Experimental|Respiratory exercises plus method JaPer|Respiratory exercises plus the new intervention protocol with an inspirometer (JaPer Method)
89363950|NCT04442542|Active Comparator|Protocol of use of inspirometer in a conventional way|Respiratory exercises plus conventional use of the inspirometer.
89363951|NCT04246788|Experimental|Cohort 1 : experimental group|5 sessions per week of 30 minutes of robot-assisted rehabilitation with the G-EO system during two weeks
89363952|NCT04246788|Active Comparator|Cohort 2 : controle group|3 sessions per week of 30 minutes of classical physiotherapy during two weeks
89363953|NCT05727982||NSTEMI patients|Patients no ST-segment elevation myocardial infarction (NSTEMI)
89363954|NCT05727982||SA patients|Patients with Stable Angina (SA) diagnosis
89363955|NCT05727982||MVD patients|Patients with consecutive Mitral Valve Disease patients (MVD)
89363956|NCT03220854|Experimental|A: SBRT (body) irradiation only|Patients will receive a standard treatment regimen of SRT (refer to Section 6.3). The term SRT encompasses all radiotherapy using a stereotactic setup, both stereotactic radiosurgery (SRS) for metastatic lesions in the brain and stereotactic body radiotherapy (SBRT) for SRT delivered to all other locations
89363957|NCT03220854|Experimental|B: Patients receiving SBRT and SRS (body and brain) irradiation|Patients will receive a standard treatment regimen of SRT (refer to Section 6.3). The term SRT encompasses all radiotherapy using a stereotactic setup, both stereotactic radiosurgery (SRS) for metastatic lesions in the brain and stereotactic body radiotherapy (SBRT) for SRT delivered to all other locations
89363958|NCT03220854|Experimental|C: Patients receiving SRS (brain) irradiation only|Patients will receive a standard treatment regimen of SRT (refer to Section 6.3). The term SRT encompasses all radiotherapy using a stereotactic setup, both stereotactic radiosurgery (SRS) for metastatic lesions in the brain and stereotactic body radiotherapy (SBRT) for SRT delivered to all other locations
89363959|NCT02467894|Experimental|Group-based Care|Participants who are randomized to group-based care will attend monthly outpatient clinic visits as part of a group of 8-10 patients with CKD and hypertension.
89363960|NCT02467894|No Intervention|Usual Care|Participants who are randomized to usual care will see their provider on clinic days when there is no group meeting.
89363961|NCT03305224|Other|Ra-223 + Enzalutamide|
89363962|NCT03305068|Placebo Comparator|the use of a COX-II inhibitor in shoulder surgery.|Arm 1 shoulder replacement, both primary and reverse
89001429|NCT00181181|Active Comparator|Atorvastatin|Atorvastatin for 3 months
89001430|NCT00181181|Placebo Comparator|Placebo|
89001431|NCT04576468|Experimental|open flap debridement|envelope full thickness flap reflection, removal of granulation tissue then suturing with simple loop sutures.
89001432|NCT04576468|Experimental|perforated membrane (PM)|envelope full thickness flap reflection, removal of granulation tissue placing resorbable membrane after perforating it over the vertical defect then suturing with simple loop sutures.
89001433|NCT04576468|Experimental|leucocyte platelet rich fibrin (L-PRF)|envelope full thickness flap reflection, removal of granulation tissue after withdrawal of blood and placing it in intraspin centrifuge , placing the resulting L-PRF in the defect then suturing with simple loop sutures.
89001434|NCT04576468|Experimental|L-PRF + PM|envelope full thickness flap reflection, removal of granulation tissue after withdrawal of blood and placing it in intraspin centrifuge , placing the resulting L-PRF covered by resorbable membrane after perforating it in the defect then suturing with simple loop sutures.
89363963|NCT03305068|Placebo Comparator|the use of a COX-II inhibitor in arhroscopic shoulder surgery.|Arm 2 arthroscopic rotator cuff repair
89363964|NCT04242810|Active Comparator|Active rTMS|rTMS applied over memory task-based brain target
89363965|NCT04242810|Placebo Comparator|Sham rTMS|Sham rTMS applied over memory task-based brain target
89363966|NCT01317420|Experimental|Monotherapy|BI 836845 dose escalation, infusion, once every three weeks, monotherapy
89363967|NCT04490590|Experimental|Chidamide+ Etoposide capsule|"Chidamide: 30mg, twice a week(BIW), PO.~Etoposide capsule:50mg, quaque die （QD）, PO, d1-10，21days for one cycle. Patients receive the other treatment of chidamide and etoposide capsule, and those who have achieved PD(progressive disease) will give the other treatment."
89363968|NCT01344798|Experimental|Dose level 1|AAV1-gamma-sarcoglycan vector dose level: 3x10e9 vg/100µl
89363969|NCT01344798|Experimental|Dose level 2|AAV1-gamma-sarcoglycan vector dose level: 1.5x10e10 vg/100µl
89363970|NCT01344798|Experimental|Dose level 3|AAV1-gamma-sarcoglycan vector dose level: 4.5x10e10 vg/300µl
89363971|NCT03300154|Experimental|Financial incentives|
89363972|NCT03300154|Experimental|Framing (SMS)|
89363973|NCT03300154|No Intervention|Usual care|
89363974|NCT01317498|Placebo Comparator|Standard Monitoring|The patients in the standard monitoring arm will receive routine laboratory monitoring as provided to all patients in public HIV clinics in Vietnam, including CD4 count, complete blood count, and liver functions tests every 6 months.
89178398|NCT02549794|Active Comparator|High concentration (370)|CT angiography with hign concentration iodine contrast agent of 370 mg iodine/ml
89178399|NCT02549794|Experimental|Low concentration (320)|CT angiography with low concentration iodine contrast agent of 320 mg iodine/ml
89178400|NCT02549794|Experimental|Low concentration (270)|CT angiography with low concentration iodine contrast agent of 270 mg iodine/ml
89178401|NCT00825448|Experimental|2|patient in hospital a week before the date of surgery for the treatment of his addiction alcohol
89178402|NCT00825448|No Intervention|1|no treatment of his addiction alcohol during a week before the date of surgery
89178403|NCT00621322|Placebo Comparator|Control Group|Healthy adults between and including 18 to 45 years of age at the time of first vaccination, who received 2 doses of the control GSK Biologicals' AS01B adjuvanted system, at Day 0, intramuscularly in the non-dominant arm and at Day 30, intramuscularly in the dominant arm.
89363975|NCT01317498|Active Comparator|Virological Monitoring|The patients in the virological monitoring arm will have routine laboratory monitoring as in the standard monitoring arm and in addition will have a viral load test performed every 6 months while in treatment. The first test will be done 6 months after initiating ART.
88835025|NCT03223649|Experimental|Walking bouts|Six daily 3 hour sessions with prompted 3-minute moderate-intensity walking bouts performed on a treadmill every 30 minutes throughout the 3 hour duration. There will be a total of 6 walking bouts (18 minutes total) each day. Moderate-intensity walking speed and grade will be selected to achieve 80% of the heart rate achieved at the ventilatory threshold as determined during a V02max test.
89178404|NCT00621322|Active Comparator|GSK692342_F1 Group|Healthy adults between and including 18 to 45 years of age at the time of first vaccination, who received 2 doses of the non-adjuvanted GSK692342 vaccine formulation 1 (F1), at Day 0, intramuscularly in the non-dominant arm and at Day 30, intramuscularly in the dominant arm.
89178405|NCT00621322|Experimental|GSK692342_F2 Group|Healthy adults between and including 18 to 45 years of age at the time of first vaccination, who received 2 doses of the adjuvanted GSK692342 vaccine formulation 2 (F2), at Day 0, intramuscularly in the non-dominant arm and at Day 30, intramuscularly in the dominant arm.
89178406|NCT00621322|Experimental|GSK692342_F3 Group|Healthy adults between and including 18 to 45 years of age at the time of first vaccination, who received 2 doses of the adjuvanted GSK692342 vaccine formulation 3, at Day 0, intramuscularly in the non-dominant arm and at Day 30, intramuscularly in the dominant arm.
89001435|NCT04576351||1|"Sub cohort 1:~Participants in the WHO NOR Solidarity multicenter trial on the efficacy of different anti-viral drugs in SARS CoV-2 infected patients.~Eligibility: consenting adults (age ≥18) hospitalized with definite COVID-19 included in the WHO COVID-19 Study. Participants invited to join the study will be those who are admitted to a collaborating hospital; no wider recruitment efforts are expected."
89178407|NCT00621322|Experimental|GSK692342_F4D1 Group|Healthy adults between and including 18 to 45 years of age at the time of first vaccination, who received 2 doses of the adjuvanted GSK692342 vaccine formulation 4 dosage 1 (F4D1), at Day 0, intramuscularly in the non-dominant arm and at Day 30, intramuscularly in the dominant arm.
89178408|NCT00621322|Experimental|GSK692342_F4D2 Group|Healthy adults between and including 18 to 45 years of age at the time of first vaccination, who received 2 doses of the adjuvanted GSK692342 vaccine formulation 4 dosage 2 (F4D2), at Day 0, intramuscularly in the non-dominant arm and at Day 30, intramuscularly in the dominant arm.
88835026|NCT02360215|Experimental|WBRT + Memantine|Whole brain radiation therapy (WBRT) and memantine
88835027|NCT02360215|Experimental|HA-WBRT/IMRT+ Memantine|Whole brain radiation therapy with hippocampal avoidance (HA-WBRT) using intensity modulated radiation therapy (IMRT) and memantine
88835028|NCT05719688|Experimental|Mechanical thrombectomy:Thrombectomy system|Subjects will be treated with Thrombectomy system,Thrombectomy system is an intraarterial thrombectomy removal device that can be re-inserted into the sheath to restore blood flow by removing blood clots in occluded vessels.
89178409|NCT00833872|Experimental|LEO 22811 solution|
89178410|NCT00833872|Placebo Comparator|placebo solution|
89178411|NCT00839488|Active Comparator|I|pantoprazole 40 mg iv qd
89178412|NCT00839488|Active Comparator|II|famotidine 20 mg q12h
89178413|NCT00839566|Experimental|AV ablation|
89178414|NCT00839566|Active Comparator|Rate control|Rate control by drugs
89178415|NCT00839566|No Intervention|Sinus rhythm|
89178416|NCT00833950|Experimental|narrow band noise|Phase out in narrow band noise tinnitus patients
88835029|NCT05719688|Active Comparator|Intracranial thrombectomy stent :Solitaire FR Revascularization Device|Subjects will be treated with Solitaire FR Revascularization Device ,the Device made by Micro Therapeutics Inc. DBA ev3 Neurovascular
88835030|NCT01349192|Experimental|Treatment|Subjects are treated with two oral antibiotics, topical antibiotics, and are instructed to use environmental decontamination techniques.
89178417|NCT00825526|Experimental|Early Intervention, MBSR therapy|Group that receives Mindfulness Based Stress Reduction Therapy immediately after randomization
89178418|NCT00825526|Active Comparator|Delayed Treatment Arm, MBSR Therapy|Group that receives Mindfulness Based Stress Reduction Therapy within 3 months of randomization
89178419|NCT00834028||1|patients with hepatocellular carcinoma receive transcatheter arterial chemoembolization
89178420|NCT00839644|Active Comparator|2|
89178421|NCT00839644|Active Comparator|3|
89363976|NCT04242654|Experimental|Doppler ultrasound|Placement of Doppler US on chest to obtain newborn's heart rate.
89363977|NCT04242654|No Intervention|Stethoscope|Placement of stethoscope on chest to obtain newborn's heart rate.
89363978|NCT03299998||BLOCK+|Patients who underwent maxillary and mandibulary block before surgery
89363979|NCT03299998||BLOCK -|Patients who did not undergo maxillary and mandibulary block before surgery.
89363980|NCT04240470|Experimental|Thrombectomy|Participants will receive endovascular treatment (mechanical thrombectomy) alone without using IV rt-PA.
89363981|NCT02467114|Experimental|All study participants|Stimulation with TMS, a sham coil & no intervention
89363982|NCT02467036|Experimental|Family Based Behavioral Treatment Egg|The FBT+Egg group will participate in group-based FBT and will be assigned to eat eggs a minimum of 5 days a week for breakfast. Families are provided eggs each week to facilitate compliance, along with recipes
89363983|NCT02467036|Active Comparator|Family Based Behavioral Treatment Cereal|The FBT+Cereal group will participate in group-based FBT and will be assigned to eat cereal a minimum of 5 days a week for breakfast. Families are provided cereal each week to facilitate compliance.
89363984|NCT05468632||Glucagon like peptide-1 (GLP-1) naive participants with Type 2 Diabetes (T2D)|Glucagon like peptide-1 (GLP-1) naive adult type 2 diabetes (T2D) participants who initiated once weekly (OW) semaglutide were treated according to current clinical practice, applicable local labels, and standard of care as per physicians' discretion.
89363985|NCT03299920|Active Comparator|Intervention|Patients will receive standardized instruction from a study nurse, tailored to understanding pain management after nerve blocks and maximizing utilization of non-opioid analgesics.
89363986|NCT03299920|Other|Control|Patient will receive conventional instructions on postoperative pain management.
89363987|NCT02466880|Experimental|Telemedicine|Diabetes education and support via telemedicine
88835031|NCT01349192|No Intervention|Observational|Subjects are tracked and not treated for their MRSA. If the subject reaches a protocol defined exacerbation within the first 28 days then they will be treated per choice of their primary Pulmonologist.
88835032|NCT02360371|Placebo Comparator|Placebo (oral)|Within-subject double-blind, administration of placebo oral capsule. Order of dose randomized session days 3-5.
88835033|NCT02360371|Experimental|Hydromorphone (oral) 2mg|Within-subject double-blind, administration of hydromorphone via oral capsule. Order of dose randomized session days 3-5.
89363988|NCT02466880|Active Comparator|Usual care|Diabetes education and support in person
89363989|NCT05727826|Experimental|stroke patients|individuals with hemiplegia after Hemorrhagic or Infarction stroke
89363990|NCT05459506||Subjects with Post Acute Sequale SARS-CoV-2 (PSAC)|Participants with PASC
89363991|NCT05459506||Subjects with COVID but not PASC|Subjects confirmed COVID-19 positive without Post Acute Sequale SARS-CoV-2 (PASC)
88835034|NCT02360371|Experimental|Hydromorphone (oral) 4mg|Hydromorphone oral capsule administered in double-blind manner on Day 2 as first study drug administration. Hydromorphone 4mg dosing day was set for safety purposes and non-randomized.
88835035|NCT02360371|Experimental|Hydromorphone (oral) 8mg|Within-subject double-blind, administration of hydromorphone via oral capsule. Order of dose randomized session days 3-5.
88835036|NCT02362321|Experimental|Dexamethasone|Participants allocated to the treatment group received a daily dosage of 12mg (4mg three times a day) of dexamethasone for three weeks. Corticosteroid treatment was then tapered off over the next week (8mg for 48 hrs, 4mg for 48 hrs, 2mg for 48 hrs and 1mg for 24 hrs).
88835037|NCT02362321|Placebo Comparator|Control|Identical oral capsules filled with lactose were administered to the control (placebo) group for 28 days.
88835038|NCT05719376|Experimental|Experimental|
88835039|NCT05719376|Other|control|Follow the criteria for investigational product
89363992|NCT04763044|Other|Period 1|0 ppm F (placebo, negative control), 250 ppm F as MFP (dose-response control), 1100 ppm F as MFP (reference), 2800 ppm F as MFP (dose-response control)
89363993|NCT04763044|Other|Period 2|0 ppm F (placebo, negative control), 250 ppm F as MFP (dose-response control), 1100 ppm F as MFP (reference), 2800 ppm F as MFP (dose-response control)
89363994|NCT04763044|Other|Period 3|0 ppm F (placebo, negative control), 250 ppm F as MFP (dose-response control), 1100 ppm F as MFP (reference), 2800 ppm F as MFP (dose-response control)
89363995|NCT04763044|Other|Period 4|0 ppm F (placebo, negative control), 250 ppm F as MFP (dose-response control), 1100 ppm F as MFP (reference), 2800 ppm F as MFP (dose-response control)
89363996|NCT04763044|Other|Period 5|1100 ppm SnF2 toothpaste only
89363997|NCT03299764|Experimental|Intervention|Non-invasive ventilation with pursed lip breathing ventilation device
89363998|NCT03299764|Active Comparator|Control|Non-invasive ventilation with standard non-invasive ventilation device
89363999|NCT01315028|Experimental|Psychological Therapy|Cognitive Interpersonal Therapy (CIT) was a psychological therapy which emphasised assessment, engagement and formulation; normalizing and compassionate understanding; specific cognitive-behavioural and interpersonal strategies; self-management and social rhythm regulation; affect regulation, and staying well (Gumley & Schwannauer, 2006).
88835040|NCT02413879|Experimental|Treatment Group|All study subjects will be treated using the CleanCision device.
88835041|NCT05718908||Fibromyalgia patients|All patients will be administered with one sachet of food supplement (FibrofixPlus®) per day, for 8 weeks.
89178422|NCT00839644|Active Comparator|1|
89364000|NCT01315028|Active Comparator|Treatment As Usual|All participants continued to receive their usual care from their local community mental health team and other psychological therapies were not withheld during the conduct of the trial.
89364001|NCT02720536|Experimental|Deferasirox|Treatment will be administered daily for up to 24 months. For each patient the daily dose is calculated based on the patient's actual body weight.
89178423|NCT00834184|Experimental|A|nikkomycin Z 250 mg BID versus placebo BID x 14 days
89364002|NCT05453032|Experimental|Patients with BPD assigned to the trial of 10 active tDCS sessions followed by psychotherapy|Patients diagnosed with Borderline Personality disorder and BPDSI score is > or = 17 will be assigned for active tDCS session (NeuroConn, Germany) candidates will have 20-minute session per day for 10 weekdays in 2 weeks. Then they will attend short term psychotherapy session for 3 months.
89364003|NCT05727748|Other|Control group|The control group continued their daily activities for 12 weeks and did not participate in any new physical activity program during the study.
89364004|NCT05727748|Experimental|Multimodal training group|The session consisted of four stations where participants simultaneously trained physical aspects (cardiorespiratory fitness, strength, balance, and flexibility) and cognitive aspects (reaction time, memory, decision making, semantics, and processing speed).
88835042|NCT00354991|Experimental|1|Losartan/HCTZ
88835043|NCT05718752||Healthy men|no intervention
88835044|NCT05718752||Healthy women|no intervention
88835045|NCT00355069|Experimental|1|Received the Basic Pediatric Chronic Care Model AND the Medication Assessment Prompt AND family education
88835046|NCT00355069|Experimental|2|Received the Basic Pediatric Chronic Care Model AND the Medication Assessment Prompt but NOT family education
88835047|NCT00355069|Experimental|3|Received the Basic Pediatric Chronic Care Model AND family education but NOT the Medication Assessment Prompt
89178424|NCT00834184|Experimental|B|nikkomycin Z 500 mg BID versus placebo BID x 14 days
89178425|NCT00834184|Experimental|C|nikkomycin Z 750 mg BID versus placebo BID x 14 days
89364005|NCT05727748|Experimental|Multimodal training group with augmented reality|The session consisted of six stations where participants simultaneously trained physical aspects (cardiorespiratory fitness, strength, balance, and flexibility) and cognitive aspects (reaction time, memory, decision making, semantics, and processing speed). Four stations are the same of the previous group and the other 2 stations are with augmented reality. These 2 stations worked the same cognitive and physical components but through the portable exergame platform for the elderly.
89364006|NCT03299452|Experimental|Alphacait-guided therapy|Drugs screened by the Alphacait screening system will be administered in accordance with the protocol of the drug specification or the CPSC guidelines until the patient progresses, intolerant, the patient withdrawn or the investigator determines that the medication must be discontinued.
89364007|NCT03168438|Experimental|Arm 1: Letetresgene autoleucel (GSK3377794)|Eligible participants will be leukapheresed to manufacture engineered T-cells. Participants will then receive letetresgene autoleucel (GSK3377794), as a single intravenous (IV) infusion after completing lymphodepleting chemotherapy.
88835048|NCT00355069|Placebo Comparator|4|Received the Basic Pediatric Chronic Care Model only (NO Medication Assessment Prompt and NO family education)
88835049|NCT02986399||Standard care|Hip fracture patients operated at Akershus University hospital in 2012 and 2013.
88835050|NCT02986399||Fast track patient pathway|Hip fracture patients operated at Akershus University hospital in 2014 and 2015.
88835051|NCT02118818||NO rheumatic heart disease by echo|There will be no intervention. This is an observational trial to examine the differences in genetic variants and gene expression between patients with and without RHD. We will be using next generation sequencing to identify these differences.
88835052|NCT02118818||Rheumatic heart disease by echo|There will be no intervention. This is an observational trial to examine the differences in genetic variants and gene expression between patients with and without RHD. We will be using next generation sequencing to identify these differences.
88835053|NCT02112578|Experimental|Meclizine|Meclizine 25 mg, tablets
88835054|NCT02112578|Active Comparator|Dimenhydrinate|Dimenhydrinate 50 mg, soft Capsgel
88835055|NCT01958762|Other|Screening for cancers in the oral cavity|
88835056|NCT02415439|Experimental|VBP15- 0.1 mg/kg SAD|Subjects were orally administered a single dose of VBP15 at 0.1 mg/kg under fasted conditions.
88835057|NCT02415439|Experimental|VBP15- 0.3 mg/kg SAD|Subjects were orally administered a single dose of VBP15 at 0.3 mg/kg under fasted conditions.
88835058|NCT02415439|Experimental|VBP15- 1.0 mg/kg SAD|Subjects were orally administered a single dose of VBP15 at 1.0 mg/kg under fasted conditions.
88835059|NCT02415439|Experimental|VBP15- 3.0 mg/kg SAD|Subjects were orally administered a single dose of VBP15 at 3.0 mg/kg under fasted conditions.
88835060|NCT02415439|Experimental|VBP15- 8.0 mg/kg Fasting SAD|Subjects were orally administered a single dose of VBP15 at 8.0 mg/kg under fasted conditions.
88835061|NCT02415439|Experimental|VBP15- 8.0 mg/kg Fed SAD|Subjects were orally administered a single dose of VBP15 at 8.0 mg/kg within 30 minutes of beginning a high fat/high high calorie meal.
88835062|NCT02415439|Experimental|VBP15- 20.0 mg/kg SAD|Subjects were orally administered a single dose of VBP15 at 20.0 mg/kg under fasted conditions.
88835063|NCT02415439|Placebo Comparator|Placebo - SAD|Subjects were orally administered a placebo under fasted conditions.
89178426|NCT00834184|Experimental|D|nikkomycin Z 750 mg TID versus placebo TID x 14 days
89178427|NCT00839722|Experimental|1|fertility after embolization
89178428|NCT00825604|No Intervention|Without PCI|Optimized medical treatment, physical training and smoking cessation
89364008|NCT03168438|Experimental|Arm 2: Letetresgene autoleucel (GSK3377794) with pembrolizumab|Eligible participants will be leukapheresed to manufacture engineered T-cells. Participants will then receive letetresgene autoleucel (GSK3377794), as a single intravenous (IV) infusion after completing lymphodepleting chemotherapy, followed by pembrolizumab 200 mg every 3 weeks.
89178429|NCT00825604|Active Comparator|With PCI|optimized medical treatment, physical training and smoking cessation with complimentary treatment with percutaneous coronary intervention(PCI)
89364009|NCT03299374|Active Comparator|Falls Group|Falls prevention intervention
89364010|NCT03299374|Experimental|Pilates Group|Pilates intervention
89364011|NCT03299296|Experimental|Rivaroxaban arm|Rivaroxaban 10 Milligrams
89364012|NCT03299296|Active Comparator|Enoxaparin Arm|'Enoxaparin 40 Milligrams /0.4 Milliliters Prefilled Syringe
89364013|NCT02466724|Experimental|Web Group|Patients given web site (aiddly) instructions for colonoscopy
89178430|NCT02549950|Active Comparator|Conventional OrthodonticTreatment|Conventional orthodontic mechanics: canine and incisor retraction
89178431|NCT02549950|Experimental|Accelerated Tooth Movement|Accelerated orthodontics: Peizo-Corticision Accelerated canine and Incisor retraction
89364014|NCT02466724|No Intervention|Paper Group|Patients given paper instructions for colonoscopy
89364015|NCT03137784|Other|1(NVA237 50 ug/NVA237 25 ug/placebo)|Treatment sequence: NVA 237 50 ug, 25 ug and placebo
89364016|NCT03137784|Other|2(NVA237 50 ug/placebo/NVA237 25 ug)|Treatment sequence: NVA 237 50 ug, placebo and 25 ug
89364017|NCT03137784|Other|3 (NVA237 25 ug/NVA237 50 ug/placebo)|Treatment sequence: NVA237 25 ug, 50 ug and placebo
89178432|NCT00834262||A|
89364018|NCT03137784|Other|4 (NVA237 25 ug/placebo/NVA237 50 ug)|Treatment sequence: NVA 237 25 ug, placebo and 50 ug
89364019|NCT03137784|Other|5 (placebo/NVA237 50 ug/ NVA237 25 ug)|Treatment sequence: Placebo, NVA237 50 ug and 25 ug
89364020|NCT03137784|Other|6 (placebo/ NVA237 25 ug/NVA237 50 ug)|Treatment sequence: placebo, NVA237 25 ug and 50 ug
89178433|NCT00853385|Experimental|5mg|
89364021|NCT02466256|Placebo Comparator|Autosert Group|Procedure / Surgery : Intraocular lens implantation with Autosert injector
89178434|NCT00853385|Experimental|10 mg|
89178435|NCT00853385|Placebo Comparator|Placebo Sequence 1|
89364022|NCT02466256|Placebo Comparator|Royale Group|Procedure / Surgery : Intraocular lens implantation with Royale Injector
89364023|NCT02466256|Placebo Comparator|Monarch III Injector|Procedure / Surgery : Intraocular lens implantation with Monarch III group
89364024|NCT01314716|Experimental|AZLI-AZLI|Participants were randomized to receive blinded AZLI for 2 cycles of 28 days on treatment with each cycle followed by 28 days off treatment, followed by open-label AZLI for 28 days plus 56 days of treatment-free follow-up.
89364025|NCT01314716|Placebo Comparator|Placebo-AZLI|Participants were randomized to receive blinded placebo to match AZLI for 2 cycles of 28 days on treatment with each cycle followed by 28 days off treatment, followed by open-label AZLI for 28 days plus 56 days of treatment-free follow-up.
89364026|NCT05727358|Experimental|intervention group|G-ACT
89364027|NCT05727358|No Intervention|control group|
89364028|NCT03144180|No Intervention|Control|The Q-cup will not be used to collect umbilical cord blood.
89364029|NCT03144180|Active Comparator|Study Group|The Q-cup will be used to collect umbilical cord blood.
89364030|NCT03299218|No Intervention|Control|Receiving current Government of Punjab health services
89364031|NCT03299218|Experimental|Cash-based transfers|Cash-based transfers only by BISP
89364032|NCT03299218|Experimental|Cash with SBCC|Cash-based transfers and Social & behaviour change communication (SBCC)
89364033|NCT03299218|Experimental|Cash with SNF (Wawamum)|Cash-based transfers and SNF (Wawamum)
89364034|NCT03299218|Experimental|Cash,SNF (Wawamum) & SBCC|Cash-based transfers, SNF (Wawamum) and SBCC
89178436|NCT00853385|Placebo Comparator|Placebo Sequence 2|
89178437|NCT00853385|Active Comparator|adalimumab|
89178438|NCT00622336|Experimental|Lenalidomide 25mg (CC-5013)|Oral 25mg daily on Days 1-21 every 28 days
89178439|NCT00779766|Experimental|Cervarix Group|Subjects received 3 doses of Cervarix™ vaccine. Cervarix™ vaccine was administered intramuscularly in the deltoid muscle of the non-dominant arm according to a 0, 1, 6-month schedule.
89178440|NCT00779766|Placebo Comparator|Placebo Group|Subjects received 3 doses of placebo. Placebo was administered intramuscularly in the deltoid muscle of the non-dominant arm according to a 0, 1, 6-month schedule.
89364035|NCT01344954|Experimental|25mg TB-402|
89364036|NCT01344954|Experimental|50mg TB-402|
89364037|NCT01344954|Active Comparator|10mg QD Rivaroxaban|
89364038|NCT05727280|Experimental|Intervention Group|After the first meeting with the patients in the intervention group, the patients will be informed about the application of the Progressive Relaxation Exercise and the exercise application will be taught. After open heart surgery, progressive relaxation exercise will be applied to the patient on the 1st, 2nd and 3rd days of his admission to the service. The patient will be asked to perform the progressive relaxation exercise twice a day, once during the day and once in the evening. Before each daytime application, the score given by the patient to the SF-MPQ will be recorded. Patients will be asked to repeat the same application two hours after dinner. In the morning of the next day after each application, the score given by the patient to the RCSQ will be recorded by the researcher.
89178441|NCT00846365|Experimental|Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD|(dependant on blood pressure)
89178442|NCT00846365|Experimental|Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD|(dependant on blood pressure)
89178443|NCT00846365|Active Comparator|Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD|(dependant on blood pressure)
89178444|NCT00839878||A|
89178445|NCT00834496||1|"Our experience with the use of Sirolimus is delineated below. About 15% to 20% of our patients are currently switched to Sirolimus.Indications for conversion from calcinurin inhibitors (CNIs) to Sirolimus more than 90 days post liver transplantation include:~CNI renal toxicity.~Hepatic fibrosis on biopsy.~CNI neurologic toxicity.~Post transplant diabetes. Any of the above 4 indications makes a patient a candidate for conversion from CNIs to Sirolimus at or > 90 days after liver transplantation."
88835064|NCT02415439|Experimental|VBP15- 1.0 mg/kg 14 Day MAD|Subjects were orally administered VBP15 at 1.0 mg/kg for 14 days under fasted conditions.
88835065|NCT02415439|Experimental|VBP15- 3.0 mg/kg 14 Day MAD|Subjects were orally administered VBP15 at 3.0 mg/kg for 14 days under fasted conditions.
88835066|NCT02415439|Experimental|VBP15- 9.0 mg/kg 14 Day MAD|Subjects were orally administered VBP15 at 9.0 mg/kg for 14 days under fasted conditions.
88835067|NCT02415439|Experimental|VBP15- 20.0 mg/kg 14 Day MAD|Subjects were orally administered VBP15 at 20.0 mg/kg for 14 days under fasted conditions.
88835068|NCT02415439|Placebo Comparator|Placebo MAD|Subjects were orally administered placebo for 14 days under fasted conditions.
88835069|NCT05717036||TS Meter-DSP Measurement and Refractix DSP Measurement|The study will involve blood serum samples from (36) participants. Participants will be those presenting at a plasma collection center for routine plasma donation. Ordinary pre-screening for plasma donation includes a fingerstick and the collection of one small capillary tube (<0.085ml) of blood. Participants will be asked to provide a second capillary tube (<0.085ml) of blood from this fingerstick.
88835070|NCT02363803|Placebo Comparator|Normal saline infusion then lidocaine infusion|Intravenous infusion of normal saline over a 40 minute period. second intervention: Intravenous infusion of lidocaine [5mg/kg] over a 40 minute period.
89178446|NCT00834730|Active Comparator|Ketamine|Ketamine 2mg/kg IV
89178447|NCT00834730|Experimental|N2O gas|50%-70% N2O gas inhalation
89364039|NCT05727280|No Intervention|Control Group|After the first meeting with the patients in the control group, the routine care and treatment practices planned by the service will continue. No additional intervention is planned for the patients in this group. After open heart surgery, patients will be asked to fill out the SF-MPQ and RCSQ on the 1st, 2nd and 3rd days of the patient's admission to the service. After the completion of the study, progressive relaxation exercise training will be given to the patients in the control group.
89178448|NCT02601924|Active Comparator|Topical Pressure Massage Block injection|Topical pressure massage at site of alveolar nerve block injection.
89178449|NCT02601924|Active Comparator|Topical Anesthetic Gel Block injection|Topical anesthetic gel (20% Benzocain) at site of inferior alveolar nerve block injection.
89364040|NCT05414786|Experimental|Experimental group|"2 doses eOD-GT8 60mer mRNA Vaccine (100µg), 2 vaccinations, 8 weeks apart~No control group. There is no blinding and no randomization in this open label study"
89364041|NCT05329402|Active Comparator|Disposable Powered Articulating Endoscopic Linear Cutter Stapler|The Disposable Powered Articulating Endoscopic Linear Cutter Stapler is intended for transection, resection, and/or creation of anastomoses. The instrument has application in multiple open or minimally invasive general, gynecologic, urologic, thoracic, and pediatric surgical procedures. It can be used with staple line or tissue buttressing materials. The instrument may also be used for transection and resection of liver parenchyma (hepatic vasculature and biliary structures), pancreas, kidney and spleen.
89364042|NCT05329402|Experimental|ECHELON Flex Powered Articulating Endoscopic Linear Cutters|ECHELON Flex Powered Articulating Endoscopic Linear Cutters has application in multiple open or minimally invasive general, gynecologic, urologic, thoracic, and pediatric surgical procedures.
88835071|NCT02363803|Active Comparator|Lidocaine infusion, then normal saline infusion|Intravenous infusion of lidocaine [5mg/kg] over a 40 minute period. second intervention: Intravenous infusion of normal saline over a 40 minute period.
88835072|NCT02364271||Not low risk for MACE in 30 days|"Patients with not low risk of major adverse cardiac events within 30 days Patients with TIMI>0 or mHEART>2~Routine blood test for hs-cTnT and Thrombolysis in myocardial infarction (TIMI) score were performed on study patients~Protocol amendment:~In October 2014, mHEART score of the study patients was determined retrospectively"
88835073|NCT02364271||Low risk for MACE in 30 days|"Patients with low risk of major adverse cardiac events within 30 days~Patients with TIMI=0 and mHEART<=2~Routine blood test for hs-cTnT and Thrombolysis in myocardial infarction (TIMI) score were performed on study patients~Protocol amendment:~In October 2014, mHEART score of the study patients was determined retrospectively"
89178450|NCT02601924|Active Comparator|Topical Pressure Massage Infiltration|Topical pressure massage at site of maxillary anterior infiltration
89178451|NCT02601924|Active Comparator|Topical Anesthetic Gel Infiltration|Topical anesthetic gel (20% Benzocain) at site of maxillary anterior infiltration
89178452|NCT00840112|Experimental|LCHAD/TFP with peripheral neuropathy|Subjects diagnosed with LCHAD or TFP and with documented peripheral neuropathy
89178453|NCT04101474|Active Comparator|Ketamine group|half of participants will take ketamine
89178454|NCT04101474|No Intervention|Placebo group|the other half of participants will not take any drugs
89178455|NCT00840190|Experimental|P1446A-05|
89001436|NCT04576351||2|"Sub cohort 2:~Patients with COVID-19 and neurological symptoms related to COVID-19 admitted to the Norwegian Departments of Neurology or other relevant Departments (both hospitalized and outpatient visits) and persons with neurological symptoms participating in other COVID-19 studies and not already participating in the WHO NOR Solidarity multicenter trial."
89001437|NCT00187590|Experimental|Intervention|Phone call after an ER visit.
89001438|NCT00187590|No Intervention|Control|No phone call after an ER visit.
89001439|NCT00583063|Experimental|A|Sunitinib taken by mouth every day. Rapamycin (taken by mouth) will be started on Day 15 and then taken every day. Drugs can be taken until disease progression.
89001440|NCT00583063|Experimental|B|Rapamycin taken by mouth every day. Sunitinib (taken by mouth) will be started on Day 15 and then taken every day. Drugs can be taken until disease progression.
89001441|NCT04576312|Experimental|Cohort 1|Single dose of UNI911 inhalation (4 mL 0.1% ~ 3,4 mg) and intranasal spray (2 x 150 µL, 1% ~ 2,5 mg)
89001442|NCT04576312|Experimental|Cohort 2|Single dose of UNI911 inhalation (1 mL 1% ~ 8,4 mg) and intranasal spray (2 x 150 µL, 1% ~ 2,5 mg)
89001443|NCT04576312|Experimental|Cohort 3|Single dose of UNI911 inhalation (3 mL 1% ~ 25,2 mg) and intranasal spray (2 x 150 µL, 1% ~ 2,5 mg)
89001444|NCT04576312|Experimental|Cohort 4|Single dose of UNI911 inhalation (6 mL 1% ~ 50,4 mg) and intranasal spray (2 x 150 µL, 1% ~ 2,5 mg)
89001445|NCT04576312|Experimental|Cohort 5|UNI911 inhalation (6 mL 1% ~ 50,4 mg) and intranasal spray (2 x 150 µL, 1% ~ 2,5 mg) BID for 2,5 days.
89001446|NCT04576312|Experimental|Cohort 6|UNI911 inhalation (1 mL 1% ~ 8,4 mg) and intranasal spray (2 x 150 µL, 1% ~ 2,5 mg) BID for 6,5 days.
89001447|NCT04576312|Experimental|Cohort 7|UNI911 inhalation (3 mL 1% ~ 25,2 mg) and intranasal spray (2 x 150 µL, 1% ~ 2,5 mg) BID for 6,5 days.
89001448|NCT04576312|Placebo Comparator|Placebo (applicable for cohorts 1-5)|Placebo, administered in a double-blinded fashion (except for the first subjects of cohorts 1-4) at the same dose and frequency as UNI911 inhalation and intranasal spray.
89001449|NCT04576234|Experimental|intermittent entral feeding group|Intermittent enteral feeding group recieved intermittent feeding as the feed was given over a 24 hour period with intervals of rest (e.g. three hours feeding two hours rest) by using syringe pump and Feeds were administered according to guidelines as the head of the patient's bed was elevated at least 30 degrees from the horizontal before initiating feeding, the feeding schedule was started at a rate of 50 ml/hr in adults to promote tolerance,the administration rate of isotonic formulas increased in 20-25 ml/hr increments every eight hours until the desired rate was achieved, the tube was flushed regularly with 20 to 30 ml of warm water every four hours during continuous feeding and before and after intermittent feeding and medication administration, the gastric residual volume was checked every 4-6 hr routinely
89001450|NCT04576234|Experimental|, feeding bag group|Feeding bag group received hospital blended formual which was 300 ml of feeds every 2hrs with 4hrs rest at night and given in 10 minutes with following the same guidelines in the intermittent enteral feeding group
89001451|NCT00209391|Experimental|Gadodiamide Injection|All subjects will receive a single intravenous bolus injection via a power injector of Omniscan (Gadodiamide injection) at a dose of 0.1 mmol/kg.
89001452|NCT00181298|Active Comparator|1|
89001453|NCT00181298|Placebo Comparator|2|
89001454|NCT04576273||Non-parasitic|
89001455|NCT04576273||Parasitic|
89001456|NCT00583180||A|Capsaicin treated patients
89001457|NCT00583180||P|Placebo treated patients
89001458|NCT00583258|Experimental|A|
89001459|NCT00583258|Placebo Comparator|B|
89178456|NCT04101708|Experimental|high dose dual group|Patients in high dose dual group will receive lansoprazole (Takepron) 30mg po qid, amoxicillin 750mg po qid for 14d
89001460|NCT04576039|Experimental|presenting with thickened endometruim|women presenting with thickened endometrium after the use of ulipristalacetate will undergo a saline infusion in the uterus and immediate ultrasonographic control to visualise the morphology of the endometrium.
89001461|NCT00187629|Experimental|1|dietary phosphorus
89001462|NCT00187629|Active Comparator|2|other
89001463|NCT00583297||ABCD Subjects|The cohort will consist of original subjects of the ABCD trial who consent to participate in the genetic sub-study
89001464|NCT00583336|Experimental|Diagnostic|
89001465|NCT04576390|Active Comparator|Group O|On the day of procedure, the recruited patients in Group O will be given Ondansetron 4 mg diluted for up to 5ml using normal saline by a colleague not participating to the study or the patient care & will label the syringes as antiemetic.
89001466|NCT04576390|Active Comparator|Group P|On the day of procedure, the recruited patients in Group P will be given Palonosetron 75 mcg diluted for up to 5ml using normal saline by a colleague not participating to the study or the patient care & will label the syringes as antiemetic.
89001467|NCT00583570|Experimental|A|
89001468|NCT00583648|Experimental|1|Recieves urinalysis by nurse per set protocol based off of inclusion criteria
89001469|NCT00583648|No Intervention|2|ordering of test will be up to the treating physician
89001470|NCT00181571|Active Comparator|1|Concerta
89001471|NCT00181571|Placebo Comparator|2|Placebo
89001472|NCT00187707|Other|Gabapentin|Subjects will take a single dose of 400 mg of gabapentin
89001473|NCT00583726|Active Comparator|1|The control arm receives written information and pedometers
89001474|NCT00583726|Experimental|2|This arm also receives telephone counseling.
89001475|NCT00583765||A|Critically ill patients with acute renal failure requiring continuous renal replacement therapy
89001476|NCT00187746|Experimental|Age 18-25 years|African American subjects between the ages 18 to 25 years given Adefovir dipivoxil.
89001477|NCT00187746|Experimental|Age 48-55 years|African American subject between the ages 48 to 55 years given Adefovir dipivoxil.
88835074|NCT02366611|Experimental|Transcranial Direct Current Stimulation (tDCS)|tDCS is a method of non-invasive brain stimulation that is based on the application of a weak direct current to the head that flows between two relatively large electrodes-anode and cathode. tDCS offers a unique analgesic modality of central pain neuromodulation by altering the activity of key sensory and motor cortical structures. Participants in this arm will undergo 20 tDCS sessions, tDCS in clinic and remotely supervised tDCS, and 2mA of transcranial direct current stimulation will be applied for 20 minutes.
88835075|NCT02366611|No Intervention|Chemoradiotherapy Standard of Care|The control group will consist of patients receiving the Standard of care and no neuromodulation.
88835076|NCT03417193|Active Comparator|Opioid based Anesthesia|General anesthesia will be induced using Propofol , fentanyl , and Rocuronium . Ketamine will be administered on induction of anesthesia with the same dose to be repeated every hour. Anesthesia will be maintained with Remi-fentanyl , sevoflurane and nitrous oxide.
89364043|NCT01352832|Experimental|Interactive DVD|"Patients randomized to this arm will receive a DVD DVD (How To Talk To Your Doctor about NSAIDs, HTTTYD-NSAIDs) that presents culturally appropriate stories through which a viewer can learn risk factors for adverse effects related to NSAIDs; and communication behaviors for talking about NSAIDs with their doctor."
89364044|NCT01352832|Placebo Comparator|Usual Care|Patients randomized to this arm receive their usual care.
89364045|NCT01347918||control|Healthy controls
89364046|NCT01347918||IBS|Patients that fulfil the Rome III criteria for irritable bowel syndrome (IBS)
89364047|NCT05727124|Active Comparator|Evaluation of Poul Gjessing spring for orthodontic maxillary canine retraction|20 Orthodontic patient treated by Poul Gjessing spring for canine retraction split mouth.
88835077|NCT03417193|Active Comparator|Opioid Free Anesthesia|-General anesthesia will be induced using dexmedetomidine and lidocaine started 10 minutes before induction, Propofol and Rocuronium . Ketamine will be administered on induction of anesthesia with the same dose to be repeated every hour. Anesthesia will be maintained with IV infusion of dexmedetomidine , lidocaine , sevoflurane and nitrous oxide.
88835078|NCT02366845|Active Comparator|Clinician Chosen Dosing|"Admitted University of Colorado Hospital or Denver Health bleeding patients with chronic liver disease determined to receive fresh frozen plasma (FFP) for clinical indications as determined by hospital clinician. The total dose will be determined by the physician's judgment which is the current standard of care. The physician chosen dose will be utilized but physician will be unaware of which dosing strategy has been utilized.~INR measurements will be performed before (pre) and after (post) transfusion of plasma has been administered. Primary and secondary outcome measures will be collected. No other transfused blood component, crystalloid or colloidal fluid will be infused between the first and second INR studies except plasma."
88835079|NCT02366845|Experimental|Algorithm Dosing|"Admitted University of Colorado Hospital or Denver Health bleeding patients with chronic liver disease determined to receive fresh frozen plasma (FFP) for clinical indications as determined by hospital clinician. This group will receive plasma doses based on the study dosing algorithm table.~A pre-transfusion INR (before transfusion) and a target post-transfusion INR (after transfusion) will be used to determine dose of FFP. The study table will reveal the dose in (ml/kg) of FFP to be transfused. INR measurements will be performed before (pre) and after (post) transfusion of plasma has been administered. Primary and secondary outcome measures will be collected. No other transfused blood component,crystalloid or colloidal fluid will be infused between the first and second INR studies except plasma."
88835080|NCT02367391|Experimental|Motivational Text Messages|
88835081|NCT02367391|Sham Comparator|Control|
89364048|NCT05727124|Active Comparator|Evaluation of T loop for orthodontic maxillary canine retraction|20 Orthodontic patient treated by T loop for canine retraction split mouth
89364049|NCT01347996|Experimental|histamine dihydrochloride and IL-2|histamine and IL-2 subcutaneous injections
89364050|NCT05727046||Children with cerebral palsy and Children with other diagnoses|"Of the children with special needs included in the study, 60% were parents of children with cerebral palsy.~40% of the children with special needs included in the study had Hydrocephalus, Arthrogryposis, Multiplex Congenita, Down Syndrome, Microcephaly, Alpha-thalassemia mental retardation syndrome (ATRX), Spinal Muscular Atrophy (SMA) Type 1, Spinal Muscular Atrophy (SMA) Type 2, L2 hydroxy glutaric aciduria, Prader Willi syndrome, Periventricular leukomalacia grade 1, Hypotonia, Angelman syndrome, Genetic chromosomal abnormality, Dandy-walker syndrome, Western syndrome, Infantile epileptic encephalopathy, Stroke-like migraine attacks after radiation therapy (SMART syndrome), Trigonocephaly, Motor developmental delay, Lissencephaly, Spina bifida, Leigh syndrome and Epilepsy."
89364051|NCT01345032|Experimental|Home visits|Nutritional follow-up after discharge, conducted as nutritional counselling performed as in-person counselling in the participants homes
89364052|NCT01345032|Experimental|Telephone consultation|Nutritional follow-up after discharge, conducted as nutritional counselling performed as telephone consultation
89364053|NCT01345032|No Intervention|Control|No follow-up after discharge
89364054|NCT01348074|Experimental|Double dose|Re-initiation with warfarin at twice the usual maintenance dose the first 2 days, then maintenance dose.
89364055|NCT01348074|No Intervention|Usual maintenance dose|Usual maintenance dose from Day 1, i.e. no postoperative loading dose.
89364056|NCT01352910|Experimental|effective rTMS|
89364057|NCT01352910|Sham Comparator|Sham rTMS|
89364058|NCT01352988|Experimental|Fumaric acid esters|
89364059|NCT02466802|Experimental|A: regorafenib and sildenafil citrate|Patients receive regorafenib and sildenafil citrate by mouth every day (PO QD) on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89364060|NCT01353066|Active Comparator|Intensive Medical Treatment|
89364061|NCT01353066|Experimental|Intensive medical treatment (IMM)+RYGBP|
89364062|NCT01348230||prior preterm delivery at 24-32 weeks|collect their first morning urine samples before each of their remaining prenatal care appointments for our studies
88835082|NCT02368093|Experimental|Dextromethorphan hydrobromide|Dextromethorphan hydrobromide; Detosiv Slow Release® (60mg per tablet, Lotus Pharmaceutical Company, Taipei, Taiwan), 120mg per day with once daily dose taken after breakfast]
88835083|NCT02368093|Placebo Comparator|Placebo|placebo pills with the same appearance as Detosiv tablets.
88835084|NCT05719129||DWD participants|Individuals that voluntarily chose to participate in DWD seminar.
88835085|NCT04345081||SRNSM Group|"Under the age of 65 with uni- or bilateral primary breast cancer ( clinical Stage 0-III), needing skin sparing mastectomy, nipple sparing mastectomy or patients require risk reducing mastectomy independently of the axillary surgery, having immediate or delayed-immediate implant based reconstruction.~This Group receive Skin Reducing Nipple Sparing Mastectomy"
88835086|NCT04345081||SSM Group|"Under the age of 65 with uni- or bilateral primary breast cancer ( clinical Stage 0-III), needing skin sparing mastectomy, nipple sparing mastectomy or patients require risk reducing mastectomy independently of the axillary surgery, having immediate or delayed-immediate implant based reconstruction.~This Group receive Skin Sparing Mastectomy"
88835087|NCT05719051||High-dose group|Total Intravenous albumin infusion >1.5g/kg per week while hospitalization
88835088|NCT05719051||Medium-dose group|Total Intravenous albumin infusion 1.0 to 1.5g/kg per week while hospitalization
88835089|NCT05719051||Low-dose group|Total Intravenous albumin infusion <1.0g/kg per week while hospitalization
88835090|NCT03342937|Experimental|Oxaliplatin+Capecitabine+Pembrolizumab|
88835091|NCT05718739|Experimental|FOG@Home|Patients with Parkinson's disease who agreed to be monitored using cameras and acceleration measurements during daily life.
88835092|NCT05718661|Experimental|Virtual Reality Glasses Group|The intervention group will watch a virtual reality video with mobile virtual glasses by the researcher (SŞ) and the stress level on the smart wristband will be recorded. In addition, necessary variables will be recorded with the data collection form.
88835093|NCT05718661|Placebo Comparator|Non-Virtual Reality Glasses Group|The plain version of the video, which was shown to the intervention group by the researcher (SŞ) to the placebo group, will be watched over the phone with the naked eye and the stress level on the smart bracelet will be recorded. In addition, necessary variables will be recorded with the data collection form.
88835094|NCT05718661|No Intervention|Control Group|Anxiety control will be done by the researcher (SU) for the control group.
88835095|NCT05718349||Non-cholestasis|Patients planned for pancreaticoduodenectomy or liver resection (with or without hepaticojejunostomy) who do not have cholestasis preoperatively.
88835096|NCT05718349||Drained|Patients planned for pancreaticoduodenectomy or liver resection (with or without hepaticojejunostomy) who had cholestasis and underwent ERCP (endoscopic retrograde choledochopancreatography) with stenting to normalize the enterohepatic circulation.
88835097|NCT05718349||Cholestasis|Patients planned for pancreaticoduodenectomy or liver resection (with or without hepaticojejunostomy) who have cholestasis preoperatively and did not undergo drainage.
88835098|NCT00354757|Active Comparator|2 arms|PPI 1
88835099|NCT00354757|Active Comparator|PPI|PPI 2
88835100|NCT03328819|Experimental|Acupuncture for Depression/Acupuncture for pain|The computer-generated permuted block randomization was used so that the participating patients were randomly assigned on an exactly 1:1 ratio to either the depression-pain group, in which the depression-specific acupoints were first targeted (12 sessions over six weeks), followed by the pain-specific acupoints (12 sessions over six weeks)
88835101|NCT03328819|Experimental|Acupuncture for pain/Acupuncture for Depression|The computer-generated permuted block randomization was used so that the participating patients were randomly assigned on an exactly 1:1 ratio to either the depression-pain group, in which the pain-specific acupoints (six weeks 12 sessions) were first targeted followed by the depression-specific acupoints (six weeks 12 sessions).
88835102|NCT02376283|Other|STEMI prasugrel|Patients with diabetes mellitus admitted with STEMI who are under 75 years of age and greater than 60Kg in weight receiving Prasugrel Loading (60mg) and maintenance (10mg per day).
88835103|NCT02376283|Other|STEMI clopidogrel|Patients admitted with STEMI over the age of 75 or under 60 Kg receiving clopidogrel loading (600 mg) and then maintenance (75mg per day).
88835104|NCT02376283|Other|NSTEMI clopidogrel|Patients admitted with NSTEMI/UA over the age of 75 or under 60 Kg receiving clopidogrel loading (600 mg) and then maintenance (75mg per day).
88835105|NCT02376283|Other|Patients with NSTEMI|who are under 75 years of age and greater than 60Kg in weight receiving Prasugrel loading (60mg) however: - i. After sample collection patients treated with intracoronary stent placement on the same day as loading will receive prasugrel maintenance dose (10mg per day) as per licensing agreement for prasugrel ii. After sample collection patients who are not stented after loading will receive clopidogrel maintenance dose (75mg per day).
88835106|NCT02376283|Other|Patients admitted with STEMI receiving ticagrelor loading|Patients admitted with STEMI receiving ticagrelor loading (180 mg) and then maintenance (90mg bd per day)
88835107|NCT02376283|Other|Patients Admitted with NSTEMI receiving ticagrelor loading|Patients Admitted with NSTEMI receiving ticagrelor loading (180 mg) and then maintenance (90mg bd per day).
88835108|NCT02376361|Active Comparator|Surveillance Group|Monthly blood flow surveillance by ultrasound dilution technique and standard of care.
88835109|NCT02376361|No Intervention|Control Group|Control group will receive standard monitoring (standard care).
88835110|NCT02301793|Experimental|Contemporary Education Format|"Nurses in this arm received education about venous thromboembolism (VTE) in a web-based contemporary interactive format.~Intervention: Nurse education in contemporary format"
88835111|NCT02301793|Active Comparator|Traditional Education Format|"Nurses in this arm received education about venous thromboembolism (VTE) in a web-based traditional linear PowerPoint format with voice over.~Intervention: Nurse education in traditional format"
88835112|NCT02380183|Experimental|Intervention|Civco needle guidance device will be used while the nerve block is performed.
88835113|NCT02380183|No Intervention|Standard of Care|Needle guidance device will not be used while nerve block is performed; nerve block is performed by hand alone.
88835114|NCT02380261|Experimental|Systane|Systane® Lid Wipes, 1 per eyelid, used once and discarded after each use, for 21 days
88835115|NCT02382913|Experimental|Group 1|Subjects received acellular pertussis (aP) vaccine with different antigen dose formulations: low dose of PT, FHA, PRN, followed by one fixed dose of diphtheria and tetanus vaccine (adsorbed, reduced antigen content, Germany) administered one month apart.
88835116|NCT02382913|Experimental|Group 2|Subjects received acellular pertussis (aP) vaccine with different antigen dose formulations: medium dose of PT, FHA, PRN, followed by one fixed dose of diphtheria and tetanus vaccine (adsorbed, reduced antigen content, Germany) administered one month apart.
89178457|NCT04101708|Active Comparator|half-dose clarithromycin-containing bismuth quadruple group|Patients in half-dose clarithromycin-containing bismuth quadruple group will receive lansoprazole (Takepron) 30mg po bid, amoxicillin 1000mg po bid, bismuth subcitrate (Colloidal Bismuth Pectin) 200mg po bid, and clarithromycin (Klacid) 250mg po bid for 14d
89178458|NCT00825760|Other|1|Single treatment
89178459|NCT00825760|Other|2|12 treatments, once weekly
89178460|NCT00779142|Other|Methotrexate 25mg/ml|Methotrexate intravenous 25mg/ml: Methotrexate intravenous 25mg/ml delivered once or twice (based on the therapeutic response) over a period of 2 months maximum. Total dosage 400ug in each dose to subjects with diabetic macular edema resistant to conventional therapies.
89178461|NCT00840346|Experimental|1|The first patients enrolled in the trial will be successively distributed into three cohorts of patients for each dose level of panobinostat (20 mg, 30 mg, 40 mg) in combination with idarubicin and cytarabine, according to the classical 3+3 schedule
89534612|NCT01236547|Experimental|Arm I (paclitaxel, pazopanib hydrochloride, IMRT)|Patients receive paclitaxel IV over 1 hour once weekly and pazopanib hydrochloride PO QD for 2-3 weeks. Patients then receive concurrent paclitaxel IV over 1 hour once weekly and pazopanib hydrochloride PO QD for 6-7 weeks (or until radiation treatment is completed) and IMRT 5 days per week for 6.5 weeks (total of 66 Gy in 33 fractions). Beginning 25-31 days after the completion of IMRT, patients receive paclitaxel IV over 1 hour once weekly and pazopanib hydrochloride PO QD. Treatment repeats every 3 weeks for 4 cycles (for patients with no measurable disease) or continues in the absence of disease progression or unacceptable toxicity (for patients with measurable disease).
89178462|NCT04105140|Experimental|male oxytocin group|male subjects with oxytocin treatment
89178463|NCT04105140|Placebo Comparator|male placebo group|male subjects with placebo treatment
89178464|NCT00622180|Active Comparator|Daavlin Right vs. Excilite Left|Right hand treated with narrow-band UVB light and left hand treated with focal 308nm light.
89178465|NCT00622180|Active Comparator|Excilite Right vs. Daavlin Left|Right hand treated with focal 308-nm light and left hand treated with narrow-band UVB light
89178466|NCT02601768||ASD II|Transcatheter closure of ASD II
89178467|NCT00840502||Pregnant women|Pregnant women who present at the SMRU antenatal clinics on the Thai Burmese border.
89178468|NCT00840580|Experimental|Vigamox|One drop 4 times a day in study eye for one week prior to surgery, followed by one drop 4 times a day for two weeks beginning Day 1 post surgery.
89178469|NCT00840580|Active Comparator|Cravit|One drop 4 times a day in study eye for one week prior to surgery, followed by one drop 4 times a day for two weeks beginning Day 1 post surgery.
89178470|NCT00773136|Active Comparator|Bimatoprost Suspension|Intervention to be administered: Each subject was given two suspensions, one mixed with Bimatoprost and one mixed with normal saline. They were instructed to use each suspension to a pre-determined eyelash (prepared prior to study enrollment in double blind fashion and marked after randomization with right and left). The intervention was the one eye with the Bimatoprost.
89178471|NCT00843388|Active Comparator|1|60 days treatment with tablet hexalacton 25 mg OD.
88835117|NCT02382913|Experimental|Group 3|Subjects received acellular pertussis (aP) vaccine with different antigen dose formulations: high dose of PT, FHA, PRN, followed by one fixed dose of diphtheria and tetanus vaccine (adsorbed, reduced antigen content, Germany) administered one month apart
88835118|NCT02382913|Experimental|Group 4|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: low dose of PT, FHA, PRN, low dose of D (diphteria) toxoid, fixed dose of T (tetanus) toxoid, followed by one administration of saline solution one month apart.
89001478|NCT00181649|Experimental|Recombinant human prolactin|
89001479|NCT00583843||Ultrasound|The group of women who are being followed by Ultrasound.
89178472|NCT00843388|Placebo Comparator|2|Inactive drug of 25 mg OD
89178473|NCT00843544|Experimental|Integrative Medicine|
89178474|NCT00843544|No Intervention|Control|
89178475|NCT02548234|Experimental|Mirror therapy|Mirror therapy group received training for 1.5 hours/day, 3 days/week, for 4 weeks and home programs for 30-40 min/day, 5 days/week.
89178476|NCT02548234|Experimental|Bilateral arm training|Bilateral arm training group received training for 1.5 hours/day, 3 days/week, for 4 weeks and home programs for 30-40 min/day, 5 days/week.
89178477|NCT02602860|Experimental|Levetiracetam|"Cohort 1: Half of the subjects will receive LEV as a 5 minute iv infusion during the second Positron Emission Tomography (PET) scan, 60 minutes after the start of [11C]UCB-J administration.~Cohort 2: Half of the subjects will receive LEV as a 5 minute iv infusion during the first PET scan, 60 minutes after the start of [11C]UCB-J administration. The dose of LEV (500 mg to 2500 mg) or BRV (50 mg to 200 mg) will be decided based on the data obtained in Cohort 1. Subjects will return for a second PET imaging session (Visit 4), 7 to 28 days after completion of their first session (Visit 3) to enter the BRV arm."
88835119|NCT02382913|Experimental|Group 5|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: medium dose of PT, FHA, PRN, low dose of D toxoid, fixed dose of T toxoid, followed by one administration of saline solution one month apart.
88835120|NCT02382913|Experimental|Group 6|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: high dose of PT, FHA, PRN, low dose of D toxoid, fixed dose of T toxoid, followed by one administration of saline solution one month apart.
88835121|NCT02382913|Experimental|Group 7|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: low dose of PT, FHA, PRN, double dose of D toxoid, fixed dose of T toxoid, followed by one administration of saline solution one month apart.
88835122|NCT02382913|Experimental|Group 8|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: medium dose of PT, FHA, PRN, double dose of D toxoid, fixed dose of T toxoid, followed by one administration of saline solution one month apart
88835123|NCT02382913|Experimental|Group 9|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: high dose of PT, FHA, PRN, double dose of D toxoid, fixed dose of T toxoid, followed by one administration of saline solution one month apart.
88835124|NCT02382913|Active Comparator|Group 10|Subject received one dose of a licensed TdaP booster vaccine (containing 8 μg each of PT, FHA and 2.5 μg of PRN antigens and 2.5 Lf of diphtheria toxoid and 5 Lf of tetanus toxoid) followed by one administration of saline solution one month apart
88835125|NCT05718037|Experimental|LY|Young adult subjects received low dose of BV211
88835126|NCT05718037|Experimental|HY|Young adult subjects received high dose of BV211
88835127|NCT05718037|Placebo Comparator|Placebo|Young adult subjects received placebo
88835128|NCT05718037|Experimental|LO|Old adult subjects received low dose of BV211
88835129|NCT05718037|Experimental|HO|Old adult subjects received high dose of BV211
88835130|NCT05718037|Active Comparator|Control Vaccine|Old adult subjects received control vaccine
88835131|NCT05717881|Experimental|Propolis|"Propolis supplements were packaged in marine capsules and consisted of poplar propolis powder (propolis concentrate, carob powder, magnesium stearate and silicon dioxide), concentrated to 30% total polyphenols.~Each supplementation period lasted 3 months, with a 2-week wash-out period, to allow total excretion of polyphenols by the body and do not interfere with the new supplementation phase.~The subjects in this study were submitted to five visits, allowing the tracking of biological parameters (clinical examination, fasting blood samples, HGPO) during the study. During the supplementation phases, follow-up by telephone call was performed."
88835132|NCT05717881|Placebo Comparator|Placebo|"Placebo powder capsules (maltodextrin, fatty acids, magnesium salts and silicon dioxide) are presented in the same packaging to have an identical appearance and taste. Patients in the propolis group were dosed with propolis to reach 6 mg total polyphenols/kg body weight, based on the results of a previous preclinical study in mice.~Each supplementation period lasted 3 months, with a 2-week wash-out period, to allow total excretion of polyphenols by the body and do not interfere with the new supplementation phase.~The subjects in this study were submitted to five visits, allowing the tracking of biological parameters (clinical examination, fasting blood samples, HGPO) during the study. During the supplementation phases, follow-up by telephone call was performed."
88835133|NCT00355303|Active Comparator|Misoprostol tablet, PGE2 gel|participants are assigned to one of two arms for the duration of the study In one group induction of labour is done by intravaginal misoprostol tablets at 4 hrly interval with maximum of five doses.In other group PGE2 gel is applied in poaterior fornix at six hourly interval.
88835134|NCT05717569|Active Comparator|Group A|Group A: Stoss vitamin D therapy
88835135|NCT05717569|Active Comparator|Group B|Group B: Oral vitamin D therapy .
88835136|NCT05716633||Acute Pancreatitis|Patients with acute pancreatitis will undergo serial MRI
88835137|NCT02385097|Experimental|Chloroprocaine HCl 2% (20 mg/mL)|Chloroprocaine 2 % Solution for injection, single administration by axillary nerve route 20 mL
88835138|NCT02385097|Active Comparator|Ropivacaine 0.75% (7.5 mg/mL)|Ropivacaine 0.75% Solution for injection, single administration by axillary nerve route 20 mL
88835139|NCT02387359|Active Comparator|3.0 mg plecanatide|Plecanatide 3.0 mg dosed daily for 12 weeks
88835140|NCT02387359|Active Comparator|6.0 mg plecanatide|Plecanatide 6.0 mg dosed daily for 12 weeks
88835141|NCT02387359|Active Comparator|Matching placebo|Placebo dosed daily for 12 weeks
88835142|NCT02387749|Experimental|mesenchymal stem cells|The BM aspirate will be diluted at 6:1 ratio with phosphate buffer saline with 2 ml EDTA (30 ml BM aspirate+ 5 ml PBS/EDTA buffer).MNCs will be separated under aseptic conditions using a Ficoll. Hypaque desity gradient by centrifugation at 1800 rpm for 20 min then the MNCs will be plated in 40 ml(αMEM), serum free media; mesencult(MSCs culture),penicillin (100 U/ml),streptomycin(10 mg/ml),0.5 ml amphotericin B(all from Gibco BRL) and 10 ng/ml basic fibroblast growth factor (b-FGF)(R&D system, Minneapolis, MN) and will be incubated at 370 c in a humidified atmosphere containing 5% CO2 .after one day ,nonadherent cells will be cultured in the presence of Mesenchymal media for 3 weeks changed every week. After reaching 80% confluence the MSCs will be placed in 10 ml saline and infused IV.
88835143|NCT05712655||Study group|Post-pubertal females with forward head posture and temporomandibular disorders
88835144|NCT05712655||Control group|Post-pubertal females with neutral head posture and with no temporomandibular disorders
88835145|NCT02390791|Experimental|enhanced myADHDportal.com|Version of the myADHDportal.com web software enhanced with family-management support to enable parents to be active partners in optimizing and maintaining medication continuity for their child
89001480|NCT04575454|Other|Comatose or post-comatose patients|
89364063|NCT01348230||prior preterm delivery at 32-34 weeks|collect their first morning urine samples before each of their remaining prenatal care appointments for our studies
88835146|NCT02390791|Active Comparator|treatment as usual standard portal|Standard version of myADHDportal.com web software
88835147|NCT02392351|Experimental|Renal Denervation|Percutaneous renal denervation using the Vessix Reduce™ Catheter and Vessix™ Generator (Vessix Renal Denervation System).
88835148|NCT02392351|Sham Comparator|Masked Procedure|Percutaneous renal angiography
89364064|NCT01348230||prior preterm delivery at 34-36 weeks|collect their first morning urine samples before each of their remaining prenatal care appointments for our studies
89364065|NCT01348308|Active Comparator|Maraviroc|Maraviroc 300, 600 or 1200mg per day
88835149|NCT02393677|Placebo Comparator|Ropivacaine|amide local anesthetic
88835150|NCT02393677|Active Comparator|Ropivacaine with Dexmedetomidine|combination of amide local anaesthetic and alpha2 agonist
88835151|NCT02394457|Experimental|Intravenous Cosyntropin Group A|Cosyntropin 500 mcg in 1000cc Normal Saline
88835152|NCT02394457|Active Comparator|Epidural Blood Patch Group B|Epidural Blood Patch and I000cc Normal Saline
88835153|NCT05686213|Experimental|combined aerobic exercise + resistance exercise intervention (AE + RE)|Physical exercise during neaodjuvant chemoradiation
88835154|NCT05686213|Experimental|Aerobic exercise prior to daily radiotherapy sessions (ExPR)|Physical exercise during neaodjuvant chemoradiation
88835155|NCT05686213|No Intervention|Usual care control (UC)|The control group will receive usual care and will be requested to maintain their usual daily physical activities.
88835156|NCT04923763||Tongue_examination|The general public will be invited for tongue examination. The data will be used to establish the automatic tongue video analysis system.
88835157|NCT00355771|Experimental|Treatment Group 1|
88835158|NCT00355771|Placebo Comparator|Treatment Group 2|
88835161|NCT05664139|Experimental|Experimental Arm|"Recombinant Human Adenovirus Type 5 Injection: 1ml or 2ml, d1, q3w, 4 cycles;~Camrelizumab: 200mg, d2, q3w;~Nab-paclitaxel: 260mg/m2, d1, q3w, 4-6 cycles;"
88835162|NCT05463211|Experimental|Trexo Plus Pediatric Exoskeleton|Experimental lower-limb wearable pediatric exoskeleton used biweekly in clinical and school settings.
88835163|NCT03224351|Placebo Comparator|Part 1: Placebo|Participants received placebo matched to VX-659/TEZ/IVA in TC treatment period for 4 weeks and placebo matched TEZ/IVA in washout period for 4 days.
88835164|NCT03224351|Experimental|Part 1: VX-659/TEZ/IVA TC - Low Dose|Participants received VX-659 80 milligram (mg) once daily (qd)/TEZ 100 mg qd/IVA 150 mg every 12 hours (q12h) in TC treatment period for 4 weeks and TEZ 100 mg qd/IVA 150 mg q12h in washout period for 4 days.
88835165|NCT03224351|Experimental|Part 1: VX-659/TEZ/IVA TC - Medium Dose|Participants received VX-659 240 mg qd/TEZ 100 mg qd/IVA 150 mg q12h in TC treatment period for 4 weeks and TEZ 100 mg qd/IVA 150 mg q12h in washout period for 4 days.
88835166|NCT03224351|Experimental|Part 1: VX-659/TEZ/IVA TC - High Dose|Participants received VX-659 400 mg qd/TEZ 100 mg qd/IVA 150 mg q12h in TC treatment period for 4 weeks and TEZ 100 mg qd/IVA 150 mg q12h in washout period for 4 days.
88835167|NCT03224351|Active Comparator|Part 2: TEZ/IVA|Following run-in period with TEZ 100 mg qd/IVA 150 mg q12h for 4 weeks, participants received TEZ 100 mg qd/IVA 150 mg q12h in TC treatment period for 4 weeks and TEZ 100 mg qd/IVA 150 mg q12h in washout period for 4 weeks.
88835168|NCT03224351|Experimental|Part 2: VX-659/TEZ/IVA TC|Following run-in period with TEZ 100 mg qd/IVA 150 mg q12h for 4 weeks, participants received VX-659 400 mg qd/TEZ 100 mg qd/IVA 150 mg q12h in TC treatment period for 4 weeks and TEZ 100 mg qd/IVA 150 mg q12h in washout period for 4 weeks.
88835169|NCT03224351|Placebo Comparator|Part 3: Placebo|Participants received placebo matched to VX-659/TEZ/VX-561 in TC treatment period for 4 weeks.
88835170|NCT03224351|Experimental|Part 3: VX-659/TEZ/VX-561 TC|Participants received VX-659 400 mg qd/TEZ 100 mg qd/VX-561 200 mg qd in TC treatment period for 4 weeks.
89364066|NCT01348308|Placebo Comparator|Placebo|Placebo 300, 600 or 1200mg per day
89364067|NCT04078386|Experimental|RC18 240mg|
89364068|NCT04078386|Experimental|RC18 160 mg|
89364069|NCT04078386|Placebo Comparator|Placebo|
89364070|NCT04074174|Experimental|NNC0174-0833 treatment-free period; NNC0174-0833 treatment|During the NNC0174-0833 treatment-free period participants will receive OC tablets and acetaminophen. During the NNC0174-0833 treatment period participants will receive OC tablets and acetaminophen in addition to NNC0174-0833.
89364071|NCT01348386|Experimental|KOH 10%|Treatment consists of the application of topical 10% KOH in an aqueous solution.
89364072|NCT01348386|Experimental|KOH 15%|Treatment consists of the application of topical 15% KOH in an aqueous solution
89364073|NCT01348386|Placebo Comparator|PLACEBO|100 milliliters of saline solution
89364074|NCT03620292|Experimental|Intraoperative NIR fluorescence imaging|"A non-randomized, non-blinded, prospective, single center pilot dose escalation study with bevacizumab-800CW for NIR fluorescence image guided surgery in hilar cholangiocarcinoma~IV-administration of 10, 25 or 50 mg of the fluorescent tracer bevacizumab-800CW to a total of 15 patients with resectable hilar cholangiocarcinoma 3 days prior to surgery.~Peroperative open air NIR fluorescence imaging~Ex vivo endoscopic and histopathological NIR fluorescence imaging"
89364075|NCT01345266|Other|Inhalation Profiling|All subjects have Inhaltion profiling, there are no other arms.
89364076|NCT05252026|Experimental|PROCARE-I (UP-A for indicated purposes)|To ensure cost-effectiveness, PROCARE-I intervention will be designed as a brief 8-session child-focused programme by adapting the core modules from UP-A, along with one individual session with adolescent and parents. Sessions will be delivered in reduced groups, using a typical indicated preventive intervention format focused on cost-effectiveness.
89364077|NCT05252026|Experimental|Active control condition|"The active control condition will be based on the U talk programme developed by Prf. Jill Ehrenreich-May at University of Miami and colleagues. It follows a similar structure as the UP-A original programme and allows for one alternative compare condition to PROCARE-I. The U Talk programme support-based group condition will be used as active control condition."
89364078|NCT01353378|Experimental|dexmedetomidine|intravenously injecting 0.125microgram/kg and 0.25microgram/kg within 10 minutes as soon as the operation begins respectively.
89364079|NCT01465334|Experimental|Treatment Naive|"Participants were assigned to 1 of 2 groups based on prior treatment status. Both groups received the same therapy as follows (cycle duration=28 days):~Induction Part A: Ofatumumab + HDMP 2-4 cycles~Ofatumumab: cycle 1 - 300 mg intravenously (IV) Day 1 then 1000 mg IV Days 8, 15, 22; cycles 2-4 - 1000 mg IV Days 1, 8, 15, 22~High-Dose Methylprednisolone (HDMP): 1000 mg/m2 IV Days 1-3~Participants with nodal complete response at cycle 2 re-staging then discontinued Part A therapy.~Induction Part B: Ofatumumab + Alemtuzumab 1-6 cycles~Ofatumumab: 1000 mg IV Day 1~Alemtuzumab: 30 mg subcutaneously Days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24 and 26~Participants with at least stable disease could continue continue to Part C or, if eligible, proceed to allogeneic stem cell transplant (SCT) off study.~Maintenance Part C: Ofatumumab + Alemtuzumab up to 26 cycles~Ofatumumab: 1000 mg IV Day 1 every other cycle~Alemtuzumab: 30 mg subcutaneously Days 14, 28"
88835171|NCT05658055|Active Comparator|Amoxicillin combined with vonoprazan|The subjects will be given 20mg vonoprazan twice a day and 1000mg amoxicillin three times a day. These two drugs were taken continuously for 14 days
88835172|NCT05658055|Experimental|Probiotics combined with vonoprazan and amoxicillin|The subjects will be given 20mg vonoprazan twice a day, 1000mg amoxicillin three times a day and probiotics three times a day. These three drugs were taken continuously for 14 days.
88835173|NCT04745533||SARS-CoV2 contacts|Subjects considered close contacts of COVID-19 patients according to the definition of the Ministry of Health in the health area of Cáceres.
88835174|NCT03911375|Experimental|Mindfulness Based Stress Reduction (MBSR)|Program of 30 hours of duration divided into 9 sessions with a weekly frequency of 2.5 h and an intensive session between week 6 and 7 of the program with a duration of 7.5 hours.
88835175|NCT03911375|No Intervention|Control|Participants assigned to the control group will follow the usual treatment, according to their diagnosis.
88835176|NCT05459155|Experimental|Pharmacist team post-intervention|The direct subjects will be the inpatient pharmacists who round with general medicine teams and approve inpatient medication orders. They will be given full access to the Synapse Medicine medication decision support platform.
88835177|NCT05459155|No Intervention|Pharmacist team pre-intervention|Pre-intervention, the inpatient pharmacists will round with general medicine teams and approve inpatient medication orders under conditions of usual care. They will base their recommendations on their knowledge and training and any tools (electronic or otherwise) that they choose to use.
88835178|NCT01721876|Experimental|Volasertib and Cytarabine|
88835179|NCT01721876|Placebo Comparator|Placebo and Cytarabine|
88835180|NCT05455411|Experimental|Group-based Parent-implemented Social Communication Training|A group-based parent-implemented social communication treatment program for up to 8 parents of children with autism spectrum disorder
88835181|NCT05455411|Active Comparator|Individual-based Parent-implemented Social Communication Training|An individual-based parent-implemented social communication treatment program for a parent of a child with autism spectrum disorder
88835182|NCT03224585|Experimental|Anakinra|100 mg subcutaneous injection
88835183|NCT03224585|Placebo Comparator|Placebo|100 mg NaCl 0.9% subcutaneous injection
89001481|NCT00583882|Other|1|Change every 6 days, rewire every 6 days
89001482|NCT00583882|Other|2|New site every 6 days
88835184|NCT05452681|Experimental|Y-AMBIENT|"Y-AMBIENT is a four-month, telephone-based intervention that includes three themed education sessions with three follow-up sessions, written materials, and videos. All themed education and follow-up sessions are conducted according to the respective Y-AMBIENT session outlines and audio-recorded. Session 1, titled My Self, My Soul, covers topics related to spiritual growth and finding meaning in illness. Session 2, titled My Body, covers topics related to breast changes, aches/pains, fatigue, and weight changes. Session 3, titled My Mind and My Relationships, covers topics related to anxiety, fear, and relationships with others. The sessions will take approximately one hour, with follow-ups lasting about 20 minutes. Participants will receive both printed and electronic PDF versions of written materials, in addition to video links, to reinforce content delivered during Sessions."
88835185|NCT05452681|Active Comparator|Attention Control|"The control condition will consist of receiving a culturally-targeted cookbook applied by an adapted Food for Thought cookbook, a guide to grocery shopping smart, and telephone socialization calls. We opted to use the cookbook and guide as conversation pieces given cultural practices associated with food and avert financial constraints with shopping tips. During three, one-hour socialization calls, we will use scripted questions to encourage discussion about the participant, cookbook and guide, and obtain information about survivorship concerns without providing coaching. The follow-up calls will last about 20 minutes."
88835186|NCT01457612|Placebo Comparator|Placebo1|Placebo Beverage 1 without fiber
88835187|NCT01457612|Active Comparator|Strawberry|Strawberry Beverage 20g/BID
88835188|NCT01457612|Placebo Comparator|Placebo2|Placebo Beverage 2 with Fiber
88835189|NCT03423641||Direct Acting Antivirals|Patients who receive a direct acting antiviral enter the DAA cohort at the time of initiation of the drug.
88835190|NCT03423641||Comparison|The exposure time of patients who have not received a direct acting antiviral (patients can change from the comparison to the DAA group once they receive the medication)
88835191|NCT04832659|Active Comparator|CEASE|Those assigned to the Active Comparator arm will receive the CEASE intervention.
88835192|NCT04832659|Experimental|CEASE + BIO|Those assigned to the Experimental CEASE + BIO arm will receive the CEASE intervention plus Biomarker Informed Outreach (BIO).
88835193|NCT01112072|Active Comparator|Intacs combined with CXL|Intacs placement followed by collagen crosslinking with UV light and riboflavin
88835194|NCT01112072|Active Comparator|Intacs followed by CXL|Intacs placement, to be followed by corneal collagen crosslinking with UV light and riboflavin 3 months later
88835195|NCT05437159|Experimental|Sub-syllabic learning and fMRI|60 adults with neurotypical speech development will participate in this arm. Subjects will learn novel 1-syllable nonsense words formed by non-native phoneme combinations during 6 training sessions over 2 days. Following training, subjects will participate in a functional magnetic resonance imaging (fMRI) session on a third day to measure brain activity associated with producing the words learned during training and with a set of unfamiliar words also formed by non-native phoneme combinations.
88835196|NCT05437159|Experimental|Sub-syllabic learning and anodal tDCS of inferior frontal sulcus|35 adults with neurotypical speech development will participate in this arm. Subjects will learn novel 1-syllable nonsense words formed by non-native phoneme combinations. During the training, anodal transcranial direct current stimulation (tDCS) will be applied to the the subject's left inferior frontal sulcus.
88835197|NCT05437159|Experimental|Sub-syllabic learning and anodal tDCS of cerebellum|35 adults with neurotypical speech development will participate in this arm. Subjects will learn novel 1-syllable words formed by non-native phoneme combinations. During the training, continuous anodal transcranial direct current stimulation (tDCS) will be applied to the the subject's right cerebellum.
88835198|NCT05437159|Sham Comparator|Sub-syllabic learning and sham tDCS|35 adults with neurotypical speech development will participate in this arm. Subjects will learn novel 1-syllable words formed by non-native phoneme combinations. During training, Sham transcranial direct current stimulation stimulation (tDCS) will be delivered to the subject's brain.
88835199|NCT05437159|Experimental|Multisyllabic learning and fMRI in adults|30 adults persistent developmental stuttering (AWS) and 30 adults with neurotypical speech development (ANS) will participate in this arm. Subjects will learn nonsense words formed by novel combinations of 3 syllables that are legal in American English during 6 training sessions over 2 days. Following training, subjects will participate in a functional magnetic resonance imaging (fMRI) session on a third day to measure brain activity associated with producing the words formed by pairing 2 learned 3-syllable strings learned during training and those formed by pairing 2 unfamiliar 3-syllable strings. Behavioral measures extracted from the data will be used to compare performance before and after training and across the AWS and ANS participants.
88835200|NCT05437159|Experimental|Multisyllabic learning in children|45 children with persistent developmental stuttering (CWS) and 45 children with neurotypical speech development (CNS) will participate in this arm. Subjects will learn nonsense words formed by novel combinations of 2 syllables that are legal in American English during 6 training sessions over 2 days. Behavioral measures extracted from the data will be used to compare performance before and after training and across the CWS and CNS participants.
88835201|NCT05437159|Experimental|Sub-syllabic learning in PPA|30 adults with primary progressive aphasia (PPA) will participate in this arm. Subjects will learn novel 1-syllable nonsense words formed by non-native phoneme combinations during 8 training sessions over 2 days. Following training, subjects will complete a behavioral test to compare their performance on the words learned during training with a set of unfamiliar words also formed by non-native phoneme combinations.
88835202|NCT05662514|Experimental|Probiotic group|Esomeprazole 20 mg and bismuth 2g twice daily before meals, amoxicillin 1 g, and clarithromycin 500 mg twice daily after meals, probiotic once a day with one packet each time 2 hours after taking medicine above in the evening, for 2 weeks.
88835203|NCT05662514|Placebo Comparator|Placebo group|Esomeprazole 20 mg and bismuth 2g twice daily before meals, amoxicillin 1 g, and clarithromycin 500 mg twice daily after meals, placebo once a day with one packet each time 2 hours after taking medicine above in the evening, for 2 weeks.
88835204|NCT04825795||DPP4-inhibitor|Patients who were prescribed DPP4-inhibitor during the period between two coronary CT scan.
88835205|NCT04825795||No DPP4-inhibitor|Patients who were not prescribed DPP4-inhibitor during the period between two coronary CT scan.
88835206|NCT03225599|Experimental|Procedure|
88835207|NCT05659238||1|those who exposed early to TV (before 1 year age)with long time of exposure/day (6hours\day or more)
89364080|NCT01465334|Experimental|Relapsed/Refractory|"Participants were assigned to 1 of 2 groups based on prior treatment status. Both groups received the same therapy as follows (cycle duration=28 days):~Induction Part A: Ofatumumab + HDMP 2-4 cycles~Ofatumumab: cycle 1 - 300 mg intravenously (IV) Day 1 then 1000 mg IV Days 8, 15, 22; cycles 2-4 - 1000 mg IV Days 1, 8, 15, 22~High-Dose Methylprednisolone (HDMP): 1000 mg/m2 IV Days 1-3~Participants with nodal complete response at cycle 2 re-staging then discontinued Part A therapy.~Induction Part B: Ofatumumab + Alemtuzumab 1-6 cycles~Ofatumumab: 1000 mg IV Day 1~Alemtuzumab: 30 mg subcutaneously Days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24 and 26~Participants with at least stable disease could continue continue to Part C or, if eligible, proceed to allogeneic stem cell transplant (SCT) off study.~Maintenance Part C: Ofatumumab + Alemtuzumab up to 26 cycles~Ofatumumab: 1000 mg IV Day 1 every other cycle~Alemtuzumab: 30 mg subcutaneously Days 14, 28"
89364081|NCT01348464||lifestyle, wound satisfaction|single site access three site access for appendectomy
89364082|NCT04019262|Active Comparator|40 Gy in 15 fractions|Patients randomized to 40 Gy in 15 fractions will receive 75 mg/m^2 temozolomide per day for 15 days starting the first day of radiotherapy. This treatment will be followed by standard monthly 5 day cycles at 150 mg/m^2 for upto 1 year.
89364083|NCT04019262|Active Comparator|25 Gy in 5 fractions|Patients randomized to 25 Gy in 5 fractions will receive 150 mg/m^2 temozolomide per day for 5 days starting the first day of radiotherapy. This treatment will be followed by standard monthly 5 day cycles at 150 mg/m^2 for upto 1 year.
89364084|NCT03626246||Kidney disease|Patients who participate in our study are 40 years old or older and have a Chronic kidney disease stage 3, 4 or 5.
89364085|NCT00702208|Other|Single arm study|Paired laboratory results for clinician-collected and Screener collected specimens for cytology (and high-risk human papillomavirus testing for sub-sample)
89001483|NCT00583882|Other|3|New site every 12 days
89001484|NCT03453034|Experimental|TQ-B3233 capsule|QD or BID; patients are given the doses according to the protocal, and a cycle is 28 days.
88817044|NCT03184233|Active Comparator|Craniotomy without RVP|"Subjects receive a Magnetic Resonance Imaging of the brain pre-and postoperatively as standard of care. To screen for rapid ventricular pacing induced micro-infarcts, the contralateral hemisphere (contralateral to the hemisphere operated on) and fossa posterior will be evaluated. Troponin levels will be determinated preoperatively, peroperative and at 6, 12 and 24 hours postoperative by blood sample. Maximum cTnl level and cTnl level 24 hours will be compared. Brain oxygenation (Sct O₂) by near-infrared spectroscopy will be monitored.~No rapid ventricular pacing is applied perioperatively."
88817045|NCT03184194|Experimental|Nivolumab-daratumumab|daratumumab 16 mg/kg: 8 times once weekly, then 8 times every 2 weeks; then every 4 weeks; nivolumab: 240 mg every 2 weeks during first 6 cycles, followed by 480 mg every 4 weeks
88817046|NCT03184194|Experimental|Nivolumab-daratumumab with cylclophosphamide|daratumumab 16 mg/kg: weekly for 8 weeks, then Q2W for 16 weeks, ten Q4W thereafter; nivolumab: 240 mg every 2 weeks during first 6 cycles, followed by 480 mg every 4 weeks; low-dose cyclophosphamide 50mg daily on days 1-28 of each 28-day cycle;
88817047|NCT03111667|Experimental|Student Participants: Teen Marijuana Check Up|2 Session Motivational Enhancement Therapy intervention for adolescents who use marijuana.
89364086|NCT02464618|No Intervention|Usual care|The social contact of patients in this arm will not be contacted
89364087|NCT02464618|Active Comparator|Social contact intervention|The social contact of patients in this arm will be contacted and asked to facilitate the endoscopy care plan of the patient
89364088|NCT05322746|Experimental|Group A|"Focal Muscle vibration will be apply to:~Tibialis anterior~The distal quadriceps~Belly of the gastrocnemius/soleus muscles.~Sinusoidal vibration intensity range 120 Hz.~Each muscle will vibration for 10 minutes~10 minutes per muscle duration; total 30 minutes"
89364089|NCT05322746|Active Comparator|Group B|"Focal Muscle vibration similar to Group A with following:~Conventional Therapy TENS with pulse width 250ms, intensity 14Hz for 30 minutes~Exercise therapy:~Stretching Exercise to:~Calf~Hamstring~Quadriceps"
89364090|NCT05322746|Active Comparator|Group C|"TENS with pulse width 250ms, intensity 14Hz for 30 minutes~Exercise therapy:~Stretching Exercise to:~Calf~Hamstring~Quadriceps"
88835208|NCT05659238||2|those who exposed later to TV (after 2 years of age) with short time of exposure/day.(2 hours \day or less)
88835209|NCT03226223|Placebo Comparator|Naltrexone 0 mg|This aim assess the effects of pretreatment with 0 mg of naltrexone on laboratory measures of the abuse potential of methamphetamine (30mg/70 kg).
88835210|NCT03226223|Experimental|Naltrexone 50 mg|This aim assess the effects of pretreatment with 50 mg of naltrexone on laboratory measures of the abuse potential of methamphetamine (30mg/70 kg).
88835211|NCT05620771|Experimental|Y90 + Atezolizumab and Bevacizumab|
88835212|NCT05620771|Experimental|Y90 + TKI|
88835213|NCT05716880|Experimental|KA+MPD|Ketosteril + Medium Protein Diet (MPD) for 12 months
88835214|NCT05716880|Active Comparator|MPD|Medium Protein Diet (MPD) for 12 months
88835215|NCT04735991|No Intervention|Control group|The patient's family members need to fill in the family member quality of life questionnaire during the screening and follow-up period. They are able to contact the doctor for questions in terms of medical treatment.
88835216|NCT04735991|Experimental|Study group|The family members of the patients need to fill in the family member quality of life questionnaire during the screening period and follow-up period, and are involved in an interactive management program on the mobile terminal, full participation required.
88835217|NCT05419297|Active Comparator|Active drug arm|Subjects who meet eligibility criteria and complete a single blind placebo lead in will be provided placebo buprenorphine buccal film that mimics the actual drug comparator and is continued by a blinded individual throughout the duration of the trial.
88835218|NCT05419297|Placebo Comparator|Placebo arm|Subjects who meet eligibility criteria and complete a single blind placebo lead in will be provided active buprenorphine buccal film that is titrated to the effective dose and continued by a blinded individual throughout the duration of the trial.
88835219|NCT03226457|Active Comparator|Empagliflozin/Placebo|Empagliflozin (SGLT2 inhibitor) 25mg capsules once daily for 6 weeks, minimum of a 2 week washout period, then 6 weeks placebo
88835220|NCT03226457|Active Comparator|Placebo/Empagliflozin|Placebo for 6 weeks, minimum of a 2 week washout period, followed by Empagliflozin (SGLT2 inhibitor) 25mg capsules once daily for 6 weeks
88835221|NCT05610787|Experimental|Active Driver Primary Arm|Up to 40 patients whom receive the Active Driver from implant.
88835222|NCT05610787|No Intervention|IKUS Comparator|All patients whom receive the (FDA approved) IKUS Driver from implant and are entered into the ACTION Registry.
88835223|NCT04344548|Experimental|Treatment group|Adult patients with COVID-19 infection with NEWS 2 score >4
88835224|NCT01963065||Moderately pre-term infants and their mothers|cohort of moderately pre-term infants and their mothers
88835225|NCT03721029|Experimental|Intraoperative nerve monitoring|Patients that undergo robotic-assisted radical prostatectomy with the use intraoperative nerve monitoring, via electromyography, to identify the exact location of the somatic fibers in the pelvic nerves that seem crucial for urinary continence control and erectile function
88835226|NCT03721029|Active Comparator|Control Cohort|Patients that undergo standard of care robotic-assisted radical prostatectomy.
88835227|NCT03228017|Other|Psoriatic Disease Patients|Moderate to severe psoriatic disease
88835228|NCT03228017|No Intervention|Healthy Control|
88835229|NCT02978300|Active Comparator|NIV/HFNC group|Continuous NIV for at least 4 hours until clinical improvement then intermittent 1-hour sessions for a minimal duration of 12 hours a day. Between NIV sessions HFNC will be delivered as in the HFNC group.
88835230|NCT02978300|Experimental|HFNC group|Continuous HFNC alone 24h/24 until weaning or intubation.
88835231|NCT00357422|Active Comparator|surgery|
88835232|NCT00357422|Active Comparator|local therapy|
88835233|NCT05647538||control group|underwent normal cesarean section without Postpartum hemorrhage after delivery
88835234|NCT05647538||case group|cases underwent bilateral uterine artery ligation after Postpartum hemorrhage or Intrapartum hemorrhage after cesarean section.
88835235|NCT03358355|Experimental|Intervention|Subcutaneous injection of unacylated ghrelin: Doses of 10 ug/kg, 20 ug/kg, and 40 ug/kg
88835236|NCT05716568|Active Comparator|Standard contrast dose|Standard contrast dose administration
88835237|NCT05716568|Active Comparator|Calculated contrast dose|Contrast dose by calculation
88835238|NCT05716568|Active Comparator|Calculated contrast dose -50%|Contrast dose by calculation, with extra dilution by 50%.
88835239|NCT02959268|Other|Single arm Al-Sense diagnostic|Investigator blinded to subject assessments
88835240|NCT00356005|Experimental|Azithromycin + Artesunate|Azithromycin + Artesunate treatment
88835241|NCT00356005|Active Comparator|Artesunate|Artesunate treatment controls
88835242|NCT00376337|Active Comparator|1|infusion for 3-12 weeks
88835243|NCT00376337|Experimental|2|infusion for 3-12 weeks
88835244|NCT02959346|Sham Comparator|Sham Acupuncture|After recruitment, participants will be randomized to receive acupuncture or sham acupuncture treatment. In the sham acupuncture group, participants will receive sham acupuncture.
88835245|NCT02959346|Experimental|Acupuncture|After recruitment, participants will be randomized to receive acupuncture or sham acupuncture treatment. In the acupuncture group, participants will receive acupuncture.
89364091|NCT02464774|Experimental|Breast-Conserving Therapy|"Patients undergo lumpectomy with surgical axillary staging with all lesions resected to negative margins.~Within 4-8 weeks after surgery, patients receive adjuvant chemotherapy as follows:~TC for stage I: Docetaxel 75 mg/m + Cyclophosphamide 600 mg/m, cycled every 21 days for 4 cycles.~TAC for stage II: Docetaxel 75 mg/m + Doxorubicin 50 mg/m + Cyclophosphamide 500 mg/m, cycled every 21 days for 6 cycles.~Within 4-8 weeks after completion of chemotherapy, patients undergo radiation therapy as follows:~N0: Radiation therapy to whole breast (+boost to tumor bed). N1: Radiation therapy to whole breast (+boost to tumor bed), infraclavicular region, and supraclavicular area with or without radiation therapy to internal mammary nodes."
89364092|NCT02464774|Active Comparator|Mastectomy|"Patients undergo mastectomy (MT) with surgical axillary staging.~Within 4-8 weeks after surgery, patients receive adjuvant chemotherapy as follows:~TC for stage I: Docetaxel 75 mg/m + Cyclophosphamide 600 mg/m, cycled every 21 days for 4 cycles.~TAC for stage II: Docetaxel 75 mg/m + Doxorubicin 50 mg/m + Cyclophosphamide 500 mg/m, cycled every 21 days for 6 cycles."
89364093|NCT05583578|Experimental|Active tDCS|
89364094|NCT05583578|Sham Comparator|Sham tDCS|
89178478|NCT02602860|Experimental|Brivaracetam|"Cohort 1:Half of the subjects will receive BRV as a 5 minute iv infusion during the second Positron Emission Tomography (PET) scan, 60 minutes after the start of [11C]UCB-J administration.~Cohort 2:Half of the subjects will receive BRV as a 5 minute iv infusion during the first PET scan, 60 minutes after the start of [11C]UCB-J administration. The dose of BRV (50-200 mg) will be decided based on the data obtained in Cohort 1. Subjects will return for a second PET imaging session,7 to 28 days after completion of their first session to enter the LEV arm.~Cohort 3:void Cohort 4:Subjects will take oral BRV (25-100 mg bid) for 4 days and a single dose of BRV on Day 5. Pre-/post-block scans will be obtained at the first dose, one post-block scan after the last dose. Additional post-block scans may be obtained 8-10 and 28h or later after last dose; if last scan not needed, subject will return 7 to 28 days later for a post-block scan. Dose range for LEV in Cohort 4 will be 250 to <1500mg."
89364095|NCT05549726|Experimental|Dynamic choice prevention (including CAB LA)|The Dynamic Choice Delivery Model includes integrated PrEP and PEP services at outpatient clinics, antenatal clinics, and via VHT workers in community households. CAB-LA will be integrated into the dynamic choice delivery model as an additional biomedical prevention option in a patient-centered delivery model based on the precede framework.
88817048|NCT03111667|Other|Student Participants: Treatment As Usual|Students will receive referrals to local agencies and other resources as typically done by school based staff. At the end of research follow-up period, students in this condition will be eligible to receive the active intervention.
89364096|NCT05549726|Active Comparator|Standard of Care|The standard of care for PEP or PrEP differs according to each country's guidelines.
89364097|NCT05536232|Experimental|LCD|
89364098|NCT00973856|Experimental|PURELL Left Hand/ Placebo Right Hand|"One product will be assigned to each hand to minimize treatment confusion for the participants.~PURELL VF481 Left Hand/ Placebo Right Hand"
89364099|NCT00973856|Placebo Comparator|Placebo Solution Left Hand/ PURELL Right hand|"One (1) product will be assigned to each hand to minimize treatment confusion for the participants PURELL VF481 Right Hand/ Placebo Left Hand~One (1) pump of test product (approximately 1.5ml) is applied to a wooden applicator and gently rubbed into the wart, then covered with a latex free adhesive bandage (it is not necessary to wait until dry) each night before bed"
89364100|NCT01348620|Experimental|Single port laparoscopic device|
89364101|NCT01348620|Active Comparator|Four-port laparoscopic device|
89364102|NCT01353456|Active Comparator|Dexmedetomidine|
88835246|NCT04329273|Experimental|Training group|"For the balance exercise the participants will perform one-legged stance of certain duration, on a stable surface.~For the sliding leg curl exercise the participants lay supine on a mat, wearing only socks in order to create a slippery surface between their heels and the gym floor. The player begins by extending the hip and having the working leg on knee flexion. The contralateral limb is on hip flexion and knee flexion. The base of support is the shoulder blades, the elbows and the heel of the working leg. After assuming this position, the player begins to extend the knee, as slowly as possible, resisting the low friction properties of the ground.~The core stability program consists of front plank, side planks, supine bridge, leg lowering and superman exercise. These exercises will be performed at the end of the training session, in contrast to the balance and hamstring exercises which will be executed before the training session."
88817049|NCT03111667|Experimental|Interventionist Participants: Gold Standard Coaching|Interventionists will receive weekly coaching and feedback about sessions and skills from the project PI.
88817050|NCT03111667|Active Comparator|Interventionist Participants: As Needed Coaching|Interventionists will receive coaching and feedback about sessions and skills from the project PI only when sessions fall below adherent skill levels.
88835247|NCT04329273|No Intervention|Control group|The participants in this group will follow only the usual training program
89178479|NCT00840736|Active Comparator|1|Laparoscopic adjustable gastric banding
89364103|NCT01353456|Placebo Comparator|Normal saline|
88817051|NCT03111667|No Intervention|Administrator Participants: Environment|School Administrators will provide data about the school environment.
89178480|NCT00840736|Active Comparator|2|vertical banded gastroplasty
89364104|NCT00920972|Experimental|Stratum 1|Recipients with non-malignant disorders, excluding thalassemia. Related or unrelated 8/8 HLA-matched bone marrow
89364105|NCT00920972|Experimental|Stratum 2|Recipient with transfusion dependent thalassemia. Related or unrelated. 8/8 HLA-matched bone marrow or 5-8/8 HLA-matched UCB
89364106|NCT00920972|Experimental|Stratum 3|Recipient with hemoglobinopathy Related or unrelated. 7/8 HLA-matched bone marrow or 5-8/8 HLA-matched UCB
89364107|NCT00920972|Experimental|Stratum 4|Recipient with non-malignant disorder, excluding hemoglobinopathy Related or unrelated. 7/8 HLA-matched bone marrow or 5-8/8 HLA-matched UCB
89364108|NCT01353534|Experimental|Group 1|3.8 mcg with AS03 adjuvant at D0 and 21
89364109|NCT01353534|Experimental|Group 2|15 mcg at D0 and 21
89364110|NCT01353534|Experimental|Group 3|15 mcg + 50 mcg VEP at D0 and 21
89364111|NCT01353534|Experimental|Group 4|30 mcg + 50 mcg VEP at D0
89364112|NCT01345422|Experimental|Wii Balance Board|Wii Balance Board Training
89364113|NCT01345500|Experimental|Higher Carbohydrate/Lower Fat Diet|
89364114|NCT01345500|Experimental|Lower Carbohydrate/Higher Fat Diet|
89364115|NCT01345500|Active Comparator|Individualized Counseling|
89364116|NCT04948814|Experimental|ASD children|20 ASD children who meet the eligibility requirements will receive a fecal microbiota transplantation following a 2-week treatment with Vancomycin (40mg/kg/day) after 3 month waiting period. Fresh stool sample will be obtained from the donor. Fecal bacteria transplantation will be achieved via endoscopy, nasogastric/nasointestinal tubes, the proximal colon by colonoscopy, or the distal colon by enema, rectal tube, or sigmoidoscopy or a combined approach. The amount of fecal bacterial liquid transplantation for children is 5ml/kg each time. Fecal microbiota transplantation will be conducted at week 3-4, week 6-7, week 9, week 11 and week 13 for total 5 round.
89364117|NCT02718898|Experimental|Ixekizumab|"Blinded Treatment Period: 160 milligrams (mg) ixekizumab given subcutaneously (SC) at baseline followed by 80 mg ixekizumab every 2 weeks (Q2W) SC from week 2 to week 10. At week 12, 80 mg ixekizumab and placebo given SC.~Open Label Period: 80 mg ixekizumab given SC every 4 weeks (Q4W) with an option for Q2W dosing starting at week 24, week 28 or week 40."
89364118|NCT02718898|Placebo Comparator|Placebo|"Blinded Treatment Period: Placebo given SC at baseline followed by placebo given SC Q2W from week 2 to week 10. At week 12, 160 mg ixekizumab given SC.~Open Label Period: 80 mg ixekizumab given SC Q4W with an option for Q2W dosing starting at week 24, week 28 or week 40."
89364119|NCT01353690|Experimental|AMDC|
89364120|NCT03619616|Experimental|ZSP1603 (single dose)-7.5 mg (Cohort 1)|Subject adminsitered at a dose of ZSP1603 7.5 mg on day 1 under fasted condition.
89364121|NCT03619616|Experimental|ZSP1603 (single dose)-12.5mg (Cohort 2)|"Subject adminsitered at a dose of ZSP1603 12.5 mg or placebo on day 1 under fasted condition.~Enrollment into Cohort 2 will begin upon assurance of safety for Cohort 1."
89364122|NCT03619616|Experimental|ZSP1603 (single dose)-25 mg (Cohort 3)|"Subject adminsitered at a dose of ZSP1603 25 mg or placebo on day 1 under fasted condition.~Enrollment into Cohort 3 will begin upon assurance of safety for Cohort 2."
89364123|NCT03619616|Experimental|ZSP1603 (single dose)-50 mg (Cohort 4)|"Subject adminsitered at a dose of ZSP1603 50 mg or placebo on day 1 under fasted condition.~Enrollment into Cohort 4 will begin upon assurance of safety for Cohort 3."
89364124|NCT01317264|Placebo Comparator|Placebo milk drink|
89364125|NCT01317264|Experimental|Millk drink with oat β-glucan|
89364126|NCT01317264|Experimental|Milk drink with barley β-glucan|
89364127|NCT01317264|Experimental|Milk drink with mutant-barley β-glucan|
89364128|NCT01348932||Asthma|The relationship between single nucleotide polymorphisms of chitinase 3-like 1 gene, YKL-40 serum levels and adult asthma
89364129|NCT03986580|Other|Annular closure device|Single arm study; all patients treated with an annular closure device
89364130|NCT03682614|Experimental|HCG group|All patients will accept HCG 500IU intrauterine injection 2 days before blastocyte transfer
89364131|NCT03682614|Placebo Comparator|control group|All patients will accept same dose of culture medium intrauterine injection 2 days before blastocyte transfer
88817052|NCT03111667|No Intervention|School Staff Participants: Environment|Staff will provide data about the school environment
88817053|NCT03096132|Active Comparator|Family Based Behavioral Treatment|The program includes information about diet and physical activity education, in addition to parent management skills and behavior therapy strategies in a weekly group setting.
89364132|NCT04489654|Active Comparator|study|Test group will receive immediate implant with modified socket shield and deproteinized bovine bone mineral (DBBM) OneXeno Graft. ( OneGraft, Germany) put in the buccal gap
88817054|NCT03096132|Experimental|Guided Self-Help Fam. Based Bx Treatment|The program includes information about diet and physical activity education, in addition to parent management skills and behavior therapy strategies in a guided self-help manual.
88817055|NCT03096041|Experimental|Experimental arm|Auriculotherapy for analgesic use
88817056|NCT03096041|Placebo Comparator|Controle arm|Placebo auriculotherapy
88817057|NCT02984124|Experimental|Intervention|Participants (n= approximately 100 plus family members) who are randomized to the intervention arm of the study will participate in a discussion about CPR with a study doctor.
88817058|NCT02984124|Placebo Comparator|Usual Care with Attention Control|Participants (n= approximately 100 plus family members) who are randomized to the usual care arm will receive a friendly visit in the hospital from research personnel to ask if they have any questions or concerns. Follow up assessments and time windows will be explained. Importance of their participation in the study will be emphasized.
88817059|NCT02917473|Other|Control|"Education and counseling as commonly delivered to the patients in clinical practice.~Brief oral counseling to the patient focusing on sun protection, self-skin examination, medical skin examination, increased risk of melanoma for their first-degree relatives, who should be informed orally by the patients to protect themselves from UV radiation, perform self-skin examination and ask their GP or dermatologist to perform annual skin examination"
89001485|NCT03452995|Active Comparator|Physiotherapy: LYMPHO DRAINAGE|Patients will be treated on the second postoperative day, on the 4th postoperative day and on the 6th post-operative day by means of Manual lymphodrainage consisting in special massage technique that allows lymphatic drainage, or removal of interstitial fluid stagnation according to Vodder, in association to the standard rehabilitation protocol for TKA (Kinetec, functional rehabilitation and walking training
89364133|NCT04489654|No Intervention|control|Control group will receive an immediate implant with modified socket shield technique but without deproteinized bovine bone mineral (DBBM) OneXeno Graft. ( OneGraft, Germany) in the buccal gap
89364134|NCT03660228|Experimental|Peri-Transfusion QOL Assessment|"Participants will be given a study packet containing a paper copy of the QUALMS~Study participants will fill out the survey on the day before their first/next pRBC transfusion.~Study participants will receive a second paper copy of the QUALMS, along with a stamped envelope addressed to the appropriate site~The second assessment will be scored and compared with the first, and both the patient and provider will be sent a report with the results"
89364135|NCT02684734||Patients on no immunosuppressant|This includes patients on no medication or mesalamine.
89364136|NCT02684734||Patients on immunosuppressants|This includes patients on biologics, azathioprine (AZA), 6-mercaptopurine (6-MP), or corticosteroid. These patients will be sub-analyzed to: a) Patients on one immunosuppressive therapy with AZA, 6-MP, biologic or corticosteroid; b) Patients on combination therapy with AZA or 6-MP and biologic; c) Patients on triple therapy with corticosteroid, AZA or 6-MP, and biologic; d) Patients on corticosteroid and one other immunosuppressive therapy such as AZA, 6-MP, or biologic.
89364137|NCT01317888|Experimental|Treated with MAB-425|All patients receive the same treatment of MAb-425 +Iodine 125 in a total of three injections.
89364138|NCT05726734|Active Comparator|Vonoprazan-containing Triple Therapy|Vonoprazan 20mg bid, Amoxicillin 1.0g tid and Metronidazole 0.4g tid for 14 days
89364139|NCT05726734|Experimental|Empiric Bismuth Quadruple Therapy|Esomeprazole 20mg bid, Bismuth Potassium Citrate 600mg bid, Amoxicillin 1.0g tid and Metronidazole 0.4g tid for 14 days
89364140|NCT01317966||rhIL-11Combinating Low-dose Rituximab|"rhIL-11 (interleukin-11, Juheli) 50 mcg/kg subcutaneously daily for 14 days~Rituximab 100mcg weekly for 4 weeks"
89364141|NCT01345734||Liraglutide|
89364142|NCT01318044|Active Comparator|Propofol group: propofol|
89364143|NCT01318044|Active Comparator|Thiopental group: thiopental|
89364144|NCT01353768||No treatment|zanamivir aqueous solution administered previously as part of the Compassionate Use Program
89001486|NCT03452995|Active Comparator|Physiotherapy: KINESIOTAPING|Patients will be treated on the second postoperative day, on the 4th postoperative day and on the 6th post-operative day through the use of patches acting through the sensory system giving stimuli to receptors on the skin, in association to the standard rehabilitation protocol for TKA (kinetec, functional rehabilitation and walking training .
89364145|NCT01353846|Active Comparator|Natural cycle|
89364146|NCT01353846|Active Comparator|Artificial cycle|"Drugs: Agonist GnRH Acetate Triptoreline Acetate Triptorelina (Agonist GnRH), 3.75 mg. single dose. Estradiol Valerate, orally Initially 4 pills daily during 4 days, and after increase the dose to 6 mg orally daily.~Natural micronized progesterone, 400 mg/12 hours vaginal administration"
89364147|NCT01349010|Placebo Comparator|Placebo|Placebo Arm: Placebo 1 tablet bid. p.o
89364148|NCT01349010|Active Comparator|Probucol|Probucol Arm: Imported Probucol 250 mg (1 tablet) bid. p.o
89364149|NCT01345812|Active Comparator|urine-derived FSH|Follicle stimulating hormone
89001487|NCT03452995|Experimental|Physiotherapy:LYMPHO+KINESIO|Patients will ne treated with both kinesiotaping and lymphodreinage on the second post-operative day, on 4 days post-operative and on the 6th post-operative day, in association to the standard rehabilitation protocol for TKA (kinetec, functional rehabilitation and walking training
89001488|NCT03452956||FTD Cohort|No intervention-observation only
89364150|NCT01345812|Active Comparator|recombinant FSH|Follicle stimulation hormone
89364151|NCT05232370|No Intervention|Control Group|"Recipients of a RT, from a living related donor (DVR) or living unrelated donor (DVNoR) who agreed to participate and signed the Letter of Consent under Information.~Randomly assigned to control group (Without losartan or enalapril)"
89364152|NCT05232370|Experimental|Enalapril group|"Recipients of a RT, from a living related donor (DVR) or living unrelated donor (DVNoR) who agreed to participate and signed the Letter of Consent under Information.~Randomly assigned to Enalapril group"
89364153|NCT05232370|Experimental|Losartan group|"Recipients of a RT, from a living related donor (DVR) or living unrelated donor (DVNoR) who agreed to participate and signed the Letter of Consent under Information.~Randomly assigned to Losartan group"
89364154|NCT01349088|Experimental|Motesanib|Eligible patients will be enrolled to receive ixabepilone, capecitabine, plus motesanib.
89364155|NCT04490434|Experimental|Cohort 1, A (DWP14012/Celecoxib)|Patients treated with DWP14012, Celecoxib will be enrolled. DDI will be evaluated.
89364156|NCT04490434|Experimental|Cohort 1, B (DWP14012/Celecoxib)|Patients treated with DWP14012, Celecoxib will be enrolled. DDI will be evaluated.
89364157|NCT04490434|Experimental|Cohort 2, C (DWP14012/Naproxen)|Patients treated with DWP14012, Naproxen will be enrolled. DDI will be evaluated.
89364158|NCT04490434|Experimental|Cohort 2, D (DWP14012/Naproxen)|Patients treated with DWP14012, Naproxen will be enrolled. DDI will be evaluated.
89364159|NCT04490434|Experimental|Cohort 3, E (DWP14012/Meloxicam)|Patients treated with DWP14012, Meloxicam will be enrolled. DDI will be evaluated.
89364160|NCT04490434|Experimental|Cohort 3, F (DWP14012/Meloxicam)|Patients treated with DWP14012, Meloxicam will be enrolled. DDI will be evaluated.
89364161|NCT01353924|Active Comparator|Bet v 1aF1 + Bet v 1aF2 -Alum|
89364162|NCT01353924|Placebo Comparator|Alum-Placebo|
89364163|NCT04643782|Other|Single Arm Study|After consent, subjects will wear the ANNE sleep system during an attended PSG study for 1 night.
89364164|NCT03143166|Experimental|All participants|Dabigatran etexilate given without rabeprazole and then Dabigatran etexilate given without rabeprazole.
89364165|NCT02466568|Experimental|Phase I and Phase II Treatment Arm|Participants will receive nivolumab and GM.CD40L. Treatment will be administered on an outpatient basis. The nivolumab will be given first followed by the GM.CD40L vaccine for those enrolled on this arm.
89364166|NCT02466568|Active Comparator|Phase II Control Arm|Nivolumab treatment without GM.CD40L. Nivolumab will be given every 2 weeks at a dose of 3mg/kg.
89364167|NCT02466100|Experimental|Goc Intervention|Patient education materials, study nurse phone call, tip sheet, provider tip sheet
89364168|NCT02466100|No Intervention|usual care|care as usual in the community
89364169|NCT02843646|Experimental|Walk Aide training|This group of children will receive six weeks of Walk Aide training. During training, children will wear the Walk Aide. This device triggers ankle dorsiflexion, and controls the timing and duration of personal nerve stimulation during the swing phase of gait. The duration of the stimulus is gradually increased along with the wearing of the Walkaide. Subjects will begin by wearing the prosthesis for 30 minutes. The wearing time will be increased to waking hours of the subject, depending on their age. The electrodes will be placed on the client before the session is to begin, and taken off immediately after WalkAide usage. The skin will be checked before and after WalkAide electrode usage. The skin will be cleaned with an alcohol wipe before the electrodes are applied.
89364170|NCT02843646|Placebo Comparator|Delayed Walk Aide training|This group of children will not receive Walk Aide training during the first six weeks of enrollment. This group will serve as a comparator group to Arm 1. After six weeks, children in this group will be given the option to complete the 6-week Walk Aide training protocol that is given in Arm 1.
89364171|NCT02466178||Serene RF System|Percutaneous delivery of radiofrequency (RF) energy to create a temporary conduction block to the corrugator and/or procerus muscles.
89364172|NCT05264818||Case group: primary open angle glaucoma|
89364173|NCT05264818||Control group: No Absence of optic nerve pathology|
89364174|NCT02879994|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for up to 35 courses in the absence of disease progression or unacceptable toxicity.
89178481|NCT00853307|Experimental|Alisertib 50 mg|Alisertib 50 mg, capsules, orally, twice daily for 7 days, followed by 14-day washout period in 21-day cycles until disease progression or unacceptable treatment-related toxicity (Up to 26 Cycles).
89364175|NCT02466022|Experimental|Dexmedetomidine|Patients will receive one 0.5ug/kg bolus of Dexmedetomidine over 10 minutes for sedation prior to spinal anesthetic (12.75mg of heavy Bupivicaine and 10ug of Fentanyl) and 0-4mg of Midazolam for rescue sedation
89364176|NCT02466022|Placebo Comparator|Normal Saline|Patients will receive 0.1cc/kg Normal Saline bolus delivered over 10 minutes for control arm prior to spinal anesthetic (12.75mg of heavy Bupivicaine and 10ug of Fentanyl) and 0-4mg of Midazolam for rescue sedation
89364177|NCT03943758|Experimental|prepackaged Low-residue diet group|The prepackaged Low-residue diet (Maifu Nutrition Technology Co. Ltd, Beijing, China). One package of the prepackaged Low-residue diet contained quantity of heat amounts to 268 kilocalories with 12.0 g of protein, 9.6 g of lipid, and 34.1 g of carbohydrate.
89364178|NCT03943758|Active Comparator|self-prepared Low-residue group|Subjects in the self-prepared Low-residue diet group were instructed to follow and prepare an Low-residue diet in the day prior to colonoscopy
89364179|NCT03937596|Experimental|D-Cycloserine|Participants will orally ingest a capsule containing 100mg of the antibiotic d-cycloserine daily (Monday-Friday) for the first 2 weeks of rTMS treatment (10 sessions), followed by 2 weeks of rTMS without adjunctive medication.
89364180|NCT03937596|Placebo Comparator|Placebo|Participants will orally ingest a capsule identical to that containing the study medication, however this capsule will contain a placebo. They will ingest this capsule daily (Monday-Friday) for the first 2 weeks of rTMS treatment (10 sessions), followed by 2 weeks of rTMS without adjunctive medication.
89364181|NCT03578172|Experimental|Experimental-HMG stimulation group|Women will be subjected to ovarian stimulation for endometrial preparation using human menopausal gonadotrophin before blastocyst transfer
89364182|NCT03578172|Active Comparator|Control-HRT group|Women will be subjected to hormone replacement therapy for endometrial preparation before blastocyst transfer
89364183|NCT05726500|Other|Open Abdomen|
89364184|NCT05726500|Other|Closed Abdomen|
89364185|NCT01345890|Experimental|electrical stimulation|stroke patients
89364186|NCT01354080|Experimental|tensegrity massage|In this group of patients massage sessions based on the tensegrity method were applied.
89364187|NCT01354080|Active Comparator|classical massage|In this group of patients classical massage sessions were applied
89364188|NCT03928158|Experimental|LCZ 696|Initial dose - 50 mg twice daily, up-titration to 200 mg twice daily. Patients will also receive standard therapy for heart failure (β-blockers, diuretics, MRAs)
89364189|NCT03928158|Active Comparator|Valsatran|Initial dose - 40 mg twice daily, up-titration to 160 mg twice daily. Patients also will receive standard therapy for heart failure (β-blockers, diuretics, MRAs)
89364190|NCT01354158|Experimental|Droxidopa|The dose-titration response to ascending doses of Droxidopa (placebo, 100mg, 200mg, 400mg) will be measured four separate days.
89364191|NCT02466490|Experimental|Fimasartan 60 mg Tablets|FMS 60 mg tablets once a day during the initial 8 treatment weeks of the study
89364192|NCT02466490|Active Comparator|Fimasartan 120 mg Tablets|FMS 120 mg tablets once a day during 4 weeks (treatment weeks 8 to 12)
89178482|NCT00825058|Experimental|1|
89178483|NCT00825058|Placebo Comparator|2|
89178484|NCT00825058|Active Comparator|3|
89178485|NCT00701831|Experimental|1|Insulin glargine
89178486|NCT00840892|Experimental|Intercom|INTERdisciplinary COMmunity-based COPD management (INTERCOM)
89178487|NCT00840892|No Intervention|Usual Care|
89364193|NCT02466490|Active Comparator|Fimasartan; Hydrochlorothiazide 60/12.5|FMS 60 mg + HCTZ 12.5 mg tablets (fixed dose combination) once a day during 4 weeks (treatment weeks 8 to 12)
89364194|NCT02466490|Experimental|Fimasartan; Hydrochlorothiazide 120/12.5|FMS 120 mg + HCTZ 12.5 mg tablets (fixed dose combination) once a day during 12 weeks (treatment weeks 12 to 24)
89364195|NCT01345968|Placebo Comparator|NaCl 0.9%|
89364196|NCT01345968|Experimental|Ferinject|
89364197|NCT04547842|Active Comparator|Group M: patients receive Mirtazapine|the patient will receive an oral disintegrating tablet (ODT) of mirtazapine 30 mg with sips of water and 100 ml 0.9% sodium chloride (normal saline [NS]) (IVI) over 15 min as a placebo 1 h preoperatively
89364198|NCT04547842|Active Comparator|Group D: patients receive Dexamethasone|the patient will receive a placebo tablet identical to Mirta tablet orally with sips of water and Dex 8 mg ampoule diluted in 100 ml 0.9% NS IVI over 15 min, 1 h preoperatively.
89364199|NCT01354236||School dropouts|Students who quit school without graduation
89364200|NCT01354236||Controls|Normally enrolled students matched for age, gender, school and educational level
89364201|NCT03928080||Experimental cohort|Primary study to assess diagnostic accuracy
89364202|NCT03928080||Confirmation cohort|Second cohort to confirm results from the first study on independent population
89001489|NCT00181805||Subject with History of GERD|Children and adolescents ages 12-17 years, inclusive, seen at Children's Hospital, Boston or Massachusetts General Hospital between 1977 and 1990 for symptoms of GERD and also had biopsies and / or a pH probe that was positive for GERD.
89001490|NCT00181805||Controls with out GERD|Individuals that do not have a history of GERD or other GI problems prior to age 21 and whose date of birth are with in a year of a subjects
89001491|NCT00583999||A|bariatric surgery
89001492|NCT00584038|No Intervention|1 Standard Care (SC)|Participants receive usual contraceptive care administered by clinic provider.
89001493|NCT00584038|Other|2 Standard Care + Educational (SCE)|Participants receive standard contraceptive care from clinic provider, followed by 45-minute educational intervention.
89001494|NCT00584038|Other|3 Standard Care + Educational + Phone Calls (SCEP)|Participants receive standard contraceptive care from clinic provider, followed by phone calls weekly until onset of menses and monthly thereafter for six consecutive months.
89364203|NCT03142932|Active Comparator|Control|A certified smoking cessation interventionist (SCI) will deliver standardized smoking cessation counseling using the National Cancer Institute (NCI) 5 A's model.
89364204|NCT03142932|Experimental|COach2Quit|"A certified smoking cessation interventionist (SCI) will deliver standardized smoking cessation counseling using the National Cancer Institute's 5 A's model.~Participants in the COach2Quit arm will be provided with an individualized carbon monoxide (iCO) monitor along with instructions on the use of the monitor and the COach2Quit application."
89364205|NCT03536676|Active Comparator|Traditional School Breakfast Program|The breakfasts for the 3-week program will adhere to the United States Department of Agriculture nutrition requirements for Grades 6-8.
89364206|NCT03536676|Experimental|'Egg-Cellent' Breakfast in the Classroom|The breakfasts for the 3-week program will adhere to the United States Department of Agriculture nutrition requirements for Grades 6-8 but will include an additional 2 large eggs/breakfast.
89364207|NCT01346046||Those with Type 2 diabetes|270 subjects with Type 2 diabetes
88818195|NCT02639637|Placebo Comparator|Placebo then Sitagliptin: Valsartan|Subjects in this arm will receive placebo/d for one week as well as valsartan 160 mg/d for one week. After this subjects will report for study day #1. During the study day, subjects will be given intra-arterial neuropeptide Y. A four week washout of medication will occur after the study day. Subjects will then receive sitagliptin 100mg/d and valsartan 160 mg/d for one week followed by study day #2.
88818196|NCT01332188|Experimental|AC-170 0.05%|
88818197|NCT01332188|Experimental|AC-170 0.1%|
89364208|NCT01346046||Non diabetic|30 healthy subjects
89364209|NCT00702052|Experimental|Everolimus|Participants received everolimus tablets, 10 mg, orally, once daily during each 28 day cycle until determination of objective tumor progression or unacceptable toxicity, or death, or consent withdrawal, or discontinuation from the study for any other reason.
89364210|NCT04499326|Experimental|Intervention|Patients undergoing catheter ablation of VT
89364211|NCT04499326|Active Comparator|Comparator|Patients undergoing AAD therapy for VT
89364212|NCT03140280|Experimental|Dietary Intervention|Freeze-dried black raspberry powder administration.
89364213|NCT01354392|Experimental|AZD1152|
89364214|NCT01318200|Active Comparator|Transarterial Chemoembolization|
89364215|NCT01318200|Active Comparator|CyberKnife SBRT|
88818198|NCT01332188|Experimental|AC-170 0.24%|
88818199|NCT01332188|Placebo Comparator|AC-170 0%|
88818200|NCT01794455|Experimental|Phase 1: Sertraline|Eight-week trial of sertraline mono therapy, dosing ranging from 50mg- 200mg daily.
88818201|NCT01794455|Experimental|Phase 2: Candesartan|For subjects who do not remit to sertraline, they will receive candesartan for 12 weeks, with doses ranging from 4mg - 32mg daily.
88818202|NCT01795079|Experimental|Active tDCS|Subjects will undergo 20 minutes active tDCS.
88818203|NCT01795079|Sham Comparator|Sham tDCS|Subjects will undergo 20 minutes of sham stimulation.
88818204|NCT04769141||Hypertension patients|a prospective 4-month, cohort feasibility study will evaluate blood pressure (n=20) using the CURATE.AI platform.
88818205|NCT04769141||Diabetic patients|a prospective 4-month, cohort feasibility study will evaluate glycaemic (n=20) control using the CURATE.AI platform.
88818206|NCT01271036|Experimental|Formula PD-F-7716|Apply a dime-size amount on each application site as instructed during the 1-week study period
88818207|NCT04749485|Experimental|HX008|
88818208|NCT01332500||adult migraineurs with/without aura|Adult migraine patients >18-65 years who have initiated treatment for migraine with Treximet ™ or other orally administered triptan.
88818209|NCT01812005|Experimental|Cohort A (alisertib, rituximab)|Patients receive alisertib PO BID on days 1-7. Patients unable to achieve CR after course 4 also receive rituximab IV on day 1 of courses 5-12. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89364216|NCT01346124|Experimental|IMPT|High dose IMPT
89364217|NCT01346202||chronic pain|260 consecutive patients with verified chronic pain syndromes
89364218|NCT01354470|Experimental|Modafinil|
89364219|NCT01354470|Placebo Comparator|placebo (cornstarch)|
89364220|NCT01354548|Experimental|TheraBite grupp|
89364221|NCT01354548|No Intervention|Conventional treatment|
89364222|NCT04911608|Experimental|cervical manipulation|"The cervical spinal manipulation will consist of one session of a standard technique that will be performed by an experienced (>10 years) doctor of physical therapy practitioner. The technique is described by Gibbons and Tehan as a high-velocity, mid-range, low amplitude force at the segment of pain and/or segmental restrcition. The participant will lay comfortably in a supine position, the practitioner will then use his clinical discretion to select the most appropriate or symptomatic cervical motion segments and attempt to localize the manual thrust at those levels. A maximum of 2 attempts for each side of the cervical spine will be allowed regardless of the having achieved joint cavitation. This type of cervical manipulation procedure is described by Gibbons and Tehan as Minimal Leverage Thrust and it results in optimal patient comfort while receiving the treatment thus reducing post-treatment soreness/pain."
89364223|NCT04911608|Experimental|cervical mobilization|The cervical spinal mobilization treatment will also consist of one session of a standard technique that will be performed by an experienced (>10 years) doctor of physical therapy practitioner. For this procedure, the participant will lay comfortably in a prone position, the practitioner will then use his clinical discretion to select the most appropriate or symptomatic cervical motion segments and attempt to localize the manual forces at those segments. The magnitude of a mobilization-or how hard the therapist pushes on the spine-is usually reported as the magnitude of force. For an oscillatory posterior-anterior (PA) mobilization technique, the maximum magnitude of applied force is usually reported as the mean of the force peaks that occur during a specified period.34 The cervical mobilization will consist of oscillations of 1Hz and magnitude forces of 30 Newtons (N) for 30 seconds, 90N for 120 seconds and 30N for 30 seconds at the localized segment.
89364224|NCT04911608|No Intervention|postural correction education|Participants will be presented with a standardized educational short video regarding the importance of postural correction movements.
89364225|NCT01349478|Experimental|study arm|
89364226|NCT01349556|Experimental|Tretinoin pre-treatment|
89364227|NCT03480126|Placebo Comparator|Herbal Tea 1|Placebo Tea should will be ingested 3 times per day for 3 months
89364228|NCT03480126|Experimental|Herbal Tea 2|Experimental Herbal Tea A will be ingested 3 times per day for 3 months
89364229|NCT03480126|Experimental|Herbal Tea 3|Experimental Herbal Tea B will be ingested 3 times per day for 3 months
89364230|NCT03480126|Experimental|Herbal Tea 4|Experimental Herbal Tea C will be ingested 3 times per day for 3 months
89364231|NCT01349634|No Intervention|Comparison group|This arm will use the salt that is on the open market, which is primarily non-iodized salt. Iodized salt may enter in these communities through the normal trade route. No active interference with salt trade will occur in these communities.
89364232|NCT01349634|Experimental|Early delivery of iodized salt|Iodized salt that is produced nationally for the open market (which meets only about 10% of national needs) will be directed to these communities through the normal trade system or by direct delivery to the communities.
89364233|NCT01346358|Experimental|IMC-CS4 Weight Based Dosing|Participants receiving IMC-CS4 intravenously (weight based dosing)
89364234|NCT01346358|Experimental|IMC-CS4 Non-Weight Based Dosing|Participants receiving IMC-CS4 intravenously (non-weight based dosing)
89364235|NCT01349712||Coumadin (warfarin)|Subjects are required to be currently receiving coumadin (warfarin) treatment.
89364236|NCT03462498|Active Comparator|1-month DAPT|1-month dual antiplatelet therapy (DAPT) composed of aspirin and P2Y12 receptor antagonists and clopidogrel monotherapy for 59 months
89001495|NCT00584155|Placebo Comparator|1|Each patient will receive a bottle containing normal saline and 0.03% ofloxacin.
89364237|NCT03462498|Active Comparator|12-month DAPT|1-month dual antiplatelet therapy (DAPT) composed of aspirin and P2Y12 receptor antagonists; 11-month DAPT composed of aspirin and clopidogrel and aspirin monotherapy for 48 months
89364238|NCT04282590|Experimental|Treatment Period 1: TRK-750, Treatment Period 2: placebo|
89364239|NCT04282590|Experimental|Treatment Period 1: placebo, Treatment Period 2: TRK-750|
89364240|NCT01354626|Experimental|High fat diets|High-fat-Low-protein or High-fat-high-protein
89364241|NCT01354626|Other|Control group|Low-protein-low-fat (according to healthy eating guidelines)
89364242|NCT03136380|Experimental|Part 1: Group A|Subjects will receive GSK1325756H 10 mg in P-1, GSK1325756H 50 mg in P-2 and placebo in P-3 after a high fat meal. There will be a washout period of at least 7 days between each treatment period.
89364243|NCT03136380|Experimental|Part 1: Group B|Subjects will receive GSK1325756H 10 mg in P-1, placebo in P-2 and GSK1325756H 100 mg in P-3 after a high fat meal. There will be a washout period of at least 7 days between each treatment period.
89364244|NCT03136380|Experimental|Part 1: Group C|Subjects will receive placebo in P-1, GSK1325756H 50 mg in P-2 and GSK1325756H 100 mg in P-3 after a high fat meal. There will be a washout period of at least 7 days between each treatment period.
89364245|NCT03136380|Experimental|Part 2: Group D|Subjects will receive GSK1325756H 50 mg after a low fat meal and fasted state respectively. There will be a washout period of at least 7 days between each treatment period.
89364246|NCT03136380|Experimental|Part 2: Group E|Subjects will receive GSK1325756H 50 mg after a fasted state and a low fat meal respectively. There will be a washout period of at least 7 days between each treatment period.
89364247|NCT01346436|Active Comparator|Robotic|Use of daVinci surgical system (Intuitive Surgical Inc, Sunnyvale, CA) for the treatment of complex pelvic floor dysfunction
89364248|NCT01346436|Active Comparator|Laparoscopy|Use of standard laparoscopy for the treatment of complex pelvic floor dysfunction
89364249|NCT01354704|Active Comparator|lovenox|patient under lovenox 4000 IU
88835248|NCT02979145||Patients with CMT|Two groups of patients will be included: Group 1 (Definitive): Children with known CMT where genetic testing confirms the diagnosis, or children with a clinical diagnosis including electrophysiology confirming the presence of CMT and a corresponding family history where a first or second degree relative has a genetic diagnosis; or Group 2 (At risk): A clinical diagnosis of CMT awaiting genetic testing or confirmatory electrophysiology and evidence of a genetic diagnosis in a first or second degree relative; or individuals identified as being at risk of a CMT diagnosis (prodromal patients), without the onset of signs or symptoms.
88835249|NCT02979145||Controls|Healthy controls will be included from unaffected family members or friends accompanying patients at INC sites. Healthy controls are defined as boys and girls aged 0-≤4 years without a diagnosis of CMT or any of the other study exclusion criteria.
88835250|NCT03424187|Experimental|whole chickpea|a test meal containing 26g available carbohydrates from chickpea (full structure)
88835251|NCT03424187|Experimental|flour chickpea|a test meal containing 26g available carbohydrates from flour chickpea (destroyed structure)
88835252|NCT03424187|Experimental|intact cell chickpea|a test meal containing 26g available carbohydrates from intact cell chickpea flour (full structure)
89364250|NCT01354704|Active Comparator|enoxa|patients under Enoxa 4000 IU
88835253|NCT05716412||Adopted adolescents and their adoptive parents|Adopted before the age of one, currently between 12 to 18 years old
89364251|NCT01354704|No Intervention|total knee replacement|patients undergoing total knee replacement
88835254|NCT05716412||Adolescents and their biological related parents|Matched to adoptive adolescents
88835255|NCT05716412||Additional community sample|
88835256|NCT05641610|Experimental|ZS801|Single intravenous (i.v.) infusion of ZS801 Intervention: Gene Therapy / Gene Transfer
88835257|NCT02979223|Experimental|PMC/PEG-Asc|Picolyte 1 bottle/170cc at one day before colonoscopy, 7 PM. And then, Intake Coolprep 1L at the day of colonoscopy, 5 AM
88835258|NCT02979223|Active Comparator|PEG-Asc/PMC|Intake Coolprep 1L at one day before colonoscopy, 7 PM. And then, Intake Picolyte 1 bottle/170cc at the day of colonoscopy, 5AM
89364252|NCT01354704|No Intervention|total hip replacement|patient undergoing total knee replacement
89364253|NCT01346670|Experimental|LipoCol and Mevacor|To evaluate the relative bioavailability of lovastatin and its ß-hydroxy acid of 600 mg LipoCol Forte® Capsules compared to that of one 20 mg Mevacor Tablet after single oral administration in healthy subjects using a 2x2 crossover design
89364254|NCT01354782|Experimental|Roflumilast|(This is a pharmacokinetic study)
88835259|NCT01805271|Experimental|Everolimus|1 or 2 tablets/day (i.e.5 or 10 mg/day )
88835260|NCT01805271|Placebo Comparator|Placebo|1 or 2 tablets/day
88835261|NCT03427931|Experimental|Continuous Glucose Monitor (CGM)|Study subjects will collect Continuous Glucose Monitor data by wearing the device at home a minimum of 28 days but may continue for up to 3 months.
89001496|NCT00584155|Experimental|2|Each patient will receive a bottle containing Lactated Ringer's solution and 0.03% ofloxacin.
89364255|NCT03136068|Experimental|Digoxin|Subjects assigned to the intervention arm will receive a 1 mg intrafetal digoxin injection under ultrasound guidance
89364256|NCT03136068|Placebo Comparator|Placebo|Subjects assigned to the control arm will receive an ultrasound-guided intrafetal saline injection of the equivalent volume
89364257|NCT01350024|Active Comparator|Frontal Nerve Block|Patients will receive a frontal nerve block for anesthesia
89364258|NCT01350024|Active Comparator|Subconjucntival Injection|Patients will receive a subconjunctival injection for anesthesia
89364259|NCT01346748|Experimental|Statin|
89364260|NCT01318590|Experimental|Celiac bloc|The experimental arm will consist of the fractional injection on both sides of the celiac trunk, via EUS, of a local anesthetic (10 ml of Bupivacaine 0.5% (gr / ml)) and an injection of steroids (Triamcinolone 40 mg). In this group antibiotic prophylaxis will be administered after administration of sedation (Cephazolin 1gr IV or Gentamycin).
89364261|NCT01318590|Sham Comparator|Conservative treatment|Subject will undergo standard EUS without any additional interventions.
89364262|NCT01346826|Active Comparator|2 hours-infusion group|Number of patients: 57 (Standard 2 hours-infusion group)
89364263|NCT01346826|Experimental|1 hour-infusion group|Number of patients: 59 (1 hour-infusion group)
89364264|NCT01346826|Experimental|30 minutes-infusion group|Number of patients: 59 (30 minutes-infusion group)
89364265|NCT01354860|Experimental|Moxibustion treatment plus usual care|
89364266|NCT01354860|No Intervention|usual care alone|
88835262|NCT05385289|Experimental|First wave with 6 participants|"Once selected, an individual online information session will be scheduled with each selected participant to explain the project and its practical implications. At this time, six of the twelve participants will be provided a link to complete online measures as the A-baseline phase, to constitute their own non-intervention control condition on the target behavior (i.e., rumination) and on positive and negative emotions. The other six participants will be entered into a 3-week waiting list period with a sequential introduction, to provide another non-intervention control condition.~The A-baseline phase length will include at least 5 measures and most 10 measures, resulting in 10 potential starting point for the B-experimental phase. This range will be determined to estimate autocorrelation and its associated bias."
88835263|NCT05385289|Experimental|Second wave with 6 other participants|After three weeks, the six participants on the waiting list will also begin the same A-baseline phase as the six participants of the first wave.
88835264|NCT01768767|Experimental|Ketamine/Lithium|Participant will receive ketamine/lithium
88835265|NCT01768767|Active Comparator|Ketamine|Participant will receive ketamine
88835266|NCT01768767|Placebo Comparator|Placebo|Participant will receive placebo
88835267|NCT00376493|Active Comparator|1|Use of antibiotics after hospital discharge
88835268|NCT00376493|Placebo Comparator|2|Use of placebo
88835269|NCT03362879||Participants with advanced Parkinson's disease|Participants with advanced Parkinson's disease on current treatment with levodopa-carbidopa intestinal gel (LCIG) for at least 12 months.
88835270|NCT05574530|Experimental|Colon-delivered multivitamin supplement|Colon-delivered multivitamin mix with vitamin B2, B3, B6, B9, vitamin C and D3. These vitamins are delivered as capsules coated by a eudragit S100 coating layer, in order to prevent systemic absorption of the vitamins in the small intestine.
88835271|NCT05574530|Placebo Comparator|Placebo supplement|Placebo supplement containing microcrystalline cellulose, coated in the same way as the experimental product in order to prevent systemic absorption in the small intestine.
88835272|NCT03231917|Experimental|Water Infusion first|In this group patients will receive a colonoscopy with water infusion for mucosal inspection and then receive a colonoscopy with CO2 insufflation.
88835273|NCT03231917|Experimental|CO2 Insufflation First|In this group patients will receive a colonoscopy with CO2 insufflation for mucosal inspection and then receive a colonoscopy with water infusion.
88835274|NCT02979067|Active Comparator|High-flow 100% oxygen|Nasal oxygen flow
88835275|NCT02979067|Active Comparator|Low-flow 100% oxygen|Nasal oxygen flow
88835276|NCT02979067|Active Comparator|High-flow 30% oxygen|Nasal oxygen flow
88835277|NCT05716256|Experimental|Ulinastatin|The experimental groups （Rocuronium-Ulinastatin group and Cisatracurium-Ulinastatin group）received ulinastatin 5000U/kg followed by rocuronium 0.6 mg/kg or cisatracurium 0.1 mg/kg
88835278|NCT05716256|Sham Comparator|Conventional treatment group|The control groups（Rocuronium-Saline group and Cisatracurium-Saline group） received normal saline 0.1ml/kg followed by rocuronium 0.6 mg/kg or cisatracurium 0.1 mg/kg
88835279|NCT03667365|Experimental|aortic valve replacement|
88835280|NCT03667365|Active Comparator|strict clinical surveillance|
88835281|NCT03362957|Experimental|GAE Procedure|Patients will be randomized to receive the Geniculate Artery Embolization Procedure
88835282|NCT03362957|Sham Comparator|Sham Procedure|Patients will be randomized to a sham procedure.
88835283|NCT03362957|Experimental|Crossover Arm|If after 1 month patients see no improvement, they will be unblinded and crossover to receive the Geniculate Artery Embolization Procedure
88835284|NCT00356083|Experimental|switch from morphine to methadon|
88835285|NCT02977832|Experimental|odyliresin|Odyliresin (Iresine celosia) 2 ml
88835286|NCT02977832|Experimental|alphalytic|alpha-antagonist (alfuzosin 10 mg)
88835287|NCT04344236|No Intervention|Control|
88835288|NCT04344236|Experimental|Saline oral/nasal rinse|
88835289|NCT04344236|Experimental|0.5% Povidone/Iodine oral/nasal rinse|
88835290|NCT04344236|Experimental|0.12% Chlorhexidine oral/nasal rinse|
88835291|NCT00355537|Experimental|Active|
88835292|NCT00355537|Placebo Comparator|Placebo|
88835293|NCT00003207|Experimental|Phase 1 (Doxil & PSC 833)|Patients will receive Doxil at the standard dose of 20 mg/m2 IV for the 1st cycle. On the 2nd cycle of Doxil, the first patient will receive Doxil at 40% of standard dose or 8 mg/m2 (dose level 1) IV over one hr. 15 mn after the 2nd and subsequent cycles of Doxil, PSC 833 will be given at 2 mg/kg for 2 hrs. Simultaneously, a 72 hour CIVI of PSC 833 will be started with the loading dose. If no DLT occurs, then a double dose escalation of Doxil (dose levels 3, 5, 7 ) will be given to the same patient in the subsequent cycles until DLT occurs. On the 2nd cycle, Doxil will be given at the next dose level above the starting dose tolerated by the first patient. If no DLT occurs, a double dose escalation will also be done for the subsequent cycles (dose levels 5, 7, 9). The single-patient-cohort will terminate when a patient experiences DLT or when two episodes of grade 2 toxicity occur. At that point patients will be enrolled into cohorts of 3 patients to determine the MTD.
88835294|NCT02978144|Other|Healthy volunteers|Healthy controls who never smoked (less than 100 lifetime cigarettes) with normal spirometry will be injected with AxV-128 labeled with 99mTc followed by SPECT-CT (AxV-128/Tc SPECT-CT imaging).
88835295|NCT02978144|Other|Current smokers|Healthy controls who are currently smoking (> 10 pack years) with normal spirometry will be injected with AxV-128 labeled with 99mTc followed by SPECT-CT (AxV-128/Tc SPECT-CT imaging).
88835296|NCT02978144|Other|Patients with moderate COPD|Patients with moderate COPD will be injected with AxV-128 labeled with 99mTc followed by SPECT-CT (AxV-128/Tc SPECT-CT imaging).
88835297|NCT02978144|Other|Patients with severe COPD|Patients with severe COPD will be injected with AxV-128 labeled with 99mTc followed by SPECT-CT (AxV-128/Tc SPECT-CT imaging).
88835298|NCT00003387|Experimental|Chemo + radiation|
88835299|NCT00003387|Experimental|Induction chemo + chemo & radiation|
88835300|NCT03430349|Experimental|Novel OPV2 Candidate 1|Participants received one vaccination with novel OPV2 candidate 1 on study Day 0, administered orally as six drops (0.3 mL total; approximately 10⁶ 50% cell culture infectious dose units [CCID50]).
89364267|NCT03422562|Active Comparator|Probiotic|Florababy probiotic (0.5g per day) will be started at or after 72 hours of life and will be administered in 1ml sterile water prior to feed.
88835301|NCT03430349|Experimental|Novel OPV2 Candidate 2|Participants received one vaccination with novel OPV2 candidate 2 on study Day 0, administered orally as six drops (0.3 mL total; approximately 10⁶ CCID50).
89364268|NCT03422562|No Intervention|Control|Standard of care arm
89364269|NCT03422016||autistic spectrum disorder|intelligence quotient IQ>85 age 4-25yrs
89364270|NCT03422016||control|age 4-25yrs no eye disorder
89364271|NCT01355016|Experimental|MDT-637|Active formulation
89364272|NCT01355016|Placebo Comparator|Placebo|Matched Placebo Comparator
89364273|NCT01346982|Experimental|Silimarine|darunavir + ritonavir + silimarine
89364274|NCT02719002|Experimental|OCT C-scan|
89364275|NCT02585232|Active Comparator|Care Consultation (CC)|"Care Consultation (CC): is an established telephone-based, empowerment intervention that uses coaching and emotional support to mobilize family caregivers and individuals with dementia through psychoeducation, resource referral, psychosocial support, and encouragement of informal and formal service use utilization. A computerized clinical tool called the Care Consultation Information System (CCIS) guides the care consultant through a standardized delivery of protocol components. Rather than a strong focus on assessment, this intervention is designed to quickly identify areas of unmet need through brief trigger questions called the initial assessment - much like an interview guide - which then immediately shapes development of concrete action plans."
89364276|NCT02585232|Experimental|Care Consultation + Counseling (CC+C)|Care Consultation + Counseling (CC+C): is consistent with the original CC protocol in that the therapist partners with each dyad in a patient-centered way to prioritize unmet needs as identified during the CC initial assessment. Once this phase has been completed, typically within the first 2 sessions, the CC+C therapist will determine when to initiate counseling sessions targeting 8-10 domains of potential distress (grief, hostility, sexual intimacy, etc.). The counseling component of the CC+C intervention incorporates elements of existing manualized interventions that have been tailored for this population and follow a cognitive behavioral therapy framework.
89364277|NCT01355328|Experimental|laser|
89364278|NCT01355328|No Intervention|control|
89364279|NCT02556606|Experimental|Ketamine 0.10 mg/kg|randomly assigned to a single 40 min infusion of either KET 0.1mg/Kg
89364280|NCT02556606|Experimental|Ketamine 0.25 mg/kg|randomly assigned to a single 40 min infusion of either KET 0.25mg/Kg
89364281|NCT02556606|Experimental|Ketamine 0.50 mg/kg|randomly assigned to a single 40 min infusion of either KET 0.50mg/Kg
89364282|NCT02556606|Active Comparator|Midazolam 0.03 mg/kg|randomly assigned to a single 40 min infusion of either MID 0.03mg/Kg
89364283|NCT01355640|Experimental|breast-feeding group|Mothers console their babies by breast-feeding during heel lance.
89364284|NCT01355640|Experimental|non-nutritive sucking|"Every mother was given a vacuum pacifier( the brand is Goodbaby) to console her baby during heel lance."
89364285|NCT01355640|No Intervention|control group|A research nurse also explained the study to the control group parents. Standard clinic procedure for infant injection was also implemented. Mothers in control group also lay on the side of the bed comfortably with their infants in their arms after the infants' soiled diapers were changed.
88835302|NCT02977988|Experimental|Mindfulness Meditation|Mindfulness-Based Relapse Prevention-Women (MBRP-W)
88835303|NCT02977988|Active Comparator|Active Comparator|Brain and Recovery (B&R)
88835304|NCT04706897|Sham Comparator|Normal saline (Control) group|A loading infusion of the 50 ml syringe (A) containing normal saline was started at rate of 0.2 ml/ kg/hr ten minutes before induction (as masking for mixture in group S). Then anesthesia was induced with 2 mg/kg ideal body weight (IBW) of propofol , patients were intubated with the aid of 0.5 mg/kg IBW atracurium and received 0.1ml/kg from syringe (C) containing fentanyl (1 mic/kg of IBW).
89364286|NCT01350570|Experimental|acupuncture group 1|Acupoints ST25 and BL25 will be used in the group. ST25 locate at the abdomen, while BL25 locate at the back.
89364287|NCT01350570|Experimental|acupuncture group 2|Acupoints LI11 and ST37 will be used in this group. LI11 is located at upper limb while ST37 is located at the lower limb.
89364288|NCT01350570|Experimental|acupuncture group 3|All acupoints used in acupuncture group1 and acupuncture group2 will be used in this group.
89364289|NCT01350570|Active Comparator|Loperamide|Loperamide will be used as an active comparator to the acupuncture groups.
89364290|NCT01355718||Repaglinide|
88835305|NCT04706897|Experimental|Dexmedetomidine, ketamine and lidocaine (Study) group|A loading infusion of syringe (B) containing the mixture was started at rate of 0.2 ml/kg/h ten minutes before induction. Then anesthesia was induced with 2 mg/kg IBW of propofol, patients were intubated with the aid of 0.5 mg/kg IBW atracurium and received 0.1ml/kg from syringe (D) containing normal saline (as masking for fentanyl in the control group).
88835306|NCT00003213|Experimental|Oral Granisetron + Dexamethasone|"1 mg Granisetron in the morning~1 Metoclopramide placebo in the afternoon~1 mg Granisetron in the evening 4 mg Dexamethasone in the morning"
89364291|NCT01347138|Experimental|case management|case management regulary
89364292|NCT01347138|No Intervention|Control|usual care
89364293|NCT03377790|Active Comparator|VP-102|VP-102 is contained within a single-use applicator. The VP-102 applicator consists of a plastic tube containing a sealed glass ampule and an applicator tip. One ampule contains 450 μL of VP-102 (0.7% [w/v] cantharidin) solution.
89364294|NCT03377790|Placebo Comparator|Placebo|Placebo is contained within a single-use applicator. The placebo applicator consists of a plastic tube containing a sealed glass ampule and an applicator tip. One ampule contains 450μl of placebo solution with the same color and consistency as VP-102.
89364295|NCT02717494|Experimental|Arm 1A (PPV-23)|In Step 1, women in Arm 1A were administered a 0.5 milliliter (mL) dose of PPV-23 intramuscularly once.
89364296|NCT02717494|Experimental|Arm 1B (PCV-10)|In Step 1, women in Arm 1B were administered a 0.5 mL dose of PCV-10 intramuscularly once.
89364297|NCT02717494|Placebo Comparator|Arm 1C (placebo)|In Step 1, women in Arm 1C were administered a 0.5 mL dose of 0.9 percent Sodium Chloride (NaCl) intramuscularly once.
88835307|NCT00003213|Experimental|Metoclopramide + Dexamethasone|20 mg Metoclopramide (1 x morning, 1 x afternoon, 1 x evening) 4 mg Dexamethasone in the morning
88835308|NCT01445067|Active Comparator|Arm 1: BMS-927711 (300 mg)|
88835309|NCT01445067|Active Comparator|Arm 2: BMS-927711 (600 mg)|
88835310|NCT05716022||Hiatal Hernia Group|The subject has a history of acid reflux and/or hiatal hernia undergoing surgical repair by thoracic surgery at the University of Virginia.
88835311|NCT05716022||Control Group|Patients undergoing bronchoscopy for clinical purposes at the University of Virginia endoscopy suite without a clinical diagnosis of hiatal hernia and/or pulmonary fibrosis.
88835312|NCT03847675|Experimental|Intervention|"The research assistant introduces the adapted 'Reach out and Read program and informs participants about the benefits of reading to children at an early age. A 4:50 minutes video clip would be shown during the initial visit. This video discusses the benefits of reading displaying practical tips for parents; it includes tips on how to read, pointing at the words.~A schematic pamphlet highlighting the importance of reading Arabic to children and the impact of such reading on children's brain development, vocabulary acquisition and behavior in addition to the impact on the parent child bond and relationship is given to the parents.~After each visit participants will receive an age appropriate book for their child.~Focus groups will be conducted by a qualitative researcher"
88835313|NCT03847675|No Intervention|Control|The research assistant gives routine advice on child development including importance of reading and advice on nutrition and safety and gives parents a leaflet about early child development and complementary feeding
88835314|NCT03376061|Active Comparator|TA Topical|1 syringe of 50ml of topical Tranexamic Acid (5g) or placebo. The topical will be poured into the pericardial mediastinal cavities in 2 equal doses, 25ml when the pt comes off-pump and the other 25ml before sternotomy is closed.
88835315|NCT03376061|Active Comparator|TA Intravenous|2 syringes of 50ml (5mg) Tranexamic Acid for intravenous injection or placebo.
88835316|NCT02978989|Placebo Comparator|LC & nonsolo approach|The surgical intervention is nonsolo LC.
88835317|NCT02978989|Active Comparator|LC & solo approach|The surgical intervention is solo LC.
88835318|NCT02977910|Experimental|with repair of deltoid ligament|open reduction and internal fixation with repair of deltoid ligament
88835319|NCT02977910|No Intervention|without repair of deltoid ligament|open reduction and internal fixation without repair of deltoid ligament
89001497|NCT00584311|Experimental|1|All patients (with no structural damage on the plain x-ray) will receive a MRI and Ultrasound (US) of their most involved joint and an asymptomatic joint.
89364298|NCT02717494|Experimental|Arm 2A (PPV-23)|In Step 2, women who received placebo in step 1 that were randomized to Arm 2A were administered a 0.5 mL dose of PPV-23 intramuscularly once.
88835322|NCT05715944|Experimental|AZD 1222|"AZD1222 vaccine~Dose Formulation:~10 mM histidine, 7.5% (w/v) sucrose, 35 mM sodium chloride, 1 mM magnesium chloride, 0.1% (w/v) polysorbate 80, 0.1 mM edetate disodium, 0.5% (w/v) ethanol, at pH 6.6~Current/Former names/alias(es):ChAdOx1 nCoV-19"
88835323|NCT03376295||Subjects diagnosed with COPD|Chronic obstructive pulmonary disease
88835324|NCT03381989|Experimental|Single arm: open-label treatment|The BASILICA procedure has three steps: (1) leaflet traversal with a guidewire, followed by (2) leaflet laceration, immediately followed by (3) TAVR.
88835325|NCT03244865||Pregnant Females|"All patients admitted to the Labor & Delivery Suite at UF Health, will be eligible for inclusion in the study except minors and those unable to consent for themselves.~Nothing is required of the subjects. They will be non-invasively monitored for one to several hours. The information obtained will not be used for medical decision-making and there is no significant risk to the patient or her fetus. No longitudinal follow-up is planned or indicated."
88835326|NCT03832712|Active Comparator|Surgical|Participants randomized to surgery
88835327|NCT03832712|Active Comparator|Medical|Participants randomized to best medical treatment
88835328|NCT05715866|Experimental|non-invasive neurostimulation experimental group (NEG)|The non-invasive neuromodulation experimental group, made up of 10 participants, are treated 20 sessions with the NXSignal non-invasive neuromodulation device (NESA)
88835329|NCT05715866|Experimental|Experimental group Therapeutic Exercise (TEG)|The experimental group of therapeutic exercise, made up of 10 participants, receives 3 weekly sessions of one hour duration for 16 weeks, and 1 weekly session until week 20, of an adapted program of cardiovascular exercises in a small group format, supervised by a physical therapist.
88835330|NCT05715866|Sham Comparator|Control group (CG)|The control group, made up of 10 participants, the caregivers receive recommendations about sleep habits through an information brochure.
88835331|NCT03247985|Active Comparator|PROLENE Polypropylene Tacking Mesh|Participants will be randomized to Tacking Mesh for their inguinal hernia surgery.
88835332|NCT03247985|Active Comparator|ProGrip Self-fixating Mesh|Participants will be randomized to Self-fixing mesh for their inguinal hernia surgery
88835333|NCT04329351|Experimental|Guided bone regeneration Group|After extraction, Guided bone regeneration was conducted using the PTFE-d membrane (CytoplastTM Ti-250 Titanium-Reinforced, Anterior Narrow 12 mm x 24 mm, Osteogenics, Lubbock, TX, USA) was customized with scissors and adjusted over the socket, exceeding three millimeters from its margins. Then, the membrane was inserted subperiostally under the buccal and palatal flaps with the help of the Molt detacher. Minimal flap reflection was performed to stabilize the membrane, which was maintained intentionally exposed to the oral environment. Before suturing, the passive stability of the membrane over the alveolus was confirmed, as well as the absence of folds or wrinkles in the membrane. The flaps were then be approached in the pre-extraction position and sutured with crossed sutures, aiming to increase the stability of the membrane, with PTFE 4-0 thread (Cytoplast PTFE, CS0618PREM, Osteogenics, Lubbock, TX, USA).
88835334|NCT04329351|Placebo Comparator|Non-Guided bone regeneration group|After extraction, no further treatment (No addition of Guided bone regeneration) was performed. The flaps were then repositioned and sutured with 5.0 nylon thread (Ethicon, Jonhson's Jonhson, São José dos Campos).
88835335|NCT05715788||patients ventilated in prone position|Patients ventilated in prone position
88835336|NCT05715788||Patients ventilated in prone position with NO inhalation|Patients ventilated in prone position with NO inhalation
89364299|NCT02717494|Experimental|Arm 2B (PCV-10)|In Step 2, women who received placebo in step 1 that were randomized to Arm 2B were administered a 0.5 mL dose of PCV-10 intramuscularly once.
89364300|NCT02717494|Experimental|Step 3 (PCV-10)|In Step 3, women who received placebo in step 1 and failed entry into step 2 due to ongoing new pregnancy were administered a 0.5 mL dose of PCV-10 intramuscularly once.
89364301|NCT03306342|Experimental|IOL implantation experimental|hydrophobic, trifocal intraocular lens POD F GF
89364302|NCT01350726||Normal control|Subjects without liver cirrhosis and normal volunteers.
89364303|NCT01350726||Cirrhosis group|Subjects with liver cirrhosis.
89364304|NCT01355874|Experimental|Iferanserin|
89364305|NCT01355874|Experimental|Placebo|
89364306|NCT01355874|Experimental|Iferanserin + Placebo|
89364307|NCT02422368|Experimental|Methylprednisolone + ASTED|"ASTED (Antioxidant Supplements for Thyroid Eye Disease) includes : B-Carotene (6 mg)+ Vit.C (200 mg) + Vit.E (200 mg) + Nicotinamide(20mg) + Selenium(200mic.) + Zinc oxide (8 mg) + Copper gluconate or oxide (1mg) + Manganese chloride (1.8 mg), Twice a day for 6 months~Methylprednisolone includes :~Methylprednisolone tablet of 50 and 5 mg, company….) 1mg/kg for the first 2 weeks, 0.8mg/kg for 2 weeks, 0.7 mg/kg for 2 weeks, and then tapering off the methylprednisolone in 6 weeks (total duration of 12 weeks) by 8-10 mg per week. For example, a patient with 75 kg weight will receive 75 mg for 2 weeks, 60 mg for 2 weeks, 52.5 mg for 2 weeks, and then decreasing by 8-10 mg per week for 6 weeks. The dose regiment will be written and handed to the patient on the first visit and will be monitored during the follow up."
89364308|NCT02422368|Placebo Comparator|Methylprednisolone + Placebo|Placebo Twice a day for 6 months Methylprednisolone prescribes as the same as arm 1
89364309|NCT01355952|Experimental|Alpha Lipoic Acid|taking 1800mg daily (600mg 3 times per day) Alpha Lipoic Acid (ALA) open-label for 10 weeks.
89364310|NCT02292108|Experimental|Hypnosis and dietetic counselling|Patient will benefit of usual dietetic counselling and experimental hypnosis
89364311|NCT02292108|Other|dietetic counselling|Patient will only benefit of usual dietetic counselling
88835337|NCT00003225|Experimental|Ethyol plus Irinotecan|Ethyol 740 mg/m2 will be administered intravenously over 10 minutes. 10 minutes after completion of the Ethyol infusion, Irinotecan 250 mg/m2 will be given over 90 minutes IV.
89364312|NCT01347450|Experimental|Cocoa, Placebo|
88835338|NCT03249779|Experimental|Scrambler|All participants will receive electrical stimulation applied to the lower extremities using the Scrambler.
89364313|NCT05720572|Experimental|Antazoline|"Any patient fulfilling the inclusion criteria will be prepared to pharmacological cardioversion in a standard way comprising of standard baseline 12-lead ECG, continuous ECG monitoring, periodic noninvasive blood pressure monitoring (BP) and iv line.~After drug administration the patient will be observed for 3 hours after the first dose with exit ECG and BP measure taken at the end of observation. Further treatment of the patient depends on clinical state and follows appropriate clinical guidelines."
89364314|NCT05720572|Active Comparator|Propafenone|"Any patient fulfilling the inclusion criteria will be prepared to pharmacological cardioversion in a standard way comprising of standard baseline 12-lead ECG, continuous ECG monitoring, periodic noninvasive blood pressure monitoring (BP) and iv line.~After drug administration the patient will be observed for 3 hours after the first dose with exit ECG and BP measure taken at the end of observation. Further treatment of the patient depends on clinical state and follows appropriate clinical guidelines."
89364315|NCT01356030|Active Comparator|EUS-FNA|
89364316|NCT01356030|Active Comparator|ERCP Brushing and Biopsy|
88835339|NCT03382847|Experimental|Intervention arm|HCV negative patients will receive a heart transplant from a HCV positive donor. Post-transplant, there will be surveillance for the development of viremia, and treatment of viremia. Following treatment, there will be surveillance for a sustained virologic response to HCV treatment.
88835340|NCT04735211||Children whom develop chronic postsurgical pain|Children whom had chronic pain at 3 moths after surgery
88835341|NCT04735211||Children whom not develop chronic postsurgical pain|Children whom not develop chronic pain at 3 moths after surgery
89364317|NCT01347528|Experimental|TELEmonitoring intervention|
89364318|NCT01347528|No Intervention|Usual care|
89364319|NCT02465944|Experimental|FFP104 - 2.5 mg/kg|FFP104
89364320|NCT02465944|Experimental|FFP104 - 5.0 mg/kg|FFP104
89364321|NCT02465944|Placebo Comparator|Placebo|Placebo
89364322|NCT04471792|Experimental|Creatine monohydrate|Creatine Monohydrate will be given at a 5 day loading period (10g/day) followed by a maintenance phase (5 g/day). The objectives of the current trial are to investigate if creatine supplementation plus muscle stretching improves 6-minute walking distance and muscle oxygenation in patients with peripheral artery disease.
89364323|NCT04471792|Placebo Comparator|Cellulose|These participants will consume a fiber supplement in place of creatine monohydrate at a matched dose with muscle stretching.
89364324|NCT01356186|Experimental|Post Admission Cognitive Therapy (PACT)|Six (6) 60-90 Minutes Sessions of Post Admission Cognitive Therapy Delivered Preferably Over 3 Consecutive Days of Inpatient Stay
89364325|NCT01356186|No Intervention|Enhanced Usual Care (EUC)|Treatment As Usual and Study Assessment Services
89364326|NCT01347684|Active Comparator|Standard care using current drugs|Standard care with drug intervention
89364327|NCT01347684|Experimental|Behavioral therapy, splint therapy and physical therapy|Using rehabilitation for comparing use of drug
89364328|NCT05716750|Other|Osteomalasia|Our study, which is the only group planned prospectively, aims to compare clinical and laboratory data and serum prolidase activity and leptin levels in 38 patients diagnosed with osteomalacia after and before 8 weeks of 50,000 IU D vit treatment.
88835342|NCT00376415|Experimental|Lessertia Fructescens|Participants received 400mg lessertia fructescens leaf powder capsules twice daily for 3 months.
88835343|NCT00376415|Placebo Comparator|Placebo|Participants received an identical placebo capsule twice daily for 3 months.
88835344|NCT05303779|Experimental|experimental group|experimental group will receive eye exercises in addition to medication and eye glasses post strabismus surgery
88835345|NCT05303779|Active Comparator|control group|control group will receive medication and eye glasses post strabismus surgery
88835346|NCT04734899|Active Comparator|Control grup|"All individuals participating in the study will be taught the exercises given to strengthen weakened muscles, stretch shortened structures and increase proprioception by the physiotherapist and will be asked to do these exercises at least twice a day for 8 weeks.~The home program will be followed by the exercise daily form."
88835347|NCT04734899|Experimental|Foot core grup|In addition to the exercise program given to the control group, foot core training will be added and taught by the physiotherapist and they will be asked to do these exercises at least twice a day for 8 weeks.
88835348|NCT03440723|Active Comparator|Standard Dilation Exam|Participants receive two standard digital cervical dilation examinations conducted by two different physicians.
88835349|NCT03440723|Experimental|Dilation Exam with DilaCheck|Participants receive two cervical dilation examinations using DilaCheck devices conducted by two different physicians.
88835350|NCT05614076|Experimental|Conservation of the demineralized chalky white enamel margin of class V cavities|for cavity design in this arm we Conserved the demineralized chalky white enamel margin of class V cavities then application of resin composite restoration
88835351|NCT05614076|Active Comparator|Total removal of demineralized enamel margin of class V cavities|for cavity design in this arm is Total removal of demineralized enamel margin of class V cavities and restoration with resin composite
88835352|NCT03838094|Active Comparator|MTA Group|pulpotomy technique using fast-setting mineral trioxide aggregate (MTA) to be considered the control group for vital pulp therapy and was placed over the amputated pulps for 18 months. This group will be compared with the Biodentine group as the intervention group
88835353|NCT03838094|Experimental|Biodentine group|3 mm- thick Biodentine covered radicular pulp to allow pulp regeneration
88835354|NCT03441269|Active Comparator|400mg/dose|Oral Ibuprofen dose of 400mg/dose for mild to moderate acute pain in ED patients.
88835355|NCT03441269|Active Comparator|600mg/dose|Oral Ibuprofen dose of 600mg/dose for mild to moderate acute pain in ED patients.
88835356|NCT03441269|Active Comparator|800mg/dose|Oral Ibuprofen dose of 800mg/dose for mild to moderate acute pain in ED patients.
88835357|NCT05367596|Experimental|Continuous Energy Restriction (CER)|Continuous energy restriction (CER; 1,200-1,500 kcal/day). Participants in both groups will have a daily late-evening snack and participate in remotely supervised exercises.
88835358|NCT05367596|Experimental|Alternate-Day Moderate Fasting (ADMF).|Alternate-Day Moderate Fasting (ADMF). Participants in both groups will have a daily late-evening snack and participate in remotely supervised exercises.
88835359|NCT03383627|Experimental|Continuous glucose monitoring|"If subjects meet inclusion criteria then they will return to the research site on Day 1 to place Freestyle Libre Pro device by the research staff for 14-day monitoring.~Subjects will be advised to return to the research site on Day 14 to remove the CGM device for analysis. On Day 14, blood will be drawn for HbA1c and fructosamine, The blood drawn for this research will be approximately 10-15 milliliters.~There are no drug washout periods. Subjects will continue to take all their medications and/or insulins as prescribed by their doctor.~Baseline data including age, race, ethnicity, past medical history, home medication list, and diabetes related laboratory data will be collected."
88835360|NCT05366426|Experimental|Experimental group|Pelvic floor muscle training exercise program will be applied with EMG biofeedback.
88835361|NCT05366426|Sham Comparator|Sham Group|Pelvic floor muscle training exercise program will be applied with EMG biofeedback as a sham.
88835362|NCT05366426|Other|Control Group|Pelvic floor muscle training program will be applied as home exercise
88835363|NCT03252353|Active Comparator|Octreotide capsules|Octreotide capsules
88835364|NCT03252353|Placebo Comparator|Matching Placebo|Matching placebo capsules
88835365|NCT05349734|Experimental|overbody blanket|
88835366|NCT05349734|Active Comparator|underbody blanket|
88835367|NCT03441581|Experimental|Eluxadoline 100 mg with BAM|IBS-D participants with evidence of Bile Acid Malabsorption (BAM) treated with eluxadoline 100 mg oral tablets twice daily (BID) with food for 4 weeks.
88835368|NCT03441581|Experimental|Eluxadoline 100 mg without BAM|IBS-D participants without evidence of BAM treated with eluxadoline 100 mg oral tablets BID with food for 4 weeks.
88835369|NCT02265510|Experimental|Phase 1a: INCB052793 Monotherapy|
88835370|NCT02265510|Experimental|Phase 1b: INCB052793 Combination Therapy|
88835371|NCT02265510|Experimental|Phase 2: INCB052793 and itacitinib Combination Therapy|
88835372|NCT03254147||patients prescribed with Oral Anti-coagulants|warfarin and non-vitamin K dependent oral anti-coagulants
88835373|NCT04735601|Experimental|Ahmed valve coated with PLGA is implanted in secondary glaucoma in Sturge Weber syndrome|Ahmed valve coated with PLGA is implanted in secondary glaucoma in Sturge Weber syndrome
88835374|NCT04735601|Active Comparator|Ahmed valve implanted in secondary glaucoma in Sturge Weber syndrome|Ahmed valve will be implanted alone with no PLGA
88835375|NCT04735757||Healthy volunteers|Healthy volunteers, matched by age and gender to patient groups.
88835376|NCT04735757||COVID-19 patients|Patients discharged from the ICU after invasive ventilation for COVID-19.
88835377|NCT04735757||ICU patients|Patients discharged from the ICU after invasive ventilation for ARDS.
88835378|NCT03384329|Experimental|Resveratrol Pill|
88835379|NCT03384329|Placebo Comparator|Placebo|
88835380|NCT02959034||BMI > 95%|No Intervention
88835381|NCT02959034||Healthy Weight Siblings|Control
88835382|NCT02959034||Healthy Weight Unrelated|Control
88835383|NCT03384953|Experimental|Clinical Hypnosis - Group Treatment|Subjects will receive 8 weeks of a manualized clinical hypnosis for chronic pain treatment in a group setting. Assessments will be completed before, immediately after, and at 3- and 6- months post-treatment to assess for treatment gains.
89364329|NCT05709886|Experimental|EUS-LA by LaserPro Diode Laser System|This trial is a prospective, single-arm, multi-center clinical trial. Four hospitals with national medical trial institution qualifications are selected as clinical trial centers. Qualified participants will receive endoscopic ultrasound (EUS)-guided laser ablation (LA) by LaserPro Diode Laser System according to the routine procedures. The results will be recorded according to the requirements of the primary and secondary efficacy indicators. After then, statistical comparisons of effectiveness and safety of the procedure will be made according to groups.
89364330|NCT01350882|Experimental|A|Patients randomized into the arm blind A. Rituximab is allowed as additional treatment from J12, within the limit of 2 infusions of rituximab. In case of insufficient efficacy of the treatment of acute humoral rejection, investigators may propose an additional infusion of rituximab from J12, without patient withdrawn. In this case (2nd infusion effective in group A and 1st infusion effective group B), a additional consultation (CS) will be provided as part of the study 7 days after infusion. In case of insufficient efficacy of the treatment,in fairness to care for patients between the 2 treatment groups, the investigators may propose to a 3rd infusion patients in group B (2nd infusion effective for this group). To prevent patients from group A will receive a 3rd infusion of rituximab, unblinding will be applied in this case by the investigator before the administration of additional treatment with rituximab.
89364331|NCT01350882|Placebo Comparator|B|Patients randomized into the arm blind B. Rituximab is allowed as additional treatment from J12, within the limit of 2 infusions of rituximab. In case of insufficient efficacy of the treatment of acute humoral rejection, investigators may propose an additional infusion of rituximab from J12, without patient withdrawn. In this case (2nd infusion effective in group A and 1st infusion effective group B), a additional consultation (CS) will be provided as part of the study 7 days after infusion. In case of insufficient efficacy of the treatment,in fairness to care for patients between the 2 treatment groups, the investigators may propose to a 3rd infusion patients in group B (2nd infusion effective for this group). To prevent patients from group A will receive a 3rd infusion of rituximab, unblinding will be applied in this case by the investigator before the administration of additional treatment with rituximab.
89364332|NCT01357200||critically ill obese adults|Age ≥ 18 years, body mass index (BMI) ≥ 30, in intensive care unit (ICU) requiring tube feeding ≥ 3 days
89364333|NCT01357278|Experimental|Rehabilitation and patient education|"Supervised rehabilitation consists of exercises for strength, balance and coordination twice weekly, and a home-training programme once weekly.~Patient education will be offered every eight week."
89364334|NCT01357278|No Intervention|Patient education|Patient education will be offered every eight week.
88835384|NCT03384953|Experimental|Clinical Hypnosis - Individual Treatment|Subjects will receive 8 weeks of a manualized clinical hypnosis for chronic pain treatment in an individual, 1:1 setting. Assessments will be completed before, immediately after, and at 3- and 6- months post-treatment to assess for treatment gains.
89364335|NCT04489966|Experimental|Aerobic training group|The aerobic training group was performed 3 times/week for 60 minutes/session(including 5 minutes of warm-up, 50 minutes aerobic rhythmic exercise and 5 minutes to relax) for moderate(60 to 70% of participants' HRmax) aerobic rhythmic exercise. All patients received an open class, relate to diabetes health education. The intervention lasted for 6 months.
89364336|NCT04489966|No Intervention|Control group|Patients in control group remained the original lifestyle unchanged. All patients received an open class, relate to diabetes health education.
88835385|NCT03443063|Experimental|Group 1: Severe Renal Impairment|Participants with severe renal impairment (estimated glomerular filtration rate [eGFR] 15 to 29 milliliters per minute (mL/min/1.73 square meter [m^2]) and not on dialysis) will receive a single dose of 10 milligrams (mg) lemborexant (oral tablet) in the morning after an overnight fast.
88835386|NCT03443063|Experimental|Group 2: Normal Renal Function|Participants with normal renal function (eGFR ≥90 mL/min/1.73 m^2) demographically matched to participants in Group 1 will receive a single dose of 10 mg lemborexant (oral tablet) in the morning after an overnight fast.
88835387|NCT03256253|Experimental|pregabalin|pregabalin up to daily dose of 600 mg
88835388|NCT03256799|Experimental|Ivacaftor/Ataluren|
88835389|NCT03257189|Other|Single Arm|"This single arm consists of all subjects which will interact with the device under investigation as well as comparator devices.~This includes the Physiological signal monitor intervention, Heart rate and heart rate variability comparison device intervention, Respiration rate comparison device intervention, and Activity classification intervention."
88835390|NCT01238211|Experimental|Treatment (daunorubicin hydrochloride, cytarabine, dasatinib)|"INDUCTION THERAPY (course 1): Patients receive daunorubicin hydrochloride IV on days 1-3, cytarabine IV continuously over 168 hours on days 1-7, and dasatinib PO QD on days 8-21. Patients with responsive disease on day 21 undergo consolidation therapy, and patients with non-responsive disease on day 21 (bone marrow cellularity >= 20% and leukemia blasts >= 5%) receive a second course of induction therapy.~INDUCTION THERAPY (course 2): Patients receive daunorubicin hydrochloride IV on days 1-3, cytarabine IV continuously over 120 hours on days 1-5, and dasatinib PO QD on days 6-19. Patients achieving complete response receive consolidation therapy.~CONSOLIDATION THERAPY: Patients receive high-dose cytarabine IV over 3 hours on days 1, 3, and 5, and dasatinib PO QD on days 6-26 or 7-27. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients in complete remission receive continuation therapy."
89364337|NCT04489966|Experimental|Intervention group|The intervention was aerobic rhythmic exercise, with intensive training under the guidance and supervision of a professional.The aerobic training program required participants to exercise 3 days/week for 60 minutes/session (including 5-10 minutes of warm-up and 5-10 minutes flexibility exercises). Participants were educated on aerobic exercises (aerobic dancing) with music.The intervention lasted for one year.
89364338|NCT04489966|No Intervention|Compared group|The control group was instructed to maintain their usual habits and received no structured exercise intervention. But the form, frequency and time of movement of each participant must be recorded.Participants receive an open diabetes health education class once a month, which is taught by a specially trained diabetes nurse.
89178488|NCT00835744|Placebo Comparator|A|Patients undergo a standard treatment with clomiphene citrate from day 3 until day 7 of the cycle at a dose of 50 mg daily. If no reaction on day 13 of the cycle, an increased dose of 100 mg of clomiphene citrate is administered from day 13 until day 17 of the cycle.
89364339|NCT02476084||Conventional synthetic DMARD naïve|"Naive RA patients commencing Methotrexate and Hydroxychloroquine.~Musculoskeletal Ultrasound imaging, synovial biopsy, biological samples collection, questionnaires."
89364340|NCT02476084||DMARD-IR: anti-TNF|"Conventional synthetic DMARD inadequate responders commencing Anti-TNF~Musculoskeletal Ultrasound imaging, synovial biopsy, biological samples collection, questionnaires."
89364341|NCT02476084||DMARD-IR: anti-IL6|"Conventional synthetic DMARD inadequate responders commencing anti-IL6~Musculoskeletal Ultrasound imaging, synovial biopsy, biological samples collection, questionnaires."
89364342|NCT02476084||DMARD-IR: anti-CTLA-4|"Conventional synthetic DMARD inadequate responders commencing anti-CTLA-4~Musculoskeletal Ultrasound imaging, synovial biopsy, biological samples collection, questionnaires."
89364343|NCT02476084||DMARD-IR: anti-CD20|"Conventional synthetic DMARD inadequate responders commencing anti-CD20~Musculoskeletal Ultrasound imaging, synovial biopsy, biological samples collection, questionnaires."
89178489|NCT00835744|Active Comparator|B|Patients undergo a standard treatment with clomiphene citrate from day 3 until day 7 of the cycle at a dose of 50 mg daily. If no reaction on day 13 of the cycle, gonadotropins (75IU) are administered from day 13 until day 17 of the cycle.
89178490|NCT00841048|Experimental|1|AZD4017 in ascending doses (start dose 75mg od)
89178491|NCT00841048|Placebo Comparator|2|Placebo
89178492|NCT00778830|Experimental|Cetuximab plus FOLFIRI|
89364344|NCT01844856|Experimental|Eravacycline, 1.0 mg/kg q12h|Eravacycline was administered intravenously (IV) at a dose of 1.0 milligram per kilogram of body weight (mg/kg) every 12 hours (q12h) for a minimum of 4 days and a maximum of 14 days. Eravacycline treatment was to be stopped when symptoms of complicated intra-abdominal infection (cIAI) resolved, there was treatment failure, or the maximum allowed number of infusion days was reached.
89364345|NCT01844856|Active Comparator|Ertapenem, 1.0 g q24h|Ertapenem was administered IV at a dose of 1.0 gram (g) every 24 hours (q24h) for a minimum of 4 days and a maximum of 14 days. Ertapenem treatment was to be stopped when symptoms of cIAI resolved, there was treatment failure, or the maximum allowed number of infusion days was reached.
89364346|NCT02465788|Experimental|755nm alexandrite laser with bipolar RF|GentleTouch (Helos) combines 755nm alexandrite laser energy with bipolar RF energy.
89364347|NCT00618098|Experimental|Octaplex (human prothrombin complex concentrate)|Participants to receive1 or more Octaplex infusions intravenously until their International Normalized Ratio (INR) was < 1.5.
89364348|NCT00618098|Active Comparator|Fresh frozen plasma|Participants to receive1 or more fresh frozen plasma infusions intravenously until their International Normalized Ratio (INR) was < 1.5.
89001498|NCT00584350|Experimental|A: Hydratation according LVEDP + NaHCO3|"Hydration with bolus of NaCl 0.9 to reach a LVEDP of 18 mmHg or more. This procedure is done while the patient is in the laboratory, with a catheter in the left ventricle.~At the same time, an infusion of a sodium bicarbonate solution (150 mEq/L) is started at a rate of 1 ml/kg/h (max 110 ml/h) for 7 hours."
89364349|NCT02464228|Experimental|Tipifarnib|tipifarnib, oral
89001499|NCT00584350|Active Comparator|B: Standard hydratation|hydratation with normal saline (1 cc/kg/h; max 110 cc/h) starting at 8PM the day before the test and ending at 8PM the day of the test (24 hours total).
89178493|NCT00778830|Experimental|Cetuximab plus FOLFOX|
89178494|NCT04102332||Before arm|usual infusion practices (neutral solvent-purged infusers)
89178495|NCT04102332||After arm|Safe Infusion Device
89178496|NCT00772668|Experimental|RCVELP|"Rituximab, Cyclophosphamide, Bortezomib, Prednisone (RCVELP):~Rituximab~Induction: 375 mg/m2 IV infusion on Day 1 of every 21 days cycle for 8 cycles~Maintenance: 375/m2 Days 1, 8, 15, 22 every 6 months for up to 4 cycles~Cyclophosphamide: 750 mg/m2 intravenous piggyback (IVPB) on Day 1 of every 21 day cycle for 8 cycles~Bortezomib: 1.6 mg/m2 IV push on Days 1 and 8 of every 21 days cycle for 8 cycles~Prednisone: 100 mg PO daily on Days 1-5 of every 21 day cycle for 8 cycles"
89178497|NCT00786474|Placebo Comparator|Placebo|
89178498|NCT00786474|Experimental|Dalteparin|
89178499|NCT00784875|Experimental|Period A|2-week double-blind placebo lead-in period. Period A is the first of four 2-week treatment periods.
89178500|NCT00784875|Experimental|Period B|Patients will receive LY2624803, zolpidem or placebo in a sequence of four 2-week treatment periods. Period B is the second of four 2-week treatment periods.
89178501|NCT00784875|Experimental|Period C|Patients will receive LY2624803, zolpidem or placebo in a sequence of four 2-week treatment periods. Period C is the third of four 2-week treatment periods.
89178502|NCT00784875|Experimental|Period D|Patients will receive LY2624803, zolpidem or placebo in a sequence of four 2-week treatment periods. Period D is the fourth of four 2-week treatment periods.
89001500|NCT00584350|Experimental|C: Hydratation with sodium bicarbonate|hydratation with sodium bicarbonate (150 mEq/L) at 3 cc/kg/h (max 330 cc/h) for 1 hour before the test and then, to be continued at 1 cc/kg/h (max 110 cc/h) for 6 hours (total of 7 hours of hydratation).
89364350|NCT04051736|Experimental|group 1|180 2-month-old subjects will be enrolled with vaccination schedule as follows: 1st: Salk-IPV; 2nd: Sabin-IPV; 3rd: Sabin-IPV
88835391|NCT00375947|Experimental|1|Home-based hand exercise program
88835392|NCT00375947|Placebo Comparator|2|Sham hand cream
88835393|NCT04735445|Active Comparator|Conventional screening|Standard screening in the participating centers, adjusted to the recommendations of the European AIDS Society (EACS).
89001501|NCT00182039|Experimental|A|metoprolol
89364351|NCT04051736|Active Comparator|group 2|180 2-month-old subjects will be enrolled with vaccination schedule as follows: 1st: Salk-IPV; 2nd: Salk-IPV; 3rd: Salk-IPV
89364352|NCT05687968|Experimental|eHealth care group|"The eHealth group will receive instant feedback from the nutritionists and/or AI after recording their dietary food image, and receive 3D/AR MetaFood food portion and nutrition education."
89364353|NCT05687968|Experimental|control group|The control receive conventional health and nutrition education from state registered dietitian.
88835394|NCT04735445|Experimental|Enhanced screening|Expanded screening for early detection of lung, liver, anal, cervical, breast, prostate, colorectal and skin cancer.
88835395|NCT04344314|Other|Small gauge arm|2 PIVCs of same gauge and different lengths
88835396|NCT04344314|Other|Large gauge arm|2 PIVCs of same gauge and different lengths
88835397|NCT03259139|Experimental|Experimental: Violence with guns|Participants in this condition will play a video game with violent content which includes guns.
88835398|NCT03259139|Experimental|Experimental: Violence without guns|Participants in this condition will play a video game with violent content which does not include guns. Instead, the violence will include weapons such as swords.
88835399|NCT03259139|Other|Control: No violence|Participants in this condition will play a video game which contains no violent content or weapons.
88835400|NCT03260699|No Intervention|Control group|Subjects will receive two out-patient physical therapy (PT) visits per week for 2 weeks, followed by additional PT visits at clinician's discretion after TKA.
88835401|NCT03260699|Experimental|Bracing group|Subjects will be fitted with the Ongoing Care Solutions, Inc (OCSI) Rehabilitator brace prior to surgery. This brace will be worn for 6 weeks before surgery. The brace will be worn again after surgery ~10 days after surgery or when staples are removed until the end of the study. Participants will also have two PT visits per week for 2 weeks, followed by additional PT visits at clinician's discretion.
88835402|NCT05128136|Experimental|Silicone IVR 46mm external diameter|Non-medicated 46 mm ring.
88835403|NCT05128136|Experimental|Silicone IVR 56mm external diameter|Non-medicated 56mm ring.
88835404|NCT05128136|Experimental|Silicone IVR 66mm external diameter|Non-medicated 66mm ring.
88835405|NCT05440721|Active Comparator|Treatment A (device Clickotine®)|User will open and use Treatment A (Clickotine® device) several times a day up to their quit date to complete a program of 21 Missions.
88835406|NCT05440721|Sham Comparator|Treatment B (smoking education)|Treatment B app provides education and support to smokers seeking to quit. When a user has a craving or wants support or education, they can log into the app.
88835407|NCT04344158|Experimental|AK105 combined with Anlotinib|AK105 200mg intravenously (IV) on day 1 of each 21-day cycle plus Anlotinib capsules 10mg given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
88835408|NCT04344158|Active Comparator|Sorafenib Tosylate Tablets|Sorafenib Tosylate Tablets 400mg given orally, twice daily in 21-day cycle.
88835409|NCT00003249|Experimental|Arm I|Patients receive oral carboxyamidotriazole (CAI) as a test dose on day 1. Patients receive oral ketoconazole on day 7, followed by CAI plus ketoconazole on day 8. CAI and ketoconazole are administered in combination on day 1 and days 3-28 of the first course. Ketoconazole is administered alone on day 2 of the first course. Subsequent courses begin at 28 day intervals in the absence of disease progression or unacceptable toxic effects. Cohorts of 3 patients are evaluated at each dose level prior to dose escalation. If one of three patients within a cohort experiences dose limiting toxicity (DLT), that dose level is expanded to incorporate six patients. If two or more patients experience DLT, the next lower dose is declared to be the maximum tolerated dose.
88835410|NCT03268343|Experimental|Schedule A: Fed Then Fasted|"Schedule A (12 subjects):~Period 1: Cytisine (2 x 1.5 mg tablets) will be administered 30 minutes after the start of a high fat breakfast (fed state).~Period 2: Cytisine (2 x 1.5 mg tablets) will be administered after an overnight fast of at least 10 hours (fasting state)."
88835411|NCT03268343|Experimental|Schedule B: Fasted Then Fed|"Schedule B (12 subjects):~Period 1: Cytisine (2 x 1.5 mg tablets) will be administered after an overnight fast of at least 10 hours (fasting state).~Period 2: Cytisine (2 x 1.5 mg tablets) will be administered 30 minutes after the start of a high fat breakfast (fed state)."
88835412|NCT04329663|Experimental|training group|Ten children with ADHD who got the 20 sessions training of the Indonesian computer-based game prototype. They we were assessed by CATPRS, BRIEF and fMRI BOLD
88835413|NCT03744637|Experimental|Panel A: MK-5475 120 ug/165 ug/240 ug/240 ug/240 ug (Parts 1 and 2)|Participants in Panel A will receive a single inhaled dose of MK-5475 120 ug in Period 1 of Part 1, followed by MK-5475 165 ug in Period 2, followed by MK-5475 240 ug in Period 3. Each dose will be separated by at least a 7-day washout. In Part 2 Period 2, participants will receive a single inhaled dose of MK-5475 240 ug and undergo a right heart catheterization (RHC). In Part 2 Period 3, participants will receive a single inhaled dose of MK-5475 240 ug and undergo a functional respiratory imaging (FRI).
88835414|NCT03744637|Experimental|Panel B: 300 ug/360 ug/360 ug (Part 2)|Participants in Panel B will receive a single inhaled dose of MK-5475 300 ug in Period 1 of Part 2. In Period 2 of Part 2, participants will receive a single inhaled dose of MK-5475 360 ug and undergo FRI. In Period 3 of Part 2, participants receive a single inhaled dose of MK-5475 360 ug and undergo RHC. Each dose will be separated by at least a 7-day washout.
88835415|NCT03744637|Experimental|Panel C: 300 ug/360 ug/360 ug (Part 2, Expansion)|Participants in Panel C will receive a single inhaled dose of MK-5475 300 ug in Period 1 of Part 2. In Period 2 of Part 2, participants will receive a single inhaled dose of MK-5475 360 ug and undergo FRI. In Period 3 of Part 2, participants receive a single inhaled dose of MK-5475 360 ug and undergo RHC. Each dose will be separated by at least a 7-day washout.
88835416|NCT03744637|Experimental|Panel D: 480 ug/120 ug/120 ug (Part 2)|Participants in Panel D will receive a single inhaled dose of MK-5475 480 ug in Period 1 of Part 2. In Period 2 of Part 2, participants will receive a single inhaled dose of MK-5475 120 ug and undergo FRI. In Period 3 of Part 2, participants receive a single inhaled dose of MK-5475 120 ug and undergo RHC. Each dose will be separated by at least a 7-day washout.
88835417|NCT03744637|Placebo Comparator|Placebo (Part 1)|Participants will receive a single inhaled dose of matching placebo in Part 1.
88835418|NCT00003255|Experimental|topotecan + carboplatin|Patients receive continuous intravenous infusions of topotecan and carboplatin for 5 days. Treatment repeats every 3-4 weeks during induction (two courses) and every 6-10 weeks during consolidation. No more than four courses of treatment are given. Patients are followed every 6 months for 5 years.
88835419|NCT03269435|Experimental|Greater Occipital Nerve Block|"Bilateral greater occipital nerve block with bupivacaine 0.5%~+ Normal saline IV"
88835420|NCT03269435|Active Comparator|Metoclopramide|"Metoclopramide 10mg IV~+ Bilateral greater occipital nerve block with normal saline"
89001502|NCT00182039|Placebo Comparator|B|placebo
89001503|NCT00584389|Experimental|1|Rimonabant treatment (20mg/d) for 12 weeks
89001504|NCT00584389|Other|2|Dietary intervention
88818210|NCT01812005|Experimental|Cohort B (alisertib, rituximab)|Patients receive alisertib as in Cohort A. Patients achieving SD or asymptomatic progressive disease after 2 courses also receive rituximab IV on day 1 of courses 3-10. Patients unable to achieve CR by course 4, receive rituximab as in Cohort A. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89001505|NCT00584428|Experimental|1|
89001506|NCT00216372|Experimental|1|
89001507|NCT00216372|Placebo Comparator|2|
89001508|NCT00584584|Experimental|1|
89001509|NCT00584584|Placebo Comparator|2|
89001510|NCT00584662|Active Comparator|1|Oxymetazoline Hydrochloride
89001511|NCT00182156||1|conventional HD
88818211|NCT01332578|Experimental|Test Product|Paracetamol, phenylephrine and ascorbic acid to be administered in 150 milliliters (mL) of hot water.
88818212|NCT01332578|Active Comparator|Paracetamol tablet|Two paracetamol 500 mg tablets to be administered with 150 mL of hot water.
88818213|NCT01795859|Experimental|SD-809 ER Tablets|SD-809 ER tablets are available in three dose strengths: 6, 9 and 12 mg, all of which are identical in size, shape and color (white). All are administered three times a day, with the 6 mg final dose is placebo.
88818214|NCT01795859|Experimental|SD-809 Tablets|SD-809 tablets are available in three dose strengths: 6, 9 and 12 mg, all of which are identical in size, shape and color (white). All are administered three times a day, with the 6 mg final dose is placebo.
88818215|NCT01333592|Experimental|KAD-1229|
88818216|NCT01812473||Patients admitted to the Intensive Care Unit|All patients admitted to the Intensive Care Unit, treated with voriconazole are eligible for the study.
88818217|NCT01375946|Experimental|AG200-15 location|The subject will wear AG200-15 for 7 days and be exposed to one of 5 external conditions (normal, treadmill, cold water, whirlpool, dry sauna).
88818218|NCT01371032|Active Comparator|Video-Miller laryngoscope|using the screen (Video laryngoscopy group)
88818219|NCT01371032|Active Comparator|Direct laryngoscopy|without use the screen (Direct laryngoscopy group)
88818220|NCT01267292|Experimental|Buspirone plus Methylphenidate|[week 1: Buspirone 30 mg twice a day (9am and 6pm) on Monday through Sunday; no Methylphenidate or Methylphenidate placebo] [week 2: Buspirone 45 mg twice a day (9am and 6pm) on Monday through Sunday; 0mg Methylphenidate (placebo) on Monday at 10am; Methylphenidate once a day (10am) on Wednesday and Friday, and on each of these 2 days the Methylphenidate dose will be different (15 mg, 30mg, 60 mg, or 0mg)] [week 3: Buspirone 45 mg twice a day (9am and 6pm) on Monday through Sunday; Methylphenidate once a day (10am) on Monday and Wednesday, and on each of these 2 days the Methylphenidate dose will be different (15 mg, 30mg, 60 mg, or 0mg)]
88818221|NCT01267292|Placebo Comparator|Placebo for Buspirone plus Methylphenidate|[week 1: Placebo for Buspirone twice a day (9am and 6pm) on Monday through Sunday; no Methylphenidate or Methylphenidate placebo] [week 2: Placebo for Buspirone twice a day (9am and 6pm) on Monday through Sunday; 0mg Methylphenidate (placebo for Methylphenidate) on Monday at 10am; Methylphenidate once a day (10am) on Wednesday and Friday, and on each of these 2 days the Methylphenidate dose will be different (15 mg, 30mg, 60 mg, or 0mg)] [week 3: Placebo for Buspirone twice a day (9am and 6pm) on Monday through Sunday; Methylphenidate once a day (10am) on Monday and Wednesday, and on each of these 2 days the Methylphenidate dose will be different (15 mg, 30mg, 60 mg, or 0mg)]
88818222|NCT04749095|Active Comparator|Erector block|
88818223|NCT04749095|Active Comparator|sham block|
88818224|NCT01797029|Experimental|Vaccine|
88818225|NCT01797029|Placebo Comparator|Placebo|
88818226|NCT01377584|Experimental|Patients in the Couple-oriented intervention|Patients randomly assigned to the couple-oriented (CO) group will attend two face to face sessions with their partner and participate in an individual telephone follow-up session.
88818227|NCT01377584|Other|Patients in Usual Care|Patients will not attend any intervention sessions.
88818228|NCT01377584|Experimental|Patients in the Patient-oriented intervention|Patients randomly assigned to the patient-oriented (PT) group will attend two face to face sessions and participate in a telephone follow-up session.
88818229|NCT01377584|Experimental|Partners in the Couple-oriented intervention|Partners randomly assigned to the couple-oriented (CO) group will attend two face to face sessions with the patient and participate in an individual telephone follow-up session.
88818230|NCT01377584|Other|Partners in Usual Care|Partners will not attend any intervention sessions.
88818231|NCT01377584|Experimental|Partners in the Patient-oriented intervention|Partners randomly assigned to the patient-oriented (PT) group will not attend any intervention sessions.
88818232|NCT01734161|Active Comparator|Dexamethasone|One dose of 8 mg of intravenous dexamethasone diluted in 50 ml of normal saline given as an infusion over 10 minutes.
88818233|NCT01734161|Placebo Comparator|Placebo|One dose of 50 ml of 0.9% normal saline that will be given as an infusion over 10 minutes.
88818234|NCT01272284|Other|Altis® SIS|Subjects enrolled with Altis® SIS
88818235|NCT01734239|Experimental|Pneumovax™ 23: Participants Between 2 and 49 Years|Participants received a single, 0.5-mL intramuscular injection of Pneumovax™ 23 on Day 1
88818236|NCT01734239|Experimental|Pneumovax™ 23: Participants >=50 Years|Participants received a single, 0.5-mL intramuscular injection of Pneumovax™ 23 on Day 1
88818237|NCT04346576|Experimental|Probiotics (LcS per 65 mL) prevent health problems in children|Probiotic test product was fermented milk containing 6.5 billion of LcS per 65 mL (108 CFU/mL), manufactured by Yakult Vietnam, Co., Ltd. The nutritional composition of the test product is 0.8 g of protein, <0.1 g of fat, 12.4 g of carbohydrates, and the total energy is 52.7 kcal per bottle. Subjects were asked to drink one bottle of the test product per day after lunch for 12 weeks on consecutive days. The test products were stored in a refrigerator (< 10°C), protected from direct sunlight, and used before their expiration date. Adherence to the intervention protocol was confirmed as follows; teachers at kindergartens or parents at home provided the probiotic drinks (1 bottle/day x 7 days/week) after lunch.
89364354|NCT01350960|Placebo Comparator|saline 0.9%|
89001512|NCT00182156||2|short daily HD
89001513|NCT00182156||3|PD
89001514|NCT00584779|Experimental|1|
89001515|NCT00584779|Experimental|2|
89001516|NCT00584779|Experimental|3|
89001517|NCT00584779|Experimental|4|
89001518|NCT00216411|Experimental|Dysport|
89001519|NCT00216411|Placebo Comparator|Placebo|
89364355|NCT01350960|Experimental|Cohort 1|0.5 mg/kg in Healthy Subjects
89364356|NCT01350960|Experimental|Cohort 2|1.5 mg/kg in Healthy subjects
89364357|NCT01350960|Experimental|Cohort 3|5.0 mg/kg in Healthy subjects
89001520|NCT00585091|Other|A|All patients undergo repeated phenylephrine infusions during standard up-titration and maintenance of carvedilol treatment.
89001521|NCT00585208|Active Comparator|Active drug|Ramelteon - this group receives active drug at a fixed dose of 8mg daily throughout study
89001522|NCT00585208|Placebo Comparator|Placebo (sugar pill)|placebo (sugar pill) - this arm receive the fake pill, also know as placebo or the sugar pill
89001523|NCT00585364||CF (non-ABPA)|cystic fibrosis and culture positive for A. fumigatus in airway cultures.
89001524|NCT00585364||CF and ABPA|cystic fibrosis and diagnosis of ABPA
89001525|NCT00585364||healthy control|healthy non-CF
89001526|NCT00585403||Children|Early and late pubertal girls and boys
89001527|NCT00585442|Experimental|Calcitriol|
89364358|NCT01350960|Experimental|Cohort 4|10 mg/kg in Healthy subjects
89364359|NCT01350960|Experimental|Cohort 5|TBD mg/kg in FH subjects
89364360|NCT01351038|Experimental|treatment|3 cycles(repeated q21d) Epirubicine 50mg/m² i.v. d1 Oxaliplatin 100mg/m² i.v. d1 Capecitabine 500mg/m² bid d1-d21 Panitumumab 9mg/kg i.v. d1
89364361|NCT02465710||pelvic organ prolapse|All women who underwent surgical treatment of pelvic organ prolapse in this study.
89364362|NCT01351116|Experimental|EBR plus HDRIB|External Beam Radiation (EBR) plus High Dose Rate Intraluminal Brachytherapy (HDRIB)
89001528|NCT00585442|Placebo Comparator|Placebo|
89001529|NCT00585481||1|All subjects will perform samples collection for RSV analysis. Subject's enrolled in Porto Alegre's site will perform lung function tests.
89001530|NCT00585520|Active Comparator|PG|
89001531|NCT00585520|Placebo Comparator|PLA|
89001532|NCT00408395|Experimental|1: Trivalent Seasonal Influenza Vaccine|
89001533|NCT00408395|Experimental|2: Adjuvanted Trivalent Seasonal Influenza Vaccine|
89001534|NCT00585598||1|all patients that are admitted to the trauma bay with a supralaryngeal airway
89001535|NCT00585676||Diabetic|Patients with Diabetes
89001536|NCT00585676||Abnormal glucose level|Patients who were screened and had abnormal blood glucose levels
89001537|NCT00585676||Control|Non-diabetic (normal glucose screening)
89001538|NCT00585754|Active Comparator|Guanfacine|
89001539|NCT00585754|Placebo Comparator|PLA|
89001540|NCT00585793||PEPFAR 1|
89001541|NCT00585871|Experimental|Clonidine therapy group|clonidine 0.1 TID
89001542|NCT00585871|Active Comparator|Metoprolol control group|metoprolol 25 TID
89001543|NCT00408512|Active Comparator|Thiazides|Thiazidic diuretic
89001544|NCT00408512|Active Comparator|Non Tiazidic|Non tiazidic diuretic treatment: Any other therapy can be considered in this arm: example: CCB, BB, ACEi, ARB
89001545|NCT00585949||Angiography|Patients undergoing coronary angiography without percutaneous coronary angioplasty
89001546|NCT00585949||Percutaneous Coronary Angioplasty|Patients with stable coronary artery disease undergoing angioplasty
89001547|NCT00585988|Other|1|
89001548|NCT00585988|Other|2|
89001549|NCT04722393|Experimental|Pulmonary Rehabilitation Group|An 8-week comprehensive outpatient PR program including respiratory exercises, aerobic and strengthening training
89001550|NCT04722393|Other|Control Group|Respiratory exercises
89001551|NCT00586027||NT-proBNP|150 consecutive patients undergoing cardiac surgery with an intraoperative measured cardiac output <2L/min/m².
89001552|NCT04722861||Primary Glaucoma|Patients with primary glaucoma diagnosed by glaucoma professionals
89001553|NCT04722861||Glaucoma Suspect Controls|Glaucoma suspect controls had a diagnosis of glaucoma suspect or ocular hypertension, and also were required to have a presenting Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity of 20/40 or better in both eyes.
89001554|NCT03452722||Study group|Applied rtPA
89001555|NCT03452722||Control study|rtPA not applied
89001556|NCT03452683|No Intervention|Usual Care|Participants randomized to the Usual Care arm will receive educational handouts.
89001557|NCT03452683|Experimental|Movn Mobile App|Participants randomized to the Movn Mobile App arm will have the Movn app downloaded to their cell phone. Participants will enter in their weight and symptoms into the app every day.
89001558|NCT00408551|Experimental|FOLFOX6|Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1. Patients also receive fluorouracil IV continously over 46 hours beginning on day 1.
89364363|NCT01351116|Active Comparator|EBR|External Beam Radiation (EBR)
89364364|NCT01356264|Experimental|multimodal prehabilitation begun preop|The prehabilitation program will begin several weeks preop and continue in the postoperative period
89364365|NCT01356264|Active Comparator|Multimodal prehabilitation begun postop|The prehabilitation program will begin after the surgery.
89364366|NCT01356342|Experimental|AdimFlu-S 2010-2011, 6 months~<3 years|
89364367|NCT01356342|Experimental|AdimFlu-S 2010-2011,3~<9 years|
89364368|NCT01356342|Experimental|AdimFlu-S 2010-2011,9~<18 years|
89364369|NCT01788306|Active Comparator|Intervention (OOPEN+BBCC)|Study intervention, overdose prevention, education, intervention, brief behavioral change counseling, take-home naloxone, referral to local available resources.
89364370|NCT01788306|No Intervention|Control|Standard of care, referral to local available resources.
89364371|NCT02464462|Experimental|CaD Group|This arm received total of 1800 IU of vitamin D3 and 720 mg of calcium
89364372|NCT02464462|Placebo Comparator|Placebo Group|This arm received rice powder pills
89364373|NCT03135210|Active Comparator|Open-Chain Leg Exercise|Individuals in the open-chain group will progress through standard mobility progression.
89364374|NCT03135210|Experimental|Closed-Chain Leg Exercise|Individuals in the closed-chain group will progress through standard mobility exercises with the addition of closed-chain leg exercises using the MOVEO platform.
88835421|NCT05288582|Other|Perfluorohexyloctane eye drop|Participants will have their tear lipid layer assessed. They will then have the eye drop instilled and will have an additional assessment of the tear lipid layer within 5 minutes of instillation of the the drop, and again 15 minutes after instillation.
88835422|NCT03279731|Active Comparator|Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml|Pre-filled, multi-dose pen that delivers doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, or 3 mg via subcutaneous injection. Matching the recommended dosage and administration guidelines of the FDA-approved labeling for the use of liraglutide (Saxenda), the medication will be initiated at 0.6 mg daily for 1 week, and then increased by 0.6 mg/day in weekly intervals until a dose of 3.0 mg/day is achieved. Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist.
88835423|NCT03279731|Placebo Comparator|Placebo|Pre-filled, multi-dose pen that delivers doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, or 3 mg of placebo via subcutaneous injection. The placebo will be initiated at 0.6 mg daily for 1 week, and then increased by 0.6 mg/day in weekly intervals until a dose of 3.0 mg/day is achieved.The inactive ingredients include: disodium phosphate dihydrate, 1.42 mg; propylene glycol, 14 mg; phenol, 5.5 mg; and water for injection.
88835424|NCT03390257|Experimental|3NT flexible endoscope|Evaluation of 3NT flexible endoscope in terms of access and evaluation of the nasal anatomy
88835425|NCT04524403|Experimental|Miricorlilant - 600 mg|Patients who meet the entry criteria for the Study CORT118335-877 will be randomized to receive 600 mg miricorilant once daily for 26 weeks.
88835426|NCT04524403|Experimental|Miricorlilant - 900 mg|Patients who meet the entry criteria for the Study CORT118335-877 will be randomized to receive 900 mg miricorilant once daily for 26 weeks.
88835427|NCT04524403|Placebo Comparator|Placebo|Patients who meet the entry criteria for the Study CORT118335-877 will be randomized to receive placebo once daily for 26 weeks.
88835428|NCT05107934|Experimental|RPH-104 80 mg|Patients will receive RPH-104 dose 160 mg subcutaneously on Day 0, and 80 mg on Day 7, Day 14 and thereafter once in two weeks.
88835429|NCT05107934|Placebo Comparator|Placebo|Patients (who achieved clinical response defined above by the randomized withdrawal baseline) will receive placebo subcutaneously once every 2 weeks.
88835430|NCT03391115||Inpatient Participants|"Patients admitted to University of Colorado Hospital with at least one of the following diagnoses:~Heart Failure~COPD~Cancer"
88835431|NCT03391115||Nurse Participants|"Bedside nurses who provide care at the inpatient level for the following diseases:~Heart Failure~COPD~Cancer"
88835432|NCT04343690|Experimental|Health Care Workers|Faculty, staff, and trainees dealing with COVID-19 pandemic
88835433|NCT00356707||1|This cohort comprises women from the Black Women's Health Study, a prospective study of African American women, who lived in the Los Angeles, New York, or Chicago metropolitan areas at the time of completion of the 1995, 1997, or 1999 questionnaires.
88835434|NCT05099588||Infants treated for ROP|
88835435|NCT03397121|Experimental|Inclisiran|Inclisiran sodium 300 milligrams (mg) will be administered as a SC injection on Day 1, Day 90 then every 6 months.
88835436|NCT03397121|Placebo Comparator|Placebo|Placebo will be administered as SC injections of saline solution on Day 1, Day 90 then every 6 months.
88835437|NCT05267821|Active Comparator|Anakinra 4 mg/kg/day|IV Anakinra 4mg/kg/day x 7 days
89364375|NCT02464150|Experimental|Participants|Participants are subjected to gluten intervention in an unblinded fashion.
89364376|NCT02464384|Other|cohort study|Collection of blood samples and ultrasound / MRI and x-ray examination.
88835438|NCT05267821|Active Comparator|Anakinra 8 mg/kg/day|IV Anakinra 8 mg/kg/day x 7 days
88835439|NCT05267821|Active Comparator|Anakinra 12 mg/kg/day|IV Anakinra 12 mg/kg/day x 7 days
88835440|NCT05267821|Active Comparator|Anakinra 16 mg/kg/day|IV Anakinra 16 mg/kg/day x 7 days
88835441|NCT05267821|Placebo Comparator|Placebo|IV placebo x 7 days
88835442|NCT02264574|Experimental|IBR + OB|Ibrutinib (IBR) given orally at a dose of 420 mg/day until progressive disease or unacceptable toxicity. Intravenous obinutuzumab (OB) given on Days 1 and 2 (100 mg on Day 1 and 900 mg on Day 2), 1000 mg on Days 8 and 15 of Cycle 1 and 1000 mg on Day 1 of each cycle up to 6 cycles or until progressive disease or unacceptable toxicity.
88835443|NCT02264574|Experimental|CLB + OB|"Chlorambucil (CLB) given orally at a dose of 0.5 mg/kg body weight up to a total of 6 cycles on Days 1 and 15 of each cycle or until disease progression or unacceptable toxicity.~Intravenous obinutuzumab given on Days 1 and 2 (100 mg on Day 1 and 900 mg on Day 2), 1000 mg on Days 8 and 15 of Cycle 1 and 1000 mg on Day 1 of each cycle up to 6 cycles or until disease progression or unacceptable toxicity."
88835444|NCT03398213|Experimental|Acupuncture|Acupuncture for treatment of COPD exacerbation + standard conventional care for COPD exacerbation
88835445|NCT03398213|Sham Comparator|Sham procedure|Ear stimulation with plaster + standard conventional care for COPD exacerbation
88835446|NCT03398213|No Intervention|Standard care|Standard conventional care for COPD exacerbation
88835447|NCT03668821||Carotid Artery Disease|Patients with Carotid Artery Disease. Quality of life and frailty questionnaires
89364377|NCT01351194|Experimental|RFA group|For PRFA, we used a commercially available system with a 375-KHz computer-assisted radiofrequency generator (Elektrotom HiTT 106, Berchtold, Medizinelektronik, Germany) and an open-perfused electrode (Berchtold, Tuttlingen, Germany) of 15 cm (or 20 cm), 14 Ga, and a 15 mm (or 20 mm) active electrode tip with microbores.
89364378|NCT01351194|Experimental|HR group|SR was carried out under general anesthesia using a right subcostal incision with a midline extension. Intra-operative ultrasonography was performed routinely to evaluate the tumor burden, liver remnant, and the possibility of a negative resection margin. Anatomic resection, in the form of segmentectomy and/or subsegmentectomy as described by Makuuchi et al. (16) was the preferred surgical method of liver resection. Pringle's maneuver was routinely used with a clamp and unclamp time of 10 min and 5 min, respectively; this technique was used repeatedly throughout the entire procedure.
88835448|NCT03668821||Aneurysmal Disease|Patients with Aneurysmal Disease. Quality of life and frailty questionnaires
88835449|NCT03668821||Peripheral Artery Disease|Patients with Peripheral Artery Disease. Quality of life and frailty questionnaires
88835450|NCT03624049|Other|Community Exercise Program|Participation in Health Class including: Arthritis Exercise Foundation Exercise Class, Tai Chi for Arthritis, EnhanceFitness Class, or Healthier Living Class.
88835451|NCT03400163|Experimental|Treatment Group D:|Administered as specified on specified days
88835452|NCT03400163|Placebo Comparator|Treatment Group E:|Administered as specified on specified days
88835453|NCT04412863|Experimental|Cohort 1d|VIR-2218 given by subcutaneous injection
88835454|NCT04412863|Experimental|Cohort 2d|VIR-2218 and pegylated interferon-alfa 2a given by subcutaneous injection
89364379|NCT04270864|Experimental|Regimen A1|Combination between nivolumab IV Q3W and dual intratumoral injections of Ipilimumab and Tilsotolimod Q3W
89364380|NCT04270864|Experimental|Regimen A2|Combination between nivolumab IV Q3W and dual intratumoral injections of Ipilimumab and Tilsotolimod QW
89364381|NCT01318668|Experimental|Nicotine vaccination|18 week treatment with Nicvax
88835455|NCT04412863|Experimental|Cohort 3d|VIR-2218 and pegylated interferon-alfa 2a given by subcutaneous injection
88835456|NCT04412863|Experimental|Cohort 1e|VIR-2218 given by subcutaneous injection
88835457|NCT04412863|Experimental|Cohort 2e|VIR-2218 and pegylated interferon-alfa 2a given by subcutaneous injection
88835458|NCT04412863|Experimental|Cohort 3e|VIR-2218 and pegylated interferon-alfa 2a given by subcutaneous injection
88835459|NCT04412863|Experimental|Cohort 1f|VIR-2218 and pegylated interferon-alfa 2a given by subcutaneous injection
88835460|NCT04412863|Experimental|Cohort 2f|VIR-2218 and pegylated interferon-alfa 2a given by subcutaneous injection
88835461|NCT04412863|Experimental|Cohort 3f|VIR-2218 and pegylated interferon-alfa 2a given by subcutaneous injection
88835462|NCT05498298|Experimental|Gtec|
88835463|NCT03400475|Experimental|Simvastatin group (Treatment)|Will receive 0.1 ml prepared Simvastatin in 1.2% (W/V) Lecithin/isopropyl palmitate solution (Lipoil®), Poloxamer 407 gel (Polox Gel 20%®) applied topically into the peri-implant gingival sulcus using a plastic syringe with a blunt cannula.
88835464|NCT03400475|Placebo Comparator|Control group|Will receive a placebo of 0.1 ml 40% (W/V) Lecithin/isopropyl palmitate solution (Lipoil®), Poloxamer 407 gel (Polox Gel 20%®) applied topically into the peri-implant gingival sulcus using a plastic syringe with a blunt cannula.
88835465|NCT04412317||Children < 15 years old|Patients under 15 years old who consults a physician on an outpatient basis or in the emergency room and who requires a Sars-CoV-2 RT- PCR (nucleic acid using real-time reverse-transcriptase polymerase-chain-reaction) diagnostic
88835466|NCT01641900|Experimental|Schizophrenia|"Outpatients with a Structural Clinical Interview confirmed DSM-IV diagnosis of schizophrenia.~All participants receive two interventions: 3 mg eszopiclone and Placebo Intervention conditions are separated by 1 week."
88835467|NCT01641900|Experimental|Healthy Controls|Adult participants screened to exclude a personal history of mental illness, family history of schizophrenia spectrum disorder, and psychoactive medication use. All participants receive two interventions: 3 mg eszopiclone and Placebo Intervention conditions are separated by 1 week.
88835468|NCT03834571|Experimental|Arm I (standard care, carboplatin, paclitaxel)|"STANDARD CARE: Patients receive cisplatin IV over 30-60 minutes on days 1, 8, 15, 22, 29, and 36. Patients also undergo radiation therapy over 2-5 fractions 5 days a week for up to 8 weeks in the absence if disease progression or unacceptable toxicity. 4-8 weeks following standard of care.~4-8 weeks following standard care, patients receive carboplatin IV over 1 hour and paclitaxel IV over 3 hours on day 1. Courses repeat every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity."
89001559|NCT00408551|Experimental|FOLFIRI|Patients receive irinotecan hydrochloride IV over 1 hour and leucovorin calcium IV over 2 hours on day 1. Patients also receive fluorouracil IV continuously over 46 hours beginning on day 1.
89001560|NCT00408551|Experimental|FUDR|Patients receive floxuridine IV continuously on days 1-14.
89364382|NCT01318746||Healthy group|15 persons with normal renal function
89364383|NCT01318746||Renal failure|15 persons with renal failure (GFR < 60 ml/min)
89364384|NCT01357434||Adolescents|Participants 12-21 years old.
89364385|NCT01351272|Experimental|methylphenidate, non-retard|
89364386|NCT01351428|Experimental|NICOM group|Vasodilator therapy begins when SVR increases by 20% or greater than baseline. Therapy is titrated according to hemodynamic profile and clinical signs and symptoms.
89364387|NCT02193048||Patients newly diagnosed with Crohn's disease|This study will evaluate a new clinical scoring system in patients receiving routine treatment
89364388|NCT05006326|Experimental|68Ga-PSMA PET/MR|The investigators selected patients with a high clinical suspicion of HCC, or patients with confirmed HCC without tumour-related treatment who were to be biopsied or surgically resected to obtain pathological results. Patients signed an informed consent form and underwent 68Ga-PSMA PET/MR imaging (or PET/CT imaging if the patient had a contraindication to MR imaging).
89364389|NCT02162472||Adalimumab|Subjects will receive adalimumab as standard of care for psoriasis
89364390|NCT02162472||Methotrexate|Subjects will receive methotrexate as standard of care for psoriasis
89364391|NCT05003830||AD group|Patients who meet the core clinical diagnostic criteria for Alzheimer's disease as defined by NIA-AA for mild cognitive decline or probable Alzheimer's disease.
89364392|NCT05003830||Healthy control group|Age-matched subjects, who are healthy and have no clinically significant related abnormalities in their physical examinations, laboratory tests, vital signs, or ECG. In addition, no first-degree family history of early-onset AD or other neurodegenerative diseases related to dementia.
89364393|NCT00701662|Experimental|Vivaglobin|Vivaglobin® is a 16% (160 mg/mL) liquid formulation of human normal immunoglobulin for subcutaneous infusion. Subjects will receive weekly infusions of Vivaglobin® at a weekly dosage calculated based on previous intravenous immunoglobulin treatment (between 0.1 to 0.5 g/kg body weight per week).
89364394|NCT01356420|Experimental|Cholesterol supplementation|All new subjects will come to their first visit with an least 3 weeks of stable cholesterol intake. Typically and preferably this will include egg yolk as cholesterol supplement, but in some instances e.g. intolerance to egg yolk it may include a new encapsulated cholesterol preparation, Sloesterol.
89364395|NCT04489576|Active Comparator|Group (1): Treatment with keratin cure hair|Group (1): Patients will be treated with Keratin cure ® hair treatment. It will be applied once with use of a flat iron.
89364396|NCT04489576|Active Comparator|Group (2): Treatment with Qod max keratin hair|Group (2): Patients will be treated with QOD Max ® keratin hair treatment. It will be applied once with use of a flat iron.
89364397|NCT04489576|Placebo Comparator|Group (3): Treatment without keratin hair treatment|Group (3): Patients will be treated without keratin hair treatment, but the same steps of keratin application will be followed.
89364398|NCT02464306|Experimental|SOT Recipients|SOT recipients (heart, lung, kidney, liver, kidney-pancreas, and pancreas) with a first-episode of CDI. Patients will be treated with fidaxomicin 200 mg PO twice daily for 10 days. The rate of sustained clinical response (SCR; cure without recurrence at 30 days) will be assessed.
89364399|NCT02464306|No Intervention|Historical Cohort|Historical cohort of SOT recipients who received standard of care therapy for CDI at our institution.
89364400|NCT01575990|Experimental|Making A Decision About CRC Screening|A decision support intervention that is a literacy sensitive paper based tool with educational information targeted to the patient's age and gender.
89364401|NCT01575990|Placebo Comparator|Drivers 65 Plus|The placebo comparator is an attention control with information about driving tips for drivers age 65 and older.
89364402|NCT04489810|Placebo Comparator|Meal A + Placebo|350 mg Placebo capsule, taken by mouth, once, with Meal A
89364403|NCT04489810|Experimental|Meal A + Glutalytic®|350 mg Glutalytic® capsule, taken by mouth, once, with Meal A
89364404|NCT04489810|Experimental|Meal A + DE111®|350 mg DE111® capsule, taken by mouth, once, with Meal A
89364405|NCT04489810|Experimental|Meal B + Placebo|350 mg Placebo capsule, taken by mouth, once, with Meal B
89364406|NCT01351662|Experimental|Self management program|"The Arthritis Self-Management Program (ASMP) will be administered to 15 African American lupus patients participating in an ongoing SLE Clinic Database Project at the Medical University of South Carolina (MUSC). Fifteen other patients will serve as controls and receive usual care."
88835469|NCT03834571|Active Comparator|Arm II (standard care, active monitoring)|"STANDARD CARE: Patients receive cisplatin IV over 30-60 minutes on days 1, 8, 15, 22, 29, and 36. Patients also undergo radiation therapy over 2-5 fractions 5 days a week for up to 8 weeks in the absence if disease progression or unacceptable toxicity. 4-8 weeks following standard of care.~4-8 weeks following standard care, patients undergo active monitoring at 3, 6, 9, 12, 18 and 24 months."
88835470|NCT05647668|Active Comparator|laparoscopic Nissen fundoplication|Creation of a 360° fundoplication wrap over a 30-Fr intra-esophageal bougie.
89364407|NCT01351818||Growth hormone|Patients with a condition
89364408|NCT02463916|Active Comparator|Immediate exercise|This group will immediately commence an 8 week exercise programme.
89364409|NCT02463916|Active Comparator|Delayed exercise|This group will continue regular activities for 8 weeks and then commence 8 week exercise programme.
89364410|NCT02463994|Experimental|MPDL3280A + HIGRT|
89364411|NCT01356654|Sham Comparator|SHAM TDCS|
89364412|NCT01356654|Active Comparator|True TDCS|
89364413|NCT02079948|Active Comparator|Methotrexate + Folic Acid|Participants in the methotrexate condition will consume a dose of 15 mg/week of methotrexate during months 2 - 6. Participants will also consume 1 mg of folic acid/day for six days per week.
89364414|NCT02079948|Placebo Comparator|Placebo + Folic Acid|Participants in the placebo condition will consume microcrystalline cellulose once per week. The number of capsules consumed on this day will match the number of capsules consumed by participants in the methotrexate condition. There are no active ingredients in the placebo capsules.
88835471|NCT05647668|Active Comparator|laparoscopic Toupet fundoplication|Creation of a 270° fundoplication wrap over a 30-Fr intra-esophageal bougie.
88835472|NCT00359918|Experimental|Prehospital facilitated PCI|
88835473|NCT00359918|Active Comparator|Primary PCI|
88835474|NCT03402659|Experimental|neflamapimod|40 mg hard gelatin capsules, taken twice daily with food.
88835475|NCT03402659|Placebo Comparator|placebo|hard gelatin capsules containing excipients only, weight- and size-matched; taken twice daily with food.
88835476|NCT05270096||Relapsed leukemia|"T-ALL:~First relapse with high MRD after re-induction Newly diagnosed with high MRD after consolidation~B-ALL:~1st relapse high risk group, Second or higher relapse, post CAR-T or post HSCT~AML:~Second or higher relapse"
88835477|NCT00376571|Experimental|Stenting of main vessel and side branch|Percutaneous coronary intervention
88835478|NCT00376571|Experimental|No side branch treatment|Percutaneous coronary intervention
89364415|NCT02079948|Experimental|Functional MRI Experimental Tasks|15 participants will be randomly assigned to complete the fMRI visits at the baseline and 6 month.
89364416|NCT02079948|Experimental|Muscle Biopsy|10 participants will be randomly assigned to complete the skeletal muscle tissue sample at the baseline and 6 month visits.
89534613|NCT01236547|Active Comparator|Arm II (paclitaxel, placebo, IMRT)|Patients receive paclitaxel IV over 1 hour once weekly and placebo PO QD for 2-3 weeks. Patients then receive concurrent paclitaxel IV over 1 hour once weekly and placebo PO QD for 6-7 weeks (or until radiation treatment is completed) and IMRT 5 days per week for 6.5 weeks (total of 66 Gy in 33 fractions). Beginning 25-31 days after the completion of IMRT, patients receive paclitaxel IV over 1 hour once weekly and placebo PO QD. Treatment repeats every 3 weeks for 4 cycles (for patients with no measurable disease) or continues in the absence of disease progression or unacceptable toxicity (for patients with measurable disease).
89364417|NCT02463838|Experimental|Care Support Intervention|Eligible members are assigned a CareSupport Coordinator who carries a caseload of 25-35 members. A team of 5 Coordinators is supervised by a master's level Social Worker. Community Coordinators work with members to conduct standardized assessments to develop a Care Plan shared with other providers within and outside of SFHP. Coordinators provide members advocacy and navigation across systems of care, to improve coordination focus on treatment goals. Coordinator focus on prevention and early intervention around disease management, advocacy, appointment reminders and accompaniment, home visits, and regular communication with primary care and other providers. Coordinators are encouraged to be accountable for coordinating and following through on all aspects of a member's needs.
89364418|NCT02463838|No Intervention|Usual Care|All eligible SFHP members randomized to usual care will receive medical and health plan by virtue of enrollment in the SFHP and Medi-Cal. Services include assignment to a primary care physician and access to all services available through Medi-Cal in the county of San Francisco.
89364419|NCT01357824||Patients admitted for elective surgery|The patient admitted for elective surgery can be included, and will both the case and control, as we intubate the same patient twice, with and without Sellick´s maneuver.
89364420|NCT03620214||healthy children|Healthy children consulting at the odontology department of Reims CHU for carious screening or orthodontic diagnosis; excluding research
89364421|NCT04178824|Experimental|Experimental 15% discount intervention|15% discount on fruits, vegetables and non-caloric beverages at the designated supermarkets
89364422|NCT04178824|Experimental|Experimental 30% discount intervention|30% discount on fruits, vegetables and non-caloric beverages at the designated supermarkets
89364423|NCT04178824|No Intervention|No intervention control group|0% discount on fruits, vegetables and non-caloric beverages at the designated supermarkets
89364424|NCT01357902|Experimental|Lamictal|Chinese healthy male subjects were randomized to receive single dose of either 5 mg lamotrigine dispersible/chewable tablets or 25mg compressed/standard tablets.
89364425|NCT03247764||patients with the comorbidity of epilepsy and depression|the clinical data, psychological assessment, and drug treatments will be investigated in patients with the comorbidity of epilepsy and depression
89364426|NCT05313776||Post-stroke|"People with a first ever ischemic stroke of the middle cerebral artery presenting severe motor deficits of the upper-limb at onset.~The patients"
89364427|NCT05313776||Controls|Age and sexe matched healthy subjects without known neurological and or psychological deficits.
89364428|NCT01318824|Placebo Comparator|I=NIPPV|This group receiving Nasal Intermittent Positive Pressure Ventilation (NIPPV) treatment.
89364429|NCT01318824|Experimental|II=BiPAP|This group receive Bi-Level Positive Airway Pressure (BIPAP) treatment
89364430|NCT02465476|No Intervention|normal care|patient who will have normal treatment pathway
89364431|NCT02465476|Experimental|telemedicine|patient who will have telemedicine
89364432|NCT02878590|Experimental|BONGO DEVICE|All participants that qualify will receive the intervention of the Bongo device
89364433|NCT05634382|Experimental|Intravenous thrombolysis bridging with endovascular thrombectomy|
89364434|NCT05634382|Active Comparator|Direct endovascular thrombectomy without intravenous thrombolysis|
89364435|NCT01317732|Experimental|MOTIONPOD (TM)|
89364436|NCT01317810||Subjects with Overactive Bladder (OAB)|Combination of new OAB subjects and existing subjects on OAB medication
89364437|NCT05625958|Experimental|Cilioscleral Interposition Device|Any patients corresponding to inclusion / exclusion criteria
89364438|NCT04634409|Placebo Comparator|Placebo (Pbo)|"Treatment 1: Pbo administered intravenously (IV).~Treatment 8: Pbo For 700 mg Bamlanivimab (BAM) + 500 mg VIR-7831 (Amendment (C-e)) administered IV.~Treatment 11: Pbo For 175 mg Bebtelovimab (BEB) & 700 mg BAM +1400 mg Etesevimab ( ETE) +175 mg BEB (Low Risk Participants) administered IV.~Pooled Placebo (Addendum 4, IV) administered IV.~Pooled Placebo (Addendum 4, SC) administered SC."
89364439|NCT04634409|Experimental|BAM + ETE|"Treatment 2: 175 mg BAM +350 mg ETE administered IV.~Treatment 3: 700 mg BAM +1400 mg ETE administered IV.~Treatment 4: 2800 mg BAM +2800 mg ETE administered IV.~Treatment 6: 350 mg BAM +700 mg ETE administered IV.~Unintentional Dosing: 700 mg BAM +700 mg ETE administered IV.~700 mg BAM + 1400 mg ETE 30-min (Addendum (2)) administered IV.~700 mg BAM + 1400 mg ETE 15-min (Addendum (2)) administered IV."
89364440|NCT04634409|Experimental|BAM|"Treatment 5: 700 mg BAM administered IV.~700 mg BAM 15-min (Addendum (2)) administered IV."
89364441|NCT04634409|Experimental|BAM + VIR-7831|Treatment 7: 700 mg BAM + 500 mg VIR-7831 (Amendment (C-e)) administered IV.
89364442|NCT04634409|Experimental|BEB|"Treatment 9: 175 mg BEB (Amendment (f), Low Risk Participants) administered IV.~Treatment 12: 175 mg BEB (Amendment (f), High Risk Participants) administered IV.~70 mg BEB 140 mg/Min (Addendum 4, IV) administered IV.~175 mg BEB 140 mg/Min (Addendum 4, IV) administered IV.~175 mg BEB 350 mg/Min (Addendum 4, IV) administered IV.~1750 mg BEB 350 mg/Min (Addendum 4, IV) administered IV.~280 mg BEB (Addendum 4, SC) administered SC.~560 mg BEB (Addendum 4, SC) administered SC."
89364443|NCT04634409|Experimental|BAM+ ETE + BEB|"Treatment 10: 700 mg BAM +1400 mg ETE +175 mg BEB (Amendment (f), Low Risk Participants) administered IV.~Treatment 13: 700 mg BAM +1400 mg ETE +175 mg BEB (Amendment (f), High Risk Participants) administered IV.~Treatment 14: 700 mg BAM + 1400 mg ETE + 175 mg BEB(Amendment (g), High Risk, Updated Centers for Disease Control and Prevention (CDC) Criteria) administered IV.~175/700/1400 mg BAM + ETE + BEB 350 mg/Min (Addendum 4, IV) administered IV."
89364444|NCT01352052|No Intervention|waiting list assignment|6 months waiting list assignment followed by the 2-week interdisciplinary rehabilitation programme
89364445|NCT01352052|Active Comparator|Intervention: interdisciplinary rehabilitation programme|A two-weeks non-residential, group-based, psycho-educative treatment course conducted by an interdisciplinary team.
89364446|NCT01352130|Active Comparator|Ondansetron|Patients given Ondansetron
89364447|NCT01352130|Active Comparator|Granisetron|Patients given Granisetron
89364448|NCT02463604|Experimental|Remote Ischemic Preconditioning|"A blood pressure cuff is placed on upper arm and inflated to 200 mmHg for 5 minutes and then deflated for 5 minutes. This cycle is repeated 3 times in total.~The procedure has to be completed between 5 and 60 minutes prior coronary angiography."
89364449|NCT02463604|Sham Comparator|Control|"A blood pressure cuff is placed on upper arm and inflated to 10 mmHg for 5 minutes and then deflated for 5 minutes. This cycle is repeated 3 times in total.~The procedure has to be completed between 5 and 60 minutes prior coronary angiography."
89364450|NCT03235518||Structure Interviews with FSW|Structured interviews with 200 purposively sampled FSW will be conducted. These interviews will be conducted prior to focus group discussion (FGD) and in-depth qualitative interview (IDI) with FSW. Structured interviews will take approximately 45-60 minutes to complete and will be administered privately in Kiswahili, Dholuo or English by trained female research staff. Quantitative interviews will be administered to conduct an assessment of FSW sociodemographics, sexual behaviour patterns and HIV-related knowledge, attitudes and practices regarding HIV prevention and other factors that might affect initiation and adherence to PrEP use, ability to use PrEP covertly, HIV testing history, mobility patterns, social networks, pregnancy intentions, ability to use condoms consistently with clients, and regular partners, and interpersonal violence from clients, regular partners and the police.
89364451|NCT03235518||Focus Group Discussions with FSW|Three to five FGDs of up to 10 FSW per group will be conducted. These FGD will take place prior to FSW IDI. FSW who participated in FGDs will be ineligible for participation in the IDI. All group discussions will last approximately 1.5 to 2 hours and be conducted in Kiswahili, Dholuo or English. Each group discussion will be facilitated by trained female research staff and held in a private space at a pre-specified location. The themes that will be explored in the FGDs include: FSW social networks, participation in PrEP studies, barriers and facilitators to PrEP use and use of resource transfers for PrEP adherence. In addition, participants will complete a brief demographic survey.
89364452|NCT03235518||In-Depth Qualitative Interviews with FSW|30 IDI will be conducted with FSW. FSW who participated in FGDs will be ineligible for participation in the IDI. All in-depth interviews will be conducted by trained female research staff using a semi-structured interview guide. All interviews will be held in a private space at a pre-specified location within the community. The topics that will be discussed in the IDI with FSW include demographics, social support, dynamics of sex work, HIV prevention methods (including condom use), perception of HIV risk and development of PrEP intervention.
89364453|NCT03235518||In-Depth Qualitative Interviews with MC|30 IDI will be conducted with MC. All IDI will last approximately 60-90 minutes and be conducted in Kiswahili, Dholuo, or English. Each interview will be conducted by a trained male research staff using semi-structured interview guide. All interviews will be held in a private space at a pre-specified location. Topics include demographics, relationships with FSW, HIV prevention methods (including use of condoms), perception of HIV risk and development of PrEP intervention.
89364454|NCT03235518||In-Depth Qualitative Interviews with HCPs|30 IDI will be conducted with health care provider (HCP). All IDI will last approximately 60-90 minutes and be conducted in English. Each interview will be conducted by trained research staff using a semi-structured interview guide. Interviews will be held in a private space at the health facility where they work or another venue preferred by the HCP. Topics include demographics, health care needs of FSW and sources of care, HIV prevention needs of FSW, PrEP for FSW and training needs for HCP.
89364455|NCT05605834|Experimental|Hydrogen peroxide 9.5% bleaching using a tray with reservoir.|9.5% hydrogen peroxide bleaching (POLA DAY advanced tooth whitening system, SDI) using a tray with reservoir.
89364456|NCT05605834|Active Comparator|Hydrogen peroxide 9.5% bleaching using a tray without reservoir.|9.5% hydrogen peroxide bleaching (POLA DAY advanced tooth whitening system, SDI) using a tray without reservoir.
89364457|NCT00005780|Experimental|Etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab|Etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (EPOCH-R) followed by idiotype vaccine and granulocyte-macrophage colony-stimulating factor (GM-CSF).
89364458|NCT01356732|Experimental|Sufentanil|
89364459|NCT02463682|Active Comparator|Sensor-Augmented Pump Open-Loop Care (Week 1)|The subjects Sensor-Augmented Pump Open-Loop Care for the first week of the study before any adjustments to pump settings.
89364460|NCT02463682|Experimental|Closed-Loop Control System with Zone MPC and HMS|The artificial pancreas system will be allowed to employ its Model Predictive Control algorithm to make decisions about insulin delivery based on measured glucose levels. The Health Monitoring System algorithm uses the same CGM data as the MPC control algorithm but utilizes a separate algorithm for trending and predictions of future glucose values. Using a redundant and independent algorithm is an important safety feature of the overall AP device.
89364461|NCT01356810|Placebo Comparator|Standard Care|Delirium management defined by the attending physician.
89364462|NCT01356810|Experimental|Environmental Intervention|
89534614|NCT03329495|Active Comparator|SMA-orientated right hemicoloectomy|SMA-orientated right hemicoloectomy
89001561|NCT00586183|Experimental|1|The subject will then be positioned in the PET scanner . After optimal positioning of the left ventricle within the field of view, a transmission scan will be performed with either a germanium-68 or CT source for subsequent attenuation correction.
89001562|NCT04575415||Arm 1:Bevacizumab plus Erlotinib/Gefitinib/Icotinib|Patients with EGFR-mutant NSCLC would receive bevacizumab plus first-generation EGFR-TKIs in clinical routine care. Bevacizumab 15 mg/kg or clinical routine dose would be intravenous infusion on day 1 once every 3 weeks. Erlotinib 150 mg tablets once daily or Gefitinib 250mg once daily or Icotinib 125mg three times a day would be administered.
89364463|NCT05602246|Experimental|Transobturator cystocele repair (TOCR)|"The technique of TOCR was published previously including a video [Kalis et al. Trans-obturator cystocele repair (TOCR) of level 2 paravaginal defect. Int Urogynecol J. 2020, 31(11):2435-38. doi:10.1007/s00192-020-04337-x].~The anterior vaginal wall is incised in the midline and the pubocervical fascia is dissected to open the paravaginal space towards the ATFP and the fascia of the obturator internus muscle. 3-4 continuous non-locking stitches of non-absorbable suture 1-0 Ti-Cron™ braided polyester are taken into the pubocervical fascia and threaded using Shirodkar needles through skin incisions in genitofemoral sulci passing through the full thickness of the obturator membrane, obturator internus muscle. After closure of the vaginal skin incision, both ends of the Ti-Cron™ sutures are tied ensuring the obliteration of the paravaginal defect.~Indometacin rectal suppository 100 mg is inserted transrectally for early postoperative pain management."
89364464|NCT05602246|Active Comparator|standard anterior colporrhaphy (anterior repair - AR)|The anterior vaginal wall is incised in the midline from the level of the bladder neck up to vaginal apex or anterior vaginal fornix. The bladder is sharply dissected from the vaginal wall with pubocervical fascia attached to the bladder wall. The fascia is approximated in the midline with several simple interrupted 0 polyglactin 910 sutures or equivalent. The surplus of distended vaginal epithelium is trimmed. The vaginal incision is closed using a continuous non-locking polyglactin 910 2-0 suture or equivalent. Indometacin rectal suppository 100 mg is inserted transrectally for early postoperative pain management.
89364465|NCT01978938|Experimental|Eravacycline|Eravacycline was administered IV at a dose of 1.5 mg per kilogram (kg) of body weight every 24 hours (q24h). At minimum, the first 3 doses were administered IV. After an IV-to-PO transition, provided adequate clinical improvement, participants were administered 200 mg PO twice a day for a total therapy of 7 dosing cycles.
89364466|NCT01978938|Active Comparator|Levofloxacin|Levofloxacin (750 mg) was administered IV q24h. At minimum, the first 3 doses were administered IV. After an IV-to-PO transition, provided adequate clinical improvement, participants were administered 750 mg PO once a day for a total therapy of 7 dosing cycles.
89364467|NCT02465554||No atherosclerosis cohort|"This group will have patients who have undergone clinically-indicated CT coronary angiography (CT-A) and who have no plaque and an Agatston score of 0. They will then undergo a myocardial contrast echocardiography study during vasodilator stress to subdivide risk further into No atherosclerosis/endothelial function normal and No atherosclerosis/endothelial function abnormal. Blood will then be collected for metabolomics, lipidomic and whole genome sequencing."
89534615|NCT03329495|Experimental|SMV-orientated right hemicoloectomy|SMV-orientated right hemicoloectomy
89534616|NCT03329339|No Intervention|2 L PEG with ascorbic acid group|
89178503|NCT04104711|Experimental|Home visits+Health education group|"Home visits were paid 3 times at 3-month intervals. After the home visits started, reminder messages supporting the home visit process were sent at two-week intervals.~Nursing interventions were applied in accordance with the subscales of the Health Belief Model by taking into account the individual differences of the participants and were performed within the scope of the basic dimensions of diabetes management such as nutrition, exercise, medication management, oral care and foot care. In addition, the importance of annual monitoring of HBA1c, blood lipid, albumin/ creatinine levels, fundus examination, blood pressure monitoring, sleep hygiene, avoidance of smoking and alcohol was also explained."
89178504|NCT04104711|No Intervention|No nursing intervention group|"The participants in the control group who have standart care by other health services were contacted 3 times at 3-month intervals through telephone calls, and were applied the data collection tools only. They have no nursing intervention by the researcher.~At the end of the study, for ethical statement the participants in the control group were given health training and the training booklet was distributed to them."
89178505|NCT02602665|Experimental|Shallow catheter tip placement|Patients randomized to shallow tip placement will have the tip of the catheter placed approximately one vertebral body above to even with the carina.
89178506|NCT02602665|Experimental|Deep catheter tip placement|Patients randomized to deep tip placement will have the tip of the catheter placed 1.5 to 2.5 vertebral bodies below the carina.
88835479|NCT00376727|Experimental|Phase I dose escalation study|
88835480|NCT03282071|Experimental|Joyful Parenting Intervention|Subjects will participate in two-session interactive talks on joyful parenting (a core session intervention and booster intervention) and one family gathering activity; questionnaire evaluation will be conducted at baseline, post-session,1 month and 3 month after core session.
89178507|NCT02602431|Active Comparator|Extra-oral laser irradiation|infra-red wave laser, 660nm, 100mW, and 107J/cm2
89178508|NCT02602431|Placebo Comparator|Extra-oral placebo|Laser point will be placed in region without irradiation on.
88835481|NCT03282071|No Intervention|Control|No intervention will be provided to control groups during study period.
88835482|NCT05239585|Experimental|Remote EEG monitoring|All subjects will pilot the use of wireless EEG technology in neonates with mild neonatal encephalopathy and neonates with spells to see if this device can be used to determine the risk for neonatal seizure and need for escalation of care and full scalp EEG
88835483|NCT04335331||PreDM CDS|The PreDM CDS is a passive electronic health record button that appears automatically under the Assessment/ Plan only for patients with prediabetes. When clinicians choose to click on this button, the PreDM CDS displays the last three measurements of weight, body mass index (BMI), hemoglobin A1c (HbA1c), fasting glucose, random glucose, and creatinine. This tool included order options enabling prediabetes management in a single location within the electronic health record.
89178509|NCT02602431|Active Comparator|Intra-oral laser irradiation|red wave laser, 660nm, 100mW, and 107J/cm2
89178510|NCT02602431|Placebo Comparator|intra-oral placebo|Laser point will be placed in region without irradiation on.
89178511|NCT00592553|Experimental|High-Dose Ataluren|Participants will receive ataluren suspension orally 3 times a day (TID), 20 milligrams/kilogram (mg/kg) at morning, 20 mg/kg at midday, and 40 mg/kg at evening (total daily dose 80 mg/kg) for 48 weeks.
89364468|NCT02465554||Atherosclerosis cohort|"This group will have patients who have undergone clinically-indicated CT coronary angiography (CT-A) and who have non-critical plaque (<50% diameter) and at least 1 high risk feature according to the ROMICAT indices. They will then undergo a myocardial contrast echocardiography study during vasodilator stress to subdivide risk further into atherosclerosis/endothelial function normal and atherosclerosis/endothelial function abnormal. Blood will then be collected for metabolomics, lipidomic and whole genome sequencing."
89364469|NCT05589298||PSODEEP1 Sweden|Patients with self reported MD given diagnosis of psoriasis and/or psoriatic arthritis in Sweden.
89364470|NCT05589298||PSODEEP1 Denmark|Patients with self reported MD given diagnosis of psoriasis and/or psoriatic arthritis in Denmark.
89364471|NCT05589298||PSODEEP1 Chile|Patients with self reported MD given diagnosis of psoriasis and/or psoriatic arthritis in Chile.
89364472|NCT02465320|Active Comparator|COL-1077|lidocaine bioadhesive gel, 10%
89364473|NCT02465320|Placebo Comparator|Placebo|placebo bioadhesive gel
89364474|NCT02465008|Experimental|levobupivaciane group|Levobupivacaine group (L- bupivacaine 0,25% -2,5 mg/ml-) 60 ml. Total dosis in topical use 150 mg (administered irrigation 30 ml into the surgical pocket bilaterally intraoperatively).
89364475|NCT02465008|Placebo Comparator|Placebo Comparator (saline solution)|Placebo group (saline solution) 60 ml (administered irrigation 30 ml into the surgical pocket bilaterally intraoperatively).
89364476|NCT01356888|Active Comparator|Abbott Laboratories - Xience Prime DES|
89364477|NCT01356888|Experimental|Biotronik - Orsiro DES|
89364478|NCT01352208|Experimental|ASP9521|
89364479|NCT01330485|Experimental|Affect Regulation Training|Affect Regulation Training as described in Berking & Whitley, 2014.
89364480|NCT01330485|Active Comparator|Common Factor Control Condition (CFC)|Common factor based therapy control condition
89364481|NCT01330485|No Intervention|Waitlist Control Condition|Wait List Control
89364482|NCT03041090|Experimental|Static Imaging participants|"This arm of the study assessed participants' static PET/CT images. These were the standard of care images acquired after their standard of care uptake time. These images were assessed visually by a board certified physician and using the Time Activity Curves from the sensor data.~Intervention was Lucerno sensors (Lucerno Device Identity Document (LD ID), Lucerno Device 1 (LD1), Lucerno, Lara) placed on participant to monitor radiotracer activity at and around injection site."
89364483|NCT03041090|Experimental|Dynamic image participants|"This arm of the study assessed participants' dynamic PET/CT images. These were the study related images of and around the injection site acquired during the participants' standard of care uptake time. These images were assessed visually by a board certified physician and using the Time Activity Curves from the sensor data.~Intervention was Lucerno sensors (LD ID, LD1, Lucerno, Lara) placed on participant to monitor radiotracer activity at and around injection site."
89364484|NCT04105114|Experimental|Complete Spinal Cord Injury - Gravity Neutral Stepping|Group 1 will begin with a 3-4-month preparation phase and up to 12 sessions in the gravity neutral device (GND) will occur. The training sessions in the GND will be used to obtain the optimal stimulation parameters. Next, participants will enter Intervention Phase 1 where they will receive training sessions 3 days/week for approximately 2 hours. This will be done in the GND in the presence of stimulation. Afterwards, Intervention 2 will include the same training procedures with the addition of Buspirone or Placebo in a cross-over fashion halfway through this phase.
88835484|NCT00359996|Active Comparator|Health disparities collaborative|The HDC incorporates rapid quality improvement (QI), a chronic care model, and best practices. This study determines if the HDC improves diabetes care and whether more intensive interventions with additional learning sessions for health centers, provider training in behavioral change, and patient empowerment materials enhance care further.
89534617|NCT03329339|Experimental|1 L PEG with ascorbic acid with PLD|
88835485|NCT00359996|Active Comparator|Control|No additional educational sessions added to usual care of patients.
88835486|NCT05236153|Other|RV mapping|Participants will undergo a sinus rhythm electroanatomic RV substrate map prior to TPVR.
88835487|NCT05468606|Experimental|GA2 group (unadjuvanted group)|Immunization with 50 GA2-infected mosquito bites
88835488|NCT05468606|Placebo Comparator|Infectivity controls (placebo group)|Mock-immunization with 50 uninfected-mosquito bites
88835489|NCT05468606|Experimental|BCG group|Immunization with 50 GA2-infected mosquito bites and a standard intradermal BCG vaccination (0.1 mL)
89534618|NCT05037591|Placebo Comparator|placebo A|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
88835490|NCT05468606|Experimental|YF-17D group|Immunization with 50 GA2-infected mosquito bites and a one fifth fractional (0.1 mL) intradermal YF-17D vaccination
88835491|NCT05468606|Experimental|Imiquimod group|Immunization with 50 GA2-infected mosquito bites and 250mg imiquimod cream 5%
88835492|NCT04293289|Other|Treatment|"BNCT(Boron Neutron Capture Therapy)~SPM-011 iv administrates at 200 mg/kg/hr for 2 hours before neutron irradiation. During neutoron irradiation with CICS-1, SPM-011 iv continues at 100mg/kg/hr."
88835493|NCT04290871|Experimental|Treatment Group|Nitric Oxide gas will be administered in the ventilatory circuit.
88835494|NCT04290871|Sham Comparator|Control Group|The delivery system will be set up anyway without study gas administration
88835495|NCT03283787|Active Comparator|Group 1|MicroMatrix® and Cytal™ Wound Matrix 2-Layer
88835496|NCT03283787|Active Comparator|Group 2|MicroMatrix® and Cytal™ Wound Matrix 2-Layer plus NPWT
88835497|NCT03283787|Active Comparator|Group 3|Negative Pressure Wound Therapy
89364485|NCT04105114|Experimental|Complete Spinal Cord Injury - Exoskeleton Assisted Stepping|Group 2 will begin with a 3-month preparation phase and up to 12 sessions in the Ekso device stepping overground. Next, participants will enter Intervention Phase 1 where they will receive training sessions 3 days/week for approximately 2 hours in the Ekso overground, in the presence of stimulation and Buspirone/placebo. The second phase will include the same training procedures except for the removal of Buspirone/placebo administration. The third phase will include sessions twice per week in the Ekso overground with stimulation and one day per week using a rolling walker with stimulation. The last phase will include 2 sessions per week using the rolling walker and one day per week in the Ekso, both in the presence of stimulation and Buspirone/placebo.
89364486|NCT04105114|Experimental|Incomplete Spinal Cord Injury - Overground Stepping|Group 3 will begin with a 3-month preparation phase and up to 12 sessions in the Ekso device stepping overground. Next, participants will enter Intervention Phase 1 where they will receive training sessions 3 days/week for approximately 2 hours. The first hour will be done in the Ekso overground and the second hour will use the rolling walker overground, both in the presence of stimulation. Afterwards, the second phase will include the same training procedures with the addition of Buspirone/placebo.
89364487|NCT03222882|Experimental|RIF group|According to the histological dating and transcriptomic profile of endometrium of hormone replacement cycle in control group, to explore the effectiveness of intervention by advanced or delayed personal embryo transfer . The establishment of standard control group: Frozen embryo transfer patients according to the inclusion and exclusion criteria were evaluated for histological dating and transcriptomic profile by endometrial biopsy on day P＋7 in an HRT cycle. After routine time transfer in the frozen embryo transfer cycle, the standard of histological dating and transcriptomic profile were determined according to the pregnancy outcome of the FET cycle .
89364488|NCT01352364|Experimental|deaf children|
89364489|NCT02071875||Nautilus NeuroWaveTM recording|Nautilus NeuroWaveTM recording 15 minute recording
89364490|NCT05309330||Participants with CeD|Participants diagnosed with CeD will be observed prospectively for CeD symptom patterns over a 3-month period.
89364491|NCT05573230|Experimental|Midazolam + LY3502970|Midazolam administered orally followed by LY3502970 given orally.
89364492|NCT05573230|Experimental|Cyclosporine + Midazolam + LY3502970|Cyclosporine administered in combination with midazolam and LY3502970 given orally.
89364493|NCT03635034|Experimental|No Bladder catheter|"Subjects will not have bladder catheter inserted during their ablation procedure.~Intervention: No catheter"
89364494|NCT03635034|Active Comparator|Bladder catheter inserted|"Bladder catheter will be inserted prior to starting ablation procedure after the subject is under general anesthesia.~Intervention: bladder catheter inserted"
89364495|NCT01357044|Active Comparator|Plant extracts|
89364496|NCT01357044|Placebo Comparator|Placebo|
89364497|NCT04856722|Experimental|mini-PNL group|In which PCNL will be performed using miniature nephroscope
89364498|NCT04856722|Experimental|RIRS group|In which RIRS will be performed using a flexible ureteroscope
89364499|NCT04856722|Experimental|SWL group|In which extracorporeal shock wave lithotripsy will be performed using Dornier lithotripter SII
89364500|NCT05559190|Experimental|Pulsed electromagnetic field and selected graduated abdominal exercises (group A)|The interventions were done preoperatively, received pulsed electromagnetic therapy (PEMFT) on abdominal muscles,15 Hz frequency, 20 gauss amplitude with a rectangular waveform, for 20 minutes then they performed the selected graduated abdominal strengthening exercises for 30 minutes, three sessions per week for six weeks.
89364501|NCT05559190|Active Comparator|Selected graduated abdominal exercises (group B)|The interventions were done preoperatively, patients performed the selected graduated abdominal strengthening exercises for 30 minutes, three sessions per week for six weeks.
89364502|NCT05559190|Active Comparator|Pulsed electromagnetic field (group C)|The interventions were done preoperatively, they received pulsed electromagnetic therapy (PEMFT) on abdominal muscles,15 Hz frequency, 20 gauss amplitude with a rectangular waveform, for 20 minutes only.
89364503|NCT05559190|No Intervention|Control group|Patients were instructed to presume in normal activities of daily living preoperatively, without any abdominal exercises or PEMFT.
88835498|NCT03284411|Experimental|Spinal Cord Stimulation|Each subject was programmed to 4 different amplitude settings: 80%, 60%, 40% and 20% of perception threshold amplitude
88835499|NCT03465787|Experimental|Lurasidone HCL 160 mg|Lurasidone HCL 160 mg/day
88835500|NCT03465787|Active Comparator|Quetiapine XR 600 mg|Quetiapine XR 600 mg/day
88835501|NCT05071352|Experimental|Nefopam group|"Adjunct continuous infusion of nefopam plus standard of care in ICU for assessment and management of pain, sedation, and delirium.~Nefopam will be administered as an initial dose of 20 mg IV dose infused over 15 minutes then, as continuous infusion of 5 mg/hr for 24 hours."
88835502|NCT05071352|Placebo Comparator|Control group|Standard of care in the ICU for assessment and management of pain, sedation, and delirium.
88835503|NCT05259878||Control|A Control group of students at CFB Borden will be recruited to complete questionnaires.
89364504|NCT05550142|Experimental|SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine 50μg|Two doses were administered by intramuscular injection, 28 days apart
88835504|NCT05259878||Patients with chronic pain|Patients are active service members, ranging from the age of 18-60 years old, referred primarily from the National Capital Region, CFB Petawawa, CFB Kingston, and CFB Trenton for consultation and management
88835505|NCT03403517|Experimental|Methylprednisolone|10 mg/kg, single preoperative infusion
88835506|NCT03403517|Active Comparator|Dexamethasone|8 mg dexamethasone, single preoperative infusion
88835507|NCT04281979|Experimental|Study Agent|
88835508|NCT04281979|Placebo Comparator|Placebo|
88835509|NCT03404219|Experimental|Intervention|Mobile intervention (i.e., Ecological momentary intervention [EMI]) addressing social motivation and social skills. Twice daily notifications sent to deliver EMI content. Social goal reminders and steps provided to support goal attainment. Social Skills Training content delivered via brief video clips.
88835510|NCT01640808|Experimental|NIK-333(peretinoin)|
88835511|NCT01640808|Placebo Comparator|Placebo|
89364505|NCT05550142|Experimental|SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine 100μg|Two doses were administered by intramuscular injection, 28 days apart
89364506|NCT00116142|Other|Arm1: Androgen Suppression Therapy + Radiation Therapy|Androgen Suppression Therapy and Radiation therapy
89364507|NCT00116142|Experimental|Arm 2: Docetaxel + Androgen Suppression Therapy + Radiation Therapy|Docetaxel plus androgen suppression therapy and radiation therapy
89364508|NCT01357122|Experimental|NCI Insertion|
89178512|NCT00592553|Experimental|Low-Dose Ataluren|Participants will receive ataluren suspension orally TID, 10 mg/kg at morning, 10 mg/kg at midday, and 20 mg/kg at evening (total daily dose 40 mg/kg) for 48 weeks.
89178513|NCT00592553|Placebo Comparator|Placebo|Participants will receive placebo matched to ataluren orally TID at morning, midday, and evening for 48 weeks.
89364509|NCT01357122|Active Comparator|Standard Forceps Insertion|
89364510|NCT02463214|No Intervention|Standard Room|Standard bone marrow transplant recovery, single occupancy, room
89364511|NCT02463214|Experimental|Engineered Room|Single occupancy bone marrow transplant recovery room, engineered with touchless devices, and surfaces coated with either copper or titanium dioxide.
89364512|NCT05547256|Experimental|Group A|Two doses were administered by intramuscular injection, 28 days apart
89364513|NCT05547256|Experimental|Group B|Two doses were administered by intramuscular injection, 28 days apart
89364514|NCT03135522|Active Comparator|Zinc Acetate 50 mg oral capsule|50 mg zinc acetate oral capsules, over-encapsulated, administered starting at 1 capsule/day and escalated to 3 capsules/day by Day 8 post-randomization (if tolerated)
89364515|NCT03135522|Placebo Comparator|Placebo oral capsule|Placebo matched to zinc acetate 50 mg oral capsule active arm, administered starting at 1 capsule/day and escalated to 3 capsules/day by Day 8 post-randomization (if tolerated)
89364516|NCT02463292||patient group|The patient group will consist of a maximum of 350 patients (male and female subjects,18 years to 30 years of age, in command of the German language)) with congenital heart disease (Tetralogy of Fallot, Transposition of the great arteries, univentricular heart disease, ventricular septal defect) treated at the cardiologic department of the University Hospital Zurich. Eligible patients will be contacted by the study nurse during the outpatient consultation at the university hospital. No intervention.
89178514|NCT00699023|Experimental|1|ezetimibe tablets 10 mg/die + simvastatin tablets 20 mg/die six weeks
89178515|NCT00699023|Placebo Comparator|2|placebo + simvastatin tablets 20 mg/die six weeks
89178516|NCT00853229|Experimental|pregabalin/placebo|pregabalin and placebo given using a cross-over design
89178517|NCT00853229|Experimental|placebo/pregabalin|placebo and pregabalin given using a cross-over design
89178518|NCT02612753|Experimental|Aphasics Patients|Patients which have difficulties to speak. Improvement of language for aphasics patients.
89364517|NCT02463292||peer control group|The control group will be recruited as good friends (same gender, approx. same age of the patients, in command of the German language). The patients will be given a study information for controls to hand this to their good friend and ask the friend to contact the study nurse for participation in the study. No intervention.
89364518|NCT01361334|Experimental|Pazopanib|Pazopanib treatment
89364519|NCT02463370|Experimental|Group II|Group II patients will receive local anesthetic infiltration in two injections on each side of the face at the maxillary and infra-orbital areas and the remaining injections are placebo (saline).
89364520|NCT02463370|Experimental|Group V|Group V patients will receive local anesthesia in five injections on each side of the face at the infra-orbital area, supratrochlear area, medial to the medial canthus, nasal still and anterior septum. The remaining maxillary injection is placebo.
89364521|NCT01757782|Active Comparator|Oral Sildenafil|In group A, newborns received oral Sildenafil solution through feeding tube which was prepared by crushing a 50 mg tablet of sildenafil in distilled water to make a concentration of 5 mg/ml. The protocol for dosing was (1) first dose of 1 mg/kg/dose within 30 minutes admission or within 12 hours of delivery (whichever earlier), (2) Dosing every six hours for a maximum of 8 doses.
89364522|NCT01757782|Placebo Comparator|Distilled water|In group B, newborns received placebo. The protocol for dosing was (1) first dose of 1 mg/kg/dose within 30 minutes admission or within 12 hours of delivery (whichever earlier), (2) Dosing every six hours for a maximum of 8 doses.
89364523|NCT01358136||Hemithyroidectomy|Patients with benign nontoxic goiter who have an indication for hemithyroidectomy
89364524|NCT02023905|Experimental|Arm 1: Everolimus|If the tumor is 1p/19q intact, then patients will be further selected by whether or not their tumor demonstrates activation of the PI3K/mTOR pathway. If activation is present, patients will be treated with single-agent everolimus at 10 mg daily continuously for up to 24 cycles, after which patients will be followed with interval MRIs until progression.
89534619|NCT05037591|Placebo Comparator|placebo B|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
89534620|NCT05037591|Placebo Comparator|placebo C|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
89364525|NCT02023905|Experimental|Arm 2: Everolimus and Temozolomide|If the tumor is 1p/19q intact, then patients will be further selected by whether or not their tumor demonstrates activation of the PI3K/mTOR pathway. If activation is not present, patients will be treated with combined everolimus and Temozolomide (TMZ). Everolimus will be given at 10 mg daily continuously for up to 24 cycles, and Temozolomide will be dosed initially at 150 mg/m^2 per day for 5 days out of a 28-day cycle for up to 12 cycles, after which patients will be followed with interval MRIs until progression.
89178519|NCT02612753|Sham Comparator|Aphasics Patients control|Patients which have difficulties to speak will receive Sham tDCS +SLT for aphasics patients control
89364526|NCT02023905|Experimental|Arm 3: Everolimus (1p/19q co-deletion present)|If the tumor is 1p/19q intact, then patients will be further selected by whether or not their tumor demonstrates activation of the PI3K/mTOR pathway. If 1p/19q co-deletion is present, patients will be treated with single-agent everolimus at 10 mg daily continuously for up to 24 cycles, after which patients will be followed with interval MRIs until progression.
89364527|NCT02465242||NPi greather than 3|All patients will undergo initial pupillometry evaluation with recording of the NPi in the initial evaluation in the emergency department as per standard evaluation of all trauma patients. If pupils are unequal, group assignment will be determined by lowest pupil reading. Patients with an NPi greater than 3 will be assigned to this group. Pupillometry readings will be gathered for the first 7 days of hospital admission or until discharge. 30, 60, and 90 day post-injury outcomes will be collected.
89364528|NCT02465242||NPi less than or equal to 3|All patients will undergo initial pupillometry evaluation with recording of the NPi in the initial evaluation in the emergency department as per standard evaluation of all trauma patients. If pupils are unequal, group assignment will be determined by lowest pupil reading. Patients with an NPi less than or equal to 3 will be assigned to this group. Pupillometry readings will be gathered for the first 7 days of hospital admission or until discharge. 30, 60, and 90 day post-injury outcomes will be collected.
89364529|NCT01318980|Experimental|Period 1 Cohort 1 - GSK2190915 100mg|Period 1 - GSK2190915 100mg tablet.
89364530|NCT01318980|Experimental|Period 1 Cohort 2 - GSK2190915 100mg plus microtracer|Period 1 - GSK2190915 100mg tablet plus [14C] radiolabelled GSK2190915 microtracer solution.
89364531|NCT01318980|Experimental|Period 2 GSK2190915 100mg to proximal small bowel|100mg of ground half 200mg GSK2190915 tablet administered to the proximal small bowel via Enterion capsule.
89364532|NCT01318980|Experimental|Period 3 GSK2190915 100 mg to distal small bowel|100mg of ground half 200mg GSK2190915 tablet administered to the distal small bowel via Enterion capsule.
89364533|NCT01318980|Experimental|Period 4 - GSK 100mg enteric-coated tablet|100mg enteric-coated GSK2190915 coated tablet.
89364534|NCT02465086|Experimental|Training|This arm, which is a half of the sample size, will be receiving training of linguistic recursion
88818238|NCT01734317|Experimental|Dressing|Mepilex Transfer Ag is a soft silicone wound contact layer that absorbs and transfers exudate, maintains a moist wound healing environment and has antimicrobial properties.
88818239|NCT01334216|Active Comparator|CHICA Smoking Cessation Module|This arm had the CHICA smoking cessation module turned on
89364535|NCT02465086|No Intervention|No training|The no intervention group, which is a half of the sample size, will not be recieving training in linguistic recursion.
89364536|NCT01333683||Control|Normal subjects
89364537|NCT01333683||AH|Arterial hypertension patients
89364538|NCT01361412|Experimental|ToleroMune Ragweed 4|
89364539|NCT01361412|Experimental|ToleroMune Ragweed Regimen 3|
88818240|NCT01334216|Placebo Comparator|CHICA Placebo|This arm had CHICA without the smoking cessation module
88818241|NCT02640807|Experimental|CYT107 high frequency|Patients will receive Interleukin-7 (CYT107 liquid solution) at 10µg/kg twice a week for 4 weeks
88818242|NCT02640807|Experimental|CYT107 low frequency|Patients will receive Interleukin-7 (CYT107 liquid solution) at 10µg/kg twice a week for the first week, followed by CYT107 and Placebo once a week for the three following weeks
88818243|NCT02640807|Placebo Comparator|Control|Patients will receive Placebo (NaCl 0.9%) twice a week for 4 weeks
89178520|NCT00853151|Experimental|LY2428757 plus TT223 3 milligrams (mg)|Weekly LY2428757 plus 3 milligrams (mg) daily TT223
89178521|NCT00853151|Experimental|LY2428757 plus TT223 2mg|Weekly LY2428757 plus 2 mg daily TT223
89178522|NCT00853151|Experimental|LY2428757 plus placebo|Weekly LY2428757 plus daily TT223 placebo
89364540|NCT01361412|Experimental|ToleroMune Ragweed Regimen 2|
88818244|NCT01335230||10 HIV mono-infected subjects|10 subjects infected with HIV only
89364541|NCT01361412|Placebo Comparator|Placebo|Placebo
89364542|NCT01361412|Experimental|ToleroMune Ragweed Regimen 1|
89364543|NCT01330563|Experimental|CKD-501|"Subjects received Ketoconazole 200 mg twice daily for 5 days in one period and in the other period, Subjects don't receive Ketoconazole.~In addition, The CKD-501 is administered on day 5"
89364544|NCT01330563|Experimental|ketoconazole|"Subjects received Ketoconazole 200 mg twice daily for 5 days in one period and in the other period, Subjects don't receive Ketoconazole.~In addition, The CKD-501 is administered on day 5"
89364545|NCT05099952|Experimental|Arm I - BBT-CI|Patients participate in BBT-CI over 60 minutes for 2 sessions and phone calls over 15 minutes once weekly for 4 weeks.
89364546|NCT05099952|Active Comparator|Arm II- therapist|Patients meet with therapist over 60 minutes for 2 sessions and phone calls over 15 minutes once weekly for 4 weeks.
89364547|NCT05099952|Experimental|Observational Study|Patients wear actigraphy watch and complete sleep log at baseline (over the weekend prior to first day of CRT), and weeks 1, 3, and 6 during treatment. Patients also undergo collection of cheek cell samples and may undergo collection of blood samples at weeks 1, 3 and 6 during treatment. Patients' medical records are also reviewed.
89364548|NCT02464930||No-GERD Controls|"NERD controls will be enrolled from subjects presenting to the endoscopy unit who are being evaluated for reasons other than GERD or BE surveillance. These are patients who are referred to the endoscopy unit for: evaluation of anemia, dysphagia, occult blood positivity, gastrointestinal blood loss etc.~No history of GERD~Response no to presence of symptoms on a standardized GERD questionnaire~No prescriptions for acid suppressive medication over the past 2 years as documented in electronic pharmacy records.~Normal endoscopy that does not find Barrett's esophagus, hiatus hernia or erosive esophagitis."
89364549|NCT02464930||GERD Controls|"Respond yes to the presence of symptoms on a standardized GERD questionnaire~Prescriptions for acid suppressive medication as documented in electronic pharmacy records."
89364550|NCT02464930||BE Cases|• Patients who present for evaluation of reflux symptoms and are found to have at least 1 cm of columnar lined esophagus on endoscopy with intestinal metaplasia on biopsies. This will include patients with esophageal adenocarcinoma
88835512|NCT03404375|Other|Term patients|This study only has one arm: term pregnant patients scheduled for cesarean sections. The surgeon will clinically estimate blood loss and the research team will estimate blood loss using the Gauss Triton system. This will be done on all 242 patients.
89364551|NCT03636009|Experimental|Concurrent traction|Concurrent traction and neuromobilization technique at each scheduled session Active exercise program (4-5 exercises) at each session Manual therapy to cervical and thoracic spine at each session
89364552|NCT03636009|Active Comparator|Sequential traction|Sequential traction and neuromobilization technique at each scheduled session Active exercise program (4-5 exercises) at each session Manual therapy to cervical and thoracic spine at each session
89364553|NCT02464852|Other|Snood|All recruited participants will try out the snood
88835513|NCT00421681|Experimental|A|"Treatment Arm A will develop tailored/negotiated contracts with the exercise instructor to maintain post intervention exercise adherence at home or in the community. Half of the participants in this negotiated maintenance arm will be randomly assigned to receive telephone calls to reinforce adherence and half will be assigned to a no telephone calls group."
89364554|NCT01330641|Active Comparator|Anterior injection Route|Group of patients injected with medication using the anterior route
89178523|NCT00853151|Placebo Comparator|Placebo plus Placebo|Weekly LY2428757 placebo plus daily TT223 placebo
89364555|NCT01330641|Active Comparator|Posterior Injection|Group of patients receiving injection through a posterior route
89364556|NCT01330641|Active Comparator|Lateral Injection|Group of patients receiving subacromial injection through a lateral route
89364557|NCT01333761|Experimental|TCD/Cardiox FDS/TEE testing|All patients enrolled will be evaluated with TCD and Cardiox FDS and TEE for the presence of RTLS.
89364558|NCT01333839|Active Comparator|standard exercise intervention|12 weeks of endurance exercise training
89364559|NCT01333839|Active Comparator|modified exercise intervention|combined endurance + strength exercise training
89364560|NCT01333839|Active Comparator|modified 2 exercise intervention|combined endurance + strength exercise training + oral protein supplements
88818245|NCT01335230||10 HCV mono-infected subjects|10 subjects infected with HCV only
88818246|NCT01335230||10 HIV/HCV co-infected subjects|10 subjects infected with both HIV and HCV
88818247|NCT01335230||10 control subjects|10 subjects without HIV, HCV, or both
88818248|NCT01797575|Active Comparator|Aspirin|research subject will be taking aspirin 1000mg (2 capsules of 500mg) every morning in addition to his/her mood stabilizing drug (lithium, anticonvulsants, any atypical antipsychotics) or combinations
88818249|NCT01797575|Active Comparator|N-acetyl-cysteine|research subject will be taking N-acetyl-cysteine (NAC) 1000mg (2 capsules of 500mg) two times a day in addition to his/her mood stabilizing drug (lithium, anticonvulsants, any atypical antipsychotics) or combinations
89364561|NCT02875080|Experimental|OPC-34712 disintegrating tablet with water|OPC-34712 (4 mg) orally disintegrating tablet is administered with water.
89364562|NCT02875080|Experimental|OPC-34712 disintegrating tablet without water|OPC-34712 (4 mg) orally disintegrating tablet is administered without water.
89364563|NCT02875080|Experimental|OPC-34712 conventional tablet with water|OPC-34712 (4 mg) conventional tablet is administered with water.
89364564|NCT01315041|Active Comparator|"Pi medicine"|
89364565|NCT01315041|Placebo Comparator|Placebo|
89364566|NCT01358214||Patients treated with a surgical mesh|This arm of study patients is defined by patients treated with a TiLOOP® Tape mesh between 2007 and 2009 at the Franziskus Krankenhaus, Berlin. The sample of the treated population represents the patient population for which the medical device is intended. To minimize selection bias without compromising patients' rights and welfare, all treated patients will be invited. These patients will be asked to participate in the validation of the questionnaire on quality of life. In addition to this safety and effectiveness of the surgical mesh implantation will be collected
89364567|NCT01358214||Intended to be treated with a mesh|This arm of the study populations is defined by patients in whom a clinical anamnesis independent of the requirements of this study suggests that a sub-urethral sling operation is indicated. These patients will be asked to participate in the validation of the questionnaire on quality of life.
89364568|NCT01358214||Non-symptomatic Population|This arm of the study population is defined by women that show no symptoms of incontinence. They will be asked to participate in the validation of the questionnaire on quality of life.
89364569|NCT04897503|Active Comparator|CXL using Riboflavin/Dextran solution|Corneal collagen crosslinking using 0.1% riboflavin mixed with 20% dextran
88835514|NCT00421681|Experimental|B|"Treatment Arm B will be mainstreamed into an ongoing facility-based exercise program for post intervention exercise adherence. Persons in this mainstream follow up arm will be randomly assigned such that half will receive regular telephone reinforcement follow up and half will not."
88835515|NCT05068310||Patients with non-melanocytic lesions and tumors and pigmented lesions and tumors|Patients with non-melanocytic lesions and tumors and pigmented lesions and tumors who are scheduled for skin biopsy or excision
88835516|NCT03404609|Experimental|Accelerated course of modified continuous theta-burst stimulation (cTBSmod)|Participants received 5 consecutive days of accelerated cTBSmod to the right frontal pole. Each cTBSmod session was comprised of 1800 pulses, delivered in a continuous train of 600 bursts. Each burst contained 3 pulses at 30 Hz, repeated at 6 Hz. Ten sessions were applied per day (18,000 pulses/day, hourly) (90,000 total pulses) using a Magventure Magpro X100. Stimulation was delivered at 90% resting motor threshold (depth corrected). Localite Neuronavigation System was used to position the TMS coil over the individualized stimulation target.
89364570|NCT04897503|Active Comparator|CXL usinng Riboflavin/Methylcellulose solution|Corneal collagen crosslinking using 0.1% riboflavin mixed with 1.0% hydroxypropylmethylcellulose ( HPMC)
89364571|NCT01333917|Experimental|Curcumin|4g Curcumin C3 tablet daily
89364572|NCT02463526|Experimental|Group 1 - MWM condition/Sham condition|Subjects will receive treatment for 4 times with Mulligan's Mobilization with Movement (MWM) condition, and after 72 hrs, will be treated 4 times with the sham condition.
89364573|NCT02463526|Experimental|Group 2 - Sham condition/MWM condition|Subjects will receive treatment for 4 times with sham condition, and after 72 hrs, will be treated 4 times with the Mulligan's Mobilization with Movement (MWM) condition.
89364574|NCT01330797||LOCS III|Cohort is composed of cases with a diagnosis of wet age-related macular degeneration and those that received intravitreal ranibizumab
89364575|NCT03129360|Experimental|Levetiracetam 185 mg|A single dose of 185mg of levetiracetam administered orally to participants. Participants undergo a 15-minute MRI scan using arterial spin labeling (ASL) before dosing and two hours post-dosing.
88835517|NCT02263326|Experimental|dolutegravir plus lamivudine|dolutegravir 50 mg plus lamivudine 300 mg once daily
88835518|NCT02263326|Active Comparator|Continue current ART regimen|Continue current DHHS recommended or alternative three-drug antiretroviral regimen
88835519|NCT02977520|Experimental|Interventional group|Obtain the CTA data of cerebral aneurysms and built the 3D printing models. Combined with the 3D model, the neurosurgeon can complete the discussion of preoperative prediction of aneurysms and recognize the adjacent bone, blood vessels, aneurysm directions and so on. In addition, the model can also be used to the young doctor's training, and the patient and their families can be convenient and intuitive understanding of the disease, so as to form a good communication between doctors and patients.
88835520|NCT02977520|No Intervention|general group|Obtain the CTA data of cerebral aneurysms, the neurosurgeon complete the discussion of preoperative prediction of aneurysms.
88835521|NCT03406325||urticaria|Patients with this condition
88835522|NCT03406325||asthma|Patients with this condition
88835523|NCT03406325||eczema|Patients with this condition
88835524|NCT03406325||food allergy|Patients with this condition
88835525|NCT03406325||anaphylaxis|Patients with this condition
88835526|NCT03406325||mastocytosis|Patients with this condition
88835527|NCT03406325||mast cell activating syndrome|Patients with this condition
89364576|NCT03129360|Experimental|Levetiracetam 500mg|A single dose of 500mg of levetiracetam administered orally to participants. Participants undergo a 15-minute MRI scan using arterial spin labeling (ASL) before dosing and two hours post-dosing.
88835528|NCT04344925||Aerosol-reducing Mask|The participant will be placed on BIPAP using the aerosol-reducing mask. In the case where the patient is located in a care area where BIPAP is prohibited with a standard mask, they will assigned the aerosol-reducing mask.
88835529|NCT04344925||Standard Mask|The patient will be placed on BIPAP using the standard mask. In the case where the patient is located in a care area where BIPAP is prohibited with a standard mask, they will assigned the aerosol-reducing mask.
88835530|NCT00356317|Experimental|1|Participants will receive a 15-week family therapy
88835531|NCT00356317|Active Comparator|2|Participants will receive a 3-week family therapy (treatment as usual)
88835532|NCT05485038|Experimental|Awake surgery|Critical steps of brain mapping and tumor removal will be performed in awake patient
88835533|NCT05485038|Active Comparator|General anesthesia|Brain mapping and tumor removal will be performed in asleep patient
88835534|NCT00356473|Placebo Comparator|Placebo|Placebo
88835535|NCT00356473|Experimental|Atorvastatin|Atorvastatin
89364577|NCT03129360|Placebo Comparator|Placebo|A single dose of placebo administered orally to participants. Participants undergo a 15-minute MRI scan using arterial spin labeling (ASL) before dosing and two hours post-dosing.
89534621|NCT05037591|Placebo Comparator|placebo D|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
89534622|NCT05037591|Placebo Comparator|placebo E|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
89534623|NCT05037591|Placebo Comparator|placebo F|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
89364578|NCT05074524|Experimental|rTMS group|Active rTMS treatment will be delivered at 10 Hz, 100% resting motor threshold, 2000 pulses delivered in five seconds per train with 10-second intra-train pause, delivered once daily five days per week, Monday through Friday for 10 days (10 total treatments). This protocol is adapted from Shen and colleagues (2016), who did not report any adverse events. Liu and colleagues (2020) also used the same protocol and only reported mild side effects of dizziness, headache, and insomnia, which resolved by the 30-day follow-up. However, it is unclear whether these side effects resolved sooner than the 30-day follow-up.
89364579|NCT05074524|Sham Comparator|Placebo Group|The control group will undergo the same seat positioning and comfort measures but will not have a resting motor threshold determination. The coil will be turned 90 degrees counter-clockwise, and the side of the coil will rest on the scalp over the area of the skull corresponding to the motor cortex, so the participant will feel the coil making contact. The same treatment protocol in the active rTMS group will be initiated to mimic the sound of rTMS treatment, though no pulses will be delivered to the participant because of the coil rotation.
89364580|NCT01315275|Experimental|Ranibizumab|
89364581|NCT01358292|Experimental|Semi-extended surgical technique|The experimental technique for implanting an intramedullary tibia nail is with the knee in 10-20 degrees of flexion.
89364582|NCT01358292|Active Comparator|Standard Surgical Technique|The standard surgical technique in intramedullary tibia nailing is with the knee in almost 90 degrees of flexion.
89364583|NCT02463136|Experimental|Behaviour and brain training|fMRI-based neurofeedback
89364584|NCT01331031||Adolescents|Adolescents between 10 and 20 years of age and enrolled in a municipal school system.
89364585|NCT01361646|Experimental|LC350189|
89364586|NCT01361646|Active Comparator|Febuxostat|
89364587|NCT01361646|Placebo Comparator|Placebo|
88835536|NCT05461742|Experimental|Physical activity intervention|All participants will receive a physical activity intervention consisting of goal setting, in-person physical activity sessions, and written materials.
88835537|NCT03407651|Experimental|Part 1a|Coagulation Factor VIIa variant, 18 µg/kg by intravenous route
88835538|NCT03407651|Experimental|Part 1b|Coagulation Factor VIIa variant, 30 µg/kg by subcutaneous route
88835539|NCT03407651|Experimental|Part 2|Coagulation Factor VIIa variant, 30, 60, 90, 120 µg/kg by subcutaneous route
88835540|NCT00356941|Experimental|Chemoradiation Treated Patients|Patients receiving Docetaxel, Oxaliplatin and radiotherapy.
88835541|NCT05456672|Experimental|Dietary intervention|Dietary intervention using standardized test meals
88835542|NCT03338881|Experimental|[14C]-TAK-659 100 mg|[14C]-TAK-659 100 mg, solution, orally, once, in the fasted state on Day 1. Participant will have the option to continue treatment with TAK-659 100 mg, tablets, orally, once daily in a 28-day treatment cycle for up to 12 months or until disease progression or unacceptable toxicity, or the start of another anticancer therapy in post-ADME study period.
89178524|NCT00700349|No Intervention|1|Individuals who were rejected from receiving a loan from a micro-lending organization were randomized to continue receiving no loan.
89364588|NCT02462902|Experimental|5% albumin Infusion|(250 ml over 15 to 30 minutes)
89364589|NCT02462902|Active Comparator|0.9% sodium chloride solution|0.9% sodium chloride solution (total of 30ml/kg over 15 to 30 minute)
89364590|NCT01365702||Tiotropium in TB destroyed lung|
89364591|NCT03165045||patients treated with Spiolto® Respimat®|Patients with COPD
89364592|NCT02462746|No Intervention|No supplement|This group subjects will not receive the supplement
89364593|NCT02462746|Active Comparator|1.5 gram of l-cysteine|Intervention: single dose of 1.5 g L-Cysteine.
89364594|NCT02462746|Active Comparator|3 grams of l-cysteine|Intervention: single dose of 3.0 g L-Cysteine.
89534624|NCT05037591|Placebo Comparator|placebo G|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
89534625|NCT05037591|Placebo Comparator|placebo H|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
88835543|NCT03450083|Active Comparator|Benralizumab treatment group|Benralizumab Active treatment group delivered subcutaneously
88835544|NCT03450083|Placebo Comparator|Placebo group|Placebo treatment group delivered subcutaneously
89534626|NCT05037591|Placebo Comparator|placebo I|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
88835545|NCT03289507|Active Comparator|Treatment1|Longvida Capsule formulation A
88835546|NCT03289507|Active Comparator|Treatment 2|Longvida Capsule formulation B
88835547|NCT03289507|Experimental|Treatment3|Curcuma longa extract of Rhizomes
88835548|NCT03578549||Oximetry testing of healthy teeth and those requiring removal|"To assess the ability of pulse oximeter to assess the presence of pulse in teeth and to correlate pulse oximeter readings with conventional pulp testing measures including cold test, electrical pulp test, percussion and palpation testings, pulse oximeter will be used with a special holding frame, for 15-30 seconds.~Note: the reading will not affect clinical practice; it is simply to gather data to see if pulse oximetry can facilitate diagnostic practices in the future"
88835549|NCT05042960|Experimental|50% brightness group|Participants will be using a computer screen reducing screen brightness 50%.
88835550|NCT05042960|Experimental|Light App group|Participants in this group will use a modulating computer screen tone with flux or night shift app.
88835551|NCT05042960|No Intervention|Control group|Participants in this group will be a control with no change in screen features
88835552|NCT03580343|Experimental|Tofacitinib Treatment|11mg extended-release tofacitinib, once daily, oral
88835553|NCT05445440|Experimental|Part 1|
88835554|NCT05445440|Experimental|Part 2|
88835555|NCT05041322|Placebo Comparator|Placebo|Subjects take placebo pills (twice a day) for 14 Days.
88835556|NCT05041322|Active Comparator|Buspirone|"Subjects take 30 mg buspirone HCl (15 mg twice a day) for 14 Days.~Other Names:~Buspar"
88835557|NCT00422825|Experimental|Imatinib 800mg|
88835558|NCT00422825|Active Comparator|Imatinib 400mg|
88835559|NCT03453515|Experimental|HEART|Interactive website with five modules to address safer sex motivation, knowledge, attitudes/norms, self-efficacy, and sexual communication skills. Program takes approximately 30-45 minutes to complete.
88835560|NCT03453515|Other|Growing Minds|Attention-matched control website with five modules to address an introduction to mindsets, growth mindsets of intelligence, growth mindsets of self-control, growth mindsets of people, and an integrative summary. Program takes approximately 30-45 minutes to complete.
88835561|NCT03456245||Vision device validation|In the single arm of this study, all members of this group were examined using a number of mobile eyesight assessment devices.
88835562|NCT05229614|Experimental|Solid cancers with stable disease|"Only cancer patients under treatment with pembrolizumab monotherapy, administered within clinical practice and according to the Italian Drug Regulatory Agency (Agenzia Italiana del Farmaco, AIFA), will be enrolled.~Patients diagnosed with NSCLC, HNSCC, melanoma and urothelial carcinoma will be eligible for the study."
88835563|NCT05433194|Experimental|Phase I Test group 1: ABO1009-DP|Intramuscularly injecting 15 μg of ABO1009-DP into lateral deltoid region of the upper arm of subjects on D0.
88835564|NCT05219396||mobile bearing (MB)|
88835565|NCT05219396||medial congruent (MC)|
89534627|NCT05037591|Placebo Comparator|placebo J|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
89534628|NCT05037591|Placebo Comparator|placebo K|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
89534629|NCT05037591|Placebo Comparator|placebo L|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
89534630|NCT05037591|Placebo Comparator|placebo M|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
89534631|NCT05037591|Placebo Comparator|placebo N|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
88835566|NCT05219396||posterior stabilized (PS)|
88835567|NCT02260986|Experimental|Placebo qw|Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 followed by a single injection weekly (qw) from Week 1 to Week 51.
89534632|NCT05037591|Placebo Comparator|placebo O|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
88835568|NCT02260986|Experimental|Dupilumab 300 mg q2w|Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by placebo (for Dupilumab) alternating with single 300 mg injection of Dupilumab every 2 weeks (q2w) from Week 1 to Week 51. During weeks in which Dupilumab was not administered, participants received placebo.
88835569|NCT02260986|Experimental|Dupilumab 300 mg qw|Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection of Dupilumab qw from Week 1 to Week 51.
88835570|NCT05421650|Active Comparator|Control group|Concurrent chemoradiation therapy (CCRT)
88835571|NCT05421650|Experimental|Experimental group|Surgical debulking of bulky or multiple lymph node followed by CCRT
88835572|NCT05210582|Experimental|Afamelanotide|
88835573|NCT05009420|Experimental|Avocado|Identify avocatin b (C17 lipid) in plasma of individuals that consumed 1 avocado.
89001563|NCT04575415||Arm 2:Bevacizumab plus Afatinib/Dacomitinib|Patients with EGFR-mutant NSCLC would receive bevacizumab plus second-generation EGFR-TKIs in clinical routine care. Bevacizumab 15 mg/kg or clinical routine dose would be intravenous infusion on day 1 once every 3 weeks.Afatinib 40 mg or clinical routine dose once daily or Dacomitinib 45mg or clinical routine dose once daily or clinical routine dose would be administered.
89534633|NCT05037591|Placebo Comparator|placebo P|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
89534634|NCT05037591|Placebo Comparator|placebo Q|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
89364595|NCT02463058|Experimental|Research arm|"10 young and healthy civilian volunteers will participate in this study. The subjects will undergo 5 experiment days:~Recruitment , medical examination and VO2max test.~Acclimatization day by performing moderate exercise protocol under hot and humid climate.~3 days of performing moderate exercise under hot and humid conditions protocol, each day dressed with different protective garment:~Protective garment in current use + NBC mask.~The new BC protective undergarment + standard combat uniforms~The new BC protective undergarment + standard combat uniforms + NBC mask"
89364596|NCT01361724|Other|One on one with a PT|The participant will work one-on-one with a trained for PT for 3 days a week for four weeks.
89364597|NCT01361724|Other|Group exercise class|The participant will be in a group exercise class. That will meet 3 days a week for 4 weeks.
89364598|NCT01361724|Other|Home Program|The participant will meet one time with a physical therapist and will be given a home program--which is standard of care--to follow for 4 weeks.
89364599|NCT01358448|No Intervention|Newsletter|
89364600|NCT01358448|Experimental|Growth Monitoring|
89364601|NCT01358448|Experimental|Growth Monitoring plus Family-based Behavioral Counseling|
89001564|NCT04575415||Arm 3:Bevacizumab plus Osimertinib|Patients with EGFR-mutant NSCLC would receive bevacizumab plus third-generation EGFR-TKIs in clinical routine care. Bevacizumab 15 mg/kg or clinical routine dose would be intravenous infusion on day 1 once every 3 weeks. Osimertinib 80 mg tablets once daily would be administered.
88835574|NCT05408156|Experimental|Customized insoles group|The participant allocated in the CIG will receive a semi-flexible non-moulded insole with a 2.5mm coverage with Shore A 28, a 5mm retrocapital bar with a Shore A 22 and a 2mm infracapital bar of the first metatarsal with a Shore A 35, produced in acetate. -ethylene vinyl (EVA) and manufactured by researcher C. The insole will be used on both feet to maintain symmetry between the limbs and generate greater comfort, since this will not be a corrective intervention.
89178525|NCT00700349|Experimental|2|"Individuals who were rejected from receiving a loan from a micro-lending organization were randomized to receive a second look, to be reconsidered for a loan by loan officers."
89001565|NCT00586222|Placebo Comparator|2|
89001566|NCT00586222|No Intervention|Healthy Comparsions|We will compare the BP group with 32 age-, gender-, and handedness-matched healthy adolescents. Subjects who have a first or second degree relative with a psychiatric history will be excluded from the healthy comparison group. Subjects must be safe to undergo MRI scanning as per Mayo MRI safety screening which is explained in detail elsewhere in this protocol. We will exclude the subjects with cardiac pacemakers, metallic clips, other bodily metallic implants and dental braces because of the MRS procedure. Subjects who cannot complete clinical assessments or the MRI scan and subjects who are not fluent in English will be excluded from the study.
88835575|NCT05408156|Sham Comparator|Sham Insoles Group|The SIG will receive the same unmolded insole with a semi-flexible base and 2.5mm coverage with Shore A 28, but without the bars used in the intervention group.
88835576|NCT05647356|Experimental|Bicalutamide|Adult females with polycystic ovary syndrome (PCOS) and evidence of clinical or biochemical androgen excess will be recruited.
88835577|NCT05647278|Experimental|Tegoprazan 50mg QD|Tegoprazan 50mg, tablets, orally, qd given in combination with amoxicillin 750mg capsules, orally, qid for up to 2 weeks
88835578|NCT05647278|Active Comparator|Esomeprazole 20 mg BID|"esomeprazole 20 mg, tablets, orally, bid given in combination with amoxicillin 1000mg，clarithromycin 500mg bid，colloidal bismuth pectin 200mg bid for up to 2 weeks.~OR esomeprazole 20 mg, tablets, orally, bis in die given in combination with amoxicillin 750mg capsules, orally, quarter die for up to 2 weeks."
88835579|NCT05407142|Experimental|The study group consisted of 3,500 volunteers who received the CoviVac vaccine|"Subgroup 1 - 2100 volunteers who will be vaccinated with the Nobivac vaccine twice with an interval of 21 days and revaccinated at 6 months with one dose of the KoviVac vaccine.~Cohort 1 - The first 1000 volunteers of the study group will be used to assess the efficacy + safety + immunogenicity of the vaccine under study.~Cohort 2 - Next 1100 volunteers of the study group will be used to analyze the efficacy + safety of the vaccine under study.~Subgroup 2 - 1400 volunteers who will be vaccinated with CoviVac vaccine three times at intervals of 21 days intramuscularly at a dose of 0.5 ml.~The data of 1400 volunteers vaccinated three times with an interval of 21 days will be used to assess the effectiveness + safety + immunogenicity of the vaccine under study."
88835580|NCT05407142|Other|Control group|The data from volunteers from the control group will be used to evaluate the effectiveness of the investigational vaccine.
88835581|NCT00360152|Active Comparator|Positive Axillary Ultrasound|Positive Axillary Ultrasound -> Fine Needle Aspiration Biopsy -> Cytopathology and Reverse Transcription-Polymerase Chain Reaction (RT-PCR) -> Positive Cyto=Axillary Lymph Node Dissection, Negative Cyto=Sentinel Lymph Node Biopsy -> Pathology
88835582|NCT00360152|Active Comparator|Negative Axillary Ultrasound|Negative Axillary Ultrasound -> Sentinel Lymph Node Biopsy/Fine Needle Aspiration Biopsy -> Reverse Transcription-Polymerase Chain Reaction (RT-PCR) and Pathology
89001567|NCT00586222|Experimental|1|
89001568|NCT00586300|Active Comparator|1|Physical training program
89001569|NCT00586300|Active Comparator|2|Self-management training program
89364602|NCT02462668|Placebo Comparator|Control|"Preoxygenation with Bag-mask ventilation before fibreoptic bronchoscopy assisted intubation.~Intervention: Bag-mask ventilation."
89364603|NCT02462668|Experimental|NIPPV|"The NIPPV group preoxygenation with noninvasive positive pressure ventilation(NIPPV), And then receives fibreoptic bronchoscopy intubation through a face mask (there is a small hole allow to insert the tracheal tube through the mask into trachea) during NIPPV.~Intervention: noninvasive positive pressure ventilation(NIPPV)"
89364604|NCT01333995|No Intervention|Usual Health Message|No intervention mothers will recieve standard maternal and child care education
89364605|NCT01333995|Sham Comparator|Peer counseling on infant feeding|Peer counseling intervention group will recieve nutrition education on initiation of breastfeeding within one hour of delivery, continuation of exclusive breastfeeding until six months, and timely introduction of safe, nutritionally adequate complementary feeding after six months.
88835583|NCT05181800||FIRMAGON Cohort|
89364606|NCT03620136|Experimental|locoregional analgesia by a block on the adductor channel|
89364607|NCT03620136|Experimental|locoregional analgesia by periarticular local infiltrations|
88835584|NCT02977364|Experimental|HS-10241 100mg|HS-10241 100mg daily
88835585|NCT02977364|Experimental|HS-10241 200mg|HS-10241 200mg daily
88835586|NCT02977364|Experimental|HS-10241 400mg|HS-10241 400mg daily
88835587|NCT02977364|Experimental|HS-10241 600mg|HS-10241 600mg daily
88835588|NCT02977364|Experimental|HS-10241 800mg|HS-10241 800mg daily
88835589|NCT02977364|Experimental|HS-10241 1000mg|HS-10241 1000mg daily
88835590|NCT05181020|Experimental|Maternal Voice Exposure|Infants enrolled will be exposed to maternal voice for 20 min immediately prior to being offered oral feedings. This exposure will be conducted 2 times a day until infant starts taking all enteral feeds orally.
88835591|NCT05383664|Experimental|Clinical Screening|Subjects will be screened for systemic blood markers responsive to 3-4 subsequent UV exposure over the course of 4-5 laboratory visits over the course of one week.
88835592|NCT00359606|Experimental|Treatment (5-fluoro-2-deoxycytidine, tetrahydrouridine)|Patients receive tetrahydrouridine PO on day 1; 5-fluoro-2-deoxycytidine PO on days 1 and 8; tetrahydrouridine IV over 3 hours on days 2-5, 8, and 9-12; and 5-fluoro-2-deoxycytidine IV over 3 hours on days 2-5 and 9-12 of course 1. For all subsequent courses, patients receive tetrahydrouridine IV over 3 hours and 5-fluoro-2-deoxycytidine IV over 3 hours on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88835593|NCT02259582|Placebo Comparator|Arm 1 Pem, carbo, placebo x 4 cycles|Pemetrexed (500 mg/m2),carboplatin (area under the concentration-time curve of 6 mg/mL x min) once every 21 days X 4 cycles, pemetrexed maintenance and placebo starting at Day 84
88835594|NCT02259582|Active Comparator|Arm 2 Pem, carbo x 4 cycles, one course of dem|Pemetrexed (500 mg/m2), carboplatin (area under the concentration-time curve of 6 mg/mL x min) x 4 cycles, one course of demcizumab 5mg/kg, maintenance pemetrexed + placebo starting on Day 84
88835595|NCT02259582|Active Comparator|Arm 3 pem, carbo, dem x 4 cycles, dem retreatment|Pemetrexed (500 mg/m2), carboplatin (area under the concentration-time curve of 6 mg/mL x min) x 4 cycles, maintenance pemetrexed starting on Day 84. 2 courses of demcizumab 5 mg/kg
88835596|NCT05161364||A: PFA|partial foot amputation secondary to peripheral neuropathy
88835597|NCT05161364||B: PN|peripheral neuropathy
88835598|NCT02977208|Active Comparator|Homozygous for the wild type allele|"Patients with 18 years old or older with epilepsy, neuropathic pain or any chronic pain undergoing chronic treatment with gabapentin are being recruited.~Sparse blood sampling are being collected up to 4 h after administration of the drug for pharmacokinetic study. Urine sampling are being collected during the dosing interval, only in patients hospitalized at the Hospital Estadual de Américo Brasiliense (HEAB). Blood sample are being collected for DNA extraction. DNA are being extracted from the whole blood of all patients for genotyping of the SLC22A2 c.808G>T and SLC22A4 c.1507C>T polymorphisms."
88835599|NCT02977208|Active Comparator|Homo- or heterozygous for rare alleles|"Patients with 18 years old or older with epilepsy, neuropathic pain or any chronic pain undergoing chronic treatment with gabapentin are being recruited.~Sparse blood sampling are being collected up to 4 h after administration of the drug for pharmacokinetic study. Urine sampling are being collected during the dosing interval, only in patients hospitalized at the Hospital Estadual de Américo Brasiliense (HEAB). Blood sample are being collected for DNA extraction. DNA are being extracted from the whole blood of all patients for genotyping of the SLC22A2 c.808G>T and SLC22A4 c.1507C>T polymorphisms."
88835600|NCT03238651|Experimental|Dose Escalation Part Schedule A: TAK-659 60 mg in Cohort 1|TAK-659, tablet, orally, once daily, in a 28-day treatment cycle for up to 12 months or until disease progression or unacceptable toxicity, with a starting dose of 60 milligram (mg) in Cohort 1. Dose escalation will follow a standard 3+3 schema . If 60 mg, once daily is safe and tolerable, then the dose will be escalated to 80 mg, once daily and subsequently in 20 mg increments until MTD and/or RP2D is determined. Based on emerging safety, tolerability, PK data, a lower dose will be permitted.
88835601|NCT03238651|Experimental|Dose Escalation Part Schedule B: TAK-659 80 mg in Cohort 1|TAK-659, tablet, orally, once daily as 7 days on and 7 days off treatment (dosing on 7 days followed by 7 days of rest) in a 28-day treatment cycle for up to 12 months or until disease progression or unacceptable toxicity, with a starting dose of 80 mg in Cohort 1. Dose escalation will follow a standard 3+3 schema. An alternative intermittent regimen may be evaluated if deemed necessary per the emerging data.
88835602|NCT03238651|Experimental|Expansion Part: TAK-659 MTD/RP2D|TAK-659, tablet, orally, once daily, in a 28-day treatment cycle until disease progression or unacceptable toxicity in participants with follicular lymphoma (FL) or marginal zone lymphoma (MZL) who are relapsed and/or refractory. Dose and dosing schedule for this part will be MTD/RP2D determined from results of dose escalation part.
88835603|NCT04866108|Experimental|Experimental|Fruquintinib, 4mg/d, qd po, 2 weeks on, 1 week off; Capecitabine: 825mg/m2, bid po, 2 weeks on, 1 week off
88835604|NCT04343768|Experimental|Hydroxychloroquine + Lopinavir / Ritonavir + Interferon-β 1a|
88835605|NCT04343768|Experimental|Hydroxychloroquine + Lopinavir / Ritonavir + Interferon-β 1b|
88835606|NCT04343768|Active Comparator|Control group: hydroxychloroquine + Lopinavir / Ritonavir|
88835607|NCT04964492||responders to treatment|A patient will be defined as a responder to hydroxocobolamin infusion if there is an increase of more than 20% in Average blood pressure, relative to the pre-treatment value, for at least 15 minutes within one hour of treatment administration.
88835608|NCT04964492||non-responders to treatment|A patient will be defined as a non-responder to hydroxocobolamin infusion if there is not an increase of more than 20% in Average blood pressure, relative to the pre-treatment value, for at least 15 minutes within one hour of treatment administration.
88835609|NCT03221335|Experimental|EUS-guided RFA|EUS-guided RFA would be performed using a 19-gauge RFA electrode and a VIVA RF generator (STARmed, Korea).
88835610|NCT05925946|Experimental|Intervention Group|"Phase1 (Partial diet replacement) (850 Kcal/day) (12-20 weeks)):~Phase 2 (Gradual increase in calories) (20-28 weeks) (1100 Kcal/day):~Phase 3 (Weight loss maintenance) (29-104 weeks) (up to 1200Kcal/day) :"
89364608|NCT02462824|Experimental|Home-based exercise intervention|PAD Participants randomized to the home-based exercise intervention will be asked to take part in walking exercise to determine whether a patient-centered home-based exercise program improves walking ability, mobility, pain, and social functioning.
89364609|NCT02462824|No Intervention|Usual care group|PAD participants randomized to usual care will not receive any study interventions. Rather, they will receive usual care from their own physicians.
89364610|NCT01319448|Active Comparator|Daily proguanil|Standard policy of a supply of proguanil tablets to be taken daily
88835611|NCT05925946|No Intervention|Control Group|Subjects will be given routine care for diabetes and obesity management with no change in medication. The meal plan for the control group will consist of 1400 Kcal/day achieved through small frequently distributed meals constituting around 15% of protein, 60% of carbohydrates and 25% of fat; with a menu resembling standard Indian dietary patterns and meal combinations.
88835612|NCT05925933|Experimental|High Protein Diet|High protein diet (carbohydrates 45%, protein 29%, and fat 26%) over 8-week periods. All assessments as done on day 1 will be repeated on day 60.
88835613|NCT05925933|Other|Control Group|Equicaloric normal diet (carbohydrates 60%, protein 15%, and fat 25%)
88835614|NCT05925842||Participants with PsA without Axial Involvement|
88835615|NCT05925842||Participants with PsA with Axial Involvement|
88835616|NCT05925829|Experimental|SVF and aaPRP treatment|Patients treated with SVF and aaPRP
88835617|NCT05925816|Experimental|Video|Short video with BA intervention ideas
88835618|NCT05925816|Experimental|Active game|Feedback Twine game
88835619|NCT05925816|Sham Comparator|Neutral game|Neutral Twine game
89364611|NCT01319448|Experimental|IPT with MQ+AS bimonthly|Intermittent Preventive Treatment (IPT) consisting of a bimonthly course of treatment with mefloquine-artesunate (MQ+AS)
89364612|NCT01319448|Experimental|IPT with SP+AQ bimonthly|IPT with bimonthly course of treatment with sulfadoxine-pyrimethamine plus amodiaquine (SP+AQ)
88835620|NCT05925816|No Intervention|No intervention|
88835621|NCT05925816|Experimental|Video + Active game|Combines Video and Active game
89364613|NCT03296878|Other|Own-Price Elasticity|"The price of eggs will vary (own-price elasticity) while the price of other foods in the mock grocery store will remain constant."
89364614|NCT03296878|Other|Cross-Price Elasticity|"The eggs will remain constant while the price of other foods in the mock grocery store will vary (cross-price elasticity)."
89364615|NCT01365780|Active Comparator|With HBOT|Patients, who receive hyperbaric Oxygen Therapy after their surgical treatment
88835622|NCT05925816|Active Comparator|Video + Neutral game|Combines Video and Neutral game
88835623|NCT05925790||Inflammatory phenotype|"Patients with the inflammatory phenotype of recurrent pericarditis exhibit signs indicating the presence of an inflammatory process during a recurrence. These signs may include one or more of the following:~Fever~Elevated C-reactive protein (CRP)~Elevated white blood cell (WBC) count~Elevated erythrocyte sedimentation rate (ESR)~Pericardial late gadolinium enhancement (LGE) on cardiac magnetic resonance imaging (CMR)~Pericardial contrast enhancement on computed tomography (CT)"
88835624|NCT05925790||Non-inflammatory phenotype|"Patients with the non-inflammatory phenotype of recurrent pericarditis do not exhibit any of the signs typically associated with an active inflammatory process during a recurrence. These patients present without:~Fever~Elevated CRP~Elevated WBC count~Elevated ESR~Pericardial LGE on CMR~Pericardial contrast enhancement on CT"
89001570|NCT00586300|Active Comparator|3|Physical and self-management training programs
89001571|NCT00586417|Experimental|1|This is a basic research study. There are no treatments with drugs or devices. Wound healing is being studied in healthy volunteers.
89001572|NCT00586534|Active Comparator|I/GDC|NIDA approved Individual/Group Drug Counseling (I/GDC) cocaine treatment
89001573|NCT00586534|Experimental|I/GDC + VR/CER|Second Arm:NIDA approved Individual/Group Drug Counseling (I/GDC) cocaine treatment plus virtual reality (VR) based cue exposure/extinction software and cellular phone-based computerized extinction reminder (CER) technology for use in high-risk situations outside treatment sessions.
88835629|NCT05925647|Experimental|Messenchymal stem cell secretome|The hypoxic mesenchymal stem cell secretome has been developed up to chapter 7, stored at -196 C to -135 C in cryopreservation, and has passed quality tests.
88835630|NCT05925647|Placebo Comparator|Placebo|Nacl 0,9% infusion
88835631|NCT05925543||all neonates diagnosed with biliary atresia and managed by Kasai portoenterostomy.|all neonates diagnosed with biliary atresia in the previous period 2019 and managed by Kasai portoenterostomy.
88835632|NCT05925491|Experimental|Neoadjuvant Pembrolizumab|patients will receive pembrolizumab 200 mg + cisplatin 75mg/mq and docetetaxel 75 mg/mq every three weeks (Q3W) for 3 courses, followed by standard of care
88835633|NCT05925413|Experimental|Cadonilimab+TACE|Cadonilimab (15mg/kg Q3W D1)+TACE
88835634|NCT05925387|Experimental|Experimental Group|All volunteers completed a pre-test, which includes an additional two scales along with the sociodemographic data form, and two post-tests, which only include the scales. Both groups will receive the Child Abuse and Neglect Awareness Training, which will last approximately 60 minutes. Both groups will complete the pre-test and post-tests at the same time. However, immediately after the pre-test, the experimental group will receive the training and then complete the 1st post-test, followed by the 2nd post-test one month later. Additionally, the second post-test will be administered to both groups simultaneously one month after the completion of the first post-test. After the completion of all the tests, the control group also received the same training, and both groups received participation certificates. Apart from these tasks, there are no other responsibilities.
89001574|NCT00586807|Other|Infliximab|Subjects on infliximab
89001575|NCT00586885|Experimental|1|Single arm, active treatment
89001576|NCT00587002|Active Comparator|1|Gender comparison
89364616|NCT01365780|No Intervention|Without HBOT|"Patients who receive the same surgical treatment of their radius fracture than the patients of the group with HBOT, but no hyperbaric oxygen therapy (comparison group)"
88835635|NCT05925387|No Intervention|Control Group|"Participants in the control group do not receive the intervention. They took both pretest and post-tests. The control group, on the other hand, did not receive the training but completed the first post-test simultaneously with both groups, without distinguishing between the experimental and control groups.~They only complete online surveys. However, to follow the ethical rules, at the end of the trial, all nursing students will take the same education as their peers."
89364617|NCT01319604|Experimental|Study device during 3 hours|
89364618|NCT01319604|Experimental|Study device during 6 hours|
88835636|NCT05925374|Experimental|Training group|Professionals working at a primary care site who has direct interaction with patients. They receive a one-time 2-hour interactive in-person training focused on improving care for patients who use drugs and reducing provider-based stigma. Their baseline attitudes and intended actions are compared to their post-intervention answers to questions in the same domains. Thus, the participants act as their own comparison group, where baseline answers are compared to post-intervention answers.
88835637|NCT05925361|Experimental|intervention|All participants will undergo a laparoscopic single flap peritoneum vaginoplasty
88835638|NCT05925335|Experimental|Transcatheter mitral valve-in-valve implantation|
88835639|NCT05925283|Placebo Comparator|midazolam|Patients were assigned to receive oral midazolam 0.5mg.kg-1 approximately 30-40 minutes before surgery using a computer-generated random number table.
88835640|NCT05925283|Experimental|esketamine|Patients were assigned to receive intranasal esketamine 1mg/kg approximately 30-40 minutes before surgery using a computer-generated random number table.
88835641|NCT05925283|Experimental|midazolam and esketamine|Patients were assigned to receive intranasal esketamine 0.6mg/kg and oral midazolam 0.3mg.kg-1 approximately 30-40 minutes before surgery using a computer-generated random number table.
88835642|NCT05925205|Experimental|Group A|Experimental group 1.
88835643|NCT05925205|Experimental|Group B|Experimental group 2.
88835644|NCT05925205|Experimental|Group C|Experimental group 3.
88835645|NCT05925153||College Students|
88835646|NCT05925010|Experimental|Supplementation with soluble fibre from guar|In the intervention group, the patients consume the standardized meal instead of breakfast and add 10 g of soluble fiber in the form of Optifibre (food for special medical purposes) to this cereal porridge.
88835647|NCT05925010|No Intervention|No supplementation with soluble fibre from guar|In the control group, the patients eat the standardized meal without adding soluble fiber in the form of Optifibre.
89364619|NCT01319604|Experimental|Study device during 9 hours|
89364620|NCT01319604|Experimental|Study device during 12 hours|
89364621|NCT01319604|Experimental|Study device during 15 hours|
89364622|NCT01319604|Experimental|Study device during 18 hours|
88835648|NCT05924958|Experimental|Eprolidone intervention in patients with chronic heart failure|The Pulidone group received conventional medication combined with 25 mg/day of Eprolidone, gradually increasing to 50 mg/day for 4 consecutive weeks
88835649|NCT05924958|No Intervention|Patients in the conventional treatment group|Other conventional anti chronic heart failure drugs for the conventional treatment group taking non aldosterone receptor blockers
88835650|NCT05924945|Active Comparator|Bridge™ active device|The active Bridge device delivers electrical stimulation to the cranial and occipital nerves.
89364623|NCT01319604|Experimental|Study device during 21 hours|
89364624|NCT01319604|Experimental|Study device during 24 hours|
89364625|NCT01319604|Active Comparator|Tonometric assessment during 24 hours|
89364626|NCT02462434|Experimental|Early palliative care team consultation|Early pediatric palliative care team consultation for single ventricle patients will occur in this group following birth but prior to the first stage palliative surgery.
89364627|NCT02462434|No Intervention|Usual care|Usual care for single ventricle patients will be provided with palliative care team consultation occurring at any point (if it is determined the child and family would benefit from palliative care consultation) during the child's neonatal hospital stay.
89364628|NCT01334073|Experimental|Axitinib plus everolimus|
89364629|NCT01331265||no treatment|
88835651|NCT05924945|Sham Comparator|Bridge™ sham device|The sham device has the same appearance and will require the same placement technique as the Bridge (active) device but will not deliver electrical impulses
88835652|NCT05924893|Experimental|Naltrexone group|25 eyes with refractory non infective corneal ulcer were subjected to daily insertion of a NTX film in the lower conjunctival fornix for 2 weeks
89364630|NCT03296722|No Intervention|Control group|The control group comprised 41 patients, which was to go once a month to receive nutritional intervention with the prescription of a hypocaloric diet on the part of the nutritionist. The control group had a monthly monitoring for 3 months.
89364631|NCT03296722|Experimental|Intervention group|The intervention group made up of 42 patients using the transtheoretical model and MI through sessions group and sessions individual with topics of healthy eating habits taught by a nutritionist, physical activity and exercise manual taught by a physical therapist, preparation of healthy food with menu taught by graduates in gastronomy and confrontation of barriers given by a psychologist. The intervention group had a monthly monitoring for 3 months. The diet that was prescribed to the intervention group was with the characteristics of the DASH diet.
89364632|NCT02462590|Active Comparator|Lactobacillus rhamnosus GG|Patients allocated to the intervention group will receive 1x1010 colony forming units (CFU) of L. rhamnosus GG (Culturelle, Locin Industries Ltd) in 1 capsule suspended in tap water, administered through a nasogastric (or orogastric) or nasoduodenal (or oroduodenal) tube twice daily while patients are in the ICU. The first dose will be within 72 hours of intubation. Patients in the ICU who await discharge and can swallow pills will take the capsules orally.
88835653|NCT05924893|Experimental|Control|25 eyes with refractory non infective corneal ulcer were treated by carboxymethyl cellulose sodium 0.5 % eye drops
88835654|NCT05924763|Experimental|BiCRI|Biphasic Cartilage Repair Implant
88835655|NCT05924737|Experimental|Sleep|Sleep deprivation
88835656|NCT05924724|Experimental|Usage Flash-Glucose Monitoring FGM|Participants in this arm will transition from routine care using SMBG to using FGM after one week. They will receive training on how to use the FGM device. The FGM will be used continuously from that point until delivery, throughout the entire pregnancy.
88835657|NCT05924724|No Intervention|Usage Self-Monitoring Blood Glucose SMBG|Participants in this arm will remain in the routine care using SMBG. They will use it continuously from diagnosis until delivery, throughout the entire pregnancy.
88835658|NCT05924711||Case group|The case group will consist of 20 patients who will have implants diagnosed with peri-implantitis, according to the 2017 World Workshop Classification case definition.
88835659|NCT05924711||Control group|The control group will include 20 subjects who will have implants with peri-implant health according to the 2017 World Workshop Classification case definition.
89364633|NCT02462590|Placebo Comparator|Placebo|Patients allocated to the placebo group will receive a capsule identical in appearance to the L. rhamnosus GG capsule, but containing microcrystalline cellulose. The placebo will also be suspended in tap water and similarly administered twice a day. When suspended in water, the placebo has identical appearance and consistency as the probiotic. The placebo will be prepared by the manufacturer of L. rhamnosus GG, Culturelle, and has been used successfully in a recent RCT in the ICU population [Morrow 2010]. This has also been used successfully in the PROSPECT Pilot Trial.
89364634|NCT01361880|Other|Reduce infant mortality|The overall purpose of this study is to develop and evaluate a systematic approach to improve African-American parental behaviors specifically with regards to the infant sleep environment
88835660|NCT05924659|Experimental|Neurofeedback|1 week of cerebral training with a neurofeedback strategy based on increased alpha EEG activity
88835661|NCT05924659|Placebo Comparator|Placebo|1 week of cerebral training with a placebo strategy based on time increase of performance, without neurofeedback
88835662|NCT05924633|Experimental|Intervention group|The intervention group will receive a supplement to take daily for 4 weeks. The supplement contains a combination of a protein hydrolysate and beta-glucan (Wellmune®).
88835663|NCT05924633|Placebo Comparator|Control group|The control group will consume a placebo supplement containing maltodextrin daily for 4 weeks.
88835664|NCT05924607|Experimental|Standard clamshells method|The patient is asked to lie in a side-lying position with the weak limb up, both hips flexed at 45°, the knees flexed at 90°, and neither the feet nor back not in contact with the wall. Keeping both their heels and the first metatarsal head together, the patient separated their knees and rotated the weak limb upward. The patients is instructed not to tip it backward and to hold the pelvis in a neutral position.Common treatment will be given to each patient includes hot pack for 10 minutes and knee isometric contraction exercises and SLR( 3-5 sets of 10 repetitions)
88835665|NCT05924607|Experimental|Targeted VMO strengthening|The patient is asked to lie in a supine lying position with arm next to the body. After that asked the patient to perform SLR exercise in an external hip rotation with the simultaneous contraction of the ankle dorsiflexors. Common treatment will be given to each patient includes hot pack for 10 minutes and knee isometric contraction exercises and SLR( 3-5 sets of 10 repetitions
88835666|NCT05924581|Experimental|Clinical assessment of spinal stiffness|"Patients' back flexibility will be assessed during the medical examination or physiotherapy session through one of the following non-invasive tests:~Thoracic Stiffness Test (TST)~Scoliosis stiffness test (SST)~Kyphosis Stiffness Test (KST) Each test will be carried out at the beginning of the visit and repeated at the end 2 times by different operators, or once by the same operator to verify that the measurements taken at different times are reliable and that the measurements taken by two different operators are reliable."
89364635|NCT01928199|Active Comparator|Sitagliptin|"Sitaglipitin tablets will be administered orally for 3 months from randomization~Initial dose will be 100mg/daily, adjusted per renal function:~Creatinine clearance > or = 50mL/min: 100mg/day Creatinine clearance > or = 30 and <50mL/min: 50mg/day Creatinine clearance <30 mL/min or on dialysis: 25mg/day"
89364636|NCT01928199|Placebo Comparator|Placebo|Placebo tablets (identical to active comparator in appearance) will be administered orally for 3 months. Starting dose and adjustment based on renal function will be identical to active comparator
89364637|NCT03713866|Experimental|EP Imaging and Testing|MRI images,120 lead body surface mapping and NIPS testing will be completed to correlate areas of VT scar.
89364638|NCT03128892|Experimental|Test Subject|All subjects are enrolled into the test group and all subjects received the Noninvasive Oxygen Reserve Index - RD Lite Sensors
89364639|NCT03296644|Active Comparator|PowerScope2 group (G1)|Class II correction using PowerScope2
88818250|NCT01797575|Active Comparator|Aspirin and NAC|research subject will be taking aspirin 1000mg (2 capsules of 500mg) every morning and NAC 1000mg (2 capsules of 500mg) two times a day in addition to his/her mood stabilizing drug (lithium, anticonvulsants, any atypical antipsychotics) or combinations.
89364640|NCT03296644|Active Comparator|Forsus group (G2)|Class II correction using Forsus
88818251|NCT01797575|Placebo Comparator|Sugar Pill|research subject will be taking 4 capsules of matching sugar pill( placebo) in the morning and 2 capsules of matching placebo in the evenings in addition to his/her mood stabilizing drug (lithium, anticonvulsants, any atypical antipsychotics) or combinations
88818252|NCT03009032|Experimental|PMT25341|A mixture of prebiotics, probiotics, oligonutrients, essential aminoacids, omega-3 fatty acids
88818253|NCT03009032|Placebo Comparator|PLACEBO|Lactose
88818254|NCT02641353|Experimental|Treatment A: Apremilast 30 mg Tablet - Fasted|A single oral dose of 30 mg apremilast tablet after an overnight fast.
88818255|NCT02641353|Experimental|Treatment B: Apremilast 30 mg Oral Suspension - Fasted|A single oral dose of 30 mg apremilast oral suspension formulation (6 mL) after an overnight fast.
88818256|NCT02641353|Experimental|Treatment C - Apremilast 30 mg Oral Suspension - Fed|A single oral dose of 30 mg apremilast oral suspension formulation (6 mL) after a high-fat meal.
88818257|NCT01335542|Active Comparator|Epidural Pathway (PCEA+FNB)|
88818258|NCT01335542|Active Comparator|Peri-Articular Injection|
88818259|NCT01378520|Experimental|ketoconazole|600 mg ketoconazole
88818260|NCT01378520|Placebo Comparator|inert powder|inert powder in capsule
88818261|NCT01378988|Experimental|Dose level 1|Dexmedetomidine 0.7 mcg/kg loading dose and 0.5 mcg/kg/hr maintenance infusion
88818262|NCT01378988|Experimental|Dose level 2|Dexmedetomidine 1.0 mcg/kg loading dose and 0.75 mcg/kg/hr maintenance infusion
88818263|NCT01335620|Other|Tenofovir/Emtricitabine and Raltegravir|"Single arm study~tenofovir/emtricitabine 245/200 mg once daily and raltegravir 400 mg twice daily"
88818264|NCT01272830|Experimental|oral Apatone®B|An amalgam of Vitamins C & K3
88818265|NCT01272830|Placebo Comparator|Placebo|Oral capsule of similar appearance and taste without Apatone®B
88818266|NCT01335932|Experimental|IV Ganciclovir|5mg/kg IV twice daily for 5 days, then followed by either IV ganciclovir or oral valganciclovir once daily until hospital discharge
88818267|NCT01335932|Placebo Comparator|Placebo|normal saline IV twice daily for 5 days, then followed by either IV normal saline or oral placebo once daily until hospital discharge
88818268|NCT01273766|Experimental|Arm I|Patients receive oral deferasirox once daily for up to 6 months or until blood counts recover in the absence of disease progression or unacceptable toxicity.
88818269|NCT01273766|No Intervention|control arm|blood tested on healthy patients
88818270|NCT01273766|No Intervention|correlative|treated off study with or without oral deferasirox (patient choice) but lab draws to gather lab analysis
88818271|NCT01379222|Experimental|ENGAGE PAS De Novo Subjects|The Endurant Stent Graft System Bifurcated device is administered to patients diagnosed with an abdominal aortic or aortoiliac aneurysm who are considered candidates for endovascular repair, per the FDA approved Instructions For Use (IFU).
88818272|NCT01379924|Experimental|Young Parents Program plus Parenting/Life Skills modules|In addition to receiving standard medical and social services for young parents and their children, patient takes part in 5 one on one modules during the first year of child's life aimed at educational attainment, budgeting, child development, safety in the home and substance abuse.
88818273|NCT01379924|Active Comparator|Young Parents Program usual care|Patients receive regular standard of care without modules.
88818274|NCT01275092|Experimental|CorPath robotic-assisted PCI|CorPath 200 robotic-assisted PCI
88818275|NCT04741269||Lack of knee flexion|"During preoperative clinical exam, highlight of a lack of knee flexion. The lack of knee flexion consists in an asymmetric heel-bottom distance or an asymmetric goniometric measure of knee flexion.~All others characteristics are also analyzed like in group 2, as : rest of knee motion, MRI meniscus shift, arthroscopic shift"
88818276|NCT04741269||Full knee flexion|"During preoperative clinical exam, highlight of a lack of knee flexion. The lack of knee flexion consists in an asymmetric heel-bottom distance or an asymmetric goniometric measure of knee flexion. Patients in group 2 don't have any asymmetric full knee flexion.~All others characteristics are also analyzed like in group 2, as : rest of knee motion, MRI meniscus shift, arthroscopic shift"
88818277|NCT01403090|Experimental|Angel Catheter|
88818278|NCT02642991|Experimental|Phenacite Test lens then comfilcon A control lens|Participants were randomized to wear Phenacite test lens for one week then cross-over to wear comfilcon A control lens for one week.
88818279|NCT02642991|Active Comparator|Comfilcon A control lens then Phenacite test Lens|Participants were randomized to wear comfilcon A control lens for one week then cross over to Phenacite test lens for one week.
88818280|NCT01403246|Experimental|Lenalidomide with Chlorambucil|
88818281|NCT01734551|Active Comparator|Morphine|Initial dose is 0.4mg/kg/day, divided every 3-4 hours, given PO with feeds. Drug is required until symptoms of withdrawal no longer cause the infant feeding, behavior, or elimination problems, up to 3 months.
88818282|NCT01734551|Active Comparator|Clonidine|Dose is started at 5 mcg/kg/day, given PO with feeds, divided every 3-4 hours. Drug is required until symptoms of withdrawal no longer cause the infant feeding, behavior, or elimination problems, up to 3 months.
88818283|NCT01276184|No Intervention|Usual Care|Participants follow the usual practices for scheduling their follow up visit(s) for vaccination at the clinic. Participants will receive the standard reminder from the clinic for their scheduled appointment(s) (phone call, letter, etc, as appropriate).
88818284|NCT01276184|Experimental|SMS Text Message|Participants in both the Usual Care group and the SMS Text Message group will receive the standard reminder from the clinic for their scheduled appointment(s) (phone call, letter, etc, as appropriate). Women in the SMS Text Message group that reschedule a vaccination visit will receive text message reminders one per day for each of the seven days prior to the rescheduled visit.
88818285|NCT01815515|Experimental|18F-DCFBC|Participants with hormone-naive prostate cancer (HNPC) and castration-resistant prostate cancer (CRPC) with metastatic lesions detected on conventional imaging modalities (contrast-enhanced computed tomography [CECT] and bone scintigraphy [BS]) undergo PET imaging with 18F-DCFBC radiotracer.
89178526|NCT02612675|Active Comparator|Standard ONS|Nutritional beverage (Oral Nutrition Supplement) designed for oral consumption
89178527|NCT02612675|Experimental|Low Carbohydrate ONS|Nutritional beverage (Oral Nutrition Supplement) designed for oral consumption
89178528|NCT00853073|Active Comparator|Bevacizumab|subjects will receive 1.0mg (0.04cc of 25 mg/ml) subconjunctival bevacizumab either temporal or nasal to the bleb following bleb needling procedure in addition to 0.1 cc mitomycin C.
89178529|NCT00853073|Placebo Comparator|balanced salt solution|patients randomized to treatment B are given 0.04cc of balanced salt solution injected in identical fashion either temporal or nasal to the bleb following bleb needling procedure in addition to 0.1 cc mitomycin C.
89364641|NCT01845441|Experimental|Dexmedetomidine arm|Precedex will be started after randomization/prior to catheterization and will be stopped at the end of the procedure. It will be used for an average of 90 minutes and will be used as a continuous intravenous infusion started at 0.3 mcg/kg/hour. If HR > 80 and BP > 120/70, a full loading dose (1.0 mcg/kg/hour) will be administered over 10 minutes. If HR is 60 - 80 or systolic BP is 90 - 120, or age > 65 years, a reduced loading dose of 0.5 mcg/kg will be given over 10 minutes. If no volume overload history, 500mL of colloid (hespan or albumin) will be bolused with 0.2mg of glycopyrrolate. Every 10 minutes, Precedex will be titrated by 0.1 mcg/kg/hour to achieve and maintain RASS of 0 to -1.
89364642|NCT01845441|Active Comparator|Control arm|Our usual standard of care is to attempt the intervention without sedation. As per attending physician discretion, Fentanyl (50mcg) and/or Midazolam (0.5 mg) intravenous boluses will be used to control aggressive patient movement that adversely affects the technical capacity of the procedure. The boluses will be repeated at interval of 10 minutes, as necessary. Control arm patients will receive a normal saline placebo drip for the purposes of ensuring patient assessor blindness.
89178530|NCT00846053|Other|Stable lung function|* Group S (n = 14) will consist of CF patients, aged 12-21 years old, who underwent FDG-PET with stable lung function during the past 4 years, defined as less than 2% decline per year. There is no therapeutic intervention and FDG-PET scan will be performed in both cohorts.
89178531|NCT00846053|Other|Rapidly deteriorating lung function|* Group R (n = 14) will contain CF patients, aged 12-21 years old, who underwent FDG-PET with rapidly deteriorating lung function during the past 4 years with greater than 4% per year decline. There is no therapeutic intervention and FDG-PET scan will be performed in both cohorts.
89178532|NCT00700505|Experimental|Heating Garment|FlowPants(R) Garment with Heating
89178533|NCT00845897|Placebo Comparator|1|Placebo (saline) injections into 6 sites in the calf muscle
89178534|NCT00845897|Active Comparator|2|Total 200 units of Botulinum Toxin injected into 6 sites into the calf muscles.
89178535|NCT00845897|Active Comparator|3|300 units of botulinum toxin injected into 6 sites in the calf muscle
88818286|NCT01404260|Experimental|Gemcitabine +Carboplatin +Gefitinib|Arm A: Gemcitabine 1250mg/m2+Carboplatin AUC=5, every 4 weeks, maximum 4 cycles, Gefitinib 250mg/d every cycle d15-25, and Gefitinib 250mg/d from d15 of last cycle until disease progression
88818287|NCT01404260|Active Comparator|Gemcitabine +Carboplatin|Arm B: Gemcitabine 1250mg/m2+Carboplatin AUC=5, every 4 weeks, maximum4 cycles, observation until disease progression
88818288|NCT01735877|Experimental|Mirror therapy|All eligible patients will be randomly allocated into 2 groups. Group 1 will be given Mirror therapy
88818289|NCT01735877|Sham Comparator|Control group|Group 2 will be given sham mirror therapy
88818290|NCT02235909|Experimental|Double-blind: Azilsartan Medoxomil - Low dose|6-week, double-blind (DB), randomized, treatment phase (DB Phase): Azilsartan medoxomil Low-dose (AZM-L), 10 mg once daily.
88818291|NCT02235909|Active Comparator|Double blind phase: Losartan|6-week, double-blind (DB), randomized, treatment phase (DB Phase): Starting at Losartan 25/50 and force titrated to 50/100 mg daily at Week 2.
88818292|NCT02235909|Active Comparator|WITHDRAWAL Phase: Azilsartan medoxomil LOW-dose|Experimental Arm in the Withdrawal Phase, subjects will be randomized (1:1) to continue taking their previously assigned active treatment ( Azilsartan medoxomil low dose) that was taken in Double blind OR to be switched to placebo.
88818293|NCT02235909|Placebo Comparator|WITHDRAWAL Phase: PLACEBO to match azilsartan medoxomil LOW DOSE|PLACEBO Arm in the Withdrawal Phase for subjects who were on Azilsartan medoxomil LOW dose) in Double blind then randomized (1:1) to placebo for withdrawal phase
88818294|NCT02235909|Experimental|Open Label Phase: Azilsartan Medoxomil|Azilsartan Medoxomil 10 mg which can be titrated to higher dose(s) (up to 40 mg for subjects <50 kg or up to 80 mg for subjects ≥50 kg)
88818295|NCT02235909|Other|"Open Label Phase: Other"|If add-on therapy is needed, a calcium channel blocker, such as amlodipine; a diuretic, such as hydrochlorothiazide; or a beta-blocker such as metoprolol will be determined per the investigator's clinical judgment.
88818296|NCT02235909|Active Comparator|Withdrawal Phase: Losartan 50 mg|Withdrawal Phase, subjects will be randomized (1:1) to continue taking their previously assigned active treatment or to be switched to placebo.
88818297|NCT02235909|Placebo Comparator|Withdrawal Phase: PLACEBO to Losartan|Placebo Arm In the Withdrawal Phase, subjects will be randomized (1:1) to continue taking their previously assigned active treatment or to be switched to placebo.
88818298|NCT02235909|Experimental|Double-blind: Azilsartan Medoxomil - Medium dose|6-week, double-blind (DB), randomized, treatment phase (DB Phase), Azilsartan medoxomil Medium-dose (AZM-M), 20 mg once daily at Week 2.
88818299|NCT02235909|Experimental|Double-blind: Azilsartan Medoxomil - High dose|6-week, double-blind (DB), randomized, treatment phase (DB Phase): Azilsartan medoxomil High-dose (AZM-H), 40 mg AZM-M
88818300|NCT02235909|Experimental|WITHDRAWAL Azilsartan Medoxomil - Medium dose|Experimental Arm in the Withdrawal Phase, subjects will be randomized (1:1) to continue taking their previously assigned active treatment ( Azilsartan medoxomil MEDIUM dose) that was taken in Double blind OR to be switched to placebo.
88818301|NCT02235909|Experimental|WITHDRAWAL Azilsartan Medoxomil - High dose|Experimental Arm in the Withdrawal Phase, subjects will be randomized (1:1) to continue taking their previously assigned active treatment ( Azilsartan medoxomil HIGH dose) that was taken in Double blind OR to be switched to placebo.
88818302|NCT02235909|Experimental|WITHDRAWAL Phase: PLACEBO to match azilsartan medoxomil MEDIUM DOSE|PLACEBO Arm in the Withdrawal Phase for subjects who were on Azilsartan medoxomil MEDIUM dose) in Double blind then randomized (1:1) to matching placebofor withdrawal phase
88835667|NCT05924555||LcFAOD-patients|Patients with long-chain Fatty Acid Oxidation including CPT2-, CACT-, VLCAD-, LCHAD-, or MTP-deficiency
88835668|NCT05924555||Healthy controls|Controls are matched based on Age, Sex, BMI and comparable activity score assessed using the SQUASH questionnaire
88835669|NCT05924542|Experimental|Intervention Group|"Participants had access to the Kelaa Mental Resilience App for 4 weeks. Thus, participants in the intervention group could complete a maximum of 28 sessions and track a maximum of 28 nights. It was completely left to the user to what extent s/he wanted to engage with the app. The app seeks to translate insights from scientific research on psychology, sleep medicine, and neuroscience into an action-based program. It draws on the tenets of clinical, health, positive, cognitive, biological, and social psychology to foster recovery and growth. Kelaa aims to reduce stress and increase well-being of the user, specifically in the workplace. Users learn new behaviors and best practices through different means, for example, based on CBT and mindfulness based cognitive therapy. The app is designed to implement lifestyle changes through (1) measuring behavior, cognitions, and emotions (tracking module) and (2) providing psycho-educational content (intervention module)."
88835670|NCT05924542|No Intervention|Wait-list Control Group|"Participants in the waitlist control group received no intervention and no tracking opportunity for the duration of the trial (6 weeks), yet they had unrestricted access to treatment as usual within their companies. Upon completion of the trial, participants in the waitlist control group received access to the Kelaa app."
89364643|NCT03296488|Experimental|Nalbuphine Sebacate|receive single dose of NALDEBAIN (150 mg Nalbuphine Sebacate, 75 mg/ml, 2 ml/vial) intramuscularly 24±12 hours before surgery.
89364644|NCT03296488|Active Comparator|Fentanyl Citrate|receive intravenous patient-controlled analgesia with fentanyl through 48 hours after surgery.
88835671|NCT05924529||Samoans in American Samoa|Cognitive assessments will be administered to all participants to assess cognitive status. Gold standard evaluations will be administered to cross-validate the results of the cognitive assessments. Blood will be extracted from all participants to cross-validate results from the prior cognitive assessments and Gold Standard evaluations and conduct plasma and genetic analysis.
89364645|NCT01365858|Experimental|Virtual reality-based cognitive training|
89364646|NCT01365858|Active Comparator|Cognitive rehabilitation (without extra computer training)|
89364647|NCT01365936|Active Comparator|menotrophin|In this prospective trial, women with PCOS (according to Rotterdam criteria) were randomized (80 patients) after GnRH analogue suppression to stimulation with HMG (n=38) or rFSH (n=42) using a low dose step up protocol in ICSI cycles.
89364648|NCT01365936|Active Comparator|recombinant FSH|Patients were randomized after GnRH analogue suppression to stimulation with HMG (n=38) or rFSH (n=42) using a low dose step up protocol in ICSI cycles.
89364649|NCT02462356|Active Comparator|Conventional VATS|Via conventional VATS lobectomy and systematic lymph node dissection for lung cancer
89364650|NCT02462356|Experimental|Uniportal VATS|Via uniportal VATS lobectomy and systematic lymph node dissection for lung cancer
89364651|NCT02462512||FNAB of Thyroid nodule|The Patients with thyroid nodule who are scheduled for FNAB
89364652|NCT01358838|Active Comparator|laser|
89364653|NCT01358838|No Intervention|no laser|
89364654|NCT01334151|Active Comparator|Humalog®|Humalog®, administered subcutaneously on 1 occasion
89364655|NCT01334151|Experimental|BIOD- 105|BIOD- 105 administered subcutaneously on 1 occasion
89364656|NCT01334151|Experimental|BIOD-107|BIOD-107 administered subcutaneously on 1 occasion
89364657|NCT01361958|Experimental|T1 received 0.625 mg NOMAC + 1.5 mg E2|
89364658|NCT01361958|Experimental|T2 received 1.25 mg NOMAC + 1.5 mg E2|
89364659|NCT01361958|Experimental|T3 received 2.5 mg NOMAC + 1.5 mg E2|
89364660|NCT01361958|Experimental|T4 received 2.5 mg NOMAC + Lactose|
88835672|NCT05924490|Experimental|Real-time strategy-based videogame training|Participants played a real-time strategy-based videogame in laboratory setting, Rise of Nations, for 2 hours a day, two days per week, for 5 weeks.
88835673|NCT05924490|Active Comparator|Crystallized intelligence training|Participants completed a series of crossword puzzles each week, for 5-6 weeks. Training sessions were completed at the participants' home or area of preference. Participant received a periodic phone call (2 times per week) from research staff to update any notes or details regarding participants' study progress.
88835674|NCT05924451|Active Comparator|Early loading|The implants will be restored with a PMMA (polymethyl methacrylate) prosthesis in normal occlusion.
88835675|NCT05924451|Experimental|Immediate loading|The implants will be restored with a permanent prosthesis (monolithic zirconia) placed on the implants as an immediate loading.
88835676|NCT05924425|Experimental|Daridorexant 50 mg|"Patients will receive daridorexant 50 mg during one month (Period A or Period B).~Daridorexant is an orally administered dual orexin type 1 and type 2 (OX1 and OX2) receptor antagonist (DORA) being developed for the treatment of insomnia."
88835677|NCT05924425|Placebo Comparator|Placebo-controlled arm|Patients will receive a placebo matching to daridorexant 50 mg during one month (Period A or Period B).
88835678|NCT05924399|Experimental|Affect Labeling Training|Participants complete a total of six training sessions, twice a week for three consecutive weeks. In each session, they spend 40 minutes completing computer-based inhibitory regulation training utilizing four strategies.
88835679|NCT05924373|Experimental|single-dose group|Human Dental Fulp Stem Cells Injection: 1X 10^7 cells/periodontaldefect site.
88835680|NCT05924373|Experimental|two-dose group (low-dose)|Human Dental Pulp Stem Cells Injection: 1X 10^6 cells/periodontaldefect site. Continuous administration twice, with an interval of 89 days between each administration.
88835681|NCT05924373|Experimental|two-dose group (high-dose)|Human Dental Pulp Stem Cells Injection: 1X 10^7 cells/periodontaldefect site. Continuous administration twice, with an interval of 89 days between each administration.
88835682|NCT05924347||Cohort 1|60 adolescent girls (8-10 years old) at increased risk for idiopathic scoliosis development (an older sibling or parent diagnosed with idiopathic scoliosis)
88835683|NCT05924347||Cohort 2|60 adolescent girls or boys with the 22q11.2DS with increased risk for idiopathic-like scoliosis development.
88835684|NCT05924308|Sham Comparator|control group|
88835685|NCT05924308|Experimental|treatment group|
88835686|NCT05924230|Active Comparator|RL 10|Patients of this group will receive Ringer's lactate (RL) 10ml/kg
88835687|NCT05924230|Active Comparator|RL 15|Patients of this group will receive 15ml/kg of Ringer's lactate solution
88835688|NCT05924178|Experimental|experimental group|Before ACL reconstruction,40 minutes of rehabilitation training was performed 3 times a week for 6 weeks, and gotted regular treatment. The ACL reconstruction was followed by a 0.5 year rehabilitation.
88835689|NCT05924178|Active Comparator|control group|Regular rehabilitation training was not performed before ACL reconstruction, got regular treatment. The ACL reconstruction was followed by a 0.5 year rehabilitation.
88835690|NCT05924165|Active Comparator|Opioid group|Patients will be prescribed 5mg Oxycodone, Q6 PRN postoperatively.
88835691|NCT05924165|Active Comparator|NSAID|Patients will be prescribed 10mg Ketorolac, Q6 PRN postoperatively.
88835692|NCT05924139|Experimental|Omega-3 fatty acid|Nordic Naturals (Ultimate Omega) will be used as the intervention at a dose of 4 grams/day (3840 mg total fish oil with 1950 mg EPA and 1350 mg DHA
88835693|NCT05924139|Placebo Comparator|Coconut oil|dose of 4 grams/day
88835694|NCT05924113|Experimental|Post-Lung Transplant|Subjects that received a single or double lung transplants at Mayo Clinic Florida from 1/1/2020 to the present will participate in open sessions of Latin Dance over a 12-week period.
88835695|NCT05924100|Experimental|Luspatercept|
88835696|NCT05924074|Experimental|SF3B1 mutant Myelodysplastic syndromes patients (MDS)|Patients diagnosed with MDS carrying the SF3B1 somatic mutation associated myelodysplastic neoplasm with ring sideroblasts
88835697|NCT05924074|Active Comparator|Monoclonal Gammapathy of Unknown Significance patients (MGUS)|MGUS patients, referred to as normal bone marrow controls
88835698|NCT05924061||Pregnant women with preeclampsia between 20-28 weeks (study group)|Maternal serum cathepsin B and pentraxin 3 levels in 20-28 weeks pregnant women with preeclampsia
89534635|NCT05037591|Placebo Comparator|placebo R|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
88835699|NCT05924061||Healthy pregnant women between 20-28 weeks ( control group)|Maternal serum cathepsin B and pentraxin 3 levels in 20-28 weeks healthy pregnant women ( control group)
88835700|NCT05923983|Experimental|Intervention Group|
88835701|NCT05923983|Other|Control Group|
88835702|NCT05923957||Intervention|High frequency electrical stimulation was done for thirty minutes per day for five days a week for four consecutive weeks. The stimulator provides a biphasic current of 100 Hz frequency. The pulse duration was 200 msec with an (on-off). Stimulus mode (20sec stimulation, 20 sec pause). The maximal stimulation amplitude was 40 - 60 mA
88835703|NCT05923931|Experimental|non-cooling blanket group|Cooling body temperature by: control the temperature of the emergency room to 20-24℃, 4℃ fluid infusion, ice packs, evaporation, etc.
89364661|NCT03039686|Experimental|RO7239361 Low Dose|Participants received low dose RO7239361 SC on specified days of the 48-week DB period. Following the DB period participants received low dose RO7239361 on specified days for up to 192 weeks during the open-label period followed by 24 weeks of follow-up.
88835704|NCT05923931|Active Comparator|Cooling blanket group|On the basis of the cooling methods of non-cooling blanket group, combine the cooling blanket to cool down. The cooling blanket is required to be activated within 30min after admission. The blanket temperature will be set at 4-10℃, and the target body temperature is 38℃.
88835705|NCT05923918|Experimental|test 1|PBK_M2101, 2-Day Regimen
88835706|NCT05923918|Experimental|test 2|PBK_M2101, 1-Day Regimen
88835707|NCT05923918|Active Comparator|active Comparator|active Comparator, 2-Day Regimen
88835708|NCT05923840|Active Comparator|Female Postural Tachycardia Syndrome (POTS) patients without orthostatic hyperpneic hypocapnia|Female POTS patients without orthostatic hyperpneic hypocapnia identified by tilt table testing and respiratory monitoring.
88835709|NCT05923840|Active Comparator|Female POTS patients with orthostatic hyperpneic hypocapnia|Female POTS patients without orthostatic hyperpneic hypocapnia identified by tilt table testing and respiratory monitoring.
88835710|NCT05923840|Active Comparator|Healthy Female vounteers|Healthy Female vounteers
88835711|NCT05923814|Experimental|treatment arm|
88835712|NCT05923801|Active Comparator|BT ECT|Participants showing no response will be switched to BT ECT until remission is achieved.
89364662|NCT03039686|Experimental|RO7239361 High Dose|Participants received high dose RO7239361 SC on specified days of the 48-week DB period. Following the DB period participants received high dose RO7239361 on specified days for up to 192 weeks during the open-label period followed by 24 weeks of follow-up.
89364663|NCT03039686|Placebo Comparator|Placebo|Participants received matching placebo solution subcutaneously (SC) on specified days of the 48-week double-blind (DB) period. Following the DB period participants received low dose or high dose RO7239361 on specified days for up to 192 weeks during the open-label period followed by 24 weeks of follow-up.
89364664|NCT03296410|Experimental|EV71 and two measles attenuated live vaccine|infants vaccinated with enterovirus type 71 inactivated vaccine (human diploid cell) and two measles attenuated live vaccine at 8 months old, and vaccinated with the second dose of enterovirus type 71 inactivated vaccine (human diploid cell) at 9 months old.
89364665|NCT03296410|Experimental|EV71 and attenuated Japanese encephalitis vaccine|infants vaccinated with enterovirus type 71 inactivated vaccine (human diploid cell) and live attenuated Japanese encephalitis vaccine at 8 months old, and vaccinated with the second dose of enterovirus type 71 inactivated vaccine (human diploid cell) at 9 months old.
89364666|NCT03296410|Active Comparator|two measles attenuated live vaccine|infants vaccinated with two measles attenuated live vaccine at 8 months old
89364667|NCT03296410|Active Comparator|live attenuated Japanese encephalitis vaccine|infants vaccinated with live attenuated Japanese encephalitis vaccine at 8 months old
89364668|NCT03296410|Active Comparator|EV71 vaccine|infants vaccinated with enterovirus type 71 inactivated vaccine (human diploid cell) at 8 months old, and vaccinated with the second dose of enterovirus type 71 inactivated vaccine (human diploid cell) at 9 months old.
89364669|NCT05189184|Experimental|Study group|Inductive therapy with Camrelizumab and Apatinib Plus Albumin-bound paclitaxel and cisplatin
89364670|NCT04639089|Experimental|We will apply 10cm plasma contain 1 million platlets on the sternal edge before sternal closure|We will apply 10cm plasma contain 1 million platlets on the sternal edge before sternal closure
88835713|NCT05923801|Active Comparator|RUL ECT|Participants showing no response will continue with RUL ECT until remission is achieved.
88835714|NCT05923762||18-85 years of age|
88835715|NCT05923723|Experimental|Dietary intervention|
88835716|NCT05923723|Placebo Comparator|Placebo|
88835717|NCT05923710|Active Comparator|Primary anterior cruciate ligament repair|Investigators performed arthroscopic primary repair in 18 patients with proximal ACL tears.
88835718|NCT05923710|Active Comparator|Primary anterior cruciate ligament repair and lateral extraarticular tenodesis (LET)|Investigators performed arthroscopic primary repair and lateral extraarticular tenodesis (LET) with iliotibial band in 20 patients with proximal ACL tears.
88835719|NCT05923697|Experimental|AF-EMDR|Intervention: a total of four 90 min. sessions of AF-EMDR twice per week added to TAU.
88835720|NCT05923684|Experimental|NLP Intervention Experimental Arm|20 men with newly diagnosed clinically localized prostate cancers and utilize NLP to extract key content using the top five sentences by NLP probability for key content areas will be generated and will be provided to patients and providers within 2 weeks after each case.
88835721|NCT05923671||Thin Phenotype|Participants with transparent free gingiva of the maxillary central incisor
89364671|NCT04639089|Placebo Comparator|We will apply 10cm saline on the sternal edge before sternal closure|We will apply 10cm saline on the sternal edge before sternal closure
89364672|NCT03290872|Active Comparator|Carpentier Edwards Physio 2 Complete flexible mitral ring|Mitral Valve Annuloplasty Ring Repair using Carpentier Edwards Physio 2 Complete flexible mitral ring
89364673|NCT03290872|Active Comparator|Simplici T Partial flexible mitral annuloplasty ring|Mitral Valve Annuloplasty Ring Repair using Simplici T Partial flexible mitral annuloplasty ring
89364674|NCT01362036|Experimental|TXA127 sc injectable|All cohorts will recieve TXA127; Cohorts receive either 300, 600, or 900 ug/kg daily
89364675|NCT03589300|Other|Persona TM Tibia subjects|Subjects that receive the Persona TM Tibia implant
89364676|NCT04613661||Researcher 1|The first researcher assessing elbow, wrist, and ankle spasticity, respectively
88835722|NCT05923671||Thick Phenotype|Participants with non-transparent free gingiva of the maxillary central incisor
88835723|NCT05923645|Experimental|High frequency repetitive Transcranial Magnetic Stimulation|"Children who have given consent for the study and are fulfilling the inclusion and exclusion criteria will be enrolled and given Transcranial magnetic stimulation (TMS) as per protocol as described below over 12 week along with AI based remedial intervention.~TMS protocol - 5 Hz High frequency rTMS, at 100% RMT, 60 pulses per train, total 10 trains , gap between 2 consecutive trains of 30 sec, at left IPL and left STG localised using 10-20 EEG based system at P3 and P5 respectively , using figure of 8 coil~1st cycle of 10 sessions over 10 consecutive days, 2nd cycle of 5 sessions over 5 consecutive days , 3rd cycle for 5 sessions over 5 consecutive days ; gap of 6 weeks between 2 consecutive cycles Total 3 cycles per patient"
89364677|NCT04613661||Researcher 2|The second researcher assessing elbow, wrist, and ankle spasticity, respectively
89364678|NCT01358916|No Intervention|Usual information policy|No specific intervention
88835724|NCT05923632|Experimental|Pediatric patients with type 1 diabetes|By providing standard diabetes education before the digital game intervention the child who enters the game will be asked to fill in the Child with Type 1 Diabetes Descriptive Information Form the Quality of Life in Children with Type 1 Diabetes Scale and the Diabetes Management Self-Efficacy Scale in Children with Type 1 Diabetes.After the children in the experimental group are informed about the digital game designed according to the The Roy Adaptation Model(RAM) and The Information-Motivation-Behavioral Skills Model(IMB) in diabetes management active participation of the children in the digital game will be ensured for 9 weeks and participation status will be followed in the background of the game.At the end of 9 weeks children will be asked to complete all stages of the game.Children who do not complete the game will be contacted once a week in line with the followup and reminders will be made.At the 12th week(3 weeks after the training) all the scales will be administered again.
88835725|NCT05923632|No Intervention|Pediatric patients with type 1 diabetes receiving routine care|At the beginning of the study, standard diabetes education will be given and they will be asked to fill in the Children with Type 1 Diabetes Information Form, the Quality of Life Scale for Children with Type 1 Diabetes, and the Diabetes Management Self-Efficacy Scale. All scales will be administered again in the 12th week from the beginning of the study.
89001577|NCT04575493|Experimental|Test Group|No of enrolled Pts. 102 Drug Cap. Crano-cure 500mg. Quantity 500 mg Bd Usage 1 cap Bd Duration of study 14 days Follow up 1st follow up after 2 weeks 2nd follow up after 4 weeks
89364679|NCT01358916|Other|Antibiotic therapy guidelines|
89364680|NCT05288504|Experimental|AVTX-002|Approximately 40 subjects will receive AVTX-002 at a dose of 600 mg three times during the study.
89364681|NCT05288504|Placebo Comparator|Placebo|Approximately 40 subjects will receive placebo sourced as normal saline three times during the study.
89364682|NCT01362114|Experimental|Sihogayonggolmoryeo-tang extract|"name of product: 'SIHOGAYONGGOLMORYU TANG EXTRACT GRAN'~standard code for item: 200005676~shape, type: extract(brown)~usage, content: adults;three times a day, each taken before or between meals~dose, standard: 2.5g for each sack, capsulated~storage : airtight container, stored in room temperature~expiration date : 36months after manufacture~macufacturing company: KyungBangnShinYak inc."
89364683|NCT01362114|Placebo Comparator|Placebo; corn flour,|"raw material: total contents(500㎎); cornstarch 50.0%(250.0㎎), 당수화물 49.45%(247.25㎎), caramel pigment 0.5%(2.5㎎), SsangHwa fragrance 0.05%(0.25㎎)~shape, type: extract(brown)~usage, dose: adults: three times a day, 1 sack before or between meals~dose, standard: 2.5g for each sack, capsulated~storage : airtight container, stored in room temperature~expiration date : 36 months after manufacture~manufacturing company: KyungBangnShinYak inc."
89364684|NCT03296254|Experimental|Course A|Body Mindfulness Exercised followed by Sitting Mindfulness Exercises. Written material and sound recordings will be offered as support elements.
89364685|NCT03296254|Experimental|Course B|Sitting Mindfulness Exercises followed by Body Mindfulness Exercises. Written material and sound recordings will be offered as support elements.
89364686|NCT03735290|Experimental|Phase 1b: Cohort 1, ilixadencel + pembrolizumab|3 x 10⁶ DCs (Dendritic Cells) of ilixadencel, 2x over 4 weeks (w). Pembrolizumab I.V. q3w
89364687|NCT03735290|Experimental|Phase 1b: Cohort 2, ilixadencel + pembrolizumab|10 x 10⁶ DCs of ilixadencel, 2x over 4 weeks. Pembrolizumab I.V. q3w
89364688|NCT03735290|Experimental|Phase 1b: Cohort 3, ilixadencel + pembrolizumab|10 x 10⁶ DCs of ilixadencel, 3x over 10 weeks. Pembrolizumab I.V. q3w
89364689|NCT03735290|Experimental|Phase 1b: Cohort 4, ilixadencel + pembrolizumab|Ilixadencel 3 times over 10 weeks: 1st dose 20 x 10⁶ DCs ilixadencel; 2nd dose 10 x 10⁶ DCs; 3rd dose 10 x 10⁶ DCs. Pembrolizumab I.V. q3w
89364690|NCT03735290|Experimental|Phase 2 exp. cohorts HNSCC/NSCLC/Gastric/GEJ|Subjects with HNSCC, NSCLC, gastric or gastroesophageal junction (GEJ) adenocarcinoma. ilixadencel administered intra-tumorally up to 3 times over 10 weeks; dose determined after Phase 1b. Pembrolizumab I.V. q3w according to currently approved doses and indications.
89534636|NCT05037591|Placebo Comparator|placebo S|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
89364691|NCT03735290|Active Comparator|Phase 2 comparator cohorts HNSCC/NSCLC/Gastric/GEJ|Subjects with HNSCC, NSCLC, gastric/GEJ adenocarcinoma receiving active treatment with pembrolizumab I.V. q3w according to currently approved doses and indications.
89364692|NCT01359072|Experimental|Immediate Intervention Treatment|
89364693|NCT01359072|Experimental|Wait list|
89364694|NCT03290716|Experimental|SS+SSSC|Salt substitute plus stepwise salt supply control
89364695|NCT03290716|Experimental|SS only|Salt substitute only
89364696|NCT03290716|Experimental|SSSC only|Stepwise salt supply control only
89001578|NCT04575493|Active Comparator|control group|No of enrolled Pts. 103 Drug Tab. Ciprofloxacin 500mg Quantity 500mg Bd Usage 1 Tab Bd Duration of study 14 days Follow up 1st follow up after 2 weeks 2nd follow up after 4 weeks
89001579|NCT00587119|Experimental|1|Single arm, active treatment
89364697|NCT03290716|No Intervention|control|No salt substitute and no stepwise salt supply control
89364698|NCT04702152|Experimental|Experimental group|This is a within-subject study with a single group of participants
89364699|NCT04669704|Experimental|Tablet application|"A protocol of exercises based on the current scientific evidence will be provided through a tablet application. A follow-up of the use of the application will be carried out. A minimum of 4-week home exercise intervention will be performed, which will have to be carried out daily by the patient autonomously at home for at least 5 days per week, starting after baseline measurement.~The exercise program will be individualized according to each pathology."
89364700|NCT04669704|Active Comparator|Conventional treatment|In the control condition, participants will receive a home exercise program on paper. The exercise program will be the conventionally prescribed one by the Andalusian Public Health Service. Participants will be told to perform exercises during a minimum of 4 week at home for at least 5 days per week, starting after baseline measurement.
89364701|NCT03296176|Experimental|presymptomatic|
89364702|NCT03296176|Experimental|symptomatic|
89364703|NCT03296176|Other|controls|
89364704|NCT03619538|Placebo Comparator|control group|
89364705|NCT03619538|Experimental|Nefopam group|
89364706|NCT01366248||IO Clinic Breast Cancer Patients|Includes patients who are receiving care for their breast cancer at participating Seattle area IO clinics.
89364707|NCT01366248||CSS Match-Control Patients|For each IO clinic patient, an average of two (up to four) matched comparison cases will be recruited from the Washington State Cancer Surveillance System (CSS). Matched comparison cases from CSS will be identified by CSS and confirmed by the FHCRC investigator.
89364708|NCT03290638|Experimental|Dehydrated Human Amnion Chorion Membrane|This membrane was investigated to evaluate its use as an open barrier for guided bone regeneration (GBR) after tooth extraction and to determine whether intentional exposure of this membrane to the oral environment compromises ridge dimensions and bone vitality for implant placement.
89534637|NCT05037591|Placebo Comparator|placebo T|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
89364709|NCT03290638|Active Comparator|Type I Bovine Collagen Membrane|This membrane has been tested as an open barrier for GBR after tooth extraction. The intentional use of this membrane to the oral environment did not compromise ridge dimensions and bone vitality for implant placement.
89364710|NCT05188950|Experimental|treatment group|The intervention involved the participants' use of the mobile application.
89364711|NCT05188950|No Intervention|control group|As usual.
88835726|NCT05923619|Experimental|Total pulpotomy|The coronal pulp tissue was completely removed with a high-speed sterile carbide bur under abundant water coolant. A cotton pellet moistened with 2.5% sodium hypochlorite was used to achieve hemostasis. Following the achievement of hemostasis, an average of 3 mm thick MTA material (Angelus, Londrina, PR, Brazil) was used to cover the pulp chamber. In the same session, the pulp chamber was closed with approximately 2 mm thick flowable glass ionomer cement (Glass Liner, WP), and coronal restoration was completed with composite filling (Estelıte® Sıgma Quıck, Tokuyama).
88835727|NCT05923619|Active Comparator|Root canal treatment|The working length was determined using a 15 K type file and apex locator (Morita Root ZX, Tokyo, Japan) and checked by radiography. The chemomechanical preparation was completed using the R25 (Resiproc, VDW, Munich, Germany) file in the mesial root canals and the R25, R40, and R50 files in the distal root canals, respectively, at the WL. During the chemomechanical preparation, the root canals were irrigated with 2.5% NaOCl after every three pecking motions; and total volume of NaOCl was 10 ml. In the final irrigation, the root canal was irrigated with 5 ml 17% Ethylene diamine tetraacetic acid (EDTA), for 1 minute, following with 2 ml distilled water. Following the retention of 5 ml of 2.5% NaOCl in the root canal for 1 minute, 5 ml of distilled used to neutralize the effect of NaOCl in the root canal.Tthe root canals were filled with the lateral condensation using epoxy-resin-based sealer (AH Plus, Dentsply DeTrey GmbH, Konstanz, Germany).
88835728|NCT05923580|Experimental|Goup-based cardiac telerehabilitation|Group-based cardiac telerehabilitation promotes information, skills, and support for the management of coronary artery disease in coronary patients. The rehabilitation model includes independent familiarization with information content, assignments, and group meetings, as well as the opportunity for a chat and peer support. The intervention is a health professional- lead, and registered rehabilitation model with a start and end.
88835729|NCT05923580|No Intervention|Usual care for cardiac patients|The coronary patient is in primary care under the supervision of a nurse and a doctor.
89364712|NCT03296098|Experimental|ulipristal acetate|Subjects will be administered ulipristal acetate in 5 mg dosages and instructed to take two pills once daily for 6 months.
89364713|NCT01366326|Experimental|Arm 1|Methylnaltrexone bromide
89364714|NCT01822275|Other|Low Dose WBRT|Once the patient has had surgery, patients will receive 6 weeks of radiation therapy with concurrent chemotherapy on protcol. This will be followed by either 6 or a maximum of 12 cycles of adjuvent chemotherapy with Temodar.
89364715|NCT03296020|No Intervention|control group|"After the surgery, during the hospitalization ,the control group would get as is customary in our ENT department :acetaminophen syrup+ syrup oxycode( as necessary).~After the discharge from the hospital - the patients would take( as is customary in our ENT department): acetaminophen syrup ( as necessary) and other painkillers ( as necessary).~The families would ask to follow treatment protocols for 7 days and will fill a questionnarie every day during the 7 days."
89364716|NCT03296020|Experimental|"case group-HONEY"|"After the surgery, during the hospitalization ,the case group would instructed to use honey twice a day( 5 ml- one tea spoon each time)+acetaminophen syrup + syrup oxycode( as necessary).~After the discharge from the hospital - the patients would take:acetaminophen syrup ( as necessary) and other painkillers+honey twice a day( 5 ml- one tea spoon each time) .~The families would ask to follow treatment protocols for 7 days and will fill a questionnarie every day during the 7 days."
89364717|NCT03295942|Experimental|OMP-336B11|Intravenous (in the vein) infusions of OMP-336B11
89364718|NCT04631796|Experimental|LID020098|Lehfilcon A contact lenses worn in both eyes for 2 weeks. Lenses will be removed nightly for cleaning and disinfection.
89364719|NCT05655026|Experimental|x≤300 HFNO or standard oxygen supplementation|bronchoscopy, taking blood gas, taking blood for blood test
89364720|NCT05655026|Experimental|100<x≤200 NIV or HFNO|bronchoscopy, taking blood gas, taking blood for blood test
89364721|NCT05655026|Experimental|x≤100 NIV or intubation|bronchoscopy, taking blood gas, taking blood for blood test, intubation
89364722|NCT03290482||EE Study Patients 2000-2008|"All patients with the diagnosis of EE from the study period 2000 to 2008. Sixty patients participated in the 10 year follow up phone interview and questionnaire. These are the subjects we will contact to see if they are interested in participating in this study.~If interested in participating, subjects will complete:~Evaluation by the PI physical examination~Complete the modified Mayo dysphagia Questionnaire (MDQ) and the Eosinophilic Esophagitis Activity Index (EEsAI) questionnaires~Barium Esophagram with maximal and minimal esophageal diameter measurement~EsophaCap cytology"
88835730|NCT05923554|Active Comparator|Un-congruous single tooth peri implantitis|Patients were treated through non-surgical periodontal treatment for the peri-implant mucositis resolution
88835731|NCT05923554|Placebo Comparator|Congruous single tooth peri implantitis|Patients were treated through non-surgical periodontal treatment for the peri implant mucositis resolution
89001580|NCT00587236||1|Patients with chronic ulcerative colitis and concurrent primary sclerosing cholangitis.
89364723|NCT04625478||Patients having had an osteo-articular infection with Stahylococcus|Patients having had an osteo-articular infection with Stahylococcus managed at the Croix Rousse hospital
88818303|NCT02235909|Experimental|WITHDRAWAL Phase: PLACEBO to match azilsartan medoxomil HIGH DOSE|PLACEBO Arm in the Withdrawal Phase for subjects who were on Azilsartan medoxomil HIGH dose) in Double blind then randomized (1:1) to matching placebofor withdrawal phase
88818304|NCT01404572|Active Comparator|Atazanavir + 10% aspartame|
88818305|NCT01404572|Active Comparator|Atazanavir + 4.2% aspartame|
88818306|NCT01404572|Active Comparator|Atazanavir + 4.2% aspartame and sucralose|
88818307|NCT05588817|Active Comparator|Group 1|Normal control
88818308|NCT05588817|Active Comparator|Group 2|Diagnosed Rhomatoid arthritis patients
88818309|NCT01799135|Experimental|Experimental Arm|"Stereotactic Body Radiation Therapy: either 54 Gy in 3 fractions or 50-60 Gy in 5 fraction over a span of 15 days at most.~DCE-MRI was performed at four time points during therapy: at baseline prior to SBRT, 1-2 days after the first treatment fraction, 1-2 weeks after the end of the SBRT course, and 3 months after completing radiotherapy.~4D-CT scan 3 months after completing radiotherapy."
88818310|NCT01381172|Experimental|Treatment|The treatment group receives the OPTIMIZER System implant and continues with optimal heart failure medical therapy.
88818311|NCT01381172|Other|Control|The Control group will not receive the OPTIMIZER System and will continue with optimal heart failure medical therapy.
88818312|NCT01736267|Experimental|Non-NF2 ABI surgery|All subjects will be part of a single arm involving placement of the Nucleus ABI541 Auditory Brainstem Implant (ABI) device. The Nucleus 24 was discontinued and is no longer available.
88818313|NCT01381406||COPD patients|Patients who are at least 40 years of age and diagnosed with COPD using ICD-9 codes of 491.xx, 492.xx, and 496.xx in an administrative claims database.
88818314|NCT04949919|Experimental|ESRD patients with supervised training|The participants will receive in-hospital supervised exercise training prior to HD
88818315|NCT01799213|Experimental|Active Treatment|Eligible subjects will be randomized to Meloxicam 15 mg po per day (QD) vs placebo
88818316|NCT01799213|Placebo Comparator|Placebo|Eligible subjects will be randomized to Meloxicam 15 mg po QD vs placebo
88818317|NCT04928781|Experimental|Smoking Cessation Counseling - Intervention Arm|Intervention arm. All patients enrolled in the study will be provided with smoking cessation counseling.
88818318|NCT04928781|No Intervention|Retrospective Chart Review - Control Arm|Control arm. A retrospective chart review will be conducted to create a randomly selected cohort of patients that meet inclusion and exclusion criteria and did not receive smoking cessation counseling to serve as the control arm.
88818319|NCT01381952|Experimental|Reduced radiation dose (ClarityIQ)|Low dose DSA (75% reduction compared to normal dose) with novel X-ray imaging technology
88818320|NCT01381952|Active Comparator|Normal radiation dose (AlluraXper)|Normal dose DSA with conventional X-ray technology.
88818321|NCT01815671|Other|Lateral horizontal body position|Subjects randomized to receive colonoscopy in the lateral horizontal position, This is the standard position. The other position - tilt down is the intervention
88818322|NCT01815671|Other|Lateral tilt down body position|Subjects randomized to receive colonoscopy in the lateral tilt down position
88818323|NCT01382108||Normal participants|
88818324|NCT01382108||Meibomian Gland Dysfunction|
88835732|NCT05923541|Experimental|RD13-02 cell infusion|drugs use generic name : RD13-02 CAR-T cell injection; dosage form : Cell injection; dosage : 2×10^8 CAR+ T cells; frequency : Once.
88835733|NCT05923515|Experimental|JMKX000197 Dose 1|eight dose levels of JMKX000197 are evaluated in the dose escalation part.In the expansion cohort part, the biologically active dose(s) confirmed in the dose escalation part with one or more dosing regimens will be selected.
88835734|NCT05923515|Experimental|JMKX000197 Dose 2|eight dose levels of JMKX000197 are evaluated in the dose escalation part.In the expansion cohort part, the biologically active dose(s) confirmed in the dose escalation part with one or more dosing regimens will be selected.
88835735|NCT05923515|Experimental|JMKX000197 Dose 3|eight dose levels of JMKX000197 are evaluated in the dose escalation part.In the expansion cohort part, the biologically active dose(s) confirmed in the dose escalation part with one or more dosing regimens will be selected.
88835736|NCT05923515|Experimental|JMKX000197 Dose 4|eight dose levels of JMKX000197 are evaluated in the dose escalation part.In the expansion cohort part, the biologically active dose(s) confirmed in the dose escalation part with one or more dosing regimens will be selected.
88835737|NCT05923515|Experimental|JMKX000197 Dose 5|eight dose levels of JMKX000197 are evaluated in the dose escalation part.In the expansion cohort part, the biologically active dose(s) confirmed in the dose escalation part with one or more dosing regimens will be selected.
88835738|NCT05923515|Experimental|JMKX000197 Dose 6|eight dose levels of JMKX000197 are evaluated in the dose escalation part.In the expansion cohort part, the biologically active dose(s) confirmed in the dose escalation part with one or more dosing regimens will be selected.
88835739|NCT05923515|Experimental|JMKX000197 Dose 7|eight dose levels of JMKX000197 are evaluated in the dose escalation part.In the expansion cohort part, the biologically active dose(s) confirmed in the dose escalation part with one or more dosing regimens will be selected.
88835740|NCT05923515|Experimental|JMKX000197 Dose 8|eight dose levels of JMKX000197 are evaluated in the dose escalation part.In the expansion cohort part, the biologically active dose(s) confirmed in the dose escalation part with one or more dosing regimens will be selected.
88835741|NCT05923463|Experimental|precision-enhanced feedback email messages|Providers receive an enhanced monthly email containing precision audit and feedback (A&F).
88835742|NCT05923463|Active Comparator|standard feedback email messages|"Providers receive the standard one size fits most A&F monthly email."
88835743|NCT05923450||Tumor Deposits|Colorectal cancers with and without tumor deposits, undergoing curative surgery and adjuvant chemotherapy
88835744|NCT05923320|Experimental|experimental group -assigned intervention|The experimental group was given training on infancy vaccines and breastfeeding. The times of the trainings are determined based on the Postpartum Care Management Guide of the Ministry of Health. In the hospital on the first day after birth, 2-7. days and 30-42. Three days in total, trainings were given on breastfeeding and childhood vaccinations by making home visits. The training content has been prepared by taking into account the Ministry of Health Breastfeeding Guide (5) and the Ministry of Health's vaccination calendar and the Primary Care Vaccine Guide. The trainings will be given to the puerperant women individually. About 30 minutes of training will be given and their questions, if any, will be answered.
88835745|NCT05923320|No Intervention|control grouup|no training was given to the control group
89364724|NCT01656434|Experimental|NOMAC-E2|Participants received a NOMAC-E2 tablet (2.5 mg nomegestrol acetate and 1.5 mg 17ß-estradiol), taken orally once daily for 13 cycles. Each cycle was 28 days. For each cycle, participants received NOMAC-E2 tablets on Days 1 to 24 and placebo tablets on Days 25 to 28.
88835746|NCT05923281|Experimental|Treatment A|K-877 0.2 mg/day
88835747|NCT05923281|Experimental|Treatment B|K-877 0.4 mg/day
88835748|NCT05923281|Placebo Comparator|Control A|Placebo
88835749|NCT05923216|Experimental|High dose|20 patients Intervention: Dietary Supplement: High dose OIT
88835750|NCT05923216|Active Comparator|Low dose|20 patients Intervention: Dietary Supplement: Low dose OIT
88835751|NCT05923151|Experimental|The cranial-caudal mixed medial approach group|75 patients were diagnosed with right colon cancer and underwent the cranial-caudal mixed medial approach for laparoscopic right hemicolectomy with complete mesocolic excision.
88835752|NCT05923151|Other|the medial approach group|73 patients were diagnosed with right colon cancer and underwent the medial approach for laparoscopic right hemicolectomy with complete mesocolic excision.
88835753|NCT05923047|Experimental|Combined group|In-office nasal polypectomy group with mepolizumab
88835754|NCT05923047|Experimental|Medical group|(mepolizumab)
89001581|NCT00587236||2|Patients with chronic ulcerative colitis and known dysplasia or cancer.
89364725|NCT01656434|Active Comparator|NETA-EE|Participants received a NETA-EE tablet (1 mg norethisterone acetate and 10 μg ethinylestradiol), taken orally once daily for 13 cycles. Each cycle was 28 days. For each cycle, participants received NETA-EE tablets on Days 1 to 24; EE 10 μg tablets on Days 25 and 26; and ferrous fumarate 75 mg tablets on Days 27 and 28.
89364726|NCT01319214|Experimental|Inderal, neutral cues|
89001582|NCT00587392||A|Active NDO Endoscopic Full-thickness Plicator Procedure
89001583|NCT00587470|Experimental|1|Atacand treatment.
89001584|NCT00587470|Placebo Comparator|2|Placebo
89001585|NCT04575103|Active Comparator|Antipsychotics|Patients treated with antipsychotics as provided by their psychiatrist in order to treat disease best possible and in accordance with guidelines.
88835755|NCT05923047|Active Comparator|Surgical group|In-office nasal polypectomy
88835756|NCT05923034||had a computed tomography scan of the chest within 24 hours after stroke onset|
88835757|NCT05923021|Experimental|Cheek acupuncture treatment group|"Needle selection: Select disposable trocars（φ0.18 × 25mm） (Wujiang Jiachen acupuncture and moxibustion Instrument Co., Ltd.) .~Acupoints selection: bilateral Sanjiao points, bilateral head points, bilateral neck points, Needling depth: about 5mm-7.5mm, Needle retaining time: 30 minutes, course of treatment: 3 times a week, with a total of 36 cheek acupuncture treatments for 12 weeks."
89001586|NCT04575103|No Intervention|Control|Healthy controls, not treated with antipsychotics.
89001587|NCT00587626|Active Comparator|1|InterX treatment plus rehabilitation exercises
89001588|NCT00587626|Placebo Comparator|2|Inactive InterX treatment plus rehabilitation exercises
89001589|NCT00587665|Experimental|1|Low dose ketamine given
89001590|NCT00587665|Placebo Comparator|2|Saline given as control
89364727|NCT01319214|Experimental|Inderal, drug cues|
89364728|NCT01319214|Experimental|Placebo, neutral cues|
89364729|NCT01319214|Experimental|Placebo, drug cues|
89364730|NCT01331499|Experimental|Bipolar Sealer|Standard of care blood sparing techniques with bipolar sealer
89364731|NCT01331499|Active Comparator|Control|Standard of care blood sparing techniques without the use of bipolar sealer
89364732|NCT01359228|Experimental|Rifaximin|rifaximin (XIFAXAN®) 1650 mg/day (550 mg tablet three times a day) for 14 days
88835758|NCT05923021|Sham Comparator|Sham cheek acupuncture treatment group|"Needle selection: Select disposable flat head trocars（φ0.18 × 25mm） (Wujiang Jiachen acupuncture and moxibustion Instrument Co., Ltd.) .~Acupoints selection: Translate the bilateral Sanjiao points forward by 1cm（towards the front midline of the body）, translate the bilateral head points forward by 1cm, bilateral back points, Needling depth: Retained on the surface of the skin with the help of a cannula， Needle retaining time: 30 minutes, course of treatment: 3 times a week, with a total of 36 times of cheek acupuncture treatments for 12 weeks."
88835759|NCT05923021|Active Comparator|Drug group|"Drug name: Sertraline Hydrochloride Tablets (trade name: Levofloxacin Sertraline, produced by Pfizer Pharmaceutical Co., Ltd., batch number: H10980141),~Dosage form: tablets~Usage: Take orally. 50 mg/d, taken after breakfast.~Depending on the patient's condition, the dosage can be increased to 200mg/d, taken after breakfast, or divided twice a day after meals~Treatment cycle: a total of 12 weeks."
88835760|NCT05922995|Experimental|Treatment Phase|Tasimelteon will be administered in 20 mg capsules on a nightly basis for 4 weeks during the treatment phase.
88835761|NCT05922852||SGLT2i+ARNI|patients in this group received SGLT2i combined with ARNI medication。
89178536|NCT04115891|Experimental|Lavender oil group|"100 % pure, high strength lavender oil inhalation in a separate room for 3 minutes, prior to tooth extractions.~Anxiety scale (FIS) Pain scale 1 (FLACC) Pain scale 2 (WBS) Vital signs 1 (systolic and diastolic blood pressure) Vital signs 2 (heart rate) Vital signs 3 (saturation)"
89364733|NCT01359228|Placebo Comparator|sugar pill|Placebo 1 tablet three times a day for 14 days.
88835762|NCT05922852||SGLT2i only|patients in this group received SGLT2i medication only。
88835763|NCT05922852||ARNI only|patients in this group received ARNI medication only。
88835764|NCT05922852||control|patients in this group received neither SGLT2i nor ARNI。
88835765|NCT05922839|Experimental|Zanubrutinib in the Treatment of Relapsed/Refractory wAIHA|Zanubrutinib 160mg, orally, twice daily, for a minimum of 3 months For effective patients, continue to use for 2 years after achieving optimal therapeutic effect.
88835766|NCT05922813|Experimental|BMI2004 Inj.|hyaluronidase, recombinant
88835767|NCT05922813|Placebo Comparator|0.9% NaCl|Normal Saline
88835768|NCT05922800|Experimental|Electro Press Needle|Body acupoints of Yintang (GV29), Dazhui (GV14), Guanyuan (CV4), bilateral Zigong (EX-CA1), and bilateral Sanyinjiao (SP6) and auricular acupoints of Heart (CO15), Chuiqian (LO4) and Shenmen (TF4) will be selected for treatment. Auricular acupoints on right and left ear will be stimulated alternatively, one side on each time.The treatment will last 40mins for each session, 3 sessions a week (ideally every other day) for a succession of 6 weeks.
88835769|NCT05922800|Active Comparator|Gamma-Oryzanol|The patients in this group were given 10mgx100 tablets/bottle of gamma-oryzanol tablets (Tianjin Lishen Pharmaceutical), 20mg each time, three times a day, for 6 months.
88835770|NCT05922748|Experimental|Patient|suffering from brain damage
88835771|NCT05922748|Active Comparator|healthy control subjects for imaging|healthy control subjects for imaging
88835772|NCT05922748|Active Comparator|healthy control subjects for purely behavioural studies|healthy control subjects for purely behavioural studies
88835773|NCT05922735||Population living with HIV and PrEP users|Population of people living with HIV and PrEP users followed in the infectious disease departments in Ile de France and in the province.
88835774|NCT05922696|Active Comparator|Group A|Group A: Weekly Cholecalciferol: 25 eligible hemodialysis patients on oral cholecalciferol 50.000IU Cholecalciferol, once weekly, for 3 months' duration
89364734|NCT01334307|Experimental|Lung Volume Reduction Coil (LVRC)|Lung Volume Reduction Coil (LVRC)
89001591|NCT00587704|Other|Nerve Stimulation|Use of nerve stimulator for placement of PVB nerve block
89364735|NCT01334307|Placebo Comparator|Control|Standard of Care
89364736|NCT02931396|Experimental|FES intervention|Study participants who are randomized into the intervention group will be fitted with a portable commercially available surface FES device and instructed in its use by a study investigator. Participants will be directed to use the FES 30 minutes a day for the first week, one hour a day during the next week, 90 minutes a day during the third week, and then a minimum of 2 hours per day or 10 hours per week for the next three months at home.
89364737|NCT02931396|No Intervention|Control|Participants will be asked to continue their activities of daily living as usual.
89364738|NCT03607058|Active Comparator|Kinect + Exercise Training|Xbox Kinect and exercise training will be applied together for 8 weeks. Selected balance, coordination and walking exercises according to the individual needs of patients. A treatment session in this arm will consist of Kinect games for 40 minutes and exercise training for 20 minutes. In this arm, patients will play each game as two repetitions. Each game lasts about 3-4 minutes, and patients will be seated for resting between the games. After 10 weeks washout period only exercise training will be applied for 8 weeks.
89364739|NCT03607058|Active Comparator|Exercise Training|Exercise training will be applied for 8 weeks. Selected balance, coordination and walking exercises according to the individual needs of patients. After 10 weeks washout period exercise training and Xbox Kinect will be applied together for 8 weeks.
89364740|NCT01366482|Experimental|Drug-eluting balloon|Subjects are randomized to have a lesion treated with a paclitaxel-coated balloon Intervention: Cotavance Drug-Eluting Balloon
89364741|NCT01366482|Experimental|Plaque excision + drug-eluting balloon|Subjects are randomized to have a lesion treated with plaque excision (PE) followed by treatment with a paclitaxel-coated balloon Intervention: SilverHawk/TurboHawk + Cotavance Drug-Eluting Balloon
89364742|NCT01366482|Experimental|Severely Ca++ Group|Subjects with a severely calcified lesion will be assigned to a non-randomized arm and treated with plaque excision followed by a drug-eluting balloon Intervention: SilverHawk/TurboHawk + Cotavance Drug-Eluting Balloon
89534638|NCT05037591|Experimental|sea grape extract A|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
89178537|NCT04115891|Sham Comparator|Control group|"No application prior to interventions. No lavender oil inhalation.~Anxiety scale (FIS) Pain scale 1 (FLACC) Pain scale (WBS) Vital signs 1 (systolic and diastolic blood pressure) Vital signs 2 (heart rate) Vital signs 3 (saturation)"
89178538|NCT00862277||Group 1: Menactra® from Previous Studies|Subjects previously received only one dose of meningococcal vaccine, Menactra® in Study MTA04, MTA12, MTA19, or MTA21.
89178539|NCT00862277||Group 2: Menomune® from Previous Study|Subjects previously received only one dose of meningococcal vaccine, Menomune® in Study MTA04
89364743|NCT01366560|Experimental|GSK962040|The subjects will be administered GSK962040 125 mg tablet as a single dose on Day 1 of study treatment visit. After 2 hours, the subjects will be administered wireless motility capsule. The subjects will be observed for expulsion of WMC in stool. Each subject will attend the clinical unit for two study treatment visits which will be separated by at least one week.
89364744|NCT01366560|Placebo Comparator|Placebo|The subjects will be administered placebo tablet as a single dose on Day 1 of study treatment visit. After 2 hours, the subjects will be administered wireless motility capsule. The subjects will be observed for expulsion of WMC in stool. Each subject will attend the clinical unit for two study treatment visits which will be separated by at least one week.
89364745|NCT05172128|Experimental|Blueberry supplementation|All participants will receive 18 grams lyophilized blueberry supplement mixed with water twice daily for 12 weeks.
89364746|NCT02461030|Experimental|CSPR + NS treatment|"In-office and at home Colgate sensitive pro-relief - CSPR~Intervention: Non-surgical periodontal treatment (full-mouth debridement, scaling and root planing with ultrasonic/hand instruments) associated with In-office application of Colgate Sensitive Pro-Relief (CSPR) + tooth brushing with at home CSPR toothpaste during 8 weeks."
89364747|NCT02461030|Placebo Comparator|Villevie® + NS treatment|"In-office Villevie® prophy paste + Colgate Toothpaste~Treatment: In-office application of a Villevie® (fluoride-free) prophy paste + tooth brushing with a Colgate Cavity Protection Toothpaste during 8 weeks, after non-surgical periodontal treatment. (Full-mouth debridment/ Scaling and root planing with ultrasonic/hand instruments)"
89364748|NCT01359384||affected patients|25 patients suffering from severe immune deficiency under immunoglobulin therapy
89364749|NCT01359384||non-affected patients|25 matched controls not suffering from severe immune deficiency
88835775|NCT05922696|Active Comparator|Group B|Group b: Monthly Cholecalciferol: 25 eligible hemodialysis patients on oral cholecalciferol 200.00IU Cholecalciferol, once monthly, for 3 months' duration
88835776|NCT05922670|Experimental|SGM BH-Works Implementation|For this phase of the study, the adapted version of the BH-works program (SGM BH-Works) will be implemented into LGBTQ+ Community Organizations. The BH-Works program offers screening, training, and referral coordination.
88835777|NCT05922631|Experimental|APRV group|In APRV group, ventilator parameters were set according to the study protocol, P high: Tidal volume (VT) was set at 6ml/kg of ideal body weight, and plateau pressure (Pplat) was measured. Initial Phigh was set at Pplat, usually 20-32 cmH2O. The APRV end-expiratory flow rate was set at 75% of the peak expiratory flow rate.
88835778|NCT05922631|Placebo Comparator|LTV group|The ARDSnet method was used for LTV group mechanical ventilation, and the tidal volume was set according to 4-8ml/kg, so that the Pplat was <30cmH2O
88835779|NCT05922592|Experimental|The sinus membrane will be elevated by using balloon technique with simultaneous Implant placement.|
89178540|NCT00862277||Group 3: Control|Meningococcal vaccine-naive age matched subjects
89178541|NCT04120337|Experimental|RemovAid Device + lidocaine patch|Test device with lidocaine patch for local anesthesia
89178542|NCT04120337|Experimental|RemovAid Device + lidocaine injection|Test device with lidocaine injection for local anesthesia
89178543|NCT04120337|Active Comparator|Standard removal technique + lidocaine injection|Standard technique involves a scalpel, forceps, and tweezers with lidocaine injection for local anesthesia
89178544|NCT00852995|Experimental|A - Low Q7D|Low dose HP802-247, applied at each visit
89178545|NCT00852995|Experimental|B - Low Q14D|Low dose HP802-247 applied at Visits 1, 3, 5, 7, 9, 11 and Placebo at Visits 2, 4, 6, 8, 10, and 12
89178546|NCT00852995|Experimental|C - High Q7D|High dose HP802-247, applied at each visit
89178547|NCT00852995|Experimental|D - High Q14D|High dose HP802-247, applied at Visits 1, 3, 5, 7, 9, 11 and Placebo at Visits 2, 4, 6, 8, 10, and 12
89178548|NCT00852995|Placebo Comparator|E - Vehicle|Placebo (Vehicle), applied at each visit
89178549|NCT00701987|Experimental|1|ALS-357 applied topically twice weekly for four weeks.
89178550|NCT00701987|Experimental|2|ALS-357 applied topically every other day for four weeks.
89364750|NCT03295864|Experimental|Patients with Chiari type 1 malformation|Tympanometry measurement at inclusion and 6 months after surgery
89364751|NCT03295864|Experimental|Healthy volunteers|Tympanometry measurement at inclusion. Every healthy volunteer will be match with a patient for his age and his BMI (body mass index).
89364752|NCT05190276||The hematoma group|with symptomatic epidural hematoma after surgery
89364753|NCT05190276||The control group|without symptomatic epidural hematoma after surgery
89364754|NCT01599494|Experimental|Single-Dose MK-8962 + recFSH|
89178551|NCT00701987|Experimental|3|ALS-357 applied topically once daily for four weeks.
89178552|NCT00701987|Experimental|4|ALS-357 applied topically twice daily for four weeks.
89178553|NCT04117061|No Intervention|Control|Patient gets usual diagnostic path: after inconclusive ultrasound is refered to CT scan.
89364755|NCT01599494|Active Comparator|Reference Group recFSH only|
89364756|NCT03295786|Placebo Comparator|Placebo|Patients randomized to this group will receive 6 monthly infusions of placebo/vehicle
89364757|NCT03295786|Experimental|CDNF mid-dose|Patients randomized to this group will receive 6 doses of CDNF titrated to mid-dose
89364758|NCT03295786|Experimental|CDNF high-dose|Patients randomized to this group will receive 6 doses of CDNF titrated to high-dose
89364759|NCT02462278|Experimental|TempuRing|Women will wear the continuous temperature sensor, TempuRing, for 3 menstrual cycles.
89364760|NCT03198052|Experimental|CAR-T cell therapy group|Patients will receive 3 or more cycles of the CAR-T cells treatment via systemic or regional injection, from 1x10e6/kg-10x10e6/kg weight.
89534639|NCT05037591|Experimental|sea grape extract B|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
89364761|NCT03194932|Experimental|Treatment|"In Part 1, venetoclax with cytarabine will initially be given at dose level 1 and escalated based on tolerability. Idarubicin will be given only at dose level 4.~Note: Part 1 has been completed.~Two expansion cohorts will be enrolled:~Cohort A will be a group of 12 participants receiving the recommended phase 2 doses (RP2D) of venetoclax plus cytarabine.~Cohort B will be a group of 12 participants receiving the RP2D of venetoclax plus cytarabine and idarubicin.~Intrathecal Triple Therapy (ITMHA) will be given prior to cycle 1. Patients without evidence of central nervous system (CNS) leukemia will receive no further IT therapy during cycle 1. Patients with CNS disease will receive weekly ITMHA beginning on day 8 until the cerebrospinal fluid becomes free of leukemia.~Cohort C: Participants will receive venetoclax PO on days 1-21, azacitidine IV on days 1-7, and cytarabine Q12H on days 8-11."
89364762|NCT03144388|Experimental|Variable Stepping Training|High intensity stepping training in multiple environments, including overground, on a treadmill and on stairs.
89364763|NCT03144388|Active Comparator|Variable Non-specific Training|High intensity non-stepping training, including balance, strength, and cycling tasks
88835780|NCT05922592|Experimental|The sinus membrane will be elevated by using Densah burs with simultaneous Implant placement|
88835781|NCT05922553|Experimental|Active Ingredient Mukbang|Active Ingredient Mukbang will be allocated to the participants in the experimental group. The videos which presented the food images, eating sound and a relaxing and pleasant atmosphere will be sent in sequence through the short video platforms on the smart phone to the participants in the experimental group.
89364764|NCT03290170|Experimental|Measured resection technique|Measured resection surgical technique
89364765|NCT03290170|Experimental|Gap Balancing Technique|Gap Balancing surgical technique
89364766|NCT03037580|Experimental|Oral treprostinil|Sustained-release oral tablets for TID administration
89364767|NCT03037580|Placebo Comparator|Placebo|Placebo (sugar pill) for TID oral administration
89364768|NCT03290092|Experimental|Treatment|
89364769|NCT03290014||Good sleepers|COPD patients with good sleep quality according to CASIS score will be studied with polysomnography, actigraphy and OSLER test
88835782|NCT05922553|Active Comparator|Common Mukbang|Common Mukbang on short video platforms will be allocated to the participants in the conditional group. The Mukbang videos which made and uploaded by popular Mukbang makers will be sent in sequence through the short videos platforms on the smart phone to the participants in the experimental group.
88835783|NCT05922553|Placebo Comparator|General short videos|General short videos without food cues will be allocated to the participants in the placebo control group. There will be no restrictions on the type of short video platforms and specific video content.
88835784|NCT05922540||those with favorable prognosis|
88835785|NCT05922540||those with unfavorable prognosis|
88835786|NCT05922488|Experimental|Umbilical cord milking|In the cesarean section or vaginal delivery, the obstetrician will gently grasp the uncut umbilical cord and squeeze it from the placenta several times toward the infant usually within 20 seconds.
88835787|NCT05922488|Experimental|delayed cord clamping|In the cesarean section or vaginal delivery the delivering obstetrician will wait at least 60 s before clamping the umbilical cord. Infants will be dried and will be given gentle tactile stimulation to promote the respiratory effort.
88835788|NCT05922475|Experimental|Post-exercise protein|Consumed 40 g of supplemental protein immediately after exercise sessions and in between breakfast and lunch on non-exercise days.
88835789|NCT05922475|Experimental|Pre-sleep protein|Consumed 40 g of supplemental protein 30 minutes before sleep every day.
89364770|NCT03290014||Bad sleepers|COPD patients with poor sleep quality according to CASIS score will be studied with polysomnography, actigraphy and OSLER test
88835790|NCT05922475|Placebo Comparator|Resistance exercise training only|Did not consume supplemental protein.
88835791|NCT05922436|Experimental|QLG2071|QLG2071 25mg: 50ml
89364771|NCT03295708|Experimental|experimental group|the experimental group will be given 4 fish oil capsules (1g/one capsule)twice daily after two meals at roughly the same time each day,lasting for the first 6 months.fish oil capsule will be provided by the Hunan Kangqi100 Biological Technology Co.Ltd.
89364772|NCT03295708|Placebo Comparator|control group|the control group will be given 4 soybean oil capsules ( placebo capsule,1g/one capsule) twice daily after two meals at roughly the same time each day,lasting for the first 6 months.placebo capsule will be provided by the Hunan Kangqi100 Biological Technology Co.Ltd.The placebo capsule's appearance and flavor are made the exactly the same as the fish oil capsules .
89364773|NCT05155826|No Intervention|standard care (control group)|Patient benefit the standard care during the placement of Cook's balloon (standard care).
89364774|NCT05155826|Experimental|standard care and virtual reality (experimental group)|Patient benefit the standard care during placement of Cook's balloon (standard care) with the use of a virtual reality.
89364775|NCT05154734|Experimental|Belimumab|Belimumab will be intravenously administered with a dose of 10mg/kg on Days 0,14 and28, then every 28 days until week 48, with a final evaluation at week 52.
89364776|NCT03289624|Experimental|SHARE for Chronic Conditions|"Six weekly SHARE for Chronic Conditions (SHARE-CC) sessions will be conducted in the dyad's home or another location preferred by the participants. A care plan (the SHARE plan) is created that reflects the mutual decisions made by the dyad as a result of their participation in the SHARE-CC program. The SHARE plan is intended to help the caregiver (CG) ensure the PWCC's values and preferences are supported when decisions have to be made in an emergency or in the end stages of the disease. SHARE plans will be documented in a notebook that also contains information on key topics and provides links to local and online resources and services."
89364777|NCT03289624|No Intervention|Health Coaching|Six 30-minute weekly telephone calls to provide information and education related to the PWCC's conditions and information about services and care options will be conducted.
89364778|NCT01183520|Active Comparator|90 grams of Salmon|Subjects will consume 90 grams of salmon twice a week for 4 weeks
88835792|NCT05922436|Active Comparator|Cleviprex®|Cleviprex® 25mg: 50ml
89364779|NCT01183520|Active Comparator|180 grams of salmon|Subjects will consume 180 grams of salmon twice a week for 4 weeks
89364780|NCT01183520|Active Comparator|270 Grams of Salmon|Subjects will consume 270 grams of salmon twice a week for 4 weeks
89364781|NCT02978404|Experimental|Radiosurgery and Nivolumab|"Interventions: Nivolumab (240mg IV q2week or 480mg IV q4week) and Radiosurgery (15-20 Gray (Gy) in 1 fraction)~Upon entering this trial, patients with metastatic brain disease(s) will receive Nivolumab. One to 2 week after receiving the first dose of Nivolumab, radiosurgery will be delivered at doses ranging from 15 to 20 Gy in 1 fraction to the brain metastases to a maximum volume of 10 cubic centimeter."
89364782|NCT04489186|Experimental|All subjects|Single arm feasibility study with a wearable device intervention for cardiorespiratory and activity monitoring in subjects with cystic fibrosis.
89364783|NCT04441918|Experimental|Test group|
89364784|NCT04441918|Experimental|Control group|
89364785|NCT03289546|Experimental|Mindfulness training only|1 mindfulness training class (1 hour) every week for 8 weeks.
89364786|NCT03289546|Experimental|Aerobic training only|3 aerobic training sessions (1 hour) per week for 12 weeks.
89364787|NCT03289546|Experimental|mindfulness + aerobic training|2 aerobic training sessions + 1 mindfulness training class every week for 8 weeks, then continue with 3 aerobic training sessions/ week for 4 additional weeks.
89364788|NCT03289546|No Intervention|Usual care|
89364789|NCT01331577|Experimental|Cognitive behavioural Intervention|
89364790|NCT01331577|Experimental|Integrative Kinesiology Intervention|
88835793|NCT05922384|Experimental|7shRNA modified CD34+stem cells|Patients undergo high-dose chemotherapy or chemoradiotherapy according to institutional guidelines and then received hematopoietic stem cell transplant on day 0
88835794|NCT05922371||Sepsis|Adult patients admitted to critical care with a presumed diagnosis of sepsis.
89364791|NCT01331577|No Intervention|Waiting-List control group|
89364792|NCT04735718|Experimental|Cerviron vaginal ovules|Since Cerviron® has an innovative composition, we preferred an exploratory approach for the design of the present clinical investigation. The main objectives and clinical endpoints are the performance and the safety profile of the investigational device.
89364793|NCT03289468||Group1|Endometrial Benign Disease
88835795|NCT05922371||Cardiac surgery|Adult cardiac surgery patients that are free from infection undergoing their first cardiac surgery.
88835796|NCT05922358|Experimental|hypersensitivity group|Corresponding intervention measures are given for different levels of hypersensitivity reactions
89178554|NCT04117061|Active Comparator|Observation|Patient after inconclusive primary evaluation is observed in emergency room for 8-12 hours and after the clinical evaluation, laboratory results and ultrasound examination is repeated.
89364794|NCT03289468||Group2|Endometrial Cancer and Precancerous Lesions
89364795|NCT04441606|Experimental|Different types of cancer|"The study population will include up to 50 patients with disease in whom a diagnostic challenge is met, including but not limited to:~Inconclusive findings on 18F-FDG PET/CT or other imaging modalities.~Better delineation of tumor extent prior to therapy~Malignancies known to show variable avidity to FDG and at times, no uptake at all (e.g. Exocrine Pancreatic cancer, Gastric carcinoma, Mucin-producing or Signet-ring carcinoma).~Patients unable to optimally comply with the required preparation for FDG imaging.~The study population will include only patients treated in Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel, and referred by their attending physicians, of whom are part of the hospital staff."
89364796|NCT03532191|Experimental|PrEP-OI Intervention|All clinics that have crossed over to initiate the intervention at this time. The order of crossover is determined at random.
89364797|NCT03532191|No Intervention|Control until randomized for intervention|All clinics that have not yet initiated the intervention at this time (i.e., control clinics). A new clinic will cross over to receive the intervention each month, with the order of clinic crossover determined at random, until all clinics are receiving the intervention.
89001592|NCT00587704|Other|Anatomic landmarks|Use of anatomic landmarks for placement of PVB block
89178555|NCT00592319|Experimental|PDL+Celebrex|endoscopic treatment with once-time PDL radiation at 6.0-8.0 J on laryngeal papilloma, followed by oral taking of 9-month Celebrex (100mg, BID), in 15 subjects
89364798|NCT01331655|Experimental|Arm 1|
89364799|NCT01331655|Experimental|Arm 2|
89364800|NCT01331655|Active Comparator|Arm 3|
88835797|NCT05922345|Experimental|TQB2450 injection + docetaxel injection matching placebo + AL2846 capsules|TQB2450 injection combined with docetaxel injection matching placebo and AL2846 capsules 21 days as a treatment cycle.
88835798|NCT05922345|Active Comparator|TQB2450 matching placebo + docetaxel injection + AL2846 matching placebo|TQB2450 matching placebo combined with docetaxel injection and AL2846 matching placebo 21 days as a treatment cycle.
88835799|NCT05922306|Active Comparator|Continuous Combination Therapy Cohort|Patients with primary CHB with HBsAg ≥ 1500 IU/ml and HBV-DNA < 500 IU/ml and patients with CHB after treatment with NAs will be enrolled. After fully informed consent, pegylated interferon alpha-2b 180µg will be administered by subcutaneous injection once a week for up to 96 weeks.
89178556|NCT00592319|Active Comparator|standard surgery|"once-time and routine surgery, with either of carbon dioxide (CO2) laser radiation at 10.0-20.0 W or cold surgery with microinstruments, in 15 subjects"
89364801|NCT03295474||Rehabilitation using telehealth technology|
89364802|NCT01331733||hMG-HP|Patients with a condition
89364803|NCT01331733||hMG-HP + GnRH antagonist|Patients with a condition
89364804|NCT01334385||OEF/OIF Veterans through VA ECHCS|
89364805|NCT01085578|Placebo Comparator|Cohort1|CG400549/placebo
89364806|NCT01085578|Placebo Comparator|Cohort2|CG400549/placebo
89364807|NCT01085578|Other|Cohort3|CG400549
89364808|NCT03289390||Acetaminophen to close PDA|Infants with PDA treated with acetaminophen beyond 14 days of life or in whom acetaminophen is used due to contraindication to ibuprofen
89364809|NCT03289312||Sepsis|Diagnosis of new onset sepsis within 24h without history of tumor, hematological or immunological disease, and treatment with chemotherapy agents or corticosteroids within 6 months prior to or during the hospitalization.
89364810|NCT03289312||Health control|Health vonlunteers
89534640|NCT05037591|Experimental|sea grape extract C|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
89001593|NCT00587821||1|The first 250 samples will be used as a training set and results of these breast biopsies (benign or malignant) will be used to determine the peptide profile characteristic of a diagnosis of breast cancer on biopsy.
89364811|NCT04488796|Experimental|Assigned Strategies: Opt-in|"Participants in this group will be assigned two behavioural strategies under the theme of moving more and will be asked to Place a check in the box [agree] if you will breakup your sitting throughout your work hours by X this week. The strategy statement is followed up by; OR, click the next button at the bottom. Within the opt-in condition, the default is to not participate (by clicking next): participants are not required to explicitly state they do not want to do the strategy"
89364812|NCT04488796|Experimental|Assigned Strategies; Active Choice|"Participants in this group will be assigned two behavioural strategies under the theme of moving more. In the Active choice condition, participants will be required to either, Place a check in one box: I will break up my sitting throughout my work hours by [strategy] this week or, I will not break up my sitting throughout my work hours by [strategy] this week."
88835800|NCT05922306|Experimental|Pulsed Combination Therapy Cohort|Patients with primary CHB with HBsAg ≥ 1500 IU/ml and HBV-DNA < 500 IU/ml and patients with CHB after treatment with NAs will be enrolled. After fully informed consent, pegylated interferon alpha-2b 180µg will be administered by subcutaneous injection once weekly for 8 weeks of treatment and discontinued for 4 weeks up to 96 weeks.
88835801|NCT05922228|Experimental|Neural flossing with proprioceptive neuromuscular facilitation|nerve flossing technique protocol along with contract relax technique of proprioceptive neuromuscular facilitation is used
88835802|NCT05922228|Active Comparator|Neural flossing without proprioceptive neuromuscular facilitation|only nerve flossing technique protocol is used
88835803|NCT05922189|Experimental|SBS Decompression Technique|The technique was preformed until the investigator felt a relaxation of the structures, with a maximum duration of 5 minutes.
88835804|NCT05922189|Placebo Comparator|Placebo Technique|The technique was preformed during 2 minutes.
88835805|NCT05922163|Experimental|Intervention Group|Receive the usual blood transfusion education (i.e. Zoom lecture) with the developed VR (Virtual Reality) video education.
88835806|NCT05922163|No Intervention|Control Group|Receive the usual blood transfusion education (i.e. Zoom lecture) only.
88835807|NCT05922150|Experimental|LLLT and ozone group|administered of low level laser therapy and ozone gel after extraction of impacted mandibular third molar
88835808|NCT05922150|Experimental|LLLT group|administered of low level laser therapy after extraction of impacted mandibular third molar
88835809|NCT05922150|Experimental|ozone group|administered of low ozone gel after extraction of impacted mandibular third molar
88835810|NCT05922150|No Intervention|control group|routinely extraction of impacted mandibular third molar
88835811|NCT05922137|Placebo Comparator|Usual Diet advice|Usual diet advice + standard medical treatment
88835812|NCT05922137|Active Comparator|ORIENT diet intervention|6 month intervention of ORIENT diet + standard medical treatment
88835813|NCT05922111|Experimental|cervical ripening balloon for 1 hour|Eligible women will undergo the usual procedure of CRB insertion using a double lumen Cook cervical ripening balloon (CCRB). The CRB will be removed approximately after an hour in the intervention group and thereafter, the women will proceed amniotomy or Pitocin use at the discretion of the labor and delivery physician
89364813|NCT04488796|Experimental|Assigned Strategies; Enhanced Active Choice|"Participants in this group will be assigned two behavioural strategies under the theme of moving more. In the Enhanced Active Choice condition, participants will to required to choose between two alternatives: I will break up my sitting throughout my work hours this week by [strategy] to reduce my risk of diabetes, mental health issues and other detrimental health outcomes and I want to win the eGiftcard or, I will not break up my sitting time during my work hours by [strategy] this week even if it means I increase my risk of developing diabetes, mental health issues and other detrimental health outcomes and I don't care about winning an eGiftcard"
88835814|NCT05922111|Active Comparator|cervical ripening balloon for 12 hours|Eligible women will undergo the usual procedure of CRB insertion using a double lumen Cook cervical ripening balloon (CCRB). The CRB will be removed approximately after 12 hours in the control group and thereafter, the women will proceed amniotomy or Pitocin use at the discretion of the labor and delivery physician
89364814|NCT04488796|Experimental|Choice of Assignment; Opt-in|"Those opting to be assigned strategies (Choice Strategy Assignment group) will be assigned two random strategies, just like the No Choice Strategy Assignment group; however, they remain different from the No Choice Strategy Assignment group because they were given and chose the option to be given strategies. Those selecting to choose and manage their own strategies Choice Strategy Self-Selection group will be presented the same ten strategies each week, in random order, and will have the option to choose two strategies. The strategies can remain the same or change from week to week."
89364815|NCT04488796|Experimental|Choice of Assignment; Active Choice|"Those opting to be assigned strategies (Choice Strategy Assignment group) will be assigned two random strategies, just like the No Choice Strategy Assignment group; however, they remain different from the No Choice Strategy Assignment group because they were given and chose the option to be given strategies. Those selecting to choose and manage their own strategies Choice Strategy Self-Selection group will be presented the same ten strategies each week, in random order, and will have the option to choose two strategies. The strategies can remain the same or change from week to week."
89364816|NCT04488796|Experimental|Choice of Assignment; Enhanced Active Choice|"Those opting to be assigned strategies (Choice Strategy Assignment group) will be assigned two random strategies, just like the No Choice Strategy Assignment group; however, they remain different from the No Choice Strategy Assignment group because they were given and chose the option to be given strategies. Those selecting to choose and manage their own strategies Choice Strategy Self-Selection group will be presented the same ten strategies each week, in random order, and will have the option to choose two strategies. The strategies can remain the same or change from week to week."
89364817|NCT00897104|Experimental|1|Rizatriptan
89364818|NCT00897104|Experimental|2|Sumatriptan
88835815|NCT05922098|Experimental|experimental group|Texture Modified Foods Manual for chewing dysfunctions (including IDDSI)
88835816|NCT05922098|No Intervention|control group|Traditional Soft Food Care Manual
88835817|NCT05922072|Active Comparator|Long NPO group|6,4 and 2 hours NPO for solids/ formula milk, breast milk and clear fluid respectively
88835818|NCT05922072|Experimental|Short NPO group|6,4 and 1-hour NPO for solids/ formula milk, breast milk and clear fluid respectively
88835819|NCT05922020|Active Comparator|"Conservative O2"|During the first treatment session, which will last for 40 minutes, O2 supplementation will be titrated to an SpO2 between 90% and 94%.
88835820|NCT05922020|Experimental|"Liberal O2"|During the second treatment session, which will last for 40 minutes, O2 supplementation will be titrated to an SpO2 > 96%.
89364819|NCT00897104|Placebo Comparator|3|Placebo
89364820|NCT03289156|Active Comparator|Arousal Reappraisal|Brief educational intervention about the stress response and arousal reappraisal
89364821|NCT03289156|Active Comparator|Exercise|Three 5-minute bouts of aerobic exercise at increasing intensities
89364822|NCT03289156|Experimental|Arousal Reappraisal + Exercise|Brief educational intervention about the stress response and arousal reappraisal followed by three 5-minute bouts of aerobic exercise at increasing intensities with practice applying the arousal reappraisal learned earlier.
88835821|NCT05921929|Experimental|One single oral dose per participant|
89364823|NCT03289156|No Intervention|Control|Time-matched rest
89364824|NCT03289078|Experimental|Thermal care|Spa Treatment realised daily 6 days a week during 18 days
89364825|NCT03289078|No Intervention|Standard Care|Usual care
89364826|NCT00792506|Experimental|ITF2357|Eligible patients had to be treated with weekly single doses of ITF2357 according to the above mentioned treatment plan.
89364827|NCT03288922|Experimental|Limited BF OL-HDF with SHF|Limited blood flow pre-dilution online hemodiafiltration using super high-flux dialyzer which had larger pore size than standard high-flux dialyzer was assigned as the new intervention to compare the efficacy of protein-bound toxin removals with the control period.
89364828|NCT03288922|Active Comparator|High-efficiency OL-HDF|High-efficiency post-dilution online hemodiafiltration using standard high-flux dialyzer was assigned as the control period.
88835822|NCT05921890|Experimental|GS3-007 oral liquid|36 subjects，12 subjects in each dose group. Two dose groups were planned: 0.8 mg/kg and 1.6 mg/kg once a day for 4 weeks. According to the research progress of 1.6mg/kg QD, it was decided whether to add 0.8 mg/kg twice a day for 4 weeks.
88835823|NCT05921877||Patients with functional hypothalamic amenorrhea|Women aged 15-34 years Diagnosis of functional hypothalamic amenorrhea (for at least 2 years) No interventions to be administered
88835824|NCT05921877||Healthy controls|Women aged 15-34 years Normal menstrual cycles No interventions to be administered
89364829|NCT02462200|Active Comparator|BCS Arm (breast-conserving surgery - standard of care)|"Defined as partial mastectomy, lumpectomy, or local excisional biopsy with or without needle/wire localization~The ICG will be prepared per manufacturer instructions and diluted to allow for intravenous dosing up to 0.5 mg/kg (except for those patients with iodine or seafood allergies or in cases where the goggles are unavailable for use).~Following the BCS procedures, the surgeon or a study team member will don the goggles and state the NIR fluorescence margin information of the excised primary tumor specimen and of and CSM that are taken."
88835825|NCT05921851||cardiac arrest|Cardiac arrest group: Patients who experience cardiac arrest during emergency diagnosis and treatment will use the time of cardiac arrest as the event time.
88835826|NCT05921851||control|The patient did not experience sudden cardiac arrest during the emergency diagnosis and treatment period, and was treated at the 24-hour time window in the emergency roomCollect data and use the end of the window as the event time.
88835827|NCT05921838||ET patients|patients suffer from primary thrombocytosis
89364830|NCT02462200|Experimental|CSM Arm (breast-conserving surgery with cavity shave margins)|"Partial mastectomy, lumpectomy, or local excisional biopsy with or without needle/wire localization with the addition of additional tissue specimens from all 6 margins (anterior, posterior, superior, inferior, medial, lateral) of the wound cavity if possible. In cases where an additional margin would involve the skin at the anterior margin and/or the pectoral muscle at the posterior margin, only the 4 (or 5) remaining margins should be obtained~A margin thickness of 1 cm will be the defined goal to establish uniformity among different surgeons and allow for appropriate pathological evaluation~The ICG will be prepared per manufacturer instructions and diluted to allow for intravenous dosing up to 0.5 mg/kg (no iodine or seafood allergies).~Following the BCS procedures, the surgeon or a study team member will don the goggles and state the NIR fluorescence margin information of the excised primary tumor specimen and of any CSM that are taken."
89364831|NCT04488718|Experimental|EnergieShake® Junior Powder Complete (test)|EnergieShake® Junior Powder Complete will be consumed by children, as a supplement to normal diet, over a period of 7 day period to determine its acceptability (liking, compliance) and tolerance (gastro-intestinal tolerance). The dose will be the same as currently consumed product (all children recruited to the study will be consuming an oral nutritional supplement).
89364832|NCT03295162|Experimental|Sepsis A Group|neonates diagnosed with Sepsis and will receive melatonin. 10 mg product as a total dose of 20 mg .together with conventional treatment of Neonatal sepsis
89364833|NCT03295162|Sham Comparator|Sepsis B Group|neonates diagnosed with Sepsis and willnot receive melatonin., they will recieve only the conventional treatment of Neonatal Sepsis
89364834|NCT03295162|No Intervention|Control|healthy neonates, in whom sepsis will be ruled-out on the basis of absence of any clinical or laboratory evidence suggestive of infection.
89364835|NCT05230238|Experimental|pituitary stimulation|Patients will receive pituitary stimulation as oncology pain treatment.
89364836|NCT04586842|Experimental|Community-based Occupational Therapy|Experimental study group that will receive a domiciliary and community-based occupational therapy on mental health, developed on the basis of the Model Of Human Occupation.
89364837|NCT04586842|Active Comparator|Standard community-based intervention|Control group of the study that will receive community-based interventions, public or private level (e.g. community nursing, social education and/or psychology).
89364838|NCT03295084|Experimental|Irinotecan|Dose escalation study in cohorts of minimum 3 patients of an Irinotecan tablet taken once daily for 14 days within 3 week treatment cycle
89364839|NCT03295084|Experimental|Irinotecan with Capecitabine|Dose escalation study in cohorts of minimum 3 patients of an Irinotecan tablet taken once daily in combination with Capecitabine tablet taken twice daily for 14 days within 3 week treatment cycle
89364840|NCT01339689|Experimental|Ganaxolone|active
89364841|NCT01339689|Placebo Comparator|Placebo|non-active
89364842|NCT03038126|Active Comparator|CCHT|Veterans Administration (VA) CCHT with an established guideline-based CKD DMP, augmented laboratory monitoring, and decision support from the VA Renal Inter-disciplinary Safety clinic (RISC).
89364843|NCT03038126|Placebo Comparator|Usual care|
89364844|NCT00702806|Experimental|Org 36286 120 μg + Puregon® 150 IU|On Cycle Day 2 or Day 3, a single intra-abdominal injection of Org 36286 120 μg was administered to participants. On stimulation Day 8, a daily subcutaneous dose of Puregon® 150 IU was administered up to and including the time of Pregnyl® administration as a single dose of 10,000 IU subcutaneously. The maximum treatment duration of Puregon® 150 IU was 19 days. Orgalutran® 0.25 mg was administered subcutaneously once daily up to and including the day of Pregnyl®, when the leading follicle reached a size of >= 14 mm.
89364845|NCT00702806|Experimental|Org 36286 180 μg + Puregon® 150 IU|Cycle Day 2 or Day 3, a single intra-abdominal injection of Org 36286 180 μg was administered to participants. On stimulation Day 8, a daily subcutaneous dose of Puregon® 150 IU was administered up to and including the time of Pregnyl® administration as a single dose of 10,000 IU subcutaneously. The maximum treatment duration of Puregon® 150 IU was 19 days. Orgalutran® 0.25 mg was administered subcutaneously once daily up to and including the day of Pregnyl®, when the leading follicle reached a size of >= 14 mm.
88835828|NCT05921838||healthy doner|Healthy individuals without blood system diseases
88835829|NCT05921825||Non survivors group|At 28 day, patients were divided into Non survivors group and Survivors group.
88835830|NCT05921825||Survivors group|At 28 day, patients were divided into Non survivors group and Survivors group.
88835831|NCT05921799||General anesthesia Patients|Subjects experiencing general anesthesia such that viscoelastic testing is performed to assess coagulopathy.
88835832|NCT05921773|Experimental|GAD Patients with Intervention|The feedback group will get real neurofeedback about changes in anxiety-related cerebral hemodynamics. AI-fNIRS neurofeedback will be provided 3 times a week, for a total of 4 weeks.
88835833|NCT05921773|Sham Comparator|GAD Patients with Sham Controls|The sham group will be shown playbacks of someone's real feedback sessions. Sham AI-fNIRS neurofeedback will be provided 3 times a week, for a total of 4 weeks.
88835834|NCT05921734|Experimental|AF-termination Group|
88835835|NCT05921734|Active Comparator|Prespecified-ablation Group|
89364846|NCT00702806|Experimental|Org 36286 240 μg + Puregon® 150 IU|Cycle Day 2 or Day 3, a single intra-abdominal injection of Org 36286 240 μg was administered to participants. On stimulation Day 8, a daily subcutaneous dose of Puregon® 150 IU was administered up to and including the time of Pregnyl® administration as a single dose of 10,000 IU subcutaneously. The maximum treatment duration of Puregon® 150 IU was 19 days. Orgalutran® 0.25 mg was administered subcutaneously once daily up to and including the day of Pregnyl®, when the leading follicle reached a size of >= 14 mm.
89364847|NCT00702806|Active Comparator|Puregon® 150 IU|On stimulation Day 8, a daily subcutaneous dose of Puregon® 150 IU was administered up to and including the time of Pregnyl® administration as a single dose of 10,000 IU subcutaneously. The maximum treatment duration of Puregon® 150 IU was 19 days. Orgalutran® 0.25 mg was administered subcutaneously once daily up to and including the day of Pregnyl®, when the leading follicle reached a size of >= 14 mm.
88835836|NCT05921721|Experimental|EOS imaging system|Participants will undergo CT and EOS imaging pre- and post- operatively. The EOS is being compared to the reference method CT scan.
88835837|NCT05921708||X Generation|Generation X refers to those born between 1965 and 1979 (1).
88835838|NCT05921708||Y Generation|Generation Y is a population, also known as the Millennials, who was born between 1980 and 1994 (1).
88835839|NCT05921708||Z Generation|Generation Z are individuals born between 1995 and 2015 (1).
88835840|NCT05921695|Active Comparator|Normal Saline infusion group|During the emergency department, the normal saline infusion was not restricted.
88835841|NCT05921695|Experimental|Ringer lactate infusion group|Use ringer lactate or other balanced crystallographic solution instead of normal saline. Strictly limit the amount of normal saline infusion. Normal saline will only be infused by medical advice if the patient has hypochloremia or needs saline as solvent.
88835842|NCT05921682||Patients with heat stroke|Patients with heat stroke presenting to the emergency department at the study site
88835843|NCT05921669|Experimental|Experimental Group 1: The group in which breastfeeding training was given to mothers and fathers|"Face-to-face theoretical breastfeeding training and then practical training (breastfeeding techniques, burping, changing diapers, milking by hand or pump, etc.) will be given by the researcher to the mothers and fathers. This training is planned to take 30-45 minutes. Then, an additional 15-30 minutes of father-supported breastfeeding training will be given to fathers. At the end of the training, the Breastfeeding Booklet prepared by the researchers will be given to the parents."
88835844|NCT05921669|Experimental|Experimental Group 2: The group in which breastfeeding training was given only to the mother|"Only mothers will receive face-to-face theoretical breastfeeding training followed by practical training (breastfeeding techniques, flatulence, changing diapers, milking by hand or pump, etc.). This training is planned to take 30-45 minutes. At the end of the training, mothers will be given a Breastfeeding Booklet prepared by the researchers."
88835845|NCT05921669|No Intervention|Control Group: No intervention was made, group receiving routine hospital care)|No additional training will be given to this group by the researcher, apart from the trainings included in the routine procedures of the hospital.
88835846|NCT05921630|Placebo Comparator|Control group|Control group The control group was given standard routine information by the technician before spirometry.
89178557|NCT04115813|Experimental|Intervention Arm|The intervention arm participants received the Project YES! intervention for the first phase and then after midline data collection went into a maintenance phase.
89364848|NCT01334463||mTBI+PTSD|History of active duty-related mild TBI and history of active duty-related PTSD
89364849|NCT01334463||mTBI Only|History of active duty-related mild TBI and no history of active duty-related PTSD
89364850|NCT01334463||PTSD Only|No history of active duty-related mild TBI and history of active duty-related PTSD
89364851|NCT01334463||No mTBI, No PTSD|No history of active duty-related mild TBI and no history of active duty-related PTSD
89364852|NCT04441281|Active Comparator|Single-tooth tenaculum (Pozzi forceps)|In the control arm, a single-tooth tenaculum, Pozzi forceps, used during routine IUD insertion, is employed to hold and stabilize the cervix.
89364853|NCT04441281|Experimental|AspivixTM cervical vacuum tenaculum|In the experimental arm, the investigational AspivixTM cervical vacuum tenaculum is employed to hold and stabilize the cervix.
89364854|NCT01331889||Potassium concentration|plasma potassium concentrations in the Fluid Management System (FMS) reservoir, arterial blood, and central venous blood
89364855|NCT03635931|Active Comparator|Concentrated Growth Factor|plaque control, scaling and root planing if required, surgical application of CGF
89364856|NCT03635931|No Intervention|Control Group|plaque control, scaling and root planing if required
89364857|NCT01331967|Experimental|Pioglitazone, Placebo|
89364858|NCT00696878|Experimental|Corifollitropin alfa 150 µg|Up to 3 COS cycles (also called treatment cycles) were performed, each including the following: A single injection of 150 µg corifollitropin alfa was administered on Day 2 or 3 of the menstrual cycle (Stimulation Day 1). Administration of GnRH antagonist (0.25 mg/day) started on Stimulation Day 5 or 6 and continued through day of administration of recombinant Human Chorion Gonadotropin ([rec]hCG) (5,000-10,000 IU/250 µg). Administration of (rec)hCG occurred when 3 follicles ≥17 mm were observed on ultrasound scan (USS). Daily dosing with Follicle Stimulating Hormone (FSH) (not to exceed 225 IU/day) began on Stimulation Day 8 and continued up to day of (rec)hCG administration. Progesterone for luteal phase support was administered starting on the day of oocyte pick-up (34-36 hours after [rec]hCG) and continued for approximately 6 weeks. After COS cycles 1 and 2, Frozen-Thawed Embryo Transfer cycles (up to 3 after each COS cycle) could occur.
89364859|NCT01231971||Cognitively Normal (CN)|150 newly enrolled participants with no apparent memory problems, and CN participants followed from the ADNI1 study
89364860|NCT01231971||Early Mild Cognitive Impairment (EMCI)|100 newly enrolled early amnestic MCI participants, and approximately 200 EMCI participants will be followed from the ADNI-GO study
89364861|NCT01231971||Late Mild Cognitive Impairment (LMCI)|150 newly enrolled late MCI participants, and LMCI participants followed from the ADNI1 study
89364862|NCT01231971||Alzheimer's Disease (AD)|150 newly enrolled mild AD participants
89364863|NCT01231971||Significant Memory Concern (SMC)|100 newly enrolled participants with Significant Memory Concern (SMC)
89364864|NCT01150929|Active Comparator|Fixed bearing|One of the 2 used implants.
89364865|NCT01150929|Active Comparator|Rotating platform|One of the 2 used implants.
89364866|NCT03288688|Experimental|Exercise program and education|An exercise program in the form of home exercise videos will be given to the participants in this group. They will be asked to perform a minimum of two 35-minute exercise sessions per week, over a period of 11 weeks. They will also be required to attend three group exercise sessions, to confirm correct execution of the exercises. A short educational presentation on injury prevention will be offered at the beginning of the study, followed by three informative e-mails over the course of the study.
89364867|NCT03288688|No Intervention|No intervention|Participants in this group will be asked to continue their usual activities.
89364868|NCT03295006||Previous Therasphere treatment|Patients who had received TheraSphere yttrium-90 microspheres
89364869|NCT00731757|Experimental|1|Patients being treated with Humira.
89364870|NCT03625622|Placebo Comparator|Placebo|Placebo, orally administered once daily for 26 weeks.
89364871|NCT03625622|Active Comparator|AR1001 - 10 mg|Active, AR1001 - 10 mg, orally administered once daily for 26 weeks.
89364872|NCT03625622|Active Comparator|AR1001 - 30 mg|Active, AR1001 - 30 mg, orally administered once daily for 26 weeks.
89364873|NCT03108274|Experimental|Part 1: Danicopan and Midazolam|"Period 1: Participants received a single dose of midazolam.~Period 2: Participants received multiple doses of danicopan, in addition to coadministration with a single dose of midazolam.~Scheduled pharmacokinetics (PK) blood samples were collected, with a washout period of at least 3 days between the dose in Period 1 and the first dose in Period 2."
89364874|NCT03108274|Experimental|Part 2: Danicopan and Fexofenadine|"Period 1: Participants received a single dose of fexofenadine.~Period 2: Participants received multiple doses of danicopan, in addition to coadministration with a single dose of fexofenadine.~Scheduled PK blood samples were collected, with a washout period of at least 3 days between the dose in Period 1 and the first dose in Period 2."
89364875|NCT03108274|Experimental|Part 3: Danicopan and MMF|"Period 1: Participants received a single dose of MMF.~Period 2: Participants received multiple doses of danicopan, in addition to coadministration with a single dose of MMF.~Scheduled PK blood samples were collected, with a washout period of at least 3 days between the dose in Period 1 and the first dose in Period 2."
89364876|NCT01334541||SAFE VET|
89364877|NCT01334541||E-CARE|
89364878|NCT04296357||IVF children|Children born from in-vitro fertilization
89364879|NCT04296357||IVM children|Children born from in-vitro maturation
89364880|NCT02332564||Coronary Artery Disease|Patient with significant coronary artery disease
89364881|NCT02332564||No Coronary Artery Disease|Patient without significant coronary artery disease
89364882|NCT01332045|Sham Comparator|Saline boluses in nerve catheter|A nerve catheter will be placed in the adductor canal using saline instead of Ropivacaine for intermittent boluses.
89364883|NCT01332045|Active Comparator|Continuous saphenous nerve block|Postoperative intermittent boluses of 15 Ml Ropivacaine 7,5 mg/Ml every 12 hours for three days
89364884|NCT03294928|Experimental|progressive increasing of PEEP level|four-step measurements of central artery blood pressure evaluating contour wave analysis during a progressive increasing of PEEP level.
89364885|NCT02278588||PD-R|Parkinson's disease receiving rasagiline
89364886|NCT02278588||PD-NMAO|Parkinson's disease not receiving any MAO-B inhibitors
89364887|NCT02278588||HC|Healthy Controls
89364888|NCT03288610||With inflammatory response|"Patients with postoperative inflammatory response as defined by the occurrence of severe SIRS and/or postoperative vasodilation syndrome.~Severe SIRS is defined by meeting at least 2 SIRS criteria during 6 consecutive hours or at least 3 SIRS criterias. Classical SIRS criteria include: temperature >38,3 or <36°C, heart rate >90/min, respiratory rate >20/min or PaCO2 <32mmHg, GB>12000 ou <4000 c/mm3.~Postoperative vasodilation syndrome is defined by the need of continuous infusion of norepinephrine (whatever the dose) to maintain the mean arterial pressure above 60 mmHg associated to a cardiac index above or egal to 2.2 L/min/m2.~Patients without postoperative severe SIRS and without postoperative vasodilation syndrome"
89364889|NCT00696800|Experimental|150 µg Corifollitropin Alfa|Participants received a single subcutaneous (SC) injection of 150 µg Corifollitropin Alfa (org 36286) on day 2 or 3 of the menstrual cycle (Stimulation Day 1); 7 daily SC injections from Stimulation Days 1 to 7 with placebo-recFSH; followed by daily SC injections with 200 IU recFSH up to the day of hCG. Daily SC injections of Ganirelix were administered from Stimulation Day 5 to the day of hCG; at which time a single dose of hCG was given when 3 follicles >= 17 mm. On the day of oocyte pick up (OPU) daily doses of progesterone were started and continued for up to 6 weeks or menses.
89178558|NCT04115813|Other|Comparison Arm|The comparison arm was a usual care arm during the first phase (and primary analysis). After midline data collection the comparison arm began receiving the Project YES! intervention.
89178559|NCT00862121|Experimental|Mesalazine|Mesalazine (Mesalamine) 2 g sachet; 6 g daily
89364890|NCT00696800|Active Comparator|200 IU recFSH|Participants received a single SC injection of placebo Corifollitropin Alfa on day 2 or 3 of the menstrual cycle (Stimulation Day 1); 7 daily SC injections with 200 IU recFSH from Stimulation Days 1 to 7; followed by daily SC injections with 200 IU recFSH up to the day of hCG. Daily SC injections of Ganirelix were given from Stimulation Day 5 to the day of hCG; at which time a single dose of hCG was administered when 3 follicles >= 17 mm. On the day of OPU daily doses of progesterone were started and continued for up to 6 weeks or menses.
89364891|NCT03294772|Experimental|Hand sanitizer group|DCCs received alcohol-based hand sanitizer and a program educational. Characteristics of the hydroalcoholic gel (Alco aloe gel): chlorhexidine digluconate at 0.2% solution, phenoxyethanol 1%, benzalkonium chloride 0.1%. aloe barbadensis 5%, ethyl alcohol 70%, excipients c.s.p. 100 ml. Alcohol of between 70%, ph = 7-7,5.
89364892|NCT03294772|Experimental|Liquid soap group|DCCs received soap and program educational. The liquid soaps used for handwashing in this study did not contain specific antibacterial component, ph= 5.5.
89364893|NCT03294772|No Intervention|Control group|No hand sanitizer or educational program were used.
89178560|NCT00862121|Placebo Comparator|Placebo|Placebo to Mesalazine (Mesalamine) 2 g sachet; 6 g daily
89178561|NCT00784719|Experimental|Treatment 1|
89178562|NCT00784719|Experimental|Treatment 2|
89178563|NCT00784719|Experimental|Treatment 3|
89178564|NCT00784719|Experimental|Treatment 4|
89178565|NCT00784719|Active Comparator|Active comparator|
89178566|NCT00784719|Placebo Comparator|Placebo|
89364894|NCT03288532|No Intervention|Arm A (active monitoring)|Participants randomised to Arm A will be allocated to active monitoring for 1 year, in line with current standard-of-care in resected primary RCC at high or intermediate risk of relapse
89364895|NCT03288532|Experimental|Arm B (durvalumab monotherapy)|Participants randomised to Arm B will receive durvalumab (1500mg) 4 weekly for 1 year (13 cycles maximum)
89364896|NCT03288532|Experimental|Arm C (durvalumab + tremelimumab)|Participants randomised to Arm C will receive durvalumab (administered as per arm B, i.e. 13 cycles maximum) and tremelimumab (75mg) on day 1 and week 4 visits (i.e. 2 cycles)
88835847|NCT05921630|Experimental|Leaflet group|Information via leaflets: The subjects were given a leaflet prepared by the researchers based on literature review . The leaflet contained written and visual information about the steps of spirometry. The patients then underwent routine spirometry.
88835848|NCT05921630|Experimental|Video|Video-assisted education: Using a mobile phone, patients were shown a two-minute video prepared by the researchers in accordance with the guidelines that demonstrated how spirometry is performed.
88835849|NCT05921630|Experimental|Leaflet + Video|Education via leaflets + video: Subjects in this group were first given a leaflet and shown the video. They later underwent routine spirometry.
88835850|NCT05921617||Observation group|
88835851|NCT05921539|Experimental|hydrodilatation and axillary nerve injection|patient received ultrasound-guided steroid hydrodilatation via posterior recess
88835852|NCT05921539|Active Comparator|hydrodilatation only|patient received ultrasound-guided steroid hydrodilatation only
88835853|NCT05921526|Experimental|Intervention|Point-of-care lung ultrasound
88835854|NCT05921526|Active Comparator|Control|Chest X-ray
88835855|NCT05921513|Placebo Comparator|NC Group|This group is provided normal saline mouth-rinse to rinse 2 times per day along with placebo gel to be applied 2 times and placebo oral spray.
88835856|NCT05921513|Experimental|S Group|This group is provided StellaLife Oral Care kit's mouth-rinse, gel and spray 2 times per day.
88835857|NCT05921513|Active Comparator|C Group|This group is provided chlorhexidine mouth-rinse and placebo gel and spray 2 times per day.
88835858|NCT05921500|Experimental|Internal bleaching of discolored primary anterior teeth by using sodium peborate|Internal bleaching of discolored primary anterior teeth by using sodium peborate
88835859|NCT05921474||Patients with Unbiopsied, Presumed Stage I/IIA NSCLC Undergoing SABR|The first cohort will be comprised of patients with suspected stage I/IIA NSCLC with plans to undergo curative SABR.
89178567|NCT04120103|Experimental|Doll therapy|"Experimental: Doll Therapy Intervention A total of 30 patients were included in the study. All patients that meet the study inclusion criteria will be included in the study The patients in the intervention group will have Doll therapy for 60 days and weekly patient visits. The study will be started with control group patients. At the beginning of the study and after 60 days, Introductory Information Form, Mini Standard Mini Mental Test and Cohen-Mansfield Agitation Inventory will be applied to patients in intervention and control groups for data collection. Dementia patients will be given a baby, patients will be followed for two months. There will be monitoring once a week."
89178568|NCT04120103|Active Comparator|Routine nursing care|"The nursing care provided by the institution was applied to the dementia patients in the routine nursing care group. Routine nursing care group interventions in the institution; Monitoring of life signs, application of drug treatments, participation in social activities such as listening to music, reading prayer, initiatives such as assisting patients in performing daily living activities.~There was no intervention other than routine care. The patients were followed up for two months.The patients were followed up for two months.Data collection forms were applied at the beginning, first and second months of the study."
89178569|NCT00852917|Experimental|1: Tramadol Once A Day 100mg|
89178570|NCT00852917|Experimental|2: Tramadol Once A Day 200mg|
89178571|NCT00852917|Experimental|3: Tramadol Once A Day 300mg|
89178572|NCT00852917|Placebo Comparator|4: Placebo|
89364897|NCT00598208|Experimental|1|60 µg Org 36286 (corifollitropin alfa)
89364898|NCT00598208|Experimental|2|120 µg Org 36286 (corifollitropin alfa)
89364899|NCT00598208|Experimental|3|180 µg Org 36286 (corifollitropin alfa)
89364900|NCT00598208|Active Comparator|4|Follitropin beta injection
89364901|NCT03108118||Acute respiratory failure|We are enrolling patients who are intubated because of acute respiratory distress syndrome, pneumonia, septic shock, or severe acute brain injury (GCS ≤ 8 prior to intubation). This population is targeted for study because they are at relatively high risk of requiring prolonged mechanical ventilation.
89364902|NCT02462044|Experimental|240|Group 240 will receive CM with 240 mg Iodine/ml IDR 2.0 gI/s
89364903|NCT02462044|Experimental|300|Group 300 will receive CM with 300 mg Iodine/ml IDR 2.0 gI/s
89364904|NCT02462044|Experimental|370|Group 370 will receive CM with 370 mg Iodine/ml IDR 2.0 gI/s
88835860|NCT05921474||Patients with Stage I-IIA NSCLC Undergoing SABR|The second cohort will be comprised of patients with biopsy proven NSCLC, with clinically staged I/IIA disease with a plan to undergo definitive therapy with SABR.
88835861|NCT05921461||Control NON-PAD|Measurement using the VOTIS PedCheck system
88835862|NCT05921461||PAD patients|Measurement using the VOTIS PedCheck system
88835863|NCT05921422||Case group|Children and adolescents with cerebral palsy who are 11-15 years old, diagnosed with cerebral palsy (any type), and who attend a Danish mainstream school at time of enrollment
88835864|NCT05921422||Control group|Children and adolescents without cerebral palsy in the same age range as case-participants (11-15 years old) and attend Danish mainstream schools.
88835865|NCT05921357||Peri-implantitis|Implants with a pocket depth of more than 5 mm and bleeding on probing
89364905|NCT03294616|Experimental|scleroderma patients-0|for acute study: The experiment in patients will be performed in 4 randomized sessions on separate days (at least 3 days apart): one control session with sham-TEA and 3 TEA sessions at various parameters. TEA will be applied on both acupoints ST36 and PC6; the following sets of parameters will be tested for TEA at ST36: A) standard parameters: the set used in the previous SSc study: 25 Hz, 0.3ms, 2s-on and 3s-off; B) same as A but pulse width of 0.6ms; C) same as B but 0.1s-on and 0.4s-off. For TEA at PC6, 25 Hz will be replaced by 100Hz because TEA at PC6 is used to treat symptoms and 100Hz is believed to be better than 25Hz. The patient will be fasted overnight, and the test will last 2 hours (1 hour fasting and 1 hour postprandial).
89364906|NCT03294616|Experimental|scleroderma patient-1|for chronic study: 2 weeks of Sham transcutaneous electroacupuncture treatment, 2 weeks of wash out, 2 weeks of transcutaneous electroacupuncture/Sham transcutaneous electroacupuncture treatment. Best parameter gained from acute study will be used.
89364907|NCT03294616|Experimental|scleroderma patients-2|for chronic study: 2 weeks of transcutaneous electroacupuncture treatment, 2 weeks of wash out, 2 weeks of transcutaneous electroacupuncture/Sham transcutaneous electroacupuncture treatment. Best parameter gained from acute study will be used.
89364908|NCT00289874|Experimental|1|montelukast
89364909|NCT00289874|Placebo Comparator|2|placebo
89364910|NCT02461732|Active Comparator|CBT for Substance Dependence|Standard CBT for substance use disorders
89364911|NCT02461732|Experimental|Integrated CBT for PTSD and Substance Dependence|Integrated CBT for PTSD and substance use disorders, combining elements of cognitive processing therapy for PTSD with coping skills and relapse prevention for substance use disorders
89364912|NCT02039830|Experimental|Group physiotherapy|12 weekly treatment visit + daily home exercise program
89364913|NCT02039830|Active Comparator|Individual one-on-one physiotherapy|12 weekly treatment visit + daily home exercise program
89364914|NCT00245570|Experimental|1|Montelukast - Salmeterol - Placebo
89364915|NCT00245570|Experimental|2|Montelukast - Placebo - Salmeterol
89364916|NCT00245570|Experimental|3|Salmeterol - Montelukast - Placebo
89364917|NCT00245570|Experimental|4|Salmeterol - Placebo - Montelukast
88835866|NCT05921357||Peri-implant mucositis|Implants with no bone loss but bleeding on probing
89364918|NCT00245570|Experimental|5|Placebo - Montelukast - Salmeterol
89364919|NCT00245570|Experimental|6|Placebo - Salmeterol - Montelukast
88835867|NCT05921357||Peri-implant health|Implants with no bone loss but no bleeding on probing
88835868|NCT05921344|Experimental|Preclinical Research of mμSORS for Noninvasive Blood Glucose Detection|Enrolled subjects will perform oral glucose tolerance test. A measurement session of blood glucose consists of plasma sample and a measurement by mμSORS will be conducted synchronously.
88835869|NCT05921331|Experimental|The RJBC-APP group|Participants randomized to the RJBC-APP group should register on the RJBC-APP, through which they can receive treatment reminders, matters needing attention as well as science knowledge and communicate with the medical staff.
88835870|NCT05921331|Active Comparator|The Control group|Participants randomized to the Control group have no access to the RJBC-APP and post-surgical follow-up can only be conducted in outpatient clinic.
88835871|NCT05921318||more than 5/10 HLA-mismatched allo-HSCT|more than 5/10 HLA-mismatched allo-HSCT
89364920|NCT02461888|Experimental|Ixazomib, CD|"Ixazomib, cyclophosphamide and dexamethasone (ICD) will be administered as part of a 28 days cycle until disease progression, intolerance, toxicity or withdrawal.~Dosing schedule:~Ixazomib 4mg orally on days 1, 8 and 15~Cyclophosphamide 500mg orally on days 1, 8 and 15~Dexamethasone 40mg orally on days 1-4 and 12-15"
89364921|NCT02461888|Active Comparator|CD|"Cyclophosphamide and dexamethasone (CD) will be administered as part of a 28 days cycle until disease progression, intolerance, toxicity or withdrawal.~Dosing schedule:~Cyclophosphamide 500mg orally on days 1, 8 and 15~Dexamethasone 40mg orally on days 1-4 and 12-15"
89364922|NCT00229970|Experimental|1|Placebo
89364923|NCT00229970|Experimental|2|MK0476 7 mg injection
89364924|NCT00229970|Experimental|3|MK0476 14 mg injection
89534641|NCT05037591|Experimental|sea grape extract D|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
88835872|NCT05921292|Experimental|Omeza Products Used in Combination|Subjects in this single-arm study will have the targeted wound/ulcer treated with Omeza combination therapy which includes the use of lidocaine lavage (2mL vial), cod liver oil skin protectant (2mL vial), and collagen matrix wound dressing (2ml vial). Patients will be treated weekly for four weeks. Treatment may be continued weekly for an additional 8 weeks with participant and investigator agreement.
88835873|NCT05921227|Experimental|Alternative Treatment Including Augmentative and Alternative Communication|Once children are shown to not respond to the usual Vocabulary Acquisition and Usage for Late Talkers (VAULT) treatment, they will be placed in this arm, which will train them to use an Augmentative and Alternative Communication device as an additional means to use to 'say' a word.
88835874|NCT05921227|Active Comparator|Usual Vocabulary Acquisition and Usage for Late Talkers (VAULT) treatment|Children who do appear to respond to treatment will continue with the full course of usual Vocabulary Acquisition and Usage for Late Talkers (VAULT) intervention.
88835875|NCT05921214|Experimental|Familiar Words|In this condition, children will learn new words that come from semantic categories (e.g., animals, body parts) from which they currently understand at least several words.
88835876|NCT05921214|Active Comparator|Less-Familiar Words|In this condition, children will learn new words that come from semantic categories (e.g., animals, body parts) from which they currently understand few or no words.
88835877|NCT05921201|Experimental|Relax, Reflect, and Empower application|Participants in the RRE group will select an Avatar from a pool of 20 Avatars as their companion over the 3 months. The Avatar wellness check-in in the RRE group includes a daily brief check-in of 5-minute/day (4 days/week), and a weekly full wellness check-in of 15 minutes/week for 3 months. The daily brief check-in includes a wellbeing and mood check and a 3-minute relaxation meditation. The weekly full wellness check-in includes reflection activities in addition to the daily check-in activities.
88835878|NCT05921201|Active Comparator|Daily check-in text messages|Participants will receive a wellness check-in text message 5 days/week [4 daily wellness check-in (2-3 minutes/day) +1 weekly wellness check-in (4-5 minutes/week)] for 3 months.
88835879|NCT05921188|Experimental|More Familiar Sounds|Children in this condition will learn new words whose sounds are more like the sounds in the words the child already understands.
88835880|NCT05921188|Active Comparator|Less Familiar Sounds|Children in this condition will learn new words whose sounds are less like the sounds in the words the child already understands.
88835881|NCT05921110|Active Comparator|PENG Block %0,25|PENG Block will be applied with 0.25% bupivacaine in 20 ml volume under ultrasound guidance.
88835882|NCT05921110|Active Comparator|PENG Block %0,16|PENG Block will be applied with 0.16% bupivacaine in 20 ml volume under ultrasound guidance.
88835883|NCT05921110|No Intervention|Control Group|Control
88835884|NCT05921097||T1DM|People with type 1 diabetes
88835885|NCT05921071|Active Comparator|Tranexamic acid arm|One gram of tranexamic acid (Hexakapron) is administered intravenously before surgery.
88835886|NCT05921071|Placebo Comparator|Placebo arm|patients will receive 10 ml of normal saline 0.9% intravenously.
88835887|NCT05921058|Experimental|Messenchymal stem cell secretome|The hypoxic mesenchymal stem cell secretome has been developed up to chapter 7, stored at -196 C to -135 C in cryopreservation, and has passed quality tests.
88835888|NCT05921058|Placebo Comparator|Placebo|Nacl 0,9% infusion
88835889|NCT05921032|Other|Lumbar stabilisation exercise (LSE)|Lumbar stabilisation exercise (LSE) group will perform eight weeks exercise intervention for two sessions in a week. Each session took about 45 minutes to complete. The total exercise sessions were 16 sessions. LSE group will be focused on strengthening the deep trunk stabilising muscles (i.e., transverse abdominal, internal oblique and lumbar multifidus) and control pelvis muscles.
88835890|NCT05921032|Other|Lumbar muscle strengthening exercise (LMSE)|Lumbar muscle strengthening exercise (LMSE) group will perform eight weeks exercise intervention for two sessions in a week. Each session took about 45 minutes to complete. The total exercise sessions were 16 sessions. LMSE group aims to strengthen the trunk flexor and extensor muscles.
88835891|NCT05921032|No Intervention|Control group|The control group will be given a diary to record their daily activities which consist of their 24 hours diet recall for 8 weeks and involvement of any physical activity throughout the 8 weeks. This diary will be collected during follow up (1 month after post-intervention). Upon completion of the trial, participants in the control group will receive either LSE or LMSE or combination of both exercises depending on their preference.
88835892|NCT05921019|Experimental|laser acupuncture group|"This study will use the Handylaser Trion laser manufactured by RJ Laser, Germany.~It will be used for 40 seconds to deliver 6 J of energy as a pulsed wave (Noiger E) at each acupoint near palms or plantar, such as bilateral LI 4, PC6, KI 3, LR 3.~For distal points in the four limbs, the laser will be used for 40 seconds at each acupoint to deliver 6J of energy as a pulsed wave (Noiger B), such as bilateral LI11, GB 34, ST 36, SP 6."
88835893|NCT05921019|Sham Comparator|sham laser acupuncture group|This study will use the sham Handylaser Trion laser manufactured by RJ Laser, without any laser beam delivering. The acupoints of the sham-laser acupuncture are the same as those of the laser acupuncture group.
88835894|NCT05920993||Healthy adults|Measures of tongue function were collected from two groups of individuals(healthy adults and stroke patients with dysphagia ). The items of measurement about healthy adults are the maximal tongue pressure, tongue endurance, and lingual swallowing pressures of saliva, 3-ml water, IDDSI 2, IDDSI3, and IDDSI 4 liquids.
88835895|NCT05920993||Stroke patients with dysphagia|The items of measurement about stroke patients with dysphagia are the maximal tongue pressure, tongue endurance, and lingual swallowing pressures of saliva.
89178573|NCT00700583|Experimental|1|
89178574|NCT00913055|Experimental|One hydrated 84mg Octreotide implant|hydrated implant
89364925|NCT02460796||hippotherapy group or study group|8 weeks of hippotherapy therapy: Familiarization sessions were initially 15 minutes and gradually evolved to 30 minutes in order to allow all participants to adapt to the horse's rhythmic movements and to the act of mounting the horse. Each session had warm up before the training and exercises for relaxation in the end of each session.
89364926|NCT02460796||control group|8 weeks of Parkinson's disease lectures: this group did not hippotherapy classes in the same period.
88835896|NCT05920980|Experimental|Lidocaine group|Patients in the lidocaine groups, lidocaine 1.5mg/kg/h was continuously infused (using ideal body weight) during the whole procedure, postoperative analgesia pump with lidocaine (lidocaine 50mg/kg, sufentanil 2ug/kg, glassetron 12mg), diluted to 200ml with saline until 72h after surgery. Blood samples will be collected from some patients in the lidocaine group for the measurement of lidocaine plasma concentration.
88835897|NCT05920980|Placebo Comparator|Placebo group|In the placebo group, the same volume of normal saline will be administered during anesthesia. The postoperative PCIA device will contain sufentanil 2 μg/kg, granisetron 12 mg diluted to 200 mL in 0.9% normal saline solution with a total volume of 200 mL.
88835898|NCT05920954|Experimental|Urgent ERCP|Urgent ERCP (<24 Hours).
88835899|NCT05920954|Experimental|Early ERCP|Early ERCP(24 to 48 Hours).
89364927|NCT03288064|Experimental|Corinthian currant supplementation|Corinthian currant supplementation: 1.5 g CHO/kg BW prior to exercise
89364928|NCT03288064|Experimental|Glucose supplementation|Glucose drink (Top Star 100, Esteriplas, Portugal) supplementation: 1.5 g CHO/kg BW prior to exercise
88835900|NCT05920928|Experimental|Long course chemoRadiotherapy (50.4Gy in 28 fr)|Neoadjuvant Long course radiotherapy (50.4 Gy in 28 fr) with concurrent capecitabine (825mg/m2) for locally advanced rectal cancer
88835901|NCT05920928|Experimental|Short course chemoRadiotherapy (25Gy in 5 fr)|Neoadjuvant short course radiotherapy (25 Gy in 5 fr) with concurrent capecitabine (825mg/m2) for locally advanced rectal cancer
88835902|NCT05920902||Acute ischemia stroke|Best medcine treatment. It including antiplatelet drugs, statins, hypotensive drugs, antidiabetics, neurotrophic drugs, butylphthalide, edaravone.
88835903|NCT05920889|Active Comparator|Semaglutide Group|Prescribe study drug: Patients randomized into the semaglutide group will receive 0.5mg subcutaneous injection of the drug before or during EVT, and 7 days after the procedure. i.e. semaglutide group will receive a total of 2 injections.
88835904|NCT05920889|No Intervention|Standard of care|Standard medical therapy
88835905|NCT05920876|Experimental|QLS32015|Dose escalation and does expansion of QLS32015 injection will be evaluated.
88835906|NCT05920837||Stroke|Sample of stroke patients
89364929|NCT03288064|Placebo Comparator|Water ingestion|Water ingestion: 7 ml/kg BW prior to exercise
88835907|NCT05920811|Active Comparator|conventional obturator|maxillary obturator fabricated from cast metal framework, heat-cured acrylic resin
89364930|NCT02461810|Experimental|SpineJack® system|VCF treatment system Vertebral fracture surgery
89364931|NCT02461810|Active Comparator|Balloon Kyphoplasty|VCF treatment system Vertebral fracture surgery
89364932|NCT01882036|Active Comparator|Gastric Bypass w/ matched hypocaloric diet|
89364933|NCT01882036|Active Comparator|Hypocaloric Diet|
89364934|NCT03619460|Experimental|piezoelectric extraction|The flap will be raised using a Piezoelectric elevator, the eventual bone around the third molar crown will be removed with the same piezoelectric lever used for luxation and root extraction. The eventual rizectomy will be performed using a piezoelectric saw.
88835908|NCT05920811|Experimental|3 d printed obturator|3d printed obturator with full digital workflow ( intraoral scanning, made of selective laser melting, 3d printed resin
89364935|NCT03619460|Active Comparator|conventional extraction|The flap will be raised using a manual elevator and the eventual bone around the third molar crown will be removed with a bone bur with a straight handpiece while the eventual rizectomy will be performed using a bone bur. Manual levers will be used for luxation and tooth extraction
88835909|NCT05920785||Metabolically healthy obesity|"Patients diagnosed with exogenous constitutional obesity, but without complications of this disease"
88835910|NCT05920785||Metabolically unhealthy obesity|"Patients diagnosed with Exogenous constitutional obesity with the presence of complications of this disease: arterial hypertension, dyslipidemia, impaired carbohydrate metabolism, type 2 diabetes hyperuricemia"
88835911|NCT05920785||Control group|Healthy children with normal body weight
88835912|NCT05920707|Active Comparator|Intranasal Oxytocin|Administer oxytocin (24 IU) intranasally.
89364936|NCT05235100|Experimental|Apatinib arm|Apatinib 500mg QD, used 2 weeks prior to IMRT, concurrent with pre-operative IMRT, and 1 month after end of IMRT
88835913|NCT05920707|Active Comparator|Intranasal Arginine Vasopressin|Administer Arginine Vasopressin (20 IU) intranasally.
89364937|NCT03287986||Suicide attempters|Depressed patients over 60 years of age with a personal history of suicide attempts scanned with MRI
89364938|NCT03287986||Patient controls|depressed patients over 60 years of age without a personal history of suicide attempt scanned with MRI
89364939|NCT03287986||Healthy Controls|Healthy subjects over 60 years, not depressed and without personal history of severe mental illness or suicide attempts, scanned with MRI
89364940|NCT04612010|Active Comparator|Alpha frequency|Wobble oscillation will revolve the individual alpha frequency
88835914|NCT05920707|Placebo Comparator|Intranasal placebo|Administer placebo intranasally.
89364941|NCT04612010|Active Comparator|Alpha frequency plus|Wobble oscillation will revolve the individual alpha frequency plus 0.5Hz
89364942|NCT04612010|Sham Comparator|Theta frequency|Wobble oscillation will revolve the individual theta frequency
89364943|NCT03294382|Experimental|Botulinum toxin|5U Botulinum toxin in 0.1 mL normal saline, administered in one of the intercanthus
89364944|NCT03294382|Placebo Comparator|Normal Saline|0.1 mL normal saline, administered in the other intercanthus
89364945|NCT05205434|Experimental|Synchronous telerehabilitation program (Video conference)|Participants will exercise program at home for an average of 30 minutes a day, 3 days a week, under the supervision of a physiotherapist via synchronized video conference. The program will continue for 8 weeks. The exercise program will consist of physical exercises (aerobic and strength exercises) along with breathing exercises and an educational program. Physical exercises will be adjusted in 3 different difficulty levels: sitting, standing with or without support.
89364946|NCT05205434|Experimental|Asynchronous telerehabilitation programme (Mobil app.)|The same exercises as in the synchronous telerehabilitation program will be done at the same frequency. Participants will watch the videos sent by the investigator via the mobile application and then do the exercises at home. The participants will meet with the investigator once a week to an update exercise program.
89364947|NCT05205434|No Intervention|Control|Participants in this group will only receive an educational program
89364948|NCT03294226|Experimental|AuraGain|After anesthetic induction, AuraGain is inserted for airway management. Size of the device is selected according to the manufacturer's recommendation; size 1.5 for 5-10kg, size 2 for 10-20kg.
88835915|NCT05920707|No Intervention|Intranasal nothing (control)|Control condition
88835916|NCT05920694|Active Comparator|CPAP Group|Participants randomized to CPAP will initiate CPAP therapy at the beginning of the study.
88835917|NCT05920694|Placebo Comparator|Delayed CPAP Group|Participants randomized to delayed CPAP (waitlist control) will initiate CPAP therapy immediately after 12 weeks. The investigators recognize that adherence to CPAP therapy is a common barrier to effective clinical treatment of OSA and to rigorous research on CPAP and has been significantly correlated with improvements in insulin resistance, including in a small of study of women with PCOS. After receiving this device, participants can meet with a study psychiatrist and his team within 3 days of initiating CPAP therapy and as needed for up to a month after initiating therapy. No visits in this time period will be billed to insurance.
88835918|NCT05920655||1( Surgical menopause)|Surgical menopause : At least 6 months after hysterectomy and salphingo-oopherectomy
88835919|NCT05920655||2 ( Natural menopause )|Natural menopause :Healthy female patients who have not had a menstrual period for at least 1 year and have not received any treatment for this reason before
88835920|NCT05920655||3 (Control )|Healthy women aged 30-45 years with regular menstrual cycles and no symptoms of menopause
88835921|NCT05920616|Other|Hospitalized|Participants who were hospitalized due to their COVID-19 illness.
88835922|NCT05920616|Other|Non-Hospitalized|Participants who had COVID-19 but did not require hospitalization secondary to their illness.
88835923|NCT05920564|Experimental|Intervention group|
88835924|NCT05920564|Active Comparator|Control group|
88835925|NCT05920551|Experimental|Gastrocnemius Stretching Group|Patients will receive ultrasound therapy, fascia strengthening exercises, and gastrocnemius stretching exercises.
88835926|NCT05920551|Active Comparator|Control Group|Patients will receive ultrasound therapy and fascia strengthening exercises without gastrocnemius stretching exercises.
88835927|NCT05920538|Experimental|Nicardipine|Using nicardipine 0.5 mg(0.5ml) subcutaneously infiltrated by ultrasound before redial artery cannulation.
88835928|NCT05920538|Placebo Comparator|Normal saline|Using normal saline 0.5ml subcutaneously infiltrated by ultrasound before redial artery cannulation
88835929|NCT05920525|Experimental|Electrical stimulation|In this group of patients, retraction of upper anterior teeth will be done using backward traction, and the remodeling will be enhanced by very light electrical stimulation by a specific device.
88835930|NCT05920525|Active Comparator|Traditional retraction of the front teeth|In this group of patients, traditional traction of the front teeth will be employed without any acceleration method.
88835931|NCT05920499|Experimental|Intervention group|The INTEGO practices (INTEGO is a GP morbidity registry in Flanders Belgium) that will be assigned to the intervention group will receive an extended electronic feedback report with multiple components, directly implemented in their EHR (electronic health record), on the pneumococcal vaccination coverage in adults at risk in their practice ('push system'). There will be a direct connection between the EHR of the practice and a SAS visual analytics tool in the Healthdata environment (single-sign-on connection), that will show the extended feedback. This report will be available at baseline and updated every two months based on the current situation.
88835932|NCT05920499|Active Comparator|Control group|Every GP center assigned to the control group will only have access to the clinical AUDIT to identify patients that may benefit from a pneumococcal vaccination. GP centers in the control group will not receive an extended feedback report at baseline and every 2 months afterwards.
89364949|NCT03294226|Active Comparator|I-gel|After anesthetic induction, I-gel is inserted for airway management. Size of the device is selected according to the patient's weight; size 1.5 for 5-10kg, size 2 for 10-20kg.
89364950|NCT05225636|Active Comparator|Radial access|The ischemic stroke treatment will be performed through the radial artery (as first option)
89364951|NCT05225636|Active Comparator|Femoral access|The ischemic stroke treatment will be performed through the femoral artery (as first option)
89364952|NCT03287518|Active Comparator|Verum|WAK2017 One (1) ml IP should be taken with breakfast and one (1) ml with supper every day.
89364953|NCT03287518|Placebo Comparator|Placebo|"The placebo liquid is identical in colour and flavor to the verum. In order to maintain the blind with respect to the odour, the placebo will contain 3% Concentrated Aged Garlic Extract (DER 0.9-1.2:1), which is considered as inactive with respect to a potential beneficial effect.~One (1) ml IP should be taken with breakfast and one (1) ml with supper every day."
89364954|NCT05225246||Readmission group|Patients who had heart surgery and returned unplanned to the University Hospital Basel within 30 days of leaving the hospital (outpatient or inpatient)
88835933|NCT05920486|Experimental|High-Intensity Laser Therapy (HILT) Group|Participants in the HILT group will receive an 8-week course of High-Intensity Laser Therapy (HILT) for the treatment of sacroiliitis. HILT will be administered using a Class IV laser with a wavelength of 980 nm, power output of 10 W, spot size of 0.5 cm, and a dose of 60 J/cm2 per session. The laser will be applied to the affected area of the sacroiliac joint, with the aim of achieving a sensation of warmth in the region. The treatment sessions will be delivered for 10 minutes per session, with a total of 12 sessions over 8 weeks. Participants will receive no other specific interventions during the study period.
88835934|NCT05920486|Sham Comparator|Sham-Control Group|Participants in the sham-control group will receive a sham HILT treatment for the treatment of sacroiliitis. The sham treatment will be delivered using a device that looks like the HILT device, but does not emit laser energy. The device will be applied to the affected area of the sacroiliac joint, with the aim of achieving a sensation of warmth in the region. The treatment sessions will be delivered for 10 minutes per session, with a total of 12 sessions over 8 weeks. Participants will receive no other specific interventions during the study period.
88835935|NCT05920473|Experimental|rTMS intervention group|Participants will undergo rTMS treatment using the Magstim Rapid 2 magnetic stimulation device. The coil was placed positioned tangentially on the scalp, targeting the hot spot (thumb movement area) in the ipsilateral cerebral hemisphere. The stimulation protocol will involve 10-Hz stimulation for 2 seconds, followed by a followed by a 10-second rest, which was repeated 50 times. Patients will receive treatment once a day, five days a week (Monday to Friday), for a total of two consecutive weeks.
88835936|NCT05920473|Sham Comparator|Sham group|Patients in the sham group underwent sham stimulation using the Magstim Rapid 2 magnetic stimulation device with the same protocol. The coil was positioned to target the same hot spot, with an angulation parallel to the gyrus to the gyrus in order to additionally minimize the rTMS effect.
88835937|NCT05920460|Experimental|Experimental Group|The Cognitive Behavioral Therapy group received seven weekly face-to-face sleep group Cognitive Behavioral Therapy sessions lasting for 50-60 min. The Cognitive Behavioral Therapy program was developed by the research team after reviewing the literature and consulting with experts. Cognitive Behavioral Therapy was held in a lecture hall located in the PPFK branch office before individual counseling was initiated.
88835938|NCT05920460|No Intervention|Control Group|The study participants of the control arm were interviewed separately and were given general health advice.
88835939|NCT05920447||ETT|"the patients in group T were intubated with Endotracheal tube (ETT) (flexicare) size 7 for female and 8 for male~The patients were ventilated with a volume-controlled mode at a Tidal Volume (TV) 7ml/kg, Respiratory Rate 12 /min, I: E 1:2. The patient was then positioned in the lithotomy position.~Ventilatory parameters including expired TV, peak airway pressure, inspired- expired TV and the end-tidal carbon dioxide were all monitored and recorded every 5 min.~In case of leaking from the LMA that interfere with the ventilation before the patients were being positioned in the lithotomy position, the patients were excluded and replaced by another.~The incidence of aspiration as revealed clinically( witnessed vomiting followed by decreased oxygen saturation, increased airway pressure, tachycardia, etc..) and confirmed radiologically, Failure of insertion or intubation, sore throat and air leak were reported as a complications."
88835940|NCT05920447||LMA|"The patients in group L were intubated with an I gel Laryngeal mask airway (LMA) , the size was selected based on the body weight according to the manufacturer's instructions,~The patients were then ventilated with a volume-controlled mode of ventilation at a Tidal Volume (TV) 7ml/kg, Respiratory Rate 12 /min, I: E 1:2. The patient was then positioned in the lithotomy position and secured~Ventilatory parameters including expired TV, peak airway pressure, TV inspired- TV expired and the end-tidal CO2 were all monitored and recorded every 5 min.~In case of leaking from the LMA that interfere with the ventilation before the patients were being positioned in the lithotomy position.~The incidence of aspiration as revealed clinically( witnessed vomiting followed by decreased oxygen saturation, increased airway pressure, tachycardia, etc..) and confirmed radiologically, Failure of insertion or intubation, sore throat and air leak were reported as a complications."
88835941|NCT05920434|Experimental|Foot reflexology group|Individuals in the foot reflexology group were treated by the researcher once a week for a total of 60 minutes, 30 minutes on each foot, for 6 weeks (28,29) (Figure 2C).
89001594|NCT00587821||2|The predictive capacity of this profile will then be prospectively assessed using the next 250 samples, which will serve as a validation set. Subjects who are candidates for enrollment on cohort B of this study (metastatic disease)
89178575|NCT00913055|Experimental|One non-hydrated 84mg Octreotide implant|
88835942|NCT05920434|Experimental|Foot bath group|In the first meeting, each participant in the foot bath group was informed about the way of doing a footbath in practice. Each participant in the foot bath group was asked to apply a foot bath for 10 minutes, 3 times a week, and twice a day for 6 weeks. A plastic foot bath tub (42 x 37 x 12 cm) without a massage function is provided for each of the participant s (Figure 2D). In order not to miss the applications, the participant was followed up by phone on the specified days (3 times a week, Monday-Wednesday-Friday). Th participant was told that the foot bath water should be at 40 degrees celsius and that his feet should be kept in water for 10 minutes, approximately 10 cm above the ankle (24). The participant came to the clinic for the forms and protective sensory examination in the 2nd, 4th, and last week.
88835943|NCT05920434|No Intervention|Control group|Forms and protective sensory examination tests were applied to the participant s in the control group, as in the intervention groups, and no application was made other than standard nursing care.
88835944|NCT05920421|Placebo Comparator|interscalen group|"(29) patients will receive interscalene block before induction of general anethesia.~patients will receive 30 ml of bupivacaine 0.25 %+250 mg of magnesium sulphate."
88835945|NCT05920421|Experimental|subomohyoid infracavicular group|(29) patients will receive subomohyoid infraclavicular block before induction of general anethesia. patients will receive 30 m lof bupivacaine 0.25 %+250 mg of magnesium sulphate.
89534642|NCT05037591|Experimental|sea grape extract E|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
88835946|NCT05920421|Experimental|subomohyoid subscapularis group|(29) patients will receive subomohyoid subscapularis block before induction of general anethesia . patients will receive 30 ml of bupivacaine0.25 %+250 mg of magnesium sulphate.
88835947|NCT05920395|No Intervention|Healthy control group|26 healthy volunteers without any intervention, detecting gastrointestinal hormone levels and intestinal microbiota and their metabolites.
88835948|NCT05920395|Experimental|PDS electroacupuncture group|Each with 26 patients who were treated with electro-acupuncture.
88835949|NCT05920395|Sham Comparator|PDS sham electroacupuncture group|Each with 26 patients. Shallow acupuncture needles are used and then disconnected from the electrode.
88835950|NCT05920395|Experimental|EPS electroacupuncture group|Each with 26 patients who were treated with electro-acupuncture.
88835951|NCT05920395|Sham Comparator|EPS sham electroacupuncture group|Each with 26 patients. Shallow acupuncture needles are used and then disconnected from the electrode.
88835952|NCT05920382|Experimental|Radiofrequency arm|After identifying the nerves to be treated via ultrasound and confirming with neurostimulation, 1 ml of 2% lidocaine will be administered, followed by radiofrequency ablation. The physical parameters used are as follows: 90 seconds, 80 degrees Celsius, with a 22g needle with an active tip of 10 mm.
88835953|NCT05920382|Sham Comparator|Control arm|In the same manner as with the RF group, the nerves to be treated are identified via ultrasound and confirmed by neurostimulation. Subsequently, sham radiofrequency is performed for 90 seconds.
88835954|NCT05920369|Experimental|low-energy extracorporeal shockwave and a tailored exercise program|"the patient will be positioned lying supine with the affected shoulder in an abducted position to expose the axillary cords. Each patient received a total of 3000 shocks, which were delivered to different areas, including 1000 shocks to the axillary area, 500 shocks to the upper arm, 1000 shocks along the course of the cords, and 500 shocks to the antecubital space. Extracorporeal shock wave therapy (ESWT) was administered in two sessions during the first two weeks of the intervention, and one session each in the 3rd and 4th weeks. The energy flux density was 4 Hz with a 0.056-0.068 mJ/mm range.~in addition to the following types of exercises: Snow Angel, Butterfly Wings, Forward Pinky Slide, Corner Stretch, Chest Stretch, Self-tissue Stretching, Overhead Moose Stretch, and Crescent Side Bend exercises"
88835955|NCT05920369|Active Comparator|low-energy extracorporeal shockwave|the patient will be positioned lying supine with the affected shoulder in an abducted position to expose the axillary cords. Each patient received a total of 3000 shocks, which were delivered to different areas, including 1000 shocks to the axillary area, 500 shocks to the upper arm, 1000 shocks along the course of the cords, and 500 shocks to the antecubital space. Extracorporeal shock wave therapy (ESWT) was administered in two sessions during the first two weeks of the intervention, and one session each in the 3rd and 4th weeks. The energy flux density was 4 Hz with a 0.056-0.068 mJ/mm range.
88835956|NCT05920369|Active Comparator|tailored exercise program|Snow Angel, Butterfly Wings, Forward Pinky Slide, Corner Stretch, Chest Stretch, Self-tissue Stretching, Overhead Moose Stretch, and Crescent Side Bend exercises. a combination of all these types of exercises will be used. Repeat these exercises 5 times, with 3 repetitions done each day for four consecutive weeks.
88835957|NCT05920330|Other|Single Arm|A device-nasal plug will be self-inserted into the nose with a diagonal channel embedded to redirect nasal airflow patterns to different nasal regions. A nose clip will be used to pinch the nose externally, similar to what synchronized swimmers use.
88835958|NCT05920317||Principal group|Analysis of the CT scans
88835959|NCT05920304|Experimental|virtual Hospital at Home (vHaH)|Participants are transferred home for telemedicine supported home-based admission.
88835960|NCT05920304|No Intervention|Continued conventional hospitalisation|Participants will follow a conventional hospital admission.
88835961|NCT05920278||Healthy Adult Volunteers|Minimum of ten (10) subjects meeting the eligibility criteria.
88835962|NCT05920265|Experimental|Quadratus Lumborum Block|
88835963|NCT05920265|Experimental|Fascia Iliac Block|
88835964|NCT05920265|Active Comparator|control|
88835965|NCT05920239||Control Group|Individuals who were not suspected of having adhesive capsulitis based on clinical examination and MRI.
88835966|NCT05920239||Intervention Group|Patients diagnosed with adhesive capsulitis based on evaluations conducted by clinical specialists, primarily in the fields of physical medicine and rehabilitation, orthopedics and traumatology, and confirmed by two experienced radiologists specializing in musculoskeletal imaging through the evaluation of MRI.
89534643|NCT05037591|Experimental|sea grape extract F|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
89534644|NCT05037591|Experimental|sea grape extract G|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
89534645|NCT05037591|Experimental|sea grape extract H|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
89534646|NCT05037591|Experimental|sea grape extract I|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
88835967|NCT05920200||Patients with groin and femoral hernia/IG|
88835968|NCT05920200||Patients with umbilical hernia/IG|
88835969|NCT05920200||Patients with ventral and incisional hernia/InG|
88835970|NCT05920187|Active Comparator|Mediterranean diet group|following dietary intervention based on Mediterranean diet
88835971|NCT05920187|Active Comparator|Anti-inflammatory diet group|following dietary intervention based on IBD-Anti-inflammatory diet.
88835972|NCT05920187|No Intervention|control group|Patients of the control group will not be instructed to follow a specific dietary intervention.
89364955|NCT05225246||control group|Patients who had heart surgery and did not return unplanned to the University Hospital Basel within 30 days of leaving the hospital (outpatient or inpatient)
89364956|NCT03287440|Active Comparator|COPD Wellness With Health Advocate|This arm will be given low-intensity pulmonary rehabilitation, COPD Wellness, for individuals with moderate-to-severe COPD with an additional assignment of a health advocate to address unmet social needs as an adherence strategy.
89364957|NCT03287440|Active Comparator|COPD Wellness|This arm will only be given low-intensity pulmonary rehabilitation, COPD Wellness, for individuals with moderate-to-severe COPD.
89364958|NCT05654792||NOP-LBBB|Patients with new-onset persistent left bundle branch block after transcatheter aortic valve implantation
89364959|NCT05224934|Experimental|Ultra-hypofractionated radiotherapy|Patients receive ultra-hypo-fractionated radiotherapy with 25Gy to 50Gy in five fractions, followed by surgery done at 1 to 2 months post-RT
89364960|NCT05224466||A|defined as patients survived on PD for more than 10 years
89364961|NCT05224466||B|defined as patients survived on PD for 5-10 years
88835973|NCT05920174|Experimental|single|"Patients with motor disability（Complete or incomplete quadriplegia due to spinal cord injury, brain stem stroke, amyotrophic lateral sclerosis and other motor neuron disorders).~Implantation of NEO device."
88835974|NCT05920161|Experimental|Acute Stress|Participants complete the socially evaluated cold pressor test (SECPT), a validated laboratory-based stress induction procedure involving submerging an arm in an ice bath
88835975|NCT05920161|Active Comparator|No Stress|Participants complete a matched condition with no stress-related exposure involving submerging an arm in warm water
88835976|NCT05920057|Experimental|interventional group|senior citizens aged 60 and more were randomly assigned into two equal groups at and placed in the study group, which received the constructive emotional management interventions
88835977|NCT05920057|No Intervention|control group|the control group, which received the elderly clubs' regular services
88835978|NCT05920044|Experimental|Intervention Group:|Participants will receive an eight-week individualized balance and proprioception training program.
88835979|NCT05920044|Active Comparator|Control group|Participants will continue their usual care, including general strength and flexibility exercises.
88835980|NCT05920031|Experimental|Cross-education training only|Participants will perform resistance exercises at 60% of their 1 repetition maximum (1RM) with the less affected limb.
88835981|NCT05920031|Experimental|Mirror therapy only|Participants will perform bilateral upper limb movements while observing the reflection of the less affected limb in a mirror.
88835982|NCT05920031|Experimental|Combined cross-education and mirror therapy|Participants will perform resistance exercises with the less affected limb while observing its reflection in a mirror.
88835983|NCT05920031|Active Comparator|Conventional rehabilitation|Participants will receive conventional rehabilitation for post-stroke upper limb motor impairments.
88835984|NCT05920018|Active Comparator|Dietary supplement|"Vivomixx®/VSL#3 sachets p.o. (1.800 bio bacteria/d) and~Conjugated linoleic acid (CLA/Tonalin® FFA 80) capsules p.o. (2 g/d)"
88835985|NCT05920018|Placebo Comparator|Placebo-control|"Maltose as Placebo to Vivomixx® and~Sunflower oil as Placebo to Conjugated linoleic acid (CLA/Tonalin® FFA 80)"
88835986|NCT05919992|Experimental|Metyrapone And Hydrocortisone|During one of the study periods, subjects receive hydrocortisone 19.9 mg/d subcutaneously via a pump in a pulsed fashion (eight times/day) and metyrapone per os (starting with a dose of 500 mg/d, then the dose will be increased the next days until 3000mg/d is achieved).
88835987|NCT05919992|Placebo Comparator|Placebo|During the other study period, subjects receive placebo (0,9% NaCl solution) 19.9 mg/d subcutaneously via a pump in a pulsed fashion and the same dose of placebo tablets p.o instead of metyrapone
88835988|NCT05919979|Experimental|Fasting, then fasting+exercise|
88835989|NCT05919979|Experimental|Fasting + Exercise, then fasting|
88835990|NCT05919966||chlorhexidine group|Patients were bathed one day involving the use of wipes soaked in a 2% chlorhexidine gluconate (CHG) solution and the next day using a towel soaked with water and soap during the MICU stays.
88835991|NCT05919966||usual care group|Patients were bathed with towels soaked in water and soap on a daily basis during the MICU stays.
89364962|NCT05224466||C|defined as patients survived on PD within 5 years
89364963|NCT04051034|Experimental|Omega 3 supplementation|12 weeks: Active: 1.25 g capsules/ [1.25 g capsule contains min. 750 mg EPA + 250 mg DHA] with heat therapy increasing internal body temperature 1.2C above baseline for 90 min each bout..
89364964|NCT04051034|Experimental|Placebo|12 weeks: Placebo: 1.25 g capsules/ [1.25-gram high oleic safflower oil capsule]with heat therapy increasing internal body temperature 1.2C above baseline for 90 min each bout..
89364965|NCT03287284|Active Comparator|LLLT Group|Active Low Level Laser Therapy application with a dose of 240 Joules before resistance training
89364966|NCT03287284|Placebo Comparator|Placebo Group|Placebo Low Level Laser Therapy application before resistance training
89364967|NCT01334619|Other|ropivacaine volume titration|
89364968|NCT05223764||Fertility preservation population|all women who underwent oocyte cryopreservation cycles for oncological purposes from January 2001 to December 2017 at Fertility Center of Humanitas Research Hospital, Rozzano (Milano), Italy
89364969|NCT03223623|Active Comparator|FHD|adults with Focal Hand Dystonia
89364970|NCT03223623|Placebo Comparator|Healthy Volunteer|adult healthy volunteers
89364971|NCT05223686|Experimental|Human CD19-CD22 Targeted T Cells Injection|Single administration：1.0×10^6 CAR+T, 3.0×10^6 CAR+T，6.0×10^6 CAR+T
88835992|NCT05919953|Experimental|Virtual reality and therapeutic education|"Multimodal tele-rehabilitation consisting of therapeutic education and immersive virtual reality neck exercises.~The duration of the intervention will be 6 weeks, including 5 virtual reality sessions (15-20 minutes per session, without supervision of the physiotherapist) and 1 teleconsultation session with a physiotherapist (30 minutes per session) per week.~In addition, participants will receive several brochures to read on their own (therapeutic education). These brochures will be discussed with the physiotherapist during the teleconsultations."
88835993|NCT05919927||Type II diabetes patients|Neuropsychological examination is done and medical information is gathered from the medical records.
88835994|NCT05919927||Healthy controls|Neuropsychological examination, medical examination and laboratory tests.
88835995|NCT05919706|Experimental|Experimental Group|Pre-test data were collected from patients with Patient Information and Follow-up Form, Diabetes Self-Management Scale (DSMQ) and Short Form-36 Quality of Life Scale (SF-36). After the pre-test, a educational program and a game-based mobile technology application were carried out for 4 weeks, 2 days a week at intervals. After the educational program were completed, motivational interviews were conducted once a week for 4 weeks. In this process, it was ensured that the game-based mobile technology application continued. Post-test data were collected with DSMQ and SF-36 at 2 months (8 weeks after the pre-test). After the post-test, the patients were followed up for 4 weeks. After the follow, with the Patient Information and Follow-up Form, DSMQ, SF-36, and the Satisfaction Questionnaire the follow-test data was collected.
88835996|NCT05919706|No Intervention|Control Group|Pre-test data were collected from patients with Patient Information and Follow-up Form, Diabetes Self-Management Scale DSMQ) and Short Form-36 Quality of Life Scale (SF-36). After the pre-test data were collected, no intervention was applied to the patients for 3 months (12 weeks), except for routine nursing care. Posttest data were collected with DSMQ and SF-36 2 months (8 weeks) after the pretest data. After the last test, the patients were followed up for 4 weeks, and 3 months (12 weeks) after the start of the study, the Patient Information and Follow-up Form (only the parts containing the features related to the disease and metabolic control variables), DSMQ and SF-36 Scale and follow-up test data were collected.
88835997|NCT05918445|Experimental|PM8002|PM8002 IV every 2 weeks(q2w) or every 3 weeks(q3w)
88835998|NCT05918146|Experimental|Intervention group|Dextrose injection, one time
88835999|NCT05918146|Placebo Comparator|Control group|Normal saline injection, one time
88836000|NCT05918133|Other|PM8002+nab-paclitaxel|PM8002 at 20 mg/kg (Q2W) and nab-paclitaxel at 100 mg/m2 on the 1st, 8th, and 15th days of each cycle until unacceptable toxicity or disease progression were observed. Each cycle contains 28 days.
88836001|NCT05918107|Other|PM8002+pemetrexed+platinum|Subjects will be administered with PM8002 plus pemetrexed+platinum via intravenously (IV) Q3W for 4-6 cycles,followed by PM8002 until disease progression intolerable toxicity for a maximum of 2 years.
88836002|NCT05917496||Patients|Children aged 11 months to 21 months on the day of inclusion in the study, with profound congenital deafness and having benefited from unilateral or bilateral cochlear implantation before 18 months of life inclusive, followed at Necker-Enfants Malades hospital and who receive a speech therapy.
88836003|NCT05913089|Experimental|TQB2450 injection + Chemotherapy|TQB2450 injection combined with chemotherapy, 21 days as a treatment cycle.
88836004|NCT05913089|Experimental|TQB2450 injection + Anlotinib Hydrochloride Capsule|TQB2450 injection combined with anlotinib hydrochloride capsule, 21 days as a treatment cycle.
88836005|NCT05911152||Intracorporeal anastomosis|Patients underwent laparoscopic colorectal surgery with intracorporeal anastomosis
88836006|NCT05911152||Extracorporeal anastomosis|Patients underwent laparoscopic colorectal surgery with extracorporeal anastomosis
88836007|NCT05902000|Experimental|Thrombectomy + Carotid Stenting|"After emergency admission,intravenous thrombolysis will be administered if possible. Standard endovascular thrombectomy (EMT) and balloon angioplasty will be performed. The method of EMT and the order of endovascular treatment were selected by each center. After EMT and balloon angioplasty, patients with eTICI≥2b_50 were maintained for more than 10 minutes for randomization. In the intervention arm, emergent carotid stenting will be performed. Standardized treatment with antiplatelet and other drugs will be given. A loading dose of antiplatelet agents (aspirin 300 mg and clopidogrel 300 mg) or Tirofiban was given as an intraoperative drug treatment to endovascular therapy prior to emergency balloon dilation or stenting. Intravenous sedation or general anesthesia will be permitted.~Oral dual antiplatelet treatment for more than 1 month. Tirofiban is maintained for 24-48 hours, overlapping with oral antiplatelet for 4-6 hours, after excluding intracranial hemorrhage."
88836008|NCT05902000|No Intervention|Thrombectomy alone|Intracranial thrombectomy alone（balloon dilation of the ipsilateral internal carotid artery if necessary）
88836009|NCT05897268|Experimental|Cryoablation combined with Tislelizumab and Lenvatinib|Cryoablation treatment starts at day 0. Tislelizumab and Lenvatinib will be initiated on day 1 after cryoablation. Tislelizumab will be administered at 200 mg i.v. every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent. Lenvatinib will be administered (bodyweight ≥ 60 kg, 12 mg; < 60 kg, 8 mg) orally daily every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
88836010|NCT05897177||Normal patients|
88836011|NCT05897177||Observational group|
88836012|NCT05895019||Patients with Parkinson's disease|Patients with Parkinson's disease
88836013|NCT05895019||Non-Parkinson's patients|Non-Parkinson's patients
88836014|NCT05893056|Experimental|Cryoablation combined with Tislelizumab and lenvatinib|Cryoablation treatment starts at day 0. Tislelizumab and Lenvatinib will be initiated on day 14 after cryoablation. Tislelizumab will be administered at 200 mg i.v. every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent. Lenvatinib will be administered (bodyweight ≥ 60 kg, 12 mg; < 60 kg, 8 mg) orally daily every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
89534647|NCT05037591|Experimental|sea grape extract J|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
89534648|NCT05037591|Experimental|sea grape extract K|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
89534649|NCT05037591|Experimental|sea grape extract L|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
89364972|NCT04496804|Experimental|Behavioral Intervention for Physical Activity in MS (BIPAMS)|The current behavioral intervention consists of two primary components; an Internet website and one-on-one video chats with a behavioral coach. The Internet website involves content delivered through interactive video courses. The interactive video courses are based on elements of social cognitive theory. Each courses consists of an introduction, the primary content, and a take home message. The interactive courses include embedded, supplementary options such as videos on content and worksheets related to the topic. A pedometer is provided for tracking steps, and these steps will be entered into the website so progress can be monitored. The chats support adherence to the intervention, discussion of website material, supportive accountability, and reporting of adverse events/injuries. The chats are conducted face-to-face through Skype. The chats occur 7 times during the first 2 months, 4 times during the second 2 months, and twice during the final 2 months of the intervention.
89364973|NCT04496804|Sham Comparator|Wellness for MS (WellMS)|Provides an Internet website and one-on-one video chats that discuss materials about self-managing multiple sclerosis (MS) consequences and health indicators through methods other than physical activity. The materials are transformations of brochures provided by the National MS Society, including Gait or Walking Problems: The Basic Facts; MS and Your Emotions; Pain: The Basic Facts; Solving Cognitive Problems; Taming Stress in MS; Food for Thought: MS and Nutrition; and Vitamins, Minerals, and Herbs: An Introduction. The delivery of the Internet materials and chat sessions will occur on the same time schedule and frequency as the intervention condition, and will have a comparable time commitment. The control condition will not involve tracking steps and a pedometer with not be provided.
89534650|NCT05037591|Experimental|sea grape extract M|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
89534651|NCT05037591|Experimental|sea grape extract N|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
88836015|NCT05892172||HFrEF group|HFrEF was defined as Left ventricular ejection fraction ≤40%
88836016|NCT05892172||HFmrEF group|HFmrEF was defined as Left ventricular ejection fraction 41%~49%
88836017|NCT05892172||HFpEF group|HFpEF was defined as Left ventricular ejection fraction ≥50%
88836018|NCT05891379||Exposed group|intravenous Intravenous methylprednisolone (IVMP) plus intravenous inebilizumab
88836019|NCT05891379||Non-exposed group|IVMP plus oral immunosuppressant (Mycophenolate Mofetil or Azathioprine)
88836020|NCT05889650|Experimental|1st stage - prophylactic|External lumbar drainage @15mmHg if intracranial pressure is not raised on admission
88836021|NCT05889650|Experimental|2nd stage - treatment|External lumbar drainage @20mmHg if / when intracranial pressure >20mmHg and tier 1 therapies cannot achieve ICP<20mmHg
88836022|NCT05889650|No Intervention|Usual treatment|Usual treatment as per SIBICC algorithm
88836023|NCT05889546||Active SCLC Diagnosis|
88836024|NCT05888324||Patients with PDPH after epidural analgesia for labor, requiring BP|Patients with PDPH after epidural analgesia for labor, requiring BP
88836025|NCT05883852|Experimental|Arm A：TCbHP|Docetaxel 75mg/m2 ivgtt d1+ carboplatin AUC=6 ivgtt d1+ trastuzumab first dose 8mg/kg (maintain 6mg/kg) d1 ivgtt d1+ Pertuzumab first dose 840mg (maintain 420mg) ivgtt d1, 3 weeks of treatment, a total of 6 courses. After the completion of chemotherapy, the dual-target therapy was continued for one year.
88836026|NCT05883852|Active Comparator|Arm B：EC-THP|Epirubicin 90 mg/m2 ivgtt d1+ cyclophosphamide 600 mg/m2 iv d1, 3 weeks of treatment, a total of 4 courses; Docetaxel 100mg/m2 ivgtt d1+ trastuzumab first dose 8mg/kg (maintenance 6mg/kg) d1 ivgtt d1+ pertuzumab first dose 840mg (maintenance 420mg) ivgtt d1, 3 weeks of treatment, a total of 6 courses. After the completion of chemotherapy, the dual-target therapy was continued for one year.
88836027|NCT05882760|Experimental|Tetric N Bond Universal®|Cavities in this group will be restored with Conventional Hybrid Composite Restoration bonded with Etch & Rinse Technique using Tetric N Bond Universal®.
88836028|NCT05882760|Active Comparator|Self Etch Tetric N Bond Universal®|Cavities in this group will be restored with Conventional Hybrid Composite Restoration bonded with Self Etch Technique using Tetric N Bond Universal®.
88836029|NCT05882760|Active Comparator|GC Fuji IX, GC, Japan®|Cavities in this group will be restored with GC Fuji IX, GC, Japan®
88836030|NCT05882760|Active Comparator|Activa TM Bioactive Restorative ®|Cavities in this group will be restored with Activa TM Bioactive Restorative ®
88836031|NCT05881200|Experimental|Magnetic mitohormesis|Treatment using the BIXEPS machine
88836032|NCT05879458|Experimental|Treatment Arm|Open-Label Ritlecitinib
88836033|NCT05879432|Experimental|LSALT Peptide|LSALT peptide 10 mg IV administered over 1 hour twice daily, every 12 ± 1 hour, for 5 days
88836034|NCT05879432|Placebo Comparator|Placebo|Placebo IV administered over 1 hour twice daily, every 12 ± 1 hour, for 5 days
88836035|NCT05876650|Experimental|Pilates exercise Group|6 Pilates exercises that are Swan, Swimming, Prone press up, Dart, Arm arch and Scarecow.
88836036|NCT05876650|Experimental|Yoga Group|6 Yoga poses: Warrior pose 1, Triangle pose, Child pose, Cow face pose, Bound angle pose, half bow pose.
88836037|NCT05875090|Experimental|AI-enhanced Retinography-based screening|"Screening in Lisbon arm will be done by an Artificial Intelligence (AI) software reading an optic disc entered retinography. Outcome of this analysis is referral vs non-referral based on a pre-established threshold.~IOP 24mmHg or higher will be also be referred, regardless of optics disc analysis"
88836038|NCT05875090|Active Comparator|OCT-based screening|"Screening in the Minho arm will be done based on optic coherence Tomography (OCT) retinal nerve fibre layer thickness (RNFL). Existence of a single sector outside normal limits (>95%) will be considered referrable.~IOP 24mmHg or higher will be also be referred, regardless of optics disc analysis"
88836039|NCT05872360|Active Comparator|Bundle Group 1 with Nutrilite Lifestyle|"Amway All-plant protein booster: 450g/bottle, containing the following active ingredients and with the guideline of Nutrilite Lifestyle:~All-plant protein~Peptide~HA (hyaluronicacid)~Calcium~Magnesium~Glucosamine~Facility: EMS (electric muscle stimulation)~Nutrition Guideline: Nutrilite Lifestyle"
88836040|NCT05872360|Active Comparator|Bundle Group 2 without Nutrilite Lifestyle|"Amway All-plant protein booster: 450g/bottle, containing the following active ingredients:~All-plant protein~Peptide~HA (hyaluronicacid)~Calcium~Magnesium~Glucosamine~Facility: EMS (electric muscle stimulation)"
88836041|NCT05872360|Placebo Comparator|Control Group 1|Placebo for all-plant protein booster: 450g/bottle, containing the following ingredients: Maltodextrin
88836042|NCT05872360|Placebo Comparator|Control Group 2 with Nutrilite Lifestyle|"Placebo for all-plant protein booster: 450g/bottle, containing the following ingredients: Maltodextrin~Nutrition Guideline: Nutrilite Lifestyle"
88836043|NCT05859529|Experimental|Experimental：JS002 AI|The drug was administered by a single subcutaneous injection via AI
88836044|NCT05859529|Active Comparator|Experimental：JS002 PFS|The drug was administered by a single subcutaneous injection via PFS
89364974|NCT03294070|Experimental|Fimasartan 60 mg + amlodipine besylate 5 mg|Fimasartan 60 mg + amlodipine besylate 5 mg. In subjects with a DBP equal to or greater than 90 mmHg and / or SBP equal to or greater than 140 mmHg at week 8, the investigator will have the option, according to his clinical criteria, to add 12.5 mg of HCTZ QD (in these cases, the subject will receive one 60 mg Fimasartan tablet plus 12.5 mg HCTZ plus one 5 mg amlodipine besylate tablet.
89364975|NCT04075370||Single arm study|In this feasibility study, longitudinal mixed methods will be used to measure cognitive function and symptoms by objective tests, interviews, and biomarker assay in adults with brain cancer over time: prior to radiation (XRT; T1), 2-weeks post-XRT (T2), 2-3 months post-XRT (T3).
89364976|NCT03299140|Other|Family Focused Therapy|Only 1 arm
89364977|NCT04479566|Experimental|lithium carbonate|Patients undergoing video assisted thoracic surgery during the morning will take 250mg lithium carbonate 6 hours after surgery.
89364978|NCT04479566|Placebo Comparator|calcium carbonate|Patients undergoing video assisted thoracic surgery during the morning will take calcium carbonate 500mg 6 hours after surgery.
89364979|NCT06030297|Experimental|Biomarker Optimization (Stanford)|Screening for neuropathy, foot problems and diabetes Diode laser testing of C:Aδ ratio Non-invasive speckle imaging Quantitative sensory testing ZTlido 1.8% lidocaine patch testing in some subjects
89364980|NCT06030297|Experimental|Neuropathy assessment and biomarker testing (Utah)|History, physical, and neurological exam Nerve conduction study Medical record review of neuropathy history PROMIS pain severity and interference testing Brief pain inventory Norfolk quality of life questionnaire Quantitative sensory testing 3mm skin punch biopsy Diode laser testing of C:Aδ ratio Non-invasive speckle imaging
88836049|NCT05857553|Experimental|Treatment Group|Participants in the treatment group will receive $500 per month for 12 months
88836050|NCT05857553|Active Comparator|Control Group|Participants in the control group will not receive monthly cash benefits.
88836051|NCT05857514|Active Comparator|Rectal indomethacin|
88836052|NCT05857514|Active Comparator|Pancreatic duct stent and rectal indomethacin|
88836053|NCT05851170|Experimental|Use of warm compresses and almond oil use during the second stage|Warm compresses will be attached to the perineum between pushing During active pushing - almond oil will be used on the perineum (our routine care).
89534652|NCT05037591|Experimental|sea grape extract O|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
88836054|NCT05851170|Active Comparator|Use of almond oil use (routine care) during the second stage|During active pushing - almond oil will be applied on the perineum
89534653|NCT05037591|Experimental|sea grape extract P|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
88836055|NCT05842577|Experimental|Telerehabilitation Group (TG)|The TG consisted of 30 sessions lasting approximately 45 minutes (3-5/week for 6-10 weeks) of motor, and cognitive rehabilitation exercises in non-immersive VR-based TR modality using the VRRS Tablet system (Khymeia Srl, Noventa Padovana, Italy).
88836056|NCT05842577|Active Comparator|Control Group (CG)|The CG carried consisted of 30 sessions lasting approximately 45 minutes (3-5 days/week for, 6-10 weeks) of at-home conventional rehabilitation via structured self-administered exercises without the use of any technological devices.
88836057|NCT05842122|Active Comparator|Pharmacy PrEP/PEP for a fee|Pharmacy providers offer clients PrEP and PEP services for a fee of 250 Kenyan Shillings (KES) per visit (study team compensates pharmacy providers 0 KES per visit).
88836058|NCT05842122|Active Comparator|Pharmacy PrEP/PEP for free|Pharmacy providers offer clients PrEP and PEP services for a fee of 0 KES per visit (study team compensates pharmacy providers 250 KES per visit).
88836059|NCT05842122|Active Comparator|HTS counselor supported pharmacy PrEP/PEP for free|HIV testing service (HTS) counselors support pharmacy providers in offering clients PrEP and PEP services for a fee of 0 KES per visit (study team compensates pharmacy providers 100 KES per visit).
88836060|NCT05842122|Active Comparator|Pharmacy referral to clinic-based PrEP/PEP|Pharmacy providers offer clients referral to PrEP and PEP services at nearby public clinics for a fee of 0 KES per referral (study team compensates pharmacy providers 100 KES per referral).
88836061|NCT05839353||simulated training by Serious Game (SG)|Simulated training (by SG) for the use of the SBAR tool associated with the usual instructions issued in routine care, on the management of dyspnea
88836062|NCT05839353||usual instructions issued in routine care|Usual instructions issued in routine care, on the management of dyspnea
88836063|NCT05838456|Experimental|Hospital 1 - 3 months with no Viz.AI software, then 12 months with Viz.AI software|
88836064|NCT05838456|Experimental|Hospital 2 - 6 months with no Viz.AI software, then 9 months with Viz.AI software|
88836065|NCT05838456|Experimental|Hospital 3 - 9 months with no Viz.AI software, then 6 months with Viz.AI software|
88836066|NCT05838456|Experimental|Hospital 4 - 12 months with no Viz.AI software, then 3 months with Viz.AI software|
88836067|NCT05835752|Experimental|RAY1225(Part A)|Escalating doses of RAY1225 administered subcutaneously (SC) once in healthy participants.
88836068|NCT05835752|Experimental|Placebo (Part A)|Placebo administered SC once in healthy participants.
88836069|NCT05835752|Experimental|RAY1225 (Part B)|Escalating doses RAY1225 administered SC once weekly for four weeks in healthy participants.
88836070|NCT05835752|Experimental|Placebo (Part B)|Placebo administered SC once weekly for four weeks in healthy participants.
88836071|NCT05835752|Experimental|RAY1225(Part C)|Three dose levels of RAY1225 administered SC once weekly for four weeks in participants with Obese.
88836072|NCT05835752|Experimental|Placebo (Part C)|Placebo administered SC once weekly for four weeks in participants with Obese.
88836073|NCT05834465||Group 1|After using a non-contact tonometer to measure, the intraocular pressure is reduced by 0-10mmHg.
88836074|NCT05834465||Group 2|After using a non-contact tonometer to measure, the intraocular pressure is reduced by 10-20mmHg.
88836075|NCT05834465||Group 3|After using a non-contact tonometer to measure, the intraocular pressure is reduced over 20mmHg.
88836076|NCT05832892|Experimental|surufatinib + KN046 + nab-paclitaxel + gemcitabine|"In the phase Ib of dose escalation, all patients enrolled will receive: nab-paclitaxel at 125 mg/m2 on days 1 and 8, gemcitabine at 1000 mg/m2 on days 1 and 8, KN046 at 5 mg /kg on day 1, plus surufatinib per cohort escalation assignment starting with 200 mg. The combination treatment repeats every 3 weeks, until disease progression, death, intolerable toxicity, or withdrawal of informed consent. Dose-limiting toxicity will be evaluated 28 days after first dose to determine the recommended phase 2 dose (RP2D) of surufatinib.~Patients enrolled in the phase II of dose expansion will receive the combination regimen of nab-paclitaxel plus gemcitabine plus KN046 plus surufatinib as determined in the phase Ib."
88836077|NCT05832398|Experimental|Organoid guided chemotherapy|Patients will receive sensitive chemotherapy in organoid drug test once every two weeks for 6 cycles as adjuvant chemotherapy
88836078|NCT05832398|Active Comparator|FOLFOX regimen|Patients will receive FOLFOX regimen once every two weeks for 6 cycles as adjuvant chemotherapy
88836079|NCT05824325|Experimental|Experimental: HER2 ADC|Patients diagnosed with HER2 ultra-low or no expression are recruited
88836080|NCT05824325|Experimental|Experimental: TROP2 ADC|Patients diagnosed with HER2 ultra-low or no expression are recruited.
88836081|NCT05823987|Experimental|H101 + Tislelizumab+ Lenvatinib|H101 intratumorally injection starts at day 0. Tislelizumab plus lenvatinib will be initiated on day 1. Tislelizumab will be administered at 200 mg i.v. every 3 weeks plus a lenvatinib (bodyweight ≥ 60 kg, 12 mg; < 60 kg, 8 mg) orally daily every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
88836082|NCT05823467|Experimental|Post operative Antibiotic|Patients in this arm will have a prescription for one week or post operative antibiotic ( 7-day course of TMP-SMX DS )
88836083|NCT05823467|Experimental|Post operative Wound VAC|Patient will have a 7-day application of ciNPT dressing post operatively.
88836084|NCT05823467|No Intervention|No Intervention|Patient will be treated as standard of care which is no intervention.
88836085|NCT05823337|Active Comparator|only given diet therapy|only diet theraphy
88836086|NCT05823337|Experimental|given diet therapy and selenium|diet theraphy and 200 mcg selenium
88836087|NCT05821595|Experimental|JYB1907 Dose 1|"Five dose levels of JYB1907 are evaluated in the dose escalation part.In the expansion cohort part, the biologically active dose(s) confirmed in the dose escalation part with one or more dosing regimens will be selected.~The dose of JYB1907 is based on the actual body weight as measured prior to each intravenous administration."
88836088|NCT05821595|Experimental|JYB1907 Dose 2|"Five dose levels of JYB1907 are evaluated in the dose escalation part.In the expansion cohort part, the biologically active dose(s) confirmed in the dose escalation part with one or more dosing regimens will be selected.~The dose of JYB1907 is based on the actual body weight as measured prior to each intravenous administration."
88836089|NCT05821595|Experimental|JYB1907 Dose 3|"Five dose levels of JYB1907 are evaluated in the dose escalation part.In the expansion cohort part, the biologically active dose(s) confirmed in the dose escalation part with one or more dosing regimens will be selected.~The dose of JYB1907 is based on the actual body weight as measured prior to each intravenous administration."
88836090|NCT05821595|Experimental|JYB1907 Dose 4|"Five dose levels of JYB1907 are evaluated in the dose escalation part.In the expansion cohort part, the biologically active dose(s) confirmed in the dose escalation part with one or more dosing regimens will be selected.~The dose of JYB1907 is based on the actual body weight as measured prior to each intravenous administration."
88836091|NCT05821595|Experimental|JYB1907 Dose 5|"Five dose levels of JYB1907 are evaluated in the dose escalation part.In the expansion cohort part, the biologically active dose(s) confirmed in the dose escalation part with one or more dosing regimens will be selected.~The dose of JYB1907 is based on the actual body weight as measured prior to each intravenous administration."
88836092|NCT05819957|Experimental|Experimental patients|MSA patients included in the therapeutic education program
88836093|NCT05818696|Experimental|LMC - CUE|In this arm, participants will receive Lethal Means Counseling before receiving CBT for Uncertainty-Enhanced (CUE).
88836094|NCT05818696|Experimental|CUE - LMC|In this arm, participants will receive CBT for Uncertainty-Enhanced (CUE) before receiving Lethal Means Counseling.
89178576|NCT04117139|Other|Study Group|In addition to other standard imaging modalities in the fast track cancer program, included patients will have a PET/MRI done.
88836095|NCT05815693|No Intervention|Group 1|usual care for anxiety, depression, chronic pain and insomnia
88836096|NCT05815693|Experimental|Group 2|mindfulness-based stress reduction (MBSR) for anxiety, depression, chronic pain and insomnia
88836097|NCT05798039|Experimental|ENRICHed NFP|Participants will receive additional heart health-focused materials and guidance in sessions with their nurse home visitor. The nurse will help them choose and work towards behavior goals to support their health. This will include goals for activity, diet, weight, blood pressure, diabetes, smoking, social relationships, sleep, parenting, and getting health care.
88836098|NCT05796791|Experimental|Treatment of tobacco use disorder with ketamine|
88836099|NCT05794152|Other|Standardized breakfast|Egg (50g), whole-wheat bread (35g), celery (30g), and dried bean curd (10g)
88836100|NCT05794152|Other|Standardized snack|Tomato (50g) and skim milk (200g)
89178577|NCT02612597|Experimental|Bedrest|4 days of bedrest
89178578|NCT02612597|Experimental|Exercise Training|6 weeks of aerobic endurance exercise training with 4 supervised sessions per week at an average intensity of 65 % of maximal heart rate
89178579|NCT00845429|Experimental|Group 1: Standard-dose Cell-based Influenza Vaccine|Participants will receive a single dose of standard-dose cell-based influenza virus vaccine.
89178580|NCT00845429|Experimental|Group 2: High-dose Cell-based Influenza Vaccine|Participants will receive a single dose of high-dose cell-based influenza virus vaccine.
89364981|NCT06030297|Active Comparator|Crossover testing in participants with painful neuropathy (ZTlido 1.8% lidocaine patch)|History, physical, and neurological exam Nerve conduction study Medical record review of neuropathy history PROMIS pain severity and interference testing Brief pain inventory Norfolk quality of life questionnaire Quantitative sensory testing 3mm skin punch biopsy Diode laser testing of C:Aδ ratio Non-invasive speckle imaging ZTlido 1.8% lidocaine patch application to both feet for 7 days up to 12 hours per day.
89534654|NCT05037591|Experimental|sea grape extract Q|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
88836101|NCT05794152|Other|Standardized lunch|Rice (40g), oats (40g), shrimp (70g), lettuce (80g), lean pork (30g), carrot (10g), soaked auricularia auricula (20g), broccoli (80g), cucumber (10g), tomato egg drop soup (200g), salt (3g), and oil (8g)
89178581|NCT00845429|Active Comparator|Group 3: Licensed Fluzone® Influenza Vaccine|Participants will receive a single dose of licensed Fluzone® influenza vaccine.
88836102|NCT05792566|Experimental|Real life usability testing|"B) Real Life Usability Testing. We will conduct a real life usability test in a sample of 6 pediatric cancer survivors. EX@HOME: Patients will perform an individualized aerobic and resistance exercise intervention, choosing from a list of PA, progressing from light to moderate-to-vigorous intensity totaling 30-45 min/d, 4-5 weekly/wk. for 4 weeks. The social-cognitive-theory-based mobile app will support the exercise intervention. One-on-one messaging chats with a PA coach through the mobile app will facilitate exercise goal establishment and attainment."
89178582|NCT00699101|Experimental|A|Conture Multi-Lumen Balloon
89178583|NCT00593333|Active Comparator|1, A|Standard femoral intramedullary nail that utilizes a piriformis fossa portal in the treatment of fractures of the subtrochanteric and diaphyseal shaft regions of the femur.
89178584|NCT00593333|Experimental|2, B|Trigen Trochanteric Femoral Nail (Smith & Nephew, Memphis)using a trochanteric insertion portal in the treatment of fractures of the subtrochanteric and diaphyseal shaft regions of the femur
89178585|NCT04117217||Central venous lines|Patients having a central venous catheter placed at Banner University Medical Center, University of Arizona
89178586|NCT04117217||Cardiac catheterization|Patients undergoing a cardiac catheterization procedure done at Banner University Medical Center, University of Arizona
89178587|NCT02613533|Experimental|Narrow Angle Glaucoma Study Group|Subjects will be given 10ml/kg of water over 15 min prior to surgery and Intra-ocular pressure measurement (IOP) is checked every 15 min before and after surgical procedure.
89178588|NCT00844883|Experimental|sorafenib and drug eluting beads|single arm
89178589|NCT00851903|Experimental|Combination insulin glargine and sitagliptin|"Insulin glargine administered once a day, in the evening, at dinner or at bedtime. Starting dose: - last dose administered in the core study for patients previously treated with insulin glargine, - 0.2 U/Kg of body weight for patients previously treated with sitagliptin. Monitoring of blood glucose and titration: all patients, irrespective of their previous treatment group in the core study were empowered to adjust their insulin doses, under strict investigator's supervision. The goal was to achieve through a force titration 70 < Fasting Plasma Glucose (FPG) ≤ 100 mg/dL (3.9 <FPG ≤ 5.5 mmol/L).~Sitagliptin: stable dose of 100 mg once a day administered with or without food."
89178590|NCT02612441|Experimental|1 real Acupuncture group-intervention|real Acupuncture Needles
89178591|NCT02612441|Sham Comparator|2 sham Acupuncture group|sham Acupuncture Needles
89178592|NCT00587457|Experimental|CAT-8015 5 microgram per kilogram (mcg/kg)|Participants received a single intravenous infusion of 5 mcg/kg moxetumomab pasudotox (CAT-8015) on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until progressive disease (PD) or until otherwise they become ineligible.
89178593|NCT00587457|Experimental|CAT-8015 10 mcg/kg|Participants received a single intravenous infusion of 10 mcg/kg moxetumomab pasudotox (CAT-8015) on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until progressive disease (PD) or until otherwise they become ineligible.
89178594|NCT00587457|Experimental|CAT-8015 20 mcg/kg|Participants received a single intravenous infusion of 20 mcg/kg moxetumomab pasudotox (CAT-8015) on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until progressive disease (PD) or until otherwise they become ineligible.
89178595|NCT00851747|Experimental|C Phosphatidylcholine Deoxycholate|Phosphatidylcholine Deoxycholate Injections. Group C will receive only study drug injections
89178596|NCT00851747|Placebo Comparator|A Saline|Group A will serve as a control and will receive only injections of saline as a placebo.
89178597|NCT00851747|Active Comparator|B PhosphatidylcholineDeoxycholate/Saline|Group B will receive saline injections on one side of the body and receive study drug injections on the contralateral side.
89178598|NCT04100031|Experimental|BCL group|
89178599|NCT04100031|Active Comparator|control group|
89178600|NCT02612519|Experimental|Alfapump - Substudy 1|Alfapump implantation
89178601|NCT02612519|Active Comparator|TIPS - Substudy 1|TIPS implantation
89178602|NCT02612519|Experimental|Alfapump - Substudy 2|Alfapump implantation
89178603|NCT02612519|No Intervention|Standard - Substudy 2|Standard treatment
89534655|NCT05037591|Experimental|sea grape extract R|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
89534656|NCT05037591|Experimental|sea grape extract S|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
88836103|NCT05789745|Experimental|rhu-pGSN|Treated with 5 doses of rhu-pGSN
88836104|NCT05789745|Placebo Comparator|normal saline|Treated with 5 doses of saline
88836105|NCT05788406|Experimental|Short Foot Exercises Group|İnsole+Short Foot Exercises group
88836106|NCT05788406|Experimental|Balance Exercises Group|İnsole+Balance exercises group
88836107|NCT05788406|Experimental|Control Group|İnsole group
88836108|NCT05787899||Hypothermia Protocol|
88836110|NCT05783726|Other|Control|The control arm will show the products with no label.
89364982|NCT06030297|Placebo Comparator|Crossover testing in participants with painful neuropathy (placebo patch)|History, physical, and neurological exam Nerve conduction study Medical record review of neuropathy history PROMIS pain severity and interference testing Brief pain inventory Norfolk quality of life questionnaire Quantitative sensory testing 3mm skin punch biopsy Diode laser testing of C:Aδ ratio Non-invasive speckle imaging Placebo patch application to both feet for 7 days up to 12 hours per day.
89364983|NCT06030271|Experimental|TrueCross microcatheter|The TrueCross Single-use Microcatheter will be used in percutaneous coronary intervention(PCI) of the enrolled subjects.
89364984|NCT06030232||Observation group|Patients who received radioembolization for colorectal cancer liver metastases
89364985|NCT06030219|Experimental|Omadacycline|Subjects will receive 3 tablets on day 1 and day 2 (450 mg) followed by 2 tablets (300 mg) for days 3 through 10.
89364986|NCT06030219|Active Comparator|Vancomycin (oral)|Vancomycin 125 mg capsules will be taken four times daily for a total of 10 days.
89364987|NCT06030219|Active Comparator|Moxifloxacin|Moxifloxacin 400 mg tablets will be taken once per day for a total of 10 days.
89364988|NCT06030180|Other|Single Arm Study|
89364989|NCT06030167|Other|Assessment of attachment and psychosocial functioning in adults with ASD|Questionaires about attachment, psychosocial functioning, depressive symptoms, paranoid ideation, and emotion regulation were administered to 83 autistic adults (50 males, 33 females).
89364990|NCT06030128|Experimental|Core stabilization exercise group|All participants will undergo 16 session exercise program for 2 months. Each session will last for 60minutes. The exercise program will be arranged in a group format with class size ranging from 6 - 8per class. Subjects will be divided into experimental and control groups.
89364991|NCT06030128|No Intervention|waiting list control group|Participants in the control group will not receive exercise training at first but were evaluated at the same time as participants in the experimental group.
89364992|NCT06030115||Cardiac Rehab Patients|All participants referred to the clinic meeting the inclusion and exclusion criteria who wanted to participate in the study.
89364993|NCT06030102||Healthy young population|
89364994|NCT06030011|Experimental|NYU Electronic Patient Visit Assessment (ePVA) plus Usual Care|
89364995|NCT06030011|Active Comparator|Usual Care|
88836111|NCT05783726|Experimental|Experimental: Nutriscore Label|The Nutriscore label applies a letter grade (A, B, C, D or E) to a product based on certain nutrient criteria.
89364996|NCT06029933||Fluad Recipients|Kaiser Permanente Northern California members aged ≥65 years who receive Adjuvanted Quadrivalent Inactivated Influenza Vaccine (aIIV4)
88836112|NCT05783726|Experimental|Experimental: Adapted Peruvian Nutrient Label|"The adapted label is a black octagon with the words in Spanish saying Excess of sugar,Excess of saturated fat, or Excess of salt/sodium depending on the nutrition contents of the product. Below the octagon is a box with words in Spanish saying Avoid high consumption"
88836113|NCT05783726|Experimental|Experimental: Guideline Daily Amount Label|The Guideline Daily Amount label highlights the nutrient contents of the product by serving. It lists the calories, total fat, saturated fat, sugar, and sodium, as well are their % of the daily value.
89178604|NCT00702065||1|
89364997|NCT06029933||Fluzone High-Dose Recipients|Kaiser Permanente Northern California members aged ≥65 years who receive High-Dose Quadrivalent Inactivated Influenza Vaccine (HD-IIV4)
89364998|NCT06029881||Obstructive sleep apnea patients|"Patients admitted for complaints of sleep disturbances with no prior significant cardiovascular disease.~Inclusion criteria:~18 < age <70~BMI < 35 kg/m2~Exclusion criteria:~Being under any kind of OSA treatment (cPAP therapy, etc.)~Having been diagnosed with Atrial fibrillation, significant valvular heart disease, or ventricular dysfunction~Age <18 or age > 70~BMI > 35 kg/m2"
89364999|NCT06029868|Experimental|Black seed|Black seed oil capsule taken orally
89365000|NCT06029868|Placebo Comparator|Placebo|Placebo capsule taken orally
89365001|NCT06029855|Active Comparator|Kabat Therapy|Kabat exercises primarily assist functional response in defective muscles through the general structure of muscles experiencing resistance. After 6th week, resting and voluntary symmetries were recorded.
89365002|NCT06029855|Experimental|Mime Therapy|Mime therapy utilizes emotional input to access better movement patterns. It is beneficial as it improves circulation and maintains muscle properties.
89365003|NCT06029829|Experimental|Immunomonotherapy plus Chemotherapy plus Anti-angiogenesis Therapy|Any first-line treatment that includes immunotherapy、 Chemotherapy and Anti-angiogenesis Therapy
89178605|NCT00702065||2|
88836114|NCT05780177|Experimental|BBTI|Participants in this arm will receive 4 sessions (20-60 minutes) of a brief behavioral treatment for insomnia (BBTI). Relaxation techniques are not a component of BBTI.
88836115|NCT05780177|Active Comparator|PMRT|Participants in this arm will receive 4 sessions (20-60 minutes) of progressive muscle relaxation training (PMRT).
88836116|NCT05779605|Experimental|Home-based training|12 weeks of home-based exercise training using modern technology to transfer exercise data remotely. The participants receive a heart rate monitor and sensor. Three sessions per week will be performed (36 sessions overall).
88836117|NCT05779605|Active Comparator|Center-based training|12 weeks of centre-based exercise training under supervision physiotherapists specializing in exercise rehabilitation. The participants receive a heart rate monitor and sensor. The patients in the Center-based training group receive an individually tailored training program on a treadmill and a bicycle ergometer. Three sessions per week will be performed (36 sessions overall).
88836118|NCT05771090|Experimental|Study arm|Participants in the study arm will undergo the study procedure which are different induced glycaemic states.
88836119|NCT05759364|Active Comparator|Intervention group- IV PAPAVERINE 80 mg|Administration of IV PAPAVERINE 80 mg in 100 ml of saline, once within half an hour before inserting a single-balloon balloon catheter
88836120|NCT05759364|Placebo Comparator|Conrol group- Placebo group.|Administration of 100 ml of saline within half an hour before the insertion of a single-balloon catheter
88836121|NCT05754931|Experimental|deep neck flexor group|"Deep neck flexors stretch~Conventional Therapy:~Moist heat therapy for 10 minutes, TENS 10 min, cervical active ROMS, Non-thrust mobilizations"
88836122|NCT05754931|Active Comparator|muscle energy technique|"Post isometric stretch on trapezious and suboccipital muscles~Conventional Therapy:~Moist heat therapy for 10 minutes, TENS 10 min, cervical active ROMS, Non-thrust mobilizations"
88836123|NCT05754632|Experimental|BFR Intervention Group|"In addition to the standard ACL rehabilitation protocol, the experimental group will complete 2 exercises using the Delfi BFR cuff 2x/week for 8 weeks during their treatment session at Connecticut Children's Sports Physical Therapy on the second post-operative visit. Cuff size will be determined by patient thigh circumference Limb occlusion pressure will be determined in supine position and all exercises will be completed at 80% occlusion.~Long Arc Quadriceps (LAQ) progression Shuttle progression Post-op visit 2- 2 weeks Quadriceps Set Standing Straight Leg Raise 2 weeks-4 weeks Available range LAQ Standing terminal knee extension 4 weeks-8 weeks LAQ (0-90°) Single Limb Shuttle/Leg Press"
88836124|NCT05754632|No Intervention|No Intervention/Control Group|"In addition to the standard ACL rehabilitation protocol, the control group will complete the same exercises as the experimental group starting on the second post-operative visit.~Long Arc Quadriceps (LAQ) progression Shuttle progression Post-op visit 2- 2 weeks Quadriceps Set Standing Straight Leg Raise 2 weeks-4 weeks Available range LAQ Standing terminal knee extension 4 weeks-8 weeks LAQ (0-90°) Single Limb Shuttle/Leg Press"
88836125|NCT05749926|Active Comparator|Comirnaty® BNT162b2 /Omicron BA.4-5 vaccine (Pfizer-BioNTech)|Length of use : 1 day
88836126|NCT05749926|Experimental|VidPrevtyn® Beta vaccine (Sanofi/GSK)|Length of use : 1 day
88836127|NCT05749146|Experimental|Palliative care at home|Randomized to intervention arm
88836128|NCT05749146|Active Comparator|Augmented control|Randomized to augmented control (visits to the caregiver from a CHW without training in dementia or palliative care)
88836129|NCT05740540|Experimental|Implantation, controller development, and evaluation|This phase includes installing the device and setting the individual up for home use, creating advanced controllers for walking and evaluating the effect of the device over several months.
88836130|NCT05737238|No Intervention|Baseline phase (Phase A)|At the start of the study, all participants are assigned to the baseline phase (phase A). During phase A, patients do not receive interventions related to executive function problems. The start of the intervention phase (phase B) is determined randomly for each participant, given the restriction that phase A should last for at least three weeks (21 days) and at most five weeks (30 days). This means that phase B can start on any day between the 21th and the 30th days, resulting in a total of 10 possible assignments. So, in the first three weeks, all participants are in phase A. The duration of phase A will thus be different for each subject. Phase A acts as a control and is therefore compared with phase B.
88836131|NCT05737238|Experimental|Intervention phase (Phase B): Goal Management Training|During the intervention phase (phase B), all included participants will have 6 sessions of Goal Management Training (GMT; twice per week) in which two individual chosen IADL-tasks will be subdivided into multiple steps under guidance of a therapist using the GMT method. In addition participants play the compensatory brain game in which they are challenged to apply the learned GMT strategy in an imaginary and safe environment.
88836132|NCT05737238|No Intervention|Follow-up period|A follow-up period of three weeks takes place after phase B. During this follow-up period, patients receive no intervention.
88836133|NCT05730205|Active Comparator|Nexplanon|
88836134|NCT05730205|No Intervention|Baseline|
88836135|NCT05720364|Experimental|TP-05, Fasted Group|Single dose of TP-05 (lotilaner oral), fasted
88836136|NCT05720364|Experimental|TP-05, High-Fat Group|Single dose of TP-05 (lotilaner oral) following a high-fat meal
88836137|NCT05720364|Experimental|TP-05, Low-Fat Group|Single dose of TP-05 (lotilaner oral) following a low-fat meal
89001595|NCT00587899|Other|1|The treatment group will undergo operation for mitral valve disease with an additional procedure called Pulmonary Vein Isolation.
89365004|NCT06029816|Experimental|Arm1-Exon 18|Exon 18 G719X, E709X, etc，Up to 14 patients will be enrolled in this group and will be treated with neratinib tablets in 28-day cycles，
89365005|NCT06029816|Experimental|Arm2-Exon 20|S768I in exon 20，Up to 14 patients will be enrolled in this group and will be treated with neratinib tablets in 28-day cycles，
89365006|NCT06029816|Experimental|Arm3-Exon 21|L861Q of exon 21，Up to 14 patients will be enrolled in this group and will be treated with neratinib tablets in 28-day cycles，
88836138|NCT05710861|Experimental|F-HIFU Group|50 to 75 years old patients fit for a Radical Prostatectomy when active surveillance is not recommended and who do not want a radiation therapy: harboring a non-treated localized PC, with a maximum Gleason score of 3+4 , ISUP 2 and less than 50% of positive prostate biopsy (favorable intermediate risk), with or without contralateral microfocus score 3+3 (ISUP 1) of less than 3 mm, with a tumor visible on MRI and biopsy-proven with systematic and targeted biopsy with at least 2 biopsies per target and 12 systematic biopsies, Tumor involving maximum 2 biopsy-proven contiguous sextants. Patients with multiple MRI targets may be included if only one target is biopsy-proven, T1c-T2 stage, PSA <20 ng/ml, prostate volume less than 100 ml, fully informed patient accepting, after a decent reflexion time, to participate to the study by signing a consent form, affiliated or beneficiary patient to the French social security system
88836139|NCT05710861|Active Comparator|Prostatectomy Group|50 to 75 years old patients fit for a Radical Prostatectomy when active surveillance is not recommended and who do not want a radiation therapy: harboring a non-treated localized PC, with a maximum Gleason score of 3+4 , ISUP 2 and less than 50% of positive prostate biopsy (favorable intermediate risk), with or without contralateral microfocus score 3+3 (ISUP 1) of less than 3 mm, with a tumor visible on MRI and biopsy-proven with systematic and targeted biopsy with at least 2 biopsies per target and 12 systematic biopsies, Tumor involving maximum 2 biopsy-proven contiguous sextants. Patients with multiple MRI targets may be included if only one target is biopsy-proven, T1c-T2 stage, PSA <20 ng/ml, prostate volume less than 100 ml, fully informed patient accepting, after a decent reflexion time, to participate to the study by signing a consent form, affiliated or beneficiary patient to the French social security system
89365007|NCT06029803|Experimental|Adrenal Venous Sampling via Antecubital Approach|Patients in the experimental group will undergo adrenal venous sampling via antecubital vein approach.
88836140|NCT05709899|Other|Group I : Bilateral erector spinae plane block at L1|"Ultrasound (US) will be used to identify the level of L1 after skin sterilization with the patient on the lateral position. A high frequency linear-array US transducer covered in a sterile sleeve will be placed in a longitudinal parasagittal orientation 3 cm lateral to the midline to identify the trapezius above, the rhomboid major in the middle, and the erector-spinae muscle on the bottom, and the transverse Processes with shimmering pleura in between. 2-3 ml of 2% lidocaine depocaine HCL will be infiltrated.16-G, 8-cm Tuohy needle will be then introduced medially in the plane of the US beam and directed towards the transverse process. Once the needle is underneath the anterior fascia of the erector spinae muscle. 20 ml of bupivacaine 0.25% sunnypivacaine will be injected in this potential space over five minutes. The injectate will be observed spreading underneath the ES muscle lifting the muscle of the transverse process. This will be repeated on the opposite side."
89365008|NCT06029803|Active Comparator|Adrenal Venous Sampling via Femoral Approach|Patients in the active comparator group will undergo adrenal venous sampling via femoral vein approach.
89365009|NCT06029790|Experimental|gum chewing|"All participants will receive standard postoperative care, 2 L/min of oxygen delivered via nasal cannula if oxygen saturation is below 95%. In addition, participants will be encouraged to use the incentive spirometer 10 times per hour to prevent respiratory complications such as pneumonia. In the postoperative period, all participants will be removed from bed and mobilized as soon as possible.~For the patients in the experimental group, sugar-free xylitol gum containing 1.2-1.37 grams of xylitol per piece, available in the market, will be used. Participants in the experimental group will start chewing gum on the first postoperative day and will be allowed to chew a single piece of gum 3 times a day at 9:00, 14:00 and 19:00, respectively, for 15 minutes. The gum will be given to the participants regularly by a researcher until the first reported flatulence."
89365010|NCT06029790|No Intervention|control group|"All participants will receive standard postoperative care, 2 L/min of oxygen delivered via nasal cannula if oxygen saturation is below 95%. In addition, participants will be encouraged to use the incentive spirometer 10 times per hour to prevent respiratory complications such as pneumonia. In the postoperative period, all participants will be removed from bed and mobilized as soon as possible.~The control group will receive only standard care."
89365011|NCT06029777||Retrospective cohort|"The retrospective cohort will include 2190 patients who underwent a clinically indicated cCTA between 2017 and 2019 at the Radiology Unit of San Raffaele Hospital.~No other interventions will be performed. Patients will be solely contacted via a telephone call to assess their clinical status."
89365012|NCT06029764|Experimental|experimental group|The study will enroll patients with lumbar degeneration undergoing 1-2 level intervertebral fusion, and for patients with asymptomatic and non-instability intervertebral discs adjacent to the operative level with vacuum signs, extended one-level interbody fusion will be performed.
89001596|NCT00587899|No Intervention|2|The control group of patients will undergo operation for mitral valve disease without the additional Pulmonary Vein Isolation
89001597|NCT00182468|Experimental|1|Women are screened for intimate partner violence prior to seeing a health care provider.
89001598|NCT00182468|No Intervention|2|Women see their health care provider without being asked about intimate partner violence.
89001599|NCT00587938||A|BNP level from protocol blood tests initiated in the ED, reported to ED physician prior to ED disposition.
88836141|NCT05709899|Other|Group II : Transmuscular quadratus lumborum block at L1|"Patient will be positioned in left lateral to obtain appropriate view of QL. Aseptic precautions will be taken by wearing sterile gown and sterile drapes. By using Ultrasound MacroMaxx™ with linear probe (HFL38_10-5 MHz) covered with sterile plastic sheath SiteRite placed in the anterior axillary line to visualize the typical triple abdominal layers. Then, the probe will be placed in the midaxillary line and at this juncture the layers of abdominal layers will start to taper. When the probe will be placed in the posterior axillary line as per the posterior approach, sonoanatomy will show first the transversus abdominis disappearing then the internal oblique and external oblique forming aponeurosis and appearance of QL noticed. At the junction of the tapered ends of abdominal muscles and QL, a 21 g 100 mm SonoPlexStimu cannula needle will be inserted in plane. Under ultrasound guidance, in that space 20 mL of 0.25% bupivacaine sunnypivacainewill be injected separating the fascia."
88836142|NCT05708092|Active Comparator|NeuroResource Facilitation|As part of the NRF intervention group, participants will receive specialized care management, both in prison and after the participant goes home. While in the State Correctional Institution (SCI), participants will meet weekly to monthly depending on resource needs, and how close participant is to release with a NeuroResource Facilitator in person who will help participants to understand more about their challenges. Participants may also be referred to a group run by the Facilitator in conjunction with staff from the prison. The facilitator will also tell the participant about resources that are available to help after the participant's release and help participants get connected to them.
88836143|NCT05708092|No Intervention|Standard of Care|As part of the SoC, participants will receive the re-entry services normally receive if not in the study including (but not limited to) Treatment Services, Educational and Vocational Training, Mental Health Management, Reentry and Transitional Services, Population Management and Community Corrections.
89178606|NCT04099563|Experimental|PF-04965842|Following an overnight fast for at least 10 hours, participants will receive PF-04965842 oral single dose of 200 mg (2 × 100 mg tablets) on Day 1, at approximately 08:00 am plus or minus 2 hours in the morning. On Days 3 to 8, participants will receive PF-04965842 oral dose of 200 mg (2 × 100 mg tablets) QD in the morning at approximately similar clock hour as on Day 1. On Day 3 and Day 6-8, the dosing of PF-04965842 will be after collection of pre-dose blood samples (under fasted condition for at least 10 hours). On Day 8, the dosing will be under fasted condition at approximately 8:00 am plus or minus 2 hours in the morning.
89178607|NCT02613689|Experimental|Scheduled Gradual Reduction (SGR)|Subjects will receive the Scheduled Gradual Reduction (SGR) intervention, as well as SMS support text messages.
89178608|NCT02613689|Active Comparator|Control Group|Subjects will receive SMS support text messages
89178609|NCT00767325|Experimental|Abatacept, 10 mg/kg|
89178610|NCT00851591|Experimental|Fenugreek category 1|receive fenugreek
89178611|NCT00851591|Placebo Comparator|Placebo Category 2|receive placebo
89178612|NCT04119947|Experimental|SY-009 dose 1|A single dose of SY-009 (0.5-40mg) taken orally.
89178613|NCT04119947|Experimental|SY-009 dose 2|A single dose of SY-009 (0.5-40mg) taken orally.
89178614|NCT04119947|Experimental|SY-009 dose 3|A single dose of SY-009 (0.5-40mg) taken orally.
89178615|NCT04119947|Experimental|SY-009 dose 4|A single dose of SY-009 (0.5-40mg) taken orally.
89178616|NCT04119947|Experimental|SY-009 dose 5|A single dose of SY-009 (0.5-40mg) taken orally.
89178617|NCT04119947|Experimental|SY-009 dose 6|A single dose of SY-009 (0.5-40mg) taken orally.
89178618|NCT04119947|Placebo Comparator|SY-009 matching placebo|from 2-40mg
89178619|NCT04115579|Experimental|Biscuit 1 Control|Consumption of control biscuit for breakfast and afternoon snack and impact on postprandial glucose and insulin
89178620|NCT04115579|Experimental|Biscuit 2 Test|Consumption of test biscuit for breakfast and afternoon snack on postprandial glucose and insulin
89178621|NCT00702455|Active Comparator|Self-Directed|
89178622|NCT00702455|Active Comparator|Guided|
89178623|NCT04116905|Experimental|Intensive Lifestyle Intervention|Participants in the intensive lifestyle intervention arm are offered individual and group sessions designed to help achieve and maintain a 15% weight loss.
88836144|NCT05706233||Erector Spina Plane Block (ESPB)|
88836145|NCT05706233||Intravenous Group (IV)|
89178624|NCT04116905|Active Comparator|Conventional Treatment|The conventional treatment arm provides group sessions on metabolic syndrome management and social support, aimed at a 5% weight loss.
89178625|NCT02612363|Experimental|Early goal directed sedation group|"Dexmedetomidine for sedation in early goal directed sedation group~Analgesia~Dexmedetomidine start at 0.7ug/kg/hour~Dose range: 0.2- 0.7 u/kg/hour~Supplemental other sedatives at lowest effective dose Target Richmond Agitation-Sedation Scale score of -2 to +1 to achieve sedation goal in EGDS group"
89178626|NCT02612363|Placebo Comparator|Standard sedation|"Control drug for sedation in early goal directed sedation group~Analgesia~Control drug~Supplemental other sedatives at lowest effective dose for standard sedation Target Richmond Agitation-Sedation Scale score of -2 to +1 to achieve sedation goal"
89178627|NCT00913211|Experimental|rTMS only|brain stimulation to non-stroke primary motor area
89178628|NCT00913211|Experimental|Finger tracking training|Motor learning training using finger flexion/extension tracking movements toward a target.
89178629|NCT00913211|Experimental|rTMS and finger tracking|Combination of rTMS and tracking
89178630|NCT00913211|Placebo Comparator|Sham|Sham rTMS treatment
89178631|NCT00702611|Experimental|1|Seven apheresis treatments over seven consecutive weeks (1/week) in conjunction with a starting dose of 40mg of oral prednisone per day at Week 00 for two weeks which will be tapered down to zero 5 mg/week within nine weeks
89178632|NCT00702611|Active Comparator|2|Treatment with starting dose of 40mg of oral prednisone per day at Week 00 for two weeks and tapered down to zero 5 mg/week within nine weeks
89178633|NCT04119869|Experimental|iaya Smart Phone Application|"Pre-study evaluation~Access to the smartphone intervention over the course of 12 weeks~Post-study evaluation and interview"
89178634|NCT00912899|Experimental|One|Noscapine HCl
89365013|NCT06029764|No Intervention|control group|The control group underwent intervertebral fusion only at the responsible segment.
89365014|NCT06029738|Experimental|Experimental group|Intervention (Metacognitive Education for Obsessive-Compulsive Disorder (MCT-OCD)): MCT-OCD is a group education for OCD patients
89365015|NCT06029738|No Intervention|Control group|
89365016|NCT06029699|Active Comparator|high flow nasal cannula group|patients put on high flow nasal cannula after extubation
89365017|NCT06029699|Active Comparator|non invasive positive pressure ventilation group|patients put on non invasive positive pressure ventilation group after extubation
88836146|NCT05705050|Experimental|Aminophylline group|Patients will receive 4 mg/kg aminophylline diluted in 100 ml normal saline over 20 minutes after induction of anesthesia and positioning of patients in lithotomy position.
88836147|NCT05705050|Placebo Comparator|Control group|Patients will receive 100 ml normal saline over 20 minutes after induction and lithotomy positioning.
89365018|NCT06029686|Experimental|Stimulation|Patients will be asked to stimulate using a non invasive vibrotactile device.
89365019|NCT06029660|Experimental|Treatment|Treatment Arm: Subjects in the treatment arm will have both an EVAR device and IMPEDE-FX RapidFill implants inserted.
89365020|NCT06029660|Active Comparator|Control|Control Arm: Subjects in the control arm will only have an EVAR device implanted.
89365021|NCT06029634||virologic breakthrough|CHB patients withdraw NAs with virologic breakthrough
89365022|NCT06029634||virologic response|CHB patients withdraw NAs with virologic response
89365023|NCT06029634||healthy group|The healthy (non-HBV infected) group completed a standard HBsAg vaccination scheduled before entering the study
89365024|NCT06029608||Magnetically-controlled Capsule endoscopy group|Using magnetic-controlled capsule gastroscopy for postoperative assessment in elderly patients and patients with underlying diseases
89365025|NCT06029608||Conventional endoscopy group|Using conventional endoscopy for postoperative assessment in elderly patients and patients with underlying diseases
89365026|NCT06029595|Experimental|CHF6001 - CHF6001 total daily dose 3200 μg;|
89365027|NCT06029595|Placebo Comparator|Placebo|
89365028|NCT06029582|Experimental|Virtual Reality headset|Individuals will wear the Virtual Reality Headset that produce a calming scenario
89365029|NCT06029582|No Intervention|controls|no headset
89365030|NCT06029569|Experimental|Rapamycin coated balloon dilation catheter for arteriovenous fistula|Experimental group rapamycin balloon therapy for autologous arteriovenous fistulas with stenosis or occlusion
88836148|NCT05699772|Experimental|Telehealth GLB-TBI (tGLB-TBI)|"The goal of the tGLB-TBI program is to help the participant achieve and maintain a 5-7% weight-loss using a two-pronged approach:~Physical activity: This is based upon recommendations by the American Heart Association and the American College of Sports Medicine (ACSM) to achieve 150 minutes of moderate intensity activity each week. Walking is the primary activity recommended.~Healthy eating: Based on United States Department of Agriculture guidelines, the GLB emphasizes healthy eating patterns and tracking dietary intake.~The tGLB-TBI was modified from the DPP-GLB and is a one-year program with 22 sessions. It begins with 12 weekly sessions called the Core Program, followed by a Transition phase consisting of 2 bi-weekly and 2 monthly sessions, and a Support Phase consisting of 6 monthly sessions. Sessions will be delivered in a group setting via telehealth (Microsoft Teams)."
89365031|NCT06029569|Sham Comparator|Paclitaxel release high-pressure shunt balloon dilation catheter|Strict or occluded autologous arteriovenous fistula treated with paclitaxel balloon therapy in the control group
89365032|NCT06029543||Gambian Women|Gambian women aged 15 and older with lung function impairment as measured by spirometry
89365033|NCT06029491|Experimental|Treatment Arm|Each subject will undergo baseline evaluation for acute ischemic stroke due to large vessel occlusion, per standard of care and undergo mechanical thrombectomy procedure, aspiration to remove the thrombus in the neuro-vasculature using the RapidPulseTM Aspiration System.
89365034|NCT06029400||Retrospective cohort|The retrospective arm of the study will include 200 patients meeting the inclusion criteria who have received a cardiac CT from January 2013 to date of approval amendment. (2013 was chosen as starting year to retrieve CT and clinical date in order to have at least 5 years of follow-up per patients).
89001600|NCT00587938||B|BNP level from protocol blood tests initiated in the ED, NOT reported to ED physician prior to ED disposition.
89365035|NCT06029400||Prospective cohort|The prospective arm of the study will include 2000 consecutive patients meeting the inclusion criteria, candidate to cardiac CT along the 7 years after date of approval.
89365036|NCT06029387||Retrospective cohort|"The retrospective cohort will include 2500 patients who underwent a clinically indicated cCTA examination for CAD evaluation.~Duration of enrollment: enrollment of patients via a telephone call will last 15 months starting from the beginning of the study (month 0).~Duration of total follow-up: no follow-up is planned. Duration of total study period: total retrospective study duration will be 30 months"
89365037|NCT06029387||Prospective cohort|"The prospective cohort will include 500 patients undergoing a clinically indicated cCTA for CAD evaluation.~Duration of enrollment: enrollment of patients at the time of cCTA examination will last 12 months.~Duration of total follow-up: each patient will be followed up for 36 months from the date of the cCTA.~Duration of total study period: total prospective study duration will be 54 months (last patient enrolled at month 12 + 36 months of follow-up + 6 months for data analysis)."
89365038|NCT06029374|Active Comparator|Functional Treatment|
89365039|NCT06029374|Active Comparator|Forearm Cast and Finger Splint|
89365040|NCT06029361|Experimental|SELFIT device group|25 patients in experimental group will receive 15 minutes with the SELFIT system during the 45 minutes of physical therapy
89365041|NCT06029361|Active Comparator|Control Group|45 minutes of conventional physical therapy
89365042|NCT06029205|Experimental|The Effect of Conscious Awareness-Based Educatıon on Perceived Work Stress in Nurses|mindfulness-based education
89365043|NCT06029205|Placebo Comparator|The effect of stress coping training on nurses|stress coping training
89365044|NCT06029166|Other|Hematologic malignancy patients requiring a treatment by Bruton's tyrosine kinase inhibitor|Consecutive adult patients with a definite diagnosis of hematologic malignancy requiring a treatment by Bruton's tyrosine kinase (BTK) inhibitor (ibrutinib, acalabrutinib, zanubrutinib) during at least 12 months will be included to receive an insertable subcutaneous cardiac monitor (ISCM).
88836149|NCT05699772|Active Comparator|Brain Health Group (BHG)|The Brain Health Group (BHG) meets at the same frequency as the GLB-TBI (i.e., 22 group-based sessions, 12 weekly, 4 bi-monthly, and 6 monthly).The focus of the BHG is on brain health education, self-management, and problem-solving and the BHG did not receive any education on weight-loss strategies. Sessions will be delivered in a group setting via telehealth (Microsoft Teams).
88836150|NCT05693753|Experimental|Xenogenic collagen matrix (XCM)|Multiple coronally advanced flap technique (mCAF) with the use of a XCM
88836151|NCT05693753|Active Comparator|Connective tissue graft (CTG)|Multiple coronally advanced flap technique (mCAF) with the use of a CTG
89365045|NCT06029101|Experimental|chiari I malformation patients undergoing craniectomy|modalities and outcomes of surgical treatment of chiari I malformation patients
89365046|NCT06028958|Active Comparator|Neck Isometrics Exercises|This group of participants will receive neck isometric exercises along with routine physical therapy and a hot pack. In this regimen, the patient is commanded to apply minimal resistance on the physiotherapist's hand in front, back, and lateral positions. This resistance is applied for 10 sec with a 15 sec hold with 10-15 repetitions. The protocol will be given to the participants for two weeks. Each session will be of 40 minutes.
88836152|NCT05693454|Placebo Comparator|Control|local wound infiltration at the end of spine surgery with NaCl
88836153|NCT05693454|Active Comparator|Arm I|local wound infiltration at the end of spine surgery with Ropivacain
88836154|NCT05693454|Active Comparator|Arm II|local wound infiltration at the end of spine surgery with a combination of Levobupivacaine and Tramadol
88836155|NCT05691270|Other|Pilot Study Participants|All adolescents who engage with the IN-Control Program will be asked if they would like to formally enroll as a study participant after interaction with the navigator. However, enrollment is not required to receive support from the navigator.
88836156|NCT05684952|Experimental|Treatment group|Subjects need to take the Chinese herbal medicine (Shenlingcao oral liquid) 200 ml twice per day for 4 weeks. Shenlingcao oral solution is comprised of American Ginseng (Panacis Quinquefolii Radix), Lucid Ganoderma (Ganoderma), Rose (Rosae Rugosae Flos) and fermented Cordyceps powder.
89365047|NCT06028958|Experimental|Global Posture Re-Education|This group of participants will receive the Global Posture Re-Education technique with a hot pack. The protocol will be given to the participants for two weeks (1 session on an alternative day with the home plan). Each session will be of 40 minutes.
89365048|NCT06028919|Other|Temperature controlled DiamondTemp (DT) ablation catheter|Intervention arm
89365049|NCT06028919|Other|Power controlled Tacticath/Tactiflex ablation catheter|Control arm
88836157|NCT05684952|Placebo Comparator|Control group|Subjects need to take the placebo of Shenlingcao oral liquid 200 ml twice per day for 4 weeks.
88836158|NCT05672108|Experimental|Lung chemoembolization|Patients receive lipiodol intra-arterially (IA), mitomycin IA, and embospheres IA and undergo TACE on study. Patients also undergo angiography and computed tomography (CT) at baseline and follow up.
88836159|NCT05668429|Experimental|Single dose of [14^C]-Ibrexafungerp|Each subject will receive a dose of [14C]-Ibrexafungerp at 12 h intervals for 7 doses in total.
88836160|NCT05665556||Pulmonary Arterial Hypertension (Group I)|Group I Pulmonary Arterial Hypertension associated with Connective Tissue Diseases
88836161|NCT05665556||Pulmonary Arterial Hypertension (Group IV)|Group IV Pulmonary Arterial Hypertension associated with Connective Tissue Diseases
88836162|NCT05664490|No Intervention|Standard-of-Care Mental Health Services|Participants randomized to this group will receive standard-of-care mental health services as specified in the South African Department of Health Adult Primary Care Guidelines.
88836163|NCT05664490|Experimental|Youth Friendship Bench SA + Standard-of-Care|Participants randomized to this group will receive the Youth Friendship Bench SA intervention in addition to standard-of-care mental health services as specified in the South African Department of Health Adult Primary Care Guidelines.
88836164|NCT05621941|Experimental|Game-Supported Goal Management Training|Seven treatment sessions given once a week (60 minutes) under guidance of a clinical neuropsychologist and cognitive trainer or occupational therapist.
88836165|NCT05621941|Active Comparator|Information Group|Seven information sessions given once a week (60 minutes) under guidance of a clinical neuropsychologist.
88836166|NCT05613426|Active Comparator|Intensive statin group|Rosuvastatin, 20 mg per day after randomization
88836167|NCT05613426|Experimental|Combined intensive statin and PCSK9 inhibitor group|Evolocumab, 140 mg twice a month after randomization, and Rosuvastatin, 20 mg per day after randomization
88836168|NCT05613426|Experimental|PCSK9 inhibitor alone group|Evolocumab, 140 mg twice a month after randomization
88836169|NCT05603065|Active Comparator|Chemotherapy|
88836170|NCT05603065|Active Comparator|Radiotherapy|
88836171|NCT05601700|Experimental|Experimental arm|Letrozole 2.5 mg daily, per os, until progression or up to 60 months, whichever comes first
89365050|NCT06028867|Experimental|Chlorhexidine 0,12% + Sodium DNA mouthwash|Patients are treated with a mouthwash containing Chlorhexidine 0,12% + Sodium DNA
89365051|NCT06028867|Active Comparator|Chlorhexidine 0,20% mouthwash|Patients are treated with a mouthwash containing Chlorhexidine 0,20%
89365052|NCT06028867|Placebo Comparator|Placebo mouthwash|Patients are treated with a placebo mouthwash
88836172|NCT05601700|Active Comparator|Control arm|Carboplatin AUC 5 + Paclitaxel 175 mg/mq, IV, on day 1 every 21 days, for 6-8 cycles.
88836173|NCT05601362|Active Comparator|Gamified Attention Bias Modification|Digital therapeutic intervention based on Attention Bias Modification Training (ABMT) designed to decrease negative attention bias.
88836174|NCT05601362|Sham Comparator|Gamified Placebo Training|Identical version of the gamified behavioral intervention without manipulation designed to decrease negative attention bias
88836175|NCT05592938|Experimental|rPBI|26Gy in 5 daily fractions over 1-week
88836176|NCT05585138|Experimental|Segmental breathing exercise|"segmental breathing exercise (apical costal expansion exercises, lateral costal expansion exercises, posterior costal expansion exercises) combined with Conventional Treatment ( deep breathing exercise ).~Group-A (interventional group) will receive segmental breathing exercises for one month 5 days a week and 2 sessions per day for 15 minutes for each patient"
89001601|NCT00587977||1|Aortic aneurysm repair
89001602|NCT00587977||2|Aortic aneurysm growth
89001603|NCT00587977||3|Aortic aneurysm growth stable.
88836177|NCT05585138|Active Comparator|conventional therapy|Conventional Treatment (deep breathing exercise). conventional treatment will be for one month 5 days a week 10 to 15 repetitions of deep breathing exercise 2times a day.
88836178|NCT05582629|Experimental|Arm 1|JT001 (VV116) Day 1: 0.6g, Q12H X 2 times Day 2-5: 0.3g, Q12H X 8 times Oral tablet
89365053|NCT06028854||High Neutrophil count|Patients with high neutrophil count in their preoperative complete blood count
89365054|NCT06028854||Low Neutrophil count|Patients with low neutrophil count in their preoperative complete blood count
89365055|NCT06028841|Experimental|VLA1553|
89365056|NCT06028815|Experimental|Experimental group|Informal carers receive 10 music therapy sessions
89365057|NCT06028815|No Intervention|Control group|Informal carers do not receive music therapy sessions
89365058|NCT06028789||Study group|Patients undergoing elective thoracic aortic surgery.
88836179|NCT05582629|Placebo Comparator|Arm 2|Placebo Day 1: 6 tablets, Q12H X 2 times Day 2-5: 3 tablets, Q12H X 8 times Oral tablet
88836180|NCT05579600|Experimental|Caring Contact letters|Caring Contact letters will be mailed to a randomly selected group of managed care subscribers over a 6-month period following jail release.
89365059|NCT06028789||Control group|Patients admitted to our institution with active infectious endocarditis.
89365060|NCT06028763|Experimental|Group 1 (main)|Treatment consists of 2 stages. 1 stage starts with lipoaspiration of subcutaneous adipose tissue from patients. This tissue will then undergo Mesenchymal Stem Cells (MSC) isolation, cultivation and become a biocomposite hydrogel with growth factors. The 2 stage involves ankle joint arthroscopy using the hydrogel for cartilage therapy. To ensure proper hydrogel fixation, we'll clean cartilage remnants, remove fibrous tissue, and create 10mm deep, 2.5mm diameter microperforations. Cartilage donor site prep during arthroscopy will remove non-viable tissue and establish communication with underlying bone marrow. After stopping bleeding, heparin-conjugated fibrin hydrogel with MSCs and growth factors (TGF-β1 and BMP-4) will be implanted using epinephrine-soaked gauze. Hydrogel gels in 3-5 mins. Ankle joint movement tests will confirm successful implantation. Joint stability, articular congruence, and joint condition will be inspected.
89365061|NCT06028763|Active Comparator|Group 2 (control)|Patients from control group will undergo arthroscopic debridement of the joint with microfracturing (traditional method of treatment).
89365062|NCT06028737|Active Comparator|Perioperative 4+4 FLOT cycles|4 cycles of neoadjuvant FLOT chemotherapy scheme, followed by surgery and 4 cycles of adjuvant FLOT chemotherapy scheme.
89365063|NCT06028737|Experimental|Total Neoadjuvant ChemoTherapy (TNT) 8 FLOT cycles|8 cycles of total neoadjuvant FLOT chemotherapy scheme, followed by surgery.
88836181|NCT05579600|Experimental|Reports, re-engagement, and training|Behavioral health providers (n=120) will be trained in evidence-based suicide prevention screening and intervention practices, in addition to receiving weekly reports with information on clients who have been released from jail to encourage outreach efforts for re-engagement with the healthcare system.
88836182|NCT05576532|Experimental|bcl-2 inhibitor plus IM2 regimen|bcl-2 inhibitor plus IM2 regimen
88836183|NCT05573074|Experimental|tPBM Group|Visit 1: t-PBM at irradiance dose of 291.7 mW/cm2 (333s) Visit 2 - 18: randomized to receive active t-PBM of 291.7 mW/cm2 (333s) Visit 19: t-PBM at irradiance dose of 291.7 mW/cm2 (333s)
88836184|NCT05573074|Active Comparator|Sham Group|Visit 1: t-PBM at irradiance does of 291.7 mW/cm2 (333s) Visit 2 - 18: randomized to receive Sham of 0 mW/cm2 (333s) Visit 19: t-PBM at irradiance dose of 291.7 mW/cm2 (333s)
88836185|NCT05566730|Experimental|CT-MICART App|Participants in this arm will receive daily EMAs for 6 weeks.
88836186|NCT05562453|Experimental|Investigational device|The investigational device (FlowOx2.0) is composed of a Pressure Chamber and a Control Unit (and disposable parts). All subjects will receive the commercial Pressure Chamber (and disposable parts). Subjects randomized to the investigational device arm will receive a Control Unit that generates intermittent negative pressure (INP) of - (minus) 40 mmHg.
88836187|NCT05562453|Sham Comparator|Comparator|The investigational device (FlowOx2.0) is composed of a Pressure Chamber and a Control Unit (and disposable parts). All subjects will receive the commercial Pressure Chamber (and disposable parts). Subjects randomized to the comparator arm will receive a Control Unit that generates INP pulses of only - (minus) 10 mmHg.
88836188|NCT05558150|Experimental|ilaprazole & aceclofenac 1|"Period 1 : Ilaprazole 10mg/tab, one a day, 5 days~Period 2 : aceclofenac 100mg/tab, twice a day, 4 days and aceclofenac 100mg/tab, one a day one at the 5 day~Period 3 : Ilaprazole 10mg/tab, one a day, 5 days + aceclofenac 100mg/tab, twice a day, 5 days"
88836189|NCT05558150|Experimental|ilaprazole & aceclofenac 2|"Period 1 : Ilaprazole 10mg/tab, one a day, 5 days + aceclofenac 100mg/tab, twice a day, 5 days~Period 2 : Ilaprazole 10mg/tab, one a day, 5 days~Period 3 : aceclofenac 100mg/tab, twice a day, 4 days and aceclofenac 100mg/tab, one a day one at the 5 day"
88836190|NCT05558150|Experimental|ilaprazole & aceclofenac 3|"Period 1 : aceclofenac 100mg/tab, twice a day, 4 days and aceclofenac 100mg/tab, one a day one at the 5 day~Period 2 : Period 3 : Ilaprazole 10mg/tab, one a day, 5 days + aceclofenac 100mg/tab, twice a day, 5 days~Period 3 : Ilaprazole 10mg/tab, one a day, 5 days"
89365064|NCT06028711|Experimental|Education program and Pulmonary rehabilitation|Conventional pulmonary rehabilitation coupled with original education program.
89365065|NCT06028711|Other|Pulmonary rehabilitation|Conventional pulmonary rehabilitation
89365066|NCT06028685|Active Comparator|experimental group|The experimental group will receive low-level laser stimulation on seven acupoints. The stimulation will be administered three times per week for a duration of six weeks.
89365067|NCT06028685|Placebo Comparator|control group|The control group will receive sham low-level laser stimulation on the acupoints, without emitting laser beams.
89365068|NCT06028633|Experimental|Arm I|Participants will receive pembrolizumab IV 200 mg D1 every 3 weeks, lenvatinib 8 mg orally every day, albumin-bound paclitaxel IV 100mg/m2 D1, 8 every 3 weeks,until disease progression, intolerable toxicity, investigator decision, or completion of 35 cycles(for pembrolizumab) and 4-6 cycles(for albumin-bound paclitaxel).
89365069|NCT06028581|Experimental|Experimental Group|Breastfeeding support system will be applied to newborn babies in addition to breast milk.
89365070|NCT06028581|No Intervention|Control Group|Newborn babies will receive breast milk.
89365071|NCT06028555||Estetrol/drospirenone (E4/DRSP)|Users: Starters and re-starters
89365072|NCT06028555||Ethinyl estradiol/levonorgestrel (EE/LNG)|Users: Starters and re-starters
89365073|NCT06028425|Experimental|LOXO-783 (Fasted State)|LOXO-783 administered orally to participants who are in fasted state
89365074|NCT06028425|Experimental|LOXO-783 (Fed State - Low Fat Meal)|LOXO-783 administered orally to participants who are on low fat meal
89365075|NCT06028425|Experimental|LOXO-783 (Fed State - High Fat Meal)|LOXO-783 administered orally to participants who are on high fat meal
89365076|NCT06028412|Experimental|Segmentectomy|
89365077|NCT06028412|Placebo Comparator|lobectomy|
89365078|NCT06028399|Experimental|Concurrent Training|Concurrent training combines aerobic and resistance training within the same session for 30 - 60 minutes, comprising 3 sessions per week for 12 weeks.
89365079|NCT06028399|Active Comparator|Aerobic Training|Aerobic training for 30 - 60 minutes comprises 3 sessions per week for 12 weeks.
88836191|NCT05558150|Experimental|ilaprazole & aceclofenac 4|"Period 1 : Ilaprazole 10mg/tab, one a day, 5 days~Period 2 : Ilaprazole 10mg/tab, one a day, 5 days + aceclofenac 100mg/tab, twice a day, 5 days~Period 3 : aceclofenac 100mg/tab, twice a day, 4 days and aceclofenac 100mg/tab, one a day one at the 5 day"
89365080|NCT06028373|Experimental|ATG-031|"Patients with advanced solid tumors or B-cell non-Hodgkin lymphomas will be enrolled in the Dose-Escalation Phase.~Dose levels are 0.03 mg/kg、 0.1 mg/kg、0.3 mg/kg 、1.0 mg/kg 、2.0 mg/kg、4.0 mg/kg 、6.0 mg/kg 、9.0 mg/kg."
89365081|NCT06028308|Experimental|Sound 1|A sound will be played while moving the head
89365082|NCT06028308|Experimental|Sound 2|A sound (different from Sound 1) will be played while moving the head
89365083|NCT06028308|No Intervention|No Sound|No sound will be played while moving the head
89365084|NCT06028269|Experimental|Sound 1|A sound will be played while moving the head
89365085|NCT06028269|Experimental|Sound 2|A sound (different from Sound 1) will be played while moving the head
88836192|NCT05558150|Experimental|ilaprazole & aceclofenac 5|"Period 1 : Ilaprazole 10mg/tab, one a day, 5 days + aceclofenac 100mg/tab, twice a day, 5 days~Period 2 : aceclofenac 100mg/tab, twice a day, 4 days and aceclofenac 100mg/tab, one a day one at the 5 day~Period 3 : Ilaprazole 10mg/tab, one a day, 5 days"
89365086|NCT06028269|No Intervention|No Sound|No sound will be played while moving the head
89365087|NCT06028256|Experimental|Norepinephrine|The interventional group will receive a continuous infusion of norepinephrine 5 minutes (0.01μg/kg*min) before anesthesia induction until skin incision.
89365088|NCT06028256|Placebo Comparator|Placebo|the placebo group will receive a continuous infusion of normal saline (10 ml/h) 5 minutes before anesthesia induction until skin incision.
88836193|NCT05558150|Experimental|ilaprazole & aceclofenac 6|"Period 1 : aceclofenac 100mg/tab, twice a day, 4 days and aceclofenac 100mg/tab, one a day one at the 5 day~Period 2 : Ilaprazole 10mg/tab, one a day, 5 days~Period 3 : Ilaprazole 10mg/tab, one a day, 5 days + aceclofenac 100mg/tab, twice a day, 5 days"
89365089|NCT06028243|Experimental|Intervention Group|"The Healthy Living Awareness Program for the Prevention of Osteoporosis (HLAPPO-IMB) was implemented in three stages.~Information stage: The researchers provided the intervention group participants with online training in healthy living awareness to prevent osteoporosis. The training consisted of four sections: osteoporosis and diagnosis-treatment methods, current approaches to the prevention of osteoporosis, osteoporosis and nutrition, and osteoporosis and physical exercise. At the end of the training, the participants were informed about the healthy life diary and record.~Motivation stage: The researchers regularly texted reminder notifications concerning the prevention of osteoporosis. The records in their diaries were reviewed. The researchers provided individual counseling to the participants by telephone.~Behavior skills stage: The target behavior skills were improved self-efficacy in doing weight-bearing exercises, taking calcium, and engaging in physical activity."
89365090|NCT06028243|No Intervention|Control Group|The control group was not trained. Data collection forms applied to the intervention group were also applied to the control group simultaneously.
89365091|NCT06028217||survival group|patients still survive at 28 days
89365092|NCT06028217||mortality group|patients die within 28 days
89365093|NCT06028204||Biologic Naïve Group|This will aim to include 50 patients who have been referred with possible asthma or have a diagnosis of asthma, and are established on treatment in the form of bronchodilators and/or inhaled corticosteroids who are not candidates for biologic therapy at present
88836194|NCT05535946|Experimental|ABX464 50mg - Responder subjects at the end of induction|Subjects will be orally dosed during 44 weeks
89365094|NCT06028204||Biologic Group|This will aim to include 10 patients who have been referred with an established diagnosis of asthma and are on treatment in the form of bronchodilators and/or inhaled corticosteroids and have been selected as suitable candidates for commencing biologic therapy.
88836195|NCT05535946|Experimental|ABX464 25mg - Responder subjects at the end of induction|Subjects will be orally dosed during 44 weeks
89365095|NCT06028191|Other|Kabat Technique along with baseline treatment|Kabat technique will be performed for 15 min along with baseline treatment will be given to Group A. They will have 45 min-1 hour session thrice a week in duration of six weeks.
89365096|NCT06028191|Experimental|Kabat Technique and LLLT along with baseline treatment|Kabat technique will be performed for 15 min and LLLT will be performed for 10 min to eight points of the effected side for 2 min at each point along with baseline treatment. They will have 45 min-1 hour session thrice a week in duration of six weeks
89365097|NCT06028178||Experimental group|The experimental group will recruit 300 participants undergoing blood culture, droplet digital PCR and transcriptome analysis.
89365098|NCT06028178||Control group|The control group will recruit 60 participants undergoing blood culture only.
89365099|NCT06027242|Placebo Comparator|Without oral glutamine supplementation|15 g Maltodextrin for 28 days after surgery with tolerable oral intake or enteral feeding
89365100|NCT06027242|Active Comparator|With oral glutamine supplementation|10 g glutamine +5 g Maltodextrin for 28 days after surgery with tolerable oral intake or enteral feeding
89365101|NCT06026449|Experimental|Primary sclerosing cholangitis|
89365102|NCT06026449|Experimental|Ulcerative Colitis|
89365103|NCT06026293||subjects that participates to a previous clinical trial|
89365104|NCT06025929|Experimental|Maitland Group|Maitland Group received Maitland's mobilization techninque in addition to an intereferential therapy.
89365105|NCT06025929|Active Comparator|Mulligan Group|Mulligan Group received Mulligan's mobilization techninque in addition to an intereferential therapy.
89365106|NCT06025695|Active Comparator|HRV Group|Participants receive 2 doses of GSK's liquid oral live attenuated HRV study intervention administered at Day 1 and Month 1, according to the immunization schedule for HRV study intervention licensed outside of China.
89365107|NCT06025695|Experimental|HRV PCV-free Group|Participants receive 2 doses of the PCV-free liquid formulation of GSK's oral live attenuated HRV study intervention administered at Day 1 and Month 1, according to the immunization schedule for HRV study intervention licensed outside of China.
89365108|NCT06025500||EBV-patients|Patients who are scheduled for a bronchoscopic lung volume reduction treatment using endobronchial valves.
89365109|NCT06024863||Sportsmen|Sportsmen (at least 1 hour of physical activity per week) over 35 years of age, referred by their doctor for a screening stress test on a bicycle ergometer in the sports medicine unit from September 2011 to August 2014
89365110|NCT06024330||Positive VAN scale|"Motor Function: Check for arm drift with arms extended, palms up, and eyes closed for 10 seconds. If present, proceed to the VAN criteria.~V (Visual): Assess for reported double vision, field cut, or vision loss, or difficulty seeing fingers in a quadrant. If any visual disturbances are found, the patient is VAN positive.~A (Aphasia): Identify difficulties forming words, repeating a short sentence, recognizing two objects, or following simple commands. If any aphasia symptoms are observed, the patient is VAN positive.~N (Neglect): Check for forced gaze, inability to track a pen to one side, or lack of sensation in limbs. If any neglect signs are detected, the patient is VAN positive."
89365111|NCT06024330||Negative VAN scale|"A negative VAN scale indicates that a potential stroke patient does not exhibit the primary signs associated with a large vessel occlusion (LVO). Specifically, the patient demonstrated no arm drift during the initial motor function test. If the motor assessment is proceeded to the VAN criteria, the patient shows no visual disturbances like double vision or field cuts (V), no aphasia symptoms such as difficulty forming words or repeating sentences (A), and no signs of neglect, like forced gaze or lack of sensation in limbs (N)"
89365112|NCT06024330||Positive VES scale|"Eye Deviation: Scored as 1 if there's a forced deviation of both eyes to any side; otherwise, scored as 0.~Aphasia: Scored as 1 if the patient is awake and exhibits one or more of the following:~Inability to repeat a sentence. Inability to name an object. Talking incoherently or not obeying commands. Being mute. Otherwise, scored as 0. Neglect: Scored as 1 if the patient can perceive touch on both sides individually but fails to feel it on one side when stimulated simultaneously. Otherwise, scored as 0.~Obtundation: Scored as 1 if the patient cannot maintain wakefulness during a conversation; otherwise, scored as 0.~The VES can range from 0 to 4. A score of 1 or higher suggests a positive likelihood for ELVO. Additionally, if a patient tests positive for aphasia, neglect can be deduced by noting if the patient disregards the examiner on one side but is responsive when the examiner switches sides."
89365113|NCT06024330||Negative VES scale|"Eye Deviation: No forced deviation of both eyes is observed. Aphasia: The patient, while awake, can repeat sentences, name objects, speaks coherently, follows commands, and is not mute.~Neglect: The patient can perceive touch both when sides are stimulated individually and simultaneously.~Obtundation: The patient remains awake and alert during conversation. A total score of 0 on the VES scale represents a VES negative outcome."
89365114|NCT06024330||Positive LARIO scale|"Facial Palsy: The presence of facial muscle weakness or paralysis scores 1, while a normal facial expression scores 0.~Arm Weakness: A score of 1 is given for arm drift, no effort against gravity, or no movement at all. No drift is scored 0.~Grip Strength: Reduced or absent grip strength scores 1, while a normal grip scores 0.~Language: Changes in speech, global aphasia, or the patient being mute results in a score of 1. Normal language is scored 0.~Neglect: A score of 1 is given if the patient exhibits extinction to bilateral simultaneous stimulation in one or more sensory modality, doesn't recognize their own hand, or consistently orients only to one side of the body. The absence of these signs scores 0.~A cumulative score exceeding 3 on the LARIO Stroke Scale categorizes the patient as LARIO positive,"
88836196|NCT05535946|Placebo Comparator|Placebo - Responder subjects at the end of induction|Subjects will be orally dosed during 44 weeks
88836197|NCT05535946|Experimental|ABX464 50mg - Non responder subjects at the end of induction|Subjects will be orally dosed during 44 weeks
88836198|NCT05535946|Experimental|ABX464 25mg - Non responder subjects at the end of induction|Subjects will be orally dosed during 44 weeks
88836199|NCT05526716|Experimental|Concomitant group (V116 + QIV followed by placebo)|Participants will receive a single 0.5 mL intramuscular (IM) injection of V116 and a single 0.5 mL IM injection of QIV on Day 1 and a single 0.5 mL injection of placebo on Day 30
89365115|NCT06024330||Negative LARIO scale|"Facial Palsy: No observable facial muscle weakness or paralysis. Arm Weakness: The arm remains steady without drift and exhibits normal effort against gravity.~Grip Strength: The patient displays normal grip strength. Language: The patient speaks normally, without aphasia or muteness. Neglect: No signs of sensory extinction upon bilateral simultaneous stimulation, proper recognition of their own hand, and balanced orientation to both sides of the body.~A cumulative score of 3 or less on the LARIO Stroke Scale classifies the patient as LARIO negative,"
89365116|NCT06023446||Pre-Dementia Alzheimer's|By clinical assessment, these participants will either be cognitively normal, or have mild cognitive impairment. They will enter the study having already completed some biomarker testing for Alzheimer's disease (e.g., amyloid PET, cerebrospinal fluid measurement amyloid and tau). In this group, the biomarker testing is positive/abnormal, indicating a pre-dementia stage of Alzheimer's disease. In the language of the 2018 NIA-AA Research Framework, these participants have A+ in their AT(N) biomarker profile, and are at clinical stage 1-3.
89365117|NCT06023446||No Evidence of Alzheimer's|By clinical assessment, these participants will either be cognitively normal, or have mild cognitive impairment. They will enter the study having already completed some biomarker testing for Alzheimer's disease (e.g., amyloid PET, cerebrospinal fluid measurement amyloid and tau). In this group, the biomarker testing is negative/normal. In the language of the 2018 NIA-AA Research Framework, these participants have A- in their AT(N) biomarker profile, and are at clinical stage 1-3.
89365118|NCT06022497|Experimental|Intervention Group|In the intervention group, Tidal Model-based emotion regulation nursing interventions were applied in addition to the routine treatment. Tidal Model-based emotion regulation nursing interventions were structured as eight sessions in total. Each individual in the intervention group participated in a session for a total of 8 weeks, one session per week. All interviews were conducted face to face.
89365119|NCT06022497|No Intervention|Control Group|The control group received only routine treatment.
89365120|NCT06015009|Experimental|Intervention group|Child-caregiver dyads in the intervention group will use the mHealth app for 12 weeks with personalised nurse support via interactive communication technologies. The design of the app will be guided by the theory of unpleasant symptoms.
89365121|NCT06011785|Experimental|Intervention Group|Participants have Silicosis and wish to be included in the intervention group
89365122|NCT06009939||Healthy men aged 20-30 years old|"Foot: 10 minutes of baseline measurement, 5 minutes of occlusion and 5 minutes of Post-occlusive reactive hyperemia (PORH) measurement.~Arm: 10 minutes of baseline measurement, 5 minutes of occlusion and 5 minutes of Post-occlusive reactive hyperemia (PORH) measurement."
89365123|NCT06009939||Healthy women aged 20-30 years old|"Foot: 10 minutes of baseline measurement, 5 minutes of occlusion and 5 minutes of Post-occlusive reactive hyperemia (PORH) measurement.~Arm: 10 minutes of baseline measurement, 5 minutes of occlusion and 5 minutes of Post-occlusive reactive hyperemia (PORH) measurement."
89365124|NCT06009939||Healthy men aged 50-60 years old|"Foot: 10 minutes of baseline measurement, 5 minutes of occlusion and 5 minutes of Post-occlusive reactive hyperemia (PORH) measurement.~Arm: 10 minutes of baseline measurement, 5 minutes of occlusion and 5 minutes of Post-occlusive reactive hyperemia (PORH) measurement."
89365125|NCT06009939||Healthy women aged 50-60 years old|"Foot: 10 minutes of baseline measurement, 5 minutes of occlusion and 5 minutes of Post-occlusive reactive hyperemia (PORH) measurement.~Arm: 10 minutes of baseline measurement, 5 minutes of occlusion and 5 minutes of Post-occlusive reactive hyperemia (PORH) measurement."
89365126|NCT06005090||FCL group|Plate fixation performed with the use of far cortical locking (2 point screw fixation into the plate and far cortex of the diaphysis)
89365127|NCT06005090||BL group|Traditional 3 point fixation of the screw into two cortices of the diaphysis and into the plate
89365128|NCT06002464|Active Comparator|ESP|Post operative analgesia with bilateral continuous erector spinae plane block catheter
89365129|NCT06002464|Experimental|ESP ACU|Post operative analgesia with bilateral continuous erector spinae plane block catheter combined with daily session of acupuncture
88836200|NCT05526716|Experimental|Sequential group (placebo + QIV followed by V116)|Participants will receive a single 0.5 mL IM injection of QIV and a single 0.5 mL IM injection of placebo on Day 1 and a single 0.5 mL injection of V116 on Day 30
88836201|NCT05507216|Experimental|ABX464 50mg|Subjects will be orally dosed daily in a fed condition (regular breakfast) in the morning with a glass of water during 8 weeks
88836202|NCT05507216|Experimental|ABX464 25mg|Subjects will be orally dosed daily in a fed condition (regular breakfast) in the morning with a glass of water during 8 weeks
88836203|NCT05507216|Placebo Comparator|Placebo|Subjects will be orally dosed daily in a fed condition (regular breakfast) in the morning with a glass of water during 8 weeks
88836204|NCT05507203|Experimental|ABX464 50mg|Subjects will be orally dosed daily in a fed condition (regular breakfast) in the morning with a glass of water during 8 weeks
88836205|NCT05507203|Experimental|ABX464 25mg|Subjects will be orally dosed daily in a fed condition (regular breakfast) in the morning with a glass of water during 8 weeks
89365130|NCT06002425|Active Comparator|Control group|In this arm, participants receive treatment plans directly from clinicians without the assistance of ChatGPT.
88836206|NCT05507203|Placebo Comparator|Placebo|Subjects will be orally dosed daily in a fed condition (regular breakfast) in the morning with a glass of water during 8 weeks
88836207|NCT05502523|Active Comparator|Group I (pulmonary vein first approach procedure)|Patients undergo pulmonary vein first approach surgical procedure on day of surgery.
88836208|NCT05502523|Active Comparator|Group II (pulmonary artery first surgical procedure)|Patients undergo pulmonary artery first approach surgical procedure on day of surgery.
88836209|NCT05502159|Active Comparator|Group M-TAPA = M-TAPA group|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by a pain nurse blinded to the procedure. 0,5 mg/kg meperidin will be performed for rescue analgesia.
88836210|NCT05502159|Active Comparator|Group EOB = EOB group|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by a pain nurse blinded to the procedure. 0,5 mg/kg meperidin will be performed for rescue analgesia.
89001604|NCT00588016|Experimental|Itraconazole|Topical application of Itraconazole in Sterile Water 100 mg/1000 ml, irrigating each nostril with 20 ml of solution twice daily for 7 days.
89001605|NCT00588133|Experimental|1|New drug dosing schedule
89365131|NCT06002425|Experimental|GPT-Assisted Group|In this arm, participants receive treatment plans from clinicians with the assistance of ChatGPT.
89365132|NCT06002412||Beijing Obstetrics and Gynecology Hospital affiliated to Capital Medical University|Beijing Obstetrics and Gynecology Hospital affiliated to Capital Medical University collects clinical information and ultrasound images of sagittal, NT and choroid plexus views of the fetus which was obtained from early pregnant women who underwent NT sweeps.
89365133|NCT06002412||Peking University Third Hospital|Peking University Third Hospital collects clinical information and ultrasound images of sagittal, NT and choroid plexus views of the fetus which was obtained from early pregnant women who underwent NT sweeps.
89365134|NCT06002412||Changsha Hospital for Maternal and Child Health Care|Changsha Hospital for Maternal and Child Health Care collects clinical information and ultrasound images of sagittal, NT and choroid plexus views of the fetus which was obtained from early pregnant women who underwent NT sweeps.
89365135|NCT06002412||Second Xiangya Hospital of Central South University|Second Xiangya Hospital of Central South University collects clinical information and ultrasound images of sagittal, NT and choroid plexus views of the fetus which was obtained from early pregnant women who underwent NT sweeps.
88836211|NCT05496296|Active Comparator|Standard of Care Dressing for Pressure Injury|Standard wound dressings recommended by the National Pressure Injury Advisory Panel (NPIAP), according to the wound stage, will be utilized to treat pressure injuries. These include hydrocolloid, hydrogel, polymeric membranes, foam, collagen dressings, and negative pressure wound therapy. Dressings will be changed according to wound conditions, and type of dressing selected.
88836212|NCT05496296|Active Comparator|Altrazeal® Transforming Powder Dressing|Altrazeal® Transforming Powder Dressing will be applied during the Baseline visit. It should be left in place for up to 30 days, and topped off (additional powder applied if needed) at each subsequent visit. Secondary dressing, including a contact layer over the Altrazeal® and a secondary dressing (like gauze or foam) may be applied over the contact layer.
89365136|NCT05998278|Experimental|Experimental group|Experimental group received targeted biopsy plus personalized systematic biopsy
89365137|NCT05998278|No Intervention|Control group|Control group received targeted biopsy plus systematic biopsy
89365138|NCT05988320|Experimental|Experimental: Applications to the Intervention Group|Pranayama breathing will be performed by the caregivers of cancer patients in the Medical Oncology clinic for a total of 4 weeks, covering 15-20 minutes every day, for a total of 4 weeks. information will be given about the benefits and benefits, and any questions will be answered. The application steps will be repeated both by explaining and showing, until the caregiver learns, and if there are any points that they cannot do, they will be corrected. When the caregivers are observed to perform the application fully, they will be asked to do the pranayama breathing exercise every day for 4 weeks and will provide the effectiveness and continuity of the application by providing the same researcher 3 days a week (Tuesday, Thursday, Saturday) with a smartphone WhatsApp video call.
89365139|NCT05988320|No Intervention|Applications to the Control Group|Only the pre-test will be applied to the caregivers of cancer patients in the Medical Oncology clinic in the control group. After the caregiver introduction form and Piper fatigue scale application, no breathing exercises will be performed. Individuals will continue their daily lives. Four weeks later the Piper fatigue scale will be administered again. After the Piper fatigue scale is applied, pranayama breathing exercise training will be given to all control group patients and they will be applied for 2 sessions.
89365140|NCT05987319|Experimental|General Treatment|Subjects will receive treatment on the face, neck and/or body for conditions such as but not limited to wrinkles, fine lines, crepey skin, acne scars, active acne, enlarged pores, stretch marks or loose skins.
89365141|NCT05987319|Experimental|Split-face treatment|Subjects will receive split-face treatments where each side of the face may be treated with different tips.
89365142|NCT05981183|Experimental|Intervention A|Participants will receive 15 minutes of taVNS after an initial 15 minute rest-period and a 15 minute baseline measurement period. For participants assigned to Intervention A, the pulse width = 250 μs, and frequency = 50 Hz.
89365143|NCT05981183|Experimental|Intervention B|Participants will receive 15 minutes of taVNS after an initial 15 minute rest-period and a 15 minute baseline measurement period. For participants assigned to Intervention B, the pulse width = 300 μs, frequency = 25 Hz.
89365144|NCT05976308|Experimental|Therapy group|
89365145|NCT05976308|Placebo Comparator|Control group|
89365146|NCT05976295|Experimental|Therapy group|
89365147|NCT05976295|Placebo Comparator|Control group|
89365148|NCT05968625|Experimental|Thermoformed retainers (TFR)|Thermoformed retainers are constructed from an Erkodur blank (ERKODENT® Erich Kopp GmbH, Pfalzgrafenweiler, Germany) with 1.0 mm in thickness, following the manufacturer's instructions.
89365149|NCT05968625|Experimental|Direct 3-D printed retainers (3DPR)|Private dental laboratories directly print the retainers using a NextDent 3D printer and NextDent ortho Flex resin. Thickness of 0.80mm
89534657|NCT05037591|Experimental|sea grape extract T|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
89001606|NCT00588133|Active Comparator|2|Standard drug dosing schedule
89001607|NCT00588172|Sham Comparator|1|Individuals with no nsSNPs or mutations known to alter oct1 function
89365150|NCT05967260|Experimental|Intervention|Participants will use the DailyDose Smart Snack smart phone application which contains an AI-based model that predicts the likelihood of overnight low glucose at bedtime every night and will recommend a personalized snack to help avoid nocturnal hypoglycemia. The nutritional content of the snack (carbohydrate, protein, fat, etc.) will be dependent on the predicted overnight minimum glucose and the predicted time of the minimum overnight glucose level. During this arm, participants will also be asked to wear a smart watch overnight, weigh themselves weekly, and answer a one-item sleep quality scale survey weekly.
89365151|NCT05967260|Active Comparator|Control|Participants will wear Dexcom G6 CGM and will manage their glucose as usual. Participants will be asked to wear a smart watch overnight to collect sleep metrics, weigh themselves weekly in the morning before eating, and answer a one-item sleep quality scale survey weekly.
89534658|NCT03334097|Experimental|Experimental arm|There will only one experimental arm in order to study test-retest validity after having validate the questionnaire. The beginning of the maternal education takes place between 26 and 30 weeks of gestation and ends between 32 and 36 weeks of gestation. Hence, to study responsiveness, questionnaires will be filed at the beginning of the maternal education and after the two educational sessions related to childbirth.
88836213|NCT05484739|Experimental|Very hot and dry|Subjects will be exposed to 3 hours in a climate chamber set to approximately 47 deg C and 15% relative humidity, which reflects a very hot and dry heat wave condition similar to the 2018 Los Angeles heat wave. Four visits will be required to complete this arm, with each visit a different cooling modality applied.
88836214|NCT05484739|Experimental|Hot and humid|Subjects will be exposed to 3 hours in a climate chamber set to approximately 41 deg C and 40% relative humidity, which reflects hot and humid heat wave similar to the 1995 Chicago heat wave. Four visits will be required to complete this arm, with each visit a different cooling modality applied.
89365154|NCT05964465|Experimental|Treatment|The treatment group will receive dupilumab at 300mg SC Q2weeks. The first dose will be administered via subcutaneous injection in clinic at baseline. Subjects will self-administer study drug (dupilumab 300 mg) subcutaneous every 2 weeks after initial dosing at visit 2.
89365155|NCT05963152|Placebo Comparator|Control|Habitual Physical Activity
89365156|NCT05963152|Experimental|Morning exercise|Exercise training between 6-10am
89365157|NCT05963152|Experimental|Afternoon exercise|Exercise training between 4-8pm
89365158|NCT05959720||Eligible patients|All patients deemed eligible to intensive protocol of treatment are going to be included as sole group. There is no intervention or control group in this trial.
89365159|NCT05950633|Active Comparator|Standard of Care|Participants will receive standard postoperative instructions only
89365160|NCT05950633|Active Comparator|Active Recovery|Participants will receive active recovery instructions with specific walking goals, abdominal strengthening exercises, and pelvic floor exercises
89365161|NCT05950321|Active Comparator|Cervical epidural group|Paramedian cervical epidural injection for cervical radiculopathy
88836215|NCT05471180|Placebo Comparator|Control group|Control group (n=39) - 3M Cavilon ® protective spray film + simulation of the use of laser (placebo) - after cleaning the skin, the pain scale will be applied and after application of FBM in the same points of the group that will undergo irradiation. To mimic the action of the laser, the BIP noise will be recorded and its activation will be done by the nursing employee who provides the care, after simulating the use of the laser, the use of the 3M Cavilon ® protective spray film will be applied. The application of the laser will be immediate in 8 points of the perineum region in the areas that present lesions, these applications will occur 1 x a day every 24 hours for three consecutive days. Skincare will be maintained with 3M Cavilon ® Cleansing Solution and the use of 3M Cavilon ® Protective Spray Film. A photographic record of the lesion will be made on days 0 and 3 of treatment and after 2 days after treatment to monitor the recovery of the IAD
88836216|NCT05471180|Experimental|Experimental group|Experimental group (n= 39) 3M Cavilon ® protective spray film + FBM - skin cleaning and pain scale application will be performed and after laser application in 8 points of the affected perineum region, these applications will occur 1 x a day every 24 hours for three days. Skincare will be maintained with 3M Cavilon ® Cleansing Solution and the use of 3M Cavilon ® Protective Spray Film. The photographic record of the lesion will be performed on days 0 and 3, 5 and 7 days of treatment. To monitor the participants and observe the recovery and obtainment of skin healing. It will be used the Globaid tool that will be applied in both groups.
88836217|NCT05469425|Experimental|Preoperative home-based exercise training|Patients allocated to this group will receive usual care plus a preoperative home-based exercise program consisting of aerobic and resistance exercise. In addition, a physical therapist will carry out weekly telephone supervision with all participants.
88836218|NCT05469425|No Intervention|Control Group|"Patients allocated to this group will receive usual care and must complete the outcome measures.~In addition, a physical therapist will carry out weekly telephone calls with all participants to monitor adverse events."
89365162|NCT05950321|Active Comparator|Radiofrequency group|Pulsed radiofrequency applied to nerve roots for cervical radiculopathy
89365163|NCT05948020|Experimental|CBT102-A group|10 subjects receive oral CBT102-A with three meals per day for a total of 20 days
89365164|NCT05948020|Placebo Comparator|Placebo group|5 subjects receive oral placebo with three meals per day for a total of 20 days
89365165|NCT05935735|Experimental|BBTI Group|Participants will receive 4 in-person sessions of Brief Behavioral Therapy for insomnia as part of their intensive outpatient treatment of substance use recovery
89365166|NCT05935735|No Intervention|SOC Group|Participants will receive their usual substance abuse treatment as part of their intensive outpatient treatment of substance use recovery
89365167|NCT05928117|Experimental|Experimental|Intervention: Mobile education given in the line of coping with fear The first one is 28-30th of pregnancy. week, the second is 36-38. It will meet in three meetings in total, the third of which will be within 12-24 hours postpartum.
89365168|NCT05928117|No Intervention|Control|Standart care
89365169|NCT05927701||Non-Surgical Group|Patients treated non-surgically during adolescence (<18 years of age) with a baseline Cobb >40º and minimum 20 years of follow-up.
89365170|NCT05927701||Surgical Group|Patients treated surgically during adolescence (<18 years of age) with a baseline Cobb >40º, and minimum 20 years of follow-up
89365171|NCT05926180|Experimental|DZD9008 + Probe Drugs|Single dose of 2 mg midazolam (oral solution), 0.25 mg digoxin (tablet) and 10mg rosuvastatin (tablet) and in combination with 300 mg DZD9008 (tablet)
89365172|NCT05921175|Active Comparator|RGT+ conventional physiotherapy|16 sessions of robotic gait training (RGT) + conventional physiotherapy in 8-10 weeks
89365173|NCT05921175|Experimental|RGT+ tSCS + conventional physiotherapy|Phase 2: 16 sessions of RGT training + transcutaneous electrical stimulation (tSCS) + functional training in 8-10 weeks.
89365174|NCT05917067||Children (<18 years) that will undergo total thyroidectomy for any indication|
89365175|NCT05905926|Experimental|Tenapanor|Eligible patients from the parent study will continue tenapanor at the same dose assigned in the parent study which can be titrated to either 50 mg BID or 25 mg BID per Investigator guidance after a patient's first week on the assigned dose.
88836219|NCT05467748|Experimental|combination of tazemetostat and pembrolizumab|Enrolled patients will receive combination treatment for whole study duration (2 years). For first cycle, patient will start tazemetostat one week prior to start every 3 week pembrolizumab intravenous infusion (pembrolizumab will be given day 8 only for the first cycle, rest of cycles will be day 1 of each cycle).
88836220|NCT05460871|No Intervention|Control|Participants will receive standard peri-operative pain management
88836221|NCT05460871|Experimental|Study (Pregabalin)|Participants will receive pregabalin orally 75mg twice daily x 7 days prior to surgery, 150mg twice daily x 7 days after surgery, followed by 75mg twice daily x 7 days. Then Stop.
88836222|NCT05460390|Experimental|TDM based adalimumab dose optimization group|Therapeutic drug monitoring (TDM) provides an opportunity for a proactive and individualized therapy optimization based on serum drug concentration and anti-drug antibodies development.
88836223|NCT05460390|No Intervention|Standard of care|Standard of care practice for RA management is based on disease activity guided therapy adjustments.
88836224|NCT05459181|No Intervention|Control arm|465 participants undergoing standard of care post-transplant surveillance
88836225|NCT05459181|Experimental|Intervention arm|465 participants undergoing HeartCare protocol surveillance
89365176|NCT05892666||Emergency department|ED care for acute ambulatory conditions by physicians unfamiliar with the patients.
89365177|NCT05892666||Walk-in clinics|In-person or virtual care in a walk-in clinic for acute ambulatory conditions by physicians unfamiliar with the patients. In-person and virtual care will be assessed together as part of the care offer in outpatient clinics, but separately as a sub-analysis.
89365178|NCT05892666||Primary care practice|In-person or virtual care in a primary care clinic for acute ambulatory conditions (patients attached to a primary care practice, seen by their family physician or a colleague on a same-day appointment for urgent needs). In-person and virtual care will be assessed together as part of the care offer in outpatient clinics, but separately as a sub-analysis.
89365179|NCT05889234||Modified electroconvulsive therapy group|The adolescent MDD receiving modified electroconvulsive therapy and conventional medication.
88836226|NCT05457998||Main study population: Cognitively unimpaired individuals (50-80 y)|"Participants will be enrolled based on a predetermined ratio of Alzheimer's Disease plasma and PET biomarker risk levels (e.g., as P-tau217 and amyloid PET).~FOLLOW-UP FOR 4 YEARS: Cognitive testing, blood draws and retinal imaging will be conducted at baseline and 12 months. Cognitive testing and blood draws will be conducted at 24 months and 36 months.~MRI and amyloid PET scans will be performed at screening/baseline and 24 months. An additional amyloid PET scan will be performed at 48 months."
89001608|NCT00588172|Active Comparator|2|Individuals with nsSNPs or mutations known to alter oct1 function
89365180|NCT05889234||Non-modified electroconvulsive therapy group|The adolescent MDD receiving only conventional medication.
89365181|NCT05889234||Healthy controls group|Healthy adolescents.
89365182|NCT05859594|Experimental|Experimental (laughter yoga) group|The intervention group will receive eight online laughter yoga sessions, two sessions per week for four weeks. In this study, the number of laughter yoga sessions was determined in line with the studies in the literature. Each laughter yoga session is planned to last approximately 40-45 minutes. Each session of laughter yoga consists of clapping and warm-up exercises, deep breathing exercises, childlike play and laughter.
89365183|NCT05859594|No Intervention|Control group|The control group will receive no intervention for 4 weeks.
88836227|NCT05457998||Sub-group 1: Optional Tau PET imaging sub-study|"An optional tau PET imaging sub-study will be conducted in 70 subjects from the main study population who elect to participate.~If enrolled in the optional tau PET imaging sub-study, participants will have three tau PET scans with [18F]RO-948: at baseline, 24 months, and 48 months."
89365184|NCT05849064|Active Comparator|Behavioral Control|Participants randomized to the behavioral control group will receive standardized (i.e., all participants in this group will receive the same interventions) behavioral management strategies that include activity, hydration, nutrition, sleep, and stress management strategies.
89365185|NCT05849064|Experimental|Targeted Intervention|Participant receives exercises or strategies based on their clinical concussion domain given to them by their neuropsychologist: 1) Anxiety/Mood, 2)Headache/Migraine, 3)Vestibular, 4)Ocular, 5)Cognitive.
89365186|NCT05845086|Experimental|Intervention group (Preoperative patient education)|In addition to the usual care provided by the nurses, the intervention group will be provided with multimedia-supported written and verbal pre-operative patient training, reinforced by the teach-back method, created according to the literature.
89365187|NCT05845086|No Intervention|Control group (Usual care)|The control group continued to receive the usual care
89365188|NCT05833360||Control Cohort|Participants without cancer, with general medical comorbidities
89365189|NCT05833360||Cancer Predisposition Cohort|Participants without cancer, with comorbidities that induce cancer predisposition.
89365190|NCT05833360||Pre-Malignant Condition Cohort|Participants without cancer, with pre-malignant conditions
89365191|NCT05833360||Cancer Patients Cohort|Participants with a cancer diagnosis.
89365192|NCT05830851|Active Comparator|aerobic exercise|Walk on a treadmill during 20-30 minutes at 60-80% of Heart Rate max
89365193|NCT05830851|Sham Comparator|Sham tDCS|Application of tDCS during 30 seconds of 2 mA-intensity.
89365194|NCT05830851|Experimental|real tDCS|Application of real tDCS during 20 minutes at 2 mili Amper (mA)-intensity.
89365195|NCT05830448|Experimental|Cognitive Behavioral Therapy (CBT)|CBD is a model that applies learning theories to assist people when they encounter difficulties and life problems that they cannot cope with in their daily lives. It focuses on the elements that affect emotions and behaviors, that is, the thought system. CBT is a process that involves changing the automatic thoughts and evaluations that occur when people are faced with negative situations with different thoughts that can create alternatives and restructuring these thoughts. The approach essentially argues that the way events are perceived and interpreted is more important than how they happen. Systematic errors in information processing, which cause people to perceive themselves, their environment and their future negatively, cause stress and symptoms of mental disorders. There are studies showing that cognitive behavioral therapy reduces stress levels and stress symptoms.
89365196|NCT05830448|Active Comparator|Mobile Mental Health Support System created by the Turkish Ministry of Health|"This system aims to protect and support the mental health of the health personnel of the Ministry of Health. It is a mobile application that allows video calls with a secure and official channel with voluntary adult and child-adolescent mental health and diseases specialists for himself and his children. Personnel who want to benefit from the said service will be able to access the service by downloading the Ministry of Health RUHSAD application to their mobile devices after searching for Mental Health Support System in the mobile application markets and following the instructions."
89365197|NCT05828472|Experimental|Group 1：Dose1|8 subjects received Dose 1 of MY008211A Tablets, and 2 subjects received placebo, continually 7 days
89365198|NCT05828472|Experimental|Group 2：Dose2|8 subjects received Dose 2 of MY008211A Tablets, and 2 subjects received placebo, continually 7 days
89365199|NCT05828472|Experimental|Group 3：Dose3|8 subjects received Dose 2 of MY008211A Tablets, and 2 subjects received placebo, continually 7 days
89365200|NCT05828472|Experimental|Group 4: Dose4|8 subjects received Dose 4 of MY008211A Tablets, and 2 subjects received placebo, continually 7 days
89365201|NCT05827601||Avian Influenza Outbreak Farms|People involved in outbreak management, ranging from poultry farm owners and their family to inspectors through veterinarians and cullers/cleaners, will be invited to take part in the study at the earliest step possible after outbreak detection. Self sampling by nasopharyngeal swab will be requested every 2 days during 2 weeks.
89365202|NCT05827601||Poultry Farm Sentinel Network|"People working in poultry farms and in contact with animals will be invited to join the cohort. Self sampling by nasopharyngeal swab will be requested every 2 weeks for the whole duration of the study.~anticipated: 15"
89365203|NCT05827601||Wild bird/life Rehabilitation Centre Sentinel Network|"People working in wild bird/life rehabilitation centers and in contact with animals will be invited to join the cohort. Self sampling by nasopharyngeal swab will be requested every 2 weeks for the whole duration of the study.~anticipated: 25"
89365204|NCT05827601||Pig Industry Veterinarian Sentinel Network|"Veterinarians working in the pig industry and in contact with animals will be invited to join the cohort. Self sampling by nasopharyngeal swab will be requested every 2 weeks for the whole duration of the study.~anticipated: 15"
89365205|NCT05827198|Placebo Comparator|Control sugar candies|Control chewable candy made with sugar and provided at a dose of 50 g (corresponding to 2 servings)
88836228|NCT05457998||Sub-group 2: Optional Tau PET tracer comparison sub-study|"An optional tau PET tracer comparison sub-study will be conducted in 30 subjects from the main study population who elect to participate.~Tau PET scans with 2 tracers ([18F]RO-948 and [18F]MK-6240) will be performed at baseline and 24 months. An additional Tau PET scan with [18F]RO-948 will be performed at 48 months."
89001609|NCT00209742|Experimental|2|
89001610|NCT00209742|Experimental|3|
89001611|NCT00209742|Active Comparator|1|
89365206|NCT05827198|Active Comparator|Test low sugar candies dose 1|low-sugar chewable candy containing Soluble Corn Fiber + Inulin + Erythritol provided at a dose of 50 g (corresponding to 2 servings)
89365207|NCT05827198|Active Comparator|Test low sugar candies dose 2|64% reduced sugar chewable candy containing Soluble Corn Fiber + Resistant wheat dextrins provided at a dose of 50 g (corresponding to 2 servings)
89365208|NCT05827198|Active Comparator|Test low sugar candies dose 3|82% reduced sugar chewable candy containing Soluble Corn Fiber + Resistant wheat dextrins provided at a dose of 50 g (corresponding to 2 servings)
89365209|NCT05825898||Conservative management|Patients with TR who did not undergo a tricuspid valve intervention
89365210|NCT05825898||Isolated tricuspid valve surgery|Patients with TR who underwent a Isolated tricuspid valve surgery.
89365211|NCT05825898||Transcatheter tricuspid valve intervention|Patients with TR who underwent a transcatheter tricuspid valve intervention.
89365212|NCT05821517|Active Comparator|Standard of care|An anticipated analgesia protocol composed of PARACETAMOL 1g +/- OXYNORM 5 mg or 10 mg according to patients weight and pain intensity as evaluated by a simple numeric rating scale is administred prior to the reduction procedure. Inhaled equimolar mixture of oxygen and notrous oxyde (MEOPA) at a 15L/min flux is administered concomitantly to the reduction procedure.
89365213|NCT05821517|Experimental|Medical device : VR headset|"Use of a  virtual reality  (VR) headset of  Pico G2  type with  HypnoVR  software and audio headset  Taotronics BH22  during all the reduction care"
89365214|NCT05821517|Experimental|Medication : Methoxyflurane analgesia|Self administered inhalated methoxyflurane (maximal inhaled dose : 3 mL)
89365215|NCT05807919|Experimental|Diet low in all FODMAP groups|
89365216|NCT05807919|Experimental|Diet - Mediterranean|
89365217|NCT05803811|Experimental|Low dose|Daily dose of 1.4 mg of Vitamin B2 (Riboflavin) once a day for 12 weeks
89365218|NCT05803811|Experimental|Mid dose|Daily dose of 10 mg of Vitamin B2 (Riboflavin) once a day for 12 weeks
89365219|NCT05803811|Experimental|high dose|Daily dose of 75 mg Vitamin B2 (Riboflavin) once a day for 12 weeks
89365220|NCT05803811|Placebo Comparator|Placebo|One capsule of 570 mg (consisting of microcrystalline cellulose) once a day for 12 weeks
89365221|NCT05801120|Experimental|Ketogenic food products one time|Dietary Supplement: Ketogenic food products Participants will be given a ketogenic food product prior to the hyperbaric oxygen exposure.
89365222|NCT05801120|Experimental|Experimental: Ketogenic food products two times|Dietary Supplement: Ketogenic food products Participants will be given a ketogenic food product prior to the hyperbaric oxygen exposure.
89365223|NCT05801120|Experimental|Experimental: Ketogenic food products three times|Dietary Supplement: Ketogenic food products Participants will be given a ketogenic food product prior to the hyperbaric oxygen exposure.
89365224|NCT05798273|Other|intra-arterial injection of [68Ga]Ga-PSMA-11|eligible for intra-arterial injection (age >18 years) with enhancing glioma or brain metastases eligible for (re-)resection.
89365225|NCT05780606|Other|Voluntary|
89365226|NCT05764057|Experimental|Dapagliflozin 10mg daily + standard of care|Dapagliflozin 10mg per day will be administered orally, as in clinical practice
89365227|NCT05764057|Placebo Comparator|Placebo + standard of care|Placebo will be administered orally
89365228|NCT05732337|Other|Poxclin Coolmousse|A cooling mousse for application to the skin supplied in a 100 mL plastic bottle with a pump (a foamer)
89365229|NCT05730465|No Intervention|Standard of Care|Participants will receive routine stroke discharge education which is standard of care. A stroke nurse will provide and review with the patient a short informational pamphlet on the importance of blood pressure monitoring.
89365230|NCT05730465|Experimental|Access to Blood Pressure Monitoring|Participants will also receive the teaching administered to the control group. In addition, they will be given an Omron Home Blood Pressure Cuff furnished by the study. The nurse will provide additional education on on how to use the cuff, and how to record values in a blood pressure log.
89365231|NCT05725187||Low risk group for paroxysmal atrial fibrillation|Subject patients are above 20 in age who are hospitalized in our hospital or outpatients with arrhythmia symptoms after the clinical research approval. The sinus rhythm electrocardiogram at the time of the patient's participation in the study is put into the artificial intelligence prediction algorithm, and the risk stratification results are blinded and are not informed to both the research director and the subjects. For the low-risk group, after attaching the wearable electrocardiogram to the subject, the electrocardiogram recorded a week later is analyzed to confirm the occurrence of atrial fibrillation.
89365232|NCT05725187||High risk group for paroxysmal atrial fibrillation|Subject patients are above 20 in age who are hospitalized in our hospital or outpatients with arrhythmia symptoms after the clinical research approval. The sinus rhythm electrocardiogram at the time of the patient's participation in the study is put into the artificial intelligence prediction algorithm, and the risk stratification results are blinded and are not informed to both the research director and the subjects. For the highrisk group, after attaching the wearable electrocardiogram to the subject, the electrocardiogram recorded a week later is analyzed to confirm the occurrence of atrial fibrillation.
88836229|NCT05438316|Other|Sequence TR|25 subjects assigned to the sequence TR will receive a single 10 mg dose of the test product Ramipril (1 x 10 mg tablet), marked as T in the sequence, in Period 1 and a single 10 mg dose of the reference product Tritace® (1 x 10 mg tablet), marked as R in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken. /
88836230|NCT05438316|Other|Sequence RT|25 subjects assigned to the sequence RT will receive a single 100 mg dose of the reference product Tritace® (1 x 10 mg tablet), marked as R in the sequence, in Period 1 and a single 10 mg dose of the test product Ramipril (1 x 10 mg tablet), marked as T in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
89365233|NCT05722366|Active Comparator|Active Video Game İntervention|"The active video games intervention will be carried out with a virtual reality system (XBOX360, Microsoft, USA) consisting of a console and a sensor.~Active video games consist of Bowling, River Rush, Rally Ball and Reflex Ridge games.~Participants will exercise for a total of 25 minutes with light-paced games for warm-up for the first 5 minutes, then brisk games with different body movements until the 15 minutes are complete, and light-paced games for 5 minutes to cool down.~Participants will complete active video games in the same order."
88836231|NCT05436548|Experimental|Brief and frequent Work-life check-ins between clinic supervisors and each staff member|Primary care clinics assigned to the intervention will conduct frequent (every 8 weeks) supervisor-employee brief (30 min) check-ins to identify work stressors. Supervisors at such clinics will complete training on how to use the check-ins to address work stressors.
88836232|NCT05436548|Experimental|Usual practice, waitlist controls|Primary care clinics randomly assigned to the control condition will continue as usual practice. If the check-is are effective in reducing burnout, then supervisor-level training will become available to supervisors at the end of the study
89365234|NCT05722366|Active Comparator|Aerobic Exercise Intervention|The exercise intervention will consist of a continuous moderate intensity walking session on the treadmill. After the first 5 minutes of warm-up,a at 55-70% of the peak heart rate reserve(HRR)with a 15-minute walking session, and 5 minutes of cooling down total of 25 minutes of exercise will be performed.
89365235|NCT05716100|Experimental|XEN1101 25 mg/day|XEN1101 25 mg/day
89365236|NCT05716100|Experimental|XEN1101 15 mg/day|XEN1101 15 mg/day
88836233|NCT05432700|No Intervention|Control group: usual clinical practice.|"The women will receive an initial Health Literacy Survey (HLS-EU-Q16) via the email account registered on the platform. From this point until birth, no further notifications will be sent.~Subsequently, reminders will be planned via email to obtain information on BF follow-up, avoiding providing any extra information on BF and, where appropriate, referring to the BF support services available in their area, following a standard clinical practice. During pregnancy, the pregnancy programme of the local and national government provides parenting education and breastfeeding workshops, with various manuals published.~Surveys adapted to this group will be sent out at birth, at 15 days, 6 weeks, 3 and 6 months. The variables to be collected are socio-demographic, related to health literacy, obstetric-neonatal, and breastfeeding variables."
88836234|NCT05432700|Experimental|Intervention group: LactApp|"From the initial registration in LactApp during the third trimester, women will be able to consult all the information available in the application. The women will receive an initial Health Literacy Survey (HLS-EU-Q16), from this point until birth, no further notifications will be sent. A reminder schedule will be made via email to obtain information on the follow-up of the BF.~LactApp® works as a self-administered questionnaire based on decision trees constructed with questions and answers developed by professional breastfeeding experts, supported by scientific evidence and updated official health recommendations. In addition, the app will remind them of the topics according to the estimated date of birth provided. Surveys adapted to this group will be sent out at birth, at 15 days, 6 weeks, 3 and 6 months. The variables to be collected are socio-demographic, related to health literacy, obstetric-neonatal, and breastfeeding variables."
89365237|NCT05716100|Placebo Comparator|Placebo|Placebo
89365238|NCT05714072|Experimental|Ruxolitinib plus Abemaciclib|"This will be a phase 1 study with a traditional 3+3 design of combination ruxolitinib (at fixed doses of 10mg BID or 15mg BID) and abemaciclib. There are 3 planned dose levels of abemaciclib: 50, 100 and 150 mg. Cycles will be 4 weeks (28 days) long and DLT window will consist of first cycle."
89365239|NCT05705154|Active Comparator|Standard treatment|"Standard treatment consists of virtual MDT discussion with referrer and advice signposting into local services for specific issues. If a patient is severely affected enough to be seen face to face, they are offered an interdisciplinary consultation, and tailored input from PT OT and psychological services.~Access to standardised information covering the following topics: sleep, pacing, activity management, school reintegration, managing friendships, eating well and emotional wellbeing.~More complex or severely affected patients will receive one to one treatment with members of the MDT as required."
89365240|NCT05705154|Experimental|Intervention|"As above standard intervention plus the new co-designed intervention.~Based on clinical expertise and theory, it is anticipated the following elements may be included in the intervention:~Progressive breathing pattern retraining, including education, self-observation, relaxation, body scanning, postural re-alignment~Identifying the connections between body and mind to address anxiety and breathlessness~Coping skills for managing anxiety using principles from narrative therapy and mindfulness~Online materials to improve self-efficacy with home practice~Social connection with other CYP for peer support, and resource sharing~Activities to help CYP reconnect with their usual activities, skills, abilities, interests, support systems."
89365241|NCT05702658|Experimental|experimental arm|Individuals who receive CAPS
89365242|NCT05702658|No Intervention|control|Individuals who receive treatment as usual
89365243|NCT05686317|Experimental|APTURE shunt + medical therapy|
89365244|NCT05686317|Sham Comparator|Sham + medical therapy|
89365245|NCT05686109||Monitoring device Biobeat®|"Biobeat® non-invasive monitoring devices can be used in an out-of-hospital perioperative setting to observe patients' vital signs up to 5 days postoperatively.~The Biobeat® portable adhesive device will be installed after the surgery, in the recovery room. All patients will be equipped with a portable single-use Biobeat® Bluetooth device that will be positioned at chest level and connected via Bluetooth to the patient's cell phone. These patches have been FDA approved since 2019 (new approval in 2022) for non-invasive (systolic, diastolic, and mean) blood pressure measurement without a cuff. The following other parameters will also be recorded: peripheral oxygen saturation, heart rate, respiratory rate and body temperature based on the analysis of the plethysmography wave. This data will be recorded as soon as the patches are installed."
89365246|NCT05680233|Experimental|OA-235i (4-40 mg)|"Single ascending dose (SAD): OA-235i (4-40 mg) administered subcutaneously (SC) once to adult subjects with suspected or confirmed diagnosis of noncirrhotic nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH) without advanced hepatic fibrosis.~Multiple dose (MD): OA-235i (dose level to be determined from SAD) administered subcutaneously (SC) once daily for 7 days to adult subjects with suspected or confirmed diagnosis of noncirrhotic nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH) without advanced hepatic fibrosis."
89365247|NCT05674630|Experimental|Magic Touch drug eluting balloon based strategy - 6/12 months invasive follow up|Patients randomized to DEB-based strategy will receive treatment with DEB (Magic Touch, Concept Medical®) throughout the entire lesion length, followed by final assessment with FFR and IVUS at 6 or 12 months in a randomized fashion.
89365248|NCT05674630|Active Comparator|Drug eluting stent based strategy - 6/12 months invasive follow up|Percutaneous transluminal coronary angioplasty and drug eluting stent implantation according to local standard of care, including optimization techniques (e.g. post-dilatation) which are left at operators' discretion, followed by final assessment with FFR and IVUS at 6 or 12 months in a randomized fashion.
89365249|NCT05652673|Experimental|Early discontinuation of nivolumab|
89365250|NCT05645250||Negatives cases|
88836235|NCT05427734|Experimental|Jaspr2.0|Suicide prevention platform that includes evidence-based practices for suicide prevention and alcohol misuse for use in primary care. Jaspr2.0 includes psychoeducation, behavioral skills training, crisis stabilization planning, lethal means management, brief interventions for the treatment of alcohol misuse, and messages of hope, wisdom, and insights from people with lived experience (PLE). Participants in this condition will also have access to the Jaspr2.0 companion mobile app, Jaspr-at-Home.
89001612|NCT03452605|Experimental|high cocoa flavanol drink|high cocoa flavanol drink (900 mg cocoa flavanol dissolved in 300 ml skimmed milk) 2h pre-fMRI
89365251|NCT05645250||Positive cases|
89365252|NCT05643534|Experimental|Tenpanor 50 mg BID|Patients will be randomized to receive 50 mg tenapanor twice daily
89365253|NCT05643534|Experimental|Tenpanor 25 mg BID|Patients will be randomized to receive 25 mg tenapanor twice daily
89365254|NCT05643534|Placebo Comparator|Placebo Comparator|Patients will be randomized to receive matching placebo twice daily
89365255|NCT05643404||Isolated LBBB|Subjects with left bundle branch block in the absence of clinically detectable heart disease
89365256|NCT05643404||Matched controls without LBBB|Subjects without left bundle branch block and in the absence of clinically detectable heart disease
89365257|NCT05642585|Experimental|Group 1: Dose1|Participants randomized to receive MY008211A tablets or placebo on Day 1.
89365258|NCT05642585|Experimental|Group 2: Dose2|Participants randomized to receive MY008211A tablets or placebo on Day 1.
89365259|NCT05642585|Experimental|Group 3: Dose3|Participants randomized to receive MY008211A tablets or placebo on Day 1.
89365260|NCT05642585|Experimental|Group 4: Dose4|Participants randomized to receive MY008211A tablets or placebo on Day 1.
89365261|NCT05642585|Experimental|Group 5: Dose5|Participants randomized to receive MY008211A tablets or placebo on Day 1.
89365262|NCT05642585|Experimental|Group 6: Dose6|Participants randomized to receive MY008211A tablets or placebo on Day 1.
89365263|NCT05642585|Experimental|Group 7: Dose7|Participants randomized to receive MY008211A tablets or placebo on Day 1.
89365264|NCT05638932||Interleukin-6 receptor inhibitor (IL6Ri) initiators vs Janus kinase inhibitor (JAKi) initiators|Hospitalized patients who initiate an IL6Ri versus JAKi in addition to a corticosteroid of interest
89365265|NCT05624125|Active Comparator|Beetroot juice|The beetroot juice intervention comes in a single 70 ml drink and is manufactured by James White Drinks. Each drink contains beetroot juice and 2% lemon juice, made from concentrates. Each serving of 70 mL of beetroot juice contains 400 mgs (6.45 millimoles) of nitrate and will be taken twice daily for a total daily dose of 800 mgs (12.90 millimoles) of nitrate.
89365266|NCT05624125|Placebo Comparator|Placebo|The placebo comes in a single 70 ml drink and is manufactured by James White Drinks. The placebo contains beetroot juice and 2% lemon juice, made from concentrates, and is filtered to remove nitrate.
89365267|NCT05621395|Experimental|E-OJ-01|1 capsule (400 mg) orally to be taken after breakfast daily for 60 days
89365268|NCT05621395|Placebo Comparator|Microcrystalline cellulose|1 capsule (400 mg) orally to be taken after breakfast daily for 60 days
88836236|NCT05427734|Active Comparator|Active-Control app + electronic wellness resources brochure|Well-regarded suicide prevention self-help app, plus an electronic wellness resources brochure containing links to health and wellness materials, psychoeducation about suicide, depression, self-help recovery-focused resources (e.g., Alcoholics Anonymous, other 12-Step programs, Moderation Management, etc.), and phone/text information for the National Suicide Prevention Lifeline.
88836237|NCT05426525|Experimental|Empagliflozin|Participants will be provided 10-25mg empagliflozin per day for 13 weeks.
88836238|NCT05426525|Placebo Comparator|Multivitamin-Placebo|Participants will be provided 1 multivitamin-placebo per day for 13 weeks.
89178635|NCT00700895|Experimental|Pharmacogenetics-guided dosing group|For patients randomized to the pharmacogenetics-guided dosing group, this 10mls of blood will be immediately sent for genotyping studies. Genotyping results will be available for pharmacogenetics-guided dosing within 3 working days, (ranging 3 to 5 days). During this period, if patients need to be initiated on anticoagulation, a low molecular weight heparin, Fraxiparine, will be given. Fraxiparine will be overlapped with warfarin for 2 to 3 days until target INR is achieved. Elective cases should have the pharmacogenetics-based warfarin dose available at the time of warfarin therapy.
89178636|NCT00700895|Experimental|Traditional dosing group|For patients randomized to the traditional dosing regime, the blood will be stored and genotyped retrospectively at the end of the study. Overlapping of warfarin with Fraxiparine or heparin till target INR is achieved is allowed for this group as per normal clinical practice. All warfarin dosage adjustments based on INR results will be according to the current protocol used by the NUH Anticoagulant Clinic.
89178637|NCT00861341|Experimental|Pioglitazone with or without Aspirin|Blood samples will be taken at time 0 to measure platelet aggregation. 30mg Pioglitazone will be ingested and another blood sample will be obtained 90-180 minutes later for platelet aggregation. After 6-9 days, subjects will ingest 81mg of aspirin. Another blood sample will be obtained 2-24 hours later for baseline determination of platelet aggregation and activation after taking aspirin. Subjects will then ingest 30mg pioglitazone and a final blood sample will be obtained 90-180 minutes later to measure platelet aggregation.
89178638|NCT00766467|Experimental|Group 1|Armodafinil
89178639|NCT00766467|Placebo Comparator|Group 2|Placebo
89178640|NCT00850499|Experimental|VELCADE and fludarabine (Group A)|VELCADE 1.6 mg/m2 intravenously (IV) on Days 1, 8, 15, and 22 and fludarabine 40mg/m2/day orally on Days 1 to 5 of every 35-day cycle
89178641|NCT00850499|Active Comparator|fludarabine and rituximab (Group B)|fludarabine 40mg/m2/day orally on Days 1 to 5 and rituximab 375mg/m2 on Day 1 of every 35-day cycle
89178642|NCT00860951|Other|Brain Computer Interface Keyboard|What effect does the environment (BCI, AT device, Computer) have on the accuracy of typing using a BCI keyboard?
89365269|NCT05620953||SARI case|
89365270|NCT05618652|Active Comparator|Clinician Coaching Immediate Intervention Arm-- Caregivers|"Clinicians who receive the intervention will participate for up to 12 months, which includes completion of didactics, 8 audio-recorded clinical encounters, 4 feedback sessions, and completion of a post-intervention brief interview and survey. After completing didactic training elements, clinicians will receive coaching and professional feedback on their communication with caregivers of children in the hospital. The investigators will provide clinicians with illustrative examples from their encounters to prompt discussion and self-reflection.~Caregivers of hospitalized children will not know if their clinician has received the communication intervention. The investigators will recruit 40 caregivers in this arm."
89178643|NCT03123549|Experimental|Simplify Disc|Simplify Disc at two levels of the cervical spine
89178644|NCT03123549|No Intervention|Historical Control|This study will utilize a non-concurrent historical control with subject-level data on a parallel group design. The historical control group will be formed from the randomized ACDF arm of a previously completed two level cervical disc trial.
89178645|NCT00844805|Experimental|Infliximab + Naproxen|Infliximab administered at a dose of 5 mg/kg intravenously on Day 1 of Weeks 0, 2, 6, 12, 18, and 24, combined with naproxen administered at a daily dose of 1000 mg for 28 weeks during the 28-week treatment phase.
89178646|NCT00844805|Placebo Comparator|Placebo + Naproxen|Placebo administered intravenously on Day 1 at Weeks 0, 2, 6, 12, 18, and 24, combined with naproxen administered at a daily dose of 1000 mg for 28 weeks, during the 28-week treatment phase.
89178647|NCT00844805|Experimental|Naproxen Only (Follow-Up)|For participants who achieved partial remission during 28-week treatment phase, naproxen was continued at a daily dose of 1000 mg administered orally for an additional 24 weeks in the follow-up phase.
89178648|NCT00844805|No Intervention|No Treatment (Follow-Up)|For participants who achieved partial remission during Treatment phase, no treatment was administered for an additional 24 weeks in the follow-up phase.
89178649|NCT04022265|Active Comparator|Control Site -Drill site|The control sites (Drills) will be prepared with a lanceolate drill (FS 230, Sweden / Martina), with a maximum diameter of 2.3 mm,
88836239|NCT05417698|Experimental|Exercise only (Ex only)|"Participants in the Exercise only group will be performing home-based, equipment-free HIIT exercise for 20 minutes, 3 times a week for the duration of the 8-weeks, achieving ≥80% of predicted heart rate maximum (HRmax; 220-age) during the high-intensity intervals. Participants are also required to exercise at least 17 out of 20 on the Rate of Perceived Exertion (RPE) scale."
88875181|NCT02508636|Experimental|Combination Therapy: Enzalutamide, Leuprolide, Radiotherapy|"Participants will receive Enzalutamide: 160 mg per day, to begin within 0-7 days of the date of the first Luteinizing Hormone-Releasing Hormone (LHRH) agonist administration for total duration of 24 months as well as a single Leuprolide 7.5mg injection every month; single 22.5 mg injection every 3 months; single 30mg injection every 4 months; single 45 mg injection every 6-months based on the manufacturer for a total of 24 months.~Radiation therapy should begin approximately 8 weeks (+/- 1 week) after the date of the first LHRH agonist/antagonist injection of hormone therapy is given and continue for a total of 5 weeks."
89178650|NCT04022265|Experimental|Test site -sonic site|test sites will be prepared with conical diamond inserts of increasing diameter (SFS99.000.014 to SFS99.000.024, Komet-Brasseler-GmbH, Germany) mounted on a sonic-air surgical instrument
89178651|NCT03043209||Genomic sequencing|Perform Genomic sequencing in peripheral blood DNA and discarded myocardium from cardiac procedures
89365271|NCT05618652|Other|Clinician Coaching Wait-List Control Arm-- Caregivers|"Clinicians in the wait-list control arm will initially serve as the control arm then receive the intervention to provide feasibility and acceptability data. The clinicians randomized the control arm will undergo didactics and feedback once their pre-intervention audio-recordings are complete.~Caregivers of hospitalized children will not know if their clinician has yet received the communication intervention. The investigators will recruit 40 caregivers in this arm prior to clinicians receiving the intervention."
88836240|NCT05417698|Experimental|Exercise and Mediterranean Diet (Ex + MedDiet)|"Participants in Ex+MedDiet arm will be required to adhere to a non-caloric restrictive Mediterranean diet throughout the 8-weeks according to a Mediterranean diet booklet provided by the researcher. In brief, diet encompasses a focus on minimally processed food, incorporating a wide variety of fruits, vegetables, legumes and wholegrains, whilst utilising olive oil as the main source of fat. They will be encouraged to eat more oily and white fish, with moderate consumption of nuts, poultry and dairy products, and low consumption of red/processed meat and alcohol.~Participants in this group will also be performing home-based, equipment-free HIIT exercise for 20 minutes, 3 times a week for the duration of the 8-weeks, achieving ≥80% of predicted heart rate maximum (HRmax; 220-age) during the high-intensity intervals. Participants are also required to exercise at least 17 out of 20 on the Rate of Perceived Exertion (RPE) scale."
89365272|NCT05614063|Experimental|XEN1101 25 mg/day|XEN1101 25 mg/day
89365273|NCT05614063|Experimental|XEN1101 15 mg/day|XEN1101 15 mg/day
88836241|NCT05417698|No Intervention|Control|Participants will be asked to maintain their diet and physical activity levels throughout the 8 weeks.
89365274|NCT05614063|Placebo Comparator|Placebo|Placebo
88836242|NCT05415384|Experimental|Surgical Stabilization of Rib Fractures plus Multimodal Pain Therapy plus CRYOABLATION|Adding Cryoablation of levels 3-8, in addition to patients that undergo SSRF for multiple rib fractures.
88836243|NCT05415384|Active Comparator|Surgical Stabilization of Rib Fractures plus Multimodal Pain Therapy|Standard surgical treatment of patients with multiple rib fractures plus Multimodal Pain Therapy
88836244|NCT05414981|Active Comparator|ABI-H3733|
88836245|NCT05414981|Placebo Comparator|Placebo|
88836246|NCT05403138|Experimental|Daratumumab|Induction Period: Participants received daratumumab (8mg/kg) via intravenous (IV) every 2 weeks for two cycles. This was followed by the Maintenance Period: Participants received daratumumab (4mg/kg) via IV infusion every 4 weeks from the third dose (Week 4) onwards.
88836247|NCT05403138|Placebo Comparator|Placebo|Placebo contains the same buffer components without the active ingredient. Induction Period: Participants received matching placebo (8mg/kg) via intravenous (IV) every 2 weeks for two cycles. This was followed by the Maintenance Period: Participants received matching placebo (4mg/kg) via IV infusion every 4 weeks from the third dose (Week 4) onwards.
88836248|NCT05394220||Parapneumonic effusion|Patients with parapneumonic effusion
89365275|NCT05605574|Experimental|1 / Assessments and Conversation|Baseline and follow-up assessments and conversations at three timepoints
89365276|NCT05605574|No Intervention|2 / Survey|Following each AYA/caregiver dyad s completion of timepoint 3, a one-time survey will be sent to a primary clinical attending and APPs who cared for the AYA during the study period
89365277|NCT05600127|Experimental|Avelumab|3 cycles of avelumab (Bavencio), 800mg intravenous instillation in 60 min, every 2 weeks.
89365278|NCT05568160|Experimental|Intervention|
89365279|NCT05568160|Active Comparator|Control|
89365280|NCT05565261||Group 1: Complete Dentures|The group consists of patients using conventional complete dentures applied to edentulous patients.
89365281|NCT05565261||Group 2: Implant Supported Overdentures|The group consists of patients who use implant-supported overdentures after 2 dental implants have been surgically placed in edentulous patients and osseointegration has occurred.
88836249|NCT05394220||Non-parapneumonic effusion|Patients with pleural effusion but not parapneumonic in nature
88836250|NCT05392192|Experimental|ADX-629|Subjects will be randomized to receive ADX-629 300mg tablets administered orally twice a day for 14 days.
88836251|NCT05392192|Placebo Comparator|Placebo|Subjects will be randomized to receive matching placebo tablets administered orally twice a day for 14 days.
88836252|NCT05385757||Childhood Uveitis|Children <18 years old newly diagnosed with non-infectious uveitis
89365282|NCT05552287|Experimental|Intensified induction scheme with Infliximab|Intensified induction scheme with Infliximab. IFX will be given intravenously at 10 mg/kg at week 0, and 5 mg/kg at weeks 2, 4, and 8 to all patients (induction). Maintenance will start at week 12, and then ideally continue every 6 weeks.
88836253|NCT05363644|Experimental|Single Arm Study Group|Placement of a sheet of BioDFence G3 to the neurovascular bundle.
88836254|NCT05358574||Patients who received the Anatomical Shoulder Bipolar|Patients who received the Anatomical Shoulder Bipolar and were operated according to the product's IFU and surgical technique
88836255|NCT05353972|Experimental|Cohort 1|Single dose of IMG or placebo solution, intravenously administered
89365283|NCT05550948|Experimental|alpha tPBM + cognitive training|three days per week for a 2-month intervention period (5 ALL and 5 HL)
89365284|NCT05550948|Experimental|gamma tPBM + cognitive training|three days per week for a 2-month intervention period (5 ALL and 5 HL)
89365285|NCT05550948|Experimental|sham tPBM + cognitive training|Sham stimulations will act as the control for this study three days per week for a 2-month intervention period (5 ALL and 5 HL)
89365286|NCT05550363|Experimental|DEXYCU|DEXYCU, 103.4 mcg/mcl dexamethasone: equivalent dexamethasone dose: 517 mcg
89365287|NCT05550363|Placebo Comparator|Placebo|Placebo/vehicle, 0 mcg/mcl dexamethasone: equivalent dexamethasone dose: 0 mcg
89365288|NCT05542407|Experimental|Obese|Subjects with BMI > 30 kg/m2
89365289|NCT05542407|Experimental|Non-Obese|Subjects with BMI ≤ 29.9 kg/m2
89365290|NCT05535062|Active Comparator|Dash Protocol|Patients will be randomized after consent to receive standard Dash protocol
88836256|NCT05353972|Experimental|Cohort 2|Single dose of IMG or placebo solution, intravenously administered
88836257|NCT05353972|Experimental|Cohort 3|Single dose of IMG or placebo solution, intravenously administered
88836258|NCT05353972|Experimental|Cohort 4|Single dose of IMG or placebo solution, intravenously administered
88836259|NCT05353972|Experimental|Cohort 5|Single dose of IMG or placebo solution, intravenously administered
88836260|NCT05353972|Experimental|Cohort 6|Single dose of IMG or placebo solution, intravenously administered
88836261|NCT05353972|Experimental|Cohort 7|Single dose of IMG or placebo solution, intravenously administered
88836262|NCT05353140|Experimental|Percutaneous left atrial appendage occlusion (LAAO)|"Device: The WATCHMAN/WATCHMAN FLX device~Drug: Rivaroxaban 15 mg QD + Clopidogrel 75mg QD for 45 days, followed by Aspirin 100mg QD + Clopidogrel 75mg QD for 10.5 months after LAAO"
88836263|NCT05353140|Active Comparator|Novel oral anti-coagulation (NOAC)-based anti-thrombotic therapy|Drug: Rivaroxaban 15 mg QD + Clopidogrel 75mg QD for 12 months
88836264|NCT05351944|Experimental|The intervention group (group A) DBT skills|"Will attend Dialectical Behavioral Therapy skills group for both the children and their parents, DBT is an evidence based comprehensive cognitive behavioral treatment for complex mental disorders and have been adapted for intractable behavioral disorders involving emotion dysregulation, skills will be provided in group therapy as fixed weekly sessions over 9-month duration for all the children and the parents in group A including:~Emotion regulation skills module over 8 weeks.~Mindfulness skills module over 3 weeks~Interpersonal effectiveness skills module over 7 weeks.~Distress tolerance skills module over 8 weeks.~Walking the middle path skills module over 3 weeks."
88836265|NCT05351944|Active Comparator|the control group (group B)|Will receive psychoeducation and medications targeting ADHD symptoms (stimulants or atomoxetine according to FDA approved dose per age and weight) according to the international guidelines for management of ADHD according to symptom severity, given that assessment before and after intervention will be done by different medical personnel than those providing the intervention for the two groups.
88836266|NCT05346055|Other|Engage Prism 2.0|Engage Prism is a 9-week program that integrates Engage- a form of behavioral talk therapy treating depression, and guided use of Prism technology- a software that aims to improve social support and interaction of older adults.
88836267|NCT05340465|Active Comparator|Group 1. Oral iron|Oral iron is started on day 7 of life if baby is feeding 100 mL/kg/day. Iron supplements of up to 12 mg/kg/day are given based on CBC, retic, ret-hgb, serum ferritin and zinc protoporphyrin to heme ratio (ZnPP/H). Iron supplements are adjusted every 2 weeks following iron studies.
88836268|NCT05340465|Experimental|Group 2|Infants randomized to this arm will receive Darbe 10 mcg/kg q week started on day 3 of life. In addition, beginning on day 7, they will receive LMW-ID: 10 mg/kg x 1, retreat if ferritin < 76 mcg/L
88836269|NCT05340465|Experimental|Group 3|Infants randomized to this arm will receive Darbe 10 mcg/kg q week started on day 3 of life. In addition, beginning on day 7, they will receive LMW-ID: 20 mg/kg x 1, retreat if ferritin < 76 mcg/L
88836270|NCT05340465|Experimental|Group 4|Infants randomized to this arm will receive Darbe 10 mcg/kg q week started on day 3 of life. In addition, beginning on day 7, they will receive FMX: 10 mg/kg x 1, retreat if ferritin < 76 mcg/L
88836271|NCT05340465|Experimental|Group 5|Infants randomized to this arm will receive Darbe 10 mcg/kg q week started on day 3 of life. In addition, beginning on day 7, they will receive FMX: 20 mg/kg x 1, retreat if ferritin < 76 mcg/L
88836272|NCT05332522|Experimental|Neuroplasticity-based Computerized Cognitive Remediation|Participants will receive a 45-hour of Neuroplasticity-based Computerized Cognitive Remediation
88836273|NCT05332405|Experimental|Study Group|Participants will have planned surgical procedure to repair the median or ulnar nerve compression. During the procedure, the doctor will administer a small injection of indocyanine green (ICG) and laser angiography using the SPY Elite device will be used to evaluate blood flow and extent of nerve decompression at the surgical site. Participation will also involve filling out two questionnaires on pain and function level and an examination of hand strength and range of motion.
88836274|NCT05314231|Experimental|ALXN1720|Participants will receive a single dose of ALXN1720, given as a SC infusion at a dose of 1500 mg.
88836275|NCT05312697|Experimental|Setrusumab QM -->Setrusumab QM|"During Retreatment Period: Setrusumab will be administered via intravenous (IV) infusion once a month (QM) for 12 months.~During Extension Period: Setrusumab will be administered via IV infusion QM for at least 12 months or until commercially available."
88836276|NCT05312697|Experimental|Setrusumab QM --> Setrusumab TBD|"During Retreatment Period: Setrusumab will be administered via IV infusion QM for 12 months.~During Extension Period: Setrusumab will be administered via IV infusion at a dose frequency to be determined (TBD) for at least 12 months or until commercially available."
88836277|NCT05312411|Experimental|UB-TT170 following SCRI-E2CAR_EGFrtv1|Following CAR T cell administration, subjects will receive a first Course of 3 escalating doses of UB-TT170 over 2 weeks followed by fixed weekly dosing for 2 weeks. If eligible, subjects may proceed to Courses 2 - 4 consisting of 7 weekly doses of UB-TT170.
88836278|NCT05309824||Atrial fibrillation|
88836279|NCT05309824||Left ventricular hypertrophy|
88836280|NCT05309824||Pulmonary hypertension|
88836281|NCT05309824||Coronary atherosclerotic heart disease|
88836282|NCT05309824||Heart failure with retained ejection fraction|
89365291|NCT05535062|Active Comparator|Modified Dash protocol with the New feature enabled|Patients will be randomized after consent to receive modified Dash protocol with the New feature enabled
89365292|NCT05530759||Ancillary-Correlative (biospecimen collection)|Patients undergo collection of blood and buccal samples before or after SOC biopsy or tumor resection. Patients undergo collection of tumor tissue at time of SOC biopsy or tumor resection. Patients' medical records are also reviewed. Patients' archived tissue or blood samples may also be collected.
89365293|NCT05517642|Experimental|Ad5-nCoV-IH|Participates age 18 or older who have completed a course of primary and first booster vaccination at least 16 weeks before, and who have sub-optimal antibody response to the first booster dose, will receive a second booster dose of IH Convidecia vaccine.
89365294|NCT05517642|Active Comparator|mRNA vaccine BNT162b2 (Pfizer)|Participates age 18 or older who have completed a course of primary and first booster vaccination at least 16 weeks before, and who have sub-optimal antibody response to the first booster dose,will receive a second booster dose of mRNA vaccine BNT162b2 (Pfizer).
88836283|NCT05309265|Other|Breast cancer patients with work difficulties|Breast cancer patients with work difficulties can receive any of the three types of support, or a combination of these: information, occupational therapy and social support, in order to overcome barriers and return to work/continue to work
88836284|NCT05303090|Experimental|H101 + Tislelizumab+ Lenvatinib|(Dose escalation and cohort expansion) H101 administered by intratumoral injection in combination with Tislelizumab administered intravenously (IV), and Lenvatinib administered orally.
89365295|NCT05497219|Other|Healthy adults|Adults aged 18 or older with no history of swallowing impairment
89365296|NCT05497219|Other|Parkinson Disease|Adults with a neurologist-confirmed diagnosis of Parkinson Disease who also report symptoms of swallowing impairment, defined as a score >/= 200 on the Sydney Swallow Questionnaire.
89365297|NCT05497219|Other|Chronic Obstructive Pulmonary Disease|Adults with a respirologist-confirmed diagnosis of Chronic Obstructive Pulmonary Disease who also report symptoms of swallowing impairment, defined as a score >/= 200 on the Sydney Swallow Questionnaire.
89365298|NCT05497219|Other|Acute Stroke|Adult inpatients in the acute stage post stroke who are referred for swallowing assessment.
89365299|NCT05493982|Experimental|Receives Stanford vaping prevention curriculum (pilot phase)|Stanford vaping prevention curriculum is administered as pilot arm preceding main experimental intervention.
89365300|NCT05493982|Experimental|Receives Stanford vaping prevention curriculum (randomized phase)|Stanford vaping prevention curriculum is administered.
89534659|NCT02492399|Other|myectomy by Morrow|"Procedure: myectomy by Morrow.~Will be included in a group of 30 patients with obstructive hypertrophic cardiomyopathy and mitral insufficiency. In the case of conservation SAM syndrome and mediated mitral insufficiency, the result will be read as unsatisfactory. Patients will perform advanced myoectomy. All patients who need to be supplemented by the operation extension myoectomy subsequently run out in the second group. When it is impossible to eliminate mediated mitral regurgitation without mitral valve replacement, patients performed myoectomy and mitral valve replacement. The result in this case is read as completely unsatisfactory. Upon reaching 15% replacement mitral valve study terminated.~Evaluation results will be made myoectomy as TEE and direct tensiometer."
89365301|NCT05493982|No Intervention|Does not receive Stanford vaping prevention curriculum (randomized phase)|Receives another curriculum or no vaping prevention education.
88836286|NCT05254600|Experimental|Intervention group|Intervention group will attend the RISE for Nurse Leaders program, which consists of nine 90-minute weekly psychoeducational group sessions facilitated by a licensed mental health counselor (LMHC)
88836287|NCT05254600|Active Comparator|Wait-list control group|Control group will attend the RISE for Nurse Leaders program after the 3-month wait-list period
88836288|NCT05243329|Experimental|Psilocybin treatment for treatment-resistant PTSD|"Experimental Treatment:~Experimental: Psilocybin~10mg (low dose) on Day 7~25mg (high dose) on Day 14~10mg dose (optional top-up low dose) at Month 7~Treatment Description:~Drug: Psilocybin drug product suspension~Psilocybin is manufactured as a bulk API powder. The psilocybin drug product suspension is prepared by a compounding pharmacist at the clinic site. The psilocybin drug product suspension will be mixed in a glass with water to produce the psilocybin solution for oral consumption. Subjects will be instructed to orally consume the study medication in the glass in its entirety.~Psilocybin will be administered in the following doses and at the following time points for this study:~1 mL of 10mg/mL (low dose) on Day 7 (10 mg)~2.5 mL of 10 mg/mL (high dose) on Day 14 (25 mg)~[Optional dose] 1 mL of 10mg/mL (low dose) on Month 7/Day 210 (10 mg)"
88836289|NCT05242562|Experimental|Pleinvue|a 1L poly ethylene glycol PEG solution with added ascorbate (Pleinvue, Norgine, active ingredients PEG 3350, Sodium ascorbate, Sodium sulfate, Ascorbic acid, Sodium chloride, Potassium chlorid)
88836290|NCT05242562|Active Comparator|Moviprep|a 2L PEG solution with added ascorbate (Moviprep, Norgine, active ingredients Macrogol 3350, Sodium Sulphate Anhydrous, Sodium chloride, Potassium chloride, Ascorbic acid, Sodium ascorbate)
89365302|NCT05490420|Sham Comparator|Control|17 participants who meet the inclusion criteria will be applied conventional exercise which includes nerve gliding and tendon gliding exercises. And also sham (placebo) upper extremity manual lymphatic drainage will be applied. Sham (placebo) manual lymphatic drainage will include only classical massage not manual lymphatic drainage techniques. Participants will be treated for a total of 6 weeks, 2 days a week. Each session will last approximately 20-30 minutes, and the exercises will be performed in 3 sets with 10 repetitions.
88836291|NCT05238766|No Intervention|Treatment as Usual|This arm does not receive any intervention. It will serve as a comparison for the experimental arm.
88836292|NCT05238766|Experimental|Treatment + DEAL|Parents in the Treatment plus Defuse Experience Accept Live (T+DEAL) arm will attend five 45-min DEAL sessions with a therapist. Across the five sessions, the therapist will 1) introduce caregivers to behavior change strategies that maximize contact with positive-maintaining contingencies related to adherence, while undermining the contingencies that maintain accommodation, and 2) provide caregivers with new treatment-related committed actions that are sensitive to positive changes in parent-child interactions.
89178652|NCT00765999|Experimental|Linaclotide|Linaclotide 290 μg/day capsules, administered orally once daily for up to 78 weeks in participants with either CC or IBS-C. Dose reduction to 145 μg/day was permitted at the discretion of the Investigator if a participant experienced AEs intolerable enough to prompt consideration of study withdrawal. After a temporary suspension of dosing, participants may have received either 145 μg/day or 290 μg/day of linaclotide, at the discretion of the Investigator. Subsequent dose adjustments (increases or decreases between 290 μg/day and 145 μg/day) were permitted also at the Investigator's discretion.
88836293|NCT05237297|Active Comparator|ilaprazole & naproxen|"Period 1 : Ilaprazole 10mg/tab, one a day, 5 days~Period 2 : naproxen 500mg/tab, twice a day, 4 days and naproxen 500mg/tab, one a day one at the 5 day~Period 3 : Ilaprazole 10mg/tab, one a day, 5 days + naproxen 500mg/tab, twice a day, 5 days"
88836294|NCT05237297|Active Comparator|ilaprazole & aceclofenac|"Period 1 : Ilaprazole 10mg/tab, one a day, 5 days~Period 2 : aceclofenac 100mg/tab, twice a day, 4 days and aceclofenac 100mg/tab, one a day one at the 5 day~Period 3 : Ilaprazole 10mg/tab, one a day, 5 days + aceclofenac 100mg/tab, twice a day, 5 days"
88836295|NCT05237297|Active Comparator|ilaprazole & celecoxib|"Period 1 : Ilaprazole 10mg/tab, one a day, 5 days~Period 2 : celecoxib 200mg/cap, twice a day, 4 days and celecoxib 200mg/cap, one a day one at the 5 day~Period 3 : Ilaprazole 10mg/tab, one a day, 5 days + celecoxib 200mg/cab, twice a day, 5 days"
88836296|NCT05235945|Experimental|Online exercise intervention|A four-week preoperative physical activity intervention, involving a combination of supervised and unsupervised (live or pre-recorded), online exercise sessions. These sessions will be designed to meet the National physical activity guidelines (2020) of at least 150 minutes of low-moderate or 75 minutes of vigorous physical activity per week (or a combination of the two). The intervention will involve moderate intensity activities that aim to increase or maintain muscle strength (resistance training) as well as short bouts of vigorous aerobic exercise, using major muscle groups in the lower and upper body.
88836297|NCT05235945|No Intervention|Control|Usual care
88836298|NCT05218434|Experimental|Part A-Drug (AX-158 or Placebo)|AX-158 oral single or placebo (single ascending dose).
88836299|NCT05218434|Experimental|Part B-Drug (AX-158)|AX-158 oral single dose with and without food
88836300|NCT05218434|Experimental|Part C-Drug (AX-158 and Placebo)|AX-158 oral or placebo daily dose for 10 days (multiple ascending dose).
88836301|NCT05216952|Experimental|UPA 90mg|Participants receive ulipristal acetate 90mg PO followed by self-administration of misoprostol 800mcg vaginally 6 to 18 hours following ulipristal acetate administration.
88836302|NCT05213676|Active Comparator|Inhaled Nitric Oxide (iNO) use|The center will use iNO per their usual protocol in the initial resuscitation period (defined as birth through stabilization and CDH repair). No center will alter any component of their standard clinical practice guideline or protocol governing CDH care.
88836303|NCT05213676|Active Comparator|De-implementation of Inhaled Nitric Oxide (iNO) use|The center will stop using iNO in the initial resuscitation period (defined as birth through stabilization and CDH repair).
88836304|NCT05211739|Other|LID205255 Toric, then Biofinity Toric|Lehfilcon A toric contact lenses worn first, with comfilcon A toric contact lenses worn second, as randomized. Each product will be worn bilaterally (in both eyes) during waking hours for at least 5 days per week, with up to 10-12 hours wear time per day over a 30-day period. CLEAR CARE will be used for nightly contact lens cleaning and disinfection.
88836305|NCT05211739|Other|Biofinity Toric, then LID205255 Toric|Comfilcon A toric contact lenses worn first, with lehfilcon A toric contact lenses worn second, as randomized. Each product will be worn bilaterally (in both eyes) during waking hours for at least 5 days per week, with up to 10-12 hours wear time per day over a 30-day period. CLEAR CARE will be used for nightly contact lens cleaning and disinfection.
88836306|NCT05206110|Experimental|Peri- and postoperative 10 mg Ketolorac|Patients undergoing LAVH, RARP or TLH will receive dosages of 10 mg ketolorac (IV).
88836307|NCT05206110|Active Comparator|Peri- and postoperative standard-dose 30 mg Ketolorac|Patients undergoing LAVH, RARP or TLH will receive standard dosages of 30 mg ketolorac (IV).
88836308|NCT05194839|Experimental|RIST4721 400 mg|RIST4721 400 mg: 4 active (100 mg) tablets once daily for 12 weeks
88836309|NCT05194839|Experimental|RIST4721 200 mg|RIST4721 200 mg: 2 active (100 mg) tablets + 2 placebo tablets once daily for 12 weeks
88836310|NCT05194839|Placebo Comparator|Placebo|Placebo: 4 placebo tablets once daily for 12 weeks
88836311|NCT05178095|Experimental|AI|Colonoscopy with AI
88836312|NCT05178095|Placebo Comparator|No AI|Colonoscopy without AI
88836313|NCT05169736|Experimental|Internet-based Cognitive Behavior Therapy|ICBT, were participants receive 8 out of 15 possible modules, depending on their current problems and needs, 8 week long internet intervention for coping with mental health issues related to the climate crisis.
88836314|NCT05169736|No Intervention|Wait-list control|Participants in the control group will be instructed to wait. Once intervention group will be finished, participants in control group will be able to access the same intervention.
88836315|NCT05165810|Active Comparator|Arm 1: standard ART initiation + government-based HIV care + routine adherence support|Participants randomized to Arm 1 will i) initiate ART on a standard timeline [usual care], ii) receive ongoing care in a government HIV clinic [usual care], and iii) receive routine adherence support should they experience treatment failure at 6 months [usual care].
88836316|NCT05165810|Experimental|Arm 2: same-day ART + government-based HIV care + routine adherence support|Participants randomized to Arm 2 will i) initiate ART on the day of enrollment [experimental], ii) receive ongoing care in a government HIV clinic [usual care], and iii) receive routine adherence support should they experience treatment failure at 6 months [usual care].
88836317|NCT05165810|Experimental|Arm 3: standard ART initiation + community-based HIV care + routine adherence support|Participants randomized to Arm 3 will i) initiate ART on a standard timeline [usual care], ii) receive ongoing care in a PWID-focused community-based site [experimental], and iii) receive routine adherence support should they experience treatment failure at 6 months [usual care].
88836318|NCT05165810|Experimental|Arm 4: standard ART initiation + government-based HIV care + enhanced adherence support|Participants randomized to Arm 4 will i) initiate ART on a standard timeline [usual care], ii) receive ongoing care in a government HIV clinic [usual care], and iii) receive enhanced adherence support should they experience treatment failure at 6 months [experimental].
88836319|NCT05165810|Experimental|Arm 5: same-day ART initiation + community-based-based HIV care + routine adherence support|Participants randomized to Arm 5 will i) initiate ART on the day of enrollment [experimental], ii) receive ongoing care in a PWID-focused community-based site [experimental], and iii) receive routine adherence support should they experience treatment failure at 6 months [usual care].
89365303|NCT05490420|Experimental|experimental|17 participants who meet the inclusion criteria will be applied both conventional exercise and upper manual lymphatic drainage (MLD). MLD is a manual technique that is applied to the lymphatic system with a pressure of approximately 40-50mmHg and increases the working speed of lymphatic nodules/collectors. Its main purpose is to support microcirculation by accelerating lymphatic flow and to prevent/remove interstitial fluid accumulation that may cause fascial adhesions. Within the scope of this research, an application will be made to cover the entire upper extremity lymphatic system. MLD will last approximately 20-30 minutes. Conventional exercise, which includes nerve gliding and tendon gliding exercises, will be performed in 3 sets with 10 repetitions. Participants will be treated for a total of 6 weeks, 2 days a week.
89365304|NCT05488873|Experimental|Placebo|Participants will apply 4 mL QD Placebo topical solution
89365305|NCT05488873|Experimental|WST-057 Active|Participants will apply 4 mL QD WST-057 Active topical solution.
89365306|NCT05486663|Experimental|Tactile/kinesthetic Group|After the stability of the general health status of the babies is ensured and the oral feeding decision is made, tactile / kinesthetic application will be made for 14 days, 2 times a day, for 15 minutes just before feeding.
89365307|NCT05486663|No Intervention|Control Group|Tactile / kinesthetic applications will not be applied to the control group and these babies will be followed for 14 days and at discharge after the stability of the general health status of the babies is ensured and the oral feeding decision is made.
89365308|NCT05470686|Other|HEART SURGERY PATIENTS with cardio pulmonary bypass|
89365309|NCT05470439|Experimental|MI-CARE Intervention|Pharmacist-community health worker team providing coordinated care tailored to high-risk patients with hypertension. MI-CARE intervention participants will meet with the pharmacist-CHW team for medication optimization and tailored case management. Pill counts will be completed to assess adherence and BP will be measured at each visit to guide antihypertensive medication optimization and provide feedback to participants about their adherence and BP control. Intervention visits will be followed by a booster one month later.
89365310|NCT05470439|No Intervention|Waitlist Control|Participants enrolled in this arm will receive usual medical care
89365311|NCT05447897|Other|Stakeholder Advisory Group|"To co-design an implementation strategy that targets critical components in the delivery of SCT or LCS services for patients who smoke.~Convene a stakeholder advisory group (CHC providers, quality improvement specialists, community engagement staff, and specialty providers) to review the results of the literature review and quantitative analysis of deidentified data in order to select a set of implementation strategies from a menu of strategies to implement. The team will meet with the stakeholder advisory group four times for 1-2 hours each."
89365312|NCT05438498|Other|Evusheld (AZD7442)|Evusheld (tixagevimab+cilgavimab) 600 mg IM or IV administered one time only
89365313|NCT05436964|Placebo Comparator|Placebo group|Use 250 ml of saline as placebo group.
89365314|NCT05436964|Experimental|Experimental group|Use dexmedetomidine as experimental group
89365315|NCT05417477|Experimental|chronic inflammatory rheumatism or osteoarthritis|"The experimental intervention consists in providing the patient with access to a specific version of the application ''MedicApp'' for the duration of the study.~The intervention will be limited for each patient to the entry of their data on the application at regular intervals during the study.~The interface on the rheumatologist side will contain the demographic characteristics of the patient, his history, the treatments and the pathology requiring the use of physiotherapy Then, at regular intervals, the scores of the questionnaires addressed to the patient will be available on his interface. The interface, on the physiotherapist side, will contain the summary of the patient's clinical history, his treatments and the reason for the physiotherapy sessions. Then, at regular intervals, the physiotherapist will indicate the patient's locomotor assessment, the type of intervention performed and the final summary."
89365316|NCT05413655|Experimental|1000 mg|The recruited patient randomly assigned to this arm will take 1000 mg EX039 per day
89178653|NCT00765843|Active Comparator|custom foot orthoses|Subjects will receive custom fabricated orthoses created from casts of the feet and according to individualized prescriptions. These orthoses are to be used in the standardized shoes provided to all subjects in the study.
89178654|NCT00765843|Active Comparator|pre-fabricated orthoses|Subjects will be provided pre-fabricated (non-customized) orthoses. These orthoses are to be used in the standardized shoes provided to all subjects in the study. for use in their shoes.
89365317|NCT05413655|Experimental|750 mg|The recruited patient randomly assigned to this arm will take 750 mg EX039 per day
89365318|NCT05413655|Placebo Comparator|placebo|The recruited patient randomly assigned to this arm will take placebo per day
89178655|NCT00765843|Sham Comparator|sham insoles|Subjects will receive sham orthoses that are soft and pliable, but not designed to relieve pain. These orthoses are to be used in the standardized shoes provided to all subjects in the study.
89178656|NCT04099407|Experimental|Antifibrotic plus standard of care treatment|Prolonged release pirfenidone formulation in combination with standard of care treatment.
89178657|NCT00765063|Experimental|Active|Active study treatment
89365319|NCT05412706|Experimental|Treatment Arm|Treatment with Niraparib must be started after at least 2 weeks and no later than 6 weeks after the end of platinum-based induction therapy.
89365320|NCT05408494|Sham Comparator|Non-gamified program with sham ICT|One group will be assigned to a 12-month mobile weight loss program that includes digital self-monitoring, simplified and self-selected dietary targets (to align with neurotraining and promote autonomy , and behavioral strategies with sham.
88836320|NCT05165810|Experimental|Arm 6: same-day ART initiation + government-based-based HIV care + enhanced adherence support|Participants randomized to Arm 6 will i) initiate ART on the day of enrollment [experimental], ii) receive ongoing care in a government HIV clinic [usual care], and iii) receive enhanced adherence support should they experience treatment failure at 6 months [experimental].
89365321|NCT05408494|Active Comparator|Non-gamified program with Active ICT|One group will be assigned to a 12-month mobile weight loss program that includes digital self-monitoring, simplified and self-selected dietary targets (to align with neurotraining and promote autonomy , and behavioral strategies with active neurotraining.
89365322|NCT05408494|Experimental|Gamified program with sham ICT|One group will receive fully-gamified version of the program with a sham.
89365323|NCT05408494|Experimental|Gamified program with Active ICT|One group will receive fully-gamified version of the program with active neurotraining.
89365324|NCT05407571|Other|Echogenic Amniotic Fluid|estimation the nature of echogenic amniotic fluid.to overcome unnecessary intervention due to turbid amniotic fluid, assessing the neonatal outcome and estimation the gestational age at time of delivery in patients with echogenic amniotic fluid.
89365325|NCT05388071||Intervention: Treatment with the aid of telemedicine|Telemedicine will be used to treat patients at an ambulance station. The medical interventions will be performed by a TeleSAN after delegation through a tele-EMS-physician if possible.
89365326|NCT05388071||No intervention: Usual treatment|Treatment will be performed as usual without the usage of telemedicine.
89365327|NCT05362786|Experimental|Dose Arm 1|Subjects with chronic kidney disease will receive allogeneic bone marrow-derived mesenchymal stem cells (MSC) in two intravenous infusions of 100x10^6 cells at time zero and three months
89365328|NCT05362786|Experimental|Dose Arm 2|Subjects with chronic kidney disease will receive allogeneic bone marrow-derived mesenchymal stem cells (MSC) single intravenous infusion of 200x10^6 cells
89365329|NCT05349084|Other|PET-cCTA-cFFR|patients presenting with stable angina and a moderate pretest likelihood for CAD who are already scheduled to undergo ICA for the clinical indication of angina will be recruited to undergo PET-cCTA-cFFR
89365330|NCT05339243|Active Comparator|ES 1|Two capsules orally once daily after breakfast for 84 days
88836321|NCT05165810|Experimental|Arm 7: standard ART initiation + community-based-based HIV care + enhanced adherence support|Participants randomized to Arm 7 will i) initiate ART on a standard timeline [usual care], ii) receive ongoing care in a PWID-focused community-based site [experimental], and iii) receive enhanced adherence support should they experience treatment failure at 6 months [experimental].
88836322|NCT05165810|Experimental|Arm 8: same-day ART initiation + community-based-based HIV care + enhanced adherence support|Participants randomized to Arm 8 will i) initiate ART on the day of enrollment [experimental], ii) receive ongoing care in a PWID-focused community-based site [experimental], and iii) receive enhanced adherence support should they experience treatment failure at 6 months [experimental].
88836323|NCT05163392|Experimental|SilverD|"The SIlverD arm includes:~For standard dressing: a silverlon antimicrobial patch, CHG swabs for cleaning, an occlusive dressing with window, and driveline anchors. The driveline dressing change frequency will be weekly.~For sensitive skin dressing: a silverlon antimicrobial patch, Providone/iodine swabs for cleaning, an occlusive dressing with window, and sensitive driveline anchors. The driveline dressing change frequency will be weekly."
89365331|NCT05339243|Active Comparator|HT ES1|Two capsules orally once daily after breakfast for 84 days
89365332|NCT05339243|Placebo Comparator|Placebo|Two capsules orally once daily after breakfast for 84 days
89365333|NCT05338398|Placebo Comparator|Control Group (Group 1): Standard Therapy|"Group 1 will receive standard therapy with conventional oral care to prevent oral mucositis consisting of oral hygiene and rinses/mouthwashes with saline solutions 3-5 times daily.~Half of the subjects in Group 1 will also receive Bocaliner™ devices"
89365334|NCT05338398|Experimental|Intervention Group (Group 2): Benzydamine mouthwash|Group 2 will receive benzydamine mouthwashes 3-5 times daily. Half of the subjects in Group 1 will also receive Bocaliner™ devices.
88875182|NCT02512224||Parenteral nutrition|investigators selected participants aged 20 years or older who had undergoneparenteral nutrition by central venous port insertion between April 1, 2012, and March 31, 2013.
89178658|NCT04098939||Healthy participants|Participants without any known cardiac or pulmonary disease.
89365335|NCT05314179|Experimental|DOULA -AC|Four hours/week of Doula and Patient engagement.
89365336|NCT05307276|Other|Healthy volunteers|Following the selection visit (#V0) to verify the inclusion and non-inclusion criteria, participants will make 2 visits (#V1 and #V2) including in particular a Respiratory Functional Exploration (EFR) and a triangular
89365337|NCT05306548|Active Comparator|Surgery treatment strategy|Primary open surgical carpal tunnel release. Treatment effect is monitored on scheduled follow-up visits. Re-operation may be performed if medically indicated (e.g. postoperative complication, or failure of the primary procedure)
89178659|NCT04098939||Heart disease participants|Participants with heart disease.
89365338|NCT05306548|Experimental|Injection treatment strategy|Primary treatment with ultrasound-guided corticosteroid injection. Treatment effect is monitored on scheduled follow-up visits. One additional injection may be administered, and subsequently surgical carpal tunnel release is performed in case of unsatisfactory treatment effect of the injection therapy. Treatment effect is graded on a 5-leve scale by subject from 1 (complete improvement) to 5 (severe worsening) of symptoms. Incomplete improvement (score 2 or higher) results in a second injection or secondary surgery.
89365339|NCT05303662||ERCP-patients Netherlands|Patients undergoing ERCP in the study site in the Netherlands
89178660|NCT04098939||Lung disease participants|Participants with lung disease.
89178661|NCT00764751|Experimental|1|
89178662|NCT00764751|Active Comparator|2|
89178663|NCT00764751|Placebo Comparator|3|
89365340|NCT05303662||ERCP-patients Italy|Patients undergoing ERCP in the study site in Italy
89365341|NCT05303662||ERCP-patients United States|Patients undergoing ERCP in the study site in the Netherlands
89365342|NCT05303662||ERCP-patients India|Patients undergoing ERCP in the study site in India
89365343|NCT05296941|Experimental|Brush biopsy|Brusch biopsy at baseline and at 3 or 6 months
89365344|NCT05296941|Active Comparator|Care as usual|Control at 3 or 6 month, surgical biopsy when needed
89365345|NCT05291286|Experimental|BXQ-350|BXQ-350 will be administered by IV infusion
89365346|NCT05291286|Placebo Comparator|Placebo|Placebo (0.9% normal saline) will be administered by IV infusion
88836324|NCT05163392|Active Comparator|ControlD|"The ControlD arm includes:~For standard dressing: No antimicrobial barrier, CHG swabs for cleaning, an occlusive dressing with window, and driveline anchors. The driveline dressing change frequency will be every 96 hours.~For sensitive skin dressing: No antimicrobial barrier, Providone/iodine swabs for cleaning, an occlusive dressing with window, and driveline anchors. The driveline dressing change frequency will be every 96hr."
88836325|NCT05157113|Active Comparator|Dropless Regimen|"Intraoperative subconjunctival injection of triamcinolone acetonide (20mg) delivered 4-5 mm posterior to the limbus at the end of surgery~Intraoperative intracameral injection of cefuroxime delivered at the end of surgery.~No postoperative drops."
88836326|NCT05157113|Active Comparator|Standard Regimen|"Intraoperative intracameral injection of cefuroxime delivered at the end of surgery.~Neomycin/Polymyxin B ophthalmic solution: one drop to the operative eye four times daily for 1 week, then stop.~Ketorolac 0.5% ophthalmic solution: one drop to the operative eye four times daily for 1 month or until the bottle runs out.~Prednisolone acetate 1% ophthalmic solution: one drop to the operative eye four times daily for 1 month, then stop."
88836327|NCT05155618|Experimental|Intervention group (IG)|Participants randomized to the IG will be offered an individualized counseling during cancer treatments that includes both a dietary and physical activity suggestions to control side effects, to cope with feelings of anxiety or depression and to improve quality of life.
88836328|NCT05155618|No Intervention|Control group (CG)|Participants included in the CG will receive at baseline general advice and materials available for patients undergoing RT. According to the crossover design, the CG will cross to the intervention as proposed for the IG, after the initial 6-month period.
88836329|NCT05154240|Active Comparator|INS018_055|oral doses of INS018_055_single dose; oral doses of INS018_055_multiple ascending dose over 10days.
88836330|NCT05154240|Placebo Comparator|Placebo|No active ingredient. Frequency similar to the 2 arms above.
88836331|NCT05145192|Experimental|COSMED K5 CPET|Participants in this arm will complete the CPET using the COSMED K5 wearable metabolic system at first visit and the ParvoMedics TrueOne® 2400 automated metabolic gas analysis system at second visit.
88836332|NCT05145192|Active Comparator|ParvoMedics CPET|Participants in this arm will complete the CPET using the ParvoMedics TrueOne® 2400 automated metabolic gas analysis system at first visit and the COSMED K5 wearable metabolic system at second visit.
89365347|NCT05283109|Experimental|Tumor Associated Antigen Peptide Vaccine in Combination with Hiltonol|The study vaccine is comprised of three different peptides (small proteins) mixed with Hiltonol®. The three peptides that make up the study vaccine are called pp65, EphA2, and survivin.
89178664|NCT00764673|Other|Primary|Post market study
89365348|NCT05270031|Experimental|Eustachian tube dilation|Surgical Eustachian tube dilation in general anaesthesia
89365349|NCT05270031|No Intervention|Control Group|nasal saline spray
89365350|NCT05242289|Active Comparator|Treated|"Treatment using the medical cytokine adsorption device in conjunction with lung transplantation"
89365351|NCT05242289|No Intervention|Non-treated|No additional treatment in conjunction with lung transplantation
89365352|NCT05239104||Children aged 1 month - 14 years 11 months with a severe illness/injury|"Children aged 1 month - 14 years 11 months presenting to hospital with symptoms of an acute severe illness/injury that started within the last 2 weeks. Severe defined as a child showing emergency signs or requiring hospital admission for treatment."
89365353|NCT05237687|Active Comparator|Intervention|Patients randomized to the intervention will initially take 0.5 mg sirolimus. The dose will be adjusted weekly to obtain a sirolimus levels of 5-7 ng/ml whole blood in the first months. After the first month, the patient will have monthly blood work and will be followed in clinic every 3 months. Functional assessment and aging biomarkers will be obtained at baseline and 1 year follow up. Completion of the 1-year treatment period will be followed by a follow-up visit 4 weeks later.
89365354|NCT05237687|No Intervention|Control|Interventions: standard of care Patients are not going to receive any additional intervention.
89365355|NCT05235113|Active Comparator|Remote Exercise with tele-exergame|Subjects will perform exercises remotely twice a week with tele-exergaming platform.
89365356|NCT05235113|Sham Comparator|home-based exercise without technology|Subjects will perform exercises at home without tele-exergaming platform twice a week.
89365357|NCT05225012|Experimental|PrEliMS Intervention|"We will ask participants to complete the anxiety/depression questionnaires and visual analogue scales once a week throughout the participants involvement in the study (estimated to be 9 weeks). The baseline will be established over a period of the first three weeks (before participants start the intervention). Participants will also be asked to complete a second set of questionnaires (secondary measures) before starting the intervention, to assess quality of life, stress, the impact of MS, MS-related self-efficacy and fatigue.~The procedure will then repeated with newly recruited participants, and the newly refined workbook will be used. Participants within this phase will also be invited to feedback interviews a week after completion of the intervention."
89365358|NCT05219760|Active Comparator|LIVIA 1|LIVIA 1 is a 12-week intervention composed of 10 sessions, whereby we recommend completing one session per week. It includes psychoeducational content and exercises that are based on empirically validated intervention tools, mainly issued from Cognitive-Behavioral Therapy.
89365359|NCT05219760|Experimental|LIVIA 2.0|LIVIA 2.0 is a 12-week intervention composed of 10 sessions, whereby we recommend completing one session per week. It includes psychoeducational content and exercises that are based on empirically validated intervention tools, mainly issued from Cognitive-Behavioral Therapy but also from positive psychology and cognitive psychopathology frame.
89365360|NCT05219526|Experimental|Subject BGMS measurement|Blood glucose measurement using BGMS
89365361|NCT05210569||Bilateral implantation of the Vivity IOL|Vivity intraocular lens (IOL)
88836333|NCT05144243|Experimental|Venetoclax in Combination with Azacitidine|Participants will receive oral tablet venetoclax dose ramp-up only in Cycle 1 Days 1-3 until target dose is reached. Particpants will then receive oral tablet venetoclax at the target dose every day (QD) on Cycle Days 1 - 28 plus Azacitidine through subcutaneous injection (SC) QD on Cycle Days 1 - 7 (28-day cycle).
89365362|NCT05200143|Experimental|Cabozantinib + Ipilimumab + Nivolumab|Ipilimumab 1 mg/kg + Nivolumab 3 mg/kg IV every 3 weeks + Cabozantinib 40 mg PO daily for 4 cycles followed by Nivolumab 480 mg IV every 4 weeks + Cabozantinib 40 mg PO daily for up to 24 months.
88836334|NCT05139238|Active Comparator|Oral Nifedipine|Oral nifedipine: Once diagnosis of hypertensive emergency is confirmed on repeat blood pressure, patients randomized to oral nifedipine will receive 10mg initially, with repeated doses of 20mg every 20min, for up to a maximum of 5 doses or until the therapeutic blood pressure goal of <160 systolic and <105 diastolic is achieved. If the therapeutic goal is not achieved after 5 doses, crossover to the alternative study medication will occur.
88836335|NCT05139238|Active Comparator|Intravenous labetalol|Intravenous Labetalol: Patients randomized to IV labetalol will receive 20mg initially, followed by escalating doses of 40mg, 80mg, 80mg, then 80mg every 20 minutes until the therapeutic goal is achieved, for a maximum of 5 doses. If the therapeutic goal is not achieved after 5 doses, crossover to the alternative study medication will occur.
88836336|NCT05138614|Experimental|Full MISSION|CTI + DRT + PS + MOUD
88836337|NCT05138614|Experimental|CTI & DRT|CTI + DRT + MOUD
88836338|NCT05138614|Experimental|CTI & PS|CTI + PS + MOUD
88836339|NCT05138614|Experimental|DRT & PS|DRT + PS + MOUD
88836340|NCT05138614|Other|MOUD only|MOUD
88836341|NCT05120141|Experimental|Prototype 1 Mouth Rinse|Participants will brush their teeth using soft bristled Toothbrush and Colgate Cavity Protection Toothpaste twice daily and rinse with 20 milliliters (mL) of the Prototype 1 Mouth Rinse for 30 seconds, twice a day following brushing on Day 0 under supervision and up to 12 weeks unsupervised at home.
88836342|NCT05120141|Experimental|Prototype 2 Mouth Rinse|Participants will brush their teeth using soft bristled Toothbrush and Colgate Cavity Protection Toothpaste twice daily and rinse with 20 mL of the Prototype 2 Mouth Rinse for 30 seconds, twice a day following brushing on Day 0 under supervision and up to 12 weeks unsupervised at home.
88836343|NCT05120141|Experimental|Prototype 3 Mouth Rinse|Participants will brush their teeth using soft bristled Toothbrush and Colgate Cavity Protection Toothpaste twice daily and rinse with 20 mL of the Prototype 3 Mouth Rinse for 30 seconds, twice a day following brushing on Day 0 under supervision and up to 12 weeks unsupervised at home.
88836344|NCT05120141|Active Comparator|Listerine Cool Mint Mouth Rinse (Positive Control)|Participants will brush their teeth using soft bristled Toothbrush and Colgate Cavity Protection Toothpaste twice daily and rinse with 20 mL of the Listerine Cool Mint Mouth rinse for 30 seconds, twice a day following brushing on Day 0 under supervision and up to 12 weeks unsupervised at home.
89365363|NCT05198271|Experimental|Management of risk factors|"-6 month program for reduction /correction of risk factors in patient with active RA :~Smoking cessation~weightloss~Increased physical activity~Periodontal treatment~Decreased anxiety"
89365364|NCT05153967||Pediatric Myeloablative allo-HSCT|Participants ages 4 to 17 years old with SCD who underwent or are scheduled to undergo myeloablative allo-HSCT.
89365365|NCT05153967||Pediatric Standard Disease-Modifying Therapy|Participants ages 4 to 17 years old with SCD who receive standard therapy.
89001613|NCT03452605|Placebo Comparator|low cocoa flavanol drink|low cocoa flavanol drink (30 mg cocoa flavanol dissolved in 300 ml skimmed milk), matched for theobromine, caffeine and macronutrients with the high cocoa flavanol drink 2h-pre fMRI
89365366|NCT05153967||Adult Non-Myeloablative allo-HSCT|Participants ages 18 to 65 years old with SCD who underwent or are scheduled to undergo non-myeloablative allo-HSCT.
89365367|NCT05153967||Adult Standard Disease-Modifying Therapy|Participants ages 18 to 65 years old with SCD who receive standard therapy.
89365368|NCT05148442|Experimental|IBI322|
89365369|NCT05148325|Experimental|Single group|First Phase: dose escalation study. It was divided into six dose groups: 0.1mg/kg, 0.3mg/kg, 0.5mg/kg ,1.0mg/kg, 3.0mg/kg and 10.0mg/kg. The safety, tolerability and pharmacokinetics of bat4706 injection were explored according to the 3 + 3 dose increasing mode. It is expected that 18-36 cases will be included in the group Second Phase: dose expansion study. After the completion of dose increment, 1-2 tolerated doses were selected for extended research on melanoma (20-40 cases), so as to provide recommended doses for subsequent clinical trials
89365370|NCT05144373|Experimental|Gross motor intervention|Participants will receive a home-based, parent-administered body-weight supported treadmill intervention from about 10 months of age until walking onset.
89365371|NCT05144373|Experimental|Gross and fine motor intervention|"Besides the body-weight supported treadmill intervention as illustrated above, participants will receive additional fine motor intervention using sticky mittens from about 10 months of age for five months."
89365372|NCT05144373|No Intervention|Control|Participants will not receive specific intervention.
89365373|NCT05144360|Experimental|Atenas association|"The study is triple-dummy. The patient must take 3 tablets once a day, as follows:~1 tablet Atenas, oral;~1 tablet empagliflozin placebo, oral;~1 tablet telmisartan + amlodipine placebo, oral."
89365374|NCT05144360|Active Comparator|Empagliflozin + telmisartan + amlodipine|"The patient must take 3 tablets once a day, as follows:~1 tablet Atenas placebo, oral;~1 tablet empagliflozin, oral;~1 tablet telmisartan + amlodipine, oral."
89365375|NCT05142254|Experimental|Tadalafil and Hydroxyurea|Tadalafil 2.5-5 mg/day and Hydroxyurea 20 mg/kg/day
89365376|NCT05142254|Placebo Comparator|Placebo and Hydroxyurea|Placebo and Hydroxyurea 20 mg/kg/day
89365377|NCT05141019|Experimental|Immediate panel-based pharmacogenetic genotyping|Subjects assigned to the immediate pharmacogenetic genotyping group will be tested and have their results both entered into their electronic health record as well as provided to them within 2-4 weeks from enrollment.
89365378|NCT05141019|Other|Delayed panel-based pharmacogenetic genotyping|Subjects assigned to delayed panel-based pharmacogenetic genotyping will be tested, but their results will not be released until after their participation in the study has ended (12 months after enrollment).
89365379|NCT05127187||Detainees in an Administrative Detention Center|
89365380|NCT05125978|Experimental|Canadá association|"The study is triple-dummy, thus the patient must take 3 tablets twice a day, as follows:~1 tablet Canadá, oral;~1 placebo tablet of tramadol, oral;~1 placebo tablet of dipyrone, oral."
89365381|NCT05125978|Active Comparator|Tramadol|"The study is triple-dummy, thus the patient must take 3 tablets twice a day, as follows:~1 tablet tramadol, oral;~1 placebo tablet of Canadá, oral;~1 placebo tablet of dipyrone, oral."
89365382|NCT05125978|Active Comparator|Dipyrone|"The study is triple-dummy, thus the patient must take 3 tablets twice a day, as follows:~1 tablet dipyrone, oral;~1 placebo tablet of tramadol, oral;~1 placebo tablet of Canadá, oral."
89365383|NCT05116878|Experimental|Omega-3 Group|Subjects will receive omega-3 supplementation (Nature's Bounty Fish Oil 1400 mg, containing 980 mg Omega-3 per capsule), to begin taking 3 days prior to surgical resection of their vestibular schwannoma. Subjects will continue to take the omega-3 supplementation for 6 weeks post-operatively.
89365384|NCT05116878|Placebo Comparator|Placebo Group|Subjects will receive a placebo to begin taking 3 days prior to clinical care of surgical resection of vestibular schwannoma. Subjects will continue to take the placebo for 6 weeks post-operatively.
88836345|NCT05120141|Active Comparator|Hydroalcohol Mouth Rinse (Negative Control)|Participants will brush their teeth using soft bristled Toothbrush and Colgate Cavity Protection Toothpaste twice daily and rinse with 20 mL of the Hydroalcohol Mouth Rinse for 30 seconds, twice a day following brushing on Day 0 under supervision and up to 12 weeks unsupervised at home.
88836346|NCT05119231|Experimental|Pulmonary Vein Isolation|"Pulmonary Vein Isolation (radiofrequency ablation or cryoablation) of atrial fibrillation according to local standards:~Trial participants will assigned to the PVI-arm will undergo catheter ablation within 48 hours after baseline evaluation, with the aim to achieve isolation of all pulmonary veins and restore sinus rhythm.~Dependent of the local standards an echocardiography or cardiac MRI will be performed prior to the procedure. If necessary, a transesophageal echocardiography must be performed to exclude presence of atrial thrombus.~Anticoagulation will be initiated/continued for at least 3 months after the procedure."
89365385|NCT05098574|Experimental|Combined oral contraceptive (3mg drospirenone/ 0.02mg ethinyl estradiol)|Continuous treatment with 3mg drospirenone/ 0.02mg ethinyl estradiol for 12 weeks
89365386|NCT05098574|Placebo Comparator|Placebo|Continuous treatment with placebo for 12 weeks
89365387|NCT05097430|Experimental|Alcohol-focused brief intervention|Intervention arm participants will be provided with an electronically-delivered, personalized drinking feedback report that compares their drinking with other Canadian males of the same age. This report also includes other relevant feedback, including an assessment of severity of alcohol use, and it provides recommendations for safe levels of alcohol consumption.
89365388|NCT05097430|No Intervention|Treatment as usual|Treatment as usual (TAU) participants will not receive the intervention.
89365389|NCT05093192|Experimental|Cohort 1: Pre-treatment CLL|This group comprises patients who are diagnosed with CLL, but are asymptomatic and not receiving anti-CLL treatments (e.g. watch-and-wait disease).
89365390|NCT05093192|Experimental|Cohort 2: During treatment CLL|This group comprises patients who are diagnosed with CLL, have symptomatic disease, and are undergoing anti-CLL treatments (e.g. chemo-immunotherapy).
89365391|NCT05093192|Experimental|Cohort 3: Post-treatment CLL|This group comprises patients who were diagnosed with CLL, but are considered to be in either complete or partial remission following anti-CLL treatment for at least 6-months.
89365392|NCT05070728|Sham Comparator|Sham Comparator|sham injection
89365393|NCT05070728|Active Comparator|FAI insert (0.05 mg fluocinolone acetonide)|FAI insert (0.05 mg fluocinolone acetonide)
89178665|NCT00764517|Experimental|Previously untreated|"Patients enrolled with untreated, newly diagnosed mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL) [Group I].~Patients receive vorinostat PO on days 1-14, cladribine IV over 2 hours on days 1-5, and rituximab IV on day 3 (weekly for the first course). Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity."
89365394|NCT05065229|Experimental|A|Right foot no.520 Left foot no.521
89365395|NCT05065229|Experimental|B|Right foot no.521 Left foot no.520
89365396|NCT05017597|Experimental|Fatigue management|"Prescribed exercises by Physical Therapy Problem-Solving Sessions to resume activities that ther person needs to do, wants to do or is expected to do.~Four online educational modules: What is Cancer-Related Fatigue? Nutrition, Sleep Hygiene and Exercise"
89365397|NCT04997278|Experimental|Coordinated Reset- Spinal Cord Stimulation|All subjects will undergo spinal cord stimulation (SCS) implantation and will be optimized on standard SCS (sSCS) settings using the standard clinical protocol, including paresthesia mapping, threshold finding, and adjustment of stimulation parameters to provide reduction in pain. Therapeutic sSCS will be maintained for a minimum of one month prior to baseline assessment. Following a washout period of three hours assessments will be performed and Coordinated Reset- spinal cord stimulation (CR-SCS) will be enabled by means of a firmware upgrade. Personnel from Boston Scientific will perform this upgrade. The simulator will then be programmed to deliver CR-SCS. At the end of one month of CR-SCS (with stimulation parameters similarly held constant for the last 7 days), baseline assessment will be repeated after a three hour washout period. Finally, a firmware downgrade will be performed by Boston Scientific Personnel, and patients will be treated with sSCS at their previous settings.
89365398|NCT04994600||EFA_1st_phase|Exploratory factor analysis group. All staff members (physicians, specialist nurses, respiratory therapists) of Charite intensive care units
89365399|NCT04994600||CFA_2nd_phase|Confirmatory factor analysis group. All staff members (physicians, specialist nurses, respiratory therapists) of collaborating intensive care units.
89178666|NCT00764517|Experimental|Relapsed|"Patients with relapsed disease including indolent Non-Hodgkins Lymphoma (NHL), mantle cell lymphoma (MCL), or chronic lymphocytic leukemia (CLL) [Group II].~Patients receive vorinostat PO on days 1-14, cladribine IV over 2 hours on days 1-5, and rituximab IV on day 3 (weekly for the first course). Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity."
89178667|NCT00764361|Experimental|NanoDOX™ Hydrogel|1.0% doxycycline gel
89178668|NCT00764361|Placebo Comparator|Placebo|placebo gel
89178669|NCT00763971|Experimental|Lisdexamfetamine Dimesylate (LDX)|Overencapsulated LDX 30, 50, or 70mg
89178670|NCT00763971|Active Comparator|Methylphenidate Hydrochloride|Overencapsulated Concerta 18, 36, or 54mg
89178671|NCT00763971|Placebo Comparator|Placebo|Overencapsulated Placebo
89178672|NCT00763815|Experimental|Lixisenatide|2-step initiation regimen of lixisenatide: 10 microgram (mcg) once daily (QD) for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment.
89178673|NCT00763815|Placebo Comparator|Placebo|2-step initiation regimen of volume matching placebo: 10 mcg QD for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment.
89178674|NCT00763269|Experimental|A|sensitive toothpaste
89178675|NCT00763269|Active Comparator|B|Triclosan control toothpaste
89178676|NCT00763035|Active Comparator|A|Arm A will get Dobutamine Stress test with cardiac MR (CMR). Both arms will then cross over to the other arm to get the second test. So each participant will undergo two types of testing.
89178677|NCT00763035|Active Comparator|B|Arm B will get Regadenoson stress test with CMR. Both arms will then cross over to the other arm to get the second test. So each participant will undergo two types of testing.
89178678|NCT00844649|Experimental|Albumin-bound paclitaxel (ABI-007)/Gemcitabine|ABI-007 125 mg/m2 administered in combination with gemcitabine 1000 mg/m2 weekly for 3 weeks followed by one week of rest.
89178679|NCT00844649|Active Comparator|Gemcitabine|Gemcitabine, 1000 mg/m2 administered weekly for 7 weeks followed by a week of rest (Cycle 1), followed by cycles of weekly administration for 3 weeks followed by a week of rest (Cycle 2 onward).
89178680|NCT04098861|Experimental|once daily group|"Latanoprost/Timolol Fixed Combination (LTFC) will be administered once daily for 4 weeks. The IOP will be determined on Day 14 and 28. The following examinations will be performed: evaluation of conjunctiva hyperemia, anterior chamber reaction, applanation tonometry, measurement of blood pressure and heart rate.~For once daily dosing, the eye drops will be instilled at 8am every morning. The IOP will be taken at 9am-12pm on study day."
89178681|NCT04098861|Experimental|twice daily group|"Latanoprost/Timolol Fixed Combination (LTFC) will be administered twice daily for 4 weeks. The IOP will be determined on Day 14 and 28. The following examinations will be performed: evaluation of conjunctiva hyperemia, anterior chamber reaction, applanation tonometry, measurement of blood pressure and heart rate.~For twice dosing, the eye drops will be instilled at 8am and 8pm. The IOP will be taken at 9am-12pm on study day."
89365400|NCT04992390|Experimental|Immediate intervention arm|Immediate access to the brief digital imagery-competing task intervention plus symptom monitoring for 4 weeks including completing a daily count of the number of their intrusive memories in week 4 (primary outcome).
89178682|NCT00762723|Experimental|Group 1|Trinica Anterior Lumbar Plate System with fixed screws only
89178683|NCT00762723|Experimental|Group 2|Trinica Anterior Lumbar Plate System with variable screws only
89178684|NCT00762723|Experimental|Group 3|Trinica Anterior Lumbar Plate with hybrid screw configuration (2 fixed-angle screws with 2 variable-angle screws).
89365401|NCT04992390|Experimental|Delayed intervention arm|Usual care for 4 weeks including completing a daily count of the number of their intrusive memories in week 4 (primary outcome), followed by access to the brief digital imagery-competing task intervention plus symptom monitoring for 4 weeks.
89365402|NCT04988386|Experimental|AG10|Open-label study all participants will receive AG10 during this study.
89365403|NCT04976881|No Intervention|Usual Care|Usual care includes: 1) no specific materials to promote medication reconciliation, reproductive planning, or patient education on diabetes self-management within the context of preconception care, 2) variable physician preconception counseling without any EHR notifications or counseling support; and 3) no specific patient support or prompts to promote healthy behaviors post-visits.
89178685|NCT04098705|No Intervention|Pre-intervention|Pre-intervention period
89178686|NCT04098705|Experimental|Post-intervention|Post-intervention period
89178687|NCT00850343|Experimental|Certolizumab pegol 200 mg|Participants received 200 mg certolizumab pegol by subcutaneous injection once every 2 weeks for up to 52 weeks or until approval of certolizumab pegol for rheumatoid arthritis in Japan.
89178688|NCT00850343|Experimental|Certolizumab pegol 400 mg|Participants received 400 mg certolizumab pegol by subcutaneous injection once every 4 weeks for up to 52 weeks or until approval of certolizumab pegol for rheumatoid arthritis in Japan.
89178689|NCT00849875|Experimental|Group A|All patients are to receive the same treatment consisting of 24 injections of the immunotherapeutic GSK2132231A combined with a course of 8 cycles of dacarbazine given at the beginning of the treatment
89178690|NCT00844415|Experimental|dabigatran etexilate|open label; patient to receive dabigatran etexilate BID for three days
89178691|NCT00843635|Experimental|Arm A - Tadalafil 10mg|Patients will receive 10mg/day Tadalafil orally on days 1 - 20 in the absence of unacceptable toxicity.
89178692|NCT00843635|Experimental|Arm B - Tadalafil 20mg|Patients will receive 20mg/day Tadalafil orally on days 1 - 20 in the absence of unacceptable toxicity.
89178693|NCT00843635|Placebo Comparator|Arm C - Placebo|Patients receive oral placebo once daily on days 1-20 in the absence of unacceptable toxicity.
89178694|NCT00699179||A|
89178695|NCT04116827||Tamoxifen group|Pre-menopausal breast cancer patients who underwent proper surgical treatment, chemotherapy, or radiation therapy, and are scheduled for application of tamoxifen and goserelin
89178696|NCT00843167|Experimental|Sulforaphane Supplement|Patients receive oral broccoli sprout extract supplementation three times daily for 2-8 weeks in the absence of unacceptable toxicity.
89178697|NCT00843167|Placebo Comparator|Placebo|Patients receive oral placebo supplementation three times daily for 2-8 weeks in the absence of unacceptable toxicity.
89365404|NCT04976881|Active Comparator|PREPARED Strategy|Our PREPARED strategy will utilize health information and consumer technologies to 'hardwire' preconception care and promote diabetes self-management among reproductive-aged, adult women with T2DM in primary care. PREPARED will leverage electronic health record technology at clinic visits to: [1] promote medication reconciliation and safety, [2] prompt provider preconception counseling, and [3] deliver low literacy print tools to reinforce counseling and promote diabetes self-care. Post-visit, text messaging will be used to: [4] encourage healthy lifestyle behaviors.
89365405|NCT04970108|Experimental|Egito|"The study is triple-dummy. The patient must take 3 tablets once a day, as follows:~1 tablet Egito, oral;~1 tablet empagliflozin placebo, oral;~1 tablet telmisartan placebo, oral."
89365406|NCT04970108|Active Comparator|Empagliflozin + telmisartan|"The patient must take 3 tablets once a day, as follows:~1 tablet Egito placebo, oral;~1 tablet empagliflozin, oral;~1 tablet telmisartan, oral."
89365407|NCT04968015|Experimental|VEN-CYTA|Venetoclax 600mg/day, Per Os (PO), D1 to D14 / 28 days cycle Cytarabine 50 mg/m2/12h Subcutaneous (SC), D1 to D5 / 28 days cycle
89365408|NCT04968015|Active Comparator|IDA-CYTA|Idarubicin 8mg/m2, Intravenous (IV), at D1 / 28 days cycle Cytarabine 50 mg/m2/12h, SC, D1 to D5 / 28 days cycle
89365409|NCT04955366|Active Comparator|Belatacept group (Control Group)|"Participants will receive the following:~Belatacept: 5 mg/kg i.v. monthly~Blood draws for PD studies at baseline/Month 0 and Month 6 fora total of two timepoints.~HLA labs at 6, 12 and 24 months~Basic chemistry panel (CP Basic) every 3 months per clinical protocol for efficacy analysis~Hemoglobin A1c at Screening visit~Urine pregnancy test via test kit for WOCP at Screening visit~BK and CMV testing at 6, 12, and 24 months"
88836347|NCT05119231|Sham Comparator|Sham Control Arm|"Sham Pulmonary Vein Isolation~Trial participants will assigned to the SHAM-arm will undergo their procedure within 48 hours after baseline evaluation. The Sham procedure will include deep sedation according to the respective PVI protocol for at least one hour, femoral vein/artery puncture with introduction of sheaths and an electrical cardioversion in presence of persistent atrial fibrillation.~Dependent of the local standards an echocardiography or cardiac MRI will be performed prior to the procedure. If necessary, a transesophageal echocardiography must be performed to exclude presence of atrial thrombus.~Anticoagulation will be initiated/continued for at least 3 months after the procedure."
88836348|NCT05116735|Experimental|laparoscopic partial cystectomy with omentoplasty|laparoscopic partial cystectomy with omentoplasty
88836349|NCT05103904|Experimental|Treatment (Lenvatinib)|Patients receive lenvatinib PO QD. Treatment repeats every 28 days in the absence of disease progression, unacceptable toxicity, or patient withdrawal from the protocol therapy
88836350|NCT05093582|Active Comparator|Levcromakalim|Intravenous infusion of levcromakalim (1 mg/20 ml). The infusion is administered at constant speed by an automatic pump, lasting 20 minutes.
88836351|NCT05093582|Placebo Comparator|Placebo|Intravenous infusion of placebo (sterile saline, 20 ml). The infusion is administered at constant speed by an automatic pump, lasting 20 minutes.
88836352|NCT05090384|Experimental|Steroid Taper|All enrolled patients start on the same dose of steroids for treatment of GVHD, blood samples are taken at week 1 and 2 post study start and biomarkers plus clinical response determines how steroid treatment is continued
88836353|NCT05090215|Active Comparator|Exercise intervention group|2 resistance training session per week using a home-based resistance training pack and 75 minutes of vigorous or 150 minutes of moderate aerobic exercise per week (as per UK government guidelines) for 12 weeks. They will have 4 assessment points, pre-op, prior to the start of the exercise programme postoperatively, at 6 weeks post commencement of exercise and at 12 weeks to conclude the study. The assessment will include bloods, cardiopulmonary exercise testing, muscle ultrasound to ascertain muscle structure, functional composite scores and quality of life questionnaires.
88836354|NCT05090215|Placebo Comparator|Control group|This group will receive standard postoperative care. They will also have 4 assessment points, pre-op, prior to the start of their standard postoperative care, 6 and finally 12 weeks later to conclude the study. The assessment will include bloods, cardiopulmonary exercise testing, muscle ultrasound to ascertain muscle structure, functional composite scores and quality of life questionnaires.
88836355|NCT05085405|Experimental|Clinician Notification only|
88836356|NCT05085405|Experimental|Clinician Notification with Nurse Facilitation only|
88836357|NCT05085405|Experimental|Clinician Notification / Patient Activation|
88836358|NCT05085405|Experimental|Clinician Notification with Nurse Facilitation / Patient Activation|
88836359|NCT05082688|Experimental|1: Young adults herpes zoster vaccination|Young adults between 18 and 35 years old will receive the herpes zoster vaccine (Shingrix). 60 days later, they will receive a booster dose.
88836360|NCT05082688|Experimental|2: Older adults herpes zoster vaccination|Adults older than 60 years of age will receive the herpes zoster vaccine (Shingrix). 60 days later, they will receive a booster dose.
88836361|NCT05082688|Experimental|3: Young adults influenza vaccination|Young adults between 18 and 35 years old will receive the influenza vaccine (Fluarix Tetra).
88836362|NCT05082688|Experimental|4: Older adults influenza vaccination|Adults older than 60 years of age will receive the influenza vaccine (Fluarix Tetra).
89001614|NCT03452566|Experimental|ingenol mebutate gel|Phase 1/2, always 3 consecutive days, with 24 hours interval, dosage from 5 mg/cm2 to 18 mg/cm2 in a 3+3 design.
88836363|NCT05082688|Placebo Comparator|5: Young adults herpes zoster vaccination related placebo|Young adults between 18 and 35 years old will receive the placebo injection (0.9% NaCl). 60 days later, they will receive another placebo.
88836364|NCT05082688|Placebo Comparator|6: Young adults influenza vaccination related placebo|Young adults between 18 and 35 years old will receive the placebo injection (0.9% NaCl).
88836365|NCT05062915|No Intervention|Baseline population|Historic cohorte for comparisson in study 1. Baseline population 1 all patients with AVS. Baseline 2 population part of baseline 1 but with peripheral cause of AVS. Are offered late onset vestibular rehabilitaion if they have balance deficit.
88836366|NCT05062915|Active Comparator|Study population|"The study population is divided into 2 groups, based on the findings in the clinical investigation.~study population 1: all patients with acute Vestibular syndrome (AVS) Study population 2: all patients from study group 1, with vestibular/peripheral cause of AVS. They are offered early onset rehabilitation.~Arm 1 and 2 are compared for cost-effectiveness and compared to the costs of the diagnosis."
88836367|NCT05046158|Active Comparator|Transforming Powder Dressing|Half of the subjects will be randomized to Transforming Powder Dressing to treat their diabetic foot ulcers. Wounds will be evaluated weekly, debrided if needed, photographed, and measured. A wound dressing will be applied using Transforming Powder Dressing and the wound will be offloaded when necessary (pressure taken off of the wound using a total contact cast or other device). Wound healing progress will be monitored and compared to other standard of care dressings used to treat diabetic foot ulcers.Surveys regarding pain and quality of life will be completed at each study visit.
88836368|NCT05046158|Active Comparator|Standard of Care Dressing|Half of the subjects will be randomized to receive standard of care wound dressings to treat their diabetic foot ulcers. Wounds will be evaluated weekly, debrided if needed, photographed, and measured. A wound dressing will be applied using standard of care wound products, and the wound will be offloaded when necessary (pressure taken off of the wound using a total contact cast or other device). Wound healing progress will be monitored and compared to transforming powder dressings used to treat diabetic foot ulcers. Surveys regarding pain and quality of life will be completed at each study visit.
89178698|NCT00849017|Experimental|albiglutide|albiglutide weekly injection
89178699|NCT00849017|Placebo Comparator|placebo|albiglutide matching placebo
89178700|NCT00849017|Experimental|albiglutide up-titration|albiglutide weekly injection uptitration at week 12
89178701|NCT00842543|Experimental|Overweight|Overweight Boys receiving either Fruit and Vegetable Juice Concentrate (FVJC) or Placebo, 1 capsule, twice a day, for 6 months
89178702|NCT00842543|Experimental|Lean|Lean Boys receiving either Fruit and Vegetable Juice Concentrate (FVJC) or Placebo, 1 capsule, twice a day, for 6 months
89178703|NCT00785928|Experimental|Placebo|
89178704|NCT00785928|Experimental|1 mg LY2127399|
89178705|NCT00785928|Experimental|3 mg LY2127399|
88836369|NCT05045703|Experimental|Vitamin A palmitate|Vitamin A palmitate, 15,000 IU daily for 4 months
88836370|NCT05041478|Experimental|Cold EMR with adjuvant STSC to margins|Standard cold EMR technique with adjuvant snare tip soft coagulation to defect margins
88836371|NCT05041478|Active Comparator|Cold EMR|Standard Cold EMR resection technique
88836372|NCT05033392|Experimental|Toripalimab group|Toripalimab is administrated with160mg and repeated every 2 weeks.
88836373|NCT05029414|Experimental|Intervention group: EVT + BMT|Patients randomized to the EVT arm will undergo endovascular therapy (EVT) in addition to best medical treatment (BMT). All decisions regarding EVT device and EVT technique will be made by the treating physician.
88836374|NCT05029414|No Intervention|Control group: BMT|Patients randomized to the control arm will NOT undergo EVT but will get best medical treatment (BMT) including intravenous thrombolysis (IVT) or antiplatelet therapy if indicated under current international guidelines and according to routine clinical practice.
89178706|NCT00785928|Experimental|10 mg LY2127399|
89178707|NCT00785928|Experimental|30 mg LY2127399|
89178708|NCT00785928|Experimental|60 mg LY2127399|
89178709|NCT00785928|Experimental|120 mg LY2127399|
89178710|NCT00842309|Active Comparator|D-cycloserine|100mg of d-cycloserine in pill form administered 1 hour before behavior therapy sessions once a week for 8 weeks.
89178711|NCT00842309|Placebo Comparator|Placebo|Placebo in pill form administered 1 hour before behavior therapy sessions once a week for 8 weeks.
89178712|NCT00699257||Oxford® Partial Knee System|
89178713|NCT04119401|Active Comparator|doppler-guided|ligation of hemorrhoidal arteries with doppler guidance
89178714|NCT04119401|Experimental|finger-guided group|ligation of hemorrhoidal arteries without doppler guidance but with finger detection
89178715|NCT02613065|Experimental|Eggwhite protein shake|Participants drink a NOW Foods protein shake (~20% daily energy requirements) at the beginning of each of the three daily meals. Kcals/meal are dependent upon participant's baseline Resting Metabolic Rate value.
89178716|NCT02613065|Active Comparator|Maltodextrin carbohydrate shake|Participants drink a NOW Foods carbohydrate shake (~20% daily energy requirements) at the beginning of each of the three daily meals. Kcals/meal are dependent upon participant's baseline Resting Metabolic Rate value.
89178717|NCT00842153|Experimental|Clobetasol Propionate Foam|Topical foam formulation that includes clobetasol propionate (Steroid)
89178718|NCT00842153|Placebo Comparator|Vehicle Foam|Vehicle foam is the same as the clobetasol propionate foam except it does not include the active drug.
88836375|NCT05018078|Experimental|Coronavirus vaccination|Patients in the experimental need to accept the coronavirus vaccination
88836376|NCT05007730|Experimental|Intervention Arm|
88836377|NCT05002660|Experimental|Group 1 (Intervention)|"For Change Club members (CCM) only: CCM will participate in meetings of the Change Club and continue implementation of a change to the community environment for up to an additional 24 months. Change Club members will also be asked to recruit 10 or more friends and family members (FFM) to participate in the research study.~In addition, 100 community residents (CR) will be recruited into the study. Family members, friends and community residents do not participate in the Change Club, but may hear about Change Club activities in their community."
88836378|NCT05002660|Experimental|Group 2 (Control)|Control group participants will participate in no intervention activities during the 3-year research study.
88836379|NCT04990037|Experimental|CAN04 and FOLFIRINOX|Subjects will receive bi-weekly doses of CAN04 in combination with FOLFIRINOX given as standard regimen.
88836380|NCT04985812|Experimental|JNJ-67484703|Participants will receive multiple doses of JNJ-67484703.
88836381|NCT04985812|Placebo Comparator|Placebo|Participants will receive multiple doses of placebo.
88836382|NCT04980092||Post-ICU group|Observational foolow-up
88836383|NCT04978116|Experimental|Chest X-Ray (CXR)|Only CXR (image and standardized report) will be available to the clinician in charge of the patient (standard of care). LDCT and LUS will be performed but not available (clinician will be blinded to LDCT and LUS).
88836384|NCT04978116|Experimental|Low-dose CT scan (LDCT)|Only LDCT (image and standardized report) will be available to the clinician (first intervention arm). CXR and LUS will be performed but not available (clinician will be blinded to CXR and LUS).
88836385|NCT04978116|Experimental|Lung ultrasonography (LUS)|Only LUS (image and standardized report) will be available to the clinician (second intervention arm). CXR and LDCT will be performed but not available (clinician will be blinded to CXR and LDCT).
88836386|NCT04961944||Hypersensitivity pneumonitis|see elegibility criteria
88836387|NCT04959474|Active Comparator|Arm I (standard dietary recommendations, SABR, surgery)|Patients receive standard dietary recommendations. Patients undergo SABR every other day for 5 fractions. Within 4-12 weeks of completion of SABR, patients undergo surgical resection with sentinel lymph node biopsy.
88836388|NCT04959474|Experimental|Arm II (caloric restriction diet, SABR, surgery)|Beginning 1 week before the start of SABR, patients undergo a caloric restriction diet for 6-12 weeks (for the duration of radiation treatment, until post radiation follow-up appointment) consisting of reducing calorie intake by 25%. Patients undergo SABR every other day for 5 fractions. Within 4-12 weeks of completion of SABR, patients undergo surgical resection with sentinel lymph node biopsy.
88836389|NCT04956354||Phase 1a|"Once the setup of the study sensors is complete, clinical and physiological data will be continuously acquired for 8h during daytime, for 4 consecutive days. In addition, photographs of the skin at the site of placement of the sensors will be taken before sensors placement and after removal.~Hourly axillary temperature measured by the bedside nurse (as part of routine care) will be manually recorded for each patient by the research team. A temperature and humidity recorder will also be placed around 15cm from the infants to continuously record air temperature and humidity."
88836390|NCT04956354||Phase 1b|"Once the setup of the study sensors is complete, clinical and physiological data will be continuously acquired between 2h to 8h during daytime, for 2 to 4 consecutive days. In addition, photographs of the skin at the site of placement of the sensors will be taken before sensors placement and after removal.~A temperature and humidity recorder will also be placed around 15cm from the infants to continuously record air temperature and humidity."
88836391|NCT04956354||Phase 2|"Once the setup of the study sensors is complete, clinical and physiological data will be continuously acquired for a longer monitoring period - i.e., 96 consecutive hours. In consideration with device battery life, the devices will be replaced daily. In addition, photographs of the skin at the site of placement of the sensors will be taken at baseline, device replacement, and at 96h. The research team will also measure respirations using uncalibrated RIP belts at the level of the chest and abdomen (2 to 3 continuous hours each day). Two respiratory bands will be placed circumferentially around the infant's chest and around the abdomen to measure chest and abdominal wall movements, respectively.~A temperature and humidity recorder will also be placed around 15cm from the infants to continuously record air temperature and humidity."
88836392|NCT04953143|Experimental|Pilot|"Inpatient longitudinal palliative care intervention that includes the following domains:~Therapeutic relationship: Developing trust and credibility with patients and their families~Symptom management: Proactive symptom management for common advanced liver disease symptoms including pain, fatigue, anorexia, breathlessness, depression and anxiety~Coping with illness: Introduction of strategies to improve adjustment and meaning in life; bolstering caregiver coping~Prognostic awareness and illness understanding: Assessing patients' level of prognostic awareness and discussing strategies to help patients cope with uncertainty~Treatment decision-making: Supporting patients and caregivers in their medical decision-making and assessing their values in decision-making~End-of-life care: Review/discuss selection of healthcare proxy, preferences for end-of-life care"
88836393|NCT04932941|Experimental|MP1032|Participants will receive MP1032 300 milligrams (mg) twice daily (BID) with hospital selected SoC for 28 days.
88836394|NCT04932941|Placebo Comparator|Placebo|Participants will receive placebo matched to MP1032 with hospital selected SoC for 28 days.
88836395|NCT04927884|Experimental|All subjects|Sacituzumab plus chemoimmunotherapy (cyclophosphamide, N-803, and PD-L1 t-haNK)
88836396|NCT04923958|Experimental|Evaluation of various novel TB triage and diagnostic tests.|For the novel TB triage and diagnostic tests, the investigators will conduct large-scale evaluation of design-locked tests in a cohort of adults with presumed TB, with nested feasibility/pilot studies of early and late prototype tests. The investigators aim to enroll 300-450 participants per year at each of five enrollment sites for evaluation of various novel TB triage and diagnostic tests and 50 health workers to assess test usability.
88836397|NCT04923958|Experimental|Evaluation of novel rDST assays|Clinicians at participating sites will be asked to refer adult patients with rifampin-resistance identified by routine molecular testing. The investigators aim to enroll 100-200 patients per year at each of three enrollment sites for evaluation of novel rDST assays.
88875183|NCT02512224||Enteral nutrition|investigators selected participants aged 20 years or older who had undergone enteral nutrition by percutaneous endoscopic gastrostomy, percutaneous transesophageal gastrotubing, or ileostomy between April 1, 2012, and March 31, 2013.
89365410|NCT04955366|Experimental|Abatacept Group (Conversion Group)|"Participants will receive the following:~Abatacept 125 mg s.c. weekly~Safety labs every 2 weeks (months 0-3) then monthly (months 4-12)~Blood draws forPK atMonth 6, Month 12, and two random time points in between Month 6 and Month 12 for a total of four time points.~Blood draws for PD studies at baseline/Month0 and Month 6 fora total of two timepoints.~HLA labs at 6, 12 and 24 months~Basic chemistry panel (CP Basic) at each study visit per clinical protocol for efficacy analysis~Hemoglobin A1c at Screening visit~Urine pregnancy test via test kit for WOCP at screening~BK and CMV testing at 6, 12, and 24 months"
89365411|NCT04934371|Active Comparator|active TDCS and listening therapy|TDCS will be administered with NeurConn1 Channel DC-Stimulator Plus (neuroCare Group, München, Germany) according to established guidelines and procedures. The active tDCS will be delivered for 20 minutes at 2mA with a 15-s ramp-up and ramp-down period. Excitatory/anodal tDCS or sham will be administered alongside active listening therapy 5 times a week for 2 weeks.
88836398|NCT04901572|Other|QART Imaging|"Cells will be individually selected with the system's micromanipulator under bright-field imaging. The cells will be representative of the cell population to be selected in ICSI procedures, covering the entire range of human sperm cell dimensions. Each selected cell will be simultaneously imaged by the QART system in two modalities:~Standard brightfield.~QART's imaging methodology."
88836399|NCT04894708|Other|AI colonoscopy|colonoscopy with artificial intelligence added
88836400|NCT04894708|Sham Comparator|conventional colonoscopy|conventional colonoscopy
88836401|NCT04881058|Experimental|PicoSure Device|The PicoSure device will be used on the face for the treatment of pigmentation and mild to moderate wrinkles.
88836402|NCT04875884|Experimental|MRI group|Subjects enrolled in this study will undergo both standard and new MRI techniques. The standard MRI is needed for your routine care and as ordered by the referring doctor. The new MRI is performed for research purposes. Participants will be imaged with both methods and the results will be compared.
88836403|NCT04870918|Experimental|self-care intervention|First, health education will be carried out by the nurse. The consultations will be individual, weekly (Wednesdays), the others, therefore, will be biweekly, extending to the 30/30 days the following, individually in order to observe the difficulties and doubts of each patient. Counting the meetings in a total of 12 in the first 6 months.
88836404|NCT04870918|No Intervention|usual care|The control group will go through medical consultations as instructed by the doctor and will not receive intervention for health education by the nurse.
88836405|NCT04868773|Experimental|Cabozantinib in Combination with TAS-102 (trifluridine/tipiracil)|Subjects will receive cabozantinib in combination with TAS-102. Patients will receive cabozantinib on Days 1 - 28 and TAS-102 on Days 1-5 and Days 8-12, for a cycle length of 28 days.
88836406|NCT04865029|Experimental|Treatment Arm|Standard of Care along with Estradiol Cypionate 5mg intramuscular injection at admission and Progesterone 200mg by mouth daily for 5 days starting at admission.
88836407|NCT04865029|Other|Control Arm|"Standard of Care along with placebo injection and placebo pill~Standard of Care consistent with the National Institutes of Health (NIH) COVID-19 Treatment Guidelines"
89365412|NCT04934371|Sham Comparator|sham TDCS and listening therapy|The sham stimulation will also last for 20 min with 15 sec ramp-up and ramp-down, except the current will be turned down gradually to 0 milliamperes (mA) after 30 seconds. The sham procedure provides the same tingling and itching sensation felt during active tDCS. The sham parameters were chosen based on previous reports that the perceived sensations on the skin, such as tingling, fade out in the first 30 s of tDCS
89365413|NCT04922476|Experimental|Probiotic|Alflorex® The participants consume one probiotic capsule a day for 12 weeks.
88836408|NCT04855708|Experimental|Virtual visit|Patients will have 2-week post-operative virtual visit
88836409|NCT04855708|Active Comparator|Office visit|Patients will return to the office for a 2-week post-operative visit
88836410|NCT04840303|Experimental|Hub user group|This group receives community-based mental wellness youth hub services for young people to enhance personal strengths and overall mental well-being.
88836411|NCT04840303|No Intervention|non-hub user active control group|This group does not receive the community-based mental wellness youth hub services but other generic youth services in the community.
88836412|NCT04840303|No Intervention|non-hub user community control group|This group does not receive any youth services in the community.
88836413|NCT04805957|Experimental|Treatment|All subjects will receive 1.47umol/kg/day sulforaphane for 12 weeks. Pills are taken once a say with a meal.
88836414|NCT04804579|Experimental|Fall Prevention Intervention|"The Intervention involves 3 primary components: virtual group sessions, at-home exercises, and weekly phone check-ins.~Virtual Group Session will be held via phone/video call for approximately 30 minutes per week for 10 weeks.~At-Home Exercises will be assigned by a registered occupational therapist member of the study team, and participants will be instructed to complete them independently at home 3 times per week. Participants will record the exercises that they complete.~Weekly Phone Check-Ins will occur once per week. These check-ins will be used to provide support and problem solving as needed, and individualized reminder systems will be set up to prompt the participant to engage in their weekly exercises (e.g., set up alarm on phone, notifications through calendar app)."
89178719|NCT00762411|Experimental|LY450139|Participants received 60 milligrams (mg) LY450139 orally once daily for 2 weeks followed by 100 mg LY450139 orally once daily for 2 weeks, then 140 mg LY450139 orally once daily until Week 88.
88836415|NCT04804579|No Intervention|Control Group|Participants will be provided with an educational pamphlet that includes resources related to falls and alcohol use.
88836416|NCT04801758|Experimental|Analytical Treatment Interruption|Participants who received VRC01 or placebo and got HIV while enrolled in HVTN 704/HPTN 085 (NCT02716675).
88836417|NCT04797884|Experimental|TheraBionic Arm - Active Arm|For subjects who are randomized to the active arm, the device will be programmed with hepatocellular carcinoma-specific modulation frequencies and will be activated for >200 one-hour treatment sessions.
88836418|NCT04797884|Placebo Comparator|Placebo Arm|For subjects randomized to the placebo arm, the device will not emit any hepatocellular carcinoma-specific modulation frequencies and will be activated for >200 one-hour treatment sessions.
88836419|NCT04797585|Active Comparator|Laparoscopic supracervical hysterectomy|Minimally invasive procedure to remove a woman's uterus
88836420|NCT04797585|Experimental|Vaginal hysterectomy|Surgical procedure to remove the uterus
89365414|NCT04900636|Experimental|Telemedicine Arm|Use of a telemedicine platform combined with face-to-face visits according to protocol
89365415|NCT04900636|No Intervention|Control Arm|conventional follow-up according to routine clinical practice.
89365416|NCT04889209|Experimental|Cohort 1 Group 10E|Adaptive design cohort with participants that previously (>/=12 weeks) received Emergency Use Authorization (EUA)-dosed vaccination with Janssen - Ad26.COV2-S 5x10^10 vp stratified with two age ranges of 18-55 years (n = 25) and 56 or older (n = 25) randomized to receive a single intramuscular (IM) injection of a 100-mcg dose of mRNA-1273.211 (delayed boost dose). N = 50
88836421|NCT04796779|Experimental|CLC Group|Participants who skip or successfully complete the run-in will be randomly assigned 2:1 to the use of closed-loop control (CLC group) system using Tandem t:slim X2 with Control-IQ Technology vs Standard of Care (SC group) for 3 weeks. Participants randomized to the intervention group will use the Tandem t:slim X2 with Control-IQ Technology v1.0 during the first 13 weeks of the study (RCT phase, weeks 1-13) and then use Tandem t:slim X2 insulin pump with Control-IQ Technology v1.5 for the remaining 13 weeks of the study (extension phase, weeks 14-26).
89365417|NCT04889209|Experimental|Cohort 1 Group 11E|Adaptive design cohort with participants that previously (>/=12 weeks) received Emergency Use Authorization (EUA)-dosed vaccination with Pfizer/BioNTech - BNT162b2 at 30 mcg for two doses stratified with two age ranges of 18-55 years (n = 25) and 56 or older (n = 25) randomized to receive a single intramuscular (IM) injection of a 100-mcg dose of mRNA-1273.211 (delayed boost dose). N = 50
89365418|NCT04889209|Experimental|Cohort 1 Group 12E|Adaptive design cohort with participants that previously (>/=12 weeks) received Emergency Use Authorization (EUA)-dosed vaccination with Janssen - Ad26.COV.2.S at 5x10^10 vp stratified with two age ranges of 18-55 years (n = 25) and 56 or older (n = 25) randomized to receive a single intramuscular (IM) injection of a 50-mcg dose of mRNA- 1273 N = 50
88875184|NCT02513940|Experimental|Testosterone - progesterone - placebo|Subjects received transdermal testosterone gel 1% 100 mg once daily in the morning and two (2) oral placebo capsules x 7 days. After a washout of at least 13 days, they then received oral progesterone 400 mg (2 x 200 mg capsules) once every evening for 7 days and transdermal placebo gel once daily every morning for 7 days. After a washout period of at least 13 days, they then received transdermal placebo gel once daily every morning for 7 days and oral placebo once daily every morning x 7 days
89178720|NCT00762411|Placebo Comparator|Placebo|Participants received placebo orally once daily for the first 76 weeks. At the end of 76 weeks, participants in the placebo arm received LY450139 titrated up to 140 mg orally once daily until Week 88.
89365419|NCT04889209|Experimental|Cohort 1 Group 13E|Adaptive design cohort with participants that previously (>/=12 weeks) received Emergency Use Authorization (EUA)-dosed vaccination with Moderna-mRNA-1273 at 100mcg for two doses stratified with two age ranges of 18-55 years (n = 25) and 56 or older (n = 25) randomized to receive a single intramuscular (IM) injection of a 50-mcg dose of mRNA-1273. N = 50
89365420|NCT04889209|Experimental|Cohort 1 Group 14E|Adaptive design cohort with participants that previously (>/=12 weeks) received Emergency Use Authorization (EUA)-dosed vaccination with Pfizer/BioNTech - BNT162b2 at 30mcg for two doses stratified with two age ranges of 18-55 years (n = 25) and 56 or older (n = 25) randomized to receive a single intramuscular (IM) injection of a 50-mcg dose of mRNA-1273. N = 50
89365421|NCT04889209|Experimental|Cohort 1 Group 15E|Adaptive design cohort with participants that previously (>/=12 weeks) received Emergency Use Authorization (EUA)-dosed vaccination with Janssen - Ad26.COV.2.S 5x10^10 vp for one or two doses stratified with two age ranges of 18-55 years (n= 30) and 56 or older (n = 30) randomized to receive a single intramuscular (IM) injection of a 5-mcg dose of NVX-CoV2373 (SARS-COV-2). N =60
89365422|NCT04889209|Experimental|Cohort 1 Group 16E|Adaptive design cohort with participants that previously (>/=12 weeks) received Emergency Use Authorization (EUA)-dosed vaccination with Moderna - mRNA-1273 at 100 mcg for two doses stratified with two age ranges of 18-55 years (n = 30) and 56 or older (n = 30) randomized to receive a single intramuscular (IM) injection of a 5-mcg dose of NVX-CoV2373 (SARS-COV-2). N =60
89365423|NCT04889209|Experimental|Cohort 1 Group 17E|Adaptive design cohort with participants that previously (>/=12 weeks) received Emergency Use Authorization (EUA)-dosed vaccination with Pfizer/BioNTech - BNT162b2 at 30 mcg for two doses stratified with two age ranges of 18-55 years (n = 30) and 56 or older (n = 30) randomized to receive a single intramuscular (IM) injection of a 5-mcg dose of NVX-CoV2373 (SARS-COV-2). N =60
89365424|NCT04889209|Experimental|Cohort 1 Group 1E|Adaptive design cohort with participants that previously (>/=12 weeks) received Emergency Use Authorization (EUA)-dosed vaccination with Janssen - Ad26.COV.2.S at 5x10^10 vp stratified with two age ranges of 18-55 years (n = 25) and 56 or older (n = 25) randomized to receive a single intramuscular (IM) injection of 100-mcg dose of mRNA-1273 (delayed boost dose). N = 50
89365425|NCT04889209|Experimental|Cohort 1 Group 2E|Adaptive design cohort with participants that previously (>/=12 weeks) received Emergency Use Authorization (EUA) -dosed vaccination with Moderna - mRNA-1273 at 100 mcg for two doses stratified with two age ranges of 18-55 years (n = 25) and 56 or older (n = 25) randomized to receive a single intramuscular (IM) injection of a 100-mcg dose of mRNA-1273 (delayed boost dose). N = 50
89365426|NCT04889209|Experimental|Cohort 1 Group 3E|Adaptive design cohort with participants that previously (>/=12 weeks) received Emergency Use Authorization (EUA) -dosed vaccination with Pfizer/BioNTech - BNT162b2 at 30 mcg for two doses stratified with two age ranges of 18-55 years (n = 25) and 56 or older (n ˜ 25) randomized to receive a single intramuscular (IM) injection of a 100-mcg dose of mRNA-1273 (delayed boost dose). N = 50
89365427|NCT04889209|Experimental|Cohort 1 Group 4E|Adaptive design cohort with participants that previously (>/=12 weeks) received Emergency Use Authorization (EUA)-dosed vaccination with Janssen - Ad26.COV2-S at 5x10^10 vp stratified with two age ranges of 18-55 years (n = 25) and 56 or older (n = 25) randomized to receive a single intramuscular (IM) injection of Ad26.COV2.S 5x10^10 vp (delayed boost dose). N = 50
89365428|NCT04889209|Experimental|Cohort 1 Group 5E|Adaptive design cohort with participants that previously (>/=12 weeks) received Emergency Use Authorization (EUA)-dosed vaccination with Moderna - mRNA-1273 at 100 mcg for two doses stratified with two age ranges of 18-55 years (n = 25) and 56 or older (n = 25) randomized to receive a single intramuscular (IM) injection of Ad26.COV2.S 5x10^10 vp (delayed boost dose). N = 50
89178721|NCT00761865|Active Comparator|Air Cast Stirrup Brace|50 patients will be randomly assigned to receive the Air Cast Stirrup Brace.
89178722|NCT00761865|Active Comparator|High Tide Fracture Boot|50 patients will be randomly assigned to the High Tide Fracture Boot.
89178723|NCT00841763|Experimental|TIV + aH5N1|First dose of the non-adjuvanted trivalent influenza virus vaccine (TIV) followed by two doses of the adjuvanted monovalent influenza virus vaccine (aH5N1).
89178724|NCT00841763|Active Comparator|PL + aTIV|First dose of placebo (PL-saline) followed by two doses of the adjuvanted trivalent influenza virus vaccine (aTIV).
89365429|NCT04889209|Experimental|Cohort 1 Group 6E|Adaptive design cohort with participants that previously (>/=12 weeks) received Emergency Use Authorization (EUA)-dosed vaccination with Pfizer/BioNTech - BNT162b2 at 30 mcg for two doses stratified with two age ranges of 18-55 years (n = 25) and 56 or older (n = 25) randomized to receive a single intramuscular (IM) injection of Ad26.COV2.S 5x10^10 vp (delayed boost dose). N = 50
89365430|NCT04889209|Experimental|Cohort 1 Group 7E|Adaptive design cohort with participants that previously (>/=12 weeks) received Emergency Use Authorization (EUA)-dosed vaccination with Janssen - Ad26.COV.2.S 5x10^10 vp stratified with two age ranges of 18-55 years (n=˜ 25) and 56 or older (n = 25) randomized to receive a single intramuscular (IM) injection of a 30-mcg dose of BNT162b2 (delayed boost dose). N = 50
89365431|NCT04889209|Experimental|Cohort 1 Group 8E|Adaptive design cohort with participants that previously (>/=12 weeks) received Emergency Use Authorization (EUA)-dosed vaccination with Moderna - mRNA-1273 at 100 mcg for two doses stratified with two age ranges of 18-55 years (n = 25) and 56 or older (n = 25) randomized to receive a single intramuscular (IM) injection of a 30-mcg dose of BNT162b2 (delayed boost dose). N = 50
88836422|NCT04796779|Active Comparator|SC Group|Participants who skip or successfully complete the run-in will be randomly assigned 2:1 to the use of closed-loop control (CLC group) system using Tandem t:slim X2 with Control-IQ Technology vs Standard of Care (SC group) for 3 weeks. Participants randomized to the SC group will use their existing insulin therapy in conjunction with study Dexcom G6 CGM during the first 13 weeks of the study (RCT phase, weeks 1-13). The SC group will then transition to using the Tandem t:slim X2 insulin pump with Control-IQ Technology v1.5 and study Dexcom G6 CGM for the remaining 13 weeks of the study (weeks 14-26).
88836423|NCT04793815|Experimental|Cryo-activation and anti-PD-1 monotherapy combination|
89365432|NCT04889209|Experimental|Cohort 1 Group 9E|Adaptive design cohort with participants that previously (>/=12 weeks) received Emergency Use Authorization (EUA)-dosed vaccination with Pfizer/BioNTech - BNT162b2 at 30 mcg for two doses stratified with two age ranges of 18-55 years (n = 25) and 56 or older (n = 25) randomized to receive a single intramuscular (IM) injection of a 30-mcg dose of BNT162b2 (delayed boost dose). N = 50
89365433|NCT04889209|Experimental|Cohort 2|A prospective design cohort with naïve to COVID-19 vaccine and infection participants of > / = 18 years of age to receive COVID-19 vaccine intramuscularly under Emergency Use Authorization dosing (EUA) (two vaccinations of mRNA-1273 at the 100mcg dose at a 28 days of interval) followed by a delayed booster vaccination (50 mcg mRNA-1273) after a minimum of 12 weeks. Additional pools of subjects can be included as additional COVID-19 vaccines are awarded EUA (e.g., Janssen - Ad26.COV2.S or Novavax- NVX-CoV2373). A second booster (fourth dose) will be administered intramuscular using Moderna mRNA-1273.222 at 50 mcg at a 4-12 month interval N=250
89365434|NCT04889092|Experimental|blood flow restriction exercise|8 weeks (20 sessions) of blood flow restriction knee extension/flexion exercise
89365435|NCT04889092|Active Comparator|traditional resistance exercise|8 weeks (20 sessions) of traditional knee extension/flexion resistance exercise
89365436|NCT04884568|Experimental|Exufiber|This is an open, non-randomised , single arm study
89365437|NCT04864743|Experimental|Arm 1-ADVATE+FRSW117(25 IU/kg)|Subjects received two treatments: 25 IU/kg ADVATE in the first period, followed by 25 IU/kg FRSW117 in the second period, with a washout period before each treatment.
89365438|NCT04864743|Experimental|Arm 2-ADVATE+FRSW117( 50 IU/kg)|Subjects received two treatments: 50 IU/kg ADVATE in the first period, followed by 50 IU/kg FRSW117 in the second period, with a washout period before each treatment.
89365439|NCT04828096|Active Comparator|Penta-one retainer|Penta-one retainer is one wire that is been in use for many years. Penta-one retainer is to be bonded on the lower anterior 6 teeth (canine-to-canine)- Half of the retainers are going to be bonded with sandblasted enamel and half without.
88836424|NCT04781816|Experimental|SAR443122|SAR443122 for 12 weeks
88836425|NCT04781816|Placebo Comparator|Placebo|Matching placebo
89001615|NCT03452488|Placebo Comparator|Arm 1 - Placebo oral capsule|"4 capsules taken twice a day: in the morning and in the evening with the meal approximately at 12-hour distance for 26 weeks.~Component : Microcrystalline cellulose, Colloidal anhydrous silica"
89178725|NCT00838331|Experimental|Fresh blood, then aged blood|
89178726|NCT00703001|Active Comparator|1--Educational Intervention|Students in this arm will receive several in-class educational modules on basic oral health topics.
89178727|NCT00703001|Active Comparator|2--Referral intervention|Parents of student subjects will receive assistance in accessing oral health care for their child
88836426|NCT04768920|Experimental|Teletx|The evidence-based manualized psychosocial programs that will be delivered via telehealth are adaptations of cognitive behavioral therapy, motivational interviewing, and other psychosocial interventions to enhance initial and ongoing treatment engagement. TeleTx consists of up to 8 ~30-50 minute psychosocial sessions delivered via phone or videoconference platform (e.g. Zoom etc).
88836427|NCT04762134|Experimental|STI PrEP arm|doxycycline capsules 100mg orally daily for 12 months. Though the usual treatment dose of doxycycline is 100mg twice daily
88836428|NCT04762134|Experimental|STI PEP arm|doxycycline 200mg orally once within 24-72 hours following each sexual encounter deemed at risk (i.e. condomless anal or oral sex), to a maximum of six pills (i.e. 600 mg total) per week
88836429|NCT04758195|Experimental|Transanal irrigation|Transanal irrigation (TAI) is performed using the irrigation bag, electronic irrigation system, or balloon catheter with syringe. TAI is performed with up to 2000 ml tap water every 24-48 hours (3-7 times per week) over the course of 6 months.
88836430|NCT04758195|Active Comparator|Best supportive therapy|Best supportive therapy consists of dietary modification, pelvic floor muscle training, biofeedback, and necessary medication.
88836431|NCT04752358|Experimental|Autologous genetically modified ADP-A2M4CD8 cells|
89365440|NCT04828096|Experimental|Ortho-FlexTech retainer|Ortho-Flextech chain wire is relatively new in the market and needs to be evaluated. Ortho-Flextech retainer is to be bonded on the lower anterior 6 teeth (canine-to-canine)- Half of the retianers are going to be bonded with sandblasted enamel and half without.
89365441|NCT04828096|Experimental|Memotain retainer|Memotain wire is relatively new in the market. It requires digital scanning and the technique is said to be very exact. Memotain retainer is to be bonded on the lower anterior 6 teeth (canine-to-canine)- Half of the retianers are going to be bonded with sandblasted enamel and half without.
89365442|NCT04767061|Active Comparator|Beta Blocker ABAB Sequence|"This arm will follow an ABAB sequence. A representing ON beta blockers and B representing OFF beta blockers. Subjects in this arm will continue their home dose during the initial A period, they will then crossover into Period 2, where dose reduction will begin until they are off of beta blockers. After Period 2, the subjects have the option to decide if they want to be on or off their beta blocker and proceed with the Follow-Up Phase, or continue to Period 3 if they don't feel ready to make that decision to stay on or go off their beta blocker yet. During Period 3, they will restart beta-blockers, gradually uptitrating until reaching their home dose and finally during Period 4, we will again conduct a dose reduction until off of beta blockers."
89178728|NCT00785538|Experimental|IMC-A12|All participants will receive intravenous (I.V.) infusions of IMC-A12, with the dose depending on which cohort they are enrolled into. A minimum of three participants will be enrolled in each cohort. When all participants complete a cohort, dose escalation to the next cohort will occur.
89178729|NCT04102488|Experimental|6-step hygiene technique, application time of 30 seconds|
89178730|NCT04102488|Experimental|6-step hygiene technique, application time of 15 seconds|
89178731|NCT04102488|Experimental|3-step hygiene technique, application time of 30 seconds|
89178732|NCT04102488|Experimental|3-step hygiene technique, application time of 15 seconds|
88836432|NCT04736329|Active Comparator|Telmisartan|Telmisartan (20 up to 80mg) for RAAS inhibition, as part of their heart failure therapy.
88836433|NCT04736329|No Intervention|Enalapril|Enalapril (2.5 up to 20mg ) for RAAS inhibition, as part of their heart failure therapy.
88836434|NCT04735068|Experimental|Binimetinib and Hydroxychloroquine|"Hydroxychloroquine (HCQ)in combination with Binimetinib (B). The starting dose for HCQ will be 400mg. Tablets of HCQ are available in 200 mg strength. HCQ will be administered in divided doses (every 12 hours) with or without food.~The starting dose of B is 45mg. B will be administered in divided doses (every 12 hours) with or without food"
88836435|NCT04721548|Placebo Comparator|Minoxidil´s Placebo|The recommended dosage is 1 ml of the solution twice a day (morning and evening).
89178733|NCT03993834||Normal modified Allen Test|Patients undergoing transradial coronary angiography with a modified Allen-Test ≤ 15 seconds
89178734|NCT03993834||Abnormal modified Allen Test|Patients undergoing transradial coronary angiography with a modified Allen-Test > 15 seconds
89178735|NCT04101162|Other|liver biopsy|
89178736|NCT04101162|Other|ATI|
89178737|NCT02602704|Active Comparator|Bazedoxifene & Calcium/Vit D|"Enrollment: 57~Drug: Bazedoxifene 20 mg/day (Viviant)~Drug: Elemental calcium 1200mg daily and vitamin D 800 IU daily (Caltrate D 400 * 2/day)"
89178738|NCT02602704|Active Comparator|Calcium/Vit D|"Enrollment: 57~Drug: Elemental calcium 1200mg daily and vitamin D 800 IU daily (Caltrate D 400 * 2/day)"
89178739|NCT02601690||Blood Sampling|Participants allergic to one or more of cat, rye grass, ragweed or house dust mite.
89178740|NCT04105296|Experimental|EKSO+ES|6 months of exoskeleton training with spinal cord epidural stimulation.
89178741|NCT00916422|Experimental|Depigoid Phleum pratense 1000DPP/Ml|Depigmented and Polymerized Allergen extract of Phleum Pratense.Subcutaneous Immunotherapy in an up-dosing cluster regimen for 4 weeks, followed by monthly injections for 2 years.
89365443|NCT04767061|Active Comparator|Beta Blocker BABA Sequence|"This arm will follow a BABA sequence. A representing ON beta blockers and B representing OFF of beta blockers. Subjects in this arm will have their previously prescribed beta blocker dose reduced until they are completely off of beta blockers during Period 1. They will then crossover into Period 2, where uptitration will begin until they are back on their previously prescribed dose of beta blockers. After Period 2, the subjects have the option to decide if they want to be on or off their beta blocker and proceed with the Follow-Up Phase, or continue to Period 3 if they don't feel ready to make that decision to stay on or go off their beta blocker yet. During Period 3, we will again conduct a dose reduction, until the subject is off of beta blockers and finally during Period 4, we will uptitrate them back to their home dose of beta blockers."
89365444|NCT04753294|Experimental|Avance Solo NPWT System|Treatment with negative pressure wound therapy for Venous leg ulcers, Diabetic foot ulcers, and Pressure ulcers.
89365445|NCT04753294|Experimental|Avance Solo Adapt NPWT System|Treatment with negative pressure wound therapy for Pressure ulcers.
89365446|NCT04750967|Experimental|Active|Greater occipital nerve and supraorbital nerve block with 1% lidocaine once a week for first four weeks then once a month for 5 months
89365447|NCT04750967|Active Comparator|Control|Amitriptyline 25 mg daily for 6 months
89365448|NCT04742075|Active Comparator|(A) Olaparib|Olaparib 300 mg tablets twice daily until progressive disease or unacceptable toxicity.
89365449|NCT04742075|Experimental|(B) Olaparib + durvalumab|"Olaparib 300 mg tablets twice daily until progressive disease or unacceptable toxicity.~Durvalumab 1500 mg IV every 4 weeks for 24 months or until disease progression or unacceptable toxicity."
89365450|NCT04742075|Experimental|(C) Olaparib + durvalumab + UV1|"Olaparib 300 mg tablets twice daily until disease progression or unacceptable toxicity.~Durvalumab 1500 mg IV every 4 weeks for 24 months or until disease progression or unacceptable toxicity.~Eight UV1 vaccinations during the first 5 month: Four UV1 vaccinations 300 μg (+ 75 μg of sargramostim) during the first 10 days with a minimum of 2 days apart. From cycle 2-5 subjects will receive one UV1 (+ sargramostim) vaccination every 4th week."
89365451|NCT04729517|Active Comparator|Azelastine Hydrochloride|Patients that will receive azelastine hydrochloride are defined as the active control arm.
89365452|NCT04729517|Experimental|AI201901|Patients that will receive AI201901 are defined as the test arm.
89365453|NCT04720963|Placebo Comparator|group P (Placebo group)|intranasal placebo about 30min before anesthesia induction
89365454|NCT04720963|Experimental|group R (remimazolam group)|intranasal remimazolam about 30min before anesthesia induction
89365455|NCT04720963|Active Comparator|group D (Dexmedetomine group)|intranasal dexmedetomidine about 30min before anesthesia induction
89365456|NCT04696315||SCD subjects with positive amyloid|In this study, the participants are from two research centers in China and Germany. All participants will conduct amyloid PET scanning, after which they are classified into two grous (SCD with amyloid+ and SCD with amyloid-). SCD subjects with positive amyloid show the evidence of amyloid deposition in brain. They have higher risk of conversion to mild cognitive impairment and dementia compared with SCD with negative amyloid. They are also considered as preclinical AD.
88836436|NCT04721548|Experimental|Topical Minoxidil 5%|The recommended dosage is 1 ml of the solution twice a day (morning and evening).
88836437|NCT04718493|Experimental|Stent|
88836438|NCT04718493|Active Comparator|Dilatation|
88836439|NCT04717089||postoperative patients admitted to TMH extended post anaesthetic care in PACU|"Exclusion criteria:~Patients awaiting ICU admission in the ordinary recovery room~Patients requiring level 3 intensive care on arrival at the recovery room"
88836440|NCT04717089||Postoperative patient admitted to ICU with case matched|"Inclusion criteria:~o Based on case matched with the extended post anaesthetic care in PACU"
89365457|NCT04696315||SCD subjects with negative amyloid|In this study, the participants are from two research centers in China and Germany. All participants will conduct amyloid PET scanning, after which they are classified into two grous (SCD with amyloid+ and SCD with amyloid-). SCD subjects with negative amyloid do not show the evidence of amyloid deposition in brain. They have lower risk of conversion to mild cognitive impairment and dementia compared with SCD with positive amyloid.
89530329|NCT02455843|Experimental|Microwave plus chemotherapy|In combination group, patients will be treated with microwave ablation in primary tumor sites followed by chemotherapy （For non-squamous cell lung cancer，patients will be treated with pemetrexed，500mg/m2, d1, ivdrip, or docetaxel,75mg/m2, d1, ivdrip or gemcitabine 1250mg/m2, d1 d8, ivdrip,or novelbine 25mg/m2 d1 d8, ivdrip, paclitaxel 175mg/m2 d1 ivdrip plus cisplatin 75mg/m2, d1 d2, ivdrip or carboplatin with an area under the curve of 5 d1 ivdrip. For squamous cell lung cancer，patients will be treated with docetaxel,75mg/m2, d1, ivdrip or gemcitabine 1250mg/m2, d1 d8, ivdrip plus cisplatin 75mg/m2, d1 d2, ivdrip or carboplatin with an area under the curve of 5 d1 ivdrip；repeated every 3 weeks and up to 6 cycles are administrated ）
88836441|NCT04712799|Experimental|COPD patients|Wlaking tests before and afrer 1 spray with oxymetazoline
88836442|NCT04712734|Experimental|Iloperidone|
88836443|NCT04712474|Experimental|In-home decluttering|Study participants receive weekly sessions of in-home decluttering for 10 weeks.
88836444|NCT04712474|No Intervention|Delayed treatment|Study participants receive weekly session of in-home decluttering after a 10 week delay.
88836445|NCT04704648|Other|Surgical Excision|Treatment involves EXCISION ONLY (surgery) for the conjunctival lesion with 3 mm margins. Surgeons (registered as investigators at each site) will perform the operation in accordance with the procedures outlined in the AMC-104 manual of procedures (MOP). Standard of care topical antibiotics are given for infection prevention following surgery. No drugs or device treatments are administered for treatment of OSSN in this protocol.
88836446|NCT04698343|Experimental|Noninvasive Peripheral Nerve Stimulation (NPNS)|NPNS device programmed to deliver active stimulation.
88836447|NCT04687098|Other|Risk-adapted postremission treatment.|Induction (idarubicin, cytarabine), first consolidation (high dose cytarabine), risk- stratification: allogeneic matched related or unrelated donor transplant vs. consolidation courses.
88836448|NCT04683406|Experimental|ZSP1273 600 mg + Oseltamivir Placebo BID|Subjects received 5 doses of ZSP1273 at 600 mg once a day along with matching placebo of oseltamivir placebo orally twice daily (BID) with approximately 12 hour (+/- 2) intervals, over 5 days
88836449|NCT04683406|Active Comparator|Oseltamivir 75mg + ZSP1273 Placebo|Subjects received 10 doses of Oseltamivir at a dose of 75 mg twice daily (BID) with matching placebo of ZSP1273 orally once a day with approximately 12 hour (+/- 2) intervals, over 5 days
88836450|NCT04683406|Placebo Comparator|Placebo Comparator|Subjects received 5 doses of matching placebo of ZSP1273 and Oseltamivir twice daily (BID) with approximately 12 hour (+/- 2) intervals, over 5 days
88836451|NCT04679298||Apixaban|N=20
88836452|NCT04679298||Edoxaban|N=20
88836453|NCT04679298||Dabigatran|N=20
88836454|NCT04679298||Rivaroxaban|N=20
88836455|NCT04677465|Experimental|RheOx Treatment|
88836456|NCT04677465|Sham Comparator|Sham Procedure|
88836457|NCT04676087|Experimental|Treatment (mogamulizumab, ECP)|"INDUCTION (WEEKS 1-7): Patients receive mogamulizumab IV over 60 minutes on days 1, 8, 15, 22, and 36 in the absence of disease progression progression and unacceptable toxicity. Patients also undergo extracorporeal photopheresis on days 1, 8, 15, 22, 29, and 36 in the absence of disease progression and unacceptable toxicity.~TREATMENT (CYCLES 1-12): Patients receive mogamulizumab IV over 60 minutes on days 1 and 15, and undergo extracorporeal photopheresis on days 1 and 15 of cycles 1-6, then day 1 of subsequent cycles. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression and unacceptable toxicity.~MAINTENANCE (CYCLES 13+): Patients with clinical benefit may continue extracorporeal photopheresis on day 1. Cycles repeat every 28 days in the absence of disease progression and unacceptable toxicity."
88836458|NCT04672590||Cases|Patients admitted to a study hospital meeting criteria for confirmed or probable acute new-onset neurological disease and confirmed or probable COVID-19.
88836459|NCT04672590||Controls|Patients admitted to a study hospital meeting criteria for confirmed or probable COVID-19, without confirmed or probable acute new-onset neurological disease.
89534660|NCT02492399|Other|extended myectomy|"Procedure: extended myectomy.~Will be included in a group of 30 patients with obstructive hypertrophic cardiomyopathy and mitral insufficiency. Intraoperatively for all patients will be executed TEE to calculate the volume of excision. All patients will be performed extended myoectomy which supplemented resection and release of the papillary muscles. In case of unsatisfactory MV repair will reconnect the device artificial circulation and mitral valve replacement. The result in this case will become engrossed in reading as completely unsatisfactory. At achievement of 15% prosthetics of the mitralny valve research stops.~Evaluation results will be made myoectomy as TEE and direct tensiometer ."
88836460|NCT04671459|Experimental|TTFields and SRS based on MRI or FET-PET|All subjects will receive TTFields and radiosurgery plus/minus FET PET imaging to define tumor volume.
88836461|NCT04664426||Kidney transplant recipients|Kidney transplant recipients will undergo examination according to the E-PSS, amTCNS, QST (thermal threshold testing), and NCS (amplitude, velocity and distal latency of measurements at the sural sensory nerve, ulnar sensory nerve, peroneal motor nerve, tibial motor nerve and ulnar motor nerve, soleus H reflex will be measured).
88836462|NCT04662086|Experimental|Acebilustat|Participants are randomized to receive either active acebilustat or matching placebo for 28 days.
88836463|NCT04662086|Experimental|Camostat|Participants are randomized to receive either active camostat or matching placebo for 10 days.
88836464|NCT04662073|Experimental|Camostat|Participants are randomized to receive camostat for 10 days.
88836465|NCT04662073|Placebo Comparator|Matching Placebo|Participants are randomized to receive placebo to match camostat for 10 days.
88836466|NCT04656418|Experimental|CSL312|Participants received a CSL312 loading dose of 400 mg as two 200 mg SC injections in Month 1 along with CSL312 of 200 mg subcutaneous (SC) injections, once monthly from Months 2 to 6.
88836467|NCT04656418|Placebo Comparator|Placebo|Participants received a CSL312 matched loading dose of placebo as two SC injections in Month 1 along with CSL312 matched placebo SC injections, once monthly from Months 2 to 6.
88836468|NCT04647877|Experimental|Phenytoin 10 percent cream|Phenytoin 10 percent cream, 2 to 4 times daily application, 2 weeks long
88836469|NCT04647877|Experimental|Phenytoin 20 percent cream|Phenytoin 20 percent cream, 2 to 4 times daily application, 2 weeks long
88836470|NCT04647877|Placebo Comparator|Placebo cream|Placebo cream, 2 to 4 times daily application, 2 weeks long
88836471|NCT04629599|Experimental|Interpersonal psychotherapy for major depression following perinatal loss|Participants in the IPT condition will receive 12 group sessions and 2 individual (pre-group and 1-month booster) sessions as outlined in the manual The individual sessions prepare patients to use the group effectively, to keep group members focused on their treatment goals, and to maintain treatment gains. In addition, 3 of the 12 group sessions will invite women to include their partners or other support people to bolster the woman's social support system and to reduce conflicts over how to react to the loss. These sessions are important because relationship distress is common following perinatal loss. Our IPT intervention allows new women to enter the group every 4 weeks of the 12-week group. Group sessions are semi-structured, and each woman will cover the four group topics three times, approaching each topic from a different stage in the mourning process.
89178742|NCT00916422|Placebo Comparator|2|Placebo. Dosing regimen: An up-dosing cluster regimen for 4 weeks, followed by monthly injections for 2 years
89534661|NCT02492633|Active Comparator|Standard|The Standard Intervention will be offered to residents at all of Beacon Communities properties, regardless of the presence of this study.
89365458|NCT04688034|Experimental|OP-724 400 mg / 20 mL / vial (20 mg / mL)|"Dose: [Cohort 1] 140 mg/m2/4 hours (starting dose) , [Cohort 2] 280 mg/m2/4 hours~Administration method: In the single administration, the safety of concomitant use with the investigational drug and antiretroviral drug will be confirmed and then the cycle administration will be started. For the single administration, at 14 days before the first cycle of administration, the dose planned for the first cycle with continuous intravenous administration for 4 hours will be administrated once. When an integrase inhibitor is used in combination as a key drug for antiretroviral drugs, it should be administered at the same time as the start of investigational drug administration only after the single administration. For the cycle administration, the continuous intravenous administration for 4 hours twice a week is defined as one cycle, and 12 cycles (12 weeks in total) will be performed."
89365459|NCT04681638|Experimental|Plasma|Pathogen-Reduced Plasma resuscitation
89365460|NCT04681638|Active Comparator|Crystalloid|Standardized crystalloid resuscitation
89365461|NCT04669275|Experimental|telephone counseling|People receiving telephone counselling.
89365462|NCT04669275|Experimental|telephone counselin|People receiving telephone counselling.
88836472|NCT04629599|Active Comparator|Coping with Depression|The Coping with Depression (CWD) course is a structured, manualized psycho-educational group treatment for MDD. The CWD course is based on social learning theory which posits that depression is associated with a decrease in pleasant and an increase in unpleasant person-environment interactions. The problems shown by depressed individuals are viewed as behavioral, with cognitive patterns that can be unlearned or relearned. Its effectiveness is comparable to other forms of psychotherapy in depression. The course content is cognitive-behavioral in nature and is designed to train skills that can be used in the alleviation of depression. The skill modules focus on relaxation, cognitive skills, and behavioral activation. As in the pilot trial, CWD will consist of an individual pregroup session, 12 group therapy sessions (allowing new women to enter every 4th session) and a 1-month individual booster session to provide an identical treatment dose as the experimental condition.
88836473|NCT04622306|Active Comparator|Control Latex Condom C|Commercial Natural Rubber Latex Male Condom
88836474|NCT04622306|Experimental|Polyurethane Condom A|Polyurethane Condom A (002)
88836475|NCT04622306|Experimental|Polyurethane Condom B|Polyurethane Condom B (001)
88836476|NCT04610515||Symptomatic Individuals with infection with SARS-COV2 (ie exposed cohort)|Symptomatic Individuals test positive for SARS-COV2. Participants will be enrolled soon after infection and followed to assess for long term outcomes.
88836477|NCT04610515||Symptomatic Individuals without infection with SARS-COV2 (ie unexposed cohort)|Symptomatic Individuals test negative for SARS-COV2. Participants will be enrolled soon after testing and followed to assess for long term outcomes.
88836478|NCT04608539|Experimental|Intravenous iron group|Single-dose intravenous infusion of 20 mg/kg body weight ferric derisomaltose/iron isomaltoside 1000 (MonoFer®)
88836479|NCT04608539|Active Comparator|Oral iron group|Oral therapy with 100 mg oral ferrous sulfate twice daily
88836480|NCT04601103|Experimental|Comparator: No SLS Toothpaste|3M Oral Rinse in combination with no SLS toothpaste (A)
88836481|NCT04601103|Experimental|Comparator: Medium SLS Toothpaste|3M Oral Rinse in combination with medium SLS toothpaste (B)
88836482|NCT04601103|Experimental|Comparator: High SLS Toothpaste|3M Oral Rinse in combination with high SLS toothpaste (C)
88836483|NCT04586166|Experimental|RP Sling Group|Participants assigned to the retropubic (RP) sling group will have the RP sling placement procedure
88836484|NCT04586166|Experimental|SIS Group|Participants assigned to the single-incision sling (SIS) group will have the SIS placement procedure
88836485|NCT04581499|Experimental|DynamiCare Motivation Support Program|Intervention Group members will receive 32 weeks of remote Contingency Management (CM; financial motivational incentives), Recovery Coaching, substance testing, appointment reminding/tracking, and in-app Cognitive Behavioral Therapy (CBT). After 32 weeks, coaching, testing, appointment tracking and CBT will continue until an overall 12 months in the project is completed.
88836486|NCT04581499|Other|Untreated or Routine Care Control Group|Control participants will receive substance tests at the same frequency as Intervention participants, and the same incentive amounts for tests as treatment participants. Controls' payments, however, will not be contingent on positive/negative results, but rather only on valid, on-time submission. Controls will not receive coaching, CBT or rewards for appointments.
88836487|NCT04575597|Experimental|Part 1: Molnupiravir 200 mg|200 mg molnupiravir administered orally every 12 hours for 5 days (10 doses total)
88836488|NCT04575597|Experimental|Part 1: Molnupiravir 400 mg|400 mg molnupiravir administered orally every 12 hours for 5 days (10 doses total)
88836489|NCT04575597|Experimental|Part 1: Molnupiravir 800 mg|800 mg molnupiravir administered orally every 12 hours for 5 days (10 doses total)
88836490|NCT04575597|Placebo Comparator|Part 1: Placebo|Placebo matching molnupiravir administered orally every 12 hours for 5 days (10 doses total)
88836491|NCT04575597|Experimental|Part 2: Molnupiravir 800 mg|800 mg Molnupiravir (dose to be selected) administered orally every 12 hours for 5 days (10 doses total)
88836492|NCT04575597|Placebo Comparator|Part 2: Placebo|Placebo matching molnupiravir administered orally every 12 hours for 5 days (10 doses total)
88836493|NCT04571138|Experimental|SCRI-CAR22v2|Patients will receive SCRI-CAR22v2 in either Phase I or Phase II
88836494|NCT04562792|Experimental|Patients with relapsed/refractory ALL and AML|Patients in this arm will receive daunorubicin 6.75mg/m2 daily for 5 consecutive days.
89365463|NCT04666701|Experimental|Escócia association|"The study is triple-dummy. The patient must take 3 pills, with a minimum interval of 6/6 hours for a maximum of 5 days, if pain, as follows:~1 tablet Escócia association, oral~1 dragee Placebo Scopolamine, oral~1 tablet Placebo Ketorolac, sublingual"
89365464|NCT04666701|Active Comparator|Ketorolac|"The study is triple-dummy. The patient must take 3 pills, with a minimum interval of 6/6 hours for a maximum of 5 days, if pain, as follows:~1 tablet Ketorolac, sublingual~1 tablet Placebo Escócia association, oral~1 dragee Placebo Scopolamine, oral"
89365465|NCT04666701|Active Comparator|Scopolamine|"The study is triple-dummy. The patient must take 3 pills, with a minimum interval of 6/6 hours for a maximum of 5 days, if pain, as follows:~1 dragee Scopolamine, oral~1 tablet Placebo Ketorolac, sublingual~1 tablet Placebo Escócia association, oral"
88836495|NCT04551066|Experimental|Group A : parsaclisib + ruxolitinib|Participants will receive parsaclisib and ruxolitinib starting from Day 1 for the duration of study, ruxolitinib dose will be determined by baseline platelet count.
89534662|NCT02492633|Experimental|Enhanced|At a subset of 6 Beacon Communities properties, residents will receive an 'enhanced intervention' in addition to the 'standard intervention' that Beacon Communities is already providing.
89178743|NCT00860405|Experimental|1|Investigational drug: HES 130/0.4 (6%) in sodium chloride (Voluven®, solution for infusion)
89178744|NCT00860405|Active Comparator|2|Control drug: Human serum albumin (HSA 50g/L)
89534663|NCT03329261|Active Comparator|Arm 1 (single dose)|Will receive a clopidogrel loading dose of 600 mg PO, then a daily dose of clopidogrel 75 mg PO until the angioplasty is performed. After coronary intervention, a daily dose of clopidogrel 150 mg PO for 7 days will be given, followed by a daily single dose of clopidogrel (75 mg PO) for 21 days. Maintenance therapy will be clopidogrel daily dose of 75 mg PO thereafter, until the end of the study.
89534664|NCT03329261|Active Comparator|Arm 2 (double dose)|Will receive a clopidogrel loading dose of 600 mg PO, then a daily dose of clopidogrel 75 mg PO until the angioplasty is performed. After coronary intervention, a daily dose of clopidogrel 150 mg PO for 7 days will be given, followed by a daily double dose of clopidogrel (150 mg PO) for 21 days. Maintenance therapy will be clopidogrel daily dose of 75 mg PO thereafter, until the end of the study.
88836496|NCT04551066|Placebo Comparator|Group B : placebo + ruxolitinib|Participants will receive placebo and ruxolitinib starting from Day 1 for the duration of study, ruxolitinib dose will be determined by baseline platelet count.
88836497|NCT04546724|Active Comparator|VLA1553|Single intramuscular vaccination on Day 1 with VLA1553, a lyophilized live-attenuated Chikungunya vaccine candidate; 1x10E4 TCID50 per dose
88836498|NCT04546724|Placebo Comparator|Placebo|Single intramuscular vaccination on Day 1 with Phosphate-Buffered Saline (PBS) as placebo
88836499|NCT04546711||Ketogenic Diet|"Baseline Assessments~Ketogenic diet intervention~3 and 6 month Assessments"
88836500|NCT04544813|Experimental|Cohort A: JNJ-77474462 SC (Wave 1)|Participants will receive single dose of JNJ-77474462 subcutaneously (SC).
89178745|NCT04104906|Experimental|motor control training|8-week exercise program, twice a week, with motor control training
88836501|NCT04544813|Experimental|Cohort B: JNJ-77474462 SC (Wave 1)|Participants will receive single dose of JNJ-77474462 SC.
88836502|NCT04544813|Experimental|Cohort C: JNJ-77474462 SC (Wave 1)|Participants will receive single dose of JNJ-77474462 SC.
88836503|NCT04544813|Experimental|Cohort D: JNJ-77474462 SC (Wave 1)|Participants will receive single dose of JNJ-77474462 SC.
88836504|NCT04544813|Experimental|Cohort E: JNJ-77474462 IV (Wave 1)|Participants will receive single dose of JNJ-77474462 intravenously (IV).
88836505|NCT04544813|Experimental|Cohort F: JNJ-77474462 SC (Wave 2)|Participants will receive single dose of JNJ-77474462 SC.
88836506|NCT04544813|Experimental|Cohort G: JNJ-77474462 SC (Wave 2)|Participants will receive single dose of JNJ-77474462 SC.
88836507|NCT04544813|Experimental|Cohort H: JNJ-77474462 IV (Wave 2)|Participants will receive single dose of JNJ-77474462 IV.
88836508|NCT04544813|Experimental|Cohort I: JNJ-77474462 IV (Wave 2)|Participants will receive single dose of JNJ-77474462 IV.
88836509|NCT04544813|Active Comparator|Cohort J: Anakinra SC|Participants will receive a SC injection of anakinra once daily for 3 days.
88836510|NCT04530513|Experimental|Dose Level 1|
88836511|NCT04530513|Experimental|Dose Level 2|
88836512|NCT04530513|Experimental|Dose Level 3|
88836513|NCT04530513|Experimental|Dose Level 4|
88836514|NCT04530513|Experimental|De-escalation Level|
88836515|NCT04524364|Other|Participants with Paroxysmal Atrial Fibrillation (PAF)|Participants with PAF and who are candidates for catheter ablation will be enrolled.
88836516|NCT04520113|Active Comparator|Standard Tracing|"Households of tuberculosis index patients receive standard household contact tracing during regular weekday business hours."
88836517|NCT04520113|Experimental|Holiday Tracing|Households of tuberculosis index patients in rural South Africa receive household contact tracing during holidays (Christmas and Easter).
89365466|NCT04649866|Experimental|Test group|Endothelial dysfunction will be tested using Strain-gauge plethysmography to measure forearm blood flow during infusions of acetylcholine [ACh] and sodium nitroprusside [SNP]
89365467|NCT04649866|Active Comparator|Control group|Endothelial dysfunction will be tested using Strain-gauge plethysmography to measure forearm blood flow during infusions of acetylcholine [ACh] and sodium nitroprusside [SNP]
89365469|NCT04638660|Experimental|Phentolamine Ophthalmic Solution 0.75%|One drop in both eyes at or near bedtime (8PM to 10PM)
89365470|NCT04638660|Placebo Comparator|Phentolamine Ophthalmic Solution Vehicle|One drop in both eyes at or near bedtime (8PM to 10PM)
89365471|NCT04629963|Experimental|Aim 1: Pain Evaluation|Participants will complete the validated pain questionnaire, the Brief Pain Inventory Short Form (BPISF). Participants will receive a non-invasive physical exam and pain assessment by a pain specialist.
89365472|NCT04629963|No Intervention|Aim 2: Qualitative Interview|Participants will complete individual interviews moderated by the research staff. Interviews will be based on the guide but will be minimally structured to facilitate exploration of novel topics as raised by participants and to ensure information-rich data on topics of interest. Individual interviews will be ~30-45 minutes in length, conducted in the subject's primary language with the use of an interpreter as appropriate. All interviews will be audio-recorded with participants' permission, transcribed, and translated into English for analysis.
89365473|NCT04629963|Experimental|Aim 3: Enrollment in a digital program assessing stress, pain, and cardiovascular health|"Continuous cardiovascular, stress, and pain data collection will occur for 6 months after enrollment. Biometric data including continuous heart rate, actigraphy, sleep, and derived physiological parameters will be collected using the wearable device. Pain and stress evaluations will be administered via a smartphone app as a survey of stress, pain, or cardiovascular symptoms.~Participants will complete surveys assessing chronic pain, mental health, trauma history, migration stress, and cardiovascular risk factors and disease Total cholesterol, HDL, LDL, triglycerides, and glucose will be measured using a lipid analyzer with a fingerstick blood sample. Height, weight, and blood pressure will also be measured."
89365474|NCT04604236|Experimental|Mapping Enhanced Counseling (MEC)|MEC will target attitudes and norms. Attitudes include motivation for change, such as problem recognition and a belief that treatment will help. Subjective norms include normative beliefs about SU in adolescence (e.g., belief that it is ok to allow SU with parental supervision; experimentation is normal) and expectations about treatment.
89365475|NCT04604236|Experimental|Active Linkage (AL)|AL will target perceived control. Perceived control includes perceived logistical barriers and the degree to which individuals feel they can overcome them.
88836518|NCT04520113|Experimental|Evening / Weekend Tracing|Households of tuberculosis index patients in urban South Africa receive household contact tracing during evenings and weekends.
88836519|NCT04512846||CK-SBRT with TACE group|The hepatocellular carcinoma patients (5-10cm）who received SBRT with TACE.
88836520|NCT04512846||CK-SBRT group|The hepatocellular carcinoma patients (5-10cm）who received SBRT alone.
88836521|NCT04504916|Experimental|Zilovertamab vedotin|Participants will receive zilovertamab vedotin at 2.0 mg/kg given intravenously on Day 1 and Day 8 of repeated 21-day cycles. Treatment will continue until progressive disease or discontinuation.
88836522|NCT04501679|Experimental|Nemolizumab|Participants weighing less than (<) 90 kilogram (kg) will receive two subcutaneous (SC) injections of 30 milligrams (mg) nemolizumab (60 mg loading dose) at baseline then one SC injection once for every 4 weeks (Q4W). Participants weighing greater than or equal to (>=) 90 kg will receive two SC injections of 60 mg nemolizumab at baseline (no loading dose) and two SC injections Q4W throughout the treatment period of 16 weeks.
89365476|NCT04601051|Experimental|Polyneuropathy Part 1: NTLA-2001|Participants, assigned to one of 4 dose-escalation cohorts, will receive a single dose of NTLA-2001.
89365477|NCT04601051|Experimental|Polyneuropathy Part 2: NTLA-2001|Participants, assigned to the dose-expansion cohort, will receive a single dose of NTLA-2001.
89365478|NCT04601051|Experimental|Cardiomyopathy Part 1 (UK only): NTLA-2001|Participants, assigned to one of 2 dose-escalation cohorts, will receive a single dose of NTLA-2001.
89365479|NCT04601051|Experimental|Cardiomyopathy Part 2 (UK only): NTLA-2001|Participants, assigned to the dose-expansion cohort, will receive a single dose of NTLA-2001.
88836523|NCT04501679|Placebo Comparator|Placebo|Participants weighing < 90 kg will receive two SC injections of matching placebo at baseline, then one SC injection Q4W. Participants weighing >= 90 kg will receive two SC injections of matching placebo at baseline, then two SC injections Q4W throughout the treatment period of 16 weeks.
88836524|NCT04501367|Experimental|DEXTENZA Group|Patients undergoing vitrectomy with internal limiting membrane peel
88836525|NCT04501367|Experimental|Second DEXTENZA Group|Patients undergoing vitrectomy with internal limiting membrane peel
88836526|NCT04501367|Experimental|Topical Prednisolone Acetate 1% Group|Patients undergoing vitrectomy with internal limiting membrane peel
88836527|NCT04500483||Burn outpatients|Burn patients treated for minor burns in an outpatient setting
88836528|NCT04500483||ICU survivors|Critically ill patients who survived ICU stay and are admitted in a general ward
88836529|NCT04500288|Experimental|LEFT Device Arm|Subjects in this arm will wear the LEFT device for 1 month
88836530|NCT04491617|Active Comparator|Standard Opioid Protocol (Control)|Standard postoperative medications (opioids and non-opioids) are prescribed upon discharge after surgery
88836531|NCT04491617|Experimental|Restrictive Opioid Protocol (Intervention)|Only non-opioid analgesics (i.e. ibuprofen and acetaminophen) are prescribed upon discharge after surgery. Patients are allowed to request an opioid prescription if they so desire
89365480|NCT04601051|Experimental|Polyneuropathy Follow-on Dosing (PN Part 1 Dose Level 1 Subjects only): NTLA-2001|Participants assigned to the follow-on dosing cohort will receive a subsequent dose of NTLA-2001.
89365481|NCT04598438|Experimental|Music intervention treatment group|Participants attending the music behavioral early intervention program
89365482|NCT04598438|Active Comparator|Arts and crafts active control group|Participants attending the arts and crafts developmental enhancement program
89365483|NCT04593329|Experimental|TIRADENTES|"The study is triple-dummy. The patient must take 3 pills, with a minimum interval of 6/6 hours for 3 days, if pain, as follows:~1 tablet Tiradentes association, oral;~1 capsule tramadol placebo, oral;~1 tablet dipyrone placebo, oral."
89365484|NCT04593329|Active Comparator|DIPYRONE|"The patient must take 3 pills, with a minimum interval of 6/6 hours for 3 days, if pain, as follows:~1 tablet dipyrone, oral;~1 tablet Tiradentes association placebo, oral;~1 capsule tramadol placebo, oral."
89365485|NCT04593329|Active Comparator|TRAMADOL|"The patient must take 3 pills, with a minimum interval of 6/6 hours for 3 days, if pain, as follows:~1 capsule tramadol, oral;~1 tablet dipyrone placebo, oral;~1 tablet Tiradentes association placebo, oral."
89365486|NCT04579588||COVID-19 participants|
89365487|NCT04579588||Control participants|
89365488|NCT04563546|Other|MI Patients in northern Tanzania|Patients presenting to KCMC emergency department with acute MI
89365489|NCT04520373|Experimental|Treatment Group 1: AD-MSC Injection|Patients will receive a single dose of autologous, adipose derived mesenchymal stem cells one time. The cells are isolated from patient's adipose tissue and expanded for intrathecal delivery.
89365490|NCT04520373|Active Comparator|Treatment Group 2: Best Medical Management|Patients will be observed over six months while attending physical and occupational therapy. After six months, patients will receive a single dose of autologous, adipose derived mesenchymal stem cells one time. The cells are isolated from patient's adipose tissue and expanded for intrathecal delivery.
89365491|NCT04502290|Experimental|Combined non-invasive brain and Functional Electrical Stimulation|In this arm of the study participants will receive repeated non-invasive brain stimulation synchronously paired with FES
89365492|NCT04499521|Experimental|Arm A: BrachyGel in fractions 3 and 5|BrachyGel VHPS in fractions 3 and 5 and standard packing in fractions 2 and 4
88836532|NCT04487392|Active Comparator|Estrogen vaginal cream group (group A)|22 participants will be included in this group. The participants selected for group A will be provided with estriol 0.01% vaginal cream, which should be applied at home.
89365493|NCT04499521|Experimental|Arm B: BrachyGel in fractions 2 and 4|BrachyGel VHPS in fractions 2 and 4 and standard packing in fractions 3 and 5
89365494|NCT04498988||Substance use disorder (SUD) group|In the substance use disorder (SUD) group, participants had a diagnosis of alcohol and/or tobacco use disorder according to the Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5) but no lifetime non-substance-related addictive disorder (ND).
89365495|NCT04498988||Non-substance-related addictive disorder (ND) group|In the non-substance-related addictive disorder (ND) group, participants were included who fulfilled two or more criteria for a DSM-5 gambling disorder or for an addictive behavior related to Internet use (not for gambling, gaming, or shopping), gaming, or shopping assessed with adapted criteria from DSM-5 substance use disorder (SUD). Participants in the ND group had no lifetime SUD.
89365496|NCT04498988||Control group|The control participants had no current or lifetime substance use disorder (SUD) or non-substance-related addictive disorder (ND).
89365497|NCT04492384||inpatients|Patients treated from COVID-19 in hospital
89365498|NCT04492384||outpatients|Patients treated from COVID-19 at home
89365499|NCT04453657|Experimental|Intervention|There is only one arm in this study. All recruited and consented participants will fill out a pre-survey, engage with the digital toolkit for 15 weeks, then fill out a post-survey.
89365500|NCT04448392|Other|Neonatal HSV disease requiring suppressive therapy|All subjects enrolled in the study will receive 2 (up to 7) days of valacyclovir 20 mg/kg every 8 hours after completion of standard of care treatment course with acyclovir.
89365501|NCT04423796|Experimental|Robotic assisted early mobilization|Robotic assisted early mobilization started within 72 hours of ICU admission.
89365502|NCT04423796|Active Comparator|Early mobilization|Early mobilization started within 72 hours of ICU admission without the use of a robotic assistance. Mobilization is done by personell.
88836533|NCT04487392|Experimental|Photobiomodutation group (group B)|22 participants will be included in this group. The participants selected for group B will be undergo photobiomodulation with red LED.
88836534|NCT04485546|Experimental|OXERVATE™ 0.002% (20 mcg/mL) cenegermin-bkbj|
88836535|NCT04478344|Experimental|Ultrasound guided hydrodissection to superior cluneal nerve|Patients with superior cluneal nerve enttrappment given by ultrasound guided perineural injection with a mixture of 1 mL of 50% dextrose, 4 mL of 1% lidocaine, and 5 mL of 0.9% normal saline to superior cluneal nerve of affected side.
88836536|NCT04478344|No Intervention|Control arm|Patients without superior cluneal nerve entrappment
88836537|NCT04475497|Experimental|Blood mangement group|The intervention will include pre-surgical optimization blood management referral based on pre-operative Hgb levels <11.0. Treatment will include PO iron, IV iron, B12 or folate per blood management algorithm.
89365503|NCT04388904|Experimental|Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (FDC)|Participants will receive oral tablet containing Darunavir 800 milligram (mg)/ Cobicistat 150 mg/ Emtricitabine 200 mg/ Tenofovir Alafenamide 10 mg (D/C/F/TAF) fixed-dose combination (FDC) once daily within 24 hours of the screening/baseline visit.
89365504|NCT04373941|Experimental|Kasai GCSF|The Kasai GCSF group will receive the standard of care PLUS 3 consecutive daily doses of 10 ug/kg of GCSF to be administered subcutaneously by day 3 post Kasai surgery
89365505|NCT04373941|No Intervention|Kasai no GCSF|The no GCSF group will not receive GCSF and receives the standard of care
89365506|NCT04373941|Experimental|No Kasai GCSF|The No Kasai GCSF group will receive the standard of care PLUS 3 consecutive daily doses of 10 ug/kg of GCSF to be administered subcutaneously once the diagnosis of BA is established
88836538|NCT04475497|Active Comparator|Usual care|Usual care per surgeon preference can include iron by mouth or no iron therapy.
88836539|NCT04442295|Experimental|Single Ascending Doses|Enrollment of patients in two age groups. A Sentinel group of 2 patients aged 13 to 18 years of age, inclusive, and an expanded group of 2 patients 2 to 12 years of age to receive single doses. There will be an option to dose up to 6 additional patients at each dose level and an option to expand the maximum tolerated dose level with 5 additional patients.
88836540|NCT04442295|Experimental|Multiple Ascending Doses|Enrollment of patients in two age groups. A Sentinel group of 2 patients aged 13 to 18 years of age, inclusive, and an expanded group of 2 patients 2 to 12 years of age to receive multiple doses. There will be an option to dose up to 6 additional patients at each dose level and an option to expand the maximum tolerated dose level with 10 additional patients.
89365507|NCT04373941|No Intervention|No Kasai No GCSF|The No Kasai No GCSF group will receive the standard of care and will not receive GCSF
89365508|NCT04367480|Experimental|Group I (Active TENS)|Patients wear an active wireless TENS device 5 hours daily for up to 6 weeks in the absence of unacceptable toxicity.
89365509|NCT04367480|Placebo Comparator|Group II (Placebo TENS)|Patients wear a placebo wireless TENS device 5 hours daily for up to 6 weeks in the absence of unacceptable toxicity.
89365510|NCT04355780||Subgroup 1|Composed of HCT patients with respiratory failure requiring intubation and mechanical ventilation.
89365511|NCT04355780||Subgroup 2|Composed of oncology patients (solid tumor or leukemia patients) who have not undergone HCT and who have respiratory failure requiring intubation and mechanical ventilation.
89365512|NCT04355780||Subgroup 3|Composed of chimeric antigen T-cell receptor infusion recipients who have respiratory failure requiring intubation and mechanical ventilation.
89365513|NCT04348604|Experimental|Customized Adherence Enhancement for AYA|This arm will receive the experimental intervention, Customized Adherence Enhancement for Adolescents and Young Adults (CAE-AYA).
89365514|NCT04348604|Active Comparator|Enhanced Treatment as Usual (ETAU)|This arm will receive the control intervention, Enhanced Treatment as Usual (ETAU).
89365515|NCT04328350||AYA who are on treatment 2-12 months post -diagnosis|"AYA will complete questionnaires assessing peer versus family connectedness, peer/romantic competence, coping, distress, social support, and quality of life.A study-specific needs assessment regarding interest in social functioning interventions will also be completed.~Participants (30 on-therapy) will be interviewed to further explore aspects of peer/family connectedness and intervention interest."
89365516|NCT04328350||AYA who are off -therapy 1 to 4 years|"AYA will complete questionnaires assessing peer versus family connectedness, peer/romantic competence, coping, distress, social support, and quality of life.A study-specific needs assessment regarding interest in social functioning interventions will also be completed.~Participants (20 off-therapy) will be interviewed to further explore aspects of peer/family connectedness and intervention interest."
89365517|NCT04309942|Experimental|Guided Clinical Pharmacy Consultation group|Patients following either Revlimid - Velcade - Dexamethasone or Revlimid - Dexamethasone protocols with the benefit of a Guided Clinical Pharmacy Consultation before beginning oral anticancer treatment for multiple myeloma.
89365518|NCT04309942|No Intervention|Standard group|Patients following either Revlimid - Velcade - Dexamethazone or Revlimid - Dexamethazone protocols but without the benefit of a Guided Clinical Pharmacy Consultation before beginning oral anticancer treatment for multiple myeloma.
89365519|NCT04281706||Etomidate-Time-Frame|Patients that underwent cardiac surgery between October 1st, 2012 and September 30th, 2013
89365520|NCT04281706||Propofol-Time-Frame|Patients that underwent cardiac surgery between February 1st, 2014 and January 31st, 2015
89365521|NCT04279834|Active Comparator|PAP Treatment|Participants will receive a PAP device and will attend four weekly sessions to receive education about this treatment.
89365522|NCT04279834|Active Comparator|Sleep Education I|Participants will attend four weekly sessions to receive education about strategies to improve sleep.
89365523|NCT04263415|Placebo Comparator|group P|once-weekly injection with placebo pen.
89365524|NCT04263415|Experimental|group S|Once-weekly application of semaglutide
89365525|NCT04249219|Experimental|E-Cigarette Ads|All individuals in the study will see the same e-cigarette advertisements presented in a random order.
89365526|NCT04246437|Experimental|[18F]F-DOPA|All patients will receive [18F]F-DOPA for PET imaging to measure pre-synaptic dopamine in the brain.
88836541|NCT04427293|Experimental|Open Label|All participants will receive lenvatinib 12mg daily for 7 days and pembrolizumab 200 mg IV on day 1 prior to surgery
88836542|NCT04391842|Experimental|Experimental: SAM ultrasound and diclofenac patch|Patients receive treatment from the SAM Ultrasonic Diathermy Device for 4 hours every day for 7 days combined with 1% diclofenac patch. The SAM device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity.
88836543|NCT04383262|Experimental|Lexiva|Lexiva/fosamprenavir at the FDA approved and manufacturers recommended dose (1,400mg twice daily) for 12 weeks
88836544|NCT04383262|Placebo Comparator|Placebo|standard of care
89178746|NCT04104906|Active Comparator|exercises|8-week exercise program, twice a week.
89365527|NCT04223193|Experimental|Tavapadon|Participants will receive tavapadon tablet titrated up to 15 milligram (mg) once daily (QD) orally for 27 weeks.
89365528|NCT04223193|Placebo Comparator|Placebo|Participants will receive placebo matching to tavapadon tablet QD orally for 27 weeks.
88836545|NCT04373057|Experimental|Galacto-oligosaccharide|"Phase I: Subjects will receive GOS, at dose levels 0.75g, 1.5g, and 2.9 g/day administered once daily. GOS will be dosed per the following schedule using a modified 3+3 design: 0.75g x 4 days, followed by 1.5g x 4 days, followed by 2.9g for the duration of the study starting from about 30 days before transplant to about 4 weeks after transplant.~Phase II: Subjects will receive GOS, at dose levels 0.25*MTD, 0.5*MTD, and MTD with MTD determined by the phase 1 of the study, once daily from about 30 days before transplant to about 4 weeks after transplant."
88836546|NCT04373057|Placebo Comparator|Maltodextrin|Phase II: Subjects will receive maltodextrin at comparable dose level as GOS (in Phase II) once daily from about 30 days before transplant to about 4 weeks after transplant.
89365529|NCT04222660|Experimental|Type 2 diabetes without neuropathy|Subjects with type 2 diabetes will be enrolled and determination if they have neuropathy will be determined from their clinical record and evaluation.
89365530|NCT04222660|Experimental|Type 2 diabetes with neuropathy|Subjects with type 2 diabetes will be enrolled and determination if they have neuropathy will be determined from their clinical record and evaluation.
89365531|NCT04222660|Experimental|Normal subjects, aged match with no symptoms of diabetes|Healthy, aged matched control subjects will be enrolled and determination if they have neuropathy will be determined from their clinical record and evaluation.
89365532|NCT04206371|Other|Defibrillation testing during ICD replacment|
89365533|NCT04184700|Experimental|EHCF + LGG|Extensively hydrolyzed casein formula plus Lactobacillus rhamnosus GG
89365534|NCT04184700|Active Comparator|RHF|Extensively hydrolyzed rice formula
89365535|NCT04184700|Active Comparator|EHWF|Extensively hydrolyzed protein formula
89365536|NCT04184700|Active Comparator|AAF|Amino acid based formula
89365537|NCT04184700|Active Comparator|SF|Soy formula
89365538|NCT04178941|Experimental|Intervention (Single Arm)|The intervention is a combined educational outreach and audit and feedback strategy that includes providing the hospital's own continuous pulse oximetry use data back to them on a weekly basis. The data will be accompanied by staff-targeted educational materials and outreach sessions summarizing the current evidence and guideline recommendations for continuous pulse oximetry use in bronchiolitis.
88836547|NCT04360681|Experimental|Lofexidine (LFX)|LFX starting dosage is two 0.2 mg LFX tablet taken orally 2 times daily (i.e., 0.8 mg/day). At study visit 2 (Day 3), the dosage is increased to 1.2mg/day (3 tablets, BID). At visit 3 (Day 5), the dose is increased to the target dose of 1.6mg/day (4 tablets, BID). Participants enter the flexible dosing period at visit 4, at which point the LFX dose can be maintained at 1.6 mg/day or decreased to 1.2 mg/day based on symptoms and the clinical judgement of the investigator. The flexible dosing period extends through to visit 6, however, doses will be adjusted during the study as needed.
88836548|NCT04360681|Placebo Comparator|Placebo (PLB)|A placebo drug will be employed as the comparison group to active study drug.
88836549|NCT04337255|Active Comparator|MIND DIET intervention|Allocation and blinding 3 year intervention of MIND Diet + counseling
88836550|NCT04337255|Placebo Comparator|Usual care diet intervention|3 year Intervention of usual care diet + counseling
88836551|NCT04337203|Experimental|SHARE-S|Three components consisting of electronic referral, health coaching and tailored text/email messages for patients that have been referred to the cancer survivorship clinic.
88836552|NCT04330248|Experimental|Erdafitinib and Carbamazepine|Participants will receive single oral dose of erdafitinib dose 1 on Day 1 30 minutes after the start of a standardized breakfast in Period 1 followed by repeated doses of carbamazepine orally every 12 hours from Days 15 to 35 (carbamazepine Dose 1 from Days 15 to 17, Dose 2 from Days 18 to 20, and then Dose 3 from Days 21 to 35) 30 minutes after the start of standardized meal (breakfast and dinner) in Period 2. After 8 Days of Dose 3 carbamazepine treatment, on Day 28, participants will receive a single oral dose of erdafitinib dose 1 with that day's carbamazepine dose.
88836553|NCT04328844|Experimental|Group 1: Cutaneous Melanoma|IOA-244 in combination with avelumab
88836554|NCT04328844|Experimental|Group 2: Uveal Melanoma|IOA-244 as monotherapy
88836555|NCT04328844|Experimental|Group 3: Myelofibrosis|IOA-244 in combination with ruxolitinib
88836556|NCT04328844|Experimental|Group 4: Mesothelioma|IOA-244 in combination with pemetrexed/cisplatin/avelumab
88836557|NCT04328844|Experimental|Group 5: NSCLC 1st line|IOA-244 in combination with pemetrexed/cisplatin/avelumab
88836558|NCT04328844|Experimental|Group 6: NSCLC 2nd/3rd line|IOA-244 in combination with avelumab
89365539|NCT04167527|Experimental|Immediate mechanical thrombectomy(iMT)|Treatment initiation within 8 hours of symptom onset. Arterial puncture and revascularization will be performed using EmboTrap II Retriever. The procedure will be completed within two hours of arterial access.
89365540|NCT04167527|Active Comparator|Initial medical management (iMM)|Standard medical therapy based on current AHA (American Heart Association) guidelines. Rescue mechanical thrombectomy (rMT) is allowed for patients initially assigned to iMM if they suffer major neurological worsening that clearly requires an intra-arterial intervention in the judgment of the treating team.
89365541|NCT04137731|Experimental|IFC Treatment|The IFC treatment will be used for 30 minutes, twice a day for two days after the total knee arthroplasty
88836559|NCT04328844|Experimental|Group 7: NHL-FL and NHL-PTCL|IOA-244 as monotherapy
88836560|NCT04327024|Experimental|Verinurad 12 + allopurinol|"Dose [mg] verinurad/allopurinol:~Step 1 - titration_3/100 Step 2 - titration_7.5/200 Step 3 - target dose 12/300"
88836561|NCT04327024|Experimental|Allopurinol alone|"Dose [mg] verinurad/allopurinol:~Step 1 - titration_0/100 Step 2 - titration_0/200 Step 3 - target dose 0/300"
88836562|NCT04327024|Placebo Comparator|Placebo|Placebo [mg] in 3 steps 0/0
89365542|NCT04137731|Placebo Comparator|Placebo|One set of device is programmed to be used as Placebo, the subject will feel the vibration but will not receive a therapeutic signal.
88836563|NCT04322149|Experimental|AT-1501|4 sequential dose cohorts
88836564|NCT04315272|Active Comparator|Azithromycin|A single dose of azithromycin will be administered to children between the ages of 8 days and 59 months old.
88836565|NCT04315272|Placebo Comparator|Placebo|A single dose of placebo will be administered to children between the ages of 8 days and 59 months old.
88836566|NCT04309474|Experimental|Elezanumab|Participants will receive elezanumab dose A
88836567|NCT04309474|Placebo Comparator|Placebo|Participants will receive placebo for elezanumab
88836568|NCT04304352|Experimental|Metronomic VEX|Metronomic VEX (Oral Cyclophosphamide 50 mg daily continuous, Oral Capecitabine 500 mg, thrice daily continuous, Oral Vinorelbine 40 mg day 1,3 and 5 every week
88836569|NCT04297592|Active Comparator|Additional Antibiotic Group|Patients will receive an oral antibiotic to be started after completion of standard perioperative antibiotics following primary hip or knee arthroplasty. Oral antibiotic will either be a first-generation cephalosporin (Cefadroxil or Cephalexin) or Doxycycline based upon patient allergies, kidney function and result of nasal colonization testing for MRSA.
88836570|NCT04297592|No Intervention|Control Group - No Additional Antibiotic|Patients will receive standard perioperative antibiotics following primary hip or knee arthroplasty and no additional antibiotics.
89178747|NCT05542290|Experimental|With capsular tension ring implantation|We performed phacoemulsification lens extraction and intraocular lens implantation with capsular tension ring implantation combined with goniosynechialysis.
88836571|NCT04294459|Experimental|Cohort A: Participants with cPRA >=99.90%|Participants with calculated panel reactive antibodies (cPRA) >=99.90% (indicating active candidates on kidney transplant waitlist) received isatuximab 10 milligrams per kilogram (mg/kg), intravenous (IV) infusion, once weekly (QW) for 4 weeks (i.e., on Day 1, Day 8, Day 15 and Day 22 of Cycle 1) and then every 2 weeks (Q2W) for subsequent treatment cycles (each cycle of 28 days) until unacceptable adverse events (AEs) or participant's decision to stop the treatment (maximum treatment duration: 13 weeks).
89365543|NCT04114071|Experimental|Physical Activity intervention group|Older overweight or obese Black women who participate in the physical activity intervention group will receive a daily text message from the TOSS study for 12 weeks, a Fitbit device plus have access to the Fitbit community option on their Fitbit app as an opportunity for virtual peer support. They will also receive an instruction pamphlet that describes the health benefits of regular physical activity (PA), safety instructions for PA, the national PA guidelines for older adults, suggested strategies to increase number of steps and an accelerometer pre and post-intervention.
88836572|NCT04294459|Experimental|Cohort B: Participants with cPRA 80.00% to 99.89%|Participants with cPRA between 80.00% to 99.89% (indicating active candidates on kidney transplant waitlist with no living donor cleared for donation) received isatuximab 10 mg/kg, IV infusion, QW for 4 weeks (i.e., on Day 1, Day 8, Day 15 and Day 22 of Cycle 1) and then Q2W for subsequent treatment cycles (each cycle of 28 days) until unacceptable AEs or participant's decision to stop the treatment (maximum treatment duration: 13 weeks).
88836573|NCT04268121|Experimental|Phase II|Prospective, open, multi center, one-arm, national phase II study evaluating the benefits in terms of disease-free survival (DFS) at 12 months after the administration of neoadjuvant treatment in patients with localized digestive neuroendocrine carcinomas
89365544|NCT04114071|Active Comparator|Control group|The control will only receive a weekly neutral text message during the 12-week intervention. For this project, a neutral text message is defined as a message that only provides facts about a topic.They will also receive a Fitbit device, an instruction pamphlet that describes the health benefits of regular physical activity (PA), safety instructions for PA, the national PA guidelines for older adults, suggested strategies to increase number of steps and an accelerometer pre and post-intervention
89365545|NCT04095663|Active Comparator|Partial Colectomy|Elective segmental colectomy for diverticular disease involves removal of the segment of colon (most commonly sigmoid and/or left colon) where there has been disease identified by computed tomography imaging or colonoscopy. Elective colectomy usually removes the affected colon along with adjacent segments that have diverticula, with a primary anastomosis performed to reestablish bowel continuity. Most surgeons now perform the procedure using a laparoscopic approach, when possible, and sometimes use a temporary, protective stoma if the re-connection is considered high-risk. The technique for laparoscopic resection is not specified by the protocol (allows for any number of laparoscopic port sites, all incision types, hand-assistance and robotic) with details of the technique recorded. If randomized to elective colectomy, patients will be encouraged to undergo the procedure within 6 weeks of assignment.
89365546|NCT04095663|Active Comparator|Medical Management|"Medical management for diverticular disease has been used for over 30 years and includes a set of interventions, all components of which have been the subject of small, but often positive trials. All patients randomized to medical management or who select it as their treatment in the observational cohort will view a video (provided in English and Spanish) that explains each element of the medical management toolbox: diet and exercise recommendations, fiber supplementation (e.g., augmenting dietary fiber or over the counter fiber supplements), with mesalazine tablets or suppositories, probiotics and rifamycin. In consultation with their physician, they will be recommended to a regimen of diet and exercise and fiber supplementation. Clinicians will be asked to consider rifamycin (dose/frequency) for those with AUD who are not responding to diet and exercise and mesalazine (dose/frequency) for those with lingering symptoms who are not responding to diet and exercise."
89365547|NCT04088760|Experimental|TCRαβ+/CD19+ depleted HSCT|
89365548|NCT04054310|Experimental|Study-gate|Single arm of biopsy naïve participants suspected of having NAFLD or NASH, who have been referred for a liver biopsy as part of routine clinical care
89365549|NCT04051294|Experimental|Intervention group 1: commercial kombucha|8oz
89365550|NCT04051294|Experimental|Intervention group 2: brewed kombucha|8oz
89365551|NCT04051294|Active Comparator|Control group 1: tea|8oz
89365552|NCT04051294|Placebo Comparator|Control group 2: water|8oz
89365553|NCT04049539|Experimental|Treatment (liposome-encapsulated daunorubicin-cytarabine)|Within 14-33 days after the start of previous cycle of chemotherapy, patients receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1 and 3 in the absence of disease progression or unacceptable toxicity.
89365554|NCT03989752|Experimental|Wearable robotic exoskeleton-assisted walking program|Total of 34 training sessions (60 min/session) during 16 weeks (1-3 session/week). Session intensity will be individualized and safely progressed thereafter (standing time, number of steps) to maintain a moderate-to-vigorous intensity (Borg rate of perceived exertion ≥12/20).
89530330|NCT02455843|Placebo Comparator|chemotherapy|In chemotherapy group,patients will be treated with chemotherapy alone（For non-squamous cell lung cancer，patients will be treated with pemetrexed，500mg/m2, d1, ivdrip plus cisplatin 75mg/m2, d1 d2, ivdrip or carboplatin with a area uder the curve of 5 d1 ivdrip. For squamous cell lung cancer，patients will be treated with docetaxel,75mg/m2, d1, ivdrip or gemcitabine 1250mg/m2, d1 d8, novelbine 25mg/m2 d1 d8, ivdrip, paclitaxel 175mg/m2 d1 ivdrip plus cisplatin 75mg/m2, d1 d2, ivdrip or carboplatin with an area under the curve of 5 d1 ivdrip；repeated every 3 weeks and up to 6 cycles are administrated ）
88836574|NCT04268121|Active Comparator|Prospective cohort|Evaluation of DFS at 12 months in patients who underwent surgery and received adjuvant chemotherapy
88836575|NCT04266223|Experimental|Mask-free surface monitoring|Lay in treatment position for 20 minutes with surface monitoring technology activated
88836576|NCT04256512|Experimental|Prevention (Elasto Gel Therapy Mittens and Foot Wraps)|Patients wear Elasto Gel Therapy Mittens and Foot Wraps on both hands and feet 15 minutes prior to each infusion, during the entire infusion, and for 15 minutes after the completion of each infusion during their three months of treatment.
88836577|NCT04254978|Experimental|Bomedemstat|Bomedemstat administered daily for 169 consecutive days
88836578|NCT04252612|Experimental|Cohort 1: Pramlintide 60 mcg twice daily|Participants will self inject Pramlintide 60 mcg twice daily for two weeks prior to surgical resection of tumor.
89365555|NCT03976323|Experimental|Pembrolizumab + Pemetrexed + Platinum Therapy + Olaparib|"For the Induction Phase, participants receive 4 cycles:~Pembrolizumab 200 mg intravenous (IV) on Day 1 of each 21-day cycle (cycles 1 through 4) PLUS Pemetrexed 500 mg/m^2 IV on Day 1 of each 21-day cycle (cycles 1 through 4) PLUS Platinum chemotherapy, investigator's choice: carboplatin area under the curve (AUC) 5 mg/mL/min IV on Day 1 of 21-day cycle (Cycles 1 through 4) OR cisplatin 75 mg/m^2 IV on Day 1 of 21-day cycle (Cycles 1 through 4).~If the participant has a complete or partial response or stable disease to induction therapy, the participant is randomized to maintenance therapy.~For the Maintenance Phase, participants receive Pembrolizumab IV on Day 1 of each 21-day cycle for up to 31 cycles PLUS maintenance oral olaparib 300 mg twice daily. In the Maintenance Phase, the participant continues to receive maintenance olaparib until progressive disease, physician decision or intolerable toxicity."
89365556|NCT03976323|Active Comparator|Pembrolizumab + Pemetrexed + Platinum Therapy + Pemetrexed|"For the Induction Phase, participants receive 4 cycles:~Pembrolizumab 200 mg intravenous (IV) on Day 1 of each 21-day cycle (cycles 1 through 4) PLUS Pemetrexed 500 mg/m^2 IV on Day 1 of each 21-day cycle (cycles 1 through 4) PLUS Platinum chemotherapy, investigator's choice: carboplatin area under the curve (AUC) 5 mg/mL/min IV on Day 1 of 21-day cycle (Cycles 1 through 4) OR cisplatin 75 mg/m^2 IV on Day 1 of 21-day cycle (Cycles 1 through 4). If the participant has a complete or partial response or stable disease to induction therapy, the participant is randomized to maintenance therapy. For the Maintenance Phase, participants receive Pembrolizumab IV on Day 1 of each 21 day-cycle for up to 31 cycles PLUS maintenance pemetrexed IV 500 mg/m^2 on Day 1 of each 21-day cycle. In the Maintenance Phase, the participant continues to receive maintenance pemetrexed until progressive disease, physician decision or intolerable toxicity."
89365557|NCT03969511|Experimental|Direct angio-suite admission|Upon arrival in angio-suite and after neurological examination with scoring NIHSS and pre stroke mRS, and performing the blood sample, patient undergoes rotational CBCT in order to exclude intracerebral hemorrhage and cerebral angiography to confirm proximal arterial occlusion. Mechanical thrombectomy is then performed as well as intravenous thrombolysis in the absence of contraindications.
89365558|NCT03969511|Active Comparator|Standard management|Arrival is in the MRI/CT-scan room or in the emergency department. Directly after neurological examination and blood sample, patient undergoes imaging and then bridging therapy, mechanical thrombectomy or intravenous thrombolysis alone when indicated.
89365559|NCT03966677||P-GHR|Patients with persistent severe pain after groin hernia repair.
89365560|NCT03966677||NP-GHR|Patients without pain after groin hernia repair.
89365561|NCT03966677||NP|Healthy non-operated controls
88836579|NCT04252612|Experimental|Cohort 2: Pramlintide 60 mcg three times daily|Participants will self inject Parmlintide 60 mcg three times daily for two weeks prior to surgical resection of tumor.
88836580|NCT04252612|Experimental|Cohort 3: Pramlintide 120 mcg three times daily|Participants will self inject Parmlintide 120 mcg three times daily for two weeks prior to surgical resection of tumor.
88836581|NCT04251156|Experimental|Semaglutide|Once-weekly injections of gradually increased doses of semaglutide
88836582|NCT04251156|Placebo Comparator|Placebo (semaglutide)|Once-weekly injections of gradually increased doses of semaglutide placebo
88836583|NCT04249986|Active Comparator|The Borg Rating of Perceived Exertion between 17 and 19 lb BPW|Participants will be randomized to both 17 and 19 pounds for the first hike and the alternate condition for the second hike. A random number generator will create 1 block that includes 10 participants in each block to ensure comparable numbers to subjects starting at different base backpack weight. Participants assignments will then be included in a sealed manila envelopes.
88836584|NCT04249986|Active Comparator|The Borg Rating of Perceived Exertion between 19 and 17 lb BPW|Participants will be randomized to both 19 or 17 pounds for the first hike and the alternate condition for the second hike. A random number generator will create 1 block that includes 10 participants in each block to ensure comparable numbers to subjects starting at different base backpack weight. Participants assignments will then be included in a sealed manila envelopes.
88836585|NCT04243330|No Intervention|Implementation as Usual|Implementation support consisting of clinical decision support tools, trainings, technical assistance and quality assurance to support implementation of VA Suicide Risk Identification Strategy. Available to all facilities.
88836586|NCT04243330|Experimental|Audit and Feedback|Audit and Feedback will serve as the first stage implementation intervention for sites that do not meet the benchmark for adequate implementation following 9 months of implementation as usual.
88836587|NCT04243330|Experimental|External Facilitation|Audit and Feedback plus External Facilitation will serve as the second stage implementation intervention for sites that still do not meet the benchmark for adequate implementation following 9 months of implementation as usual plus audit and feedback.
88836588|NCT04226742|Experimental|Treatment|Participants randomly assigned to this condition will receive the ADAPT platform (treatment) for a treatment period of 8 weeks.
88836589|NCT04226742|Active Comparator|Control|Participants randomly assigned to this condition will receive a similar self-guided platform (control) for a treatment period of 8 weeks.
88836590|NCT04223934|Experimental|optima4BP|"Treating physicians receive periodic (every 5-8 weeks) medication treatment recommendations intended to optimize the current patient treatment.~The recommendations are generated based on periodic remote data collected from the patient and from the Electronic Health Record. The analysis of the data allows assessment of the patient's response to current treatment and need for a treatment optimization. If a treatment optimization is needed, one is generated and sent to the treating physician for consideration."
88836591|NCT04223934|No Intervention|Standard of Care (SOC)|The treating physician follows usual care practices.
88836592|NCT04223882|Experimental|Group Intervention- Management of stress|Patients in the intervention group will receive usual medical care and more stress management intervention. Stress management with cognitive behavioral techniques will be implemented one month after hospital discharge in the intervention group. Group sessions will be held between 6-9 people. There will be 3 1-hour meetings for 3 weeks. The intervention will be performed by psychologist.
88836593|NCT04223882|Active Comparator|Group Control|Patients in the control group will receive usual medical care.
88836594|NCT04210505|Experimental|Nasal Povidone-Iodine Decolonization Intervention|Intranasal povidone-iodine (3M Skin and Nasal Antiseptic) will be applied to the patients' noses at each hemodialysis session.
89365562|NCT03960307||Septic patients|ICU patients with resuscitated sepsis, based on the sepsis-3 criteria. (n=30)
89365563|NCT03960307||Healthy controls|Apparently healthy controls (n=10)
89365564|NCT03908879|Experimental|Intraosseous (IO) catheter placement confirmation methods|All patients will undergo all three confirmation methods/procedures. Method 1 is a triage test and an index test. Method 2 is an index test. Method 3 is a reference standard. None of the procedures being performed in this study are regulated by the United States Food and Drug Administration.
89365565|NCT03826628|Experimental|0.5% Rapamycin cream, topical|Rapamycin cream topical, 0.5% w/w, applied once daily before bed on affected area for 26 weeks
89365566|NCT03826628|Experimental|1.0% Rapamycin cream, topical|Rapamycin cream topical, 0.5% w/w, applied once daily before bed on affected area for 26 weeks
89365567|NCT03826628|Placebo Comparator|Placebo|Placebo cream topical, applied once daily before bed on affected area for 26 weeks
89365568|NCT03813238|Experimental|TEV-50717|administered as oral tablets at a starting dose of 6 mg once daily
88836595|NCT04210505|No Intervention|Concurrent Control|Standard of Care. This will be usual care at each hemodialysis center.
88836596|NCT04194528|Experimental|Oxycodone/acetaminophen (5/325 mg) DMP|The intervention is the Proteus digital medicine program consisting of a mobile application, a patch worn on the body, and oxycodone/acetaminophen 5/325 mg co-encapsulated with ingestible sensors. The duration of the intervention is 6 weeks.
88836597|NCT04192006|Active Comparator|Conventional|Jig-based procedure
88836598|NCT04192006|Experimental|Robotic arm-assist|Mako robotic-arm assist based procedure
88836599|NCT04189614|Experimental|Cofetuzumab Pelidotin|Participants will receive 2.8mg/kg of cofetuzumab pelidotin by IV every 3 weeks
89365569|NCT03813238|Placebo Comparator|Placebo|Matching placebo
88836600|NCT04181632|Active Comparator|Shot Blocker|The three interventional groups are currently marketed distraction devices. Arm 1 will be Shot Blocker® Number 1-25 (RED).
89365570|NCT03810482|Experimental|The study population|"The study population as described by eligibility criteria.~Intervention: 6 minute walking test Intervention: pedometer"
89365571|NCT03782493|Experimental|Enhanced Milieu Teaching-Sentence Focus|The study intervention is a behavioral intervention which will include individually teaching caregivers to use the intervention strategies from the Enhanced Milieu Teaching-Sentence Focus (EMT-SF) intervention using a manualized protocol (Teach-Model-Coach-Review). Caregivers will participate in 66 intervention sessions across 18 months, targeting vocabulary and grammar as well as the transition to decontextualized language.
89365572|NCT03782493|No Intervention|Business-as-usual control|Caregivers in the control group will participate in community-based intervention services and receive the same printed intervention instructions, books, and toys at the same intervals as the treatment group, but will not receive EMT-SF intervention.
89365573|NCT03772028|No Intervention|conventional surgery|Primary cytoreductive surgery without HIPEC
89365574|NCT03772028|Experimental|HIPEC|Primary cytoreductive surgery with HIPEC with cisplatin
89365575|NCT03770390|Other|The study population|"Patients included in this study have pectus excavatum. The have either already undergone corrective surgery during the four years prior to the inclusion period, or are scheduled for surgery during the inclusion period.~Intervention: Surgical correction of pectus excavatum"
88836601|NCT04181632|No Intervention|Control Group|The control group is the current clinical standard of care option for pre-allergy injection application. Ethyl Chloride/Pain Ease Spray Number 76-100 (YELLOW).
88836602|NCT04181632|Active Comparator|Buzzy I|The three interventional groups are currently marketed distraction devices. Arm 2 will be Buzzy® I (vibrating only) Number 26-50 (GREEN).
88836603|NCT04181632|Active Comparator|Buzzy II|The three interventional groups are currently marketed distraction devices. Arm 3 will be Buzzy® II (vibrating and ice wings) Number 51-75 (BLUE).
88836604|NCT04179396|Experimental|Arm A: Oral rucaparib and enzalutamide|
88836605|NCT04179396|Experimental|Arm B: Oral rucaparib and abiraterone|
88836606|NCT04174144||TLIF group|Participants with degenerative spondylolysthesis who underwent a single-level TLIF procedure.
88836607|NCT04163094|Experimental|Treatment arm|Patients will receive 8 W_ova1 vaccinations before and during neoadjuvant chemotherapy and adjuvant chemotherapy.
88836608|NCT04158440|Experimental|4cycles(Toripalimab IV 240mg + platinum-based doublet chemotherapy)+13 cycles(Toripalimab IV 240mg)|Participants receive totally 4 cycles of Toripalimab combined with platinum doublet chemotherapy during perioperative period ;After surgery, participants receive consolidation therapy of Toripalimab
88836609|NCT04158440|Active Comparator|4cycles(Placebo + platinum-based doublet chemotherapy)+13 cycles(Placebo )|Participants receive totally 4 cycles of Placebo combined with platinum doublet chemotherapy during perioperative period ;After surgery, participants receive consolidation therapy of Placebo
89365576|NCT03769506|Experimental|ASP-1929 Photoimmunotherapy|Use of ASP-1929 Photoimmunotherapy
89365577|NCT03769506|Active Comparator|Physician's Choice SOC|docetaxel, cetuximab, methotrexate, paclitaxel
88836610|NCT04154267|Experimental|Intervention|In addition to the routine evaluation commonly carried-out at this post-transplant period, protocol biopsies will be performed at the 10th-week post-transplantation in high-risk transplant recipients. Biopsy fragments will be evaluated for tissue immune aggression (mainly cellular and antibody-mediated rejections) and other conditions such as infections, particularly polyomavirus and cytomegalovirus and medication toxicities.
88836611|NCT04154267|No Intervention|Control|Patients will only undergo routine noninvasive evaluation at this post-transplant period
88836612|NCT04146012|Active Comparator|Early Access|Artegraft® Collagen Vascular Graft™ (Artegraft) will be accessed in less than 72 hours after implantation.
88836613|NCT04146012|Active Comparator|Normal Access|Artegraft® Collagen Vascular Graft™ (Artegraft) will be accessed after 10 days as per current IFU.
88836614|NCT04138030|Active Comparator|Conventional Endoscopic Mucosal Resection|Conventional Endoscopic Mucosal Resection (EMR), if necessary, to 15-40mm laterally spreading adenomas.
88836615|NCT04138030|Active Comparator|Cold Snare Endoscopic Mucosal Resection|Cold Snare Endoscopic Mucosal Resection (EMR), if necessary, to 15-40mm laterally spreading adenomas.
89365578|NCT03740165|Experimental|Pembrolizumab + Olaparib|Participants receive carboplatin/paclitaxel via intravenous (IV) infusion for five 3-week cycles PLUS pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for up to 35 cycles PLUS olaparib 300 mg via oral tablet twice each day (BID), starting with Cycle 7. Participants who experience severe hypersensitivity reaction to paclitaxel or an AE requiring discontinuation of paclitaxel may receive docetaxel (75 mg/m^2 Q3W) plus carboplatin AUC 5 Q3W after Sponsor consultation. Participants may also receive bevacizumab via IV infusion on Day 1 of each 3-week cycle at the Investigator's discretion.
89365579|NCT03740165|Experimental|Pembrolizumab + Placebo for Olaparib|Participants receive carboplatin/paclitaxel via IV infusion for five 3-week cycles starting in Cycle 1 PLUS pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for up to 35 cycles PLUS placebo for olaparib via oral tablet BID, starting with Cycle 7. Participants who experience severe hypersensitivity reaction to paclitaxel or an AE requiring discontinuation of paclitaxel may receive docetaxel (75 mg/m^2 Q3W) plus carboplatin AUC 5 Q3W after Sponsor consultation. Participants may also receive bevacizumab via IV infusion on Day 1 of each 3-week cycle at the Investigator's discretion.
89365580|NCT03740165|Active Comparator|Placebo for Pembrolizumab + Placebo for Olaparib|Participants receive carboplatin/paclitaxel via IV infusion for five 3-week cycles PLUS placebo for pembrolizumab (normal saline or dextrose) via IV infusion on Day 1 of each 3-week cycle for up to 35 cycles PLUS placebo for olaparib via oral tablet BID, starting with Cycle 7. Participants who experience severe hypersensitivity reaction to paclitaxel or an AE requiring discontinuation of paclitaxel may receive docetaxel (75 mg/m^2 Q3W) plus carboplatin AUC 5 Q3W after Sponsor consultation. Participants may also receive bevacizumab via IV infusion on Day 1 of each 3-week cycle at the Investigator's discretion.
89365581|NCT03737240|Experimental|IDegLira|Participants in this group will receive IDegLira (with metformin, unless contraindicated) for 26 weeks.
89365582|NCT03737240|Active Comparator|Basal-Bolus Insulin|Participants in this group will receive basal-bolus insulin (with metformin, unless contraindicated) for 26 weeks. The basal-bolus insulin regimen includes Insulin Degludec (U-100) and Insulin Aspart.
89365583|NCT03733717|Experimental|Isatuximab|Administered intravenously every week in Cycle 1 (4 weeks) followed by every 2 weeks (Q2W) in subsequent cycles.
89365584|NCT03692312|Experimental|Tideglusib|Weight adjusted tideglusib, orally, once daily
89365585|NCT03692312|Placebo Comparator|Placebo|Matching placebo, orally, once daily
89365586|NCT03639051|Experimental|Active Treatment|Target Lung Denervation (TLD) with the Nuvaira Lung Denervation System (RF energy delivered) and optimal medical care for COPD.
88836616|NCT04136223||RA-ILD|"Consecutive adult patients (aged >18 years) with RA* and interstitial lung disease~*in accordance with the American College of Rheumatology (ACR) classification criteria of 2010"
88836617|NCT04124185||Patients with Achromatopsia|
89365587|NCT03639051|Sham Comparator|Sham Control|Sham Targeted Lung Denervation (TLD) procedure with the Nuvaira Lung Denervation System (catheter placement and balloon deployment in all treatment locations, no RF energy delivered) and optimal medical care for COPD.
89365588|NCT03632044|Experimental|Suprazygomatic maxillary nerve blockade|A single injection into the pterygopalatine fossa bilaterally of 0.2% ropivacaine at a dose of 0.15 mL/kg (block) after the induction of general anesthesia.
89365589|NCT03632044|Sham Comparator|25 Gauge needle|Subcutaneous placement of a 25 Gauge needle as a sham comparator after the induction of general anesthesia. Nothing will be injected.
89530331|NCT04761887|Experimental|Cool Block|Ropivacaine administered at approximately 4C, via a TAP block.
88836618|NCT04117035|Placebo Comparator|Control arm|Standard care
88836619|NCT04117035|Experimental|Intervention|
88836620|NCT04111978|Experimental|Letrozole (aromatase inhibitor)|Letrozole, 2.5 mg Femara tablet, administered once daily for 5 years or until symptoms of toxicity or progression of underlying disease
88836621|NCT04111978|Placebo Comparator|Placebo|Placebo tablet of Femara (without aromatase inhibitor), 0 mg Femara tablet, administered once daily for 5 years or progression of underlying disease
88836622|NCT04105543|Experimental|CLR 131 Dose Escalation|"Enrollment will start at dose level 1 (first 4 participants). Participants will receive 2 doses of CLR 131 intravenously with the first dose on day 1 followed by the second dose on day 8.~Dose Level -1 (de-escalation dose, if toxicities warrant) = 12.5 mCi/m^2 Dose Level 1 (beginning dose) = 15.6 mCi/m^2 Dose Level 2 (escalation dose) = 18.75 mCi/m^2~Dose escalation will proceed with no limiting toxicities at each level (maximum of 8 participants at each dose level). With maximum tolerated dose confirmed, an expansion phase will proceed."
88836623|NCT04096014|Active Comparator|Ensure Enlive|
88836624|NCT04096014|Placebo Comparator|Standard of Care|
88836625|NCT04095923|Experimental|Social media game|Private Facebook group with weekly walking challenges, Fitbit wearable activity monitor, and brief counseling
88836626|NCT04095923|Active Comparator|Standard self-regulation|Fitbit wearable activity monitor and brief counseling
88836627|NCT04085458|Other|Severe hemophilia A patients|Prophylactic treatment regimens should be guided by clinical judgement based on individual patient characteristics and treatment response.
89365590|NCT03617198|Experimental|Cohort 1|Cohort 1 subjects will begin treatment interruption approximately 24 hours after they receive the modified T-cells. All other study procedures are the same as Cohort 2.
89365591|NCT03617198|Experimental|Cohort 2|Cohort 2 subjects will begin treatment interruption approximately 8 weeks after they receive the modified T-cells. All other study procedures are the same as Cohort 1.
89365592|NCT03601728|Experimental|Enhanced Monitoring Program|Four weeks prior to the scheduled (elective) surgery, participants will receive a 60-minute in person education session how to increase the level of physical activity. This will be followed by 4 weeks of keeping this level of physical activity, which will be monitored and supported by personalized interactive prompts delivered by a smartwatch. This approach is called personalized prehabilitation.
89365593|NCT03601728|No Intervention|Regular Monitoring Program|Participants randomized to this arm will receive standard perioperative care.
89365594|NCT03553875|Active Comparator|Memantine|Memantine administered in tablet form twice daily titrated to a maximum dose of 20 mg for 12 weeks.
89365595|NCT03553875|Placebo Comparator|Placebo|Subjects in the placebo control group will receive a matched placebo pill with no active ingredients. This will be administered twice daily for 12 weeks.
89365596|NCT03535324|Experimental|PROA for optimization|Development of a Program for optimizing the use of antibiotics (PROA) in Spanish (Antimicrobial Stewardship Program, ASP, in English), based on Reinforcement, Guidance and Support Programs, to prescribing physicians for the optimization of antimicrobial use based on a non-tax counseling program and evidence-based recommendations. The intervention will be carried out at the cluster level (group of patients belonging to a specific hospital service that meet the inclusion criteria). The intervention will consist in carrying out the audit with recommendation on days 3 and 5-7 after the extraction of negative blood cultures to assess the possibilities of de-escalation, sequential oral therapy and end of early treatment based on the available evidence.
89365597|NCT03535324|Other|Control|There will be no intervention.
89365598|NCT03532178|Experimental|Group A|rocuronium + sugammadex / succinylcholine + normal saline
89365599|NCT03532178|Experimental|Group B|succinylcholine + normal saline / rocuronium + sugammadex
88836628|NCT04077580|Experimental|Methenamine hippurate|Tablets containing 1 g methenamine hippurate, dosage 1 tablet morning and evening.
88836629|NCT04077580|Placebo Comparator|Placebo|Placebo tablets containing 1 g of lactose, with identical size, shape and stamps
88836630|NCT04076618|Experimental|Weight Loss plus Vest|
88836631|NCT04076618|Active Comparator|Weight Loss Plus Resistance Exercise Training|
88836632|NCT04076618|Active Comparator|Weight Loss|
88836633|NCT04069884|Experimental|Arm I (Clinical low-risk, RecurIndex high-risk)|Regional nodal irradiation (RNI) was given along with whole breast irradiation (WBI) or Chest wall irradiation (CWI) for breast-conserving patients and total mastectomy patients, respectively.
88836634|NCT04069884|Active Comparator|Arm II (Clinical low-risk, RecurIndex high-risk)|No Regional nodal irradiation (RNI) , whole breast irradiation (WBI) for breast-conserving patients and No Chest wall irradiation (CWI) for total mastectomy patients.
88836635|NCT04055792|Experimental|Sintilimab combine with Anlotinib|Sintilimab 200 mg on day 1 and oral daily Anlotinib 12 mg on days 1-14 once every 3 weeks
88836636|NCT04048512||Resection with intraoperative ECMO/CPB|Patients suffering of neoplastic thoracic disease, undergoing thoracic resection with intraoperative use of Extra Corporeal Membrane Oxygenator (ECMO) or Cardio Pulmonary By pass (CPB)
88836637|NCT04048512||Resection without intraoperative ECMO/CPB|Patients suffering of neoplastic thoracic disease, undergoing thoracic resection without intraoperative use of Extra Corporeal Membrane Oxygenator (ECMO) or Cardio pulmonary By Pass (CPB)
88836638|NCT04038645|Active Comparator|Experimental Group (laser)|"The patients (n=18) will receive infrared LEDs in 6 points (3 on the right side and 3 on the left side) using a mask developed for the research . The irradiations will be performed with red LED ( wavelength = 660 nm) with output power of 100 milliwatt (mW) . The LED light outputs will be positioned in direct contact with the skin. During application of the LED both patient and operator will wear goggles.~The red diode laser will be used. The power of the device is 100 mW and the wavelength used was 660nm (± 10nm). The diameter of the fiber optic of the apparatus has 600 μm, therefore a spot (area) of 0.002826cm2. The energy delivered per point is 1 Joule. 10 seconds of application is required. As 6 points are irradiated, the total energy delivered is 6 Joules. The energy density is 354 J / cm2 and the power density would be 35.4 W / cm2. The points will be determined by the same operator, obeying the protocol."
88836639|NCT04038645|Placebo Comparator|Control group (Placebo)|The patients (n=18) will receive the LED at the same points recommended for the experimental group, but will be off. So that the patient does not identify the sound of activation of the device (beep), it will be recorded, and connected at the time of the application of the laser. The questionnaire to assess the impact of treatment on quality of life will be applied at baseline and after 8 days (by the same evaluator), as well as the evaluation of serum CRP.
88836640|NCT04037826|Experimental|L. reuteri Gastrus|L. reuteri Gastrus (L. reuteri DSM 17938 and L. reuteri ATCC PTA 6475)
88836641|NCT04037826|Placebo Comparator|Placebo|Placebo chewable tablets
89178748|NCT05542290|Other|Without capsular tension ring implantation|We performed phacoemulsification lens extraction and intraocular lens implantation without capsular tension ring implantation combined with goniosynechialysis.
88836642|NCT04036539|Placebo Comparator|Control (placebo)|Patients in Control will receive the photobiomodulation placebo,application, but with the laser off. Procedures will be performed immediately after the application of forces (placement of elastic bandages) on the tooth, as described: Simulations will be performed with the same laser.This will require 10 seconds of application simulation per point. As 10 points will be simulated, it will take 100 seconds for this simulation.5 points lingual and 5 points at vestibular
88836643|NCT04036539|Experimental|Experimental:|Experimental: Molar verticalization + PBM (n = 17 + 3) - patients will receive laser treatment (photobiomodulation) in order to modulate orthodontic movement and act on inflammation and pain. The procedures will be performed immediately after the application of forces (placement of elastic bandages) on the tooth, as described:The irradiations will be performed with the red diode laser ( = 660 nm) with 100 milliwatts output power The power of the device will be 100miliWatts and the wavelength used will be 808 nanometers (± 10nm). The optical fiber diameter of the device is 600 micrometer, therefore a spot (area) of 0.002826 centimeter2. The energy delivered per point will be 1Joule. This will require 10 seconds of application per point. As 10 points will be irradiated, the total application time will be 100 seconds and the total energy delivered will be 10Joule. The energy density will be 25 Joule / cm2 and the power density will be 35.38 Watt / cm2
88836644|NCT04033159|Experimental|cohort 1|DYN101 in a low dose (1.5 mg/kg), (unless the independent data monitoring committee [IDMC] advises otherwise). In each cohort, there will be 3-4 subjects with a mutation in DNM2 (subcohort a) and 2-3 subjects with a mutation in MTM1 (subcohort b).
89365600|NCT03526549|Experimental|CCH-aaes Treatment in Parent Studies (EN3835-302/303)|Participants who received CCH-aaes treatment in EN3835-302/303 were followed for 180 days of observation with no treatment. Participants who were identified as received CCH-aaes in the parent studies following the 180-day Observation Phase and entered the Open-label Phase of the study. Participants in the Open-label Phase who qualified for, and opted for, retreatment were administered CCH-aaes up to 1.68 mg at 3 treatment sessions, at 21-day intervals.
88836645|NCT04033159|Experimental|cohort 2|DYN101 in a middle dose (4.5 mg/kg), (unless the IDMC advises otherwise). In each cohort, there will be 3-4 subjects with a mutation in DNM2 (subcohort a) and 2-3 subjects with a mutation in MTM1 (subcohort b).
88836646|NCT04033159|Experimental|cohort 3|DYN101 in a high dose (9 mg/kg), (unless the IDMC advises otherwise). In each cohort, there will be 3-4 subjects with a mutation in DNM2 (subcohort a) and 2-3 subjects with a mutation in MTM1 (subcohort b).
88836647|NCT04008407|Active Comparator|ESD|Lesion with overt stigmata of SMIC or those with high risk (=> 10%) for covert SMIC.
88836648|NCT04008407|Active Comparator|EMR|Lesion with no overt or a low risk for (<10%) for covert SMIC
88836649|NCT04001062|Active Comparator|Non-operatively|"Adults 18 and older~Native English-speaker~Non-thumb isolated single metacarpal shaft closed fracture (both scissoring and non-scissoring injuries)"
88836650|NCT04001062|Active Comparator|Surgical|"Adults 18 and older~Native English-speaker~Non-thumb isolated single metacarpal shaft closed fracture (both scissoring and non-scissoring injuries)"
88836651|NCT04000360|Experimental|High-Intensity Exercise Group|Mild to moderate Parkinson's disease patients: The exercise group will be asked to cycle 3x/week for 12 months on a Peloton bicycle which will be delivered to their home.
88836652|NCT04000360|No Intervention|Usual and Customary Care Group|Mild to moderate Parkinson's disease patients, receiving no exercise intervention through the research. They will continue to receive usual and customary care for their Parkinson's disease during the 12 month period.
88836653|NCT03996915|Experimental|experimental PDT group|G1-20 patients Photodynamic therapy with methylene blue as photosensitizer device irradiation with low intensity laser (wave length = 660 nm) 9 J (Joules) per point (6 points) and radiant 90 seconds. Photosensitiser (PS) will be applied in sufficient quantity to cover the middle third and back of the tongue and wait for 5 minutes.Six points with the distances of 1 cm between them will be irradiated.
88836654|NCT03996915|Active Comparator|control tongue scrapper group|G2-20 patients Tongue scrapping will be performed by the same operator in all patients. Posterior -anterior movements will be performed with the scrapper over the lingual dorsum in order to promote the mechanical removal of tongue coating
88836655|NCT03995927||Data collection/questionnaire|Data collection for patient medical charts and patient fill out questionnaires first visit and post-treatment visits
88836656|NCT03977259|No Intervention|Standard fortification|Standard of care fortification with multicomponent human milk fortifier (24 kcal/oz) and liquid protein (0.27 g/dL); additional protein and/or calories added only for growth faltering.
88836657|NCT03977259|Experimental|Individually targeted fortification|"Standard of care fortification plus extra protein and/or calories to ensure that base milk has protein 1 g/dL and calories 67/dL."
88836658|NCT03974217|Experimental|Talazoparib Part I|"Talazoparib is administered orally on a daily basis~Hydroxyurea is allowed for up to two cycles per institutional guidelines"
88836659|NCT03974217|Experimental|Talazoparib + Decitabine Part II|"Talazoparib is administered orally on a daily basis~Hydroxyurea is allowed for up to two cycles per institutional guidelines~Decitabine on days 1-5"
88836660|NCT03973684|Active Comparator|aPDT group|G1- 40 patient 40 patients will be included in this group. One section of Pdt will be performed with the photosensitizer (PS). PS will be applied in sufficience quantity to cover the middle third and back of the tongue and wait for 5 minutes.six points with the distances of 1 cm between them will be irradiated. The apparatus shall be precalibrated at wavelength 660nm for 90 seconds per point.
88836661|NCT03973684|Experimental|experimental tongue scrapper group|40 patients will be included in this group. Tongue scrapping will be performed by the same operator in all patients. Posterior -anterior movements will be performed with the scrapper over the lingual dorsum. in order to promote the mechanical removal of tongue coating
88836662|NCT03971045|Experimental|Pembrolizumab and metronomic cyclophosphamide|.Patients will be treated with pembrolizumab administered as an intravenous infusion at 200 mg in 21-day treatment cycles and oral cyclophosphamide (CTX) 50 mg per day in metronomic administration as a 21 days cycle
89365601|NCT03526549|Other|Placebo Treatment in Parent Studies (EN3835-302/303)|Participants who received placebo in the parent studies, were followed for 180 days of observation with no treatment. After Day 180, all participants who received placebo during the double-blind parent studies were discontinued. No treatment was administered.
89365602|NCT03519997|Experimental|Pembro + Bavi|Pembrolizumab 200 mg IV every 3 weeks plus, Bavituximab 3mg/kg IV weekly
88836663|NCT03969888|Experimental|ABBV-3067 50 mg + Placebo for ABBV-2222|Participants received ABBV-3067 50 mg tablet orally once daily (QD) plus placebo matching ABBV-2222 capsule, orally QD for 28 days.
88836664|NCT03969888|Experimental|ABBV-3067 150 mg + Placebo for ABBV-2222|Participants received ABBV-3067 150 mg tablet orally QD plus placebo matching ABBV-2222 capsule, orally QD for 28 days.
88836665|NCT03969888|Experimental|ABBV-3067 150 mg + ABBV-2222 10 mg|Participants received ABBV-3067 150 mg tablet orally QD plus ABBV-2222 10 mg capsule orally QD for 28 days.
88836666|NCT03969888|Experimental|ABBV-3067 150 mg + ABBV-2222 30 mg|Participants received ABBV-3067 150 mg tablet orally QD plus ABBV-2222 30 mg capsule orally QD for 28 days.
88836667|NCT03969888|Experimental|ABBV-3067 150 mg + ABBV-2222 100 mg|Participants received ABBV-3067 150 mg tablet orally QD plus ABBV-2222 100 mg capsule orally QD for 28 days.
88836668|NCT03969888|Experimental|ABBV-3067 150 mg + ABBV-2222 200 mg|Participants received ABBV-3067 150 mg tablet orally QD plus ABBV-2222 200 mg capsule, orally QD for 28 days.
88836669|NCT03969888|Experimental|ABBV-3067 150 mg + ABBV-2222 300 mg|Participants received ABBV-3067 150 mg tablet orally QD plus ABBV-2222 300 mg capsule, orally QD for 28 days.
88836670|NCT03969888|Placebo Comparator|Placebo for ABBV-3067 + Placebo for ABBV-2222|Participants received placebo matching ABBV-3067 tablet orally QD plus placebo matching ABBV-2222 capsule, orally QD for 28 days.
88836671|NCT03966716|Experimental|Arthroplasty|Arthroplasty, hemi or total depending on patient characteristics and surgeon's choice
88836672|NCT03966716|Active Comparator|Internal Fixation|Internal fixation with 2-3 screws or pins, or sliding hip screw device, depending on each hospital's routine
88836673|NCT03960983|Experimental|Elderly pacients with complete dentures and Tongue Scraper|Treatment with tongue scraper (n = 20). The participants will be submitted to hygiene procedures for the mucosa and dentures. The evaluation of repeated before these steps
88836674|NCT03960983|Active Comparator|Elderly pacients with complete dentures and PDT|Treatment with Photodynamic therapy (n = 20). The participants will be submitted to hygiene procedures for the mucosa and dentures. The evaluation of halitosis and the microbiological analysis will be repeated before these steps
89365603|NCT03511976|No Intervention|Business as Usual (BAU)|One-third of participants will be assigned to this condition and will receive academic accommodations and interventions as deemed appropriate by their teachers, school personnel, and parents. This condition is intended to mirror current standard procedures for youth with ADHD. Thus, the specific accommodations and interventions are expected to vary across students. Some students' parents and physicians may choose to start stimulant medication with a goal of improving classroom performance.
89365604|NCT03511976|Experimental|Response to Intervention (RTI): Tier 1|Two-thirds of participants will be assigned to the RTI Tier 1 Arm. Teachers of students in this arm will receive consultation in RTI Tier 1 Classroom Management strategies.
89365605|NCT03511976|Experimental|RTI: Daily Report Card (DRC)|Students assigned to the RTI Tier 1 Arm, who do not respond to the initial RTI Tier 1 Classroom Management strategies, will move to the RTI DRC Arm of the study. Teachers of students in this arm of the study will receive consultation to implement a daily report card.
89365606|NCT03511976|Experimental|RTI: Enhanced|Half of students in the RTI DRC Arm who do not respond to the DRC intervention will be randomly assigned to the RTI: Enhanced Arm. Students in this arm will receive a more intensive classroom behavioral intervention directed at individual target behaviors through an enhanced DRC.
89365607|NCT03511976|Experimental|Medication|Half of students in the RTI DRC Arm who do not respond to the DRC intervention will be randomly assigned to the Medication arm and will receive stimulant medication as an additional intervention.
89365610|NCT03452111|Experimental|Nestorone (NES) + testosterone (T) combined gel|A combination Gel with Nestorone® (NES) and Testosterone (T) applied transdermally (NES/T gel). The amount of gel to be applied daily will be approximately 5 mL in volume (2.5 mL to each shoulder and upper arm per day).
89365611|NCT03449901|Experimental|Cohort 1: ADI-PEG 20 + Gemcitabine + Docetaxel|"ADI-PEG 20 will be given on Day -7 of Cycle 1 and then on Days 1, 8, and 15 of each subsequent cycle. Cycles are 21 days. ADI-PEG 20 will be given on an outpatient basis at a dose of 36 mg/m2 via intramuscular injection into either the deltoid or gluteal muscle.~Gemcitabine will be given intravenously at a dose of 600 mg/m2 over 90 minutes on Days 1 and 8 of each cycle. Docetaxel will be given intravenously at a dose of 60 mg/m2 over 60 minutes on Day 8 of each cycle. Patients started on gemcitabine at a dose of 900 mg/m2 or 750 mg/m2 or docetaxel at a dose of 75 mg/m2 per previous protocol version will be allowed to continue at that dose level~After Cycle 8, patients may continue on ADI-PEG 20 alone (without gemcitabine and docetaxel) upon request.~Treatment may continue for up to 34 cycles (103 weeks)"
88836675|NCT03952468|Active Comparator|TMS + Brief Cognitive Behavioral Therapy|Combined transcranial magnetic stimulation and brief cognitive behavioral therapy for suicide
88836676|NCT03952468|Sham Comparator|Sham TMS + Brief cognitive behavioral therapy|Sham Transcranial magnetic stimulation and brief cognitive behavioral therapy for suicide
88836677|NCT03942406|Experimental|BPZE1 Intranasal Prime, BPZE1 Boost|Individual will receive an intranasal dose of BPZE1 via the VaxINator atomization device and a dose of intramuscular (I.M.) placebo. Individuals will receive a boost dose of intranasal BPZE1 via the VaxINator™ atomization device.
88836678|NCT03942406|Experimental|BPZE1 Intranasal Prime, Placebo Boost|Individual will receive an intranasal dose of BPZE1 via the VaxINator atomization device and a dose of intramuscular (I.M.) placebo. Individuals will receive a boost dose of intranasal placebo via the VaxINator™ atomization device.
89365612|NCT03449901|Experimental|Cohort 2: ADI-PEG 20 + Gemcitabine + Docetaxel|"ADI-PEG 20 will be given on Day -7 of Cycle 1 and then on Days 1, 8, and 15 of each subsequent cycle. Cycles are 21 days. ADI-PEG 20 will be given on an outpatient basis at a dose of 36 mg/m2 via intramuscular injection into either the deltoid or gluteal muscle.~Gemcitabine will be given intravenously at a dose of 600 mg/m2 over 90 minutes on Days 1 and 8 of each cycle. Docetaxel will be given intravenously at a dose of 60 mg/m2 over 60 minutes on Day 8 of each cycle. Patients started on gemcitabine at a dose of 900 mg/m2 or 750 mg/m2 or docetaxel at a dose of 75 mg/m2 per previous protocol version will be allowed to continue at that dose level~After Cycle 8, patients may continue on ADI-PEG 20 alone (without gemcitabine and docetaxel) upon request.~Treatment may continue for up to 34 cycles (103 weeks)"
89365613|NCT03435380|Experimental|Control (C)|Targeted mailed educational materials (C).
89365614|NCT03435380|Experimental|Patient activation (PA)|C + patient activation (PA) consisting of (1) smartphone app with HIPAA compliant survivorship care plan that can be viewed, printed, or emailed to their primary care provider; and (2) two-way (interactive) tailored text messages with links to video vignettes discussing the primary barriers to breast MRI and mammography.
89365615|NCT03435380|Active Comparator|Patient activation + primary care provider activation (PA+PCP)|C + PA + PCP activation (PA+PCP) with physician materials about breast cancer risk in this population along with national and international guidelines for breast cancer surveillance.
89365616|NCT03428711|Placebo Comparator|Placebo Oral Tablet|Placebo comparator twice-a-day, for 12 months
89365617|NCT03428711|Experimental|Mesoglycan Oral Tablet|"a mixture of glycosaminoglycans (mainly heparan-sulphate, dermatan sulfate), inhibitors of thrombin and of Factor Xa and active in restore flow-mediated vasodilation.~50 mg, twice-a-day, for 12 months"
89365618|NCT03382457|Experimental|Treatment|Treatment with the Edwards Cardioband Tricuspid Valve Reconstruction System
89365619|NCT03379688||Cardiac surgery patients|Patients undergoing cardiac surgery at Charité Campus Mitte
89365620|NCT03363659|Experimental|DSF-Cu with temozolomide and radiation|Disulfiram (DSF; oral) / copper gluconate (Cu; oral) dosed at 125 mg / 2 mg, twice daily. Temozolomide will be administered following the standard Stupp protocol at a dose of 75 mg/m2 for 42 days with concurrent radiation therapy. Temozolomide maintenance dose will be 150 mg/m2 once daily on Days 1-5 of every 28-day cycle while DSF-Cu is continued twice daily, as tolerated, for the duration of the Temozolomide adjuvant treatment. Patients demonstrating continued benefit from the adjuvant temozolomide after 6 cycles can continue treatment to a maximum of 12 cycles
89365621|NCT03328078|Experimental|Emavusertib (CA-4948) dose escalation|Part A1: Dose-level cohorts with up to approximately 6 patients each will be used to define the Maximum Tolerated Dose (MTD) for emavusertib.
89365622|NCT03328078|Experimental|Emavusertib (CA-4948) and ibrutinib dose escalation|Part A2: Evaluate escalating dose levels of oral emavusertib in combination with 560 mg daily (QD) of oral ibrutinib. The starting dose of emavusertib to be used in combination will be 200 mg twice a day (BID). It is anticipated that 12 to 20 patients at a potential dose level will be required to establish optimal combination dosing.
89365623|NCT03328078|Experimental|Emavusertib (CA-4948) and ibrutinib dose expansion|In two PCNSL Expansion Cohorts (Part B), emavusertib in combination with ibrutinib will be administered in patients with PCNSL. In Cohort 1, emavusertib 100 mg BID will be administered with ibrutinib 560 mg QD consecutively in a 28-day cycle in approximately 6 to 9 patients. In Cohort 2, CA-4948 200 mg BID will be administered with ibrutinib in at least 9 patients.
89365624|NCT03308877|Experimental|Brief Motivational Intervention (BMI)|
89365625|NCT03308877|Active Comparator|Standard Care (SC)|
89365626|NCT03299166|Experimental|Troriluzole|
89365627|NCT03299166|Placebo Comparator|Placebo|
89365628|NCT03284138|Active Comparator|rTMS treatment|patient will be treated with 10 sessions in 5 days with low frequency (1Hz) of Repetitive Transcranial Magnetic Stimulation (rTMS)
89365629|NCT03284138|Sham Comparator|Placebo treatment|patient will be treated with 10 sessions in 5 days with low frequency (1Hz) of Sham-controlled
89365630|NCT03245593||Shared Decision making for care|
89365631|NCT03245593||Standard decision making for care|
89365632|NCT03204812|Experimental|Treatment (tremelimumab, durvalumab)|Patients receive tremelimumab IV over 60 minutes and durvalumab IV over 60 minutes on day 1. Treatment repeats every 28 days for up to 4 cycles for tremelimumab and up to 13 cycles for durvalumab in the absence of disease progression or unacceptable toxicity.
89365633|NCT03201250|Experimental|Treatment|"Combination of cabozantinib, carfilzomib and dexamethasone~Cabozantinib: patients will receive cabozantinib orally once daily continuously during the four weeks of a 28-day cycle.~Carfilzomib: carfilzomib will be administered intravenously over 10 minutes, on two consecutive days, each week for three weeks (Days 1, 2, 8, 9, 15, and 16), followed by a 12-day rest period (Days 17 to 28). Each 28-day period is considered one treatment cycle.~Dexamethasone: dexamethasone will be administered at 40 mg orally or intravenously on days 1, 8,15 and 22 of each 28-day cycle (for patient age ≥ 75, acceptable to be given as 20 mg orally or intravenously on days 1, 2, 8, 9, 15, 16, 22, 23)"
89365634|NCT03194750|Experimental|Share Data|
89365635|NCT03194750|Active Comparator|Do Not Share Data|
89365636|NCT03181204||Patients likely to develop COPD|"Patients in this group are relatively light smokers who have developed chronic obstructive lung disease (COPD).~Intervention: Bronchial biopsy~Intervention: Skin biopsy~Intervention: Blood sample"
89365637|NCT03181204||Patients not likely to develop COPD|"Patients in this group are heavy smokers who have no signs of chronic obstructive lung disease (COPD).~Intervention: Bronchial biopsy~Intervention: Skin biopsy~Intervention: Blood sample"
89530332|NCT04761887|Active Comparator|Room Temp Block|Ropivacaine administered at approximately 20-25C, via a TAP block.
88836679|NCT03942406|Experimental|Boostrix IM Prime, BPZE1 Boost|Individual will receive an intranasal dose of placebo via the VaxINator atomization device and a dose of intramuscular (I.M.) Boostrix (aP vaccine comparator). Individuals will receive a boost dose of intranasal BPZE1 via the VaxINator™ atomization device.
89365638|NCT03166384|Active Comparator|control group|"For the patients in the control group, surgeon dose not use electrosurgical bipolar sealing device at all and use conventional tie and ligation methods during tissue dissection and vessel ligation.~interventions: 'conventional suture and tie'"
88836680|NCT03942406|Active Comparator|Boostrix IM Prime, Placebo Boost|Individual will receive an intranasal dose of placebo via the VaxINator atomization device and a dose of intramuscular (I.M.) Boostrix (aP vaccine comparator). Individuals will receive a boost dose of intranasal placebo via the VaxINator™ atomization device.
88836681|NCT03940235|Experimental|Stereotactic body Radiotherapy (SBRT) only|ARM 1: salvage SBRT for lymph nodes and/or bone metastases. All the radiologically documented lesions will be treated simultaneously.
88836682|NCT03940235|Active Comparator|Stereotactic body Radiotherapy (SBRT) and hormonotherapy (ADT)|ARM 2: salvage SBRT (as described for ARM 1) + 6-month ADT (luteinizing hormone-releasing hormone (LHRH) agonist or antagonist). ADT should start within one week before the start of SBRT.
88836683|NCT03939156||Group 1 - before starting ET|women candidate to receive ET and interviewed before starting treatment
88836684|NCT03939156||Group 2 - within 1 year of ET|women interviewed within 1 years from beginning of ET
88836685|NCT03939156||Group 3 - between 4 and 6 years of ET|women interviewed after more than 4 years but no more than 6 years of ET
88836686|NCT03935893|Experimental|Tumor Infiltrating Lymphocytes (TIL)|Patients with locally advanced, recurrent, or metastatic gastric/esophagogastric, colorectal, pancreatic, sarcoma, mesothelioma, neuroendocrine, cutaneous/anal squamous cell, Merkel cell, cancers refractory to systemic therapy, and those with deficient mismatch repair and/or microsatellite instability cancers will receive the lymphocyte depleting preparative regimen consisting of fludarabine and cyclophosphamide, followed by infusion of up to 2x10^11 lymphocytes infused through a central vein catheter and administered at a dose of 600,000 IU/kg (based on total body weight) as an intravenous bolus over a 15-minute period approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to a maximum of 6 doses.
88836687|NCT03927612|Experimental|Alternate Perspective|After experiencing VR scenarios, participants will experience the interactions again from the virtual counterpart's perspective within the VR system.
88836688|NCT03927612|Placebo Comparator|Control Perspective|After experiencing VR scenarios, participants will experience the interactions again from the same perspective in the VR system.
88836689|NCT03924908|Experimental|VRH|Virtual reality hypnosis
88836690|NCT03924908|Active Comparator|VR|Virtual reality
88836691|NCT03916510|Experimental|Dosing schedules 1 to 4|"Dosing Group 1:~- Loading dose pre chemoradiation (CRT) - 1x10^12 viral particles (vp)~Dosing Group 2:~Loading dose pre CRT - 1x10^12 vp~Maintenance dose post CRT - 1x10^12vp~Dosing Group 3:~Loading doses pre CRT - 3x10^12vp~Maintenance dose post CRT - 3x10^12vp~Dosing Group 4:~Loading dose pre CRT - 3x10^12vp~Concurrent doses on Week 1, Day 1 and Day 5 of CRT - 3x10^12vp~Maintenance post CRT - 3x10^12vp"
88836692|NCT03915652|Experimental|Rheum iCMP Wave 1|20 patients enrolled immediately in Rheum iCMP
88836693|NCT03915652|Experimental|Rheum iCMP Wave 2|20 patients enrolled in Rheum iCMP after 4 months; will receive monthly lupus educational materials mailed to their home during the first 4 months
88836694|NCT03915587|Other|Fluid Challenge|After defining fluid responders from non-responders in this single arm prospective trial, we will compare the predictive utility of non-invasive devices such as the CipherOx-CRI and IVC CI to currently employed indices (heart rate, systolic blood pressure, urine output and pulse pressure variability) to gauge the need for additional fluid and ongoing resuscitation.
88836695|NCT03909100|Experimental|CoolSculpting® System|Participants received up to two CoolSculpting® treatment sessions for the abdomen, flanks or both 8 weeks apart. A treatment session was comprised of timed segments of cooling (treatment cycles) followed by 2 minutes of manual massage. Up to 12 cycles per treatment session were performed at the investigator's discretion.
88836696|NCT03901482|Experimental|STS101 Low Dose|STS101 (dihydroergotamine nasal powder), low dose
88836697|NCT03901482|Experimental|STS101 High Dose|STS101 (dihydroergotamine nasal powder), high dose
89365639|NCT03166384|Experimental|study group|"For the patients in the study group, the surgeon uses electrosurgical bipolar sealing device during tissue dissection and vessel ligation as much as possible.~interventions: electrosurgical bipolar sealing devices"
89365640|NCT03025763||Coronal Nonsyndromic Craniosynostosis, trios|Participants with diagnosis of coronal, nonsyndromic craniosynostosis including affected and unaffected biological parents
88836698|NCT03901482|Placebo Comparator|STS101 Placebo|STS101 Placebo
88836699|NCT03896295|Experimental|M281|
88836700|NCT03882723|Experimental|Randomized Crossover Trial with 4 NIV Masks|Order of the masks (BiTrac MaxShield™ with standard elbow, BiTrac™ Full Face with standard elbow, Respironics PerforMax with standard elbow, and Respironics AF531 with standard elbow) were randomly chosen. Investigators randomly assigned all masks for paper raffling from container. All subjects performed 20 minutes on each mask followed by 5 minutes wash out between masks. EPAP levels will be 0, 2, 4, & 5 (5 minutes for each level) while IPAP remains at 5 higher than EPAP. FiCO2 and EtCO2 were collected at 4:00, 4:30 and 5:00 minute mark for each EPAP level. Also, subjective mask comfort was assessed via visual analog scale (VAS) with 1 referring to least comfortable and 5 being the most comfortable after 5 each EPAP setting.
88836701|NCT03861143|Experimental|BT-11 low-dose (440 mg)|Oral, once daily tablet
88836702|NCT03861143|Experimental|BT-11 high-dose (880 mg)|Oral, once daily tablet
88836703|NCT03861143|Placebo Comparator|Placebo|Oral, once daily tablet
89178749|NCT04099758|Experimental|Mindfulness of the breath meditation|10 minute mindfulness of the breath meditation practice delivered online via audio-recording.
89365641|NCT03025763||Coronal, nonsyndromic craniosynostosis|Participants with coronal, nonsyndromic craniosynostosis when biological parents are not available
89365642|NCT03025763||Unaffected controls|Unaffected controls who may have undergone clinically indicated craniofacial surgery for trauma or conditions other than craniosynostosis or bone disease
89365643|NCT02976701|Experimental|DLBS1033|DLBS1033 enteric-coated tablet is administered at the dose of 980 mg (two tablets@490 mg) three times daily, everyday for four weeks of study period
89365644|NCT02976701|Placebo Comparator|Placebo|Placebo is administered two tablets three times daily, everyday for four weeks of study period
89365645|NCT02853305|Experimental|Pembrolizumab + ST Chemotherapy (Pembro Combo)|Participants receive pembrolizumab 200 mg IV on Day 1 of each 3-week cycle for a maximum of 35 doses PLUS standard therapy (ST) chemotherapy with EITHER cisplatin 70 mg/m^2 IV on Day 1 (or Day 2 if required per local guidelines) of each 3-week cycle + gemcitabine IV infusion 1,000 mg/m^2 on Day 1 and Day 8 of each 3-week cycle, OR carboplatin at an area under the curve 5 (AUC 5) (or AUC 4.5 if required per local guidelines) IV on Day 1 (or Day 2 if required per local guidelines) of each 3-week cycle + gemcitabine 1,000 mg/m^2 IV on Day 1 and Day 8 of each 3-week cycle. Eligible participants who stop pembrolizumab with Stable Disease (SD) or better but progress after discontinuation may be able to initiate a second course of pembrolizumab for up to 17 cycles (up to approximately 1 additional year) at the investigator's discretion.
89365646|NCT02853305|Experimental|Pembrolizumab (Pembro)|Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 3-week cycle for a maximum of 35 doses. Eligible participants who stop pembrolizumab with SD or better but progress after discontinuation may be able to initiate a second course of pembrolizumab for up to 17 cycles (up to approximately 1 additional year) at the investigator's discretion.
89365647|NCT02853305|Active Comparator|ST Chemotherapy (Chemo)|Participants receive ST chemotherapy with EITHER cisplatin 70 mg/m^2 IV on Day 1 (or Day 2 if required per local guidelines) of each 3-week cycle + gemcitabine IV infusion 1,000 mg/m^2 on Day 1 and Day 8 of each 3-week cycle OR carboplatin at AUC 5 (or AUC 4.5 if required per local guidelines) IV on Day 1 (or Day 2 if required per local guidelines) of each 3-week cycle + gemcitabine 1,000 mg/m^2 IV on Day 1 and Day 8 of each 3-week cycle.
89365648|NCT02839980||orthopedics (gr1) surgery|parient admitted to the orthopedics (gr1) surgery ward for an elective or semi-emergent surgical procedure.
89365649|NCT02839980||thoracic (gr2) surgery|parient admitted to the thoracic (gr2) surgery ward for an elective or semi-emergent surgical procedure.
89365650|NCT02839980||abdominal (gr3) surgery|parient admitted to the abdominal (gr3) surgery ward for an elective or semi-emergent surgical procedure.
89365651|NCT02839980||ICU (gr4)|patients admitted to the ICU with an antcipated length of stay of 3 days or more
89178750|NCT04099758|Placebo Comparator|Audio-recording control|10 minute non-fiction audio-recording delivered online
89365652|NCT02838927||Hypoparathyroidism|No intervention.
89365653|NCT02815995|Experimental|Adipocytic Tumors Group|"Adipocytic Tumors Group consists of well-diff/de-differentiated, pleomorphic and myxoid LPS.~Age group ≥12 and <18: Dosages of study drugs to be determined (TBD).~Age group ≥ 18: Durvalumab 1500 mg and Tremelimumab 75 mg every 4 weeks for 4 cycles followed by durvalumab 1500 mg every 4 weeks for up to 8 additional cycles.~Combination of both agents administered every 4 weeks for a maximum of 4 doses, after which durvalumab continues as a single agent every 4 weeks till progression or unacceptable toxicity for a maximum of 8 additional doses."
89365654|NCT02815995|Experimental|Vascular Tumors Group|"Vascular Tumors Group consists of leiomyosarcomas, angiosarcomas, epithelioid hemangioendotheliomas, and hemangiopericytomas.~Age group ≥12 and <18: Dosages of study drugs to be determined (TBD).~Age group ≥ 18: Durvalumab1500 mg and Tremelimumab 75 mg every 4 weeks for 4 cycles followed by Durvalumab 1500 mg every 4 weeks for up to 8 additional cycles.~Combination of both agents administered every 4 weeks for a maximum of 4 doses, after which durvalumab continues as a single agent every 4 weeks till progression or unacceptable toxicity for a maximum of 8 additional doses."
89365655|NCT02815995|Experimental|Undifferentiated Pleomorphic Sarcoma Group|"Age group ≥12 and <18: Dosages of study drugs to be determined (TBD).~Age group ≥ 18: Durvalumab 1500 mg and Tremelimumab 75 mg every 4 weeks for 4 cycles followed by Durvalumab 1500 mg every 4 weeks for up to 8 additional cycles.~Combination of both agents administered every 4 weeks for a maximum of 4 doses, after which durvalumab continues as a single agent every 4 weeks till progression or unacceptable toxicity for a maximum of 8 additional doses."
89365656|NCT02815995|Experimental|Synovial Sarcoma Group|"Age group ≥12 and <18: Dosages of study drugs to be determined (TBD).~Age group ≥ 18: Durvalumab 1500 mg and Tremelimumab 75 mg every 4 weeks for 4 cycles followed by durvalumab 1500 mg every 4 weeks for up to 8 additional cycles.~Combination of both agents administered every 4 weeks for a maximum of 4 doses, after which Durvalumab continues as a single agent every 4 weeks till progression or unacceptable toxicity for a maximum of 8 additional doses."
89365657|NCT02815995|Experimental|Osteosarcoma Group|"Age group ≥12 and <18: Dosages of study drugs to be determined (TBD).~Age group ≥ 18: Durvalumab 1500 mg and Tremelimumab 75 mg every 4 weeks for 4 cycles followed by durvalumab 1500 mg every 4 weeks for up to 8 additional cycles.~Combination of both agents administered every 4 weeks for a maximum of 4 doses, after which Durvalumab continues as a single agent every 4 weeks till progression or unacceptable toxicity for a maximum of 8 additional doses."
89365658|NCT02815995|Experimental|Other Sarcomas Group|"Age group ≥12 and <18: Dosages of study drugs to be determined (TBD).~Age group ≥ 18: Durvalumab 1500 mg and Tremelimumab 75 mg every 4 weeks for 4 cycles followed by durvalumab 1500 mg every 4 weeks for up to 8 additional cycles.~Combination of both agents administered every 4 weeks for a maximum of 4 doses, after which Durvalumab continues as a single agent every 4 weeks till progression or unacceptable toxicity for a maximum of 8 additional doses."
89365659|NCT02778529|Other|Upper Limb Assessment on ADLs|Bilateral assessment robots (BiAS) Evaluate upper limb kinematics of Stroke, Amputees, SCI, Cerebral Palsy and Health Subjects will be assessed as they complete unilateral and bilateral activities of daily living. Subjects will complete exercises in 1 session
89365660|NCT02735902|Experimental|vitamin K antagonist or Direct oral anticoagulant treatment|"In this group, patients will receive monotherapy via anticoagulant (AVK or DOAC) excepted rivaroxaban; this treatment given corresponds to the anticoagulant treatment the patient was receiving before surgery. A data collection book for monitoring INR values and dates for the next 12 months is given to the patient.~Intervention: anticoagulant"
89365661|NCT02735902|Active Comparator|vitamin K antagonist or Direct oral anticoagulant + Aspirin|"In this group, patients will receive combination therapy via anticoagulant (AVK or DOAC) and aspirin, whose daily dose is between 75 mg and 100 mg; the anticoagulant treatment administered corresponds to the anticoagulant treatment the patient was receiving before the procedure, monitored and adapted according to current recommendations. A data collection book for monitoring INR values and dates for the next 12 months is given to the patient.~Intervention: anticoagulant Intervention: Aspirin"
89365662|NCT02664701|Active Comparator|Individual supportive therapy|"Patients randomized to this arm will have individual supportive therapy.~Intervention: Baseline evaluation with a psychiatrist~Intervention: Individual supportive therapy~Intervention: Evaluations with a psychiatrist"
89365663|NCT02664701|Experimental|Cognitive behavioural group therapy|"Patients randomized to this arm will have cognitive behavioural therapy.~Intervention: Baseline evaluation with a psychiatrist~Intervention: Cognitive behavioural group therapy~Intervention: Evaluations with a psychiatrist"
88836704|NCT03853317|Experimental|Treatment with avelumab, haNK™ and N-803|The primary objective is to determine the efficacy of the combination treatment of avelumab, haNK, and N-803 in subjects with MCC that has progressed on or after checkpoint inhibitor therapy by objective response rate (ORR) using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) based on Blinded Independent Central Review (BICR).
88836705|NCT03845010|Active Comparator|Sotalol|
88836706|NCT03845010|Active Comparator|Flecainide and verapamil|
88836707|NCT03845010|Active Comparator|Catheter ablation|
88836708|NCT03829371|Experimental|ARM A (enrollment closed)|"Velcade (V):~1.3 mg/m2 subcutaneously on days 1, 4, 8, 11, 22, 25, 29 and 32 in cycles 1-4;~1.3 mg/m2 subcutaneously on days 1, 8, 22 and 29 from cycle 5.~Melphalan (M):~- 9 mg/m2 orally on days 1, 2 3 and 4 of each cycle.~Prednisone (P):~- 60 mg/m2 orally on days 1, 2, 3 and 4 of each cycle. Each cycle is a 42-day cycle. Duration: Maximum 9 cycles can be performed."
88836709|NCT03829371|Experimental|ARM B (enrollment closed)|"Lenalidomide (R):~-25 mg orally on days 1-21 of each cycle.~Dexamethasone (d):~-40 mg orally on days 1, 8, 15 and 22 of each cycle. Each cycle is a 28-day cycle. Duration: until PD or intolerance."
88836710|NCT03829371|Experimental|ARM A2|"Velcade (V):~- 1.3 mg/m2 subcutaneously twice weekly on weeks 1, 2, 4, and 5 of cycle 1 (days 1,4,8,11,22,25,29,32) and once weekly on weeks 1, 2, 4, and 5 of cycles 2 through 9 (days 1,8,22,29).~Melphalan (M):~- 9 mg/m2 orally on days 1, 2, 3 and 4 of each cycle.~Prednisone (P):~- 60 mg/m2 orally on days 1, 2, 3 and 4 of each cycle.~Daratumumab:~-16 mg per kilogram of body weight or 1800 mg Daratumumab subcutaneous (SC) (according to local clinical practice) with oral or intravenous dexamethasone (to manage infusion reactions) at a dose of 20 mg once weekly in cycle 1 (days 1,8,15,22,29,36), every 3 weeks in cycles 2 through 9 (days 1,22), and every 4 weeks thereafter until disease progression or unacceptable toxic effects. Dexamethasone at a dose of 20 mg was substituted for prednisone on day 1 of each cycle."
88836711|NCT03829371|Experimental|ARM B2|"Lenalidomide (R):~- 25 mg orally on days 1-21 of each cycle.~Dexamethasone (d):~- 40 mg orally on days 1, 8, 15 and 22 of each cycle. Each cycle is a 28-day cycles.~Daratumumab:~-intravenous at a dose of 16 mg per kilogram of body weight or 1800 mg Daratumumab subcutaneous (SC) (according to local clinical practice) once weekly during cycles 1 and 2, every 2 weeks during cycles 3 through 6, and every 4 weeks thereafter; preinfusion medications were administered approximately 1 hour before each daratumumab dose."
88836712|NCT03826264||Korea Centers|Seoul, Korea All Patients undergoing TAVR
88836713|NCT03826264||Stanford University|California, USA All Patients undergoing TAVR
89365664|NCT02609464|Active Comparator|Inturrupted Knotte Sutures|
89365665|NCT02609464|Active Comparator|Barbed Sutures|
88836714|NCT03826264||Northwestern University|Evanston, Illinois, USA All Patients undergoing TAVR
88836715|NCT03826264||Cheng-Hsin Hospital|Taipei, Taiwan All Patients undergoing TAVR
88836716|NCT03812874|Experimental|PTX-9908 Injection group|IV injection.
88836717|NCT03812874|Placebo Comparator|Placebo/Vehicle group|IV injection
88836718|NCT03786198|Experimental|a) Home-based walking intervention|Home-based walking intervention, wearing a wrist worn activity tracker, for 24 weeks + standard adjuvant AI therapy
88836719|NCT03786198|Active Comparator|b) Physical activity according to standard recommendations|Physical activity according to standard recommendations, wearing a wrist worn activity tracker (with no feedback about performed activity), for 24 weeks + standard adjuvant AI therapy
88836720|NCT03785964|Experimental|Double-Blind Phase - Nirogacestat|Nirogacestat 150 mg by mouth, twice daily
88836721|NCT03785964|Placebo Comparator|Double-Blind Phase - Placebo|Placebo 150 mg by mouth, twice daily
88836722|NCT03785964|Experimental|Open-Label Phase - Nirogacestat|Nirogacestat 150 mg by mouth, twice daily
89365666|NCT02524275|Experimental|Treatment (docetaxel, capecitabine)|Patients receive docetaxel IV over 1 hour on day 1 and capecitabine PO BID on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
88836723|NCT03783975|Experimental|Simplified Cascade Screening|Free, mail-in, saliva-based screening for the KCNQ1 Thr224Met variant.
88836724|NCT03779230|Experimental|L19TNF|Patients will be assigned to the following increasing dose levels of L19TNF: 10 and 13 μg/kg.
88836725|NCT03743428|Experimental|Apatinib-FOLFIRI|Apatinib Mesylate Tablets 250mg po qd Irinotecan 180 mg/m2 IV over 30-90 minutes,day 1 Leucovorin 400 mg/m2 IV infusion to match duration of irinotecan infusion,day 1 5-FU 400 mg/m2 IV bolus day 1,then 1200 mg/m2/d x 2 days (total 2400 mg/m2 over 46-48 hours) continuous infusion Repeat every 2 weeks.
88836726|NCT03743428|Active Comparator|Bevacizumab-FOLFIRI|Bevacizumab Injection 5mg/kg IV,day 1 Irinotecan 180 mg/m2 IV over 30-90 minutes,day 1 Leucovorin 400 mg/m2 IV infusion to match duration of irinotecan infusion,day 1 5-FU 400 mg/m2 IV bolus day 1,then 1200 mg/m2/d x 2days (total 2400 mg/m2 over 46-48 hours) continuous infusion Repeat every 2 weeks.
88836727|NCT03741582||Control - San Cristobal|"1021 individuals located in an area with no access to the intervention (TransMicable). The control area was defined by a 800-meter buffer around each projected station of the car, San Cristobal was an area with a projected but non financed Cable Car."
88836728|NCT03741582||Intervention - Ciudad Bolviar|1031 individuals who live in the area of influence of TransMiCable. The area of influence of TransMiCable was defined by a 800-meter radial buffer around each station of the cable car.
88836729|NCT03739710|Experimental|Part 1: Participants receiving feladilimab and ipilimumab|
89365667|NCT02509039|Experimental|CC-122|CC-122 is administered orally, on a 5 continuous days out of 7 days per week intermittent dosing schedule.
88836730|NCT03739710|Experimental|Part 1: Participants receiving dostarlimab plus GSK4428859A/EOS884448/belrestotug|
89365668|NCT02499120|Experimental|Palbociclib plus Cetuximab|Palbociclib, 125 mg, orally once daily (QD) with food on Day 1 to Day 21 followed by 7 days off treatment in a 28-day cycle; in combination with Cetuximab, 400 mg/m2 initial dose as a 120-minute IV infusion followed by 250 mg/m2 weekly infused over 60 minutes.
88836731|NCT03739710|Experimental|Part 1: Participants receiving dostarlimab plus GSK4428859A/EOS884448/belrestotug plus GSK6097608|
88836732|NCT03739710|Active Comparator|Part 2: Participants receiving SoC: docetaxel|
88836733|NCT03739710|Experimental|Part 2: Participants receiving feladilimab and docetaxel|
88836734|NCT03734666|Experimental|Mindfulness Based Relapse Prevention|Participants will receive Mindfulness Based Relapse Prevention (MBRP), an existing substance use treatment, which has been modified to focus explicitly on smoking cessation and reduced alcohol use, creating Mindfulness Based Relapse Prevention - Smoking and Alcohol (MBRP-SA).
88836735|NCT03734666|Active Comparator|Cognitive Behavioral Therapy|Participants will receive Cognitive Behavioral Therapy (CBT) a well-established and commonly used treatment for substance abuse behaviors that utilizes problem solving and coping skills.
88836736|NCT03728608|Active Comparator|Group 1--Short Dwell|Premature VLBW (very low birth weight) male and female infants will be randomly assigned to have their feeding tubes removed at 0-48 hours for the first 4 weeks of life.The feeding tube lumen, interluminal liquid and hub will be analyzed for level of contamination.
88836737|NCT03728608|Active Comparator|Group 2--Long Dwell|Premature VLBW (very low birth weight) male and female infants will be randomly assigned to have their feeding tubes removed at 7 days for the first 4 weeks of life.The feeding tube lumen, interluminal liquid and hub will be analyzed for level of contamination.
88836738|NCT03718325|Other|Burst-SCS/sham SCS|First, participants will receive clinically-effective Burst-SCS per their standard of care. Study evaluations will be completed prior to and after stimulation. Then, participants will have their stimulation adjusted to receive sham (no) SCS. Study evaluations will be completed prior to and after this sham.
88836739|NCT03718325|Other|Sham SCS/Burst-SCS|First, participants will receive sham (no) SCS. Study evaluations will be completed prior to and after this sham. Then, participants will have their stimulation adjusted to receive clinically-effective Burst-SCS per their standard of care. Study evaluations will be completed prior to and after stimulation.
89365669|NCT02499120|Active Comparator|Placebo plus Cetuximab|Placebo orally QD with food on Day 1 to Day 21 followed by 7 days off treatment in a 28-day cycle; in combination with Cetuximab, 400 mg/m2 initial dose as a 120-minute IV infusion followed by 250 mg/m2 weekly infused over 60 minutes.
88836740|NCT03714984|Experimental|Pre operative exercise|The educational pelvic floor intervention group will receive one months before surgery a physiotherapy visit were will be explain to patients and care giver the pelvic floor anatomy and biomechanics and how perform the exercises to be follow at home focusing on pelvic muscles awareness and contraction. Patients and care giver will receive a daily exercise diary to fill at home and will be advised to follow the exercise program.
88836741|NCT03714984|Active Comparator|Control group|The control group will be just informed about the study protocol and will not receive any pre-operative intervention.
88836742|NCT03714373|Experimental|OLE DCCR|75 - 525 mg DCCR
88836743|NCT03714373|Experimental|RW DCCR|75 - 525 mg DCCR
88836744|NCT03714373|Placebo Comparator|RW Placebo|75 - 525 mg Placebo for DCCR
89365670|NCT02444754||Health services research (surveys, questionnaires)|Patients complete survey items across a number of domains (patient characteristics, access to health care, perceived quality of care, clinical trial knowledge and attitudes, and cancer related health needs). Patients also complete questionnaires to obtain demographics information including age, education, race and ethnicity, marital status, employment status, insurance coverage, and income, as well as health status/indicators. Cancer-related characteristics, including diagnosis, stage, time since diagnosis, and treatments received are obtained self-report and patients' medical records.
88836745|NCT03695081|Experimental|Patient Pathway Pharmacist intervention|"Medication reconciliation at admission to hospital~Medication review post surgery~Optimised list of drugs in the discharge summary, in accordance with hospital procedures~Medication reconciliation, six weeks after discharge~Medication review, six weeks after discharge"
88836746|NCT03695081|No Intervention|No intervention|Business as usual. The Patient Pathway Pharmacist is not involved and the nurses and physicians are responsible for medicine reconciliation, -review and section in the discharge summary.
88836747|NCT03691064||LUTATHERA|Treated per labeled LUTATHERA dosing regimen.
89365671|NCT02310451|Experimental|metastatic melanoma|Patients affected by advanced melanoma not resectable (stage IIIc) or metastatic (stage IV)
89365672|NCT02227992|Experimental|EVARREST™ Sealant Matrix|EVARREST™ Sealant Matrix/Fibrin Sealant Patch is a sterile bio-absorbable combination product consisting of two constituent parts- a flexible matrix and a coating of two biological components (Human Fibrinogen and Human Thrombin).
89365673|NCT02227992|Active Comparator|SURGICEL® Absorbable Hemostat|SURGICEL® Absorbable Hemostat (oxidized regenerated cellulose) is a sterile absorbable knitted fabric prepared by the controlled oxidation of regenerated cellulose.
89365674|NCT02175251|Active Comparator|low frequency (1Hz)|low frequency
89365675|NCT02175251|Sham Comparator|Sham Comparator|Sham Comparator
89365676|NCT02175251|Experimental|high frequency (20Hz)|high frequency
89365677|NCT02106598|Experimental|Phase 2 - Head and Neck Cancer|Patients with early oral cavity squamous cell carcinoma, and prior to standard of care wide local resection of the primary tumor and elective neck dissection, will receive a locally-administered, peritumoral injection of fluorescent cRGDY-PEG-Cy5.5-C dots (0.25 - 1 ml) around the primary lesion while under standard-of-care anesthesia for identification of optically-avid SLNs and to assess for metastatic disease. After completion of the neck dissection, nodal specimens will be examined ex vivo for fluorescence signal. Any fluorescent and non-fluorescent nodes will be compared to determine the true positive and false positive rates for cancer detection in this pilot study. No change in standard of care surgical practice will occur.
89365678|NCT01871766|Experimental|Low-Risk, Subset 1|"Lymph node sampling will take place pretreatment and pre-surgery. Participants receive 12 weeks of chemotherapy (vincristine, dactinomycin and cyclophosphamide). They are then evaluated to determine how the tumor responded to treatment. Twelve additional weeks of chemotherapy (vincristine and dactinomycin) is given, followed by evaluation for tumor response. No further treatment is given, and participants are observed closely. Myeloid growth factor is given if needed.~Participants also receive ^1^1C-methionine as described in the intervention section."
89365679|NCT01871766|Experimental|Low-Risk, Subset 2|"Lymph node sampling will take place pretreatment and pre-surgery. Participants receive 12 weeks of chemotherapy (vincristine, dactinomycin, cyclophosphamide). The tumor is evaluated to determine how it responded to treatment. Radiation therapy and/or surgical resection is performed to destroy or remove the remaining tumor. Twelve additional weeks of chemotherapy (vincristine, dactinomycin, cyclophosphamide) is given, followed by evaluation for tumor response. If delayed for medical reasons, radiation therapy and/or surgical resection is done at this time. Participants then receive 16 weeks of additional chemotherapy (vincristine, dactinomycin and cyclophosphamide). No further treatment is given, and participants are observed closely. Myeloid growth factor will be given if needed.~Participants also receive ^1^1C-methionine as described in the intervention section."
89365680|NCT01871766|Experimental|Intermediate-Risk|"Lymph node sampling takes place pretreatment and pre-surgery. Participants receive 12 weeks of chemotherapy (vincristine, dactinomycin, cyclophosphamide). The tumor is evaluated for treatment response. Radiation therapy and/or surgical resection is done. Twelve weeks of chemotherapy (vincristine, dactinomycin, cyclophosphamide) is followed by evaluation for tumor response. If delayed for medical reasons, radiation therapy and/or surgical resection is done at this time. Participants receive 16 weeks of chemotherapy (vincristine, dactinomycin, cyclophosphamide) followed by 12 weeks of maintenance treatment (bevacizumab, sorafenib, oral cyclophosphamide). No further treatment is given, and participants are observed closely. Myeloid growth factor is given if needed.~Participants also receive ^1^1C-methionine as described in the intervention section."
89530333|NCT03249025|Experimental|Lidocaine-Ketamine Infusion|Lidocaine-Ketamine Infusions 1 time per month for 6 months. Pretreatment with Midazolam 1-3 mg IV Push or Subcutaneously and Clonidine 0.1 mg PO prior to infusion.
89530334|NCT02729831|Experimental|Interactive Decision Aid and Usual Care|Group receiving brief interactive decision aid and being seen by a provider assigned to usual care. The decision aids are the Shared Decision Points for hip and knee osteoarthritis from Healthwise.
88836748|NCT03690921|Experimental|Treatment (LET-IMPT, chemotherapy)|Patients undergo linear energy transfer-optimized intensity modulated proton therapy 5 times per week for 5-6 weeks. Patients also receive standard cisplatin and fluorouracil IV weekly for up to 6 weeks in the absence of disease progression or unacceptable toxicity.
88836749|NCT03684889|Experimental|SCRI-huCAR19v2|Patients will receive SCRI-huCAR19v2 in either Phase 1 or Phase II
88836750|NCT03684889|Experimental|SCRI-huCAR19v1 - [CLOSED]|Patients will receive SCRI-huCAR19v1 in either Phase 1 or Phase II. As of 02/13/2020 this study cohort is permanently closed.
88836751|NCT03680677||Cancer Directed Therapy or Best Supportive Care|Cancer-directed therapy with intensive regimens, clinical trial, hypomethylating agent, hypomethylating agent combinations, targeted agents alone, or best supportive care
88836752|NCT03680677||Transplant|Bone marrow or peripheral blood graft (BMT) or CAR T-cell therapy
88836753|NCT03657147|Experimental|Question Prompt List and Video|Participants will watch an educational video and question prompt list will be provided. Glaucoma visits will be audio-taped. A 15-20-minute interview will be conducted after the visit by a research assistant.
88836754|NCT03657147|No Intervention|Usual Care|The usual care group will not receive any intervention. Glaucoma visits will be audio-taped. A 15-20-minute interview will be conducted after the visit by a research assistant.
88836755|NCT03647306|Active Comparator|Extended Overnight Fast|The extended overnight fast group will have scheduled meal times for the entire 6 day semi ambulatory and in lab session. Subjects will consume approximately 33% of their daily calories at breakfast, lunch and dinner, respectively. This is a model for fasting dietary chronotype.
88836756|NCT03647306|Experimental|Early Total Caloric Intake|The Early Total Caloric Intake study group will have scheduled meal times for the entire 6 day semi ambulatory and in lab session and will consume 60% of their daily calories during breakfast. The remaining 40% of daily calories will be consumed during lunch and dinner. This is a model for early dietary chronotype.
88836757|NCT03647306|Experimental|Late Total Caloric Intake|The Late Total Caloric Intake study group will have scheduled meal times for the entire 6 day semi ambulatory and in lab session and will consume 40% of daily calories during breakfast and lunch. The remaining 60% of daily calories will be consumed during dinner. This is a model for late dietary chronotype.
89178751|NCT05491434|No Intervention|Control|The usual pre-surgical preparation and conditioning will be carried out, without providing nutritional supplements or increased physical activity
89365681|NCT01871766|Experimental|High-Risk|"Lymph node sampling takes place pretreatment and pre-surgery. Participants receive 6 weeks (2 cycles) chemotherapy (vincristine and irinotecan). The tumor is evaluated for treatment response. 3 cycles of chemotherapy [vincristine, doxorubicin, cyclophosphamide/ifosfamide, etoposide (or etoposide phosphate) (VDC/IE)] are given. Dexrazoxane is given prior to each dose of doxorubicin. Radiation therapy begins at week 4 or 20 (depending on tumor location) while receiving vincristine and irinotecan. 2 cycles of VDC/IE, 4 cycles of modified vincristine, dactinomycin, cyclophosphamide (VAC), then 2 cycles of modified vincristine/irinotecan (total of 54 weeks). High risk participants also receive additional maintenance therapy beginning week 55 with anti-angiogenic chemotherapy (bevacizumab, sorafenib, cyclophosphamide). Myeloid growth factor is given as needed.~Participants also receive ^1^1C-methionine as described in the intervention section."
89365682|NCT01728155|No Intervention|Group1|initial observation (chemotherapy is only given if there is subsequent progression)
89365683|NCT01728155|Active Comparator|Group 1: chemotherapy|chemotherapy and surgery
89365684|NCT01728155|Experimental|Group 2|chemotherapy and surgery
88836758|NCT03635489|Experimental|Bevacizumab + Paclitaxel + Carboplatin|Participants will receive paclitaxel, carboplatin intravenous (IV) infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting from Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab for a total of 21 cycles of bevacizumab in the absence of disease progression, unacceptable toxicity, or withdrawal, whichever occurs first.
88836759|NCT03635489|Placebo Comparator|Placebo + Paclitaxel + Carboplatin|Participants will receive paclitaxel, carboplatin IV infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and placebo IV infusion starting from Cycle 2 for a total of 5 cycles, followed by maintenance therapy placebo for a total of 21 cycles of placebo in the absence of disease progression, unacceptable toxicity, or withdrawal, whichever occurs first.
89365685|NCT01728155|Experimental|Group 3|chemotherapy and surgery
89365686|NCT01728155|No Intervention|Group 4|Observation
89365687|NCT01728155|Experimental|Group 5|chemotherapy
89365688|NCT01728155|Experimental|Group 6|chemotherapy and surgery
89365689|NCT01728155|Experimental|Group 7|chemotherapy and surgery
89365690|NCT01728155|Experimental|Group 8|chemotherapy, surgery, radiotherapy and 13 cis-retinoic acid
89365691|NCT01728155|Experimental|Group 9|chemotherapy, surgery, radiotherapy and 13 cis-retinoic acid
89365692|NCT01728155|Experimental|Group 10|chemotherapy, surgery,
89365693|NCT01648816||postpartum depression|caucasian mothers with postpartum depression
89365694|NCT01648816||control|caucasian mothers without depression
89365695|NCT01628029|Experimental|Arm I (methylphenidate, melatonin, light therapy, CBT)|Patients undergo CBT comprising 3 30-minute counseling sessions between baseline and day 14. Patients also receive methylphenidate hydrochloride PO BID and therapeutic melatonin PO QD, and undergo light therapy over 30 minutes for 15 days.
89365696|NCT01628029|Experimental|Arm II (placebo, placebo, sham light therapy, CBT)|Patients undergo CBT as in Arm I. Patients also receive methylphenidate placebo PO BID and melatonin placebo PO QD, and undergo sham light therapy over 30 minutes for 15 days.
89365697|NCT01628029|Experimental|Arm III (methylphenidate, melatonin, sham light therapy, CBT)|Patients undergo CBT as in Arm I. Patients also receive methylphenidate hydrochloride PO BID and therapeutic melatonin PO QD, and undergo sham light therapy over 30 minutes for 15 days.
89365698|NCT01628029|Experimental|Arm IV (methylphenidate, placebo, light therapy, CBT)|Patients undergo CBT as in Arm I. Patients also receive methylphenidate hydrochloride PO BID and melatonin placebo PO QD, and undergo light therapy over 30 minutes for 15 days.
89365699|NCT01628029|Experimental|Arm V (placebo, melatonin, light therapy, CBT)|Patients undergo CBT as in Arm I. Patients also receive methylphenidate placebo PO BID and therapeutic melatonin PO QD, and undergo light therapy over 30 minutes for 15 days.
89365700|NCT01628029|Experimental|Arm VI (placebo, placebo, light therapy, CBT)|Patients undergo CBT as in Arm I. Patients also receive methylphenidate placebo PO BID and melatonin placebo PO QD, and undergo light therapy over 30 minutes for 15 days.
88836760|NCT03633617|Experimental|Part A: Dupilumab or Placebo|Part A consists of a 24-week double-blind treatment period. Participants will be randomized to receive dupilumab or placebo. At the end of the double-blind treatment visit (week 24), eligible participants may enter Part C. Participants who do not enter Part C will enter a 12-week follow-up period.
89178752|NCT05491434|Experimental|Experimental|In addition to the usual pre-surgical preparation and conditioning, a nutritional supplement and increased physical activity will be provided in a controlled manner for 3 weeks.
89365701|NCT01628029|Experimental|Arm VII (methylphenidate, placebo, sham light therapy, CBT)|Patients undergo CBT as in Arm I. Patients also receive methylphenidate hydrochloride PO BID and melatonin placebo PO QD, and undergo sham light therapy over 30 minutes for 15 days.
89365702|NCT01628029|Experimental|Arm VIII (placebo, melatonin, sham light intervention, CBT)|Patients undergo CBT as in Arm I. Patients also receive methylphenidate placebo PO BID and therapeutic melatonin PO QD, and undergo sham light therapy over 30 minutes for 15 days.
89365703|NCT01538342|Other|chronic plaque psoriasis|3 biopsies: 2 lesional and 1 non-lesional
89365704|NCT01538342|Other|pustular psoriasis|3 biopsies: 2 lesional and 1 non-lesional
89365705|NCT01538342|Other|erythrodermic psoriasis|3 biopsies: 2 lesional and 1 non-lesional
89365706|NCT01538342|Other|atopic dermatitis|2 biopsies: 1 lesional and 1 non-lesional
89365707|NCT01538342|Other|healthy patients|1 biopsy of healthy skin.
89365708|NCT01346787|Experimental|Carfilzomib Cyclophosphamide Dexamethasone|The treatment period includes administration of Carfilzomib Cyclophosphamide Dexamethasone for 9 courses. In order to assess the toxicity of treatment, patients will attend the study centre visits at each scheduled carfilzomib administration. The response will be assessed after each cycle.
89365709|NCT01283295||Immune complications|Transplant recipients who develop a clinically recognized complication with potential immune etiology or ramifications. Examples include opportunistic infection, rejection, malignancy, alloantibody formation or immunosuppressive drug toxicity.
89365710|NCT01283295||Stable Transplant Recipient|Patients who demonstrate immune stability characterized by stable graft function without evident complication. These patients serve as comparators for Group 1
88836761|NCT03633617|Experimental|Part B: Dupilumab or Placebo|Part B consists of a 24-week double-blind treatment period. Participants will be randomized to receive dupilumab dosing regimen 1, dupilumab dosing regimen 2 or placebo. At the end of the double-blind treatment visit (week 24), eligible participants may enter Part C. Participants who do not enter Part C will enter a 12-week follow-up period.
88836762|NCT03633617|Experimental|Part C: Dupilumab|Part C is a 28-week extended active treatment period. Participants will receive dupilumab dosing regimen 1, dupilumab dosing regimen 2. At the end of the treatment period (week 52), participants will enter a 12-week follow-up period.
88836763|NCT03631784|Experimental|Cohort A|Participants received 1 cycle of carboplatin area under the curve (AUC) 6 mg/mL/min with paclitaxel 200 mg/m^2 and pembrolizumab 200 mg on Day 1. Approximately 3 weeks later, participants received carboplatin AUC 2 mg/mL/min with paclitaxel 45 mg/ m^2 administered weekly for 6 weeks along with 2 cycles of pembrolizumab 200 mg administered every 3 weeks (Q3W) in conjunction with standard thoracic radiotherapy (TRT) (60 Gray [Gy] in 2 Gy fractions administered 5 days per week for 6 weeks). Participants then received 14 additional cycles of pembrolizumab 200 mg administered Q3W. 1 cycle=21 days.
88836764|NCT03631784|Experimental|Cohort B|Participants received 3 cycles of cisplatin 75 mg/m^2 with pemetrexed 500 mg/m^2 and pembrolizumab 200 mg on Day 1 of each cycle. Treatment was given in conjunction with standard TRT (60 Gy in 2 Gy fractions administered 5 days per week for 6 weeks) in cycles 2 and 3. Participants then received 14 additional cycles of pembrolizumab 200 mg administered Q3W. 1 cycle=21 days.
88836765|NCT03617705|Other|All participants (HIV+ and HIV- drinkers)|All participants were planned to complete the BACtrack Skyn biosensor in two lab sessions, and wear the Skyn biosensor for two weeks in the field. However, due to COVID, not all participants were able to complete the lab sessions.
88836766|NCT03610997|Other|Photorefractive keratectomy|The children will undergo PRK in the affected eye(s) using previously derived formulas for PRK.
88836767|NCT03591562||COSYCONET COPD Subcohort|"MRI and CT of the lung will be performed in a multi-centre subcohort of 370 patients having already participated in the precursor trial  Image-Based Structural and Functional Phenotyping of the COSYCONET Cohort Using MRI and CT (MR-COPD), NCT 02629432."
88836768|NCT03591484|Experimental|G1 dentate healthy older|Treatment with Photodynamic therapy (n = 20). The dentate participants will received periodontal treatment. The evaluation of halitosis and the microbiological analysis will be repeated before these steps
88836769|NCT03591484|Experimental|G2 healthy older/dentures|Treatment with Photodynamic therapy (n = 20). The participants will be submitted to hygiene procedures for the mucosa and dentures. The evaluation of halitosis and the microbiological analysis will be repeated before these steps
88836770|NCT03591484|Active Comparator|G3 dentate older bronchiectasis|Treatment with tongue scraper (n = 20). The dentate participants with bronchiectasis will received periodontal treatment. The evaluation of halitosis and the microbiological analysis will be repeated before these steps
88836771|NCT03591484|Active Comparator|G4 older bronchiectasis /dentures|Treatment with tongue scraper (n = 20). The participants will be submitted to hygiene procedures for the mucosa and dentures. The evaluation of halitosis and the microbiological analysis will be repeated before these steps
88836772|NCT03576885|Active Comparator|Treatment group - active|inhaled nitric oxide treatment will start at 20 ppm and continue for 2 weeks or until resolution of pulmonary hypertension, whichever comes first.
88836773|NCT03576885|Placebo Comparator|Treatment group - placebo|Placebo treatment will start at 20 ppm and continue for 2 weeks or until resolution of pulmonary hypertension, whichever comes first.
88836774|NCT03576885|No Intervention|Control group|Enrolled infants with no evidence of pulmonary hypertension will serve as the control group for incidence of death or bronchopulmonary hypertension
88836775|NCT03576612|Experimental|Cohort 1: MGMT Unmethylated Patients|After confirmation of high grade glioma, AdV-tk injection into wall of resection cavity. Valacyclovir starting 1-3 days post-surgery for 14 days. Radiation begins approximately day 8 and continues for 6 weeks. Temozolomide started after complete valacyclovir and stop when MGMT unmethylated result obtained. Nivolumab every 2 weeks x 26 doses up to 52 weeks. MRI every 8 weeks until progression.
88836776|NCT03576612|Experimental|Cohort 2: MGMT Methylated & undetermined Patients|After confirmation of high grade glioma, AdV-tk injection into wall of resection cavity. Valacyclovir starting 1-3 days post-surgery for 14 days. Radiation begins approximately day 8. Temozolomide started after complete valacyclovir and continue during radiation then 5 week break and then begin adjuvant temozolomide dosing. Nivolumab every 2 weeks x 26 doses up to 52 weeks. MRI every 8 weeks until progression.
88836777|NCT03576105|Experimental|experimental group|G1 - 17 patients Photodynamic therapy with convention methylene blue as photosesintizer irrigation /sterile saline Conventional methylene blue as photosensitizer -Irrigation with 0,04mL of photosensitizer (0,005%) inside the gingival sulcus around the third molar with pericoronarite for 3 minutes Photodynamic therapy -Device irradiation with low intensity laser λ = 660 nm, 9J per point and radiant 90 seconds
88836778|NCT03576105|Active Comparator|positive control group|G2 - 17 patients Photodynamic therapy with oral formula of methylene blue as photosesintizer, treatment identical to G1, however methylene blue will be delivered in a new formulation for oral use (patent aplicattion INPI BR1020170253902) irrigation /sterile saline Photodynamic therapy -Methylene blue for oral use as photosensitizer-Irrigation with 0,04mL of photosensitizer (0,005%) inside the gingival sulcus around the third molar with pericoronarite for 3 minutes Device irradiation with low intensity laser λ = 660 nm, 9J per point and radiant 90 seconds
88836779|NCT03574038|Active Comparator|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation
88836780|NCT03574038|Sham Comparator|Sham Stimulation|Sham Stimulation
88836781|NCT03568318|Placebo Comparator|Placebo / Upadacitinib + Topical Corticosteroids|Participants will receive placebo orally once a day (QD) for 16 weeks in the double-blind treatment period. At Week 16 participants will be re-randomized to receive either upadacitinib 15 mg or upadacitinib 30 mg QD up to Week 260. Participants will also receive concomitant topical corticosteroids following a step-down regimen through Week 52.
88836782|NCT03568318|Experimental|Upadacitinib 15 mg QD + Topical Corticosteroids|Participants will receive upadacitinib 15 mg orally once a day for up to 260 weeks. Participants will also receive concomitant topical corticosteroids following a step-down regimen through Week 52.
89178753|NCT00838097||Darbepoetin alfa|Participants with chronic kidney disease who received darbepoetin alfa for the treatment of anaemia as part of routine clinical practice.
88836783|NCT03568318|Experimental|Upadacitinib 30 mg QD + Topical Corticosteroids|Participants will receive upadacitinib 30 mg orally once a day for up to 260 weeks. Participants will also receive concomitant topical corticosteroids following a step-down regimen through Week 52.
88836784|NCT03568318|Experimental|Long-Term Extension|Participants who reach Week 260 in Studies M16-045, M18-891, and M16-047 will have the opportunity to roll over into the blinded LTE period of M16-047 to continue receiving the same daily dose of upadacitinib for up to Week 524.
88836785|NCT03564483||Registry Observational Study|All women presenting for evaluation of Extramammary Paget's Disease (EMPD) at Mayo Clinic in Rochester MN.
88836786|NCT03550794|Experimental|Thiamine|200mg parenterally administered thiamine hydrochloride given twice daily for a 3 days (6 doses)
88836787|NCT03550794|Placebo Comparator|Placebo|Matching placebo (50ml 0.9%NACL) given twice daily for 3 days (6 administrations)
89178754|NCT05603351|Experimental|Preventive prostate examination by bpMRI|"The cohort consists of patients:~with age 50-69 years~without any contraindications to MRI or biopsy~without known status of prostate cancer or prostate biopsy in the past (interventions for BPH are not a restriction)~without known BRCA mutation~without PSA test or prostate MRI in the past 2 years~without any signs of prostatitis or urinary tract infection in the past 6 months."
89365711|NCT01283295||Pre-Transplant Longitudinal|Patients who are candidates for kidney, pancreas, liver or lung transplant will be enrolled and followed longitudinally.
88836788|NCT03536572|Active Comparator|Sleep Apnea Self-Management Program|Protocol-based sleep apnea and CPAP education and support
88836789|NCT03536572|Experimental|Individualized Pressure Adjustment|Additional education and support that will allow them to adjust their PAP pressures
88836790|NCT03533673|Experimental|Cohort 1|A one-time intravenous infusion of ACTUS-101 (dose level 1)
88836791|NCT03533673|Experimental|Cohort 2|A one-time intravenous infusion of ACTUS-101 (dose level 2)
88836792|NCT03533673|Experimental|Cohort 3|A one-time intravenous infusion of ACTUS-101 (dose level 3)
89365712|NCT01283295||Organ Donors|Donors for individuals meeting the criteria for Cohorts 1-3
89365713|NCT01283295||Disease state|Individuals with liver, renal or pulmonary diseases that may lead to the development or organ failure.
88836793|NCT03532282|Active Comparator|ONLINE ONLY|Online cognitive behavioral therapy for insomnia
88836794|NCT03532282|Experimental|STEPPED CARE|Cognitive behavioral therapy for insomnia online or therapist-led or sequentially both
88836795|NCT03513302|Placebo Comparator|placebo|
88836796|NCT03513302|Active Comparator|nitrate|
89365714|NCT01283295||Normal Volunteers|
89365715|NCT01097928||Patients undergoing Pulmonary Embolectomy|
89365716|NCT01033565|Experimental|Natrol|Subjects receive Natrol (sustained release melatonin) 5mg tablet 30 minutes prior to bedtime for 10 to 14 days
89365717|NCT01027143|Experimental|omega-3 fatty acids|3 softgels (EPA, DHA) twice daily
88836797|NCT03506880|Experimental|MADD Materials|Handbook developed by MADD and the PI to guide parents in discussing underage drinking, behaviors, and consequences with their teens
88836798|NCT03506880|Experimental|Surgeon General Materials|Information published by the Surgeon General about teens and drinking
88836799|NCT03506880|No Intervention|Control|TAU
88836800|NCT03506321|Other|LANS|Lesions are assessed with chromoendoscopy, HD-WL & NBI
88836801|NCT03471793||Colonic polyp|Patients referred for EMR of a colonic polyp >20mm
88836802|NCT03471403||FAP|FAP patients with duodenal adenomas
88836803|NCT03471156||Post EMR|Patients are observed post EMR procedure for pain. Standard of care data is collected
88836804|NCT03467516|Experimental|Tumor Infiltrating Lymphocytes (TIL)|Patients with uveal melanoma will receive the lymphocyte depleting preparative regimen consisting of fludarabine and cyclophosphamide followed by infusion of up to 2x10^11 TIL infused intravenously through a central vein catheter and Aldesleukin, administered at a dose of 600,000 IU/kg (based on total body weight) as an intravenous bolus over a 15-minute period approximately every 8 hours beginning within 24 hours of TIL infusion and continuing for up to a maximum of 6 doses.
88836805|NCT03456102|Other|Pravastatin 80 mg|Pravastatin 80 mg, isoniazid 300 mg, rifampin 450 mg (weight <50 kg) or 600 mg (weight >50 kg), pyrazinamide 20-25 mg/kg, and ethambutol 15-20 mg/kg daily for 14 days Arm 2 will only be recruited if pravastatin 40 mg is well tolerated and safe, yet drug exposures are significantly reduced due to the known interaction with rifampin.
89365718|NCT01027143|Placebo Comparator|control|Soybean oil: 3 matched softgel caps twice daily
89365719|NCT01023984|Active Comparator|TEM - Transanal Endoscopic Microsurgery|TEM under general anesthesia
89365720|NCT01023984|Active Comparator|ESD - Endoscopic Submucosal Dissection|ESD under sedation
89365721|NCT00981656|Experimental|3DCRT + CT|Concurrent three-dimensional conformal radiation therapy (3DCRT) and radiosensitizing chemotherapy (CT) consisting of either cisplatin alone or the combination of mitomycin and 5-fluorouracil. Protocol treatment must begin with 15 weeks after a transurethral resection of the tumor (TURBT).
88836806|NCT03456102|Other|Pravastatin 120 mg|Pravastatin 120 mg, isoniazid 300 mg, rifampin 450 mg (weight <50 kg) or 600 mg (weight >50 kg), pyrazinamide 20-25 mg/kg, and ethambutol 15-20 mg/kg daily for 14 days Arm 3 will only be recruited if pravastatin 80 mg is well tolerated and safe, yet drug exposures are significantly reduced due to the known interaction with rifampin.
88836807|NCT03456102|Other|Pravastatin 160 mg|Pravastatin 160 mg, isoniazid 300 mg, rifampin 450 mg (weight <50 kg) or 600 mg (weight >50 kg), pyrazinamide 20-25 mg/kg, and ethambutol 15-20 mg/kg daily for 14 days Arm 4 will only be recruited if pravastatin 120 mg is well tolerated and safe, yet drug exposures are significantly reduced due to the known interaction with rifampin.
88836808|NCT03456102|Other|Pravastatin 40 mg|Pravastatin 40 mg, isoniazid 300 mg, rifampin 450 mg (weight <50 kg) or 600 mg (weight >50 kg), pyrazinamide 20-25 mg/kg, and ethambutol 15-20 mg/kg daily for 14 days
89178755|NCT00703313|Active Comparator|2|described in intervention
89178756|NCT00703313|Active Comparator|3|described in intervention
89178757|NCT00703313|Active Comparator|1|described in intervention
89178758|NCT00703079||Group A|>15 patients treated only with SSA (octreotide-LAR or lanreotide depot)
89178759|NCT00703079||Group B|>15 patients treated with surgery after a period of SSA treatment of 6-24 months
89365722|NCT00895622|No Intervention|Low Risk|No treatment given.
88836809|NCT03451448||Healthy volunteers|Healthy volunteers to undergo MRI using USPIO contrast
88836810|NCT03451448||Stable coronary artery disease|Patients with coronary artery disease without recent (3 months) acute coronary syndrome or revascularisation
88836811|NCT03451448||Recent acute coronary syndrome|Patients with recent (3 months) type 1 myocardial infarction
88836812|NCT03448666|Experimental|pembrolizumab and elettrochemiotherapy|drug: Pembrolizumab 200 mg flat dose every three weeks procedure: elettrochemiotherapy once after first pembrolizumab dose
88836813|NCT03442738||Group I Endocuff group|Group I Endocuff cap use
88836814|NCT03442738||Group II standard colonoscope|Group II standard colonoscope, no further device used
89178760|NCT00703079||Group C|>15 patients cured after surgery only
89178761|NCT00703079||Group D|>15 patients treated with surgery first and then with SSA after 6-12 months
89178762|NCT00840827|Experimental|all patients|Lenalidomide 10mg po daily/ CSA 250mg orally twice daily
89178763|NCT00860249|No Intervention|Usual Care|Usual Care. Participants in this arm will receive Usual care until outcome assessment is performed at 6 months following randomization. At that time, they will be sent a letter reminding them to obtain the ordered preventative service test, however no further outcomes will be assessed. Thus, during the course of the study, all participants in this arm will have solely received usual care.
89178764|NCT00860249|Experimental|Behavioral: Letter Only|Behavioral: Letter Only Prior to a scheduled upcoming appointment, participants will get a letter signed by their physician that provides brief information about colorectal cancer (CRC) and notes the importance of CRC screening.
89178765|NCT00860249|Experimental|Behavioral: Letter and Educational DVD|Behavioral: Letter and Educational DVD Participants will get a letter from their physician that provides brief information about colorectal cancer (CRC) and notes the importance of CRC screening. It will be accompanied by an educational DVD about the screening. The participants will receive this prior to a scheduled upcoming appointment with their physician.
89178766|NCT00840749|Experimental|CyberKnife Stereotactic Radiotherapy|
89178767|NCT00840749|Active Comparator|Surgery|
89178768|NCT00703469|Experimental|1|
89178769|NCT00703469|Placebo Comparator|2|
89178770|NCT00859937|Experimental|Arm I|Patients receive dasatinib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89178771|NCT04030715|Other|the successful group|divide the subject to two groups based on the success or failure of eradication, and analyze the influential factors of eradication. Build a predictive model for the success of eradication.
89178772|NCT04030715|Other|the failure group|divide the subject to two groups based on the success or failure of eradication, and analyze the influential factors of eradication. Build a predictive model for the success of eradication.
89178773|NCT00592007|Experimental|A|Single-arm study
89178774|NCT00913289|Other|adipose tissue derived stromal cells|
89178775|NCT00837473|Other|Plexur-P Bone Void Filler|Single arm. Open Label.
89178776|NCT00703547|Experimental|Subjects receiving treatment in cohort 1|Subjects will receive one of the following sequences; ABDF,BADF, BDAF or BDFA (A=Placebo, B= GSK586529 dose 1 (3 milligrams), D = GSK586529 dose 3, F = GSK586529 dose 5).
89178777|NCT00703547|Experimental|Subjects receiving treatment in cohort 2|Subjects will receive one of the following sequences; ACEG,CAEG, CEAG or CEGA (A = Placebo, C= GSK586529 dose 2, E = GSK586529 dose 4, G = GSK586529 dose 6)
89178778|NCT04030793|Experimental|Individualized stimulation group|Based on transcranial direct current stimulation (tDCS) simulation, individualized stimulation on leg motor areas during 30 minutes.
89178779|NCT04030793|Active Comparator|Conventional stimulation group|Conventional stimulation on leg motor areas during 30 minutes.
89178780|NCT00839423|Placebo Comparator|Placebo|
89178781|NCT00839423|Experimental|Vortioxetine (Lu AA21004) 5 mg|
89178782|NCT00839423|Experimental|Vortioxetine (Lu AA21004) 10 mg|
88836815|NCT03440398|Active Comparator|Open NSM|Conventional Nipple Sparing Mastectomy
88836816|NCT03440398|Experimental|Robotic NSM|Robotic Nipple-Sparing Mastectomy
88836817|NCT03439865|Experimental|standard of care treatment + ivacaftor|topical nasal steroid spray and culture-directed antibiotics + ivacaftor 150 mg tablet
88836818|NCT03439865|Placebo Comparator|standard of care treatment|topical nasal steroid spray and culture-directed antibiotics
88836819|NCT03427346|Active Comparator|EMR|Endoscopic mucosal resection
88836820|NCT03427346|Active Comparator|ESD|Endoscopic submucosal dissection
88836821|NCT03427125|Experimental|Tenapanor 10 mg, 20 mg, 30 mg BID|During the 26-week open label part, all enrolled subjects will receive 30 mg BID doses of tenapanor. Investigators may decrease or increase the dose in 10 mg increments to a minimum of 10 g BIDor a maximum of 30 mg BID
88836822|NCT03427125|Placebo Comparator|Placebo|Placebo
88836823|NCT03427125|Active Comparator|Sevelamer Carbonate|Subjects randomized into the active control group, for safety analysis, will receive sevelamer carbonate, open label, for the entire 52-week study period. Sevelamer carbonate will be dosed based on package insert instructions (standard of care)
88836824|NCT03420274|Experimental|Intervention|This arm will utilize a point-of-care shared decision-making tool (NEST).
88836825|NCT03420274|Placebo Comparator|Control|This group will utilize usual care with respect to healthcare provider practice for education and counseling.
88836826|NCT03419637|No Intervention|Control - Standard of Care|The standard of care consists of in-clinic counseling, informational handouts, and access to patient medical records
89178783|NCT00839423|Other|Venlafaxine XL 225 mg|Active Reference
89178784|NCT00837161|Experimental|Philips MR guided HIFU system|Patient receiving HIFU treatment
89178785|NCT00859547|Experimental|Recombinant thrombin (rThrombin), 1000 IU/mL|
89178786|NCT00859469|Experimental|Oxaliplatin and Gemcitabine|Gemcitabine 1000 mg/m² IV infusion over 90 minutes, then Oxaliplatin 100 mg/m² IV infusion over 2 hours repeated for 14 days up to 6 cycles
89178787|NCT00703625|Experimental|Cohort 1|"Temsirolimus IV 15 mg weekly~Docetaxel 60 mg/m2 IV once every three weeks."
89178788|NCT00703625|Experimental|Cohort 2|"Temsirolimus IV 25 mg weekly~Docetaxel IV 60 mg/m2 once every 3 weeks"
89178789|NCT00703625|Experimental|Cohort 1A|"Temsirolimus IV 15 mg weekly~Docetaxel IV 50 mg/m2 every 3 weeks."
89365723|NCT00895622|Experimental|Intermediate Risk|54 Gy radiotherapy
88836827|NCT03419637|Experimental|Intervention - Mobile app|The mobile app, or app, is used to document before and after photos of the excised skin areas and to document related diagnoses. The app allows patients to view a skin history summary report and a reference on their skin ﬁndings and procedures.
88836828|NCT03377296|Experimental|Plasmodium Vivax infection|"Both volunteers will be infected with Plasmodium Vivax (as described below in full in Interventions). i.e., there is only one arm to this study."
89365724|NCT00895622|Experimental|High Risk|60 Gy radiotherapy
88836829|NCT03371706|Experimental|Communication Bridge™|Participants receive Communication Bridge™, a multi-component, participation-focused, dyadic intervention in which both the person with PPA and their co-enrolled communication partner are intervention recipients. Communication Bridge™ is modelled on the Living with Aphasia: Framework for Outcome Measurement (A-FROM) and the Care Pathway Model that was developed for persons living with primary progressive aphasia. Consistent with participation-focused intervention models personally salient training stimuli are incorporated into all therapy activities in the Experimental arm.
88836830|NCT03371706|Active Comparator|Evidence-Based Impairment Focused|The Control arm includes a non-dyadic intervention in which the person with PPA is the active intervention recipient and their communication partner is in a supporting role. In the Control arm, participants receive a speech-language intervention designed to address impairment and functional limitations, comprised of activities that address word retrieval and 'automatic' speech production using fixed, non-personalized, stimuli across participants.
88836831|NCT03360708|Experimental|Treatment (vaccine therapy)|Patients receive malignant glioma tumor lysate-pulsed autologous dendritic cell vaccine ID on days 1, 3, and 5 of courses 2 and 3, and on day 1 of subsequent courses. Treatment with malignant glioma tumor lysate-pulsed autologous dendritic cell vaccine repeats every 21 days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
88836832|NCT03359863|Experimental|Treatment Arm|Subjects will receive Pirfenidone as part of treatment for their restrictive chronic lung allograft dysfunction (RCLAD).
88836833|NCT03353688|Active Comparator|Directional DBS guided by behavior|Directional stimulation with the Boston Scientific Vercise PC IPG with directional DBS lead, guided by behavioral assessments during device activation.
88836834|NCT03353688|Placebo Comparator|Omnidirectional DBS guided by behavior|"Omnidirectional (ring mode) stimulation with the Boston Scientific Vercise PC IPG with directional DBS lead, guided by behavioral assessments during device activation."
88836835|NCT03353688|Active Comparator|Directional DBS guided by biomarkers|Directional unilateral subthalamic stimulation with the Boston Scientific Vercise PC IPG with directional DBS lead, guided by electrophysiology biomarkers measured during surgery (nested exploratory treatment arm).
88836836|NCT03341273|Experimental|Azithromycin|500 mg of Azithromycin (2 capsules of 250 mg) administered orally as a single dose on Day 1, followed by 250 mg capsule of Azithromycin administered orally once daily for 4 days (Day 2 through Day 5). N=337
88836837|NCT03341273|Placebo Comparator|Placebo|2 capsules of Azithromycin placebo administered orally as a single dose on Day 1, followed by 1 capsule of Azithromycin placebo administered orally once daily for 4 days (Day 2 through Day 5). N=337
88836838|NCT03330691|Experimental|Patient-derived CD19- and CD22 specific CAR v1|Patient-derived CD19-specific CAR also expressing an HER2t and CD22-specific CAR T-cells also expressing an EGFRt
88836839|NCT03330691|Experimental|Patient-derived CD19- and CD22 specific CAR v2|Patient-derived CD19-specific CAR also expressing an HER2t and CD22-specific CAR T-cells also expressing an EGFRt
88836840|NCT03325062|Experimental|Experimental: MOVE|Movement pattern training in addition to contemporary progressive rehabilitation
88836841|NCT03325062|Active Comparator|CONTROL|Contemporary progressive rehabilitation
88836842|NCT03319901|Experimental|Venetoclax + Chemotherapy|"Venetoclax is administered orally once daily for 21 days in each cycle~Standard Chemotherapy will be administered every 28 days"
88836843|NCT03301766|Experimental|Lidocaine 5% patch|"Patients will receive a 7 day supply (21 patches) of lidocaine 5% patches upon discharge from the emergency department in addition to standard therapy at the discretion of the treating emergency department physician."
88836844|NCT03301766|Active Comparator|Non-medicated patch|"Patients will receive a 7 day supply (21 patches) of non-medicated patches upon discharge from the emergency department in addition to standard therapy at the discretion of the treating emergency department physician."
88836845|NCT03248167|Experimental|Cannabidiol (CBD 600 mg daily)|6 weeks, such that both participants and study staff are blind to treatment condition.
89178790|NCT00703703|Experimental|1|Darifenacin
89365725|NCT00847535|Other|1|Transurethral dose escalation
88836846|NCT03248167|Placebo Comparator|Placebo|6 weeks, such that both participants and study staff are blind to treatment condition.
88836847|NCT03244306|Experimental|Autologous CD22-specific CAR T-cells expressing EGFRt|
88836848|NCT03243552|Active Comparator|L-DOPA versus Placebo|L-DOPA or placebo (1:1 randomization). Dosing will begin at 25mg carbidopa/100mg L-DOPA in 3 divided doses, with a fixed-flexible titration schedule, allowing dose increases once per week of 100mg L-DOPA. Maximum dose is 600mg/d.
88836849|NCT03243552|Experimental|Social Skills|All participants will receive 16-week manualized social skills training.
88836850|NCT03242278||NVAF patients receiving 20 mg rivaroxaban|NVAF patients who receive a standard dose of rivaroxaban (20 mg daily)
88836851|NCT03242278||NVAF patients receiving 15 mg rivaroxaban|NVAF patients who receive a reduced dose of rivaroxaban (15 mg daily)
89178791|NCT00703703|Active Comparator|2|Tolterodine
89178792|NCT00703703|Placebo Comparator|3|Placebo
89178793|NCT00859313|Experimental|Sufentanil NanoTab PCA System/15 mcg|
89178794|NCT02611973|Experimental|HU without aspirin|
89178795|NCT02611973|Active Comparator|HU + aspirin maintenance|
89178796|NCT02611973|Other|HU + AAG|Observational arm
89365726|NCT00847535|Other|2|Periurethral dose escalation
89365727|NCT00742157|Other|UNMC Group|Compare the low and high dose effects of Growth Hormone from previously pooled patients (high dose) and UNMC patients (low dose).
89178797|NCT00771810|Placebo Comparator|Placebo|Combination gemcitabine and platinum-based chemotherapy with concurrent placebo
89178798|NCT00771810|Experimental|TXA127 100 ug/kg|Combination gemcitabine and platinum-based chemotherapy with concurrent 100 ug/kg/day TXA127
88836852|NCT03220737|Experimental|Cohort 1 (active, 12-17 yrs)|Subjects aged 12 - 17 were administered a 100 mL oral dose of Vaxchora vaccine on Day 1, and had study visits on Day 11, 29, 91 and 181. Cohort 1 subjects that continued in the long-term follow-up sub-study had visits on days 365, 547 and 730.
88836853|NCT03220737|Placebo Comparator|Cohort 1 (placebo, 12 - 17 yrs)|Subjects aged 12 - 17 were administered a 100 mL oral dose of 0.9% saline on Day 1, and had study visits on Day 11, 29, 91 and 181.
88836854|NCT03220737|Experimental|Cohort 2 (active, 6 - 11 yrs)|Subjects aged 6 - 11 were administered a 100 mL oral dose of Vaxchora vaccine on Day 1, and had study visits on Day 11, 29, 91 and 181.
88836855|NCT03220737|Placebo Comparator|Cohort 2 (placebo, 6 - 11 yrs)|Subjects aged 6 - 11 were administered a 100 mL oral dose of 0.9% saline on Day 1, and had study visits on Day 11, 29, 91 and 181.
88836856|NCT03220737|Experimental|Cohort 3 (active, 2 - 5 yrs)|Subjects aged 2 - 5 were administered a 50 mL oral dose of Vaxchora vaccine on Day 1, and had study visits on Day 11, 29, 91 and 181.
88836857|NCT03220737|Placebo Comparator|Cohort 3 (placebo, 2 - 5 yrs)|Subjects aged 2-5 were administered a 50 mL oral dose of 0.9% saline on Day 1, and had study visits on Day 11, 29, 91 and 181.
88836858|NCT03220737|Other|Historical Control: Adult Bridging Population|This arm consists of historical data from Vaxchora vaccine subjects from study PXVX-VC-200-004. The data was included in study PXVX-VC-200-006 as a comparator bridging population for the Day 11 seroconversion. NCT02094586 PubMed ID:29317118
88836859|NCT03198728|Experimental|SOV2012-F1-treated|200 patients treated with SOV2012-F1, starting dose of 600 mg - (400 mg with morning meal and 200 mg with evening meal). Dose titrated on Days 28 and 56 up to a maximum of 600 mg TU in the morning and 400 mg in the evening or down to 200 mg TU in the morning based on plasma T at Days 14 and 42.
88836860|NCT03198728|Active Comparator|Andro-Gel™ treated|100 patients treated with AndroGel, starting dose of 40.5 mg QD. Dose titrated according to approved label, using samples from Days 14 and 42 and dose adjustments on Days 28 and 56.
88836861|NCT03198663|Experimental|POSSE Intervention|
88836862|NCT03198663|Other|Control|Delayed intervention
88836863|NCT03192852|Experimental|Violet LED (405 nm)+ gel placebo|20 patients will be submitted to dental bleaching involving the teeth 15-25 and 45 - 35 with Violet LED 405 nm (Bright Max Whitening, MMO, São Carlos, SP, Brazil) with gingival barrier + gel placebo
88836864|NCT03192852|Active Comparator|Violet LED + CP 35%|20 patients will be submitted to dental bleaching involving the teeth 15-25 and 45 - 35 with carbamide peroxide 35% ( Whiteform - Fórmula & Ação, São Paulo, Brazil) actived with Violet LED 405 nm (Bright Max Whitening, MMO, São Carlos, SP, Brazil) with gingival barrier
88836865|NCT03192852|Active Comparator|HP 35%|20 patients will be submitted to dental bleaching involving the teeth 15-25 and 45 - 35 with hydrogen peroxide 35% (Whiteness HP, FGM, Joinvile, SC, Brasil) and gingival barrier
89178799|NCT00771810|Experimental|TXA127 300 ug/kg|Combination gemcitabine and platinum-based chemotherapy with concurrent 300 ug/kg/day TXA127
89178800|NCT00836927|Experimental|Ridaforolimus 10 mg Days 1-5|Ridaforolimus 10 mg administered orally once daily on Days 1-5 per week. Participants may continue ridaforolimus intravenous (IV) infusion at the same dose from the parent trial before being switched to ridaforolimus oral tablet.
89530335|NCT02729831|Experimental|Video decision aid and usual care|Group receiving long video decision aids and being seen by a provider assigned to usual care. The decision aids are the DVD and Booklets for hip and knee osteoarthritis from Health Dialog.
88836866|NCT03192852|Experimental|HP 35% + Violet LED + Gingivoplasty|20 patients will be submitted to dental bleaching involving the teeth 15-25 and 45 - 35 with Violet LED 405 nm (Bright Max Whitening, MMO, São Carlos, SP, Brazil) with gingival barrier split-mouth at first session. After 48 hours will be do Gingivoplasty.
88836867|NCT03192852|Active Comparator|CP 35%|20 patients will be submitted to dental bleaching involving the teeth 15-25 and 45 - 35 with carbamide peroxide 35% ( Whiteform - Fórmula & Ação, São Paulo, Brazil)
88836868|NCT03190590|Active Comparator|Transcranial direct current stimulator (tDCS)|tDCS is delivered noninvasively via electrodes applied to the surface of the head, and a mild electrical current is given during motor training.
89178801|NCT00836927|Experimental|Ridaforolimus 10 mg Days 1-6|Ridaforolimus 10 mg administered orally once daily on Days 1-6 per week. Participants may continue ridaforolimus IV infusion at the same dose from the parent trial before being switched to ridaforolimus oral tablet.
89178802|NCT00836927|Experimental|Ridaforolimus 20 mg Days 1-5|Ridaforolimus 20 mg administered orally once daily on Days 1-5 per week. Participants may continue ridaforolimus IV infusion at the same dose from the parent trial before being switched to ridaforolimus oral tablet.
89178803|NCT00836927|Experimental|Ridaforolimus 30 mg Days 1-5|Ridaforolimus 30 mg administered orally once daily on Days 1-5 per week. Participants may continue ridaforolimus IV infusion at the same dose from the parent trial before being switched to ridaforolimus oral tablet.
89178804|NCT00836927|Experimental|Ridaforolimus 40 mg Days 1-5|Ridaforolimus 40 mg administered orally once daily on Days 1-5 per week. Participants may continue ridaforolimus IV infusion at the same dose from the parent trial before being switched to ridaforolimus oral tablet.
88836869|NCT03190590|Active Comparator|Transcranial magnetic stimulation (TMS)|TMS is delivered noninvasively via a hand-held coil applied to the surface of the head, and a magnetic pulse probes cortical circuitry [this is not repetitive TMS and so does NOT modulate brain excitability.]
89530336|NCT02729831|Experimental|Interactive Decision Aid and Provider Report|Group receiving brief interactive decision aid and being seen by a provider assigned to intervention arm. The decision aids are the Shared Decision Points for hip and knee osteoarthritis from Healthwise. The provider intervention is a report that includes the patients' goals and treatment preferences.
89530337|NCT02729831|Experimental|Video decision aid and Provider report|Group receiving long video decision aids and being seen by a provider assigned to intervention arm. The decision aids are the hip or knee DVD and Booklets for hip and knee osteoarthritis from Health Dialog. The intervention is a report that includes the patients' goals and treatment preferences.
89530338|NCT03245905|Experimental|Chidamide|Chidamide should be given at a fixed time with fixed dosage
89530339|NCT03248713|Active Comparator|Mifepristone|Mifepristone 600 mg/day in 2 tablets
88836870|NCT03190590|Placebo Comparator|Sham-tDCS|delivered by briefly turning on and off the stimulator at the beginning of training, which mimics the sensation of true stimulation.
88836871|NCT03186118|Experimental|Cohort A|Participants will receive CD19-targeting CAR T cells. Participants who have a total CD19 antigen load in bone marrow of <15% will be assigned to Cohort A, to receive up to 6 T-APC treatments.
88836872|NCT03186118|Experimental|Cohort B|Participants will receive CD19-targeting CAR T cells. Participants for whom laboratory testing on Study Day 14 indicates they are at risk for early loss of CAR T cells will be assigned to Cohort B to receive up to 6 T-APC treatments. If laboratory testing prior to planned T-APC treatment indicates loss of CAR-T cells, participants may move to Cohort C.
88836873|NCT03186118|Experimental|Cohort C|Participants will receive CD19-targeting CAR T cells. Participants for whom laboratory testing shows loss of CAR T cells within 6 months will be assigned to Cohort C. They will receive another CAR T cell infusion followed by up to 6 T-APC treatments.
88836874|NCT03186118|Experimental|Cohort D|Participants will receive CD19-targeting CAR T cells. Participants who do not meet assignment rules for Cohorts A, B, or C will be followed after CAR T cell infusion in Cohort D.
88836875|NCT03159624|Experimental|Treatment Group|2x3 cm Biodesign™ SIS graft placement + overlying Doyle silastic sheet placement over the resulting exposed septum cartilage/bone
88836876|NCT03159624|Active Comparator|Control Group|Thin Doyle silastic sheet placement alone over the resulting exposed septum cartilage/bone
88836877|NCT03156114|Experimental|Part I - Dose--Escalation|
88836878|NCT03156114|Experimental|Part II - Dose-Expansion|
88836879|NCT03144804|Experimental|Lamivudine|"Lamivudine administered orally every 4 weeks~Treatment cycles will last 28 consecutive days~The dosage will be determine by the PI"
88836880|NCT03142334|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 17 cycles (up to approximately 1 year).
88836881|NCT03142334|Placebo Comparator|Placebo|Participants receive placebo (saline solution) via IV infusion on Day 1 of each 3-week cycle for up to 17 cycles (up to approximately 1 year).
88836882|NCT03135847|Experimental|Amputee and Able Bodied Subjects|Map the locations in the skin or deeper muscle where limb movement perceptions occur. Use tactors (small robots providing touch and vibration) to mechanically provide sensation to the residual muscles in amputees and the intact muscles in able-bodied. The functional experiments will occur concurrently with development and application of new prosthetic socket designs to incorporate control and feedback.
89365728|NCT00539591|Experimental|Temozolomide/peginterferon alfa-2b|"Stratum B: Resected Stage IIIC, unresectable Stage III, Stage IV, and recurrent patients~Stratum B is divided into 2 groups based on the presence (Stratum B1) or absence (Stratum B2) of measurable disease. Subjects will receive 8 weekly doses of peginterferon alfa-2b 0.5 mcg/kg/dose subcutaneously (SQ) in combination with temozolomide 75mg/m2/dose by mouth (PO) daily for 6 weeks followed by 2 week break. The duration of each treatment course will be 8 weeks. Strata B2 (no measurable disease) will proceed with 7 courses as outlined."
88836883|NCT03131024|Experimental|Aerobic exercise|The exercise arm includes a single bout of supervised treadmill walking scheduled such that it would end approximately 24 hours prior to each of the participant's scheduled anthracycline treatment time.
88836884|NCT03131024|Experimental|50% caloric restriction|The caloric restriction arm will restrict their total caloric intake by 50% for 48 hours prior to each anthracycline treatment.
88836885|NCT03131024|No Intervention|Usual care|The usual care arm will be asked to maintain their typical exercise and diet throughout treatment.
88836886|NCT03126539|Experimental|Group A|Sulforaphane will be applied topically to both sites for up to 7 consecutive nights. Biopsies will be obtained prior to, and immediately after this intervention, on standard photoprotected and photoexposed sites.
88836887|NCT03126539|Experimental|Group B|Two photoprotected sites will be identified. Sulforaphane will be applied topically to a single selected site for up to 7 consecutive nights. Both site will be exposed to UV. Biopsies of both sites will be obtained prior to, and 24 hours after UV exposure.
88836888|NCT03123250|Experimental|Aquablation procedure|
88836889|NCT03121404||Cirrhosis Patient|Patients will be identified from the transplant list. Inclusion criteria will be all subjects with cirrhosis of any etiology who will undergo liver transplantation. . Rectus abdominis muscle biopsy will be obtained directly after induction of anesthesia for the procedure. In addition patients will have anthropometric measurements taken within 2 weeks of surgery. For the cirrhotic patients this includes hand grip test and dual energy x-ray absorption (DEXA).
88836890|NCT03121404||Healthy Controls|Controls will be identified from the abdominal surgery operating room lists at Cleveland Clinic. Rectus abdominis muscle biopsy will be obtained directly after induction of anesthesia for the procedure. In addition patients will have anthropometric measurements taken within 2 weeks of surgery which will not include DEXA or hand grip test.
88836891|NCT03117400||Bland blue defect|The defect after endoscopic mucosal resection of the colonic large laterally spreading lesion (20mm or more) is blue without any other defect features (as described in the second group, 'non bland blue defect'). The blue is the result of the submucosal injection of dye (indigo carmine), used to lift lesions before starting the resection.
88836892|NCT03117400||Non bland blue defect|The defect after endoscopic mucosal resection of the colonic large laterally spreading lesion (20mm or more) is not just blue, but contains other defect features, such as visible vessels, herniation of vessels, submucosal fat, exposed muscle, fibrous bands, submucosal haemorrhage or non stained submucosa.
88836893|NCT03113435|No Intervention|Standard|In this group standard care will be provided to patients undergoing major abdominal surgery, regarding hemodynamic optimization
88836894|NCT03113435|Active Comparator|NICE group|In this arm patients will be treated according to stroke volume optimization described in NICE program
88836895|NCT03113435|Experimental|Oxygen consumption group|In this arm patients will receive hemodynamic optimization based on their oxygen consumption need
88836896|NCT03107923||Preoperative myocardial reserve yes/no|Patients with extensive myocardial fibrosis typically presents with limited myocardial contractile reserve that can be assessed by a dobutamine stress test. The patients will be allocated to a responder and non-responder group according to the results from this test.
88836897|NCT03100552||Study population|Patients referred to a tertiary endoscopic resection practice found to have an SSP >= 8mm. Endoscopic imaging applied to the sessile serrated polyp (SSP) to determine the presence or absence of dysplasia.
88836898|NCT03099096|Experimental|Mepolizumab SC 100 mg/milliliter (mL) in autoinjector|Three doses of mepolizumab liquid drug product in autoinjector will be self-administered by the subject/caregiver at 4-weekly intervals; 2 doses will be administered under observation in the clinic (at Week 0 and 8). One dose will be administered outside the clinic and without observation (within 24 hours after attending the clinic at Week 4).
89365729|NCT00539591|Experimental|Peginterferon alfa-2b/non-pegylated interferon alfa-2b|Stratum A: Resected Stages IIC, IIIA, and IIIB patients will receive recombinant interferon alfa-2b 20 million units/m2/day intravenously (IV) 5 consecutive days per week for 4 weeks followed by peginterferon alfa-2b 1mcg/kg subcutaneously (SQ) once a week for 48 weeks.
89365730|NCT02460718|No Intervention|control group|Participants received 1-hour group diabetes education class covering diabetes basics, healthy eating, stress reduction, physical activity, social support, and how to get the most out of their doctors visit. Participants also received a diabetes report card showing their Hba1c, blood pressure, ldl cholesterol, and body weight.
88836899|NCT03043664|Experimental|Arm 1|Keytruda (pembrolizumab) 200 mg intravenous (IV) infusion every 3 weeks and Somatuline Depot (lanreotide) 90 mg subcutaneous (SQ) injection every 3 weeks.
88836900|NCT03041467|Experimental|IN.PACT AV DCB|"PTA will be performed using the IN.PACT AV Access Drug Coated Balloon. IN.PACT AV Access DCB was the device name used during the clinical study. Medtronic has changed the name of the device to IN.PACT™ AV Paclitaxel-Coated Balloon Catheter (also referred as IN.PACT AV DCB). Hence, throughout posting, the study device will be referred to as the IN.PACT AV DCB."
89365731|NCT02460718|Experimental|Encourage study|"Participants in the intervention arm were paired with a peer coach, interacting by telephone weekly for the first 8 weeks and then monthly for a total of 10 months.~Participants also received 1-hour group diabetes education class covering diabetes basics, healthy eating, stress reduction, physical activity, social support, and how to get the most out of their doctors visit. Participants also received a diabetes report card showing their Hba1c, blood pressure, ldl cholesterol, and body weight."
89365732|NCT03635853|Experimental|patients with palmar arsenical keratosis|patients are given an ointment containing extract from cock's comb twice daily for three months
89365733|NCT03293992|Experimental|0.01% RO7058584 or Matching Placebo|
89365734|NCT03293992|Experimental|0.1% RO7058584 or Matching Placebo|
89365735|NCT03293992|Experimental|1% RO7058584 or Matching Placebo|
88836901|NCT03041467|Active Comparator|Standard Balloon Angioplasty|PTA will be performed using a commercially available uncoated PTA balloon.
88836902|NCT03019406|Experimental|Cohort 1: Avalglucosidase Alfa 20 mg/kg|Avalglucosidase alfa, 20 mg/kg intravenous (IV) infusion every other week (qow) for 25 weeks in the Primary Analysis Period (PAP), followed by same treatment from Week 26 up to Week 371 in extension treatment period (ETP).
88836903|NCT03019406|Experimental|Cohort 2: Avalglucosidase Alfa 40 mg/kg|Avalglucosidase alfa 40 mg/kg IV infusion qow for 25 weeks in the PAP, followed by same treatment from Week 26 up to Week 371 in ETP.
88836904|NCT03019406|Experimental|Cohort 3a: Avalglucosidase Alfa 40 mg//kg|After determination of the highest tolerated avalglucosidase alfa dose in Cohort 1 and Cohort 2 (after at least 5 participants in each Cohort 1 and Cohort 2 had received the 7th dose of avalglucosidase alfa or completed Week 13 with a minimum of 6 infusions), participants received avalglucosidase alfa 40 mg/kg (the highest tolerated dose) IV infusion qow for 25 weeks in PAP, followed by same treatment from Week 26 up to Week 371 in ETP.
88836905|NCT03019406|Experimental|Cohort 3b: Alglucosidase Alfa in PAP|After determination of the highest tolerated avalglucosidase alfa dose in Cohort 1 and Cohort 2 (after at least 5 participants in each Cohort 1 and Cohort 2 had received the 7th dose of avalglucosidase alfa or completed Week 13 with a minimum of 6 infusions), participants received alglucosidase alfa at their current stable dose (defined as dose [between 20 mg/kg qow and 40 mg/kg weekly as per physician] administered regularly for a minimum of 6 months immediately prior to entry in this study) IV infusion for 25 weeks in PAP. After PAP, participants received avalglucosidase alfa 40mg/kg IV infusion qow from Week 26 up to Week 371 in ETP.
88836906|NCT03001518||Surgery|No intervention. Patients who undergo surgical resection of their pancreatic cancer.
88836907|NCT02992522|Experimental|Treatment (lenalidomide, venetoclax, obinutuzumab)|Patients receive lenalidomide PO on days 1-21 and venetoclax PO on days 1-28. Patients also receive obinutuzumab IV on days 1, 8, and 15 of course 1, and day 1 of courses 2-6. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
89365736|NCT03293992|Experimental|RO7058584 and Latanoprost 0.005%|
89365737|NCT01332201|Experimental|Advagraf|
89365738|NCT01332201|Active Comparator|Prograf|
89365739|NCT03293914|Experimental|Intervention|Participants will be invited to enroll in an occupational therapy (OT) lifestyle redesign intervention focused on diabetes management. The intervention includes approximately 8 one-hour OT sessions over 4 months.
89365740|NCT03293914|No Intervention|Usual Care Control|Participants will not be contacted; outcome data will be extracted from medical records.
89365741|NCT01332279|Experimental|Treatment (enzyme inhibitor and radiation therapy)|Patients receive RAD001 PO and erlotinib hydrochloride PO QD. Treatment continues for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo EBRT BID 5 days a week for 5 weeks.
89365742|NCT03298906|Experimental|Esketamine + Ticlopidine|Participants will self-administer one 14 milligram (mg) spray of intranasal esketamine into each nostril at Time 0 and again 5 minutes later on Day 1, a total dose of 56 mg (Treatment A) in Treatment Period 1. After that participants will receive 250 mg of ticlopidine tablets orally twice daily on Day -9 through Day 1, and will self-administer one 14 mg spray of intranasal esketamine into each nostril at Time 0 and again 5 minutes later in the morning of Day 1, a total dose of 56 mg (Treatment B) in Treatment Period 2. A washout period of greater than or equal to (>=)10 days will separate the esketamine self-administrations between 2 treatment periods.
88836908|NCT02972593|Other|Liberal|Blood and blood products for transfusion. Transfusion will be done to keep Hgb >7 g/dL.
88836909|NCT02972593|Other|Conservative|Blood and blood products for transfusion. Transfusion will be done to keep Hgb > 5.5 g/dL.
88836910|NCT02969681|Experimental|Ascorbic Acid with chemotherapy group|"Ascorbic Acid with mFOLFOX6 with or without bevacizumab Ascorbic Acid (1.5g/kg/day, D1-3) every 2 weeks~mFOLFOX6:~Oxaliplatin 85 mg/m² d1 concurrent with~Leucovorin 400 mg/m², followed by~Bolus 5FU 400 mg/m² , followed by~Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks~with or without bevacizumab 5mg/kg, every 2 weeks"
88836911|NCT02969681|Active Comparator|Chemotherapy group|"mFOLFOX6:~Oxaliplatin 85 mg/m² d1 concurrent with~Leucovorin 400 mg/m², followed by~Bolus 5FU 400 mg/m² , followed by~Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks~with or without bevacizumab 5mg/kg, every 2 weeks"
89365743|NCT03298828|Experimental|CD19 CAR|Patients meeting the eligibility criteria will have leukapheresis to isolate the blood immune cells used to manufacture the CD19 CAR T-cells. Patients will receive lymphodepletion with fludarabine and cyclophosphamide prior to infusion of the CD19 CAR T-cells.
89365744|NCT03298828|Experimental|CD19 CAR and PD-1 knock out|Patients meeting the eligibility criteria will have leukapheresis to isolate the blood immune cells used to manufacture the CD19 CAR and PD-1 knock out engineered T-cells. Patients will receive lymphodepletion with fludarabine and cyclophosphamide prior to infusion of the CD19 CAR and PD-1 knock out engineered T-cells.
89365745|NCT02461576||HIV-1 infected|this is a study comparing Xpert HIV-1 VL assay quantitation to an already FDA approved HIV-1 quantitative HIV-1 RNA assay in known HIV-1 infected individuals
88836912|NCT02967107|Active Comparator|Cold snare polypectomy|Cold snare resection, if necessary, multi-piece to resect sessile serrated adenoma (SSA) 8-20mm
89365746|NCT02461342||Dr.Tang's research group|Dr.Tang's research group for genetic, environment and its interaction analysis of human complex disease
89365747|NCT03878277|Experimental|Cold Brew Coffee|6 days of drinking 1 bottle of Starbucks® Cold brew 325ml [205 mg caffeine] every morning between 6am-9am.
88836913|NCT02967107|Active Comparator|Endoscopic mucosal resection|Endoscopic mucosal resection (EMR), if necessary, multi-piece to resect sessile serrated adenoma (SSA) 8-20mm
88836914|NCT02956590|Active Comparator|Pitavastatin|Study Drug
88836915|NCT02956590|Placebo Comparator|Placebo|Placebo
88836916|NCT02949700|Experimental|Single arm, treatment|"Patients in the Phase I trial will be assigned to a single arm, experimental treatment which will test dose escalation for metformin in the context of chemo-radiation, with toxicity as the primary outcome.~Patients in the Phase II trial will be assigned to a single arm, experimental treatment consisting of metformin plus chemo-radiation."
88836917|NCT02947087|Active Comparator|Prolastin-C|Subjects will be given Prolastin-C intravenously at 60mg/kg weekly for 4 weeks.
88836918|NCT02947087|Placebo Comparator|Placebo|Subjects will be given Saline weekly for 4 weeks.
88836919|NCT02868216|Experimental|anger management training|treatment group- Two monthly sessions will address the events triggering anger, the physiology of anger and the influence on the cardiovascular system, the dimesions of anger: cognitive, emotional and behavioral.
88836920|NCT02868216|No Intervention|Without management training|No anger management training
88836921|NCT02864550|Experimental|Doxycycline arm|Participants in this intervention group will receive doxycycline 100mg orally daily, which is available as a 100mg capsule. This single daily dose was chosen to maximize adherence, given the common use of once-daily Human Immunodeficiency Virus (HIV) pre-exposure prophylaxis (PrEP), as well as its efficacy as once-daily prophylaxis against malaria and its utility as dosing as infrequent as once weekly for another spirochete infection, leptospirosis.
88836922|NCT02864550|Placebo Comparator|Placebo arm|Participants in this control group will receive a placebo capsule identical in appearance, taste, and size to the capsule provided to the intervention group.
88836923|NCT02841995|Experimental|Cohort 1: Belumosudil 200 mg QD|Participants received belumosudil 200 mg orally QD in each 28-day treatment cycle until disease progression, unacceptable toxicity, or death whichever occurred first (maximum duration: 64.2 months).
88836924|NCT02841995|Experimental|Cohort 2: Belumosudil 200 mg BID|Participants received belumosudil 200 mg orally BID in each 28-day treatment cycle until disease progression, unacceptable toxicity, or death whichever occurred first (maximum duration: 45.9 months).
89365748|NCT03286972||PET/MRI|"All participants will undergo a diagnostic PET/CT and a Radiation Treatment Planning CT per SOC procedures. In addition, all participants will undergo an additional imaging set consisting of a PET/MRI. It is anticipated that most patients will undergo the PET/MRI on the same day as their PET/CT negating the need for a second injection of the FDG radioisotope used for SOC PET imaging. All participants will receive gadolinium contrast per SOC dosing guidelines for the MRI portion of the PET/MRI. Both SOC MMRI pulse sequences and investigational sequences will be utilized in this study.~If a second dose of the radioisotope is need to complete the PET/MRI (unable to perform both PET scans on the same day) only a 50% dose of FDG will be administered due to the increased sensitivity the PET/MRI scanner."
88836925|NCT02841995|Experimental|Cohort 3: Belumosudil 400 mg QD|Participants received belumosudil 400 mg orally QD in each 28-day treatment cycle until disease progression, unacceptable toxicity, or death whichever occurred first (maximum duration: 49.2 months).
88836926|NCT02822768|Active Comparator|Packing|The patient is to have a long piece of gauze within the abscess cavity in an attempt to keep it open and allow purulent material to continue to drain after the initial incision and release of purulent material has been performed.
88836927|NCT02822768|Placebo Comparator|No packing|The patient is not to have packing of the abscess as part of the incision and drainage procedure
88836928|NCT02799485|Experimental|Treatment (recombinant EphB4-HSA fusion protein)|Patients receive recombinant EphB4-HSA fusion protein IV over 1 hour on days 1 and 15. Patients with disease progression after 2 or more courses who have not experienced toxicity may receive recombinant EphB4-HSA fusion protein IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 12 courses in the absence of further disease progression or unacceptable toxicity.
88836929|NCT02739295|Experimental|G-CSF|An intravenous dose of 5 microg/kg of G-CSF (Neupogen) will be administered daily, from admission (day 0) to day 4.
88836930|NCT02739295|Placebo Comparator|Placebo|An intravenous dose of 5 ml of NaCl 0.9% will be administered daily, from admission (day 0) to day 4.
88836931|NCT02738125||Subjects starting/ receiving adalimumab|Subjects starting/ receiving Adalimumab for UC
88836932|NCT02684825|Experimental|Continuous plus standard cardiac monitoring|Continuous cardiac monitoring by Reveal LINQTM- LNQ11 Internal Loop Recorder (ILR) plus standard cardiac monitoring
88836933|NCT02684825|No Intervention|Standard cardiac monitoring|Routine cardiac monitoring with follow-up at the same frequency, but with no Implantable Loop Recorder
89365749|NCT03286894||1264 healthy schoolchildren|There is only one study group consisting of 1264 children recruited at school.
89365750|NCT03697629|Experimental|Daratumumab|Increased infusion rate daratumumab monotherapy
88836934|NCT02682342||Healthy Subjects|Healthy subjects meeting inclusion criteria will be administered a 75 g glucose solution one time (orally). Subjects will be ages 21-70 years with no evidence of diabetes, hypertension, metabolic syndrome, or high cholesterol at the time of screening. Potential subjects with a history of atherosclerotic disease, chronic renal insufficiency (plasma creatinine > 1.5 men, > 1.5 women), liver enzymes > 2.5x normal, pregnant at the time of screening will be excluded
88836935|NCT02672449|Experimental|External beam radiotherapy|A total of 65 consecutive newly diagnosed prostate cancer patients with 2013 NCCN high risk category will be consecutively enrolled in a prospective phase II trial on Carbon Ions Boost Followed by Pelvic Photon Radiotherapy .
89365751|NCT03286816|Experimental|Lactate infusion|Subjects will receive an intravenous lactate infusion to elevate plasma lactate levels
89365752|NCT03286816|Placebo Comparator|NaCl infusion|As a control condition, subjects will receive intravenous NaCl infusion
89365753|NCT01334697|Experimental|Cardiotrophin-1|
89365754|NCT01334697|Placebo Comparator|Placebo|
89365755|NCT02460094|Experimental|Panel 1: BIIB092/ Placebo|BIIB092 or matching placebo administered by intravenous (IV) injection, up to a maximum of 3 doses once every four weeks.
88836936|NCT02643966|Experimental|Whole breast ultrasound|All women will receive both 3D mammography and whole breast ultrasound for breast cancer screening; the order of interpretation will vary for each of two radiologists
88836937|NCT02640534|Experimental|Enzalutamide + Metformin|Enzalutamide 160 mg od + metformin 850 mg bid until disease progression
88836938|NCT02640534|Active Comparator|Enzalutamide|Enzalutamide 160 mg od until disease progression
89365756|NCT02460094|Experimental|Panel 2: BIIB092/ Placebo|BIIB092 or matching placebo administered by intravenous (IV) injection, up to a maximum of 3 doses once every four weeks.
89365757|NCT02460094|Experimental|Panel 3: BIIB092/ Placebo|BIIB092 or matching placebo administered by intravenous (IV) injection, up to a maximum of 3 doses once every four weeks.
89365758|NCT02460094|Experimental|Panel 4: BIIB092/ Placebo|BIIB092 or matching placebo administered by intravenous (IV) injection, up to a maximum of 3 doses once every four weeks.
89365759|NCT03642951|Active Comparator|Active Treatment Group|"Each patient will receive daily 40 min treatment five days per week for two weeks. The procedure during each treatment session will consist of positioning the device centered at 15% of the nasion-inion distance anterior to the Cz electrode placement in standard EEGs, with the patient relaxing in a chair.~The stimulus parameters used will be 480 stimulus trains of 100 ms in duration, each train delivered every 5 s for total session duration of 40 min. The investigator will measure the subject for accurate placement of the device prior to each visit. Once the placement of the device is confirmed, the study technician administering the treatment will tum on the device using an app downloaded to an electronic device connected by Bluetooth to the device."
89365760|NCT03642951|Sham Comparator|Sham Treatment Group|"Each patient will receive daily 40 min treatment five days per week for two weeks. The procedure during each treatment session will consist of positioning the device centered at 15% of the nasion-inion distance anterior to the Cz electrode placement in standard EEGs, with the patient relaxing in a chair.~The stimulus parameters used will be 480 stimulus trains of 100 ms in duration, each train delivered every 5 s for total session duration of 40 min. The investigator will measure the subject for accurate placement of the device prior to each visit. Once the placement of the device is confirmed, the study technician administering the treatment will tum on the device using an app downloaded to an electronic device connected by Bluetooth to the device.~Note: While the device looks and is operated the same as the active device, subjects in this group will be stimulated with the placebo device so no active stimulation will be given."
89365761|NCT04485663|Experimental|ALG-010133|Subcutaneous injections of ALG-010133 in HV or CHB subjects up to every 7 days for up to 12 weeks
89365762|NCT04485663|Placebo Comparator|Placebo|Subcutaneous injections of placebo in HV or CHB subjects up to every 7 days for up to 12 weeks
89365763|NCT01332513|Experimental|ABFCED sequence|Each subject will participate in six study periods in the bioavailability phase, wherein the subjects will receive a 300 milligram (mg) twice daily (BID) dosing of ezogabine modified release (MR) tablet in periods A, B, C, D and E and will receive 200 mg three times daily (TID) dosing of ezogabine immediate release (IR) tablet in period F. Following the completion of the crossover phase, subjects will be re-randomized to one of five cohorts receiving 600 mg doses of either G, H, I, J or K for the food effect phase.
89365764|NCT01332513|Experimental|BCADFE sequence|Each subject will participate in six study periods in the bioavailability phase, wherein the subjects will receive a 300 mg BID dosing of ezogabine MR in periods A, B, C, D and E and will receive 200 mg TID dosing of ezogabine IR in period F. Following the completion of the crossover phase, subjects will be re-randomized to one of five cohorts receiving 600 mg doses of either G, H, I, J or K for the food effect phase.
89365765|NCT01332513|Experimental|CDBEAF sequence|Each subject will participate in six study periods in the bioavailability phase, wherein the subjects will receive a 300 mg BID dosing of ezogabine MR in periods A, B, C, D and E and will receive 200 mg TID dosing of ezogabine IR in period F. Following the completion of the crossover phase, subjects will be re-randomized to one of five cohorts receiving 600 mg doses of either G, H, I, J or K for the food effect phase.
89530340|NCT03248713|Placebo Comparator|Placebo|matching placebo in 2 tablets
88836939|NCT02628366|Experimental|Personalized Dialysate Temperature|Dialysis centres randomized to the intervention arm will provide temperature-reduced personalized hemodialysis. A nurse will set the temperature of the dialysate to 0.5°C below each patient's body temperature measured just before starting the dialysis treatment. We are aware that some dialysis machines (e.g. Fresenius 5008) are only able to modify dialysate temperature by 0.5°C increments. For centres with those machines, the nurse will set the dialysate temperature 0.5 to 0.9 °C below each patient's body temperature (measured before starting the hemodialysis treatment) to a minimum of 35.5°C.
88836940|NCT02628366|No Intervention|Fixed Dialysate Temperature at 36.5°C|Dialysis centres in the control group will provide usual care, which is standard dialysis using a fixed dialysate temperature of 36.5°C
88836941|NCT02616484|Active Comparator|Dichloroacetate, then Placebo|"This group will start on the Dichloroacetate (DCA) treatment which will last for 4 months. After 4 months a 1 month washout period will occur. After the 1 month the group will crossover to the placebo treatment for 4 months.~Participants will be genotyped to determine GSTZ1 (glutathione S-transferase Zeta-1) haplotype status, which will stratify this group into 1 of 2 dose regimens"
88836942|NCT02616484|Placebo Comparator|Placebo, then Dichloroacetate|"This group will start on the placebo treatment which will last for 4 months. After 4 months a 1 month washout period will occur. After the 1 month the group will crossover to the Dichloroacetate (DCA) treatment for 4 months.~Participants will be genotyped to determine GSTZ1 (glutathione S-transferase Zeta-1) haplotype status, which will stratify this group into 1 of 2 dose regimens"
89178805|NCT02612051|Experimental|Part A, Cohort 1: GSK3008348 1-3000 mcg/Placebo|Healthy subjects will receive single 3 ascending doses of GSK3008348 (ranging from 1 to 3000 microgram [mcg]) and matching placebo by nebulisation in one of the four treatment period according to randomization. There will be washout period of at least 6 days between the doses. Actual doses may involve either an increase or a decrease in the planned dose as well as a repeat of the previous.
88836943|NCT02586038|Experimental|MLN-DEX-CYCLO arm|"Patients will receive nine 28-days induction cycles.~MLN9708: 4,0 mg orally on days 1, 8, 15 Dexamethasone: 40 mg orally on days 1, 8, 15, 22. Cyclophosphamide: 300 mg/sqm orally on days 1, 8, 15"
88836944|NCT02586038|Experimental|MLN-DEX-THAL arm|"Patients will receive nine 28-days induction cycles.~MLN9708: 4,0 mg orally on days 1, 8, 15 Dexamethasone: 40 mg orally on days 1, 8, 15, 22. Thalidomide: 100 mg/day orally"
89178806|NCT02612051|Experimental|Part A, Cohort 2: GSK3008348 1-3000 mcg/Placebo|Healthy subjects will receive single 3 ascending doses of GSK3008348 (ranging from 1 to 3000 microgram [mcg]) and matching placebo by nebulisation in one of the four treatment period according to randomization. There will be washout period of at least 6 days between the doses. Actual doses may involve either an increase or a decrease in the planned dose as well as a repeat of the previous.
89365766|NCT01332513|Experimental|DECFBA sequence|Each subject will participate in six study periods in the bioavailability phase, wherein the subjects will receive a 300 mg BID dosing of ezogabine MR in periods A, B, C, D and E and will receive 200 mg TID dosing of ezogabine IR in period F. Following the completion of the crossover phase, subjects will be re-randomized to one of five cohorts receiving 600 mg doses of either G, H, I, J or K for the food effect phase.
89178807|NCT02612051|Experimental|Part A, Cohort 3: GSK3008348 1-3000 mcg/Placebo|Healthy subjects will receive single 3 ascending doses of GSK3008348 (ranging from 1 to 3000 microgram [mcg]) and matching placebo by nebulisation in one of the four treatment period according to randomization. There will be washout period of at least 6 days between the doses. Actual doses may involve either an increase or a decrease in the planned dose as well as a repeat of the previous.
89178808|NCT02612051|Experimental|Part B, Cohort 4: GSK3008348/Placebo, IPF, Period 2 PET Scan|IPF subject will receive single dose of GSK3008348 (safe and tolerated dose as per cohort 1 to 3) or Placebo in two treatment periods according to randomization. There will be washout period of 6 to 28 days between the doses. Subjects will receive up to three microdose administrations of [18F]-FBA-A20FMDV2 for the PET scanning in period 2.
89178809|NCT02612051|Experimental|Part B, Cohort 5: GSK3008348/Placebo, IPF, Period 2 PET Scan|IPF subject will receive single dose of GSK3008348 (safe and tolerated dose as per cohort 1 to 3) or Placebo in two treatment periods according to randomization. There will be washout period of 6 to 28 days between the doses. Subjects will receive up to three microdose administrations of [18F]-FBA-A20FMDV2 for the PET scanning in period 2.
89178810|NCT02612051|Experimental|Part B, Cohort 6: GSK3008348/Placebo, IPF, Period 2 PET Scan|IPF subject will receive single dose of GSK3008348 (safe and tolerated dose as per cohort 1 to 3) or Placebo in two treatment periods according to randomization. There will be washout period of 6 to 28 days between the doses. Subjects will receive up to three microdose administrations of [18F]-FBA-A20FMDV2 for the PET scanning in period 2.
89178811|NCT02612051|Experimental|Part B, Cohort 7: GSK3008348/Placebo, IPF, Period 2 PET Scan|IPF subject will receive single dose of GSK3008348 (safe and tolerated dose as per cohort 1 to 3) or Placebo in two treatment periods according to randomization. There will be washout period of 6 to 28 days between the doses. Subjects will receive up to three microdose administrations of [18F]-FBA-A20FMDV2 for the PET scanning in period 2.
89178812|NCT02612051|Experimental|Part C, Cohort 8: GSK3008348, IPF, PET Scan|IPF subject will receive single dose of GSK3008348 (safe and tolerated dose as per Part B) in two treatment periods. There will be washout period of 6 to 14 days between the doses. Subjects will receive up to three microdose administrations of [18F]-FBA-A20FMDV2 for the PET scanning in both periods.
89178813|NCT00771030|Placebo Comparator|Placebo SC (Cohorts 1-3)|Participants received placebo to brodalumab by subcutaneous (SC) injection once every 2 weeks for a total of six doses.
89178814|NCT00771030|Placebo Comparator|Placebo IV (Cohorts 5-6)|Participants received placebo to brodalumab by intravenous (IV) infusion every 4 weeks for a total of two doses.
89178815|NCT00771030|Experimental|Brodalumab 50 mg SC (Cohort 1)|Participants received 50 mg brodalumab by subcutaneous injection once every 2 weeks for a total of six doses.
89178816|NCT00771030|Experimental|Brodalumab 140 mg SC (Cohort 2)|Participants received 140 mg brodalumab by subcutaneous injection once every 2 weeks for a total of six doses.
89178817|NCT00771030|Experimental|Brodalumab 210 mg SC (Cohort 3)|Participants received 210 mg brodalumab by subcutaneous injection once every 2 weeks for a total of six doses.
89178818|NCT00771030|Experimental|Brodalumab 420 mg IV (Cohort 5)|Participants received 420 mg brodalumab by IV infusion once every 4 weeks for a total of two doses.
89178819|NCT00771030|Experimental|Brodalumab 700 mg IV (Cohort 6)|Participants received 700 mg brodalumab by IV infusion once every 4 weeks for a total of two doses.
89178820|NCT00768300|Experimental|Ambrisentan|
89178821|NCT00768300|Placebo Comparator|Placebo|
89178822|NCT00768222|Active Comparator|Chinese Silk Suture|Natural, non-absorbable silk suture made from entwined thread from silkworm larva, commercially available in China, used in a simple interrupted transdermal suture pattern
89178823|NCT00768222|Experimental|VICRYL* Plus Suture|Synthetic absorbable surgical suture composed of a copolymer of 90% glycolide and 10% L-lactide and containing triclosan antibacterial, used in a subcuticular closure technique
89365767|NCT01332513|Experimental|EFDACB sequence|Each subject will participate in six study periods in the bioavailability phase, wherein the subjects will receive a 300 mg BID dosing of ezogabine MR in periods A, B, C, D and E and will receive 200 mg TID dosing of ezogabine IR in period F. Following the completion of the crossover phase, subjects will be re-randomized to one of five cohorts receiving 600 mg doses of either G, H, I, J or K for the food effect phase.
88836945|NCT02581254|Experimental|Thin Wire Snare Arm|Use of Thin Wire Snare to resect polyp <10mm
88836946|NCT02581254|Experimental|Thick Wire Snare Arm|Use of Thick Wire Snare to resect polyp <10mm
89178824|NCT00768144|Experimental|Sunitinib|Patients received oral Sunitinib at the daily dose of 37.5 mg continuously over a 28- day treatment cycle. Treatment continued until clinical or radiological evidence of progressive disease or excessive toxicity.
88836947|NCT02579811|Experimental|Axitinib|All subjects will be given axitinib on an individualized dosing schedule. Axitinib will be administered orally beginning with 5mg twice a day and can be escalated or reduced if specific grade 2 or greater toxicity develops. Axitinib will continue until progression. At progressive disease, dose escalation above current dose is allowed based on investigator discretion of clinical benefit. However, axitinib should be discontinued if a subject experiences a second RECIST progressive disease following dose escalation, patient intolerability, or at provider discretion.
89178825|NCT00784836|Experimental|Avonex|Avonex 30 mcg given subcutaneously, once weekly, for 18 months.
89178826|NCT03985644||Fulfilling Hangzhou criteria|"Patients flfilling Hangzhou critieria:~Without macrovascular invasion Tumor burden <=8 cm Preoperative AFP level <=400 ng/mL Histopathologic grades I, II"
89178827|NCT03985644||Exceeding Hangzhou criteria|Patients exceeding Hangzhou critieria
89178828|NCT04104984|Experimental|control group not follow NICE guide lines|All pregnant women who fulfil the same inclusion criteria, exclusion criteria, diagnoses established as short cervix , and do not managed according to NICE guide lines will be treated and managed according to their units as a control group.
89178829|NCT04104984|Experimental|study group follow NICE guide lines|- All pregnant women will attend hospital between 14-24 weeks and fulfil inclusion and exclusion criteria will be approached for possibility to be included in the study . and will be managed according NICE guide lines
89178830|NCT00784758|Experimental|Fenzian Device|Subjects randomized to this arm will receive treatment with the Fenzian Device
89178831|NCT00784758|Sham Comparator|Sham Device|Subjects randomized to this arm will receive treatment with the sham device.
89178832|NCT00768066|Experimental|1|Participants will receive an injection of 100 million or 200 million autologous human mesenchymal stem cells (hMSCs).
89178833|NCT00768066|Experimental|2|Participants will receive an injection of 100 million or 200 million autologous human bone marrow cells (hBMCs).
89178834|NCT00768066|Placebo Comparator|3|Participants will receive a placebo injection of phosphate-buffered saline (PBS) and 1% human serum albumin (HAS).
89178835|NCT00767676|Other|1|
89178836|NCT00767520|Active Comparator|A|
89178837|NCT00767520|Placebo Comparator|B|
89178838|NCT02601612|Experimental|Group 1: D46cpΔM2-2 Vaccine|RSV-seropositive children will receive a single dose of 10^6 PFU D46cpΔM2-2 vaccine at study entry (day 0).
89178839|NCT02601612|Placebo Comparator|Group 1: Placebo|RSV-seropositive children will receive a single dose of placebo at study entry (day 0).
89178840|NCT02601612|Experimental|Group 2: D46cpΔM2-2 Vaccine|RSV-seronegative infants and children will receive a single dose of 10^5 PFU D46cpΔM2-2 vaccine at study entry (day 0).
89178841|NCT02601612|Placebo Comparator|Group 2: Placebo|RSV-seronegative infants and children will receive a single dose of placebo at study entry (day 0).
89178842|NCT00838565|Placebo Comparator|Placebo|
89178843|NCT00838565|Experimental|PF-04236921|
89178844|NCT00858845|Experimental|Clonidine patch|Participants assigned to wear a clonidine patch.
89178845|NCT00858845|Placebo Comparator|Placebo|Participants assigned to wear a matching placebo patch.
89178846|NCT04030949||Ateendes STD clinics Östergötland physician appointment|"Attendees with an appointment to a physician (if she has symptoms or if she wishes a gynecological exam).~The exam starts with an Abbot multi-collect swab taken from the anal verge, at the opening of the anal canal.~A pediatric proctoscope (a proctoscope designed and manufactured to examine children) is used for sampling the rectal specimens using an Abbot multi-collect swab and a standard Sigma swab of Sigma virocult, followed by vaginal speculum exam. Firstly samples from the lateral fornix for wet smear are collected, secondly a swab for methylene-blue staining from the endocervical orifice followed by two Abbot multi-collect swabs for chlamydia/gonorrhoea and M.genitalium respectively from the orifice, the portio and the vaginal wall and one standard Sigma swab of Sigma virocult from the same areas. Lastly a sample is collected from the distal urethra and stained with methylene blue."
89365768|NCT01332513|Experimental|FAEBDC sequence|Each subject will participate in six study periods in the bioavailability phase, wherein the subjects will receive a 300 mg BID dosing of ezogabine MR in periods A, B, C, D and E and will receive 200 mg TID dosing of ezogabine IR in period F. Following the completion of the crossover phase, subjects will be re-randomized to one of five cohorts receiving 600 mg doses of either G, H, I, J or K for the food effect phase.
88836948|NCT02577549|Experimental|Diet & Exercise|Participants will attend an exercise class 3 days/week for 18 months. The exercise program will consist of a 15-minute aerobic phase, a 20-minute strength training phase, a second 15-minute aerobic phase, and a 10 minute cool down phase. Participant's will also attend individual and group diet sessions. Each participant's minimum weight loss goal will be 10% of baseline body weight.
88836949|NCT02577549|Active Comparator|Attention Control|The attention control intervention will cover an 18-month period. There will be five total face to face group meetings over the 18 months, with one meeting each at months 1, 3, 6, 9, and 15; and during the other months (months 2-5, 7-11, 13-17) participants will receive a combination of informational packets, webinars, phone sessions, and/or emails based on continued monitoring of participant needs and delivered via their preferred mode of contact.
88836950|NCT02554383|Active Comparator|Treatment A|Amoxicillin-clavulanate (90/6.4 mg/kg/d in 2 divided dosed for 10 days)
88836951|NCT02554383|Placebo Comparator|Treatment B|Placebo made to match the study antibiotic will be taken bid orally for 10 days
88836952|NCT02533960||NOAC|"Ischemic stroke substudy: inclusion of 1000 patients under treatment with non-vitamin K antagonist oral anticoagulants (NOACs).~Hemorrhagic stroke substudy: inclusion of 334 patients under treatment with non-vitamin K antagonist oral anticoagulants (NOACs)."
88836953|NCT02533960||VKA|"Ischemic stroke substudy: inclusion of 1000 patients under treatment with vitamin K antagonists (VKA).~Hemorrhagic stroke substudy: inclusion of 333 patients under treatment with vitamin K antagonists (VKA)"
88836954|NCT02533960||Without OAC|"Ischemic stroke substudy: inclusion of 1000 patients without oral anticoagulation.~Hemorrhagic stroke substudy: inclusion of 333 patients without oral anticoagulation."
88836955|NCT02522871|Experimental|OCS Liver System|OCS Liver System
89365769|NCT03293836|Experimental|Radiofrequency treatment|Radiofrequency ablation of insufficient saphenous and perforating veins plus multilayer compressive bandage treatment
89365770|NCT03293836|Active Comparator|Multilayer Compressive Bandage only|Receive only compressive treatment
89365771|NCT03286660|Other|COPD patients|"All convenient COPD patients admitted in real life for a rehabilitation program were included.~Exercises consist on a Chair Rise Tests and short questionnaire were added to the usual tools for the evaluation."
89365772|NCT03625778|Placebo Comparator|Placebo Cohort 1|Participants will receive subcutaneous (SC) placebo matched to MEDI0382 Cohort 1 once daily for 9 weeks.
89365773|NCT03625778|Experimental|MEDI0382 Cohort 1|Participants will receive SC MEDI0382 titrated doses of Dose 1 to 7 once daily (7-step titration/ 1 week per dose) from Weeks 1 to 7 followed by additional treatment of SC MEDI0382 Dose 7 once daily from Weeks 7 to 9.
89365774|NCT03625778|Placebo Comparator|Placebo Cohort 2|Participants will receive SC placebo matched to MEDI0382 Cohort 2 once daily for 14 weeks.
88836956|NCT02522871|Other|Control|Standard of care (ice)
88836957|NCT02519439|Experimental|ganaxolone|Up to a maximum of 1800 mg/day
89365775|NCT03625778|Experimental|MEDI0382 Cohort 2|Participants will receive SC MEDI0382 titrated doses of Doses 1, 2, 3, 5, and 7 once daily (5-step titration/ 2 week per dose) from Weeks 1 to 10 followed by additional treatment of SC MEDI0382 Dose 7 once daily from Weeks 11 to 14.
89365776|NCT03625778|Placebo Comparator|Placebo Cohort 3|Participants will receive SC placebo matched to MEDI0382 Cohort 3 once daily for 18 weeks.
89365777|NCT03625778|Experimental|MEDI0382 Cohort 3|Participants will receive SC MEDI0382 titrated doses of Doses 1, 8, 4, and 7 once daily (4-step titration/ 4 week per dose) from Weeks 1 to 16 followed by additional treatment of SC MEDI0382 Dose 7 once daily from Weeks 17 to 18.
89365778|NCT04269538|Experimental|SAD Cohorts 1-2 Experimental Arm|Experimental Arm Active drug 150 mg and 450 mg SC dosing
89365779|NCT04269538|Placebo Comparator|SAD Cohorts 1-2 Placebo Arm|Placebo Arm
89365780|NCT03298750|Experimental|Mechanical stimulation|Mechanical stimulation of ovarian tissue
88836958|NCT02514226|Placebo Comparator|G1-control group|"Arm description: G1 - control group - (n = 30) dental hygiene orientation (DHO) + supragingival treatment + simulation of using photodynamic therapy (PDT).~In G1, all participants will receive supragingival treatments by an experienced specialist with universal curettes and ultrasound. Supragingival treatment will be performed above the gingival margin. The simulation of using photodynamic therapy (PDT) will be performed with laser turned off. No antibiotics and oral antiseptics will be prescribed."
88836959|NCT02514226|Active Comparator|G2- positive control group|"Arm description: G2 - positive control group (gold standard) - (n = 30) - DHO + periodontal treatment + simulation of using PDT.~All participants will receive periodontal treatment - scaling and root planning (SRP) by an experienced specialist with universal curetes and ultrasound in a full mouth manner. The simulation of using photodynamic therapy (PDT) will be performed with laser turned off. No antibiotics and oral antiseptics will be prescribed"
89365781|NCT03619382||Healthy|Subjects identified to have a healthy foot/ankle
89365782|NCT03625700||Hypoxia|"Patients without chronic obstructive pulmonary disease: blood oxygen saturation <94 % irrespective of supplemental oxygen~Patients with chronic obstructive pulmonary disease: blood oxygen saturation <88% irrespective of supplemental oxygen"
88836960|NCT02514226|Active Comparator|G3 -experimental active comparator group|"Arm description: G3 - experimental group - (n = 30) DHO +SRP + PDT with methylene blue~In G3, periodontal treatment and photodynamic therapy (PDT) will be performed. The scaling and root planing will be performed identical as G2. The PDT will be administered in periodontal pockets > 4mm. Methylene blue will be applied in the deep of periodontal pockets. After 5 minutes of application the red laser diode (λ = 660 nm) will be applied with output power of 100 mW with 90 seconds of exposure, i.e. 9J in each point. Applications will be held in six sites around the tooth in all teeth. To finalize, 1 minute of irradiation in scan around each tooth and rinsing with saline solution to remove the photosensitizer"
88836961|NCT02476682||Normal subjects|blood or stool samples will be collected from people referred for screening colonoscopy
88836962|NCT02476682||Colorectal cancer|blood or stool samples will be collected from people with colorectal cancer detected at colonoscopy or resection
88836963|NCT02476682||Polyps <10mm and no high risk features|blood or stool samples will be collected from people with no polyps or low risk polyps (<10mm, no villous component or dysplasia) detected at colonoscopy
88836964|NCT02476682||Advanced Mucosal Neoplasia|blood or stool samples will be collected from people with AMN detected at resection
88836965|NCT02476682||Sessile Serrated Adenoma|blood or stool samples will be collected from people with SSP detected at resection
88836966|NCT02476682||non-colorectal neoplastic disease|Participants with disease that is not colorectal neoplasia. Analysis of this cohort is not a primary endpoint but the investigators will report assay positivity in this group on an opportunistic basis. This cohort will include patients diagnosed with, for example, inflammatory bowel disease or extracolonic cancer.
88836967|NCT02470416|Active Comparator|Case|Patients who have had a previous diagnosis and/or treatment of a duodenal/ampullary polyp at Westmead hospital
88836968|NCT02470416|Active Comparator|Control|Age matched controls having VCE for OGIB/IDA at Westmead hospital.
88836969|NCT02378038|Experimental|PNT2258|PNT2258 will be administered at 120 mg/m2 on days 1-5 of a 21-day cycle for 8 induction cycles followed by continuation phase therapy at a dose of 100 mg/m2 on days 1-4 of a 28-day cycle.
88836970|NCT02364687||Participants|Participants will have previously had an MRI scan and will undergo a CT scan.
88836971|NCT02359175|Active Comparator|Active Epidural analgesia|Epidural catheter: Bupivacain 1,0 mg/ml + Fentanyl 2 micrograms/ml. Oral analgesia: Paracetamol, NSAID and placebo tablets.
88836972|NCT02359175|Active Comparator|Placebo Epidural analgesia|Epidural analgesia: Placebo. Oral analgesia: Paracetamol, NSAID and opioids tablets.
88836973|NCT02310139||Failed/Difficult Colonoscopy|Patients referred for colonoscopy because of previously failed attempt at complete caecal intubation.
88836974|NCT02306707||Endoscopic Mucosal Resection|Patients who are referred for Endoscopic Mucosal Resection of Stomach Lesions will be included in this cohort.
88836975|NCT02306603||Endoscopic Mucosal Resection|Patients who are referred for Endoscopic Mucosal Resection of Duodenal and Ampullary Lesions will be included in this cohort.
88836976|NCT02305290||Endoscopic Mucosal Resection|Patients who are referred for Endoscopic Mucosal Resection of Upper Gastrointestinal Lesions will be included in this cohort.
88836977|NCT02238938|Experimental|en-bloc resection|En- bloc resection is done after marking by use of different customary endoscopic knifes including combining devices as hybrid knife to cut down the lesion. After submucosal injection of liquid (saline or equivalent) to elevate the tissue it will be dissected and removed by a snare of adequate size solitarily. Since the aim of this method is the total resection basally and laterally, only one session is intended.
88836978|NCT02238938|Active Comparator|piecemeal resection|"Piecemeal resection will be done by snare following marking and submucosal injection of saline or equivalent liquids. Small leftover adenoma tissue will be resected thoroughly by snare or forceps. High resolution endoscopes are mandatory.~After three months, an APC therapy will follow any piecemeal resection, if necessary, another resection of leftover adenoma will be done. This second session can be done by sigmoidoscopy."
88836979|NCT02215980|Experimental|A|"Lenalidomide: at the dose of 25 mg/daily as oral administration (PO) on days 1-21.~Dexamethasone: at the dose of 20 mg as oral administration (PO) once weekly. Each cycle will be repeated every 28 days until progression or intolerance."
88836980|NCT02215980|Experimental|B|"Lenalidomide: at the dose of 25 mg/daily as oral administration (PO) on days 1-21~Dexamethasone: at the dose of 20 mg as oral administration (PO) once weekly. Each cycle will be repeated every 28 days, for a total of 9 cycles.~Maintenance until progression or intolerance:~- Lenalidomide: 10 mg/daily on days 1-21 of each 28-day cycle"
88836981|NCT02198976||Barrett's Oesophagus|Patients with Barrett's Oesophagus with either high grade dysplasia (HGD) or intramucosal cancer (IMC)
88836982|NCT02196649|Experimental|Endoscopic Clipping|Participants randomised to the arm will receive endoscopic clips to their defect following EMR.
88836983|NCT02196649|No Intervention|No Endoscopic Clipping|These participants will receive standard of care practice only.
88836984|NCT02147184||SSRI Group|Participants within one month of starting an SSRI
88836985|NCT02147184||Unmedicated Group|No treatment with SSRIs
88836986|NCT02130362||Immunosuppressant Therapy|Pediatric patients who are being prescribed and treated with immunosuppressant therapy
88836987|NCT02130362||Adalimumab (Humira) Treatment|Pediatric patients who are prescribed and treated with adalimumab
89530341|NCT03245671|Active Comparator|Decadron|Patients in the Decadron group will receive epidural injections containing a total of 15 mg Decadron.
88836988|NCT02101021|Experimental|Momelotinib|Participants will receive momelotinib plus nab-paclitaxel and gemcitabine.
88836989|NCT02101021|Placebo Comparator|Placebo|Participants will receive placebo to match momelotinib plus nab-paclitaxel and gemcitabine.
88836990|NCT02088632|Active Comparator|Incobotulinumtoxina|Xeomin 25-100 units injected to chosen area one time.
88836991|NCT02088632|Placebo Comparator|Placebo Comparator|Placebo Comparator is 1-2 ml normal saline solution injected to chosen area one time.
88836992|NCT02031536|Experimental|Arm A (everolimus)|Patients receive everolimus PO QD on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
88836993|NCT02031536|Placebo Comparator|Arm B (placebo)|Patients receive placebo PO QD on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
89365783|NCT03625700||Normoxia|"Patients without chronic obstructive pulmonary disease: blood oxygen saturation 94-98% in combination with supplemental oxygen OR blood oxygen saturation ≥94% without supplemental oxygen.~Patients with chronic obstructive pulmonary disease: blood oxygen saturation 88-92% in combination with supplemental oxygen OR blood oxygen saturation ≥88% without supplemental oxygen."
89365784|NCT03625700||Hyperoxia|"Patients without chronic obstructive pulmonary disease: blood oxygen saturation >98% in combination with supplemental oxygen~Patients with chronic obstructive pulmonary disease: blood oxygen saturation >92% in combination with supplemental oxygen"
89365785|NCT03293602|Experimental|F-MISO PET imaging|F-MISO PET imaging will be added to the preoperative staging explorations of a patient with high risk prostate cancer candidate to radical prostatectomy. Patient will be selected during multidisciplinary meeting and urology consultation of Bordeaux and Toulouse university hospitals. Functional MRI imaging should be available before surgery. If patient consent to participate in the study, F-MISO PET imaging will be planed before prostatectomy. Results of this exam will not be considered for patient therapeutic management.
89365786|NCT03650036|Experimental|Group 1|In group 1, Pulp Therapy will be done with the CTZ paste (composed of 62.5 mg of chloramphenicol, 62.5 mg of tetracycline, 125 mg of zinc oxide) will be manipulate with 0.1ml of eugenol in a sterile glass plate with flexible metal spatula at the time of use and will be taken at the tip of a number 5 exploratory probe and dispensed at the entrances of the root canals where it will be accommodated with light pressure of sterile cotton balls. The CTZ paste will be protected with a thin layer of gutta-percha, previously heated in an alcohol lamp and placed in a thin layer on the CTZ pulp. The gutta-percha blade will be condensed with medium size amalgam presser and has the objective of physically isolating the CTZ paste from the restorative material.
89365787|NCT03650036|Experimental|Group 2|In Group 2, Pulp Therapy will be done with ZOE paste. The mechanical preparation of the root canals with 2% chlorhexidine solution and first-series K files will be performed. The instrumentation limit shall be 1 mm short of the radiographic apex. After finishing the chemical-mechanical preparation, drying of the root canals with sterile absorbent paper cones and ZOE paste insertion with K files will be performed. The zinc oxide of the ZOE paste will be supplied in 250mg capsules and handled with 0.1ml eugenol in a sterile glass plate with metal spatula at the time of use. The protection of the ZOE paste will follow the same sequence as the CTZ paste.
89365788|NCT03298672|Experimental|NDX-1017|NDX-1017 will be administered via subcutaneous injection
89365789|NCT03298672|Placebo Comparator|Placebo|Placebo will be administered via subcutaneous injection
89365790|NCT04049162|Experimental|Blueberry Plus Exercise (BB-EX)|BB-Ex participants will consume lyophilized blueberry powder, mixed with water (18 grams, equivalent to 3/4ths cup of blueberries) with 2 daily meals (36 g/d blueberry powder total; approx. 1.5 servings/d)
89365791|NCT04049162|Placebo Comparator|Blueberry Placebo Plus Exercise (P-EX)|Participants randomized to P-EX treatment will consume an indistinguishable placebo powder, matched for color, flavor, consistency, and caloric content, in the same manner.
89365792|NCT04489264||ASCT group|patients who achieved CR or PR after 6-8 cycles first-line therapy receive ASCT as consolidation therapy
89365793|NCT04489264||Observation group|patients who achieved CR or PR after 6-8 cycles first-line therapy finish their therapy and go into follow-up
89365794|NCT03298594|Experimental|specific cervicograph|Specific cervicograph, including an alert line (normal progression of cervical dilation, i.e. 1 cm per hour) and an action line 2 hours after the alert line. This should be completed after the diagnose of active labor
89365795|NCT03298594|No Intervention|Usual cervicograph|The usual cervicograph in our unit is not having lines
89365796|NCT03286582|Experimental|AC-203|
89365797|NCT03286582|Active Comparator|Clobetasol|
89365798|NCT05202002|Active Comparator|Educational video|Participants will receive an online video clip, explaining the benefits of breastfeeding.
89365799|NCT05202002|Sham Comparator|Control group|Participants will not receive the video clip
88836994|NCT02028455|Experimental|Phase 1 - Cohort 1A|This phase 1 cohort will receive Patient Derived CD19 specific CAR T cells at a dose of 5x10^5 CAR T cells/kg
88836995|NCT02028455|Experimental|Phase 1 - Cohort 1B|This phase 1 cohort will receive Patient Derived CD19 specific CAR T cells at a dose of 1x10^6 CAR T cells/kg
88836996|NCT02028455|Experimental|Phase 1 - Cohort 1C|This phase 1 cohort will receive Patient Derived CD19 specific CAR T cells at a dose of 5x10^6 CAR T cells/kg
88836997|NCT02028455|Experimental|Phase 1 - Cohort 1D|This phase 1 cohort will receive Patient Derived CD19 specific CAR T cells at a dose of 1x10^7 CAR T cells/kg
88836998|NCT02028455|Experimental|Phase 1 - Cohort 1F1|This phase 1 cohort will receive Patient Derived CD19 specific CAR T cells at a dose of 5x10^5 CAR T cells/kg following prescribed lymph-depletion with fludarabine and cyclophosphamide
88836999|NCT02028455|Experimental|Phase 1 - Cohort 1F2|This phase 1 cohort will receive Patient Derived CD19 specific CAR T cells at a dose of 1x10^6 CAR T cells/kg following prescribed lymph-depletion with fludarabine and cyclophosphamide
88837000|NCT02028455|Experimental|Phase 2|The phase 2 cohort will receive Patient Derived CD19 specific CAR T cells at a dose of 1 x 10^6 CAR T cells/kg following lymphodepletion if indicated.
88837001|NCT02023996|Experimental|PET Imaging With 89Zr-DFO-Trastuzumab|Patients will receive 5 mCi + 0.5 mCi of 89Zr-DFO-trastuzumab given IV over 5-10 min. Injection of cold trastuzumab will be mixed with 89Zr-DFO-trastuzumab so that total mass is equal to 50 mg [1]. In the first ten patients we wish to obtain normal organ dosimetry, pharmacokinetics & determine optimal imaging time, therefore these patients will undergo imaging at 4 time points post injection, whole body counts & blood draws. Subsequent patients will receive the antibody & will only undergo imaging at a single time point (based on the first 10 patients) & will not have whole body counts or serial bloods for pharmacokinetics. The administration of 89Zr-DFO-trastuzumab to patients undergoing a second study will be identical as for their baseline study. Patients undergoing a second injection will only have one scan that will be performed within 1 day before or 2 days after their optimum imaging time point, determined from their baseline imaging study.
88837002|NCT02020720|Experimental|Diagnostic (18F-DOPA-PET)|Within 1 week of biopsy or resection, patients undergo 18F-DOPA PET/CT scan and pMRI and DTI at baseline. Patients then undergo stereotactic craniotomy or image-guided biopsy.
88837003|NCT02019641|Experimental|Aerobic Exercise Intervention (AET+)|Participant with interstitial lung disease performed aerobic exercise three times a week plus weekly education for 10 weeks
88837004|NCT02019641|Active Comparator|Control Group (CON)|Participant with interstitial lung disease performed weekly education for 10 weeks, then crossed over to perform aerobic exercise three times a week for 10 weeks
88837005|NCT02000141||Endoscopic Mucosal Resection|Endoscopic Mucosal Resection of Colonic Advanced Mucosal Lesions
88837006|NCT01968200|Experimental|Enalapril concomitant|Enalapril started concomitantly to AC-containing treatments
89365800|NCT02460640|Active Comparator|Tap Block|the intervention will be tap block after induction of anesthesia with ropivacaine 0,5% 15ml and continuous patient-controlled analgesia with morphine
89365801|NCT02460640|Active Comparator|No Tap Block|the patients who not receive tap block but they will be as intervention intravenous Patient controlled analgesia
89365802|NCT03568760|Experimental|SFA treatment|Semantic feature analysis
89365803|NCT03568760|Placebo Comparator|Comprehension training|Comprehension training
89365804|NCT03298516|Experimental|Arm A: DCLL9718S|Participants will receive escalating doses of DCLL9718S intravenously (IV) in each 21-day cycle to determine MTD and RP2D in dose-escalation stage followed by DCLL9718S IV at RP2D in each 21-day cycle in dose-expansion stage until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
89365805|NCT03298516|Experimental|Arm B: DCLL9718S and Azacitidine|Participants will receive escalating doses of DCLL9718S (starting dose: at least one dose level below a completed and tolerated DCLL9718S monotherapy in Arm A) IV in each 28-day cycle and azacitidine 75 milligrams per square meter (mg/m^2) subcutaneously (SC) or IV on Days 1-7 of each 28-day cycle to determine MTD and RP2D of DCLL9718S in dose-escalation stage followed by DCLL9718S IV at RP2D in each 28-day cycle and azacitidine 75 mg/m^2 SC or IV on Days 1-7 of each 28-day cycle in dose-expansion stage until disease progression, unacceptable toxicity, or any other discontinuation criteria are met. Azacitidine may also be given on Days 1-5 and Days 8-9 depending on institutional preference.
89365806|NCT03293446|Experimental|Patients with chronic kidney disease|
89365807|NCT03293446|Active Comparator|Healthy controls|
89365808|NCT03288298|Experimental|luteolin|a natural extract derived flavinoids
89365809|NCT03288298|Active Comparator|nano-luteolin|nano-particles derived from a natural extract luteolin
89365810|NCT03298282||Imaging Registry|Imaging cohort: Patients with intermediate lesions
89365811|NCT03298204||Chemoradiotherapy|
88837007|NCT01968200|Experimental|Enalapril after injury|Enalapril prescribed to selected patients showing laboratory evidences of injury after chemotherapy at follow-up visits.
88837008|NCT01964430|Experimental|nab-Paclitaxel 125 mg/m^2 plus gemcitabine 1000 mg/m2|Participants received nab-Paclitaxel 125 mg/m^2 administered as an intravenous (IV) infusion over 30 to 40 minutes, followed by gemcitabine 1000 mg/m^2 as an IV infusion over 30 to 40 minutes on Days 1, 8 and 15 of each 28-day treatment cycle for 6 cycles, unless there was evidence of radiologic disease recurrence, unacceptable toxicity, subject or physician decision, withdrawal of consent, or death.
88837009|NCT01964430|Active Comparator|Gemcitabine 1000 mg/m^2|Participants received gemcitabine 1000 mg/m^2 administered as an IV infusion over 30 to 40 minutes on Days 1, 8 and 15 of each 28-day treatment cycle for 6 cycles, unless there was evidence of radiologic disease recurrence, unacceptable toxicity, subject or physician decision, withdrawal of consent, or death.
88837010|NCT01934868|Experimental|Prolotherapy Injections|"Each patient will be evaluated clinically and the spinal levels to be injected will be decided upon during each visit. The levels to be injected will largely depend on the pain referral patterns. All prolotherapy injections will be performed under ultrasound guidance.~A prolotherapy solution of 20% dextrose combined with 1% lidocaine will be injected to facet capsular ligaments and interspinous ligaments of the lumbar spine and the posterior sacroiliac ligaments. Six points will be injected in each treatment session. These sessions will be 4 weeks apart."
88837011|NCT01934868|Active Comparator|Epidural Steroid Injections (ESI)|Those patients assigned to the ESI group will receive epidural steroid injections with 80mg methylprednisolone and 10mg buvicaine to the interlaminar space. These will be performed 4 weeks apart and under fluoroscopy. The level that will be injected will depend both on the clinical presentation as well as the size of the interlaminar space seen under fluoroscopy.
88837012|NCT01913717|Experimental|External beam radiotherapy|External beam radiotherapy
88837013|NCT01863043|Active Comparator|Routine aspiration of gastric contents|Infants will have routine aspiration of gastric contents prior to each feeding to monitor the amount of residual gastric contents remaining in the stomach.
89365812|NCT03298204||Chemoradiotherapy following chemotherapy|
88837014|NCT01863043|Experimental|No aspiration of gastric contents|Infants will not have routine aspiration of gastric contents prior to every feeding to assess residual gastric contents.
89001616|NCT03452488|Experimental|Arm 2 - BIO101 - Half daily dose 350 mg|"4 capsules taken twice a day (2 placebo and 2 experimental study drug) in the morning and in the evening with the meal approximately at 12-hour distance for 26 weeks.~Study Drug Component : 251 mg per capsule including 175 mg of active principle 20-hydroxyecdysone (20E) containing also the following compendial excipients: colloidal silica, microcrystalline cellulose and magnesium stearate."
89365813|NCT03298204||Chemoradiotherapy followed by chemotherapy|
89365814|NCT03298126|Active Comparator|TR BAND Protocol A|In this group, air removal from TR band was initiated after 2 hours of TR band application. 3 ml of air was removed periodically at an interval of 15 minutes until all the air is eliminated from the band. In case of bleeding or hematoma while deflating air, 4 ml of air was re-injected and observed for 30 minutes until next attempt was made to deflate the band. The data including the attempts made at deflating TR band, time and amount of air injected along with the response to each deflation i.e. occurrence of bleeding or hematoma was noted down in the proforma
89530342|NCT03245671|Active Comparator|Kenalog|Patients in the Kenalog group will receive epidural injections containing a total of 80 mg Kenalog.
89530343|NCT03254641||hypogondal men|men referred for hCG stimulation test
89530344|NCT02729753|Other|CryoBalloon™ Full Ablation System|To evaluate CryoBalloon™ Full Ablation System for the ablation of 360 degrees of human esophageal epithelium in patients scheduled to undergo esophagectomy.
89530345|NCT02729753|Other|CryoBalloon™ Swipe Ablation System|To evaluate CryoBalloon™ Swipe Ablation System for the ablation of 90 degrees of human esophageal epithelium in patients scheduled to undergo esophagectomy.
88837015|NCT01841359|No Intervention|Baseline|"Baseline Arm/Phase 1, is comprised of study visits 1 and 2. Visit 1: Screening visit. Eligible individuals who provided informed consent were asked to keep a 3-day log of food intake, blood glucose (8 per day), as well as any hypoglycemic symptoms, concurrent with a 3 day period of blinded (masked) continuous glucose monitoring device wear.~Visit 2: a baseline mixed meal tolerance test was performed. Glucose, hormonal responses, and satiety were assessed. Glucose and symptom logs were reviewed."
88837016|NCT01841359|Experimental|Pramlintide|"At the end of Visit 2 (following the baseline mixed meal tolerance test), pramlintide was prescribed, with instructions for titration from minimal to maximal dose (15 to 120 µg). During the treatment phase (8 weeks), the participants were asked to keep record of all hypoglycemic symptoms and blood glucose measurements..~Visit 3: (week 4 of treatment) focused on evaluation of symptoms and side effects. Participants again completed a food and glucose diary for 3 days with concurrent wear of a blinded (masked) continuous glucose monitoring device.~Visit 4: (week 8 of treatment), participants received a dose of pramlintide 15 minutes prior to undergoing a repeat mixed meal tolerance test. (the dose administered was the maximally tolerated dose of pramlintide used during the 8 week outpatient treatment phase)."
88837017|NCT01788592||Drug eluting stent|Patients who receiving drug eluting stents
88837018|NCT01786486||Delivery system entry|
88837019|NCT01683279|Experimental|CAR+ T cells|Subjects will receive two days of cyclophosphamide for a total of 3g/m^2 followed several days later by a single dose of Autologous CD19 CAR+ EGFTt + T cells
88837020|NCT01660451|Experimental|Copanlisib (indolent NHL)|Part A: Participants in this arm will be patients with indolent NHL.
88837021|NCT01660451|Experimental|Copanlisib (aggressive NHL)|Part A: Participants in this arm will be patients with aggressive NHL.
88837022|NCT01660451|Experimental|Copanlisib (indolent B-cell NHL)|Part B: Participants in this arm will be patients with indolent B-cell NHL.
88837023|NCT01601678|Active Comparator|Peroral Endoscopic Myotomy POEM|Patients with Achalasia, designated to receive a myotomy of the lower esophageal sphincter, who have been randomised into the POEM therapy group
88837024|NCT01601678|Active Comparator|Laparoscopic Heller Myotomy LHM|Patients with Achalasia, designated to receive a myotomy of the lower esophageal sphincter, who have been randomised into the LHM therapy group.
88837025|NCT01586065|Experimental|CGM in adolescents with poorly-controlled T1D|Adolescents with poorly controlled type 1 diabetes on insulin pumps were admitted to the clinical research center (CRC) and a continuous glucose sensor was inserted. Sensor glucose (SG) values were compared to plasma glucose measured at least hourly using Yellow Springs Instrument's (YSI) glucose analyzer. SG rather than YSI was used for treatment decisions unless YSI was <70 mg/dL or specific criteria indicating SG and YSI were very discordant were met.
88837026|NCT01579734|Placebo Comparator|Placebo|1 tablet day for 5 years
88837027|NCT01579734|Active Comparator|Tamoxifen|Tamoxifen 5 mg, (1 tablet) day for 5 years
88837028|NCT01566240|Active Comparator|Chemoradiation|Radiotherapy (external beam and brachytherapy) plus concurrent Cisplatin weekly for 5 weeks
88837029|NCT01566240|Experimental|Induction Chemotherapy + Chemoradiation|6 cycles of weekly Paclitaxel and Carboplatin followed by Chemoradiation as per Active Comparator
88837030|NCT01556399||Duodenal adenomas|Patients who consent to participate in this study will have a small sample of their adenoma and normal tissue sent for molecular testing.
88837031|NCT01550198||Newborns|"Critically ill newborns admitted to level III neonatal intensive care unit of a university hospital, who will be monitored using transpulmonary ultrasound dilution (advanced hemodynamic monitoring)"
88837032|NCT01529047|Experimental|In-person PFI|In-person personalized feedback intervention
88837033|NCT01529047|Experimental|Web-based PFI|Web-based personalized feedback intervention
88837034|NCT01529047|No Intervention|Assessment Only|Complete online survey assessments only.
88837035|NCT01390584|Experimental|ABVD + INRT|"Induction ABVD chemotherapy: Patients receive doxorubicin hydrochloride IV, bleomycin sulfate IV, vinblastine IV over 3-5 minutes, and dacarbazine IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for 2 courses.~PET-CT scan: Then patients undergo fludeoxyglucose F 18 (18 FDG) positron emission tomography (PET)/computed tomography (CT). If results are negative, patients receive the following treatment.~ABVD + INRT: Patients receive doxorubicin hydrochloride, bleomycin sulfate, vinblastine, and dacarbazine as in induction chemotherapy. Treatment repeats every 28 days for 4 courses. Within 3-6 weeks after completion of chemotherapy, patients undergo involved-node radiotherapy (INRT) 5 days a week for approximately 3½ weeks."
88837036|NCT01390584|Experimental|ABVD + BEACOPP + INRT|"Induction ABVD chemotherapy: Patients receive doxorubicin hydrochloride IV, bleomycin sulfate IV, vinblastine IV over 3-5 minutes, and dacarbazine IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for 2 courses.~PET-CT scan: Then patients undergo fludeoxyglucose F 18 (18 FDG) positron emission tomography (PET)/computed tomography (CT). If results are positive, patients receive the following treatment.~BEACOPP + INRT: Patients receive doxorubicin hydrochloride IV and cyclophosphamide IV over 60 minutes on day 1, etoposide IV over 60 minutes on days 1-3, procarbazine hydrochloride orally (PO) on days 1-7, prednisone PO on days 1-14, and bleomycin sulfate IV and vincristine sulfate IV on day 8. Treatment repeats every 21 days for 4 courses. Within 3-6 weeks after completion of chemotherapy, patients who achieve complete response with a negative 18FDG-PET/CT scan undergo INRT 5 days a week for approximately 3½ weeks."
88837037|NCT01374841|Experimental|Stem Cell Transplant+Cyclophosphamide|patients with high-risk hematologic malignancies will receive hematopoietic stem cell transplantation from haploidentical donors after treatment with cyclophosphamide
88837038|NCT01368731|No Intervention|nil prophylactic coagulation|
88837039|NCT01368731|Active Comparator|Prophylactic coagulation|
88837040|NCT01242800|Active Comparator|Arm I|Patients receive standard palliative therapy, if needed, to address symptoms such as tumor ulceration, pain, bulky adenopathy causing arm symptoms, and other similar situations. Therapy may consist of radiotherapy alone, surgery alone, or a combination of both.
88837041|NCT01242800|Experimental|Arm II|Patients undergo surgery comprising breast-conserving therapy (BCT) or total mastectomy according to patient and treating physician preference. Surgery is to occur no later than 10 weeks after completion of 32 weeks of systemic therapy. Free surgical margins must be achieved with re-excision or mastectomy for patients undergoing BCT. After completion of BCT, patients undergo radiotherapy once a day, 5 days per week. Patients who had mastectomy undergo radiotherapy at the discretion of treating physician.
89365815|NCT03298126|Active Comparator|TR BAND PROTOCOL B|In this group deflation was initiated after 2 hours of TR band application as described by Cohen and Alfonso. [6] 5 ml of air was deflated at first attempt. Next attempt was carried out after 15 minutes in which further 5 ml was removed. After 15 minutes, the remaining 2 ml of air was released from the band. In case of bleeding or hematoma at any attempt, 6 ml air was re-injected and interval for 15 minutes taken to attempt further air deflation. All the attempts and its response were recorded in the proforma filled out by the assessor.
89365816|NCT05160740|Experimental|ICG molecular fluorescence imaging guided surgery|ICG molecular fluorescence imaging will be used in local hepatectomy of primary liver cancer in this group
89365817|NCT05160740|Placebo Comparator|No ICG molecular fluorescence imaging guided surgery|ICG molecular fluorescence imaging will not be used in local hepatectomy of primary liver cancer in this group
89365818|NCT03286192|Experimental|Single-Arm Intervention|All participants in this arm receive compassion cultivation training
89365819|NCT05073614|Other|patients with chronic gastritis|patients with symptomatic chronic gastritis will undergo upper endoscopy, gastric biopsies will be obtained to establish giagnosis of chronic gastritis, detection of h.pylori and assessment of heparanase expression.
89365820|NCT03286036||Lung cancer patients|Patients with lung cancer who undergo surgical resection of the tumor
88837042|NCT01216683|Experimental|Arm A then Arm D (Induction with Bendamustine + Rituximab; Continuation with Rituximab)|"Arm A (induction): Patients receive rituximab intravenously (IV) on day 1 and bendamustine hydrochloride IV over 1 hour on days 1 and 2. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.~Arm D (continuation): Beginning 4 weeks after the completion of induction therapy, patients who have stable disease or better at time of post-induction restaging receive rituximab IV on day 1. Treatment repeats every 8 weeks for 2 years in the absence of disease progression or unacceptable toxicity."
88837043|NCT01216683|Experimental|Arm B then Arm E (Induction with Bendamustine + Rituximab + Bortezomib; Continuation with Rituximab)|"Arm B (induction): Patients receive rituximab IV on day 1; bortezomib IV on days 1, 4, 8, and 11; and bendamustine hydrochloride IV over 1 hour on days 1 and 4. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.~Arm E (continuation): Beginning 4 weeks after the completion of induction therapy, patients who have stable disease or better at time of post-induction restaging receive rituximab as in arm D."
89365821|NCT03285802|Experimental|Letrozole and Everolimus|Letrozole 2.5mg daily q 30 days Everolimus 10mg daily q 28 days
88837044|NCT01216683|Experimental|Arm C then Arm F (Induction with Bendamustine+Rituximab; Continuation with Lenalidomide + Rituximab)|"Arm C (induction): Patients receive rituximab IV on day 1 and bendamustine hydrochloride IV over 1 hour on days 1 and 2. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.~Arm F (continuation): Immediately after completing induction therapy, patients who have stable disease or better at time of post-induction restaging receive oral lenalidomide on days 1-21. Treatment repeats every 4 weeks for 13 courses in the absence of disease progression or unacceptable toxicity. Beginning 4 weeks after the completion of induction therapy, these patients receive rituximab IV on day 1. Treatment repeats every 8 weeks for 2 years in the absence of disease progression or unacceptable toxicity."
88837045|NCT01166113|Experimental|PCP|
89365822|NCT03293290|Experimental|PrEP|For participants who are eligible for PrEP and willing to participate, subjects on PrEP will be followed for 1 year with quarterly assessments.
88837046|NCT01160107|Experimental|RP followed MPR|
88837047|NCT01145495|Experimental|Treatment (lenalidomide, rituximab)|Patients receive lenalidomide PO QD on days 1-21. Treatment with lenalidomide repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity. Patients also receive rituximab IV on days 1, 8, 15, and 22 and in weeks 13, 21, 29, and 37 in the absence of disease progression or unacceptable toxicity.
88837048|NCT01124695|Experimental|Tamoxifen|Patients receive oral tamoxifen citrate once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicities.
88837049|NCT01105169|Active Comparator|GG genotype and magnesium treatment|Participants who have the GG genotype will be assigned to magnesium glycinate.
88837050|NCT01105169|Placebo Comparator|GG genotype and placebo|Participants who have the GG genotype will be assigned to placebo group
88837051|NCT01105169|Active Comparator|GA/AA genotype and magnesium treatment|Participants who have the GA/AA genotype will be assigned to magnesium glycinate
88837052|NCT01105169|Placebo Comparator|GA/AA genotype and Placebo|Participants who have the GA/AA genotype will be assigned to placebo group
88837053|NCT01084083|Experimental|Group 1|After induction therapy with Paclitaxel and Cisplatin, patients undergo low-dose intensity-modulated radiotherapy (IMRT) 5 days per week for approximately 5 weeks (27 fractions). Patients also receive cetuximab IV over 1-2 hours once weekly for 6 weeks.
89365823|NCT03929822||Contrast-Enhanced Spectral Mammography (CESM)|Women called back from an abnormal screening mammogram/tomosynthesis exam will be offered CESM as part of their diagnostic work up. The radiologist will interpret the low energy images and record their findings.
89365824|NCT04969796|Experimental|REACH Hope|Participants receive the REACH behavioral intervention coupled with the Department of Defense Hope Box app.
89365825|NCT04969796|Active Comparator|Wait list control|Participants receive the REACH behavioral intervention coupled with the Department of Defense Hope Box app.
89365826|NCT02461264|Active Comparator|ARM A|Two packed red blood cells will be transfused in patient with anemia defined as a hemoglobin level below 8 g / dL. Clinical and biological monitoring will be carried out later each day. If the hemoglobin is <8 g / dL, two new packed red blood cells are transfused and so on.
89365827|NCT02461264|Experimental|ARM B|Single red blood packed cells Transfusion will be administered in patient with anemia defined as a hemoglobin level below 8 g/dL. Clinical and biological monitoring will be carried out later each day. If the hemoglobin is <8 g / dL, a single unit is transfused and so on.
89365828|NCT03770780|Experimental|SAGE-718|
89365829|NCT03770780|Placebo Comparator|Placebo|
89365830|NCT03297970||Bogota School Children Cohort|"Children are classified according to exposure levels of:~Micronutrient biomarker indicators:~Ferritin~Hemoglobin~Mean corpuscular volume~Zinc~Vitamin A~Vitamin B12~Folate~Vitamin D~Serum fatty acids~Inflammatory biomarkers:~C-reactive protein~Diet~Socioeconomic status indicators~Anthropometric indicators~Incidence of infectious morbidity symptoms~DNA biomarkers"
89365831|NCT05130086|Experimental|Islatravir|60 mg Islatravir taken orally in tablet form once monthly for up to 24 weeks
89365832|NCT05111210||Group 1: 10 patients with cutaneous psoriasis|Visits for research are done as part of the care, no visits are added. There is only 1 visit for patients of this group, they will be sampled once with 51 mL of blood before initiation of a biotherapy and some data will be collected
89365833|NCT05111210||40 patients with a medical decision to treat cutaneous psoriasis with an anti-IL-23 biologic|Visits for research are done as part of the care, no visits are added. Two visits are planned for this group of patients : before and after initiation of therapy. These patients will be sampled twice with 51 mL of blood. Skin biopsies will be obtained from a subset of 10 patients to analyse the skin transcriptome, before and after treatment with anti-IL-23 biologics Data will be collected at the two timepoints.
89365834|NCT03285334|Experimental|XP-endo Shaper|The XP-endo Shaper is an innovative single instrument manufactured from Max wire. Its special ability to shift crystalline structure at body temperature in order to adapt to the root canal wall, has provided a unique instrument with the promise of anatomical shaping.
89365835|NCT03285334|Active Comparator|iRace|rotary files
89365836|NCT03285256|Experimental|Experimental Memory Training|Experimental memory training program
88837054|NCT01084083|Experimental|Group 2|After induction therapy with Paclitaxel and Cisplatin, patients undergo standard-dose IMRT 5 days per week for approximately 6 weeks (33 fractions). Patients also receive cetuximab IV over 1-2 hours once weekly for 7 weeks.
88837055|NCT01079780|Active Comparator|Arm A (IC)|Patients receive cetuximab (500 mg/m2) intravenously (IV) over 60-120 minutes and irinotecan hydrochloride (180 mg/m2) over 60-90 minutes on day 1. Treatment repeats every 2 weeks until disease progression or unacceptable toxicities.
89365837|NCT03285256|Active Comparator|Comparator Memory Training 1|Comparator memory training program
89365838|NCT03285256|Active Comparator|Comparator Memory Training 2|Alternative comparator memory training program
89365839|NCT03297814|Active Comparator|Platelet lysate|A total of 5 ml platelet lysate will be intramuscularly injected in 4 doses with 2 week interval
89365840|NCT03297814|Placebo Comparator|placebo|A total of 5 ml of Normal Saline will be intramuscularly injected in 4 doses with 2 week interval
89365841|NCT03297736|Active Comparator|Control|Subjects receive the control device.
89365842|NCT03297736|Experimental|Investigational device|Subject receives the 3D CAD/CAM autograft prosthesis implant.
89365843|NCT05110274|Experimental|Sequential measurements of metabolic flexibility|Study participants will undergo three assessments of metabolic flexibility. Two measurements of metabolic flexibility will be conducted during two separate overnight stay in a metabolic chamber approximately 5-7 days apart. The third measurement of metabolic flexibility will be assessed during a hyperinsulinemic-euglycemic clamp procedure conducted 7-28 days following the completion of the second overnight stay in the metabolic chamber.
89365844|NCT02461186|Experimental|Arterolane maleate-piperaquine phosphate (Synriam)|
89365845|NCT02461186|Experimental|Dihydroartemisinin-piperaquine phosphate (Duocotexin)|
89365846|NCT04921670||Group A-Standard monitoring group (Reactive drug monitoring)|Participants assigned to this group will be managed the same as normally done per routine care, which involves adjusting their infliximab dose and/or dosing interval based on Inflammatory Bowel Disease (IBD) symptoms and routine care laboratory test results. The primary gastroenterologist will not be given the results of the infliximab and infliximab antibody level results of participants in this group unless their routine laboratory test results or IBD symptoms suggest their IBD may be worsening.
89365847|NCT04921670||• Group B- Infliximab level and infliximab antibody monitoring group (Proactive drug monitoring)|Participants assigned to the infliximab level and infliximab antibody level monitoring group will be managed based on the infliximab level and infliximab antibody level results as well as their IBD symptoms and the results of routine care laboratory tests. The goal is to keep infliximab levels in the optimal range with little to no antibodies. The primary gastroenterologist will remain blinded to the results of the infliximab level/infliximab antibody level test results and the participants' dose will be adjusted by one of the other study doctors who is not blinded to the results.
88837056|NCT01079780|Experimental|Arm B (ICR)|Patients receive ramucirumab (8 mg/kg) IV over 60 minutes on day 1 and cetuximab and irinotecan hydrochloride as in arm A. Treatment repeats every 2 weeks until disease progression or unacceptable toxicities.
88837057|NCT01079780|Experimental|Arm C (mICR)|Patients receive reduced dose of ramucirumab (6 mg/kg) IV over 60 minutes on day 1 and cetuximab (150 mg/m2) and irinotecan hydrochloride (400 mg/m2) as in arm B. Treatment repeats every 2 weeks until disease progression or unacceptable toxicities.
88837058|NCT01063179|Experimental|Arm A: VMPT|Induction therapy with nine 5-week courses of VELCADE/Melphalan/Prednisone/Thalidomide (V-MPT) followed by maintenance therapy with Thalidomide and VELCADE
88837059|NCT01063179|Active Comparator|VMP|"Induction therapy with nine 5-week courses of either VELCADE/Melphalan/Prednisone (V-MP).~No maintenance is scheduled."
89001617|NCT03452488|Experimental|Arm 3 - BIO101 - Full daily dose 700 mg|"4 capsules taken twice a day (4 experimental study drug) in the morning and in the evening with the meal approximately at 12-hour distance for 26 weeks.~Study Drug Component : 251 mg per capsule including 175 mg of active principle 20E containing also the following compendial excipients: colloidal silica, microcrystalline cellulose and magnesium stearate."
89365848|NCT03297658|Active Comparator|electro-acupuncture (EA) intervention|Micro electrodes will be placed at PC 4 and 6 , LI 4 and ST36. subjects will receive electro-acupuncture (EA) (treatment) mixed frequency( continuous plus dense disperse) will be at 2Hz and 100 Hz the amplitude will be 1000 microA.
89365849|NCT03297658|Sham Comparator|sham electro acupuncture|Micro electrodes will be placed at PC 4 and 6 , LI 4 and ST36. subjects Receive sham (control) will not have stimulation.
89365850|NCT03285022|Experimental|Zinc modified glass ionomer|Zinc modified glass ionomer (chemfill rock) galss ionomer used as restoration for posterior teeth in case of partial caries removel
89365851|NCT03285022|Active Comparator|Conventionel glass ionomer|Conventional glass ionomer used as restoration for posterior teeth in case of partial caries removel
89530346|NCT03254407|Other|Screening medical record|Screening medical record for possible IV-PO switch Possbile IV/PO switch communicated to prescriber by phone or e-note
89530347|NCT03254563||Obese with NAFLD|Patients who have NAFLD based upon ultrasound
88837060|NCT01013961|Active Comparator|Arm A (standard dose)|"Patients receive alemtuzumab subcutaneously (SC) on days 1-3, 6, 8, 10, 13, 15, 17, 20, 22, 24, 27, 29, and 31 and standard-dose rituximab 375 mg/m^2/week intravenously (IV) on days 8, 15, 22, and 29 in cycle 1 (33-day cycle). In cycle 2 and subsequent cycles (28-day cycle), patients receive alemtuzumab SC on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26 and standard-dose rituximab IV on days 3, 10, 17, and 24. Treatment repeats every 28 days for up to 3 cycles.~Alemtuzumab dose for cycle 1 week 1 requires a 'dose ramp' (3 mg day 1, 10 mg day2, and 30 mg day 3 of cycle 1) and then is 30 mg 3 times a week."
89178847|NCT04030949||Ateendes STD clinics Östergötland, nurse appointment|"The participant collects the rectal sample for chlamydia and gonorrhea (Abbot multi-collect swab) first and is instructed to try not to touch the perianal/perineal areas. Then the vaginal samples for chlamydia/gonorrhoea and M.genitalium are collected.~There is a group of women who have been tested positive for chlamydia by self-collected vaginal swab which is sent to the patient by mail. Those are requested to attend the STD-clinic for partner tracing and are offered antibiotic treatment with doxycycline. Those accepting to participate in the study will answer the study questions and will be tested again and a nurse will collect firstly an Abbot multi-collect swab from the anal verge, at the opening of the anal canal and then two rectal swabs using a pediatric proctoscope (one Abbot multi-collect and one standard Sigma swab of Sigma virocult) and the participant will self-collect a new vaginal sample for chlamydia/gonorrhea and one for M.genitalium (two Abbot multi-collect swabs)"
89178848|NCT04030949||Ateendes STD clinics Östergötland+Jönköping partner chlamydia|"Women attending the STD clinics because of a verified chlamydia infection of their current partner. This group of patients is examined and tested by a nurse or doctor before doxycycline treatment is offered.~Those accepting to participate in the study answer the questions about the experience of receptive anal sex and fellatio (and condom use) during the last 12 months and even additional questions regarding fellatio and whether it happened that a male partner ejaculated in oral cavity of the participant.~The first sample is an Abbot multi-collect swab taken from the anal verge and the anal canal and two more swabs are taken under the use of a pediatric proctoscope: one Abbot multi-collect and one standard Sigma swab of Sigma virocult and finally vaginal samples are collected (one Abbot multi-collect and one standard Sigma swab of Sigma virocult)"
89178849|NCT05565287|Experimental|Brazelton and Prechtl Assessment Group|Parental advise and intervention based on the combination of neonatal neurobehaviourism (Brazelton) and motor behaviour (Prechtl)
89178850|NCT05565287|No Intervention|No intervention group|Basic hospital guidelines
89178851|NCT00770562|Active Comparator|Dexamethasone|Participants received 40 milligrams (mg) dexamethasone, orally, once per day for 4 consecutive days (Days 1, 2, 3, and 4). Participants in this treatment arm who failed to achieve a sustained response and had a platelet count of less than or equal to (≤)20 x 10^9 platelets per liter (L; from Day 30 up to end of 6 months) were treated with salvage treatment of dexamethasone 40 mg, orally, once per day for 4 consecutive days (Days 1, 2, 3, and 4) and rituximab 375 mg per square meter (mg/m^2), intravenously (IV), with premedication of oral acetaminophen 500 mg and chlorpheniramine 10 mg IV on Days 7, 14, 21, and 28.
89178852|NCT00770562|Experimental|Dexamethasone plus Rituximab|Participants received dexamethasone 40 mg, orally, once per day for 4 consecutive days (Days 1, 2, 3, and 4) and rituximab 375 mg/m^2, IV, with premedication of oral acetaminophen 500 mg and chlorpheniramine 10 mg IV on Days 7, 14, 21, and 28. Nonresponsive participants with platelets less than (<) 20 x10^9/L or with active bleeding could have also received an additional treatment course of dexamethasone 40 mg, orally, once per day for 4 consecutive days (Days 1, 2, 3, and 4) and rituximab 375 mg/m^2, IV on Days 7, 14, 21, and 28 administered with immunoglobulin (IgG) IV (at investigator discretion) and/or low/medium dose steroids (at investigator discretion) on Days 7, 14, 21, and 28.
89178853|NCT00836693|Experimental|Tadalafil|
89178854|NCT00836693|Placebo Comparator|Placebo|
89178855|NCT00770484|Experimental|Propranolol then placebo|Active treatment
89178856|NCT00770484|Placebo Comparator|Placebo then propranolol|Placebo Treatment
89365852|NCT03292978|Experimental|probiotics intervention|"The probiotic is provided in sachets as a 2g powder dried with corn starch.~The powder is orally taken once daily for 4 weeks.~The powder contains totally 11 log 10 colony forming units(CFU) of probiotics.~The types of probiotics are Lactobacillus.rhamnosus, Lactobacillus.acidophilus, Bifidobacteria.animalis and Bifidobacteria.longum."
89365853|NCT03292978|Placebo Comparator|non-probiotic control|The placebo is corn starch alone provided and the shape, color, weight,flavor and taste are same with the powder of probiotics intervention.
88837061|NCT01013961|Experimental|Arm B (low dose)|"Patients receive alemtuzumab SC on days 1-3, 6, 8, 10, 13, 15, 17, 20, 22, 24, 27, 29, and 31 and low-dose rituximab at 20 mg/m^2 IV on days 6, 8, 10, 13, 15, 17, 20, 22, 24, 27, 29, and 31 in cycle 1 (33-day cycle). In cycle 2 and subsequent cycles (28-day cycle), patients receive alemtuzumab SC and low-dose rituximab IV on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26. Treatment repeats every 28 days for up to 3 cycles.~Alemtuzumab dose for cycle 1 week 1 requires a 'dose ramp' (3 mg day 1, 10 mg day2, and 30 mg day 3 of cycle 1) and then is 30 mg 3 times a week."
88837062|NCT00980590|Experimental|Airway Scope|Intubation with Airway Scope
88837063|NCT00980590|Active Comparator|Macintosh laryngoscope|Intubation with Macintosh laryngoscope
88837064|NCT00979680|Active Comparator|High-dose Radiotherapy|
88837065|NCT00979680|Active Comparator|Chemo-radiotherapy|
88837066|NCT00959712|No Intervention|Control|Subjects are given a pedometer and step count log in which to record their daily step counts for 1 year.
88837067|NCT00959712|Active Comparator|ECA Interaction|"Subjects are given pedometers and step count logs in which to record their daily steps for 1 year. Subjects are also given a tablet computer and instructed to interact with the ECA (Embodied Conversational Agent) Tanya every day for 2 months."
88837068|NCT00834093|Experimental|EBV-stimulated cytotoxic T-lymphocyte (EBV-CTL) Immunotherapy|Eligible participants underwent a blood draw to obtain peripheral blood mononuclear cells (PBMCs) used for preparation of the immunotherapy product [estimated preparation time 14-16 weeks]. Participants received palliative chemotherapy for NPC as standard of care during the period required for T-cell production. Participants who achieved a partial response or better while receiving palliative chemotherapy continued to receive chemotherapy for 3 to 6 cycles and were only eligible for immunotherapy when progressive disease (PD) was confirmed. Each participant received a minimum of 2 EBV-CTL infusions, given 2 weeks apart, at doses of 1x108 cells/m2. A 3rd infusion was offered to participants 8-12 weeks after the 2nd infusion based on response, tolerability and sufficient immunotherapy product reserves.
88837069|NCT00779194|Experimental|1|SLE subjects receiving the study drug, Rapamune.
89178857|NCT04099602|Experimental|Massage group|Twice a day after the birth of the baby was massaged by the researcher for 5 days. Bilirubin levels were measured twice daily by the transcutaneous bilirubin meter before the morning massage and 2 hours after the evening massage for 5 days. In the morning (between 07:00-09:00 am) and in the evening (between 19:00-21:00 pm) twice a day, 15-20 minutes baby massage was applied.
89365854|NCT04488640||Thyroid fine needle aspiration biopsy group|A group of 760 people who had a thyroid nodule and who had a thyroid fine needle aspiration biopsy for diagnosis.
89365855|NCT04488640||Thyroid core needle aspiration biopsy group|A patient group with 760 people who had a thyroid nodule and who had a thyroid fine needle aspiration biopsy for diagnosis and who underwent a core needle biopsy again. A total thyroidectomy was performed in 88 of these patients. Surgical pathology results, core needle results and TIRADS scores were compared.
89365856|NCT03512210|Experimental|MINMON 24 weeks with SOF/VEL 12 Weeks|Participants received Sofosbuvir/Velpatasvir (SOF/VEL [Tradename: Epclusa®]) tablet for 12 weeks with a minimal monitoring (MINMON) strategy for 24 weeks
89365857|NCT03284944||Control (Before) Period|Use of standard-volume blood collection tubes (6 weeks)
89365858|NCT03284944||Intervention (After) Period|"Use of small-volume (soft-draw) blood collection tubes (6 weeks following 2-week washout period)"
89365859|NCT03422276|Active Comparator|Rehabilitation Discharge Plan|Commission on Accreditation of Rehabilitation Facilities (CARF) standards for discharge following an inpatient rehabilitation stay for a traumatic brain injury, including patient and family education, written discharge care instructions, and telephone follow up from a clinical provider.
89365860|NCT03422276|Active Comparator|Rehabilitation Transition Plan|Approximately 12 scheduled contacts from a TBI care manager 6 months following discharge in addition to the CARF standards for discharge.
89365861|NCT02461108|Experimental|Price difference|Introduce a 10% price difference between foods labeled as nutritious and foods labeled as less nutritious and frame the price difference as either a Subsidy, Tax, or combination of a Tax and Subsidy.
88837070|NCT00779194|No Intervention|2|Healthy control group donating blood for the main study.
88837071|NCT00779194|No Intervention|3|SLE subjects donating blood for Genetic sub-study
88837072|NCT00779194|No Intervention|4|Healthy control subjects donating blood for the Genetic sub-study
88837073|NCT00665600|Experimental|1|Levalbuterol 0.63 mg TID
88837074|NCT00665600|Experimental|2|Levalbuterol 1.25 mg TID
88837075|NCT00665600|Active Comparator|3|Racemic Albuterol 2.5 mg TID
89365862|NCT02461108|No Intervention|No price difference|No price difference between nutritious and less nutritious foods.
89365863|NCT00383721|Experimental|MF/F MDI 400/10 mcg BID|
89365864|NCT00383721|Experimental|MF/F MDI 200/10 mcg BID|
89365865|NCT00383721|Experimental|MF MDI 400 mcg BID|
89365866|NCT00383721|Active Comparator|Formoterol MDI 10 mcg BID|
89365867|NCT00383721|Placebo Comparator|Placebo MDI BID|
89365868|NCT03292822|Experimental|Licochalcone A|Licochalcone A is a chalconoid, a type of natural phenols. It can be isolated from root of Glycyrrhiza glabra (liquorice) or Glycyrrhiza inflata. It shows antimalarial, anticancer, antibacterial and antiviral (specifically against influenza neuraminidase) properties.
88837076|NCT00665600|Placebo Comparator|4|Placebo TID
88837077|NCT00606294|Experimental|Cohort 1 (closed to accrual)|Cohort 1 (closed to accrual) Cohort 1 (closed to accrual) There will be no change or intervention in a patient's treatment regime using chemoradiation where both the primary and the neck nodes receive 70Gy. This is currently one accepted standard of care. In a subcohort of patients in Cohort 1 with tumors that are positive for HPV who exhibited no evidence of hypoxia on their baseline 18F-FMISO PET/ CT scan or whose tumors have early resolution of hypoxia on their repeat early response 18F-FMISO PET/CT scan will undergo an alternative treatment where the primary tumor site receives 70Gy while the neck nodes receive 60Gy followed by a planned FDG PET/CT scan and observation.
89365869|NCT03292822|Active Comparator|Paclitaxel|chemotherapeutic drug
89365870|NCT03395288|Experimental|RCT treatment arm|Participants in this arm will dissolve one (1) level teaspoon of the nutraceutical powder (D-mannose) in at least 200 ml of water one time a day, approximately every 24 hours. (200 ml of water = 6.7 fluid ounces). Duration of study drug is 90 days.
89365871|NCT03395288|No Intervention|RCT control arm|Participants in this arm will not use any additional intervention.
89365872|NCT03395288|Experimental|Observational arm|Participants in this arm will either take a total of 1000 mg D-mannose in capsule form every 12 hours OR they will dissolve one (1) level teaspoon of the nutraceutical powder (D-mannose) in at least 200 ml of water one time a day, approximately every 24 hours. (200 ml of water = 6.7 fluid ounces). Duration of study drug is 90 days. Participants in this arm of the study have different home medications prior to study enrollment than participants in the RCT treatment arm.
89365873|NCT03297502|Experimental|Pimecrolimus cream, 1%|
89365874|NCT03297502|Active Comparator|Elidel (pimecrolimus) cream 1%|
89365875|NCT03297502|Placebo Comparator|placebo|
89530348|NCT03254563||Obese without NAFLD|Patients who do not have NAFLD based upon ultrasound
89530349|NCT02516891|Experimental|hydrophilic wire/Drug-Eluting Stents|Will include 100 patients with coronary bifurcation lesions in that they will be treated with stents and in which the technique is used jailed guide.
89001618|NCT03452449||Lumbar spine surgery|Patients undergoing planned lumbar spine surgery
89001619|NCT00588328|Experimental|1|
89001620|NCT00588367||1|Suspected pancreatic ductal adenocarcinoma.
89365876|NCT05067452|No Intervention|Standard of care including diabetes self-management education|"Control participants will receive standard of care as offered by clinical partners to all T2DM patients, including referral to nutritional counseling, T2DM support groups, and participation in local diabetes self-management programs. Control participants are also often provided referral information for locally available food support services in the region that provide diabetes-appropriate foods. Control participants will participate in the Diabetes Self-Management Program, an evidence-based program that takes place over 6 weeks that meets the standard of care for diabetes education.~At the end of follow up, the control arm will receive three months diabetes-tailored food support consisting of diabetes-tailored grocery boxes and nutrition case-management."
89365877|NCT05067452|Experimental|Diabetes-tailored food support plus diabetes self-management education|"The intervention has two components: 1) diabetes-tailored food support that consists of weekly, home-delivered medically tailored meals, and monthly home-delivered healthy groceries, from baseline to 24 weeks, and 2) three case-management sessions with client services staff from the partnering nutrition agency over the 12 weeks of intervention.~The intervention will be delivered in addition to a base condition consisting of remote participation in the Diabetes Self-Management Program, an evidence-based diabetes education program that takes place over 6 weeks also received by the control group as part of the standard of care."
89365878|NCT01334775|Experimental|Experimental - Cousin Biotech Adhesix|Placement of a self-adhering (sutureless) surgical mesh in open anterior inguinal hernia repair
89365879|NCT01334775|Active Comparator|Conventional - Cousin Biotech Biomesh P8|Placement of the conventional (sutured) surgical mesh in open anterior inguinal hernia repair
88837078|NCT00606294|Experimental|Cohort 2 (closed to accrual)|Experimental: Cohort 2 (closed to accrual) Cohort 2 HPV+ tumors that demonstrate no evidence of hypoxia on an 18F-FMISO PET scan will receive 30Gy to the surgical bed and neck lymph nodes concurrent with standard chemotherapy followed by a 3-4 month post-treatment neck dissection. In patients who exhibit a complete response with this method of treatment, no further treatment is necessary. For patients within this select group who still have pathologic nodal disease, further standard chemoradiation will be given. All other patients in this cohort (i.e. those who are not in the select HPV+ tumor group outlined above) will receive standard of care treatment following their surgery.
89365880|NCT03292744|Experimental|Alfacalcidol|Alfacalcidol 0,5 mcg once daily for 90 days
89365881|NCT03292744|Placebo Comparator|Placebo|Amylum same capsule form, weight and colour with treatment arm
89365882|NCT01329861|Experimental|Internet delivered CBT|Internet delivered cognitive behavioral intervention, 8 weeks treatment.
88837079|NCT00583596|Experimental|implant to close PDA|
88837080|NCT00551928|Active Comparator|A|Oral therapy with Lenalidomide Melphalan and Prednisone.
88837081|NCT00551928|Active Comparator|B|High dose Melphalan therapy (200mg/sm)with autologous stem cell support, for 2 cycles every 4 months (only 1 cycle if the patient reached almost a VGPR after the 1st MEL200)
88837082|NCT00330564|Experimental|SU011248 (Sutent, Sunitinib Malate)|50 mg/day orally for 4 weeks
88837083|NCT00316888|Experimental|Arm I (closed to accrual as of 11/3/2008)|Patients receive cisplatin IV over 60 minutes on days 1, 29, 57, and 85 and fluorouracil IV continuously over 96 hours on days 1-4, 29-32, 57-60, and 85-88. Patients also receive cetuximab IV over 120 minutes on day 50 and then IV over 60 minutes on days 57, 64, 71, 78, 85, 92, and 99 and undergo radiotherapy once daily 5 days a week for 5 weeks, beginning on day 57. Treatment continues in the absence of disease progression or unacceptable toxicity.
88837084|NCT00316888|Experimental|Arm II (open to accrual on 8/18/2009)|Patients receive cetuximab IV over 120 minutes on day 1 and then IV over 60 minutes on days 8, 15, 22, 29, 36, 43, and 50. Patients also receive cisplatin IV over 60 minutes on days 1 and 36, fluorouracil IV continuously over 96 hours on days 8-11 and 36-39, and undergo radiotherapy once daily 5 days a week for 5 weeks beginning on day 8. Treatment continues in the absence of disease progression or unacceptable toxicity.
88837085|NCT00309478|Experimental|2 (CMF scheme)|6 cycles CMF scheme (cyclophosphamide, methotrexate, fluorouracil)
88837086|NCT00309478|Experimental|1 (Nol + Zol)|Zoladex (3 years) combined with Nolvadex (5 years)
88837087|NCT00282854||Group I: Cases|Children with rolandic epilepsy
88837088|NCT00282854||Group II: Controls|Individuals group matched to cases for ethnicity, sex and area of residence but lacking a primary brain disorder.
88837089|NCT00274924|Experimental|Group I (PET negative)|Patients receive rituximab IV, cyclophosphamide IV, doxorubicin hydrochloride IV, and vincristine IV on day 1, and oral prednisone once daily on days 1-5. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.
89365883|NCT01329861|No Intervention|Control condition|Wait-list condition, received treatment after post-treatment assessment.
88837090|NCT00274924|Experimental|Group II (PET positive)|Patients receive R-ICE comprising rituximab IV on day 1, ifosfamide IV continuously over 24 hours and carboplatin IV over 30 minutes on day 2, and etoposide IV over 2 hours on days 1-3. Patients also receive filgrastim (G-CSF) subcutaneously once daily starting on day 4 and continuing until blood counts recover. Treatment repeats every 14 days for 4 courses in the absence of disease progression or unacceptable toxicity.
88837091|NCT00104884|Experimental|Depsipeptide|Depsipeptide is administered as a 4-hour IV infusion weekly in doses of 13 mg/m^2 for 3 weeks. Repeat cycle every 28 days until unacceptable toxicity or disease progression.
88837092|NCT00096174|Experimental|Cisplatin, C225, Radiation|"Cetuximab therapy: Patients receive an initial loading dose of cetuximab intravenously (IV) over 2 hours on day 1. Patients then receive cetuximab IV over 1 hour on days 8, 15, 22, 29, 36, 43, 50, and 57.~Chemoradiotherapy: Beginning on day 15 of cetuximab therapy, patients undergo radiotherapy once daily, 5 days a week, for at least 7 weeks. Patients also receive cisplatin IV over 1-2 hours on days 15, 36, and 57.~Cetuximab maintenance therapy: After the completion of chemoradiotherapy, patients continue to receive cetuximab IV over 1 hour once weekly for 6-12 months."
88837093|NCT00080938|Experimental|Temozolomide and Radiation|Temozolomide:administered orally. Radiation: whole brain radiation therapy
89365884|NCT04189978||2001-2002 study participants|Children who participated in the study conducted in 2001-2002, their parents and the siblings who were exposed to the same environment at this period.
89365885|NCT03035942|Experimental|D Group|Dexamethasone 8 mg
89001621|NCT00588367||2|Chronic pancreatitis and slated for decompression treatment.
89001622|NCT00588367||3|Autoimmune pancreatitis.
89365886|NCT03035942|Experimental|O group|Ondansetron 4 mg
89365887|NCT03035942|Placebo Comparator|S group|Normal saline (5 mL total volume)
89365888|NCT04189354|Experimental|Active t-DCS|Use of the t-DCS machine with the following stimulation parameters: current intensity of 2mA, electrode size of 25 cm2, duration of stimulation 20 minutes (excluding the fade-in and fade-out periods of 15 seconds).
89365889|NCT04189354|Sham Comparator|Sham t-DCS|"The condition of use in sham mode follows the same procedure as the active t-DCS except that the active stimulation lasts only 30 seconds at 3mA (60 seconds of active stimulation taking into account the periods of fade in and fade out).~The stimulator remains switched on during the procedure but does not deliver current. The devices are fully automatic and deliver an active or sham current according to a randomized stimulation code whose meaning is unknown by the operator, in order to respect the triple blind."
89365890|NCT01334853||Cohort 1|50 eosinophilic subjects to be evaluated
89365891|NCT01334853||Cohort 2|50 non-eosinophilic subjects to be evaluated
89365892|NCT03386708|Experimental|hUC-MSC intrauterine injection group|Human umbilical cord mesenchymal stem cells (hUC-MSC) (SCLnow 19#)
89365893|NCT02820519|Experimental|Loxapine|Loxapine Capsules 10 mg Day 1- 14: 10 mg b.i.d Day 15-28: 10 mg t.i.d Day 29-42: 20 mg b.i.d. Day 43-56: 20 mg t.i.d. Dosages will be escalated according to analgesic efficacy and tolerability.
88837094|NCT00074282|Experimental|Arm A (PCR)|"Treatment consisted of 6 cycles of pentostatin, cyclophosphamide, and rituximab (PCR) given every 28 days.~Rituximab administered as follows: For the first infusion, all patients receive 100 mg dose (regardless of weight/BSA). For subsequent infusions, all patients receive rituximab 375 mg/m2.~Pentostatin and cyclophosphamide administered as follows: Pentostatin given at 4 mg/m2 either as an IV push or IV over 10-30 minutes in 250 mL NS or D5W on day 1 every 4 weeks of cycles 1-6. Cyclophosphamide given at 600 mg/m2 IV over 30-60 minutes in 250 mL NS on day 1 every 4 weeks of cycle 1-6."
88837095|NCT00074282|Experimental|Arm B (Alemtuzumab: CR, nPR)|Patients who achieved a confirmed CR or nPR, were registered to receive Alemtuzumab (Arm B). When the patient was registered to Arm B, the drug was administered three times a week for four weeks. The dose was 30 mg per dose. A twelve-week treatment-free period had to elapse before CAMPATH-1H began following completion of PCR for Arm B patients
88837096|NCT00074282|Experimental|Arm C (Alemtuzumab: PR, <PR, PD)|For those patients not achieving a CR or nPR (thus patients either achieved PR, SD, or PD), Alemtuzumab (Arm C) was administered three times a week for eighteen weeks at a dose of 30 mg TIW. For PR, SD and PD patients, the timing of CAMPATH-1H was left to the discretion of the investigator, and treatment could begin earlier but no less than two weeks and no longer than eight weeks after the completion of the last PCR course. Patients determined to have PD during treatment with PCR did not need to complete all 6 cycles of PCR to go on to Arm C, however, completing a minimum of 2 cycles was required.
88837097|NCT00071981|Experimental|Arm I (12MP)|Patients receive 2 injections of multi-epitope peptide vaccine comprising 12 melanoma peptides restricted by Class I MHC (12MP) emulsified with sargramostim (GM-CSF) and Montanide ISA-51 (incomplete Freund's adjuvant) or Montanide ISA-51 VG (ISA-51) intradermally (ID) and subcutaneously (SC) on day 1 of weeks 1-3 and 1 injection at the primary site only on day 1 of weeks 5-7.
88837098|NCT00071981|Experimental|Arm II (12MP/Tet)|Patients receive 2 injections of multi-epitope peptide vaccine comprising multi-epitope melanoma peptide vaccine (12MP) and 1 tetanus peptide melanoma vaccine emulsified with GM-CSF and ISA-51 (incomplete Freund's adjuvant) ID and SC on day 1 of weeks 1-3 and 1 injection at the primary site only on day 1 of weeks 5-7.
89001623|NCT00588484||1|Men, age 35 to 65, being seen at the Mayo Clinic Department of Cardiovascular Health clinic, or has an appointment for a carotid duplex ultrasound exam.
89365894|NCT01334931|Experimental|Large field of view|Patients will have coronary angiography performed with large field of view lens
89365895|NCT01334931|Active Comparator|Medium field of view|Patients will have coronary angiography performed with medium field of view lens
89365896|NCT02460250|Experimental|Fibroscan|All included patients will undergo a Fibroscan (either Fibroscan Touch model or 402 model which enable CAPTM data extraction) once all eligibility criteria have been checked. Liver recipients will be followed up during one year. Biological and medical data used by all transplant sites for the follow-up of transplant patient will be collected
89365897|NCT01332591|Active Comparator|Complete revascularization|"Percutaneous coronary intervention of non-infarct coronary arteries"
89365898|NCT01332591|No Intervention|Conservative management|standard guideline-based medical therapy
89365899|NCT02616146|Experimental|ENG-E2 125 μg/300 μg|Participants will receive up to 13 cycles of ENG-E2 125 μg/300 μg. Each cycle will consist of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
89365900|NCT02616146|Active Comparator|LNG-EE 150 μg/30 μg|Participants will receive up to 13 cycles of LNG-EE 150 μg/30 μg. Each cycle will consist of one tablet per day for 21 days, followed a 7-day tablet-free interval.
89365901|NCT01332669|Active Comparator|chemoembolization|HCC patients received chemoembolization
89365902|NCT01332669|Other|Historical use of c-TACE using Lipiodiol and doxorubicin|The control arm will be of the patients that have been treated historically in the centers with conventional TACE (that is Lipiodiol plus doxorubicin).
88837099|NCT00071981|Experimental|Arm III (12MP/6MHP)|Patients receive 2 injections of multi-epitope peptide vaccine comprising multi-epitope melanoma peptide vaccine (12MP) and 6 melanoma helper peptides (6HP) emulsified with GM-CSF and ISA-51 (incomplete Freund's adjuvant) ID and SC on day 1 of weeks 1-3 and 1 injection at the primary site only on day 1 of weeks 5-7.
89178858|NCT04099602|No Intervention|Control group|The control group who were administered standard care and bilirubin levels were measured twice daily by the transcutaneous bilirubin meter for 5 days
89178859|NCT04098042||Scaffold|"Patients receiving during PCI the implantation of at least one Magnesium Made Bioresorbable Scaffold Magmaris"
89178860|NCT00835679|Experimental|Cohort A (no systemic neoadjuvant therapy)|Patients receive no systemic neoadjuvant therapy between enrollment and the time of definitive surgical resection of liver metastases. Liver biopsies were performed at surgery since this cohort received no systemic therapy.
89178861|NCT00835679|Experimental|Cohort B (cetuximab)|Patients receive 400 mg/m^2 cetuximab IV over 120 minutes on day 1 and 250 mg/m^2 cetuximab IV over 60-120 minutes on day 8. Definitive surgical resection of liver metastases will take place on day 15.
89178862|NCT00835679|Experimental|Cohort C (dasatinib)|Patients receive dasatinib 100 mg orally once daily on days 1-14. Definitive surgical resection of liver metastases will take place on day 15.
89178863|NCT00835679|Experimental|Cohort D (cetuximab, dasatinib)|Patients receive 400 mg/m^2 cetuximab IV over 120 minutes on day 1 and 250 mg/m^2 cetuximab IV over 60-120 minutes on day 8 AND dasatinib 100 mg orally once daily on days 1-14. Definitive surgical resection of liver metastases will take place on day 15.
89178864|NCT04100070|Other|Standard monitoring|"Usual follow-up of children by pediatricians as recommended by relevant Authorities (HAS) both in terms of frequency of visits and rhythm of biological controls.~Standard technical training, maintenance and monitoring by the CSII service provider as defined by the official specifications (LPPR)"
89365903|NCT03297268||Phase 1-Controlled Validation & Study Planning|Phase 1 is focused on refining and ultimately verifying BESI's basic sensing and notification functionality and validating BESI's environmental assessments in a controlled setting - namely the laboratory and homes of two healthy volunteers. This phase also serves to support further requirements gathering to refine BESI for community-based deployment. No interventions are delivered.
89365904|NCT03297268||Phase 2 - In-situ Validation and Ethnographic Analysis|Phase 2 starts the deployment of the technology within a community context, with the goals of validating the system's ability to assess agitation and environmental events in-situ and developing the cyber-sociophysical system models based on the dyad-specific relationship between agitation and the environment. A hybrid remote ethnographic methodology will be used, combining remote BESI measurement and caregiver diaries and a time-series design for the administration of the assessment battery.
89365905|NCT03297268||Phase 3 - Intervention with Home-Based Caregivers|Phase 3 is the intervention phase and the full realization of BESI. The goal is to employ the validated assessment capabilities and the developed modeling techniques to enable real-time, dyad-specific caregiver notifications that empower a caregiver to intervene with the PWD and/or environment before agitation escalation. In addition to validation of the BESI's ability to provide such appropriate notifications, Phase 3 will also serve as a pilot study about the effect that these notifications have on caregiver empowerment (as measured by self-efficacy) and the frequency and severity of PWD agitation, thus providing proof-of-concept for BESI's potential to improve dyad outcomes and motivating a larger-scale followup study to establish proof-of-practice.
89365906|NCT04050566||Mothers|900 mothers recruited during pregnancy
89178865|NCT04100070|Other|Intensive monitoring|"Usual follow-up of children by pediatricians as recommended by relevant Authorities (HAS) both in terms of frequency of visits and rhythm of biological controls completed by a personalized vision of the patient glycaemic data along the study.~Intensive technical training, maintenance and monitoring by the CSII service provider with a higher frequency of contacts during the period (additional nurse visits)."
89178866|NCT04119245|Experimental|study group|"after induction of general anesthesia, a proper size of Igel will be inserted after compelete muscle relaxation. In order to confirm proper positioning of the I-gel,a fiberoptic bronchoscope will be pass through the device and pushed forward up to1 cm proximal to it to obtain a glottic view, leak airway pressure test will be done.~Afterwards the same patient will be placed in the lateral decubitus position ,confirmation of I-gel position using fiberoptic bronchoscope will be done and recorded.The leak air way pressure test will be done as previously done in supine position and recorded.~The patient will be returned to supine position."
89178867|NCT00766506|Experimental|Fentanyl IONSYS|Participants will receive 40 microgram (mcg) of fentanyl dose up to a maximum of 240 mcg (6 doses each of 10 minutes duration) per hour but not more than a maximum of 80 doses within a 24 hour period from an Iontophoretic Transdermal System (IONSYS).
89178868|NCT00766506|Active Comparator|Morphine IV PCA|Morphine sulphate solution will be administered intravenously (directly into the vein, IV) by a patient-controlled analgesia (PCA) pump using set bolus (a large amount) doses with a fixed lock out period as per physician's discretion (maximum total dose of 20 milligram per 2 hours) for 72 hours.
88837100|NCT00071981|Experimental|Arm IV (6MHP)|Patients receive 2 injections of multi-epitope peptide vaccine comprising melanoma helper peptide vaccine (6HP) emulsified with GM-CSF and ISA-51 (incomplete Freund's adjuvant) ID and SC on day 1 of weeks 1-3 and 1 injection at the primary site only on day 1 of weeks 5-7.
89178869|NCT04097886|Experimental|Morning Exercise Group|Participants perform moderate exercise in the morning.
89178870|NCT04097886|Experimental|Evening Exercise Group|Participants perform moderate exercise in the evening.
89178871|NCT00770328|Experimental|Pentoxifylline|Patients receive Pentoxifylline 400 mg po TID for 8 weeks.
88837101|NCT00070291|Experimental|Cyclosporine|High dose cyclosporine weeks 1-6, then maintenance dose cyclosporine weeks 7-36. If CR, PR, or SD at week 36 evaluation, treatment is complete. If progression occurs during weeks 7-36, patients will re-register to Step 2 at time of PD and begin high dose therapy (weeks 1-6), followed by maintenance therapy (weeks 7-36). At second progression patients will end protocol treatment.
88837102|NCT00064350|Experimental|Induction then Sorafenib|"Induction: All patients receive oral sorafenib twice daily on days 1-28. Treatment continues for 2 cycles in the absence of disease progression or unacceptable toxicity. Patients with stable disease proceed to randomization. Patients with responding disease continue to receive sorafenib for up to 1 year in the absence of disease progression.~Randomization: Patients with stable disease after the induction treatment were randomized to either the sorafenib arm or the placebo arm. Patients on the sorafenib arm receive sorafenib twice daily for up to 1 year in the absence of disease progression or unacceptable disease."
88837103|NCT00064350|Placebo Comparator|Induction then Placebo then Sorafenib|"Induction: All patients receive oral sorafenib twice daily on days 1-28. Treatment continues for 2 cycles in the absence of disease progression or unacceptable toxicity. Patients with stable disease proceed to randomization. Patients with responding disease continue to receive sorafenib for up to 1 year in the absence of disease progression.~Randomization: Patients with stable disease after the induction treatment were randomized to either the sorafenib arm or the placebo arm. Patients on the placebo arm receive oral placebo twice daily for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients on the placebo arm who develop disease progression within 1 year after randomization may cross over to sorafenib arm."
88837104|NCT00064350|Other|Induction, not randomized|"Induction: All patients receive oral sorafenib twice daily on days 1-28. Treatment continues for 2 cycles in the absence of disease progression or unacceptable toxicity.~Post-induction: Patients with responding disease or disease progression were not randomized in Step 2. Patients with responding disease continue to receive sorafenib for up to 1 year in the absence of disease progression, while patients with disease progression were removed from the study."
88837105|NCT00063986|Experimental|Minimally invasive esophagectomy (MIE)|Within 4 weeks of registration patients will undergo minimally invasive esophagectomy (MIE). However, there will be up to 5 months allowed between registration and MIE for those patients needing neoadjuvant therapy prior to undergoing MIE.
88837106|NCT00060346|Experimental|Rituximab + CHOP|"Rituximab 375 mg/m2 day 1 of a 21-day cycle, followed by:~Cyclophosphamide 750 mg/m2 Doxorubicin 50 mg/m2 Vincristine 1.4 mg/m2 and Prednisone 100 mg/m2 daily"
88837107|NCT00057954|Experimental|Transplant|Reduced toxicity conditioning regimen followed by allogeneic sibling or unrelated transplant. The conditioning regimen includes Extracorporeal Photopheresis, Pentostatin and total body irradiation (TBI). After allogeneic bone marrow transplantation, cyclosporin, mycophenolate mofetil (MMF), and methotrexate (MTX) will be given to prevent graft-versus-host disease (GVHD).
88837108|NCT00049530|Experimental|PEG-interferon alfa-2b|Patients receive PEG-interferon alfa-2b subcutaneously (SC) once weekly. Treatment continues until basic fibroblast growth factor level is suppressed to normal or until a maximum weekly dose is reached. If there is disease progression, patients then discontinue treatment. If there is no disease progression, patients receive PEG-interferon alfa-2b SC weekly for up to 1 year in the absence of disease progression or unacceptable toxicity.
88837109|NCT00045305|Experimental|Arm I|"Preparative Regimen: Patients underwent photopheresis on two consecutive days and received pentostatin 4 mg/m2/d (total dose = 8 mg/m2) by continuous IV infusion on two consecutive days following photopheresis. Total body irradiation was administered on two consecutive days following pentostatin for a total of 600 cGy given in three 200 cGy fractionated doses.~Transplantation: Unmanipulated allogeneic bone marrow or G-CSF mobilized peripheral blood stem cells were infused on day 0 within 48 hours of completion of TBI. Minimum cell dose was 2 ×106 CD34 cells/kg recipient.~Acute graft-vs-host-disease (GVHD) prophylaxis: Patients received Cyclosporine or Tacrolimus per institutional preference or protocol beginning no later than day -1. Methotrexate (MTX) was administered on day +1 and +3. Mycofenolate mofetil (MMF) was introduced on day 100 and could be tapered and discontinued after 12 months if no active cGVHD."
88837110|NCT00033657|Experimental|Cisplatin / Irinotecan / Radiation therapy (Arm A)|"Days 1 - 35 : Concurrent radiation therapy (RT) and Cisplatin / Irinotecan Chemotherapy. Radiotherapy 45 Gy administered at 1.8 Gy per day, 5 days a week for 5 weeks. Cisplatin 30 mg/m² days 1, 8, 22, 29. Irinotecan 65 mg/m² days 1, 8, 22, 29. Chemotherapy should begin within 24 hours of start of radiotherapy~Days 63 - 77 : Surgical Resection At least 28 days after surgical resection, begin adjuvant chemotherapy: cisplatin 30 mg/m² and irinotecan 65 mg/m² days 1 and 8 of three 3-week cycles"
88837111|NCT00033657|Experimental|Paclitaxel / Cisplatin / Radiation therapy (Arm B)|"Days 1 - 35 : Concurrent radiation therapy (RT) and Paclitaxel/Cisplatin Chemotherapy. Radiotherapy 45 Gy administered at 1.8 Gy per day, 5 days a week for 5 weeks. Paclitaxel 50 mg/m² (1 hr) days 1, 8, 15, 22, 29. Cisplatin 30 mg/m² days 1, 8, 15, 22, 29. Chemotherapy should begin within 24 hours of start of radiotherapy.~Days 63 - 77 : Surgical Resection At least 28 days after surgical resection, begin adjuvant chemotherapy: paclitaxel 175 mg/m² and cisplatin 75 mg/m² day 1 of three 3-week cycles."
88837112|NCT00003389|Experimental|Arm A (ABVD)|Arm A (ABVD): Patients receive doxorubicin (25 mg/m²), bleomycin (10 u/m²), vinblastine (6 mg/m²), and dacarbazine (375 mg/m²) intravenously (IV) on days 1 and 15. Courses repeat every 28 days. Patients are restaged after 4 courses. Patients who are in complete remission receive 2 additional courses. Patients with a partial response or less are evaluated after 6 courses, and if there is an ongoing response, patients may receive 2 additional courses for a total of 8. If no ongoing response is observed, patients are removed from the study. All patients with massive mediastinal disease, regardless of stage, receive radiotherapy 2-3 weeks after completion of chemotherapy.
89001624|NCT00588484||2|Women, age 35 to 65, being seen at the Mayo Clinic Department of Cardiovascular Health clinic, or has an appointment for a carotid duplex ultrasound exam.
89178872|NCT00770328|Placebo Comparator|Placebo|Patients take a placebo TID for 8 weeks.
89365907|NCT04050566||Children|900 children born to the recruited mothers
89365908|NCT03107806|Other|Glucose monitoring by OptiScanner®|Glucose monitoring and intervention guided by OptiScanner®
88837113|NCT00003389|Active Comparator|Arm B (Stanford V)|Arm B (Stanford V): Patients receive Stanford V chemotherapy comprising doxorubicin (25 mg/m²) and vinblastine (6 mg/m²) IV on day 1 of weeks 1, 3, 5, 7, 9, and 11; vincristine (1.4 mg/m²) and bleomycin (5 u/m²) IV on day 1 of weeks 2, 4, 6, 8, 10, and 12; mechlorethamine (6 mg/m²) IV on day 1 of weeks 1, 5, and 9 (if mechlorethamine is unavailable, may substitute with cyclophosphamide [375 mg/m²] IV); etoposide (60 mg/m²) IV on days 1 and 2 of weeks 3, 7, and 11; and oral prednisone (40 mg/m²) every other day of weeks 1-9 followed by a taper. All patients with bulky disease receive radiotherapy 2-3 weeks after completion of chemotherapy.
88837114|NCT00003138|Active Comparator|Supportive Care|Patients received red cell and platelet transfusions for symptoms or to maintain hematocrit at or above 25% by volume. Patients who required transfusion support for symptomatic anemia prior to entering the study and who developed an increase in their transfusion requirement of >= 50% shall cross over to the Erythropoietin treatment arm, after at least four months on the supportive therapy arm.
88837115|NCT00003138|Experimental|Erythropoietin|Erythropoietin was administered at 150 units/kg subcutaneously every day. If patients stopped responding, they were subsequently treated with Erythropoietin (150 units/kg) and filgrastim and then Erythropoietin (300 units/kg) and filgrastim.
88837116|NCT00002525|Experimental|Perioperative 5-FU|"Within 24 hours of the colon resection, patients receive perioperative fluorouracil intravenously (IV) over 24 hours for 7 days.~After surgery (beginning 21-35 days post-surgery), 5-FU was given at a dose of 425 mg/m^2 IV push on days 1-5, and leucovorin calcium was given at a dose of 20mg/m^2 IV push on days 1-5"
88837117|NCT00002525|Active Comparator|No perioperative 5-FU|"Patients receive no perioperative fluorouracil.~After surgery (beginning 21-35 days post-surgery), 5-FU was given at a dose of 425 mg/m^2 IV push on days 1-5, and leucovorin calcium was given at a dose of 20mg/m^2 IV push on days 1-5"
88837118|NCT04031911|Other|Control group|Control group benefiting from standard support (AFU (Association Française d'Urologie) information sheet), but applied in a more supervised way (communication document, process studies, etc.).
88837119|NCT04031911|Experimental|Study group|"Study group benefiting from a short spa treatment (5 days) with hydroposturotherapy (HPT arm) in Vittel or Capvern: posturotherapy, lumbar percussion and controlled hyperdiuresis."
88837120|NCT05475522|Experimental|Ultrasound|Intraoperative extent of tumor resection will be assessed using sonography
88837121|NCT05475522|Active Comparator|Fluorescence|Intraoperative extent of tumor resection will be assessed using fluorescence with 5-aminolevulinic acid
88837122|NCT05470374|Experimental|Ultrasound|Glioma resection with intraoperative sonography
88837123|NCT05470374|No Intervention|Non-ultrasound|Glioma resection without intraoperative sonography
88837124|NCT05646966|Active Comparator|healthy subjects|healthy subjects
88837125|NCT05646966|No Intervention|stroke patients|first time stroke patients
88837126|NCT02259348|Experimental|Participants|Participants undergo a conditioning regimen with cyclophosphamide, fludarabine, aldesleukin (interleukin-2), natural killer cell therapy, anti-thymocyte globulin, rituximab, thiotepa, and melphalan prior to transplantation of T-cell depleted HPC transplant on day 0 and CD45RA-depleted HPC transplant on day 1. Beginning Day 6 post-transplant, patients receive G-CSF daily until ANC recovers to normal level.
88837127|NCT04864626||patient with eating disorder|
88837128|NCT03162211|Experimental|Feedback Arm|A registry platform including access to all self-report rating scales and the feedback mechanism will be made available to all patients. Patients in the experimental group will receive automated reminders (by text message, phone and/or email) to complete outcome measures each week. Feedback forms will be comprehensive and condensed to a one page report including graphical presentations of symptom course and text. Clinician feedback forms will include content on depression severity over time and recommendations for individualized treatment. Patient feedback forms will also incorporate depression severity over time as well as summary information on achievement towards personalized treatment goals. The intervention will last 6-months, with feedback forms being generated once per week for the first three month and then each month for a total of fifteen feedback time points. Patients in the feedback group will be encouraged to meet with their clinician each month to discuss the feedback.
88837129|NCT03162211|No Intervention|No Feedback Arm|A registry platform including access to all self-report rating scales and the feedback mechanism will be made available to all patients. Patients in the control group will not receive regular reminders or be sent feedback reports on an automatic regular basis.
88837130|NCT03994705|Experimental|Dose-Escalation|
88837131|NCT03984487|Experimental|STRW|Participants will receive the daily living skills intervention, Surviving and Thriving in the Real World (STRW).
88837132|NCT03984487|Active Comparator|PEERS|Participants will receive a social skills intervention, Program for the Education and Enrichment of Relational Skills (PEERS).
88837133|NCT03984253||Severe Asthma|All patients with severe asthma who will be treated in the participating centers should be continuously enrolled in the register.
89365909|NCT03107806|Other|Blinded continuous glucose monitoring|Blinded continuous glucose monitoring by OptiScanner® and glucose lowering intervention guided by routine glucose measurements
88837134|NCT03960541|Experimental|Efprezimod alfa Treatment|Participants received an intravenous infusion of 240 mg of efprezimod alfa on Days 0, 14, and 28.
88837135|NCT03960541|Placebo Comparator|Placebo|Participants received an intravenous infusion of placebo (sterile saline solution) on Days 0, 14, and 28.
88837136|NCT03587207|Experimental|MenABCWY Group|Healthy subjects between, and including, 10 to 25 years of age at the time of the first vaccination (equally distributed across the 2 age strata of 10 to 17 years and 18 to 25 years) received one dose of MenABCWY twice, 2 months apart (Day 1 and Day 61).
89365910|NCT04050800|Experimental|Healthy Controls|Subjects will be administered two sequential doses of the radiopharmaceutical under nearly zero-biological-change conditions.
89365911|NCT01332747|Experimental|Safoof e Muhazzil in its conventional powder form|safoof e muhazzil in its conventional powder form 5 gms twice daily given orally
89365912|NCT01332747|Experimental|compressed tablet of safoof e muhazzil|compressed tablet of safoof e muhazzil is given in equivalent dose orally
89365913|NCT01332747|Active Comparator|atorvastatin|atorvastatin 10mg daily as a standard control
89365914|NCT03284632||Smokers|
89365915|NCT03284632||E-cigarette users|
89365916|NCT03284632||Non-smokers|
88837137|NCT03587207|Active Comparator|rMenBOMV+ACWY_S Group|Healthy subjects between, and including, 10 to 25 years of age at the time of the first vaccination (equally distributed across the 2 age strata of 10 to 17 years and 18 to 25 years) concomitantly received one dose of rMenB+OMV NZ (Bexsero) and one dose of MenACWY (Menveo) in the same arm twice, 2 months apart (Day 1 and Day 61).
88837138|NCT03587207|Active Comparator|rMenBOMV+ACWY_D Group|Healthy subjects between, and including, 10 to 25 years of age at the time of the first vaccination (equally distributed across the 2 age strata of 10 to 17 years and 18 to 25 years) concomitantly received one dose of rMenB+OMV NZ (Bexsero) and one dose of MenACWY (Menveo) in 2 different arms twice, 2 months apart (Day 1 and Day 61).
88837139|NCT03587207|Active Comparator|rMenBOMV Group|Healthy subjects between, and including, 10 to 25 years of age at the time of the first vaccination (equally distributed across the 2 age strata of 10 to 17 years and 18 to 25 years) received one dose of rMenB+OMV NZ (Bexsero) twice, 2 months apart (Day 1 and Day 61).
88837140|NCT03587207|Active Comparator|MenACWY Group|Healthy subjects between, and including, 10 to 25 years of age at the time of the first vaccination (equally distributed across the 2 age strata of 10 to 17 years and 18 to 25 years) received one dose of MenACWY (Menveo) once at Day 1, which was the first and last vaccination for MenACWY group.
88837141|NCT03901261|Experimental|Down syndrome patients|
88837142|NCT03866785|Other|STEP 1: Patient with prostate cancer|First, patients with prostate cancer will be included during step 1. They will have an interview.
88837143|NCT03866785|Other|STEP 2: Patient with prostate cancer and a physical activity|"Secondly, patient with prostate cancer and a physical activity will be included during step 2. They are called peer.~They will have a questionnaire Adult Physical Activity Questionnaire (APAQ), an activity actigraph and a peer training. The peer will help patients to realize the Physical Activity Program during step 3."
88837144|NCT03866785|Other|STEP 3: Physical Activity Program|"Finally, patients with prostate cancer (different from step 1) and who agrees to participate at the Physical Activity Program will be included during step 3.~They will have an activity actigraph and a questionnaire Adult Physical Activity Questionnaire (APAQ) at inclusion and 3 months later.~They will receive the Physical Activity Program."
88837145|NCT04345159||Patient with autoimmune disease|Selected using appropriate keywords in the Foundation Rothschild Hospital EMR, consenting to participate in the study.
88837146|NCT05723263|Experimental|Standard Pay-it-forward|"free gonorrhea/chlamydia testing~minimal engagement"
88837147|NCT05723263|Experimental|Community engaged Pay-it-forward|"Free gonorrhea/chlamydia testing~Stronger engagement"
88837148|NCT05723263|Other|Control arm|"Test available for a fee~No engagement"
88837149|NCT03416621|Active Comparator|Experimental: Cognitive behavioral cessation counseling|Standard smoking cessation plus support text messages
88837150|NCT03416621|Placebo Comparator|Placebo Comparator: Counseling and placebo drug intervention|enhanced cue exposure treatment (lab-based + interactive SMS texting) + DCS placebo
88837151|NCT03416621|Experimental|Active Comparator: Counseling and active drug intervention|enhanced cue exposure treatment (lab-based + interactive SMS texting) + active DCS. In addition to an in-person screening visit, we will conduct three in-person treatment visits and an in-person follow-up visit.
88837152|NCT03417557|Experimental|Comfilcon A lens (test)|Subjects are randomized to wear comfilcon A lens for up to 3 hours, either as first or second lens during this cross over study.
88837153|NCT03417557|Active Comparator|Omafilcon B Lens (control)|Subjects are randomized to wear omafilcon B lens for up to 3 hours, either as first or second lens during this cross over study.
88837154|NCT03459131|Other|BIOFINITY ENERGYS then BIOFINITY|Comfilcon A with Digital Zone Optics™ contact lenses worn first, followed by comfilcon A contact lenses. Each product will be worn bilaterally (in both eyes) for 7 days in a daily wear modality.
88837155|NCT03459131|Other|BIOFINITY then BIOFINITY ENERGYS|Comfilcon A contact lenses worn first, followed by comfilcon A with Digital Zone Optics™ contact lenses. Each product will be worn bilaterally (in both eyes) for 7 days in a daily wear modality.
88837156|NCT03417713||All Subjects|This group/cohort is expected to be representative of the general population that would require mobile fluoroscopic imaging with C-arm devices, such as OEC Elite.
88837157|NCT03592121|Experimental|AB-101|Apply to both nipple/areola regions approximately 1 hour prior to sexual activity
88837158|NCT03592121|Placebo Comparator|Placebo|Apply to both nipple/areola regions approximately 1 hour prior to sexual activity
88837159|NCT04332809|Active Comparator|Saline-gentamicin irrigation|layer-by-layer irrigation of the appendectomy wound will be performed using Saline-gentamicin solution
88837160|NCT04332809|Active Comparator|Saline irrigation|layer-by-layer irrigation of the appendectomy wound will be performed using Saline solution
88837161|NCT04332809|No Intervention|No irrigation|ayer-by-layer irrigation of the appendectomy wound will not be performed
88837162|NCT03596723|Experimental|KPI-121 1% BID (twice daily)|
88837163|NCT03596723|Active Comparator|Prednisolone acetate QID (four times daily)|
88837164|NCT04355117|Experimental|Treatment: TEV-48125|
88837165|NCT04357379|Experimental|IQOS group|
88837166|NCT03463889|Experimental|Diagnostic (Gallium Ga 68-labeled PSMA-11, PET/MRI)|Participants receive 68Ga-PSMA IV over 1-2 minutes and then undergo PET/MRI 60 minutes after injection. Patients may undergo a second PET/MRI 2-6 months after completion of first scan.
88837167|NCT04484207|Experimental|Video-based intervention|A brief video about coping with COVID-19 stress presented to the participants
88837168|NCT04484207|Experimental|vignette intervention|A brief vignette about coping with COVID-19 stress presented to the participants
88837169|NCT04484207|No Intervention|Control|Only assessment, no intervention arrm
88837170|NCT04485455|Experimental|iTBS Therapy|Teenage participants with depression will receive iTBS therapy using a Transcranial Magnetic Stimulation (TMS) protocol delivering electro-magnetic stimulation
88837171|NCT04525079|Experimental|Cohort 1|Cohort 1 will receive a dose of CT-P59 or matching placebo
88837172|NCT04525079|Experimental|Cohort 2|Cohort 2 will receive a dose of CT-P59 or matching placebo
88837173|NCT04525079|Experimental|Cohort 3|Cohort 3 will receive a dose of CT-P59 or matching placebo
88837174|NCT04525079|Experimental|Cohort 4|Cohort 4 will receive a dose of CT-P59 or matching placebo
89365917|NCT05098652|Experimental|Immediate Intervention|Complete baseline survey, complete 3 weeks of daily diaries and intermittent survey, receive 12 weeks of CurB-IT, then complete 3 rounds of 21-day daily diaries and intermittent surveys while receiving attention during the 12-week intervals between daily diaries.
89365918|NCT05098652|Active Comparator|Delayed intervention|Complete baseline survey, complete 3 weeks of daily diaries, receive 12 weeks of attention, complete 3 weeks of daily diaries and 1 intermittent survey, receive 12 weeks of CurB-IT, then complete 2 rounds of 21-day daily diaries and intermittent surveys while receiving attention during the 12-week intervals between daily diaries.
89365919|NCT03472833|Experimental|High-dose|"Intervention with high dose oral vitamin D3 supplementation.~1 drop equals 400 I.U. This group will get 180.000 I.U. on day 1, and then 4000 I.U. per day for 60 days."
89365920|NCT03472833|Active Comparator|Standard-dose|"Intervention with standard dose oral vitamin D3 supplementation.~1 drop equals 400 I.U. This group will get 800 I.U. per day for 60 days."
89365921|NCT03284554|Active Comparator|Encapsulated nutients|"Encapsulated nutrients known to be able to stimulate GLP-1 and PYY release. Encapsulated with coating providing release at pH≈7.0 (in the distal part of the ileum).~The encapsulated nutrients will be provided 30 minutes prior to the ad libitum test breakfast and 3 hour prior to the ad libitum test lunch, respectively."
89365922|NCT03284554|Sham Comparator|Non-encapsulated nutrients|"Nutrients known to be able to stimulate GLP-1 and PYY release if they are encapsulated to provide release at pH ≈7.0 (in the distal part of the ileum). The same capsules in a non-coated form will be provided in order to study the effect of the coating.~The non-encapsulated nutrients will be provided 30 minutes prior to the ad libitum test breakfast and 3 hour prior to the ad libitum test lunch, respectively."
89365923|NCT03284554|Placebo Comparator|Placebo|"Nutrients known to have limited stimulation on GLP-1 and PYY release. Encapsulated with coating providing release at pH≈7.0 (in the distal part of the ileum).~The placebo capsules will be provided 30 minutes prior to the ad libitum test breakfast and 3 hour prior to the ad libitum test lunch, respectively."
89365924|NCT03785288|Active Comparator|ARM A: 3 treatments of 7Gy|Arm A: accepted randomization to HDR vaginal brachytherapy in 3 treatments (fractions) of 7Gy for a total dose of 21gy
89365925|NCT03785288|Active Comparator|ARM B: 6 treatment of 4Gy|Arm B: accepted randomization to HDR vaginal brachytherapy 6 treatments (fractions) of 4Gy for a total does of 24gy
89365926|NCT03785288|Active Comparator|ARM AB: 6 treatment of 4Gy|Arm AB: initially randomized to ARM A but wanted to switch to ARM B treatment of HDR vaginal brachytherapy 6 treatments (fractions) of 4Gy for a total does of 24gy
89365927|NCT03785288|Active Comparator|ARM BA: 3 treatments of 7Gy|initially randomized to ARM B but wanted to switch to ARM A of HDR vaginal brachytherapy in 3 treatments (fractions) of 7Gy for a total dose of 21gy
89365928|NCT03292354|Active Comparator|Body Weight (BW)|Patients referred for CCTA in this group receive a personalised contrast media protocol. Contrast media administration based on body weight.
89365929|NCT03292354|Active Comparator|Cardiac output (CO)|Patients referred for CCTA in this group receive a personalised contrast media protocol. Contrast media administration based on cardiac output.
89365930|NCT03292354|Active Comparator|Lean Body weight (LBW)|Patients referred for CCTA in this group receive a personalised contrast media protocol. Contrast media administration based on Lean Body Weight.
89365931|NCT03292354|No Intervention|Control group|Patients in this group will be included retrospectively and have received the standard CM injection protocol previously used in our department.
89365932|NCT01332825|No Intervention|olfactory dysfunction|subjects diagnosed with olfactory dysfunction
89365933|NCT01332825|No Intervention|normal olfaction, no saline|no smell dysfunction, not randomized to saline nasal irrigation for 7 days
88837175|NCT04734509|Experimental|Porter Brown Breathing system|"The Porter Brown has a double mask system that is characterized by a mask-within-a-mask scavenging system. The system includes easy to remove inner masks which vent into the outer mask. This helps in cleaning and sterilization. The soft inner part of the mask system provides a comfortable fit and an excellent seal around the patient's nose.~This mask is routinely used in inhalation sedation for children's dental treatment.~This is a sterilisable system."
88837176|NCT04734509|Experimental|Silhouette Breathing system|The Silhouette is a single-use nasal mask and breathing circuit with lightweight tubing and an adhesive strip across the bridge of the nose to secure the mask in place and create a good seal around the patient's nose.
88837177|NCT03467477|Experimental|Flortaucipir PET Scan|
88837178|NCT04555031|Experimental|kalifilcon A lenses|
88837179|NCT04555031|Active Comparator|Dailies Total 1|
88837180|NCT04555031|Active Comparator|Precision 1|
88837181|NCT04555031|Active Comparator|Biotrue ONEday|
88837182|NCT03468179|Experimental|Oatmeal|Subjects will arrive for study fasting. IV access will be obtained, and baseline blood drawn. They will be fed 80gm/100kg oatmeal, and blood levels will be drawn at 30, 60, 90, and 120 minutes.
88837183|NCT03472469|Active Comparator|Original MMPR - descending dose arm|Drugs are scheduled around the clock as follows: 1. Acetaminophen 1g intravenously (IV)/per oral (PO) q6 hours in the first 48 hours, and Acetaminophen 1g PO q6 hours thereafter; 2. Ketorolac 30mg IV once and Celebrex 200mg PO q12 hours in the first 48 hours, and Naproxen 500mg PO q12 hours thereafter; 3. Tramadol 100mg PO q6 hours in the first 48 hours, and Tramadol 100mg PO q6 hours thereafter; 4. Pregabalin 100mg PO q8 hours in the first 48 hours, and Gabapentin 300mg PO q8 hours thereafter; 5. Lidocaine patch q12 hours in the first 48 hours, and Lidocaine patch q12 hours thereafter; and 6. Opioids (Regional anesthesia) in the first 48 hours, and Opioids and Regional anesthesia thereafter.
88837184|NCT03472469|Active Comparator|MAST MMPR - escalating dose arm|Drugs are scheduled around the clock as follows: 1. Acetaminophen 1g PO q6 hours at admission and thereafter; 2. Ketorolac 30mg IV once and Naproxen 500mg PO q12 hours at admission and thereafter; 3. No drug; 4; Gabapentin 300mg PO q8 hours at admission and thereafter; 5. Lidocaine patch q12 hours at admission and thereafter; and 6. Tramadol and Opioids and Regional anesthesia at admission and thereafter.
88837185|NCT04926233||COPD patients from US IBM Marketscan database|
88837186|NCT04926233||COPD patients from UK CPRD GOLD database|
88837187|NCT04943159|Experimental|Afamelanotide group A|
88837188|NCT04943159|Experimental|Afamelanotide group B|
88837189|NCT04734665|Experimental|experimental|Platinum-sensitive recurrent ovarian cancer patients previously treated with a PARP inhibitor, Non-mucinous
88837190|NCT02259114|Experimental|Continuous Dosing Regimen|Participants receive birabresib capsules once daily in a fasted state in the morning on Days 1-21 of each 21-day cycle. Starting dose for dose escalation is 80 mg.
88837191|NCT02259114|Experimental|Days 1-7 Dosing Regimen|Participants receive birabresib capsules once daily in a fasted state in the morning on Days 1-7 of each 21-day cycle. Starting dose for dose escalation is 100 mg.
88837192|NCT03611777||subjects with Pulmonary Disease, Chronic Obstructive|
88837193|NCT04864470|Experimental|Intervention|"Stroke Odysseys is a performing arts intervention for people who have had strokes which provides an opportunity for communication of experiences of stroke to an audience through acquired skills in movement, music, song and the spoken word.~Stroke Odysseys comprises three distinct stages:~weekly workshops over 12 weeks for stroke participants facilitated by an integrated team of expert artists and ambassadors from the charity Rosetta Life~a smaller group of ambassadors recruited from the workshops will be trained to become co-facilitators (stroke ambassadors)~a performance tour including education and taster workshops for audiences."
88837194|NCT05458362|Experimental|EMI group|"For two weeks after the intervention session, participants will report on their anxiety level four times per day. When participants endorse elevated anxiety, they will receive a message relevant to their most stressful symptom at the moment reminding them of the topics covered in the intervention session.~As the efficacy of the EMI component is being tested, only the EMI group will receive EMI."
88837195|NCT05458362|Active Comparator|Control group|The control group will not receive EMI prompts and will be offered to complete EMI after the follow-up assessment.
88837196|NCT03473171|Experimental|Nasal non-invasive ventilation with RAM cannula|
88837197|NCT05441514|Experimental|Treatment (cobimetinib, enasidenib mesylate)|Patients receive cobimetinib PO QD on days 1-21 and enasidenib mesylate PO QD on days 1-28 of each cycle. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity.
89365934|NCT01332825|Other|normal olfaction|normal olfaction, randomized to saline nasal irrigation for 7 days
88837198|NCT03613493|Other|HPV self-sampling kit + Interview|Participants will receive an HPV self-sampling kit to screen for HPV and then are interviewed about their experience using the tool.
88837199|NCT03613493|Experimental|Culturally-targeted Fear appeal message HPV self-sampling kit|Participants will receive an HPV self-sampling kit to screen for HPV, accompanied by a culturally-targeted fear appeal message
88837200|NCT03613493|Experimental|Fear appeal message HPV self-sampling kit|Participants will receive an HPV self-sampling kit to screen for HPV, accompanied by a culturally-targeted fear appeal message
88837201|NCT03613493|Active Comparator|HPV self-sampling kit|Participants will receive an HPV self-sampling kit to screen for HPV
88837202|NCT04492397|Experimental|Test Contact lens|Subjects will be randomized to wear test lenses for one week and then switch to control lenses for one week.
88837203|NCT04492397|Active Comparator|Control Contact Lens|Subjects will be randomized to wear control lenses for one week and then switch to test lenses for one week.
88837204|NCT02258334|Experimental|Fluzone® Quadrivalent vaccine Group 1|Adults 18 to < 65 years of age randomly assigned to receive an intramuscular injection of Fluzone® Quadrivalent vaccine
88837205|NCT02258334|Experimental|Fluzone® Intradermal vaccine Group 2|Adults 18 to < 65 years of age randomly assigned to receive an intradermal injection of Fluzone® Intradermal vaccine
88837206|NCT02258334|Experimental|Fluzone® Quadrivalent vaccine Group 3|Adults ≥ 65 years of age randomly assigned to receive an intramuscular injection of Fluzone® Quadrivalent vaccine
88837207|NCT02258334|Experimental|Fluzone® High-Dose vaccine Group 4|Adults ≥ 65 years of age randomly assigned to receive an intramuscular injection of Fluzone® High-Dose vaccine
89365935|NCT03284476||ICU patients|Collection of medical data of Patients with peritonitis (nosocomial or community-acquired) or Patients with post-operative peritonitis
89365936|NCT01332903|Experimental|1|[14C] AZD5069
88837208|NCT03478163|No Intervention|Control|The patient will not receive antibiotics as part of the study, though if at any time her provider chooses to administer antibiotics either prophylactically or for treatment she will not prohibited in any way from this or any other treatment as appropriate.
88837209|NCT03478163|Experimental|Antibiotics|The patient will receive a 24-hour course of antibiotics. The primary antibiotic of choice will be cefazolin 1 gm iv q8 hours. If the patient has contraindications to the use of cefazolin including cefazolin allergy, hypersensitivity, or severe beta lactam allergy, then clindamycin 900 mg iv q8 hours will be used instead.
88837210|NCT05646810|Active Comparator|Lidocaine|Nerve block
88837211|NCT05646810|Placebo Comparator|Isotonic saline|Nerve block
88837212|NCT04449263|Experimental|Lens A (Test)|Subjects will be randomized to wear Lens A (test) the control Lens B for 2 weeks in this randomized, cross-over bilateral dispensing study.
89365937|NCT03292276|Experimental|Amadeo training|All participants will receive 40 sessions of treatment (45-minute) for 8 consecutive weeks (5 days/week). The robotic exercises will be carried in passive modality (15 minutes), passive/plus (15 minutes), assisted modality (15 minutes).
89365938|NCT03292276|Active Comparator|occupational therapy|All participants will receive 40 sessions of treatment (45-minute) for 8 consecutive weeks (5 days/week). The control group will receive the same amount of training by physiotherapist skilled in occupational tharapy.
89365939|NCT01335087|Active Comparator|Lifestyle|Standard care for OSA: lifestyle, and sleep hygiene counselling
89365940|NCT01335087|Experimental|Continuous positive airway pressure CPAP|CPAP treatment every night plus standard care for OSA: lifestyle, and sleep hygiene counselling
89365941|NCT01335087|No Intervention|Reference|This group will be followed according to cardiovascular protocols and will be evaluated as a reference group.
89365942|NCT03292120|Experimental|patients with septic shock|
89365943|NCT01337427|Placebo Comparator|Placebo for 48 weeks, BIIB017 for 48 weeks|Placebo every 2 weeks for 48 weeks followed by 125 mcg BIIB017 SC every 2 or 4 weeks for 48 weeks.
89365944|NCT01337427|Experimental|BIIB017 every 2 weeks for 96 weeks|125 mcg BIIB017 SC every 2 weeks for 96 weeks.
89365945|NCT01337427|Experimental|BIIB017 every 4 weeks for 96 weeks|125 mcg BIIB017 SC every 4 weeks for 96 weeks.
89365946|NCT03283228||CD11b and CD56 markers|Cd11b and Cd56 as Prognostic Markers in Acute Myeloid Leukemia
89365947|NCT03283228||Haematological parameters in cases of adult AML|Study correlation between CD56 and CD11b expression with haematological parameters in cases of adult AML
89365948|NCT01335165|Experimental|TT30 (ALXN1102 Formulation)|IV: 0.1, 0.3, and 1.0 mg/kg
88837213|NCT04449263|Active Comparator|Lens B (Control)|Subjects will be randomized to wear Lens B (control) and Lens A (Test) for 2 weeks in this randomized, cross-over bilateral dispensing study.
88837214|NCT04449263|Active Comparator|Habitual Lenses|All subjects will wear their habitual lenses for two weeks prior to randomization of Test lens A and control lens B.
89365949|NCT01335165|Experimental|TT30 (ALXN1103 Formulation)|"IV: 3.0, 6.0, and 10.0 mg/kg~SC: 1.0 and 3.0 mg/kg"
89365950|NCT02459938|Experimental|ZP-Glucagon 0.5 mg|glucagon applied to the ZP transdermal microneedle patch system at a dose of 0.5 mg applied by means of a purpose built reusable applicator and worn for 30 minutes
88837215|NCT05646732|Experimental|TMS-fMRI|Participants will undergo simultaneous TMS-fMRI as part of this study. There will be two locations stimulated: one control region and one target region. Participants will be randomized with respect to the order of receiving stimulation at the locations, but all participants will receive stimulation at both locations as part of the study. All participants will be considered as one group but we will evaluate order effects as an explanatory variable.
88837216|NCT04413929||Ergoferon|Oral administration in the therapeutic dosage specified in the instructions for medical use.
88837217|NCT04960202|Experimental|PF-07321332/ritonavir|Orally administered PF-07321332+ritonavir
89365951|NCT02459938|Experimental|ZP-Glucagon 1.0 mg|glucagon applied to the ZP transdermal microneedle patch system at a dose of 1.0 mg applied by means of a purpose built reusable applicator and worn for 30 minutes
89365952|NCT02459938|Active Comparator|Glucagon by injection, 0.5 mg|glucagon applied as GlucaGen (NovoNordisk) injector system at a dose of 0.5 mg
89365953|NCT02459938|Active Comparator|Glucagon by injection, 1.0 mg|glucagon applied as GlucaGen (NovoNordisk) injector system at a dose of 0.5 mg
89365954|NCT04850313|No Intervention|Conventional Treatment|"Corneal ulcer scraping sent for microbial culture~Admission to the hospital for initiation of fortified vancomycin 25mg/mL every 1 hour alternating with fortified tobramycin 15mg/mL every 1 hour, preservative free artificial tears every 2 hours, and doxycycline 100mg twice daily.~After 48 hours of conventional treatment, consent will be obtained regarding the use of experimental treatment with ProKera Plus® versus continuing conventional method of treatment"
88837218|NCT04960202|Placebo Comparator|Placebo|Orally administered placebo
88837219|NCT03615911|Experimental|Vaccination with 10^7 PFU MVA-MERS-S|"Vaccinations occur on days 0 and 28~A subgroup will additionally receive a late booster immunization with 10^8 PFU MVA-MERS-S 12 months (+/- 4 months) after prime immunization."
89365955|NCT04850313|Experimental|ProKera Plus® Treatment|1. Experimental Treatment Arm , ProKera Plus® will be placed in the eye with the corneal ulcer
89365956|NCT03284164|Experimental|Healthy Subjects|Healthy Subjects matched to RI subjects Tenofovir Exalidex (TXL)
89365957|NCT03284164|Experimental|Severe RI|Severe Renal Impairment subjects Tenofovir Exalidex (TXL)
89365958|NCT01335243|Experimental|TLIF surgery|
89365959|NCT03107728|Experimental|Advanced orthotic brace|
89365960|NCT03107728|Active Comparator|Conventional orthotic brace|
89365961|NCT01337583|Experimental|Dapivirine|Vaginal ring containing 25mg of dapivirine
89365962|NCT01337583|Placebo Comparator|Placebo Ring|Vaginal ring containing no drug substance
89365963|NCT03107962|Experimental|PD-1 Blocking Antibody|Pembrolizumab
89365964|NCT05094050|Experimental|Arm 1: ABBV-951|Participants will receive ABBV-951 for 2 consecutive days in the abdomen (Period 1), flank (Period 2), arm (Period 3) and thigh (Period 4).
89365965|NCT05094050|Experimental|Arm 2: ABBV-951|Participants will receive ABBV-951 for 2 consecutive days in the arm (Period 1), abdomen (Period 2), thigh (Period 3) and flank (Period 4).
89365966|NCT05094050|Experimental|Arm 3: ABBV-951|Participants will receive ABBV-951 for 2 consecutive days in the thigh (Period 1), arm (Period 2), flank (Period 3) and abdomen (Period 4).
89365967|NCT05094050|Experimental|Arm 4: ABBV-951|Participants will receive ABBV-951 for 2 consecutive days in the flank (Period 1), thigh (Period 2), abdomen (Period 3) and arm (Period 4).
89365968|NCT03200457|Experimental|Patients with hepatic iron overload or steatosis|Each patient (80) will have two MRI exams on the same day: one performed in common practice on a 1.5 Tesla device and the other on a 3 Tesla device.
89365969|NCT02460406|Other|control group|traditional physiotherapy (stretching, normal range of movement, walking)
89365970|NCT02460406|Active Comparator|intervention group|progressive functional strength training protocol on lower extremities consisted of functional squat system with virtual reality in leg press, plyometric exercises, exercises with Bosu ball & heel-rise exercises.
89365971|NCT04891172|No Intervention|Control|The Control group will be receive Standard of care only
89365972|NCT04891172|Experimental|C-IVIG|The intervention group will receive the single dose of C-IVIG (0.15g/kg) with Standard of Care
89365973|NCT03284086|Other|paraplegic|Well-trained participants with a spinal cord injury (<Th1) were included in this group.
89365974|NCT03284086|Other|able bodied|Upper-body trained, able-bodied participants were included in this group.
88837220|NCT03615911|Experimental|Vaccination with 10^8 PFU MVA-MERS-S|"Vaccinations occur on days 0 and 28~A subgroup will additionally receive a late booster immunization with 10^8 PFU MVA-MERS-S 12 months (+/- 4 months) after prime immunization."
88837221|NCT03618017|Experimental|CCC Website|The intervention, ConnectedCancerCare (CCC) Website is a personalized, navigation tool that is tailored to patients' preferences for provider roles in follow-up care, their satisfaction with their current primary care provider, and their worry about cancer recurrence. It involves a personalized, patient-facing website which includes a baseline survey, tailored educational modules, and a guide for their survivorship care, as well as a text or email based reminder system. The intervention also includes a provider-facing summary document, which will be faxed to both the oncology and primary care teams.
88837222|NCT03618017|Other|Static care plan|"The control arm will receive is a static survivorship care plan template in PDF format that includes information similar to what an oncologist currently provides as standard of care."
88837223|NCT03619811|Experimental|Symptomatic|This study examines the efficacy of the upper esophageal sphincter assist device as an adjunct to Proton-pump inhibitors (PPI) therapy in symptomatic subjects. (Reflux Band® Upper Esophageal Sphincter (UES) Assist Device)
88837224|NCT03619889|Sham Comparator|Sham simulation group|A simulation of the pressure release technique, applying a soft pressure or contact in the same muscles sites or trigger points than in the intervention group.
88837225|NCT03619889|Experimental|Pressure release technique group|The release pressure technique is applied in the trigger points of masticatory and neck muscles (upper trapezius, sternal and clavicular sternocleidomastoid, deep and superficial masseter, posterior, medium and anterior temporalis.
88837226|NCT02959112|Active Comparator|Epinephrine sprayed on the papilla and rectal indomethacin|Epinephrine 1 mg/1 mL + 9 mL of sterile water are sprayed on the papilla at the end of the endoscopic retrograde cholangiopancreatography and 100 mg of indomethacin rectal suppository is administered at the beginning of the procedure
88837227|NCT02959112|Placebo Comparator|Sterile water sprayed on the papilla and rectal indomethacin|10 mL of sterile water are sprayed on the papilla at the end of the endoscopic retrograde cholangiopancreatography and 100 mg of indomethacin rectal suppository is administered at the beginning of the procedure
88837228|NCT03481595|No Intervention|Group A|Group A will receive standard, routine medical care. If you are randomized to standard, routine medical care you will need to communicate with your Doctor and clinical care team through conventional methods such as over the phone or through MyChart.
89365975|NCT03284008|Experimental|Manual manoeuver + stretching|Patients will receive a manual manoeuver treatment and education to perform stretching exercises at home.
89365976|NCT03284008|Active Comparator|stretching exercise|Patients will receive education to perform stretching exercises at home.
88837229|NCT03481595|Experimental|Group B|Group B will be asked to use the HealthLoop mobile application on their mobile device during the post-operative period in addition to standard, routine medical care. Patients randomized to use the Health Loop app will be able to communicate with their Doctor and clinical care team directly through the app. Patients will also participate in mobile and web-based surveys, receive reminders related to their healthcare, and receive information personalized to their treatment plan.
88837230|NCT04957550|Experimental|Treatment group A|SHR0302 tablets dose 1+ Placebo dose 2
88837231|NCT04957550|Experimental|Treatment group B|SHR0302 tablets dose 2+ Placebo dose 1
88837232|NCT04957550|Placebo Comparator|Treatment group C|Placebo dose1 + placebo dose 2
88837233|NCT03622619|Experimental|Manuka eye drops|
88837234|NCT03622619|Active Comparator|Systane Ultra|
88837235|NCT02977598||non-diabetic|According to the 75 g oral glucose tolerance test participants were categorized into the three groups; non-diabetic, prediabetic, and diabetic based on the criteria of the American Diabetes Association.
89365977|NCT01337661||COPD subjects|Adult male and female subjects with COPD
89365978|NCT03135249|Other|Alemtuzumab treatment.|"Patients with relapsing-remitting multiple sclerosis previously treated with natalizumab, the following treatment arms with alemtuzumab will be implemented:~Year One: Alemtuzumab 12 mg (1.2 ml) IV Infusion via pump over a minimum of four hours daily for five days to be given within eight hours after dilution.~Year Two: Alemtuzumab 12 mg (1.2 ml) IV Infusion via pump over a minimum of four hours daily for three days to be given within eight hours after dilution."
89365979|NCT03292042|Experimental|Experimental Group|"This group will carry out the lifestyle intervention (Physical health promotion program) during 6 months.~The group will attend a session per week."
89365980|NCT03292042|No Intervention|Control group|usual care
89365981|NCT01335321|Active Comparator|Hylan GF-20 alone|This arm will receive a knee infiltration with 6ml of Hylan GF-20 only
89365982|NCT01335321|Experimental|Triamcinolone|This arm will receive a knee infiltration with 6ml of Hylan GF-20 associated with 1ml of triamcinolone
89365983|NCT03635697|Experimental|Mindfulness Intervention Group|Participants in this group will listen to a short mindfulness audio clip during 6 of their NST appointments.
89365984|NCT03635697|No Intervention|Control Group|Participants in this group will have the regular standard of care for their NST appointments.
89365985|NCT03291730|Experimental|Hand Lettering|"The participant will engage in art-therapy by tracing and coloring a detailed letter or word~Participants will also be guided through a relaxation breathing and journaling exercise that can be incorporated into the art activity."
88837236|NCT02977598||prediabetic|According to the 75 g oral glucose tolerance test participants were categorized into the three groups; non-diabetic, prediabetic, and diabetic based on the criteria of the American Diabetes Association.
88837237|NCT02977598||diabetic|According to the 75 g oral glucose tolerance test participants were categorized into the three groups; non-diabetic, prediabetic, and diabetic based on the criteria of the American Diabetes Association.
88837238|NCT04428359|Experimental|Measles, Mumps, Rubella vaccine|All Group A patients will receive intralesional MMR.
88837239|NCT04428359|Experimental|Vitamin D3|All Group B patients will receive intralesional Vitamin D3
88837240|NCT02257632|Experimental|Group 1|6 monthly intravitreal injections of 0.5 mg ranibizumab
89365986|NCT01333137|Active Comparator|Gemcitabine and Carboplatin|Gemcitabine 1000 mg/m2/day on Days 1 & 8 and carboplatin at AUC 2 on Days 1 and 8 every 21 days.
88837241|NCT02257632|Experimental|Group 2|3 monthly intravitreal injections of 2 mg aflibercept followed by 3 monthly intravitreal injections of 0.5 mg ranibizumab
88837242|NCT04943120|Experimental|"Snow-Plow technique"|In class II cavities, application of X-tra Base bulk fill flowable composite (VOCO) in 1 mm thickness without curing followed by X-tra Fill bulk fill packable composite (VOCO) to restore the proximal wall. Polymerization as one unit for 20 seconds.
88837243|NCT04943120|Active Comparator|Bulk Fill technique|In class II cavities, application of 4 mm increment of X-tra Fill bulk fill packable composite (VOCO) to restore the proximal wall. then the restoration id fully polymerized.
88837244|NCT04415489|Active Comparator|Office Hysteroscopy|Use of office hysteroscope with operative port to evaluate uterine cavity, and potentially treat minor abnormalities within the same procedure with hysteroscopic graspers. This involve inserting the hysteroscope through the cervix and instillation of saline for a direct look at the cavity.
88837245|NCT04415489|No Intervention|Saline Infusion Sonography (SIS)|This is our institution's current first line approach for screening evaluation of the uterine cavity. If not enrolled in the study, patients are required to do this to move forward with embryo transfer. It involves instillation of saline into the uterus via a small catheter with simultaneous imaging with pelvic ultrasound.
88837246|NCT04937036||COMISA group|Patients with diagnosed COMISA.
88837247|NCT04937036||Healthy controlls|Healthy indyviduals.
88837248|NCT05436054|Active Comparator|Picoprep|"Picoprep®:~Active substances: An envelope Picoprep® contains 10 mg sodium picosulfate, 3,5 g magnesium oxide, and 12 g citric acid.~Mechanism of action: Sodium picosulfate is a peristaltic agent that increases the peristalsis of the intestine. Magnesium oxide and citric acid are osmotic agents to increase water content in the bowel.~Dosage and administration: consist of 2 envelopes, the first envelope, after dissolving in 150 ml water, should be taken 10-18 hours before the colonoscopy, then at least 250mlX5 clear fluid (not only water) over the next hours before the second dose is taken. The second envelope should be taken 4-6 hours before colonoscopy followed by 250mlX3 clear fluid (not only water) over the next hours before colonoscopy. The total fluid intake is approximately 2.3 L."
88837249|NCT05436054|Experimental|Plenvu|"Plenvu®:~Active substances:~Dose nr. 1~1 envelope contains 1 g potassium chloride, 100 g macrogol 3350, 2 g sodium chloride, and 9 g sodium sulfate.~Dose nr. 2 1 envelope A contains 1,2 g potassium chloride, 40 g macrogol 3350, and 3,2 g sodium chloride.~1 envelope B contains 7,54 g ascorbic acid (Vit. C) and 48,11 g sodium ascorbate.~Mechanism of action: Macrogol 3350 is an osmotic laxative. The added electrolytes are to prevent electrolyte shifting and systemic disturbances.~Dosage and administration: two separate nonidentical 500 ml doses are given. 2-day regime: dose nr.1 envelope is dissolved in 500 ml post water and drunk over 30 minutes. Should be taken at 6 o'clock evening before colonoscopy day. Dose nr.2 envelope A and B are dissolved in 500 ml post water and drunk over 30 minutes. Should be taken at 6 o'clock on the morning of colonoscopy day.~After each dose of the dissolved Plenvu®, the patient should drink at least 500ml clear fluid."
88837250|NCT04383665|Sham Comparator|STN DBS off|
88837251|NCT04383665|Experimental|STN DBS 10Hz|
88837252|NCT04383665|Active Comparator|STN DBS 130Hz|
88837253|NCT02977130|Experimental|Map group|patients receiving general shared care for diabetes and the conversation map intervention
88837254|NCT02977130|Active Comparator|Control group|patients receiving general shared care for diabetes
88837255|NCT01642914|Experimental|Linaclotide 290 micrograms|Linaclotide 290 micrograms
88837256|NCT01642914|Experimental|Linaclotide 145 Micrograms|Linaclotide 145 micrograms
88837257|NCT01642914|Placebo Comparator|Placebo|Matching placebo
88837258|NCT04381481|Experimental|Control beverage, text snack|"The participant will see fruit drinks with no nutrition claims (task 1). They will see a snack with a text warning WARNING: High in added sugar (task 2)."
88837259|NCT04381481|Experimental|Control beverage, control snack|The participant will see fruit drinks with no nutrition claims (task 1). They will see a snack with a barcode label (control label) (task 2).
88837260|NCT04381481|Experimental|Control beverage, graphic snack|"The participant will see fruit drinks with no nutrition claims (task 1). They will see a snack with a graphic label (image of sugar cubes in a cup) along with the text WARNING: High in added sugar (task 2)."
89365987|NCT01333137|Experimental|P276-00 along with Gemcitabine and carboplatin|P276-00 will be administered at starting dose of 100 mg/m2/day (and higher if tolerated) in 200 mL of 5% dextrose as an iv infusion over 30 minutes, on Days 1 to 5, along with gemcitabine 1000 mg/m2/day and carboplatin at AUC 2 on Days 1 & 8 every 21 days.In Phase 2 component, P276-00 will be administered at recommended phase II dose of P276-00 in combination with standard dose of gemcitabine and carboplatin.
88837261|NCT04381481|Experimental|Claim 1 beverage, text snack|"The participant will see fruit drinks with the nutrition claim No Artificial Sweeteners (task 1). They will see a snack with a text warning WARNING: High in added sugar (task 2)."
88837262|NCT04381481|Experimental|Claim 1 beverage, control snack|"The participant will see fruit drinks with the nutrition claim No Artificial Sweeteners (task 1). They will see a snack with a barcode label (control label) (task 2)."
88837263|NCT04381481|Experimental|Claim 1 beverage, graphic snack|"The participant will see fruit drinks with the nutrition claim No Artificial Sweeteners (task 1). They will see a snack with a graphic label (image of sugar cubes in a cup) along with the text WARNING: High in added sugar (task 2)."
88837264|NCT04381481|Experimental|Claim 2 beverage, text snack|"The participants will see fruit drinks with the nutrition claim 100% Vitamin C daily value (task 1). They will see a snack with a text warning WARNING: High in added sugar (task 2)."
88837265|NCT04381481|Experimental|Claim 2 beverage, control snack|"The participants will see fruit drinks with the nutrition claim 100% Vitamin C daily value (task 1). They will see a snack with a barcode label (control label) (task 2)."
88837266|NCT04381481|Experimental|Claim 2 beverage, graphic snack|"The participants will see fruit drinks with the nutrition claim 100% Vitamin C daily value (task 1). They will see a snack with a graphic label (image of sugar cubes in a cup) along with the text WARNING: High in added sugar (task 2)."
88837267|NCT04381481|Experimental|Claim 3 beverage, text snack|"The participants will see fruit drinks with the nutrition claim 100% All Natural (task 1). They will see a snack with a text warning WARNING: High in added sugar (task 2)."
88837268|NCT04381481|Experimental|Claim 3 beverage, control snack|"The participants will see fruit drinks with the nutrition claim 100% All Natural (task 1). They will see a snack with a barcode label (control label) (task 2)."
88837269|NCT04381481|Experimental|Claim 3 beverage, graphic snack|"The participants will see fruit drinks with the nutrition claim 100% All Natural (task 1). They will see a snack with a graphic label (image of sugar cubes in a cup) along with the text WARNING: High in added sugar (task 2)."
88837270|NCT01642602|Experimental|Dexlansoprazole 30 mg|Dexlansoprazole 30 mg delayed-release capsules orally once daily for up to 4 weeks.
88837271|NCT03488849|Experimental|SureCRIC|SureCRIC-aided cricothyroid membrane identification
88837272|NCT03488849|Active Comparator|Freehand|Freehand cricothyroid membrane identification
88837273|NCT04371419|Experimental|Control - CDC - Mask (Control) - Concordant|Control Intro, CDC Social Distancing, Mask Control version delivered by minority doctor of same background as the recipient - other definitions are similar
88837274|NCT04371419|Experimental|Control - CDC - Mask (Control) - Discordant|Control Intro, CDC Social Distancing, Mask Control version delivered by majority doctor of different background as the recipient - other definitions are similar
88837275|NCT04371419|Experimental|Control - MGH - Mask (Control) - Concordant|Control Intro, MGH Social Distancing, Mask Control version delivered by concordant doctor
88837276|NCT04371419|Experimental|Control - MGH - Mask (Control) - Discordant|Control Intro, MGH Social Distancing, Mask Control version delivered by discordant doctor
88837277|NCT04371419|Experimental|Ack. Discrimination- MGH - Mask (Control) - Concordant|Introduction Acknowledges past discrimination, MGH doctor talks about Social Distancing, Mask Control all by concordant MD
88837278|NCT04371419|Experimental|Ack. Discrimination- MGH - Mask (Control) - Discordant|Introduction Acknowledges past discrimination, MGH doctor talks about Social Distancing, Mask Control all by discordant MD
88837279|NCT04371419|Experimental|Ack. econ. circumstance- MGH - Mask (Control ) Concordant|Intro econ. circumstance -MGH - Mask (Control ) Concordant
88837280|NCT04371419|Experimental|Ack. econ. circumstance - MGH - Mask (Control ) Discordant|
88837281|NCT04371419|Experimental|Control Intro - CDC - Mask (antiStigma) Concordant|Control Intro - CDC - Mask (antiStigma) Concordant messenger
88837282|NCT04371419|Experimental|Control Intro - CDC - Mask (antiStigma) Discordant|Control Intro - CDC - Mask (antiStigma) discordant messenger
88837283|NCT04371419|Experimental|Control - MGH - MaskS (antiStigma) Concordant messenger|Control - MGH - MaskS (antiStigma) Concordant sender
88837284|NCT04371419|Experimental|Control- MGH-MaskS (antiStigma) Discordant messenger|Control - MGH - MaskS (antiStigma) Discordant sender
88837285|NCT04371419|Experimental|Ack. Discrimination - MGH - MaskS (antiStigma) Concordant|Acknowledge Discrimination - MGH - MaskS (antiStigma) Concordant sender
88837286|NCT04371419|Experimental|Ack. Discrimination - MGH - MaskS (antiStigma) Discordant|Acknowledge Discrimination - MGH - MaskS (antiStigma) Discordant sender
88837287|NCT04371419|Experimental|Ack. Econ Hardship- MGH - Mask (antiStigma) Concordant|Acknowledge Econ Hardship- MGH - Mask (antiStigma) Concordant sender
88837288|NCT04371419|Experimental|Ack. Econ Hardship- MGH - Mask (antiStigma) Discordant|Acknowledge Econ Hardship- MGH - Mask (antiStigma) discordant sender
88837289|NCT04371419|Placebo Comparator|Info later - Pure Control|This group will not receive the videos but will receive information later.
88837290|NCT04848194|Other|All patients|All patients with psoriasis recruted by dermatological departement.
88837291|NCT02256540|Placebo Comparator|Placebo patch - placebo tablets|Postmenopausal women will be given a placebo patch to wear two days prior to exercise visit and a placebo tablet to take the morning of the exercise visit.
88837292|NCT02256540|Experimental|Placebo patch - Resveratrol tablets|Postmenopausal women will be given a placebo patch to wear for two days prior to the exercise visit and a resveratrol tablet (dosed at 250mg) to take the morning of the exercise visit.
88837293|NCT02256540|Active Comparator|Climara patch - placebo tablets|Postmenopausal women will be given a transdermal estrogen patch to wear (0.05mg/day) for two days prior to the exercise visit and a placebo tablet to take the morning of the exercise visit.
88837294|NCT04366583|Experimental|Argon plasma coagulation plus distilled water injection|The patients in this group received Argon plasma coagulation therapy, PSD-60/Endoplasma (Olympus Corporation, Tokyo, Japan), following distilled water injection at index endoscopy. Then participants were treated with intravenous pantoprazole (Pantoloc i.v., Nycomed GmbH, Singen, Germany) 40 mg every 12 hours during the first 3 days, followed by oral pantoprazole (Pantoloc, Takeda GmbH, Oranienburg, Germany) 40 mg daily until the end of56-day study period.
88837295|NCT04366583|Active Comparator|Hemoclipping plus distilled water injection|The patients in this group received hemoclipping (Olympus HX 110/610, Olympus Corporation, Tokyo, Japan), following distilled water injection at index endoscopy. Then participants were treated with intravenous pantoprazole (Pantoloc i.v., Nycomed GmbH, Singen, Germany) 40 mg every 12 hours during the first 3 days, followed by oral pantoprazole (Pantoloc, Takeda GmbH, Oranienburg, Germany) 40 mg daily until the end of56-day study period.
89365988|NCT03283618|No Intervention|Control Group|The control group will receive the mHealth devices (scale, blood pressure cuff, and accelerometer watch) as well as caloric and step goals, but no health coaching. They will complete the same pre- and post-intervention measurements and consultations with the medical doctor and registered dietitian.
89365989|NCT03283618|Experimental|Video Conference-based Health Coaching|The video conference-based health coaching group will receive the mHealth devices (scale, blood pressure cuff, and accelerometer watch) meet the medical doctor at baseline and at 12 weeks via the Amwell® app using their smartphone. The participants will receive health coaching by meeting weekly (12 times) with the registered dietitian (RD) to discuss behavior modification, exercise, and nutrition goals.
89365990|NCT02459704|Experimental|SCPF + EMD (TEST)|Semilunar coronally positioned flap with Enamel matrix derivative (Emdogain)
89365991|NCT02459704|Active Comparator|SCPF (CONTROL)|Semilunar coronally positioned flap alone
89365992|NCT03041727|Active Comparator|Standard Group|"The subjects will be treated with a standard protocol of stretching and strengthening exercises , we require them to do the exercises by themselves during five weeks, one a day.~To make sure that they will do the protocol, we'll give them a diary to sign the daily section."
88837296|NCT03627299|Experimental|Deceased donor HCV RNA PCR+|Participants who receive a kidney from HCV RNA PCR + deceased donor will receive 300 mg glecaprevir/pibrentasivir 120 mg once daily by mouth for 4 weeks
89365993|NCT03041727|Experimental|Intervention group|The subjects will be treated with the same protocol of the Standard Group, but in two section, they will receive a Fascial Manipulation approach.
89365994|NCT02459626||HFpEF and servere diastolic dysfuntion|Left ventricular ejection fraction (LV-EF) > 50%, echocardiographic criteria for diastolic dysfunction, New York Heart Association classification (NYHA)=>2, Diagnostic P-V-loops and MRI
89365995|NCT02459626||HFpEF no servere diastolic dysfuntion|LV-EF > 50%, no echocardiographic criteria for diastolic dysfunction, NYHA=>2, Diagnostic P-V-loops and MRI
88837297|NCT05646264|No Intervention|Monotherapy group|Single use of second-generation antipsychotic drugs (including olanzapine, risperidone, aripiprazole, etc.)
88837298|NCT05646264|Experimental|Joint group|second-generation antipsychotic drugs (including olanzapine, risperidone, aripiprazole, etc.) Add Agomelatine
88837299|NCT04841954|Experimental|Prick-test|
89365996|NCT02459626||No HF or diastolic dysfunction|LV-EF > 50%, no diastolic dysfunction, no heart failure, Diagnostic P-V-loops and MRI
89365997|NCT01333215||Group 1|Depressed older suicide non-attempters
88837300|NCT04734431||Survivors|Patients admitted in geriatrics that survived of a bacterial infection after 30 days (still admitted or discharged), and treated by antibiotics.
88837301|NCT04734431||Death|Deceased individuals admitted for a bacterial infection in geriatrics, despite receiving an antimicrobial therapy.
88837302|NCT01640184|Active Comparator|Active vitamin D|Patients in oral medicine group will be treated by active vitamin D and other general treatments according to the suggestions in Kidney Developement Improvement Global Outcomes (KDIGO) guidelines.
88837303|NCT01640184|Experimental|Ultrasonic ablation|Patients in Ultrasonic ablation group will be treated by ultrasound guided percutaneous parathyroid gland radio frequency ablation.
88837304|NCT01640184|Active Comparator|Parathyroidectomy|Patients in parathyroidectomy group will be treated by parathyroid surgery.
88837305|NCT04904978|Experimental|Trial Group|Use of Blanx Black Toothpaste
89365998|NCT01333215||Group 2|Depressed older suicide attempters
89365999|NCT01337817|Experimental|Ariva Silver Wintergreen|Subjects allow study product lozenge to dissolve in mouth, smoke a cigarette, then answer questionnaires about product taste and effect on desire to smoke.
89366000|NCT01337817|Active Comparator|Ariva Wintergreen|Subjects allow study comparator lozenge to dissolve in mouth, smoke a cigarette, then answer questionnaires about product taste and effect on desire to smoke.
89366001|NCT03282838|Experimental|DFN-15 (fasted)|
89366002|NCT03282838|Experimental|DFN-15 (fed)|
89366003|NCT03282838|Experimental|Comparator (fed)|
89366004|NCT01333293|Experimental|Omalizumab|
89366005|NCT01333293|Placebo Comparator|Placebo|
89366006|NCT03291574|Experimental|Electroacupuncture group|Acupuncture at Baihui, Nei guan, bilateral Zu sanli and bilateral Tian shu
88837306|NCT04904978|Active Comparator|Control Group|Use of Colgate Sensation White toothpaste.
88837307|NCT04903574|Experimental|Sedentary behavior smartphone app|This arm will be assigned to download and use a smartphone app that prompts you to stand up when your smartphone detects 30 minutes of sitting.
88837308|NCT04903574|Active Comparator|Pregnancy smartphone app|This arm will download and use a commercially available pregnancy smartphone app that does not attempt to change activity behavior.
88837309|NCT03630185|Experimental|Custom-manufactured compression hosiery (Isobar)|The custom-fitted garment is manufactured specifically for each patient based on measurements taken with a 3-dimensional volumetric laser scan of the extremity, and can be sized individually to each limb.
89001625|NCT00182663|Experimental|Treatment (immunomodulator, antiangiogenesis, steroid therapy)|Patients receive thalidomide PO QD dexamethasone PO once weekly, and clarithromycin PO BID. Treatment continues for 1 year in the absence of disease progression or unacceptable toxicity. Treatment with thalidomide continues in the absence of disease progression or unacceptable toxicity.
89366007|NCT03291574|Placebo Comparator|Sham electroacupuncture group|Sham acupuncture at Baihui, Nei guan, bilateral Zu sanli and bilateral Tian shu
89366008|NCT03282760|Experimental|Human Neural Stem Cells Suspension|Intraventricular injections of Allogenic human Neural Stem Cells (hNSCs) in four different dosages (5, 10,16 or 24 millions)
89366009|NCT04535440||Rectal varices with bleed|
89366010|NCT04535440||Rectal varices without bleed|
89366011|NCT04431466|Active Comparator|Standard of care|Standard of care (SOC) treatment
89366012|NCT04431466|Experimental|SOC plus ivermectin 100 mcg/kg|SOC plus ivermectin 100 mcg/kg
89366013|NCT04431466|Experimental|SOC plus ivermectin 200 mcg/kg|SOC plus ivermectin 200 mcg/kg
89366014|NCT04431466|Experimental|SOC plus ivermectin 400 mcg/kg|SOC plus ivermectin 400 mcg/kg
89366015|NCT03282604||male|
89366016|NCT03282604||female|
88837310|NCT03630185|Active Comparator|Off-the-rack stockings (Sigvaris)|Currently available off-the-rack compression hosiery are manufactured in eight fixed sizes (S-XLFC) that cannot be varied in size over their length to accommodate unusual anatomic patterns (eg., small ankle with large calf or vice versa) and may not achieve a comfortable fit that meets the compression goal over a uniform distribution of the limb.
89366017|NCT03291418|Experimental|ATB-346 OR Placebo|Intervention: Drug: ATB-346 dosed orally at 250 mg once daily for 14 days Intervention: Drug: Placebo (for ATB-346) dosed once daily for 14 days
89366018|NCT03291418|Active Comparator|Naproxen sodium|Intervention: Drug: naproxen sodium dosed orally at 550 mg twice daily for 14 days
88837311|NCT05421702|Active Comparator|Group A Operable colon cancer cases|All patients with operable colon cancer who will undergo laparoscopic conventional colectomy
88837312|NCT05421702|Active Comparator|Group B Operable colon cancer cases|All patients with operable colon cancer who will undergo laparoscopic complete mesocolic excision
88837313|NCT02256384|Experimental|Respiratory Acoustic Monitoring|All participants will wear the respiratory acoustic monitoring device.
88837314|NCT03631433|Active Comparator|ibuprofen|A registered pharmacist compounded identical appearing tablets of 200 mg ibuprofen and tablets of 200 mg ibuprofen/216.7 mg acetaminophen. The tablets were placed in identical-appearing bottles (60 tabs of 200 mg ibuprofen or 60 tabs of a combination of 200 mg ibuprofen/216.7 mg acetaminophen). At the end of the debridement appointment, the patient received either a bottle containing 60 tabs of 200 mg ibuprofen or 60 tabs of 200 mg ibuprofen/216.7 mg acetaminophen. The patients were instructed to take 3 tablets every 6 hours as needed for pain.
89366019|NCT03282526|Experimental|Whole body plethysmography|
89366020|NCT03282526|Active Comparator|spirometery|
89366021|NCT02885181|Experimental|GS-9876 - 30 mg|GS-9876 30 mg + filgotinib placebo for 12 weeks
89366022|NCT02885181|Experimental|GS-9876 - 10 mg|GS-9876 10 mg + filgotinib placebo for 12 weeks
89366023|NCT02885181|Experimental|Filgotinib|Filgotinib + GS-9876 placebo for 12 weeks
89366024|NCT02885181|Placebo Comparator|Placebo|GS-9876 placebo + filgotinib placebo for 12 weeks
89366025|NCT02459782|Other|US Guided Dual Quadrant Peribulbar block|Ultrasound guided Dual Quadrant Peribulbar Anaesthesia
89366026|NCT02884089|Placebo Comparator|Placebo + Metformin|Single dose of placebo administered orally followed by a single dose of metformin administered orally in one of four study periods.
89366027|NCT02884089|Experimental|Abemaciclib + Metformin|Single dose of abemaciclib administered orally followed by a single dose of metformin administered orally in one of four study periods.
89366028|NCT02884089|Placebo Comparator|Placebo + Iohexol|Single dose of placebo administered orally followed by a single dose of iohexol administered intravenously (IV) in one of four study periods.
89366029|NCT02884089|Experimental|Abemaciclib + Iohexol|Single dose of abemaciclib administered orally followed by a single dose of iohexol administered intravenously (IV) in one of four study periods.
89366030|NCT04150354|Experimental|Participants allocated to Cogito Companion|Participants will have access the Cogito Companion for a three-month period post-consent. Passive data collection will also occur during this period. As a secure, privacy-compliant mobile app, the Cogito Companion facilitates the non-invasive collection, transfer, integration, analysis, and reporting of objective behavioral indicators.
89366031|NCT01315431|Experimental|Tesetaxel-capecitabine|
88837315|NCT03631433|Experimental|ibuprofen/acetaminophen combination|A registered pharmacist compounded identical appearing tablets of 200 mg ibuprofen and tablets of 200 mg ibuprofen/216.7 mg acetaminophen. The tablets were placed in identical-appearing bottles (60 tabs of 200 mg ibuprofen or 60 tabs of a combination of 200 mg ibuprofen/216.7 mg acetaminophen). At the end of the debridement appointment, the patient received either a bottle containing 60 tabs of 200 mg ibuprofen or 60 tabs of 200 mg ibuprofen/216.7 mg acetaminophen. The patients were instructed to take 3 tablets every 6 hours as needed for pain.
89366032|NCT03265054||re-thrombosis|adult patients with a VTE history with at least 3 months of anticoagulant treatment, which suffered from a re-thrombosis within 5 years after stopping the anticoagulant treatment
89366033|NCT03265054||no thrombosis recurrence|adult patients with a VTE history with at least 3 months of anticoagulant treatment, without thrombosis recurrence
88837316|NCT04343612|Experimental|Anodal|Anode placer over the affected primary motor cortex, cathode over contralateral supra orbital area. 2 mA, 20min stimulation
88837317|NCT04343612|Experimental|Bilateral|Anode placer over the affected primary motor cortex, cathode over unaffected motor cortex. 2 mA, 20min stimulation
88837318|NCT04343612|Experimental|Cathodal|Cathode placer over the unaffected primary motor cortex, anode over contralateral supra orbital area. 2 mA, 20min stimulation
88837319|NCT04343612|Placebo Comparator|Placebo|anode montage but current is ramped up over 15 secondes, then ramped down. 2 mA, 20min stimulation
88837320|NCT03489941|Experimental|EM-100|One drop of EM-100 in either the right or left eye once on Day 1.
88837321|NCT03489941|Experimental|Zaditor®|One drop of Zaditor® in either the right or left eye once on Day 1.
88837322|NCT03489941|Experimental|Vehicle|One drop of Vehicle in either the right or left eye once on Day 1.
88837323|NCT03585114|Experimental|PyL-PET|Male participants diagnosed with metastatic castrate resistant prostate cancer (mCRPC) and are scheduled to start a new treatment will receive [F-18] DCFPyL PET/CT imaging before starting new treatment and after 6 weeks on treatment.
88837324|NCT05646186|Experimental|Personalised diet based on microbiome analysis|Personalized diet application based on artificial intelligence-assisted microbiome analysis. After the microbiome analysis is made from the stool samples to be taken from the individuals, a personalized diet program will be created with an artificial intelligence-based algorithm and a diet will be applied for 6 weeks with the support of a professional dietitian.
88837325|NCT05646186|Active Comparator|Low FODMAP diet|After the microbiome analysis is made from the stool samples to be taken from the individuals, low fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAP) diet will be applied for 6 weeks with the support of a professional dietitian.
88837326|NCT02973659|Experimental|patients with palmar hyperhidrosis|oxybutynin Vs placebo
88837327|NCT02973659|Experimental|patients with plantar hyperhidrosis|oxybutynin Vs placebo
88837328|NCT02973659|Experimental|patients with axillary hyperhidrosis|oxybutynin Vs placebo
88837329|NCT03491891||derivation cohort|no interventions will be administrated
88837330|NCT03491891||validation cohort|no interventions will be administrated
88837331|NCT00377663|Experimental|1|Participants will use the AsthmaNet web site.
88837332|NCT00377663|No Intervention|2|Participants will not use the AsthmaNet Web site.
88837333|NCT04439396|Placebo Comparator|Control|Saline injection administered during surgical procedure
88837334|NCT04439396|Experimental|Low Dose (15mg) Toradol|15mg ketorolac (toradol) administered during surgery
88837335|NCT04439396|Experimental|High Dose (30mg) Toradol|30mg ketorolac (toradol) administered during surgery
88837336|NCT03493607|Experimental|AMO-01|Intravenous Infusion
89366034|NCT01335555||Patients Pre and Post-chemotherapy|
89366035|NCT03874546|Experimental|Prognostic evaluation|Questionnaire at Day1, Day7 and 6 months.
88837337|NCT02976974|Experimental|Manual therapy (MT)|MT: Manual Therapy. Application of different manual therapy techniques through posterior and inferior humeral head slides, as well as scapular movements. Also, rotator interval stretching will be done.
88837338|NCT02976974|Experimental|Therapeutic exercise (E)|"E: Therapeutic Exercise.~Shoulder extension: Elastic bands. Shoulder flexion: Elastic bands Shoulder external rotation: Elastic bands. Scapulothoracic stability: Movement of scapular adduction guided by the physiotherapist, keeping the position for few seconds ; standing push up on the wall.~Thoracic column movements: Flexion-extension"
88837339|NCT02255760|Experimental|MEDI3902 - Dose 1|Participants will receive a single intravenous (IV) dose of MEDI3902 infused for a minimum of 13 minutes on Day 1.
88837340|NCT02255760|Experimental|MEDI3902 - Dose 2|Participants will receive a single IV dose of MEDI3902 infused for a minimum of 38 minutes on Day 1.
88837341|NCT02255760|Experimental|MEDI3902 - Dose 3|Participants will receive a single IV dose of MEDI3902 infused for a minimum of 75 minutes on Day 1.
88837342|NCT02255760|Experimental|MEDI3902 - Dose 4|Participants will received a single IV dose of MEDI3902 infused for a minimum of 150 minutes on Day 1.
88837343|NCT02255760|Placebo Comparator|Placebo|Participants will receive a single dose of placebo by IV infusion up to a maximum of 12 hours.
88837344|NCT03497585||Activity Pacing Framework|Adult patients attending rehabilitation programmes underpinned by the activity pacing framework.
88837345|NCT05369754|Experimental|YBSW015 injection 180mg|
88837346|NCT05369754|Experimental|YBSW015 injection 450mg|
88837347|NCT05369754|Experimental|YBSW015 injection 900mg|
88837348|NCT05369754|Experimental|YBSW015 injection 1800mg|
88837349|NCT03637517|Experimental|DSM265-TPGS 34% SDD, 400 mg fasted|Spray dried dispersion (SDD) formulation, powder containing 34.25% DSM265-TPGS (tocopheryl polyethylene glycol succinate)
88837350|NCT03637517|Active Comparator|DSM265-TPGS 34% SDD, 400 mg fed|Spray dried dispersion (SDD) formulation, powder containing 34.25% DSM265-TPGS (tocopheryl polyethylene glycol succinate)
89366036|NCT03282448|Experimental|Family therapy|Adolescent mothers and their family members will receive a total of 10 weekly, 30-minute, video-based family therapy sessions.
89366037|NCT03282448|No Intervention|Historical comparison group|The Edinburgh Postnatal Depression Scale scores of adolescent mothers in the intervention group will be compared to those of adolescent mothers, who were previously enrolled in the home visiting programs, at the same time points.
89366038|NCT01335711|Experimental|IMP_C/C IL28B|C/C IL28B subjects to whom IMP will be administrated prior to SOC
88837351|NCT03637517|Active Comparator|DSM265 25% SDD, 400 mg fasted|Spray dried dispersion (SDD) formulation, powder containing 25% DSM265 as free base
88837352|NCT04820426||Rheumatoid Arthritis patients|Rheumatoid arthritis patients will be evaluated in terms of the presence of neuropathic pain and its effect on the quality of life, at their admission.
88837353|NCT05645952||Patients diagnosed with DCMP during study period|Patients newly diagnosed with DCMP between January 2015 and December 2020
88837354|NCT05651256|Experimental|TREATMENT|BEFORE TREATMENT/AFTER TREATMENT A 1 cc marked insulin syringe was used for intramuscular injection of the prepared solution, according to the locations and amounts proposed with a total dose of 100 U (Type A toxinum botulinum, Allergan) in each patient, distributed at the different injection sites: 40 U in the masseter muscle, (0.1 cc=10 U), 20 U in the area of greatest hypertrophy (anterior inferior masseter), 10 U in the direction of the mandibular inferior border and 10 U in the area of the posterior inferior masseter; 20 U in the lateral pterygoid muscle (10 U extraorally between the zygomatic arch and sigmoid notch and 10 U intraorally, behind the maxillary tuberosity); 20 U in the TMJ, 10mm anterior to the tragus and 2mm below the zygomatic arch and 20 U in the anterior part of the temporalis muscle.
88837355|NCT00377195|Experimental|1|
88837356|NCT04297631|Experimental|Vancomycin Powder|All patients getting vancomycin to see concentration after 24hrs in knee drain and serum levels.
88837357|NCT04297631|Experimental|Tobramycin Powder|All patients getting Tobramycin to see conceration after 24hrs in knee drain and serum levels.
88837358|NCT05645874||Control (no underlying neurological disorder)|
88837359|NCT05645874||Neurodevelopmental disorder_Genetic cause known|
88837360|NCT05645874||Neurodevelopmental disorder_Acquird (cause known)|
88837361|NCT05645874||Neurodevelopmental disorder_Cause unknown|
88837362|NCT04296227|Experimental|ISO 81060-2:2018.|The intended purpose of the test is to evaluate the Vital Detect blood pressure monitor to ISO 81060-2:2018. The intended use for these products are manual and automatic Non-Invasive Blood Pressure monitoring on adults age 18 and older.
88837363|NCT04430582||Hypoglycemia after upper gastrointestinal (GI) surgery|Participants with hypoglycemia after upper GI surgery, recruited from the Joslin Hypoglycemia Clinic and from other hypoglycemia studies at Joslin.
88837364|NCT04430582||Asymptomatic post-bariatric participants|Participants with a history of bariatric surgery, but without a diagnosis of hypoglycemia, or symptoms of hypoglycemia. They will be recruited by advertisement flyers at postoperative surgical clinics at local hospitals (e.g. Brigham and Women's and Beth Israel Deaconess Hospitals) and from other hypoglycemia studies at Joslin.
88837365|NCT04430582||Hypoglycemia no upper GI surgery & no diabetes (DM) or pre-DM|Participants with hypoglycemia and no history of upper gastrointestinal surgery, and NO current diagnosis of diabetes or pre-diabetes, recruited from the Joslin Hypoglycemia Clinic, or from other hypoglycemia studies at Joslin.
88837366|NCT04430582||Controls, no hypoglycemia or history of upper GI surgery|Participants without hypoglycemia or upper gastrointestinal surgery (controls), recruited by local advertisement. Some participants may be recruited from other hypoglycemia studies at Joslin.
88837367|NCT04292639|Experimental|Respiratory Rate|The purpose of this study is to conduct a Respiratory Rate accuracy validation comparing the Vital USA Vital Detect to an FDA cleared End Tidal Carbon Dioxide monitor Reference Standard (GE Datex-Ohmeda). This report documents exclusively the results of the Respiratory Rate accuracy performance for the Vital USA Vital Detect.
88837368|NCT04812470|Experimental|Autologous tumor infiltrating lymphocytes (TIL)|Autologous TIL administered via hepatic arterial infusion followed by low dose Interleukin-2 after preconditioning chemotherapy with Melphalan.
88837369|NCT03502265|Experimental|Otteroo adjunct|A single-subject research design will be used: measures of infant development will be collected across a 4-week baseline period (standard care), 4 weeks of intervention (standard care and Otteroo use), and a 4 weeks of reversal/retention period (standard care). There is only one arm due to the study design. It is a within-subjects comparison, not a between-subjects comparison of different study arms.
88837370|NCT05651178|Experimental|Human CD19-CD22 Targeted T Cells Injection|Single administration: 1.0×10^6 CAR+T cells/kg, 3.0×10^6 CAR+T cells/kg, 5.0×10^6 CAR+T cells/kg
88837371|NCT02976194|Experimental|pro-re-nata|Ranibizumab 0.5mg is injected in to the vitreous cavity. An injection is given every 4 weeks three times, and then the patient will be followed up every 4 weeks. An addition injection is given as needed. Recurrence is defined as increase of exudative changes, or increase of 10% or more in central subfield macular thickness (CSMT) measured using optical coherence tomography. Aqueous humor is sampled from the anterior chamber before injection at baseline, 8 weeks and 20 weeks.
88837372|NCT00360776|Experimental|Arm I|"Patients will receive tipifarnib by mouth twice a day for 3 weeks. Treatment may repeat every 4 weeks for up to eight courses.~Patients will undergo blood collection periodically for laboratory studies. After finishing treatment, patients will be evaluated every 6 months for 5 years."
88837373|NCT04800458|Experimental|thrombocytopenic patients|
88837374|NCT04343300|Other|Control group|Control group without Pilates exercise during 12 weeks Participants were advised to keep their routine Falls diary calendar
88837375|NCT04343300|Experimental|Pilates group|Pilates classes were held twice weekly for one hour. The classes were divided into a warm-up, mat Pilates with accessories and a cool-down. Participants used small items of equipment such as bands, circles or rings, blocks, spyke balls and foam rollers. The intervention lasted 12 weeks; the classes were supervised twice a week. The supervised exercises were evaluated every four weeks (frequency and intensity) focused on the lower limb (muscles related to gait), core and trunk (muscles related to posture). The participants were asked to perform supplementary at-home workouts three times a week using a booklet and video that was provided to the participants. The video and booklet to introduce the six principles of Pilates, warm-up exercises, exercises on the chair, mat Pilates exercises and cool-down exercises. Participants were advised to perform these exercises three times a week for 30 minutes at home.
88837376|NCT04274075|Experimental|GDC-9545 Treatment Sequence A, B, and C|Participants randomized to this arm will receive one dose of GDC-9545 at the start of each of three periods according to the treatment sequence A, B, and C (refer to the intervention descriptions). The washout period between doses will be a minimum of 10 days.
88837377|NCT04274075|Experimental|GDC-9545 Treatment Sequence B, C, and A|Participants randomized to this arm will receive one dose of GDC-9545 at the start of each of three periods according to the treatment sequence B, C, and A (refer to the intervention descriptions). The washout period between doses will be a minimum of 10 days.
88837378|NCT04274075|Experimental|GDC-9545 Treatment Sequence C, A, and B|Participants randomized to this arm will receive one dose of GDC-9545 at the start of each of three periods according to the treatment sequence C, A, and B (refer to the intervention descriptions). The washout period between doses will be a minimum of 10 days.
88837379|NCT04274075|Experimental|GDC-9545 Treatment Sequence A, C, and B|Participants randomized to this arm will receive one dose of GDC-9545 at the start of each of three periods according to the treatment sequence A, C, and B (refer to the intervention descriptions). The washout period between doses will be a minimum of 10 days.
88837380|NCT04274075|Experimental|GDC-9545 Treatment Sequence B, A, and C|Participants randomized to this arm will receive one dose of GDC-9545 at the start of each of three periods according to the treatment sequence B, A, and C (refer to the intervention descriptions). The washout period between doses will be a minimum of 10 days.
88837381|NCT04274075|Experimental|GDC-9545 Treatment Sequence C, B, and A|Participants randomized to this arm will receive one dose of GDC-9545 at the start of each of three periods according to the treatment sequence C, B, and A (refer to the intervention descriptions). The washout period between doses will be a minimum of 10 days.
88837382|NCT02976350||Patients with HFpEF|Male patients with heart failure with preserved ejection fraction
88837383|NCT02976740|Experimental|SBRT+GM-CSF+Tα1|Metastasis lesion will be treated with a SBRT of 50Gy/4-10F from day 1 to day 10 . Subcutaneous injection of Immunological Agent- human recombined granulocyte-macrophage colony stimulating factor (125ug/m² per day) will be executed from day 1 to day 14 in this cycle. Another metastasis lesion will be treated likewise concurrently with rhGM-CSF in a consecutive cycle. Subcutaneous injection of another Immunological Factors Thymosin Alpha 1(1.6mg Biw)will be executed from the fist WEEK to the 12th Weeks.
89366039|NCT01335711|Active Comparator|SOC_C/C IL28B|C/C IL28B subjects to whom only SOC will be administrated
89366040|NCT01335711|Experimental|IMP_non-C/C IL28B|non-C/C IL28B subjects to whom IMP will be administrated prior to SOC
89366041|NCT01335711|Active Comparator|SOC_non-C/C IL28B|non-C/C IL28B subjects to whom only SOC will be administrated
89366042|NCT01333371|Active Comparator|closed reduction with percutaneous k-wire fixation and casted|
89366043|NCT01333371|Active Comparator|open reduction internal fixation with a volar locked plate|
89366044|NCT01333449|Experimental|Single Arm|Decitabine 20mg/m^2 infusion one hour per day, for 5days,every 28days,total 2-6cycles.
89366045|NCT02809677|Other|Non-Interventional Longitudinal Study|This is a 52 week non-placebo controlled and non-randomized clinical research study to see whether treating Major Depressive Disorder (MDD) in caregivers of children with asthma will improve asthma outcomes in children. Caregivers may choose to receive an antidepressant medication that is considered standard medical care for MDD, or may opt out of antidepressant treatment. No treatment is withheld from participants and no placebos are used, thus there is no active intervention in this study.
89366046|NCT02789007|Other|parabolic flight|To evaluate Structural and functional changes, Cognitive performance, and specifically spatial cognition, Key neurotrophins...
89366047|NCT01333605|Experimental|IGEV regimen|Ifosfamide 1200 mg/m2 at days 1-4, Mesna 400 mg 0,4,8h at days 1-4, Gemcitabine 800 mg/m2 at day 1 and day 4, Vinorelbine 20 mg/m2 at day 1, Prednisone 100 mg at days 1-4. Frequency of cycles: every 3 weeks. Numbers of cycles: 4 cycles
89366048|NCT01341561||weaning patients|
89366049|NCT05186103||HS-ASD|high-severity ASD
89366050|NCT05186103||LS-ASD|low-severity ASD
89366051|NCT05186103||control|typical development
88837384|NCT03639857|Experimental|532nm laser and topical corticosteroid|532nm laser is applied to the patient's lesion in-clinic in addition to a topical corticosteroid.
88837385|NCT03639857|Experimental|1064nm laser and topical corticosteroid|1064nm laser is applied to the patient's lesion in-clinic in addition to a topical corticosteroid.
88837386|NCT03639857|Active Comparator|Topical corticosteroid alone|Topical corticosteroid is applied to the patient's lesion.
88837387|NCT04342910|Experimental|camrelizumab (SHR-1210) combined with apatinib|Participants will receive camrelizumab on Day 1 and Day 15 of each 28-day cycle and apatinib mg/day up to 2 years.
89366052|NCT05182515|No Intervention|Standard of Care|Standard of care including Dexamethasone
89366053|NCT05182515|Experimental|Therapeutic plasma exchanges|Drug: Therapeutic plasma exchanges at day 1, 3 and 5 plus Standard of care including Dexamethasone
89366054|NCT05182437|Experimental|LINAC-based Stereotactic Radiotherapy|The intervention will consist of a single LINAC based SRT treatment and is given by the radiation-oncologist after detailed localisation of the epileptogenic zone (EZ) with the neurologist, radiologist and neurosurgeon.
88837388|NCT04342910|Active Comparator|Paclitaxel or Irinotecan|Participants receive paclitaxel on Days 1, 8, and 15 of each 28-day cycle, or irinotecan on Days 1 and 15 of each 28-day cycle.
88837389|NCT03504839|Other|Intervention|S-ICD implantation.
88837390|NCT04714073|Experimental|Reference: BI 706321 alone|First treatment period
88837391|NCT04714073|Experimental|Test: BI 706321 + Itraconazole|Second treatment period
88837392|NCT04342676|Experimental|patients|LNR measured by (number of metastatic lymph nodes/total number of lymph nodes excised). and K ras (polymerase chain reaction (PCR) and pyrosequencing targeted for KRAS codons 12-13 was performed )
88875185|NCT02513940|Experimental|Testosterone - placebo - progesterone|Subjects received transdermal testosterone gel 1% 100 mg once daily in the morning and two (2) oral placebo capsules x 7 days. After a washout of at least 13 days, they then received transdermal placebo gel once daily every morning for 7 days and oral placebo ( 2 capsules) once daily every morning x 7 days. After a washout period of at least 13 days, they then received oral progesterone 400 mg (2 x 200 mg capsules) once every evening for 7 days and transdermal placebo gel once daily every morning for 7 days.
89366055|NCT05182437|No Intervention|Current standard care|Current standard care includes anti-epileptic drugs and neuromodulation (i.e. Deep Brain Stimulation or Vagus Nerve Stimulation and/or Anti-epileptic continuation).
89366056|NCT02881047|Experimental|rAblative Fractional Laser for Sclerotic GVHD-Associated Joint|"Range of motion limitations and joint contractures due to sclerotic GVHD across a specific joint / limb"
89366057|NCT05182281|Experimental|Whole Body Vibration and Infrared Therapy Group|Patients in the whole body vibration and infrared group received vibration therapy with a frequency of 60 Hz and amplitude of 0.5-2 mm and infrared therapy at a wavelength of 550-950 nm 20 minutes daily session, 2 days per weeks for 3 months.1000 mg Ca and 880 IU vitamin D treatment were given.
89366058|NCT05182281|Active Comparator|Infrared Therapy Group|Patients in infrared therapy group received infrared therapy at a wavelength of 550-950 nm 20 minutes daily session, 2 days per weeks for 3 months.1000 mg Ca and 880 IU vitamin D treatment were given.
89366059|NCT05182281|Other|Classical Treatment Group|1000 mg Ca and 880 IU vitamin D treatment were given.
89366060|NCT01337895|Active Comparator|Lifestyle counselling|These participants will be assigned to a 500 kcal/day energy-restricted diet that is low in dairy products (no more than 1 serving per day).
89366061|NCT01337895|Experimental|High dairy|These participants will be assigned a 500 kcal/day energy-restricted diet that is high in dairy (4 or more servings per day).
89366062|NCT01341717|Experimental|Sitagliptin along with metformin and insulin|
89366063|NCT01341717|Active Comparator|Glimepiride as an active comparator to Sitagliptin|
89366064|NCT03157089|Experimental|All patients|
89366065|NCT03635541||observational group of NAFLD|Liver biopsy proved NAFLD patients, observational study. Oral advice on lifestyle would be given at each visit.
88837393|NCT04269629||patients with a history of an anaphylactic sting reaction|At Visit 1, patients will be included after carefully reviewing all inclusion and exclusion criteria. All data concerning the index sting, laboratory parameters like immunoglobulin E (IgE) and tryptase levels and skin test results will be recorded as well as the concomitant diseases and medication. Visit 2 will be performed after VIT updosing is finished. At this Visit data concerning the immunotherapy - premedication, preparation, updosing protocol, the outcome of possible large, local reactions (LLR) and systemic reactions (SR) and changes in diseases and medication will be recorded. One year after reaching the maintenance dose, Visit 3 will be performed. At this Visit data concerning the maintenance phase like premedication and possible side effects will be recorded as well as the outcome of insect stings.
88837394|NCT01641822|Active Comparator|AZLI|Participants will be randomized to receive 3 cycles of treatment, each cycle consisting alternating regimens: AZLI for 28 days followed by TIS for 28 days.
88837395|NCT01641822|Placebo Comparator|Placebo|Participants will be randomized to receive 3 cycles of treatment, each cycle consisting alternating regimens: placebo to match AZLI for 28 days followed by TIS for 28 days.
88837396|NCT04250987|Experimental|IC connected to a sensor|Single use of a IC connected to a sensor
88837397|NCT05651100|Experimental|arm 1|sequential CD19 and CD22 targeted CAR-T cells treat
88837398|NCT04393844|Placebo Comparator|with obturator|A group using an obturator when performing peripherally inserted central venous catheterization in children under 18 years of age under general anesthesia.
89366066|NCT03158727|Experimental|Cx611|Subjects treated in an intensive care unit for sCABP, but that may be screened at the emergency department, will receive SoC therapy according to local guidelines plus two intravenous central line infusions of Cx611 at a fixed dose of 160 million expanded allogeneic adipose-derived stem cells (eASCs) each.
89366067|NCT03158727|Placebo Comparator|Placebo|Subjects treated in an intensive care unit for sCABP, but that may be screened at the emergency department, will receive SoC therapy according to local guidelines plus two intravenous central line infusions of Ringer Lactate.
89366068|NCT01338129|Experimental|vitamin c|administration of vitamin c for 45 days following ankle fracture operation
89366069|NCT01338129|Placebo Comparator|placebo|placebo pills
89366070|NCT05181969||Dextran sulfate absorption (LIPOSORBER® D - Kaneka Pharma Europe NV)|Apheresis therapy
88837399|NCT04393844|Experimental|without obturator|A group that does not use an obturator when performing peripherally inserted central venous catheterization in children under 18 years of age under general anesthesia.
89001626|NCT00588679|Experimental|1|Patients taking part in this study will have one MRI and one MRSI scan acquired in succession during a single MR examination. For those patients who have undergone prostate biopsy it is recommended that this should be done at least eight weeks after the prostate biopsy and should take one hour to one hour and ten minutes total to complete.
89001627|NCT00588718||Cases|Infants who meet the entry criteria
89366071|NCT05181969||Lipid filtration (Octo Nova®, Diamed Medizintechnik)|Apheresis therapy
89366072|NCT05181969||Direct absorption of lipoproteins (DALI®; ADS 4008, Fresenius)|Apheresis therapy
89366073|NCT05181969||Therasorb (TheraSorb® - LDL adsorbers, Miltenyi Biotec)|Apheresis therapy
89366074|NCT00089895|Experimental|Eptifibatide|Eptifibatide in addition to standard of care such as standard doses of aspirin, unfractionated heparin or low-molecular-weight heparin.
89366075|NCT00089895|Placebo Comparator|Placebo|Placebo in addition to standard of care such as standard doses of aspirin, unfractionated heparin or low-molecular-weight heparin.
89366076|NCT01335945|Other|Cryoablation|Freezing of the celiac plexus
89366077|NCT01338285||1|Workers exposed to high levels of formaldehyde and unexposed workers in Guangdong Province, China.
89366078|NCT01338363||All first time users of esomeprazole|
89366079|NCT01338363||All first time users of other PPIs|
89366080|NCT01338363||All first time users of H2-receptor antagonists|
89366081|NCT05166681|Active Comparator|control group|cases allocated to that arm are those cases having their surgical wound closure by the traditional techniques involving subcutaneous layer closure as one or more raws of sutures and then skin layer closure
88837400|NCT04393532|Experimental|Laparoscopic hernia repair using Su2ura Approximation Device|"Surgery will be performed under general anesthesia. Standard antibiotic prophylaxis will be administered at induction of anesthesia. A single surgeon, the PI, will perform the procedure. A surgical assistant will be selected by the PI from the surgical staff of the department.~The procedure will involve placement of laparoscopic ports, reduction of the hernia sac, closure of the defect with the Su2ura Approximation device and fixation of mesh with tacks over the closed defect.~Study follow up visits: at post operation discharge, 14 days, 3 months, 6 months."
88837401|NCT03507569|Experimental|RO7017773|The first two participants of the first cohort are anticipated to receive a single dose of RO7017773 orally. The doses to be tested in the subsequent cohorts of participants will be determined by review of PET scan, PK, and safety results from the previous dose level.
88837402|NCT03508661|Experimental|SPIN-SSLED Program|13-session SPIN-SSLED Program
89178873|NCT04097496|Experimental|Act Out! Intervention|Eligible classrooms will be randomized to attend a 1-hour ACT OUT! interactive, semi-improvisational psychodrama performance. The ACT OUT! intervention is an established theater program (https://www.claudemcnealproductions.com/act-out-ensemble/). The ACT OUT! production will include three to five vignettes paired with moderated discussions between the audience and the actors, the latter who will remain partly in character for the duration of the intervention. Vignettes will be different for each grade level included in the study (4th, 7th, and 10th). Public documentation of the guidelines for the ACT OUT! intervention will be made available as a supplemental file attached to the primary outcomes paper for the study.
89178874|NCT04097496|No Intervention|Control|Classrooms randomized to this arm will continue with their school day as normal, except that they will complete the data collection tools.
88837403|NCT05358990|Experimental|Plain Language Recommendation (PLR)|New easy to read COVID-19 recommendations available on the COVID19 Living Map of Recommendations and Gateway to Contextualization (RecMap).
88837404|NCT05358990|Active Comparator|Standard Language Version (SLV)|Original recommendation as initially published by the guideline organization.
88837405|NCT04871958|Experimental|rtCGM/MDI|Real-time CGM, insulin therapy by multiple daily injections managed according to CGM
88837406|NCT04871958|Experimental|rtCGM/V-Go|Real-time CGM, insulin therapy by V-Go insulin pump managed according to CGM
88837407|NCT04871958|No Intervention|blindCGM/MDI|Blind CGM, insulin therapy by multiple daily injections managed according to standard care (capillary glucose measurements)
88837408|NCT04342598||Adult outpatient pulmonary MDR-TB patients|
88837409|NCT04342598||Household contact controls|
89178875|NCT00916500|Experimental|CISPLATIN|Patients With Locally Advanced Cervical Cancer Who Underwent Concurrent Chemoradiation; Cisplatin 75mg/m2 IV Every 3 Week For 3 Cycles; External Pelvic Radiation 40 Gy; Brachytherapy Up to 85-90 Gy To Point A
89178876|NCT03110094|Other|Rheumatoid arthritis - Adalimumab|
89366082|NCT05166681|Experimental|Single layer wound closure group|cases allocated to that group are those having their surgical wound closure with the new technique involving part of the subcutaneous layer and the subdermal layer
89366083|NCT05166291|Experimental|traditional anesthesia (TA)|traditional anesthesia
88837410|NCT04342598||Non-household contact controls|
88837411|NCT03645785|Active Comparator|Normal Diet/Drinking|Baseline diet and drinking patterns for patients. This is the pre-intervention baseline for cross-over analysis
89366084|NCT05166291|Experimental|comfort-in injection system (CIS)|comfort-in injection system (CIS)
89366085|NCT01341873|Experimental|Group I (FCI)|FCs receive 4 sessions of an APN FCI beginning during the admission for transplant and continuing for up to 100 days after transplant.
89178877|NCT03110094|Other|Healthy volunteer|
89178878|NCT02600988|No Intervention|Group 1: Control|Control group is composed by the first 50 patients included in the study. Those patients will not receive the treatment. Evaluations and follow-up will be the same as in the other groups.
89366086|NCT01341873|Other|Group II (control)|FCs receive standard supportive care.
89366087|NCT01338441|Experimental|Erythromycin|
89366088|NCT01338441|Placebo Comparator|Placebo|
88837412|NCT03645785|Experimental|Increased fluid Intake and Citrate Supplementation|Patients will increase fluid (with goal to double their baseline) and further take a citrate supplement in the form of True Lemon (citric acid).
88837413|NCT05650944||Covid-19 Survivor groups|Covid-19 survivor groups are hematological parameters
88837414|NCT05650944||Covid-19 Non-survivor groups|Hematological parameters in patients with severe COVID-19 who have died.
88837415|NCT04783220|Experimental|Intervention|The parents of babies in this group will receive an educational and intervention program
88837416|NCT04783220|No Intervention|Control|The parents of babies in this group will receive the standard parent education and follow-up.
88837417|NCT03511001|Experimental|E-Cigarette|6 weeks of JUUL electronic cigarettes
88837418|NCT03511001|Active Comparator|Assessment Only|6 weeks of smoking as usual
89366089|NCT01341951|Experimental|G-CSF therapy in acute liver failure and alcoholic hepatitis|G-CSF therapy given in cases with acute liver failure and alcoholic hepatitis
88837419|NCT04035356||HAART 300|HAART 300 Aortic Annuloplasty Device
88837420|NCT04035356||HAART 200|HAART 200 Aortic Annuloplasty Device
88837421|NCT03647033|No Intervention|phacoemulsification alone|routine phacoemulsification cataract surgery with intraocular lens implantation
88837422|NCT03647033|Experimental|phacoemulsification and iStent|phacoemulsification cataract surgery with intraocular lens implantation combined with iStent implantation
89001628|NCT00588718||Controls|Banked blood samples from newborns who do not meet inclusion criteria for this study will be held at Stanford University Core Laboratory and will constitute controls. Proteomic and genomic profiles in blood samples of cases will be compared with blood samples of controls.
89366090|NCT01338519||PCOS and hirsutism|
89366091|NCT01336101|Other|SFA stenting|
88837423|NCT04778930|Experimental|Group A_Intervention Group|It will consist of 18 sessions, 3 times a week, for 6 consecutive weeks; on the one hand, 12 face-to-face sessions of approximately 90 minutes duration, in which the Physical Therapy treatment will be carried out based on training of specific tasks directed to objectives and training of gait with a treadmill; In addition, a therapeutic education program will be carried out, with 6 telehealth sessions lasting approximately 60 minutes, which will include action observation activities. The face-to-face sessions will be held at the Physical Therapy Teaching Unit at University of Alcalá, and the telehealth sessions of the Therapeutic Education program will be carried out by remote assistance through a digital platform. All will be carried out by specialist Physical Therapists, members of the research team.
88837424|NCT04778930|Experimental|Group B_Control Group|The subjects in this group will receive their usual Physical Therapy intervention regimen for 6 weeks at their referral center and the same telehealth Therapeutic Education program of the intervention group.
88837425|NCT04871022|Active Comparator|Double layer unlocked uterine closer|Double layer closure with a first continuous unlocked suture of the deep portion of the myometrium and a second unlocked continuous suture that approximate the upper portion of the myometrium.
88837426|NCT04871022|Experimental|Purse uterine closer|Purse suture of the uterus with a first continuous purse suture of the deep portion of the myometrium and a second unlocked continuous suture including the remaining part of the myometrium
88837427|NCT04362254|Experimental|Spesolimab arm|
88837428|NCT03511937|Experimental|Sugar-Sweetened Beverage Health Warning Label|
88837429|NCT03511937|Other|Neutral Label|
88837430|NCT05640258|Experimental|seasickness susceptibility and vestibular time constant|"All study participants underwent rotatory chair testing in a velocity step protocol to determine the Vestibular time constant.~testing were preformed at baseline, before commencing active duty on a ship, 3 month and 6 month follow up after the beginning of active sailing."
88837431|NCT00361478|Experimental|1|"Mother and Baby Program comprising exercise and education."
88837432|NCT00361478|Active Comparator|2|Education only
88837433|NCT04018118||Eosinophilia/Hypereosinophilic syndrome|patient with eosinophilia and/or hypereosinophilic syndrome
88837434|NCT01641198|Active Comparator|Configuration 1|Device placement: B (Brånemark) at two sites, SW (Swede-Vent) at two sites, SC (Screw-Vent) at one site
88837435|NCT01641198|Experimental|Configuration 2|Device placement: B (Brånemark) at one site, SW (Swede-Vent) at two sites, SC (Screw-Vent) at two sites
88837436|NCT01641198|Experimental|Configuration 3|Device placement: B (Brånemark) at two sites, SW (Swede-Vent) at one site, SC (Screw-Vent) at two sites
88837437|NCT04214951||Recombinant human thrombopoietin (rh-TPO) group|Patients who fail previous steroids and eltrombopag and then switch to Rh-TPO will be enrolled. The reason for switch will be recorded. Patients will be given rh-TPO 300 U/kg once daily for 21 days. Rh-TPO will be terminated any time the platelet counts increased above 100 × 10^9/L. The efficacy, safety, and patient/physician preference will be assessed.
88837438|NCT04214951||Eltrombopag group|Patients who fail previous steroids and rh-TPO and then switch to eltrombopag will be enrolled. The reason for switch will be recorded. Patients will be given eltrombopag 50mg once daily for 6 weeks. Eltrombopag will be terminated any time the platelet counts increased above 300× 10^9/L.The efficacy, safety, and patient/physician preference will be assessed.
88837439|NCT04012814|Experimental|Subject treatment group|Treatment group receiving up to 4 diode treatments and up to 8 RF treatments.
88837440|NCT04770506||Lithiasis patients|Lithiasis patients: diagnosis of recurrent NL confirmed by URO CT with presence of idiopathic hypercalciuria and metabolic workup available.
88837441|NCT04770506||Control group|Control group: patients without NL matched for age and sex and who had a bone mineral densitometry or abdominal CT.
88837442|NCT05637918||Group 1 (Patients who recorded as Grade 0)|"Patients whose antrum appears empty in supine and right lateral decubitus (RLD) positions by gastric ultrasound (Grade 0). Groups are classified according to the qualitative evaluation of the antrum by gastric sonographic examination.~The nature of the gastric contents (empty, clear liquid, dark liquid/solid) is established based on the qualitative findings by gastric antral ultrasonography. The qualitative evaluation of the antrum was recorded according to the 3-point grading system as Grade 0, Grade 1, and Grade 2.~Grade 0: antrum appears empty in both positions. Grade 1: antrum appears empty in the supine position but a small volume of gastric clear fluid is visible in the RLD position.~Grade 2: antral clear fluid visualized in both the supine and RLD position"
88837443|NCT05637918||Group 2 ( Patients who recorded as Grade 1)|"Patients whose antrum appears empty in the supine position but a small volume of gastric clear fluid is visible in the RLD position by gastric ultrasound (Grade 1). Groups are classified according to the qualitative evaluation of the antrum by gastric sonographic examination The nature of the gastric contents (empty, clear liquid, dark liquid/solid) is established based on the qualitative findings by gastric antral ultrasonography. The qualitative evaluation of the antrum was recorded according to the 3-point grading system as Grade 0, Grade 1, and Grade 2.~Grade 0: antrum appears empty in both positions. Grade 1: antrum appears empty in the supine position but a small volume of gastric clear fluid is visible in the RLD position.~Grade 2: antral clear fluid visualized in both the supine and RLD position"
88837444|NCT04762082|Experimental|Treatment A: Test|Single oral dose of tadalafil gummy 10 mg, chewed, administered with approximately 240 mL of room temperature water, under fasted conditions
89001629|NCT00588757|Active Comparator|1|Optease filter
89366092|NCT01338597|Experimental|standard|3 trocars are needed. two in the circumareolar region and one in the parasternal region. the dissection area begins from the trocar site and extends to the neck.
88837445|NCT04762082|Active Comparator|Treatment B: Reference|Single oral dose of tadalafil oral tablets 10 mg, administered with approximately 240 mL of room temperature water, under fasted conditions
88837446|NCT04762082|Experimental|Treatment C: Test|Single oral dose of tadalafil gummy 10 mg, chewed, administered with approximately 240 mL of room temperature water, under fed conditions
88837447|NCT04762082|Experimental|Treatment D: Test|Single oral dose of tadalafil gummy 10 mg, chewed, administered with no water, under fasted conditions
88837448|NCT04762082|Experimental|Treatment E: Test|Single oral dose of tadalafil gummy 10 mg, swallowed whole, administered with approximately 240 mL of room temperature water, under fasted conditions
88837449|NCT03514277|Active Comparator|Local infiltration of EXPAREL and Bupivacaine|
88837450|NCT03514277|Active Comparator|Local infiltration of Exparel|
88837451|NCT03514277|Active Comparator|Local infiltration of Bupivacaine|
88837452|NCT04861740|Experimental|Screening + Autism ALERT|Clinics in the intervention arm receive Autism ALERT plus an ASD screening intervention (START Autism).
88837453|NCT04861740|Active Comparator|Screening Only|Clinics in the comparison intervention (control) arm receive the ASD screening intervention only (START Autism).
88837454|NCT04227119|Experimental|Irrigated ablation catheter and 5F balloon tipped PA catheter|Participants undergoing cardiac ablation will have cardiac pressures measured with an irrigated ablation catheter (standard protocol for this procedure) and a 5F balloon tipped pulmonary artery (PA) catheter (for study purposes only).
88837455|NCT04861428|Experimental|IQOS / Smoking as usual|Two weeks of IQOS, followed by two weeks of cigarette smoking as usual.
88837456|NCT04861428|Active Comparator|Smoking as usual / IQOS|Two weeks of cigarette smoking as usual, followed by two weeks of IQOS.
88837457|NCT00361946||lean subjects|BMI <85th for age, normal glucose tolerance
88837458|NCT00361946||obese subjects|BMI> 95th for age normal glucose tolerance
88837459|NCT00361946||Type diabetes|BMI > 85th for age , history of Type 2 diabetes as per ADA criteria
88837460|NCT03651479|Experimental|real boxing group|In the real boxing (RB) group in addition to the NDT program, real boxing training will be given.
88837461|NCT03651479|Experimental|virtual boxing group|In the virtual boxing (VB) group, in addition to the NDT program, virtual boxing training will be given by using Kinect Xbox Boxing.
88837462|NCT05334108|Other|Cohort 1|"ecopipam HCl oral tablets of 12.5, 50, 75, and 100 mg daily for up to 20 days~Cohort 1 Probe Substrate Cocktail given on 2 separate days:~midazolam: 1 µg infused IV~caffeine: 200 mg oral tablet~omeprazole: two 20 mg oral tablets~dextromethorphan: 1.6mL (containing ~10 mg) oral solution"
88837463|NCT05334108|Other|Cohort 2|"ecopipam HCl oral tablets of 12.5, 50, 75, and 100 mg daily for up to 20 days~Cohort 2 Probe Substrate given on 2 separate days:~- bupropion: 100mg oral tablet"
88837464|NCT05334108|Other|Cohort 3|"ecopipam HCl oral tablets of 12.5, 50, 75, and 100 mg daily for up to 20 days~Cohort 3 Probe Substrate Cocktail given on 3 separate days:~midazolam: 10 µg/mL given as 1mL oral solution.~dabigatran: 375 µg/mL and pitavastatin: 10 µg/mL given as 1mL oral solution~rosuvastatin: 25 µg/mL and atorvastatin: 50 µg/mL given as 2mL oral solution"
88837465|NCT04342832|Active Comparator|Early invasive treatment (cryoballoon ablation)|
88837466|NCT04342832|No Intervention|Standard medical care|
88837467|NCT04419792||Narcolepsy|
88837468|NCT03984656|Active Comparator|AL group|patients will receive a local infiltration of 10 mL Lidocaine without epinephrine 20 mg/mL
88837469|NCT03984656|Experimental|Serratus group|patients will receive ultrasound guided serratus plane block injection of 30 mL Ropivacaine 4.75 mg/mL
88837470|NCT03653351|Sham Comparator|Sham tDCS and MBSR|Includes a combination of 8 weeks of in-class group MBSR + sham tDCS and daily at home MBSR + sham tDCS.
88837471|NCT03653351|Active Comparator|Active tDCS and MBSR|Includes a combination of 8 weeks of in-class group MBSR + active tDCS and daily at home MBSR + active tDCS.
88837472|NCT03966248|Experimental|Chinese Tuina group (CTG)|The participants in CT group will receive the traditional Chinese Tuina therapy on the basis of KOA health education and home-exercise.
88837473|NCT03966248|Active Comparator|Physical Manual group (PMG)|The participants in PM group will receive the modern physical manual therapy on the basis of KOA health education and home-exercise.
88837474|NCT03515681|Experimental|Intervention|Subjects randomized to intervention will receive text messages to promote seeking care and improving compliance with blood pressure treatment.
88837475|NCT03515681|No Intervention|Control|Subjects randomized to the control arm will receive the messages regarding their kiosk blood pressure levels currently provided by higi to kiosk users. These messages are provided at the kiosk at the time of the blood pressure measurement (no text messages).
88837476|NCT03655301|Experimental|Copanlisib (Aliqopa, BAY80-6946)|All subjects will receive a single dose of metformin 1000 mg on Days 1 and 8 in a fasting state. Subjects will also receive a single i.v. dose of 60 mg copanlisib on Day 8 as part of the combination with metformin.
88837477|NCT04318106|Experimental|'Experimental' coloured spectacle lenses|Precision tinted lenses available from Cerium Technologies (TM) which will be the optimum chromaticity to alleviate visual stress symptoms. To be worn for a minimum of 10 weeks for concentrated tasks.
88837478|NCT04318106|Placebo Comparator|'Control' coloured spectacle lenses|Precision tinted lenses available from Cerium Technologies (TM) which will be individually determined as being sub-optimal to alleviate visual stress symptoms. This colour will be as similar to the 'experimental' colour as possible and will not be aversive to the participant. To be worn for a minimum of 10 weeks for concentrated tasks.
88837479|NCT04342988|Other|Cequa Treatment In Cataract Patients with Dry Eye Disease|Duration of Study Treatment - 4 weeks All patients will receive cyclosporine ophthalmic solution (0.09%) BID in both eyes for 28 days, 1 drop per dose. Dosing will be BID, both eyes, assuming both eyes will eventually undergo cataract surgery. Otherwise, single eye treatment in the operative eye will be permitted.
89001630|NCT00588757|Active Comparator|2|Tulip filter
88837480|NCT05279430|No Intervention|Control arm|Patients allocated to the control arm will not receive inspiratory muscle training. They will be checked each week by a physiotherapist responsible for training intervention who will measure their maximal inspiratory pressure
88837481|NCT05279430|Active Comparator|Inspiratory muscle training|Patients allocated to the IMT arm will be instructed to train at home twice daily, for 20 minutes each session, using a Threshold inspiratory muscle trainer (Respironics Inc., Parsippany, NJ). They will be instructed by a physiotherapist responsible for training intervention and educated to maintain diaphragmatic breathing during the training period. The subjects will start breathing at a resistance equal to 25% to 30% of their maximal inspiratory mouth pressure (MIP) for 1 week. The respiratory therapist will examine the patients at weekly intervals by checking the diary card and measuring the MIP each time. The resistance will be modified each session according to the 25% to 30% of their MIP measured.
88837482|NCT04304846||AMPLIFy group|Mother, premature child and teacher will complete questionnaires and interviews on attachment, maternal stress and child behavior
88837483|NCT03656939||Prevenar 13 cohort|This is a non-interventional study. Children in the study receive Prevenar 13 per normal medical practice.
88837484|NCT04291898|Active Comparator|Device: ASO|Participants implanted with the AMPLATZER™ Septal Occluder (ASO)
88837485|NCT04291898|Active Comparator|Device: FSO|Participants implanted with the Occlutech Figulla Flex II® (FSO).
88837486|NCT04291898|Active Comparator|Device: GSO/GAO|Participants implanted with the GORE® CARDIOFORM ASD Occluder (GSO/GAO)
88837487|NCT04740476|Experimental|STK-001 multiple dose levels|Enrollment of patients after completion of study STK-001-DS-101 if eligible for additional dosing in this extension study. Patients will receive IT administration of study drug STK-001 at the dose level they received while participating in Study STK-001-DS-101, or at a dose level recommended by the Safety Monitoring Committee (SMC).The highest dose administered in this study may not exceed that which has already been evaluated in an STK-001 Phase 1/2 study, and doses above 30 mg/dose in this study require approval from the Food and Drug Administration (FDA). Patients will initially receive 3 doses, one every approximately 4 months (16 weeks). Patients who are tolerating treatment may continue treatment with doses approximately every 4 months, with an End of Study/Follow-up Visit 24 weeks after the last dose of study drug. Patients who do not continue treatment after the third dose will have a Follow-up Visit (V5) at Week 48 and an End of Study Visit at Week 56.
88837488|NCT05630586|Active Comparator|Semaglutide 0.5 mg|"Inj. Semaglutide 0.5 mg s.c., 0.5 mg per week for 4 weeks~+ standard care"
88837489|NCT05630586|Other|Control|Standard care
88837490|NCT04870866|Experimental|NR treated|Nicotinamide ribonuceloside (NR), sold under the trade name Niagen™
88837491|NCT04262102|Active Comparator|Group 1 (SD_SF)|Women will follow a personalized standard diet, described in National Diet Surveys. And their children will be spoon-fed during complementary feeding.
88837492|NCT04262102|Experimental|Group 2 (SD_BLW)|Women will follow a personalized standard diet, described in National Diet Surveys. And their children will follow a baby-led weaning approach for complementary feeding.
88837493|NCT04262102|Experimental|Group 3 (HFV_SF)|Women will follow personalized diet, high in fruits and vegetables. And their children will be spoon-fed during complementary feeding.
88837494|NCT04262102|Experimental|Group 4 (HFV_BLW)|Women will follow personalized diet, high in fruits and vegetables. And their children will follow a baby-led weaning approach for complementary feeding.
88837495|NCT05620758|Experimental|Nd YAG laser|
88837496|NCT05620758|Experimental|Diode laser 980 nm|
88837497|NCT05620758|Experimental|Diode laser 940 nm|
88837498|NCT05620758|Experimental|Diode laser 660 nm|
88837499|NCT05620758|Experimental|Diode laser 635 nm|
88837500|NCT02976506|Experimental|Unsupervised exercise program|To verify the interference of an unsupervised exercise program on blood pressure, physical fitness, quality of life and safety in elderly hypertensive patients. Participants were divided into the study group or control group
88837501|NCT02976506|Experimental|Physical fitness and quality of life|To verify the interference of a walking program on physical fitness and quality of life.
88837502|NCT02976662|Experimental|Artificial shrinkage|Elimination of blastocoelic fluid by creating a large hole in the zona pellucida at the cellular junction of the trophectoderm cells located far away from the inner cell mass with a laser pulse before vitrification.
88837503|NCT02976662|No Intervention|Without Artificial shrinkage|Vitrify expanded blastocysts.
88837504|NCT03657407|Active Comparator|B&O|29 women randomized to Belladonna & Opium suppository
88837505|NCT03657407|Sham Comparator|Placebo|27 women randomized to Glycerin suppository
88837506|NCT04243772||Lithiasic patients|Lithiasic patients of the CHU Brugmann Hospital
88837507|NCT01639560|Active Comparator|Varenicline|1 mg of varenicline twice per day for 12 weeks.
88837508|NCT01639560|Placebo Comparator|placebo|1 placebo tablet twice a day for 12 weeks
88837509|NCT04243616|Experimental|Drug Treatment|Cemiplimab, Paclitaxel, Carboplatin (not mandatory), Doxorubicin, Cyclophosphamide
88837510|NCT04209335|Other|healthy working age population|isometric core muscle endurance tests (McGill V-sit, Biering-Sorensen and sideplank)
88837511|NCT00361556|Active Comparator|1|The Back Book
88837512|NCT00361556|Active Comparator|2|The Back Guide
88837513|NCT00361556|Active Comparator|3|General health book
88837514|NCT04205669|Active Comparator|Individual Treatment|
88837515|NCT04205669|Active Comparator|Household Treatment|
88837516|NCT01601652|Experimental|Omeagven|
88837517|NCT03516227|Experimental|HRVBF|Heart rate variability biofeedback
88837518|NCT03516227|No Intervention|Control|Usual Care
88837519|NCT03520283|Experimental|Supportive Care (MAP)|Participants complete MAP in-clinic over 60-90 minutes.
89001631|NCT00182702|Experimental|Treatment|Patients receive ixabepilone IV over 3 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
88837520|NCT05107440|Experimental|BREATHE|This is an eight-week intervention involving two sessions per week, hosted virtually on Zoom. The main session is scheduled to last 60 min and the session hosts remain online for an additional 15 minutes to answer individual questions on the management of symptoms and activities that have not been addressed during the main session. The content was developed based on clinical experience, best available evidence for the management of specific symptoms (chronic fatigue, post-exertional malaise, breathing discomfort) in other conditions, including post-viral syndromes, and the current understanding and recommendations for rehabilitation of people living with long COVID. Long COVID can be isolating, and challenges often interfere with everyday lifestyle and socialization. The investigators have incorporated breakout rooms (where the group is divided into two smaller groups based on current activity limitations) to include elements of peer support.
88837521|NCT04186481||Minitac Ti 2.0 suture anchor|Subjects who have undergone extremities repair using the Minitac Ti 2.0 Suture anchor
88837522|NCT03952130|Experimental|LY900014|Participants received 100 units per milliliter (U/mL) LY900014 subcutaneously (SC) 0-2 minutes before each meal with either basal insulin glargine or insulin degludec given SC once daily.
88837523|NCT03952130|Active Comparator|Insulin Lispro (Humalog)|Participants received 100 U/mL insulin lispro SC 0-2 minutes before each meal with either basal insulin glargine or insulin degludec given SC once daily.
88837524|NCT03661541|Experimental|Group A, 6 or more outbreaks per 12 months|"Subjects will be recruited in three groups, all of whom are infected with HSV-1, as shown by having IgG against HSV-1:~Group A: 12 subjects with 6 or more herpes labialis outbreaks in the past 12 months.~Subjects in group A will receive 2% Squaric Acid Dibutyl Ester (SADBE) dose on the arm after their initial blood samples are obtained. Group A subjects will have blood collected and tests repeated 2 and 8 weeks later.~Subjects in Groups B and C will be matched to the subjects in Group A so that demographic characteristics (i.e., gender distribution, age and weight) are within broadly similar ranges."
88837525|NCT03661541|No Intervention|Group B, 1 or 2 outbreaks per 12 months|"Subjects will be recruited in three groups, all of whom are infected with HSV-1, as shown by having IgG against HSV-1:~Group B: 12 subjects with 1 to 2 outbreaks in the past 12 months. Subjects in Groups B and C will be matched to the subjects in Group A so that demographic characteristics (i.e., gender distribution, age and weight) are within broadly similar ranges. Invite these back for a further blood draw on Day 0."
88837526|NCT03661541|No Intervention|Group C, zero outbreaks per 12 months|"Subjects will be recruited in three groups, all of whom are infected with HSV-1, as shown by having IgG against HSV-1:~Group C: 12 subjects with zero outbreaks in the past 12 months. Subjects in Groups B and C will be matched to the subjects in Group A so that demographic characteristics (i.e., gender distribution, age and weight) are within broadly similar ranges. Invite these back for a further blood draw on Day 0."
88837527|NCT03661697|Experimental|Lytera Arm|4 week washout period with skin care regimen including Lytera 2.0 followed by 2 laser treatments.
88837528|NCT03661697|Active Comparator|Laser only arm|4 week washout period with a basic skin care regimen, no Lytera 2.0, followed by 2 laser treatments.
88837529|NCT02975648|Active Comparator|Usual Care|At discharge, paticipants received guidance from health professionals. The paticipants had a medical return five to seven months after the percutaneous coronary intervention.
88837530|NCT02975648|Experimental|Educational model + follow up|The paticipants received the hospital's instructions at discharge and participated in the educational program (booklets with telephone follow-up). The paticipants had a medical return five to seven months after discharge
88837531|NCT05575362|Experimental|Epley Manuver group|Group A is Experimental group will receive Epley's maneuver and Cawthorne Cooksey exercise for two weeks.
88837532|NCT05575362|Active Comparator|half somersault group|Group B is Control group will receive Half somersault maneuver and Cawthorne Cooksey exercise for two weeks.
88837533|NCT04735133|Experimental|intervention grpup|pNPWT device was placed in the pNPWT group for seven days. The incision area was evaluated during the first seven days, and on the 15th, 21st, and 30th days postoperatively for the presence of hematoma, seroma, wound dehiscence/evisceration, and SSI.
88837534|NCT04735133|No Intervention|control group|"The wound of the control group was covered with a sterile gauze dressing. After the wound was left closed for 48 hours in the clinical routine, the surgical site was left open, supporting healing. Therefore, the dressing of the control group was removed after 48 hours, and the wound was left open.~The incision area was evaluated during the first seven days, and on the 15th, 21st, and 30th days postoperatively for the presence of hematoma, seroma, wound dehiscence/evisceration, and SSI."
88837535|NCT03925532|Experimental|Supportive Care (denosumab)|Patients receive 2 doses of denosumab SC between days 70-130 and days 250-310 after allogeneic hematopoietic stem cell transplant in the absence of disease progression or unacceptable toxicity.
88837536|NCT04851912||General|Participants with or without psychiatric disorders
88837537|NCT03922490|Experimental|Knee Arthroscopy + Adipose Derived Stem Cells (ADSC)|Experimental Group: will undergo diagnostic knee arthroscopy with injection of adipose derived stem cells. Will also carry out all procedures associated with study (Physical Exam, Magnetic Resonance Imaging (MRIs), X-rays, Questionnaires).
88837538|NCT03922490|Other|Observation Cohort: Knee Arthroscopy|Observational Group: will undergo diagnostic knee arthroscopy (No injection of adipose derived stem cells). Will also carry out all procedures associated with study (Physical Exam, MRIs, X-rays, Questionnaires).
88837539|NCT04242680|Experimental|Brainstim DLPFC|tRNS over bilateral DLPFC + cognitive training
88837540|NCT04242680|Experimental|Brainstim PPC|tRNS over bilateral PPC + cognitive training
89366093|NCT01338597|Experimental|limited dissection|the dissection is reduced by creating a long tunnel from the trocar site and the dissection area confined in the upper chest wall and in the neck.
89366094|NCT01336179|Experimental|Miswak, dental plaque and gingivitis|
89366095|NCT01336179|Active Comparator|Toothbrush, dental plaque and gingivitis|
89366096|NCT01342185|Experimental|Medical ozone therapy with tianyi|
89366097|NCT01342185|Active Comparator|medical ozone therapy with humares|
89366098|NCT01342185|Placebo Comparator|Diammonium glycyrrhizinate Capsules|
89366099|NCT02714218|Experimental|Nivolumab 3 mg/kg IV + Ipilimumab 1 mg/kg IV|Specified dose on specified days
89366100|NCT02714218|Experimental|Ipilimumab 3 mg/kg IV + Nivolumab 1 mg/kg IV|Specified dose on specified days
89366101|NCT02714218|Experimental|Nivolumab 6 mg/kg IV + Ipilimumab 1 mg/kg|Specified dose on specified days
89366102|NCT01342263|No Intervention|Usual Care|Does not get to participate in the interactive chronic disease website.
89366103|NCT01342263|Experimental|iCDM|The iCDM will support patient self-management through collaborative planning and goal setting, education and skill development, support for behaviour change, and regular patient monitoring with follow-up. For each chronic condition, we have outlined sample patient signs and symptoms to be monitored, frequency of patient provider contact and frequency of patient prompt questions on their condition. The main premise of the iCDM is that only those patients who generate 'alerts' will be contacted by the iCDM nurse allowing for the potential to manage more patients than through traditional means of required patient follow-up regardless of patient condition . Across these five diseases are the following cross-cutting features: nutrition therapy, exercise therapy, psychological support, medication adherence and smoking cessation.
89366104|NCT05185869|Experimental|AG+SHR6390|Subjects will receive SHR6390 plus nab-paclitaxel and gemcitabine
88837541|NCT04242680|Sham Comparator|Brainstim Sham|Sham tRNS (bilateral DLPFC/bilateral PPC) + cognitive training
88837542|NCT04680260|Active Comparator|A: Standard of care|Standard decision making regarding adjuvant chemotherapy with fluoropyrimidine and oxaliplatin as per institutional standards.
88837543|NCT04680260|Experimental|B: ctDNA guided therapy approach|Post ablation ctDNA results will be used for treatment decision.
88837544|NCT04211636||Complete SCI, AIS A|Patients with complete spinal cord injury (AIS A)
88837545|NCT04211636||Incomplete SCI, AIS B, C, D|Patients with incomplete spinal cord injury (AIS B, C, D)
88837546|NCT04211636||Vertebral injuries without SCI|Patients with vertebral injuries without spinal cord injury (control)
88837547|NCT01640964|Experimental|Part A: Terlipressin acetate|Patients received terlipressin acetate 2 mg intravenous (IV) bolus injection.
88837548|NCT01640964|Experimental|Part A: Serelaxin (RLX030)|Randomized patients received an intravenous serelaxin infusion at two different infusion rates: 80 μg/kg/day for 60 min followed by 30 μg/kg/day for at least 60 min.; duration of infusion depends on time required for completion of magnetic resonance angiography (MRA) data acquisition
88837549|NCT01640964|Experimental|Part B Serelaxin (RLX030)|The patients enrolled in this part of the study received an intravenous (iv) serelaxin infusion at two different infusion rates: 80 μg/kg/day for 60 min followed by 30 μg/kg/day for at least 60 min; duration of infusion depends on time required for completion of Portal pressure gradient (PPG) data acquisition.
88837550|NCT04343066|Experimental|External hex implant|External hexagone implant connection
88837551|NCT04343066|Experimental|Internal hex implant|Internal implant connection
88837552|NCT03663101|Experimental|Pre-Randomization, Run-In period (part A)|Crossover run-in part A - Subjects will be injected (Test 1) with either saline or local anaesthetic (lidocaine). One week later, they will be crossed over, injected with the other agent (Test 2).
88837553|NCT03663101|Experimental|Dysport dose 1 (part B)|Dysport dose 1 as a single-dose, intradermal injection.
88837554|NCT03663101|Experimental|Dysport dose 2 (part B)|Dysport dose 2 as a single-dose, intradermal injection.
89366105|NCT03154047|Experimental|Open label|Open Label Study Drug NEOD001
88837555|NCT03663101|Experimental|Dysport dose 3 (part B)|Dysport dose 3 as a single-dose, intradermal injection.
88837556|NCT03663101|Placebo Comparator|Placebo (saline solution) (part B)|Placebo single-dose, intradermal injection.
88837557|NCT05430048|Active Comparator|Desmopressin group (Group D)|patients will received single puff (10 μg) of nasal desmopressin in the nasal cavity at the side of surgery 30 min preoperative.
88837558|NCT05430048|Active Comparator|Bisoprolol group (group B)|patients will receive Oral bisoprolol 2.5 mg (Concor 2.5 mg; Merck/Amoun) 90 min preoperative.
89366106|NCT02457676|Experimental|Alert Program for Self-Regulation|Participants with FASD who received the Alert Program for Self-Regulation therapy between the two testing periods.
88837559|NCT02975570|Experimental|DAZZLE-24 wks|Delamanid, Linezolid, Levofloxacin, Pyrazinamide (DAZZLE) treatment regimen- delamanid 100 mg PO BID, linezolid 600 mg PO QD, levofloxacin 1000 mg PO QD, and pyrazinamide 20-30 mg/Kg PO QD for 24 weeks, with linezolid dose reduction to 300 mg daily after 16 weeks (these doses are the usual doses for treatment of TB for all 4 study agents).
88837560|NCT02975570|Experimental|DAZZLE-32 wks|Delamanid, Linezolid, Levofloxacin, Pyrazinamide (DAZZLE) delamanid 100 mg PO BID, linezolid 600 mg PO QD, levofloxacin 1000 mg PO QD, and pyrazinamide 20-30 mg/Kg PO QD for 32 weeks, with linezolid dose reduction to 300 mg daily after 16 weeks (these doses are the usual doses for treatment of TB for all 4 study agents).
88837561|NCT02975570|Experimental|DAZZLE-40 wks|Delamanid, Linezolid, Levofloxacin, Pyrazinamide (DAZZLE) treatment regimen: delamanid 100 mg PO BID, linezolid 600 mg PO QD, levofloxacin 1000 mg PO QD, and pyrazinamide 20-30 mg/Kg PO QD for 40 weeks, with linezolid dose reduction to 300 mg daily after 16 weeks (these doses are the usual doses for treatment of TB for all 4 study agents).
88837562|NCT02975570|Experimental|DAZZLE-48 wks|Delamanid, Linezolid, Levofloxacin, Pyrazinamide (DAZZLE) treatment regimen- delamanid 100 mg PO BID, linezolid 600 mg PO QD, levofloxacin 1000 mg PO QD, and pyrazinamide 20-30 mg/Kg PO QD for 48 weeks, with linezolid dose reduction to 300 mg daily after 16 weeks (these doses are the usual doses for treatment of TB for all 4 study agents).
89001632|NCT00588796||Healthy Volunteers|Healthy Volunteers
89001633|NCT00588796||Burn patients|Patients who have sustained burn injury greater than or equal to 20% of total body surface area
89001634|NCT00588796||Trauma patients|Patients who have undergone trauma
89366107|NCT02457676|No Intervention|FASD Alert Waitlist|Participants with FASD who did not receive therapy between the two testing periods but were provided intervention on study completion.
88837563|NCT02975570|Experimental|DAZZLE-56 wks|Delamanid, Linezolid, Levofloxacin, Pyrazinamide (DAZZLE) treatment regimen- delamanid 100 mg PO BID, linezolid 600 mg PO QD, levofloxacin 1000 mg PO QD, and pyrazinamide 20-30 mg/Kg PO QD for 56 weeks, with linezolid dose reduction to 300 mg daily after 16 weeks (these doses are the usual doses for treatment of TB for all 4 study agents).
88837564|NCT02975570|Active Comparator|WHO MDR-TB regimen- 9 mos or 20-24 mos|MDR-TB treatment with 9-month or 20-24 month WHO approved regimen. The WHO guidelines recommend the following 5-agent treatment regimen for MDR-TB: pyrazinamide; a fluoroquinolone; a parenteral agent (typically amikacin or kanamycin); ethionamide (or prothionamide); and either cycloserine or para-aminosalicylic acid, with preference for cycloserine.
88837565|NCT05230602|Experimental|Study Group|The participants will fill the study scales and will be instructed to eat the tzabar fruit twice a day for two weeks
88837566|NCT05230602|No Intervention|Control Group|The participants will fill the study scales and will be instructed not to change their diet for two weeks
88837567|NCT05428644|Active Comparator|reflexology hand massage group|In addition to the standard nursing care of the hospital, individuals in the reflexology hand massage will be given a 10-minute massage for both hands, a total of 20 minutes, after the extubation procedure.
88837568|NCT05428644|Placebo Comparator|placebo hand massage group|In addition to the standard nursing care of the hospital, individuals in the placebo hand massage group will be given a 10-minute massage for both hands, a total of 20 minutes, after the extubation procedure.
88837569|NCT05220384|Other|Personalized In-person therapy|
88837570|NCT05220384|Other|Generalized, Video-based therapy|
88837571|NCT03907748|Experimental|Music Intervention|The music intervention will be provided to participant dyads (people with dementia and their cohabiting family caregivers) allocated to the first intervention. Caregivers will be trained to use the music intervention in three 2-hour training sessions with an intervention trainer (a music therapist). Training will take place at the dyad's home. The caregiver will then be asked to deliver the music intervention to the person with dementia at least 5x per week for 30 minutes.
88837572|NCT03907748|Active Comparator|Reading Intervention|The reading intervention will be provided to participant dyads (people with dementia and their cohabiting caregivers) allocated to the second intervention. Caregivers will be trained to use the reading intervention in three 2-hour training sessions with an intervention trainer. Training will take place at the dyad's home. The caregiver will then be asked to deliver the reading intervention to the person with dementia at least 5x per week for 30 minutes.
88837573|NCT03907748|No Intervention|Standard Care|Participant dyads (people with dementia and their cohabiting caregivers) allocated to the standard care group will not receive any training or be asked to deliver an intervention.
88837574|NCT05369520|Experimental|Group 1 - Thoracic stimulation|Participants will receive 8 weeks TCSCS at the mid/low thoracic spinal cord levels.
88837575|NCT05369520|Experimental|Group 2- Lumbosacral stimulation|Participants will receive 8 weeks TCSCS at the lumbosacral spinal cord levels.
88837576|NCT03524339|Placebo Comparator|Placebo|
88837577|NCT03524339|Experimental|Tamsulosin|
88837578|NCT03895112|Experimental|AVID200|intravenous in dose cohorts of 70mg/m2 or 180 mg/m2
88837579|NCT05440370|Experimental|MegaCarti® application after microfracture|The experimental group is applied with MegaCarti® after microfracture. Afterwards, they visit at 6 weeks, 12 weeks, 24 weeks, and 48 weeks to conduct examinations and assess Questionnaires. Long-term follow-up Study is performed to subject that completes 48-week visit, at every 6 months for 5 years.
88837580|NCT05440370|Active Comparator|Microfracture only|The control group undergoes microfracture and they visit at 6 weeks, 12 weeks, 24 weeks, and 48 weeks after surgery to conduct examinations and assess Questionnaires.
88837581|NCT05196516||Cases|Individuals at age 18 to 65 with a SARS-CoV-2 infection proven by a polymerase chain reaction (PCR) test at least 12 weeks prior to inclusion and who have been referred to the clinic of post-COVID conditions.
88837582|NCT05196516||Controls|Healthy volunteers at age 18 to 65 with a SARS-CoV-2 infection proven by a PCR test at least 12 weeks prior to inclusion.
88837583|NCT04201106|No Intervention|Control|In the control group, the participants will not be taking any placebos or undergoing any other study-related treatments.
88837584|NCT04201106|Experimental|Open Label Placebo Group with Rationale|
88837585|NCT04201106|Active Comparator|Open Label Placebo Group without Rationale|
88837586|NCT04174313||VILI VORTEX and No VILI VORTEX|Measurement of pulmonary pressures and volumes in the same patient
88837587|NCT03664193|Other|Single Arm|Patients will receive 35 Gy in 5 fractions. Also, patients will receive 0.5-2 Gy per fx for a total dose of 37.5, 40, 42.5, or 45 Gy. Patients will also have an option to have a rectal balloon or a rectal spacer prior to receiving radiation therapy.
89366108|NCT02457676|No Intervention|Typically Developing Control|Normally developing controls not exposed to alcohol in utero who were not treated between the two testing periods.
89366109|NCT01338675|Experimental|Busulfan|First dose: busulfan (120 mg/m2 ivs once daily) (if age<1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study
89366110|NCT03852862|Experimental|Serratus plane block with paravertebral block|Association of Serratus plane block and paravertebral block for anesthesia
88837588|NCT04668248|Experimental|Simulation intervention|Providers assigned to the intervention arm will participate in a short simulation training at the beginning of their 2-week block (planned for their second day). The training will take place at the Neil and Elise Wallace STRATUS Center for Medical Simulation at Brigham and Women's Hospital and will follow all of their recommended and hospital-recommended practices on social distancing, including the learning limits.
88837589|NCT04668248|Active Comparator|Online education intervention|Providers assigned to the control arm will receive online educational training about other poorly-prescribed medications, including albumin, transfusion, and blood product repletion guidelines.
88837590|NCT03526055|Active Comparator|<500 µS Pulse Width|Intervention includes spinal cord stimulation will be programmed to <500 µS pulse width and patient will undergo an Algovita Spinal Cord Stimulation System trial procedures. Following the trial procedure, the subject's EPG will be set to the appropriate pulse width, based on the arm assigned, and then programmed to achieve optimal pain relief.
88837591|NCT03526055|Experimental|>1000 µS Pulse Width|Intervention includes spinal cord stimulation will be programmed to >1000 µS pulse width and patient will undergo an Algovita Spinal Cord Stimulation System trial procedures. Following the trial procedure, the subject's EPG will be set to the appropriate pulse width, based on the arm assigned, and then programmed to achieve optimal pain relief.
88837592|NCT03871790||Participants with colorectal cancer|Participants with colorectal cancer ongoing surgery older than 18 years old.
88837593|NCT03871790||Participants with pancreatic cancer|Participants with pancreatic cancer ongoing surgery older than 18 years old.
88837594|NCT05380050|Experimental|Inpatient GMT plus Attention Training|Goal Management Training is a group metacognitive intervention to improve ability to complete complex task more effectively. 2-hour session are conducted in-person weekly over 10-weeks. A second weekly session includes Attention training which is conducted one-on-one with the therapist in the clinic. Participant completed 5-6 hours of homework between sessions.
88837595|NCT05380050|Experimental|Telehealth GMT plus Attention Training|Goal Management Training is a group metacognitive intervention to improve ability to complete complex task more effectively. 2-hour session are conducted over the VA VideoConnect weekly over 10-weeks. A second weekly session includes Attention training which is conducted one-on-one with the therapist via VA VideoConnect. Participant completed 5-6 hours of homework between sessions
88837596|NCT05380050|Placebo Comparator|Brain Health Workshop|Brain Health Workshop includes educational information about the brain to control for GMT and National Geographic Movies is used as a control to equate time with therapist in Attention Training. Each session occurs weekly for 2-hours over 10-weeks.
89001635|NCT00588835|Experimental|A|Aprepitant 125mg oral on day 1 and 80mg on day 2 and 3 during CE treatment.
89366111|NCT03852862|Active Comparator|paravertebral block alone|Paravertebral block for anesthesia
89366112|NCT01336257|Experimental|Electronic Reminder|alert from SEBASTIAN decision support system
89366113|NCT01336257|No Intervention|control|
89366114|NCT03107650||High risk patients|Patients with high risk of suboptimal mesorectum quality and/or positive circumferential margin after the application of the preoperative prediction model developed
89366115|NCT03107650||Low risk patients|Patients with low risk of suboptimal mesorectum quality and/or positive circumferential margin after the application of the preoperative prediction model developed
89366116|NCT05185791||Pre-ERAS® implementation phase|"Current clinical practice~Current perioperative management~All consecutive patients included for CRS+-HIPEC treatment~Period of inclusion : 3 months (01.10.2021 - 31.12.2021)~Survey of intended changes in clinical practice will be sent to each leader center~No specific intervention. Only descriptive recordings of pre-intra-post-operative clinical endpoints (ERAS® core items) and demographic parameters.~Clinical and surgical outcomes will be recorded until 30 postoperative days (POD). Functional recovery parameters will be recorded for the first 5 POD"
89001636|NCT00588835|Active Comparator|B|CE cycle with standard anti-emetic regimen.
89366117|NCT05185791||Post-ERAS® implementation phase|"After implementation 2 months of delay before starting the recordings~Clinical practice and perioperative management with new practice according guidelines and local commitment for the new change~All consecutive patients included for CRS±HIPEC treatment~Period of inclusion : 3 months (01.03.2022 - 31.05.2022)~Max 2 months of delay allowed between the two phases~Intervention will take place during an implementation period of 2 months. This period will let the centers to set the newly implemented clinical practices.~After that, the remaining 3 months of the study will consist in descriptive recordings of pre-intra and post-operative clinical endpoints and demographic parameters (ERAS® core items).~Clinical and surgical outcomes will be recorded until 30 postoperative days (POD). Functional recovery parameters will be recorded for the first 5 POD."
89366118|NCT02457286|Experimental|Metformin|Metformin is being compared to exercise and diet modifications. The study will be incorporating the use of a Fibroscan device (Echosens) at the initial visit and upon completion of the study, which works by measuring shear wave velocity. In this technique, a 50-MHz wave is passed into the liver from a small transducer on the end of an ultrasound probe
89366119|NCT02457286|Experimental|Lifestyle modification|The researchers are interested in learning if the addition of metformin to lifestyle modifications is more helpful in treating participants condition or disorder. The study will be incorporating the use of a Fibroscan device (Echosens) at the initial visit and upon completion of the study, which works by measuring shear wave velocity. In this technique, a 50-MHz wave is passed into the liver from a small transducer on the end of an ultrasound probe
89366120|NCT01342497|Experimental|BBR-012|
89366121|NCT01342497|Placebo Comparator|Placebo|
89366122|NCT03264976||Group 1|Patients without DR. Information and samples of all trial participants at enrollment will be collected at the inception of the study, including: basic information, basic medical records, hematological examination, ophthalmic examination. These information and examinations will be collected at regular intervals: every 12 months until 5 years.
89366123|NCT03264976||Group 2|"Patients with mild non-proliferative DR (NPDR). Diagnosed according to Diabetic retinopathy PPP - Updated 2016.~Information and samples of all trial participants at enrollment will be collected at the inception of the study, including: basic information, basic medical records, hematological examination, ophthalmic examination. These information and examinations will be collected at regular intervals: every 12 months until 5 years."
89366124|NCT03264976||Group 3|"Patients with moderate NPDR. Diagnosed according to Diabetic retinopathy PPP - Updated 2016.~Information and samples of all trial participants at enrollment will be collected at the inception of the study, including: basic information, basic medical records, hematological examination, ophthalmic examination.These information and examinations will be collected at regular intervals: every 12 months until 5 years."
89366125|NCT03264976||Group 4|"Patients with moderate NPDR. Diagnosed according to Diabetic retinopathy PPP - Updated 2016.~Information and samples of all trial participants at enrollment will be collected at the inception of the study, including: basic information, basic medical records, hematological examination, ophthalmic examination. These information and examinations will be collected at regular intervals: every 12 months until 5 years."
89366126|NCT03264976||Group 5|"Proliferative DR (PDR). Diagnosed according to Diabetic retinopathy PPP - Updated 2016.~Information and samples of all trial participants at enrollment will be collected at the inception of the study, including: basic information, basic medical records, hematological examination, ophthalmic examination.These information and examinations will be collected at regular intervals: every 12 months until 5 years."
89366127|NCT03282370|Experimental|JECEVAX|JECEVAX - VABIOTECH Vietnam Liquid form Composition: 0.5 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 28-34 days
89366128|NCT03282370|Active Comparator|JEVAX|JEVAX - VABIOTECH Vietnam Liquid form Composition: 1,0 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 28-34 days
88837597|NCT03667547|Experimental|Raltegravir|Participants will receive a single oral dose of raltegravir 1200 mg (600 mg tablet X 2) in a fasted state on Day 0 and will be followed up to 2 weeks
88837598|NCT04735055||Artificial intelligence (AI) machine learning group|"90% machine learning part has also been divided into 2 parts as 70% for AI learning and 30% for testing the learning.~70% of the acute pancreatitis patients (approximately 840 pts) will form the model training group of the study. 30% of the acute pancreatitis patients (approximately 360 pts) will form the testing group of the study.~Since cross-validation will also be applied to the model here, the data will also change within itself, and also the distribution will be optimized to increase the predictive power."
88837599|NCT04735055||Validation group|"10% of the acute pancreatitis patients (approximately 134) will form the validation group of the study.~Since cross-validation will also be applied to the model here, the data will also change within itself, and also the distribution will be optimized to increase the predictive power."
89366129|NCT01342575|Experimental|Intra-operative maneuver group|
89366130|NCT01338831|Experimental|Breast & Prostate Cancer Group|Dose Escalation
89366131|NCT01338831|Experimental|Breast Cancer Group|Dose Expansion
88837600|NCT00361088|Experimental|Phase I|
88837601|NCT00361088|Experimental|Phase II|
89366132|NCT01338831|Experimental|Prostate Cancer Group|Dose Expansion
89366133|NCT01338831|Experimental|Uterine Leiomyoma Group|Dose Expansion
89366134|NCT03282214|Experimental|Self-management energy conservation|Thai women with breast cancer randomized to the group will receive four sessions approximately every three weeks with the PI. The women will be instructed on how to do a self-management energy conservation program.
89366135|NCT03282214|No Intervention|Control|The participants will be given two pamphlets (general issues about breast cancer and self-care activities for patients receiving chemotherapy) provided by the health care team at the study sites. The participants in the control group will be encouraged to maintain their current daily activities during the 12-week period The participants will wear a pedometer to record the number of steps which is one of the activity outcomes.
89366136|NCT05185635|Experimental|Healthy Spanish-speakers|
89366137|NCT01336335|Experimental|CPAP|OSA treatment with CPAP
89366138|NCT01336335|No Intervention|control|no intervention
89366139|NCT03590002|Experimental|Electronic ICU Medical Transfer Tool|ICUs allocated to the experimental arm will have access to the electronic Medical Transfer of Care Documentation Tool within the clinical information system (CIS) in order to prepare ICU transfer of care documents for the receiving medical care team.
89366140|NCT03590002|No Intervention|Dictated ICU Medical Transfer|Usual Care, ICUs in the control group will only have access to the dictation documentation system as the standard method to prepare ICU medical transfer documents. New ICU medical staff responsible for preparing transfer documents will receive the usual training on the dictation system.
89366141|NCT01338909|Experimental|Prasugrel|Prasugrel 60mg immediate loading dose (Day 0)followed by 10mg/day starting from Day 1 until Day 5
88837602|NCT02975726|Experimental|Peritoneal Dialysis Catheter Insertion|Catheters will be inserted at the bedside in a special procedure room.Argyle PD catheter kits will be used:2 cuffed curled catheters at 57cm or 62cm lengths. At time of PD catheter insertion,most patients will be drained of 5-10L of ascites or more to decrease the chance of catheter leaks.The volume removed will be at sole discretion of physician doing the procedure.Patients will be administered 25% Human Serum Albumin injection: 100cc after the 5-10L drainage,and 200cc if 10-15L is removed.Patients will undergo an initial drain and training with a specialized nurse.Patients in this arm will be instructed to drain a maximum of 2L per day after the initial drain.Monthly bloodwork will be performed.
89001637|NCT00589147|Active Comparator|1|One study group will consist of patients treated with the modular cemented tibia.
88837603|NCT02975726|Active Comparator|Large Volume Paracentesis|Patients in this arm of the study will continue their usual practice of LVP as required. They will continue to undergo their LVP procedures through their regular means.Monthly bloodwork will be performed.
89001638|NCT00589147|Active Comparator|2|Study arm will consist of patients that are treated with non-modular cemented tibia.
89366142|NCT01338909|Active Comparator|Clopidogrel|Clopidogrel 150mg/day starting from Day 1 until Day 5
89366143|NCT01342653|Experimental|NIPS plus HIPEC plus adjuvant chemotherapy|
88837604|NCT04160975|Experimental|Black R/Race C/Doctor/Standard Script|Video which contains a racially concordant actor playing a doctor and reading a standard script. The receiver of the message will be Black.
88837605|NCT04160975|Experimental|Black R/Race C/Layperson/Standard Script|Video which contains a racially concordant actor playing a layperson and reading a standard script. The receiver of the message will be Black.
88837606|NCT04160975|Experimental|Black R/Race D/Doctor/Standard Script|Video which contains a racially discordant actor playing a doctor and reading a standard script. The receiver of the message will be Black.
88837607|NCT04160975|Experimental|Black R/Race D/Doctor/Acknowledgement Script|Video which contains a racially discordant actor playing a doctor and reading an acknowledgement script. The receiver of the message will be Black.
88837608|NCT04160975|Experimental|White R/Race C/Doctor/Standard Script|Video which contains a racially concordant actor playing a doctor and reading a standard script. The receiver of the message will be White.
88837609|NCT04160975|Experimental|White R/Race D/Doctor/Standard Script|Video which contains a racially discordant actor playing a doctor and reading a standard script. The receiver of the message will be White.
88837610|NCT04172402|Experimental|NGS|"Eligible patients will receive Nivolumab 240mg on day 1, gemcitabine 800 mg/m2/day on day 1 and S-1 orally 80-120 mg/day (depending on patient's body surface area (BSA)) on day 1 to 10 in a 2-week cycle.~BSA < 1.25 m2: 80 mg/day~1.25 m2 ≤ BSA < 1.5 m2: 100 mg/day~BSA ≥ 1.5 m2: 120 mg/day The treatment will be administered until disease progression, intolerable toxicity, or consent withdrawal during any time of the study."
88837611|NCT04153409|Experimental|Active|Subjects will be given two 30 mg capsules of the investigational medicinal product (LAT8881), and instructed to take both capsules within the first hour of the onset of a migraine of moderate to severe intensity.
89366144|NCT02458456|Sham Comparator|IHG 5% Hypertensive|Participants who are either un-medicated pre-hypertensive or medicated for blood pressure management conducting isometric resistance training using a hand dynamometer at 5% of their maximum voluntary contraction. Participants with perform 4 x 2 minutes isometric handgrip exercises 3 times per week under supervision for 8 weeks.
88837612|NCT04153409|Placebo Comparator|Placebo|Subjects will be given two capsules of placebo, and instructed to take both capsules within the first hour of the onset of a migraine of moderate to severe intensity.
88837613|NCT04165616||Individuals with stroke|
88837614|NCT01638390|Other|Treatment of Myopia|The reduction or elimination of myopia from ≥ -1.00 D to ≤ -8.00 D with ≤ -0.50 D cylinder and MRSE ≤ -8.25 D.
88837615|NCT04662242|Experimental|low serum selenium with selenium supplement|Patients having low serum selenium with selenium supplement given
89366145|NCT02458456|Experimental|IHG 30% Hypertensive|Participants who are either un-medicated pre-hypertensive or medicated for blood pressure management conducting isometric resistance training using a hand dynamometer at 30% of their maximum voluntary contraction. Participants with perform 4 x 2 minutes isometric handgrip exercises 3 times per week under supervision for 8 weeks.
88837616|NCT04662242|Placebo Comparator|low serum selenium with placebo supplement|Patients having low serum selenium with placebo given
88837617|NCT04662242|Active Comparator|non-low serum selenium with selenium supplement|Patients having normal serum selenium with selenium supplement given
88837618|NCT04662242|Placebo Comparator|non-low serum selenium with placebo supplement|Patients having normal serum selenium with placebo given
88837619|NCT03535571|Experimental|Salmon Protein Hydrolysate (CollaGo®)|Dose: 1 sachet of CollaGo® will be mixed with 100-300 mL of water and consumed daily at breakfast.
88837620|NCT04658966||cases|Women with a history of pre-eclampsia
88837621|NCT04658966||controls|Women with no history of hypertensive disorder during pregnancy
88837622|NCT04332185|Experimental|Vestibulart socket therapy|(VST) included the following steps. a-traumatic tooth extraction, the socket curetted and rinsed with normal saline thoroughly . One-cm long vestibular access incision was made using a 15c blade 3-4 mm apical to the mucogingival junction at the related socket. A subperiosteal tunnel was created connecting the socket orifice and the vestibular access incision using periotomes and micro periosteal elevators A flexible cortical membrane shield that is made of cortical bone of heterologous origin of 0.6 mm thickness was hydrated and then trimmed and introduced from the vestibular access incision reaching 1 mm below the socket orifice through the tunnel then stabilized using a micro screw to the alveolar bone apical to the base of the socket .
88837623|NCT03675581|Experimental|All subjects|
88837624|NCT02975960|Experimental|Stromal vascular fraction injection|Injection of autologous stromal vascular fraction on hand.
88837625|NCT04154540|Experimental|demyelinating hereditary neuropathy|adult patients with demyelinating hereditary neuropathy type CMT 1A.
89001639|NCT00589147|Active Comparator|3|Study arm will consist of patients that are treated with non-modular uncemented tibia.
89178879|NCT02600988|Experimental|Group 2: 1000IU/day of Vitamine D|It is composed by the following 50 patients joining the study. They will take 1000 IU of vitamin D once a day.
89178880|NCT02600988|Experimental|Group 3: 5000IU/day of Vitamine D|It is composed by the last 50 patients joining the study. They will take 5000 IU of vitamin D once a day.
89178881|NCT05499078|Experimental|SULFEX 13081.22|Patients with dry or irritated nose treated with SULFEX 13081.22 nasal spray for 6 days (with at least 1 spray use a day).
89178882|NCT04097574|Active Comparator|NPO-13 0.8%|Low dose
89178883|NCT04097574|Active Comparator|NPO-13 1.6%|High dose
89178884|NCT04097574|Placebo Comparator|NPO-13 0%|Placebo
89366146|NCT02458456|Experimental|IHG 30% Normotensive|Participants who are normotensive conducting isometric resistance training using a hand dynamometer at 30% of their maximum voluntary contraction. Participants with perform 4 x 2 minutes isometric handgrip exercises 3 times per week under supervision for 8 weeks.
89366147|NCT02458456|Sham Comparator|IHG 5% Normotensive|Participants who are normotensive conducting isometric resistance training using a hand dynamometer at 5% of their maximum voluntary contraction. Participants with perform 4 x 2 minutes isometric handgrip exercises 3 times per week under supervision for 8 weeks.
89178885|NCT04099680|Active Comparator|Partial-thickness bed preparation|Partial-thickness bed preparation for free gingival graft procedure.
89178886|NCT04099680|Experimental|Full-thickness bed preparation|Full-thickness bed preparation with bone screw placement for anchoring the sutures.
89178887|NCT00766038|Experimental|1|The GH treatment arm will receive a starting dose of 400 microgramsg/day, with increases (or decreases) in dose by 100-200 micrograms/day each month, monitoring for side effects, until goal IGF-1 (in the upper quartile of the range for age and body weight) is reached up to maximum dose of 1,000 microgramsg/day. Dose adjustments may be modified by the investigators for participants receiving oral estrogens or other circumstances know to influence GH dosing or atypical responses to treatment.
89178888|NCT00766038|Placebo Comparator|2|Doses for participants receiving placebo will also be adjusted monthly to maintain the blinding.
89178889|NCT04100304|Other|patient under going liver resection|
89178890|NCT00765882|Experimental|1|Linaclotide 290 micrograms
89178891|NCT00765882|Experimental|2|Linaclotide 145 micrograms
89178892|NCT00765882|Placebo Comparator|3|Matching placebo
89178893|NCT05297136|Experimental|Pre-op Stenting|Pre-operative pancreatic stent inserted by Endoscopic Retrograde Cholangiography, followed by distal pancreatectomy
88837626|NCT04154540|Experimental|demyelinating inflammatory neuropathy|adult patients with acquired demyelinating inflammatory neuropathy.
88837627|NCT03678311|Other|Sleep Apnea ahi > 5|If Sleep Apnea index is > 5 and diagnosed with Long QT Syndrome
88837628|NCT03821636|Sham Comparator|Standard Roux-en-Y|
88837629|NCT03821636|Active Comparator|Long alimentary limb Roux-en-Y|
88837630|NCT05122026|Experimental|Arm 1: One month of daily isoniazid and rifapentine (4 weeks)|"DTG 50 mg orally BID~DTG 50 mg + 2 NRTI each morning (non-study)~2nd dose: DTG 50 mg each evening (during 1HP)~1HP: INH 300 mg + RPT 600 mg each morning for 4 weeks"
88837631|NCT05122026|Experimental|Arm 2: Three months of once-weekly isoniazid and rifapentine (12 weeks)|"DTG 50 mg orally BID~DTG 50 mg + 2 NRTI each morning (non-study)~2nd dose: DTG 50 mg each evening (during 3HP)~3HP: INH 900 mg + RPT 900 mg each week for 12 weeks"
88837632|NCT04658498|Experimental|Usual Care (UC)|Intermittent spontaneous breathing periods
88837633|NCT04658498|Experimental|UC + High-intensity inspiratory muscle training (HI-IMT)|
88837634|NCT04658498|Experimental|UC + Low-intensity inspiratory muscle training (LI-IMT) (sham IMT)|
89178894|NCT05297136|Active Comparator|Surgery alone|Distal pancreatectomy alone
89178895|NCT00769860|Active Comparator|1|Arimoclomol
89178896|NCT00769860|Placebo Comparator|2|
89178897|NCT02600754|Experimental|IT-PST|IT-PST refers to problem-solving therapy that will be tele-delivered by licensed mental health clinicians co-located in an aging-service agency (Meals on Wheels and More).
89366148|NCT02458456|Experimental|IHG 10% Hypertensive|Participants who are either un-medicated pre-hypertensive or medicated for blood pressure management conducting isometric resistance training using a hand dynamometer at 10% of their maximum voluntary contraction. Participants with perform 4 x 2 minutes isometric handgrip exercises 3 times per week under supervision for 8 weeks.
89366149|NCT02458456|Experimental|IHG 10% Normotensive|Participants who are normotensive conducting isometric resistance training using a hand dynamometer at 10% of their maximum voluntary contraction. Participants with perform 4 x 2 minutes isometric handgrip exercises 3 times per week under supervision for 8 weeks.
89366150|NCT03264820|Experimental|Patients with scleroderma and potential arterial disease|"The patients (33) will undergo a medical examination in order to analyse their medical history, parameters and check inclusion and non-inclusion criterions.~Then will be performed :~Visit 1 :~Biology report * (* Biological evaluation carried out in all healthy subjects and in subjects whose biological check-up dates more than 2 years,+ urinary pregnancy test (if applicable))~Laser measurements at the forearm (with laser speckle)~Laser measurements at the level of each finger~Pain evaluation (EVA)~Measurement of blood pressure and heart rate~Environmental measures and skin temperature~Visit 2 :~Laser measurements at the level of each finger~Pain evaluation (EVA)~Measurement of blood pressure and heart rate~Environmental measures and skin temperature"
89366151|NCT03264820|Experimental|Healthy volunteers|"The healthy volunteers (11) will undergo :~Visit 1 :~Biology report (+ urinary pregnancy test (if applicable))~Laser measurements at the forearm (with laser speckle)~Laser measurements at the level of each finger~Pain evaluation (EVA)~Measurement of blood pressure and heart rate~Environmental measures and skin temperature~Visit 2 :~Laser measurements at the level of each finger~Pain evaluation (EVA)~Measurement of blood pressure and heart rate~Environmental measures and skin temperature"
89366152|NCT03282136|Active Comparator|incretin arm|T2DM with HF treated by CRTd participants will be assigned prospectively to an intervention (incretin therapy plus conventional hypoglycemic drug therapy) according to study protocol to evaluate the effect of the drug on cardiac deaths, all cause deaths, and hospital admission for heart failure.
88837635|NCT04655430|Experimental|3-second SDF application|3-second application time of silver diamine fluoride (38% SDF) in arresting dental caries in the primary teeth of preschool children.
88837636|NCT04655430|Experimental|5-second SDF application|5-second application time of silver diamine fluoride (38% SDF) in arresting dental caries in the primary teeth of preschool children.
88837637|NCT04655430|Experimental|10-second SDF application|10-second application time of silver diamine fluoride (38% SDF) in arresting dental caries in the primary teeth of preschool children.
88837638|NCT04655430|Experimental|15-second SDF application|15-second application time of silver diamine fluoride (38% SDF) in arresting dental caries in the primary teeth of preschool children.
88837639|NCT04655430|Experimental|30-second SDF application|30-second application time of silver diamine fluoride (38% SDF) in arresting dental caries in the primary teeth of preschool children.
88837640|NCT04655430|Experimental|45-second SDF application|45-second application time of silver diamine fluoride (38% SDF) in arresting tooth decay (dental caries) in the primary teeth of preschool children.
88837641|NCT04655430|Experimental|60-second SDF application|60-second application time of silver diamine fluoride (38% SDF) in arresting dental caries in the primary teeth of preschool children.
88837642|NCT04655430|Experimental|120-second SDF application|120-second application time of silver diamine fluoride (38% SDF) in arresting dental caries in the primary teeth of preschool children.
88837643|NCT04655430|Experimental|180-second application time|180-second application time of silver diamine fluoride (38% SDF) in arresting dental caries in the primary teeth of preschool children.
88837644|NCT02958878|Experimental|A|Tamsulosin 0.4mg given the night before surgery and another dose the day of surgery in the morning.
88837645|NCT02958878|Placebo Comparator|B|Placebo medication given the night before surgery and another dose the day of surgery in the morning
89178898|NCT02600754|Experimental|IT-SCM|IT-SCM refers to self-care management support that will be tele-delivered by trained lay advisers (TLAs) co-located in an aging-service agency (Meals on Wheels and More).
88837646|NCT03813524|Experimental|Cardiovalve Transfemoral Mitral Valve|Replacement valve delivered through a transfemoral access and transseptal approach
88837647|NCT03812276||Study Group|Neodent Acqua GM Helix dental implants will be placed. Multiple implants may be placed in a single subject.
88837648|NCT04154384|Experimental|Pilot Study of Pain Management Strategies|Orthopedic trauma patients will work with a Life Care Specialist (LCS) and will receive personalized pain management strategies to avoid potential opioid misuse. Participants will be followed for one year post operation. An official pain management protocol will be developed during the pilot portion of this study.
89366153|NCT03282136|Placebo Comparator|conventional hypoglycemic drug arm|T2DM with HF treated by CRTd participants will be assigned prospectively to placebo comparator (placebo plus conventional hypoglycemic drug therapy) according to study protocol to evaluate the effect of the drug on cardiac deaths, all cause deaths, and hospital admission for heart failure.
88837649|NCT04154384|Experimental|Life Care Specialist (LCS) Intervention|In addition to receiving current standard-of-care for pain management in the aftermath of trauma, participants will have the full communication of opioid risk - via the validated Opioid Risk Tool (ORT) and a detailed substance abuse and mental health screening. As part of the daily LCS intervention, the inpatients will engage in behavioral pain management, opioid education and harm-reduction strategies (naloxone education), while also being screened for eligibility for respective referrals for complex needs, such as mental health and substance use disorders. Upon discharge, each participant will be educated by the LCS on future available modes of contact (telephone, email, video-call, follow up- visits at 2-, 6- and 12-weeks).
89366154|NCT03156621|Experimental|Alirocumab SC Q2W|"Alirocumab SC every 2 weeks (Q2W) from baseline (day 1) through week 10 during the double-blind treatment period~Starting at week 12, and continuing through week 22, participants will receive open-label alirocumab SC Q2W"
89366155|NCT03156621|Experimental|Placebo SC Q2W|"Matching placebo SC Q2W from baseline through week 10 during the double-blind treatment period~Starting at week 12, and continuing through week 22, participants will receive open-label alirocumab SC Q2W"
89366156|NCT03282058|Experimental|Silastic Stent|"At the time of surgery, if the patient is identified in the silastic stent arm, dressing of the septal donor site with silastic stents will be performed after reconstruction has been achieved and the surgeon feels that the surgery proceeded routinely."
89366157|NCT03282058|No Intervention|No Stent|"At the time of surgery, if the patient is identified in the no silastic stent arm, dressing of the septal donor site without the stent will be performed after reconstruction has been achieved and the surgeon feels that the surgery proceeded routinely - this is currently the standard of care."
89366158|NCT03264898||FIT Group|Fecal immunochemical tests will be completed.
89366159|NCT03281980|Experimental|Intervention (UCT+HE+PS)|The participants of this arm will receive UCT and HE along with psychosocial stimulation (PS)
89366160|NCT03281980|Sham Comparator|Government Intervention (UCT+HE)|The participants of this arm will receive only UCT and HE
89366161|NCT03281980|No Intervention|Comparison|
89366162|NCT03156543|Experimental|Group A|This group will have the jumpstart dressing pre-operatively and a standard dressing post operatively.
88837650|NCT04154384|Active Comparator|Standard of Care with Clinical Coordination|Participants will receive the current standard-of-care for pain management in the aftermath of trauma, including a standardized prescription protocol, and hospital-system approved discharge instructions which provide written instruction on how to taper opioid use and links to written/online resources for opioid misuse, overdose prevention, and State-approved disposal options.
88837651|NCT02976116|Experimental|Fruquintinib & Gefitinib|Drug: Fruquintinib and Gefitinib
88837652|NCT01600716|Experimental|OnabotulinumtoxinA|OnabotulinumtoxinA 100 U is administered into the detrusor at Day 1. After a minimum of 12 weeks, patients could request/qualify for a second onabotulinumtoxinA 100 U injection.
88837653|NCT01600716|Other|Placebo (Normal Saline)|Placebo (normal saline) is administered into the detrusor at Day 1. After a minimum of 12 weeks, patients could request/qualify for an onabotulinumtoxinA injection.
89366163|NCT03156543|Experimental|Group B|This group will have the jumpstart dressing pre-operatively and a jumpstart dressing post operatively.
89366164|NCT03264586|Active Comparator|Lidocaine-prilocaine cream|"Women who were assigned randomly to receive EMLA cream had a 5gm dose of cream applied to the intact surface of the perineum and area covered with an occlusive dressing to facilitate pemetration thrug stratum corneum~EMLA cream was applied, 1 hour before the expected time of birth.~With the assistance at birth, the residue of cream was removed to prevent contact with the fetus, because sodium hydroxide, which is a component of the cream, can cause fetal eye irritation.~No additional anesthetic was applied if episiotomy was necessary.~Before commancement of perineal repair any residual cream was wiped off."
89366165|NCT03264586|Active Comparator|mepivacaine infiltration group|"In the mepivacaine group, 10 ml of 1% mepivacaine solution was injected slowly when the fetal head was crowned with frequent aspiration to avoid intravascular injection.~In the mepivacaine group, if an episiotomy was indicated, it was performed after infiltration of perineal tissue with 10 ml of 1% mepivacaine solution.~The suture procedure was delayed 10 minutes after the injection of the aneathetic"
89366166|NCT01342731|Experimental|Tigecycline|Tigecycline 100 mg of tigecycline intravenous infusion for 30 minutes followed by 50 mg every 12 hours for 7 to 14 d
89366167|NCT03271996|Experimental|Primary closure|Excision of sinus and paramedian closure according to modified Karydakis technique
89366168|NCT03271996|Experimental|Fistulectomy|Removal / fistulectomy by scalpels or trephines of primary and drainage orifices and healing of the wound by second intention
89366169|NCT01342809|Experimental|Follow up|Close follow up from written guidelines, supervision provided.
88837654|NCT03680105|Experimental|Part 1; Cohort 1; RJX or Placebo|Participants in Part 1; Cohort 1 will receive a single 0.024 mL/kg dose of RJX or matching placebo on Day 1.
89366170|NCT01342809|No Intervention|Usual Treatment|
89366171|NCT02459860|Experimental|Problem Solving Treatment|Problem Solving Treatment Individual, face-to-face PST sessions over a span of 8 weeks and 3 monthly booster sessions. The PST protocol is highly structured, time-limited, and manual-driven; sessions include PST hand outs and homework as well as social and behavioral activation strategies.
89366172|NCT02459860|Active Comparator|Enhanced Usual Care|Enhanced Usual Care EUC patients will receive psychoeducational materials on depression and depression treatment of older persons. EUC patients will continue to receive the full complement of PACE services (medical, rehabilitation, social) including referrals to specialty mental health services, if indicated.
89366173|NCT01339065|Active Comparator|Ketamine|will be given low sub-anesthetic doses of Ketamine 0.5mg/kg.
89366174|NCT01339065|Placebo Comparator|Placebo|will get placebo treatment
89366175|NCT02460016|Experimental|AK0529|AK0529 pellets
88837655|NCT03680105|Experimental|Part 1; Cohort 2; RJX or Placebo|Participants in Part 1; Cohort 2 will receive a single 0.076 mL/kg dose of RJX or matching placebo on Day 1.
88837656|NCT03680105|Experimental|Part 1; Cohort 3; RJX or Placebo|Participants in Part 1; Cohort 3 will receive a single 0.240 mL/kg dose of RJX or matching placebo on Day 1.
88837657|NCT03680105|Experimental|Part 1; Cohort 4; RJX or Placebo|Participants in Part 1; Cohort 4 will receive a single 0.5 mL/kg dose of RJX or matching placebo on Day 1.
88837658|NCT03680105|Experimental|Part 1; Cohort 5; RJX or Placebo|Participants in Part 1; Cohort 5 will receive a single 0.759 mL/kg dose of RJX or matching placebo on Day 1.
88837659|NCT03680105|Experimental|Part 1; Cohort 6; RJX or Placebo|Participants in Part 1; Cohort 6 will receive a single dose of RJX or matching placebo, to be determined following review of safety and PK data from Cohorts 1 to 5, on Day 1.
88837660|NCT03680105|Experimental|Part 2; Cohort 1; RJX or Placebo|"Participants in Part 2; Cohort 1 will receive a dose of RJX or matching placebo, determined based on the findings of Part 1, every day for 7 days.~The Part 2; Cohort 1 dose will be 1 log down from the maximum tolerated dose determined in Part 1 or at a dose determined to be safe and well tolerated in Part 1 with an acceptable PK profile."
88837661|NCT03680105|Experimental|Part 2; Cohort 2; RJX or Placebo|Participants in Part 2; Cohort 2 will receive an escalated dose of RJX or matching placebo, determined based on the findings of Part 1, every day for 7 days.
88837662|NCT03680105|Experimental|Part 2; Cohort 3; RJX or Placebo|Participants in Part 2; Cohort 3 will receive an escalated dose of RJX or matching placebo, determined based on the findings of Part 1, every day for 7 days.
88837663|NCT04844814|Experimental|Anakinra|Anakinra 100 mg/d+Placebo of Prednisone
88837664|NCT04844814|Active Comparator|Prednisone|Prednisone 30 mg/d+Placebo of Anakinra
88837665|NCT04833270|Experimental|KM non-pharmacological treatment group|Non-pharmacological treatment including Korean medicine will be implemented to the participants twice a week for total 8 weeks. The specific intervention will be determined according to the physician's choice, and information will be recorded in the case report form.
88837666|NCT04833270|Active Comparator|Pharmacological treatment group|Pharmacological treatment will be implemented to the participants twice a week for total 8 weeks. The specific intervention will be determined according to the physician's choice, and information will be recorded in the case report form.
88837667|NCT03535649||Vedolizumab|Participants diagnosed with moderate to severe active UC and having failed tumor necrosis factor alpha (TNF alpha) antagonist therapy and who have initiated vedolizumab intravenous treatment between 17 August 2017 and the date when at least 100 cases are collected from approximately 15 participating sites will be observed from the date of UC diagnosis until the date when participant is enrolled into the study or until the end of treatment or death of participants or lost-to-follow up.
88837668|NCT02975102|Experimental|CBL-101 Eye Drops|The test article, CBL-101 Eye Drops, is a CE-marked medical device containing 0.15% hyaluronic acid. An oxide (Oxyd®) used as mild preservative, rapidly turns into oxygen, water and ions on contact with the eye. The formula is presented in 10 mL bottles.
88837669|NCT02975102|Active Comparator|Vismed® Multi|The comparator product, Vismed® Multi ophthalmic solution (CE marked), contains 0.18% sodium hyaluronate, is unpreserved and presented in 10 mL bottles.
89366176|NCT03281746|Active Comparator|Group I (standard prevention education)|Patients undergo dental examination at baseline and then receive standard prevention education at diagnosis discussing the effects of prolonged neutropenia on oral hygiene, importance of a regular oral hygiene regimen, and the long term clinical outcomes of oncologic patients. Patients also receive fliers with pictograms describing proper brushing, use of mouth wash, and common oral complications during therapy, as well as a bottle and prescription for chlorhexidine gluconate 0.12% rinse.
89366177|NCT03281746|Experimental|Group II (standard and one-on-one education, consultation)|Patients undergo dental examination and receive standard prevention education as in Group I. Patients also receive one-on-one prevention education and counseling with the physician and pediatric dental resident.
89366178|NCT05187507|Other|Children using fluoridated toothpaste|
88837670|NCT05011656|Experimental|1- Seraph-100 plus State of the Art Care|The Seraph 100 Filter is a single use, disposable column packed with ultra-high molecular weight polyethylene beads which have been modified to contain endpoint attached heparin on the surface. Seraph 100 is an extracorporeal broad-spectrum sorbent hemoperfusion device for reduction of pathogens from the bloodstream. It is intended for use with standard, commercially available bloodlines compatible with the pump system used. Female Luer connectors are required to connect to the Seraph 100 blood ports.
88837671|NCT05011656|Active Comparator|2 - State of the Art Care|"State of the Art careis defined as the treatment algorithms outlined in the Surviving Sepsis Campaign for the treatment of septic shock, available at https://www.sccm.org/SurvivingSepsisCampaign/Home"
88837672|NCT03536819|Experimental|Treatment|Participants receive Votiva treatment
89366179|NCT05187507|Other|Children using low- fluoridated toothpaste|
89366180|NCT05187507|Experimental|Children using Theobromine toothpaste (2%).|
89366181|NCT05187507|Experimental|Children using Theobromine toothpaste(4%)|
89366182|NCT01339143|Active Comparator|Pioglitazone|pioglitazone: 15mg, QD, PO, 16 weeks
89366183|NCT01339143|Experimental|vildagliptin|vildagliptin 50mg,BID,PO,16 weeks
89366184|NCT03281434|Active Comparator|Collagen peptide|Supplement will be delivered twice daily (30g per supplement) of hydrolyzed collagen peptides
89366185|NCT03281434|Experimental|Whey protein|Supplement will be delivered twice daily (30g per supplement) of whey protein isolate
89366186|NCT05185245|Experimental|Liver Transplantation|
89366187|NCT03271684|Experimental|intervention group|Will receive one session of up to one-hour per week over a six-week period in self-management in addition to their usual rehabilitation and workbook.
89366188|NCT03271684|Other|control group|Will receive booklet consist of home exercises and education besides the usual care
89366189|NCT05130411|Experimental|DLM - Test product|The dietary supplement is designed to be taken in servings of two gummies per day.
89366190|NCT03264430|Active Comparator|The ketamine group|The ketamine group will receive intrathecal bupivacaine (7.5 mg) in 1.5 ml (Marcaine, Astra Zeneca, France, 0.5%) and ketamine (25mg) in 0.5 ml (Ketam, EIPICO, Egypt, 50 mg/mL),. Total volume is 2 ml will injected
89366191|NCT03264430|Placebo Comparator|The control group|group will receive only intrathecal bupivacaine (7.5 mg) in 1.5 ml plus 0.5ml normal saline to achieve total volume of 2 ml.
89366192|NCT01339221||Cohort A|Children confirmed with G1 and/or P[8] cases from the RotaBel study
88837673|NCT04651868|Experimental|CCK + GLP-2|A 180 mins intravenous infusion with cholecystokinin (0.4 pmol × kg^-1 × min^-1) and a 210 mins intravenous infusion with GLP-2 (10 pmol × kg^-1 × min^-1)
88837674|NCT04651868|Experimental|CCK + placebo|A 180 mins intravenous infusion with cholecystokinin (0.4 pmol × kg^-1 × min^-1) and a 210 mins intravenous infusion with isotonic NaCl
88837675|NCT04651868|Experimental|Placebo + GLP-2|A 180 mins intravenous infusion with isotonic NaCl and a 210 mins intravenous infusion with GLP-2 (10 pmol × kg^-1 × min^-1)
88837676|NCT04651868|Experimental|Placebo + placebo|A 180 mins intravenous infusion with isotonic NaCl and a 210 mins intravenous infusion with isotonic NaCl
88837677|NCT05356416|Experimental|Ischemic compression|Patients in Group B will receive a single session of ischemic compression technique for ischemic compression technique sustained pressure on the trigger points will be maintained for 30 seconds.
88837678|NCT05356416|Active Comparator|Dry Needling|Patients in dry needling (DN) group will receive a single session of DN of 10 minutes with sterile needles insert on trigger points in scalene muscles as first twitch response will obtained needles will be manipulated in and out of the muscles to get 2 or 3 more local responses.
88837679|NCT04734587||Chronic Total Occlusion|Chronic total occlusion patients undergoing percutaneous coronary intervention.
88837680|NCT04734587||Non-Chronic Total Occlusion|Non-Chronic total occlusion patients undergoing percutaneous coronary intervention.
88837681|NCT04651010|Experimental|Multimodal MRI|
88837682|NCT04195308|Experimental|Active TBS-DLPFC|The active group will receive theta-burst TMS stimulation.
88837683|NCT04195308|Sham Comparator|Sham TBS-DLPFC|The sham group will receive sham theta-burst TMS stimulation. Participants will have the option of open label TBS-DLPFC treatment following study completion.
88837684|NCT05314673|Active Comparator|Preoperative intralesional injection of bevacizumab + pterygium excision+ autograft|Patients receiving intralesional injection of 0.05 ml (1.25 mg) of Bevacizumab, one month before surgical treatment. Surgical treatment consisted of lesion excision and conjunctival autograft performed by a single trained surgeon.
88837685|NCT05314673|Active Comparator|pterygium excision+ autograft|Patients undergoing only pterygium surgical treatment.
88837686|NCT04634318|Active Comparator|Respiratory rehabilitation program group (RR).|Post-COVID-19 patients carrying out a respiratory rehabilitation program (RR).
88837687|NCT04634318|Experimental|Respiratory tele-rehabilitation program group (TRR).|Post-COVID-19 patients carrying out a respiratory tele-rehabilitation program (TRR).
89366193|NCT01339221||Cohort B|Children hospitalized for severe gastroenteritis in the study hospitals and tested positive for rotavirus
89366194|NCT03269890|Experimental|Capsule and cutaneous blocks|7.5 mL of 0.5% bupivacaine + Epinephrine 5 ug/ ml for both blocks per side. once before surgery
89366195|NCT03269890|Active Comparator|US-intermediate cervical plexus block|15 mL of 0.5% isobaric bupivacaine + Epinephrine 5 microgram/ ml. per side. once before surgery
89366196|NCT03269812|Experimental|laparoscopic operated group|Under general anesthesia and insertion of ports for laparoscopic instruments, laparoscopic assisted mobilization of sigmoid colon and dissection till pelvis and removal of a ganglionic segment of colon and laparoscopic assisted pull through of colon then colo-anal anastomosis will be done,
89366197|NCT03269812|Experimental|non laparoscopic operated group|Under general anesthesia ,abdominal exploration ,removal of a ganglionic part by soav ,duhamel procedures and trans-anal pull through procedures.
89366198|NCT01336725||Morbid obesity|All attending learning and mastery courses for persons with morbid obesity
88837688|NCT05314595|Experimental|modified technique|women were underwent modified technique (PPC+ bilateral uterine artery ligation)
88837689|NCT03796442|Experimental|AVALUS group|patients who will undergo aortic valve replacement with Avalus bioprosthesis
88837690|NCT03796442|Active Comparator|CEPME group|patients who will undergo aortic valve replacement with Carpentier-Edwards Perimount Magna Ease bioprosthesis
88837691|NCT03688685|Experimental|Open-label study of CAD-1883|Open-label study designed to evaluate the safety, tolerability, and efficacy of CAD-1883 administered twice daily orally to adult subjects with ET
88837692|NCT04633304|Other|AVF|Single arm study using primary and secondary end points as comperators between subjects.
88837693|NCT04823208|Experimental|LY3437943|LY3437943 administered subcutaneously (SC)
88837694|NCT04823208|Placebo Comparator|Placebo|Placebo administered SC
88837695|NCT04419636|Experimental|Part A Single doses|Lu AG06466 in fast and fed state
88837696|NCT04419636|Experimental|Part B Repeated doses|Lu AG06466 after light meal
88837697|NCT05440292|Experimental|Hotspot-rTMS Group|rTMS stimulate on the hotspot of unaffected hemisphere
89178899|NCT02600754|No Intervention|Wait-list control (Usual Care or UC)|Participants who will serve as controls with telephone safety calls
89178900|NCT00858143||1|
89178901|NCT04118933|Experimental|MSI-H advanced colorectal cancer|
89178902|NCT00913367|Active Comparator|Amaryl group|
89366199|NCT03270124|Active Comparator|No Resistance Exercise and No Activity Goal Arm|Blinded use of Fitbit with no daily activity goal and no resistance exercises
89366200|NCT03270124|Experimental|Resistance Exercise and Activity Goal Arm|Unblinded use of Fitbit with a daily activity goal (steps per day) and resistance exercises
89178903|NCT00913367|Experimental|Amaryl M group|
89178904|NCT00922805|Active Comparator|fiber-enriched formula then fiber-free formula|Subjects first receive a fiber-enriched formula for one week but then will be crossed over and receive a fiber-free formula
88837698|NCT05440292|Experimental|fMRI-rTMS Group|rTMS stimulate on the motor task activation poin (targeted by fMRI) of unaffected hemisphere
88837699|NCT04113785||Klassic TKA|Subjects implanted with a Klassic TKA. Subjects will undergo flouoroscopic evaluation during a deep knee bend evaluation and the postoperative kinematics will be reported.
88837700|NCT04112069|Active Comparator|Usual care|Participants randomized to usual care first started the usual care arm (UC) managing their diabetes with continuous subcutaneous insulin infusion (pump therapy) for approximately 5 days. All subjects wore a Dexcom G5 continuous glucose monitor (CGM). If randomized to the usual care arm first, subjects crossed over to the bionic pancreas arm following a 2-day washout period.
88837701|NCT04112069|Experimental|iLet Bionic Pancreas with Humalog or Novolog|Participants randomized to the iLet with humalog/novolog first started the insulin-only iLet arm using the insulin analog that they use for their usual care (either Humalog or Novolog) for approximately 5 days. All subjects wore a Dexcom G5 CGM. If randomized to the bionic pancreas arm first, subjects crossed over to the usual care arm following a 2-day washout period.
88837702|NCT03544307|Experimental|Taekwondo Training|Taekwondo training was performed 60 minutes/day, 3 days/week for 12-weeks. Exercise intensity was set at 30-40% of heart rate reserve (HRR) and gradually increased to 50-60% over 12 weeks.
88837703|NCT03544307|No Intervention|Control|Sedentary control asked not to exercise
88837704|NCT04086407|Experimental|Forehead sensor recording precision head pitch and roll angle|During an overnight polysomnography, participants were coached by sleep research technologists to sleep with their head in positions hypothesized to minimize apnea severity ≤20⁰ or ≥160⁰, and those hypothesized to maximize apnea severity between 30⁰ and 150⁰. Head roll angles were measured and recorded by the participant's forehead sensor attached with adhesive and tape. Extreme head positions were attempted with the torso in both supine and non-supine positions so show insensitivity to torso position. A custom interface was developed to maintain compatibility with specific bedside polysomnography recorder auxiliary inputs. Sleep epochs were considered those where the subject slept for at least 10 minutes. Each head position epoch was analyzed for apnea hypopnea index and oxygen desaturation.
88837705|NCT04411290||Total Thyroidectomy (TT)-indicated patients|Patients with presumably benign thyroid disease (multinodular goitre, solitary thyroid nodule, toxic goitre, etc.) Patients with thyroid carcinoma (biopsy-proved) Total thyroidectomy preference by the primary surgeon
88837706|NCT04098575||Patients receiving Empagliflozin until mid Sep 2015|Patients receiving Empagliflozin before the EMPA-REG-OUTCOME study was published time until mid-Sept. 2015; Cohort 1
89178905|NCT00922805|Active Comparator|fiber-free formula then fiber-enriched formula|Subjects receive first formula only then will be crossed over and receive a fiber-enriched formula
89178906|NCT00704015|Experimental|A|Smoking cessation
89178907|NCT00704015|No Intervention|B|
89178908|NCT00828113|Experimental|Extended treatment|52-week varenicline therapy + individual smoking cessation counseling
89178909|NCT00828113|Active Comparator|Standard treatment|13 weeks of varenicline therapy + individual smoking cessation counseling
89178910|NCT00707135|Experimental|1|
89366201|NCT01339377|Experimental|AO-1000 Treatment|Oxygen-ozone treatment with the AO-1000 device
89366202|NCT03281356|Experimental|Intervention Group|
89366203|NCT05250999|Experimental|Skin stretch sensory stimuli|Skin stretch sensory stimuli along with conventional physiotherapy
89366204|NCT05250999|Experimental|Transcutaneous Electrical Nerve Stimulation|Transcutaneous electrical nerve stimulation along with conventional physiotherapy
89366205|NCT05250999|Active Comparator|Control Group|Conventional physiotherapy included balance exercises, static exercise and dynamic exercise.
89366206|NCT05250921|Experimental|Corticision|Corticision will be performed on the lower anterior teeth using a surgical blade and a hammer.
89366207|NCT05250921|Active Comparator|Conventional method|A fixed appliance will be applied using conventional braces without any surgical procedure.
89366208|NCT03281122|Experimental|Arm A|Specified dose on specified days
89366209|NCT03281122|Placebo Comparator|Arm B|Specified dose on specified days
89366210|NCT03635463|Experimental|twin block appliance|this group will receive conventional twin block appliance and followed up every month for 9 months.
89366211|NCT03635463|Experimental|modified twin block appliance group|modified twin block appliance group , this group will receive the modified appliance and followed up every month for 9 months
89366212|NCT02713594|Placebo Comparator|Control|Counseling from WTQL
89366213|NCT02713594|Experimental|Incentive|Counseling from WTQL; Financial incentive to participate
89366214|NCT01339455|Experimental|AHSCT|All patients undergo autologous hematopoietic stem cell transplantation in a two stage process.
89366215|NCT01339533|Experimental|APRV ls|APRV low stretch will titrate Plow to maintain release volumes between 4 and 8 cc/kg.
89366216|NCT01339533|Active Comparator|AC/VC Conventional Ventilation|Standard volume control ventilation with the ARDS Net protocol.
89366217|NCT01339533|Experimental|APRV h|APRV Habashi protocol which sets Plow equal to 0.
88837707|NCT04098575||Patients receiving Empagliflozin until CV Label Change time|Patients receiving Empagliflozin starting from the EMPA-REG-OUTCOME study being published until CV Label Change time from mid-Sept. 2015-mid-Jan. 2017; Cohort 2
88837708|NCT04098575||Patients receiving Empagliflozin until last available data cut|Patients receiving Empagliflozin starting from mid-Jan. 2017 until last; Cohort 3
88837709|NCT05350410|Experimental|HALT-AD|"This arm includes cognitively normal midlife and older-adult participants with the following inclusion criteria:~Signed informed consent must be obtained and documented (from the participant)~Sufficient proficiency in English or Spanish to undergo clinical assessment and participate~Ages 50-85~Montreal Cognitive Assessment-Telephone/Blind Version (T-MoCA) score ≥18/22~Technical ability to participate~Sufficient vision and hearing to participate~Ability to sit comfortably for a period of at least 30 minutes~A total of 20 participants will be enrolled at UCSD~10 will complete the English version~10 will complete the Spanish version~Aim is to recruit 50% women and to enroll a diverse participant sample across varied age ranges within both language groups."
88837710|NCT03776240|Experimental|HD201|Trastuzumab Single-dose 6mg/kg body weight by 90 minute intravenous infusion
88837711|NCT03776240|Active Comparator|EU-licensed Herceptin|Trastuzumab Single-dose 6mg/kg body weight by 90 minute intravenous infusion
88837712|NCT03776240|Active Comparator|US-licensed Herceptin|Trastuzumab Single-dose 6mg/kg body weight by 90 minute intravenous infusion
88837713|NCT04106492|Experimental|Dose Escalation Cohort (10 mL SQL70)|Participants will receive 10 mL of SQL70 biopolymer injected intratumorally on Day 1 of each 21-day cycle into a single lesion and then receive escalating doses of SQP33 protodrug administered IV from Day 1 through Day 5 (5 doses) of each 21-day cycle.
88837714|NCT04106492|Experimental|Dose Escalation Cohort (20 mL SQL70)|Participants will receive 20 mL of SQL70 biopolymer injected intratumorally on Day 1 of each 21-day cycle into a single lesion and then receive escalating doses of SQP33 protodrug administered IV from Day 1 through Day 5 (5 doses) of each 21-day cycle.
89178911|NCT00769704|Active Comparator|GM-CSF|Granulocyte macrophage colony-stimulating factor (GM-CSF) was administered at a dose of 125 μg/m²/day subcutaneously for 14 days, followed by a 14-day rest period for 24 weeks. Participants could continue treatment until clinically relevant disease progression, intolerability, withdrawal of consent, complete remission, or lack of response by 12 months, for a maximum of 18 months.
89178912|NCT00769704|Experimental|Talimogene Laherparepvec|Participants received talimogene laherparepvec on Days 1 and 15 of each 28-day cycle for 24 weeks. The initial dose of talimogene laherparepvec was at a concentration of 10⁶ plaque forming units (PFU)/mL, injected into 1 or more skin, subcutaneous or nodal tumors. Subsequent doses began at least 3 weeks after the first dose and consisted of talimogene laherparepvec at a concentration of 10⁸ PFU/mL. Participants could continue treatment until clinically relevant disease progression, intolerability, withdrawal of consent, complete remission, lack of response by 12 months, or disappearance of all injectable lesions, for a maximum of 18 months.
89366218|NCT03281044|Experimental|FMT group|Patient group receiving active FMT capsules
89178913|NCT00818753|Experimental|Dabigatran 110 mg|experimental drug therapy in this indication
89178914|NCT00818753|Experimental|Dabigatran 150 mg|experimental drug therapy in this indication
89178915|NCT00818753|Active Comparator|Unfractionated Heparin|standard therapy in this indication as comparator
89178916|NCT00704249|Experimental|1|Full-dose nevirapine from baseline (200 mg bid).
89178917|NCT00704249|Active Comparator|2|Nevirapine with an increase in the initial dose (200 mg once daily for 14 days and 200 mg bid thereafter)
89178918|NCT00765726|Other|Moroctocog alfa(AF-CC)|
89178919|NCT04100226|Experimental|Interstitial lung patients with low vitamin D|Arm 1:(interventional group): interstitial lung diseases patients with low vitamine D will receive Vitamin D supplementation in form of Vitamin D3 (1.25(OH)2 cholecalciferol) in dose of 200.000 IU intramuscular injection every 2 weeks for 3 months for deficient vitamin D level patients and every month for 3 months for insufficient vitamin D level patients beside ca supplementation in form ca carbonate 600 mg oral capsule once daily for 3 months for all patients in addition to current treatment.
89178920|NCT04100226|No Intervention|interstitial lung diseases patients with low vitamin D|Arm 2(control group): interstitial lung diseases patients with vitamin D deficient / insufficient will receive their current treatment only without vitamin D supplementation.
89178921|NCT00765336|Active Comparator|Minocycline Extended-Release Tablets|
89178922|NCT00765336|Placebo Comparator|Placebo|
89178923|NCT00818519|Experimental|EE20/Drospirenone (YAZ, BAY86-5300)|In the active treatment group, participants received 24 consecutive days of active tablets followed by 4 consecutive days of inactive tablets. The active tablet contained 3 mg DRSP (Drospirenone) and 20µg EE (Ethinyl estradiol).
89366219|NCT03281044|Placebo Comparator|Placebo group|Patient group receiving placebo capsules
89366220|NCT03269656||AGES-Reykjavik participants|Exploring whether pre-diagnostic serum levels of 25(OH)D among older individuals living in Iceland were associated with survival after cancer diagnosis. We also assessed the risk of being diagnosed with cancer in association with 25(OH)D levels.
89178924|NCT00818519|Placebo Comparator|Placebo|The participants of the placebo group received inert but identical-appearing, color-matched tablets.
89178925|NCT00827567|Experimental|RAD 001|RAD001-10 mg by mouth once everyday
89366221|NCT01336881||Correlative (tissue analysis)|Archived tumor tissue samples are analyzed for hepatoblastoma and other liver tumor biomarkers by microRNA array profiling and exome sequencing. Results are then compared with patients' clinical data.
89366222|NCT02458612|Other|control group|We will apply only upper limbs exercises with traditional therapy.
89366223|NCT02458612|Active Comparator|intervention group|We will apply mirror therapy and progressive strength training for upper extremities.
89366224|NCT03264274|Other|Aflibercept + DCE-US|Aflibercept: 4mg/kg IV every 2 weeks until discontinuation due to progression. DCE-US before treatment, and at 2 weeks and 8 weeks after the first Aflibercept administration.
89366225|NCT01339611|Experimental|Educational Program|Patients who are going to use of oral anticoagulant will participate in an individual orientation, using instructional material (slides and illustrative booklet) during hospitalization period and the telephone follow-up at a week and four weeks after discharge
88837715|NCT04106492|Experimental|Cohort A|Participants will receive SQL70 biopolymer injected intratumorally on Day 1 of each 21-day cycle into a single lesion as determined in Dose Escalation. Then will receive a lower dose than RP2D of SQP33 protodrug administered IV from Day 1 through Day 5 (5 doses) of each 21-day cycle.
88837716|NCT04106492|Experimental|Phase 2a Expansion Group 1 (Extremity STS)|Participants with soft tissue sarcomas of the extremity AJCC Stage III OR IV (>5 cm injectable tumors locally advanced and or metastatic, not amendable to primary surgical intervention and who are anthracycline naïve.
88837717|NCT04106492|Experimental|Phase 2a Expansion Group 2 (Unresectable STS)|Locally advanced, unresectable or metastatic, soft tissue sarcomas who are anthracycline naïve.
88837718|NCT04106492|Experimental|Phase 2a Expansion Group 3a (Head and Neck)|Participants with histologically or cytologically confirmed relapsed or metastatic squamous-cell carcinoma of the head and neck, who have exhausted curative intent therapies or patients with distant metastases who may have received one or less chemotherapy regimen.
89178926|NCT00765102|Experimental|Romidepsin + Bortezomib|"Romidepsin was given as an infusion on Days 1, 8 and 15 of each 28-day cycle. Bortezomib was administered twice a week for two consecutive weeks (Days 1, 4, 8 and 11) followed by a 17-day rest period.~Patients were treated to a maximum response plus two additional cycles or a maximum of eight cycles."
89178927|NCT00809354|Active Comparator|IV Placebo + NSAID|Oral NSAID
89178928|NCT00809354|Experimental|Tanezumab 5 mg|IV tanezumab 5 mg every 8 weeks (through Week 48)
89366226|NCT01339611|Other|usual care|Patients who are going to use of oral anticoagulant will have usual orientation from the health service (illustrative booklet) during hospitalization time. No telephone follow-up after discharge.
88837719|NCT04100720|Experimental|Cardiovalve Transfemoral Tricuspid Valve|Replacement (Implant) delivered through a transfemoral access
88837720|NCT02976272||patients with myeloma multiple|
89178929|NCT00809354|Experimental|Tanezumab 10 mg|IV tanezumab 10 mg every 8 weeks (through Week 48)
89178930|NCT00809354|Experimental|Tanezumab 5 mg + NSAID|IV doses of tanezumab 5 mg every 8 weeks (through Week 48) plus oral naproxen 500 mg BID for 56 weeks or oral celecoxib 100 mg BID for 56 weeks
88837721|NCT01600326|Active Comparator|Tenotomy Group|Subject enrolled in this arm will receive treatment for tendinitis and pain evaluation of pain pre and post treatment.
89178931|NCT00809354|Experimental|Tanezumab 10 mg + NSAID|IV doses of tanezumab 10 mg every 8 weeks (through Week 48) plus oral naproxen 500 mg BID for 56 weeks or oral celecoxib 100 mg BID for 56 weeks
89178932|NCT00834899|Experimental|1|As soon as eligible patients are identified and provide consent to participate in the study, patients randomized to the eptifibatide arm will receive two 180 mcg/kg boluses of eptifibatide 10 minutes apart (i.e., a double bolus), followed by a continuous infusion at 2 mcg/kg/min for 6 hours.
89178933|NCT00834899|Placebo Comparator|2|As soon as eligible patients are identified and provide consent to participate in the study, patients randomized to the placebo arm will receive a saline solution delivered at a volume and rate identical to that of the active drug.
89178934|NCT04100460|Experimental|7.25 grams of Arabinoxylan leaf fiber extract|Participants are given 7.25 grams of Arabinoxylan daily
89178935|NCT04100460|Experimental|14.5 grams of Arabinoxylan leaf fiber extract|Participants are given 14.5 grams of Arabinoxylan daily
89178936|NCT04100460|Placebo Comparator|Control - No Arabinoxylan (Maltodextrin)|Participants are given no Arabinoxylan
88837722|NCT01600326|Active Comparator|Plasma Injection Group|Treatment is Ultrasound guided platelet rich plasma injection.
88837723|NCT04082819|Other|Low Blood Pressure|Low blood pressure (systolic: 0-129, diastolic: 0-79)
89178937|NCT00764946|Experimental|1|raltegravir
89178938|NCT00764868|Experimental|LDX|Lisdexamfetamine Dimesylate (LDX)
88837724|NCT04082819|Other|Medium Blood Pressure|Medium blood pressure (systolic: 130-160, diastolic: 80-100)
88837725|NCT04082819|Other|High Blood Pressure|High blood pressure (systolic: 161 or higher, diastolic: 101 or higher)
88837726|NCT00361790|Other|1|
88837727|NCT04081961||Asymptomatic current smokers|No respiratory symptoms and preserved pulmonary function based on spirometry (FEV1/FVC of at least 0.70 after bronchodilation treatment and FVC ≥80% of the expected value)
89178939|NCT00764790|Experimental|Fluarix Dose A Group|"Subjects were administered 1 or 2 doses* of Fluarix vaccine (at Day 0 or at Days 0 and 28) intramuscularly, in the non-dominant upper arm (children >12 months of age) or in the anterolateral thigh (children <12 months of age).~* Only those subjects who had no history of prior influenza vaccination (i.e. unprimed subjects) received 2 doses."
89178940|NCT00764790|Experimental|Fluarix Dose B Group|"Subjects were administered 1 or 2 doses*, half the volume of dose A, of Fluarix vaccine (at Day 0 or at Days 0 and 28) intramuscularly, in the non-dominant upper arm (children >12 months of age) or in the anterolateral thigh (children <12 months of age).~* Only those subjects who had no history of prior influenza vaccination (i.e. unprimed subjects) received 2 doses."
89366227|NCT02457208|Experimental|2HRZE/4HR|"2HRZE/4HR~Intensive phase: 2 months HRZE - once daily~Continuation phase: 4 months HR - once daily~Adults will be treated with fixed dose combination (FDC) tablets containing:~Intensive phase (content per tablet)~Isoniazid -75 mg,~Rifampicin - 150 mg,~Pyrazinamide - 400 mg,~Ethambutol - 275 mg~Continuation phase (content per tablet)~Isoniazid 150 mg~Rifampicin 300 mg~*Drug dosing will be adjusted by patient body weight."
89366228|NCT01337037||standard VATS group|patients undergo standard VATS lobectomy using non-modified equipments,without limits of staples
89366229|NCT01337037||modified equipments group|patients undergo VATS lobectomy with modified VATS lobectomy equipments designed designed according to the experience of chinese lobectomy surgery: Lobectomy Equipments Pack (Manufacturer B.J.ZH.F.Panther Medical Equipment Co.,Ltd.).
89366230|NCT01337037||less staples group|patients undergo VATS lobectomy with at most 4 staples used.
89366231|NCT01337037||open group|patients undergo lobectomy by thoracotomy approach
89366232|NCT01339845|Active Comparator|Vaccine arm|Thirty clusters (approximately 80,000 people) will receive cholera vaccine alone
89366233|NCT01339845|Active Comparator|Vaccine plus hygiene and safe water arm|Thirty clusters (approximately 80,000 people)will receive both cholera vaccine and behaviour change
89366234|NCT01339845|No Intervention|Non-intervention arm|30 neighbourhoods(approximately 80,000 people) will continue their standard habits and practices
88837728|NCT04081961||"Grey zone current smokers"|Initially preserved pulmonary function based on spirometry, but with clinical symptoms based on COPD Assessment Test (CAT≥10) and results of the 6-min walk test (6 MWT) less than 450 meters.
89366235|NCT02457130|Experimental|Group A|"After providing written informed consent, eligible subjects will be randomized in a 1:1 fashion to group A or B.~Ticagrelor (180-mg loading dose the first day followed by 90-mg b.i.d. maintenance dose) for one week; washout period of 2-4 weeks; crossover to clopidogrel (600-mg loading dose the first day followed by 75-mg daily maintenance dose) for one-week."
89366236|NCT02457130|Experimental|Group B|"After providing written informed consent, eligible subjects will be randomized in a 1:1 fashion to group A or B.~Clopidogrel (600-mg loading dose the first day followed by 75-mg daily maintenance dose) for one-week; washout period of 2-4 weeks; crossover to ticagrelor (180-mg loading dose the first day followed by 90-mg b.i.d. maintenance dose) for one week."
89366237|NCT01337193|Active Comparator|Pelvic floor muscle exercises|Three pelvic floor muscle exercises will be performed with verbal cueing from the instructor.
89366238|NCT01337193|Experimental|Pelvic floor exercises with biofeedback|Pelvic floor exercises will be performed with biobeedback cueing.
89366239|NCT03280810|Experimental|Movement group|patients with schizophrenia (experimental group) have psycho-corporal training once a week, during 1 hour and a half for a period of two months
89366240|NCT03280810|No Intervention|Control group|No intervervention : patients with schizophrenia (comparator group) who don't have psycho-corporal training
89366241|NCT02457052|Experimental|DATP +|Introduction of a device allowing a custom sitting to help patients with swallowing disorders .
89366242|NCT02457052|No Intervention|DATP -|No introduction of a device allowing a custom sitting to help patients with swallowing disorders .
89366243|NCT05250531|Experimental|GROUP 1|33 patients in the multicomponent treatment group selected to group 1 (G1) will be treated with telerehabilitation for a total of 6 sessions of two hours once a week for 3 weeks. After 1 month, one more session will be applied for a two-hour follow-up and sustainability.
89366244|NCT05250531|Active Comparator|GROUP 2|As a control group, 33 patients selected to Group 2 (G2) will be given exercise and training with telerehabilitation.
89366245|NCT01340001|Sham Comparator|Sham Electrical stimulation of the nucleus basalis of Meynert|Deep brain stimulation
89366246|NCT01340001|Experimental|Electrical stimulation of the nucleus basalis of Meynert|Deep brain stimulation
89366247|NCT05250453||Cardiac arrest|All patients having sudden cardiac arrest out-of-hospital in Pirkanmaa, Finland
89366248|NCT05250453||ResusInj|OHCA survivors having CPR related injuries or carotid stenosis analyzed by CT
89366249|NCT05250453||ResusCPC|OHCA survivors neurological outcome
89366250|NCT03263884|Experimental|Real treatment group|"Transcranial magnetic stimulation (TMS) is used to stimulate small regions of the brain. During a TMS procedure, a magnetic field generator, or coil, is placed near the head of the person receiving the treatment. The coil produces small electric currents in the region of the brain just under the coil via electromagnetic induction.~The protocol used in this research includes 20 minutes of 10Hz stimulation, 5 seconds on, 10 seconds off, at 110% RMT, for a total of 4000 pulses."
89366251|NCT03263884|Sham Comparator|Sham treatment group|Sham coil is used to mimic the clicking sound of the TMS coil and skin stimulation
89366252|NCT01337271|Active Comparator|PSV|
89366253|NCT01337271|Experimental|NAVA|
89366254|NCT03268798|Experimental|Wrist extension training|
89366255|NCT01340079|Experimental|Virtual world|Virtual world delivery method
89366256|NCT01340079|Active Comparator|face to face|face to face method of health education
89366257|NCT03268720|Other|healthy controls|FODMAP low diet gluten-free diet
88837729|NCT04081961||Current smokers with COPD|Current smokers with a confirmed diagnosis of COPD (GOLD stage I-III)
88837730|NCT04821102|Experimental|JOINTSTEM|Autologous Adipose Tissue derived MSCs
88837731|NCT04821102|Placebo Comparator|Saline|saline
88837732|NCT04143438|Experimental|Undergoing EOS 3D imaging|Patients with patello-femoral instability will undergo EOS 3D Imaging protocol before and after undergoing corrective surgery
88837733|NCT00361868|Experimental|1|
89366258|NCT03268720|Other|NCGS patients|FODMAP low diet gluten-free diet
89366259|NCT03280654||Group 1:VAI levels <7,55|7,55 value was calculated as cut-off level for VAI by ROC analyse and area under curve was calculated as 0,487 Group 1 was defined as VAI levels <7,55
89366260|NCT03280654||group 2:VAI levels >=7,55|7,55 value was calculated as cut-off level for VAI by ROC analyse and area under curve was calculated as 0,487 group 2 was defined as VAI levels >=7,55
89366261|NCT03280576||Sepsis|Patients with sepsis
89366262|NCT03280576||Cardiac Surgery|Patients undergoing cardiac surgery
89366263|NCT03280576||Healthy controls|Normal individuals
89366264|NCT03280498|Other|Intubation with Cole formula|ASA I-II pediatric patients in the age range of 2-10 years, planned to undergo elective surgeries under general anesthesia with endotracheal entubation,
89366265|NCT01340157|Experimental|Fasting|Treatment A: 1200mg fexinidazole administered in fasting conditions by oral route
89366266|NCT01340157|Experimental|Meal 1: Plumpy Nuts|Treatment B: 1200mg fexinidazole administered in fed conditions (meal 1) by oral route
89366267|NCT01340157|Experimental|Meal 2: Rice + beans|Treatment B: 1200mg fexinidazole administered in fed conditions (meal 2) by oral route
89366268|NCT02459470|Experimental|SVV and PPV|"SVV(stroke volume variation): recorded using the Flotrac/Vigileo system (Edwards Lifesciences)~PPV(pulse pressure variation): recorded using philips Intelivue MP70 monitors (Philips Medical System)~Intervention: Other: Fluid loading using HES 130/0.4; voluven; Fresenius Kabi; Stans, Switzerland"
89366269|NCT01340235|Experimental|Oral erythromycin|Oral erythromycin
89366270|NCT02459548|Experimental|Primary Care Group|This group will be follow up in Primary Care at 1, 3 and 6 month. At each visit patients receive advice on CPAP treatment, management of adverse effects associated with CPAP, making anthropometric and blood pressure measurements and also were asked to complete questionnaires.
88837734|NCT00361868|Active Comparator|2|
88837735|NCT04990362|Experimental|MD + Seed oil|"Pomegranate oil + Mediterranean Diet 30 patients Mediterranean dietary protocol Dietary Supplement: Pomegranate oil in a glass bottle of 30ml Dietary Supplement: Mediterranean dietary protocol~Intervention:~Mediterranean diet, Pomegranate oil"
88837736|NCT04990362|Active Comparator|MD|Mediterranean Diet 30 patients Mediterranean dietary protocol Dietary Supplement: Mediterranean dietary protocol Intervention: Mediterranean diet
88837737|NCT04564872|Experimental|HSK7653 10 mg|
88837738|NCT04564872|Experimental|HSK7653 25 mg|
88837739|NCT04564872|Active Comparator|Linagliptin 5 mg|
88837740|NCT04079348|Active Comparator|Oasis ECM|The patient will undergo harvesting of a split-thickness skin graft using a dermatome set at standard depth with the subsequent application Oasis Extracellular Matrix to their donor site wound.
88837741|NCT04079348|Active Comparator|Standard wound care|The patient will undergo harvesting of a split-thickness skin graft using a dermatome set at standard depth with the subsequent application of standard wound care to their donor site wound.
88837742|NCT04074668||Type 1 Diabetes|All participants will undergo DXA scan, magnetic resonance imaging (MRI) studies of the kidneys, PET/CT using 11-C acetate to measure renal oxygen consumption, hyperinsulinemic-euglycemic clamp to quantify insulin sensitivity, and renal clearance testing using iohexol and para-aminohippurate (PAH) to quantify glomerular filtration rate (GFR) and effective renal plasma flow (ERPF).
88837743|NCT04074668||Healthy Controls|All participants will undergo DXA scan, magnetic resonance imaging (MRI) studies of the kidneys, PET/CT using 11-C acetate to measure renal oxygen consumption, hyperinsulinemic-euglycemic clamp to quantify insulin sensitivity, and renal clearance testing using iohexol and para-aminohippurate (PAH) to quantify glomerular filtration rate (GFR) and effective renal plasma flow (ERPF).
88837744|NCT04343144|Experimental|Nivolumab|
88837745|NCT04343144|No Intervention|Standard of Card|
88837746|NCT04075409|Experimental|Extensive metabolizers|Participants will receive assigned single and multiple doses of padsevonil.
88837747|NCT04075409|Experimental|Intermediate metabolizers|Participants will receive assigned single and multiple doses of padsevonil.
88837748|NCT04075409|Experimental|Poor metabolizers|Participants will receive assigned single and multiple doses of padsevonil.
88837749|NCT03743246|Experimental|Administration of JCAR017|Subjects will receive Lymphodepleting chemotherapy with intravenous (IV) fludarabine (30 mg/m2/day for 3 days) plus cyclophosphamide IV (300 mg/m2/day for 3 days) (flu/cy) concurrently, followed by JCAR017 cells infusion. Phase 1 will evaluate up to 5 JCAR017 cells dose levels and dose escalation/de-escalation will follow a modified toxicity probability interval (mTPI-2) algorithm. The declared RP2D in Phase 1 will be applied to the subjects enrolled in Phase 2
88837750|NCT04074941|Experimental|Low sodium diet|This group will get a low sodium diet (<0.9 mg per kcal of energy intake).
88837751|NCT04074941|Active Comparator|Usual sodium diet|This group will get a usual sodium diet (~2 mg per kcal of energy intake).
88837752|NCT05346666|Active Comparator|Control Group|Group 1 received the conventional treatment for Status Epilepticus including propofol (loading dose is 3 to 5 mg/kg with maintenance of 1 to 15 mg/kg/h), phenobarbital (initial loading dose is 5 to 15 mg/kg over 1 hour. Infusion rates can be maintained at 0.5 to 15 mg/kg/h), and midazolam (a loading dose of 0.2 mg/kg is given with maintenance doses ranging between 0.05 and 2.0 mg/kg/h).
88837753|NCT05346666|Experimental|Tocilizumab Group|Group 2 received the same treatment in group 1 in addition to tocilizumab that was initiated at a dose of 4mg/kg administered twice monthly with 1-week intervals for 3 months. A monthly dose (8mg/kg) of tocilizumab was added if needed.
88837754|NCT03694613|Other|Placental/Umbilical Cord Blood sample|Placental/Umbilical Cord Blood sample will be collected after delivery from every participant.
88837755|NCT03674294|Experimental|Palonosetron/Dexamethasone/Aprepitant|
89178941|NCT00764790|Active Comparator|Fluzone Group|"Subjects were administered 1 or 2 doses* of Fluzone vaccine (at Day 0 or at Days 0 and 28) intramuscularly, in the non-dominant upper arm (children >12 months of age) or in the anterolateral thigh (children <12 months of age).~* Only those subjects who had no history of prior influenza vaccination (i.e. unprimed subjects) received 2 doses."
88837756|NCT03674294|Placebo Comparator|Palonosetron/Dexamethasone/Placebo|
88837757|NCT03669146|Experimental|Hyperopic subjects receiving glasses|Randomized +5.00 to +7.00 diopter hyperopic subjects that will receive partial refractive correction and will be instructed to do accommodation exercises on a daily basis.
89178942|NCT00756444|Active Comparator|Panitumumab plus Chemotherapy|Subjects receiving cisplatin and 5/FU and receiving Panitumumab who have with Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck
88837758|NCT03669146|No Intervention|Hyperopic subjects uncorrected|Randomized +5.00 to +7.00 diopter hyperopic subjects that will serve as the control to the experimental arm who will receive no correction but be observed for the duration of the study.
89534665|NCT05037435|Experimental|The pentavalent rotavirus vaccine - Rota-V-Aid™ (live attenuated oral, freeze-dried)|Live attenuated bovine-human [UK] reassortant rotavirus vaccine manufactured by the Serum Institute of India, Limited (SIIL). The pentavalent vaccine contains rotavirus serotypes G1, G2, G3, G4, and G9 (≥5.6 log10 FFU/serotype/dose). The vaccine is lyophilized and supplied with 2.5 ml of citrate bicarbonate buffer added for reconstitution before oral administration.
88837759|NCT03669146|Active Comparator|Highly hyperopic subjects corrected|If a subject is found to be greater than +7.00 diopters hyperopic during the screening phase of the study, they will receive glasses correction and be followed during the study period.
88837760|NCT04842864|Experimental|Young|10 healthy men and women 18-35 yo.
88837761|NCT04842864|Active Comparator|Older adults|10 healthy men and women 65-85 yo
88837762|NCT03706313|Active Comparator|Genicular nerve block with bupivacaine|"The ultrasound-guided genicular nerve block will be performed at the site of the superior lateral, the superior medial, and the inferior medial genicular nerves. Color Doppler will be used to identify the arterial structures which serve as landmarks for the corresponding nerves.~After skin local anesthetic infiltration, a 10 cm 21G insulated block needle will be inserted and aligned with the ultrasound scanning plane. Once satisfactory position of the needle is confirmed, 5mL of a solution containing 15 ml 0.25% bupivacaine with 2mg dexamethasone or 5mL saline will be slowly injected. Spread of local anesthetic will be documented adjacent to the target nerve. This procedure will be performed at the site of the three genicular nerves described."
89178943|NCT00756444|Active Comparator|Chemotherapy Alone|Subjects receiving cisplatin and 5/FU and not receiving Panitumumab who have with Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck
89178944|NCT04100616||Obsese individuals|Patients with a BMI greater than or equal to 30
89178945|NCT00769002|Active Comparator|Natural Infection|previously naturally infected
89534666|NCT05037435|Placebo Comparator|Diluent is a sterile solution (Citrate Bicarbonate Buffer)|Same constituents as the active vaccine but without the viral antigens; manufactured by SIIL.
88837763|NCT03706313|Placebo Comparator|Genicular nerve block with saline|"The ultrasound-guided genicular nerve block will be performed at the site of the superior lateral, the superior medial, and the inferior medial genicular nerves. Color Doppler will be used to identify the arterial structures which serve as landmarks for the corresponding nerves.~After skin local anesthetic infiltration, a 10 cm 21G insulated block needle will be inserted and aligned with the ultrasound scanning plane (in-plane approach). Once satisfactory position of the needle time is confirmed, 5mL of a saline will be slowly injected. Spread of local anesthetic will be documented adjacent to the target nerve. This procedure will be performed at the site of the three genicular nerves described."
88837764|NCT05369364|Experimental|Zanubrutinib and HD-DXM|Dexamethasone 40 mg per day, 4 consecutive days (the 4-day course of dexamethasone was repeated in the case of lack of response by day 10) and Zanubrutinib 80mg qd po, 6 consecutive weeks
88837765|NCT05369364|Active Comparator|HD-DXM|Dexamethasone 40 mg per day, 4 consecutive days (the 4-day course of dexamethasone was repeated in the case of lack of response by day 10)
88837766|NCT03421106|Experimental|Intervention Food Pantries|Food pantries will transform to offer healthier and more appealing food ; the effect on clients will be measured.
88837767|NCT03421106|Active Comparator|Control Food Pantries|Food pantries will make no changes during the evaluation period; the effect on clients will be measured.
88837768|NCT04542642|Active Comparator|reSET-O|Prescription Digital therapeutic
88837769|NCT04542642|Experimental|PEAR-008|Investigational Digital Therapeutic
88837770|NCT03706469|Experimental|Fasted (T2 50 mg+T3 50 mg+T3 600 mg+T2 600 mg)+Fed (T3 600 mg)|TAK-831 T2 50 milligram (mg), tablet, orally, once, under fasted condition on Day 1 of Treatment Period 1, followed by TAK-831 T3 50 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 2, followed by TAK-831 T3 600 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 3, followed by TAK-831 T2 600 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 4, further followed by TAK-831 T3 600 mg, tablet, orally, once, under fed condition on Day 1 of Treatment Period 5. There will be a washout period of at least 7 days between study drug in-take in subsequent treatment periods.
88837771|NCT03706469|Experimental|Fasted (T3 50 mg+T2 600 mg+T2 50 mg+T3 600 mg)+Fed (T3 600 mg)|TAK-831 T3 50 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 1, followed by TAK-831 T2 600 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 2, followed by TAK-831 T2 50 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 3, followed by TAK-831 T3 600 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 4, further followed by TAK-831 T3 600 mg, tablet, orally, once, under fed condition on Day 1 of Treatment Period 5. There will be a washout period of at least 7 days between study drug in-take in subsequent treatment periods.
88837772|NCT03706469|Experimental|Fasted (T2 600 mg+T3 600 mg+T3 50 mg+T2 50 mg)+Fed (T3 600 mg)|TAK-831 T2 600 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 1, followed by TAK-831 T3 600 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 2, followed by TAK-831 T3 50 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 3, followed by TAK-831 T2 50 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 4, further followed by TAK-831 T3 600 mg, tablet, orally, once, under fed condition on Day 1 of Treatment Period 5. There will be a washout period of at least 7 days between study drug in-take in subsequent treatment periods.
88837773|NCT03706469|Experimental|Fasted (T3 600 mg+T2 50 mg+T2 600 mg+T3 50 mg)+Fed (T3 600 mg)|TAK-831 T3 600 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 1, followed by TAK-831 T2 50 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 2, followed by TAK-831 T2 600 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 3, followed by TAK-831 T3 50 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 4, further followed by TAK-831 T3 600 mg, tablet, orally, once, under fed condition on Day 1 of Treatment Period 5. There will be a washout period of at least 7 days between study drug in-take in subsequent treatment periods.
88837774|NCT04532034|Experimental|Peer-Delivered Decision Support Intervention|
88837775|NCT04067232|Experimental|Patients with posttraumatic forearm impairment|All patients with a one-sided posttraumatic impairment of forearm pro- and/or supination at least 3 months after injury
88837776|NCT03381482||Controls|Group 1: the 4ml of CSF collected in the surgery context will be kept for the study, and 6x5ml of blood will be added to the usual samples.
88837777|NCT03381482||Asymptomatic cases with high risk to develop AD|Group 2: 10ml of CSF and 6x5ml of blood will be collected
88837778|NCT03381482||Cases with isolated cognitive complaint|Group 3: 10ml of CSF and 6x5ml of blood will be collected
88837779|NCT03381482||Prodromal AD|Group 4: 10ml of CSF and 6x5ml of blood will be collected
88837780|NCT03381482||Mild to moderate probable AD-type dementia|Group 5: 10ml of CSF and 6x5ml of blood will be collected
88837781|NCT03545165|Experimental|All Subjects|"177Lu-PSMA-617 [1.85 GBq (50 mCi) - 9.25 GBq (250 mCi)] x2 doses, 2 weeks apart (Treatment Visit #1 and #2), IV administration~177Lu-J591 [1.35 GBq/m2 or 36.5 mCi/m2] x2 doses, 2 weeks apart (Treatment Visit #1 and #2), IV administration~68Ga-PSMA-HBED-CC [185 ±74 MBq or 5 ±2 mCi] intravenous during screening and at 12 weeks (±1 week) with standard imaging"
88837782|NCT02974946|Experimental|Study group|Patients will receive the RenalGuard system
88837783|NCT02974946|No Intervention|Control group|Standard practice will be performed with no RenalGuard system
89178946|NCT00769002|Active Comparator|FluShield - influenza positivity|prior FluShield ipsilateral vaccinated
89178947|NCT00769002|Active Comparator|FluShield - influenza positivity2|prior FluShield contralateral vaccinated
89178948|NCT00769002|Active Comparator|FluMist|prior FluMist vaccinated.
89178949|NCT04100382|Experimental|Laser and SLA implants|Surgical placement of short implants in maxillary posterior teeth with Laser surface treated and SLA surface treated dental implants
89366271|NCT02459548|Other|Sleep Unit Group|This group will be follow up in Sleep unit at 1, 3 and 6 month. At each visit patients receive advice on CPAP treatment, management of adverse effects associated with CPAP, making anthropometric and blood pressure measurements and also were asked to complete questionnaires.
89366272|NCT05243979||Group (A)|40 patients with CKD (1-3) not on renal replacement therapy.
89178950|NCT04099212||Cases|Patients with HS I-II in monotherapy treatment of topical resorcinol 15%
89178951|NCT00753012|Experimental|Lisdexamfetamine|"Adults who meet DSM-IV-TR criteria for ADHD.~Group 1 is normotensive adults; Group 1 does not have high blood pressure. Group 2 is primary hypertensive adults; Group 2 does have high blood pressure and is being treated with stable doses of hypertensive medications achieving a blood pressure of <135/85."
89366273|NCT05243979||Group (B)|40 persons with normal kidney function and GFR ( control ).
89366274|NCT03263962||With canrenone|Patients with canrenone
89366275|NCT03263962||Without canrenone|Patients without canrenone
89366276|NCT02459314|Placebo Comparator|soymilk|Soymilk (SM) contained 5 gm soy protein and 6.5 gm sugar per 180 mL package.
89366277|NCT02459314|Active Comparator|sterol/fiber-enriched soymilk|PLant sterol and soluble fiber-enriched soymilk (SFSM) contained 1 gm free plant sterol, 5 gm inulin (soluble fiber), 5 gm soy protein and 6.5 gm sugar per 180 mL package
89366278|NCT03280420|Active Comparator|early catheter removal|30 patients will receive Tamsulosin hydrochloride 0.4 mg once daily and the catheter will be removed after 3 days.
89366279|NCT03280420|Active Comparator|late catheter removal|30 patients will receive Tamsulosin hydrochloride 0.4 mg once daily and the catheter will be removed after 7 days.
89366280|NCT05186649||Experimental Group|Consecutive patients with severe mitral stenosis and clot in left atrial appendage (LAA) on transesophageal echocardiography fulfilling the inclusion criteria will be recruited for this study. An ACUSON 128-XP echocardiographic system equipped with omniplane and biplane transesophageal probes will be used for this study. TEE followed by CT Angiography will be performed according to the standard procedure after obtaining informed consent.
89366281|NCT02458534|Experimental|Mcgrath Mac videolaryngoscope|Participants perform three intubation attempts using Mcgrath Mac videolaryngoscope in the manikin with the normal airway setting. Then the participants perform three intubation attempts using the manikin with difficult airway setting.
89366282|NCT02458534|Experimental|C-MAC videolaryngoscope|Participants perform three intubation attempts using C-MAC videolaryngoscope in the manikin with the normal airway setting. Then the participants perform three intubation attempts using the manikin with difficult airway setting.
88837784|NCT04968522|Placebo Comparator|Placebo comparator 2|Participants will be allocated a randomly allocated sequence of treatment. The randomisation will be in two-week pairs - so the order of treatment (A) and placebo (P) to be randomly assigned within each two-week cycle (over 8 weeks). Placebo will be matched in dose to their stimulant dose at enrolment to the trial as determined and titrated by their primary paediatrician. This dose will remain constant for the course of the trial (8 weeks). Placebo will be orally administered, unless this is not possible for clinical reasons.
89366283|NCT02458534|Active Comparator|Macintosh laryngoscope|Participants perform three intubation attempts using macintosh laryngoscope in the manikin with the normal airway setting. Then the participants perform three intubation attempts using the manikin with difficult airway setting.
89366284|NCT05184465|Experimental|Bupivacaine|"Spinal anesthesia was administered to the patients for anesthetic support of the surgical intervention.Intrathecal injections were performed with a 24G or 25G Pencil point needle in the L3-L4 interval. Spinal puncture was performed while the patient was sitting on the table.Spinal anesthesia was performed with 3 ml of 0.5% bupivacaine. Then the patient was placed on his back.Surgery was allowed to start after 40 minutes if the upper level of the sensory block reached the Th10 segment."
88837785|NCT04968522|Experimental|Stimulant|"The stimulants used in the trial are commercially available and will be used in accordance with the approved labelling. Participants must be on a stable dose of stimulant medication for at last 1 month prior to the study. The dose is individualized and titrated by treating primary paediatrician. This will represent the starting dose for the trial, and this will remain stable through the course of the 8-week trial. This study is a N-of-1 RCT of currently prescribed stimulant medications for treatment of ADHD symptoms in children with FASD, relative to matched placebo capsules. Based on pilot data from this group, psychostimulant medications prescribed in this population may include:~Methylphenidate IR~Methylphenidate LA~Dexamphetamine~Children will take the required number of capsules to match the total prescribed dose (e.g. 30mg Ritalin LA is 3x10mg capsules)."
88837786|NCT03546491|Experimental|Preventive Gel|0.4% stannous fluoride
88837787|NCT03546491|Active Comparator|Marketed Control|0.243 % Sodium Fluoride
88837788|NCT03714659|Experimental|Intervention|Group will receive a single injection of autologous, micro-fragmented adipose tissue into the torn meniscus and knee joint. The group will then be followed for one year, filling out pain and function questionnaires.
89366285|NCT05184465|Experimental|Levobupivacaine|"Spinal anesthesia was administered to the patients for anesthetic support of the surgical intervention.Intrathecal injections were performed with a 24G or 25G Pencil point needle in the L3-L4 interval. Spinal puncture was performed while the patient was sitting on the table.Spinal anesthesia was performed with 3 ml of 0.5% Levobupivacaine. Then the patient was placed on his back.Surgery was allowed to start after 40 minutes if the upper level of the sensory block reached the Th10 segment."
89366286|NCT05184465|Experimental|Hyperbaric bupivacaine|"Spinal anesthesia was administered to the patients for anesthetic support of the surgical intervention.Intrathecal injections were performed with a 24G or 25G Pencil point needle in the L3-L4 interval. Spinal puncture was performed while the patient was sitting on the table.Spinal anesthesia was performed with 3 ml of 0.5% Hyperbaric bupivacaine. Then the patient was placed on his back.Surgery was allowed to start after 40 minutes if the upper level of the sensory block reached the Th10 segment."
89366287|NCT03263728|Experimental|Stress Cardiac MR|
89366288|NCT03263338|Active Comparator|Group A|Participants will select a time in bed target and will receive sleep tips by text messages to help reach the selected target.
89366289|NCT03263338|Experimental|Group B|Participants will select a time in bed target and will receive sleep tips by text messages to help reach the selected target. In addition, participants in this study arm will receive additional motivational text messages beyond those given to Group A, and unique to Group B.
89366290|NCT03263338|Experimental|Group C|Participants will select a time in bed target and will receive sleep tips by text messages to help reach the selected target. In addition, participants in this study arm will receive additional motivational text messages beyond those given to Group A, and unique to Group C.
89366291|NCT01340313||Group 1|4 times evaluation according to doses in 1 group
88837789|NCT01637142|Experimental|LY2140023 + [14C]-LY2140023|Treatment Period 1: On Day 1, a single oral dose of 80 milligrams (mg) LY2140023 (parent compound) followed by a single 2-hour intravenous (IV) infusion of approximately 100 micrograms (µg) LY2140023 containing approximately 100 nanocuries (nCi) [14C]-LY2140023.
88837790|NCT01637142|Experimental|LY2140023 + [14C]-LY404039|Treatment Period 2: On Day 1, a single oral dose of 80 mg LY2140023 (parent compound) followed by a single 2-hour IV infusion of approximately 100 µg LY404039 containing approximately 100 nCi [14C]-LY404039 (active metabolite).
88837791|NCT04055519|Other|LID017569, then Biofinity|Lehfilcon A contact lenses worn first, followed by comfilcon A contact lenses, as randomized. Each product will be worn in both eyes on a daily wear basis at least 8 hours a day, 5 days a week, for 30 days. Lenses will be removed nightly for cleaning and disinfection.
88837792|NCT04055519|Other|Biofinity, then LID017569|Comfilcon A contact lenses worn first, followed by lehfilcon A contact lenses, as randomized. Each product will be worn in both eyes on a daily wear basis at least 8 hours a day, 5 days a week, for 30 days. Lenses will be removed nightly for cleaning and disinfection.
89366292|NCT03152019|Active Comparator|Protopic® 0.1% (Tacrolimus) ointment|Protopic® 0.1% ointment, packed in blinded tube of 30g.
88837793|NCT01636986|Experimental|DT1|Delefilcon A contact lenses worn bilaterally on a daily wear, daily disposable basis for 4 weeks
89366293|NCT03152019|Placebo Comparator|Placebo ointment|Same formulation as the Protopic® 0.1% ointment but without tacrolimus, packed in blinded tube of 30g.
89366294|NCT05007639||Patients diagnosed BEFORE implementation of the public health intervention program|All adult patients (≥18 years old) diagnosed between 1 November 2006 and 31 December 2007 in the Aquitaine and Midi-Pyrénées administrative districts in South-West France (6 million inhabitants, 10% of the French population) with primary STS of any stage were included. Patients with visceral, bone, uterus or Kaposi's sarcoma, gastrointestinal stromal tumors, or mesotheliomas were not included. Patients being treated for recurrence, and patients diagnosed outside of the administrative districts were not eligible. STS diagnoses were made in public or private pathology laboratories. Data were collected from all relevant sources: pathology reports, medical records from private and public centers,
89366295|NCT05007639||Patients diagnosed DURING implementation of the public health intervention program|"Same eligibility criteria as for the group before implementation of the public health intervention program, except that patients were diagnosed between 1 january 2008 and 31 october 2008."
88837794|NCT01636986|Active Comparator|1DAVM|Etafilcon A contact lenses worn bilaterally on a daily wear, daily disposable basis for 4 weeks
88837795|NCT04055675||Asymptomatic Male Volunteers|These are subjects over the age of 18 who have no acute symptoms, volunteered to provide a urine sample, and are male.
88837796|NCT04055675||Asymptomatic Female Volunteers|These are subjects over the age of 18 who have no acute symptoms, volunteered to provide a urine sample, and are female.
88837797|NCT04831944|Experimental|Treatment Group 1 : Severe hepatic impairment|Child Pugh (CP) assessment score of 10-14 points
88837798|NCT04831944|Experimental|Treatment Group 2 : Moderate hepatic impairment|Child Pugh (CP) assessment score of 7-9 points
88837799|NCT04831944|Experimental|Treatment Group 3 : Mild hepatic impairment|Child Pugh (CP) assessment score of 5-6 points
88837800|NCT04831944|Experimental|Treatment Group 4 : Normal hepatic impairment|Normal hepatic function
88837801|NCT02974712|Experimental|Fentanyl|After routine Induction, fentanyl was administrated.
88837802|NCT02974712|Placebo Comparator|Saline|After routine Induction, same volume saline was administrated.
88837803|NCT04526340|Experimental|Nutrient day|on the nutrient day the subjects will take the testing food/nutrient capsules with 500 ml water
88837804|NCT04526340|Placebo Comparator|Control day|on the control day the subjects will take 500 ml water without nutrient/food capsules
88837805|NCT02974556|Active Comparator|Standard surgical treatment group|"Colon cancer patients (high-risk T3 and T4) without peritoneal or systemic metastases are resected for cure.~Standard adjuvant systemic chemotherapy (FOLFOX or CAPOX regimens for 6 months) will be reserved in pT3 tumors with poor prognostic factors, pT4 tumor and if lymph-nodes metastases are present. Presence or absence of peritoneal recurrence will be evaluated by MDCT."
88837806|NCT02974556|Experimental|Proactive management group|"Colon cancer patients (high-risk T3 and T4) without peritoneal or systemic metastases are resected for cure. Simultaneously patients will undergo infracolic omentectomy, appendectomy, exeresis of the liver round ligament and, in women, a bilateral oophorectomy. At the end of surgical procedure HIPEC will be performed with oxaliplatin 460 mg/m2 and before the beginning of HIPEC an intravenous infusion of 400 mg/m2 of 5-FU and 20 mg/m2 of leucovorin will be administered.~Standard adjuvant systemic chemotherapy (FOLFOX or CAPOX regimens for 6 months) will be reserved in pT3 tumors with poor prognostic factors, pT4 tumor and if lymph-nodes metastases are present. Presence or absence of peritoneal recurrence will be evaluated by MDCT."
89366296|NCT05007639||Patients diagnosed AFTER implementation of the public health intervention program|"Same eligibility criteria as for the group before implementation of the public health intervention program, except that patients were diagnosed between 1 November 2008 and 31 December 2009."
88837807|NCT04523142|Experimental|CyclASol Ophthalmic Solution|Cyclosporine A solution in vehicle
89366297|NCT05198115|Active Comparator|Aerobic group|The intervention consisted of aerobic exercise training, which was taught to participants face-to-face at a meeting. At the end of the session, we provided the intervention group with CDs and educational posters containing all the exercises
88837808|NCT04538456||used electronic Patient Reported Outcome Measures|Lung cancer patients who have used the electronic Patient Reported Outcome Measures system before and after COVID-19 lock down or new patients who have completed their first electronic Patient Reported Outcome Measures after COVID-19 lock down.
88837809|NCT04538456||never used electronic Patient Reported Outcome Measures|Lung cancer patients who have never completed electronic Patient Reported Outcome Measures.
88837810|NCT04819152||Exposed|Several studies will be performed based on this cohort. I each study the exposed group will be a group of tobacco users evaluatedin the relevant study. This could be a vulnarable group tobacco users such as: users without a job, with short or no education, without permanent housing, diagnosed with mental illness, diagnosed with chronic obstructive pulmonary disease (COPD), undergoing surgery, adolescents, elderly, migrants, or pregnant women.
88837811|NCT04819152||Unexposed|In each study the unexposed group will consist of tobacco user from the study cohort without the condition examined in the relevant study.
88837812|NCT03557333|Experimental|INP104|24-week treatment period for all participants followed by a 28-week treatment extension period for a subset of participants
88837813|NCT04537520|Experimental|Experimental Group|treatment with the device Kerecis Omega3 Wound
88837814|NCT04537520|No Intervention|Control Group|treatment with SOC treatment
88837815|NCT04050605|Experimental|somofilcon A toric (habitual), then fanfilcon toric (test)|Participants are habitual wearers of somofilcon A toric lens and refitted with fanfilcon A toric lens.
88837816|NCT04818450|Experimental|Gabapentin|Start gabapentin 100 mg at 9.00 PM on the second night of ICU admission and titrate gabapentin dose as needed. Maximum gabapentin dose in this study is 300 mg/day.
88837817|NCT04818450|No Intervention|Standard care|Not receiving gabapentin.
88837818|NCT02974790||Circulatory failure|Patients with a circulatory failure due to a sepsis or not
88837819|NCT04035161|Experimental|Investigational Product|Skin will be prepared with investigational product
89366298|NCT05198115|Placebo Comparator|Eight Weeks of Aerobic Exercise|The control group was subjected to all the pre-and post-assessments but were not asked to perform the exercise intervention. Instead, we phone-called them to give a reminder for filling out the questionnaires.
89366299|NCT04813107|Active Comparator|APL-1202 in combination with tislelizumab|
88837820|NCT04035161|Other|Reference Standard|Skin will be prepared with reference standard
88837821|NCT04035161|Active Comparator|Active Control|Skin will be prepared with active comparator
88837822|NCT04035161|Other|Negative Control|Skin will be prepared with negative control
88837823|NCT05369286|Experimental|dose level 1 of max-40279 combined dose level 1 of toripalimab|"MAX-40279-01 and toripalimab"
89366300|NCT04813107|Placebo Comparator|Tislelizumab alone|
89366301|NCT01340391|Experimental|splinting method|A new splinting method has been invented. This is a study using the splint / cast in treatment of distal radius fractures.
88837824|NCT05369286|Experimental|dose level 2 of max-40279 combined dose level 1 of toripalimab|"MAX-40279-01 and toripalimab"
88837825|NCT05369286|Experimental|dose level 2 of max-40279 combined dose level 2 of toripalimab|"MAX-40279-01 and toripalimab"
88837826|NCT05369286|Experimental|dose level 3 of max-40279 combined dose level 2 of toripalimab|"MAX-40279-01 and toripalimab"
88837827|NCT05369286|Experimental|recommend dose of max-40279 combined recommend dose level of toripalimab|"MAX-40279-01 and toripalimab"
88837828|NCT04037969|Experimental|Nesofilcon A/Delefilcon A|Nesofilcon A was worn in right eye and delefilcon A worn in the left eye.
88837829|NCT04037969|Experimental|Delefilcon A/Nesofilcon A|Delefilcon A was worn in right eye and Nesofilcon A worn in the left eye.
89366302|NCT02714062|Placebo Comparator|Placebo|Days 1-56: Placebo
89366303|NCT02714062|Experimental|VI-0521 Mid Dose|"Days 1-14: VI-0521 (Phentermine/Topiramate 3.75 mg/23 mg)~Days 15-56: VI-0521 (Phentermine/Topiramate 7.5 mg/46 mg)"
88837830|NCT03583814|Active Comparator|CASE Program only|"During the Active Trial Phase, families of children with asthma status defined as not well controlled will complete the CASE program. Outcomes for participants assigned to the CASE program will be compared in a pre-post within subject comparison. Regardless of intervention arm assignment, children are expected show improvement in asthma outcomes. The stepped wedge trial design of the overall study allows for comparison of outcomes of communities in the pre-active trial baseline control period, active trial phase, and post-active trial phase follow-up period."
89178952|NCT00806156|Experimental|NKTR-102 q14d|NKTR-102 was administered as an intravenous (IV) infusion over 90 ± 10 minutes, on Day 1 of each 2-week [± 2 days] cycle at a dose of 170 mg/m^2 for the first 4 patients enrolled and at a dose of 145 mg/m^2 for the remainder of the patients.
88837831|NCT03583814|Active Comparator|CASE and HARP Programs|"During the Active Trial Phase, families of children with asthma status that is defined as poorly controlled will complete the CASE and HARP programs. Outcomes for participants assigned to this arm (CASE and HARP) will be compared in a pre-post within subject comparison. Regardless of intervention arm assignment, children are expected show improvement in asthma outcomes. The stepped wedge trial design of the overall study allows for comparison of outcomes of communities in the pre-active trial baseline control period, active trial phase, and post-active trial phase follow-up period."
88837832|NCT03583814|No Intervention|Standard Care|Cluster-based randomization in the Stepped Wedge Trial allows for comparison of Community Based Outcomes for clusters (communities defined by school catchment areas) who are not yet in the active trial phase and are receiving Standard of Care at that time.
88837833|NCT04508192|Experimental|Copenhagen Adduction|The CA is a high-intensity partner exercise where the player is lying on their side using the elbow of the lower forearm to support their body and the other arm placed along their body. The upper arm is supported by the partner who places their one hand under the knee and the other under the ankle, holding the leg approximately in the height of their hip. The player performs a 3-second concentric movement lifting their body until it reaches a straight line. At the same time, the other leg is adducted so that it touches the other leg. A 3-second eccentric adduction then follows with the body lowered halfway to the ground and the foot of the lower leg touching the ground without supporting the body.
88837834|NCT04508192|Active Comparator|Adductor Squeeze|The SQ exercise is an isometric hip adduction exercise with the player holding a ball between their knees. The player lies supine with the ball placed between the knees with the knees and hips flexed and the feet flat on the surface with the first toe is pointed straight forward.the player is asked to press against the ball as hard as they can The contraction is held for 10 seconds
88837835|NCT03718871|Experimental|Healer HIV testing intervention|We will follow Ugandan National protocols to administer voluntary HIV testing at 9 TH practice locations throughout Mbarara District over a 9 month period.
88837836|NCT03718871|No Intervention|Healer control arm|Patients will undergo protcolized usual TH care at 8 practices, which include HIV education and a referral to receive VCT through existing resources. Study staff will contact the client at 3 months following enrollment to assess for self-report of VCT.
88837837|NCT05448872||Sacubitril/Valsartan|Heart Failure (HF) patients treated with Sac/Val
88837838|NCT00362726|Active Comparator|A|
88837839|NCT00362726|Active Comparator|B|
88837840|NCT00362726|Active Comparator|C|
88837841|NCT00362726|Active Comparator|D|
88837842|NCT00362726|Active Comparator|E|
88837843|NCT04011774|Experimental|PLANI-REV|Persons with schizophrenia who will benefit from the fifteen weekly sessions of PLANI-REV group program
88837844|NCT04011774|Active Comparator|RELAXATION|Persons with schizophrenia who will benefit from a non cognitive stimulation, namely RELAXATION, in a day-care clinic or day-care therapeutic activities center during fifteen weekly sessions. This activity will be 15 groups sessions of relaxation.
88837845|NCT03530072||Cases|Subjects with Fever and Neutropenia
88837846|NCT04471194|Experimental|Self-Sampling Intervention|Participants in this group will receive cervical and colorectal cancer self-sampling kits, instructions for completing the self-sampling kits, and educational materials about cervical and colorectal cancer.
88837847|NCT04471194|No Intervention|Control|Participants in this group will receive a standardized letter informing them that they are out-of-date for both cervical and colorectal cancer screenings and should schedule an appointment with their provider to receive these screenings.
88837848|NCT04467996|Active Comparator|6 hour IUBT placement|
88837849|NCT04467996|Active Comparator|18 hour IUBT placement|
88837850|NCT03261206|No Intervention|5-ASA Continuation|Half of the subjects will continue on aminosalicylate therapy using the same dose and brand for the duration of the study
88837851|NCT03261206|Experimental|5-ASA Withdrawal|Half of the subjects will discontinue their aminosalicylate therapy
88837852|NCT05330754||Control group|No caffeine intake
88837853|NCT05330754||Safe level Group|Caffeine daily intake ≤200 mg/day
88837854|NCT05330754||Unsafe level group:|Caffeine daily intake >200 mg/day
88837855|NCT02374112|Experimental|Experimental|Creatine supplementation
88837856|NCT02374112|Placebo Comparator|Control|Placebo supplementation
88837857|NCT03506672|Experimental|Experimental group|Approach based on the meanings of vocal behaviours
88837858|NCT03506672|Active Comparator|Control group|Usual practices of formal caregivers regarding vocal behaviours
88837859|NCT03251378|Experimental|3 mg Dose Escalation|3 mg of Fruquintinib (HMPL-013), tablet taken daily, 3 weeks on, 1 week off
88837860|NCT03251378|Experimental|5 mg Dose Escalation|5 mg of Fruquintinib (HMPL-013), tablet taken daily, 3 weeks on, 1 week off
88837861|NCT03251378|Experimental|Fruquintinib Expansion Cohort A|5 mg fruquintinib (HMPL-013) tablet taken daily, 3 weeks on, 1 week off in patients with advanced solid tumors.
88837862|NCT03251378|Experimental|Metastatic Colorectal Cancer Expansion Cohort B|5 mg fruquintinib (HMPL-013) tablet taken daily, 3 weeks on, 1 week off in patients with metastatic colorectal cancer who have progressed on or had intolerable toxicity to TAS-102, regoragenib, or both.
88837863|NCT03251378|Experimental|Metastatic Colorectal Cancer Expansion Cohort C|5 mg fruquintinib (HMPL-013) tablet taken daily, 3 weeks on, 1 week off in patients with metastatic colorectal cancer who have not been treated with TAS-102 or regorafenib.
88837864|NCT03251378|Experimental|Metastatic Breast Cancer Expansion Cohort D|5 mg fruquintinib (HMPL-013) tablet taken daily, 3 weeks on, 1 week off in patients with metastatic Her2-negative, hormone receptor positive breast cancer.
88837865|NCT03251378|Experimental|Metastatic Breast Cancer Expansion Cohort E|5 mg fruquintinib (HMPL-013) tablet taken daily, 3 weeks on, 1 week off in patients with metastatic triple negative (Her2-negative, ER-negative, PR-negative) breast cancer.
88837866|NCT03752177|Experimental|LY3415244 Dose Escalation|Participants received 3 milligrams (mg) LY3415244 (Cohort A1), 10 mg LY3415244 (Cohort A2), 30 mg LY3415244 (Cohort A3) and 70 mg LY3415244 (Cohort A4) as an intravenous (IV) infusion on day (D)1 and D15 of each 28-day cycle every 2 weeks (Q2W).
89178953|NCT00806156|Experimental|NKTR-102 q21d|NKTR-102 was administered as an IV infusion over 90 ± 10 minutes, on Day 1 of each 3-week [± 2 days] cycle at a dose of 170 mg/m^2 for the first 6 patients enrolled and at a dose of 145 mg/m^2 for the remainder of the patients.
89366304|NCT02714062|Experimental|VI-0521 Top Dose|"Days 1-14: VI-0521 (Phentermine/Topiramate 3.75 mg/23 mg)~Days 15-28: VI-0521 (Phentermine/Topiramate 7.5 mg/46 mg)~Days 29-42: VI-0521 (Phentermine/Topiramate 11.25 mg/69 mg)~Days 43-56: VI-0521 (Phentermine/Topiramate 15 mg/92 mg)"
89366305|NCT01315587|Active Comparator|intermittent theta burst stimulation|
89366306|NCT01315587|Active Comparator|repetitive Transcranial Magnetic Stimulation|
88837867|NCT03752177|Experimental|LY3415244 Dose Expansion|Phase 1b dose expansion was planned but not initiated as dose escalation ended at cohort A4. Study did not achieve its primary objective of establishing a recommended phase 2 dose (RP2D) due to early termination of the study by Cohort A4.
88837868|NCT02271932||Surgery|Surgical management with appendectomy consists of hospital admission with initiation of intravenous antibiotics and urgent appendectomy .
88837869|NCT02271932||Non-operative|Non-operative management consists of hospital admission for observation with a minimum of 24 hours of intravenous antibiotics and a minimum of 12 hours nil per os (NPO). With clinical improvement, patients are switched to oral antibiotics and discharged home with a prescription for oral antibiotics to complete a total antibiotic course of 7 days (including the duration of intravenous antibiotics).
88837870|NCT01601496|Experimental|FUSION Vascular Graft|All subjects who received a FUSION Vascular Graft at the baseline implant procedure.
88837871|NCT03224858|Experimental|SUMMIT intervention group|This group will transfer primary care to the SUMMIT team, which consists of: 1 primary care provider, 1 clinical nurse, 1 team manager, 2 care-coordinators, 2 behavioralists, 1 clinical pharmacist. This interdisciplinary team will have reduced patient panel load and increased flexibility in time and scheduling in order to foster trust and continuity with the patient with a goal of decreasing treatment burden and increasing patient capacity. Specific activities that participants will receive include: 1) comprehensive initial intake and care plan development that incorporates patient goal setting; 2) flexible scheduling of appointments with outreach; 3) transitional care coordination; 4) built-in behavioural counselling and case management; 5) regular review of care plan by team members.
88837872|NCT03224858|Active Comparator|enhanced usual care group|This group will continue to receive primary care as usual for 6 months. This includes care provided by the patient's existing primary care provider, access to a clinic's Health Resilience outreach worker, mental health consultation, and other services provided by usual care. After 6 months, the baseline survey is administered and the participant will transfer care to the intervention as described above in the SUMMIT intervention group.
88837873|NCT03211832|No Intervention|Control|The control group will conduct usual public health practice.
88837874|NCT03211832|Active Comparator|Intervention|Participating local health departments will help develop and choose several dissemination activities they prefer for their local health department to receive. Dissemination activities may include multi-day in-person training workshops, electronic information exchange modalities, remote technical assistance, and information on ways to enhance organizational climates favorable to evidence-based diabetes and chronic disease prevention and control.
88837875|NCT04887948|Experimental|Coadministration Group|Participants receive an injection of pneumococcal vaccine (20vPnC) and of COVID-19 vaccine (BNT162b2) at the same visit.
88837876|NCT04887948|Active Comparator|20vPnC-only Group|Participants receive an injection of pneumococcal vaccine (20vPnC) and of saline at the same visit.
88837877|NCT04887948|Active Comparator|BNT162b2-only Group|Participants receive an injection of COVID-19 vaccine (BNT162b2) and of saline at the same visit.
88837878|NCT04882800|Experimental|First Intervention|Participants will be fit with currently available Lyric extended wear hearing aid device A in right ear and Lyric extended wear hearing aid with fitting modification device B in left ear for 14 days (Day 1 - Day 14 of study). They will then switch and be fit with Lyric extended wear hearing aid with fitting modification device B in the right ear and the commercially available Lyric device A in the left ear for 14 days (Day 15-Day 28 of study)
88837879|NCT04854564||End-stage liver disease (ESLD) patients|These potential liver transplant candidates are patients with end-stage liver disease (ESLD) who have been assigned to the liver transplant waitlist.
89366307|NCT01315587|Placebo Comparator|Sham TMS|
89366308|NCT04782063|No Intervention|No Intervention: Standard Infant Feed Group|Infants will receive human milk or formula milk ad libitum.
88837880|NCT04854564||Caregivers of potential liver transplant candidates|They are the primary caregivers for the patients.
88837881|NCT03799289|Experimental|Iyengar Yoga|Participants randomized to the yoga intervention arm will receive 12 weeks of group-based yoga instruction, following a 12-week standard behavioral weight loss program. Group-based yoga instruction will occur twice per week and classes will be 60 minutes in duration. The yoga program will consist of breathing, postural, and meditation practices and home-based yoga practice will also be prescribed.
88837882|NCT03799289|Active Comparator|Cooking/dietary education|Participants randomized to the cooking/dietary education intervention arm will receive 12 weeks of group-based, cooking/dietary education instruction, following a 12-week standard behavioral weight loss program. This group-based instruction will occur twice per week and classes will be 60 minutes in duration. Classes will focus on providing basic nutrition knowledge and culinary skills, and will include cooking demonstrations.
88837883|NCT04851444|Experimental|SI-F019|SI-F019 administered intravenously (IV).
89366309|NCT04782063|Other|Calibrated Infant Feed Group|Infants will have reduced human milk or formula milk intake.
89366310|NCT03268564|Experimental|HIVST-online promotion|"Health promotion for those who are not users of previous HIVST-online services (i.e. not re-testers):~Viewing a promotion video and a demonstration video~Brief motivational interviewing through telephone~Visiting the HIVST-online webpage~Receiving a free self-testing kit and follow-up reminders~Health promotion for re-testers:~Viewing a promotion video and a demonstration video~Visiting the HIVST-online webpage~Receiving a free self-testing kit and follow-up reminders"
89366311|NCT03280342|Active Comparator|IR-TPM (Topamax)|IR-TPM (Topamax)
89366312|NCT03280342|Active Comparator|XR-TPM (Trokendi XR)|
89366313|NCT04966689|Experimental|combined speech and music therapy|the telerehabilitation intervention that include both speech therapy and music therapy at the same time
89366314|NCT04966689|Active Comparator|speech therapy|A behavioural speech therapy program including breathing exercises, loudness, pitch, and intelligibility which are adapted from Lee Silverman Voice Treatment (LSVT) and voice exercises Which is delivered through telerehabilitation
89366315|NCT04966689|Active Comparator|music therapy|music exercises Will be designed based on the music therapy protocols of previous studies Which is delivered through telerehabilitation
89366316|NCT03280186|Experimental|Patients With SVMs|Patients with SVMs will be included in the group and undergo surgery.
88837884|NCT03810053|Experimental|Mobile App/Online Module|Subjects will watch a short video containing information about cancers and benefits of uptake cancer prevention and early detection measures. Information regarding gender, age, smoking status, BMI and positive cancer history in family will be captured. Subjects will be provided with a list of cancer prevention and early detection measures based on the responses provided.
88837885|NCT03829488|Experimental|Plasma-Lyte 148 (approx. pH 7.4) IV Infusion|Plasma-Lyte 148 (approx. pH 7.4) IV Infusion intravenous fluid therapy will be used for all maintenance, replacement and resuscitation purposes from randomization onwards until 48 hours post-transplant, or until fluid therapy is no longer required, if earlier.
88837886|NCT03829488|Active Comparator|0.9% SODIUM CHLORIDE 9g/L injection BP|0.9% saline intravenous fluid therapy will be used for all maintenance, replacement and resuscitation purposes from randomization onwards until 48 hours post-transplant, or until fluid therapy is no longer required, if earlier.
88837887|NCT03883607|Experimental|Elafibranor 80 mg|Participants received Elafibranor 80 mg tablet orally once daily for 12 weeks.
88837888|NCT03883607|Experimental|Elafibranor 120 mg|Participants received Elafibranor 120 mg tablet orally once daily for 12 weeks.
89366317|NCT01315743|Experimental|Intervention|
89366318|NCT05155839|Experimental|MRG001|All patients in Phase Ia (dose escalation) and Phase Ib (dose expansion) will be administrated MRG001 on Day 1 of every 3 weeks (21-day cycle).
88837889|NCT04846296||study group|Between 10-16 years old Cobb angle 10-40 degrees Being treated with conservative treatment (brace- exercise) for scoliosis Accepted to answer the questionnaire
88837890|NCT03805308|No Intervention|Medical Management|Patients randomized to the medical therapy arm will receive standard medical therapy based on current AHA guidelines.
88837891|NCT03805308|Experimental|Intra-arterial Therapy|For patients randomized to the intra-arterial therapy arm, sites will use local protocols for femoral access, sedation, heparin infusion, monitoring, etc. Mechanical thrombectomy will be performed with FDA-approved thrombectomy devices in accordance with the IFU.
89366319|NCT03268642||Life-support Based Comprehensive Treatment Regimen group|"meet all the following conditions:~intravenous immune globulin;~large dose of glucocorticoids;~mechanical ventilation;~hemodynamic support: intra-aortic balloon pump (IABP) or/and extracorporeal membrane oxygenation (ECMO);~continuous renal replacement therapy."
88837892|NCT04826796|Experimental|Whatsapp intervention group|In addition to standard care, participants will be included into a peer support Whatsapp group on Whatsapp with other participants and trained peer supporters after study entry. Standard weekly prompt text messages will be sent to the group by peer supporters to encourage questions and discussion related to breastfeeding. Peer supporters will provide breastfeeding and emotional support. Intervention will last for 6 months after birth.
88837893|NCT04826796|No Intervention|Control group|Participants in the control group will continue to receive standard care.
88837894|NCT03926039|Experimental|sharing decision-making program interventions|"Description of conventional traditional treatment options and add sharing decision-making program The intervention measures in this study sharing decision-making plan mainly includes sharing the decision-making talks and the decision-making assistance tools used in the process."
88837895|NCT03926039|No Intervention|Description of traditional treatment options|Description of conventional traditional treatment options
88837896|NCT04393662||Tenodesis group|Tenodesis as surgical treatment option for a lesion of the long head of the biceps tendon (LHBT)
88837897|NCT04393662||Tenotomy group|Tenotomy as surgical treatment option for a lesion of the long head of the biceps tendon (LHBT)
88837898|NCT04000373|Other|gait training with exoskeleton device|uncontrolled pre-post intervention study of gait training using the Ekso GT™exoskeleton
88837899|NCT04049123|Active Comparator|Insulin Lispro (Humalog)|15 units (U) Insulin Lispro (Humalog) administered once, subcutaneously (SC), in one of three study periods.
88837900|NCT04049123|Experimental|LY900014|7 U, and 15 U LY900014 administered once, SC, in two of three study periods.
88837901|NCT04382196||Health care workers|Health care workers at university hospital
89366320|NCT03268642||conventional therapy group|"meet one of the following conditions:~without/insufficient intravenous immune globulin;~without/with various doses of glucocorticoid ;~vasoactive drug;~without/delayed mechanical ventilation;~without/delayed hemodynamic support;~without/delayed continuous renal replacement therapy."
88837902|NCT04051463|Active Comparator|Netarsudil|A drop of Netarsudil 0.02% ophthalmic solution will be instilled into both eyes once daily at night.
88837903|NCT04051463|Placebo Comparator|Placebo|A placebo eye drop, consisting of the vehicle for netarsudil ophthalmic solution without the active ingredient, will be instilled into both eyes once daily at night.
88837904|NCT04826328|Experimental|FX301 Low Dose Low Volume|65 mg of funapide given as a single injection nerve block adjacent to the sciatic nerve of the popliteal fossa
89366321|NCT03279796|Experimental|Autologous adipose-derived MSCs|The dose of adipose-derived mesenchymal stem cells was related to body weight, and 1 × 10 ^ 6 cells were a unit. One unit of adipose-derived mesenchymal stem cells was injected every 10 kg of body weight and injected once a week for three times.
89366322|NCT03279796|Active Comparator|Compound betamethasone|1ml dexamethasone mixed with 0.5-2ml of saline to achieve the same injection volume with the cell suspension (which contains betamethasone dipropionate 5mg and betamethasone sodium phosphate 2mg) ), once a week for three times.
89366323|NCT05250219||patients for tonsils|40 patients for tonsils
88837905|NCT04826328|Experimental|FX301 Low Dose High Volume|130 mg of funapide given as a single injection nerve block adjacent to the sciatic nerve of the popliteal fossa
88837906|NCT04826328|Experimental|FX301 High Dose Low Volume|130 mg of funapide given as a single injection nerve block adjacent to the sciatic nerve of the popliteal fossa
88837907|NCT04826328|Experimental|FX301 High Dose High Volume|260 mg of funapide given as a single injection nerve block adjacent to the sciatic nerve of the popliteal fossa
88837908|NCT04826328|Placebo Comparator|Normal Saline|Low or high matching volume of preservative-free normal saline given as a single injection adjacent to the sciatic nerve of the popliteal fossa
88837909|NCT04054661|Other|G6PD Diagnostic Testing|"Participants provided whole blood samples as well as fingerstick capillary blood samples.~At the clinic site lab, study staff conducted the SD Biosensor STANDARD point-of-care G6PD test and the point-of-care HemoCue hemoglobin test on both finger stick blood and whole blood samples.~At the reference laboratory, G6PD activity was measured from whole blood samples using the Pointe Scientific G6PD reference assay and hemoglobin was measured using a hematology analyzer."
88837910|NCT04132973|Experimental|Compassion guided self-help|Participants will engage in a six-week online compassion-based self-help programme with email guidance from the researcher.
88837911|NCT04184297||Subjects initiated with Tiotropium and Olodaterol (Tio+Olo)|
88837912|NCT04184297||Subjets initiated with LABA/LAMA/ICS|Long-acting beta2/ Long-acting muscarinic antagonists/Inhaled corticosteriods
88837913|NCT04713839||Participants|The participants were invited to the study, then each participant was asked to complete the self-report questionnaires.
89366324|NCT05250219||patients for appendixes|40 patients for appendixes)
89366325|NCT03263494|Active Comparator|CGM|
89366326|NCT03263494|No Intervention|BGM|
88837914|NCT04031885|Experimental|Abemaciclib + Fulvestrant|150 milligram (mg) Abemaciclib given orally twice a day (BID) with 500 mg fulvestrant given by intramuscular (IM) injection on Cycle 1 Day 1 (C1D1) and Cycle 1 Day 15 (C1D15), then Day 1 of each subsequent cycle.
88837915|NCT04031885|Active Comparator|Standard Chemotherapy|Standard chemotherapy of physician's choice (capecitabine, docetaxel, nab paclitaxel, or paclitaxel), administered according to product label.
88837916|NCT04029545|Experimental|PN40082|PN40082 (manufactured by Prollenium Medical Technologies) is a clear, colorless gel in 1.0 mL pre-filled syringes with 25 mg/mL of stabilized hyaluronic acid and lidocaine 0.3% w/w. The study device will be provided by the Sponsor.
88837917|NCT04029545|Active Comparator|RV001 with lidocaine cream|RV001 (manufactured by Prollenium Medical Technologies) is a clear, colorless gel in 1.0 mL pre-filled syringes with 25 mg/mL of stabilized hyaluronic acid to be used with LMX4, a topical lidocaine. The study device will be provided by the Sponsor. LMX4 will be provided in commercial stock packaging by the Sponsor
89178954|NCT00764478|Experimental|Asenapine 5 mg BID|Participants were administered one 5 mg asenapine tablet, sublingually BID for 21 days
89366327|NCT03151395|Other|Total Group|Moderate to very severe Chronic Obstructive Pulmonary Disease (COPD) patients with at least 1 documented moderate or severe Acute exacerbation of COPD (AECOPD) in the year before enrolment and for whom sputum and blood samples are collected during specified visits
89366328|NCT03279172|Experimental|Group Direct Laryngoscope|direct laryngoscope (macintosh laryngoscope) is used in elective surgeries with maximal duration time for two hours. Standard anaesthesia was used on group and BIS monitorisation was applied. A record was made of IOP, hemodynamic changes and oxygen saturation at 3 and 10 minutes after intubation. Throat pain was evaluated by questioning the patient at 10 minutes and 24 hours after waking from general anaesthesia. The duration of intubation was recorded as the time from the laryngoscope entering the mouth to removal with end-tidal carbon dioxide on the monitor. Macintosh laryingoscope, BIS monitoring and tonometry would be used in Group Direct Laryngoscope.
89366329|NCT03279172|Experimental|Group videolaryngoscope|Videolaryngoscope is used in elective surgeries with maximal duration time for two hours. Standard anaesthesia was used on group and BIS monitorisation was applied. A record was made of IOP, hemodynamic changes and oxygen saturation at 3 and 10 minutes after intubation. Throat pain was evaluated by questioning the patient at 10 minutes and 24 hours after waking from general anaesthesia. The duration of intubation was recorded as the time from the laryngoscope entering the mouth to removal with end-tidal carbon dioxide on the monitor. Video laryingoscope, BIS monitoring and tonometry would be used in Group Video Laryngoscope.
89366330|NCT03278392|Experimental|Psychosocial challenge task|Participants will be assigned to complete the Trier Social Stress Test (TSST) immediately after consuming a standardized breakfast drink
88837918|NCT04029545|Experimental|RV001|RV001 (manufactured by Prollenium Medical Technologies) is a clear, colorless gel in 1.0 mL pre-filled syringes with 25 mg/mL of stabilized hyaluronic acid to be used alone. The study device will be provided by the Sponsor.
88837919|NCT04029311|Experimental|Combination Therapy with Preferred Mask|Preferred Mask refers to a type of existing medical mask used for PAP therapy.
89366331|NCT03278392|Sham Comparator|Placebo challenge task|Participants will be assigned to complete the placebo non-stress task immediately after consuming a standardized breakfast drink
89366332|NCT01340469|Active Comparator|study|Probiotics supplementation .
89366333|NCT01340469|Placebo Comparator|control|The control group received daily placebo liquid .
88837920|NCT04029311|Experimental|Combination Therapy with Custom Mask|Custom Mask refers to a mask which is supported by an interface which attaches directly to the patient's oral appliance.
88837921|NCT01638000|Experimental|Mirabegron 50 mg|Participants who received mirabegron 50 mg once daily for 12 weeks.
88837922|NCT01638000|Active Comparator|Solifenacin 5 mg|Participants who received solifenacin 5 mg once daily for 12 weeks.
88837923|NCT04023695|Active Comparator|Corticosteroid with lidocaine with epinephrine|This arm includes an injection mixture of corticosteroid and lidocaine with epinephrine
88837924|NCT04023695|Experimental|Corticosteroid with normal saline|This arm includes a mixture of corticosteroid and normal saline. The purpose of normal saline is the keep the volume and concentration similar when compared to the injections containing lidocaine.
89178955|NCT00764478|Experimental|Asenapine 10 mg BID|Participants were administered one 10 mg asenapine tablet, sublingually BID for 21 days
89366334|NCT02713828|Experimental|Phase I: Glembatumumab Vedotin|Glembatumumab vedotin once every three weeks (q3w) by 90-minute intravenous (IV) infusion, until disease progression or intolerance. The Dose-Limiting Toxicity (DLT) evaluation period for determination of the appropriateness of dose-escalation will be through the end of the second treatment cycle.
89366335|NCT02713828|Experimental|Phase II: Glembatumumab Vedotin|Glembatumumab vedotin once every three weeks (q3w) by 90-minute intravenous (IV) infusion, until disease progression or intolerance. The Maximum Tolerated Dose (MTD) determined in Phase I will be used in Phase II.
89366336|NCT05183997|Placebo Comparator|Group (A) : 30 patients (control group):|Patient will receive 20 to 30 ml bupivacaine plus 2 ml of normal saline .
89366337|NCT05183997|Experimental|Group (B) : 30 patients (verapamil group):|Patient will receive 20 to 30 ml bupivacaine plus 5 mg of verapamil diluted in 2 ml of normal saline.
89366338|NCT05119101|Active Comparator|Magnesium sulphate|patients will recieve Mg sulphate as loading dose of 4 g diluted in 200 ml normal saline intravenous over 10 minutes followed by 1 g/h infusion for 24 h.
89366339|NCT05119101|Active Comparator|Dexamedotomidine adjuvant to Magnesium sulphate|Patients will reccieve Mg sulphate as loading dose of 4 g diluted in 200 ml normal saline intravenous over 10 minutes followed by 1 g/h infusion for 24 h. in addition they will receive an intravenous infusion of dexmedetomidine .5 μg/kg diluted in 200 ml normal saline intravenous over 10 minutes followed by .15 μg/kg/hr infusion for 24 h.
89366340|NCT03268252||2x/year MDA|Diethylcarbamazine 6 mg/kg + Albendazole 400 mg given twice per year
89366341|NCT03268252||1x/year MDA|Diethylcarbamazine 6 mg/kg + Albendazole 400 mg given once per year
89366342|NCT03268486||Triple monitoring|Pregnant women with singleton term pregnancies, spontaneous or induced/augmented labor, cephalic presentation, > 18 years of age, able to provide written informed consent, no contraindications to internal FHR monitoring and no known contraindication to vaginal delivery. After giving written informed consent, women will be simultaneously monitored with scalp electrode, Doppler, trans-abdominal ECG, abdominal EHG and TOCO, as soon as internal monitoring is possible.
89366343|NCT01340547|Other|Single Arm|Single Arm, non-blinded, non-randomized
89366344|NCT03268408||Intervention|"Intervention aimed at improving self-efficacy parenting which consists in sending to new parents, during the first year of life of their son, eight newsletters with advices and recommendations on child care and development (project Baby Newsletter)."
89366345|NCT03268408||Control|Usual care
89366346|NCT01340703|Other|optic disc pit maculopathy|
89366347|NCT03263182||Nchelenge Facilities|Purposively selected health facilities based on criteria including: high demand for services, perceived need for support for quality improvement, and presence of a SBA to mentor.
89366348|NCT05002881|Active Comparator|Moringa oleifera (E-HS-01)|One capsule to be taken stat
89366349|NCT05002881|Placebo Comparator|Placebo|One capsule to be taken stat
89366350|NCT02458300|Placebo Comparator|Control Arm|Nebulized hypertonic saline. Aspiration of secretions
89366351|NCT02458300|Active Comparator|Intervention Arm.|Nebulization of hypertonic saline. Application of Prolonged slow expiration technique (PSE) expiratory volume. Patient coughing Provocation (TP) Inspiratory maneuver to rhinopharyngeal cleaning DRR Aspiration of secretions
89366352|NCT02456818||Centers using contact isolation|"Isolation triggered by the detection of ESBL-EC at hospital admission in surveillance screening or during the hospitalization by weekly screening or clinical cultures~Contact isolation terminated, after at least two negative consecutive fecal screening cultures~Contact isolation resumed, if subsequent ESBL-EC positive cultures are identified for the same patient including readmissions~Contact isolation must include:~Patient placement in single rooms~Cohorting only possible, when no single rooms available and corresponding ESBL-EC strains are phenotypically identical~Staff and visitors wearing gloves and gowns as contact precautions when entering the room, patient when leaving the room"
88837925|NCT04013789|Other|DACP FreshTech, then DACP|DACP FreshTech contact lenses worn first, followed by DACP contact lenses, as randomized. Each product was worn in both eyes for approximately 8 hours per day for 1 week with a new pair of lenses worn each day.
88837926|NCT04013789|Other|DACP, then DACP FreshTech|DACP contact lenses worn first, followed by DACP FreshTech contact lenses, as randomized.. Each product was worn in both eyes for approximately 8 hours per day, for 1 week with a new pair of lenses worn each day.
88837927|NCT04211909|Experimental|SOF/VEL|Participants with chronic HCV infection (genotype 1 or 2), who are treatment-naive or treatment-experienced with interferon (IFN)-based treatments will receive SOF/VEL for 12 weeks.
88837928|NCT04211909|Experimental|SOF/VEL/VOX|Participants with chronic HCV infection (genotype 1), who are treatment-experienced with nonstructural protein 5A (NS5A) direct-acting antiviral (DAA)-based treatments of at least 4 weeks duration will receive SOF/VEL/VOX for 12 weeks.
88837929|NCT03559205|No Intervention|MSK-Tracker (before)|Before - (Usual care in clinic consultations)
88837930|NCT03559205|Active Comparator|MSK-Tracker (after)|After - (MSK-Tracker in clinic consultations)
88837931|NCT04223843|Experimental|Active Arm|Tiotropium + Olodaterol Fixed Dose Combination (FDC) via Respimat
88837932|NCT04223843|Placebo Comparator|Placebo Arm|Matching placebo via Respimat
88837933|NCT01637922|Active Comparator|Methadone group|patients on stable methadone therapy (at least 30 days) up to a maximum of 180mg per day
88837934|NCT01637922|Active Comparator|Buprenorphine|patients on stable buprenorphine/naloxone therapy (at least 30 days) up to a maximum dose of 24mg/6mg per day.
89366353|NCT02456818||Centers using no contact isolation|"not regularly isolating for ESBL-EC~ESBL-EC colonized or infected patients with urinary or fecal incontinence or diarrhea (>3 loose bowel movements/day) isolated in single rooms with above described contact precautions"
89366354|NCT03268174|Active Comparator|AO+Mist|AO+Mist
89366355|NCT03268174|Placebo Comparator|Placebo|Placebo
88837935|NCT05722951|Active Comparator|Control group|levetiracetam
88837936|NCT05722951|Experimental|Treatment group|metformin
89366356|NCT01340781||Hospitalized medical patients|"Adult age 18-65 years old admitted to the general medical floors at MetroHealth Medical Center who are expected to stay a minimum of 48 hours.~Potential subjects cannot have a known diagnosis of OSA, a tracheostomy, respiratory failure requiring noninvasive ventilation, currently pre or post surgical intervention, or clinically unstable patients with plans for transfer to a higher acuity of care or transferred from intensive care."
89366357|NCT03277222|Active Comparator|IN insulin 40 IU|Drug: IN insulin Dosage form: intranasal Dose: 40 IU Frequency: bid Duration: 16 weeks
89366358|NCT03277222|Placebo Comparator|IN Sterile Saline|Drug: Sterile Saline Dosage form: intranasal Frequency: bid Duration: 16 weeks
89001640|NCT00182780|Experimental|Arm I - American ginseng (low dose)|"Patients receive oral American ginseng twice daily for 8 weeks in the absence of unacceptable toxicity.~After 8 weeks of treatment, patients in arms I-III may continue to receive American ginseng on the optional continuation portion of the study for an additional 8 weeks. Patients in arm IV may begin oral American ginseng twice daily for 8 weeks on the optional continuation portion of the study.~Quality of life is assessed at baseline, every 2 weeks during treatment, and at the end of treatment.~PROJECTED ACCRUAL: A total of 280 patients (70 per treatment arm) will be accrued for this study within 35 months."
89001641|NCT00182780|Experimental|Arm II - American ginseng (mid-dose)|"Patients receive oral American ginseng at the mid-dose twice daily for 8 weeks in the absence of unacceptable toxicity.~After 8 weeks of treatment, patients in arms I-III may continue to receive American ginseng on the optional continuation portion of the study for an additional 8 weeks. Patients in arm IV may begin oral American ginseng twice daily for 8 weeks on the optional continuation portion of the study."
89001642|NCT00182780|Experimental|Arm III - American ginseng (high-dose)|"Patients receive oral American ginseng at the high dose twice daily for 8 weeks in the absence of unacceptable toxicity.~After 8 weeks of treatment, patients in arms I-III may continue to receive American ginseng on the optional continuation portion of the study for an additional 8 weeks. Patients in arm IV may begin oral American ginseng twice daily for 8 weeks on the optional continuation portion of the study."
89001643|NCT00182780|Other|Arm IV - Placebo|"Patients receive oral placebo twice daily for 8 weeks in the absence of unacceptable toxicity.~After 8 weeks of treatment, patients in arms I-III may continue to receive American ginseng on the optional continuation portion of the study for an additional 8 weeks. Patients in arm IV may begin oral American ginseng twice daily for 8 weeks on the optional continuation portion of the study."
89178956|NCT00764478|Placebo Comparator|Placebo BID|Participants were administered one asenapine-matched placebo tablet sublingually BID for 21 days
89366359|NCT01316679||group A|Patients with known HCC
89366360|NCT01316679||Group B|Patients with liver disease but no HCC
89366361|NCT01316679||Group C|Control; patients with no known liver disease or HCC
89366362|NCT03277144|Experimental|TST-TriStaple(3lines stapler)Technology|During gastrectomy for gatric cancer without anastomosis with the duodenum, Duodenal Stump is closed with a TriStaple (three-lines linear stapler) Technology device.
89366363|NCT03277144|Active Comparator|OCT (other conventional techniques)|During gastrectomy for gatric cancer without anastomosis with the duodenum, Duodenal Stump is closed with conventional techniques including manual sutures and devices with only two lines of staples.
89366364|NCT05387902||ECMO|Patients receiving hemodynamic support with ECMO during high-risk PCI
89366365|NCT05387902||ECMO Standby|Patients with ECMO standby during high-risk PCI
89366366|NCT04931667|Experimental|0.07 mg Lorecivivint|One intra-articular injection of 0.07 mg Lorecivivint in 2 ml vehicle in one or both knees as clinically indicated. Bilateral injection of 0.07 mg LOR are allowed.
89366367|NCT03262948|Experimental|nab-paclitaxel plus carboplatin|nab-paclitaxel 260mg/m2,i.v., plus carboplatin AUC = 6,i.v., starting from randomization, once every 3 weeks, for 4-6 cycles, or progression, or intolerance,or death or start a new anti-tumor treatment, whichever occurs first.
89366368|NCT03262948|Active Comparator|Paclitaxel plus carboplatin|paclitaxel 175 mg/m2,i.v., plus carboplatin AUC = 6,i.v., starting from randomization, once every 3 weeks, for 4-6 cycles, or progression, or intolerance,or death or start a new anti-tumor treatment, whichever occurs first.
89366369|NCT03276598|Active Comparator|Amlodipine|One of the four monotherapy treatment periods.
89366370|NCT03276598|Active Comparator|Bisoprolol|One of the four monotherapy treatment periods.
89366371|NCT03276598|Active Comparator|Hydrochlorothiazide|One of the four monotherapy treatment periods.
89366372|NCT03276598|Active Comparator|Losartan|One of the four monotherapy treatment periods.
89366373|NCT03276598|Placebo Comparator|Placebo|Placebo treatment period.
88837937|NCT04838652|Experimental|Pembrolizumab plus Chemotherapy|All patients will receive 1 dose of 200 mg pembrolizumab IV as single agent upfront, followed by 2 cycles of IV P-ICE (pembrolizumab, ifosfamide, carboplatin, etoposide) and a PET/CT-based restaging. Following a PET-guided treatment strategy, patients will then receive either another 2 cycles of IV P-ICE in case of a negative PET (i.e., Deauville score 1-3), or 2 to 4 cycles of IV P-DHAP (pembrolizumab, dexamethasone, cytarabine, cisplatin) in case of a positive PET (i.e., Deauville score > 3). After completion of treatment with P-ICE or P-DHAP, respectively, patients will receive a consolidation therapy with pembrolizumab for another 6 cycles. In case of non-CR after at least 4 cycles of combination therapy (4x P-ICE or 2x P-ICE + 2x P-DHAP), physicians may decide to go for HDCT or an alternative standard of care treatment option.
88837938|NCT05722795|Experimental|Short term Imatinib|Imatinib 400 mg x 1 for 10 days before surgery.
88837939|NCT05119699|Experimental|Active rTMS treatment|Patients will receive accelerated TBS
88837940|NCT05722717||MIS-C|Children with a history of MIS-C: as defined according to WHO criteria, who were 0-18 at the time of MIS-C.
88837941|NCT05722717||Post COVID-Condition|Children with post-COVID condition who were 0-18 at the time of SARS-CoV-2 infection: as defined according to the WHO case definition.
88837942|NCT05722717||Control|'Exposed' control group: children with a history of proven SARS-CoV-2 infection (RT-PCR, antigen test or serology positive) who were 0-18 at the time of SARS-CoV-2 infection.
88837943|NCT04810494|Experimental|test drug|2% Lidocaine
88837944|NCT04810494|Placebo Comparator|Placebo|0.9% Normal Saline
88837945|NCT05722639||Representative sample of the U.S. population|"Subjects will be fitted with two electrophysiology acquisition systems (one is FDA-approved, and the other is the one evaluated).~Signals from both systems will be acquired simultaneously while the subjects rest and perform no cognitive tasks.~Following, the signals from both devices will be assessed by an electrophysiology expert to determine if they are of equal quality."
88837946|NCT05270928|Experimental|IBI346|Single arm
88837947|NCT02832271|Active Comparator|green tea group|green tea extract SUNPHENON EGCg for women with ultrasound confirmed endometriosis
88837948|NCT02832271|Placebo Comparator|placebo group|placebo fro women with ultrasound confirmed endometriosis
88837949|NCT05109169|Sham Comparator|Self-guided multidomain lifestyle intervention|In this group, participants will build their own healthy lifestyle program based on standard healthy lifestyle advice that they will receive at individual consultations with the study physician/nurse as part of the study visits, covering four main components (diet, physical activity, cognitive training, and cardiovascular/metabolic risk monitoring). The intervention duration is 2 years.
88837950|NCT05109169|Active Comparator|FINGER 2.0 multidomain lifestyle-based intervention|"Within this group, participants will receive a structured intensive lifestyle intervention through individual consultations and group meeting sessions. Four main lifestyle components will be included (diet, physical activity, cognitive training, and cardiovascular/metabolic risk monitoring) as well as social interaction through the group meetings/sessions.~In this group, participants eligible for metformin treatment will be further randomised to either:~2000mg/day~1000mg/day~placebo.~Metformin and placebo will be dispensed every 3 months, both administered orally. The intervention duration is 2 years"
88837951|NCT04291014|Experimental|BWLT once daily|Participants in this arm will receive bright white light therapy daily once a day (in the evening)
89001644|NCT00589225||1|Genetic Analysis
89366374|NCT03263104|Experimental|Lactobacillus plantarum ECGC 13110402|Lactobacillus plantarum ECGC 13110402 equivalent to 2x10^9 CFU (0.1 g) with the addition of filling carrier (0.12 g; 30% w/v maltodextrin and 5% w/v sucrose) as a capsular format (vegetable) to be consumed twice daily, before breakfast and dinner with 250mL of water.
89366375|NCT03263104|Placebo Comparator|Maltodextrin|Maltodextrin (an oligosaccharide without prebiotic effect) (0.12 g; 30% w/v maltodextrin and 5% w/v sucrose) as a capsular format (vegetable) to be consumed twice daily, before breakfast and dinner with 250mL of water.
89366376|NCT03275896|Experimental|Descemet Membrane Transplantation|Patients with severe, symptomatic Fuch's Endothelial Dystrophy (FED) will be offered Descemet Membrane Transplantation (DMT) for their condition.
89366377|NCT03275272|Other|level of IGF-1 in infant|Measurment of blood level of IGF-1 In infants
89366378|NCT02875860|Other|Standardized postnatal care (Expectant)|Mothers will be expectantly managed during pregnancies and babies receive standardized postnatal care at a tertiary center used to manage babies with CDH. The recommendation is that they adhere to consensus guidelines published on the study website.
88837952|NCT04291014|Experimental|BWLT twice daily|Participants in this arm will receive bright white light therapy daily twice a day (morning and evening).
88837953|NCT04291014|Experimental|BWLT weekly|Participants in this arm will receive bright white light therapy once weekly (in the evening).
88837954|NCT04291014|Experimental|DRLT twice daily|Participants in this arm will receive dim red light twice daily (morning and evening).
88837955|NCT05722405|Other|Ixazomib|Ixazomib as the single drug for maintenance. This group as control arm
88837956|NCT05722405|Experimental|Ixazomib plus low-dose lenalidomide|Ixazomib combined with low-dose lenalidomide(10mg) for maintenance
88837957|NCT04780074|Active Comparator|Standard product (SP): USP CoQ10 powder, hard capsules|100 mg per capsule; dosage: 2 capsules - 200 mg total CoQ10
88837958|NCT04780074|Experimental|Investigational product 1 (IP1): CoQ10 in soybean oil, softgels|100 mg per softgel; dosage: 2 softgels - 200 mg total CoQ10
88837959|NCT04780074|Experimental|Investigational product 2 (IP2): Q-Gel hydrosoluble/bioenhanced CoQ10, softgels|100 mg per softgel; dosage: 2 softgels - 200 mg total CoQ10
88837960|NCT04780074|Experimental|Investigational product 3 (IP3): Qunol Mega Ubiquinol, softgels|100 mg per softgel; dosage: 2 softgels - 200 mg total CoQ10
88837961|NCT04780074|Experimental|Investigational product 4 (IP4): HydroQsorb Coenzyme Q10, hard capsules|100 mg per capsule; dosage: 2 capsules - 200 mg total CoQ10
88837962|NCT02826733||Normal|"Every child meet the age criteria and without ductus arteriosus persistence ultrasound or detectable neurological disorders after clinical, neurophysiological and radiological (ETF , Scanner, MRI).~EEG NIRS MRI"
88837963|NCT02826733||cerebral neurological disease|"Group of children meeting the criteria of age and having a detectable neurological disease after clinical, neurophysiological and radiological (ETF , Scanner, MRI) The children present either convulsions or a cerebrovascular accident or a neurological pain . Each condition being verified by a pathological electroencephalogram .~EEG NIRS MRI"
88837964|NCT04770090|Experimental|Early stage cervical cancer|Patients with cervical cancer eligible for surgery, stage IA1 to IB2
88837965|NCT02767531|Experimental|Orlistat|120 mg of Orlistat will be given 3 times to patients weighing greater than 50 kg and patients weighing less than 40 kg will be given 60 mg of Orlistat 3 times a day for 3 months.
88837966|NCT02767531|No Intervention|Off drug|Standard therapy will be given for three months
88837967|NCT05722249|Experimental|Arm A, Study Period 1 (Mindfulness and Sleep Hygiene):|"Immediately after the sleep hygiene content, the overview of the mindfulness intervention will be offered. All enrolled participants in Arm A, Study Period 1, will attend a 15 minute in-person Introduction to Mindfulness session after randomization."
88837968|NCT05722249|Active Comparator|Arm B, Study Period 1 (Physical Activity and Sleep Hygiene):|All enrolled participants in the inpatient units randomly assigned to Arm B during Study Period 1 will receive written guidelines about physical activity during the nightshift (please see Appendix V). These guidelines will instruct them to achieve the goal of up to 15 minutes of physical activity between midnight and 0500 each nightshift during the 8-week study period. Each enrolled participant will view a video with voice over of the study team physical therapist demonstrating the methods.
88837969|NCT04419324|Other|esophago-gastroscopy endoscopy with narrow band imaging|a transoral flexible endoscope with magnifying narrow band imaging in nasopharyngeal examination
88837970|NCT05722171|Experimental|gdT cell injection targeting B7-H3 chimeric atigen receptor|UTAA06 injection
88837971|NCT04419246|Active Comparator|Group I|interscalene block + General anesthesia
88837972|NCT04419246|Active Comparator|Group T|Tranexamic acid +General anesthesia
88837973|NCT04419246|Sham Comparator|Group S|General anesthesia
88837974|NCT05722093|Experimental|Manzi Guben granules|Administration cycle of Manzhi Guben granules: 1-4 weeks; Usage: 10g once, twice a day, washed with boiling water.
88837975|NCT05722093|Placebo Comparator|placebo group|Administration cycle of Manzhi Guben granules simulator: 1-4 weeks; Usage: 10g once, twice a day, washed with boiling water.
88837976|NCT05083039||750 volunteers who will be vaccinated with the BiVac polio vaccine|Group 1 - 750 volunteers, Vaccine 0.2 ml, post-vaccination observation period of 12 months.
88837977|NCT05083039||750 volunteers who will be given a Placebo.|Group 2 - 750 volunteers, Vaccine 0.2ml, post-vaccination observation period of 12 months.
88837978|NCT04758312|Experimental|MY-Skills Mobile Intervention|MY-Skills Mobile is an 8-week intervention merging yoga and self-management offered via remote tools including Zoom (video-conferencing software), Canvas (education software), and Qualtrics (survey software) that can be accessed via a computer or tablet. The self-management content is delivered primarily through asynchronous tools that include educational videos and interactive activities for goal setting, action plan, monitoring goals, and problem-solving practice. Yoga is offered synchronously via Zoom two-times per week for 60 minutes (120 minutes per week). The synchronous yoga sessions will be offered at a time that best accommodates participants' schedules. Yoga will become progressively challenging over the eight weeks and will include seated and standing postures.
88837979|NCT05721625|Experimental|Exercise group|The aerobic exercise program will be applied at moderate intensity 3 days a week for 8 weeks. Walking will be recommended as an aerobic exercise
88837980|NCT05721625|Active Comparator|Massage group|Connective tissue massage will be applied by the physiotherapist 3 days a week for 8 weeks. While postpartum women are in the sitting position, this massage will be applied on whole back.
88837981|NCT02649907|Experimental|Weight loss|3 months weight loss intervention by behavioral intervention
88837982|NCT04411134|Experimental|Arm 1|Approximately 3x10^8 or 1.5x10^9 E7 TCR T cells will be injected on day 0 and 1.5x10^9 E7 TCR T cells on day 31 (2 escalating dose levels)
88837983|NCT04411134|Experimental|Arm 2|The MTD from among dose level 1 and dose level 2
88837984|NCT04229303|Experimental|Part 1 - ZP-059 5mg|"Part 1: administration of single ascending doses (SAD) of ZP-059.~Cohort 1: 5mg (1 x 5 mg capsule) ZP-059 single dose administered via DPI (RS01 monodose device) on Day 1."
88837985|NCT04229303|Experimental|Part 1 - ZP-059 10mg|"Part 1: administration of single ascending doses (SAD) of ZP-059.~Cohort 2: 10mg (2 x 5 mg capsule) ZP-059 single dose administered via DPI (RS01 monodose device) on Day 1."
88837986|NCT04229303|Experimental|Part 1 - ZP-059 20mg|"Part 1: administration of single ascending doses (SAD) of ZP-059.~Cohort 3: 20mg (4 x 5 mg capsule) ZP-059 single dose administered via DPI (RS01 monodose device) on Day 1."
89001645|NCT00589264|Experimental|1|iron + copper + zinc
88837987|NCT04229303|Experimental|Part 1 - ZP-059 40mg|"Part 1: administration of single ascending doses (SAD) of ZP-059.~Cohort 4: 40mg (8 x 5 mg capsule) ZP-059 single dose administered via DPI (RS01 monodose device) on Day 1."
88837988|NCT04229303|Experimental|Part 2 - ZP-059 10mg bid|"Part 2: administration of multiple ascending doses (MAD) of ZP-059 on Days 1 to 10.~Cohort 1: 10mg (2 x 5 mg capsule) ZP-059 twice daily (bid) administered via DPI (RS01 monodose device) for 9 days and once in the morning of Day 10."
88837989|NCT04229303|Experimental|Part 2 - ZP-059 20mg bid|"Part 2: administration of multiple ascending doses (MAD) of ZP-059 on Day 1 to 10.~Cohort 2: 20mg (4 x 5 mg capsule) ZP-059 twice daily (bid) administered via DPI (RS01 monodose device) for 9 days and once in the morning of Day 10."
88837990|NCT04229303|Experimental|Part 2 - ZP-059 40mg qd|"Part 2: administration of multiple ascending doses (MAD) of ZP-059 on Day 1 to 10.~Cohort 3: 40mg (8 x 5 mg capsule) ZP-059 once daily (qd) administered via DPI (RS01 monodose device) on Days 1 to 10."
89366379|NCT02875860|Experimental|Prenatal Intervention (FETO)|Patients will undergo fetoscopic endoluminal tracheal occlusion and ideally prenatal reversal of the occlusion followed by standardized postnatal care as in the expectant . In this study FETO (where GoldBal2 detachable balloon and Baltaccidbpe100 Delivery Catheter are used) is to be done between 30 weeks plus 0 day and 31 weeks plus 6 days and removal of the balloon at 34 weeks plus 0 day to 34 weeks plus 6 days.
89366380|NCT03267706|Active Comparator|Palliative Care Comprehensive Tool|Clinicians within the study will be randomly assigned and trained on the use of the Palliative Care Comprehensive Tool
89366381|NCT03267706|No Intervention|Usual Care|Clinicians within the study will be randomly assigned to usual palliative care (without the newly introduced tool)
89366382|NCT03262792|Placebo Comparator|Placebo|Microcrystalline cellulose
89366383|NCT03262792|Active Comparator|Andrographis Paniculata 150|Andrographis Paniculata 150 mg
89366384|NCT03262792|Active Comparator|Andrographis Paniculata 300|Andrographis Paniculata 300 mg
89366385|NCT01359462|Experimental|Tolvaptan 15mg tablet|
89366386|NCT02457988|Experimental|Vivify Kit|Patients with cirrhosis will undergo home monitoring for 30 days post-discharge through the use of the Vivify kit which contains a wireless tablet with daily medication/diet/symptom questionnaires and vital sign monitoring.
89366387|NCT02457988|No Intervention|Standard of Care|Patients with cirrhosis will undergo standard of care, which includes a post-discharge lab check and follow-up clinic appointment. Otherwise, no day-to-day monitoring of these patients will occur.
89366388|NCT02875392|Experimental|Fucoidan use|FucoHiQ(275mg Oligo Fucoidan + 275mg HS Fucoxanthin) 550mg/capsule 6 per day(before breakfast and supper)
89366389|NCT02875392|Placebo Comparator|placebo pills|placebo capsule 6 per day (before breakfast and supper)
89366390|NCT03262636|Other|Diagnostic value of Second Window ICG|"The primary study objective is to determine the diagnostic value of Second Window ICG (delayed, high dose IV administration of ICG) in the surgical resection of nervous system tumors.~The first objective is to determine safety/efficacy of high dose, delayed indocyanine green (second window ICG) during surgery of nervous system tumors."
88837991|NCT04229303|Experimental|Part 3 - ZP-059 / Oral Voriconazole|Crossover treatment period: Single inhaled dose (20 mg) of ZP-059 5mg capsules administered via DPI, and a single dose of oral voriconazole (200 mg Vfend® tablet) on the morning of Day 1 of the respective treatment period with a washout period of at least 96 hours.
88837992|NCT04229303|Experimental|Part 3 - Oral Voriconazole / ZP-059|Crossover treatment period: Single dose of oral voriconazole (200 mg Vfend® tablet), and a single inhaled dose (20 mg) of ZP-059 5mg capsules administered via DPI on the morning of Day 1 of the respective treatment period with a washout period of at least 96 hours.
88837993|NCT04419012||Patients with AF treated with VKA|
88837994|NCT04419012||Patients with AF treated with NOAC|
88837995|NCT05721547||RC Repair Group|Participants who had undergone the same arthroscopic RM surgical procedure and technique; had undergone acromioplasty and/or tenodesis with RM repair; had undergone arthroscopic RM surgery from the upper extremity of the dominant side; had completed six months following surgery
88837996|NCT05721547||Healthy Group|Participants who had not undergone any shoulder surgery, had no history of shoulder-related pain, discomfort, or trauma in the last year
88837997|NCT05266092||Participants with chronic kidney disease undergoing hemodialysis|
88837998|NCT05266092||Participants with chronic kidney disease, not in dialysis|
88837999|NCT05266092||Participants with chronic kidney disease undergoing peritoneal dialysis|
89366391|NCT03262636|Other|Optimal timing and dose of SWG|"The second study objective is to calculate diagnostic test characteristics (sensitivity/specificity) of delayed, high dose indocyanine green (second window ICG) as a diagnostic aid during surgery of nervous system tumors.~The third study objective is to optimize timing and dose of second window Indocyanine Green during surgery of nervous system tumors, based on sensitivity/specificity."
89366392|NCT03267784|Experimental|Experimental: allo-APZ2-DFU|Application of IMP on patients wound
89366393|NCT01366794|Experimental|Type 2 diabetes|Administration of macronutrients in type 2 diabetes
89366394|NCT01366794|Experimental|Healthy volunteers|Administration of macronutrients in healthy volunteers
89366395|NCT01359540||APEX Modular|APEX Modular Stem group
89366396|NCT01359540||ARC Stem|ARC Stem group
89366397|NCT03262480|Active Comparator|Stroke volume optimization|Colloid aliquots of 200 ml 6% hydroxy ethyl starch 130/ 0.4 (Voluven) will be administered within 10 minutes and stroke volume response will be recorded .If stroke volume increase by more than 10 % for 20 minutes, the aliquot will be repeated.
88838000|NCT05266092||Healthy participants|
88838001|NCT05263986|Experimental|Assigned Interventions|In the 5-day PK lead-in period, patients will receive a single oral dose of 600 mg MRTX849 on Day 1 and there will be no drug administration in the subsequent 4 days. Following the PK lead-in period, patients will receive MRTX849 600 mg BID (an interval of approximate 12 hours between 2 doses) orally in 3-week cycles until disease progression, unacceptable AEs, patient refusal, or death. Dosing schedules may be adjusted depending on safety results.
88838002|NCT00377507|Experimental|catechin|mask containing catechins
88838003|NCT00357721|Active Comparator|A1|
88838004|NCT00357721|Active Comparator|A2|
88838005|NCT00357721|Active Comparator|A3|
88838006|NCT04227600|Experimental|Part1 JR-171|Drug: JR-171 IV infusion, dose escalation
89001646|NCT00589264|Active Comparator|2|iron + copper only
89001647|NCT00209898|Active Comparator|Rapid standard of care|Rapid standard of care treatment after screening
88838007|NCT04227600|Experimental|Part2 JR-171|Drug: JR-171 IV infusion, dose escalation, low dose, high dose
88838008|NCT03504410|Experimental|CPI-613 + HD Cytarabine and Mitoxantrone|"CPI-613 + High Dose Cytarabine and Mitoxantrone~CPI-613 at 2,000 mg/m2/day from day 1 to 5.~Cytarabine at 1gm/m2 (5 doses), every 12 hours starting day 3. Mitoxantrone at 6gm/m2 (3 doses), everyday following the 1st, 2nd and 5th doses of Cytarabine."
89001648|NCT00209898|Active Comparator|Ordinary standard of care|Subject put on ordinary waiting list for hcv treatment in Our outpatient clinic
89001649|NCT00182819|Other|radiotherapy|Radiotherapy (control arm), 50.4 Gy, standard fractionation (28 x 1.8 Gy), conformal techniques
89001650|NCT00182819|Experimental|Temozolomide|Temozolomide 75 mg/m2 daily x 21 days, q 28 days until progression or for max. 12 cycles (experimental arm)
89001651|NCT00589498|Experimental|1|Subjects who are randomized to overfeed will visit with the General Clinical Research Center dieticians as often as necessary to gain 2 kg of fat (about 4 kg overall) over a period of 8 weeks.
89001652|NCT00589498|No Intervention|2|Subjects who are randomized to non-overfeeding will continue with their normal diet and activity levels for a period of 8 weeks.
89001653|NCT00589615|Active Comparator|1|The multidisciplinary osteoporosis prevention study started with a five-day program at a rehabilitation centre and will be followed by one-day group appointments twice.
89001654|NCT00589615|No Intervention|2|The control group will get information about osteoporosis through media and health care system.
89001655|NCT00589732|Experimental|Valsartan treatment gorup|Valsartan 160mg per day group
89001656|NCT00589732|No Intervention|No Valsartan treatment group|No valsartan treatment
89001657|NCT00589771|Experimental|A|"Capsule Saccharomyces boulardii 250 mg TDS for six weeks.~Ispahgula husk 1 Tsf daily after dinner for six weeks."
89001658|NCT00589771|Placebo Comparator|B|"Capsule Placebo TDS for six weeks.~Ispaghula husk 1 Tsf daily after dinner for six weeks"
89001659|NCT00589810||Controls|Controls = Patients in Genebank that had BMS placed that did not go on to have ISR within 1 year of BMS placement and have not had prior ISR in any vessel ever. If testing is available, the Control status will be further verified by angiographic documentation of <50% luminal loss with the stent or negative stress test six or more months after stenting.
89001660|NCT00589810||Cases|Cases = Patients in Genebank that had BMS placed that went on to have ISR which is defined as PCI or CABG to the Target Vessel within 1 year of the BMS placement.
89001661|NCT00589927|Experimental|cilostazol|Cilostazol 200mg loading dose within 1 hours after successful stenting, followed by 100mg bid for 8 months
89001662|NCT00589927|Placebo Comparator|placebo|Control placebo 200mg loading dose within 1 hours after successful stenting, followed by 100mg bid for 8 months
89001663|NCT00589966|Experimental|Coping Skills Training|
89001664|NCT00589966|Active Comparator|Prostate Cancer Education|
89001665|NCT00590083|Experimental|Virus Specific Cytoxic T lymphocytes|Virus Specific Cytoxic T lymphocytes
89001666|NCT00590356|Active Comparator|A2|AngioSeal®
89001667|NCT00590356|Experimental|A1|StarClose®
89001668|NCT04574791|No Intervention|Multimodal Pain Regimen|current standard of care post-operative pain regimen in the hospital, which comprises of standing doses of oral acetaminophen 975 mg three times a day, gabapentin 300 mg two times a day, and intravenous ketorolac 30 mg three times a day for patients <65 years and 15 mg IV Q8h for patients who are >65 years, supplemented with PRN oxycodone and tramadol.
89001669|NCT04574791|Experimental|Multimodal Pain Regimen + Tizanidine|current standard of care post-operative pain regimen in the hospital, which comprises of standing doses of oral acetaminophen 975 mg three times a day, gabapentin 300 mg two times a day, and intravenous ketorolac 30 mg three times a day for patients <65 years and 15 mg IV Q8h for patients who are >65 years, supplemented with PRN oxycodone and tramadol supplemented with standing doses of oral tizanidine in the hospital and for 14 days after discharge
89001670|NCT00183014|Experimental|1|discussion session and exercise class
89001671|NCT00183014|Active Comparator|2|exercise class only
89001672|NCT04574674|Experimental|Flexibility exercise group|"Participants will be asked to follow a 12-week flexibility exercise training programme. Participants will be asked to perform a minimum amount of flexibility exercise of 1 set/week for each of six exercises and will have the opportunity to increase their volume of exercise to 2 sets or 3 sets/week per exercise if it is their choice.~Participants will perform 6 flexibility exercises per week (2 different for legs, 1 shoulder and arms, 1 chest, 1 back and 1 core). Passive static stretching exercises will be performed."
89001673|NCT04574674|Experimental|Resistance exercise group|"Participants will be asked to follow a 12-week home-based exercise programme. Participants will be asked to perform a minimum amount of resistance exercise of 1 set/week for each of six exercises and will have the opportunity to increase their volume of exercise to 2 sets or 3 sets/week per exercise if it is their choice.~Participants in the resistance exercise group will be asked to perform a total of 6 exercises per week (2 different leg exercises, 1 shoulder exercise, 1 chest exercise, 1 back exercise and 1 core exercise). Body weight and resistance bands exercises will be used. Participants will be asked to perform each set to complete as many repetitions as possible until fatigue."
89001674|NCT00590434||1|Patients older than 80 years presenting for average risk screening or surveillance colonoscopy
89366398|NCT03262480|Sham Comparator|Central venous pressure dynamic|Colloid aliquots of 200 ml 6% hydroxy ethyl starch 130/ 0.4(Voluven) will be administered within 10 minutes and CVP response will be recorded. If CVP failed to rise sustainably for more than 2 mmHg for 20 minutes, the aliquot will be repeated.
89366399|NCT01359618|Experimental|Part A 1|TC-5214
89366400|NCT01359618|Experimental|Part A 2|TC-5214 placebo
89366401|NCT01359618|Experimental|Part B 1|TC-5214 8 mg + moxifloxacin placebo
89366402|NCT01359618|Experimental|Part B 2|TC-5214 supratherapeutic dose + moxifloxacin placebo
89366403|NCT01359618|Active Comparator|Part B 3|TC-5214 placebo + moxifloxacin 400 mg
89366404|NCT01359618|Placebo Comparator|Part B 4|TC-5214 placebo + moxifloxacin placebo
89366405|NCT03267550|Experimental|remote programming system|
89366406|NCT03267628|Sham Comparator|Saline intrathecal as well as saline in Blocks|These 25 patients will receive 0.3ml saline added to the spinal anaesthetic and 25 ml saline both sides as a QLB2.
89366407|NCT03267628|Active Comparator|Saline intrathecal as well as local anaesthetic in Blocks|These 25 patients will receive 0.3ml saline added to the spinal anaesthetic and 25 ml local anaesthetic both sides as a QLB2.
89366408|NCT03267628|Active Comparator|Intrathecal morphine as well as local anaesthetic in Blocks|These 25 patients will receive 0.3ml (150mcg) morphine added to the spinal anaesthetic and 25 ml local anaesthetic both sides as a QLB2.
89366409|NCT03267628|Active Comparator|Intrathecal morphine as well as saline in Block|These 25 patients will receive 0.3ml (150mcg) morphine added to the spinal anaesthetic and 25 ml saline both sides as a QLB2.
88838009|NCT03504410|Active Comparator|Control (HAM) and control sub-groups (MEC and FLAG)|"High Dose Cytarabine and Mitoxantrone~Cytarabine at 1gm/m2 (5 doses), every 12 hours starting day 3. Mitoxantrone at 6gm/m2 (3 doses), everyday following the 1st, 3rd and 5th doses of Cytarabine.~Mitoxantrone, Etoposide and Cytarabine~Etoposide 80mg/m over 60 minutes as a central line IV infusion; 6 doses Day 1 though 6 Cytarabine 1000mg/m2 over 3 hours as a central line IV infusion: 6 doses, Day 1 through 6 Mitoxantrone 6 mg/m2 over 30 minutes as a central line IV infusion: 6 dose, Day 1 through 6~Fludarabine, Cytarabine and Filgrastim~Fludarabine 30mg/m2/day over 30 minutes as a central line IV infusion; 5 doses Day 1 though 5 Cytarabine 2g/m2 over 4 hours as a central line IV infusion: 4 hours after Fludarabine: 5 doses, Day 1 through 5 Filgrastim 5µg/kg/day by SQ or as per institutional guidelines starting from Day 1 through Day 5"
89366410|NCT05189886||Prospective|The prospective phase will enroll patients planning to undergo TAVR, at the discretion of Drs. Wan and Fatemi, and if they meet all of the inclusion criteria and none of the exclusion criteria. All patients who provide consent will undergo the TAVR procedure where the valve will be double inflated. Echocardiogram results and procedure details will be collected as data. At the patient's 30-day follow-up clinic visit, as per standard of care, they will be re-evaluated with an echocardiogram. Details from that follow-up visit and the echocardiogram results will be collected as data. Prospective enrollment will begin upon IRB approval and we plan to continue enrollment until December 31, 2023, or once 200 participants are reached, whichever comes first.
89366411|NCT05189886||Retrospective|The retrospective phase will collect data from previous TAVR procedures completed between February 2019 and October 1, 2021. Data from up to 200 patient charts will be collected using the Society of Thoracic Surgeons/American College of Cardiology that is maintained by the CMH Cardiology Department. The population will be de-identified as the purpose is to obtain descriptive information from the medical records to utilize for propensity match scoring.
89366412|NCT01359696|Experimental|A|
89366413|NCT03268018|Other|Single arm|
88838010|NCT03579186|Experimental|Gait|Patients undergoing a routine clinical gait assessment at the Brain Fit Club at BIDMC will have their posture and gait measured before and during optokinetic stimulation (OKS).
88875186|NCT02513940|Experimental|Progesterone - testosterone - placebo|Subjects received oral progesterone 400 mg (2 x 200 mg capsules) once every evening for 7 days and transdermal placebo gel once daily every morning for 7 days. After a washout period of at least 13 days, they then received transdermal testosterone gel 1% 100 mg once daily in the morning and two (2) oral placebo capsules x 7 days. After a washout period of at least 13 days, they then received transdermal placebo gel once daily every morning for 7 days and oral placebo (2 capsules) once daily every morning x 7 days
89001675|NCT00590434||2|Patients younger than 80 years presenting for average risk screening or surveillance colonoscopy
89001676|NCT00590473|Active Comparator|1|Unilateral Placement of Interstim IPG
89366414|NCT04323904||Hantavirus Group|Patients with cultural, serological, molecular evidence of hantavirus infection
89001677|NCT00590473|Active Comparator|2|Bilateral Placement of Interstim IPG
89001678|NCT00590512|Active Comparator|High Sodium|High sodium
89366415|NCT04323904||Control group|Controls will be included at the same hospitals that conduced cases based on matching of demographics, underlying diseases and duration of hospitalization (i.e. one control per case, both in the same hospital)
89366416|NCT03262714|Experimental|Dancing|Elderly women randomized to the dance intervention programme.
89366417|NCT03262714|Experimental|Walking|Elderly women randomized to the walking intervention programme.
89366418|NCT03262714|Active Comparator|Stretching|Elderly women randomized to the stretching intervention programme.
89366419|NCT03127644|Experimental|Sodium Zirconium Cyclosilicate (ZS) 5g|Suspension administered 5g orally three times daily for 48 hours.
89366420|NCT03127644|Experimental|Sodium Zirconium Cyclosilicate (ZS) 10g|Suspension administered 10g orally three times daily for 48 hours.
89366421|NCT03127644|Placebo Comparator|Placebo|Placebo suspension administered orally placebo three times daily for 48 hours.
89366422|NCT01366950|Experimental|Excercise group|
89366423|NCT01366950|No Intervention|Reference|
89366424|NCT01362426||001|paliperidone palmitate Dosage and administration will be according to the paliperidone palmitate approved Australian Product Information.
89366425|NCT01362504||Clinical sepsis|
89366426|NCT01362504||Proven sepsis|
89366427|NCT01362504||Control group|healthy neonates
89366428|NCT01367028|Other|A: Trastuzumab+Docetaxel|
89366429|NCT01367028|Experimental|B: Trastuzumab+Docetaxel+Bevacizumab|
89366430|NCT01367028|Experimental|C: Trastuzumab+Docetaxel+NPLD|
89366431|NCT01367028|Experimental|D: Trastuzumab+Docetaxel+NPLD+Bevacizumab|
88838011|NCT04243421|Experimental|Group with implants|"Flap will be elevated following the crestal and releasing incisions (if necessary).~After having completed the cleaning, the surgeon will perform the osteotomy. After the use of the final drill ᴓ3.2 the surgeon will take the measurement of the buccal and palatal/lingual walls height.~If wall discrepancy is 1.5-2mm the site will be included in the study. Clinical photographs of probe within the osteotomy have to be taken. The osteotomy will be prepared with the conical drill, therefore the implant will be inserted in a special manner - lower part of the sloped collar will be located at the buccal aspect of the osteotomy preparation. At the buccal aspect the implant will positioned at the crestal bone level, while at the palatal aspect it will be either at the level of the bone crest or 0.5 mm below."
89366432|NCT03965962|Experimental|Group 1: VRVg-2 + HRIG|Participants received 0.5 milliliters (mL) intramuscular (IM) injection of VRVg-2 formulation on Days 0, 3, 7, 14 and 28 along with HRIG injection at Day 0.
89366433|NCT03965962|Active Comparator|Group 2: Verorab + HRIG|Participants received 0.5 mL IM injection of Verorab on Days 0, 3, 7, 14 and 28 along with HRIG injection at Day 0.
89366434|NCT03965962|Active Comparator|Group 3: Imovax Rabies + HRIG|Participants received 1 mL IM injection of Imovax Rabies on Days 0, 3, 7, 14 and 28 along with HRIG injection at Day 0.
89366435|NCT03965962|Experimental|Group 4: VRVg-2|Participants received 0.5 mL IM injection of VRVg-2 formulation on Days 0, 3, 7, 14 and 28.
89366436|NCT03262402|Experimental|HIV-infected group|Patients will be treated for their chronic periodontitis (basic periodontal treatment) and samples of gingival crevicular fluid and saliva will be collected at baseline, 30 days and 60 days after the periodontal treatment for the study analysis.
89366437|NCT03262402|Active Comparator|Non-HIV infected group|Patients will be treated for their chronic periodontitis (basic periodontal treatment) and samples of gingival crevicular fluid and saliva will be collected at baseline, 30 days and 60 days after the periodontal treatment for the study analysis.
88875187|NCT02513940|Experimental|Progesterone - placebo - testosterone|Subjects received oral progesterone 400 mg (2 x 200 mg capsules) once every evening for 7 days and transdermal placebo gel once daily every morning for 7 days. After a washout period of at least 13 days, they then received transdermal placebo gel once daily every morning for 7 days and oral placebo (2 capsules) once daily every morning x 7 days. After a washout period of at least 13 days, they then received transdermal testosterone gel 1% 100 mg once daily in the morning and two (2) oral placebo capsules x 7 days.
89366438|NCT05188794|Active Comparator|group L|Lateral transversus abdominis plane(TAP) block
89366439|NCT05188794|Active Comparator|Group P|Posterior transversus abdominis plane block
89366440|NCT03273088|Experimental|AryoGen Pharmed etanercept|Altebrel (etanercept prefilled syringe produced by AryoGen Pharmed Company) 25mg/0.5ml in prefilled syringe.
89366441|NCT03273088|Active Comparator|Pfizer etanercept|Enbrel® (etanercept prefilled syringe produced by Pfizer Company) 25mg/0.5ml in prefilled syringe.
89366442|NCT04235634||Intra-arterial Prostglandin therapy|Minimal invasive Cannulation of the Superior Mesenteric Artery (SMA) and subsequent intra-arterial application of prostaglandin E1 (Initial Bolus 20ug, followed by continuous Infusion of 60-80ug/24hr for 24-72hrs)
89366443|NCT03262090|No Intervention|control group|Subjects were randomly assigned to receive saline before skin incision
89366444|NCT03262090|Active Comparator|0.2ug/kg dexmedetomidine|Subjects were randomly assigned to receive 0.2ug/kg intravenous dexmedetomidine before skin incision
89366445|NCT03262090|Active Comparator|0.4ug/kg dexmedetomidine|Subjects were randomly assigned to receive 0.4ug/kg intravenous dexmedetomidine before skin incision
89366446|NCT03262090|Active Comparator|0.6ug/kg dexmedetomidine|Subjects were randomly assigned to receive 0.6ug/kg intravenous dexmedetomidine before skin incision
89366447|NCT03262090|Active Comparator|0.8ug/kg dexmedetomidine|Subjects were randomly assigned to receive 0.8ug/kg intravenous dexmedetomidine before skin incision
89366448|NCT03262090|Active Comparator|1.0ug/kg dexmedetomidine|Subjects were randomly assigned to receive 1.0ug/kg intravenous dexmedetomidine before skin incision
89001679|NCT00590512|Active Comparator|Low sodium|Low sodium
89366449|NCT01359774|Other|Healthy volunteers|
89366450|NCT01359774|Other|Huntington patients|
89366451|NCT03272854||Renal Transplant Recipients|A cohort or renal transplant recipients, all more than 1 year after transplantation at inclusion
89001680|NCT00590551|Experimental|1-6|
89366452|NCT03151551|Experimental|Ixekizumab|"160 milligrams (mg) ixekizumab given subcutaneously (SC) at baseline for all participants.~80 mg ixekizumab given once every 2 weeks (Q2W) SC from week 2 to week 12 and once every 4 weeks (Q4W) thereafter for participants with moderate-to-severe plaque Ps.~80 mg ixekizumab given SC Q4W starting week 4 for participants not meeting criteria for moderate-to-severe plaque Ps."
89366453|NCT03151551|Active Comparator|Adalimumab|"80 mg adalimumab given SC at baseline followed by 40 mg Q2W given SC starting week 1 for participants with moderate-to-severe plaque Ps.~40 mg adalimumab given Q2W SC at baseline followed by 40 mg Q2W starting at Week 2 given SC for participants not meeting criteria for moderate-to-severe plaque Ps."
89366454|NCT01362582|No Intervention|Chemotherapy, Nutritional Care|"5-Fluorouracil (5-FU) 2000mg/m2 IV (24-hour)/folinic acid (FA) 200mg/m2 IV (30 min) will be administered weekly over four weeks with additional oxaliplatin 85 mg/m2 IV (2-hour) on days 8 and 22. Therapy will be interrupted between days 23 to 42. The next cycle will be started on day 43.~Subjects in the control group receive Best Supportive Nutritional Care. BSNC is defined as nutritional consultation and recommendation by experienced ecotrophologists."
89366455|NCT01362582|Experimental|PN, Chemotherapy, Nutritional Care|"5-Fluorouracil (5-FU) 2000mg/m2 IV (24-hour)/folinic acid (FA) 200mg/m2 IV (30 min) will be administered weekly over four weeks with additional oxaliplatin 85 mg/m2 IV (2-hour) on days 8 and 22. Therapy will be interrupted between days 23 to 42. The next cycle will be started on day 43.~Patients receive also Best Supportive Nutritional Care defined as nutritional consultation and recommendation by experienced ecotrophologists.~Intervention: Supportive Parenteral Nutrition"
89366456|NCT03272776||Protector Laryngeal Mask Airway|Patients undergoing anesthesia in which airway management includes a Protector Laryngeal Mask and fulfill the inclusion criteria of the study.
89366457|NCT01367106|Experimental|exposed offspring|
89366458|NCT01367106|Other|controls|
89530350|NCT02516891|No Intervention|Non hydrophilic wire/Drug-Eluting Stents|Will include 100 patients with coronary bifurcation lesions in that they will be treated with stents and in which the technique is used jailed guide.non hydrophilic guide.
88838012|NCT02464969|Experimental|Apixaban|Subjects between birth to <18 years will be dosed on a body weight tiered regimen. Subjects ≥35kg will receive 10mg twice daily(BID) for 7 days followed by 5mg BID thereafter;<35kg to 25kg will receive 8mg BID for 7 days followed by 4mg BID thereafter;<25 to 18kg will receive 6mg BID for 7 days and then 3mg BID thereafter;<18 to 12kg will receive 4mg BID for 7 days and then 2mg BID thereafter;<12 to 9kg will receive 3mg BID for 7 days and then 1.5mg BID thereafter;< 9kg to 6kg will receive 2 mg BID for 7 days and 1mg BID thereafter;<6kg to 5kg will receive 1mg BID for 7 days and 0.5mg BID thereafter;<5kg to 4kg will receive 0.6mg twice daily for 7 days and 0.3mg BID thereafter;PK cohort neonates ≥ 2.6kg will receive 0.1mg BID. Dose will be adjusted as determined by PK measurements (ie, to 0.2mg BID, 0.1mg daily or dose will stay the same).For the post PK cohort Neonates ˂4kg to 2.6kg, if confirmed by PK sub analysis,subjects will receive 0.2mg BID for 7 days and 0.1mg BID thereafter.
88838013|NCT04739982|Experimental|Treatment|The GuessWhat app is a charades style game and app that engages parent and child in fluid social interaction where the parent must guess what the child is acting out based on the prompt shown on the phone screen. Participants will use their own personal phone to download the study app. Parent and child will be encouraged to play using the emojis and emotion game mode at least 3 individual game sessions per week. Parents are asked to play GuessWhat with their child 3-4 times per week for 4 weeks.
88838014|NCT04739982|No Intervention|Treatment as Usual|Participants in control group will continue their treatment as usual.
88838015|NCT05392530|Experimental|Treatment Sequence ABC|Participants will receive single oral dose of final marketing image (FMI) candidate #1 of macitentan (Treatment A [test]) under fed condition in Treatment Period 1, followed by single oral dose of FMI candidate #2 of macitentan (Treatment B [test]) under fed conditions in Treatment Period 2, and then single oral dose of the reference formulation of macitentan (Treatment C) under fed conditions in Treatment Period 3. The study intervention administrations will be separated by at least 14 days to allow adequate washout duration following the single doses.
89178957|NCT05755022|Experimental|Maxillary segment repositioning by utilizing reverse engineering using the 3D photogrammetry.|"The printed stereolithographic model with the adapted miniplates will be scanned using 3D photogrammetry technique and a specific software dedicated for image acquisition will be used.~A guide will be designed on the reproduced virtual model. This guide will be used intraoperative as a locating and positioning guide for the maxilla and the plates."
88838016|NCT05392530|Experimental|Treatment Sequence BCA|Participants will receive Treatment B in Treatment Period 1 followed by Treatment C in Treatment Period 2, and then Treatment A in Treatment Period 3 on Day 1. The study intervention administrations will be separated by at least 14 days to allow adequate washout duration following the single doses.
88838017|NCT05392530|Experimental|Treatment Sequence CAB|Participants will receive Treatment C in Treatment Period 1 followed by Treatment A in Treatment Period 2, and then Treatment B in Treatment Period 3 on Day 1. The study intervention administrations will be separated by at least 14 days to allow adequate washout duration following the single doses.
89534667|NCT03329183|Experimental|HD-FOLFIRI|Advanced CRC patients with Wild-type UGT1A1*6 and *28 receive high-dose FOLFIRI regimen (Irinotecan 260mg/m2 2h, leucovorin 400mg/m2, 5- fluorouracil 400mg/m2 , 5- fluorouracil 2400 mg/m2 46h, 14 days per course.)
89534668|NCT03329183|No Intervention|SD-FOLFIRI|Advanced CRC patients with Wild-type UGT1A1*6 and *28 receive standard-dose FOLFIRI regimen (Irinotecan 180mg/m2 2h, leucovorin 400mg/m2, 5- fluorouracil 400mg/m2 , 5- fluorouracil 2400 mg/m2 46h, 14 days per course)
89534669|NCT03329183|No Intervention|SD-FOLFOX-6|Advanced CRC patients with Wild-type UGT1A1*6 and *28 receive standard-dose FOLFOX-6 regimen (Oxaliplatin 130mg/m2 2h, leucovorin 400mg/m2, 5- fluorouracil 400mg/m2 , 5- fluorouracil 2400 mg/m2 46h, 14 days per course)
88838018|NCT05392530|Experimental|Treatment Sequence ACB|Participants will receive Treatment A in Treatment Period 1 followed by Treatment C in Treatment Period 2, and then Treatment B in Treatment Period 3 on Day 1. The study intervention administrations will be separated by at least 14 days to allow adequate washout duration following the single doses.
88838019|NCT05392530|Experimental|Treatment Sequence CBA|Participants will receive Treatment C in Treatment Period 1 followed by Treatment B in Treatment Period 2, and then Treatment A in Treatment Period 3 on Day 1. The study intervention administrations will be separated by at least 14 days to allow adequate washout duration following the single doses.
88838020|NCT05392530|Experimental|Treatment Sequence BAC|Participants will receive Treatment B in Treatment Period 1 followed by Treatment A in treatment period 2, and then Treatment C in Treatment Period 3 on Day 1. The study intervention administrations will be separated by at least 14 days to allow adequate washout duration following the single doses.
88838021|NCT03559829|Experimental|Single Arm - Intervention arm|RAPAEL Smart Glove Arm The participant will be issued a Smart Glove and a tablet preloaded with the game software. The available games provide various kinds of motion tasks such as ADL-related tasks presented in an entertaining manner. The learning schedule algorithm automatically adjusts to the optimal level of difficulty to balance challenge and motivation. The participant will be expected to use the Smart Glove at home for 60 min per day for at least 5 days per week.
88838022|NCT03498014|Active Comparator|Prescription as standard|
88838023|NCT03498014|Experimental|Pharmacogenetic-guided prescription|
88838024|NCT02460133|Other|HCV Genotype 1, with and without cirrhosis|
88838025|NCT02220452|Experimental|music listening during anesthesia|In patients allocated to the music listening group, audiotapes will be placed on patients' ears, playing soothing and relaxing music throughout anesthesia
88838026|NCT02220452|Active Comparator|absence of music listening during anesthesia|In patients allocated to absence of music listening group, audiotapes will be placed on the patients' ears, without however playing any music
88838027|NCT04735614|Experimental|ThoraxBelt|Received ThoraxBelt after the surgery. Standard care for pain management will be the same as the Standard Care Arm.
88838028|NCT04735614|No Intervention|Standard care|Standard care with IV PCA and on-request oral painkiller.
88838029|NCT04256603|Other|Gabapentin early|Gabapentin prior to admission
88838030|NCT04256603|Other|Gabapentin late|Gabapentin during admission
88838031|NCT04256603|Other|No gabapentin|No gabapentin
88838032|NCT02975180|Experimental|FES|Unilateral and bimanual activities are performed with FES applied to the hemiparetic arm.
88838033|NCT02975180|Experimental|Conventional|Unilateral and bimanual activities are performed with no FES applied to the hemiparetic arm.
88838034|NCT03545334|Experimental|Comparison result lymphoscintigraphy with ICG lymphography|"The patient first receives a standard Tc-99m-based lymphoscintigraphy. The identified lymph nodes are not marked in the patients, so that the surgeons are not affected in lymph node identification during ICG and near infrared fluorescence imaging. The surgeon also has no access to lymphoscintigraphy images.~Transcutaneous ICG lymphography is then performed by intradermal injection of ICG around the scar of the primary tumor excision and transcutaneous fluorescence evaluation with the Visionsense™ VS3 - Stereoscopic High Definition Visualisation System (VS3-3DHD) and results are compared."
88838035|NCT03560141|Other|LID011121 (OD) / Biofinity (OS)|LID011121 contact lens worn in the right eye, with comfilcon A contact lens worn in the left eye, as randomized, for one night of extended (overnight) wear.
88838036|NCT03560141|Other|Biofinity (OD) / LID011121 (OS)|Comfilcon A contact lens worn in the right eye, with LID011121 contact lens worn in the left eye, as randomized, for one night of extended (overnight) wear.
88838037|NCT02199002|Other|healthy volunteers|healthy volunteers (no gastric complains)
88838038|NCT02199002|Other|PPI responders|proven reflux, good symptom relief upon PPI therapy
88838039|NCT02199002|Other|PPI non-responders|proven reflux disease, poor symptom control (less then 50% symptom reduction) upon PPI therapy (2x40mg omeprazole)
88838040|NCT02199002|Other|Barrett - no dysplasia|proven barrett with no dysplasia on biopsies
89534670|NCT03235453|Experimental|Binary rhythm|Experimental: binary rhythm The randomized group for binary-rhythm intervention will receive a 12-week intervention with dance lessons. Classes will be divided into: Heating and stretching (5 minutes), main part (binary) (35 minutes) and relaxation (5 minutes).
88838041|NCT02199002|Other|barrett - high grade dysplasia|proven barrett with high grade dysplasia on biopsies
88838042|NCT04418700|Experimental|Breath Stacking technique|"The intervention group will receive routine physical therapy associated with the Breath Stacking technique in 2 daily sessions of up to 20 minutes.~The technique consists of an Instrument composed of a one-way valve coupled to a face mask to promote the accumulation of successive inspiratory volumes."
88838043|NCT04418700|No Intervention|Routine physical therapy|The control group will receive only routine physical therapy. Routine physiotherapy consists of breathing exercises, using techniques bronchial hygiene and pulmonary reexpansion, and motor physiotherapy through exercise passive, active-assisted or active mobilization, stretching, training activities of daily living, positioning and removal of the bed and guidelines for post-discharge.
88838044|NCT05721079|Experimental|ECP with standard triple IST|
88838045|NCT05721079|Active Comparator|standard triple IST|
88838046|NCT03562559||TKA Patients|
88838047|NCT00357799|Active Comparator|VeinViewer Arm|Attempts at IV placement will be made with use of the VeinViewer Machine
88838048|NCT00357799|No Intervention|Conventional Method|IV attempted with conventional method
89534671|NCT03235453|Experimental|Quaternary rhythm|The randomized group for the quaternary rhythm intervention will receive a 12-week intervention with dance classes. Classes will be divided into: Heating and stretching (5 minutes), main part (quaternary rhythm) (35 minutes) and relaxation (5 minutes).
88838049|NCT04727970|Experimental|Tricaprilin|Tricaprilin will be administered for 5-21 days. The total daily dose (individual per subject up to a maximum of 10g/kg/day) will be split into 4 doses administered orally, approximately every 6 hours.
88838050|NCT03459638||Periodontitis|Screening for DM, ASCVD, MetS and OSAS in patients with periodontitis
88838051|NCT03459638||No periodontitis|'Screening for DM, ASCVD, MetS and OSAS in patients without periodontitis
89534672|NCT05027373|Experimental|SSGJ-613|
89534673|NCT05027373|Placebo Comparator|Placebo|
88838052|NCT03563027|No Intervention|Control|This arm serves as control and uses a wearable device to track daily step counts
88838053|NCT03563027|Experimental|Social Incentive Gamification|This arm uses a wearable device to track daily step counts, is entered into social incentive gamification, and selects a support sponsor
88838054|NCT03563027|Experimental|Social Incentive Gamification and Financial Incentive|This arm uses a wearable device to track daily step counts, is entered into social incentive gamification, selects a support sponsor, and receives a financial incentive
88838055|NCT04711590||Successful extubation|The patients pass the spontaneous breathing trial and are successful extubated without reintubation within 72 hours. .
88838056|NCT04711590||Failed extubation|The patients pass the spontaneous breathing trial and are successful extubated with reintubation within 72 hours. .
88838057|NCT02975024||Mucograft|Laser speckle contrast imaging of the oral mucosa and wound fluid measurement and quantitative determination of VEGF after mandibular vestibuloplasty. Individuals of this pre-defined group are candidates of vestibuloplasty, where the keratinized gingiva will be enlarged by a combination of apically repositioned split thickness flap with a xenogeneic collagen matrix (Mucograft).
88838058|NCT02975024||strip gingival graft + Mucograft|Laser speckle contrast imaging of the oral mucosa and wound fluid measurement and quantitative determination of VEGF after mandibular vestibuloplasty. Individuals of this pre-defined group are candidates of vestibuloplasty, where the keratinized gingiva will be enlarged by a combination of apically repositioned split thickness flap with a strip gingival graft and a xenogeneic collagen matrix (Mucograft). The strip gingival graft is harvested from the patient's palate.
88838059|NCT02068430|Experimental|Riboflavin 0.1% & UV-X™ Illumination System|UV-X Cross linking: After topical anesthesia, 1 drop of Riboﬂavin 0.1% ophthalmic solution will be instilled topically in the eye every 2 minutes for 30 minutes. At the end of the 30 minute riboﬂavin pre-treatment period, the eye will be examined with blue light for the presence of a yellow ﬂare in the anterior chamber. When the yellow ﬂare in the anterior chamber is conﬁrmed, the eye will be aligned under the UV-X™ light with the treatment plane at a working distance that is 50mm from the UV-X™ beam aperture.
89534674|NCT02492555|Experimental|Scheduled (SI)|"Scheduled means screening every 3rd month ( home FC and DA) plus when needed and upgrade of ususal treatment"
89534675|NCT02492555|Active Comparator|On Demand (OD)|"On Demand means screening of home FC and DA when the patients feel for it and upgrade of usual treatment"
89366459|NCT05169216|Experimental|Cognitive-Behavioral Therapy Group|"A mental training program was carried out with the following objectives: (a) to learn to manage their level of activation; (b) to train their ability to concentrate; (c) to optimize their self-confidence; (d) to learn to compete by improving their racing routines; and (d) to integrate mental training into their day-to-day life.~The athletes worked in small groups of four athletes. In addition, the days that the psychologist attended the concentration, he was also present in the training sessions, with the aim of giving them feedback on the strategies acquired. The psychologist was present in various phases throughout the concentration and there was also a constant online monitoring. Each week, a sheet of tasks to be executed and a diary were provided to verify compliance with the guidelines."
88838060|NCT02440334|Experimental|Contrast Ultrasound Reccurence Screening|Patients scheduled for MRI/CT follow up of a renal cancer previously treated by cryoablation therapy who will also undergo a contrast-enhanced ultrasound exam. This is a one-time imaging study and contrast ultrasound exams will be compared to the clinically scheduled MRI/CT.
88838061|NCT02065700|Experimental|Filgotinib 200 mg once daily|Filgotinib 200 mg (2 x 100 mg) once daily (morning)
88838062|NCT02065700|Experimental|Filgotinib 100 mg twice daily|Filgotinib 100 mg twice daily (morning and evening)
88838063|NCT03127592|Experimental|Group 1|1 active treatment (Fixed Dose Combination) + 2 placebos
88838064|NCT03127592|Active Comparator|Group 2|1 active treatment (Cyclobenzaprine) + 2 placebos
88838065|NCT03127592|Active Comparator|Group 3|1 active treatment (Etodolac) + 2 placebos
88838066|NCT02974400|Experimental|Internet-based guided self-help|Internet-based, guided, CBT-oriented self-help treatment for persecutory ideation and auditory verbal hallucinations with access to a self-help website including regular written electronic contact with a guide and access to smartphone-based interactive worksheets (8 weeks)
88838067|NCT02974400|No Intervention|Wait-List|Wait-list control group (8 weeks)
88838068|NCT02444234|Experimental|Tedizolid PO|Tedizolid phophate 200mg tablet
88838069|NCT02444234|Experimental|Tedizolid IV|Tedizolid phophate 200mg IV
88838070|NCT02444936|Active Comparator|ZOSTAVAX|ZOSTAVAX shingles vaccine Zoster vaccine live Single 0.65mL subcutaneous injection
88838071|NCT02444936|No Intervention|Control|There is no drug given in this arm.
88838072|NCT02445014|Experimental|MGH SECM Imaging Capsule|Subject will swallow the SECM imaging capsule and images will be acquired using the SECM Imaging system.
88838073|NCT02445326|Experimental|OTX-DP|OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use
88838074|NCT02445326|Placebo Comparator|PV|PV (placebo drug delivery vehicle)
88838075|NCT02287831|Experimental|umbilical cord mesenchymal stem cells|Multiple intra muscular injection of mesenchymal stem cells derived from human umbilical cord.
88838076|NCT05052853|Experimental|NMDAE|An NMDA enhancer
88838077|NCT05052853|Placebo Comparator|Placebo|Placebo
88838078|NCT05030701||cancerous patients|
88838079|NCT05030701||non cancerous patients|
88838080|NCT05720845|Active Comparator|conventional mechanical ventilation|Conventional mechanical ventilation for General Anesthesia
88838081|NCT05720845|Experimental|VESPA|ventilatory strategy to prevent atelectasis for General Anesthesia
88838082|NCT02978599|Experimental|AVL-3288 10 mg|AVL-3288 10 mg daily for 5 days
88838083|NCT02978599|Experimental|AVL-3288 30 mg|AVL-3288 30 mg daily for 5 days
88838084|NCT02978599|Placebo Comparator|Placebo|Placebo daily for 5 days
88838085|NCT05720533|Experimental|Disitamab Vedotin Combined With Sintilimab|Treatment regimen is Disitamab vedotin 2.5mg/kg and Sintilimab 200mg every 21 days, until disease progression or intolerable adverse reactions or death.
88838086|NCT04744766|Active Comparator|Hadfield technique group|central/mammary duct excision is done by the ordinary method described by Hadfield
88838087|NCT04744766|Active Comparator|Al Masad technique group|same procedure with de-epithelization of the upper pararaeolar area
88838088|NCT02446496|Experimental|Group A|Subjects will receive a single oral dose of cefadroxil tablet manufactured by GSK under fasting condition in treatment period 1 followed by 7 days washout interval from the first study drug administration. After the washout interval the subjects will receive a single dose of cefadroxil tablet manufactured by NP under fasting condition in treatment period 2
88838089|NCT02446496|Experimental|Group B|Subjects will receive a single oral dose of cefadroxil tablet manufactured by NP under fasting condition in treatment period 1 followed by 7 days washout interval from the first study drug administration. After the washout interval the subjects will receive a single dose of cefadroxil tablet manufactured by GSK under fasting condition in treatment period 2
88838090|NCT04344691|No Intervention|Control|5 minutes waiting time
88838091|NCT04344691|Experimental|Stretching|Rectus femoris static stretching during 90' (with three hold-relax progressions until final ROM)
88838092|NCT05720221||Adalimumab group|"Patients receive adalimumab (Humira) at an induction dose of 160/80 mg (week 0 and 2) and at a maintenance dose of 40 mg every other week.~The efficacy of the drug will be assessed."
89001681|NCT00216996||Burn patients|Receiving standard TPN with or without glutamine enrichment
89001682|NCT00590785|Experimental|1|
89530351|NCT04487197||Cohort 1|"Adult patients (age ≥ 18 years),~kidney or pancreas or pancreatic islets transplantation~transplanted patients (period: 01.01.2020 to 30.06.2020)"
89530352|NCT04487197||Cohort 2|"Adult patients (age ≥ 18 years),~kidney or pancreas or pancreatic islets transplantation~Transplanted patients in follow-up since 01.01.2020 or trasplanted patients after 30.06.2020."
89530353|NCT03248635||Focus group|Male and female adults age 40-75
89530354|NCT03245515|Experimental|BMS-986195|A single oral solution dose of BMS-986195
89366460|NCT01359852|Experimental|001|"[11C] JNJ-42491293 + JNJ-40411813 Part C:[11C] JNJ-42491293 (300 to 370 MBq) will be dosed as an i.v.bolus injection. Volunteers will be pre-treated with JNJ-40411813 between 1.5 to 3 hours prior to the second and prior to the third PET scan,[11C] JNJ-42491293 + JNJ-40411813 Part D:[11C] JNJ-42491293 (300 to 370 MBq) will be dosed as an i.v. bolus injection.~Volunteers will be treated with a single dose of up to 500 mg JNJ-40411813 prior to the second scan and will have a third scan at least 2 hours later to evaluate the rate of clearance of JNJ-40411813 from the brain,[11C] JNJ-42491293 Part A: [11C] JNJ-42491293 (300 to 370 MBq) will be dosed as an i.v. bolus injection and have a 120 minute PET scan.,[11C] JNJ-42491293 Part B:[11C] JNJ-42491293 (300 to 370 MBq) will be dosed as an i.v. bolus injection have a 90 minute PET scan and have arterial and venous blood sampling."
89366461|NCT05075434|Experimental|Intervention Group|This group will receive the protocol prescribed by the health centre (calf stretching exercises, plantar fascia, proprioception exercises, ultrasound, magnet therapy and gait re-education and proprioceptive exercises for 40-45 minutes). In addition, you will receive 15 minutes of the instrumental technique of diacutaneous fibrolysis. Participants will receive 8 treatment sessions spread over 4 weeks (2 sessions per week).
89366462|NCT05075434|Active Comparator|Control Group|This protocol will be the one prescribed by the health centre. It consists of calf stretching exercises, plantar fascia, proprioceptive exercises, ultrasound, magnetic therapy and gait re-education and proprioceptive exercises for 40-45 minutes. Participants will receive 8 treatment sessions spread over 4 weeks (2 sessions per week).
89366463|NCT03262168|Other|Study Group One|Six Minute Walk Test distance <450metres. Exercise programme including inspiratory muscle trainer for 12 weeks. Contact weekly (via phone or email).
89366464|NCT03262168|Other|Study Group Two|Six Minute Walk Test distance >450metres. Exercise programme including walking for 12 weeks. Contact every second week (via phone or email).
89366465|NCT03262168|Other|Study Group One - phase 2|Six Minute Walk Test distance <450metres. Exercise programme including inspiratory muscle trainer for 12 weeks. Contact weekly (via phone or email).
89366466|NCT03262168|Other|Study Group Two - phase 2|Six Minute Walk Test distance >450metres. Exercise programme including walking for 12 weeks. Contact every second week (via phone or email).
89366467|NCT01359930|Active Comparator|Naltrexone and Bupropion SR|
89366468|NCT01359930|Placebo Comparator|Placebo|
89366469|NCT05075512|Experimental|experimental group|anlotinib combined with fulvestrant
89366470|NCT01316757|Experimental|Treatment|Patients receive cetuximab IV over 60 minutes, paclitaxel IV over 1 hour, and carboplatin IV over 30 minutes on day 1. Beginning in course 2, patients also receive erlotinib hydrochloride PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89366471|NCT01367340|Experimental|Exercise and physical activity|
89366472|NCT01367340|Active Comparator|Exercise only|
89366473|NCT01316835||Type 2 Diabetes Mellitus, No treatment|
89366474|NCT01362660||Infants with potential exposure in utero|
89001683|NCT00590785|Experimental|2|
89366475|NCT05074966|Experimental|mXELOX plus cetuximab|"Patients will receive the study drug after randomization, and those with effective efficacy evaluation (CR, PR or SD) will receive intravenous chemotherapy for up to 9 cycles, and then enter the maintenance treatment stage until PD, death, intolerable toxicity or withdrawal of informed consent (whichever occurs first)~Cetuximab: 500 mg/m2, IV, d1, q2w; Oxaliplatin: 85 mg/m2, IV, d1,q2w; Capecitabine: 850 mg/m2, po, bid, d1-10, q2w;~maintenance stage: Cetuximab: 500 mg/m2, IV, d1, q2w; Capecitabine: 850 mg/m2, po, bid, d1-10, q2w;"
89366476|NCT05074966|Active Comparator|FOLFOX plus cetuximab|"Patients will receive the study drug after randomization, and those with effective efficacy evaluation (CR, PR or SD) will receive intravenous chemotherapy for up to 9 cycles, and then enter the maintenance treatment stage until PD, death, intolerable toxicity or withdrawal of informed consent (whichever occurs first)~Cetuximab：500 mg/m2, IV, d1, q2w Oxaliplatin： 85 mg/m2, IV d1, q2w; Leucovorin： 400 mg/m2 IV d1, q2w; 5-FU： 400 mg/m2 IV bolus on d1, then 1200 mg/m2/d x 2d(total 2400 mg/m2 over 46-48 hours) IV continuous infusion, q2w;~maintenance stage: Cetuximab: 500 mg/m2, IV, d1, q2w; Leucovorin： 400 mg/m2 IV d1, q2w; 5-FU： 400 mg/m2 IV bolus on d1, then 1200 mg/m2/d x 2d(total 2400 mg/m2 over 46-48 hours) IV continuous infusion, q2w （Cetuximab combined with capecitabine can be used according to the patient's wishes and the nursing situation of intravenous catheterization）"
89366477|NCT01340859|Experimental|Post Admission Cognitive Therapy (PACT)|Six (6) 60-90 Minutes Sessions of Post Admission Cognitive Therapy Delivered Preferably Over 3 Consecutive Days of Inpatient Stay
89366478|NCT01340859|No Intervention|Enhanced Usual Care (EUC)|Treatment As Usual and Study Assessment Services
89366479|NCT01362738|Active Comparator|Ablation of PV and extra-PV triggers|Conventional approach which includes pulmonary vein isolation (PVI) and ablation of extra-pulmonary triggers
89366480|NCT01362738|Active Comparator|LAA isolation along with the conventional ablation strategy|LAA isolation along with the conventional ablation strategy
88838093|NCT05720221||Ustekinumab group|"Patients receive ustekinumab (Stelara) through intravenous infusion with a weight based dose for treatment induction, followed by a subcutaneous dose injection with a fixed dose (90 mg) for maintenance every 8 weeks.~The efficacy of the drug will be assessed."
88838094|NCT02448368|Experimental|Treatment A|RDEA3170, 5 mg (FN24), administered in the fasted state.
89366481|NCT01341015|Experimental|ultrasound for fracture|All patients receive ultrasound for potential ankle fracture.
88838095|NCT02448368|Experimental|Treatment B|RDEA3170, 5 mg (FN24), administered in the fed state (high-fat, high-calorie meal).
88838096|NCT02448368|Experimental|Treatment C|RDEA3170, 10 mg (FN25), administered in the fasted state.
88838097|NCT02448368|Experimental|Treatment D|RDEA3170, 10 mg (FN25), administered in the fed state (high-fat, high-calorie meal).
88838098|NCT02448368|Experimental|Treatment E|RDEA3170, 2.5 mg (FN17), administered as 10 mg (4 × 2.5 mg), in the fasted state.
88838099|NCT02448368|Experimental|Treatment I|RDEA3170, 10 mg (FN26), administered in the fasted state.
88838100|NCT02448368|Experimental|Treatment J|RDEA3170, 10 mg (FN26), administered in the fed state (high-fat, high-calorie meal).
88838101|NCT02448368|Experimental|Treatment K|RDEA3170, 2.5 mg (FN17), administered as 10 mg (4 × 2.5 mg), in the fasted state.
88838102|NCT02978365|Experimental|Patients|Male patients who undergone shoulder surgery to repair chronic instability (at least 1 shoulder dislocation prior to surgery). Time since surgery will be between 26 and 28 weeks. Patients will go through filling questionnaires and isokinetic strength measurements.
88838103|NCT05013307|Experimental|CASE|In this prospective study the investigators aim to quantify participants' responses to physical activity. Participants will be asked to engage in physical activity, to identify any provocation of symptoms in adolescents ranging from ages 10 to 22 years. Responses to physical activity will be measured through physiologic markers (e.g., blood pressure, heart rate, oxygen saturation, rate of perceived exertion, dyspnea). Additionally, participants will be monitored for any changes in symptoms that occur during or after physical activity as measured by the modified PCSS symptom inventory.
88838104|NCT01258231||Cardiac surgery|Adult patients undergoing cardiac surgery
88838105|NCT02448914|Experimental|TRIGEL first, then Duodopa|"First Intervention (Day 1): TRIGEL, intestinal gel (20 mg/mL levodopa, 5 mg/mL carbidopa monohydrate, and 20 mg/mL entacapone).~Second Intervention (Day 2): Duodopa, intestinal gel (20 mg/mL levodopa and 5 mg/mL carbidopa monohydrate).~Both TRIGEL and Duodopa treatment consists of 3 individually adjusted and pre-defined doses: a morning dose, a continuous 14 h infusion, and extra bolus doses (if required).~All TRIGEL doses correspond to 80% of the pre-study individually optimised doses of Duodopa. All Duodopa doses correspond to 100% of the pre-study individually optimized doses of Duodopa.~Administration is done through duodenal or upper jejunal infusion via the patient's permanently inserted gastrojejunostomy tube by means of an ambulatory infusion pump."
88838106|NCT02448914|Experimental|Duodopa first, then TRIGEL|"First Intervention (Day 1): Duodopa, intestinal gel (20 mg/mL levodopa and 5 mg/mL carbidopa monohydrate).~Second Intervention (Day 2): TRIGEL, intestinal gel (20 mg/mL levodopa, 5 mg/mL carbidopa monohydrate, and 20 mg/mL entacapone).~Both TRIGEL and Duodopa treatment consists of 3 individually adjusted and pre-defined doses: a morning dose, a continuous 14 h infusion, and extra bolus doses (if required).~All TRIGEL doses correspond to 80% of the pre-study individually optimised doses of Duodopa. All Duodopa doses correspond to 100% of the pre-study individually optimized doses of Duodopa.~Administration is done through duodenal or upper jejunal infusion via the patient's permanently inserted gastrojejunostomy tube by means of an ambulatory infusion pump."
89366482|NCT01360008||Cryo ablation|Patients with first Ablation of atrial fibrillation treated by cryo ablation
89366483|NCT01360008||RF ablation|Patients with first Ablation of atrial fibrillation treated by Radio frequency ablation
89366484|NCT03267004|Experimental|Meal Order 1|Meal A will be served to participant in meal session 1 and Meal B in meal session 2.
89366485|NCT03267004|Experimental|Meal Order 2|Meal B will be served to participant in meal session 1 and Meal A in meal session 2.
89366486|NCT01341093|Active Comparator|usual care|
89366487|NCT01341093|Experimental|educational program+telephone follow up|
89366488|NCT03267082|Experimental|Evaluation the role of Laparoscopic management of perforated a|
89366489|NCT01341171||tamoxifen or aromatase inhibitors|
89366490|NCT03266926||Postoperative Patients with premarin|Patients who undergo vaginal surgery at Sunnybrook Health Sciences Centre (SHSC) who require vaginal packing postoperatively and receive premarin vaginal cream coated packing.
89530355|NCT03363503|Experimental|Salmeterol/Fluticasone Capsair®|Salmeterol/Fluticasone 50/500 mcg Inhalation Powder (1 puff) twice daily (approximately every 12 hr) via Capsair® for 8 weeks
89366491|NCT03266926||Postoperative Patients with bupivacaine|Patients who undergo vaginal surgery at Patients who undergo vaginal surgery (SHSC) who require vaginal packing postoperatively and receive bupivacaine soaked packing.
88838107|NCT05002309|Experimental|Psychotherapy|Cognitive-behavioural therapy
89366492|NCT01362816||Palliative care cancer patients|"Inclusion criteria are:~Patient has a cancer diagnosis (radiological, histological, cytological or operative evidence), local, loco-regional or metastatic disease, defined as a palliative care patient; enrolled in a palliative care programme, age 18 years or older, able to provide written informed consent, able to complete the data collection tool, preferably without help, available for follow up registration"
89366493|NCT01343745|Placebo Comparator|Placebo|Placebo pMDI
89366494|NCT01343745|Experimental|Low dose|BDP/formoterol pMDI low dose
89366495|NCT01343745|Experimental|High dose|BDP/Formoterol pMDI high dose
89366496|NCT03267160||Sepsis with cardiopulmonary failure|Patient with sepsis and also respiratory and heart involvement, confirmed by Hemodynamic parameters
89366497|NCT03267160||Sepsis without cardiopulmonary failure|Patient with sepsis without respiratory and heart involvement
89366498|NCT01367418|Experimental|Thoracic Epidural Analgesia (TEA)|TEA is used for perioperative pain management, having been used both intra- and postoperatively, up to 48 h.
89366499|NCT01367418|Active Comparator|Patient controlled analgesia (PCA)|PCA is the standard of pain management and is usually used for up to 48 h postoperative for pain management following radical prostatectomy.
89366500|NCT03266692|Experimental|ACTR087 in combination with SEA-BCMA|
89366501|NCT03147495||the study group|The participants with medial compartment knee osteoarthritis and without lateral compartment knee osteoarthritis according to the Ahlbäck classification.
89366502|NCT03147495||the control group|The healthy volunteers without knee osteoarthritis according to the American College of Rheumatology criteria for the classification and reporting of OA of the knee joint. Radiographic evidence of the knee with Ahlbäck classification grade 0.
88838108|NCT05002309|Experimental|Pharmacotherapy|Antidepressant medication
88838109|NCT00363272|Experimental|Arm I|Patients receive ispinesib IV over 1 hour on days 1, 8, and 15. Treatment repeats every 28 days for 24 courses in the absence of disease progression or unacceptable toxicity.
89366503|NCT01360086|Experimental|Perioperative CT with 5FU-Cisplatine-Cetuximab|6 cycles of intravenous Cetuximab (500mg/m²), Cisplatine (50mg/m²) and LV5FU2s (folinic acid 400mg/m², 5FU bolus 400mg/m², and continuous infusion of 5FU 2400mg/m²) every 2 weeks. Surgery was planned 3-4 weeks after the end of neaodjuvant CT and postoperative CT, with the same regimen, planned for 6-8 weeks after surgery.
89366504|NCT04454346|Experimental|Double Foley Catheter|The patients allocated to this arm were randomly and did not differ from the Single Foley Catheter or Cook Balloon arm regard to patients' demographic features and characteristics. The connected FCs were inserted into the cervix using long forceps and advanced to the internal os level. One of the Foley balloons was inflated with 80 ml of saline, and the other FC, now the cervicovaginal balloon, was pulled out with mild traction until the balloon could be visualized and inflated with 20 ml of saline. The vaginal speculum was removed, and the cervicovaginal balloon was inflated further to a total of 80 ml of saline. Both catheters were taped to the inner aspect of the thigh without tension
89366505|NCT04454346|Experimental|Single Foley Catheter|The patients allocated to this arm were randomly and did not differ from the Double Foley Catheter or Cook Balloon arm regard to patients' demographic features and characteristics. a 16-F FC was inserted into the cervix using long forceps. Then, the balloon was inflated with 80 ml of saline using a standard 20 ml syringe. The catheter was then pulled out until the balloon covered the internal os. The speculum was removed, and the catheter was fixed under slight tension to the inner aspect of the thigh
89366506|NCT04454346|Experimental|Cook Balloon|The patients allocated to this arm were randomly and did not differ from the Double Foley Catheter or Single Foley Catheter arm regard to patients' demographic features and characteristics. Cook cervical ripening group, the device was applied according to the manufacturer's instructions, and each balloon was inflated with 80 ml saline. The catheter was taped to the inner aspect of the thigh without tension.
89366507|NCT05183451|Experimental|LG (Group A)|En- masse retraction using NiTi closed coil springs rendering 200 g/side were employed following first premolars extraction and insertion of buccal TADs to provide maximum anchorage. Retraction was done along with the application of LLLT till the end of retraction.
89366508|NCT05183451|Active Comparator|NLG (Group B)|En- masse retraction using NiTi closed coil springs rendering 200 g/side were employed following first premolars extraction and insertion of buccal TADs to provide maximum anchorage. No LLLT was applied to this group
89366509|NCT02458924|Active Comparator|Schizophrenia|Skin niacin test was performed by two concentrations including 0.5 ml solutions of 0.01 M and 0.1 M diluted methyl nicotinate. The two solutions were applied for one minute to the inside of the different forearms of each individual.
88838110|NCT04341974||surgical patients|Adult patients undergoing major elective general abdominal surgery for ontological disease
88838111|NCT02978287|No Intervention|BAVU Solution 0. hour (control)|Viability, Calcium sensing receptor and parathormone levels of Parathyroid cells at 0. hour
89366510|NCT02458924|Active Comparator|Bipolar disorder|Skin niacin test was performed by two concentrations including 0.5 ml solutions of 0.01 M and 0.1 M diluted methyl nicotinate. The two solutions were applied for one minute to the inside of the different forearms of each individual.
89366511|NCT02458924|Active Comparator|First degree relatives|Skin niacin test was performed by two concentrations including 0.5 ml solutions of 0.01 M and 0.1 M diluted methyl nicotinate. The two solutions were applied for one minute to the inside of the different forearms of each individual.
88838112|NCT02978287|Experimental|BAVU Solution 6. hour|Viability, Calcium sensing receptor and parathormone levels of Parathyroid cells at 6. hour
88838113|NCT02978287|Experimental|BAVU Solution 12. hour|Viability, Calcium sensing receptor and parathormone levels of Parathyroid cells at 12. hour
88838114|NCT02978287|Experimental|BAVU Solution 18. hour|Viability, Calcium sensing receptor and parathormone levels of Parathyroid cells at 18. hour
88838115|NCT02978287|Experimental|BAVU Solution 24. hour|Viability, Calcium sensing receptor and parathormone levels of Parathyroid cells at 24. hour
88838116|NCT05719753|Placebo Comparator|Standard of Care|Bard Catheter
88838117|NCT05719753|Experimental|Camstent Coated Catheter|The Camstent Coated Foley Catheter is an all-silicone two-way Foley-type urinary catheter, to which a proprietary polymeric coating has been applied.
88838118|NCT01152541|Active Comparator|Hypotonic Riboflavin|Administration of hypotonic riboflavin every 2 minutes for the duration of UV exposure.
88838119|NCT01152541|Active Comparator|Riboflavin/dextran|Administration of Riboflavin/dextran every 2 minutes for the duration of UV exposure.
88838120|NCT01638546|Experimental|Arm I (veliparib and temozolomide)|Patients receive veliparib PO BID on days 1-7 and temozolomide PO on days 1-5.
88838121|NCT01638546|Active Comparator|Arm II (placebo and temozolomide)|Patients receive placebo PO BID on days 1-7 and temozolomide as in Arm I.
88838122|NCT04948489|Experimental|LNG IUD+ Norethindrone Acetate|All eligible participants will have the LNG-IUD. Experimental participants will also receive norethindrone acetate 5 mg by mouth daily for 12 months.
88838123|NCT04948489|Placebo Comparator|LNG IUD+Placebo|All eligible participants will have the LNG-IUD. Participants in the placebo comparator group will also receive a placebo tablet, 1 tablet by mouth daily for 12 months.
88838124|NCT03466944||5-24 year old paediatric patients with childhood Leukaemia|Cooperative paediatric individuals and young adults (5-24-years-old) with proven Acute Lymphoblastic Leukaemia (ALL) or Acute Myeloblastic Leukaemia (AML) planned for bone marrow transplantation.
88838125|NCT03839953|Active Comparator|Best Medical Therapy|After undergoing revascularization for critical limb ischemia, patients will receive best medical therapy under the supervision of a vascular internal medicine specialist. This care will include advice on smoking cessation, physical activity guidelines, blood pressure regulation, statin administration and possible anti-platelet administration.
88838126|NCT03839953|Experimental|Supervised Exercise Program|Patients will receive best medical therapy plus participation in a 12-week supervised exercise program.
88838127|NCT05719597|Experimental|PEP (Positive Expiratory Pressure)|Group A
88838128|NCT05719597|Experimental|IS (Incentive Spirometry)|Group B
88838129|NCT05723497|Experimental|Elderberry juice|Participants will consume elderberry juice twice/day for 1-week.
88838130|NCT05723497|Placebo Comparator|Placebo beverage|Participants will consume placebo beverage twice/day for 1-week.
88838131|NCT03833713|Experimental|SMS Intervention|Once-weekly automated SMS dialogue sessions or micro-interventions and use behavior change techniques including self-monitoring with performance feedback and goal support
88838132|NCT03833713|Active Comparator|SMS Assessments|Once-weekly SMS assessments related to their target risk behavior without receiving any feedback or goal support
88838133|NCT05717335||Patients with ventricular entry during surgery (vascular, tumoral and epilepsy).|Group of patients operated on for periventricular lesions with ventricular entry and placement of TachoSil directly over the area of ventricular opening in order to avoid complications.
88838134|NCT00363428|Placebo Comparator|Control|Receive standard care and educational material on exercise and lifestyle choices of well-being
88838135|NCT00363428|Experimental|Lifestyle intervention|
89534676|NCT03235765||Cohort A|Patients who are diagnosed with metastatic/recurrent non-small cell lung cancer and planned to receive first line chemotherapy
88838136|NCT05717257|Experimental|Dapagliflozin|Dapagliflozin will be added on top of the standard optimized medical therapy for heart failure and reduced ejection fraction
88838137|NCT05717257|No Intervention|Control|Participants assigned to this group will continue the standard optimized medical therapy
88838138|NCT04341818|Experimental|Strength Training and Vitamin D monthly|Four weeks of Vitamin D (50.000 IU once per month) followed by a 10 week guided resistance training (progressive strength training in a fitness center is applied; the intensity is adjusted continuously in order to obtain a sufficient training stimulus). During the training period the vitamin D intake remains. Over the whole study period participants get 400 mg calcium/day.
88838139|NCT04341818|Experimental|Strength Training and Vitamin D daily|Four weeks of Vitamin D (800 IU once per day) followed by a 10 week guided resistance training (progressive strength training in a fitness center is applied; the intensity is adjusted continuously in order to obtain a sufficient training stimulus). During the training period the vitamin D intake remains. Over the whole study period participants get 400 mg calcium/day.
88838140|NCT04341818|Experimental|Strength Training and no Vitamin D|Four weeks of no vitamin D administration followed by a 10 week guided resistance training (progressive strength training in a fitness center is applied; the intensity is adjusted continuously in order to obtain a sufficient training stimulus). During the training period the vitamin D intake remains. Over the whole study period participants get 400 mg calcium/day.
89001684|NCT00183209|Experimental|14 session behavioral intervention|7 sessions addressing problem alcohol and drug use and 7 session addressing parenting challenges (monitoring, negotiation, etc) based on based on Social Action Theory (Ewart, 1991) and Motivational Interviewing
89001685|NCT00183209|Active Comparator|Brief Video Intervention|Single session brief video intervention to build motivation to reduce or eliminate problem drinking/drug use
89366512|NCT02458924|Active Comparator|Health controls|Skin niacin test was performed by two concentrations including 0.5 ml solutions of 0.01 M and 0.1 M diluted methyl nicotinate. The two solutions were applied for one minute to the inside of the different forearms of each individual.
89366513|NCT01367496|Experimental|Arm 1|
88838141|NCT05715541|Other|Comparison of INR Control and Drug Compliance Values by Groups|"Follow-up of the patients in the control group continued in the outpatient clinic.~This application includes an interface where patients can enter drug treatment information such as INR values, disease diagnosis, how many times a day and how many mg they take, and a chat box section where they can communicate with their physicians, including emergencies. The doctor reviewed the patient's INR findings once they were relayed by the patient, then told them to adjust the patient's warfarin dosage and schedule the next INR check. The application sent notifications to the patients every day about when and how many mg of the drug they would take"
89366514|NCT01367496|Experimental|Arm 2|
89366515|NCT01367496|Experimental|Arm 3|
89366516|NCT01367496|Experimental|Arm 4|
89366517|NCT02458846|Experimental|Screened Schools|25 schools. Screening involved: crowded HOTV acuity test, Preschool Randot Stereoacuity Test, and Plusoptix autorefractor. Referral criteria followed AAPOS guidelines for screening for amblyopia and amblyopia risk factors. Children who fail any one of the three tests (including uncooperative/unable children) will be given a referral letter, which includes an assigned appointment time for a comprehensive eye exam at school with a licensed optometrist. Any needed glasses will be dispensed at no cost to the parents. 6 months after the eye exam, we will follow up with a phone call to parents to offer any additional support (such as replacing broken/lost glasses)
88838142|NCT02451488|Experimental|GM-CSF|Patients will be treated with 14 days of GM-CSF self-administered subcutaneously daily for 14 days in a dose of 125 µg/m2 beginning on the day of enrollment. Patients will be instructed in the self-administration of GM-CSF and after they have demonstrated competency with the procedure, they will self-administer the treatment at home. Patients will undergo surgery within 1 day to 5 days after cessation of the GM-CSF therapy.
89366518|NCT02458846|No Intervention|Care As Usual Schools|"25 schools were randomly allocated to the care as usual schools. No intervention was provided by the research team, however, children may have received optometry/ophthalmology care via regular referral channels (e.g., family physicians, teachers)"
89366519|NCT05183373||Aneurysmal coronary artery disease|Patients with coronary artery ectasia or/and aneurysm diagnosed during coronary angiography
88838143|NCT02451488|Other|Standard of Care|no neo-adjuvant therapy prior to surgical intervention
88838144|NCT05576701|Experimental|Laughter Therapy|Laughter therapy consists of group-based interventions that include yoga breathing exercises and stillness. Laughter education is a form of exercise with gratuitous laughter and childlike play. Laughter therapy practices consist of four steps. These; warming exercises, deep exercises, playing childlike games and entertainment (eg greeting laughter, lion laughter, milk waving sounds, quiet laughter, etc.). Laughter therapy sessions in the study were carried out for 4 weeks and three times a week. Laughter therapy has been applied by researchers who have a leader certificate.
88838145|NCT05576701|Active Comparator|Control|"The patients in the control group, on the other hand, did not undergo any intervention other than their routine treatment and care. The patients were followed for four weeks. Before the study, data collection tools were applied to the patients. Again, after the study started and the study ended, all other data collection tools were applied, except the Patient Information Form."
88838146|NCT04341506||Participant ECG|The study has one arm, I.e., we will collect daily ECGs in 100 participants and track their ECG over three months. We will then compare ECGs pre and post COVID-19 diagnosis in any participant diagnosed with COVID-19 to assess for any early ECG changes that may aid with diagnosing.
88838147|NCT05717101||Observational (medical records)|Patients who have undergo contrast-enhanced harmonic endoscopic ultrasound imaging have their medical records reviewed.
88838148|NCT03172494|Experimental|Insulin degludec/liraglutide|
88838149|NCT03172494|Active Comparator|Insulin degludec|
88838150|NCT03172494|Active Comparator|Liraglutide|
88838151|NCT02452346|Experimental|All Patients|Tosedostat 120 mg PO once daily will be administered.
88838152|NCT02959255|Active Comparator|10-day concomitant PAMC|40mg esomeprazole twice daily, 500mg clarithromycin twice daily, 1gr amoxicillin twice daily, and 500mg metronidazole twice daily for 10 days
89001686|NCT00183326|Experimental|1|Participants will receive trauma-focused cognitive behavioral therapy
89366520|NCT05183373||Abdominal aortic aneurysm|Patients with diagnosed with abdominal aortic aneurysm
89366521|NCT05183373||Coronary artery disease|Patients with diagnosed with coronary artery disease
89366522|NCT05074576|Experimental|Mulligan group|In addition to the conventional treatments, Sustained Natural Apophysial Gliding (SNAG) a type of Mulligan mobilization technique is applied.
89366523|NCT05074576|Other|Control group|Electroterapy agents are applied in the contro group
89366524|NCT01341249|Experimental|DW224aa|DW224aa given by oral administration
89366525|NCT01341249|Active Comparator|DW224a|DW224aa given by oral administration
89366526|NCT01362972||plerixafor + granulocyte colony stimulating factor (G-CSF)|Patients who receive plerixafor+granulocyte colony stimulating factor (G-CSF) for the mobilisation of peripheral blood (PB) CD34+ cells and who have undergone autologous haematopoietic stem cell (HSC) transplantation.
89366527|NCT01362972||plerixafor + G-CSF + chemotherapy|Patients who receive plerixafor+granulocyte colony stimulating factor (G-CSF)+chemotherapy for the mobilisation of peripheral blood (PB) CD34+ cells and who have undergone autologous haematopoietic stem cell (HSC) transplantation.
89366528|NCT01362972||granulocyte colony stimulating factor (G-CSF) + chemotherapy|Patients who receive granulocyte colony stimulating factor (G-CSF) + chemotherapy for the mobilisation of peripheral blood (PB) CD34+ cells and who have undergone autologous haematopoietic stem cell (HSC) transplantation.
89366529|NCT01362972||granulocyte colony stimulating factor (G-CSF) alone|Patients who receive granulocyte colony stimulating factor (G-CSF) alone for the mobilisation of peripheral blood (PB) CD34+ cells and who have undergone autologous haematopoietic stem cell (HSC) transplantation.
89366530|NCT01360164|Experimental|Human umbilical cord mesenchymal stem cells transplantation|Participants will be given umbilical cord mesenchymal stem cells transplantation with a 1 year follow-up.
89366531|NCT02459158|Experimental|Low dose of ME1100|
89366532|NCT02459158|Experimental|High dose of ME1100|
88838153|NCT02959255|Active Comparator|14-day concomitant PAMC|(40mg esomeprazole twice daily, 500mg clarithromycin twice daily, 1gr amoxicillin twice daily, and 500mg metronidazole twice daily for 14 days.
88838154|NCT05716945|Experimental|Intervention STEP I (Year 1 after DMEK)|
88838155|NCT05716945|Active Comparator|Control STEP I (Year 1 after DMEK)|
88838156|NCT05716945|Experimental|Intervention STEP II (Year 2 after DMEK)|
88838157|NCT05716945|Active Comparator|Control STEP II (Year 2 after DMEK)|
88838158|NCT05716867||Children with early childhood caries aged between 36-71 month|
88838159|NCT05716867||Caries free children aged between 36-71 month|
89534677|NCT03235765||Cohort B|Patients with recurrent/metastatic non-small cell lung cancer who have been receiving molecular targeted therapy, including immune checkpoint inhibitor, and have tumor shrinkage with the agent.
89534678|NCT03235375|Experimental|Group 1: End Stage Renal Disease (ESRD)|Subjects with CrCl <20ml/min will receive MEDI0382 administered subcutaneously
88838160|NCT04341584|Experimental|ANAKINRA|"Treatment includes the administration of Two IV infusions / day of ANAKINRA KINERET® 200mg (Total 400 mg) at day 1 (D1), D2 and D3, two IV infusions / day of ANAKINRA KINERET® 100mg (Total 200 mg) at day 4 (D4), and one IV infusion of ANAKINRA KINERET® 100mg (Total 100 mg) at day 5 (D5).~In case of absence of improvement at D4 (absence of clinical improvement AND absence of decrease of CRP level > 50%), 3 supplementary days of treatment at 400 mg/day will be done at D4, D5, D6 followed by a decrease at 200 mg/day at D7 and 100 mg/day at D8 and stop thereafter"
88838161|NCT04341584|No Intervention|Standard of care|
88838162|NCT05716711|Experimental|GROUP 1|"GROUP 1~1st GROUP LAVENDER OIL EXTRACT WILL BE APPLIED TO 20 PATIENTS WITH COLOSTOMY FOR 1 MONTH WITH 20 DROPS A DAY INTO THE STOMA BAG"
88838163|NCT05716711|Experimental|GROUP 2|2nd GROUP MINT OIL EXTRACT WILL BE APPLIED TO 20 PATIENTS WITH COLOSTOMY DURING 1 MONTH.
88838164|NCT05716711|No Intervention|CONTROL GROUP|20 PATIENTS WITH COLOSTOMY WITH NO INTERVENTION
88838165|NCT05570929||Kidney Donor|Defined as a human individual donating a kidney
88838166|NCT05570929||Kidney Recipient|Defined as a patient suffering from chronic kidney disease being the recipient of a kidney transplant
88838167|NCT04341428|Experimental|DWP14012 20mg|Orally, once daily
88838168|NCT04341428|Active Comparator|Lansoprazole 15mg|Orally, once daily
88838169|NCT03171168|Active Comparator|Traditional Physical Therapy|Participants will have traditional physical therapy up to 20 sessions, up to two sessions per week. This will involve exercise and modalities as decided by the therapists and medical providers. Participants will have a home exercise program for the remainder of the year.
88838170|NCT03171168|Experimental|AposTherapy|Participants will have AposTherapy instead of traditional physical therapy over the course of one year. This will include 7 sessions of gait assessment and re-calibration with daily at home exercise with the device over the year.
88838171|NCT02977975|Experimental|Raw sauerkraut|75 grams of raw, traditionally produced, lacto-fermented sauerkraut, each day for 6 weeks.
88838172|NCT02977975|Other|Pasteurized sauerkraut|75 grams of pasteurized sauerkraut, each day for 6 weeks.
88838173|NCT02978053|Experimental|Bright light|10 000 lux
88838174|NCT02978053|Placebo Comparator|Red light|400 lux
88838175|NCT02453360|Experimental|5 ml|Following negative aspiration, SSACNB volume will be randomized and subjects will receive 5, 10 or 20 ml of 0.5% bupivacaine will be incrementally injected. Randomization of the volume of bupivacaine will be determined by opening a sequential, pre-sealed envelope with the group assignment designated within. All studied volumes are well within the acceptable range for SSACNB.
88838176|NCT02453360|Experimental|10 ml|Following negative aspiration, SSACNB volume will be randomized and subjects will receive 5, 10 or 20 ml of 0.5% bupivacaine will be incrementally injected. Randomization of the volume of bupivacaine will be determined by opening a sequential, pre-sealed envelope with the group assignment designated within. All studied volumes are well within the acceptable range for SSACNB.
88838177|NCT02453360|Experimental|20 ml|Following negative aspiration, SSACNB volume will be randomized and subjects will receive 5, 10 or 20 ml of 0.5% bupivacaine will be incrementally injected. Randomization of the volume of bupivacaine will be determined by opening a sequential, pre-sealed envelope with the group assignment designated within. All studied volumes are well within the acceptable range for SSACNB.
88838178|NCT05568901|Active Comparator|LMC Alone|Caregivers who received standardized lethal means counseling (LMC) from the study team as well as a 1-page handout summarizing the counseling recommendations
88838179|NCT05568901|Experimental|LMC + Gun Locks|Caregivers who received standardized lethal means counseling (LMC) from the study team, 1-page handout summarizing the counseling recommendations, as well as the additional provision of 2 cable-style gun locks
88838180|NCT05714137|Experimental|Proximal massage and fist clenching|The experimental group of 36 patients underwent proximal massage and fist clenching after IV insertion. Proximal massage: For a total of 5 to 10 minutes, twice daily for 4 days, between 30 seconds- 1 minute in sessions of approximately 20 strokes, a light massage is administered utilizing the palm surfaces of the fingers. Fist Clenching : Under the researcher's supervision, participants in the activity known as palm fisting squeeze a soft palm ball 20 times in each of twice a day for four days, lasting between 30 seconds - 1 minute. The Peripheral Venous Catheter-Related Phlebitis Risk Scale, the Phlebitis Diagnostic Scale, and the Patient Information Form were employed right after following PVC (0. hour). The Phlebitis Diagnostic Scale was used for 96 hours to assess the patient's vascular access at the 24th, 48th, 72nd, and 96th hours.
89534679|NCT03235375|Experimental|Group 2: Severe and ESRD Subjects|Subjects with CrCl >20 and < 30 ml/min will receive MEDI0382 administered subcutaneously
89534680|NCT03235375|Active Comparator|Group 3: Healthy Subjects|Subjects with CrCl >90 ml/min will receive MEDI0382 administered subcutaneously
89534681|NCT03235375|Experimental|Group 4: Moderate Renal Disease|Subjects with CrCl > or equal to 30 and < 60 mL/min will receive MEDI0382 administered subcutaneously
89534682|NCT03329105|Experimental|Sea Salt Mouth Rinse|
89534683|NCT03329105|Active Comparator|Standardized Oral Health Practices|
89534684|NCT03334019||subjects|Data collected on general population, farmers and veterinarians though questionnaires and blood samples.
89534685|NCT05048511||Normal|Women with sufficient vitamin D level, when 25(OH)D >20 ng/ml
89534686|NCT05048511||Deficient|women deficiency vitamin D level, when 25(OH)D <20 ng/ml
88838181|NCT05714137|No Intervention|Standard care for PVC|The standard care group of 36 patients received typical nursing PVC care. Standard nurse PVC care: Only standard PVC care and follow-up were provided. It was carefully avoided that the patients would interact with one another or be in the same patient room. The Peripheral Venous Catheter-Related Phlebitis Risk Scale, the Phlebitis Diagnostic Scale, and the Patient Information Form were employed right after following PVC (0. hour). The Phlebitis Diagnostic Scale was used for 96 hours to assess the patient's vascular access at the 24th, 48th, 72nd, and 96th hours.
88838182|NCT05716399|Experimental|Transcutaneous electric stimulation pretreatment group|30 minutes before the implementation of spinal anesthesia, TEAS (density wave 10/50Hz, one side of Neiguan and Quchi points connected to two electrodes on the same wire on the electroacupuncture instrument) was continuously performed on both sides of Neiguan and Quchi points.
89178958|NCT05755022|Active Comparator|Maxillary segment repositioning by utilizing reverse engineering using the commercial scanners.|• The printed stereolithographic model with the adapted miniplates will be scanned using the commercial scanners and imported for virtual designing of the positioning and locating guide that will be used intraoperative for positioning the maxilla.
89366533|NCT01343979||positive|Patients with clinically suspected H1N1 infection confirmed by positive H1N1 PCR
88838183|NCT05716399|Active Comparator|Transcutaneous acupoint electrical stimulation treatment group|Within 30 minutes after the occurrence of hypotension, TEAS (density wave 10/50Hz, one side of Neiguan point and Quchi point connected to two electrodes on the same wire on the electroacupuncture instrument) was continuously performed on both sides of Neiguan and Quchi points.
88838184|NCT05716399|Sham Comparator|Transcutaneous acupoint pseudo electric stimulation group|Paste the electrode, turn on the power, but no current output.
88838185|NCT02453672|Experimental|SB8|SB8, single dose of 3 mg/kg, IV infusion
88838186|NCT02453672|Active Comparator|EU Sourced Avastin®|EU Sourced Avastin®, single dose of 3 mg/kg, IV infusion
88838187|NCT02453672|Active Comparator|US Sourced Avastin®|US Sourced Avastin®, single dose of 3 mg/kg, IV infusion
88838188|NCT03119064|Experimental|Dose 1|"Temozolomide: 50mg/m2/day until disease progression.~Nanoliposomal irinotecan :~Dose Level 1 50mg/m2 IV every 2 weeks"
88838189|NCT03119064|Experimental|Dose 2|"Temozolomide: 50mg/m2/day until disease progression.~Nanoliposomal irinotecan :~Dose Level 2 70 mg/m2 IV every 2 weeks"
88838190|NCT03119064|Experimental|Dose 3|"Temozolomide: 50mg/m2/day until disease progression.~Nanoliposomal irinotecan :~Dose Level 3 80mg/m2 IV every 2 weeks"
88838191|NCT00358033|Experimental|group intervention|pharmacist-led group intervention in behavioral and pharmacologic therapy
88838192|NCT00358033|Active Comparator|individual|pharmacist-based individual clinic visits with behavioral and pharmacologic intervention for cardiac risk reduction
88838193|NCT00358033|No Intervention|usual care|usual care
88838194|NCT02453750|Experimental|Hypersaline and Bronchodilator Response|After the subject has performed post-bronchodilator spirometry, they will inhale 5 mls of 3% hypertonic saline for 7 minutes by nebulizer.
88838195|NCT03107286||Tc-99m MAG3|Children ages 1-6 years old will be eligible to participate. Routine imaging is performed immediately as a dynamic acquisition with 80 frames over 20 min. (15 s per frame). Subjects in each age group will be additionally imaged 2-3 h post-administration. It is important to note that the patient volunteers will not receive any additional radiation exposure for inclusion in this study. They are only being ask to allow imaging at one additional time point.
89366534|NCT01343979||negative|Patients with clinically suspected H1N1 infection and negative H1N1 PCR
89366535|NCT03634956|Experimental|Group I.IONM in thyroid surgery|Group I.IONM in thyroid surgery.Once the vagus has been detected,nerve conduction data will be detected with IONM. If the muscle relaxant effect is not detected, it will be detected with TOF device.
88838196|NCT02454296|Active Comparator|Paracervical Block with lidocaine|A paracervical block will be done prior to the placement of laminaria with 1% lidocaine and sodium bicarbonate.
88838197|NCT02454296|Sham Comparator|Sham paracervical block|A sham block will be done prior to the placement of laminaria using a capped needle
88838198|NCT03836833|Experimental|4in1 granules|Abacavir/Lamivudine/ Lopinavir/Ritonavir (30/15/ 40/10mg ;4-in-1) Fixed-Dose Combination in granules formulation administered twice daily for at least 3 weeks, Followed by Lopinavir/Ritonavir (40/10mg pellets) plus dual Abacavir/Lamivudine (60/30mg dispersible tablets) administered twice daily for at least 3 weeks.
88838199|NCT03836833|Experimental|LPV/r Pellets Plus ABC/3TC|"Lopinavir/Ritonavir (40/10mg pellets) plus dual Abacavir/Lamivudine (60/30mg dispersible tablets) administered twice daily for at least 3 weeks.~Followed by Abacavir/Lamivudine/ Lopinavir/Ritonavir (30/15/ 40/10mg ;4-in-1) Fixed-Dose Combination in granules formulation administered twice daily for at least 3 weeks"
88838200|NCT04744142|No Intervention|Placebo|Received 10% protein in nutrition + placebo supplement
88838201|NCT04744142|Experimental|Ketone|Received 10% protein in nutrition + 3x20g B-hydroxybutyrate per day
88838202|NCT04744142|Experimental|High protein|Received 30% protein in nutrition + placebo supplement
88838203|NCT04744142|Experimental|High protein + ketone|Received 30% protein in nutrition + 3x20g B-hydroxybutyrate per day
88838204|NCT05716243|Active Comparator|Group A|Group A will receive a standard intraoperative analgesia protocol
89366536|NCT01344135|Placebo Comparator|Group 1 (placebo control)|60 clinically stable COPD patients with muscle atrophy, eligible for out-patient pulmonary rehabilitation
89366537|NCT01344135|Experimental|Group 2 (nutritional intervention)|60 clinically stable COPD patients with muscle atrophy, eligible for out-patient pulmonary rehabilitation
89366538|NCT01367574|Experimental|Arm 1|
89366539|NCT01367574|Experimental|Arm 2|
89366540|NCT01367574|Experimental|Arm 3|
89366541|NCT05074108|Experimental|Pilot study|Adapt and pilot a nutrition-based intervention. The program will take a holistic approach to educate participants about basic nutrition and cooking skills, sleep, and mindfulness strategies to enhance mental health.
89366542|NCT04693689|Experimental|Conventional vaccine, 0% adoption rate|"Our survey follows a 2 x 5 between-subjects design. The two dimensions we vary are vaccine technology (conventional vs. RNA) and the hypothetical adoption rate of the new vaccine in the country (0%, 20%, 40%, 60%, 80%). We elicit subjects' willingness to receive the new COVID-19 vaccine given the vaccine technology and a hypothetical adoption rate of the new vaccine.~In this arm, we elicit subjects' willingness to receive a conventional vaccine if its current adoption rate in the country is 0%."
89366543|NCT04693689|Experimental|Conventional vaccine, 20% adoption rate|"Our survey follows a 2 x 5 between-subjects design. The two dimensions we vary are vaccine technology (conventional vs. RNA) and the hypothetical adoption rate of the new vaccine in the country (0%, 20%, 40%, 60%, 80%). We elicit subjects' willingness to receive the new COVID-19 vaccine given the vaccine technology and a hypothetical adoption rate of the new vaccine.~In this arm, we elicit subjects' willingness to receive a conventional vaccine if its current adoption rate in the country is 20%."
89366544|NCT04693689|Experimental|Conventional vaccine, 40% adoption rate|"Our survey follows a 2 x 5 between-subjects design. The two dimensions we vary are vaccine technology (conventional vs. RNA) and the hypothetical adoption rate of the new vaccine in the country (0%, 20%, 40%, 60%, 80%). We elicit subjects' willingness to receive the new COVID-19 vaccine given the vaccine technology and a hypothetical adoption rate of the new vaccine.~In this arm, we elicit subjects' willingness to receive a conventional vaccine if its current adoption rate in the country is 40%."
88838205|NCT05716243|Experimental|Group B|Group B will receive a NOL-guided analgesia protocol
88838206|NCT03098238|Other|Patients without humoral rejection or DSA|Renal transplant patients with systematic kidney biopsy at 3 months and 12 months Patients without humoral rejection or DSA (Donor Specific Antibodies)
89366545|NCT04693689|Experimental|Conventional vaccine, 60% adoption rate|"Our survey follows a 2 x 5 between-subjects design. The two dimensions we vary are vaccine technology (conventional vs. RNA) and the hypothetical adoption rate of the new vaccine in the country (0%, 20%, 40%, 60%, 80%). We elicit subjects' willingness to receive the new COVID-19 vaccine given the vaccine technology and a hypothetical adoption rate of the new vaccine.~In this arm, we elicit subjects' willingness to receive a conventional vaccine if its current adoption rate in the country is 60%."
89366546|NCT04693689|Experimental|Conventional vaccine, 80% adoption rate|"Our survey follows a 2 x 5 between-subjects design. The two dimensions we vary are vaccine technology (conventional vs. RNA) and the hypothetical adoption rate of the new vaccine in the country (0%, 20%, 40%, 60%, 80%). We elicit subjects' willingness to receive the new COVID-19 vaccine given the vaccine technology and a hypothetical adoption rate of the new vaccine.~In this arm, we elicit subjects' willingness to receive a conventional vaccine if its current adoption rate in the country is 80%."
89366547|NCT04693689|Experimental|RNA vaccine, 0% adoption rate|"Our survey follows a 2 x 5 between-subjects design. The two dimensions we vary are vaccine technology (conventional vs. RNA) and the hypothetical adoption rate of the new vaccine in the country (0%, 20%, 40%, 60%, 80%). We elicit subjects' willingness to receive the new COVID-19 vaccine given the vaccine technology and a hypothetical adoption rate of the new vaccine.~In this arm, we elicit subjects' willingness to receive an RNA vaccine if its current adoption rate in the country is 0%."
89530356|NCT03363503|Active Comparator|Salmeterol/Fluticasone Diskus®|Salmeterol/Fluticasone 50/500 mcg Inhalation Powder (1 puff) twice daily (approximately every 12 hr) via Diskus® for 8 weeks
88838207|NCT03098238|Other|Patient without humoral rejection with a DSA|Patient without humoral rejection with a DSA (Donor Specific Antibodies)Patients with a graft biopsy for a donor-specific anti-HLA antibody
88838208|NCT03098238|Other|Patients with humoral rejection|Patients with humoral rejection
88838209|NCT03398694|Experimental|Arm 1|This is a single arm study so this arm will include all eligible subjects. All subjects will have radiosurgery 1-4 days prior to surgical resection.
88838210|NCT03362502|Experimental|PF-06939926|
88838211|NCT02457260|Experimental|Healthy control|10 healthy adults, age 70 or older to receive 14 Nitrogen (14N) sodium nitrite, 40 mg tid
88838212|NCT02457260|Experimental|HFpEF|10 adults with heart failure and preserved ejection fraction age 70 or older to receive 14N sodium nitrite, 20 or 40 mg tid depending on dose stratification for safety
88838213|NCT02457260|Experimental|HFrEF|10 adults with heart failure and reduced ejection fraction aged 70 or older to receive 14N sodium nitrite, 20 or 40 mg tid depending on dose stratification for safety
88838214|NCT05233410|Experimental|Ruxolitinib|Ruxolitinib cream 1.5% twice daily (BID) for 16 weeks followed by ruxolitinib cream 1.5% BID for an additional 16-week treatment extension period.
88838215|NCT05233410|Placebo Comparator|Vehicle|Vehicle cream for 16 weeks followed by crossover to ruxolitinib cream 1.5% BID in a 16-week treatment extension period.
88838216|NCT04602390|Experimental|ANK-700 SAD Cohort 1, Dose A|All enrolled patients will receive one dose of ANK-700 Dose A
88838217|NCT04602390|Experimental|ANK-700 SAD Cohort 2, Dose B|All enrolled patients will receive one dose of ANK-700 Dose B
88838218|NCT04602390|Experimental|ANK-700 SAD Cohort 3 Dose C|All enrolled patients will receive one dose of ANK-700 Dose C
88838219|NCT04602390|Experimental|MAD Cohort 4 ANK-700 Dose A or Placebo|All enrolled patients will receive three doses of ANK-700 Dose A or placebo
88838220|NCT04602390|Experimental|MAD Cohort 5 ANK-700 Dose B or placebo|All enrolled patients will receive three doses of ANK-700 Dose B or placebo
88838221|NCT05710471|Experimental|Brolucizumab|new drug (brolocizumab) and novel treatment protocol
88838222|NCT05710471|Active Comparator|Aflibercept|aflibercept and continuing on the traditional T&E protocol. There will also be a rescue option for those in the aflibercept arm who are not responding well to also switch to brolocizumab
88838223|NCT02457728|Experimental|Inguinal herniation|In patients with bilateral herniations it should be explored if one glue device (LiquiBandFix8) for mesh fixation and closure of peritoneum is sufficient.
88838224|NCT02458352|Other|Standard dose CT, Ultra-low dose CT|Standard dose non-contrast enhanced CT (clinically indicated) and Ultra low dose non-contrast enhanced CT (as part of the trial)
88838225|NCT05652894|Experimental|HX008|Subjects receive HX008 200 mg intravenous (IV) every 3 weeks (Q3W)
89366548|NCT04693689|Experimental|RNA vaccine, 20% adoption rate|"Our survey follows a 2 x 5 between-subjects design. The two dimensions we vary are vaccine technology (conventional vs. RNA) and the hypothetical adoption rate of the new vaccine in the country (0%, 20%, 40%, 60%, 80%). We elicit subjects' willingness to receive the new COVID-19 vaccine given the vaccine technology and a hypothetical adoption rate of the new vaccine.~In this arm, we elicit subjects' willingness to receive an RNA vaccine if its current adoption rate in the country is 20%."
89366549|NCT04693689|Experimental|RNA vaccine, 40% adoption rate|"Our survey follows a 2 x 5 between-subjects design. The two dimensions we vary are vaccine technology (conventional vs. RNA) and the hypothetical adoption rate of the new vaccine in the country (0%, 20%, 40%, 60%, 80%). We elicit subjects' willingness to receive the new COVID-19 vaccine given the vaccine technology and a hypothetical adoption rate of the new vaccine.~In this arm, we elicit subjects' willingness to receive an RNA vaccine if its current adoption rate in the country is 40%."
89366550|NCT04693689|Experimental|RNA vaccine, 60% adoption rate|"Our survey follows a 2 x 5 between-subjects design. The two dimensions we vary are vaccine technology (conventional vs. RNA) and the hypothetical adoption rate of the new vaccine in the country (0%, 20%, 40%, 60%, 80%). We elicit subjects' willingness to receive the new COVID-19 vaccine given the vaccine technology and a hypothetical adoption rate of the new vaccine.~In this arm, we elicit subjects' willingness to receive an RNA vaccine if its current adoption rate in the country is 60%."
89366551|NCT04693689|Experimental|RNA vaccine, 80% adoption rate|"Our survey follows a 2 x 5 between-subjects design. The two dimensions we vary are vaccine technology (conventional vs. RNA) and the hypothetical adoption rate of the new vaccine in the country (0%, 20%, 40%, 60%, 80%). We elicit subjects' willingness to receive the new COVID-19 vaccine given the vaccine technology and a hypothetical adoption rate of the new vaccine.~In this arm, we elicit subjects' willingness to receive an RNA vaccine if its current adoption rate in the country is 80%."
89366552|NCT03266614|Experimental|Recovery 4 US|This group receives a smartphone with the Recovery 4 US application and access to the application website.
89366553|NCT03266614|No Intervention|Services as usual|This group receives a smartphone but no access to the Recovery 4 US application.
89366554|NCT03126786|Active Comparator|Active|Treatment will consist of IVT injection of Aflibercept followed by an SC injection of CLS-TA
89366555|NCT03126786|Sham Comparator|Control|Treatment will consist of IVT aflibercept injection followed by a sham SC procedure
89366556|NCT04593771|Experimental|Experimental group|80 healthy people were randomly assigned to the experimental group and the control group. The experimental group was injected with BCG-PPD once.
89366557|NCT04593771|Other|control group|80 healthy people were randomly assigned to the experimental group and the control group. The control group was injected with BCG-PPD was marketed once.
89366558|NCT05183061||Hypotensive group|Hypotenson is defined as systolic blood pressure (SBP) < 80 mmHg or a drop more than 20% from baseline SBP for longer than 10 minutes or a drop that requires treatment either vasopressor or inotropic drugs.
89366559|NCT05183061||Non-hypotensive group|The pateints who did not develop hypotensive episodes as aforementioned.
89366560|NCT01360242|Active Comparator|MIMI procedure (two-step strategy)|Thrombus aspiration is performed to achieve TIMI-3 flow. Once TIMI-3 flow is restored and sustained for > 10 minutes, the initial procedure is stopped regardless of the presence of any residual stenosis. A second coronary angiogram is performed 24-48 hours later and the physician is free to decide on the best treatment, i.e. surgery, medical treatment, or stent implantation (drug-eluting stent if indicated for on-label patients). If stenting is required and the thrombus is still too large (greater than twice the artery width), the physician could postpone stent implantation for days or weeks.
88838226|NCT05652894|Active Comparator|Investigator's Choice Chemotherapy|"mFOLFOX6~mFOLFOX6+Bevacizumab~mFOLFOX6+Cetuximab~FOLFORI~FOLFORI+Bevacizumab~FOLFORI+Cetuximab"
88838227|NCT04591080|Experimental|GUMMETAL TiNbTaZr|"TiNbTaZr (Beta-Titanium) Alloy used to manufacture orthodontic archwires. We will be using an archwire with the size of 0.016 x 0.022"
88838228|NCT04591080|Active Comparator|Stainless Steel (CrNi)|"Stainless steel (18% Chromium and 8% Nickel) used as the control, and linked anteriorly to the GUMMETAL counterpart. Size of archwire is 0.016 x 0.022"
88838229|NCT05652816|Sham Comparator|STSG (Split-Thickness Skin Graft)|Patients treated with the standard treatment; autologous skin graft
88838230|NCT05652816|Experimental|Amnion Bilayer Only|Patients treated with artificial graft only
88838231|NCT05652816|Experimental|Amnion Bilayer seeded with co-culture|Patients treated with artificial graft seeded with autologous keratinocyte co-cultured with amnion epithelial stem cells
88838232|NCT05702593|Other|Surface EMG Data Collection|For each subject, EMG activity was recorded from the left and right superficial masseter muscles using a multichannel EMG device.The EMG recordings were obtained with three repetitions during mandibular rest, and maximal voluntary isometric contractions (MVIC) in intercuspation (isometry) pre and post-treatment. The EMG data were recorded for 5 seconds, and three trials with 30 seconds of rest between contractions were performed [Tosato, SENIAM].
88838233|NCT05702593|Other|Pressure pain threshold|The pressure pain threshold was measured using a mechanical pressure algometer (model Baseline® Dolorimeters - Fabrication Enterprises Inc) with a contact head of 1 cm2 area.
88838234|NCT05702593|Other|Maximum Active Mouth Opening (MMO)|A tape measure was used to determine the maximum active mouth opening (MMO).
88838235|NCT05702593|Other|Hamstring Flexibility|The Maximal Hip Flexion Active Knee Extension (MHFAKE) Test, which is an adapted active knee extension test, was performed to evaluate the hamstring flexibility of the participant.
88838236|NCT05702593|Other|Tragus Wall Distance|Tragus wall distance measurement was used to evaluate spinal mobility.
88838237|NCT05702593|Experimental|Static stretching|The participant was positioned supine for static stretching to be applied to the hamstring muscles
88838238|NCT05702593|Experimental|Myofascial Release|For hamstring muscles, the participants were asked to assume a long sitting position on a firm, flat surface with their arms behind their backs and their body weight on their palms.
88838239|NCT02959099||Cases|Patients with acute coronary syndrome (ACS).
88838240|NCT02959099||Controls|Patients without acute coronary syndrome (ACS).
88838241|NCT01636362|Experimental|Mepitel Ag|Mepitel Ag is an antimicrobial, meshed, non-adherent wound contact layer allowing passage of exudate and providing fixation and protection of tissues.
88838242|NCT00359047|Experimental|Documentation|Written educational material on osteoporosis for the participant and the physician.
88838243|NCT00359047|Experimental|Video|A 15-minute educational video on osteoporosis as well as written documentation on osteoporosis for the participant and the physician.
88838244|NCT05544175|Experimental|NEUROMOdulation pain therapy in combination with intensive physiotherapy|"Neuromodulation therapy (low-voltage electrical stimulation of the posterior roots of the spinal cord) by electrodes inserted epidurally from a laminotomy in the lumbosacral region.~Intensive, four hour per day, individual physiotherapy (soft techniques, methods based on neurophysiology, so-called neuroproprioceptive facilitation, inhibition (Vojta's reflex method, Motor programs activating therapy, Proprioceptive neuromuscular stimulation, Bobath concept) will be combined with methods of acquiring motor skills (individualized therapy using the knowledge of sensorimotor learning) will take minimally one month."
88838245|NCT00358423|Experimental|A|
88838246|NCT00358423|Placebo Comparator|B|
89366561|NCT01360242|Sham Comparator|Immediate Stenting (one-step strategy)|The physician is encouraged to implant a stent after the thrombus aspiration (drug-eluting stent if indicated for on-label patients).
89366562|NCT04581057|Experimental|First CVE|
89366563|NCT02456506|Experimental|Hyperfractionated IMRT Group|IMRT (total dose of 65Gy, division 54 times, twice a day, once 1.2Gy, irradiation interval of 6-8 hours)
89366564|NCT02456506|Active Comparator|Conventional Fraction IMRT Group|IMRT (total dose of 60Gy, division 27 times, once a day, every 2.2Gy)
88838247|NCT02896712|Active Comparator|ACT plus CM|Acceptance and Commitment Therapy along with Contingency Management for cocaine use will be administered to help decrease experiential avoidance while increasing acceptance and willingness to experience unpleasant thoughts, feelings, and physical symptoms.
88838248|NCT02896712|Active Comparator|ACT plus CM, with Placebo|Acceptance and Commitment Therapy along with Contingency Management for cocaine use will be administered and augmented with a placebo capsule during Phase 2 (weeks 5-12).
88838249|NCT02896712|Experimental|ACT plus CM, with Modafinil|Acceptance and Commitment Therapy along with Contingency Management for cocaine use will be administered and augmented with a Modafinil (300mg) capsule during Phase 2 (weeks 5-12).
88838250|NCT02896712|Active Comparator|DC plus CM|Drug Counseling and Contingency Management for cocaine use will be administered to help educate patients about important concepts in addiction recovery.
88838251|NCT02896712|Active Comparator|DC plus CM, with Placebo|Drug Counseling and Contingency Management for cocaine use will be administered and augmented with a placebo capsule during Phase 2 (weeks 5-12).
88838252|NCT02896712|Experimental|DC plus CM, with Modafinil|Drug Counseling and Contingency Management for cocaine use will be administered and augmented with a Modafinil (300mg) capsule during Phase 2 (weeks 5-12).
88838253|NCT04744064|Experimental|Soccer and protein supplementation|Soccer training and post exercise supplementation of protein enriched beverage
88838254|NCT04744064|Experimental|Soccer and carbohydrate supplementation|Soccer training and post exercise supplementation of carbohydrate enriched beverage
88838255|NCT04744064|No Intervention|Control group|A preliminary control group continueing normal lifestyle
89366565|NCT01367652|Active Comparator|Letrozole|2.5 mg tablet
88838257|NCT05346601|Other|Chiauranib(In the fasting state)|Experimental: Chiauranib Patients receive 50mg Chiauranib po only once In the fasting state and after 14 days receive 50mg Chiauranib po Only once with High Fat Diet
88838258|NCT05346601|Other|Chiauranib(In the high fat diet state)|Experimental: Chiauranib Patients receive 50mg Chiauranib po only once with High Fat Diet and after 14 days receive 50mg Chiauranib po Only once In the fasting state
88838259|NCT05336695|Experimental|Cognitively Normal Subjects and ADRD subjects|Cognitively Normal Subjects and ADRD subjects
88838260|NCT02766686|Experimental|Radiotherapy with protons|Proton radiotherapy 74-80 Gray equivalent (GyE), 2Gy per fraction, 5 fractions peer week
88838261|NCT02766686|Active Comparator|Radiotherapy with photons|Photon-Intensity-Modulated Radiation Therapy (IMRT) without lymph drainage vessels, 74-80 Gy, 2Gray (Gy) per fraction, 5 fractions peer week
88838262|NCT02766686|Other|Radiotherapy with photons with lymph drainage vessels|Photon-IMRT with lymph drainage vessels, 74-80 Gy, 2Gy per fraction, 5 fractions peer week
88838263|NCT00708890|Experimental|Intervention group|
88838264|NCT00708890|No Intervention|Control group|Will only get a standard information about TSG group (information about meeting etc.)
88838265|NCT00669266||Tumor|Tumor material and corresponding biosamples from patients with adrenal tumors
88838266|NCT00669266||control group|Biomaterial from patients without adrenal tumor
88838267|NCT05524285|Experimental|experimental group|Intracranial Support Catheter
88838268|NCT05524285|Active Comparator|control group|Guide Catheter
88838269|NCT05693155||Individuals with a gambling problem|Recruited from a gambling disorder treatment unit and/or from social media advertising addressing individuals with a gambling problem.
88838270|NCT05693155||Concerned significant others|Recruited as concerned signifiant others of patients at a gambling disorder treatment unit and/or in social media advertising addressing concerned significant others of individuals with a gambling problem.
89001687|NCT00183326|Active Comparator|2|Participants will receive child-centered supportive therapy
89001688|NCT00477295|Active Comparator|Zonisamide|
89366566|NCT01367652|Active Comparator|Femara|2.5 mg tablet
89366567|NCT02456584|Experimental|DMPA 150|single subcutaneous injection of 150mg/mL of DMPA in the abdomen
89366568|NCT02456584|Experimental|DMPA 300|single subcutaneous injection of 300mg/2mL of DMPA in the abdomen
89366569|NCT02456584|Active Comparator|DMPA 104|two injections, given at three months intervals, of 104mg/0.65mL of DMPA in the abdomen
89366570|NCT01360320|Experimental|Green tea extract|Powdered decaffeinated green tea extract of Camellia Sinensis, packed in hard gelatine capsules containing either 150 mg EGCG, bid for 3 years
89366571|NCT01360320|Placebo Comparator|Placebo|Placebo, packed in hard gelatine capsules, bid for 3 years
89366572|NCT03146403|Experimental|GEN-003|60μg of each GEN-003 antigen with 50μg Matrix-M2 adjuvant, administered as a 0.5mL intramuscular (IM) injection
89366573|NCT03146403|Placebo Comparator|Placebo|0.9% normal saline administered as a 0.5mL intramuscular (IM) injection
89366574|NCT03261778|Experimental|Acromion 2.0 Brace|
89366575|NCT03261778|Active Comparator|Mitella Sling|
88838271|NCT05522881||HPV positive-Post treatment|The subject has received any anti-cancer treatment with pathological report of squamous cell carcinoma of oropharynx (soft palate, tonsil, base of tongue, pharyngeal wall, uvula or vallecula) and positive p16 immunohistochemical staining.
88838272|NCT05522881||HPV negative-Post treatment|The subject has received any anti-cancer treatment with pathological report of squamous cell carcinoma of oropharynx (soft palate, tonsil, base of tongue, pharyngeal wall, uvula or vallecula) and negative p16 immunohistochemical staining.
88838273|NCT05522881||HPV positive-Treatment-naïve|The subject has received no anti-cancer treatment with pathological report of squamous cell carcinoma of oropharynx (soft palate, tonsil, base of tongue, pharyngeal wall, uvula or vallecula) and positive p16 immunohistochemical staining.
88838274|NCT05522881||HPV negative-Treatment-naïve|The subject has received no anti-cancer treatment with pathological report of squamous cell carcinoma of oropharynx (soft palate, tonsil, base of tongue, pharyngeal wall, uvula or vallecula) and negative p16 immunohistochemical staining.
88838275|NCT04344379|Active Comparator|Arm Title : hydroxychloroquine|
88838276|NCT04344379|Placebo Comparator|Placebo of hydroxychloroquine|
88838277|NCT04344379|Active Comparator|azythromycin|
89366576|NCT01367730||osteoporosis and osteopenia|Subjects will be stratified based on DXA BMD T-scores.
89366577|NCT02458144|Other|"MIS anterior group"|"Total Hip Arthroplasty anterior surgical approach"
88838278|NCT02465216|Experimental|2 mcg ID93 + 2 mcg GLA-SE Vaccine|Two intramuscular injections of ID93 + GLA-SE at Days 0 and 56. Low dose of antigen and low dose of adjuvant.
88838279|NCT02465216|Experimental|10 mcg ID93 + 2 mcg GLA-SE Vaccine|Two intramuscular injections of ID93 + GLA-SE at Days 0 and 56. High dose of antigen and low dose of adjuvant.
88838280|NCT02465216|Experimental|2 mcg ID93 + 5 mcg GLA-SE Vaccine|Two intramuscular injections of ID93 + GLA-SE at Days 0 and 56. Low dose of antigen and high dose of adjuvant. Placebo injection at Day 28 to maintain blind with the 3 dose arm.
88838281|NCT02465216|Placebo Comparator|Placebo|Two intramuscular injections of normal saline at Days 0 and 56, or Days 0, 28, and 56.
88838282|NCT02465216|Experimental|2 mcg ID93 + 5 mcg GLA-SE Vaccine 3 doses|Three intramuscular injections of ID93 + GLA-SE at Days 0, 28, and 56. Low dose of antigen and high dose of adjuvant.
88838283|NCT05448703||Group 1|Lung cancer patients treated with thoracic radiotherapy
88838284|NCT02465372|Experimental|CSPAP|Schools in this arm will receive the Comprehensive School Physical Activity Program training.
88838285|NCT02465372|No Intervention|Control|Standard practice.
88838286|NCT00359125|Active Comparator|1|RU-486, 600 mg/day for 1 week.
88838287|NCT00359125|Placebo Comparator|2|Placebo, 600 mg/day for 1 week
88838288|NCT05688709|Active Comparator|Control group|"Psychosocial services (PSS) are offered by a trained health worker in a designated space within the health facility. They assess youth for PSS needs and depending on the identified needs, health workers determine the relevant approach for providing PSS. Health workers refer PSS they cannot offer to established referral networks. Specifically, for ART adherence, health workers use the 5As principles to offer adherence psychosocial support. These are;~Assess patient psychosocial concerns and needs that may hinder adherence to ART.~Advise on the benefits of disclosure and support systems to adherence.~Assist patients identify the support systems that will enable them to adhere to treatment.~Agree on family and community support systems (expert client in the community).~Arrange for the patient to join psychosocial support groups and use support systems."
88838289|NCT05688709|Experimental|Intervention|In addition to MOH standard care, we will enrol YLHIVA on a WhatsApp PSG and assign them trained peer counsellors. We will allocate YLHIVA to a WhatsApp group depending on their age and the health facility where they seek care (12). YLHIVA will interact with each other and their peer counsellors through one-on-one private communications and on the group chat.
88838290|NCT05686603|Experimental|P-MLA|a fractional 1064-nm neodymium-doped yttrium aluminum garnet (Nd:YAG) picosecond laser with MLA handpiece (P-MLA for short)
88838291|NCT05686603|Sham Comparator|AF-Er|ablative fractional 2940-nm Er:YAG laser (AF-Er for short)
88838292|NCT03042468|Experimental|All subjects|"177Lu-PSMA-617 [50mCi (1.85GBq) - 300mCi (11.1GBq)] intravenous X2 doses, 2 weeks apart (Visit 1 and 2)~68Ga-PSMA-HBED-CC [5 ±2mCi or 185 ±74MBq] intravenous during screening and at 12 weeks with standard imaging"
88838293|NCT05158452||Observational (focus group)|Participants attend a focus group over 90-120 minutes providing feedback on GCPP intervention.
88838294|NCT04486326|Experimental|crofelemer|125mg bid
88838295|NCT04486326|Placebo Comparator|placebo|bid
88838296|NCT05297773|Experimental|Aerobic Training|Three sessions per week during 4-6-months according to each individual treatment plan. Participants allocated in this group will perform moderate-intensity cycling exercise.
88838297|NCT05297773|Experimental|Resistance training|Three sessions per week during 4-6-months according to each individual treatment plan. Participants allocated in this group will perform weight-machine strength exercises of the upper and lower body.
88838298|NCT05297773|Active Comparator|Control Group|One session per week of relaxation/stretching.
88838299|NCT05652426||Group 1|Basal cerebral oximetry levels between 41-60%
88838300|NCT05652426||Group 2|Basal cerebral oximetry levels > 61%
88838301|NCT05295901|Experimental|experimental group|"In the pre-test phase (first interview) - Patient Diagnosis Form, COPD Self-efficacy Scale, Chronic Disease Care Assessment Scale-Patient Form, COPD Assessment Test (CAT), Modified Medical Research Council (mMRC) Dyspnea Scale average 15-20 min. will be implemented.~After the pre-test, the mCOPD mobile application will be installed on the phones of the patients and it will be checked whether the mobile application is working. mobile application content will be explained. In addition, a pulse oximeter device will be given to the patients by the researcher to record their pulse and saturation values and its use will be explained.~In the final test phase (final interview); The COPD Self-Efficacy Scale, the Chronic Disease Care Assessment Scale-Patient Form, the COPD Assessment Test (CAT), the Modified Medical Research Council (mMRC) Dyspnea Scale and the Satisfaction Questionnaire will be applied to determine the degree of satisfaction"
89366578|NCT02458144|Other|"MIS anterolateral group"|"Total Hip Arthroplasty anterolateral surgical approach"
89366579|NCT01316991|Active Comparator|Chewing gum|Subject will chew gum at defined intervals
89366580|NCT01316991|Placebo Comparator|No Gum|No chewing gum will be provided to subject
88838302|NCT05295901|No Intervention|control group|"In the pre-test phase (first interview); Patient Diagnosis Form, COPD self-efficacy scale, Chronic Disease Care Assessment Scale-Patient Form, COPD Assessment Test (CAT), Modified Medical Research Council (MRC) Dyspnea Scale will be applied. No action will be taken after the interview.~In the final testing phase (final interview); After applying the COPD Self-Efficacy Scale, the Chronic Disease Care Assessment Scale-Patient Form, the COPD Assessment Test (CAT), the Modified Medical Research Council (MRC) Dyspnea Scale, the mCOPD application will be installed on their phones and training"
88838303|NCT04450836|Experimental|Arm A (R-TT)|Regorafenib followed by trifluridine-tipiracil.
88838304|NCT04450836|Experimental|Arm B (TT-R)|Trifluridine-tipiracil followed by Regorafenib.
88838305|NCT04436406|Experimental|Advanced malignant disease (non-small cell lung cancer or malignant melanoma)|"Group 1: Participants with non-small cell lung cancer (NSCLC) as per inclusion/exclusion criteria undergo baseline PD-L1 expression testing by immunohistochemistry and [99m-Tc]-anti-PD-L1 single-domain antibody SPECT/CT imaging at 0 and 9 weeks.~FDG-PET/CT is also performed at baseline (0) and first follow-up (9) weeks scans, in addition to standard CT clinical imaging at 0, 9 and 18 weeks.~Group 2: Participants with malignant melanoma (MM) as per inclusion/exclusion criteria undergo baseline PD-L1 expression testing by immunohistochemistry and [99m-Tc]-anti-PD-L1 single-domain antibody SPECT/CT imaging at 0 and 12 weeks.~FDG-PET/CT is also performed as standard clinical imaging at baseline (0), first follow-up (12) weeks and 24 weeks."
89534687|NCT03329027|Experimental|Vibrating Mode 1|Patients will receive vibrating capsule for 8 weeks of treatment (5 capsules/week)
88838306|NCT05679193|Experimental|Propranolol|Participants will receive Propranolol capsule for a period of 22-28 days, low dose (1 capsule/20mg propranolol twice daily) treatment the first- and last- three days of the treatment period. Higher dose (2 capsules/40mg propranolol twice daily) for the rest of the treatment period.
88838307|NCT05679193|Placebo Comparator|Placebo|Participants will receive Propranolol capsule for a period of 22-28 days, low dose (1 capsule twice daily) treatment the first- and last- three days of the treatment period. Higher dose (2 capsules twice daily) for the rest of the treatment period.
88838308|NCT04795752|Experimental|TearCare Group (Study Device)|
88838309|NCT04795752|Active Comparator|Restasis Group (Control)|
88838310|NCT05501353||Group1|Patients with various types of metastatic colorectal cancer who had underwent the radical resection of colorectal cancer and were planning to undergo radical resection of metastasis
88838311|NCT04795128|Other|IBI322|Single arm
88838312|NCT05292001|Experimental|Treatment|Single infusion of low molecular weight Iron Dextran
88838313|NCT05292001|Placebo Comparator|Placebo|Single infusion of normal saline
88838314|NCT01634178|Experimental|Sequence 1: Apremilast Fasted / Fed|In Period 1 participants will receive a single 30 mg apremilast tablet administered under fasted conditions and in Period 2 participants will receive a single 30 mg apremilast tablet administered after a high fat meal.
88838315|NCT01634178|Experimental|Sequence 2: Apremilast Fed / Fasted|In Period 1 participants will receive a single 30 mg apremilast tablet administered after a high fat meal and in Period 2 participants will receive a single 30 mg apremilast tablet administered under fasted conditions.
88838316|NCT00358267|Active Comparator|RFA|Radiofrequency Ablation (RFA) involves inserting a special needle into the inferior (lower) turbinate that releases high frequency energy, which produces heat. The energy and heat cause tissue denaturation (protein damage) and vaporization. The vaporization reduces tissue volume, and denaturation causes healing with scar tissue formation and contraction of surrounding tissue. This procedure can be done under local anesthesia at the doctor's office.
88838317|NCT00358267|Active Comparator|PRIT|Partial Resection of Inferior Turbinate (PRIT) involves surgically removing a small piece off the turbinate, which also reduces its size.
88838318|NCT03832075|Experimental|postmenopausal osteoporosis|Postmenopausal osteoporotic patients evaluated with Berg Balance Scale, Timed Up and Go test and Korebalance balance system for balance disorder.
88838319|NCT04418934|Experimental|Investigational Product|Blood product from these donors will be processed and stored using the Hemanext One device.
88838320|NCT04418934|No Intervention|Control Product|Blood product from these donors will be stored in a Haemonetics Leukotrap Whole Blood System.
88838321|NCT05652192|Experimental|Experimental|"SBRT: Metastases were treated with SBRT, GTV 45Gy/3F/3d, each course of radiotherapy only treated metastases within 1 organ.~Chemotherapy(GP or TP) was combined with tislelizumab for 4-6 cycles and tislelizumab was maintained until 2 years or disease progression or intolerable toxicity or death.~Maintain: (1) For newly diagnosed metastatic patients, nasopharyngeal and metastatic lymph node irradiation was started 4 weeks after systemic therapy, using IMRT technique, only radiating the GTV of the nasopharyngeal and cervical region, DT 66 Gy/30 F/6 weeks was recommended. Tislelizumab was continued during radiotherapy and tislelizumab was used during maintenance."
88838322|NCT00359359|Experimental|Sagopilone and cisplatin|The study drug sagopilone was administered in combination with a fixed dose of cisplatin
88838323|NCT04782804|Active Comparator|Capecitabine|Capecitabine as Adjuvant Therapy Oral capecitabine (1250 mg/m²) was given post operatively twice a day on days 1 to 14 of a 3-weekly cycle for 24 weeks (eight cycles), and observation commenced within 16 weeks of surgery.
88838324|NCT04782804|Experimental|Capecitabine+PD-1 Antibody（Tislelizumab）|Capecitabine+PD-1 Antibody（Tislelizumab）as Adjuvant Therapy Oral capecitabine (1250 mg/m²) was given post operatively twice a day on days 1 to 14 of a 3-weekly cycle for 24 weeks (eight cycles), and observation commenced within 16 weeks of surgery. PD-1 Antibody（Tislelizumab, 200mg） was given q3w iv.
88838325|NCT04418388|Experimental|A|
88838326|NCT04418388|Experimental|B|
88838327|NCT04418388|Experimental|C|
88838328|NCT05282017||Case Group|Meets the COVID-19 like case definition AND Tests positive for at least one SARS-CoV-2 RT-PCR test or Quick-Test (Antigen) with specimens collected between 14 days prior to and including within 24 hours of the day of hospital admission (day 0).
89534688|NCT03329027|Experimental|Vibrating Mode 2|Patients will receive vibrating capsule for 8 weeks of treatment (5 capsules/week)
89534689|NCT03329027|Sham Comparator|Sham|Patients will receive sham capsule for 8 weeks of treatment (5 capsules/week)
88838329|NCT05282017||Control Group|Meets the COVID-19 case definition AND Tests negative for all SARS-CoV-2 RT-PCR or Quick-Test (Antigen) tests with specimens collected between 14 days prior to and including a negative test the day at hospital admission (day 0).
88838330|NCT04781400|Experimental|Remote service delivery model PLUS mobile phone support|Remote service delivery plus mobile intervention via SMS will include weekly check-ins from study staff, calls from a trained counsellor on request, and access to a two-way messaging feature.
89178959|NCT03968276|Experimental|use of digital tablet|"if the patient is included in the study, an educational tablet (digital tablet) is given to the patient.~The first connection to the tablet and then to the My medication protects my vessels application is made by the investigator in the presence of the patient. The application is configured by the investigator with the choice of the vascular pathology(s) corresponding to the patient included and the prescribed anti-thrombotic treatments. Thus, for each patient, the content of the tablet is adapted and personalized according to his vascular profile.~After discharge from hospital, the patient has the educational tablet at his disposal for 1 month at home. The application offers patients various information supports (tools, questionnaires and pill box). Throughout its use, it may contact the investigating physician via a telephone number available within the application if it encounters a problem related to the study."
89178960|NCT00805766|Experimental|TA-650|
89366581|NCT03634878|Experimental|Perineal ultrasound to visualize the strips and their position|
89366582|NCT01317381||ICU patients|Admitted patients to the ICU
88838331|NCT04781400|Active Comparator|Remote service delivery model|Remote service delivery model.
88838332|NCT05651880|Experimental|Patient treated with baricitinib|Patient treated with baricitinib at a dose of 4 mg per day, taken orally in the morning, with one tablet per day for 6 months.
88838333|NCT05668195|Experimental|aerobic exercise group|The patients aged 6-12 with a diagnose of ADHD of this group receive systematic aerobic exercise and intelligent monitoring system in executive skill training for 13 weeks, including those taking methylphenidate or not.
88838334|NCT05668195|Active Comparator|executive skill training group|The patients aged 6-12 with a diagnose of ADHD of this group receive executive skill training for 13 weeks, including those taking methylphenidate or not.
88838335|NCT05245825|Experimental|Flaxseed and dietary plan|30 g of ground flaxseed daily and a dietary plan
88838336|NCT05245825|Other|Control|Dietary plan controlled in alpha-linolenic acid consumption
89366583|NCT01360476|Active Comparator|Vitamin D|
88838337|NCT05651646|Experimental|Interventional Arm|A total of 50 subjects who are undergoing dorsal column stimulator trial will be studied and placed on the SECURE study where their trial leads will be anchored using the StimfixTM system. The trial duration will be for seven days as per standard of care.
88838338|NCT05651490|Experimental|Intervention Group (PST-D)|Participants in the intervention group will receive usual care comprising of routine follow-up checks from their hospitals on top of the intervention (PST-D). The intervention consists of one introductory session, up to eight weekly treatment sessions, and three monthly maintenance sessions; these are individual sessions of approximately 30 to 45 minutes each and will be conducted over the phone, video call, or face-to-face depending on the participant's preference.
88838339|NCT05651490|Active Comparator|Attention control group|The participants in the control group will receive usual care comprising of routine follow-up checks from their hospitals. They will also receive one introductory session and up to eight weekly treatment sessions; these are individual sessions of approximately 30 to 45 minutes each and will be conducted over the phone, video call, or face-to-face depending on the participant's preference.
88838340|NCT02978443|Experimental|Nivolumab-Ipilimumab Combination Therapy|All patients will receive nivolumab administered IV over 60 minutes at 1 mg/kg combined with ipilimumab administered IV over 90 minutes at 3 mg/kg every 3 weeks for 4 treatment cycles (Induction) then continue with nivolumab administered IV over 60 minutes at 3 mg/kg every 2 weeks until progression, intolerable toxicity, or a maximum of 48 weeks, whichever comes first (Maintenance). Patients exhibiting complete response (CR) should continue nivolumab monotherapy at least 12 weeks beyond documentation of CR, if possible.
88838341|NCT04343911|No Intervention|conventional positioning|positioning with shoulder braces
88838342|NCT04343911|Active Comparator|positioning on Pink Pad ®|
88838343|NCT02465450|Experimental|JBT101 (lenabasum) 1 mg|JBT-101 1 mg once a day on Days 1-28
88838344|NCT02465450|Experimental|JBT-101 (lenabasum) 5 mg|JBT-101 5 mg once a day on Days 1-28
88838345|NCT02465450|Placebo Comparator|Placebo|Placebo once a day on Days 1-28.
88838346|NCT02465450|Experimental|JBT-101 (lenabasum) 20 mg QD|JBT-101 20 mg once a day on Days 29-84.
88838347|NCT02465450|Experimental|JBT-101 (lenabasum) 20 mg BID|JBT-101 20 mg twice daily on Days 29-84.
88838348|NCT02465450|Placebo Comparator|Placebo BID|Placebo twice daily on Days 29-84.
88838349|NCT00358345||1|Intermediate AMD
88838350|NCT00358345||2|Newly diagnosed CNV
88838351|NCT04000152|Active Comparator|Control group (group 1)|Deferred single day 6/7 blastocyst transfer with blastocyst selection according to morphology.
88838352|NCT04000152|Experimental|Intervention group (group 2)|Deferred single day 6/7 blastocyst transfer with blastocyst selection according to the analysis of the spent culture media (niPGT-A).
88838353|NCT04192500|Experimental|OVX836 - 90µg dose|Adjuvant-free recombinant influenza candidate vaccine based on the Nucleoprotein (NP) of the influenza virus. One single administration intramuscularly of a 90µg dose on Day 1.
88838354|NCT04192500|Experimental|OVX836 - 180µg dose|Adjuvant-free recombinant influenza candidate vaccine based on the Nucleoprotein (NP) of the influenza virus. One single administration intramuscularly of a 180µg dose on Day 1.
88838355|NCT04192500|Active Comparator|Quadrivalent seasonal influenza vaccine (Influvac TetraTM)|Licensed quadrivalent seasonal influenza subunit vaccine for season 2019-2020. One full dose to be administered at Day 1
88838356|NCT00608972|Experimental|Doxil, Carboplatin and Bevacizumab|
88838357|NCT02729714|Active Comparator|Suvorexant or Placebo|10 Suvorexant or Placebo mg orally at bedtime with an optional up-titration to 15 mg Suvorexant or Placebo orally at bedtime after 2 weeks. The first treatment period will be 4 weeks. Subjects will be randomized 1;1 to receive Suvorexant or matching placebo. Followed by a 2 week washout period with placebo. Subjects will then be crossed over into the alternate treatment group. Subjects on active treatment for period 1 will be switched to placebo, those on placebo in period 1 will switch to Suvorexant
89001689|NCT00477295|Active Comparator|Carbamazepine|
89366584|NCT01360476|Placebo Comparator|placebo|
88838358|NCT02729714|Placebo Comparator|Placebo or Suvorexant|First treatment period will be 4 week which subjects will be randomized 1;1 with either Suvorexant or placebo. Followed by 2 week washout period with placebo. Subjects will then be crossed over into the alternate treatment group. Subjects on active treatment for period 1 will be switched to placebo, those on placebo in period 1 will switch to Suvorexant.
89366585|NCT03261856||small intetsinal bacterial overgrowth|Glucose breath test, 75 g glucose in 250 ml water. Breath samples collected at baseline and every 15 min for 2 hours
89366586|NCT03261856||Fructose breath Test|Fructose breath test, 25 g fructose in 250 ml water. Breath samples collected at baseline and every 30 min for 3 hours
89366587|NCT03261856||Lactose Breath test|Lactose breath test, 25 g lactose in 250 ml water. Breath samples collected at baseline and every 30 min for 5 hours
88838359|NCT02555982|Experimental|EXPERIMENTAL GROUP|"Patients eligible for inclusion will be randomized to one of the two groups:~Experimental group: 60 patients will receive 2 injections of Btx A (BOTOX - Allergan), one on D0 and one at 12W (into each splenius capitis).~Control group: 60 patients will receive 2 injections of placebo, one on D0 and one at 12W (into each splenius capitis)."
88838360|NCT02555982|Other|CONTROL GROUP|"Patients eligible for inclusion will be randomized to one of the two groups:~Experimental group: 60 patients will receive 2 injections of Btx A (BOTOX - Allergan), one on D0 and one at 12W (into each splenius capitis).~Control group: 60 patients will receive 2 injections of placebo, one on D0 and one at 12W (into each splenius capitis)."
88838361|NCT04744688||48 cytoreductive surgery with HIPEC patients|48 patients with peritoneal metastases from colorectal cancer undergoing cytoreductive surgery with HIPEC (cytoreductive surgery with HIPEC patients)
88838362|NCT04744688||48 minimally invasive patients|48 rectal cancer patients undergoing minimally invasive rectal cancer resection
88838363|NCT04802382|Experimental|Arm 1 - CimetrA-1|a total dose containing a combination of Artemisinin 12 mg, Curcumin 40 mg, Boswellia 30 mg, and Vitamin C 120 mg in spray administration - divided into 4 separate doses given as an add on therapy, 4 doses over 48 hours (day 1 and day 2), twice a day (morning and evening).
88838364|NCT04802382|Experimental|Arm 2 - CimetrA-2|a total dose containing a combination of Artemisinin 8.4 mg, Curcumin 28 mg, Boswellia 21 mg, and Vitamin C 84 mg in spray administration - divided into 4 separate doses given as an add on therapy, 4 doses over 48 hours (day 1 and day 2), twice a day (morning and evening).
88838365|NCT04802382|Placebo Comparator|Arm 3 - Placebo|composed of the same solvent but without active ingredients, given as an add on therapy in spray administration, 4 doses over 48 hours (day 1 and day 2), twice a day (morning and evening).
89366588|NCT01317069|Experimental|Fluorouracil implant|
89366589|NCT01367808|Placebo Comparator|Placebo|
89366590|NCT01367808|Active Comparator|Vorikonazole|
89366591|NCT01367808|Active Comparator|Posakonazole|
88838366|NCT05648916||Patients with and without HO before Celecoxib clinical pathway|Patients with and without heterotopic ossification (HO) before the clinical pathway was changed to include celecoxib following cementless total hip joint replacement surgery between periods 2009-2012.
88838367|NCT05648916||Patients with and without HO after Celecoxib clinical pathway|Patients with and without heterotopic ossification (HO) after the clinical pathway was changed to include celecoxib following cementless total hip joint replacement surgery between periods 2013-2020.
88838368|NCT02508012|Experimental|Immuno monitoring|in case of loss of response, the clinician uses immunomonitoring data to adapt the treatment following a treatment algorithm.
88838369|NCT02508012|No Intervention|No immuno monitoring|in case of loss of response, immunomonitoring data are not transmit to the clinician who adapts the treatment with classical biological informations.
88838370|NCT05648058|Experimental|nefopam|administration of intravenous nefopam to prevent Rituximab Transfusion Reaction
88838371|NCT05648058|Active Comparator|diphenhydramine|administration of intravenous diphenhydramine to prevent Rituximab Transfusion Reaction
88838372|NCT05653609||Telemonitoring|Patients monitored by the Cureety digital platform
88838373|NCT05218135||Intervention|Breakthrough improvement collaborative
88838374|NCT02978131||Patients with a clinical diagnosis of TB|Patients with a clinical diagnosis of TB. Retrospective study on biopsy samples
89178961|NCT02608970|Experimental|BMS-986177|BMS-986177 specified dose on specified days
89178962|NCT02608970|Other|Placebo|Placebo specified dose on specified days
89366592|NCT01317225|Experimental|17 α hydroxyprogesterone caproate|17α-Hydroxyprogesterone caproate.
89366593|NCT01317225|Placebo Comparator|Placebo|Saline solution.
89366594|NCT01363206|Experimental|Single arm open label|GM-CSF and Ipilimumab
89366595|NCT01344213|Active Comparator|Pregabalin|Oral single-dose of pregabalin (150 mg) and 1 capsule of placebo (P) 1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg.
89366596|NCT01344213|Active Comparator|Celecoxib|Oral single-dose of celecoxib (400 mg) and 1 capsule of placebo (C) 1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg.
89366597|NCT01344213|Active Comparator|Pregabalin with celecoxib|Oral single-dose of pregabalin (150 mg) and celecoxib (400 mg) (PC) 1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg.
89366598|NCT01344213|Placebo Comparator|Placebo|Oral single-dose of placebo 2 capsules 1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg
89366599|NCT04416048|Experimental|Rivaroxaban|Subjects will receive treatment with rivaroxaban. (for more information see intervention description)
89366600|NCT04416048|Other|Standard of Care|Subjects will receive standard of care (SOC) treatment SOC with prophylactic LMWH or UFH
89366601|NCT04941742||Active eosinophilic esophagitis|
89366602|NCT04941742||Eosinophilic esophagitis in remission|
89366603|NCT04941742||No eosinophilic esophagitis|
89366604|NCT04766385|Experimental|KHK7791|During the dosing period, subjects administer the study drug (KHK7791 or placebo) twice daily just before meals in a double blind. The starting dose of the study drug is 5 mg at a time, and the dose is adjusted in the range of 5, 10, 20, and 30 mg at a time based on the dose adjustment criteria described in the study protocol. Dosage adjustment is performed step by step.
89366605|NCT04226664|Active Comparator|Intervention|Bariatric surgery will consist of laparoscopic Roux-en-Y gastric bypass or sleeve gastrectomy performed at the discretion of the surgeon and according to local standards.
89366606|NCT04226664|No Intervention|Control|Medical Weight Management (MWM) corresponds to the standard medical practice for weight loss that is available at the local participating centre, and thus reflects the local standard of care.
88838375|NCT05449561||Discrete Choice qualitative interview|We will invite at least 20 participants with at least mild level of depressive symptoms to participate in individual interviews. The interviews will be in semi-structured format. Upon provision of informed consent and completion of demographics survey, we will ask respondents a single question of what matters to them when considering the use of psychotherapy, with adequate probes during the conversation. This will ensure uniformity of the topics to be discussed, and the level of digression allowed.
88838376|NCT05210101|Other|Sotrovimab|Two intravenous (IV) doses of sotrovimab were be administered in total - the first on Treatment Day 1 (500mg) and the second on Treatment Day 2, approximately 8-14 weeks after the first dose, at a higher 2000mg dose, in light of the reduced antiviral susceptibility of the BA.2 subvariant to sotrovimab, with the dosing interval determined by theoretical modeling of the duration of efficacy of sotrovimab as antiviral prophylaxis based on the rising prevalence of the Omicron BA.2 subvariant.
88838377|NCT04344067|No Intervention|Control Group|
89366607|NCT03266224||Wryneck|those with a condition
89366608|NCT01317459|Experimental|Lifestyle counselling|
89366609|NCT01317459|Experimental|No intervention|Care as usual
89366610|NCT04488406||Graves' Orbitopathy|Graves' Orbitopathy patients who undergoing orbital decompressive surgery
89366611|NCT04488406||Control Patients|Patients undergoing eye surgery for unrelated reasons
89366612|NCT01363284|Experimental|Duloxetine|The first week of the treatment is the placebo treatment. The effect of placebo will be taken into consideration for further evaluation the duloxetine effect on clinical pain and descending pain inhibition capabilities.
89366613|NCT03265912||Mild Traumatic Brain Injury|Subjects enrolled in the GE healthcare study: Advanced MRI Applications for Mild Traumatic Brain Injury-Phase 2 (mTBI-phase 2), mTBI (Mild Traumatic Brain Injury) patient group also called as Arm 1 in this study.
89366614|NCT03265912||Non Mild Traumatic Brain Injury|Subjects enrolled in the GE healthcare study, Advanced MRI Applications for Mild Traumatic Brain Injury-Phase 2 (mTBI-phase 2), non-TBI (Non Mild Traumatic Brain Injury) patients also called as Arm 2 in this study.
89366615|NCT01363362|Experimental|glaucoma patients|Glaucoma patients undergoing selective laser trabeculoplasty for further IOP reduction
89366616|NCT03265834|Experimental|Long course antibiotic therapy (28 days)|Antibiotic therapy for a duration of 28 days
89366617|NCT03265834|Active Comparator|Short course antibiotic therapy (≤10 days)|Antibiotic therapy for a duration of ≤10 days
89366618|NCT01319292||Asthma children|children with asthma symptoms through screening
89366619|NCT01319292||normal children|children without symptoms of asthma
88838378|NCT04344067|Experimental|Far Infrared Therapy Group|In this study, the top radiator of the far infrared emitter was set at a height of 25 cm above the umbilicus with a treatment time of 40 minutes during the initial 1 hour of both the first daily and the last night-time indwelling dialysate of each daily regular peritoneal dialysis regimen.
89366620|NCT03733353|Other|Cohort 1|12 healthy volunteers; 8 on EDP1815, 4 on placebo. Dose=1/10th of HED, capsule, once daily, 15 days
89366621|NCT03733353|Other|Cohort 2|12 healthy volunteers; 8 on EDP1815, 4 on placebo. Dose= 1 x HED, capsule, once daily, 15 days
89366622|NCT03733353|Other|Cohort 3|12 subjects with mild to moderate psoriasis; 8 on EDP1815, 4 on placebo. Dose= 1 x HED, capsule, once daily, 29 days
89366623|NCT03733353|Other|Cohort 4|24 subjects with mild to moderate psoriasis; 16 on EDP1815, 8 on placebo. Dose= 5 x HED capsule, once daily, 29 days
88838379|NCT02959333|Experimental|hAEC treatment|hAEC: human amniotic epithelial cells 3-5*10^7 /5 ml
89178963|NCT00805532|Experimental|Behavioral Activation|Behavioral Activation (BA), modified to be delivered in 6-8, 60 minute sessions to address PTSD-related problems.
89178964|NCT00805532|Active Comparator|Treatment as Usual|Treatment As Usual for PTSD (TAU) within VA PTSD specialty clinics. Actual clinical practice varies between sites and between providers within sites, as is typical of the VA health care system.
89178965|NCT05752838||Diagnosed with LDH and had LDH-related radiating leg pain|
89178966|NCT04019756||Patients with cancer|50 patients ultimately diagnosed with bladder cancer and 50 control patients (diagnosis of cancer reversed at cystoscopy or cystoscopy for another cause)
89366624|NCT03733353|Other|Cohort 5|24 subjects with mild to moderate atopic dermatitis; 16 on EDP1815, 8 on placebo. Dose= 5 x HED, mini-tablets in capsule, once daily, 29 days
89366625|NCT03733353|Other|Cohort 6|24 subjects with mild to moderate psoriasis; 16 on EDP1815, 8 on placebo. Dose=5 x HED, mini-tablets in capsule, once daily, 29 days.
89366626|NCT03733353|Other|Cohort 7|24 subjects with mild to moderate atopic dermatitis; 16 on EDP1815, 8 on placebo. Dose= 5 x HED, capsule, once daily, 56 days
89366627|NCT03733353|Other|Cohort 8|24 subjects with mild to moderate psoriasis; 16 on EDP1815, 8 on placebo. Dose= 8 x HED, tablet, once daily, 56 days
89366628|NCT03733353|Other|Cohort 9|24 subjects with mild to moderate psoriasis; 16 on EDP1815, 8 on placebo. Dose= 2 x HED, capsule, once daily, 56 days
89366629|NCT03733353|Other|Cohort 10|24 subjects with mild to moderate atopic dermatitis; 16 on EDP1815, 8 on placebo. Dose= 4 x HED, capsule, once daily, 56 days
89366630|NCT01367964|Experimental|ACTH treatment|Infants with a Type 3 EEG (pre-hypsarhythmia) will be treated with ACTH for 2 weeks.
89366631|NCT02458222|Experimental|game therapy then standard therapy|participants will take part in language game therapy followed by standard aphasia therapy
89366632|NCT02458222|Experimental|standard therapy then game therapy|participants will have standard aphasia therapy first then will take part in language game therapy
89366633|NCT04386837||Aphasics|Patients with a left MCA infarct due to CVA will be included in the study. Each subject will be administered an aphasia screening test less than 3 minutes in length. The same test will be administered by another clinician to the same patient within a maximum of 12 hours to assess the inter-rater reliability of the test.
89366634|NCT01347723||Supportive care (pain therapy)|Patients undergo scrambler therapy for 30 minutes daily for up to 10 consecutive days. Treatment continues in the absence of unacceptable toxicity.
89366635|NCT03265756||Healthy children|250 3D facial images of healthy children under 5yrs of age in the Democratic Republic of Congo (DRC).
89366636|NCT03265756||Suspected Pneumonia|50 young children (under 5 yrs) in hospital/clinics in Butembo DRC with suspected pneumonia
89366637|NCT01317537|Experimental|Received personal health record|received personal health record access
89366638|NCT01317537|No Intervention|No personal health record|did not receive personal health record
89366639|NCT05234788|Experimental|TransRadial access|Patients in this group are thus treated using a TRA approach
89366640|NCT05234788|Active Comparator|TransFemoral Access|Patients in this group are thus treated using a TFA approach.
88838380|NCT02959411|Experimental|Tolvaptan|Tolvaptan 15-60 mg, once daily for 4 days or until hospital discharge
88838381|NCT02959411|Active Comparator|Standard of care diuretic therapy|Usual standard of care diuretic therapy for patients with acute decompensated heart failure
88838382|NCT05449873|Experimental|Patients with recurrent hepatocellular carcinoma after locoregional treatment|Patients with chronic liver disease have recurrent hepatocellular carcinoma which is diagnosed on contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI).
88838383|NCT02977819|Experimental|Meditation program|Meditation courses and at-home practice
88838384|NCT02977819|Active Comparator|English learning courses|English learning courses and at-home practice
88838385|NCT02977819|No Intervention|No intervention|Follow-up without Meditation courses or English Learning courses
88838386|NCT05190991|Experimental|RPH-104 80 mg q2w (160 mg q2w) depending on the dose in the core CL04018065 study|RPH-104 80 mg once every 2 weeks subcutaneously or RPH-104 160 mg once every 2 weeks subcutaneously (In case of FMF attack development, patients who receive 80 mg of the drug may be switched to the increased maximum drug dose 160 mg based at the discretion of the investigator. A dose of 160 mg should be administered by two subcutaneous injections in two different quadrants.)
88838387|NCT05183503||TMD group|Patients diagnosed with TMD
88838388|NCT05434585|Experimental|Test group 1: ABO1009-DP|Intramuscularly injecting 15 μg of ABO1009-DP into lateral deltoid of the upper arm of subjects on D0 and D28, respectively.
88838389|NCT05434585|Experimental|Test group 2: ABO-CoV.617.2|Intramuscularly injecting 15 μg of ABO-CoV.617.2 into lateral deltoid of the upper arm of subjects on D0 and D28, respectively.
88838390|NCT05434585|Placebo Comparator|Control group: Placebo|Intramuscularly injecting placebo into lateral deltoid of the upper arm of subjects on D0 and D28, respectively
88838391|NCT05427955|Active Comparator|One-level Erector Spinae Plane Block|After the linear ultrasound (US) probe will be placed 2-3 cm lateral to the T5 spinous process, 30 ml of 0.25% bupivacaine hydrochloride will be injected cauda-cranially into the interfacial space below the erector spinae muscle, above the transverse process.
88838392|NCT05427955|Active Comparator|Bi-level Erector Spinae Plane Block|After the linear ultrasound (US) probe will be placed 2-3 cm lateral to the T4 spinous process, 15 ml of 0.25% bupivacaine hydrochloride will be injected cauda-cranially into the interfacial space below the erector spinae muscle, above the transverse process. Next, the needle will be withdrawn till subcutaneously and the linear US probe will be placed 2-3 cm lateral to the T6 spinous process. Finally, 15 ml of 0.25% bupivacaine hydrochloride will be injected cranio-caudally into the interfacial space below the erector spinae muscle, above the transverse process.
88838393|NCT05426161|Experimental|Botulinum Toxin A|Open-label study
88838394|NCT05426005|Experimental|Cadonilimab|Cadonilimab alone
88838395|NCT05630833|Experimental|Gepotidacin + Placebo|
88838396|NCT05630833|Active Comparator|Nitrofurantoin + Placebo|
88838397|NCT00359671|Experimental|1|Arm 1: study drug
88838398|NCT00359671|Other|2|Arm 2: study drug + comparator
88838399|NCT02978209|No Intervention|Only moisturizer, no carbamide|20 patients with Ichthyosis Vulgaris at age 0-80 years old. One body half
88838400|NCT02978209|Active Comparator|Moisturizer + 7,5 % carbamide|20 patients with Ichthyosis Vulgaris at age 0-80 years old. Other body half
88838401|NCT04744909|Experimental|Percutaneous tracheotomy using a new device|
88838402|NCT03830905|Experimental|XC221|XC221 200 mg orally. 2 tablets of XC221 100 mg once daily during 3 days of treatment period
88838403|NCT03830905|Placebo Comparator|Placebo|Placebo orally. 2 tablets of Placebo once daily during 3 days of treatment period
88838404|NCT05404321||Patient with early stage triple negative breast cancer|
88838405|NCT04343833|Active Comparator|Control with Standard dental implant|Patients were treated with implants Inhex Ticare Standard (Mozo Grau, Ticare, Valladolid, Spain). The implants presented a surface treated with Reabsorbable Blast Media (RBM), conical macro-design with non-aggressive threads, internal connection, and platform switching. On the implant shoulder, the beveled design of the platform was characterized by a rounded shape of 45º.
88838406|NCT04343833|Experimental|Test with the new implant design|Patients were treated with Implants Inhex Quattro Ticare (Mozo Grau, Ticare, Valladolid, Spain). The implants also presented a surface treated with RBM, conical macro-design with expanded micro threads, internal connection, and platform switching.On the implant shoulder, the beveled design of the platform was characterized by a rounded shape of 45º.
88838407|NCT05141539|Experimental|Rehabilitation assessment software|This arm applies the developed rehabilitation assessment software by using two web cameras placed in the front and the side of the subject. The subject sits between two cameras. The observer asks the subject to move the head in each direction, to open the mouth, and to move the tongue. The software will measure CROM, mouth opening, and tongue movement.
89001690|NCT00183365|Experimental|1|Participants will receive the Protecting Families Program with individual parent training
89001691|NCT00183365|Active Comparator|2|Participants will receive parent training alone
89366641|NCT01347801|Placebo Comparator|2C - 1|TNF and OGTT and saline
89366642|NCT01347801|Active Comparator|2C - 2|TNF and OGTT and GLP-1
89366643|NCT01347801|Placebo Comparator|2C - 3|TNF and IVGTT and saline
89366644|NCT01347801|Active Comparator|2C - 4|TNF and IVGTT and GLP-1
89366645|NCT01347801|Placebo Comparator|2A-1|Saline infusion and OGTT
89366646|NCT01347801|Placebo Comparator|2A-2|Saline and IVGTT
89366647|NCT01347801|Active Comparator|2A-3|TNF and OGTT
89366648|NCT01347801|Active Comparator|2A-4|TNF and IVGTT
89366649|NCT01347801|Experimental|1C|OGTT and corresponding IVGTT
89366650|NCT03265678||Arm|Registered participants will undergo a clinical assessment to determine whether they have high or low levels of skin ageing. The study will recruit 5 subjects with low levels of skin ageing and 5 subjects with high levels of skin ageing. Recruited patients will undergo skin punch biopsies, blood sampling and collection of lifestyle data.
89366651|NCT04733560|Experimental|Pudendal nerve block|25 women will receive pudendal nerve blocks of 0.25% Bupivicaine 10ml administered vaginally prior to making any surgical incisions.
89366652|NCT04733560|Sham Comparator|Placebo|25 women will receive sham pudendal nerve blocks using normal saline. These will also be administed vaginally prior to making any surgical incisions.
89366653|NCT01347957|Experimental|Nitric Oxide (NO) Gel|
89366654|NCT01347957|Placebo Comparator|Placebo Gel|
89366655|NCT04735965|Experimental|Dexmedetomidine group|
89366656|NCT04735965|Active Comparator|Meperidine group|
89366657|NCT04735965|Placebo Comparator|Control group|
89366658|NCT03265990|Experimental|Group A|Conventional haemrrhoidectomy,Ferguson technique
88838408|NCT05141539|Experimental|video-fluoroscopic swallowing and FOIS.|This arm applies video-fluoroscopic swallowing (VFSS) and functional oral intake scale (FOIS) to measure the direct, dynamic view of oral, pharyngeal, and upper esophageal function during swallowing with food and liquid mixed with barium, and the functional intake of dysphagic patients, respectively.
88838409|NCT05133115|Experimental|Intervention Group|Schools with adolescents aged 12 to 15 in a context at risk. They will follow the intervention for 6 weeks (6 sessions, once a week).
88838410|NCT05133115|No Intervention|Control Group|Schools in the control group will be all waitlisted to receive the intervention during the following academic year should it prove effectiveness. They will fill in the same research questionnaires as the Intervention group and at the same time period (January to December 2022).
88838411|NCT02977897||Diarrhea on MMF|Solid organ transplant recipients on MMF who develop diarrhea while taking the drug. Fecal calprotectin will be measured in their stool and Octreotide Acetate will be used to treat their diarrhea.
88838412|NCT05129059|Experimental|Logotherapy|Participants will receive individual logotherapy counseling by the investigator for 8 visits in 4 weeks.
88838413|NCT05129059|No Intervention|Control|Participants will receive routine care.
88838414|NCT05128201|Experimental|System treatment plus consolidative radiotherapy and Maintenance treatment|4-6 Cycles System chemotherapy (Camrelizumab , Gemcitabine and cisplatin or nedaplatin) ; And local consolidative radiotherapy for all metastatic lesion (30-45Gy/3-8F) and Maintenance of Camrelizumab (total 2 years; from first cycles of System chemotherapy to last cycles of miantenance of camrelizumab)
88838415|NCT05115019|Experimental|Group A (RUTI)|Participants will receive one dose of RUTI® vaccine at the baseline visit, which will be administered subcutaneously in the deltoid region at a dose of 25 µg of fragmented, purified and liposomed heat-inactivated Mycobacterium tuberculosis bacilli (FCMtb) in an injection volume of 0.3 m
88838416|NCT05115019|Placebo Comparator|Group B (Placebo)|Participants will receive one dose of sterile physiological serum at the baseline visit, which will be administered subcutaneously in the deltoid region.
88838417|NCT00359905|Experimental|Silodosin|
88838418|NCT00359905|Active Comparator|Tamsulosin|
89366659|NCT03265990|Experimental|Group B|Ligasure haemorrhoidectomy
89366660|NCT01344525|No Intervention|Control group|Nutritional counselings every 6 months, no further intervention
89366661|NCT01344525|Experimental|"low-calorie-diet (LCD)-based lifestyle intervention"|12 months multidisciplinary weight loss program including three months low-calorie formula diet (800 kcal) (OPTIFAST®52 program)
89366662|NCT01344525|Experimental|Laparoscopic gastric sleeve intervention|
89366663|NCT01344525|Experimental|Conventional bariatric surgery|Gastric Banding and Gastric Bypass
89366664|NCT03265444|Experimental|CS10BR05|The single injection of CS10BR05 Inj. in the carotid artery
89366665|NCT02456428||Treated with incretins|Current use of incretin-based drugs ((DPP-4 inhibitors [sitagliptin, vildagliptin, and saxagliptin] or GLP-1 analogs [exenatide, liraglutide]) alone or in combination with other anti-diabetic drugs (if the prescription overlaps with the index or event day with a 30-day grace period).
89366666|NCT02456428||Treated with insulin|Current use of insulins between base cohort entry and the index or event day (alone or in combination with other anti-diabetic drugs) and no current use of incretin-based drugs.
89366667|NCT02456428||Treated with ≥2 oral hypoglycemic agents|Current use of 2 or more non-insulin anti-diabetic medications (biguanides, sulfonylureas, thiazolidinediones, alpha-glucosidase inhibitors, meglitinides) (if the prescriptions overlap with the index or event day with a 30-day grace period), and no current use of incretin-based drugs or insulins.
89366668|NCT02456428||Treated with single oral agent|Current use of any single non-insulin anti-diabetic medications (biguanides, sulfonylureas, thiazolidinediones, alpha-glucosidase inhibitors, meglitinides) (if the prescription overlaps with the index or event day with a 30-day grace period) and no current use of more than 2 OHAs, incretin-based drugs, or insulins.
89366669|NCT02456428||Not currently exposed group|All patients not currently exposed to: incretin-based drugs, insulins, ≥2 OHAs, or a single OHA.
89366670|NCT01344603||epidural|
88838419|NCT00359905|Placebo Comparator|Placebo|
89366671|NCT01344603||standard|
89366672|NCT01348035||Water Load Group|Water load group: 2.5 ~ 3 L water intake daily for 12 months (50ml/Kg body weight/day). When large amount water intake is not sustainable, patients can reduce the amount of water intake to the levels as much as large he or she can sustain.
89366673|NCT01348035||Non-Water Loaded Group|Non-water load group: The patients are free to access water intake, as they like.
89366674|NCT03265522|Experimental|"Group 1: ThinkMed resource at baseline"|"The ThinkMed resource contains an information booklet, recipe books, menu plan cards, shopping list cards and goal setting cards. Participants will receive this resource on one occasion at baseline (n=20)"
89366675|NCT03265522|Experimental|"Group 2: ThinkMed resource (staged)"|"This group of participants will receive the ThinkMed resource at monthly intervals for 5 months accompanied by telephone feedback from the research dietitian (n=20)"
89366676|NCT03265522|Placebo Comparator|Group 3: Standard Care (control) group|"Participants will continue with the standard care provided by their physician. Participants will receive the ThinkMed resource after their final 6 month study visit (i.e. delayed intervention) (n=20)"
88838420|NCT05086939|Experimental|Autologous Mesenchymal Stromal Cells (MSC)|Treatment with 40 millions of autologous autologous adult mesenchymal stem cells from expanded bone marrow administered intra-articularly.
89366677|NCT01348113|Experimental|Brief Alcohol Intervention|
89366678|NCT01348113|No Intervention|No intervention|
89366679|NCT03259516|Experimental|Nivo + FC|Nivolumab 1 mg/kg days 1,15 iv q28days Fludarabine 25 mg/m2 days 1-3 iv q28days Cyclophosphamide 300 mg/m2 days 1-3 iv q28days
88838421|NCT05086939|Experimental|Allogenic Mesenchymal Stromal Cells (MSC)|Treatment with 40 millions of adult allogeneic expanded bone marrow mesenchymal stem cells administered intra-articularly.
88838422|NCT05086939|Active Comparator|Active Control|Hyaluronic Acid 60mg/3ml administered intra-articularly.
88838423|NCT00358813|Experimental|Subjects receiving casopitant|Eligible subjects will receive a 100 milligrams oral dose of casopitant once daily for five consecutive days.
88838424|NCT02977663|Other|Magnetic Resonance Imaging (MRI)|Thoracic Magnetic Resonance Imaging (MRI)
88838425|NCT04344223|Experimental|Experimental balance shoes|Tests and familiarization phases with experimental balance shoes (Axis Comfort Development®)
88838426|NCT04344223|Active Comparator|Personal shoes|"Same tasks than the condition Experimental balance shoes but realized with personal shoes (own personal shoes of subjects)"
88838427|NCT04344613|Experimental|Blood samples|
88838428|NCT05081635||Delphi panel|The Delphi panel will include 30 Portuguese experts in post-graduate medical education. The expert panel will include participants from the residency programs directors' coordination group, from the medical residents representing committee, from patients representing associations, from health institutions management teams, from the Portuguese Medical Association and also authors of relevant scientific articles on medical education. Study participants will be required to answer the questions of 3 questionnaires included in each of the 3 rounds of the study.
88838429|NCT05603455|Experimental|Bifidobacterium adolescentis group|Bifidobacterium adolescentis supplementation
88838430|NCT05603455|Placebo Comparator|Placebo group|Placebo supplementation
88838431|NCT04343599|Experimental|Hypopressive exercises|Patients completed 10 weeks of abdominal hypopressive exercises with two sessions of 30 minutes per week.
88838432|NCT04343599|No Intervention|Control group|Patients allocated to the control group did not receive any treatment.
88838433|NCT04884061||Experimental|Patients hospitalized with SARS-CoV2 infection proven by RT-PCR test
88838434|NCT04884061||Comparator|Patients hospitalized with lower respiratory tract infections unrelated to SARS-CoV2 (RT-PCR negative for SARS-CoV2)
88838435|NCT04884061||Comparator 2|Patients who have had bronchoscopy performed as part of the assessment of a distal pulmonary nodule (RT-PCR negative for SARS-CoV2).
88838436|NCT04871191|Active Comparator|Rituximab + cDMARD|Rituximab will be administered at 375 mg/m²/week for four consecutive weeks. Maintenance rituximab at a fixed dose of 500 mg will be administered at week 24 and at week 52. The choice of the cDMARD will be left to the treating clinician and will include either methotrexate, azathioprine or mycophenolate mofetil, but the choice will be preferably methotrexate. Methotrexate will be administered orally or subcutaneously at 0.3 mg/kg/week, azathioprine orally at 2-3 mg/kg/d and mycophenolate mofetil orally at 2-3 g/d.
88838437|NCT04871191|Experimental|Tocilizumab|Tocilizumab will be administered subcutaneously every week at a fixed dose of 162 mg per week.
89366680|NCT03259516|Experimental|Nivo + LDAC + ATRA|Nivolumab 1 mg/kg days 1,15 iv q28days Cytarabine 10 mg/m2 bid days 1-10 sc q28days All-trans retinoic acid (ATRA) 45 mg/m2 po qd
88838438|NCT04871191|Experimental|Abatacept|Abatacept will be administered subcutaneously every week at a fixed dose of 125 mg per week.
88838439|NCT04864795||Single Cohort|Patient data will be collected from patient records and/or during a routine clinical visit. This will include treatments prescribed, routine assessments and measurements collected at routine clinical visits, as well as hospitalisations and other relevant patient data.
89366681|NCT03259516|Experimental|Nivo + LDAC + Sildenafil|Nivolumab 1 mg/kg days 1,15 iv q28days Cytarabine 10 mg/m2 bid days 1-10 sc q28days Sildenafil 20 mg tid
89366682|NCT03259516|Experimental|Nivo + Melphalan|Nivolumab 1 mg/kg days 1,15 iv q28days Melphalan 2 mg qd days 1-10 q28days
89366683|NCT03259516|Experimental|Nivo + 5-aza|Nivolumab 1 mg/kg days 1,15 iv q28days 5-azacitidine 75 mg/m2 days 1-7 q28days
89366684|NCT01344681|Experimental|Arm A|Micafungin sodium
89366685|NCT01344681|Active Comparator|Arm B|Itraconazole
89366686|NCT01348191||Elective caesarean section|"Population: ten pregnant women, scheduled for elective caesarean section with a term pregnancy ( > 37 weeks).~Inclusion criteria~Elective caesarean section~Term pregnancy > 37 weeks~Age > 18 years~Exclusion criteria~Previous caesarean scar~Gestational age < 37 weeks~Maternal temperature > 37.8 degrees Celsius~Meconium stained liquor~Foetal distress~Maternal diabetes~Seropositivity~Use of thyroid medication~Maternal thyroid disease~Age < 18 years"
89366687|NCT03259360|Experimental|The Put It Out Project (POP):|a culturally tailored intervention developed for SGM young adults on Facebook
89366688|NCT03259360|Experimental|Tobacco Status Project (TSP):|the original TSP intervention (non-tailored) delivered to groups of only SGM participants on Facebook
89366689|NCT01348269|Active Comparator|Aclasta|
89366690|NCT01348269|Placebo Comparator|NaCl Solution|
89366691|NCT03259594|Experimental|endophytic group|participants are with endophytic renal cyst and undergo laparoscopic deroofing.2 day before laparoscopic deroofing, they were given intravenous 100 g of amino acids supplementation.
89366692|NCT03259594|Sham Comparator|exophytic group|participants are with exophytic renal cyst and undergo laparoscopic deroofing.2 day before laparoscopic deroofing, they were given intravenous 100 g of amino acids supplementation.
89366693|NCT03259672|Active Comparator|Sevoflurane|
89366694|NCT03259672|Experimental|Desflurane|
89366695|NCT03547960|Experimental|Guar gum in women with early GDM|5 g of Guar gum fibre supplement with meals three times a day (total daily 15 g) for 12 weeks
89366696|NCT03547960|Placebo Comparator|Control/Cellulose in women with early GDM|5 g of Cellulose fibre supplement with meals three times a day (total daily 15 g) for 12 weeks
89001692|NCT04571788||FCB group|FCB group received FCB implantation
89001693|NCT04571788||Control group|Control group undergoes silicone scleral pad surgery
89001694|NCT00476593|Experimental|Diclofenac|Preservative- free Diclofenac Na 0.1 % eye drops were applied in one consecutively assigned eye of healthy volunteers four times a day for three days, after which macular thichness was measured in both subjects' eyes with the OCT .
89366697|NCT03259438|Experimental|Qigong|This course will meet twice weekly for 2 hours and 15 minutes per class for ten weeks. Topics will include guided instruction in the theory and background of qigong and healing. Practice will include gentle stretching and guided qigong movement as well as seated and lying down meditations. Participants will be asked to complete about 30 minutes a day of home assignments.
89366698|NCT03259438|Active Comparator|Healthy Living (CHIP + Pre-Train)|This course will meet twice weekly for 2 hours and 15 minutes per class for ten weeks. Topics will include plant based nutrition counseling via the Comprehensive Health Improvement Program (CHIP) as well as core-stretching, strengthening, and light aerobic movements through a Pre-Train exercise program. Participants will be asked to complete about 30 minutes a day of home assignments.
89366699|NCT03261388||ABLE POWER Program|Participants on the Activity-Based Locomotor Exercise Program (ABLE) waitlist will be enrolled prior to beginning the ABLE program. This waiting period will allow outcomes to be compared (in the same participant) before receiving the intervention and after receiving the intervention.
89366700|NCT03265288|Experimental|LAU-7b|Active drug fenretinide (as LAU-7b capsules)
89366701|NCT03265288|Placebo Comparator|Placebo|Placebo oral capsule (as inactive capsules identical to active arm)
89366702|NCT03261466|Active Comparator|Active group Bifidobacterium breve BR03 and B632|This arm will receive a supplementation of probiotic containing Bifidobacterium breve B632 and Bifidobacterium breve BR03, 15 gtt/die (3x108 CFU/die) once a day.
89366703|NCT03261466|Placebo Comparator|Placebo group|This arm will receive a supplementation with a same product equal to the active product but without bifidobacterium inside.
89366704|NCT02458066|Active Comparator|Bendiocarb|IRS: bendiocarb
89366705|NCT02458066|Active Comparator|Deltamethrin|IRS: deltamethrin
89366706|NCT03261310|Experimental|Acetaminophen & Craniotomy|Drug: Acetaminophen 1000mg administered intravenously during craniotomy
89366707|NCT03261310|Placebo Comparator|Placebo & Craniotomy|Placebo administered intravenously during craniotomy.
89366708|NCT03261310|Experimental|Acetaminophen & Laminectomy|Acetaminophen 1000mg administered intravenously during laminectomy.
89366709|NCT03261310|Placebo Comparator|Placebo & Laminectomy|Placebo administered during laminectomy.
89366710|NCT03259126|Experimental|SCUT|"Use of a Small Curtain under table (SCUT) placed under the cranial part of the angiographic table"
89366711|NCT03259126|No Intervention|Control|Control Group without the SCUT
88838440|NCT05016505|Experimental|Compliance through reduction (relocation and reduction of personal smoking) and cessation|Smokers will be referred by the survey team to peer educators from a community-based organization trained to provide peer to peer health education including tobacco cessation support. The peer educator will coordinate smoking cessation support, including serving as a liaison between participant and research team, providing information regarding the smoke-free policy and opportunities for relocation, and connecting participant to access to tobacco replacement therapy and/or physician support if deemed appropriate.
88838441|NCT05016505|Experimental|Compliance through resident endorsement|Buildings assigned will be targeted for a series of 2 in-residence programs that involve community forums and the creative arts to garner resident endorsements of smoke-free living environments. Premised on resident engagement, this arm seeks to impact social and physical dimensions of the residential environment to achieve compliance. The sessions will: 1) inform residents of risks associated with smoking and secondhand smoke; 2) identify reasons to have a smoke-free home, 3) ask residents to sign a pledge on paper and/or virtually; 4) display smoke-free signage on doors and/or social media pages with an original hashtag (#Smokefree[building address]); and 5) refer residents to the Smoke-free NYCHA website for information on the policy and existing cessation resources.
88838442|NCT05016505|Experimental|Compliance through reduction/cessation plus resident endorsement (combined)|The combined intervention will be carried out in the buildings assigned to this RCT arm, which will provide in-residence programs based on the resident endorsement treatment and the smoking relocation/cessation treatment. Both will occur simultaneously with one geared toward all building residents (resident endorsement) and the other targeting smokers (smoking relocation/cessation) with the goal of reducing both personal smoking and secondhand smoke exposure.
88838443|NCT05016505|No Intervention|Standard NYCHA approach (control)|Buildings and study participants assigned to this arm will be recruited and followed over a 12-month period to assess outcomes. No additional programs or services will be delivered to the buildings or residents assigned to this arm beyond standard programs that NYCHA may provide to support the smoke-free mandate. Field staff will document any policy-related signage, activities or information to which these participants are exposed.
89366712|NCT03259048||pediatric group|pediatric group from age of one day to eighteen years.
89366713|NCT02456272|Experimental|External hearing aid & Otosclerosis surgery|Trying an hearing aid for at least two months and then undergo otosclerosis surgery
89366714|NCT02456350|Experimental|Anti-CD19-CAR transduced T cells|Patients will receive a lymphodepleting preconditioning regimen followed by anti-CD19- CAR-transduced T cells.
89366715|NCT02456038|Experimental|Asfotase Alfa (ALXN1215)|Asfotase Alfa (ALXN1215) is administered 6mg/kg in total per week, divided into 3 times.
89366716|NCT03258736|Other|Caudal block|Caudal block Marcaine
89366717|NCT03258736|Other|ilionguinal/iliohypogastric block|ilionguinal/iliohypogastric block Marcaine
89366718|NCT01368120|Experimental|IV Clear™|
89366719|NCT01368120|Active Comparator|Tegaderm CHG™|
89366720|NCT01368120|Placebo Comparator|Vehicle Control Dressing|
89366721|NCT04971486|Experimental|Performance Feedback|Practice of a joystick based motor sequence task. Participants receive feedback on their response time to complete the trials in the practice block.
89366722|NCT04971486|Experimental|Performance plus Positive Feedback|Practice of a joystick based motor sequence task. Participants receive feedback on their response time to complete the trials in the practice block plus positive social comparative feedback.
88838444|NCT05015023|Experimental|Intervention|The behavioral intervention will be conducted on the experimental group for consecutive six months. The components of the intervention will be group health education, provision of IEC materials/Leaflets, and home visits.
88838445|NCT05015023|No Intervention|Control|The routine care will be continued in the control group.
89178967|NCT03947138|Experimental|GC3107_Part1|Part 1 GC3107(BCG Vaccine) Single intradermal Injection of 0.05 mL into the end of deltoid muscle in outer aspect of upper arm
89366723|NCT01363518||Operative|Operative group would have had surgery to treat their broken humerus.
89366724|NCT01363518||Nonoperative|Nonoperative group would have been treated with a brace, no surgery.
89366725|NCT04226274|Experimental|REN001|Oral
89366726|NCT01319370|Placebo Comparator|vehicle of 5% Minoxidl topical foam|vehicel foam in twice daily application in temple and vertex region
89366727|NCT01319370|Active Comparator|5% Minoxidil topical foam|5% Minoxidil topical in twice daily application in temple and vertex region
89366728|NCT01363752|Active Comparator|Advagraf + MMF + Steroids|Without sirolimus
89366729|NCT01363752|Experimental|Advagraf + MMF + Steroids + Sirolimus|With sirolimus; MMF withdrawn on Day 28; Sirolimus introduced on Day 28
88838446|NCT02977429|Active Comparator|standard group|"The patients with ScvO2 ≥ 70% will receive the conventional fluid therapy.than collect the data of ScvO2 and Pcv-aCO2:~ScvO2≥70%，and furthermore, Pcv-aCO2 is divided into ≤6mmHg and >6mmHg"
89366730|NCT01368198|Active Comparator|Ocular Emulsion|An Ocular Emulsion
89366731|NCT01368198|Active Comparator|OPTIVE™|An OPTIVE™
89366732|NCT01360710|Experimental|Moxonidine|
89366733|NCT01360710|Active Comparator|Irbesartan|
89366734|NCT01368354|Active Comparator|CLTS Arm|To induce behavioural changes by confronting the community with their open defecation behaviour. This will lead to voluntary construction and use of latrines and improved hygiene behaviour. CLTS involves facilitating a process to inspire and empower rural communities to stop open defecation and to build and use latrines, without offering external hardware subsidies. Communities are encouraged to appraise and analyse their own sanitation profile, including the extent of open defecation and the spread of faecal-oral contamination.
89366735|NCT01368354|No Intervention|Control arm|
89366736|NCT01363830|Experimental|Two-Week Post-Operative Restriction|Restrict bending, lifting, and twisting for two-weeks following discectomy.
89366737|NCT01363830|Active Comparator|Six-Week Post-Operative Restriction|Restrict bending, lifting, and twisting for six-weeks following discectomy.
88838447|NCT02977429|Sham Comparator|control group|"The patients with ScvO2 <70% will receive the standardized fluid therapy for 6 hours.than collect the data of ScvO2 and Pcv-aCO2:~ScvO2<70%，and furthermore, Pcv-aCO2 is divided into ≤6mmHg and >6mmHg"
88838448|NCT02976805|Experimental|Regimen A|4L PegLyte + 15 mg bisacodyl
89366738|NCT01360788||Healthy control subjects|Subjects with a significant smoking history (more than 10 pack-years) and a normal lung function.
89366739|NCT01360788||Asymptomatic GOLD stage I COPD patients|GOLD stage I COPD (post-bronchodilator forced expiratory volume in 1 second [FEV1] > 80% predicted and FEV1/ forced vital capacity [FVC] < 0.7 and a smoking history > 10 pack-years) were recruited. A Medical Research Council (MRC) dyspnea score ≥ 2 was used to define the presence of symptoms (dyspnea). Concretely, this group did not present any respiratory symptoms, with a MRC dyspnea score of 1/5.
89366740|NCT01360788||Symptomatic GOLD stage I COPD patients|GOLD stage I COPD (post-bronchodilator forced expiratory volume in 1 second [FEV1] > 80% predicted and FEV1/ forced vital capacity [FVC] < 0.7 and a smoking history > 10 pack-years) were recruited. A Medical Research Council (MRC) dyspnea score ≥ 2 was used to define the presence of symptoms (dyspnea) in this group.
88838449|NCT02976805|Experimental|Regimen B|6L PegLyte + 15 mg bisacodyl
89178968|NCT03947138|Experimental|GC3107_Part2|Part 2 GC3107(BCG Vaccine) Single intradermal Injection of 0.05 mL into the end of deltoid muscle in outer aspect of upper arm
89178969|NCT03947138|Active Comparator|BCG SSI_Part1|Part 1 Intradermal BCG SSI inj Single intradermal Injection of 0.05 mL into the end of deltoid muscle in outer aspect of upper arm
89366741|NCT01368510|Experimental|OCD Active CBT|Adults with obsessive-compulsive disorder (OCD) will be treated with cognitive-behavioral therapy (CBT) from the time of enrollment.
89366742|NCT01368510|Active Comparator|OCD Waitlist|Adults with OCD will receive waitlist treatment at enrollment. Nonresponders will cross over to CBT.
89366743|NCT01368510|No Intervention|Healthy Control|Healthy control adults will be given no intervention.
89366744|NCT01360944|Experimental|LAS 41004, variant 1, once daily|variant 1, once daily
89366745|NCT01360944|Experimental|LAS41004, variant 2, once daily|variant 2, once daily
89366746|NCT01360944|Experimental|LAS41004, variant 3, once daily|variant 3, once daily
89366747|NCT01360944|Experimental|LAS41004, variant 4, once daily|variant 4, once daily
89366748|NCT01360944|Experimental|LAS41004, variant 5, once daily|variant 5, once daily
89366749|NCT01360944|Experimental|LAS41004, variant 6, once daily|variant 6, once daily
89366750|NCT01360944|Placebo Comparator|reference|once daily, 100microgram
89366751|NCT01360944|Active Comparator|reference, once daily|once daily
88838450|NCT04835623|Experimental|Cyclosporine|Participants receive Cyclosporine 0.09% Ophthalmic Solution (Cequa), 1 drop, each eye, twice a day for 12 weeks
88838451|NCT04500613|Active Comparator|ESPB with Bupivacaine and Dexamethasone|12 pediatric spinal fusion surgery patients will be randomized to receive intraoperative ultrasound-guided bilateral ESPB with 0.25% bupivacaine with 2mg preservative free dexamethasone with a maximum of 30 mL total per side, depending on the patient's weight.
89366752|NCT01364064|Active Comparator|Conventional adjuvant Temozolomide|TMZ d 1-5 of 28-d cycle 6 cycles
89366753|NCT01364064|Experimental|Dose intensive Temozolomide|TMZ d 1-21 of 28-d cycle 6 cycles
89366754|NCT01361022|Active Comparator|Brotizolam tablet|Brotizolam tablets 250mcg : at least 6 and 24 subjects will be enrolled in the pre-study and main study, respectively
89366755|NCT01361022|Experimental|Lendormin tablet|Lendormin tablets 250mcg: at least 6 and 24 subjects will be enrolled in the pre-study and main study, respectively
89366756|NCT01364142||thoracic surgery|Patients undergoing thoracic surgery in which one lung ventilation is needed.
89366757|NCT01364220|Experimental|Rosuvastatin|Rosuvastatin 20mg tablet, once daily, for 14 days
89366758|NCT01364220|Placebo Comparator|Placebo|Placebo tablet, once daily, for 14 days
89366759|NCT01368744||OSNA Breast Cancer System|
89366760|NCT01361100|Experimental|Oncoral test|
89366761|NCT01368978|Experimental|Test (with the InsuPatch device)|Device use
89366762|NCT01368978|No Intervention|Control (without the InsuPatch device)|
89366763|NCT01361256|Experimental|WA- NG Telescope Prothesis|Implantable Miniature Telescope for end stage AMD (Age-related Macular Degeneration)
88838452|NCT04500613|Placebo Comparator|No ESPB|12 pediatric spinal fusion surgery patients will be randomized to not receive an intraoperative ultrasound-guided bilateral ESPB. These patients will still receive the standard anesthesia regimen during and after surgery.
88838453|NCT04498585|Experimental|Intervention|Participants who will be receiving standard ICU care and additionally the VR stimulation during their ICU stay.
89366764|NCT02713204|Experimental|REGN910-3 (3 mg: 2 mg)|Participants were administered intravitreal injection of REGN910-3 (3 milligram [mg]:2 mg) every 4 weeks (Q4) on Day 1, Week 4, and Week 8 for 3 initial doses followed by every Week 8 (Q8) dosing beginning at Week 16 up to Week 32.
89366765|NCT02713204|Experimental|REGN910-3 (6 mg:2 mg)|Participants were administered intravitreal injection of REGN910-3 (6 mg:2 mg) Q4 on Day 1, Week 4 and Week 8 for 3 initial doses. At Week 12, participants were re-randomized to receive REGN910-3 (6 mg:2 mg) Q8 or Q12 (beginning at Week 16 or Week 20) through Week 32.
89366766|NCT02713204|Experimental|Aflibercept (IAI) 2 mg|Participants were administered intravitreal injection of Aflibercept (IAI) 2 mg Q4 on Day 1, Week 4 and Week 8 for 3 initial doses up to Week 12. At Week 12, participants were re-randomized to receive IAI Q8 or Q12 (beginning at Week 16 or 20) or REGN910-3 (6 mg:2 mg) Q8 beginning at Week 16 through Week 32.
89366767|NCT03695172|Active Comparator|TAP block|Patients will receive bilateral TAP blocks after delivery and within one hour of skin closure with 25 mL of 0.2% ropivacaine with epinephrine 1:400,000 per side.
89366768|NCT03695172|Active Comparator|QL block|Patients will receive bilateral QL blocks after delivery and within one hour of skin closure with 25 mL of 0.2% ropivacaine with epinephrine 1:400,000 per side.
89366769|NCT03695172|Active Comparator|ESP block|Patients will receive bilateral ESP blocks after delivery and within one hour of skin closure with 25 mL of 0.2% ropivacaine with epinephrine 1:400,000 per side.
89366770|NCT03721107|Experimental|Cohort C: Blautix|Participants diagnosed with Irritable bowel syndrome subtype C (IBS-C) received two capsules of Blautix orally, twice daily for 8 weeks. Maximum daily dose of Blautix (strain of Blautia hydrogenotrophica) will be 10^10 to10^11 most probable number (MPN).
88838454|NCT04498585|No Intervention|Control|Patients in the ICU who will be receiving standard ICU care during their ICU stay. Participants in this arm will not be receiving VR stimulation.
88838455|NCT02976259|Experimental|Patient HIV primary infection|HIV primary infection Patient male receiving Dolutegravir
88838456|NCT04984681|Experimental|Mindfulness-based Stress Reduction|Mindfulness-based stress reduction sessions received by the treatment group will include an orientation, approximately 8 intervention sessions, and an exit interview.
88838457|NCT04984681|Other|Usual Care|The control condition will continue receiving usual care or standard of care.
88838458|NCT02977351|Experimental|Atherosclerosis|Patients with atherosclerosis and chronic periodontitis
88838459|NCT02977351|Active Comparator|Systemically healthy|Patients with Systemically healthy and chronic periodontitis.
88838460|NCT04482751||Infertile women|the group consists of 80 infertile patients undergoing IVF
89366771|NCT03721107|Placebo Comparator|Cohort C: Placebo|Participants diagnosed with IBS-C received two capsules of placebo matched to Blautix orally, twice daily for 8 weeks.
89366772|NCT03721107|Experimental|Cohort D: Blautix|Participants diagnosed with Irritable bowel syndrome subtype D (IBS-D) received two capsules of Blautix orally, twice daily for 8 weeks. Maximum daily dose of Blautix (strain of Blautia hydrogenotrophica) will be 10^10 to10^11 MPN.
89366773|NCT03721107|Placebo Comparator|Cohort D Placebo|Participants diagnosed with IBS-D received two capsules of placebo matched to Blautix orally, twice daily for 8 weeks.
89366774|NCT01364376|Active Comparator|FOLFOX|
89366775|NCT01364376|Experimental|SOX|
88838461|NCT04474015|Active Comparator|Part A, Group 1|Forearm stimulation during wake (study PART A) - electrode placement = volar surface of forearm, 2 electrodes (cathode and anode): Group 1 will receive forearm stimulation at 0.75 Hz with an oscillating direct current (DC) waveform while awake.
88838462|NCT04474015|Active Comparator|Part A, Group 2|Forearm stimulation during wake (study PART A) - electrode placement = volar surface of forearm, 2 electrodes (cathode and anode): Group 2 will receive forearm stimulation at 0.75 Hz with a modified alternating current (AC) waveform while awake.
89530357|NCT03248791|Active Comparator|Phenylephrine|Will receive spinal anesthesia using Bupivacaine. Then, phenylephrine infusion by a starting rate of 0.75 mcg/Kg/min. The rate will be then adjusted according to the patient blood pressure
88838463|NCT04474015|Active Comparator|Part A, Group 3|Forearm stimulation during wake (study PART A) - electrode placement = volar surface of forearm, 2 electrodes (cathode and anode): Group 3 will receive forearm stimulation at 3.0 Hz with an alternating current (AC) sinusoidal waveform while awake.
88838464|NCT04474015|Active Comparator|Part B, Group 4|Scalp stimulation during sleep (study PART B) - bilateral electrode pairs placed on the upper forehead near the midline (F3 and F4) and adjacent to the ear in the mastoid region (M1 and M2). roup 4 will receive scalp stimulation at 0.75 Hz with an oscillating direct current (DC) waveform during sleep.
88838465|NCT04474015|Active Comparator|Part B, Group 5|Scalp stimulation during sleep (study PART B) - bilateral electrode pairs placed on the upper forehead near the midline (F3 and F4) and adjacent to the ear in the mastoid region (M1 and M2). Group 5 will receive scalp stimulation at 0.75 Hz with a modified alternating current (AC) waveform during sleep.
88838466|NCT04474015|Active Comparator|Part B, Group 6|Scalp stimulation during sleep (study PART B) - bilateral electrode pairs placed on the upper forehead near the midline (F3 and F4) and adjacent to the ear in the mastoid region (M1 and M2). Group 6 will receive scalp stimulation at 3.0 Hz with an alternating current (AC) sinusoidal waveform during sleep.
88838467|NCT04474015|Active Comparator|Part C, Group 7|Pulsed Stimulation: Group 7 (Part C)will receive a series of brief stimulations of up to 500 millisecond duration and of up to 5 milliamperes of current, using either metal electrodes or sponge electrodes as stimulating electrodes.
88838468|NCT04975243|Experimental|Unwanted Fine Facial Hair|Up to three (3) treatments with GentleMax Pro/ GentleMax Pro Plus TM for Laser Hair Removal
88838469|NCT04814095|Experimental|Targeted therapy|
88838470|NCT04813783||Control group|The first group of 26 volunteers who meet the inclusion criteria of the study will form the control group. These participants will be given clinical routine training about mucositis care.
88838471|NCT04813783||Intervention Group|In the study, in order to prevent/minimize the flow of information between the control and intervention groups, the data of the control group will be collected first. Data collection will be suspended in the clinic for three months after the control group data is completed. After this period, data of the enterprise group will be collected. Participants in the intervention group will be provided with mucositis training within the scope of the Mucositis Care Protocol in line with the MASCC / ISOO 2019 Recommendations.
88838472|NCT04813549||Rheumatoid Arthritis patients|Rheumatoid arthritis patients will be evaluated in terms of the presence of secondary fibromyalgia and its effect on the quality of life, at their admission.
88838473|NCT02976727|Experimental|GroupA (Vit-D pretreated AFL-PDT group )|Group A was treated with topical VitD-assisted AFL-PDT
88838474|NCT02976727|Active Comparator|GroupB (Conventional AFL PDT group )|Group B was treated with conventional AFL-PDT
88838475|NCT04945447|Experimental|Intervention group - Medical clinics|Medical clinics receiving the pharmacist intervention described in the intervention group for patient level
88838476|NCT04945447|No Intervention|Control group - medical clinics|All medical clinics that are enrolled in the trial will eventually receive the intervention at some point. As some medical clinics act as the control group to being with.
88838477|NCT04945447|Experimental|Intervention group - patient level|"The intervention consists of two subgroups: Intervention pharmacist and intervention proposals. As the pharmacist conducts medication reviews of the polypharmacy patients in the medical clinic they can make a note to the physician about fx a specific medication the physician needs to pay attention to. These polypharmacy patients are enrolled in the group intervention proposals and are asked to complete questionaries at baseline and follow-up. Ultimately, it is up to the physician to react to the note in the polypharmacy patients medical record. Therefore the pharmacist only makes a note in the journal of the patient and does nothing else.~The group intervention pharmacist is polypharmacy patients where the pharmacist conducts a medication review and develops suggested interventions proposals for each participant"
88838478|NCT04945447|No Intervention|Control group - patient level|The control group will have access to usual care and other health services within the healthcare systems. Participants randomised to the control group are invited to participate in the evaluation of the current treatment in the primary health care sector
88838479|NCT02977117|Experimental|Dialysate magnesium 1.0 mmol/L|Increase dialysate magnesium from 0.5 mmol/L to 1.0 mmol/L.
88838480|NCT02977117|Active Comparator|Dialysate magnesium 0.5 mmol/L|Maintain dialysate magnesium at 0.5 mmol/L.
88838481|NCT04793269||Long COVID|Patients with long COVID syndrome
88838482|NCT00361465||Parkinsonian patients presenting of the dystonia|15 Parkinsonian patients presenting of the dystonia of ONE or OFF at the time of the phases of driving fluctuations. These patients must present a dystonia of the upper limb, mainly localised than the level of the segment brachial or in distality.
88838483|NCT00361465||patients carrying a primary education dystonia affecting|15 patients carrying a primary education dystonia affecting at least one of the two upper limbs, without excessive involuntary movements
88838484|NCT00361465||patients carrying a secondary dystonia|15 patients carrying a secondary dystonia (consecutive with a perinatal suffering) affecting at least one of the two upper limbs, without excessive involuntary movements
88838485|NCT00361465||pilot subjects|30 healthy pilot subjects paired in sex, age (± 5 years), dominant laterality and level of schooling (15 subjects paired with the Parkinsonian patients and 15 subjects paired with the patients dystonic
88838486|NCT00360841|Experimental|A|The subjects in arms A and B will receive auricular acupuncture. The subjects in arms A will receive auricular acupuncture (at 2nd and 4th chemotherapy courses) as well as the sham auricular acupuncture (at the 3rd chemotherapy course).
88838487|NCT00360841|Sham Comparator|B|The subjects in arms A and B will receive auricular acupuncture. The subjects in arm B will receive the sham auricular acupuncture (at the 2nd and 4th chemotherapy courses) and auricular acupuncture (at the 3rd chemotherapy course).
88838488|NCT00360841|No Intervention|C|No treatment received.
88838489|NCT00360451|Experimental|1|Adolescent only Penn Resiliency Program
88838490|NCT00360451|Experimental|2|Adolescent plus parent Penn Resiliency Program
88838491|NCT00360451|No Intervention|3|Control
88838492|NCT04343131|Active Comparator|Mediterranean diet|Mediterranean diet for 7 days
88838493|NCT04343131|Active Comparator|Low-carb/high protein diet|Low-carb/high protein diet for 7 days
88838494|NCT04343131|Active Comparator|Reference diet|Reference diet for 7 days
88838495|NCT02977273|Experimental|Test Meal 1|Thin/100% portion
88838496|NCT02977273|Experimental|Test Meal 2|Thin/150% portion
88838497|NCT02977273|Experimental|Test Meal 3|Thick/100% Portion
88838498|NCT02977273|Experimental|Test Meal 4|Thick/150% Portion
88838499|NCT04898647|Experimental|Patients with confirmed HVS|presence of unexplained elsewhere fundoscopic abnormalities AND either IgM concentration above 30 g/L (densitometry) or cryoglobulin activity
88838500|NCT04898647|Active Comparator|Patients with confirmed absence of HVS|
88838501|NCT04898647|Experimental|Remaining patients|
88838502|NCT00421759|Experimental|1|85 elderly individuals with somatosensory deficits
88838503|NCT00421759|Experimental|2|85 elderly individuals with recurrent falls
88838504|NCT04895839|Experimental|Intervention Arm|
88838505|NCT02977039|Experimental|NDPR diet|Subjects randomized to the nutrient dense plant rich (NDPR) diet will eat foods with high micronutrient density, and favorable glycemic index. The diet is low in saturated fat, high in fiber, and rich in phytochemicals. Total caloric intake will range from 1600-2000/day based on individual needs. Foods include vegetables (30-70% of calories), fruits (15-20% of calories), Beans/Legumes (20-30% of calories), raw nuts and seeds (10-20% of calories), fish or fat-free dairy (twice weekly or less), poultry, eggs and oils (once weekly or less) and limited beef, cheese/milk, processed food and beef.
88838506|NCT02977039|Experimental|USDA diet|Subjects randomized to the healthy U.S.-Style pattern diet will eat the types and proportions of foods Americans typically consume, but in nutrient-dense forms and appropriate amounts. It is designed to meet nutrient needs while not exceeding calorie requirements and while staying within limits for overconsumed dietary components. Total caloric intake will range from 1600-2000/day based on individual needs. Foods include fruits, vegetables (dark green, red/orange, beans, and peas, starchy vegetables), grains (whole grains and refined grains), protein foods (meat, poultry, eggs, seafood, nuts, seeds and soy products), dairy, and oils.
88838507|NCT04886245|Experimental|facial palsy|Patient with peripheral facial palsy, irrespective of grade, whether or not previously treated
88838508|NCT04886245|Sham Comparator|healthy volunteers|- Subject without major facial sequelae
88838509|NCT04061083|Experimental|Continuous Endotracheal Cuff Pressure Control|Continuous endotracheal cuff pressure control using smart cuff manager during the first 48 hours of intubation in the intensive care unit
88838510|NCT04061083|Experimental|Intermittent Endotracheal Cuff Pressure Control|Intermittent cuff pressure control through manual manometer measurement performed 3 times per day during the first 48 hours of intubation in the intensive care unit
88838511|NCT04061083|No Intervention|Standard Care|ET cuff pressure control will be provided with pilot balloon fingers during the first 48 hours of intubation in the intensive care unit
88838512|NCT02976025|Experimental|Longitudinal Remote Consultation|This is the active treatment arm consisting of 10 cluster randomized health centers receiving both training in collaborative care and longitudinal remote consultation (LRC) support.
88838513|NCT02976025|Active Comparator|Collaborative Care|This comparator arm will consist of 10 cluster randomized health centers who receive training in collaborative care.
88838514|NCT04034329||ASVAL - group|GSV diameter ≤ 6 mm
88838515|NCT04034329||EVLA-group|GSV diameter > 6 mm
88838516|NCT04010305|Placebo Comparator|Placebo|Sublingual Film with no active drug; single administration with the possibility of repeating dose after 1 hour in case of lack of significant efficacy
88838517|NCT04010305|Experimental|20 micrograms|Sublingual Film containing 20 micrograms BXCL501; single administration with the possibility of repeating dose after 1 hour in case of lack of significant efficacy
88838518|NCT04010305|Experimental|60 micrograms|Sublingual Film containing 60 micrograms BXCL501; single administration with the possibility of repeating dose after 1 hour in case of lack of significant efficacy
88838519|NCT04010305|Experimental|120 micrograms|2 Sublingual Films, each containing 60 micrograms BXCL501; single administration of 2 films with the possibility of repeating dose after 1 hour in case of lack of significant efficacy
88838520|NCT04010305|Experimental|180 micrograms|2 Sublingual Films, each containing 60 micrograms BXCL501.
88838521|NCT00361933|Experimental|1|
88838522|NCT03987763|Experimental|IDP-122 Lotion|Two cohorts of pediatric participants (1 cohort of participants age 12 to 16 years 11 months and 1 cohort of participants age 6 to 11 years 11 months) will apply IDP-122 Lotion to Investigator identified lesions affecting a minimum of 10% body surface area (BSA) once daily for 8 weeks.
88838523|NCT02975635||Oral patient information only|Patients are given oral information only (information as usual). After patients have made their decisions (repair or replacement), a questionnaire survey is conducted.
88838524|NCT02975635||Written patient education before oral patient information|Patients are given a flow chart in advance of oral information. After patients have made their decisions (repair or replacement), a questionnaire survey is conducted.
88838525|NCT04785859||Moderate-severe bronchopulmonary dysplasia|Neonates of less than 30 weeks´ gestation, born at any of the study centers, or transferred from other centers in the first 24 hours of life, with the diagnosis of moderate-severe bronchopulmonary dysplasia at 36 weeks' postmenstrual age.
89366776|NCT01344837||Observational|Archived serum and tumor tissue samples are analyzed for synuclein-γ (SNCG) expression and other biomarker expression, including TP53 (p53), HER-2, folate receptor alpha (FOLR1), estrogen receptor (ER), progesterone receptor (PR), phosphatase and tensin homolog (PTEN), phosphorylated AKT (pAKT), pERK, and p16 by microarray analysis, IHC assays, and western blot. Results are then compared with patients' existing clinical, demographic, and pathology data, including history of breast cancer (metachronous) or breast cancer diagnosed at the same time as the endometrial cancer (synchronous).
89366777|NCT01369056|Experimental|Advanced Adherence Counseling (AdvAdh)|Please see the Intervention Description section
89366778|NCT01369056|No Intervention|Control|Standard of care (including counseling regarding antiretroviral treatment adherence) received by HIV/AIDS patients at the study clinic
89366779|NCT01348503|Experimental|Open Label, Single Arm|Dose escalation of lenalidomide in combination with sorafenib at standard doses in patients with advanced, unresectable hepatocellular carcinoma.
89366780|NCT03260998||diabetic patients type 1|electrocardiogram will be done for 60 children and adolescents with type 1 diabetes
89366781|NCT03260998||healthy persons|electrocardiogram will be done for 60 age and sex matched non diabetic children and adolescents
89366782|NCT01344915|Active Comparator|Knee brace|
89366783|NCT01344915|Active Comparator|Locked knee brace|
89366784|NCT03914248||Active large vessel vasculitis|PET/MR scan
89366785|NCT01369290||Drug 1|Venlafaxine
89366786|NCT01369290||Drug 2|Bupropion
89366787|NCT01369290||Drug 3|Escitalopram
89366788|NCT01369290||Drug 4|Duloxetine
88838526|NCT04785859||no moderate-severe bronchopulmonary dysplasia|Neonates of less than 30 weeks´ gestation, born at any of the study centers, or transferred from other centers in the first 24 hours of life, without the diagnosis of moderate-severe bronchopulmonary dysplasia at 36 weeks' postmenstrual age.
88838527|NCT02976883|Experimental|[18F]HX4 diagnostic PET/CT scan|[18F]HX4 (370 MBq) will be administered by a single intravenous injection, after which patients will be required to wait for ≤4.0 h and undergo a PET/CT scan.
88838528|NCT02976571|Experimental|Sub cutaneous+Intraperitoneal|Sub cutaneous Bupivacaine+ Intraperitoneal bupivacaine
88838529|NCT02976571|Active Comparator|Sub cutaneous+Placebo|Sub cutaneous Bupivacaine+ Intraperitoneal Nacl 0.9%
88838530|NCT02976571|Active Comparator|Placebo+Intraperitoneal|Sub cutaneous Nacl 0.9%+ Intraperitoneal bupivacaine
88838531|NCT02976571|Placebo Comparator|Placebo+Placebo|Sub cutaneous Nacl 0.9%+ Intraperitoneal Nacl 0.9%
89366789|NCT01369290||Psychotherapy|Cognitive behaviour therapy
88838532|NCT04731025|Placebo Comparator|Irrigation of implants with sterile isotonic saline|The placebo solution will consist of 500 mL of sterile isotonic (9%) saline contained in a infusion bag.
89366790|NCT04173975|Experimental|With knee exoskeleton|"The rehabilitation training will be focused on lower limb with specific activities for knee instability, and will concern both physical training (e.g., locomotion task, balance exercise, muscle reinforcement, proprioceptive task) and occupational treatment tasks (e.g., transferring/mobility, meal preparation, house-working).~Each session will be 45 minutes long. Three time per week, for three weeks.~The patients allocated in this arm will perform the training wearing the BELK device."
88838533|NCT04731025|Experimental|Irrigation of implants with a triple antibiotic solution|The antibiotic solution will contain 1000 mg vancomycin, 80 mg gentamicin and 1000 mg cefazolin in 500 mL sterile isotonic (9%) saline
88838534|NCT04730635|Experimental|Donepezil|Participants receive donepezil in doses up to 10 mg once daily (QD), orally in a scheduled titration for Days 1-56. The total treatment duration is 56 days.
89366791|NCT04173975|No Intervention|Without exoskeleton|"The rehabilitation training will be focused on lower limb with specific activities for knee instability, and will concern both physical training (e.g., locomotion task, balance exercise, muscle reinforcement, proprioceptive task) and occupational treatment tasks (e.g., transferring/mobility, meal preparation, house-working).~Each session will be 45 minutes long. Three time per week, for three weeks.~The patients allocated in this arm will perform the training without any exoskeleton."
89366792|NCT03533452|Active Comparator|PRE-GA|10 mL of 0.5% ropivacaine injection before the start of surgery and 10 ml of normal saline (0.9%) injection at the end of surgery through the interscalene catheter
89366793|NCT03533452|Sham Comparator|POST-GA|10 ml of normal saline (0.9%) injection before the start of surgery and 0.5% ropivacaine injection at the end of surgery through the interscalene catheter
89366794|NCT03258346|Experimental|Exercise and Pomegranate Juice|Exercise training with daily consumption of pomegranate juice containing polyphenols
89366795|NCT03258346|Placebo Comparator|Exercise and Placebo|Exercise training with daily consumption of pomegranate juice with polyphenols removed
89366796|NCT03488082|Experimental|Measurement of the bold signal|
89366797|NCT04138797|Experimental|Electrophysiological exploration & ECG Biosemi|
88838535|NCT04730635|Placebo Comparator|Placebo|Participants receive placebo QD, orally for Days 1-56. The total treatment duration is 56 Days.
88838536|NCT04726189|Active Comparator|Standard care exercises|This is the currently used treatment in the nine weeks of immobilisation with an orthosis.
88838537|NCT04726189|Experimental|Early progressive strength exercise|This exercise program initiates early (second week) and continues with resistance exercises with progression of the load according to individual participant toleration.
88838538|NCT04723225|Experimental|Experimental|Cat-Cow is one of the essential postures in yoga for its beneficial reasons. It is an alternate shift of posture from flexion of the back (rounded) to the extension of the back (arched). During each set of movement, inhalation and exhalation will be guided.
88838539|NCT04723225|No Intervention|Control|In control intervention group usual care will be provided.
88838540|NCT00360919|Experimental|A|Cheese
88838541|NCT00360919|Placebo Comparator|B|Fruits and vegetables
88838542|NCT04363021||cases|Cases will be defined as women with systemic sclerosis, specific vascular complications (digital ulcers, specific cardiac involvement of systemic sclerosis including pulmonary arterial hypertension, renal crisis) and with a previous pregnancy longer than 6 months before systemic sclerosis diagnosis.
88838543|NCT04363021||controls|Controls will be defined as women with systemic sclerosis, no specific vascular complication and with a previous pregnancy longer than 6 months before systemic sclerosis diagnosis.
89366798|NCT04359147|Active Comparator|Yohimbine|10 mg
88838544|NCT04676347||Eligible population|All patients admitted in the semi-intensive care units attending the study. Be basing on the average number of patients yearly treated in those units, we expect to have at least 39000 patients during the 5 years of the study.
89366799|NCT04359147|Active Comparator|Hydrocortisone|10 mg
89366800|NCT04359147|Active Comparator|Yohimbine + Hydrocortisone|10 mg each
89366801|NCT04359147|Placebo Comparator|Placebo|
89366802|NCT03260764|Experimental|group A|
89366803|NCT03260764|Placebo Comparator|group B|
89366804|NCT03260764|Experimental|group C|
89366805|NCT03260764|Placebo Comparator|group D|
88838545|NCT04676035|Experimental|SHR3680+ Midazolam, Warfarin, Omeprazole, VitaminK1|administrate Midazolam, Warfarin, Omeprazole, VitaminK1 on Day1 and Day22, SHR3680 on day 6-27.
88838546|NCT03917797|Experimental|MSC treatment|Intervention: a previously selected dose of MSCs (Phase IIa) will be administered by i.v. infusion at baseline and 6 months of follow-up (total 12 months), to patients with Severe Renal SLE subject also to Standard of Care treatment with Methylprednisolone and Cyclophosphamide followed by Mycophenolate.
88838547|NCT03917797|Placebo Comparator|Placebo|Intervention: A Placebo (infusion vehicle) will be administered by i.v. infusion at baseline and 6 months of follow-up (total 12 months), to patients with Severe Renal SLE subject also to Standard of Care treatment with Methylprednisolone and Cyclophosphamide followed by Mycophenolate.
88838548|NCT04342507|Other|Group A: conservative|conservative treatment with lid hygiene, warm compression, and dexamethasone/tobramycin ointment for at least 20 days
88838549|NCT04342507|Experimental|Group B: probiotics|in addition to the conservative treatment they receive probiotics mixture (Streptococcus thermophilus, Lactococcus lactis, Lactobacillus delbrueckii subsp. bulgaricus) once a day up to 3 months.
88838550|NCT04359199||Radiotherapy with chemotherapy|Patients treated with definitive RT and chemotherapy (cisplatin) or targeted therapy (cetuximab)
89366806|NCT01364454|Experimental|Eligible patients' paper-based reminder|
89366807|NCT01364454|No Intervention|Control group|
89366808|NCT03260374||children with cochlear implant|"30 subjects whose age ranges from 2-6 years old who are implanted with Medel multichannel cochlear implant male and female will be included and will undergo:-~Electric compound action potential~Electric stapedial reflex threshold~Electric auditory brain stem response"
89366809|NCT01369368|Experimental|1|Azacitidine, valproic acid, all-trans retinoic acid, hydroxyurea, eventually donor leukocyte infusions
89366810|NCT03258424|Active Comparator|PTI-428|Subjects will receive once daily dosing of PTI-428 or placebo for 14 days.
89366811|NCT03258424|Placebo Comparator|Placebo|Subjects will receive once daily dosing of PTI-428 or placebo for 14 days.
89366812|NCT01348581|Experimental|Marigen Wound Dressing|
88838551|NCT04359199||Radiotherapy with immunotherapy|Patients treated with definitive RT and immunotherapy (pembrolizumab, nivolumab, or durvalumab)
88838552|NCT00360997|Other|Behavioural|Conventional UK physical therapy (Con UK PT)
88838553|NCT00360997|Experimental|Con UK PT + MTS|Con UK PT + 30/60 or 120 minutes MTS
88838554|NCT04328857|Experimental|Treatment|Upper limb rehabilitation with pseudoelastic orthosis
88838555|NCT04328857|No Intervention|Control|Upper limb rehabilitation without pseudoelastic orthosis
88838556|NCT03844633|Experimental|Intervention arm|Intramuscular injectable depot medroxyprogesterone acetate (1 mL of medroxyprogesterone acetate sterile aqueous suspension 150 mg/mL) provided within 48 hours of childbirth
88838557|NCT03844633|Placebo Comparator|Placebo arm|0.9% sodium chloride injection provided within 48 hours of childbirth
88838558|NCT03844633|No Intervention|Open arm|No intervention provided
88838559|NCT00362089|Active Comparator|Marinol|Intervention group with Marinol D40 fish oil capsules
88838560|NCT00362089|No Intervention|Nutrition counseling|Control group
88838561|NCT04342741|Active Comparator|Foley catheter inpatient|Participants had intracervical ripening with foley catheter after admission into the ward.
88838562|NCT04342741|Active Comparator|Foley catheter outpatient|Participants had intracervical ripening with foley catheter and allowed home.
88838563|NCT04328701|Experimental|Mindfulness-based CBT|All participants will receive four individual mindfulness-based CBT sessions.
88838564|NCT04328701|No Intervention|Treatment as Usual|All participants will undergo surgery as usual, with no additional intervention.
89366813|NCT04103619|Active Comparator|AccuTite|15 patients will receive AccuTite treatment only
89366814|NCT04103619|Active Comparator|AccuTite & Morpheus 8 Arm|15 patients will receive AccuTite and Morpheus8 treatment and additional 2 monthly Morpheus8 treatments
89366815|NCT01369446||Women undergoing IVF treatment|
89366816|NCT03258268|Experimental|Standard of Care with DSS|"Patients will receive standard of care with a board certified physician with EASY DSS.~The choice of treatment will be made by the investigator. In the investigational arm this will be based on the clinical judgment of the investigator supplemented with support from the EASY DSS and in the control arm this will be based on the clinical judgment of the investigator alone."
89366817|NCT03258268|Active Comparator|Standard of Care without DSS|"Patients will receive standard of care with a board certified physician without EASY DSS.~The choice of treatment will be made by the investigator. In the investigational arm this will be based on the clinical judgment of the investigator supplemented with support from the EASY DSS and in the control arm this will be based on the clinical judgment of the investigator alone."
89366818|NCT01369524||ICUpatient with need of fluid|age > 18 - haemodynamic monitoring - informed consent - admission on ICU
89366819|NCT03257956|Experimental|Investigational Group|The RHEA device and Patient Monitor Device are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
89366820|NCT03257956|Active Comparator|Reference Group|The reference device and Patient Monitor Device are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
89366821|NCT01348659|Active Comparator|7.2% NaCl/hydroxyethyl starch|250 ml of 7.2% NaCl in hydroxyethylstarch (HES 200/0,5) (Hyperhaes®, Fresenius Kabi)
89366822|NCT01348659|Active Comparator|0.9% NaCl|250 ml of NaCl 0.9% (Natriumklorid Braun 9 mg/ml)
89366823|NCT01370070|Experimental|MK-2206|
89366824|NCT03252574|Other|Sequence AB|No mask, followed by AIR+ Smart Mask only (A), then AIR+ Smart Mask with micro-ventilator (B)
88838565|NCT04660669|Other|ESDM 15h|This arm receives 15 hours per week of ESDM intervention from ESDM therapists. The parents benefit from a 20 hour parent training program delivered in the participating center.
88838566|NCT04660669|Other|ESDM 8h + MOOC|This arm receives 8 hours per week of ESDM intervention from ESDM therapists in addition to whatever community service the parents choose. The parents benefit from a training program remotely delivered via a MOOC platform as well as parental supervision of sessions delivered at home 1 hour per week for the duration of the study.
89178970|NCT03947138|Active Comparator|BCG SSI_Part2|Part 2 Intradermal BCG SSI inj Single intradermal Injection of 0.05 mL into the end of deltoid muscle in outer aspect of upper arm
88838567|NCT03822637|Experimental|20% n-acetylcystine (NAC)|NAC (trade name: Mucomyst) is manufactured by American Regent. The active drug studied here is 20% NAC coadministered with albuterol and delivered via nebulizer three times per day for fourteen days.
88838568|NCT03822637|Placebo Comparator|0.9% saline|Normal saline will be coadministered with albuterol as the placebo agent via a nebulizer three times per day for fourteen days.
88838569|NCT05444101|No Intervention|Waitlist control|Participants randomized to condition 1 are not offered any treatment components immediately upon enrollment, but will be offered a treatment component of own choice at the end of the study. Total number of sessions: 2 (2 contact hours) following study completion.
88838570|NCT05444101|Experimental|Mindful attention|Participants randomized to condition 2 will receive the Mindful attention treatment component. Total number of sessions: 2 (2 contact hours).
88838571|NCT05444101|Experimental|Decentering|Participants randomized to condition 3 will receive the Decentering treatment component. Total number of sessions: 2 (2 contact hours).
88838572|NCT05444101|Experimental|Values and committed action|Participants randomized to condition 4 will receive the Values and committed action treatment component. Total number of sessions: 2 (2 contact hours).
88838573|NCT05444101|Experimental|Mindful attention + Decentering|Participants randomized to condition 5 will receive the Mindful attention treatment component and the Decentering treatment component in different orders. Total number of sessions: 4 (4 contact hours).
88838574|NCT05444101|Experimental|Mindful attention + Values and committed action|Participants randomized to condition 6 will receive the Mindful attention treatment component and the Values and committed action treatment component in different orders. Total number of sessions: 4 (4 contact hours).
88838575|NCT05444101|Experimental|Decentering + Values and committed action|Participants randomized to condition 7 will receive the Decentering treatment component and the Values and committed action treatment component in different orders. Total number of sessions: 4 (4 contact hours).
88838576|NCT05444101|Experimental|Mindful attention + Decentering + Values and committed action|Participants randomized to condition 8 will receive the Mindful attention treatment component, the Decentering treatment component, and the Values and committed action treatment component in different orders. Total number of sessions: 6 (6 contact hours).
88838577|NCT02975089|No Intervention|Control|A leaflet of healthy diet for elderly
88838578|NCT02975089|Experimental|Nutritional Intervention 1|"Multi-nutrient supplement"
88838579|NCT02975089|Experimental|Nutritional Intervention 2|"Multi-nutrient & soy protein supplement"
88838580|NCT02975089|Experimental|Nutritional Intervention 3|Nutrition education on balanced diet & food supplement
88838581|NCT02976493||MM patients receiving elotuzumab|Non-Interventional Study of all patients with relapsed or refractory multiple myeloma (MM) who are beginning to receive elotuzumab at the selected sites.
88838582|NCT02412306|Experimental|Blinatumomab 9-28 µg/day Phase 1b Adult Population|Participants received blinatumomab by continuous intravenous (CIV) infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose for adults was 9 µg/day for the first week of cycle 1, escalated to 28 µg/day starting from Week 2 and all cycles thereafter.
88838583|NCT02412306|Experimental|Blinatumomab 5-15 µg/m^2/day Phase 1b Pediatric Population|Participants received blinatumomab by CIV infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. For pediatric participants the initial dose was 5 µg/m²/day for the first week of cycle 1, escalated to 15 µg/m²/day starting from week 2 and all cycles thereafter.
88838584|NCT02412306|Experimental|Blinatumomab 9-28 µg/day Phase 2 Adult Population|Participants received blinatumomab by CIV infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose for adults was 9 µg/day for the first week of cycle 1, escalated to 28 µg/day starting from Week 2 and all cycles thereafter.
88838585|NCT02412306|Experimental|Blinatumomab 9-28 µg/day Adult Expansion Population|Participants received blinatumomab by CIV infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose for adults was 9 µg/day for the first week of cycle 1, escalated to 28 µg/day starting from Week 2 and all cycles thereafter.
88838586|NCT02412306|Experimental|Blinatumomab 5-15 µg/m^2/day Pediatric Expansion Population|Participants received blinatumomab by CIV infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. For pediatric participants the initial dose was 5 µg/m²/day for the first week of cycle 1, escalated to 15 µg/m²/day starting from week 2 and all cycles thereafter.
88838587|NCT05616468|Experimental|BGT007 Cell Injection|"In this study, 23 patients diagnosed with recurrent/metastatic nasopharyngeal carcinoma will receive a single intravenous infusion of BGT007 cells after enrollment, with a dose of 5.0 × 10^5cells/kg，1.0 × 10^6cells/kg，3.0 × 10^6cells/kg，6.0 × 10^6cells/kg，1.0 × 10^7cells/kg。 One subject was enrolled in each of the first two dose groups, and the other three dose groups were enrolled in accordance with the conventional 3+3 dose increase."
89178971|NCT00764322|Experimental|Tamoxifen 20|One arm, containing the ultra-rapid and extensive metabolizer genotypes, continues treatment with tamoxifen at 20mg.
89178972|NCT00764322|Active Comparator|Tamoxifen 40|This arm, containing the intermediate and poor metabolizer genotypes, receives escalated treatment with tamoxifen at 40mg.
89178973|NCT03908060|Experimental|Intravenous single-dose methadone|A 10 ml syringe with 2 mg/ml of methadone will be prepared and and study drug will be administered as intravenous bolus dose (0.2 mg/kg) corresponding to 1 ml for every 10 kg of ideal body weight (height (cm) - 105).
89366825|NCT03252574|Other|Sequence BA|No mask, followed by AIR+ Smart Mask with micro-ventilator (B), then AIR+ Smart Mask only (A).
89366826|NCT01345071||RA patients|RA patients with active disease or current use of anti-TNF. Treatment is according to treat to target principles.
89366827|NCT04847310|Experimental|Group 1|
89366828|NCT04847310|Experimental|Group 2|
89366829|NCT04847310|Active Comparator|Group 3|
89366830|NCT01348737|Experimental|AZD3839|Oral Treatment
89366831|NCT01348737|Placebo Comparator|AZD3839 Placebo|Oral Treatment
89366832|NCT01369602|Experimental|healthy controls|healthy subjects (creatinine clearance > 90 mL/min)
89366833|NCT01369602|Experimental|ESRD / severe renal insufficiency|Severe (creatinine clearance 15 to 29 mL/min) OR ESRD (creatinine clearnace <15 mL/min OR requiring dialysis)
89366834|NCT01369602|Experimental|Moderate renal impairment|Moderate (creatinine clearance = 30 to 59 mL/min)
89366835|NCT01369602|Experimental|Mild renal impairment|Mild (creatinine clearance = 60 to 89 mL/min)
89366836|NCT01364532|Experimental|Transulnar arterial access|Transulnar arterial access for coronary angiography, ad-hoc or elective PCI
89366837|NCT01364532|Active Comparator|Transradial arterial access|Transradial arterial access for coronary angiography, ad-hoc or elective PCI
89366838|NCT03260608|Experimental|Intervention|Telesupport: eight weekly phone calls of psychoeducation and support on the illness of their relatives. Patients will also receive printed materials on problematic behaviors about dementia.
88838588|NCT02274168|Other|Conventional RF catheter ablation|Conventional RF ablation will be performed without using ICD-EG information
88838589|NCT02274168|Other|Investigational RF Catheter Ablation using ICD-EG information|RF Catheter Ablation will be performed using ICD-EG information
89366839|NCT03260608|No Intervention|Control|No active intervention. Patients will only receive printed materials on problematic behaviors about dementia and no contact by the research team.
89366840|NCT01345149|Experimental|Diet + Exercise|"Diet: Intensive counselling about calorie restriction to reduce weight gain by dietician.~Exercise: Individual counselling"
89366841|NCT01345149|Experimental|Exercise|Exercise: Individual counselling
89366842|NCT01345149|No Intervention|Control|Standard treatment without intervention.
89366843|NCT03252496|Experimental|Combination|250 mL colloid over 5 minutes followed by 500 mL crystalloid over 55 minutes then 250 mL colloid over 60 minutes. Cesarean delivery performed under spinal anesthesia (intrathecal bupivacaine 12.5 mg and intrathecal fentanyl 15 μg). Ultrasound assessment of the Inferior vena cava diameter. Intravenous ephedrine and intravenous syntocinon will be administered.
89366844|NCT03252496|Active Comparator|Crystalloid|250 mL crystalloid over 5 minutes followed by 500 mL crystalloid over 55 minutes then 250 mL crystalloid over 60 minutes. Cesarean delivery performed under spinal anesthesia (intrathecal bupivacaine 12.5 mg and intrathecal fentanyl 15 μg). Ultrasound assessment of the Inferior vena cava diameter. Intravenous ephedrine and intravenous syntocinon will be administered.
88838590|NCT04285723||alpelisib|Patients treated with alpelisib
88838591|NCT02975011||Lumbar stenosis group|Lumbar stenosis patients will be administered integrative Korean medicine treatment consisting of herbal medicine, Chuna manipulation, bee venom pharmacopuncture and pharmacopuncture, acupuncture, electroacupuncture, cupping, and other interventions, as needed.
88838592|NCT01352221|Experimental|ST10|ST10 (Ferric Maltol) 30mg capsules, taken orally twice a day
89366845|NCT01345227|Experimental|Intra BM islet infusion|single intra BM islet infusion at the level of the iliac crest will be performed in patients having contraindications for intraportal infusion
89366846|NCT03237234|Sham Comparator|Motor Training + Sham tDCS|Individuals will participate in 3 consecutive sessions of lower extremity motor skill training while receiving sham transcranial direct current stimulation (tDCS).
89366847|NCT03237234|Experimental|Motor Training + tDCS|Individuals will participate in 3 consecutive sessions of lower extremity motor skill training combined with transcranial direct current stimulation (tDCS) delivered at 2mA to the motor cortex.
89366848|NCT03688425|Experimental|IOL implantation experimental|hydrophobic, trifocal intraocular lens POD L GF with light distribution far > intermediate > near
89366849|NCT03688425|Active Comparator|IOL implantation active comparator|hydrophobic, trifocal intraocular lens POD F GF with light distribution far > near > intermediate
89366850|NCT03252418|Experimental|ascorbic acid|injection of 1 ml intamucosal ascorbic acid 3 times with 1 week interval
89366851|NCT03252418|Experimental|diode laser|photothermolysis by diode laser in one session
89366852|NCT01348893|No Intervention|Physical education as usual|High school physical education curriculum established by the school, including competitive sports, aerobic and anaerobic activities, balance and coordination skills. Yoga is not a component of the curriculum.
89366853|NCT01348893|Experimental|Yoga during physical education|
89366854|NCT03260452|Experimental|Patients|'Abdominal subcutaneous biopsies and Blood test'
89366855|NCT01364610|Active Comparator|Standard Care|Group 1 will have standard catheter based pH-metry. All participants will answer a questionnaire assessing tolerance and satisfaction of both the siting and placement methods and the 24 hour monitoring period.
89366856|NCT01364610|Active Comparator|Bravo pH Monitoring System|Group 2 will undergo unsedated peroral placement of the Bravo capsule. All participants will answer a questionnaire assessing tolerance and satisfaction of both the siting and placement methods and the 24 hour pH monitoring period.
89366857|NCT03687567||HBA|alpha-Thalassemia
89366858|NCT03687567||HBB|beta-Thalassemia
89366859|NCT01364688|Experimental|Treatment|oral alfacalcidol
89366860|NCT01364688|No Intervention|Control|No drug
89366861|NCT03260686|Experimental|Video Guided Group|Participants receive standard care physiotherapy for their upper limb rehabilitation, with exercises given either verbally or in writing as decided by the prescribing clinician. In addition the participants will receive a personalised video guide of their exercises, filmed during their therapy session to use for independent practice when back on the ward.
89366862|NCT03260686|No Intervention|Treatment as usual|Participants receive standard care physiotherapy for their upper limb rehabilitation, with exercises given either verbally or in writing as decided by the prescribing clinician
89366863|NCT03252106|Experimental|Contour augmentation|
89366864|NCT01370148|Experimental|Subjects with severe hepatic impairment|
89366865|NCT01370148|Active Comparator|Subjects with normal hepatic function|
89366866|NCT03260296||University students|university students who use smartphones
89366867|NCT04497402||female COVID19 patients|Females with COVID19 disease
89366868|NCT04497402||male COVID19 patients|Males with COVID19 disease
89366869|NCT04497402||female matched COVID19-free patients|Free from disease COVID19 Females matched.
89366870|NCT04497402||male matched COVID19-free patients|Free from disease COVID19 males matched.
89366871|NCT01370226|Active Comparator|CBI|Computer delivered Brief Intervention
89366872|NCT01370226|Active Comparator|TBI|Therapist delivered Brief Intervention
89366873|NCT01370226|No Intervention|EUC|Enhanced Usual Care
89366874|NCT02455414||Wolfram Syndrome Group|"Participant has confirmation of a WFS1 mutation OR~Both of the following conditions: diabetes mellitus requiring insulin and optic nerve atrophy diagnosed by a physician. Both conditions diabetes mellitus and optic nerve atrophy had to be diagnosed at age younger than 18 years old"
89366875|NCT02455414||WFS Pre-symptomatic Sibling Group|"Has had genotyping~Willingness to share result of genotyping~Participant has confirmation of WFS1 (+/+) mutation but is asymptomatic."
89366876|NCT02455414||WFS Control Sibling Group|"Has had genotyping~Willingness to share result of genotyping~Patient has confirmation of NO WFS1 mutation (-/-) or confirmation as a carrier (+/- or -/+)."
89366877|NCT02455414||T1DM Group|"Age within the 0-28 yrs age range of WS participant~Dx of T1 diabetes mellitus"
89366878|NCT02455414||Healthy Control (HC) Group|• Age within the 0-28 yrs age range of WFS participants
89366879|NCT02455414||Proxy Group|Adult Biological parent(s), biological caregiver or non-biological caregiver of adult and minor participants in the any of the groups.
88838593|NCT01352221|Placebo Comparator|Placebo|Matching placebo capsules for ST10 (Ferric Maltol), taken orally twice a day
89366880|NCT01348971|Experimental|Sodium nitrate|Preoperative oral administration of sodium nitrate. 700 mg the night before surgery and 700 mg three hours before surgery
89366881|NCT01348971|Placebo Comparator|Placebo|Preoperative oral administration of sodium chloride the night before surgery and three hours before surgery
89366882|NCT03260062|Experimental|PEARLS|Participants in this arm will receive 10 1-hour weekly sessions of the PEARLS intervention
89366883|NCT03260062|Active Comparator|Control|Participants in this arm will receive 10 1-hour weekly sessions of the standard of care LSL Speech Therapy
89366884|NCT04684953|Active Comparator|Thyroid autotransplantation|Implantation of 5-10 gm thyroid gland after mincing it in saline in quadriceps femoris muscle.
88838594|NCT03681769|Experimental|Intermittent Theta Burst Stimulation (iTBS) to the left dlPFC|For intermittent theta burst stimulation (iTBS) (Aim 1), participants will receive 20 trains of stimulation over the dlPFC (middle frontal gyrus) (F3) (each train: 3 pulse bursts presented at 5 hertz, 15 pulses/sec for 2 sec, 8 sec rest, 200 pulses/train; 110% resting motor threshold, MagPro; 600 pulses total) using a figure 8 coil (Coil Cool-B65 A/P).
88838595|NCT03681769|Sham Comparator|Sham iTBS to the left dlPFC|The MagVenture MagPro system has an integrated, active sham which passes current through two surface electrodes placed on the scalp. The electrodes will be placed on the left frontalis muscle for all sessions. A patient identification card will randomize participants to receive either real or sham stimulation. This system maintains blinding by a gyroscope in the coil which indicates to the clinical staff whether the coil should be rotated up or down for this participant once the card is entered into the machine. One side of the coil is active, the other is sham. The integrity of the double-blind procedure will be assessed by asking the patients and study personnel rate their confidence regarding whether they thought they received real or sham (scale 1-10).
88838596|NCT03681769|Experimental|cTBS to the mPFC|For continuous theta burst stimulation (Aim 2), participants will receive 1 train of stimulation over the left frontal pole (FP1) (each train: 3 pulse bursts presented at 5 hertz, 15 pulses/sec for 40 sec, 600 pulses/train, 110% resting motor threshold, MagPro; 600 pulses total) using a figure 8 coil (Coil Cool-B65 A/P). This protocol has been shown to attenuate the mPFC and striatum in cocaine dependent individuals in the past (61-63) and has been more effective than 1200 or 1800 pulses of cTBS in attenuating depression (The time between the end of the TBS procedures and the beginning of the behavioral assessments, as well as the scalp-to-cortex distance (which effects the actual TMS dose given to the cortex) will be compiled and used as covariates in subsequent analyses.
89366885|NCT04684953|Other|control group|the patients in this group won't undergo thyroid autotransplantation. instead, hormonal replacement therapy shall be prescribed for them.
89366886|NCT03259984||Aim 1|This experiment will use the next generation sequencing reduced representation bisulfite sequencing to define patterns of DNA methylation in skeletal muscle and whole blood tissue of metabolically well-characterized lean healthy, obese nondiabetic, and type 2 diabetic volunteers. The investigators will test the hypotheses that: (a) There is an increased methylation of genes involved in mitochondrial biogenesis and oxidative phosphorylation and altered methylation of promoters of genes coding for extracellular matrix and cytoskeletal proteins in insulin resistance, (b) The altered methylation patterns observed correspond to protein and mRNA expression changes, and (c) There are coordinated patterns of DNA methylation between the skeletal muscle and whole blood tissues in insulin resistance.
89366887|NCT03259984||Aim 2|This experiment will test the hypotheses in lean healthy, obese non-diabetic and type 2 diabetic volunteers that: (a) Increased methylation of the PGC-1α promoter predicts a decreased response of this gene to a single bout of exercise, and (b) Altered methylation of promoters of nuclear encoded mitochondrial genes predicts a decreased response of this gene to a single bout of exercise.
89366888|NCT03259984||Aim 3|This experiment will test the hypothesis in lean healthy, obese non-diabetic and type 2 diabetic volunteers that: (a) There is decreased methylation of genes involved in mitochondrial biogenesis and oxidative phosphorylation, and the altered methylation corresponds to protein and mRNA (messenger ribonucleic acid) expression changes, (b) There is altered methylation of genes involved in inflammation and cytoskeletal structure.
89366889|NCT01345383||Current smokers|
89366890|NCT03252184|Experimental|Phase 1 - Low level laser therapy - 1 (G1)|Low level laser therapy with energy dose of 18J will be applied on left brachial artery of the subject.
89366891|NCT03252184|Experimental|Phase 1 - Low level laser therapy - 1 (G2)|Low level laser therapy with energy dose of 36J will be applied on left brachial artery of the subject.
88838597|NCT03681769|Sham Comparator|Sham cTBS to the mPFC|The MagVenture MagPro system has an integrated, active sham which passes current through two surface electrodes placed on the scalp. The electrodes will be placed on the left frontalis muscle for all sessions. A patient identification card will randomize participants to receive either real or sham stimulation. This system maintains blinding by a gyroscope in the coil which indicates to the clinical staff whether the coil should be rotated up or down for this participant once the card is entered into the machine. One side of the coil is active, the other is sham. The integrity of the double-blind procedure will be assessed by asking the patients and study personnel rate their confidence regarding whether they thought they received real or sham (scale 1-10).
88838598|NCT03678805|Experimental|Acceleration|The impacted canines will undergo acceleration by corticotomy accompanied with traditional traction techniques.
88838599|NCT03678805|Active Comparator|Traditional Traction|"Traditional traction will be employed in this group of patients with impacted canines.~Traditional withdrawal techniques will be used."
88838600|NCT03671005|Experimental|Mindfulness-based group therapy (MBGT)|The mindfulness-based group therapy (MBGT) involves a four-week manual with three group therapy sessions per week in addition to TAU. The therapy represents the first German group-based mindfulness manual for psychosis. One sixty-minute session was held by a certified psychotherapist who is experienced in mindfulness-based therapy. A trained co-therapist implements two 30-minute sessions. On a weekly basis, a new theme is discussed in the three sessions to ensure the internalization of different mindfulness concepts. Namely, the topics Mindfulness of the Breath (1), Mindfulness of the Senses in the Context of Nature (2), Mindfulness of Detachment (3), and Mindfulness in the Context of Bodily Awareness (4) are addressed during the group-sessions.
88838601|NCT03671005|Active Comparator|treatment as usual (TAU)|Treatment as usual (TAU) at the ward consists of a variety of daily activity groups the patients can choose from. Every patient at the ward receives a daily schedule depending on individual needs for therapy. The therapies offered at the ward include occupational therapy, physiotherapy, psychoeducative groups, and concentration practice of two levels, all not related to mindfulness interventions. In addition to the group activities at the ward, every patient receives individual psychotherapy sessions at least once a week, held by a certified psychiatrist or psychologist. Psychopharmacological treatment is provided by the physicians, and social workers are available in order to support patients in managing their everyday lives after the stationary treatment. Weekly group meetings at the ward, together with the treating physicians, psychotherapists, social workers and the respective patient, foster the exchange success and possible improvements of the treatment.
88838602|NCT05195034|Active Comparator|DEX group|The DEX group patients will be received dexmedetomidine intraoperatively.
88838603|NCT05195034|Placebo Comparator|Placebo group|The placebo group patients will be received 0.9% saline intraoperatively.
88838604|NCT04790058||Physicians using CSRS practice recommendation to treat syncope patients in ED.|During the control period, there will be no interventions. The intervention is the knowledge translation of the CSRS practice recommendations. The components of the practice recommendations include: 1) evidence-informed systematic clinical evaluation with appropriate history, physical examination and in-ED investigations (e.g. troponin testing, work-up for pulmonary embolism and CT head) for detecting serious underlying conditions and predicting 30-day serious outcomes; 2) application of the CSRS for risk-stratification at the end of ED visit after no serious underlying conditions for the syncope were identified; 3) use of patient information materials to aid in disposition; 4) the use of 15-day outpatient cardiac monitoring for CSRS medium and high-risk patients upon ED discharge. The ED physician or non-ED physician performing consultation on the patient can apply all the components of the practice recommendation and decide disposition of the patients who are eligible to be studied.
88838605|NCT05496894|Experimental|Mitoxantrone Hydrochloride Liposome Injection 4 mg/m^2 group|Participants will receive Mitoxantrone Hydrochloride Liposome Injection 4 mg/m^2 every 3 months (Q3M).
88838606|NCT05496894|Experimental|Mitoxantrone Hydrochloride Liposome Injection 8 mg/m^2 group|Participants will receive Mitoxantrone Hydrochloride Liposome Injection 8 mg/m^2 every 3 months (Q3M).
88838607|NCT05496894|Experimental|Mitoxantrone Hydrochloride Liposome Injection 12 mg/m^2 group|Participants will receive Mitoxantrone Hydrochloride Liposome Injection 12 mg/m^2 every 3 months (Q3M).
88838608|NCT04418544||Control|Do not test positive for COVID
88838609|NCT04418544||COVID-19 Positive|Test positive for Covid using swab test.
88838610|NCT05474508|Experimental|Diaphragmatic breathing along with aerobic exercises|Experimental Group (Group A) will receive both aerobic exercises and diaphragmatic breathing exercise. Exercise programs will consist of 1 set of contractions per day and each set will include 30 repetitions for 6 weeks. Exercise protocol consist of at least 150 minutes of moderate-intensity aerobic activity every week dividing the 150 minutes into 30-minute workouts on 5 days of the week or into smaller 10-minute sessions throughout each day will be carried out for 6 weeks
88838611|NCT05474508|Active Comparator|Diaphragmatic breathing only without aerobic exercises|Active comparator (Group B) will receive only diaphragmatic breathing exercises. Exercise programs will consist of 1 set of contractions per day and each set will include 30 repetitions for 6 weeks.
88838612|NCT02021604|Experimental|Pancreatic Imaging with Fluorodopa F 18|
88838613|NCT02016378|Sham Comparator|sham retraining|Participants in this condition will participate in a computerized task wherein the size of pictures of drug and non-drug related stimuli are increased or decreased based on the tilt (left or right) of the pictures, but without regard to the content (i.e., drug or non-drug).
88838614|NCT02016378|Active Comparator|Bias retraining|Participants in this condition will participate in 6 sessions of a computerized bias retraining.
88838615|NCT04192968||Patients|Children implanted cochlear since 3 years in uni or bilateral and followed in the pediatric otolaryngology department of Necker-Enfants Malades Hospital.
88838616|NCT04192968||Patients with disappointing language development or poor cortical responses|Children having participated in the main ImplantHear3 study and who present with disappointing language development or poor cortical responses.
88838617|NCT03518034|Active Comparator|AndroGel 1.62%|Participants receive topical testosterone starting with a 40.5 mg dose (2 pump actuations) of the study drug once daily (OD). Participants may receive a dose in the range of 20.25 mg (1 actuation) to 101.25 mg (5 actuations) in 20.25 mg increments during the course of the study if titrations are necessary.
88838618|NCT03518034|Placebo Comparator|Placebo|Participants receive matching placebo OD.
88838619|NCT04776798|Experimental|Biomechanical Taping|"Anti pronation taping will apply bilaterally with Dynamic Tape®. The tape will attach to the dorsal aspect of the foot.~A home-based exercise program will apply in the first session. Printouts showing the exercises will give to the patients. Exercises will be done at home for 4 weeks, 5 d/w."
88838620|NCT04776798|Placebo Comparator|Placebo Taping|"Placebo Taping will apply bilaterally to each individual in the control group by the same physiotherapist, without any effect on increased pronation.~A home-based exercise program will apply in the first session. Printouts showing the exercises will give to the patients. Exercises will be done at home for 4 weeks, 5 d/w."
88838621|NCT05180058|Experimental|Wrapping + Breastmilk Group|Preterm newborns will be wrapped by the researcher 10 minutes before OGT insertion. Then, 2 ml of breast milk will be given by the researcher with a sterile syringe 2 minutes before the OGT insertion to the same newborn. Breast milk will be given slowly into the mouth of the preterm newborn, on the upper part of the tongue, through an injector. Preterm newborns will be recorded with a video camera for 10 minutes before the procedure and for 5 minutes during and after the procedure. Then, using video recordings, the pain and comfort of newborns will be evaluated at the 1st minute before the procedure, at the 1st minute and 2nd minute (4 measurements) during and after the procedure.
88838622|NCT05180058|Experimental|Wrapping + Oral Sucrose Group|Preterm newborns will be wrapped by the researcher 10 minutes before OGT insertion. Then, 2 ml of 20% oral sucrose will be given to the same newborn by the researcher with a sterile syringe 2 minutes before OGT insertion. Oral sucrose will be slowly introduced into the mouth of the preterm newborn on the upper part of the tongue through an injector. Preterm newborns will be recorded with a video camera for 10 minutes before the procedure and for 5 minutes during and after the procedure. Then, using video recordings, the pain and comfort of newborns will be evaluated at 1 minute before the procedure, during and after the procedure at 1 minute and 2 minutes (4 measurements).
89366892|NCT03252184|Experimental|Phase 1 - Low level laser therapy - 1 (G3)|Low level laser therapy with energy dose of 54J will be applied on left brachial artery of the subject.
89366893|NCT03252184|Placebo Comparator|Phase 1 - Placebo low level laser therapy - 1 (G4)|Low level laser therapy with equipment turn off (placebo) be applied on left brachial artery of the subject.
89366894|NCT03252184|Experimental|Phase 2 - Low level laser therapy - 2 (G1)|Low level laser therapy with energy dose of 30J will be applied on left brachial artery of the subject.
88838623|NCT05180058|Experimental|Fetal Position + Breastmilk Group|The fetal position will be given to the preterm newborn immediately after 2 ml of breast milk is given by the researcher 3 minutes before OGT insertion. Breast milk will be given slowly into the mouth of the preterm newborn, on the upper part of the tongue, through an injector. The preterm newborn will remain in the fetal position for 5 minutes during and after the procedure. Newborns will be recorded with a video camera before, during and after the procedure. Then, using video recordings, the pain and comfort of newborns will be evaluated at the 1st minute before the procedure, at the 1st minute and 2nd minute (4 measurements) during and after the procedure.
88838624|NCT05180058|Experimental|Fetal Position + Oral Sucrose Group|The fetal position will be given to the preterm newborn immediately after 2 ml of oral sucrose is given by the researcher 3 minutes before OGT insertion. Oral sucrose will be slowly injected into the mouth of the preterm newborn on the upper part of the tongue by means of an injector. At the end of the 3rd minute, the clinic nurse will insert the OGT as part of the treatment. The preterm newborn will remain in the fetal position for 5 minutes during and after the procedure.
88838625|NCT04789278|Experimental|Notification|"Patients randomized to notification will receive a message sent by either the electronic health record (EHR) patient portal or postal mail that will inform them of the CAC identified on their previous chest CT. It will provide an overview of CAC, an image of their chest CT, and a recommendation that they discuss this finding with their clinician. These clinicians will be notified of these findings via an earlier EHR message. Any treatment decisions will be made by the patient and their clinician.~Patients randomized to notification who are not prescribed a statin medication and do not have a documented discussion regarding statin therapy within three months will be sent a second message at that time. Their primary care providers will receive a second EHR message concurrently."
88838626|NCT04789278|No Intervention|Usual Care|Both arms have previously had their CT scans reported according to standard clinical practice. This may include notification of the CAC in the imaging report. The usual care arm will not receive any additional notification beyond this standard of care during the project.
88838627|NCT05178966|Experimental|Bp OneDay programm|The BP One-Day program is based on a single day of psychoeducation .
88838628|NCT05178966|No Intervention|Waiting List|Patients assigned in control group will be placed in waiting list and will benefit from the program after their participation to this study. During study participation, they will receive treatment as usual.
88838629|NCT04801524|No Intervention|Holdout Arm|In the Holdout arm: patients will not receive a second text message about COVID-vaccine.
88838630|NCT04801524|Experimental|Self-benefit sub-arm|In the Self-benefit sub-arm, participants will be reminded that the vaccine helps protect themselves from COVID.
88838631|NCT04801524|Experimental|Prosocial-benefit sub-arm|In the Prosocial-benefit sub-arm, participants will be reminded that the vaccine helps protect their family, friends, and community from COVID.
88838632|NCT04801524|Experimental|Early-access and self-benefit sub-arm|In the Early access + self-benefit sub-arm, participants will be reminded that they have early access to COVID-19 vaccine and should take the opportunity to protect themselves from COVID.
88838633|NCT04801524|Experimental|Early-access and prosocial-benefit sub-arm|In the Early access + prosocial-benefit sub-arm, participants will be reminded that they have early access to COVID-19 vaccine and should take the opportunity to protect their family, friends, community from COVID.
88838634|NCT04801524|Experimental|Fresh start and self-benefit sub-arm|In the Fresh start + self-benefit sub-arm, participants will be reminded that the vaccine offers the promise of a fresh start and they should take the opportunity to protect themselves from COVID and chart a new path forward.
89366895|NCT03252184|Experimental|Phase 2 - Low level laser therapy - 2 (G2)|Low level laser therapy with energy dose of 60J will be applied on left brachial artery of the subject.
89366896|NCT03252184|Placebo Comparator|Phase 2 - Placebo low level laser therapy - 2 (G3)|Low level laser therapy with equipment turn off (placebo) be applied on left brachial artery of the subject.
88838635|NCT04801524|Experimental|Fresh start and prosocial-benefit sub-arm|In the Early access + prosocial-benefit sub-arm, participants will be reminded that the vaccine offers the promise of a fresh start and they should take the opportunity to protect their family, friends, community from COVID and help our nation chart a new path forward.
88838636|NCT05172882|Experimental|Wound Infiltration|Wound infiltration will be applied to the surgical incision site for patients in this group. Infiltration fluid will contain 20 ml 0.25% bupivakain.
88838637|NCT05172882|Experimental|Transversalis Fascia Plane Block|Transversalis fascia plane block will be performed on only one periinguinal side for patients in this group. Block fluid will contain 20 ml 0.25% bupivakain.
88838638|NCT02666118|Active Comparator|Preemptive Interscalene Block - Single Shot|
88838639|NCT02666118|Active Comparator|Postoperative Interscalene Block - Single Shot|
89366897|NCT03252184|Experimental|Phase 3 - Low level laser therapy - 3 (G1)|Low level laser therapy with energy dose of 30J will be applied on left brachial artery of the subject.
88838640|NCT02666118|Active Comparator|Preemptive Interscalene Block - Catheter|
88838641|NCT02666118|Active Comparator|Postoperative Interscalene Block - Catheter|
88838642|NCT02635932|Experimental|Functional Splint group|Patient will be using the functional splint during their activity daily life
88838643|NCT02635932|Active Comparator|Night Splint group|Patients will use the night splint during the sleep time
88838644|NCT05337774|Experimental|Blast-related mTBI group|Assessments will include:(i) neuropsychological and neurobehavioral testing, (ii) MRI, with a special emphasis on (iii) PET, using emerging tracers for tauopathy ([18F]PI-2620), and amyloid ([18F]florbetaben).
88838645|NCT05337774|Experimental|mTBI not blast-related (control group 1)|Assessments will include:(i) neuropsychological and neurobehavioral testing, (ii) MRI, with a special emphasis on (iii) PET, using emerging tracers for tauopathy ([18F]PI-2620), and amyloid ([18F]florbetaben).
88838646|NCT05337774|Experimental|no history of TBI (control group 2)|Assessments will include:(i) neuropsychological and neurobehavioral testing, (ii) MRI, with a special emphasis on (iii) PET, using emerging tracers for tauopathy ([18F]PI-2620), and amyloid ([18F]florbetaben).
88838647|NCT02561598||Malignant Hyperthermia|Samples from persons who have a malignant hyperthermia diagnosis.
88838648|NCT02561598||Controls|Children who participated in pharmacogenetic research and had exposure to malignant hyperthermia triggering agents.
88838649|NCT05291988|Experimental|Screening (S2S education, FIT kit)|Participants receive S2S online screening education and FIT kit for sample collection.
88838650|NCT02389218|Experimental|Cryoablation|Cryoballoon single ablation (as described in the reference) at entry after randomization to this group. Single procedure,not to be repeated.
88838651|NCT02389218|Active Comparator|Drug|Conventional, available anti arrhythmic drugs (propafenone, sotalol or flecainide), in a first stage, sequential, with amiodarone in second stage
88838652|NCT01953120|Experimental|Belatacept|Survival and rejection in patients switched to belatacept.
88838653|NCT05343858|Experimental|Group 1: Spirulina platensis|10 volunteers will consume 16g / day (in 2 doses of 8g) of a nutritional supplement of Spirulina platensis
88838654|NCT05343858|Experimental|Group 2: Chlorella vulgaris|10 volunteers will consume 16g / day (in 2 doses of 8g) of a nutritional supplement of Chlorella vulgaris
88838655|NCT05343858|Placebo Comparator|Group 3: Control|10 volunteers will consume 16g / day (in 2 doses of 8g) of a control supplement
88838656|NCT01634100|Experimental|A (Reference)|Empagliflozin (BI 10773), Film-coated tablet, single dose
88838657|NCT01634100|Experimental|B (Test 1)|Empagliflozin (BI 10773), Film-coated tablet, single dose, and Rifampicin,Film-coated tablet single dose
88838658|NCT01634100|Experimental|C (Test 2)|Empagliflozin (BI 10773), Film-coated tablet, single dose, and Probenecid Tablet twice daily
88838659|NCT01633944|Placebo Comparator|Placebo|Twice Daily Dosing
88838660|NCT01633944|Experimental|Buprenorphine HCl Buccal Film|Twice Daily Dosing
88838661|NCT04592419|Experimental|KSI-301 (Arm A)|"Intravitreal injection of KSI-301 (5 mg) at Day 1, Week 4, and once every 8 weeks through Week 20 followed by an individualized dosing regimen of Intravitreal injection of KSI-301 (5 mg) from Week 24 to Week 44.~In the Extension Phase, participants randomized to KSI-301 (5 mg) in the Primary Study will continue to receive KSI-301 (5 mg) based on protocol-defined disease activity criteria."
89366898|NCT03252184|Experimental|Phase 3 - Low level laser therapy - 3(G2)|Low level laser therapy with energy dose of 60J will be applied on left brachial artery of the subject.
89366899|NCT03052920|Experimental|Cochlear Implantation|Cochlear implantation of the poor hearing ear
89366900|NCT01345461||Healthy adult volunteers|Twelve healthy adult volunteers (6 men, 6 women)
89366901|NCT03252262|Active Comparator|Jack Satter House|Residents of Jack Satter House who participated in the Vitalize 360 Program.
89366902|NCT03252262|Active Comparator|Center Communities of Brookline|Residents of Center Communities of Brookline who participated in the Vitalize 360 Program.
89366903|NCT03252262|Active Comparator|Simon C. Fireman|Residents of Simon C. Fireman who participated in the Vitalize 360 Program
89366904|NCT01349127|Active Comparator|20µg Vitamin D3|Arm will receive per day one gelatin capsule containing 20µg (800IU) of vitamin D3 (Cholecalciferol).
89366905|NCT01349127|Active Comparator|20µg Vitamin D3 + 500 mg Calcium|Arm will receive per day one gelatin capsule containing 20µg (800IU) of vitamin D3 (Cholecalciferol) and one tablet of calcium carbonate containing 500mg of calcium.
89366906|NCT01349127|Placebo Comparator|Placebo|Arm will receive one gelatin capsule containing 0µg (0IU) of vitamin D3 (Cholecalciferol).
89366907|NCT03486964||DPP-4 plus other therapies|Patients in therapy with DPP-4 inhibitors in addition to sulfonylureas and/or biguanides and/or thiazolidinediones and/or insulin
89366908|NCT03486964||Other therapies|Patients in therapy with other hypoglycemic classes, such as sulphonylureas and/or biguanides and/or thiazolidinediones and/or insulin.
89366909|NCT01364844|Experimental|DS7423|
89366910|NCT04005027|Experimental|Intermittent graded exercise (INT)|The intermittent graded exercise test (INT) increase treadmill speed incrementally using three minute stage duration on a motorised treadmill. However, the speed within each three minute exercise bout will vary every 30 s between the target speed, and a complete pause for 30 s. The acceleration of the treadmill belt will be set to its maximum capability.
89366911|NCT04005027|Active Comparator|Continuous graded exercise (CONT)|The continuous graded exercise test (CONT) will increase treadmill speed incrementally using three minute stage duration on a motorised treadmill
89366912|NCT03259906|Active Comparator|Osteosynthesis using a posterior plate|
89366913|NCT03259906|Active Comparator|Osteosynthesis using an anterior plate|
89366914|NCT01369836|Experimental|20 mg soft gelatin capsule|
89366915|NCT01369836|Experimental|40 mg (20 mg*2) soft gelatin capsule|
89366916|NCT01369836|Active Comparator|Placebo|
89366917|NCT01317303|Experimental|PAS25|PAS25 refers to the intervention 'paired-associative stimulation' with peripheral ulnar nerve stimulation followed by TMS to the motor cortex 25 ms after.
88838662|NCT04592419|Active Comparator|Aflibercept (Arm B)|"Intravitreal injection of aflibercept (2 mg) once every 4 through Week 20 followed by an individualized dosing regimen of Intravitreal injection of Aflibercept (2 mg) once every 4 weeks from Week 24 to Week 44.~In the Extension Phase, participants randomized to aflibercept in the Primary Study will cross over to treatment with KSI-301 (5 mg). They will receive their first dose of KSI-301 (5 mg) at Week 48 and will receive additional treatment with KSI-301 (5 mg) based on protocol-defined disease activity criteria."
88838663|NCT00589316|Experimental|Treatment (chemo, TBI, transplant, immunosuppression)|"RADIOIMMUNOTHERAPY: Patients receive therapeutic iodine I 131 monoclonal antibody BC8 via central line on day -14.~NONMYELOABLATIVE CONDITIONING: Patients receive FLU IV over 30 minutes on days -6 to -2 and CY IV over 1 hour on days -6 and -5. Patients undergo TBI on day -1.~TRANSPLANTATION: Patients undergo allogeneic bone marrow transplantation on day 0.~POST-TRANSPLATATION IMMUNOSUPPRESSION: Patients receive CY IV over 1-2 hours on day 3, MMF IV or PO TID on days 4 to 35, and tacrolimus IV over 1-2 hours or PO on days 4 to 180 with taper on day 84."
88838664|NCT01633788|Experimental|AGN-195263 0.1%|1 drop of AGN-195263 0.1% instilled in each eye twice daily.
88838665|NCT01633788|Experimental|AGN-195263 0.03%|1 drop of AGN-195263 0.03% instilled in each eye twice daily.
88838666|NCT01633788|Experimental|AGN-195263 0.01%|1 drop of AGN-195263 0.01% instilled in each eye twice daily.
88838667|NCT01633788|Placebo Comparator|AGN-195263 Vehicle|1 drop of AGN-195263 vehicle (placebo) instilled in each eye twice daily.
88838668|NCT04263493|Active Comparator|Early mobilization (loading)|"This constitutes the currently accepted regime and is therefore considered the control group.~Cast/orthopedic boot for 6 weeks No weight bearing: week 0-2 Partiel weightbearing from week 3 Full weightbearing from week 7 ROM exercises 5 times a day from week 3"
88838669|NCT04263493|Experimental|Delayed mobilization (loading)|Loading of the Achilles tendon is delayed for 6 weeks. Cast/orthopedic boot for 12 weeks No weight bearing: week 0-6 Partiel weightbearing from week 7 Full weightbearing from week 13 ROM exercises 5 times a day from week 3
88838670|NCT02032524|Experimental|Avalglucosidase Alfa|administered intravenously every 2 weeks
89366918|NCT01317303|Experimental|cTBS-PAS|40 seconds of continuous Theta-burst stimulation, followed by PAS25 which refers to the intervention 'paired-associative stimulation' with peripheral ulnar nerve stimulation followed by TMS to the motor cortex 25 ms after.
89366919|NCT01317303|Experimental|iTBS|190 seconds of intermittent theta-burst stimulation
88838671|NCT02713880||Patients with Transthyretin-Related Familial|Patients with Transthyretin-Related Familial Amyloidotic Polyneuropathy or high-grade suspicion for Transthyretin-Related Familial Amyloidotic Polyneuropathy
89366920|NCT01317303|Experimental|cTBS-iTBS|40 seconds of continuous Theta-burst stimulation, followed by 190 seconds of intermittent Theta-burst stimulation
89366921|NCT03251950|Experimental|Intervention group|15 week healthy eating and gardening curriculum to be implemented in Osage Nation Early Childhood Programs; 15 week healthy eating parenting curriculum to be implemented online to parents of enrolled children
89366922|NCT03251950|Other|Control group|Wait list control -- to receive intervention after serving as wait list group
89366923|NCT01349205|Experimental|Caffeine and Sodium Benzoate 10 mg/kg IV|Group 1 of randomized study.
89366924|NCT01349205|Experimental|Caffeine and Sodium Benzoate 20 mg/kg IV|Group 2 of randomized study
89366925|NCT01349205|Placebo Comparator|0.9 NS Saline|Control group of randomized study.
89366926|NCT03251794||threatened preterm labor|women presented to the reception unit from 28-37 weeks by regular contractions and opened cervix
89366927|NCT01370304|Experimental|active rTMS and active Venlafaxine|
89366928|NCT01370304|Experimental|active rTMS and sham Venlafaxine|
89366929|NCT01370304|Sham Comparator|sham rTMS and active Venlafaxine|
89366930|NCT01349283|Experimental|HepavaxGene Stratum 1a|Subjects of mothers with chronic hepatitis B (positive for both HBsAg and hepatitis B envelope antigen - HBeAg)
89366931|NCT01349283|Active Comparator|Comparator vaccine Stratum 1a|Subjects of mothers with chronic hepatitis B (positive for both HBsAg and HBeAg)
89366932|NCT01349283|Experimental|HepavaxGene Stratum 1b|Subjects of mothers with chronic hepatitis B (positive for HBsAg only)
89366933|NCT01349283|Active Comparator|Comparator vaccine Stratum 1b|Subjects of mothers with chronic hepatitis B (positive for HBsAg only)
89366934|NCT01349283|Experimental|HepavaxGene Stratum 2|Subjects of mothers without chronic hepatitis B (negative for both HBsAg and HBeAg)
89366935|NCT01349283|Active Comparator|Comparator vaccine Stratum 2|Subjects of mothers without chronic hepatitis B (negative for both HBsAg and HBeAg)
89366936|NCT01370382||Time interval|"Patients are divided according to the interval between the onset of chest pain symptoms and presentation at the hospital in an early(<4 hours) and late(> = 4 hours) group."
89366937|NCT01345617||cystic fibrosis patients|cystic fibrosis patients
89366938|NCT01345617||non-cystic fibrosis patients|non-cystic fibrosis patients
88838672|NCT04786080|Experimental|Parent Positive|This is an app developed for use on a smartphone providing a flexible digital space where parents can get support and advice to help them manage their children's behaviour. The app will be free and parents will be able to access the information when needed and in the order they choose. Parents in the intervention group will receive access during the immediate post-randomisation period.
88838673|NCT04786080|No Intervention|Follow-Up as Usual|FAU was selected as a comparator because of the pragmatic nature of the trial. Individuals randomised to FAU will receive no intervention for the first 10 weeks while the data for baseline (T1), T2 and T3 are collected. They will then be given access to all three zones of the app.
88838674|NCT00421837||controls|household and other close contacts
89366939|NCT03259828|Experimental|Adjuvant image-guided radiotherapy|Adjuvant radiotherapy with image guidance via cone beam computed tomography. Treatment is identical to the current standard of care.
89366940|NCT03259750||professional athletes|athlete who volunteered in this study that should be a member of a professional sport team, All athletes must complete self reported outcome instrument (FAAM-T)
89366941|NCT03246490|Other|All Participants|All participants complete the same study procedures, which involve drinking alcohol to a .08 blood alcohol level and walking short distances while their blood alcohol level is increasing to .08 and decreasing down to .00.
88838675|NCT00421837||cases|elderly (>55) subjects hospitalized with Influenza
88838676|NCT00361543|Active Comparator|1|Raloxifene Hydrochloride
88838677|NCT00361543|Placebo Comparator|2|placebo tablet
88838678|NCT04568239||M184V + group and M184 - group|
88838679|NCT04329585|Experimental|GABA antagonist|In the end of the experiment, 0.2mg of flumazenil(GABA antagonist) is given to the participant.
88838680|NCT04329585|Placebo Comparator|Placebo|In the end of the experiment, the same volume of normal saline is given to the participant.
88838681|NCT00384267||Neonates|Inpatient
88838682|NCT00003441|Experimental|Irofulven|6-hydroxymethylacylfulvene (MGI-114) IV over 5 minutes daily for 5 consecutive days every 28 day cycle.
88838683|NCT00002805|Experimental|Treatment|Induction will consist of one course of cytarabine and mitoxantrone. Patients achieving a complete or partial response by the end of induction will start intensification. Intensification will consist of one course of chemotherapy (Cytarabine (Ara-C), Etoposide (VP-16), Filgrastim (G-CSF)). Patients who do not attain a CNS remission following the completion of intensification therapy, or who develop recurrence of CNS disease and have not previously received radiation therapy involving the central nervous system should receive craniospinal radiotherapy. Continuation Therapy: cladribine (2CdA), Etoposide.
88838684|NCT03620773|Other|Clinical Investigation|"Participants will include youth who are scheduled for, and will undergo, vertical sleeve gastrectomy (VSG) surgery at the Bariatric Surgery Clinic at Children's Hospital of Colorado.~To understand how bariatric surgery affects renal function, all participants will undergo assessment of Glomerular Filtration Rate, (Iohexol Inj 300 mg/mL) and Effective Renal Plasma Flow (Aminohippurate Sodium Inj 20%). In addition, participants will undergo imaging assessment that includes renal Blood Oxygen Level Dependent (BOLD) and Arterial Spin Labeling (ASL) MRI."
88838685|NCT00002829|Experimental|Bone Marrow Transplantation|
88838686|NCT03614221|Experimental|Lindioil|Lindioil ointment is applied twice daily for 6 weeks, followed by a washout period of 4 days to 8 weeks depending on the results of the first treatment period and the amount of time it takes the participant to relapse to IGA ≥ 2 and less than 1-point of change from baseline1ST IGA. If relapse to IGA ≥ 2 and less than 1-point of change from baseline1ST IGA is achieved, the patient is using Protopic ointment 0.1% twice daily for another 6 weeks. If the criteria for entering the 2nd treatment are not achievable after 8-week of ceasing 1st treatment, the subject will be followed up for another 6 weeks to the end of the study
89001695|NCT00476593|Experimental|Dexamethasone|Benzalkonium-reserved Dexamethasone Sodium Phosphate 0.1% was applied in one consecutively assigned eye of healthy volunteers six times a day for three days, after which macular thickness was assessed in both subjects's eyes with the OCT.
89366942|NCT03966339|Experimental|GH group|Growth Hormone adding to controlled ovarian hyperstimulation
89366943|NCT03966339|No Intervention|control group|regular controlled ovarian hyperstimulation
89366944|NCT03251716|Experimental|berberine adjunctive group|Only one treatment group in this study, without a preset control group,subjects who meet the criteria will entere the berberine adjunctive group
89366945|NCT03251872|Experimental|Drug: Olaparib|Olaparib up to 400 mg BID (100 to 400 mg) for 16 weeks
89001696|NCT00210132|Experimental|Ropivacaine|
89001697|NCT00183404|Experimental|Olanzapine|Participants will take open olanzapine for up to 20 additional weeks after phase 1.
89366946|NCT02455258|Experimental|Dance/Movement Therapy (DMT)|
89366947|NCT02455258|Active Comparator|Aerobics Exercise (AE)|
89366948|NCT02455258|No Intervention|Waiting List|This group is placed on a waiting list and asked to refrain from making any changes to their current lifestyle.
89366949|NCT03251404|Active Comparator|Knee Control original|The Knee Control program exercise program will be performed during the warm-up to each football practice (at least twice per week) during the 12 week intervention period.
89366950|NCT03251404|Experimental|Knee Control+|The Knee Control+ is an extension of the original Knee Control exercise program offering a wider selection of exercises (to increase adherence) and more physically challenging exercises (adapted for athletes in the late teens and provide further stimuli to increase player performance and neuromuscular function). The program will be performed during the warm-up to each football practice (at least twice per week) during the 12 week intervention period.
89366951|NCT02930226|Experimental|1 unit FDP-CPD|Subjects are to have sufficient plasma withdrawn during a single WB collection visit to allow re-infusion with 1 unit of autologous FDP-CPD
89366952|NCT02930226|Experimental|Reinfusion 1 unit FDP-ACD|Subjects are to have sufficient plasma withdrawn during 1 plasmapheresis collection visit to allow re-infusion with 1 unit of autologous FDP-ACD
89366953|NCT02930226|Experimental|Reinfusion 2 units FDP-CPD|Subjects are to have sufficient plasma withdrawn during 2 separate WB collection visits to allow re-infusion with 2 units of autologous FDP-CPD
89366954|NCT02930226|Experimental|Reinfusion 2 units FDP-ACD|Subjects are to have sufficient plasma withdrawn during 1 plasmapheresis collection to allow re-infusion with 2 units of autologous FDP-ACD
89366955|NCT02930226|Active Comparator|Reinfusion 3 units FDP, 3 units FFP (1st)|Subjects plasma withdrawn during 2 or 3 plasmapheresis collections to allow re-infusion with 3 units of autologous FDP-ACD and 3 units of autologous control FFP. Subjects will receive in total 6 units over the course of 2 infusion visits. Subjects are to be randomized to treatment schedule arms that dictate the sequence for infusing FDP-ACD and FFP across the 2 infusion visits
89366956|NCT02930226|Active Comparator|Reinfusion 3 units FDP, 3 units FFP (2nd)|Subjects plasma withdrawn during 2 or 3 plasmapheresis collections to allow re-infusion with 3 units of autologous FDP-ACD and 3 units of autologous control FFP. Subjects will receive in total 6 units over the course of 2 infusion visits. Subjects are to be randomized to treatment schedule arms that dictate the sequence for infusing FDP-ACD and FFP across the 2 infusion visits
89366957|NCT03251560|Experimental|Fuke Qianjin capsule|Fuke Qianjin capsule, 2 pills each time,three times a day, orally (0.4g/pill）,for 2months,
89366958|NCT03251560|Placebo Comparator|Placebo oral capsule|placebo pills, 2 pills each time,three times a day, orally, for 2months
89366959|NCT03160521|Experimental|Risperidone ISM 75 mg|Patients assigned to this arm will received 75 mg of Risperidone ISM during double-blind treatment period.
88838687|NCT03614221|Active Comparator|Protopic|Protopic ointment 0.1% is applied twice daily for 6 weeks, followed by a washout period of 4 days to 8 weeks depending on the results of the first treatment period and the amount of time it takes the participant to relapse to IGA ≥ 2 and less than 1-point of change from baseline1ST IGA. If relapse to IGA ≥ 2 and less than 1-point of change from baseline1ST IGA is achieved, the patient is using Lindioil ointment twice daily for another 6 weeks. If the criteria for entering the 2nd treatment are not achievable after 8-week of ceasing 1st treatment, the subject will be followed up for another 6 weeks to the end of the study
88838688|NCT00003489|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
89366960|NCT03160521|Experimental|Risperidone ISM 100 mg|Patients assigned to this arm will received 100 mg of Risperidone ISM during double-blind treatment period.
89366961|NCT03160521|Placebo Comparator|Placebo|Patients assigned to this arm will received placebo of Risperidone ISM during double-blind treatment period.
89366962|NCT02722434|Experimental|Arm I (MC5-A scrambler therapy)|Patients undergo MC5-A scrambler therapy over 30 minutes for 10 consecutive weekdays.
89366963|NCT02722434|Active Comparator|Arm II (TENS therapy)|Patients undergo TENS therapy over 30 minutes daily for 14 days.
89366964|NCT03251248|Experimental|First MSB11455 Then Neulasta|
89366965|NCT03251248|Experimental|First Neulasta Then MSB11455|
88838689|NCT03596905|Experimental|0.5 mg plecanatide|Plecanatide 0.5 mg Taken orally once daily for 4 weeks Group A: 6 to 11 years old
88838690|NCT03596905|Experimental|1.0 mg plecanatide|Plecanatide 1.0 mg Taken orally daily for 4 weeks Group A: 6 to 11 years old Group B: 12 to < 18 years old
89366966|NCT03246256||Group 1|Patients with acute ischaemic stroke who were administered intavenous thrombolysis or patients with acute ischaemic stroke refusing intravenous thrombolysis; recall in both cases 60 to 90 minutes after the informed consent procedure
88838691|NCT03596905|Experimental|2.0 mg plecanatide|Plecanatide 2.0 mg Taken orally daily for 4 weeks Group B: 12 to < 18 years old
88838692|NCT03596905|Experimental|3.0 mg plecanatide|Plecanatide 3.0 mg Taken orally daily for 4 weeks Group B: 12 to < 18 years old
88838693|NCT03596905|Placebo Comparator|Matching placebo|Matching placebo Taken orally daily for 4 weeks Group A: 6 to 11 years old Group B: 12 to < 18 years old
88838694|NCT00003495|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
88838695|NCT00003501|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
88838696|NCT04563403|Experimental|Treatment with Multiple Stimuli|Projection-based augmented reality therapy (P-ARET) with Multiple Stimuli (MS) (P-ARET MS). Intervention group that receives P-ARET treatment varying the stimuli available in the system (different cockroaches in colour, size, etc).
89366967|NCT03246256||Group 2|1st of 2nd degree relatives of patients with acute ischaemic stroke, who witnessed the informed consent procedure
89366968|NCT03246256||Group 3|Stroke patients with acute or subacute ischaemic stroke with a contraindication for intravenous thrombolysis
89366969|NCT03246256||Group 4|Patients without an ischaemic stroke but similiar risk factors (admitted to the Departement of Cardiology and Pneumology, Charité, Campus Benjamin Franklin, Berlin, Germany)
89366970|NCT03246256||Group 5|Patients with acute ischaemic stroke who were administered intavenous thrombolysis - recall 24 hours after the informed consent procedure
89001698|NCT00183521|Experimental|1|Participants will receive raise-CO2 breathing regulation training
89001699|NCT00183521|Experimental|2|Participants will receive lower-CO2 breathing regulation training
89366971|NCT04438590|Experimental|Kelulut Honey|"Medical Grade Kelulut Honey which will be in 2 doses.~The first would be diluted to 800 ml of water, and the second dose in 400ml of water."
89366972|NCT04438590|Active Comparator|Carborie|Carborie Load which will be 100g of carbohydrate in 800 ML of water and 50g of carbohydrate in 400ml of water.
89366973|NCT03246178|Other|MSD-HSCT|This group received treatment of matched sibling donor - hematopoietic stem cell transplantation (MSD-HSCT).
88838697|NCT04563403|Experimental|Treatment with Single Stimuli|Projection-based augmented reality therapy (P-ARET) with Single Stimuli (SS) (P-ARET SS). Intervention group that receives P-ARET treatment using a single stimulus (one cockroach).
88838698|NCT00002835|Experimental|Arm I|"3 courses of early intensification:~First course: Ifosfamide (IFF) IV continuously and Etoposide (VP-16) IV over 2 hours every 12 hours on days 1-3. Filgrastim (G-CSF) administered subcutaneously (SC) beginning on day 5 and continuing until blood counts recover then autologous peripheral blood stem cells (PBSC) are harvested, selected for CD34 positive cells, and purged in vitro. If more than 5% of the WBC contains lymphoma cells after induction, then 2 courses of IFF and VP-16 are administered before PBSC harvest.~Second course: IFF IV continuously on days 1-3, mitoxantrone (DHAD) IV on day 1, and G-CSF SC as in first course.~Third course: Carmustine IV over 1 hour on day -6, ARA-C and VP-16 IV every 12 hours on days -5 to -2, and melphalan IV on day -1. PBSC are reinfused on day 0. G-CSF is administered SC beginning on day 0 and continuing until blood counts recover. Each course lasts 3 weeks in the absence of disease progression or unacceptable toxicity."
88838699|NCT00002835|Experimental|Arm II|IDSHAP during 4 week courses 2 and 5, MBIDCOS during courses 3 and 6, and IFF and VP-16 IV over 1 hour on days 1-3 and DHAD IV over 15 minutes on day 1 during courses 1, 4, and 7.
88838700|NCT00003351|Experimental|Arm I: irinotecan|"Patients receive irinotecan intravenously over 90 minutes every week for 4 weeks followed by a 2 week rest period. Treatment is repeated every 6 weeks in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed before and during treatment. Patients are followed every 3 months for 2 years, then annually for 1 year."
88838701|NCT00003351|Experimental|Arm II: irinotecan|"Patients receive irinotecan intravenously over 90 minutes every 3 weeks for 6 weeks. Treatment is repeated every 6 weeks in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed before and during treatment. Patients are followed every 3 months for 2 years, then annually for 1 year."
88838702|NCT00361153|Active Comparator|1|Colesevelam hydrochloride
88838703|NCT00361153|Placebo Comparator|2|placebo
88838704|NCT04342117||Duvelisib|Patients who take duvelisib.
88838705|NCT04342117||Other PI3K-inhibitors|Patients who take a PI3K-inhibitor other than duvelisib
88838706|NCT00003513|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
88838707|NCT03576001|Experimental|Multi-modality intervention group|Hybrid exercise (functional electrical stimulation - leg cycling, FES LC plus arm ergometry) plus Testosterone undecanoate
88838708|NCT03576001|Placebo Comparator|Placebo group|Hybrid exercise plus placebo medication
88838709|NCT03568201|Experimental|patients|Patients suspected of iliac kinking will have a transcutaneous oximetry test during hip flexion
88838710|NCT03568201|Sham Comparator|controls|Healthy asymptomatic athletes will have a transcutaneous oximetry test during hip flexion
88838711|NCT04220827|Experimental|Treatment (paclitaxel)|Patients receive paclitaxel IP over 1 hour once weekly during weeks 1-3 and 5-7 in the absence of disease progression or unacceptable toxicity.
88838712|NCT03567109||Shoulder rotator cuff tendinopathy|unilateral rotator cuff tendinopathy, 3 months or more duration, confirmed by imagery,
88838713|NCT03567109||chronic low back pain|non specific chronic (3 months) low back pain
88838714|NCT03567109||carpal tunnel syndrome|unilateral carpal tunnel syndrome, confirmed by electromyogram, 3 months or more duration
88838715|NCT03567109||control|healthy subjects
88838716|NCT04159857|Active Comparator|One-hand|During LTCS, the fetal head traditionally is delivered by one-hand manual extraction (a surgeon inserts one hand into the uterus via the hysterotomy and lifts the fetal head out of maternal pelvis, subsequently significant abdominal pressure is required to squeeze the fetal head out of hysterotomy) along with application of significant abdominal/fundal pressure.
88838717|NCT04159857|Experimental|Two-hand|An innovative approach to manual head extraction, with surgeon's both hands formed as a pair of forceps, has been used by the PI of this study for years during the LTCS for head extraction in the difficult situations described above without complication, often time it was used after one hand approach failed to deliver the infant, vacuum/forceps and abdominal pressure usually was not needed in these cases.
88838718|NCT04192357|Experimental|WLM3P|Participants will receive the M3F program. The M3F program is divided into three phases, being the first two of weight loss and the third phase of weight maintenance.
88838719|NCT04192357|Active Comparator|Low-carb diet|Participants will receive the low-carb diet program. The low-carb diet program is divided into two phases, being the first of weight loss which follows a low carb diet, and a second phase of weight maintenance.
88838720|NCT00361309|Experimental|SU011248|Patients will receive SU011248 37.5 mg/day for 4 weeks continuously followed by 2 weeks of rest per cycle (each cycle = 6 weeks). Patients will be continued on treatment until disease progression, limiting toxicity, or patient withdrawal of consent.
88838721|NCT04154943|Experimental|Cemiplimab|Will receive IV infusion Q3W
88838722|NCT00003369|Experimental|tirapazamine/cisplatin|tirapazamine and cisplatin given Day 1 of each 21-day treatment cycle
88838723|NCT04342351|Experimental|Experimental: sacubitril/valsartan|sacubitril/valsartan will be applied from 25mg b.i.d to 100mg b.i.d. for 3 months
88838724|NCT04342351|Active Comparator|Active Comparator: perindopril|perindopril will be applied from 2mg q.d, to 8mg q.d for 3 months
88838725|NCT04342273|Experimental|KW-6356 therapeutic dose|Oral administration
88838726|NCT04342273|Experimental|KW-6356 supratherapeutic dose|Oral administration
88838727|NCT04342273|Placebo Comparator|Placebo|Oral administration
88838728|NCT04342273|Active Comparator|Moxifloxacin|Oral administration
88838729|NCT00003525|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
88838730|NCT00003375|No Intervention|Observation|Observation only.
88838731|NCT00003375|Experimental|Radiation therapy|Radiation therapy only.
88838732|NCT00003375|Experimental|Radiation plus PCV chemotherapy|Radiation and Procarbazine/CCNU/Vincristine (PCV) chemotherapy
88838733|NCT04329195|Experimental|1: discontinuation of RAS blocker therapy|discontinuation of RAS blocker therapy
89366974|NCT03246178|Experimental|HFD-HSCT|This group received treatment of haploid family donor - hematopoietic stem cell transplantation (HFD-HSCT).
89366975|NCT03954015|Other|patients over age 30 with suspicious BIRADS 4/5 Lesions|Patients who are scheduled to undergo biopsy will be recruited to undergo imaging evaluation with CEDM, CEMR and CEUS.
88838734|NCT04329195|Active Comparator|2: continuation of RAS blocker therapy|continuation of RAS blocker therapy
89366976|NCT03251092|Active Comparator|SAD PTI-808 Active|Three cohorts of SAD are planned for evaluation where subjects will be randomized to PTI-808 or placebo.
88838735|NCT03498391|Experimental|Propofol|Propofol sedation titrated to clinical effect as measured by Richmond Agitation-Sedation Scale.
89366977|NCT03251092|Placebo Comparator|SAD PTI-808 Placebo|Three cohorts of SAD are planned for evaluation where subjects will be randomized to PTI-808 or placebo.
89366978|NCT03251092|Active Comparator|MAD PTI-808 Active|Three cohorts of MAD are planned for evaluation where subjects will be randomized to PTI-808 or placebo.
88838736|NCT03498391|Experimental|Ketamine|Ketamine sedation titrated to clinical effect as measured by Richmond Agitation-Sedation Scale.
88838737|NCT03492463|Active Comparator|Nicotine e-cigs + Nicotine patches|Participants will receive e-cigarettes containing nicotine and nicotine patches (21mg/24hr) and will be asked to switch from cigarette use to use of the study e-cigarettes for eight weeks.
88838738|NCT03492463|Active Comparator|Non-nicotine e-cigs + Nicotine patches|Participants will receive e-cigarettes not containing nicotine and nicotine patches (21mg/24hr) and will be asked to switch from cigarette use to use of the study e-cigarettes for eight weeks.
88838739|NCT03492463|Active Comparator|Nicotine e-cigs + Placebo patches|Participants will receive e-cigarettes containing nicotine and placebo patches (21mg/24hr) and will be asked to switch from cigarette use to use of the study e-cigarettes for eight weeks.
88838740|NCT03492463|Placebo Comparator|Non-nicotine e-cigs + Placebo patches|Participants will receive e-cigarettes not containing nicotine and placebo patches (21mg/24hr) and will be asked to switch from cigarette use to use of the study e-cigarettes for eight weeks.
88838741|NCT00003963|Experimental|Vinorelbine and Rituxan|"Week 1-4: Rituxan is given at 375 mg/m2 weekly x4. Vinorelbine (25mg/m2) given 1 week after the first rituxan dose and immediately after the second rituxan dose.~Week 5-8: Rituxan given every 2 weeks. Vinorelbine given weekly x3, with one week off.~Week 9-12: Schedule same as week 5-8. Week 13 and following: If subject doesn't have disease progression, they may continue on Vinorelbine until progression or until clinically indicated."
88838742|NCT00004857|Experimental|Fludarabine + Campath-1H|Standard of care induction with fludarabine followed by consolidation antibody therapy
88838743|NCT03476239|Experimental|Blinatumomab|"Treatment consisted of two induction cycles and up to 3 consolidation cycles of treatment for responders.~In the first induction cycle, the initial dose of blinatumomab was 9 μg/day for Days 1-7 and then escalated (dose step) to 28 μg/day starting on day 8 (week 2) through day 29 (week 4). This is followed by two weeks without blinatumomab treatment.~In subsequent cycles (beginning with the second induction cycle and continuing through consolidation, for applicable participants) 28 μg/day was administered for all 4 weeks of continuous treatment, followed by a treatment-free interval of two weeks."
88838744|NCT04073043|Experimental|Intervention Group|The intervention group will have access to the web-based intervention along with telephone coaching. Participants in the intervention will receive 7 coach calls over a period of 12 weeks.
89366979|NCT03251092|Placebo Comparator|MAD PTI-808 Placebo|Three cohorts of MAD are planned for evaluation where subjects will be randomized to PTI-808 or placebo.
88838745|NCT04073043|No Intervention|Control Group|The control group will have access only to the web-based intervention without telephone support
88838746|NCT00004875||Standard Heparin|
88838747|NCT00004875||Enoxaprin|
88838748|NCT04071171|Active Comparator|Phoxilium®|
88838749|NCT04071171|Experimental|Biphozyl®|
88838750|NCT00003573|Experimental|Treatment 1, Etoposide, 50mg/m2/day|"Patients begin treatment within 1 month of surgery. Patients receive 6 weeks of radiation therapy to the head and spine, with boosts to the posterior fossa and to sites of metastasis. Patients also receive 2 courses of oral etoposide once daily for 3 weeks concurrent with and immediately following radiotherapy (weeks 1-3 and 5-7).~Patients then receive adjuvant chemotherapy consisting of cisplatin IV once every 4 weeks for 3 courses beginning on week 11, oral etoposide daily for 21 days every 4 weeks for 3 courses (weeks 11, 15, and 19), cyclophosphamide IV on days 1 and 2 with filgrastim (G-CSF) SQ daily for at least 10 days every 4 weeks for 8 courses (weeks 23-51), and vincristine IV on days 1, 8, and 15 every 4 weeks for 8 courses (weeks 23-51)."
89001700|NCT00183521|Active Comparator|3|Participants will receive no breathing regulation training
89366980|NCT03251092|Active Comparator|FE PTI-808 Active|Subjects will be randomized to Fed or Fasted on Days 1 and 12. Follow up visits will occur 7 days post Day 12 dose.
89366981|NCT03251092|Placebo Comparator|FE PTI-808 Placebo|Subjects will be randomized to Fed or Fasted on Days 1 and 12. Follow up visits will occur 7 days post Day 12 dose.
88838751|NCT00003573|Experimental|Treatment 2, Etoposide, 35mg/m2/day|"Patients begin treatment within 1 month of surgery. Patients receive 6 weeks of radiation therapy to the head and spine, with boosts to the posterior fossa and to sites of metastasis. Patients also receive 2 courses of oral etoposide once daily for 3 weeks concurrent with and immediately following radiotherapy (weeks 1-3 and 5-7).~Patients then receive adjuvant chemotherapy consisting of cisplatin IV once every 4 weeks for 3 courses beginning on week 11, oral etoposide daily for 21 days every 4 weeks for 3 courses (weeks 11, 15, and 19), cyclophosphamide IV on days 1 and 2 with filgrastim (G-CSF) SQ daily for at least 10 days every 4 weeks for 8 courses (weeks 23-51), and vincristine IV on days 1, 8, and 15 every 4 weeks for 8 courses (weeks 23-51)."
88838752|NCT00003591|Experimental|Pacilitaxel + External Beam Radiation Therapy (PXRT)|Paclitaxel 50 mg/m2 given on Days 1, 8, 15, 22, 29 and 36. Radiation therapy: 50.4 Gy/28 fractions (1.8 Gy per fraction) once a day in 5.5 weeks.
89366982|NCT03251092|Experimental|Part 2 PTI-808 + PTI-801 + PTI-428 Active|One cohort is planned where subjects will be randomized to either the triple active arm (dosed with PTI 808+PTI 801+PTI 428) OR placebo arm.
89366983|NCT03251092|Placebo Comparator|Part 2 matching Placebos|In all three cohorts in part 2, subjects will be randomized to active drug or placebo. The placebo arm for all cohorts consists of placebo capsules matching PTI-808+PTI-801+PTI-428.
88838753|NCT02975323|Experimental|Single|To administer Carvedilol 12.5 mg orally and measure Wedge pressure gradient in hepatic veins followed by change in hepatic vein wave form
88838754|NCT00003597|Experimental|Cohort 1|Chemotherapy days 0-4, G-CSF (5 μg/kg/d) as a daily subcutaneous injection beginning on Day 5. All patients receive recombinant human thrombopoietin (rhTPO). rhTPO began on the last day of ICE (Ifosfamide, Carboplatin and Etoposide) chemotherapy (Day 4) and subsequent doses will be administered on Days 6, 8, 10 and 12 (5 doses total). The initial dose of rhTPO was 1.2 μg/kg/dose and was subsequently escalated to 2.4 and 3.6 μg/kg/dose as tolerated. Therapy will continue for maximum six courses. Pharmacokinetic data will be obtained (during course one only).
89178974|NCT03908060|Active Comparator|Intravenous single-dose morphine|A 10 ml syringe with 2 mg/ml of morphine will be prepared and study drug will be administered as intravenous bolus dose (0.2 mg/kg) corresponding to 1 ml for every 10 kg of ideal body weight (height (cm) - 105).
89366984|NCT03251092|Experimental|Part 2 dual active arm PTI-801+PTI-428+ PTI-808 placebo|One cohort is planned where subjects are randomized to either 808 placebo + dual active arm (dosed with placebo matching PTI 808 plus PTI 801 + PTI 428) OR placebo arm.
88838755|NCT00003597|Experimental|Cohort 2|"Chemotherapy days 0-4, G-CSF (5 μg/kg/d) as a daily subcutaneous injection beginning on Day 5. All patients receive recombinant human thrombopoietin (rhTPO). The dose of rhTPO 1.2 μg/kg/dose and subsequently escalated to 2.4 and 3.6 μg/kg/dose as tolerated. Patients assigned to Cohort II will receive pre-chemotherapy rhTPO at 3.6 μg/kg/dose on Days -5, -3, -1, and post-chemotherapy rhTPO on Days +4, +6, and +8 (6 doses total. Subsequent courses of chemotherapy will begin as soon as the ANC recovers to~≥ 1,000/μL and the platelet count to ≥ 100,000/μL between days 21 and 35. Therapy will continue for maximum six courses. Pharmacokinetic data will be obtained (during course one nly). For the second cohort, full data collection will occur for cycles one and two and limited data collection for cycles 3, 4, 5, and 6."
88838756|NCT04188379|Experimental|efgartigimod|Patient receiving efgartigimod
89366985|NCT03251092|Active Comparator|Part 2 dual active arm PTI-801+PTI-808+PTI-428 placebo|One cohort is planned where subjects are randomized to either 428 placebo + dual active arm (dosed with placebo matching PTI 428 plus PTI 808 and PTI 801) OR placebo arm.
88838757|NCT04188379|Placebo Comparator|Placebo|Patients receiving placebo
88838758|NCT00004893|Experimental|IL12 Therapy|Patients begin therapy no sooner than 3 weeks and no later than 6 weeks since last chemotherapy dose. Patients receive interleukin-12 subcutaneously twice a week. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients are followed at least every 3 months for 1 year. If no progression after 1 year, may be followed as needed for new signs or symptoms and survival for 5 years.
89001701|NCT00476476|Experimental|Erlotinib|Patients rcvd oral erlotinib 150 mg/day. Cohort 1 pts would have at least 28 days and no more than 42 days of therapy in advance of definitive therapy (surgery or chemoradiation). Cohort 2 pts continued on therapy (28 days per cycle) until disease progression, unacceptable toxicity or withdrawal of consent. Two potential dose reductions were prescribed to 100 and 50 mg/day.
89366986|NCT03251092|Active Comparator|Part 3 CF MAD PTI-808 + PTI-801 + PTI-428|In all cohorts in Part 3, subjects will be will be randomized to receive 7 days of PTI-808 or placebo followed by 14 days of co-administration of PTI-808+PTI-801+PTI-428 or matching placebos. A follow-up will occur on Day 28.
89178975|NCT00752856|Experimental|1 - Kaletra + Isentress taken twice daily|Kaletra (lopinavir/ritonavir 400/100 mg) + Isentress (Raltegravir 400 mg) twice-daily
89530358|NCT03248791|Experimental|Norepinephrine|Will receive spinal anesthesia using Bupivacaine. Then, norepinephrine infusion by a starting rate of 0.1 mcg/Kg/min. The rate will be then adjusted according to the patient blood pressure
88838759|NCT00004893|No Intervention|Observation|Patients are observed for 6 months. If disease progresses during first 6 months, patients may receive interleukin-12 as in arm I. Patients without disease progression within first 6 months may also then receive interleukin-12 as in arm I. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients are followed for toxicity only until interleukin-12 is discontinued.
88838760|NCT00004011|Experimental|preooperative chemo followed by surgery|carboplatin paclitaxel conventional surgery
88838761|NCT00004011|Active Comparator|Surgery alone|conventional surgery
88838762|NCT00004029|Experimental|Arm I|atients in cohorts of 3-6 receive 3 vaccinations with rV-PSA at 4-week intervals (days 1, 29, 57, and 85) in the absence of disease progression or unacceptable toxicity. Response assessment is performed at eight weeks. Patients who discontinue therapy prior to eight weeks are considered unevaluable for response. If dose limiting toxicity is observed in 2 of 6 patients entered at a dose level, no further patients are entered at that level and the MTD is defined as the preceding dose level. Ten additional patients are treated at the MTD and receive granulocyte-macrophage colony-stimulating factor (GM-CSF) administered subcutaneously on day -1 through day 2 of each cycle. Patients who are HLA-A2 positive, have received all 3 rV-PSA vaccinations without unacceptable toxicity, and have been off study for at least 30 days due to disease progression may continue treatment with rV-PSA at the highest dose level and the addition of GM-CSF.
88838763|NCT03443245||Stroke patients|Patient will have thrombolysis treatment as part of their standard care.
88838764|NCT03443245||Healthy Volunteers|Healthy volunteers to act as control group for stroke patients.
88838765|NCT00362323|Experimental|1|
88838766|NCT00362323|Active Comparator|2|
89366987|NCT03251092|Placebo Comparator|Part 3 CF MAD PTI-808 placebo+PTI-801 placebo+PTI-428 placebo|In all cohorts in Part 3, subjects will be randomized to receive 7 days of PTI-808 or placebo followed by 14 days of co-administration of PTI-808+PTI-801+PTI-428 or matching placebos. A follow-up will occur on Day 28.
89366988|NCT03251092|Active Comparator|Part 4 CF PTI-808 + PTI-801 + PTI-428|In cohorts 3 & 4 subjects will be randomized to receive PTI-808 + PTI-801 with or without PTI-428 or matching placebos. A follow-up will occur on Day 42.
88838767|NCT00362713|Experimental|A|3 mg/kg or 10 mg/kg
88838768|NCT02382601||Small for Gestational Age Pregancies (controls)|Small for gestational age (SGA) pregnancies that do not develop IUGR will be considered controls. Each subject will have an ultrasound, MRI, maternal blood and cord blood collection, placental analysis, neurological function assessments (infant), and body fat measurements (infant).
88838769|NCT02382601||IUGR Pregnancies (cases)|Small for gestational age (SGA) pregnancies that do develop IUGR will be considered cases. Each subject will have an ultrasound, MRI, maternal blood and cord blood collection, placental analysis, neurological function assessments (infant), and body fat measurements (infant).
88838770|NCT00004929|Experimental|Vaccine|Patients receive vaccination with glycosylated MUC-2 antigen with keyhole limpet hemocyanin conjugate subcutaneously (SQ) plus immunological adjuvant QS21 SQ on weeks 1-3, 7, 15, and 27 for a total of 6 vaccinations. Patients are followed every 3 months for 1 year or until disease progression.
88838771|NCT00003657|Experimental|High Dose ICF with Amifostine|"Patients undergo peripheral blood stem cell transplantation (PBSC) harvest on day -8,~ifosfamide IV, carboplatin IV etoposide IV (ICE) by 96 hour continuous infusion on days -7 to -4.~Patients receive amifostine IV twice a day on days -7 to -3.~PBSCs are reinfused on day 0.~Filgrastim (G-CSF) is administered subcutaneously beginning on day 0 at least 2 hours after infusion of the stem cells and continuing until blood cell counts recover.~Patients are followed monthly for the first 2 months and then for survival."
88838772|NCT00004095|Experimental|Irinotecan Plus Gemcitabine|
88838773|NCT00004101|Experimental|Arm I|Patients receive monoclonal antibody Hu1D10 IV over 2-4 hours on days 1, 8, 15, and 22. Treatment continues in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of monoclonal antibody Hu1D10 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 3 or 6 patients experience dose limiting toxicity. Once the MTD is determined, an additional cohort of 3-6 patients receive Hu1D10 IV over 2-4 hours on days 1-5.
88838774|NCT00003675|Experimental|Oral Topotecan 5 days|Patients receive intervention twice daily for 5 days
88838775|NCT00003675|Experimental|Oral Topotecan 10 days|Patients receive intervention once daily for 10 days
88838776|NCT04712487||Routine discectomy|Patients undergoing routine spine surgery due to degenerative disease of the spine
88838777|NCT00384579|Experimental|1|Botulinum Toxin B
88838778|NCT00384579|Placebo Comparator|2|Placebo
88838779|NCT00384657|Experimental|Group I|iv iron sucrose
88838780|NCT00384657|No Intervention|Group II|Patients will receive conventional treatment of Chronic Heart Failure.
88838781|NCT00004161|Experimental|Arm I|Patients receive oral fenretinide daily (except days 1-3 each month) for 6 months. Patients then receive oral fenretinide daily (except days 1-3 each month) for 6 months. Patients are followed every 3 months.
88838782|NCT00004161|Experimental|Arm II|Patients receive oral placebo daily (except days 1-3 each month) for 6 months. Patients then receive oral fenretinide daily (except days 1-3 each month) for 6 months. Patients are followed every 3 months.
88838783|NCT00003693|Experimental|MTD Group|
89366989|NCT03251092|Active Comparator|Part 4 CF PTI-808 + PTI-801 + PTI-428 placebo|In cohorts 3 & 4, subjects will be randomized to receive PTI-808 + PTI-801 with or without PTI-428 or matching placebos. A follow-up will occur on Day 42.
89366990|NCT03251092|Placebo Comparator|Part 4 CF PTI-808 placebo + PTI-801 placebo + PTI-428 placebo|In cohorts 3 & 4, subjects will be randomized to receive PTI-808 + PTI-801 with or without PTI-428 or matching placebos. A follow-up will occur on Day 42.
88838784|NCT00005037|Experimental|Temozolomide|Temozolomide capsule once a day for 42 days every 10 weeks.
88838785|NCT00385047|Experimental|Group A|FMP 2.1 50 μg FMP2.1/AS01B
88838786|NCT00385047|Experimental|Group B|FMP 2.1 50 μg FMP2.1/AS02A
88838787|NCT00004203|Experimental|Arm A|On Day 1 of each 21-day treatment cycle, patients receive 130 mg/m2 oxaliplatin diluted in 250 to 500 mL Dextrose 5% in Water infused intravenously over 2 hours through a peripheral or central vein
88838788|NCT00004221|Experimental|Treatment (Combination chemotherapy, PBSC)|See detailed description.
89001702|NCT00183560|Experimental|1|Participants will receive mindfulness based cognitive therapy
88838789|NCT00004227|Placebo Comparator|Arm I|"Patients undergo radiotherapy beginning on day 1. Patients are assigned to 1 of 3 radiotherapy groups:~Group 1: Patients undergo concurrent boost radiotherapy comprised of radiotherapy once daily 5 days a week for 3.5 weeks followed by radiotherapy twice daily 5 days a week for 2.5 weeks.~Group 2: Patients undergo radiotherapy once daily 5 days a week for 7 weeks.~Group 3: Patients undergo radiotherapy twice daily 5 days a week for 6-6.5 weeks."
88838790|NCT00004227|Active Comparator|Arm II|"Patients receive a test dose of cetuximab IV over 10 minutes on day 1. Patients who do not experience grade 4 anaphylactic reaction receive a loading dose of cetuximab IV over 2 hours beginning 30 minutes after completion of test dose. Patients receive maintenance cetuximab IV over 1 hour on day 8. Maintenance cetuximab repeats every week for 7 courses. Beginning on day 8, patients undergo radiotherapy as in arm I concurrently with maintenance cetuximab. There must be an hour interval between the completion of cetuximab infusion and the start of any radiotherapy.~Radiotherapy groups remain the same as in Arm I:~Group 1: Patients undergo concurrent boost radiotherapy comprised of radiotherapy once daily 5 days a week for 3.5 weeks followed by radiotherapy twice daily 5 days a week for 2.5 weeks.~Group 2: Patients undergo radiotherapy once daily 5 days a week for 7 weeks.~Group 3: Patients undergo radiotherapy twice daily 5 days a week for 6-6.5 weeks."
88838791|NCT00003621|Experimental|carmustine + etoposide + cisplatin + radiation therapy|Patients receive carmustine IV over 1 hour on days 1-3, oral etoposide on days 1-21 and 29-49, and cisplatin IV over 1-2 hours on days 1-3 and 29-31. Treatment repeats every 8 weeks for 3 courses. Patients receive radiotherapy concurrently with the third course of chemotherapy. Quality of life is assessed every 4 months for 1 year, every 6 months for 4 years, and then annually for 5 years. Patients are followed every 3 months for 5 years and then annually thereafter.
88838792|NCT02972619|Experimental|Intervention|Structured multicomponent intervention (MCI)
88838793|NCT02972619|No Intervention|Usual Care|Control group receive usual care in the polyclinics
88838794|NCT00004233|Experimental|5-FU, Leucovorin and PN-401|PN401 is given on Days 1-3 weekly for six weeks; 5FU and leucovorin are given on Day 1 weekely for six weeks; followed by two weeks of rest. Continued in 8 week cycles until one of the criteria for removal from treatment is met.
88838795|NCT00004239|Experimental|Compound 506U78|Compound 506U78 will be administered intravenously over 2 hours on days 1, 3 and 5 of each 28 day treatment cycle.
88838796|NCT00003723|Experimental|Gemcitabine/Cisplatin|Gemcitabine 1000 mg/m^2 days 1, 8 15 (q 28 days) cisplatin 30 mg/m^2 days 1, 8, 15 (q 28 days)
88838797|NCT00384735||1A|Intensive - 3 monthly follow up
88838798|NCT00384735||1B|Intensive - 6 monthly follow up
88838799|NCT00384735||IIA|Cost Effective - 3 monthly follow up
88838800|NCT00384735||IIB|Cost Effective - 6 monthly follow up
88838801|NCT00004251|Experimental|Letrozole|Letrozole 2.5 mg po daily
88838802|NCT00005067|Experimental|Treatment (motexafin lutetium, PDT)|Patients receive lutetium texaphyrin IV over 10-15 minutes 3-24 hours before photodynamic therapy (PDT). Optical fibers attached to a laser are inserted through a catheter into the prostate. The laser delivers 730 nm light to the prostate until the specified fluence is delivered. Patients undergo biopsy of the prostate and bladder before and after PDT. Cohorts of 3-6 patients receive escalating doses of lutetium texaphyrin and light fluence until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose limiting toxicity.
88838803|NCT00004263|Experimental|Cytarabine + UCN-01|
88838804|NCT00003735|Experimental|Stratum 1 - Stage 1|Topotecan hydrochloride (0.8 mg/m²/day) by mouth for 21 days. Bone marrow will be obtained on approximately Day 28 of Course 1 and 2 and in any course where the CBC suggests that a relapse has occurred. One additional course may be given if the blood is cleared of blasts and the bone marrow is M1, M2 or M3. The patient is off protocol therapy if blasts are still present in the blood and the marrow is M3. Subsequent courses of topotecan may be given only if the bone marrow after Course 2 is M1 or M2. If the bone marrow is M2 on Day 28 of any course, another bone marrow aspirate will be done at the end of the next course. If the patient is in CR, a bone marrow aspirate will be required only every other course unless the peripheral blood suggests that a relapse has occurred. Each subsequent course should begin within six weeks of the start of the previous course.
88875188|NCT02513940|Experimental|Placebo - testosterone - progesterone|Subjects received transdermal placebo gel once daily every morning for 7 days and oral placebo once daily every morning x 7 days. After a washout period of at least 13 days, they then received transdermal testosterone gel 1% 100 mg once daily in the morning and two (2) oral placebo capsules x 7 days. After a washout period of at least 13 days, they then received oral progesterone 400 mg (2 x 200 mg capsules) once every evening for 7 days and transdermal placebo gel once daily every morning for 7 days.
89001703|NCT00183560|Active Comparator|2|Participants will receive maintenance antidepressant pharmacotherapy
89001704|NCT00183560|Placebo Comparator|3|Participants will receive placebo plus clinical management
89001705|NCT00183599|Experimental|1|
89001706|NCT00183599|Experimental|2|
89001707|NCT00183599|Experimental|3|
89001708|NCT00476086|Experimental|Oxaliplatin/ Gemcitabine Then Radiation|Patients rcvd IV chemotherapy on days 1 and 15 of a 4-week cycle: gemcitabine 1000 mg/m2 and oxaliplatin 65 mg/m2 for up to 3 cycles. Two dose reductions per study drug were permitted. On study, chemotherapy was followed by radiation therapy (RT) within 4-6 weeks of last chemotherapy. RT regimen was tumor-volume directed.
89001709|NCT00183638|Experimental|1|Participants will receive Internet-based tailored prevention messages
89001710|NCT00183638|Active Comparator|2|Participants will receive non-tailored messages containing information on reproductive health
89001711|NCT00476047|Experimental|Treatment (monoclonal antibody therapy)|Patients receive tositumomab and iodine I 131 tositumomab IV over 90 minutes on day 0 and then again 7-14 days later over 30-60 minutes.
89001712|NCT00183716|Experimental|1|Participants will receive Trauma Recovery and Empowerment Model and usual care
89001713|NCT00183716|Active Comparator|2|Participants will receive usual care
89001714|NCT00476008|Placebo Comparator|Placebo|One tablet placebo morning and evening (BID) for 12 months
89001715|NCT00476008|Active Comparator|Memantine|One tablet memantine (Namenda)10mg morning and evening (BID) for 12 months.
89001716|NCT04722705|Experimental|combined IPL/fractional Er:YAG laser treatment site|"At baseline, three lesions were randomized to IPL / fractional Er:YAG laser combination therapy site.~Topical anesthetic cream was applied to the scar 30 minutes before laser treatment. The same dermatologist performed all laser treatments including IPL and 2,940 nm Er:YAG fractional laser. The face was cooled after treatment with gauze soaked in ice water.~The laser treatment was conducted total three sessions, immediately at suture removal, 4 weeks after suture removal and 8 weeks after suture removal. The evaluation of scar site was conducted 3 months later after last treatment."
89001717|NCT04722705|Active Comparator|fractional Er:YAG laser treatment alone site|"At baseline, three lesions were randomized to fractional Er:YAG laser combination therapy site.~Topical anesthetic cream was applied to the scar 30 minutes before laser treatment. The same dermatologist performed 2,940 nm Er:YAG fractional laser. The face was cooled after treatment with gauze soaked in ice water.~The laser treatment was conducted total three sessions, immediately at suture removal, 4 weeks after suture removal and 8 weeks after suture removal. The evaluation of scar site was conducted 3 months later after last treatment."
89001718|NCT04722705|No Intervention|untreated control site|At baseline, three lesions were randomized to untreated control site. Topical anesthetic cream was applied to the scar 30 minutes before laser treatment. The evaluation of scar site was conducted 3 months later after last treatment.
89001719|NCT00183755||1|Control participants
89001720|NCT00183755||2|Participants with MDD
89001721|NCT00412035|Active Comparator|Botox|Botulinum toxin A injection
89001722|NCT00412035|Placebo Comparator|Placebo|saline injection
89001723|NCT00183833|Experimental|A|Xeloda plus gleevec
89178976|NCT00752856|Active Comparator|2 - Atripla taken once daily|Sustiva (EFV 600 mg), Viread (TDF 300 mg) and Emtriva (FTC 200 mg) taken as Atripla® once-daily
89178977|NCT03727568|Experimental|Cryobiopsy: longer freezing time|Group nº1: A total of 3 samples with a freezing time of 7 seconds at least for the first biopsy and a freezing time from ≥5 seconds for the following biopsies.
89178978|NCT03727568|Experimental|Cryobiopsy: shorter freezing time|Group nº 2: A total of 8 samples with a freezing time of 3 seconds at least for the first biopsy and a freezing time from <5 seconds for the following biopsies.
89178979|NCT05745740|Experimental|RC48-ADC + Pyrotinib|
89178980|NCT04096404|No Intervention|Control|no advice
89001724|NCT02963402||Tocilizumab treated|
89001725|NCT02963402||Anti-TNF treated|
89001726|NCT00425516|No Intervention|standard (A)|3 FEC100 followed 3 Taxotere
89001727|NCT00425516|Experimental|Modulated (B)|possibility treatments receive: 2 FEC100 followed by 4 Taxotere 4 FEC100 followed by 2 Taxotere 6 FEC 100
89001728|NCT00412191|Experimental|Subjects in treatment regimen A|Subjects in treatment regimen A will receive 100 and 200 mg lamotrigine XR in fasting condition.
89001729|NCT00412191|Experimental|Subjects in treatment regimen B|Subjects in treatment regimen B will receive 100 mg lamotrigine XR in fasting condition.
89001730|NCT00412191|Experimental|Subjects in treatment regimen C|Subjects in treatment regimen C will receive 100 mg lamotrigine XR in fed condition.
89001731|NCT00412230||no treatment|
89001732|NCT00412230||2|
89001733|NCT00408785|Experimental|A|Injection
89001734|NCT00408785|Placebo Comparator|B|Injection
89001735|NCT00475735|Experimental|MK-0249|Total time in the study will be ~10 weeks.
89001736|NCT00475735|Active Comparator|Concerta|Total time in the study will be ~10 weeks.
89001737|NCT00475735|Placebo Comparator|Placebo|Total time in the study will be ~10 weeks.
89001738|NCT00475657|Experimental|A|
89001739|NCT00210405|Active Comparator|Food aid only|Children in this arm received fortified food aid commodities supplied through the maternal and child health and nutrition program implemented by World Vision. They received fortified corn-soy blend, which contained iron.
89001740|NCT00210405|Experimental|Micronutrient sprinkles + food aid|Children in this arm were enrolled in the food assisted program, and therefore received fortified food aid, as well as 60 sachets of a multiple micronutrient powder (Sprinkles) containing iron, zinc, vitamin A, vitamin C and folic acid
89001741|NCT02963480||Sepsis|Patients, who developed postoperative sepsis
89366991|NCT01345695||Treatment|Data collected on persons living in the catchment area for a WHP telemedicine center
89366992|NCT01345695||Control|Data collected on persons living in the catchment area where there is not a WHP telemedicine center
89366993|NCT01365000|Experimental|NKTR118 Formulation 1|Fasted
89366994|NCT01365000|Experimental|NKTR118 Formulation 2|Fasted
89366995|NCT01365000|Experimental|NKTR118 Formulation 3|Fasted
89366996|NCT01365000|Experimental|NKTR118 Formulation 1a|Fed
88838805|NCT00003735|Experimental|Stratum 2 - Stage 2|Topotecan hydrochloride (0.8 mg/m²/day) by mouth for 21 days. Bone marrow will be obtained on approximately Day 28 of Course 1 and 2 and in any course where the CBC suggests that a relapse has occurred. One additional course may be given if the blood is cleared of blasts and the bone marrow is M1, M2 or M3. The patient is off protocol therapy if blasts are still present in the blood and the marrow is M3. Subsequent courses of topotecan may be given only if the bone marrow after Course 2 is M1 or M2. If the bone marrow is M2 on Day 28 of any course, another bone marrow aspirate will be done at the end of the next course. If the patient is in CR, a bone marrow aspirate will be required only every other course unless the peripheral blood suggests that a relapse has occurred. Each subsequent course should begin within six weeks of the start of the previous course.
88838806|NCT00005085|Experimental|Arm I|Patients receive rebeccamycin analogue IV once on day 1. Treatment repeats every 21 days for a maximum of 12 courses in the absence of unacceptable toxicity or disease progression. Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.
89366997|NCT01365000|Experimental|NKTR118 Formulation 3a|FED
89366998|NCT01349361|Experimental|Daylight-PDT|
89366999|NCT01345773||Patients receiving gastric cancer surgery|
89367000|NCT03246100|No Intervention|Control|These patients will receive no reminders from the health department and will receive usual care.
89367001|NCT03246100|Experimental|Autodialer R/R|Autodialer calls (up to 3 reminders)- with brief education message + practice name + practice phone #
89367002|NCT03246100|Experimental|Mail R/R|Mailed reminder (up to 3 reminders)-- with brief education message + practice name + practice phone #
89367003|NCT03147040|Experimental|Carboplatin/Atezolizumab|Carboplatin AUC=1.5, weekly schedule, maximum 12 administrations Atezolizumab, 1200 mg flat dose, 3-weekly schedule, starting after two administrations of carboplatin
89367004|NCT03245944|Active Comparator|early angioplasty|Patients who initiated hemodialysis with a CVC, then had a new AVF created after commencing dialysis, and then had a 6-week postoperative ultrasound that revealed an immature AVF (diameter < 4 mm diameter or blood flow < 500 ml/min). These patients who an early angioplasty intervention group that will undergo a routine Angioplasty at 6 weeks after AVF creation
89001742|NCT02963480||SIRS|Patients, who developed postoperative SIRS
89001743|NCT00217269|Experimental|1|Endeavor Drug Eluting Stent
89001744|NCT00217269|Active Comparator|2|Taxus Drug Eluting Stent
89367005|NCT03245944|Experimental|late Angioplasty|Patients who initiated hemodialysis with a CVC, then had a new AVF created after commencing dialysis, and then had a 6-week postoperative ultrasound that revealed an immature AVF (diameter < 4 mm diameter or blood flow < 500 ml/min). These patients who a late angioplasty intervention group in which early Angioplasty will be avoided and subsequently be performed only if the 3-month ultrasound indicates persistent AVF immaturity
89367006|NCT03251170|Experimental|Ketamine group|This group of patients will receive: 1 mg/Kg ketamine + 0.05 mg/Kg midazolam for induction of anesthesia. Endotracheal tube will be inserted aided by 1 mg/Kg succinyl choline. Patients will undergo surgical procedure to eliminate the source of sepsis e.g. abdominal exploration. Invasive blood pressure monitor will be connected to the patient through an arterial catheter. Electrical velocimetry (cardiometry) device will be connected to the patient to measure cardiac output, stroke volume, and systemic vascular resistance.
89367007|NCT03251170|Active Comparator|Fentanyl|2.5 mg/Kg fentanyl + 0.05 mg/Kg midazolam for induction of anesthesia. Endotracheal tube will be inserted aided by 1 mg/Kg succinyl choline. Patients will undergo surgical procedure to eliminate the source of sepsis e.g. abdominal exploration. Invasive blood pressure monitor will be connected to the patient through an arterial catheter. Electrical velocimetry (cardiometry) device will be connected to the patient to measure cardiac output, stroke volume, and systemic vascular resistance.
89367008|NCT03539601|Experimental|Crisaborole ointment, 2%|This treatment arm will be administered both in Cohort 1 and Cohort 2.
89367009|NCT03539601|Active Comparator|Hydrocortisone butyrate cream, 0.1%|This treatment arm will be administered in Cohort 1 only.
89367010|NCT03539601|Active Comparator|Pimecrolimus cream, 1%|This treatment arm will be administered in Cohort 2 only.
89367011|NCT03539601|Placebo Comparator|Crisaborole Vehicle|This treatment arm will be administered both in Cohort 1 and Cohort 2.
89367012|NCT03245788|Experimental|Lay Navigation|Patients with even MRN.
89367013|NCT03245788|No Intervention|Usual Care|Patients with odd MRN.
89367014|NCT03245710|Experimental|Zhibai Dihuang powder|Arm: Experimental: Zhibai Dihuang Formula powder Zhibai Dihuang Formula powder: Traditional Chinese medicine formula powder product 5g by mouth, after meal, 3 times in one day for 12 weeks
89367015|NCT03245710|Placebo Comparator|placebos|Arm: placebo Comparator placebos 5g by mouth after meal, 3 times in one day for 12 weeks
89367016|NCT03250858|Placebo Comparator|Non-personalised advice|"Control group. Online (web-based) delivery of non-personalised dietary, weight and physical activity advice based on the UK general health guidelines.~This is an online trial and this arm will be using the e-Nutri web application. Participants in this group will receive online general recommendations (non-personalised)."
89367017|NCT03250858|Experimental|Personalised advice|Online (web-based) delivery of personalised dietary, weight and physical activity advice based on the individual's dietary intake, weight and physical activity levels, generated by the e-Nutri web application. Participants in this group will receive online personalised reports.
89367018|NCT04652583|Active Comparator|Active Stimulation 20 minutes|Intramuscular stimulation
89367019|NCT04652583|Active Comparator|Active Stimulation 60 minutes|Intramuscular stimulation
88838807|NCT00004317|Experimental|1|This group of infants is treated with a loading dose of oral pyrimethamine followed by a higher dose for the first two months then a lower dose for the remainder of the 12 months. Sulfadiazine and leucovorin calcium are also given orally for 12 months. The pyrimethamine loading dose is omitted if prior prenatal therapy was given.
88838808|NCT00004317|Experimental|2|This group of infants is treated with a higher dose of oral pyrimethamine for the first 6 months and then the lower dose for the remainder of the 12 months. Sulfadiazine and leucovorin calcium are administered concurrently.
88838809|NCT02973243||Manual Respiration Rate Measurement|Patients with manually measured respiratory rate
88838810|NCT02973243||Automatic Respiration Rate Measurement|Patients with automatically measured respiratory rate
88838811|NCT00005097|Experimental|Polyphenon E & Placebo|"Each subject will receive both the Polyphenon E and placebo, one on each arm.~One arm will be assigned to be treated with topical Polyphenon E daily for 12 weeks and the other with placebo vehicle in a random, double blind manner daily for 12 weeks."
88838812|NCT00003765|Experimental|Arm I|Patients receive O6-benzylguanine IV over 1 hour, then, 1 hour later, carmustine IV is administered over 1 hour. Treatment is repeated every 6 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients each receive escalating doses of carmustine until the maximum tolerated dose (MTD) is reached. The MTD is defined as the dose level at which fewer than 2 of 6 patients experience dose limiting toxicity (DLT). If myelosuppression is the DLT, stratum 1 is closed and patients are accrued to stratum 2. If neutropenia is the DLT in stratum 2, patients receive filgrastim (G-CSF) subcutaneously beginning on day 2 and continuing until blood counts recover.
88838813|NCT00005145||Observational, no interventions|
88838814|NCT00003783|Experimental|Complete Response and no CNS 3|See detailed description.
88838815|NCT00003783|Experimental|Complete Response and CNS 3|See detailed description.
88838816|NCT00003789|Experimental|Arm I|Patients undergo hyperthermic isolated perfusions of the lower limb by either the external iliac vessels or the common femoral vessels. Patients undergo perfusions of the upper extremity by the axillary artery and vein using an infraclavicular/axillary incision. Melphalan is introduced into the perfusion by slow injection over 5 minutes and allowed to remain for a total of 60 minutes.
88838817|NCT00003789|Experimental|Arm II|Patients undergo hyperthermic isolated perfusions as in arm I. Tumor necrosis factor is administered by slow injection into the arterial line and allowed to remain for a total of 90 minutes. Melphalan is introduced into the perfusion as in arm I and allowed to remain for a total of 60 minutes.
89367020|NCT04652583|Sham Comparator|Sham Stimulation 20 minutes|Muscle-free-zone stimulation
89367021|NCT02455180|Experimental|4x 1 gram bolus (q12H) dosage regimen|1 gram of intravenous Vitamin C (ascorbic acid) is given 4 times at 12 hour intervals (total dose 4 grams).
89367022|NCT02455180|Experimental|4x 5 grams bolus (q12H) dosage regimen|5 grams of intravenous Vitamin C (ascorbic acid) is given 4 times at 12 hour intervals (total dose 20 grams).
89367023|NCT02455180|Experimental|4 gram continuous dosage regimen|1 gram per 12 hours of intravenous Vitamin C (ascorbic acid) is given continuously for 48 hours
89367024|NCT02455180|Experimental|20 gram continuous dosage regimen|5 gram per 12 hours of intravenous Vitamin C (ascorbic acid) is given continuously for 48 hours
89367025|NCT03514719|Experimental|89Zr-avelumab PET|89Zr-avelumab injection followed by 89Zr-avelumab PET
89367026|NCT03251014|Experimental|YSS/salmon group|YSS followed by salmon
89367027|NCT03251014|Experimental|Salmon/YSS group|Salmon followed by YSS
89367028|NCT01349439|Experimental|Propranolol + Memory Reactivation|This arm involves recalling the traumatic event after administration of propranolol
89367029|NCT01349439|Experimental|Placebo + Memory reactivation|This arm involves recalling the traumatic event after administration of a placebo
89367030|NCT01349439|Experimental|Placebo + No Memory Reactivation|This arm involves administration of a placebo without recalling the traumatic event
88838818|NCT00384891|Experimental|Synergo + MMC|Combined bladder wall hyperthermia and intravesical instillation with cooled Mitomycin-C
88838819|NCT00384891|Active Comparator|Bacillus Calmette-Guérin|Intravesical instillation with BCG (Bacillus Calmette-Guérin)
88838820|NCT00384969|Experimental|1|RAD001 and Sorafenib
88838821|NCT00004467|Placebo Comparator|Placebo|
88838822|NCT00004467|Experimental|N-acetylcysteine (NAC)|
88838823|NCT00003819|Experimental|vaccine|This is a dose escalation study. Patients receive TF(c)-KLH conjugate with adjuvant QS21 subcutaneously weekly for 3 weeks, then once during weeks 7 and 19. Cohorts of 5 patients each receive escalating doses of TF(c)-KLH vaccine until the optimal dose, based on antibody response, is reached. Patients are followed monthly for 6 months, then every 3 months for 1 year.
88838824|NCT00003831|Experimental|Lymph node sampling|Patients undergo pulmonary resection. No additional lymph nodes are removed. Patients are followed at 4, 6, 8, 12, 18, 24, and 36 months and then annually thereafter until death.
89001745|NCT00475423|Experimental|1|
89001746|NCT02963519|Experimental|VistaCare®|VistaCare® Medical device for treatment into an editable atmosphere
89367031|NCT01349439|Experimental|Propranolol + No Memory Reactivation|This arm involves administration of propranolol without recalling the traumatic event
89367032|NCT01349439|Other|Open-label Propranolol + Memory Reactivation|All participants terminating the double-blind phase of the study will receive open-label reconsolidation blockade treatment with propranolol combined with recall of the traumatic event for six weeks.
89367033|NCT03250936||Trampoline group|Child patients with trauma due to trampoline from june 2016 to december 2016 consulting in emergencies unit of Rennes' hospital
89367034|NCT03250936||Control group|Child patients with trauma related to sport from june 2016 to december 2016 consulting in emergencies unit of Rennes' hospital
89367035|NCT03620331|Active Comparator|Non Surgical + Surgical|Non surgical approach (NS) followed by surgical treatment (S) of peri-implantitis
89367036|NCT03620331|Experimental|Immediate Surgery|Direct surgical approach (S), without a previous non surgical approach
89367037|NCT03245554|Experimental|placebo and propranolol|We used propranolol and placebo as an control drug to treat with patients.
89367038|NCT01346007|Active Comparator|patients|Children with idiopathic nephrotic syndrome in remission treated with low-dose prednisolone and/or mycophenolate mofetil and/or cyclosporine A
89367039|NCT01346007|Active Comparator|controls|
88838825|NCT00003831|Active Comparator|Lymph node dissection|Patients undergo removal of nearly all of the lymph nodes from the central part of the chest between the lungs, followed by pulmonary resection. Patients are followed at 4, 6, 8, 12, 18, 24, and 36 months and then annually thereafter until death.
88838826|NCT02678312|Experimental|Part 1: LCZ696 open label|LCZ696 open label: For Age Groups 1 and 2, either 1) 0.8 mg/kg or 2) 3.1 mg/kg or both. For Age Group 3, either 1) 0.4 mg/kg or 2) 1.6 mg/kg or both. After LCZ696 PK assessment, patients will be maintained on open-label Enalapril provided locally by the study site, or standard of care also provided locally by the study site, for heart failure treatment, if patient intended to participate in Part 2.
88838827|NCT02678312|Active Comparator|Part 2: Enalapril|The target dose for enalapril is 0.2 mg/kg bid (0.4 mg/kg total daily dose) with a maximum dose of 10 mg bid (20 mg total daily dose). Administered in a double-blind fashion.
88838828|NCT02678312|Experimental|Part 2: LCZ696|LCZ696 3.125 mg granules and adult formulation (50, 100, 200 mg) can be given based on patient weight. Administered in a double-blind fashion.
88838829|NCT00003849|Experimental|rituximab|Patients receive rituximab IV over 4-6 hours on day 1 weekly for 4 weeks. Patients are followed at 1, 3, 6, 9, and 12 months, then every 6 months for 3 years, then annually thereafter.
88838830|NCT00422006|Experimental|1|Non diabetic non dyslipidemic patient
88838831|NCT00422006|Experimental|2|Patient with metabolic syndrome
88838832|NCT00422006|Experimental|3|Patients with type II diabetes
88838833|NCT00422006|Experimental|4|Patient with a single lipidic anomaly
88838834|NCT02466230|Experimental|Active rTMS|Subjects in the active rTMS arm will receive daily active repetitive transcranial magnetic stimulation (rTMS) treatments for 25 days (Monday through Friday for 5 consecutive weeks). Active rTMS with the FDA approved Neuronetics TMS system will be administered. Each treatment will target the left dorsolateral prefrontal cortex. rTMS will be administered at 10Hz with a duty cycle of 4 seconds on and 26 seconds off for 37.5 min.
88838835|NCT02467166|Experimental|Circa™ Probe|The Circa™ Probe will be used during the RFCA to monitor esophageal temperature. Following ablation, the esophagoscopy will be performed to examine the esophagus for resulting thermal lesions.
88838836|NCT00453674||Adrenocortical carcinoma|Adrenocortical carcinoma
88838837|NCT00003855|Experimental|Surgery + radiotherapy|"Patients undergo axillary lymph node dissection involving removal of at least level I and II nodes, followed by whole-breast radiotherapy (exclusive of a third supraclavicular field) 5 days a week for a maximum of 7 weeks. Patients may receive adjuvant systemic therapy at the discretion of the treating physician.~Patients are followed up at 30 days, at 6, 12, 18, 30, and 36 months, and then annually for a total of 10 years."
88838838|NCT00003855|Active Comparator|Radiotherapy|"Patients undergo breast radiotherapy only. Patients may receive adjuvant systemic therapy at the discretion of the treating physician.~Patients are followed up at 30 days, at 6, 12, 18, 30, and 36 months, and then annually for a total of 10 years."
88838839|NCT02468804|Experimental|Parkinson's Disease Subjects, (rTMS)|The PD subjects will be randomized, and on a separate day receive a course of either real (rTMS) or sham TMS. Twenty minutes after this treatment subjects will again perform the same working memory task (at 9am to control for fatigue and diurnal effects) while having MEG data recorded
89367040|NCT02455102|Active Comparator|Electronic alert|Physicians, whose patients with atrial fibrillation do not receive stroke preventive measures, will receive an electronic warning alert.
89367041|NCT02455102|No Intervention|No electronic alert|Physicians, whose patients with atrial fibrillation do not receive stroke preventive measures, will receive no electronic warning alert.
88838840|NCT02468804|Experimental|Control Subjects (rTMS)|The control subjects will be randomized, and on a separate day receive a course of either real (rTMS) or sham TMS. Twenty minutes after this treatment subjects will again perform the same working memory task (at 9am to control for fatigue and diurnal effects) while having MEG data recorded
89001747|NCT02963519|Active Comparator|Dressings|Dressings Adapted to the case
89367042|NCT01349517|Other|MIE Group|The patients in this group would perform minimal invasive three-incision subtotal esophagectomy (thoracoscopic and/or laparoscopic)
88838841|NCT02468804|Sham Comparator|Parkinson's Disease Subjects, (sTMS)|The PD subjects will be randomized, and on a separate day receive a course of either real (rTMS) or sham TMS. Twenty minutes after this treatment subjects will again perform the same working memory task (at 9am to control for fatigue and diurnal effects) while having MEG data recorded
88838842|NCT02468804|Sham Comparator|Control Subjects (sTMS)|The control subjects will be randomized, and on a separate day receive a course of either real (rTMS) or sham TMS. Twenty minutes after this treatment subjects will again perform the same working memory task (at 9am to control for fatigue and diurnal effects) while having MEG data recorded
88838843|NCT02469116|Experimental|Arm 1: (docetaxel, carboplatin, pegylated G-CSF)|"Docetaxel intravenously over 1 hour followed by carboplatin intravenously over 30 minutes-1 hour on day 1 every 21 days for maximum of 6 cycles~Pegylated G-CSF on day 2 every 21 days for maximum of 6 cycles"
88838844|NCT00003861||Ancillary-Correlative (molecular genetic features)|Previously collected blood and tissue samples are analyzed via RT-PCR and flow cytometry.
88838845|NCT00003873|Experimental|Arm I|Patients receive fluorouracil IV as a continuous infusion for 28 days.
88838846|NCT00003873|Experimental|Arm II|Patients receive eniluracil/fluorouracil orally twice a day for 28 days.
88838847|NCT00363116|Active Comparator|5 Dose Daclizbumab|daclizumab 1 mg/kg/dose every 14 days for 5 doses
88838848|NCT00363116|Active Comparator|2 Dose Daclizaumab|daclizumab 2 mg/kg/dose every 14 days for 2 doses
88838849|NCT00363116|Active Comparator|Control|no antibody induction
89367043|NCT01349517|Other|Three-incision esophagectomy group|The patients in this group would perform three-incision subtotal esophagectomy (thoracotomy and laparotomy)
89178981|NCT04096404|Active Comparator|Non genetic personalised advice|dietary and physical activity advice based on reported dietary intake and physical activity
89178982|NCT04096404|Experimental|Genotype- based personalised advice|dietary and physical activity advice based on genotype, reported dietary intake and physical activity
89178983|NCT02600832|Experimental|AABM Training|Immediately following screening, patients will be randomly assigned to receive 9 sessions of real AABM training (16 subjects each) taking place over three weeks.
89178984|NCT02600832|Sham Comparator|Sham Training|Immediately following screening, patients will be randomly assigned to receive 9 sessions of sham training (16 subjects each) taking place over three weeks.
89178985|NCT02600676|Active Comparator|TENS, 10 weeks (active) 2 hours a day.|26 children.
89178986|NCT02600676|Placebo Comparator|TENS, 10 weeks (placebo) 2 hours a day.|26 children.
89178987|NCT00755196|Active Comparator|1|AN2728 Ointment, 5%
89178988|NCT00755196|Placebo Comparator|2|AN2728 Ointment vehicle
88838850|NCT02470910|Experimental|Magnetic resonance imaging|MRI examination after intraprostatic fiducial markers have been placed and prior to beginning radiotherapy
89001748|NCT00475306|Active Comparator|Metoclopramide 20+diphenhydramine|Metoclopramide 20 mg + diphenhydramine, delivered intravenously over 15 minutes
89178989|NCT04020510|Active Comparator|Standard Injections|For idiopathic overactive bladder, 100 units of onabotulinumtoxinA mixed in 10mL of injectable saline injected in 20 sites with 0.5mL per injection along the posterior wall of the bladder above the trigone. For neurogenic overactive bladder, 200 units of onabotulinumtoxinA mixed in 30mL of injectable saline injected in 30 sites with 1mL per injection along the posterior wall of the bladder above the trigone.
89178990|NCT04020510|Experimental|Reduced Injections|"For idiopathic overactive bladder, 100 units of onabotulinumtoxinA mixed in 10mL of injectable saline injected in 5 sites with 2mL per injection in an X configuration on posterior wall of the bladder above the trigone. For neurogenic overactive bladder, 200 units of onabotulinumtoxinA mixed in 10mL of injectable saline injected in 5 sites with 2mL per injection in an X configuration on posterior wall of the bladder above the trigone."
89178991|NCT00805142|Experimental|Opioid-Naive Participants (Tapentadol PR)|Opioid-naive participants are defined as those who had moderate to severe cancer pain that is not controlled sufficiently with non-opioid medications. Treatment period comprises of Titration and Maintenance period. Titration period (3-14 days) is duration between start of treatment to day before initial dose in the maintenance period. Treatment will be initiated with tapentadol prolonged release (JNS024PR, PR) 25 milligram (mg) oral tablet twice daily. Dose will be increased or decreased as per Investigator's discretion up to Day 14. Maximum dose limit will be 500 mg per day. Participants will then be assigned to the treatment in the maintenance period (15-19 days). The maintenance period is duration between the first dose and the final assessment in the maintenance period. Participants will receive tapentadol PR oral tablet twice daily for 5 days at the same dose used on last day of titration period.
89001749|NCT00475306|Active Comparator|Metoclopramide 20+placebo|Metoclopramide 20 mg + placebo, delivered intravenously over 15 minutes
89178992|NCT00805142|Experimental|Opioid-Switch Participants (Tapentadol PR)|Opioid-switching participants are defined as those who had moderate to severe cancer pain that is controlled sufficiently with opioid therapy. Treatment period comprises of Titration and Maintenance period. Titration period (3-14 days) is duration between start of treatment to day before initial dose in maintenance period. Initial dose of tapentadol PR is selected according to daily dose of opioid (morphine sustained release [SR] preparation, oxycodone hydrochloride [HCl] SR tablet or fentanyl patch). Equivalent dose of tapentadol PR oral tablet twice daily is given depending on daily dose of opioid at completion of Screening period. Maximum dose limit is 500 mg per day. Participants will then be assigned to treatment in maintenance period (15-19 days). Maintenance period is defined as duration between first dose and final assessment in maintenance period. Participants will receive tapentadol PR oral tablet twice daily for 5 days at same dose used on last day of titration period.
89178993|NCT00761631|Experimental|Single|Open label
89367044|NCT01349517|Other|Ivor-Lewis esophagectomy group|The patients in this group would underwent Ivor-Lewis esophagectomy
89367045|NCT01349517|Other|Sweet esophagectomy group|The patients in this group would underwent Sweet esophagectomy.
89367046|NCT03245476|Active Comparator|manual therapy and home-exercises|corticoid injection + physiotherapy with a focus on manual therapy and home-exercises
89367047|NCT03245476|Active Comparator|education and supported home exercises|corticosteroid injection + physiotherapy with focus on education and supported home exercises
88838851|NCT02473718|Experimental|Fluid minimization group|Patients in the fluid minimization arm will have daily fluid intake and output, baseline central venous pressure, mean arterial pressure, central venous oxygen saturation, pulse pressure variation, and inferior vena cava diameters during inspiration and expiration recorded by a dedicated research fellow. Patients who are intubated will also have corrected flow time, stroke volume, cardiac output, and cardiac index recorded via CardioQ. A fluid challenge in the form of a leg raise or infusion of 250 mL of crystalloid over 5 minutes will then be performed and the parameters repeated. The patient will be judged to be fluid responsive or nonresponsive based on the changes in the parameters. Fluid nonresponsive patients will receive the intervention of the fluid minimization protocol by concentrating continuous infusions, discontinuing maintenance fluids, and minimizing carrier fluids. Diuretics and/or ultrafiltration will be utilized to maintain an even to negative fluid balance.
89534690|NCT05048277|Experimental|Single Arm Study|"The intervention will consist of one 60-minute long session conducted through NYU ZOOM. Each session will be between one parent and one study consultant. The session is goal-oriented and solution-focused. During the SSC, consultants will identify the participant's hope for the session and a specific modifiable goal. From this, the consultant will discuss the smallest-possible step participants can take toward overcoming their identified problem and work together in creating an Action Plan, which will present three specific actions the participant can take to accomplishing the session's established goals. Following completion of the two-week follow-up assessment, additional resources personalized to participants will also be provided (i.e., referrals for further services and online resources for parents/children). Ultimately, this intervention is a way to potentially jumpstart progress and facilitate hope and agency."
89534691|NCT05025969||Glioma|(20 grade II gliomas, 20 grade III gliomas and 20 glioblastomas)
88838852|NCT02473718|No Intervention|Usual care group|Patients in the usual care arm will have daily fluid intake and output, baseline central venous pressure, mean arterial pressure, central venous oxygen saturation, pulse pressure variation, and inferior vena cava diameters during inspiration and expiration recorded by a dedicated research fellow. Patients who are intubated will also have corrected flow time, stroke volume, cardiac output, and cardiac index recorded via CardioQ.
89534692|NCT05025969||Brain metastasis|"The brain metastasis cohort consists of 80 patients, including 30 patients for whom the matched primary tumour is available"
89534693|NCT02491541|Experimental|Changchun Werersai|A rabies vaccine (Vero Cell) for human use produced by Changchun Werersai Biotech Pharmaceutical Co., Ltd.
88838853|NCT00003909|Experimental|Arm I|Approximately 2-5 hours before radiotherapy, patients receive motexafin gadolinium IV over 5 minutes. Patients undergo radiotherapy 5 days a week for 6 weeks.
88838854|NCT02474498|Active Comparator|EMD alone|During flap access surgery, the granulation tissue will be removed and the root surfaces will be carefully instrumented with ultrasonic and hand instruments. The furcation defects in this group will receive the application of enamel matrix derivative (EMD - Emdogain® Straumann, Basel, Switzerland) and after the flap will be repositioned.
88838855|NCT02474498|Active Comparator|βTCP/HA alone|During flap access surgery, the granulation tissue will be removed and the root surfaces will be carefully instrumented with ultrasonic and hand instruments. The furcation will be filled with a bone substitute consisting of beta tricalcium phosphate/hydroxyapatite (βTCP/HA- Bone Ceramic® Straumann, Basel, Switzerland)
88838856|NCT02474498|Active Comparator|EMD + βTCP/HA|During flap access surgery, the granulation tissue will be removed and the root surfaces will be carefully instrumented with ultrasonic and hand instruments. The furcation will be filled with a mixture of enamel matrix derivative proteins (EMD) (Emdogain® Straumann, Basel, Switzerland) and bone substitute consisting of βTCP/HA (Bone Ceramic® Straumann, Basel, Switzerland). Immediately after debridement, EMD will be applied on the root surfaces. The remaining part of the material in the seringe will be then mixed with the bone substitute on a sterile dappen. This mixture will be used to completely fill the defect (EMD + βTCP/HA).
88838857|NCT02476448|Active Comparator|Normal Saline|Infused into the bladder to allow for visualization of bladder walls and urine jets.
88838858|NCT02476448|Experimental|Dextrose 10%|Infused into the bladder to allow for visualization of bladder walls and colored urine jets.
88838859|NCT02476448|Experimental|Phenazopyridine|Will be administered (orally) preoperatively and will be evaluated for its colorization properties during cystoscopy.
88838860|NCT02476448|Experimental|Sodium Fluorescein|Will be administered (intravenously) prior to the cystoscopy and will be evaluated for its colorization properties during cystoscopy.
88838861|NCT02496104||Preterm infants|Preterm infants born between 25 weeks and 32 weeks + 6 days of gestation
88838862|NCT02496104||Term newborns|Infant born at term
88838863|NCT04744610|Other|4-hour delayed radiographs|The follow-up radiographs was taken 4 h after the HSG operation.
88838864|NCT02483468|Experimental|tDCS|Active Transcranial Direct Current Stimulation - Stimulation of the left dorsolateral prefrontal cortex with 2mA of electrical current
88838865|NCT02483468|Sham Comparator|tDCS (sham)|Inactive (sham) Transcranial Direct Current Stimulation
88838866|NCT02279823|Experimental|CB-03-01 solution|Topical solution applied twice daily for 26 weeks
88838867|NCT02279823|Active Comparator|Minoxidil Solution 5%|Topical solution applied twice daily for 26 weeks
88838868|NCT02279823|Placebo Comparator|Placebo solution|Topical solution applied twice daily for 26 weeks
89534694|NCT02491541|Active Comparator|Jilin Maifeng|A rabies vaccine (Vero Cell) for human use produced by Jilin Maifeng Biotech Pharmaceutical Co., Ltd.
88838869|NCT02480582|Experimental|Almond, then No Food, then Cheese Savouries|Participants first received a mid-morning snack of almonds (0.9g/kg). After a washout period of 5 days, they then received no food. Finally, after another washout period participants received a mid-morning snack of cheese savouries (0.9g/kg).
88838870|NCT02480582|Experimental|Cheese Savouries then Almond, then No Food|Participants first received a mid-morning snack of cheese savouries (0.9g/kg). After a washout period of 5 days, they then received a mid-morning snack of almonds (0.9g/kg). Finally, after another washout period participants received no food.
88838871|NCT02480582|Experimental|No Food, then Cheese Savouries, then Almond|Participants first received no food. After a washout period of 5 days, they then received a mid-morning snack of cheese savouries (0.9g/kg). Finally, after another washout period participants received a mid-morning snack of almonds (0.9g/kg).
89001750|NCT00475306|Active Comparator|Metoclopramide 10 + placebo|Metoclopramide 10mg + placebo, delivered intravenously over 15 minutes
89001751|NCT00475306|Active Comparator|Metoclopramide 10+diphenhydramine|Metoclopramide 10 mg + diphenhydramine 25 mg, delivered intravenously over 15 minutes
89001752|NCT00475228|Experimental|Arm I|Levonorgestrel IUD will be inserted immediately after completion of D&E
89001753|NCT00475228|Active Comparator|Arm 2|Levonorgestrel IUD will be inserted at standard time post-procedure (3-6 weeks post D&E procedure)
89178994|NCT00763698|Experimental|QuickFlex micro 1258T left heart lead|
89367048|NCT03250780|Experimental|Patients with extensive colitis|Patients with extensive colitis, for at least 8-10 years, already on the surveillance programme or newly referred whilst attending their outpatients IBD clinic at Leeds Teaching Hospitals NHS Trust will be screened by one of the research doctors who will be performing the surveillance colonoscopy.
89178995|NCT04620668|Experimental|Treatment Group (Wysa)|
89178996|NCT04620668|No Intervention|Control Group|
89178997|NCT04098627|Experimental|Intervention|Once weekly 30-minute long group laughter therapy session for 8 weeks while patients are on dialysis
89178998|NCT04098627|No Intervention|Usual Care|Usual care
89178999|NCT00763386|Active Comparator|1|Study arm will consist of patients that are treated with the NexGen LPS-Flex Fixed Bearing Knee.
89179000|NCT00763386|Active Comparator|2|Study arm will consist of patients that are treated with the NexGen Legacy Posterior Stabilized Knee.
89179001|NCT00761319|Experimental|Travoprost|One drop self-administered in the study eye(s) once daily for 90 days
89179002|NCT00761319|Active Comparator|Latanoprost|One drop self-administered in the study eye(s) once daily for 90 days
89179003|NCT00762996|Active Comparator|etafilcon A/etafilcon A|Period 1: etafilcon A, Period 2: etafilcon A
89179004|NCT00762996|Active Comparator|etafilcon A/omafilcon A|Period 1: etafilcon A, Period 2: omafilcon A
89179005|NCT00762996|Active Comparator|omafilcon A/etafilcon A|Period 1: omafilcon A, Period 2: etafilcon A
89179006|NCT00762996|Active Comparator|omafilcon A/omafilcon A|Period 1: omafilcon A, Period 2: omafilcon A
89179007|NCT02601534|Experimental|Zero-time Exercise (PA) group|"The intervention arm (PA group) aims to improve family communication and well-being, reduce sedentary behavior and increase physical activity. The programme includes a knowledge and motivation enhancement session at baseline, an experience sharing session at 3 months, a family gathering session at 6 months, and a holistic health session at 12 months after the first session as well as biweekly/monthly mobile messages.~The holistic health session is not a part of the cRCT, it aims to collect one-year feedback from participants and provides additional health information to improve dietary habits."
89179008|NCT02601534|Placebo Comparator|Healthy Eating (HE) group|"The control arm (HE group) aims to improve family communication and well-being and enhance healthy eating habits. Participants are required to engage their family members in their activities. The programme includes a knowledge and motivation enhancement session at baseline, an experience sharing session at 3 months, a family gathering session at 6 months, and a holistic health session at 12 months after the first session as well as biweekly/monthly mobile messages.~The holistic health session is not a part of the cRCT, it aims to collect one-year feedback from participants and provides additional health information to improve physical activity habit."
89179009|NCT00762606|Active Comparator|Phaco|Cataract extraction surgery utilizing Phacoemulsification
89001754|NCT00184067|Experimental|Peptide vaccine with Montanide ISA 51 + GM-CSF|Peptide vaccine with Montanide ISA 51 GM-CSF
89001755|NCT00184067|Active Comparator|Peptide vaccine with Montanide ISA 51|Peptide vaccine with Montanide ISA 51
89001756|NCT00217308|Experimental|Lactobacillus|
89001757|NCT00217308|Placebo Comparator|Placebo capsules|
89001758|NCT00184106|Active Comparator|Cognitive Therapy|Cognitive Therapy
89001759|NCT00184106|Active Comparator|Seroxat and SE|SSRI with Self exposure
89001760|NCT00184106|Active Comparator|Seroxat and Cognitive Therapy|Combination of Seroxat and Cognitive Therapy
89001761|NCT00184106|Placebo Comparator|Pill-Placebo|Pill Placebo
89001762|NCT00184145|Experimental|EMDR|The experimental group was treated for animal phobia by EMDR, control group received an attention placebo (relaxation plus breathing exercises). Afterwards, both groups were treated by exposure therapy (therapy of choice for animal phobia).
89179010|NCT00762606|Active Comparator|SICS|Small incision cataract surgery (SICS)
89179011|NCT00818441|Experimental|Cohort A|Dacomitinib (PF-00299804) in patients with EGFR mutated NSCLC or clinical characteristics defined above to enhance for EGFR mutated NSCLC
89179012|NCT00818441|Experimental|Cohort B|Dacomitinib in patients with HER2 mutated or amplified NSCLC
89179013|NCT00704639|Experimental|Single arm|Chemoradiation (Cetuximab, Carboplatin and Radiotherapy)
89179014|NCT00826943|Active Comparator|Levocetirzine|5 mg daily x 7 days (note = cross over = all participants receive active comparators and placebo)
89179015|NCT00826943|Active Comparator|cetirizine|10 mg daily x 7 days. Note = crossover study, so all participants recieve all active comparators and placebo.
89367049|NCT01349751|Active Comparator|isobaric levobupivacaine|spinal isobaric levobupivacaine
89367050|NCT01349751|Active Comparator|hyperbaric levobupivacaine|hyperbaric levobupivacaine
89367051|NCT03245632||Carbapenem-Resistant K. pneumoniae|Patients with clinical confirmed Carbapenem-Resistant Klebsiella pneumoniae infection.
89367052|NCT03245632||Carbapenem-Sensitive K. pneumoniae|Any patients with clinical confirmed Carbapenem-Sensitive Klebsiella pneumoniae infection.
89367053|NCT01346163|Active Comparator|PF-03654746|H3 receptor antagonist currently being developed for the treatment of cognitive impairment associated with schizophrenia (CIAS) as well as with Alzheimer's disease.
89367054|NCT01346163|Placebo Comparator|Placebo|
89367055|NCT03245164|Experimental|Physiotherapy group exercises|This group continued physiotherapy group exercises for 12 weeks.
89367056|NCT03245164|Experimental|Basketball program|Basketball educaiton was presented for 12 weeks.
89367057|NCT03245164|No Intervention|Control group|This group did not continue any physical activity regularly.
89367058|NCT03004131|Experimental|fixed drug combination|MP29-02 or MP-AzuFlu as fixed drug combination of azelastine hydrochloride and fluticasone propionate nasal spray (Dymista) plus Placebo tablet
88838872|NCT02480582|Experimental|Cheese Savouries, then No Food, then Almond|Participants first received a mid-morning snack of cheese savouries (0.9g\kg). After a washout period of 5 days, they then received no food. Finally, after another washout period participants received a mid-morning snack of almonds (0.9g\kg).
88838873|NCT02480582|Experimental|Almond, then Cheese Savouries, then No Food|Participants first received a mid-morning snack of almonds (0.9g\kg). After a washout period of 5 days, they then received a mid-morning snack of cheese savouries (0.9g\kg). Finally, after another washout period participants received no food.
88838874|NCT02480582|Experimental|No Food, then Almond, then Cheese Savouries|Participants first received no food. After a washout period of 5 days, they then received a mid-morning snack of almonds (0.9g/kg). Finally, after another washout period participants received a mid-morning snack of cheese savouries (0.9g\kg).
88838875|NCT00005289||1988-1991|
88838876|NCT00005289||2003-2004|
88838877|NCT02415842||H1N1_AS Group|Subjects 19-40 years of age (in H1N1 cohort of primary completed study Q-PAN H1N1-019 (113536) (A/California/07/2009)) who were administered adjuvanted (AS03A) pandemic vaccine with 3.75 µg HA (hemagglutinin) at Days 0 and 21 and TIV at Day 42.
88838878|NCT02415842||H1N1_NAS Group|Subjects 19-40 years of age (in H1N1 cohort of primary completed study -Q-PAN H1N1-019 (113536) (A/California/07/2009)) who were administered unadjuvanted pandemic vaccine with 15 µg HA (hemagglutinin) at Days 0 and 21 and TIV at Day 42
88838879|NCT02415842||H5N1_AS Group|Subjects 18-49 years of age (in H5N1 cohort of primary completed study CC-PAN H5N1-001 (114371)(A/Indonesia/5/2005 RG)) who were administered adjuvanted (AS03A) pandemic vaccine with 3.75 µg HA (hemagglutinin) at Days 0 and 21
88838880|NCT02415842||H5N1_NAS Group|Subjects 18-49 years of age (in H5N1 cohort of primary completed study CC-PAN H5N1-001 (114371)(A/Indonesia/5/2005 RG)) who were administered unadjuvanted pandemic vaccine with 15 µg HA (hemagglutinin) at Days 0 and 21.
88838881|NCT02415842||H9N2_AS Group|Subjects 18-64 years of age (in H9N2 cohort of primary completed study Q-PAN H9N2-001 (116358) (A/chicken/Hong Kong/G9/1997 NIBRG-91)) who were administered adjuvanted (AS03A) pandemic vaccine with 3.75 µg HA (hemagglutinin) at Days 0 and 21 and saline placebo at Day 182.
88838882|NCT02415842||H9N2_NAS Group|Subjects 18-64 years of age (in H9N2 cohort of primary completed studyQ-PAN H9N2-001 (116358)(A/chicken/Hong Kong/G9/1997 NIBRG-91)) who were administered unadjuvanted pandemic vaccine with 15 µg HA (hemagglutinin) at Days 0 and 21 and with saline placebo at Day 182.
88838883|NCT02415842||DQIV_NAS Group|Subjects 18-≤39 years of age (in D-QIV cohort of primary completed study FLU D-QIV-015 (201251) (A/Christchurch/16/2010 (H1N1)pdm09, A/Texas/50/2012 (H3N2), B/Massachusetts/02/2012, B/Brisbane/60/2008)) who were administered 15 µg HA (no AS) of each of 4 strains (total 60 µg HA) at Day 0.
88838884|NCT02415842||QPAN_C Group|Subjects 18-40 years of age (in Q-PAN cohort of primary completed study Q-PAN-005 (110624)) who were administered 3.8 µg A/Indonesia/5/05 (H5N1) with AS03A on Day 0; phosphate buffer saline (PBS) preserved with 20 ppm thimerosal on Day 182; 3.8 µg A/turkey/Turkey/1/05 (H5N1) with AS03A on Day 549.
88838885|NCT02415842||QPAN5_G Group|Subjects 18-40 years of age (in Q-PAN cohort of primary completed study Q-PAN-005 (110624)) who were administered PBS preserved with 20 ppm thimerosal on Day 0; 3.8 µg A/turkey/Turkey/1/05 (H5N1) with AS03A on Days 182 and 549.
88838886|NCT02415842||H5N1_VT Group|Subjects 18-60 years of age (in H5N1 cohort of primary completed study H5N1-012 (107495) A/Vietnam/1194/2004-like or A/Indonesia/05/2005-like) who received two administrations of the adjuvanted (AS03A) pandemic influenza vaccine (3.8 µg) containing the Vietnam (VT) strain at Day 0 and Month 12.
88838887|NCT02415842||H5N1_IN Group|Subjects 18-60 years of age (in H5N1 cohort of primary completed studyH5N1-012 (107495) A/Vietnam/1194/2004-like or A/Indonesia/05/2005-like) who received one administration(3.8 µg) of the adjuvanted (AS03A) pandemic influenza vaccine containing the Vietnam (VT) strain at Day 0 and one administration(3.8 µg) of the adjuvanted (AS03A) pandemic vaccine containing the Indonesia (IN) strain at Month 12.
88838888|NCT02415842||H5N1_PAS Group|Subjects 6-35 months of age (in H5N1 cohort of primary completed study Q-PAN H5N1-AS03-021 (114464)(A/Indonesia/5/2005 RG)) who were administered adjuvanted (AS03B) pandemic vaccine with 1.9 µg HA (hemagglutinin) at Days 0 and 21.
88838889|NCT02415842||H5N1_PCN Group|Subjects 6-35 months of age (in H5N1 cohort of primary completed study Q-PAN H5N1-AS03-021 (114464)(A/Indonesia/5/2005 RG)) who were administered placebo at Days 0 and 21.
88838890|NCT04040361|Experimental|Pembrolizumab+Ramucirumab+Surgery|Pembrolizumab and Ramucirumab will be administered simultaneously for non small cell lung cancer patients for 2 cycles before surgery.
88838891|NCT02481206|Experimental|Wearable Cardioverter Defibrillator|End Stage Renal Disease (ESRD) patients beginning hemodialysis will use a Wearable Cardioverter Defibrillator for six months
88838892|NCT02481206|No Intervention|Conventional Treatment|Conventional Treatment
88838893|NCT02415998||TEE|
88838894|NCT00005379||IV drug users and their sexual contacts|This group will be made up of an already-recruited cohort
88838895|NCT00005379||Children who receive primary care at Bellevue Hospital|
88838896|NCT00005379||Bellevue Hospital inpatients/outpatients|Inpatients being treated for TB and outpatients receiving prophylactic treatment
88838897|NCT02481440|Experimental|hUC-MSC Transplantation|Repeated intrathecal administrations of 1x10E6 human umbilical cord mesenchymal stem cells per kg in subjects with spinal cord injury with an interval of one month between each administration
88838898|NCT02481596|Experimental|REACH + FAMS|"Participants will receive FAMS components (monthly phone coaching and text messages supporting a goal set in coaching, plus the option to invite a family member/support person to receive text messages) for six months.~All participants will receive text messages advising how to access their study A1c test results, quarterly newsletters on healthy living with diabetes, and have access to a Helpline for study- and diabetes medication-related questions."
89001763|NCT00184223|Experimental|motivational interviewing|Manual guided motivational interviewing in addition to treatment as usual
89179016|NCT00826943|Placebo Comparator|placebo|one tablet daily x 7 days; note that this is a crossover study so all participants receive all active comparators and placebo
89179017|NCT04041557||adults with CHD|Adults with congenital heart disease 18-32 years of age
89179018|NCT04041557||controls|healthy peers
88838899|NCT02481596|Experimental|REACH|"Participants will receive REACH text messages (individual-focused text messaging tailored to user's individual barriers to adherence, messages assessing medication adherence with feedback, and targeted to address other self-care behaviors).~All participants will receive text messages advising how to access their study A1c test results, quarterly newsletters on healthy living with diabetes, and have access to a Helpline for study- and diabetes medication-related questions."
88838900|NCT02481596|Active Comparator|Helpline & A1c results|"Participants assigned to the control group will complete measures at each time point and maintain care as usual (i.e., medical treatment and physician monitoring).~All participants will receive text messages advising how to access their study A1c test results, quarterly newsletters on healthy living with diabetes, and have access to a Helpline for study- and diabetes medication-related questions."
88838901|NCT00005577|Experimental|Arm I|Patients receive gemcitabine IV over 30 minutes weekly for 2 weeks. Patients achieving objective response or stable disease after 3 weeks may receive additional courses of therapy every 3 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of gemcitabine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose limiting toxicity.
88838902|NCT00386217||Telephone Survey|90 minute Telephone survey of female cancer survivors
88838903|NCT00005601|Experimental|rituximab+dexamethasone+cisplatin+cytarabine+sargramostim|"Patients receive rituximab IV on days 1, 8, 15, and 22 for the first course only. Patients receive dexamethasone orally or IV on days 1-4, cisplatin IV continuously for 24 hours on day 1, cytarabine IV over 3 hours every 12 hours for 2 doses on day 2, and sargramostim (GM-CSF) subcutaneously on days 3-12 or until blood counts recover. Chemotherapy repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.~Patients are followed every 3 months for 1 year, every 4 months for 1 year, and then every 6 months for 3 years."
88838904|NCT00005613|Experimental|Autologous Transplant|autologous hematopoietic progenitor cell transplant
88838905|NCT00005613|Experimental|Allogeneic Transplant|allogeneic hematopoietic progenitor cell trasnplant
88838906|NCT02256631|Experimental|Dose Group 1|Infants in Dose Group 1 received a single VRC01 20 mg/kg injection less than 72 hours after birth.
88838907|NCT02256631|Experimental|Dose Group 2|Infants in Dose Group 2 received a single VRC01 40 mg/kg injection less than 72 hours after birth.
88838908|NCT02256631|Experimental|Dose Group 3|Infants in Dose Group 3 received a VRC01 40 mg/kg injection less than 5 days after birth. They then received a VRC01 20 mg/kg injection monthly for at least 6 months and no more than 18 months while breastfeeding.
88838909|NCT02256631|Experimental|Dose Group 4, Cohort 1|Infants in Cohort 1 received a single VRC01LS injection less than 72 hours after birth. Dose was based on weight: 80 mg for infants weighing less than 4.5 kg and 100 mg for infants weighing 4.5 kg or greater.
88838910|NCT02256631|Experimental|Dose Group 4, Cohort 2|Infants in Cohort 2 received an initial VRC01LS injection no longer than 5 days after birth. Dose was based on weight: 80 mg for infants weighing less than 4.5 kg and 100 mg for infants weighing 4.5 kg or greater. A second dose of 100 mg VRC01LS was administered at Week 12 if an infant was still breastfeeding.
88838911|NCT02256631|Experimental|Dose Group 5, Cohort 1|Infants in Cohort 1 received a single VRC07-523LS injection less than 72 hours after birth. Dose was based on weight: 80 mg for infants weighing less than 4.5 kg and 100 mg for infants weighing 4.5 kg or greater.
88838912|NCT02256631|Experimental|Dose Group 5, Cohort 2|Infants in Cohort 2 received an initial VRC07-523LS injection no longer than 5 days after birth. Dose was based on weight: 80 mg for infants weighing less than 4.5 kg and 100 mg for infants weighing 4.5 kg or greater. A second dose of 100 mg VRC07-523LS was administered at Week 12 if an infant was still breastfeeding.
88838913|NCT00005655|Experimental|1|rhIL-12 in combination with rhIL-2
89179019|NCT00707369|Experimental|test|Mechanical debridement plus 500 mg amoxicillin and 400 mg metronidazole three times daily for 7 days. Supportive periodontal therapy in 3-month intervals.
89179020|NCT00707369|Placebo Comparator|control|Mechanical debridement plus two placebo tablets three times daily for 7 days. Supportive periodontal therapy in 3-month intervals.
88838914|NCT02972697|Experimental|11C-acetate PET|11C-acetate and FDG PET/MRI and PET/CT will be performed.
88838915|NCT03407443|Experimental|Exposure to Make the Connection messages|
88838916|NCT03407443|Active Comparator|Active Control group|
88838917|NCT03407443|No Intervention|No exposure control group|
88838918|NCT03390673|Experimental|HD204|Bevacizumab Single-Dose 1mg/kg body weight by 90 minute intravenous infusion
88838919|NCT03390673|Active Comparator|EU-licensed Avastin|Bevacizumab Single-Dose 1mg/kg body weight by 90 minute intravenous infusion
88838920|NCT03390673|Active Comparator|US-licensed Avastin|Bevacizumab Single-Dose 1mg/kg body weight by 90 minute intravenous infusion
88838921|NCT02975791|Active Comparator|palpation|"Marking the cricothyroid membrane after ultrasound~The intervention is to mark the cricothyroid membrane in order to know exactly where it is in case that it should be needed fur emergency cricothyrotomy. The doctors mark the cricothyroid membrane with a pen after using palpation for identification."
88838922|NCT02975791|Active Comparator|ultrasound|"Marking of the cricothyroid membrane after Palpation~intervention is to mark the cricothyroid membrane in order to know exactly where it is in case that it should be needed fur emergency cricothyrotomy doctors mark the cricothyroid membrane with a pen after using ultrasonography for the identification"
88838923|NCT04155775|Experimental|Best Practice Alert|Platelet transfusion orders for patients with a recent platelet count exceeding 50,000 per microliter (50k/uL) will trigger an alert in the electronic health record that displays current guidelines for platelet transfusion. The alert will allow providers to bypass the recommendation and continue with platelet ordering by selecting a clinical acknowledgement / exception to recommendation.Exclusions will be built into the alert to avoid triggering in operative or procedural settings, for neurosurgery providers, or patients on anti-platelet medications.
88838924|NCT04155775|No Intervention|No Best Practice Alert|For this group, no visible best practice alert will activate in the electronic health record for platelet transfusion orders and recent counts above 50k/uL.
88838925|NCT00005727|Experimental|Intervention|Specially-designed nutrition education curriculum designed to lower dietary fat intake in people with low literacy skills.
88838926|NCT00005727|Active Comparator|Control|General nutrition education curriculum.
88838927|NCT00005739||Community-based therapy (case)|Community-based directly observed therapy (DOT) - A community-based intervention conducted by trained graduates of a TB directly observed therapy (DOT) program (peer workers)
88838928|NCT00005739||Self-administered treatment (control)|Clinic directly observed therapy (DOT) - Traditional self-administered preventive treatment
88838929|NCT02974933|Experimental|apatinib|combined with pemetrexed
88838930|NCT00005775|Experimental|Glutamine|TrophAmine (B. Braun/McGaw) with cysteine hydrochloride (40mg/gm amino acids) with L-glutamine added (20% of the total amount of amino acids)
88838931|NCT00005775|Placebo Comparator|Placebo|Standard TrophAmine (B. Braun/McGaw) with cysteine hydrochloride (40mg/gm amino acids)
88838932|NCT02519036|Experimental|ISIS 443139 10 mg|Participants received ISIS 443139, 10 milligrams (mg), by intrathecal injection, on Study Days 1, 29, 57, and 85.
88838933|NCT02519036|Experimental|ISIS 443139 30 mg|Participants received ISIS 443139, 30 mg, by intrathecal injection, on Study Days 1, 29, 57, and 85.
88838934|NCT02519036|Experimental|ISIS 443139 60 mg|Participants received ISIS 443139, 60 mg, by intrathecal injection, on Study Days 1, 29, 57, and 85.
88838935|NCT02519036|Experimental|ISIS 443139 90 mg|Participants received ISIS 443139, 90 mg, by intrathecal injection, on Study Days 1, 29, 57, and 85.
88838936|NCT02519036|Experimental|ISIS 443139 120 mg|Participants received ISIS 443139, 120 mg, by intrathecal injection, on Study Days 1, 29, 57, and 85.
88838937|NCT02519036|Placebo Comparator|Placebo|Participants received placebo, by intrathecal injection, on Study Days 1, 29, 57, and 85.
88838938|NCT00005793|Experimental|Combination Chemotherapy|Patients receive induction chemotherapy with daunorubicin IV over 10-15 minutes on days 1-3, cytarabine IV continuously on days 1-5, topotecan IV continuously on days 6-8, and etoposide IV over 60 minutes on days 9 and 10. Within 4 weeks of hematologic recovery, patients achieving remission after induction receive consolidation chemotherapy with cytarabine IV over 1 hour every 12 hours on days 1, 3, and 5. Subsequent courses of consolidation chemotherapy begin within 2 weeks of documentation of hematologic recovery from the prior consolidation course. Consolidation chemotherapy continues for 4 courses in the absence of unacceptable toxicity or disease progression.
88838939|NCT00005799|Experimental|Treatment (chemotherapy, TBI, HSCT)|"CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -4 to -2. Patients also undergo low-dose TBI on day 0.~TRANSPLANTATION: Patients undergo allogeneic PBSC or bone marrow transplantation on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine PO BID on days -3 to 100 with taper to day 177 and mycophenolate mofetil PO BID on days 0-40 with taper to day 96. Patients with mixed chimerism, persistent or progressive disease, and no evidence of graft-versus-host disease and who have been off immunosuppression for at least 2 weeks undergo DLI over 30 minutes. DLI may be repeated every 65 days for up to 3 doses."
88838940|NCT00386373|Experimental|Imatinib Mesylate|
88838941|NCT00005811|Experimental|Treatment (topotecan hydrochloride)|"INDUCTION: Patients receive topotecan hydrochloride IT over 5 minutes twice weekly for 6 weeks.~CONSOLIDATION: Beginning 1 week after completion of induction, patients receive topotecan hydrochloride IT over 5 minutes weekly for 4 weeks in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Beginning 2 weeks after completion of consolidation, patients receive topotecan hydrochloride IT over 5 minutes twice monthly for 4 months and then monthly through year 1."
88838942|NCT01689831|Experimental|Aplisol, potency determination|To confirm the potency of Aplisol formulated with newly produced Tuberculin PPD compared to PPD-S2 standard.
88838943|NCT01689831|Active Comparator|Reference standard PPD-S2, reference|Reactivity of Aplisol compared to reference standard PPD-S2.
88838944|NCT02520518|Experimental|Dapagliflozin: ad libitum dietary intake|Daily oral administration of dapagliflozin with ad libitum dietary intake. The dose of dapagliflozin will begin as one 5 mg tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two 5 mg tablets per day for the remainder of the study.
89179021|NCT02611661|Other|Stratum 1: Observe|"PET/MRI within 36 hours of standard of care hepatic radioembolization received off study~No further treatment just observation"
89367059|NCT03004131|Placebo Comparator|Placebo|Nasal spray with no active dose plus Placebo tablet
88838945|NCT02520518|Experimental|Dapagliflozin: weight maintenance|Daily oral administration of dapagliflozin with supplemented dietary intake to achieve weight maintenance. The dose of dapagliflozin will begin as one 5 mg tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two 5 mg tablets per day for the remainder of the study.
88838946|NCT02520518|Placebo Comparator|Placebo: ad libitum dietary intake|Daily oral administration of a placebo with ad-libitum dietary intake. Matching placebo for dapagliflozin 5 mg will begin as one tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two tablets for the remainder of the study.
88838947|NCT02520518|Placebo Comparator|Placebo: dietary restriction|Daily oral administration of a placebo plus dietary restriction such that weight loss is matched to participants in Arm 1. Matching placebo for dapagliflozin 5 mg will begin as one tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two tablets for the remainder of the study.
88838948|NCT01689987|Experimental|Treatment (HCQ, sirolimus, cy/dex)|Patients receive hydroxychloroquine PO daily on days 1-28 (days 5-28 of course 1), sirolimus PO on days -2 to 4, and cyclophosphamide IV continuously and dexamethasone PO on days 1-4. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
88838949|NCT01685619||AML Cohort|This cohort is comprised of participants who have acute myelogenous leukemia (AML).
88838950|NCT01685619||MDS Cohort|This cohort is comprised of participants who have myelodysplastic syndrome (MDS).
88838951|NCT01680939|Experimental|Morphine|Receives morphine for post-surgical pain
89367060|NCT03004131|Active Comparator|active control|fluticasone propionate nasal spray (Flonase) plus loratadine 10 mg tablets (Claritin)
88838952|NCT01680939|Experimental|Ibuprofen|Receives ibuprofen for post-surgical pain
88838953|NCT01689597|Active Comparator|Low dose epidural morphine|One dose of 1.25 mg epidural morphine
88838954|NCT01689597|Active Comparator|High dose epidural morphine|One dose of 2.5 mg epidural morphine
88838955|NCT01689597|Placebo Comparator|Saline|One dose of 10 ml saline administered through an epidural catheter
88838956|NCT01686477|Active Comparator|Unfortified Human Donor Milk|Used to make up any shortfall in mother's own milk
88838957|NCT01686477|Active Comparator|Fortified Human Donor Milk|Used to make up any shortfall in mother's own milk
88838958|NCT01686477|Active Comparator|Preterm Formula|Used to make up any shortfall in mother's own milk
88838959|NCT05140161|Experimental|Collagen 1|Medium porosity collagen sponge is used in the operated nail grooves. The hallux is covered with a non-stick dressing, five gauze surrounding it and a cohesive bandage
89367061|NCT03245086||Transanal hemorrhoid dearterialization (THD)|Patients with prolapsed, non-incarcerated, reducible hemorrhoids in at least 3 columns undergoing transanal hemorrhoid dearterialization (THD).
89367062|NCT03245086||Ferguson hemorrhoidectomy|Patients with prolapsed, non-incarcerated, reducible hemorrhoids in at least 3 columns undergoing Ferguson hemorrhoidectomy.
89179022|NCT02611661|Experimental|Stratum 2: Percutaneous ablation|"PET/MRI within 36 hours of standard of care hepatic radioembolization received off study~Percutaneous ablation can be radiofrequency ablation (RFA), microwave ablation (MWA), cryoablation, and irreversible electroporation"
88838960|NCT05140161|Experimental|Collagen 2|High porosity collagen sponge is used in the operated nail grooves. The hallux is covered with a non-stick dressing, five gauze surrounding it and a cohesive bandage
88838961|NCT05140161|No Intervention|Control group|No hemostatic device is used in the nail grooves. No hemostatic device is used in the nail grooves. Only non-stick dressing, five gauze pads and cohesive bandage are used
88838962|NCT02521766|Experimental|All HMIOL Cohort|HMIOL implantation with or without optic exchange
88838963|NCT02521766|Experimental|Cohort 1|HMIOL implantation with no optic exchange
88838964|NCT02521766|Experimental|Cohort 2|HMIOL implantation with optic exchange
88838965|NCT02521766|Other|Fellow Eye|IOL implantation per standard of care
88838966|NCT01689675|Experimental|Computer based pain management|The computer-based self-management program (CBSM) intervention will be administered over 8 sessions during the average 4 week period patients are receiving their standard on-site rehabilitation care. Patients will come to the center to receive their standard care and then interact with the computer for the 25-30 minute CBSM intervention. The primary goals of treatment include developing skills for managing acute injury and related pain including: reducing fear avoidance beliefs and catastrophizing, improving mood, increasing perceptions of control and self-efficacy, maintaining activity and reducing pain. Skills are presented and modeled by computer-based video during sessions, audio will be used to explain models and teach skills such as relaxation training.
88838967|NCT01689675|Active Comparator|Education control|The computer exposure will be administered over 8 sessions during the average 4-week period patients are receiving their standard on-site rehabilitation care. Patients will come to the center to receive their standard care and then interact with the computer for the 25-30 minute control condition. The primary goal of this condition is to provide a control for computer exposure. Briefly, the first session will concentrate on establishing the patient's ability to interact with the computer. The materials will provide general education regarding the injury and methods for preventing re-injury. This condition will not provide teaching and practice of specific pain management and coping management skills. This control computer education activity will equalize the computer exposure of the two groups and the duration of time devoted to injury care.
88838968|NCT02482610|Active Comparator|Glucose|This study day will last approximately three hours and will be separated from the other arms by four days for men and one month for women.
88838969|NCT02482610|Experimental|Glucose with Whole Fat Milk|This study day will last approximately three hours and will be separated from the other arms by four days for men and one month for women.
88838970|NCT02482610|Experimental|Glucose with Non-fat Milk|This study day will last approximately three hours and will be separated from the other arms by four days for men and one month for women.
88838971|NCT02483000|Experimental|Treatment (PRIT)|"B9E9-FP INFUSION: Patients receive B9E9-fusion protein IV over a minimum of 2 hours on day -17.~CLEARING AGENT INFUSION: Patients receive clearing agent IV over a minimum of 30 minutes on day -15.~RADIOBIOTIN INFUSION: Patients receive indium In 111-DOTA-biotin IV and yttrium Y 90 DOTA-biotin IV over 2-5 minutes on day -14.~BEAM CHEMOTHERAPY: Patients receive BEAM chemotherapy comprising carmustine IV over 3 hours on day -7; etoposide IV over 2 hours BID and cytarabine IV over 4 hours BID on days -6 to -3; and melphalan IV over 30 minutes on day -2.~STEM CELL INFUSION: Patients undergo autologous PBSCT on day 0 per standard of care."
88838972|NCT02088151|Experimental|Treatment|Patients receive selective retinal pigment epithelium laser treatment
88838973|NCT02279745|Experimental|Oral Ralinepag|Ralinepag immediate-release (IR) capsules of 10, 20, 30, 40, and 100 mcg or extended-release (XR) tablets of 50, 250, and 400 mcg for oral administration.
88838974|NCT02484092|Experimental|SPK-9001|Single intravenous (i.v.) infusion of SPK-9001 [an adeno-associated viral (AAV) vector with human factor IX gene] Intervention: Gene Therapy / Gene Transfer
88838975|NCT02420210|Experimental|Treatment (bendamustine, obinutuzumab, dexamethasone)|Patients receive bendamustine hydrochloride IV over 30 minutes on days 1 and 2, obinutuzumab IV over 4 hours on days 1 or 2, 8, and 15 (on both days 1 and 2 in course 1 only), dexamethasone PO daily on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
89179023|NCT02611661|Experimental|Stratum 3: SBRT|"PET/MRI within 36 hours of standard of care hepatic radioembolization received off study~The planned SBRT dose will be 30 Gy in 5 fractions of 6 Gy each. It is recommended that each fraction be separated by a minimum of 12 hours and a maximum of 8 days."
89179024|NCT02611661|Experimental|Stratum 4: SBRT + Percutaneous Ablation|"PET/MRI within 36 hours of standard of care hepatic radioembolization received off study~Percutaneous ablation can be radiofrequency ablation (RFA), microwave ablation (MWA), cryoablation, and irreversible electroporation~The planned SBRT dose will be 30 Gy in 5 fractions of 6 Gy each. It is recommended that each fraction be separated by a minimum of 12 hours and a maximum of 8 days."
89179025|NCT02611661|No Intervention|Stratum 5: Referral for systemic therapy|"PET/MRI within 36 hours of standard of care hepatic radioembolization received off study~Referred for further systemic therapy and are not candidates for further locoregional therapy on study."
89367063|NCT01349985|Experimental|AGATE|To evaluate whether AGATE, a smartphone medication reminder and assessment system, effectively measures and enhances medication adherence in the context of naltrexone treatment for problem drinking.
89367064|NCT01349985|Active Comparator|SASED|The control condition for the proposed study is a smartphone alcohol and side-effects diary (SASED, a smartphone alcohol and side effects diary).
89367065|NCT03250546|Experimental|Haplo-identical group|
89367066|NCT03250546|Active Comparator|HLA-9/10 MMUD group|
89367067|NCT01350063|Experimental|Aquatabs and Safe Storage Vessel|Households in this group will receive Aquatabs for water purification, a safe water storage container to prevent contamination during storage in the home, and training and encouragement to treat and safely store their water using the provided products.
89367068|NCT01350063|Experimental|Safe Storage Vessel|Households in this group will receive a safe water storage container, and training and encouragement to safely store their water using the provided products. If our study shows that treatment of tubewell water at the household level is effective in protecting children's health, they will receive a six-month supply of water treatment tablets at the end of the study.
89367069|NCT01350063|Other|Standard practice|Households in this group will not receive any water treatment or storage intervention during the study. They will continue their usual water collection and storage practices. If our study shows that treatment and safe storage of tubewell water at the household level is effective in protecting children's health, they will receive the same safe water storage container as Groups 1 and 2 as well as a six-month supply of water treatment tablets at the end of the study.
89367070|NCT00700804|Experimental|High Calcium Diet|
89367071|NCT00700804|Experimental|Low Calcium Diet|
88838976|NCT02974777|Active Comparator|Bleeding prevention group|Patients with reduction of standard dose DAPT due to low platelet reactivity to asprin and/or P2Y12 inhibitor
88838977|NCT02974777|Active Comparator|Ischemia prevention group|Patients with intensification of standard dose DAPT due to high platelet reactivity to asprin and/or P2Y12 inhibitor
89367072|NCT03635307||Operated patients with volume expansion|
88838978|NCT02485964|Other|Blood Draw Only|One time blood draw at time of consent; No treatment
88838979|NCT04821609|Experimental|Resistance training group|Twice a week sessions supervised and group, during 12 weeks
88838980|NCT04821609|No Intervention|Control Group|The control group will follow the usual physical therapy management, which does not include resistance training
88838981|NCT00361699|Active Comparator|Pravastatin|Patient has 10mg oral administration of Pravastatin per day. It starts within one month from their entry and continues every day until the end of the study or its endpoints.
88838982|NCT00361699|No Intervention|No intervention|Patient has no intervention.
88838983|NCT04829799|Active Comparator|Control Group|Subjects will receive intracameral 1% preservative-free lidocaine following paracentesis
88838984|NCT04829799|Experimental|Study Experimental Group|Subject will receive Omidria (phenylephrine and ketorolac (1.0%/0.3%) added to the ophthalmic irrigating solution during the cataract extraction procedure
88838985|NCT02975947|Active Comparator|Control Group|Standard intraoperative warming measures including heated blankets, heating with forced warmed air, warming of fluids, and insulation of limbs and head.
88838986|NCT02975947|Experimental|Study Group|The study group will receive warmed (37°C), humidified (98% RH) carbon dioxide delivered into the open peritoneal cavity.
88838987|NCT01789333|Experimental|9 mw/cm2 at 10 minutes group|30 patients will be treated with UVA light source at 9 mw/cm2 at 10 minutes. Drug: Riboflavin Dose:1 drop every 2 to 3 minutes for 15 to 20 minutes
88838988|NCT02524106|Experimental|Bococizumab|150 mg bococizumab injected subcutaneously every 2 weeks for a duration of 52 weeks
88838989|NCT02524106|Placebo Comparator|Placebo|150 mg placebo injected subcutaneously every 2 weeks for a duration of 52 weeks
88838990|NCT04827459|Experimental|MI Sleep Coach Mobile Application|The Sleep Coach app includes evidence-based CBT-I strategies, interactive activities and a computerized dialogue agent to engage users in the adoption of and adherence to CBT-I strategies.
88838991|NCT04117477|Experimental|Xylitol wipes|
88838992|NCT04117477|Placebo Comparator|Placebo wipes|
88838993|NCT04824027|Experimental|HMI Group|Women undergoing standard neoadjuvant chemotherapy for breast cancer
88838994|NCT02524418|Other|Cholangiopancreatoscopy|A standard of care Endoscopic Retrograde Cholangiopancreatoscopy (ERCP) will be performed using the Spyglass DS. The clinical outcomes will be collected and analyzed.
88838995|NCT04820049|Placebo Comparator|Placebo group|
88838996|NCT04820049|Experimental|F573 group|
88838997|NCT01761877|Experimental|Sulindac (Clinoril)|Women taking aromatase inhibitors for adjuvant therapy for their breast cancer will receive 150 mg of sulindac twice daily for 12 months. They will receive up to 4 MRI within 12 months.
88838998|NCT01761877|No Intervention|Observational|Women taking aromatase inhibitors for adjuvant therapy for their breast cancer will continue their treatment will be monitored with MRI and standard of care tests every 6 months for up to 12 months.
89367073|NCT02928094|Experimental|A: Ad5FGF-4|Ad5FGF-4, administered one time at 6x10e9 viral particles in buffer, and maximally-tolerated medical therapy for angina.
89367074|NCT02928094|Placebo Comparator|B: Placebo|Placebo buffer, administered one time, and maximally-tolerated medical therapy for angina.
89367075|NCT03421041|Experimental|Dexamethasone group|
89367076|NCT03421041|No Intervention|control group|
89530359|NCT05582603|Experimental|Computerized Cognitive Training|Individuals enrolled in Phase I and II will complete a Computerized Cognitive Training (CCT) based on an intervention with 15 different cognitive tasks in the form of games aimed at enhancing memory, attention, reasoning, perception and coordination skills. The CCT will be implemented in an app designed by CogniFit (CogniFit Inc., San Francisco, USA) to be used in tablets or mobile phones.
89530360|NCT03254251|Experimental|Stair Climbing (SC)|N=20, 12 weeks of stair climbing exercise training.
89530361|NCT03254251|No Intervention|No Exercise (CON)|N=21, No exercise for 12 weeks
88838999|NCT02421146|Sham Comparator|Sham tDCS - Healthy Controls|The sham group session will contain 20 minute sessions of transcranial direct current stimulatio , but only the first minute will be with 2mA, then unbeknownst to the subject, the unblinded research assistant will turn off the stimulation.
88839000|NCT02421146|Active Comparator|tDCS - Healthy Controls|will receive real transcranial direct current stimulation. Real tDCS stimulation will involve ten 20 minute stimulations daily (at 2 mA anode over the left DLPFC while cathode over the right suborbital region) on 5 weekdays of two consecutive weeks
88839001|NCT02421146|Sham Comparator|Sham tDCS - Patients|The sham group session will contain 20 minute sessions of transcranial direct current stimulation as well, but only the first minute will be with 2mA, then unbeknownst to the subject, the unblinded research assistant will turn off the stimulation.
88839002|NCT02421146|Active Comparator|tDCS - Patients|will receive real transcranial direct current stimulation . Real tDCS stimulation will involve ten 20 minute stimulations daily (at 2 mA anode over the left DLPFC while cathode over the right suborbital region) on 5 weekdays of two consecutive weeks
88839003|NCT02488070|Experimental|Diagnostic (68Ga-PSMA PET/CT or PET/MRI)|Patients receive gallium Ga 68-labeled PSMA ligand Glu-urea-Lys(Ahx) IV and then undergo PET/CT or PET/MRI approximately 45-60 minutes later.
88839004|NCT02974699|Experimental|Potato Starch (Bob's Red Mill)|Daily dietary supplementation with Potato Starch (48g total/day) suspended in water. 24g will be consumed 2 times per day.
88839005|NCT02974699|Placebo Comparator|Resource ThickenUp Pregelatinized Starch|Daily dietary supplementation with Pregelatinized Starch (48g total/day) suspended in water. 24g will be consumed 2 times per day.
88839006|NCT04824651||Solid cancer|objective : 800 participants for adult cohort, 100 for pediatric cohort (solid cancer and malignant hemopathy)
88839007|NCT04824651||Solid organ transplantation|objective : 700 participants for adult cohort, 50 for pediatric cohort
88839008|NCT04824651||Allogeneic hematopoietic stem cell transplantation|objective : 350 participants for adult cohort, 50 for pediatric cohort
88839009|NCT04824651||Chronic renal failure|Patients with chronic renal failure stage 4, 5 who receive dialysis or not. objective : 350 participants for adult cohort, 30 for pediatric cohort
88839010|NCT04824651||Autoimmune and autoinflammatory systemic diseases|Systemic lupus erythematosus ,Systemic Vasculitides,... objective : 750 participants for adult cohort, 130 for pediatric cohort
88839011|NCT04824651||Multiple sclerosis/ Neuromyelitis optica diseases|MS defined by Mac Donald et al. 2017 and Neuromyelitis optica defined by Wingerchuk et al. 2015 ; objective : 600 participants for adult cohort
88839012|NCT04824651||Chronic inflammatory rheumatism|Ankylosing spondylitis and rheumatoid polyarthritis objective : 600 participants for adult cohort
88839013|NCT04824651||Hypogammaglobulinemia|objective : 300 participants for adult cohort
88839014|NCT04824651||Obese non diabetic|BMI ≥ 30 objective : 1400 participants for adult cohort, 100 for pediatric cohort
88839015|NCT04824651||Diabetic (type I and II) obese or not|objective : 1400 participants for adult cohort, 100 for pediatric cohort
88839016|NCT04824651||People living with HIV-1|objective : 1400 participants for adult cohort
88839017|NCT04824651||Senior group (free from chronic conditions of interest listed above)|≥75 years objective : 450 participants for adult cohort
88839018|NCT04824651||Control group (free from chronic conditions of interest listed above)|18 to 74 years objective : 1400 participants for adult cohort, 100 for pediatric cohort (from 5 to 17 years old)
88839019|NCT04824651||Control AZ-PF group (free from chronic conditions of interest listed above)|Participants with first dose of Astra-Zeneca vaccine AZD1222 and second dose of Pfizer ARNm vaccine BNT162b2 objective : 200 participants for adult cohort
88839020|NCT04824651||Major sickle cell syndrome|100 for pediatric cohort (from 5 to 17 years old)
88839021|NCT05138913|Experimental|Study group|Arthroscopic treatment with TXA injection
88839022|NCT05138913|Placebo Comparator|Control group|Arthroscopic treatment with normal saline injection
88839023|NCT02421224|Active Comparator|Usual Care|Participants will receive in-person group counseling from a trained smoking cessation counselor. Participants will learn about reasons to quit smoking, strategies for quitting smoking, and additional resources available to support the quit attempt. Participants will also complete a quit plan.
88839024|NCT02421224|Experimental|Deposits|Same as Usual Care, plus participants will have to deposit a certain amount of their own money as an incentive to quit smoking. Participants will be able to make additional voluntary deposits above the minimum amount. The participant will be refunded all deposits if he quits smoking at 3 months, as verified by a urine cotinine test. The participant will forfeit all deposits if he continues to smoke at 3 months, as verified by a urine cotinine test.
88839025|NCT02421224|Experimental|Small Individual Bonus|Same as Usual Care, plus each participant will receive a monetary bonus from the study investigators if he or she quit smoking, as verified by a urine cotinine test.
88839026|NCT02421224|Experimental|Large Individual Bonus|Same as Usual Care, plus each participant will receive a monetary bonus from the study investigators if he or she quit smoking, as verified by a urine cotinine test. The bonus is twice the value of that in the Small Individual Bonus group.
88839027|NCT02421224|Experimental|Team Bonus|Same as Usual Care, plus each participant will be randomly assigned one teammate to provide social support during the quit attempt. If the participant and assigned teammate both quit smoking at 3 months, as verified by a urine cotinine test, then each will receive a monetary bonus. The team bonus is equal in value to that in the Large Individual Bonus group.
88839028|NCT02421224|Experimental|Deposits plus Small Individual Bonus|Same as Usual Care, plus the participant will follow the protocol for deposits as described for the Deposits group and will follow the protocol for the monetary bonus as described for the Small Individual Bonus group.
89001764|NCT00184223|Other|control group|treatment as usual
89001765|NCT00184262|Active Comparator|ERP cognitive therapy|
89530362|NCT04585685|Experimental|2 week baseline, CPT + SC|Participants in this arm are randomized to a 2-week baseline period with repeated weekly assessment after the initial intake. Following the 2-week baseline, participants are randomly assigned to receive 12 weekly sessions of Cognitive Processing Therapy (CPT), followed by a 3-week return to baseline period, followed by 6 weekly sessions of Self-Compassion Therapy (SC).
88839029|NCT02421224|Experimental|Deposits plus Large Individual Bonus|Same as Usual Care, plus the participant will follow the protocol for deposits as described for the Deposits group and will follow the protocol for the monetary bonus as described for the Large Individual Bonus group.
89367077|NCT03244774|Experimental|Apatinib plus POF|"This study will include a sequential evaluation of 3 subjects per cohort. Cohort 1: apatinib 250 mg per day and POF. Cohort 2: apatinib 375 mg per day and POF. Cohort 3: apatinib 500 mg per day and POF. Cohort 4: apatinib 625 mg per day and POF. Cohort 5: apatinib 750 mg per day and POF.~A dose limiting toxicity (DLT) event is defined as any of the following events in the first 4-week period:~CTCAE Grade 4 event (except for neutropenia lasting for ≤ 5 days);~Grade 3 non-hematologic toxicity (except for nausea and vomiting that could be improved with optimal supportive care, escalation of alkaline phosphatase)~If a DLT is experienced in any cohort, the cohort will be expanded to 6 subjects. If 2 DLTs are experienced in any cohort, the dose escalation ceased. The MTD was defined as the dose having at most two out of six patients experience DLT."
89367078|NCT01346553|Experimental|ESVV treatment|using ESVV device
89367079|NCT01350219|Experimental|Cord blood stem cell|Human cord blood-derived multipotent stem cells (CB-SC) display unique phenotypes, such as the expression of embryonic stem (ES) cell markers, multipotential of differentiations, very low immunogenecity, and immune modulations.
88839030|NCT02421224|Experimental|Deposits plus Teammate|Same as Usual Care, plus the participant will follow the protocol for deposits as described for the Deposits group and will be randomly assigned one other participant to serve as a teammate who provides social support during the quit attempt.
88839031|NCT02421224|Experimental|Deposits plus Team Bonus|Same as Usual Care, plus the participant will follow the protocol for deposits as described for the Deposits group, will be randomly assigned a teammate, and will follow the protocol for the monetary bonus as described for the Team Bonus group.
89367080|NCT03250468|Experimental|CBT-I|Participants randomized to receive the intervention will attend 6 weekly group-based CBT-I sessions. Each 90-minute group will include 6-12 participants.
89367081|NCT03250468|No Intervention|Wait-list control|The wait-list control group will receive treatment as per our standard cardiac rehabilitation program. After completion of the 3-month follow-up questionnaire, wait-list control participants may take part in the intervention.
88839032|NCT04821219|Experimental|Tumoroid generation|Single arm, including all the patients enrolled to generate tumor models
88839033|NCT04825353|Experimental|ECIRS-Group|
88839034|NCT04825353|Active Comparator|SPCNL-GRoup|
88839035|NCT04106089|Experimental|Observation-Intervention-Observation|5 days of observation, 5 days of extended vitals check, 5 days returning to regular vitals checks
88839036|NCT04106089|Experimental|Observation-Observation-Intervention|5 days of observation, 5 more days of observation, 5 days of extended vitals check
88839037|NCT03320317||Colorectal cancer|
88839038|NCT03319849|Experimental|NT-501|
88839039|NCT03319849|Sham Comparator|Sham|
88839040|NCT01501201|Experimental|Gastric By-Pass|group treated with Gastric By-Pass
89367082|NCT01346631|Experimental|paleolithic diet|Subjects will adhere to a paleolithic diet for the duration of three months
89367083|NCT02903823|Experimental|Baclofen injection at designated spinal level|Days 2,3,4,5 a baclofen injection bolus will be given in the catheter, located at C4, T4, T10 and L2 respectively. Effect of baclofen injection (50 microgram bolus) upon rigidity will be assessed manually using the Modified Ashworth rating score for selected upper and lower extremities.
88839041|NCT01501201|Active Comparator|optimized medical management|group receiving an optimized medical management
88839042|NCT04097275||Participants with an Inborn Error of Metabolism|
89001766|NCT00184262|Experimental|ERP behavioral therapy|
89001767|NCT00184301|Experimental|inpatient treatment|inpatient treatment during 1 year
89367084|NCT03244930|Experimental|Arm 1|Plerixafor 0.12 mg/kg SC will be administered in the evening, 11 hours prior to initiation of apheresis. G-CSF will be administered in the morning at 10 mcg/kg SC for 4 days prior to apheresis.
89367085|NCT03250312|Active Comparator|The OMT group|This group will be treated by the osteopathic manipulation techniques (OMT). The types of OMT techniques used will include muscle energy, articular, or high velocity-low amplitude (HVLA) as indicated by the physical findings and will be at the discretion of the treating physician. Additional techniques such as still, counter strain, facilitated positional release, balanced ligamentous tension, and cranial techniques may also be used at the discretion of the treating physician. The treatment will conclude with 2 minutes of pedal lymphatic pumping. The total treatment time will not to exceed 20 minutes.
89367086|NCT03250312|No Intervention|The control group|"The control group will wait in another room for approximately 30 minutes.~To encourage participation in the proposed study, participants who are assigned to the control group will have an opportunity to receive OMT after the second blood draw"
89367087|NCT01350297|Experimental|Patients|Patients
88839043|NCT04096729||patients who have consulted and need compression therapy using|1) age from 18 to 75 years; 2) compression therapy prescribed by a phlebologist. The exclusion criterion is hearing impairment, which could interfere with a telephone questionnaires.
88839044|NCT03299959|Experimental|Agili-C|
88839045|NCT03299959|Active Comparator|Surgical Standard of Care (SSOC)|
88839046|NCT00362869|Experimental|1|Dosage 1X10^9 given orally in a sodium bicarbonate solution
88839047|NCT00362869|Experimental|2|Dosage 5X10^9 given orally in a sodium bicarbonate solution
88839048|NCT00362869|Placebo Comparator|5|Sodium bicarbonate placebo solution
88839049|NCT00362869|Experimental|4|Dosage 5X10^10 given orally in a sodium bicarbonate solution
88839050|NCT00362869|Experimental|3|Dosage 1X10^10 given orally in a sodium bicarbonate solution
88839051|NCT04087213|Experimental|The HemoCare™ Hemodialysis System|The HemoCare™ Hemodialysis System is intended for hemodialysis treatment, including short daily and nocturnal hemodialysis, of renal failure patients. The HemoCare™ Hemodialysis System is intended for use in chronic dialysis facilities, self-care dialysis facilities, or the home setting. All treatments must be prescribed by a physician and administered by a trained operator. Treatments must be performed under the supervision or assistance of a medical professional or a care partner who has been trained and deemed competent in the use of the device by the prescribing physician.
88839052|NCT03292237|No Intervention|Standard Nutrition Arm|"In ICU:~After enrolment, patients allocated to the standard nutrition therapy (control) group will commence or continue nutrition via an enteral tube to a target rate according to unit protocol including the use of promotility agents and the placement of nasojejunal feeding tubes if required.~PN will only be used if the above methods have been attempted, or an absolute contraindication to EN develops.~Unless there is specific indication for a compounded PN solution, the PN used in the standard care group will be the same as used in the intervention arm.~After ICU:~Nutrition management will be as per usual site management at that hospital.~Nutrition intake amounts will be recorded 3 times per week using provided study documents and assessment tools."
88839053|NCT03292237|Experimental|Intensive Arm|"Intervention~In ICU:~Supplemental PN will be commenced within 2 hours of randomisation. The starting dose of PN will be determined by the amount of energy received in the 24 hours prior to randomisation~The need for the intervention will be based on the adequacy of nutrition provision from both PN and EN and assessed daily until ICU discharge~If there is an actual or anticipated interruption of EN for greater than 2 hours the PN must be run at 20 kcal/kg calculated body weight until EN is recommenced. After the interruption, EN should be recommenced as per local protocol.~After ICU:~An intensive nutrition intervention will be provided on the ward in the intervention group. This will include daily review from dedicated study dietitians and a clearly protocolized hierarchical management plan which reflects best practice clinical management."
88839054|NCT00361777||Possible Cushing's|Patients with possible cushion's syndrome
89001768|NCT00184301|Active Comparator|outpatient treatment|intensive outpatient treatment consisting of two-weekly group sessions during 1 year
89367088|NCT01350375|Placebo Comparator|Saline|
89367089|NCT01350375|Active Comparator|Botox|
89367090|NCT02855697|Experimental|Olaparib +/- cediranib|Patients are administered two courses of maintenance olaparib following chemotherapy. It is possible for patients to take cediranib during the second course of olaparib if recommended as per the protocol.
89001769|NCT00184379|Experimental|1 S+E|Relatives of patients with schizophrenia, who receive education
89001770|NCT00184379|No Intervention|2 S-E|Relatives of patients with schizophrenia, who do not receive education
88839058|NCT02422940|Active Comparator|dalfampridine-ER 7.5 mg|"Dalfampridine-ER 7.5 mg tablets taken orally twice daily, approximately 12 hours apart.~Subjects who received active treatment in the antecedent core study will retain the dose assignment to which they were initially randomized (7.5 mg or 10 mg dalfampridine-ER tablets). Subjects who received placebo in the core study will be randomly assigned to receive 7.5 mg or 10 mg dalfampridine-ER tablets in this extension study."
88839059|NCT02422940|Active Comparator|dalfampridine-ER 10 mg|"Dalfampridine-ER 10 mg tablets taken orally twice daily, approximately 12 hours apart.~Subjects who received active treatment in the antecedent core study will retain the dose assignment to which they were initially randomized (7.5 mg or 10 mg dalfampridine-ER tablets). Subjects who received placebo in the core study will be randomly assigned to receive 7.5 mg or 10 mg dalfampridine-ER tablets in this extension study."
88839060|NCT04072549|Experimental|Summer Programming|The summer day camps are not singularly focused, such as sport camps or academic only camps. Rather, the camps provide indoor and outdoor opportunities for children to be physically active each day, provide enrichment and academic programming, as well as provide breakfast, lunch, and snacks. To standardize programming, the schools operate their camps on the same daily schedules which are developed by the same district-level personnel, with identical programmatic content delivered across all schools. The schools also provide the same meals to all children enrolled. The meals adhere to the Summer Food Service Program nutrition guidelines and are reimbursed through existing federal food programs.
88839061|NCT04072549|No Intervention|Comparison/Control|The children in the control group will be children enrolled in the same schools as those randomized to receive summer programming. The comparison/control group will not receive a voucher to attend a summer camp.
88839062|NCT02526680|Experimental|Glaucoma Subjects|27 glaucoma subjects will be given the OrCam low vision aid device to use for 1 month.
88839063|NCT00588523|Experimental|1|temozolomide followed by high dose busulfan and thiotepa
89001771|NCT00184379|Experimental|3 B+E|Relatives of patients with bipolar disorder, who receive education
89001772|NCT00184379|No Intervention|4 B-E|Relatives of patients with bipolar disorder, who do not receive education
89001773|NCT00210678||Group: 1|Men with premature ejaculation (PE)
89001774|NCT00210678||Group: 2|Men without PE
89001775|NCT00184418||All patients admitted to a psychiatric acute ward|
89001776|NCT00217542|Experimental|Treatment (chemotherapy, biological therapy)|Patients receive azacitidine SC once daily on days 1-4 and 15-17 and recombinant interferon alfa-2b SC on days 8, 10, 12, 15, 17, 19, 22, 24, and 26 during course 1. Beginning in course 2 and for all subsequent courses, patients receive azacitidine SC once daily on days 1-3 and 15-17 and interferon alfa-2b SC on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26. Treatment repeats every 28 days for up to 12 total courses in the absence of disease progression or unacceptable toxicity.
89001777|NCT00184496|Active Comparator|methadon|Morphine methadone stop and go switch
89001778|NCT00184496|Active Comparator|Methadone|Methadon morphine overlap switch
89001779|NCT00217776|Active Comparator|Open Airways Educational Intervention|Children in this arm will receive the Open Airways educational program which is an evidenced based asthma educational program for children, developed by the investigator.
89001780|NCT00217776|Active Comparator|Open Airways and Peer Asthma Action Intervention Education|Children in this arm will receive BOTH the Open Airways asthma education program and the Peer Asthma Action education program.
89001781|NCT00217776|No Intervention|Control Arm|Children in the Control Arm will be interviewed in person at baseline, 12 month and 24 months.
89001782|NCT04722471||400 mg|Treatments where 400 mg tablet presentation of micronized vaginal progesterone was used, the protocol being one vaginal tablet twice a day.
89001783|NCT04722471||200 mg|Treatments where 200 mg tablet presentation of micronized vaginal progesterone was used, the protocol being two vaginal tablets twice a day.
89001784|NCT00217854|Other|Open label inhaled fluticasone|Patients are treated with open label high dose fluticasone for 30 days then discontinued. Comparisons are pre- and post- treatment single arm.
89001785|NCT00217893|Experimental|1|Combination of counseling, cotinine feedback, and contingent incentives.
89001786|NCT00217893|Active Comparator|2|Usual education program
89001787|NCT00210951||Participants Receiving Epoetin Alfa or Another Erythropoietin|Participants will not receive any intervention in this study. Participants with chronic renal disease receiving treatment with epoetin alfa or other recombinant erythropoietins will be prospectively observed to monitor incidence of pure red cell aplasia and/or antibodies to erythropoietin. Participants will receive standard-of-care treatment for their chronic renal (or other) disease from their individual Investigators.
89001788|NCT00184925|Active Comparator|subglottic drainage|suctioning of subglottis with cannula
89001789|NCT00211029||Participants Receiving Epoetin Alfa or Another Erythropoietin|Participants will not receive any intervention in this study. Participants with chronic renal disease receiving treatment with epoetin alfa or other recombinant erythropoietins will be prospectively observed to monitor incidence of pure red cell aplasia and/or antibodies to erythropoietin. Participants will receive standard-of-care treatment for their chronic renal (or other) disease from their individual Investigators.
89001790|NCT00218010||Methadone maintained lactating women|Methadone maintained women who chose to breastfeed their infants provided breast milk and plasma samples for this study.
89001791|NCT00218049|Experimental|1|50 mg of GBR 12909
89001792|NCT00218049|Experimental|2|75 mg of GBR 12909
89001793|NCT00218049|Experimental|3|100 mg of GBR 12909
89001794|NCT00211068||Epoetin alfa|Four control patients will be matched to each index patients enrolled in protocol EPO-IMU-301 identified as having chronic kidney disease and an immune-mediated cause of pure red cell aplasia (PRCA) indicated by the presence of anti-erythropoietin (EPO) antibodies in their serum at the time of loss of efficacy.
89001795|NCT00185159|Experimental|1|olmesartan medoxomil
89001796|NCT00185159|Placebo Comparator|2|placebo
89001797|NCT02963636|Experimental|Pharmacist clinical intervention|Patients exposed to the pharmacist intervention
89001798|NCT00218127|Experimental|1|LAAM WtDosing up to 1.0 mg/kg Stable 1.0 mg/kg/day for 20 weeks
89367091|NCT03250000||COPD-stable|Stable COPD patients at pulmonology consultation in Ziekenhuis Oost-Limburg (ZOL) Genk
89001799|NCT00218127|Experimental|2|LAAM MaxEffect to 48 mg Adjust to effect (+/-)
89001800|NCT00218127|Experimental|3|LAAM Fixed Dose up to 48 mg 48 mg
89001801|NCT00185198|Active Comparator|Arm 1|
89001802|NCT00185198|Placebo Comparator|Arm 2|
89367092|NCT03250000||COPD-Ex|Patients admitted to the respiratory ward of ZOL Genk with a diagnosis of acute exacerbation, based on the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria.
89367093|NCT03250156|Experimental|MBAT with proctored practice|Participants will engage in Mindfulness Based Attention Training (MBAT) in 4, 2-hour training classes with 1 class per week. Participants in the proctored practice group will complete assigned, out of class mindfulness exercises during the duty day - for example, as part of their daily physical training (e.g., mindful cooldown, final 15 minutes of PT is spent engaging in a mindfulness exercise using a guided recording).
88839064|NCT02527694|Experimental|Flexible EMS Stretcher Cart Group|Patients in this group will be transported on the new flexible EMS stretcher cart and receive mechanical CPR during transport to the hospital. The intervention will be given during elevator transport (if applicable) as well as in the moving ambulance.
88839065|NCT02527694|No Intervention|Standard Stretcher Cart Group|Patients in this group will be transported on the standard stretcher cart and receive manual CPR during transport to the hospital. The resuscitation protocol will follow the current standard protocol used by the EMS providers.
88839066|NCT02974387|Active Comparator|Fluorometholone(FMl)|Patients will be randomized to the eye and will receive FML in one eye.
88839067|NCT02974387|Active Comparator|Loteprednol (Lotemax)|Patients will be randomized to the eye and will receive Lotemax in contralateral eye.
88839068|NCT02440633|Experimental|14C-OPS-2071|Suspension containing 50 mg of 14C-OPS-2071
88839069|NCT00534703|Active Comparator|AAV1/SERCA2A|SERCA gene therapy
88839070|NCT00534703|Placebo Comparator|Placebo|Placebo (saline solution)
88839071|NCT00430183|Experimental|Arm A: docetaxel + LHRH agonist + surgical intervention|"Patients receive six cycles of docetaxel administered every 3 weeks combined with 18-24 weeks of androgen deprivation therapy. During each cycle of chemotherapy, all patients should undergo premedication with dexamethasone 8 mg orally prior to docetaxel. Dexamethasone may also be given intravenously according to institutional guidelines.~Patients will also receive androgen deprivation for 18-24 weeks of an LHRH agonist (eg, leuprolide acetate, goserelin acetate). Additional premedication and antiemetics may be given at the physician's discretion and as defined by the protocol.~Patients will undergo standard surgical intervention. The surgical procedures will be performed within 60 days of the completion of neoadjuvant therapy. Patients are allowed to receive adjuvant external beam radiation at the discretion of the treating physician and as defined per the protocol. It must be initiated within 6 months of the date of surgery."
88839072|NCT00430183|Other|Arm B: surgical intervention|All patients undergo standard surgical intervention. The surgical procedures will be performed within 60 days of randomization. Patients are allowed to receive adjuvant external beam radiation at the discretion of the treating physician and as defined per the protocol. Adjuvant radiation must be initiated within 6 months of the date of surgery.
89179026|NCT02611739|Experimental|Intervention Group|"Children in the experimental treatment condition will sit in front of the nurse and beside (or on the lap) of a parent. Medi-Port (humanoid robot) will be positioned beside the child (at eye-level) and will execute a pre-programmed series of behaviours to distract the child before, during, and after the SCP needle insertion. The nurse will insert the needle according to hospital procedures, using minimal distraction (e.g., What's on TV?). The estimated time for port procedures and completion of the needle insertion will range from 10-30 minutes. The total estimated time which includes the completion of surveys and questionnaires on the pain intensity of the SCP needle insertion procedure and acceptability of Medi-port will be approximately 1 hour. There will be no follow-up visits."
89179027|NCT02611739|Active Comparator|Control Group|"Following consent and randomization, children in the (control) usual care condition will sit in front of the nurse and beside (or on the lap) of a parent. Medi-Port (humanoid robot) will be positioned beside the child (at eye-level) and will execute a standard set of dancing movements only. The nurse will insert the needle according to hospital procedures, using minimal distraction (e.g., What's on TV?). The estimated time for port procedures and completion of the needle insertion will range from 10-30 minutes. The total estimated time which includes the completion of surveys and questionnaires on the pain intensity of the SCP needle insertion procedure and acceptability of Medi-port will be approximately 1 hour. There will be no follow-up visits."
89179028|NCT04030637||CRC cases|samples will be collected from subjects with known diagnosis of colorectal cancer
89179029|NCT04030637||Healthy cases|samples will be collected from healthy subjects with normal colonoscopy findings
89179030|NCT04030637||Cases with pathologies|samples will be collected from subjects whose colonoscopies showed other pathologies (e.g. inflammatory polyps, adenomas, diverticular diseases)
89179031|NCT00834041|Experimental|Aliskiren 2 mg/kg|Oral mini-tablets (3.125 mg) of aliskiren dosed at 2 mg/kg body weight once each morning
89179032|NCT00834041|Experimental|Aliskiren 6 mg/kg|Oral mini-tablets (3.125 mg) of aliskiren dosed at 6 mg/kg body weight once each morning
89179033|NCT00760929|Placebo Comparator|Placebo for R1507 (16mg/kg iv)|
89367094|NCT03250156|Active Comparator|MBAT with non-proctored practice|Participants will engage in Mindfulness Based Attention Training (MBAT) in 4, 2-hour training classes with 1 class per week. Participants in the non-proctored practice group will complete assigned, out of class mindfulness exercises on their own time with no structured duty day support.
89179034|NCT00760929|Placebo Comparator|Placebo for R1507 (9mg/kg iv)|
89367095|NCT03250156|No Intervention|No Training Control|This group will receive no intervention.
89367096|NCT03894501|Experimental|Mindfulness Oriented Recovery Enhancement|The Mindfulness Oriented Recovery Enhancement arm will participate in eight, weekly, two-hour group sessions.MORE sessions involve mindfulness training to prevent opioid relapse and reduce pain, cognitive reappraisal to decrease negative affect and regulate opioid craving, and savoring to augment natural reward processing and evoke positive emotion. Each session begins with a mindful breathing meditation, followed by a debriefing session. The therapist then debriefs participants' homework practice of using mindfulness, reappraisal, and savoring skills to cope with pain and enhance well-being in everyday life. During this debrief of the homework. Next, new psychoeducational material is introduced. Sessions culminate with an experiential exercise, and close with a brief mindful breathing meditation. Participants are asked to practice 15 minutes of mindfulness/reappraisal/savoring skills each day.
89367097|NCT03894501|Other|Methadone program behavioral treatment as usual|In the methadone programs, clients typically come to the clinic regularly to get their methadone dose. Clients see their clinic substance abuse counselor for individual counseling, usually weekly at the beginning of treatment, with decreasing frequency if they remain abstinent and progress through treatment. Depending on clients' stage of MMT and success with remaining abstinent from drugs, they may be required to attend clinic treatment groups. Also, some clients may choose to go to voluntary counseling, educational, or support groups.
89367098|NCT03249922||Treatment Group|"All patients who are considered candidates for spinal cord stimulator implant will be assigned to the Treatment Group. Participiants will be clinically evaluated and given the Owenstry low back disability index, WHODAS 12, Beck depression index and SF-36."
88839073|NCT04341415|Experimental|Auricular neuromodulation|
88839074|NCT04341415|Sham Comparator|Control|
89367099|NCT03244228|Experimental|Part 1a SAD HTL0016878/Placebo|In Part 1a, single ascending doses of HLT0016878 or matching placebo will be administered to groups of 12 subject each (9 active, 3 placebo). Each subject will have up to four treatment sessions separated by an appropriate wash-out. Healthy, young, male subjects.
88839075|NCT02443519|Experimental|MBCT for Migraine|In this arm, participants will receive 8 weeks of the manualized treatment Mindfulness Based Cognitive Therapy (MBCT; Day & Thorn). Participants will attend weekly 75-90 minute individual sessions for eight weeks. At each weekly session one of eight broad topics are addressed and discussed (Automatic-Pilot, Dealing with Barriers, Mindfulness of Breath, Staying Present, Allowing/Letting Be, Cognitive Restructuring, Self Care, Application to Headache Pain). Homework is assigned each week, and participants are expected to develop a daily formal mindfulness practice (body scan meditation, seated meditation, breathing meditation, etc). Participants are provided with a course manual, reading materials, and audio recordings to facilitate meditation practice.
88839076|NCT02443519|No Intervention|Wait List/Treatment as Usual|Patients will continue with standard care. Patients will be offered MBCT after the primary endpoint.
89367100|NCT03244228|Experimental|Part 1b single dose HTL0016878|In Part 1b, a single dose of HTL0016878 will be administered to 6 subjects on two occasions: once in the fasted and once the fed state. This will be open-label. Healthy, young, male or female subjects.
89367101|NCT03244228|Experimental|Part 1c single dose HTL0016878|In Part 1c, a single dose of HTL0016878 will be administered to up to 6 (optional up to 12) healthy elderly subjects This will be open-label. Healthy, elderly, male subjects.
88839077|NCT00362947|Placebo Comparator|A|A - Parnaparin 8.500 UI aXa od (therapeutic doses) for 10 days followed by placebo for 20 days
88839078|NCT00362947|Active Comparator|B|B - Parnaparin 8.500 UI aXa od for 10 days followed by 6.400 UI aXa once daily (intermediate therapeutic doses) for 20 days
88839079|NCT00362947|Active Comparator|C|C - Parnaparin 4.250 UI aXa od (prophylactic doses) for 30 days
88839080|NCT00362479|Experimental|1|
88839081|NCT02444143|Active Comparator|IBW|tacrolimus extended release 0.15 mg/kg/day based on Ideal Body Weight (IBW)
88839082|NCT02444143|Experimental|ABW|tacrolimus extended release 0.15 mg/kg/day based on adjusted Body Weight (aBW)
88839083|NCT02445625|Experimental|BCI to train joint attention in ASD|We are using Brain Computer Interfaces implemented by EEG in 16 ASD subjects
88839084|NCT02445859|Active Comparator|Standard regimen|Cefuroxime 1.5grams pre-operatively Repeated every 4 hours
88839085|NCT02445859|Experimental|Interventional regimen|Cefuroxime continuous infusion targeting 64mg/l serum concentrations.
88839086|NCT02446483|Experimental|Group A|Thirty subjects will receive a single oral dose of idiazole 20mg DR tabs under fasting condition in treatment period 1 followed by 7 days washout interval from the first study drug administration. After the washout interval the subjects will receive a single dose of PARIET 20 mg DR tabs under fasting condition in treatment period 2.
88839087|NCT02446483|Experimental|Group B|Thirty subjects will receive a single oral dose of PARIET 20 mg DR tabs under fasting condition in treatment period 1 followed by 7 days washout interval from the first study drug administration. After the washout interval the subjects will receive a single dose of idiazole 20mg DR tabs under fasting condition in treatment period 2.
88839088|NCT02447575|Other|MDI use Evaluation|"All subjects took 2 or more puffs of the placebo metered dose inhaler (MDI), attaching the Cognita electronic flowmeter to show measurements during the MDI use.~The inhaler technique is also evaluated by study staff prior to an education demonstration."
88839089|NCT02449291|Experimental|APD421 standard|Single (standard) dose IV APD421
88839090|NCT02449291|Experimental|APD421 high|Single (high) dose IV APD421
88839091|NCT02449291|Placebo Comparator|Placebo|Single IV placebo
88839092|NCT04744753|Active Comparator|study group|. This group involved 75 patients with history of fertilization failure in which oocytes were activated by calcium ionophores
88839093|NCT04744753|No Intervention|control group|This group involved 75 patients with history of fertilization failure in which oocytes were not activated by calcium ionophores
89001803|NCT04722198|Experimental|PS128|Each PS128 capsule contained >1 × 10^10 colony forming units (CFU) with microcrystalline cellulose and weights 425 ± 25 mg
89367102|NCT03244228|Experimental|Part 2a MAD HTL0016878/Placebo|In Part 2a, multiple doses of HTL0016878 will be administered to up to 5 cohorts (N=8, 6 active, 2 placebo) during one study session of 7 days. Healthy, young, male or female subjects.
89001804|NCT00185237|Experimental|Arm 1|
89001805|NCT00185237|Placebo Comparator|Arm 2|
89001806|NCT00185276|Experimental|Arm 1|
89001807|NCT00185276|Experimental|Arm 2|
89001808|NCT00218166|No Intervention|A|Within subject design
88839094|NCT02420041|Active Comparator|Fluoroscopic Guidance|Patients referred to the Naval Medical Center-San Diego Pain Medicine Clinic. Need a history and physical showing objective findings of sacroiliac joint (SIJ) dysfunction. If the patient meets inclusion / exclusion criteria, they will be presented with the study. After accepting and being consented, they will then be scheduled. The day of the appointment they will be randomised to Group A or B. In Group A : Fluoroscopy will be used to Guide Needle Placement to inject Steroid into joint. Then complete the multidimensional pain inventory (MPI) and rate their pain on the NRS from 0-11. After procedure, they will rate their pain from 0-10 in the recovery area and then be discharged to home. They will complete an MPI, Patient Global Impression of Change (PGIC), numerical rating scale (NRS), and adverse events questionnaire 1-2 weeks post-procedure and 3 months post-procedure.
88875189|NCT02513940|Experimental|Placebo - progesterone - testosterone|Subjects received transdermal placebo gel once daily every morning for 7 days and oral placebo once daily every morning x 7 days. After a washout period of at least 13 days, they then received oral progesterone 400 mg (2 x 200 mg capsules) once every evening for 7 days and transdermal placebo gel once daily every morning for 7 days. After a washout period of at least 13 days, they then received transdermal testosterone gel 1% 100 mg once daily in the morning and two (2) oral placebo capsules x 7 days.
89001809|NCT00185315|Experimental|Arm 1|
89001810|NCT00185354|Experimental|Arm 1|
89179035|NCT00760929|Experimental|R1507 (16mg/kg iv)|
89179036|NCT00760929|Experimental|R1507 (9mg/kg iv)|
89179037|NCT00818207|Other|Full Smoking Cessation Treatment Coverage (100%)|A subject randomized to the intervention group will be eligible for smoking cessation treatment (SCT) reimbursement during the 26-week period following the randomization.
89367103|NCT03244228|Experimental|Part 2b MAD HTL0016878/Placebo|In Part 2b, multiple doses of HTL0016878 will be administered to up to 3 cohorts of healthy, elderly subjects (N=8, 6 active, 2 placebo) during one study session of 7 days. Healthy, young, male or female subjects.
89367104|NCT01350531|Experimental|Skills training|
89367105|NCT01350531|Experimental|Contingency Management|
89179038|NCT00818207|Other|No Smoking Cessation Treatment Coverage (0%)|Subjects in the control group choosing to quit using an SCT method will not be eligible for smoking cessation treatment (SCT) reimbursement and, thus, will have to purchase their treatment out of pocket.
89179039|NCT00704795||1|Patients with type 1 diabetes mellitus
89179040|NCT00704795||2|Healthy control subjects matched for body mass index (BMI), age and gender.
89179041|NCT00707525|No Intervention|1|Natural cycle oocyte donation
89179042|NCT00707525|Active Comparator|2|"Stimulated cycle oocyte donation.~Long protocol down-regulation with a GnRH agonist, starting on the midluteal phase of the previous cycle with leuprolide acetate (0.2mg/day).~Once evidence of downregulation is documented, leuprolide will be halved to 0.1 mg daily.~COH with be carried on with gonadotropins (150UI/day of rFSH and 75 UI/day of HP-hMG). The dose can be adjusted according to ovarian response as judged by ultrasound and by serum oestradiol (E 2 ) concentrations."
89179043|NCT00704951||Patients|Immunosuppressed/Immunocompromised patients at high risk for invasive fungal infections
89179044|NCT00707603||Hepatitis C subjects|Due to start therapy for Hepatitis C
89179045|NCT00707603||Controls|Healthy males
89179046|NCT00760617|Experimental|New generation influenza vaccine GSK2186877A Group|Subjects aged ≥65 years received 1 dose of New generation influenza vaccine GSK2186877A
89367106|NCT02454010|Experimental|Lowest dose of FF-21101(90Y)|In the therapeutic phase subjects in this cohort will receive one dose of radiolabeled FF21101
89179047|NCT00760617|Active Comparator|Fluarix elderly Group|Subjects aged ≥65 years received 1 dose of Fluarix vaccine
89179048|NCT00760617|Active Comparator|Fluarix young Group|Subjects aged 18-40 years received 1 dose of Fluarix vaccine
89367107|NCT02454010|Experimental|2X Lowest dose of FF-21101(90Y)|In the therapeutic phase subjects in this cohort will receive one dose of radiolabeled FF21101 that is 2X the lowest dose
89367108|NCT02454010|Experimental|3X Lowest dose of FF-21101(90Y)|In the therapeutic phase subjects in this cohort will receive one dose of radiolabeled FF21101 that is 3X the lowest dose
89367109|NCT02454010|Experimental|4X Lowest dose of FF-21101(90Y)|In the therapeutic phase subjects in this cohort will receive one dose of radiolabeled FF21101 that is 4X the lowest dose
89367110|NCT02454010|Experimental|5X Lowest dose of FF-21101(90Y)|In the therapeutic phase subjects in this cohort will receive one dose of radiolabeled FF21101 that is 5X the lowest dose
89367111|NCT02454010|Experimental|Expansion Phase (Cohort 6), Ovarian|In the expansion phase, subjects in this cohort will be diagnosed with epithelial ovarian, peritoneal or fallopian tube carcinoma and will receive a dose of 25 mCi/m2 FF-21101(90Y)
88839095|NCT02420041|Experimental|Ultrasound Guidance|Patients referred to the Naval Medical Center-San Diego Pain Medicine Clinic. Need a history and physical showing objective findings of SIJ dysfunction. If the patient meets inclusion / exclusion criteria, they will be presented with the study. After accepting and being consented, they will then be scheduled. The day of the appointment they will be randomised to Group A or B. In Group B Ultrasound will be used to Guide Needle Placement to inject steroid into joint. Then complete the MPI and rate their pain on the NRS from 0-11. After procedure, they will rate their pain from 0-10 in the recovery area and then be discharged to home. They will complete an MPI, Patient Global Impression of Change (PIGC), NRS, and adverse events questionnaire 1-2 weeks post-procedure and 3 months post-procedure.
88839096|NCT02421055||Group 1|Roux-en-Y Gastric Bypass
88839097|NCT02421055||Group 2|Sleeve Gastrectomy
88839098|NCT02450383|Active Comparator|Control|Autologous subepithelial connective tissue graft
88839099|NCT02450383|Experimental|Experimental|Acellular Dermal Matrix
88839100|NCT02421211|Experimental|Panel 1|Participants will receive Simeprevir (SMV) 150 milligram (mg) capsule (Treatment A) along with Sofosbuvir (SOF) 400 mg tablet, orally, once daily (Treatment C) from Day 1 until Day 14 followed by SMV 150 mg capsule (Treatment A) along with fixed dose combination (FDC) tablet of 90 mg Ledipasvir (LDV)/400 mg SOF (Treatment B), orally, once daily from Day 15 until Day 70.
88839101|NCT02421211|Experimental|Panel 2|Participants will receive FDC tablet of 90 mg LDV/400 mg SOF (Treatment B), orally, once daily from Day 1 until Day 14 followed by SMV 150 mg capsule (Treatment A) along with FDC tablet of 90 mg LDV/400 mg SOF (Treatment B), orally, once daily from Day 15 until Day 56.
88839102|NCT02421757|Experimental|Transcutaneous Magnetic Stimulation|Transcutaneous Magnetic Stimulation
88839103|NCT02421757|Placebo Comparator|Sham Device|Sham Device
88839104|NCT02423317|Active Comparator|Intubation with Miller's blade|After induction and muscle paralysis, Miller's blade was introduced in the patient's mouth. After visualization of vocal cord, patient was intubated with appropriate sized tracheal tube.
88839105|NCT02423317|Experimental|Intubation with Airtraq laryngoscope|After induction and muscle paralysis, Airtraq laryngoscope's blade was introduced in the patient's mouth. After visualization of vocal cord as a reflected image in the viewfinder of the device, patient was intubated with appropriate sized tracheal tube.
88839106|NCT02424175|Experimental|Patients with PSC|This is an open label study. All patients enrolled will receive a fecal microbiota transplantation.
88839107|NCT03093259|Experimental|ABX464 Treatment Arm|Subjects will receive 50 mg of ABX464 orally once daily for 56 days.
88839108|NCT03093259|Placebo Comparator|ABX464 matching placebo Treatment Arm|Subjects will receive 50 mg of ABX464 matching Placebo orally once daily for 56 days.
88839109|NCT02528318|Experimental|50 mg/kg|"Lucinactant for inhalation 50 mg total phospholipids (TPL)/kg with nCPAP~1 repeat dose allowed if repeat dosing criteria are met."
88839110|NCT02528318|Experimental|75 mg/kg|"Lucinactant for inhalation 75 mg TPL/kg with nCPAP~1 repeat dose allowed if repeat dosing criteria are met."
88839111|NCT02528318|Experimental|100 mg/kg|"Lucinactant for inhalation 100 mg TPL/kg with nCPAP~1 repeat dose allowed if repeat dosing criteria are met."
88839112|NCT02528318|Experimental|150 mg/kg|"Lucinactant for inhalation 150 mg TPL/kg with nCPAP~1 repeat dose will be allowed if repeat dosing criteria are met."
88839113|NCT02528318|Active Comparator|nCPAP alone|nCPAP therapy alone
88839114|NCT02423408|Experimental|TNX-201|4 X 35 mg capsules to be taken when qualifying tension-type headache occurs
88839115|NCT02423408|Placebo Comparator|Placebo|4 X placebo capsules to be taken when qualifying tension-type headache occurs
88839116|NCT02528786|Other|All Participants|Participants who received namilumab previously in M1-1188-002-EM (PRIORA, [NCT01317797]) will have blood samples collected on Day 1.
88839117|NCT02424968|Experimental|Infusion of Allogeneic CD8+ Memory T-cells|All participants receive allogeneic CD8+ memory T-cells 30 to 60 days after standard non-myeloablative allogeneic hematopoietic cell transplant (aHCT).
88839118|NCT02424799|Experimental|Part A: Dose group 1|Subjects will be treated topically with 0.5 % GSK2646264 cream and placebo cream on an area of approximately 12 x 3 centimetre (cm) on the volar aspect of the arm which approximates to 0.2% total body surface area (BSA), on each arm. On Day 2 and Day 3 subjects will receive active treatment and placebo on the same arms as on Day 1, with the percentage BSA being 1% on Day 2 and 5% on Day 3.
88875190|NCT02515656|Experimental|POLYGYNAX®|Name : POLYGYNAX® Active components : nystatin 100 000 IU + neomycin sulphate 35 000 IU + polymyxin B sulphate 35 000 IU Dosage : 1 capsule intravaginally per day (administered at bedtime lying down) 12 vaginal soft capsules
89001811|NCT00185354|Active Comparator|Arm 2|
88839119|NCT02424799|Experimental|Part A: Dose group 2|Subjects will be treated topically with 1 % GSK2646264 cream and placebo cream on the morning and evening of Day 1 starting at the final % BSA dosed at Day 3 in group 1 which is anticipated to be 5%. In dose group 2, the starting BSA will increase to 10% at Day 3 and then 20% by Day 5. Administration of the evening (PM) dose will be dependent on the data from Part A Dose group 1.
89179049|NCT04098783|Experimental|Nursing interventions (home visit and health education) group|Nursing interventions group: Home visit, health education At the Intervention group; the researcher made pretest (baseline measurements) before the nursing interventions at the first home visit. The researcher offered education and guide about prevention of lymphedema after the baseline measurements at the first home visit. Second and third home visits were made three and six months after the first visit. At the second and the third home visits, the measurements were repeated, and the nursing interventions were maintained in the direction of the patients' individual needs.
89179050|NCT04098783|No Intervention|No Nursing interventions group|No Nursing interventions group; the researcher administered the pretests at first home visit. The measurements were repeated in the third and sixth months after the first home visit. The researcher also given at the end of the sixth month, all of the nursing interventions, given to the intervention group, for the control group.
89001812|NCT00185393|Experimental|Arm 1|
89001813|NCT00185393|Other|Arm 2|
88839120|NCT02424799|Experimental|Part B|Cold urticaria subjects will receive treatment to 4 defined areas (right and left arms and legs). Subjects will be treated with maximum tolerated strength of GSK2646264 cream (0.5% or 1%) and placebo cream in morning or in morning and evening to 2 specified areas of ~5% BSA on the subject's legs for the CU assessment and to 2 specified areas of 0.2% BSA on the volar aspect of the arm. The maximum tolerated strength and evening dosing will be dependent on the data from the Part A
88839121|NCT02424799|Experimental|Part C|Chronic spontaneous urticaria subjects will be treated with the maximum tolerated strength of GSK2646264 cream from Part A (0.5% or 1%) and placebo cream onto defined areas (right and left arms and, legs and front torso) from Days 1 to 7. The total % BSA for an individual subject will be decided by the investigator prior to randomization. The maximum % BSA and the frequency of dosing will be decided after part A of the study.
88839122|NCT02492750|Experimental|Arm A (lenalidomide, dexamethasone, anakinra)|Patients receive lenalidomide PO on days 1-21 and dexamethasone PO on days 1, 8, 15, and 22. Patients also receive anakinra SC on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity
88839123|NCT02492750|Active Comparator|Arm B (lenalidomide, dexamethasone, placebo)|Patients receive lenalidomide and dexamethasone as in Arm A. Patients also receive placebo SC on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88839124|NCT02453347|Experimental|CES Therapy|All participants will complete CES treatment over the course of four weeks. Assessments will take place at baseline and at post-test four weeks later.
88839125|NCT02493452|Active Comparator|3.0 mg plecanatide|Plecanatide 3.0 mg dosed daily for 12 weeks
88839126|NCT02493452|Active Comparator|6.0 mg plecanatide|Plecanatide 6.0 mg dosed daily for 12 weeks
88839127|NCT02493452|Active Comparator|Matching placebo|Placebo dosed daily for 12 weeks
88839128|NCT02428309|Experimental|Low Dose Treg Cohort|3-6 participants will receive a single infusion of 1 x 10^ 8 autologous polyclonal Tregs (ex vivo selected and expanded)
88839129|NCT02428309|Experimental|Medium Dose Treg Cohort|Sequential dose escalation, 3-6 subjects will receive a single infusion of 4 x 10^ 8 autologous polyclonal Tregs (ex vivo selected and expanded)
88839130|NCT02428309|Experimental|High Dose Treg Cohort|Sequential dose escalation, 3-6 participants will receive a single infusion of 16 x 10^ 8 autologous polyclonal Tregs (ex vivo selected and expanded)
88839131|NCT02429869|Experimental|Everolimus|
88839132|NCT02430337|Experimental|Technology-Assisted SafeCare|A modified version of SafeCare, using a tablet and online program to complete a portion of the session
88839133|NCT02430337|Active Comparator|SafeCare-as-usual|SafeCare as it is usually delivered
88839134|NCT02493608|Active Comparator|scalpel group|Scalpel is the device used to make abdominal wall incision in this group of patient.
88839135|NCT02493608|Active Comparator|Diathermy group|In this study group, abdominal wall incisions are made with diathermy which is a electrosurgical instrument.
88839136|NCT02494076|Experimental|EzPAP|Patients randomized to the EzPAP arm will receive first-line therapies and PEP therapy via EzPAP. All patients will receive 4 cycles with 12 breaths per cycle. 4 cycles is considered one time administration.
89001814|NCT00409019|Experimental|1|Study cancelled: Withdrawn before enrollment of any participants
89179051|NCT04098549|Experimental|Rapid-Slow|"This arm will begin with intervention rapid (rapid rate of fall in plasma glucose) for the first study visit and proceed to intervention slow (slow rate of fall in plasma glucose) for the second study visit."
88839137|NCT02494076|Sham Comparator|Standard care|Patients randomized to the control arm will receive first-line therapies and standard therapy.
88839138|NCT02431273|Experimental|TDF (Single IVR)|"All subjects will be asked to wear Single (TDF) IVRs for 7 days."
88839139|NCT02431273|Experimental|TDF-FTC (Dual IVR)|"If the TDF IVR is determined as safe, study participants will be asked to replace it with Dual (TDF-FTC) IVRs for 7 days. There will be follow-up visit between removal of a single IVR and replacing it with a dual IVR."
88839140|NCT02431273|Experimental|TDF-FTC-MVC (Triple IVR)|"If the TDF-FTC IVR is determined as safe, study participants will be asked to replace them with Triple (TDF-FTC-MVC) IVRs for 7 days. There will be follow-up visit between removal of a dual IVR and replacing it with a triple IVR."
88839141|NCT02428478|Active Comparator|Desipramine First, Placebo Second|Desipramine 200 mg administered 2 hours before normal sleep time on first study night, then a 1-week non-treatment period, then placebo-matching desipramine administered 2 hours before normal sleep time on second study night.
88839142|NCT02428478|Active Comparator|Placebo First, Desipramine Second|Placebo-matching desipramine administered 2 hours before normal sleep time on first study night, then a 1-week non-treatment period, then desipramine administered 2 hours before normal sleep time on second study night.
89001815|NCT00409019|Experimental|2|Study cancelled: Withdrawn before enrollment of any participants
89367112|NCT02454010|Experimental|Expansion Phase (Cohort 7), Adv Tumors|In the expansion phase, subjects in this cohort will be diagnosed with triple negative breast cancer (TNBC), head and neck squamous cell carcinoma (HNSCC), biliary cancer (cholangiocarcinoma or gall bladder carcinoma), pancreatic carcinoma, colorectal cancer and will receive a dose of 25 mCi/m2 FF-21101(90Y)
89367113|NCT03249688|Other|Control|Regular health advice
89367114|NCT03249688|Experimental|Multidomain 1|Multidomain lifestyle
89367115|NCT03249688|Experimental|Multidomain 2|Multidomain lifestyle + medical food
89367116|NCT01346865|Experimental|cilostazol|cilostazol 100mg
89367117|NCT01346865|Placebo Comparator|dual therapy group|Placebo
89367118|NCT03244462|Experimental|Oral BAY1834845|"Study Part A, cross over sequence:~single oral dose of BAY1834845~single oral dose of BAY1834845 + i.v. BAY1834845~single oral dose of BAY1834845 under fed conditions"
89367119|NCT03244462|Experimental|Oral BAY1834845 + i.v. BAY1834845|"Study Part A, cross over sequence:~single oral dose of BAY1834845+ i.v. BAY1834845~single oral dose of BAY1834845~single oral dose of BAY1834845 under fed conditions"
89367120|NCT03244462|Experimental|Oral Methotrexate|"Study part B, cross over sequence:~single oral dose of methotrexate (MTX)~single oral dose of MTX + single oral dose of BAY1834845"
89367121|NCT03244462|Experimental|Oral Methotrexate + oral BAY1834845|"Study part B, cross over sequence:~single oral dose of methotrexate (MTX) + single oral dose of BAY1834845~single oral dose of MTX"
89367122|NCT01346943|Experimental|AAA Stent Graft System|Altura Medical AAA Stent Graft System
89367123|NCT03244150||School sample|Conducted in 1983 and included 1260 students in high school or trade school.
89367124|NCT03244150||Nationwide sample|Conducted in 1985 and included a representative sample of 2498 teenagers drawn from the Danish Civil Registration (CPR)
89367125|NCT01347021|Active Comparator|sacrospinous, pelvic prolapse.|Women with pelvic prolapse grade III/IV were randomly allocated to the sacrospinous colpopexy (25 women) or high uterosacral (26 women)
89367126|NCT01347021|Active Comparator|uterosacral , pelvic prolapse.|Women with pelvic prolapse grade III/IV were randomly allocated to the sacrospinous colpopexy (25 women) or high uterosacral (26 women)
89367127|NCT03244540|Experimental|PCA|Subarchnoid anesthesia with bupivacaine PCA with morphine in the PACU
88839143|NCT04341493|Experimental|Nitazoxanide + hydroxychloroquine|Hydroxychloroquine 400 mg PO every 12 hours for two days and then 200 mg PO every 12 hours for four days + Nitazoxanide 500 mg PO every 6 hours for six days
88839144|NCT04341493|Active Comparator|Hydroxychloroquine|Hydroxychloroquine 200 mg PO every 12 hours for 7 days
88839145|NCT02431741|Experimental|Mepilex Transfer Ag|Non controlled investigation
88839146|NCT02432287|Experimental|Metformin|Metformin, an FDA approved first-line drug for the treatment of type 2 diabetes, has known beneficial effects on glucose metabolism.
89367128|NCT03244540|Experimental|TAP|"Subarchnoid anesthesia with bupivacaine TAP (transversus abdominis plane block) ultrasound-guided regional block between abdominal wall muscles to treat acute postoperative pain. Stimuplex Ultra 360 needle will be used and 0.375 % ropivacaine administered (0.2 mL/kg) at the and of cesarean section.~PCA with morphine in the PACU"
89367129|NCT03244540|Experimental|QLB|"Subarchnoid anesthesia with bupivacaine QLB (quadratus lumborum block) ultrasound-guided regional block between abdominal wall muscles to treat acute postoperative pain. Stimuplex Ultra 360 needle will be used and 0.375 % ropivacaine administered (0.2 mL/kg) at the and of cesarean section.~PCA with morphine in the PACU"
89367130|NCT01347099|Experimental|Internet CBT|Internet-delivered CBT. Contact with therapist thru an e-mail system. 10 weeks.
88839147|NCT02432287|Experimental|Placebo|Placebo
88839148|NCT02532998|Experimental|Treatment Sequence 1|Period 1: fludrocortisone + eplerenone + AZD9977 Period 2: fludrocortisone + eplerenone + AZD9977 Placebo Period 3: fludrocortisone + AZD9977 Placebo Period 4: fludrocortisone + AZD9977 Period 5: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment Period 6: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment
88839149|NCT02532998|Experimental|Treatment Sequence 2|Period 1: fludrocortisone + AZD9977 Placebo Period 2: fludrocortisone + eplerenone + AZD9977 Period 3: fludrocortisone + AZD9977 Period 4: fludrocortisone + eplerenone + AZD9977 Placebo Period 5: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment Period 6: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment
89001816|NCT00409019|Experimental|3|Study cancelled: Withdrawn before enrollment of any participants
89367131|NCT01347099|Placebo Comparator|Support therapy|10 weeks. Therapist support contact through e-mail.
89367132|NCT03243916|Experimental|combination|TACE plus cyber knife
89367133|NCT03893799|Experimental|Cohort 1, Healthy Volunteers|Dose A, single dose
89367134|NCT03893799|Experimental|Cohort 2, Healthy Volunteers|Dose B, single dose
89367135|NCT03893799|Experimental|Cohort 3, Healthy Volunteers|Dose C, single dose
89367136|NCT03893799|Experimental|Cohort 4, Subjects with CKD Stage 3|Dose D, single dose
89367137|NCT03893799|Experimental|Cohort 5, Subjects with CKD Stage 3|Dose E, single dose
89367138|NCT03893799|Experimental|Cohort 6, Subjects with CKD Stage 4|Dose F, single dose
89367139|NCT03893799|Experimental|Cohort 7, Subjects with CKD Stage 4|Dose G, single dose
89367140|NCT03893799|Experimental|Cohort 8, Subjects with CKD Stage 3 or 4|Dose H, single dose
89367141|NCT03893799|Experimental|Cohort 9, Subjects with CKD Stage 3 or 4|Dose I, single dose
89367142|NCT03249610|Experimental|Jindal Steel Pvt Ltd|Lifestyle intervention given
89367143|NCT03249610|Experimental|Maruti Udyog Ltd|Lifestyle intervention given
89367144|NCT03249610|No Intervention|Tata Capital|Control arm so no intervention given
89367145|NCT03249610|No Intervention|Powergrid Corporation|Control arm so no intervention given
89367146|NCT02389803|Experimental|Nutritional supplementation standardized formula|Powder added to water, containing about 25% of recommended Daily Recommended Intake (DRI) for Calories, high protein (25% of calories) and multi vitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake )
89367147|NCT02389803|Placebo Comparator|Placebo comparator|Low caloric formula (Powder added to water), without added vitamins and mineral
88839150|NCT02532998|Experimental|Treatment Sequence 3|Period 1: fludrocortisone + AZD9977 Period 2: fludrocortisone + AZD9977 Placebo Period 3: fludrocortisone + eplerenone + AZD9977 Placebo Period 4: fludrocortisone + eplerenone + AZD9977 Period 5: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment Period 6: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment
88839151|NCT02532998|Experimental|Treatment Sequence 4|Period 1: fludrocortisone + eplerenone + AZD9977 Placebo Period 2: fludrocortisone + eplerenone + AZD9977 Period 3: fludrocortisone + AZD9977 Period 4: fludrocortisone + AZD9977 Placebo Period 5: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment Period 6: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment
88839152|NCT02532998|Experimental|Treatment Sequence 5|Period 1: fludrocortisone + eplerenone + AZD9977 Period 2: fludrocortisone + eplerenone + AZD9977 Placebo Period 3: fludrocortisone + AZD9977 Placebo Period 4: fludrocortisone + AZD9977 Period 5: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment Period 6: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment
88839153|NCT02532998|Experimental|Treatment Sequence 6|Period 1: fludrocortisone + AZD9977 Placebo Period 2: fludrocortisone + eplerenone + AZD9977 Period 3: fludrocortisone + AZD9977 Period 4: fludrocortisone + eplerenone + AZD9977 Placebo Period 5: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment Period 6: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment
88839154|NCT02532998|Experimental|Treatment Sequence 7|Period 1: fludrocortisone + AZD9977 Period 2: fludrocortisone + AZD9977 Placebo Period 3: fludrocortisone + eplerenone + AZD9977 Placebo Period 4: fludrocortisone + eplerenone + AZD9977 Period 5: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment Period 6: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment
89179052|NCT04098549|Experimental|Slow-Rapid|"This arm will begin with intervention slow (slow rate of fall in plasma glucose) for the first study visit and proceed to intervention rapid (rapid rate of fall in plasma glucose) for the second study visit."
89179053|NCT04098159|Experimental|ESRD Patients have functioning or failing VAs (AVFs or AVGs).|
89179054|NCT00760383|Experimental|EAA+PT|20 g EAA daily for 7 days prior to TKA surgery and for 14 days after surgery.
89179055|NCT00760383|Placebo Comparator|ALA+PT|20 g NEAA daily for 7 days prior to TKA surgery and for 14 days after surgery.
89179056|NCT04098471|Experimental|single transanal loca excision|
89179057|NCT04098471|Experimental|transanal local excision following radiotherapy|
89179058|NCT04098471|Experimental|total mesorectal excision|
89179059|NCT00759915|Other|1|Treatment A (test product) followed by Treatment B (reference product)
89179060|NCT00759915|Other|2|Treatment B (reference product) followed by Treatment A (test product)
89179061|NCT00759759|Other|1|Treatment A (test product) followed by Treatment B (reference product)
89179062|NCT00759759|Other|2|Treatment B (reference product) followed by Treatment A (test product)
89179063|NCT00759681|Active Comparator|Control|Gelfoam and Thrombin
89179064|NCT00759681|Experimental|Investigational Device|ArterX Surgical Sealant
89179065|NCT00826241|Experimental|Temozolomide + Lapatinib|Temozolomide starting dose 125 mg/m^2 daily by mouth on days 1-7 & 15-21 of a 28 day cycle. Lapatinib starting dose 1250 mg daily by mouth.
89179066|NCT00707681|Active Comparator|I|MS-20
89179067|NCT00707681|Placebo Comparator|2|Placebo
89179068|NCT04039451||people who live in rural areas in Assuit governorate|The study will performed on people who live in rural areas in Assuit governorate (all households) regardless of sex or age.
89179069|NCT00758589|Experimental|AZD1981 50 mg|AZD1981 50 mg Twice Daily (Bid)
89179070|NCT00758589|Placebo Comparator|Placebo|Placebo
89179071|NCT00758589|Experimental|AZD1981 400 mg|AZD1981 400 mg Twice Daily (Bid)
89179072|NCT00758589|Experimental|AZD1981 1000 mg|AZD1981 1000 mg Twice Daily (Bid)
89367148|NCT03341715|Experimental|Mavoglurant (AFQ056)|The investigators will use a single dose of the AFQ056 (200 mg) versus placebo in random assignment single-blind fashion, administered 2 hours prior to the MRI and other measures, in two separate experimental study visits.
89179073|NCT02601183||Ischemic stroke|The patients in the group are diagnosed as ischemic stroke by CT or MRA examination within 8h following stroke attack.
89179074|NCT02601183||Hemorrhagic stroke|The patients in the group are diagnosed as hemorrhagic stroke by CT or MRA examination within 8h following stroke attack.
89179075|NCT00833417|Experimental|Vismodegib 150 mg|Patients received vismodegib 150 mg orally once daily until disease progression; intolerable toxicity, most probably attributable to vismodegib; or withdrawal from the study.
89367149|NCT03341715|Placebo Comparator|Placebo|The investigators will use a single dose of the AFQ056 (200 mg) versus placebo in random assignment single-blind fashion, administered 2 hours prior to the MRI and other measures, in two separate experimental study visits.
89179076|NCT00762372|Experimental|desflurane|
89179077|NCT00762372|Experimental|desflurane/N2O|
89179078|NCT00762372|Active Comparator|sevoflurane/N2O|
89179079|NCT00833261|Experimental|Single Arm: Chemotherapy with Concurrent Radiation therapy|Nab-Paclitaxel, Cetuximab, Cisplatin, and Radiation Therapy intensity-modulated radiation therapy
89179080|NCT00833105|Experimental|AMES treatment|The subject will receive 25 treatment sessions, conducted 2-3 times per week on the AMES device. Each session will consist of testing followed by 30 minutes of wrist and finger rehabilitation using the AMES device.
89179081|NCT02600598|Experimental|LEO 43204 Group A|Group A - Experimental LEO 43204, applied once daily for 3 consecutive days in patients with actinic keratosis
89179082|NCT02600598|Experimental|LEO 43204 Group B|Group B - Experimental LEO 43204, applied once daily for 3 consecutive days in patients with actinic keratosis
89179083|NCT00833027|Experimental|1|Sitagliptin
89179084|NCT05758493|Experimental|Patients with ATTR-CM|Patients with ATTR-CM will undergo hybrid 124I-Evuzamitide PET/MRI imaging (or PET/CT) at baseline and in a subgroup, repeat imaging will be performed at an interval of 6-12 months.
89179085|NCT00752622|Experimental|Shortened interval|Infliximab 5 mg/kg, then Infliximab 5 mg/kg every 6 weeks
89179086|NCT00752622|Experimental|Increased dose|Infliximab 5 mg/kg, then Infliximab 7 mg/kg every 8 weeks
89179087|NCT00913601|Experimental|Dextra|Unilateral sacral nerve stimulation dextra for 4 weeks
89179088|NCT00913601|Experimental|Sinistra|Unilateral sacral nerve stimulation sinistra 4 weeks
88839155|NCT02532998|Experimental|Treatment Sequence 8|Period 1: fludrocortisone + eplerenone + AZD9977 Placebo Period 2: fludrocortisone + AZD9977 Period 3: fludrocortisone + eplerenone + AZD9977 Period 4: fludrocortisone + AZD9977 Placebo Period 5: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment Period 6: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment
88839156|NCT00363194|Experimental|Lead-In cohort|In Part 1 of Lead-In cohort, subjects will be dosed with a single dose of pazopanib with a high-fat breakfast to establish safety and tolerability.
88839157|NCT02453581|Experimental|OZ439 100mg|OZ439 100mg Powder for Oral Suspension
88839158|NCT02453581|Experimental|OZ439 200mg|OZ439 200mg Powder for Oral Suspension
88839159|NCT02453581|Experimental|OZ439 500mg|OZ439 500mg Powder for Oral Suspension
88839160|NCT02533466|Experimental|Test Product|Subjects will apply a full ribbon of dentifrice and brush their teeth for 1 timed minute using a wetted toothbrush, swish the resulting slurry around the mouth for 30 seconds making sure it contacts the selected teeth, spit out slurry and rinse mouth for 10 seconds with water.
88839161|NCT02533466|Placebo Comparator|Reference Product|Subjects will apply a full ribbon of dentifrice and brush their teeth for 1 timed minute using a wetted toothbrush, swish the resulting slurry around the mouth for 30 seconds making sure it contacts the selected teeth, spit out slurry and rinse mouth for 10 seconds with water.
88839162|NCT02454127|Active Comparator|Atkins Diet|Atkins Diet (dietary counseling)
88839163|NCT02454127|Active Comparator|Zone Diet|Zone Diet (dietary counseling)
88839164|NCT02454127|Active Comparator|Weight Watchers Diet|Weight Watchers Diet (dietary counseling)
88839165|NCT02454127|Active Comparator|Ornish Diet|Ornish Diet (dietary counseling)
88839166|NCT02974244||exenatide once weekly|type 2 diabetes who initiated exenatide once weekly treatment in the index period
88839167|NCT02974244||basal insulin|type 2 diabetes patients who initiated basal insulin treatment in the index period
88839168|NCT04743986|Experimental|Platelet Rich Plasma (PRP)|Patients had 10ml venous blood drawn. Injection was performed under ultrasound guidance by one of two musculoskeletal radiologists. Injection was 3-5ml at the site of tendon pathology with the remainder of the PRP preparation infiltrated into the subacromial space. A leukocyte-poor preparation was used from a pre-packaged kit (RegenLab, Lausanne, Switzerland). The samples were centrifuged at 1500g for 5 mins to yield approx 5.5ml of 80% platelets at 1.6x concentration. The supernatant was then resuspended by inverting the tube several times and was drawn into a separate 5-ml syringe for subacromial injection.
88839169|NCT04743986|Active Comparator|Corticosteroid (CS)|Patients had 10ml venous blood drawn. Injection was performed under ultrasound guidance by one of two musculoskeletal radiologists. The blood sample was kept for a similar time delay for centrifugation prior to injection, and was then discarded. 1ml of 40-mg/ml triamcinolone was suspended in 2ml of 0.5% bupivicaine. Injection was performed through a lateral subacromial approach after needle fenestration of the supraspinatus tendon under ultrasound visualization. CS was infiltrated into the subacromial bursa and not the tendon itself.
88839170|NCT04743752||Group OSA+NSCLC|According to the baseline sleep monitor results, participants will be divided into Group OSA+NSCLC if apnea hypopnea index(AHI) no less than 15.
88839171|NCT04743752||Group NSCLC|According to the baseline sleep monitor results, participants will be divided into Group NSCLC if apnea hypopnea index(AHI) less than 15.
88839172|NCT03016897||Group 1|Participants enrolled solely in ALS AT HOME Outcome measurement devices will be provided. Respirometer, Handgrip Meter, Skulpt Chisel, ActigraphyMeter
88839173|NCT03016897||Group 2|Current participants of the Answer ALS study Outcome measurement devices will be provided. Respirometer, Handgrip Meter, Skulpt Chisel, ActigraphyMeter
88839174|NCT03016897||Group 3|Participants without neurological disease (controls) Outcome measurement devices will be provided. Respirometer, Handgrip Meter, Skulpt Chisel, ActigraphyMeter
88839175|NCT02974322|Experimental|GED-0301 1 x 160 mg once daily|GED-0301 1 x 160 mg tablet once daily (QD)
88839176|NCT02974322|Experimental|GED-0301 - 4 x 40 mg once daily|GED-0301 4 x 40 mg tablets once daily (QD)
88839177|NCT02974322|Placebo Comparator|Placebo once daily|Placebo once daily (QD)
88839178|NCT02436031|Active Comparator|Desipramine First, Placebo Second|Desipramine 200 mg administered 2 hours before normal sleep time on first study night, then a 1-week non-treatment period, then placebo-matching desipramine administered 2 hours before normal sleep time on second study night.
88839179|NCT02436031|Experimental|Placebo First, Desipramine Second|Placebo-matching desipramine administered 2 hours before normal sleep time on first study night, then a 1-week non-treatment period, then desipramine administered 2 hours before normal sleep time on second study night.
88839180|NCT02454283|Experimental|Vanoxerine HCl|Vanoxerine HCl, 400 mg (2 x 200 mg capsules), orally, single dose
88839181|NCT02454283|Placebo Comparator|Placebo|identically matching placebo capsules, orally, single-dose
88839182|NCT02437669|Experimental|Intranasal hydromorphone|Hydromorphone, intranasal. 2 mg/mL concentration. Initial dose: 0.03 mg/kg, maximum single dose 4 mg. Rescue dose: 0.015 mg/kg, maximum single dose 2 mg.
88839183|NCT02430818|Experimental|Ketamine|Ketamine is a dissociative agent that is thought to modulate pain by binding to NMDA receptors. Participants assigned to the ketamine arm will be given 0.4 mg/kg IV of ketamine (40 mg maximum).
88839184|NCT02430818|Experimental|Morphine|Morphine is an opioid that acts on opioidergic receptors to modulate pain. Participants in the opioid arm will receive 0.1 mg/kg IV of morphine (10 mg maximum).
88839185|NCT02455453|Experimental|Diagnostic FFNP-PET/CT Scan|"(2) 18F-FFNP-PET/CT scans~First one prior to estradiol challenge test~Second one immediately following one day of estradiol challenge test~(1) FDG-PET/CT scan at screening~The estradiol challenge test will consist of administering a total of 6 mg of estradiol dosed orally as three 2 mg tablets with each tablet being administered approximately 8 hours apart and within a 24 hour period. This estradiol medication will be provided to the patient by the study."
89367150|NCT03249298|Active Comparator|Crystalloids|"Bolus of crystalloids~Bolus of 250 ml crystaloids will be infused regarding the measures"
89367151|NCT03249298|Active Comparator|Colloids|"Bolus of colloids~Bolus of 250 ml colloids will be infused regarding the measures"
89367152|NCT04541979|Active Comparator|Aerosolized DNase I|
89367153|NCT04541979|Placebo Comparator|NaCl|
89367154|NCT03243994|Experimental|COPD|Patients with COPD without Cor Pulmonale
89367155|NCT03243994|Experimental|COPD + Cor Pulmonale|Patients with Cor Pulmonale in addition
89367156|NCT03312309|Experimental|RIF group|"According to the histological dating of endometrium of natural/hormone replacement cycle in control group, to explore the effectiveness of intervention by advanced or delayed personal embryo transfer .~The establishment of standard control group: Frozen embryo transfer patients according to the inclusion and exclusion criteria were evaluated for histological dating by endometrial biopsy on 7 days after ovulation/P+7. After routine time transfer in the frozen embryo transfer cycle, the standard of histological dating were determined according to the pregnancy outcome of the FET cycle .~pET in RIF patients was delayed one(ovulation +4/P+4, OV/P+4) / two days(OV/P+3) or advanced one day(OV/P+9). Day 5 blastocysts were transferred with this strategy in natural cycles."
89367157|NCT02454868|Experimental|Study arm|There is a single study arm. Remifentanil will be infused before intubation. The first patient will receive remifentanil 2mg/kg. If a success occurs the next patient's dose will be decreased by 0.25mg/kg and else it will be increased by 0.25mg/kg. This rule will apply recursively as Dixon's Up-And-Down Method.
89399180|NCT03696459|Experimental|Part 2 Group 1: Treatment Sequence EHFG|Participants will receive single oral dose of JNJ-53718678, 500 mg suspension with single oral dose of moxifloxacin placebo and JNJ 53718678 placebo (Treatment E) in Period 1, then participants will receive single oral dose of moxifloxacin 400 mg with single oral dose of JNJ-53718678 placebo (Treatment H) in Period 2 then will receive single oral dose of JNJ-53718678, 4500 mg (dose will be based on review of safety, tolerability, and PK data obtained in Part 1 [either from Panel 3 or 4], this dose may be lower/higher) suspension with single oral dose of moxifloxacin placebo (Treatment F) in Period 3 followed by single oral dose of JNJ-53718678 placebo with single oral dose of moxifloxacin placebo (Treatment G) in Period 4, on Day 1 of each treatment period. There will be a washout period of at least 7 days between study drug intake in subsequent treatment periods.
89399181|NCT03696459|Experimental|Part 2 Group 2: Treatment Sequence FEGH|Participants will receive Treatment F in Period 1, then Treatment E in Period 2, then Treatment G in Period 3 followed by Treatment H in Period 4 on Day 1 of each treatment period.
89399182|NCT03696459|Experimental|Part 2 Group 3: Treatment Sequence GFHE|Participants will receive Treatment G in Period 1, then Treatment F in Period 2, then Treatment H in Period 3 followed by Treatment E in Period 4 on Day 1 of each treatment period.
89399183|NCT03696459|Experimental|Part 2 Group 4: Treatment Sequence HGEF|Participants will receive Treatment H in Period 1, then Treatment G in Period 2, then Treatment E in Period 3 followed by Treatment F in Period 4 on Day 1 of each treatment period.
88839186|NCT02997865|Experimental|Stepped Care for Depression|Participants will receive cognitive behavior therapy for depression, plus referral to their own physician for discussion of antidepressant medication if symptoms do not improve within 5-10 weeks. Participants will also receive individually-tailored heart failure self-care education and support.
88839187|NCT02997865|No Intervention|Enhanced Usual Care|Participants will receive individually-tailored heart failure self-care education and support. With the participant's permission, his or her personal physician will be notified about the patient's depression. The participant will be asked to discuss depression treatment options with his or her personal physician.
88839188|NCT02457403|Experimental|ROTEM|Transfusion guided by ROTEM during OLT
88839189|NCT02457403|Active Comparator|Conventional|Transfusion guided by conventional labs
88839190|NCT02533934|Experimental|Treatment with Sofosbuvir based HCV Therapy|Prospective and retrospective treatment for HCV
88839191|NCT02983513|Experimental|Early Intervention|"The early intervention program is delivered during the NICU stay, according to the MITP and Premie Start Protocol, in order to train parents to: recognize signs of infant stress and alert-available behavior to promote mother-infant interaction; adopt principles of graded stimulation; optimize interactions and avoid overwhelming infants through facilitation strategies (for example, engage and support the visual attention of the newborn). The program is held in eight main sessions and one additional post-discharge session.~In addition parents are trained and invited to daily promote preterm baby massage therapy and visual attention according to a detailed protocol."
88839192|NCT02983513|No Intervention|Standard Care|Standard Care according to NICU protocols including Kangaroo Mother Care, nesting and minimal handling
89399184|NCT03696381|Experimental|Real tRNS|Real tRNS + Guttmann NeuroPersonalTrainer (GNPT) 3 days per week over 8 weeks.
89399185|NCT03696381|Sham Comparator|Sham tRNS|Sham tRNS + Guttmann NeuroPersonalTrainer (GNPT) 3 days per week over 8 weeks.
89399186|NCT03624153|Experimental|Robotic-assisted intervention|70 minutes Robotic-assisted intervention.
89399187|NCT03624153|Active Comparator|Conventional intervention|70 minutes conventional rehabilitation.
89399188|NCT03624075|No Intervention|control group|The control group had a protocol of a health education / self-gestation session lasting 60 minutes. This session should include topics such as definition of knee OA, guidance on knee anatomy and physiology, prayer over articulation, rehabilitation and practice of exercises, and as volunteer to receive an educational and self explanatory primer with all the content that is exposed during a lesson .
88839193|NCT02459119|Experimental|Regorafenib|Regorafenib will be administered orally to all patients on study. The drug will be taken once a day for 3 of every 4 week cycle (3 weeks on/1 week off). The dose is 120 mg once daily for the first cycle, then 160 mg once daily from the second cycle if no significant Regorafenib-associated toxicities occur during the first cycle. Drug dosage may be modified if toxicities occur. Patients will undergo up to 4 cycles of treatment and may continue on additional at the discretion of the investigator.
89179089|NCT00913601|Experimental|Bilateral|Bilateral sacral nerve stimulation 4 weeks
89534695|NCT02167945|Experimental|ABT-450/r/ABT-267 plus ABT-333 with or without ribavirin (RBV)|Participants with HCV GT1b without cirrhosis received the 3-DAA (ABT-450/ritonavir/ABT-267 and ABT-333) regimen: two 75 mg ABT-450/50 mg ritonavir/12.5 mg ABT-267 tablets taken orally every morning (QD) and one ABT-333 250 mg tablet taken orally twice a day (BID) for 12 weeks. Participants with HCV GT1a without cirrhosis and those with HCV GT1b with cirrhosis received the 3-DAA regimen and weight-based ribavirin (RBV; 1000 to 1200 mg divided twice daily per local label) for 12 weeks. Participants with HCV GT1a with cirrhosis received the 3-DAA regimen and weight-based RBV per local label for 24 weeks.
88839194|NCT02535026||Breast Cancer Participants|Breast tissue samples from female participants with a breast cancer diagnosis that undergo an anatomopathological examination of surgical specimens and/or core needle biopsies will be considered for analysis in this study.
88839195|NCT02956525|Experimental|Dexibuprofen 200 mg - Fed|Fed condition
88839196|NCT02956525|Experimental|Dexibuprofen 200 mg - Fasting|Fasting condition
88839197|NCT02519023|Experimental|TAP-Block with liposomal bupivacaine|TAP infiltration will contain 10 mL of 0.25 % bupivacaine with epinephrine injected followed by 20 mL of a 50:50 mixture of liposomal bupivacaine and normal saline. This will then be repeated on the contralateral side. In the same arm the surgeon infiltration into the incision will consist of 10 ml of normal saline per port site, 5 ml prior to incision and 5 ml prior to closure at each port site.
88839198|NCT02519023|Active Comparator|Surgical infiltration with bupivacaine|Surgical Infiltration of the study solution will be performed both prior to incision and at the end of surgery just prior to closure of incisions. At each time, the surgeon will inject 5 mL of 0.25% bupivacaine into each of the port site incisions.
88839199|NCT02535572|Experimental|FEAST|Patients will receive the FEAST form of ECT
88839200|NCT02535572|Active Comparator|RUL UB|Patients will receive the standard of care, right unilateral ultrabrief ECT (RUL UB)
88839201|NCT02497040|Experimental|bupivacaine,levobupivacaine|20 ml of 0.5% bupivacaine 20 ml of 0.5% levobupivacaine
88839202|NCT02497040|Active Comparator|levobupivacaine|20 ml of 0.5% levobupivacaine saline as a placebo
88839203|NCT02497040|Active Comparator|bupivacaine|20 ml of 0.5% bupivacaine saline as a placebo
88839204|NCT02523235|Active Comparator|proximal catheter insertion|"Adductor canal catheters: Inserted as described by Jæger et al., 2013: …we performed an ultrasound survey at the medial part of the thigh, halfway between the superior anterior iliac spine and the [superior border of the] patella. In a short axis view, we identified the femoral artery underneath the sartorius muscle, with the vein just inferior and the saphenous nerve just lateral to the artery.~Popliteal catheters: Using an ultrasound, the bifurcation of the sciatic nerve will be identified in short axis and marked at a point immediately distal at which point the two main branches of the sciatic nerve are separate and a hypoechoic area can be viewed between the two. This level will be marked on the skin. The needle will be inserted to intersect the sciatic nerve 6-7 cm proximal to the mark on the skin (therefore, proximal to the sciatic bifurcation) and injection with saline used to ensure subepimyseal spread."
88839205|NCT02523235|Experimental|distal catheter insertion|"Adductor canal catheters: Inserted as described by Manickam et al. 2009~Popliteal catheters: Using an ultrasound, the bifurcation of the sciatic nerve will be identified in short axis and marked at a point immediately distal at which point the two main branches of the sciatic nerve are separate and a hypoechoic area can be viewed between the two. This level will be marked on the skin. The needle tip will be inserted into the hypoechoic area between the two branches of the sciatic nerve immediately distal to the sciatic nerve bifurcation between the paraneurium and epineurium (the subparaneural space/compartment). As described by Tran et al, An adequate position was defined as the presence of circular expansion of the paraneural sheath... Once circular expansion was obtained, we injected."
88839206|NCT02498522|Experimental|metformin arm|83 patients will continue metformin until end of 1st trimester (14 weeks gestation)
88839207|NCT02498522|Placebo Comparator|control arm|83 patients will stop metformin at diagnosis of pregnancy ( 5-6 weeks gestation)
89534696|NCT05048355|Experimental|Power Knee Mainstream Dynamic|
89534697|NCT05048355|Active Comparator|Passive MPK|
89179090|NCT00754650|Experimental|Bevacizumab 15 mg/kg|Participants received bevacizumab 15 mg/kg intravenously on Day 1 of each 3-week cycle for 8 cycles.
89179091|NCT00707837|Experimental|Infant Formula|Preterm infant formulas containing lipid soluble compounds
89534698|NCT03328871|Experimental|Fractional CO2 Laser and PRP injection|One of the striae gravidarum areas will be treated by fractional laser once every three months for 2 times combined with PRP injection once a month for 6 times.
89534699|NCT03328871|Experimental|Nanofat grafting and PRP injection|Another area will be treated by nanofat grafting once every three months for 2 times and PRP therapy once a month for 6 times.
88839208|NCT02459197|Active Comparator|T4P1001|
88839209|NCT02459197|Sham Comparator|Placebo|
88839210|NCT02431052|Placebo Comparator|Olumacostat Glasaretil Gel, Vehicle QD|Olumacostat Glasaretil Gel, Vehicle, applied once daily to the face for 12 weeks
88839211|NCT02431052|Placebo Comparator|Olumacostat Glasaretil Gel, Vehicle BID|Olumacostat Glasaretil Gel, Vehicle, applied twice daily to the face for 12 weeks
88839212|NCT02431052|Experimental|Olumacostat Glasaretil Gel, 4.0% QD|Olumacostat Glasaretil Gel, 4.0%, applied once daily to the face for 12 weeks
88839213|NCT02431052|Experimental|Olumacostat Glasaretil Gel, 7.5% QD|Olumacostat Glasaretil Gel, 7.5%, applied once daily to the face for 12 weeks
88839214|NCT02431052|Experimental|Olumacostat Glasaretil Gel, 7.5% BID|Olumacostat Glasaretil Gel, 7.5%, applied twice daily to the face for 12 weeks
88839215|NCT02919787|Active Comparator|Surgery and then postoperative adjuvant chemotherapy|Surgery and then postoperative adjuvant chemotherapy
89179092|NCT00707837|Active Comparator|Preterm formulas|Standard preterm infant formula and discharge formulas
89179093|NCT02611271||Piperacillin/Tazobactam|Critically ill patients teated with piperacillin/tazobactam undergoing renal replacement therapy and cytosorb absorption during sepsis
89179094|NCT02611271||Imipenem/Cilastatin|Critically ill patients teated with imipenem/cilastatin undergoing renal replacement therapy and cytosorb absorption during sepsis
89179095|NCT00705185||1|Adults with Major Depressive Disorder- as defined by the criteria in the DSM-IV
89367158|NCT03243760|Experimental|Cohort A: Single dose CCI15106 7.5 mg /Placebo|Healthy subjects will receive single dose of either 1 capsule CCI15106 7.5 milligram (mg) or matching placebo by inhalation via Modified Air Inlet Rotahaler™ device according to randomization.
88839216|NCT02919787|Experimental|Neoadjuvant chemotherapy, surgery, adjuvant chemotherapy|Neoadjuvant chemotherapy, surgery, adjuvant chemotherapy
88839217|NCT02459275|Experimental|PEP uP Protocol|Participants will receive the PEP uP protocol with the pro motility agent. The intervention will be provided until the tube feeds are stopped or patient is fed meals orally and will be tracked until hospital discharge or 60 days which ever occur first.
88839218|NCT02459275|No Intervention|Standard of Care|Standard formula polymeric tube feeds started at a rate of 20 ml/hour. Gastric residual volume (GRV) will be checked every 4 hours. GRV is reinfused to the patient each time it is checked. GRV threshold is 200-500 ml. If the patient is tolerating tube feeds as determined by measuring the GRV, the rate is advanced by 20 ml/hour every 4 hours up to the goal rate. Participants will be followed until the tube feeds are stopped or patient is fed meals orally and will be tracked until hospital discharge or 60 days which ever occur first.
88839219|NCT02498834|Experimental|Educational Video and Question Prompt List|Parents and adolescents in this group will watch a short educational video in English or Spanish on an iPad about the importance of encouraging adolescents to ask questions and to be involved during their pediatric asthma visits to improve their self-management skills. Also, the adolescents in this group will be handed a question prompt list to complete, which will be collected after the medical visit.
88839220|NCT02498834|No Intervention|Control group|Standard of care will be used
88839221|NCT02524561|Active Comparator|CEE pill, active progesterone|Conjugated equine estrogens 0.45 mg/day, placebo patch, Prometrium (micronized progesterone USP encapsulated with peanut oil) 200 mg daily for the first 12 days of each month at bedtime
88839222|NCT02524561|Active Comparator|estradiol patch, active progesterone|Transdermal estradiol, 50 mcg/day, placebo tablet, Prometrium (micronized progesterone USP encapsulated with peanut oil) 200 mg daily for the first 12 days of each month at bedtime
88839223|NCT02524561|Placebo Comparator|placebo|Placebo tablet, placebo patch, placebo progesterone
88839224|NCT02431598|Active Comparator|Eovist (gadoxetate disodium)|While in the MRI scanner, the subject will receive a clinical dose of Eovist, Dotarem, or normal saline. Each subject will receive all three, in random order, blinded to which agent is received in a given instance.
88839225|NCT02431598|Active Comparator|Dotarem (gadoterate dimeglumine)|While in the MRI scanner, the subject will receive a clinical dose of Eovist, Dotarem, or normal saline. Each subject will receive all three, in random order, blinded to which agent is received in a given instance.
88839226|NCT02431598|Active Comparator|Saline|While in the MRI scanner, the subject will receive a clinical dose of Eovist, Dotarem, or normal saline. Each subject will receive all three, in random order, blinded to which agent is received in a given instance.
88839227|NCT04743739|Active Comparator|Rituximab monotherapy|Rituximab 1000mg I.V. on Days 1 and 181, and will be retreated or not on Days 15 and 195 according to the CD19+ B cells count.
88839228|NCT04743739|Experimental|Rituximab combined with cyclosporine|"Rituximab 1000mg I.V. on Days 1 and 181, and will be retreated or not on Days 15 and 195 according to CD19+ B cells count.~cyclosporine (CsA) will be started at a dose of 3mg/kg/day p.o. divided into 2 equal doses given at 12 hour intervals. Doses of CsA will be adjusted according to the blood levels of CsA. CsA will be tapered after 6 months and discontinued over a 3 month period."
88839229|NCT02499380||Treatment|Patients treated with PneumRx Coil System
88839230|NCT02461693|Experimental|Caffeine|One-time treatment with 200mg caffeine pill
88839231|NCT02461693|Placebo Comparator|Placebo|One-time treatment with lactose-based placebo pill
88839232|NCT02525263|Experimental|Neo-Kidney Augment|NKA is made from expanded autologous selected renal cells (SRC) obtained from the patient's kidney biopsy. To manufacture NKA, kidney biopsy tissue from each enrolled patient will be sent to RegenMedTX, LLC, where renal cells will be expanded and SRC selected. SRC will be formulated in a gelatin based hydrogel at a concentration of 100 x 106 cells/mL, packaged in a 10 mL syringe, and shipped to the clinical site for use.
88839233|NCT02525575|Experimental|Project Life Force Group Treatment|"Project Life Force Clinical Intervention: is a manualized, weekly 90-minute group treatment lasting 3 months coinciding with the time frame for enhanced monitoring of Veterans identified as high-risk. The use of Dialectical Behavior Therapy skills in PLF differs from other DBT interventions in that it focuses primarily on emotion regulation (ER), distress tolerance and interpersonal effectiveness in the specific context of implementing a safety plan. Mindfulness is not covered. PLF is augmented with additional skill modules on strengthening friendships and education pertaining to suicide risk, suicide means restriction and suicide prevention mobile Apps."
88839234|NCT02525653|Experimental|Albumin-Bound Paclitaxel and Gemcitabine|During each 21-day cycle, albumin-bound paclitaxel at 100mg/mg2 over 120 minutes and gemcitabine at 1000mg/m2 over 30 minutes will be given intravenously on days 1 and 8 of each 21 day cycle. Treatment will continue until disease progression or intolerable side effects. After the 4th cycle of treatment, patients will have the option of discontinuing gemcitabine and proceeding with weekly albumin-bound paclitaxel as maintenance therapy.
88839235|NCT02431754|Experimental|Tadalafil|"5 milligrams (mg) tadalafil administered once daily orally for 8 weeks in one of two treatment periods.~0.2 mg tamulosin once daily or 4 mg silodosin twice daily.~Participants will remain on stable dose of alpha1 blocker through both treatment periods."
88839236|NCT02431754|Placebo Comparator|Placebo|"Placebo administered once daily orally for 8 weeks in one of two treatment periods.~0.2 mg tamulosin once daily or 4 mg silodosin twice daily.~Participants will remain on stable dose of alpha1 blocker through both treatment periods."
88839237|NCT02499692|Experimental|SYNERGYTM Coronary Stent System|Device:SYNERGY MONORAIL Everolimus-Eluting Platinum Chromium Coronary Stent System
89179096|NCT00705185||2|Healthy Controls- research subjects who have not met criteria for any lifetime Axis-I disorder (DSM-IV)
88839238|NCT02526277|Active Comparator|MMF07 Foot Massager device|Participants randomized to the MMF07 Foot Massager device arm will be provided the MMF07 Foot Massager device and instructed to set this device at setting 3, then increase or decrease the setting to their desired level of comfort, to be used for 30 minutes at bedtime.
88839239|NCT02526277|Active Comparator|Heat therapy|Participants randomized to heat therapy will be provided an electric heating pad and will be instructed to use this pad at a medium setting for 30 minutes at bedtime.
88839240|NCT02526277|Active Comparator|MMF07 Foot Massager device and heat therapy|Participants randomized to both the MMF07 Foot Massager device and heat therapy will be provided both the MMF07 Foot Massager device and electric heating pad. Participants will be instructed to set the MMF07 Foot Massager device at setting 3, then increase or decrease the setting to their desired level of comfort. They will also be instructed to use the electric heating pad at a medium setting at the same time for 30 minutes at bedtime.
88839241|NCT02526277|No Intervention|No treatment|Participants receiving no intervention will be asked to not alter their nighttime routine.
88839242|NCT02500628|Experimental|Fibromyalgia|Fibromyalgia (subgroups: opioid responsive, opioid resistant, opioid intolerant) Metformin 500 mg orally in the morning
89367159|NCT03243760|Experimental|Cohort B: Single dose CCI15106 15 mg /Placebo|Healthy subjects will receive single dose of either 15 mg CCI15106 (2 capsules of 7.5 mg) or matching placebo by inhalation via Modified Air Inlet Rotahaler™ device according to randomization.
89179097|NCT04093440|Other|Observation|lifestyle modification: nutrition counselling, diet and physical exercise monitoring, smoking cessation, and medication optimization
89179098|NCT00761748|Experimental|SenSura|SenSura Uro 2-piece. Is a urostomy bag with the intended use of collecting urine from a stoma. Consist of a base plate and a bag that is attached to the base plate.
89179099|NCT00761748|Active Comparator|Convatec|Convatec Uro 2-piece Is a urostomy bag with the intended use of collecting urine from a stoma. Consist of a base plate and a bag that is attached to the base plate.
89179100|NCT00825305|Experimental|Zagreb (2-1-1)|Rabies PCEC vaccine was applied according Zagreb schedule with 2 vaccinations on day 0, 1 vaccination on day 7 and day 21, respectively
89179101|NCT00825305|Active Comparator|Essen (1-1-1-1-1)|Rabies PCEC vaccine was applied according Essen schedule, i.e. 1 vaccination on day 0, day 3, day 7, day 14 and day 28, respectively.
89179102|NCT00754572|Experimental|1|
89179103|NCT00824993|Experimental|Ibandronate + Calcium + Vitamin D|Ibandronate infusion of 3 mg by vein over 15 to 30 seconds for 4 doses at 3-6 weeks after transplant, and at Months 3, 6, and 9 after the transplant. Calcium 500 mg by mouth everyday for 12 months. Vitamin D 400 units by mouth 2 times a day for 12 months.
89179104|NCT00824993|Experimental|Calcium + Viatmin D|Calcium 500 mg by mouth everyday for 12 months. Vitamin D 400 units by mouth 2 times a day for 12 months.
89179105|NCT04095312|Experimental|pancreaticobiliary disease|10 pancreaticobiliary disease cases
89179106|NCT04095312|Experimental|Urinary tract disease|13 urinary tract disease cases
89179107|NCT04095312|Experimental|Colon disease|10 colon disease cases
89179108|NCT04093674|Experimental|Clinical evaluation|Clinical periodontal parameters
89179109|NCT04093674|Experimental|Laser Doppler Flowmetry|Laser Doppler Flowmetry evaluation
89179110|NCT04093674|Experimental|Patient centered outcomes|Pain and discomfort/ Esthetics
89179111|NCT04095390|Experimental|Arm A|Hormone receptor positive,HER2 positive participants will receive Pyrotinib in combination with CDK4/6 Inhibitor SHR6390 plus Letrozole until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
89179112|NCT04095390|Experimental|Arm B|Hormone receptor negative,HER2 positive participants will receive Pyrotinib in combination with CDK4/6 Inhibitor SHR6390 plus Capecitabine until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
89179113|NCT04095390|Experimental|Arm C|Hormone receptor negative,HER2 positive participants will receive Pyrotinib in combination with CDK4/6 Inhibitor SHR6390 until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
89179114|NCT02599818|Experimental|NavSTAR|Participants in this arm will receive services from the NavSTAR Patient Navigation team. The Patient Navigator will work with patients for up to 3 months post-hospital discharge to resolve internal barriers (e.g., ambivalence about treatment; low motivation; competing life demands, etc.) and external barriers (e.g., lack of transportation; lack of ID card, etc.) to appropriate utilization and engagement in addiction treatment and medical care. Interventions include motivational interventions and patient navigation with proactive case management, tailored to participants' specific needs.
88839243|NCT02500628|Experimental|Antipsychotic use|Antipsychotic use (subgroups: no side effects, dyskinesia, weight gain) Metformin 500 mg orally in the morning
88839244|NCT02526667|Experimental|Chlorhexidine Gluconate Cloth|2% CHG, single application
89179115|NCT02599818|No Intervention|TAU (Treatment as Usual)|Participants in this arm will receive usual care, which includes in-hospital services from a multidisciplinary substance use disorder consultation liaison team.
88839245|NCT02526667|Placebo Comparator|Vehicle Cloth|Excipients on cloth
89179116|NCT04095468||Resectable rectal cancer|
88839246|NCT02526667|Active Comparator|Active Chlorhexidine gluconate solution|Dynahex 2% CHG
88875191|NCT02515656|Active Comparator|miconazole + placebo|Name : GYNODAKTARIN® Active components : miconazole nitrate 400 mg Dosage : 1 capsule intravaginally per day (administered at bedtime, lying down) 3 vaginal soft capsules followed by 9 placebo vaginal soft capsules
89179117|NCT04095468||Rectal cancer with threatened mesorectal fascia|
89179118|NCT00832091|Active Comparator|1|There are 3 groups of patients with venous stasis (VS) ulcers. Each group included 18 patients receiving active drug and 6 receiving placebo. There were 3 concentrations used for topical administration to the active drug groups: 0.01% weight/weight (w/w), 0.03% w/w, and 0.1% w/w thymosin beta 4 gel applied once daily for up to 84 days
89367160|NCT03243760|Experimental|Cohort C: Single dose CCI15106 30 mg /Placebo|Healthy subjects will receive single dose of either 30 mg CCI15106 (4 capsules of 7.5 mg) or matching placebo by inhalation via Modified Air Inlet Rotahaler™ device according to randomization.
88839247|NCT02535806|Experimental|Treatment Arm|"Velcade will be given IV push on days 1,4,8 and 11 at a dose of 1.3 mg/m2/dose. At least 72 hours must have relapsed between doses.~IT Methotrexate (CNS Negative patients only) on days 1 and 8; age based dosing IT Methotrexate/Hydrocortisone/AraC (CNS positive patients only) on days 1, 8, 15 and 22; age based dosing.~Dexamethasone: Days 1-5 and 15-19; 10mg/m2/dose PO BID. Mitoxantrone: Days 1 and 2; 10mg/m2/dose Vincristine: days 1, 8, 15, and 22 at 1.5 mg/m2 (Maximum dose 2 mg) PEG-asparaginase: Days 3 and 17, 2500 IU/m2/dose"
88839248|NCT02865343|Active Comparator|Non-invasive Ventilation(NIV)|Subjects randomized to NIV will perform 12-weeks of FES-row training while receiving bi-level positive airway pressure ventilation applied through a full face-mask.
88839249|NCT02865343|Placebo Comparator|Sham Non-invasive ventilation(NIV)|Subjects randomized to Sham-NIV will perform 12-weeks of FES-row training while receiving sham ventilation applied through a full face-mask.
88839250|NCT02536040|Experimental|38% diamine silver fluoride|Topical application of 38% diammine silver fluoride to active cavity
88839251|NCT02536040|Placebo Comparator|Water|Topical application of fluoride free water to active cavity
88839252|NCT02536196|Experimental|Intervention|Embolic Protection with transcatheter aortic valve implantation (TAVI)
88839253|NCT02536196|Active Comparator|Control Arm|Transcatheter aortic valve implantation (TAVI) without embolic protection
88839254|NCT02461771|Experimental|Pegcetacoplan Cohort 1|4 mg of pegcetacoplan 100 μL IVT injection
88839255|NCT02461771|Experimental|Pegcetacoplan Cohort 2|10 mg of pegcetacoplan 100 μL IVT injection
88839256|NCT02461771|Experimental|Pegcetacoplan Cohort 3|20 mg of pegcetacoplan 100 μL IVT injection
88839257|NCT02815345|Experimental|Measure of the nasal cavity|"The nasal cavity of all the included neonates will be measured using rhinometry during their hospitalization every weeks. So one to 8 measurement will be performed for each neonates.~Some included neonates will also have rhinomanometry measurements."
88839258|NCT04341649|Active Comparator|Head massage by therapist|Head massage therapist will practice massage covering the scalp, front head, occipital area and neck.
88839259|NCT04341649|Active Comparator|Helmet massage BREO|Breo helmet will be installed for massaging the head at different defined places.
88839260|NCT04341649|Active Comparator|Low Laser Therapy|Laser light can penetrate the skin and stimulate the nervous connections. The investigators will use a laser pen (Min Sheng).
88839261|NCT04341649|Active Comparator|Sham Low Laser Therapy|The investigators will use the same laser pen, but without laser beam.
88839262|NCT04341649|Active Comparator|TENS ear stimulation|The investigators will use the (Hwato) device that provides electrical pulse at various frequency and intensity. This TENS device is a prototype modified for ear stimulation.
88839263|NCT04341649|Active Comparator|Deep and Slow breathing|This intervention is guided by an app that leads to a full respiratory.
88839264|NCT04341649|Sham Comparator|Relaxed Reading time|Participants will read the newspaper in a quiet environment.
88839265|NCT02463799|Experimental|sipuleucel-T and radium 223 combination|"Radium-223 will be administered by intravenous injection over 1 minute at 50kbq (1.35 microcurie) per kg body weight per standard of care every 4 weeks at weeks 0, 4, 8, 12, 16, and 20~Sipuleucel-T will be administered intravenously per standard of care every 2 weeks at weeks 6, 8, and 10"
88839266|NCT02463799|Active Comparator|sipuleucel-T alone|Sipuleucel-T will be administered intravenously per standard of care every 2 weeks at weeks 6, 8, and 10
88839267|NCT02537444|Experimental|Regimen 1|Drug: acalabrutinib monotherapy
88839268|NCT02537444|Experimental|Regimen 2|Drug: Combination of acalabrutinib and pembrolizumab
88839269|NCT02464033|Experimental|A|All patients will from Day 1 receive 2 000 IU vitamin D per os per day during 15 months, and from Days 1-90 receive etanercept (Enbrel) injected subcutaneously 0.8 mg/kg body weight (max 50 mg) once a week, and receive 2 subcutaneous injections of 20 μg Diamyd in a prime-and-boost regimen on Days 30 and 60.
88839270|NCT02432300|Experimental|Intervention|Treatment sessions with a virtual treatment program called Emotion Builder
88839271|NCT02432456|Placebo Comparator|Placebo Infusion|"Subjects in this arm will receive the institutional standard of care for rib fractures along with a placebo (NaCl) infusion.~All patients will undergo Intercostal Nerve Blockade with administration of scheduled medications including acetaminophen, ibuprofen, pantoprazole, and methocarbamol. All subjects will receive adjunct opioids."
88839272|NCT02432456|Experimental|Ketamine Infusion|"Subjects in this arm will receive the institutional standard of care for rib fractures along with a ketamine infusion.~All patients will undergo Intercostal Nerve Blockade with administration of scheduled medications including acetaminophen, ibuprofen, pantoprazole, and methocarbamol. All subjects will receive adjunct opioids."
88839273|NCT02531971|Active Comparator|Fentanyl citrate (36 h), Duragesic (192 h), Mylan (192 h)|Volunteers received a single-dose of 100 µg fentanyl citrate infusion (Study Session I) and blood samples obtained 0-36 h, washout at least one week, then wore a Duragesic® fentanyl TDDS (25 µg/h) for 72 h (Study Session II) and blood samples obtained 0-192 h, washout at least one week, then wore a Mylan fentanyl TDDS (25 µg/h) for 72 h (Study Session III) and blood samples obtained 0-192 h
88839274|NCT02531971|Active Comparator|Fentanyl citrate (36 h), Mylan (192 h), Duragesic (192 h)|Volunteers received a single-dose of 100 µg fentanyl citrate infusion (Study Session I) and blood samples obtained 0-36 h, washout at least one week, then wore a Mylan fentanyl TDDS (25 µg/h) for 72 h (Study Session II) and blood samples obtained 0-192 h, washout at least one week, then wore a Duragesic® fentanyl TDDS (25 µg/h) for 72 h (Study Session III) and blood samples obtained for 0-192 h
88839275|NCT02464657|Experimental|Ph 1 Nivolumab (1mg) + Idarubicin + Cytarabine|"Phase I dose of Nivolumab 1 mg/kg by vein on Day 24 of a 28 day cycle. Phase I and Phase II dose of Idarubicin 12 mg/m2 by vein daily for 3 on Days 1 - 3 of a 28 day cycle.~Phase I and Phase II dose of Cytarabine (Ara-C) 1.5 g/m2 by vein daily on Days 1 - 4 of a 28 day cycle.~Phase I and Phase II dose of Solumedrol 50 mg or Dexamethasone 10 mg by vein daily for 3 - 4 days with Ara-C on Days 1 - 4 of a 28 day cycle."
88839276|NCT02464657|Experimental|Ph 1 Nivolumab (3 mg) + Idarubicin + Cytarabine|"Phase I dose of Nivolumab 3 mg/kg by vein on Day 24 of a 28 day cycle. Phase I and Phase II dose of Idarubicin 12 mg/m2 by vein daily for 3 on Days 1 - 3 of a 28 day cycle.~Phase I and Phase II dose of Cytarabine (Ara-C) 1.5 g/m2 by vein daily on Days 1 - 4 of a 28 day cycle.~Phase I and Phase II dose of Solumedrol 50 mg or Dexamethasone 10 mg by vein daily for 3 - 4 days with Ara-C on Days 1 - 4 of a 28 day cycle."
88839277|NCT02464657|Experimental|Ph 2 Nivolumab (3 mg) + Idarubicin + Cytarabine|"Phase II dose of Nivolumab 3 mg/kg by vein on Day 24 of a 28 day cycle. Phase I and Phase II dose of Idarubicin 12 mg/m2 by vein daily for 3 on Days 1 - 3 of a 28 day cycle.~Phase I and Phase II dose of Cytarabine (Ara-C) 1.5 g/m2 by vein daily on Days 1 - 4 of a 28 day cycle.~Phase I and Phase II dose of Solumedrol 50 mg or Dexamethasone 10 mg by vein daily for 3 - 4 days with Ara-C on Days 1 - 4 of a 28 day cycle."
88839278|NCT02533063|Active Comparator|Combination Treatment|"In the loading + vibration group (intervention group), subjects will be seated in the VibeTech One system and vibratory acceleration will be 30Hz and the applied load will be 50% of body weight up to a device maximum applied load of 100 lbs. Vibration intensity will initially be set to 0.2 g and will increase by 0.2 g every other week, as tolerated by the subject, and max out at 1.0 g."
88839279|NCT02533063|Sham Comparator|Sham Treatment|"In the loading only group (control group) participants will be seated in the vibration device (VibeTech One) and will experience loading of their leg muscles through the device."
88839280|NCT02467075|Active Comparator|Iopamidol 300 (Contrast)|Subjects scheduled for a clinical CT will be randomized to receive weight-based low-osmolality iodinated contrast with the CT. All subjects will receive a minimum of 1 mL/kg/hr of isotonic volume expansion for at least three hours before and three hours after the CT.
88839281|NCT02467075|Placebo Comparator|Placebo (Normal Saline)|Subjects scheduled for a standard of care CT will be randomized to receive weight-based normal saline instead of contrast material with the CT. All subjects will receive a minimum of 1 mL/kg/hr of isotonic volume expansion for at least three hours before and three hours after the CT.
88839282|NCT02533921|Other|Standard of Care|Usual care as in including both a Primary Care Physician (PCP) and neurologist.
88839283|NCT02533921|Active Comparator|Interdisciplinary outpatient palliative care|Usual care augmented by an outpatient interdisciplinary palliative care team.
88839284|NCT02535481|Experimental|Epidermal Graft|The Cellutome Epidermal Graft Harvesting System will be used to harvest epidermal grafts as per existing normal clinical practice.
88839285|NCT02535481|Experimental|Split Thickness Skin Graft|Split thickness skin graft will be harvested using air dermatome as per normal clinical practise.
88839286|NCT00363961|Experimental|1|resistance exercise
88839287|NCT00363961|Sham Comparator|2|flexibility exercises
88839288|NCT02535949|Experimental|Tranexamic Acid 2 Gram|One time dose IV TXA 2 Grams given over 10 minutes within 2 hours of initial injury
88839289|NCT02535949|Experimental|Tranexamic Acid 4 Gram|One time dose IV TXA 4 Grams given over 10 minutes within 2 hours of initial injury
88839290|NCT02535949|Placebo Comparator|Placebo|Matching Volume Normal Saline Placebo given IV over 10 minutes within 2 hours of initial injury
88839291|NCT02536105|Active Comparator|Methylphenidate HCl ER tablets 1|During the open-label optimization phase, one of the methylphenidate hydrochloride extended-release products will be titrated at weekly intervals of 18mg increments until an optimal dose is achieved or a maximum of 72mg per day is reached. During the double-blind phase, participants will receive blinded treatment each week. The dose of each methylphenidate hydrochloride extended-release product will be determined by the optimized dose during the open-label optimization phase
88839292|NCT02536105|Placebo Comparator|Placebo|During the double-blind period, in one of the 4 study weeks, the study participant will take a blinded placebo instead of one of the the 3 active comparators.
88839293|NCT02536105|Active Comparator|Methylphenidate HCl ER tablets 2|During the open-label optimization phase, one of the methylphenidate hydrochloride extended-release products will be titrated at weekly intervals of 18mg increments until an optimal dose is achieved or a maximum of 72mg per day is reached. During the double-blind phase, participants will receive blinded treatment each week. The dose of each methylphenidate hydrochloride extended-release product will be determined by the optimized dose during the open-label optimization phase
88839294|NCT02536105|Active Comparator|Methylphenidate HCl ER for suspension|During the open-label optimization phase, one of the methylphenidate hydrochloride extended-release products will be titrated at weekly intervals of 18mg increments until an optimal dose is achieved or a maximum of 72mg per day is reached. During the double-blind phase, participants will receive blinded treatment each week. The dose of each methylphenidate hydrochloride extended-release product will be determined by the optimized dose during the open-label optimization phase
88839295|NCT02758951|Experimental|Perioperative systemic therapy and CRS-HIPEC|"At the discretion of the treating physician, perioperative systemic therapy consists of either four 3-weekly neoadjuvant and adjuvant cycles of capecitabine with oxaliplatin (CAPOX), six 2-weekly neoadjuvant and adjuvant cycles of 5-fluorouracil/leucovorin with oxaliplatin (FOLFOX), or six 2-weekly neoadjuvant cycles of 5-fluorouracil/leucovorin with irinotecan (FOLFIRI) followed by either four 3-weekly (capecitabine) or six 2-weekly (5-fluorouracil/leucovorin) adjuvant cycles of fluoropyrimidine monotherapy. Bevacizumab is added to the first three (CAPOX) or four (FOLFOX/FOLFIRI) neoadjuvant cycles.~CRS-HIPEC is performed according to the Dutch protocol in all study centres."
88839296|NCT02758951|Active Comparator|Upfront CRS-HIPEC alone|CRS-HIPEC is performed according to the Dutch protocol in all study centres.
88839297|NCT02436668|Active Comparator|Ibrutinib|"Ibrutinib daily in combination with:~Nab-paclitaxel and gemcitabine"
88839298|NCT02436668|Placebo Comparator|Placebo|"Placebo daily in combination with:~Nab-paclitaxel and gemcitabine"
88839299|NCT02503982|Experimental|Solid Organ Transplanted children|Intervention: treatment with prophylactic oral valganciclovir with a fixed dose of 17 mg/kg once daily for prophylaxis, and stratified dose reductions for impaired renal function. Max dose was 900 mg.
89367161|NCT03243760|Experimental|Cohort D: Single dose CCI15106 30 mg /Placebo-BAL|Healthy subjects will receive single dose of either 30 mg CCI15106 (4 capsules of 7.5 mg) or matching placebo by inhalation via Modified Air Inlet Rotahaler™ device according to randomization. BAL procedures will be performed in this cohort additionally.
89367162|NCT03243760|Experimental|Cohort E: Single dose CCI15106 45 mg /Placebo|Healthy subjects will receive single dose of either 45 mg CCI15106 (6 capsules of 7.5 mg) or matching placebo by inhalation via Modified Air Inlet Rotahaler™ device according to randomization.
89367163|NCT03243760|Experimental|Cohort F: Single dose CCI15106 60 mg /Placebo|Healthy subjects will receive single dose of either 60 mg CCI15106 (8 capsules of 7.5 mg) or matching placebo by inhalation via Modified Air Inlet Rotahaler™ device according to randomization.
89367164|NCT03243760|Experimental|Cohort G: CCI15106 7.5 mg /Placebo BID 14 Days|Healthy subjects will receive repeat dose of either 7.5 mg CCI15106 (1 capsule) or matching placebo twice daily (BID) for 14 days by inhalation via Modified Air Inlet Rotahaler™ device according to randomization.
88839300|NCT02438540|Experimental|metformin & acupuncture|Metformin 500 mg (one/two/three times per day), to control their diabetes during the period of this study as previously, and acupuncture treatment including electro body acupuncture and Auricular acupuncture for 30 minutes, 10 times, every other day, for 3 weeks.
88839301|NCT02438540|Placebo Comparator|metformin & placebo|Metformin 500 mg (one/two/three times per day), to control their diabetes during the period of this study as previously, and placebo acupuncture treatment, needling not in right acupoints and EA machine was switched off during 30 minutes of therapeutic time. For ear acupuncture was just used sticky layers without seeds. All placebo treatment used for 30 minutes, 10 times, every other day, for 3 weeks.
88839302|NCT02506634||Participants with upper gastrointestinal symptoms|Participants are stratified at baseline based on their main upper gastrointestinal symptoms and then evaluated for GERD using different methods (i.e., reflux esophagitis on endoscopy or positive acid exposure time (AET) on reflux monitoring). Patients would then be given Esomeprazole MUPS（ Multiple Unit Pellet System）20 mg bid for evaluating the ability of the PPI Test for GERD. According to the guidelines, the duraion of PPI treatment was 4 weeks and 8 weeks for endoscopy negative patients and patients has reflux esophagitis, respectively.
88839303|NCT02506868|Experimental|BCD-066|Patients in this arm will receive weekly subcutaneous injections of BCD-066 (darbepoetin alfa) with dose level titration to maintain target hemoglobin level (100 - 120 g/l) for 52 weeks
88839304|NCT02506868|Active Comparator|Aranesp|Patients in this arm will receive weekly subcutaneous injections of Aranesp (darbepoetin alfa) with dose level titration to maintain target hemoglobin level (100 - 120 g/l) for 52 weeks
88839305|NCT02541422|Active Comparator|NAC group|Patients receiving NAC after drinking to breathalyzer value 0.1
88839306|NCT02541422|Placebo Comparator|Placebo group|Patients receiving placebo after drinking to breathalyzer value 0.1
88839307|NCT02541812|Experimental|Patients|Ten sessions of 1Hz repetitive Transcranial Magnetic Stimulation of the dorsal anterior cingulate cortex in patients with obsessive compulsive disorder
88839308|NCT02541812|Active Comparator|Healthy Control Subjects|One session of 1Hz repetitive Transcranial Magnetic Stimulation of the dorsal anterior cingulate cortex in healthy control individuals
88839309|NCT02542046||Barium|Patients who received barium sulfate oral contrast for abdominopelvic CT
88839310|NCT02542046||diatrizoate|Patients who received diatrizoate oral contrast for abdominopelvic CT
89179119|NCT00832091|Placebo Comparator|2|There were 3 groups of patients with venous stasis (VS) ulcers. Each group included 18 patients receiving active drug and 6 receiving placebo. There was one concentration of placebo gel for topical administration to the placebo group. The concentration was 0.0% weight/weight (w/w) thymosin beta 4 gel applied once daily for up to 84 days
88839311|NCT02542046||iohexol|Patients who received iohexol oral contrast for abdominopelvic CT
88839312|NCT02439164|Experimental|Glioma group|Patients in this group will be administered sedatives (midazolam or propofol or dexmedetomidine) titrating to mild sedation.
88839313|NCT02439164|Active Comparator|non-neurosurgical group|patients in this group will be administered the same sedative midazolam as compared glioma group, and titrate to mild sedation.
88839314|NCT02542280|Experimental|endometrial injury|Endometrial injury during ovarian stimulation combined with intrauterine insemination.
89179120|NCT00708149|Active Comparator|1|lansprazole 30 mg qd from NG route or orally
89179121|NCT00708149|Placebo Comparator|2|control group without any PPI, H2 blockers or other medications for treating peptic ulcers.
89534700|NCT05464589|Experimental|Transcutaneous Tibial Nerve Stimulation + Pelvic Floor Muscle Strengthening|"Pelvic floor muscle strengthening through Kegel exercises along with the transcutaneous tibial nerve stimulation.~Pelvic Floor Muscle-strengthening exercises - Kegels' exercises 15 repetitions, 3 times a day For 6 weeks, daily.~Transcutaneous Tibial Nerve Stimulation for 30 minutes on the right lower limb 6 sessions, one per week."
89534701|NCT05464589|Active Comparator|Pelvic Floor Muscle Strengthening|"Pelvic floor muscle strengthening through Kegel exercises.~Pelvic floor muscle exercises - Kegels; exercises 15 repetitions, 3 times a day For 6 weeks, daily."
88839315|NCT02542280|Active Comparator|no endometrial injury|Ovarian stimulation combined with intrauterine insemination.
88839316|NCT04341272|Active Comparator|Upper Extremity Compression Device|Patients randomized to have pneumatic compression device placed on upper extremity following surgery
88839317|NCT04341272|Other|Control|Patients randomized to have pneumatic compression device placed on lower extremity following surgery
88839318|NCT02440022|Experimental|Lutonix DCB|Percutaneous transluminal angiography (PTA) will be performed using the Lutonix AV drug coated balloon.
88839319|NCT02440022|Active Comparator|Standard Balloon Angioplasty Catheter|Percutaneous transluminal angiography (PTA) will be performed using a commercially available uncoated PTA balloon. Balloons with an external wire support, cutting/scoring component or other similar modifications are not permitted. Multiple balloons, inflations and/or prolonged inflation may be used.
88839320|NCT02440178|Experimental|micafungin prophylaxis|Patients received 50 mg micafungin intravenously once daily from the initiation of induction chemotherapy to recovery of neutrophil count (absolute neutrophil count > 500/μg for three consecutive days), suspected fungal infection, or occurrence of drug-related toxicity.
88839321|NCT02543840|Experimental|Implementation Facilitation|Implementation Facilitation consists of the Center for Disease Control's Replicating Effective Programs, plus External Facilitation. The intervention lasts 6 months followed by a 6-month step-down period.
88839322|NCT02543840|Placebo Comparator|Educational Materials|Dissemination of available materials explaining the Collaborative Chronic Care Model and implementation tools. Sites randomized to delay initiation of facilitation will have these materials plus technical assistance for 4 or 8 months prior to full implementation facilitation.
88875192|NCT02515890|Experimental|Dexmedetomidine Only|All subjects receive saline (control), followed by a dexmedetomidine infusion. They also experience intermittent experimental pain delivered by peripheral nerve stimulation.
89179122|NCT00916734|Experimental|Spinal Manipulation Group|Subjects who received spinal thrust manipulation as an intervention.
89179123|NCT00916734|Active Comparator|McKenzie MDT Group|
88839323|NCT02546570|Experimental|Healthy adult controls (18-55)|Drug: oxytocin and placebo nasal spray (within-subjects design, blinded and counterbalanced for two lab sessions); dosage=24 international units (IU). Participant inserts nasal spray container 1cm into nostril at angle of 45 degrees and sprays. Will wait 15 seconds then repeat administration to other nostril (alternating between nostrils). Participants will receive 6 puffs in total (3 in each nostril).
88839324|NCT02546570|Experimental|Adults with PTSD (18-55)|Drug: oxytocin and placebo nasal spray (within-subjects design, blinded and counterbalanced for two lab sessions); dosage=24 international units (IU). Participant inserts nasal spray container 1cm into nostril at angle of 45 degrees and sprays. Will wait 15 seconds then repeat administration to other nostril (alternating between nostrils). Participants will receive 6 puffs in total (3 in each nostril).
88839325|NCT02546570|Experimental|Trauma-exposed/no-PTSD adults (18-55)|Drug: oxytocin and placebo nasal spray (within-subjects design, blinded and counterbalanced for two lab sessions); dosage=24 international units (IU). Participant inserts nasal spray container 1cm into nostril at angle of 45 degrees and sprays. Will wait 15 seconds then repeat administration to other nostril (alternating between nostrils). Participants will receive 6 puffs in total (3 in each nostril).
88839326|NCT02743351|Experimental|ProTmune|"Conditioning regimen consisting of one of the following five preparative regimens: fludarabine and busulfan (FluBu4); busulfan (Bu) and cyclophosphamide (Cy); Cy and >or=12 Gy total body irradiation (TBI); TBI and etoposide; or fludarabine and melphalan (FluMel 140).~Subjects will receive mPB cells from an available 8/8 HLA-A, -B, -C, and -DRB1-matched unrelated peripheral blood cell donor that were programmed ex vivo with ProTmune."
88839327|NCT02743351|Active Comparator|Control Arm|"Conditioning regimen consisting of one of the following five preparative regimens: fludarabine and busulfan (FluBu4); busulfan (Bu) and cyclophosphamide (Cy); Cy and >or=12 Gy total body irradiation (TBI); TBI and etoposide; or fludarabine and melphalan (FluMel 140).~Subjects will receive unmanipulated mPB cells from an available 8/8 HLA-A, -B, -C, and -DRB1-matched unrelated peripheral blood cell donor."
88839328|NCT02548910|Experimental|Phlebotomy|For patients randomized to phlebotomy, the intervention will consist of the standard of care (low CVP surgery), plus whole blood phlebotomy. Blood will be collected in citrated whole blood collection bag.
88839329|NCT02548910|No Intervention|Control|Standard of care (low CVP surgery). In this arm, standard anesthesia will be maintained.
88839330|NCT02538523|Active Comparator|Erchonia FX-635|The Erchonia FX-635 is made up of 3 independent 17 milliWatts (mW), 635 nanometer (nm) red laser diodes mounted in scanner devices with flexible arms positioned equidistant from each other.
88839331|NCT02538523|Placebo Comparator|Placebo Laser|The Placebo Laser has the same appearance as the Erchonia FX-635 but does not emit any therapeutic light.
88839332|NCT02510144|Active Comparator|Chlorhexidine|A preoperative Chlorhexidine gluconate solution 4.0% (i.e Hibiclens)
88839333|NCT02510144|Experimental|Benzoyl Peroxide|A preoperative 5% benzoyl peroxide wash prep (i.e. Brevoxyl-4 and Brevoxyl-8)
88839334|NCT02538679|Placebo Comparator|PLACEBO|No TAP block performed
88839335|NCT02538679|Experimental|US TAP Bupivacaine/Epinephrine|Ultrasound guided bupivacaine 0.25% with epinephrine 1:400k will be injected to the transversus abdominis plane.
88839336|NCT02538679|Experimental|Lap TAP Bupivacaine/Epinephrine|Laparoscopic guided bupivacaine 0.25% with epinephrine 1:400k will be injected to the transversus abdominis plane.
88839337|NCT02511236|Experimental|Group Cognitive Behavioral Therapy|Participants may receive 8 group cognitive behavioral therapy (CBT) sessions and eight weeks of transdermal nicotine patches (TNP) [21mg (4 weeks), 14mg (2 weeks), and 7mg (2 weeks)].
88839338|NCT02511236|Active Comparator|General Health Education|Participants may receive group general health education (GHE) sessions and eight weeks of transdermal nicotine patches (TNP) [21mg (4 weeks), 14mg (2 weeks), and 7mg (2 weeks)].
88839339|NCT02467387|Experimental|Experimental: Human (aMBMC)|Intervention: One time intravenous infusion of 1.5 million (aMBMC) per kg administered at approximately 2mL/min. Maximum dose as for 100kg subject or 150 million cells for any subject 100kg or more.
88839340|NCT02467387|Placebo Comparator|Placebo:Lactated Ringer's Solution (LRS)|Intervention: One time intravenous infusion of 1.5mL/kg Lactated Ringer's Solution (LRS) administered at a constant rate of approximately 2mL/min.
88839341|NCT05073068|Experimental|AM exercise|
88839342|NCT05073068|Experimental|PM exercise|
88839343|NCT05073068|Active Comparator|Control|
88839344|NCT02974478|Experimental|Orange juice with meals|Effect of orange juice consumption with three meals per day (without snacking) on glucose metabolism and antioxidative status
88839345|NCT02974478|Experimental|Orange juice between meals|Effect of orange juice consumption between three meals per day (without snacking) on glucose metabolism and antioxidative status
88839346|NCT02974478|Experimental|Sugar sweetened beverage between meals|Effect of sugar sweetened beverage consumption between three meals per day (without snacking) on glucose metabolism and antioxidative status
88839347|NCT02512874|Other|Pulmonary Rehabilitation|One arm study - all participants will go to pulmonary rehabilitation, received questionnaires, Dual-energy X-ray absorptiometry (DEXA) scans, Dynamometer and gait speed tests and activity measured through an activity monitor.
88839348|NCT02721979|Experimental|Treatment (apalutamide)|Patients receive apalutamide PO QD for 90 days in the absence of disease progression or unacceptable toxicity.
88839349|NCT02551094|Active Comparator|colchicine|0.5 mg tablet of colchicine taken once a day
88839350|NCT02551094|Placebo Comparator|colchicine placebo|0.5 mg tablet of placebo taken once a day
89367165|NCT03243760|Experimental|Cohort H: CCI15106 15 mg /Placebo BID 14 Days|Healthy subjects will receive repeat dose of either 15 mg CCI15106 (2 capsules of 7.5 mg) or matching placebo BID for 14 days by inhalation via Modified Air Inlet Rotahaler™ device according to randomization.
89367166|NCT03243760|Experimental|Cohort I: CCI15106 30 mg /Placebo BID 14 Days-BAL|Healthy subjects will receive repeat dose of either 30 mg CCI15106 (4 capsules of 7.5 mg) or matching placebo BID for 14 days by inhalation via Modified Air Inlet Rotahaler™ device according to randomization. BAL procedures will be performed in this cohort additionally.
89367167|NCT03243760|Experimental|Cohort J: CCI15106 =<30 mg /Placebo BID 14 Days|Healthy subjects will receive repeat dose of either =< 30 mg CCI15106 (less than or equal to 4 capsules of 7.5 mg) or matching placebo BID for 14 days by inhalation via Modified Air Inlet Rotahaler™ device according to randomization. The dose for cohort J is unknown at this time and will depend on results seen in the previous cohorts.
89367168|NCT03243760|Experimental|Cohort K: Single dose CCI15106 30 mg /Placebo-COPD|COPD patients will receive single dose of either 30 mg CCI15106 (4 capsules of 7.5 mg) or matching placebo by inhalation via Modified Air Inlet Rotahaler™ device according to randomization.
89367169|NCT02454400|Other|Pre-surgery physiotherapy|Twice a week, in 9 weeks
89367170|NCT02454400|Other|Waiting-list|Standard information by the orthopedic surgeon
88839351|NCT02513498|Experimental|Treatment (ixazomib citrate)|Patients receive ixazomib citrate PO once weekly on days 1, 8, and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with complete response, partial response, or stable disease may receive an additional 6 courses of ixazomib citrate.
88839352|NCT04787354|Active Comparator|Control arm|"Standard adjuvant XELOX 8 cycles~Oxaliplatin: 130 mg/m2/day(day 1) Capecitabine: 2,000 mg/m2/day(day 1-14), q 3weeks, total 8 cycles"
89367171|NCT03753087|Experimental|Empagliflozin|Patients will receive standard care for Heart Failure and Diabetes Mellitus + Empagliflozin 10mg once daily
89367172|NCT03753087|Active Comparator|Control|Patients will receive standard care for Heart Failure and Diabetes Mellitus with no SGLT-2 inhibitors
89367173|NCT02454712|Experimental|PF614|PF614 is the drug under evaluation. Doses may range from 15 mg to 640 mg. N=6 subjects per cohort. For Cohort 7, N=16 subjects in crossover study ± naltrexone.
88839353|NCT04787354|Experimental|Study arm|"Adjuvant XELOX 4 cycles followed by capecitabine monotherapy 4 cycles~Oxaliplatin: 130 mg/m2/day(day 1) Capecitabine: 2,000 mg/m2/day(day 1-14), q 3weeks, 4 cycles~followed by~Capecitabine: 2,000 mg/m2/day(day 1-14), q 3weeks, 4 cycles"
89367174|NCT02454712|Active Comparator|Oxycodone extended-release (OxyContin)|Initial dose (Cohort 1) will be 10 mg. Subsequent doses will be 10, 20, 40, or 80 mg. N=2 subjects per cohort. Active comparator will not be used in Cohort 7.
89367175|NCT03249064||Vitiligo untreated patients|
88839354|NCT02514044|Experimental|Dexedrine+sham tDCS+speech therapy|10 mg Dexedrine and speech therapy for 10 days
88839355|NCT02514044|Experimental|active tDCS+placebo+speech therapy|1.5 mA anodal tDCS and speech therapy for 10 days
89367176|NCT03249064||Control. Patients without vitiligo|
89367177|NCT00832455|Experimental|Montelukast|
88839356|NCT02514044|Experimental|Dexedrine+tDCS+speech therapy|10 mg Dexedrine, 1.5 mA anodal tDCS, and speech therapy for 10 days
88839357|NCT02514044|Experimental|sham stimulation+placebo+speech therapy|Sham stimulation, placebo and speech therapy for 10 days
88839358|NCT02514044|Experimental|Dexedrine+tDCS+Speech Therapy|10 mg Dexedrine, 1.5 mA anodal tDCS, and speech therapy for 1 day
88839359|NCT02514044|Experimental|placebo+tDCS+Speech Therapy|1.5 mA anodal tDCS, and speech therapy for 1 day
89367178|NCT01350765|Experimental|Intervention|This would be the interventional arm of the study, where the LHWs would receive additional training for identification and management of birth asphyxia, lbw, and sepsis.
89367179|NCT01350765|Active Comparator|Control|This would be the comparative group of the study in which the LHWs would perform the usual routine tasks assigned to them by their program.
89367180|NCT01350843|Experimental|Orange Juice|Juice high in flavonoids
89367181|NCT01350843|Placebo Comparator|Orange Drink|Sugars matched, low flavonoids orange drink
89367182|NCT03248752|Active Comparator|Group 1 - Self monitored|Fitbit use and reports details: Participants will receive a Fitbit device to wear for 3 months. They will engage with the Fitbit application on their smartphone or tablet device and receive a Weekly Progress Report from Fitbit.
89367183|NCT03248752|Experimental|Group 2 - Partner monitored|Fitbit use and reports details: Participant will receive a Fitbit device to wear for 3 months. They will engage with the Fitbit application on their smartphone or tablet device. Participant will also engage with their partner through the Fitbit application. They will have access to their partner's daily progress and be able to communicate through the application. They will also receive their partner's Weekly Fitbit Reports and have a weekly discussion about the Weekly Fitbit Report.
89367184|NCT00687531|Experimental|Mometasone Furoate|Mometasone Furoate 400 mcg once daily in the evening through 12 weeks.
89367185|NCT01347411|No Intervention|Control|Usual treatment
89367186|NCT01347411|Experimental|CPAP|Treatment with CPAP
89367187|NCT03243526|Placebo Comparator|Central venous pressure group|fluid therapy to maintain CVP not 5 cmH2o
89367188|NCT03243526|Experimental|Pulse pressure variation|fluid therapy will be guided by PPV to be less than 14%
89367189|NCT04487002|Experimental|group A|underwent localized resection
89367190|NCT03248518|Active Comparator|Usual Care alone|Participants receive written information about fatigue which is designed as self-management guide.
89367191|NCT03248518|Active Comparator|CBA + usual care|In addition to usual care, participants receive a talking therapy using a cognitive behavioural approach. The talking therapy will be delivered via telephone by a trained rheumatology health care professional who will contact the participant for 8 sessions over a period of 6 months.
89367192|NCT03248518|Active Comparator|PEP + usual care|In addition to usual care, participants receive a personalised exercise programme. After an initial face-to-face assessment, the remaining programme will be delivered via telephone by a trained rheumatology health care professional who will contact the participant for 7 sessions over a period of 6 months.
89367193|NCT00423579|Experimental|Ezetimibe/Simvastatin 10/20 mg + Simvastatin placebo|Subjects will receive 2 tablets. The first tablet is Ezetimibe/Simvastatin 10/20 mg. The second tablet is simvastatin placebo. Subjects will receive a maximum of 6 weeks of treatment
89367194|NCT00423579|Active Comparator|Ezetimibe/Simvastatin placebo + Simvastatin 40 mg|Subjects will receive 2 tablets. The first tablet is Ezetimibe/Simvastatin placebo. The second tablet is simvastatin 40 mg. Subjects will receive a maximum of 6 weeks of treatment.
89367195|NCT03243682|Active Comparator|Bidirectional Shock Wave Lithotripsy|alternating bidirectional (under and over table) approach
89367196|NCT03243682|Active Comparator|Standard Shock Wave Lithotripsy|standard unidirectional approach
89534702|NCT03094221||Arrhythmia Mapping|The study sample includes patients referred for three different types of cardiac arrhythmias, which will be the studied categories: 1) atrial flutter/fibrillation, 2) atrial tachycardia, 3) ventricular tachycardia. Patients will undergo standard of care mapping and ablation procedures.
88839360|NCT02515058|Experimental|PUROS (Non-Freeze-Dried bone allograft)|Ridge preservation bone grafting surgery with Non-Freeze-Dried cancellous bone allograft (PUROS)
88839361|NCT02515058|Active Comparator|FDBA (Freeze-Dried bone allograft)|Ridge preservation bone grafting surgery with Freeze-Dried cancellous bone allograft (FDBA)
88839362|NCT02552810|Active Comparator|Plasma of Argon|Abutment cleaning by plasma of Argon protocol .
88839363|NCT02552810|Active Comparator|Steam clean|Abutment cleaning by steam clean device.
88839364|NCT02553746|Experimental|Ultrasound|
88839365|NCT02553746|Active Comparator|Landmarks|
88839366|NCT02554760|Experimental|All Study Participants|This is a split body study in which all subjects will receive bilateral flank treatment with CoolSculpting. The investigator will determine one flank for treatment using the CoolCore applicator without an accessory for a duration of 60 minutes at a protocol-defined temperature. The contralateral flank will be treated with the standard CoolCore Applicator using an applicator accessory, the Crown Cooling Insert (CCI) at a protocol-defined temperature for a duration of up to 45 minutes. All enrolled subjects receive identical treatments; the investigator will use alternate subject numbers to balance which flank to treat with and without the CoolCore applicator accessory, such that all even subject numbers will receive treatment using the Standard CoolCore on the right flank and odd subject numbers will receive the same treatment on the left flank.
88839367|NCT02555228|Experimental|Simethicone premedication|Liquid simethicone (1ml volume) in 5mls of water
88839368|NCT02555228|Placebo Comparator|Placebo|Just 5 mls of water
88839369|NCT04654130|Experimental|Neurofeedback (NFB)|Participants in the NFB condition will complete 19 weekly sessions of NFB from home with research staff supervision (via videoconferencing), and pre-, post- and 3-month follow-up assessments.
88839370|NCT04654130|No Intervention|Wait List|Participants in the Wait List condition will receive no NFB for approximately 31 weeks, and will be asked to complete pre-, post- and 3-month follow-up assessments. After study completion, they will be offered the same 19 weeks of NFB.
88839371|NCT02555306|Experimental|Low Dose DE-122|Single intravitreal injection of DE-122 Low Dose Injectable Solution
88839372|NCT02555306|Experimental|Medium-Low Dose DE-122|Single intravitreal injection of DE-122 Medium-Low Dose Injectable Solution
88839373|NCT02555306|Experimental|Medium-High Dose DE-122|Single intravitreal injection of DE-122 Medium-High Dose Injectable Solution
88839374|NCT02555306|Experimental|High Dose DE-122|Single intravitreal injection of DE-122 High Dose Injectable Solution
88839375|NCT02556554|No Intervention|Routine Care|Standard of Care in the Pregnancy and Women's Health clinic.
88839376|NCT02556554|Active Comparator|Dexcom G4 Platinum CGM system|An intervention arm using the Dexcom G4 or G5 Platinum® CGM system during pregnancy.
88839377|NCT02556554|Active Comparator|Dexcom G4 Platinum CGM system with Share™|A treatment arm using the Dexcom G4 or G5 Platinum® CGM system with Share™ remote monitoring capabilities during pregnancy.
88839378|NCT02556788|Experimental|CD5789 (Trifarotene) 50µg/g Cream|CD5789 (trifarotene) 50µg/g Cream
88839379|NCT02556788|Placebo Comparator|Placebo Cream|Placebo Cream
88839380|NCT02516150|Experimental|Glucagon with Ethanol|Volunteers will receive an infusion of IV ethanol that will increase their BAC (blood alcohol content) to 0.1. Once their BAC has stabilized at 0.1%, 50 micrograms of glucagon will be administered via subcutaneous injection.
88839381|NCT02516150|Active Comparator|Glucagon without Ethanol|Volunteers will not receive an infusion of IV ethanol at this visit. 50 micrograms of glucagon will be administered via subcutaneous injection.
88839382|NCT04025060|Experimental|Caffeine-free Soda|Consumption of caffeine-free soda daily for two weeks
89367197|NCT04533945|Other|FreeStyle Libre Device|Inpatients admitted to the medical-surgical units that are eligible for the trial will have the FreeStyle Libre device will be placed by the inpatient diabetes team at the discharge and glucose log will be obtained in 2 weeks followed by Hba1c in 3 months.
89367198|NCT03248362|Experimental|TPTNS Intervention|Transcutaneous posterior tibial nerve stimulation (TPTNS) delivered in 30 minute sessions twice weekly over a 6 week period. The tibial nerve, which lies immediately posterior to the medial malleolus will be stimulated electrically using a portable TENS machine and two surface electrodes. The cathode electrode will be positioned behind the medial malleolus and the anode 10cm cephalad to it. Standardised stimulation parameters will be applied at 10 Hz frequency, 200µs-1 pulse width in continuous mode and stimulation intensity (mA-1) will be adjusted on a session-by-session basis according to individual resident comfort levels.
88839383|NCT04025060|Experimental|Carbonated Water|Consumption of unsweetened, carbonated water daily for two weeks
88839384|NCT04025060|Active Comparator|Regular Soda|Consumption of regular soda daily for two weeks
89367199|NCT03248362|Sham Comparator|Sham stimulation|Sham stimulation comprises low intensity, sub-clinical stimulation of the lateral sub-malleolar area, positioned specifically on the lateral aspect to avoid the tibial nerve, which runs close to the skin surface behind the medial malleolus. The stimulation parameters are identical to the TPTNS stimulation other than the intensity of the current which will be set at 4mA, rather than adjusted individually as it is in the TPTNS intervention group. The current will be initially increased until the resident reports feeling some sensation following which the current will be reduced down to 4mA. All residents will be informed that they may not feel anything with this intervention and that this is quite normal.
88839385|NCT04002908||In-facility Observations|Mothers and their LBW babies will be observed starting within 6 hours of birth until the baby is discharged from the health facility.
88839386|NCT04002908||Prospective cohort study - Quantitative|Mothers and their low-birth weight babies will be enrolled 72 hours after birth and followed through 12 months postpartum. The prospective cohort survey (which includes anthropometric measurements and feeding observations) occurs at multiple time points over this 12-month period.
88839387|NCT04002908||Prospective cohort study - Qualitative|"Research specialists at each site will be speaking to key informants (includes doctors, nurses, midwives, community health workers (CHWs), Ministry of Health (MOH) officials, supply chain & milk bank experts) who are knowledgeable about breastfeeding policy, supply chain, or milk banks. Clinicians in study health facilities who work on labor and delivery, postnatal, newborn and neonatal ICU wards. They participate in In-depth interviews. Mothers, family members and health care workers of LBW babies, as well as community leaders (including religious leaders) who are knowledgeable about infant feeding in their communities will participate in focus group discussions. Focus group discussion will take up to 2 hours. In-depth interviews will take up to 1 hour.~Mothers (6-month extension): Mothers chosen and consented for IDIs will include those currently enrolled in the prospective cohort. Additionally, their infants need to be between 9 and 12 months of age."
88839388|NCT04002908||Retrospective Chart review|The retrospective chart review is a review of secondary data of mothers and their LBW babies who were born in the study health facilities prior to the start of the study.
88839389|NCT04002908||Donor Human Milk Readiness Assessment|"Key stakeholders in the area of newborn health who determine policy and procedures or who are directly involved with the provision of care. This includes clinicians, nurses, lactation/nutrition specialists, hospital leadership and/or Ministry of Health officials present in the study health facilities.~This is a one-time data collection exercise in the form of either: (1) a largely qualitative facility readiness assessment tool with some qualitative questions for facility staff or (2) a facility tool observing the flow of milk along with key informant interviews in the study facilities. This could take anywhere from 1hr to a day depending on the tool administered, key informants involved and size of the study facility."
88839390|NCT04542434|Experimental|Niclosamide|
88839391|NCT04542434|Placebo Comparator|Placebo|
88839392|NCT02557178|Experimental|Activity Monitor plus Health Coaching|Device: Actigraph Participants will wear the device daily during weeks 1, 9, and 17. Daily steps and activity will be measured. It will identify if they complete a prescribed exercise regimen. Participants in the intervention condition (wearing the Actigraph) will also receive supportive health coaching to encourage them to exercise.
88839393|NCT02557178|No Intervention|Control|Device: Actigraph Participants will wear the device daily during weeks 1, 9, and 17. Daily steps and activity will be measured. It will identify if they complete a prescribed exercise regimen.
88839394|NCT04415528|Experimental|Intervention group|The intervention group will begin receiving the group intervention within one - two weeks of Time 1 assessment. This group will receive Time 2 assessments at the end of the group delivery. Time 3 assessments will be administered eight weeks after the completion of group delivery.
88839395|NCT04415528|Active Comparator|Wait listed control group|The wait listed control group will be assessed at Time 1, eight weeks before receiving the intervention. This group will receive Time 2 assessments at the beginning of their group delivery. This group will complete Time 3 assessments eight weeks after the completion of group delivery.
88839396|NCT03943628|Experimental|Familias Unidas|Consists of eight parent group sessions and four family sessions with the adolescent.
88839397|NCT03943628|Other|Community Practice|Consists of community practice.
88839398|NCT04186286|Active Comparator|1st drug Ivabradine|Patients will take Ivabradine first followed by Propranolol and Placebo
88839399|NCT04186286|Active Comparator|2nd drug Ivabradine|Patients will take either Propranolol or placebo first and then Ivabradine
88839400|NCT04186286|Active Comparator|3rd drug Ivabradine|Patients will take Propranolol and placebo first and then Ivabradine
88839401|NCT02560922|Experimental|Pain Coping Skills Training|This group will take part in an 11-week pain coping skills training (CST) intervention.
88839402|NCT02560922|No Intervention|Wait list Control|The other group will be the wait list group and will receive the pain CST program after completing all follow-up study measures.
88839403|NCT04341038|Experimental|Intervention|"Methylprednisolone pulses 120mg/day for 3 consecutive days (if they were not previously administered) with Tacrolimus at the necessary dose to achieve plasma levels of 8-10 ng/ml.~In addition, these patients can receive all the treatments considered necessary for their clinical management."
89367200|NCT01351155|Active Comparator|polyurethane foam (Allewyn adesive)|Polyurethane foam is applied as skin protective dressing device before NIV and kept on site till the 7th day of treatment Intervention: active prophilactic barrier against skin breakdown
88839404|NCT04341038|No Intervention|Usual care|These patients can receive all the treatments considered necessary for their clinical management, except cyclosporine and tacrolimus.
88839405|NCT04743050|Active Comparator|Control Group|The control group will be a group without EFA supplementation.
88839406|NCT04743050|Experimental|1st Experimental Group|The first experimental group will receive supplementation with pure ALA fraction of EFA esters. 5 ml a day of OmegaRegen Original containing 2.9 g of ALA, 0.9 g of oleic acid and 0.8 g of linoleic acid for six months.
88839407|NCT04743050|Experimental|2nd Experimental Group|The second test group will receive supplementation of the EPA and DHA fraction of EFA esters. 5 ml a day of OmegaRegen EPA+DHA containing 0.032 g of EPA, 0.192 g of DHA, 0.9 g of oleic acid and 0.8 g of linoleic acid for six months.
89534703|NCT03328793|Experimental|Music Intervention (Intervention Group)|"The patients will assist to a live music session of 30 minutes which will be given by musicians (volunteers) and will undergo:~mood assessment~emotion assessment~mobility assessment~communication assessment"
88839408|NCT04743050|Experimental|3rd Experimental Group|The second test group will receive supplementation of the EPA and DHA fraction of EFA esters. 5 ml a day of OmegaRegen MAMA containing 2.9 g of ALA, 0.032 g of EPA, 0.192 g of DHA, 0.9 g of oleic acid and 0.8 g of linoleic acid for six months.
89367201|NCT01351155|Active Comparator|polyurethane film (Tegaderm)|The polyurethane film is applied ss skin protective dressing device before NIV and kept on site till the 7th day of treatment Intervention: active prophilactic barrier against skin breakdown
89367202|NCT01351155|Active Comparator|Hydrocolloid (Duoderm)|Hydrocolloid is applied ss skin protective dressing device before NIV and kept on site till the 7th day of treatment Intervention: active prophilactic barrier against skin breakdown
89367203|NCT01351155|No Intervention|Control|In this no-intervention arm, any skin protective dressing devices is applied before NIV starting
88839409|NCT02561702|Experimental|Mexiletine first/placebo second|Participants will receive 150 mg of mexiletine by mouth 3 times daily for 5-7 days followed by 7 day washout period and 5-7 days of placebo (240 mg of lactose powder) taken by mouth 3 times daily
88839410|NCT02561702|Experimental|placebo first/mexiletine second|Participants will receive placebo (240 mg of lactose powder) taken by mouth 3 times daily for 5-7 days followed by 7 day washout period and 5-7 days of 150 mg of mexiletine by mouth 3 times daily
88839411|NCT02563496|Experimental|Tafenoquine 50 mg|Subjects with weight band of >=5 to <=10 kilogram (kg) will receive 50 mg tafenoquine on Day 1. Subject may receive CQ per local/national guidelines.
88839412|NCT02563496|Experimental|Tafenoquine 100 mg|Subjects with weight band of >10 to <=20 kg will receive 100 mg tafenoquine on Day 1. Subject may receive CQ per local/national guidelines.
88839413|NCT02563496|Experimental|Tafenoquine 150 mg|Subjects with weight band of >10 to <=20 kg will receive 150 mg tafenoquine on Day 1. Subject may receive CQ per local/national guidelines.
88839414|NCT02563496|Experimental|Tafenoquine 200 mg|Subjects with weight band of >20 to <=35 kg will receive 200 mg tafenoquine on Day 1. Subject may receive CQ per local/national guidelines.
88839415|NCT02563496|Experimental|Tafenoquine 300 mg|Subjects with weight band of >35 kg will receive 300 mg tafenoquine on Day 1. Subject may receive CQ per local/national guidelines.
88839416|NCT02563808|Active Comparator|Standard Decision Aid|The brochure with standard information on surgery for early-stage breast cancer
88839417|NCT02563808|Experimental|Post-surgical Regret Decision Aid|The brochure that incorporates additional information on the rates of regret after surgical treatment of early-stage breast cancer.
88839418|NCT02540161|Experimental|non-bevacizumab failures - 18 mg/kg|Non-bevacizumab failure (either no prior bevacizumab or bevacizumab stable/responder, which is defined as stable for at least 6 months from prior treatment with bevacizumab without experiencing a bevacizumab adverse event of special interest (AESI) while on a bevacizumab-containing regimen) will receive Sym004 intravenously every two weeks.
88839419|NCT02540161|Experimental|bevacizumab failures - 18 mg/kg|Prior progression on a bevacizumab-containing regimen (defined as having progressed/grown through bevacizumab by RANO criteria within 2 months of prior bevacizumab treatment) will receive Sym004 intravenously every two weeks.
88839420|NCT02540161|Experimental|non-bevacizumab failures - 24 mg/kg|Non-bevacizumab failure (either no prior bevacizumab or bevacizumab stable/responder, which is defined as stable for at least 6 months from prior treatment with bevacizumab without experiencing a bevacizumab adverse event of special interest (AESI) while on a bevacizumab-containing regimen) will receive Sym004 intravenously every two weeks.
88839421|NCT02540161|Experimental|bevacizumab failures - 24 mg/kg|Prior progression on a bevacizumab-containing regimen (defined as having progressed/grown through bevacizumab by RANO criteria within 2 months of prior bevacizumab treatment) will receive Sym004 intravenously every two weeks.
88839422|NCT02467465|Experimental|Physical therapy modalities|Manual therapy techniques aimed to relaxed gastrocnemius and soleus muscles tone, movilizations, stretching and home exercises.
88839423|NCT02467465|Experimental|Invasive Physical therapy modalities|Manual therapy techniques aimed to relaxed gastrocnemius and soleus muscles tone, movilizations, stretching and home exercises. Previously, DN will be applied in gastrocnemius and soleus muscles.
89367204|NCT02454556|Experimental|FOLITIME®|Therapy will be initiated in the early follicular phase (cycle day 2 or 3) subcutaneously at a dose of 225 IU per day, until sufficient follicular development is attained.
89367205|NCT02454556|Active Comparator|Gonal-F®|Therapy will be initiated in the early follicular phase (cycle day 2 or 3) subcutaneously at a dose of 225 IU per day, until sufficient follicular development is attained.
89367206|NCT01352481|Experimental|Intervention group|
89367207|NCT01352481|No Intervention|Control group|
89367208|NCT03248050|Experimental|Intervention pharmacy|Pharmacies in the intervention group will receive training, materials, and monitoring visits to encourage them to inform women who buy mifepristone + misoprostol or misoprostol alone to call the MSZ call centre for advice on how to use the pills before they take them.
89367209|NCT03248050|No Intervention|Control pharmacy|
89534704|NCT03328793|Active Comparator|Documentary watching (Control Group)|"The patients will watch a documentary for 30 minutes in the presence of a volunteer and will undergo:~mood assessment~emotion assessment~mobility assessment~communication assessment"
89367210|NCT01352559|Experimental|responders|50 ≤ Decrease rate(%) of HAM-D score
89367211|NCT01352559|Active Comparator|non-responders|nonresponders is a patients having 50 > Decrease rate(%) of HAM-D score
89367212|NCT03243292||Treated|Subjects that received Bronchial Thermoplasty in a prior study (AIR, RISA, or AIR2)
89367213|NCT03243292||Control|Subjects that participated in prior study (AIR) or (RISA) but did not receive Bronchial Thermoplasty Treatment. Determine if the Control group of subjects asthma has progressed any different from those subjects treated with BT.
89367214|NCT03243292||Sham|Subjects that participated in the AIR2 study, were blinded and did not receive the treatment. Determine if the Sham group of subjects asthma has progressed any different from those subjects treated with BT.
89367215|NCT03126513|Experimental|G-POEM in refractory gastroparesis|Participants with refractory gastroparesis will be confirmed by endoscopy, clinical and scintigraphy studies.
89367216|NCT03247894||MS patients who after labour|Patients with multiple sclerosis after labour in tertiary center was screened for progression of MS in 10 months period after labour
89367217|NCT03243214|Active Comparator|PD-MCI, TMS|The patient is treated with TMS stimulation according to protocol with an active coil.
89367218|NCT03243214|Sham Comparator|PD-MCI, Sham-TMS|The patient is treated with Sham-TMS stimulation according to protocol with an inactive coil.
89367219|NCT01346319|Active Comparator|Testosterone undecanoate|
89367220|NCT01346319|Placebo Comparator|Placebo|
89367221|NCT01350609|Experimental|Nifedipine/Candesartan (fixed dose)|
89367222|NCT01350609|Active Comparator|Nifedipine/Candesartan (loose)|
89367223|NCT01351311|Experimental|Exercise Group|Resistance exercise with swiss ball and drug treatment
89367224|NCT01351311|Other|Control Group|Drug treatment
88839424|NCT02564354|Experimental|ΔF508 Homozygous|QR-010 administered intranasally as an atomized liquid 10 mg (5 mg per nostril), 3 times weekly for 4 weeks.
88839425|NCT02564354|Experimental|ΔF508 Compound Heterozygous|QR-010 administered intranasally as an atomized liquid 10 mg (5 mg per nostril), 3 times weekly for 4 weeks.
88839426|NCT02467777|Active Comparator|Forced Air|Bair Hugger
89367225|NCT03269409|Sham Comparator|Hip Decompression with lactated ringers|Subjects will receive standard of care hip decompression along with an injection of approximately 5 mls. of lactated ringers.
89367226|NCT03269409|Experimental|Hip Decompression with ADRC|Subjects in this arm will have Adipose Derived Regenerative Cells (ADRC)harvested through autologous liposuction and processed outside the body using The Celution 800/GP System (Cytori Therapeutics) before having approximately 5 mls. of ADRCs transplanted into the femoral head after standard of care hip decompression.
88839427|NCT02467777|Active Comparator|Conductive Warming|VitaHeat
88839428|NCT02564432||POP 10 patient cohort|This is an observational study
88839429|NCT02540629|No Intervention|Before intervention|The before intervention group will include patients from January, 2013 through December, 2014, as to refer to the historic control population who did not receive any of study interventions.
89367227|NCT03248206|Active Comparator|PNF exercise program group|The PNF home-program exercise group: perform grade 1&2 two times a day, at least 3 times per week, for 3 sets of 12 repetitions to increase neuromuscular and musculoskeletal endurance. (Grade 1: The participants performs the diagonal- spiral pattern that will enhance the strength or movement of a targeted muscle or muscle group.; Grade 2:The participants performs PNF exercise with elastic bands . )
89367228|NCT03248206|Experimental|PNF in conjunction with tendon gliding exercise group|Patients in PNF in conjunction with TGE group will perform PNF grade 1&2 as well as tendon gliding exercise two times a day, at least 3 times per week, for 3 sets of 10 repetitions. Training duration for both the two groups is twelve weeks.
89367229|NCT01351389|Active Comparator|Brief Motivational Intervention (BMI)|
89367230|NCT01351389|Active Comparator|Brief Advice|
89367231|NCT03242902|Experimental|Light intensity 1|The light intervention includes exposure to white light (10.000 lux) at a distance of 45 cm for 30 minutes within the first half hour after awakening during 3 weeks and 4 days. This can be done while engaged in other activities, for example reading the newspaper or eating breakfast.
89367232|NCT03242902|Experimental|Light intensity 2|The light intervention includes exposure to white light (10-20 lux) at a distance of 45 cm for 30 minutes within the first half hour after awakening during 3 weeks and 4 days. This can be done while engaged in other activities, for example reading the newspaper or eating breakfast.
89367233|NCT02454634|Experimental|IDH1 peptide vaccine|The IDH1 peptide vaccine is a 20mer peptide encompassing the IDH1R132H-mutated region emulsified in Montanide®. It is injected subcutaneously and administered in combination with topical imiquimod. The vaccine is administered 8 times every 2 or 4 weeks.
88839430|NCT02540629|Experimental|After intervention|The main study phase was planned to begin in January, 2016 through December, 2017, for a total of two years. Patients during the main study phase will have received one or more study interventions as applicable. However, because we could not continue our project in 2017, we changed after period. We included implementation period (2015) in after period. Therefore, final after period begins in January 2015 to December 2016.
88875193|NCT02515890|Experimental|Midazolam Only|Subjects receive saline (control), followed by midazolam infusion. They also experience intermittent experimental pain delivered by peripheral nerve stimulation.
89367234|NCT04487158|Active Comparator|Small Changes|
89367235|NCT04487158|Experimental|INSPIRE|
89367236|NCT03242746||Control group|"The study will include 150 women of reproductive age (21-45 years) who wished to have future pregnancies and had cervical biopsy or Pap test, without any other cervical procedure, in the same calendar year.~a 3-years follow-up for pregnancy outcome~Transvaginal ultrasound for pretreatment cervical dimensions/volume"
89367237|NCT03242746||LEEP group|"The study will include 150 women of reproductive age (21-45 years) planning for excisional treatment for CIN who wished to have future pregnancies. Women are included irrespective of their parity, previous obstetric history, and CIN grade.~a 3-years follow-up for pregnancy outcome~Transvaginal ultrasound for pretreatment cervical dimensions/volume~Transvaginal ultrasound for posttreatment cervical dimensions/volume in the follow-up visit~Estimation of cone dimensions/volume~Calculation of the proportion of volume/length excised"
89367238|NCT03247426||Evaluation individuals with exercise|Individuals who work in sitting position and do regular exercises will be recruited.
88839431|NCT02568644|Experimental|Extract of ginger|People (both genders) who went to the emergency room of the Hospital Vera Cruz (Belo Horizonte, MG, BR) with a migraine attack received two capsules of ginger extract (containing 5% of gingerols) and intravenous ketoprofen (100mg).
89367239|NCT03247426||Evaluation individuals without exercise|Individuals who work in sitting position and do not perform regular exercises will be recruited.
88839432|NCT02568644|Placebo Comparator|Cellulose|People (both genders) who went to the emergency room of the Hospital Vera Cruz (Belo Horizonte, MG, BR) with a migraine attack received two placebo capsules (cellulose) and intravenous ketoprofen (100mg).
88839433|NCT02541409|Active Comparator|SOF+PEG+RBV|Sofosbuvir (400mg/daily) + Pegylated Interferon alfa-2a (180µg/weekly) + Ribavirin (800mg/daily) for 12 weeks
88839434|NCT02541409|Active Comparator|SOF+RBV|Sofosbuvir (400mg/daily) + Ribavirin (800mg/daily) for 24 weeks
88839435|NCT02569112|Active Comparator|cryolipolysis|Each patient is their own control and one side will have only a cryolipolysis treatment while the other side will have a cryolipolysis treatment plus multipolar radiofrequency and varipulse treatment.
88839436|NCT02569112|Experimental|cryolipolysis, multipolar RF, varipulse|Each patient is their own control and one side will have only a cryolipolysis treatment while the other side will have a cryolipolysis treatment plus multipolar radiofrequency and varipulse treatment.
88839437|NCT02569658|Experimental|Tranexamic Acid Group|Group will be administered 1 gram tranexamic acid IV bolus (10 ml solution) 10 minutes prior to incision.
88839438|NCT02569658|Placebo Comparator|Placebo Group|Group will be administered 10 ml normal saline placebo IV bolus 10 minutes prior to incision
88839439|NCT02541565|Experimental|Treatment (pembrolizumab, combination chemotherapy)|Patients receive pembrolizumab IV over 30 minutes on day 1 and prednisone PO on days 1-5. Patients also receive rituximab IV, cyclophosphamide IV, doxorubicin hydrochloride IV, and vincristine sulfate IV on day 2 of course 1 and on day 1 of subsequent courses. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
88839440|NCT04708184|Experimental|GLPG3970 solution|Single oral dose of GLPG3970 in fasted conditions
88839441|NCT04708184|Experimental|GLPG3970 tablet fasted|Single oral dose of GLPG3970 in fasted conditions
88839442|NCT04708184|Experimental|GLPG3970 tablet fed|Single oral dose of GLPG3970 in fed conditions
88839443|NCT04707950|Active Comparator|study group will be given tranexamic acid|"Participants will be divided into two groups: a study group & a control group. In addition to the standard management, the study group will be given TXA 1 gm (100 mg/ml) slowly intravenous infusion during delivery after clamping of the cord (administered over 10 minutes at 1 ml/minute).~The second dose of TXA 1 g Intravenous can be given if:~Bleeding continues after 30 minutes~Bleeding restarts within 24 hours of completing the first dose While the control group will not be given TXA and we will compare the results in both groups (amount of blood loss during operation to assess the efficacy of TXA in the prevention of PPH and reduction of intraoperative and postoperative blood loss and to assess its safety and benefit in the reduction of incidence of hysterectomy or blood transfusion requirements)."
88839444|NCT04707950|Placebo Comparator|Control group|The control group will not be given Tranexamic acid but only the standard management ( Oxytocin )
88839445|NCT03681236|No Intervention|No alveolar recruitment maneuver|Applying ventilation with tidal volume 6-8mL/kg (ideal body weight) and PEEP 5cmH₂O
88839446|NCT03681236|Active Comparator|Alveolar recruitment maneuver|Applying ventilation with tidal volume 6-8mL/kg (ideal body weight) and PEEP 5cmH₂O. In addition to this, performing alveolar recruitment maneuver at 2 moments: before surgical incision, end of pneumoperitoneum
88839447|NCT03593564|Experimental|KINDER Participant|The intervention will be provided with a 8-part psychoeducational intervention delivered online on a weekly basis. Online modules will be comprised of a short (approximately 3 minute) videos followed by more specific text-based information and links to additional resources. At the end of the module, participants will complete a short quiz, followed by a reflection exercise to reinforce learning. Each model, participants will be asked to select a goal to complete a pleasurable activity and receive an option to set a text or email reminder to do so.
88839448|NCT04044560|Experimental|Blinatumomab Treatment|Eligible patients with detectable MRD will taper immunosuppressive medications, if applicable, and undergo treatment with blinatumomab. The duration of each cycle of blinatumomab treatment is 6 weeks. Adult and pediatric patients will be treated for 4 weeks followed by a 2-week treatment free period. Patients may receive up to 4 cycles total of blinatumomab therapy.
88839449|NCT02569892|Experimental|Laser Arm|Participants receive treatment with sub-threshold macular laser photocoagulation
88839450|NCT02569892|Sham Comparator|Sham Laser Arm|Participants receive sham treatment with sub-threshold macular laser photocoagulation (with power setting at zero)
88839451|NCT02571218|Active Comparator|mCPVA|"Subjects in the mCPVA arm will undergo intervention called modified circumferential pulmonary vein ablation, which is considered to be the standard ablation treatment for AF."
88839452|NCT02571218|Experimental|Substrate+mCPVA|Subjects in the Substrate+mCPVA arm will undergo intervention of substrate mapping and substrate-targeted ablation guided by the investigational device, followed by completion of modified circumferential pulmonary vein ablation.
88839453|NCT02573402|Experimental|Transcutaneous Tibial Nerve Stimulation|Transcutaneous Tibial Nerve Stimulation (TTNS) applied to subjects for 2-week protocol.
88839454|NCT02573402|Sham Comparator|Control|Sham stimulation.
88839455|NCT03791060|Experimental|Secukinumab Subcutaneous Injection|"300 mg q weekly for 5 weeks followed by 300 mg q 4 weeks.~Each subject will receive 300mg of Secukinumab by using 2 syringes of 150mg each as a subcutaneous injection at weeks 0,1,2,3,4 then every 4 weeks for a total of 9 doses over 24 weeks."
88839456|NCT02578238||Participants With Pediatric CD|Participants with pediatric CD who have been prescribed Humira® (adalimumab) by the treating physician.
89367240|NCT03242980|No Intervention|Enhanced adherence counseling|Individuals with elevated VL are required to attend a minimum of 2 session of enhanced adherence counselling performed at monthly intervals. A follow-up VL is done at 8 to 12 weeks after the first counselling session.
89367241|NCT03242980|Experimental|Structured EAC plus SMS|The behavioral intervention will consist of structured adherence counseling and a short text message (SMS). A culturally adapted graphical brochure was specifically developed to guide adherence-counselling for individuals with unsuppressed VL.
89367242|NCT03242668|Experimental|PVB using PVC for PCA in VATS|The VATS was performed.Paravertebral space was identified by loss of resistance technique combined with video-assisted inside thoracic space before chest close.PVC was inserted.Initiated dose of 0.3ml/kg of Bupivacaine Hydrochloride 1.25mg/ml and Fentanyl Citrate 2 micrograms/ml was administered then continued PCA with background rate 3ml/h, bolus dose 2ml was infused through PVC.
89367243|NCT03247192|Experimental|Whey protein-placebo|"Participants received a dose of 35 grams of whey protein before resistance training (RT) and a dose of 35 grams of maltodextrin (placebo) after RT.~Participants were personally supervised by physical education professionals with substantial RT experience. The sessions were performed 3 times per week on Mondays, Wednesdays, and Fridays, with 3 sets of 08-12 repetition maximums. The RT program was a whole-body program with eight exercises, including: chest press, seated row, triceps pushdown, preacher curl, horizontal leg press, knee extension, leg curl and seated calf raise. Participants were afforded a 1 to 2 min rest interval between sets and 2 to 3 min between each exercise. The training load was consistent with the prescribed number of repetitions for the three sets of each exercise."
89367244|NCT03247192|Experimental|Placebo-whey protein|"Participants received a dose of 35 grams of maltodextrin (placebo) before resistance training (RT) and a dose of 35 grams of whey protein after RT.~Participants were personally supervised by physical education professionals with substantial RT experience. The sessions were performed 3 times per week on Mondays, Wednesdays, and Fridays, with 3 sets of 08-12 repetition maximums. The RT program was a whole-body program with eight exercises, including: chest press, seated row, triceps pushdown, preacher curl, horizontal leg press, knee extension, leg curl and seated calf raise. Participants were afforded a 1 to 2 min rest interval between sets and 2 to 3 min between each exercise. The training load was consistent with the prescribed number of repetitions for the three sets of each exercise."
89367245|NCT03247192|Placebo Comparator|Placebo-placebo|"Participants received a dose of 35 grams of maltodextrin (placebo) before and after resistance training.~Participants were personally supervised by physical education professionals with substantial RT experience. The sessions were performed 3 times per week on Mondays, Wednesdays, and Fridays, with 3 sets of 08-12 repetition maximums. The RT program was a whole-body program with eight exercises, including: chest press, seated row, triceps pushdown, preacher curl, horizontal leg press, knee extension, leg curl and seated calf raise. Participants were afforded a 1 to 2 min rest interval between sets and 2 to 3 min between each exercise. The training load was consistent with the prescribed number of repetitions for the three sets of each exercise."
89367246|NCT03242512|Experimental|30 mg single dose cohort|Subjects would receive a 30 mg single dose of TK006.
89367247|NCT03242512|Experimental|60 mg single dose cohort|Subjects would receive a 60 mg single dose of TK006.
89367248|NCT03242512|Experimental|120 mg single dose cohort|Subjects would receive a 120 mg single dose of TK006.
89367249|NCT03247270|Experimental|Intervention I|Physical exercise intervention: 12 week exercise program with low-intensity fitness training 3 times per week.
89367250|NCT03247270|Experimental|Intervention II|Physical exercise intervention:12 week exercise program with moderate to high-intensity fitness training 3 times per week
89367251|NCT03247270|No Intervention|Control group|Control group, who will have a physiotherapy session once and will be given general advice about physical activity.
89367252|NCT03778372||study|pediatric patients undergoing outpatient strabismus surgery, and receiving methadone
89189251|NCT04071444|Experimental|Baduanjin program|The entire program continued for 6 months (December, 2018 to July, 2019), and the intervention was performed for 60 min 3 times per week; particular attention was paid to the disease characteristics of the patients with chronic schizophrenia and to preventing excessive fatigue. Every session began with a 20-min warm-up, followed by 20 min of Baduanjin program, and ended with a cool-down session. The participants were instructed, with the assistance of a video, to practice Baduanjin program in a group by two authors who are experienced in the psychiatric nurses and had been trained in this program.
89367253|NCT03778372||control|pediatric patients undergoing outpatient strabismus surgery, and not receiving methadone
89367254|NCT03242200|Other|Mobile Health App|Participants will be prompted to complete questionnaires.
89367255|NCT04486846|Experimental|eVisit|The study intervention will be an electronically performed surveillance program replacing face-to-face clinic follow-up visits. At 3 month intervals for 1 year, the patient will receive an email reminder generated by the patient portal to complete lab testing and eVisit questionnaire.
88839457|NCT03256916|Experimental|Nelfinavir Arm|"If patient is randomized to nelfinavir arm then nelfinavir will be given orally with food at the dose of 1250 mg bid 5-7 days prior to start of chemoradiation.~Then Pelvic EBRT (45-50 Gy/23-25 #/5weeks) + Weekly cisplatin 40mg/m2 & ICRT 7Gy X4 # will be given."
88839458|NCT03256916|Other|Standard Arm|"If patient is randomized to standard arm (Cisplatin +Pelvic EBRT and Brachytherapy).~In this patient will receive Pelvic EBRT (45-50 Gy/23-25 #/5weeks) + Weekly cisplatin 40mg/m2 & ICRT 7Gy X4 #"
89367256|NCT03247114|Experimental|Water-glucose-sucralose-fructose-sucrose|First plain water, then glucose, then sucralose, then fructose and then sucrose
89367257|NCT03247114|Experimental|water-sucralose-glucose-sucrose-fructose|First plain water, then sucralose, then glucose, then sucrose and then fructose
89367258|NCT03247114|Experimental|Glucose-water-fructose-sucralose-sucrose|First glucose, then plain water, then fructose, then sucralose and then sucrose
89367259|NCT03247114|Experimental|Glucose-fructose-water-sucrose-sucralose|First glucose, then fructose, then plain water, then sucrose and then sucralose
89367260|NCT03247114|Experimental|Fructose-glucose-sucrose-water-sucralose|First fructose, then glucose, then sucrose, then plain water and then sucralose
89367261|NCT03247114|Experimental|Fructose-sucrose-glucose-sucralose-water|First fructose, then sucrose, then glucose, then sucralose and then plain water
89367262|NCT03247114|Experimental|Sucrose-fructose-sucralose-glucose-water|First sucrose, then fructose, then sucralose, then glucose and then plain water
89367263|NCT03247114|Experimental|Sucrose-sucralose-fructose-water-glucose|First sucrose, then sucralose, then fructose, then plain water and then glucose
89367264|NCT03247114|Experimental|Sucralose-water-sucrose-glucose-fructose|First sucralose, then plain water, then sucrose, then glucose and then fructose
89367265|NCT03247114|Experimental|Sucralose-sucrose-water-fructose-glucose|First sucralose, then sucrose, then plain water, then fructose and then glucose
89367266|NCT03246880|Experimental|Tamsulosin 0.2mg+Tadalafil 5mg|Tamsulosin 0.2mg+Tadalafil 5mg, po, q.d.
89367267|NCT03246880|Active Comparator|Tamsulosin 0.2mg|Tamsulosin 0.2mg, po, q.d.
89367268|NCT03246880|Active Comparator|Tadalafil 5mg|Tadalafil 5mg, po, q.d.
88839459|NCT02579876|Active Comparator|Viaskin Milk 500 mcg|Viaskin patch containing milk protein. The patch is applied to the skin
88839460|NCT02579876|Placebo Comparator|Viaskin Placebo|Viaksin patch without any milk protein.
89367269|NCT03242044|Experimental|Resuscitation with intact umbilical cord|This is a one arm study. Pregnant women greater than 18 years of age with a fetus with left or right sided congenital diaphragmatic hernia of age that consent to the protocol will be enrolled in the study. This is a pilot feasibility study that will assess maternal and infant tolerance to resuscitation with an intact umbilical cord as well as the optimal method for performing an advanced resuscitation with the umbilical cord intact. For this reason patients will not be randomized.
89367270|NCT02711644|Experimental|Supportive Lifestyle Counselling|Two supportive lifestyle counselling sessions with Registered Dietitian from study entry to 34 weeks.gestation.
89367271|NCT02711644|Active Comparator|Standard Lifestyle Counselling|Two standard counselling sessions with Registered Dietitian from study entry to 34 weeks gestation
89367272|NCT02690584|Experimental|Metacognitive therapy|Metacognitive therapy, one 45-60 min session weekly during 10 weeks.
89367273|NCT03242122|Active Comparator|CHO Control 1 Glucose|25 g glucose
89367274|NCT03242122|Experimental|CHO Experimental 1 Slowly Digested|25 g slowly-digested carbohydrate blend
89367275|NCT03242122|Experimental|CHO Experimental 2 Digestion Resistant|25 g digestion-resistant carbohydrate blend
89367276|NCT03242122|Experimental|CHO Experimental 3 Low Sugar|25 g low sugar carbohydrate blend
88839461|NCT02787668|Experimental|Carbohydrate-restricted diet|This diet is designed to minimize intake of carbohydrate sources such as added sugars, high glycemic grains, and fructose and will provide ≤10% energy from CHO, 25% energy from protein, and ≥65% energy from fat.
88839462|NCT02787668|Active Comparator|Control, low-fat diet|The control, low-fat diet will contain 55:25:20 %energy from CHO:protein:fat based on the USDA MyPlate Daily Food Plan. For example, an 1800kcal/d plan will include 5 ounces lean meats, 3 cups low-fat dairy, 6 ounces of whole grains, 1 ½ cups fruit, 2 ½ cups vegetables (starchy and non-starchy) and limited fats.
88839463|NCT02582216|Experimental|Open label|3D augmented reality
88839464|NCT02582840|Experimental|dapagliflozin 5mg|dapagliflozin tablet 5mg
89367277|NCT03242122|Experimental|CHO Experimental 4 Maltodextrin|25 g maltodextrin
89367278|NCT03242122|Active Comparator|CHO Control 2 Glucose|25 g glucose
89367279|NCT03258034|Experimental|Conversion treatment|after 3-4 cycles S1/Paclitaxel chemotherapy plus Apatinib,subsequent surgery will be conducted with curative intent.
89367280|NCT03258190|Experimental|Lime Powder Regimen|Participants were asked to take LPR twice a day for 6 months
89367281|NCT03258190|Placebo Comparator|Placebo|Participants were asked to take Placebo twice a day for 6 months
89367282|NCT03258112|Other|catheter ablation|all patients indicated for catheter ablation of RVOT or LVOT ventricular arrhythmia are included in one arm for electrophysiological diagnosis of the origin of arrhythmia then for radiofrequency catheter ablation
89367283|NCT03241966||People with Parkinson's Disease|Individuals diagnosed with idiopathic Parkinson's disease without dementia.
88839465|NCT02582840|Experimental|dapagliflozin 10mg|dapagliflozin tablet 10mg
88839466|NCT02582840|Placebo Comparator|Placebo|dapagliflozin tablet 5mg placebo or 10 mg placebo
88839467|NCT02583230|Experimental|MedLink|For 8 weeks, the patient who is newly prescribed antidepressant medication will receive a mobile phone app (and a phone if they do not have a compatible Android phone) and a GSM enable pill bottle in order to provide and receive feedback regarding medication adherence.
88839468|NCT00365222|Experimental|1|
88839469|NCT04340804|Experimental|Kcal labelling|Participants allocated to this group will see on the screen the amount of food increasing or decreasing based on how many times they tap on the corresponding keys and a real-time kcal counter synchronised with the food amount changes (i.e., increasing/decreasing).
88839470|NCT04340804|Experimental|PACE labelling|Participants allocated to this group will see on the screen the amount of food increasing or decreasing based on how many times they tap on the corresponding keys and a real-time PACE counter (as minutes needed to walk to burn off the calories) synchronised to the food amount changes (i.e., increasing/decreasing) with 4 min being equivalent to 20 kcal.
88839471|NCT04340804|Experimental|Kcal and PACE labelling|Participants allocated to this group will see on the screen the amount of food increasing or decreasing based on how many times they tap on the corresponding keys and a real-time kcal and PACE counters synchronised to the food amount changes (i.e., increasing/decreasing).
88839472|NCT04340804|No Intervention|No labelling|Participants allocated to this group will only see on the screen the amount of food increasing or decreasing based how many times they tap on the corresponding keys.
88839473|NCT02580188|No Intervention|Moderate block|Maintenance dose of 0.15-0.3 mg/kg/hr rocuronium as continuous infusion during surgery for the maintenance of train of four count 1-2 (moderate block). At the end of surgery neostigmine 50 ㎍/kg with glycopyrrolate 10 ㎍/kg are administered IV for reversal of neuromuscular block.
89367284|NCT03241966||Informant|Family member, spouse, significant other, caregiver, or other close associate of someone with Parkinson's disease.
89367285|NCT03257722|Experimental|Phase 1 Dose Escalation|Sequential cohorts of 3 patients will receive pembrolizumab 200 mg intravenously every 3 weeks, in addition to the oral drug, idelalisib, every day for 21 days. The first group of 3 will receive idelalisib 50 mg twice daily; the next cohort will receive idelalisib 100 mg twice daily; the last cohort will receive idelalisib 150 mg twice daily.
89367286|NCT03257722|Experimental|Phase 2 Efficacy|All patients in the efficacy assessment phase will be treated with pembrolizumab (200 mg intravenously every 3 weeks) in combination with oral idelalisib (dose not exceeding 150 mg twice daily, per the phase 1 assessment) for 18 weeks before maintenance with pembrolizumab 200 mg intravenously every 3 weeks for up to 2 years, until disease progression or unacceptable toxicity.
89367287|NCT03268005|Experimental|Faster aspart + insulin degludec with or without metformin|
89367288|NCT03268005|Active Comparator|NovoRapid/NovoLog + insulin degludec with or without metformin|
88839474|NCT02580188|Experimental|Deep block|Maintenance dose of 0.4-0.9 mg/kg/hr rocuronium as continuous infusion during surgery for the maintenance of post tetanic count 1-2 (deep block). At the end of surgery, sugammadex 4 mg/kg are administered IV for reversal of neuromuscular block
89367289|NCT03239314|Active Comparator|group I|Group I (MS): received single shot 20 ml 0.5% isobaric bupivacaine + 2.0 ml normal saline solution injected into the adductor canal preoperatively.
89367290|NCT03239314|Active Comparator|group II|Group II (MD): received 20 ml 0.5% isobaric bupivacaine + 8.0 mg dexamethasone (2.0 ml) injected into adductor canal preoperatively.
89367291|NCT02454244|Experimental|Amygdala Retraining Technique (ART) with Mindfulness|Consists of 10 weekly sessions, followed by 3 monthly sessions
89367292|NCT02454244|Experimental|Mindfulness Compassion|Includes the attentional training aspect of mindfulness and meditation practices, proved to bring benefits in relation to fibromyalgia and CFS symptoms, as fatigue and pain. Compassion training focuses on the ability to be kind to participants and their own experience, specifically to their experience of suffering. The protocol consists of 10 weekly sessions, followed by 3 following monthly sessions
89367293|NCT02454244|Active Comparator|Relaxation|Consists of 10 weekly sessions, followed by 3 monthly sessions
89367294|NCT03257644|Experimental|Cohort 1|Ruxolitinib phosphate cream 0.5%.
89367295|NCT03257644|Experimental|Cohort 2|Ruxolitinib phosphate cream 1.5%.
89367296|NCT03257644|Experimental|Cohort 3|Ruxolitinib phosphate cream 0.75%.
89367297|NCT03257644|Experimental|Cohort 4|Ruxolitinib phosphate cream 1.5%.
89367298|NCT03257644|Experimental|Cohort 5|Ruxolitinib phosphate cream 0.75%.
89367299|NCT03257644|Experimental|Cohort 6|Ruxolitinib phosphate cream 1.5%.
88839475|NCT04741958|Experimental|ultra sound guided percutaneous core needle biopsy|60 patients that had radiographic evidence of thoracic mass suspected of malignancy .Twenty masses were in the lung, seventeen lesions were in the pleura, ten masses were in the mediastinum, eleven enlarged palpable lymph nodes, and two masses were in chest wall. The sensitivity, PPV and accuracy for detection of chest tumors in chest wall, mediastinum, lung, and pleura were (100 %) for all, and in LN (88.9, 100 and 90.9 %) respectively. The overall diagnostic performance of sonar guided true cut needle biopsy in diagnosis was 97.78 % sensitivity, 98.18% accuracy, and 100 % PPV
89367300|NCT03257878||Systemic sclerosis (SSc)|validated Korean version of the SF36 and EQ-5D
89367301|NCT03257878||Rheumatoid arthritis (RA)|validated Korean version of the SF36 and EQ-5D
89367302|NCT03257878||Systemic lupus erythematosus (SLE)|validated Korean version of the SF36 and EQ-5D
89367303|NCT03257878||Sjogren's syndrome|validated Korean version of the SF36 and EQ-5D
89367304|NCT03257878||Control|validated Korean version of the SF36 and EQ-5D
88839476|NCT02584790|Other|Post radiotherapy 8 weeks NPC patient|All post-radiotherapy 8 weeks NPC patient will routinely undergo laryngoscope examination (WL system) and NP biopsy will be taken at the same time to determine if there is any residual NPC. In this study, laryngoscope with NBI system will be used. NBI system will be turn on during the post radiotherapy 8 week laryngoscope examination in additional to routine WL system
88839477|NCT02584868|Experimental|Volulyte|Investigational drug: HES 130/0.4 (6%) in an isotonic electrolyte solution (brand name=Volulyte®)
88839478|NCT02584868|Active Comparator|Voluven|Control drug: HES 130/0.4 (6%) in sodium chloride 0.9% (brand name=Voluven®)
88839479|NCT02586896|Experimental|Strengths-based Case Management (SBCM)|The structure of SBCM follows the widely accepted functions of case management-assessment, planning, linking, monitoring and advocacy-and the theory-driven gestalt of the strengths perspective. Strengths-based principles include an emphasis on client strengths, teaching clients a method for setting and completing goals, and development of a strong working alliance.
89189252|NCT04071444|No Intervention|Control group|The control group (CG) received routine care.
89367305|NCT03241888|Active Comparator|MA|Patients will receive megestrol acetate 160 mg by mouth daily for at least 3 months.Then every 3 months, an hysteroscope will be used to evaluate the endometrial condition, and the findings will be recorded.
89367306|NCT03241888|Active Comparator|LNG-IUS|Patients will receive LNG-IUS insertion for at least 3 months. Then every 3 months, an hysteroscope will be used to evaluate the endometrial condition, and the findings will be recorded.
89367307|NCT03241888|Experimental|MA+LNG-IUS|Patients will receive MA (160mg po qd) plus LNG-IUS insertion for at least 3 months. Then every 3 months, an hysteroscope will be used to evaluate the endometrial condition, and the findings will be recorded.
89367308|NCT02454088|Active Comparator|Triamcinolone acetate|Injection of Calcium hydroxylapatite with Triamcinolone acetate
89367309|NCT02454088|Placebo Comparator|Placebo|Injection of Calcium hydroxylapatite with a placebo
89367310|NCT02456116|Experimental|acupuncture/PCA/NSAID|"standard program with defined points:~Ear acupuncture needles bitten once (day 0-5)~Body acupuncture, once a day 20 minutes (day -1/ 0/ 2/ 4), depth of the prick 0.5 - 1 cm, with DeQI feeling/sensation is released"
89367311|NCT02456116|Sham Comparator|sham acupuncture/PCA/NSAID|"standard program with defined points:~Ear sham-acupuncture needles bitten once (day 0-5)~Body sham-acupuncture, once a day 20 minutes (day -1/ 0/ 2/ 4), depth of the prick 0.5"
89367312|NCT02456116|Other|PCA/NSAID|minimal intervention (included in every arm) standard boli of morphine by pressing a button of PCA availability in the postoperative period (day 0-4) readout once a day NSAID (non-steroid antiinflammatory drug) 2x i.v. (75mg diclofenac-sodium, 30 mg orphenadrine citrate) (day 0-4)
89367313|NCT04481607|Experimental|TQB3454 tablets|TQB3454 tablets administered orally once. Then TQB3454 tablets administered orally, once daily in 28-day cycle after 7 days of first administration.
89367314|NCT01352871||Concentration / meditation|The subject will try to influence the innate immune response by concentration / meditation in advance of and during endotoxemia
89367315|NCT03239236|Experimental|t-RSI|"Rapid sequence induction t-RSI. Traditional rapid sequence induction with Anesthetics. Preoxygenation via face mask, no ventilation with no PEEP until intubation. Aspiration of gastric air via nasogastric tube at the beginning of laparoscopy. Impression of gastric inflation at laparoscopy will be assessed by taking images of the stomach at the beginning of laparoscopy.~Arterial blood gas samples will be taken at different time points."
89367316|NCT03239236|Experimental|m-RSI-PEEP|"Rapid sequence induction m-RSI-PEEP. Modified rapid sequence induction with Anesthetics and PEEP. Preoxygenation via facemask with PEEP of 10 mbar. PEEP will be continued until intubation.~Aspiration of gastric air via nasogastric tube at the beginning of laparoscopy. Impression of gastric inflation at laparoscopy will be assessed by taking images of the stomach at the beginning of laparoscopy.~Arterial blood gas samples will be taken at different time points."
89367317|NCT03239236|Experimental|m-RSI-vent|"Rapid sequence induction m-RSI-vent. Modified rapid sequence induction with Anesthetics and intermittent ventilation. Preoxygenation via facemask with 10 mbar PEEP and 8 mbar pressure support. Backup frequency set at 10/min. Ventilation via anesthetic machine until intubation.~Aspiration of gastric air via nasogastric tube at the beginning of laparoscopy. Impression of gastric inflation at laparoscopy will be assessed by taking images of the stomach at the beginning of laparoscopy.~Arterial blood gas samples will be taken at different time points."
89367318|NCT03239236|Experimental|m-RSI-vent-cric|"Rapid sequence induction m-RSI-vent-cric. Modified rapid sequence induction with Anesthetics and intermittent ventilation and cricoid pressure. Same as modified rapid sequence induction with intermittent ventilation arm with additional cricoid pressure.~Aspiration of gastric air via nasogastric tube at the beginning of laparoscopy. Impression of gastric inflation at laparoscopy will be assessed by taking images of the stomach at the beginning of laparoscopy.~Arterial blood gas samples will be taken at different time points."
88839480|NCT02586896|Active Comparator|Screening, Assessment and Referral (SAR)|Following randomization, participants in the SAR condition will be provided with minimal scripted feedback to let them know that their assessment indicates substance dependence, and given a recommendation to seek treatment.
89367319|NCT01353027|Placebo Comparator|Placebo|
89367320|NCT01353027|Experimental|AVI-6002|Phosphorodiamidate morpholino antisense oligomer with positive charges on selected subunits (PMOplus™)
89367321|NCT01343121|Other|sample collection|"This is a single arm study. Patients will be seen on day 1, 8, 15 and 22 and will have the following samples collected:~Pre gemcitabine urine sample~Blood sample 30 minutes post Gemcitabine infusion~Urine and blood sample 2 hours post Gemcitabine infusion"
89367322|NCT01351779||Progressive glaucoma|Patients with primary open angle glaucoma identified to have an optic disc hemorrhage
89367323|NCT03239392|Experimental|BNZ-1|IV PEGylated BNZ132-1-40
89367324|NCT01353105|Experimental|Ex vivo lung transplantation|single-group studies
89367325|NCT03239158|Active Comparator|Cancer ablation|In this group, the patients will receive ablation therapy (e.g. cryosurgery or irreversible electroporation) first for big tumors (> 2 cm). The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
88839481|NCT02586974|Experimental|Group H+WB|32 patients will receive warmed, humidified CO2 insufflation with the Humigard® device, along with the hot air warming blanket used as a routine in our institution (forced air warming blanket at 38°C : Bear Hugger®)
89367326|NCT03239158|Active Comparator|Life information rehabilitation therapy|"In this group, the patients will drink Qilisheng Immunoregulatory Oral Solution for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
89367327|NCT03239158|Experimental|Combination therapy|"In this group, the patients will receive the combination therapy including ablation and life information rehabilitation therapy. The ablation therapy (e.g. cryosurgery or irreversible electroporation) will be performed first for big tumors (> 2 cm), then Qilisheng Immunoregulatory Oral Solution will be provided for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
89367328|NCT03239158|No Intervention|Control|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
89367329|NCT01353183|Experimental|Colonic biopsies|Colonic biopsies obtained during the course of colonoscopy or rectosigmoidoscopy
89367330|NCT03257800|Active Comparator|ketamine-propofol group|"Ketamine (50mg/ml) at 0.5 mg.kg-1 was injected intravenously 1min prior 3 mgkg-1 of propofol and 1 min before LMA insertion in Ketamine-propofol group.~sevoflurane 6-7% was used on vaporizer setting with 50% nitrous oxide in oxgen prior intravenous anesthesia. The loss of eyelash reflex was considered as the desired end point for induction."
89367331|NCT03257800|Placebo Comparator|propofol group|"0,9% saline solution ( Placebo ) at the same volume as ketamine (50mg/ml) was injected intravenously 1min prior propofol 3 mg.kg-1 and 1 min before LMA insertion in propofol group.~sevoflurane 6-7% was used on vaporizer setting with 50% nitrous oxide in oxgen prior intravenous anesthesia. The loss of eyelash reflex was considered as the desired end point for induction."
88839482|NCT02586974|No Intervention|Group WB|32 patients will receive standard CO2 insufflation, along with the hot air warming blanket used as a routine in our institution (forced air warming blanket at 38°C : Bear Hugger® and a standard insufflation with non-humidified, non-heated CO2)
88839483|NCT05249504|Experimental|1. Intervention group|"AMICOPE multicomponent intervention:~Physical activity (VIVIFRAIL program): 10 hours.~Nutrition: 6,5 hours.~Psychology: 6,5 hours.~Personal autonomy: 4,5 hours~Learn about community resources: 2, 5 hours"
88839484|NCT05249504|Active Comparator|2. Control group|Control group participants will receive usual advice on healthy lifestyle habits and a follow-up phone call from healthcare professionals.
89367332|NCT01351857|Other|Transition Coordinator|A Transition Coordinator, a Certified Diabetes Educator, will provide transition support and the link between pediatric and adult diabetes care. The Transition Coordinator is central to the intervention and will provide ongoing contact with the medical system as well as education and clinical support where appropriate.
89530363|NCT04585685|Experimental|2 week baseline, SC + CPT|Participants in this arm are randomized to a 2-week baseline period with repeated weekly assessment after the initial intake. Following the 2-week baseline, participants are randomly assigned to receive 6 weekly sessions of Self-Compassion Therapy (SC), followed by a 3-week return to baseline period, followed by 12 weekly sessions of Cognitive Processing Therapy (CPT).
89367333|NCT01351857|No Intervention|Current Standard of Care|Subjects in the control group will transition to adult care equal to the intervention group and will differ only by exclusion of Transition Coordinator. Control group will receive the current standard of diabetes care otherwise unchanged. Three months following randomization, subjects in the control group will be referred to the adult endocrinologist in the same way as subjects in the intervention group
89367334|NCT03241654||the lowest trigger sensitivity|The flow trigger of ventilator was set as the lowest level of sensitivity.
89367335|NCT03241654||the highest trigger sensitivity|The flow trigger of ventilator was set as the highest level of sensitivity.
89367336|NCT01351935|Experimental|AVL-292|
89367337|NCT01353261||Elective Cases|Patients with stable CAD undergoing PCI
89367338|NCT01353261||AMI Cases treated with clopidogrel|Patient with AMI undergoing PCI
89367339|NCT01353261||AMI Cases treated with prasugrel|Patients with AMI undergoing PCI
89367340|NCT01352013|Placebo Comparator|Colored olive oil|
89367341|NCT01352013|Active Comparator|Omega-3 (oil)|
89367342|NCT03241576|Experimental|Small portion size provision|Participants in this arm are served a small serving of a lunchtime food to eat (session 1).
89367343|NCT03241576|Active Comparator|Large portion size provision|Participants in this arm are served a large serving of a lunchtime food to eat (session 1).
89367344|NCT01353339|Placebo Comparator|sugar pill|
89367345|NCT01353339|Active Comparator|levofloxacin|
89367346|NCT03241498|No Intervention|Control arm|All patients allocated to the control group, who on checking meet the study entry criteria and who consent (written informed consent) to participate in the research, will be asked to complete the three study questionnaires (see below) and will be advised that repeat questionnaires will be distributed by post at the end of the study (6 months) for completion at home and return by post. The patients will continue to receive all services provided by the GP practice (normal care) but will not receive the bespoke clinical pharmacist intervention which is being evaluated in this research study.
89367347|NCT03241498|Experimental|Intervention arm|Participants meeting all study entry criteria who are allocated to the intervention group will also be asked to complete the three study questionnaires. Having completed the questionnaires they will receive the medicines optimisation intervention by the clinical pharmacist. They will be asked to return for repeat appointments with the clinical pharmacist at 2 and 4 months and will be advised that they will be asked to complete the study questionnaires again at the end of the study (at home, via post at 6 months).
89367348|NCT03239080|Active Comparator|Denosumab|Subcutaneous injections of denosumab 60mg will be given in 4 doses at each visit (at baseline, 6, 12 and 18 months).
89367349|NCT03239080|Placebo Comparator|Placebo|Subcutaneous injections of placebo (0.9% Sodium Chloride solution) will be given in 4 doses at each visit (at baseline, 6, 12 and 18 months).
89367350|NCT03149055|Experimental|Isavuconazole prophylaxis|Intravenous or oral: Isavuconazonium sulfate 372 mg Q 8hour for 6 doses as loading dose, followed by 372 mg Q day as maintenance dose. The minimum duration of prophylaxis with isavuconazole will be through D +60. Beyond day +60 discontinuation is at the discretion of the treating physician.
89367351|NCT03257488|Active Comparator|Screening device-Traditional device|The patients included in the A Group will be studied during the first night with the screening device (type IV portable monitoring Somnocheck micro Weinmann) and with the traditional one during the following night.
89367352|NCT03257488|Active Comparator|Traditional device-Screening device|The patients included in the B Group will be studied during the first night with the traditional device and with the screening one (type IV portable monitoring Somnocheck micro Weinmann) during the following night.
89367353|NCT01317693|Experimental|Treatment LI-ESWT|Device: Extracorporeal Shockwave Therapy Generator (Omnispec model ED1000) Gel is spread around the penis and on the Shock Wave applicator and Treatment (12 sessions in total) of 300 shocks per site, on 5 penile anatomical sites.
89367354|NCT03241264|Experimental|Module A|Lyophilized Formulation
89367355|NCT03241264|Experimental|Module B|Frozen Formulation
89367356|NCT01353417||Renal allograft|
89367357|NCT03257332||EDFI Cohort|Subjects should have received surgery for rectal cancer (low anterior resection).
89367358|NCT01317771||Proximal Biceps Tendon Tenodesis|
89367359|NCT03257176|Experimental|Stepping Stones and Creating Futures|Receive the 21 session intervention
89367360|NCT01352091|Experimental|Switch to Zoladex + AI for 3-2 years|Patients who took tamoxifen or Fareston for 2-3 years were randomized into 2 groups (335 patients for each group). One group would switch to receive Zoladex 3.6mg depot subcutaneously every month and Aromidex 1mg/d po for another 3-2 years
89367361|NCT01352091|Experimental|TAM|Patients who took tamoxifen or Fareston for 2-3 years were randomized into 2 groups (335 patients for each group). One group would receive TAM 20mg/d treated for 3-2 years.
89367362|NCT03257098|Experimental|allo-APZ2-CVU|Application of IMP on patients wound
89367363|NCT01353573|Active Comparator|Fixed Gantry Radiosurgery|Single fraction radiosurgery will be prescribed using a Fixed Gantry Linear Accelerator
89367364|NCT01353573|Experimental|Robotic Radiosurgery|Single fraction radiosurgery will be prescribed using a robotic linear accelerator
88875194|NCT02515890|Experimental|Ketamine Only|All subjects receive saline (control), followed by ketamine infusion. They also experience intermittent experimental pain delivered by peripheral nerve stimulation.
89367365|NCT03257020||Normal subject|Measure BMO-MRW and RNFL with SD-OCT. If the BMO-MRW and RNFL is within the normal range and those with no history of ocular disease, an intraocular pressure < 21 mmHg, an absence of glaucomatous optic disc appearance, and a normal visual field, they will be classified into normal group.
89367366|NCT03257020||Glaucoma patients|Measure BMO-MRW and RNFL with SD-OCT. If the BMO-MRW and RNFL is below the normal range and those with glaucomatous optic disc and two consecutive abnormal visual field test results with open angles on gonioscopy, glaucomatous optic neuropathy, RNFL defects congruent with visual field defects, they will be classified into glaucoma patients.
89367367|NCT02964897|Experimental|Intervention Arm with Peer Support|Veterans in this arm will receive the peer-support intervention, in addition to the usual care from the Health Care for Reentry Veterans Program.
89367368|NCT02964897|Other|Comparison Arm with Usual Care|Veterans in this arm will be receiving usual care from the Health Care for Reentry Veterans program (but they will not receive the peer-support intervention). They will be selected to be frequency-matched to veterans in the intervention arm by date of release from incarceration.
89367369|NCT03256942|Experimental|Etermis 4® Treatment|"Etermis 4® will be applied according to the method of administration described in the current version of the Instructions for Use (IFU) until optimal cosmetic result is obtained at the discretion of the treating investigator.~Single injection session, injections into the lips."
89367370|NCT03256942|No Intervention|No Treatment|
89367371|NCT03238846|No Intervention|3MF: 3-month ART dispensing at facilities|Ten sites at which patients will receive standard of care where ART is dispensed three monthly from the facility based on usual practice at the clinic. The approach will be consistent with applicable country guidelines at the time of study.
89367372|NCT03238846|Experimental|3MC: 3-month ART dispensing in CARGs|Ten sites at which patients will receive ART dispensed three monthly in CARGs. Providers at facilities will assist in the formation of CARGs and will provide all enrolled patients with a 3 month supply of ART and associated HIV medications. All other aspects of care will be as per standard of care for the enrolling clinic.
89367373|NCT03238846|Experimental|6MC: 6-month ART dispensing in CARGs|Ten sites at which patients will receive ART dispensed six monthly in CARGs. Providers at facilities will assist in the formation of CARGs and will provide all enrolled patients with a 6 month supply of ART and associated HIV medications. All other aspects of care will be as per standard of care for the enrolling clinic.
89367374|NCT02954523|Experimental|Phase I and Phase II|"Osimertinib (AZD9291) will be given at a 80mg/day dose taken orally across all levels of the dose escalation schedule.~Dasatinib is taken orally and will be given at up to 4 dose levels. Level -2 (50 mg once daily), Level -1 (70 mg once daily), Level 1 (the starting dose - 50 mg twice daily), Level 2 (70 mg twice daily).~Dose escalation will only include 2 dose levels (Levels 1 and 2); in addition there will be 2 dose levels below the starting dose level if dose reductions are necessary (Levels -1 and -2).~There is no limit to the number of cycles a patient can receive.~The phase II portion of the study will use the maximum tolerated dose of dasatinib determined in the phase I portion. Osimertinib (AZD9291) will be given at the same 80mg dose as the phase I portion."
89367375|NCT03238768|Experimental|Enhanced Nutrition|Infants randomized to the study protocol will start on higher initial amounts of calories, proteins and fats. They will also undergo faster increases of these nutrients during their first week of life.
89367376|NCT03238768|Active Comparator|Standard Nutrition|Infants randomized to the standard nutrition protocol will start on standard amounts of calories, proteins and fats per the usual NICU routine. They will also undergo standard increases of these nutrients during their first week of life.
89367377|NCT01352247|Experimental|Unicompartmental Knee Replacement|"TOPKAT will be pragmatic in terms of implant selection for the knee replacement operation. Providing the inclusion criteria are met, surgeons will be entirely free to use an implant of their choice or will use the current implants used at their institution. Implant type used on each patient will be recorded.~A partial knee replacement or UKR involves only the diseased area of the joint being replaced. The healthy compartment of the knee is retained and artificial implants are inserted in place of the diseased area. This is done via a minimally invasive surgical procedure."
89367378|NCT01352247|Experimental|Total Knee Replacement|"TOPKAT will be pragmatic in terms of implant selection for the knee replacement operation. Providing the inclusion criteria are met, surgeons will be entirely free to use an implant of their choice or will use the current implants used at their institution. Implant type used on each patient will be recorded.~A total knee replacement involves all surfaces of the knee being replaced. The procedure involves excising both diseased and normal femoral condyles, the tibial plateau and often the patella. This is done through a large skin incision which provides easy access to the knee joint. Each component will be replaced with an artificial implant, which may be cemented in position."
89367379|NCT04486612||hypotension|
89367380|NCT04486612||non-hypotension|
88839485|NCT02946866||Cerebral cavernous malformation|Patients with newly diagnosed, cerebral cavernous malformation who will visit one of the study centers during the period from June 2016 to December 2017. Patients would be eligible for enrollment if they were 18 years of age or older and had at least 1 cavernous malformation. All patients who would visit a study center during the enrollment period and meet these criteria will be asked to join the study. The cohort will consists of patients who agree to participate. Target population of this study is 228 patients.
88839486|NCT02791568||Pilot Study|"Ultrasound Scan~MRI Scan~Blood/Urine collection"
88839487|NCT02791568||Main Study- Control Group|"Ultrasound Scan~MRI Scan~Blood/Urine collection"
88839488|NCT02791568||Main Study- Study Group|"Ultrasound Scan~MRI Scan~Blood/Urine collection"
88839489|NCT02791568||Main Study- Ferumoxytol Group|"Ultrasound Scan~MRI Scan~Blood/Urine collection~Ferumoxtyol Infusion"
88839490|NCT05371730|Experimental|NK cells|
88839491|NCT05247944||F-BEVAR|Patients with complex abdominal aortic aneurysm who underwent fenestrated and branched endovascular aortic repair (F-BEVAR) at the Aortic Center of Lille (ACL; Lille, France).
88839492|NCT05247944||OPEN SURGERY REPAIR|Patients with complex abdominal aortic aneurysm who underwent open surgery repair the Unit of Vascular Surgery of Policlinic Gemelli (FPUG; Rome, Italy).
88839493|NCT05247554|Experimental|Hydroxychloroquine+low-dose prednisone|Hydroxychloroquine, tablets, 400mg/day for 6 months combined with Prednisone, 20mg/day for 1 month, then 10mg/day for 20 weeks (ie up to M6). The cumulative doses of prednisone during the 6 months of the study will be 1820mg
88839494|NCT05247554|Active Comparator|Medium-dose prednisone|"prednisone, tablets, 40mg/day for 4 weeks, then 30mg/day for 2 weeks, then 20mg/day for 2 weeks, then 15mg/day for 2 weeks, then 10mg/day for 14 weeks (i.e. up to M6).~The cumulative doses of prednisone during the 6 months of the study will be 2870mg "
88839495|NCT05217368|Experimental|experimental group/mandala painting|Mandala painting will be done in addition to routine antenatal education.
88839496|NCT05217368|No Intervention|antenatal education class|Only routine antenatal education will be done.
88839497|NCT02596022|Experimental|CI-581a|Administration of CI-581a followed 2 weeks later by CI-581b
88839498|NCT02596022|Active Comparator|CI-581b|Administration of CI-581b followed 2 weeks later by CI-581a
89367381|NCT01343433||Control group|Chamber allocation will determine which patient receives bright light therapy. We selected four patient chambers at the Intensive Care Unit, each with the capacity of two patient beds. In two chambers patients will receive bright light therapy. Patients in the other two rooms are only exposed to environmental light
89367382|NCT01343433||Treatment group (bright light therapy)|Chamber allocation will determine which patient receives bright light therapy. We selected four patient chambers at the Intensive Care Unit, each with the capacity of two patient beds. In two chambers patients will receive bright light therapy. During our study, light therapy will be applied with instrument 'Litepod' (manufactured by Goodlite, Donker Curtiusstraat 7/407, Amsterdam), which gives an intensity of 10000 lux at a distance of 22 centimetres.Patients will receive bright light therapy for three hours in the morning, from eight o'clock till eleven o'clock.
89367383|NCT03241108|Experimental|NI-0101|A therapeutic humanized monoclonal antibody, administered by intravenous infusion every 2 weeks.
89367384|NCT03241108|Placebo Comparator|Placebo|The placebo matches NI-0101 without active ingredient, administered by intravenous infusion every 2 weeks.
89367385|NCT01353651|Experimental|Endovascular treatment|
89367386|NCT01353651|Active Comparator|Open repair treatment|
89367387|NCT01343511|Experimental|Rehabilitation plus hCB-MNCs treatment|Participants will be given rehabilitation therapy plus human cord blood mononuclear cells transplantation with a 6 months follow-up.
89367388|NCT01343511|Experimental|Rehabilitation plus hCB-MNCs and hUC-MSCs therapy|Participants will be given rehabilitation therapy plus combination of hCB-MNCs together with hUC-MSCs transplantation with a 6 months follow-up.
89367389|NCT03240718|Experimental|Laser treated HSc scar|Co2 laser treatment
88839499|NCT05208320|Experimental|intervention ward|"Patients received interventions as follow:~The health education syllabus included 4 chapters: (1) introduction to hypertension, (2) complications of high blood pressure, (3) lifestyle management, and (4) SCORE - European High-Risk Chart~Home health education by Community Health Workers every month for 6 months"
88839500|NCT05208320|No Intervention|control ward|Patients received usual care, consisted of existing services in the community
88839501|NCT00364442|Experimental|Arm 1|investigational drug
88839502|NCT00364520||Shanghai Workers|Shanghai Workers
88839503|NCT02597582|Active Comparator|Ligusure assisted neck dissection|"The study group patients were treated using the LigaSure vessel sealing system (Small Jaw® with ForceTriad®; Covidien, Colorado, USA) for dissection and hemostasis throughout the whole procedures during neck dissection.~Participants were asked to take a Voren enteric-microencapsulated (Diclofenac 50 mg/capsule) capsule 3 times a day for pain relief postoperatively. An additional capsule before sleep was allowed if persistent pain was told by the patient. When intolerable pain was complained in spite of oral analgesic, pethidine (meperidine 50 mg/ampule) injection was prescribed every 6 hours."
88839504|NCT02597582|Other|Conventional neck dissection|"The control group patients were treated using conventional cold instrument dissection, monopolar electrocautery hemostasis, and suture ligation during neck dissection.~Participants were asked to take a Voren enteric-microencapsulated (Diclofenac 50 mg/capsule) capsule 3 times a day for pain relief postoperatively. An additional capsule before sleep was allowed if persistent pain was told by the patient. When intolerable pain was complained in spite of oral analgesic, pethidine (meperidine 50 mg/ampule) injection was prescribed every 6 hours."
89367390|NCT03240718|No Intervention|Control scar|Standard care
89367391|NCT01352325|Experimental|system constellations seminar (exp. group)|Study participants randomized to this group receive the intervention (system constellation seminar) 4 months prior to the control group
89367392|NCT01352325|Experimental|system constellations seminar (control group)|Study participants randomized to this group receive the intervention (system constellations seminar) 4 months after the experimental group.
89367393|NCT03238456|Experimental|Intervention|The intervention entitled Motivating Pacifika Against Cigarettes and Tobacco (MPACT) was implemented for eight weeks starting on the quit date that the participant chose with their assigned coach during the baseline assessment. At the baseline assessment, each participant watched an introductory video that described the online smoking cessation program. The online program was accessed through the participant's Facebook account. The program included eight education modules and a forum. Participants also received automated daily text messages to provide support and encouragement during the quitting process.
88839505|NCT05371574|Active Comparator|Tranexamic acid|Each participant will receive 1gram of tranexamic acid
89367394|NCT03238456|No Intervention|Control|Participants in the control group set a quit date within two weeks of their baseline assessment and watched an introductory video that described the smoking cessation program. They received one text message every other week over a period of eight weeks following the quit date. The messages were delivered by a web-based system not connected to the online intervention program. Participants were also given a handout listing local tobacco cessation and education resources, a link to a generic online smoking cessation program, a fact sheet on smoking and tobacco use among PI young adults, and a quit kit containing chewing gum and a stress ball.
89367395|NCT01353729|Experimental|Treatment A|Treatment A will include combination of zanamivir 600 mg IV plus placebo for moxifloxacin
89367396|NCT01353729|Experimental|Treatment B|Treatment A will include combination of zanamivir 1200 mg IV plus placebo for moxifloxacin
89367397|NCT01353729|Experimental|Treatment C|Treatment C will include zanamivir placebo plus placebo for moxifloxacin
89367398|NCT01353729|Experimental|Treatment D|Treatment D will include moxifloxacin plus zanamivir placebo
89367399|NCT03238378|Experimental|Therapy|Brachytherapy d1-5(6) Hyperthermia d2 + 5
89367400|NCT02453854|Active Comparator|Treatment as Usual|A Treatment as Usual (TAU) group received a psycho-educational programme for weight management over one year
89367401|NCT02453854|Experimental|Group Motivational Intervieiwng|A Motivational interviewing group received one year of programme using motivational interviewing as the approach for treatment.
89367402|NCT01357317|Active Comparator|Lanthanum Carbonate|Lanthanum Carbonate: initial dose 500 mg TID with meals, titrated at monthly intervals in 500 mg increments or decrements, with goal of returning to normal the level of the abnormal baseline marker(s) of phosphorus homeostasis (serum phosphorus, PTH or TRP). Normality for this marker will be defined as serum phosphorus of 2.6-4.6 mg/dl, PTH of 10-65pg/ml and TRP>=80%.
88839506|NCT05371574|Active Comparator|clonidine|Each participant will receive 0.2mg of oral clonidine
88839507|NCT02599766|Experimental|animal assisted therapy|"Standard therapy that is done in the presence and with integrating an animal."
88839508|NCT02599766|Active Comparator|standard therapy|"Standard therapy without the presence of an animal."
89367403|NCT01357317|Active Comparator|Calcium Acetate|Calcium Acetate: initial dose 667 mg TID with meals, titrated at monthly intervals in 667 mg increments or decrements, with goal of returning to normal the level of the abnormal baseline marker(s) of phosphorus homeostasis. The maximum daily intake of elemental calcium should not exceed 1500 mg in order to comply w/recommendations from K-DOQI [5](this is approximately equal to three 667mg tablets of calcium acetate TID).
89367404|NCT01357317|Active Comparator|Dietary instructions|Dietary instructions consisting of pamphlets describing foods high in phosphorus and consultation with a renal dietitian if necessary, with the goal of return to normal the level of the abnormal marker of phosphorus homeostasis. Rescue therapy with a phosphorus binder of the treating physician's choice will be allowed in patients who fail to normalize elevated baseline serum phosphorus levels after 3 months following dietary instructions.
89367405|NCT03238612|Experimental|FFA, clarithromycin, oseltamivir|oseltamivir 75mg + clarithromycin 500mg + FFA 200mg all twice daily for 2 days, followed by oseltamivir 75mg twice daily for 3 days
89367406|NCT03238612|Placebo Comparator|Oseltamivir alone|oseltamivir 75mg + two placebo capsules (identical in appearance to clarithromycin and FFA capsules respectively) twice daily for 2 days, followed by oseltamivir 75mg twice daily for 3 days
89367407|NCT03137121|Experimental|Olanzapine|Patients will receive 5 mg olanzapine orally for 1 to 7 days daily.
89367408|NCT03137121|Placebo Comparator|Placebo|Patients will receive a placebo orally for 1 to 7 days daily.
89367409|NCT02453776|Experimental|PRECISION dosing|Infliximab may vary between 1-10 mg/kg and the interval between 4 and 12 weeks.
89367410|NCT02453776|No Intervention|Conventional dosing of Infliximab|Infliximab 5 mg/kg every 8 or 6 weeks
89367411|NCT02915679|Other|Study participant|"All the participants performed blood sample for genetic purpose, psychiatric assessment and pain investigation:~81 depressed patients admitted after a recent suicidal act (<8 days)~81 depressed subjects with a past history of suicidal act (>1month)~80 depressed subjects without any personal history of suicidal behaviour"
89367412|NCT03256864|Experimental|Tacrolimus and Everolimus BID|"TAC BID (C0 2.5-5 ng/mL) EVR BID (1.0 mg BID targeted to C0 3-8 ng/mL)~Other Names:~Prograf~Advagraf~Zortress~Certican"
89367413|NCT03256864|Experimental|Tacrolimus and Everolimus QD|"TAC QD (C0 2.5-5 ng/mL) EVR QD (2.0 mg QD targeted to C0 3-8 ng/mL)~Other Names:~Prograf~Advagraf~Zortress~Certican"
89367414|NCT01317849|Experimental|vitamin supplements|
88839509|NCT05371418|Experimental|guided regeneration (GTR) followed by orthodontic intrusion|Ten over erupted teeth were selected with an angular bone loss with presence of their opposing for spilt mouth study aged from 20- 35 years old, were treated by GTR followed by Orthodontic intrusion
88839510|NCT05371418|Experimental|Orthodontic intrusion followed by GTR|Ten over erupted teeth were selected with an angular bone loss with presence of their opposing for spilt mouth study aged from 20- 35 years old, were treated by orthodontic intrusion followed by GTR
88839511|NCT05371340|Experimental|Postmenopausal women: Experimental group|Quercetin 500 mg. One capsule once a day.
88839512|NCT05371340|Placebo Comparator|Postmenopausal women: Placebo group|Placebo (methylcellulose E4M) 500 mg, once capsule once a day.
88839513|NCT02601170|Experimental|PRP Group|single intra-articular injection of 2mL PRP (RegentKit-THT-1, RegenLab SA, Mont-sur-Lausanne, Switzerland)
88839514|NCT02601170|Active Comparator|HA Group|five weekly intra-articular injections of 2.5 mL of hyaluronate sodium (ARTZDispo, Seikagaku Corporation Japan).
88839515|NCT05371262|Active Comparator|10-12.5 μg/kg/day of L-T4|Children with congenital hypothyroidism who received an initial L-T4 dose of 10-12.5 μg/kg/day.
88839516|NCT05371262|Active Comparator|12.6-15 μg/kg/day of L-T4|Children with congenital hypothyroidism who received an initial L-T4 dose of 12.6-15 μg/kg/day.
88839517|NCT02602496|Experimental|Control|3 servings of refined grains per day.
88839518|NCT02602496|Experimental|Fruits and Vegetables|5 servings of fruits and vegetable per day.
88839519|NCT02602496|Experimental|Whole Grain|3 servings of whole grains per day.
88839520|NCT02603666|Other|Elastography|Fibroscan elastography device for evaluation of liver disease in CF patients.
88839521|NCT00366002|Experimental|1|Darifenacin
88839522|NCT05366972|Active Comparator|Patients diagnosed with low back pain|Measurements of the back muscles and thoracolumbar fascia will be made by ultrasonography.
88839523|NCT05366972|Active Comparator|Healthy volunteers|Measurements of the back muscles and thoracolumbar fascia will be made by ultrasonography.
88839524|NCT02605304|Experimental|Arm A: LDV/SOF + RBV|Ledipasvir/sofosbuvir + ribavirin for 12 weeks, followed by 24 weeks of post-treatment follow-up.
88839525|NCT02605304|Experimental|Arm B: LDV/SOF|Ledipasvir/sofosbuvir for 24 weeks, followed by 24 weeks of post-treatment follow-up.
88839526|NCT05365880|Experimental|Liquid Lidocaine|The investigational treatment is 1.5 mL of aqueous 2% lidocaine.
88839527|NCT05365880|Placebo Comparator|Sham Placebo|The placebo arm is 1.5mL of aqueous of saline.
88839528|NCT04741490|Experimental|treatment group|The adjuvant treatment of radiotherapy combined with carrilizumab lasted for 6 cycles
88839529|NCT05603468|Experimental|Platelet Rich Plasma group|patients rejected with platelet rich plasma
88839530|NCT05603468|Active Comparator|Corticosteroid group|patients rejected with corticosteroid
88839531|NCT05603468|Placebo Comparator|Normal saline group|patients rejected with normal saline
88839532|NCT02606708|Experimental|Accelerated intensity modulated radiation therapy (AIMRT)|All patients shall receive a total of 40.5 Gy to the entire breast in 2.7 Gy/fraction x 15 fractions, Monday to Friday for 3 weeks delivered prone in uniform daily doses through IMRT tangent fields. A concurrent boost to the original tumor bed of 0.50 Gy will be delivered.
88839533|NCT05365256|Active Comparator|Standard time occupation of treatment period|habitual distraction of patients during chemotherapy sessions authorized as part of routine care (doing nothing, discussion, reading, games, etc.).
88839534|NCT05365256|Experimental|time occupation of treatment period by virtual reality|Use of virtual reality as a distraction during chemotherapy sessions. A virtual reality headset will be worn for 15 minutes per hour of treatment (with a maximum of three sessions per cycle of chemotherapy)
88839535|NCT02607254|Experimental|Pregabalin Treatment phase|All patients will be initially treated with pregabalin in a single blind fashion
88839536|NCT02607254|Experimental|Withdrawal phase|After finishing the treatment phase, some patients will be randomized to the placebo or continue on pregabalin for the 4 weeks of withdrawal phase.
88839537|NCT02609204|Experimental|Healthy Controls|Participants with normal eye exams and no history of eye diseases will best tested with Diopsys NOVA.
88839538|NCT02611154|Experimental|Intranasal Testosterone|All participants will be receiving intranasal testosterone and will follow the same study procedures.
88839539|NCT05140538|Active Comparator|Group 1|SRP + Biorepair Total Protective Repair toothpaste for home oral hygiene twice a day
88839540|NCT05140538|Experimental|Group 2|SRP + Biorepair Total Protective Repair toothpaste + Biorepair mouthwash (3 in 1) for home oral hygiene twice a day
88839541|NCT05548244|Experimental|MDD patients|Participants will be seen for a maximum of 16 sessions over 16 weeks. Two extra sessions will be allowed during treatment.
88839542|NCT02613338||DePuy Attune PS FB knee system|Patients implanted with a DePuy Attune posterior stabilizing fixed bearing knee system
88839543|NCT02614274|Experimental|Nutraceutical joint health formulation|A Proprietary Blend
88839544|NCT05104502|Experimental|Fasting|Dietary fasting.
88839545|NCT05083988|Experimental|audiovisual distraction|
88839546|NCT05083988|Experimental|audiodistraction|
89367415|NCT01317849|Placebo Comparator|Placebo|
89367416|NCT03754036|Experimental|Sleep Extension|Increase in time in bed of 1.5 hours per night for one week
89367417|NCT03754036|Experimental|Sleep Restriction|Decrease in time in bed of 1.5 hours per night for one week
89367418|NCT01317927|Experimental|Warfarin, Belinostat|Warfarin 5 mg po will be given on Day -14 and Day 3. Belinostat 1000 mg/m² will be given as a 30 minute IV infusion on Days 1 - 5
89367419|NCT03256786||Active warming|preoperative 15 min of surface warming using a forced air warmer before spinal anesthesia and coloading of warmed intravenous fluid
89367420|NCT03256786||Control|no preoperative warming and room temperature intravenous fluid
89367421|NCT03256708|Experimental|Prolardii|Prolardii GR Caps includes 4 strains of living lyophilized lactic bacteria (Lactobacillus rhamnosus GG, Bifidobacterium lactis B94, Lactobacillus casei 5773 and Lactobacillus acidophilus LA3), a yeast (Saccharomyces boulardii), a fructo-oligosaccharide (Actilight) and a dry extract of Inula helenium.
89367422|NCT03256708|Placebo Comparator|Placebo|Inactive ingredients
89367423|NCT03240796|Experimental|minimal invasive surgery and secondary IOL implantation|
89367424|NCT03240796|Active Comparator|traditional cataract surgery and secondary IOL implantation|
89367425|NCT04461483|Experimental|Part 1, Cohort 1; TAK-935 200 mg|Part 1, Cohort 1; TAK-935 200 mg, tablets, orally once on Days 1 in fasted state.
89367426|NCT04461483|Experimental|Part 1, Cohort 2; TAK-935 600 mg|Part 1, Cohort 2; TAK-935 600 mg, tablets, orally once on Days 1 in fasted state.
89367427|NCT04461483|Experimental|Part 1, Cohort 3; TAK-935 1200 mg|Part 1, Cohort 3; TAK-935 1200 mg, tablets, orally once on Days 1 in fasted state.
88839547|NCT02617784|Experimental|Regimen A: Oseltamivir with HD|Participants will receive 30 milligrams (mg) of oseltamivir via oral suspension approximately 1 hour after alternating HD sessions. Sessions will occur three times per week within the 6.5-week study period, and participants will receive a total of 9 doses of oseltamivir.
88839548|NCT02617784|Experimental|Regimen B: Oseltamivir with CAPD|Participants will receive 30 mg of oseltamivir via oral suspension once weekly after dialysis exchange. CAPD sessions will occur four times every 24 hours, and participants will receive a total of 6 doses of oseltamivir within the 6-week study period.
88839549|NCT05537168||Pediatric cardiac surgery|All patients with pediatric cardiac surgery under cardiopulmonary bypass between 2008 and 2018 will be included
88839550|NCT00366158|Experimental|1|Ventricular Instrinsic Preference (VIP) turned ON
88839551|NCT00366158|Active Comparator|2|Ventricular Instrinsic Preference (VIP) turned OFF
88839552|NCT04955756|Experimental|mNGS group|
88839553|NCT04955756|Experimental|PCR group|
88839554|NCT05732012|Experimental|Group-1|Interventions applied on Group-1 participants.
88839555|NCT05732012|No Intervention|Group-2|No interventions applied on Group-2 participants.
88839556|NCT02974166|Active Comparator|Conventional Group|Individuals with temporomandibular disorder were used rigid occlusal splints and medication (Ibuprofen and Cyclobenzaprine Hydrochloride) under the dentist professor supervision. Likewise, speech therapists performed assessments, measurements, massages, stretches and therapeutic exercises for head, neck and mouth regions during four weeks.
88839557|NCT02974166|Experimental|Osteopathic Group|Individuals with temporomandibular disorder received the same assistance of Conventional Group, cited above, plus the osteopathic care during 20 to 30 minutes once a week until the end of dental and speech therapy treatments (4 weeks).
88839558|NCT05493098|Experimental|Experimental group|The experimental group will include 18 participants with episodic tension-type headache. The treatment will include dry needling of the suboccipital, levator scapula, upper trapezius, masseter, sternocleidomastoid, splenius capitis, and cervicis, frontalis, and temporalis muscles and routine physical therapy. The needles will be inserted to obtain local twitch response, and this process will continue until no more local twitch response occurs in each session. Then the needles will be left in place for 20 minutes. In each session, three muscles from one side will be needled. Routine physical therapy will include information on nature, management, course of episodic tension-type headaches, and Multimodal care that includes craniocervical exercises and postural correction. The treatment will last two weeks, six sessions, three times a week.
89367428|NCT04461483|Placebo Comparator|Part 1, Cohort 1-3; Placebo|Part 1, Cohort 1-3; TAK-935 placebo-matching tablets, orally once on Days 1 in fasted state.
89367429|NCT04461483|Experimental|Part 2, Cohort 4: TAK-935 100 mg|Part 2, Cohort 4: TAK-935 100 mg, tablets, orally twice on Days 1-7 in fasted state with multiple doses with titration.
88875195|NCT02515890|Experimental|Saline/Midazolam/Saline/Ketamine|"All subjects receive saline (control), followed by midazolam infusion. They also experience intermittent experimental pain delivered by peripheral nerve stimulation.~Subjects then returned at least 1 week later for another set of experimental sessions with the same design, however the saline was followed by ketamine infusion."
89189253|NCT00128856|Experimental|Gemcitabine + Adriamycine + Paclitaxel|Neoadjuvant chemotherapy consisted of adriamycine 40 mg/m2, administered on day 1 as an i.v. infusion. Paclitaxel 150 mg/m2 was administered on day 2 as an i.v infusion followed by gemcitabine 2000 mg/m2 as an i.v. infusion. The three drugs were administered every two weeks for 6 cycles.
89367430|NCT04461483|Experimental|Part 2, Cohort 4: TAK-935 200 mg|Part 2, Cohort 4: TAK-935 200 mg, tablets, orally twice on Days 8-14 in fasted state with multiple doses with titration.
89367431|NCT04461483|Experimental|Part 2, Cohort 4: TAK-935 300 mg|Part 2, Cohort 4: TAK-935 300 mg, tablets, orally twice on Days 15-21 in fasted state with multiple doses with titration.
89367432|NCT04461483|Placebo Comparator|Part 2, Cohort 4: Placebo|Part 2, Cohort 4: TAK-935 placebo-matching tablets, orally twice on Days 1-21 in fasted state.
89367433|NCT03256084|Experimental|Colorectal Cancer|"Localized stage II/III (group 1), metastatic non resectable (group 2), metastatic potentially resectable (group 3).~Additional blood samples specific for the research will be collected. Tissue samples will be taken on surgical specimens from surgery."
89367434|NCT04486300|No Intervention|Season of presentation|Comparison of number of presented cases in each season
89367435|NCT04486300|Active Comparator|Intervention|Surgical intervention of failed Pneumatic cases is done
89367436|NCT04486534||Case group|36 patients between the ages of 18-65, who have been followed up for at least 3 months with the diagnosis of unilateral transtibial amputation and who have been using prostheses for at least 3 months
89367437|NCT04486534||Control group|36 age and body mass index (BMI)-matched healthy controls
88875196|NCT02515890|Experimental|Saline/Ketamine/Saline/Midazolam|"All subjects receive saline (control), followed by ketamine infusion. They also experience intermittent experimental pain delivered by peripheral nerve stimulation.~Subjects then returned at least 1 week later for another set of experimental sessions with the same design, however the saline was followed by midazolam infusion."
88875197|NCT02516046|Experimental|Flortaucipir PET Scan|
89179124|NCT04016051|Experimental|Clarithromycin DST|"Participants received oral administration of Clarithromycin DST twice a day:~125.0 mg straw, participants with body weight between 12 and 19 kg (approximate age 2-4 years).~187.5 mg straw, participants with body weight between 20 and 29 kg (approximate age 4-8 years).~250.0 mg straw, participants with body weight between 30 and 40 kg (approximate age 8-12 years).~For oral intake of DST granules, the lower end of the straw was to be dipped into a glass with a clear, cool or lukewarm, preferably flavored beverage of participant choice. Suitable beverages were lemonade (carbonated or not), clear fruit juices without pulp, tea or water. The beverage was to be sipped smoothly through the straw."
89179125|NCT04016051|Active Comparator|Clarithromycin Syrup|"Participants received oral administration of Clarithromycin Syrup twice a day:~2.5 ml (125 mg) participants with body weight between 12 and 19 kg (approximate age 2-4 years).~3.75 ml (187.5 mg) participants with body weight between 20 and 29 kg (approximate age 4-8 years).~5 ml (250 mg) participants with body weight between 30 and 40 kg (approximate age 8-12 years)."
89179126|NCT00761514|Experimental|1|All subjects will receive Adalimumab
89179127|NCT00831779|Experimental|Dapagliflozin|
89179128|NCT00831779|Placebo Comparator|Placebo|
89179129|NCT04098510|Experimental|MitoQ|Subjects ingest 160 mg of MitoQ
89179130|NCT05441891|No Intervention|Control group|Participants assigned to the control group are cited to the Health centre, but they do not suffer any intervention. These subjects followed the same evaluation and data collection process.
89179131|NCT05441891|Active Comparator|Auditory intervention filter-modulated|Participants assigned to this group listened classical music modulated by an equalizer for 30 minutes, 2 sessions a day separated by at least 3 hours, for 10 days (Monday to Friday for 2 weeks).
89367438|NCT03240484||Spine Fusion and Total Hip Replacement|Any patient who has undergone spine fusion (SF) and total hip arthroplasty (THA). Patients will undergo x-ray imaging and complete functional assessment questionnaires. Patients may additionally be asked to participate in a gait analysis in a Human Movement Laboratory.
89367439|NCT03240484||Total Hip Replacement Group|Any patient who has had THA only (no spine fusion surgery). Patients will undergo x-ray imaging and complete functional assessment questionnaires. Patients may additionally be asked to participate in a gait analysis in a Human Movement Laboratory.
89367440|NCT03240484||Spine Fusion Only Group|Any patient who has had spine fusion only (no hip replacement surgery). Patients will undergo x-ray imaging and complete functional assessment questionnaires.
89367441|NCT01353807|Active Comparator|Fish oil supplementation|These women received 4 1-g capsules of fish oil per day providing 2,7 grams long chain n-3 fatty acids per day, from gestation week 30 until delivery
89367442|NCT01353807|Placebo Comparator|Olive oil|These women received 4 1-g capsules with olive oil per day from gestational week 30 until delivery
89367443|NCT01353807|No Intervention|No oil supplement|These women received no capsules with oil
89367444|NCT03238066|Experimental|Treatment Arm|"The physician can choose either HDR or PDR brachytherapy.~If HDR BT is chosen:~d1: hyperthermia (IHT) 60 minutes + 10Gy HDR brachytherapy (HDRBT) d22: IHT 60 minutes + 10 Gy HDRBT d43: IHT 60 minutes + 10 Gy HDRBT~If PDR BT is chosen:~d1-3: IHT 60 minutes + 30Gy PDRBT d29-31: IHT 60 minutes + 30Gy PDRBT"
89367445|NCT02901483|Experimental|PEP503+Cisplatin+Radiotheraphy|"Phase 1b: There are 6 levels (L1- 5% + 40mg/m2 weekly cisplatin, L2- 10% + 40mg/m2 weekly cisplatin, L3- 15% + 40mg/m2 weekly cisplatin, L4-22% + 100mg/m2 tri-weekly cisplatin, L3a- 15% + 100mg/m2 tri-weekly cisplatin, and L5- 33% + 100mg/m2 tri-weekly cisplatin) in this phase 1b study. Only primary tumor will receive PEP503 implementation via intratumor injection. A 3 + 3 dose escalation study design will be adopted in this phase to identify the recommended intratumor injection volumes of PEP503.~Phase 2: The recommended volume identified from phase 1b will be applied in phase 2 for both primary tumor and ≥ 3 cm lymph node lesions."
89367446|NCT03256396|Experimental|Group E|PEEP set according to esophageal pressure measured
89367447|NCT03256396|No Intervention|Group C|PEEP set at 5 cm H2O
88875198|NCT02517996|Experimental|1% Lidocaine|Patients randomized in this arm will receive preemptive bilateral pudendal nerve block with 20 cubic centimeters 1% lidocaine after anesthesia induction.
89367448|NCT01353885||Anterior Approach THA|500 Patients will be included who have received a total hip arthroplasty using the Anterior Approach. The anterior approach to total hip arthroplasty refers to an internervous approach to the hip, where the incision is made from the middle of the iliac crest, then curved distally and laterally to the anterior superior iliac spine (Kelmanovich et al., 2003). To optimize feasibility and applicability of our results, we will not standardize the use of cemented components, the implant manufacturer, or the femoral head size. Surgeons will use the manufacturer specific guides for insertion of the total hip arthroplasty.
88839559|NCT05493098|Placebo Comparator|Control group|"The control group will include 18 participants with episodic tension-type headache. The treatment will include sham dry needling of the suboccipital, levator scapula, upper trapezius, masseter, sternocleidomastoid, splenius capitis, and cervicis, frontalis and temporalis muscles and routine physical therapy. The sham dry needling method includes the insertion of the needles subcutaneously and no local twitch response will be obtained. The needles will be left in the place for 20 minutes. In each session, three muscles from one side will be needled. Routine physical therapy will include information on nature, management, course of episodic tension-type headaches, and Multimodal care that includes craniocervical exercises and postural correction. The treatment will last two weeks, six sessions, three times a week."
88839560|NCT04828772||Cohort 1|COVID-19 participants receiving anticoagulants
89179132|NCT00758043|Experimental|T12PR24 (eRVR+)|Randomized Group: Telaprevir + Peg-IFN-alfa-2a + RBV for 12 weeks, followed by Peg-IFN-alfa-2a + RBV for 12 weeks; subjects achieved an extended rapid viral response (eRVR+) and were randomized to this group
88839561|NCT04828772||Cohort 2|COVID-19 participants not receiving anticoagulants
88839562|NCT05731778|Experimental|Stannous fluoride test toothpaste|Currently marketed as the new Colgate Total SF containing Stannous Fluoride
89179133|NCT00758043|Experimental|T12PR48 (eRVR+)|Randomized Group: Telaprevir + Peg-IFN-alfa-2a + RBV for 12 weeks, followed by Peg-IFN-alfa-2a + RBV for 36 weeks; subjects achieved an extended rapid viral response (eRVR+) and were randomized to this group
89179134|NCT00758043|Experimental|T12PR48 (eRVR-)|Assigned Group: Telaprevir + Peg-IFN-alfa-2a + RBV for 12 weeks, followed by Peg-IFN-alfa-2a + RBV for 36 weeks; subjects did not achieve an extended rapid viral response and were assigned to this group
89179135|NCT00758043|Experimental|Other|Other Group: Subjects who received at least 1 dose of study drug, but prematurely discontinued treatment before Week 20, were not randomized or assigned to a treatment regimen.
89179136|NCT00831701|Active Comparator|Tamsulosin|Tamsulosin treatment
88839563|NCT05731778|Placebo Comparator|Colgate flouride toothpaste|Colgate Dental Cream containing Stannous Sodium Fluoride
88839564|NCT05477264|Experimental|Tislelizumab therapy|"Induction therapy: Tislelizumab combined with radiation~Maintenance therapy(after termination of combination therapy)"
88839565|NCT00364676|Experimental|1|Patients are dosed on Day 1 and Day 8 of a 21-day cycle.
88839566|NCT00364676|Experimental|2|Patients are dosed on Day 1 of a 21-day cycle.
88839567|NCT05731700|Experimental|Drug eluting balloon|Treatment of a single in-stent restenosis coronary artery lesion with drug eluting balloon
88839568|NCT05731466|Other|CardioMems (Clinical Indication)|Single Arm, CardioMems implantation on clinical indication. No control group. Every participant is his/her own control (longitudinal follow-up)
88839569|NCT04622540|Experimental|Experimental group|Application of external biliary drainage
88839570|NCT04622540|No Intervention|Control group|Conventional duct-to-duct anastomosis (with or without internal stent)
88839571|NCT04741880|Experimental|Group L (Lidocaine)|Lidocaine bolus 1.5 mg.kg-1 intravenous before the onset of lidocaine infusion Lidocaine 2mg.kg-1.h-1
88839572|NCT04741880|Placebo Comparator|Group S (saline solution)|Lidocaine bolus 0.75 mg.kg-1 intravenous before the onset of saline infusion Saline solution infusion
88839573|NCT05447234|Experimental|TCRX-T|"① 1x10^7/m2 ;~3x10^7/m2；~1x10^8/m2；~3x10^8/m2；~1x10^9/m2。"
88839574|NCT05433818|Experimental|Skin-to-skin care|"Pregnant women will assigned to SSC were inform about SSC. SSC will ensured postpartum in a supported diagonal-flexion position continuously by the researchers for 45-120 minutes. Mothers in group A also benefit from the hospital's routine breastfeeding education service.~As a result, after the SSC application, the mother will be evaluated with the breastfeeding efficiency scale and the maternal attachment scale."
88839575|NCT05433818|Active Comparator|Breastfeeding Education|Group B will received face-to-face breastfeeding education in the first phase of labor. A copy of the brochure will given to the pregnant women. In the early postpartum period, breastfeeding will encouraged practically and observed by the researchers. Participants' questions will answered. As a result, after the breastfeeding education, the mother will be evaluated with the breastfeeding efficiency scale and the maternal attachment scale.
88839576|NCT05433818|No Intervention|Kontrol|No intervention will made to Group C by the researchers. Participants will benefit from the hospital's routine care and breastfeeding education services. As a result, postpartum mother will be evaluated with breastfeeding efficiency scale and maternal attachment scale.
88839577|NCT04621838|Experimental|Assigned intervention.|"Silicone Foam Dressing. Silicone Foam Lite.~Subjects will undergo treatment of their chronic or acute wound as indicated in the instructions for use with Silicone Foam dressing and Silicone Foam Lite Dressing."
89179137|NCT00831701|Placebo Comparator|Placebo|Placebo treatment
89179138|NCT00705419||Previous vicriviroc 30 mg QD|Subjects who previously received vicriviroc 30 mg daily in a Phase 2 or 3 clinical trial.
89179139|NCT00705419||Previous vicriviroc 20 mg QD|Subjects who previously received vicriviroc 20 mg daily in a Phase 2 or 3 clinical trial.
89179140|NCT00705419||Control Group|Subjects who previously received active control or placebo in a Phase 2 or 3 clinical trial involving vicriviroc.
89001817|NCT00409058|Experimental|Teen Online Problem Solving|The TOPS program has 10 sessions that provide training in stress management, problem solving, communication, and social skills to all enrolled families, while the remaining 6 sessions address content related to the stressors and burdens of individual families. Each self-guided online session includes real adolescents talking about how TBI affected them, content regarding the skill, video clips showing adolescents and/or families modeling the skill, and exercises giving the family an opportunity to practice the skill. After the completion of the self-guided web pages, the family will meet with the therapist via videoconference; the therapist will review the exercises and help the family implement the problem-solving process with a problem or goal identified by the family.
89001818|NCT00409058|Experimental|Internet Resources Comparison|Families in the IRC group will also receive a computer, printer, and high-speed internet access if they do not currently have these. Additionally, IRC families receive access to a home page of brain injury resources and links (identical to those given on the TOPS and TOPS-TO homepage) but will not be able to access specific session content. This will enable us to equate the groups with respect to access to the information and resources available on the Web.
89001819|NCT00409136||Alert|Physicians alerted about their high risk patients who are not receiving any VTE prophylaxis.
89001820|NCT00409136||No Alert|Physicians not alerted about their high risk patients who are not receiving any VTE prophylaxis.
89001821|NCT00211263|Experimental|Enhanced Clinical Intervention|
89001822|NCT00211263|Active Comparator|Clinical Intervention|
89001823|NCT00185510|Experimental|Arm 1|
89001824|NCT00185510|Placebo Comparator|Arm 2|
89001825|NCT00218244|Active Comparator|1 Controlled use|Reduction in tobacco toxicants by switching to a lower nicotine tobacco product under a controlled use condition.
89001826|NCT00218244|Active Comparator|2 Uncontrolled use|Reduction in tobacco toxicants by switching to a lower nicotine tobacco product under an uncontrolled use condition.
89001827|NCT00218244|Placebo Comparator|3 Behavioral|Reduction in smokeless tobacco use using behavioral techniques only.
89001828|NCT00218283|Experimental|1 - Nicotine Lozenge|Use of nicotine lozenge plus behavioral counseling to help reduce tobacco use prior to quit date.
89001829|NCT00218283|Placebo Comparator|2 Behavioral counseling|Use of behavioral counseling alone to help reduce tobacco use prior to quit date.
89001830|NCT00218322|Placebo Comparator|1|Treatment with placebo or atomoxetine for 12 weeks.
89001831|NCT00218322|Experimental|2|
89001832|NCT00186173|Experimental|After school sports|After school team sports intervention designed specifically for overweight and obese children
89001833|NCT00186173|Active Comparator|After school health education|After school heath and nutrition education program
89001834|NCT00218517|Experimental|1|
89001835|NCT00218517|Placebo Comparator|2|
89001836|NCT00218556|Experimental|Depression prevention|Cognitive behavioral treatment for depression.
89001837|NCT00218556|No Intervention|Control|Treatment as usual.
89001838|NCT00218595|Experimental|DBT|
89001839|NCT00218595|Active Comparator|I/GDC|
89001840|NCT02962713|Active Comparator|ART with Equia|Occlusal-proximal restoration in primary molars using Equia (Easy/Quick/Unique/Intelligent/Aesthetic) from GC Corp, encapsulated, pre-dosed and mechanized handling.
89001841|NCT02962713|Experimental|ART with Giomer Beautifil-Bulk Restorative|Occlusal-proximal restoration in primary molars using Giomer Beautifil-Bulk Restorative (SHOFU Inc)
89001842|NCT00218673|Experimental|experimental|social network
89001843|NCT00218673|No Intervention|control|testing and counseling
89001844|NCT00218712|Experimental|1|Participants will receive personalized cognitive counseling
89001845|NCT00218712|Active Comparator|2|Participants will receive standard counseling
89001846|NCT00218790|No Intervention|Control group|The control group received standard dialysis at a temperature of 37 degrees Celcius
89001847|NCT00218790|Experimental|Experimental group|Subjects in the experimental group received cool dialysate during treatment
89001848|NCT00186758|Sham Comparator|1, Phase l, True or Sham|this treatment will be True or Sham (placebo) on one side of the head, phase I
89001849|NCT00186758|Active Comparator|2, phase ll, Sham or True|This treatment will be Sham(placebo)or True on the other side of the head phase II.
89001850|NCT00186914|Other|1|
89001851|NCT00186953|Other|1|
89001852|NCT00187031|Other|1|
89001853|NCT00187070|Other|1|
89001854|NCT00187148|Other|1|
89001855|NCT02962479||TNF blocker-naïve ankylosing spondylitis patients|
89001856|NCT02962479||TNF blocker-exposed ankylosing spondylitis patients|
89001857|NCT02962479||TNF blocker-naïve nrSpA patients|
89001858|NCT02962479||TNF blocker-exposed nrSpA patients|
89001859|NCT02962479||Healthy Participants|
89001860|NCT00187187|Active Comparator|Implantable Defibrillator (ICD) VVI-40|The DAVID II Clinical Study evaluates the hypothesis that, in patients needing an ICD but without overt indications for pacing, AAI pacing with maximal concomitant drug therapy (AAI-70)will not increase the rate of the combined endpoint of mortality or hospitalization for new or worsened heart failure, compared to patients with ventricular backup pacing (VVI-40).
89179141|NCT02599935|Experimental|educational intervention and supplements|structured educational intervention and dietary supplements
89179142|NCT02599935|Active Comparator|usual interventions|Usual treatment without nutritional supplements or structured assessment
89179143|NCT05425355|Experimental|Intravenous (IV) acetaminophen plus oral placebo|In this group, the IV study drug will be IV acetaminophen and the oral study drug will be a placebo tablet.
89367449|NCT01353885||Posterior Approach THA|100 patients will be enrolled who have received a total hip arthroplasty using the posterior approach. The posterior approach is performed by making a curved incision posteriorly on the greater trochanter (Jolles & Bogoch, 2004). The fascia lata is then incised and the fibers of the gluteus maximus split using dissection (Jolles & Bogoch, 2004). To ensure the feasibility and applicability of our findings, we will not standardize the use of cemented components, the implant manufacturer, or the femoral head size used in the posterior approach.
89367450|NCT01353885||Anterolateral Approach THA|100 patients will be enrolled who have had a total hip arthroplasty using the anterolateral approach. An anterolateral approach to THA utilizes an intermuscular approach by incising the patient posteriorly and distally to the anterior superior iliac spine, extending distally to the greater trochanter along the shaft of the femur (Kelmanovich et al., 2003). To optimize the feasibility and applicability of our results, the implant manufacturer, femoral head size or the use of cemented components will not be standardized in this study.
89367451|NCT03256318||Children in Sports and Rec|Children with disabilities who enter the study between ages 5 and 10 who are participating in a Sports and Recreation Program. They will receive no intervention, only surveys.
89367452|NCT03256318||Comparison Children|Children with disabilities who enter the study between ages 5 and 10 and end participation in Sports and Recreation Program at a later date. They will receive no intervention, only surveys.
89367453|NCT02874651|Experimental|Apatinib|In the phase IIb part of this trial, patients in this arm will take oral apatinib until disease progression, intolerable toxicity, death or to a maximum of 2 years.
89367454|NCT02874651|Placebo Comparator|Placebo|In the phase IIb part of this trial, patients in this arm will take oral placebo until disease progression, intolerable toxicity, death or to a maximum of 2 years.
89367455|NCT02453932|Experimental|Tianzhi granule|Tianzhi granule and placebo identified to donepezil
89367456|NCT02453932|Active Comparator|Donepezil|Donepezil and placebo identified to Tianzhi granule
89367457|NCT02453932|Placebo Comparator|Placebo|Placebo identified toTianzhi granule and placebo identified to donepezil
89367458|NCT04387851||Placebo|Placebo effects are defined as the positive effects occurring after the (supposed) administration of an inert treatment, which, through a given learning process, is believed to have positive effects.
89367459|NCT04387851||Nocebo|Nocebo effects are defined as the negative effects occurring after the (supposed) administration of an inert treatment, which, through a given learning process, is believed to have negative effects.
88839578|NCT04551326|Experimental|hamstring stretching|Participants' lower limb will be positioned in maximal hip flexion and gradually moved to maximal knee extension by physical therapist. The procedure will take one minute for each lower limb.
88839579|NCT04490486|Experimental|Group 1: (UCMSCs)|Participants in this group will receive the 2 intravenous (IV) UCMSCs intervention on day 0 and day 3.
89367460|NCT00700570|Experimental|1|
89367461|NCT02453698|Experimental|Methylphenidate|
89367462|NCT02453698|Placebo Comparator|Control Group|
89367463|NCT01744041|Experimental|Dyadic Interpersonal Psychotherapy|Brief Interpersonal Psychotherapy during pregnancy followed by dyadic mother-infant psychotherapy for one year postpartum
89367464|NCT01744041|Active Comparator|Enhanced Treatment as Usual|Personalized referral to community resources for depression treatment
89367465|NCT03255694|Experimental|PEG-somatropin|After the first stage (52 weeks) of Phase II clinical trial, the initial medication dose of this extension period is 0.2 mg/kg weight/week of PEG-rhGH for the high dose group, low dose group and negative control group, and it is adjusted in accordance with yearly height velocity (HV) and IGF-1 SDS of each visit. The maximum dose shall not exceed 0.4 mg/kg weight/week.
89367466|NCT02840643|Experimental|Constraint Therapy and Bimanual Therapy|Children in this arm will receive 90 hours (6 hrs/day, 5 days/week, 3 weeks) of Intensive Hand Therapy (constraint therapy), followed by 90 hours (6 hrs/day, 5 days/week, 3 weeks) of Intensive Bimanual Hand Therapy (bimanual therapy). During constraint therapy, children will wear a mitt over their less-impaired hand and actively use their more-impaired hand in therapy. Therapy will involve playing games, practicing activities of daily living, doing arts and crafts, and practicing repetitive hand movements. During bimanual therapy, children will actively use both hand in therapy. Therapy will involve playing games, practicing activities of daily living, doing arts and crafts, and practicing repetitive hand movements.
89367467|NCT02840643|Experimental|Bimanual Therapy and Constraint Therapy|Children in this arm will receive 90 hours (6 hrs/day, 5 days/week, 3 weeks) of Intensive Bimanual Hand Therapy (bimanual therapy), followed by 90 hours (6 hrs/day, 5 days/week, 3 weeks) of Intensive Hand Therapy (constraint therapy). During bimanual therapy, children will actively use both hand in therapy. Therapy will involve playing games, practicing activities of daily living, doing arts and crafts, and practicing repetitive hand movements. During constraint therapy, children will wear a mitt over their less-impaired hand and actively use their more-impaired hand in therapy. Therapy will involve playing games, practicing activities of daily living, doing arts and crafts, and practicing repetitive hand movements.
89367468|NCT03238144|Other|MRF +/-contrast enhanced MRI|MRF with or without contrast enhanced MRI
89367469|NCT01354041|No Intervention|Treatment-as-usual|Participants in the Treatment as usual (TAU) arm will not receive any specific Fear of Cancer Recurrence (FCR) intervention during the study period. However, they will be offered an optional full-day workshop at the end of the study.
88839580|NCT04490486|Placebo Comparator|Group 2: (Placebo)|Participants in this group will receive the placebo, a solution of 1% human serum albumin in Plasmalyte A, on day 0 and day 3.
88839581|NCT05421728|Experimental|Participants: ENACT Group Visit|Participants will engage in two 2-hour group visits related to advance care planning, including printed advance care planning resources.
88839582|NCT05421728|Active Comparator|Participants: Mailed Resources|Participants will receive printed advance care planning resources by mail.
89367470|NCT01354041|Experimental|Acceptance and Commitment Therapy|"Participants in the intervention arm will receive seven sessions of a mindfulness and values-based living intervention, led by a trained licensed facilitator, conducted in groups of 10-12 participants and include components specifically designed to reduce FCR. The intervention arm will include six weekly 90 minute group sessions and one followup 90 minute group session booster session held three weeks later. The group sessions will be interactive and experiential and include homework practice for generalizing skills."
89179144|NCT05425355|Active Comparator|Intravenous (IV) placebo plus oral acetaminophen|In this group the IV study drug will be normal saline and the pill will be acetaminophen
88839583|NCT05421728|No Intervention|Clinic Stakeholders|"Clinic stakeholders providing care for participants enrolled in the Participants: Enact Group Visits arm. Demographics, and adverse event data will not be collected for this arm."
88839584|NCT05421728|No Intervention|Caregivers|Caregivers will be consented via postcard consent to facilitate patient participants' engagement in the trial and group visits. Outcome measure, demographics, and adverse event data will not be collected for this arm, however caregivers will assist participants in providing outcome measure data (responding to surveys, etc.)
88839585|NCT00365924|Other|Forteo|
88839586|NCT05731310|Experimental|Angong Niuhuang Pill Group|Take half an Angong Niuhuang pill every day for 4 weeks
88839587|NCT05731310|Experimental|Angong Niuhuang pill combined with music electroacupuncture group|Take half an Angong Niuhuang pill every day for 4 weeks and Daily music scalp acupuncture treatment
88839588|NCT05731310|No Intervention|General control group|no intervention
88839589|NCT04303286||Recovery Group|The liver function of HCC patients on the fifth day after the operation is recovered.
89179145|NCT00705497|Experimental|1|
89367471|NCT03238222|Experimental|MOSAIC Treatment|MOSAIC treatment plus Usual NHS Care. MOSAIC treatment comprises 2 x 60-minute individual face-to-face consultations (weeks 1 & 2) and 2 x 20-minute follow-up telephone calls (weeks 6 & 12) with a trained physiotherapist.
89367472|NCT03238222|No Intervention|Usual Care Comparison|Usual NHS care for people with intermittent claudication typically consists of an initial assessment, drug therapy and simple advice to walk provided by a vascular specialist and delivered in the vascular outpatient clinic.
88839590|NCT04303286||Recovery Delay Group|The liver function of HCC patients on the fifth day after the operation is delayed recovered.
88839591|NCT04303286||Control Group|The patients on benign disease of the liver
88839592|NCT05360030|Experimental|active stimulation of M1|pcTBS was administered to the left M1 at 80% resting motor threshold (RMT), consisting of a burst of 3 pulses given at 50 Hz repeated every 5 Hz. A total of 1,200 pulses were delivered with the TMS coil positioned in a posterior-anterior (PA) direction parallel to the midline.
88839593|NCT05360030|Experimental|active stimulation of DLPFC|pcTBS was administered to the left DLPFC at 80% resting motor threshold (RMT), consisting of a burst of 3 pulses given at 50 Hz repeated every 5 Hz. A total of 1,200 pulses were delivered with the TMS coil positioned in a posterior-anterior (PA) direction parallel to the midline.
88839594|NCT05360030|Sham Comparator|SHAM stimulation|The Sham stimulation was delivered using the same protocol, with the coil being orientated at 90° to the scalp so that the magnetic field would be delivered away from the scal
88839595|NCT05731232|Placebo Comparator|Pacebo|Capsules containing maize starch with identical appearance as verum. One capsule taken per day before bedtime. Treatment duration 12 weeks.
88839596|NCT05731232|Experimental|Vivatlac Synbiotikum|Vivatlac Synbiotikum for twelve weeks. One capsule containing a mixture of nine different probiotic bacteria with a total amount of 4.5 x 10˄9 colony forming units taken per day before bedtime. Treatment duration 12 weeks.
88839597|NCT05731154||thyroid eye disease group|"Patients who were diagnosed as thyroid eye disease. Periorbital images are taken by DSLR camera in the studio. Periorbital selfie images are taken by the patients with 6 smartphones including various camera modules.~CAS of TAO is evaluated by 3 ophthalmologists based on the periorbital digital images taken by DSLR camera and symptoms."
88839598|NCT05731076|Experimental|Self-management support nutrition and exercise group|Educate how to plain regular exercise and eat enough protein diet with self-management support.
89367473|NCT01354119|Active Comparator|Early intervention|Early intervention: stent-graft just after acute phase
88839599|NCT05731076|No Intervention|Routine health education group|Routine health education.
88839600|NCT00364910|Experimental|Cognitive behavioral therapy (CBT)|Participants will receive cognitive behavioral therapy
88839601|NCT00364910|Active Comparator|Educational session and treatment as usual|Participants will receive an educational session and treatment as usual
89367474|NCT01354119|No Intervention|Conservative|Conservative: medial follow-up without early intervention
89367475|NCT03240562|Sham Comparator|IV-PCA group|no block performing, only use intravenous patient controled analgesia(IV-PCA)
89367476|NCT03240562|Experimental|SAPB group|serratus anterior plane block(SAPB) and intravenous patient controled analgesia(IV-PCA)
88839602|NCT05730998|Experimental|Intervention group|1 capsule (120 mg) of Anthocran phytosome will be taken 1 times a day, for 6 months, with control every 2 months and phone call every month of treatment.
88839603|NCT05730998|Placebo Comparator|Placebo group|1 capsule of placebo will be taken 1 times a day, for 6 months, with control every 2 months and phone call every month of treatment.
88839604|NCT05341778|Experimental|Pilates exercises|The Pilates method's exercises emphasize breathing and the activation of the deep stabilizing muscles of the trunk in coordination with the PFM. The pilates method consists of exercises that emphasize pelvic stability, mobility, and body alignment. PMFE are performed in tandem with breathing, with concurrent trunk muscle recruitment in various positions.
89179146|NCT00752895|Experimental|Arm I - Ginseng|Patients receive oral American ginseng extract twice daily.
89179147|NCT00752895|Placebo Comparator|Arm II - Placebo|Patients receive oral placebo twice daily.
89179148|NCT00831389|Experimental|Closed Loop (CL) Phase|Closed Loop (CL) Phase
89367477|NCT01354275|Active Comparator|GnRH Agonist|oral contraceptive pill and GnRH Agonist IVF/ICSI cycle
89367478|NCT01354275|Active Comparator|GnRH Agonist Arm|Oral contraceptive pill and day 21 GnRH agonist began, Day 3 of menstruation 150 IU FSH will be started. If 3 or more follicle reach >17 mm hCG will be administered.
88839605|NCT05341778|Active Comparator|Pelvic floor exercise|These exercises are intended to strengthen weak perineal and pelvic floor muscles.
88839606|NCT04742426|Active Comparator|WHO group|minimal setting of personal protective equipment (COVID 19) recommended by WHO
88839607|NCT04742426|Experimental|Super-safe setup|maximal super-safe setup of personal protective equipment
88839608|NCT04740944|Experimental|Intervention group|the intervention group was subjected to salutogenic approach-based interview consisting of 16 sessions twice a week.
88839609|NCT04740944|No Intervention|Control group|The control group continued their routine activities and was interviewed face-to-face 5 times.
89179149|NCT00831389|No Intervention|Standard of Care (OL) Phase|Standard of Care (OL) Phase or Open Loop Phase
88839610|NCT05272202|Experimental|Median nerve stimulation|
88839611|NCT04741412||Hypohidrotic Ectodermal Dysplasia|all household members with hypohidrotic ectodermal dysplasia (HED), a rare hereditary developmental disorder
88839612|NCT04741412||Control|individuals of the same age group, but without HED, including pregnant women
88839613|NCT05726474|Experimental|Combined exercise|
88839614|NCT05726474|Experimental|High interval training|
88839615|NCT05726474|No Intervention|Usual care|
88839616|NCT04668638|Other|Control group|Group 1 (Control Group) will not immediately receive respiratory rehabilitation but between the 2nd and 4th months postdiagnosis.
89179150|NCT04093713|Other|participants|participants are subjected to a novel technique to block the inferior alveolar nerve depending on extraoral landmarks
89367479|NCT03255850||Adolescents with CHD|Adolescents with CHD are required to complete the Chinese version of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), Center for Epidemiological Studies -Depression Scale (CES-DC) and Rosenberg Self-Esteem Scale (RSES)
89367480|NCT03255850||Healthy control|Data of healthy control who completed the Chinese version of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), Center for Epidemiological Studies -Depression Scale (CES-DC) and Rosenberg Self-Esteem Scale (RSES) are retrieved from previous studies.
89179151|NCT04093635||Group I|Those patients that will be treated by NPWT.
89367481|NCT03255850||Childhood cancer survivors|Data of childhood cancer survivors who completed the Chinese version of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), Center for Epidemiological Studies -Depression Scale (CES-DC) and Rosenberg Self-Esteem Scale (RSES) are retrieved from previous studies.
89367482|NCT01318161|Experimental|Epidural anesthesia and analgesia|
88839617|NCT04668638|Other|Intervention group|Group 2 (Intervention Group) will immediately receive rehabilitation between the diagnosis and the 2nd month postdiagnosis.
89179152|NCT04093635||Group II|Those patients will be treated with standard saline moist wound care and dressing.
88839618|NCT05707442|Experimental|Stent Implantation|The endovascular procedure was performed under general anesthesia. Intravenous heparin was administered during the stent procedure to increase the activated clotting time to > 250 s. An 8F guiding catheter was delivered to the internal jugular vein near the skull base. A 6F Navien intermediate guide catheter was then placed into the distal transverse sinus near the torcula through the 8F guiding catheter. A microguidewire was navigated across the stenosis using a microcatheter, followed by the deployment of a self-expanding stent (eg, Precise or Wallstent) adjusted to the normal sinus venous diameter adjacent to the stenosis. Venography and manometry were performed after the procedure.
88875199|NCT02517996|Placebo Comparator|Normal Saline|Patients randomized in this arm will receive preemptive bilateral pudendal nerve block with 20 cubic centimeters normal saline after anesthesia induction.
88875200|NCT02518230|Other|Neurally Adjusted Ventilatory Assist|Subject will be randomized to NAVA ventilation. Intervention is mechanical ventilation with Neurally Adjusted Ventilatory Assist for 12 hours.
89179153|NCT00916851||Control group|Normally developing children and adolescents
89179154|NCT00916851||ADHD group|Children and adolescents with ADHD
89179155|NCT00916851||ASD group|Children and adolescents with ASD
89179156|NCT00831311|Experimental|1|DTaP IPV HB-PRP~T vaccine group
88875201|NCT02518230|Other|Synchronized Interm. Mandatory Assist|Subject will be randomized to SIMV(PC)PS ventilation. Intervention is mechanical ventilation with Synchronized Intermittent Mandatory Assist with Pressure Support for 12 hours.
89179157|NCT00831311|Active Comparator|2|PENTAXIM™ and ENGERIX B® vaccines group
89179158|NCT04093479||BMI, oxytocin|Repeteadly blood samples will be taken
89179159|NCT00831233|Experimental|Degarelix 240 mg/80 mg|Degarelix 240 mg (40 mg/mL) + 80 mg (20 mg/mL)
89179160|NCT00831233|Active Comparator|Goserelin (3.6 mg) + bicalutamide (50 mg)|Goserelin (3.6 mg) + bicalutamide (50 mg)
89179161|NCT05438277|Experimental|methylprednisolone acetate (MPA)|subacromial or glenohumeral shoulder injection
89179162|NCT05438277|Active Comparator|triamcinolone acetonide (TA)|subacromial or glenohumeral shoulder injection
89179163|NCT00761280|Experimental|trabedersen 10 µM|10 µM trabedersen (AP 12009), intratumoral infusion, every other week, 11 cycles, maximum 21 weeks
89367483|NCT01318161|Active Comparator|Patient controlled analgesia|
89367484|NCT03255538|Experimental|DFM: Mean pressure|In this group, deep friction massage will be applied with the mean pressure, previously obtained in a baseline assessment.
89367485|NCT03255538|Experimental|DFM: Mean pressure - 25%|In this group, deep friction massage will be applied will less 25% of the pressure previously obtained in a baseline assessment.
89367486|NCT03255538|Experimental|DFM: Mean pressure +25%|In this group, deep friction massage will be applied will an increment of 25% of the pressure previously obtained in a baseline assessment.
89367487|NCT03255538|No Intervention|Control session|In this group, the participants will rest for 15 minutes
89367488|NCT03255226|Experimental|Tolvaptan|Tolvaptan 1% granules or tolvaptan 15 mg tablet with water once daily.
89367489|NCT03237988|Active Comparator|Sequence ABC|100 mg CPI-444, given orally as a 1 × 100-mg capsule, after an overnight fast of at least 10 hours (fasted); 100 mg CPI-444, given orally as a 1 × 100-mg tablet, after an overnight fast of at least 10 hours (fasted); 100 mg CPI-444, given orally as a 1 × 100-mg tablet, 30 minutes after the start of a high-fat breakfast (fed).
89367490|NCT03237988|Active Comparator|Sequence BCA|100 mg CPI-444, given orally as a 1 × 100-mg tablet, after an overnight fast of at least 10 hours (fasted); 100 mg CPI-444, given orally as a 1 × 100-mg tablet, 30 minutes after the start of a high-fat breakfast (fed); 100 mg CPI-444, given orally as a 1 × 100-mg capsule, after an overnight fast of at least 10 hours (fasted).
89367491|NCT03237988|Active Comparator|Sequence CAB|100 mg CPI-444, given orally as a 1 × 100-mg tablet, 30 minutes after the start of a high-fat breakfast (fed); 100 mg CPI-444, given orally as a 1 × 100-mg capsule, after an overnight fast of at least 10 hours (fasted); 100 mg CPI-444, given orally as a 1 × 100-mg tablet, after an overnight fast of at least 10 hours (fasted).
89367492|NCT03237832|Placebo Comparator|Cohort 1|Cohort 1 (sentinel group): 1 subject received 50 mg ARN-6039 and 1 subject placebo Cohort 1: 7 subjects received 50 mg ARN-6039 and 1 subject placebo
89367493|NCT03237832|Placebo Comparator|Cohort 2|Cohort 2 (sentinel group): 1 subject received 100 mg ARN-6039 and 1 subject placebo Cohort 2: 7 subjects received 100 mg ARN-6039 and 1 subject placebo
89367494|NCT03237832|Placebo Comparator|Cohort 3|Cohort 3 (sentinel group): 1 subject received 150 mg ARN-6039 and 1 subject placebo Cohort 3: 7 subjects received 150 mg ARN-6039 and 1 subject placebo
89367495|NCT03237832|Placebo Comparator|Cohort 4|Cohort 4 (sentinel group): 1 subject received 200 mg ARN-6039 and 1 subject placebo Cohort : 7 subjects received 200 mg ARN-6039 and 1 subject placebo
89367496|NCT03237832|Placebo Comparator|Cohort 5|Cohort 5 Period 1, fasted (sentinel group): 1 subject received 300 mg ARN-6039 and 1 subject placebo Cohort 5 Period 1, fasted: 7 subjects received 300 mg ARN-6039 and 1 subject placebo Cohort 5 Period 2, fed (sentinel group): 1 subject received 300 mg ARN-6039 and 1 subject placebo Cohort 5 Period 2, fed: 7 subjects received 300 mg ARN-6039 and 1 subject placebo
89367497|NCT03237676|Experimental|Individualised structured cognitive rehabilitation therapy|Participants of interventional arm will receive individualised structured cognitive rehabilitation therapy at the proposed health centre (University Malaya Medical Centre, Malaysia).
89367498|NCT03237676|Active Comparator|Patient-centred cognitive therapy|Participants of conventional arm will receive an existing cognitive rehabilitation treatment available at the proposed health centre (University Malaya Medical Centre, Malaysia).
89367499|NCT03240250||Uni-portal VATS|VATS uni-portal lobectomy and lymphoadenectomy
89367500|NCT03240250||Three-portal VATS|VATS three-portal lobectomy and lymphoadenectomy
88839619|NCT05707442|Active Comparator|Medical Therapy|The medical treatment consisted of acetazolamide (0.5-4 g/day) and short-term mannitol (bolus of 0.25-1 g/kg body weight) for a duration of about 1 week or repeated lumbar punctures to reduce intracranial pressure (20 mL each), as well as analgesics for headaches. The initial dosage of acetazolamide was 0.5 g daily in two divided doses, followed by dosage increases of one tablet every week up to a maximum dosage of 4 g/day. The dosage escalation was stopped if the participant had papilledema grade <1 in both eyes, unless the presence of other symptoms such as headache or tinnitus suggested that the dosage escalation should continue. The dosage for the participants who were unable to tolerate the study drug was decreased gradually to a minimum of one half tablet daily. In addition, the weight loss program included a low-calorie diet (≤425 kcal/day) with a target weight loss of approximately 5-10%.
89367501|NCT03237598||male|young (≥18 and ≤45), adult (45~60), and old (>60) , n=1960
89367502|NCT03237598||female|young (≥18 and ≤45), adult (45~60), and old (>60) , n=2348
89367503|NCT03255460||Multiple Sclerosis individuals|Multiple sclerosis patients included in this study. Inclusion and exclusion criteria were considered.
89367504|NCT03255460||Healthy individuals|Those without chronic disease were included in the study. Inclusion and exclusion criteria were considered.
89367505|NCT03239782|Experimental|Metabolically unhealthy|"Subjects classified as metabolically unhealthy (MONW) go on to participate in a calorie restriction intervention.~MONW subjects will participate in a supervised weight loss program to help ensure they are under a similar weekly energy deficit and achieve a 5 % weight loss at approximately the same time. Participants will be prescribed a reduced-calorie diet (~500 kcal/d below their needs for weight maintenance), and will be instructed not to change their physical activity habits, in order to achieve a weekly weight loss of ~0.5 kg.~The macronutrient composition of the diet will be the same for all groups (55-60 % of energy from carbohydrate, 15-20 % from protein, and 20-30 % from fat); no vitamins or other nutritional supplements will be given."
89367506|NCT02455726|Experimental|Mg-group|"Standard therapy plus magnesium oxide.~Standard therapy: oxycodone 5 mg and pregabalin 25 mg per day for two weeks. Starting by day 2, the opioid dose will be titrated every 48 hours in order to reach the maximum therapeutic goal and to minimize side effects.~A rescue dose: paracetamol 1g (maximum dose 3 g per day)."
88839620|NCT04604132|Experimental|Derazantinib|In Substudies 1 and 3.1, patients with HER2-negative adenocarcinoma of the stomach or gastro-esophageal junction harboring FGFR genetic aberrations will receive derazantinib.
89367507|NCT02455726|Placebo Comparator|C-group|"Standard therapy plus fructose.~Standard therapy: oxycodone 5 mg and pregabalin 25 mg per day for two weeks. Starting by day 2, the opioid dose will be titrated every 48 hours in order to reach the maximum therapeutic goal and to minimize side effects.~A rescue dose: paracetamol 1g (maximum dose 3 g per day)."
88839621|NCT04604132|Experimental|Derazantinib-paclitaxel-ramucirumab|In Substudies 2 and 3.2, patients with HER2-negative adenocarcinoma of the stomach or gastro-esophageal junction harboring FGFR genetic aberrations will receive derazantinib-paclitaxel-ramucirumab in combination.
88839622|NCT04604132|Experimental|Derazantinib-atezolizumab|In Substudy 3.3, patients with HER2-negative adenocarcinoma of the stomach or gastro-esophageal junction harboring FGFR genetic aberrations will receive derazantinib-atezolizumab in combination.
89179164|NCT00761280|Active Comparator|Chemotherapy|temozolomide: capsules, up to 200 mg/sqm/day, 5 days per cycle, up to 26 cycles; carmustine: i.v. administration, up to 200 mg/sqm/day, 1 day per cycle, up to 8 cycles; lomustine: capsules, 110 mg/sqm/day, 1 day per cycle, up to 8 cycles. Only 1 of these 3 drugs/interventions is administered per patient in the comparator arm.
89179165|NCT04093089|Experimental|Test Group|
89367508|NCT04488328|Experimental|Magnetic Therapy Group|patients received the routine medical treatment (Bisphosphonates, Calcium, and Vitamin D) in addition to pulsed magnetic therapy on the pelvic region for 12 weeks
89367509|NCT04488328|Experimental|Exercise group|patients received the routine medical treatment in addition to moderate-intensity aerobic exercise for 12 weeks
88839623|NCT04604132|Active Comparator|Standard of care|In Substudy 3.4, patients with HER2-negative adenocarcinoma of the stomach or gastro-esophageal junction harboring FGFR genetic aberrations will receive the Standard of Care drugs paclitaxel-ramucirumab in combination.
88839624|NCT04799808||BioNTech cohort|The BioNTech cohort is composed of 1000 study participants who will be protected from SARS-CoV-2 infection by comirnaty vaccine from BioNTech. The study participants consist of mildly immunocompromised dialysis patients, severely immunocompromised solid organ transplant recipients, and the staff caring for them in the nephrology dispensaries.
88839625|NCT04799808||Moderna cohort|The Moderna cohort is composed of 1000 study participants who will be protected from SARS-CoV-2 infection by Moderna Biotech vaccine. The study participants consist of mildly immunocompromised dialysis patients, severely immunocompromised kidney transplant recipients, and the staff caring for them in the nephrology dispensaries.
89367510|NCT04488328|Experimental|Combined Magnetic Therapy and Exercise Therapy group|patients received the routine medical treatment in addition to pulsed magnetic therapy and moderate-intensity aerobic exercise for 12 weeks
89367511|NCT04488172|Experimental|Epilepsy subjects|Receiving multi-vitamins supplementation (B6, B9, D, E, Q10) for 6 months trial
89367512|NCT03237520|Experimental|Virtual Reality Therapy|Intervention: Virtual Reality therapy(VRT) reinforcing modified Constraint Induced Movement therapy(mCIMT) VRT will be administered using computer based program. mCIMT will be administered using the physical rehabilitation protocol.
89367513|NCT03237520|Active Comparator|mCIMT|Intervention: Modified Constraint Induced Movement Therapy Only mCIMT will be administered using the physical rehabilitation protocol.
89367514|NCT03237754|Experimental|Real Neurostimulation|4 weeks of neurostimulation (using tDCS)
89367515|NCT03237754|Sham Comparator|Sham Neurostimulation|4 weeks of sham Treatment with the same device used for real neurostimulation
89367516|NCT03237442|Experimental|group 1|
89367517|NCT03237442|Active Comparator|group 2|
88839626|NCT05193188|Experimental|Anlotinib combined with PD-1 monoclonal antibody|Anlotinib, a multi-target tyrosine kinase inhibitor，oral，12mg/10mg/8mg，2 weeks on and 1 week off; PD-1 monoclonal antibody，PD-1 inhibitor，Intravenous injection，once 3 week.
88839627|NCT05193188|Active Comparator|Anlotinib monotherapy|Anlotinib, a multi-target tyrosine kinase inhibitor，oral，12mg/10mg/8mg，2 weeks on and 1 week off.
88839628|NCT04799262|Experimental|Tofacitinib+Prednisone|Tofacitinib was given at the dose of 10mg daily through the 24 weeks. Prednisone (or equivalent oral GCs) of 15 mg daily at baseline willed be tapered to 2.5 mg or less within 20 weeks. Unless specifically considered by patients and physicians, the GC will be tapered followed the predefined taper regimen depending on the response to treatment judged by PMR-AS. The PMR-AS will be determined every two weeks; if<10 the GC daily dosage was decreased by 2.5mg; if>17, the GC daily dosage was increased to the previous dosage; if 10≤PMR-AS≤17, the GC daily dosage was maintained at the previous stable dose.
89367518|NCT04488016|Experimental|Cohort 1 -Part 1|Subjects will be randomized to one of 4 sequences ABC, BAC, ABD, or BAD. Subjects will receive 100 mg acalabrutinib capsule, fasted state (>10 h) in Treatment A , 100 mg acalabrutinib tablet (Variant 1), fasted state (>10 h) in Treatment B, 100 mg acalabrutinib tablet (Variant 1), fed state in Treatment C, Rabeprazole 20 mg ×1 (fasted) at 2 hours before administration of 100 mg acalabrutinib tablet (Variant 1)* and following prior administration of rabeprazole 20 mg BID (with meals) on Days -3, -2 and -1 in Treatment D.
89367519|NCT04488016|Experimental|Cohort 2- Part 1|Subjects will be randomized to one of 4 sequences ABC, BAC, ABD, or BAD. Subjects will receive 100 mg acalabrutinib capsule, fasted state (>10 h) in Treatment A , 100 mg acalabrutinib tablet (Variant 1), fasted state (>10 h) in Treatment B, 100 mg acalabrutinib tablet (Variant 1), fed state in Treatment C, Rabeprazole 20 mg ×1 (fasted) at 2 hours before administration of 100 mg acalabrutinib tablet (Variant 1)* and following prior administration of rabeprazole 20 mg BID (with meals) on Days -3, -2 and -1 in Treatment D.
89367520|NCT04488016|Experimental|Cohort 3- Part 1|Subjects will be randomized to one of 4 sequences ABC, BAC, ABD, or BAD. Subjects will receive 100 mg acalabrutinib capsule, fasted state (>10 h) in Treatment A , 100 mg acalabrutinib tablet (Variant 1), fasted state (>10 h) in Treatment B, 100 mg acalabrutinib tablet (Variant 1), fed state in Treatment C, Rabeprazole 20 mg ×1 (fasted) at 2 hours before administration of 100 mg acalabrutinib tablet (Variant 1)* and following prior administration of rabeprazole 20 mg BID (with meals) on Days -3, -2 and -1 in Treatment D.
89367521|NCT04488016|Experimental|Cohort 4 - Part 1|Subjects will be randomized to one of 4 sequences: ABC, BAC, ABD, or BAD. Subjects will receive 100 mg acalabrutinib capsule, fasted state (>10 h) in Treatment A , 100 mg acalabrutinib tablet (Variant 1), fasted state (>10 h) in Treatment B, 100 mg acalabrutinib tablet (Variant 1), fed state in Treatment C, Rabeprazole 20 mg ×1 (fasted) at 2 hours before administration of 100 mg acalabrutinib tablet (Variant 1)* and following prior administration of rabeprazole 20 mg BID (with meals) on Days -3, -2 and -1 in Treatment D.
89367522|NCT04488016|Experimental|Cohort 1- Part 2|Subjects will be randomized to one of 2 sequences in a 2×4 crossover: ABCD or BADC. In Part 2, subjects will be receiving 100 mg acalabrutinib tablet (Variant 1), Variant 2, Variant 3, and 100 mg acalabrutinib solution.
88839629|NCT04741022||CAD with OSA|coronary artery disease with Obstructive sleep apnea
88839630|NCT04741022||CAD without OSA|coronary artery disease without Obstructive sleep apnea
89179166|NCT04093089|Placebo Comparator|Control Group|
89179167|NCT00916890|Active Comparator|Oral extended-release morphine|
89367523|NCT04488016|Experimental|Cohort 2 - Part 2|Subjects will be randomized to one of 2 sequences in a 2×4 crossover: ABCD or BADC.In Part 2, subjects will be receiving 100 mg acalabrutinib tablet (Variant 1), Variant 2, Variant 3, and 100 mg acalabrutinib solution.
89367524|NCT03239704|Experimental|Telemedicine Follow-Up and Telemedicine Monitoring|
89367525|NCT03239704|Active Comparator|Minimal Intervention|
89367526|NCT03239860|Experimental|Dose 1 GNbAC1|Monthly IV
89367527|NCT03239860|Experimental|Dose 2 GNbAC1|Monthly IV
89367528|NCT03239860|Experimental|Dose 3 GNbAC1|Monthly IV
89367529|NCT04486690|Experimental|propofol group|"Propofol infusion, 25-150mic/kg/min.~Fentanyl infusion, 1-2 mcg/kg/h.~Atracurium infusion, 3-12 mic/kg/min"
89367530|NCT04486690|Active Comparator|ketofol group|"Ketofol 25-150 mic/kg/min with propofol to ketamine ratio 1:1.~Fentanyl infusion, 1-2 mcg/kg/h.~Atracurium infusion, 3-12 mic/kg/min"
89367531|NCT03240094|Experimental|Nutritional telemonitoring|Participants in the intervention group receive a telemonitoring intervention, including self-measurements of body weight, nutritional status, appetite, diet quality, and physical activity. Additionally, participants receive guidance on nutrition and physical activity by means of customized and general television messages and/or if necessary personal guidance by a nurse.
89367532|NCT03240094|No Intervention|Usual care|Participants in the control group receive usual care.
89367533|NCT03255304|Experimental|health prime|
89367534|NCT03255304|Experimental|palatability prime|
89367535|NCT03255148|Experimental|Oxytocin|Syntocinon nasal spray (40 IU/ml; oxytocin, product code RVG 03716); single intranasal dose of 24 international units (IU; 3 puffs of 4 IU per nostril)
89367536|NCT03255148|Placebo Comparator|Placebo|saline natriumchloride solution nasal spray; single intranasal dose (3 puffs per nostril)
88839631|NCT01196130||Biomarker Assessment|Leftover sample of tumor tissue from a previous procedure used for biomarker testing. Blood drawn for biomarker testing, to check for levels of cytokines, and to check the circulating tumor cells (CTCs). Cancer Symptom Questionnaire completion about cancer symptoms.
88839632|NCT01041534||Adjustable Gastric Band (AGB) surgery|Patients who have undergone adjustable gastric band (AGB) surgery at the UWMC or other sites that have agreed to cooperate with our site (letter of cooperation and HIPAA waiver approved by our IRB) between April 1, 2007 and July 1, 2008.
88839633|NCT00851136|Experimental|1|
88839634|NCT02618642|Active Comparator|Piler light + red filter|Group x: irradiation with a red filter (visible red radiation and infrared; 650-800 nm and 800-3900 nm, respectively) time of phototherapy treatment: 10 minutes for one session 10 irradiations to the biceps brachii muscle
88839635|NCT02618642|Active Comparator|Piler light + blue filter|Group y: irradiation with a blue filter (blue radiation; 440-480 nm) time of phototherapy treatment: 10 minutes for one session 10 irradiations to the biceps brachii muscle
89367537|NCT04487626|Experimental|Artificial Intelligence assisted Scoring Group|Patients in this group go through colonoscopy under the AI monitoring device.
89367538|NCT03239548||Doctor|It refers to the doctors with minimum qualification as M.B.B.S and B.A.M.S; working on various posts in the clinical areas of all the departments of selected hospitals.
89367539|NCT03239548||Nurses|It refers to the Registered Nurses working on various posts in the clinical areas of all the departments of selected hospitals and Principals, Vice Principals of selected colleges.
89367540|NCT03239548||Key informants|It refers to the general public including patients admitted and attending O.P.D and their attendants with minimum qualification as graduation.
89367541|NCT02455882||Neoadjuvant|Patients initiating standard of care treatment with primary systemic therapy for breast cancer
89367542|NCT02455882||Adjuvant|Patients initiating standard of care treatment with surgery followed by adjuvant chemotherapy for breast cancer
88839636|NCT02618642|Active Comparator|Piler light without a filter|Group v: irradiation without a filter (white radiation in the entire spectrum and near-infrared radiation; 480-3400 nm) one session lasted 10 minutes 10 irradiations to the biceps brachii muscle
88839637|NCT02618642|Placebo Comparator|placebo|Group z: placebo irradiation (without a filter, 3 min, distance: 100 cm). time of phototherapy treatment: 3 minutes for one session distance of 1meter 10 irradiations to the biceps brachii muscle
89367543|NCT02455882||Recurrence|Patients with a history of breast cancer who are diagnosed with disease recurrence
89367544|NCT03234946|No Intervention|Group A|Relatives of patients with diabetes who will only attend sessions at the center along with the patients on all the interventions of the center (except psychology and psychiatry), receiving instructions from each area on the first and fourth visit. When the patient with diabetes is in the psychology or psychiatry consultation, the relative will also be evaluated in these areas in an analogue form.
89367545|NCT03234946|Experimental|Group B|Relatives who will receive multidisciplinary care at the center The subjects from group B will be asked to be accompanied by another relative. If they accept, they will be included as a patient of the CAIPaDi program to receive all the interventions of the second, third and fourth visits in an individual form, without following the patient with diabetes.
89367546|NCT03254914||Control Site|Measure Clinic Blood Pressure
89367547|NCT03254914||Test Site|Measure Clinic Blood Pressure and Home Blood Pressure
89367548|NCT03237130||preoperative enhanced chest CT|The cohort contains patients with preoperative therapies and patients without preoperative therapies. Each patient receives regular preoperative enhanced chest CT; for patients with preoperative therapies, they usually undergo twice enhanced chest CT examination at before and after preoperative therapies, the CT images after preoperative therapies will be used for analysis
89367549|NCT03234868|Experimental|Optical impression|The optical impression system used for the study is TRIOS (3 shape). First of all, the operators in charge of taking the digital impressions are going to get trained prior the study and will calibrate (learning curve). MIS Scan bodies will be placed on the multi-unit plaforms, an x-ray will be taken in order to check the fit) and the impression will be realised following the instruction given by the system (first the maxillary and mandibular impressions followed by the bite registration). Shade will be chosen using VITA toothguide 3D master (to pick the right zirconia shade).
89367550|NCT03234868|Active Comparator|Conventional impression|Once the impression coping is placed on the multi-unit plaform, the fit will be checked with an intra-oral X-ray. The impressions will be made with medium viscosity silicon. As a second step, alginate antagonist impression will be done. Bite will not be recorded (single tooth missing). The two impressions will be placed in a hermetic plastic bag and send to lab. Shade will be chosen using VITA toothguide 3D master.
89179168|NCT00916890|Active Comparator|Oral extended-release oxycodone|
89179169|NCT00916890|Active Comparator|Transdermal fentanyl|
88839638|NCT04774848|Active Comparator|High Frequency Jet Ventilation (HFJV) with intrathoracic liver|Babies known to have the presence of the liver in the intrathoracic space will be placed on the HFJV at delivery or as soon as possible after consent. During analysis, these babies will be compared to babies with intrathoracic liver and randomized to high frequency oscillating ventilator.
88839639|NCT04774848|Active Comparator|High Frequency Jet Ventilation (HFJV) without intrathoracic liver|Babies who do not have any liver in the intrathoracic space will be placed on the HFJV at delivery or as soon as possible after consent. During analysis, these babies will be compared to babies without intrathoracic liver and randomized to high frequency oscillating ventilator.
88839640|NCT04774848|Active Comparator|High Frequency Oscillatory Ventilation (HFOV) with intrathoracic liver|Babies known to have the presence of the liver in the intrathoracic space will be placed on the HFOV at delivery or as soon as possible after consent. During analysis, these babies will be compared to babies with intrathoracic liver and randomized to HFJV.
88839641|NCT04774848|Active Comparator|High Frequency Oscillatory Ventilation (HFOV) without intrathoracic liver|Babies who do not have any liver in the intrathoracic space will be placed on the HFOV at delivery or as soon as possible after consent. During analysis, these babies will be compared to babies without intrathoracic liver and randomized to HFJV.
88839642|NCT04774458|Experimental|Fluoroscopic-guided cervical epidural access|Cervical epidural access with loss of resistance technique using CLO view at 50 degree under fluoroscopic guidance.
88839643|NCT00366470|Experimental|A|Vitamin D in doses of 100,000 IU
88839644|NCT00366470|Placebo Comparator|B|
88839645|NCT04773210||Mini tube system|Mini tube system (FLOW-JAC System, Bogotá, Colombia) orthodontic treatment.
88839646|NCT04773210||Conventional ligating brackets|Conventional ligating brackets (Gemini 3M Unitek Orthodontic Products bracket, Calif, USA) with Nitinol Classic or superelastic (SE) archwires 0.014 and 0.016 orthodontic treatment.
88839647|NCT00366782|Experimental|1|One vaccination with rB/HPIV3 vaccine (at higher dose) given as nose drops to adults 18 to 49 years of age
88839648|NCT00366782|Experimental|2|One vaccination with rB/HPIV3 vaccine (at higher dose) given as nose drops to HPIV3-seropositive children 15 to 59 months of age). This arm may enroll after Arm 1 depending on the effect of the vaccine on Arm 1.
88839649|NCT00366782|Experimental|3|One vaccination with rB/HPIV3 vaccine (at lower dose) given as nose drops to seronegative children or infants 6 to 36 months of age. This arm may enroll after Arm 2.
88839650|NCT00366782|Experimental|4|One vaccination with rB/HPIV3 vaccine (at higher dose) given as nose drops to seronegative children or infants 6 to 36 months of age. This arm may enroll after Arm 2.
88839651|NCT00366782|Placebo Comparator|5|One vaccination with placebo vaccine given as nose drops to adults, HPIV3-seropositive children, or seronegative children or infants
88839652|NCT01116804|Other|inoperable liver cancer patients|
88839653|NCT00586872||1|patients with barretts esophagus and/or early esophageal adenocarcinoma who have undergone endoscopic mucosal resection
88839654|NCT02620904|Active Comparator|mifepristone|following informed consent women will be randomized and the mifepristone group will take 200 mg by mouth immediately prior to induction of labor for fetal demise on labor and delivery
88839655|NCT02620904|Placebo Comparator|placebo pill|following informed consent women will be randomized and the placebo group will take a placebo pill by mouth (similar in properties to the mifepristone group, but it will lack any active drug) immediately prior to induction of labor for fetal demise on labor and delivery
88839656|NCT00300768|Experimental|2 mg moxidectin|2 mg moxidectin (Dose-escalation 1st step)
88839657|NCT00300768|Active Comparator|Ivermectin 150 mcg/kg|Active comparator arm (ivermectin 150 mcg/kg).
88839658|NCT00300768|Experimental|4 mg moxidectin|4 mg moxidectin (dose escalation second step)
88839659|NCT00300768|Experimental|8 mg moxidectin|8 mg moxidectin (dose escalation third step)
88839660|NCT02621060|Placebo Comparator|Placebo|1200 mg dose per day, three capsules of 400 mg, times daily 1/ 2 hour before meals during 90 days.
88839661|NCT02621060|Experimental|Chlorogenic acid|1200 mg dose per day, three capsules of 400 mg, times daily 1/ 2 hour before meals during 90 days.
88839662|NCT04740788||Monofocal IOL|Patients already implanted with a monofocal IOL
88839663|NCT04522856||A|Local
88839664|NCT04522856||B|Nested
88839665|NCT04740554||Duchenne Muscular Dystrophy group with Deflazacort|Individuals Duchenne Muscular Dystrophy, with age 11 to 18 years which make use of deflazacort.
88839666|NCT04740554||Duchenne Muscular Dystrophy group with Prednisone/Predisolone|Individuals Duchenne Muscular Dystrophy, with age 11 to 18 years which make use of Prednisone/Predinisolone.
88839667|NCT04740554||Duchenne Muscular Dystrophy group without Corticosteroids therapy|Individuals Duchenne Muscular Dystrophy, with age 11 to 18 years which don't use of corticosteroids.
88839668|NCT04740554||Control Group Typically Developing|Individuals with typical development age 11 to 18 years which don't use of corticosteroids.
88839669|NCT02624180|Experimental|Colchicine|Colchicine 0.6 mg daily by mouth
88839670|NCT02624180|Placebo Comparator|Placebo|Placebo for colchicine 1 tablet by mouth daily
88839671|NCT04339946||Patients with suspicious of rectosigmoid endometriosis|
88875202|NCT02519244|Experimental|Robot-assisted rehabilitation|Subjects will participate in individualized locomotion training sessions using wearable lower limb exoskeleton, Ekso®. Each training session will last up to 60 minutes, 5 days per week for 3 weeks, for a total of 15 sessions. During the training, subjects will wear a lower extremity exoskeleton robotic walking device. Subjects will participate in individualized treatment sessions which may include: sit to stand, static and dynamic standing balance, weight shifting, walking, turning, and stand to sit.
88875203|NCT02520414|Experimental|Symphion®|Patients treated in-office with Symphion® Bipolar Hysteroscopic Tissue Resection System.
88839672|NCT05068232|Experimental|Participants With Extensive Small Cell Lung Cancer (All Participants)|"This arm will involve all participants in the study who have extensive small cell lung cancer that has not responded to previous treatments. All participants will receive the same treatment of study drugs and radiation treatment in cycles (a specific window of time).~You will receive up to four 21-day cycles of chemotherapy using carboplatin, etoposide and durvalumab (immunotherapy) as part of a standard care treatment plan recommended by your doctor. These drugs will be combined with ablative radiation treatment during the second cycle of chemotherapy.~After completing these four cycles of chemotherapy (with radiation treatment added in cycle 2), you will continue to receive a fixed dose of durvalumab until your cancer progresses, you experience serious side effects, you decide to no longer be part of the study or the study doctor request to take you off the study for medical reasons."
88839673|NCT02625428|Experimental|For Cause|For cause biopsies to evaluate a recent rise in serum creatinine.
88839674|NCT02625428|Experimental|Surveillance|Surveillance biopsies done after transplant mostly looking for subclinical rejection.
88839675|NCT05055596|Experimental|Gentle Movement|
88839676|NCT05055596|Active Comparator|Health Coaching|
88839677|NCT04326764|Experimental|Panobinostat|Panobinostat 20 mg oral three times weekly every second week
88839678|NCT04326764|No Intervention|Standard of Care|Treatment according to local standards
88839679|NCT04741178||Patient with Covid-pneumonia|Patient with CT scan of pulmonary infiltrates suggestive of Covid pneumonia
88839680|NCT02626910||Second Life: People with disabilities|People with disabilities recruited from the virtual world, Second life.
88839681|NCT02626910||Second Life: People without disabilities|People without disabilities recruited from the virtual world, Second life.
88839682|NCT02626910||Second Life: Clinicians|Clinicians recruited from the virtual world, Second life.
88839683|NCT02626910||Urban group|People with and without disabilities recruited from an Urban setting.
88839684|NCT05187546|Experimental|Imaging characteristics of [18F]PI-2620 for detection of Tau deposition in the brain of PSP patients|All eligible PSP patients will receive two injections of the investigational imaging agent [18F]PI-2620: at a baseline PET imaging session and at a follow-up PET imaging session to evaluate the test-retest imaging characteristics. 10 PSP patients will be required to complete the study arm.
88839685|NCT05187546|Experimental|Imaging characteristics of [18F]PI-2620 for detection of Tau deposition in the brain of NDC subjects|All eligible non-demented control (NDC) subjects will receive two injections of the investigational imaging agent [18F]PI-2620: at a baseline PET imaging session and at a follow-up PET imaging session to evaluate the test-retest imaging characteristics. 5 NDC subjects will be required to complete the study arm.
88839686|NCT02627924||Adalimumab|Participants diagnosed with rheumatoid arthritis who were prescribed adalimumab according to their physician's discretion and routine clinical practice.
88839687|NCT02628236|Experimental|ALA|20% aminolevulinic acid applied via Kerastick to individual AK lesions on the upper extremities and covered with occlusive dressing for 3 hours prior to BLU-U treatment
88839688|NCT02629094|Experimental|Treatment|Intervention: Eplerenone will be administered for 6 months as follows: 25 mg once daily for 1 week and then 50 mg once daily for the remainder of the study.
88839689|NCT02630030|Experimental|Ixazomib|Patients receive ixazomib PO 3 hours before surgery.
88839690|NCT04289792|Experimental|SBRT with concurrent chemotherapy|SBRT with nab-Paclitaxel plus Gemcitabine (nab-P+Gem) chemotherapy
88839691|NCT02631590|Experimental|Combination Therapy|Treatment Plan: Cisplatin (25 mg/m^2 ) + Gemcitabine (1000 mg/m^2) + copanlisib (60 mg) on days 1 and 8 with day 15 off to be administered on an every 21-days schedule.
88839692|NCT02253654|Experimental|Epoetin alfa Alternative Titration|Participants received epoetin alfa administered intravenously three times a week during hemodialysis for up to 37 weeks. For the first two weeks the dose of epoetin alfa was based on the dose at the time of screening. Beginning at week 3 dose changes may have occurred every 2 weeks according to the alternative dosing algorithm, where smaller, frequent dose adjustments were permitted based on six hemoglobin categories.
88839693|NCT02253654|Active Comparator|Epoetin alfa USPI Titration|Participants received epoetin alfa administered intravenously three times a week during hemodialysis for 37 weeks. For the first two weeks the dose of epoetin alfa was based on the dose at the time of screening. Beginning at week 3 dose decreases were permitted every 2 weeks and beginning at week 5 dose increases could only occur ≥ 4 weeks from the last dose increase, according to the United States package insert (USPI) dosing algorithm which includes four categories of hemoglobin levels.
88839694|NCT02252406|Experimental|Ranolazine|Ranolazine would start with 500 mg BID and be force titrated to 1 gram po BID after 3 weeks. Down titration would only be allowed for side effects. This would be on top of all standard medical therapy.
88839695|NCT02252406|Placebo Comparator|Placebo|Placebo arm would start with 500 mg matching placebo tablet BID and be force titrated to 1 gram matching placebo tablet twice a day after 3 weeks. Down titration would only be allowed for side effects (if reported). This would be on top of all standard medical therapy.
88839696|NCT05178186|Other|Thyroid carcinoma|Patients with thyroid carcinoma submitted to thyroidectomy
88839697|NCT05101200|Experimental|High Dose Neural Mobilization Technique|Patients in this Group will receive High Dose Neural Mobilization Technique
88839698|NCT05101200|Experimental|Low Dose Neural Mobilization Technique|Patients in this Group will receive Low Dose Neural Mobilization Technique
88839699|NCT02246478|Placebo Comparator|Placebo|
88839700|NCT02246478|Active Comparator|TAS-205 low dose|
88839701|NCT02246478|Active Comparator|TAS-205 middle dose|
88839702|NCT02246478|Active Comparator|TAS-205 high dose|
88839703|NCT02252016|Experimental|Immediate Treatment|Participants will take grazoprevir 100 mg + elbasvir 50 mg once daily during the 12-week treatment period and then will be monitored for safety during a 24-week follow-up period.
89179170|NCT00916890|Active Comparator|Transdermal buprenorphine|
89367551|NCT03234868|Experimental|Digital workflow|The implant crowns issued from digital impressions will be done according a cast less / full digital workflow. The STL files collected from the TRIOS will be sent directly to the lab. The designing of the full zirconia crowns will be performed in the TRIOS 3SHAPE program. The resulting files will be sent to the CAM unit production (Amman Girrbach milling machine & MAZAK CNC machine: Mcenter to be specify (Berlin or Israel) to be milled (milled & sintered only) considering the direct adaption for a Multi-Unit connection. A superficial make-up will be done on the monolithic crown in the lab. And finally, the products will be delivered to the dentist.
89367552|NCT03234868|Active Comparator|Conventional workflow|"The implant crowns issued from conventional impressions will be realised by sending the impressions to the lab (Mirko Picone). The lab will pour the impressions in dental stone (class 4 scannable without powdering: extra hard and scanning powder included). Then, the technician will realize a mock-up of the crown's framework on a temporary abutment in DuraLay Resin.~The mock up will be scanned with ZIRKONZAHN scanner (or equivalent) and send this information to a central fabrication facility for milling (Amman Girrbach milling machine & MAZAK CNC machine:~Mcenter: to be specify (Berlin or Israel). The lab technician will get the Zi framework back and will apply veneer ceramic."
89367553|NCT03237052|Experimental|model|model aided decision
89367554|NCT03237052|Active Comparator|non-model|real-world psychiatrist decision
89367555|NCT03237208|Active Comparator|TENS|Patients receiving the real transcutaneous electrical nerve stimulation (TENS) with 100 hertz, pulse width 200 microseconds, voltage 2 milliampere
89367556|NCT03237208|Sham Comparator|placebo group|Patients receiving the application of transcutaneous electrical nerve stimulation, but transcutaneous electrical nerve stimulation will not be activated.
89367557|NCT04487938||Tobacco use and/or alcohol consumption|
89367558|NCT04487938||No tobacco use and/or alcohol consumption|
89367559|NCT03234712|Experimental|ABBV-321|ABBV-321 will be administered via intravenous infusion at escalating dose levels until the maximum tolerated dose is reached and a recommended Phase 2 dose is determined.
89367560|NCT04876794|Experimental|Arm 1|Participants with SCI will undergo a training programme with the ABLE Exoskeleton device three times a week for four to six weeks for a total of 12 sessions.
89367561|NCT02455960|Experimental|Arginine|Participants need to take arginine 3 g/day orally for 3 days before CT with contrast media injection
89367562|NCT02455960|Placebo Comparator|Placebo|Participants need to take placebo (corn powder) 3 g/day orally for 3 days before CT with contrast media injection
89367563|NCT03236818|Other|Upfront combination therapy|Combination of an ERA and PDE-5I (Sildenafil, Tadalafil, Bosentan, Macitentan)
89367564|NCT04809246|No Intervention|Standard of care|The first group (n=240) of participants enrolled in the study will be assigned to the control period to receive the standard of care.
89367565|NCT04809246|Experimental|'One-stop-shop' intervention|Following the control period, the second group (n=300) of participants enrolled in the study will be assigned to the intervention period to receive the 'one-stop-shop' intervention.
89367566|NCT04486144|Experimental|COVID19 Positive: Intervention Group (Receive extract)|These are patients that are COVID19 positive who elect to try the extract.
89367567|NCT04486144|No Intervention|COVID19 Positive: Comparison Group (Do NOT receive extract)|These are patients that are COVID19 positive who do NOT elect to try the extract
89367568|NCT04486144|Experimental|COVID19 Exposed: Intervention Group (Receive extract)|These are patients that are COVID19 negative at the start, live with a COVID19 positive patient and who elect to try the extract.
89367569|NCT04486144|No Intervention|COVID19 Exposed: Comparison Group (Do NOT receive extract)|These are patients that are COVID19 negative at the start, live with a COVID19 positive patient and who elect to NOT try the extract.
89367570|NCT04760808||AIS group|
88839704|NCT02252016|Placebo Comparator|Deferred Treatment|Participants will take placebo tablets once daily during the 12-week treatment period and will then be monitored for safety during a 4-week follow-up period. Participants will then begin open-label treatment with grazoprevir 100 mg + elbasvir 50 mg for a 12-week treatment period and will then be monitored for safety during a 24-week follow-up period.
88839705|NCT05066100|Experimental|Pregnant women with FIRN|Women desiring to breastfeed and identified during their pregnancy as having flat, inverted or retracted nipples
88839706|NCT02249832|Experimental|seated robot-assisted ankle therapy|All participants received eighteen 1 hour sessions (3x/week for 6 weeks) of seated robot-assisted ankle training with the MIT anklebot. Upon analysis, subjects were stratified based on average admission gait speed on the 10 Meter Walk Test at comfortable pace according to clinically established gait speed performance groups: low (<0.4m/sec), moderate (0.4m/sec-0.8m/sec) and high (>0.8m/sec) functioning.
88839707|NCT02248974|Active Comparator|LVAD Decision Aid|Decision aid presented to subjects was developed from patient and clinician feedback to increase patient knowledge on the risks, benefits, misconceptions or mispredictions regarding LVADs to help patients make an informed decision on accepting or declining LVAD placement.
88875204|NCT02521974|Experimental|SABIN monovalent OPV2 vaccine|SABIN monovalent OPV2 is a licensed, monovalent, live attenuated poliomyelitis virus vaccine of the Sabin strain Type 2 (P 712, Ch, 2ab), propagated in MRC5 human diploid
89367571|NCT04760808||Control Group|
89367572|NCT03236896|Active Comparator|Exercise Intervention|This group will participate in a weekly exercise regimen and actively log the physical activity in a diary. They will complete the daily hot flash diary, MENQOL scale and calorimeter. All subjects will complete questionnaire (MENQOL Scale,) before the start of the study, at the sixth week of the study and after the completion of the twelfth week. A 2-week baseline assessment of hot flashes using the hot flash diary and fitbit flex will be followed by 12 weeks of assessment during the exercise intervention.
89367573|NCT03236896|Active Comparator|No Exercise|They will complete the daily hot flash diary, MENQOL scale and calorimeter. All subjects will complete questionnaire (MENQOL Scale,) before the start of the study, at the sixth week of the study and after the completion of the twelfth week. A 2-week baseline assessment of hot flashes using the hot flash diary and fitbit flex will be followed by 12 weeks of assessment during the exercise intervention.
89367574|NCT03236974|Active Comparator|Standard arm|Fulvestrant, 500 mg
89367575|NCT03236974|Experimental|AZD9496|250 mg bd taken orally for 5-14 days
89367576|NCT03748043|Experimental|lactoferrin+ferric hydroxide polymaltose|lactoferrin 100 mg /day plus ferric hydroxide polymaltose 6 mg /kilogram body wight for 3 months
89001861|NCT00187187|Active Comparator|Implantable Defibrillator (ICD) AAI-70|The DAVID II Clinical Study evaluates the hypothesis that, in patients needing an ICD but without overt indications for pacing, AAI pacing with maximal concomitant drug therapy (AAI-70)will not increase the rate of the combined endpoint of mortality or hospitalization for new or worsened heart failure, compared to patients with ventricular backup pacing (VVI-40).
89001862|NCT00412386||BAV|patients with BAV
89367577|NCT03748043|Experimental|ferric hydroxide polymaltose|6 mg /kilogram body wight of ferric hydroxide poly maltose per day for 3 months
89367578|NCT03254992|Experimental|ASD - Abstract task|Experimental group using Kinect with more virtual activity.
89367579|NCT03254992|Experimental|ASD - Tangible task|Experimental group using Keyboard with more real activity.
89367580|NCT03254992|Active Comparator|TD - Abstract task|Control group using Kinect with more virtual activity.
89367581|NCT03254992|Active Comparator|TD - Tangible task|Control group using Keyboard with more real activity.
89367582|NCT03750773|Active Comparator|Subjects receiving gabapentin drug|Administration of Gabapentin 600mg orally every 8 hours. Women will receive gabapentin for a total of 48 hours after cesarean
89367583|NCT03750773|Placebo Comparator|Subjects receiving placebo oral capsule|Administration of identical placebo capsule orally every 8 hours. Women will receive placebo for 48 hours after cesarean
89367584|NCT02874924|Experimental|Rapamycin|Rapamycin 1mg taken once daily for 8 weeks
89367585|NCT02874924|Placebo Comparator|Placebo|Placebo taken once daily for 8 weeks
89367586|NCT02874924|Experimental|Rapamycin Alone - Cardiovascular Effects|No placebo control; Rapamycin 1mg once daily for 8 weeks
89367587|NCT03254836||Colorectal cancer undergoing elective surgery|"All patients eligible for elective curative intended surgery for colonic adenocarcinoma at Zealand University Hospital.~Patients will recieve treatment as per standard of care."
89001863|NCT00412386||Normal control|normal patients
89367588|NCT04425863||Mild cases|This group includes patients diagnosed positive for COVID-19 via rtPCR and presenting only mild symptoms such as: fever not above 38.5 °C; isolated diarrheal episodes, hyposmia or hypogeusia, mild desaturation (93 - 96 %), dyspnea without matter, polymyoarthralgias, persistent headache, abdominal pain.
89367589|NCT04425863||Moderate cases|This group includes patients diagnosed positive for COVID-19 via rtPCR and presenting either: 3 severe symptoms (i.e. fever above 38.5 °C, diarrhea with more than 3 daily depositions, flictenular conjunctivitis, strong desaturation (92% or less), tachypnea (FR> 25 / minute) or 2 severe symptoms + 2 mild symptoms (fever not above 38.5 °C; isolated diarrheal episodes, hyposmia or hypogeusia, mild desaturation (93 - 96 %), dyspnea without matter, polymyoarthralgias, persistent headache, abdominal pain)
89367590|NCT04425863||Severe cases|This group includes patients diagnosed positive for COVID-19 via rtPCR and presenting either: 4 severe symptoms or 3 severe symptoms and not less than 2 mild symptoms or clinical signs of bilateral viral pneumonia
89367591|NCT01370772|Active Comparator|Standard R-FC arm|"Standard R-FC arm 6 cycles every 28 days~Cycle 1:~Rituximab : 375 mg/m² i.v on day 1~Fludarabine : 40 mg/m² per os, days 2-4, repeated every 28 days~Cyclophosphamide : 250 mg/m² per os, days 2-4, repeated every 28 days For patients with Leucocyte count > 25* G/L : rituximab in two equal doses at D1, D2~Cycle 2-6:~Rituximab: 500 mg/m² i.v on day 1, repeated every 28 days~Fludarabine : 40 mg/m² per os, days 2-4, repeated every 28 days~Cyclophosphamide : 250 mg/m² per os, days 2-4, repeated every 28 days"
89367592|NCT01370772|Experimental|DenseR-FC arm|"DenseR-FC arm =1 prephase R Dense course +6 R-FC courses~Prephase:~- Rituximab: 500 mg on day 0, 2000 mg on days 1, 8, and D15 For patients with Leucocyte count > 25* G/L : rituximab 250 mg D-1, D0 prephase~Cycle 1-6 (cycle 1 beginning at D22):~Rituximab: 500 mg/m2 i.v on day 1, repeated every 28 days~Fludarabine : 40 mg/m² per os, days 2-4, repeated every 28 days~Cyclophosphamide : 250 mg/m² per os, days 2-4, repeated every 28 days"
89001864|NCT00211926|Experimental|StaphVAX|
89367593|NCT03254524||Patients visiting an emergency department in New York State|
89367594|NCT03747965|Experimental|Mesothelin-directed CAR-T cells infusion|"Patients receive mesothelin-directed CAR-T cells infusion with dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation."
89367595|NCT03254446|Experimental|TRC150094 45 mg|TRC150094 45 mg Tablet to be administered orally once a day for 50 weeks
89367596|NCT03254446|Placebo Comparator|Placebo|Matching Placebo Tablet to be administered orally once a day for 50 weeks
89367597|NCT01365078|Experimental|Echium oil (SDA-rich oil)|
89367598|NCT01365078|Placebo Comparator|High-oleic acid sunflower oil (HOSO)|low in SDA
89367599|NCT03234634|No Intervention|Group 1: patients with good collateral|
89367600|NCT03234634|Experimental|Group 2a, patient with poor collaterals|Group 2 patients (poor collateral group) will be randomized into endovascular thrombectomy group (2a) and best medical treatment group (2b), if femoral puncture is possible between 150 minutes and 600 minutes after last seen well.
89367601|NCT03234634|No Intervention|Group 2b, patients with poor collaterals|Group 2 patients (poor collateral group) will be randomized into endovascular thrombectomy group (2a) and best medical treatment group (2b), if femoral puncture is possible between 150 minutes and 600 minutes after last seen well.
89001865|NCT00211926|Placebo Comparator|Placebo|
89001866|NCT00218946|No Intervention|control|no fluid, no pacifier
89367602|NCT01370928|Experimental|Prototype colonoscope|The new colonoscope to be tested
89367603|NCT01370928|Active Comparator|Standard colonoscope|The standard colonoscope used world-wide today.
89367604|NCT03234244|Active Comparator|Bazedoxifene 20mg|Subjects will take bazedoxifene 1 Tablet.
89367605|NCT03234244|Active Comparator|Cholecalciferol|Subjects will take Cholecalciferol 2 Tablets.
89367606|NCT03234244|Experimental|Bazedoxifene 20mg and Cholecalciferol|Subjects will take bazedoxifene 1 tablet and Cholecalciferol 2 tablets at once.
89367607|NCT03254680|Experimental|Turmeric Oil|stable dose of orally administered turmeric oil
89367608|NCT03234400|Experimental|25 mg Dapivirine Vaginal Ring|Participants will insert one Dapivirine Vaginal Ring, 25 mg to be replaced every 4 weeks for 8 weeks, then worn for an additional 5 weeks for a total of 13 weeks. Participants will continue follow-up for an additional one to three days after final VR removal.
89367609|NCT03234400|Experimental|100 mg Dapivirine Vaginal Ring|Participants will insert one Dapivirine Vaginal Ring, 100 mg to be used continuously for 13 weeks. Participants will continue follow-up for an additional one to three days after final VR removal.
89367610|NCT03234400|Experimental|200 mg Dapivirine Vaginal Ring|Participants will insert one Dapivirine Vaginal Ring, 200 mg to be used continuously for 13 weeks. Participants will continue follow-up for an additional one to three days after final VR removal.
89367611|NCT04360187|Experimental|Crisaborole ointment|Crisaborole ointment application twice daily for 28 days
89367612|NCT04360187|Placebo Comparator|Crisaborole Placebo Vehicle|Vehicle Ointment application twice daily for 28 days
89367613|NCT03234322|Experimental|Intervention group|In the intervention group the routine health check is expanded by usage of a non-invasive diabetes risk score.
89367614|NCT03234322|No Intervention|Control group|In the control group the routine health check is conducted.
89367615|NCT03254290|Experimental|Experimental NeoMTA|The new formulation of MTA (does not contain bismuth oxide) will be used in one tooth receiving a pulpotomy to determine if the color of the tooth changes over time.The new formulation has received the FDAs 510(k) substantial equivalence clearance for Class II dental materials and is equivalent to its MTA predicate (ProRoot, Dentsply Tulsa Dental, Tulsa, OK, USA).
89367616|NCT03254290|Active Comparator|Formocresol|"Control group. This group will receive the gold standard formulation of a formocresol pulpotomy."
88839708|NCT02248974|No Intervention|No LVAD Decision Aid|The standard education processis institution-specific and unstandardized. The education consists of viewing education pamphlets that are created by device manufacturers. The traditional informed consent process may also include viewing and manipulating the actual device and meeting a patient with a device already implanted. Additionally, the LVAD coordinator describes the device and answers any questions LVAD candidates have.
88839709|NCT02246166|Experimental|Test tablet|Tablet containing Paracetamol, Pseudoephedrine Hydrochloride, Dextromethorphan Hydrobromide and Chlorpheniramine Maleate Tablets (II) (Paracetamol 500mg, pseudoephedrine 30mg, chlorpheniramine 2mg and dextromethorphan 15mg).
88839710|NCT02246166|Placebo Comparator|Placebo|Matching placebo tablet
88839711|NCT02706847|Experimental|Upadacitinib 15 mg|"Period 1: Participants receive upadacitinib 15 mg once daily for 24 weeks.~Period 2: Participants will continue on upadacitinib 15 mg once daily from Week 24 to Week 260."
89367617|NCT03254368|Experimental|0.05 mg ZGN-1061 (A)|0.05 mg ZGN-1061 subcutaneous injection once every 3 days
88839712|NCT02706847|Experimental|Upadacitinib 30 mg|"Period 1: Participants receive upadacitinib 30 mg once daily for 24 weeks.~Period 2: Participants continue on upadacitinib 30 mg once daily until implementation of Protocol Amendment 4, then participants begin to receive upadacitinib 15 mg once daily up to Week 260."
89367618|NCT03254368|Experimental|0.3 mg ZGN-1061 (B)|0.3 mg ZGN-1061 subcutaneous injection once every 3 days
89367619|NCT03254368|Experimental|0.9 mg ZGN-1061 (C)|0.9 mg ZGN-1061 subcutaneous injection once every 3 days
89367620|NCT03254368|Experimental|1.8 mg ZGN-1061 (CC)|1.8 mg ZGN-1061 subcutaneous injection once every 3 days
89367621|NCT03254368|Placebo Comparator|Placebo (D)|Placebo subcutaneous injection once every 3 days
89534705|NCT03328637|Experimental|Intervention|Patients in the intervention group will be provided Cognitive Behavioral Therapy (CBT). CBT is a common psychological intervention based on the notion that thoughts trigger the emotions. In CBT patients are trained to monitor their thoughts and identify those that trigger addictive feelings and actions while they learn new coping skills and ways to prevent a relapse (Beck, Wright, Newman & Liese, 2001). The treatment period of CBT is three months consisting of a weekly session and total 12 sessions. Initial stage of therapy is behavioral, centering on specific behaviors and situations. Latter on there is more of a focus on the cognitive assumptions and distortions that have developed and the effects of these on behavior.
88839713|NCT02706847|Placebo Comparator|Placebo / Upadacitnib 15 mg|"Period 1: Participants receive placebo once daily for 12 weeks followed by upadacitinib 15 mg once daily for 12 weeks.~Period 2: Participants will continue on upadacitinib 15 mg once daily from Week 24 to Week 260."
88839714|NCT02706847|Placebo Comparator|Placebo / Upadacitnib 30 mg|"Period 1: Participants receive placebo once daily for 12 weeks followed by upadacitinib 30 mg once daily for 12 weeks.~Period 2: Participants continue on upadacitinib 30 mg once daily until implementation of Protocol Amendment 4, then participants begin to receive upadacitinib 15 mg once daily up to Week 260."
88839715|NCT02245620|Experimental|Elamipretide|Elamipretide given as an intravenous infusion of 0.25 mg/kg/hr at a rate of 60 mL/hr for 2 hours.
88839716|NCT02245620|Placebo Comparator|Placebo|Placebo (lyophilized excipients without elamipretide) given as an intravenous infusion at a rate of 60 mL/hr for 2 hours.
89367622|NCT04498169|Experimental|Once Daily Netarsudil Ophthalmic Solution|One drop of Netarsudil 0.02% ophthalmic solution in the study eye in the evening for an 8 week period in up to 20 subjects.
89367623|NCT04498169|Experimental|Twice Daily Netarsudil Ophthalmic Solution|One drop of Netarsudil 0.02% ophthalmic solution in the study eye in the morning and in the evening for an 8 week period in up to 20 subjects.
89367624|NCT03236740|Active Comparator|Metformin|Metformin 500mg bid in morning and evening after meals to be taken for 6 months.
89367625|NCT03236740|Active Comparator|OCP|OCP containing 35 microgram ethinylestradiol and 2-milligram cyproterone acetate to taken from the first day of the menstruation, oral administration of one pill daily for 21 days consecutively, then discontinue using the pill for seven days, and on the eighth day, restart taking the pill. OCP to be taken for 6 months.
89367626|NCT02453464|Experimental|Sevacizumab+FOLFIRI|Two weeks as one cycle. Cycle 1: FOLFIRI on day1-2, Sevacizumab on day3; Cycle 2 and after: Sevacizumab on day 1, and then FOLFIRI on day1-2
89367627|NCT03695393|Experimental|Intervention- ACT Therapy|Participants randomized to this group will receive three ACT sessions over 1 month
89367628|NCT03695393|No Intervention|Standard of Care|Participants in the control group will receive standard care as normally provided to patients by civil society organizations.
89367629|NCT03233932|Active Comparator|LeuplinⓡInj|LeuplinⓡInj(=leuprorelin acetate 3.75mg)
89367630|NCT03233932|Experimental|CKD-841|CKD-841(=leuprorelin acetate 3.75mg)
89367631|NCT03236584|Active Comparator|lamivudine adefovir|
89367632|NCT03236584|Experimental|tenofovir|
89367633|NCT01562093|Experimental|local nasal steroids|
89367634|NCT01562093|Placebo Comparator|placebo|
89367635|NCT03254056|Active Comparator|Conventional Technique|The edges of the fascia will be hold by the surgical instruments. The fascial defect will be repaired by using devices which are generated for laparotomy operations.
89367636|NCT03254056|Active Comparator|Berci Technique|This instrument facilitates full thickness abdominal wall closure under the view of laparoscopic optic.
89367637|NCT03694925||Primary total knee arthroplasty|Primary TKA patients included in the study, to provide a baseline level for calprotectin.
89367638|NCT03694925||Aseptic revision total knee arthroplasty|Aseptic revision TKA patients included in the study. These are patients who are not considered infected according to Musculoskeletal Infection Society criteria for infection.
89367639|NCT03694925||Revision septic total knee arthroplasty|Septic revision TKA patients included in the study. These are patients who are considered infected according to Musculoskeletal Infection Society criteria for infection.
89367640|NCT03234088|Other|Home HF monitoring|Digital scale readings are transmitted wirelessly to the handheld device. Patients will remotely log on to a secure server to answer daily symptom questions. Patients will complete surveys after voluntarily completing the informed consent process and at study closeout.
89367641|NCT03233776|Experimental|Anakinra|Dosage form: intravenous. Dosage: either 100 mg, 200 mg or 300 mg. Frequency: once daily. Duration: 15 days (day -2 until day +12).
88839717|NCT02244996|Experimental|Lycium Barbarum|Daily Lycium Barbarum dosage: 10g of granules for 12 months
89534706|NCT03328637|No Intervention|Control|Control group will not receive CBT however, primary care service providers and mental health professionals will provide any required routine care according to their clinical judgment and available resources.
89534707|NCT05025891|No Intervention|Arm 1: control|Patients continue consultations as usual in HDJA or at UMIT.
88839718|NCT02244996|Placebo Comparator|Placebo|Placebo
88839719|NCT02470741|Experimental|Letrozole|Oral letrozole 2.5mg/day
88839720|NCT02470741|Placebo Comparator|Placebo and Letrozole|Intermittent oral letrozole 2.5mg/day for 2 months and an identical placebo capsule for 4 months
88839721|NCT02543437|Other|Trident Acetabular X3 Insert|28mm, 32mm and 36mm liner
89001867|NCT00218946|Experimental|water|water, no pacifier
89367642|NCT03253900|Experimental|Experimental group|A group of rowers to be administered to intervention on a Stable rowing simulator, a Slides based rowing simulator or a Tilt board based rowing simulator.
89367643|NCT04614168|Active Comparator|Group 1 - Standard Care|This group will continue on their standard diabetes care. They will be required to undergo three periods of blinded continuous glucose monitoring each lasting 20-days at: baseline, 4 months and 8 months. Participants in this group will undergo a hyperinsulinaemic hypoglycaemic clamp study at baseline and 8 months. They will also complete quality of life and diabetes treatment questionnaires at baseline and 8 months.
89367644|NCT04614168|Experimental|Group 2- Automated insulin delivery and low carbohydrate diet|This group will be placed on an automated insulin delivery system: Tandem t:slim x2 insulin pump with Control IQ technology and Dexcom G6 continuous glucose monitor. They will also be asked to follow a low-carbohydrate diet of 30-40g of carbohydrate per main meal. At baseline they will have a 20-day period of blinded continuous glucose monitoring. Participants in this group will undergo a stepped hyperinsulinaemic hypoglycaemic clamp study at baseline and 8 months. They will also complete quality of life and diabetes treatment questionnaires at baseline and 8 months.
89367645|NCT02453230|Active Comparator|light on|BPP done with lights on
89367646|NCT02453230|No Intervention|light off|Biophysical profile examinations done with the light off
89367647|NCT02453152||Males with X-linked myotubular myopathy|History and physical, Tidal breathing, Maximal respiratory pressures, Peak cough flow, Pediatric Evaluation of Disability Inventory, PedsQL Multidimensional Fatigue Scale, Review of ventilation requirements
89367648|NCT01372488|Active Comparator|Study group|Study group will be provided with suture removal instructions and suture removal kit and asked to consider removing their own sutures
89367649|NCT01372488|Placebo Comparator|Control group|Control group will be asked to have their sutures removed as they normally would (see family doctor or clinic)
89367650|NCT03234010|Experimental|FT21092 Group|7 day at-home use of electronic cigarette FT21092 followed by a 2 day in-clinic period.
89367651|NCT03234010|Experimental|FT21093 Group|7 day at-home use of electronic cigarette FT21093 followed by a 2 day in-clinic period.
89367652|NCT03234010|Experimental|FT21096 Group|7 day at-home use of electronic cigarette FT21096 followed by a 2 day in-clinic period.
89367653|NCT03234010|Experimental|FT21097 Group|7 day at-home use of electronic cigarette FT21097 followed by a 2 day in-clinic period.
89367654|NCT01365234|Experimental|20066 Lead|Non-randomized study. Intervention: Device: Pacing Lead
89367655|NCT02453308|Active Comparator|ACT-arms|"1.1 Artemether-lumefantrine for 3 days.~1.2 Dihydroartemisinin-piperaquine for 3 days~1.3 Artesunate-Mefloquine for 3 days"
89534708|NCT05025891|Experimental|Arm 2: teleconsultation alone|Patients are directed to the tele-monitoring platform without specific accompaniment.
89534709|NCT05025891|Experimental|Arm 3: teleconsultation and mediation|Patients are referred to the tele-monitoring platform with specific support with mediation.
89534710|NCT03328559|Other|early stage bronchial cancer|Early stage which can benefit from a surgical resection. A taking will be made in preoperative then in every consultation of follow-up after the intervention
88839722|NCT02544607|Experimental|Ketamine + MRI|All eligible participants will receive open label ketamine and undergo Magnetic Resonance Imaging (MRI).
88839723|NCT02243280|Experimental|Arm A|ABT-493 200 mg once daily (QD) + ABT-530 120 mg QD for 12 weeks in HCV genotype 1-infected participants without cirrhosis
88839724|NCT02243280|Experimental|Arm B|ABT-493 200 mg once daily (QD) + ABT-530 40 mg QD for 12 weeks in HCV genotype 1- infected participants without cirrhosis
88839725|NCT02243280|Experimental|Arm C|ABT-493 200 mg once daily (QD) + ABT-530 120 mg QD for 8 weeks in HCV genotype 1-infected participants without cirrhosis (never opened - Sponsor decision)
88839726|NCT02243280|Experimental|Arm D|ABT-493 200 mg once daily (QD) + ABT-530 40 mg QD for 8 weeks in HCV genotype 1-infected participants without cirrhosis (never opened - Sponsor decision)
88839727|NCT02243280|Experimental|Arm E|ABT-493 200 mg once daily (QD) + ABT-530 120 mg QD + ribavirin (RBV) 800 mg QD for 12 weeks in HCV genotype 1-infected participants with compensated cirrhosis (never opened - Sponsor decision)
88839728|NCT02243280|Experimental|Arm F|ABT-493 200 mg once daily (QD) + ABT-530 120 mg QD for 12 weeks in HCV genotype 1- infected participants with compensated cirrhosis
88839729|NCT02243280|Experimental|Arm G|ABT-493 200 mg once daily (QD) + ABT-530 40 mg QD + ribavirin (RBV) 800 mg QD for 12 weeks in HCV genotype 1-infected participants with compensated cirrhosis (never opened - Sponsor decision)
88839730|NCT02243280|Experimental|Arm H|ABT-493 200 mg once daily (QD) + ABT-530 40 mg QD for 12 weeks in HCV genotype 1-infected participants with compensated cirrhosis (never opened - Sponsor decision)
88839731|NCT02243280|Experimental|Arm I|ABT-493 300 mg once daily (QD) + ABT-530 120 mg QD for 12 weeks in HCV genotype 4-, 5-, and 6-infected participants without cirrhosis
88839732|NCT02243280|Experimental|Arm J|ABT-493 200 mg once daily (QD) + ABT-530 40 mg QD for 12 weeks in HCV genotype 4-, 5-, and 6-infected participants without cirrhosis (never opened - Sponsor decision)
88839733|NCT02243280|Experimental|Arm K|ABT-493 300 mg once daily (QD) + ABT-530 120 mg QD for 8 weeks in HCV genotype 1- infected participants without cirrhosis
88839734|NCT02549365|Experimental|Intervention|Administration of Live attenuated influenza vaccine (LAIV) as per national guidance. Surveillance thereafter through nasal swabbing in the event of influenza-like illness.
88839735|NCT02549365|Other|Controls|Surveillance in siblings of participants in the Intervention arm, through nasal swabbing in the event of influenza-like illness, irrespective of their vaccination status.
88839736|NCT04744675|Experimental|Treatment|"The intervention group will receive:~Suprascapular nerve block - 3 mL of 0.5% Bupivacaine and 1 mL of 40 mg/mL Kenalog~Median nerve block - 3.5 mL of 0.5% Bupivacaine and 0.5 mL of 40 mg/mL Kenalog~Ulnar nerve block - 3.5 mL of 0.5% Bupivacaine and 0.5 mL of 40 mg/mL Kenalog"
88839737|NCT04744675|Placebo Comparator|Placebo|"Placebo~The placebo group will receive:~Suprascapular nerve injection - 4 mL of normal saline~Median nerve injection - 4 mL of normal saline~Ulnar nerve injection - 4 mL of normal saline"
88839738|NCT02471521|Experimental|Neuromuscular blocker|During induction of anesthesia, mask ventilation by pressure controlled ventilation is performed with after rocuronium administration in children while continuous gastric auscultation and abdominal sonography are performed.
88839739|NCT02471521|Active Comparator|Non-neuromuscular blocker|During induction of anesthesia, mask ventilation by pressure controlled ventilation is performed without rocuronium in children while continuous gastric auscultation and abdominal sonography are performed.
88839740|NCT02624479|Experimental|Fast first|Sodium thiosulfate fast release formulation first, followed by medium and slow
88839741|NCT02624479|Experimental|Medium first|Sodium thiosulfate medium release formulation first, followed by slow and fast
88839742|NCT02624479|Experimental|Slow first|Sodium thiosulfate slow release formulation first, followed by fast and medium
88839743|NCT04341337||expert|interviews of expert of pipac about ethical issues
88839744|NCT02554435|Active Comparator|Pedometer|All participants will be given 5 A's counseling and a digital pedometer (Digi-walker CW-700/701, YAMAX, San Antonio, TX). Participants will be asked to log their daily steps measured by the pedometer in an activity diary.
88839745|NCT02554435|Experimental|Electronic Activity Monitor (EAM)|"All participants will be given an EAM (UP24 by Jawbone, San Francisco, CA) and the corresponding UP24 application (app) on their smart device. In addition to monitoring activity, the app allows for social comparison and social interaction. Participants will friend other participants to utilize these features."
88839746|NCT02555449|Experimental|[¹⁴C]-LY3202626|Single oral dose of LY3202626 containing 100 micro curies of radioactivity
88839747|NCT02248818|Experimental|AZD8108|Subjects will participate in 1 of 7 groups and receive single or multiple doses of AZD8108 or matching placebo. In each group 6 subjects will receive AZD8108
88839748|NCT02248818|Placebo Comparator|Placebo to match AZD8108|Subjects will participate in 1 of 7 groups and receive single or multiple doses of AZD8108 or matching placebo. In each group 2 subjects will receive matching placebo
88839749|NCT02472223|Active Comparator|Betadine 5%|One time in-office administration (4-5 drops) of Betadine 5% limited to 2 minutes, followed by saline lavage.
88839750|NCT02472223|Placebo Comparator|Artificial Tears|One time in-office administration (4-5 drops) of artificial tears limited to 2 minutes, followed by saline lavage.
88839751|NCT02596087|No Intervention|Normal Use of EHR|Sites will configure their EHR systems so that alerts will not be triggered for providers in the control arm if the patient does not have the condition on her/his problem list.
88875205|NCT02522442|Experimental|Auto BiLevel Group|Auto Bilevel; auto-titrating bilevel positive airway pressure device with pressure flexing used as experimental treatment for obstructive sleep apnea
88875206|NCT02522442|Active Comparator|CPAP Group|CPAP; continuous positive airway pressure used as comparator treatment for obstructive sleep apnea
88875207|NCT02523690|Experimental|Intervention|Lorcaserin will be administered as a single dose on day 1 and day 3 to participants in this arm.
89179171|NCT02599701|Placebo Comparator|Placebo|A single dose of placebo with exactly the same characteristics of the active drug at bedtime.
89179172|NCT02599701|Experimental|Gabapentin|A single dose of Gabapentin 300mg at bedtime.
88839752|NCT02596087|Experimental|Intervention Arm|Sites will configure their EHR systems so that alerts for these conditions will be triggered for providers in the intervention arm if the patient does not have the condition on her/his problem list. Each alert will be actionable and allow the provider to add the problem to her or his patient's problem list with a single click. The provider will also be able to override the rule of the patient does not have the condition (in which case the alert will not be displayed again unless new information that would trigger the alert is added to the patient's record), or defer the alert until later.
88839753|NCT02247960|Active Comparator|Ciprofloxacin|Antibiotic
88839754|NCT02247960|No Intervention|No Antibiotic|No Antibiotic
88839755|NCT02472457|Placebo Comparator|Free Diet|No dietary restrictions
88839756|NCT02472457|Active Comparator|Crohn Disease Exclusion Diet|The CDED is a palatable diet that excludes foods suspected to have a role in intestinal inflammation.
88839757|NCT02473783|Experimental|Treatment Group|The subjects with major depressive disorder who are screened into this study were scheduled for T1-weighted MRI (MRI examination results within 6 months before study are acceptable) prior to the visit of SPECT scans to confirm the absence of organic lesion in the brain and to co-register with SPECT images for the delineation of brain anatomical locations. After the screening visit, eligible subjects received I-123-ADAM SPECT before and after the pharmacological intervention with Sertraline HCl for a treatment period of six weeks. The subjects were observed until no clinically significant adverse events at the drug administration visits before being dismissed.
88839758|NCT02543749|Experimental|DC vaccine|"Autologous DC pulsed with leukemia-associated peptides+adjuvant.~Ten vaccinations over 26 weeks with 10 x 106 freshly thawed DC Intradermal injections (1-2 ml volume)"
88839759|NCT02632526|Experimental|AZD5718 amorphous form, treatment 1 (Part A)|Starting dose 25 mg/day, single ascending dose
88839760|NCT02632526|Experimental|AZD5718 amorphous form, treatment 2 (Part A)|Single dose of AZD5718 amorphous suspension
88839761|NCT02632526|Experimental|AZD5718 amorphous form, treatment 3 (Part A)|Single dose of AZD5718 amorphous suspension
88839762|NCT02632526|Experimental|AZD5718 amorphous form, treatment 4 (Part A)|Single dose of AZD5718 amorphous suspension
88839763|NCT02632526|Experimental|AZD5718 amorphous form, treatment 5 (Part A)|Single dose of AZD5718 amorphous suspension
88839764|NCT02632526|Experimental|AZD5718 amorphous form, treatment 6 (Part A)|Single dose of AZD5718 amorphous suspension
88839765|NCT02632526|Experimental|AZD5718, crystalline form, treatment 7 (Part A)|Crystalline suspension (Part A), dosage lower than highest dose used with amorphous suspension, single ascending dose
88839766|NCT02632526|Experimental|AZD5718 crystalline form, treatment 8 (Part A)|Crystalline suspension (Part A), dosage lower than highest dose used with amorphous suspension, single ascending dose
88839767|NCT02632526|Experimental|AZD5718 amorphous form, treatment 1 (Part B)|Once or twice daily from Days 2 to 9 and single doses on Days 1 and 10, dosage TBD (Part A)
88839768|NCT02632526|Experimental|AZD5718 amorphous form, treatment 2 (Part B)|Once or twice daily from Days 2 to 9 and single doses on Days 1 and 10, dosage TBD (Part A)
88839769|NCT02632526|Experimental|AZD5718 amorphous form, treatment 3 (Part B)|Once or twice daily from Days 2 to 9 and single doses on Days 1 and 10, dosage TBD (Part A)
88839770|NCT02632526|Experimental|AZD5718 amorphous form, treatment 4 (Part B)|Once or twice daily from Days 2 to 9 and single doses on Days 1 and 10, dosage TBD (Part A)
88839771|NCT02632526|Experimental|AZD5718 amorphous/crystalline form, repeat 1 (Part A)|Single dose of AZD5718 amorphous form (Part A) Crystalline form (Part A), dosage lower than highest dose used with amorphous form, single ascending dose
88839772|NCT02632526|Experimental|AZD5718 amorphous/crystalline form, repeat 2 (Part A)|Single dose of AZD5718 amorphous form (Part A) Crystalline form (Part A), dosage lower than highest dose used with amorphous form, single ascending dose
88839773|NCT02632526|Experimental|AZD5718 amorphous/crystalline, repeat 3 (Part A)|Single dose of AZD5718 amorphous form (Part A) Crystalline form (Part A), dosage lower than highest dose used with amorphous form, single ascending dose
89001868|NCT00218946|Experimental|sucrose|Sucrose, no pacifier
89001869|NCT00218946|Experimental|pacifier|No fluid, pacifier
89001870|NCT00218946|Experimental|water and pacifier|water, pacifier
89001871|NCT00218946|Experimental|sucrose and pacifier|sucrose, pacifier
89001872|NCT00218985|Experimental|exercise training|
89001873|NCT00218985|No Intervention|physician's advice|patients follow their physician's advice in regard to physical activity.
89001874|NCT00187421|No Intervention|1|Graft patency assessment by routine clinical assessment with/without intraluminal coronary probe
89001875|NCT00187421|Experimental|2|Graft patency assessment by indocyanine green angiography and transit-time flowmetry
89001876|NCT00211965|Experimental|vaccine|single dose
89001877|NCT00211965|Placebo Comparator|placebo|single dose
89001878|NCT00187460|Active Comparator|Early Feedback Arm|Hospital corporations randomized to receive early feedback in the form of a report card
89001879|NCT00187460|Active Comparator|Delayed Feedback Arm|Hospitals randomized to receive delayed feedback in the form of a hospital report cared, 21 months after the early feedback arm.
89001880|NCT00212004|Active Comparator|Pioglitazone|Participants in the pioglitazone group were administered a pioglitazone tablet (15 mg) once a day. In the event of the side effects such as oedema, the dosage of pioglitazone was reduced to half or a quarter of the original dosage. Otherwise, we tried to increase the dose of pioglitazone to 30mg/day.
89001881|NCT00212004|Active Comparator|Control|Participants assigned to Control group were treated with diet and exercise therapy or sulfonylurea (SU) or other additional drugs than pioglitazone.
89001882|NCT00187538|Active Comparator|1|
89001883|NCT00187538|Active Comparator|2|
89001884|NCT00187538|Active Comparator|3|
89001885|NCT00187538|Active Comparator|4|
89001886|NCT00187577|Active Comparator|application to eyelid of latanoprost solution|Subject will apply latanoprost solution with applicator daily to affected eye lid(s)
89001887|NCT00187577|Active Comparator|Application of bimatoprost to eyelid|Subject will apply bimatoprost solution with applicator daily to affected eye lid(s)
89001888|NCT00187733||Fasting|Other: Fasting blood and urine collection
89001889|NCT00212160|Experimental|RYGB with omentectomy|Subjects undergoing RYGB will be randomized to also have the greater omentum removed at the time of surgery.
89001890|NCT00212160|No Intervention|RYGB without omentectomy|Subjects undergoing RYGB will be randomized to NOT have the greater omentum removed at the time of surgery.
89001891|NCT00212160|No Intervention|Normal body weight|Healthy normal weight subjects studied via hyperinsulinemic-euglycemic clamp to obtain reference values for insulin sensitivity and other metabolic parameters.
89001892|NCT00212160|No Intervention|Tissue samples|Tissue samples (omental fat, subcutaneous fat, muscle,and blood)are obtained from subjects of varying weights during abdominal surgery in order to compare various parameters, including inflammation, oxidative stress, and gene expression, among tissues across weight classes.
89001893|NCT00187850|Experimental|PP|Partial pulpotomy
89001894|NCT00187850|Other|DPC|Direct pulp capping
89001895|NCT00219336|Experimental|Self-motivational Choices|Students and nonstudents were mailed a brochure prepared as part of the PHC study intervention, Making Healthy Choices for a Healthy Baby in English or Mujeres y Salud Eligiendo Opciones Saludables in Spanish. This brochure allows women to make informed decisions about preventing an AEP. The MF materials included nonstigmatizing messages about drinking and contraception embedded among other health messages. Similar to Project CHOICES, this group also received a brochure on birth control practices.
89001896|NCT00219336|Active Comparator|Information Only|Students and nonstudents were mailed a brochure prepared by the CDC. The brochure (English: Think Before You Drink: You Can Hurt Your Unborn Baby; Spanish: Piénselo Antes de Beber: Puede Lastimar a Su Futuro Bebe), available at the CDC website, targets women of childbearing-age, discusses FAS and the negative effects of a mother's drinking on her unborn child, and recommends calling Alcoholics Anonymous or an alcohol treatment program for help to stop drinking. The CDC brochure did not contain information about how to contracept effectively.
89001897|NCT00219375|Experimental|E1|This arm is conducted as a separate study (12-601-0001)
89001898|NCT00219375|Experimental|E2|This arm is conducted as a separate study (12-603-0001).
89001899|NCT00219375|No Intervention|conventional therapy|This arm is conducted as a separate study (12-602-0001)
89001900|NCT00188279|Experimental|MnDCT|
89001901|NCT00188318|Experimental|Hyperfractionated Accelerated Radiotherapy|Hypofractionated Accelerated Radiotherapy with integrated neck surgery
89001902|NCT00219531||control|subjects with no irritable bowel syndrome or gastrointestinal complaints and regular menstrual cycle.
89001903|NCT00219531||IBS|women with IBS symptoms and normal menstrual cycle.
89179173|NCT04093401|No Intervention|Control|Subjects will be assigned to the control arm if their subject ID is an odd number. Control arm subjects will not receive counseling for individualized risk assessment for developing a second basal cell carcinoma.
89534711|NCT03328559|Other|advanced stage bronchial cancer|Patients locally moved forward or at a metastatic stage handled by chemotherapy
89001904|NCT00188513|Experimental|Conformal intensity modulated radiotherapy (IMRT)|All patients shall receive a continuous course of intensity modulated conformal radiotherapy consisting of 66 Gy in 22 (3 Gy) fractions over 4.5 weeks.
89001905|NCT00212472|Active Comparator|1|Low-dose treatment (50 FVIII u/kg three times a week).
89001906|NCT00212472|Active Comparator|2|High-dose treatment (200 FVIII u/kg per day).
89001907|NCT00411606||1|Subjects with no allergies
89001908|NCT00411723|Experimental|1|
89001909|NCT00411723|Placebo Comparator|2|
89367656|NCT02453308|Active Comparator|TACT-arms|"2.1: Artemether-lumefantrine for 3 days.plus: Amodiaquine for 3 days.~2.2: Dihydroartemisinin-piperaquine for 3 days. plus: Mefloquine hydrochloride for 3 days.~2.3 Dihydroartemisinin-piperaquine for 3 days. plus: Mefloquine hydrochloride for 3 days."
89367657|NCT04258020|Experimental|Experimental: alternating BiPAP and HFNC|Patients will be placed on alternating BiPAP and HFNC for 24 hours following extubation
89367658|NCT04258020|No Intervention|Historical Control: standard of care|A historical control cohort will be composed of patients treated according to their physician's standard of care following removal from mechanical ventilation.
89367659|NCT03236350|Experimental|CRIC Treatment|An autoRIC® Device will be placed on the upper arm daily to complete the preset protocol and will be repeated daily for 28 days.
89367660|NCT03236350|Sham Comparator|Sham Control|An autoRIC® Device visually identical to that used in the CRIC protocol will be placed on the upper arm daily to complete the preset protocol and will be repeated daily for 28 days.
89367661|NCT01365312|Experimental|Ethanol|Assigned intervention is a 70% ethanol lock, placed every 72 hours for 15 minutes, for the duration of the PICC line.
89367662|NCT01365312|Placebo Comparator|Heparinized saline|Intervention is to place a heparinized saline lock every 72 hours for 15 minutes, for the duration of the line.
88839774|NCT02632526|Experimental|AZD5718 amorphous form, repeat 1 (Part B)|Twice daily dosing (Day 1 - 9) and once daily dosing (Day 10), dosage TBD (Part A)
88839775|NCT02632526|Experimental|AZD5718 amorphous form, repeat 2 (Part B)|Twice daily dosing (Day 1 - 9) and once daily dosing (Day 10), dosage TBD (Part A)
89367663|NCT04495283|Experimental|PGB and APAP (Group A)|Group A receives PGB plus APAP prior to surgery and placebo 1 post-surgery.
89367664|NCT04495283|Experimental|APAP (Group B)|Group B receives placebo 2 prior to surgery and APAP post-surgery.
88839776|NCT04740866|Active Comparator|Adjuvant Radiotherapy|Irradiation of both the bladder tumor bed and pelvic lymph nodes using Intensity-Modulated Radiation-Therapy [IMRT] technique.
88839777|NCT04740866|No Intervention|Observation after radical Cystectomy|observation following radical cystectomy
88839778|NCT04340414|Experimental|NCP patient with severe ARDS and/or high ventilator supported|The NCP patient with severe ARDS and/or high ventilator supported condition was eligibilitable for enrollment
88839779|NCT02247804|Experimental|Bimatoprost SR 15 μg|Study Eye: bimatoprost sustained release (SR) 15 μg administered on Day 1 (Period 1), Week 16 (Period 2), and Week 32 (Period 3); timolol vehicle administered once in the morning and once in the evening for up to 20 months. Non-Study Eye: sham administration on Day 1 (Period 1), Week 16 (Period 2), and Week 32 (Period 3); timolol 0.5% administered once in the morning and once in the evening for up to 20 months.
88839780|NCT02247804|Experimental|Bimatoprost SR 10 μg|Study Eye: bimatoprost SR 10 μg administered on Day 1 (Period 1), Week 16 (Period 2), and Week 32 (Period 3); timolol vehicle administered once in the morning and once in the evening for up to 20 months. Non-Study Eye: sham administration on Day 1 (Period 1), Week 16 (Period 2), and Week 32 (Period 3); timolol 0.5% administered once in the morning and once in the evening for up to 20 months.
88839781|NCT02247804|Active Comparator|Timolol 0.5%|Study Eye and Non-Study Eye: sham administered on Day 1 (Period 1), Week 16 (Period 2), and Week 32 (Period 3); timolol 0.5% administered once in the morning and once in the evening for up to 20 months.
88839782|NCT00366860|Experimental|Soy bread|Soy bread (75-100 mg isoflavone/day) for 12 weeks
88839783|NCT00366860|Active Comparator|Wheat bread|Wheat bread for 12 weeks
88839784|NCT02635880|Experimental|Investigational Enlighten Device|Laser treatment for removal of benign pigmented lesions (BPLs) with Nd:YAG dual-wavelength, dual-pulse duration laser.
88839785|NCT04943822|Placebo Comparator|conventional education service program|Including the written and verbal health education on preoperative preparation, stoma surgery and postoperative stoma care. At discharge, ET nurses offered teaching information and support for patients, including selection of pouching appliances, drug instructions, health education At each outpatient follow-up, both stomas and patients needed to be assessed. The condition of stoma and peristomal skin, nature and volume of effluent, date of pouch appliances and stoma complications were recorded by ET nurses.
88839786|NCT04943822|Experimental|mobile care device|The participants in the intervention group were given the same routine care as the control group pre- and postoperatively. ET nurses taught patients and their family members how to use the home care mobile app before discharge. The home care mobile app was designed and developed for the discharged stoma patients by the research team and an information technology company in March 2021. Patients could receive stoma care from ET nurses through this mobile app at home, not just going to an outpatient clinic. The Major function modules of this mobile app were as follows: (a) appointment: The app users were able to complete the basic personal and medical information and make an appointment with the ET nurse; (b) photograph diagnosis: The ET nurses could make a diagnosis based on the patients' uploaded stoma photographs; and (c) consultation: Patients were able to contact their ET nurses for help and support. This mobile app was used to supplement the outpatient follow-up.
88875208|NCT02523690|Placebo Comparator|Control|Placebo will be administered as a single dose on day 1 and day 3 to participants in this arm.
88875209|NCT02523924|Experimental|18F-DCFPyL PET/CT|Men with an elevated PSA following radical prostatectomy imaged with 18F-DCFPyL PET/CT
89367665|NCT04495283|Experimental|Placebo (Group C).|Group C receives placebo 1 prior to surgery and placebo 2 post-surgery.
89367666|NCT03253822|Experimental|Intervention group|"This group receives a baseline questionnaire before their screening invitation. Respondents are included, and those receiving a screening reminder receive the decision aid.~At least three months after their screening invitation the included citizens (baseline questionnaire respondents) will receive a follow-up questionnaire."
89367667|NCT03253822|No Intervention|Control group|This group receives a baseline questionnaire before their screening invitation. Respondents are included. At least three months after their screening invitation, baseline questionnaire respondents will receive a follow-up questionnaire.
89367668|NCT03253822|No Intervention|Historic cohort|A group of people already invited for colorectal cancer screening. This group receives a questionnaire at least three months after their screening invitation. Respondents are included in the study.
89534712|NCT03235297||Healthy subjects|Healthy subjects
89534713|NCT03235297||Subjects with COPD|Subjects with a diagnosis of COPD
88839787|NCT05026320|Experimental|Naproxen Topical Gel (BAYH006689)|UI Number: 1614000-268; Subjects will be randomized into one of the three treatment groups in a 2:2:1 (active:active:placebo) allocation. Treatment consists of a twice daily (bid) application (approximately 12 hours apart) of the assigned topical gel over 5 consecutive days, beginning on the evening of Day 1 and ending (last application) on the morning of Day 6 (total of 10 applications). In order to assure adequate representation of different types of soft tissue injuries, at least 25 randomized subjects must enter the study with a lower extremity sprain/strain injury (cohort) and at least 50 randomized subjects with a lower extremity contusion injury (cohort).
88839788|NCT05026320|Active Comparator|Diclofenac Diethylamine Gel|UI Number: Not applicable; Subjects will be randomized into one of the three treatment groups in a 2:2:1 (active:active:placebo) allocation. Treatment consists of a twice daily (bid) application (approximately 12 hours apart) of the assigned topical gel over 5 consecutive days, beginning on the evening of Day 1 and ending (last application) on the morning of Day 6 (total of 10 applications). In order to assure adequate representation of different types of soft tissue injuries, at least 25 randomized subjects must enter the study with a lower extremity sprain/strain injury (cohort) and at least 50 randomized subjects with a lower extremity contusion injury (cohort).
88839789|NCT05026320|Placebo Comparator|Placebo Gel|UI Number: 1614000-272; Subjects will be randomized into one of the three treatment groups in a 2:2:1 (active:active:placebo) allocation. Treatment consists of a twice daily (bid) application (approximately 12 hours apart) of the assigned topical gel over 5 consecutive days, beginning on the evening of Day 1 and ending (last application) on the morning of Day 6 (total of 10 applications). In order to assure adequate representation of different types of soft tissue injuries, at least 25 randomized subjects must enter the study with a lower extremity sprain/strain injury (cohort) and at least 50 randomized subjects with a lower extremity contusion injury (cohort).
88839790|NCT00367328|Active Comparator|A|Oral Antibiotics in standard care vs. Laser treatment
88839791|NCT04740320||Healthy Volunteers|Volunteers asked to register details on a SARS-CoV-2 specific web page UKcovidchallenge.com. They will be contacted with a short webform questionnaire to be performed prior to a follow-up telephone questionnaire or will be asked to complete a telephone questionnaire. If inclusion/exclusion criteria are met, appointment for a screening visit will be scheduled. Screening appointments will be conducted at hVIVO. Written consent for screening will be obtained prior to any history-taking, examination or tests are carried out. Medical history will be requested from GP to assess suitability. Once the SARS-CoV-2 characterization study is approved, potential participants will be given the study specific PIS detailing the full study and experimental procedures. The opportunity to discuss further and ask questions will be available prior to booking a study visit.
88839792|NCT04840784|Experimental|ETH-155008|Dose level: 10mg/day, 20mg/day, 40mg/day, 60mg/day, 80mg/day, 100mg/day. Each dose level will recruit 3-6 subjects, taking ETH-155008 tablets once daily.
88839793|NCT02640716|Active Comparator|training group|Intervention: Multi-domain adaptive internet-based training program, including processing speed, attention, long-term memory, working memory, flexibility, calculation, and problem solving. 5 x 30 minutes per week, for 7 weeks.
88839794|NCT02640716|Placebo Comparator|control group|Intervention: placebo program: a fixed, primary difficulty level task. 5 x 30 minutes per week, for 7 weeks.
88839795|NCT04068272|Experimental|Treatment|The patient will receive investigational product in one eye and placebo in the other eye. The allocation of treatment / placebo is masked and randomized
88839796|NCT04068272|Placebo Comparator|Placebo|The patient will receive investigational product in one eye and placebo in the other eye. The allocation of treatment / placebo is masked and randomized
88839797|NCT02243202|Experimental|Canagliflozin + Phentermine|300 mg capsule of Canagliflozin along with 15 mg capsule of Phentermine, taken once daily, orally for 26 weeks.
88839798|NCT02243202|Experimental|Canagliflozin + Placebo (Phentermine)|300 mg capsule of Canagliflozin along with matching placebo to Phentermine, taken once daily, orally for 26 weeks.
88839799|NCT02243202|Experimental|Phentermine + Placebo (Canagliflozin)|15 mg capsule of Phentermine along with matching placebo to Canagliflozin, taken once daily, orally for 26 weeks.
88839800|NCT02243202|Placebo Comparator|Placebo|Matching placebo to Canagliflozin and Phentermine, taken once daily, orally for 26 weeks.
88839801|NCT02243046|Placebo Comparator|Control toothpaste|1450 ppm Fluoride toothpaste
88839802|NCT02243046|Experimental|Experimental toothpaste|1450 ppm sodium fluoride toothpaste with a zinc base
88839803|NCT02243046|Active Comparator|Active comparator|1450 ppm sodium fluoride/triclosan toothpaste
89367669|NCT01365390||Cohort A|Subjects aged < 6 years who are registered in primary care clinics of any of the participating countries (Estonia, Lithuania, Poland, Romania and Slovenia).
88839804|NCT04016636||Single Group Study. Patients with CLL receiving ibrutinib.|"In this study the investigator does not assign specific interventions to the study participants. Participants will receive interventions as part of routine medical care, and the investigator will observe the effect of the intervention.~This study will collect prospective real-world data to describe the quality of life (QOL) in patients with CLL receiving ibrutinib in routine Argentinian clinical practice over a 12-month follow-up period.~The primary data source for this observational study will be the medical records of each enrolled patient, as well as questionnaires concerning quality of life. Data will be collected at baseline and on months 1,3,6 and 12 during a prospective period."
88839805|NCT02207946|Experimental|200 Units incobotulinumtoxinA (Xeomin)|Single injection cycle, total dose of up to 200 Units, intramuscular injection into muscles of wrist (mandatory) and shoulder and/or elbow (both optional).
88839806|NCT02207946|Placebo Comparator|Placebo|Single injection cycle, intramuscular injection into muscles of wrist (mandatory) and shoulder and/or elbow (both optional).
88839807|NCT03976076|Experimental|JBPOS0101 (investigational product)|During Treatment Period 1, the IP was administered at 6 mg/kg, per oral (PO), twice a day (BID), once in the morning and 12 hours following the morning dose during the first 7 days of Treatment Period 1. Starting from the PM dose on Visit 3, the dose was escalated and patients received the Investigational Product (JBPOS0101) (IP) at a dose of 9 mg/kg orally BID. Starting on Day 15, the dose was escalated again and patients received the IP at a dose of 15 mg/kg orally BID until the end of Treatment Period 1 (Day 28). Each dose of the IP was administered after at least a 2-hour fast. Food was given 2 hours after dosing.
89367670|NCT03253510|Experimental|Poly-amide|new thermoplastic material used as a denture base, that has excellent ethetics and flexibility
89367671|NCT03253510|Active Comparator|poly-methyl methacrylate|Polymethylmethacrylate is one of the most widely used denture base material, because of its good biocompatibility, reliability and dimensional stability
88839808|NCT04933500||Conventional epidural|epidural needle: Tuhoy needle 1.3mm (18 G) with 20G multi-orifice epidural catheter
88839809|NCT04933500||Dural puncture epidural|epidural needle;Tuhoy needle 1.3mm (18G)with 20G multi-orifice epidural catheter and 25G Whitacre spinal needle
88839810|NCT05588726|Active Comparator|Sleep Hygiene|
88839811|NCT05588726|Experimental|Mindfulness|
88839812|NCT04235036|Experimental|Rituximab + Ibrutinib|Eligible patients will be those with a first episode of symptomatic cGVHD, requiring systemic immunosuppression for control of symptoms. Following study entry, patients will be started on rituximab plus ibrutinib.
88839813|NCT03875300|Experimental|Participants in the Intervention Group|Intervention Group - will undertake a programme of 7 x 2 hour group sessions, following the scripted 'Foodwise in Pregnancy' manual of nutrition information; practical cooking sessions; and information on low impact exercise.
88839814|NCT03875300|No Intervention|Participants in the Control Group|Control Group - will continue with routine antenatal care, unchanged.
88839815|NCT02560051|Active Comparator|Definitive local therapy|3 cycles of chemotherapy (doxorubicin, ketoconazole, docetaxel and estramustine) + 12 months ADT (degarelix)
88839816|NCT02560051|Active Comparator|Nodal only/Low-volume bone|4 cycles of chemotherapy (doxorubicin, ketoconazole, docetaxel and estramustine) + 18 months ADT (degarelix)
88839817|NCT02560051|Active Comparator|High volume/no prior tx|5 cycles of chemotherapy (doxorubicin, ketoconazole, docetaxel and estramustine) + 24 months ADT (degarelix)
88839818|NCT03786770|Experimental|Cohort 1: Dose A|DAXI for injection for the treatment of Forehead Lines (FHL) and Glabellar Lines (GL)
88839819|NCT03786770|Experimental|Cohort 2: Dose B|DAXI for injection for the treatment of Forehead Lines (FHL) and Glabellar Lines (GL)
88839820|NCT03786770|Experimental|Cohort 3: Dose C|DAXI for injection for the treatment of Forehead Lines (FHL) and Glabellar Lines (GL)
88839821|NCT03786770|Experimental|Cohort 4: Dose D|DAXI for injection for the treatment of Forehead Lines (FHL) and Glabellar Lines (GL)
88839822|NCT02474407|Experimental|diazepam nasal spray (DZNS)|One dose of diazepam nasal spray is administered as two intranasal sprays; one in each nostril using a nasal spray device.
88839823|NCT02474407|Active Comparator|diazepam rectal gel (DRG)|A single rectal dose of diazepam will be administered to subjects according to the Diastat prescribing information.
89367672|NCT03744845|No Intervention|Control group|Usual anesthetic care.
88839824|NCT05588492|Experimental|Rifamycin containing regimen|Rifamycin containing regimen
88839825|NCT05588492|Experimental|Rifamycin-free regimen|Rifamycin-free regimen
88839826|NCT02475031|Placebo Comparator|Placebo Group (TAP-S)|(TAP-S) - the On-Q reservoir will be filled with saline and set to infuse at rate of 10 ml/hr through the TAP catheter
88839827|NCT02475031|Active Comparator|Active Group (TAP-C)|(TAP-C) - The On-Q reservoir will be filled with 0.2% ropivacaine and set to infuse at rate of 10 ml/hr through the TAP catheter
88839828|NCT03777956|Active Comparator|Lacosamide|Lacosamide (50 mg) are given as capsules and taken orally twice a day, up to 200 mg b.i.d.
88839829|NCT03777956|Placebo Comparator|Placebo|Placebo are given as capsules, same as lacosamide, and taken orally twice a day, without active ingredient.
88839830|NCT02476357|Active Comparator|Harmonic|Harmonic Scalpel (HS; Ethicon Endo-Surgery, Cincinnati, OH)
88839831|NCT02476357|Active Comparator|Control|Monopolar scalpel and ligature
88839832|NCT02519491|Active Comparator|Modified Allen's Test|The Modified Allen's Test to assess radial and ulnar patency.
89367673|NCT03744845|Experimental|Virtual Reality Intervention Group|Virtual Reality Distraction
89367674|NCT03634020|Experimental|DynamX Sirolimus-eluting Coronary Bioadaptor System|2.5 - 3.5mm 14mm, 18mm and 28mm
89367675|NCT03253666||Nurses' Health Study|"See Detailed Description"
89367676|NCT03253666||Health Professionals Follow-Up Study|"See Detailed Description"
89367677|NCT03253432||Strata 0-0.05|Lowest probability of having familial hypercholesterolemia
89367678|NCT03253432||Strata 0.06-0.15|Second lowest probability of having familial hypercholesterolemia
88839833|NCT02519491|Active Comparator|Iphone assessment|iPhone assessment of radial and ulnar patency.
88839834|NCT02560753|Experimental|T3D-959 3mg|Nine subjects will take 3mg by mouth once daily for two weeks, with or without food.
88839835|NCT02560753|Experimental|T3D-959 10mg|Nine subjects will take 10mg by mouth once daily for two weeks, with or without food.
88839836|NCT02560753|Experimental|T3D-959 30mg|Nine subjects will take 30mg by mouth once daily for two weeks, with or without food.
88839837|NCT02560753|Experimental|T3D-959 90mg|Nine subjects will take 90mg by mouth once daily for two weeks, with or without food.
88839838|NCT02481505|Experimental|3 mL Chloroprocaine HCl 1%|Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl)
88839839|NCT02481505|Experimental|4 mL Chloroprocaine HCl 1%|Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl)
88839840|NCT02481505|Experimental|5 mL Chloroprocaine HCl 1%|Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl)
88839841|NCT02563093|Experimental|Study Group 1|Adults 18 to < 65 years of age randomly assigned to receive an intramuscular injection of one dose of Fluzone Quadrivalent vaccine
89534714|NCT03093987|No Intervention|control group|usual care
88839842|NCT02563093|Experimental|Study Group 2|Adults 18 to < 65 years of age randomly assigned to receive an intradermal injection of one dose of Fluzone Intradermal Quadrivalent vaccine
88839843|NCT02563093|Experimental|Study Group 3|Adults ≥ 65 years of age randomly assigned to receive an intramuscular injection of one dose of Fluzone Quadrivalent vaccine
88839844|NCT02563093|Experimental|Study Group 4|Adults ≥ 65 years of age randomly assigned to receive an intramuscular injection of one dose of Fluzone High-Dose vaccine
88839845|NCT02564029|Experimental|PF-06372865 dose level 1|17.5 milligram (mg) single dose
88839846|NCT02564029|Experimental|PF-06372865 dose level 2|52.5 mg single dose
88839847|NCT02564029|Placebo Comparator|Placebo|Single dose
88839848|NCT02564029|Active Comparator|Lorazepam|2mg single dose
88839849|NCT05588336|Active Comparator|10 mcg/kg intrathecal morphine|For postoperative analgesia, before surgical incision, 10 mcg/ideal body weight morphine HCl (in 2 ml volume) was administered intrathecally at L4-5 interspace in the lateral decubitis position.
88839850|NCT05588336|Active Comparator|7 mcg/kg intrathecal morphine|For postoperative analgesia, before surgical incision 7 mcg/ideal body weight morphine HCl (in 2 ml volume) was administered intrathecally at L4-5 interspace in the lateral decubitis position.
88839851|NCT05588258|Active Comparator|Pharmacy cream 10% urea|Use of pharmacy cream in prevention
88839852|NCT05588258|Active Comparator|Supermarket cream 10% urea|Use of supermarket cream in prevention
88839853|NCT02564497|Other|Process E Belatacept|Active Pharmaceutical Ingredient (API) of Belatacept manufactured by Process E
88839854|NCT02564497|Other|Process C Belatacept|Active Pharmaceutical Ingredient (API) of Belatacept manufactured by Process C
88839855|NCT03957278|Experimental|DAISe System|The DAISe System consists of the DAISe thrombectomy device used in with the Q Aspiration Catheter.
88839856|NCT02565901|Experimental|Arm I (sirolimus, docetaxel, carboplatin)|Patients receive docetaxel IV over 30-60 minutes and carboplatin IV over 30 minutes on day 1. Beginning in cycle 2 and continuing in subsequent cycles, patients also receive sirolimus PO on day -2. Treatment repeats every 21 days for 10 cycles in the absence of disease progression or unacceptable toxicity.
88839857|NCT02565901|Experimental|Arm II (sirolimus, docetaxel, carboplatin)|Patients receive sirolimus PO on day -2. Patients also receive docetaxel IV over 30-60 minutes and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 10 cycles in the absence of disease progression or unacceptable toxicity.
88839858|NCT03926624|Experimental|Experimental|DFP-10917 Dose: 6 mg/m²/day administered by continuous infusion for 14 days followed by a 14-day resting period per 28-day treatment cycle. If a patient experiences a significant treatment-related AE, the patient may undergo one dose reduction of DFP-10917 to 4 mg/m²/day x 14 days for subsequent treatment cycles
88839859|NCT03926624|Active Comparator|Control|"Non-Intensive:~LoDAC: 20 mg SC BID 10 days~Azacitidine: 75 mg/m²/day SC 7 days(or 5+2)~Decitabine: CIV 20 mg/m²x5 days~Venetoclax + LoDAC/Azacitidine/Decitabine:LoDAC-Venetoclax ramp-up to 600 mgxday. Cytarabine SC 20 mg/m²xday D1-10. Azacitidine or Decitabine-Venetoclax ramp-up to 400 mgxday. Azacitidine IV or SC 75 mg/m² D1-7. Decitabine IV 20 mg/m² on D1-5 or 1-10.~Intensive:~High DAC: cytarabine 1-2 g/m² up to 5 days, max total dose 10 g/m²~FLAG: D1-5: fludarabine 30 mg/m² IV for 30min, D1-5: cytarabine 1-2 g/m² for 4hr daily x 5 & G-CSF 5 mcg/kg or 300 mcg/m² until PMN recovery, with or without idarubicin D1-3 8 mg/m² IV dailyx3 (FLAG-Ida)~MEC: D1-6: mitoxantrone 6 mg/m² IV bolus, etoposide 80 mg/m² IV 1hr & cytarabine 1g/m² IV 6hr.~CLAG/M or Ida = cladribine 5 mg/m² D1-5, cytarabine 2 g/m² D1-5, G-CSF 300 μg D0-5, mitoxantrone 10 mg/m² D1-3 or Idarubicin 10 mg/m² D1-3.~Intermediate DAC: cytarabine 20 mg/m² IV dailyx5"
88839860|NCT02566135|Active Comparator|Group-I|Tracheal intubation using I-gel and ventilating bougie insertion. In Group-I, following general anaesthesia I-gel is to be inserted, through it ventilating bougie is to be inserted then I-gel is to be removed and endotracheal tube is to be railroaded over ventilating bougie. Then ventilating bougie is to be removed.
88839861|NCT02566135|Active Comparator|Group-C|Tracheal intubation using C-LMA and ventilating bougie insertion. In Group-C, following general anaesthesia C-LMA is to be inserted, through it ventilating bougie is to be inserted then C-LMA is to be removed and endotracheal tube is to be railroaded over ventilating bougie. Then ventilating bougie is to be removed.
88839862|NCT03565640|Active Comparator|Capio Slim Device|Participants will be randomized to the sacrospinous ligament fixation with use of Capio Slim Device
88839863|NCT03565640|Experimental|Anchorsure Device|Participants will be randomized to the sacrospinous ligament fixation with use of Anchorsure Device
88839864|NCT05588024||Head Up CPR based bundle of care|All patients in the registry receive the Head Up CPR based bundle of care.
88839865|NCT04744597|Experimental|Real execution group|The real execution group will perform the acute intervention by the actual performance of the Fitt's law task.
88839866|NCT04744597|Experimental|Motor imagery group|The motor imagery group will perform the acute intervention by simulating (mental process) the Fitt's law task.
88839867|NCT04744597|Active Comparator|Control group|The control group will perform skip counting.
88839868|NCT03551210|Experimental|Nemonoxacin|"Nemonoxacin solution for infusion, 500 mg (250 ml), daily, as single intravenous infusion over 90-110 minutes followed by infusion of Placebo (100 ml), solution for infusion, over a minimum duration of 60 minutes.~Then will be switched to oral therapy with Nemonoxacin capsules, 500 mg once daily (two 250 mg capsules)."
88839869|NCT03551210|Active Comparator|Tavanic®|"Tavanic® solution for infusion, 500 mg (100 ml), daily, as single intravenous infusion over a minimum duration of 60 minutes with previous infusion of Placebo (250 ml), solution for infusion, over 90-110 minutes.~Then will be switched to oral therapy with Tavanic®, over-encapsulated film coated tablets, 500 mg once daily (two capsules each containing 250 mg film coated tablet)."
89367679|NCT03253432||Strata 0.16-0.19|Moderate probability of having familial hypercholesterolemia
89367680|NCT03253432||Strata 0.20-0.34|Second highest probability of having familial hypercholesterolemia
89367681|NCT03253432||Strata greater than or equal to 35|Highest probability of having familial hypercholesterolemia
89534715|NCT03093987|Experimental|critical care ultrasound|Circulation management will be adjusted according to the results of critical ultrasound combined with clearance of lactic acid in patients with shock.
88839870|NCT02482675|Active Comparator|Glucose|This study day will last approximately three hours and will be separated from the other arms by four days for men and one month for women.
88839871|NCT02482675|Experimental|Glucose with Non-fat Milk|This study day will last approximately three hours and will be separated from the other arms by four days for men and one month for women.
88839872|NCT02482675|Experimental|Glucose with Whey Protein Isolate|This study day will last approximately three hours and will be separated from the other arms by four days for men and one month for women.
88839873|NCT02482675|Experimental|Glucose with Sodium Caseinate|This study day will last approximately three hours and will be separated from the other arms by four days for men and one month for women.
88839874|NCT04339088||HIFU|Patients that have undergone high focused ultrasound treatment for varicose veins
88839875|NCT03466424||Group 1|preoperative short-course radiotherapy(5×6Gy) followed by 4×mFOLFOX6 chemotherapy
88839876|NCT03466424||Group 2|preoperative short-course radiotherapy(5×7Gy) followed by 4×mFOLFOX6 chemotherapy
88839877|NCT03466424||Group 3|preoperative short-course radiotherapy(5×8Gy) followed by 4×mFOLFOX6 chemotherapy
88839878|NCT02566369|Experimental|CD5789 (trifarotene) 50μg/g Cream|CD5789 (trifarotene) 50μg/g Cream
88839879|NCT02566369|Placebo Comparator|Placebo Cream|Placebo cream
88839880|NCT05587790|Experimental|Weight Management Intervention|During a 12-month period, participants will attend a total of 22 diet improvement sessions, each of which will last approximately 45-minutes. Twelve sessions will be held in the first 5 months and will be focused on safe and efficient weight loss. The participants will learn to create a personalized weight loss diet from their kitchen based on their diet practice and food preference. The next 10 sessions will be held in the last 7 months and will be focused on weight maintenance and healthy eating. The participants will build skills to select foods and create meals that prevent them from overeating. Participants will be followed by daily self-weighing for 1 year after intervention.
88839881|NCT02569411|No Intervention|No Incentive|Those allocated to the control group will be contacted by email, mail, and phone, but will not receive a financial incentive
88839882|NCT02569411|Experimental|Incentive|Those allocated to the intervention group will be contacted by email, mail, and phone, and will be asked to provide the IPD from their RCT and they will be given a financial incentive.
88839883|NCT04743427|Experimental|physical therapy inervention|"hot pack~Three active exercises"
88839884|NCT04743427|Experimental|Body-blade exercises in addition to physical therapy intervention|"Three Body-blade exercises will be performed in random order (Two sets of, 3-minute exercise and 5-minute break, for each exercise )~hot pack~Three active exercises"
88839885|NCT02569723|Experimental|carbon C 14 oxaliplatin and oxaliplatin|Patients receive carbon C 14 oxaliplatin microdose IV over 120 minutes. Beginning not more than 4 weeks after the initial carbon C 14 oxaliplatin microdose administration, patients receive FOLFOX6 comprised of leucovorin calcium IV, fluorouracil IV over 2 hours (over 46-48 hours via ambulatory infusion pump on days 1 and 2), and oxaliplatin (contain carbon C 14 microdose course I only) IV over 2 hours on day 1.
88839886|NCT02570425|Placebo Comparator|Spiromax followed by Turbohaler|Training on BF Spiromax followed by SYMBICORT Turbohaler
88839887|NCT02570425|Placebo Comparator|Turbohaler followed by Spiromax|Training on SYMBICORT Turbohaler followed by BF Spiromax
88839888|NCT02571439|Experimental|Surgical TAP block|surgeon administered intraoperative TAP block using 0.5% ropivacaine
88839889|NCT02571439|Active Comparator|Conventional TAP block|Conventional, Anesthesiologist administered post-operative TAP block using 0.5% ropivacaine
88839890|NCT02573857|Experimental|DSM265 P. falciparum|Cohort 1: the efficacy of a single administration of 400 mg DSM265 for the clearance of asexual blood stages of P. falciparum will be determined. Activity of a second single dose of 400 mg DSM265 against gametocytes will be assessed in this cohort only if sexual stages are identified by PCR following the initial drug treatment.
88839891|NCT02573857|Experimental|OZ439 P. vivax|Cohort 2: subjects will be infected with P. vivax by IBSM, then treated with a single 200 mg dose OZ439. If recrudescence occurs following initial drug treatment with 200 mg OZ439, then affected participants who reach the treatment threshold will receive a single 400 mg dose of OZ439.
88839892|NCT02573857|Experimental|DSM265 P. vivax|Cohort 3: subjects will be infected with P. vivax by IBSM, then treated with a single 400 mg dose of DSM265
88839893|NCT02576041|Experimental|Placebo (run-in); Bilastine|At V0, the enrolled patient received the complete drug-kit and started a 7 (+3)-day wash-out period with placebo. At the end of the 7 (+3)-days of placebo-treatment period, patients repeated the F1-high speed simulator test at Visit V1, and afterwards initiated the 7 (+3)-day treatment period with active treatment (bilastine).
88839894|NCT02576899|Active Comparator|Stage 1b Study of ACT-PT vs. FFS|This study involves a randomized clinical trial study of Veteran smokers with PTSD and tobacco dependence randomized to one of two different types of psychosocial treatment: ACT-PT versus the American Lung Association's Freedom From Smoking Program [FFS]. This study has two primary aims: 1) Evaluate the relative feasibility and acceptability of the two interventions (including ease of recruitment, randomization proportion, staff and Veteran acceptance of the treatment, retention rates, treatment adherence, fidelity, ease of the assessment process), and 2) Evaluate the preliminary efficacy of ACT-PT vs. FFS with the primary outcomes of tobacco use, PTSD symptoms, health-related quality of life, and functional impairment.
89179174|NCT04093401|Experimental|Individualized risk assessment|Subjects will be assigned to the intervention arm (i.e., informed of their individualized risk assessment) if their subject ID is an even number. Subjects in the intervention arm will be informed of their estimated 1-year, 3-year, and 5-year risk of developing a second basal cell carcinoma.
89534716|NCT03328481|Experimental|Loss-of-resistance|Patients in this group will receive Loss-of-resistance Quadratus lumborum block with 30 ml bupivacaine 0.25% in addition to general anesthesia.
89534717|NCT03328481|Active Comparator|Ultrasound-guided|Patients in this group will receive Ultrasound-guided Quadratus lumborum block type-II with 30 ml bupivacaine 0.25% in addition to general anesthesia.
89534718|NCT02452801|Experimental|ALKS 5461|Sublingual tablet
89534719|NCT03094065|Active Comparator|News with Spin|News items reporting results of pre-clinical studies with spin.
89367682|NCT04466592|Experimental|Supportive intervention|A research psychologist will support participants, promoting their competences in the recover of work and social activities, such as the compliance.
88839895|NCT02576899|Placebo Comparator|Freedom From Smoking|The American Lung Association's Freedom from Smoking program (FFS) is a commonly used smoking cessation intervention that is used in community treatment programs.
88839896|NCT03678428|Experimental|FUDR/Oxaliplatin HAI plus irinotecan|"Patients will receive Systemic CPT-11 + HAI (FUDR+L-OHP) every 28 days:~Irinotecan 150 mg/m2 IV over 90 minutes on Day 1; followed by Oxaliplatin 85 mg/m2 over 3 hours through the HAI pump on Day 1 and 0.12 mg/kg/day floxuridine (FUDR) and 25 mg dexamethasone in normal saline to a total volume of 300 ml will be administered through the HAI pump.~then Irinotecan 150 mg/m2 IV over 90 minutes on Day 15, followed by Oxaliplatin 85 mg/m2 IV over 3 hours on Day 15.~This will be repeated on Day 1 of each 28-day cycle. FUDR will be administered through a 14-day continuous infusion with the HAI pump."
89367683|NCT03233620|Other|working age patients|Prospective cohort of 250 patients.
88839897|NCT03678428|Active Comparator|FOLFOXIRI|"Patients will receive Systemic FOLFOXIRI every 28 days:~Irinotecan 150 mg/m2 IV over 90 minutes on Day 1 and Day 15; Oxaliplatin 85 mg/m2 IV in 3-6 hours on Day 1 and Day 15; Leucovorin 200mg/m2 and 5-FU 2400mg/m2 CIV in 46 hours on Day 1 and Day 15."
88839898|NCT02577445||CSA patients without remedē system|For all patients diagnosed with CSA who will not move forward with remedē® system therapy, the intention is to obtain information on their alternate therapy, if any, and safety information, including all cause mortality and all cause hospitalizations during phone calls at 6, 12 and 24 months after enrollment.
88839899|NCT02577445||CSA patients with remedē system|"For all patients diagnosed with CSA and referred for implant / or have already been implanted with remedē system, information from the implant procedure will be collected.~Patients will be asked to complete quality of life questionnaires at baseline and during follow-up visits.~Patients will be evaluated at the time of therapy activation which may be followed by one or more titration visits. Patient follow-ups will be programmed at 6 and 12 months, and yearly, up to 5 years post-implant, until the last patients reach their 2-year follow-up.~Echocardiogram for patients with reduced ejection fraction (≤ 45%) and follow-up respiratory polygraphy are considered standard of care, however, to ensure sufficient data, related to the study objectives, are being collected, baseline and 12-months echocardiogram for a subgroup of patients and respiratory polygraphy at 12-month follow-up for all patients must be done when participating in this study:"
88839900|NCT02577601|Active Comparator|UPA Only|During the first treatment month, 1 dose of the study medication ulipristal acetate (UPA) will be given when the follicle is a certain size (approximately cycle day 10). Following this, there will be daily study visits for 7 days unless evidence of ovulation occurs earlier.
88839901|NCT02577601|No Intervention|Washout Cycle|The month following this first treatment month (washout-cycle),there will be no study visits during this menstrual cycle but there will be contact with study staff (1 or 2 times) by telephone or email to discuss any health changes that are experiencing.
89367684|NCT04445220|Experimental|Low dose cohort|SBI-101 device containing 250 million MSCs
89367685|NCT04445220|Experimental|High dose cohort|SBI-101 device containing 750 million MSCs
89367686|NCT04445220|No Intervention|Case controls|Case control subjects will receive only standard-of-care treatment and will be followed for the same safety assessments as active study participants.
89367687|NCT03253276|Active Comparator|Obeticholic Acid|Patients with primary biliary cirrhosis are treated 3 months with OCA (active drug) or placebo in a double-blind cross-over study design.
89367688|NCT03253276|Placebo Comparator|placebos|Patients with primary biliary cirrhosis are treated 3 months with OCA (active drug) or placebo in a double-blind cross-over study design.
89367689|NCT01372644|Experimental|ADH, ALH, LCIS, SOM 230|Women who meet eligibility criteria.
89367690|NCT01371084|Experimental|Physical activity treatment group|Participants randomized to the intervention group will be provided access to a portable pedal exercise machine, a pedometer and a worksite wellness motivational website for 12 weeks. As part of this website, participants will be emailed behavioral intervention materials a maximum of three times per week targeted at reducing sedentary time.
89367691|NCT01371084|Placebo Comparator|Wait List Control|
89367692|NCT03233386||Condition 1|Mexico City Cohort
89367693|NCT03233386||Condition 2|Monterrey Cohort
89367694|NCT03233386||Condition 3|Guadalajara Cohort
89367695|NCT03253198|Active Comparator|Preoperative block plus saline|Preoperative interscalene brachial plexus single-shot block using 25ml of 0.5% Ropivicaine plus postoperative 40cc local infiltration of saline
89367696|NCT03253198|Active Comparator|Preoperative block plus Bupivacaine extended-release liposome|Interscalene brachial plexus single shot block preoperatively (25 ml of 0.5% ropivicaine) + Postoperative Infiltration of local anesthetic/analgesic (20 cc Bupivacaine extended-release liposome injection (Exparel) + Diluted in 20cc of Saline into the capsule, subscapularis, deltoid, pectoralis major and subcutaneous tissues)
89367697|NCT03253042|Experimental|WBV exercise program|8-week exercise program associated with the vibratory platform. Each exercise session will consist of 4 series of an isometric half-squat exercise with 1 minute and a half of duration and a rest interval of 1 minute. The vibratory platform will be connected at the beginning of each series, set at a vibration frequency of 40 Hertz (Hz) and peak-to-peak amplitude of 4 millimeters (mm) resulting in a peak acceleration of 128 ms2 (12.8 g). This should provide the equivalent of 3600 vertical vibrations, totaling 14400 vibrations per training session.
89367698|NCT03253042|Sham Comparator|Sham WBV exercise program|8-week exercise program in which each session will consist of 4 series of an isometric half-squat exercise with 1 minute and a half of duration and a rest interval of 1 minute. The vibratory platform will remain off at all sessions. A device will be attached to the side of the platform in order to produce a sound, similar to the sound produced by the vibrating platform when it is in operation.
89367699|NCT03252730|Experimental|WO 4260 Cosmetic Product for Topical Use|WO 4260 is used to treat dry and itchy scalp
89367700|NCT03252886|Active Comparator|DL user|Experienced emergency physicians who primarily use the direct laryngoscopy (DL) for endotracheal intubation during cardio-pulmonary resuscitation.
89189254|NCT00128778|Experimental|Arm A: PLD|Pegylated liposomal doxorubicin (PLD) after induction chemotherapy in patients with metastatic breast cancer (MBC). Patients without disease progression following first-line induction chemotherapy consisting of three cycles of doxorubicin (75 mg/m2) followed by three cycles of docetaxel (100 mg/m2) both every 21 days, were randomized to PLD (40 mg/m2) every 28 days for six cycles or to observation.
89367701|NCT03252886|Active Comparator|VL user|Experienced emergency physicians who primarily use the videolaryngoscopy (VL) for endotracheal intubation during cardio-pulmonary resuscitation.
89367702|NCT03117738|Experimental|AstroStem|
88839902|NCT02577601|Active Comparator|UPA + COC|During the second treatment month, 1 dose of the study medication ulipristal acetate (UPA) will be given when the follicle is a certain size (approximately cycle day 10) and then 2 days later start birth control pills. Following this, there will be daily study visits for 7 days unless evidence of ovulation occurs earlier.
88839903|NCT02577991|No Intervention|Control group|No steroid
88839904|NCT02577991|Experimental|IV steroid|10 mg of intraoperative intravenous decadron with gel foam sponge placed on cervical plate
89367703|NCT03117738|Placebo Comparator|Placebo-Control|
89367704|NCT03229330|Experimental|Intervention|Low-level Light Therapy: Wavelength of 660 nm (red laser) and Conventional treatment: Topical treatment with compressive therapy, exercises of lower extremities, resting; once a week for 16 weeks.
89367705|NCT03229330|Active Comparator|Controls|Conventional treatment: Topical treatment with compressive therapy, exercises of lower extremities, resting; once a week for 16 weeks.
89367706|NCT04292106|Placebo Comparator|Placebo|
89367707|NCT04292106|Experimental|Red Spinach Extract (RSE)|
89367708|NCT03236272||case group|patients with ARDS
89367709|NCT03236272||control group|patients Without ARDS
89367710|NCT03235882||observational group|"Infants born 24-32 weeks.~Inclusion criteria:~Have gastric aspirate and oral secretions obtained within 45 minutes from birth via:~a naso- or orogastric tube inserted in the delivery room if clinically indicated as part of resuscitation or~a nasogastric tube inserted as part of routine management of preterm infants.~Written informed consent has been obtained"
89367711|NCT03236116|Experimental|Almond Group|Participants will consumed almonds every day for 6 months, but will not be allowed to consume any other nuts or nut products.
89367712|NCT03236116|Experimental|Control Group|Participants will continue with their normal eating routine for 6 months, but will not be allowed to consume any nuts or nut products.
89367713|NCT04485988||No-beta blocker|
89367714|NCT04485988||beta blocker|
89367715|NCT04163484||Stable coronary artery disease|
89367716|NCT04163484||ST-elevation myocardial infarction|
89367717|NCT04163484||Non-ST-elevation myocardial infarction|
89367718|NCT04234464|Experimental|A/B - Treatment with BDA MDI 160/180 followed by treatment with Placebo MDI|Subjects randomized to receive a single dose of BDA MDI 160/180 in treatment period 1, and a single dose of Placebo MDI in treatment period 2.
89367719|NCT04234464|Experimental|B/A - Treatment with Placebo MDI followed by treatment with BDA MDI 160/180|Subjects randomized to receive a single dose of Placebo MDI in treatment period 1, and a single dose of BDA MDI 160/180 in treatment period 2.
89367720|NCT04485910|Active Comparator|Single step media|Embryos cultured in single step media
88839905|NCT02577991|Experimental|Local steroid|40 mg of triamcinolone on gel foam sponge dabbed on the anterior cervical plate
89367721|NCT04485910|Active Comparator|Sequential media|Embryos cultured in sequential media
89534720|NCT03094065|Experimental|News without spin|News items reporting results of pre-clinical studies without spin.
89367722|NCT03235570|Experimental|Pemigatinib|Part 1 is an open-label dose-escalation design based on observing each dose level for a period of 21 days. Part 2 will evaluate the recommended dose determined in Part 1.
89367723|NCT01371162|Experimental|A1 Healthy Volunteers|
88839906|NCT05024227|Experimental|Experimental: nursing education interventions|nursing education interventions (including e-health platform assistance)
88839907|NCT05024227|No Intervention|No Intervention: Routine care|Only the original form of nursing education leaflets are given
88839908|NCT04956133|Experimental|Physical activity|Participants will be offered online, individualized physical activity sessions 2-3 times/week for 15-45 minutes/session for 8-12 weeks.
88839909|NCT04847167|Experimental|Single balloon enteroscopy assisted ERCP using a mechanistic loop resolution strategy group|All ERCP was performed with the patient in the prone position using a SBE (SIF-H290S; Olympus Corp., Japan) under CO2 insufflation and conscious sedation. A soft transparent hood (D-201-11804; Olympus Corp., Japan) was used in all cases. The SBE was introduced alternately with an overtube apparatus (ST-SB1S; Olympus Corp., Japan) following the mechanistic loop resolution strategy under endoscopic and fluoroscopic guidance. The overtube was advanced along the enteroscope, by gently pulling the enteroscope, like as ERCP accessory advancement over the guidewire.
88839910|NCT02207634|Placebo Comparator|Placebo|Participants received placebo subcutaneous injections either once every 2 weeks (Q2W) or once a month (QM) according to their own preference. Participants continued with their background statin therapy during the course of the study.
88839911|NCT02207634|Experimental|Evolocumab|Participants received evolocumab 140 mg Q2W or 420 mg QM subcutaneous injections according to their own preference. Participants continued with their background statin therapy during the course of the study.
88839912|NCT04712383|Experimental|Fitbit Care intervention arm|The experimental arm will receive the full Fitbit Care product suite (Fitbit wrist-worn device, Fitbit connected weight scale, and Fitbit Premium + Health Coaching service). Participants in the experimental arm will also be offered support in improving health behaviors that are important to them, including activity, nutrition, sleep, stress management, and medication adherence.
88839913|NCT04712383|No Intervention|Fitbit study control arm|Participants in the control arm will have access to standard healthcare benefits available to all employees, but will not have access to any of the Fitbit Care interventions
88839914|NCT02485561|Active Comparator|Information only|INTERVENTION: Information about colon cancer and screening tests from sources such as the Centers for Disease Control and Prevention Screen for Life campaign.
88839915|NCT02485561|Experimental|Screener Narrative|INTERVENTION: Information + Personal Narrative from someone who was screened for colon cancer
88839916|NCT02485561|Experimental|Survivor Narrative|INTERVENTION: Information + Personal Narrative from someone who was screened for, and diagnosed with, colon cancer
88839917|NCT02486263|Experimental|Study|Treated with omeprazole. This group of subjects will have prescribed restricted feeding volumes, monitored feeding duration time and positioning restrictions
88839918|NCT02486263|Other|Conventional|Treated with omeprazole. This group of subjects will receive the current standard treatment for Gastro-esophageal reflux disease (GERD) which includes use of acid suppressive medication with no restrictions of the feeding volume, duration or positioning.
88839919|NCT00422149|Active Comparator|1|SUBLIVAC® Grasses treatment
88839920|NCT00422149|Placebo Comparator|2|Placebo treatment
89534721|NCT02491619|Experimental|Orthodontic decompensation|Orthodontic decompensation in patients with class III dentofacial deformities
89534722|NCT02452879|Experimental|Electroacupuncture group|Needle on bilateral BL33 acupoint 50-60mm with a 60°angle. A feeling of soreness and distension will be felt when needling into the 3rd posterior sacral foramina(S3). Needle with 75mm long needle. An electric stimulator is put on. SDZ-V electric stimulator (produced by Suzhou Medical Instrument Co.Ltd). continuous wave(CW), 10Hz. Stop turning up the current intensity when patients could not stand. 3 times a week. Once every other day. The treatment period lasts eight weeks. totally 24 times.30min/time.
88839921|NCT03452228|Experimental|evinacumab|
88839922|NCT03452228|Experimental|Placebo|
88839923|NCT04341727|Active Comparator|Hydroxychloroquine alone|Arm 1: Hydroxychloroquine 400mg orally twice a day for one day, followed by 200mg twice a day for four consecutive days (Five days in total). The drug will be supplied in 200mg tablets.
88839924|NCT04341727|Active Comparator|Hydroxychloroquine plus azithromycin|"Arm 2: Hydroxychloroquine 400mg orally twice a day for one day, followed by 200mg twice a day for four consecutive days (Five days in total). The drug will be supplied in 200mg tablets.~AND Azithromycin 500mg orally once, followed by 250mg daily for four consecutive days (five days total). The drug will be supplied in 250mg tablets."
88839925|NCT04341727|Active Comparator|Chloroquine alone|Arm 3: Chloroquine phosphate 1000mg orally once, followed in 12 hours by 500mg, then 500mg orally twice daily for 4 days (Five days in total). The drug will be supplied in 500mg tablets.
88839926|NCT04341727|Active Comparator|Chloroquine plus azithromycin|"Arm 4: Chloroquine phosphate 1000mg orally once, followed in 12 hours by 500mg, then 500mg orally twice daily for 4 days (Five days in total). The drug will be supplied in 500mg tablets.~AND Azithromycin 500mg orally once, followed by 250mg daily for 4 consecutive days (5 days total).The drug will be supplied in 250mg tablets."
89367724|NCT01371162|Placebo Comparator|A2|
89367725|NCT01371162|Experimental|B1 HCV Infection|
88839927|NCT04320901|Experimental|Harmonic|Endoscopic procedure will be done by Harmonic ACE7+
89367726|NCT01371162|Placebo Comparator|B2|
89367727|NCT04485832|Active Comparator|Intervention|
89367728|NCT04485832|Active Comparator|Control|
89367729|NCT03235648|Experimental|cardiophrenic nodes excision in ovarian cancer|We are going to evaluate the comorbidites and impact of cardiophrenic lymph nodes excision in cases of advanced ovarian cancer with positive cardiophrenic lymph nodes
89367730|NCT03229096|Experimental|Apatinib plus XELOX|Patients will be given the perioperative chemotherapy of Apatinib plus XELOX once recruited
89367731|NCT03232996|Experimental|Experimental Group|Computer Game based balance and walk rehabilitation
89367732|NCT03123588|Experimental|Group A : Ruxolitinib and anagrelide placebo|Ruxolitinib or placebo will be administered orally twice a day at a starting dose of 10 mg.
88839928|NCT04320901|Experimental|Ligasure|Endoscopic procedure will be done by Ligasure
88839929|NCT04272385||Focus Group|Qualitative research done with a group of patients with TN. Patients will describe their experience of living with the disease and what outcomes of treatment they consider to be important.
88839930|NCT04272385||Delphi survey|Group of relevant stakeholders - patients, clinicians and researchers will rate the outcomes of treatment in a 3 round Delphi survey.
88839931|NCT04272385||Consensus meeting|Group of relevant stakeholders - patients, clinicians and researchers will rate the outcomes of treatment and finalise the COS for Trigeminal Neuralgia.
88839932|NCT04247737|Experimental|gluten free diet|six week gluten free diet
88839933|NCT04244227|Experimental|Active treatment|Participants will self-administer treatment with the Empower device at the active treatment anatomic location once daily for three weeks. Participants will complete daily and weekly surveys to evaluate the effects of the Empower active treatment.
88839934|NCT04244227|Sham Comparator|Sham treatment|Participants will self-administer treatment with the Empower device at the sham treatment anatomic location once daily for three weeks. Participants will complete daily and weekly surveys to evaluate the effects of the Empower sham treatment.
88839935|NCT02580799||Breast Cancer Pathology Samples|Breast cancer pathology samples were evaluated for a period of 70 days.
88839936|NCT04340102|Experimental|BecomeAnEx|Participants will have three individual meetings with a research staff person while they are in the hospital. At these meetings participants will answer questions about their smoking and interest in quitting, learn about BecomeAnEx, and register with the BecomeAnEx program so that they can use it when you leave the hospital. Participants will be given two weeks of nicotine replacement therapy when they leave the hospital. Participants will be asked to use BecomeAnEx as much as they want when they leave the hospital program.
88839937|NCT02581111|Experimental|Naloxone|Naloxone 8-mg IV given once after baseline ABG
88839938|NCT02581111|Sham Comparator|Placebo|Equivalent volume of saline given once
88839939|NCT05587400|Experimental|patients with pulmonary artery hypertension and/or right ventricular dysfunction|
88839940|NCT04339868|Active Comparator|Terlipressin group|Terlipressin acetate 1 mg in 0.9% normal saline (NaCl) 50 mL (0.02 mg/mL) Initial dose 20 mcg/hr (1 mL/hr) titrate increase 1 mL/hr every 30 min to 100 mcg/hr (5 mg/hr) to keep mean arterial blood pressure (MAP) > 65 mmHg If MAP > 75 mmHg for > 30 min, decrease epinephrine and norepinephrine until < 0.15 mcg/kg/min, then decrease terlipressin until stop
88839941|NCT04339868|Placebo Comparator|Placebo group|Placebo 0.9% NaCl 50 mL Initial dose 1 mL/hr titrate increase 1 mL/hr every 30 min to 5 mg/hr to keep mean arterial blood pressure (MAP) > 65 mmHg If MAP > 75 mmHg for > 30 min, decrease epinephrine and norepinephrine until < 0.15 mcg/kg/min, then decrease placebo until stop
88839942|NCT05585216|Experimental|PRP combined with leg swing and quadriceps strengthening exercise|Group A received twice intra-articular injection of platelet-rich plasma (2 ml, 2 weeks apart) and regular leg swing and quadriceps strengthening exercise for three months.
88839943|NCT05585216|Active Comparator|intra-articular combination injections of PRP and HA|Group B received twice intra-articular combination injections of PRP (2 ml) and HA (2 ml) every 2 weeks.
88839944|NCT03334526|Experimental|healthy volunteers|
88839945|NCT02489227|Active Comparator|Humira (adalimumab)|Adalimumab (Humira) 40mg 2 doses at week 0/Day 0, then 1 dose every 2 weeks starting at Week 1 until Week 15. At Week 16 subjects initially randomized to adalimumab will be assigned (1:1) to CHS-1420 or continue adalimumab treatment, 1 dose every 2 weeks for weeks 17-23. The assignments for treatment sequences (Treatment Period 1 and Treatment Period 2) were made randomly at the beginning of Treatment Period 1. At week 24 subjects will switch to CHS-1420 open label until study end.
89367733|NCT03123588|Active Comparator|Group B : Anagrelide and Ruxolitinib PLacebo|Anagrelide or placebo will be administered orally twice a day at a starting dose of 1 mg. Use of anagrelide will be consistent with approved prescribing information.
89367734|NCT04114812|Experimental|Blended learning|Participants in the blended learning group will be taught abdominal ultrasound by an e-learning platform and practical near-peer tutoring classes over 16 weeks, summing up to 5 hours of e-learning and 16 hours of near-peer tutoring classes.
89367735|NCT04114812|Active Comparator|Standard course|Participants in the standard course or control group will participate in a 2.5-day course in abdominal ultrasound, comprising 5 hours of lectures and 16 hours of ultrasound training.
89367736|NCT03232762|Active Comparator|Diet A|high proportion of calories from refined grains as a carbohydrate source
89367737|NCT03232762|Active Comparator|Diet B|a high proportion of calories from whole grains
88839946|NCT02489227|Experimental|CHS-1420|CHS-1420 40mg 2 doses at Week 0/Day 0 then 1 dose every 2 weeks starting at Week 1 for 23 weeks. At Week 24 subjects will continue on to CHS-1420 open label until study end.
88839947|NCT02490631|No Intervention|Control Arm|Standard of care pre-operative cleansing with soap and water the night before and morning of surgery
88839948|NCT02490631|Experimental|Intervention Arm|2% chlorhexidine gluconate cloths the night before and morning of surgery
88839949|NCT02207556|Experimental|Doxycycline|Doxycycline will be administered at dose of 100mg orally twice daily for 1 year.
88839950|NCT02494297||Cyproterone Acetate and Ethinyl Estradiol|Users of Diane 35 (EE/CPA, BAY86-5264)
88839951|NCT03732638|Experimental|DBT Rimegepant/OL Rimegepant|"DBT Phase (Weeks 1 through 12): Participants received a single oral dose of rimegepant 75 mg tablet every other day (EOD) for 12 weeks.~OLE Phase (Weeks 13 through 64): Participants who continued to meet study entry criteria and had acceptable laboratory test results per protocol, entered the OLE phase and received a single oral dose of rimegepant 75 mg tablet EOD for 52 weeks. If participants had a migraine on a day that they were not scheduled to dose with rimegepant, they could take one tablet of rimegepant 75 mg on that calendar day to treat a migraine (as needed [PRN] dosing).~After completing the OLE phase, participants had follow-up safety visits 2 and 8 weeks after the End-of-Treatment (EOT) visit. Participants who did not complete the DBT phase and/or did not enter or complete the OLE phase were to complete the EOT visit, the 2-week follow-up safety visit, and the 8-week follow-up safety visit after their early discontinuation."
89367738|NCT01370850||Normal|Normal results from the clinical exam and free of ocular pathology.
89367739|NCT01370850||Glaucoma|Clinical exam results consistent with glaucoma; visual field defects consistent with glaucoma and/or structural damage consistent with glaucoma.
89367740|NCT01370850||Retina|Clinical exam results consistent with retina pathology.
89367741|NCT01372722|Experimental|Sham then Stimulation|
89367742|NCT01372722|Experimental|Stimulation then Sham|
89367743|NCT02821026|Experimental|Omental islet transplant|At the time a suitable islet preparation becomes available, the patient will receive allogeneic islet cells placed in an omental pouch. Islet transplant will be performed under Anti-Thymocyte Globulin induction immunosuppression (5 doses, day -2 prior to transplant to day 2 post-transplant). Maintenance mycophenolate mofetil therapy (1-2 g/day as BID dosing) will be started on Day -1 pre-transplant. Tacrolimus will be administered orally twice daily on Day 1 post-transplant to maintain a trough level of 10-12 ng/mL for 3 months, then 6-10 ng/mL thereafter. Etanercept will be given IV before the islet transplant (50 mg), and then at 25 mg (subcutaneously) on POD +3, +7 and +10. Sirolimus will be used in case of tacrolimus or/and mycophenolate mofetil intolerance.
89367744|NCT03107494|Experimental|Treatment with GATS|Gala Airway Treatment System (GATS) / RheOx
89367745|NCT03123354|Experimental|Test group|All subjects are enrolled in the test group and receive an O3 regional oximeter sensor during their scheduled, general cardiac catheterization procedure.
89367746|NCT03232606||Asthmatic children|Asthmatic children aged 6 to 17 year old coming to follow-up at asthma clinic
89367747|NCT03235102||People with Obesity|People with obesity, or weight loss patients. Potential respondents will be recruited from various Internet patient panels to participate in a cross-sectional, online survey.
89367748|NCT03235102||Healthcare Providers|PCPs will include family practitioners; general practitioners; internal medicine; nurse practitioners; and dietitians. Specialists will include endocrinologists and bariatric surgeons, and any of the above if they focus on obesity treatment. Potential respondents will be recruited from various Internet patient panels to participate in a cross-sectional, online survey.
89367749|NCT03235102||Employers|Employers in Canada. Potential respondents will be recruited from various Internet patient panels to participate in a cross-sectional, online survey.
89367750|NCT02452996|Active Comparator|6 mg/kg GNbAC1|7 subjects randomized 5:2 active treatment:placebo
89367751|NCT02452996|Active Comparator|18 mg/kg GNbAC1|7 subjects randomized 5:2 active treatment:placebo
89367752|NCT02452996|Active Comparator|36 mg/kg GNbAC1|7 subjects randomized 5:2 active treatment:placebo
89367753|NCT04421027|Experimental|Baricitinib + Standard of Care (SOC)|4 milligrams (mg) of baricitinib (given as two 2 mg tablets) administered orally every day (QD) with standard of care.
89367754|NCT04421027|Placebo Comparator|Placebo + SOC|Placebo (given as two placebo tablets) administered orally QD with standard of care.
88839952|NCT03732638|Placebo Comparator|DBT Placebo/OL Rimegepant|"DBT Phase (Weeks 1 through 12): Participants received a single oral dose of placebo matching to rimegepant tablet EOD for 12 weeks.~OLE Phase (Weeks 13 through 64): Participants who continued to meet study entry criteria and had acceptable laboratory test results per protocol, entered the OLE phase and received a single oral dose of rimegepant 75 mg tablet EOD for 52 weeks. If participants had a migraine on a day that they were not scheduled to dose with rimegepant, they could take one tablet of rimegepant 75 mg on that calendar day to treat a migraine (PRN dosing).~After completing the OLE phase, participants had follow-up safety visits 2 and 8 weeks after the End-of-Treatment (EOT) visit. Participants who did not complete the DBT phase and/or did not enter or complete the OLE phase were to complete the EOT visit, the 2-week follow-up safety visit, and the 8-week follow-up safety visit after their early discontinuation."
89367755|NCT03228628|Experimental|Nitrous oxide|will inhale experimental treatment (50% N2O - 50% O2)
89367756|NCT03228628|Placebo Comparator|Placebo|will inhale medical air (22% O2 - 78% N2)
88839953|NCT02572609|Experimental|Mucosolvan ® adult syrup|
88839954|NCT02572609|Experimental|Ambroxol hydrochloride soft pastille|
88839955|NCT02585245||NRS2002 Nutrition Risk Screen|Patients identified at HIgh, medium or Low Risk in Hospitalized patients. Determining accuracy of identifiying patients affected by malnutrition.
88839956|NCT02585245||ThedaCare RD/RN Nutrition Risk Screen|Patients identified at HIgh, medium or Low Risk in Hospitalized patients. Determining accuracy of identifiying patients affected by malnutrition.
88839957|NCT02587117|Experimental|lycopene group|Lycopene- 4 mg capsule by mouth single dose per day for 2 months
88839958|NCT02587117|Active Comparator|Prednisolone group|Prednisolone- 40 mg capsule by mouth single dose per day for 2 months
88839959|NCT03266588|Experimental|Rimegepant|
89367757|NCT03228550|Experimental|Efamol Active 50+ and exercise|Efamol Active 50+ Multinutrient supplement and aerobic exercise
89367758|NCT03228550|Experimental|Efamol Active 50+ and non-exercise|Efamol Active 50+ Multinutrient supplement and non-aerobic exercise
89367759|NCT03228550|Experimental|Placebo and exercise|Placebo supplement and aerobic exercise
89367760|NCT03228550|Experimental|Placebo and non-exercise|Placebo supplement and non- exercise
89367761|NCT03228706|Experimental|Intervention Group|All the participants who are randomly assigned to the intervention group will be undergoing the Know Your Medicine-Take it for Health (KYM-TIFH) program, which is a one-off structured group-based intervention (SGBI).
89367762|NCT03228706|No Intervention|Control Group|All the participants who are randomly assigned to the control group will not be given any information related to KYM-TIFH. However, they will be assigned to the venue for the control group and will be asked to fill in questionnaires with the assistance of four facilitators. A briefing on how to answer the questionnaire will be given by the main facilitator and all facilitators are allowed to answer any questions raised by respondents related to the questionnaire. However, they are not allowed to answer on behalf of the respondents. After the completion of the questionnaire, they will be informed about the subsequent follow-up measurement after three, six and twelve months. After that, they will be dismissed and having usual care provided by the health clinic as before without any changes.
89367763|NCT04419311|Experimental|Ultra-congruent insert group|Ultra-congruent inserts were used during total knee arthroplasty in patients randomized to this group.
89367764|NCT04419311|Experimental|Posterior cruciate ligament-stabilized insert|Posterior cruciate ligament-stabilized inserts were used during total knee arthroplasty in patients randomized to this group.
89367765|NCT03232528|Experimental|Herb-partitioned moxibustion|Drug: Herbal cake, Device: Moxibustion. Herbal cakes formula: Monkshood 10g, Cinnamon 2g, Salvia miltiorrhiza 3g, Flos Carthami 3g, Radix Aucklandiae 2g. Herbs are smashed into powder. Every 2.5g medicine powder is mixed with 3g millet wine and then pressed into herbal cakes using a specific mold. Each cake should be 23mm in diameter and 5mm in height. Then, ignited moxa cones are placed on top of each herbal cake. Herbal cakes with moxa cones will be positioned at acupuncture points ST25, ST37 and CV6. The entire treatment will be done once a day for 1 moxa cone every acupuncture point, 30 minutes at a time, 3 times a week, for a total of 12 weeks.
89367766|NCT03232528|Sham Comparator|Sham herb-partitioned moxibustion|Drug: Herbal cake, Device: Sham moxibustion. Herbal cakes formula: Monkshood 10g, Cinnamon 2g, Salvia miltiorrhiza 3g, Flos Carthami 3g, Radix Aucklandiae 2g. Herbs are smashed into powder. Every 2.5g medicine powder is mixed with 3g millet wine and then pressed into herbal cakes using a specific mold. Each cake should be 23mm in diameter and 5mm in height. Then, ignited moxa cones are placed on top of each herbal cake. Small cardboard sheets with the same size as the herbal cakes will be wrapped with aluminum foil and placed under each herbal cake. These herbal cakes will be positioned at acupuncture points ST25, ST37 and CV6. The entire treatment will be done once a day for 1 moxa cone every acupuncture point, 30 minutes at a time, 3 times a week, for a total of 12 weeks.
89367767|NCT03232450|Active Comparator|PFO Closure|Subjects randomized to this arm will receive 81 mg enteric coated aspirin, a Cardiovascular Implantable Device (CIED), Gore Cardioform Septal Occluder.
89367768|NCT03232450|Other|Control|Subjects randomized to this arm will receive 81 mg enteric coated aspirin, a Cardiovascular Implantable Device (CIED)
89367769|NCT03228316|Experimental|the study group one|20 patients with superior hypogastric plexus block
89367770|NCT03228316|Experimental|the study group two|20 patients with superior hypogastric plexus block combined to pulsed radiofrequency on sacral nerve roots 2,3 and 4
89367771|NCT04411667|Experimental|Group A (study drug+SOC)|Standard of care plus IVIG (Octagam) 0.5g/kg IVPB actual body weight daily x 3 days, with premedication methylprednisolone 40 mg IV push x 1 30-50 minutes before each IVIG infusion. Initial infusion rate of IVIG (Octagam) will be of 0.6 mL/kg/hour, increasing to a maximum rate of 100ml/hr, if tolerated.
89367772|NCT04411667|No Intervention|Group B (SOC)|Standard of Care
89367773|NCT03223012||Participants not included in the AbbVie care program|Participants receiving adalimumab not included in the AbbVie care patient support program.
89367774|NCT03223012||Participants included in the AbbVie care program|Participants receiving adalimumab included in the AbbVie care patient support program.
89367775|NCT03747731||Resistive Index and Peep Titration|"Enrolled patients will receive a sequential, step-wise increase in PEEP from 0 cmH2O to 12 cmH2O. The inter-lobar arterioles will be sampled at each PEEP increment and the IR will be measured as the average of three values recorded at the upper and lower pole and at the mesorenes in each kidney.~Gas exchanges, HR, systolic, diastolic and mean PA, Pmax, P1 and P2 airway, total resistance and ohmic resistance and static respiratory compliance indexed for body weight (RRSmaxI, RRSminI, CrsI) will be measured at each Peep Level.~The physiologic measurements will be obtained at regular intervals (within 15 minutes at each PEEP level) throughout the PEEP titration period."
88839960|NCT02587351|Active Comparator|Metoprolol succinate|Metoprolol succinate extended release tablets (50 mg) starting dose followed by a dose titration procedure which will result in a final dose of 25mg (1/2 of one tablet daily), 50 mg, or 100 mg (two tablets daily).
88839961|NCT02587351|Placebo Comparator|Placebo|Matched placebo
88839962|NCT05249491||Group 1|Children with black tooth stain
88839963|NCT05249491||Group 2|Children without black tooth stain
89189255|NCT00128778|No Intervention|Arm B: Observation|Patients without disease progression following first-line induction chemotherapy consisting of three cycles of doxorubicin (75 mg/m2) followed by three cycles of docetaxel (100 mg/m2) both every 21 days, were randomized to observation.
89367776|NCT03232372|Experimental|External-Connection non-submerged Imp|We will place implants with external connection and non- submerged to assess the bone loss around
89367777|NCT03232372|Experimental|Internal Connection Submerged implants|We will place implants with internal connection and submerged to assess the bone loss around
89367778|NCT03232372|Experimental|Internal Connection non-Submerged Impl|We will place Internal connection implant and non-Submerged Implants to assess the bone loss around
89367779|NCT03232294||the study group|A total of 96 women with low risk pregnancy coming to the clinic for a routine antenatal examination in 26-28th gestational weeks were included to this study
89367780|NCT03750617|Experimental|pre-endoscopic screening risk assessment|
88839964|NCT05538338|Active Comparator|Intervention Group|an intrauterine infusion of platelet rich plasma (PRP) will be administered to this group
88839965|NCT05538338|Placebo Comparator|Control Group|an intrauterine infusion of normal saline will be administered to this group
88839966|NCT05249413||Endophthalmitis after primary cataract surgery.|Cases diagnosed as acute post-operative endophthalmitis after primary cataract surgery.
88839967|NCT05249335|Experimental|OST|2 days split dosing regimen
88839968|NCT05249335|Active Comparator|2L-PEG/Asc|2 days split dosing regimen
88839969|NCT04034797|Experimental|Photo|
88839970|NCT04034797|Active Comparator|No photo|
88839971|NCT03992209|Other|Standard handwashing by anesthesia provider|Anesthesia provider will conduct patient care per their usual standard practice in the operating room.
88839972|NCT03992209|Active Comparator|Protocolized hand washing by anesthesia provider|Anesthesia provider will conduct patient care using a personal hand washing device to optimize hand washing and captures hand washing events in real time.
88839973|NCT00364273|Experimental|Subjects receiving treatment sequence 1 : Cohort 1|Eligible subjects will receive placebo, GSK159802 300 micrograms, GSK159802 600 micrograms, GSK159802 900 micrograms and GSK159802 1200 micrograms.
89189256|NCT05673252||Cervical cancer patients|The population is represented by women being admitted to the Gynecology Ward who are affected by cervical cancer.
89189257|NCT04901910|Experimental|Physical Activity (PA) Social Media Group|This will be an 8 week Social Media Group available to the participant focused on health and well-being.
89367781|NCT03750617|No Intervention|routine screening|
89367782|NCT03222622|Experimental|Cohort 1|65 patients with mild to moderate psoriasis will be randomized to receive 1% Icotinib hydrochloride cream, applied twice daily for 12 consecutive weeks. The drug will be applied topically to the psoriasis site.
89367783|NCT03222622|Experimental|Cohort 2|65 patients with mild to moderate psoriasis will be randomized to receive 2% Icotinib hydrochloride cream, applied twice daily for 12 consecutive weeks. The drug will be applied topically to the psoriasis site.
89367784|NCT03222622|Experimental|Cohort 3|65 patients with mild to moderate psoriasis will be randomized to receive 4% Icotinib hydrochloride cream, applied twice daily for 12 consecutive weeks. The drug will be applied topically to the psoriasis site.
89367785|NCT03222622|Placebo Comparator|Cohort 4|65 patients with mild to moderate psoriasis will be randomized to receive placebo cream (blank cream containing no icotinib hydrochloride), applied twice daily for 12 consecutive weeks. The drug will be applied topically to the psoriasis site.
89367786|NCT03752021||Laboring Subjects|Subjects with a planned cesarean delivery who labor prior to their scheduled date or those who are in labor and require an unplanned but non-emergent cesarean delivery. These subjects will be approached upon admission to the study facility by the researcher for potential enrollment to allow adequate time to consider participation, ask questions, provide consent, and prior to procedure (Myometrial Sampling).
89367787|NCT03752021||Non Laboring Subjects|Subjects with a planned cesarean delivery will be approached by the researcher during prenatal visits or at the study facilities prior to planned procedure (Myometrial Sampling)
89367788|NCT03751943|Other|NanoFuse® PL Gutter|NanoFUSE® Bioactive Matrix (75%) w/autograft (25%) within one posterolateral gutter (unilateral)
89367789|NCT04358549|Experimental|Favipiravir Treatment Arm|Day 1: favipiravir 1800 mg BID plus Standard of Care (SOC) Days 2-14: 1000 mg BID plus SOC. For subjects with Child-Pugh A liver impairment: Days 2-14: 800 mg BID plus SOC
89367790|NCT04358549|Other|Standard of Care Arm|Standard of Care for 14 days
89367791|NCT01562483|Experimental|delta-9-tetrahydrocannabinol (namisol)|
88839974|NCT00364273|Experimental|Subjects receiving treatment sequence 2 : Cohort 1|Eligible subjects will receive GSK159802 150 micrograms, placebo, GSK159802 600 micrograms, GSK159802 900 micrograms and GSK159802 1200 micrograms.
89367792|NCT01562483|Placebo Comparator|Placebo|
89367793|NCT00700180|Experimental|1|
89367794|NCT00700180|Experimental|2|
89367795|NCT03222778||hypovolemia (fluid responsiveness)|The patients with fluid responsiveness (an increase in stroke volume index of ≥12%) after fluid challenge using 6 ml/kg of balanced 6% hydroxyethyl starch 130/0.4 (Volulyte; Fresenius Kabi, Bad Homburg, Germany)
89367796|NCT03222778||NO hypovolemia (NO fluid responsiveness)|The patients without fluid responsiveness after fluid challenge using 6 ml/kg of balanced 6% hydroxyethyl starch 130/0.4 (Volulyte; Fresenius Kabi, Bad Homburg, Germany)
89367797|NCT03222544|Experimental|Photodynamic Therapy|The photosensitizer, methylene blue, is applied topically to the ulcer surface and the ulcer was shielded from light for 15 min. Then the ulcer area is illuminated using a photon therapy instrument for 20 minutes. Photodynamic therapy is applied once a day for a total of seven times.
89367798|NCT03222544|Active Comparator|Photon therapy|The placebo is applied topically to the ulcer surface and the ulcer was shielded from light for 15 min. Then the ulcer area is illuminated using a photon therapy instrument for 20 minutes. Photon therapy is applied once a day for a total of seven times.
89367799|NCT03228862|Experimental|D40000|Patients are randomly assigned to receive Ergocalciferol 40000 IU once weekly
89367800|NCT03228862|Experimental|D60000|Patients are randomly assigned to receive Ergocalciferol 60000 IU once weekly
89367801|NCT03228862|Experimental|D80000|Patients are randomly assigned to receive Ergocalciferol 80000 IU once weekly
88839975|NCT00364273|Experimental|Subjects receiving treatment sequence 3 : Cohort 1|Eligible subjects will receive GSK159802 150 micrograms, GSK159802 300 micrograms, placebo, GSK159802 900 micrograms and GSK159802 1200 micrograms.
89367802|NCT03228238|Experimental|Dual subgroup|Standard medication for variant angina plus Vitamin C+E plus Statin Vitamin C and Vitamin E : Ascorbic acid Tablet 1g / Tocopherol Capsule 400IU Statin : Atorvastatin calcium 10mg
89367803|NCT03228238|Experimental|Statin subgroup|Standard medication for variant angina plus Statin Statin : Atorvastatin calcium 10mg
89367804|NCT03228238|Experimental|Vitamin subgroup|Standard medication for variant angina plus Vitamin C+E Vitamin C and Vitamin E : Ascorbic acid Tablet 1g / Tocopherol Capsule 400IU
89367805|NCT03228238|Active Comparator|Control group|Control subgroup : Standard medication for Variant angina only
88839976|NCT00364273|Experimental|Subjects receiving treatment sequence 4 : Cohort 1|Eligible subjects will receive GSK159802 150 micrograms, GSK159802 300 micrograms, GSK159802 600 micrograms, placebo and GSK159802 1200 micrograms.
88839977|NCT00364273|Experimental|Subjects receiving treatment sequence 5 : Cohort 1|Eligible subjects will receive GSK159802 150 micrograms, GSK159802 300 micrograms, GSK159802 600 micrograms, GSK159802 900 micrograms and placebo.
89367806|NCT03232216|Experimental|Vitamin D3 supplementation. Deficiency.|Vitamin D3 50.000 UI in each packet of powder for solution. Two packets every week for 5 weeks.
89367807|NCT03232216|Placebo Comparator|Placebo. Deficiency.|Placebo of Vitamin D3 50.000 UI in each packet of powder for oral solution. Two packets every week for 5 weeks.
89367808|NCT03232216|Experimental|Vitamin D3 supplementation.Insufficiency|Vitamin D3 50.000 UI in each packet of powder for oral solution. Two packets every week for 3 weeks.
88839978|NCT00364273|Experimental|Subjects receiving treatment sequence 1 : Cohort 2|Eligible subjects will receive placebo, salmeterol, GSK159802 low dose (LD) and GSK159802 maximum tolerated dose (MTD).
88839979|NCT00364273|Experimental|Subjects receiving treatment sequence 2 : Cohort 2|Eligible subjects will receive salmeterol, GSK159802 MTD, placebo and GSK159802 LD.
88839980|NCT00364273|Experimental|Subjects receiving treatment sequence 3 : Cohort 2|Eligible subjects will receive GSK159802 LD, placebo, GSK159802 MTD and salmeterol.
88839981|NCT00364273|Experimental|Subjects receiving treatment sequence 4 : Cohort 2|Eligible subjects will receive GSK159802 MTD, GSK159802 LD, salmeterol and placebo.
88839982|NCT00364273|Experimental|Subjects receiving treatment sequence 1 : Cohort 3|Eligible subjects will receive placebo, salmeterol, GSK159802 300 micrograms and GSK159802 1200 micrograms.
88839983|NCT00364273|Experimental|Subjects receiving treatment sequence 2 : Cohort 3|Eligible subjects will receive salmeterol, GSK159802 1200 micrograms, placebo and GSK159802 300 micrograms.
88839984|NCT00364273|Experimental|Subjects receiving treatment sequence 3 : Cohort 3|Eligible subjects will receive GSK159802 300 micrograms, placebo, GSK159802 1200 micrograms and salmeterol.
88839985|NCT00364273|Experimental|Subjects receiving treatment sequence 4 : Cohort 3|Eligible subjects will receive GSK159802 1200 micrograms, GSK159802 300 micrograms, salmeterol and placebo.
88839986|NCT00364273|Experimental|Subjects receiving treatment sequence 5 : Cohort 3|Eligible subjects will receive GSK159802 1200 micrograms, salmeterol, GSK159802 300 micrograms and placebo.
88839987|NCT02495467|Experimental|MED Placebo then MED2005|Participants first receive MED Placebo to be used at least 4 times during a 4 week period. Following a 1-week treatment-free cross-over period participants receive MED2005 (0.2% glyceryl trinitrate gel) to be used at least 4 times during a 4 week period. Treatments are provided in single unit dose aluminium tubes packed in boxes of 5. Each tube will contain sufficient gel to apply a pea sized amount (approximately 300 mg).
88839988|NCT02495467|Experimental|MED2005 then MED Placebo|Participants first receive MED2005 (0.2% glyceryl trinitrate gel) to be used at least 4 times during a 4 week period. Following a 1-week treatment-free cross-over period participants receive MED Placebo to be used at least 4 times during a 4 week period. Treatments are provided in single unit dose aluminium tubes packed in boxes of 5. Each tube will contain sufficient gel to apply a pea sized amount (approximately 300 mg).
88839989|NCT03432247|Experimental|Interactive Music Therapy|Six 45-minute individual interactive music therapy sessions.
88839990|NCT03432247|Active Comparator|Verbal-based support|Six 45-minute individual verbal support sessions
89189258|NCT04901910|Experimental|Verdi plus PA Social Media Group|This will be an 8 week Social Media Group available to the participant focused on health and well-being.
88839991|NCT05249179|Experimental|Group 1 (Oral stimulation)|The group that will receive oral stimulation with the Backman method once a day from the 29th week
88839992|NCT05249179|Experimental|Group 2 (Pacifier)|The group that will be given a pacifier three times a day from the 29th week
88839993|NCT05249179|Experimental|Group 3 (oral stimulation + pacifier)|Starting from the 29th week, the group will be given a pacifier three times a day and a Backman oral stimulation will be applied once a day.
88839994|NCT05249179|No Intervention|Group 4 (Enteral feeding by tube)|The group fed enterally by tube in routine practice, in which no intervention will be made.
88839995|NCT05249023|Experimental|Irritable Bowel Syndrome (IBS) participants|100 mM sodium butyrate solution containing indigo carmine as a dye agent will be administered to subjects in this arm.
88839996|NCT05249023|Experimental|Healthy participants|100 mM sodium butyrate solution containing indigo carmine as a dye agent will be administered to subjects in this arm.
88839997|NCT04743037|No Intervention|Standard of Care (SOC)|The 15 attentional control group stroke survivors will receive phone calls over the 12-week intervention checking in with them on how they are doing in their everyday life. They will also receive stroke education materials, but they will not receive the same iSMART intervention as the intervention group.
88839998|NCT04743037|Experimental|iSMART|"The 15 iSMART participants will engage in video conference sessions between the pre and post visits. A health coach will collaboratively work with the participant to practice treatment strategies and set goals in weekly individual sections. In addition, all participants will engage in weekly group sessions with a health coach in order to learn and practice specific self-management skills and strategies in a group context. In addition, iSMART entails using an interactive SMS to provide ongoing support and self-monitoring of behavior change goals. The SMS is programmed to touch participants daily; the SMS system prompts participants to report their daily activities and progress in achieving goals via check-in messages and sends immediate, tailored feedback about their progress. If a participant is making progress toward their goal, the SMS system will suggest a change to the participant's goal between visits."
88839999|NCT02495623|Active Comparator|Low Dose|21 mg SYN-010
88840000|NCT02495623|Active Comparator|High Dose|42 mg SYN-010
88840001|NCT02495623|Placebo Comparator|Placebo|Placebo
88840002|NCT05248087|Experimental|The rapid maxillary expansion|The rapid maxillary expansion will be applied using a McNamara-type (bonded) appliance.
88840003|NCT05248087|Active Comparator|The slow maxillary expansion|The slow maxillary expansion will be applied using a removable palatal expansion appliance.
88840004|NCT02495779|Experimental|Intervention|Given emtricitabine/tenofovir for 2-3 weeks. Brief CBT-based counseling to promote PrEP adherence
88840005|NCT02502019|Experimental|HEMOBLAST|All subjects will have the investigational device implanted
88840006|NCT05247931||CASE|patients experiencing a recurrent stroke while on ASA therapy
88840007|NCT05247931||CONTROL|ASA-naïve patients experiencing a first atherothrombotic stroke
88840008|NCT05247775|Experimental|Patients with prostate cancer|We performed urethral pressure profilometry prior to open retropubic radical prostatectomy (ORRP). Patients were interviewed about the urinary incontinence by the usage of pads and International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form (ICIQ-UI SF) prior to ORRP and at 2, 8, 16 and 24 weeks after ORRP.
88875210|NCT02525718|Placebo Comparator|Placebo|Subjects will be randomly selected to receive saline (placebo), administered to the breast area to cover the intercostal nerves supplying the breast tissue during surgery.
89367809|NCT03232216|Placebo Comparator|Placebo. Insufficiency.|Placebo of Vitamin D3 50.000 UI in each packet of powder for oral solution. Two packets every week for 3 weeks.
89367810|NCT03228082|Experimental|Home Blood Pressure Monitoring (HBPM)|"Home monitoring of blood pressure will be performed. Blood pressure measurements will be entered automatically through a smartphone application into a patient-controlled medical record ('Patients Know Best'). The data will be available to the study coordinator, who will provide patients within 1 week with feedback on the measurements. If necessary lifestyle advice will be given, in case of hypertension patients will be referred to their GP.~Once monthly a questionnaire on well-being (SF-12) and symptoms will be completed. After 6 months and 1 year patients will also receive a questionnaire on feasibility and usability of the blood pressure device."
89367811|NCT03228082|No Intervention|Control group|Patients in the control group will be asked to register their blood pressure if measured during a doctor's visit, and to note medication use if applicable. They will also be asked to complete a short questionnaire on well-being (SF-12) once per month, which will be evaluated at the end of the study. No interim contact with the study coordinator is scheduled.
89367812|NCT03222700||robotic thyroidectomy group|
89367813|NCT03222700||open thyroidectomy group|
89367814|NCT03231982|Experimental|Group I|Fixed-Dose combination of Candesartan cilexetil 8mg and Amlodipine 5mg(or Fixed-Dose combination of Candesartan cilexetil 16mg and Amlodipine 5mg), once a day for 8 weeks
89367815|NCT03231982|Active Comparator|Group II|Candesartan cilexetil 8mg and Amlodipine 5mg(or Candesartan cilexetil 16mg and Amlodipine 5mg), once a day for 8 weeks
89367816|NCT03222466|Experimental|Co-created PEM|A co-created PEM has been designed in collaboration with patients. Participants receiving the intervention will be asked to read and answer questions before and after viewing the co-created PEM.
89367817|NCT03222466|No Intervention|Traditional PEM|Participants will be asked to read and answer questions before and after viewing the traditional PEM created by clinicians and researchers.
89367818|NCT03222154|No Intervention|Control|20 volunteers without intervention. At the end of the study they received an application of shock wave therapy.
89367819|NCT03222154|Placebo Comparator|Placebo|20 volunteers who received simulation of the application of shock wave therapy
89367820|NCT03222154|Experimental|Experimental|20 volunteers who received shock wave therapy
89367821|NCT03222388||IIEF5 paper-electronic|
89367822|NCT03222388||IIEF5 electronic-paper|
89367823|NCT03222388||IIEF15 paper-electronic|
89367824|NCT03222388||IIEF15 electronic-paper|
89179175|NCT04093245|No Intervention|Phase I-A (Local project set-up)|An executive committee will oversee the entire project. This committee, led by the nominated PI and Director of Nursing, will meet every 4 weeks during this four-year project. The team may include, depending on the hospital site: an administrator, the ED Director, the ED Head nurse, a community and/or hospital-based geriatric nurse specialist, an ED physician, a hospitalist, a geriatrician, a family physician, a home care nurse/coordinator, an inpatient unit manager, the research coordinator, and a local patient/caregiver. Each local team will be responsible for selecting and implementing the ACE intervention(s) best suiting their milieu, and will include locally identified champions to lead the local implementation.
89189259|NCT04901910|No Intervention|Attention-Control condition Social Media Group|This will be an 8 week Social Media Group available to the participant with social media topics.
89367825|NCT03222388||IIEF5 electronic-electronic|
89367826|NCT03222388||IIEF15 electronic-electronic|
89367827|NCT03120130|Experimental|Cohort 1|This cohort will include 3 patients with the first calculated dose of Amblyomin-X drug. The patient will receive the intravenous drug. If no Dose-limiting toxicity (DLT) in this group the study continues including the next cohort. However, if If only one patient in a given cohort develops DLT, three more patients will be included at that dose level, up to a maximum total of six patients per dose level. If two or more of the three patients of a certain dose level develop DLT, this dose level is considered very toxic, and the study does not proceed. If this occurs at the first dose level, the study will be finalized. If only one in six patients at a dose level develops DLTs, escalation proceeds until Tolerated Maximum Dose.
89367828|NCT03120130|Experimental|Cohort 2|This cohort will include 3 patients with the second calculated dose of Amblyomin-X drug. The patient will receive the intravenous drug. If no Dose-limiting toxicity in this group the study continues including the next cohort
89367829|NCT03120130|Experimental|Cohort 3|This cohort will include 3 patients with the third calculated dose of Amblyomin-X drug. The patient will receive the intravenous drug. If no Dose-limiting toxicity in this group the study continues including the next cohort
89367830|NCT03120130|Experimental|Cohort 4|This cohort will include 3 patients with the fourth calculated dose of Amblyomin-X drug. The patient will receive the intravenous drug. If no Dose-limiting toxicity in this group the study continues including the next cohort
89367831|NCT03120130|Experimental|Cohort 5|This cohort will include 3 patients with the fifth calculated dose of Amblyomin-X drug. The patient will receive the intravenous drug. If no Dose-limiting toxicity in this group the study continues including the next cohort
89367832|NCT03120130|Experimental|Cohort 6|This cohort will include 3 patients with the sixth calculated dose of Amblyomin-X drug, the last dose calculated. The patient will receive the intravenous drug.
89367833|NCT03119974|Other|Tpo-RA discontinuation|
89367834|NCT03119896|Experimental|Intervention Group (using Navigator Tool)|The participants will receive a copy of the Navigator Tool Intervention, a paper-based information pack including the My Pain Concerns Form, suggested questions to ask your healthcare professional, a goal setting sheet and information on common self-management strategies. They will be encouraged to fill in some of the forms before the consultation, and some during the consultation. They will have consultations with a healthcare professional who has undergone a Self-management Awareness Training with the Thistle Foundation.
89001910|NCT00188630|Active Comparator|N-Acetylcysteine|IV NAC as a 100mg/kg bolus at the start of the surgical procedure (prior to the initiation of CPB), followed by a 10 mg/kg/hr infusion until 4 hours after completion of surgery
89367835|NCT03119896|No Intervention|Control Group (not using Navigator Tool)|These participants will not have access to the Navigator Tool Intervention, and will have consultations with a healthcare professional who has not undergone the Self-management Awareness Training.
89367836|NCT03231592|Experimental|CSA Group|This group will receive CSA Shares (a selection of fresh fruits and vegetables from a local farm) each week for 24 weeks over the summer of 2017 and 2018. The CSA does not operate over the winter.
89367837|NCT03231592|Active Comparator|Enhanced Usual Care Group|This group will receive a handout about healthy eating, in addition to routine care in their primary care practice.
89367838|NCT03228004|Experimental|Intervention Group|Participants will be provided with training on how to upload glucose data via GLOOKO and will receive reminders to upload glucose data on a biweekly basis between clinic visits.
89367839|NCT03222310|Experimental|Ipatasertib|Participants will receive one 100 milligram (mg) ipatasertib tablet orally on Day 1 of treatment in treatment period 1 followed by two 100 mg itraconazole capsules orally on Days 15 to 23 along with one 100 mg of ipatasertib on Day 19 in treatment period 2. Both the treatment period will be separated by a washout period of 14 days.
89367840|NCT03222232||chronic intestinal failure patients|Patients with chronic intestinal failure on home parenteral support and enrolled in the Copenhagen Intestinal failure database between January 1, 2002 and December 31, 2015.
89367841|NCT04485520|Experimental|Carica Papaya extract|Carica Papaya at 3%
89367842|NCT04485520|Active Comparator|Chlorhexidine|0.12% chlorhexidine mouthwash formulation (commercially available)
89367843|NCT03231514|Placebo Comparator|Carbohydrate Diet & Placebo & Exercise|This group receives the carbohydrate-based diet and flavored placebo pre-workout drink. All participate in the exercise intervention.
89367844|NCT03231514|Active Comparator|Carbohydrate Diet & Carbohydrate Supplement(Carb10) & Exercise|This group receives the carbohydrate-based diet and supplemental carbohydrate. Will be compared to Carbohydrate & Placebo for effects of supplement. All participate in the exercise intervention.
89367845|NCT03231514|Experimental|Ketogenic Diet & Placebo & Exercise|This group receives the ketogenic diet and flavored placebo. It is both an experimental (vs. carbohydrate diet & placebo) and placebo control group (vs. ketogenic & supplement). All participate in the exercise intervention.
89367846|NCT03231514|Experimental|Ketogenic Diet & Carbohydrate Supplement (Carb10) & Exercise|This group receives the ketogenic diet and supplemental carbohydrate. All participate in the exercise intervention.
89367847|NCT03231436|Experimental|Fixed dose of 12.5mg bupivacaine|Participants that receive the same dose of intrathecal bupivacaine and 25mcg of fentanyl, regardless of their height.
89367848|NCT03231436|Active Comparator|Height-adjusted dose of bupivacaine|Participants that receive the dose of intrathecal bupivacaine adjusted to their height and 25mcg of fentanyl
89367849|NCT02452450|Experimental|Ibuprofen lysine|
89367850|NCT02452450|Experimental|Ibuprofen sodium|
89367851|NCT02452450|Experimental|Ibuprofen liquid capsules|
89367852|NCT02452450|Active Comparator|Ibuprofen acid|
89367853|NCT02452450|Active Comparator|Paracetamol|
89367854|NCT02452372|Active Comparator|givosiran (ALN-AS1)|
89367855|NCT02452372|Placebo Comparator|Sterile Normal Saline (0.9% NaCl)|
89367856|NCT03221920|Experimental|Very Low Carbohydrate Diet|The patient will be evaluated for baseline clinical and laboratory values, and counselled on very low carbohydrate diet.
89367857|NCT03221920|No Intervention|Control|The patient will be evaluated for baseline clinical and laboratory values, and counselled on normal healthy .
89367858|NCT01204684|Experimental|Tumor Lysate-pulsed DC vaccination|Cohort #1 will receive autologous tumor lysate-pulsed DC vaccination together with a placebo cream or intramuscular injection of saline.
89367859|NCT01204684|Experimental|Tumor lysate-pulsed DC vaccination+0.2% resiquimod.|Cohort #2 will receive autologous tumor lysate-pulsed DC vaccination together with adjuvant 0.2% resiquimod.
89367860|NCT01204684|Experimental|Tumor-lysate pulsed DC vaccination +adjuvant polyICLC.|Cohort #3 will receive autologous tumor lysate-pulsed DC vaccination together with adjuvant poly ICLC (TLR3 agonist).
89367861|NCT03227302||attending obstetrician|the low grade doctor who can do caesarean operation with no pregnant complications.
89367862|NCT03227302||associate chief obstetrician|The middle grade doctor who can do caesarean operation with no or mild or middle pregnant complications.
89367863|NCT03227302||chief obstetrician|the high doctor who can do all caesarean operation without limitations
89367864|NCT00594334|Experimental|E, I|
89367865|NCT03227380|Other|radiological evaluation|to explore by thoracic densitometry with contrast the spared segments after stapling of the intersegmental plan following a thoracoscopic segmentectomy
89367866|NCT03229018|Other|voxel size|200 μm and 300 μm Voxel Sizes
89367867|NCT00238420|Experimental|Group I (paclitaxel, trastuzumab, radiation therapy)|Patients receive paclitaxel IV over 1 hour on days 1, 8, 15, 22, 29, 36, and 43 and trastuzumab IV over 90 minutes on day 1 and then over 30 minutes on days 8, 15, 22, 29, 36, and 43. Patients also undergo radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, 36-40, 43-47, and 50. Treatment continues in the absence of disease progression or unacceptable toxicity.
89367868|NCT00238420|Experimental|Group II (paclitaxel, radiation therapy)|Patients receive paclitaxel and undergo radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, 36-40, 43-47, and 50.
89367869|NCT03221998|Experimental|IV paracetamol|Patients in the first group will receive in the operating room before surgery 1 gram (100 ml) of intravenous paracetamol ( IV paracetamol) for 15 minutes intraoperative
89367870|NCT03221998|Placebo Comparator|IV saline (NaCl 0.9 %)|Patients in the second group will receive 100 mL NACL 0.9% (IV NaCl 0.9 %)intraoperative
89367871|NCT03221686|Placebo Comparator|Control|Total daily protein intake: 1.5 g protein/kg body weight
89367872|NCT03221686|Active Comparator|Intervention|55 mg zinc/day, 1251 mg vitamin C/day, and 15 g arginine/day. Total daily protein intake: 1.5 g protein/kg body weight
89367873|NCT03231280|Experimental|SB-061|SB-061
89367874|NCT03231280|Placebo Comparator|Placebo|Placebo
89367875|NCT03231202|Experimental|Embolization|"The intervention arm will perform SAE as a central embolization of the splenic artery.~Additional peripheral embolization is left to the discretion of the interventional radiologist.~The study does not interfere with local diagnostic work-up and treatment protocols."
88840009|NCT03157687||Healthy controls|"Blood sampling for nutrition and inflammatory status~Stool sampling before preventive gastroscopy and colonoscopy~Questionnaires about general health, gastrointestinal symptoms and 3-day food record~Collection of biopsies in duodenum during gastroscopy~Collection of biopsies in terminal ileum, cecum, colon ascendens, sigma"
88840010|NCT03157687||Inflammatory bowel disease (IBD)|"Blood sampling for nutrition and inflammatory status~Stool sampling before indicated gastroscopy and colonoscopy~Questionnaires about general health, gastrointestinal symptoms and 3-day food record~Collection of biopsies in duodenum during gastroscopy~Collection of biopsies in terminal ileum, cecum, colon ascendens, sigma"
88840011|NCT03157687||Liver transplantation recipient (LTX)|"Blood sampling for nutrition and inflammatory status~Stool sampling before indicated gastroscopy and colonoscopy for evaluation of liver transplantation (LTX)~Questionnaires about general health, gastrointestinal symptoms and 3-day food record~Collection of biopsies in duodenum during gastroscopy~Collection of biopsies in terminal ileum, cecum, colon ascendens, sigma"
89534723|NCT02452879|Placebo Comparator|Placebo group|with the patient in the prone position. The acupoint routine disinfection of skin, and then the fixed pad is adhered on the acupoint. The 1.5 inches blunt tip needle pierce through the fixed pad, then it reaches the surface of the skin, uniform lifting thrusting and twirling all 3 times but do not pierce the skin. Then connect the electric acupuncture apparatus with special power supply wire electrode (special power line as the middle wire cut, looks as normal; that electroacupuncture instrument display connected to the state, but the actual without electricity), in the bilateral Zhongliao points, Hui Yang points on the needle handle; the period of treatment and the other manipulation of the placebo group are same as the deep needling acupoint group.
88840012|NCT02828839|Experimental|Treatment Arm|Subjects will receive standard of care prostate biopsies through the use of a trans-rectal ultrasound probe for needle placement and guidance. The intervention for all patients receiving a prostate biopsy will include the use of an investigational single use, disposable stainless steel access needle and a single use, disposable polymeric needle guide.
88840013|NCT05217277||patient with juvenile idiopathic arthritis and gingivitis|It is a group of patients between the ages of 5 and 16 who have recently been diagnosed with juvenile idiopathic arthritis and gingivitis, have not used medication yet.
88840014|NCT05217277||healthy patient group with gingivitis|It is a group of healthy patients with gingivitis between the ages of 5-16 who have not taken antibiotics in the last 3 months.
88840015|NCT05217277||healthy patient group without gingivitis|It is a group of healthy patients without gingivitis between the ages of 5-16 who have not taken antibiotics in the last 3 months.
88840016|NCT05217277||patient with juvenile idiopathic arthritis and without gingivitis|It is a group of patients between the ages of 5 and 16 who have recently been diagnosed with juvenile idiopathic arthritis and without gingivitis, have not used medication yet.
88840017|NCT05216497|Experimental|Ingavirin®, 90 mg capsules|Ingavirin®, 90 mg capsules will be administered on top of standard therapy: days 1-3: 180 mg (2 capsules once a day); days 4-7: 90 mg (1 capsule 1 time per day).
88840018|NCT05216497|Placebo Comparator|Placebo|Placebo capsules will be administered on top of standard therapy: days 1-3: 2 capsules once a day; days 4-7: 1 capsule 1 time per day.
88840019|NCT02502487|Placebo Comparator|Tetracaine gel group|Dorsal penile nerve block with saline and tetracaine gel into urethra before rigid cystoscopy
88840020|NCT02502487|Experimental|Dorsal penile nerve block group|Dorsal penile nerve block with ropivacaine and plain lubricating gel into urethra before rigid cystoscopy
88840021|NCT02502487|Experimental|Combination group|Dorsal penile nerve block with ropivacaine and tetracaine gel into urethra before rigid cystoscopy
88840022|NCT05473832|Experimental|Group 1|
88840023|NCT05473832|Experimental|Group 2|
88840024|NCT05473832|Experimental|Group 3|
88840025|NCT05473832|Experimental|Group 4|
88840026|NCT02632045|Experimental|Ribociclib (LEE-011)/Fulvestrant|LEE-011 is administered orally, 600mg, daily for 3 weeks and 1 week off. Fulvestrant is administered intramuscularly, 500mg, every 2 weeks x 3, then every 4 weeks.
89001911|NCT00188630|Placebo Comparator|Placebo|The control arm will instead receive placebo (5% dextrose solution), both as a bolus and infusion.
88840027|NCT02632045|Placebo Comparator|Placebo/Fulvestrant|Placebo is administered orally, 600mg daily for 3 weeks and 1 week off. Fulvestrant is administered intramuscularly, 500mg, every 2 weeks x 3, then every 4 weeks.
89179176|NCT04093245|Experimental|Phase I-B (Implementation):|The investigators will implement the context-adapted ACE program with the support of administrators and local implementation teams who will have the responsibility to roll out the different elements of the intervention within their respective hospitals. It may include a series of systematic pre-discharge, post-discharge and across transitions period interventions for eligible patients: 1) a GEM nurse to support patients during the post-discharge transition period, 2) pre- and post-hospitalization medication list reconciliation, 3) systematic discharge summaries given to patients and/or caregiver, and sent to their family physician, 4) a planned follow-up appointment with their family physician, 5) a systematic follow-up phone call, 6) access to wiki-based patient-oriented KT tools, 7) access to a community-based telemonitoring service.
89179177|NCT04093245|Experimental|Phase IC (Study description)|Results from each center will be analysed over time. Guided by previous work in healthcare governance, the investigators will analyze the impact of the sequential interventions within the context of a major health reform in Quebec aiming at implementing an integrated health system and within the PI program's overall goal of creating a Learning Health System. This will be accomplished by conducting a comparative case study across the four study sites to compare the barriers, facilitators and local solutions implemented to gain a better understanding about how the ACE program could eventually be scaled up elsewhere.
89179178|NCT02599896|Experimental|Group 1|5 mg/kg/IV on Day 0
89179179|NCT02599896|Experimental|Group 2|5 mg/kg SC on Day 0
89179180|NCT02599896|Experimental|Group 3|20 mg/kg IV on Day 0
89179181|NCT02599896|Experimental|Group 4|40 mg/kg IV on Day 0
89534724|NCT02452879|Active Comparator|Solifenacin Succinate group|Solifenacin Succinate Tablets (made by the Anse Tailai Pharmaceutical (China) R & D limited company) 5mg, 1 tablets each time, 1 times / day, oral administration of 30min before meal, even for 8 weeks.
89534725|NCT05048121|Experimental|CLS02021 - Investigational Product arm|Cosmetic cream with proprietary cosmetic ingredient CLS02021.
89179182|NCT02599896|Experimental|Group 5|5 mg/kg SC on Day 0, Week 12 and Week 24
89179183|NCT02599896|Experimental|Group 6|20 mg/kg IV on Day 0, Week 12 and Week 24
89179184|NCT02599896|Experimental|Group 7|5 mg/kg SC on Day 0, Week 4
89179185|NCT02599896|Experimental|Group 8|20 mg/kg IV on Day 0, Week 4
89179186|NCT04094922|Experimental|Intervention|Free access to the Swedish PTSD Coach smartphone app for three months.
89179187|NCT04094922|No Intervention|Waitlist|Delayed access to the Swedish PTSD Coach smartphone app. Access is given after post-intervention data collection at three months.
89179188|NCT04095000|Experimental|FACE-TC SP|The current FACE-TC protocol consists of three weekly 60 to 90-minute sessions in a dyadic format facilitated by a trained/certified interviewer. If our community partners recommend otherwise, this structure could change. Each session is followed by a 10-minute assessment, using process measures to assess participants' ratings of the quality of communication and satisfaction.
89179189|NCT04095000|Active Comparator|Treatment As Usual|Treatment as Usual comparison condition will also be assessed and measures administered at the same time intervals.
89179190|NCT00824369|No Intervention|Anti-retroviral therapy|Anti-retroviral therapy
89179191|NCT00824291|Placebo Comparator|1|
89179192|NCT00824291|Experimental|2|
89179193|NCT05239871||Women with surgical diagnosis of parametrial endometriosis|This cohort will include patients with surgical diagnosis of parametrial endometriosis
89179194|NCT05239871||Women without surgical diagnosis of parametrial endometriosis|This cohort will include patients without surgical diagnosis of parametrial endometriosis
89179195|NCT00804986|Experimental|0.5 mg LY2428757|Once weekly, subcutaneous injection of 0.5 milligram (mg) LY2428757 for 12 weeks. All injections were administered by study site personnel who were blinded to treatment assignment.
89179196|NCT00804986|Experimental|2.0 mg LY2428757|Once weekly, subcutaneous injection of 2.0 mg LY2428757 for 12 weeks. All injections were administered by study site personnel who were blinded to treatment assignment.
89179197|NCT00804986|Experimental|6.2 mg LY2428757|Once weekly, subcutaneous injection of 6.2 mg LY2428757 for 12 weeks. All injections were administered by study site personnel who were blinded to treatment assignment.
89534726|NCT05048121|Placebo Comparator|PLC01021 - Placebo Control arm|Cosmetic cream, identical to the studied product but without cosmetic ingredient. Color, texture, scent and the packaging are identical as a IP.
89534727|NCT03328403|Experimental|Aspiration First|Aspiration thrombectomy with large bore catheters
89179198|NCT00804986|Experimental|12.0 mg LY2428757|Once weekly, subcutaneous injection of 12.0 mg LY2428757 for 12 weeks. All injections were administered by study site personnel who were blinded to treatment assignment.
89179199|NCT00804986|Experimental|17.6 mg LY2428757|Once weekly, subcutaneous injection of 17.6 mg LY2428757 for 12 weeks. All injections were administered by study site personnel who were blinded to treatment assignment.
89179200|NCT00804986|Placebo Comparator|Placebo|Once weekly, subcutaneous injection of placebo for 12 weeks. All injections were administered by study site personnel who were blinded to treatment assignment.
89534728|NCT03328403|Experimental|Stent retriever first|Thrombectomy with a licensed stent retriever device
89534729|NCT05026515||4 years and under|Children coming at dental appointment, aged 4 years and under
89534730|NCT05026515||5 to 6 years|Children coming at dental appointment, aged 5 to 6 years
89534731|NCT05026515||7 years and over|Children coming at dental appointment, aged 7 years and over
88840028|NCT02503735|Other|12 weeks treatment with Sofosbuvir/Ledipasvir (400mg/90mg)|10 patients with hepatitis C (HCV) and HCV-associated CKD that will receive 12 weeks treatment with Sofosbuvir/Ledipasvir (400mg/90mg)
89179201|NCT00752232|Experimental|ACC-001+QS-21|Active vaccine + adjuvant, IM injection, dose of 3, 10, 30 micrograms, Day 1, month 3, 6, 9, 12
89179202|NCT00752232|Experimental|ACC-001|Active vaccine, IM injection, dose of 3, 10, 30 micrograms, Day 1, month 3, 6, 9, 12
89179203|NCT00752232|Placebo Comparator|QS-21|Adjuvant, IM injection, dose of 50 micrograms, Day 1, month 3, 6, 9, 12
89179204|NCT00752232|Placebo Comparator|PBS|Placebo, IM injection, Day 1, month 3, 6, 9, 12
88840029|NCT04001881||Hypotension group|spinal anesthesia in Hypotensive patients with low LV-EF Transthoracic echocardiography of IVC before spinal anaesthesia
88840030|NCT04001881||Normotension group|spinal anesthesia IN Normotensive patients with low LV-EF Transthoracic echocardiography of IVC before spinal anaesthesia
88840031|NCT03019640|Experimental|Treatment (chemotherapy, NK infusion, stem cell transplant)|See Detailed Description.
89367876|NCT03231202|No Intervention|Observation|The control arm in this randomized controlled trial will include only NOM patients diagnosed with splenic injuries OIS grade 4 or 5 and suitable for observation alone, and will comprise clinical observation according to local routines and protocols.
88840032|NCT02339779|Experimental|Autologous fat transfer reconstruction|Breast reconstruction achieved by serial autologous fat transfer (AFT) procedures, accompanied by external tissue expansion of the breast.
88840033|NCT02339779|Active Comparator|Reconstruction with breast implants|Control group will receive implant-based reconstruction, in some cases preceded by the implantation of a tissue expander.
88840034|NCT02136901|Experimental|Investigational arm|The patients randomized to the Investigational Group will receive the NUsurface® Meniscus Implant.
88840035|NCT02136901|Active Comparator|Control Arm|The patients randomized to the Control Group of the study will receive Non-Surgical Care (the current standard of care for this patient population).
88840036|NCT00585338|Experimental|Tandem 532/1064 nm Laser|Treatment of Vascular LesionsWith a Tandem 532/1064 nm Laser
88840037|NCT00581204||Diagnostic Tool|Near-Infrared Diffuse Optical Spectroscopy Imaging
88840038|NCT02506309|Experimental|SIS single incision sling|SIS - Innovative fixation single incision sling A third generation of the Mid-urethral slings inserted through a SIS single incision sling (SIS) to treat female stress urinary incontinence (SUI).
88840039|NCT02506309|Active Comparator|TOT trans obturator tape/sling|TOT - inside-out trans-obturator tape/sling Trans-obturator slings (TOT) now represent a gold standard in the treatment of female stress urinary incontinence (SUI).
88840040|NCT00580892||Airway and Pleural Disorders|Optical Coherence Tomography imaging
88840041|NCT00580736|Experimental|Optical Clearing|Optical Clearing
88840042|NCT02507011|Experimental|Carvedilol First|Crossover Design: Participants receive Carvedilol first and placebo second
88840043|NCT02507011|Placebo Comparator|Placebo First|Crossover Design: Participants receive placebo first and Carvedilol second
88840044|NCT05379218|Experimental|Intervention Arm - Remote Ischemic Conditioning|Remote Ischemic Conditioning
88840045|NCT05379218|No Intervention|Control Arm - No Remote Ischemic Conditioning|No intervention. A blood pressure cuff will be placed on the infant's arm but will not be inflated.
88840046|NCT02977286|Experimental|Naloxegol Oral Tablet|"Intervention: Naloxegol 25 mg (or 12.5 mg) tablet po (enteral) daily AND Docusate Sodium 100mg Oral Capsule twice daily AND Study laxative protocol daily [that may include Senna 217 mg Oral Tablet, Polyethylene Glycols (Miralax), Magnesium Citrate Oral Liquid Product (Citromag), Bisacodyl 10 mg Suppository (Dulcolax) and Methylnaltrexone (Relistor)] until one of the following:~Adverse event potentially attributable to the study drug.~Use of Relistor.~Scheduled opioid therapy is stopped for ≥ 24 hours and participant has ≥ 1 SBM since enrollment.~The participant has been administered 10 days of study medication.~The participant is discharged from the ICU.~The participant requires the initiation of a strong CYP3A4 inhibitor medication.~Other Name: Movantik"
88840047|NCT02977286|Placebo Comparator|Placebo Oral Tablet|"Intervention: Placebo tablet po (enteral) daily AND Docusate Sodium 100 mg Oral Capsule twice daily AND Study laxative protocol daily [that may include Senna 217 mg Oral Tablet, Polyethylene Glycols (Miralax), Magnesium Citrate Oral Liquid Product (Citromag), Bisacodyl 10 mg Suppository (Dulcolax) and Methylnaltrexone (Relistor)] until one of the following:~Adverse event potentially attributable to the study drug.~Use of Relistor.~Scheduled opioid therapy is stopped for ≥ 24 hours and participant has ≥ 1 SBM since enrollment.~The participant has been administered 10 days of study medication.~The participant is discharged from the ICU.~The participant requires the initiation of a strong CYP3A4 inhibitor medication.~Other Name: AstraZeneca provided Movantik placebo"
88840048|NCT05345210|Active Comparator|Vonoprazan Fumarate+Amoxycillin+Clarithromycin 14days (VAC14)|Vonoprazan Fumarate 20mg bid po Amoxycillin 1000mg bid po Clarithromycin 500mg bid po for 14 days
88840049|NCT05345210|Experimental|Vonoprazan Fumarate+Amoxycillin 14days (VA14)|Vonoprazan Fumarate 20mg bid po Amoxycillin 1000mg bid po for 14 days
88840050|NCT05345210|Experimental|Vonoprazan Fumarate+Amoxycillin 7days (VA7)|Vonoprazan Fumarate 20mg bid po Amoxycillin 1000mg bid po for 7 days
88840051|NCT05345210|Experimental|Vonoprazan Fumarate+Tetracycline+Furazolidone 14days (VTF14)|Vonoprazan Fumarate 20mg bid po Tetracycline 500mg tid po Furazolidone 100 bid po for 14 days
88840052|NCT05345210|Experimental|Vonoprazan Fumarate+Tetracycline+Furazolidone 7days (VTF7)|Vonoprazan Fumarate 20mg bid po Tetracycline 500mg tid po Furazolidone 100 bid po for 7 days
88840053|NCT00540566||Optical Biopsy|Optical Biopsy imaging
88840054|NCT02976896|Experimental|Apatinib Mesylate|Patients will receive Apatinib Mesylate at 500mg/times,oral one times daily for 28 days.
88840055|NCT01810705|Experimental|GRASPA|"patients will receive one injection of GRASPA (100 IU/kg) after each course of low-dose cytarabine (see Arm Control)"
88840056|NCT01810705|No Intervention|Control|patients will receive successive courses of low intensive chemotherapy, as subcutaneous low-dose cytarabine 20mg twice daily for 10 days per course (from day 1 to day 10), each course occurring every 28 days, for a duration up to 24 months
88840057|NCT01712191|Experimental|NUsurface Meniscus Implant|
89367877|NCT03221530|Experimental|EISR-I|Participants in the Early Intervention for Suicide Risk Among Immigrant Youth (EISR-I) family-based intervention will attend 8 in-person sessions with at least one parent/guardian.
89367878|NCT03221530|Active Comparator|Enhanced usual care|Participants in the usual care arm will receive a safety planning and assessment feedback session from the research team and will receive usual care in the behavioral health clinic where the study takes place.
88840058|NCT02508103|Experimental|Oxytocin, then Placebo|"Participants were randomized to receive Intransal Oxytocin for late luteal phase administration during one menstrual cycle, then received Intranasal Placebo for late luteal phase administration of a subsequent menstrual cycle.~Intranasal Oxytocin spray (40 IU, 3x/day) for 4-5 days; Intranasal Placebo spray (3x/day) for 4-5 days"
89367879|NCT02452294|Experimental|Buparlisib|Patients will receive oral buparlisib 100 mg once daily and continue on study treatment until evidence of disease progression, death, or unacceptable adverse events.
89367880|NCT03221608|Active Comparator|surgery alone(open/laparoscopic)|The patients with colorectal cancer (T4N0-2M0) who have a high risk of developing colorectal Peritoneal Carcinomatosis (PC) undergo curative surgery(open/laparoscopic).
89367881|NCT03221608|Experimental|surgery and HIPEC|Standard surgical treatment and HIPEC with Lobaplatin.
88840059|NCT02508103|Experimental|Placebo, then Oxytocin|"Participants were randomized to receive Intranasal Placebo for late luteal phase administration during one menstrual cycle, then received Intransal Oxytocin for late luteal phase administration of a subsequent menstrual cycle.~Intranasal Oxytocin spray (40 IU, 3x/day) for 4-5 days; Intranasal Placebo spray (3x/day) for 4-5 days"
88840060|NCT02508259|Active Comparator|Suramin|20 mg/kg suramin in 50 ml of saline by intravenous infusion over 30 minutes
89367882|NCT04492475|Experimental|Remdesivir plus Interferon Beta-1a|200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10-day total course and 44 mcg of interferon beta-1a administered by a 0.5 mL subcutaneous injection on Days 1, 3, 5, and 7 while hospitalized for a total of 4 doses.
89367883|NCT04492475|Placebo Comparator|Remdesivir plus Placebo|200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10-day total course and a 0.5 mL placebo injection administered subcutaneously on Days 1, 3, 5, and 7 while hospitalized for a total of 4 doses.
88840061|NCT02508259|Placebo Comparator|Saline|50 ml of saline by intravenous infusion over 30 minutes
88840062|NCT04707859||Cohort|"Participants consenting to the study will undergo:~a1) An interview a2) Blood samples withdrawals a3) ECG a4) Non-enhanced CT a5) CCTA a6) Follow-up for > 10 years~Patients with suspicion of coronary stenosis detected by CCTA will after undergo:~b1) Rb PET b2) 15O-water PET b3) Invasive coronary angiography with 3 vessel measurement of fractional flow reserve (FFR), coronary flow reserve (CFR) and index of microvascular resistance (IMR)"
88840063|NCT02713646||patients with primary trigeminal neuralgia|
88840064|NCT02713646||healthy subjects|
89367884|NCT03231124|Experimental|LEO 32731|"Incremental dosing of LEO 32731 progressing to a maximum of 30 mg.~Days 1 - 3: 10 mg dose twice a day for three days~Days 4 - 6: 20 mg dose twice a day for three days~Days 7 - 11: 30 mg dose twice a day for five days~Days 12: 30 mg dose once in the morning"
88840065|NCT04708093|Experimental|whole body vibration training (WBVT)|whole body vibration group
88840066|NCT04708093|No Intervention|Controlled|advised about healthy dieting
88840067|NCT05237180|Experimental|patient group|8 training sessions on spatial localisation
89367885|NCT03231124|Placebo Comparator|Placebo|"Incremental dosing of placebo progressing to a maximum of 30 mg.~Days 1 - 3: 10 mg dose twice a day for three days~Days 4 - 6: 20 mg dose twice a day for three days~Days 7 - 11: 30 mg dose twice a day for five days~Days 12: 30 mg dose once in the morning"
89367886|NCT03227068|Experimental|PEDSS - symptom management|Content for the PEDSS - symptom management includes the most commonly experienced treatment-related physical symptoms, descriptions of each symptom, strategies to reduce symptom distress, and when and how to contact the cancer care team.
89367887|NCT03227068|Experimental|PEDSS - support for the caregiver|Content for the PEDSS - support for the caregiver includes five topics and suggestions on how caregivers can care for themselves during this time.
89367888|NCT03231046|Experimental|CBCT-US Fusion Arm|Clear Guide SCENERGY, CBCT-US
89367889|NCT03231046|Active Comparator|EM Fusion or No Fusion Arm|
89530364|NCT04585685|Experimental|4 week baseline, CPT + SC|Participants in this arm are randomized to a 4-week baseline period with repeated weekly assessment after the initial intake. Following the 4-week baseline, participants are randomly assigned to receive 12 weekly sessions of Cognitive Processing Therapy (CPT), followed by a 3-week return to baseline period, followed by 6 weekly sessions of Self-Compassion Therapy (SC).
88840068|NCT05237180|No Intervention|control croup|Non training sessions
88840069|NCT02509585|Experimental|Tc99m tilmanocept|2 mCi (74 MBq), 50 ug of Tc99M tilmanocept single administration
88840070|NCT00596401||1|HP eradication group
88840071|NCT00596401||2|No eradication group
88840072|NCT00596401||3|No Hp group
88840073|NCT02240706|Active Comparator|Arm B|Best Supportive Care Alone
88840074|NCT02240706|Experimental|Arm A|BI 836858 plus Best Supportive Care
88840075|NCT00534469|Experimental|HD ARA-C with or without Idarubicin|"This study was designed as a single-arm study.~Strata were:~HD ARA-C w/ Idarubicin, CR<6 months N = 24 patients. HD ARA-C w/ Idarubicin, CR>6 months N=1. HD ARA-C consolidation, CR<6 months N=5. HD ARA-C consolidation, CR>6 months N= 0."
88840076|NCT03757351|Experimental|DNL747 First, Placebo Second|
88840077|NCT03757351|Experimental|Placebo First, DNL747 Second|
88840078|NCT03757351|Experimental|Open-Label Extension|Conducted in the Netherlands only.
88840079|NCT04341805|Active Comparator|Group A. Physiological saline.|The surgical procedure in group A consisted of the placement of a 6.4cm diameter circular prosthesis (BARD Hernia Patch) at the intra-abdominal level. Subsequently, the liquid contained in the 10 ml opaque vial was administered (Ecolav Physiological Washing Serum 0.9%, (SSF).
88840080|NCT04341805|Experimental|Group B. Solution hyperoxygenated fatty acids|The surgical procedure in group B consisted of the placement of a 6.4cm diameter circular prosthesis (BARD Hernia Patch) at the intra-abdominal level. Subsequently, the liquid contained in the 10 ml opaque vial (AGHO solution) was administered according to randomization.
88840081|NCT01600092|Experimental|RotaTeq™ Experimental Formulation|Three 2.0 mL oral doses of RotaTeq™ experimental formulation. Vaccination 1 will be administered between 6 and 12 weeks of age and the third vaccination will be administered before 32 weeks of age. Each vaccination will be separated from the next by ≥ 4 weeks (28 days)
89001912|NCT00219687|Active Comparator|1|When a 911 call is determined to be a cardiac arrest, the caller reporting the event who needs or desires instructions to perform CPR while waiting for EMS to arrive will receive dispatcher-assisted CPR instructions with chest compressions only
89367890|NCT03230812|Experimental|Experimental: carnitine intervention (in all participants)|All subjects will undergo oral Carnitene (L-Carnitine or levocarnitine) supplementation for 96 days.The total dosage of L-carnitine per day will be 2970mg. Consumption of the chewing tablets will be divided over the day. Intake of these chewing tablets will be during breakfast (990mg), lunch (990mg) and during diner (990mg). Since the chewing tablets are only available in concentrations of 330mg, participants have to consume 3 chewing tablets per meal, a total of 9 chewing tablets each day.
89367891|NCT03221452|Other|Intervention|The intervention includes 4 every other week, 2-hour educational sessions to teach compensatory strategies along with skill development and training. Educational sessions will include content on common cognitive problems experienced by people with T2DM and discussion of compensatory strategies to improve cognitive skills as well as content on behaviors and lifestyle strategies to maintain cognitive functioning. Each participant will use the online training program (BrainHQ/Posit Science) for a minimum of 45 minutes 3 times a week and to record practice times and dates. Tasks in the computer training are arranged so that as the user moves forward, the tasks become more challenging. Each task is in a game-like format.
89367892|NCT04936763|Experimental|Janesse 20|
89367893|NCT03221296|Experimental|Vestibular Training (Intervention Group)|"For the actual intervention, participants will be asked to commit a total of approximately 20 minutes a day of vestibular exercise, divided into three separate sessions (i.e. three 7 minute sessions).~These will include eye movement exercises, walking and balancing. Every 2 weeks, there will be a slight change to the exercises to increase difficulty. (i.e. balancing on one leg or walking with head turns)"
89367894|NCT03221296|No Intervention|Usual Care (Control group)|Patients that are randomized to standard of care Control group will undergo Baseline and 12-week assessments including vestibular testing and questionnaires.
89367895|NCT03230656|Experimental|Early therapy 1 month post-injury|"Early cognitive-communication therapy 1 month post-injury:~working memory strategies~executive function program~divided attention program~environmental changes~identification of problematic cognitive-communication situations"
89367896|NCT03230656|Active Comparator|Waitlist therapy 2 months post-injury|"Waitlist early cognitive-communication therapy 2 months post injury:~- Same cognitive-communication therapy is administered"
89367897|NCT03751865|Experimental|CBT group|This intervention aims for distress reduction, symptom coping, and life quality enhancement. It is a gender-specific CBT tailor-made for the at-risk population. The intervention is delivered by a registered clinical psychologist.
89367898|NCT03751865|Active Comparator|Psychoeducation group|The content of the psycho-education program will be related to healthy living content and mental health knowledge, such as food hygiene, psychological well-being, knowledge about psychosis and common mental disorder and food nutrition. In addition, a weekly call to remind the subject about healthy living will also be provided to the subjects. The intervention is delivered by a registered social worker.
89367899|NCT03221062|Experimental|Laser en Bloc Resection|Laser en Bloc Resection of bladder tumor(laser ERBT)
89367900|NCT03221062|Experimental|Hydroknife en Bloc Resection|Hydroknife en Bloc Resection of bladder tumor (Hydroknife ERBT)
89367901|NCT03221062|Experimental|conventional transurethral resection|conventional transurethral resection of bladder tumor(cTURBT)
89367902|NCT04486235|Experimental|Intervention|Receive experiential pamphlet
88840082|NCT01600092|Active Comparator|RotaTeq™ Existing Formulation|Three 2.0 mL oral doses of RotaTeq™ existing formulation. Vaccination 1 will be administered between 6 and 12 weeks of age and the third vaccination will be administered before 32 weeks of age. Each vaccination will be separated from the next by ≥ 4 weeks (28 days).
89367903|NCT04486235|No Intervention|Control|No materials, usual care
89367904|NCT03747653||Arm 1|Participants will receive a single intravenous (i.v.) injection of ADVATE followed by a single intravenous (i.v.) injection of Recombinant Human Coagulation Factor VIII-Fc fusion protein for Injection (FRSW107) at a low dose.
89367905|NCT03747653||Arm 2|Participants will receive a single intravenous (i.v.) injection of ADVATE followed by a single intravenous (i.v.) injection of Recombinant Human Coagulation Factor VIII-Fc fusion protein for Injection (FRSW107) at a high dose.
89367906|NCT03226834|Active Comparator|MUSIC CARE|Listening for 20 min of one of the music style U sequences proposed by the medical device MUSIC CARE
89367907|NCT03226834|Experimental|PERSONAL PLAY-LIST|Listening for 20 min of patient's play-list
89530365|NCT04585685|Experimental|4 week baseline, SC + CPT|Participants in this arm are randomized to a 4-week baseline period with repeated weekly assessment after the initial intake. Following the 4-week baseline, participants are randomly assigned to receive 6 weekly sessions of Self-Compassion Therapy (SC), followed by a 3-week return to baseline period, followed by 12 weekly sessions of Cognitive Processing Therapy (CPT).
89530366|NCT03254173|Active Comparator|Arm A|Mirtazapine 30 mg oral tablets ( Remeron 30 mg oral tablets ) , as half tablet daily , i.e , 15mg daily , before sleep for a duration of 8 weeks
88840083|NCT02588599|Experimental|Erchonia LUNULA|The Erchonia LUNULA emits both red light (635 nm) and blue light (405 nm) to the affected toenail for 12 minutes per treatment for 4 treatments, each treatment one week apart.
88840084|NCT02240628|Active Comparator|Propofol-Lidocaine mixture|All patients from both groups will receive a Synera Patch. Patients in this group will receive Propofol mixed with Lidocaine. Pain will be evaluated during the Propofol injection by both a blinded observer and a blinded anesthesia member.
89367908|NCT03230968|No Intervention|Phase 1 without intervention|In selected heath centers we interviewed all consenting patients older than 15 years. Before the physician consultation, we investigated sociodemographic, epidemiologic, clinical characteristics and reason for seeking health services. Immediately after consultation, we asked the patient his/her diagnoses. We confirmed all diagnoses with treating physicians. If the patient had been diagnosed with respiratory disease, we collected information on prescribed treatment, and classified the type of respiratory disease and comorbidities based on the 10th International Classification of Diseases (ICD-10). Patients were given follow up one month later.
89367909|NCT03230968|Active Comparator|Phase 2 with intervention|"We trained health personnel from the participating health centers on implementation of the proposed model based on the AIRE guidelines previously approved by the AIRE committee of the National Institute for Respiratory Diseases. The AIRE guidelines have been adapted from WHO Practical Approach to Lung Health. Once the model was in action we interviewed all consenting patients older than 15 years as in phase 1."
89367910|NCT03230578||Pharmacists|Actively employed and currently licensed and working in rural counties in New Mexico.
89367911|NCT03230578||Women|Reproductive age, 18-45 years old from rural counties in New Mexico and who are fluent in English.
88840085|NCT02240628|Placebo Comparator|Propofol -Saline mixture|All patients from both groups will receive a Synera Patch. Patienst in this group will receive Propofol mixed with Saline. Pain will be evaluated on Propofol injection by both a blinded observer and a blinded anesthesia member.
88840086|NCT02589067|Experimental|Experimental|Randomized to 15mL 0.12% Chlorhexidine Gluconate oral rinse, to be used twice daily for 60 seconds for 7 days.
88840087|NCT02589067|Placebo Comparator|Placebo|Randomized to 15mL saline placebo oral rinse, to be used twice daily for 60 seconds for 7 days.
88840088|NCT02511379|Experimental|Systane Balance|Propylene Glycol 0.6% eye drops, 1 drop QID (with the last dose of each day at bedtime) in each eye for 90 days
88840089|NCT02207400|Experimental|Experimental Dentifrice|Participants were advised to brush their teeth with experimental dentifrice containing sodium bicarbonate plus 1150 parts per million (ppm) fluoride as sodium fluoride
88840090|NCT02207400|Active Comparator|Reference Dentifrice|Participants were advised to brush their teeth with reference dentifrice containing 1100ppm fluoride as sodium fluoride
88840091|NCT02511535|Experimental|Allergic patients|Allergic patients receive TBE booster vaccination
88840092|NCT02511535|Experimental|Allergic patients with de-sensitization treatment|Allergic patients with de-sensitization treatment receive TBE booster vaccination
88840093|NCT02511535|Active Comparator|Healthy controls|Healthy controls receive TBE booster vaccination
88840094|NCT04341961|Experimental|Pom Juice|The study participants will all be asked to drink pomegranate juice for 2 weeks, and 4 weeks of continued usual diet and avoid pomegranate juice (other than what is given to you), berries (strawberries, blackberries, raspberries (red, black, yellow), cranberries), walnuts, pecans, hazelnuts, pecans, chestnuts, red and white guava, pomegranates, flaxseeds, dark chocolate and cocoa, coffee, tea, rose hip, olives, artichoke, dried herbs and beefsteak tongue mushrooms).
88840095|NCT03545035||Study group|All patients being observed during the study duration.
88840096|NCT03539341|Experimental|PLH-Thailand parenting programme|Trained facilitators and coaches will deliver the programme over eight weekly sessions at the Udon Thani Regional Hospital during the feasibility pilot and the RCT. During the RCT, the 60 parents/primary caregivers in the intervention group will be divided into 4 groups of 15 participants, with each group overseen by 2 facilitators and 1 coach. Core session activities may include discussion about assigned home activities, core parenting principles, illustrated stories, role-plays, and problem solving. Home visits will be conducted by facilitators to those parents/primary caregivers who miss sessions or require additional support, and SMS/LINE messages will be delivered to all participants twice per week with relevant parenting tips and reminders to attend the upcoming session.
88840097|NCT03539341|Other|Control (care as usual)|The control will be an inactive condition of standard care at the time of the intervention. 'Standard care' may include access to Parent Schools in Mother and Child Health clinics at public hospitals, which are provided in some provinces and districts in Thailand. The delivery of services at Parent Schools are guided by the Ministry of Public Health Handbook for Parent Schools, which appear to be open to adaptation at the local level. At Parent Schools, three to five sessions are provided to parents in groups or one-on-one by hospital health personnel.
88840098|NCT02589847|Experimental|RBX2660 Open-label|RBX2660 (microbiota suspension)
88840099|NCT02589847|Other|Historical control antibiotics|Retrospective Historical Control with standard of care
88840100|NCT02512393|Experimental|Active tDCS|This group will receive five daily sessions of 2mA, 20 minutes of Transcranial Direct Current Stimulation (tDCS). The anode electrode will be placed over M1 (C3 or C4 according to the 10-20 system for EEG electrode placement) of the hemisphere contralateral to the affected knee, and the cathode electrode will be placed over the supraorbital region (SO) ipsilateral to the affected knee (M1-SO montage). In addition, the following test will performed: X-Rays, Walking Test, Assessment of Physical Performance, Assessment of Sensitivity to Heat, Assessment of Sensitivity to Pressure, Assessment of Sensitivity to Mechanical Stimulation, Assessment of balance, chair stand, and gait speed, Assessment of conditioned pain modulation, and Blood test.
89179205|NCT02600520|Active Comparator|Rosuvastatin Group|SRP followed by RSV gel LDD
89179206|NCT02600520|Active Comparator|Atorvastatin Group|SRP followed by ATV gel LDD
89367912|NCT03226600|Active Comparator|Connective Tissue Graft|Connective Tissue is harvested from the palate of the subject then placed over the recession defect on the facial of the designated tooth. A coronally advanced flap is raised to cover the connective tissue graft and the recession.
89367913|NCT03226600|Experimental|OrACELL|Allograft Tissue (human dermis) is removed from packing and placed over the recession defect on the facial of the designated tooth. A coronally advanced flap is raised to cover the OrACELL graft and the recession.
89367914|NCT03227614|No Intervention|Control|This arm of participants will not experience the intervention of having a support person of the patient's choice support the patient during their abortion.
88840101|NCT02512393|Sham Comparator|Sham tDCS|This group will receive five daily sessions of 2mA, current for 30 seconds tDCS. The anode electrode will be placed over M1 (C3 or C4 according to the 10-20 system for EEG electrode placement) of the hemisphere contralateral to the affected knee, and the cathode electrode will be placed over the supraorbital region (SO) ipsilateral to the affected knee (M1-SO montage). In addition, the following test will performed: X-Rays, Walking Test, Assessment of Physical Performance, Assessment of Sensitivity to Heat, Assessment of Sensitivity to Pressure, Assessment of Sensitivity to Mechanical Stimulation, Assessment of balance, chair stand, Assessment of conditioned pain modulation, and gait speed and Blood test.
88840102|NCT04743115|Experimental|the Dose Escalation Level|"In the first 3-patient cohort, the dose of BS HH 002.SA will be 0.2 mg/m2/day. Enrollment to the next higher dose cohort will be initiated only if none of the 3 patients exhibits a DLT in the first 28-day cycle. Dose escalation will proceed according to a modified Fibonacci scheme, eg, increments of 100%, 100%, 66%, and 33% and the dose of BS-HH-002.SA will be 0.4, 0.8, 1.3, 1.7 mg/m2/day.~The dose will be administered subcutaneously once daily on Days 1 through 6 and on Days 10 through 15 of a 28 day cycle."
88840103|NCT02592421|Active Comparator|Dapagliflozin|20 subjects will receive dapagliflozin 10mg
88840104|NCT02592421|Placebo Comparator|Placebo|10 subjects will receive placebo
88840105|NCT02512783|Active Comparator|Lidocaine|Administration of 1ml of pre-treatment 1% lidocaine immediately prior to propofol induction.
88840106|NCT02512783|Placebo Comparator|Normal Saline|Administration of 1ml of pre-treatment normal saline immediately prior to propofol induction.
88840107|NCT02513095|Experimental|Ryanodex|Ryanodex (dantrolene sodium) for injectable suspension administered as an IV bolus, in addition to standard of care (SOC) treatment.
88840108|NCT02513095|No Intervention|Standard of Care only (SOC)|Standard of Care (SOC) treatment only, consisting of body cooling and supportive measures implemented immediately.
88840109|NCT02592655|Active Comparator|Pneumatic Tourniquet|All participants randomly allocated to receive all interventions. Pneumatic Tourniquet: The Automatic Tourniquet System (ATS) 1500 by Zimmer (formerly Aspen Labs) is a pneumatic tourniquet that is typically used in surgical settings, and is representative of best outcome under the ideal circumstances of a controlled environment. The 10 cm (4 inch) wide cylindrical cuff was used for all participants.
88840110|NCT02592655|Active Comparator|Windlass Tourniquet|Windlass Tourniquet with a 3.8 cm (1.5 inch) wide strap is representative of the typical use device in civilian prehospital and military combat environments. In accordance with current prehospital guidelines: If distal perfusion is observed after One Windlass Tourniquet is applied then a second windlass tourniquet will be applied immediately proximal to the first windlass tourniquet so that the participant has Two Windlass Tourniquets applied.
88840111|NCT02592655|Experimental|Tourniquet Tape 10 cm|Tourniquet Tape 10 cm wide is a highly elastic transparent occlusive tape that is expected to create sufficient circumferential pressure to occlude arterial blood flow when tightly wrapped around a limb. The tape should be applied in mostly overlapping layers. The final wrap should be applied without tension to prevent the elastic tension from causing the tape to unwind itself.
88840112|NCT02592655|Experimental|Tourniquet Tape 5 cm|Tourniquet Tape 5 cm wide is a highly elastic transparent occlusive tape that is expected to create sufficient circumferential pressure to occlude arterial blood flow when tightly wrapped around a limb. The tape should be applied in mostly overlapping layers. The final wrap should be applied without tension to prevent the elastic tension from causing the tape to unwind itself.
88840113|NCT02513641|Experimental|Moderate Hypoxia|2-weeks of nightly exposure (7-12 hrs per night) to moderate hypoxia (~2,400 meters) using the Hypoxico Altitude Training Systems device.
88840114|NCT02513719||XIENCE PRIME SV Everolimus Eluting Coronary Stent|Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
88840115|NCT02514889|Active Comparator|Calorie-counting|Intervention protocol adapted from Diabetes Prevention Program lifestyle change intervention.
88840116|NCT02514889|Experimental|MyPlate|Intervention protocol adapted from Dietary Approaches to Stop Hypertension dietary pattern.
88840117|NCT03230773|Experimental|Defibrillator - Model 1|Time taken to open, attach and then discharge the defibrillator on a manikin during a simulated cardiac arrest scenario.
88840118|NCT03230773|Experimental|Defibrillator - Model 2|Time taken to open, attach and then discharge the defibrillator on a manikin during a simulated cardiac arrest scenario.
88840119|NCT03230773|Experimental|Defibrillator - Model 3|Time taken to open, attach and then discharge the defibrillator on a manikin during a simulated cardiac arrest scenario.
88840120|NCT03230773|Experimental|Defibrillator - Model 4|Time taken to open, attach and then discharge the defibrillator on a manikin during a simulated cardiac arrest scenario.
88840121|NCT03230773|Experimental|Defibrillator - Model 5|Time taken to open, attach and then discharge the defibrillator on a manikin during a simulated cardiac arrest scenario.
88840122|NCT03230773|Experimental|Defibrillator - Model 6|Time taken to open, attach and then discharge the defibrillator on a manikin during a simulated cardiac arrest scenario.
88840123|NCT02515825||AMBIENCE|CADence System testing followed by coronary angiogram
88840124|NCT02515825||AMBIENCE plus R&R Substudy|CADence System testing for repeatibility and reproducibility (4x by 2 operators) followed by coronary angiogram
88840125|NCT04340869|Experimental|Theobromine|Natural extract from Cocoa
88840126|NCT04340869|Active Comparator|Remin Pro|Fluoride , Hydroxyapatite , and Xylitol
88840127|NCT04340869|Experimental|Combination|Remin Pro and Theobromine
89001913|NCT00219687|Active Comparator|2|When a 911 call is determined to be a cardiac arrest, the caller reporting the event who needs or desires instructions to perform CPR while waiting for EMS to arrive will receive dispatcher-assisted CPR instructions with chest compressions and breaths
88840128|NCT02553109||small unruptured paraclinoid aneurysm|Patients with newly diagnosed, small (less than 5mm) unruptured paraclinoid aneurysms who will visit one of the study centers during the period from January 2015 to February 2017. Patients would be eligible for enrollment if they were 20 years of age or older and had an unruptured paraclinoid aneurysm that is less than 5 mm in the largest dimension. All patients who would visit a study center during the enrollment period and meet these criteria will be asked to join the study. The cohort will consists of patients who agree to participate. Target population of this study is 645 aneurysms.
88840129|NCT02343757|Other|PET/CT vs. PET/MRI|"Patients will be included if presenting with the clinical suspicious of AD, Mild Cognitive Impairment (MCI) or other cognitive impairment to be further determined.~Patients will undergo two doubles scans in two steps with a maximum of 2 week between both: the first step will be one day double scan with FDG imaged by PET-CT and PET-MRI; and the second step will be one day double scan with 18F-florbetapir imaged by PET-CT and PET-MRI at a different timepoints as shown in figure 1."
88840130|NCT02593903|Experimental|Antibiotics Group|Patients randomized to this arm will receive prophylactic oral antibiotics following the surgery and catheter placement (Septra, 3 mg/kg/dose once daily), and will continue the medication for until the day before catheter removal 4-8 days post-operation.
88840131|NCT02593903|No Intervention|No Antibiotics Group|Patients randomized to this arm will receive regular clinical care without prophylactic antibiotics, including catheter placement/removal.
88840132|NCT02596321|Experimental|Mitizax ALK HDM tablet|Standardised allergen extract from the house dust mites Dermatophagoides pteronyssinus and Dermatophagoides farinae developmental unit, dose standard for ALK HDM tablets (12DU)
88840133|NCT02596321|Placebo Comparator|Placebo tablet|Placebo tablet
88840134|NCT02596867|Experimental|open label single arm, drug propanolol|all subjects will receive the experimental drug
88840135|NCT02597101|Placebo Comparator|Placebo|5 mg saxagliptin, once a day, together with optimised (after titration) metformin (500-2000 mg/day) and 60 mg placebo tablet twice daily
88840136|NCT02597101|Experimental|AZD9668|60 mg AZD9668 twice daily in addition to 5 mg saxagliptin, once a day, together with optimised (after titration) metformin (500-2000 mg/day)
89179207|NCT02600520|Placebo Comparator|Placebo group|SRP followed by placebo gel LDD
89179208|NCT02600442||main and unique cohort|
88840137|NCT05578261|Experimental|Active|"All of the participants will accept one session iTBS over right Crus I/II. The total pulses of every session are 1200 pulses (600 pulses with 15 minutes interval)~*iTBS = intermittent theta burst stimulation."
88840138|NCT02599441||Ankle fracture cases|
88840139|NCT02600611|Experimental|iclaprim|iclaprim 80 mg intravenous every 12 hours
88840140|NCT02600611|Active Comparator|vancomycin|vancomycin 15 mg/kg intravenous every 12, 24 or 48 hours based on creatinine clearance
88840141|NCT02600767|Other|Artemether-Lumefantrine|Three days of standard treatment. This is a standard combination therapy for the treatment of P. falciparum malaria.
88840142|NCT04743193||sevoflurane 8 %|In the initial phase, after reaching 1 (MAK) level with 1lt / min fresh gas flow and 8% sevoflurane concentration, anesthesia maintenance will be continued with 0.5 lt / min fresh gas flow and 2 -4% sevoflurane concentration with the target of 1 MAC.
88840143|NCT04743193||sevoflurane 2.5 %|In the initial phase, after reaching 1 MAK level with 4 lt / min fresh gas flow and 2.5% sevoflurane concentration, anesthesia maintenance will be continued with 0.5 lt / min fresh gas flow and 2 -4% sevoflurane concentration with the target of 1 MAC.
88840144|NCT05371171|Experimental|skin graft|
88840145|NCT05371171|Placebo Comparator|no skin graft|
88840146|NCT05366491|Active Comparator|bronchial asthma patients|patients diagnosed with bronchial asthma
88840147|NCT05366491|Active Comparator|healthy controls|healthy subjects with age and sex matched to bronchial asthma patients
88840148|NCT05362591|Experimental|resin bonded bridge with no preparation|resin bonded bridge without enamel preparation
88840149|NCT05362591|Active Comparator|resin bonded bridge with minimal preparation|resin bonded bridge with minimal preparation on tooth enamel
88840150|NCT02608177|Experimental|Linagliptin/Glipizide|Arm receives 4 weeks of study drug linagliptin followed by 4 weeks of glipizide
88840151|NCT02608177|Experimental|Glipizide/Linagliptin|Arm receives 4 weeks of study drug glipizide followed by 4 weeks linagliptin
88840152|NCT05555095||OSF HealthCare|Subjects from OSF HealthCare
88840153|NCT05555095||Federally Qualified Health Center (FQHC) - 1|Subjects from Eagle View Community Health System enrolled in MIC Program
88840154|NCT05555095||Federally Qualified Health Center (FQHC) - 2|Subjects from Chestnut Health System Inc. enrolled in MIC Program
88840155|NCT05555095||Federally Qualified Health Center (FQHC) - 3|Subjects from Heartland Community Health System enrolled in MIC Program
88840156|NCT05555095||Federally Qualified Health Center (FQHC) - 4|Subjects from Aunt Martha's enrolled in MIC Program
88840157|NCT02608489|Active Comparator|Diqufosol|3% Diquafosol Tetrasodium Ophthalmic Solution
88840158|NCT02608489|Placebo Comparator|Hyaluronate|0.1% Sodium Hyaluronate Ophthalmic Solution
88840159|NCT02609113|Active Comparator|Strong Magnetic Wristband|Magnetic wristband of 1,795 Gauss strength
88840160|NCT02609113|Placebo Comparator|Weaker Magnetic Wristband|Magnetic wristband of 5 Gauss strength.
88840161|NCT02611765|Experimental|Enhanced therapy|Benzathine penicillin G intramuscular 7.2 million units Three doses of 2.4 million units of intramuscular benzathine penicillin G administered weekly (a total of 7.2 million units)
88840162|NCT02611765|Active Comparator|Standard therapy|Benzathine penicillin G intramuscular 2.4 million units A single intramuscular injection of 2.4 million units of benzathine penicillin G
89179209|NCT00760266|Experimental|Aliskiren/HCTZ 300/25 mg|
89530367|NCT03254173|Placebo Comparator|Arm B|Placebo oral tablets , as half tablet daily before sleep for a duration of 8 weeks
89179210|NCT00760266|Active Comparator|HCTZ 25 mg|
89179211|NCT00753714|Experimental|A|Gemcitabine administered intravenously at 1200 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle up to plus Vandetanib 100 mg orally once-daily, from Day 1.Patients will receive gemcitabine for up to a maximum of 6 cycles, after which period patients should continue on daily oral dosing with vandetanib alone until progression. Once a patient has met the study criteria for disease progression on vandetanib/gemcitabine or placebo/gemcitabine, randomised treatment must be permanently discontinued.
89367915|NCT03227614|Experimental|Support Person Intervention|This arm of participants will experience the intervention of having a support person of the patient's choice support them during their abortion procedure.
88840163|NCT02612857|Placebo Comparator|Placebo|normal saline subcutaneous injections once a week for 24 weeks.
88840164|NCT02612857|Experimental|IMO-8400 Dose Group 1|IMO-8400 Dose Group 1 subcutaneous injections once a week for 24 weeks.
88840165|NCT02612857|Experimental|IMO-8400 Dose Group 2|IMO-8400 Dose Group 2 subcutaneous injections once a week for 24 weeks.
88840166|NCT05553769|Experimental|10 week training, 10 week detraining, 10 week retraining|Participants (healthy untrained men and women, age 18-40) will conduct 10-week RT intervention and a 10-week DT period and the exact same 10-week RT intervention again. RT consists of two training sessions per week of total body workouts.
88840167|NCT05553769|Experimental|10 week non-training, 20 week continuous training|Participants (healthy untrained men and women, age 18-40) start with a 10-week non-training period and then continues with a 20-week RT intervention. RT consists of two training sessions per week of total body workouts.
89367916|NCT03220984|Experimental|Immunotherapy group|All enrolled patients receive a total of 12 times of Immuncell-LC therapy
89367917|NCT03220594||Hypogastric artery ligation (HAL)|Patients who underwent only hypogastric artery ligation performed during the delivery of their babies. Six months after the operation they will evaluated for their ovarian reserve via hormones and astral follicle count (AFC)
89367918|NCT03220594||HAL and hysterectomy|Patients who underwent both hypogastric artery ligation and hysterectomy performed during the delivery of their babies. Six months after the operation they will evaluated for their ovarian reserve via hormones and astral follicle count (AFC)
89367919|NCT03220594||Postpartum|Postpartum control group constituted of patients delivered baby without any complication and evaluated 6 months later.
89367920|NCT03220828|No Intervention|Control|The control group will be provided standard of care, which is no use of technologies.
89367921|NCT03220828|Experimental|Intervention Group VR|Interventional arm will use technology based distractions (Virtual Reality)
89367922|NCT03220906||Arterial line|Children undergoing surgical procedure with planned arterial cannula placement.
89367923|NCT03226444|Experimental|0.005% Lacripep|0.005% Lacripep ophthalmic solution
88840168|NCT05550571|Experimental|Patients treated with the device|
88840169|NCT02615743|Experimental|Intervention Group|Caregivers of intervention arm participants will receive daily text message reminders about asthma controller medication use, as well as an electronic monitoring device to track the participant's medication usage for 60 days following hospital discharge. At the end of 30 days, participants will be able to opt out of daily text messages if they choose. All caregivers of participants will also complete a 30-minute survey at the time of enrollment and 2 brief telephone followups at 30 and 60 days.
88840170|NCT02615743|Other|Control Group|Caregivers of control arm participants will receive an electronic monitoring device to track their medication usage for 60 days following hospital discharge. At 30 days, caregivers of participants will be able to opt in to receive daily text message reminders about asthma medication use. Caregivers of all participants will also complete a 30-minute survey at the time of enrollment and 2 brief telephone followups at 30 and 60 days.
88840171|NCT02616523|Active Comparator|dexmedetomidine|The investigators will compare fentanyl consumption in participants undergoing laparoscopic intestine resection intra and postoperatively. Dexmedetomidine group will receive dexmedetomidine infusion 0,5 mcg/kg/h beside boluses of fentanyl.
89367924|NCT03226444|Experimental|0.01% Lacripep|0.01% Lacripep ophthalmic solution
89367925|NCT03226444|Placebo Comparator|placebo|placebo solution
89367926|NCT04358081|Experimental|Arm 1: hydroxychloroquine + aithromycin placebo|Hydroxychloroquine 600mg o.d. as loading dose (Day 1) +followed by 200mg t.i.d was initiated within 8-12 hours of the loading dose (not to exceed 12 hours) Azithromycin (AZT) placebo o.d.
89367927|NCT04358081|Experimental|Arm 2: hydroxychloroquine + azithromycin|Hydroxychloroquine 600 mg o.d. as a loading dose (Day 1) followed by 200 mg t.i.d. was initiated within 8-12 hours of the loading dose (not to exceed 12 hours) Azithromycin: 500 mg as a loading dose (Day 1) followed by 250 mg o.d. Day 2 - Day 5
89367928|NCT04358081|Placebo Comparator|Arm 3: hydroxychloroquine placebo + azithromycin placebo|Hydroxychloroquine placebo o.d. (day 1) followed by hydroxychloroquine placebo t.i.d Azythromycin placebo o.d.
89367929|NCT03220672|Experimental|Expertimental|The sample will receive a tailored assessment and educational intervention on Motor Control of the Pelvic Floor Muscle
89367930|NCT03230500|Experimental|Computer guided immediate implant placement|For the test group, the computer aided surgical guide will be used for implant drilling and placement.
89367931|NCT03230500|Active Comparator|Free hand immediate implant placement|For the control group, free hand implant drilling and placement will be performed guided by the extraction socket walls.
89367932|NCT03222934||Nasal disorders|patients with nasal disorders with free sphenoid sinus
89367933|NCT02452138||Low EAA|Endotoxin Activity Assay [EAA] level < 0.40 EAA units
89367934|NCT02452138||Intermediate EAA|Endotoxin Activity Assay [EAA] level between 0.40-0.59 EAA units
89367935|NCT02452138||High EAA|Endotoxin Activity Assay [EAA] level >= 0.60 EAA units
89367936|NCT03230344|Active Comparator|Group 1|Periodontal treatment initiated with scaling and root planing along with root canal treatment and followed by open flap debridement after 6 weeks.(Open flap debridement simultaneously with root canal treatment )
89367937|NCT03230344|Experimental|Group 2|Periodontal treatment initiated with scaling and root planing followed by open flap debridement after 6 weeks. Endodontic treatment will be initiated after 3 months of periodontal surgery.(open flap debridement and delayed root canal treatment )
89367938|NCT03230422|Experimental|normal airway|Time (normal airway) using the novel King Vision™ Pediatric aBlade (KV) video laryngoscope, C-MAC™ D-blade Ped (DP), C-MAC™ Miller Blade (MB), shortened as VL, compared with conventional direct laryngoscopy (DL)
89367939|NCT03230422|Experimental|difficult airway|Time (difficult airway) using the novel King Vision™ Pediatric aBlade (KV) video laryngoscope, C-MAC™ D-blade Ped (DP), C-MAC™ Miller Blade (MB), shortened as VL, compared with conventional direct laryngoscopy (DL)
89530368|NCT02516735|Experimental|Group 1|I-scan with magnification targeted biopsies for gastric intestinal metapalsia.
89367940|NCT04355663|Experimental|Motor program activating therapy|MPAT is method developed and verified by our team. In this therapy, patients are corrected into a postural position where the joints are functionally centered. Somatosensory (manual and verbal) stimuli are then applied to activate motor programs in the brain, which then lead to the co-contraction of the patient's whole body when laying, sitting, standing up or moving forward. Activated programs are repeated under various conditions and in different situations and environments to teach the patients to automatically use the acquired motor skills in daily life. Therapy was realized within the ambulatory area of the Department of Neurology at Kralovske Vinohrady University Hospital in Prague.
89367941|NCT04355663|Experimental|Vojta's reflex locomotion|VRL is a standard approach for patients with MS in the Czech Republic. In the therapy, global patterns of the reflex locomotion are activated by stimulation of specific zones, with the individual placed in a precisely determined initial position (supine, prone and side laying, low kneeling position). These movement patterns have the qualities of the forward movement (locomotion) and the movement responses are precisely defined. Reflex locomotion (reflex turning and reflex creeping) is used in therapy to activate involuntarily responses of muscle function, which are necessary for spontaneous movements. Therapy was realized at the Department of Rehabilitation and Sport Medicine at Motol University Hospital.
89367942|NCT04355663|Experimental|Functional electric stimulation|Functional electric stimulation in the postural corrected position was developed at our workplace. Participants first underwent individual two-hour session consisting of postural correction using MPAT and the device (The WalkAide® System, Innovative Neurotronics Inc., 4999 Aircenter Circle, Suite 103 Reno, NV 89502, USA) programming (28). Patients received the device to use as much as they felt they were able to during their normal daily living activities thereafter.
89367943|NCT03220360|Experimental|indirect pulp capping group|Sixty children with deep caries of deciduous teeth underwent indirect pulp capping, and they were selected and randomized into four groups according to pulp capping agents: MTA group, calcium hydroxide group, Biodentine group and TheraCal group.
89367944|NCT03220360|Experimental|direct pulp capping group|Sixty children with deep caries of deciduous teeth underwent direct pulp capping, and they were selected and randomized into four groups according to pulp capping agents: MTA group, calcium hydroxide group, Biodentine group and TheraCal group.
89367945|NCT03220360|Experimental|vital pulpotomy group|Forty-five children with deep caries of deciduous teeth underwent vital pulpotomy, and they were selected and randomized into four groups according to pulp capping agents: MTA group, calcium hydroxide group, Biodentine group and TheraCal group.
89367946|NCT03230188||Severe Asthmatics|Individuals with severe asthma that are already enrolled in the University of Wisconsin Severe Asthma Research Program III study will fill out asthma and psychological questionnaires (non-diagnostic), will undergo Cognitive Function Testing (non-diagnostic), and will undergo a simulated and actual functional Magnetic Resonance Imaging (research grade) scan.
89367947|NCT03751787|Experimental|cranial osteopathy|The group will receive treatment with osteopathic cranial osteopathy
89189260|NCT00709488|Experimental|Litx™ BPH Therapy|
89367948|NCT03751787|Placebo Comparator|comfort massage|The group will benefit from a placebo manipulation by an osteopathic student who has not yet been trained in cranial osteopathy.
89367949|NCT03220438|Active Comparator|TMS|rTMS
89367950|NCT03220438|Sham Comparator|Sham TMS|A sham coil will be used. This condition controls for the auditory artifacts induced by rTMS.
89367951|NCT03750383|Experimental|EDP-938 and cyclosporine interaction (Part 1)|
89367952|NCT03750383|Experimental|EDP-938 and prednisone interaction (Part 2)|
89367953|NCT03220516|Experimental|single-use digital ureteroscope|Participants under this arm will undergo retrograde intrarenal surgery (RIRS) procedure under the single use digital ureteroscope.
89367954|NCT03220516|Experimental|reusable fiberoptic ureteroscopes|Participants under this arm will undergo the RIRS procedure under the reusable fiberoptic ureteroscope
88840172|NCT02616523|Active Comparator|lidocaine|Lidocaine group will receive lidocaine infusion 1,5 mg/kg/h during the laparoscopic intestine resection.
88840173|NCT02616523|Placebo Comparator|placebo|The placebo group will receive intravenous infusion of normal saline only.
88840174|NCT05528419|Experimental|Sacubitril valsartan|
89367955|NCT03220516|Experimental|reusable digital flexible ureteroscopes|Participants under this arm will undergo the RIRS procedure under the reusable digital flexible ureteroscope.
89189261|NCT00714246|Experimental|Phase I - Dose Level 1|Carboplatin AUC 5 mg/ml/min (Day 1) Docetaxel 60 mg/m2 (Day 1) Bortezomib 0.7 mg/m2 (Day 1,4,8,11)
89367956|NCT03226210|Experimental|NovoRapid group (group Asp)|
89367957|NCT03226210|Experimental|Prandilin group (group Lis)|
89367958|NCT03750305|Active Comparator|psychoeducation/TAU|TAU consists of psycho-education for a period of 12 weeks, consisting of 6 2-hour sessions. Psycho-education is offered in groups,
89367959|NCT03750305|Experimental|imCT intervention|For a period of 12 weeks, 12 1-hour sessions of imagery-focused Cognitive Therapy delivered weekly by a trained therapists, divided in an in depth identification (4 sessions) of images followed by imagery interventions, (6 sessions) and a consolidation phase (2 sessions).
88840175|NCT05528419|Active Comparator|Valsartan|
89367960|NCT03226054|Other|PPI Taper|PPI Taper using Lifestyle Modifications, per study protocol
89367961|NCT03750149|Experimental|Ophthalmologic Disease|Patients with glaucoma, AMD, diabetic maculopathy, epiretinal membranes, and healthy patients will undergo a reading analysis using the EyeTracker
89367962|NCT03225976|Experimental|Infrared LED group (G-I)|The Light-Emitting Diode Device with wavelength of 904nm will be applied throughout the quadriceps femoralis extension bilaterally.
89367963|NCT03225976|Experimental|Red LED group (G-V)|The Light-Emitting Diode Device with a wavelength of 620nm will be applied throughout the quadriceps femoralis extension bilaterally.
88840176|NCT04340713|Experimental|Information support group|The experimental group was given information support program intervention on the basis of routine information communication.
88840177|NCT04340713|No Intervention|Routine care group|The control group was given routine information communication.
89367964|NCT03225976|Sham Comparator|Sham Group (G-S)|The Sham Light-Emitting Diode Device will be positioned throughout the quadriceps femoral muscle extension, however, there will be no light emission.
89367965|NCT03225976|Experimental|Infrared plus Red LED group (G-IV)|The Light-Emitting Diode Device with a wavelength of 620nm plus 904nm will be applied throughout the quadriceps femoralis extension bilaterally.
89367966|NCT03225898|Experimental|Resistance Exercise with Blood flow restriction|Subjects will perform 4 sets with 30, 15, 15, 15 repetitions at 30% 1RM.
89367967|NCT03225898|Active Comparator|High-intensity resistance exercise|Subjects will perform 4 sets of 8 repetitions at 70% 1RM.
89367968|NCT03229954|Experimental|IV iron (Monofer) group|Iron isomaltoside(Monofer) will be injected intravenously and injection dose will be calculated using Ganzoni formula.
89367969|NCT03229954|Active Comparator|Oral iron group|Ferrous sulfate(Feroba-YOU) 160mg/day for 12 weeks will be taken per oral.
89367970|NCT03230110||Chronic Hypretension in Pregnancy|Pregnant subjects between 10-20 weeks gestation with chronic hypertension (on medication or hypertensive blood pressures documented at 2 clinic visits)
89367971|NCT03230110||Normotensive in Pregnancy|Pregnant subjects between 10-20 weeks gestation with normal blood pressure, and not on any treatment for chronic hypertension and no history of chronic hypertension, and matched for body mass index (+/- 3 kg/m2) with the chronic hypertension group.
89367972|NCT03226132|Experimental|Brief Behavioral Treatment for Insomnia|Brief Behavioral Treatment for Insomnia
89367973|NCT03226132|Active Comparator|Repeated Contact|Repeated Contact
89367974|NCT03220126|Experimental|LY3074828 - Treatment 1|Single intravenous (IV) dose of LY3074828
89367975|NCT03220126|Experimental|LY900021 - Treatment 2|Single subcutaneous (SC) dose of LY900021 (LY3074828 coadministered with LY9999QS)
89367976|NCT03220126|Experimental|LY900021 - Treatment 3|Single SC dose of LY900021 (LY3074828 coadministered with LY9999QS)
88840178|NCT04741867|Experimental|receiving health education|
88840179|NCT04741867|Experimental|Level of compliance|
88840180|NCT04741867|Experimental|Coping with stress|
88840181|NCT04340791|No Intervention|Default proportion & no labelling|"No intervention:~Default proportion condition (33% lower energy density items - 67% higher energy density items). Lower energy density items will be defined as lower ED ≤ median of ED distribution within a food category.~No labelling."
88840182|NCT04340791|Experimental|Default proportion & labelling|"When energy density of a food item ≤ median of energy density distribution within a food category, healthier choice badges will be added to the food item pictures on the online supermarket. Instructions will introduce the badges to the participants as In the online supermarket, the green tick allows you to see which products (e.g. muesli) in each product category (e.g. cereals) are healthier choices with fewer calories per gram than most other products in the same category."
88840183|NCT04340791|Experimental|Increased proportion & no labelling|The proportion of lower energy density items vs. higher energy density items will be reversed (67% lower - 33% higher) relative to the default proportion condition (33% lower - 67% higher). Lower energy density items will be defined as lower ED ≤ median of ED distribution within a food category.
89189262|NCT00714246|Experimental|Phase I - Dose Level 2A|Carboplatin AUC 6 mg/ml/min (Day 1) Docetaxel 60 mg/m2 (Day 1) Bortezomib 0.7 mg/m2 (Day 1,4,8,11)
89189263|NCT00714246|Experimental|Phase I - Dose Level 2B|Carboplatin AUC 6 mg/ml/min (Day 1) Docetaxel 60 mg/m2 (Day 1) Bortezomib 1.0 mg/m2 (Day 1,4,8,11)
89367977|NCT03220126|Experimental|LY900021 - Treatment 4|Single SC dose of LY900021 (LY3074828 coadministered with LY9999QS)
89367978|NCT02452684||Participants with insomnia|Participants with insomnia who will receive eszopiclone, per approved label.
89367979|NCT03119428|Experimental|OMP-313M32|Intravenous (in the vein) infusions of OMP-313M32 as a single agent
89367980|NCT03119428|Experimental|OMP-313M32 and Nivolumab|Intravenous (in the vein) infusions of OMP-313M32 in combination with nivolumab
89367981|NCT03119818|Experimental|Patients suffering from ESRD treated by chronic hemodialysis|Patients aged from 18 to 80 years old, suffering from ESRD, treated by chronic hemodialysis since at least 6 months and whose phosphatemia at the beginning of HD sessions ranged from 1.5 to 3 mmol/L. Phosphorus (31P) magnetic resonance spectroscopy will be performed in these patients during hemodialysis in order to measure intracellular phosphate and ATP concentrations and intracellular pH evolution during hemodialysis.
89367982|NCT03229642|Experimental|Active rTMS treatment|The rTMS parameters were as follows: 15Hz frequency, pulse intensity 100% of the rMT, 60 pulses per train, inter train pause of 26 sec, 40 stimulation trains, and 2400 total pulses for a total duration of 20 min. The patients received one rTMS session per day during the first five days of treatment, and then twice a week for the following three weeks, for a total of 11 rTMS sessions.
89367983|NCT03229642|Sham Comparator|Sham rTMS treatment|The rTMS parameters were as follows: 15Hz frequency, pulse intensity 100% of the rMT, 60 pulses per train, inter train pause of 26 sec, 40 stimulation trains, and 2400 total pulses for a total duration of 20 min, with a figure-of-eight sham coil. The patients received one rTMS session per day during the first five days of treatment, and then twice a week for the following three weeks, for a total of 11 rTMS sessions.
89367984|NCT03119506||Long Recess Duration/Before Lunch|
89367985|NCT03119506||Short Recess Duration/Before Lunch|
89367986|NCT03119506||Long Recess Duration/After Lunch|
89367987|NCT03119506||Short Recess Duration/After Lunch|
89367988|NCT03219814|Experimental|Cognitive Dissonance Intervention|"Participants in the Cognitive Dissonance condition will complete tasks from Becker et al.'s (2005) 2-session adaptation of the Body Project. In the intervention groups, participants will be asked to consider the costs of pursuing the thin ideal in verbal, written, and behavioural exercises. Participants will be asked to assume the role as a body activist, and will be given several opportunities to vocalize opposition to the social forces that drive the thin ideal throughout the sessions.~The first session will involve exercises and discussions about the thin ideal and the costs associated with pursuing it. They will be given a homework assignment to complete at home over the next week. In the following week's session the participants will engage in a role-play exercise, as well as continuing the discussion on the costs of pursuing the thin ideal."
88840184|NCT04340791|Experimental|Increased proportion & labelling|"The proportion of lower energy density items vs. higher energy density items will be reversed (67% lower - 33% higher) relative to the default proportion condition (33% lower - 67% higher). Lower energy density items will be defined as lower ED ≤ median of ED distribution within a food category.~When energy density of a food item ≤ median of energy density distribution within a food category, healthier choice badges will be added to the food item pictures on the online supermarket. Instructions will introduce the badges to the participants as In the online supermarket, the green tick allows you to see which products (e.g. muesli) in each product category (e.g. cereals) are healthier choices with fewer calories per gram than most other products in the same category."
88840185|NCT02974465|Experimental|Experimental Group|protocol of Biofeedback Electromyography plus conventional physical therapy treatment
88840186|NCT02974465|Sham Comparator|Control Group|consisted of Sham- Biofeedback Electromyography plus conventional physical therapy treatment
88840187|NCT05483413|Experimental|Progressive Relaxation Exercises|Progressive relaxation exercises will be applied to this group for 8 weeks.
88840188|NCT05483413|No Intervention|Standard of Care|This group will continue their routine coping habits against sleep and fatigue problems in the postmenopausal period for 8 weeks.
89399189|NCT03624075|Placebo Comparator|Placebo group|The placebo group will simultaneously receive two techniques of applying tensionless KT. The first technique that will be applied is inverted 'Y' on the rectus femoris. In the second technique to be applied, the tape body will be divided lengthwise into four narrow strips. The two pieces intersect the front of the knee. For this application, the volunteer will be positioned in the dorsal position without knee flexion and the tape will be applied by a trained researcher. In the case of bilateral OA, in both techniques of application, the most affected member based on the NPRS score will be the one that will undergo the intervention. All volunteers will remain with the tape for 72 hours.
88840189|NCT05480293|Experimental|SCT510A|SCT510A(1.25mg), Vitreous injection, injection once every 4 weeks
88840190|NCT05480293|Active Comparator|Ranibizumab|Ranibizumab(0.5mg), Vitreous injection, injection once every 4 weeks
88840191|NCT05731609|Experimental|Resistance Intensive Personal Training (RIPT)|All participants will participate in this arm involving 12 weeks of training 2-3 days/week in a group setting with each session involving 1:1 support for each participant's power training.
88840192|NCT00422305||1-Healthy Infants|"Group 1: The investigators will recruit 80 healthy infants born at > 37 weeks gestation, and between 2 and 36 months of age. Infants will be excluded for any of the following reasons:~Congenital cardio-respiratory disease~Hospitalization for respiratory illness~Treatment with asthma medications~Small for gestational age at birth"
88840193|NCT00422305||2-Healthy Infants computerized Tomography|"Group 2: The investigators recruited 4 infants born at > 37 weeks gestation and they were evaluated between 2 and 36 months of age when scheduled for high resolution computed tomography (HRCT) imaging for non-respiratory medical problems. Subjects were enrolled and HRCT of the chest were obtained. Infants were excluded for the following reasons:~Congenital cardio-respiratory disease~Hospitalization for respiratory illness~Treatment with asthma medications"
88840194|NCT00422305||3-Premature Infants|"Group 3: The investigators have recruited 45 infants born prematurely at 23-35 weeks gestation. Subjects were evaluated at corrected age at between 2 and 24 months. The subjects had no oxygen requirements, and were clinically stable outpatients when evaluated. Infants were excluded for any of the following reasons:~Congenital cardio-respiratory disease~Severe developmental delay"
88840195|NCT05461417||D-SAD group|Patients equipped with Panthera D-SAD MAO
88840196|NCT05731531|Other|Group A|Group of 50 patients who undergo BIG placement
88840197|NCT05731531|Other|Group B|Group of 50 patients who undergo endoscopic sleeve gastroplasty
88840198|NCT05731531|Other|Group C|Group of 50 patients who undergo Surgical sleeve gastrectomy
88840199|NCT05731531|Other|Group D|Group of 50 patients who undergo RYGB
88840200|NCT05731531|Other|Group E|Group of 50 healthy subjects
88840201|NCT00365677|Experimental|Zyoptix Tissue Saving Aspheric|The Bausch & Lomb Zyoptix Tissue Saving Aspheric algorithm is used for treatment with LASIK for the correction of myopia and myopic astigmatism.
88840202|NCT00365677|Active Comparator|Zyoptix Tissue Saving|The Bausch & Lomb Zyoptix Tissue Saving algorithm is used for treatment with LASIK for the correction of myopia and myopic astigmatism.
88840203|NCT05731375||Study population|Patients with large B-cell lymphoma or T-cell lymphoma scheduled for 6 full-dose cycles of 1st line immunochemotherapy with (R-)CHOP
88840204|NCT00365833||Recipients of Kidney Transplant|Patients Transplanted with Live or Deceased Donor's Kidney. Standard of Care treatment pre- and post-transplant.
88840205|NCT00364741|Active Comparator|A|Fraction of inspired oxygen (FiO2) = 0.30
88840206|NCT00364741|Active Comparator|B|FiO2 = 0.80
88840207|NCT04743817|Experimental|OtoSet - Ear Cleaning Sytem|
88840208|NCT05731297||women victims of CRSV|"Inclusion criteria: Women victims of CRSV living in the places of enrolment in RDC, aged over 18 years and giving their consent to participate to this study.~Exclusion criteria: Pregnant women and women under 18 years old."
88840209|NCT05731297||women without a history of CRSV|"Inclusion criteria: women without a history of CRSV living in the places of enrolment in RDC, aged over 18 years and giving their consent to participate to this study.~Exclusion criteria: Pregnant women and women under 18 years old."
89189264|NCT00714246|Experimental|Phase I - Dose Level 3|Carboplatin AUC 6 mg/ml/min (Day 1) Docetaxel 60 mg/m2 (Day 1) Bortezomib 1.0 mg/m2 (Day 1,4,8,11)
88840210|NCT05731219|Experimental|B7-H3 target, CAR gene modified gdT cell injection|UTAA06 injection After the subjects who signed the informed consent form were screened by the inclusion/exclusion criteria, the qualified subjects will enter 1.0 in order of priority × 10^8，3.0 × 10^8 and 6.0 × 10^8 CAR gdT groups were administered once.
88840211|NCT05730985|Experimental|Intevention group|Experimental formula (Miotrof®) to take 1 sachet per day for 4 months
88840212|NCT05730985|Placebo Comparator|Placebo group|Placebo formula to take 1 sachet per day for 4 months
89367989|NCT03219814|Active Comparator|Mediapsychoeducation Intervention|"Participants in the Mediapsychoeducation condition will complete two sessions of tasks as outlined for Becker et al.'s (2005) media psychoeducation group, which includes no cognitive dissonance tasks. The first session will have the participants discuss the thin ideal and the media's influence on it. They will then watch a 35-minute psychoeducational video on the influence that advertisements have on body image and perpetuating the thin ideal. They will be assigned homework to complete at home during the week between the sessions. The second session will include a discussion surrounding the attainability to the thin ideal, and this discussion will also be expanded to include all forms of media. Participants will then be asked to consider and discuss differences between media images and themselves, as well as whether achieving this ideal is realistic, and the costs in trying to achieve this thin ideal. They will then watch a 20-minute video on eating disorders."
89367990|NCT03219814|No Intervention|Waitlist Control|The participants in the Waitlist condition will be given the Cognitive Dissonance intervention between 5 and 6 weeks after their second assessment-only session (the cognitive dissonance intervention will be offered and scheduled 1 week after their 1-month online follow-up questionnaire).
89367991|NCT03219814|No Intervention|Body-Satisfied Assessment Only Condition|Body-satisfied women will be recruited to engage in the assessment portion of the study only (i.e. they will be given NO intervention but are serving as a control in terms of eye-tracking assessment). Body-satisfied women will be assessed to compare their attention to weight words with body-dissatisfied women's attention to weight words. This comparison will be done with an aim of replicating the findings of Tobin (2015), to ensure that for this particular sample, body-dissatisfied women exhibit stronger attentional biases for weight words than body-satisfied women. Attention to weight words in body-satisfied women will be assessed at two time points, one week apart, to ensure there are no spurious changes in attention in body satisfied women.
89367992|NCT04345367|Experimental|Abrocitinib 200 mg plus placebo injection|Abrocitinib 200 mg daily through Week 26, plus placebo injections every other week through Week 24
89367993|NCT04345367|Active Comparator|Dupilumab 300 mg plus placebo tablets|Dupilumab 300 mg every other week (2 injections on Day 1) through Week 24, plus placebo tablets daily through Week 26
89367994|NCT03229720|Active Comparator|Audio-Visual Distraction Group|In this arm, the patient will be introduced to the audio-visual distraction device and given some instruction on how to use it and rules while using it. other than that, the dental procedure is as same as the other arm group.
89367995|NCT03229720|No Intervention|Normal Dental Environment Group|Normal Dental Environment without any distractions.
89367996|NCT03225742||urinary catheterization time; one day|the patient urinary catheterization after surgery; one day
89367997|NCT03225742||urinary catheterization time; two day|the patient urinary catheterization after surgery; two day
89367998|NCT02452606|Experimental|Stalevo®|Participants who are assigned to Stalevo Arm will take Stalevo® at bedtime for 3 month.
89367999|NCT03225352|Experimental|Sequence 1: starting with BAYE4465 500 mg|Participants will participant four treatment periods with four different treatments. Treatment assignment adhere to Williams design
89368000|NCT03225352|Experimental|Sequence 2: starting with BAYE4465 1000 mg|Participants will participant four treatment periods with four different treatments. Treatment assignment adhere to Williams design
89368001|NCT03225352|Experimental|Sequence 3: starting with Nurofen|Participants will participant four treatment periods with four different treatments. Treatment assignment adhere to Williams design
89368002|NCT03225352|Experimental|Sequence 4: starting with Dolormin Extra|Participants will participant four treatment periods with four different treatments. Treatment assignment adhere to Williams design
89368003|NCT03217240||Congenital Heart Disease|Tetralogy of Fallot Repair/Pulmonary Hypertension Cardiac Magnetic Resonance - MRI Cardiopulmonary Exercise Test Blood Sampling for all participants
88840213|NCT04541875||Cystic fibrosis|"Patients aged 18+ and diagnosed with cystic fibrosis.~Patients will answer the MAR-Scale once every three months for a year."
88840214|NCT04541875||Hemophilia A or B|"Patients aged 18+ and diagnosed with hemophilia A or B.~Patients will answer the MAR-Scale once every three months for a year."
88840215|NCT04541875||Idiopathic pulmonary fibrosis|"Patients aged 18+ and diagnosed with idiopathic pulmonary fibrosis.~Patients will answer the MAR-Scale once every three months for a year."
88840216|NCT04541875||Myasthenia gravis|"Patients aged 18+ and diagnosed with myasthenia gravis.~Patients will answer the MAR-Scale once every three months for a year."
88840217|NCT04541875||Sickle cell disease|"Patients aged 18+ and diagnosed with sickle cell disease.~Patients will answer the MAR-Scale once every three months for a year."
88840218|NCT04340401|Experimental|TNT+SHR1210|"Patients with high-risk locally advanced rectal cancer will receive chemotherapy and SHR-1210 before chemoradiaton, after chemoradiaton, patient will receive consolidation chemotherapy. This arm is called Total Neoadjuvant Treatment (TNT) plus SHR-1210. The neoadjuvant chemotherapy regimen is designed as 3 cycles of CapeOX ( Capecitabine + Oxaliplatin ) plus SHR-1210 over a period of approximately 8 weeks. Tumor response will be evaluated after chemotherapy. Then patients will undergo 22f-IMRT (Intensity modulated radiotherapy) with capecitabine. Patients will receive two more cycles of consolidation CapeOX if tolerable when there was no progressed disease in induction CapeOX.~Finally, patients will receive TME (Total mesorectal excision) following TNT+SHR1210 if no metastasis occurs."
88840219|NCT05726149|Experimental|Real UHCDS a-TDCS + Therapeutic Exercise|Real unihemispheric concurrent dual-site anodal transcranial direct current stimulation combined with therapeutic exercise
88840220|NCT05726149|Sham Comparator|Sham UHCDS a-TDCS + Therapeutic Exercise|Sham unihemispheric concurrent dual-site anodal transcranial direct current stimulation combined with therapeutic exercise
88840221|NCT05726149|Active Comparator|Therapeutic Exercise|Therapeutic exercise.
88840222|NCT04340635||Multi-center data collection|Without intervention
89368004|NCT03217240||Healthy Volunteer|Cardiac Magnetic Resonance - MRI Cardiopulmonary Exercise Test Blood Sampling for all participants
89368005|NCT02451280|Experimental|Unilateral Hybrid Intervention Group|Participants will receive 6 weeks of bilateral RT training using the BMT and UAT training in each session.
88840223|NCT04143607|Experimental|ASK120067+ placebo Gefitinib|ASK120067 (80 mg orally, twice daily) plus placebo Gefitinib (250 mg orally, once daily), in accordance with the randomization schedule.
88840224|NCT04143607|Active Comparator|Gefitinib + placebo ASK120067|Gefitinib (250 mg orally, once daily) plus placebo ASK120067 (80 mg orally, twice daily), in accordance with the randomization schedule.
89368006|NCT02451280|Experimental|Bilateral Hybrid Intervention Group|Participants will receive 6 weeks of bilateral RT training using the BMT and BAT training in each session.
89368007|NCT02451280|Experimental|Robot-Assisted Training Group|Participants will receive 6 weeks of RT training using the BMT in each session.
89368008|NCT03120208|Experimental|women in the nonexposed group without a hemorrhage|
88840225|NCT04126291|Experimental|Evaluation of whiteboard videos|Participants will be provided an internet link via email to access the videos and questionnaires through REDCap (Research Electronic Data Capture), and responses will be tracked. Before viewing, participants will complete a pre-questionnaire to collect demographic and practice data and ratings of perceived self-efficacy/confidence and knowledge in talking about weight-related issues. This pre-questionnaire only needs to be completed once. Participants will then be asked to watch each video. Immediately after watching each video, participants will rate their perceived change in self-efficacy/ confidence and knowledge to help elucidate outstanding educational gaps. For those who consent to do a follow up questionnaire four-six months later, they will be sent an email link to complete a satisfaction questionnaire and rate their perceived self-efficacy/confidence and change in practice to help elucidate outstanding educational gaps.
88840226|NCT04110067||1|SMILE - Correction of eyes with myopia of more than -7.75 D
89368009|NCT03120208|Experimental|women in the exposed group with a hemorrhage|
89368010|NCT03120208|Experimental|Partners|
89368011|NCT03225040||Acromegaly patients on pegvisomant|25 subjects with acromegaly on pegvisomant therapy with a normal IGF-1 level for at least 1 year.
89368012|NCT04404725|Experimental|comfilcon A then samfilcon A|Subjects were randomized to wear comfilcon A for one month then Samfilcon A for one month in this randomized, bilateral cross-over study.
89368013|NCT04404725|Active Comparator|samfilcon A then comfilcon A|Subjects were randomized to wear samfilcon A for one month then comfilcon A for one month in this randomized, bilateral cross-over study.
89368014|NCT03208348|Experimental|Pilot virtual reality|Children with anxiety will have a single visit to test the virtual reality system and measure its affects on their anxiety ratings.
88840227|NCT04802863|Experimental|Five doses of XNW4107 with imipenem/cilastatin|Each subject will receive a total of five doses of 250 mg XNW4107 in combination with 500 mg imipenem/500 mg cilastatin via IV infusion administered every 6 hours with each administration infused over 60 minutes.
88840228|NCT04756843|Experimental|Early treatment|Treatment started in the early mixed dentition phase
88840229|NCT04756843|Experimental|Late treatment|Treatment started in the late mixed dentition phase
88840230|NCT04677751|Experimental|Experimental group|
88840231|NCT04652869|Experimental|Mindfulness Training|Mindfulness training
88840232|NCT04652869|Experimental|Transcranial Direct Current Stimulation (tDCS)|Transcranial direct current stimulation targeting the dorsolateral prefrontal cortex
89368015|NCT03208270|Experimental|Antithrombin supplementation|Patients randomized to the study group will receive supplementation of antithrombin concentrate to maintain a functional antithrombin level between 80%-120%.
89368016|NCT03208270|Active Comparator|No Antithrombin supplementation|"Patients randomized to the control group will never receive supplementation of antithrombin unless heparin resistance occurs."
89368017|NCT04343261|Experimental|COVID-19 patients treated with convalescent plasma|Severely ill COVID-19 patients treated with convalescent plasma
89368018|NCT03208426|Experimental|Sequential therapy for 14 days|Sequential therapy for 14 days (experimental) D1-D7: (Nexium, esomeprazole 40mg bid + amoxicillin (Brand name: Amoxicillin Capsule) 1000mg bid) for 7 days D8-D14: (Nexium, esomeprazole 40mg bid + Klaricid XL, clarithromycin 500mg bid + Flagyl, metronidazole 500mg bid) for another 7 days
89368019|NCT03208426|Active Comparator|bismuth quadruple therapy for 10 days|Bismuth quadruple therapy for 10 days (active comparator) D1-D10: (Nexium, esomeprazole 40mg bid + KCB F.C. TABLETS, dibismuth trioxide 120mg qid + Flagyl, metronidazole 500mg tid + tetracycline (Brand name: Tetracycline Capsule ) 500mg qid) for 10 days
89368020|NCT04336475|Experimental|Group 1|exercise regimen and oral hygiene care advices
89368021|NCT04336475|Active Comparator|Group 2|oral hygiene care advices
89368022|NCT03224962||diagnostic tool|Light induced fluorescence camera Caries detection dye. visual assessment method (ICDAS criteria)
89368023|NCT03216070|Experimental|Arm1 Low Dose Dasatinib|We will give 50mg of dasatinib orally daily for 6 months
89368024|NCT04335929|Experimental|Internet-based Cognitive Behavior Therapy|The intervention offered is a CTB-based internet intervention, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is 8-week long e-learning intervention, with new modules introduced weekly and assignments are given to practice techniques learned.
89368025|NCT03215602|Experimental|NEMEX and education + strength training|"Participants will undergo 12 weeks of twice weekly exercise. Each exercise session will last for 70-90 min. and will consist of 1 hour of specific exercises to optimize sensorimotor control and achieve compensatory functional stability performed in a multiple-joint weight-bearing specific manner. The final part of the session will consist of focused knee extensor strength training performed in gym machines (knee extension & leg-press) in a combination of low-load fatiguing exercises (knee-extension) followed by high-load exercises (leg-press).~Additionally, participants will receive 2 educational sessions, which include disease- and exercise specific counseling."
89179212|NCT00753714|Placebo Comparator|B|Gemcitabine administered intravenously at 1200 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle up to plus Vandetanib 100 mg Matching Placebo orally once-daily, from Day 1.Patients will receive gemcitabine for up to a maximum of 6 cycles, after which period patients should continue on daily oral dosing with placebo alone until progression. Once a patient has met the study criteria for disease progression on vandetanib/gemcitabine or placebo/gemcitabine, randomised treatment must be permanently discontinued.
89179213|NCT00759954|Other|1|Treatment A (test product) followed by Treatment B (reference product)
89179214|NCT00759954|Other|2|Treatment B (reference product) followed by Treatment A (test product)
89179215|NCT00804908|Placebo Comparator|Placebo for ABT-888 BID + TMZ QD|Placebo for ABT-888 twice daily (BID) for 7 days every 28 days plus temozolomide (TMZ; by body surface area) 150 mg/m2 once daily (QD) for 5 days every 28 days.
89179216|NCT00804908|Active Comparator|ABT-888 20 mg BID + TMZ QD|ABT-888 20 mg twice daily (BID) for 7 days every 28 days plus temozolomide (TMZ; by body surface area) 150 mg/m2 once daily (QD) for 5 days every 28 days.
89179217|NCT00804908|Active Comparator|ABT-888 40 mg BID + TMZ QD|ABT-888 40 mg twice daily (BID) for 7 days every 28 days plus temozolomide (TMZ; by body surface area) 150 mg/m2 once daily (QD) for 5 days every 28 days.
89179218|NCT00808808||Arm A (Control)|A control arm of usual care offering TIV with baseline advertisement
89368026|NCT03215602|Active Comparator|NEMEX and education|"Participants will undergo 12 weeks of twice weekly exercise. Each exercise session will last for approximately 60 min. and will consist of 1 hour of specific exercises to optimize sensorimotor control and achieve compensatory functional stability performed in a multiple-joint weight-bearing specific manner.~Additionally, participants will receive 2 educational sessions, which include disease- and exercise specific counseling."
89368027|NCT03207646|Experimental|smartphone-based cardiac rehabilitation|The BrightHeart® mobile application is installed on the smartphone and a heart coach set up and guides the participant through a cardiac care program.
89368028|NCT03207646|No Intervention|Control|Standard-of-care alone.
89368029|NCT05115383|Active Comparator|Sedentary Group|Individuals who are physically active for less than 75 minutes of moderate to vigorous physical activity a week will be placed in the sedentary group.
89179219|NCT00808808||Arm B (Choice)|An intervention arm offering choice of TIV or FluMist with baseline advertisement, including advertisement to highlight the availability of FluMist
89179220|NCT00808808||Arm C (Choice Plus)|An intervention arm offering choice of TIV or FluMist with enhanced advertisement and additional incentives for receiving an influenza vaccination
89179221|NCT02608034|Experimental|Part 1: Vemurafenib+Itraconazole|Part 1: Participants will receive vemurafenib orally BID up to Day 20 (Period A) followed by vemurafenib orally BID along with itraconazole orally once in the morning from Days 21 to 40 (Period B).\nPart 2: Participants will receive vemurafenib orally BID up to Day 20 (Period A) followed by vemurafenib orally BID along with rifampin orally once in the morning from Days 21 to 40 (Period B).
89179222|NCT02608190|Experimental|Active training|Patients will undergo active working memory training (see description of protocol).
89179223|NCT02608190|Active Comparator|Passive training|Patients will undergo passive working memory training (see description of protocol).
89189265|NCT00714246|Experimental|Phase I - Dose Level 4|Carboplatin AUC 6 mg/ml/min (Day 1) Docetaxel 75 mg/m2 (Day 1) Bortezomib 1.0 mg/m2 (Day 1,4,8,11)
89189266|NCT00714246|Experimental|Phase I - Dose Level 5|Carboplatin AUC 6 mg/ml/min (Day 1) Docetaxel 75 mg/m2 (Day 1) Bortezomib 1.3 mg/m2 (Day 1,4,8,11)
89368030|NCT05115383|Active Comparator|Active Group|Individuals who are physically active for greater than 150 minutes of moderate to vigorous physical activity will be placed in the active group.
89368031|NCT02450968|Active Comparator|Dexamethasone|Dexamethasone 4 mg capsules, twice per day, orally
89368032|NCT02450968|Placebo Comparator|Placebo|Placebo capsules twice per day, orally
89368033|NCT03749993|Other|Screening Arm|Screening
89368034|NCT03225118||HIV/ATI|HIV-infected Adults (age 18-65 years) on ART with suppressed viremia willing to interrupt treatment and then restart once criteria is met.
89368035|NCT03749915|Active Comparator|Comparator: Ametop only|Ametop Gel applied as sole topical anesthetic.
89368036|NCT03749915|Experimental|Intervention: Pain Ease Cold Spray|Pain Ease Cold spray applied immediately before IV insertion, as an adjunct to Ametop Gel.
89368037|NCT03207724|Experimental|Xilonix plus Onivyde and 5FU|interleukin-1-alpha antagonist (Xilonix) in addition to standard chemotherapy of onivyde and 5-fluorouracil/folinic acid (leucovorin)
88840233|NCT04652869|Experimental|Mindfulness + tDCS|Mindfulness training with transcranial direct current stimulation targeting the dorsolateral prefrontal cortex
88840234|NCT04622839|Experimental|Group 1|Participants will not be aware of the relation to the group they are randomized into in comparison to the other study groups; for example, if they were assigned a higher or lower frequency of ice usage (with Intervention 1 being frequency of ice usage), etc.
88840235|NCT04622839|Experimental|Group 2|Participants will not be aware of the relation to the group they are randomized into in comparison to the other study groups; for example, if they were assigned a higher or lower frequency of ice usage (with Intervention 1 being frequency of ice usage), etc.
88840236|NCT04622839|Experimental|Group 3|Participants will not be aware of the relation to the group they are randomized into in comparison to the other study groups; for example, if they were assigned a higher or lower frequency of ice usage (with Intervention 1 being frequency of ice usage), etc.
88840237|NCT00366379|Experimental|1|
88840238|NCT00366379|Experimental|2|
88840239|NCT00366379|Experimental|3|
88840240|NCT00366379|Experimental|4|
88840241|NCT00366379|Experimental|5|
88840242|NCT02619799|Active Comparator|GROUP A(MAGNESIUM GROUP)|MAGNESIUM GROUP received 50 mg(0.1 ml) of intrathecal magnesium sulphate diluted to 1 ml with 0.9% normal saline combined with 14-16 ml of epidural 0.75% ropivacaine as a part of combined spinal epidural technique at L2-L3/L3-L4 interspace.
88840243|NCT02619799|Active Comparator|GROUP B(MIDAZOLAM GROUP)|MIDAZOLAM GROUP received 1mg(0.2ml) of intrathecal midazolam diluted to 1ml with 0.9% normal saline combined with 14-16 ml of epidural 0.75% ropivacaine as a part of combined spinal epidural technique at L2-L3/L3-L4 interspace.
88840244|NCT02621983|Active Comparator|Aerobic Exercise|Subjects with a diagnosis of SCZ will complete aerobic exercises consisting of spin classes 3 times a week on a stationary bicycle ergometer. Exercise time will progress from an initial 20 minutes per session to a maximum of 45 minutes by increasing 5 minutes each week for 12 weeks.
88840245|NCT02621983|Active Comparator|Balance and Stretching|Subjects with a diagnosis of SCZ will complete a balance and stretching program consisting of progressive whole body stretching and toning exercises. Exercise time will progress from an initial 20 minutes per session to a maximum of 45 minutes by increasing 5 minutes each week for 12 weeks.
88840246|NCT04741165|Experimental|Experimental: HX008+Bevacizumab|Participants receive HX008 200 mg intravenous (IV) every 3 weeks (Q3W) plus bevacizumab 15 mg/kg, IV, Q3W.
88840247|NCT04741165|Experimental|Experimental: HX008+Lenvatinib|Participants receive HX008 200 mg intravenous (IV) every 3 weeks (Q3W) plus lenvatinib 12 mg (for participants with screening body weight ≥60 kg) or 8 mg (for participants with screening body weight <60 kg) orally once a day (QD).
88840248|NCT04741243|Experimental|Extracorporeal shock wave therapy|was used for 15 minutes in a prone position for both groups (A&B) before the treatment. shock wave were used to heat small areas, and allow for decrease pain, muscle spasm, and provide vasodilatation of the blood vessels supplying the area
89534732|NCT03241069|Experimental|patients with acute dyspnea|"patients presenting to the emergency department with acute onset dyspnea are assessed for acute heart failure using the bio impedance technology (BIOPAC system) to measure the cardiac output in different clinical situations.~FIRST: the cardiac output (CO) is measured at the reference position. Inbetween each step the patient was put in the reference position during 5 minutes."
88840249|NCT04741243|Experimental|dietary modification|Dietary modifications are changes made during food preparation, processing, and consumption to increase the bioavailability of micronutrients-and reduce micronutrient deficiencies-in food at the commercial or individual/household level.
88840250|NCT05138497|Experimental|HILIT group|An experimental group (EG) that after an initial evaluation and with their consent, will be subjected to a directed physical training program for 12 weeks with 3 weekly sessions (Monday, Wednesday and Friday), with a duration of 50 min per session. The exercises to be carried out will be divided into three different phases: warm-up during the first 10 minutes; the main part with a duration of 30 minutes (where each exercise should be performed for 20 to 30 seconds as intense or fast as possible without generating joint impact, and then take a break for 10 to 15 seconds, before repeating it); and the return to calm, based mainly on stretching exercises with a total duration of 10 minutes.
88840251|NCT05138497|No Intervention|Control group|A control group (CG) that will not undergo treatment, which will be evaluated in the pre and post phase of the study. The participants assigned to this group will receive general advice on the positive effects of the regular practice of physical activity, and they will be given the guide of recommendations for the promotion of physical activity.
88840252|NCT02623855|Active Comparator|Park prescription|Park prescription, pedometry.
88840253|NCT02623855|Experimental|Park prescription and family outings|Park prescription, pedometry, case management and 3 weekly family outings.
88840254|NCT02625181|Experimental|PONV clinical decision support system|Automated recommendations on PONV prophylaxis provided to anesthesia providers through the anesthesia information management system and email.
88840255|NCT05442229||Normally developing child|Normal development is defined as children without intellectual development disorders, developmental speech or language disorders, ASD (autism spectrum disorder), and ADHD (attention deficit hyperactivity disorder).
88840256|NCT05442229||Abnormally developed child|Abnormal development is defined as that hospital visits of children were professionally assessed for MR (mental retardation), ASD (autism spectrum disorder), and ADHD (attention deficit hyperactivity disorder). Diagnostic criteria were all referred to Diagnostic and Statistical Manual of Mental Disorders，DSM-5.
88840257|NCT04362631||Adults|Adults 18 years or older
88840258|NCT02625571|Experimental|Intervention|
88840259|NCT05046223|Experimental|high-flow nasal oxygen|THRIVE( Transnasal humidified rapid-insufflation ventilatory exchange), a method of high-flow nasal oxygen (HFNO), is planned to applied for bronchoscopic interventions
88840260|NCT05046223|Active Comparator|supraglottic devise|iGel, a supraglottic devise with tip in upper esophagus, is planned to applied for bronchoscopic interventions
88840261|NCT04741321||Pre-test group|After translation to Spanish, VQ-6 questionnaire is given to 20 patients to assess understanding by the patient.
89189267|NCT00714246|Experimental|Phase II|Carboplatin AUC 5 mg/ml/min (Day 1) Docetaxel 60 mg/m2 (Day 1) Bortezomib 0.7 mg/m2 (Day 1,4,8,11)
89368038|NCT03225274|Experimental|Experimental Group|Experimental Group consist of 30 subjects. Pre-assessment of respiratory status among children was assessed. Then after 5 minutes of administration of Nebulization, breathing exercises as therapeutic play (balloon inflation, candle blowing, blow air into water with a straw was administered for 15 minutes once in a day for 3 days consecutively and then post-assessment was taken daily 5 minutes after the administration of breathing exercises as therapeutic play.
89368039|NCT03225274|No Intervention|Comparison Group|Comparison Group consist of 30 subjects. Pre-assessment of respiratory status among children was assessed. Then only nebulization therapy was administered and then post-assessment was taken daily after 25 minutes of administered.
89368040|NCT05050409|Experimental|Brief mindfulness followed by brief mindfulness for non-responders|1 session of brief mindfulness, plus standard of care. At the one-month post-surgical follow-up, non-responders will receive another single session of brief mindfulness. Responders will continue to receive standard of care.
89368041|NCT05050409|Experimental|Standard care followed by brief mindfulness for non-responders|Patients will attend a 2-hour preoperative class involving pain coping education and are offered prehabilitation services. At the one-month post-surgical follow-up, non-responders will receive one session of brief mindfulness. Responders will continue to receive standard of care.
89368042|NCT05050409|Experimental|Brief mindfulness followed by MORE for non-responders|1 session of brief mindfulness, plus standard of care. At the one-month post-surgical follow-up, non-responders will receive the 8 session MORE intervention. Responders will continue to receive standard of care.
89368043|NCT05050409|Experimental|Standard care followed by MORE for non-responders|Patients will attend a 2-hour preoperative class involving pain coping education and are offered prehabilitation services. At the one-month post-surgical follow-up, non-responders will receive the 8 session MORE intervention. Responders will continue to receive standard of care.
89368044|NCT03207880|Experimental|MLPT|Multi-level pregnancy test
89368045|NCT03214822|No Intervention|HMF (standard of care)|"The HMF Control Group will receive the current standard feeding protocol of human milk fortified with bovine (cow) human milk fortifier (HMF)"
89368046|NCT03214822|Experimental|H2MF|"The H2MF Intervention Group will receive identical treatment with human-derived human milk fortifier (H2MF) replacing standard bovine HMF until the baby reaches an adjusted gestation age of 33 weeks; followed by a 5 day ween to standard HMF according to the manufacturer's recommendation."
89368047|NCT04333199|No Intervention|Control|Patients do not receive an email
89368048|NCT04333199|Experimental|Timely nudge - view results|"Patients are emailed about myGeisinger when they have a lab result ready to view. The email includes a View My Lab Results button, which encourages them to click as a pre-commitment step that then brings them to the myGeisinger sign-up page."
89368049|NCT04333199|Experimental|Timely nudge - get started|"Patients are emailed about myGeisinger when they have a lab result ready to view. The email includes a Get Started With myGeisinger button that is transparent about the next step in the process, before the patient can view test results."
89368050|NCT03119116||Stroke Prevention with Rivaroxaban in NVAF Patients|All NVAF patients above 18 years for age prescribed with Rivaroxaban during the study period
88840262|NCT04741321||Test and re-test group|80 patients will be recruited to answer VQ-6 questionnaire and SF-12 questionnaire. After 3-4 weeks, these patients will be re-asked with the same questionnaires.
89368051|NCT03119116||Stroke Prevention with Dabigatran in NVAF Patients|All NVAF patients above 18 years for age prescribed with Dabigatran during the study period
89368052|NCT03119116||Stroke Prevention with Apixaban in NVAF Patients|All NVAF patients above 18 years for age prescribed with Apixaban during the study period
89368053|NCT03207802||Cohort 3|This cohort is living at home with a chronic condition.
89368054|NCT04332419|Experimental|PET/CT & PET/MR|One-time PET/MR imaging in addition to the standard PET/CT imaging, both performed on the same day of the treatment procedure (Selective Internal Radiation Therapy Y-90 RE). Participants will be randomized to receive either of the imaging modalities first, based on the availability of the imaging device, and less than 1 hour apart.
89368055|NCT02450734||Carotid endarterectomy|Realisation of an ultrasound-guided intermediate cervical plexus block for anesthesia of carotid endarterectomy
88840263|NCT04740853|Experimental|Sensory Integration Therapy+Special Education|"The therapy program was prepared and applied according to the Ayres theory and based on the basic principles of sensory integration therapy prepared by Parham depending on the evaluation results. Therapy was applied to the intervention group, with a 45-minute session+15 minutes of family information once a week for eight weeks, in addition to the special education sessions they received twice a week in special education institutions. The sensory integration therapy included sensory diet practices and activities consisting of vestibular, tactile, proprioceptive, auditory and visual stimuli.~The intervention group continued special education sessions in special education and rehabilitation centers twice a week for eight weeks. In the special education sessions, reading, writing, sequencing, arithmetic, language, organization, memory studies were applied."
88840264|NCT04740853|Active Comparator|Special Education|The control group continued special education sessions in special education and rehabilitation centers twice a week for eight weeks. Within the scope of special education sessions, reading, writing, sequencing, arithmetic, language, organization, memory studies were applied.
89189268|NCT04071288||laparoscopic burch colposuspension|who underwent total laparoscopic hysterectomy for benign causes and had simultaneous incontinence; patients undergoing laparoscopic burch colposuspension
89368056|NCT03224806|Other|Wholegrain bread|
89368057|NCT03224806|Other|White bread|
89368058|NCT03224806|Other|15% fiber-rich bread|
89368059|NCT03224806|Other|30% fiber-rich bread|
89368060|NCT03207568|Experimental|Relay Pro Device|The Relay Pro thoracic stent-graft will be used to treat pathologies eligible for thoracic endovascular aortic repair (TEVAR).
89368061|NCT03224884|Active Comparator|Interscalene block|Patients randomized to receive an interscalene block .
89368062|NCT03224884|Experimental|Supraclavicular block|Patients randomized to receive a supraclavicular block.
89368063|NCT04329923|Active Comparator|Cohort 1 HCQ|COVID-19 PCR+ patients quarantined at home randomized to this arm will be treated with hydroxychloroquine 400 mg twice a day for up to 14 days
88840265|NCT02628223|Active Comparator|180 degrees|180 degrees of Selective Laser Trabeculoplasty using Neodymium:Yttrium Aluminum Garnet (YAG) laser
89368064|NCT04329923|Placebo Comparator|Cohort 1 Placebo|COVID-19 PCR+ patients quarantined at home randomized to this arm will be treated with placebo twice a day for up to 14 days. Crossover is allowed if symptoms worsen after 7 days of treatment.
88840266|NCT02628223|Active Comparator|360 degrees|360 degrees of Selective Laser Trabeculoplasty using Neodymium:Yttrium Aluminum Garnet (YAG) laser
88840267|NCT02630017|Experimental|ADHD group|Adults with ADHD
88840268|NCT02630017|Experimental|non-ADHD group|Adults without ADHD
88840269|NCT02630719|Active Comparator|Timolol eye drops|All subjects received timolol eye drops or placebo (artificial tears) for two months then crossed over to the opposite medication for the final two months of the study.
88840270|NCT02630719|Placebo Comparator|Artificial tears|All subjects received timolol eye drops or placebo (artificial tears) for two months then crossed over to the opposite medication for the final two months of the study.
88840271|NCT02630953|Active Comparator|Original Tailored Intervention|This existing empirically supported Spanish-language PA intervention, which is based on Social Cognitive Theory and the Transtheoretical Model (TTM), emphasizes behavioral strategies for increasing PA levels (goal-setting, self-monitoring, problem-solving barriers, increasing social support, self-rewards for meeting PA goals).
88840272|NCT02630953|Experimental|Enhanced Tailored Intervention|We designed the Enhanced Tailored Intervention to build upon our previous research in order to outperform the original tailored intervention, in a cost effective, theoretically guided and data driven manner with potential for dissemination. Participants in the Enhanced Tailored Intervention will receive an interactive technology based intervention that: 1) addresses important SCT constructs for increasing PA that were not significantly changed in the original parent trial (enjoyment/outcome expectations and social support) and 2) provides greater accountability and interactivity for self-monitoring (through text messages), as requested by participants in the original parent trial.
88840273|NCT02633371|Experimental|Oxybutynin|Oxybutynin 3% gel, 1 gram of product (56 mg oxybutynin) topically to each armpit daily for 4 weeks
88840274|NCT04159519|Experimental|Treatment reduction arm|All participants will receive Fasenra® 30 mg Q8W + SMART or Symbicort® reliever only (starting with medium-dose Symbicort® 200/6 μg ×2 inhalations BID maintenance + Symbicort® 200/6 μg reliever PRN; tapering to Symbicort® 200/6 μg reliever only, as per tapering scheme and depending on degree of asthma control). The reduction period in this arm will last 32 weeks.
88840275|NCT04159519|Experimental|Reference arm|All participants will receive Fasenra® 30 mg Q8W + high-dose Symbicort® maintenance ×2 inhalations BID + Ventolin® (salbutamol 100 μg) reliever PRN therapy. Eligible participants randomised to the reference arm will continue on high-dose Symbicort® maintenance treatment and Ventolin® reliever treatment for 32 weeks.
89179224|NCT00589784|Experimental|Treatment|Sunitinib will be administered at a dose of 50 mg orally once daily for four consecutive weeks, followed by a two-week rest period. Intra-patient dose reduction may be required depending on the type and severity of individual toxicity encountered. Imaging studies will be performed after every other cycle. Patients may continue on study as long as they are tolerating treatment and in the absence of disease progression.
89179225|NCT00759876|Experimental|Ataluren|Participants will receive ataluren 3 times per day with meals at doses of 20 milligrams per kilogram (mg/kg) (breakfast), 20 mg/kg (lunch), and 40 mg/kg (dinner) for up to 89 weeks.
88840276|NCT04079491||dental hygienists|all dental hygienists members in the trade union for dental hygienists
88840277|NCT02634073|Experimental|Treatment A: Lamivudine 300 milligram(mg)|Participant will receive single dose of Lamivudine 300 mg (30 ml of 10 mg/ml Oral Solution) after overnight fasting. Treatment period will be separated by at least 7 day wash out period.
88840278|NCT02634073|Experimental|Treatment B: Lamivudine 300 mg + Sorbitol 3.2 g (low dose)|Participant will receive single dose of Lamivudine 300 mg (30 ml of 10 mg/ml Oral Solution) + oral solution of Sorbitol 3.2 g after overnight fasting. Treatment period will be separated by at least 7 day wash out period.
88840279|NCT02634073|Experimental|Treatment C: Lamivudine 300 mg + Sorbitol 10.2 g (medium dose)|Participant will receive single dose of Lamivudine 300 mg (30 ml of 10 mg/ml Oral Solution) + oral solution of Sorbitol 10.2 g after overnight fasting. Treatment period will be separated by at least 7 day wash out period
89179226|NCT04569344||Patients with Covid-19|Patients with laboratory test positive for SARS-CoV-2 virus
89368065|NCT04329923|Experimental|Cohort 2 HCQ high dose|Hospitalized COVID-19 PCR+ patients randomized to this arm will be treated with hydroxychloroquine 600 mg twice a day for up to 14 days
89368066|NCT04329923|Active Comparator|Cohort 2 HCQ low dose|Hospitalized COVID-19 PCR+ patients randomized to this arm will be treated with hydroxychloroquine 600 mg once a day for up to 7 days
88840280|NCT02634073|Experimental|Treatment D: Lamivudine 300 mg + Sorbitol 13.4 g (high dose)|Participant will receive single dose of Lamivudine 300 mg (30 ml of 10 mg/ml Oral Solution) + oral solution of Sorbitol 13.4 g after overnight fasting. Treatment period will be separated by at least 7 day wash out period
88840281|NCT02637427|Experimental|Fresh frozen plasma transfusion|Pre-procedure fresh frozen plasma transfusion (15 cc per Kg, range 10-20 cc/Kg, to a maximum of 5 units)
88840282|NCT02637427|No Intervention|No transfusion|No transfusions prior to the procedure
88840283|NCT04400071|Experimental|Active Music Engagement|See intervention description.
88840284|NCT04400071|Active Comparator|Audio Storybooks|See intervention description.
88840285|NCT02638051|Experimental|Study Group|Modulated Electro-Hyperthermia (mEHT): 150 Watt x 60 min/session every 2nd day for 4 weeks (14 sessions); TCM Herbal Decoction: Shi Pi Decoction administered orally twice a day (200 mL x 2) 30 min after breakfast and supper, for 4 weeks.
89179227|NCT05742854|Active Comparator|Oxytocin|(subjects administered oxytocin as a uterotonic agent) (5 IU oxytocin diluted with 10 ml saline followed by slow injection) (for 3 minutes)
89534733|NCT03241069|Experimental|the sitting position|the patient is put at the sitting position and we measure the cardiac output by BIOPAC system (patient is put to a 90 degree sitting position during 1 to 2 minutes then the CO is measured 5 minutes later)
89534734|NCT03241069|Experimental|a passive leg rising maneuver|we make a passive leg rising and we measure the cardiac output by BIOPAC system (45 degree passive leg rising was done for 1 to 2 minutes and CO was measured during the maneuver 5minutes later.)
89368067|NCT04329923|Experimental|Cohort 3 HCQ|Health care workers at high risk of contracting COVID-19 randomized to this arm will be treated with hydroxychloroquine 600 mg once a day for 2 months
89368068|NCT04329923|Placebo Comparator|Cohort 3 Placebo|Health care workers at high risk of contracting COVID-19 randomized to this arm will be treated with placebo for 2 month. Crossover is allowed if subject becomes SARS-CoV2 positive.
89368069|NCT03207178|Experimental|Mixed CD19/CD20 CAR-T Transfer|Subjects with CD19+/CD20+ B-cell lymphomas will be infused with CD19-targeting CAR T Cells and CD20-targeting CAR T Cells in one time or in parts
89368070|NCT03213496|Experimental|Walk prescription|Walk prescription for all weeks before non-cardiac surgery. Duration of walk must be of 30-40 minutes every day for five days at the week or until complete 150 minutes at the week, for all weeks up to the surgery.
89368071|NCT03213496|Other|Conventional care|Currently patients do not receive exercise (walk)-prescription before non cardiac surgery.
89368072|NCT03224728||2 different Intraocular lenses|2 different intraocular lenses were compared
89368073|NCT03207412|Experimental|Minimally invasive implantation|Patients receive minimally invasive implantation, and 200 million hAECs is implanted into bilateral ovarian tissue by Ultrasound-guided puncture.
89368074|NCT03207412|Experimental|Intravenous infusion|100 million hAECs is administered by intravenous infusion every 30 days, for 3 times.
89368075|NCT04403399|Experimental|Varenicline then Placebo|Varenicline 0.5 mg BID orally for 3 weeks, followed by a 3-week washout period, then placebo BID orally for 3 weeks
89368076|NCT04403399|Experimental|Placebo then Varenicline|Placebo BID orally for 3 weeks, followed by a 3-week washout period, then Varenicline 0.5 mg BID orally for 3 weeks
89368077|NCT03224572|Experimental|The study group|The study group will receive intravenous high-dose vitamin C 30 gm in 500 ml normal saline in 1-hour infusion, once per week, and total 4-week treatment.
89368078|NCT03224572|Placebo Comparator|The control group|The control group will receive 500 ml normal saline in 1-hour infusion, once per week, and total 4-week treatment.
89368079|NCT02452216|Experimental|Ferumoxytol group|All subjects in the experimental arm will have a single intravenous dose of ferumoxytol (5 mg Fe/kg), to be administered 24 hours before the subject undergoes ferumoxytol-enhanced magnetic resonance imaging (MRI). These subjects will subsequently undergo surgery, and tissue analysis of surgically resected samples (specifically the number of iron-containing and non-iron-containing macrophages) will be correlated with imaging features on ferumoxytol-enhanced MRI.
89368080|NCT03749759|Experimental|Biofeedback measurement|A Biofeedback measurement will be done during cataract surgery of both eyes
88840286|NCT02638051|Active Comparator|Control Group|IPCI: CDDP (30-60 mg) with 5FU (500-600 mg/sqm of body surface), both dissolved in 100 mL of normal saline, after abdominal paracentesis and catheterization with following closed drainage of the ascites up to small amount of remaining liquid. After IPCI, the catheter occluded. Administered biweekly during four weeks of the course, totally two times.
89179228|NCT05742854|Active Comparator|Carbetocin|subjects administered carbetocin as a uterotonic agent) (100µg carbetocin diluted with 10 ml saline followed by slow injection (for 3 minutes))
88840287|NCT00367393|Experimental|1|Pimecrolimus cream 1%
89001914|NCT02963051|Experimental|Neuroendocrine prostate cancer (NEPC)|"Subjects with neuroendocrine prostate cancer (NEPC)~Copper will be administered intravenously at a dose of 1, 3, 5, or 7 mg on cycle 1 days 1, 8, 15. Disulfiram will administered orally at a dose of 80 mg three times a day starting on cycle 1 day 2. Copper gluconate will be administered orally at a dose of 1.5 mg three times a day starting on cycle 1 day 16."
89179229|NCT00823979|Experimental|UK- 453,061 Dose One|
89179230|NCT00823979|Experimental|UK- 453,061 Dose Two|
89368081|NCT03207334|Experimental|Midostaurin and Cytarabine|Treatment will consist of 3 phases: induction (a 28-42 day cycle), followed by consolidation (up to 4 cycles). Each cycle in the consolidation phase will last 28 days. Subjects will proceed from one phase to the next if they have achieved or maintained a complete remission or complete remission with incomplete blood count recovery by International Working Group 2003 response criteria. Patients may receive a allogeneic hematopoietic stem cell transplant between the end of the induction phase.
89368082|NCT03751475|Experimental|OptiMA|The enrolled subjects will follow the nutritional Optima strategy.
89368083|NCT03751475|Active Comparator|Control|The enrolled subjects will follow the standard nutritional protocol currently in use in the Democratic Republic of Congo
89368084|NCT03212950|Experimental|Fast-CL|Glucose control using DreaMed Glucositter and Fiasp® (Fast-CL)
89368085|NCT03212950|Active Comparator|Regular-CL|Glucose control using DreaMed Glucositter and regular insulin Aspart
89368086|NCT03207490|Experimental|Robot group|Receive 1 hour of AMADEO (robot-assisted therapy) for the hand and 1 hour of daily standard rehabilitation therapy
89368087|NCT03207100|Experimental|Analgesia-first minimal sedation group|Using analgesia-first minimal sedation strategy to implement antihypertensive therapy.
89368088|NCT03207100|Active Comparator|Antihypertensive drug treatment group|Using routine antihypertensive drugs to implement antihypertensive therapy.
89368089|NCT03212092|Experimental|Multivitamin, mineral & n-3 FA|The daily supplementation of multivitamin- and mineral in 2 capsules and n-3 fatty acids in 2 softgel capsules.
89368090|NCT03212092|Placebo Comparator|Placebo|The placebo consists of daily supplementation of 2 capsules with rice bran extract, hypromellose and 1.6 mg riboflavin. And 2 softgel capsules with a vegetable oil.
89368091|NCT01561937|Experimental|Pre-warfarin treatment (trial part A)|
89368092|NCT01561937|Experimental|Post-warfarin treatment (trial part B)|
89368093|NCT03210766||Nabilone|Patients affected by Failed Back Surgery Syndrome (FBSS)
89368094|NCT03210766||THC/CBD|Patients affected by Failed Back Surgery Syndrome (FBSS)
89179231|NCT00823979|Active Comparator|Comparator|
89179232|NCT04093284|Experimental|Group A|The needle-free jet injector Continuous insulin therapy for 9 days, then changed to conventional insulin pen therapy for 9 days
89179233|NCT04093284|Experimental|Group B|The conventional insulin pen therapy for 9 days, then changed to needle-free jet injector Continuous insulin therapy for 9 days
88840288|NCT00367471|Active Comparator|Group A|Subjects in Treatment Group A (in cohorts of three) will receive oral lapatinib QD (Days 1 to 28). Following lapatinib administration on Day 1, paclitaxel will be administered intravenously over one hour followed immediately by an IV infusion of carboplatin over not less than 15 minutes. Carboplatin will be followed by an initial loading dose of trastuzumab by 90 minute IV infusion (first dose only) with subsequent IV doses of trastuzumab to be given weekly over 30 minute infusion. Doses of paclitaxel and carboplatin will be administered weekly (Day 1, 8, and 15). Trastuzumab is administered on Day 1, 8, 15, and 22. Treatment cycles are repeated every four weeks.
88840289|NCT00367471|Active Comparator|Group B|Subjects in Treatment Group B (in cohorts of three) will receive oral lapatinib QD (Days 1 to 28). Following lapatinib administration on Day 1, paclitaxel will be administered intravenously over one hour followed immediately by a ≥15 minute intravenous infusion of carboplatin. Doses of paclitaxel, and carboplatin will be administered weekly (Day 1, 8, and 15) for three weeks with cycles repeated every four weeks.
88840290|NCT04380883|Experimental|InnoSEAL+TRB|InnoSEAL is a hemostatic patch which will be applied along with TRB to control bleeding from access site
88840291|NCT04380883|Active Comparator|TRB alone|
88840292|NCT03643003|Experimental|Music Therapy|"Music therapy consists of live singing of participant-preferred music, with guitar accompaniment, by a board-certified music therapist (i.e., MT-BC), following a protocol regarding how to manipulate the music in real time per participant responses. Order is randomly assigned, and all participants engage in both study arms."
89179234|NCT02599584|Experimental|precritical staff|4 min of precritical team staff for anticipation of risk and role attribution during the critical events if they occur. athe staff will take place after briefing of the scenario and before the start of the scenario.
88840293|NCT03643003|Placebo Comparator|Non-Music Verbal Interaction|"Non-music verbal interaction consists of conversation of participants' interests, without music, by a board-certified music therapist, following a protocol regarding how to respond verbally in real time per participant responses. Order is randomly assigned, and all participants engage in both study arms."
89179235|NCT02599584|No Intervention|control|screening of normal labs results during 4 min, after briefing of the scenario and before the start of the scenario
89179236|NCT04094766|Experimental|BLLCAR-L10D treatment group|In BLLCAR-L10D treatment group, patients will be treated with dual specificity CD19 and CD22 CAR-T cells with a escalation approach, 3 CAR-T dosage will be tested in this study: 0.5×10^6, 1.5×10^6, 2.0×10^6 CAR-T cells/kg.
88840294|NCT02207244|Experimental|Group I|Participants will receive guselkumab 100 milligram (mg) at Weeks 0, 4, 12 and 20. Starting at Week 28, participants will receive guselkumab 100 mg or placebo through Week 72 depending upon randomized treatment group and PASI response. Placebo for guselkumab at Week 16, starting at Week 28, participants will continue to receive placebo for guselkumab through Week 72 depending upon randomized treatment group and PASI response. Placebo for adalimumab [two 0.8 milliliter (mL) injections] at Week 0 followed by one 0.8 mL injection at Weeks 1, 3, 5, and every 2 week (q2w) through Week 23 to maintain the blind. All participants will receive guselkumab q8w starting at Week 76 through Week 252.
88840295|NCT02207244|Placebo Comparator|Group II|Participants will receive placebo for guselkumab at weeks 0, 4, 12 and starting at week 28 thereafter up to week 72 depending upon PASI response. Placebo for adalimumab (two 0.8 mL injections) at week 0, followed by one 0.8 mL injection at weeks 1, 3, and 5, and q2w through week 23. At week 16, placebo participants will cross over to receive guselkumab 100 mg at Weeks 16 and 20, starting at week 28, participants will continue to receive guselkumab 100 mg or placebo through week 72 depending upon PASI response. All participants will received guselkumab q8w starting at Week 76 through Week 252.
88840296|NCT02207244|Active Comparator|Group III|Participants will receive adalimumab 80 mg (two 40 mg [0.8 mL] injections) at Week 0 followed by adalimumab 40 mg at weeks 1, 3, 5, and q2w through week 23 and placebo for guselkumab at weeks 0, 4, 12, 16, and 20. Participants will receive guselkumab or placebo starting at week 28 through week 72 depending upon PASI response. All participants will received guselkumab q8w starting at Week 76 through Week 252.
89179237|NCT02606786|Experimental|stabilization exercises|Lumbopelvic stabilization exercises have been shown to decrease pain and disability in those with low back pain. The objective of this exercise program is to recruit and train the primary stabilizing muscles of the spine in order for them to more appropriately support the spine.
89179238|NCT05428722|Experimental|deep breathing group|The intervention group is the group in which the investigators applied deep breathing exercises with incentive spirometer starting from the preoperative period.
89179239|NCT05428722|No Intervention|Control group|The control group is the group that receives standard clinical care.
89368095|NCT03747341|Experimental|Part A (Healthy Participants): Placebo-Buprenorphine Low|"Three treatment periods consisting of 3 days each of investigational treatment~1=placebo + fentanyl,~2=low dose buprenorphine + fentanyl,~3 (optional)=low dose buprenorphine only~Fentanyl was administered as a bolus over 90 seconds in escalating doses of 0.075, 0.15, 0.25 and 0.35 mg/70 kg.~Each dosing period was followed by 10-17 days of washout."
89530369|NCT02516735|Active Comparator|Group 2|Standard endoscopy with a standard biopsy protocol from the five standard biopsy sites following the updated Sydney System including two from the distal antrum (within 2-3cm from the pylorus, greater/lesser curvature), one from the incisura and two from the mid corpus (greater/lesser curvature).
89179240|NCT00708383|Experimental|1|Embryo culture medium supplemented with 0.5% HSA and 10% SSS
89530370|NCT03248323||pre-con|
89179241|NCT00708383|Active Comparator|2|Embryo culture medium supplemented with 0.5% HSA only
89179242|NCT02606864|Experimental|BAYa2502 without food|Oral intake of a single 120 mg nifurtimox dose under fasted conditions
89179243|NCT02606864|Experimental|BAYa2502 with food|Oral intake of a single 120 mg nifurtimox dose under fed conditions after ingestion of a high calorie and high fat breakfast
89179244|NCT02606942||Dancers with knee injury|A cohort of dancers with reported knee injury. Questionnaires, physical exam, US of the knee
89179245|NCT02606942||Dancers with no knee injury|A cohort of dancers without reported knee injury. Questionnaires, physical exam, US of the knee
89179246|NCT02606942||Non-dancers athletes|A cohort of non-dancers athletes without knee injuries. Questionnaires, physical exam, US of the knee
89179247|NCT05521607|Other|Enable high qualitative estimation of bilirubin levels in the blood of new-borns|There is only one arm in this study which is to enable high qualitative estimation of bilirubin levels in the blood of new-borns, independent of skin color, using Picterus JP.
88840297|NCT02638207|Experimental|0.5 g/kg NewGam|All patients will receive a loading dose of 2.0 g/kg Newgam (administered over two consecutive days), followed by seven infusions of the maintenance dose the patient has been randomized to (0.5g/kg NewGam), also administered over two consecutive days every 3 weeks (±4 days).
88840298|NCT02638207|Experimental|1.0 g/kg NewGam|All patients will receive a loading dose of 2.0 g/kg Newgam (administered over two consecutive days), followed by seven infusions of the maintenance dose the patient has been randomized to (1.0g/kg NewGam), also administered over two consecutive days every 3 weeks (±4 days).
88840299|NCT02638207|Experimental|2.0 g/kg NewGam|All patients will receive a loading dose of 2.0 g/kg Newgam (administered over two consecutive days), followed by seven infusions of the maintenance dose the patient has been randomized to (2.0g/kg NewGam), also administered over two consecutive days every 3 weeks (±4 days).
88840300|NCT04363879|Active Comparator|Endometrial scratch with Pipelle curette|For patients in the Pipelle curette group, physicians inserted the Pipelle curette into the uterus and removed an adequate endometrial sample using vigorous motion.
88840301|NCT04363879|Experimental|Endometrial scratch with Shepard catheter|For patients in the Shepard catheter group, physicians performed a four-quadrant scratch technique by inserting the Shepard insemination catheter into the uterus at 12:00. The catheter was then turned one-quarter turn and withdrawn. This was repeated two more times so that four endometrial quadrants were touched by the catheter at 12:00, 3:00, 6:00, and 9:00.
89179248|NCT00823901|Experimental|Clindamycin/Tretinoin Gel|Participants applied Clindamycin Phosphate 1.2% And Tretinoin 0.025% Gel on entire face (forehead, nose, chin, cheeks) once daily at night for 12 weeks
89179249|NCT00823901|Placebo Comparator|Placebo gel|Participants applied Placebo gel with no active medication on entire face (forehead, nose, cheeks, chin) once daily at night for 12 weeks.
89179250|NCT00823823|Active Comparator|Bivalved cast|Patients with a displaced distal radius or mid-diaphyseal forearm fracture requiring closed reduction will be immobilized in a bivalved cast
89179251|NCT00823823|Active Comparator|Circumferential cast|Patients with a displaced distal radius or mid-diaphyseal forearm fracture requiring closed reduction will be immobilized in a circumferential cast
89179252|NCT05740592|Experimental|tooth-tooth borne RPE with MOPs|many approaches have been established to speed up orthodontic tooth movement and to decrease adverse effects. These methods are classified as, microinvasive methods include cortectomies and distraction osteogenesis and microinvasive methods include micro-osteoperforations (MOPs) and piezocision Microtrauma to the bone showed increase the synthesis of cytokines and chemokines, which are routinely released when orthodontic forces are applied . As a result, the affected area is undergoing a faster bone regeneration process
89179253|NCT05740592|Experimental|Tooth-Tooth borne RPE with Piezocision group|"Piezosurgery is an ultrasonic micro vibration-based bone cutting method. It used as a careful, promising, and soft tissue sparing method. In addition to its simplicity of use in the clinic, scientific evidence from animal models measuring wound healing and bone formation suggests that, piezosurgery has a better tissue response than traditional bone-cutting procedures~."
89179254|NCT05740592|Active Comparator|Tooth-Bone borne RPE group (MARPE)|The MARPE is a RPE device with a rigid element that attached to palate by the aid of miniscrew, exerting the expansion force directly to the maxilla's basal bone
89179255|NCT04540094|Experimental|5% Human Albumin Solution|Participants allocated to the treatment arm will receive intravenous 5% Human Albumin Solution (HAS) administered as the sole intravenous fluid during the initial 6-hour resuscitation period. The clinician can deliver up to 10ml/kg in the first 3 hours using 250ml boluses of HAS based on clinical judgement, using clinical assessment supplemented by technology if that is their usual practice. This will be followed by repeat clinical assessment after each bolus (including vital signs; lactate testing). After 3 hours further HAS boluses up to 6 hours post-randomisation will be at clinical discretion and will be documented in the CRF. Patients in the albumin arm should not receive balanced crystalloid as a resuscitation fluid in the first 6 hours.
89179256|NCT04540094|Active Comparator|Intravenous balanced crystalloid|Participant allocated to the usual care arm will receive intravenous balanced crystalloid administered as the sole intravenous fluid during the initial 6 hour resuscitation period. The clinician can deliver up to 30ml/kg in the first 3 hours using 250ml boluses of balanced crystalloid based on clinical judgement, using clinical assessment supplemented by technology if that is their usual practice. This will be followed by repeat clinical assessment after each bolus (including vital signs; lactate testing). Thereafter, further crystalloid boluses up to 6 hours will be at the discretion of the clinical team and will be documented in the CRF. Patients in the balanced crystalloid arm should not receive albumin as a resuscitation fluid in the first 6 hours.
89179257|NCT02926898|Experimental|Cohort 2: ZX008 0.5 mg/kg/day|ZX008 0.5 mg/kg/day (maximum 20 mg/day) dose supplied as an oral solution administered twice a day (BID) in equally divided doses with food.
89179258|NCT02926898|Placebo Comparator|Cohort 2: Matching Placebo|Matching placebo administered twice a day (BID) in equally divided doses with food.
89179259|NCT02606630|Experimental|ABT-555|ABT-555 will be administered at Visit 4 for Part 2 only
89179260|NCT00759564|Experimental|IV CP-70,429 and cross over to PF-03709270|
89179261|NCT00816023|Experimental|Ecallantide Low Dose|target steady state concentration of 0.15 mg/L
89179262|NCT00816023|Experimental|Ecallantide Medium Dose|target steady state concentration of 0.75 mg/L
89179263|NCT00816023|Experimental|Ecallantide High Dose|target steady state concentration of 2.25 mg/L
89179264|NCT00816023|Placebo Comparator|Placebo|placebo
89179265|NCT00759174||Case Group|
89179266|NCT00815633|Experimental|Alefacept|Treatment Group (only one group)
89179267|NCT02610881|Experimental|Iron and Folic Acid (IFA)/Micronutrient Powders (MNP)|Participants will receive iron and folic acid (IFA) drops for one month followed by a two week washout period. Participants will then receive micronutrient powders (MNP) for one month. Mothers of participants will receive counseling on the benefits of iron intake, side effects of IFA, and preservation of IFA bottles and MNP sachets.
89179268|NCT02610881|Experimental|Micronutrient Powders (MNP)/Iron and Folic Acid (IFA)|Participants will receive micronutrient powders (MNP) for one month followed by a two week washout period. Participants will then receive iron and folic acid (IFA) drops for one month. Mothers of participants will receive counseling on the benefits of iron intake, side effects of IFA, and preservation of IFA bottles and MNP sachets.
88840302|NCT02207088|Experimental|3-DAA (Direct Acting Antivirals) with or without RBV|3-DAA (ombitasvir/paritaprevir/ritonavir 25 mg/150 mg/100 mg once daily [QD] and dasabuvir 250 mg twice daily [BID]) with or without ribavirin (RBV; dosed divided twice a day) for 12 or 24 weeks
88840303|NCT02638597|Experimental|Gemfibrozil|Participants in this arm will receive smoking cessation counseling and will be provided gemfibrozil 600 mg twice daily by mouth for 9 weeks, starting one week prior to target quit date and ending with study completion
88840304|NCT02638597|Other|Waitlist|Participants in this arm will receive the smoking cessation counseling but will not receive medication. After completing the trial without medication, participants who continue to smoke and have a desire to quit may choose to enter the gemfibrozil arm.
88840305|NCT03585595|Experimental|Intensive treatment group|Systolic BP target <120 mmHg for the intensive treatment group
88840306|NCT03585595|Active Comparator|Standard treatment group|Systolic BP <140 mmHg for the standard treatment group
88840307|NCT04333615|Sham Comparator|Control Session|The control session will consist of resting on the treadmill for 30 min. It will be recommended that the patient do cycles in which he / she stands for 3 to 5 minutes and sits for 2 to 3 minutes in between, aiming to minimize the effect of body positioning on cardiovascular responses.
88840308|NCT04333615|Experimental|Self-selected Session|In the self-selected exercise session, individuals will perform 30 min of exercise with self-selected intensity. This means that the duration of the series and the intensity (speed) of the treadmill are at the discretion of the patient. The important thing is that in the end it totals 30 minutes of exercise. This choice of intensity and duration of the series can be made regardless of the occurrence of pain.
88840309|NCT04333615|Active Comparator|Walking with pain|In the exercise until maximum pain session (current recommendation of walking exercise prescription for patients with PAD), individuals will perform series of 3 to 5 minutes with adjusted intensity so that they feel moderate to maximum pain. This means that the patient will start walking and the Physical Education professional, experienced and able to prescribe exercises for patients with PAD, will adjust the treadmill speed so that the patient walks with moderate pain or even maximum pain. There will be rest intervals of 2 to 3 minutes. The patient will be encouraged to complete a total of 30 minutes of exercise.
88840310|NCT04339309|Active Comparator|Kiel Center|Non-surgical periodontal treatment with interdental hygiene devices in periodontitis patients.
88840311|NCT04339309|Active Comparator|Cairo Center|Non-surgical periodontal treatment without interdental hygiene devices in periodontitis patients.
88840312|NCT02206620|Experimental|Donepezil|Donepezil 5 mg per day for week 1-3 or 12-14. 10 mg/day for weeks 4-6 or 14-18, if tolerated.
89179269|NCT00830765|Placebo Comparator|1 Placebo|The participant will receive a weekly injection of placebo from the time of enrollment up until 34 weeks' gestation or delivery, whichever occurs first.
88840313|NCT02206620|Placebo Comparator|Placebo|Placebo 5 mg per day for week 1-3 or 12-14. 10 mg/day for weeks 4-6 or 14-18, if tolerated.
88840314|NCT02239926|Active Comparator|Ranolazine|tablet, 1000 mg twice daily for four weeks
88840315|NCT02239926|Placebo Comparator|Placebo|Placebo
88840316|NCT02239692|Active Comparator|PICOPREP day-before dosing schedule|Both doses administered the day before colonoscopy.
88840317|NCT02239692|Experimental|PICOPREP tailored dosing schedule|First dose one day before colonoscopy or on the day of colonoscopy, dependent on the planned time for colonoscopy, and second dose on the day of colonoscopy.
88840318|NCT00367705|Active Comparator|T|VSL-#3
88840319|NCT00367705|Placebo Comparator|P|
88840320|NCT04340089||observation group|the patients can go to squatting on the toilet at any time as they want to after taking the capsule
88840321|NCT04340089||control group|The patients can move freely
88840322|NCT02641249|No Intervention|No vibration|In the same subject cardiorespiratory parameters - heart rate, respiratory rate and oxygen saturation were compared during the procedure (vibration) and without procedure (no vibration). The same subject had both control and treatment periods.
88840323|NCT02641249|Experimental|Vibration|In the same subject cardiorespiratory parameters - heart rate, respiratory rate and oxygen saturation were compared during the procedure (vibration) and without procedure (no vibration). The same subject had both control and treatment periods.
88840324|NCT04860414|Experimental|Major Cognitive Impairment|
89179270|NCT00830765|Active Comparator|Progesterone|The participant will receive weekly injections of 100mg of OHP17 from the time of enrollment until 34 weeks' gestation or delivery, whichever occurs first.
88840325|NCT04860414|Experimental|Minor Cognitive Impairment|
88840326|NCT04860414|Active Comparator|No Cognitive Impairment|
88840327|NCT02641561|Placebo Comparator|A (NS+Placebo)|Normal Saline (intravenous during procedure) + Placebo (100mg suppository per rectum prior to procedure )
88840328|NCT02641561|Active Comparator|B (NS+IND)|Normal Saline (intravenous during procedure) + Indomethacin (100mg suppository per rectum prior to procedure )
88840329|NCT02641561|Active Comparator|C (LR+Placebo)|Lactated ringer's solution (1 Liter, intravenous prior to procedure) + Placebo (100mg suppository per rectum prior to procedure)
88840330|NCT02641561|Experimental|D (LR+IND)|Lactated ringer's solution (1 Liter, intravenous prior to procedure) + Indomethacin (100mg suppository per rectum prior to procedure)
88840331|NCT02206152|Placebo Comparator|Placebo|Normal Saline IV infusion given during a controlled hyperinsulinemic hypoglycemic insulin clamp
88840332|NCT02206152|Experimental|Treatment with N-Acetyl Cysteine|N-acetyl cysteine IV infusion given as a 150 mg/kg loading dose over the first hour and then follow that with a 50 mg/kg maintenance dose infused over the next 4 hours during a controlled hyperinsulinemic hypoglycemic insulin clamp
88840333|NCT05342376|Active Comparator|Dexmedetomidine|This is group D, which will receive 10 micro-gram Dexmeditomidine diluted in 02 ml normal saline to be administered intravenously in 10 minutes after umbilical cord is clamped..
88840334|NCT05342376|Active Comparator|Saline|This group S will receive 02 ml normal saline intravenously as placebo in 10 minutes after umbilical cord is clamped..
88840335|NCT02239536|Experimental|Hot snare polypectomy|Intervention: Procedure: removal of eligible polyps using hot snare polypectomy technique
88840336|NCT02239536|Experimental|Hot snare polypectomy(saline injection)|Intervention: Procedure: removal of eligible polyps using hot snare polypectomy after saline injection technique
88840337|NCT02239224|Experimental|Cohort 1: ATYR1940 0.3 mg/kg|Participants will receive ATYR1940 0.3 milligrams/kilograms (mg/kg) intravenous (IV) infusion once weekly for 4 weeks.
89368096|NCT03747341|Experimental|Part A (Healthy Participants): Placebo-Buprenorphine High|"Three treatment periods consisting of 3 days each of investigational treatment~1=placebo + fentanyl,~2=high dose buprenorphine + fentanyl,~3 (optional)=high dose buprenorphine only~Fentanyl was administered as a bolus over 90 seconds in escalating doses of 0.075, 0.15, 0.25 and 0.35 mg/70 kg.~Each dosing period was followed by 10-17 days of washout."
88840338|NCT02239224|Experimental|Cohort 2: ATYR1940 1.0 mg/kg|Participants will receive ATYR1940 1.0 mg/kg IV infusion once weekly for 4 weeks.
88840339|NCT02239224|Experimental|Cohort 3: ATYR1940 3.0 mg/kg|Participants will receive ATYR1940 3.0 mg/kg IV infusion once weekly for 12 weeks.
88840340|NCT02239224|Placebo Comparator|Placebo|Participants will receive placebo matched to ATYR1940 IV infusion once weekly for 4 weeks in Cohorts 1 and 2 and for 12 weeks in Cohort 3.
89368097|NCT03747341|Experimental|Part A (Healthy Participants): Buprenorphine Low-Placebo|"Three treatment periods consisting of 3 days each of investigational treatment~1=low dose buprenorphine + fentanyl,~2=placebo + fentanyl,~3 (optional)=low dose buprenorphine only~Fentanyl was administered as a bolus over 90 seconds in escalating doses of 0.075, 0.15, 0.25 and 0.35 mg/70 kg.~Each dosing period was followed by 10-17 days of washout."
89530371|NCT00709319||Primary|Subjects vitreomacular traction, visual acuity 20/63 to 20/400, retinal thickness >300 microns in the central subfield on OCT, and cataract extraction not being performed in conjunction with vitrectomy.
88840341|NCT01600014|Active Comparator|Ingenol mebutate gel, 0.015%|Topical field treatment once daily for 3 consecutive days on the face or scalp
88840342|NCT01600014|Placebo Comparator|Vehicle gel|Topical field treatment once daily for 3 consecutive days on the face or scalp
88840343|NCT02237196|Experimental|AMG 157+Cat Immunotherapy|"AMG 157 will be administered every four weeks.~Cat immunotherapy will be administered weekly."
88840344|NCT02237196|Active Comparator|AMG 157 Placebo+Cat Immunotherapy|"Placebo for AMG 157 of similar appearance will be administered every four weeks.~Cat immunotherapy will be administered weekly."
88840345|NCT02237196|Experimental|AMG 157+Cat Immunotherapy Placebo|"AMG 157 will be administered every four weeks.~Placebo for Cat immunotherapy will be administered weekly."
88840346|NCT02237196|Placebo Comparator|Placebo-Placebo|"Placebo for AMG 157 will be administered every four weeks.~Placebo for cat immunotherapy will be administered weekly."
88840347|NCT03953755|No Intervention|Control 1|no/mild tricuspid regurgitation - left-side surgery alone
88840348|NCT03953755|No Intervention|moderate TR - left-side surgery|moderate tricuspid regurgitation - left-side surgery alone
88840349|NCT03953755|Experimental|moderate TR - left-side surgery+TVS|moderate tricuspid regurgitation - left-side surgery+tricuspid valve surgery
88840350|NCT03953755|No Intervention|Control 2|tricuspid regurgitation - left-side surgery +tricuspid valve surgery
88840351|NCT04418310|Active Comparator|Lay open and curettage|Lay open and curettage in Pilonidal sinus
88840352|NCT04418310|Active Comparator|Endoscopic (E.P.Si.T) method|Endoscopic (E.P.Si.T) method in the treatment of sacrococcygeal pilonidal sinus disease
88840353|NCT04776096|Experimental|Bepotastine besilate 1,5% preservative free|Bepotastine besilate 1,5% in preservative-free bottle, administered once a day during the morning.
88840354|NCT04776096|Active Comparator|Olopatadine hydrochloride 0,2% with BAK|Olopatadine hydrochloride 0,2% with BAK as preservative, administered once a day during the morning.
88840355|NCT02237118|Active Comparator|Mepitel One|Pain on dressing removal, by VAS
89179271|NCT04093206|Experimental|EpiCor and Vitamin C|EpiCor (90mg/5ml) and Vitamin C (25mg/5ml) given at dose of 5ml to children 1-2 years old, 7.5ml to children 3-4 years old and 10ml to children 5-6 years old
89179272|NCT04093206|Active Comparator|Vitamin C|Vitamin C (25mg/5ml) given at dose of 5ml to children 1-2 years old, 7.5ml to children 3-4 years old and 10ml to children 5-6 years old
89179273|NCT00705887|No Intervention|Control|Brochure from the American Academy of Dermatology on protecting your skin from UV rays.
89368098|NCT03747341|Experimental|Part A (Healthy Participants): Buprenorphine High-Placebo|"Three treatment periods consisting of 3 days each of investigational treatment~1=high dose buprenorphine + fentanyl,~2=placebo + fentanyl,~3 (optional)=high dose buprenorphine only~Fentanyl was administered as a bolus over 90 seconds in escalating doses of 0.075, 0.15, 0.25 and 0.35 mg/70 kg.~Each dosing period was followed by 10-17 days of washout."
89368099|NCT03747341|Experimental|Part B (Opioid-Tolerant): Placebo-Buprenorphine Low|"Opioid-tolerant participants in Part B undergo a washout of their own opioids during which these were replaced with oral oxycodone, and continue at stable doses of oxycodone from at least 48 hours before Period 1 to the end of Period 2.~Two treatment periods:~1=placebo (Day 1),~2=low dose buprenorphine + fentanyl (Day 3)~Fentanyl was administered as a bolus over 90 seconds in escalating doses of 0.25, 0.35, 0.5 and 0.7 mg/70 kg."
89179274|NCT00705887|Experimental|Intervention|Participation in a brief motivational enhancement session. These participants also received the same American Academy of Dermatology brochure on protecting your skin from UV rays.
89179275|NCT00830375|Experimental|Memantine|10-30mg, memantine
89179276|NCT00803270|Active Comparator|Surgical Treatment|Surgical treatment will consist of the following evidence-based stress incontinence procedures: mid-urethral slings (TVT, TOT, TVT-O), fascial slings, and Burch colposuspension.
89179277|NCT00803270|Active Comparator|Non Surgical Treatment|"The non-surgical treatment will include two components:~Pharmacological therapy with any FDA approved overactive bladder (OAB) drug in approved doses; and~Behavioral therapy."
89179278|NCT00708539|Active Comparator|1|Crinone vaginal gel 8% 90 mg once daily
89179279|NCT00708539|Active Comparator|2|Progesterone mic 400 mg three times daily
88840356|NCT02237118|Active Comparator|UrgoTul|Pain on removal by VAS
88840357|NCT02234622|Experimental|Holistic Yoga Program|The Holistic Yoga Program (HYP) (postures, breathing practices, deep muscle contraction practices, relaxation) is a 16 week, 90 minute weekly group intervention.
89179280|NCT05516537|Experimental|Guidelines for Exercise in Multiple Sclerosis (GEMS)|Participants in this condition will receive a 4-month home-based, remotely supported aerobic and resistance exercise program based on the Guidelines for Exercise in Multiple Sclerosis (GEMS).
89179281|NCT05516537|Sham Comparator|FLEX Stretching and Toning Program|Participants in this condition will receive a 4-month home-based, remotely supported stretching program emphasizing flexibility and range of motion as important components of fitness based on Stretching for People with MS: An Illustrated Manual from the National MS Society.
89179282|NCT00751998||Arm 1|Test of SpyGlass device
89179283|NCT00914420|Experimental|Intrepide|Group A- Primary stenting with Intrepide trapidil eluting stent
89179284|NCT00914420|Experimental|Taxus|Group B Stenting with Taxus DES
89179285|NCT04094532|Active Comparator|ultrasound guided transverse thoracic muscle plane block|
88840358|NCT02234622|Active Comparator|Wellness Lifestyle Program|The Wellness Lifestyle Program (WLP) is a 16 week, 90 minute weekly group intervention consisting of low intensity walking with didactics about wellness topics.
88840359|NCT03755245|Other|[68Ga]Ga-DOTA-Siglec-9|Intravenous 140 MBq bolus injection of [68Ga]Ga-DOTA-Siglec-9 radiopharmaceutical
88840360|NCT05588947|Experimental|Tele-TaCAS|Two Take Charge sessions delivered by telehealth six weeks apart, the first being at 2 to 16 weeks after stroke, the earliest possible time after discharge to the community.
88840361|NCT05588947|Active Comparator|Control|Life After Stroke: Survivor Stories video played by telehealth at 2 to 16 weeks after stroke, the earliest possible time after discharge to the community.
88840362|NCT02203032|Experimental|Open-label ustekinumab|
88840363|NCT02203032|Experimental|Double-blind guselkumab|
88840364|NCT02203032|Experimental|Double-blind ustekinumab|
89179286|NCT04094532|Sham Comparator|ultrasound guided sham block|
89179287|NCT00708773|Experimental|Single Arm|
89179288|NCT05758259|Experimental|combination vitamin D oral and topical cholecalciferol|combination topical vitamin D and supplementation Daily supplementation (1x/day, in the morning) and topical application (2x/day, in the morning and in the afternoon, minimum duration 4 hours on the skin) for 56 days Daily supplementation (1x/day, in the morning) and topical application (2x/day, in the morning and in the afternoon, minimum duration 4 hours on the skin) for 56 days
89179289|NCT05758259|Active Comparator|oral placebo and topical vitamin D|oral placebo and topical vitamin D Daily supplementation (1x/day, in the morning) and topical application (2x/day, in the morning and in the afternoon, minimum duration 4 hours on the skin) for 56 days
89179290|NCT05758259|Placebo Comparator|oral placebo and basic ingredient placebo topical vitamin D|Daily supplementation (1x/day, in the morning) and topical application (2x/day, in the morning and in the afternoon, minimum duration 4 hours on the skin) for 56 days
89179291|NCT02607644|Experimental|Laryngeal Tube (LT)|VBM Laryngeal Tube (Intervention)
89179292|NCT02607644|Active Comparator|Laryngeal Mask Airway (LMA)|Laryngeal Mask Airway (LMA)
89530372|NCT03254329||Bangladesh|Assessment of human milk nutrient composition. Approximately 500 women and their infants recruited, 250 dyads completing study
89368100|NCT03747341|Experimental|Part B (Opioid-Tolerant): Placebo-Buprenorphine Mid|"Opioid-tolerant participants in Part B undergo a washout of their own opioids during which these were replaced with oral oxycodone, and continue at stable doses of oxycodone from at least 48 hours before Period 1 to the end of Period 2.~Two treatment periods:~1=placebo (Day 1),~2=mid dose buprenorphine + fentanyl (Day 3)~Fentanyl was administered as a bolus over 90 seconds in escalating doses of 0.25, 0.35, 0.5 and 0.7 mg/70 kg."
89179293|NCT02601066|Experimental|EPS and ECG holter monitor|Electrophysiological study (EPS) and ECG holter monitor implantation
89179294|NCT00803738|Experimental|Test Product|Terconazole Vaginal Suppository
89179295|NCT00803738|Active Comparator|Reference Product|Terazol Vaginal Suppository
89368101|NCT03747341|Experimental|Part B (Opioid-Tolerant): Placebo-Buprenorphine High|"Opioid-tolerant participants in Part B undergo a washout of their own opioids during which these were replaced with oral oxycodone, and continue at stable doses of oxycodone from at least 48 hours before Period 1 to the end of Period 2.~Two treatment periods:~1=placebo (Day 1),~2=high dose buprenorphine + fentanyl (Day 3)~Fentanyl was administered as a bolus over 90 seconds in escalating doses of 0.25, 0.35, 0.5 and 0.7 mg/70 kg."
88840365|NCT02169414|Experimental|BIA 9-1067 5 mg|1 capsule of 5 mg + 2 capsules of placebo for 18 days levodopa/carbidopa 100/25 mg was administered on Day 11 levodopa/benserazide 100/25 mg was administered on Day 18.
88840366|NCT02169414|Experimental|BIA 9-1067 15 mg|3 capsules of 5 mg for 18 days levodopa/carbidopa 100/25 mg was administered on Day 11 levodopa/benserazide 100/25 mg was administered on Day 18.
88840367|NCT02169414|Experimental|BIA 9-1067 50 mg|2 capsules of BIA 9-1067 25 mg + 1 capsule of placebo for 18 days levodopa/carbidopa 100/25 mg was administered on Day 11 levodopa/benserazide 100/25 mg was administered on Day 18.
88840368|NCT02169414|Placebo Comparator|Placebo|3 capsules of placebo for 18 days levodopa/carbidopa 100/25 mg was administered on Day 11 levodopa/benserazide 100/25 mg was administered on Day 18.
88840369|NCT02201940|Experimental|SOF/VEL|SOF/VEL for 12 weeks
88840370|NCT02201940|Placebo Comparator|Placebo|SOF/VEL placebo for 12 weeks
88840371|NCT03568435||Participants with metastatic RCC taking nivolumab|Specified dose on specified day
88840372|NCT02232984||All study patients|All study patients will be implanted with a Boston Scientific (BSC) quadripolar Cardiac Resynchronization Therapy (CRT-D) and a currently approved quadripolar left ventricular lead. At the pre-discharge visit, multiple vectors will be tested in order to assess their respective performance.
88840373|NCT03085069|Experimental|PD-L1 expression in tumor ≥ 50%|Subjects receive SHR-1210 intravenous at the dose 200mg on Day 1 every 2 weeks
88840374|NCT03085069|Experimental|PD-L1 expression in tumor ≥25-50%|Subjects receive SHR-1210 intravenous at the dose 200mg on Day 1 every 2 weeks
88840375|NCT03085069|Experimental|PD-L1 expression in tumor ≥ 1-25%|Subjects receive SHR-1210 intravenous at the dose 200mg on Day 1 every 2 weeks
88840376|NCT03085069|Experimental|PD-L1 expression in tumor < 1%|Subjects receive SHR-1210 intravenous at the dose 200mg on Day 1 every 2 weeks
88840377|NCT02169336|Experimental|DEX-IN 35mcg|DEX-IN 35mcg every 6 hours for 48 hours. DEX-IN 35mcg PRN for up to 3 additional days.
88840378|NCT02169336|Experimental|DEX-IN 50mcg|DEX-IN 50mcg every 6 hours for 48 hours. DEX-IN 50mcg PRN for up to 3 additional days.
88840379|NCT02169336|Placebo Comparator|IN Placebo|IN Placebo every 6 hours for 48 hours. IN Placebo PRN for up to 3 additional days.
88840380|NCT03043807|Experimental|chemohormonal and definitive therapy after prostatectomy|(1st) Systemic chemo-hormonal therapy with up to 6-months (~24 weeks) of adjuvant androgen deprivation (Leuprolide Acetate) and up to 6 cycles of chemotherapy (Docetaxel), (2nd) definitive local tumor control with adjuvant radiation therapy, and (3rd) consolidative stereotactic radiation to oligometastatic lesions. The men will receive a total of 2 years of androgen deprivation. Androgen blockade (Bicalutamide) will be the same throughout the course of treatment.
88840381|NCT02609828|Experimental|Arm 1|Tanezumab 20 mg subcutaneously
88840382|NCT02609828|Placebo Comparator|Arm 2|Placebo matched to active treatment subcutaneously
88840383|NCT05588635||With live birth group|patients with live birth following frozen-thawed embryo transfer
89179296|NCT00758706|Experimental|AZD1236|oral tablet, 75 mg, twice daily during 6 weeks
89179297|NCT00758706|Placebo Comparator|Placebo|Dosing to match AZD1236
89179298|NCT04097808|Experimental|collagen peptide bovine high molecular weight-Water|source: bovine; standardized to 10 g provided as single dose. Orally applied in water.
89179299|NCT04097808|Experimental|collagen peptide bovine low molecular weight-Water|source: bovine; standardized to 10 g provided as single dose. Orally applied in water.
89179300|NCT04097808|Experimental|collagen peptide bovine low molecular weight- food matrix 1|source: bovine; standardized to 10 g provided as single dose. Orally applied in Food matrix 1
89179301|NCT04097808|Experimental|collagen peptide bovine low molecular weight- food matrix 2|source: bovine; standardized to 10 g provided as single dose. Orally applied in Food matrix 2
89530373|NCT03254329||Brazil|Assessment of human milk nutrient composition. Approximately 500 women and their infants recruited, 250 dyads completing study
89001915|NCT02963051|Experimental|Adenocarcinoma CRPC with non-liver/peritoneal metastases|"Subjects with adenocarcinoma CRPC with non-liver/peritoneal metastases (lymph nodes, bone, or lung)~Copper will be administered intravenously at a dose of 1, 3, 5, or 7 mg on cycle 1 days 1, 8, 15. Disulfiram will administered orally at a dose of 80 mg three times a day starting on cycle 1 day 2. Copper gluconate will be administered orally at a dose of 1.5 mg three times a day starting on cycle 1 day 16."
89001916|NCT02963051|Experimental|Adenocarcinoma CRPC with liver and/or peritoneal mets|"Subjects with adenocarcinoma CRPC with liver and/or peritoneal metastases~Copper will be administered intravenously at a dose of 1, 3, 5, or 7 mg on cycle 1 days 1, 8, 15. Disulfiram will administered orally at a dose of 80 mg three times a day starting on cycle 1 day 2. Copper gluconate will be administered orally at a dose of 1.5 mg three times a day starting on cycle 1 day 16."
89001917|NCT00409253|Active Comparator|Urapidil|
89001918|NCT00409253|Active Comparator|Nicardipine|
89001919|NCT00212550||TB diagnosis|
89001920|NCT00188825|Experimental|basiliximab|
89534735|NCT03241069|Experimental|Valsalva maneuver|the patient was asked to perform the Valsalva maneuver and we measure the cardiac output by BIOPAC system(patients are asked to perform the Valsalva maneuver by executing a forced blow into a manometer for 30 seconds and the CO is calculated during this test.)
89534736|NCT03333785|Experimental|Intervention group|Primary care providers whose patients have been randomized to the intervention group will receive an invitation from their patient's cancer specialist provider to communicate using eOncoNote. Primary care providers and cancer specialist providers will use eOncoNote in addition to usual methods of communication.
89534737|NCT03333785|No Intervention|Control group|Primary care providers whose patients have been randomized to the control group will receive usual care (i.e. their primary care providers will not access eOncoNote to communicate with the cancer specialist providers and vice versa) and will be able to contact each other via telephone, fax, and mail consultation letters and progress notes, as per usual care.
89001921|NCT00188825|Placebo Comparator|placebo|
89001922|NCT00188942|Active Comparator|Fluoxetine + Olanzapine|
89001923|NCT00219882|Experimental|1|standardized turmeric root extract
89001924|NCT00189020|Experimental|2-dose|PCV7 at age 2 and 4 months
89001925|NCT00189020|Experimental|2+1-dose|PCV7 at age 2, 4 and 11 months
89001926|NCT00189020|No Intervention|Control|Control group
89001927|NCT00212745|No Intervention|2|Receives only EEG and questionnaire testing, no behavioral intervention or meditative relaxation
89001928|NCT00212745|Experimental|1|Andrews/Reiter behavioral treatment for epilepsy and EEG and questionnaire testing
89001929|NCT00189176|Experimental|Tetrathiomolybdate|
89001930|NCT00212862||Patients with chemotherapy induced anemia|
89001931|NCT00219999||HCV infection|current HCV infection, including intravenous drug users
89001932|NCT00219999||cryoglobulinemia|cryoglobulinemia and without HCV infection
89001933|NCT00219999||chronic liver disease|chronic liver disease not due to hepatitis C virus infection
89001934|NCT00219999||Sustained Virologic responders|successfully treated for HCV infection
89001935|NCT00219999||normal|normal, healthy volunteers
89001936|NCT00220038||Normal|700 healthy adult volunteers will be drawn from the New York City area
89001937|NCT00189527|Experimental|respiratory support|a mode of ventilation in comparison
89001938|NCT00189527|Active Comparator|Assist Control|an other mode of ventilation in comparison
89001939|NCT00212979||non intervention study|
89001940|NCT00189605|Active Comparator|1|Fluoroscopy guided transforaminal epidural steroid injection (TFESI)
89001941|NCT00189605|Experimental|2|Percutaneous Disc Decompression of the lumbar level which is secondary to radicular pain
89001942|NCT02963129|Experimental|Mupirocina|topical mupirocin nasal ointment and nasal solid petroleum jelly for 5 consecutive days and then just nasal solid petroleum jelly to complete the 60 total days
89001943|NCT02963129|Placebo Comparator|Control|topical placebo nasal ointment and nasal solid petroleum jelly for 5 consecutive days and then just nasal solid petroleum jelly to complete the 60 total days
89001944|NCT00189839|Active Comparator|1|
89001945|NCT00189839|Experimental|2|
89001946|NCT00189878|Active Comparator|1 methotrexate|patient to receive methotrexate
89001947|NCT00189878|Placebo Comparator|2 Placebo|given placebo capsules
89001948|NCT00220311|Experimental|Arm 1|
89001949|NCT00189917|Experimental|GP 1: healthy, no AD|Healthy subjects without any history of, or current signs and symptoms of atopic disease, receiving two doses IMVAMUNE (MVA-BN), subcutaneous.
89001950|NCT00189917|Experimental|GP2: prev. allerg. rhinitis|Subjects having documentation of at least one allergic rhinitis event during the previous year, receiving two doses IMVAMUNE (MVA-BN), subcutaneous..
89001951|NCT00189917|Experimental|GP3: history of AD|Subjects having documentation of a history of Atopic Dermatitis, receiving two doses IMVAMUNE (MVA-BN), subcutaneous..
89001952|NCT00189917|Experimental|GP4: active AD|Subjects presenting active Atopic Dermatitis and having an individual SCORAD value between 1 and 15, receiving two doses IMVAMUNE (MVA-BN), subcutaneous.
89001953|NCT00189956|Active Comparator|Group 1|healthy, vaccinia naïve subjects 2 x 10E7 TCID50 IMVAMUNE (MVA-BN), subcutaneous
89001954|NCT00189956|Active Comparator|Group 2|healthy, vaccinia naïve subjects 5 x 10E7 TCID50 IMVAMUNE (MVA-BN), subcutaneous
89001955|NCT00189956|Active Comparator|Group 3|"healthy, vaccinia naïve subjects~1 x 10E8 TCID50 IMVAMUNE (MVA-BN), subcutaneous"
89001956|NCT00213252|Experimental|1|
89001957|NCT00213252|Active Comparator|2|
89001958|NCT00213291|Experimental|1|
89001959|NCT00412581|Experimental|Lenalidomide + Dacarbazine|
89001960|NCT00412620|Placebo Comparator|Sugar Pill|
89001961|NCT00412620|Experimental|Group 1 Part 1 - ABT-925|
89001962|NCT00412620|Experimental|Group 1 Part 2 - ABT-925|
89001963|NCT00412620|Experimental|Group 2 - ABT-925|
88840384|NCT05588635||Without live birth group|patients without live birth following frozen-thawed embryo transfer
88840385|NCT05588557|Active Comparator|Marcaine® 100mg/20mL (0.5%) bupivacaine solution for Injection|Marcaine® at 150 mg in each cohort.
88840386|NCT05588557|Experimental|ND-340 (Bupivacaine Microsphere), 300 mg/vial bupivacaine for extended-release injectable suspension|ND-340(90-320 mg) at dose escalations
89368102|NCT04401293|Experimental|Full Dose LMWH anticoagulation therapy|Subjects in this study arm will be treated with therapeutic doses of subcutaneous low-molecular-weight heparin (enoxaparin). Enoxaparin 1mg/kg SQ BID for CrCl ≥ 30ml/min (or Enoxaparin 0.5mg/kg SQ BID for CrCl ≥ 15ml/min and < 30ml/min) during the course of their hospitalization.
89368103|NCT04401293|Active Comparator|Prophylactic/Intermediate Dose LMWH or UFH therapy|Subjects in this study arm will be treated with Local institutional standard-of-care for prophylactic-dose or intermediate-dose UFH or LMWH. Regimens allowed are UFH up to 22,500 IU daily in BID or TID doses (i.e. UFH 5000 IU SQ BID/TID or 7500 IU BID/TID), enoxaparin 30mg and 40mg SQ QD or BID (the use of weight-based enoxaparin i.e. 0.5mg/kg SQ BID for this arm is acceptable but strongly discouraged), dalteparin 2500IU or 5000IU QD.
89368104|NCT03209830|Experimental|Arm A|OSU6162, drug given to half of the patients after randomization
89368105|NCT03209830|Placebo Comparator|Arm B|Placebo oral tablet, drug given to halv of the patients after randomization
89368106|NCT03209986|Experimental|MSC group|mesenchymal stem cell transplantation via peripheral vein: 1x10E6 MSCs/kg body weight administered via peripheral vein at week 0, 4, 8.
89368107|NCT03209986|No Intervention|control|Standard medication for viral hepatitis and cirrhosis
89368108|NCT03209908||control group|In this group, pregnant women with HBsAg/HBeAg positive and HBV DNA > 106 copies/ml don not use any antiviral drugs during pregnancy.
89368109|NCT03209908||experimental group|pregnant women with HBsAg/HBeAg positive and HBV DNA > 106 copies/ml start to use Tenofovir Disoproxil Fumarate(TDF) antiviral treatment from the 32 weeks of gestation to block mother-to-child transmission of hepatitis B virus.
89368110|NCT03209440|Active Comparator|usual outpatient palliative care|During the usual care steps, patients will receive usual outpatient palliative care
89368111|NCT03209440|Experimental|Dignity Therapy - Nurse Led|During the experimental steps as part of routine palliative care service delivery, patients receive nurse-led DT.
89368112|NCT03209440|Experimental|Dignity Therapy - Chaplain Led|During the experimental steps as part of routine palliative care service delivery, patients will receive chaplain-led DT.
89368113|NCT03224494|Other|IBS Patients|"Patients 18 years or older with a diagnosis of irritable bowel symptom, as per Rome IV criteria. The diagnosis is established by the patient's gastroenterologist. Please see inclusion and exclusion section for more details.~They will undergo Rapid Barostat Bag testing, and they will answer the IBS severity scoring system questionnaire (IBS-SSS) and HAD scale questionnaire."
89368114|NCT03224494|Other|Healthy Controls|"Patients 18 years of age without IBS or other colo-rectal symptoms or pathology seen for other issues in the general GI clinic.~They will undergo Rapid Barostat Bag testing, and they will answer the IBS severity scoring system questionnaire (IBS-SSS) and HAD scale questionnaire."
89368115|NCT04319159|Experimental|BF-200 ALA|"Topical application of BF-200 ALA containing 7.8% 5-ALA (5-aminolevulinic acid).~One single Photodynamic therapy (PDT)."
88840387|NCT01632306|Experimental|LY2090314 + Gemcitabine|LY2090314 given intravenously (IV) on days 1 (at cycle 1 LY2090314 given on day 0 instead of day 1), 8 and 15 in 28 day cycle in combination with 1000 milligram/square meter (mg/m^2) gemcitabine given IV on days 1, 8 and 15. Cohort closed to new enrollment per protocol addendum.
88840388|NCT01632306|Experimental|LY2090314 + FOLFOX|LY2090314 given IV on days 1 (at cycle 1 LY2090314 given on day 0 instead of day 1), and 15 in 28 day cycle in combination with FOLFOX (leucovorin + 5-fluorouracil + oxaliplatin) given IV, on days 1 and 15 in 28 day cycle.
89368116|NCT02451904||Severe/Cerebral Malaria|Intensive monitoring
89368117|NCT02451904||Uncomplicated Malaria|Intensive monitoring
88840389|NCT01632306|Experimental|LY2090314 + Gemcitabine + Nab-paclitaxel|LY2090314 given IV on days 1 (at cycle 1 LY2090314 given on day 0 instead of day 1), 8 and 15 in 28 day cycle in combination with 1000 mg/m^2 gemcitabine + 125 mg/m^2 nab-paclitaxel given IV on days 1, 8 and 15 in 28-day cycle. New cohort opened per protocol amendment.
88840390|NCT02346565|Other|Exercise ECG|Patients will undergo an exercise test using the standard Bruce protocol. Standard end points of exercise testing will include: fatigue, severe ischaemia (severe chest pain, >2mm ST depression on ECG), hypertension (systolic BP>220mmHg), hypotension, pre-syncope or arrhythmia.
88840391|NCT02346565|Other|Stress Echocardiography|"A two-dimensional echocardiogram will be performed in the lateral decubitus position. Digitized images of the left ventricle (LV) will be obtained in the parasternal long-axis, short-axis, and apical four-, two-, and three-chamber views.~In the case of exercise stress echo, images will be acquired at rest and immediately (within 90 seconds) after peak exercise.~In the case of dobutamine stress echo, images will be acquired at rest, at the end of stage one of dobutamine administration (10mcg/Kg/min) and at peak stress."
89001964|NCT00190190|Experimental|1|With Peeling of Limiting the Intern of the Retina
89001965|NCT00190190|Active Comparator|2|Traditional Procedure Without Peeling of Limiting
89368118|NCT02451904||Sepsis|Intensive monitoring
89368119|NCT02451904||Acidosis|Intensive monitoring
89368120|NCT02451904||Encephalitis|Intensive monitoring
89368121|NCT02451904||Healthy Individuals|Monitoring
89368122|NCT03224338|Experimental|: Dolutegravir (DTG)|
89368123|NCT03224260|Experimental|Treatment A|Receive 50 mg BMS-986177 once daily or placebo
89368124|NCT03224260|Experimental|Treatment B|Receive 200 mg BMS-986177 once daily or placebo
89368125|NCT03224260|Experimental|Treatment C|Receive 500 mg BMS-986177 once daily or placebo
89368126|NCT04318535|Experimental|Participants receiving T1T2R|Participants will receive a single oral dose of Griseofulvin T1: 1 x 500 mg Tablet once in Period 1 on Day 1 followed by a washout period of at least 7 days. In Period 2 on Day 8, same participants will receive Griseofulvin T2: 1 x 250 mg Tablet once followed by a washout period of at least 7 days. In Period 3 on Day 15, same participants will receive Griseofulvin R: 1 x 500 mg Tablet once. All the above-mentioned doses will be administered with 240 +- 2 milliliters (mL) of water at ambient temperature under fed condition.
89368127|NCT04318535|Experimental|Participants receiving T2RT1|Participants will receive a single oral dose of Griseofulvin T2: 1 x 250 mg Tablet once in Period 1 on Day 1 followed by a washout period of at least 7 days. In Period 2 on Day 8, same participants will receive Griseofulvin R: 1 x 500 mg Tablet once followed by a washout period of at least 7 days. In Period 3 on Day 15, same participants will receive Griseofulvin T1: 1 x 500 mg Tablet once. All the above-mentioned doses will be administered with 240 +- 2 milliliters (mL) of water at ambient temperature under fed condition.
88840392|NCT02600065||Study cohort|"All patients who are suffering from brain tumor of brain metastases and are willing to participate.~The treatment-plan of the underlying disease remained unchanged. Blood draw and MRI from patients at several time points during and after radio(chemo)therapy."
89368128|NCT04318535|Experimental|Participants receiving RT1T2|Participants will receive a single oral dose of Griseofulvin R: 1 x 500 mg Tablet once in Period 1 on Day 1 followed by a washout period of at least 7 days. In Period 2 on Day 8, same participants will receive Griseofulvin T1: 1 x 500 mg Tablet once followed by a washout period of at least 7 days. In Period 3 on Day 15, same participants will receive Griseofulvin T2: 1 x 250 mg Tablet once. All the above-mentioned doses will be administered with 240 +- 2 milliliters (mL) of water at ambient temperature under fed condition.
89368129|NCT02451826|Active Comparator|1.5 mg tablet LNG after 12 weeks|CVR delivering 2,500 µg of Ulipristal acetate per day and a single dose of levonorgestrel delivered in a 1.5 mg tablet after 12 weeks of CVR use
88840393|NCT02201784|Active Comparator|Levobupivacaine 0.5%|intrathecal administration of 15 mg of Levobupivacaine 0.5%
88840394|NCT02201784|Active Comparator|Ropivacaine 0.75%|intrathecal administration of 22.5 mg of Ropivacaine 0.75%
88840395|NCT04340479||Absent lung ultrasound findings of active COVID infection|Absence of bilateral, diffuse pleural line abnormalities, subpleural consolidations, white lung areas and thick, irregular vertical artifacts
88840396|NCT04340479||Present lung ultrasound findings of active COVID infection|Presence of bilateral, diffuse pleural line abnormalities, subpleural consolidations, white lung areas and thick, irregular vertical artifacts
88840397|NCT02201472|Experimental|MRI with MRE|Magnetic Resonance Imaging with Magnetic Resonance Elastography using the GE MR Touch device
88840398|NCT02162329|Other|Healthy Control Group|Healthy participants fill out several questionnaires asking questions about memory and concentration, mood, fatigue, how they have been feeling, and general quality of life. The questionnaires should take about 30 minutes to complete. Electroencephalography (EEG) and magnetic resonance imaging (fMRI) scan performed. These should take a total of about 90 minutes to complete.
88840399|NCT02162329|Experimental|Tibetan Meditation Group|Participants fill out several questionnaires at baseline, at completion of meditation classes, and at follow up visit. The forms should take about 30 minutes to complete. Participants complete computer tests to check memory and concentration taking about 20 minutes to complete. Electroencephalography (EEG) performed at baseline, at completion of classes, and at follow up visit. Participants have magnetic resonance imaging (fMRI) scan of brain at baseline, at completion of meditation classes, and at follow up visit. Tests, EEG, and fMRI should take a total of about 90 minutes to complete. Participants take part in up to 16 meditation classes for a total of 8 weeks. All sessions videotaped.
88840400|NCT02162329|Other|Wait-List Group|"Participants fill out several questionnaires at baseline and at follow up visit. The forms should take about 30 minutes to complete. Participants complete computer tests to check memory and concentration taking about 20 minutes to complete. Tests, EEG, and fMRI should take a total of about 90 minutes to complete. Participants receive the standard of care for cancer patients.~After 8 week follow up visit, Wait-List Group offered meditation program."
88840401|NCT02647346|Experimental|Participant cohort|Participants with diabetes that each have a history of healed Diabetic Foot Ulcer (DFU) prior to enrollment.
88840402|NCT05441995|Experimental|Cryotherapy|
88840403|NCT05441995|Active Comparator|Inferior alveolar nerve block|
88840404|NCT02554838|Active Comparator|Rehabilitation|"Rehabilitation :~Physical activity~Home assessment and modification"
88840405|NCT02554838|Experimental|Rehabilitation and CBT|"Rehabilitation associated with cognitive behavioral therapy (CBT) :~Physical activity~Home assessment and modification~Cognitive behavioral therapy"
88840406|NCT05588089|No Intervention|Control group|"After the birth of the control group, the Personal Information Form for Fathers and Infant Care Questionnaire were applied to the fathers as pre-tests in the clinic. After the training, the fathers will be called at the 2nd, 3rd, 4th, 8th and 12th weeks, and the Fathers' Participation in Baby Care Chart will be applied 5 times during 12 weeks. In addition, Father-Infant Attachment Scale and Infant Care Questionnaire were applied to fathers at 12 weeks as posttests.~Personal Information Form for Mothers will be filled by mothers in the postpartum clinic, mothers are called at 4th, 8th and 12th weeks and Edinburgh Postpartum Depression Scale and Postpartum Quality of Life Scale are applied."
88840407|NCT05588089|Experimental|Intervention group|"For the experimental group, Personal Information Form for Fathers and Infant Care Questionnaire were applied to the fathers in the clinic after birth as a pre-test. In the clinic, baby care training was given to fathers practically in 30-35 minutes. After the applied training, the Baby Care Training Program Content prepared by the researchers was given to the fathers. After the training, the fathers were called at the 2nd, 3rd, 4th, 8th and 12th weeks, and the Paternals' Participation in Baby Care Chart was applied 5 times during 12 weeks. In addition, the fathers were called at the 12th week and the Infant Care Questionnaire Form was applied as a post-test and the Father-Infant Attachment Scale was applied.~Personal Information Form for Mothers was applied to the mothers after the birth in the clinic, and the mothers were called at the 4th, 8th and 12th weeks and the Edinburgh Postpartum Depression Scale and the Postpartum Quality of Life Scale were applied."
88840408|NCT05587933|Experimental|operative|
88840409|NCT02018263|Active Comparator|Cocaine Administration|Subjects self administer cocaine hydrochloride in both laboratory and outpatient settings
89368130|NCT02451826|Active Comparator|1.5 mg tablet LNG every 4 weeks|CVR delivering 2,500 µg of Ulipristal acetate per day and one 1.5 mg tablet levonorgestrel every 4 weeks of CVR use (three times).
88840410|NCT02018263|Active Comparator|Nicotine Administation|Subjects self administer nicotine in both laboratory and outpatient settings
88840411|NCT02018263|Active Comparator|Exercise|Subjects complete a cardiovascular exercise session in both laboratory and outpatient settings
89368131|NCT03224416|Experimental|Alcohol|In the alcohol condition (target BrAC = 0.080g%), the participant will be told he is receiving alcohol and will receive beverages of 1:4 parts vodka and tonic water with dashes of lime juice and mint, all mixed in his presence.
89368132|NCT03224416|Placebo Comparator|Placebo|"In the placebo condition (target BrAC = 0.000g%), the participant will be told he is receiving alcohol but will receive beverages of 1:4 parts flat tonic water (served from a vodka bottle) and tonic water, with a minimal amount of vodka floated on the surface (using a lime juice bottle) to provide the smell and taste of vodka, with lime juice and mint, all mixed in his presence and served in glasses with vodka-soaked rims."
89368133|NCT03224416|Sham Comparator|True Control|In the true control (or nonalcohol) condition, the participant will be told he is receiving no alcohol and will be given water (poured in his presence) in a volume comparable to the other conditions.
89368134|NCT04400903||Observational (HRV monitoring, questionnaire)|Participants undergo HRV monitoring using an activity monitor (WHOOP) for a minimum of 5 days weekly for up to 1 year in patients with newly-diagnosed PDAC and up to 5 years for patients in high risk group.
89368135|NCT03223948|Active Comparator|30 litres per minute|High flow nasal oxygen delivery device 'Optiflow'
89368136|NCT03223948|Active Comparator|45 litres per minute|High flow nasal oxygen delivery device 'Optiflow'
89368137|NCT03223948|Active Comparator|60 litres per minute|High flow nasal oxygen delivery device 'Optiflow'
89368138|NCT03223870||Oximeters|Comparison of respiratory rates with other devices in normal subjects as observational with other pulse oximeters. No treatment of interventions will be performed.
89368139|NCT03223792|Active Comparator|Control|
89368140|NCT03223792|Experimental|Investigational|
89368141|NCT03747263|Experimental|Individual Freeze-Catheter ablation|"The individualized time-to-effect protocol utilizing the AFA-Pro applies a freeze-cycle until documentation of PVI based on continuous real-time recordings from the Achieve catheter inside the PV. After documentation of PVI the freeze-cycle is prolonged for additional 90 seconds. If no PVI is achieved after 90 seconds or a temperature of -<30° is not reached after 40 seconds the freeze cycle is stopped, the cryoballoon will be repositioned to possibly achieve a better position. Afterwards the freeze-cycle will be restarted. If no real-time PV signal recording can be obtained, a standard freeze-cycle of 180 seconds is applied. No bonus-freeze-cycle is applied in this protocol."
89368142|NCT03747263|Active Comparator|Fixed Freeze-Catheter ablation|The fixed-freeze-cycle protocol utilizing the AFA-Pro comprises a fixed freeze-cycle duration of 180 seconds. If PVI is not achieved with the first freeze-cycle, another 180 seconds freeze-cycle will be applied until documented PVI. After PVI no bonus freeze-cycle is applied.
89368143|NCT01562561|Experimental|Rep + NPH|
89368144|NCT01562561|Active Comparator|NPH|
89368145|NCT03206944|Experimental|Group 1 ASA|Group 1(ASA) included 33 patients who received acetylsalicylic acid at a dose of 75 mg orally once a day in the morning.
89368146|NCT03206944|Experimental|Group 2 STE|Group 2 (STE) included 32 patients receiving tomato fruit extract (STE) (ZAAX, Sequia, Poland) at a dose of 213 mg orally once a day in the morning.
89368147|NCT03209596|Experimental|Orange juice|Seventeen individuals received 1 liter/day of pasteurized orange juice. Participants consumed the orange juice before and post exercise, the volume of juice per serving was 500 mL. On players' rest days, the juice was consumed throughout the day.
88840412|NCT05442073||Type I: ΔPes≥30%ΔPEEP|
89179302|NCT04097808|Experimental|collagen peptide fish low molecular weight-Water|source: fish; standardized to 10 g provided as single dose. Orally applied in water.
89368148|NCT03209596|Active Comparator|Control drink|Thirteen individuals received 1 liter/day of control drink. The participants consumed the control drink before and post exercise, the volume of drink per serving was 500 mL. On players' rest days, the drink was consumed throughout the day. The control drink consisted of an aqueous solution containing sucrose (44 g), glucose (22 g), fructose (22 g), citric acid (11g) (proportionally 2:1:1:0.5) (USDA, 2016) (with the same proportion of total sugars as the orange juice, and without all others bioactive compounds of juice), dyestuff sunset yellow (0.05 g) and orange essence.
89368149|NCT04454567|Experimental|ABI-H0731 + SOC NrtI|Participants with chronic hepatitis B virus (HBV) infection with partial virologic suppression on NrtI alone will receive ABI-H0731 300 mg once daily plus standard of care (SOC) NrtI for 96 weeks, followed by SOC NrtI alone for an additional 24 weeks (120 weeks total).
89368150|NCT04454567|Placebo Comparator|Placebo + SOC NrtI|Participants with chronic HBV infection with partial virologic suppression on NrtI alone will receive placebo to ABI-H0731 once daily plus SOC NrtI for 48 weeks, followed by ABI-H0731 300 mg once daily plus SOC NrtI for Weeks 48 to 96, followed by SOC NrtI alone for Weeks 96 to 120.
89368151|NCT03206632|Experimental|BI 690517 dose group 1|
89368152|NCT03206632|Experimental|BI 690517 dose group 2|
89368153|NCT03206632|Experimental|BI 690517 dose group 3|
89368154|NCT03206632|Placebo Comparator|Placebo|Matching placebo for each dose group
89368155|NCT03206554|Active Comparator|LIA|Local infiltration analgesia
89368156|NCT03206554|Sham Comparator|sham LIA|Saline injections
89368157|NCT03751319|Active Comparator|Standard Emergency Care + CGA|Standard Care is provided for the acute condition as usual by the ED personnel. Besides the standard care provided by ED personnel, patients are systemically screened and assessed by physician trained for geriatrics or geriatric emergency medicine. Geriatric multi-discipline treatment plan and recommendations are given if suitable for the case.
89368158|NCT03751319|No Intervention|Standard Emergency Care|Standard Care is provided for the acute condition as usual by the ED personnel.
89368159|NCT03209284||narrow sinuses|transcrestal sinus floor elevation in narrow sinuses
89368160|NCT03209284||wide sinuses|transcrestal sinus floor elevation in wide sinuses
89368161|NCT03209206|Experimental|Docetaxel bladder instillation arm|After Surgery, intravesical chemotherapy with in 48 hrs (Docetaxel 75 mg diluted in 100 cc of normal saline)
89368162|NCT03209206|Placebo Comparator|Control arm|After Surgery, intravesical chemotherapy with in 48 hrs (Placebo, 100 cc of normal saline)
89368163|NCT04449341|Experimental|Standard care venipuncture with additional of virtual reality|Patients undergoing blood draw while interacting with VR application Ocean Rift while wearing Oculus Go headset
89368164|NCT04449341|No Intervention|Standard care venipuncture without addition of virtual reality|Patients undergoing blood draw while wearing Oculus Go headset that is turned off
88840413|NCT05442073||Type II: ΔPes<30%ΔPEEP|
88840414|NCT02649608|Experimental|0.04 mg Lu AE04621|Patients having received a dose of 0.04 mg, independent of which Cohort they belong to.
89368165|NCT03223636||Healthy Volunteers|Healthy Volunteers
88840415|NCT02649608|Experimental|0.08 mg Lu AE04621|Patients having received a dose of 0.08 mg, independent of which Cohort they belong to.
88840416|NCT02649608|Experimental|0.2 mg Lu AE04621|Patients having received a dose of 0.2 mg, independent of which Cohort they belong to.
88840417|NCT02649608|Experimental|0.4 mg Lu AE04621|Patients having received a dose of 1.2 mg, independent of which Cohort they belong to.
88840418|NCT02649608|Experimental|0.6 mg Lu AE04621|Patients having received a dose of 0.6 mg, independent of which Cohort they belong to.
88840419|NCT02649608|Experimental|0.8 mg Lu AE04621|Patients having received a dose of 0.8 mg, independent of which Cohort they belong to.
88840420|NCT02649608|Experimental|1.0 mg Lu AE04621|Patients having received a dose of 1.0 mg, independent of which Cohort they belong to.
88840421|NCT02649608|Experimental|1.2 mg Lu AE04621|Patients having received a dose of 1.2 mg, independent of which Cohort they belong to.
88840422|NCT02168946|Experimental|Vabomere|Vabomere (meropenem 2g plus vaborbactam 2g) IV q8h, for up to 14 days
89368166|NCT03749603|Experimental|TIBAY meter|Non-invasive measurement of red blood cell Zinc Protoporphyrin (ZnPP/haem ratio-µmol/mol haem) fluorescence in the microcirculation of the lower lip.
89368167|NCT03223558|Experimental|early rehab group|start of 8 weeks cardiac rehabilitation 2 weeks following surgery
89368168|NCT03223558|Active Comparator|usual care group|start 8 weeks of cardiac rehabilitation 6 weeks post surgery
88840423|NCT02168946|Active Comparator|Best Available Therapy|Subjects will receive Best Available Therapy (IV antibiotics)
88840424|NCT02649842|Experimental|Extended Cylinder IOL|Approved toric intraocular lenses, Model ZCT450, ZCT525 or ZCT600
88840425|NCT02650856|Experimental|Group 1 Tranexamic acid|"A dosis of 2 gr of tranexamic acid (1000mg/10ml X-GEN pharmaceuticals inc.) diluted in 80ml of physiologic solution and will be divided in two applications.~First application: 40ml of the solution previously prepared is applied over the surgical site and it will be left for five minutes then drained out completely by suction.~Second application: The rest of 40ml of solution previously prepared is applied after placing the final TKR components (femoral, tibial and patellar), over the surgical site and leaving it without draining it by suction."
88840426|NCT02650856|Active Comparator|Group 2 Platelet rich plasma|"A final volumen of 16 ml of platelet rich plasma is obtained from the forearm vein of the patient and will be divided in two applications.~First application: 8 ml of PRP are applied over the surgical site and are left for five minutes then drained out completely by suction.~Second application: The rest of the 8 ml are applied after placing the final TKR cemented components (femoral, tibial and patellar), over the surgical site and leaving it without draining."
88840427|NCT02168478|Experimental|Patch Test Group|"All subjects are patched with the following: 1.Neo-Synalar Cream 2.Sodium Lauryl Sulfate and 3. Saline.~Test material is applied to the absorbent pad and allowed to remain in direct skin contact for a period of 48 hours."
88840428|NCT02302976|Experimental|acute pre-treatment with exenatide|This arm plans to explore the effects of acute pre-treatment with the glucagon like peptide-1 (GLP-1) agonist, exenatide vs. placebo, on the subjective (e.g., euphoric) and behavioral effects (e.g., self-administration) of cocaine in experienced, non-treatment seeking users of the drug. We propose to study 24 subjects in a within-subject (two-day, randomized, placebo-controlled) human laboratory study of self-regulated cocaine administration. We hypothesize that acute treatment with exenatide will reduce cocaine-induced euphoria and self-regulated cocaine administration as compared to placebo
88840429|NCT02302976|Experimental|sub-chronic (5 day) treatment with exenatide|This arm plans to explore the effects of sub-chronic (5-day) treatment with exenatide as compared to placebo on the subjective (e.g., euphoric) and behavioral (self-administration) effects of cocaine in experienced, non-treatment seeking users of the drug. Upon completion of arm 1, subjects may opt to be randomized to five days of treatment with either exenatide or placebo, followed by a one-day human laboratory study of self-regulated cocaine administration. We hypothesize that subjects treated with exenatide (up to N=12) will demonstrate decreased self-regulated cocaine administration as compared to subjects treated with placebo (up to N=12).
88840430|NCT02302976|Placebo Comparator|acute pre-treatment with placebo|This arm plans to explore the effects of acute pre-treatment with the glucagon like peptide-1 (GLP-1) agonist, exenatide vs. placebo, on the subjective (e.g., euphoric) and behavioral effects (e.g., self-administration) of cocaine in experienced, non-treatment seeking users of the drug. We propose to study 24 subjects in a within-subject (two-day, randomized, placebo-controlled) human laboratory study of self-regulated cocaine administration. We hypothesize that acute treatment with exenatide will reduce cocaine-induced euphoria and self-regulated cocaine administration as compared to placebo
88840431|NCT02302976|Placebo Comparator|sub-chronic (5 day) treatment with placebo|This arm plans to explore the effects of sub-chronic (5-day) treatment with exenatide as compared to placebo on the subjective (e.g., euphoric) and behavioral (self-administration) effects of cocaine in experienced, non-treatment seeking users of the drug. Upon completion of arm 1, subjects may opt to be randomized to five days of treatment with either exenatide or placebo, followed by a one-day human laboratory study of self-regulated cocaine administration. We hypothesize that subjects treated with exenatide (up to N=12) will demonstrate decreased self-regulated cocaine administration as compared to subjects treated with placebo (up to N=12).
89368169|NCT03223402|Experimental|nevirapine plus lamivudine|patients from one Center switching from a Nevirapine based Regimen on Nevirapine + 3TC
89368170|NCT03208972|Experimental|low dose hCG (Pregnyl)|Corifollitropin Alfa (Elonva) dosage depending on weight once administered first day of ovarian stimulation in combination 150IU low dose hCG from day 7 until final oocyte maturation.
89368171|NCT03208972|Active Comparator|hp-FSH (Menopur)|Corifollitropin Alfa (Elonva) dosage depending on weight once administered first day of ovarian stimulation in combination with hp-FSH until final oocyte maturation.
89368172|NCT03206866||patients with HCC|
89368173|NCT03206866||patients with hepatitis C Ab positive|
89368174|NCT03206866||patients with hepatitis C Ab negative|
89368175|NCT02450500|Experimental|Lifestyle counselling|This will consist of a web-based lifestyle app and personalised behaviour modification advice by a registered dietitian delivered via messaging.
89179303|NCT04097808|Experimental|collagen peptide porcine low molecular weight-Water|source: porcine; standardized to 10 g provided as single dose. Orally applied in water.
88840432|NCT05075564|Experimental|Part 1 dose escalation|ES002023 doses will be escalated in patients with advanced solid tumors with approximately 30 subjects.
88840433|NCT05075564|Experimental|Part 2 dose expansion|Part 2 of the study will consist of 3 expansion cohorts for pancreatic ductal adenocarcinoma (Cohort 2A), NSCLC (Cohort 2B), and colorectal adenocarcinoma (Cohort 2C) with 10 subjects per expansion cohort respectively at the recommended optimal biological dose determined in Part 1 dose escalation.
88840434|NCT02244164|Active Comparator|Sulfonylurea|Patient will received metformine with sulfonylurea
88840435|NCT02244164|Active Comparator|Incretinomimectics|Patients will received metformin with sulfonylurea with GLP-1 analogue
88840436|NCT02244164|Active Comparator|DPP-4 inhibitors|Patients will received metformin with DPP-4 inhibitors
88840437|NCT02152670|Experimental|Baseline|Subjects will receive 2 baseline PET scans with the radioligands (11C)(+)PHNO and (11C)(+)raclopride
88840438|NCT02152670|Experimental|Dopamine Release|Subjects will receive 1 PET scan following a PO dose of 60mg of methylphenidate to facilitate dopamine release with the radioligand (11C)(+)PHNO
88840439|NCT02152670|Experimental|Endogenous Dopamine|Subjects will receive 2 PET scans following 48 hours of dopamine depletion via AMPT with the radioligands (11C)(+)PHNO and (11C)(+)raclopride
88840440|NCT02652416|Experimental|SRD part (low dose)|Chinese, Japanese both
88840441|NCT02652416|Experimental|SRD part (medium dose)|Chinese, Japanese both
88840442|NCT02652416|Experimental|SRD part (high dose)|Chinese, Japanese both
88840443|NCT02652416|Experimental|MD part (high dose)|Chinese, Japanese both
88840444|NCT02652416|Experimental|Placebo (SRD part)|placebo
88840445|NCT02652416|Placebo Comparator|Placebo (MD part)|placebo
88840446|NCT02028806|Experimental|FOLFIRINOX|Patients will receive mFOLFIRINOX every 2 weeks: Oxaliplatin 65 mg/m2 IV over 3 hours on Day 1; Irinotecan 150 mg/m2 IV over 90 minutes on Day 1; Leucovorin(l-LV) 200 mg/m2 IV over 2 hours on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion.
88840447|NCT01756118|Experimental|BEZ235|
88840448|NCT04339712|Experimental|anakinra|In case of diagnosis of MAS, IV anakinra 200mg three times daily (every eight hours) for 7 days. Patients who will receive anakinra treatment and who suffer from kidney dysfunction will receive 50% of the dose i.e. 100mg anakinra three times daily for 15 days
88840449|NCT04339712|Experimental|tocilizumab|"In case of diagnosis of immune dysregulation IV tocilizumab 8mg/kg body weight once up to a maximum of 800mg. These patients will receive anakinra at the above dose in case they meet one of the following contra-indications for tocilizumab:~absolute neutrophil count less than 2,500/mm3;~absolute platelet count less than 100,000/mm3; and~AST or ALT more than 1.5 x the upper normal limit"
88840450|NCT02656160|Placebo Comparator|Placebo|
88840451|NCT02656160|Active Comparator|Dalfampridine|
88840452|NCT02684396|Experimental|Cohort 1: TAK-648 0.05 mg|TAK-648 0.05 mg, solution, orally, once on Day 1.
88840453|NCT02684396|Experimental|Cohort 2: TAK-648 0.15 mg|TAK-648 0.15 mg, solution, orally, once on Day 1.
88840454|NCT02684396|Experimental|Cohort 3: TAK-648 0.35 mg|TAK-648 0.35 mg, solution, orally, once on Day 1.
88840455|NCT02684396|Experimental|Cohort 4: TAK-648 0.7 mg|TAK-648 0.7 mg, solution, orally, once on Day 1.
88840456|NCT02684396|Experimental|Cohort 5: TAK-648 0.85 mg|TAK-648 0.85 mg, solution, orally, once on Day 1.
88840457|NCT02684396|Placebo Comparator|Cohort 1-5: Placebo|TAK-648 placebo-matching solution, orally, once on Day 1.
88840458|NCT02657252|Active Comparator|Glucose|An application session 0.2% Polidocanol + 70% Glucose to treat telangiectasis of the lower limb selected, with a maximum volume of 5 ml. Return to a week to investigate the adverse effects and 2 months for proof of efficacy and adverse effects
88840459|NCT02657252|Active Comparator|Polidocanol with Glucose|An application session 0.2% Polidocanol + 70% Glucose to treat telangiectasis of the lower limb selected, with a maximum volume of 5 ml. Return to a week to investigate the adverse effects and 2 months for proof of efficacy and adverse effects
89179304|NCT00591266|Experimental|Azilsartan Medoxomil 40 mg QD and Amlodipine 5 mg QD|
89179305|NCT00591266|Experimental|Azilsartan Medoxomil 80 mg QD and Amlodipine 5 mg QD|
89179306|NCT00591266|Active Comparator|Amlodipine 5 mg QD|
89179307|NCT04094376|Other|Day group|42 patients scheduled for elective laparoscopic abdominal surgeries under general anesthesia were randomly assigned to receive operation in the Day Group (8:00-12:00)
88840460|NCT02657564|Other|Polyethylene glycol (PEG)|3-L polyethylene glycol (PEG) is provided for colonoscopy preparation. Patients receive blood tests for renal function and electrolytes before and after colonoscopy.
88840461|NCT04857008|Experimental|BNT001|BNT001 is a commercially-available, prescription-only, software / medical device in the form of a digital application (digital app) for use on the participant's mobile device which delivers 10-sessions on cognitive behavioral therapy for cancer patients.
88840462|NCT04339400|Experimental|TQ05105 Tablet|TQ05105 tablet 5mg administered orally once. Then TQ05105 tablet administered orally, twice daily in 28-day cycle after 3 days of first administration.
88840463|NCT04693832|Experimental|5inD|All children receive routine antiemetic therapy before chemotherapy. Children in the experimental group will use the interactive mobile application (5inD) for seven days from the first day of chemotherapy. The games in this application will help distract their attention and manage their nausea and vomiting.
88840464|NCT04693832|No Intervention|Control group|All children receive routine antiemetic therapy before chemotherapy.
88840465|NCT02684630|Experimental|Single Platelet Product|Healthy adult volunteer blood donors that qualify for a single unit platelet collection, with or without other components, will undergo plateletpheresis on the Trima Accel® Automated Blood Collection System (Trima Accel System).
88840466|NCT02684630|Experimental|Double Platelet Product|Healthy adult volunteer blood donors that qualify for a double unit platelet collection, with or without other components, will undergo plateletpheresis on the Trima Accel® Automated Blood Collection System (Trima Accel System).
89368176|NCT03223324||Pre Term and Threatened Pre-Term Labor|abdominal fetal/maternal monitoring
89368177|NCT03206398|Other|pelvic fracture|patients with pelvic fracture will additionally be treated with anti-gravity treadmill
89368178|NCT02451748|Other|DMARD's Responder and Non-Responder|In the first group of subjects, blood samples will be obtained from (50) RA subjects with Disease modifying anti rheumatic drugs (DMARDs) such as methotrexate, plaquenil and/or prednisone that achieve remission (DAS28<2.6). The subjects that achieve remission (DAS28<2.6), blood will only be taken once at the subjects routine visit. Subject's that are non-responder to DMARDS will go onto group 2.
89368179|NCT02451748|Other|DMARD's plus Cimzia (Certolizumab pegol)|"The second group will consist of (150) RA subjects that did not respond to DMARDs. These patients will further receive (DMARDs) such as methotrexate, plaquenil and/or prednisone as well as Cimzia®. In this Arm, blood samples will be collected onset of the study as well as 3 and 6 months after treatment with Cimzia at subject's visit through our collaboration with the aforementioned rheumatologists."
89368180|NCT03223168|Experimental|Hayek RTX ventilator|Participants will receive noninvasive negative pressure ventilation.
89368181|NCT03208894|Experimental|with salbutamol|
89368182|NCT03208894|Experimental|with furosemide|
89368183|NCT03208894|Experimental|both furosemide and salbutamol|
89368184|NCT03208894|No Intervention|no inervention|
89368185|NCT02450656|Experimental|Afatinib plus selumetinib|Combination of afatinib and selumetinib at the optimal dose and regimen as determined in the phase I part of this study
89368186|NCT02450656|Active Comparator|Control|Standard-of-care second line treatment for non small cell lung cancer (docetaxel)
89368187|NCT03208816|Other|single arm|symptom management program for chemotherapy patients
88840467|NCT04670042|Experimental|SPRINT® Peripheral Nerve Stimulation (PNS) System|SPRINT PNS System will be offered to patients with postoperative knee pain following primary unilateral total knee arthroplasty (TKA) who meet eligibility criteria and consistent with established coverage policy. SPRINT PNS System will be implanted for 60 days. At the discretion of the physician, the first lead may be placed to stimulate the nerve innervating the region of greatest pain. If pain is not adequately addressed by the first lead when assessed at 10 days, a second lead may be placed approximately 2 weeks following the initial lead placement.
88840468|NCT04739618|Experimental|Single arm. Subjects receiving treatment.|Efficacy of Non-ablative Cryosurgical Freezing and Multiplex Immunotherapy as determined by overall response rate of radiographic changes according to iRECIST criteria
88840469|NCT02684942|Active Comparator|Meperidine,Fentanyl,Meperidine,Fentanyl|Injection meperidine 1 mg./kg. to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4 at first and third fraction of brachytherapy. And injection fentanyl 1 ug./kg. to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4 at second and fourth fraction of brachytherapy.
88840470|NCT02684942|Active Comparator|Fentanyl,Meperidine,Fentanyl,Meperidine|Injection meperidine 1 mg./kg. to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4 at second and fourth fraction of brachytherapy. And injection fentanyl 1 umg/kg to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4 at first and third fraction of brachytherapy.
89368188|NCT03119272||Anorexia Nervosa Patients|Inpatient population at Eating Disorders Unit (EDU) at the University of North Carolina Neurosciences Hospital. Recruited upon intake into the unit.
89368189|NCT03119272||Age and Sex Matched Healthy Controls|University of North Carolina Psychiatry email listserv.
89368190|NCT03206242||initial|0 month begin physiotherapy
89368191|NCT03206242||3 months after physiotherapy|3 months after physiotherapy
89001966|NCT00412659|Active Comparator|Midline excision|Midline excision for pilonidal sinus disease.
89001967|NCT00412659|Active Comparator|Karydakis|Karydakis operation for pilonidal sinus disease.
89368192|NCT03206242||6 months after physiotherapy|6 months after physiotherapy
89368193|NCT03206320|No Intervention|Control|
89368194|NCT03206320|Active Comparator|Reference|
89368195|NCT03206320|Experimental|New|
89368196|NCT04448561|Experimental|ASP8062 in combination with morphine|Participants received ASP8062 tablet, orally once daily on days 1 through 10. On day 10, participants also received morphine tablet as single oral dose immediately after the ASP8062 dose.
89368197|NCT04448561|Placebo Comparator|Placebo in combination with morphine|Participants received ASP8062 matching placebo tablet, orally once daily on days 1 through 10. On day 10, participants also received morphine tablet as single oral dose immediately after the ASP8062 matching placebo dose.
89368198|NCT03208660||Fycompa|Participants diagnosed with epilepsy and treated with Fycompa
89368199|NCT03208738|No Intervention|Assessment only|
89368200|NCT03208738|Experimental|VetChange mobile app|
89368201|NCT03208738|Experimental|AFT + VetChange mobile app + supportive accountability tool|
89368202|NCT03751241|Experimental|Intraocular lens types|Patients with different types of IOLs (EROV, monofocal, minimonovision) are tested for their reading quality using the EyeTracker device
89368203|NCT03206008|Placebo Comparator|Normal saline group|after loading normal saline 100cc in 10-20 minutes, continuous infusion of normal saline until the end of surgery
89368204|NCT03206008|Active Comparator|Magnesium group|after loading magnesium sulfate dosing 50 mg/kg (100cc) in 10-20 minutes, continuous infusion of magnesium sulfate 15 mg/kg/h until the end of surgery
89368205|NCT04978259|Experimental|Standard of care plus remdesivir|Local standard of care plus daily remdesivir infusion for up to 10 days (or until discharge)
89368206|NCT04978259|No Intervention|Standard of care|Local standard of care
89368207|NCT03747185|Experimental|Lumbopelvic stiffening technique|Hamstring muscle stretching with lumbopelvic stiffening technique.
89368208|NCT03747185|Active Comparator|Lumbopelvic relaxing technique|Hamstrings muscle stretching with lumbopelvic relaxing technique.
89368209|NCT03208582|Other|Single arm trial|Intervention : Risedronate Sodium (oral) Dosage: 1mg/kg/week Frequency: once/week Duration: 6 weeks
89368210|NCT03205930|Experimental|Neo-MASCT|Neoantigen Multiple Target Antigen Stimulating Cell Therapy ( Neo-MASCT)
89530374|NCT03254329||Denmark|Assessment of human milk nutrient composition. Approximately 500 women and their infants recruited, 250 dyads completing study
89530375|NCT03254329||The Gambia|Assessment of human milk nutrient composition. Approximately 500 women and their infants recruited, 250 dyads completing study
89530376|NCT03248401|Experimental|Cilostazol group|Cilostazol 200 mg or maximal tolerate dose
89001968|NCT00190229|Experimental|1|Cyclophosphamide
89179308|NCT04094376|Other|Night group|42 patients scheduled for elective laparoscopic abdominal surgeries under general anesthesia were randomly assigned to receive operation in the Night Group (18:00-22:00)
89179309|NCT04093128|Experimental|adults aged 19-57|adults aged 19-57 years old living in Amman Jordan, body mass index between 19-57
89179310|NCT04093050|Experimental|TT Genotype|
89179311|NCT04093050|Experimental|AA/AT Genotype|
89179312|NCT04092972|Experimental|Atherectomy|Atherectomy and drug-coated balloon (DCB)
89179313|NCT04092972|Active Comparator|Standard care|Standard care with predilation (POBA) and DCB
89179314|NCT05450640||Patients with haemophilia A with dispensing Emicizumab (HEMLIBRA®) in community pharmacy|This group of patients have chosen the dispensing of Emicizumab (HEMLIBRA®) in community pharmacy. This choice involves the contribution of the community pharmacist in the dispensing circuit who does not replace the hospital pharmacist but interact together for prescriptions renewals, emergency treatment or sharing information if necessary.
89179315|NCT05450640||Patients with haemophilia A with dispensing Emicizumab (HEMLIBRA®) in hospital pharmacy|This group of patients have kept the dispensing of Emicizumab (HEMLIBRA®) in hospital pharmacy
89179316|NCT02601144|Experimental|VFS|variable frequency deep brain stimulation (VFS)
89179317|NCT02601144|Active Comparator|HFS|high frequency deep brain stimulation (HFS)
89179318|NCT02601144|Active Comparator|LFS|low frequency deep brain stimulation (LFS)
89179319|NCT02601144|No Intervention|DBS off|deep brain stimulation off
89179320|NCT04093908||multi-center validation cohort|We collect retrospective data from several international centers containing preoperative variables (demographical and clinical) and postoperative outcome (UPDRS II, III, IV) one year postoperatively, and merge these data to one validation cohort.
89179321|NCT02599662|Other|Group 1: 10 Gy Low-KV IORT|10 Gy Low Kilovoltage Intraoperative Radiation: intraoperative low-kV IORT will be delivered as a single dose of 10 Gy at 2 millimeter depth. Doses will be escalated in increments of 5 Gy until completion of 20 Gy dose level or the DLT is reached and MTD is realized.
89179322|NCT02599662|Other|Group 2: 15 Gy Low-KV IORT|15 Gy Low Kilovoltage Intraoperative Radiation: intraoperative low-kV IORT will be delivered as a single dose of 15 Gy at 2 millimeter depth. Doses will be escalated in increments of 5 Gy until completion of 20 Gy dose level or the DLT is reached and MTD is realized.
89179323|NCT02599662|Other|Group 3: 20 GY Low-KV IORT|20 GY Low Kilovoltage Intraoperative Radiation: intraoperative low-kV IORT will be delivered as a single dose of 20 Gy at 2 millimeter depth. Patients will be accrued to this group until the DLT is reached and MTD is realized.
89179324|NCT00758394|Placebo Comparator|Fluoride - A|Fluoride only toothpaste
89179325|NCT00758394|Active Comparator|Total + Whitening toothpaste - B|Triclosan/fluoride toothpaste
89179326|NCT00758394|Experimental|Triclosan/fluoride/Amino Acid - C|toothpaste containing amino acid #1
89179327|NCT00758394|Experimental|Triclosan/fluoride/Cavistat -D|toothpaste containing amino acid/bicarbonate
89179328|NCT04092738|Experimental|Intervention Group|"In the intervention group, subjects will receive brief advice on occupational physical activity, sedentary behaviour and Diabetes Type 2. In addition, participants will be provided with an external movement sensor that will be linked to the Walk@WalkApp-Diab for Android and iOS. This App will monitor the time participants spend sitting, walking and standing during working hours. It will also provide participants with strategies to sit less and move more at work throughout 13 weeks. This mHealth intervention aims to change occupational sitting by replacing desk-based activities by active tasks."
89179329|NCT04092738|No Intervention|Control Group|Subjects will receive brief advice on occupational physical activity, sedentary behaviour and Diabetes Type 2.
89179330|NCT04450394|Experimental|LY3209590 Algorithm 1 (Paper)|Algorithm 1 is a paper-based algorithm where dose adjustments were manually determined by the investigator based on fasting glucose and hypoglycemia data. LY3209590 was provided in a 20 milligram (mg) vial of reconstitutable lyophilized powder. Participants received individualized LY3209590 loading dose based on the baseline median fasting glucose and body weight by subcutaneous (SC) injection on day 1 followed by weekly adjustments for the first 12 weeks, then every 4 weeks, of a 26-week treatment period, to achieve target fasting glucose of <=100 milligrams per deciliter (mg/dL).
89179331|NCT04450394|Experimental|LY3209590 Algorithm 2 (Digital)|"Algorithm 2 is a computer-based algorithm to determine dose adjustments. LY3209590 was provided in a 20 mg vial of reconstitutable lyophilized powder. Participants received individualized LY3209590 loading dose based on the baseline median fasting glucose and body weight by SC injection on day 1 followed by weekly adjustments for the first 12 weeks, then every 4 weeks, of a 26-week treatment period, to achieve target fasting glucose of <=100 mg/dL.~As per protocol amendment (d) approved on 28-Oct-2020, this arm was terminated during the early enrollment phase due to technical issues with data entry."
89530377|NCT03248401|Active Comparator|Aspirin group|Aspirin 100 mg
89530378|NCT04502927|Other|Stroke patients with hand spasticity (n=20)|
89001969|NCT00190268|Experimental|3,4-diaminopyridine|3,4-diaminopyridine
89001970|NCT00190307|Experimental|1|Aspirin:KARDEGIC
89530379|NCT04502927|Other|Healthy volunteers (n=10)|
89530380|NCT03254017|Experimental|Experimental Deep Brain Stimulation|Device：Suzhou Sceneray® DBS system
89001971|NCT02963168|Experimental|Oradoxel|To determine the MTD of Oradoxel (oral docetaxel and oral HM30181A) when administered once every 3 weeks, then to determine the MTD of Oradoxel (oral docetaxel and oral HM30181A) when administered for two days every three weeks.
89001972|NCT00409448|Experimental|CAPS|Participants will receive the Internet-based counselor-assisted problem-solving group treatment
89001973|NCT00409448|Active Comparator|IRC|Participants will receive the Internet resource comparison group treatment
89001974|NCT00190385|Active Comparator|A|
89001975|NCT00190424|No Intervention|control|
89001976|NCT00190424|Experimental|CpG-ODN|
89001977|NCT00190541|Active Comparator|1|Procedure/Surgery: Mesorectal excision with lateral lymph node dissection
89001978|NCT00190541|Experimental|2|Procedure/Surgery: Mesorectal excision without lateral lymph node excision
89530381|NCT05573399||Early oral feeding|No enteral feeding tube was placed after pancreaticoduodenectomy and oral nutrition was given early. Patients were given liquid drinks on the second day after pancreaticoduodenectomy, and solid food from the fifth day.
88840471|NCT02684942|Active Comparator|Meperidine,Meperidine,Fentanyl,Fentanyl|Injection meperidine 1 mg./kg. to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4 at first and second fraction of brachytherapy. And injection fentanyl 1 ug./kg. to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4 at third and fourth fraction of brachytherapy.
88840472|NCT02684942|Active Comparator|Fentanyl,Fentanyl,Meperidine,Meperidine|Injection meperidine 1 mg./kg. to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4 at third and fourth fraction of brachytherapy. And injection fentanyl 1 ug./kg. to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4 at first and second fraction.
88840473|NCT02684942|Active Comparator|Meperidine,Fentanyl,Fentanyl,Meperidine|Injection meperidine 1 mg./kg. to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4 at first and fourth fraction of brachytherapy. And injection fentanyl 1 ug./kg. to intravenous 5 minute before insertion the applicator and then when the patients had pain score more than 4 at second and third fraction of brachytherapy.
88840474|NCT02684942|Active Comparator|Fentanyl,Meperidine,Meperidine,Fentanyl|Injection meperidine 1 mg./kg. to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4 at second and third fractionof brachytherapy. And injection fentanyl 1 ug./kg. to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4 at first and fourth fraction of brachytherapy.
88840475|NCT04339010|Experimental|Hypopressive|"st session: the meetings were provided by a physiotherapist, who also discussed the location and function of the pelvic organs, PFM, and the transversus abdominis (TrA) muscles. The participants learned how to activate TrA muscles. The training was performed during full expiration, the physiotherapist check and coordinate the group to maintain the Tra contraction. The women were also trained to inhale through the nose and exhale through the mouth maintaining an apical breathing pattern.~nd session: The contractions were executed during six different positions the ones which they will keep following through the whole treatment.~rd session: The patients were exposed to all the six positions (supplementary material) and their three variations (positions 1, 3, 5 and 6 ). Every meeting obeyed the same schedule through the five weeks of treatment and was accompanied by two physiotherapists."
88840476|NCT04339010|Active Comparator|Hypopressive + PFMC|This group receives the same protocol than the Hypopressive group, but with a verbal command to realize the PFM contraction during the activation of the deep abdominal muscle.
88840477|NCT04739774|Experimental|Treatment R|Single dose of CHF6001
88840478|NCT04739774|Experimental|Treatment T|Single dose of CHF6001 administered after repeated doses of oral Itraconazole
88840479|NCT02685956||Vela Sentosa SA HSV1/2 PCR Test|Male and female subjects of any age with sample collected from a lesion and submitted to a clinical laboratory for the purpose of testing for the presence of HSV1 or HSV2 and diagnosing HSV infection.
88840480|NCT02660918|Experimental|Treatment|Women undergoing endometrial ablation that meet the eligibility criterial will receive a standardized paracervical injection of Bupivacaine 20 mL 0.25% at the completion of the procedure.
88840481|NCT02660918|Placebo Comparator|Control|Women undergoing endometrial ablation that meet the eligibility criterial will receive an equal volume standardized paracervical injection of Normal Saline at the completion of the procedure.
88840482|NCT02687126|Other|Pediatric Cardiac Surgical Patients|Central Venous Catheterization
88840483|NCT04564196||Induction of Labor|"Samples collected from women who present for induction of labor.~- The parturient will be asked to breathe 2 tidal volume breaths into a single breath collection bag. The breath collection bag will be closed between each breath. The combined 2 tidal volume breaths will count as a single sample.~Samples will be collected at the following time points for patients presenting for induction of labor:~A) Baseline: At presentation to labor and delivery unit and prior to initiation of augmentation of labor. A total of 1 sample.~B) End of 1st stage of labor: At complete cervix dilatation and prior to starting to push. A total of 1 sample will be taken.~C) End of 3rd stage of labor: Immediately (within 30 minutes) of delivery of the neonate. A total of 1 sample will be taken."
88840484|NCT04564196||Spontaneous Labor|"Samples will be collected from women who present in spontaneous labor~- The parturient will be asked to breathe 2 tidal volume breaths into a single breath collection bag. The breath collection bag will be closed between each breath. The combined 2 tidal volume breaths will count as a single sample.~Samples will be taken at the following endpoints:~A) End of 1st stage of labor: At completely cervix dilated and prior starting pushing. A total of 1 sample will be taken.~B) End of 3rd stage of labor: Immediately (within 30 minutes) of delivery of the neonate. A total of 1 sample will be taken."
88840485|NCT02688218|Experimental|Aerobic First, Resistance Second|Subjects will complete three 15 minute periods of aerobic exercise, with 10 minute recovery between each period. This will be followed by 5-15 minute periods of up to 7 activities of daily living with an additional 20 minute period of resistance exercise, such as straight leg raises.
88840486|NCT02688218|Experimental|Resistance First, Aerobic Second|Subjects will complete 5-15 minute periods of up to 7 activities of daily living with an additional 20 minute period of resistance exercise, such as straight leg raises. This will be followed by three 15 minute periods of aerobic exercise, with 10 minute recovery between each period.
88840487|NCT04339478||Autofluorescence|"The surgeon will perform the preplanned thyroidectomy with central lymph node compartment dissection with FLUOBEAM XS. The following intraoperative variables will be recorded for all patients:~Surgery date Duration of surgery Operation performed Procedure related comments Number and location of the visualized glands Intra-operative autofluorescence score (either 0 (no visualization or 1 visualization) for each gland"
88840488|NCT04339478||Control|"The surgeon will perform the preplanned thyroidectomy with central lymph node compartment dissection without autofluorescence device. The following intraoperative variables will be recorded for all patients:~Surgery date Duration of surgery Operation performed Procedure related comments Number and location of the visualized glands"
89001979|NCT00213525||Patients With Scleroderma|Assessments of questionnary for environmental factors research
88840489|NCT02662244|Experimental|Yag Laser Treatment Of Basal Cell Carcinoma|Study participants will be treated with long-pulsed 1064 nm Nd:YAG laser at the investigator's discretion based on the clinical endpoint (slight contraction and greying of the skin surface), the tumor characteristics, and the patient's skin phototype.
88840490|NCT01328587|Experimental|Eltrombopag|Eltrombopag will be administered for 16 to 20 weeks at a starting dose of 50mg/day (East Asian ancestry 25mg/day). The dose will decreased and increased (maximum dose 300mg/day) based on safety and response.
88840491|NCT02087449||E1-Hip Bearing|E1-Hip Bearing, Evaluate E1 Wear, Clinical Performance of E1 Liner in THA in Korean Patient Population
88840492|NCT05441761|Experimental|liposomal mitoxantrone hydrochloride|Patients with recurrent and refractory peripheral T-cell lymphoma will receive sequentially higher doses of liposomal mitoxantrone hydrochloride in combination with gemcitabine, dexamethasone, and cisplatin for 6 cycles (planned) (21 days per cycle).
88840493|NCT02685007||Inpatients|Inpatients planned for laparoscopic surgery, in the field of gynecology, urology and visceral surgery will be documented from of surgery until date of discharge from hospital
88840494|NCT04740073||Patients|Persons undergoing total knee arthroplasty
88840495|NCT04740073||Controls|Persons not undergoing total knee arthroplasty who are age and sex-matched to the patient group.
88840496|NCT05587777||Mild Cancer Related Fatigue|After treatment(6 months from inclusion) is ended a fVAS < 50
88840497|NCT05587777||Cancer related Fatigue|After treatment (6 months from inclusion) with fVAS ≥ 50 mm or a rise of fVAS of ≥ 25 mm.
88840498|NCT05587777||Healthy control|"Healthy women matches with age~50-70: women attending the mammography screening~19-50: invitation in newspaper, flyers and posters"
88840499|NCT00581503||diagnostic|oct imaging
88840500|NCT05587621|Active Comparator|Cloud-based software|cloud-based software system (CLIMEDO GmbH) will support patients in ESC/EAS LDL-C target attainment (< 55mg/dl/1.4 mol/L)
88840501|NCT05587621|Placebo Comparator|Standard Care|Patients will be treated by general practitioners (GPs) after hospital discharge. The discharge letter will recommend ESC/EAS dyslipidemia LDL-cholesterol targets (< 55mg/dl/1.4 mol/L)
88840502|NCT04739215|Experimental|Clinical Trial: Experimental Arm|Patients with heart failure with preserved ejection fraction and type 2 diabetes mellitus treated with Dapagliflozin (Forxiga) 10 mg, one capsule per day orally.
88840503|NCT04739215|Placebo Comparator|Clinical Trial: Placebo Arm|Patients with heart failure with preserved ejection fraction and type 2 diabetes mellitus treated with Placebo in a similar pattern.
88840504|NCT04739215|No Intervention|Descriptive Study|Patients with heart failure with preserved ejection fraction but with no type 2 diabetes mellitus (n=10).
88840505|NCT02665364|Experimental|IFNα-Kinoid|IFNα-Kinoid (IFN-K) adjuvanted with ISA 51 VG via intramuscular injection. 1 administration of 240 μg at W0, W1, W4 and 1 administration of 120 μg at month 3 (W12) and month 6 (W24) in addition to standard of care treatment.
88840506|NCT02665364|Placebo Comparator|Placebo|Placebo normal saline (0.9% Sodium Chloride) adjuvanted with ISA 51 VG via intramuscular injection. 1 administration of 240 μg at week (W)0, W1, W4 and 1 administration of 120 μg at month 3 (W12) and month 6 (W24) in addition to standard of care treatment.
88840507|NCT02688829|Experimental|treatment group|Implantation of the rapamycin target-eluting coronary stent system (Firehawk)in patients with coronary heart disease.
88840508|NCT00556309||Diagnostic Tool|Optical Coherence Tomography Imaging of Post Coil Aneurysm Healing.
88840509|NCT02689063|Experimental|Maxigesic IV|intravenous acetaminophen1000 mg + intravenous ibuprofen 300 mg/100 ml solution for infusion, 100 mL, every 6 hours for 48 hours
88840510|NCT02689063|Active Comparator|IV Acetaminophen|IV Acetaminophen 1000 mg/100 mL solution for infusion, 100mL. every 6 hours for 48 hours
88840511|NCT02689063|Active Comparator|IV Ibuprofen|IV Ibuprofen 300 mg/100 mL solution for infusion, 100mL every 6 hours for 48 hours
88840512|NCT02689063|Placebo Comparator|Placebo IV|Placebo IV- 100 mL saline for infusion, 100mL every 6 hours for 48 hours
88840513|NCT02690935|Experimental|2LALERG|"Interleukin 1: 17 CH Interleukin 4: 17-27 CH Interleukin 5: 17 CH Interleukin 6: 17 CH Interleukin 10: 17 CH Interleukin 12: 9 CH Interleukin 13: 17 CH Tumor Necrosis Factor Alpha: 17 CH Transforming Growth Factor Beta: 5 CH Pulmo histaminum: 15 CH SNA-HLA-II: 18 CH~Impregnated on lactose saccharose globules (380 mg/capsule)"
88840514|NCT02690935|Placebo Comparator|Placebo|Non-impregnated lactose saccharose globules (380 mg/capsule)
88840515|NCT05587387||Cohort 1|Without Nal-IRI/FL; From Jan. 2012 to Jan. 2018 (Before launch of nal-IRI)
88840516|NCT05587387||Cohort 2|With Nal-IRI/FL; From Jan. 2018 to Dec. 2021 (After launch of nal-IRI)
88840517|NCT00367861|Experimental|interruption of Glivec®|
88840518|NCT02666846|Experimental|Cohort 1: TIB200 gel 10%|All Cohort 1 participants: TIB200 gel (10%, w/w ibuprofen)
88840519|NCT02666846|Active Comparator|Cohort 1: Nurofen gel 10%|All Cohort 1 participants: Nurofen Max Strength gel (10%, w/w ibuprofen)
88840520|NCT02666846|Active Comparator|Cohort 1: Nurofen tablets|All Cohort 1 participants: Nurofen oral tablets (2 x 400 mg ibuprofen)
88840521|NCT02666846|Placebo Comparator|Cohort 1: TIB200 Placebo gel|All Cohort 1 Participants: TIB200 matching placebo gel
88840522|NCT02666846|Active Comparator|Cohort 2: DCF100 gel 2%|All Cohort 2 Participants: DCF100 gel (2% w/w diclofenac)
88840523|NCT02666846|Experimental|Cohort 2: DCF100 gel 4%|All Cohort 2 Participants: DCF100 gel (4% w/w diclofenac)
88840524|NCT02666846|Active Comparator|Cohort 2: Voltaren gel 2%|All Cohort 2 Participants: Voltaren Emulgel (2% diclofenac)
88840525|NCT02666846|Active Comparator|Cohort 2: Voltarol oral tablet|All Cohort 2 Participants: Voltarol oral tablet (50 mg - diclofenac)
88840526|NCT02666846|Placebo Comparator|Cohort 2: DCF100 Placebo gel|All Cohort 2 Participants: DCF100 matching placebo gel
88840527|NCT02666846|Active Comparator|Cohort 3: SPR300 gel (15%:7%)|All Cohort 3 Participants: Methyl-salicylate / Menthol, SPR300 gel (15%:7%, w/w; ratio of Methylsalicylate / Menthol)
88840528|NCT02666846|Placebo Comparator|Cohort 3: SPR300 Placebo gel|All Cohort 3 Participants: SPR300 matching placebo gel
88840529|NCT02643979|Experimental|Ketofol and Propofol|This arm receives a 50mg dose of Ketamine mixed with 100mg of Propofol at the start of their upper endoscopy.
88840530|NCT02643979|Active Comparator|Propofol only|This arm receives 100mg of Propofol mixed with 1mL of saline at the start of the upper gastrointestinal endoscopy.
89368211|NCT04308239|Experimental|Reactive balance training|"Four training sessions, conducted twice a week for two weeks in groups of 1-2 participants. Each session was 0.5-1 hours, with an active training time of 30 minutes for each participant.~Reactive balance training involved both slip and trip training.~Slip training involved repeatedly stepping onto a low-friction interface (nylon fabric placed over a 0.9 × 0.9 meter polycarbonate sheet) while practicing controlling/decelerating the slipping foot and properly positioning the non-slipping foot under the pelvis.~Trip training involved repeatedly practicing recovery from simulated trips on a modified treadmill. While standing on a modified treadmill, the treadmill belt was quickly accelerated posteriorly to elicit a forward loss of balance that mimicked a trip while walking. Participants attempted to step to avert a fall, and to establish a stable gait on the treadmill, after which the treadmill speed was slowed to zero to complete the trial."
89368212|NCT04308239|Active Comparator|Control balance training|"Four training sessions, conducted twice a week for two weeks in groups of 1-2 participants. Each session was 0.5-1 hours, with an active training time of 30 minutes for each participant.~The control intervention involved general balance exercises adapted from the Otago Exercise program. Briefly, all four sessions involved balance exercises and strength exercises using ankle weights, and were progressively increased as performance improved by increasing ankle weights or the difficulty of the balance exercises (e.g., not holding onto a wall or support)."
89368213|NCT03201328|Active Comparator|healthy subjects|
89368214|NCT03201328|Experimental|patients with unilateral cochlear implants|
89368215|NCT03201328|Experimental|patients with bilateral cochlear implants|
89368216|NCT03205774|Sham Comparator|Supine position|patient in supine position, lying on the back, turned in the right lateral decubitus and turned in the left lateral decubitus in a randomized way, after prolonged fasting and 10 min after free oral intake of water
89368217|NCT03205774|Sham Comparator|30° semirecumbent position|patient in semirecumbent position (head of the bed elevated to 30°), lying on the back, turned in the right lateral decubitus and turned in the left lateral decubitus in a randomized way, after prolonged fasting and 10 min after free oral intake of water
89368218|NCT03205774|Sham Comparator|45° semirecumbent position|patient in semirecumbent position (head of the bed elevated to 45°), lying on the back, turned in the right lateral decubitus and turned in the left lateral decubitus in a randomized way, after prolonged fasting and 10 min after free oral intake of water
89368219|NCT03205774|Sham Comparator|90° semirecumbent position|patient in semirecumbent position (head of the bed elevated to 90°), lying on the back, after prolonged fasting and 10 min after free oral intake of water
89368220|NCT03201172||Univation® X|
89368221|NCT03201172||iUni®|
89368222|NCT03208114|Experimental|Group A|Receiving the written information of the name of a breast milk substitute on the infant's discharge documents
89368223|NCT03208114|No Intervention|Group B|Not receiving the written information of the name of a breast milk substitute on the infant's discharge documents
89368224|NCT04302545|Experimental|Cystoinflation group|Bladder will be recognized by observing its gradual distension during bladder retro-fill with 300cc saline to perform adhesiolysis.
89368225|NCT04302545|No Intervention|Control group|Pelvic adhesiolysis will be performed without bladder retrofill.
89368226|NCT04484896|Experimental|Gain-frame Message|"Short messaging service (SMS) message: Dear group O/A Rh-D negative blood donor:~Hello! The inventory of group O/A Rh-D negative blood product is low at present, but patients with such blood group are in urgent need of blood. If you can, please consider donating blood again to save lives. Thank you for your support.~Please bring your identification (ID) card and show this message to our staff. Thank you."
89368227|NCT04484896|Experimental|Loss-frame Message|"SMS message: Dear group O/A Rh-D negative blood donor:~Hello! The inventory of group O/A Rh-D negative blood product is low at present, but patients with such blood group are in urgent need of blood. If you can, please consider donating blood again to prevent the loss of life. Thank you for your support.~Please bring your ID card and show this message to our staff. Thank you."
89368228|NCT04484896|Experimental|Information Message|"SMS message: Dear group O/A Rh-D negative blood donor:~Hello! The inventory of group O/A Rh-D negative blood product is low at present, if you can, please consider donating blood again. Thank you for your support.~Please bring your ID card and show this message to our staff. Thank you."
89368229|NCT04484896|No Intervention|Control group|Donors in this group were not received SMS reminders.
89368230|NCT03205852||group A (benefit-inform)|filling questionnaire based on benefits of surgery
89368231|NCT03205852||group B (side effect-inform)|filling questionnaire based on side-effects of surgery
89368232|NCT03200938|Experimental|PBS CIMMO|Intervention: PBS CIMMO cement
89368233|NCT03200938|Active Comparator|Zinc oxide|Intervention: Formocresol and zinc oxide
89368234|NCT04297241|Experimental|Isosorbide Dinitrate|Each enrolled participant will be on a titrated dosage of isosorbide dinitrate to determine effectiveness on both primary and secondary outcome measures.
89368235|NCT03205618||daclatasvir patients in KSA, UAE, and Qatar|patients treated with daclatasvir-containing regimens in KSA, UAE, and Qatar
89368236|NCT03749525|Placebo Comparator|placebo group|5% GS solution
89368237|NCT03749525|Active Comparator|control group|shenfu injection
88840531|NCT02667392|Experimental|Biofeedback Group|Participants will wear a pressure-sensitive insole inside the shoe of their paretic limb. An auditory tone will sound when participants have provided sufficient load to active the pressure-sensitive in-sole.
88840532|NCT02667392|Active Comparator|Verbal Feedback Group|Participants will receive verbal feedback from a physical therapist regarding the amount of loading they are exerting on their paretic limb.
88840533|NCT05587231|Experimental|Dextenza 0.4Mg Ophthalmic Insert|Dextenza (a dexamethasone ophthalmic insert manufactured by Ocular Therapeutix) will be inserted immediately after PRK surgery to administer a post surgery steroid regimen. No steroid drops will be adminstered.
88840534|NCT05587231|Active Comparator|Topical Fluorometholone|"Standard of care topical Fluorometholone drops will be used by the subjects after PRK Surgery. There will be a taper as follows:~i. 1 drop in each eye QID for 1st week postop. ii. 1 drop in each eye TID for 2nd week postop. iii. 1 drop in each eye BID for 3rd week postop. iv. 1 drop in each eye qD for 4th week postop."
88840535|NCT02692495||Body odor|individuals self-reporting recurrent episodes of uncontrollable body odor with or without halitosis
89368238|NCT03205540|Experimental|Epidural analgesia|Lumbar continuous epidural block
88840536|NCT02692495||Halitosis|individuals with extra-oral halitosis, not complaining of body odors
88840537|NCT02667704|Experimental|Nintedanib|
88840538|NCT02667704|Experimental|Bosentan|
88840539|NCT02645617|Experimental|Varnish|Dental varnish containing povidone iodine and sodium fluoride
88840540|NCT02668952|Active Comparator|Normal Saline group|0.9% Normal Saline (0.9% Sodium Chloride) injection intravenously as needed. The amount administered (dosage, frequency, and duration) will be left to the clinical judgment of the attending physicians, and will follow usual patterns of use in cardiac surgery patients.
88840541|NCT02668952|Experimental|Isolyte group|Isolyte S (B Braun, Irvine CA) injection intravenously as needed. The amount administered (dosage, frequency, and duration) will be left to the clinical judgment of the attending physicians, and will follow usual patterns of use in cardiac surgery patients. Isolyte S is a prepackaged solution containing sodium chloride 0.53%, sodium gluconate 0.5%, sodium acetate trihydrate 0.37%, potassium chloride 0.037%, and magnesium chloride hexahydrate 0.03% w/v.
88840542|NCT02648971|Active Comparator|Single Portal Knee Arthroscopy|After randomization for each patient is complete, the website will document the name of the person who logged on to perform the randomization, the date and time of the log in, and the surgical group assignment for each patient. This randomization information will be forwarded to the operating room staff so that they can prepare for each study participant's surgical procedure. Patients in Group 1 will undergo knee arthroscopy using a single portal. The details of the surgical procedure for each study participant will be documented on the IKDC Surgical Documentation Form. Study participants in each group will return for standard post-operative follow-up visits at one week, 30 days, and three months. They will return to the clinic at six months and one year for study visits.
88840543|NCT02648971|Active Comparator|Two Portal Knee Arthroscopy|Patients in Group 2 will undergo knee arthroscopy using two portals. The details of the surgical procedure for each study participant will be documented on the IKDC Surgical Documentation Form. Study participants in each group will return for standard post-operative follow-up visits at one week, 30 days, and three months. They will return to the clinic at six months and one year for study visits.
88840544|NCT02689154|Experimental|W8Loss2Go App|Subjects will complete all stages of W8Loss2Go mHealth intervention.
88840545|NCT02690168||Healthy Men|
88840546|NCT02694601|Experimental|Ketonemia following caffeine intake|"Participants have to follow three sequential visits of four hours each, which included a breakfast with one of the doses (2.5 or 5 mg/kg) of the caffeine supplement or without any supplement (baseline) and repeated blood sampling in order to evaluate ketone concentrations.~Intervention 1: Control; no caffeine intake Intervention 2: Caffeine low dose (2.5 mg/kg of BW) Intervention 3: Caffeine high dose (5.0 mg/kg of MW)"
89368239|NCT03205540|Experimental|Bilateral ACB|Ultrasound-guided bilateral adductor canal blocks
89368240|NCT02449876|Experimental|Neuroscience Education|"Subjects will have 2 sessions of education 2 weeks apart. After the first session subjects will be given a 50 page book Why Do I Hurt by Adriaan Louw. Session 1 will last approximately 60 minutes and session approximately 30 minutes."
89368241|NCT04292171|Active Comparator|Gabapentin Arm|Gabapentin 600 mg given 1-2 hours prior to surgical abortion
89368242|NCT04292171|Placebo Comparator|Placebo Arm|Placebo (vit C) given 1-2 hours prior to surgical abortion
89368243|NCT03200782|Placebo Comparator|Placebo-Placebo|subcutaneous placebo (0.67 ml of 0.9% sodium chloride) 3 hours before the test meal and an oral placebo (winthrop tablet) 2 hours before the test meal will be administered by an Independent nurse to the blinded patient
89368244|NCT03200782|Active Comparator|Investigational Drug A Empagliflozin|subcutaneous placebo (0.67 ml of 0.9% sodium chloride) 3 hours before the test meal and an 10mg of empagliflozin 2 hours before the test meal will be administered by an independent nurse to the blinded patient
89368245|NCT03200782|Active Comparator|Investigational Drug B Anakinra|subcutaneous injection of 100mg anakinra 3 hours before the test meal and an oral placebo (winthrop tablet)before the test meal will be administered by an Independent nurse to the blinded patient
89368246|NCT02449954|Active Comparator|morphine group|intravenous 0.1mg/kg morphine
89368247|NCT02449954|Active Comparator|tramadol group|intravenous 2 mg/kg tramadol
89368248|NCT02449954|Active Comparator|ketorolac group|intravenous30 mg ketorolac
89368249|NCT02448160|Experimental|alfapump with albumin treatment|patients implanted with an alfapump, receiving intermittent salt-poor Human Albumin solution treatment
88840547|NCT02694835|Experimental|DT1 UV|Delefilcon A contact lenses with Ultraviolet (UV) Absorber worn bilaterally (in both eyes) for 9 hours
88840548|NCT02694835|Active Comparator|DT1|Delefilcon A contact lenses worn bilaterally for 9 hours
88840549|NCT02696083|Experimental|Active Treatment|
88840550|NCT02650219||gaucher disease type 1|"Inclusion criteria:~Adult patients >= 18 years old~Gaucher disease type 1, proved by low betaglucosidase, with or without treatment~Patients must have read, understood and signed informed consent. intervention : genetic analyses"
89368250|NCT04393493|Experimental|GROUP A|"Furosemide 80 mg every 24 hrs (morning) intravenously every 24 hrs for 4 consecutive days, additionally:~Day 1 furosemide 100mg / day infused with 100cc of Hartmann solution~Day 2 Furosemide 200mg / day infused with 100cc of Hartmann solution~Day 3 Furosemide 300mg / day infused with 100cc of Hartmann solution~Day 4 Furosemide 400mg / day infused with 100cc of Hartmann solution"
89368251|NCT04393493|Experimental|GROUP B|"Furosemide 80 mg every 24 hrs (morning) intravenously every 24 hrs for 4 consecutive days, additionally:~Day 1 furosemide 100mg / day infused with 100cc of Hartmann solution + Chlortalidone 50mg VO every 24 hours + Spironolactone 50mg VO every 24 hrs.~Day 2 furosemide 100mg / day infused with 100cc of Hartmann solution + Chlortalidone 50mg VO every 24 hours + Spironolactone 50mg VO every 24 hrs.~Day 3 furosemide 100mg / day infused with 100cc of Hartmann solution + Chlortalidone 50mg VO every 24 hours + Spironolactone 50mg VO every 24 hrs.~Day 3 furosemide 100mg / day infused with 100cc of Hartmann solution + Chlortalidone 50mg VO every 24 hours + Spironolactone 50mg VO every 24 hrs."
89368252|NCT02448238|Experimental|probiotic|This is a single arm study all subjects will receive the study VSL#3 probiotic. Subjects will take 1 sachet of powder orally daily for 12 weeks
89368253|NCT02448082|Placebo Comparator|Shampoo (inactive)|Shampoo containing no active anti-dandruff ingredients will be used to wash the participants' hair every second day, starting from day 1 to day 15. Each participant in the placebo group will wash their hair with 25ml of the placebo shampoo per hair washing session.
88840551|NCT02650219||Control|healthy subjects intervention: genetic analyses
88840552|NCT05574439|Active Comparator|Non-responders: TCOC+ semaglutide|Semaglutide: 2.4 mg/week SC, concentration: 3.0 mg/ml) in combination with TCOC treatment (i.e. diet/weight consultations).
89368254|NCT02448082|Experimental|Sodium shale oil sulponate 1% shampoo|Shampoo containing sodium shale oil sulponate 1% will be used to wash the participants' hair every second day, starting from day 1 to day 15. Each participant in the experimental group will wash their hair with 25ml of the sodium shale oil sulponate 1% shampoo per hair washing session.
88840553|NCT05574439|Placebo Comparator|Non-responders: TCOC+ placebo|Placebo: 2.4 mg/week SC in combination with TCOC treatment (i.e. diet/weight consultations).
89368255|NCT03205228|Experimental|Flupentixol + Melitracen & placebo|Deanxit® (Flupentixol + Melitracen) 5 mg/D*4 weeks will be given
89368256|NCT03205228|Active Comparator|Proton pump inhibitor & placebo|Miracid® (Omeprazole) 20 mg/D*4 weeks will be given
89368257|NCT03205228|Active Comparator|Psychoeducation&placebo|Psychoeducation by psychologists will be advised on Day 1 and Day 14 of the study time frame
89368258|NCT04568681||Patients with dystonia|Patients with dystonia who have clinically been deemed candidates for DBS surgery.
89368259|NCT03195946|Experimental|Lu AF35700 and Cocktail of CYP450 substrates|Day 1 oral midazolam administration, Day 2 Cocktail of CYP450 substrates administration. Daily Lu AF35700 administration from Day 5 to Day 28 with co-administration on Day 27 with oral midazolam and Day 28 with CYP450 substrate cocktail
89368260|NCT03205462|Experimental|Group 1|Fluorothyazinone in a dosage of 300 mg (1 tablet) will be administrated to 5 volunteers
89368261|NCT03205462|Experimental|Group 2|Fluorothyazinone in a dosage of 600 mg (2 tablets) will be received per os (oral administration) as a single dose
89368262|NCT03205462|Experimental|Group 3|on the first day of administration, the product is received according to the following regimen: the first dosage of 60 mg (2 tablets) should be taken orally 30 minutes after meals and swallowed with room-temperature water; the second dosage - 1 tablet (300 mg) - 12 hours later, and then for 5 days the subjects will receive 2 tablets per day. The duration of antibacterial therapy is 6 days. The total dose of Fluorothyazinone per treatment course is 3900 mg.
89368263|NCT02448004|Experimental|JNJ-63623872|Participants will receive a single 600-milligram (mg) dose of JNJ-63623872 administered as three capsules containing 14C-labeled and unlabeled JNJ-63623872.
89368264|NCT02450422||Control|Use Flow cytometry (FCM) and RT-PCR to test peripheral blood mononuclear cells(PBMCs) from healthy volunteer.
89368265|NCT02450422||Cryosurgery group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received cryosurgery only, 1 day before and 2 days after the cryosurgery.
89368266|NCT02450422||DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received DC-CIK treatment only, 1 day before and 2 days after the DC-CIK treatment.
89368267|NCT02450422||Cryosurgery with DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients received cryosurgery and DC-CIK treatment both, 1 day before and 2 days after the cryosurgery with DC-CIK treatment.
89368268|NCT03747029||Patients with hyperparathyroidism|Patients aged between 18-90 years old with primary hyperparathyroidism. No intervention is provided.
89368269|NCT03747029||Patients with hypoparathyroidism|"Patients aged between 18-90 years old with diagnosed hypoparathyroidism. No intervention is provided.~."
89368270|NCT03747029||Control group|"Patients that underwent biochemical examination by primary care physician or by endocrinologist in order to assess their calcium-phosphorus metabolism state with normal results.~No intervention is provided."
89368271|NCT02447770|Experimental|Cocoa Flavanol intake escalation|Ingestion of increasing number of capsules containing Mars Cocoa Extract manufactured by the Cocoapro® process (500 mg of cocoa flavanols/capsule) during 6 weeks followed by a 2 week of washout (no capsule intake)
89368272|NCT03118882|Active Comparator|Diet Group|
89368273|NCT03118882|Active Comparator|Physical activity group|
89368274|NCT03118882|Active Comparator|Physical activity and diet group|
88840554|NCT05574439|Active Comparator|Insufficient responders: TCOC+ semaglutide|Semaglutide: 2.4 mg/week SC, concentration: 3.0 mg/ml) in combination with TCOC treatment (i.e. diet/weight consultations).
88840555|NCT05574439|Placebo Comparator|Insufficient responders: TCOC+ placebo|Placebo: 2.4mg/week SC in combination with TCOC treatment (i.e. diet/weight consultations).
88840556|NCT05574439|No Intervention|Excellent Responders|
88840557|NCT02698033||Low dose challenge passed|Individuals who tolerated without dose limiting symptoms the screening food challenge for a parent interventional trial
88840558|NCT02690948|Experimental|Pembrolizumab Monotherapy|Participants who previously received vismodegib and subsequently progressed will receive pembrolizumab IV over 30 minutes on day 1. Cycles are every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
88840559|NCT02690948|Experimental|Pembrolizumab plus Vismodegib Combination Therapy|Participants who have not progressed while receiving vismodegib will receive pembrolizumab IV over 30 minutes on day 1 and take vismodegib 150 mg by mouth daily. Cycles repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
89368275|NCT03118882|No Intervention|Control group|
89368276|NCT03205384||surgical management|Patient older than 65 years old, undergoing urgent abdominal surgery in our center
89368277|NCT03205384||not surgical management|Patients that presents a surgical disease, but we desestimate surgical procedure
89368278|NCT03204994|Experimental|Tumour injection of ICG|Indocyanine green injection into tumour before or during surgery.
89368279|NCT03118648||stroke|"Patients over 18 years old leaving the correctional institution with orientation back home~First stroke deficit with non-regressive clinical expression in 24 hours~Independent in activities of daily living and living at home before stroke. This earlier independence is confirmed by the absence of professional carers in personal care activities~Proper oral understanding as measured by score 7 in the Language Screening Test (LAST) (Flamand-Roze et al, 2011)~No psychiatric history that led to hospitalization for more than six months~Written informed consent after reading the briefing note~Patient affiliated or beneficiary of a social security scheme."
89368280|NCT03204760|Experimental|dexamethasone|Dexamethasone is a long-acting glucocorticoid with a half-life of 36 to 72 hours . It has been used safely in children with croup and bacterial meningitis . It is well absorbed both orally and parenterally .Single dose of intramuscular dexamethasone (0.6 mg/kg to a maximum of 18 mg).
89368281|NCT03204760|Experimental|prednisolone|Prednisolone is relatively short acting with a half-life of 12 to 36 hours, thereby requiring daily dosing. Outpatient steroid therapy is effective once compliance is assured.. Prolonged treatment course, vomiting, and a bitter taste may reduce patient compliance with prednisolone. Oral prednisolone for 3 days (1 mg/kg to a maximum of 40 mg), given orally in two devided doses .
89368282|NCT03200470||Suspected PJI|
89368283|NCT03200392|Experimental|L-DGG/LRB|laser root surface conditioning & laser DGG harvesting
89368284|NCT03200392|Experimental|B-DGG/LRB|laser root surface conditioning & blade DGG harvesting
89368285|NCT03200392|Active Comparator|B-DGG|blade DGG harvesting
89368286|NCT03204838||AML patients|Adult AML patients with the IDH mutation test performed at diagnosis.
89368287|NCT03204682|Experimental|Patients with chronic refractory endometriosis pain|The aim of the study is to evaluate the feasibility of transcranial magnetic stimulation (rTMS) for analgesia on chronic refractory endometriosis pain.
89368288|NCT04484662|Other|Potted Mint Plants Intervention|We will measure 2 indoor environments (living room and bedroom) for placing potted plants. We will analyze the effect of potted mint plants on indoor air quality, fungal and bacterial concentration, and explore the correlation between the intervention of potted mint plants and cardiovascular health.
89368289|NCT03195556|Experimental|Healthy subjects|Low-power contrast ultrasound perfusion imaging and measurement of ABI and TBI will be performed before and after a 15 min high-power ultrasound cavitation therapy with intermittent ultrasound and intravenous infusion of microbubbles.
89368290|NCT03195556|Experimental|Peripheral Artery Disease|Low-power contrast ultrasound perfusion imaging and measurement of ABI and TBI will be performed before and after a 15 min high-power ultrasound cavitation therapy with intermittent ultrasound and intravenous infusion of microbubbles.
89368291|NCT03204604|Experimental|Challenge A|Challenge A includes Cognitive testing - (FCSRT, Story Recall, BVRT, CogState One Card Learning), and PET scan with low calorie Ensure® shake containing no ketone esters. Dietary Supplement: Challenge A - low calorie Ensure®
89368292|NCT03204604|Experimental|Challenge B|Challenge B includes Cognitive testing - (FCSRT, Story Recall, BVRT, CogState One Card Learning), and PET scan with an Ensure® shake containing ketone esters. Dietary Supplement: Challenge B - Ensure® plus ketone esters (KE)
89368293|NCT03204370||MPS4A patients|
89368294|NCT03204292||IVC/Ao|ultrasound, the inferior vena cava and abdominal aorta were measured. Inferior vena cava width was assessed at an interval of approximately 1 cm distal from connection of the hepatic vein to the inferior vena cava. No significant changes were observed in the width of the inferior vena cava during various respiratory phases, because of the positive pressure ventilation. The widest value was always chosen for the data. The assessment of the width of the abdominal aorta was performed above arise of the celiac trunk, at the height of the vein of the lower vena cava.
89368295|NCT03200158|Other|Endoscopy biopsy and blood|The healthy volunteers were treated with endoscopy biopsy and blood.The patients were treated with bedside endoscopy biopsy and diagnosed with SRMD due to illness，then collect their blood samples.
89368296|NCT03204448||Relevant Disease Samples|Samples are tested on BioCLIA Ro60 instrument with Ro60 assay reagents, also as comparison, tested on BioFLASH instrument with QUANTA Flash Ro60 reagents
89368297|NCT03204448||Control Disease Samples|Samples are tested on BioCLIA Ro60 instrument with Ro60 assay reagents, also as comparison, tested on BioFLASH instrument with QUANTA Flash Ro60 reagents
89368298|NCT03200080|Placebo Comparator|Treatment A|Placebo oral tablet and Placebo oral capsule
89368299|NCT03200080|Experimental|Treatment B|Tozadenant 120 mg
89368300|NCT03200080|Experimental|Treatment C|Tozadenant 240 mg
89368301|NCT03200080|Experimental|Treatment D|Tozadenant 480 mg
89368302|NCT03200080|Active Comparator|Treatment E|d-amphetamine 20 mg
89368303|NCT03200080|Active Comparator|Treatment F|d-amphetamine 40 mg
89368304|NCT03200002|Experimental|Cyclophosphamide|Participants in this arm received intravenous cyclophosphamide (CYC) in the dose of 0.5 to 1 gram per m2 of body surface area.
89368305|NCT03200002|Experimental|mycophenolate mofetil|Patients in this arm received mycophenolate mofetil in the tablet form.
89368306|NCT02447536|Active Comparator|BCG-DENMARK|"Infants randomised to receive BCG-DENMARK at dismissal from the Maternity Ward will receive one 0.05 ml dose of Mycobacterium bovis BCG live attenuated vaccine BCG-Denmark 1331 (Statens Serum Institute) by intradermal injection in the left deltoid region. Dependent on national supply, infants will receive oral polio vaccine (OPV) at the time of BCG-vaccination.~NOTE: By 1st of July 2016, infants in this arm has received BCG-Japan due to a worldwide shortage of BCG-Denmark because of a halt in production of this vaccine at the Statens Serum Institut in Copenhagen."
89368307|NCT02447536|Active Comparator|BCG-RUSSIA|Infants randomised to receive BCG-RUSSIA at dismissal from the Maternity Ward will receive one 0.05 ml dose Mycobacterium bovis BCG live attenuated vaccine BCG-Russia-I (Serum Institute of India) by intradermal injection in the left deltoid region. Dependent on national supply, infants will receive oral polio vaccine (OPV) at the time of BCG-vaccination.
89368308|NCT03204136||tarcolimus|refractory inflammatory bowel disease patents who used tarcolimus to induce and maintain remission
89368309|NCT03204136||methotrexate|refractory inflammatory bowel disease patents who used methotrexate to induce and maintain remission
89368310|NCT02447380|Experimental|AZD6094 (Volitinib) in combination with docetaxel|"Subjects will receive Volitinib once daily (at the MTD determined from Phase Ib) for 21 days as one cycle.~Docetaxel 60 mg/m2 will be administered via intravenous access once every 3 weeks."
89368311|NCT02447224|Experimental|Antibiotics|Once-a-day dose of IV/IM ertapenem for at least two days and cefdinir and metronidazole, to complete 10 days total antibiotic therapy.
89368312|NCT02447224|Active Comparator|Appendectomy|Patients in the surgery therapy arm will only receive one dose of IV ertapenem prior to surgery.
89368313|NCT03199690|Experimental|Single arm|"Single arm trial design based on the dosing regimen below:~Day 1 - 7~- Dolutegravir 50 mg once daily with food~Day 8 - 14 - Dolutegravir 100 mg once daily with food~Day 15 - 28~- Rifampicin 600 mg once daily~Day 29 - 35 - Rifampicin 600 mg once daily & Dolutegravir 50 mg once daily~Day 36 - 42~- Rifampicin 600 mg once daily & Dolutegravir 100 mg once daily"
89368314|NCT03203902|Active Comparator|Psychoeducation and Therapeutic Touch|"6-week psychoeducation group. The following 1-hour modules will be delivered:~Week 1: Anger Management and Conflict Negotiation Week 2: Meditation and Breathing Techniques Week 3: Nutrition Week 4: Exercise, Leisure, and Recreation Week 5: Sleep Week 6: Wellness Recovery Action Plan (WRAP)~Directly after the psychoeducation group is completed, 30-minute therapeutic touch will be administered."
89368315|NCT03203902|Placebo Comparator|Psychoeducation and Sham Therapeutic Touch|"6-week psychoeducation group. The following 1-hour modules will be delivered:~Week 1: Anger Management and Conflict Negotiation Week 2: Meditation and Breathing Techniques Week 3: Nutrition Week 4: Exercise, Leisure, and Recreation Week 5: Sleep Week 6: Wellness Recovery Action Plan (WRAP)~Directly after the psychoeducation group is completed, 30-minute sham therapeutic touch will be administered."
89368316|NCT03203902|No Intervention|Control|No intervention
89368317|NCT03204058|Placebo Comparator|group 1|Scaling and root planing (SRP) followed by placebo gel local drug delivery
89368318|NCT03204058|Active Comparator|group 2|SRP followed by 1.2% rosuvastatin (RSV) gel
89368319|NCT03204058|Active Comparator|group 3|SRP followed by 1% Metformin ( MF) gel
89368320|NCT03199846||advanced melanoma patients|Part 1 will consist of a representative sample of advanced melanoma patients, irrespective of date of diagnosis of stage III unresectable and metastatic/stage IV, to address information objectives on treatment patterns, clinical outcomes, and resource use after the start of treatment post-launch of new drugs, ie, since 2011 for ipi and 2015 for ipi + nivo in advanced melanoma
89368321|NCT03199846||Ipi monotherapy|Part 2: patients must have been prescribed Ipi monotherapy during the index period between 01-Jan-2015 and 31-May-2016.
89368322|NCT03199846||Ipi + nivo combination therapy|Part 2: patients must have been prescribed Ipi + nivo combination therapy during the index period between 01-Jan-2015 and 31-May-2016.
89368323|NCT03199846||Dabrafenib + trametinib combination therapy|Part 2: patients must have been prescribed Dabrafenib + trametinib combination therapy during the index period between 01-Jan-2015 and 31-May-2016.
89368324|NCT03199846||Pembro monotherapy|Part 2: patients must have been prescribed Pembro monotherapy during the index period between 01-Jan-2015 and 31-May-2016
89001980|NCT00213525||Healthy Controls|Assessments of questionnary for environmental factors research
89368325|NCT03199846||Nivo monotherapy|Part 2: patients must have been prescribed Nivo monotherapy during the index period between 01-Jan-2015 and 31-May-2016
89368326|NCT03199768||Single-bed rooms|Patients are admitted to single-bed rooms at the newly built hospital in the period 20th of March to the 1th of September 2017
89368327|NCT03199768||Multi-bed rooms|Patients are admitted at multi-bed rooms with one to two fellow patients at the old hospital in the period 15th of September 2016 to the 19th of March 2017
89368328|NCT03203824|Experimental|dark chocolate|Three EEG measurements will be recorded: 1) at baseline, 2) during visualization of rest for one minute, and 3) during visualization of usual vigorous exercise for one minute. Measurements 2 and 3 will be recorded savoring dark chocolate and after fully ingesting the dark chocolate respectively.
89368329|NCT03203824|Active Comparator|non dark chocolate|three EEG measurements will be recorded: 1) at baseline, 2) during visualization of rest for one minute, and 3) during visualization of usual vigorous exercise for one minute.
89368330|NCT03118414|Experimental|Physical Exercise Group|Physical Exercise (PE) is an intervention that aim to improve balance and muscle strength of the elders. It composed of 3 steps; warming up exercise, core content of the exercise (strength and balance training) and cool down exercise program.
89368331|NCT03118414|Experimental|Virtual Reality|Virtual Reality (VR) VR is an intervention that aim to improve balance of the elders. It stimulates the auditory and visual function and concentration of the participants throughout the training. It composed of 10 games that included weight shifting from side to side, stepping into different directions, trunk flexion, extension and side bending, movements of the upper and lower limbs, and trunk twisting in this study.
89368332|NCT03118414|Experimental|Brain Exercise|"Brain Exercise (BE) BE is an intervention that aim to stimulate the cognitive function of the elders.~It stimulates the executive function, planning, concentration, visual memory and eye-hand co-ordination of the participants throughout the training"
89368333|NCT03118414|No Intervention|Control Group|No Intervention: Healthy control No intervention was given to this group of participants. The control group was reminded not to participate in any other exercise or intervention program except their routine daily activities.
89368334|NCT03203746|Experimental|Group I: Lycopene + SRP|Lycopene, 0.1 ml injected once in the periodontal pocket after scaling and root planing
89368335|NCT03203746|Active Comparator|Group II: SRP only|Scaling and root planing only without lycopene
88840560|NCT02698735|Experimental|Gentamicin|Gentamicin antibiotic
88840561|NCT02698735|Placebo Comparator|Placebo|Vehicle control
88840562|NCT02691260|No Intervention|no incentives|Participants do not receive financial incentives.
88840563|NCT02691260|Active Comparator|incentives for dietary self-monitoring|Participants receive financial incentives for dietary self-monitoring.
88840564|NCT02691260|Active Comparator|incentives for interim weight loss|Participants receive financial incentives for interim weight loss.
89368336|NCT03203746|No Intervention|Group III: healthy subjects|No intervention
89368337|NCT02447068|No Intervention|Non-treatment Control|Control arm will not have any intervention
89368338|NCT02447068|Active Comparator|Occlusive Dressing|An off-the-shelf dressing occlusive dressing will be used as an active comparator.
89368339|NCT02447068|Active Comparator|Luma Light|A NBUVB light will be used as an active comparator.
89368340|NCT02447068|Experimental|Luma Light System|The experimental arm will be a combination of an occlusive dressing and NBUVB light.
89368341|NCT02447146|Experimental|Training group|9-week resistance training program
89368342|NCT02447146|Other|Control group|'Lectures on the disease'
89368343|NCT03199456|Experimental|Zip Surgical Skin Closure Device group|The subjects randomised to this arm will be treated with the Zip device for 10 days (+/-2) days.
89368344|NCT03199456|Active Comparator|Standard of Care sutures group|The subjects randomised to this arm will be treated with standard of care sutures for 10 days (+/- 2 days).
88840565|NCT02691260|Experimental|incentives for both|Participants receive incentives for dietary self-monitoring and interim weight loss.
88840566|NCT02691416|Experimental|propofol postconditioning|1.2mg/L propofol
88840567|NCT02691416|Experimental|sevoflurane|0.5%-2% sevoflurane
88840568|NCT02650999|Experimental|Pembrolizumab|Single arm, pembrolizumab 200mg IV every 3 weeks until progression/toxicity
88840569|NCT02651545||Relapsing MS patients|Thirty (30) relapsing MS patients new to teriflunomide therapy will be enrolled.
88840570|NCT02651545||Healthy Controls|A sample of 30 healthy control volunteers, matched on demographics with the treated group will be enrolled.
88840571|NCT02691962|Experimental|Xen Matrix AB|Subjects treated with Xen Matrix AB
88840572|NCT02701387|Experimental|AnyRidge Implant|Experimental implant (Megagen AnyRidge dental implant) placed in a healed edentulous site to replace a missing tooth.
89368345|NCT03203668|Other|Choline PET/CT|Choline PET/CT imaging added to conventional imaging assessment in hyperparathyroidism (parathyroid scintigraphy, ultrasound, CT or MRI if indicated)
89368346|NCT02446678|Active Comparator|Capsule group: PillCam ESO2|Perform capsule endoscopy and esophagogastroduodenoscopy will be preformed within 24 hours after capsule ingestion
89368347|NCT02446678|No Intervention|Standard group|Perform standard esophagogastroduodenoscopy
88840573|NCT02701387|Active Comparator|EZ Plus Implant|Comparative implant (Megagen EZ Plus dental implant) placed in a healed edentulous site to replace a missing tooth.
88840574|NCT02693132|Experimental|Supervised (SUP-PA)|Weight loss intervention that focuses on supervised physical activity and involves an energy restricted diet. Physical activity will be supervised by trained staff.
89368348|NCT03203434||Esophageal anastomotic leakage|
89368349|NCT03203434||Esophageal uncomplicated controls|
89368350|NCT03203434||Pancreatic anastomotic leakage|
89368351|NCT03203434||Pancreatic uncomplicated controls|
89368352|NCT02446756|Experimental|acupuncture group|Acupuncture treatment was given once every other day and 20min each time for four weeks.
89368353|NCT02446756|Active Comparator|physiotherapy group|Physiotherapy treatment was given five times a week and 30min each time for four weeks.
89368354|NCT03199534|Experimental|Botulinum toxin A 50u|Botulinum toxin A 50 unit injection
89368355|NCT03199534|Experimental|Botulinum toxin A 100u|Botulinum toxin A 100 unit injection
89368356|NCT03199534|Experimental|Botulinum toxin A 150u|Botulinum toxin A 150 unit injection
89368357|NCT03203356||GHD children|about 30 prepubertal children affected by overt idiopathic GHD
89368358|NCT03203356||controls|about 30 prepubertal children with constitutional short stature without endocrine disease
89368359|NCT04280705|Placebo Comparator|Placebo|200 mg of Remdesivir placebo administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir placebo while hospitalized for up to a 10 days total course. n=286.
88840575|NCT02693132|Experimental|Unsupervised (UNSUP-PA)|Weight loss intervention that focuses on unsupervised physical activity (identical dose to SUP-PA) and involves an energy restricted diet (identical diet to SUP-PA). Physical activity will be self-monitored but no activity tracker will be used as an intervention tool.
88840576|NCT02693132|Experimental|Step-based (STEP)|Weight loss intervention that focuses on unsupervised physical activity prescribed as steps/day and involves an energy restricted diet (identical diet to SUP-PA and UNSUP-PA). Physical activity will be self-monitored and a pedometer will be used to track steps/day.
88840577|NCT05502211|Experimental|Lidocaine|
88840578|NCT05502211|Active Comparator|Fentanyl|
88840579|NCT04339244|Active Comparator|ONSD measurement under lower blood pressure|ONSD measurement under mean blood pressure of 60~70 mmHg
88840580|NCT04339244|Active Comparator|ONSD measurement under highly normal blood pressure|ONSD measurement under mean blood pressure of 90~100 mmHg
88840581|NCT02673944|Experimental|Peritron+|Patients will undergo a routine urodynamic evaluation, the Peritron+ will be used in conjunction with a water-based urodynamic catheter
88840582|NCT02674412|Experimental|Buspirone then Placebo|Buspirone 10 mg PO TID for two weeks, followed by a washout period for two weeks and placebo for two weeks
88840583|NCT02674412|Experimental|Placebo then Buspirone|Placebo Tablet TID for two weeks, followed by a washout period for two weeks and Buspirone 10mg TID for two weeks.
88840584|NCT00367952|Experimental|ATC 800mg BID|800mg ATC BID
88840585|NCT04708106|Experimental|RELX ENDS Tobacco Flavor|Switch from combustible cigarettes to RELX ENDS Tobacco Flavor for 56 days
88840586|NCT04708106|Experimental|RELX ENDS Menthol Flavor|Switch from combustible cigarettes to RELX ENDS Menthol Flavor for 56 days
88840587|NCT04708106|Experimental|RELX ENDS Tobacco and Menthol Flavors|Switch from combustible cigarettes to RELX ENDS Tobacco and Menthol Flavor for 56 days
88840588|NCT04708106|No Intervention|Continue-smoking|Continue smoking combustible cigarettes for 56 days
89001981|NCT00190580|Experimental|1|
89001982|NCT00190580|Experimental|2|
89368360|NCT04280705|Experimental|Remdesivir|200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10 days total course. n=286.
89368361|NCT03199378||Caucasian|English speaking Caucasian individuals
89368362|NCT03199378||African American|English speaking African American individuals
89368363|NCT03199378||Hispanic|Spanish speaking Hispanic individuals
89368364|NCT03199222|Experimental|Arm 1: Smart socket technology w/patient prompting|The prosthetic user WILL receive prompting by the smart socket technology regarding improper fit and suggestions for how to a restore a proper fit (i.e socks). Investigators will have access to the Smart Socket Technology database.
89368365|NCT03199222|No Intervention|Arm 2: Clinical protocol. No patient prompting|The prosthetic user WILL NOT receive prompting by the smart socket technology regarding improper fit and suggestions for how to a restore a proper fit (i.e socks). However, investigators will have access to the Smart Socket Technology database.
89368366|NCT03203590|Active Comparator|Oral Navelbine + Carboplatin|Neoadjuvant therapy Patients with EGFR mutation will be recruited and treated with Navelbine + Carboplatin.
89368367|NCT03203590|Experimental|Gefitinib|Neoadjuvant therapy Patients with EGFR mutation will be recruited and treated with gefitinib.
89368368|NCT02446522|Active Comparator|Open vein harvesting|Patients with IHD, who were underwent open vein harvest method (OVH)
89368369|NCT02446522|Active Comparator|Endoscopic vein harvesting|Patients with IHD, who were underwent edoscopic vein harvestingopen vein harvest method (EVH).
89368370|NCT03203278|Experimental|Web-based exercise programme|Personalised exercise programme, undertaken three times a week (with no more than two rest days between sessions) for 12 weeks
88840589|NCT02697188|Experimental|Testosterone undecanoate|Period 2 - 200 mg T (as TU) QD Period 3 - 200 mg T (as TU) BID (100 mg/dose) Period 4 - 400 mg T (as TU) BID (200 mg/dose)
88840590|NCT02697188|Active Comparator|Testosterone enanthate|Period 1 - 400 mg T (as TE) QD Period 5 - 800 mg T (as TE) BID (400 mg/dose)
88840591|NCT04707560|Experimental|Heparin Wet first group|Heparin based wet suction method of EUS FNB will go first for 2 passes and then shift to dry suction method for another 2 passes.
88840592|NCT04707560|Experimental|Dry suction first group|Dry suction method of EUS FNB will go first for 2 passes and then shift to heparin base wet suction method for another 2 passes.
88840593|NCT05421104||Ruxolitinib (RUX)|PV patients who were resistant to or intolerant of HU (as defined on the index date) and switched to RUX in the post-index period.
88840594|NCT05421104||Best available therapy (BAT)|PV patients who were resistant to or intolerant of Hydroxyurea (HU) (as defined on the index date) and continued HU treatment or switched to other available therapies other than RUX in the post-index period.
88840595|NCT02652481|Other|ImageReady MR Conditional Defibrillation System Group|"Prospective, non-randomized, confirmatory study.Subjects will initially be enrolled into Phase I to undergo a non-diagnostic study required MR Scan. Once Phase I is complete, subjects will be enrolled into Phase II where there is no requirement to undergo a non-diagnostic study required MR scan Up to 37 subjects will be used for an interim analysis. Of these subjects, the first 20 who undergo the study required MRI scan and complete the MRI + 1 Month Visit will be used for this analysis. The second cohort will consist of subjects who will receive the non-diagnostic study required MR scan until 137 CRT-D and 28 VR ( single chamber) ICD subjects undergo the study required MR scan (complete or incomplete).~De novo implants and existing implants may be enrolled in Phase I There will be a non-diagnostic study required MR scan (during the MRI visit) There will be a study required MRI visit and MRI + 1 month visit"
88840596|NCT05420714|Experimental|Professional CGM Trial|Participants will be asked to wear Dexcom Professional Continuous Glucose Monitoring (Pro-CGM) Device for 10 days. They will have 2 clinic visits with a certified diabetes care and education specialist (CDCES): initial visit for placement of the Pro-CGM and final visit to review the data with CDCES and their diabetes clinic provider. They will be asked to complete a short survey at the end of the 10 days about their experience using the Pro-CGM device and how it impacts their diabetes self-care practices.
88840597|NCT02697890|Active Comparator|FDBA (MinerOss®) + Collagen Sponge (HeliPLUG®)|"Interventions:~Procedure: Ridge preservation procedure"
89368371|NCT03203278|No Intervention|Control group|Usual care
89368372|NCT02450344|Experimental|Internet intervention|Interactive health promotion
89368373|NCT02450344|Active Comparator|Conventional intervention|Passive health promotion
89368374|NCT04362449|Experimental|Shortened hydration time with dispensary of Akynzeo|ABC-02 regime - gemcitabine and cisplatin with a shortened hydration time and administration of a newer antiemetic
89368375|NCT04362449|Active Comparator|Standard of care|ABC-02 regime - gemcitabine and cisplatin with currently approved hydration time and administration of the current choice of antiemetic
89368376|NCT02446210|Active Comparator|Healthy Controls Group|Magstim 200 magnetic stimulator for Transcranial Magnetic Stimulation and Peripheral Nerve Stimulation
88840598|NCT02697890|Experimental|FDBA (MinerOss®) + Mucograft® seal|"Interventions:~Device: Mucograft® seal Procedure: Ridge preservation procedure"
88840599|NCT05419154|Experimental|Early pain dependent weight-bearing without immobilization|Patients are advised to conduct pain-dependent full weight-bearing starting at the day of study inclusion. In case of severe swelling, a splint or below knee cast can be applied until the initial swelling subsides, but no longer than 14 days. Otherwise, no immobilization is applied. The use of crutches is allowed per the individual patients demands. The physiotherapists at the individual study centers are informed prior to study initiation and are briefed about each patient enrolled in the study. Each patient is handed an information sheet for their outpatient physiotherapist.
88840600|NCT02653183|Active Comparator|Device Aquacel Surgical|"Aquacel Surgical is a sterile, one piece post-operative dressing from Convatec.~Duration of treatment:~Total 5 days included the day of surgery and 4 post-operative days."
89001983|NCT00220584|Experimental|Open donepezil|open donepezil
89368377|NCT02446210|Active Comparator|Spinal Cord Injury Group|Magstim 200 magnetic stimulator for Transcranial Magnetic Stimulation and Peripheral Nerve Stimulation
89530382|NCT05573399||Early nasojejunal enteral nutrition|Early enteral nutrition was given early through nasojejunal tube. 5% glucose saline was given on the first day after pancreaticoduodenectomy through nasojejunal tube. Enteral nutrition was given from the second day after pancreaticoduodenectomy. When oral intake was adequate, the nasojejunal tube was removed on the sixth day.
88840601|NCT02653183|Experimental|Device Mepilex Border Post-Op|"Post-operative all-in-one self-adherent soft silicone coated foam dressing.~Duration of treatment:~Total 5 days included the day of surgery and 4 post-operative days."
88840602|NCT05418920|Experimental|the trial group (left-opening single-flap group)|left-opening single-flap group
88840603|NCT05418920|Active Comparator|the control group (double-flap group)|double-flap group
88840604|NCT02701400|Experimental|Arm I (tremelimumab, durvalumab)|Patients receive tremelimumab IV over 1 hour on day 1. Treatment repeats every 4 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients also receive durvalumab IV over 1 hour on day 1. Treatment repeats every 4 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients achieving disease control may restart treatment upon evidence of progressive disease, with or without confirmation.
88840605|NCT02701400|Active Comparator|Arm II (RT, tremelimumab, durvalumab)|Patients undergo stereotactic body radiation therapy (SBRT) or hypofractionated radiation therapy daily for 5 days over 1 week or for 3 fractions every other day for 1 week and then receive the same treatment as in Arm I.
88840606|NCT05400824||general population|Observational study of 2000 adult men and women from the general population who will benefit from a free extensive health check up in La Reunion
88840607|NCT04738994|Experimental|whey protein-enriched nutritional supplement|Standard hospital diet + 80 g/die (two servings) of whey protein-enriched nutritional supplement dissolved in 125 ml of water
88840608|NCT04738994|Active Comparator|Control group|Standard hospital diet
88840609|NCT02653417|Experimental|Regimen 1|RAD1901 5 mg/day
88840610|NCT02653417|Experimental|Regimen 2|RAD1901 10 mg/day
88840611|NCT02653417|Experimental|Regimen 3|RAD1901 20 mg/day
88840612|NCT02653417|Placebo Comparator|Regimen 4|Placebo
88840613|NCT02677766|Experimental|Intervention|Intervention of Occupational therapy consists of implementing plans of action focused on the occupational needs chosen by patients through COPM
88840614|NCT02677766|Active Comparator|usual care|Usual care consists in rehabilitation treatment delivered by a multidisciplinary team
88840615|NCT04338997|Experimental|IZD174|Intra subject dose escalation of IZD174
88840616|NCT02701868||Phase 1|Up to 40 individuals will be recruited to participate in focus groups at Pennington Biomedical Research Center. Approximately six focus groups (each with 5-10 participants) will be conducted at the Pennington Biomedical Demonstration Kitchen over the course of approximately 3 months.
88840617|NCT02701868||Phase 2|Up to 150 individuals who did not participate in Whoa Baby Phase 1 will be recruited to test the efficacy of the revised instructions on infant overfeeding in comparison with the instructions currently provided on the packaging.
88840618|NCT02705365|Experimental|Patient Navigation|Patients assigned to the patient navigator (PN) arm will be sent a letter about the program with lung screening educational materials. The PN will educate eligible patients about lung screening, explore barriers to screening, coordinate scheduling an appointment with a provider, and possibly attend the visit with the patient. The PN will further coordinate scheduling the CT scan, help the patient obtain the test, and access any required follow-up. The PN will assess the patient's interest in quitting smoking and if so, offer and help to connect the smoker to existing cessation resources in the community and provide follow-up contacts to monitor adherence to treatments.
88840619|NCT02705365|Active Comparator|Usual Care|The control group will receive usual care during the 1-year study period. After the study period, they will be offered 1:1 patient navigation to obtain lung screening and follow-up of abnormal results as well as smoking cessation guidance.
88840620|NCT02703350|Experimental|LY900014 - Test (Part A)|Individualized doses of LY900014 administered by injection under the skin once in each of 3 periods
88840621|NCT02703350|Active Comparator|Insulin Lispro - Reference (Part A)|Individualized doses of insulin lispro reference formulation administered by injection under the skin once in each of 3 periods
88840622|NCT02703350|Experimental|LY900014 - Test (Part B)|Individualized doses of LY900014 administered by injection under the skin immediately before each meal for 14 days
88840623|NCT02703350|Active Comparator|Insulin Lispro - Reference (Part B)|Individualized doses of insulin lispro reference formulation administered by injection under the skin immediately before each meal for 14 days
88840624|NCT02682056|Other|Single Study Arm|Children and adolescents with diabetes will have blood glucose levels tested using microneedle patches, intravenous (IV) catheter draw, and lancet.
88840625|NCT02706925|Experimental|BI 443651|
88840626|NCT02706925|Placebo Comparator|Placebo|
88840627|NCT05378438|Experimental|Intervention Arm|Participants allocated in this arm will be approached for a workshop related to microbe literacy. Using a microscope, live demonstration of the biological samples brought by the participants will be carried out by the team of researchers. Participants will be assisted to place biological materials under the microscope, manipulate the slides and discover the profusion of microbial life from the immediate environment. The session will be followed by question and answer round related to concurrent hygiene practices and basic sanitation to prevent infections including vaccines.
88840628|NCT05378438|No Intervention|Control arm|Participants in this arm will be consented for the study and baseline data collection will be made but there will not be any intervention. Data will be collected for baseline as well as post interventional vaccination status among the studied population.
88840629|NCT04739228|Experimental|Guided Written Disclosure Protocol Group|Guided Written Disclosure Protocol is a short-term psychological intervention that stimulates emotional expression, promotes a cognitive reworking of stressful illness events and facilitates the integration between emotional and cognitive processing of traumatic experiences. Intervention aimed at enhancing patients' quality of life, psychological well-being, and emotional regulation, and reducing psychosocial distress.
88840630|NCT04739228|Active Comparator|Active Control Group|
88840631|NCT05470465|Placebo Comparator|Treatment A: Placebo|Participants will receive placebo on days 1-21 for this treatment period. Oxycodone will be administered on days 6, 12, and 21 of this treatment period.
88840632|NCT05470465|Experimental|Treatment B: Paroxetine|Participants will receive paroxetine on days 1-21 for this treatment period. Oxycodone will be administered on days 6, 12, and 21 of this treatment period.
88840633|NCT05470465|Experimental|Treatment C: Escitalopram|Participants will receive escitalopram on days 1-21 for this treatment period. Oxycodone will be administered on days 6, 12, and 21 of this treatment period.
88840634|NCT00368030|Experimental|A|Eszopiclone 3 mg QD
88840635|NCT00368030|Placebo Comparator|B|Placebo tablet
89368378|NCT02077166|Experimental|Phase 1b: Enrolled at Lenalidomide Dose 15 mg (Dose Level 1)|Ibrutinib 560 mg administered orally (PO) once daily (QD) beginning Cycle 1 Day 1 until disease progression or unacceptable toxicity. Lenalidomide 15 mg administered PO QD on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity. Rituximab 375 mg/m^2 administered intravenously (IV) on Day 1 of each 28-day cycle for 6 cycles.
89368379|NCT02077166|Experimental|Phase 1b: Enrolled at Lenalidomide Dose 10 mg (Dose Level -1)|De-escalation cohort: Ibrutinib 560 mg administered PO QD beginning Cycle 1 Day 1 until disease progression or unacceptable toxicity. Lenalidomide 10 mg administered PO QD on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity. Rituximab 375 mg/m^2 administered IV on Day 1 of each 28-day cycle for 6 cycles.
89368380|NCT02077166|Experimental|Phase 1b: Enrolled at Lenalidomide Dose 15 mg (Dose Level 1+)|Re-escalation cohort: Ibrutinib 560 mg administered PO QD beginning Cycle 1 Day 1 until disease progression or unacceptable toxicity. Lenalidomide 15 mg administered PO QD on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity. Rituximab 375 mg/m^2 administered IV on Day 1 of each 28-day cycle for 6 cycles.
89368381|NCT02077166|Experimental|Phase 1b: Enrolled at Lenalidomide Dose 20 mg (Dose Level 2)|Ibrutinib 560 mg administered PO QD beginning Cycle 1 Day 1 until disease progression or unacceptable toxicity. Lenalidomide 20 mg administered PO QD on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity. Rituximab 375 mg/m^2 administered IV on Day 1 of each 28-day cycle for 6 cycles.
89368382|NCT02077166|Experimental|Phase 1b: Enrolled at Lenalidomide Dose 25 mg (Dose Level 3)|Ibrutinib 560 mg administered PO QD beginning Cycle 1 Day 1 until disease progression or unacceptable toxicity. Lenalidomide 25 mg administered PO QD on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity. Rituximab 375 mg/m^2 administered IV on Day 1 of each 28-day cycle for 6 cycles.
89368383|NCT02077166|Experimental|Phase 2: Enrolled at Lenalidomide Dose 20 mg|Ibrutinib 560 mg administered PO QD beginning Cycle 1 Day 1 until disease progression or unacceptable toxicity. Lenalidomide 20 mg administered PO QD on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity. Rituximab 375 mg/m^2 administered IV on Day 1 of each 28-day cycle for 6 cycles.
89368384|NCT02077166|Experimental|Phase 2: Enrolled at Lenalidomide Dose 25 mg|Ibrutinib 560 mg administered PO QD beginning Cycle 1 Day 1 until disease progression or unacceptable toxicity. Lenalidomide 25 mg administered PO QD on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity. Rituximab 375 mg/m^2 administered IV on Day 1 of each 28-day cycle for 6 cycles.
89368385|NCT05186350|Active Comparator|SpyGlass group|ERCP plus SpyGlass group
89368386|NCT05186350|Active Comparator|ESWL group|ERCP plus ESWL
89368387|NCT03199066||All NHL subtypes|no interventions
89368388|NCT03199066||DLBCL|only patients with diffuse large B-cell lymphoma
89368389|NCT03199066||FL|only patients with follicular lymphoma
89368390|NCT03199066||MCL|only patients with mantle cell lymphoma
89368391|NCT03199066||SLL/CLL|only patients with small lymphocytic lymphoma / chronic lymphocytic leukemia
89368392|NCT03199066||MZL|only patients with marginal zone lymphoma
89368393|NCT03199066||other B-cell lymphomas|only patients with B-lymphomas not described above
89368394|NCT03199066||T-cell lymphomas|only patients with all types of T-cell lymphoma
89368395|NCT03198910||Pulmonary arterial hypertension|
89368396|NCT03198910||Chronic thromboembolic pulmonary hypertension|
89368397|NCT03198832|Sham Comparator|Type 2 diabetes mellitus and periodontitis|periodontal debridement in a single session.
89368398|NCT03198832|No Intervention|Type 2 diabetes mellitus and without periodontitis|maintained every three months.
88840636|NCT02656069|Other|G-Pen first, then Lilly Glucagon|A single 1 mg subcutaneous (SC) injection of G-Pen (glucagon injection) with a 7-28 day wash-out, followed by a single 1 mg SC injection of Lilly Glucagon (glucagon injection [rDNA origin])
88840637|NCT02656069|Other|Lilly Glucagon first, then G-Pen|A single 1 mg SC injection of Lilly Glucagon (glucagon injection [rDNA origin]) with a 7-28 day wash-out, followed by a single 1 mg SC injection of G-Pen (glucagon injection)
88840638|NCT02707172|Experimental|Intervention|"Subject was first exposed to 1000 microgram of diethylhexyl phthalate on both hands, and was asked to perform the intervention, handwashing with soap, by a standardized hand washing technique.~Then the subjects in this arms are crossover to receive placebo, handwashing with water only."
88840639|NCT02707172|Placebo Comparator|Placebo|"Subject was exposed to 1000 microgram of diethylhexyl phthalate on both hands, and was asked to perform the placebo, handwashing with water, by a standardized hand washing technique.~Then the subjects in this arms are crossover to perform the intervention, handwashing with soap."
89368399|NCT04273217|Experimental|AV-1 30 mg|Participants received a single intravenous (IV) infusion (infusion duration: 1 hour) of AV-1 30 mg on Day 1.
89368400|NCT04273217|Experimental|AV-1 90 mg|Participants received a single IV infusion (infusion duration: 1 hour) of AV-1 90 mg on Day 1.
89368401|NCT04273217|Experimental|AV-1 250 mg|Participants received a single IV infusion (infusion duration: 1 hour) of AV-1 250 mg on Day 1.
89368402|NCT04273217|Experimental|AV-1 500 mg|Participants received a single IV infusion (infusion duration: 1 hour) of AV-1 500 mg on Day 1.
88840640|NCT05351762|Experimental|study arm|The study arm received nimotuzumab (400mg, every three weeks, for 2 weeks) combined with TPF chemotherapy
88840641|NCT05346536|Experimental|Metastatic pancreatic cancer treatment-naive patients|Newly diagnosed major patients with metastatic pancreatic cancer, naïve of any treatment for metastatic disease
89001984|NCT00122993|Experimental|1|Multi-component environmental intervention to prevent excess weight gain among bus drivers
89001985|NCT00122993|No Intervention|2|Control group
89368403|NCT04273217|Experimental|AV-1 1000 mg|Participants received a single IV infusion (infusion duration: 1 hour) of AV-1 1000 mg on Day 1.
89368404|NCT04273217|Placebo Comparator|Placebo|Participants received a single IV infusion (infusion duration: 1 hour) of placebo matched to AV-1 on Day 1.
89368405|NCT05234086|Active Comparator|Advanced Healing|Activities related to wound washing, microbiological load control, care of peri-ulcer tissue and application of wound healing products in accordance to condition of the ulcer
89368406|NCT05234086|Experimental|InbioDerm + C plus advanced healing|For patient who are assigned treatment with InbioDerm+C plus advanced healing a section of skin tissue and peripheral venous blood will be taken. From the skin section and through an enzymatic process with cell proliferation, skin cells will be obtained that will be integrated into de the InbioDerm+C, then will be apply to the patients with the advanced wound healing every fourteen days in accordance application program.
89368407|NCT02450188|Active Comparator|vardenafil|The study includes a total period of 10 week with a total of 3 visits for vardenafil Group (at the beginning, at 5th week and at the end). In this study we used Vardenafil 10 mg orodispersible tablets. These are the only orodispersible tablets on commerce indicated for the treatment of ED. Male patients will begin taking Vardenafil 10 mg orodispersible tablets 2 times a week for 10 weeks.
89368408|NCT02450188|Active Comparator|vardenafil+cbst|"The study includes a total period of 10 week with a total of 10 visits for vardenafil+cbst Group (one weekly visit).~Male patients will begin taking Vardenafil 10 mg orodispersible tablets 2 times a week for 10 weeks.CBST interventions used in this study includes: psycho-educational interventions on ED maintaining, on anxiety's role and sexual homework. This course is structured in 10 weekly meetings."
89368409|NCT03198676|Active Comparator|A - PrEP-001 6.4 mg - 0.8 mg/spray|PrEP-001 Nasal Powder, 0.8 mg/spray (G-006) (Formulation A)
89368410|NCT03198676|Active Comparator|B - PrEP-001 6.4 mg - 1.6 mg/spray|PrEP-001 Nasal Powder, 1.6 mg/spray (F002) (Formulation B)
89368411|NCT03198676|Active Comparator|C - PrEP-001 3.2 mg - 1.6 mg/spray|PrEP-001 Nasal Powder, 1.6 mg/spray (F002) (Formulation B)
89368412|NCT03198676|Placebo Comparator|D - Placebo|PrEP-001 Placebo Nasal Powder (matching Formulation B)
89368413|NCT03749369|Active Comparator|SRP plus salvadora persica root|Subjects receiving salvadora gel in addition to scaling and root planing
89368414|NCT03749369|Placebo Comparator|SRP only|Subjects receiving scaling and root planing only
89368415|NCT03202966|Experimental|Intervention|For each child with a developmental delay enrolled in the early intervention program, individualized rehabilitation therapy will be provided by a rehabilitation professional with a focus on the one or more domains where delays were identified (i.e. speech, motor, cognition). The intervention will be delivered either as home based rehabilitation or as centre based care. Each child will receive a minimum of one therapy session per week by the CRW and a monthly therapist visit for home based care. In center based care daily therapy will be available by either a CRW or specialist.
89368416|NCT04484506|Experimental|Stage I/II nasal ENKTL|2-3 cycles of induction pegaspargase-COEP chemotherapy followed by concurrent chemoradiotherapy, then by 1-2 cycles of pegaspargase-COEP chemotherapy as consolidation
89368417|NCT04484506|Experimental|Stage III/IV or primary extra-nasal ENKTL|6-8 cycles of pegaspargase-COEP chemotherapy with or without local radiotherapy and/or consolidative autologous stem cell transplantation
89368418|NCT02449564|Experimental|sirolimus|sirolimus 1mg daily
89368419|NCT02449642||group 1|group 1 include 10 women in which blood tests will be taken on the day of oocyte pick up
89368420|NCT02449642||group 2|group 2 include 10 women in which blood tests will be taken on the day of embryo transfer
89368421|NCT05668871|Experimental|Danning Tablet and lifestyle intervention group|Under lifestyle intervention, Danning Tablet will be taken orally from baseline to weeks 12±1.
89368422|NCT05668871|No Intervention|Lifestyle intervention group|Lifestyle intervention only.
89368423|NCT02449720|Active Comparator|Laparoscopic Bowel Surgery: IPLA|Participants will undergo laparoscopic bowel surgery. Both on entry into the abdominal cavity and prior to dissection and post-operation but prior to closure of abdominal wall a 50 ml loading dose of IPLA (0.2% Ropivacaine) solution will be distributed throughout the abdomen. Following these bolus doses an ON-Q Painbuster continuous infusion pump will be placed in close proximity to the operative region of greatest dissection and a 10ml/hr intraperitoneal infusion of IPLA (0.2% Ropivacaine, 20mg/hr) solution commenced immediately post-operation and continued for 48 hrs without disruption.
89368424|NCT02449720|Placebo Comparator|Laparoscopic Bowel Surgery: Control|Participants will undergo laparoscopic bowel surgery. Both on entry into the abdominal cavity and prior to dissection and post-operation but prior to closure of abdominal wall a 50 ml loading dose of Control (0.9% Saline, 20mg/hr) solution will be distributed throughout the abdomen. Following these bolus doses an ON-Q Painbuster continuous infusion pump will be placed in close proximity to the operative region of greatest dissection and a 10ml/hr intraperitoneal infusion of Control (0.9% Saline, 20mg/hr) solution commenced immediately post-operation and continued for 48 hrs without disruption.
89368425|NCT02449720|Active Comparator|Open Bowel Surgery: IPLA|Participants will undergo open bowel surgery. Both on entry into the abdominal cavity and prior to dissection and post-operation but prior to closure of abdominal wall a 50 ml loading dose of IPLA (0.2% Ropivacaine) solution will be distributed throughout the abdomen. Following these bolus doses an ON-Q Painbuster continuous infusion pump will be placed in close proximity to the operative region of greatest dissection and a 10ml/hr intraperitoneal infusion of IPLA (0.2% Ropivacaine, 20mg/hr) solution commenced immediately post-operation and continued for 48 hrs without disruption.
89368426|NCT02449720|Placebo Comparator|Open Bowel Surgery: Control|Participants will undergo open bowel surgery. Both on entry into the abdominal cavity and prior to dissection and post-operation but prior to closure of abdominal wall a 50 ml loading dose of Control (0.9% Saline, 20mg/hr) solution will be distributed throughout the abdomen. Following these bolus doses an ON-Q Painbuster continuous infusion pump will be placed in close proximity to the operative region of greatest dissection and a 10ml/hr intraperitoneal infusion of Control (0.9% Saline, 20mg/hr) solution commenced immediately post-operation and continued for 48 hrs without disruption.
89368427|NCT03194620|Placebo Comparator|Control|Single oral intake of flavanol-free fruit-flavored non-dairy drink
89368428|NCT03194620|Experimental|Theaflavins|Single oral intake of a fruit-flavored non-dairy drink containing a mixture of theaflavins
89368429|NCT03194620|Experimental|Procyanidin Dimer B2 (DB2)|Single oral intake of a fruit-flavored non-dairy drink containing Procyanidin Dimer B2 (DB2)
89368430|NCT03194620|Experimental|(-)-Epigallocatechin-3-O-gallate (EGCG)|Single oral intake of a fruit-flavored non-dairy drink containing (-)-Epigallocatechin-3-O-gallate (EGCG)
88840642|NCT02683772|Experimental|iVAPS with AutoEPAP|This is a crossover study. During overnight PSG, Astral device will be set using iVAPS with AutoEPAP on the first night, and on iVAPS with manual EPAP on the second night.
88840643|NCT02683772|Active Comparator|iVAPS with manual EPAP|This is a crossover study. During overnight PSG, Astral device will be set using iVAPS with manual EPAP on the first night, and on iVAPS with AutoEPAP on the second night.
88840644|NCT02708641|Experimental|AML patients|pembrolizumab 200 mg given IV once every three weeks
88840645|NCT02657629|Active Comparator|Continuous Feeding Regimen|Enteral feedings given as combination of continuous nocturnal feedings and intermittent bolus daytime feedings.
88840646|NCT02657629|Active Comparator|Intermittent Bolus Feeding Regimen|Enteral feedings given as intermittent bolus feedings for entire 24 hour period.
88840647|NCT02683928|Experimental|GBR 830|Two doses of GBR 830, 10 mg/kg (solution for infusion, prepared in normal saline) administered intravenously (IV) four weeks apart.
88840648|NCT02683928|Placebo Comparator|Placebo|Two doses of placebo (formulation buffer for infusion, prepared in normal saline) administered IV four weeks apart.
88840649|NCT02708186|Experimental|Nelotanserin|Nelotanserin 80 mg
88840650|NCT02708186|Placebo Comparator|Placebo|Placebo
88840651|NCT02710591|Experimental|Rimeporide|"Multiple oral doses of rimeporide ranging from 50 to 300 mg will be administered three times a day (TID) for a total of 4 weeks. 4 ascending dose levels will be studied sequentially in ascending order. Rimeporide is provided as hard gel 25 mg or 50 mg capsules.~Each patient will participate in only 1 dose cohort. 5 patients are expected to be recruited in each cohort through all participating sites."
88840652|NCT04339322||Patients with Covid-19|Patients with clinical presentation and confirmed as Covid-19 according to the definition of Egyptian Ministry of Health
88840653|NCT02710981|Active Comparator|Clomiphene citrate only|women with prior 5 ovulatory cycles of Clomiphene citrate induction, but without conception (clomiphene citrate failure), with thin endometrium (<8mm) in at least 3 cycles.
88840654|NCT02710981|Experimental|Sildenafil vaginal gel and Clomiphene|Women who did not conceive on the Clomiphene citrate only cycle (41 women) were given Clomiphene citrate 100 mg/ day starting from day of the cycle for 5 days, with the addition to sildenafil vaginal gel 5 gm twice daily starting from day 8 of the cycle until day of HCG injection.
88840655|NCT04189796|Active Comparator|Jarlsberg|Daily intake of Jarlsberg Cheese in at least 6 weeks
88840656|NCT04189796|Sham Comparator|Camembert|Daily intake of Camembert Cheese in 6 weeks
89368431|NCT03194620|Experimental|(-)-Epicatechin-3-O-gallate (ECG)|Single oral intake of a fruit-flavored non-dairy drink containing (-)-Epicatechin-3-O-gallate (ECG)
88840657|NCT02711839|Placebo Comparator|Control Group|Commercial diabetic formula
88840658|NCT02711839|Experimental|Treatment Group|White sweet potato formula
88840659|NCT04738916|Experimental|Vibration Group|The vibration group was included in the low frequency (25 Hz), low amplitude (2mm), fixed six-week training on two non-consecutive days of the week.
88840660|NCT04738916|No Intervention|Control Group|No training was given to the control group.
88840661|NCT05331404|Experimental|Presbycusis|Patients with presbycusis who receive rehabilitation with hearing aids
88840662|NCT05331404|Active Comparator|Aged control group|Aged control group: 15 subjects with normal or near-normal hearing thresholds
88840663|NCT05331404|Active Comparator|Young control group|Young control group: 15 subjects with normal hearing thresholds
88840664|NCT04739917|Experimental|Arm N Vaccine|30 malaria-naïve subjects from non-endemic areas of Cali, Colombia.
88840665|NCT04739917|Placebo Comparator|Arm N Placebo|30 malaria-naïve subjects from non-endemic areas of Cali, Colombia.
88840666|NCT04739917|Experimental|Arm S Vaccine|30 semi-immune subjects from malaria endemic areas of Chocó, Colombia.
88840667|NCT04739917|Placebo Comparator|Arm S Placebo|30 semi-immune subjects from malaria endemic areas of Chocó, Colombia.
88840668|NCT02713711|No Intervention|control group|The control group plaques did not receive any treatment.
88840669|NCT02713711|Experimental|phototherapy group|Twelve sessions of phototherapy (UV-B) applied on psoriatic plaques according to individual initial evaluation of Minimal Erythema Dose (MED).
88840670|NCT02713711|Experimental|balneotherapy|Twelve sessions of 15 minutes of balneotherapy (warm water, 32 °C and natural sea salt, 250 g/L) applied on psoriatic plaques.
88840671|NCT02713711|Experimental|balneophototherapy|Twelve sessions of both balneotherapy and phototherapy treatments on the same conditions described above applied on psoriatic plaques.
88840672|NCT02659501|Active Comparator|Bupivacaine with epinephrine injections|Patients in the control arm of the study will be treated intra-operatively with standard of care, 0.5% bupivacaine and epinephrine injection (1:200,000), with 50 mg delivered into each breast pocket to perform a field block of the breast pocket (see below). Postoperatively, these patients will be treated with standard postoperative pain control, including narcotics as needed, such as morphine sulfate and hydrocodone/acetaminophen, and muscle relaxants, such as diazepam.
88840673|NCT02659501|Experimental|Liposomal bupivacaine|Patients in the experimental arm of the study will be treated intra-operatively with 1.33% liposomal bupivacaine, with 133 mg delivered to perform a field block of each breast pocket. Postoperatively, these patients will be treated with standard postoperative pain control, including narcotics as needed, such as morphine sulfate and hydrocodone/acetaminophen, and muscle relaxants, such as diazepam.
88840674|NCT02718157|Experimental|Accuracy Testing|Comparison between GenePOC PCR and Reference Method
88840675|NCT02720107|Experimental|fingolimod|Patients did not receive any protocol specified treatment during this follow-up study. Patients remained on their current treatment regime (fingolimod), as determined by their regular treating physician (i.e. 0.5 mg fingolimod daily, single-arm).
89001986|NCT00220818|Experimental|Lansoprazole 1.0 mg/kg QD|
89368432|NCT03194620|Active Comparator|(-)-Epicatechin (EC)|Single oral intake of a fruit-flavored non-dairy drink containing (-)-Epicatechin (EC)
89368433|NCT03194620|Experimental|(-)-Epigallocatechin (EGC)|Single oral intake of a fruit-flavored non-dairy drink containing (-)-Epigallocatechin (EGC)
89368434|NCT03194620|Experimental|Thearubigins|Single oral intake of a fruit-flavored non-dairy drink containing thearubigins
89368435|NCT03203122|Experimental|Study group|Patients are randomized to treatment of either right or left side. The other side works as control
89368436|NCT03203122|Sham Comparator|Comparator Group|Patients are randomized to treatment in either right or left side. The other side works as control
89368437|NCT04384523|Experimental|OsrHSA 20 mg/kg IV|
89368438|NCT04384523|Experimental|OsrHSA 40 mg/kg IV|
89368439|NCT04384523|Experimental|OsrHSA 80 mg/kg IV|
89368440|NCT04384523|Experimental|OsrHSA 140 mg/kg IV|
89368441|NCT04384523|Experimental|OsrHSA 200 mg/kg IV|
88840676|NCT02662387|Active Comparator|High flow nasal cannula (HFNC)|Non-invasive positive pressure ventilation
88840677|NCT02662387|Experimental|HFNC and external nasal dilator (END)|high flow nasal cannula and external nasal dilator
88840678|NCT02722837|Experimental|SOF/VEL|SOF/VEL for 12 weeks
88840679|NCT02710526|Experimental|32 mg CAM2038 weekly|Group 1, 32 mg of CAM2038 subcutaneous weekly injection at multiple injection sites
88840680|NCT02710526|Experimental|128 mg CAM2038 monthly injection|Group 2: 128 mg of CAM2038 subcutaneous monthly injection in the buttocks
88840681|NCT02710526|Experimental|160 mg CAM2038 monthly injection|Group 3: 24mg sublingual BPN for the first 7 days, and then 160 mg of CAM2038 subcutaneous monthly injection in the buttocks starting on Day 8.
88840682|NCT04339231|Active Comparator|Ropivacaine group|The block of the sphenopalatine ganglion will be performed bilaterally through a cotton bud soaked with the anesthetic solution ropivacaine, at a concentration of 1%, advancing it through the nasal cavities towards the posterior nasopharynx wall. A slight resistance in the progression of the cottonoid indicates its contact with the mucosa of the posterior pharyngeal wall. The cottonoid will remain in this position for 20 minutes, so that there is absorption of the anesthetic solution through the mucosa up to the sphenopalatine ganglion, which, in general, is found anatomically around 3 millimeters in depth from the surface. After the established time, the cotton buds are removed.
88840683|NCT04339231|Placebo Comparator|Saline 0,9% group|The block of the sphenopalatine ganglion will be performed bilaterally through a cotton bud soaked with saline solution, in a concentration of 0.9%, advancing it through the nasal cavities towards the posterior wall of the nasopharynx. A slight resistance in the progression of the cottonoid indicates its contact with the mucosa of the posterior pharyngeal wall. The cottonoid will remain in this position for 20 minutes, so that the solution is absorbed by the mucosa up to the sphenopalatine ganglion, which, in general, is anatomically three millimeters deep from the surface. After the established time, the cotton buds are removed.
88840684|NCT02724787|Other|Open Trial|All Veterans will receive the same emotion regulation treatment titled, Manage Emotions to Reduce Aggression.
88840685|NCT02725645|Experimental|Healthy school children|elementary school children will be presented with different backpack loading conditions
88840686|NCT02664961|Experimental|TRC105 and/or bevacizumab|All subjects will begin by receiving single agent TRC105 weekly. In the case of a complete response to single agent TRC105, subjects will continue to receive single agent TRC105 for at least 3 months following complete response. In the case of a partial response (without a complete response) to single agent TRC105, bevacizumab every two weeks will be added. In the absence of a partial or complete response to single agent TRC105, subjects will receive single agent bevacizumab every two weeks. In the absence of a complete response to single agent bevacizumab, or for subjects who have documented disease progression on a prior bevacizumab containing regimen, subjects will receive TRC105 weekly and bevacizumab every two weeks.
89368442|NCT02446054|Experimental|One Arm Study|provide Musashino T2DM diet for 12 weeks to T2DM patients, to evaluate the effect on glycosylated hemoglobin (HbA1c), progression and compliance during study period.
89368443|NCT03202888|Experimental|Intervention|After completing enrollment surveys, including measures of patient activation and medical knowledge, participants will be invited to use the novel IT. The technology is a mobile responsive website for survey data collection made by our technology vendor, QuesGen. Patients and family members will be able to access the website from any personal device with internet access: laptop, tablet, or smart phone. QuesGen will send a text message reminder to participants with a link to specific questionnaires at scheduled time intervals. Frequency of text messaging will likely be daily, but will ultimately reflect family and patient feedback in Aim 1. In addition to text reminders, participants will be able to answer questionnaires at-will by accessing the mobile responsive website.
89368444|NCT02446288|Active Comparator|TMJ Next Generation|The TMJ NextGeneration device consists of a pair of small, hollow ear inserts. These ear inserts are custom-fit to each subject's ear canals. They are constructed from methacrylate polymers - the same material as has been used in hearing aids. The devices rest in the outer third of the ear canal and have a small retraction post that allows for removal of the device from the ear. The devices conform to the shape of the individuals' ear canals when the jaw is in the open position and permit full passage of sound into each ear. The proposed mechanisms of action of the inserts are to support the TMJ and associated secondary musculature to reduce strain in the TMJ area and to provide cognitive awareness to the wearer regarding para-functional habits, i.e., jaw clenching.
89368445|NCT02446288|Active Comparator|DSG Relaxer|The occlusal splint to be used in this study will be the DSG Relaxer™. The DSG Relaxer™ is a device that has been FDA cleared for the treatment of medically diagnosed migraine pain as well as migraine associated tension-type headaches and relieving bruxism and TMJ syndrome through the reduction of trigeminally innervated muscular therapy.
89368446|NCT02445976|Experimental|Prior Abiraterone or Enzalutamide|Seviteronel: given orally once daily in 28-day cycles
88840687|NCT02725801|Active Comparator|one-port|intervention is placement of one-port tissue expander at time of reconstruction
88840688|NCT02725801|Active Comparator|two-port|intervention is placement of two-port tissue expander at time of reconstruction
88840689|NCT02665273|Experimental|Greater occipital nerve block|Bilateral greater occipital nerve block with 3cc of 0.5% bupivacaine, delivered using fan technique
88840690|NCT02665273|Sham Comparator|Sham|Bilateral intradermal injection of 0.5cc of 0.5% bupivacaine, delivered superficially to the area overlying the greater occipital nerve
89368447|NCT02445976|Experimental|Prior Abiraterone and Enzalutamide|Seviteronel: given orally once daily in 28-day cycles
89368448|NCT03198442|Experimental|Breast PET|PET imaging of breast with patient in prone position.
89368449|NCT03198364|Experimental|START + Mobile Augmentation|4 Sessions of In-Person Psychoeducation called Safety and Recovery Therapy (START) with 12 weeks of augmentation by use of automated software to prompt users to engage in personalized adaptive coping
89368450|NCT03198364|Active Comparator|START|4 Sessions of In-Person Psychoeducation called Safety and Recovery Therapy (START)
89368451|NCT03198208||Reference group|No fentanyl dose administered during surgery
89368452|NCT03198208||Comparative group|Fentanyl dose administered during surgery
89368453|NCT01044056|Active Comparator|Levonorgestrel/ethinylestradiol oral contraceptive pill|Microgynon(R), 1 tablet every day for 21 days; each tablet contains 0.150 mg levonorgestrel (LNG) and 0.030 mg ethinylestradiol (EE).
89368454|NCT01044056|Active Comparator|Norelgestrominum and ethinylestradiol contraceptive patch|Evra(TM), One patch applied on lower abdomen for 7 days for 3 consecutive weeks, 3 patches in total. Each patch contains 6 mg norelgestromin and 0.750 mg EE releasing 0.150 mg norelgestromin and 0.020 mg EE per day.
88840691|NCT02713178|Active Comparator|EXPAREL 133 mg|Single dose of 133 mg (10 mL) EXPAREL (bupivacaine liposome injectable suspension) expanded in volume with 10 mL of normal saline for a total volume of 20 mL.
89368455|NCT01044056|Active Comparator|Etonogestrel and ethinylestradiol contraceptive vaginal ring|Nuvaring(R), Place the ring in the vagina for 21 days, remove for one week. Repeat with new Ring. Dose: per ring 11.7 mg ENG and 2.7 mg EE releasing a daily average amount of 0.120 mg ENG and 0.015 mg EE.
89368456|NCT03198286|Experimental|Supportive care (survivor care plan, survey)|Patients receive a customized treatment summary and survivor care plan via the Carevive Survivor Care Planning System and review it during their follow-up visit. Patients also complete a survey on a tablet computer over 10-20 minutes before and after their follow-up visit.
89368457|NCT03203044|No Intervention|Regular Diet Arm|Maintains a regular diet for the duration of the study.
88840692|NCT02713178|Active Comparator|EXPAREL 266 mg|Single dose of 266 mg (20 mL) EXPAREL (bupivacaine liposome injectable suspension).
88840693|NCT02713178|Placebo Comparator|Placebo|Normal saline (20 mL).
89368458|NCT03203044|Experimental|Soylent Diet Arm|Receives a Soylent dietary intervention on days 3-6 of the study.
89368459|NCT01005056||Marvelon®|Single arm study. All participants receive Marvelon® according to the approved dosage and administration method.
89368460|NCT04796714|Sham Comparator|Double antiplatelet therapy group|Patient randomized in this group will receive 1 tablet containing clopidogrel 75 mg and 1 bag containing aspirin 160 mg as treatment. This treatment will start on the day of LAAC procedure and continued for 3 months.
89368461|NCT04796714|Experimental|Aspirin group|Patients randomized in this group: will receive 1 bag containing aspirin 160 mg as treatment. This treatment will start on the day of LAAC procedure and continued for 3 months.
89368462|NCT04382651|Experimental|MAS825 + SoC|Single dose of MAS825 10 mg/kg by intravenous infusion in addition to SoC
89368463|NCT04382651|Placebo Comparator|Placebo + SoC|Single dose of matching Placebo by intravenous infusion in addition to SoC
89368464|NCT02445898|Active Comparator|Methylprednisolone|Preoperative single high dose of Solu-Medrol 125 mg iv.
89368465|NCT02445898|Placebo Comparator|Isotonic Sodium Chloride|Preoperative single dose of isotonic Sodium Chloride
89368466|NCT03202576|No Intervention|Nasogastric tube standard securement|Standard securement of nasogastric tube with adhesive tape
89368467|NCT03202576|Experimental|Nasogastric Tube Nasal Bridle Securement|Securement of NG with AMT Micro Bridle
89368468|NCT03749291|Experimental|Obemat2.0 Intervention Group|Obese children (BMI >97th percentile of the Spanish curves from Hernández 1988) Ages: 8 to 13 at baseline (9 to 15y at the end of the intervention)
89368469|NCT03749291|Active Comparator|Control Group|Obese children (BMI >97th percentile of the Spanish curves from Hernández 1988) Ages: 8 to 13 at baseline (9 to 15y at the end of the intervention)
89368470|NCT02445820||HES|Balanced HES 130/0.4 used as and pump prime and for intraoperative fluid therapy.
89368471|NCT02445820||Crystalloid|Balanced Crystalloid used as a pump prime and for intraoperative fluid therapy.
89368472|NCT03749213|Experimental|Icotinib|Patients with EGFR-mutant Stage ⅢA-N2 Non-small Cell Lung Cancer which can be potentially radical treated by surgery are arranged to receive Icotinib as neoadjuvant therapy before surgery and adjuvant therapy or till progressive disease or unaccepted toxicity.
89368473|NCT04484116||Succesful surgery|PTH 24 hours after surgery <150pg/mL
89368474|NCT04484116||Unsuccessful surgery|PTH 24 hours after surgery >150pg/mL
89368475|NCT03198130|Experimental|REGN2810|REGN2810 administered IV over a 30 minute infusion
89368476|NCT03202654|Experimental|Corn Oil Intervention|Study products delivering 4 tablespoons/day corn oil will be administered for 4-week treatment period.
89368477|NCT03202654|Active Comparator|Coconut Oil Intervention|Study products delivering 4 tablespoons/day coconut oil will be administered for 4-week treatment period.
89530383|NCT03253939||Case group|Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy procedure
88840694|NCT02665741|Other|Control|Standard colonoscopy - no distal colonoscope attachment will be used in this arm
88840695|NCT02665741|Experimental|Olympus transparent cap|The Olympus transparent cap will be attached to the distal end of colonoscope prior to starting the procedure
88840696|NCT02665741|Experimental|Medivators Endocuff|The Medivators Endocuff will be attached to the distal end of colonoscope prior to starting the procedure
88840697|NCT05267756|Experimental|intervention Group|"Patient will be receive .~usual care that included the education patients(e.g., information, and behavior modification advice techniques) based on the latest clinical practice guidelines (Qaseem et al., 2017 ; Delitto et al., 2012). Also, Patients understood their back problem by reassurance that the condition is not a serious disease and information about the nature of the disorder and prognosis and course of recovery. And what should be done to reduce worry (e.g., stay active and returning to normal activities as soon as possible, avoid worry, coping with having a sore back, and positive attitudes towards back pain are important). The given pamphlets produced by the Saudi Spine Society.~The intervention group will have in addition to the usual care, virtual reality immersive based-exercise game, the participants will download (kurki-application), and will given VR glasses"
88840698|NCT05267756|No Intervention|Control Group|"Patient will be receive .~usual care that included the education patients(e.g., information, and behavior modification advice techniques) based on the latest clinical practice guidelines (Qaseem et al., 2017 ; Delitto et al., 2012). Also, Patients understood their back problem by reassurance that the condition is not a serious disease and information about the nature of the disorder and prognosis and course of recovery. And what should be done to reduce worry (e.g., stay active and returning to normal activities as soon as possible, avoid worry, coping with having a sore back, and positive attitudes towards back pain are important). The given pamphlets produced by the Saudi Spine Society.~The control group will have in addition to usual care that included the education patients, a Brochure for LBP therapeutic exercises"
88840699|NCT02726971|Experimental|Low dose of oestrogen|"Patients in this group will build artificial cycle by Femoston.(oral one red tablet daily for 11 days and oral one yellow tablet in the next 10 days). This process will last for 3 months after the surgery.~P.S.1.A red tablet contains 2mg estradiol. 2.A yellow tablet contains 2mg estradiol and 10mg dydrogesterone."
88840700|NCT02726971|Active Comparator|High dose of oestrogen|"Patients in this group will build artificial cycle by Femoston.(oral three red tablets daily for 11 days and oral two yellow tablets in the next 10 days). This process will last for 3 months after the surgery.~P.S.1.A red tablet contains 2mg estradiol. 2.A yellow tablet contains 2mg estradiol and 10mg dydrogesterone."
88840701|NCT04048850||Patients living with HCV +/- HIV|HCV monoinfected and human immunodeficiency virus (HIV)-HCV co-infected, HCV treatment-naïve or peginterferon/ribavirin-experienced patients with HCV genotype 1a, without baseline NS5A resistance, 1b, or 4 and substance use treated with elbasvir/grazoprevir 50-100 mg fixed-dose-combination, 1 tablet by mouth daily, for 12 weeks.
88840702|NCT02727751|Experimental|50mg BID|Tenapanor, 50 mg BID (100 mg total)
88840703|NCT02713256|Experimental|CFZ533 10mg/kg|CFZ533 intravenously over approximately one hour
88840704|NCT05153551|Experimental|PEARS assessment|
88840705|NCT05152849|Experimental|AXA1125 33.9g|33.9 g AXA1125 administered orally BID with or without food
88840706|NCT05152849|Placebo Comparator|Placebo|Matching Placebo administered orally BID with or without food
88840707|NCT02714504|No Intervention|observational|No anti-mold prophylaxis given on the basis of results of baseline presence of skin lesions
88840708|NCT02714504|Experimental|Anti-mold prophylaxis|Anti-mold prophylaxis with either voriconazole or posaconazole for patients with baseline skin lesions in the extremities positive for Fusarium spp.
88840709|NCT02665975|Experimental|Experimental group: iCBT|CBT-based internet-intervention for tinnitus The intervention offered is a CTB-based internet intervention, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is 8 week long e-learning intervention, with new modules introduced weekly and assignments given to practice techniques learnt.
88840710|NCT02665975|Active Comparator|Face-to-face clinical tinnitus care|Receive individual face-to-face tinnitus care, and follow-up appointments as required.
88840711|NCT02718248|Experimental|CHESS Mobile Health Group|The intervention will be six weekly one hour sessions of face-to-face problem solving therapy combined with the CHESS Mobile Health smart phone application (Comprehensive Health Enhancement Support System - CHESS). The CHESS Mobile Health smart phone application enables users to access relevant resources, create a support network and check in regularly with carers. The intervention will be delivered by Dr. Hatcher, a staff psychiatrist in Liaison Psychiatry at The Ottawa Hospital General Campus.
88840712|NCT02668003|Experimental|Cognitive Behavioural Therapy|Brief Cognitive Behavioural Therapy delivered by telephone
88840713|NCT02668003|No Intervention|Treatment as usual|The group allocated to usual care will receive no additional intervention - this will reflect the fact there is no specific intervention provided to patients currently for the prevention of CWP. Participants in this group will receive usual care and there will be no restriction on what this can involve. CBT is not readily available within the NHS and is generally restricted to persons who have developed specific conditions rather than persons at risk of those conditions.
88840714|NCT02724800|Active Comparator|CBTI|CBTI consists of five in-person sessions within an eight week period. Topics covered include: sleep education, stimulus control, sleep restriction, relaxation strategies, cognitive therapy, and sleep hygiene.
88840715|NCT02724800|Active Comparator|BBTI|BBTI consists of one in-person session with three weekly follow-up sessions (in-person or phone) in a four week period. Topics covered include: sleep education, stimulus control, and sleep restriction.
88840716|NCT02730247|Experimental|ramucirumab + nab-paclitaxel|"Ramucirumab will be administered through a vein in the arm as a 60 minute infusion at a dose of 8 mg/kg on days 1 and 15 of a 28-day cycle.~The nab-paclitaxel will be administered through a vein in the arm as a 30 minute infusion at a dose of 100 mg/m2 on days 1, 8 and 15 of a 28 day cycle."
88840717|NCT03889106||Lassa fever|
88840718|NCT04738604|Active Comparator|Zenit Nano Ceramic Composite (PRESIDENT DENTAL, GmbH, Munich, Germany)|Zenit Nano Ceramic Composite (PRESIDENT DENTAL, GmbH, Munich, Germany) is the ideal choice for single-tooth restorations, both in the anterior and the posterior region. It has an ultrafine, radiopaque porcelain filler for use in adhesive filling treatment. It can be polished to a high lustrer due to the ultra- fine particle filler, extremely homogeneous restorations can be placed which are easily polished to a high luster. The mechanical properties of a light-cured dental composite material are particularly dependent on its filler content, the type of incorporated fillers and the efficiency of the filler-resin coupling, so high Vickers hardness, compressive strength and flexural strength are recorded refereed to Zenit filler content 83% by weight (70% by volume) and size 0.7 microns
89368478|NCT04238780|Active Comparator|ESP( Erector Spinae Plane Block)|"After induction parturient in the ESPB underwent bilateral ESPB at the level of T7 using a linear ultrasound (US) transducer.~Intravenous fentanyl patient control device 24-hour fentanyl consumption will be recorded."
89001987|NCT00220818|Experimental|Lansoprazole 2.0 mg/kg QD|
89001988|NCT00213759|Active Comparator|groupe filigrastin|
89001989|NCT00213759|Placebo Comparator|groupe placebo|
89001990|NCT00123032|Experimental|1|This group will focus on improving their diet and increasing physical activity at home and at school.
89368479|NCT04238780|Active Comparator|control group|"No regional anesthesia technique will be applied to the control group.~Intravenous fentanyl patient control device 24-hour fentanyl consumption will be recorded."
89530384|NCT03253939||Control group|Cytoreductive surgery alone
88840719|NCT04738604|Experimental|Ceram•X (Dentsply De Trey GmbH, Konstanz, Germany)|contains organically modified ceramic nanoparticles (2 to 3 nm) and nano-fillers (10 nm) that are combined with conventional glass fillers (mean particle size: 1.1 to 1.5 μm). Nanoparticles and nano-fillers comprise a polysiloxane backbone and have methacrylate groups available for polymerization. According to the manufacturer's data, filler concentration is 76% by weight and 57% by volume. Furthermore, most of the conventional resin matrix is replaced by a matrix full of highly dispersed methacrylate modified polysiloxane particles (2- 3 nm).These nano-ceramic particles are inorganic-organic hybrid particles. Both, nano-ceramic particles and nano- fillers have methacrylate groups available for polymerization. CeramX does not contain triethylene glycol dimethacrylate (TEGDMA) as it was found mutagenic and cytotoxic in vitro
88840720|NCT00369200|Experimental|Arm I|"Patients receive AFP464 IV over 3 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression.~Cohorts of 2-6 patients receive escalating doses of AFP464 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which ≤ 1 of 6 patients experience dose-limiting toxicity. An additional 10 patients whose tumor is amenable to biopsy are treated at the MTD.~Patients undergo blood collection periodically for pharmacokinetic and pharmacodynamic studies. Patients treated at the MTD also undergo tumor tissue biopsies periodically for additional pharmacodynamic and correlative biomarker studies.~After completion of study treatment, patients are followed for 4 weeks."
88840721|NCT02730403||Opioid Use Disorder Patients|
88840722|NCT05207618|Experimental|IBS PATIENTS|Natural specific tannin, chestnut
88840723|NCT02669329|Experimental|Upper arm treatment with vacuum applicator|Subjects with clearly visible fat sufficient for treatment received bilateral CoolSculpting treatments, 1 treatment on each arm.
88840724|NCT02727842|Experimental|Treatment group|All patients will receive the CP950 Sound Processor and be part of the treatment group for one month which is programmed via the wireless programming pod
88840725|NCT05144906||Blind women|The blind women group will include women who are congenitally blind or that were blinded early in life (up to the age of 7).
88840726|NCT05144906||Sighted women|Women with normal or corrected-to-normal eye sight.
88840727|NCT02670343|Experimental|Oral Testosterone Undecanoate|A single dose of oral testosterone undecanoate equivalent to 200 mg of testosterone in the form of two soft gelatin capsules containing 158 mg of testosterone undecanoate will be administered to each subject.
88840728|NCT02730260|Active Comparator|Directive|Participants receive up to 7 directive smoking cessation coaching telephone calls from the quitline over 9 weeks.
88840729|NCT02730260|Experimental|Nondirective|Participants receive up to 7 nondirective smoking cessation coaching telephone calls from the quitline over 9 weeks.
88840730|NCT05128370||Stroke group|Stroke patients who can walk independently for at least 10 meters without rest. Unilateral walking aids are allowed.
88840731|NCT02730884|Experimental|Rigosertib|Participants receive oral Rigosertib under fasting conditions twice a day on a continuous basis. Quality of life questionnaire completed on Day 1 of Cycle 1.
88840732|NCT02732587|Experimental|125 mg Saracatinib|125 mg Saracatinib once daily for 8-11 days
88840733|NCT02731820|Experimental|Treatment group|Potassium citrate Calcium carbonate Vitamin D3
88840734|NCT02731820|Placebo Comparator|Control group, Placebo|Placebo (Excipients) Calcium carbonate Vitamin D3
88840735|NCT02732899|Experimental|Group 1|Sirolimus 440ug for intravitreal injection will be provided in sterile single-use glass vials. One single-dose vial will be packaged in a box for each patient injection. Sirolimus injections will be given at baseline, week 4, 12, 20 and 28. EYLEA® (aflibercept) intravitreal injections will be given at week 1, 8, 16, 24 and 32.
88840736|NCT02732899|Active Comparator|Group 2|Intravitreal injection of EYLEA® (aflibercept) will be given at baseline, week 8, 16, 24 and 32. Sham injections will be given at week 1, 4, 12, 20, and 28 in order to maintain masking of patient to treatment assignment
88840737|NCT04339153|Experimental|Parent Training (PT)|The goal of intervention plan is to teach the basic applied behaviour analysis techniques to find out the antecedent of the problem behaviour, enhance adaptive skills and reduce noncompliance. Sessions will be interactive, and action-oriented through the provision of workbooks, modelling, videos, rehearsal (with child when present), homework tasks, and feedback (Bearss et al., 2015). The parents will be trained on the protocol and delivered 60 to 90 minutes preferably individual sessions over 24 weeks.
89179332|NCT04450394|Active Comparator|Insulin Degludec|Insulin degludec was provided as 100 units/milliliter (U/mL) in a prefilled pen. Participants received individually adjusted doses once daily by SC injection with a starting dose of 10 units, during the 26-week treatment period, to achieve target fasting blood glucose of <=100 mg/dL.
89001991|NCT00123032|No Intervention|2|A control group will not receive any intervention.
89001992|NCT00221013|Experimental|Higher intensity CRRT regimen|
89001993|NCT00221013|Active Comparator|Lower intensity CRRT regimen|
89179333|NCT00758160|Experimental|OROS methylphenidate|Participants willl receive Osmotic Release Oral Delivery System (OROS) methylphenidate (MPH) 18 milligram (mg), 36 mg or 54 mg once daily for 8 weeks. Dose will be adjusted for each participant based on clinical responses and/or side effects.
89368480|NCT03197974|Other|Mindfulness for Bipolar|Introduction to, and training in the skills of mindfulness, self-compassion, and values-oriented action, and how these can be applied to managing symptoms of bipolar disorder.
89368481|NCT03197974|Other|Psychoeducation for Bipolar|Information about bipolar disorder and the patient's role in managing the condition, including identifying triggers, and responding to early warning signs of episodes, and developing a healthy lifestyle
89368482|NCT00944216|Experimental|Salkera Emollient Foam Treatment|All participants will receive this intervention.
89530385|NCT03346031|No Intervention|Group 1|Group 1 is control group that does not listen to music
89530386|NCT03346031|Active Comparator|Music Therapy Group 2|Group 2 is the group listening to preoperative music
89530387|NCT03346031|Active Comparator|Music Therapy Group 3|Group 3 is the preoperative and peroperative music listening group (continuous)
89530388|NCT03245203|Experimental|Experimental group|beacizumab+ neoadjuvant chemotherapy (FOLFIRI+beacizumab)
89530389|NCT03245203|Active Comparator|Control group|neoadjuvant CRT for consecutive 5 weeks
89189269|NCT04071288||mid urethral sling operations|who underwent total laparoscopic hysterectomy for benign causes and had simultaneous incontinence; patients undergoing mid-urethral sling operations
89368483|NCT03202732|Other|DiabetesFlex|"In DiabetesFlex intervention, patients are offered 3 consultations/year. One mandatory consultations (30 minutes). The patient, an endocrinologist and a diabetes nurse attend.~Two optional consultations, patients can choose between face-to-face consultations, a telephone consultation or to cancel the consultation.~Ahead of the consultations, patients fill out the AmbuFlex Diabetes questionnaire and deliver a blood and urine sample.~Based on the patient's response to the AmbuFlex Diabetes questionnaire, the result of the blood sample and the urine sample, the diabetes nurse assign the patient to a face-to-face consultation, a telephone consultation or no consultation with an endocrinologist, a diabetes nurse or a dietician."
89368484|NCT03202732|No Intervention|Standard care|"Standard diabetes care consists of 3 consultations (15 minutes)/year with a physician or a diabetes nurse by turns.~Ahead of the consultation patients send in a blood sample for measuring HgA1c, urine sample for measuring urin-albumin creatinin ratio and other blood samples depending of arrangements made in the last consultation.~Once a year in relation to a consultation, patients fill in the Problem Area In Diabetes (PAID) (20) scale together. Furthermore, based on the patients or healthcare professional judgement, patients see a dietician when needed."
89368485|NCT00878462|Experimental|Sequence 1|Subjects randomly assigned to this sequence receive in order: Treatment A, C, B, A, C, B. Each treatment was one dose, and each patient received a dose in the morning and evening for 3 consecutive days.
89368486|NCT00878462|Experimental|Sequence 2|Subjects randomly assigned to this sequence receive in order: Treatment A, B, C, A, B, C. Each treatment was one dose, and each patient received a dose in the morning and evening for 3 consecutive days.
89368487|NCT00878462|Experimental|Sequence 3|Subjects randomly assigned to this sequence receive in order: Treatment B, C, A, B, C, A. Each treatment was one dose, and each patient received a dose in the morning and evening for 3 consecutive days.
89368488|NCT00878462|Experimental|Sequence 4|Subjects randomly assigned to this sequence receive in order: Treatment B, A, C, B, A, C. Each treatment was one dose, and each patient received a dose in the morning and evening for 3 consecutive days.
89368489|NCT00878462|Experimental|Sequence 5|Subjects randomly assigned to this sequence receive in order: Treatment C, B, A, C, B, A. Each treatment was one dose, and each patient received a dose in the morning and evening for 3 consecutive days.
89368490|NCT00878462|Experimental|Sequence 6|Subjects randomly assigned to this sequence receive in order: Treatment C, A, B, C, A, B. Each treatment was one dose, and each patient received a dose in the morning and evening for 3 consecutive days.
89368491|NCT03197818|Experimental|CHF 5993 100/6/12.5 µg|Fixed combination of extrafine beclometasone dipropionate 100 µg plus formoterol fumarate 6 µg plus glycopyrronium bromide 12.5 µg / metered dose (BDP/FF/GB) (Beclometasone dipropionate / Formoterol Fumarate / glycoppyronium Bromide)
89368492|NCT03197818|Active Comparator|Symbicort Turbuhaler 160/4.5 µg|Fixed combination of 160 µg budesonide + 4.5 µg formoterol fumarate (160µg + 4.5 µg expresses the delivered dose; 200 µg + 6 µg expresses the metered dose) ( BUD/FF) (Budesonide/Formoterol Fumarate)
89368493|NCT00754520|Experimental|Ceramic On Metal|This arm utilizes the ceramic on metal articulation using the M2a-38™ mm cup.
89368494|NCT00754520|Active Comparator|Metal on Metal|This arm utilizes the metal on metal articulation using M2a-38™ mm cup.
89368495|NCT01562249|Experimental|Experimental group|Inclusion criteria were: Skeletal Class III orthognathic surgery patients; adults (age above 18 years), agreement to perform orthognathic surgery and to undergo all of the necessary procedures determined by the multidisciplinary team (i.e. orthodontic preparation, clinical orofacial myofunctional and electromyographic assessment, surgery, post surgery orthodontic treatment, post surgery clinical orofacial myofunctional and electromyographic assessment and orofacial myofunctional treatment when necessary). Exclusion criteria were: previous orthognathic surgery; previous head and neck surgery; neurologic and/or systemic diseases; facial trauma; syndromes; cognitive impairment; and communication and hearing deficits.
89534738|NCT05025579|Experimental|Exercise group|Considering the protocol suggested in the literature and by examining exercise samples for geriatric individuals, an exercise protocol was created. The first week started with aerobic exercises with a total of 120 minutes, and the next week increased to 160 minutes . A 6-week exercise program was planned and applied 4 days a week in which the intensity was increased gradually. People 's heart rate, blood pressure and respiratory frequency exercise program implementation before and after was recorded in the evaluation form.
89534739|NCT03240991||Quality of life questionnaires|Data will be collected retrospectively and prospectively.
89534740|NCT03333707|Experimental|Active|Participants will be provided will full access to the Pacifica app.
88840738|NCT04339153|No Intervention|Parent Education (PE)|"The Parent education group will serve as an attention-placebo condition to control for general effects of the intervention.~There will be 12 core sessions and 1 home visit regarding knowledge of autism, learning about the principles of managing behavior, teaching new skills; improving social interaction and communication. Each session will last for 60 to 90 minutes over 24 weeks."
88840739|NCT03647462|Experimental|CPAP Intervention Pathway|"Patients will receive continuous positive airway pressure (CPAP) therapy in the hospital followed by home CPAP therapy. Their home CPAP therapy will include wireless connectivity, which includes adherence data. Furthermore, the patients will be entered into our usual automated platform (USleep; ResMed Corp) in which patients with suboptimal CPAP use will be sent messages (based on patient preference) in order to ensure adherence to therapy. This platform is already a standard part of our usual care.~The patients will receive CPAP in addition to contemporary standard of care pharmacotherapy for their underlying COPD. They will follow up at the Fontana Sleep Center within 1 month after discharge for assessment of CPAP use and asked to complete a questionnaire packet. Patients will be followed during the 30-day period and assessed for readmission rates, time to readmission, adherence to CPAP therapy, and presence of symptoms."
89001994|NCT00213954|Other|interscalene block|Locoregional anesthesia selection
89001995|NCT00213954|Other|axillary block|Locoregional anesthesia selection
89189270|NCT02574546||Surgery|Women undergoing mastectomy are eligible for enrollment.
89534741|NCT03333707|No Intervention|Wait List|Participants will be placed on a wait list and will receive access to the app after 1 month.
89534742|NCT03240757|Active Comparator|Breakfast without exercise|Each subject of the same arm underwent 2 interventions: breakfast with/without exercise
89530390|NCT02516423|Experimental|ixazomib + lenalidomide + dexamethasone + zoledronic acid|Patients receive 4 mg ixazomib by mouth on days 1, 8 and 15. Patients also receive 15 mg lenalidomide by mouth on days 1-21, 12 mg dexamethasone by mouth on days 1, 8, 15, and 22 and zoledronic acid (dose based on creatinine clearance on day 1) IV infusion on day 1. Patients receive treatment every 28 days for a maximum of 6 cycles.
88840740|NCT03647462|No Intervention|Usual Care Pathway|Patients will receive contemporary standard of care pharmacotherapy for their underlying COPD condition and will not receive CPAP therapy for the duration of the study. They will be asked to follow up at the Fontana Sleep Center within 1 month after discharge for a repeat outpatient portable sleep study and asked to complete a questionnaire packet. The results of the outpatient portable sleep studies will be compared with the in-patient portable sleep study. Patients will also be asked to follow up with the Fontana Sleep Center within 1 month after discharge for assessment of primary and secondary outcomes. Patients will be followed during the 30-day period and assessed for readmission rates, time to readmission, adherence to CPAP therapy, and presence of symptoms.
88840741|NCT02733757|No Intervention|Sub-Tenon's group control|2% Lidocaine without epinephrine
88840742|NCT02733757|Experimental|Sub-Tenon's group clonidine|2% Lidocaine without epinephrine plus clonidine 1 µg/kg
88840743|NCT02733757|No Intervention|Peribulbar group control|2% Lidocaine without epinephrine
88840744|NCT02733757|Experimental|Peribulbar group clonidine|2% Lidocaine without epinephrine plus clonidine 1 µg/kg
88840745|NCT00368264|Experimental|1|azathioprine plus 4 infusions of infliximab (5 mg/kg)
88840746|NCT00368264|Placebo Comparator|2|azathioprine plus 4 placebo infusions
88840747|NCT05086406|No Intervention|In-Office Visit Group|This control group will undergo standard in-office pre-operative counseling visit.
88840748|NCT05086406|Experimental|Virtual Visit Group|This study group will receive pre-operative counseling via video, created by the Department of Gynecology at Cleveland Clinic Florida, followed by a virtual visit with a gynecologic surgery provider.
88840749|NCT02734147|Active Comparator|High dose IV ascorbic acid|Patients will receive 67 mg/kg IV ascorbic acid in 100 ml normal saline over 30 minutes every 8 hours (200 mg/kg/day) for 72 hours.
88840750|NCT02734147|Placebo Comparator|Placebo|The placebo group will receive 100 ml 0.9% NaCl over 30 minutes every 8 hours for 72 hours.
88840751|NCT02673541|Active Comparator|AXIOS™ stent|1. Arm 1 will undergo EUS-guided cystogastrostomy/enterostomy and placement of the AXIOS™ stent 10-15mm (saddled diameter; choice at the discretion of the treating gastroenterologist) though the tract into the collection cavity, and correct positioning of the inner flange confirmed by EUS prior to deploying within the stomach or duodenum. Necrosectomy will be performed at the discretion of the attending gastroenterologist. Repeat endoscopy will be performed for stent removal at or before 60 days at the discretion of the attending gastroenterologist
88840752|NCT02673541|Active Comparator|double pigtail stents|2. Arm 2 will undergo EUS-guided cystogastrostomy/enterostomy and placement of multiple double pigtail stents (i.e. ≥2) through the tract into the collection cavity. Necrosectomy will be performed at the discretion of the attending gastroenterologist. Routine repeat treating gastroenterologist for stent removal will not be necessary, but left to the discretion of the attending gastroenterologist.
88840753|NCT02732366|Experimental|Group-based exercise and peer coaching|This treatment arm will include physical therapist-led group-based exercise, goal-setting, peer coaching training, individualized home program, and activity monitoring.
88840754|NCT02732366|Active Comparator|Usual PT and attention control grp class|This arm consists of the continuation of one-on-one PT along with participation in an attention control - healthy living class.
88840755|NCT03609320|Experimental|Single Arm|These practices, which previously received standard of care, will receive The STOP-HPV Trial 5: Bundle Intervention
88840756|NCT03609008|Active Comparator|Levcromakalim|18 participants will randomly be allocated in a 2:1 order to receive 1 mg levcromakalim or placebo (isotonic saline)
88840757|NCT03609008|Placebo Comparator|Saline|18 participants will randomly be allocated in a 2:1 order to receive 1 mg levcromakalim or placebo (isotonic saline)
88840758|NCT02732600|No Intervention|Standard Implementation|Standard Implementation sites will receive written guidance and limited consultation by the investigators' team.
88840759|NCT02732600|Experimental|Facilitated Implementation|Facilitated Implementation sites will receive one year of support based on the i-PARIHS implementation model which includes training, implementation planning, ongoing external facilitation, feedback and consultation.
88840760|NCT02734238|Placebo Comparator|Energy Deficit|Participants randomly assigned to the control condition will be subject to exercise-induced energy expenditure resulting in a 55% energy deficit and will be administered sesame oil placebo injections during phase 2 of the trial.
88840761|NCT02734238|Experimental|Energy Deficit + Testosterone|Participants randomly assigned to the intervention condition will be subject to exercise-induced energy expenditure resulting in a 55% energy deficit and will be administered testosterone enanthate injections during phase 2 of the trial.
88840762|NCT02734849|Experimental|25 mg AK001|25 mg AK001 will be administered as multiple doses
88840763|NCT02734849|Experimental|250 mg AK001|250 mg AK001 will be administered as multiple doses
88840764|NCT02734849|Placebo Comparator|Placebo|A placebo comparator consisting of inactive excipients will be administered as multiple doses
88840765|NCT04707547|Experimental|Radiofrequency Ablation|Malignant Liver Tumors With Radiofrequency Ablation (RFA) Therapy
88840766|NCT04707547|Placebo Comparator|Radiofrequency Ablation combine with Nivolumab|Malignant Liver Tumors With Radiofrequency Ablation (RFA) Therapy, and improving immune systems by Nivolumab
88840767|NCT02735551|Active Comparator|Non-LARC Group: Short Acting Method|"All groups will receive the same standardized contraceptive counseling (LARC forward counseling). Participants who chose a short-acting hormonal method (e.g. contraceptive pills, ring, or patch) will receive a prescription to the pharmacy of their choice, as is the current practice for students who present for contraceptive services"
89001996|NCT00213954|Other|lumbar block|Locoregional anesthesia selection
89530391|NCT02516423|Active Comparator|zoledronic acid|Patients receive zoledronic acid (dose based on creatinine clearance on day 1) IV on day 1. Patients receive treatment every 28 days for a maximum of 6 cycles.
89530392|NCT03245281|Experimental|Diuretic Suspension (DS)|
89530393|NCT03245281|Experimental|Diuretic Increase (DI)|
89530394|NCT03245281|Experimental|Diuretic and Medication Suspension (DMS)|
88840768|NCT02735551|Active Comparator|Control Group: Referral for LARC Placement|"All groups will receive the same standardized contraceptive counseling (LARC forward counseling). Randomized to referral for LARC placement to local clinic."
88840769|NCT02735551|Active Comparator|LARC Group: Same Day LARC Placement|"All groups will receive the same standardized contraceptive counseling (LARC forward counseling). Randomized to same day LARC placement (intervention)."
89368496|NCT01562249|Active Comparator|Instruction Group|Inclusion criteria were: Skeletal Class III orthognathic surgery patients, adults (age above 18 years), agreement to perform orthognathic surgery and to undergo all of the necessary procedures determined by the multidisciplinary team (i.e. orthodontic preparation, clinical orofacial myofunctional and electromyographic assessment, surgery, post surgery orthodontic treatment, post surgery clinical orofacial myofunctional and electromyographic assessment and orofacial myofunctional treatment when necessary). Exclusion criteria were: previous orthognathic surgery; previous head and neck surgery; neurologic and/or systemic diseases; facial trauma; syndromes; cognitive impairment; and communication and hearing deficits.
89368497|NCT01562249|No Intervention|Control group|Inclusion criteria for this group were: adults (age above 18 years); absence of stomatognathic system alterations; absence of alterations in the scapular region; complete permanent dentition (absence/extraction of the third molar was accepted); Skeletal and Angle's Class I facial pattern; and absence of malocclusion. Exclusion criteria were: previous orthodontic treatment; and history of previous oral motor intervention.
89368498|NCT03197896|Experimental|Group I (prostate cancer information)|The educator reviews general information about the prostate Cancer
89368499|NCT03197896|Active Comparator|Group II (general health information)|The educator reviews topics about health promotion actions.
88840770|NCT02736175|Experimental|OTX-DP|OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use
88840771|NCT02736175|Placebo Comparator|PV|PV (placebo drug delivery vehicle)
88840772|NCT02735174|Experimental|Single arm asthma self-management|"Interventions include:~Sensor cap system for inhalers App for SmartPhone Motivational interviews Telehealth clinic visits"
88840773|NCT02735642|Experimental|SMART Randomization 1 - Referral|Participants who are HIV positive will be enrolled in the SMART trial adaptive linkage to care intervention pilot. (HIV Positive Cohort approximately N=108).
88840774|NCT02735642|Experimental|SMART Randomization 1 - Referral and SMS|Participants who are HIV positive will be enrolled in the SMART trial adaptive linkage to care intervention pilot. (HIV Positive Cohort approximately N=108).
88840775|NCT02735642|Experimental|SMART Randomization 2 - SMS|HIV positives that have not successfully linked to care after the first randomization will be re-randomized to receive either an SMS message or economic incentive to link to care. (HIV Positive Cohort approximately N=108).
88840776|NCT02735642|Experimental|SMART Randomization 2 - Incentive|HIV positives that have not successfully linked to care after the first randomization will be re-randomized to receive either an SMS message or economic incentive to link to care. (HIV Positive Cohort approximately N=108).
88840777|NCT02735642|Other|High Risk Negative Cohort (N=185)|A subset of negatives identified as 'high risk' from the CAPI baseline survey will be invited to participate in the primary prevention intervention (N=185).
88840778|NCT02735642|Other|All participants. Approximately (N=1200)|HIV testing options that female youth can choose from include: (1) oral fluid HIV self-testing (OHIVST) at their convenience; (2) immediate staff-aided testing at home/mobile site; and (3) a referral to a health care facility where HIV testing will be done by a health care provider (standard facility-based HTS).
88840779|NCT03449576|Experimental|Trauma Management Therapy|Trauma Management Therapy (TMT) consists of a combination of 12 sessions of individualized exposure therapy and 24 sessions of group-based social and emotion rehabilitation.
89368500|NCT03442088|Experimental|Apremilast for Treatment of Psoriasis with the AM-endotype|Psoriasis patients with the AM-endotype will be followed during treatment over 16 weeks with 5 monthly individual blood draws will be enrolled.
88840780|NCT03449576|Active Comparator|Exposure Therapy with Psychoeducation|Exposure Therapy with Psychoeducation (EXP+EDU) consists of a combination of 12 sessions of individualized exposure therapy and 24 session of group-based psychoeducation.
88840781|NCT05446610|Experimental|Gut barrier function treatments|Stressor, fibre, combination of treatments.
88840782|NCT02736955|Experimental|Valbenazine|Fixed dose of valbenazine administered once daily for up to 72 weeks
88840783|NCT00369356|Sham Comparator|1|Bare Metal Stenting
88840784|NCT00369356|Active Comparator|2|Stenting with DES
88840785|NCT00369356|Experimental|3|Bare metal stenting and administration of prednisone
88840786|NCT03409562|Experimental|Pain Neurophysiology Education and motor control training|This group will undergo two pain neurophysiology education sessions prior to motor control training.
88840787|NCT03409562|Active Comparator|motor control training alone|This group will only perform motor control training.
88840788|NCT05446441|Experimental|Intervention;|Endoscopic thyroidectomy was performed in a standardized fashion by multi-institutional Chinese experienced surgeons using the same gasless unilateral transaxillary approach.
88840789|NCT05446441|Active Comparator|Control|Conventional open surgery was performed in a standardized fashion by multi-institutional Chinese experienced surgeons.
89368501|NCT03202420|Experimental|TOPS|Participants will attend weekly TOPS meetings with standard weekly weigh ins
89368502|NCT03746795|No Intervention|Standard spirometry|Standard spirometry measurement with a pneumotachograph alone.
89368503|NCT03746795|Experimental|EIT alone|Spirometric examinations realized using the EIT
88840790|NCT05446532||Not apply|None. Just registration epidemiology dates
88840791|NCT02677753|Active Comparator|Fluoroscopy guided PNE|Fluoroscopy will be utilized to assist with placement and/or confirm correct placement of lead wires.
88840792|NCT02677753|No Intervention|PNE without fluoroscopic guidance|No fluoroscopy will be used during or after the placement of the lead wires.
88840793|NCT04958798|Experimental|Culturally Centered MOUD Implementation|Culturally centered program-level implementation intervention to increase the use of medications for opioid use disorder in healthcare and treatment settings serving AI/AN communities
88840794|NCT02679469|Experimental|Nalmefene hydrochloride 10 mg|nalmefene 10 mg tablet
89001997|NCT00213954|Other|parasacral plexus block|Locoregional anesthesia selection
89001998|NCT00191126|Other|A|
88840795|NCT05445973|Experimental|Real-Time Contrast-Enhanced Ultrasonography-CT/MRI Fusion Guidance|To investigate whether CEUS-CT/MRI fusion imaging improved the visualization of small (≤ 3 cm) primary and secondary malignant liver tumors that were inconspicuous on B-mode US for percutaneous RFA.
88840796|NCT05445986||group1|socket with intact buccal bone plate
88840797|NCT05445986||group 2|socket with damaged buccal bone plate
88840798|NCT02681809|Experimental|Ocriplasmin 0.0625mg|
88840799|NCT02681809|Experimental|Ocriplasmin 0.125mg|
88840800|NCT02681809|Sham Comparator|Sham injection|
88840801|NCT05445661|Experimental|Injectable poly-L-lactic acid|One of the subject's arms will be treated with injectable poly-L-lactic acid (PLLA, Sculptra® Aesthetic; Galderma Laboratories; Fort Worth, TX).
88840802|NCT05445661|Sham Comparator|Normal Saline|One of the subject's arms will be treated with injectable normal saline
88840803|NCT05445271|Active Comparator|Group 1|30 patients who will be intubated with a video laryngoscope and who meet the inclusion criteria are randomly selected by lottery method. After obtaining the consent of the patient's family, the patient is taken to the operating room and monitored. 5 minutes after sedation with 1 mg midazolam, the optic nerve sheath diameter of both eyes is measured with a linear ultrasound probe and recorded (T0). 5 minutes after the patient is intubated with a video laryngoscope, the optic nerve sheath diameter of both eyes is measured and recorded (T1). After the patient's extubation at the end of the case, the optic nerve sheath diameter of both eyes is measured and recorded (T2). Vitals (pulse, blood pressure, saturation) involved in T0, T1 and T2 processes are recorded.
88840804|NCT05445271|Active Comparator|Group 2|30 patients who will be intubated with a normal laryngoscope and who meet the inclusion criteria are randomly selected by lottery method. After obtaining the consent of the patient's family, the patient is taken to the operating room and monitored. 5 minutes after sedation with 1 mg midazolam, the optic nerve sheath diameter of both eyes is measured with a linear ultrasound probe and recorded (T0). 5 minutes after the patient is intubated with a normal laryngoscope, the optic nerve sheath diameter of both eyes is measured and recorded (T1). After the patient's extubation at the end of the case, the optic nerve sheath diameter of both eyes is measured and recorded (T2). Vitals (pulse, blood pressure, saturation) involved in T0, T1 and T2 processes are recorded.
88840805|NCT05445271|Active Comparator|Group 3|30 patients who will be ventilated with a laryngeal mask airway (LMA) and who meet the inclusion criteria are randomly selected by lottery method. After obtaining the consent of the patient's family, the patient is taken to the operating room and monitored. 5 minutes after sedation with 1 mg midazolam, the optic nerve sheath diameter of both eyes is measured with a linear ultrasound probe and recorded (T0). The optic nerve sheath diameter of both eyes is measured and recorded 5 minutes after LMA is placed on the patient (T1). After the patient's extubation at the end of the case, the optic nerve sheath diameter of both eyes is measured and recorded (T2). Vitals (pulse, blood pressure, saturation) involved in T0, T1 and T2 processes are recorded.
88840806|NCT04805125|Active Comparator|Moderna mRNA COVID-19 vaccine|"The Moderna COVID-19 Vaccine, mRNA-1273 (100 μg) is administered intramuscularly as a series of two doses (0.5 mL each), given 28 days apart.~ARM CLOSED"
88840807|NCT04805125|Active Comparator|Comirnaty® (Pfizer / BioNTech) mRNA COVID-19 vaccine|"Active:~The comparator product is the first licensed vaccine against SARS-CoV-2 in Switzerland.~Pfizer-BioNTech COVID-19 Vaccine, BNT162b2 (30 µg) Comirnaty®, is administered intramuscularly (IM) as a series of two 30 µg doses of the diluted vaccine solution (0.3 mL each) according to the following schedule: a single dose followed by a second dose 21 days later.~ARM CLOSED"
88840808|NCT04339075||Venablock|Patients that have undergone Venablock treatment
88840809|NCT05445115|Experimental|Treatment|Actual treatment device
89179334|NCT05699564|Experimental|Early biomarker-based cardiological assessment and structured feedback in the EHR|We will perform cardiac biomarker testing with NT-proBNP and hs-cTnT measurements on emergency department admission in all participants, regardless of randomization status. The results will be provided in the patient's EHR, regardless of randomization status. For patients randomized to the intervention group, we will provide a note in the patient's EHR that includes assessment of probability that myocardial injury or dysfunction are the underlying pathophysiology responsible for tachypnea, as evaluated by the cardiac biomarker algorithm of the study. We will inform on general recommendations for work up and treatment.
89179335|NCT05699564|No Intervention|Standard of care|Routine standard of care according to the treating physician
88840810|NCT05445115|Sham Comparator|Sham|Sham/placebo device
88840811|NCT05444959|Experimental|HMB supplementation|"The experimental procedure for each participant in this group includes a two 21-days periods HMB supplementation.~HMB will be administered in the form of blinded liquid containing 1 mL HMB free acid per 30 drops. The liquid HMB will be ingested with at least 100 mL of water. Each participant will ingest individualized dose of 90 mg HMB/kgFFM/day of liquid HMB free acid in a split dose per day. On training days in the S group during the first and the second period of supplementation and on training days in W group during the second period of supplementation the supplement will be taken before (half of the individual daily dose) and immediately after training session (second half of the individual daily dose), On rest days the supplements will be taken in the morning (half of the individual daily dose) and before bedtime (second half of the individual daily dose)."
89001999|NCT00191126|Experimental|B|
89002000|NCT00123188|Experimental|Ultrasound and Biopsy|Transvaginal Ultrasound and Endometrial Biopsy
89179336|NCT02599740|Placebo Comparator|Placebo|Rice only
89179337|NCT02599740|Active Comparator|Assumed active|Assumed key active consumed with rice
89179338|NCT02599740|Active Comparator|Natural fruit extract|Natural fruit extract consumed with rice
89179339|NCT02606552|Active Comparator|Dabigatran plus aspirin|Medical treatment with dabigatran plus aspirin after 3months triple therapy (Dabigatran plus DAPT (dual-antiplatelet therapy))
89179340|NCT02606552|Experimental|Dabigatran plus clopidogrel|medical treatment with dabigatran plus clopidogrel after 3months triple therapy (Dabigatran plus DAPT)
89179341|NCT02606552|Other|Amplazter Cardiac Plug (ACP)|Amplazter Cardiac Plug (ACP) device-using percutaneous left atrial appendage closure
89368504|NCT03746795|Experimental|Simultaneous standard spirometry and EIT|Simultaneous measurement by spirometer and EIT
89368505|NCT03202498|Experimental|Cohort 1 (4g Yaq-001)|Standard medical treatment + Yaq-001 (4 g/ day)
89368506|NCT03202498|Placebo Comparator|Cohort 1 (4g Placebo)|Standard medical treatment + placebo-control (placebo for 4 g of Yaq-001/ day)
89368507|NCT03202498|Experimental|Cohort 2 (8g Yaq-001)|Standard medical treatment + Yaq-001 (8 g/ day)
89368508|NCT03202498|Placebo Comparator|Cohort 2 (8g Placebo)|Standard medical treatment + placebo-control (placebo for 8 g of Yaq-001/ day)
89368509|NCT01562405|Experimental|ACE-011 (sotatercept)|ACE-011, Lenalidomide or pomalidomide, Dexamethasone
89368510|NCT03194386|No Intervention|Control|usual care
89368511|NCT03194386|Active Comparator|Reassurance|15 minutes psychologist visit
89368512|NCT03194386|Experimental|R-TEP EMDR|Recent Traumatic Episode Protocol Eye-Movement Desensitization and Reprocessing (R-TEP EMDR) At the end of cares, before ED discharge, a trained psychologist will conduct a single R-TEP EMDR session. Each session may last about 60 minutes
88840812|NCT05444959|Placebo Comparator|Placebo treatment|"The experimental procedure for each participant in this group includes a two 21-days periods Placebo supplementation.~PLA (liquid placebo similar in appearance, taste and smell to HMB, but containing no HMB) will be placed in the blinded liquid form. PLA will be ingested with at least 100 mL of water. Each participant will ingest individualized dose of 90 mg PLA/kgFFM/day of liquid PLA in a split dose per day. On training days in the S group during the first and the second period of supplementation and on training days in W group during the second period of supplementation, the PLA will be taken before (half of the individual daily dose) and immediately after training session (second half of the individual daily dose), On rest days the PLA will be taken in the morning (half of the individual daily dose) and before bedtime (second half of the individual daily dose)."
88840813|NCT00368017|Active Comparator|1|
89368513|NCT03748745|Experimental|Cohort A|SH229 (600 mg) once daily, Daclatasvir dihydrochloride (60 mg) once daily.
89368514|NCT03748745|Experimental|Cohort B|SH229 (600 mg) once daily, Daclatasvir dihydrochloride (60 mg) once daily.
88840814|NCT00368017|Placebo Comparator|2|
88840815|NCT04672447|Experimental|L-Citrulline + Glutathione|Citrulline: 2 grams/day, Glutathione: 200mg/day for 4 weeks
88840816|NCT04672447|Experimental|L-Citrulline|Citrulline: 6 grams/day
88840817|NCT04672447|Placebo Comparator|Placebo|Maltodextrin: 6 grams/day
88840818|NCT05444647||HER2-positive|patients with newly diagnosed early stage HER2-positive breast cancer with an indication for standard trastuzumab-containing neoadjuvant treatment.
89368515|NCT03298334|Active Comparator|Receives Vaginal Seeding|
89368516|NCT03298334|Sham Comparator|No Vaginal Seeding|
89368517|NCT03194230|No Intervention|Without cervical dilator|Induction of labour by oral of 400µg of misoprostol each 3 hours.
89368518|NCT03194230|Experimental|With cervical dilator|Induction of labour by cervical placement of hygroscopic dilators for 3 hours and oral of 400µg tablets of misoprostol each 3 hours.
88840819|NCT04739137||Study group|100 patients with diagnosed macular edema will be enrolled
88840820|NCT05444491||MRD positive group|ColonAiQ polygene methylation test was performed on peripheral blood plasma samples from the enrolled patients 4 weeks after surgery. If gene methylation levels in the samples exceeded the threshold, the patients were enrolled in the MRD positive group. The 2-year total tumor recurrence rate of patients in the MRD positive group was calculated, and the positive prediction rate of postoperative plasma ctDNA methylation-MRD detection results for 2-year tumor recurrence rate after colorectal cancer radical resection was calculated.
88840821|NCT05444491||MRD negative group|ColonAiQ polygene methylation test was performed on peripheral blood plasma samples from the enrolled patients 4 weeks after surgery. If the gene methylation level detected in the samples did not exceed the threshold, the patients were enrolled in the MRD negative group. The 2-year total tumor recurrence rate of patients in the negative MRD group was calculated, and the negative prediction rate of postoperative plasma ctDNA methylation-MRD test results for 2-year tumor recurrence rate after radical resection of colorectal cancer was calculated.
88840822|NCT04633759|Experimental|Blood Flow Restriction Exercise|Participant will participate in a supervised low load blood flow restriction exercise program twice a week for 8 weeks.
88840823|NCT05436223|Experimental|Human CD19 Targeted T Cells Injection|Single administration：2.0×10^6 CAR+T/kg
88840824|NCT04536103||Cleveland Clinic Foundation (CCF) Volunteers|The group will be used for evaluating differences between standard T1rho and T2 imaging vs accelerated T1rho and T2 imaging techniques that will be developed from this study.
89002001|NCT00213993|Experimental|A|antiperspirant topically to one foot once daily
89368519|NCT03746717|Experimental|Prineo|Skin closure with Dermabond Prineo occlusive wound closure system
89368520|NCT03746717|Active Comparator|Staples|Skin closure with staples
89368521|NCT03119194|Experimental|Reguimen A - [14C]-BIA 9-1067|"100 mg [14C]-BIA 9-1067 Capsule containing not more than 3.3 MBq (89.2 µCi) 14C; will be administered with 240 mL water.~Single dose administration on a single occasion."
89368522|NCT05582564|Other|concrete text|Italian and French unvaccinated cohorts (n= 164; n=163)
89368523|NCT05582564|Other|abstract text|Italian and French unvaccinated cohorts (n=155; n=153)
89368524|NCT05582564|Other|abstract task|Italian and French unvaccinated cohorts (n=54; n=55)
89368525|NCT05582564|Other|concrete task|Italian and French unvaccinated cohorts (n=55; n=56)
89368526|NCT05582564|Other|control|Italian and French unvaccinated cohorts (n=103; n=110)
89368527|NCT03194152|Experimental|Peanut|Daily consumption of 2 servings of roasted peanuts for 12 weeks Intervention: Dietary Supplement: Roasted peanuts
89368528|NCT03194152|Experimental|Control|Daily consumption of isocaloric matched snack food for 12 weeks Intervention: Other: High Carbohydrate Snack
89368529|NCT03107338|Active Comparator|DEXKETOPROFEN TROMETAMOL|Patients received a dose of 25 mg DKT in an oral suspension 15 minutes before surgery
89368530|NCT03107338|Placebo Comparator|Placebo|Patients received a dose of 500 mg Vitamin C in an oral suspension 15 minutes before surgery
89530395|NCT02454439|Experimental|CRT-D or CRT-P ON|This is a pilot, prospective, controlled, two-parallel arm, randomized, double-blind design and multicentric clinical trial comparing a CRT-D or CRT-P ON group vs. CRT-D or CRT-P OFF group in HF with reduced ejection fraction patients with NICD.
89530396|NCT02454439|Other|CRT-D or CRT-P OFF|This is a pilot, prospective, controlled, two-parallel arm, randomized, double-blind design and multicentric clinical trial comparing a CRT-D or CRT-P ON group vs. CRT-D or CRT-P OFF group in HF with reduced ejection fraction patients with NICD.
89530397|NCT03248011|Experimental|Flexibility|Stretching exercise
88840825|NCT04536103||Traveling Volunteers|The group will be recruited at CCF and be scanned at CCF, University of California San Francisco, University of Kentucky and Albert Einstein College of Medicine.
88840826|NCT04536103||ACL tear Volunteers|This group will be recruited at CCF and scanned at baseline and 1-year at all of the three MR systems at CCF (Siemens, GE, Philips).
88840827|NCT04536103||Group Matched to ACL tear Volunteers|This group will be recruited at CCF and scanned at baseline and 1-year at all of the three MR systems at CCF (Siemens, GE, Philips).Traveling Volunteers share the same inclusion and exclusion criteria as this group, therefore subjects can participate the study and serve as subjects within both groups
88840828|NCT05444179|Active Comparator|Intervention group|"The participant will be provided an educational module entitled Mommies can Eat and Exercise with No Stress (MomEENS), in which the module will be delivered through a booklet and video. The MomEENS module consist of five key recommendations: 1. Eat healthy foods ;2. Eat foods rich in iron and folic acid; 3. Eat foods rich in omega-3 fatty acids; 4. Increase steps in a day and; 5. Increase body flexibility and strength. All the key recommendations will be explained in the booklet, while the video will provide full guidance on how to exercise during postpartum at home, explaining key recommendations 4 and 5. Face-to-face consultation with the participants will be held during baseline and 4th week to enhance the participation. Besides, Whatsapp and Facebook page group is developed as a step to enhance the compliance of participants. All the participants will be contacted once for every two weeks, lasting for about 5 to 10 minutes for each call to monitor the participant's progress."
88840829|NCT05444179|No Intervention|Control group|The participants in the control group will be received advice on the standardised Malaysian food pyramid and be instructed to follow their usual standard care as suggested by their healthcare provider. Postpartum women in Malaysia typically attend postpartum healthcare visits with an exam on day 30 after childbirth but receive no other routine care following this appointment unless a specific health problem has been identified. Participants in the control group performed the same evaluations. They received the same incentives as those in the intervention group, but they did not receive any educational module and contact from the investigator during the 8 weeks follow-up.
88840830|NCT04738903|Active Comparator|Custom Q treatment group|For every patient, the eye with the greater myopic spherical equivalent (SE) will be assigned for the Custom-Q treatment group.
88840831|NCT04738903|Active Comparator|Wave-front optimized (WFO) group|For every patient, the other eye with the lesser myopic SE will be assigned for the WFO treatment group
88840832|NCT05434897|Experimental|2% dose AK3280 cream|After the 4-week screening period, Eligible subjects will be administered daily 2% dose AK3280 cream b.i.d. for 12weeks.
88840833|NCT05434897|Experimental|4% dose AK3280 cream|After the 4-week screening period, Eligible subjects will be administered daily 4% dose AK3280 cream b.i.d. for 12weeks.
88840834|NCT05434897|Experimental|8% dose AK3280 cream|After the 4-week screening period, Eligible subjects will be administered daily 8% dose AK3280 cream b.i.d. for 12weeks.
88840835|NCT05434897|Active Comparator|Placebo cream|The same subject will be randomized to receive topical administration of AK3280 cream or placebo cream at S1 and S3, respectively.
88840836|NCT05443789|Experimental|Proton pump inhibitor education|The general practices in this arm will receive the education visits about Proton pump inhibitor.
88840837|NCT05443789|Placebo Comparator|Other education|The general practices in this arm will receive an educational visit on another topic (asthma).
88840838|NCT04738747|Experimental|Study arm (receive a WHOOP device)|Participants randomized to the WHOOP group will be given WHOOP wrist and arm bands to wear 24/7 after an orientation on their use
88840839|NCT04738747|No Intervention|Control arm (no intervention)|The control group will not have any intervention
88840840|NCT05443477|Experimental|Hericium Erinaceus Mycelium|patients with premenstrual syndrome received supplementation of Hericium Erinaceus Mycelium capsules
88840841|NCT05443477|Experimental|Probiotic|patients with premenstrual syndrome received supplementation of Probiotic capsules
88840842|NCT05443477|Placebo Comparator|control|patients with premenstrual syndrome received supplementation of placebo capsules
88840843|NCT05424523||Omalizumab|Patients with confirmed diagnosis of allergic asthma, who were prescribed omalizumab
88840844|NCT05443243||Varus Stems|Patients with a THA Stem implanted in Varus position
88840845|NCT05443243||Neutral stems|Patients with a THA Stem implanted in Neutral position
88840846|NCT05413759|Experimental|Pharmaceutical care in multiprofessional collaboration|Medication reconciliation (hospital admission and discharge), disease-modifying antirheumatic drugs (DMARD) treatment information interview and 2 motivational interviews (after discharge, at 2 months and 6 months after the inclusion).
88840847|NCT05413759|No Intervention|Control group (usual practices group)|Usual follow-up during the 12-month follow-up.
88840848|NCT04147039|Experimental|Intervention|Receives the MINISTOP 2.0 mobile phone app for 6 months
88840849|NCT04147039|No Intervention|Control|Receives standard care through primary child health care
88840850|NCT04338607||All study patients|All study patients will be in one group.
89530398|NCT03248011|Experimental|Strength|Eccentric hamstring strengthening exercise
88840851|NCT05442931|Experimental|Pregabaline|Preoperative oral dose of pregabalin for control blood pressure and decrease dose of nitroglycerine consumption
88840852|NCT05442931|Experimental|Magnesium sulfate|Preoperative intravenous dose for control blood pressure and heart rate
88840853|NCT05442931|Experimental|Nitroglycrine|Measuring the total dose of nitroglycerine used, using a syringe pump
88840854|NCT05393479|Experimental|Intervention Arm: Thinking Healthy Programme|"Perinatal women identified with depression in intervention arm will be engaged in 2 modules, one during pregnancy and one during postnatal. Each module has 3 sessions each focusing on a) mother's health, b) the mother-baby relationship, and c) the mother's relationship with others. Altogether 8 sessions (including 1 introductory session, 6 THP sessions, and 1 closing session) each lasting 30 minutes to 1 hour will be provided to intervention arm participants. In the third session of each module that deals with the mother's relationship with others, family members will be engaged as well. Questionnaire evaluation will be conducted at baseline, post-Module 1 (after 2 months from recruitment date) and at 3 months post delivery after completing Module 2 and closing session."
89002002|NCT00191243|Experimental|A|
89002003|NCT00191243|Experimental|B|
89002004|NCT00214032|Experimental|1|pycnogenol daily
89179342|NCT04094220|Experimental|Lateral lumbar interbody fusion|Patients in this group received lateral lumbar interbody fusion alone. Patients who suffered residual neurologic symptoms postoperatively will received conservative treatment for at least 3 months.Patients were considered to have unsuccessful indirect decompression if they had less than 20% improvement according to the Oswestry Disability Index (ODI) by 3 months postoperatively.
89179343|NCT04094220|Experimental|Lateral lumbar interbody fusion plus posterior decompression|Patients in this group received lateral lumbar interbody fusion plus posterior decompression.
89179344|NCT00757848|Experimental|AZD9668|
89179345|NCT00757848|Placebo Comparator|Placebo|
89179346|NCT02599506||breast cancer radiation therapy|Observation over a period of all treatment sessions for radiotherapy
89179347|NCT02601222|Experimental|Runzao zhiyang capsule|Runzao zhiyang capsule: 4 pills each time, 3 times a day, oral， Urea Cream (topical application, apply to the affected area and gently rub) 2 times a day.
89179348|NCT02601222|Placebo Comparator|Runzaozhiyang capsule agent simulation|Runzaozhiyang capsule agent simulation:4 pills each time, 3 times a day, oral, Urea Cream (topical application, apply to the affected area and gently rub) 2 times a day.
89179349|NCT02608736|Experimental|Valproic Acid|Valproic acid will be orally administered in a total dose of 1500mg per day (500mg, every 8 hours), for three months.
89179350|NCT02608736|Placebo Comparator|Placebo|Placebo will be orally administered in a total dose of three capsules per day (every 8 hours), for three months.
89179351|NCT04015986|Experimental|Intervention arm|MDCF-2 prototype with four complimentary food ingredients without powdered milk (rationale: lead with evidence from the recently completed pre-POC clinical trial of promoting growth promoting microbiota and positive effects on growth).
89179352|NCT04015986|Active Comparator|Control arm|Rice-lentil based RUSF (rationale: reference standard of care for post-SAM, MAM; based on knowledge of its effects on child growth and the gut microbiota)
89179353|NCT05734898|Experimental|rrAML|
89179354|NCT05424510|Active Comparator|Fluid Bolus (FB+)|Patients in the FB+ group will receive a single bolus of 500 ml of Ringer's Lactate over 5-10 minutes.
89179355|NCT05424510|Placebo Comparator|Non fluid bolus (FB-)|Patients in the FB- group will not receive a fluid bolus.
89179356|NCT02607566|Experimental|Iyengar Yoga|Iyengar Yoga Intervention twice weekly for 60 minutes for 12 weeks.
89179357|NCT02607566|Active Comparator|Standard Exercise Program|professionally supervised program of aerobic exercise including use of an indoor walking track, treadmills, stationary bicycles and elliptical machines, held for 60 minutes twice weekly for 12 weeks
89179358|NCT02607410|Active Comparator|sitagliptin|100mg every day of sitagliptin in patients that were previosly using metformin and glyburide
89530399|NCT03248011|Experimental|Neuromuscular|Balance exercise
89179359|NCT02607410|Active Comparator|NPH insulin|NPH insulin will be applied bedtime every night in patients that awere previously using metformin and glyburide,The insulin dosage will be adjusted to fasting glycemia between 90 and 100 mg / dL
89179360|NCT02599038|Experimental|Serine supplementation|Serine oral administration 20mg/kg/day
89179361|NCT05423964|Active Comparator|Artificial Intelligence Endoscopy Room|The fellows will be randomized on a daily basis to perform colonoscopies in a room with AI (intervention)
89179362|NCT05423964|Active Comparator|Non-Artificial Intelligence Endoscopy Room|The fellows will be randomized on a daily basis to perform colonoscopies in a non-AI endoscopy room (standard of care).
89179363|NCT05693090|Experimental|Escalation Cohort|Adult participants with EGFR-mutated Non-Small Cell Lung Cancer
89002005|NCT00214032|Placebo Comparator|2|placebo daily
89002006|NCT00123266|Experimental|Active|
89002007|NCT00221169|Other|surgical candidates|surgical candidates who underwent PET CT evaluation
89179364|NCT05693090|Experimental|Expansion Cohort|Adult participants with EGFR-mutated Non-Small Cell Lung Cancer
89179365|NCT04092426||patients with keratoconus|"patients with keratoconus attending refractive surgery centers in Assiut will be subjected to the following :-~Full history and clinical evaluation.~collection of individual data ( residency , occupation , special habbit , chronic illness )~Analysis of results to assess prevelance of keratoconus and its distribution geographically in Assiut"
89179366|NCT05692466||Active|Newly diagnosed cancer patients.
89179367|NCT05692466||Control|Historically diagnosed cancer patients.
89179368|NCT02598804|Experimental|Intervention group|"No single group but 2 groups :~Intervention group (5 educational workshop in addition to spa therapy)~Control group (Written information booklet in addition to spa therapy)"
89179369|NCT02598804|Other|control group|"No single group but 2 groups :~Intervention group (5 educational workshop in addition to spa therapy)~Control group (Written information booklet in addition to spa therapy)"
89179370|NCT00917202|Experimental|MB3|3 days
89179371|NCT00917202|Experimental|MB5|5 days
89179372|NCT00917202|Experimental|MB7|
89179373|NCT02606240||Mild to Moderate ARDS on PRISMALUNG|Extracorporeal CO2 removal (ECCO2R) with the PRISMALUNG device in patients with mild to moderate Acute Respiratory Distress Syndrome (ARDS).
89179374|NCT02600052|Experimental|GPNF|Patients will be submitted to aerobic training, with prior application of PNF technique and after its completion. Aerobic training program will consist of walking on a treadmill for 30 minutes with 5 minute initial heating and 5-minute cool-down. The training intensity will correspond to 60% of maximal oxygen consumption (VO2max) or 70% of maximum heart rate (MHR) predicted by age is determined by the formula: HR max = 208 - (0.7 x age). The speed and incline of the treadmill will be adjusted according to the patient's performance, so that they maintain the same intensity throughout the course of the training.
89179375|NCT02600052|Active Comparator|GCONTROL|Patients will be submitted to aerobic training, with prior application of relax technique and after its completion. Aerobic training program will consist of walking on a treadmill for 30 minutes with 5 minute initial heating and 5-minute cool-down. The training intensity will correspond to 60% of maximal oxygen consumption (VO2max) or 70% of maximum heart rate (MHR) predicted by age is determined by the formula: HR max = 208 - (0.7 x age). The speed and incline of the treadmill will be adjusted according to the patient's performance, so that they maintain the same intensity throughout the course of the training.
89530400|NCT03248011|No Intervention|Control|No exercise
89530401|NCT03253861||control patients|patients without an infected pancreatic necrosis
88840855|NCT05393479|No Intervention|Control Arm: Usual Care|Subjects in the control arm will receive usual care, where perinatal women identified with depression, are provided with psychoeducation about their condition and about the availability of services at the health facility and other health information. They will be then referred to the health facility where trained health workers are available.
88840856|NCT05442385||cardiac patients admitted to PICU|To describe the clinical patterns of infants and children with cardiac disease admitted to PICU and their outcome.
88840857|NCT05442307|Experimental|asthma education|The general practices in this arm will receive the education visits about asthma.
88840858|NCT05442307|Placebo Comparator|Other education|The general practices in this arm will receive an educational visit on another topic (PPI).
88840859|NCT05440513|Experimental|Renal Pelvic Denervation|Using the natural orifice of the urethra, the ureters are accessed (bilaterally and in sequence), to allow for an ablation device to be placed into the renal pelvis where RF energy is delivered to ablate renal nerves.
88840860|NCT05439967|Experimental|Intervention|
88840861|NCT05439967|Active Comparator|Conventional Training|
88840862|NCT05439499|Experimental|FCN-437c+Letrozole/anastrozole ± Goserelin acetate|
88840863|NCT05439499|Placebo Comparator|Placebo+Letrozole/anastrozole ± Goserelin acetate|
88840864|NCT04003987|Active Comparator|ESP Block|For the ESP block the ultrasound is positioned in a parasagittal fashion, 2-3 inches lateral to the spinous process. This approach visualizes the transverse process. The needle is inserted cranial-to-caudal to make contact with the shadow of the transverse process, with the needle tip deep to the fascial plane of the erector spinae muscle. Injection of saline confirms the location of the needle, and the anesthetic is injected (40 ml into each side; 20 ml injected at T8 and 20 ml injected at T12)
88840865|NCT04003987|Active Comparator|TAP Block|For the TAP block, the ultrasound probe is placed transverse to the abdominal wall, between the iliac crest and the costal margin. The needle is placed in the plane of the probe and advanced until it is between the internal oblique and the transversus abdominis muscles. Once in the plane, 2 mL of saline is injected to confirm needle position, then the local anesthetic solution is injected (40 ml into each side; 20 ml injected for subcostal TAP and 20 ml injected for posterior TAP).
88840866|NCT03984331|Experimental|Fish skin|All patients will receive both treatments, fish skin and cadaver skin, as early cover after early debridement. This group of wounds will receive only fish skin.
88840867|NCT03984331|Active Comparator|Cadaver skin|All patients will receive both treatments, fish skin and cadaver skin, as early cover after early debridement. This group of wounds will receive only cadaver skin.
88840868|NCT05448001|Experimental|Study Group|
88840869|NCT05448001|Active Comparator|Control Group|
88840870|NCT05366257||CAR-T: Inpatient (IP) Cohort|Patients received CAR-T infusion in IP setting
88840871|NCT05366257||CAR-T: Outpatient (OP) Cohort|Patients received CAR-T infusion in OP setting
88840872|NCT05366257||Allo-HSCT cohort|Patients received allogeneic hematopoietic stem cell transplant
88840873|NCT05447845||Healthy|healthy volunteers with no known ocular condition
88840874|NCT05447845||Patients|Subjects with diseases of the eye or the orbit
88840875|NCT05447767|Active Comparator|intra-articular injection of BMAC|intra-articular injection of BMAC
88840876|NCT05447767|Active Comparator|intra-osseous and intra-articular injection of BMAC|intra-osseous and intra-articular injection of BMAC
88840877|NCT05447767|Active Comparator|intra-articular injection of at- SVF|intra-articular injection of at- SVF
88840878|NCT05447767|Active Comparator|intraosseous and intra-articular injection of at-SVF|intraosseous and intra-articular injection of at-SVF
88840879|NCT05447611||high score CARE group|"Patient-perceived empathy was assessed using the Consultation and Relational Empathy (CARE) questionnaire that has been validated in cancer care. This is a self-reported ten-point questionnaire with a five-point Likert-type scale ranging from poor to excellent Likert-type scale. It has excellent psychometric properties with α = 0.92. High scores indicate a higher perception of the health care personnel empathy.~The three distinct empathic processes were also assessed with the CARE measure. 'Relationship' was assessed with items 1-3, 'emotional process' with items 4-6, and 'cognitive process' with items 7-10."
88840880|NCT05447611||lower score CARE group|In line with the recent literature, we considered differentiating the study population into two groups: those with a high perceived empathy (maximum CARE score) and those without.
88840881|NCT05447455|Active Comparator|TAP block group|A 22-gauge spinal needle was introduced from medial to lateral in-plane to the ultrasound probe, and 20 mL of bupivacaine 0.25% was injected under visualization in the plane between the transversus abdominis muscle and the fascia deep to the internal oblique muscle on each side.
88840882|NCT05447455|Active Comparator|LAWI group|40 mL of bupivacaine 0.25% was injected subcutaneously into the surgical wound (20 mL on each of the upper and lower sides) by the obstetrician before skin closure
88875211|NCT02525718|Active Comparator|0.25 % bupivacaine w/ epinephrine & 4mg dexamethasone|"Subjects will be randomly selected to receive selective block with a local anesthetic solution containing 0.25 % bupivacaine (2.5 mg/ml) with 1:100,000 epinephrine and 4 mg dexamethasone. The injection will be performed in certain locations of the breast area to cover the intercostal nerves supplying the breast tissue.~Subjects will be randomly selected to receive the local anesthetic solution containing 0.25 % bupivacaine (2.5 mg/ml) with 1:100,000 epinephrine and 4 mg dexamethasoneadministered to the breast area to cover the intercostal nerves supplying the breast tissue during surgery."
89179376|NCT05754476||Brain Diseases|This study does not limit the kinds of brain diseases. The cohort includes patients with suspected or known brain diseases including tumors, vascular disorder, inflammatory disease, neurodegenerative diseases and trauma, follow-up, routine brain, and others requiring MRI exams with GBCAs.
89530402|NCT03253861||Case patients|patients with an infected pancreatic necrosis
88840883|NCT03831139|Experimental|Prevention|TIM&SARA has a duration of 16 fifty-minute sessions and is organized in five modules. The first module (2 sessions) outlines the rationale for the program and establishes connections between group leaders and adolescents. The next module (2 sessions) focuses on helping adolescents to consider already existing goals, set new ones, and learn how to achieve goals to build up the motivation of the youth to learn and apply the material of the following modules. The third module (6 sessions) focuses on understanding the relations among cognitions, emotions, and behaviors, and teaching the participating youths how to identify and challenge negative cognitions. The forth module (5 sessions) trains the youth in assertive and social competent social behavior. Finally, the last session is a review session and includes a celebration. All parts of the program use illustrative, culturally relevant situations introduced by the participating adolescents.
88840884|NCT03831139|No Intervention|Control|The youth participate in school as usual.
88840885|NCT05447299||Typically developing children|Reference group of typically developing children
88840886|NCT05447299||Cerebral palsy group|Children with a diagnosis of cerebral palsy
88840887|NCT05446987|Experimental|Position change and back massage group|The patients received changing of position every two hours as follows in the same order: supine position with a head angle of 15°, semi-fowler position with a head angle of 30°, lateral right or left position with a head angle of 15°. Also, the patients received a simple stroke of lower back massage for 5 minutes every 2 hours
88840888|NCT05446987|Experimental|Early ambulation|The patient are allowed to ambulate after 3 hours of complete bed rest in the supine position with a zero head of bed elevation angle.
88840889|NCT05256511||SARS-CoV-2 first wave|Patients with confirmed SARS-CoV-2 infection and receiving invasive mechanical ventilation for more than 48h, in the first wave of the pandemic, starting on 01-01-2020
88840890|NCT05256511||SARS-CoV-2 second wave|Patients with confirmed SARS-CoV-2 infection and receiving invasive mechanical ventilation for more than 48h, in the second wave of the pandemic, starting on 10-01-2020
88840891|NCT05446753|Experimental|Animal-based meats (ABMD group)|Participants will be instructed to substitute protein-rich foods consumed habitually with animal-based meats (ABMD group).
88840892|NCT05446753|Experimental|Plant-based meat alternatives (PBMD group)|Participants will be instructed to substitute protein-rich foods consumed habitually with Plant-based meat alternatives (PBMD group).
88840893|NCT00369733|Experimental|Single arm|Aranesp adminsitered every other week for 52 weeks
88840894|NCT05234281|Other|Low back pain|Adults with chronic low back pain and at least 4 months of decreased work participation. Intervention as for all groups but with the use of GLADRyg back rehabilitation principles.
88840895|NCT05234281|Other|Chronic Obstructive Pulmonary Disease (COPD)|Adults with COPD (FEV1<80%). Intervention as for all groups but with added pulmonary rehabilitation focus.
88840896|NCT05234281|Other|Diabetes type 2|Adults with type 2 diabetes and diabetes-related challenges including dysglycaemia, diabetic complications and/or weight issues. Intervention as for all groups but with added focus on how to make useful microchoices in terms of lifestyle.
88840897|NCT05234281|Other|Mixed anxiety/depression|"Young adults (18-35 years) with mixed anxiety/depression. Intervention as for all groups but with added focus on acceptance and commitment therapy, behavioral analysis, metacognitive therapy and physical activity."
88840898|NCT05234281|Other|Post COVID-19|Adults who have persistant fatigue and/or dyspnea following infection with COVID-19.
88840899|NCT05222737|Active Comparator|test group|intra pocket diode laser application
89179377|NCT02606318|Experimental|Adjusted the challenge-skill balance|This group received 10-session occupational therapy with adjustment of challenge-skill balance.This intervention aimed at improving the skill level for the activity has started once the balance were balanced.
89179378|NCT02606318|Other|Non-adjusted the challenge-skill balance|This group received 10-session occupational therapy without adjustment of challenge-skill balance. That is conducted the therapy in the normal manner for the day care center.
89179379|NCT00751296|Experimental|Lenalidiomide|Lenalidomide target dose of 10 mg PO OD X 3 weeks (days 1-21) followed by 1 week off therapy (days 22-28) on a 28-day cycle.
89179380|NCT04339166|Experimental|Group A|Single thawed blastocyst transfer with blastocyst selection according to the analysis of NICS and morphologic score.
89179381|NCT04339166|No Intervention|Group B|Single thawed blastocyst transfer with blastocyst selection according to morphologic score.
89179382|NCT04093830|Experimental|pre-lingually deafened children with cochlear implant|pre-lingually deafened children with cochlear implant who continuously used bimodal hearing.
89179383|NCT04093518|Active Comparator|Active Comparator|Estradiol 200µg
89179384|NCT04093518|Placebo Comparator|Placebo Comparator|Placebo
89179385|NCT02606084|Experimental|Cohort 1|Participants with mild renal impairment (Measured Creatinine Clearance [CLCR,m] greater than or equal to >= 50 to 79 milliliter/minute [mL/min]) will self-administer esketamine 28 milligram (mg) intranasally on Day 1.
89179386|NCT02606084|Experimental|Cohort 2|Participants with moderate renal impairment (CLCR,m >=30 to 49 mL/min) will self-administer esketamine 28 mg intranasally on Day 1.
89179387|NCT02606084|Experimental|Cohort 3|Participants with severe renal impairment (CLCR,m less than [<] 30 mL/min), not on dialysis will self-administer esketamine 28 mg intranasally on Day 1.
88840900|NCT05222737|Active Comparator|control group|antibiotic adminstration
88840901|NCT00368719|No Intervention|1|
88840902|NCT05445193|Experimental|Module PEaters Choice™|Using module that will be develop
88840903|NCT05445193|No Intervention|Standard nutrition information|No intervention done, just a standard information about nutrition.
88840904|NCT03647761|No Intervention|Control|Standard of care
88840905|NCT03647761|Experimental|Treatment|Tetra-grip applied
88840906|NCT03615547|Experimental|Clomifene citrate group|a daily dose of 50mg of Clomifene Citrate per os during 9 months
88840907|NCT03615547|Experimental|Placebo group|a daily dose of 50mg per os of placebo (lactose monohydrate) during 9 months.
89179388|NCT02606084|Experimental|Cohort 4|Participants with normal renal function and no evidence of kidney damage (CLCR,m >= 80 mL/min) will self-administer esketamine 28 mg intranasally on Day 1.
88840908|NCT03609541||Patient with stable COPD|Evaluation of serum amlyoid A, lipoxin A4, CRP and fibrinogen
88840909|NCT03609541||Patient with COPD exacerbation|Evaluation of serum amlyoid A, lipoxin A4, CRP and Fibrinogen at beginning and at the end of COPD exacerbation
88840910|NCT05166655|Experimental|Parkinson disease patients|Parkinson disease patients undergoing DBS Surgery of the Globus Pallidus Internus (GPi) for clinical indications
88840911|NCT05120791|Placebo Comparator|Placebo|14 days wahs-out: no fish eating 14 days: no fish eating, the participants eat vegetable bouillon (1,3g)
88840912|NCT05120791|Active Comparator|Microalgae phaeodactylum|14 days wahs-out: no fish eating 14 days: no fish eating, the participants eat vegetable bouillon (1.3g), 2.3g Microalgae Phaeodactylum
89179389|NCT05733260|Experimental|Culturally Tailored|10 weeks of resistance training utilizing culturally tailored prompts, feedback and high autonomy approaches.
89179390|NCT05733260|Experimental|Control|10 weeks of resistance training
89179391|NCT00751140|Experimental|Lymph Node Dissection at Time of Nephroureterectomy|A prospective single-arm two-stage phase II study to allow for analysis of the treatment-specific outcomes and disease-specific survival of patients treated with open or laparoscopic nephroureterectomy and bladder cuff excision along with a lymph node dissection (modified template retroperitoneal lymph node dissection).
89179392|NCT05732168||Subjects with chronic ankle instability|Men and women with recurrent unilateral ankle instability problems
89179393|NCT05732168||Control group|Healthy men and women without ankle problems
89179394|NCT02599272|Other|Rice with vegetables but no added spice|Control session - rice with control vegetables (tomatoes and aubergines) - no mixed spices
89179395|NCT02599272|Active Comparator|Rice with vegetables and low spice|Dose 1 mixed spice session - rice with 6 g powdered mixed spices and 40 g polyphenol rich vegetables (onions, ginger and garlic)
89179396|NCT02599272|Active Comparator|Rice with vegetables and high spice|Dose 2 mixed spice session - rice with 12 g powdered mixed spices and 80 g polyphenol rich vegetables (onions, ginger and garlic)
89179397|NCT02607488|Placebo Comparator|Placebo|Patients will receive an intravenous bolus of 0.1 mL/kg of saline 0.9% solution followed by a continuous infusion 0.1 mL/kg/h of Saline 0.9% which will be continued for 24 hours after surgery.
89179398|NCT02607488|Active Comparator|Lidocaine 1%|"Patients will receive an intravenous bolus of 0.1 mL/kg of lidocaine 1.5% solution followed by a continuous infusion 0.1 mL/kg/h of lidocaine 1% solution which will be continued for 24 hours after surgery.~All medications in the study protocol will be based on the dosing body weight [ideal body weight (IBW) + 0.4 × (actual body weight-IBW)]"
89179399|NCT02607488|Active Comparator|Lidocaine 1.5%|Patients will receive an intravenous bolus of 0.1 mL/kg of lidocaine 1.5% solution followed by a continuous infusion 0.1 mL/kg/h of lidocaine 1,5% solution which will be continued for 24 hours after surgery.
89179400|NCT02607488|Active Comparator|Lidocaine 2%|Patients will receive an intravenous bolus of 0.1 mL/kg of lidocaine 1.5% solution followed by a continuous infusion 0.1 mL/kg/h of lidocaine 2% solution which will be continued for 24 hours after surgery.
89179401|NCT00914498|Experimental|Xylocaine|Participants will receive local injection of 20 ml 1% Xylocaine to the skin incision site
89179402|NCT00914498|Placebo Comparator|Controls|Participants will receive injection of 0.9% NaCl 20 ml to the incision site
89179403|NCT02558582|Experimental|Immediate Rehabilitation|The PH specific rehabilitation consists of: bicycle ergometer training, respiratory training, dumbbell-training and (mental) gait training.
89179404|NCT02558582|Experimental|Immediate Rehabilitation with oxygen|"The PH specific rehabilitation consists of: bicycle ergometer training, respiratory training, dumbbell-training and (mental) gait training.~Patients who are not already under long-term oxygen therapy (LTOT) due to daytime hypoxemia will additionally be randomized to receive standardized supplemental oxygen therapy (SSOT) during training and nights."
89179405|NCT02558582|Experimental|Delayed Rehabilitation|Waiting group that participates in the rehabilitation program after 3 months. The PH specific rehabilitation consists of: bicycle ergometer training, respiratory training, dumbbell-training and (mental) gait training.
89179406|NCT02558582|Experimental|Delayed Rehabilitation with oxygen|"Waiting group that participates in the rehabilitation program after 3 months. The PH specific rehabilitation consists of: bicycle ergometer training, respiratory training, dumbbell-training and (mental) gait training.~Patients who are not already under long-term oxygen therapy (LTOT) due to daytime hypoxemia will additionally be randomized to receive standardized supplemental oxygen therapy (SSOT) during training and nights."
88840913|NCT05120791|Active Comparator|Beta-Glucan|14 days wahs-out: no fish eating 14 days: no fish eating, the participants eat vegetable bouillon (1.3g), Beta-Glucan (1.8g)
89179407|NCT00914030||A1|Patients with schizophrenia
89179408|NCT00914030||A2|Control subjects matched individually with patients with schizophrenia
89179409|NCT00914030||B1|Adult subjects with autism
89179410|NCT00914030||B2|Control subjects matched individually with adult subjects with autism
89179411|NCT00914030||C1|Children with autism
89179412|NCT00914030||C2|Control subjects matched individually with children with autism
89179413|NCT02605850|Placebo Comparator|Ground beef patty + Water|32 healthy subjects, ages 18-35 years who meet all the eligibility criteria in the screening phase of the study will receive the ground beef patty + water to evaluate the clinical efficacy of pomegranate on vascular health.Then subjects will be randomized to consume pomegranate juice or extract. At visit 2, subjects will be tested before and after meal with pomegranate juice or extract, then take pomegranate product daily for 4 weeks. At visit 3, subjects will tested before and after test meal with pomegranate products.
89179414|NCT02605850|Active Comparator|Ground beef patty + Pomegranate Extract|32 healthy subjects, ages 18-35 years who meet all the eligibility criteria in the screening phase of the study will receive the ground beef patty + water to evaluate the clinical efficacy of pomegranate on vascular health.Then subjects will be randomized to consume pomegranate juice or extract. At visit 2, subjects will be tested before and after meal with pomegranate juice or extract, then take pomegranate product daily for 4 weeks. At visit 3, subjects will tested before and after test meal with pomegranate products.
89530403|NCT04487275|Experimental|Drug|MLC901 capsules three times per day over 6 months
89530404|NCT04487275|Placebo Comparator|Placebo|Placebo capsules three times per day over 6 months
88840914|NCT05120791|Active Comparator|Combi Microalgae phaeodacytlum and Beta-Glucan|14 days wahs-out: no fish eating 14 days: no fish eating, the participants eat vegetable bouillon (1.3g), 2.3g Microalgae, Beta-Glucan (1.8g)
89179415|NCT02605850|Active Comparator|Ground beef patty + Pomegranate Juice|32 healthy subjects, ages 18-35 years who meet all the eligibility criteria in the screening phase of the study will receive the ground beef patty + water to evaluate the clinical efficacy of pomegranate on vascular health.Then subjects will be randomized to consume pomegranate juice or extract. At visit 2, subjects will be tested before and after meal with pomegranate juice or extract, then take pomegranate product daily for 4 weeks. At visit 3, subjects will tested before and after test meal with pomegranate products.
89179416|NCT05754320|Experimental|Tension Band Wire fixation|patients suffering simple olecranon fracture, randomized for treatment of tension band wire fixation
89179417|NCT05754320|Experimental|Plate fixation|patients suffering simple olecranon fracture, randomized for treatment of plate fixation
89179418|NCT00751881|Experimental|Teriflunomide 7 mg / 14 mg|Core treatment period: Teriflunomide 7 mg once daily. Extension treatment period: Teriflunomide 14 mg once daily.
89179419|NCT00751881|Experimental|Teriflunomide 14 mg / 14 mg|Core treatment period: Teriflunomide 14 mg once daily. Extension treatment period: Teriflunomide 14 mg once daily.
89179420|NCT00751881|Placebo Comparator|Placebo / Teriflunomide 14 mg|Core treatment period: Placebo (for teriflunomide) once daily. Extension treatment period: Teriflunomide 14 mg once daily.
89179421|NCT00747474|Experimental|Lipotecan|Intravenous Lipotecan (TLC388 HCl for Injection)
89179422|NCT04091802|Experimental|single layer of L-PRF|single layer of L-PRF will be put in the vertical incision
89179423|NCT04091802|Experimental|multiple layers of L-PRF|multiple layers of L-PRF will be put in the vertical incision
89179424|NCT02598570|Experimental|duvelisib|Duvelisib will be administered orally as a fixed dose in 28-day cycles.
89179425|NCT04089462|Other|"1. Five sessions per period - Two sessions per period"|
89179426|NCT04089462|Other|"2. Two sessions per period - Five sessions per period"|
89179427|NCT02599779|Experimental|Treatment arm A|"Arm-A: Pembrolizumab will be started and Stereotactic Body Radiation Therapy will be given at the time of progression on pembrolizumab and pembrolizumab will be continued.~Pembrolizumab will continue until progression as per immune related response criteria (irRC)."
89179428|NCT02599779|Experimental|Treatment arm B|"Arm B: Pembrolizumab will be started. Stereotactic Body Radiation Therapy will be given before the 2nd course of pembrolizumab and pembrolizumab will be continued.~Pembrolizumab will continue until progression as per immune related response criteria (irRC)."
89179429|NCT02597556|Active Comparator|Albendazole|Albendazole will be administered as a single 400mg chewable tablet at 0, 3, 6, 9, and 12 months.
89179430|NCT02597556|Placebo Comparator|Placebo|Matching Placebo will be administered as a single chewable tablet at 0, 3, 6, and 9 months. At month 12, all participants will receive a single 400mg Albendazole tablet.
89179431|NCT02599857|Experimental|CONCOR smartphone application|Use of CONCOR smartphone application
89530405|NCT03245359|Active Comparator|Short-term ON-Q|Single port, select-a-flow pump and ON-Q 750mL ball filled with bupivacaine 0.125% saphenous (adductor canal) nerve block and single port, fixed flow pump and 400mL ON-Q ball with bupivacaine 0.125% wide field posterior knee block to provide analgesia from surgery until medication has been depleted (typically 2-4 days)
89179432|NCT02599857|No Intervention|Standard care (no CONCOR smartphone application)|No CONCOR smartphone application
89179433|NCT04091958|Experimental|Post-tumourectomy reconstruction with myo-glandular flap.|Standard tumourectomy followed by reconstruction with myo-glandular flap.
89179434|NCT02599545||Maternal/VLBW Infant Pairs|One-hundred-fifty mother-VLBW infant pairs, a total of 300 participants, will be recruited for the final sample size of 120 pairs.
89179435|NCT02599623|Experimental|Local anesthesia|Patient operated in local anesthesia, with a mesh repair in Lichtenstein if no bowel necrosis existed.
89179436|NCT02599623|Active Comparator|General anesthesia|Patient operated in general anesthesia, with a mesh repair in Lichtenstein if no bowel necrosis existed.
89179437|NCT02599467|Experimental|case group 1: ALND|"Inclusion criteria: unilateral breast cancer surgery with Axillary lymph node dissection (ALND) during the last year and a half. Exclusion criteria: bilateral breast cancer, ipsilateral shoulder pathology, neuropathy.~Procedure: ULNT 1 and EMG recording."
89179438|NCT02599467|Experimental|case group 2: SLNB|"Inclusion criteria: unilateral breast cancer surgery with Sentinel Lymph Node Biopsy (SLNB) during the last year and a half. Exclusion criteria: bilateral breast cancer, ipsilateral shoulder pathology, neuropathy.~Procedure: ULNT 1 and EMG recording"
89179439|NCT02599467|Active Comparator|control group|"Matched by age and dominant arm to each case. Exclusion criteria: current painful conditions involving their neck or dominant upper-extremity, and chronic pain conditions or use of pain relievers.~Procedure: ULNT 1 and EMG recording."
89179440|NCT00916968|Active Comparator|Standard CR-Flex|
89179441|NCT00916968|Experimental|Gender specific CR-Flex|
89179442|NCT02599389|No Intervention|Standard balloon|Angioplasty with use of standard balloons
89179443|NCT02599389|Experimental|Drug-coated balloons|Angioplasty with use of drug-coated balloons
89179444|NCT02599389|Experimental|Drug-coated balloons and laser|Angioplasty with use of drug-coated balloons in association with Excimer Laser
88840915|NCT03562897|Experimental|Ocoxin-Viusid®|Ocoxin-Viusid® before, during and after the Chemotherapy treatment.
88840916|NCT05431309|Active Comparator|CCTA-based strategy group|Patients will be managed following the CCTA -based coronary heart disease prevention strategy for statin initiation and follow-up.
89179445|NCT04019886|Experimental|Experimental Group|"It consists following techniques-~Peri-oral stimulation~Vertebral pressure~Anterior stretch -lifting posterior basal area~Co-contraction -abdomen~Intercoastal stretch~Moderate manual pressure"
88840917|NCT05431309|Sham Comparator|Traditional strategy group|Patients will be managed following the Traditional cardiovascular disease prevention strategy based on Chinese guideline for statin initiation and follow-up.
88840918|NCT05429047||SARS-CoV-2 vaccine during pregnancy|Pregnant women who received a vaccine against SARS-CoV-2 during pregnancy and their children
88840919|NCT05429047||SARS-CoV-2 infection during pregnancy|Pregnant women who were diagnosed with a SARS-CoV-2 infection during pregnancy and their children
88840920|NCT05429047||SARS-CoV-2 vaccine or infection before pregnancy|Pregnant women who neither received a COVID-19 vaccine nor were diagnosed with COVID-19 during their pregnancy but had either a COVID-19 vaccine or infection before pregnancy and their children
88840921|NCT05429047||No exposure|Pregnant women, who were never exposed to a SARS-CoV-2 vaccine or infection until the birth and their children
88840922|NCT05119387||Individuals diagnosed with ALS|Individuals diagnosed with ALS that are being followed through the Norwegian health-care system. ALS patients ( probable or definite per El-Escorial criteria)
88840923|NCT03475147|Active Comparator|eyeFusion Control Subjects|Healthy normal controls with no known eye disorders age 18-80.
88840924|NCT03475147|Experimental|eyeFusion Patients|Scotoma subjects aged 18-80.
88840925|NCT03443167|Active Comparator|Intervention group|Training on emergency telephone numbers and mnemonics
88840926|NCT03443167|Sham Comparator|Control group|Sham generic formation on the cardiopulmonary arrest.
88840927|NCT05066737|Experimental|patients who has pelvic organ prolapse and underwent lateral suspension via V-notes surgery|
88840928|NCT03105128|Experimental|Risankizumab Dose 1 (Period 1)|Participants randomized to receive risankizumab dose 1 administered by intravenous (IV) infusion.
88840929|NCT03105128|Experimental|Risankizumab Dose 2 (Period 1)|Participants randomized to receive risankizumab dose 2 administered by intravenous (IV) infusion.
88840930|NCT03105128|Placebo Comparator|Placebo (Period 1)|Participants randomized to receive placebo for risankizumab administered by intravenous (IV) infusion.
88840931|NCT03105128|Experimental|Risankizumab Dose 1 (Period 2)|Participants who received placebo in Period 1 and participants with inadequate response at Week 12 in Period 1 randomized to receive risankizumab dose 1 administered by intravenous (IV) infusion in Period 2.
88840932|NCT03105128|Experimental|Risankizumab Dose 2 (Period 2)|Participants with inadequate response at Week 12 in Period 1 randomized to receive risankizumab dose 2 administered by subcutaneous (SC) injection in Period 2.
88840933|NCT03105128|Experimental|Risankizumab Dose 3 (Period 2)|Participants with inadequate response at Week 12 in Period 1 randomized to receive risankizumab dose 3 administered by subcutaneous (SC) injection in Period 2.
89179446|NCT04019886|No Intervention|Control Group|Outcome measure will be measured at baseline on first day prior to the intervention and on 5th day after the treatment.
89179447|NCT02597400|Experimental|HMS5552 and Metformin|"All subjects will receive the following:~Metformin500 mg BID on Days 1-2, only the morning dose on Day 3. Metformin will be taken 30 minutes prior to meals;~Metformin 500 mg BID and HMS5552 50 mg BID on Days 4-7, only the morning dose on Day 8. Metformin and HMS5552 will be taken 30 minutes prior to meals;~HMS5552 50 mg BID on Days 9 -12, only the morning dose on Day 13. HMS5552 will be taken 30 minutes prior to meals."
89179448|NCT04092543||Stroke patients|All patients diagnosed with a stroke are collected in the database.
89179449|NCT00830063|Experimental|1|
88840934|NCT03331393||RA patients treated with Abatacept|Treated with Abatacept as a first-line biologic
88840935|NCT03331393||RA patients treated with TNFi|Treated with Tumor necrosis factor inhibitor (TNFi) as a first-line biologic
88840936|NCT03122509|Experimental|durvalumab and tremelimumab plus Radiotherapy (RT)|Patients will receive 1500 mg durvalumab via IV infusion q4w for up to 4 doses/cycles and 75 mg tremelimumab via IV infusion q4w for up to 4 doses/cycles, and then continue 1500 mg durvalumab q4w starting on Week 16. Tremelimumab will be administered first. Durvalumab infusion will start approximately 1 hour after the end of tremelimumab infusion. The duration will be approximately 1 hour for each infusion. Radiotherapy (RT) will be performed using external beam ionizing radiation as standard therapy in accordance with institutional standard practice. RT will be initiated within 7 days after the first of durvalumab and tremelimumab.
89179450|NCT00830063|Experimental|2|
89179451|NCT00830063|Active Comparator|3|
89179452|NCT00830063|Placebo Comparator|4|
88840937|NCT03122509|Experimental|durvalumab and tremelimumab plus ablation|Patients will receive 1500 mg durvalumab via IV infusion q4w for up to 4 doses/cycles and 75 mg tremelimumab via IV infusion q4w for up to 4 doses/cycles, and then continue 1500 mg durvalumab q4w starting on Week 16. Tremelimumab will be administered first. Durvalumab infusion will start approximately 1 hour after the end of tremelimumab infusion. The duration will be approximately 1 hour for each infusion. The ablation will be performed percutaneously under image guidance as standard therapy at the discretion of the interventional radiologist in accordance with institutional standard practice. Ablation will be performed within 7 days after the first of durvalumab and tremelimumab.
88840938|NCT03113695|Experimental|obinutuzumab, lenalidomide, and HDMP|
88840939|NCT04892329|Experimental|EUS AI navigation system augmentation|The endoscopists in the experimental group will be assisted by EndoAngel, which can assist in identifying important anatomical structures adjacent to the pancreas in real time. The system is an non-invasive AI system .
88840940|NCT04892329|No Intervention|without EUS AI navigation system augmentation|The endoscopists in the contrpl group performs the examination routinely without special prompts.
89179453|NCT02599350||1|Patients receiving mechanical ventilation
89534743|NCT03240757|Experimental|Breakfast with exercise|Each subject of the same arm underwent 2 interventions: breakfast with/without exercise
88840941|NCT02921828||Multiple myeloma patients who received Pomalyst|Among relapsed or refractory multiple myeloma patients, all patients who received Pomalyst will be targeted in this surveillance.
88840942|NCT04874077||Case|
88840943|NCT04874077||Control|
89179454|NCT02599233||The study population|"The study population consists of adult surgery patients at the Nîmes University Hospital, with recruitment based on the operating theater program for a predefined six month period and for a predefined list of surgeries. The latter list of surgical acts was established according to the Medicalization of Information Systems Progam (PMSI) database. Patients are recruited either the day before or the day after surgery, in their respective departments.~Interventions:~In hospital pain evaluation~In hospital questionnaires~Telephone conctact at 3 months"
89179455|NCT04092621|Experimental|Rhythm-control strategy|The patient will receive 1) amiodarone 150mg bolus over ten minutes followed by intravenous (IV) 1mg/min for 6 hours and then 0.5mg/min for 18hours, and 2) direct current cardioversion (DCC) at the completion of initial 6 hour IV bolus or within 24 hours of new onset of atrial fibrillation. Patient will be placed on by mouth amiodarone 400mg three times daily for seven days, then 400mg twice daily for seven days, then 400mg once daily for seven days, then 200mg daily until stop date which will be by provider discretion after discharge from ICU. If the patient does not convert to a normal sinus rhythm with routine DCC then they will remain in the rhythm-control strategy to receive amiodarone as directed. Amiodarone may be extended at discretion of provider for 30 days with discontinuation if adverse effects. If no contraindications, anticoagulation will be recommended prior to DCC with enoxaparin 1mg/kg every 12 hours.
89179456|NCT04092621|Active Comparator|Rate-control strategy|At treating physician's discretion, one of the following, or a combination of the following, will be administered to the patient: Amiodarone, beta blockers or non-dihydropyridine calcium channel blockers, digoxin. The target heart rate is less than 120 beats per minute (bpm) or maintained hemodynamics. Patients in the rate-control arm who are hypotensive after new onset atrial fibrillation can undergo DCC at the provider's discretion and crossover into the rhythm-control arm.
89179457|NCT00750438|Experimental|Propionate ester|
89179458|NCT00750438|Placebo Comparator|Fermentable control|
89179459|NCT00750438|Placebo Comparator|Non fermentable control|
89179460|NCT04092699|Other|patient|CBCT Dicom file of patient has been scanned will be used for measurements of maxillary sinus volume by different software
89179461|NCT04092699|Other|skulls|CBCT Dicom file of patient has been scanned will be used for measurements of maxillary sinus volume by different software
89179462|NCT00586326|Experimental|Women with DCIS|Women with DCIS
89179463|NCT00917280||Parkinson's Disease|Parkinson Disease participants without dementia
89179464|NCT00917280||Control|Non-PD participants, matched for age, education and gender.
89179465|NCT00751101|Experimental|Arm A: Prior to initiation of capecitabine|Patients apply a transdermal nicotine patch once every 24 hours beginning 1 day prior to initiation of capecitabine and continuing until the end of capecitabine therapy in the absence of disease progression or unacceptable toxicity.
89179466|NCT00751101|Experimental|Arm B: After hand-foot syndrome symptoms appear|Patients apply a transdermal nicotine patch once every 24 hours beginning with the course of chemotherapy initiated after hand-foot syndrome symptoms appear and continuing until the end of capecitabine therapy in the absence of disease progression or unacceptable toxicity.
89179467|NCT00750204|Experimental|APRV|Patients will be randomized to either arm. After 24 hours they will crossover to the alternative arm of the study for an additional 24 hours. After a total of 48 hours (24 hours in each study arm) the study will conclude.
89179468|NCT00750204|Active Comparator|Conventional MV|Patients will be randomized to either arm. After 24 hours they will crossover to the alternative arm of the study for an additional 24 hours. After a total of 48 hours (24 hours in each study arm) the study will conclude.
89179469|NCT04092309|Other|ACE group|patients after bone marrow transplantation will be treated with ACE inhibitor
89179470|NCT04092309|Other|Sacubitril Valsartan group|patients after bone marrow transplantation will be treated with sacubitril valsartan
89179471|NCT04092309|Other|Control group|patients after bone marrow transplantation will be treated neither with ACE i nor with sacubitril valsartan
89179472|NCT02598414|Experimental|Bowel Anastomosis Under ICG Guidance|Patients undergo robotic colon/rectal resection and anastomosis with near-infrared ICG fluorescence imaging.
89179473|NCT02598414|Active Comparator|Standard Bowel Anastomosis|Patients undergo robotic colon/rectal resection and anastomosis without near-infrared ICG fluorescence imaging.
88840944|NCT05286385|Active Comparator|CP1150|CP1150 will be used as the comparator device for speech perception testing in quiet.
88840945|NCT05286385|Experimental|CP1150 (modified firmware)|CP1150 Sound Processor with modified firmware.
88840946|NCT05286385|Experimental|CP1150 + FF|CP1150 Sound Processor with ForwardFocus.
88840947|NCT05286385|Experimental|CP1110|CP1110 is a BTE Sound Processor.
88840948|NCT04828928|Experimental|proportion of patients with neuropathy|to prospectively study patients with a wild-type amyloid cardiopathy condition to identify and describe the associated neuropathy
89179474|NCT04020003|Other|Routine treatment|Routine treatment group: control infection, remove or control the primary disease; mechanical ventilation with low tidal volume and high PEEP mechanical ventilation strategy; strictly control volume, strengthen airway management, timely nutritional support and severe rehabilitation treatment.
89179475|NCT04091334|Experimental|Serial ultrasound group|"Will received standard care and monitoring and in addition, have focused ultrasound examination of the heart and the lungs done twice.~The investigator is supposed to titrate the treatment according to the findings on the ultrasound examinations."
89179476|NCT04091334|Active Comparator|Standard care group|Standard care and monitoring.
89179477|NCT00751023|Experimental|1|Modafinil 400 mg daily
89179478|NCT00751023|Placebo Comparator|2|Placebo
89179479|NCT04092231||1|Thirty children were between two and five years of age at the time of implantation. All were congenital pre-linguistically bilateral profound sensorineural hearing loss. Reports about basic audiological evaluation which included air and bone conduction thresholds, speech audiometry for all the study group before the implantation were obtained. They had limited benefit from consistent use of hearing aid amplification and enrolled in a rehabilitation program focused on oral communication. they underwent unilateral CI with CI experience ranged from 6 months and above.
89368531|NCT05581940||Pediatric caudal anesthesia block.|caudal epidural block is a neuraxial block to provide effective pain relief and analgesia in pediatrics undergoing infra-umbilical pediatric surgery this study aimed to compare the effectiveness of adding to general anesthesia in terms of Intra and post-op pain management. A prospective, randomized case-controlled.A total of 72 patients aged two months to six years with (ASA PS) I (ASA I) were recruited over a six-month period between December 2019 and May 2020. Patients were allocated into two groups A performed under general anesthesia with caudal block and group B performed under general anesthesia alone. Both groups were compared based on hemodynamic stability, analgesia need, pain score, and parental satisfaction. Postoperative pain was evaluated by the Pain Scale- Categorical and numerical variables of both groups were compared. Results:
89368532|NCT04223687|Experimental|Sugar-Sweetened Beverage Warning Label|
89368533|NCT04223687|Other|Neutral label|
89368534|NCT02445742|Experimental|Bosutinib|500 mg/day of Bosutinib during the study until disease progression, unacceptable toxicity, or withdrawal of consent occurs
89368535|NCT03748589|Experimental|airway type 1|The children weighed between 2-5kg are assigned into this group,they are allocated with i-gel laryngeal mask airway type 1
89368536|NCT03748589|Experimental|airway type 1.5|The children weighed between 5-12kg are assigned into this group,they are allocated with i-gel laryngeal mask airway type 1.5
89368537|NCT03748589|Experimental|airway type 2|The children weighed between 10-25kg are assigned into this group,they are allocated with i-gel laryngeal mask airway type 2
88840949|NCT04847323|Active Comparator|V-bend Bonded Retainer|"The V-bend retainer was bonded in the lingual surface of the anterior teeth. The retainer was constructed using 0.024 stainless steel wires. Differently from the conventional bonded retainers, this retainer presents V-bends in the sagittal direction, parallel to the occlusal plane in each interproximal contact point of the incisors and canines.~The retainers was bonded after adequate etching with phosphoric acid and application of adhesive with a low viscosity resin."
88840950|NCT04847323|Active Comparator|Vacuum-formed Retainer|The removable Vacuum-formed retainers were made of acetate 1mm thickness. They were made at the same appointment of debonding using plaster models. The patients were instructed to use the retainers only during nights.
89368538|NCT03748589|Experimental|airway type 2.5|The children weighed between 25-35kg are assigned into this group,they are allocated with i-gel laryngeal mask airway type 2.5
88840951|NCT04784234|Active Comparator|GlaucoCetin Peripheral Group|Primary Open Angle Glaucoma participants who meet inclusion exclusion criteria with peripheral visual field loss will be randomly assigned GlaucoCetin, a medical food in capsule form.
88840952|NCT04784234|Placebo Comparator|Placebo Peripheral Group|Primary Open Angle Glaucoma participants who meet inclusion exclusion criteria with peripheral visual field loss will be randomly assigned a placebo, with no nutritional value, in capsule form.
89368539|NCT02445508|Placebo Comparator|Placebo+Placebo|Oral ingestion of sevelamer placebo powder combined with intravenous infusion of isotonic saline.
89368540|NCT02445508|Active Comparator|Placebo+Cholecystokinin|Oral ingestion of sevelamer placebo powder combined with intravenous infusion of cholecystokinin.
89368541|NCT02445508|Active Comparator|Sevelamer+Placebo|Oral ingestion of sevelamer powder combined with intravenous infusion of isotonic saline.
89368542|NCT02445508|Active Comparator|Sevelamer+Cholecystokinin|Oral ingestion of sevelamer powder combined with intravenous infusion of cholecystokinin.
89368543|NCT03746639|Active Comparator|therapeutic ultrasound group|The patients will be treated with superficial heating, transcutaneous electrical nerve stimulation, exercise therapy and therapeutic ultrasound over the paravertebral low back region.
88840953|NCT04784234|Active Comparator|GlaucoCetin Central Group|Primary Open Angle Glaucoma participants who meet inclusion exclusion criteria with central visual field loss will be randomly assigned GlaucoCetin, a medical food in capsule form.
88840954|NCT04784234|Placebo Comparator|Placebo Central Group|Primary Open Angle Glaucoma participants who meet inclusion exclusion criteria with central visual field loss will be randomly assigned a placebo, with no nutritional value, in capsule form.
88840955|NCT04774796|Experimental|Cognitive Behavioural Therapy|Participants in this group will take part in a group CBT workshop for parents of children with food allergy. They will also have access to a self-help booklet in order to reinforce the learning that has taken place during the workshop.
88840956|NCT04774796|No Intervention|Treatment as usual|Participants in the control group will not take part in the group CBT workshop, but will have access to any treatment as usual relating to their child's food allergy. They will have access to the CBT self-help booklet after the all data collection has been finalised.
88840957|NCT05444738|Experimental|oral oxytocin|oral lollipop with oxytocin (24IU)
88840958|NCT05444738|Placebo Comparator|oral lollipop with placebo|Placebo orally (identical ingredients, except the active agent)
88840959|NCT05253859||Cystic fibrosis registry (UK or US)|People with cystic fibrosis of any genotype registered on either the UK or US CF registry
88840960|NCT04734158||Healthy control|
88840961|NCT04734158||Diabetics with macular edema|
88840962|NCT04734158||Diabetics without macular edema|
88840963|NCT05243953|Experimental|Levcromakalim|A time- and volume-controlled infusion pump is used to administer levcromakalim by intravenous infusion over 20 minutes.
88840964|NCT05243953|Placebo Comparator|Placebo (isotonic saline)|A time- and volume-controlled infusion pump is used to administer placebo (isotonic saline) by intravenous infusion over 20 minutes.
89368544|NCT03746639|Other|therapeutic ultrasound untreated group|The patients will be treated with superficial heating, transcutaneous electrical nerve stimulation, exercise therapy over the paravertebral low back region.Therapeutic ultrasound will not be applied to this group.
89534744|NCT03328247|No Intervention|Control|Control group will attend their routine melanoma follow-ups
89534745|NCT03328247|Experimental|Intervention|The intervention group will use the ASICA app in addition to their routine follow-ups
88818325|NCT01816451|Experimental|interval|The running training for interval group were performed on a treadmill for a period of 14 weeks, with a frequency of three times a week, lasting 20-minutes per session thus completing 46 sessions of training. The intensity and volume of training both were adapted according to the recommendations of the American College of Sports Medicine. The interval training group intensities ranged between 84-87% of maximal heart rate (HRmax) (vigorous intensity), 88-93%HRmax (near maximum intensity) and 94-99% HRmax (maximum intensity).
88840965|NCT02741258|Experimental|Mepitel Film|Mepitel film will be placed on the patients' skin just before the start of the radiotherapy and will be replaced once a week until the end of the radiotherapy. In case of skin toxicities mepitel film will be placed until resolution of the toxicities. In case of new skin toxicities appearance the patient will be retreated with Mepitel.
88840966|NCT02741258|Active Comparator|Excipial U hydrolotion, Flammazin skin cream|Patients will be treated with aqueous (Excipial U hydrolotion) or antiseptic (Flammazine or Ialugen Plus) cream in case of skin erythema due to radiotherapy. In case of new skin toxicities appearance the patient will be retreated with standard of care treatment.
88840967|NCT02757313|Experimental|Regular Users|People who use marijuana regularly will be given a low dose THC marijuana, high dose THC marijuana and placebo marijuana, in a randomized order, at the study visits.
88840968|NCT02757313|Experimental|Occasional Users|People who use marijuana occasionally will be given a low dose THC marijuana, high dose THC marijuana and placebo marijuana, in a randomized order, at the study visits.
88840969|NCT02672293|Experimental|Phosphate|500 mg of oral phosphate is administered after an overnight fast.
88840970|NCT04738591|Experimental|DIABE-TEXT|Participants allocated to the intervention group will receive text messages in their mobile phones with content about diabetes management, general information about diabetes, medicines, diet and physical activity recommendations and motivational prompts to engage participants in a healthy lifestyle and a good adherence to medication plan. They will also receive reminders for healthcare visits, drug dispensation from the pharmacy and updated results from blood test records.
88840971|NCT04738591|No Intervention|Usual care|Participants allocated to the control group will not receive any intervention apart from usual care.
88840972|NCT02379806|Active Comparator|Active enoxaparin 40 mg|One 0.4 ml prefilled syringe containing 40 mg enoxaparin active substance administered once daily for 10 ± 4 days
88840973|NCT02379806|Placebo Comparator|Placebo of enoxaparin 40 mg|One 0.4 ml placebo syringe of enoxaparin 40 mg administered once daily for 10 ± 4 days
88840974|NCT02636647|Active Comparator|FMT|Fecal transplant via enema once
88840975|NCT02636647|No Intervention|No treatment|No transplant performed
88840976|NCT02358356|Active Comparator|PRRT|7.8GBq 177Lu Octreotate (Lutate) given intravenously (IV) on day 1 every 8 weeks for 4 cycles.
88840977|NCT02358356|Active Comparator|CAPTEM|Oral capecitabine 750mg/m2 b.i.d. days 1-14 and temozolomide 75mg/m2 b.i.d. days 10-14 every 28 day cycle, up to 8 cycles.
88840978|NCT02358356|Experimental|PRRT/CAPTEM|7.8GBq 177Lu Octreotate (Lutate) given intravenously (IV) on day 10 every 8 weeks for 4 cycles, with concurrent oral capecitabine 750mg/m2 b.i.d. days 1-14 and temozolomide 75mg/m2 b.i.d. days 10-14 up to 4 cycles.
88840979|NCT04700761|Experimental|Group OFA (Opioid-free anesthesia)|Not using opioid analgesics during laparoscopic gynecologic surgery under general anesthesia (except a single dose of alfentanil for endotracheal intubation)
88840980|NCT04700761|Active Comparator|Group OUA (Opioid-using anesthesia)|Using opioid analgesics during laparoscopic gynecologic surgery under general anesthesia (continuous infusion of remifentanil)
88840981|NCT05206201|Experimental|ZY19489 Capsule|Experimental study drug
88840982|NCT05206201|Placebo Comparator|Placebo|Matching placebo
88840983|NCT04689776|Experimental|High Frequency Dual-Task Training (HF)|The participants of HF will receive a total of 36 training sessions, and each session will contain 90-120 minutes of training.
88840984|NCT04689776|Experimental|Low Frequency Dual-Task Training (LF)|The participants of LF will receive a total of 12 training sessions, and each session will contain 90-120 minutes of training.
88840985|NCT05194033|Experimental|Probiotics|The intervention group consumes oral probiotics 1 time/day for 7 consecutive days.
88840986|NCT05194033|Placebo Comparator|Placebos|The placebo group consumes oral placebo 1 time/day for 7 consecutive days.
88840987|NCT04668391|Experimental|Quadratus lumborum block|Ultrasound-guided anterior quadratus lumborum block at the lateral supra-arcuate ligament.
88840988|NCT04668391|Active Comparator|Thoracic epidural analgesia|Thoracic epidural analgesia at the level of T7-10.
88840989|NCT04658888|Experimental|Modified letter with self-sampling request card|This group will receive a modified letter telling the participant they are out of date with their cervical cancer screening. They will also receive information on the self-sampling kit and will be provided a card that they can send back to the study team in order to have a kit sent to their house. The kit will include a pre-paid mailer so that it can be sent back to the lab for testing. The result will then be shared with the participant.
88840990|NCT04658888|No Intervention|Standard letter|Participants will receive a standard of care letter that tells the participant they are out of date with their cervical cancer screening and should contact their primary care provider to schedule an appointment.
88840991|NCT05192551||Plenvu|A new type of low-volume bowel-prep recently approved and introduced in the Swedish market. The dose is 500 ml x 2, The first dose is given the evening before the colonoscopy and the second dose is given 4-5 hours before the colonoscopy.
88840992|NCT05192551||Laxabon|A standard high volume bowel-prep, used for a long time in Sweden. The dose is 2000 ml x 2. The first dose is given the evening before the colonoscopy and the second dose is given 4-5 hours before the colonoscopy.
88840993|NCT05192551||Vistaprep|A standard high volume bowel-prep, used for a long time in Sweden. The dose is 2000 ml x 2. The first dose is given the evening before the colonoscopy and the second dose is given 4-5 hours before the colonoscopy.
88840994|NCT05192551||Movprep|A standard median volume bowel-prep, used for a long time in Sweden. The dose is 1000 ml x 2. The first dose is given the evening before the colonoscopy and the second dose is given 4-5 hours before the colonoscopy.
88840995|NCT05192395|Experimental|Group A|fed state: period 1) DWJ15251, period 2) DWP16001 and DWC2021011 fased state: period 3) DWJ15251, period 4) DWP16001 and DWC2021011
88840996|NCT05192395|Experimental|Group B|fed state: period 1) DWP16001 and DWC2021011, period 2) DWJ15251 fased state: period 3) DWP16001 and DWC2021011, period 4) DWJ15251
88840997|NCT02350699||Control|Nautilus BrainPulse
88840998|NCT02108899|Experimental|Patients with schizophrenia|
88840999|NCT02108899|Active Comparator|Healthy subjects|
88841000|NCT05172817|Experimental|Advixa|Generic name: Adalimumab Dosage form: Injectable Route of Administration: Subcutaneous Dosage: 40mg/0.4mL Frequency: Once in 2 weeks Duration: Single dose for Phase 2 and 3 months for Phase 3
89534746|NCT03240913|Experimental|Treatment Group|
88841001|NCT05172817|Active Comparator|Humira|Generic name: Adalimumab Dosage form: Injectable Route of Administration: Subcutaneous Dosage: 40mg/0.4mL Frequency: Once in 2 weeks Duration: Single dose for Phase 2 and 3 months for Phase 3
88841002|NCT04600622|Experimental|Intervention Arm|Participants will receive Rural Diabetes One-Day Education and Care program (R-D1D). A one time, 5.5-hour multi-disciplinary diabetes self-management education and support intervention delivered via telehealth.
88841003|NCT04600622|Active Comparator|Active Comparator|Participants will receive diabetes education materials.
88841004|NCT04559737|No Intervention|Usual Care|Patients will receive Auto-Monitoring text messages. The Auto-Monitoring tool that will be used is a function within Somnoware (Somnoware, Inc.) patient management platform, which is the national KP benchmarked platform for sleep management software. Fixed scheduled follow-up visits will be scheduled at 1-month (telephone encounter), 3-months (in-person or video encounter), and 1-year (in-person or video encounter). This sequence of follow-up visits reflects current real-world practice. Patients are eligible for additional visits when self-initiated. Sleep questionnaires will be delivered at 1, 3, and 6 months and at 1 year.
88841005|NCT04559737|Active Comparator|Case Management|Patients will undergo the same follow-up process as described in the Usual Care Pathway. A population CM dashboard (Somnoware, Inc.) will be used to automatically identify PAP strugglers (defined as <70% nights with ≥4 hours use during the preceding month) for 1 year. Video encounters will be triggered for these select patients for troubleshooting. Additionally, throughout this 1-year period, Q1 window of <70% nights >4 hours will trigger a phone call and at the discretion of the case manager convert to video or in-person encounter for troubleshooting. CPAP Follow-Up Questionnaire will also be delivered to patient at 3 months and 1 year.
88841006|NCT05443958||Seizure free group|
88841007|NCT05443958||Not seizure free group|
88841008|NCT04338373|Experimental|experimental|"0.01% Atropine Sulfate solution in Comfort Drops, nightly instillations to both eyes"
88841009|NCT00368953|Experimental|1|
88841010|NCT00368953|Active Comparator|2|
88841011|NCT02200614|Experimental|Darolutamide (BAY1841788)|Participants received Darolutamide 600 mg (2 tablets of 300 mg) twice daily with food, equal to a total daily dose of 1200 mg.
88841012|NCT02200614|Placebo Comparator|Placebo|Participants received matching placebo 2 tablets twice daily with food.
88841013|NCT00369031|Experimental|1|Human Immunodeficiency Virus glycoprotein 140 (vaccine)
88841014|NCT00369031|Active Comparator|2|Human Immunodeficiency Virus glycoprotein 140 (vaccine) + Labile Toxin mutant LTK63 adjuvant
88841015|NCT00369031|Active Comparator|3|Labile Toxin mutant LTK63 adjuvant
88841016|NCT05452382||Partial colectomy|Patients with appendiceal cancer who underwent segmental resection of appendiceal adenocarcinoma
88841017|NCT05452382||Hemicolectomy|Patients with appendiceal cancer who underwent formal right hemicolectomy of appendiceal adenocarcinoma
88841018|NCT05061901|Other|Sequence TR|19 subjects assigned to the sequence TR will receive a single 20 mg dose of the test product Lisinopril (1 x 20 mg tablet), marked as T in the sequence, in Period 1 and a single 20 mg dose of the reference product Zestril® (1 x 20 mg tablet), marked as R in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
88841019|NCT05061901|Other|Sequence RT|19 subjects assigned to the sequence RT will receive a single 20 mg dose of the reference product Zestril® (1 x 20 mg tablet), marked as R in the sequence, in Period 1 and a single 20 mg dose of the test product Lisinopril (1 x 20 mg tablet), marked as T in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
88841020|NCT04398056|Experimental|Chemotherapy plus radiotherapy and Toripalimab|Patients were treated with PF chemotherapy for a maximum of six cycles followed by loco-regional radiotherapy combined with toripalimab.
88841021|NCT05451992|Placebo Comparator|Placebo|Control group that will consume a placebo product
88841022|NCT05451992|Experimental|SuperFood|The superfood group will have to consume the superfood product (vegetable smoothie)
88841023|NCT05443022|Active Comparator|Photobiomodulation group|Participants in this group will have their larger salivary glands irradiated with diode laser.
88841024|NCT05443022|Placebo Comparator|Placebo group|Participants in this group will be subjected to a simulation, where the application protocol will be repeated, but with the laser turned off.
89368545|NCT03197584|Experimental|NANT Ovarian Cancer Vaccine|avelumab, bevacizumab, capecitabine, cyclophosphamide, 5-fluorouracil, fulvestrant, leucovorin, paclitaxel, omega-3-acid ethyl esters, oxaliplatin, stereotactic body radiation therapy, ALT-803, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6301, and hank®.
89368546|NCT03722576|Experimental|Vidofludimus Calcium (VC)|Daily dosing of VC over 6 months
89368547|NCT02445664|Experimental|Video intervention|A tablet-administered educational video (10 minutes duration).
89368548|NCT02445664|No Intervention|Control|No intervention (no video)
89368549|NCT03416348|Placebo Comparator|Placebo Comparator AIM 1|Aim 1: Demonstration of a strong association of the Sweating Intensity Visual Scale (SIVS) score with the HDSS would provide validation for use of the SIVS in interpreting the iodine-starch test and would establish the value of the iodine-starch test in clinical practice guidelines for diagnosing hyperhidrosis in amputees, just as it is in dermatology practice.
89368550|NCT03416348|Active Comparator|Aluminum Chloride vs Placebo in Amputees|Aim 2: The investigators will have completed the first clinical trial of Aluminum Chloride for residual limb hyperhidrosis. The investigators will then have a solid foundation of data that demonstrates the rates of adverse effects such as skin irritation, and rates and magnitudes of improvement in subjective and objective measures of sweating.
88841025|NCT04338919|Experimental|O-APT group|Ticagrelor 90 mg twice daily plus aspirin 100mg once daily in the first month, Ticagrelor 90mg bid between the second and the sixth months Ticagrelor 45mg bid between the seventh and the twelfth months
88841026|NCT04338919|Active Comparator|S-APT group|ticagrelor 90 mg twice daily plus aspirin 100mg once daily for 12 months
88841027|NCT05442944|Experimental|A study group with physiotherapeutic intervention.|The study group - 30 people - participated in the three-week physiotherapy program.
88841028|NCT05442944|No Intervention|A Control group without physiotherapeutic intervention|The control group - 30 people - did not participate in the program.
88841029|NCT05451758|Experimental|Natural outdoor environment|The park is a well-managed green space containing trees, shrubs, flower beds, lawns and a lake, and includes facilities such as benches, wooden bridges, a bandstand and monuments. The experiment was carried out in a location defined by planted areas containing shrubs and small trees, with some distant views.
88841030|NCT05451758|Experimental|Built outdoor environment|A courtyard on the university campus was chosen as a built outdoor environment. The courtyard was surrounded by concrete and brick built settings, with no visible vegetation.
88841031|NCT05451758|Experimental|Indoor environment|The indoor setting was a seminar room: a white painted room without windows in the basement of a university building. It contained chairs, a neutral coloured picture and no vegetation.
88841032|NCT04351009|Experimental|Indocyanine green sentinel lymph node mapping|Indocyanine green dye is injected in the submucosa or subserosa around the tumor to identify sentinel lymph nodes intra-operatively with near infrared fluorescence imaging.
88841033|NCT02231892|Experimental|Real TMS|rTMS (frequency and intensity)
88841034|NCT02231892|Sham Comparator|Sham TMS|Sham setting on coil
89368551|NCT03202342|Experimental|Water/gluc/gluc+EB/EB/gluc+EB_cold|First Water 22 C, then Glucose 22 C, then Glucose + Ethyl butyrate 22 C, then Ethyl butyrate 22 C and then Glucose + Ethyl butyrate 0 C
88841035|NCT05442476|Experimental|kinesiotaping|
88841036|NCT05442476|Other|Muscle Energy Technique|
88841037|NCT05451290|Experimental|treatment arm|
88841038|NCT05452135||Healty Adults|aged between 20 - 30 years right dominant being a volunteer to participate in the study
88841039|NCT04284865|Experimental|Intervention group|The web platform includes three respiratory exercises: diaphragmatic breathing, thoracic expansion exercise and thoracic expansion exercise assisted upper limbs. It is suggested to do each of the three exercises once a day (AM and PM), four repetitions each. An electronic logbook is also available on the platform to record the duration and the type of others cardiorespiratory exercise of their choice (cycling, walking, using stairs, etc.) as well as strengthening (upper and lower body).
88841040|NCT05442320|Active Comparator|500 ppm|Toothpaste with 500 ppm fluoride (Biodent, Ilirija d.d)
88841041|NCT05442320|Experimental|1000 ppm|Toothpaste with 1000 ppm fluoride (Biodent, Ilirija d.d)
88841042|NCT05451056|Experimental|sotorasib|Sotorasib will be given 960mg daily PO until disease progression or unacceptable toxicity .
88841043|NCT04304690|Other|caregiver|caregivers from emergency, ICU, virology and infectious disease services
88841044|NCT02231580|Experimental|BN82451B|BN82451B capsule: Up to 3 dose levels (40, 60 or 80 mg) twice daily administered orally.
88841045|NCT02231580|Placebo Comparator|Placebo|Placebo capsule: Up to 3 dose levels (40, 60 or 80 mg) twice daily administered orally.
88841046|NCT05442242|Active Comparator|Unicompartmental knee osteoarthritis|
88841047|NCT05442242|Active Comparator|High tibial osteotomy|
88841048|NCT05441150|Active Comparator|Ketamine Group|Patients who received low-dose ketamine infusion
88841049|NCT05441150|Sham Comparator|Control group|Patients who received 0.9% Sodium Chloride Solution, Intravenous, (NaCl) infusion
88841050|NCT04270214|Other|Dysport|Single arm study, all participants will receive Dysport injections
88841051|NCT05018689|Active Comparator|Aevidum curriculum|Curriculum: Aevidum has developed a 5-lesson 3-hour mental health curriculum that can be broken up and integrated into existing school health curricula. The study team in partnership with the Executive Director of Aevidum will collaborate with schools to implement the curriculum to their 9th grade students.
89368552|NCT03202342|Experimental|Water/gluc+EB/gluc/gluc+EB_cold/EB|First Water 22 C, then Glucose + Ethyl butyrate 22 C, then Glucose 22 C, then Glucose + Ethyl butyrate 0 C and then Ethyl butyrate 22 C
88841052|NCT05018689|Active Comparator|Aevidum curriculum + club|Curriculum + club. Schools assigned to the curriculum plus club will also start an Aevidum club at their school. Club basic processes and ideas for events are housed on the Aevidum website. Schools will select faculty and student leaders who will participate in a kickoff web-based training at the start of the academic year. The training is led by current Aevidum student leaders at schools with successful clubs. This is a standard orientation process that Aevidum has run for many years in-person, but has been adapted to a virtual format with the COVID-19 pandemic.
88841053|NCT04217707|Other|Pre- and Post-Surgical Transgender Therapeutic Support Groups|
88841054|NCT05144022|Experimental|Interventions group: High stress condition (bungee jump)|25-30 healthy male volunteers participating in a bungee jump
88841055|NCT05144022|Placebo Comparator|Control group: No stress condition|10-15 healthy males serving as a control group without undergoing a stress event/intervention
88841056|NCT05450510|Active Comparator|Accelerated (ACCEL) physiotherapy group|They will be referred to Physiotherapy and Rehabilitation clinics for a 8-week-long Phase 2 and Phase 3 trainings. The training program includes the following exercises: cold-pack ; TENS (60-120 Hz); soft tissue massage, joint mobilizations; mobility exercises; stretching, controlled strengthening and endurance exercises.
89368553|NCT03202342|Experimental|Gluc/water/EB/gluc+EB/glucose+EB_cold|First Glucose 22 C, then Water 22 C, then Ethyl butyrate 22 C, then Glucose + Ethyl butyrate 22 C and then Glucose + Ethyl butyrate 0 C
89368554|NCT03202342|Experimental|Gluc/EB/water/gluc+EB_cold/gluc+EB|First Glucose 22 C, then Ethyl butyrate 22 C, then Water 22 C, then Glucose + Ethyl butyrate 0 C and then Glucose + Ethyl butyrate 22 C
89368555|NCT03202342|Experimental|EB/Gluc/gluc+EB_cold/water/glucose+EB|First Ethyl butyrate 22 C, then Glucose 22 C, then Glucose + Ethyl butyrate 0 C, then Water 22 C and then Glucose + Ethyl butyrate 22 C
89368556|NCT03202342|Experimental|EB/gluc+EB_cold/gluc/glucose+EB/water|First Ethyl butyrate 22 C, then Glucose + Ethyl butyrate 0 C, then Glucose 22 C, then Glucose + Ethyl butyrate 22 C and then Water 22 C
89534747|NCT03240913|Placebo Comparator|Non Treatment Group|Conventional information
88841057|NCT05450510|Active Comparator|Slow (SLOW) physiotherapy group|They will be referred to Physiotherapy and Rehabilitation clinics for a 14-week-long Phase 2 and Phase 3 trainings. The training program includes the following exercises: cold-pack ; TENS (60-120 Hz); soft tissue massage, joint mobilizations; mobility exercises; stretching, controlled strengthening and endurance exercises.
88841058|NCT04746703|Experimental|MRI before and 6 months after bariatric surgery|"Recruitment of patient with planned bariatric surgery in Louis Mourier Hospital by the nutritionist, during the preoperative day hospitalisation (performed during the multidisciplinary preparation for bariatric surgery) when patients are deemed eligible for bariatric surgery according to HAS (High Authority of Health) criteria.~Programming of MRI in the month between preoperative visit and surgery. During this exam without injection of contrast agents in the radiology department of Louis Mourier Hospital, additional sequences with specific acquisitions as previously validated in humans will be performed for the study.~Bariatric surgery will be performed as in usual care in Louis Mourier hospital. The same MRI will be performed in day hospitalization scheduled 6 months after surgery."
89368557|NCT03202342|Experimental|Gluc+EB_cold/water/glucose+EB/glucose/EB|First Glucose + Ethyl butyrate 22 C, then Water 22 C, then Glucose + Ethyl butyrate 0 C, then Glucose 22 C and then Ethyl butyrate 22 C
89368558|NCT03202342|Experimental|Gluc+EB_cold/glucose+EB/water/EB/glucose|First Glucose + Ethyl butyrate 22 C, then Glucose + Ethyl butyrate 0 C, then Water 22 C, then Ethyl butyrate 22 C and then Glucose 22 C
88841059|NCT05438810|Experimental|FCN-437c+Fulvestrant ± Goserelin acetate|
88841060|NCT05438810|Placebo Comparator|Placebo+ Fulvestrant ± Goserelin acetate|
88841061|NCT04732351||Active sentry|Cataract procedures conducted with the active Sentry handpiece
88841062|NCT04732351||Non-active sentry|Cataract procedures conducted with an handpiece different from the Active Sentry Handpiece
88841063|NCT04738513|Active Comparator|Conventional preparation technique|Monolithic Zirconia (5Y-TZP/3Y-TZP) Crowns using conventional preparation technique.
88841064|NCT04738513|Experimental|Vertical preprartion|Monolithic Zirconia (5Y-TZP/3Y-TZP) Crowns using Vertical preparation technique.
88841065|NCT04338854|Experimental|Root canal treatment|It's one of the restorative groups with LA (Local Anesthesia). An aerator and micromotor were used as cavity preparation in this group. Only conventional root canal treatment and extirpation were planned for the children included in the root canal treatment group in the measurement session.
88841066|NCT04338854|Experimental|Pulpotomy treatment|It's one of the restorative groups with LA (Local Anesthesia).An aerator and micromotor were used as cavity preparation in this group. it was noted that at least one of the approximal surfaces of the teeth had decay and iron sulfate (ViscoStat®, UltraDent, South Jordan, USA) was used as pulpotomy material
88841067|NCT04338854|Experimental|two-surface restoration with Local Anesthesia|It's one of the restorative groups with LA (Local Anesthesia).An aerator and micromotor were used as cavity preparation in this group. A Tofflemire matrix retainer and 0.05 mm thick matrix band (Hahnenkratt, Königsbach-Stein, Germany) were used in groups with a two-surface cavity.
88841068|NCT04338854|Experimental|one surface restoration with Local Anesthesia|It's one of the restorative groups with LA (Local Anesthesia).An aerator and micromotor were used as cavity preparation in this group.
88841069|NCT04338854|Experimental|two-surface restoration without Local Anesthesia|An aerator and micromotor were used as cavity preparation in this group. A Tofflemire matrix retainer and 0.05 mm thick matrix band (Hahnenkratt, Königsbach-Stein, Germany) were used in groups with a two-surface cavity.
88841070|NCT04338854|Experimental|one surface restoration without Local Anesthesia|An aerator and micromotor were used as cavity preparation in this group.
88841071|NCT04338854|Experimental|fluoride application by disposable arch tray|It's one of the protective groups.Only the micromotor was used for polishing purposes in the protective treatment groups. 2% NaF (Polimo® IMICRYL, Konya, Turkey) was preferred in groups who received fluoride application.
88841072|NCT04338854|Experimental|fluoride application by cotton roll|It's one of the protective groups. Only the micromotor was used for polishing purposes in the protective treatment groups 2% NaF (Polimo® IMICRYL, Konya, Turkey) was preferred in groups who received fluoride application.
88841073|NCT04338854|Experimental|Fissure Sealant group|It's one of the protective groups. Only the micromotor was used for polishing purposes in the protective treatment groups.
88841074|NCT02166606||Pacemaker/Lead implant|"All enrolled subjects will receive an ImageReady Magnet Resonant (MR) Conditional Pacing System and the treatment assignment will be based on an all-comers consecutive basis."
88841075|NCT04730401|Experimental|High-titre CP|200mL high-titre CP on admittance
88841076|NCT04730401|Active Comparator|low-titre CP|200ml low-titre CP on admittance
88841077|NCT04730401|Placebo Comparator|Placebo|200mL saline as placebo on admittance
89368559|NCT03202342|Experimental|Gluc+EB_cold/gluc+EB/EB/water/glucose|First Glucose + Ethyl butyrate 0 C, then Glucose + Ethyl butyrate 22 C, then Ethyl butyrate 22 C, then Water 22 C and then Glucose 22 C
89368560|NCT03202342|Experimental|Gluc+EB_cold/EB/gluc+EB/glucose/water|First Glucose + Ethyl butyrate 0 C, then Ethyl butyrate 22 C, then Glucose + Ethyl butyrate 22 C, then Glucose 22 C and then Water 22 C
89368561|NCT03236012|Experimental|Botulinum Toxin Therapy|"Test the effectiveness of Botulinum Toxin therapy in subjects who fail or do not tolerate Aluminum Chloride.~We plan to conduct an open label study of Botox, up to 400 units, in amputees who have failed treatment with a topical antiperspirant."
89368562|NCT02449486|Active Comparator|Ropivacaine|Ropivacaine 4 ml/h (8 mg/h) continuous infusion for 48 hours
89368563|NCT02449486|Placebo Comparator|Placebo|Saline infusion 4 ml/h for 48 hours
89368564|NCT03625154|Active Comparator|non operative control group|Patients with negative gravity stress (non-operative treatment/observational control group)
89368565|NCT03625154|Active Comparator|non operative experimental group|Patients with positive gravity stress (medial clear space > 4 mm on initial injury pre-reduction x-rays, who undergo a reduction with closing of the medial clear space to <4mm. Plan for nonoperative treatment of all these patients with splint and subsequent walker boot.
88841078|NCT05451121|Experimental|propofol|Patient sedation after cardiac surgery at the intensive care unit. Continuous infusion of propofol (hypnotic agent) using a syringe pump at the dose of 1-1.5 mg / kg / h
88841079|NCT05451121|Experimental|Dexmedetomidine|Patient sedation after cardiac surgery at the intensive care unit. continuous infusion of Dexmedetomidine (selective α2-adrenergic receptor (α2-AR) agonist) using a syringe pump at the dose of 0.5-1.0 mcg/ kg / h
88841080|NCT05451121|Experimental|propofol and dexmedetomidine|Patient sedation after cardiac surgery at the intensive care unit. Continuous infusion of propofol using a syringe pump at the dose of 0.5-1.5 mg / kg / h and dexmedetomidine 0.2-0.7 mcg\kg\h
88841081|NCT04967443|Active Comparator|Prazosin Hydrochloride (HCL) 2 milligram (mg) capsule Barceloneta site|One 2 mg capsule manufactured at the current site, Barceloneta
88841082|NCT04967443|Experimental|Prazosin HCL 2 mg capsule Ascoli site|One 2 mg capsule manufactured at the proposed site (Ascoli)
88841083|NCT04967443|Experimental|Prazosin HCL 1 mg capsule Ascoli site|Two 1 mg capsule manufactured at the proposed site, Ascoli
88841084|NCT04967443|Active Comparator|Prazosin HCL 5 mg capsule Barceloneta site|One 5 mg capsule manufactured at the current site, Barceloneta
88841085|NCT04967443|Active Comparator|Prazosin HCL 1 x 5 mg capsule Ascoli site|One 5 mg capsule manufactured at the proposed site, Ascoli
88841086|NCT04724317|Sham Comparator|Steroid Group|shoulder intra-articular injection of 5 ml of Bupivacaine 0.125% added to triamcinolone 40 mg under the ultrasound guidance
88841087|NCT04724317|Active Comparator|Ozone Group|shoulder intra-articular injection of 5 ml of Bupivacaine 0.125% followed by injection of 10 ml of Oxygen-Ozone mixture (15 µg/ml) under the ultrasound guidance
88841088|NCT04724317|Active Comparator|PRF Group|shoulder intra-articular injection of 5 ml of Bupivacaine 0.125% followed by pulsed radiofrequency application under the ultrasound guidance
88841089|NCT04697017|Other|Multiple births (twins and triplets)|Twins and triplets who had developmental anomalies such as cleft lip and palate, premature tooth loss, systemic diseases or syndromes that could influence oral health or had already undergone or were undergoing orthodontic therapy, as well as those whose family did not give consent, were excluded from the study
88841090|NCT04697017|Other|Singletons|Singletons who had developmental anomalies such as cleft lip and palate, premature tooth loss, systemic diseases or syndromes that could influence oral health or had already undergone or were undergoing orthodontic therapy, as well as those whose family did not give consent, were excluded from the study.
88841091|NCT04943419||Colorectal cancer|Patients with colorectal cancer qualified for elective operations.
88841092|NCT02230956|Experimental|OnabotulinumtoxinA 400 U|OnabotulinumtoxinA 400 U injection into the intra-articular space of the study knee on Day 1.
88841093|NCT02230956|Experimental|OnabotulinumtoxinA 200 U|OnabotulinumtoxinA 200 U injection into the intra-articular space of the study knee on Day 1.
88841094|NCT02230956|Placebo Comparator|Placebo|Placebo (Normal Saline) injection into the intra-articular space of the study knee on Day 1.
88841095|NCT02230410|Experimental|focal cryo ablation|Subjects with residual barrett's esophagus (less than 3 cm) post ablation will under go one CryoBalloon Focal Ablation treatment
88841096|NCT05447936|Active Comparator|Female arm|Ten healthy active female XCS past the age of 18 years were included. The duration of the study was 12 weeks divided in three dose-escalation periods of four weeks. In the first 4-week period all the participants was given 47gram Jarlsberg cheese daily. Based on the change in serum Osteocalcin level, the daily intake of Jarlsberg cheese for the next 4-week periode was desided in accordance with the RSP procedure
88841097|NCT05447936|Active Comparator|Male arm|Ten healthy active male XCS past the age of 18 years were included. The duration of the study was 12 weeks divided in three dose-escalation periods of four weeks. In the first 4-week period all the participants was given 47gram Jarlsberg cheese daily. Based on the change in serum Osteocalcin level, the daily intake of Jarlsberg cheese for the next 4-week periode was desided in accordance with the RSP procedure
88841098|NCT04739384|Experimental|Standard dose of ticagrelor (90 mg twice daily).|Standard dose of ticagrelor (90 mg twice daily) followed by lower dose of ticagrelor (60 mg twice daily).
89179480|NCT04091412|Experimental|Long-term administration of Butylphthalide Soft Capsules|In addition to standard secondary preventive drugs, such as atorvastatin calcium tablets, aspirin enteric-coated tablets and/or clopidogrel hydrogen sulphate tablets, patients in this group take Butylphthalide Soft Capsules orally, 0.2g per serving, three times a day for one year.
88841099|NCT04739384|Experimental|Low dose of ticagrelor (60 mg twice daily).|Low dose of ticagrelor (60 mg twice daily) followed by standard dose of ticagrelor (90 mg twice daily).
89179481|NCT04091412|No Intervention|Standard secondary prevention group|patients in this group take atorvastatin calcium tablets, aspirin enteric-coated tablets and/or clopidogrel hydrogen sulphate tablets as standard secondary prevention.
89179482|NCT04092075|Experimental|Treatment group|The treatment is conducted with the ToothWave toothbrush Intervention: brushing with Radio frequency (RF)-utilizing powered toothbrush
89179483|NCT04092075|Sham Comparator|Control group|Regular powered toothbrush Intervention: brushing with a regular powered toothbrush with no RF
88841100|NCT05450575||single arm, single group(No interventional)|Observational
88841101|NCT04704596|Active Comparator|dynamic lung compliance for detection of optimum PEEP|detection of optimum PEEP by measurement of the dynamic lung compliance (by the ventilator machine) after lung recruitment
89179484|NCT02599311|Other|the efficacy|transvaginal synthetic mesh
88841102|NCT04704596|Active Comparator|Lung ultrasound for detection of the optimum PEEP|Lung ultrasound will be used to detect the optimum PEEP after lung recruitment
88841103|NCT05450497|Experimental|Propofol Group|Patient sedation after cardiac surgery at the intensive care unit. Continuous infusion of propofol using a syringe pump at the dose of 1-1.5 mg / kg / h
88841104|NCT05450497|Experimental|Dexmedetomidine|Patient sedation after cardiac surgery at the intensive care unit. Continuous infusion of Dexmedetomidine using a syringe pump at the dose of 0.5-1.0 mcg/ kg / h
89368566|NCT03625154|Active Comparator|operative observational group|Patients with positive gravity stress (medial clear space > 4 mm) who undergo a reduction with closing of the medial clear space to <4mm who declined non-operative treatment but agree to be observed. These patients will undergo ORIF (Open Reduction and Internal Fixation) with plates and screws and function as a second observation group
89368567|NCT03202186|Placebo Comparator|Placebo|oral administration of Placebo capsule
88841105|NCT05450497|Experimental|Dexmedetomidine and propofol|"Patient sedation after cardiac surgery at the intensive care unit.~Sedation group DEX+PR:~continuous infusion of propofol using a syringe pump at the dose of 0.5-1.5 mg / kg / h and dexmedetomidine 0.2-0.7 mcg\kg\h"
88841106|NCT02230332|Experimental|Alendronate|Alendronate in 10mg capsules taken once daily
88841107|NCT02230332|Placebo Comparator|Placebo|Placebo capsule taken once daily
88841108|NCT04928989|Active Comparator|Convergence dialogue meeting|Digital counceling with convergence dialogue tripartite meeting. will be conducted in accordance with work dialogue for return to work. Workplace dialogue among employee with neck problems, an expert in the work environment, and the immediate manager. The purpose of the conversations is, in open dialogue, to reach a common understanding of the situation and identify possible interventions to maintain or improve the employee´s work ability.
88841109|NCT04928989|Experimental|Neck-specific exercise in addition to convergence dialogue meeting|Neck-specific exercise with digital web-based support and four visits to a physiotherapist. Neck-specific exercise will be performed based on a well-structured framework of neck-specific exercise for facilitation of deep neck muscles, increased muscle coordination, improved neck posture and increased neck muscle endurance. Plus additional convergence dialogue meeting as treatment arm no 1.
88841110|NCT02230254|Experimental|PROMUS POREMIER stent|Single-arm treatment group receiving interventional PROMUS PRIMIER study stent
88841111|NCT04927819||short-length implant (<6.5 mm)|
88841112|NCT04927819||non-short length implant (≥6.5 mm)|
88841113|NCT05447468|Experimental|scapular muscles strengthning group|Patients in this group A will receive scapular muscles (lower trapezius, middle trapezius and serratus anterior) strengthening along with conventional physiotherapy (pulsed ultrasound, static stretching of ECRB muscle and eccentric exercises of wrist extensors) for 6 weeks.
88841114|NCT05447468|Active Comparator|conventional physiotherapy group|Patients in this group B will receive conventional physiotherapy only (pulsed ultrasound, static stretching of ECRB muscle and eccentric exercises of wrist extensors) 3 sessions per week for 6 weeks.
88841115|NCT05449730||Yoga instructor|(a) overall good health and can cooperate with orders reasonably; (b) between the ages of 25 to 60 years old; (c) no limb or leg discrepancy; (d) no history of surgery on the lower limbs or spine; (e) no history of musculoskeletal injury over the lower back in the past six months; (f)practice yoga three to six days per week and at least ten years of experience in yoga
88841116|NCT05449730||Healthy adult control|(a) overall good health and can cooperate with orders reasonably; (b) between the ages of 25 to 60 years old; (c) no limb or leg discrepancy; (d) no history of surgery on the lower limbs or spine; (e) no history of musculoskeletal injury over the lower back in the past six months; (f) no experience with yoga training; (g)participated in regular exercise 2 or 3 times a week
88841117|NCT04587739|Experimental|Experimental group|
88841118|NCT05449574||people with MS|People with MS with relapsing-remitting form
88841119|NCT05449574||healthy people|people from the age of 30-45 years old
88841120|NCT04579159|Other|only control group|To investigate the specificity of the wearable and to gather more information on ECG abnormalities in the population studied, a randomly selected group of participants without wearable-detected AA within 8 weeks of screening (same number as screen-positives and verified by Telecare) will also be invited to obtain a 14day Tele ECG (patch).
88841121|NCT05447390|Active Comparator|Pulmonary Hypertension|
88841122|NCT05447390|Active Comparator|Healthy Control|
88841123|NCT04577287|Experimental|Cathodal tDCS & PT|Cathodal transcranial direct current stimulation (tDCS) will be applied for 20 mins before conventional physical therapy (about 1 hour). Cathode on the on the motor area (M1) of the affected hemisphere, anode on the supraorbital area of the unaffect hemisphere.Current intensity is fixed at 1.5 mA and current will flow continuously. Physical therapist will give an intervention program base on the same basic conventional physical therapy treatment. The scope of intervention is administered to improve motor functions and cerebral hemodynamic .
88841124|NCT04577287|Experimental|Anodal-tDCS & PT|Anodal transcranial direct current stimulation (tDCS) will be applied for 20 mins before conventional physical therapy (about 1 hours). Anode on the motor are (M1) of the affected hemisphere, and cathodal on the supraorbital area of unaffected hemisphere. Current intensity is fixed at 1.5 mA and current will flow continuously. Physical therapist will give an intervention program base on the same basic conventional physical therapy treatment. The scope of intervention is administered to improve motor functions and cerebral hemodynamic .
88841125|NCT05449184|Experimental|Balloon Eustachian Tuboplasty with Tympanostomy Tube Insertion|
89368568|NCT03202186|Experimental|Progesterone 200 mg|oral administration of progesterone 200 mg
88841126|NCT05449184|Other|Tympanostomy Tube Insertion|
88841127|NCT04569175|Experimental|3D Flair sequence|Optimized 3D FLAIR sequence before and 4 hours after the usual care MRI (with contrast product)
88841128|NCT04338542||neoadjuvant chemotherapy plus bevacizumab|Patients treated with surgery of the primary tumor, neoadjuvant chemotherapy plus bevacizumab and, finally, the surgical resection of liver metastasis.
88841129|NCT04338542||neoadjuvant chemotherapy|Patients treated with surgery of the primary tumor, neoadjuvant chemotherapy and, finally, the surgical resection of liver metastasis.
88841130|NCT04338542||control group|Patients presenting with synchronous primary tumour and metastasis resected without any preoperative systemic therapy.
88841131|NCT05449951|Experimental|Dry needling|This intervention was for three weeks in which there are 2 sessions per week. Sterile, disposable dry needles brand of JIAJAN with size of 0.30x40mm were used. Intervention was initiated after palpation of muscles(flexor carpi radials and flexor carpi ulnaris).First cleaning the area through alcohol swabs. There is a point for FCR in medial forearm, to that point 4 cm below and 1 cm medial to the midpoint of crease of elbow was needled. There is a point for FCU at the center of the proximal third segment of a line from the medial epicondyle to the ulnar styloid process was needled.Then, in swift in-and-out motions around 5mm vertical motions without rotation the needle was manipulated .About 1 minute Dry needling was executed for each targeted area, in respect to the patient's level of tolerance. This was monitored by the physiotherapist throughout the session by asking for regular verbal feedback
88875212|NCT02526654|Experimental|Glaucoma Subjects|Subjects with glaucoma were recruited based on characteristic glaucomatous disc damage and visual field changes. They will perform visual field with Heidelberg Edge Perimeter and Octopus visual field. Optical Coherence Tomography will image the retinal nerve fiber layer.
89002008|NCT06117241|No Intervention|Comparison|Participation will be for six months. Participants will meet staff at three timepoints (baseline, 3 months, 6 months) to complete questionnaires, online dietary assessment, body measures, have blood pressure measured, provide blood and stool samples, and wear an activity monitor for a week at each time point.
89002009|NCT06117241|Experimental|Intervention|Participation will be for six months. Participants will meet staff at three timepoints (baseline, 3 months, 6 months) to complete questionnaires, online dietary assessment, body measures, have blood pressure measured, provide blood and stool samples, and wear an activity monitor for a week at each time point. In addition, participants will attend weekly classes for 12 weeks and one class per month for three months. These classes will include cooking, movement, and stress reduction.
89002010|NCT06117215||women of reproductive age|women of reproductive age
89002011|NCT06117189||Adult endodontic patients|Turkish version of Oral Health Impact on Daily Life questionnaire was applied to adult endodontic patients
89002012|NCT06117150|Experimental|Drug-eluting Coronary Spur StEnt System|All subjects enrolled will receive the Drug-eluting Coronary Spur Stent System.
89002013|NCT06117137|Experimental|Control group|Control group (stander treatment of Type two diabetes mellitus without SGLT2-I )
89002014|NCT06117137|Experimental|Group dapa|Dapa group: (stander treatment of type two diabetes mellitus plus Dapagliflozin)
89002015|NCT06117137|Experimental|Group empa|Group empagliflozin: stander treatment of type two diabetes mellitus plus empagliflozin
89002016|NCT06117111||Study group|Age: minimum of 18 years, Undergoing pancreatic or ENT tumour surgery, Ability to give informed consent, Volunteering to the study. Monitored in addition to standard monitoring using PaMo device.
89002017|NCT06117098|Experimental|Mobile application|This group will receive individual guidance via the mobile application (12 weeks)
89002018|NCT06117098|Active Comparator|Group-based lifestyle intervention at the Healthy Lifestyle Centres|This group will receive a group-based lifestyle intervention program at a Healthy Lifestyle Centre (12 weeks)
89002019|NCT06117098|Experimental|Group-based lifestyle intervention at a Healthy Lifestyle Centre and recieving a mobile application|This group will receive a group-based lifestyle intervention program at a Healthy Lifestyle Centre plus the mobile application (12 weeks)
89002020|NCT06117085|Experimental|Percutaneous Treatment Arm|CellFX Percutaneous Treatment under ultrasound guidance using nanosecond Pulse Field Ablation (nsPFA)
89002021|NCT06117072|Experimental|Dash diet group, salt free diet|This randomized controlled intervention study aimed to compare the effects of a Dietary Approaches to Stop Hypertension (DASH) diet and a salt-free diet on blood pressure in hypertension patients. Methods: This study was conducted with 60 patients with primary hypertension. One group (n=30) was given an individualized DASH diet, the other group was given a salt-free diet (n=30), and the participants were followed for two months.
89002022|NCT06117046|Experimental|Cardiopeptides|Cardiopeptide was administered intravenously once a day with 60mg of cardiopeptide for 3 days
89002023|NCT06117046|No Intervention|Empety|
89002024|NCT06117033|Experimental|experimental group|Preoperative routine patient education and video-assisted mobilization training were given to patients undergoing coronary artery bypass graft surgery.
89002025|NCT06117033|No Intervention|control group|Patients in the control group received only routine patient education.
89002026|NCT06117020|Experimental|MTR-601|Safety and tolerability of oral MTR-601, a highly selective fast twitch myosin 2 ATPase inhibitor in normal healthy volunteers
89002027|NCT06117020|Placebo Comparator|Placebo|
89368569|NCT03202186|Experimental|Progesterone 300 mg|oral administration of progesterone 300 mg
89368570|NCT03202186|Experimental|Progesterone 400 mg|oral administration of progesterone 400 mg
89368571|NCT03625076|Experimental|Intra-articular Lidocaine|20 mL of 1% lidocaine injected into the joint of the dislocated shoulder
89368572|NCT03625076|Active Comparator|Procedural Sedation|Intravenous etomidate or propofol
89368573|NCT03197272|Experimental|PiXL Protocol A|PiXL treatment with UV irradiation in a central 4 mm homogenous zone of the cornea. For myopia of less than 1.0D, 10 J/cm2 will be used, for higher levels of myopia 15J/cm2 will be used.
89368574|NCT03197272|Active Comparator|PiXL Protocol B|PiXL treatment with UV irradiation in a central ring-shaped 4-mm area of the cornea. A central 2-mm zone is left untreated, and the energy is higher towards the periphery of the ring-shaped area, reaching its maximum at 2 mm from the corneal centre. For myopia of less than 1.0D, a maximum of 10 J/cm2 will be used, for higher levels of myopia a maximum of 15J/cm2 will be used.
89002028|NCT06117007|Active Comparator|Betalains|Daily consumption of 1 betalain capsule (25 mg betalains) for 28 days.
89002029|NCT06117007|Placebo Comparator|Placebo|Daily consumption of 1 placebo capsule (0 mg betalains) for 28 days.
89002030|NCT06116994|Active Comparator|control group|In the control group, subjects will receive the buccal infiltration anesthesia using the traditional dental syringe.
89002031|NCT06116994|Experimental|Test group|Subjects in the test group will receive the buccal infiltration anesthesia with the camouflaged dental syringe.
89002032|NCT06116903|Experimental|Detection of molecular abnormalities|Blood samples will be taken from 2 + 3 Cell-Free DNA Collection tubes (Roche): for the comparative performance of the two methods (main objective) 3 Cell-Free DNA Collection tubes will be collected at 3 months (post chemotherapy) to evaluate the clinical relevance of a new analysis of molecular alterations on exosomes
89179485|NCT02599311|No Intervention|the recurrence rate|transvaginal synthetic mesh
89368575|NCT02445352|Active Comparator|Rosuvastatin 5mg & Placebo & Placebo|Once a day, administration of rosuvastatin 5mg and two types of placebo for 20 weeks
88841132|NCT05449951|Other|Sustained stretching|The second group received sustained stretching protocol along with conventional therapy. Participants undergone the overall treatment sessions for three weeks (3weeks) and 2 sessions per week. The targeted muscles are wrist flexors (flexor carpi radials and flexor carpi ulnaris). Participants received 10 repetition with 30 seconds hold in each session for 10 minutes. Pre and post data in each session was measured through outcome measure tools
88841133|NCT02198664|Experimental|ARC001 placebo group|Subjects who received placebo in study ARC001.
88841134|NCT02198664|Experimental|ARC001 AR101 group|Subjects who received AR101 and tolerated up to 300 mg peanut protein (443 mg cumulative) in the DBPCFC at the end of study ARC001.
88841135|NCT05449028|Experimental|H. pylori eradication scheme A|Esomeprazole 40mg bid + amoxicillin 1g 12/12h + clarithromycin 500mg 12/12h + metronidazole 500mg 8/8h, for 14 days
88841136|NCT05449028|Experimental|H. pylori eradication scheme B|Esomeprazole 40mg bid + amoxicillin 1g 12/12h + clarithromycin 500mg 12/12h + metronidazole 500mg 12/12h, for 14 days
88841137|NCT05449028|Experimental|H. pylori eradication scheme C|Esomeprazole 40mg bid + bismuth subsalicylate 420mg 6/6h + metronidazole 375mg 6/6h + tetracycline 375mg 6/6h, for 10 days
88841138|NCT05449028|Experimental|H. pylori eradication scheme D|Esomeprazole 40mg bid + amoxicillin 1g 12/12h for 7 days, followed by esomeprazole 40mg bid + clarithromycin 500mg 12/12h + metronidazole 500mg 12/12h for 7 days
88841139|NCT05449028|Experimental|H. pylori eradication scheme E|Esomeprazole 40mg bid + amoxicillin 1g 12/12h for 7 days, followed by esomeprazole 40mg bid + amoxicillin 1g 12/12h + clarithromycin 500mg 12/12h + metronidazole 500mg 12/12h for 7 days
88841140|NCT04543825|Experimental|CPET|Patients with cirrhosis who have been wait listed for liver transplant or are undergoing liver transplant evaluation and will undergo cardiopulmonary exercise testing (CPET).
88841141|NCT04338841|No Intervention|Phase1: Before HOME-CoV rule implementation|"Observational assessment of current practices: no recommendation is performed.~Patients consulting Emergency Departments with suspected or probable COVID-19 are evaluated for potential inclusion.~Clinical, biological and imaging data that may be involved in decision-making about hospitalization are collected as well as the physician final decision (hospitalization or outpatient management) and its main determinants.~A phone-call follow-up is performed and the clinical status according to the Ordinal Scale for Clinical Improvement of COVID-19 from the World Heath Organization is collected on day 7 and day 28 following inclusion."
88841142|NCT04338841|Experimental|Phase 2: After HOME-CoV rule implementation|"Observational assessment of practices after implementation of the rule: physicians are recommended to apply the HOME-CoV rule but still free to use other determinants in their decision.~Patients consulting Emergency Departments with suspected or probable COVID-19 are evaluated for potential inclusion. Clinical, biological and imaging data that may be involved in decision-making about hospitalization are collected as well as the physician final decision (hospitalization or outpatient management) and its main determinants.~A phone-call follow-up is performed and the clinical status according to the Ordinal Scale for Clinical Improvement of COVID-19 from the World Heath Organization is collected on day 7 and day 28 following inclusion."
88841143|NCT04538287|Active Comparator|AtaCor StealthTrac Lead Model AC-1010|Subjects inserted with the AtaCor StealthTrac Lead Model AC-1010. This was the first model evaluated in the study.
88841144|NCT04538287|Active Comparator|AtaCor StealthTrac Lead Model AC-1020|Subjects inserted with the AtaCor StealthTrac Lead Model AC-1020. This was the second model evaluated in the study.
89368576|NCT02445352|Experimental|DP-R207 5/10mg & Placebo & Placebo|Once a day, administration of DP-R207 5/10mg and two types of placebo for 20 weeks
88841145|NCT04538287|Active Comparator|AtaCor StealthTrac Lead Model AC-1021|Subjects inserted with the AtaCor StealthTrac Lead Model AC-1021. This was the third model evaluated in the study.
88841146|NCT04538287|Active Comparator|AtaCor StealthTrac Lead Model AC-1012|Subjects inserted with the AtaCor StealthTrac Lead Model AC-1012. This is the fourth model currently being evaluated in the study.
88841147|NCT04338464|Experimental|Treatment Group|
88841148|NCT05448794|Experimental|evaluation prolotherapy for frozen shoulder|This pilot study highlighted that prospective studies are required to prove its clinical application for FS and other conditions.
88841149|NCT05446922|Other|MRI imaging of 10 healthy volunteers|10 healthy volunteers will proceed at an brain MRI imaging
88841150|NCT04845139|Experimental|Nivolumab administration|Nivolumab administration Q2W by intraventricular injection through Ommaya reservoir
89368577|NCT02445352|Active Comparator|Rosuvastatin 10mg & Placebo & Placebo|Once a day, administration of rosuvastatin 10mg and two types of placebo for 20 weeks
89368578|NCT02445352|Experimental|DP-R207 10/10mg & Placebo & Placebo|Once a day, administration of DP-R207 10/10mg and two types of placebo for 20 weeks
89368579|NCT02445352|Active Comparator|Rosuvastatin 20mg & Placebo & Placebo|Once a day, administration of rosuvastatin 20mg and two types of placebo for 20 weeks
89368580|NCT02445352|Experimental|DP-R207 20/10mg & Placebo & Placebo|Once a day, administration of DP-R207 20/10mg and two types of placebo for 20 weeks
89368581|NCT03693989|Experimental|PRO-145.|Difluprednate 0.05%. Prepared by Sophia Laboratories, S.A. of C.V., Zapopan, Jalisco, Mexico.
89368582|NCT03693989|Active Comparator|Prednefrin|Prednefrin® SF. Prednisolone Acetate 1%. Prepared by Allergan, S.A. of C.V.
89368583|NCT02786186||Secikinumab|Patients treated with secukinumab
89368584|NCT02786186||Approved standard of care|Patients treated with other indicated therapies (systemic, phototherapy, or biologic therapy)
89368585|NCT02445274|Experimental|Capsule-reserved surgical procedure|"In this group, the anterior lens capsule was reserved after continuous curvilinear capsulorhexis. The reserved anterior capsule was pressed flattened by the optical surface of the IOL and attached onto the posterior lens capsule.~Phacoemulsification was performed with the same device and handpieces, using the same phaco chop technique as in the conventional procedure group."
89368586|NCT02445274|No Intervention|Conventional surgical procedure|In this group, the anterior lens capsule was not reserved or attached onto the posterior lens capsule.
89368587|NCT03746561||spinal stenosis|Spinal stenosis is a narrowing of the spaces within your spine, which can put pressure on the nerves that travel through the spine. Spinal stenosis occurs most often in the lower back and the neck.
89002033|NCT06116877|Active Comparator|Group (I) non modified|Five patients will receive mandibular 2-implant retained overdentures of non-modified printable acrylic resin base material.
89179486|NCT02599311|No Intervention|the quality of life|transvaginal synthetic mesh
88841151|NCT05446844|Experimental|A protocol group|A protocol group received a nurse caring behavior protocol by the researcher
89179487|NCT02599311|Other|the rate of the LUTS|We use Tolterodine to improve patients' LUTS
89368588|NCT02445118||Adipose Allograft Matrix Injection|AAM injected to create a 2 to 3mm raised wheal on the proximal dorsal wrist of the non-dominant hand
89368589|NCT03159572||Ovarian cancer group|Patients who are diagnosed with ovarian cancer and have a plan of surgery.
89368590|NCT05234242||stationary/inpatient|
89368591|NCT05234242||ambulatory/outpatient|
89368592|NCT04206293|Experimental|Juvéderm® VOLITE|Participants received Juvéderm® VOLITE, intradermal injection on a zone of 8 centimeter (cm) x 4 cm (32 cm^2) of the volar left forearm on Day 0. The dose to be injected was decided by the investigator as per the Directions for Use. A maximum of 1 milliliter (mL) was injected on the zone treated.
89368593|NCT04939532|Active Comparator|Text-Messaging (TM)|Population health management intervention that analyzes electronic health record data to automatically identify participants with high risk for either infection or severe disease and proactivity reaches those participants via text message for testing needs (as advised by state and/or federal guidelines) and testing recommendation when applicable. This is a bi-directional text messaging system.
89534748|NCT03328169|Active Comparator|CBT-I|Cognitive Behavioral Therapy for Insomnia
89534749|NCT03328169|Experimental|Mindfulness|Mindfulness-Based Therapy
89534750|NCT03333629|Experimental|Enhanced early detection|Providers will receive training to administer enhanced early detection strategies.
88841152|NCT05446844|Active Comparator|A control group|A control group received routine nursing care by the staff nurse
88841153|NCT04738669|No Intervention|Control Arm|No intervention is being conducted in this arm. Routine care is being given to these patients. The patients will be followed up for any readmissions during the intervention period.
88841154|NCT04738669|Experimental|mHealth Arm|"This arm will receive first receive weekly telephone call followed by the SMS in Urdu regarding medication adherence according to the discharge instructions.~The calls and SMS will be sent on 7, 14, 21 and 30th day post-index discharge. The patients will be followed up for any readmissions during the intervention period."
88875213|NCT02526654|Experimental|Healthy Controls|Subjects that do not have glaucoma and are recruited for testing will perform visual field with Heidelberg Edge Perimeter and Octopus visual field. Optical Coherence Tomography will image the retinal nerve fiber layer.
88875214|NCT02527512|Active Comparator|Povidone-Iodine|"0.35% povidone-iodine (Betadine)"
88875215|NCT02527512|Active Comparator|Normal Saline|Sterile sodium chloride (NaCl) solution
88875216|NCT02528370|Experimental|telEPOC|The program consisted of: 1) Educational program about COPD. This educational program was carried-out by a respiratory nurse in two 30-minute speeches to the patient and career, once at their inclusion in the program and again 1 year later. 2) Training in using the device (smart phone) that supported the telemonitoring. 3) Daily phone calls to make self-confident the patient during the first week. Afterwards the phone calls were established according to the capacity of the patient to manage on their own.
88875217|NCT02528370|No Intervention|No telEPOC / Usual Care|"The control group follows the usual care protocol in our health system. That includes periodic control by their primary and respiratory specialist. They receive non-structured information/education about COPD and follow a programmed control agenda depending on the severity of the disease every 4-6 months.~Generally speaking the differences between the two cohorts were the educational structured program and the telemonitoring control."
88875218|NCT02529072|Experimental|Group I|Patients will receive nivolumab 3 mg/kg IV every 2 weeks for 8 weeks followed by surgery. Following resection, nivolumab and DC vaccine will be administered every 2 weeks (± 1) for a total of 3 vaccines, followed by biweekly treatment with nivolumab and monthly DC vaccinations for a total of 5 more vaccines. Patients will continue to receive nivolumab every 2 weeks until progression.
88875219|NCT02529072|Experimental|Group II|Patients will initially receive the fourth cycle of nivolumab then receive nivolumab 3 mg/kg IV and DC vaccine every 2 weeks for a total of 3 vaccines, and then surgery. Subsequent to surgery, the patient will resume biweekly treatment with nivolumab and monthly DC vaccinations for a total of 5 more vaccines. Patients will continue to receive nivolumab every 2 weeks until progression.
88875220|NCT02530476|Experimental|Phase I Group 1 Selinexor + Sorafenib|"Cohort includes those with FLT3-ITD and -D835 mutated participants with relapsed/refractory AML, including participants who may have been previously exposed to one or more FLT3-inhibitors.~Phase I Starting Dose of Sorafenib: 400 mg by mouth twice daily for a 28 day cycle.~Phase I Starting Dose of Selinexor: 80 mg by mouth twice weekly for a 28 day cycle."
88875221|NCT02530476|Experimental|Cohort 1 (FLT3-ITD inhibitor failure cohort)|"Cohort includes those with FLT3-ITD and -D835 mutated relapsed/refractory AML who have failed therapy with up to two prior salvage regimens.~Phase II Starting Dose of Sorafenib: Maximum tolerated dose combination from Phase I.~Phase II Starting Dose of Selinexor: Maximum tolerated dose from Phase I."
88875222|NCT02530476|Experimental|Cohort 2 (FLT3-ITD inhibitor naive cohort)|"Cohort includes those with FLT3-ITD and -D835 mutated relapsed/refractory AML who have failed therapy with up to two prior salvage regimens.~Phase II Starting Dose of Sorafenib: Maximum tolerated dose combination from Phase I.~Phase II Starting Dose of Selinexor: Maximum tolerated dose from Phase I."
88875223|NCT02530476|Experimental|Phase I Group 2 Selinexor + Sorafenib|"Cohort includes those with FLT3-ITD and -D835 mutated participants with relapsed/refractory AML, including participants who may have been previously exposed to one or more FLT3-inhibitors.~Phase I Starting Dose of Sorafenib: 400 mg by mouth twice daily for a 28 day cycle.~Phase I Starting Dose of Selinexor: 80 mg by mouth twice weekly for a 28 day cycle. Phase I Group 2 received Selinexor 80 mg by mouth twice weekly for a 28 day cycle."
88875224|NCT02530554|Experimental|CHG Cloth|3 min application time
88875225|NCT02530554|Active Comparator|Comparator CHG|Marketed 2% CHG
88875226|NCT02531022|Active Comparator|Control|Participants will be given standard exercise recommendations that are given to all patients based on the federal guidelines. They will monitor their step counts using a wearable device and receive daily feedback.
88841155|NCT04738669|Experimental|Teach back arm|"The trained doctors thoroughly explained the discharge instructions, medication schedule and any other self-care instructions to these participants and asked them to repeat what they have understood from the doctor verbal counselling.~If the instructions were not clearly comprehended by the patients, then the same would be repeated by the consultant doctor.~The patients will be followed up for any readmissions during the intervention period."
88841156|NCT05446688|Experimental|6MW3211|6MW3211 injection, 45mg/kg, Q2W
88841157|NCT04563806|Experimental|Device feasibility (MRI-guided surgery)|Patients undergo standard of care spine surgery with MRI-based image guidance.
88841158|NCT04738526|Active Comparator|natural tooth|
88841159|NCT04738526|Experimental|lithium disilicate (IPS e-max) ceramic crown|monolithic lithium disilicate (IPS e-max) ceramic crown for crowns in esthetic zone
88841160|NCT04738526|Experimental|New gradient technology zirconia (5Y-TZP\ 3Y-TZP) IPS e.max ZirCad Prime ceramic crown|
88841161|NCT05449483|Experimental|tislelizumab+ Paclitaxel+Cisplatin|Paclitaxel 135mg/m2 , D1; Cisplatin 80mg/m2, D1; tislelizumab 200mg D2 ; totally 2-4 cycles
88841162|NCT05448482|Experimental|Hybrid transobturator tape|"Anterior rectus fascia will be exposed and an approximately 8-10 cm × 1 cm strip of rectus fascia will be marked out. The sling will be harvested using sharp dissection. Thereafter, a Polyprolene monofilamentous mesh of 15 cm x 1 cm will be sutured to each edge of the rectus fascia sling that had been harvested.~Then, a 2-cm midline incision over the anterior vaginal wall at the level of mid-urethra. A combination of blunt and sharp dissection will be carried out to the obturator foramen bilaterally.~Next, a stab incision will be made at a point approximately 2.5 cm infero-lateral to the pubic tubercle bilaterally, corresponding to the level of clitoris. A trocar will be passed through each obturator foramen (outside-in) and the edge of the mesh will be retracted through the incision. Next, the retraction of both meshes will continue until the rectus fascia sling remain flushed with the urethra."
88841163|NCT05448482|Active Comparator|Conventional transobturator tape|The conventional mesh using mid urethral sling through the trans obturator route
88841164|NCT05448404|Experimental|18F-PSMA-1007 and 18F-FDG PET/CT scan|Patients of multiple myeloma PET/CT imaging: Within one week each patient underwent a PET/CT scan 60-min after intravenous administration of 18F-PSMA-1007 and 18F-FDG, respectively.
88841165|NCT05449093||Stage 3 Grade C Periodontitis|Generalized stage 3 periodontitis patients had interproximal clinical attachment loss ≥ 5 mm at 30 % of the teeth or more. Care was taken to ensure that clinical attachment loss was caused by periodontal causes. These patients had also radiographic bone loss extending to the mid-third of the root or beyond and probing depth ≥ 6 mm at 30 % of the teeth or more as well as Class II-III furcation involvement. The grade of periodontitis was estimated with indirect evidence of progression through % of bone loss/age. Radiographic bone loss of each natural tooth was assessed by using the panoramic radiograph. The tooth showing the most extensive bone loss was determined and % of bone loss/age were calculated. If this value was higher than 1.0, the patients were assigned to grade C.
88841166|NCT05449093||Stage 3 Grade B Periodontitis|Generalized stage 3 periodontitis patients had interproximal clinical attachment loss ≥ 5 mm at 30 % of the teeth or more. Care was taken to ensure that CAL was caused by periodontal causes.These patients had also radiographic bone loss extending to the mid-third of the root or beyond and probing depth ≥ 6 mm at 30 % of the teeth or more as well as Class II-III furcation involvement. The grade of periodontitis was estimated with indirect evidence of progression through % of bone loss/age. Radiographic bone loss of each natural tooth was assessed by using the panoramic radiograph. The tooth showing the most extensive bone loss was determined and % of bone loss/age were calculated. When this value was between 0.25 and 1.0, patients were included in grade B.
88841167|NCT05449093||Gingivitis|Gingivitis patients showed probing depth ≤ 3 mm with bleeding on probing ≥ 30 % in the entire mouth as well as no interproximal clinical attachment loss or radiographic bone loss.
88841168|NCT05449093||Periodontal Health|Periodontally healthy individuals in the control group had an intact periodontium or a reduced periodontium (without detectable interproximal clinical attachment loss or radiographic bone loss) in a non-periodontitis patient. In this group, probing depth was ≤ 3 mm and bleeding on probing was < 10 % in the whole mouth.
88841169|NCT04338308||SVG PCI|
88841170|NCT04438759|Experimental|investigational group|Virtual Reality
89179488|NCT00591773|Experimental|Azilsartan Medoxomil 40 mg QD and Chlorthalidone 25 mg QD|
89179489|NCT00591773|Experimental|Azilsartan Medoxomil 80 mg QD and Chlorthalidone 25 mg QD|
89179490|NCT00591773|Active Comparator|Chlorthalidone 25 mg QD|
89179491|NCT04091919||ASD group|Isolated ostium Secundum ASD patients who are involving in this study have been already selected for intervention before the starting time of the study. The ASD patients who will be scheduled for transcatheter closure have either haemodynamically significant shunt fraction (Qp/Qs > 1.5) or echocardiographic signs of right heart dilation or RV volume overload and pulmonary hypertension related symptoms. 2-D TTE derived Tissue Doppler and Strain Imaging will be done for all patients at baseline, 24 hours and 1-3 month post-procedure. Correlation between the device size and echocardiographic variables will be performed. Comparison between the results of the 2D-TTE derived Strain Imaging procedures will be done between baseline data and those obtained one day after the procedure and at one month follow up.
89368594|NCT04939532|Active Comparator|Text-Messaging plus Patient Navigation (TM+PN)|Population health management intervention that includes the same bi-directional text-messaging system as Arm 1 (the text messaging condition) with the addition of patient navigation. Patient navigation includes real-time assistance from a community health worker to address barriers, provide motivation, and assist with logistics of COIVD testing.
89368595|NCT03197740|Active Comparator|aricept Tab 5mg|
88841171|NCT04438759|No Intervention|reference group|standard of care
89179492|NCT04091919||Controlled group|Age matched controlled subjects without ASD
89179493|NCT04091997||endometriosis|laparoscopy and directed biopsy of lesions serum macrophage migration inhibitory factor ELIZA assay
89179494|NCT04091997||control|diagnostic laparoscopy serum macrophage migration inhibitory factor ELIZA assay
88841172|NCT04793659|Experimental|Oral Fasudil 90 mg/day|Subjects will receive a daily dose of 90 mg Fasudil for 42 days (open-label period 1). After Period 1 is complete, if the subject is a responder to Fasudil 90 mg/day, they will be randomized to either Fasudil 90 mg/day or a placebo for 6 weeks (double-blind period 1), then crossover to the other arm for 6 weeks (double-blind period 2).
88841173|NCT04793659|Experimental|Oral Fasudil 180 mg/day|If the subject is a not a responder in the open-label period 1 but tolerated Fasudil 90 mg/day, they will be escalated to Fasudil 180 mg/day (open-label period 2) for 42 days. If the subject is a responder to Fasudil 180 mg/day, they are randomized to either Fasudil 180 mg/day for 42 days or a placebo (double-blind period 1), then crossover to the other arm for 6 weeks (double-blind period 2).
88841174|NCT04793659|Placebo Comparator|Oral Placebo|Placebo comparator arm to investigational drug (Fasudil 90 mg/day or 180 mg/day).
89179495|NCT00750867|Experimental|1|Interventions included monthly infusions of intravenous immunoglobulin.
89179496|NCT04091841|Experimental|protein supplement|Intervention patients will be received protein diet (1.2 g/kg/day) and protein supplement (36 g/day) for 1 month after surgery.
89179497|NCT04091841|Placebo Comparator|Carbo Mass|Control patients will be received protein diet (1.2 g/kg/day) and Carbo Mass for 1 month after surgery.
89179498|NCT00744042|Other|asfotase alfa|asfotase alfa
89179499|NCT04091763|Experimental|Polidocanol foam sclerotherapy|"Preparation of the polidocanol foam according to Tessari technique immediately before application (so that the microbubbles of the foam did not disintegrate);~Application according to the Blanchard technique (Fig. 2) through a disposable transparent anoscope, with the patient in jackknife position, using a 20mL disposable syringe of the mixture (polidocanol + air) and a reusable 10 cm syringe extender adapted to an intravenous needle;~Patients treated in a maximum of 3 sessions at 3 weeks intervals;~Maximum dose per treatment session of 20mL of mixture of 4mL of polidocanol 3% with 16mL of air;~In each session more than one hemorrhoid cushion could be treated."
89179500|NCT04091763|Experimental|Rubber band ligation|"Use of reusable metal ligation device connected to a vacuum system (McGown suction method) to apply the rubber bands above the dentated line through a disposable transparent anoscope with the patient in jackknife position;~A maximum of 3 sessions of ligation at 3-week intervals were performed;~More than 1 band per session could be applied."
89179501|NCT00829829|Placebo Comparator|Placebo|Two subcutaneous injections of Placebo (for Rilonacept) as a loading dose on Day 1 followed by a single injection once a week (qw) from Week 1 to Week 15.
89179502|NCT00829829|Active Comparator|Rilonacept 80 mg|Two subcutaneous injections of Rilonacept 80 mg (for a total of 160 mg) as a loading dose on Day 1, followed by a single 80 mg injection of Rilonacept qw from Week 1 to Week 15.
89179503|NCT00829829|Active Comparator|Rilonacept 160 mg|Two subcutaneous injections of Rilonacept 160 mg (for a total of 320 mg) as a loading dose on Day 1, followed by a single 160 mg injection of Rilonacept qw from Week 1 to Week 15.
89179504|NCT04092036||Unstable patients|Patients on mechanical ventilation, 18 years or older and developing hypotension (Mean arterial blood pressure) <65 mmHg
89179505|NCT04091529|Experimental|Radiofrequency myolysis of uterine fibroids|54 premenopausal participants with symptomatic uterine myomas
89179506|NCT02599155|Placebo Comparator|Crystalloid group|Crystalloid group receive only crystalloid for intravenous volume expansion. The same transfusion protocol is applied in both groups.
89368596|NCT03197740|Experimental|donepezil patch 25cm2|
89368597|NCT03197740|Active Comparator|aricept Tab 10mg|
89368598|NCT03197740|Experimental|donepezil patch 50cm2|
89368599|NCT03197428|Experimental|PRP group|15 patients will receive platelet-rich plasma gel applied during the modified Broström-Gould procedure for reconstructing lateral ligament.
89368600|NCT03197428|Placebo Comparator|Control group|15 patients will receive whole blood applied during the modified Broström-Gould procedure for reconstructing lateral ligament.
88841175|NCT05448937|Experimental|3 MIX|Lesion sterilization and tissue repair; preparation of modified triple antibiotic paste tap: the chemotherapeutic agents used are metronidazole tablets 500 mg (flagyl®, sanofi, egypt), ciprofloxacin tablets 500 mg (ciproxcin®,. Epico, egypt,), and doxycycline capsules 100 mg (doxymycin™ dt, el-nile pharmaceuticals, egypt).
88841176|NCT05448937|Active Comparator|Zinc oxide and Eugenol Pulpectomy|zinc oxide and eugenol (prevestdent pro™, egypt).
89179507|NCT02599155|Active Comparator|Colloid group|Colloid group receive colloid preferentially for intravenous volume expansion, until 30 ml/kg. The same transfusion protocol is applied in both groups.
89368601|NCT04050878|Experimental|Patient with or without dental prostheses|The patient will be submitted to two facial scans, one with and another without the dental prostheses and the obtained datasets will be compared to assess the differences. Marks will be made in the face to allow for measurements (digital and conventional)
89179508|NCT00823199|Experimental|Allopurinal treatment|Allopurinal 300mg once daily by mouth for four weeks
89179509|NCT04091373|Experimental|Sequence 1|100ug SC injection cotadutide in the upper arm on Day 1, in the lower abdomen on Day 8, and in the thigh on Day 15
89179510|NCT04091373|Experimental|Sequence 2|100ug SC injection cotadutide in the thigh on Day 1, in the upper arm on Day 8, and in the lower abdomen on Day 15
89179511|NCT04091373|Experimental|Sequence 3|100ug SC injection cotadutide in the lower abdomen on Day 1, in the thigh on Day 8, and in the upper arm on Day 15
89179512|NCT04091373|Experimental|Sequence 4|100ug SC injection cotadutide in the thigh on Day 1, in the lower abdomen on Day 8, and in the upper arm on Day 15
89179513|NCT04091373|Experimental|Sequence 5|100ug SC injection cotadutide in the lower abdomen on Day 1, in the upper arm on Day 8, and in the thigh on Day 15
89179514|NCT04091373|Experimental|Sequence 6|100ug SC injection cotadutide in the upper arm on Day 1, in the thigh on Day 8, and in the lower abdomen on Day 15
89179515|NCT02611583|Active Comparator|Ibuprofen and TENS plus|Patients will receive 45 minutes of TENS therapy. All patients will receive ibuprofen.
89179516|NCT02611583|Placebo Comparator|Ibuprofen and Sham TENS plus|Patients will receive 45 minutes of sham TENS therapy. All patients will receive ibuprofen.
89179517|NCT00829439|Experimental|Levodopa/Carbidopa|"Other Names:~Sinemet L-dopa~Dosages are based on levodopa.~Each cohort of 3 subjects will be placed on an increasing dose of levodopa (2, 5, 10, and 15 mg/kg/day) for 1 week, provided subjects in the preceding cohort tolerated the lower dose.~Levodopa/Carbidopa is a combined formulation that will be dispensed as capsules. It should be taken 3 times a day."
89179518|NCT00749775||Eplerenone|Subjects who are treated with Eplerenone tablet for hypertension disease
89179519|NCT00705965|Experimental|1|Stepwise, manualized individual and group psychotherapy in addition to usual cardiological care.
89179520|NCT00705965|Active Comparator|2|Usual cardiological care including one information session.
89179521|NCT00917007||ABO compatible|
89179522|NCT00917007||ABO incompatible, antiglobulin positive|
89179523|NCT00917007||ABO incompatible, antiglobulin negative|
89179524|NCT05758103|Experimental|Mechanical debridement + probiotic supplement|Patients with peri-implant mucositis treated through non-surgical professional mechanical debridement and probiotic supplement Limosilactobacillus reuteri Prodentis® (combining L. reuteri DSM 17938 and L. reuteri ATCC PTA 5289 strains).
89179525|NCT05758103|No Intervention|Mechanical debridement|Patients with peri-implant mucositis treated through non-surgical professional mechanical debridement alone
89179526|NCT02599077|Experimental|Dienogest|the patient handling with 2 mg dienogest / day.
89179527|NCT02599077|Active Comparator|Levonorgestrel + ethinylestradiol|The patient handling with levonorgestrel + ethinylestradiol (0,10 mg - 0,02 )
89179528|NCT00829283|Active Comparator|1|Standard Care
89179529|NCT00829283|Experimental|2|Stepped-care
89179530|NCT04091139|Experimental|Unified protocol for adolescents (UP-A)|"The Unified Protocol (UP) is an emotion-focused, cognitive-behavioural intervention that is developed to target core temperamental characteristics underlying anxiety and depressive disorders. The goal of the UP is to help patients to cultivate a greater willingness to experience uncomfortable emotions and to reduce maladaptive emotion response tendencies, so as to lessen the intensity and frequency of uncomfortable emotions. Ehrenreich and colleagues modified from the original UP and developed the UP for adolescents (UP-A).~A Chinese treatment protocol would be developed based on the UP-A. Contents of the treatment includes motivational enhancement, psychoeducation of emotion, avoidance and emotion driven behaviours, interoceptive exposure, cognitive reappraisal, emotion awareness training and emotion exposure. It consists of 10 to 12 individual sessions for the adolescents, and 4 to 6 sessions for parents or guardians."
89534751|NCT03333629|No Intervention|Usual care|Providers will not change their early detection strategies, but will be monitored.
89534752|NCT05026359|Experimental|Bilateral ankle coordination training group|Exercise training of bilateral ankle coordination training group consisted of 30 minutes of bilateral ankle coordination training 3 days per week for 4 weeks (total 12 sessions)
89534753|NCT05026359|No Intervention|General rehabilitation intervention group|Exercise training of walking and balance training consisted of 30 minutes of general rehabilitation intervention group 3 days per week for 4 weeks (total 12 sessions)
88841177|NCT00370279|Active Comparator|1|scleral buckling
88841178|NCT00370279|Active Comparator|2|Primary vitrectomy without encircling band
88841179|NCT00370279|Active Comparator|3|Primary vitrectomy with encircling band
88841180|NCT00370279|Active Comparator|4|Triamcinolone assisted vitrectomy
88841181|NCT05448859||3-4 hours denudation|oocytes with 3-4 hours denudation time
88841182|NCT05448859||4-5 hours denudation|oocytes with 4-5 hours denudation time
88841183|NCT05448859||5-6 hours denudation time|oocytes with 5-6 hours denudation time
88841184|NCT05448859||6-7 hours denudation time|oocytes with 6-7 hours denudation time
88841185|NCT05448859||more than 7 hours denudation time|oocytes with more than 7 hours denudation time
88841186|NCT03203954|Active Comparator|No Training|Guided learning, standard learning: Repeat administration of standard behavioral learning task
88841187|NCT03203954|Experimental|Instructed Statistics|Guided learning, instructed statistics: Repeat administration of behavioral learning task with instructions about task statistics
88841188|NCT03203954|Experimental|Not Instructed Statistics|Guided learning, changing statistics: Repeat administration of behavioral learning task with changing task statistics
88841189|NCT05448781|Experimental|endostatin combined with PD-1 antibody and platinum-containing two-drug chemotherapy|"Recombinant human vascular endostatin (Endu): 210 mg (14 PCS), administered by continuous intravenous pumping for 72h every three weeks on the first day of each cycle.Pemetrexed: 500mg/m2, administered intravenously every three weeks on the first day of each cycle.Paclitaxel:175mg/ m2, administered intravenously every three weeks on the first day of each cycle.Albumin paclitaxel:260mg/ m2, administered intravenously every three weeks on the first day of each cycle.~Carboplatin:5/AUC, maximum dose limited to 600mg, or 75 mg/m2 cisplatin, is administered intravenously every three weeks on the first day of each cycle Tirelizumab: a recommended dose of 200mg/ time, administered every three weeks on the first day of each cycle until disease progression or unacceptable toxicity is developed."
88841190|NCT05448079|Experimental|Sexual counseling intervention group according to the PLISSIT model|Sexual counseling according to the PLISSIT model, randomized pretest-posttest
88841191|NCT05448079|Experimental|control|Non-counseling group
89179531|NCT04091139|Active Comparator|Treatment as usual (TAU)|TAU participants will receive usual clinical psychological service provided in the clinic (i.e. treatment as usual) in the first 12 weeks, before they start receiving same individual treatment program based on UP-A.
89179532|NCT05758025|Experimental|"Resection based on thymus-vascular-inferior parathyroid complex"|
88841192|NCT03219697|Experimental|Parenting education program|"8 weeks of group parenting education sessions followed by two optional booster sessions.~2 public health nurse home/virtual visits and 4 coaching calls over a period of 6 months."
88841193|NCT03219697|No Intervention|Control|Receive regular health care
89179533|NCT05758025|No Intervention|Traditional thyroidectomy method|
89179534|NCT00706199||Group A|donors
89179535|NCT02610803||Patients with ischemic stroke|Patients admitted with ischemic stroke from August 2008 to April 2011 (Retrospectively defined).
89179536|NCT00708929|Other|1|14 subjects homozygous HH for the Tyr402His single nucleotide polymorphism
89179537|NCT00708929|Other|2|14 subjects homozygous TT for the Tyr402His single nucleotide polymorphism
89179538|NCT00821873|Experimental|CR Plug BackFill|Evaluation of the CR Plug for Repair of Defects Created at the Harvest Site
89179539|NCT00706277|Active Comparator|TIVA|patients receiving total intravenous anesthesia (TIVA)
89179540|NCT00706277|Active Comparator|balanced|patients receiving balanced anesthesia
89179541|NCT00749463|Experimental|Gum 2|Nicotine Gum 2 mg for subjects smoking less than 20 cigarettes per day; 2 mg for 12 week treatments and followed by 12 week off-treatment follow-up. Recommend subject to use 8-12 pieces daily for first 8 weeks and 4-6 pieces daily the next 2 weeks, then reduce to 1-3 pieces each day in last 2 weeks
89179542|NCT00749463|Experimental|Gum 4|Nicotine Gum 4 mg for subjects smoking 20 or more cigarettes per day; 4 mg for 12 week treatments and followed by 12 week off-treatment follow-up. Recommend subject to use 8-12 pieces daily for first 8 weeks and 4-6 pieces daily the next 2 weeks, then reduce to 1-3 pieces each day in last 2 weeks
89179543|NCT00749463|Experimental|Patch|Nicotine Patch; Each will use 15 mg/16 h patch for the first 8 weeks, 10 mg/16 h for the following 2 weeks and 5 mg/16 h for the last 2 weeks. Then followed by 12 week off-treatment follow-up.
89179544|NCT00821327|Experimental|Study Arm|Gemcitabine, Cisplatin, Sunitinib
89179545|NCT05412459||The tested injected doses of 99mTc-DARPinG3 3000 μg (SPECT)|"Maximum (15) evaluable subjects with HER2-positive status in primary tumour before, after 2 and 4 courses of chemo+targeted therapy have to be enrolled in the study.~Subjects withdrawn from the study for any reason will be replaced."
89368602|NCT02450266|Active Comparator|A: Transrectal ultrasound-guided biopsy|Patients of arm A receive a systematic transrectal ultrasound-guided prostate biopsy (12-18 biopsy cores depending on individual prostate volume)
89179546|NCT05412069|Experimental|Fecobionics study|Fecobionics
89179547|NCT00706667|Placebo Comparator|1|Placebo for EPO and for Ferinject ®
89179548|NCT00706667|Active Comparator|2|Only Ferinject ® , Placebo for EPO
89179549|NCT00706667|Active Comparator|3|Ferinject ® + EPO
89179550|NCT04090437|Active Comparator|Group1 - PVI first step|"Catheter ablation procedure:~Dipole map of RA and LA at baseline (5 times for both, each for 20sec, +/- Adenosine IV)~PVI as first step~Remap to assess any change in activation~Ablate all rotors (API) in LA until SR or DCCV~Deployment of RA CTI line and demonstration of bidirectional block"
89368603|NCT02450266|Experimental|B: MRI/ultrasound fusion-guided biopsy|Patients of arm B receive a targeted MRI/ultrasound fusion-guided prostate biopsy. From each prostate lesion defined in the diagnostic multiparametric MRI two targeted biopsy cores will be taken.
89179551|NCT04090437|Active Comparator|Group2 - PVI last step|"Catheter ablation procedure:~Dipole map of RA and LA at baseline (5 times for both, each for 20sec, +/- Adenosine IV)~Ablate all rotors (API) in LA until SR or DCCV~Remap to assess any change in activation~PVI as last step even when SR achieved earlier~Deployment of RA CTI line and demonstration of bidirectional block"
89179552|NCT04090593|Experimental|Educational Module Intervention|Intervention arm patients receive educational mobile module related to chronic condition that contributed to reason for admission.
89368604|NCT03197116|Active Comparator|Telephone reminder|Interactive telephone reminder by a trained layperson with a standard script to remind return to the center for taking fecal tubes for CRC screening
89368605|NCT03197116|Placebo Comparator|No reminder|No additional reminder will be offered
89368606|NCT02444962|Experimental|HAVD implant|
88841194|NCT05442788|Experimental|HB0017 150mg|10 subjects is randomly assigned to receive HB0017 150mg or matching placebo at a ratio of 4:1.
88841195|NCT05442788|Experimental|HB0017 300mg|10 subjects is randomly assigned to receive HB0017 300mg or matching placebo at a ratio of 4:1.
88841196|NCT05442788|Experimental|HB0017 450mg|10 subjects is randomly assigned to receive HB0017 450mg or matching placebo at a ratio of 4:1.
89179553|NCT04090593|No Intervention|Hospital Practice Control|Control arm patients receive current, standard practice as related to patient education in the hospital (this does not include an educational mobile module).
89179554|NCT00917085|No Intervention|Control group|Control infants received the same standard care as infants who were not in the study. Infants were kept warm in incubators or warmer beds and were wrapped in blankets when held by their mothers. Hospital staff was responsible for providing standard care.
89179555|NCT00917085|Experimental|Skin-to-Skin group|
89179556|NCT00709007|Experimental|DAART|Participants are observed taking HIV medications by study staff on days when they receive opioid agonist therapy (sub-lingual buprenorphine) at the clinic.
89179557|NCT00709007|Active Comparator|SAT|Participants take their HIV medications on their own but visit the clinic for opioid agonist substitution therapy.
89179558|NCT00821093|Experimental|Indacaterol 150 µg|Patients inhaled indacaterol 150 μg once daily in the morning between 8:00 and 11:00 AM via a single-dose dry-powder inhaler (SDDPI) for 12 weeks. Patients also inhaled placebo to salmeterol twice daily, once in the morning between 8:00 and 11:00 AM and once in the evening between 8:00 and 11:00 PM via the manufacturer's proprietary multi-dose dry-powder inhaler (MDDPI, [DISKUS]) for 12 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
89368607|NCT04200989|Experimental|Treatment|Peanut ILIT
89368608|NCT02450110|Experimental|Intervention|Spinal cord stimulation on top of standard treatment
89179559|NCT00821093|Active Comparator|Salmeterol 50 µg|Patients inhaled salmeterol 50 μg twice daily, once in the morning between 8:00 and 11:00 AM and once in the evening between 8:00 and 11:00 PM via the manufacturer's proprietary multi-dose dry-powder inhaler (MDDPI, [DISKUS]) for 12 weeks. Patients also inhaled placebo to indacaterol once daily in the morning between 8:00 and 11:00 AM via a single-dose dry-powder inhaler (SDDPI) for 12 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
89368609|NCT02450110|No Intervention|Control|Standard treatment
89368610|NCT03748355|Other|Pharmacogenetic Analysis|A pharmacogenetic analysis will be completed for each participant upon inclusion into the study
88841197|NCT03182101|Experimental|Exposure Therapy with fidelity checklist|Therapist and parent/child participants will complete an Exposure Guide after each session.
89179560|NCT00821015|Experimental|Experimental|All study subjects will undergo cryoablation. This is a non-randomized trial.
89179561|NCT00709085||1|HCC patients without liver cirrhosis
89179562|NCT00709085||2|HCC patients with liver cirrhosis
89179563|NCT00814463|Active Comparator|Post-operative SRS|All patients will undergo SRS with the planned target volume (PTV) defined as the resection cavity plus a 3-mm margin after surgical resection of a single brain metastasis. Dose will be prescribed to the maximum isodose line completely encompassing the PTV using the guidelines established in RTOG 9005. All patients will be evaluated for neurocognitive function via Mini-Mental State Examination (MMSE), Quality of Life (QOL) via FACT-Br, and for local recurrence via MRI every 3 months over the course of the study.
89179564|NCT00706745|Placebo Comparator|placebo|The control oil is based on the general fat consumption in a Western population and consists of an equal amount (4 gr) of fat. It is a blend of palm (80%) and soybean oil (20%). Two capsules will be taken in the morning and two in the evening.
89179565|NCT00706745|Active Comparator|oil rich in cis9, trans11 CLA|Subjects will receive daily 4 g of CLA oil (2.6 g cis9,trans11-CLA), 2 capsules to be taken in the morning and 2 in the evening.
89179566|NCT05229809|Experimental|Yiqi Wenyang Jiedu prescription Group|
89179567|NCT05229809|Placebo Comparator|Simulation agent of Yiqi Wenyang Jiedu prescription Group|
89179568|NCT00709163|Active Comparator|1|
89179569|NCT00709163|Placebo Comparator|2|
89179570|NCT00913445|Active Comparator|surgery, absorbable stitches|wound healing after absorbable and nonabsorbable stitches are compared
89179571|NCT00913445|Active Comparator|surgery, nonabsorbable stitches|
89179572|NCT02611505|Experimental|Cohort 1|Participants with moderate hepatic impairment will receive esketamine solution (containing 14 milligram [mg] of esketamine base per 100 microliter [mcl]) by intranasal route into each nostril using nasal spray pump at 0 hour (h) on Day 1.
89179573|NCT02611505|Experimental|Cohort 2|Participants with mild hepatic impairment will receive esketamine solution (containing 14 mg of esketamine base per 100 mcl) by intranasal route into each nostril using nasal spray pump at 0h on Day 1.
89179574|NCT02611505|Experimental|Cohort 3|Participants with normal hepatic function and no evidence of liver damage will receive esketamine solution (containing 14 mg of esketamine base per 100 mcl) by intranasal route into each nostril using nasal spray pump at 0h on Day 1.
89179575|NCT00743652|Experimental|Group1|Subjects 6 weeks to <10 months of age with 0 prior dose of Prevnar.
89179576|NCT00743652|Experimental|Group 2|Subjects <12 months of age with 1 prior dose of Prevnar.
89179577|NCT00743652|Experimental|Group 3|Subjects <12 months of age with 2 prior doses of Prevnar.
89179578|NCT00743652|Experimental|Group 4|Subjects ≥12 months to <2 years of age.
89179579|NCT00743652|Experimental|Group 5|Subjects ≥2 years to <5 years of age
89179580|NCT00748215|Experimental|Arm I: CASAD|Oral calcium aluminosilicate anti-diarrheal (CASAD) 4 times daily for 6 weeks in the absence of disease progression or unacceptable toxicity. Participants who develop grade 3 or 4 diarrhea may receive CASAD for an additional 6 weeks.
88841198|NCT05442164||Before-group|Patients undergoing major emergency surgery before a supportive network is established
89179581|NCT00748215|Placebo Comparator|Arm II: Placebo|Oral placebo 4 times daily for 6 weeks in the absence of disease progression or unacceptable toxicity. Participants who develop grade 3 or 4 diarrhea may then receive CASAD for 6 weeks.
89368611|NCT02444884|Experimental|Stratum A1|Establish MTD in patients with solid tumors MLN8237 orally, once daily on Days 1-7
89368612|NCT02444884|Experimental|Stratum A2|MTD determined in Stratum A1in patients with solid tumors MLN8237 orally, twice daily on Days 1-7
89002034|NCT06116877|Active Comparator|Group (II) modified|Five patients will receive mandibular 2-implant retained overdentures of modified printable acrylate resin base material with zirconium oxide nanoparticles.
89002035|NCT06116864|Experimental|Endocuff + GI Genius|Endocuff is a polyp-detecting colonoscope attachment device. GI Genius is and Computer-Aid Detection (CADe) system to detect polyps
89179582|NCT04089384|Other|Control Group|Will receive individualized dietary plan - alimentary reeducation and micropore containing a point made with a black gel pen that will be placed in the ear
89179583|NCT04089384|Active Comparator|Auriculotherapy Group|Will receive individualized diet plan - diet reeducation and auricular therapy method with strategic points for obesity
89179584|NCT04089384|Placebo Comparator|Placebo group|Will receive individualized diet plan - diet reeducation and sham points, points not indicative for the proposed treatment
89179585|NCT04089540|Experimental|Study group: New intubation method|In the new intubation method the respirator is connected to the tube prior to insertion into the mouth (oral intubation) or into the nose (nasopharyngeal intubation). Therefore an oxygen flow is already administered via the tube during the intubation process.
89179586|NCT04089540|Other|Control group: Conventional intubation|In the control group the respirator is connected to the tube and ventilation is started after the insertion of the tube into the trachea. Therefore there is no oxygen flow administered during the intubation process.
89179587|NCT02598843|Active Comparator|Standard treatment protocol|Cast immobilisation with 4 weeks in equinus cast (non-weight bearing) followed by 4 weeks in semi-equinus cast (non-weightbearing) and 2 weeks in neutral cast (full weightbearing). At this point, the cast is removed and patients mobilise fully weightbearing for a further 2 weeks out of cast, with internal shoe insert heel raise. Commence physiotherapy at 10 weeks, when cast removed.
89179588|NCT02598843|Experimental|Accelerated rehabilitation|4 weeks in Ossur rebound walking boot with 2 heel wedges (3cm), 2 weeks in Ossur rebound walking boot with 1 heel wedge (1.5cm) and 2 weeks in Ossur rebound walking boot with no heel wedges (neutral position). Fully weightbearing throughout. Commence physiotherapy at 8 weeks.
89179589|NCT04089228|Experimental|Kinesiotape Group and INIT|Kinesiotaping and Integrated Neuromuscular Inhibition Technique (KT + INIT )
89179590|NCT04089228|Active Comparator|INIT Group|Integrated Neuromuscular Inhibition Technique (INIT)
89179591|NCT00917163|Experimental|Supralimus(R) Sirolimus Eluting Stent|Supralimus® Coronary Stent System consisting of the MATRIX® Coronary Stent having Sirolimus eluting from Biodegradable Polymeric Matrix on a Stainless Steel Platform, Drug concentration 1.4 µg/mm2
89179592|NCT00917163|Active Comparator|Xience V™ Everolimus Eluting Stent|The XIENCE V™ Everolimus Eluting Coronary Stent System consisting of the MULTI-LINK VISION® Coronary Stent System coated with a formulation containing everolimus, the active ingredient, embedded in a non-erodible polymer., Drug Load: 100 µg/cm2
89179593|NCT04090086|Experimental|Treatment Sequence 1: Treatment ABC|Participants will receive Treatment A (JNJ-53718678 once daily for 7 days) in Treatment Period 1, followed by Treatment B (JNJ-64417184 once daily for 7 days) in Treatment Period 2, followed by Treatment C (JNJ-53718678 once daily + JNJ-64417184 once daily for 7 days) in Treatment Period 3. There will be a washout period of at least 7 days between the treatment periods.
89179594|NCT04090086|Experimental|Treatment Sequence 2: Treatment BCA|Participants will receive Treatment B in Treatment Period 1, followed by Treatment C in Treatment Period 2, followed by Treatment A in Treatment Period 3. There will be a washout period of at least 7 days between the treatment periods.
89179595|NCT04090086|Experimental|Treatment Sequence 3: Treatment CAB|Participants will receive Treatment C in Treatment Period 1, followed by Treatment A in Treatment Period 2, followed by Treatment B in Treatment Period 3. There will be a washout period of at least 7 days between the treatment periods.
89179596|NCT04090086|Experimental|Treatment Sequence 4: Treatment ACB|Participants will receive Treatment A in Treatment Period 1, followed by Treatment C in Treatment Period 2, followed by Treatment B in Treatment Period 3. There will be a washout period of at least 7 days between the treatment periods.
89179597|NCT04090086|Experimental|Treatment Sequence 5: Treatment BAC|Participants will receive Treatment B in Treatment Period 1, followed by Treatment A in Treatment Period 2, followed by Treatment C in Treatment Period 3. There will be a washout period of at least 7 days between the treatment periods.
89179598|NCT04090086|Experimental|Treatment Sequence 6: Treatment CBA|Participants will receive Treatment C in Treatment Period 1, followed by Treatment B in Treatment Period 2, followed by Treatment A in Treatment Period 3. There will be a washout period of at least 7 days between the treatment periods.
89179599|NCT00917787||Healthy, Non-asthmatic|
89179600|NCT00917787||Asthma|
89179601|NCT00749892|Experimental|Treatment (erlotinib hydrochloride)|Participants receive erlotinib hydrochloride PO QD for 3-5 weeks in the absence of disease progression or unacceptable toxicity. Within 24 hours of the last dose, participants undergo cystectomy.
89179602|NCT04088487|Experimental|Experimental group|Participants gain access to the internet intervention after the baseline measurement (pre-test).
89179603|NCT04088487|Other|Waitlist control group|Participants gain access to the internet intervention 8 weeks after the baseline measurement (pre-test).
89179604|NCT04091256|Experimental|Clinical trials with a single arm|: Participants will be treated with desensitizing toothpaste containing zinc-carbonate hydroxyapatite nanocrystals (Zn-CHA) for 8 weeks.
89179605|NCT02595645|Experimental|Polypectomy and NGS|All patients which underwent screening colonoscopy and fulfilling the inclusion criteria are eligible. Polyps were biopsied and underwent histopathological and genetic analyses
89179606|NCT02595333|Experimental|Group SF1|primary cesarean section+postoperative analgesia with sufentanil plus flurbiprofen axetil group
89179607|NCT02595333|Experimental|Group S1|primary cesarean section+postoperative analgesia with sufentanil group
89179608|NCT02595333|Experimental|Group SF2|repeated cesarean section+postoperative analgesia with sufentanil plus flurbiprofen axetil group
89179609|NCT02595333|Experimental|Group S2|repeated cesarean section+postoperative analgesia with sufentanil group
89179610|NCT00749580|Experimental|1: Boosted PI+RAL|Group 1 Raltegravir 400 mg PO b.i.d. + their current boosted PI regimen Subjects in this study are HIV-Infected Patients who are on a stable boosted PI regimen; in this group are assigned to switched from their NRTIs as a Backbone to Raltegravir
88841199|NCT05442164||After-group|Patients undergoing major emergency surgery after a supportive network is established
88841200|NCT03123835|Other|Treatment|Patients meeting inclusion criteria for possible surgical therapies for their current condition (IE Achelasia, Enlarged Gastric Pouch and/or Gastrogastric Fistula after primary weight loss surgery, etc) will be educated on the different therapy options including traditional laparoscopic surgery and/or Endoscopic Interventions including POEM (Percutaneous Oral Endoscopic Myomectomy for the treatment of Achelasia) or Endoscoscopic Pouch/GastroJejunostomy repair or closure of the Gastrogastric Fistula as examples.
88841201|NCT04458337||SARS-CoV-2 patients undergoing a surgical procedure|The investigators propose to conduct a prospective observational cohort study on all patients suspected or confirmed being infected to SARS-CoV-2, or recovered from SARS-CoV-2, undergoing a surgery.
88841202|NCT02958943|Experimental|Electronic Alert|Each provider in the alert group will receive an on-screen notification regarding the patient's increased risk of stroke in AF and the lack of an active order for anticoagulation.
89179611|NCT00749580|No Intervention|2: Boosted PI+NRTIs|Group 2 Continue the same regimen without change
89179612|NCT02595177|Experimental|Multifocal IOL|Cataract removal with topical anesthesia and phacoemulsification is performed. At the end, multifocal intraocular lens implantation in both eyes planning for emmetropia complete the intervention.
89179613|NCT02595177|Experimental|Monovision|Cataract removal with topical anesthesia and phacoemulsification is performed. At the end, a monofocal intraocular lens implantation planning for emmetropia in one eye (dominant) and a monofocal IOL planning for 1.50 D of myopia in the other eye (non-dominant) complete the intervention.
89179614|NCT02595177|Experimental|Hybrid Monovision|Cataract removal with topical anesthesia and phacoemulsification is performed. At the end, a monofocal intraocular lens implantation in the dominant eye and a multifocal IOL in the non-dominant eye complete the intervention.
89179615|NCT02595255||High risk|Conditioning therapy for bone marrow transplantation or pelvic irradiation. Fertility preservation is usually already proposed in this group of patients. No intervention.
89179616|NCT02595255||Moderate/low risk|"Pathologies treated with chemotherapy regimen with moderate or low risk of inducing ovarian function insufficiency: AML (Acute myeloide leukemia), osteosarcoma, Ewing sarcoma, neuroblastoma, non-Hodgkin lymphoma, Hodgkin lymphoma, soft tissue sarcoma, ALL (acute lymphoblastic hormone), Wilms tumour, retinoblastoma.~This is the study group we will compare with high risk and no risk patients. No intervention"
89179617|NCT02595255||No risk|"Patients with chronic benign diseases or malignancies who don't receive any chemotherapy or other gonadotoxic treatment.~No intervention"
89179618|NCT02595021|Experimental|Total or Subtotal Colectomy|all patients who underwent total colectomy(removal of the large intestine from ileum to the rectum. After it is removed, the end of the small intestine is sewn to the rectum) or subtotal colectomy(removal of transverse colon, descending colon, sigmoid colon to the rectum. After it is removed, the end of the ascending colon is sewn to the rectum)as part of optimal cytoreductive surgery
89179619|NCT02595021|Active Comparator|Other Bowel Resection|all patients who underwent partial intestinal resection as part of optimal cytoreductive surgery
89179620|NCT02595099|Experimental|Mindfulness training|8 week programme of Mindfulness training
89179621|NCT00747006|Experimental|TI Inhalation Powder (original protocol)|Under the original protocol, subjects with Type 1 and Type 2 diabetes will have TI Inhalation Powder administered prandially during dose optimization visits and meal challenge visits (with meals of varying carbohydrate contents). Subjects with Type 2 diabetes will also use TI Inhalation Powder daily at each meal between visits.
89179622|NCT00747006|Other|TI Inhalation Powder and Humalog (Amendment 1)|Under Amendment 1, TI Inhalation Powder will be administered prandially to a new subset of subjects with Type 2 diabetes during TI dose optimization visits and TI meal challenge visits (with meals of varying carbohydrate contents). Subjects will be crossed over to administration of Humalog 15 minutes before meals during Humalog dose optimization visits and Humalog meal challenge visits (with meals of varying carbohydrate contents). Subjects will also use TI Inhalation Powder daily at each meal between visits.
89179623|NCT04091100|Active Comparator|electroacupuncture|The individuals in the electroacupuncture group were administered the therapy by a certified acupuncturist. Two Shenlong acupuncture needles were inserted in each of the trapezius and levator scapulae muscles at intervals of 0-3 mm and clips were attached to their ends. Afterwards, an electrical current of 2 mA and 60 Hz was administered using the Enraf Nonius Sonoplus 492 (OPTOMED) device for 20 minutes.
89368613|NCT02444884|Experimental|Stratum B|Expand MTD in patients with neuroblastoma MLN8237 orally, once daily on Days 1-7
89368614|NCT02450032|Experimental|G17DT|Treatment with 500µg/ 0.4mL dose of G17DT administered by intramuscular injection at 0, 2, and 6 weeks.
89368615|NCT03201796|Experimental|Group 1|Prulifloxacin 600 mg
89368616|NCT03201796|Active Comparator|Group 2|Levofloxacin 500 mg
89368617|NCT03107260|Other|Occurrence of postoperative cognitive dysfunction|
89368618|NCT02727998|Experimental|Single infusion of Ketamine with prolonged exposure|After the reactivation of the scripted memories during PE on day 2, the ketamine infusion procedure will begin inside the MRI. A physician will oversee and administer the ketamine infusions. A nurse will accompany the subject throughout the study sessions, from the insertion of bilateral cannula for drug infusion and blood sampling, to the recovery following ketamine infusion. Whilst subjects undergo the infusion, their heart rate and blood pressure will be constantly monitored. The participant will receive a steady state ketamine infusion of 0.50 mg/kg/hour. The infusion will continue for 40 minutes.
89368619|NCT02727998|Active Comparator|Midazolam with prolonged exposure|After the reactivation of the scripted memories during PE on day 2, the midazolam infusion procedure will begin inside the MRI. A physician will oversee and administer the Midazolam infusions. A nurse will accompany the subject throughout the study sessions, from the insertion of bilateral cannula for drug infusion and blood sampling, to the recovery following midazolam infusion. Whilst subjects undergo the infusion, their heart rate and blood pressure will be constantly monitored. The participant will receive a steady midazolam infusions at a rate 0.045 mg/kg for 40 minutes.
89368620|NCT02444806|Active Comparator|Full Polysomnography|Patients will have NIV settings established using overnight full polysomnography.
89368621|NCT02444806|Active Comparator|Oximetry-capnography|Patients will have NIV settings established using only Oximetry-capnography and subjective sleep comfort.
88841203|NCT02958943|No Intervention|No Alert|Each provider in the non-alert group will receive no such notification.
88841204|NCT04475822|Experimental|Intermittent fasting|During the three-month intervention period, participants were allowed to eat for eight consecutive hours and fast for 16 hours a day.The eating time can be freely chosen in the following two periods: 8:00 -- 16:00;12:00 -- 20:00.No specific restriction shall be made on the type and quantity of food.
89179624|NCT04091100|Active Comparator|myofascial release|Firstly, longitudinal stretching was done with forearm to the muscles in the person's neck in order to relax. Afterwards, the researcher placed one hand under the person's head and placed their fingertips on the muscles under the occipital bone in the neck area. The researcher applied lateral flexion to the neck with one hand while placing the other hand on the trapezius and levator scapulae muscles and then stretched the muscles with friction massage. After this step, the participant's neck was guided back into a neutral position and the pinching technique was applied to the muscles. During the administration of therapies, the trigger points on muscles were identified and friction was applied to these sites until a loosening could be felt. The myofascial release sessions concluded with the administration of the friction massage technique once again to the muscles.
89179625|NCT04091178|Experimental|VITAMIN D SUPPLEMENTATION ARM|"On day 1 of every chemotherapy cycle, the patient will be receive an oral solution of vitamin D (UVEDOSE/calciferol).~In parallel,a calcium supplementation is prescribed."
89179626|NCT04090008|Active Comparator|PRP gel|PRP gel was applied to the ulcer twice per week after preparation and then the ulcer was covered with Vaseline gauze, few layers of sterile gauze and crepe bandage.
89179627|NCT04090008|Active Comparator|Saline dressing|daily dressing of the ulcer with normal saline was done
89179628|NCT00917358|Experimental|Pegylated interferon alfa-2a|Pegylated interferon alfa-2a 135 ug/week for 24 weeks
89179629|NCT00917358|No Intervention|Observation|Retrospectively chart review of dialysis patients with acute hepatitis C who did not receive any intervention
89179630|NCT02597244|Experimental|Treatment group|Percutaneous Extraforaminotomy using BS extraforamonotomy kit(BioSpine Co.,Ltd, Seoul, South Korea)
89179631|NCT00743340|Experimental|Emtricitabine|Participants will receive emtricitabine for as long as they continue to meet specific virologic criteria and until either: (1) the participant chooses to discontinue treatment of emtricitabine and withdraw from the rollover protocol; (2) the participant experiences a toxicity that necessitates the permanent discontinuation of emtricitabine, or (3) emtricitabine is approved for market distribution in the participant's country of residence.
89179632|NCT00917046|Experimental|1 Interval training|high-intensity Interval Training
89179633|NCT00917046|Experimental|2 Moderate Training|Moderate continuous training
89179634|NCT00917046|Active Comparator|3 Recommendation of exercise|Recommendation of regular exercise at moderate intensity at individual choice
89179635|NCT04090944|Active Comparator|1st group (group B)|"The LMA LarySeal Multiple will be inserted using the blind technique which involves holding the LMA like a pen guided into the pharynx with the index finger of the operator at the junction of the tube and the bowl, with the operator at the head of the patient and the LMA facing caudally.~The position of LMA will be assessed by another anesthetist (blinded assessor) using the fiberoptic laryngoscope (KARL STORZ 11301BN1, Germany) per the grading devised by Aoyama et al."
89368622|NCT02636270|Experimental|PAPP-A2 deficient patients|Patients deficient in PAPP-A2 with short stature will be treated with Increlex (rhIGF-1)
89368623|NCT04366349|Experimental|Participants receiving melrilimab (GSK3772847) 70 milligram (mg)|Participants will receive a single dose of melrilimab (GSK3772847) 70 milligram (mg) subcutaneously (SC) injection by an health care professional (HCP).
89179636|NCT04090944|Active Comparator|2nd group:(group U)|"The LMA LarySeal Multiple will be inserted under the guide of B-mode US on the anterior neck . Transverse scans , Sagittal view and Parasagittal view.~-The position of LMA will be assessed by another anesthetist (blinded assessor) using the fiberoptic laryngoscope (KARL STORZ 11301BN1, Germany) per the grading devised by Aoyama et al."
89179637|NCT00748566|Experimental|Active treatment (switch to oral Ziprasidone)|
89179638|NCT02597166|Other|Ledipasvir/Sofosbuvir|Each tablet contains 90 mg ledipasvir and 400 mg sofosbuvir, given orally, once daily for 24 weeks.
89179639|NCT04090788|Experimental|dried bitter-gourd supplements|2.4 gram per day for 4 weeks
89534754|NCT05047497||less than 10 years working|workers who work in cement factories in a period of time less than 10 years
89002036|NCT06116864|Active Comparator|GI Genius|GI Genius is and Computer-Aid Detection (CADe) system to detect polyps
89179640|NCT04090788|Active Comparator|dried cucumber supplements|2.4 gram per day for 4 weeks
89179641|NCT00743106|Placebo Comparator|Placebo Comparator|Placebo (0.9% Nacl)infusion beginning during surgery and lasting for up to 24 hours
89179642|NCT00743106|Active Comparator|Fenoldopam Comparator|Fenoldopam (0.1 ~g/kg/min)infusion will commence after placing the patient in a lateral/flex position during the operation. The infusion will continue for a total of 24 hours.
89179643|NCT04090632|Experimental|closed kineTic chain upper Extremity Stability Test|Each patient receive the same intervention, the CKCUEST. The CKCUEST is a functional test which assess shoulder's stability. Patient is in push-up position, with 91 cm between his hands. His body is straight and his foots are squeeze. patient has to touch his hand with his other one and returns in the initial position. Then, patient repeats this movement with his other hand, etc, during 15 secondes. The CKCUEST score is the movement's number performed.
89179644|NCT04090554|Other|Cytosponge™|Single intervention arm of feasibility study
89179645|NCT02597322|Experimental|AXITINIB|
89179646|NCT04090320|Experimental|CATERPILLAR™ Arterial Embolization Device|Placement of the CATERPILLAR™ Arterial Embolization Device via percutaneous transcatheter embolization (PTE).
89179647|NCT00738699|Active Comparator|1|MORAb-003 (Farletuzumab) Plus Paclitaxel
89179648|NCT00738699|Placebo Comparator|2|Placebo Plus Paclitaxel
89179649|NCT02596932|Other|Tight control|"Intervention Standard Care:~Tight glucose control protocol: Goal maternal blood glucose 70-100, q 1 hour blood glucose checks, insulin treatment started with single maternal blood glucose level > 100mg/dL or < 60 mg/dL"
89179650|NCT02596932|Experimental|Less tight control|"Intervention:~Less Tight glucose control protocol: Goal maternal blood glucose 70-120, q 4 hour blood glucose checks (unless symptomatic), insulin treatment started with single maternal blood glucose > 120 mg/dL or < 60mg/dL"
89179651|NCT00814307|Experimental|Active 5mg|
89179652|NCT00814307|Experimental|Active 10 mg|
89179653|NCT00814307|Placebo Comparator|Placebo Sequence 1|
89179654|NCT00814307|Placebo Comparator|Placebo Sequence 2|
89179655|NCT02597010|Experimental|Nitrate rich beetroot juice|Concentrated, beetroot juice is a rich source of dietary nitrate.
89179656|NCT02597010|Placebo Comparator|Nitrate depleted placebo beetroot juice|Placebo beetroot juice is identical to active beetroot juice in every way except nitrate content.
89179657|NCT02594943|Active Comparator|Conventional Biopsy|"4 out of 8 biopsies taken with a Boston Scientific Large capacity with needle biopsy forceps from the suspected tumor tissue in the stomach. They will be taken in random order blinded for the person performing the examination."
89179658|NCT02594943|Active Comparator|Endodrill Biopsy|"4 out of 8 biopsies taken with the Endodrill 1A instrument from the suspected tumor tissue in the stomach. They will be taken in random order blinded for the person performing the examination."
89179659|NCT02596776|Active Comparator|Fat biopsy|From each abdominal and thigh biopsy, between 0.5 - 3 g of tissue is obtained (often less from the thigh), which is used for immunohistochemistry and frozen for subsequent RNA or protein isolation.
89179660|NCT02596776|Experimental|Propranolol and Fat Biopsy|From each abdominal and thigh biopsy, tissue will be examined for gene expression, with a focus on genes believed to be involved in adipose beiging (PGC1α, UCP1, TMEM26, IL4, Metrnl, CPA3, Siglec 8, tyrosine hydroxylase, others), and with immunohistochemistry, with a focus on beige adipocytes, macrophages, eosinophils and mast cells.
89179661|NCT02596776|Active Comparator|Heavy Water and Fat Biopsy|The investigator will measure in vivo adipose lipolysis and triglyceride (TG) turnover in response to cold to physiologically demonstrate the impact of cold exposure on tissue function. The subjects will then be given 50 mL sterile containers of 70% 2H2O and consume two 50 mL vials per day during the remainder of the 5-week labeling period. Plasma and urine will be collected weekly so that body 2H2O can be measured.
88818326|NCT01816451|Experimental|continuous|The running training for continuous group were performed on a treadmill for a period of 14 weeks, with a frequency of three times a week, lasting 20-minutes per session thus completing 46 sessions of training. The intensity and volume of training both were adapted according to the recommendations of the American College of Sports Medicine.The continuous group ran at an intensity of ~87% of maximal heart rate (HRmax)
89179662|NCT02594631|Active Comparator|ESWL Group|Patients in this arm will receive ESWL as treatment for acute calcular urinary retention
89179663|NCT02594631|Active Comparator|Endoscopy group|Patients in this arm will receive endoscopic treatment for acute calcular urinary retention
89179664|NCT02598180|Experimental|VergenixTM Flowable Gel|VergenixTM Flowable Gel
89179665|NCT02598336|Other|Breathing Sequence|Simultaneous measurement using Structured Light Plethysmography and Pneumotachograph Spirometry during a period of tidal breathing followed by a forced respiratory manoeuvre. This sequence is repeated twice.
89179666|NCT02598336|Other|Agreement and repeatability Breathing Sequence|Simultaneous measurement using Structured Light Plethysmography and Pneumotachograph Spirometry during a period of tidal breathing. This sequence is repeated one further time at rest, and once further time after an exercise test to elevate respiratory rate.
89179667|NCT02611895|Experimental|HIV DNA|Blood test : Quantitate the amount of HIV DNA harbored in the cytoplasm of peripheral blood CD4+ T cells
89179668|NCT00748098|Other|GSK1838262:placebo|GSK1838262 extended release tablets for Treatment Period 1 followed by Placebo for Treatment Period 2
89179669|NCT00748098|Other|Placebo:GSK1838262|Placebo for Treatment Period 1 followed by GSK1838262 for Treatment Period 2
89368624|NCT04366349|Experimental|Participants receiving melrilimab (GSK3772847) 140 milligram (mg)|Participants will receive a single dose of melrilimab (GSK3772847) 140 milligram (mg) subcutaneously (SC) injection by an health care professional (HCP).
89179670|NCT00813995|Experimental|Sitagliptin|
89179671|NCT00813995|Placebo Comparator|Placebo|
89179672|NCT02598882|Active Comparator|treadmill|patients will be 30 minutes of activity on treadmill, before and after exercise the same shall be assessed as fatigue of quadriceps by surface electromyography
89368625|NCT04366349|Placebo Comparator|Participants receiving Placebo|Participants will receive a single dose of placebo subcutaneously (SC) injection by an health care professional (HCP).
89368626|NCT02108990|Experimental|Acetaminophen 1000mg|Acetaminophen 1000mg capsule orally three times a day
89368627|NCT02108990|Experimental|Acetaminophen 500mg|500mg Acetaminophen orally three times a day
89368628|NCT03201718||Hepatitis C|Participants with Hepatitis C receiving Viekira/Exviera (paritaprevir/ritonavir/ombitasvir and dasabuvir) for 12 or 24 weeks.
89368629|NCT01562639||Nexium|
89368630|NCT01766648|Experimental|Far Cortical Locking screw fixation|Far Cortical Locking screw fixation
89368631|NCT01766648|Active Comparator|Standard screw fixation|Standard screw fixation
88841205|NCT04475822|Experimental|Low carb diet|According to the definition of low carbon diet given by R. D. Feinman et al. (Nutrition, 2015), the daily carbohydrate intake of participants in this group was limited to 130g/ D, and the recommended diet was formulated according to the standard and combined with the local eating habits in Xi 'an, and dietary habit education was conducted. Participants could eat according to the recommended diet.
88841206|NCT04475822|Experimental|Low carbon diet and intermittent fasting group|Participants fasted for 16 hours a day and ate for eight consecutive hours on the same diet as the low-carb group.
88841207|NCT04338451|Active Comparator|Music during the first part of ESWL|Patients listen to music during the first part of ESWL treatment (first 1800 SW).
88841208|NCT04338451|Active Comparator|Music during the second part of ESWL|Patients listen to music during the second part of ESWL treatment.
89368632|NCT03194074|Experimental|propofol group|Propofol/remifentanil-based general anesthesia.
89368633|NCT03194074|Experimental|desflurane group|Desflurane/remifentanil-based general anesthesia.
89368634|NCT03748277|Experimental|Minimally invasive fusion|Bilateral decompression using unilateral approach, MIS TLIF + screw fixation percutaneous
89368635|NCT03748277|Active Comparator|Open Fusion|Bilateral decompression, open fusion + screw fixation
89368636|NCT01163864|Experimental|affect regulation training|
89368637|NCT01163864|Active Comparator|health and lifestyle|
89368638|NCT03201952|Active Comparator|Ursodeoxycholic Acid/Placebos|During one of the subjects two randomized visits the subject will receive a 300mg elixir solution of ursodeoxycholic acid (UDCA) via their ileostomy that has been prepared by investigational drug services (IDS) in a 5cc elixir formulation during visit #1. During visit #2 subjects will receive a saline solution of totaling 5cc via their ileostomy that has been prepared by investigational drug services (IDS) in order to mimic the preparation of the medication comparator of ursodeoxycholic acid.
89368639|NCT03201952|Active Comparator|Placebos/Ursodeoxycholic Acid|Subjects will receive a saline solution of totaling 5cc via their ileostomy that has been prepared by investigational drug services (IDS) in order to mimic the preparation of the medication comparator of ursodeoxycholic acid during visit #1. During visit #2 subject will receive a 300mg elixir solution of ursodeoxycholic acid (UDCA) via their ileostomy that has been prepared by investigational drug services (IDS) in a 5cc elixir formulation.
89368640|NCT04179461|Experimental|Personalized Treatment|"Personalized asthma treatment plan based off of individual's asthma severity/control, personal and family medical history, history of environmental exposures, adherence, medical visits, biomarker assays, and home trigger assessment.~Study participants were prescribed recommended medications for the treatment of their asthma. These medications were prescribed through their insurance based of the of personalized treatment plan recommendation. Asthma controller medications may be increased based off of the participant's asthma control and the recommendation of the personalized plan. They would receive one of the asthma controller medications listed in the intervention."
88841209|NCT02992574|Experimental|Post Mastectomy Radiation Therapy (PMRT)|Post mastectomy radiotherapy will be given
88841210|NCT02992574|No Intervention|Observation (No PMRT)|No adjuvant radiotherapy will be given.
88841211|NCT02848027|Experimental|Regenexx-SD procedure|Measure components of knee synovial fluid collected 2-4 days before and after Regenexx SD procedure
88841212|NCT02829229|No Intervention|Usual care (UC)|Usual postpartum WIC care
88841213|NCT02829229|Experimental|Community-based obesity treatment (PP)|The PP arm includes expanded obesogenic behavior change goals, tailored skills training materials, interactive self-monitoring text messages, video testimonials, and interpersonal counseling support through health coach calls and Facebook.
88841214|NCT05439044||Patients who have received an anti-SARS-CoV-2 monoclonal antibody|Patients who have received an anti-SARS-CoV-2 monoclonal antibody, either prophylactically or curatively.
88841215|NCT04256083||AFE (amniotic fluid embolism)|Women for whom the diagnosis of amniotic fluid embolism was retained according to the UKOSS criteria.
88841216|NCT04256083||Control 1|Women admitted for prophylactic elective cesarean section.
88841217|NCT04256083||Control 2|Women with acute collapse in the peripartum period (with systolic blood pressure <80 mmHg twice and for> 5 minutes or acute peri-partum shock, for which the diagnosis of amniotic embolism has been ruled out).
88841218|NCT05428046|Experimental|MHL intervention|Mental health literacy intervention for eating disorder
89368641|NCT03193840|Experimental|old acetabular fracture|posterior wall osteotomy would be conducted for thr patient with displaced acetabular fracture without surgical treatment over three weeks.
89368642|NCT03118726||NM Perinatal Collaborative|Hospitals working with the New Mexico Perinatal Collaborative (NMPC) on implementing immediate postpartum long-acting reversible contraception programs.
89368643|NCT03748199|Experimental|POL6014|multiple ascending doses: 80, 160 and 40 mg once or twice daily
88841219|NCT05428046|Other|Waiting list|The waiting list group received MHL intervention at the end of 12 weeks follow-up assessment.
88841220|NCT04040101|No Intervention|Healthy Adult|balance assessment
88841221|NCT04040101|No Intervention|Stroke|balance assessment
88841222|NCT04040101|Experimental|Stroke smartphone training|smartphone balance training
88841223|NCT04040101|Active Comparator|Stroke traditional training|traditional physical therapy training
89368644|NCT03748199|Placebo Comparator|Placebo|Placebo will be administered orally at a dose and frequency matched to POL6014
88841224|NCT02602093|Active Comparator|Transforaminal Endoscopic Discectomy|Surgery: Patients will undergo Percutaneous Transforaminal Endoscopic Discectomy.
88841225|NCT02602093|Active Comparator|Open Microdiscectomy|Surgery: Patients will undergo conventional micro discectomy.
88841226|NCT05419778||Group A (Osteogen plug®)|The surgical procedure will be conducted following standard procedures for tooth exodontia and ridge preservation. The selected individual sites will be subjected to the standard of care extraction protocol and then randomized to receive treatment with a type I bovine Achilles tendon collagen with bioactive resorbable calcium apatite crystals (CCAC)(Osteogen) ridge augmentation procedures. Intra-oral photographs will be made at the same optic focal distance using a ruler which will be used to evaluate areas where the membrane is still exposed and not epithelized. At 4-6 weeks and again at 20 weeks postoperatively, each study subject will return for implant placement in the ridge preservation area.
88841227|NCT05419778||Group B ( MInerOss® )|The surgical procedure will be conducted following standard procedures for tooth exodontia and ridge preservation. The selected individual sites will be subjected to the standard of care extraction protocol and then randomized to a cortico-cancellous bone chips mix with polytetrafluoroethylene (dPTFE)(Cytoplast) barrier membrane ridge augmentation procedures. Intra-oral photographs will be made at the same optic focal distance using a ruler which will be used to evaluate areas where the membrane is still exposed and not epithelized. At 4-6 weeks and again at 20 weeks postoperatively, each study subject will return for implant placement in the ridge preservation area.
88841228|NCT02808962|Other|Cooled Radiofrequency Ablation|"This is a single arm, prospective observational study. All subjects enrolled are patients that meet the inclusion criteria, as deemed by a physician.~Typical standard of care for these patients is an initial visit followed by two diagnostic blocks ((0.5ml) of 1% Lidocaine per level). Subjects are asked to complete the pain diary and if they experience a 75% or more decrease in the NRS, they are scheduled for Cooled RFA of the lateral branches of S1, S2, and S3 dorsal rami nerves and of the dorsal ramus of L5 nerve."
88841229|NCT02165826|Experimental|Roflumilast 500 μg once daily|Roflumilast 500 μg tablets, orally, once daily for 12 weeks. Any participants not tolerating study treatment will be prematurely discontinued and will receive roflumilast 250 μg, tablets, orally, once daily for 8 weeks.
88841230|NCT02165826|Experimental|Roflumilast 500 μg every other day|Roflumilast 500 μg, tablets, orally, every other day, and roflumilast placebo-matching tablets, orally, every other day on non-treatment days, for 4 weeks, followed by roflumilast 500 μg, tablets, orally, once daily, for 8 weeks. Any participants not tolerating study treatment will be prematurely discontinued and will receive roflumilast 250 μg, tablets, orally, once daily for 8 weeks.
88841231|NCT02165826|Experimental|Roflumilast 250 μg once daily|Roflumilast 250 μg, tablets, orally, once daily for 4 weeks, followed by roflumilast 500 μg, tablets, orally, once daily, for 8 weeks. Any participants not tolerating study treatment will be prematurely discontinued and will receive roflumilast 250 μg, tablets, orally, once daily for 8 weeks.
88841232|NCT02535247|Experimental|Treatment|MK-3475 given intravenously at a fixed dose of 200mg every 3 weeks for up to 36 cycles
88841233|NCT02535247|Active Comparator|Combination|MK-3475 is given intravenously at a fixed dose of 200mg every 3 weeks Copanlisib is given intravenously at RP2D determined from Phase I study
88841234|NCT00370916|Experimental|Arm 1|Physician-initiated medication reconciliation
88841235|NCT00370916|Experimental|Arm 2|Pharmacist-initiated medication reconciliation
89368645|NCT04017611|Experimental|INVSENSOR00038|All subjects who are enrolled into the test group and participate in data collection receive the noninvasive INVSENSOR00038 sensor.
89368646|NCT03119350|Other|Physical Training|"There was concurrent physical training intervention: strength and aerobic exercises in the same session.~Duration: 2 weeks of adaptation and learning to exercise, 8 weeks of physical training.~Frequency: 3 times per week Duration: 55 minutes each session. Intensity: 75 to 90% of maximum heart rate."
88841236|NCT00370916|No Intervention|Arm 3|No formal medication reconciliation
88841237|NCT02509897|Active Comparator|Hypoxic training|Endurance training
88841238|NCT02509897|Placebo Comparator|Normoxic training|Endurance training
88841239|NCT04337996|Experimental|experimental arm|These are patients whose diagnosis of SARS-Cov-2 infection was made on the Gold-Standard: combined history/clinical examination, PCR and CT scan and requiring hospitalization at Tourcoing Hospital.
89368647|NCT03117296||Post procedure routine PT and or OT|Routine PT and or OT
89368648|NCT03117296||Post Procedure PT and OT pathway|Post procedure day zero nursing mobilization; post procedure day one PT and OT assessment and intervention, daily PT and OT intervention
89368649|NCT03196882|Active Comparator|Stratum 1: 40 mg/day of iron|"Ferrimanitol ovoalbumin. 40mg of iron in a sachet (powder for oral solution) by mouth, every 24 hours from 12th week of gestation to partum~Stratum 1: If the levels of Hb are situated between 110 and 130 g/L, the individual will be randomly assigned to an iron dose supplement of 40 (medium supplementation) or 80 mg/d (high supplementation)"
89534755|NCT05047497||from 10-15 years working|workers who work in cement factories in a period of time from 10-15 years
89368650|NCT03196882|Experimental|Stratum 1: 80 mg/day of iron|"Ferrimanitol ovoalbumin. 80mg of iron in a sachet (powder for oral solution) by mouth, every 24 hours from 12th week of gestation to partum~Stratum 1: If the levels of Hb are situated between 110 and 130 g/L, the individual will be randomly assigned to an iron dose supplement of 40 (medium supplementation) or 80 mg/d (high supplementation)"
88841240|NCT04417920|Active Comparator|group I (Express implant)|conjunctival peritomy superior-temporally away from the site of the fibrotic bleb at 12 o'clock, placed on the episclera under the conjunctiva and Tenon's capsule for a contact time of 3 minutes, ,triangular scleral flap , scleral dissection forward to the clear cornea to allow exposure of scleral spur then creation of a pilot hole is fashioned using a sapphire blade (Alcon laboratories,USA) then Express shunt 3 mm long device and external diameter 400 microns was implanted followed by closure of scleral flap and conjunctiva
89368651|NCT03196882|Active Comparator|stratum 2: 40 mg/day of iron|"Ferrimanitol ovoalbumin. 40mg of iron in a sachet (powder for oral solution) by mouth, every 24 hours from 12th week of gestation to partum~Stratum 2: If the levels of Hb are >130 g/L, the individual will be randomly assigned to an iron dose supplement of 40 (medium supplementation) or 20 mg/d (low supplementation)"
89368652|NCT03196882|Experimental|stratum 2: 20 mg/day of iron|"Ferrimanitol ovoalbumin. 20mg of iron in a sachet (oral solution) by mouth, every 24 hours from 12th week of gestation to partum~Stratum 2: If the levels of Hb are >130 g/L, the individual will be randomly assigned to an iron dose supplement of 40 (medium supplementation) or 20 mg/d (low supplementation)"
89368653|NCT04172831|Experimental|TNX-102 SL Tablets, 5.6 mg|1 x TNX-102 SL 2.8 mg Tablet taken sublingually each day at bedtime for 2 weeks then 2 x TNX-102 SL 2.8 mg (5.6 mg) Tablet taken sublingually each day at bedtime for 12 weeks.
89368654|NCT04172831|Placebo Comparator|Placebo SL Tablet|1 x Placebo Tablet taken sublingually each day at bedtime for 2 weeks then 2 x Placebo Tablet taken sublingually each day at bedtime for 12 weeks.
88841241|NCT04417920|Active Comparator|group II (trabeculectomy)|"Trabeculectomy with Mitomycin-C was done in superior-temporal region away from the fibrotic bleb at 12 o, clock.~conjunctival peritomy superior-temporally away from the site of the fibrotic bleb at 12 o'clock, placed on the episclera under the conjunctiva and Tenon's capsule for a contact time of 3 minutes, ,triangular scleral flap , scleral dissection forward to the clear cornea to allow exposure of scleral spur then creation of sclerectomy and peripheral iridectomy and closed scleral flab and conjunctiva by nylon 10/0 sutures"
88841242|NCT02626130|Experimental|Arm A (tremelimumab)|Patients receive tremelimumab IV over 60 minutes at weeks 1 and 5. Within 4-6 weeks later, patients undergo surgery or biopsy. After surgery or biopsy, patients receive tremelimumab IV Q4W for 3 doses, and then every Q12W in the absence of disease progression or unacceptable toxicity.
89368655|NCT03196804|Experimental|LC28-0126|LC28-0126(IV)
89368656|NCT03196804|Placebo Comparator|Placebo|Placebo of LC28-0126
89368657|NCT04839770|Experimental|Axonpen|Subjects will receive minimally invasive endoscopic surgery using the Axonpen™ system for early hematoma evacuation (within 48 hours post-ictus).
89368658|NCT03118960|Active Comparator|Freedom Bed|Bed turns and positions subjects automatically for the healing and prevention of pressure injury
89368659|NCT03118960|Active Comparator|Group II Low Air Loss/Alternating Pressure Mattress|Bed provides subjects with alternating pressure with low air loss mattress for the healing and prevention of pressure injury
89368660|NCT01562717|Experimental|Ibuprofen|
89368661|NCT01562717|Placebo Comparator|Placebo|
88841243|NCT02626130|Experimental|Arm B (tremelimumab and cryoablation)|Patients undergo cryoablation and receive tremelimumab IV over 60 minutes at weeks 1 (2-6 days after cryoablation) and 5. Within 4-6 weeks later, patients undergo surgery or biopsy. After surgery or biopsy, patients receive tremelimumab IV Q34W for 3 doses, and then Q12W in the absence of disease progression or unacceptable toxicity.
89368662|NCT03196648|Experimental|Gingival health formulation in accelerating device|The interventional gingival health formulation is applied to the participant's mouth by means of an intra-oral accelerating device for a single eight-minute application, daily. Participants were instructed to brush their teeth with an OTC toothpaste twice daily, morning and night.
89368663|NCT03196648|Experimental|Gingival health formulation on a toothbrush|The interventional gingival health formulation is applied to the participant's mouth by means of a toothbrush and OTC toothpaste, together with the formulation in equal amounts, for two-minute applications twice daily, morning and night.
88841244|NCT03853759||Patients with Heart Failure|
88841245|NCT03853759||Healthy İndividuals|
89179673|NCT02598882|Active Comparator|videogame|patients will be 30 minutes of activity with video games, before and after exercise the same shall be assessed as fatigue of quadriceps by surface electromyography
89368664|NCT03196648|Active Comparator|Control group (Split mouth design)|The control group did not receive the interventional gingival health formulation. Participants were instructed to brush their teeth with a toothbrush and OTC toothpaste twice daily, morning and night. In addition, participants were instructed to floss only half of their mouth daily, having the non-flossed half serve as an untreated comparative control of toothbrushing alone.
89368665|NCT03111914|Other|Dual Energy Computed Tomography (DECT)|This is a single-arm study. Each patient will receive an unenhanced dual energy CT scan followed by a contrast-enhanced scan as part of clinical routine work up. No change in the contrast material injection protocol will be performed for this this study.
89368666|NCT03744923|Active Comparator|Transmuscular QLB group|Ultrasound device will be used; The probe is placed in the mid-axillary line cranially to the iliac crest to identify the three muscles of the anterior abdominal wall Then, scan dorsally keeping the transverse orientation until observing that the transverse abdominus muscle becomes aponeurotic, and this aponeurosis is followed until the QL muscle is clearly visualized with its attachment to the lateral edge of the transverse process of the L2 vertebral body and visualize the thoracolumbar fascia The needle (20G spinal needle) is inserted in-plane from posterior to anterior and the tip of the needle is advanced towards then through the QL muscle, penetrating the ventral proper fascia of the QL muscle. The target site for injection is the plane between quadratus lumborum and psoas major. This will be followed by injection of Bupivacaine 0.5 % (0.25ml/kg) and lidocaine 2% (0.15ml/kg) mixed together.
89368667|NCT03744923|Active Comparator|unilateral posterior TAP block group|"under ultrasonographic guidance,the probe will be positioned transversely midway between the iliac crest and the costal margin at level of mid axillary line.~Once the external oblique muscle (EOM), internal oblique muscle (IOM) and transversus abdominis muscle (TAM) are visualized at the level of the mid-axillary line between the 12th rib and the iliac crest, the puncture area and the ultrasound probe were prepared in a sterile manner. After identification of the neuro-facial plane between IOM and TAM, the block was performed with the 20G spinal needle. The needle will be directed to approach the TAP with in-plane USG-guided technique. Once the tip of the needle placed in the space between the IOM and TAM, Inject a 1 ml test dose of lidocaine 2% for hydro visualization of needle-tip position and confirming its correct positioning. This will be followed by injection of Bupivacaine 0.5 % (0.25ml/kg) and lidocaine 2% (0.15ml/kg) mixed together."
89368668|NCT03744923|No Intervention|control group|the patients will not receive any blocks
89368669|NCT03625310|Active Comparator|Sodium Fluoride|Varnish containing 5% Sodium Fluoride, was applied to all remaining teeth of each child after dental treatment under general anaesthesia.
89368670|NCT03625310|Experimental|Sodium Fluoride with TCP|Varnish containing 5% Sodium Fluoride with tricalcium phosphate (TCP) ,varnish was applied to all remaining teeth of each child after dental treatment under general anaesthesia.
89368671|NCT03625310|Experimental|Sodium Fluoride with CXP|Varnish containing 5% Sodium Fluoride with Xylitol-coated Calcium and Phosphate (CXP) ,varnish was applied to all remaining teeth of each child after dental treatment under general anaesthesia.
89368672|NCT03625310|Experimental|Sodium Fluoride with CPP-ACP|Varnish containing 5% Sodium Fluoride with casein phosphopeptide amorphous calcium phosphate (CPP-ACP), varnish was applied to all remaining teeth of each child after dental treatment under general anaesthesia.
89368673|NCT03192982|Experimental|Foot pump (A-V Impulse, 6000 Series)|In OR before operation starts randomized to foot pump treatment post operative. Pump placed on foot immediately after operation is finished. Foot pump will be left on foot until full mobilization is reached
89368674|NCT03192982|Active Comparator|Standard treatment (compression)|"In OR before operation starts randomized to standart treatment for edema after in situ bypass.~Short-stretch bandage from toes and up yo the upper thigh 40 mm Hg"
89368675|NCT03118336|Placebo Comparator|placebo group|
89368676|NCT03118336|Experimental|empaglifozine group|
88841246|NCT02198040|Experimental|Manual Therapy group|The treatment of this group consisted of two sessions per week, one hour each. We used joint traction, passive muscles stretching and Proprioceptive Neuromuscular Facilitation
88841247|NCT02198040|Experimental|Educational group|The treatment had education and home daily exercises for the improvement of the range of motion, biceps strength, perimeter of arm and the perception of pain in patients with haemophilia and arthropathy of the elbow.
88841248|NCT02198040|No Intervention|Control group|The control group did not receive any intervention. The patients in this group were assessed by the same reviewers (blinded to the study conditions) and under the same conditions, that patients in the experimental groups.
88841249|NCT02618720|Experimental|ornidazole|oral antibiotic prophylaxis using ornidazole, which has a spectrum of activity extended to most anaerobic bacteria and whose pharmacokinetic profile allows a single administration the day before surgery, in addition to intravenous antibiotic prophylaxis could be more effective than intravenous antibiotic prophylaxis alone using cephalosporin in reducing the incidence of SSI after elective colorectal surgery. Given the number of patients operated of colorectal surgery each year, the study is of significant clinical importance
88841250|NCT02618720|Placebo Comparator|placebo|oral antibiotic prophylaxis using ornidazole, which has a spectrum of activity extended to most anaerobic bacteria and whose pharmacokinetic profile allows a single administration the day before surgery, in addition to intravenous antibiotic prophylaxis could be more effective than intravenous antibiotic prophylaxis alone using cephalosporin in reducing the incidence of SSI after elective colorectal surgery. Given the number of patients operated of colorectal surgery each year, the study is of significant clinical importance
88841251|NCT04338139|Experimental|Bio-oss Collagen|90% xengeneic bovine bone partciles + 10% collagen type I
88841252|NCT05359328|Other|Controled Hypoxia - Healthy Volunteers|
88841253|NCT02197806|Experimental|AGN-199201|1 drop of AGN-199201 ophthalmic solution followed by 1 drop of AGN-199201 vehicle in the non-dominant eye and 2 drops of AGN-199201 vehicle in the dominant eye, once and twice daily for 3 days each.
88841254|NCT02197806|Experimental|AGN-190584|1 drop of AGN-190584 ophthalmic solution followed by 1 drop of AGN-199201 vehicle in the non-dominant eye and 2 drops of AGN-199201 vehicle in the dominant eye, once and twice daily for 3 days each.
89368677|NCT02444572|Experimental|ENOXA® group|"Patients under ENOXA® 4000 IU according to randomization:~Administer ENOXA® 4000 IU (Enoxaparin 4000 IU) per day, regardless of the patient's weight at inclusion~Start injections 12 hours after the surgical procedure~Administer ENOXA® subcutaneously~The administration of ENOXA® should be at the same time on a daily basis for 30 successive days as per the american and french clinical guidelines"
89368678|NCT02444572|Active Comparator|LOVENOX® group|"Patients under LOVENOX® 4000 IU according to randomization:~Administer LOVENOX® 4000 IU (Enoxaparin 4000 IU) per day, regardless of the patient's weight at inclusion~Start injections 12 hours after the surgical procedure~Administer LOVENOX® subcutaneously~The administration of LOVENOX® should be at the same time on a daily basis for 30 successive days as per the american and french clinical guidelines"
89368679|NCT03196726|Experimental|Intervention Arm|Participants will be seen by Medical Officer and manage using standard management based on Clinical Practice Guideline for management of postnatal depression. After session with Medical Officer, participants will be seen by Nurse who additionally manage them using brief Cognitive Behavioral Therapy. Participants will be follow-up at weekly basis for 6 weeks.
89368680|NCT03196726|Placebo Comparator|Control arm|Participants will be seen by Medical Officer and manage using standard management based on Clinical Practice Guideline for management of postnatal depression. Participants will be follow-up at weekly basis for 6 weeks.
88841255|NCT02197806|Experimental|AGN-199201 + AGN-190584 in One Eye|1 drop of AGN-199201 ophthalmic solution followed by 1 drop of AGN-190584 ophthalmic solution in the non-dominant eye and 2 drops of AGN-199201 vehicle in the dominant eye, once and twice daily for 3 days each.
88841256|NCT02197806|Experimental|AGN-199201 + AGN-190584 in Both Eyes|1 drop of AGN-199201 ophthalmic solution followed by 1 drop of AGN-190584 ophthalmic solution in both eyes, once and twice daily for 3 days each.
88841257|NCT03660085|Experimental|Arm A - Early Intervention|For 180 days participants in this arm will be exposed to the intervention and 180 days afterwards they will be exposed to the standard of care.
88841258|NCT03660085|Active Comparator|Arm B - Late Intervention|For 180 days participants in this arm will be exposed to the standard of care and 180 days afterwards they will be exposed to the intervention.
88841259|NCT02323165||Burns and Wound Care|Blood samples will be taken to detect and identify a molecular detection of bacteria in the bloodstream. In addition, data will be collected from the standard of care blood samples and compared.
88841260|NCT02171845||Foetus|
88841261|NCT04109599|Experimental|PlaySmart Full Game|Adolescents, boys and girls, aged 16-19 participated in the pilot testing of the adapted game. PlaySmart is a digital intervention targeted towards preventing opioid misuse in older adolescents.
88841262|NCT04109599|Experimental|Trading Wisdom Storyline|Adolescents, boys and girls, aged 16-19 participated in beta testing this PlaySmart storyline where the player receives an opioid prescription from their dentist. This storyline includes information about safe use of opioids and the difference between use and misuse.
88841263|NCT04109599|Experimental|Lean on Me Storyline|Adolescents, boys and girls, aged 16-19 participated in beta testing this PlaySmart storyline where the player is offered opioids at a party. This storyline includes information about different forms of opioids and their effects.
88841264|NCT04109599|Experimental|Tough Love Storyline|Adolescents, boys and girls, aged 16-19 participated in beta testing this PlaySmart storyline where the player navigates supporting their partner struggling with opioid misuse. This storyline includes information about treatment and recovery resources for opioid misuse & Opioid Use Disorder.
88841265|NCT04109599|Experimental|Grandma's Pills Storyline|Adolescents, boys and girls, aged 16-19 participated in beta testing this PlaySmart storyline where the player witnesses the sharing of an opioid prescription within their family. This storyline includes information about medication safety and opioid overdose identification and response.
88841266|NCT04109599|Experimental|A Friend in Need Storyline|Adolescents, boys and girls, aged 16-19 participated in beta testing this PlaySmart storyline where the player interacts with a friend that is in distress. This storyline includes information about how to navigate peer-to-peer support.
88841267|NCT04109599|Experimental|A New Direction Storyline|Adolescents, boys and girls, aged 16-19 participated in beta testing this PlaySmart storyline where the player seeks out therapy as an option to manage stress. This storyline includes information about how to seek professional help for mental health.
88841268|NCT04109599|Experimental|Risk Sense All Levels|Adolescents, boys and girls, aged 16-19 participated in beta testing all levels of this PlaySmart mini game intended to increase perceived risk of harm of opioid misuse.
88841269|NCT04109599|Experimental|PlaySmart Full Game: Focus on Character Development|Adolescents, boys and girls, aged 16-19 participated in the pilot testing of the adapted game. PlaySmart is a digital intervention targeted towards preventing opioid misuse in older adolescents. Participants in this arm focused on beta testing character development aspects throughout the game.
88841270|NCT02229864|Experimental|Coronary artery stenting: Absorb BVS|Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS)
88841271|NCT04273802|Experimental|Cohort A - First line treatment|Untreated patients
88841272|NCT04273802|Experimental|Cohort B - Hypomethylating failure|Patients in absence of response after hypomethylating agents treatment
88841273|NCT02229552|Other|Baseline Cohort|Children completed body weight and other measures at baseline, 1-year follow up and 2-year follow up measurement periods.
88841274|NCT02042989|Experimental|MLN9708 and Vorinostat|"Dose Escalation Phase: Starting Dose of MLN9708 3 mg by mouth on day 1, 8 and 15. Starting Dose of Vorinostat: 100 mg by mouth twice a day, total of 200 mg/day Days 1 to 21.~Dose Expansion Phase Starting Doses of MLN9708 and Vorinostat: Maximum tolerated dose from Dose Escalation Phase."
88841275|NCT02214134||Lung cancer|Patients with diagnosis of lung cancer at any stage
88841276|NCT02214134||Malignant pleural mesothelioma|Patients with diagnosis of malignant pleural mesothelioma at any stage
89534756|NCT05047497||more than 15 years working|workers who work in cement factories in a period of time more than 15 years
88841277|NCT02214134||Thymic malignancy|Patients with diagnosis of thymic malignancy at any stage
88841278|NCT04248686|No Intervention|Control|Referral to standard care - student health center on campus.
88841279|NCT04248686|Active Comparator|Intervention|Online, guided self-help ED intervention that offers cognitive behavioral therapy (CBT) based tools to improve ED symptoms, while also teaching the healthy methods of behavioral WL, for individuals with clinical/sub-clinical binge-type EDs with comorbid overweight/obesity.
88841280|NCT04093531|Experimental|Ustekinumab|All subjects will receive an intravenous loading dose of 6 mg/kg at their baseline visit. 650mg acetaminophen and 60mg allegra will be given as premedication to the infusion. All patients will receive 90mg ustekinumab by a subcutaneous injection at all subsequent dosing visits. Subcutaneous injections do not require any premedication. Drug will be administered by qualified personnel.
89368681|NCT04165031|Experimental|LY3499446 Phase 1 Cohort A1 High Dose|Participants received high dose LY3499446 as oral monotherapy twice daily (BID) in 21-day cycles.
89368682|NCT04165031|Experimental|LY3499446 Phase 1 Cohort AO Mid Dose|Participant received mid dose LY3499446 as oral monotherapy once every other day (QOD) in 21-day cycles.
89368683|NCT04165031|Experimental|LY3499446 Phase 1 Cohort A-2 Low Dose|Participants received low dose LY3499446 as oral monotherapy once daily (QD) in 21-Day cycles.
89368684|NCT04165031|Experimental|LY3499446 + Combination Drugs Phase 1|"LY3499446 combined with either abemaciclib (orally), erlotinib (orally), or cetuximab (IV).~This trial was terminated prior to initiation of combination therapy cohorts."
89368685|NCT04165031|Experimental|LY3499446 Monotherapy + Combination Drugs Phase 2|"LY3499446 as oral monotherapy and LY3499446 combined with either abemaciclib (orally), erlotinib (orally), or cetuximab (IV).~The trial was terminated prior to initiation of Phase 2 of this study."
89368686|NCT04165031|Active Comparator|Docetaxel Phase 2|"Docetaxel IV infusion.~The trial was terminated prior to initiation of Phase 2 of this study."
88841281|NCT05272670|Experimental|Experimental group|A 4-week digital foot self-management program will be provided to the participants in experimental group.
88841282|NCT05272670|No Intervention|Control group|The control group received routine care that are required to attend the education sessions in the diabetes clinic according to their scheduled appointments. Routine care included routine check-ups and foot care education.
88841283|NCT04186520|Experimental|8/12 Day Production of CAR-T for NHL|"Phase 1: Determine safety of 2.5x10^6 cells/kg IL-7/IL-15 expanded CAR-20/19-T cells in patients with relapsed, refractory B-cell NHL. Patients will be enrolled in 3+3 fashion.~Phase 1b: Six to nine patient expansion cohorts at eight or 12-day manufacturing. If six patients are enrolled in Phase 1 then only six additional patients will be added. If three patients are enrolled in Phase 1 then nine additional patients will be treated for a total of 12 in each group."
88841284|NCT04186520|Experimental|8/12 Day Production of CAR-T for CLL|"Phase 1: Determine safety of 2.5x10^6 cells/kg IL-7/IL-15 expanded CAR-20/19-T cells in patients with CLL. Patients will be enrolled in 3+3 fashion.~Phase 1b: The enrollment will cap at 24 subjects."
88841285|NCT04186520|Experimental|8/12 Flexible Manufacturing with Mandated Cryopreservation|8/12 flexible manufacturing with mandated cryopreservation prior to infusion of LV20.19 CAR T-cells. The enrollment will cap at 24 subjects.
88841286|NCT04186520|Experimental|12-Day Production of Car-T Cells for NHL|"Phase 1: Determine safety of 2.5x10^6 cells/kg IL-7/IL-15 expanded CAR-20/19-T cells in patients with relapsed, refractory B-cell NHL. Patients will be enrolled in 3+3 fashion.~Phase 1b: Six to nine patient expansion cohorts at 12-day manufacturing. If six patients are enrolled in Phase 1 then only six additional patients will be added. If three patients are enrolled in Phase 1 then nine additional patients will be treated for a total of 12 in each group."
88841287|NCT04186520|Experimental|8/12 Day Production of CAR-T for Relapsed/Refractory Primary or Secondary CNS Lymphoma|"Phase 1: Determine safety of 2.5x106 cells/kg IL-7/IL-15 expanded CAR-20/19-T cells in patients with primary/secondary central nervous system (CNS) lymphoma.~Phase 1b: Safety and efficacy will be evaluated in this study that will enroll 12 to 24 patients."
88841288|NCT04186520|Experimental|Phase 2 - Efficacy of CAR-20/19-T cells in MCL|Single-stage Phase II design with three-month CR as the target endpoint.
88841289|NCT04172948|Experimental|Virtual reality arm|This arm will receive diaphragmatic breathing teaching by a medical professional and virtual reality module that teaches diaphragmatic breathing. This arm will be sent home with the virtual reality equipment and practice this breathing technique through the virtual reality module for 8 weeks.
88841290|NCT04172948|Placebo Comparator|Control|This arm will receive diaphragmatic breathing teaching by a medical professional only. They will practice this breathing technique with a paper handout of diaphragmatic breathing technique instructions for 8 weeks.
88841291|NCT04059757|Experimental|Fecal Microbiota Transplantation (FMT)|"One dose of FMT equal to 30 capsules will be administered on day 1 of a 28 day cycle. Steroids and routine GVHD prophylaxis medications and antibiotics may be administered concurrently with FMT therapy.~Participants will be followed for 28 days following completion of the FMT dose or protocol defined outcome.~aGVHD will be treated as per standard of care."
88841292|NCT04164680||Patients with disorders of consciousness|
88841293|NCT05208944|Experimental|Part A|"Safety lead-in, modified 3+3 design. Part A:~Cohort 1: THIO total 360 mg per cycle (120 mg on Days 1-3 Q3W) plus 350 mg cemiplimab on Day 5; Cohort 2 (pending emerging data from Cohort 1): THIO total 180 mg per cycle (60 mg on Days 1-3 Q3W) plus 350 mg cemiplimab on Day 5"
88841294|NCT05208944|Experimental|Part B|Cohort 1: THIO total 60 mg per cycle (20 mg on D1-3 Q3W) plus 350 mg cemiplimab on Day 5; Cohort 2: THIO total 180 mg per cycle (60 mg on D1-3 Q3W) plus 350 mg cemiplimab on Day 5; Cohort 3 (pending emerging data from Part A): THIO total 360 mg per cycle (120 mg on Days 1-3 Q3W) plus 350 mg cemiplimab on Day 5
88841295|NCT05208944|Experimental|Optional Part C|THIO total 540 mg per cycle (180 mg on D1-3 Q3W) plus 350 mg cemiplimab on Day 5
88841296|NCT01809379|Experimental|intraperitoneal chemotherapy|Intraperitoneal chemotherapy with cisplatin at a dose of 7.5 mg/m2 body surface in a 150 ml NaCl 0.9% and doxorubicin at a dose of 1.5 mg/m2 body surface in a 50 ml NaCl 0.9% solution with a flow of 30 ml/min and a max upstream pressure of 200 psi.
88841297|NCT01802840|Placebo Comparator|biscuits without soy fiber|biscuits without soy fiber
88841298|NCT01802840|Experimental|biscuits supplemented with soy fiber|biscuits supplemented with soy fiber
89368687|NCT03118258|Experimental|Pap smear|'Pap smear' arm: women are invited to participate in a preventive consultation. This consultation is followed by direct patient referral for Pap smear testing in a partner health facility.
89368688|NCT03118258|Experimental|Self-collected vaginal swab for HPV testing + pap smear triage|"'Self-collected vaginal swab for HPV testing + pap smear triage' arm : women are invited to participate in a preventive consultation. This consultation is followed by patient referral for Pap smear testing in a partner health facility if the HPV-HR test is positive.~A women who tests negative for HPV-HR can still be referred for further Pap smear testing, or can be referred for a gynaecological consultation for any other reason."
89534757|NCT03231553|Experimental|Intervention|"Receive usual NHS antenatal care and any NHS smoking cessation support which they choose to access plus an NHS leaflet giving advice on stopping smoking.~Receive MiQuit text message cessation programme."
89179674|NCT00737529|Experimental|Lenalidomide|"Single agent Lenalidomide~Lenalidomide: 10mg or 25 mg oral capsules on days 1 to 21 of each 28 day cycle and dependent on renal function; Participants with normal renal function (defined as Creatinine Clearance(CrCl)) of ≥ 60 mL/min in this study) received 25 mg of lenalidomide daily, and those with moderate renal insufficiency (CrCl) ≥ 30 mL/min but < 60 mL/min) were started at a 10-mg dose. Participants could continue to receive treatment until disease progression, development of unacceptable AEs, or voluntary withdrawal."
89179675|NCT02596542|Experimental|Water temperature|
89179676|NCT00813917|Active Comparator|varenicline|
89179677|NCT00813917|Placebo Comparator|Placebo|
89179678|NCT02596698||Adolescents with Mood Disorders|Teens aged 13-18 with a diagnosis of a mood disorder.
89179679|NCT02596698||Adolescents with no Mental Health Diagnoses|13-18, no psychiatric d/o diagnosis
89179680|NCT02611193|Experimental|Manipulative treatment|Manipulative Treatment
89179681|NCT02611193|Sham Comparator|Simulated manipulative treatment|Simulated manipulative treatment
89179682|NCT02594709|Experimental|ONSM Multisession Radiosurgery|Multisession Radiosurgery
89179683|NCT02598102|Experimental|Diclofenac sodium|Oral diclofenac 75 mg one hour prior to stent removal
89179684|NCT02598102|Placebo Comparator|Placebo|Placebo one hour prior to stent removal
89179685|NCT02598024|Experimental|Narrative Exposure Therapy (NET-R)|Revised Narrative Exposure Therapy (NET-R) is a 4-session manual-based treatment, each session lasting 60-90-minutes, and first three sessions delivered daily and the last session after a gap of 1-2 days
89179686|NCT02598024|Experimental|Control Focused Behavioural Treatment|CFBT is an intervention to facilitate natural recovery process by restoring sense of control over anxiety, fear, or distress. For this study in Nepal, a monitoring session will be added to the one-session group CFBT used by Basoglu and Salcioglu (2011), and the revised CFBT would be delivered to groups of 20-30 survivors. Each treatment session would be delivered within 1- 2 hours (90 minutes on average), at the interval of two weeks.
89179687|NCT02598024|No Intervention|Waiting List Control|The waiting list participants will receive the treatment of choice (NET-R or CBFT-R) after 3 months.
89179688|NCT02610647|Other|Control group|"Subjects randomized to this group will have a tapping test with no sensory blocking.~Intervention: Tapping test"
89179689|NCT02610647|Experimental|Wrist anesthesia|"Subjects randomized to this group will have an axillary block / regional anesthesia followed by a tapping test.~Intervention: Wrist anesthesia~Intervention: Tapping test"
89179690|NCT02610647|Experimental|Wrist anesthesia, masked|"Subjects randomized to this group will have an axillary block / regional anesthesia, will wear a blinding mask, and then will perform a tapping test.~Intervention: Wrist anesthesia~Intervention: Blinding mask~Intervention: Tapping test"
89179691|NCT02610647|Experimental|Wrist anesthesia, helmet|"Subjects randomized to this group will have an axillary block / regional anesthesia, will wear an anti-noise helmet, and then will perform a tapping test.~Intervention: Wrist anesthesia~Intervention: Anti-noise helmet~Intervention: Tapping test"
89179692|NCT02610647|Experimental|Wrist anesthesia, masked & helmet|"Subjects randomized to this group will have an axillary block / regional anesthesia, will wear a blinding mask, will wear an anti-noise helmet, and then will perform a tapping test.~Intervention: Wrist anesthesia~Intervention: Blinding mask~Intervention: Anti-noise helmet~Intervention: Tapping test"
89179693|NCT02595918|Experimental|Treatment (nivolumab)|Patients receive nivolumab IV over 30 minutes on days -56, -42, -28, and -14 in the absence of disease progression or unacceptable toxicity. Patients then undergo nephrectomy or metastasectomy on day 0.
89179694|NCT02610569|Active Comparator|standart endoscopy|Intervention: 2 standard endoscopy during anti-TNFalpha or vedolizumab treatment
89179695|NCT02610569|Experimental|PillCamCOLON (C2)|Intervention : 2 PillCamCOLON (C2) during anti-TNFalpha or vedolizumab treatment
89179696|NCT02595840|Experimental|Arm A: Afatinib|Afatinib 40 mg/d (30, or 20 mg/d in case of dose reduction during 1st line treatment)
89179697|NCT02595840|Experimental|Arm B: Pemetrexed|Pemetrexed 500 mg/m2 (375 mg/m² in case of dose reduction during induction therapy) i.v. on d1 of each 21-day cycle
89179698|NCT04089774|Experimental|Adapted Physical Activity (APA)|Supported by an Adapted Physical Activity (APA), at the rate of 3 sessions per week supervised by the association SCO STE MARGUERITE, spread over 12 months
89179699|NCT04089774|No Intervention|Kiné|Standard physiotherapy treatment, at least 20 sessions, renewed at least once, spread over 12 months
89179700|NCT00737061|Experimental|Adiana Transcervical Sterilization System|Single arm treatment
89179701|NCT02594865|Active Comparator|Glucerna|Glucerna ® 1.5 kcal (Abbott, USA), the standard enteral formula used at our ICU and the investigational enteral feeding.
89179702|NCT02594865|Active Comparator|Fresubin|Fresubin ® Energy Fibre (Fresenius, UK), the control enteral feeding.
89179703|NCT02594787|Active Comparator|Phosphorus|Intervention (500 mg of potassium phosphate) will be administered with 75 g glucose solution and diet induced thermogenesis will be measured afterwards
89179704|NCT02594787|Placebo Comparator|Placebo|Placebo (cellulose) will be administered with 75 g glucose solution and diet induced thermogenesis will be measured afterwards
89179705|NCT02594553|Experimental|Intervention|All GPs working at the participating GP out-of-hours centres that are in the intervention group will use the GP-parent information-exchange tool (interactive booklet).
89179706|NCT02594553|No Intervention|Control|All GPs working at the participating GP out-of-hours centres that are in the control group will provide care as usual.
89179707|NCT02594397|Experimental|acupoints combination 1|acupoints comination 1 includes the specific acupoint ST36 (Zusanli) and a local acupoint CV12 (Zhongwan).
89179708|NCT02594397|Active Comparator|acupoints combination 2|acupoints comination 2 includes the specific acupoint ST36 (Zusanli) and a distal acupoint PC6(Neiguan).
89179709|NCT02594397|Sham Comparator|sham acupoints combination|sham acupoints combination includes the specific acupoint ST36 (Zusanli) and a sham acupoint.
89368689|NCT05480150|Experimental|bipolar disorder|Patients with BD depressive episode received standard treatment with quetiapine fumarate tablets, starting from 50mg/ night, titrated to a therapeutic dose of 300-400mg/ night within 10 days, and maintained treatment for 4 weeks. According to the patient's condition, patients with BD depressive episode could receive another standard treatment with lurasidone, starting from 20mg/ night, titrated to a therapeutic dose of 40mg/ night within 6 days, and maintained treatment for 4 weeks. Adverse reactions and changes in condition of all patients were recorded
89368690|NCT05480150|Experimental|major depressive disorder|MDD depressive episode patients received standard treatment with escitalopram oxalate tablets, starting from 5mg/ day once, titrated to a therapeutic dose of 10-20mg/ day within 1 week, and maintained treatment for 4 weeks
89368691|NCT05480150|No Intervention|healthy control|no interventions
89368692|NCT03196570|Experimental|Intervention|After randomization into the intervention arm, participants will be instructed on how to use the Spanish language study website. During the six month intervention, they will complete online questionnaires to determine their stage of change towards increasing physical activity. A manual of information will be automatically generated based on their responses. Participants can read this information online, along with tip sheets related to increasing physical activity. On the website they can also set weekly goals and log their weekly PA. It will also include short videos with demonstrations for PA they can do at home and around their neighborhood. Information will also include community resources (community centers, public events, parks) where they can be physically active. Participants will also receive prompts and encouragement via text-message to encourage them to log into the website and continue to track their progress.
89368693|NCT03196570|Active Comparator|Contact Control|Participants in the control arm will attend the same baseline orientation sessions and measurements as the intervention arm. After randomization into the control group, participants will complete an introductory in-person session to introduce them to a website, similar in design, with information on health topics other than physical activity, including diet and other factors associated with CVD risk. It will include information from NHLBI heart health materials for Latinos. Topics include healthy eating, increasing fruit and vegetable consumption, reducing fat and salt intake, learning about cholesterol, stress management. Participants will log onto a separate website unique to the control group and complete monthly surveys on the wellness topics and their progress. Participants will also receive prompts and encouragement text-messages to encourage them to log onto the website.
89368694|NCT05464628|Experimental|Atorvastatin and ASC42|Atorvastatin followed by ASC42 daily followed by separate co-administration of atorvastatin.
89368695|NCT03196492||No hormone|Half of the cohort (n=40) will have opted to forgo hormonal contraception (HC).
89368696|NCT03196492||Depo-provera|Half of the cohort (n=40) will have opted to initiate injectable depo-provera (DMPA).
89368697|NCT04829630|Other|subjects who received three vs. four ID PEP at least two, five or 10 years earlier|"30 subjects who received three ID PEP at least two years earlier in Cambodia~30 subjects who received three ID PEP at least five years earlier in Cambodia~30 subjects who received three ID PEP at least 10 years earlier in Cambodia~30 subjects who received four ID PEP at least two years earlier in Madagascar~30 subjects who received four ID PEP at least five years earlier in Madagascar~30 subjects who received four ID PEP at least 10 years earlier in Madagascar"
89368698|NCT02712424|Active Comparator|DAR-901|0.1 mL intradermal injection of 1 mg DAR-901
88841299|NCT01723969||Colo-rectal cancer|Tumour markers testing in patients with advanced or metastatic colo-rectal cancer
88841300|NCT02229396|Experimental|Exenatide Once Weekly 2 mg and Dapagliflozin Once Daily 10 mg|
88841301|NCT02229396|Experimental|Exenatide Once Weekly 2 mg Alone|
88841302|NCT02229396|Active Comparator|Dapagliflozin Once Daily 10 mg Alone|
88841303|NCT05202158|Active Comparator|Irrigation + Genta|Patients treated with gentamicin in irrigation fluid during RIRS
88841304|NCT05202158|Sham Comparator|Irrigation|Patients treated only irrigation fluid during RIRS
88841305|NCT00370370|Active Comparator|1|Injection of intravitreal bevacizumab
88841306|NCT00370370|Active Comparator|2|Injection of bevacizumab + triamcinolone acetonide
88841307|NCT01452854||Cancer|The study cohort will include adult women of childbearing potential with a diagnosis of low grade glioma (WHO grade II) who are being treated with low doses of Temozolomide (Temodar).
88841308|NCT01457833|Active Comparator|Endobronchial valves (EBV)|Complete occlusion of one emphysematous destroyed lobe by implantation of endobronchial valves
89368699|NCT02712424|Placebo Comparator|Placebo|0.1 mL intradermal injection of sterile saline for human use
89368700|NCT03196414|Experimental|CART-138/BCMA/19/more|
89368701|NCT02449408||Overweight or Obese|Children being seen in consultation or follow-up within the Duke Division of Pediatric Endocrinology and Diabetes who are overweight or obese.
89368702|NCT02449408||Premature or Small for Gestational Age|Infants hospitalized in the Duke Transitional Care Nursery who were born prematurely or small for gestational age.
89368703|NCT02449330|Experimental|Teneligliptin in the inhibition test|Patients showing E/e' by echocardiography less than 8 at base line and assigned as Teneligliptin treatment by randomization
89368704|NCT02449330|No Intervention|Other agents in the inhibition test|Patients showing E/e' by echocardiography less than 8 at base line and assigned as anti-diabetic agents except for DPP-4 inhibitors treatment by randomization
89368705|NCT02449330|Experimental|Teneligliptin in the improvement test|Patients showing E/e' by echocardiography more than 8 at base line and assigned as Teneligliptin treatment by randomization
88841309|NCT01457833|Active Comparator|Intrabronchial valves (IBV)|Complete occlusion of one emphysematous destroyed lobe by implantation of intrabronchial valves
88841310|NCT01107613|Experimental|Intervention Arm|Opinion leader educational letter
88841311|NCT01107613|No Intervention|Control/Standard Care|Regular care
88841312|NCT01269164|Experimental|Face Transplantation|Surgical Procedure Composite Facial Transplant
88841313|NCT00370513|Experimental|Pazopanib Arm|Different doses of oral pazopanib once daily for the duration of the study starting on Day 1 of Treatment Period 1. Treatment continues until disease progression or withdrawl from study.
88841314|NCT05179382|Active Comparator|Control protocol|The control protocol will consist of an initial 10 minutes of rest, followed by 90 minutes of aerobic activity and 60 minutes of the final recovery. Hydration will not be allowed throughout the protocol.
88841315|NCT05179382|Experimental|Hydration protocol|This intervention will consist of an initial 10 minutes of rest, followed by 90 minutes of aerobic activity and 60 minutes of the final recovery. In this protocol, volunteers will be hydrated with mineral water from the 15th minute of exercise until the end of recovery.
88841316|NCT02197416|Experimental|dabigatran etexilate|
88841317|NCT00370591|Experimental|Arm 1|
88841318|NCT05166044||Safety group|All of the participants(N=12500) received one dose of EV71 vaccine and one of other vaccines(such as MMR vaccine,encephalitis vaccine,mumps vaccine,inactivated poliomyelitis vaccine,influenza vaccine and so on ) at the same time.
88841319|NCT03983863||IRB|Our target study population consists of all members/staff of NIH IRBs and IRB panels that fall under the NIH Intramural Federal Wide Assurance (FWA).
88841320|NCT00598988|Experimental|Acupuncture|Traditional Chinese acupuncture in conjunction with standard medical care
88841321|NCT00598988|Active Comparator|Standard medical care|standard medical care
88841322|NCT03956173||Clamp group|24 patients with type 1 diabetes.
88841323|NCT03080311|Experimental|APG-1252|An accelerated dose escalation scheme will be utilized initially with one patient enrolled per cohort. If at 10 mg or 20 mg dose level, any occurrence in cycle 1 of one ≥ Grade 2 adverse event related or possibly related to APG-1252 (graded as per the National Cancer Institute's Common Terminology Criteria for Adverse Events [NCI CTCAE] version 4.0) is the trigger for converting to a standard 3+3 design at that dose level.
88841324|NCT00392756|No Intervention|off treatment|Subjects undergo the baseline evaluation off treatment
88841325|NCT00392756|Experimental|GnRH Treatment|Subjects receive long term pulsatile GnRH therapy
88841326|NCT04027322|Active Comparator|Budesonide|"Drug Name: budesonide Dose: 2000mcg (2mg) of budesonide nebulizer solution is mixed with normal saline solution to make a total volume of 8mL.~Frequency: Stat Dose Route: Nebulization"
88841327|NCT04027322|Active Comparator|Dexamethasone|"Drug Name: Dexamethasone Sodium phosphate Dose: 8mg of IV formula of dexamethasone is mixed with normal saline to make a total volume of 8ml.~Frequency: Stat Dose Route: Nebulization"
88841328|NCT04027322|Placebo Comparator|Control|Drug Name: Normal Saline Dose: 8ml. Frequency: Stat Dose Route: Nebulization
88841329|NCT00371215|Experimental|1|rThrombin
88841330|NCT03845257||Patients with COPD|"The following parameters are to be evaluated:~Blood eosinophils~FeNO~Eosinophils in bronchoalveolar lavage~Tissue eosinophilia (protected specimen brush sampling, endobronchial biopsy)"
88841331|NCT03845257||Patients with asthma|"The following parameters are to be evaluated:~Blood eosinophils~FeNO~Eosinophils in bronchoalveolar lavage~Tissue eosinophilia (protected specimen brush sampling, endobronchial biopsy)"
88841332|NCT05454475||Low temperature group|The temperature is 6℃-10℃.
88841333|NCT05454475||room temperature group|The temperature is 20℃-24℃.
88841334|NCT05454475||Core temperature group|The temperature is 35℃-39℃.
88841335|NCT03056365|Experimental|Advanced Nurse (AN)|The outpatient detoxication procedure will be entirely managed by an advanced nurse team, using a predefined protocol decision algorithm. The protocol allows that the AN team autonomously manages the diazepam dosing during the detox period. Addiction physicians only intervenes in case of severe withdrawal symptoms or serious adverse events.
88841336|NCT03056365|Active Comparator|General Practitioner (GP)|"The outpatient detoxication procedure is entrusted to a GP who will manage patients and diazepam dosing as he/she thinks best (as usual control group)"
88841337|NCT00370448|Experimental|1|Training gatekeeper recruited from students and tutors and counselors
88841338|NCT00370448|Active Comparator|2|
88841339|NCT00370448|No Intervention|3|
88841340|NCT00371228|Experimental|1|Umbilical cord not cut until pulsation stops, in order to provide additional blood to newborn.
88841341|NCT00371228|No Intervention|2|Umbilical cord cut soon after birth without waiting for pulsing to stop.
89368706|NCT02449330|No Intervention|Other agents in the improvement test|Patients showing E/e' by echocardiography more than 8 at base line and assigned as anti-diabetic agents except for DPP-4 inhibitors treatment by randomization
89368707|NCT03766516||Cohort|"Any patient planning to administer BrentuximabVedotin to treat the target disease.~Any patient administering BrentuximabVedotin to treat the target disease.~Any patient tracing BrentuximabVedotin after treating the target disease.~Any patient administering another salvage option for cancer as the target disease has relapsed after terminating treatment using BrentuximabVedotin."
88841342|NCT05454644|No Intervention|Usual Pharmaceutical Care|Patients in the control arm receive usual pharmaceutical care in hospital. Reconciliation of the medication at hospital admission and a validation of the treatment modifications during the hospitalisation is carried out.
88841343|NCT05454644|Experimental|Person-Centred Prescription Model|An interdisciplinary medicine-optimisation strategy is implemented in people at the end of life (EOL) based on the person-centred prescription (PCP).
88841344|NCT05118698|Experimental|High-dose group|Participants will be allowed to drink Gynostemma pentaphyllum powder containing 12% saponin, 2 g each time, 3 times a day for 3 months.
88841345|NCT05118698|Experimental|Low-dose group|Participants will be allowed to drink Gynostemma pentaphyllum powder containing 8% saponin, 2 g each time, 3 times a day for 3 months.
88841346|NCT05118698|Placebo Comparator|Placebo group|Participants will be allowed to drink a placebo of spinach powder with almost no saponin content, 2 g each time, 3 times a day for 3 months.
88841347|NCT05454397||case group|Patients with acute stroke with nutritional risk
88841348|NCT05454332|Experimental|Early Caffeine Group|Group administering caffeine in the first 2 hours of life. Patients in the early caffeine group will receive an attack dose of caffeine 20 mg/kg and begin maintenance dose 10 mg/kg/day.
88841349|NCT05454332|Active Comparator|Control Group|Patients in the late caffeine group, receive bolus of saline solution in the first 2 hours of life, starting, at 24 hours of life, the caffeine-loading dose 20 mg/kg and after maintenance dose 10mg/kg/day.
88841350|NCT03977714|Experimental|Group A - test implant and abutment|Zirconia implant and G3-coated abutment (test implant and abutment). Dental sites that potentially qualify for dental implant rehabilitation will be randomly assigned to either the test group (zirconia implants) or the control group (titanium implants). Also, G3-coated and control (non-coated) abutments will be equally distributed on test and control implants, to discriminate between peri-implantitis prevention due to the G3-coating or due to the specific implant characteristics. This is a split-mouth study so that each participant can act as his or her own control and to allow between and within group comparisons.
88841351|NCT03977714|Experimental|Group B - test implant and control abutment|"Zirconia implant and control abutment (test implant, negative control abutment).~Dental sites that potentially qualify for dental implant rehabilitation will be randomly assigned to either the test group (zirconia implants) or the control group (titanium implants). Also, G3-coated and control (non-coated) abutments will be equally distributed on test and control implants, to discriminate between peri-implantitis prevention due to the G3-coating or due to the specific implant characteristics. This is a split-mouth study so that each participant can act as his or her own control and to allow between and within group comparisons."
88841352|NCT03977714|Experimental|Group C - control implant and test abutment|Titanium implant and G3-coated abutment (control implant, test abutment). Dental sites that potentially qualify for dental implant rehabilitation will be randomly assigned to either the test group (zirconia implants) or the control group (titanium implants). Also, G3-coated and control (non-coated) abutments will be equally distributed on test and control implants, to discriminate between peri-implantitis prevention due to the G3-coating or due to the specific implant characteristics. This is a split-mouth study so that each participant can act as his or her own control and to allow between and within group comparisons.
88841353|NCT03977714|Active Comparator|Group D - control implant and abutment|Titanium implant and control abutment (negative control implant and abutment). Dental sites that potentially qualify for dental implant rehabilitation will be randomly assigned to either the test group (zirconia implants) or the control group (titanium implants). Also, G3-coated and control (non-coated) abutments will be equally distributed on test and control implants, to discriminate between peri-implantitis prevention due to the G3-coating or due to the specific implant characteristics. This is a split-mouth study so that each participant can act as his or her own control and to allow between and within group comparisons.
88841354|NCT03977714|Experimental|Group E - test and control implants|"Zirconia implant and titanium implant for histological and histomorphometric evaluation.~This study will be performed in the area of the wisdom teeth (a non useful site that will not interfere with the rest of the study or with the patient's life), so it can only be performed in patients who no longer have these teeth. The procedure will match the procedures described for Groups A-B-C-D. Group E implants will only remain in the mouth for 2 months, after which they will be removed for further analysis. The removal of these implants, for the patient, has exactly the same implications as a normal molar extraction."
88841355|NCT03924518|Experimental|granisetron group|3ml granisetron（3mg） will be diluted in 22 mL of 0.9% normal saline,and the granisetron diluted will be intravenously injected for at 10 minutes， every 8 hours for 4 days or until leaving the ICU(death or transfer from ICU to general ward or discharge), whichever come first.
88841356|NCT03924518|Placebo Comparator|placebo group|Normal saline 25ml every 8h for 4 days or until leaving the ICU(death or transfer from ICU to general ward or discharge), whichever come first.
88841357|NCT05454163||Exposed patients|
88841358|NCT05454163||Non exposed patients|
88841359|NCT05037344|Experimental|Internet-based psychotherapy|16 weeks of internet-based cognitive behavioral therapy
88841360|NCT05037344|Active Comparator|Internet-based psychotherapy waiting group|16 weeks of internet-based cognitive bahavioral therapy after waiting of 16 weeks
88841361|NCT05454085|Other|pregnancies with neural tube defects|patients with pre-diagnosis of neural tube defects (47 patients).
89179710|NCT00917943|Experimental|Tailored Counseling Intervention Arm|Bio-behavioral and pregnancy-specific factors are used to triage women in the treatment arm to one of four levels of stepped-care that includes one in-person counseling session and at least one telephone session during pregnancy and from 6 to 11 telephone sessions over the first 9-months postpartum.
89179711|NCT00917943|No Intervention|Control Arm|Women randomized to the control arm receive the booklet, Forever Free for Baby and Me: A Guide to Remaining Smoke Free and usual prenatal and postpartum care.
88841362|NCT05454085|Other|pregnancies without neural tube defects|patients with abnormal maternal serum screening test or prenatal diagnosis test, patients with abnormal ultrasonography findings (45 patients)
88841363|NCT05453786|Experimental|Sequence A|Period 1: SID1903-R1, SID1903-R2 / Period 2: SID1903
88841364|NCT05453786|Experimental|Sequence B|- Period 1: SID1903 / Period 2: SID1903-R1, SID1903-R2
88841365|NCT03886922|Active Comparator|Glibenclamide and Levcromakalim|Participants will receive levcromakalim infusion after glibenclamide administration
88841366|NCT03886922|Active Comparator|Glibenclamide and Saline|Participants will receive placebo infusion after glibenclamide administration
88841367|NCT03886922|Sham Comparator|Placebo|Participants will receive placebo infusion after placebo administration.
89179712|NCT02594241|Active Comparator|Methylprednisolone|Patients in this arm will be given an intravenous infusion of 125 mg Methylprednisolone (Solu-Medrol) immediately after induction of general anesthesia.
89179713|NCT02594241|Placebo Comparator|Physiological saline|Patients in this arm will be given an intravenous infusion of saline immediately after induction of general anesthesia.
89368708|NCT03648814|Experimental|Intracameral injection|Intracameral Bevacizumab 1.25 mg/0.05 mL. Injection
89368709|NCT03648814|Experimental|Intravitreal injection|Intravitreal Bevacizumab 1.25 mg/0.05 mL. Injection
88841368|NCT03886922|Active Comparator|Levcromakalim and Glibenclamide|Participants will receive levcromakalim infusion before glibenclamide administration.
88841369|NCT03886922|Active Comparator|Levcromakalim and Placebo|Participants will receive levcromakalim infusion before placebo administration.
88841370|NCT04738370||Pregnancy of unknown location|Patients will be approached for recruitment following PUL classification. Sample collection at time of classification +/- 48 hours later, timed for when bloods are taken as part of routine clinical practice +/- at any time patient attends for clinically indicated blood samples.
88841371|NCT04738370||Ectopic Pregnancy|Patients will be approached for recruitment following Ectopic Pregnancy diagnosis. Ectopic pregnancies that are recruited as PUL do not need to be re-approached as they are already part of the study. Sample collection at time of diagnosis when bloods are taken as part of routine clinical practice +/- at any time patient attends for clinically indicated blood samples.
88841372|NCT05453552|Experimental|G-CSF+DAC+BF|For patients with high-risk MDS undergoing allo- HSCT, Granulocyte Colony-Stimulating Factor (G-CSF)+Decitabine+BF conditioning regimen was G-CSF 5ug/kg/day on days -17 to -10 (when white blood cell is more than 20G/L, stop using G-CSF), Decitabine 20mg/m2/day on days -14 to -10, Busulfan (BU) 3.2 mg/kg/day on days -6 to -3, Fludarabine (FLU) 30mg/m2/ day on days -7 to -3.
88841373|NCT05453552|Active Comparator|G-CSF+DAC+BUCY|For patients with high-risk MDS undergoing allo- HSCT, Granulocyte Colony -Stimulating Factor (G-CSF)+Decitabine+BUCY conditioning regimen was G-CSF 5ug/kg/day on days -17 to -10 (when white blood cell is more than 20G/L, stop using G-CSF), Decitabine 20mg/m2/day on days -14 to -10, Busulfan (BU) 3.2 mg/kg/day on days -7 to -4, Cyclophosphamide (CY) 60 mg/kg/day on days -3, -2.
88841374|NCT05453318|Experimental|Thermal ablation Arm|Treatment of cervical neoplasia by thermal ablation
88841375|NCT05018624|Experimental|Intervention group|Alcohol brief intervention, leaflets, regular personalized messages on ABI through IM Apps, real-time chat-based support through IM Apps
88841376|NCT05018624|Active Comparator|control group|Alcohol brief intervention, leaflets, regular messages on general health through IM Apps
88841377|NCT03851120|Experimental|Intervention|150 pregnant women will be given Probiotics and 480 mg DHA, psychosocial stimulation, and healthy eating education
88841378|NCT03851120|Placebo Comparator|Control|150 pregnant women will be given placebo probiotics and 240 mg DHA, psychosocial stimulation, and healthy eating education
88841379|NCT04976972|Experimental|Robotic-Total Knee Replacement (R-TKR)|NAVIO/CORI Surgical System
88841380|NCT04976972|Active Comparator|Conventional-Total Knee Replacement (C-TKR)|Non-robotic conventional instrumentation
88841381|NCT04976738|Experimental|Treatment arm: Cybis™ 10:25 THC:CBD oil|Cybis™ 10:25 THC:CBD oil administered oromucosally at doses varying from 0.5 mL once daily to 1.5 mL twice daily. Total duration of dosing is 28 days.
88841382|NCT04951934|Experimental|EmoLED Group|The EmoLED Group will undergo treatment with EmoLED twice a week for 5 consecutive weeks. The therapy, in this case, in addition to the standard treatment, will also include a treatment with the EmoLED device.
88841383|NCT04951934|Active Comparator|Control Group|The Control Group will follow the standard treatment indicated.
88841384|NCT04950296|Active Comparator|Group I: L. plantarum UALp-05TM,|One capsule to be taken orally before lunch with a glass of water. In case the dose is missed, advise participant to take before dinner.
88841385|NCT04950296|Active Comparator|Group II: L. plantarum UALp-05TM,|One capsule to be taken orally before lunch with a glass of water. In case the dose is missed, advise participant to take before dinner.
88841386|NCT04950296|Placebo Comparator|Microcrystalline Cellulose|One capsule to be taken orally before lunch with a glass of water. In case the dose is missed, advise participant to take before dinner.
88841387|NCT03787082|Experimental|Chlorhexidine Gluconate Mouthwash|rinse with chlorhexidine gluconate 0.12% (15mL) mouthwash before administration of 14N Sodium Nitrate 1,000 mg/11.18 mmol, oral
88841388|NCT03787082|Placebo Comparator|Placebo Mouthwash|rinse with placebo mouthwash (15mL) before administration of 14N Sodium Nitrate 1,000 mg/11.18 mmol, oral
88841389|NCT05451134||patients with dysglycemia|Patients with dysglycemia in the included subjects with pheochromocytoma and paraganglioma
88841390|NCT05451134||patients without dysglycemia|Patients without dysglycemia in the included subjects with pheochromocytoma and paraganglioma
88841391|NCT05449886|Experimental|Tidal volume challenge|
88841392|NCT04945304||Magnetic bariatric surgery|Bariatric procedure performed in a human using magnetic assistance in the steps of the surgery
88841393|NCT02165202|Active Comparator|Rilpivirine|Arm 1: Participants randomized to the active arm will receive rilpivirine 25 mg capsules once daily for four weeks to be taken orally with a meal. Participants will then receive IM injections of TMC278 LA, 1200 mg dose, at eight week intervals (at Weeks 4, 12, 20, 28, 36 and 44). On each dosing occasion 1200 mg of TMC278 LA will be delivered in two, 2 mL injections, one in each gluteus maximus muscle. All participants will receive a total of six doses (12 IM injections).
88841394|NCT02165202|Placebo Comparator|Placebo|Arm 2: Participants randomized to the placebo arm will receive placebo capsules once daily for four weeks to be taken orally with a meal. Participants will then receive IM injections of saline (0.9% NaCI) at eight week intervals (at Weeks 4, 12, 20, 28, 36 and 44). On each dosing occasion placebo will be delivered in two, 2 mL injections, one in each gluteus maximus muscle. All participants will receive a total of six doses (12 IM injections).
88841395|NCT03695978||Nuwiq|All patients receiving Nuwiq (recombinant FVIII)
88841396|NCT03695978||Octanate|All patients receiving Octanate (plasma derived FVIII)
88841397|NCT03695978||Wilate|All patients receiving Wilate (plasma derived FVIII/von Willebrand factor [VWF])
88841398|NCT01628874|Experimental|Lidocaine Injection|0.5 mL (5mg) of 1% lidocaine injection given with the J-Tip
89179714|NCT02594475|Experimental|Left lateral position|Endoscopic retrograde cholangiopancreatography is performed in left lateral position in this group.
89368710|NCT03192592|Experimental|Body moisturizer Apotech®|Instructions for use: Massage the product in the body twice a day (morning and evening) with gentle movements until completely absorption. Daily use for 28 days.
89368711|NCT03705260|Active Comparator|Comparator- High Risk|A high risk sub group of those assigned to the comparator arm will be identified by their most recent A1C > 8. Patients in this group will receive usual care from their Primary Care Physician and dietitian.
89368712|NCT03705260|Active Comparator|Comparator- Well Controlled|The low risk sub group from the comparator arm (A1C < 8) and those who are unlikely to benefit from an intensive behavioral intervention will get usual care by their Primary Care Physician and their dietitian.
89368713|NCT03705260|Experimental|Enhanced Care- High Risk|A high risk sub group of those assigned to the enhanced care arm will be identified by their most recent A1C > 8. Patients in this group will receive the intensive behavioral intervention which will incorporate lower carbohydrate diet, diet coaching, and more intensive glucose monitoring.
89368714|NCT03705260|Experimental|Enhanced Care- Well Controlled.|The low risk sub group from the enhanced care arm (A1C < 8) and those who are unlikely to benefit from an intensive behavioral intervention will get usual care by their PCP and their dietitian. If they are found to be poorly controlled through monthly screening for risk, they may have the opportunity to move into the Enhanced Care High Risk group.
89368715|NCT03118180|Experimental|CART19 group|All patients were included for CART19 therapy
89368716|NCT03705182|Experimental|Interventiongroup|The intervention group will be shown the fluorescent areas on their skin (fluorescence visualization feedback)
89368717|NCT03705182|No Intervention|Control group|The control group will not be shown the fluorescent areas on their skin (no feedback)
89368718|NCT03193762||Painful hospitalized patient|The anxiety of those patients will be measured with an Anxiety VAS
89368719|NCT03118102||anesthetist group|anesthetist doctor who subjected to noise in operating rooms
89368720|NCT03118102||control group|doctors in the same hospital who are not subjected to noise in operating rooms
88841399|NCT01628874|Active Comparator|lidocaine 2.5% and prilocaine 2.5% (EMLA) Cream|Patients in this arm will receive 1g EMLA cream if they are in the younger age group and 10g EMLA cream if they are in the older age group. This will be placed for a minimum of 30 minutes.
88841400|NCT04891718|Experimental|MVC-101 and Nivolumab|Patients with HNSCC who are scheduled for surgical biopsy or tumour resection surgery will be injected at least four hours to up to three days prior to surgery using the CIVO device. Each needle of the CIVO device will deliver up to 8.3 microliters of solution, including a vehicle control (sterile saline and solution stabilizer), a pre-cleaved/pre-activated drug control (cMVC-101), MVC-101 (the prodrug), or nivolumab as single agents or as combinations. Each drug will be delivered in subtherapeutic microdoses, and each microdose is simultaneously injected in a columnar fashion through each of 3, 5, or 8 needles (in a device configuration determined by tumour dimensions) into a single solid tumour or effaced metastatic lymph node.
88841401|NCT03770689|Experimental|Peposertib 50 mg + RT + Capecitabine|Participants received peposertib 50 milligram (mg) once daily in combination with capecitabine 825 milligram per square meter (mg/m^2) twice daily 5 days per week and radiotherapy (RT) of 50 to 50.4 Gray (Gy) to the tumor area and 45 Gy to the electively irradiated tissues in 25 to 28 fractions up to 5.5 weeks treatment period.
88841402|NCT03770689|Experimental|Peposertib 100 mg + RT + Capecitabine|Participants received peposertib 100 mg once daily in combination with capecitabine 825 mg/m^2 twice daily 5 days per week and RT of 50 to 50.4 Gy to the tumor area and 45 Gy to the electively irradiated tissues in 25 to 28 fractions up to 5.5 weeks treatment period.
88841403|NCT03770689|Experimental|Peposertib 150 mg + RT + Capecitabine|Participants received peposertib 150 mg once daily in combination with capecitabine 825 mg/m^2 twice daily 5 days per week and RT of 50 to 50.4 Gy to the tumor area and 45 Gy to the electively irradiated tissues in 25 to 28 fractions up to 5.5 weeks treatment period.
88841404|NCT03770689|Experimental|Peposertib 250 mg + RT + Capecitabine|Participants received peposertib 250 mg once daily in combination with capecitabine 825 mg/m^2 twice daily 5 days per week and RT of 50 to 50.4 Gy to the tumor area and 45 Gy to the electively irradiated tissues in 25 to 28 fractions up to 5.5 weeks treatment period.
88841405|NCT00371384|Experimental|2|structural massage
89368721|NCT03193918|Experimental|Crenolanib combined with ramucirumab/paclitaxel|
88841406|NCT00371384|Experimental|1|relaxation massage
89179715|NCT02594475|Active Comparator|Prone position|Endoscopic retrograde cholangiopancreatography is performed in prone position in this group.
89368722|NCT05427812|Experimental|Phase 1: Dose escalation|Participants with R/R multiple myeloma (MM) will be administered ISB 1442 weekly by subcutaneous (SC) injection in each 28-day cycle. Dose escalation will begin with an accelerated titration dose escalation and should certain conversion criteria be met, escalation will convert to the standard (3 + 3) dose escalation
89368723|NCT05427812|Experimental|Phase 2 (Dose Expansion): Cohort A: R/R Multiple Myeloma|This cohort includes the participants with pathologically confirmed R/R MM and must have received at least 3 prior lines of therapy, including proteasome inhibitors (PIs), immunomodulators (IMiDs), and anti CD38 therapies either in combination or as a single agent; and must not be candidates for regimens known to provide clinical benefit. Participants will receive the recommended Phase 2 Dose (RP2D) of ISB 1442 SC injection determined in Phase 1 of the study for treatment of R/R MM. Each treatment cycle duration is 28 days. The anticipated total duration for each participant will vary, depending on the number of cycles of treatment completed. The treatment phase will extend until participants experience disease progression or unacceptable toxicity, or until any other discontinuation criterion is met.
89368724|NCT05427812|Experimental|Phase 2 (Dose Expansion): Cohort B: R/R MM Post-T-cell-Directed Therapy|This cohort includes the participants with pathologically confirmed R/R MM post T cell-directed therapy and have received prior treatment with proteasome inhibitors (PIs), immunomodulators (IMiDs), and anti-CD38 therapies either in combination or as a single agent; and must have failed at least 3 prior lines of treatment. Participants will receive the RP2D of ISB 1442 SC injection determined in Phase 1 of the study. Each treatment cycle duration is 28 days. The anticipated total duration for each participant will vary, depending on the number of cycles of treatment completed. The treatment phase will extend until participants experience disease progression or unacceptable toxicity, or until any other discontinuation criterion is met.
89534758|NCT03231553|No Intervention|Control|Receive usual NHS antenatal care and any NHS smoking cessation support which they choose to access plus an NHS leaflet giving advice on stopping smoking.
89368725|NCT02449096|Other|ORIF group|"No arthroscope ORIF = Open reduction and internal fixation~All Patients will be operated following a standardized protocol of our foot and ankle department:~Posterior malleolus: ORIF of the posterior malleolus fractures will be performed using a one-third tubular plate in an antiglide-technique.~Lateral malleolus: If the patients suffer a fracture of the posterior and lateral malleolus, a posterolateral approach will be performed. After posterior fracture fixation a lag screw and a one-third tubular plate will be used laterally. In special cases a locking plate will be used. If the patient only suffers a lateral malleolus fracture, we utilize the standard lateral incision.~Medial malleolus: We perform a curved incision and two cannulated leg screws/tension wiring or locking plate for fixation.~Syndesmotic complex: After all, the stability of the syndesmotic complex is tested and reduction will be performed if necessary."
88841407|NCT02196714|Experimental|Glycopyrronium and Formoterol Fumarate (GFF) Dose 1|Glycopyrronium and Formoterol Fumarate metered-dose inhaler MDI (GFF MDI), Dose 1; PT003 administered as 2 inhalations twice-daily (BID)
88841408|NCT02196714|Experimental|Glycopyrronium and Formoterol Fumarate (GFF) Dose 2|Glycopyrronium and Formoterol Fumarate metered-dose inhaler MDI (GFF MDI), Dose 2; PT003 administered as 2 inhalations twice-daily (BID)
89368726|NCT02449096|Active Comparator|AORIF group|Arthroscope AORIF = Arthroscopically assisted open reduction and internal fixation Our standard operative protocol is described above. Intervention: In case of randomization to the AORIF group, the arthroscopic procedure will be performed as the first step during the surgery before internal fixation. No distraction device will be used for the ankle. To avoid lesions of the cartilage and soft tissue, the joint will first be inflated with saline, and the portals will be created by blunt dissection. A 2.7mm, 30° arthroscope will be inserted into the ankle through a standard anteromedial portal. Fluid will be aspirated and the cavity filled with water. Afterwards the standard anterolateral portal will be performed in the same way. A standardized systematic examination as described by Ferkel and Fasulo will be performed to inspect the internal structures. At this stage loose bodies and disrupted ligaments extending into the joint will be removed.
89368727|NCT03117790|Experimental|Dexmedetomidine group|Morphine (0.5 mg/ml, in a total volume of 160 ml) is used for patient-controlled analgesia. Dexmedetomidine (200 ug) is added to the formula of patient-controlled analgesia. Patient-controlled analgesia is provided during the first 3 days after surgery.
88841409|NCT02196714|Experimental|Glycopyrronium (GP) Dose 1|Glycopyrronium metered-dose inhaler MDI (GP MDI), Dose 1; PT001 administered as 2 inhalations twice-daily (BID)
88841410|NCT02196714|Experimental|Glycopyrronium (GP) Dose 2|Glycopyrronium metered-dose inhaler MDI (GP MDI), Dose 2; PT001 administered as 2 inhalations twice-daily (BID)
89368728|NCT03117790|Placebo Comparator|Placebo group|Morphine (0.5 mg/ml, in a total volume of 160 ml) is used for patient-controlled analgesia. Placebo (normal saline) is added to the formula of patient-controlled analgesia. Patient-controlled analgesia is provided during the first 3 days after surgery.
89368729|NCT03117712||Delirium|patients who develop postoperative delirium after surgery with cardiopulmonary bypass measured by Delirium scores (CAM-ICU, ICDSC), TCD for detection of HITS and carotis duplex sonography
88841411|NCT03620474|Experimental|PRI-724|"Dose: 140, 280, 380 mg / m 2/4 hr~Administration method:~【Phase I Phase】 (Level 1) 140 mg / m 2/4 hr (Level 2) 280 mg / m 2/4 hr (Level 3) 380 mg / m 2/4 hr Twice weekly, continuous 4-hour intravenous administration (tolerance of administration time: ± 15 minutes). This is one cycle and 12 cycles (12 weeks in total) are carried out. However, in Phase I phase, single dose is administered on Day - 7 (tolerance: - 7 days).~【Phase IIa phase】 Continuous intravenous administration for 4 hours twice a week at the recommended dose determined in Phase I. This is one cycle and 12 cycles (12 weeks in total) are carried out."
88841412|NCT04337905|Experimental|Children with ADHD|Children with ADHD that running the ADHD-VR diagnostic test and also did the psychiatric examination to determine the ADHD diagnosis and to rule out other mental disorders
88841413|NCT04337905|Active Comparator|Children without ADHD|Healthy children that also running the ADHD-VR diagnostic test and also psyhchiatric examination to rule out the ADHD diagnosis and other mental disorders
88841414|NCT03566264||Participants hospitalized with ADHF|
88841415|NCT00370760|Active Comparator|1|
88841416|NCT00370760|Placebo Comparator|2|
88841417|NCT05227508|Experimental|Brizo SC012|A capsule containing 400 mg. SC012 (unique soy extract) TWICE A DAY : MORNING , EVENING.
88841418|NCT05227508|Placebo Comparator|PLACEBO|A capsule containing 400 mg OF PLACEBO, TWICE A DAY: MORNING , EVENING.
88841419|NCT05203562|Active Comparator|Control group I|Patients with complete mole treated by evacuation of using suction curettage followed by conservative follow up
88841420|NCT05203562|Experimental|Prophylactic letrozole group II|Patients with complete mole treated by evacuation of using suction curettage followed by 5mg daily letrozole for 10 days followed by conservative follow up
88841421|NCT05145374||Stressful Stimuli|Participation in meal, exercise, sleep activities alone or in combination with stressful stimuli.
88841422|NCT04844138|Experimental|Online Self-Directed Program|Participants in this condition will complete our six-week online self-directed program as soon as it's available.
88841423|NCT04844138|Other|Waitlist|Participants in this condition will receive treatment as usual for six weeks, after which point they will be invited to complete our online program.
88841424|NCT05453383|Experimental|Anlotinib and Toripalimab treatment|Anlotinib Hydrochloride and Toripalimab Injection
88841425|NCT05453305|Active Comparator|Control group: Traditional venipuncture, on the stretcher.|the companion will place the child on the stretcher in the supine position with the limb to be punctured in decline. At all times, during the technique, the companion will be present, being able to participate by establishing links of consolation or distraction, as is usually done in the hospital. Simultaneously, a professional from the service will be in charge of holding the chosen extremity, as well as the opposite one. The responsible nurse will perform the venipuncture while another colleague will help with tasks of holding and/or collecting samples.
89179716|NCT00585975|Experimental|Bromfenac Ophthalmic Solution 0.18%|
89179717|NCT00585975|Experimental|Xibrom 0.09%|
88841426|NCT05453305|Experimental|Experimental group: DAK method venipuncture, simulating a hug.|the caregiver will sit in a chair placing the child on top in front of him, with one leg on each side and the arms resting on the shoulders of the companion. The patient's head will rest on the adult's shoulder, contralateral to the limb to be punctured. Simultaneously, the responsible adult patient will hold the simulating a hug. A professional will take care of immobilizing the chosen limb. The responsible nurse performed the venipuncture while another colleague helped with the tasks of holding and/or collecting samples.
88841427|NCT04766762|Experimental|Acupuncture combined with placebo group|Patients in this group will receive acupuncture combined with placebo.
88841428|NCT04766762|Other|Sham acupuncture combined with medication group|Participants in this group will receive sham acupuncture plus flunarizine hydrochloride.
88841429|NCT04330040|Experimental|Single Arm|Intervention: Drug: Olaparib
88841430|NCT02737891|Experimental|Tesofensine/Metoprolol|Oral tablets Tesofensine/Metoprolol
88841431|NCT02737891|Placebo Comparator|Placebo|Placebo tablets matching oral Tesofensine/Metoprolol
88841432|NCT04994834|Experimental|Intervention|Probiotics
88841433|NCT02196558|Experimental|E6011, 100 mg Arm|E6011 will be administered repeatedly, subcutaneously at Week 0, 1, 2, followed by every 2 weeks upto 10 weeks (treatment phase).100 mg group will receive E6011 subcutaneously, 1 ml. If a subject intends to continue administrations; the subject will receive a total of 20 subsequent biweekly administrations (40 weeks) at stable dose (Extension phase).
88841434|NCT02196558|Experimental|E6011, 200 mg Arm|E6011 will be administered repeatedly, subcutaneously at Week 0, 1, 2, followed by every 2 weeks upto 10 weeks (treatment phase). 200 mg group will receive E6011 subcutaneously, 1 ml each at two sites. If a subject intends to continue administrations; the subject will receive a total of 20 subsequent biweekly administrations (40 weeks) at stable dose (Extension phase).
88841435|NCT02196558|Experimental|E6011, 400 mg Arm|E6011 will be administered repeatedly, subcutaneously at Week 0, 1, 2, followed by every 2 weeks up to 10 weeks (treatment phase). 400 mg group will receive E6011 subcutaneously, 1 ml each at four sites or 2 ml each at two sites. If a subject intends to continue administrations, the subject will receive a total of 20 subsequent biweekly administrations (40 weeks) at stable dose (Extension Phase).
88841436|NCT04941092||patients with ARDS induced by SARS CoV 2|
88841437|NCT04941092||patients with ARDS induced by influenza|
88841438|NCT05453149|Experimental|Persons with Neurological Conditions|
88841439|NCT04902404|Experimental|First Pathways Group|Parents in the First Pathways Game group will be instructed to log into the First Pathways website daily and play First Pathways games with their child. They will receive daily reminders for the first month after randomization but will not receive reminders for the second month.
88841440|NCT04902404|No Intervention|Wait-list Control|Parents in the wait-list control group will receive access to the First Pathways game after completing their final two-month study assessment.
88841441|NCT04338217|Experimental|Bionator|The modified Bionator was used to correct the open bite malocclusion. Patients were asked to wear the appliance every day.
88841442|NCT04338217|Active Comparator|Removable Appliance with Posterior Bite Planes|A removable appliance with poster bite planes was used to correct the open bite malocclusion. Patients were asked to wear this appliance full time expect eating times.
88841443|NCT05452993|Experimental|1 - Retinophotography for diabetic retinopathy screening|Patients who accepted to participate to this study and had retinophotography for diabetic retinopathy screening.
88841444|NCT05452993|No Intervention|2 - No screening|Patients who did not meet inclusion criteria and/or refused the retinophotographies screening.
89179718|NCT04088253|Experimental|cirrhotic patient|cirrhotic patient with umbilical hernia to be operated
89179719|NCT00918021|Active Comparator|olanzapine (B)|Group B: In addition to clozapine, the participants receive their normal dosage of olanzapine (=the same as on the hospital ward) for 12 weeks, next the decreasing dosage of olanzapine for four weeks and subsequently placebo for 8 weeks.
89179720|NCT00918021|Placebo Comparator|placebo (A)|Group A: : In addition to clozapine the participants receive the decreasing dosage of olanzapine for four weeks, next placebo for 8 weeks, after that the increasing dosage of olanzapine for four weeks and subsequently the normal dosage of olanzapine for 8 weeks.
89179721|NCT02594007|Experimental|discharge home|SEEQ for 28 days. Cardiocom for 30 days
89179722|NCT02594007|Experimental|discharge to skilled nursing facility|SEEQ for 28 days, DocView for 30 days
89179723|NCT00585585|Experimental|Arm 1: Betahistine dihydrochloride|Oral betahistine dihydrochloride; daily dose 50-300 mg
89179724|NCT02594085|Experimental|Patch 3/Patch4 + Patch1/patch2 + patch 5/patch 6|"The subjects test 6 adhesive strips; two in each test period. The patches are tested in pairs i.e Patch 1 and patch 2 are a pair; Patch 3 and Patch 4 are a piar and patch 5 and patch 6 are a pair. The test order of the patch pairs is randomised between the three periods.~In this arm the the subjects test:~Test period 1: Patch 3 and Patch 4 Test period 2: Patch 1 and Patch 2 Test period 3: Patch 5 and Patch 6"
89368730|NCT03117712||No delirium|patients who develop no postoperative delirium after surgery with cardiopulmonary bypass measured by delirium scores (CAM-ICU, ICDSC), TCD for detection of HITS and carotis duplex sonography
88841445|NCT02740153||Urea Cycle Disorder with Liver Transplant|"Age 18 and under~Diagnosed with the following Neonatal-type urea cycle disorders: CPSD, OTCD, ASD or ALD~History of liver transplant"
89179725|NCT02594085|Experimental|Patch 1/Patch2 + Patch3/patch4 + patch 5/patch 6|"The subjects test 6 adhesive strips; two in each test period. The patches are tested in pairs i.e Patch 1 and patch 2 are a pair; Patch 3 and Patch 4 are a piar and patch 5 and patch 6 are a pair. The test order of the patch pairs is randomised between the three periods.~In this arm the the subjects test:~Test period 1: Patch 1 and Patch 2 Test period 2: Patch 3 and Patch 4 Test period 3: Patch 5 and Patch 6"
89179726|NCT02594085|Experimental|Patch 1/Patch2 + Patch5/patch 6 + patch 3/patch 4|"The subjects test 6 adhesive strips; two in each test period. The patches are tested in pairs i.e Patch 1 and patch 2 are a pair; Patch 3 and Patch 4 are a piar and patch 5 and patch 6 are a pair. The test order of the patch pairs is randomised between the three periods.~In this arm the the subjects test:~Test period 1: Patch 1 and Patch 2 Test period 2: Patch 3 and Patch 4 Test period 3: Patch 5 and Patch 6"
89368731|NCT03193372||Rosacea Concierge Program|Patients diagnosed with rosacea and currently receiving topical monotherapy with Finacea Foam
89534759|NCT03327935|Experimental|Nutrition|Oral nutritional supplements and dietetic advice
89179727|NCT02594085|Experimental|Patch 3/Patch4 + Patch5/patch6 + patch 3/patch 4|"The subjects test 6 adhesive strips; two in each test period. The patches are tested in pairs i.e Patch 1 and patch 2 are a pair; Patch 3 and Patch 4 are a piar and patch 5 and patch 6 are a pair. The test order of the patch pairs is randomised between the three periods.~In this arm the the subjects test:~Test period 1: Patch 3 and Patch 4 Test period 2: Patch 5 and Patch 6 Test period 3: Patch 1 and Patch 2"
88841446|NCT02740153||Urea Cycle Disorder without Transplant|"Age 18 and under~Diagnosed with the following Neonatal-type urea cycle disorders: CPSD, OTCD, ASD or ALD~No history of liver transplant, managed medically"
88841447|NCT04809662||Main cohort|This is a split-body study, with patients acting as their own controls between lesional and nonlesional skin. All patients will apply imiquimod.
88841448|NCT02196324|Active Comparator|serlopitant 5 mg tablets|serlopitant 5 mg tablets
88841449|NCT02196324|Placebo Comparator|Placebo tablets|Placebo tablets
88841450|NCT03618979|Experimental|PPP treatment|Platelet Poor Plasma (PPP) into the multifidus on each side and at each level 1 time per week for 6 weeks (series of 6 injections)
88841451|NCT03618979|Experimental|PRP treatment|5x concentration Platelet Rich Plasma (PRP) injected into the multifidus on each side and at each level 1 time per week for 6 weeks (series of 6 injections)
88841452|NCT03618979|Experimental|PRP and PL Combo treatment|5x concentration PRP injected into the multifidus, along with a facet joint injection with 14x PRP into each joint and capsule, and transforaminal epidural injection with of 3x concentrated platelet lysate (PL) and 0.5% ropivacaine on each side and at each level 1 time every 2 weeks for 6 weeks total (series of 3 injections)
88841453|NCT03448016|Experimental|Alcohol use disorders|[C-11]NOP-1A PET Scan
88841454|NCT03448016|Experimental|Controls|[C-11]NOP-1A PET Scan
88841455|NCT03390530|Active Comparator|Thyroxine treatment|Intravenous thyroxine in a dose of 8 µg/kg/day divided into two doses (every 12 hours)
88841456|NCT03390530|Placebo Comparator|Placebo treatment|Intravenous placebo treatment every 12 hours.
89179728|NCT02594085|Experimental|Patch 5/Patch 6 + Patch 3/patch 4 + patch 1/patch 2|"The subjects test 6 adhesive strips; two in each test period. The patches are tested in pairs i.e Patch 1 and patch 2 are a pair; Patch 3 and Patch 4 are a piar and patch 5 and patch 6 are a pair. The test order of the patch pairs is randomised between the three periods.~In this arm the the subjects test:~Test period 1: Patch 5 and Patch 6 Test period 2: Patch 3 and Patch 4 Test period 3: Patch 1 and Patch 2"
89179729|NCT02594085|Experimental|Patch 5/Patch 6 + Patch1/patch2 + patch 3/patch 4|"The subjects test 6 adhesive strips; two in each test period. The patches are tested in pairs i.e Patch 1 and patch 2 are a pair; Patch 3 and Patch 4 are a piar and patch 5 and patch 6 are a pair. The test order of the patch pairs is randomised between the three periods.~In this arm the the subjects test:~Test period 1: Patch 1 and Patch 2 Test period 2: Patch 3 and Patch 4 Test period 3: Patch 5 and Patch 6"
89179730|NCT02593929|Experimental|ruxolitinib|Ruxolitinib will be taken orally for 14-21 days prior to surgery, every morning and every evening, and will be discontinued after the morning dose on the day of planned surgical resection.
89179731|NCT02593851|Experimental|Part 1: Cohort 1a|Participants (greater than or equal to [>=] 6 months and less than or equal to [<=] 24 months of age) will receive JNJ-53718678, 2 milligram per kilogram body weight (mg/kg) oral solution once daily on Day 1 to Day 7. Dose and/or dosing regimen may be adapted in subsequent cohorts based on the review of the safety/tolerability and full pharmacokinetic data from Cohort 1a.
89179732|NCT02593851|Experimental|Part 1: Cohort 1b|Participants (>= 6 months and <= 24 months of age) will receive total daily dose of 6 mg/kg JNJ-53718678 oral solution or placebo [either in once daily [qd] or twice daily [bid]) on Day 1 to Day 7.
89179733|NCT02593851|Experimental|Part 1: Cohort 1c|Participants (>= 6 months and <= 24 months of age) will receive total daily dose of 18 mg/kg JNJ-53718678 oral solution or placebo [either in a qd or a bid regimen] on Day 1 to Day 7.
89179734|NCT02593851|Experimental|Part 1: Cohort 1d|Participants (>= 6 months and <= 24 months of age) will receive JNJ-53718678 oral solution or placebo [either in a qd or a bid regimen] on Day 1 to Day 7. The cohort 1d is optional and may be included at the discretion of the sponsor.
89534760|NCT03327935|Experimental|Nutrition and exercise|Oral nutritional supplements, dietetic advice and exercise training
89534761|NCT03327935|No Intervention|Control|Standard Hospital Procedure
89534762|NCT05025501|Experimental|Intervention group|"Subjects in this group will receive the Famliy based Executive Function Training  program in aiming to reduce ADHD symptoms and improve the executive function."
89179735|NCT02593851|Experimental|Part 1: Cohort 1e|Participants (>= 6 months and <= 24 months of age) will receive JNJ-53718678 oral solution or placebo [either in a qd or a bid regimen] on Day 1 to Day 7. The cohort 1e is optional and may be included at the discretion of the sponsor.
89179736|NCT02593851|Experimental|Part 1: Cohort 2a|Participants (>= 3 months and less than [<] 6 months of age) will receive total daily dose of 1.5 mg/kg JNJ-53718678 oral solution [either in a qd or a bid regimen] on Day 1 to Day 7.
89534763|NCT05025501|No Intervention|Waiting group|"Subjects in this group will not receive the Famliy based Executive Function Training  program during the study period."
89534764|NCT03240367|Experimental|coutery|Stapler bloom will be stopped with cautery
89534765|NCT03240367|No Intervention|clips|Stapler bloom will be stopped with clipping
89534766|NCT05024799|Experimental|F-P group|the combination of fentanyl and propofol
89534767|NCT05024799|Experimental|F-D group|the combination of fentanyl and dexmedetomidine
89534768|NCT05024799|Experimental|B-P group|the combination of butorphanol and propofol
89534769|NCT05024799|Experimental|B-D group|the combination of butorphanol and dexmedetomidine
89534770|NCT03333473|Experimental|Intervention|The intervention will be applied to health facilities in one district in Indonesia and one county in Kenya. The intervention package will work within existing public and private health facilities to strengthen and assess the effectiveness of facility and provider level PPFP service provision and counseling, and expand method choice for women during antenatal, early labor, and post-pregnancy pre-discharge periods. Training within the intervention package include provider-lever PPFP counseling and service provision (PPFP Clinical and Counseling Skills), as well as provider and facility-level leadership management and governance training (Facility-Level Leadership Management and Governance Training).
89179737|NCT02593851|Experimental|Part 1: Cohort 2b|Participants (>=3 months and < 6 months of age) will receive total daily dose of 4.5 mg/kg JNJ-53718678 oral solution or placebo [either in a qd or a bid regimen] on Day 1 to Day 7.
89179738|NCT02593851|Experimental|Part 1: Cohort 2c|Participants (>= 3 months and < 6 months of age) will receive total daily dose of 13.5 mg/kg JNJ-53718678 oral solution or placebo [either in a qd or a bid regimen] on Day 1 to Day 7
89179739|NCT02593851|Experimental|Part 1: Cohort 2d|Participants (>= 3 months and < 6 months of age) will receive JNJ-53718678 oral solution or placebo [either in a qd or a bid regimen] on Day 1 to Day 7. The cohort 2d is optional and may be included at the discretion of the sponsor.
89179740|NCT02593851|Experimental|Part 1: Cohort 2e|Participants (>= 3 months and < 6 months of age) will receive JNJ-53718678 oral solution or placebo [either in a qd or a bid regimen] on Day 1 to Day 7. The cohort 2e is optional and may be included at the discretion of the sponsor.
89179741|NCT02593851|Experimental|Part 1: Cohort 3a|Participants (greater than (>) 1 month and < 3 months of age) will receive total daily dose of 1 mg/kg JNJ-53718678 oral solution [either in a qd or a bid regimen] on Day 1 to Day 7.
89179742|NCT02593851|Experimental|Part 1: Cohort 3b|Participants (> 1 month and < 3 months of age) will receive total daily dose of 3 mg/kg JNJ-53718678 oral solution or placebo [either in a qd or a bid regimen] on Day 1 to Day 7.
89179743|NCT02593851|Experimental|Part 1: Cohort 3c|Participants (> 1 month and < 3 months of age) will receive total daily dose of 9 mg/kg JNJ-53718678 oral solution or placebo [either in a qd or a bid regimen] on Day 1 to Day 7.
89179744|NCT02593851|Experimental|Part 1: Cohort 3d|Participants (> 1 month and < 3 months of age) will receive JNJ-53718678 oral solution or placebo [either in a qd or a bid regimen] on Day 1 to Day 7. The cohort 3d is optional and may be included at the discretion of the sponsor.
89179745|NCT02593851|Experimental|Part 1: Cohort 3e|Participants (> 1 month and < 3 months of age) will receive JNJ-53718678 oral solution or placebo [either in a qd or a bid regimen] on Day 1 to Day 7. The cohort 3e is optional and may be included at the discretion of the sponsor.
89179746|NCT02593851|Experimental|Part 2: Cohort f|Participants of all age groups will receive daily dose of JNJ-53718678 oral solution or placebo, either in a qd or a bid regimen on Days 1 to 7.
89179747|NCT02593695|Experimental|Deep Brain Stimulation|Continuous deep brain stimulation of bilateral nucleus accumbens
89179748|NCT02593695|Active Comparator|Standard Control|Fluoxetine
89179749|NCT00734097|Experimental|Nexium 40 mgs|
89179750|NCT00819767|Experimental|Aliskiren|For the first week of the 8 week treatment period, patients received aliskiren 150 mg, placebo to aliskiren, and 2 capsules of placebo to valsartan. For the remaining 7 weeks of the study, patients received aliskiren 300 mg (two 150 mg tablets) and 2 capsules of placebo to valsartan. The tablets and capsules (2 of each) were taken orally once daily each morning. To evaluate a missed dose, the last dose of medication was administered at the clinic, and the patient was scheduled to return 2 days later for exercise testing (8 weeks + 2 days).
89179751|NCT00819767|Active Comparator|Valsartan|For the first week of the 8 week treatment period, patients received valsartan 160 mg, placebo to valsartan, and 2 tablets of placebo to aliskiren. For the remaining 7 weeks of the study, patients received valsartan 320 mg (two 160 mg capsules) and 2 tablets of placebo to aliskiren. The tablets and capsules (2 of each) were taken orally once daily each morning. To evaluate a missed dose, the last dose of medication was administered at the clinic, and the patient was scheduled to return 2 days later for exercise testing (8 weeks + 2 days).
89179752|NCT02593617|Other|University students who use alcohol|In Addiction Profile Index, university students who use alcohol in last year.
89179753|NCT02593617|Other|University students who don't use alcohol|In Addiction Profile Index, university students who don't use alcohol in last year.
89179754|NCT02593617|Other|University students who use energy drinks|In energy drink consumption questionnaire, university students who use energy drinks in last year.
89179755|NCT02593617|Other|University students who don't use energy drinks|In energy drink consumption questionnaire, university students who don't use energy drinks in last year.
89179756|NCT02593617|Other|University students who use substance|In Addiction Profile Index, university students who use substance in last year.
89179757|NCT02593617|Other|University students who don't use substance|In Addiction Profile Index, university students who don't use substance in last year.
89179758|NCT00922961|Experimental|cellular apoptosis|
89179759|NCT00918099|Active Comparator|Avaulta mesh|Avaulta mesh
89179760|NCT00918099|Active Comparator|Anterior repair|Anterior repair
89179761|NCT05297357|Experimental|Mediterranean Diet group|
89179762|NCT05297357|No Intervention|Control group|
89179763|NCT04088175|Experimental|Group 1 - Virginia Tobacco and Menthol|Subjects randomized to Group 1 will use JUUL ENDS Virginia Tobacco and Menthol flavors
89179764|NCT04088175|Experimental|Group 2 - Mint and Mango|Subjects randomized to Group 2 will use JUUL ENDS Mint and Mango flavors
89179765|NCT00733005|Experimental|Arm 1|Mometasone furoate nasal spray 200 mcg QD (once per day)
89179766|NCT00733005|Placebo Comparator|Arm 2|Matching placebo nasal spray
89368732|NCT03034772|Active Comparator|Dorzolamide-timolol|Topical dorzolamide-timolol twice daily for the study duration. All patients will continue to receive intravitreal anti-VEGF injections at regularly scheduled intervals.
89368733|NCT03034772|Placebo Comparator|Artificial tears|Topical artificial tears twice daily for the study duration. All patients will continue to receive intravitreal anti-VEGF injections at regularly scheduled intervals.
89179767|NCT00812981|Experimental|1562902A NP GROUP|Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of the new-processed (NP) 1562902A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Days 0 and 21.
89179768|NCT00812981|Experimental|1562902A CP GROUP|Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of the comparative-processed (CP) 1562902A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Days 0 and 21.
89179769|NCT00732615|Placebo Comparator|Placebo|Sterile water for injection
89179770|NCT00732615|Experimental|50, 75, 100 mcg NPSP558|Initial dose of 50mcg, to be titrated up to 75mcg and then 100mcg dependent upon response
89179771|NCT00923039||Exposed/ Not exposed|
88841457|NCT03534739|Experimental|Pain Inducing Massage|Participants will receive manual pressure applied to one myofascial trigger point.
88841458|NCT03534739|Active Comparator|Light Touch Massage|Participants will receive light touch applied to one myofascial trigger point.
89179772|NCT00732381|Experimental|Arm 1|Mometasone furoate nasal spray 200 mcg QD (once per day)
88841459|NCT03534739|Placebo Comparator|Coldpressor|Participants will place hand into water cooled to 6 degrees Celsius (males) or 8 degrees Celsius (females).
88841460|NCT05450419|Active Comparator|Vitamin D3|Patient received enteral supplementation of 576,000 IU vitamin D3 on week 1, then enteral supplementation of 72,000 IU vitamin D3 on week 2, week 3 & week 4.
88841461|NCT05450419|Placebo Comparator|Placebo|Patient received enteral supplementation of placebo on week 1, then enteral supplementation of placebo on week 2, week 3 & week 4.
88841462|NCT03507049|Active Comparator|Intervention group|The intervention Group receives operation with SI-joint arthrodesis with the iFuse implant. The patient undergoes full anesthesia. The procedure starts with an approximately 5cm long skin incision over the posterolateral aspect of the pelvis. A guide-pin is inserted over the sacroiliac joint at the desired entry-point, verified by fluoroscopy. The surgeons drills and boraches over the pin and the ifuse implant is inserted. This is repeated for a total of three implants. The wound is closed with non-resorbable suture. An injection of the SIJ with local anesthetic is performed under guidance of fluoroscopy at the time of the procedure.
88841463|NCT03507049|Sham Comparator|Sham group|"The sham operation will consist of the surgeon making the same skin incision as for an iFuse procedure, although nothing more, and then closing the wound.~The patients undergoing a sham operation will be under general anesthesia for a random time of 20-40minutes in order to keep the two procedures as similar as possible.~An injection of the SIJ with local anesthetic is performed under guidance of fluoroscopy at the time of the procedure."
88841464|NCT03507049|Other|Functional MRI study|The Swedish patients will also undergo quantitative sensory testing at inclusion and at 6 month follow-up. At the same time they will undergo a cerebral MRI and a Functional MRI looking at activation of the CNS from pain in the sacroiliac joints induced by one leg lift. The purpose of this study is to look at contributing factors in treatment response. One hopes to map which CNS mechanisms are involved in causing the chronic pain these patients experience as well as how they respond to treatment.
88841465|NCT03345446||Patients with HF-rEF|These patients have Heart Failure with Reduced Ejection Fraction (EF < 55% per the protocol).
88841466|NCT03345446||Patients with HF-pEF|These patients have Heart Failure with Preserved Ejection Fraction (EF > 55% per the protocol).
89179773|NCT00732381|Placebo Comparator|Arm 2|Matching placebo nasal spray
89179774|NCT04871711|Experimental|Delgocitinib cream 20 mg/g|Twice-daily topical application for 16 weeks
89179775|NCT04871711|Placebo Comparator|Cream vehicle|Twice-daily topical application for 16 weeks
89179776|NCT05756543||Cases|Individuals diagnosed with Parkinson's Disease consecutively recruited at the beginning of rehabilitative treatment at the Istituto Auxologico Italiano, IRCCS, San Giuseppe Hospital (Italy). Concurrent neurological, neurodevelopmental (e.g., autism), motor or psychiatric disorders were exclusion criteria.
89179777|NCT05756543||Controls|Age-matched healthy individuals recruited outside the hospital through personal contacts of the researchers and word-of-mouth.
89179778|NCT00913991|Experimental|Stress Management #1|8 weeks of individual stress management training sessions
89179779|NCT00913991|Active Comparator|Stress Management #2|8 weeks of individual stress management training sessions
89179780|NCT00732303|Experimental|1|"Pemetrexed (Alimta) 500mg/m^2 administered intravenously over approximately 10-minutes on Day 1 of a 21-day cycle x 3 cycles~Radiation will start between days -1 to 2 from day 1 of cycle 1. Day 1 radiotherapy must be a Monday, Tuesday, or Wednesday.~The planned radiation dose is 60 Gy in 2.0 Gy fractions. The entire PTV, including primary tumor and areas of known nodal disease, shall receive 60 Gy at 2.0 Gy fractions, 5 fractions/week for 30 fractions over 6 weeks."
89368734|NCT03196336|Other|Intervention|The intervention is the pharmacotherapeutic follow-up care. This service is performed according to the Pharmacotherapy Workup method, which is a protocol for the pharmacotherapeutic follow-up. This service identify, prevent and solve drug-related problems. It consiste of five pharmaceutical consultations (every up to 2-3 months) with the patient.
89368735|NCT03196336|Other|Control|The intervention is the usual procedure of dispensation of drugs. It is performed in five meetings (every up to 2-3 months) between the investigator and the patient.
89368736|NCT03196258|Experimental|intervention - CBT|Participants in this arm will receive 6 weekly one-on-one, 1-hour sessions of Cognitive Behavioural Therapy session (intervention) in addition to receiving standard of care treatment for their fracture(s).
88841467|NCT02195700|Experimental|SD-809|SD-809 tablets taken twice daily for 12 weeks.
88841468|NCT02195700|Placebo Comparator|Sugar Pill|Placebo tablets taken twice daily for 12 weeks.
88841469|NCT05349344|Experimental|Aerobic Circuit Training|Each session consists of 5 minutes of warming up,20 minutes of aerobic exercises with brief resting periods, followed by 5 minutes to cool down.
88841470|NCT05349344|Active Comparator|outdoor walk|30minutes Walking outside below 40% of HR max for 2 months.(3 times per week for 8 weeks).
88841471|NCT02740543|Active Comparator|Allergic Asthma (AA)|
88841472|NCT02740543|No Intervention|Control|
88841473|NCT02228460|Experimental|GZ/SAR402671|GZ/SAR402671 15 milligram (mg) once daily orally for 26 weeks.
89179781|NCT02593461|Experimental|Diafert|The embryo to be transferred is selected on the basis of both morphological assessment performed on Day 2 or 3 and FF G-CSF concentration. FF G-CSF concentration will be measured with the Diafert® immunoassay.
89179782|NCT02593461|Other|Control Group|The embryo to be transferred is selected on the basis of morphological assessment performed on Day 2 or 3.
89179783|NCT00813761|Other|02Optix CL and ReNu MPS with SICS|O2Optix contact lens and ReNu MultiPlus Multi-Purpose Solution
89179784|NCT00813761|Other|Proclear CL and ReNu MPS with SICS|Proclear contact lens and ReNu MultiPlus Multi-Purpose Solution
89179785|NCT00813761|Other|02Optix CL and Clear Care LCS with SICS|O2Optix contact lens and Clear Care lens care solution subject
89179786|NCT00813761|Other|Proclear CL and Clear Care LCS with SICS|Proclear contact lens and Clear Care lens care solution
88841474|NCT05349266|Experimental|ThisCART19A 2×10^6 cells/kg for dose level 1|Patients will receive 2×10^6 cells/kg of ThisCART19A
88841475|NCT05349266|Experimental|ThisCART19A 3×10^6 cells/kg as dose level 2|Patients will receive 3×10^6 cells/kg of ThisCART19A
88841476|NCT05349266|Experimental|Patients will receive 4×10^6 cells/kg as dose level 3|Patients will receive 4×10^6 cells/kg of ThisCART19A
88841477|NCT00370747|Experimental|Ecabet|Ophthalmic solution in the Study eye four times daily for 90 days.
88841478|NCT00370747|Placebo Comparator|Placebo|Ophthalmic solution in the Study eye four times daily for 90 days.
88841479|NCT02752256||Intervention/Transfer|Patients who are transferred via air ambulance to a comprehensive stroke center
88841480|NCT02752256||Control|Patients presenting directly to the comprehensive stroke center
88841481|NCT05368909|Experimental|Arm 1 before Cross Over|Participants were randomized and divided into two groups: Supplement Group and Placebo Group. In this Arm 1, participants first go through a 1-week washout period, and then take either Supplement or Placebo as assigned for 2 week.
88841482|NCT05368909|Experimental|Arm 2 after Cross Over|In Arm 2, Supplement Group and Placebo Group cross over. After a 1-week washout period, and both group will take whatever product they did not take in Arm 2, for 2 week.
88841483|NCT03454555|Active Comparator|Arm 1|Arm 1 participants will receive guideline-concordant pharmacotherapy based on clinical guidelines for opioid therapy for chronic noncancer pain plus the Shared Decision Making (SDM) intervention during their opioid management visits.
88841484|NCT03454555|Active Comparator|Arm 2|Arm 2 participants will receive the guideline-concordant pharmacotherapy based on clinical guidelines for opioid therapy for chronic noncancer pain plus the Motivational Interviewing and Cognitive Behavioral Therapy for Chronic Pain (MI+CBT-CP) Intervention.
88841485|NCT04104542|Experimental|Mindfulness MTHM|online mindfulness based stress reduction training
88841486|NCT04104542|Experimental|Mindfulness JBSA|online mindfulness based stress reduction training
88841487|NCT04104542|Sham Comparator|Healthy Lifestyle MTHM|online healthy lifestyle training
88841488|NCT04104542|Sham Comparator|Healthy Lifestyle JBSA|online healthy lifestyle training
88841489|NCT02227446|Experimental|Vancomycin Antibotic Powder|"Participants in the treatment group will receive the study intervention of a maximum dose of 1000mg of Vancomycin antibiotic powder in their wound bed, which is placed right before wound closure. Vancomycin antibiotic powder may be combined with normal saline as per clinical practice at the participating institution.~In addition, participants in this group will receive standard of care treatment for their injury, to include all institution specific standard treatment (prophylactic and otherwise) for preventing and treating infection."
88841490|NCT02227446|No Intervention|Standard of Care|Participants in this group will receive standard of care treatment for their injury, to include all institution specific standard treatment (prophylactic and otherwise) for preventing and treating infection. Participants in this group will not receive local Vancomycin antibiotic powder.
88841491|NCT00371371|Experimental|BM-MNC|autologous bone marrow-derived mononuclear cells
88841492|NCT00371371|Placebo Comparator|Placebo|Placebo
88841493|NCT04738058|Experimental|Preterm infants diagnosed as feeding intolerance will receive bovine lactoferrin|they will receive bovine lactoferrin 100mg/day with feeding for 4 weeks or until discharge for preterm that was diagnosed as feeding intolerance
88841494|NCT04738058|Placebo Comparator|Preterm infants diagnosed with feeding intolerance will receive placebo|they will receive the placebo with feeding for 4 weeks or until discharge for preterm that was diagnosed as feeding intolerance
88841495|NCT02227368|Experimental|Ticagrelor|26 Weeks of ticagrelor 90mg twice a day plus aspirin placebo once daily
88841496|NCT02227368|Active Comparator|Aspirin|26 Weeks of aspirin 100mg once daily plus ticagrelor placebo twice a day
88841497|NCT02162862|Other|Behavioral Counseling|Brief Behavioral Therapy for Sleep Disruption in IBD (BBTS-I). This treatment phase focuses on treating insomnia, a nighttime component of sleep disturbance delivered in 1:1 sessions which can be completed in person or by phone, except for initial session.
88841498|NCT02162862|Other|Behavioral counseling + bupropion-SR|Brief Behavioral Therapy for Sleep Disruption in IBD (BBTS-I) plus bupropion-SR (bupropion-Sustained Release). 8-week trial of bupropion-SR (target dose: 200-300 mg/day). bup-SR, a noradrenergic dopaminergic reuptake inhibitor (NDRI). NDRI has been shown to improve fatigue and rapid eye movement-sleep (REM) in medically ill populations.
88841499|NCT02162862|No Intervention|Healthy Control|The healthy control group includes individuals who are free of physical and psychiatric illness between the ages of 15-30.
88841500|NCT02752490|Active Comparator|Liberal use of maternal oxygen|Administration of maternal oxygen, 100% FiO2 at 10L/min via nonrebreather face mask with any category 2 tracing as defined by the American Congress of Obstetrics and Gynecology (ACOG) at the discretion of the primary nurse or physician
88841501|NCT02752490|Experimental|Indicated use of maternal oxygen|Administration of maternal oxygen, 100% fraction of inspired oxygen (FiO2) at 10 liters/min via nonrebreather face mask only in the setting of a category 2 tracing with recurrent late fetal heart rate decelerations, prolonged fetal deceleration, fetal tachycardia, or minimal to absent fetal heart rate variability lasting 30 minutes or greater. Maternal oxygen is discontinued once these conditions have resolved and may be readministered if they recur.
88841502|NCT03402607|Active Comparator|Percutaneous Local Ablation (PLA)|A PLA procedure uses high-energy radio waves to treat liver tumors. Using CT and ultrasound guidance the doctor inserts a thin, needle-like probe into the liver tumor A high-frequency current is then passed through the tip of the probe, which heats the tumor with the goal to destroy the cancer cells. This may be done as an outpatient procedure or a short (1-2 day) hospital stay. PLA is the standard treatment for patients with liver cancer who cannot undergo liver surgery.
89179787|NCT00813761|Other|02Optix CL and ReNu MPS without SICS|O2Optix contact lens and ReNu MultiPlus Multi-Purpose Solution
89179788|NCT00813761|Other|Proclear CL and ReNu MPS without SICS|Proclear contact lens and ReNu MultiPlus Multi-Purpose Solution
89179789|NCT00813761|Other|02Optix CL and Clear Care LCS without SICS|O2Optix contact lens and Clear Care lens care solution
89368737|NCT03196258|No Intervention|control|Participants in the control arm of the study will receive standard of care treatment for their fracture(s) but will not receive any Cognitive Behavioral Therapy.
89368738|NCT03704870|Active Comparator|Daily Chest Xray (standard)|
88841503|NCT03402607|Active Comparator|Hypofractionated Image-Guided Radiation Therapy (HIGRT)|HIGRT is an emerging treatment option for patients with HCC; it utilizes external radiation where multiple beams enter the body from multiple angles to treat the liver cancer over typically 5-10 treatments while minimizing radiation to normal tissues. You will receive between 5-10 fractions (treatments) of radiation. Fraction size will be either 5 or 10 Gy (pronounced Gray, a standard unit of radiation measurement) depending on your tumor size and location or underlying liver function. The total dose of radiation is 50 Gy.
88841504|NCT02752880|Experimental|YH1 group|YH1 with one batch number was manufactured by Sun Ten Pharmaceutical Co., Ltd., a renowned manufacturer of concentrated herbal extract granules conforming to the standards of good manufacturing practices (GMP) in New Taipei City, Taiwan. YH1 contains Rhizoma Coptidis (50 %) and Shen-Ling-Bai-Zhu-San (SLBZS) (50 %). SLBZS consists of Radix Ginseng, Poria, Rhizoma Atractylodis macrocephalae, Semen Lablab album, Rhizoma Dioscoreae, Embryo Nelumbinis, Radix Platycodonis, Semen Coicis, Fructus Amomi, Fructus Jujubae, and Radix Glycyrrhizae at a 3:3:3:2.3:3:1.5:1.5:1.5:1.5:1.5:3 ratio. Subjects in the YH1 group orally ingested two packages of granules (3 g/package) three times daily with warm water after a meal for 12 consecutive weeks.
88841505|NCT02752880|Placebo Comparator|placebo group|The placebo was also prepared as granules by Sun Ten Pharmaceutical Co., Ltd., and the packaging of the placebo was identical to that of YH1. Subjects in the placebo group orally ingested two packages of granules (3 g/package) three times daily with warm water after a meal for 12 consecutive weeks.
88841506|NCT05277727|Experimental|Fucoidan|"Fucoidan in Capsule~Intervention: Dietary Supplement: Probiotic"
88841507|NCT05277727|Placebo Comparator|Placebo|"Non active ingredients in a capsule~Intervention: Other: Placebo"
88841508|NCT04054232|Experimental|EHR Alert|Twenty-five participants who are flagged by the screening tool as having high risk of undiagnosed peripheral artery disease (PAD) will be randomized to have their primary care physician receive an electronic health record message regarding their high risk of having PAD and a recommendation will be made to have the participant referred for non-invasive testing called Ankle Brachial Index (ABI) testing to confirm diagnosis. For individuals who undergo ABI testing and are confirmed to have PAD, they and their physicians will be provided with American Heart Association Guidelines for the management of PAD. Each participant's medical record will be reviewed for 6 months to evaluate for referral for ABI testing, referral to cardiovascular specialists (vascular medicine, vascular surgery or a cardiologist), and for initiation of new cardiovascular related medications such as an antiplatelet, statins, or anti-hypertensive medications.
88841509|NCT04054232|No Intervention|No EHR Alert|Twenty-five participants who are flagged by the screening tool as having high risk of undiagnosed peripheral artery disease (PAD) will be randomized to the control arm and they nor their physicians will be alerted of their status for 6 months. Each participant's medical record will be reviewed for 6 months to evaluate for referral for ABI testing, referral to cardiovascular specialists (vascular medicine, vascular surgery or a cardiologist), and for initiation of new cardiovascular related medications such as an antiplatelet, statins, or anti-hypertensive medications. At the end of 6 months of observation, the primary care physician's of control participants will receive the same alert as participants in the intervention arm.
88841510|NCT02226198|Active Comparator|Rosuvastatin|6-week treatment period, and after crossover finished a 12-week efficacy maintenance phase for all patients
88841511|NCT02226198|Placebo Comparator|Placebo|6 weeks treatment during crossover
88841512|NCT02754518|Other|Open label Entresto|All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure. In this study subjects will take this drug as they normally would for their standard of care.
88841513|NCT05177029|Experimental|Part A: Lu AG06466 or Placebo|Participants will receive single dose of Lu AG06466 capsule or matching placebo orally on Day 1.
88841514|NCT05177029|Experimental|Part B: Lu AG06466 or Placebo|Participants will receive starting dose of Lu AG06466 capsule or matching placebo orally once daily from Day 1 to Day 4 followed by Lu AG06466 capsule or matching placebo at a titrated treatment dose orally once daily from Day 5 until Day 8. Participants will then receive LuAG06466 capsule or matching placebo at a higher assigned dose orally once daily from Day 9 to Day 15.
88841515|NCT05169307||CPX-351|Adult patients with newly diagnosed, therapy related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) who were treated in routine practice with Vyxeos liposomal in the UK.
88841516|NCT02751385|Experimental|All Patients|Microgynon alone in Period 1 then with Nintedanib in Period 2
88841517|NCT05349032|Other|Meriva|120 mg of curcumin in Meriva.
89368739|NCT03704870|Experimental|Chest Xray post chest tube removal only|
89368740|NCT03196102|Experimental|BTI + Cigarette smoking military tailored pamphlet|BTI + Cigarette smoking military tailored pamphlet
89368741|NCT03196102|Active Comparator|Cigarette smoking military tailored pamphlet|Cigarette smoking military tailored pamphlet
89368742|NCT03196102|Active Comparator|Standard smoking cessation pamphlet|Standard smoking cessation pamphlet
88841518|NCT05349032|Other|Longvida|120 mg of curcumin Longvida.
89368743|NCT03192514|Experimental|Electronic Deprescribing tool|GPs of enrolled patients with access to the electronic Deprescribing tool
89368744|NCT03192514|No Intervention|Usual Care|Usual care By GP´s
89368745|NCT02448940|Experimental|Species of Lactobacillus|2 capsule/day of Lactofem Containing Species of Lactobacillus
89368746|NCT02448940|Placebo Comparator|lactose|2 capsule/day Containing lactose
89399190|NCT03624075|Experimental|intervention group|The intervention group will receive the same protocol as the placebo group, differing only in relation to the tension of the bandage. According to Kase et al (2003), the techniques recommend the relief of pain and edema and performance. In the second technique to be applied, the tape body will be divided lengthwise into four narrow strips. The two pieces intersect the front of the knee. For this application, the volunteer will be positioned in the dorsal position without knee flexion and the tape will be applied by a trained researcher. In the case of bilateral OA, in both techniques of application, the most affected member based on the NPRS score will be the one that will undergo the intervention. All volunteers will remain with the tape for 72 hours.
89002037|NCT06116851||suspicion|"Inclusion criteria for the suspicion cohort include clinical suspicion for PCa and indication for PCA diagnostics based on any of the following: 1) elevated PSA (>2.5 ng/ml), 2) palpable prostate tumor/nodule, 3) image finding suggestive of PCa.~The suspicion cohort will include a total of 300 subjects who will undergo PCa diagnostics including prostate MRI, and transrectal ultrasound (TRUS) guided prostate biopsies. After the diagnostic procedures all subjects are categorized to one of the following groups: 1) subject without PCa, 2) subject with clinically non-significant PCa (ISUP grade 1/Gleason 3+3), 3) clinically significant PCa (ISUP grade >1/>Gleason 3+3).~Based on the outcome of the PCa diagnostics and planned clinical treatment, subjects may be eligible to other cohorts as well."
89002038|NCT06116851||cancer (radical prostatectomy) cohort|Inclusion criteria for the cancer cohort include clinically significant prostate cancer planned to be treated with radical prostatectomy with or without pelvic lymph node dissection. The cancer cohort will include a total of 50 subjects.
89002039|NCT06116851||benign/TURP-cohort|Inclusion criteria for the benign (TURP) cohort includes benign prostate hyperplasia (BPH) planned to be treated with transurethral resection of the prostate (TURP). The benign/TURP-cohort will include a total of 50 subjects.
89002040|NCT06116851||benign/cystectomy|Inclusion criteria for the benign/cystectomy cohort includes bladder cancer planned to be treated with removal of the urinary bladder and prostate (cystoprostatectomy). The benign/cystectomy cohort will include a total of 25 subjects.
89002041|NCT06116825|Experimental|Experiment group|In the experimental group, students from grades three to six in four primary schools in Chiayi County participated. Participating school children are taught the correct method of brushing their teeth, and flossing is also taught in the upper grades. The experimental group used toothpaste containing 1,450 ppm fluoride and asked students to use it at least twice a day, one of which was to clean their teeth before bed. During the pre-test and 4-week post-test, the plaque control index (Plaque Control Record; PCR) was checked and a self-administered questionnaire was filled out.
89002042|NCT06116825|Active Comparator|Control group|In the control group, students from grades three to six in four primary schools in Chiayi County participated. All participating children receive instruction on proper tooth brushing techniques, with flossing included in higher grades. Schoolchildren in the control group were given toothpaste containing 1,000 ppm fluoride and were asked to use it at least twice a day, including once to clean their teeth before bed. During the pre-test and 4-week post-test, the plaque control index (Plaque Control Record; PCR) was checked and a self-administered questionnaire was filled out.
89002043|NCT06116799|Experimental|Carbon fiber insole|assigned carbon fiber insole
89002044|NCT06116799|Active Comparator|Polyurethane|Assigned polyurethane insole
89002045|NCT06116799|Active Comparator|Polyethylene|assigned polyethylene insole
89002046|NCT06116773|Experimental|Training Group|Training group, in addition to secondary prevention approaches and home exercise program, will be applied 3 sessions/week, 60 minutes of supervised cardiac rehabilitation program for 8 weeks.
89002047|NCT06116773|Active Comparator|Control Group|Control group will be informed about secondary prevention approaches and a home exercise program will be recommended.
89002048|NCT06116734|Experimental|Biosimilar pegfilgrastim|Day +5 of cell infusion: Biosimilar pegfilgrastim or Lapelga™ (one dose)
89002049|NCT06116734|Active Comparator|Biosimilar filgrastim|Day +5 of cell infusion: Biosimilar filgrastim or Grastofil® (one dose for 5 days)
89002050|NCT06116695|Experimental|human-treated dentin matrix|drug: Human-treated dentin matrix young permanent molars treated with human-treated dentin matrix
89002051|NCT06116695|Placebo Comparator|mineral tri oxide aggregate|Drug: Mineral Trioxide Aggregate young permanent molars treated with Mineral Trioxide Aggregate mineral trioxide aggregate was used as control
89002052|NCT06116682|Experimental|Treatment (amivantamab)|Patients receive amivantamab IV on days 1 and 2 in week and once a week in weeks 2-4 of cycle 1 and then on days 1 and 15 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI and collection of blood samples throughout the trial.
89002053|NCT06116643|Experimental|Standard Active Therapy plus SPHi|Participants will undergo the standard active therapy of ulcerative colitis plus the addition of the ProGo medical food.
89002054|NCT06116630||Stroke|Patients who have a history of stroke will be in the first group.
89002055|NCT06116630||Control|Patients who do not have a history of stroke, but have a history of cardiovascular risk factors will be in the second group.
89002056|NCT06116565|Experimental|CM310|
89399191|NCT03692247|Other|Quantitative Sensory Testing|After answering brief questionnaires assessing psychosocial factors related to anxiety, catastrophizing, and pain, participants will undergo quantitative sensory tests where they will use a simple numeric rating scale (0-10) to rate pain and anxiety at several points during two QST sessions. During the second QST session, participants will use Unwind, a smartphone-based music intervention.
89530406|NCT03245359|Experimental|Long-term ON-Q|Single port, select-a-flow pump and two 750mL ON-Q balls filled with bupivacaine 0.125% saphenous (adductor canal) nerve block and single port, fixed flow pump and two 400mL ON-Q ball with bupivacaine 0.125% wide field posterior knee block to provide analgesia from surgery up to 7 days post-operative. The second ball for each location will be provided pre-operatively, along with patient education for connection.
89002057|NCT06116552|Experimental|More and Less Social Comprehension|Participants listen to more social and less social comprehension stories and answer comprehension questions about the stories.
89002058|NCT06116539|Experimental|Cyanoacrylate Group|In the test group, a cyanoacrylate-based tissue adhesive (PeriAcryl 90 HV; Glustitch, Delta, Canada) will be applied.
89002059|NCT06116539|Active Comparator|Suture Group|In the control group, the edges will be approximated with 4/0 monofilament non-absorbable nylon suture (Aragó, Barcelona, Spain).
89002060|NCT06116513||Patients with old troublesome radical cavities|These patients would have old Canal Wall Down cavities that were troublesome
89002061|NCT06116474|Experimental|Web based intervention group|The web-based intervention group participated in an 8-week exercise program, which consisted of three sessions per week, each lasting approximately 20 to 35 minutes.
89002062|NCT06116474|No Intervention|Control Group|The control group did not engage in any prescribed exercise protocol.
89002063|NCT06116461|Experimental|Nivolumab|Patients in the experimental arm receive three reduced nivolumab doses of 240 mg Q4W
88841519|NCT05349032|Other|NovaSol|120 mg of curcumin NovaSol
88841520|NCT05349032|Other|CurcElite|120 mg of curcumin CurcElite
88841521|NCT05349032|Other|UltaCur|120 mg of curcumin Ultracur
88841522|NCT05057689|Experimental|Intranasal Dexmedetomidine (4 mcg/kg)|Dexmedetomidine 100 mcg/mL (concentration of 200 mcg/2 mL) will be atomized for intranasal administration at a dose of 4 mcg/kg (0.04 mL/kg) according to a weight-based dosing chart. The maximum dose will be 200 mcg.
88841523|NCT05057689|Experimental|Intranasal Fentanyl (2 mcg/kg)|Fentanyl 50 mcg/mL (concentration of 100 mcg/2 mL) will be atomized for intranasal administration at a dose of 2 mcg/kg (0.04 mL/kg) according to a weight-based dosing chart. The maximum dose will be 100 mcg.
88841524|NCT05057689|Experimental|Intranasal Midazolam (5 mg/kg)|Midazolam 5 mg/mL (concentration of 10 mg/2 mL) will be atomized for intranasal administration at a dose of 0.3 mg/kg (0.06 mL/kg) according to a weight-based dosing chart. The maximum dose will be 10 mg
88841525|NCT02754674|Experimental|Transportal|this is a type of anterior cruciate ligament reconstruction. this arm for patients who underwent operation with transportal technique
88841526|NCT02754674|Experimental|Outside in|this is a type of anterior cruciate ligament reconstruction. this arm for patients who underwent operation with patients who underwent operation with outside in technique
88841527|NCT04737980|Experimental|Experimental Group: Interscalene block with liposomal bupivacaine combined with bupivacaine|Interscalene nerve block was performed utilizing ultrasound guidance with infiltration of 10 ml of liposomal bupivacaine 1.3% (133 mg) combined with 10 ml of 0.5% bupivacaine hydrochloride.
88841528|NCT04737980|Active Comparator|Control Group: Interscalene block with ropivacaine combined with dexamethasone|Interscalene nerve block was performed utilizing ultrasound guidance with infiltration of 30ml of 0.5% ropivacaine combined with a 2 ml volume of 8mg of dexamethasone.
88841529|NCT03459170|Experimental|BPX-501 T cells and rimiducid|"All subjects will receive 3 courses of BPX-501 T cell infusions at escalating dose levels (DL). DL1 on Day 0, DL2 on Days 30 and 60. The first dose of BPX-501 T cells will occur ≥30 days after hematopoietic stem cell transplant (HSCT).~Two doses of AP1903 ( 0.1 mg/kg and 0.4 mg/kg) will be investigated for the treatment of aGvHD after BPX-501 T cell infusion."
88841530|NCT05348798||Ultra endurance athletes|Individual participating in ultra endurance sports (events exceeding 6 hours) including running, cycling, triathlon, swimming and Nordic skiing. Participants are above 18 years of age and volunteer to participate in this web-based survey.
88841531|NCT02756624|Experimental|AC-170 0.24%|1 drop in each eye 3 times daily for up to 6 weeks
88841532|NCT02756624|Placebo Comparator|AC-170 Vehicle|1 drop in each eye 3 times daily for up to 6 weeks
88841533|NCT02753413|Experimental|RSV group|Subjects in this group will receive a single dose of the RSV vaccine.
88841534|NCT02753413|Active Comparator|Boostrix group|Subjects in this group will receive a single dose of Boostrix.
88841535|NCT02958800|Experimental|Intervention|The intervention consists of assigning each participant to their own single patient open label trial consisting of a 1:1 randomized sequence of two pre-determined dose reductions of atypical antipsychotics for each participant in order to determine any behavioural issues that arise from atypical antipsychotic dose alteration.
88841536|NCT04937491||Healthy volunteers|Adult healthy volunteers (students). Intervention 1: Intake of water (2% of body weight) Intervention 2: Intake of sports drink (2% of body weight) Intervention 3: Intake of soya saus (salt): 10 ml (equal to 8 g salt) Intervention 4: Intake of 90 g sugar (jelly figures)
88841537|NCT04850521||Remote monitoring|Remote monitoring software + connected devices
88841538|NCT03380000|Active Comparator|Nitrate rich beetroot juice|Subjects will consume 140 ml of beetroot juice (Beet-It Organic Shot) approximately 90 min before physiological testing.
88841539|NCT03380000|Placebo Comparator|Nitrate depleted beetroot juice|Subjects will consume 140 ml of beetroot juice (Beet-It Organic Placebo) approximately 90 min before physiological testing.
88841540|NCT02754427|Experimental|Prospective Surveillance Group|Women assigned to surveillance group were assessed for arm morbidity at pre-surgery and at 3, 6, and 9 months post-surgery. If arm morbidity was detected at any time-point post-surgery, then a physiotherapy intervention was prescribed.
88841541|NCT02754427|Active Comparator|Education Group|Participants in the education group received the usual post-operative follow-up.
88841542|NCT02973932|Experimental|Internet-based psychotherapy|
88841543|NCT04777669|Experimental|Experiment|Subjects will be tested for their ability to understand speech with and without noise reduction
88841544|NCT04759885|Experimental|Phase II: NTC015 low dose (Mannitol 50 g)|One day single dose preparation same day of colonoscopy
88841545|NCT04759885|Experimental|Phase II: NTC015 medium dose (Mannitol 100 g)|One day single dose preparation same day of colonoscopy
88841546|NCT04759885|Experimental|Phase II: NTC015 high dose (Mannitol 150 g)|One day single dose preparation same day of colonoscopy
88841547|NCT04759885|Experimental|Phase III: NTC015 selected dose|One day single dose preparation same day of colonoscopy
88841548|NCT04759885|Active Comparator|Phase III: Polyethylene glycol plus ascorbate solution (2L PEG ASC) (Moviprep®)|Two litres of Moviprep® taken according to split-dose regimen (to commence in the evening before colonoscopy)
88841549|NCT05348720||COVID-19 ICU survivor|COVID-19 patients admitted to ICU between the 1st of March 2020 and the 30rd of May 2021, who survived ICU stay and still alive 18 months after ICU discharge.
88841550|NCT05348720||Relatives|Relative of those COVID-19 patients enrolled in the 'COVID-19 ICU survivor' cohort
88875227|NCT02531022|Experimental|Intervention|Participants will be given a wearable device to monitor daily step counts with automated daily feedback on goal attainment via text message or email. A baseline step count will be calculated for each participant (weeks 1-2) and then they will be given a daily step goal with an increase of 15 percentage point each week during the 8-week ramp-up period (weeks 3-10) with a maximum goal of 10,000 steps. Then they'll be asked to maintain that step count (maintenance period). During the ramp-up and maintenance period they'll have a financial incentive of $14 allocated each week and $2 taken away each day the goal is not achieved. They'll be followed up for 8 weeks without incentives
88875228|NCT02532036|Experimental|Starter Group|Receive 1x10^7 pfu aerosol inhaled MVA85A at day 0.
88841551|NCT02754661|Experimental|COLON Capsule endoscopy|"Subjects will be instructed to follow a detailed dietary and colon preparation regimen prior to and during the CCE procedure day. With the exception of Gastrografin, all colon preparation products will be standard colon cleansing products approved by the FDA.~Between 45 and 75 minutes after the final Polyethylene Glycol (PEG) ingestion, the subject will swallow the PillCam COLON Capsule with a cup of water.~If necessary, capsule position will be monitored to ensure adequate booster administration. Subjects will keep a timed diary of key preparation steps and bowel activity, including capsule excretion. Subjects will be allowed to leave the unit 10 hours after capsule ingestion if the capsule is not yet excreted. Subjects leaving before excretion will be instructed to disconnect the recorder at excretion or 12 hours after capsule ingestion (whichever comes first)."
88841552|NCT02754661|Active Comparator|Computed Tomographic Colonography|"Subjects will be instructed to follow a detailed dietary and colon preparation regimen prior to and during the Computed Tomographic Colonography (CTC) procedure day.~The CTC procedure and study interpretation will be conducted in accordance with the ACR-SAR-SCBT-MR Practice Parameter for the Performance of CT Colonography in Adults. Colon insufflation will be performed with the subject in the lateral decubitus or supine position.With the subject in the supine position, a CT scout image will be taken to confirm adequate colon distention. If adequate bowel distention is not achieved, additional air will be insufflated into the colon. After scanning the subject in the supine position, the subject will be placed in the prone position, and additional CO2 will be administered. Subsequently, CT will be performed with the subject in the prone position. If a prone position is not possible for the subject, a left lateral decubitus position is preferred for optimal gas and fluid redistribution."
88841553|NCT02757092|Experimental|Home-based rehabilitation program|0-2 weeks,1. aerobic exercise intensity was targeted to reach 10-11 points of perceived exercise (RPE) scale 2. raised their upper limbs while simultaneously performing lower-limb stepping at place for 20 min 3.walked at a comfortable speed for 15 min twice per day.4. Triflo-II was performed 8-10 times per hour. inspiratory muscle training with the initial pressure set at 25%-30% of the maximum inspiratory pressure.3-6 weeks, aerobic exercise reach 12-15 points on the RPE scale. upper-limb resistance exercise (raising of a 250-cc water bottle) and lower-limb stepping for 20 min per day , walking exercise for a total of 30 min. Triflo-II was performed 8-10 times per hour, and train the inspiratory muscle with the pressure intensity adjusted to more than 5% of that in the first stage.
88841554|NCT02757092|Active Comparator|standard care|control group accept the pulmonary rehabilitation (breathing exercise, extremities exercise, breathing muscle training, incentive spirometry (Triflo-II) training, intermittent positive pressure ventilation, chest physical therapy and pain control) only in operation stage on before op-day 3 day and after op-day and without home based pulmonary rehabilitation.
88841555|NCT04728295|Experimental|Exablate Pallidothalamic Tractotomy|Exablate treatment for Advanced Idiopathic Parkinson's Disease
88841556|NCT04738045|Placebo Comparator|control|Remdesivir will be administrated intravenously (IV) at a dose of 200 mg loading dose then 100 mg once daily for 5 days.
88841557|NCT04738045|Experimental|interventional|Remdesivir will be administrated intravenously (IV) at a dose of 200 mg loading dose then 100 mg once daily and Lopinavir / ritonavir at a dose of 400 /100 once daily for 5 days.
88841558|NCT02755129|Other|single arm|"Single arm, all the patients enrolled will perform the same walking exercises.~On arrival to the rehabilitation center subjects will have the Reveal LINQ, the 3D-accelerometers (one on the chest by medical-grade adhesives and a second at the level of the waist over the top of a medical grade adhesive) and the Holter attached externally. Then, they will be asked to perform the following exercises:~Walking Exercises-4 Meter Gait Speed (4MGS) Test Walking exercises - Six Minute Walk (6MW) Test~Walking exercises - 4 Meter Gait Speed (4MGS) Test~Walking Exercises - Five Times Sit to Stand (FTSTS) Test~Walking Exercises - Expanded Timed Get-Up-and-Go (ETGUG) Test"
88841559|NCT04670263|Experimental|Dry Eye Disease|Subjects who will be diagnosed at baseline with Dry Eye Disease according to standard diagnosis
88841560|NCT04670263|Active Comparator|Healthy|Subjects who will be diagnosed at baseline with no Dry Eye Disease according to standard diagnosis
88841561|NCT02755285|Experimental|Single Endoscopy Procedure|All subjects will have 1 endoscopy procedure, in which they will have a white light examination followed by FICE and BLI imaging on a maximum of two (2) anatomical sites per subject.
88841562|NCT02226120|Experimental|LCZ696|Angiotensin receptor antagonist neprilysin inhibitor (ARNI) with target dose of 200 mg bid
88841563|NCT02973919|Experimental|Eye movements|Eye Movement Desensitization and Reprocessing Therapy + virtual reality exposure therapy
89534771|NCT03333473|No Intervention|Control|The health facilities control district in Indonesia and county in Kenya will continue with their standard counseling and service provision throughout the study period. At the conclusion of the study period, the facilities in these areas will receive the same intervention that Intervention facilities received prior to study startup.
89534772|NCT05018637|Experimental|WJ-MSC group|intramedullary injection of 4 x 107 WJ-MSCs (direct injection into the recently fractured vertebra) at baseline (day 0). subcutaneous injection of 20 µg teriparatide once daily for 6 months, followed by oral administration of anti-resorptive drug for 6 months.
89534773|NCT05018637|Active Comparator|Teriparatide group|subcutaneous injection of 20 µg teriparatide once daily for 6 months, followed by oral administration of anti-resorptive drug for 6 months.
89534774|NCT05018949||Patients who have undergone LL angioplasty|Patients who have undergone LL angioplasty are enrolled in study for a medical records review.
89534775|NCT03327701|Active Comparator|Experimental|Subjects will receive benralizumab 30 mg (subcutaneous) every 4 weeks for three doses followed by a fourth dose 8 weeks later.
88841564|NCT02973919|Active Comparator|Control|virtual reality exposure therapy
88875229|NCT02532036|Experimental|Group A|Receive 5x10^7 pfu aerosol inhaled MVA85A, and intramuscular saline placebo both at day 0.
89534776|NCT03327701|Placebo Comparator|Placebo|Subjects will receive placebo 30 mg (subcutaneous) every 4 weeks for three doses followed by a fourth dose 8 weeks later.
89534777|NCT05018559|Experimental|Intervention group nursing care|Participants receive a co-created physical activity intervention called BuG lesson (German: 'Bewegt und Gesund'-Stunde; English: PA and health lesson).
88841565|NCT04587973|Active Comparator|Group Dexmedetomidine|Ropivacaine plus dexmedetomidine group - Preoperative bilateral erector spinae plane block with ropivacaine 0,375% (40 ml) plus dexmedetomidine 1 mcg/kg
88841566|NCT04587973|Active Comparator|Group Ropivacaine|Plain ropivacaine group - Preoperative bilateral erector spinae plane block with ropivacaine 0,375% (40 ml)
88841567|NCT04587973|Placebo Comparator|Group Control|Control group - Preoperative bilateral erector spinae plane block with N/S 0,9% (40 ml)
88841568|NCT02756689|Active Comparator|Inpatient cervical Ripening|Subjects in this arm will be seen in the outpatient setting, and if they qualify and are randomized to the inpatient (control) group, they will be admitted to labor and delivery the next day for cervical ripening with a transcervical Foley catheter.
88841569|NCT02756689|Active Comparator|Outpatient cervical Ripening|Subjects in this arm will undergo cervical ripening with a transcervical Foley catheter in the outpatient setting (treatment arm). The transcervical catheter will be placed in the office after confirmation of fetal well-being. They will then return the next morning to be admitted to labor and delivery for oxytocin administration.
88841570|NCT04766580|Experimental|Children with ADHD group|The same protocol is used for both groups
89534778|NCT05018559|No Intervention|Control group nursing care|Participants do not receive any treatment in addition to their vocational education and training curriculum.
89534779|NCT05018559|Experimental|Intervention group automotive mechatronics|Participants receive a co-created physical activity intervention called tutoring system.
88841571|NCT04766580|Active Comparator|Children with no ADHD group|The same protocol is used for both groups
88841572|NCT04558177|Experimental|Stimulation Group|Will receive ~1.5mA transcranial stimulation for 20 minutes, 5x per week from a direct current stimulator
88841573|NCT04558177|Sham Comparator|Device placed only, no stim|Same as experimental group but the stimulation from the direct current stimulator will be initiated and then stopped
88841574|NCT02757326|Experimental|Phase Ib/II|"For Phase Ib, the planned ABC294640 (Opaganib) doses for the escalation phase are: 250, 500, and 750 mg BID given continuously. The dose will be given under fasting conditions (at least 1 hour before or 2 hours after eating). One cycle is 28 days of treatment.~For phase II study, the patients will be treated with single agent ABC294640 at the MTD determined from the phase IB study (or at the highest dose used, if MTD is not reached) until disease progression or intolerable toxicity occurs in an individual patient."
88841575|NCT02757950||Exposed cohort|Women, 18-45 years of age at the time of pregnancy, who delivered in the hospital (study centre) from May 2015 and who received one dose of Refortrix during 27 to 36 weeks of pregnancy (or as late as 20 days before delivery due date).
88841576|NCT02757950||Unexposed cohort|Women, 18-45 years of age at the time of pregnancy, who delivered in the hospital (study centre) before implementation of the maternal immunization program in Brazil in September 2014 and who did not receive Tdap vaccination during pregnancy.
88841577|NCT05348408|Active Comparator|platelet rich plasma|patients will be injected perineural platelet rich plasmawith 1.5 to 3 ml around each affected nerve
88841578|NCT05348408|Sham Comparator|contact group|only medical treatment in form of opioid and NSAIDs will be used
88841579|NCT02753881|Active Comparator|whole liver lobe cTACE doxorubicin|Participants in this arm are administered 10 cc of chemotherapy, with 50mg doxorubicin and 10 mg of mitomycin-C via cTACE delivered in a lobar (whole liver) manner.
88841580|NCT02753881|Active Comparator|superselective cTACE doxorubicin|Participants in this arm are administered 10 cc of chemotherapy, with 50mg doxorubicin and 10 mg of mitomycin-C via cTACE delivered in a super-selective (close to the tumor) manner.
88841581|NCT02545166||Carotid endarterectomy patients|40 male and female patients, aged 18 years and over, scheduled for carotid endarterectomy. Fasted pre-operative (arterial and capillary), peri-operative (arterial) and 1-hour and 24-hour post-operative (arterial) blood samples will be collected and analysed for serum purine concentration.
88841582|NCT02545166||Control patients|80 age and sex-matched control patients scheduled for non-vascular, non-oncological day surgery. A single pre-operative fasted capillary (finger-prick) blood sample will be collected and analysed for serum purine concentration.
88841583|NCT02545166||Dynamic controls|10 aortic aneurysm repair patients, 10 critical leg ischaemia patients, 10 endovascular aneurysm repair patients, 10 kidney transplant patients, and 10 free flap surgery patients.
88841584|NCT02545166||Local sampling patients|10 Patients undergoing revascularisation, 10 patients undergoing lower limb surgery with a tourniquet and 5 patients diagnosed with acute compartment syndrome.
88841585|NCT05349253|Experimental|Garlic extracts|Take 450mg of Garlic extracts(Food Item Making Report Product Name: Vegetable Extract Powder No. 1905, Item Report No.: 202004980275)
88841586|NCT05349253|Placebo Comparator|placebo|As a food ingredient that does not affect blood pressure and is harmless to the human body, it is made almost identical in weight and appearance to garlic extract.
89534780|NCT05018559|No Intervention|Control group automotive mechatronics|Participants do not receive any treatment in addition to their vocational education and training curriculum.
88841587|NCT04337437|Experimental|Genakumab injection：5 groups|150 mg/1ml/bottle, single subcutaneous injection. Group A : 0.3mg/kg, Group B : 1mg/kg, Group C : 2mg/kg, Group D：4mg/kg, Group E : 6mg/kg,
88841588|NCT04337437|Placebo Comparator|Placebo for this trial : 5 groups|"The placebo contains other excipients except Genakumab, and its appearance is consistent with that of Genakumab for injection, 150 mg/1ml/bottle, single subcutaneous injection.~Group A : 0.3mg/kg, Group B : 1mg/kg, Group C : 2mg/kg, Group D：4mg/kg, Group E : 6mg/kg,"
88841589|NCT05348096|Experimental|Low-dose ibrutinib|Patients will receive ibrutinib 140mg/day PO in combination with oral itraconazole (100mg/day) continuously for six months.
88841590|NCT04337606|Experimental|chidamide in combination with decitabine|chidamide 10mg/day, days 1-5, 20mg/day, day 8, 11,15, 18; decitabine 10 mg/day, days 1-5, every 3 weeks
88841591|NCT04337606|Experimental|decitabine in combination with Camrelizumab|decitabine 10 mg/day, days 1-5, every 3 weeks; camrelizumab 200mg d6
88841592|NCT02759354|Experimental|Group Vaxelis (3+1)|Participants previously vaccinated with a 3-dose primary series of Vaxelis® at 2, 3 and 4 months of age, and a toddler dose at 12 months of age (study V419-007).
88875230|NCT02532036|Experimental|Group B|Receive 5x10^7 pfu intramuscular MVA85A, and aerosol inhaled saline placebo both at day 0.
89534781|NCT03333239|Experimental|psychodynamic psychotherapy|
89534782|NCT03333239|Experimental|cognitive behavioral psychotherapy|
88841593|NCT02759354|Active Comparator|Group Infanrix hexa (3+1)|Participants previously vaccinated with a 3-dose primary series of INFANRIX® hexa at 2, 3 and 4 months of age, and a toddler dose at 12 months of age (study V419-007).
88841594|NCT02759354|Experimental|Group Vaxelis (2+1)|Participants previously vaccinated with a 2-dose primary series of Vaxelis® at 2 and 4 months of age, and a toddler dose at 11-12 months of age (study V419-008).
88841595|NCT02759354|Active Comparator|Group Infanrix hexa (2+1)|Participants previously vaccinated with a 2-dose primary series of INFANRIX® hexa at 2 and 4 months of age, and a toddler dose at 11-12 months of age (study V419-008).
88841596|NCT01190306|Experimental|CXL Treatment|Eyes randomized to the CXL treatment group with be treated with riboflavin and UV light.
88841597|NCT01190306|Active Comparator|Sham Control|Eyes in the control group will be treated with riboflavin only.
89179790|NCT00813761|Other|Proclear CL and Clear Care LCS without SICS|Proclear contact lens and Clear Care lens care solution
89179791|NCT00732069|Active Comparator|Placebo, then ramipril, then valsartan|placebo, ramipril, valsartan: Subjects were treated sequentially with placebo, ramipril (5mg/day by mouth), then valsartan (160mg/day by mouth). Each drug was given for 7 days after a 3-week washout.
89179792|NCT00732069|Active Comparator|Placebo, then valsartan, then ramipril|placebo, ramipril, valsartan: Subjects were treated sequentially with placebo, valsartan (160mg/day by mouth), then ramipril (5mg/day by mouth). Each drug was given for 7 days after a 3-week washout.
89179793|NCT00732069|Active Comparator|Ramipril, then placebo, then valsartan|placebo, ramipril, valsartan: Subjects were treated sequentially with ramipril (5mg/day by mouth), then placebo (once a day by mouth), then valsartan (160mg/day by mouth). Each drug was given for 7 days after a 3-week washout.
89179794|NCT00732069|Active Comparator|Valsartan, then placebo, then ramipril|placebo, ramipril, valsartan: Subjects were treated sequentially with valsartan (160mg/day by mouth), then placebo (once a day by mouth), then ramipril (5mg/day by mouth). Each drug was given for 7 days after a 3-week washout.
89179795|NCT00732069|Active Comparator|Ramipril, then valsartan, then placebo|placebo, ramipril, valsartan: Subjects were treated sequentially with ramipril (5mg/day by mouth), then valsartan (160mg/day by mouth), then placebo (once a day by mouth). Each drug was given for 7 days after a 3-week washout.
89179796|NCT00732069|Active Comparator|Valsartan, then ramipril, then placebo|placebo, ramipril, valsartan: Subjects were treated sequentially with then valsartan (160mg/day by mouth), then ramipril (5mg/day by mouth), then placebo (once a day by mouth). Each drug was given for 7 days after a 3-week washout.
89179797|NCT02593383|Experimental|Treat group 1|Group 1: 0.1% Adapalene + 1% Clindamycin Hydrochloride
89179798|NCT02593383|Experimental|Treatment group 2|Group 2: 0.1% Adapalene + 2% Clindamycin Hydrochloride
89179799|NCT02593383|Experimental|Treatment group 3|Group 3: 0.05% Adapalene + 0.5% Clindamycin Hydrochloride
89179800|NCT02593383|Experimental|Treatment group 4|Group 4: 0.05% Adapalene + 1% Clindamycin Hydrochloride
89179801|NCT02593383|Placebo Comparator|Placebo group|Placebo Group: Blank Gel
89179802|NCT02609321|Experimental|Thoracic Paravertebral Block|to identify the thoracic T3, a parallel line 2.5 cm from the spinous process is drawn and in this place the ultrasound sensor is placed. Ultrasonograph image identifies the transverse process, the intercostal cost-transverse ligament, the pleura and lung. We proceed to insert a needle between the two corresponding transverse processes and positions after passing the cost-ligament posterior intercostal and transverse to the parietal pleura. After negative aspiration for blood, 0.5% bupivacaine anesthetic is administered at doses of 1.5 mg/kg slowly. The volume is defined by the anesthesiologist. The injection of anesthetic is displayed, as well as confirmation of the correct location of the needle because the volume injected above pushes the pleura.
89179803|NCT02609321|Active Comparator|Surgical Wound Infiltration|before the close of the skin, it proceeds to infiltrate the subcutaneous tissue and skin with 0.5% bupivacaine at doses of 1.5 mg/kg, generating the widest possible dissemination of the bupivacaine in the surgical area.
89179804|NCT04856813|Experimental|active|this is the group that does a treatment with active movement, a program of pain education and a program of home exercise.
88841598|NCT02759575|Experimental|Pembrolizumab|Pembrolizumab every 3 weeks in combination with 7 weeks of radiation therapy and every 3 week cisplatin
88875231|NCT02536248|Experimental|Sitagliptin first, then Placebo|"Sitagliptin 100 mg/d for 6 weeks~Wash-out 14 days~Placebo for 6 weeks"
88875232|NCT02536248|Placebo Comparator|Placebo first, then Sitagliptin|"Placebo for 6 weeks~Wash-out 14 days~Sitagliptin 100 mg/d for 6 weeks"
89179805|NCT04856813|Active Comparator|non active|this is the group that does a treatment without active movement, a program of pain education and a program of home exercise.
88841599|NCT02760056|Active Comparator|Liothyronine (cytomel)|Subjects will be divided into 4 groups. The first group will take 25 mcg twice daily for one week. The second group will take 37.5 mcg twice daily for one week. The third group will take 50 mcg twice daily for one week. The firth group will take 75 mcg twice daily for one week
88841600|NCT02760056|Placebo Comparator|Placebo|Subject will take matching placebo twice a day for one week
88841601|NCT05343962||Parkinson's Disease (PD)|Subjects with a medical diagnosis and currently cursing with Parkinson's Disease (PD)
88841602|NCT05343962||Diabetes Mellitus type I and II (DM I/II)|Subjects with a medical diagnosis and currently cursing or who have cursed at some point in the past with SARS Covid-19 Infection (COVID-19)
88841603|NCT05343962||SARS Covid-19 Infection (COVID-19)|Subjects with a medical diagnosis and currently cursing or who have cursed at some point in the past with SARS Covid-19 Infection (COVID-19)
88841604|NCT05343962||Chronic obstructive pulmonary disease (COPD)|Subjects with a medical diagnosis and currently cursing with Chronic obstructive pulmonary disease (COPD).
88841605|NCT05343962||Stroke (ST)|Subjects with a medical diagnosis and who have cursed at some point with Stroke, either ischemic or hemorrhagic (ST)
88841606|NCT05343962||Healthy population (HP)|Healthy population (HP). No chronic or acute conditions declared.
88841607|NCT02764970||ivabradine 7.5mg orally|patients are pretreated with ivabradine and bisoprolol orally before Cardiac CT angiogram
88841608|NCT02764970||bisoprolol|patients are only pretreated with bisoprolol orally before Cardiac CT angiogram
88841609|NCT05336006|Experimental|High-intensity aerobic training with high protein diet - Group A|"High-intensity aerobic training (HAT) was given at 50 to 70 percent of maximum heart rate. Subsequent to stretching, the subjects were asked to do 30 mins of HAT exercises; consisting of 20 mins on the treadmill and 10 mins on a cycle ergometer at 50 to 70 % of MHR, lastly, 10 mins of cool down was performed.~Next the participants, in this group A were prescribed with strength training exercises with resistance depending upon each subject's individual muscle assessment.~In addition to these physical training exercises, this group also received a high protein diet in the range of 1.1 - 1.3 g/kg protein/ ideal body weight/day (>1 g/kg aBW/d), as prescribed by a qualified nutritionist."
88841610|NCT05336006|Placebo Comparator|Control group - Group B|This group is considered a control group and they were allowed to follow their regular physical activities and dietary pattern.
88841611|NCT05320718|Experimental|erector spinae plane block|A needle is inserted until the tip contacted the T5 transverse process under ultrasound guidance. After confirming the needle tip position, 20 ml of 0.5% ropivacaine was injected in the plane between the erector spinae muscles and transverse process. A catheter is inserted through the needle and then connected to a Programmed Electronic Postoperative Analgesia Pump with a programmed intermittent bolus of 10 ml ropivacaine 0.2% every 2 h after surgery
88841612|NCT05320718|Active Comparator|thoracic paravertebral block|A needle is inserted into the paravertebral space. After confirming the needle tip position, 20 ml of 0.5% ropivacaine is injected in the paravertebral space. A catheter is inserted through the needle and then connected to a Programmed Electronic Postoperative Analgesia Pump with a programmed intermittent bolus of 10 ml ropivacaine 0.2% every 2 h after surgery.
88841613|NCT05314166|Experimental|"focused attention group"|"focused attention group: adult subjects practicing face-to-face focused attention meditation."
88841614|NCT05314166|Active Comparator|"contemplation group"|"contemplation group: adult subjects practicing face-to-face contemplation meditation."
88841615|NCT05302544|Experimental|"with mixed reality training group"|2 Mixed Reality sessions per week for 8 weeks in addition to motor activities usually performed
88841616|NCT05302544|Active Comparator|"without mixed reality training group"|group: only motor activities usually performed
88841617|NCT02739698|Experimental|normothermic (36-37ºC)|Group 1, n=16(normothermic): Intraperitoneal administration of 60 mg/m2 paclitaxel per 2 liters of 1.5% dextrose in room temperature (36-37ºC).
88841618|NCT02739698|Experimental|hyperthermic (41-42ºC)|Group 2, n=16 (hyperthermic): Intraperitoneal administration of 60 mg/m2 paclitaxel per 2 liters of 1.5% dextrose in continuous hyperthermic perfusion (41-42ºC).
88841619|NCT02766374|Experimental|Heart Rate Variability Biofeedback|"During the first training session, we will measure heart rate variability (HRV) amplitude while the patient breathes for two minutes at a frequency ranging between 4.5-6.5 breaths/min, providing a pacing stimulus for this purpose. In subsequent sessions, the individual will be given personal heart rate variability biofeedback (HRV-BF), and instructed to increase the amplitude of heart rate oscillations, using a cardiotachometer tracing and frequency peaks as biofeedback stimuli, while avoiding hyperventilation symptoms, by breathing more shallowly, although slowly, at whatever frequency produces maximum-amplitude HRV."
88841620|NCT02766374|Placebo Comparator|Placebo Biofeedback|"A credible Placebo Biofeedback (PBO-BF) consists of: 1) receiving EEG/music biofeedback (actually, a mildly relaxing intervention, using EEG biofeedback to alternately increase and decrease frontal/occipital EEG alpha rhythms while listening to relaxing music), and 2) listening to recorded sounds of nature along with relaxing music with instructions to maintain a condition of relaxed alertness. For home training, subjects will be given placebo StressEraser programmed to give feedback to maintain their breathing at baseline rate."
88875233|NCT02537730|Active Comparator|Bioclean MPS VII / comfilcon A combination|Participants were randomized to the Bioclean MPS VII / comfilcon A combination for one week during the cross over study.
88875234|NCT02537730|Active Comparator|Aosept Clearcare / comfilcon A combination|Participants were randomized to the Aosept Clearcare / comfilcon A combination for one week during the cross over study.
89534783|NCT03333239|Active Comparator|psychodynamic family intervention|
89368747|NCT03193294|Active Comparator|Intervention group (coronary function test results disclosed)|In the intervention group, coronary function tests are measured and disclosed to the attending clinician permitting re-evaluation of the initial diagnosis and treatment as compared with initial angiography-guided decisions. The intervention involves measurement of CFR, IMR and RRR in a target, major coronary artery followed by coronary reactivity testing using incremental doses of acetylcholine (10-4M, 10-5M, 10-6M) to assess endothelial function, bolus infusion of ACh (10-4M) for vasospasm provocation testing, followed by administration of a bolus dose (300 micrograms) of glyceryl trinitrate. Endotypes are identified based on established criteria for abnormalities in coronary vasodilator function, vasospasm and microvascular resistance. The endotypes (diagnostic strata) are: obstructive CAD, coronary artery spasm, microvascular angina, endothelial dysfunction (no angina), normal (non-cardiac). A diagnosis may be ruled-in or ruled-out based on the test results.
89368748|NCT03193294|Sham Comparator|Usual care group (coronary function results not disclosed)|Coronary function tests are measured but not disclosed to the attending clinician or the participant. The same coronary function tests are undertaken as in the intervention group. Masking is achieved by obscuring the catheter laboratory monitors from the attending clinician and participant. The effectiveness of masking is prospectively monitored.
88841621|NCT04336904|Experimental|Favipiravir|"Experimental: Favipiravir Dosage and method of administration: Day 1: 1800mg, BID; Day 2 and thereafter: 600mg, TID, for a maximum of 14 days.~Where the subject has experienced an adverse event related to liver injury of grade≥3 (NCI CTCAE v5.0), the dose is to be reduced to 600mg BID. It is at the discretion of the investigator whether or not to perform dose reduction based on how the subject is benefiting from study treatment. The subject should be discontinued from treatment if he/she re-experiences any adverse event related to liver injury of grade≥3 after dose reduction."
88841622|NCT04336904|Placebo Comparator|Placebo|"Comparator: Placebo Dosage and method of administration: Day 1: 1800mg, BID; Day 2 and thereafter: 600mg, TID, for a maximum of 14 days.~Where the subject has experienced an adverse event related to liver injury of grade≥3 (NCI CTCAE v5.0), the dose is to be reduced to 600mg BID. It is at the discretion of the investigator whether or not to perform dose reduction based on how the subject is benefiting from study treatment. The subject should be discontinued from treatment if he/she re-experiences any adverse event related to liver injury of grade≥3 after dose reduction"
88841623|NCT02767934|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients achieving complete MRD response may receive up to 1 additional year of treatment at the discretion of the investigator.
88841624|NCT02194998|Experimental|Cohort A [INI-based ART + PTV/r/OBT + DSV +/- RBV 24 Weeks]|Participants took an INI-based (RAL or DTG) ART regimen for HIV-1 and received the following medications for 24 weeks: paritaprevir/ritonavir/ombitasvir (PTV/r/OBT), dasabuvir (DSV), and ribavirin (RBV) (RBV for all participants (version 1) and only for participants with HCV genotype 1a (version 2)).
88841625|NCT02194998|Experimental|Cohort B [INI-based ART + PTV/r/OBT + DSV +/- RBV 12 Weeks]|Participants took an INI-based (RAL or DTG) ART regimen for HIV-1 and received the following medications for 12 weeks: paritaprevir/ritonavir/ombitasvir (PTV/r/OBT), dasabuvir (DSV), and ribavirin (RBV) (RBV for all participants (version 1) and only for participants with HCV genotype 1a (version 2)).
88841626|NCT02194998|Experimental|Cohort C [PI-based ART + PTV/r/OBT + DSV +/- RBV 24 Weeks]|Participants took a PI-based (DRV or ATV) ART regimen for HIV-1 and received the following medications for 24 weeks: paritaprevir/ritonavir/ombitasvir (PTV/r/OBT), dasabuvir (DSV), and ribavirin (RBV) (RBV for all participants (version 1) and only for participants with HCV genotype 1a (version 2)).
88841627|NCT02194998|Experimental|Cohort D [PI-based ART + PTV/r/OBT + DSV +/- RBV 12 Weeks]|Participants took a PI-based (DRV or ATV) ART regimen for HIV-1 and received the following medications for 12 weeks: paritaprevir/ritonavir/ombitasvir (PTV/r/OBT), dasabuvir (DSV), and ribavirin (RBV) (RBV for all participants (version 1) and only for participants with HCV genotype 1a (version 2)).
88841628|NCT05257850|Active Comparator|Fan first|Patients use the fan first and high-flow nasal therapy thereafter
88841629|NCT05257850|Active Comparator|High-flow nasal therapy first|Patients use high-flow nasal therapy first and the fan thereafter
88841630|NCT02194062|Active Comparator|fluticasone nasal spray|Group one will be prescribed fluticasone nasal spray ( to use 2-50 mcg sprays to each nostril two times per day)
88841631|NCT02194062|Active Comparator|budesonide respule in head upright|Group two will be prescribed budesonide respules (0.5 mg/2mL) to instill into each nostril in the upright position two times per day
88841632|NCT02194062|Active Comparator|budesonide head forward|Group three will be prescribed budesonide respules (0.5 mg/2mL) to use instill into each nostril in the head forward position two times per day with their head angled downwards by having their head lean forward off the side of a bed.
88841633|NCT02768558|Experimental|Nivolumab|60 Gy of radiation therapy given concurrently with cisplatin-etoposide chemotherapy followed by nivolumab
88841634|NCT02768558|Placebo Comparator|Placebo|60 Gy of radiation therapy given concurrently with cisplatin-etoposide chemotherapy followed by placebo
88841635|NCT02193828|Experimental|AA4500 0.25 mg|Collagenase clostridium histolyticum, single 0.25 mg injection
88841636|NCT02193828|Experimental|AA4500 0.40 mg|Collagenase clostridium histolyticum, single 0.40 mg injection
88841637|NCT02193828|Experimental|AA4500 0.60 mg|Collagenase clostridium histolyticum, single 0.60 mg injection
88841638|NCT02193828|Placebo Comparator|Placebo|Placebo, single 0.25 mg, 0.40 mg, or 0.60 mg injection
88841639|NCT04738136|No Intervention|Standard of Care (SOC)|Subjects will only receive standard of care treatment for moderate severity COVID19 bronchiolitis/pneumonia.
89368749|NCT03193450|Experimental|Re-education group|Patients in this arm will receive a repeated instruction by telephone in terms of both calling and message at the forth, seventh, tenth day after the start of treatment.
89368750|NCT03193450|Active Comparator|Non re-education group|Patients in this arm only received an instruction card about the drug administration at the clinic by doctors but no re-education by telephone during treatment
89368751|NCT03193606|Experimental|nano silver fluoride solution|carious dentin to be treated with partial caries excavation with application of nano silver fluoride solution prior to glass ionomer restoration.
89368752|NCT03193606|No Intervention|no nano silver fluoride|carious dentin to be treated with partial caries excavation without application of nano silver fluoride solution restored directly with glass ionomer.
89368753|NCT03032198|Experimental|Imagio OA/US Scan|Imagio opto-acoustic gray-scale ultrasound scan
89368754|NCT02448784||Participants with DLB|Participants with DLB who will receive donepezil hydrochloride per approved label.
89368755|NCT04050488|Active Comparator|Treatment Group|Participants who receive the intervention.
89368756|NCT04050488|Placebo Comparator|Control Group|Participants who receive the placebo.
88841640|NCT04738136|Experimental|Standard of Care(SOC) + S-1226 at either 4% 8% or 12% CO2|Subjects will receive SOC plus the highest tolerated dose of S-1226 at either 4% 8% or 12% CO2 twice daily for up to 5 consecutive days.
88841641|NCT02772302|Experimental|Patients|Application of bedside, EEG-based mindBEAGLE Brain-Computer Interface
88841642|NCT02772302|Experimental|Healthy Controls|Application of bedside, EEG-based mindBEAGLE Brain-Computer Interface
88841643|NCT02192970|Experimental|Bevacizumab|Pars plana vitrectomy will be performed in the typical manner. After laser retinopexy and prior to air-gas exchange, intravitreal bevacizumab will be administered through the trocar. Either perfluoropropane (C3F8) or sulfur hexafluoride (SF6) gas will then be administered for long-term retinal tamponade and the vitrectomy ports closed in the usual manner.
89368757|NCT02448628|Experimental|CS-3150|CS-3150 1.25 to 5.0 mg , orally, once daily after breakfast for 12 weeks
89368758|NCT02449252|Experimental|ISRT group|"Six cycles chemotherapy (cyclophosphamide 750mg/square meter on day 1 + doxorubicin 50mg/square meter on day 1 + vincristine 1.4mg/square meter on day 1 (up to a maxomal dose of 2 mg) + prednisone 60mg/square meter on day 1 through 5, repeated at 21-day intervals).~Consolidation involved-site radiotherapy (ISRT) following in patients with complete or partial response beginning 1 month after the last cycle of chemotherapy."
89368759|NCT02449252|Active Comparator|IFRT group|"Six cycles chemotherapy (cyclophosphamide 750mg/square meter on day 1 + doxorubicin 50mg/square meter on day 1 + vincristine 1.4mg/square meter on day 1 (up to a maxomal dose of 2 mg) + prednisone 60mg/square meter on day 1 through 5, repeated at 21-day intervals).~Consolidation involved-field radiotherapy (IFRT) following in patients with complete or partial response beginning 1 month after the last cycle of chemotherapy."
89368760|NCT03490318||Patients with DMO and/or PDR|
89368761|NCT04779554|Experimental|Flat Dose Mitomycin C|Participants in this group will receive flat doses of mitomycin C intra-operatively: 1) 30mg at minute 0 and 2) 10mg at minute 60. Mitomycin C will be delivered via HIPEC (hyperthermic intraperitoneal chemotherapy).
88841644|NCT02192970|No Intervention|Chart review|Review records over the past 5 years of patients who underwent vitrectomy for retinal detachment repair to found out the percentage of those who had re-detachment of the retina within 6 months after surgery.
88841645|NCT05173532|Experimental|Balance Training|Static and dynamic balance and gait stability training exercises are performed with supervision by a physical therapist or physical therapist assistant for 30 minutes, 3 times per week, for 8 weeks.
88841646|NCT05173532|Active Comparator|Breathing and Stretching Exercises|Patients perform static stretches for all major muscle groups while performing diaphragmatic breathing with supervision by a physical therapist or physical therapist assistant for 30 minutes, 3 times per week, for 8 weeks.
88841647|NCT05149352|Active Comparator|Treatment as usual (TAU)|Participants will receive an evidence-based psychotherapeutic intervention combined with/or pharmacotherapy (TAU)
88841648|NCT05149352|Experimental|Treatment as usual (TAU) + Trauma-focused therapy (TFT)|Participants will receive 6 to 10, 60-90 minute TFT sessions delivered over a period of 12 weeks, in addition to TAU.
88841649|NCT05457296|Experimental|capsule hydrocortisone intake in patients with corticotrope deficiency|Hydrocortisone taken in capsule form (15mg), one intake/ one day test.
88841650|NCT05457296|Active Comparator|tablet hydrocortisone intake in patients with corticotrope deficiency|Hydrocortisone taken in tablet form (15mg), one intake/ one day test.
88841651|NCT05457296|No Intervention|healthy controls|healthy non treated controls, one day test.
88841652|NCT04336514|Experimental|Experimental Arm|
89368762|NCT04779554|Experimental|Weight-Based Mitomycin C|Participants in this group will receive weight-based dosing of mitomycin C intra-operatively: 1) 9 mg/m2 at minute 0 and 2) 3.5 mg/m2 at minute 60 for total dose of 12.5 mg/m2. Mitomycin C will be delivered via HIPEC (hyperthermic intraperitoneal chemotherapy).
89368763|NCT02444260|Sham Comparator|Intravenous Normal Saline|Intravenous Normal Saline plus Lignocaine HCl (1%) - administered by wound infiltration to a maximum dose of 4.5mg/kg ; Bupivocaine HCl (0.25%) - administered by wound infiltration to a maximum dose of 2 mg/kg plus i
89368764|NCT02444260|Active Comparator|Midazolam|Lignocaine HCl (1%) - administered by wound infiltration to a maximum dose of 4.5mg/kg Bupivocaine HCl (0.25%) - administered by wound infiltration to a maximum dose of 2 mg/kg plus Midazolam - administered intravenously. 1 mg given stat. Titrated by 1 mg to a maximum dose of 10 mg.
89368765|NCT03010930|Experimental|Increased exposure to MSG|Subjects consume vegetable broth daily containing MSG
89368766|NCT03010930|Sham Comparator|No change in exposure to MSG|Subjects consume low glutamate vegetable broth daily, sodium-matched to the broth of the experimental group with NaCl
89368767|NCT02444104||Patients with atrial fibrillation|It is Primarily a comparison of methods , non-invasive measured blood pressure versus invasively measured blood pressure and non-invasively measurement of cardiac output versus invasive cardiac output measurement in patients with atrial fibrillation.
88841653|NCT04336592||Patients|Patients scheduled to receive a surgical spine procedure at Mayo Clinic
88841654|NCT04336592||Clinicians|Surgeons, Physician pain specialists and allied health caring for participating patients
89368768|NCT02444104||Patients with highly reduced LV function|It is Primarily a comparison of methods , non-invasive measured blood pressure versus invasively measured blood pressure and non-invasively measurement of cardiac output versus invasive cardiac output measurement in patients with a highly reduced left ventricular function (LV function)
89368769|NCT02444104||Patients with aortic stenosis|It is Primarily a comparison of methods , non-invasive measured blood pressure versus invasively measured blood pressure and non-invasively measurement of cardiac output versus invasive cardiac output measurement in patients with severe aortic stenosis
89368770|NCT02444104||Patients with LVAD|It is Primarily a comparison of methods , non-invasive measured blood pressure versus invasively measured blood pressure and non-invasively measurement of cardiac output versus invasive cardiac output measurement in patients with left ventricular assist-device (LVAD)
89368771|NCT03195634||HVPG group|"When HVPG > 12 mmHg, patients would be treated with carvedilol at an initial dose of 6.25 mg once-daily that was adjusted over 5-7 days to the maximum tolerated dose, keeping heart rate >55 beats per minute, or up to 12.5 mg/day.~After about 8 weeks, the patients treated with carvedilol will received the second HVPG monitoring wether achieved a decrease in HVPG below 12 mm Hg or>20% from baseline."
89368772|NCT02448394|Experimental|Intervention|At each of the intervention sites, all newly enrolled participants will have an HIV community support worker (CSW) assigned them. Strong preference will be given to matching CSWs and clients from the same kebele (village or neighborhood of residence). CSW responsibilities include: education on HIV treatment and health promoting behaviors, social support/counseling, facilitated communication with the HIV clinic, referrals as needed for other support needs.
89368773|NCT02448394|No Intervention|Standard of Care|At control sites, patients will receive standard of care facility-based medical care and counseling, consistent with general standards of care offered to HIV patients throughout the country as determined by the Ethiopian Ministry of Health.
89368774|NCT02448550|Experimental|bivalirudin|Bivalirudin will be used for PCI with bailout glycoprotein 2b3a inhibitor use permitted.
89368775|NCT02448550|Active Comparator|unfractionated heparin|Unfractionated heparin will be used for PCI with bailout glycoprotein 2b3a inhibitor use permitted.
89368776|NCT02431364|Placebo Comparator|Placebo|Participants received matched placebo tablets to verdinexor tablets orally once daily on Days 1 and 3.
89368777|NCT02431364|Experimental|Verdinexor 5 mg|Participants received verdinexor 5 milligrams (mg) (2 tablets of 2.5 mg each) orally once daily on Days 1 and 3.
89368778|NCT02431364|Experimental|Verdinexor 10 mg|Participants received verdinexor 10 mg tablet orally once daily on Days 1 and 3.
89368779|NCT02431364|Experimental|Verdinexor 20 mg|Participants received verdinexor 20 mg tablet (2 tablets of 10 mg each) orally once daily on Days 1 and 3.
88841655|NCT04338230|Experimental|Experimental: Experimental group|Women aged 65 and over (the standardized Mini-Mental State Examination (MMSE) test cognitive levels score of 23 and above points). Progressive muscle relaxation exercises are applied to the intervention group as 30-minute sessions three times a week for eight weeks.
88841656|NCT04338230|No Intervention|No Intervention: Control group|Women aged 65 and over (the standardized Mini-Mental State Examination (MMSE) test cognitive levels score of 23 and above points).
89368780|NCT02431364|Experimental|Verdinexor 40 mg|Participants received verdinexor 40 mg tablet (4 tablets of 10 mg each) orally once daily on Days 1 and 3.
89368781|NCT03701750|Experimental|Experimental Arm|Low Molecular Weight Heparin (enoxaparin sodium) + routine luteal phase support
89368782|NCT03701750|No Intervention|Control Arm|routine luteal phase support
89368783|NCT03704402||alcohol policy group|High schools that introduced the policy
88841657|NCT04336436|Experimental|Mindfulness Training and Nutrition Counseling|"Baseline and 3-6 month follow up visits will be arranged for all participants.~Visits will be conducted at baseline prior to initiation of mindfulness training and nutrition counseling, and at the 3-6 month follow up. Clinical and laboratory assessments will be obtained at each visit."
88841658|NCT05457062||large amount of bleeding|large amount of upper GI bleeding after EGD identified
88841659|NCT05457062||no bleeding|no upper GI bleeding after EGD identified
89368784|NCT03704402||control group|High schools that did not introduce the policy
89368785|NCT03704246|Other|Anti-PD-1|Anti-PD-1 monoclonal antibody HX008 injection with a dose of 200mg (intravenous infusion, every 3 weeks)
89368786|NCT05273684|Experimental|4*4 followed by 10*1 or 10*1 followed by 4*4|Following baseline measurements, participants are allocated to the random sequence, by which they will complete the two HIIT protocols ⟨http://www.randomization.com⟩ and based on this, patients are randomized to a specific testing sequence.
88841660|NCT05457062||small amount of bleeding|small amount of upper GI bleeding after EGD identified
89368787|NCT05272592||Nursing staff|Certified local-and-international inpatient-and-outpatient nurses specialised in urology, perioperative nurses, and urology-specific advanced practice nurses/nurse practitioners will be included.
89368788|NCT05239910|Experimental|Tenalisib 400 mg BID and CHOP|
88841661|NCT02774798||Rectal Intussusception and Prolapse|"AAR measurements will be taken from patients with suspected intra-rectal intussusception or rectal prolapse. Subgroup analysis will be performed after grading of rectal prolapse according to the Oxford Grading system. The subgroups will be:~Oxford Grades 1 & 2 - intra-rectal intussusception~Oxford Grades 3 & 4 - intra-anal intussusception~Oxford grade 5 - Overt Rectal Prolapse"
88841662|NCT00371774||1|Dermatologic patients in Canada for which Amevive is clinically indicated
88841663|NCT04336358|No Intervention|Standard Early medical abortion care|Counseling, history, instruction, family planning with clinic nurse. Ultrasound to assess gestational age.
89002064|NCT06116448|Experimental|high-fidelity simulation|These students participated in a breastfeeding management scenario with a high-fidelity simulation mannikin named Noella S554.100 (n=11).
89368789|NCT05239910|Experimental|Tenalisib 800 mg BID and CHOP|
89368790|NCT03701672||Opioid Analgesic Treatment|Chronic paint patients receiving opioid treatment at a Multidisciplinary Pain Center following local SOPs
89368791|NCT03624998|Experimental|THA Patients|Orthopedic patients submitted to elective surgery (THA - Total Hip Arthroplasty)
89368792|NCT03704090|Active Comparator|Control|Standard non-pharmacological intervention during 5 days after surgery.
89368793|NCT03704090|Experimental|Treatment|Occupational therapy intervention twice a day plus standard non-pharmacological prevention intervention during 5 days after surgery.
89368794|NCT03704012|No Intervention|Routine Care|Control Group receives routine care.
88841664|NCT04336358|Experimental|Telemedicine|Online consultation questionnaire and counseling, family planning information. Instruction for the abortion received to the participants Facebook Messenger. Gestational age <9 weeks assessed by bimanual palpation, ultrasound only in case of uncertainty.
88841665|NCT04335266|Experimental|Treatment group A|Drug: SHR2554 fasted in P1, high-fat diet in P2 SHR2554 administration in fasted condition in period 1, SHR2554 administration after high-fat diet in period 2
89368795|NCT03704012|Experimental|Massage and kinesiotherapy|Intervention Group, receives massage and kinesiotherapy. Behavioral: Protocol of massage therapy and kinesiotherapy. Infants received massage and kinesiotherapy twice a day; 15 minutes each.
89368796|NCT03703934||Psoriatic Arthritis|Patients with painful psoriatic arthritis
89368797|NCT03703934||Hand Osteoarthritis|Patients with painful nodal non-erosive hand osteoarthritis
89368798|NCT03703934||Healthy Controls|Patients without a painful condition
89368799|NCT03034460|Experimental|CD5024 1% cream|Active drug;
89368800|NCT03034460|Placebo Comparator|CD5024 cream placebo|Placebo of active drug;
89368801|NCT03034460|Other|CD0271/CD1579 gel|Positive control;
89368802|NCT03034460|Other|CD0271/CD1579 gel placebo|Placebo of positive control;
89368803|NCT04162769|Experimental|12-Week Double-Blind Treatment Period: Etrasimod 1 milligrams (mg)|
89368804|NCT04162769|Experimental|12-Week Double-Blind Treatment Period: Etrasimod 2 mg|
88841666|NCT04335266|Experimental|Treatment group B|Drug: SHR2554 high-fat diet in P1, fasted in P2 SHR2554 administration after high-fat diet in period 1, SHR2554 administration in fasted condition in period 2
88841667|NCT05456438|Experimental|COCONUT OİL|"After feeding, wash hands and apply 2 drops of oil, COCONUT OİL in the 1st intervention group to the index finger and spread on the areola and nipple,~Continue this application for 10 days"
88841668|NCT05456438|No Intervention|Control group|They were told that no intervention would be performed, and that they should not use any application like herbal or chemical oils, creams, medications, etc. on the nipples during the first 10 days postpartum.
88841669|NCT05456438|Experimental|TEA TREE OİL|"After feeding, wash hands and apply 2 drops of oil, TEA TREE OİL in the 2nd intervention group, to the index finger and spread on the areola and nipple,~Continue this application for 10 days."
89368805|NCT04162769|Placebo Comparator|12-Week Double-Blind Treatment Period: Placebo|
89368806|NCT04162769|Experimental|52-Week Open-Label Extension Period: Etrasimod 2 mg|
89368807|NCT04593602|Experimental|Early Mobilization Intervention|The bedside nurse determines the prehospital Level of Function based on patient and family report and current Level of Function based on nursing mobility assessment. Each Level of Function has 3 primary activities designed to promote the patient to the next level. The nurse leads mobility activities based on the patient's current Level of Function once per shift, twice daily (AM+PM). If a patient is able to complete each of the 3 activities, the nurse on the subsequent shift will assess whether the Level of Function can be advanced. Physiotherapy consultation is available if required, although not obligatory. Patients are encouraged to spend as much time in the chair and ambulatory as possible.
89368808|NCT04593602|Active Comparator|Usual Mobility Care|Usual mobility care involves following physician orders for mobilization (i.e., bedrest, mobilization to chair with meals, physiotherapy consultation and care) as per local practice.
89368809|NCT04161131|Experimental|ONBOARD Intervention|ONBOARD consists of four 60-minute sessions over 3 months. Each session will target a key barrier to CGM use: physical, data, social, and trust. Sessions will be delivered individually to participants by a doctoral level psychologist with diabetes expertise. Each session will include relevant first-person digital stories told adults to with T1D, recounting how they managed relevant CGM barriers.
89368810|NCT03703700|Experimental|Zishen Yutai pill group|Patients who undergo the long-term protocol will start taking Zishen Yutai Pill on the day of pituitary suppression, 5g three times a day (Stopping on the first 1-4 days of menstruation), and patients who undergo the antagonist protocol will start taking Zishen Yutai Pill on the 19th to 23rd day of the previous menstruation cycle, 5g three times a day (Stopping on the first 1-4 days of menstruation). The drug will be taken till 2 weeks after transplantation. If the test result is confirmed as biochemical pregnancy (HCG>50 IU/L), patients continue to take pills till 3 weeks after the clinical pregnancy determined by the ultrasound. If it is determined that the pregnancy test is negative, stop the drug.
89368811|NCT03703700|Placebo Comparator|Placebo group|Patients who undergo the long-term protocol will start taking Placebo on the day of pituitary suppression, 5g three times a day (Stopping on the first 1-4 days of menstruation), and patients who undergo the antagonist protocol will start taking Placebo on the 19th to 23rd day of the previous menstruation cycle, 5g three times a day (Stopping on the first 1-4 days of menstruation). The drug will be taken till 2 weeks after transplantation. If the test result is confirmed as biochemical pregnancy (HCG>50 IU/L), patients continue to take pills till 3 weeks after the clinical pregnancy determined by the ultrasound. If it is determined that the pregnancy test is negative, stop the drug.
89368812|NCT04743518|Active Comparator|anti-TNF|
88841670|NCT04737824|Experimental|Experimental group A|"Participants executed two sets of twelve repetitions of an adaptation of the balloon-blowing exercise."
89179806|NCT02609243|Active Comparator|intensive consulting, conventional diet|subjects receive 16 units of nutritional consulting, first 3 weeks of intervention phase are designed as a conventional hypocaloric low-fat diet referring to DGE guidelines (below 30 % fat), followed by 11 months of isocaloric-to-moderate-hypocaloric low-fat diet (below 30 kcal% fat ) - dietary intervention without supplement
89368813|NCT04743518|Active Comparator|vedolizumab|
89368814|NCT04743518|Active Comparator|tofacitinib|
89368815|NCT04155047|Active Comparator|Glycopyrrolate Inhalation Solution|Glycopyrrolate Inhalation Solution 25mcg administered by Magnair
89368816|NCT04155047|Placebo Comparator|Placebo|Placebo Inhalation Solution administered by Magair
89368817|NCT03624530|Experimental|Prophylactic TKI Therapy|Treatment with prophylactic TKI will be initiated from day +30 to +60 post-transplants. TKI was selected according to the mutation results of ABL kinase region.
89368818|NCT03624530|No Intervention|No TKI therapy|Prophylactic TKI will not be given.
89368819|NCT03624452|Experimental|rIPC and exercise training|Those in the rIPC + exercise group will attend three 50 minute exercise sessions per week for 8 weeks at Liverpool John Moores University and 3 bouts of IPC per week at home at a time of their choice
89368820|NCT03624452|Experimental|rIPC only|Those randomly allocated into the rIPC group will self administer 3 bouts of IPC per week at home at a time of their choice.
89368821|NCT03746327|Experimental|Sivextro arm|200 mg milligram per day during 4 weeks
89368822|NCT04585802||Suicide Attempters (1)|patients with a suicide attempt
89368823|NCT04585802||Suicide Ideators (2)|patients with suicidal ideation
89368824|NCT04585802||Control Group (3)|patients without suicide attempt and without suicide ideation
89368825|NCT03746249|Experimental|Lenvatinib Plus PD-1|Participants received lenvatinib capsules 12 milligram (mg) based on the participant's body weight greater than or equal to (>=) 60 kilogram (kg) or 8 mg based on the participant's body weight less than (<) 60 kg at baseline, orally, once daily (QD) in continuous 14-day treatment cycles, and received 3mg/kg PD-1 antibody intravenously every 2 weeks up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
89368826|NCT03624686||healthy volunteer|
89368827|NCT03624686||luekemia patient|
89368828|NCT04152083|Experimental|Eptinezumab|Participants will receive a single dose of eptinezumab 100 milligrams (mg) administered via intravenous (IV) infusion on Day 0.
88841671|NCT04737824|No Intervention|Control group A|No intervention was applied.
88841672|NCT04737824|Experimental|Experimental group B|"Participants executed two sets of twelve repetitions of an adaptation of the balloon-blowing exercise for seven weeks, three times a week, at home."
88841673|NCT04737824|No Intervention|Control group B|No intervention was applied.
88841674|NCT02743442|Experimental|Transoral surgery|
88841675|NCT02760277|Experimental|Dose Level Group 1|Participants enrolled in Dose Level Group 1 will receive vamorolone 0.25 mg/kg/day.
88841676|NCT02760277|Experimental|Dose Level Group 2|Participants enrolled in Dose Level Group 2 will receive vamorolone 0.75 mg/kg/day.
88841677|NCT02760277|Experimental|Dose Level Group 3|Participants enrolled in Dose Level Group 3 will receive vamorolone 2.0 mg/kg/day.
88841678|NCT02760277|Experimental|Dose Level Group 4|Participants enrolled in Dose Level Group 4 will receive vamorolone 6.0 mg/kg/day.
88841679|NCT02776904|Other|Healthy athlete|Healthy athletes (14-18 years old) enrolled in sports program in local schools.
88841680|NCT02776904|Other|Concussed athletes|Concussed athletes from a sports related injury who are 14-18 years old and referred to a regional sports concussion clinic.
88841681|NCT02744534|Experimental|Abnormalities found with FACBC PET-CT|All participants with suspected recurrence of prostate cancer will have the FACBC PET-CT scan performed. Participants with abnormal FACBC PET-CT scan results will have a PET/ultrasound fusion targeted prostate biopsy followed a standard of care prostate biopsy.
88841682|NCT02744534|Active Comparator|No abnormalities found with FACBC PET-CT|All participants with suspected recurrence of prostate cancer will have the FACBC PET-CT scan performed. Participants without abnormal FACBC PET-CT scan results will have a standard of care prostate biopsy.
89368829|NCT04152083|Placebo Comparator|Placebo|Participants will receive a single dose of placebo matching to eptinezumab administered via IV infusion on Day 0.
89368830|NCT03698474|Active Comparator|SPMC-S|Natrium picosulfate /Magnesium citrate ( Picoprep™, oral solution) 2L in the evening before colonoscopy
89368831|NCT03698474|Active Comparator|SPMC-D|Natrium picosulfate/ Magnesium citrate ( Picoprep™, oral solution) 1L in the evening and 1L in the morning before colonoscopy
89368832|NCT03698474|Active Comparator|PEGA-S|Polyethylene glycol / Ascorbic acid ( Moviprep™, oral solution) 2L in the evening before colonoscopy
89368833|NCT03698474|Active Comparator|PEGA-D|Polyethylene glycol / Ascorbic acid (Moviprep™, oral solution) 1L in the evening and 1L in the morning before colonoscopy
89368834|NCT03698474|Active Comparator|SULF-S|Natrium/ Kalium/ Magnesium sulfate ( Eziclen™, oral solution) 1 L in the evening before colonoscopy
89368835|NCT03698474|Active Comparator|SULF-D|Natrium/ Kalium/ Magnesium sulfate ( Eziclen™, oral solution) 0,5 L in the evening and 0,5L in the morning before colonoscopy
89530407|NCT03245047|Experimental|Intervention group|Dietary Supplement: Oral Nutritional Supplement with AN777 Participants in the intervention group will be asked to consume two servings of oral nutritional supplement per day for 180 days. (Oral Consumption)
89534784|NCT05047029||Patients with cirrhosis|Patients with cirrhosis and transjugular intrahepatic portosystemic shunt implantation.
88841683|NCT04335565|No Intervention|Water|250 ml of water mixed with 1g of citric acid.
88841684|NCT04335565|Active Comparator|Sugar|65g of sugar dissolved in 250ml of water
88841685|NCT04335565|Experimental|Stevia|5g of stevia dissolved in 250ml of water
88841686|NCT04335409|Experimental|Participants irradiated for lung cancer|Participants who receive radiotherapy for lung cancer and have risk factors for developing radiation pneumonitis. Risk factors include mean dose to the ipsilateral lung >13 Gy plus at least one other factor (significant cardiovascular disease, history of heavy smoking (≥40 pack years), previous/concurrent chemotherapy or previous/adjuvant immunotherapy) or mean dose to the ipsilateral lung >20 Gy without other factors.
88841687|NCT04337125|Other|ADHD group|ADHD children with their parents
88841688|NCT04337125|Other|Control group|Children with typical development and their parents
88841689|NCT02744846||Children from birth to 5 years|"Children from birth to 5 years where:~1 or more encounters with length and weight measured in the following age interval: 0-12 m, 12-30 m, and~> 1 encounter with height and weight measured in either or both of the following age intervals: 4.0 to 5.9 y (age 5 years), or eligible to be followed to these ages for use in multiple imputation to account for missing data"
89368836|NCT02711956|Experimental|DE and DC - ZEN003694 in Combination with Enzalutamide|"Dose Escalation (DE) and Dose Confirmation (DC): ZEN003694 will be administered orally once daily with enzalutamide in 28-day cycles, enrolling mCRPC patients.~Two patient populations will be enrolled in DE and DC. Cohort A: Patients with prior progression on enzalutamide or apalutamide by PCWG2 criteria who were receiving a stable dose of enzalutamide at the time of study entry. Cohort B: Patients who were enzalutamide-naïve with prior progression on abiraterone by Prostate Cancer Working Group 2 (PCWG2) criteria."
89368837|NCT03698396|Experimental|Allogenic Islet Cell Transplantation|Transplantation of allogenic islet cell will be given to eligible patients, up to three times during the study, using cell quantities based on body weight.
89368838|NCT03703622|Experimental|Video-debriefing with standard HBB training|Health workers are given standard HBB training according to American Association of Pediatrics (AAP) plus video-debriefing. Filming of the simulated case scenarios will be done and after which the films will be used for debriefing or feedback. Participants will be encouraged to give feedback with the guidance of master trainer and the PI. Teams of three participants(birth attendant, mother and helper) will perform the HBB simulation or scenarios. After each scenario, debriefing is done until all participants have had the opportunity to participate in the simulation exercise. All the participants in this arm will undergo HBB practical sessions such as bag mask ventilation skills sessions, care of the health new-born and sick newborn baby who needs resuscitation care. Pre and post-tests will be done to assess performance of all participants.
89179807|NCT02609243|Active Comparator|conventional consulting, low-carb diet|subjects receive 8 units of nutritional consulting, first 3 weeks of intervention phase are designed as a very-low calory ketogenic (low-carb) diet (< 40 g CH / day), following 11 months are restricted to not more than 40 % energy intake by carbohydrates under isocaloric-to-moderate-hypocaloric conditions - dietary intervention without supplement
89368839|NCT03703622|Active Comparator|Standard HBB training only|Health workers are given standard HBB training according to AAP without video-debriefing. All the participants in this arm, like in intervention arm, will also undergo HBB practical sessions such as bag mask ventilation skills sessions, care of the health new-born and sick new-born baby who needs resuscitation care only. Pre-and post-tests will be done to assess performance of all participants.
89368840|NCT04149353|Experimental|PET/MR|Each patient will undergo two combined PET/MR scans. The pre-treatment and post-treatment combined PET/MR scans are for research purposes and not part of the patient's standard of care.
89368841|NCT02711800|Experimental|Lactobacillus rhamnosus|The investigators will use Culturelle®, a probiotic composed of the micro-organisms Lactobacillus GG. This formulation has been used for the treatment of gastrointestinal inflammation in numerous clinical trials. Dosing will follow the manufacturer's recommendation for children (1 capsule/packet per day), and will be monitored by Dr. Patrick Seed from the department of pediatrics. Weekly side effects and clinical changes will be monitored by both study therapist and caregiver using the Children's Global Assessment Scale and the Clinical Global Impression Scale (Severity, Improvement, and Efficacy). The intervention duration is 30 days.
89368842|NCT03701594|Experimental|Yoga-based physical therapy group|The yoga-based physical therapy session will take place in an enclosed, quiet space to minimize outside noise or distraction. The lights will be dimmed, and light, instrumental, calming music will be played throughout. The group will consist of approximately 2-5 individuals depending on the physical capabilities and assistance levels required. The session will consist of an introduction to pranayama (foundational breath-based exercises) followed by asanas, or physical postures, that will be modified according to each individual's physical abilities. The session will close with a 4-5 minute savasana performed in a supine or seated position pending patient physical abilities, which consists of progressive relaxation, guided meditation, and guided motor imagery.
89368843|NCT03701594|Active Comparator|Seated rest|Subjects will engage in 1 hour of seated rest in a relaxing environment in a group of approximately 2-5 individuals. This session will occur in the same enclosed, quiet space as condition A to minimize outside noise or distraction and to reproduce environment of condition A. The lights will be dimmed, and the same light, instrumental, calming music will be played throughout to contribute to a relaxing ambiance. Subjects will be instructed to rest quietly.
89368844|NCT03701594|Active Comparator|Conventional Physical Therapy|"Subjects will engage in 1 hour of a conventional PT session (or treatment as usual) led by a different physical therapist than who is leading the yoga-based session to minimize bias. There will be no restrictions on what can and cannot occur during conventional PT sessions in order to accurately represent and preserve the wide range of treatments that may occur during a physical therapy session in the inpatient setting. Examples of what may occur include, but are not limited to: gait, standing balance, functional mobility, or therapeutic exercise."
89368845|NCT02091154|Experimental|USDA Regulations Only|Implement USDA Regulations in assigned school cafeterias during the intervention period.
89368846|NCT02091154|Experimental|USDA Regulations and Marketing Kit|Implement new USDA regulations in assigned schools along with the Marketing Kit during the intervention period.
89368847|NCT02091154|Experimental|USDA Regulations and SLM|Implement USDA Regulations and Smarter Lunchrooms Makeover in assigned schools during intervention period.
89368848|NCT02091154|No Intervention|Control|Schools assigned to this intervention made no changes to their lunchroom or menus.
89368849|NCT02444026|Experimental|iCBT for Insomnia|The Internet intervention offered is the SHUT-i program (Sleep Healthy Using The Internet), which is based on the existing consensus concerning non-pharmacological treatment of insomnia and builds on previous validated CBT's for insomnia (CBT -I)
89368850|NCT02444026|No Intervention|Control|The control group will be offered the intervention AFTER the study
89368851|NCT01526668|Active Comparator|No contact after discharge|In Arm A: The patient do not have planned contacts with the study nurse or doctor after discharge. All patients are seen by the study nurse six weeks postoperatively.
88841690|NCT02744846||Children from birth to 10 years|"Children from birth to 10 years where:~1 or more encounters with length and weight measured in each of the following age intervals: 0-12 m, 12-30 m, and~> 1 encounter with height and weight measured in the following age interval: 9.0 to 10.9 y (age 10 years), or eligible to be followed to these ages for use in multiple imputation to account for missing data."
89368852|NCT01526668|Active Comparator|Single telephone contact|In Arm B: The patient has one planned telephone contact with the study nurse the day after discharge. All patients are seen by the study nurse six weeks postoperatively.
89368853|NCT01526668|Active Comparator|Telephone contacts regularly|In Arm C: The patient has planned telephone contacts with the study nurse the day after discharge and then once weekly until the six weeks follow-up visit postoperatively.
89368854|NCT01526668|Active Comparator|Telephone contact using CBT-inspired strategy|In Arm C: The patient has planned telephone contacts with the study nurse the day after discharge and then once weekly until the six weeks follow-up visit postoperatively. At these telephone contacts the study nurse uses a cognitive behavior therapy (CBT)-inspired strategy in counselling and support.
89368855|NCT01194622|Experimental|Azelastine, Fluticasone|TEST = MP29-02 = Combination product Azelastine Hydrochloride and Fluticasone Propionate nasal spray (= US formulation as used in pivotal studies)
88841691|NCT02762071|Active Comparator|Interscalene Nerve Block|Patients in this group will receive an interscalene nerve block containing the local anesthetic ropivacaine prior to surgery. The nerve block will be administered by a fellowship-trained anesthesiologist.
88841692|NCT02762071|Experimental|Liposomal Bupivacaine|Patients in this group will receive a periarticular injection containing liposomal bupivacaine during surgery. The injection will be administered by the surgeon.
88841693|NCT05456282|Experimental|AMPS first, then SHAM|Participants will receive first one session of automated mechanical peripheral stimulation (AMPS) with intensity at the pain threshold. Then, after a 2-week washout, they will receive one session of a simulated automated mechanical peripheral stimulation (SHAM) with intensity at the sensory threshold.
89368856|NCT01194622|Active Comparator|Fluticasone mono|REF = FLU mono Fluticasone Propionate nasal spray (= essentially combination product formulation without any AZE; US FLU mono formulation as used in pivotal studies)
89368857|NCT01194622|Active Comparator|Fluticasone|COMP = Fluticasone Propionate Nasal Spray, Roxane Laboratories = FLU mono Fluticasone propionate nasal spray (= US marketed product)
88841694|NCT05456282|Sham Comparator|SHAM first, then AMPS|Participants will receive first one session of simulated automated mechanical peripheral stimulation (SHAM) with intensity at the sensory threshold. Then, after a 2-week washout, they will receive one session of automated mechanical peripheral stimulation (AMPS) with intensity at the pain threshold.
88841695|NCT04336891||Hypoactive Sexual Desire Disorder|Women with Hypoactive Sexual Desire Disorder (HSDD, n=23)
88841696|NCT04336891||Moderate to severe VVA|Women with dyspareunia due to moderate to severe vulvovaginal atrophy (VVA) (n=12)
88841697|NCT04336891||Mild to moderate VVA|Women with dyspareunia due to mild to moderate VVA (n=37)
88841698|NCT04336891||HSDD + VVA|Women with HSDD reporting also significant dyspareunia due to moderate to severe VVA (n=9).
88841699|NCT05456048||VAH group|Patients assigned to this group received one to two cycles of VAH regimen as salvage therapy of RR-AML.
88841700|NCT05456048||VEN+HMA group|Patients assigned to this group received one to two cycles of venetoclax plus HMA regimen as salvage therapy of RR-AML.
88841701|NCT05348707||Pre Covid 19 cohort|"Infants hospitalized in the Pediatric Department of the  Hôpital Femme Mère Enfant , Lyon, France with a RT-PCR positive for Rhinovirus from 17th March 2019 to 16th March 2020."
89368858|NCT02448316|Active Comparator|endoscopic surgery|Endoscopic operation through 2 portals profound for the fascia plantaris
88841702|NCT05348707||Per Covid 19 cohort year 1|"Infant hospitalized in the Pediatric Department of the  Hôpital Femme Mère Enfant , Lyon, France with a RT-PCR positive for Rhinovirus from 17th March 2020 to 16th March 2021. The need to recruit patients for an additional per-covid year (from 17th March 2021 to 16th March 2022) will be evaluated after the data from the first 2 years of recruitment are available."
89368859|NCT02448316|Active Comparator|conservative treatment|The standard treatment here acting as controle treatment . All patients are informed to decrease activity level, use shoes with good shock absorption and are recommended to use insoles (standard orthoses) for increased shock absorption. Training is supervised every third week by a physiotherapist (week 1,3,6,9), and daily training is carried out at home. Glucocorticoid injections of 1 ml Glucocorticosteroid (methylprednisolon 40 mg) and 1 ml of Lidokaine 5mg/ml from the medial side profound to the thickened part of the fascia plantaris are given every month until the fascia thickness is below 4 mm (max 3 injections).
89368860|NCT03698318|Experimental|Subject sequence 1|Subject allocation sequence 1. Intervention : the subject will receive the five products (tested product n°1, tested product n°2, tested product n°3, tested product n°4 and tested product n°5) in a certain order of assignment of each study product (which will be randomly attributed to him via the randomization sequence).
89368861|NCT03698318|Experimental|Subject sequence 2|Subject allocation sequence 2. Intervention : the subject will receive the five products (tested product n°1, tested product n°2, tested product n°3, tested product n°4 and tested product n°5) in a certain order of assignment of each study product (which will be randomly attributed to him via the randomization sequence).
89368862|NCT03698318|Experimental|Subject sequence 3|Subject allocation sequence 3. Intervention : the subject will receive the five products (tested product n°1, tested product n°2, tested product n°3, tested product n°4 and tested product n°5) in a certain order of assignment of each study product (which will be randomly attributed to him via the randomization sequence).
89368863|NCT03698318|Experimental|Subject sequence 4|Subject allocation sequence 4. Intervention : the subject will receive the five products (tested product n°1, tested product n°2, tested product n°3, tested product n°4 and tested product n°5) in a certain order of assignment of each study product (which will be randomly attributed to him via the randomization sequence).
89368864|NCT03698318|Experimental|Subject sequence 5|Subject allocation sequence 5. Intervention : the subject will receive the five products (tested product n°1, tested product n°2, tested product n°3, tested product n°4 and tested product n°5) in a certain order of assignment of each study product (which will be randomly attributed to him via the randomization sequence).
89368865|NCT03698318|Experimental|Subject sequence 6|Subject allocation sequence 6. Intervention : the subject will receive the five products (tested product n°1, tested product n°2, tested product n°3, tested product n°4 and tested product n°5) in a certain order of assignment of each study product (which will be randomly attributed to him via the randomization sequence).
89368866|NCT03698318|Experimental|Subject sequence 7|Subject allocation sequence 7. Intervention : the subject will receive the five products (tested product n°1, tested product n°2, tested product n°3, tested product n°4 and tested product n°5) in a certain order of assignment of each study product (which will be randomly attributed to him via the randomization sequence).
89368867|NCT03698318|Experimental|Subject sequence 8|Subject allocation sequence 8. Intervention : the subject will receive the five products (tested product n°1, tested product n°2, tested product n°3, tested product n°4 and tested product n°5) in a certain order of assignment of each study product (which will be randomly attributed to him via the randomization sequence).
89368868|NCT03698318|Experimental|Subject sequence 9|Subject allocation sequence 9. Intervention : the subject will receive the five products (tested product n°1, tested product n°2, tested product n°3, tested product n°4 and tested product n°5) in a certain order of assignment of each study product (which will be randomly attributed to him via the randomization sequence).
89368869|NCT03698318|Experimental|Subject sequence 10|Subject allocation sequence 10. Intervention : the subject will receive the five products (tested product n°1, tested product n°2, tested product n°3, tested product n°4 and tested product n°5) in a certain order of assignment of each study product (which will be randomly attributed to him via the randomization sequence).
89368870|NCT03698240|Experimental|Mindfulness-based program|Children and parents receive the program
89368871|NCT03698240|No Intervention|Waiting-list|Children and parents receive no-interventions.
88841703|NCT05348707||Per Covid 19 cohort, year 2|"Infants hospitalized in the Pediatric Department of the  Hôpital Femme Mère Enfant , Lyon, France with a RT-PCR positive for Rhinovirus from 17th March 2021 to 16th March 2022. The need to recruit patients for this additional cohort will be evaluated after the data from the first 2 years of recruitment are available and analyzed."
88841704|NCT02745626|Experimental|Clear Aligner Appliance|Clear Aligners, Align Technology Inc., Santa Clara, California
88841705|NCT02745626|Experimental|Self-ligating Appliance|Carriere Self-Ligating Bracket, Carlsbad, CA
88841706|NCT02745626|Experimental|Conventional bracket appliance|Preadjusted edge wise brackets using elastomeric ties.
88841707|NCT02763865|Experimental|Active pre-SMA rTMS|The intervention to be administered is the MagVenture MagProx100 Stimulator with a Cool-B65 A/P coil l to administer active rTMS at 1Hz, 1,200sec, 110% resting motor threshold (rMT); 1200 pulses total. Two Thymapad Stimulus Electrodes will be placed in the appropriate position during active rTMS administration.This intervention method will be used for all 15 treatment sessions (20 minutes/session).
89368872|NCT05200858|Active Comparator|Active Group (AG)|Active group (AG). The AG (n=20) will be undergoing TENS therapy with an active device during 4 weeks. To deliver TENS, a band strap with hydrogel pads will be placed around the calf muscle of one lower-extremity alternating to the other side in a weekly basis.
89368873|NCT05200858|Placebo Comparator|Placebo Group (PG)|Placebo Group (PG) The PG (n=20) will be undergoing TENS therapy with a sham device as described in the AG. The sham device is identical to the active device in all respects except that it stimulates for 6 minutes during each therapy session instead of 60 minutes, and is therefore 10% of the dose.
89368874|NCT03697928||CrAT subjects|"13 healthy adult men, with a wide range of maximal aerobic capacity will be included.~Subjects will be classified as trained, physical active and untrained according to their VO2max.~Subject will perform one-legged knee extension and flexion exercise inside the MRS scanner and cycling outside the scanner"
89368875|NCT03195712||Patients with Class II and III Obesity|Patients enrolled in an outpatient weight loss program from 2010-2016.
89368876|NCT03703388|Experimental|Arctigenin 250mg|Arctigenin 250mg will be administered for 28 days.
89368877|NCT03703388|Experimental|Arctigenin 400mg|Arctigenin 400mg will be administered for 28 days.
89368878|NCT03703388|Experimental|Arctigenin 500mg|Arctigenin 500mg will be administered for 28 days.
89368879|NCT02443714|Experimental|Needle-free jet injection|Jet injectors deliver insulin at a high velocity (typically.100 m/s) across the skin in the subcutaneous tissue and may dispense the insulin over a larger area than insulin injected with a syringe.
89368880|NCT02443714|Experimental|Conventional pen|Conventional insulin administration with insulin pens.
89368881|NCT03703310|Experimental|Patidegib Topical Gel, 2%,|Participants will be randomized to receive Patidegib Topical Gel, 2%. The Patidegib Topical Gel, 2% will be dispensed to participants at each study visit and applied topically twice daily to the face.
89368882|NCT03703310|Placebo Comparator|Patidegib Topical Gel, Vehicle|Participants will be randomized to receive Vehicle. The Patidegib Topical Gel, Vehicle will be dispensed to participants at each study visit and applied topically twice daily to the face.
89530408|NCT03245047|Placebo Comparator|Control group|Participants in the control group will be asked to consume two servings of Oral nutritional supplement per day for 180 days.(Oral Consumption)
88841708|NCT02763865|Sham Comparator|Sham pre-SMA rTMS|The intervention to be administered is the eSHAM system used in conjunction with the MagVenture MagProx100 Stimulator with the Cool-B65 A/P Coil. For eSHAM administration two Thymapad Stimulus Electrodes will be placed on the scalp location that corresponded to left DLPFC. This intervention method will be used for all 15 treatment sessions (20 minutes/session). Previous studies have shown the eSHAM system effectively blinds participants to rTMS treatment (active versus sham).
89368883|NCT02440126||Group A: Natalizumab Naïve|This group will consist of up to 10 people who are naïve to natalizumab (haven't received the drug before) and are just beginning therapy. These participants will meet with the study staff at Week 0 (Baseline) prior to their natalizumab infusion. They will then have a follow up appointment every 3 months for the first 12 months of their natalizumab infusions, for a total of 5 visits. Natalizumab concentration and other biomarkers will be measured at each visit.
89368884|NCT02440126||Group B: Intracycle Regular Dosing|This group will consist of at least 50 people who are on a regular infusing cycle of 28-31 days. These participants will be consented at Week 0 (Baseline) and asked to come back each week during their regular cycle at Week 1, Week 2, and Week 3, for a total of 4 study visits. Natalizumab concentration and other biomarkers will be measured during their participation in the study.
89368885|NCT02440126||Group C: Intracycle Extended Dosing|This group will consist of up to 60 people who are on an extended infusing cycle of greater than 30 days. These participants will be consented at Week 0 (Baseline) and asked to come back each week for a blood draw to measure Natalizumab concentration and other biomarkers during their extended cycle at Week 2, and Week 4, for a total of 3 study visits.
88841709|NCT04337528|Experimental|Thrust Group|Participant will receive the thrust technique manipulation of the affected sacroiliac joint.
89368886|NCT02440126||Group D: Transition Dosing|This group will consist of up to 10 people who are on a regular infusing cycle of 28-30 days who will be transitioning to an extended dosing cycle. The decision to transition will be made by their treating neurologist. These participants will be consented at Week 0 (Baseline) and will be followed for 8 cycles. Natalizumab concentration will be measured at each cycle. During certain cycles, other biomarkers will be measured.
89368887|NCT03190408||Shock|
89179808|NCT02609243|Active Comparator|conventional consulting, conventional diet|subjects receive 8 units of nutritional consulting, first 3 weeks of intervention phase are designed as a conventional hypocaloric low-fat diet referring to DGE guidelines (below 30 % fat), followed by 11 months of isocaloric-to-moderate-hypocaloric low-fat diet (below 30 kcal% fat) - dietary intervention without supplement
89368888|NCT03703232|Other|Lower extremity amputees|Community walking trial comparing usual prosthetic foot with investigational prosthetic foot.
89368889|NCT04483570||Secondary Tethered Cord Syndrome|Children with signs of progressive deterioration in urological or neuroorthopedic system, and suspected Secondary Tethered Cord Syndrome (STCS) following primary untethering surgery.
89368890|NCT03703154||Study Arm|The patients in the study arm will be converted from immediate release Tacrolimus to Envarsus. After obtaining informed consent, participants will undergo baseline tests for cognitive function and cerebral blood flow. After 12 weeks, cognition and brain blood flow will be assesses again in all enrolled patients.
89368891|NCT03703154||Control Arm|Patients in the control arm will remain on the immediate release Tacrolimus. After obtaining informed consent, participants will undergo baseline tests for cognitive function and cerebral blood flow. After 12 weeks, cognition and brain blood flow will be assesses again in all enrolled patients.
89368892|NCT03188380||Plain abdominal radiograph (AR)|After meeting enrolment criteria each patient will have an AR performed. One image will be obtained with a vertical beam and a horizontal beam, with the patient supine.
89368893|NCT03188380||Abdominal ultrasound (AUS)|If plain abdominal radiography is inconclusive or no abnormalities typical for NEC are recorded, an AUS will be ordered.
89368894|NCT02443558|Experimental|Complete Injury|"Patients suffering from complete injury at the cervical spinal cord level (ASIA Impairment Scale A).~Brain-Computer Interface control of robotic arms. MERCURY v2.0 robotic arms."
89368895|NCT02443558|Experimental|Incomplete Injury|"Patients suffering from incomplete injury at the cervical spinal cord level (ASIA Impairment Scale B,C,D,E).~Brain-Computer Interface control of robotic arms. MERCURY v2.0 robotic arms"
89368896|NCT02443558|Active Comparator|Non-cervical injury|"Patients suffering from complete or incomplete injury of the spinal cord at a level other than the cervical (thoracic or lumbar).~Brain-Computer Interface control of robotic arms. MERCURY v2.0 robotic arms"
88841710|NCT04337528|Active Comparator|Muscle-energy group|Participant will receive the muscle-energy technique manipulation of the affected sacroiliac joint.
88841711|NCT04337528|Placebo Comparator|Placebo Group|Participant will receive a placebo manipulation of the affected sacroiliac joint.
88841712|NCT02746406|Experimental|Peritron+|SMIP assessment using Peritron+, Air-Trap Tubing, and a conventional CIC catheter
89368897|NCT02443558|Active Comparator|Healthy participants|"Healthy participants, age and sex matched to those of the other Arms.~Brain-Computer Interface control of robotic arms. MERCURY v2.0 robotic arms"
89368898|NCT04701164|Experimental|ANX005 Treatment Group - Dose 1|Participants will receive a single IV infusion of ANX005 (Dose 1) on Day 1.
89368899|NCT04701164|Experimental|ANX005 Treatment Group - Dose 2|Participants will receive a single IV infusion of ANX005 (Dose 2) on Day 1.
89368900|NCT04701164|Placebo Comparator|Placebo Group|Participants will receive a single IV infusion of placebo on Day 1.
89368901|NCT03192670|Sham Comparator|Sham control group|Sham control group received same procedure without LED-T. Device: Low-level light therapy device approved by the ethics committees of Pusan National hospital and conformity MSDS as safe treatment device for brain diseases Parameters: Neuroimaging assessment(fMRI, SPECT), Neuropsychological Behavioral Assessment(SNSB, K-MoCA, Corsiblock test, K-MBI, K-ADL, GDS, EQ-5D)
89368902|NCT03192670|Experimental|CA(Carotid artery)-stimulation group|"In CA group, total sessions of the LED-T was done for each groups and assessment of parameters was followed that.~Each group subject underwent LED therapy (30 min) once a day for 20 days, commencing at Baseline screening test.~Device: Low-level light therapy device approved by the ethics committees of Pusan National hospital and conformity MSDS as safe treatment device for brain diseases Parameters: Neuroimaging assessment(fMRI, SPECT), Neuropsychological Behavioral Assessment(SNSB, K-MoCA, Corsiblock test, K-MBI, K-ADL, GDS, EQ-5D)"
89534785|NCT02492243|Experimental|Group 1|Patients with documented myocardial infarction in the 7days prior to enrolment and left ventricular ejection fraction >=40% as assessed by echocardiography within 7 days window after MI,who are not candidate to ICD/CRT/IPG implantation after PCI undergo ILR implantation
88841713|NCT04337918|No Intervention|Prevention - Standard Precautions|Participants COVID-19 negative at baseline will be randomized to receive standard COVID-19 screening and protection (per their facility or organization's protocols).
89368903|NCT03192670|Experimental|VA(Vertebral artery)-stimulation group|"In VA group, total sessions of the LED-T was done for each groups and assessment of parameters was followed that.~Each group subject underwent LED therapy (30 min) once a day for 20 days, commencing at Baseline screening test.~Device: Low-level light therapy device approved by the ethics committees of Pusan National hospital and conformity MSDS as safe treatment device for brain diseases Parameters: Neuroimaging assessment(fMRI, SPECT), Neuropsychological Behavioral Assessment(SNSB, K-MoCA, Corsiblock test, K-MBI, K-ADL, GDS, EQ-5D)"
89534786|NCT03231319|Active Comparator|fascia iliaca compartment block+ IV-PCA|
88841714|NCT04337918|Experimental|Prevention - NORS + Standard Precautions|Participants COVID-19 negative at baseline will be randomized to receive standard COVID-19 screening and protection (per their facility or organization's protocols) plus daily NORS treatment for 14 days.
88841715|NCT04337918|Other|Treatment Sub-Study|"Volunteers who are found to be COVID-19 positive during screening will be eligible to enroll in the 21-day Treatment sub-study and receive daily NORS treatment for 14 days. Ten participants can be directly enrolled in the Treatment sub-study.~Participants enrolled in the Prevention study who meet the criteria in this section will roll over into the Treatment Sub-Study but must remain in their randomly assigned group."
88841716|NCT02765269|Experimental|IPMS group|Cancer patients with pain are asked to use the Intelligent Pain Management System as much as possible to record the degree and location of pain at least once every day. Through assessments of these pain record, physicians could give the patients appropriate advice.
88841717|NCT02765269|No Intervention|Control group|The control group are communicated through conventional method such as telephone calls or door-to-door visit to collect the pain assessment to guide doctors' therapy.
88841718|NCT02747186|Active Comparator|Buffered 1% lidocaine|"In week One each subject would receive the anesthetic, 5cc, to block the Posterior alveolar, Anterior alveolar, Palatal nerves.Maxillary molar and canine tested for pulpal anesthesia.~At least a week later, injections for the maxillary field block would involve the alternate local anesthetic combination. Maxillary molar and canine tested for pulpal anesthesia."
88841719|NCT02747186|Active Comparator|Non-Buffered lidocaine|"In week One each subject would receive the anesthetic, 5cc, to block the Posterior alveolar, Anterior alveolar, Palatal nerves. Maxillary molar and canine tested for pulpal anesthesia.~At least a week later, injections for the maxillary field block would involve the alternate local anesthetic combination. Maxillary molar and canine tested for pulpal anesthesia."
88841720|NCT02766517|Experimental|Capsaicin|Single topical dose of capsaicin
88841721|NCT04335344||Control|Healthy patients
88841722|NCT04335344||Periodontitis|Patients with periodontitis
88841723|NCT04335344||Cardiovascular disease|Patients with cardiovascular disease
88841724|NCT04335344||Periodontitis + cardiovascular disease|Patients with Periodontitis + cardiovascular disease
88841725|NCT05348239|Experimental|Oral Chlorophyllin arm|Participants will receive oral Sodium Copper Chlorophyllin at a dose of 750mg once daily (OD) on an empty stomach.
88841726|NCT02766673|Active Comparator|Full Dose Albuterol Sulfate|2.5mg of Albuterol Sulfate will be administered via nebulizer and mechanical ventilator
88841727|NCT02766673|Active Comparator|Half Dose Albuterol Sulfate|1.25mg of Albuterol Sulfate will be administered via nebulizer and mechanical ventilator
89534787|NCT03231319|Active Comparator|femoral nerve and lateral femoral cutaneous nerve block+IV PCA|
88841728|NCT02766673|Placebo Comparator|Sterile Saline|3ml of 0.9% sterile saline will be administered via nebulizer and mechanical ventilator
88841729|NCT05455580|Experimental|N-TORM Intervention|This is a non-randomized, non-blinded, quasi-experimental, pre- and post-test phase I feasibility design pilot study.
88841730|NCT02766907|Active Comparator|Study|prospective arm receiving cryopreserved amniotic membrane
88841731|NCT02766907|No Intervention|Control|Retrospective review of debridement without cryopreserved amniotic membrane
88841732|NCT02767609|Experimental|Magentic Resonance Imaging|magnetic Resonance Imaging.
89534788|NCT03231319|Placebo Comparator|IV PCA only|
88841733|NCT05348161|Other|Anti-HER2 & Immunotherapy|Advancd gastric cancer patients received anti-HER2 & immunotherapy ± chemotherapy
88841734|NCT05348161|Other|Anti-HER2|Advancd gastric cancer patients received anti-HER2 ± chemotherapy.
88841735|NCT05349578|Other|Tissue|conventional RUT using biopsied tissue
88841736|NCT05349578|Experimental|Swab|RUT using swab
88841737|NCT02973763|Experimental|Alflutinib|patients take Alflutinib orally once per day at different dose
88841738|NCT04335734|Active Comparator|Nissen fundoplication with fixation of the wrap|In this arm, which included 87 patients we performed the following manipulations: NF was supplemented with suturing wrap to the diaphragmatic crura (52 patients) on each side using two non-absorbable stitches. In case of weak conditions of crura or short esophagus (35 patients) fundoplication wrap was sutured to the body of stomach using two non-absorbable stitches on each side. .
89534789|NCT03093753|Placebo Comparator|Control (study 1)|Control will be 50g glucose dissolved in 200 mL water
88841739|NCT04335734|Active Comparator|Nissen fundoplication without fixation of the wrap|Arm included 51 patients, who underwent classic Nissen fundoplication without wrap fixation.
88841740|NCT02767843|Experimental|treatment|continuous negative external pressure (cNEP) at various negative pressures
88841741|NCT04337593|Experimental|treatment arm|2500 IU/m2 pegaspargase given on day 1, 20 mg basiliximab given on day 1 and 8, repeated every 3 weeks
88841742|NCT04790864|Experimental|Online large-group one-session treatment with post-treatment exercise targeting expectancy violation|
88841743|NCT04790864|Active Comparator|Online large-group one-session treatment with post-treatment control exercise|
88841744|NCT04737902||VATS with ESPB|Study subjects underwent anaesthesia and VATS without a change in their routine care. At the end of the surgery, an erector spinae plane block was performed for acute pain control following our institutional protocol for perioperative care.
89534790|NCT03093753|Experimental|Test (study 1)|The test meals will comprise 50 g glucose plus 50 mg oleuropein from olives dissolved in 200 mL water
89534791|NCT03093753|Placebo Comparator|Control (study 2)|Control will be white bread (109 g) to give 50 g available carbohydrates with 200 mL water
88841745|NCT04336813|Experimental|Group A|Receive ARS in lecture 1 and act as controller in lecture 2
88841746|NCT04336813|Active Comparator|Group b|Receive ARS in lecture 2 and act as controller in lecture 1
88841747|NCT04707638||Parkinson's disease or dystonia patients|Patients with Parkinson's disease or dystonia and underwent STN DBS under general anesthesia in neurosurgery department
88841748|NCT04337671|Experimental|Training group (A)|The training was a moderate intensity aerobic training on a bicycle ergo-meter(corresponding to 60% to 70% of the maximal heart rate they reach during peak oxygen uptake in the initial exercise test) for 30 to 45 min/day, 3 sessions/week for 12 weeks (36 sessions). In addition to their prescribed medications.
88841749|NCT04337671|No Intervention|control group (B)|Control group not receiving any training . They are taking their prescribed medications only.
88841750|NCT04337047||Vik sein|Vik sein users
88841751|NCT04337047||Vik asthme|Vik asthme users
88841752|NCT04337047||Vik migraine|Vik migraine users
88841753|NCT04337047||Vik depression|Vik depression users
88841754|NCT05339581|Experimental|IMRT combined with PD-1 Blockade and Lenvatinib|"Participants receive PD-1 Blockade (Pembrolizumab，Sintilimab， Camrelizumab，Tislelizumab) 200 mg intravenously on day 1 of a 21-day treatment cycle until >42 days before liver transplantation or unacceptable toxicity develops. Participants receive Lenvatinib Mesylate Capsule (Lenvima®) 8 mg orally once daily until >7 days before liver transplantation.~Neoadjuvant IMRT will be initiated at the third treatment cycle, and the dose prescription of IMRT is for planning target volume (PTV). The prescription dose to 95%PTV should be ≥50 Gy and ≤60 Gy, and been given in daily dose fractions of 2 Gy, 5 days per week. And the final prescription dose is determined according to dose constraints for organs at risk."
88841755|NCT05339581|Active Comparator|PD-1 Blockade and Lenvatinib|Participants receive PD-1 Blockade (Pembrolizumab，Sintilimab， Camrelizumab，Tislelizumab) 200 mg intravenously on day 1 of a 21-day treatment cycle until >42 days before liver transplantation or unacceptable toxicity develops. Participants receive Lenvatinib Mesylate Capsule (Lenvima®) 8 mg orally once daily until >7 days before liver transplantation.
88841756|NCT04336579||Control|Retrospective review of patients (participants) with standard analgesia post total knee arthroplasty
88841757|NCT04336579||Diaphragmatic Breathing|Intervention: Participants will perform diaphragmatic breathing exercises postoperatively as part of their multi-modal pain regimen.
88841758|NCT04064684|Experimental|Budesonide administered by nebulizer|
88841759|NCT04064684|Placebo Comparator|Placebo administered by nebulizer|
88841760|NCT05334199|Experimental|Biodegradable stent treatment group|Biodegradable stent treatment group
88841761|NCT05325385||OHCA attended by ambulance service|All adults attended by ambulance service where time of collapse and initial rhythm is known.
88841762|NCT04715906|Experimental|UP-Caregiver Group|Unified Protocol (UP) Caregiver Group will receive the UP for Transdiagnostic Treatment of Emotional Disorders for Caregivers intervention via telehealth using Zoom for a minimum of 4 up to 8 sessions ideally within 8 weeks.
88841763|NCT02192190|Placebo Comparator|Placebo|Placebo capsule orally, once daily for approximately 16 weeks. Placebo subcutaneous (SC) once every 4 weeks for 16 weeks (Treatment period = 16 weeks).
88841764|NCT02192190|Active Comparator|Celecoxib + Placebo|Celecoxib 200 milligram (mg) capsule orally once daily for approximately 16 weeks. Placebo SC once every 4 weeks for 16 weeks (Treatment period = 16 weeks).
88841765|NCT02192190|Experimental|LY2951742 5 mg + Placebo|Placebo capsule orally, once daily for approximately 16 weeks. SC injections of 5 mg LY2951742 once every 4 weeks for 8 weeks followed by placebo SC once every 4 weeks for 8 weeks (Treatment period = 16 weeks).
88841766|NCT02192190|Experimental|LY2951742 50 mg + Placebo|Placebo capsule orally, once daily for approximately 16 weeks. SC injections of 50 mg LY2951742 once every 4 weeks for 8 weeks followed by placebo SC once every 4 weeks for 8 weeks (Treatment period = 16 weeks).
89179809|NCT02609243|Active Comparator|intensive consulting, low-carb diet|subjects receive 16 units of nutritional consulting, first 3 weeks of intervention phase are designed as a very-low calory ketogenic (low-carb) diet (< 40 g CH / day), following 11 months are restricted to not more than 40 % energy intake by carbohydrates under isocaloric-to-moderate-hypocaloric conditions - dietary intervention without supplement
89179810|NCT00731679|Placebo Comparator|Placebo|Subjects received placebo tablets 3 times daily for 2 weeks and were followed for 10 weeks after completion of the treatment period.
88841767|NCT02192190|Experimental|LY2951742 120 mg + Placebo|Placebo capsule orally, once daily for approximately 16 weeks. SC injections of 120 mg LY2951742 once every 4 weeks for 8 weeks followed by placebo SC once every 4 weeks for 8 weeks (Treatment period = 16 weeks).
88841768|NCT02192190|Experimental|LY2951742 300 mg + Placebo|Placebo capsule orally, once daily for 16 weeks. SC injections of 300 mg LY2951742 once every 4 weeks for 8 weeks followed by placebo SC once every 4 weeks for 8 weeks (Treatment period = 16 weeks).
88841769|NCT02748889|Active Comparator|Carboplatin plus etoposide|Carboplatin AUC 5 iv on day 1 every 21 days for 4 cycles Etoposide 100mg/m2 iv on days 1-3 every 21 days for 4 cycles
88841770|NCT02748889|Experimental|Carboplatin, etoposide and MPDL3280A|Carboplatin AUC 5 iv on day 1 every 21 days for 4 cycles Etoposide 100mg/m2 iv on days 1-3 every 21 days for 4 cycles MPDL3280A (Atezolizumab) 1200mg iv on day 1 every 21 days until progression
88841771|NCT02749201|Experimental|Analysis|Light Intensity and gastric wall thickness analysis
88841772|NCT04334720||Observation group of positive F&M|The baseline PET/MR scan was performed before comprehensive treatment, and the contrast scan was performed after treatment and the sequence and protocol was consistent. Get psychological assessment before and after treatment and the time interval shall not exceed half a year
89179811|NCT00731679|Experimental|Rifaximin|Subjects received rifaximin 550 mg tablets 3 times daily for 2 weeks and were followed for 10 weeks after completion of the treatment period.
89179812|NCT02609087|Experimental|Sevoflurane|adjust the end-tidal sevoflurane (sevofran inhaler, Hana pharmacy, Korea) concentration maintaining the 40 ~ 50 BIS (bispectral index) with 3 ng/ml of remifentanil using TCI (target controlled infusion) pump
89534792|NCT03093753|Experimental|Test (study 2)|The test meals will comprise 109 g white bread plus 50 mg oleuropein from olives
88841773|NCT04334720||Observation group of no abnormal changes in F&M|The baseline PET/MR scan was performed before comprehensive treatment, and the contrast scan was performed after treatment and the sequence and protocol was consistent. Get psychological assessment before and after treatment and the time interval shall not exceed half a year
88841774|NCT04334720||The control group|Corresponding to the observation group, the time, sequence and protocol were consistent
88841775|NCT02224638|Active Comparator|TheraHoney HD|Honey product
88841776|NCT02224638|Active Comparator|SkinTegrity|Skin moisturizer
89368904|NCT03192670|Experimental|CA+VA dual stimulation group|"In CA+VA group, total sessions of the LED-T was done for each groups and assessment of parameters was followed that.~Each group subject underwent LED therapy (30 min) once a day for 20 days, commencing at Baseline screening test.~Device: Low-level light therapy device approved by the ethics committees of Pusan National hospital and conformity MSDS as safe treatment device for brain diseases Parameters: Neuroimaging assessment(fMRI, SPECT), Neuropsychological Behavioral Assessment(SNSB, K-MoCA, Corsiblock test, K-MBI, K-ADL, GDS, EQ-5D)"
88841777|NCT04756362||Prospective cohort|A minimum of 294 patients will be included in the evaluation of 0 and 1 hour protocol (prospective evaluation).
89368905|NCT03703544|Experimental|High glycemic index|Subjects will consume locally consumed meals which are high glycemic index for breakfast, lunch snack and dinner will be provided.Participants' blood glucose will be monitored using the Continuous Glucose Monitor.
89368906|NCT03703544|Experimental|Low glycemic index|Subjects will consume locally consumed meals which are low glycemic index for breakfast, lunch snack and dinner will be provided. Participants' blood glucose will be monitored using the Continuous Glucose Monitor.
88841778|NCT04756362||Retrospective cohort|A minimum of 1,000 patients will be included in the evaluation of prognostic value of high sensitive cardiac troponin < 5 ng/L(retrospective evaluation).
88841779|NCT04334642|Experimental|Athletes from the Paralympic Boccia Brazilian Team|The research will have as a convenience sample 11 Athletes from the Paralympic Boccia Brazilian Team, which will be compared with itself in the data analysis. This study includes the category called Other participants formed by staff, freshmen, technicians and other professionals who are present during the interventions.
88841780|NCT04690868|Experimental|ARM 1|Period 1 : Reference Drug(AD-2131) Period 2 : Test Drug(AD-213-A)
88841781|NCT04690868|Experimental|ARM 2|Period 1 : Test Drug(AD-213-A) Period 2 : Reference Drug(AD-2131)
89534793|NCT03093753|Placebo Comparator|Control (study 3)|Control will be whole-meal bread (132 g) to give 50 g available carbohydrates with 200 mL water
89534794|NCT03093753|Experimental|Test (study 3)|The test meals will comprise whole-meal bread (132 g) with 50 mg oleuropein dissolved in 200 mL water
88841784|NCT02749903|Other|Enzalutamide|Patients receive 160 mg enzalutamide orally once daily (1 cycle=28 days). Patients will remain on therapy until progression of disease or development of unacceptable toxicities or patient or physician withdrawal. Patients will undergo radiographic imaging every 2 months while on study treatment in order to determine response.
88841785|NCT04631432||Study participation|All participants will complete the same protocol
88841786|NCT04628858||Primary group|
88841787|NCT02224560|Experimental|GWP42003-P 20 mg/kg/day Dose|Participants received GWP42003-P 20 mg/kg/day administered orally, half in the morning and half in the evening. Participants titrated GWP42003-P to 20 mg/kg/day over 11 days and remained at this dose for the 12-week maintenance period. If the participant did not immediately enter the OLE study, the maintenance period was followed by a 10-day taper (10% per day) period.
88841788|NCT02224560|Experimental|GWP42003-P 10 mg/kg/day Dose|Participants received GWP42003-P 10 mg/kg/day administered orally, half in the morning and half in the evening. Participants titrated GWP42003-P to 10 mg/kg/day over 7 days and remained at this dose for the 12-week maintenance period. If the participant did not immediately enter the OLE study, the maintenance period was followed by a 10-day taper (10% per day) period.
88841789|NCT02224560|Placebo Comparator|Placebo|Participants received placebo (0 mg/mL CBD) volume matched to 1 of the 2 dose levels (10 or 20 mg/kg/day) administered orally, half in the morning and half in the evening. To maintain the blinded aspect of the study, participants titrated the placebo dose over 7 to 11 days according to the matched IMP group (7 or 11 days for the 10 or 20 mg/kg/day GWP42003-P groups, respectively) and remained at this dose for the 12-week maintenance period. If the participant did not immediately enter the OLE study, the maintenance period was followed by a 10-day taper (10% per day of the matched dose) period.
89368907|NCT02434276|Experimental|Vaccine Dose Group 8 mcg dose|VAX2012Q, 8 mcg dose
89368908|NCT02434276|Experimental|Vaccine Dose Group 12 mcg dose|VAX2012Q, 12 mcg dose
89368909|NCT02434276|Active Comparator|Control|Fluzone Quadrivalent vaccine
89368910|NCT03697694|Experimental|500mg of Aronox® >40% polyphenol aronia extract|Name: Aronia PE 40% polyphenols Description: Powdered extract obtained from aronia berries (Aronia melanocarpa) Dosage form: Capsule (opaque, beige, size 00) Strength: 500 mg aronia extract Regimen 1 capsule, once a day with breakfast (except on days when attending the laboratory) Batch number: As per label Expiry Date: As per label Manufacturer: NATUREX / Virage sante
88841790|NCT02973776|Experimental|LEO 90100 aerosol foam|"LEO 90100 calcipotriol 50 mcg/g and betamethasone 0.5 mg/g (as dipropionate) aerosol foam~Each subject has all 6 treatments applied topically at the same time, however, the location on which the treatments are applied is randomised. Subjects will receive approximately 20 μl of each investigational product applied in circles with a diameter of 2.2 cm once."
88841791|NCT02973776|Active Comparator|Dermoval®/Dermovate®|"Dermoval®/Dermovate® (clobetasol propionate 0.05%) cream~Each subject has all 6 treatments applied topically at the same time, however, the location on which the treatments are applied is randomised. Subjects will receive approximately 20 μl of each investigational product applied in circles with a diameter of 2.2 cm once."
88841792|NCT02973776|Active Comparator|Diprosone®|"Diprosone® betamethasone 0.5 mg/g (as dipropionate) ointment~Each subject has all 6 treatments applied topically at the same time, however, the location on which the treatments are applied is randomised. Subjects will receive approximately 20 μl of each investigational product applied in circles with a diameter of 2.2 cm once."
89002065|NCT06116448|Experimental|hybrid simulation|These students participated in the same breastfeeding management scenario with a standardized patient (n=11).
89368911|NCT03697694|Placebo Comparator|500mg of placebo|Name: Placebo Description: Identical formulation as the treatment consisting of colored maltodextrin using artificial colors Dosage form: Capsule (opaque, beige, size 00) Strength: 500 mg placebo Regimen 1 capsule, once a day with breakfast (except on days when attending the laboratory) Batch number: As per label Expiry Date: As per label Manufacturer: NATUREX (Advance nutraceutical) / Virage sante
89368912|NCT03190642|Active Comparator|1000mg methylprednisolone group|Evaluating effects of 1000mg of methylpresdnisolone administered immediately preoperatively and its effects on swelling.
89368913|NCT03190642|Active Comparator|125mg methylprednisolone group|Evaluating effects of 125mg of methylpresdnisolone administered immediately preoperatively and its effects on swelling.
89368914|NCT03697616|Experimental|Ridge augmentation with sticky bone and GBR|Ridge augmentation using Autologous concentrated Growth factors (CGF) enriched bone graft matrix (sticky bone) and guided bone regeneration using native collagen membrane in horizontally deficient maxilla
89368915|NCT02439892|Experimental|Early rehabilitation|Exercise and nutrition during radiotherapy: Physical exercise, nutritional advice and oral nutritional supplements.
89368916|NCT02439892|Active Comparator|Late rehabilitation|Multidimensional rehabilitation after radiotherapy: Physical exercise, nutritional advice, oral nutritional supplements and patient education
88841793|NCT02973776|Active Comparator|Elocon®|"Elocon® mometasone furoate 0.1% cream~Each subject has all 6 treatments applied topically at the same time, however, the location on which the treatments are applied is randomised. Subjects will receive approximately 20 μl of each investigational product applied in circles with a diameter of 2.2 cm once."
89368917|NCT03702686|Experimental|FEEDBACK system|Mother / infant dyad will use the FEEDBACK system during a breastfeeding session.
89368918|NCT03701438||Idelalisib|Participants currently enrolled in a Gilead-sponsored study, who are currently being treated with 100 or 150 mg of idelalisib twice daily for at least 7 consecutive days prior to receiving an influenza vaccine.
89368919|NCT02440048|Experimental|HA ®Bond-apatite|10 extraction sockets will be preserved with Bond Apatite synthetic bone substitutes as test group
89368920|NCT02440048|Active Comparator|BioOss bovine bone substitute|10 extraction sockets will be preserved with BioOss particles bovine bone substitute as a positive control
89368921|NCT02440048|No Intervention|extraction|10 extraction sockets with no use of bone substitute as negative control.
89368922|NCT04050332|Experimental|Stair Walking|Participants in this arm will engage in four minutes of stair walking while being tracked by radio frequency identification equipment.
89368923|NCT04050332|No Intervention|Control|Participants in this arm will stand in the stairwell for four minutes while being tracked by radio frequency identification equipment.
89368924|NCT03188458|Other|Second and third trimester Group|This study group will include infants whose mothers have received Boostrix during the second (21-27 weeks) and third trimester (above 28 weeks) of their pregnancy, as per routine practice.
89368925|NCT03702530|Experimental|Intervention|3x 50 L3 larvae immunisation with albendazole treatment and 2x 50 L3 larvae infection
89368926|NCT03702530|Placebo Comparator|Placebo|3x placebo immunisation with albendazole treatment and 2x 50 L3 larvae infection
89368927|NCT02443246|Experimental|Vitamin D deficiency|Group 1
89368928|NCT02443246|Experimental|Vitamin D deficiency (Low)|Group 2
89368929|NCT03702452|Experimental|Experimental group|Patients in experimental group were graded with modified Barthel index score, and according to the functional score of patients, the corresponding rehabilitation method was selected for functional rehabilitation from functional rehabilitation nursing program,twice a day with 30 min each time, last 1 week.
89368930|NCT03702452|Experimental|control group|Patients in control group were given conventional bedside rehabilitation ,twice a day with 30 min each time, last 1 week.
89368931|NCT03188302|Other|Specimen collection|Collection of stool samples
89368932|NCT02443168|Experimental|100-mg AG-221 oral solution + a microtracer of [14C]-AG- 221|Subjects will receive a 100 mg AG-221 to be swallowed with 240 mL of room-temperature, non-carbonated water.
88841794|NCT02973776|Active Comparator|Locoid®|"Locoid® hydrocortisone-17-butyrate 0.1% ointment~Each subject has all 6 treatments applied topically at the same time, however, the location on which the treatments are applied is randomised. Subjects will receive approximately 20 μl of each investigational product applied in circles with a diameter of 2.2 cm once."
89002066|NCT06116448|Experimental|telesimulation|These students participated in the same breastfeeding management scenario with a standardized patient via Microsoft Teams video conferencing. (n=11)
89368933|NCT02443168|Experimental|100-mg AG-221 tablet + 100 micrograms [14C] AG-221|Formulated tablet containing 100 mg AG-221 + IV solution containing 100 micrograms [14C] AG-221
89368934|NCT02443948||adjuvant/follow up setting|
89368935|NCT02443948||neo-adjuvant setting|
89368936|NCT02443948||advanced disease|
89368937|NCT02439580|Experimental|Annona muricata extract|Annona muricata ethanol-soluble fraction of water extract capsule, 300 mg/day, for eight weeks
89368938|NCT02439580|Placebo Comparator|Placebo|Maltose capsule, 300 mg/day, for eight weeks
89368939|NCT03031496|Experimental|Test A followed by Ref B of HCTZ 50mg+ Amiloride HCl 5mg|Eligible participants following an overnight fast of at least 10 hours, will be administered the study drug orally with 240 mL (8 fluid ounces) of water. No food will be allowed for at least 4 hours post-dose. Water will be allowed as desired except for one hour before and after drug administration.
89368940|NCT03031496|Experimental|Ref B followed by test A of HCTZ 50mg + Amiloride HCl 5mg|Eligible participants following an overnight fast of at least 10 hours, will be administered the study drug orally with 240 mL (8 fluid ounces) of water. No food will be allowed for at least 4 hours post-dose. Water will be allowed as desired except for one hour before and after drug administration.
89368941|NCT03190486|Experimental|Men contact-less with children|functional Magnetic Resonance Imaging (fMRI).
89368942|NCT03190486|Experimental|Women contact-less with children|functional Magnetic Resonance Imaging (fMRI).
89368943|NCT03190486|Experimental|Father contact-less with children|functional Magnetic Resonance Imaging (fMRI).
89368944|NCT03190486|Experimental|Mother contact-less with children|functional Magnetic Resonance Imaging (fMRI).
89368945|NCT03187990|Experimental|PET/MRI before biopsy|Patients with suspected areas on mpMRI will undergo additional [68Ga]PSMA-11 PET/MRI scan with subsequent mpMRI and PET/MRI guided biopsy.
89368946|NCT03187990|Experimental|PET/MRI after biopsy|Patients with unclear areas or a negative finding in the mpMRI for MRI guided biopsy but positive biopsy, which will undergo the additional [68Ga]PSMA-11 PET/MRI scan with [68Ga]PSMA.
89368947|NCT03697382|Experimental|Very Low Steps|Subjects will be asked to undergo reduced daily stepping to a level of 2,500 steps/d for 2 days. On the evening of day 2, they will be asked to run at 65% of VO2max for 1-hour.
89368948|NCT03697382|Experimental|Low Steps|Subjects will be asked to undergo reduced daily stepping to a level of 5,000 steps/d for 2 days. On the evening of day 2, they will be asked to run at 65% of VO2max for 1-hour.
89368949|NCT03697382|Experimental|Moderate Steps|Subjects will be asked to undergo reduced daily stepping to a level of 7,500 steps/d for 2 days. On the evening of day 2, they will be asked to run at 65% of VO2max for 1-hour.
89368950|NCT03187912|Active Comparator|Riboflavin with 20% Dextran|Riboflavin drops with Dextran
89368951|NCT03187912|Active Comparator|Riboflavin with HPMC|Riboflavin drops with HPMC
89368952|NCT03701204|Experimental|DynamiCare Rewards|The study will test the feasibility/acceptability and efficacy of DynamiCare Rewards™. DynamiCare Rewards is an iOS/Android app which automates Contingency Management (CM) to help the patient self-monitor and focus attention on his/her behavioral goals (i.e., abstinence) for alcohol or other substance use disorders.
89368953|NCT03701204|No Intervention|Control|Treatment as usual
89368954|NCT03188224|Experimental|Intervention|MyTransition app
89368955|NCT03188224|No Intervention|Control|Usual care
89368956|NCT03697226|Experimental|Dose 1|Topical ABI-1968 Cream applied at Day 1, Day 8, Day 15 and Day 22
88841795|NCT02973776|Placebo Comparator|LEO 90100 foam vehicle|"LEO 90100 foam vehicle~Each subject has all 6 treatments applied topically at the same time, however, the location on which the treatments are applied is randomised. Subjects will receive approximately 20 μl of each investigational product applied in circles with a diameter of 2.2 cm once."
88841796|NCT02161458|Experimental|Escitalopram 20mg for 2 weeks|30 cognitively normal adults aged 60-85 will receive escitalopram 20mg for 2 weeks (upward titration as: 10mg for 5 days, then 20mg for 9 days); and amyloid beta levels in the CSF will be measured at baseline (before drug administration) and after 2 weeks of study drug (active or placebo). Participants will taper off medication following the 2nd CSF measurement.
88841797|NCT02161458|Placebo Comparator|Placebo (sugar pill)|30 cognitively normal adults aged 60-85 will receive placebo for 2 weeks (upward titration as: 10mg for 5 days, then 20mg for 9 days) or 8 weeks (upward titration as: 10mg for 5 days, then 20mg for 51 days); and amyloid beta levels in the CSF will be measured at baseline (before drug administration) and after 2 or 8 weeks of study drug (active or placebo). Participants will taper off medication following the 2nd CSF measurement.
88841798|NCT02161458|Experimental|Escitalopram 30mg for 8 weeks|30 cognitively normal adults aged 60-85 will receive escitalopram 30 mg for 8 weeks (upward titration as: 10mg for 5 days, then 20mg for 5 days; then 30 mg for 46 days); and amyloid beta levels in the CSF will be measured at baseline (before drug administration) and after 8 weeks of study drug (active or placebo). Participants will taper off medication following the 2nd CSF measurement.
88841799|NCT02161458|Experimental|Escitalopram 20mg for 8 weeks|30 cognitively normal adults aged 60-85 will receive escitalopram 20mg for 8 weeks (upward titration as: 10mg for 5 days, then 20mg for 51 days); and amyloid beta levels in the CSF will be measured at baseline (before drug administration) and after 8 weeks of study drug (active or placebo). Participants will taper off medication following the 2nd CSF measurement.
88841800|NCT05144828|Experimental|Intercostal Nerve Cryoablation plus Standard of Care (SOC) Pain Control|Intercostal nerve cryoablation using the CryoICE® CRYOS-L cryoablation probe and an intercostal nerve block of nerves 4-9 performed using 0.5% Marcaine with Epinephrine plus prescribed post-operative pain medication, including tramadol, tylenol, and robaxin
88841801|NCT05144828|Active Comparator|Standard of Care (SOC) Pain Control|Intercostal nerve block of nerves 4-9 using 0.5% Marcaine with Epinephrine plus prescribed post-operative pain medication, including tramadol, tylenol, and robaxin
88841802|NCT05455255|Experimental|Experimental Group|FL will be applied to the intervention group. In this model, short videos of the course will be delivered to students via WhatsApp one week in advance. At the beginning of the lesson, students' deficiencies will be corrected by making kahoot. Afterwards, group work, case scenario, role-play scenario and conceptual map methods will be applied in the course.
88841803|NCT05455255|No Intervention|Control Group|The subject of the nursing process will be transferred to the control group with powerpoint presentations by the educator. The activities in the other group will be presented by the trainer as an example.
88841804|NCT02223858|Experimental|Positive Activities (PA)|Positive Activities (PA) Program
88841805|NCT02223858|Active Comparator|Attention Control (AC)|Attention Control (AC) Program
88841806|NCT04336501|Experimental|IM19 CAR-T group|Subject will be treated with IM19 car-t cells
88841807|NCT05041400|Other|Healthy subjects|"Evaluation carried out on a BIODEX S4 Pro isokinetic dynamometer after a standardised 10-minute warm-up on this same dynamometer .~The measurement range will be from 0° (full extension) to 90° of flexion for each knee, providing 91 degrees of measurement."
88841808|NCT02223390|Experimental|Mental health treatment|The experimental condition, ImpACT, was developed in the pilot phase of the study. The intervention will be 4 sessions of individual psychological treatment related to stress, coping, and HIV adherence, followed by three group sessions. Sessions will follow an intervention manual and be delivered by a psychiatric nurse (or equivalent nonspecialist in mental health) who is supervised by a trained clinical psychologist.
89368957|NCT03697226|Experimental|Dose 2|Topical ABI-1968 Cream applied at Day 1, Day 8, Day 15 and Day 22
89368958|NCT03697226|Experimental|Dose 3|New Topical ABI-1968 Formulation applied at Day 1, Day 8, Day 15 and Day 22
89368959|NCT03697226|Experimental|Dose 4|New Topical ABI-1968 Formulation applied at Day 1, Day 8, Day 15 and Day 22
89368960|NCT03697226|Experimental|Dose 5|New Topical ABI-1968 Formulation applied at Day 1, Day 8, Day 15 and Day 22
89368961|NCT03189940|Active Comparator|App user group|
89368962|NCT03189940|Sham Comparator|Control group|Control participants, the physicians could assess the lifestyle and recommend further lifestyle modification only on the basis of the participants' recalls
89368963|NCT04681742|Experimental|CO-OP Group|10, 45-60 minute Cognitive Orientation to daily Occupational Performance intervention sessions
89368964|NCT03190252||Trimix|Exposure to ambient pressure of maximum 11 ATA breathing Trimix. Exposure to oxygen partial pressure of 130 kPa breathing Trimix.
89368965|NCT03702296|Other|Intervention|Patients will be provided with ear plugs and eye masks, to be used from 10pm to 6am, for 3 days post-operatively.
89368966|NCT03702296|No Intervention|Control|No ear plugs or eye masks provided.
89368967|NCT03192280|Experimental|All study participants|"Each subject will receive single topical induction application of Leukotriene B4 (LTB4) on the inner arm.~Images of the treated area will be captured using multiple medical devices."
89534795|NCT03093753|Placebo Comparator|Control (study 4)|Control will be 50 g sucrose dissolved in 200 mL water
88818327|NCT01816451|No Intervention|control|The control group did not do the running training program. Control did their normal physical activities.
88818328|NCT01382186||Purposive Sampling|Purposive sampling was used to identify a sample of 33 Veterans who have been Personally Authenticated for the SM feature on MHV. Participants were recruited from each site (Tampa, Boston). Women were purposively recruited to ensure females were represented in data findings.
88818329|NCT01382186||Random Sampling|Random sampling was used to conduct a quantitative survey with 819 veterans to explore their experiences using secure messaging.
88818330|NCT02107443|Experimental|Arm I: Geriatric Assessment Intervention|At the first study visit with their oncologist, patients and their caregivers (if participating) complete the GA and receive the intervention; GA summary plus GA targeted recommendations which is provided to the oncology team to discuss and implement if they so choose.
88818331|NCT02107443|Active Comparator|Arm II: Usual Care|At the first study visit with their oncologist, patients and their caregivers (if participating) complete the GA (no GA summary or recommendations are provided).
88818332|NCT01383200|Active Comparator|Tetracaine R/Lidocaine L|Participant's Right or Left eye will receive 0.5% Tetracaine drop, at 10 minutes and 5 minutes, prior to LASIK.
88818333|NCT01383200|Active Comparator|Tetracaine L/Lidocaine R|Participant's Right or Left eye will receive 2% lidocaine gel, at 10 minutes and 5 minutes, prior to LASIK.
88818334|NCT04893135|No Intervention|G1A|Uncontrolled diabetes (HbA1c> 8.5%) over 6 months. In order to assess the effect of rapid correction of HbA1c on RANKL levels, without the practice physical activity
88818335|NCT04893135|Experimental|G1B|Uncontrolled diabetes (HbA1c> 8.5%) over 6 months. In order to assess the effect of rapid correction of HbA1c on RANKL levels, with the practice physical activity
88818336|NCT04893135|No Intervention|G2|Controlled diabetes (HbA1c level <7%). This group will study the natural course of RANKL levels in balanced diabetic patients.
88818337|NCT01404650|Experimental|AUY922|
88818338|NCT04859673|Active Comparator|study group|Patients will received 3,000 pulses, 1,500 pulses per site at a frequency of 12 Hz per session with the submaximal pressure between 0.39 and 1.95 mJ/mm2 (1.0 and 5.0 bar), depending on the level which the patient can tolerate without local anesthetics.
88818339|NCT04859673|Sham Comparator|control group|The patients in this group will be treated by sham radial extracorporeal shock wave therapy. Stimulation will not deliver as the transmitter head will be removed. The patients will receive the same frequency of air pressure and sound
88818340|NCT01276652|Active Comparator|Environmental modification|Subjects assigned to this group receive the environmental modification intervention for 48 hours beginning the morning after enrollment.
88818341|NCT01276652|No Intervention|Usual care (randomized)|"Usual care is provided for the first 48 hours. Subsequently, in the initial protocol, subjects received 48 hours of the environmental modification intervention so long as they remained in the ICU during this time. The opportunity to receive the Delayed intervention was later removed from the protocol."
88818342|NCT01276652|No Intervention|Usual care (observational)|Usual care was provided.
88818343|NCT05588037|Experimental|RRD group|to evaluate the efficacy and complications of a new minimally invasive vitreoretinal surgery combined with FLACS in the treatment of rhegmatogenous retinal detachment complicated with cataract.
88818344|NCT05588037|Experimental|ERM group|to evaluate the efficacy and complications of a new minimally invasive vitreoretinal surgery combined with FLACS in the treatment of epiretinal membrane complicated with cataract.
88818345|NCT05588037|Experimental|MH group|to evaluate the efficacy and complications of a new minimally invasive vitreoretinal surgery combined with FLACS in the treatment of macular hole complicated with cataract.
88818346|NCT05588037|Experimental|Vitreous cloudy group|to evaluate the efficacy and complications of a new minimally invasive vitreoretinal surgery combined with FLACS in the treatment of vitreous opacity complicated with cataract.
88818347|NCT02194088|Experimental|Pain medication: diclofenac and atropine|Diclofenac and Atropine combination drug Provided PO. This is a novel combination. Diclofenac 100mg + Atropine 1.2 mg in one single dose
88818348|NCT02194088|Placebo Comparator|placebo|Placebo capsules will be delivered in same number as the medication
88818349|NCT02023593|Experimental|FOLFIRI|Patients will receive FOLFIRI every 2 weeks: Irinotecan 180mg/m2 IV over 90 minutes on Day 1; Leucovorin IV over 2 hours on Day 1(l-LV 200 mg/m2 or dl-LV 400 mg/m2 ); 5-Fluorouracil 400 mg/m2 IV bolus on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion.
88818350|NCT03009734|Other|ATx201 (2% dermal formulation A) and Placebo|
88818351|NCT03009734|Other|ATx201 (2% dermal formulation B) and Placebo|
88818352|NCT03009734|Other|ATx201 (2% dermal formulation C) and Placebo|
88818353|NCT01978431|Experimental|Stimulant|Cocaine and Methylphenidate
88818354|NCT01978431|Placebo Comparator|Placebo|methylphenidate
88818355|NCT01406444|Active Comparator|rhIGF-1 followed by Risedronate|Sequential therapy with rhIGF-1 (started at a dose of 30 mcg/kg subcutaneous BID and titrated) for 6 months followed by 6 months of risedronate 35mg PO once weekly
88818356|NCT01406444|Active Comparator|Risedronate|Risedronate 35mg PO once weekly for 12 months
88818357|NCT01406444|Placebo Comparator|Placebo|Placebo for 12 months
88818358|NCT01406990||Aspirin 81 mg|Women with CAD taking 81 mg aspirin.
88818359|NCT00366639||001|
88818360|NCT01407068|Experimental|AA4500|AA4500 collagenase clostridium histolyticum
88818361|NCT01385306|Experimental|AlphaCore System|non-invasive vagus nerve stimulation (nVNS) using the AlphaCore System
88818362|NCT02685267|Active Comparator|Docetaxel/Prednisone|Docetaxel 75 mg/m2 day 1 (every 21-days) plus prednisone 5 mg po bid throughout
88818363|NCT02685267|Active Comparator|Docetaxel/Prednisone + Enzalutamide|Docetaxel 75 mg/m2 day 1 (every 21-days) plus prednisone 5 mg po bid throughout plus Enzalutamide 160 mg daily throughout. Subjects will continue enzalutamide until PD after 10 cycles of docetaxel.
89368968|NCT03190018|Experimental|Single group with CLS PD device|Aim of the intervention is to evaluate the adsorbs of uremic toxins and certain ions with Purcart and the evaluation of the glucose-salt solution ability to achieve stable osmolality. The intervention is during an eight hour study session.
89368969|NCT02443012|Experimental|Nevanac|Patients with CSME treated with argon laser photocoagulation (focal/grid laser) and Topical Gutt Nepafenac 0.1% given 8 hourly interval for 3 months
89368970|NCT02443012|Placebo Comparator|Laser|Patients with CSME treated with argon laser photocoagulation (focal/grid laser)
89368971|NCT02443090|Experimental|Fispemifene 450 mg|Fispemifene capsules will be taken orally each morning immediately after eating a meal
89368972|NCT02443090|Placebo Comparator|Placebo|Placebo capsules will be taken orally each morning immediately after eating a meal
89368973|NCT03624764|Experimental|Promontofixation using glue|Patients in this arm will have a laparoscopic promontofixation using a biocompatible cyanoacrylate adhesive replacing some sutures to maintain the strips.
89368974|NCT03624764|Active Comparator|Promontofixation using threads|Patients in this arm will have a laparoscopic promontofixation using sutures with threads to maintain the strips.
89368975|NCT03701126|Active Comparator|group A|Transversus Abdominis Plane block using 1ml/kg of bupivacaine 0.25% under ultrasound guidance
89368976|NCT03701126|Active Comparator|group B|Caudal block using 1ml/kg of bupivacaine 0.25% under ultrasound guidance
89368977|NCT02439736||CT positive for acute intracranial lesion|
89368978|NCT02442934|Experimental|Multicomponent program|Multicomponent intervention to reduce perceived discomforts in critically ill patients : the IPREA3 program
89368979|NCT02442934|Active Comparator|Standard Care|Standard care
89368980|NCT03696914||Eosinophilic|Asthmatic patients showing 3% or more sputum eosinophils
89368981|NCT03696914||Non-eosinophilic|Asthmatic patients showing less than 3% sputum eosinophils
89368982|NCT02439502|Experimental|open label|Upper and Lower digestive tract diagnostic. The Fuse® system is intended for diagnostic visualization of the digestive tract. The system also provides access for therapeutic interventions using standard endoscopy tools. Fuse Colonoscopies are indicated for use within the lower digestive tract (including the anus, rectum, sigmoid colon, colon and ileocecal valve) for adult subjects and for the upper digestive tract (including the esophagus, stomach, and duodenum).
88841809|NCT02223390|No Intervention|Standard of Care|Participants in standard of care will receive the three-session adherence counseling delivered in the clinic, along with referrals for trauma treatment.
88841810|NCT05454865|Experimental|Jin Si Herbal Tea|Jin Si Herbal Tea 1 pack (15 ml) oral use twice daily for two cycles (1 cycle = 3 wks)
89368983|NCT03187600|Active Comparator|Standard of Care|Procedure: a superiorly based pharyngeal flap surgery as per Hogan and Cable and Canady. It is performed trans-orally under general anesthetic. The soft palate is divided midline to visualize the posterior pharyngeal wall. A small flap is dissected via longitudinal incisions with a superior pedicle from the posterior pharyngeal wall at the level of the velum. The flap is then brought anteriorly, the inferior portion is lined with mucosa from the nasal portion of the soft palate and sutured in-place to create an incomplete pharyngeal obstruction that acts as a dynamic valve. Nasal stents are placed in each lateral port to prevent airway compromise and maintain flap integrity. Stents are removed two days post operatively and the patient is discharged after removal of stents and deemed to have a stable airway. Dissection will be carried out to the level of the prevertebral fascia and be comprised of mucosa and pharyngeal muscle.
88841811|NCT05454865|Placebo Comparator|Placebo group|Mimic Tea 1 pack (15ml) oral use twice daily in the first cycle, using Jin Si Herbal Tea in the 2nd cycle
88841812|NCT04507646|Experimental|True auricular acupuncture|Effective auricular acupuncture
88841813|NCT04507646|Sham Comparator|Sham auricular acupuncture|Ineffective auricular acupuncture
88841814|NCT02973841|Experimental|Sono-ease group|insertion IJV catheter using sono-ease device
88841815|NCT04507022|Experimental|HRT Plus Aromatase Inhibitor|"Hormone replacement treatment (HRT) will be used in all cases. Exogenous estradiol will be started on day 2 or 3 of the cycle. In all participants, 2 mg oral estradiol valerate, will be administered three times daily. Ultrasound evaluation of endometrium will be performed 10 to 12 days after starting E2. Trilaminar endometrium of 9 mm will be the targeted cutoff . If not yet ready, E2 supplementation will be continued with serial US assessment until the desired cutoff is achieved. Thereafter, participants will be randomized to two groups:~Group A (HRT plus AI): will be given aromatase inhibitor for 5 days only (2.5 mg twice daily), along with the oral 6 mg E2. Then, daily intramuscular (IM) P in oil (100 mg IM P) will be started in addition to the daily dose of oral 6 mg E2.~In both groups, embryos will be warmed on the 6th day of P supplementation. Before undergoing FET, endometrial thickness will be re-evaluated. IM P and 6mg E2 will be continued thereafter."
88841816|NCT04507022|Active Comparator|HRT Only|"Hormone replacement treatment (HRT) will be used in all cases. Exogenous estradiol will be started on day 2 or 3 of the cycle. In all participants, 2 mg oral estradiol valerate, will be administered three times daily. Ultrasound evaluation of endometrium will be performed 10 to 12 days after starting E2. Trilaminar endometrium of 9 mm will be the targeted cutoff . If not yet ready, E2 supplementation will be continued with serial US assessment until the desired cutoff is achieved. Thereafter, participants will be randomized to two groups Group B (HRT only): will be administered daily intramuscular (IM) P in oil (100 mg IM P) in addition to the daily dose of oral 6 mg E2.~In both groups, embryos will be warmed on the 6th day of P supplementation. Before undergoing FET, endometrial thickness will be re-evaluated. IM P and 6mg E2 will be continued thereafter."
88841817|NCT00372788|Active Comparator|1|Pemetrexed
88841818|NCT00372788|Experimental|2|AZD6244
88841819|NCT04957316|No Intervention|Control group|Conventional treatment of severe septic shock.
88841820|NCT04957316|Experimental|Blood purification group|Conventional treatment of severe septic shock and blood purification.
88841821|NCT02774941|Active Comparator|Control|Standard single patient-use small volume JN (AirLife™ Sidestream® High-Efficiency Nebulizer, CareFusion, Yorba Linda, CA)
88841822|NCT02774941|Experimental|Study|Vibrating Mesh Nebulizer (Aerogen® Solo with Ultra adapter, Aerogen Ltd, Galway, Ireland)
89534796|NCT03093753|Experimental|Test (study 4)|The test meals will comprise 50 mg oleuropein and 50 g sucrose dissolved in 200 ml water
89534797|NCT03093753|Placebo Comparator|Control (study 5)|Control will be 25 g sucrose dissolved in 200 mL water
89368984|NCT03187600|Experimental|Experimental Group|Procedure: a modified superiorly based pharyngeal flap surgery as per Hogan and Cable and Canady. It is performed trans-orally under general anesthetic. The soft palate is divided midline to visualize the posterior pharyngeal wall. A small flap is dissected via longitudinal incisions with a superior pedicle from the posterior pharyngeal wall at the level of the velum. The flap is then brought anteriorly, the inferior portion is lined with mucosa from the nasal portion of the soft palate and sutured in-place to create an incomplete pharyngeal obstruction that acts as a dynamic valve. Nasal stents are placed in each lateral port to prevent airway compromise and maintain flap integrity. Stents are removed two days post operatively and the patient is discharged after removal of stents and deemed to have a stable airway. Dissection will be carried out only to the level of the superior constrictor muscle and comprised of mucosua/submucosa
89368985|NCT03696836|Experimental|Trammpolin® meniscus prosthesis|The patients will be implanted with the Trammpolin® meniscus prosthesis
88841823|NCT04334018|Placebo Comparator|conventional CRT|
89368986|NCT02442544|Placebo Comparator|Placebo|maltodextrin 3.3 g orally/ day for 12 weeks
88841824|NCT04334018|Experimental|MPP CRT|
88841825|NCT05253001|Experimental|study group|use mobile chatbot approach to improve prenatal education
88841826|NCT05253001|Placebo Comparator|controp group|a traditional approach to prenatal education
88841827|NCT05441293||debridements group|During study peroid, the patient who received debridement surgery for pressure injury
88841828|NCT05441293||flap reconstructions group|During study peroid, the patient who received flap reconstruction surgery for pressure injury
88841829|NCT04759794|Experimental|Bile duct stenosis|This arm includes patients with bile duct stenosis. Endobiliary brushing cytology specimens will be obtained with endoscopic retrograde cholangiopancreatography (ERCP) of patients with bile duct stenosis. Cytology staining will be performed in the cytology specimens.
88841830|NCT04336423||Healthy smoker|Healthy smokers with smoking history at least 10 pack-years and normal spirometry value
88841831|NCT04336423||COPD patient|Patients with smoking history at least 10 pack-years and persistent airflow limitation that was not fully reversible (e.g. post-bronchodilator forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC) <0.7)
88841832|NCT05211505|Experimental|WO 2707|Formulation containing WO 2707 for intravaginal application
88841833|NCT00372151|Experimental|L-Theanine|
88841834|NCT00372151|Placebo Comparator|Placebo|
89368987|NCT02442544|Experimental|Prebiotic|1:1 oligofructose: inulin 8 g orally /day for 12 weeks
89368988|NCT03187522|Experimental|TREO Stent-Graft|Patients who receive a TREO Abdominal Stent-Graft System
88841835|NCT04336267|Experimental|Transcranial direct current stimulation (tDCS) group|7-day detoxification protocol + 5 consecutive days of anodal tDCS treatment over the primary motor cortex.
88841836|NCT04336267|Sham Comparator|Sham group|7-day detoxification protocol + 5 consecutive days of sham treatment over the primary motor cortex.
88841837|NCT00372476|Experimental|Imatinib + Vinorelbine|
88841838|NCT04334096|Experimental|QoL diagnosis and therapy|The first quality of life (QoL) measurement is conducted in the hospital after surgery via a digital questionnaire (EORTC QLQ-C30, QLQ-BR23) on a tablet computer. Further QoL measures are accomplished via paper-pencil in the practice of the patient's physician during aftercare (3, 6, 9, 12, 18, 24 months after surgery). Paper questionnaires are transferred by fax to a local server, automatically processed, digitized and stored in a database, and transferred back to the physician's practice (email or fax depending on preference) in form of a QoL profile. The immediate response enables patient and physician to discuss the QoL profile right away. Specific therapeutic options for the treatment of QoL have been defined: psychotherapy, social counseling, pain therapy, physiotherapy, nutrition counseling, fitness. To provide continuous medical education, quality circles for each therapeutic option have been founded. Physicians receive a list with addresses of all quality circle members.
88841839|NCT04737967|Experimental|Venlafaxine Treated Arm|
88841840|NCT04737967|Experimental|Memantine Treated Arm|
88841841|NCT05350111|Other|group supported through group education and telemedicine tools|the group of this pilot study will be compared to conventional obesity clinic
88841842|NCT03464630|Experimental|Mom & Baby Net|CBT skills based mobile intervention targeting maternal depression and sensitive responsive parenting practices for optimizing infant social-communication promotion and provision of community resources and referral
88841843|NCT03464630|Active Comparator|Depression & Developmental Awareness System|Supportive, person-centered mobile intervention targeting maternal awareness of maternal depression symptoms, infant developmental milestones, and provision of community resources and referral (active control condition)
88841844|NCT04766918|Experimental|High molecular weight hyaluronic acid|Ultrasound-guided hydrodissection with high molecular weight hyaluronic acid between carpal tunnel and median nerve (total 2 times with one-week interval)
88841845|NCT04766918|Active Comparator|Low molecular weight hyaluronic acid|Ultrasound-guided hydrodissection with low molecular weight hyaluronic acid between carpal tunnel and median nerve (total 2 times with one-week interval)
88841846|NCT04334564|Active Comparator|Test team|Patients were treated with ginkgo biloba capsule regularly. Take 2 capsules 3 times a day, orally
88841847|NCT04334564|Placebo Comparator|Control group|Patients were treated with placebo regularly.Take 2 capsules 3 times a day, orally
89368989|NCT03702140|Active Comparator|TPTD 6M|
89368990|NCT03702140|Active Comparator|TPTD 6-12M|
89368991|NCT03702140|Active Comparator|TPTD 12-24M|
89368992|NCT02433886|Experimental|Gamma Ventral Capsulotomy|
88841848|NCT04334551|Experimental|switch from etravirine to doravirine|switches to doravirine,
89002067|NCT06116448|No Intervention|control|The students in this group were the control group, and no intervention was made.
89368993|NCT03700814|Experimental|Antibiotics group|Patients in this group will receive single dose of intravenous co-amoxiclav (Dose: 25 mg/kg body weight) which will be injected 30 minutes prior to the incision during surgery.
89368994|NCT03700814|No Intervention|No antibiotics group|Patients belonging to this group will not receive any systemic antibiotic during intraoperative or post-operative period.
88841849|NCT04334785|Experimental|cryo-ablation group|In the first stage, for patients who meet the criteria, cryo-ablation will be conducted for the lump of invasive breast cancer, and traditional surgery will be conducted within 32days after cryo-surgery. In the second stage, for patients who meet the criteria, cryo-ablation will be conducted, and 5-year effectiveness and safety will be evaluated subsequently.
88841850|NCT03365414|Other|Phase I|Placebo ( Normal Saline 0.9% Infusion Solution Bag) or active comparator (Albumin (Human) 5%, USP)
88841851|NCT03365414|Other|Phase II|Placebo ( Normal Saline 0.9% Infusion Solution Bag) or active comparator (Albumin (Human) 5%, USP), whichever was not not administered in Phase I
89368995|NCT02433964|Experimental|LED group|Treated by a device LED - LED: power 60mW, 627nm wavelength ± 10nm and 1,3cm2 beam output. The energy density used was 10J / cm2 with time of 2 minutes and 47 seconds per flash of the beam, which is unique for each ten points in the lateral region of the ankle edema. The volunteers underwent previous cleaning application points with cotton soaked in 70% alcohol, positioned for high stretcher in the supine position and wearing goggles. The LED was applied in a timely manner, wherein the skin contact surfasse at an angle of 90 °, the ten points were irradiated in a 1cm2 area selected by a single investigator. One session was performed every 24 hours for six consecutive days. Ice applications were made associated with semi-rigid compression bandage, with the patient lying supine and the affected limb in elevation under a foam wedge in the same period.
89368996|NCT02433964|Placebo Comparator|Placebo group|Both volunteers LED group and the placebo group were treated with the same procedure, with the LED device in the placebo group remained off.
88841852|NCT05131399|Experimental|Self-comparison|"Patients will be fitted with 2 types of ankle foot orthoses, alternately, divided into 4 phases, in the following order:~Phase A1: Standard Plastic ankle foot orthosis Phase B1: carbon medical device ankle foot orthosis Phase A2: Standard Plastic ankle foot orthosis Phase B2: carbon medical device ankle foot orthosis Each patient is his own comparator. For all patients, the total duration of the study will be the same, and will correspond to 12 weeks."
88841853|NCT03305588|Experimental|130 Gy Radiation & Unframed Virtual Cone|130 Gy Virtual Cone Radiosurgery Unframed (Face Mask)
88841854|NCT03233594||Chiropractic Group|Participants receiving a chiropractic care technique Neuro Emotive Technique (NET) will complete initial pain evaluations and questionnaires for chronic pain symptoms. After approximately 8 weeks participants will receive follow evaluation for pain. Pre and Post PET-MRI scan will be conducted to evaluate changes.
88841855|NCT03233594||Healthy Control Group|Participants will receive initial evaluations and questionnaires followed by a PET-MRI scan.
88841856|NCT05107609|Experimental|Self-Compassion Intervention|Participants will be guided through an acute, 30-minute self-compassion intervention consisting of psychoeducation, guided loving-kindness meditation, compassionate imagery and a compassionate writing activity.
88841857|NCT05107609|No Intervention|Resting Control Intervention|Participants will be asked to sit quietly and independently for 30 minutes. They can read neutral magazines provided or their own reading/writing material, but will be asked not to use outside electronic devices or communicate with anyone external.
88841858|NCT04328558|Active Comparator|Group CPB = Clavipectoral fascia plane block group|In group CPB, CPB will be performed with patients in the supine position. The probe will be placed on the anterior border of the medial third of the clavicle. A 22-gauge block needle will be inserted in a caudal to cephalic direction, the periosteum of the clavicle and the surrounding fascia will be visualized, 20 ml of 0.25% bupivacaine will be injected between these two layers. The local anesthetic spread to medial and lateral third of the clavicle will be seen.
88841859|NCT04328558|No Intervention|Group C = Control group|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
88841860|NCT05350033|Experimental|Active-Active|Participants will receive active-tDCS stimulation (anode F4 / cathode F3) at 2 mA during 20 min in Phase 1 (5 sessions, intersession time-24h) and in Phase 2 (5 sessions, intersession time-24h).
88841861|NCT05350033|Experimental|Active-Sham|Participants will receive active-tDCS stimulation (anode F4 / cathode F3) at 2 mA during 20 min in Phase 1 (5 sessions, intersession time-24h), and sham-tDCS at 2 mA (active-stimulation lasting for 1 min) in Phase 2 (5 sessions, intersession time-24h).
89368997|NCT02433808|Experimental|Neostigmine Group|Neostigmine will be administered at the conclusion of the surgical procedure
89368998|NCT02433808|Placebo Comparator|No Neostigmine group|Saline will be administered at the conclusion of the surgical procedure
88841862|NCT05350033|Experimental|Sham-Active|Participants will receive sham-tDCS stimulation (anode F4 / cathode F3) at 2 mA (active-stimulation lasting for 1 min) in Phase 1 (5 sessions, intersession time-24h), and active-tDCS at 2 mA during 20 min in Phase 2 (5 sessions, intersession time-24h).
88841863|NCT05350033|Sham Comparator|Sham-Sham|Participants will receive sham-tDCS stimulation (anode F4 / cathode F3) at 2 mA (active-stimulation lasting for 1 min) in Phase 1 (5 sessions, intersession time-24h), and sham-tDCS at 2 mA (active-stimulation lasting for 1 min) in Phase 2 (5 sessions, intersession time-24h).
88841864|NCT05456971|Experimental|Art filler Volume|To confirm the capacity of the VOLUME filler to restore a midface volume 3 weeks after the first injection or after 6 weeks if a touch up was performed at 3 weeks.
88841865|NCT05456971|Experimental|Art Filler Lips|To confirm the capacity of the LIPS filler to restored volume of the treated lip 3 weeks after the first injection or at 6 weeks if a top up at 3 weeks is performed.
88841866|NCT04737590|Active Comparator|Bioactive glass|20 bone cysts (in 20 patients) are filled with bioactive glass
88841867|NCT04737590|Active Comparator|Allogenic bone|20 bone cysts (in 20 patients) are filled with allogenic bone
89368999|NCT02434042|Active Comparator|BB536|Bifidobacterium longum BB536 (9 log CFU/day) and dextrin
89369000|NCT02434042|Placebo Comparator|Placebo|100% dextrin
89534798|NCT03093753|Experimental|Test (study 5)|The test meals will comprise 160 mg oleuropein and 25 g sucrose dissolved in 200 ml water
89369001|NCT02439346|Experimental|BAY1143269 5 mg|Subjects received BAY1143269 5 milligram (mg) tablet orally, once daily (QD) from Day 1 to 21 in treatment cycle until evidence of tumor progression, unacceptable toxicity, consent withdrawal, or withdrawal from the study at the discretion of the investigator. A treatment cycle consisted of 21 days.
89369002|NCT02439346|Experimental|BAY1143269 10 mg|Subjects received BAY1143269 10 mg (2*5 mg) tablet orally, QD from Day 1 to 21 in treatment cycle until evidence of tumor progression, unacceptable toxicity, consent withdrawal, or withdrawal from the study at the discretion of the investigator. A treatment cycle consisted of 21 days.
89369003|NCT02439346|Experimental|BAY1143269 25 mg|Subjects received BAY1143269 25 mg tablet orally, QD from Day 1 to 21 in treatment cycle until evidence of tumor progression, unacceptable toxicity, consent withdrawal, or withdrawal from the study at the discretion of the investigator. A treatment cycle consisted of 21 days.
88841868|NCT04737434|Experimental|Extremely low frequency electromagnetic field device|with extremely low frequency electromagnetic wave
88841869|NCT04737434|Placebo Comparator|electromagnetic field with no wave|electromagnetic field with no wave
88841870|NCT05349877|Experimental|Expressive writing|Participants will be invited to join three writing activities, lasting 20 minutes daily in D1, D3, and D5 of the same week. For example, to write about a difficult or painful experience related discrimination and their feelings about it.
88841871|NCT05349877|Experimental|Self-affirmation|Aiming to build self-efficacy, participants will be invite to writing, during 20 minutes daily in D1, D3, and D5 of the same week, a letter to a sexual and gender minority peer suffering from stigma and discrimination.
89369004|NCT02439346|Experimental|BAY1143269 50 mg|Subjects received BAY1143269 50 mg (2*25 mg) tablet orally, QD from Day 1 to 21 in treatment cycle until evidence of tumor progression, unacceptable toxicity, consent withdrawal, or withdrawal from the study at the discretion of the investigator. A treatment cycle consisted of 21 days.
89369005|NCT03702062|Experimental|Observational Arm|Participants will be asked to measure self-assessed 6 minute walk test via the smart phone application twice a week for 2 months after discharge from a heart failure hospitalization, and weekly thereafter for 6 months.
89369006|NCT02439424|Experimental|Reactive ATP|"all enrolled subjects will have the Reactive ATP feature in their ICD turned on"
89369007|NCT03701984|Experimental|lidocaine infusion arm|The lidocaine group will be administered a 1,000 ml distention medium containing 5 ml lidocaine per 250 ml (DEBOCAINE (LIDOCAINE) 2% 1 VIAL 50 ML, Sigma-Tec pharmaceutical Industry. Co. Egypt) and oral placebo similar to tramadol(given 1 hour before the procedure).
89369008|NCT03701984|Active Comparator|tramadol arm|will be administered with an oral tramadol tablet (Tramal®, Memphis, Giza, Egypt) 1 h before the procedure and with a 1,000 ml distention medium containing 5 ml serum physiologic per 250 ml.
89369009|NCT03701984|Placebo Comparator|placebo group|will be administered with a 1,000 ml distention medium containing 5 ml serum physiologic per 250 ml and oral placebo(1 h before the procedure).
89369010|NCT02439190|Active Comparator|Treatment A: BMS-986120|BMS-986120 on specified days
89369011|NCT02439190|Active Comparator|Treatment B: Aspirin and Clopidogrel|Aspirin and Clopidogrel on specified days
89369012|NCT02442466|Experimental|Endothelin receptor B inhibitor BQ-788|Intra-lesion administration of an Endothelin Receptor B inhibitor (BQ-788)
89369013|NCT02442466|Experimental|PBS|Intra-lesion administration of vehicle
89369014|NCT02439034|Active Comparator|Arm A|Paracetamol
89369015|NCT02439034|Experimental|Arm B|Paracetamol + Ketoprofen
89369016|NCT03700580|Active Comparator|Hydrogel treatment|It refers to the standard treatment currently applied for foot ulcers at the Health Center where the study was conducted. The intervention was applied to the cohort, three times a week during 16 weeks or when the wound attained full epithelization. The wound bed was cleaned with physiological serum before application of Hydrogel.
89369017|NCT03700580|Experimental|P1G10 treatment|It refers to the experimental parallel intervention consisting of three weekly applications of 0.1% P1G10 dispersed in the hydrosoluble vehicle during a 16-week period, or until full epithelization of the wound. The wound bed was cleaned with physiological serum before application of the drug.
89369018|NCT02439112|Active Comparator|Exercise|Supervised exercise combined with home based exercise and physical activity
89369019|NCT02439112|No Intervention|Control|Usual care consisting of advice regarding exercise, physical activity, person lifting and moving.
89369020|NCT03696602||test with methacholine|
89369021|NCT03696602||test with exercise|
89179813|NCT02609087|Experimental|Propofol|adjust propofol (FRESOFOL MCT INJ 2% (vial), Fresinus Kabi Korea) concentration maintaining the 40 ~ 50 BIS (bispectral index) with 3 ng/ml of remifentanil using TCI (target controlled infusion) pump
89179814|NCT04812119||Patients with the CTNNB1 mutation|Patient with a diagnosed CTNNB1 mutation.
89179815|NCT00731133|Other|Disulfiram|Disulfiram at 250 mg daily
89179816|NCT00913757||Group 1|400 patients with primary HCC (Hepatocellular carcinoma)
89179817|NCT00913757||Group 2|800 patients with chronic liver disease (high risk non-cancer cases)
89179818|NCT00913757||Group 3|800 population-based controls, identified through a OMV database that will match cases by age, gender, race, and county of residency
89179819|NCT05756309|Experimental|Electrocardiogram measurements by holter device and patch-type electrocardiographic at the same time|The patient is measured electrocardiogram simultaneously through a holter device and patch-type electrocardiograph
89179820|NCT04031963||No treatment|Those with colon cancer and with adenomatous polyp and those without a previously mentioned condition.
89179821|NCT00730275|Experimental|Sitagliptin 50 mg|Participants were randomized to sitagliptin 50 mg
89179822|NCT00730275|Experimental|Sitagliptin 100 mg|Participants were randomized to sitagliptin 100 mg
89179823|NCT00730275|Experimental|Sitagliptin 200 mg|Participants were randomized to a single dose of sitagliptin 200 mg
89179824|NCT00730275|Placebo Comparator|Placebo to sitagliptin|Participants were randomized to matching placebo to sitagliptin 50 mg, 100 mg, or 200 mg
89179825|NCT04793711|Experimental|EpiCeram|Open-Label, 3 (three) times per day, topical, to hands and face, for 28 days.
89179826|NCT02609009|Experimental|Spinal Manipulation Therapy|Active chiropractic care for this RCT will consist of diversified technique prone, side posture and supine manipulations with soft-tissue therapy
89179827|NCT02609009|Other|Usual Medical Care|Control group patients will follow the usual medical visit scheduled according to their attending orthopaedists. Usual interventions generally consist in the administration of medications (NSAIDs or ibuprofen), physical therapy or exercises.
89179828|NCT00730041|Active Comparator|Palatal Implants|Pillar(R) Palatal Implants in combination with continuous positive airway pressure (CPAP) in subjects diagnosed with obstructive sleep apnea (OSA)
89179829|NCT00730041|Sham Comparator|Sham procedure|Sham (procedure but no implants inserted) in combination with continuous positive airway pressure (CPAP) in subjects diagnosed with obstructive sleep apnea (OSA)
89179830|NCT05756231|Experimental|Turkish Adaptation Study of Free and Cued Selective Reminding Test (SIHT-16)|Outcomes of Turkish adaptation of Free and cued selective reminding test (SIHT-16) is compared with memory and non-memory test in three alternative lists: a,b, and c parallel lists. The participants are assessed in neurological diagnosis routine.
89179831|NCT04790825|Experimental|Intensive periodontal treatment|Adjunctive full-mouth intensive removal of subgingival dental plaque biofilms with the use of scaling and root planing after the administration of local anesthesia.
89179832|NCT04790825|Active Comparator|Community-based periodontal care|Standard cycle of supragingival mechanical scaling and polishing.
89179833|NCT02610257|Active Comparator|Vibration Relevant|Vibration applied on the muscle belly after 'motor block' onset
89179834|NCT02610257|Active Comparator|Neutral Vibration Relevant|Vibration applied on a bony mark after 'motor block' onset
89179835|NCT02610257|Active Comparator|Neutral Vibration Non-Relevant|Vibration applied on a bony mark before 'motor block' onset
89179836|NCT02610257|Active Comparator|Vibration Non-Relevant|Vibration applied on the muscle belly after 'motor block' onset
89179837|NCT02610257|No Intervention|No Vibration|
89179838|NCT00729651|Experimental|1|Alendronate sodium/Cholecalciferol
89179839|NCT00729651|Active Comparator|2|Alendronate sodium
89534799|NCT03093753|Placebo Comparator|Control (study 6)|Normal diet 3 days prior to study visit with 109 g bread with 200 ml water on study visit
89179840|NCT00729183|Experimental|Odanacatib 50 mg|Participants receive 50 mg odanacatib and open-label 5600 IU vitamin D3 tablets once weekly for 24 months. Participants also receive 500 mg of open-label daily calcium supplement as needed to ensure a total daily calcium intake of 1200 mg.
89179841|NCT00729183|Placebo Comparator|Placebo|Participants receive matching placebo to odanacatib and open-label 5600 IU vitamin D3 once weekly for 24 months. Participants also receive 500 mg of open-label daily calcium supplement as needed to ensure a total daily calcium intake of 1200 mg.
89179842|NCT00811733|Experimental|Ofatumumab|Ofatumumab is a fully human antibody, targeting a unique epitope on the CD20 molecule expressed on human B cells.
89179843|NCT00728949|Active Comparator|IMC-A12 (cixutumumab) + antiestrogen therapy|Participants will receive intravenous IMC-A12 10 mg/kg over 1 hour every 2 weeks, as well as the same dose and schedule of the last antiestrogen therapy to which their disease became refractory.
89179844|NCT00728949|Experimental|IMC-A12 (cixutumumab)|Participants will receive only IMC-A12 (10 mg/kg over 1 hour every 2 weeks).
89179845|NCT00918177|Experimental|Early patients|
89179846|NCT00918177|Experimental|Moderate Patients|
89179847|NCT00728481|Active Comparator|Esomeprazole|Proton pump inhibitor; Nexium 40mg capsule taken twice daily by mouth for 6 weeks for subjects with positive 24 hour pH study (GERD)
89179848|NCT00728481|Active Comparator|Budesonide|Corticosteroid therapy; oral viscous Pulmicort Respules 1 gram taken by mouth orally twice daily (mixed with 1 gram packet of Sucralose [Splenda-registered trademark]) for 6 weeks in subjects with negative 24 hour pH studies (without GERD)
89179849|NCT00811655|Experimental|Pre-Operative SRS|SRS pre-operatively with the planned target volume defined as the tumor plus a 3-mm margin.
89179850|NCT02592993|Experimental|PicoWay treatment to all subjects|Subjects in this study will receive up to six (6) treatments in 3-8 weeks interval, with the PicoWay device-fractional handpiece 532nm and/or 1064nm according to the study protocol. Subjects will be followed by phone 7 days post first treatment by study staff, and will return for two follow-up (FU) visits at the clinic at: 6 weeks and 12 weeks following the last treatment.
89179851|NCT04087941|Placebo Comparator|Placebo|
89179852|NCT04087941|Experimental|VM-202|
89179853|NCT02593227|Experimental|Low dose FRα vaccine|FRα peptide vaccine with GM-CSF adjuvant - single ID administration - monthly vaccinations repeated 6 times followed by boosters every 6 months until recurrence
89369022|NCT03701906|Active Comparator|Lactobacillus PS11603 & Bifidobacterium PS10402|A mixture of 1*10E9 colony forming unit (CFU) of Lactobacillus PS11603 and 1*10E8 CFU of Bifidobacterium PS10402 in 1 vial will be dissolved and enterally administered daily until discharge from the Neonatal Unit or until the 36th post-gestational week of age.
89369023|NCT03701906|Active Comparator|Placebo|1 vial of Placebo will be dissolved and enterally administered daily until discharge from the Neonatal Unit or until the 36th post-gestational week of age.
89369024|NCT02438956|Placebo Comparator|Crystalline Cellulose|looks like and is given in the same way as the experimental treatment but contains no active ingredient
89369025|NCT02438956|Experimental|Glutathione supplement|500 mg/day Setria glutathione supplement
89369026|NCT02438800|No Intervention|Standard Counseling|Women in this arm will receive standard contraceptive counseling routinely provided during prenatal care. All participants will receive information regarding access to free LARC methods in the postpartum period.
89369027|NCT02438800|Experimental|Video Counseling|Women in this arm will receive LARC First video-based contraceptive counseling in addition to standard contraceptive counseling routinely provided during prenatal care. All participants will receive information regarding access to free LARC methods in the postpartum period.
89369028|NCT03692858|Active Comparator|Group A|
89369029|NCT03692858|Active Comparator|Group B|
89369030|NCT02442232||Normotensive|
88841872|NCT05349877|Placebo Comparator|Placebo|Participants will be instruct to write about their daily routine, during 20 minutes daily in D1, D3, and D5 of the same week.
88841873|NCT02590640|Active Comparator|Inhibitory insular rTMS|Inhibitory (1 Hz) repetitive transcranial magnetic stimulation will be applied to the insula in smokers.
88841874|NCT02590640|Sham Comparator|Sham insular rTMS|Sham repetitive transcranial magnetic stimulation will be applied to the insula in smokers.
88841875|NCT04233476|Experimental|99mTc-3PRGD2|Volunteers were injected intravenously and then scanned by SPECT/CT. Drugs use generic name：Technetium [99mTc] Hydrazinonicotinamide PEGylated Bicyclic RGD Peptide Injection dosage form:Injection dosage:0.3mCi/kg frequency:single dose
88841876|NCT00371995|Experimental|1|"Liposomal amphotericin B administered intravenously as single dose on day 1, Dosage: 5 mg/kg.~Miltefosine administered orally (50 mg capsules) for 14 days (on days 2-15)"
88841877|NCT05456737||Unilateral Group|"Participants with a diagnosis of unilateral clubfoot treated with the Ponseti method were evaluated once with the following evaluation methods:~Anthropometric measurements FPI-6 Fizyosoft Balance System Functional Activity and Skills Form. OxAFQ-C and OxAFQ-P Kiddy-Kid-Kiddo KINDL"
88841878|NCT05456737||Bilateral Group|"Participants with a diagnosis of bilateral clubfoot treated with the Ponseti method were evaluated once with the following evaluation methods:~Anthropometric measurements FPI-6 Fizyosoft Balance System Functional Activity and Skills Form. OxAFQ-C and OxAFQ-P Kiddy-Kid-Kiddo KINDL"
88841879|NCT05456737||Healty Group (Control)|"Healthy participants with normal development were evaluated once with the following evaluation methods:~Anthropometric measurements FPI-6 Fizyosoft Balance System Functional Activity and Skills Form. OxAFQ-C and OxAFQ-P Kiddy-Kid-Kiddo KINDL"
88841880|NCT04333940|Experimental|1. 3D CBCT GROUP|Preoperative 3-dimensional CBCT will be taken.
89369031|NCT02442232||Hypertensive taking ACEi|
89369032|NCT02442232||Hypertensive not taking ACEi|
89369033|NCT03692780|Experimental|Careseng 1370|
88841881|NCT04333940|Active Comparator|2D PR GROUP|Preoperative 2-dimensional periapical radiographs will be taken using paralleling technique with customized Jig
88841882|NCT04335877|Experimental|Private sector component + modified BCC|Private sector component + modified BCC + current standard of care
88841883|NCT04335877|No Intervention|Control|Current standard of care + standard BCC
89369034|NCT03692780|Placebo Comparator|Matched Placebo|
88841884|NCT04137133|Experimental|collection of expectoration, stools and blood|
88841885|NCT04647110||Swedish Anaplastic lymphoma kinase (ALK) positive Non-small cell lung cancer (NSCLC) patients|
89179854|NCT02593227|Experimental|High dose FRα vaccine|FRα peptide vaccine with GM-CSF adjuvant - triple ID administration - monthly vaccinations repeated 6 times followed by boosters every 6 months until recurrence
89369035|NCT04483492||1|newborns under 32 weeks with respiratory support if they are decided to start caffeine treatment
89369036|NCT02442154|Experimental|Early tracheostomy|To do an early tracheostomy within 24hours of admission of the severely head injured patients
89369037|NCT02442154|No Intervention|standard of care|To use the standard of care of mulago hospital for the management of the severely head injured patients
89369038|NCT04483336|Experimental|Virtual reality Distraction.|Subjects watched a video cartoon using virtual reality goggles as a distraction technique during the administration of local anesthesia.
89369039|NCT04483336|Active Comparator|TV screen Distraction|Subjects watched a video cartoon on a regular TV screen as a distraction technique during the administration of local anesthesia.
89369040|NCT02438878|Experimental|Baby Behavior|"The intervention is comprised of 2 components: HCP and medical staff training and participant education. The trainings will be video-based and aim to build providers' knowledge and skills to support parents' recognition and understanding of common healthy infant behaviors that may be misinterpreted by parents. The intervention does not include any specific recommendations for infant feeding, nor does it include any information related to the assessment, diagnosis or treatment for any medical condition.~After completion of the intervention trainings, health care providers and medical staff will be asked to use what they learned with the mothers of infants in their care. Short handouts for mothers will be provided as tools to reinforce the verbal education. All educational materials will be focused only on supporting parents' abilities to recognize and understand common, healthy infant behaviors."
89369041|NCT02438878|No Intervention|Control|The control arm will continue with standard well-baby visit practices during the intervention period and will be offered the option to complete the Baby Behavior online trainings for continuing education credits.
89369042|NCT03186976|Experimental|Aggressive Risk Factor Control|Multifaceted risk factor management relating to BP, exercise, sleep apnea, alcohol intake and diabetes management
89369043|NCT03186976|Active Comparator|Standard of Care|All patients in the control arm will receive therapies for AF as per the existing guidelines. BP, cholesterol, diabetic management will be administered as per the available guidelines.
89369044|NCT02442388|Experimental|Hand file|Instrumentation technique
89369045|NCT02442388|Experimental|ProTaper file|Instrumentation technique
89369046|NCT02442388|Experimental|Wave-One file|Instrumentation technique
89369047|NCT03186742|Experimental|Group A|The patients who had Eplerenone 50mg tab once a day added to their standard hypertensive treatment.
89369048|NCT03186742|No Intervention|Group B|The patients who did not receive an additional drug to their standard hypertensive treatment.
89369049|NCT02441920||Patients with rheumatoid arthritis|The inception cohort of 400 patients will be followed up for 20 years following recruitment.
89369050|NCT03186664|Experimental|A: Sativex+Lokomat Training|Patients Sativex responders will perform a neurorobotic-assisted gait training (RAGT, each session will last at least 45', 3 times per week, for a total amount of 20 treatment's sessions).
89179855|NCT02593227|Experimental|Low dose FRα vaccine + cyclophosphamide|Cyclophosphamide 300 mg/sqm as a 1 hour IV infusion 3 days prior to first vaccination. Followed by FRα peptide vaccine with GM-CSF adjuvant - ID administration - monthly vaccinations repeated 6 times followed by boosters every 6 months until recurrence
89369051|NCT03186664|Active Comparator|B: other antispastic+Lokomat Training|Patients treated with others antispastic drugs will perform a neurorobotic-assisted gait training (RAGT, each session will last at least 45', 3 times per week, for a total amount of 20 treatment's sessions).
89369052|NCT03189784|Experimental|mobilization group|this group will receive mobilization with movement techniques.
89369053|NCT03189784|No Intervention|Control group|The control group will receive no intervention
89369054|NCT02441842|Active Comparator|Group A : Atenolol|oral atenolol (50mg)
89369055|NCT02441842|Placebo Comparator|Group C: Placebo|glucose tablet (10mg)
89369056|NCT02441842|Active Comparator|Group L: Lisinopril|oral lisinopril (5mg)
89369057|NCT02438644||Study Population|Patients who are prescribed vismodegib in Argentina, according to standard of care and in line with the current SPC and local labeling, are eligible for observation. Dosing and treatment duration of vismodegib are at the discretion of the physician in accordance with local clinical practice and local labeling. Only patients with laBCC or mBCC will be considered in the effectiveness analysis.
89369058|NCT02438566|Active Comparator|Oral Tranexamic Acid (OTA)|Subjects will be randomized 1:1 to receive either IVTA or OTA with corresponding placebos. OTA will be given as 1950 mg 1-2 hours prior to OR and 1950 mg 2 hours after surgical close, before discharge from PACU.
89534800|NCT03093753|Experimental|Test (study 6)|High carbohydrate diet 3 days prior to study visit with 109 g bread with 200 ml water on study visit
89534801|NCT03093753|Placebo Comparator|Control (study 7)|Normal diet 3 days prior to study visit with 109 g bread with 200 ml water on study visit
89534802|NCT03093753|Experimental|Test (study 7)|High fat diet 3 days prior to study visit with 109 g bread with 200 ml water on study visit
88818364|NCT01277354|Active Comparator|Cognitive Processing Therapy|Participants are seen weekly for six weeks for therapy. At visits 2, 4, and 6 they also complete ratings.
88818365|NCT01277354|Placebo Comparator|Waitlist|Participants come in at the end of weeks 2, 4, and 6 to complete ratings but do not receive therapy.
88818366|NCT01280552|Experimental|ICT-107|Autologous dendritic cells pulsed with immunogenic peptides from tumor antigens
88818367|NCT01280552|Placebo Comparator|Control|Autologous dendritic cells that have not been pulsed with antigens
88818368|NCT02257541|Experimental|BGJ398 With Imatinib Mesylate|BGJ398 With Imatinib Mesylate In the phase Ib portion of the study, patients will receive imatinib at 400 mg once daily and BGJ398 at the standard 3+3 escalation doses for 21 days on, 7 days off (treatment schedule A).Using treatment schedule A, if dose level 1 to -2 is identified as the MTD and concern exists regarding therapeutic activity of BGJ398 at this dose level, expansions with higher dose levels (1 to 3) may be considered at the MSKCC PI's discretion, with modification of the treatment schedule. In this setting BGJ398 will be administered daily for one week followed by 3 weeks off and imatinib will be taken daily throughout the 4 week cycle period (treatment schedule B). In the phase II portion of the study, patients will receive imatinib at 400 mg once daily (standard of care first line imatinib dose) and BGJ398 at the RP2D and treatment schedule identified in the phase Ib portion of the study. One cycle is 28 days.
88818369|NCT01385696|Experimental|group A|Genuair first, HandiHaler second
88818370|NCT01385696|Experimental|group B|HandiHaler first, Genuair second
88818371|NCT01817855|Experimental|1|"Groups 1-4 multiple ascending doses of AZD7624 Healthy subjects will participate in groups 1-3. In each group 6 subjects will receive AZD7624 and 2 will receive matching placebo.~COPD patients will participate in group 4. In this group, 8 patients will receive AZD7624 and 2 patients will receive matching placebo."
88818372|NCT01817855|Placebo Comparator|2|"Groups 1-4 multiple ascending doses of placebo Healthy subjects will participate in groups 1-3. In each group 6 subjects will receive AZD7624 and 2 will receive matching placebo.~COPD patients will participate in group 4. In this group, 8 patients will receive AZD7624 and 2 will receive matching placebo."
88818373|NCT00368121|Experimental|Cetuximab + Dexamethasone|
88819246|NCT05451459|Experimental|Intervention Group|Participants in the intervention group will be offered four one-day group workshops (2-3 hours each) covering topics of 1) Sensory Integration, 2) Communication, 3) Physical activity, and 4) Sports. The workshops will be offered online via Zoom and will be video recorded. The intervention group will also receive information (activity booklets via the Fit Families App) and physical education (physical activity)-related equipment, which will be mailed to them. At the end of the workshop parents will be instructed to practice the skills they learned with their child for the next 3 weeks (for at least 3 hrs per week).
89369059|NCT02438566|Active Comparator|Intravenous Tranexamic Acid (IVTA)|Subjects will be randomized 1:1 to receive either IVTA or OTA with corresponding placebos. IVTA will be given as 1 g intravenously at time of first incision (THA or bTKA without tourniquet) or just before 1st tourniquet application (bTKA), and then again, 1 g after final surgery closure.
89369060|NCT02433652|Experimental|Trivalent dengue vaccine admixture + rDEN2Δ30-7169|Participants will receive the trivalent dengue vaccine admixture at Day 0 and the rDEN2Δ30-7169 vaccine at Day 180.
89369061|NCT02433652|Experimental|Placebo + rDEN2Δ30-7169|Participants will receive a placebo vaccine at Day 0 and the rDEN2Δ30-7169 vaccine at Day 180.
89369062|NCT03186586|Experimental|Ulipristal acetate 5mg/day/five days|Women with abnormal bleeding during use of Mirena will allocate to UPA or placebo Ulipristal acetate at 5mg/day/five days Ulipristal 5mg daily for 5 days at the bleeding episode
89369063|NCT03186586|Placebo Comparator|Placebo 1 pill/day/five days|Women with abnormal bleeding during use of Mirena will allocate to UPA or placebo Placebo at 1pill/day/five days Placebo one pill a day for 5 days at the bleeding episode
89369064|NCT02441608|Experimental|Experimental group|This study is designed as a single group assignment, because the 4 dressings (3 placebos and 1 containing the product) will be applied in all volunteers. This means that the region in which the tested product will be applied will be compared with the other placebo regions in the same volunteer.
89369065|NCT02433574|Experimental|Neoadjuvant stereotactic body radiation|Single arm study. Four cohorts of 5 patients will undergo neo-adjuvant SBRT for lung cancer. Eligible patients will have operable, borderline resectable lung cancer , they will be treated with SBRT, prior to undergoing surgical resection.
89369066|NCT02438176|Experimental|single puncture group|single trans-septal puncture
89369067|NCT02438176|Active Comparator|conventional group|conventional bilateral groin puncture
89369068|NCT02438332||NATRELLE® INSPIRA® TruForm® 1 (Smooth)|Subjects receiving primary breast augmentation with smooth NATRELLE® INSPIRA® TruForm® 1 breast implants
89369069|NCT02438332||NATRELLE® INSPIRA® TruForm® 1 (Textured)|Subjects receiving primary breast augmentation with textured NATRELLE® INSPIRA® TruForm® 1 breast implants
89369070|NCT02438332||NATRELLE® INSPIRA® TruForm® 2 (Smooth)|Subjects receiving primary breast augmentation with smooth NATRELLE® INSPIRA® TruForm® 2 breast implants
89369071|NCT02438332||NATRELLE® INSPIRA® TruForm® 2 (Textured)|Subjects receiving primary breast augmentation with textured NATRELLE® INSPIRA® TruForm® 2 breast implants
89369072|NCT02441764||Halaven|Participants who are prescribed with Halaven per approved prescribing information of Halaven.
89369073|NCT02433418|Active Comparator|Tubal flushing with Urografin®|Women will have HSG using water soluble media
89369074|NCT02433418|No Intervention|Control group|Women will not receive any intervention
89369075|NCT04484038|Other|IMRT, any mode|"External radiation therapy with 6-18 MV photons on the 62.5 Gy prostate bed in 25 2.5 Gy fractions (EQD2 71 Gy).~Serving per fraction: 2.5 Gy Total fractions: 25 No. fractions / week: 5 Total treatment time: 5 weeks Total nominal dose: 62.5 Gy EQD3 (TRT): 68.75 Gy EQD1.5 (CaP): 71.43 Gy EQD2 (CaP): 68.75 Gy EQD10 (TRA): 65.10 Gy"
89369076|NCT02433730|Active Comparator|placebo|intramuscular injection
89369077|NCT02433730|Active Comparator|testosterone|intramuscular injection
89369078|NCT02438254||FH+|Young adults with at least one parent with an alcohol or other drug use disorder history.
89369079|NCT02438254||FH-|Young adults with no histories of alcohol or other drug use disorders in any parents or grandparents.
89369080|NCT02438098|Other|Rivaroxaban arm|Pharmacokinetics / Pharmacodynamics
89369081|NCT02433262|Placebo Comparator|WHO (World Health Organisation)|"Participants will undergo oral glucose tolerance test involving drinking of 75g glucose and blood taking for fasting and 2 hours post glucose intake. Diagnosis of GDM will be made based on these criteria:~Fasting glucose >6 2 hour glucose >7.7"
89369082|NCT02433262|Active Comparator|IADPSG|Participants will undergo oral glucose tolerance test involving drinking of 75g glucose and blood taking for fasting and 2 hours post glucose intake. Diagnosis of GDM will be made based on these criteria: (International Association of Diabetes & Pregnancy Study Group) Fasting glucose >5 2 hour glucose >8.4
89369083|NCT02441530|Experimental|vitamin D|667 unit of vitamin D once a day ,two days before the expected date of menstruation and continued through the first three days of bleeding.
89369084|NCT02441530|Experimental|vitamin E|200 unit of vitamin E once a day ,two days before the expected date of menstruation and continued through the first three days of bleeding.
89369085|NCT02441530|Experimental|ibuprofen|400 mg ibuprofen twice a day, two days before the expected date of menstruation and continued through the first three days of bleeding.
88841886|NCT05455957|Experimental|Neuromuscular Training|The neuromuscular exercise training group includes single-leg stance, single leg hop and strength exercise.Each training session took approximately 60 minutes and 3 times a week for 4 weeks.The neuromuscular group included supervised, strength, balance and hop stabilization exercises on the different surfaces that focus on the restoring of static and dynamic balance. Both groups completed strength exercises in the same way. Strength exercises include ;4-way ankle theraband exercises,foot intrinsic strengthening (toe curl, doming),heel raises exercise,squat, lunge activities.Balance exercises include single-leg stance single leg hop and unticipated hop to stabilization activities.
89179856|NCT02593227|Experimental|High dose FRα vaccine + cyclophosphamide|Cyclophosphamide 300 mg/sqm as a 1 hour IV infusion 3 days prior to first vaccination. Followed by FRα peptide vaccine with GM-CSF adjuvant - ID administration - monthly vaccinations repeated 6 times followed by boosters every 6 months until recurrence
89369086|NCT02433184|Experimental|Etanercept|Treatment Arm 1 will receive etanercept and methotrexate combination therapy administered for a total duration of 48 weeks.
89369087|NCT02433184|Active Comparator|Methotrexate-treat to target|Treatment Arm 2 will receive initial methotrexate monotherapy with adoption of a treat to target protocol (standard care involving monthly DAS28-ESR assessment with escalation to combination sDMARD therapy if not achieving LDA at, or after, 8 weeks) and step-up to etanercept and methotrexate at 24 weeks if failing to achieve clinical remission
89369088|NCT02433106|Experimental|Intervention|GAA 15 Specific neuromuscular exercise training
89369089|NCT02433106|Active Comparator|Control|Control Usual training
89369090|NCT02438020|Experimental|Metformin|500 mg metformin oral intake before main meal
89369091|NCT02438020|Placebo Comparator|Placebo|Placebo tablet before main meal.
89179857|NCT04030481||Group A: Sevoflurane, sufentanil and rocuronium|sevoflurane (1-3%)and sufentanil (0.5-2 mcg/kg/h) and rocuronium (0.3～0.6mg/kg/h) used intraoperatively as required
89179858|NCT04030481||Group B: Propofol, sufentanil and rocuronium|propofol (4-12 mg/kg/h) and sufentanil (0.5-2 mcg/kg/h/) and rocuronium (0.3～0.6mg/kg/h) used intraoperatively as required
89179859|NCT04087863||Atopic Dermatitis|
89179860|NCT02592915|Experimental|Test Group|Patients randomized in the Test Group will receive the clonidine hydrochloride
89179861|NCT02592915|Placebo Comparator|Control Group|Patients randomized in the Control Group will receive the Placebo
89179862|NCT00727311||PegIntron + Rebetol|Participants with chronic hepatitis C, who are either treatment-naïve or previously relapsed after receiving interferon monotherapy
89179863|NCT04087551|Experimental|Developing the list of items for BRFES|Two groups of six community-dwelling older adults will participate in a focus group session. Each focus group session will begin with a trained facilitator using a session guide welcoming the participants and introducing the participants in the group. The session will adopt a nominal group method which includes silent generation of ideas, sharing of an idea in a 'round robin' fashion, group discussion to clarify ideas and then completing the session with anonymous voting to include items into a list of items to be included in the Balance Recovery Falls-Efficacy Scale (BRFES).
89179864|NCT02592759|Experimental|Smart Glove Group|The subjects will be treated with conventional occupational therapy for 30 minutes and smart glove treatment for 30 minutes. 5 treatments per week will be conducted a total of 2 weeks.
89179865|NCT02592759|No Intervention|Homework group|The subjects will be treated with conventional occupational therapy for 30 minutes and upper extremity rehabilitation homework which means the self training at bedside, for 30 minutes. 5 treatments per week will be conducted a total of 2 weeks.
89179866|NCT02592837|Experimental|Flex 19G EBUS-TBNA|Mediastinal and hilar lymph node sampling using the flexible 19G EBUS-TBNA needle
89179867|NCT02592837|Active Comparator|EBUS-TBNA|Mediastinal and hilar lymph node sampling using a standard 21G EBUS-TBNA needle
89179868|NCT00726999|Active Comparator|1|Gabapentin
89179869|NCT00726999|Placebo Comparator|2|Placebo Comparator -- pill matched in appearance to gabapentin
89179870|NCT00585351|Experimental|I|Advanced Notification + Ranitidine
89179871|NCT00585351|Active Comparator|II|Advanced Notification + Placebo
89179872|NCT00585351|Active Comparator|III|No advanced notification + Ranitidine
89179873|NCT00585351|Placebo Comparator|IV|No advanced notification + Placebo
89179874|NCT02592603|Active Comparator|Endocuff-assisted Colonoscopy|Endocuff-assisted Colonoscopy with the ARC Endocuff-vision® attached at the distal tip of the scope.
89179875|NCT02592603|No Intervention|Standard Colonoscopy|Standard Colonoscopy without any additional device
89179876|NCT02592681|Experimental|verum acupuncture|Participants will receive real needle insertion. The needles will be left in the acupoint for 20 min, with a manual rotation at a ten-min interval. Primary acupoints used in the verum acupuncture group will be: LR3 (Taichong), LI4 (Hegu), SP6 (Sanyinjiao), GB20 (Fengchi). Extra acupoints will be selected based on TCM pattern are GB41 (Zulinqi), SP10 (Xuehai), KI3 (Taixi), or LR2 (Xingjian).
89179877|NCT02592681|Active Comparator|acupressure|Acupressure will be applied on all the corresponding acupoints described in the acupuncture group. Duration of each session will be 15 min.
89179878|NCT02592681|Sham Comparator|control acupuncture|The number, duration, and frequency of the sessions will be the same as for the verum acupuncture group. The points chosen will be: LR7 (Xiguan), GB35 (Yangjiao), LI12 (Zhouliao), M-BW-1 (Dingchuan).
89179879|NCT05757479|Experimental|Steroid-eluting stent implant|Subjects randomized to the experimental group will receive steroid-eluting stent implantation in the affected sinus and saline rinses.
89179880|NCT05757479|Active Comparator|Nasal steroid spray|Subjects randomized to the comparator group will receive nasal steroid spray and saline rinses.
89179881|NCT00726609||Posaconazole (assigned by physician in normal practice)|"Treatment of invasive fungal infection.~Prophylaxis of invasive fungal infection."
89179882|NCT00726453|Experimental|Resolute Zotarolimus-Eluting Coronary Stent|Implantation of a Resolute Zotarolimus-Eluting Coronary Stent
89179883|NCT00726063|Experimental|Nanotite implant|Nanotite dental implant
89179884|NCT00726063|Active Comparator|Osseotite implant|Osseotite dental implant
89179885|NCT03961035||25% cycle ratio|Patients group treated with CPCTSI at a 25% cycle ratio
89179886|NCT03961035||31.3% cycle ratio|Patients group treated with CPCTSI at a 31.3% cycle ratio
89179887|NCT04019457|Experimental|Dietary fiber 1|Participants receive cereal flakes 1 to include it in their normal diet.
89179888|NCT04019457|Experimental|Dietary fiber 2|Participants receive cereal flakes 2 to include it in their normal diet.
89179889|NCT00808028|Experimental|1|dose level 1 rLP2086 vaccine
89179890|NCT00808028|Experimental|2|dose level 2 rLP2086 vaccine
89179891|NCT00808028|Experimental|3|dose level 3 rLP2086 vaccine
89179892|NCT00808028|Placebo Comparator|4|normal saline (placebo)
89369092|NCT02437942|Experimental|Biomechanics led physical therapy rehabilitation|Physical therapy exercise rehabilitation
89369093|NCT02441452|Active Comparator|Early rehabilitation|one day before surgery, patients and their families were instructed by physiotherapists than explained the importance to perform physical exercises and breath exercises in postoperative. At the postoperative recovery room, after extubation and fully awake, patients started physiotherapy exercises, as physical exercises of moving up upper and lower extremities accompanied by deep breathing exercises. After than, the patients standed up beside the bed and if there was no complications, patients performed ambulation.
89369094|NCT02441452|No Intervention|Conventional care|Usual care routine postoperative.
89369095|NCT02441140|Experimental|Culdocentesis|"Patients with known or highly likely ovarian cancer (i.e. highly elevated CA-125, ascites, pelvic mass) scheduled for cytoreductive surgery will be identified during preoperative consultation and offered participation in the study.~During Surgery:~Blood Collection~Vaginal Swab~Chromopertubation~Culdocentesis~Tissue Collection"
89369096|NCT02437786|Experimental|GRAZAX|GRAZAX
89369097|NCT02437552|Placebo Comparator|Control group: routine physiotherapy|Are patients who carry out the routine already established the Unit, consisting of the first post surgery, the patient lying down doing the breathing exercises, active exercises ends and active-assisted upper (UL) and lower limbs (LL),
89369098|NCT02437552|Active Comparator|Intervention group: ergometer cycle exercise|Are the patients who will carry out the exercises routine over the cycle ergometer twice daily from 3 PO for 5 minutes with its progressiveness at discharge for ward for 10 minutes
89369099|NCT02441296|Experimental|Formula with lactose|Carbohydrate-free formula with added lactose
89369100|NCT02441296|Experimental|Formula with maltodextrins|Carbohydrate-free formula with added maltodextrins
89369101|NCT02441296|No Intervention|Breastfeeding|Breastfed reference group
89369102|NCT03189628|Experimental|stromal vascular fraction|Transplantation of resuspended SVF
89369103|NCT03189628|Placebo Comparator|saline|1 ml saline without cells will be used as placebo.
89369104|NCT03186820|Experimental|SWAN sequence|Susceptibility Weighted Imaging as 3D SWAN sequence
89369105|NCT02441374|Experimental|Forced Use Therapy|Constriction (through the tubular mesh) of non paretic upper limb for a period of 12 and 24 hours, 5 days per week for 4 weeks.
89369106|NCT02441374|Active Comparator|Classical Kinesiotherapy|Rehabilitation of classical kinesiotherapy,at least 2 times a week for 4 weeks.
89369107|NCT03186274|No Intervention|Control Group|Those in the control group (CG) will write a pre and post-study reflection essay discussing their experiences with end of life discussions.
89369108|NCT03186274|Experimental|Facilitated Group Session|Participants in Facilitated Group Session (previously called Intervention Group 1) will watch a pre-recorded video describing the SPIKES model and then take part of a facilitated guided group session reviewing the model and group interview of standardized/simulated patient encounter.
88841887|NCT05455957|Experimental|Vestibulo-Ocular Reflex Training|The vestibulo ocular reflex training group includes head and gaze stability exercises in addition to single le stance,single leg hop and strength exercise.Each training session took approximately 60 minutes and 3 times a week for 4 weeks.In the vestibulo- ocular exercise program, individuals tried to maintain their balance with head and eye movements in addition to balance and hop stabilization activities. Both groups completed strength exercises in the same way. Strength exercises include ;4-way ankle theraband exercises,foot intrinsic strengthening (toe curl, doming),heel raises exercise,squat, lunge activities.Balance exercises include single-leg stance single leg hop and unticipated hop to stabilization activities.
88841888|NCT04061785|Active Comparator|Participants in 12 week Judo Inspired Exercise program|"The subjects will participate in a 12 week judo inspired training program (45 minute sessions once a week) with the specific aim to increase physical qualities related to falls and injuries during falls.~The subjects will be tested before and after the 12 week period"
89369109|NCT03186274|Experimental|CELA Session|Participants in the CELA Session (previously called Intervention Group 2) will watch a pre-recorded video describing the SPIKES model and then participate in an individualized standardized/simulated patient scenario that will be filmed at the Center for Experiential Learning and Assessment (CELA).
89369110|NCT02437474||Omnivorous diet|Participants are consuming meat, fish, milk/milk products, eggs, plant products.
89369111|NCT02437474||Lacto-ovo-vegetarian diet|Participants are consuming milk/milk products, eggs, plant products but no meat, fish or by-products.
89369112|NCT02437474||Vegan diet|Participants are consuming plant products but no meat, fish, milk/milk products, eggs or by-products as well as honey.
88841889|NCT04061785|No Intervention|Control Group|The subjects will go about their normal life for 12 weeks without any intervention. The persons will be tested before and after the 12 week period.
88841890|NCT05455801|Experimental|negative wound therapy group|those who receive negative pressure therapy
89369113|NCT02437708|Experimental|REP with L-PRF|The first REP session will be performed as described by Diogenes et al. (2013). For the second REP-session a venipunction will be performed before the endodontic treatment. 2 to 4 tubes of blood will be collected per tooth. These blood samples will be put into a centrifuge for 12 minutes at 2700 rpm. Fibrin clots will be collected after centrifugation and inserted in the root canal with endodontic pluggers. Medcem Portlandcement (GmbH, Swiss) will be used instead of mineral trioxide aggregate in the second session, to prevent tooth discoloration.
89369114|NCT02437708|Active Comparator|REP|A REP will be performed on immature infected permanent teeth, as described in the protocol of Diogenes et al. (2013). Medcem Portlandcement (GmbH, Swiss) will be used instead of mineral trioxide aggregate in the second session, to prevent tooth discoloration.
89369115|NCT03186430|Experimental|Comprehensive Vaccine Promotion Package|The pediatric practices randomized to this arm will receive the comprehensive adolescent vaccine promotion package. Practice physicians and staff will be familiarized with each component, and practices will be instructed to implement each vaccine-promotion component to the best of their ability.
89369116|NCT03186430|No Intervention|Standard Vaccination Promotion|The pediatric practices randomized to the control arm will not receive the comprehensive vaccine promotion package and will instead be instructed to continue offering their standard adolescent vaccination promotion practices to adolescent patients.
89369117|NCT02440984|Other|Enteric nervous system dysfunction|colonic biopsies and usual care
89369118|NCT02432794|Experimental|delay phenomenon by arteriography|"intervention: delay phenomenon by arteriography. Patients who will be subjected a delay phenomenon by arteriographic procedure before esophageal resection surgery minimum 14 days before surgery.~An angiogram of the celiac trunk is performed through a femoral access before and after the embolization. A 4-5 Fr Simmons or Cobra catheter is used for the catheterization and embolization of the left gastric artery, and 0.035-inch platinum coils are proximally placed from the main trunk in the splenic artery. When accessory left gastric arteries are present, they are catheterized and embolized as well. The right gastric artery catheterization is realized by a 4-5 Fr catheter and coils or microcoils are proximally placed in the artery as well."
89369119|NCT02432794|No Intervention|control group|Patients who will be operated directly without gastric ischemic conditioning. The investigators don't performed any arteriography before the esophageal surgical resection
89369120|NCT02440906|Experimental|Intervention|A person-centered wellness intervention that includes a patient-directed wellness account. Enrollees meet with a patient Navigator to develop a wellness plan. The enrollee can then use the flexible wellness account to make purchases that are consistent with the goals of the wellness plan. Health Navigators have monthly phone contact with enrollees and meet quarterly with them to discuss goals and spending with the express goal of improving self-management, use of preventive services, satisfaction with care, healthcare utilization and expenditures and quality of care.
89369121|NCT02440906|No Intervention|Control|Control group participants receive a monthly mailing requesting updated contact information. They can send this card via mail, or by calling the toll free number.
89369122|NCT02440906|No Intervention|Comparison|These are STAR+PLUS enrollees who meet the same enrollment criteria as the intervention and control but reside outside of the Harris Service Area. The purpose of the comparison group is to follow them and their outcomes. This group will help us to better compare the outcomes we see with those enrolled in the WIN Project to a comparable group for whom we already house data.
89369123|NCT02437630||Patients with COPD|Patients with COPD aged >40 years with Gold stage II as measured by standard lung function testing or worse and at least 10 pack year history of smoking who will have insertion of an oesophageal balloon to measure intra-thoracic pressure, fibre-optic laryngoscopy to observe movement of the larynx during respiration and facemask pneumotachograph measurement of airflow and volumes at the mouth. The facemask which will be used to deliver a positive airway pressure (continuous positive airways pressure(CPAP) This will provide face mask CPAP with variation of mouth pressure with CPAP
88841891|NCT05455801|No Intervention|conventional dressing group|those patients who heal with conventional dressing, therefore negative pressure therapy is not applied
88841892|NCT04061330|Experimental|Ketamine Group|
89369124|NCT02437630||normal subjects without copd|Subjects without COPD and normal lung function as measured by standard lung function tests who will have insertion of an oesophageal balloon to measure intra-thoracic pressure, fibre-optic laryngoscopy to observe movement of the larynx during respiration and facemask pneumotachograph measurement of airflows and volumes at the mouth which will be used to deliver a positive airway pressure (continuous positive airways pressure CPAP) This will provide face mask CPAP with variation of mouth pressure with CPAP
89369125|NCT02440750|Experimental|Dienogest|Women selected for operative hysteroscopy that received for 21 days dienogest 2 mg/die
89369126|NCT02440750|Experimental|Ulipristal acetate|Women selected for operative hysteroscopy that received for 21 days ulipristal acetate 5 mg/die
89369127|NCT03186196|Experimental|Group 1|Diet with 191 mcg/day of Folate
89369128|NCT03186196|Active Comparator|Group 2|Diet containing 90 mcg / day of Folate
89369129|NCT03186352|Experimental|after intervention|sample for microbial analysis it taken with sterile a rose bur (size 014) on micro motor after intervention
88841893|NCT04061330|Active Comparator|Opioid group|
89369130|NCT02432872|Experimental|escalated daunorubicin|Daumorubicin 60mg/m2 per day for 3 days combined with Cytaruabine 100mg/m2 per day for 7 days.
88841894|NCT00372632|Placebo Comparator|placebo|
88841895|NCT00372632|Experimental|sulfadoxine-pyrimethamine|
89369131|NCT02432872|Active Comparator|standard daunorubicin|Daunorubicin 45mg/m2 per day for 3 days combined with Cytaruabine 100mg/m2 per day for 7 days.
89369132|NCT02432872|Experimental|medium dosage cytarabine|1g/m2 q12h for 3 days as consolidation therapy.
88841896|NCT05455723|Active Comparator|Inflation-Deflation Group|
88841897|NCT05455723|Active Comparator|Magill Forceps Group|
88841898|NCT05455645|Experimental|Targeted intrinsic foot muscles exercise regimen|4 targeted intrinsic foot exercise will be performed at least 5 times per week, once in the laboratory, and four times at home. The participants will be followed up weekly at the laboratory visit. The real-time ultrasound imaging of intrinsic foot muscles will be used as guided visual biofeedback to instruct all participants to execute all exercise movement in a correct manner. If the participant misses a session, he/she is expected to replace the lost session within the same week.
88841899|NCT05455645|No Intervention|Control|continue normal physical activity,
88841900|NCT04525352|Experimental|Experimental - RP-L401|RP-L401 is a gene therapy product containing autologous genetically modified CD34+ hematopoietic cells transduced with lentiviral vector carrying the TCIRG1 transgene
88841901|NCT03991195|Experimental|Probiotic supplemented group with aMCI|Thirty participants in this group will take Bifidobacterium for three months.
89369133|NCT02432872|Active Comparator|standard dosage cytarabine|100mg/m2 cytarabine for 6 days combined with aclacinomycin 20mg per day for 6 days as consolidation therapy.
89369134|NCT03189472|Experimental|active tDCS|
89369135|NCT03189472|Sham Comparator|sham tDCS|
89369136|NCT03189550||Historical control|Patients who underwent colorectal surgery with standard perioperative care starting from June 2014 and progressing backward in time.
89369137|NCT03189550||ERAS without SOC noninvasive hemodynamic monitoring|Patients who underwent colorectal surgery after implementation of standard of care (SOC) ERAS perioperative care from July 2014 to February 2015
89369138|NCT03189550||ERAS with SOC noninvasive hemodynamic monitoring|Patients who underwent colorectal surgery after implementation of standard of care ERAS perioperative care with standard of care noninvasive hemodynamic monitoring (with the ClearSight System, Edwards Lifesciences) after February 2015
89369139|NCT03189394|Experimental|PRIDE|The in-person experimental condition, PRIDE, consists of in-person intervention activities that are scheduled over two Saturdays, back to back, approximately 3 hours each (6 hours total). This intervention consists of relationship-focused activities for couples to take part in together, focusing on relationship communication, dynamics, and sexual agreements.
88841902|NCT03991195|Placebo Comparator|Placebo group with aMCI|Thirty participants in this group will take placebo for three months.
88841903|NCT04821115|Experimental|Low intensity choc waves therapy (Experimental group)|The patients will use the device with a real applicator.
88841904|NCT04821115|Sham Comparator|Sham group|The patients will use the device with a sham applicator. Instead of a focusing lens, the applicator will have an internal foam piece that will dissipate the energy of the shockwave. Hence, the sham applicator will look, feel and sound the same as the active, but no measurable energy is emitted
89369140|NCT03189394|Experimental|ePRIDE|ePRIDE is an online adaptation of the experimental condition, PRIDE, and consists of online intervention activities that are scheduled to be completed over two weeks, lasting approximately 6 hours total. This intervention consists of relationship-focused activities for couples to take part in together, focusing on relationship communication, dynamics, and sexual agreements, and is designed for couples to take together sitting side by side.
89369141|NCT03189394|Active Comparator|Men's Health|Men's Health is the active comparator group. Participants in this group go through in-person intervention days, scheduled on Saturdays back to back, but differ from the PRIDE arm because this intervention does not focus on relationship dynamics. Instead, these two Saturday intervention days focus on general men's health, including heart health, cancer, and STDs.
89369142|NCT02437006|No Intervention|rehabilitation|half an hour physical and half an hour occupational therapy in rehabilitation
89369143|NCT02437006|Experimental|Low-intensity exercise|Low-intensity exercise plus rehabilitation
89369144|NCT02437006|Experimental|High-intensity exercise|High-intensity exercise plus rehabilitation
89369145|NCT02437240|Experimental|Pilates-based CPT|incorporated the concept of pilates training into cardiopulmonary physical therapy after cardiac surgery
89369146|NCT02437240|Active Comparator|Traditional CPT|usual bed side cardiopulmonary physical therapy after cardiac surgery
88841905|NCT04820881||Case Group|Measurement of cerebrovascular reactivity and oxygen metabolism before and after a single dose of 50mg sildenafil citrate. Diffusion tensor imaging, other structural imaging and cognitive testing will also be completed.
88841906|NCT04820881||Control Group|Measurement of cerebrovascular reactivity and oxygen metabolism before and after a single dose of 50mg sildenafil citrate. Diffusion tensor imaging, other structural imaging and cognitive testing will also be completed.
88841907|NCT04333693||Cases|Adults (age>18years) undergoing any type of vascular surgery (open surgery, endovascular surgery or hybrid procedure) in an operating theatre and either before or after surgery: lab test confirmed COVID-19 or clinical diagnosis of COVI-19 infection (no test performed)
89369147|NCT02436850|Experimental|Intervention group|The intervention group will receive large volume thoracentesis.
89369148|NCT02436850|No Intervention|Control group|The control group will be taped with an 18 gauge and 20 gauge venflons and drain will not be placed.
89369149|NCT02436928|Experimental|AT-501 High Dose vaccine|Inactivated H7N9 High Dose Antigen
89369150|NCT02436928|Experimental|AT-501 High Dose vaccine with Adjuvant|Inactivated H7N9 High Dose Antigen with Adjuvant
88841908|NCT04809883||observational study of gastric and pyloric motor function measured with Endoflip|observational study of gastric and pyloric motor function measured with Endoflip during fasting and postprandial periods There is NO intervention
88841909|NCT04792021|Active Comparator|N-acetylcysteine (NAC)|Patients receiving N-acetylcysteine (NAC)
88841910|NCT04792021|No Intervention|Control|Patients not receiving N-acetylcysteine (NAC)
88841911|NCT05093413|Experimental|Fully slept first; Sleep deprived second|Participants will be fully slept during the first experimental visit and sleep deprived during the second experimental visit
88841912|NCT05093413|Experimental|Sleep deprived first; Fully slept second|Participants will be sleep deprived during the first experimental visit and fully slept during the second experimental visit
88841913|NCT03905629||Patients aged 75 years and older hospitalized as an emergency|Patients considered will be all patients aged 75 years and older (on the day of the index admission) hospitalized as an emergency (i.e. after visit to ED) between january 2017 and december 2017.
89369151|NCT02436928|Experimental|AT-501 Low Dose vaccine|Inactivated H7N9 Low Dose Antigen
89369152|NCT02436928|Experimental|AT-501 Low Dose vaccine with Adjuvant|Inactivated H7N9 Low Dose Antigen with Adjuvant
89369153|NCT02436538||Mullerian duct anomalies|Anti Mullerian hormone level; Mullerian duct anomaly type
89369154|NCT02432014|Other|PMTO-PTC Group clinic-based|PMTO-PTC = Oregon Parent Management Training program, Parenting Through Change groups provided at a clinic.
89369155|NCT02432014|Other|PMTO Individual home-based|PMTO = Oregon Parent Management Training program, delivered individually in the home.
89369156|NCT02432014|Other|PMTO Individual clinic-based|PMTO = Oregon Parent Management Training program, delivered individually at a clinic.
89369157|NCT02432014|Other|Services as Usual|Usual child-centered services (i.e. therapy) provided by the agencies at a clinic.
89369158|NCT03191968|Experimental|Supervised PA Plus Behavioral Counseling|25 prostate cancer survivors will receive supervised physical activity and behavioral counseling (SPA+BC) based on the M-PAC. In addition to supervised physical activity, behavioral counseling sessions will be delivered with a PA specialist based on the Multi-process Action Control (M-PAC) framework and include behavior change techniques addressing information regarding the consequences, social support, goal setting, self-monitoring, cues and prompts, barrier identification, intention formation, planning, and habit and identity formation
89369159|NCT03191968|Active Comparator|Supervised PA Plus Exercise Counseling|25 prostate cancer survivors will supervised physical activity and exercise counseling (SPA+EC).In addition to the supervised exercise sessions, standard exercise counseling will be delivered by a PA specialist to teach proper PA and resistance training techniques, how to monitor intensity, and to progress PA safely and effectively to achieve the public health PA guideline.
89369160|NCT02436694|Active Comparator|Local Anesthetic ropivacaíne|Femoral nerve block with ropivacaine 0.375% and sciatic nerve block with ropivacaine 0.2%
89369161|NCT02436694|Experimental|Perineural Dexamethasone|Femoral nerve block with ropivacaine 0.375% and perineural dexamethasone and sciatic nerve block with ropivacaine 0.2% and perineural dexamethasone
89369162|NCT02436616||EEG monitoring|All subjects enrolled in this observational study will undergo EEG monitoring using the microEEG device.
89369163|NCT02436460|Experimental|AbGn-168H|AbGn-168H will be administered once weekly for four weeks via intravenous infusion.
89369164|NCT03191422|Experimental|LSVT BIG intervention recipients|Participants participated in all of the evaluation steps as well as the LSVT BIG protocol which includes 16, 1-hour intervention sessions with a certified therapist performing, targeted exercises and activities to improve participation in occupations - with a focus on large amplitude movement.
89369165|NCT03186040|Other|Lacosamide|
89369166|NCT03185962||Successful extubation|extubated successfully
89369167|NCT03185962||Extubation failure|reintubated within 48 hours
89369168|NCT03185962||NPPV/NHF|use of non-invasive positive pressure ventilation (NPPV) or nasal high flow (NHF) within 48 hours after extubation
89369169|NCT03191734|Experimental|AQUABEAM System|AQUABEAM System
89369170|NCT03191500|Experimental|steerable catheter|to study the safety and efficacy of a steerable catheter in the treatment of peripheral vascular disease
89369171|NCT02432170|Experimental|Foot/Ankles imaged with tomosynthesis|"Intervention: Digital Tomosynthesis of Foot and Ankle~The intervention, digital tomosynthesis of the foot and ankle, will be done on eligible participants. The resulting images will be compared to radiography and weight-bearing CT images from the same participants."
89369172|NCT05233540||Locally advanced or synchronous metastatic anal cancer treated with induction chemotherapy|Patients with newly diagnosed anal cancer who by standard of care are eligible for induction chemotherapy prior to definitive CRT or radiotherapy alone (RT) will be screened according to inclusion- and exclusion criteria. Patients eligible for induction chemotherapy will be patients with locally advanced or synchronous metastatic anal cancer.
89369173|NCT02440516|Active Comparator|Neurorehabilitation program|Standardized comprehensive ambulatory neurorehabilitation program
89369174|NCT02440516|Placebo Comparator|Waiting list|Waiting list
89369175|NCT02659020|Experimental|Phase 1b: Cohort 1 - 15 mg/kg Olaratumab + Gemcitabine + Docetaxel|Participants received intravenous infusions of olaratumab 15 milligrams per kilogram (mg/kg) on days 1, 8 plus gemcitabine 900 milligrams per meter square (mg/m^2) on days 1, 8 plus docetaxel 75 mg/m^2 on day 8 of a 21-day cycle until disease progression, unacceptable toxicity, death, or other discontinuation criteria were met.
89179893|NCT03466346|Active Comparator|Interpersonal psychotherapy|IPT was developed in the 1980s by Gerald Klerman and Myrna Weissman to address interpersonal issues in depression. IPT is now considered evidence-based, first-line treatment for depression. IPT improves symptoms by addressing problems in social relationships. IPT is traditionally delivered as weekly one-hour sessions over 12 weeks, focused on one interpersonal problem area.
89369176|NCT02659020|Experimental|Phase 1b: Cohort 2 overall - 20 mg/kg Olaratumab + Gemcitabine + Docetaxel|Participants received intravenous infusions of olaratumab 20 mg/kg on days 1, 8 in combination with gemcitabine 900 mg/m^2 on days 1, 8 and docetaxel 75 mg/m^2 on day 8 of a 21-day cycle until disease progression, unacceptable toxicity, death, or other discontinuation criteria were met (cohort 2). Following a protocol amendment, additional participants were enrolled into this group to confirm the safety of the 20 mg/kg dose level prior to opening the Phase 2 (cohort 2 expansion).
89369177|NCT02659020|Experimental|Phase 2: Olaratumab + Gemcitabine + Docetaxel|Participants received intravenous infusions of olaratumab loading dose 20 mg/kg on days 1, 8 of cycle 1 followed by 15 mg/kg on days 1, 8 of all subsequent cycles in combination with gemcitabine 900 mg/m^2 on days 1, 8 and docetaxel 75 mg/m^2 on day 8 of a 21-day cycle until disease progression, unacceptable toxicity, death, or other discontinuation criteria were met. This cohort is a combination of participants who never received olaratumab (olaratumab-naive) and who received commercially available olaratumab (olaratumab pre-treated) prior to enrollment.
89369178|NCT02659020|Placebo Comparator|Phase 2: Placebo + Gemcitabine + Docetaxel|Participants received intravenous infusions of placebo on days 1, 8 in combination with gemcitabine 900 mg/m^2 on days 1, 8 and docetaxel 75 mg/m^2 on day 8 of a 21-day cycle until disease progression, unacceptable toxicity, death, or other discontinuation criteria were met. This cohort is a combination of participants who never received olaratumab (olaratumab-naive) and who received commercially available olaratumab (olaratumab pre-treated) prior to enrollment.
89179894|NCT03466346|Active Comparator|fluoxetine|Fluoxetine is a selective serotonin reuptake inhibitor that is FDA approved for the treatment of depression. Compared to placebo, fluoxetine is more likely to produce symptom response for MDD. Despite the interim development of many other antidepressants since the development of fluoxetine, it remains a first line treatment for depression.
89179895|NCT03466346|Active Comparator|Fluoxetine after IPT|participants who do not remit from MDD and PTSD after treatment with IPT may be randomized to fluoxetine.
89179896|NCT03466346|Active Comparator|IPT after fluoxetine|participants who do not remit from MDD and PTSD after treatment with fluoxetine may be randomized to IPT.
89179897|NCT03466346|Active Comparator|IPT + fluoxetine|participants who do not remit from MDD and PTSD after treatment with fluoxetine may be randomized to IPT + fluoxetine.
89179898|NCT05754242|Experimental|Ascorbic acid|1.5 gr of ascorbic acid diluted in 100 ml of 0.9% saline solution will be administered intravenously during the anhepatic phase of liver transplantation
89179899|NCT05754242|Placebo Comparator|Saline solution|100 ml of 0.9% saline solution will be administered during the anhepatic phase of liver transplantation
89179900|NCT04030364|Other|Self-referral to group exercise classes|"Structured, multi-component, supervised group exercise classes are the health related intervention proposed for this study. The group classes will occur at a local CrossFit gym facility.~For the purposes of this project, all eligible Rosemount Clinic patients with type 2 diabetes mellitus will receive an email or letter mail invitation to self-refer to a structured, facility-based, supervised aerobic and resistance exercise program. Interested patients will be invited to attend a 1-hour information session at the exercise facility at the time of implementation start up where they will complete an initial baseline survey. This session will also serve as an initial meet and greet for participants to meet exercise trainers prior to starting exercise classes and to receive a tour of the facility."
89179901|NCT02606006|Active Comparator|Non-AAT Group|Inpatients in this group will receive 3-5 brief afternoon physical therapy sessions over 3-5 successive days. None of the sessions will include use of a canine for AAT. This group will include the intervention of Standard of Care Physical Therapy
89179902|NCT02606006|Experimental|AAT Group|Inpatients in this group will receive 3-5 brief afternoon physical therapy sessions over 3-5 successive days. The session on the middle day will include use of a canine for AAT. This group will receive a behavioral intervention of Canine Animal-Assisted Therapy.
89179903|NCT00809783|Experimental|Tanezumab 10 mg|Tanezumab 10 mg
89179904|NCT00809783|Experimental|Tanezumab 5 mg|Tanezumab 5 mg
89179905|NCT00809783|Experimental|Tanezumab 2.5 mg|Tanezumab 2.5 mg
89179906|NCT05675462|Experimental|H101 + Tislelizumab+ Lenvatinib|"(Dose escalation and cohort expansion) H101 administered by intratumoral injection in combination with Tislelizumab administered intravenously (IV), and Lenvatinib administered orally.~H101 intratumorally injection starts at day 0. Tislelizumab plus lenvatinib will be initiated on day 1. Tislelizumab will be administered at 200 mg i.v. every 3 weeks plus a lenvatinib (bodyweight ≥ 60 kg, 12 mg; < 60 kg, 8 mg) orally daily every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent."
89179907|NCT00914264||COPD with OSA with CPAP treatment|COPD with OSA: CPAP treatment
89179908|NCT00914264||COPD without OSA|COPD without OSA, not treat with CPAP
89369179|NCT02436382|No Intervention|Ambient Temperature of 67F|These patients will have an operating room temperature of 67F for cesarean delivery, the standard of care at our institution.
89369180|NCT02436382|Active Comparator|Ambient Temperature of 73F|These patient will have an operating room temperature of 73F for cesarean delivery, a temperature more consistent with WHO recommendations.
89179909|NCT00914264||COPD with OSA but without CPAP treatment|COPD with OSA but patient refused CPAP treatment
89179910|NCT04031261||National Validation|All patients must have a diagnosis of severe asthma, be taking high dose inhaled corticosteroids (GINA step 4 & 5), and be aged 16 years or over.
89179911|NCT04031261||Sensitivity to Change|Patients commencing a biologic treatment for their severe asthma (GINA step 4 & 5), as per National Institute for Health and Care Excellence (NICE) guidelines.
89179912|NCT05754164|Experimental|Attention Control Training|The Dot-Probe Paradigm was utilized within the Attention Bias Modification procedure. The training sessions were comprised of 80 trials, which included facial expression photos depicting happiness, neutrality, and sadness, sourced from four male and four female actors. A fixed cross (+) was presented on the computer screen's center for a duration of 500 milliseconds before each stimulus display, followed by the presentation of two images portraying distinct emotional expressions, which persisted for 500 milliseconds. After the disappearance of the images, an arrow appeared in the location where they had been displayed, and participants were instructed to select the arrow that corresponded with the presented arrow. In the ABM procedure, the arrow was consistently presented following the display of a more positive facial expression, such that in the instance of a sad-neutral face pair, the arrow would always appear in the location of the neutral facial expression image.
89179913|NCT05754164|No Intervention|Control|
89179914|NCT02608658|Experimental|Interventional Arm|The experimental arm of this study will involve all patients in this study. Subjects will be evaluated in a clinical setting and undergo a brief healthcare questionnaire, blood work, and a breath test. Subjects will then take a medical food (EnteraGam) twice daily for 8 weeks total, after which they will be seen in clinic at 4 weeks for follow up and then at 8 weeks to repeat the healthcare questionnaire, breath tests, and blood draw.
89179915|NCT00809471|Placebo Comparator|placebo|
89179916|NCT00809471|Experimental|avanafil 100 mg|
89369181|NCT03482011|Experimental|Mirikizumab|"Induction Period:~Participants received 250 milligrams (mg) mirikizumab administered subcutaneously (SC) every 4 weeks (Q4W).~Maintenance Period:~Participants received one of the four options below:~Placebo administered SC every 8 weeks (Q8W) for responders (≥PASI 90).~125 mg mirikizumab administered SC Q8W for responders (≥PASI 90).~250 mg mirikizumab administered SC Q8W for responders (≥PASI 90).~250 mg mirikizumab administered SC Q8W for non-responders (<PASI 90)."
89179917|NCT00809471|Experimental|avanafil 200 mg|
89179918|NCT00807248|Placebo Comparator|Escitalopram placebo and gaboxadol placebo|
88841914|NCT04334161||PHH patients|Patients with Roux-en-Y gastric bypass ≥1 year ago and confirmed postprandial hyperglycaemic hypoglycaemia (PHH). PHH is defined as postprandial plasma or sensor glucose<3.0mmol/l according to the International Hypoglycaemia Study Group and exclusion of other causes of hypoglycaemia
88841915|NCT04334161||non-PHH gastric bypass patients|Patients with Roux-en-Y gastric bypass ≥1 year ago without evidence of PHH.
88841916|NCT04334161||non-PHH sleeve gastrectomy patients|Patients with sleeve gastrectomy ≥1 year ago without evidence PHH.
88841917|NCT04334161||non-PHH non-surgical controls|Absence of any conditions or previous surgery known to affect gastro-intestinal integrity and food absorption.
88841918|NCT04978285||Postoperative anemia|All patients enrolled in the RELIEF trial in which a postoperative Day 1-3 hemoglobin concentration was measured. Anaemia will be defined according to the World Health Organisation definition (males Hb <130 g/L, and female Hb <120 g/L).
88841919|NCT04978285||No postoperative anemia|All patients enrolled in the RELIEF trial in which a postoperative Day 1-3 hemoglobin concentration was measured. No anaemia will be defined according to the World Health Organisation definition (males Hb ≥130 g/L, and females Hb ≥120 g/L).
88841920|NCT04964713||type 2 diabetes|T2DM was defined according to the WHO 2006 criteria. Assessing the left heart and right heart structure and function of T2DM by speckle tracking echocardiography.
88841921|NCT04964713||Prediabetes|According to the WHO 2006 criteria, combining impaired fasting glucose and impaired glucose tolerance as prediabetes. Assessing the left heart and right heart structure and function of prediabetes by speckle tracking echocardiography.
88841922|NCT04964713||normal glucose metabolism(NGM)|Assessing the left heart and right heart structure and function of NGM by speckle tracking echocardiography.
88841923|NCT04926961|Experimental|Sham stimulation first, then real stimulation|Participants will first be delivered sham TMS stimulation. Then on a separate day, participants will be delivered real TMS stimulation.
88841924|NCT04926961|Experimental|Real stimulation first, then sham stimulation|Participants will first be delivered real TMS stimulation. Then on a separate day, participants will be delivered sham TMS stimulation.
88841925|NCT04737811||Study group|The group consists of Parkinson's disease patients with dysphagia complaints. The participants will be given the Turkish version of the Swallow Disturbance Questionnaire (SDQ-T), which consisted of 15 questions and two scales evaluated with the fiberoptic endoscopic evaluation of swallowing. After two weeks, all participants will be given the SDQ-T for sampling.
88841926|NCT04540003|Experimental|Access to School Based Health Centre|Of the eight school in the intervention arm, four schools will be linked to a school based health center (SBHC) at Sprucecourt or Nelson Mandela Park Public Schools (established in partnership with the department of Pediatrics at St. Michael's hospital) and four schools will be linked to a SBHC at Parkdale Public School (established in partnership with St. Joseph's Health Centre). SBHC pediatricians will attend School Support Team (SST) meetings at all intervention schools and students with developmental concerns identified at the SST meetings will be referred to the SBHC.
89179919|NCT00807248|Active Comparator|Escitalopram 20 mg and gaboxadol placebo|
89179920|NCT00807248|Experimental|Escitalopram 20 mg and gaboxadol 5 mg|
89179921|NCT00807248|Experimental|Escitalopram 20 mg and gaboxadol 10 mg|
89179922|NCT05326295||Breast cancer patients|
89179923|NCT02610491|Placebo Comparator|Placebo|Cellulose
89179924|NCT02610491|Active Comparator|Hesperidin|Citrus peel extract
89179925|NCT02610335|Active Comparator|Control group (C)|Kyphosis reeducation + patient education + auto-reeducation at home
89179926|NCT02610335|Other|Test group (M)|Spinal mobility reeducation + patient education + auto-reeducation at home.
89179927|NCT02607332|Experimental|Paclitaxel|paclitaxel 80mg/m2/day on a Cycle1Day1, Cycle1Day8,Cycle1Day15 off 1 week schedule
89179928|NCT03356756||PET MRI exam|simultaneous combined 18F-FDG PET and cardiac MRI imaging (PET MRI) performed immediately after the PET CT exam.
89179929|NCT05297669|Experimental|group1|Generic name: Felbinac Trometamol Injection; Dosage form: Injection Dosage:94.25mg Volume:4ml Frequency:Multi-dose Duration:1 day. A total of 132 subjects received the test drug .
89179930|NCT05297669|Placebo Comparator|group2|Placebo:Normal saline Dosage form:Injection Dosage:0mg Volume:0ml Frequency:Multi-dose Duration:1 day A total of 132 subjects received the placebo.
89179931|NCT05757323|Experimental|test formula|hydrolysed protein-based infant formula
89179932|NCT05757323|Active Comparator|control formula|standard intact protein-based formula
89179933|NCT00589628|Active Comparator|1|5mg/kg/dose of infliximab IV every 4 weeks for 9 doses
89179934|NCT00589628|Active Comparator|2|10mg/kg/dose of infliximab IV every 4 weeks for 9 doses.
89179935|NCT00914576|Active Comparator|1|
89179936|NCT00914576|Placebo Comparator|2|
89179937|NCT00914654|Other|Healthty|10 healthy men
89179938|NCT00914654|Other|Asthmatics|10 male asthmatic subjects
89179939|NCT00914654|Other|Elite asthmatics|10 male elite athletes with asthma
89179940|NCT04115618|Experimental|SIB|Simultaneous integrated boost intensity-modulated chemoradiotherapy
89179941|NCT02605772|Experimental|metformin+Saxagliptin|metformin 0.5g tablet Saxagliptin 5mg tablet metformin 0.5g three times a day for three months Saxagliptin 5mg one time a day for three months
89179942|NCT02605772|Experimental|acarbose+Saxagliptin|acarbose 50mg tablet Saxagliptin 5mg tablet Saxagliptin 5mg one time a day for three months acarbose 100mg three times a day for three months
89179943|NCT00588848|Experimental|Autoadjusting CPAP (VPAP auto)|The intervention will be the use of an Autoadjusting CPAP unit that will be applied to the subject during the 8 hours overnight the first night after surgery (study night). During this time, they will undergo a full night attended polysomnogram in their hospital room.
88841927|NCT04540003|No Intervention|Control Arm: Standard of care|Of the eight schools assigned to the control condition, four will be in the South East area of the city closer to Nelson Mandela Park PS and four will be in the South West area of the city closer to St. Josephs Health Center. The eight schools will be subject to standard of care which is: when a child is identified by the SST (no pediatrician present), students identified with developmental concerns are advised to access a pediatric/developmental assessment in the community.
88841928|NCT04333927|Experimental|Treatment|Patients in treatment group will receive camrelizumab 200mg intravenously every 3 weeks until clinical or radiographic disease progression, unacceptable toxicity, death, termination of the study or withdrawal. After 1 or 2 courses of camrelizumab, patients went on to receive capecitabine (1,330 mg/m2 per day, in divided doses twice daily, 7 days per week) concurrent with radiotherapy (45 Gy to regional lymph nodes and 54 to 59.4 Gy to preoperative tumor bed).
89179944|NCT00588848|Active Comparator|CPAP arm (usual care)|The intervention will be the use of the subject's own CPAP machine and this will be applied to the subject during the 8 hours overnight the first after surgery (study night). During the study night, they will undergo full polysomnography in their hospital room.
89369182|NCT03482011|Placebo Comparator|Placebo|"Induction Period: Participants received placebo administered SC Q4W.~Maintenance Period:~Participants received one of the two options below:~Placebo administered SC Q8W for responders (≥PASI 90).~250 mg mirikizumab administered SC Q4W during week 16 to week 32 and Q8W during week 40 and 48 for non-responders (< PASI 90)."
88841929|NCT04333927|Placebo Comparator|Observation|Patients in observation group will not receive any anti-cancer therapy.
88841930|NCT04334005|Active Comparator|Usual care|Prescription of NSAIDs, ACE2 inhibitor, ARB or thiazolidinediones, according to clinician criteria, based on the current recommendations.
88841931|NCT04334005|Experimental|Intervention group|25000 UI of vitamin D supplement in addition to the above-mentioned drug recommendations.
88841932|NCT04445233||COV Participants|COVID-positive index cases (COV): Participants who are greater than or equal to 18 years of age who test positive for COVID-19 by positive NP swab
88841933|NCT04445233||COV-HC Participants|Household contact of COVID-positive index case (COV-HC): Household contacts greater than 1 year of age currently living in the same home as the COVID-positive index case
88841934|NCT00373009|Experimental|Core stabilization and psychosocial education|A core stabilization exercise program (CSEP) is used in this group and has sound biomechanical and anatomical rationale. In addition, a psychosocial education program (PSEP) will be used for this group.
88841935|NCT00373009|Active Comparator|Core stabilization exercise only|A core stabilization exercise program (CSEP) is used in this group and has sound biomechanical and anatomical rationale.
88841936|NCT00373009|Active Comparator|Psychosocial education class only.|A psychosocial education program (PSEP) will be used in this group.
88841937|NCT00373009|Other|Traditional Army training|Traditional Army training will be used in this group.
88841938|NCT00966914|Placebo Comparator|Placebo|Placebo in combination with cisplatin and either paclitaxel or docetaxel
88841939|NCT00966914|Active Comparator|Tavocept (BNP7787)|Tavocept (BNP7787) in combination with cisplatin and either docetaxel or paclitaxel
88841940|NCT00505544||Questionnaire|Questionnaires that ask about your sleep, symptoms, and mood.
88841941|NCT00505544||Questionnaire + Actigraphs|Questionnaires that ask about your sleep, symptoms, and mood. Wear actigraph to collect information on activity levels and sleep patterns for one week.
88841942|NCT04430959|Experimental|Candesartan first then Placebo|4 weeks of candesartan with crossover to the other.
88841943|NCT04430959|Placebo Comparator|Placebo first then Candesartan|4 weeks of placebo with crossover to the other.
88841944|NCT03821870||Standard treatment|Standard first line treatment
88841945|NCT04430101|Active Comparator|Negative WB radiographs and stress fluoroscopy|"Cohort 1~Negative weight bearing radiographs:~Interval between medial cuneiform and base of the second metatarsal (C1-M2) are less than 2mm increased compared to the uninjured side.~Negative stress fluoroscopy: the midfoot is tested stable"
88841946|NCT04430101|Active Comparator|Negative WB radiographs / positive stress fluoroscopy|"Cohort 2~Negative weight bearing radiographs:~Interval between medial cuneiform and base of the second metatarsal (C1-M2) are less than 2mm increased compared to the uninjured side.~Positive stress fluoroscopy: manual testing reveals midfoot instability"
88841947|NCT04430101|Other|Surgical cohort (Cohort 3)|Patients with positive weightbearing radiographs will be operated on with minimally invasive technique and followed up as an independent cohort.
88841948|NCT04820413|Experimental|FMT|
89369183|NCT02436070|Active Comparator|Control|Subjects receive general, health-related text messages applicable for children with asthma.
89369184|NCT02436070|Experimental|Test group|Subjects receive specific, targeted text messages for post-emergency department discharge asthma care.
88841949|NCT03045289|Experimental|Intervention group|Subjects are provided three meals daily, attend weekly office visits, take a daily multivitamin.
88841950|NCT03045289|No Intervention|Control Group|Women instructed to maintain current intake and take a provided multivitamin.
88841951|NCT04737655|Active Comparator|TRIMBOW + Standard of care|"Inclusion~Maintenance therapy (LAMA or LABA) for COPD~Age >18~Admission for AE of COPD~Signed Inform consent (see protocol attached)~Admitted in ICU >24h and less than 72h~Exclusion~No CI for studied medication~Not treated with studied medication for at least 3 months~Admitted in ICU for AE of COPD within the past 3 months~Intolerance to studied medication~Hospitalized since >6 days~ARDS condition (PAFI <200)~Admitted in ICU >72H~Patient with severe asthma~The use of high dose of ICS as baseline therapy~Right/left heart failure~Immunocompromized~Acute myocardial infaction~Left heart insufficiency (LVEF<35%)~Stroke <6 months prior to hospital admission~Patients will be separated in 2 randomized groups (Trimbow + SOC versus SOC) 1:1."
88841952|NCT04737655|No Intervention|standard of care|
88841953|NCT05063396|Active Comparator|opioid free anesthesia|opioid free anesthesia
88841954|NCT05063396|Placebo Comparator|Opioid-sparing anesthesia|Opioid-sparing anesthesia
88875235|NCT02538042|Experimental|MCE+|Three weeks prior to the target quit date, participants will switch to smoking very low nicotine content cigarettes and wear a 21 mg/d nicotine patch. During the 3-week, pre-quit period, participants will undergo six, 60 minute sessions during which they will view smoking-related environments and smoke their assigned cigarettes. Following the quit date, participants will quit smoking and wear the nicotine patch for 10 weeks.
88841955|NCT04737499|Experimental|CASCADe Intervention|Intervention consisted of eight weekly sessions of health education and diabetes management. Topics covered include recognition of diabetes and its complications, risk factors, nutrition knowledge, dietary practices, exercise, behavioral self-monitoring, medication adherence, and stress management. Intervention also included a home visit for training of monitoring devices use, WeChat app and acquiring family support, and weekly WeChat follow-up on education tips, monitoring data summary, and group discussion. The monitoring system used a smartphone to coordinate cloud data transmission from a set of wireless devices to capture daily monitoring data on physical activity, body weight, blood pressure and blood glucose levels.
88841956|NCT05055752|Other|PL-ASA capsule, then IR-ASA tablet|One PL-ASA 325 mg capsule, 14 day washout then one IR-ASA 325 mg tablet
88841957|NCT05055752|Other|IR-ASA tablet, then PL-ASA capsule|One IR-ASA 325 mg tablet, 14 day washout, then one PL-ASA 325 mg capsule,
88841958|NCT05042492|No Intervention|Group 1: SC (moveUP)|In group 1: moveUP (class 1, CE-marked, medical device) is being used as the rehabilitation solution after TKA. It has become a valid digital rehabilitation solution and is recognised by the Belgian government as mobile health application in rehabilitation of hip and knee arthroplasty surgeries. It's a full service with daily personalized and individualized follow up by certified physical therapists and certified health care providers. The use of tele-rehabilitation for TKA patients has been internationally recognized with the 2018 John N. Insall Award during the American Knee Society Meeting
88841959|NCT05042492|Experimental|Group 2: SC (moveUP) with 10 days of geko|In group 2: Next to SC (moveUP), the application of a single gekoTM device is used on the operated leg after surgery (day 0). This device will be worn for 24 hours and at least 8 hours from day 1 until day 10.
88841960|NCT05441059||Patients treated with mepolizumab|Patients treated with mepolizumab
88841961|NCT00373100|Experimental|Zinc|Zinc acetate
88841962|NCT00373100|Placebo Comparator|Placebo|Placebo
88841963|NCT04223323|Experimental|Intervention|The intervention arm consists of daily consumption of the investigator's intervention snack over the course of 12 weeks.
88841964|NCT04223323|Placebo Comparator|Isocaloric Control|The control arm consists of daily consumption of an isocaloric snack over the course of 12 weeks.
88841965|NCT04960748|Experimental|intervention|7-sesson group intervention that uses dyadic instruction, role playing and group sharing and discussion to reduce internalized stigma, improve disclosure decision making and healthy living, and teach advocacy skills
88841966|NCT04960748|No Intervention|wait-list control|Participants will not receive the intervention until all follow-up data has been collected.
88841967|NCT04943510|Experimental|Physical exercices arm|three randomizations will be used to determine the order of the tests that will be proposed to the subjects: on the one hand for the exercise modalities (match, anaerobic, aerobic) and, on the other hand, for the exercise modalities included in the anaerobic and aerobic exercise families: Anaerobic agility / anaerobic - linear sprints Aerobic - shuttle / aerobic - linear
88841968|NCT02973698|Other|chin-down posture maneuver|The patients in received an intervention program consisting of four weekly individual sessions of 30 minutes. In these sessions, it was performed the training of Chin-down postural maneuver with saliva and water. The participants were trained to perform the maneuver twice a day, swallowing saliva, and during meals, throughout the week, at home. The participants received a form, so they recorded the number of times they performed the maneuver at home. It allowed the control of adherence, being reinforced at each session the importance of adherence to treatment. Besides, the subjects received instructions regarding feeding. All the instructions, as well as the explanation about the maneuver, were submitted to the patients through a written document.
88841969|NCT02973698|Other|Control|The participants of this group underwent evaluation of swallowing, and the same assessment was repeated after four weeks, without any intervention during that period.
88841970|NCT02973698|Other|Orientations about swallowing|The individuals participated in an intervention program which consisted of four individual sessions a week, with 30 minutes. In these sessions, the instructions about feeding were performed. The individuals received all the instructions on a written document. In the sessions, it was verified doubts about the guidelines and treatment adherence. In this group, it was not applied the Chin-down postural maneuver.
88841971|NCT04209140||bipolar I disorders who initiate lithium treatment|
88841972|NCT04334486|Experimental|Video Game Trained|Subjects will participate in video gaming for 10 minutes prior to Eyesi simulator test of surgical skills.
88841973|NCT04334486|No Intervention|No Video Game Training|No video gaming will occur for warm up to Eyesi simulator test of surgical skills
88841974|NCT04334473|Other|cataract patients|Patients having cataract candidates for phacoemulsification with or without glaucoma are prepared to do cataract surgery with preoperative and postoperative assessment of intraocular pressure and ocular bio-metrics using UBM.
89369185|NCT03189238|Placebo Comparator|Placebo|
88841975|NCT03522740|Active Comparator|Decision Aid for Renal Therapy|Usual Care as in the 'no intervention arm' below plus access to an web-based decision aid, the Decision Aid for Renal Therapy to patients and their care-partners
88841976|NCT03522740|No Intervention|Usual Care|In-person education as would be done at study sites plus 'Choosing a Treatment for Kidney Failure', an educational booklet published by the National Kidney Foundation
88841977|NCT04762381|Active Comparator|Dexamethasone|24 mg dexamethasone as single dose intravenously peroperatively
88841978|NCT04762381|Placebo Comparator|Placebo|saline infusion intravenously in a single dose
88841979|NCT01547468|Active Comparator|Intravenous Opioids|
88841980|NCT01547468|Experimental|Femoral Nerve Catheterization|
88841981|NCT04717687|Experimental|Electrodes|Electrodes
88841982|NCT04333628|Experimental|low dose chloroquine|oral chloroquine 125mg daily for 7 days (or until the condition worsens, whichever comes first)
88841983|NCT04333628|Experimental|Regular dose chloroquine|oral chloroquine 500 mg twice daily for 7 days (or until the condition worsens, whichever comes first)
88841984|NCT04333628|Other|Standard of care|The treatment is mostly supportive in character and is given, based on patient's clinical state. Antibiotics do not help patients fight novel coronavirus.
89369186|NCT03189238|Active Comparator|PRP|
89369187|NCT03189082|Experimental|Intervention group|
89369188|NCT02431858|Experimental|Catheter Over Needle|"The femoral nerve catheter used will be the E-Catheter (Pajunk) device which is a novel catheter over needle system."
88841985|NCT03409328|Experimental|HIV and substance use prevention|Participants in the intervention condition will receive an HIV and substance use prevention program for self-identified bisexual adolescent men. The intervention content will be developed through formative research during the initial phase of the study.
88841986|NCT03409328|No Intervention|Waitlist|The control condition will be a waitlist.
88841987|NCT02241967|Experimental|tDCS Full Dose|4 active treatments
88841988|NCT02241967|Experimental|tDCS Half Dose|2 active treatments
88841989|NCT02241967|Experimental|tDCS Minimal dose|1 active treatment
88841990|NCT02241967|Sham Comparator|Sham tDCS|no active treatments
88841991|NCT03315728||Quality Improvement Strategy|First Nations communities partners are a diverse group of Indigenous communities reflecting wide variation in contextual factors: healthcare delivery and funding models; population size; remoteness; governance structures; and access to primary, secondary and tertiary care. Four diverse communities will partner in the program (two in Ontario and two in Atlantic Canada). All four communities will undertake an 18- month Quality Improvement Strategy intervention where they develop community-driven and culturally-relevant initiatives to improve diabetes care and management in their community
88841992|NCT02088931|Experimental|Single infusion polyclonal Treg|"3 subjects with inflammation on their 6-month surveillance biopsy following renal transplantation will receive a single infusion of a target of 320 million ex vivo selected and expanded autologous polyclonal Tregs.~After the therapy visit the patient will return for a total of nine (9) more visits for the main part of the study: 1 and 4 days after therapy, then once a week for 4 weeks, and then 3, 6, and 12 months after you get the therapy."
88841993|NCT00373178|Active Comparator|Metformin,lifestyle counselling|
88841994|NCT03254732|Experimental|ADI-PEG 20|This is a phase 1b, open label trial of ADI-PEG 20 (36 mg/m2) weekly in combination with pembrolizumab (1 and 2 mg/kg or 200 mg) every three weeks.
88841995|NCT04611451|Experimental|whole body vibration group|Patients in the WBV exercise group; 24 sessions of TVT exercise 3 days a week (with at least 1 day of rest between each session) was performed under the supervision of a physician for a total of 8 weeks. Patients in the WBV exercise group were also shown a classic lumbar home exercise program and they were asked to apply for 8 weeks
88841996|NCT04611451|Active Comparator|exercise|The second group (control) only received classical lumbar home exercise program.
88841997|NCT02923466|Experimental|VSV-IFNβ-NIS|VSV-IFNβ-NIS will be administered intratumorally as a single dose on day 1.
89369189|NCT02431858|Active Comparator|Catheter through needle|"The femoral nerve catheter used will be the Sonolong catheter (Pajunk) which is a traditional catheter through needle system."
89369190|NCT01374126|Experimental|Azithromycin-Artesunate|
88841998|NCT02923466|Experimental|Selection of VSV-IFNβ-NIS Monotherapy|VSV-IFNβ-NIS will be administered either intratumorally, intravenously or with a combination of intratumorally and intravenously as a single dose on day 1.
88841999|NCT02923466|Experimental|VSV-IFNβ-NIS and avelumab|"VSV-IFNβ-NIS will be administered as determined in arm 2 as a single dose on day 1.~Avelumab will be administered intravenously every 2 weeks starting on day 1."
88842000|NCT01052168|Active Comparator|Speed Group|The Speed Group, (n=20) will train in laparoscopic suturing on the validated FLS suturing model until the expert level of speed (i.e. task duration < 70 seconds) has been achieved on two consecutive attempts.
88842001|NCT01052168|Experimental|Motion Group|The Motion Group, (n=20) will train in laparoscopic suturing until expert levels of motion (pathlength 6700 and smoothness 560) have been achieved.
89369191|NCT01374126|Active Comparator|Control (artesunate alone)|
89369192|NCT02431624|Experimental|Test treatment|BTDS 40 milligram
88842002|NCT01052168|Experimental|Speed and Motion Group|The Speed and Motion Group (n=20) will train in laparoscopic suturing until expert levels of speed AND motion have been achieved.
88842003|NCT00813566|Experimental|All Participants|All participants will receive multi-tracer PET scans at up to 3 time points: baseline, at the conclusion of standard of care chemoradiation, and at the time of documented recurrence within two years.
88842004|NCT03908359|Active Comparator|traditional cataract surgery|Central anterior continuous capsulorhexis opening (5-6 mm)+ lens irrigation/aspiration + posterior capsulorhexis + anterior vitrectomy (ACCC+ I/A + PCCC + Anti-vit)
88842005|NCT03908359|Experimental|minimal invasive lens surgery|Peripheral capsulorhexis opening (1.0-1.5 mm)+lens irrigation/aspiration
88842006|NCT03879733|Experimental|Intervention group|The group of childcare centers that will receive the intervention during 10 months from sept 2018 - June 2019
88842007|NCT03879733|Other|Wait-list control|"Will receive no intervention and continue with business as usual during the primary intervention period Sept. 2018 - June 2019.~Will receive the intervention from Sept. 2019 - June 2020."
89369193|NCT02431624|Active Comparator|Reference treatment|BTDS 20 milligram
89369194|NCT02584920|Experimental|HLX01|375mg/m2 iv single dose
89369195|NCT02584920|Active Comparator|Rituximab|375mg/m2 iv single dose
89369196|NCT03185650|Other|tPAD, then PARI LC Star Nebulizer|tPAD device delivering 14% HS labelled with technetium-99m sulfur colloid particles separated by 2-28 days and then PARI LC delivering 7% HS labeled with technetium-99m sulfur colloid particles.
89369197|NCT03185650|Other|PARI LC Star Nebulizer, then tPAD|PARI LC delivering 7% HS labelled with technetium-99m sulfur colloid particles separated by 2-28 days and then tPAD device delivering 14% HS labelled with technetium-99m sulfur colloid particles
89369198|NCT01371318|Experimental|OWEMR|Medical centers will be randomized to use the Online Wound Electronic Medical Record to enhance care of patients with diabetic foot ulcers
89369199|NCT01371318|No Intervention|Standard of Care|Medical/wound centers will be randomized to continue routine care of patients with diabetic foot ulcers
88842008|NCT02885012|Experimental|Switch to Letairis from Bosentan|Subjects will be switching treatments from Bosentan (Tracleer) to Ambrisentan (Letairis)
88842009|NCT02885012|Experimental|Switch to Letairis from Macitentan|Subjects will be switching treatments from Macitentan (Opsumit) to Ambrisentan (Letairis)
89369200|NCT02431936|Experimental|Prazosin|Prescription for 1mg oral Prazosin twice per day will be administered for 71/2 days.
89369201|NCT02431936|Placebo Comparator|Placebo|Prescription for placebo identical to Prazosin dosage will be administered for twice daily for 71/2 days.
89369202|NCT03916770|Active Comparator|whole body vibration|WBV(whole body vibration) will be applied to interventional group for 4 weeks, 3 days a week, a total of 12 sessions while standing upright with the WBV powerplate pro5 device.(Vibration frequency: 30Hz, amplitude: 2.2 mm at progressively increasing duration)
89369203|NCT03916770|Sham Comparator|Sham whole body vibration|The sham WBV will be applied to the Control group. A WBV device with 99.5% weakened amplitude will be used for sham WBV. (Application duration of the sham WBV will be same as WBV in the treatment group ).
89369204|NCT03185806|Experimental|Puncture and Drainage|The enrolled SAP patients are administered puncture and drainage use 8-F or 10-F pigtail tube under guidance of B ultrasound or CT scan.
89369205|NCT03185806|No Intervention|Conservative therapy|The enrolled SAP patients are administered conservative therapy and without puncture and prolonged drainage.
89369206|NCT03481309|Active Comparator|anodal tDCS|Two electrodes will be applied to the scalp (one on the left motor cortex, one on the right supraorbital cortex). This anodal tDCS on the left motor cortex will be stimulated with 2mA for 10 minutes.
89369207|NCT03481309|Active Comparator|cathodal tDCS|Two electrodes will be applied to the scalp (one on the left motor cortex, one on the right supraorbital cortex). This cathodal tDCS on the left motor cortex will be stimulated with -2mA for 10 minutes.
89369208|NCT03481309|Sham Comparator|sham tDCS|Two electrodes will be applied to the scalp (one on the left motor cortex, one on the right supraorbital cortex). Sham stimulation with 2mA for 40 seconds will be applied.
89369209|NCT03185884|Active Comparator|Control|- 237 ml beverage; consumed once per test visit
89369210|NCT03185884|Experimental|Experimental|- 237 ml beverage; consumed once per test visit
88842010|NCT04555915||Intervention group|Intervention Group of the SafeboosC Phase III Trial
88842011|NCT04555915||Control group|Control Group of the SafeboosC Phase III Trial
89369211|NCT01372800||volunteer|
89369212|NCT03185494|Experimental|anti-CD19/22 CAR T cells|Patients receive anti-CD19/22-CAR retroviral vector-transduced autologous or donor-derived T cells on days 0,1, 2 in the absence of disease progression or unacceptable toxicity.
89369213|NCT03480841|Experimental|LENA with Feedback|Mothers who will run the Language ENhancement Assessment/intervention system with their young children, and will receive initial feedback from researchers on LENA output and how to enhance the language the home language environment.
89369214|NCT02440828|Experimental|tobramycin inhalation|twice daily tobramycin inhalation (Bramitob) 300 mg and standard intravenous antibiotics treatment
89369215|NCT02440828|Placebo Comparator|Placebo|twice daily placebo inhalation and standard intravenous antibiotics treatment
89369216|NCT02431390|Experimental|RAPAELⓇ Smart Glove group|The experimental group includes 40 stroke patients. The group will receive the conventional occupational therapy(30min per session, 5 times per week, during 4 weeks of hand dexterity training) and RAPAELⓇ Smart Glove digital treatment system training. RAPAELⓇ Smart Glove digital treatment training will consist of games and play to facilitate the function of upper limbs and brain plasticity. RAPAELⓇ Smart Glove group will be provided the 20 training session. (30min per session, 5 times per week, during 4 weeks)
89369217|NCT02431390|Active Comparator|Additional occupation therapy group|The active comparator group includes 40 stroke patients.The occupational therapy group will receive the conventional occupational therapy(30min per session, 5 times per week, during 4 weeks of hand dexterity training) sessions twice. Additional conventional occupational therapy sessions are comprised of the training for upper limb and cognition. The additional occupational therapy group will be provided the 20 additional session (30min per session, 5 times per week, during 4 weeks)
89369218|NCT02440282||Group A|patients undergo general anesthesia
89369219|NCT02440282||Group B|spinal anesthesia
88842012|NCT02885246||Influenza Virus Positive Group|The group included specimen samples with a laboratory confirmed diagnosis of influenza A and/or B, reported in the Instituto Conmemorativo Gorgas de Estudios de la Salud (ICGES) database of Panama, from January 2011 to December 2017.
88842013|NCT03802435|Experimental|Two-sessions of ultrasound-guided PIT|two-sessions of ultrasound-guided PIT with 10cc 5% dextrose (3 months interval)
89369220|NCT02440282||Group C|ultrasound-guided sciatic nerve block
89369221|NCT02440438|Experimental|Clostridium difficile infection|
89399192|NCT03692169||CSC patients|Half-dose photodynamic therapy was performed when a serous retinal detachment involving the macular fovea was present; The treatment field size was set as 3000 microns. This was achieved by administering 3mg/m² of Verteporfin intravenously over a period of 10 minutes. Fifteen minutes after commencing the verteporfin infusion the GLD was exposed to a 689 nm laser light with a florescence of 600 mw/cm² for 83 seconds and a total energy of 50 J/cm². OCTA (XR Optovue, Fremont, CA, USA) and spectral domain OCT (SD-OCT) were performed at baseline and each follow-up (one month and three months) visit after hd-PDT.
88842014|NCT03802435|Active Comparator|One-session of ultrasound-guided PIT|one-session of ultrasound-guided PIT with 10cc 5% dextrose and 10cc normal saline separately (3 months interval)
88842015|NCT03802435|Placebo Comparator|Two-session of ultrasound-guided nerve hydrodissection|two-sessions of ultrasound-guided PIT with nerve hydrodissection with 10cc normal saline (3 months interval).
88842016|NCT05008627||Doffing PPE with verbal instructions and monitor|The subject will remove the PPE according to verbal instructions by a monitor
88842017|NCT05008627||Doffing PPE without verbal instructions|The subject will remove the PPE independently without a monitor
88842018|NCT05005663|Active Comparator|group A|patients younger than 2 years
88842019|NCT05005663|Active Comparator|group B|patients older than 2 years
88842020|NCT00372853|Experimental|Arm A|
88842021|NCT00372853|Experimental|Arm B|
88842022|NCT02885636|Experimental|Inhaled albuterol|2.5 mg inhaled albuterol through a high efficiency nebulizer -single dose
88842023|NCT02885636|Placebo Comparator|Inhaled saline placebo|Inhaled saline through a high efficiency nebulizer -single dose
88842024|NCT03691129|Experimental|Yoga participant groups|Yoga participant groups will practice elderly yoga for four months. We will collect their blood before and after their participation in the elderly yoga program. There will be two subgroups which are Advanced group and Beginner group.
88842025|NCT03691129|No Intervention|Non-Yoga participant groups|Non-Yoga participant groups will not practice yoga for four months and will be used as the control. We will collect their blood before and after the elderly yoga program. There will be two subgroups which are Elderly group and Young group.
88842026|NCT03625921|Experimental|Powered device with physical therapy|Subjects will be fitted with a powered ankle-foot prosthesis (Ottobock emPOWER) and provided an intensive device-specific physical therapy (PT) intervention. The subjects will complete, on average, 8 PT training sessions lasting 30 - 45 minutes each. The subjects will also be provided with a home exercise program.
88842027|NCT03625921|Active Comparator|Powered device with standard of practice|Subjects will be fitted with a powered ankle-foot prosthesis (Ottobock emPOWER) and provided the current standard of practice training for use of this powered prosthesis. The prosthetist will confirm a stable and comfortable alignment and educate the subject on proper home usage. Next, the subject will undergo a 45 - 60 minute training with a physical therapist that is characteristic of the current standard of practice.
89369222|NCT02431546|Experimental|Mobile Health Application Group|"VIDA is a mobile technology that is well positioned to provide healthcare coaching. After completing the CR program, each participant will have access to the VIDA mobile phone platform for the 12-week intervention, and be instructed to download the app on his/her smart phone. VIDA will assign an individual professional health coach selected from a pool of well-trained and experienced health professionals-nutritionists, fitness trainers, nurses and health educators. Each coach will engage their patient in a productive and meaningful health mentorship on a daily basis. The coach and patient work as a team to successfully set goals and make small changes that add up to significant improvements in the patients' dietary choices, physical activity, medication management, as well as understanding of their health status.~Physical Activity: A goal of total number of steps to attain daily will be provided by the Duke study team to the patient and monitored using a Fitbit activity tracker."
89369223|NCT02431546|No Intervention|Usual Care Group|Participants randomized to the usual care control arm will follow standard care as ordered by their individual, treating physician. Participants in the UC control arm will not receive any specific lifestyle recommendations from study personnel. They may, however, receive any lifestyle recommendations deemed appropriate by their usual clinical care providers. All participants will be contacted by study personnel in order to schedule visits at baseline and 12-weeks for the outcome assessments.
89369224|NCT03191110||Colorectal cancer patients|
89369225|NCT02431312|Experimental|Group A: low dose, standard regimen|Participants received 3 or 4 doses of 0.3 mg INO-1800 delivered by EP in a standard regimen while continuing treatment with nucleos(t)ide analogue treatment.
89369226|NCT02431312|Experimental|Group A: mid dose, standard regimen|Participants received 3 or 4 doses of 2 mg INO-1800 delivered by EP in a standard regimen while continuing treatment with nucleos(t)ide analogue treatment.
89369227|NCT02431312|Experimental|Group A: high dose, standard regimen|Participants received 3 or 4 doses of 9 mg INO-1800 delivered by EP in a standard regimen while continuing treatment with nucleos(t)ide analogue treatment.
89369228|NCT02431312|Experimental|Group B: mid dose, standard regimen|Participants received 3 or 4 doses of 2 mg INO-1800 + 0.25 mg INO-9112 delivered by EP in a standard regimen while continuing treatment with nucleos(t)ide analogue treatment.
89369229|NCT02431312|Experimental|Group B: high dose, standard regimen|Participants received 3 or 4 doses of 9 mg INO-1800 + 0.25 mg INO-9112 delivered by EP in a standard regimen while continuing treatment with nucleos(t)ide analogue treatment.
89369230|NCT02431312|Active Comparator|Active Control: nucleos(t)ide analogue treatment|Participants continued treatment with nucleos(t)ide analogue treatment.
88842028|NCT00373087|Active Comparator|L-dopa + entacapone|L-dopa + entacapone
88842029|NCT00373087|Experimental|L dopa / placebo|L dopa / placebo
88842030|NCT02892110|Experimental|Varenicline|2 mg daily
88842031|NCT02892110|Placebo Comparator|Placebo|2 mg daily
88842032|NCT02778152|Experimental|Laser depilation|Laser depilation to the natal cleft (pilonidal region) monthly for 5 treatments with either an 810nm of Nd:YAG laser dependent on Fitzpatrick skin type and tolerability.
89369231|NCT03191344||with IPSS record/IPSS|the surgoen use the IPSS in all thyroidectomy
89369232|NCT03191344||Traditionaldescription Group/TD|the surgoen without the IPSS，use Traditional description
89369233|NCT02431156||monovision|Presbyopic patients that underwent mini-monovision correction with bilateral implantation of monofocal intraocular lenses. Their visual capacity in ADLs will be assessed.
88842033|NCT02778932||Intubation|General anesthesia including intubation and muscle relaxation
89369234|NCT02709538|Experimental|GSP 301 NS|
89369235|NCT02709538|Placebo Comparator|GSP 301 Placebo NS pH 3.7|
89369236|NCT02709538|Placebo Comparator|GSP 301 Placebo NS pH 7.0|
88842034|NCT02778932||Laryngeal Mask|General anesthesia including laryngeal mask without muscle relaxation
88842035|NCT02779166|Experimental|Intervention|Received 400mg celecoxib prior to surgery
88842036|NCT02779166|Placebo Comparator|Placebo|Received placebo pill prior to surgery
88842037|NCT03597607|Experimental|Intensive Smoking Cessation Group|This group will meet with a clinic pharmacist one on one over a period of about 12 weeks. They will have session ranging from 15 mins to 1 hour. Follow-up sessions will occur during quit week(week 1) and at weeks 2, 3, 4, 6, 8, 10, 12 and at 6 months.
89369237|NCT02431078||ZEB1 high-expression group|Participants with ZEB1 high-expression(ZEB1 expression values>the ZEB1 cut-off point) in CTCs for gastric cancer will be assigned to this group.The ZEB1 cut-off point was set at the top quartile.Routine comprehensive treatment will be performed.
89369238|NCT02431078||ZEB1 low-expression group|Participants with ZEB1 low-expression(ZEB1 expression values<the ZEB1 cut-off point) in CTCs for gastric cancer will be assigned to this group.The ZEB1 cut-off point was set at the top quartile.Routine comprehensive treatment will be performed.
89369239|NCT02435602|Active Comparator|NBI endoscopy|"GI endoscopy examination and additional the entire length of esophagus is evaluate with NBI endoscopy~Biopsy at the visually abnormal lesions~Pathologic examination of all biopsy tissue specimens~Advises of endoscopic/surgical or oncological treatment will be given to participants who will be diagnosed with ESCC or high grade dysplasia of the esophagus."
88842038|NCT03597607|Experimental|Abbreviated Smoking Cessation Group|This group will meet with a clinic pharmacist one on one over a period of about 12 weeks. They will have brief sessions (15-30 mins) at the end of week 1, week 4, week 12 and at 6 months.
88842039|NCT02898740|Experimental|Exercise|Structured exercise
88842040|NCT02898740|Active Comparator|Health Education|Health education
88842041|NCT02898974||Regular Medical Marijuana users|People with MS that are regular Medical Marijuana users
88842042|NCT02898974||Non Users of Medical Marijuana|People with MS that are non users of Medical Marijuana
88842043|NCT04400227|Experimental|Youth-Parent Dyads|Participants will receive the Family Talk intervention and followup.
88842044|NCT02901080|Experimental|Cranial electrotherapy stimulation|Alpha Stim AID cranial electrotherapy stimulation, Pregnancy test, Anxiety questionnaire, Quality of life questionnaire, Work and social questionnaire, Sleep questionnaire, Depression questionnaire, Quality of life and financial questionnaire
88842045|NCT04866589|Experimental|Distribution of free face masks|Face masks will be handed out for free to all customers entering the grocery stores.
88842046|NCT04866589|No Intervention|Control|Business as usual.
88842047|NCT04333550|Experimental|Experimental: Desferal addition to standard treatment|
88842048|NCT04333550|Experimental|Experimental: standard treatment|
88842049|NCT04737733|Other|The dementia friendly hospital program|The dementia-friendly hospital program comprised three parts; 1) Educational program for health practitioners to increase the staff's knowledge and awareness of patients with cognitive impairment and/or delirium; 2) Screening, for early identification of cognitive impairment and delirium, using the Four Assessment Test (4AT); 3) Delirium risk factor modification and management for patients defined with potential cognitive impairment and risk of delirium, implying that risk factor modifications should be implemented in the patient's care plan. For patients with suspected delirium, the program promoted an additional delirium management plan.
88842050|NCT04863625|Experimental|Experimental group|748 students from two secondary schools for the intervention group will be selected and participated in a peer led education process on substance use (smoking, drinking and chewing) prevention based on the Theory of Planned Behavior (TPB).
88842051|NCT04863625|No Intervention|Control group|748 students from two secondary schools for the control group will selected and receive t their school's regular curriculum.
88842052|NCT02827838|Experimental|Treatment (durvalumab, surgery)|Patients receive durvalumab IV over approximately 60 minutes on day 1. Treatment repeats every 2 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Within 3-17 days after last dose administration of durvalumab, patients undergo surgery. Patients may receive an additional dose of durvalumab if time to surgery is longer than 30 days.
88842053|NCT00373243|Experimental|Subjects receiving GW406381|Subjects will receive single oral dose of 20 milligram (mg) of GW406381.
88842054|NCT02758184|Experimental|ROTEM Group|Patients who are randomized to receive ROTEM
88842055|NCT02758184|Other|Control Group|Patients who are randomized not to receive ROTEM
88842056|NCT03099733|Experimental|concussion|patients who present to ED with concussion
88842057|NCT02915185|Experimental|strength training intervention|Strength training of the affected upper limb in chronic stroke survivors
88842058|NCT02915185|Experimental|direct-current brain stimulation (tDCS)|tDCS real of sham will be applied during each session of the strength training intervention
88842059|NCT02782364||Faecal Incontinence: fast-fill measurement first|Observational study where patients with faecal incontinence undergo two AAR measurements; one with the original step-wise technique and the second with the newer fast-fill technique. A further standard manometry measurement will be taken. 18 patients will undergo fast-fill measurement first.
88842060|NCT02782364||Faecal Incontinence: step-wise measurement first.|Observational study where patients with faecal incontinence undergo two AAR measurements; one with the original step-wise technique and the second with the newer fast-fill technique. A further standard manometry measurement will be taken. 18 patients will have step-wise measurement first.
88842061|NCT02909647|Active Comparator|Plan group|3D preoperative planning for the distal radius fracture was performed prior to the osteosynthesis.
89369240|NCT02435602|Active Comparator|lugol chromoendoscopy|"GI endoscopy examination and additional the entire length of esophagus is evaluate with Lugol chromoendoscopy~Biopsy at the unstained lesions >= 5 mm diameter~Pathologic examination of all biopsy tissue specimens~Advises of endoscopic/surgical or oncological treatment will be given to participants who will be diagnosed with ESCC or high grade dysplasia of the esophagus."
88842062|NCT02909647|Active Comparator|Control group|Conventional preoperative planning for the distal radius fracture was performed prior to the osteosynthesis.
88842063|NCT02902172|Other|Acetaminophen|Patients will be monitored for change in blood pressure
88842064|NCT02902172|Other|NSAID|Patients will be monitored during their postpartum stay (typical 2 days) and then again at 1 week and 6 weeks (standard practice of care) with blood pressure measurements
88842065|NCT02663102||Fluarix Tetra Group|Subjects aged 3 years and above who will receive Fluarix Tetra as per locally approved PI (which is not part of the drug use investigation).
88842066|NCT01221415||Interscalene Ultrasound|Subjects having orthopedic surgery requiring an interscalene peripheral nerve block and randomized to have the ultrasound used to locate the nerve.
88842067|NCT01221415||Interscalene Nerve Stimulator|Subjects having orthopedic surgery requiring an interscalene peripheral nerve block and randomized to have the nerve stimulator used to locate the nerve.
88842068|NCT01221415||Popliteal Ultrasound|Subjects having orthopedic surgery requiring an popliteal peripheral nerve block and randomized to have the ultrasound used to locate the nerve.
88842069|NCT01221415||Popliteal Nerve Stimulator|Subjects having orthopedic surgery requiring an popliteal peripheral nerve block and randomized to have the nerve stimulator used to locate the nerve.
88842070|NCT01221415||Femoral Ultrasound|Subjects having orthopedic surgery requiring an femoral peripheral nerve block and randomized to have the ultrasound used to locate the nerve.
88842071|NCT01221415||Femoral Nerve Stimulator|Subjects having orthopedic surgery requiring an femoral peripheral nerve block and randomized to have the nerve stimulator used to locate the nerve.
88842072|NCT02784548|Experimental|Virtual reality|Using a Virtual reality (VR) headset, motion sensors, and VR software, the investigators will create a customized VR treatment for each participant that engages them in movements and exercises involving their missing limb in a game-like environment. For example, participants may use the headset to engage in activities such as driving a race car around a course requiring both arms, ski down simulated slopes, or manipulate objects.
88842073|NCT02777749|Active Comparator|Adductor Canal Block|"15 cc's of 0.5% bupivacaine preoperatively administered by the regional pain anesthesia team in the pre-operative block area, just prior to surgery.~Adductor Canal Block (ACB)"
88842074|NCT02777749|Active Comparator|Periarticular SB|50 cc's of 0.25% bupivacaine will be injected intraoperatively, just prior to wound closure, by the performing surgeon.
89179945|NCT04115462|Active Comparator|Morphine|Each participant will receive a single dose of 20 mg morphine tablet. At estimated peak-plasma concentration testing is conducted. The subject and the assessor are both blinded to the drug administrations.
89179946|NCT04115462|Placebo Comparator|Placebo|Each participant will receive a single dose of an identical placebo tablet. At estimated peak-plasma concentration testing is conducted. The subject and the assessor are both blinded to the drug administrations.
89179947|NCT04026932|Placebo Comparator|Unmodified music group|34 participants in Group 1 will listen to the music without any modification for at least two hours a day in total.
89179948|NCT04026932|Experimental|Modified tinnitus relieving sound group|34 participants in Group 2 will listen to the music modified according to the matched dominant tinnitus pitch for at least two hours a day in total.
89179949|NCT02605460|Other|Unique|Patients will receive reduced Busulfan and Cyclophosphamide (BUCY) 2 conditioning regimen, consisting in the administration of two medications: Busulfan and Cyclophosphamide Plus: CXCR4 Antagonist. Then they will undergo a Hematopoietic Stem Cell Transplantation (Autologous or Allogeneic)
89179950|NCT04115930||Patient|Fatigue, cognition and quality of life measurements with different kind of tests and forms. EDSS and SFMC. Daily physical activity measurement 7days. Berg´s scale. Sit-Up 30 s and 6-minutes walking test. Length, weight and waist measurements.
89179951|NCT04115930||Control|Healthy volunteers. Fatigue, cognition and quality of life measurements with different kind of tests and forms. SFMC. Daily physical activity measurement 7days. Berg´s scale. Sit-Up 30 s and 6-minutes walking test. Length, weight and waist measurements.
89179952|NCT00797108|Experimental|1|Loading dose of IV sulopenem with switch to oral PF-03709270
89179953|NCT00797108|Experimental|2|IV sulopenem with switch to oral PF-03709270
89179954|NCT00797108|Active Comparator|3|IV ceftriaxone with switch to oral amoxicillin/clavulanate potassium comparator
89179955|NCT04112420|Other|Group A|200 Participants more than 60 yrs old having Trans-esophageal Echocardiography examination upon admission to ICU
89179956|NCT04112264|Experimental|Monopolar radiofrequency ablation|Patients will receive ultrasound-guided monopolar radiofrequency ablation
89179957|NCT04112264|Active Comparator|Bipolar radiofrequency ablation|Patients will receive ultrasound-guided bipolar radiofrequency ablation
89179958|NCT03244826|Experimental|Shared Care|"For the first 90 days, patients alternate between local oncologist and DFCI for weekly visits.~From 90 to 180 days, patients alternate between local and DFCI every 2-3 weeks.~Shared Care include the following~Formal Care Coordination Plan~Patient Engagement and Education~Local Oncologist Engagement and Education~Patient/Local Oncologist/Transplant Oncologist Web Portal"
89179959|NCT03244826|Other|Usual Care|"Patients receive all follow-up care at DFCI only, which is currently the Standard Care.~Majority of routine visits in first 180 days will be at DFCI."
89179960|NCT03244826|Other|Non-Randomized|Patients receive all follow-up care at DFCI only (Standard Care).
89179961|NCT02607098||Males diagnosed with male-factor infertility|This study will recruit a convenience sample of 10 men and their partners seeking consultation from a fertility urologist following the detection of male-factor infertility.
89179962|NCT02607098||Female partners|This study will recruit a convenience sample of 10 men and their partners seeking consultation from a fertility urologist following the detection of male-factor infertility.
89179963|NCT02607176|Experimental|Heweizhixie capsule|Heweizhixie capsule, 0.33g/#, 3 #, Tid, Oral
88842075|NCT02777749|Active Comparator|ACB + SB|"15 cc's of 0.5% bupivacaine preoperatively administered by the regional pain anesthesia team in the pre-operative block area, just prior to surgery.~50 cc's of 0.25% bupivacaine will be injected intraoperatively, just prior to wound closure, by the performing surgeon."
89179964|NCT04112108||mitral stenosis post percutaneous mitral commissurotomy(PTMC)|successful PTMC after follow up
89179965|NCT04111718|Experimental|Viewing of preparation|The patient will be in the room for the preparation of the PRP and will receive a description of the centrifuge process from the physician administering the injection.
89179966|NCT04111718|Sham Comparator|Blinded to preparation|The patient will leave the room after their blood is drawn and will not view the preparation of the PRP, and will also not receive a description of the centrifuge process.
89179967|NCT04111640|Experimental|Experimental group|A computer-supported cognitive training for the training of logical-executive and working-memory functions (CoRe software)
89179968|NCT04111640|Other|Control Group|Paper and pencil cognitive training (paper-and-pencil CoRe version)
89179969|NCT00915044||IBD patients|Approximately 40 patients (adults and children) suffering from IBD will be enrolled.
89179970|NCT00915044||Controls|Approximately 100 healthy controls
89179971|NCT04025996||Diseased Group|Patients with type 2 diabetic retinopathy and known cardiac dysfunction.
89179972|NCT00742560|Experimental|Elotuzumab 5 mg/kg + Lenalidomide and Dexamethasone (Phase 1)|Elotuzumab 5 mg/kg administered as an IV infusion in combination with lenalidomide 25 mg and dexamethasone 40 mg administered orally.
89179973|NCT00742560|Experimental|Elotuzumab 10 mg/kg + Lenalidomide and Dexamethasone (Phase 1)|Elotuzumab 10 mg/kg administered as an IV infusion in combination with lenalidomide 25 mg and dexamethasone 40 mg administered orally.
89179974|NCT00742560|Experimental|Elotuzumab 20 mg/kg + Lenalidomide and Dexamethasone (Phase 1)|Elotuzumab 20 mg/kg administered as an IV infusion in combination with lenalidomide 25 mg and dexamethasone 40 mg administered orally.
89369241|NCT03773952|Experimental|Oral 5-ASA + PBF-677 200 mg|Oral Mesalazine (5-ASA) (4g) + PBF-677 (200mg)
89369242|NCT03773952|Placebo Comparator|Oral 5-ASA + Placebo oral Capsules|Oral Mesalazine (5-ASA) (4g) + Placebo oral capsules
89369243|NCT02431000||Male Chemo/Radiotherapy Candidates|"Adult and post-pubertal males, 13 years of age or older, presenting to clinic because diagnosed with cancer, who wish to preserve their future fertility. Sperm and blood collected for analysis. If minors, parents or guardians have to give consent to the procedure while the boys give their assent.~This is a prospective observational cohort study."
89369244|NCT03191188|Experimental|Levothyroxine|
89369245|NCT03191188|Placebo Comparator|Placebo|
89369246|NCT02435446|Experimental|Eligible patients for cone-beam|A cone-beam computed tomography will be offered to the patients undergoing a CT scan for the diagnosis and/or the pre-operative assessment of an otosclerosis, fulfilling the inclusion criterias and without any exclusion criteria.
89369247|NCT03613662|Experimental|SP-102|SP-102
89369248|NCT01698294|Experimental|Group I (flaxseed)|"Participants receive flaxseed PO daily for 6 weeks. After a usual diet washout period of 8 weeks, patients crossover to Group II."
89369249|NCT01698294|Active Comparator|Group II (usual diet)|"Participants maintain a usual diet for 6 weeks. After a usual diet washout period of 8 weeks, patients crossover to Group I."
88842076|NCT02785172|Experimental|IDP-118 Lotion|Lotion
89179975|NCT00742560|Experimental|Elotuzumab 10 mg/kg + Lenalidomide and Dexamethasone (Phase 2)|Elotuzumab 10 mg/kg administered as an IV infusion in combination with lenalidomide 25 mg and dexamethasone 40 mg administered orally.
89179976|NCT00742560|Experimental|Elotuzumab 20 mg/kg + Lenalidomide and Dexamethasone (Phase 2)|Elotuzumab 20 mg/kg administered as an IV infusion in combination with lenalidomide 25 mg and dexamethasone 40 mg administered orally.
88842077|NCT02785172|Active Comparator|Ultravate Cream|Cream
89369250|NCT03191032|Experimental|Training Group|Early sensory re-education of the hand protocol with a sensor glove model, after a median and/or ulnar nerve injury repair
89369251|NCT03191032|No Intervention|Control Group|Conventional rehabilitation for peripheral nerve injuries if the hand, without application of any kind of early sensory re-education protocol
89369252|NCT03190876|No Intervention|Suction drain|Conventional body contouring procedure, application of Redon suction drains, drain removal when output is less than 30 ml in 24 hours or at the latest on postoperative day 7
89369253|NCT03190876|Active Comparator|Passive drain|Conventional body contouring procedure, application of drains without suction (passive drainage), drain removal when output is less than 30 ml in 24 hours or at the latest on postoperative day 7
89369254|NCT03190876|Active Comparator|No drain|Conventional body contouring procedure, no application of drains
89369255|NCT05160090|Active Comparator|Test- BUPROPION HCl MR TABLETS 300mg|Single dose of Test- BUPROPION HCl MR TABLETS 300mg
88842078|NCT02785172|Active Comparator|IDP-118 Vehicle Lotion|Lotion
88842079|NCT02785172|Active Comparator|IDP-118 Vehicle Cream|Cream
88842080|NCT02582125|Experimental|ONO-4538|ONO-4538 water-soluble injection, 100 mg/vial, 3 times once every 2 weeks in each 6-week cycle
88842081|NCT02906696|Experimental|Treatment (bosutinib)|Patients receive bosutinib PO daily on days 1-28. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
88842082|NCT02503657|Placebo Comparator|Double-Blind Treatment|"Subjects who complete all of the screening assessments and meet all inclusion/exclusion criteria will be started on MN-001 (tipelukast) 750 mg or matching placebo bid. Subjects will return to the clinic on Treatment Day 1 to receive their first dose of study medication. Subsequently, subjects will return to the clinic on a regular basis for 26 weeks.~During the Treatment Phase, safety and efficacy parameters will be assessed and concomitant medications will be documented. The safety and tolerability of MN-001 will be evaluated by an Independent Safety Monitor during this phase."
88842083|NCT02503657|Other|Open-Label Extension|Upon completion of the Double-blind Treatment Phase, subjects who were taking placebo, will participate in the open-label extension (OLE) phase for an additional 6 months. Subjects randomized to the MN-001 (tipelukast) group will continue the study drug for additional 6 months.
88875236|NCT02538042|Other|MCE- (Control)|Three weeks prior to the target quit date, participants will switch to smoking very low nicotine content cigarettes and wear a 21 mg/d nicotine patch. During the 3-week, pre-quit period, participants will undergo six, 60 minute sessions during which they will view nature environments and smoke their assigned cigarettes. Following the quit date, participants will quit smoking and wear the nicotine patch for 10 weeks.
89179977|NCT05637866||Soy Milk|Soy milk beverage
89369256|NCT05160090|Active Comparator|Reference-Elontril 300 mg|Elontril 300 mg (Bupropion HCl MR tablets 300mg)
89369257|NCT03190720|Experimental|Mobile Community First|Participants will be registered to a mobile community at first. After 6 weeks, They will leave the mobile community.
89369258|NCT03190720|Experimental|Mobile Community Later|Participants will not be registered to a mobile community at first. After 6 weeks, They will be registered to the mobile community.
89369259|NCT03538002|No Intervention|Conventional anti-reflection coated spectacle lens|Single vision lenses with correction of distant refraction and conventional anti-reflection coating
89369260|NCT03538002|Experimental|Blue-light filtering spectacle lenses|Single vision lenses with correction of distant refraction and blue-light filtering coating
89369261|NCT03692702|Experimental|WE PLAY|Teachers in this condition received the WE PLAY training.
89369262|NCT03692702|No Intervention|Control|Preschools in this condition received the same physical activity equipment that preschools in the WE PLAY condition received. Teachers were not provided with any specific instructions or information about physical activity.
89369263|NCT03117946|Experimental|Biological samples|"Blood samples will be collected at baseline, at J15/J20 after RTCT initiation, and then 1 month, 3 months and 12 months after the end of RTCT treatment, and at disease progression if applicable.~Tumor tissues will be collected if available."
89369264|NCT04516616|Experimental|Study group|Patients receive 1 cycle of cisplatin and albumin-bound paclitaxel combined neoadjuvant chemotherapy and subsequent 2 cycles of PD-1 antibody combined neoadjuvant chemotherapy.
89369265|NCT00511134|Experimental|Zyban + Lunesta|Zyban (150 mg qd x 7 days then 150 mg bid x 6 weeks) + Lunesta (3 mg qd x 6 weeks)
89369266|NCT00511134|Placebo Comparator|Zyban + Placebo|Zyban (150 mg qd x 7 days then 150 mg bid x 6 weeks) + placebo (1 pill per day x 6 weeks)
89369267|NCT02435056|No Intervention|Classic Approach|Patient fills in a paper diary in order to quantify parameters of MOH (days with headache, acute drugs consumed, etc.)
89369268|NCT02435056|Experimental|IEPR Approach|Patient has to use the electronic diary to record days with headache, acute drugs consumed, etc.
89369269|NCT02435134||Healthy participants|
89369270|NCT03634722|Experimental|The intervention group|the transcutaneous electrical nerve stimulation by PHENIX4-8-8 PLUS
89369271|NCT03634722|No Intervention|The observational group|routine nursing
89369272|NCT03118024|Active Comparator|Fluid restriction|Crystalloid fluid max. 2.0 ml/kg/h, no administration of colloids, noradrenaline max. 0.15 µg/kg/min
89369273|NCT03118024|Active Comparator|Catecholamine restriction|Noradrenaline max. 0.04 µg/kg/min, fluids max. 8.0 ml/kg/h
89369274|NCT01372956||Dyslipidemia|
89369275|NCT03634644|Active Comparator|Omega-3 fatty acid capsule|1g per capsule(EPA400mg，DHA320mg)
89369276|NCT03634644|Placebo Comparator|Placebo capsule|The placebo capsule has same appearance and packing with the Omega-3 fatty acid capsule
89369277|NCT05103228|Experimental|Lower gonadotropin dose stimulation|"Low-dose group:~150 IU follitropin alpha + 75 IU highly purified human menopausal gonadotropin (hpHMG)~10 mcg follitropin delta + 75 IU hpHMG"
89369278|NCT05103228|Experimental|Higher gonadotropin dose stimulation|"High-dose group:~225 IU follitropin alpha + 150 IU highly purified human menopausal gonadotropin (hpHMG)~15 mcg follitropin delta + 150 IU hpHMG"
89369279|NCT01372384|Experimental|Single Arm|
89369280|NCT03185416|No Intervention|Control group|The first prospective group -the control group- will consist of 30 patients receiving treatment by the Interventional Radiology team- along with their 30 primary caregivers. Neither the patient nor the caregiver will receive the palliative care training intervention. Patients and their caregivers will receive questionnaires regarding their health status (physical and psychosocial) and health services utilization at 1, 2, and 3 months post-procedure- during their follow-up visits.
89369281|NCT03185416|Experimental|Intervention Group|The second prospective component of the study -the intervention group- will include 30 patients receiving treatment by the Interventional Radiology team along with their primary caregiver. Patients and caregivers will receive a brief palliative care training intervention during their first follow-up visit. Patients and their caregivers will receive questionnaires to assess their health status (physical and psychosocial) and health services utilization outcomes at 1, 2, and 3 months post-procedure during their follow-up visits.
89369282|NCT03190798|Active Comparator|Canagliflozin Group|Assuming a 25% dropout rate, 16 individuals in the canagliflozin group
89369283|NCT03190798|Placebo Comparator|Placebo Group|Assuming a 25% dropout rate, 11 individuals in the placebo group
89369284|NCT03117478|Other|1. Participants without meditation experience|Novices. Note that there is no meditation intervention in this study but that the two groups differ in their lifetime meditation experience.
89369285|NCT03117478|Other|2. Participant with a significant meditation experience|Experts : > 5000 hours of practice during their life. Note that there is no meditation intervention in this study but that the two groups differ in their lifetime meditation experience.
89369286|NCT03117478|Other|3. Participants without meditation experience|Novices. There is no meditation intervention during the study but the investigators investigate the effects of meditation by comparing 2 groups who differ in their life time meditation experience (i.e., novices vs. experts).
89369287|NCT03117478|Other|4. Participant with a significant meditation experience|Experts : > 5000 hours of practice during their life. There is no meditation intervention during the study but the investigators investigate the effects of meditation by comparing 2 groups who differ in their life time meditation experience (i.e., novices vs. experts).
89369288|NCT03115476|Experimental|Ingenol disoxate gel 0.018%|
88842084|NCT02779543|Active Comparator|Fitbit|Subjects will be recruited from those patients attending a regularly scheduled overnight PSG sleep study at the Weill Cornell Medical College Center for Sleep Medicine. Willing subjects, after providing informed consent, will be fitted with one of the three aforementioned sleep monitoring devices (randomly assigned) on the wrist of their non dominant hand when prepared for the sleep study by a technician. Subjects willing to wear more than one sleep monitoring device may be fitted with two different sleep monitoring devices, e.g., a Fitbit and a Jawbone UP or a Fitbit and a Microsoft Band. Sleep monitoring device(s) will be removed from the subject's wrist in the morning at the conclusion of the sleep study.
89369289|NCT03115476|Experimental|Ingenol disoxate gel 0.037%|
89369290|NCT03115476|Placebo Comparator|Vehicle gel|
88842085|NCT02779543|Active Comparator|Jawbone UP|Subjects will be recruited from those patients attending a regularly scheduled overnight PSG sleep study at the Weill Cornell Medical College Center for Sleep Medicine. Willing subjects, after providing informed consent, will be fitted with one of the three aforementioned sleep monitoring devices (randomly assigned) on the wrist of their non dominant hand when prepared for the sleep study by a technician. Subjects willing to wear more than one sleep monitoring device may be fitted with two different sleep monitoring devices, e.g., a Fitbit and a Jawbone UP or a Fitbit and a Microsoft Band. Sleep monitoring device(s) will be removed from the subject's wrist in the morning at the conclusion of the sleep study.
89369291|NCT03117556|Experimental|BTS Intervention|Bilateral thoracoscopic splanchnicectomy and infusaport placement will be performed on patients randomly selected for treatment with BTS and narcotic analgesia. Narcotics will still be prescribed for pain as needed.
89369292|NCT03117556|No Intervention|No BTS Intervention|Patients chosen to be treated with narcotic analgesia alone will undergo infusaport placement only.
89369293|NCT02435290||patients with malignant cancer receiving chemotherapy|five hundred patients suffering malignant cancer from eight wards ( breast , GIT ,gynecological , genitourinary , lung , head and neck, lymphoma and myeloma ,skin and melanoma) ,receiving various chemotherapy protocols .
89369294|NCT02434978|Active Comparator|Supplementary doppler-guided endoscopic therapy|
89369295|NCT02434978|Placebo Comparator|control group|
89369296|NCT01371396|Other|Hispanic subjects|Subjects will identify as Hispanic ethnicity.
89534803|NCT03333161|Experimental|Higher TcCO2|"The investigators will evaluate the effects of attempts to increase blood carbon dioxide levels within a narrow range of 5 mm Hg (well within the range of usual clinical practice) in a cross-over manner for 24 hours at a time, over a 4-day period, and use Cardiorespiratory Monitoring to evaluate control of breathing.~The investigators will attempt to adjust PCO2 by 5 mm Hg higher from baseline (to max of 70 mm Hg), as long as pH is >7.2. The first 24 hours of the data collection will be the baseline data. Over the next 72 hours, the investigators will evaluate 3 interventions in a cross-over manner, with the initial intervention randomly assigned: Intervention 1 (24-48h of data; Increase TcCO2 by 5 mm Hg), Intervention 2 (48-72h; TcCO2 back to baseline), and Intervention 3 (72-96h; increase TcCO2 again by 5 mm Hg)."
88819286|NCT05449041||Cateract patients|Patients diagnosed with Cataract of both gender; passed the age of 18 years; without any other eye disease; suffering from other know serious disease but have a health situation in accordance with expectations related to the age.
88819287|NCT05449041||Cataract controlls|Gender- and age-matched controls to the Cataract patients, passed the age of 18 years without any eye diseases; not suffering from other know serious disease and have a health situation in accordance with expectations related to the age.
88819288|NCT00368901|Experimental|Single arm|Every other week dosing of Aranesp SC
88819289|NCT05430867|Experimental|Memantine monotherapy group|Memantine 20mg once-daily
88819290|NCT05430867|Experimental|GV-971 monotherapy group|GV-971 450mg twice a day
88819291|NCT05430867|Experimental|Memantine combined with GV-971 group|Memantine 20mg once-daily plus GV-971 450mg twice a day
88819292|NCT05448885|Experimental|Experimental: GP combined with Tislelizumab neoadjuvant therapy+CCRT+Tislelizumab adjuvant therapy|Patients receive neoadjuvant therapy with gemcitabine(1000mg per square meter on day 1,8) , cisplatin (25mg per square meter on day 1-3) and tislelizumab(200mg) every three weeks for 2 cycles before radiotherapy, then followed by concurrent IMRT and cisplatin (100mg per square meter) concurrent every three weeks during radiotherapy ,then followed by adjuvant therapy with tislelizumab(200mg) every three weeks for 13 cycles after radiotherapy
88819293|NCT01547000|Placebo Comparator|Inactive placebo|
88819294|NCT01547000|Experimental|Extended-release Guanfacine|
88819295|NCT02980016|Active Comparator|3HP (rifapentine + isoniazid)|Once weekly rifapentine (at a dose of 900 mg) plus isoniazid (at a dose of 900 mg), (with adjustment for participants weighing ≤50 kg) given for 12 weeks in Study Year 1
88819296|NCT02980016|Active Comparator|p3HP (rifapentine + isoniazid)|Once weekly rifapentine (at a dose of 900 mg) plus isoniazid (at a dose of 900 mg), (with adjustment for participants weighing ≤50 kg) given for 12 weeks in Study Years 1 and 2
88819297|NCT02980016|Active Comparator|6H|Daily self-administered isoniazid (at a dose of 300 mg/daily) (with adjustment for participants weighing ≤24 kg) given for 26 weeks (6 months) in Study Year 1
88819298|NCT05448417|Experimental|non-invasive high-frequency oscillatory ventilation|Patients were titrated for relevant parameters of noninvasive ventilation the day before the trial. In the non-invasive high-frequency oscillation ventilation mode, the support pressure is consistent with the noninvasive bi-level positive pressure mode, and the highfrequency airway pressure oscillation driven by the solenoid valve is added during the expiratory phase. The amplitude is about 4cmH2O, and the oscillation frequency is about 8HZ.
88819299|NCT05448417|Active Comparator|Bilevel positive pressure ventilation|Bilevel positive pressure ventilation Patients were titrated for relevant parameters of non-invasive ventilation the day before the trial. Noninvasive bilevel positive pressure ventilation mode pressure titration follows previous studies.
88819300|NCT05420649|No Intervention|Intubated general anesthesia LMS|Patients received LMS with intubated general anesthesia
88819301|NCT05420649|Experimental|Non-intubated LMS with apnea|Patients received non-intubated LMS with administration of muscle relaxant and optiflow(HFNO) device.
88819302|NCT05420649|Experimental|Non-intubated LMS with spontaneous breathing|Patients received non-intubated LMS optiflow(HFNO) device and maintained spontaneous breathing.
88819303|NCT01493180|Experimental|OPC-12759 ophthalmic suspension|OPC-12759 ophthalmic suspension
88819304|NCT01493180|Active Comparator|Sodium hyaluronate ophthalmic solution|Sodium hyaluronate ophthalmic solution
88819305|NCT01431014|Active Comparator|"Dexamethasonelow-dose"|5mg
88819306|NCT01431014|Experimental|"Dexamethasonehigh-dose"|15mg
88819307|NCT01431170|Experimental|Besivance Treatment Group|Besivance™ ophthalmic suspension, 0.6%
88819308|NCT01431170|Active Comparator|Polytrim Treatment Group|Polytrim ophthalmic solution
88819309|NCT05448183|Experimental|Toripalimab combined withTACE|
88819310|NCT04732455|Placebo Comparator|Group Control (C)|20 adult breast cancer patients on Taxane chemo protocol will receive 200 ml normal saline over forty minutes pre each chemotherapy session until end of the cycle.
88819311|NCT04732455|Experimental|Group lidocaine infusion (L)|20 adult breast cancer patients on Taxane chemo protocol will receive lidocaine i.v infusion (2 mg/kg) in 200ml saline over forty minutes with a maximum upper limit of 200 mg pre each chemotherapy session until end of the cycle. If any selected patient reported neuropathic pain (DN4 > 4) during the course of chemotherapy lidocaine (2 mg/kg) re-infused after each session. If lidocaine side effects such as circumoral numbness, twitches, metal test, tachy or bradycardia recorded at any time, lidocaine infusion will be reduced to 1mg/kg, if side effects persist, the patients will be managed accordingly as well as lidocaine infusion will be stopped and patient will be excluded from the study.
88819312|NCT04732455|Experimental|Group duloxetine (D)|20 adult breast cancer patients on chemotherapy will take oral duloxetine tablet 30 mg once per day starting from the night pre chemotherapy session until the end of cycle. If any selected patient reported neuropathic pain (DN4 > 4) during the course of chemotherapy the duloxetine dose will be adjusted to 60 mg daily till the end of the cycle. They also will receive 200 ml normal saline over forty minutes before each chemotherapy session until end of the cycle.
88819313|NCT04306965|Experimental|Apremilast|Apremilast will be administered to patients as 30 mg oral tablets taken twice daily for 24 weeks. An initial 5-day titration will be implemented to improve tolerability.
88819314|NCT02371746|Experimental|Cohort 1|ENV515-1 and ENV515-3 implants in Study Eye for 28 days
88819315|NCT02371746|Experimental|Cohort 2|Two ENV515-3 implants in Study Eye for 12 months with optional 6 month and 3 month extensions (total of 21 months)
89179978|NCT00740220||A|Each subject will be their own control. Each subject will perform three 6MWTs. Intra-subject reproducibility is being tested.
89179979|NCT00796718|Experimental|Capecitabine|Capecitabine orally twice daily plus standard radiotherapy for 5 weeks, followed by surgery within 6 weeks after completion of treatment.
89179980|NCT00809159|Experimental|Part 1 - AIN457A 10 mg/kg|AIN457A 10.0 mg/kg was administered intravenously as a single dose.
89179981|NCT00809159|Placebo Comparator|Part 1 - Placebo|Placebo to AIN457A was administered intravenously as a single dose
89179982|NCT00809159|Experimental|Parts 1 and 2 - AIN457A 1.0 mg/kg|AIN457A 1.0 mg/kg was administered intravenously as 2 doses 21 days apart, i.e. the first dose on day 1 and the second dose on day 22.
89179983|NCT00809159|Experimental|Part 1 and 2 - AIN457 0.1 mg/kg|AIN457A 0.1 mg/kg was administered intravenously as 2 doses 21 days apart, i.e. the first dose on day 1 and the second dose on day 22.
89179984|NCT00809159|Experimental|Part 1 and 2 - AIN457 10 mg/kg|AIN457A 10.0 mg/kg was administered intravenously as 2 doses 21 days apart, i.e. the first dose on day 1 and the second dose on day 22.
89179985|NCT02596386||potassium level in saliva|Each willing participant will undergo Sialometry
89179986|NCT02596386||blood test|blood will be drawn from the dialysis connections for Biochemistry for potassium level evaluation
89179987|NCT04111796|Experimental|group in nature|they participate in nature based-program during work hours
89179988|NCT04111796|No Intervention|control group|they participate don't in nature based-program during work hours and perform their normal work schedule
89179989|NCT00745368|Experimental|Raltegravir|Raltegravir 400 mg tablets twice daily
89179990|NCT04111562|Other|polymethyl methacrylate Cranioplasty|The Cranioplastic kit used (Teknimed, Biomaterials Innovation, Gentafix 1 ®, France) a biocompatible material that is composed of powder and liquid form of polymethyl methacrylate.
89179991|NCT04025840|No Intervention|Control|Patients in this group receive general anesthesia, without epidural block and perioperative dexamethasone. Patient-controlled intravenous analgesia is provided after surgery.
89179992|NCT04025840|Experimental|Epidural block|Patients in this group receive combined epidural-general anesthesia (0.375% ropivacaine for epidural block), without perioperative dexamethasone. Patient-controlled epidural analgesia is provided after surgery.
89179993|NCT04025840|Experimental|Dexamethasone|Patients in this group receive dexamethasone (10 mg) before anesthesia induction and general anesthesia, without epidural block. Patient-controlled intravenous analgesia is provided after surgery.
89179994|NCT04025840|Experimental|Epidural block+Dexamethasone|Patients this group receive dexamethasone (10 mg) before anesthesia induction and combined epidural-general anesthesia (0.375% ropivacaine for epidural block). Patient-controlled epidural analgesia is provided after surgery.
89369297|NCT01371396|Other|African American subjects|Subjects will self-identify as African American in origin.
89399193|NCT03624309|Experimental|Anlotinib Plus Docetaxel|Anlotinib (12mg QD PO d1-14, 21 days per cycle) and Docetaxel (75mg/m2 IV d1)
89399194|NCT03624309|Active Comparator|Docetaxel|Docetaxel (75mg/m2 IV d1)
88819316|NCT02371746|Experimental|Cohort 3|One or two ENV515-3-2 implants in Study Eye with optional 6 months and additional 6 month extension (total of 24 months)
88819317|NCT01431794|Experimental|Phase I-Gem,nab-paclitaxel,LDE225-600mg|Four cycles of Gemcitabine (gem) 1000 mg/m2 and nab-Paclitaxel 125 mg/ m2 on days 1, 8, and 15 every 28 days cycle in combination with escalating doses of oral LDE225 (Sonidegib), 600 mg daily.
88819318|NCT01431794|Active Comparator|Phase II-Arm A:Gem,nab-paclitaxel,LDE225|Four cycles of gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/m2 on days 1, 8 and 15 in combination with LDE-225 at the recommended phase 2 dose. Cycles repeated every 28 days.
88819319|NCT01431794|Active Comparator|Phase II-Arm B:Gem,nab-paclitaxel|Four cycles of gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/m2 on days 1, 8 and 15. Cycles repeated every 28 days.
88819320|NCT01431794|Experimental|Phase I-Gem,nab-paclitaxel,LDE225-400mg|Four cycles of Gemcitabine (gem) 1000 mg/m2 and nab-Paclitaxel 125 mg/ m2 on days 1, 8, and 15 every 28 days cycle in combination with escalating doses of oral LDE225 (Sonidegib), 400 mg daily.
88819321|NCT01431794|Experimental|Phase I-Gem,nab-paclitaxel,LDE225-800mg|Four cycles of Gemcitabine (gem) 1000 mg/m2 and nab-Paclitaxel 125 mg/ m2 on days 1, 8, and 15 every 28 days cycle in combination with escalating doses of oral LDE225 (Sonidegib), 800 mg daily.
88819322|NCT01549340||Participants with Allergic Rhinitis (AR)|Patients in a private allergy practice who were diagnosed with AR, with or without asthma, and advised to consider AIT between January 2005 and June 2011 and whose medical records were retrospectively reviewed.
88819323|NCT04253613||periodontal therapy|Systemically healthy subjects with periodontitis that have the sides treated with non-surgical periodontal treatment (NSPT) split-mouth designed study
88819324|NCT04253613||periodontal+laser therapy|Systemically healthy subjects with periodontitis that have the contra-lateral sides treated with laser biostimulation therapy(LBT) adjunct to non-surgical periodontal treatment(NSPT) split-mouth designed study
88819325|NCT04253613||diabetic periodontal therapy|Type 2 diabetic(DM2) subjects with periodontitis that have the sides treated with non-surgical periodontal treatment (NSPT) split-mouth designed study
88819326|NCT04253613||diabetic periodontal+laser therapy|Type 2 diabetic(DM2) subjects with periodontitis that have the contra-lateral sides treated with laser biostimulation therapy(LBT) adjunct to non-surgical periodontal treatment (NSPT) split-mouth designed study
88819327|NCT02421666|Experimental|behavioral PNMI|eligible patients received patient navigator led plus mobile phone text messaging intervention(PNMI) or standard care.
88819328|NCT02421666|No Intervention|control|eligible chronic HBV patients received standard care
88819329|NCT04204005|Active Comparator|Probiotics|Composition: 5x109 of Bifidobacterium longum (mix DLBL), 1x109 Lactobacillus reuteri LRE02 (DSM 23878) and maltodextrin (total 2 grams)
88819330|NCT04204005|Placebo Comparator|Placebo|Composition: maltodextrin (2 grams)
88819331|NCT01497860|Experimental|Vinorelbine|IV Vinorelbine (6mg/m2) provided once a week for 6 weeks followed by a 2 week rest (6 of every 8 weeks) for one year. Progression free survival will be monitored for 60 months.
88842086|NCT02779543|Active Comparator|Microsoft Band|Subjects will be recruited from those patients attending a regularly scheduled overnight PSG sleep study at the Weill Cornell Medical College Center for Sleep Medicine. Willing subjects, after providing informed consent, will be fitted with one of the three aforementioned sleep monitoring devices (randomly assigned) on the wrist of their non dominant hand when prepared for the sleep study by a technician. Subjects willing to wear more than one sleep monitoring device may be fitted with two different sleep monitoring devices, e.g., a Fitbit and a Jawbone UP or a Fitbit and a Microsoft Band. Sleep monitoring device(s) will be removed from the subject's wrist in the morning at the conclusion of the sleep study.
88842087|NCT02785406|Experimental|suvorexant|Subjects will receive suvorexant (10 mg week 1, 20 mg week 2), once daily at 10 PM.
89179995|NCT00589472|Experimental|Treatment (Antihormone therapy and enzyme inhibitor therapy)|Patients receive bicalutamide PO QD for 1 month and leuprolide acetate IM or goserelin acetate SC once a month until surgery. Patients also receive vorinostat PO QD beginning on the first day of androgen depletion therapy and continuing for up to 8 weeks or until the day of surgery. Patients then undergo an open or laparoscopic radical prostatectomy. Patients with positive surgical margins undergo immediate adjuvant external beam radiotherapy to the prostatic fossa, based on the judgment of the treating physician.
89179996|NCT00811577|Experimental|AZX100-placebo|Three trocar sites designated as anterior, lateral and posterior were randomized on each patient to receive one low dose of AZX100 3 mg/linear cm, one high dose of AZX100 10 mg/linear cm, or placebo (saline).
89179997|NCT00811577|Placebo Comparator|Placebo-only|Three trocar sites on each patient received one dose of placebo (saline).
89179998|NCT02607020|Experimental|Physical exercise|
89179999|NCT02607020|Active Comparator|Relaxation|
89180000|NCT00914342||Upper-GI symptoms in primary-care patients|
89180001|NCT02608931|Experimental|Dranabinol Capsules|The initial dose will be 2.5 mg BID (5 mg/day), and the maximum dose will be 10 mg TID (30 mg/day).
89180002|NCT02608931|Placebo Comparator|Placebo Capsules|placebo
89180003|NCT00744978|Experimental|Varenicline|
89180004|NCT00744978|Placebo Comparator|Placebo|
89180005|NCT02608775|Experimental|Metrodoloris Medical System|Application of a skin electrode
89180006|NCT02608775|Active Comparator|Aisys® care station, Acertys|SPI calculated from photoplethysmography
89180007|NCT05326217|No Intervention|Control Group|non-dysmenorrhea population with original lifestyle
89180008|NCT05326217|No Intervention|Dysmenorrhea|dysmenorrhea population without exercise intervention
89180009|NCT05326217|Experimental|Dysmenorrhea+Aerobic Exercise|dysmenorrhea population with aerobic exercise intervention
89180010|NCT05326217|Experimental|Dysmenorrhea+Resistant Exercise|dysmenorrhea population with resistant exercise intervention
89180011|NCT02610101|Active Comparator|Traditional SCD Diet|7 subjects will be randomized to a traditional SCD diet
89180012|NCT02610101|Active Comparator|Modified SCD Diet|"7 subjects will be randomized to a modified SCD diet, which includes oatmeal and rice"
89180013|NCT02610101|Active Comparator|Whole Foods Diet|"7 subjects will be randomized to a Whole foods diet without added sugars"
89180014|NCT04089618|Experimental|Baseline 10 Days|10 days baseline before intervention starts.
89180015|NCT04089618|Experimental|Baseline 17 Days|17 days baseline before intervention starts.
89180016|NCT04089618|Experimental|Baseline 24 Days|24 days baseline before intervention starts.
89180017|NCT02595606|Experimental|treatment group|treatment with 0.3% Sodium Hyaluronate, by five times a day, one or two drop each time
89180018|NCT02595606|No Intervention|control group|without treatment
88842088|NCT02785406|Placebo Comparator|Placebo|Subjects will receive placebo once daily at 10 PM.
88842089|NCT02062489|Active Comparator|Tamoxifen|20mg(2#)/day, PO, daily, five years
88842090|NCT02062489|Placebo Comparator|Placebo|2#/day, PO, daily, five years
88842091|NCT02367482||NovoTTF|NovoTTF treatment will be administered as usual during the imaging study either in monotherapy or in combination with other treatments (initiated prior to NovoTTF therapy). The treatment plan or intervention will not be altered in any way. Two AMT-PET scans will be added to the management scheme: a baseline PET shortly before and a follow-up PET scan 2-3 months after the start of NovoTTF treatment.
89180019|NCT05755685|Experimental|Group1|The preoperative clinical stage was M1c colon or peritoneal retroflex superior rectum adenocarcinoma
89180020|NCT04088838||Patients undergoing abdominal surgery|All adult patients undergoing elective abdominal surgery are eligible. Abdominal surgery includes each operation in which the peritoneal cavity is openen, i.e. laparotomy or laparoscopy.
89180021|NCT02609945|Experimental|CVT-427 (zolmitriptan inhalation powder)|"Periods 1-2: Subjects will receive Zomig oral tablet in Period 1 and Zomig nasal spray in Period 2, 1 hour apart.~Periods 3-6: Subjects will receive CVT-427 (dose levels (DL) 1, 2, 3 and 4), administered in ascending order provided that safety and tolerability data are observed to be adequate to allow dose escalation, approximately 24 hours after preceding DL."
89180022|NCT00739908|Experimental|CX157 (TriRima)|
89180023|NCT00739908|Placebo Comparator|Placebo|
89180024|NCT04578431|Experimental|Intervention groups|The participants will be given a beverage containing four artificial sweeteners (intervention) at baseline
89180025|NCT02596308|Experimental|15µg vaccine|15µg plague vaccine of 1.0ml in 120 adults aged 18-55 years old at day 0 and 28.
89180026|NCT02596308|Experimental|30µg vaccine|30µg plague vaccine of 1.0ml in 120 adults aged 18-55 years old at day 0 and 28.
89180027|NCT02609165|Active Comparator|study group|rhNGF 180 µg/ml eye drops solution
89180028|NCT02609165|Placebo Comparator|control group|vehicle eye drops solution
89180029|NCT00739596|Experimental|Aliskiren Hydrochlorothiazide (HCTZ)|
89180030|NCT00739596|Active Comparator|Amlodipine|
89180031|NCT05754905||Normal hip joint|The normal side of patients with hip joint disease
89180032|NCT05754905||Abnormal hip joint|The abnormal side of patients with hip joint disease
89369298|NCT03696290|Active Comparator|Aztreonam lysine, 3 doses per day|3 doses per day of nebulised Aztreonam lysine (75 mg) for 1 month, followed by 1 month off treatment. The month on, month off regimen will be repeated for a total peroid of 12 months.
89399195|NCT03624387|No Intervention|Control Group( No Painting Sessions)|No Geriatric Inclusive Art session.
89369299|NCT03696290|Placebo Comparator|Placebo, 3 doses per day|3 doses per day of nebulised placebo (5 mg lactose monohydrate) for 1 month, followed by 1 month off treatment. The month on, month off regimen will be repeated for a total peroid of 12 months.
89369300|NCT03696290|Active Comparator|Aztreonam lysine, 2 doses per day|2 doses per day of nebulised Aztreonam lysine (75 mg) for 1 month, followed by 1 month off treatment. The month on, month off regimen will be repeated for a total peroid of 12 months.
89369301|NCT03696290|Placebo Comparator|Placebo, 2 doses per day|2 doses per day of nebulised placebo (5 mg lactose monohydrate) for 1 month, followed by 1 month off treatment. The month on, month off regimen will be repeated for a total peroid of 12 months.
89369302|NCT03633942||Observational: LMA Supreme|"An appropriately sized LMA Supreme will be prepared by removing all air from the cuff while applying manual pressure. A water soluble non-local anesthetic containing lubricant gel will be applied to the fully deflated airway before insertion. A 1 cm column of the gel will be preloaded into the gastric port of the LMA Supreme for the Gel Test.~The cuff will be inflated with a manometer to a pressure of approximately 30cm H2O. If a significant leak is detected, the cuff will be inflated in increments of 5cm H2O until a satisfactory seal is obtained. The final cuff pressure will be recorded. The lungs will then be gently inflated by applying manual pressure to the anesthesia circuit bag while observing the gel column in the LMA Supreme gastric port for movement."
89369303|NCT02434666|Experimental|CPC-201|
89369304|NCT03696212|Experimental|grapiprant and pembrolizumab combination|Participants will be treated with grapiprant in combination with pembrolizumab.
89369305|NCT05048160|Experimental|6MW3211|"Dosage form: injection~Specification: 240 mg / 8 ml/Vial"
89369306|NCT03803280||Traditional care|Patients with major abdominal surgery without before a enhanced recovery program was stablished
89369307|NCT03803280||ERAS care|Patients with major abdominal surgery within a enhanced recovery program was stablished
89369308|NCT03692624|Experimental|Intervention Group|Biofeedback. Participants receiving the HRV-B intervention will complete a baseline assessment, a minimum of 4 weeks and up to 6 weekly training sessions (until the criterion of HRV coherence is met), and a final appointment (3-7 days later) where post-training HRV and symptom inventories will be recorded.
89369309|NCT03692624|No Intervention|Control Group|To control for the laboratory environment or other potential placebo effects, a control group will receive their usual follow-up care for their cancer diagnosis and will complete baseline and post-baseline outcome assessments without any HRV-B training.
89369310|NCT02434510||Sterile Water bath|Standard of Care group using a sterile water instrument bath
89369311|NCT02434510||CHG group|Study group using the 0.05% CHG solution in the instrument bath
89369312|NCT02430922|Experimental|iVolution stent|Patient's treated with the iVolution stent from iVascular for the treatment of femoropopliteal lesions.
89369313|NCT03692546|Experimental|Liposomal Bupivacaine (LB)|Administration of 20 ml of LB diluted with an additional 40 ml of saline was injected into a triangular soft tissue surgical field block, along with standard bupivacaine interscalene block
89369314|NCT03692546|No Intervention|Interscalene Block Alone (ISB)|Administration of 20mL of 0.5% standard bupivacaine interscalene block with no additional soft tissue surgical field block
89369315|NCT03248388|Experimental|Adults with Retinitis Pigmentosa using ARGUS II|Subjects will use the ORCAM system mounted onto the Argus II eyeglasses.
89369316|NCT02434588|Experimental|Bhattacharjee ring|
89369317|NCT03480763|Experimental|V114|Participants will receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2)
89369318|NCT03480763|Active Comparator|Prevnar 13™|Participants will receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2)
89369319|NCT02434432|Experimental|condition 1|Infants in this arm will receive their mother's choice of music recorded on an Mp player and delivered via headphones.
89369320|NCT02434432|Active Comparator|condition 2|Infants in this arm wil receive a recorded Lullaby music delivered to the infant via headphones.
89369321|NCT02434432|No Intervention|Condition 3|Infants in this arm will have the headphones applied but no music played.
89369322|NCT04223804|Placebo Comparator|Stage 1: Arm A|Participants will receive placebo.
89369323|NCT04223804|Experimental|Stage 1: Arm B|Participants will receive ABBV-181 dose A.
89369324|NCT04223804|Experimental|Stage 1: Arm C|Participants will receive ABBV-181 dose B.
89369325|NCT04223804|Placebo Comparator|Stage 2: Arm D|Participants will receive Placebo.
89369326|NCT04223804|Experimental|Stage 2: Arm E|Participants will receive ABBV-181 dose C.
89369327|NCT02434822|Experimental|Study Group 1|Participants aged 1 through 4 years at enrollment
89369328|NCT02434822|Experimental|Study Group 2|Participants aged 5 through 14 years at enrollment
89369329|NCT02434822|Experimental|Study Group 3|Participants aged 15 years and above at enrollment
89369330|NCT03692390|Experimental|Virtual Reality|Participants are distracted by wearing the virtual reality headset and watching a roller coaster app while undergoing procedural sedation
89369331|NCT03692390|No Intervention|Standard-of-Care|Participants are distracted with Standard-of-Care by doctors, nurses, nurse practitioners, child life specialists and/or parents.
89369332|NCT02430766|Experimental|IRE Group|irreversible electroporation for Unresectable Lymph Node Metastase
89369333|NCT02430766|No Intervention|Control|The patients without treatment
89369334|NCT03700502||patients with painful diabetic neuropathy|
89369335|NCT03700502||diabetics with non-pain neuropathy|
89369336|NCT03700502||gender and age matched healthy controls|
89369337|NCT03123120|Experimental|Spesolimab|1200 milligrams (mg) of Spesolimab (BI 655130) were administered every 4 weeks (q4w) via intravenous infusion over 12 weeks of treatment (3 injections of Spesolimab 1200 mg in total during the 12 weeks: at Week 0, 4, and 8 respectively).
89369338|NCT03123120|Placebo Comparator|Placebo|Matching placebo was administered via intravenous infusion over 12 weeks of treatment.
89369339|NCT03692234|Placebo Comparator|placebo|placebo capsules containing lactose - oral once weekly administration for six month
89369340|NCT03692234|Active Comparator|homoarginine|125 mg L-homoarginine supplement - oral once weekly administration for six month
89369341|NCT02430688|Experimental|IRE Group|irreversible electroporation for Unresectable Extremities Neoplasms
88842092|NCT02786810|Other|Contrast|All subjects will be recruited into this arm. All subjects will receive 0.03 ml/kg IV sulfur hexafluoride type-a lipid microspheres one time, unless a second, adjusted dose is necessary.
89180033|NCT04549493|Active Comparator|Trauma Management Therapy|1. Trauma Management Therapy (TMT; Turner, Beidel, & Frueh, 2005): TMT is a multicomponent behavioral treatment program designed to target various aspects of chronic PTSD - reducing emotional and physiological reactivity to traumatic cues, reducing intrusive symptoms and avoidance behavior, improving interpersonal skills and emotion modulation (e.g., anger control), and increasing the range of enjoyable social activities. In this investigation and in line with our previous publications, TMT will include virtual-reality augmented exposure (i.e. olfactory stimulation, heart rate, and skin conductance); group therapy to address sleep, anger, depression, and social isolation; homework assignments; and programmed practice. In the 3-week treatment program, each participant receives virtual-reality assisted exposure in the morning followed by in vivo exposure and group therapy (SER) each afternoon for a total of 29 sessions.
89180034|NCT04549493|Active Comparator|Prolonged Exposure|2. Standard Prolonged Exposure (PE; Foa, Hembree, & Rothbaum, 2007) consists of psychoeducation, imaginal exposure to trauma memories, in vivo exposure to situations that are avoided due to their association with the trauma, and emotional processing. The standard protocol consists of 12 imaginal exposure sessions, along with in vivo exposure/homework assignments and listening to a recording of the imaginal sessions at home during the evening.
89180035|NCT04549493|Active Comparator|Compressed Prolonged Exposure|3. Compressed PE consists of 10 standard PE sessions delivered on consecutive work days. The imaginal exposure sessions take place in the morning, with in vivo exposures assigned (not therapist accompanied) for the afternoons. Patients are instructed to listen to the recordings of the imaginal exposure each night. Being most concerned with having enough time for in vivo practice, Session 1 does not start on a Monday, allowing for two full weekends in order to maximize in vivo exposures. Both versions of PE average 36 total treatment hours.
89180036|NCT00742326|Experimental|Pioglitazone|pioglitazone 45 mg daily for 48 weeks
89180037|NCT00742326|Placebo Comparator|Placebo|one capsule daily for 48 weeks
89180038|NCT05757089|Experimental|ALCOFILTRUM|"ALCOFILTRUM, 4 tablets in a single dose, 30 minutes prior to consumption of alcohol.~Ingredients per tablet:~Lignin hydrolyzed 800 mg; Glycine 150 mg; Dihydromyricetin 30 mg; Vitamin B1 30 mg."
89180039|NCT05757089|No Intervention|Control|
89180040|NCT05755607|Other|laparoscopic pancreaticoduodenectomy group|The laparoscopic group will perform the surgical procedure using laparoscopic instruments, with three surgeons involved throughout the procedure.
89180041|NCT05755607|Other|Robot Pancreaticoduodenectomy|The robotic team will perform the surgery using the latest generation Da Vinci robotic surgical system, with an additional surgeon assisting in the procedure.
89180042|NCT04234919||Consented adult lung transplant recipients|
89180043|NCT00741936|Experimental|MaZiRenWan (MZRW)|MZRW granule, 7.5g/sachet
89180044|NCT00741936|Placebo Comparator|Placebo|Placebo granule, 7.5g/sachet
89180045|NCT05754749|Experimental|Contrast-enhanced digital breast tomosynthesis (CE-DBT)|Participants with known breast lesions will be imaged using contrast-enhanced digital breast tomosynthesis (CE-DBT) with Iohexol 350 mg I/mL.
89180046|NCT02608853||Liraglutide-like Cohort|
89180047|NCT02608853||LEADER™-like Cohort|
89369342|NCT02430688|No Intervention|Control|The patients without treatment
89369343|NCT03185338|Experimental|Active commuting to/from school|This intervention will be focused on children and their families following the ecological model proposed by Sallis et al., targeting mainly individual factors such as children's perceptions (safety perception on the way to school) and attitudes (independence or motivation to walk). A total of six 1-hour activities will be conducted at the classroom and two activities in the school neighborhood designed based on previous literature. Taken together, these activities will emphasize the benefits of active commuting to/from school and promote active commuting to/from school.Moreover, supporting information will be sent to families on four occasions during the intervention to encourage families to use active modes of commuting to/from school.
89180048|NCT02597868|Active Comparator|Capecitabine|Capecitabine 1250mg per BSA by mouth twice per day for 14 days, per 21 days as a cycle, until disease progress or toxicity can not be tolerated.
89180049|NCT02597868|Experimental|endocrine therapy|endocrine therapy is be gived as a sequential treatment in Metastatic breast cancer patients who are got benefit in chemotreatment,the medcine will be confirmed by the patient's past-treatment.
89180050|NCT05754671|Experimental|laryngectomized patients|
89180051|NCT05754671|Experimental|health professionals|
89180052|NCT02595294|Experimental|Cervical Lateral Glide|"15 minutes Cervical Lateral Glide neural mobilization~5 times a week~During 6 weeks~Patient's adequate cervical spine linear alignment was determined through the baseline use of a Universal Goniometer Device in each application of Cervical Lateral Glide neural mobilization."
89399196|NCT03624387|Experimental|Intervention Group( Painting Session)|Painting sessions for participants
89399197|NCT04050111|Experimental|SVF injection|"Subjects will undergo liposuction under local anesthesia. Lipoaspirate will be processed to isolate and concentrate stromal vascular fraction of cells (SVF). After SVF isolation autologous cells suspension will be injected intraarticularly into knee joint.~Interventions:~Procedure: Liposuction Other: SVF isolation Other: Intraarticular administration of autologous SVF"
89180053|NCT02595294|No Intervention|Waiting list control group|- Patients assigned to a 6 week waiting list to receive treatment
88842093|NCT02908178||Aim 1 Cohort|"The Aim 1 Cohort is constructed to perform analysis to address study objective Aim 1. This cohort includes patients diagnosed at ages 67-94 years with DCIS between January 1998 and December 2011, and received BCS as their first surgery. Patients in this cohort include those who received sentinel lymph node biopsy (SLNB) and who didn't receive SLNB.~The Aim 1 Cohort and the Aim 2 Cohort can overlap."
89180054|NCT02609867|Experimental|Flowise Cerebral Flow Diverter|Flowise Cerebral Flow Diverter (TaeWoong Medical Co., Ltd. Korea)
89180055|NCT00811187|Experimental|Lidocaine paracervical block|5cc 1% lidocaine injection in each paracervical region
89180056|NCT00811187|Placebo Comparator|Saline placebo injection|5cc Normal Saline injection in each paracervical region
89180057|NCT02593812|Experimental|"Training off medication"|"Participants will train on the postural stepping task before taking their first daily dose of standard Parkinson's medication (dopamine), i.e. while off dopamine replacement medication"
89369344|NCT03185338|Experimental|Active Physical Education lessons|This intervention has been developed by the Spanish Ministry of Health, Social Services and Equality and the Ministry of Education, Culture and Sport to increase the amount of children's PA during PE lessons in primary schools. At the time of this study, any school in Spain could choose to adopt this programme. This intervention includes two sets of eight active PE lessons specifically developed for third grade of primary school. These lessons will replace the original PE lessons in schools assigned to Active PE lesson intervention and integrated intervention.Additionally, this intervention provides some methodological advices to increase the PA time during the PE lesson (i.e. different ways to take attendance or deciding on the most suitable activity given the availability of resources).
89369345|NCT03185338|Experimental|Active school recess|This intervention has been designed based on previous research. The teacher will prepare the school playground offering adequate space and games to encourage children to be active. A sheet placed on the wall as a reminder will help teacher to remind children to participate and motivate them. On this sheet, each child will write the activity completed during the school recess every day during the intervention period.
89369346|NCT03185338|Experimental|Sleep health promotion|"Eight activities will be carried out at home and at school. During the first activity, parents and children will attend a general talk about sleep and health and will sign a contract for a healthy sleep at home. Also, children will complete a diary in which they will keep a record of their activities prior to going to bed and after waking up in the morning. At school, the first classroom-based activity will be based on the educational program I have a dream (Spanish adaptation of the SimplyHealthy@Schools International Program). The remaining classroom-based activities will include with a group art project with questions and answers about sleep, discussion groups about the sleep diary completed at home, and an abbreviated version of the Jacobson's progressive relaxation technique."
89369347|NCT03185338|Experimental|School global intervention|Also, a simultaneous implementation of all four interventions (see the others arms) will be examined in one of the intervention schools.
89369348|NCT03185338|No Intervention|Control school|Control school will be evaluate but will not receive any intervention
89369349|NCT03624296|Experimental|patient with multiple sclerosis (MS)|
89369350|NCT03692832|Experimental|Group L|40 patients undergoing laparoscopic hysterectomy
89369351|NCT03692832|Active Comparator|Group V|40 patients undergoing vaginal hysterectomy
89369352|NCT01371474||Patients prescribed PAXIL|Patients with depression or in a depressed state starting PAXIL at 20 mg/day during study period
89369353|NCT03184948|Active Comparator|Phase 1|"This is the first set of randomly selected hospitals to receive the intervention (Brilliance device). The intervention to be provided is the phototherapy device, Brilliance.~*No individual participants are recruited for this study."
89369354|NCT03184948|Active Comparator|Phase 2|"This is the second set of hospitals to receive the device. For the first three months, they receive no intervention, after which they become part of the active comparator arm. The intervention to be provided is the phototherapy device, Brilliance.~*No individual participants are recruited for this study."
89369355|NCT03184948|No Intervention|Phase 3|"This is the last set of hospitals to receive the device. For the first six months, they receive no intervention, after which the study is completed and they are given the device Brilliance.~*No individual participants are recruited for this study."
89369356|NCT03696056|Experimental|Kirtan Kriya meditation|Participants will mediate for 12 minutes a day for 8 consecutive weeks.
89369357|NCT03696056|Active Comparator|Relaxing instrumental music|Participants will relax listening to music for 12 minutes a day for 8 consecutive weeks.
89369358|NCT03185104|Experimental|Silver diamine fluoride|38% silver diamine fluoride solution (Saforide, Toyo Seiyaku Kasei Co. Ltd., Osaka, Japan) is professionally applied to exposed coronal and root surfaces of all teeth every 6 months for 36 months.
89369359|NCT03185104|Placebo Comparator|Distilled water|Distilled water is professionally applied to exposed coronal and root surfaces of all teeth every 6 months for 36 months.
89369360|NCT03700424|Experimental|Trehalose|Participants will be received intravenous trehalose infusion weekly (15 g/week) for a period of 12 weeks
89369361|NCT03700424|Placebo Comparator|Placebo|Participants will be received equal volume of normal saline weekly for a period of 12 weeks
89369362|NCT01319994|Experimental|Metformin|Metformin 850mg TDS (12 weeks)
89369363|NCT01319994|Placebo Comparator|Placebo|Placebo 850mg TDS (12 weeks)
89369364|NCT02430298|Placebo Comparator|Matched placebo|Drug: match placebo Drug: placebo suspension gargle for 2 minutes before radiation 15 minutes and placebo gelatin capsule taken orally after 21:00 hours each night throughout the study
89369365|NCT02430298|Active Comparator|Melatonin|Drug: Melatonin 20 mg/ 10 ml melatonin suspension gargle for 2 minutes before radiation 15 minutes and 20 mg melatonin gelatin capsule taken orally after 21:00 hours each night throughout the study
88875237|NCT02538354|Experimental|Riboflavin supplementation in quiescent disease|Group 1 (n=42) will consist of patients with disease in remission (quiescent disease).
89369366|NCT03624218|No Intervention|Treatment as Usual|Participants in the control arm will not receive the PE therapy, but they will rather receive the standard clinical treatment receive by all SCI patients at BIR. This includes an evaluation by a licensed psychologist and continued follow-up psychotherapy as needed. This therapy does not consist of trauma-focused therapy and will be summarized in the analysis as a part of standard of care. TAU participants will have a posttreatment assessment, as well as follow-up assessments at one and 6 months
89180058|NCT02593812|Other|"Training on medication"|"Participants will train on the postural stepping task after taking their first daily dose of standard Parkinson's medication (dopamine), i.e. while on dopamine replacement medication"
89369367|NCT03624218|Experimental|Intervention|Participants randomized to the PE intervention will receive 2-3, 60-minute sessions each week for 4-6 weeks (12 total sessions). Treatment is manualized, and includes education about common reactions to trauma, breathing retraining, prolonged (repeated) imaginal exposure to trauma memories, repeated in vivo exposure to situations that participants are avoiding due to trauma-related fear, and discussion of thoughts and feelings related to exposure exercises.
89369368|NCT03626376|Placebo Comparator|Control|suppressive antiviral treatment
89369369|NCT03626376|Active Comparator|Study Arm|oral acyclovir or oral valacyclovir
89369370|NCT03714139|Experimental|Immediate implant Loading|Immediate loading is defined as the placement of the implant and immediate prosthetic restoration
89369371|NCT03714139|No Intervention|non implant loading|there is not immediate prosthetic restoration
89369372|NCT02430454|Experimental|Experimental|Subjected to increased cognitive load
88842094|NCT02908178||Aim 2 Cohort|"The Aim 2 Cohort is constructed to perform analysis to address study objective Aim 2. This cohort includes patients diagnosed at ages 67-94 years with DCIS between January 2001 and December 2013, and received BCS as their first surgery. Patients in this cohort include those who received sentinel lymph node biopsy (SLNB) and who didn't receive SLNB.~The Aim 1 Cohort and the Aim 2 Cohort can overlap."
88842095|NCT02780869|Experimental|Investigational|HEMOBLAST Bellows
88842096|NCT02780869|Active Comparator|Control|Absorbable gelatin sponge, USP with thrombin
88842097|NCT02908490|Experimental|Initial Sildenafil|Sildenafil 50 mg orally once daily for first 3 months, then after 2-week washout, Placebo orally once daily for 3 months
88842098|NCT02908490|Placebo Comparator|Initial Placebo|Placebo orally once daily for first 3 months, then after 2-week washout, Sildenafil 50 mg orally once daily for 3 months
88842099|NCT00374036|Experimental|1|ECC
89369373|NCT02430454|No Intervention|Control|Not subjected to increased cognitive load
89369374|NCT03700346|Other|survivors|survivor at ICU discharge muscle microdialysis
89369375|NCT03700346|Other|Non survivors|death before ICU discharge muscle microdialysis
89369376|NCT01373034|Experimental|Soy Dietary Fiber|
89369377|NCT01373034|Placebo Comparator|Rice powder|
89369378|NCT03189316|Other|subjects with ovarian cyst|Peritoneal fluid sample obtained from coelioscopy for exploration of ovarian cysts and blood sample
88842100|NCT00374036|Experimental|2|FOLFIRI
89369379|NCT03189316|Other|subjects with peritoneal dialysis|Peritoneal fluid sample obtained from peritoneal dialysis fluid of patients with chronic renal insufficiency and blood sample
89369380|NCT05631613||Water for Injection -Idarubicin -Lipiodol|"Idarubicin is first dissolved in water for injection to make a solvent of~1mg/ml, which is then mixed with lipiodol to make an emulsion with a ratio of 1:2. Lipiodol-idarubicin emulsion is slowly injected, followed by embolization with embolic agents."
88842101|NCT02345018||GSV with diameters >/= 12 mm|30 patients with primary insufficiency of the GSV with diameters >/= 12 mm, treated with mechano-chemical ablation (MOCA)
88842102|NCT02345018||Antero-lateral branches|30 patients with insufficient antero-lateral branches, treated with mechano-chemical ablation (MOCA)
88842103|NCT02345018||GSV below-knee|30 patients with below-knee GSV insufficiency, treated with mechano-chemical ablation (MOCA)
88842104|NCT02910362|Experimental|Alcon phacoemulsification equipment|cataract surgery performed with the Alcon phacoemulsification equipment
88842105|NCT02910362|Active Comparator|AMO phacoemulsification equipment|cataract surgery with the AMO phacoemulsification equipment
88842106|NCT02910674|Other|One Arm|This is a comparative diagnostic study, no interventional actions are being taken.
88842107|NCT02911844|Other|Fulvestrant|500 mg administered intramuscularly (as two 5 mL injections) on days 0, 14, 28 and 56
88842108|NCT02911922|Experimental|Endorectal balloon - Radiation therapy|"Group 1 : Endorectal balloon (ERB): Immobilization device manually placed into the rectum prior to radiation treatment planning CT and daily treatment delivery, to immobilize the prostate and reduce prostate motion.~Patients on each arm will receive 5 fractions of radiation, 7.25Gy per fraction, delivered 2-3 times a week (every other day excluding weekends), to total dose of 36.25 Gy. The total duration of treatment will be no shorter than 10 days."
88842109|NCT02911922|Experimental|Rectal spacer - Radiation therapy|"Group 2 : Rectal spacer (RS): Biodegradable gel that is transperineally injected between the rectum and prostate under transrectal ultrasound guidance, to increase physical distance and thereby reduce radiation dose to the anterior rectal wall. The spacer begins to biodegrade in 2-3 months, and is fully absorbed within 6 months.~Patients on each arm will receive 5 fractions of radiation, 7.25Gy per fraction, delivered 2-3 times a week (every other day excluding weekends), to total dose of 36.25 Gy. The total duration of treatment will be no shorter than 10 days."
88842110|NCT02790788|Experimental|Steroids Group|Intervention: Stress-dose Steroids. Patients will receive methylprednisolone 40 mg (on the first, postenrollment cardiopulmonary resuscitation cycle. Otherwise, advanced life support will be conducted according to the 2015 guidelines for resuscitation). After resuscitation, patients will be treated with stress-dose hydrocortisone 240 mg daily for 7 days maximum, followed by gradual taper over the next 2 days.
88875238|NCT02538354|Experimental|Riboflavin supplementation in active disease|Group 2 (n=42) will consist of patients with active disease.
89180059|NCT04421729|Active Comparator|Savvy Caregiver Program|Savvy Caregiver Program, 6 weekly sessions, group treatment, addressing educational, informational, and psychosocial issues and community resources.
89369381|NCT05631613||Nonionic Contrast Agent -Idarubicin -Lipiodol|"Idarubicin is first dissolved in nonionic contrast agent to make a solvent of~1mg/ml, which is then mixed with lipiodol to make an emulsion with a ratio of 1:2. Lipiodol-idarubicin emulsion is slowly injected, followed by embolization with embolic agents."
89369382|NCT02430064|Experimental|Low PAMP diet then high PAMP diet|All subjects on study proceed from 7 days low PAMP diet to 4 days high PAMP diet
89369383|NCT03716089||Group A (Study group)|Group for laparoscopic resection of GIST with unfavorable group (Unfavorable group)
89369384|NCT03716089||Group B (Control group)|Group for laparoscopic resection of GIST with favorable group (favorable group)
89369385|NCT03692078|No Intervention|GROUP 1: Continue Smoking|Subjects will be asked to continue smoking their OB cigarettes ad libitum for 7 days.
89369386|NCT03692078|Experimental|GROUP 2: OTDN product 1|Subjects will reduce their normal daily cigarette consumption by at least 50% of their baseline CPD and use at least 3 product units per day for 7 days.
89369387|NCT03692078|Experimental|GROUP 3: OTDN product 2|Subjects will reduce their normal daily cigarette consumption by at least 50% of their baseline CPD and use at least 3 product units per day for 7 days.
89369388|NCT03692078|Experimental|GROUP 4: OTDN product 1|Subjects will completely switch to exclusive use of an oral tobacco-derived nicotine product, using at least 3 product units per day for 7 days.
89369389|NCT03692078|Experimental|GROUP 5: OTDN product 2|Subjects will completely switch to exclusive use of an oral tobacco-derived nicotine product, using at least 3 product units per day for 7 days.
89369390|NCT03692078|Experimental|GROUP 6: Tobacco Cessation|Subjects will completely stop all tobacco product usage for 7 days.
88842111|NCT02790788|Placebo Comparator|Control Group|Intervention: Saline placebo. Patients will receive saline placebo on the first, postenrollment cardiopulmonary resuscitation cycle. Otherwise, advanced life support will be conducted according to the 2015 guidelines for resuscitation. After resuscitation, patients will be treated with saline placebo for a maximum of 9 days (i.e. 7 days corresponding to the stress-dose hydrocortisone treatment of the experimental arm plus 2 days corresponding to the gradual taper of the stress-dose hydrocortisone treatment of the experimental arm).
88842112|NCT01929902||Surgical Patients|
88842113|NCT02793674|Other|Fisher & Paykel high flow nasal cannula|All participants in the study were on one or two high flow nasal cannula (HFNC) delivery systems. All were measured on the Fisher & Paykel HFNC delivery system. The flow rate of the HFNC was adjusted to determine if there exists a change in their effort of breathing.
88842114|NCT02793674|Other|Vapotherm high flow nasal cannula|All participants in the study were on one or two high flow nasal cannula (HFNC) delivery systems. A subgroup was measured on the Vapotherm HFNC delivery system. The flow rate of the HFNC was adjusted to determine if there exists a change in their effort of breathing.
88842115|NCT03001778|Experimental|Usability Testing|Prototype testing
88842116|NCT02888665|Experimental|Treatment (pembrolizumab, doxorubicin hydrochloride)|Patients receive pembrolizumab IV over 30 minutes on day 1 and doxorubicin hydrochloride IV over 1-3 hours on day 1 of courses 2-7 only. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
88842117|NCT02918396|Active Comparator|Conventional PVI|Conventional PVI by Radio-frequency Ablation: Wide area circumferential pulmonary vein isolation (PVI) only (current standard of care) using radio-frequency ablation catheters.
88842118|NCT02918396|Experimental|PVI + Scar-based ablation|Scar-Based Radio-frequency Ablation: Pulmonary vein isolation followed by targeting, using radio-frequency ablation, of dense LGE sites on MRI, which are confirmed on bipolar mapping to have voltage <0.3 mV.
88842119|NCT02918396|Experimental|PVI + Modeling-predicted rotors ablation|Rotor Anchors Radio-frequency Ablation: Pulmonary vein isolation followed by radio-frequency ablation of rotor anchors predicted by modeling.
88842120|NCT02781571|Experimental|SOF/VEL|SOF/VEL FDC for 12 weeks
88842121|NCT02918630|Active Comparator|Nicotine Replacement Therapy - Nicotine Patch|Participants will receive nicotine patch (21 mg) starting study Week 1. Participants will be instructed to apply a new patch each morning.
88842122|NCT02918630|Experimental|Nicotine Replacement Therapy + E-cigarette|The e-cigarette will consist of 1) a 3.3 V, 1000 mAh battery; and 2) a 1.5 Ohm, dual-coil cartomizer (SmokTech; Shenzhen, China). Study staff will load the cartomizer with 1 ml tobacco flavored 70% propylene glycol/30% vegetable glycerin liquid containing nicotine concentrations 36 mg/ml (AVAIL; Richmond, Virginia, USA).
88842123|NCT02781649|Experimental|Donor genotype 1a no resistance or 1b|Participants who receive donors found to have hepatitis C genotype 1a without resistance Zepatier one tablet daily for 12 weeks
88842124|NCT02781649|Experimental|Donor genotype 1a with resistance|Participants who receive donors found to have hepatitis C genotype 1a with nonstructural protein 5A associated resistance mutations Zepatier one tablet daily for 16 weeks Ribavirin weight based dosing for 16 weeks
88842125|NCT02781649|Experimental|Donor genotype 2 or 3|Participants who receive donors found to have hepatitis C genotype 2 or 3 Zepatier one tablet daily for 12 weeks Sofosbuvir 400 mg daily for 12 weeks
88842126|NCT02794766|Experimental|Inulin+SS|Experimental treatment: A gum of inulin 1g plus Streptococcus salivarius 1 billion colony forming units (CFU) per oral each 12 hours for 10 days
88842127|NCT02794766|Active Comparator|S salivarius|Active comparator: A gum of Streptococcus salivarius 1 billion CFU per oral each 12 hours for 10 days
89180060|NCT04421729|Active Comparator|Savvy Express|Savvy Express, 3 weekly sessions, group treatment, addressing educational, informational, and psychosocial issues and community resources.
89180061|NCT02596074|Experimental|Omiganan (CLS001)|CLS001 topical gel, 2.5%
89180062|NCT02596074|Placebo Comparator|Vehicle|Vehicle topical gel
88842128|NCT02794766|Placebo Comparator|Placebo|Placebo 1 gum per oral each 12 hours, for 10 days
88842129|NCT02794844|Experimental|Genotype Guided PPI Dosing|"Genotype Guided PPI Dosing: PI type and dosing will be recommended in real time based on patients' CYP2C19 genotype / metabolizer phenotype.~No other ARM will be studied."
89180063|NCT00917748|Experimental|1|docetaxel chemotherapy + modafinil 100 mg capsules
88842130|NCT01709539|Experimental|Diagnostiskt Centrum|Investigation at the primary care center followed by further investigation at Diagnostiskt Centrum, Kristianstad General Hospital
88842131|NCT01709539|No Intervention|Existing diagnostic procedures|Investigation at the primary care center followed by further investigation at Helsingborg General Hospital
88842132|NCT01689103|Experimental|Alliance Feedback to Therapist|Alliance feedback provided to therapist
88842133|NCT01689103|Placebo Comparator|No alliance feedback to therapist|No alliance feedback provided to therapist
88842134|NCT02795780|Experimental|Follow-up Flortaucipir PET Scan|
88842135|NCT02783443||General anesthesia|Adult patients ASA 2-3 undergoing elective total knee replacement surgery under general anaesthesia.
88842136|NCT02783443||Regional anesthesia|Adult patients ASA 2-3 undergoing elective total knee replacement surgery under regional anaesthesia.
88842137|NCT02796092|Active Comparator|Fibered platinum coils|Embolization of the pelvic veins with platinum fibered coils (Nester. Cook Europe, Bjaeverskov, Denmark)
88842138|NCT02796092|Experimental|Vascular plugs|Embolization of the pelvic veins with vascular plugs (Amplatzer Vascular Plugs II. St. Jude Medical. St. Paul, MN, USA)
89180064|NCT00917748|Placebo Comparator|2|docetaxel chemotherapy + placebo (lactose) capsules (matched to modafinil drug)
89180065|NCT02596152|Experimental|Mini-trampoline|participants allocated to this group will participate in a 12-week mini-trampoline group instructed training twice a week.
89180066|NCT02596152|Active Comparator|Nordic Walking|participants allocated to this group will participate in a 12-week Nordic Walking group instructed training twice a week.
89180067|NCT02595138|Experimental|A|zoledronic acid received
89180068|NCT02595138|No Intervention|B|observation
89369391|NCT03189160|Experimental|PEG-rhGH low dose|PEG-rhGH Injection (27IU/4.5mg/0.5ml/bottle) 0.1 mg/kg/w by subcutaneous injection for 52 weeks.
89369392|NCT03189160|Experimental|PEG-rhGH high dose|PEG-rhGH Injection (27IU/4.5mg/0.5ml/bottle) 0.2 mg/kg/w by subcutaneous injection for 52 weeks.
89369393|NCT03189160|No Intervention|Non-treatment control group|
89369394|NCT03208530|Experimental|Intervention Arm|This is a single arm study with all enrolled patients receiving the same brief motivational interview intervention.
89369395|NCT03695822|Experimental|Mirabegron|OAB female patients who will receive beta-3 agonist (mirabegron 2 mg) treatment
89369396|NCT03718507|Active Comparator|GROUP Fentanyl|patients will receive atropine (0.01-0.02 mg/kg i.v. bolus) and fentanyl (0.5-2 mcg/kg i.v. in 5 minutes) before LISA in addition to standard care (wrapping). NIRS will be monitored during the whole procedure, which will be video-recorded.
89369397|NCT03718507|Experimental|GROUP Sucrose|patients will be given atropine (0.01-0.02 mg/kg i.v. bolus) and oral sucrose 24% (0.5 ml) 2 minutes before LISA in addition to standard care (wrapping). NIRS will be monitored during the whole procedure, which will be video-recorded.
89369398|NCT03700268|Experimental|Manual fitting|The patient is receiving the classical treatment : 10 sessions of 1 hour during one year where the clinician programs manually the Cochlear implant.
89369399|NCT03700268|Experimental|Artificial Intelligence|The patient is receiving the new treatment : 4 sessions of 1 hour during one year where the clinician programs the Cochlear implant with the FOX (Fitting to Outcome eXpert) software using artificial intelligence.
89369400|NCT03188692|Experimental|BK1310|
89369401|NCT03716011|Other|DAPT 3M or DAPT 12M|After stent implantation in DAPT 3M or DAPT 12M
89369402|NCT04940832|Active Comparator|radiofrequency with corticosteroids|corticosteroids- 80mg depo-medrol Pulsed radiofrequency to 42 derees celsius for 6 minutes
89369403|NCT04940832|Active Comparator|radiofrequency without corticosteroids|Pulsed radiofrequency to 42 derees celsius for 6 minutes
89369404|NCT02430610|Experimental|IRE Group|irreversible electroporation for Unresectable Uterine Cervical Neoplasms
89369405|NCT02430610|No Intervention|Control|The patients without treatment
89369406|NCT03714061|Experimental|Pain Neuroscience Education (PNE)|The PNE will be administered following Explaining Pain concepts (Butler and Moseley, 2013), initially contextualizing the importance of the program. The program will be administered as interactive workshops lasting 50 minutes. In addition, the participants were oriented to perform at home a group o motor control exercises during three weeks, twice a week.
89369407|NCT03714061|Active Comparator|Self-Management Education (SME)|The SME education will be administered as an interactive workshop lasting 50 minutes. The program is based on the Back-book material (Roland et al, 2011), focusing on concepts targeting change of behavior and beliefs. In addition, the participants were oriented to perform at home a group o motor control exercises during three weeks, twice a week.
89369408|NCT01373112|Experimental|Static Spacer|After diagnosis of infection and informed consent, patients will be taken to the operating room. After anesthetization, patients will be randomized to either an articulating spacer or a static spacer. Randomization will be performed by prepared opaque envelopes administered by a nonparticipant in the study. After a complete debridement of devitalized tissue, explantation of the infected components and any associated cement, either an articulating or static spacer will be placed. All spacers will be formed of 3 g of Vancomycin and 1 g of Tobramycin for each 40 g packet of cement. Static spacers will be hand-made to fit the femoral and tibial exposed metaphyses as a solid block with associated antibiotic cement coated tibial and femoral intramedullary rod, such that knee motion will be minimized.
89369409|NCT01373112|Experimental|Articulating Spacer|After diagnosis of infection and informed consent, patients will be taken to the operating room. After anesthetization, patients will be randomized to either an articulating spacer or a static spacer. Randomization will be performed by prepared opaque envelopes administered by a nonparticipant in the study. After a complete debridement of devitalized tissue, explantation of the infected components and any associated cement, either an articulating or static spacer will be placed. All spacers will be formed of 3 g of Vancomycin and 1 g of Tobramycin for each 40 g packet of cement. Articulating spacers will be formed of antibiotic impregnated cement using the Stage One system (Biomet, Warsaw, IN).
89369410|NCT03695666||Cycle 1|Counted number of patients booked into clinic. No individual patient data collected.
89369411|NCT03695666||Cycle 2|Counted number of patients booked into clinic. No individual patient data collected.
89369412|NCT03188848|Experimental|BPI-3016|Single-dose subcutaneous injection of BPI-3016 with escalating dose from 0.6 mg
89369413|NCT03188848|Placebo Comparator|Placebo|Single-dose subcutaneous injection of placebo to match BPI-3016
89369414|NCT01311271|Sham Comparator|Sham rTMS-Sham rTMS|Sham rTMS for 2 weeks
88842139|NCT02889289|Experimental|Xbox One Kinect Gaming|15 sessions of supervised physical therapy using 2 commercially available Xbox One Kinect game.
89369415|NCT01311271|Experimental|Sham rTMS-Real rTMS|Sham rTMS in the first week and real rTMS in the second week
89369416|NCT01311271|Experimental|Real rTMS-Real rTMS|Real rTMS for 2 weeks
88842140|NCT02784613|Experimental|Ospemifene open label|60 mg ospemifene daily for 20 weeks
89369417|NCT03692000||Men with a history of prostate cancer|Men with a history of prostate cancer invited to participate in design-workshops , interviews or usabilitytesting.
88842141|NCT02890303|Experimental|Zepto Capsulotomy|This study will evaluate outcome in subjects who have elected to have Zepto capsulotomies during cataract surgery. Effectiveness Rate - An effectiveness rate of 95% complete capsulotomies provides reasonable assurance that the Zepto system is effective. Primary Safety Endpoint - Posterior Capsular Rupture & Vitreous Loss (4% or less)
88842142|NCT03002012|Experimental|Sertraline|Fluconazole Standard of Care + Sertraline
88842143|NCT03002012|Placebo Comparator|Control|Fluconazole Standard of Care + Placebo Oral Tablet
88842144|NCT02798354|Experimental|Reduce Elevated Blood Pressure Errors First|"Will provide baseline data on elevated blood pressure diagnosis and first intervene to reduce missed opportunities for elevated blood pressure diagnosis. Will then intervene to reduce missed opportunities for depression diagnosis and finally, intervene to reduce delayed diagnosis attributable to abnormal laboratory values.~Quality Improvement Collaborative Intervention will consist of behavioral components, i.e., training, interactions with experts, root cause analyses of errors, idea sharing, best practices dissemination, etc."
88842145|NCT02798354|Experimental|Reduce Depression Errors First|"Will provide baseline data on depression diagnosis and first intervene to reduce missed opportunities for depression diagnosis. Will then intervene to reduce delayed diagnosis attributable to abnormal laboratory values and finally, intervene to reduce missed opportunities for elevated blood pressure diagnosis.~Quality Improvement Collaborative Intervention will consist of behavioral components, i.e., training, interactions with experts, root cause analyses of errors, idea sharing, best practices dissemination, etc."
88842146|NCT02798354|Experimental|Reduce Lab Related Errors First|"Will provide baseline data on delayed diagnosis attributable to abnormal laboratory values and first intervene to reduce delayed diagnosis attributable to abnormal laboratory values. Will then intervene to reduce missed opportunities for elevated blood pressure diagnosis results and finally, to reduce missed opportunities for depression diagnosis.~Quality Improvement Collaborative Intervention will consist of behavioral components, i.e., training, interactions with experts, root cause analyses of errors, idea sharing, best practices dissemination, etc."
88842147|NCT02890381|Experimental|RSV LID cp ΔM2-2 Vaccine|Participants received a single dose of the RSV LID cp ΔM2-2 vaccine at study entry (Day 0).
88842148|NCT02890381|Placebo Comparator|Placebo|Participants received a single dose of placebo at study entry (Day 0).
88842149|NCT03005054|Experimental|StrataGraft skin tissue|
88842150|NCT02891629|Experimental|Device use in Healthy volunteers|10 healthy volunteers will be recruited
88842151|NCT02891629|Experimental|Device use in ALS patients|5 ALS patients in early stages will be recruited
88842152|NCT02891863|Experimental|Acute Testing|Single-arm study - all subjects who meet the I&E criteria, sign the consent form and have inducible VT within the protocol-specified criteria may be tested for VT conversion with the LEVER Acute Study System.
88842153|NCT03001453|Active Comparator|Liposomal bupivacaine|Periarticular infiltration cocktail of 20cc of liposomal bupivacaine with 20cc of normal saline and 40cc of 0.25% bupivacaine with epinephrine
88842154|NCT03001453|Active Comparator|Bupivacaine with epinephrine|Periarticular infiltration cocktail of 60cc of 0.25% bupivacaine with epinephrine
88842155|NCT03001843|Active Comparator|Non-Ketamine|This group will receive intraoperative narcotics as is usually done for this surgery. This arm will not receive Ketamine.
88842156|NCT03001843|Active Comparator|Ketamine|This group will receive an intraoperative infusion of ketamine rather than narcotics to control pain.
88842157|NCT03003793||Control group|Healthy control subjects
88842158|NCT03003793||Atopic dermatitis/eczema group|Patients with atopic dermatitis
88842159|NCT02784925|Other|fatty liver subjects|Ultrasound (US) B mode image is an alternative method to measure tissue structure and has proven to be an accurate technique to measure subcutaneous fat thickness.
88842160|NCT02785159|Experimental|IDP-118 Lotion|Lotion
88842161|NCT02785159|Active Comparator|Tazorac Cream|Cream
88842162|NCT02785159|Active Comparator|IDP 118 Vehicle Lotion|Lotion
88842163|NCT02785159|Active Comparator|IDP-118 Vehicle Cream|Cream
88842164|NCT02786719|Experimental|Neuroblastoma treatment without G-CSF|Induction chemotherapy only, including 6 cycles of chemotherapy, tumor resection, and stem cell collection
88842165|NCT03003949|Placebo Comparator|Placebo Patch and Placebo Capsule|Placebo patches worn for 16 weeks. On the 9th week of patch, oral placebo capsule taken daily for 12 days. Following the 16 weeks of patch use oral placebo capsule taken daily for 12 days.
88842166|NCT03003949|Active Comparator|Estradiol patch and progesterone capsule|Estradiol patches worn for 16 weeks. On the 9th week of patch, oral progesterone capsule taken daily for 12 days. Following the 16 weeks of estradiol patch use oral progesterone capsule taken daily for 12 days.
89369418|NCT02429986|Other|ASV Arm|The measures are performed during the annual consultation required by the French Social Security for the renewal of the reimbursement of the ASV care.
89369419|NCT03691922|Active Comparator|ESP Block|Preoperative US guided active Erector Spinae Plane (ESP) block and a saline PAI
88842167|NCT02896075|Experimental|Randomized cross-over approach|"The main study was conducted using a randomized controlled cross-over approach. Participants made three visits each for the two video watching interventions. The interventions were separated by a minimum of~1week as a washout. Each intervention included one day of inducing muscle soreness in one leg through eccentric muscle contractions; a second day of testing muscle soreness and pain tolerance and watching a 30-min video (either a comedy or documentary); and a third day of testing muscle soreness and pain tolerance again to see if the effects of the video viewing persisted the next day (i.e., 24 h after the video viewing)."
89180069|NCT00591149|Experimental|1|"Patients will be treated with oxaliplatin 130 MG/M2 IV over 2 hours on day 1 and docetaxel 60 MG/M2 IV over 1 hour on day 1 of a 21 day cycle. Cycles of treatment will be repeated every 3 weeks for a total of 4 cycles or until disease progression or intolerable toxicity.~Patients who were treated with 4 cycles of oxaliplatin and docetaxel and had a response or stable disease will be treated with cetuximab at 400 MG/M2 on week 1 then 250 MG/M2 weekly for a total of 12 weeks, or until disease progression or intolerable toxicity."
89369420|NCT03691922|Other|PAI with LA|Preoperative US guided ESP blockade with saline and an active Periarticular Infiltration (PAI)
89369421|NCT03453151|Experimental|Regional nerve anesthesia|
89180070|NCT00735072|Experimental|Maraviroc|Maraviroc (dose based on current medications in regimen: 150mg orally (PO) twice daily (BID) for those on a protease inhibitor-based regimen other than Tipranavir; 600mg PO BID for efavirenz-containing regimens; or 300 mg PO BID for all other regimens).
89180071|NCT00735072|Placebo Comparator|Placebo|Placebo (dose based on current medications in regimen: 150mg PO BID for those on a protease inhibitor-based regimen other than Tipranavir; 600mg PO BID for efavirenz-containing regimens; or 300 mg PO BID for all other regimens).
89180072|NCT00810641|Active Comparator|Gufoni maneuver|Gufoni maneuver for apogeotropic HC-BPPV
89180073|NCT00810641|Active Comparator|Headshaking maneuver|headshaking maneuver for apogeotropic HC BPPV
89180074|NCT00810641|Sham Comparator|sham maneuver|sham maneuver for apogeotropic HC BPPV
89180075|NCT05753813|Experimental|Study group|This is a single-arm study. all participants are assigned to this arm. all study participants will receive Phexxi, the study drug. 8 pre-filled vaginal inserters with vaginal gel, Phexxi, will be provided to each of the participants with verbal and written instructions for application. Patients will be instructed to use Phexxi twice per week, on the same days every week.
89180076|NCT04181723|Experimental|Drug - Trofinetide|Trofinetide solution of 30-60 mL based on the subject's weight at Baseline, administered twice daily by mouth or gastrostomy tube (G-tube)
89180077|NCT04181723|Placebo Comparator|Placebo|Trofinetide placebo solution of 30-60 mL based on the subject's weight at Baseline, administered twice daily by mouth or gastrostomy tube (G-tube)
89180078|NCT00793598|Experimental|Brincidofovir|"Under Amendments 1 and 2, subjects received 1 of 2 dose regimens of brincidofovir, as follows:~20 mg BCV once weekly (QW) on Days 0, 7, and 14; or~10 mg BCV twice weekly (BIW) BIW on Days 0, 3, 7, 10, and 14.~Under Amendment 3, subjects received 40 mg BCV QW for a total of 5 doses on Days 0, 7, 14, 21, and 28."
89369422|NCT03433248|Experimental|EMPA/LINA 10/5 mg QD (n=22)|8w EMPA followed by 8w EMPA/LINA 10/5 mg QD (n=22)
89369423|NCT03433248|Experimental|LINA/EMPA 5/10 mg QD (N=22)|8w LINA followed by LINA/EMPA 5/10 mg QD (N=22)
89369424|NCT03433248|Active Comparator|Gliclazide 30 mg QD/BID (N=22)|8w Gliclazide 30 mg QD, followed by 8w Gliclazide BID (N=22)
89369425|NCT02430142||Vasoocclusive testing in sepsis|Septic patients defined according to the Surviving Sepsis Campaign (SSC)
89369426|NCT02430142||Vasoocclusive testing in severe sepsis|Severe septic patients defined according to the Surviving Sepsis Campaign (SSC)
89369427|NCT02430142||Vasoocclusive testing in sepsic shock|Septic shock patients defined according to the Surviving Sepsis Campaign (SSC)
89369428|NCT03691766|Experimental|Photobiomodulation Therapy|Experimental: Photobiomodulation Therapy comprising 640 nm, 875 nm, and 905 nm light (red lights)
89369429|NCT03691766|Placebo Comparator|Control|Placebo device with different wavelengths of light without known physiologic effect.
89369430|NCT03188770||Mechanical Ventilation|Patients under mechanical ventilation in the ICU
89369431|NCT03691688||Aspirin|Aspirin 100mg
89369432|NCT03691688||Clopidogrel|Clopidogrel 75mg
89369433|NCT03619304|Experimental|no coffee|oral squamous cell carcinoma cell line without intervention
88842168|NCT02787655|Experimental|Aerobic Exercise + Cognitive Training Group|Exercise 3 times a week on a stationary ergometer @ 50-80% of maximal heart rate reserve for 20 minutes to 45 minutes per session; plus 20 minutes of cognitive training using Mindfit program
89180079|NCT00793598|Placebo Comparator|Placebo|"Under Amendments 1 and 2, subjects received placebo twice weekly (BIW) for a total of 5 doses on Days 0, 3, 7, 10, and 14.~Under Amendment 3, subjects received placebo once weekly (QW) for a total of 5 doses on Days 0, 7, 14, 21, and 28."
89180080|NCT04115072|Active Comparator|A - Single dose og PZQ|Single dose of Praziquantel 40 mg/kg Standard treatment of schistosomiasis as recommended by WHO
89180081|NCT04115072|Experimental|B - Five doses of PZQ|"Five doses of Praziquantel~1 x 40 mg/kg Praziquantel after enrollment in the study plus two single doses (40 mg/kg) after 12 and 24 hours after the first treatment~1 x 40 mg/kg Praziquantel five weeks following the 1st dose~1 x 40 mg/kg Praziquantel ten weeks following the 1st dose"
89180082|NCT04025294|Experimental|Students playing videogame|The experimental group will consist of our videogame intervention including the five mini-games.
89369434|NCT03619304|Active Comparator|green coffee|oral squamous cell carcinoma cell line with application of green coffee
89180083|NCT04025294|Active Comparator|Students receiving school climate assessment|The control group differs from the experimental group as it includes the school climate assessment tool but excludes the mini-games
89180084|NCT00796562|Experimental|Myeloablative haploidentical BMT|"All participants except those with acute lymphoblastic leukemia and lymphoblastic lymphoma: Busulfan will be administered 1 mg/kg oral (or 0.8 mg/kg IV) four times per day for four days, followed by cyclophosphamide 50 mg/kg once per day for two days.~Participants with acute lymphocytic leukemia or lymphoblastic lymphoma: Cyclophosphamide will be administered 50 mg/kg once per day for two days, followed by total body irradiation at 300 cGy per day for four days."
89180085|NCT00801632|Experimental|Kidney and Marrow Recipients|Combined kidney and bone marrow transplant
89180086|NCT04111484|Active Comparator|Adrenomedullin|Will received 19.9 picomol/kg/min of adrenomedullin over 20 min
89180087|NCT04111484|Placebo Comparator|Saline|Saline
89180088|NCT04109300|Experimental|preemptive screening|prospective HLADQA1*05A>G screening and targeted administration of combination therapy of infliximab with one of either methotrexate or azathioprine.
89180089|NCT04109300|Active Comparator|standard of care|administration of combination therapy with infliximab and one of methotrexate or azathioprine is at the discretion of the treating physician. HLADQA1*05A>G genotyping will be performed retrospectively.
89180090|NCT02604290|Experimental|Kinesio Taping method|"The tape is applied depending on the physical examination:~Muscular technique is placed along paravertebral muscles if back pain in flexion or extension improves when skin/fascial mobilisation is applied in the direction of paravertebral muscle fibers; the base is placed up or down if the mobilisation direction is up or down respectively.~Space technique is placed horizontally over the painful spinal segmental level if back pain in flexion or extension improves when skin/fascial mobilisation is applied approaching to a central point.~Fascia technique is placed horizontally over the painful area in paravertebral muscles if back pain in flexion or extension improves when skin/fascial mobilisation is applied transverse to the paravertebral muscle fibers."
89180091|NCT02604290|Sham Comparator|Kinesio Taping sham|The tape is applied with 0% tension, horizontally over two non-tender to palpation spinal segmental levels. The patient is kept in neutral position.
89180092|NCT04111328|Experimental|sufentanil administration intravenously|The dose of sufentanil for patient-controlled analgesia is 3.0μg/Kg dissolving in 100ml 0.9% normal saline (NS).The PCA pump is connected to the hand vein.The parameters were set as background dose 1.5 ml/h, PCA dose 1ml, locking time 15 min.
89180093|NCT04111328|Experimental|sufentanil administration subcutaneously|The dose of sufentanil for patient-controlled analgesia is 3.0μg/Kg dissolving in 100ml 0.9%NS.The PCA pump is connected to the deltoid subcutaneously.The parameters were set as background dose 1.5 ml/h, PCA dose 1 ml, locking time 15 min.
89180094|NCT04111328|Experimental|hydromorphone administration intravenously|The dose of hydromorphone for patient-controlled analgesia is 0.2mg/Kg dissolving in 100ml 0.9%NS.The PCA pump is connected to the hand vein.The parameters were set as background dose 1.5 ml/h, PCA dose 1 ml, locking time 15 min.
89180095|NCT04111328|Experimental|hydromorphone administration subcutaneously|The dose of hydromorphone for patient-controlled analgesia is 0.2mg/Kg dissolving in 100ml 0.9%NS.The PCA pump is connected to the deltoid subcutaneously.The parameters were set as background dose 1.5 ml/h, PCA dose 1 ml, locking time 15 min.
89180096|NCT04111328|Experimental|sufentanil and dexmedetomidine intravenously|The dose of sufentanil, dexmedetomidine,for patient-controlled analgesia is 3.0μg/Kg, dissolving in 100ml 0.9% normal saline (NS).The PCA pump is connected to the hand vein.The parameters were set as background dose 1.5 ml/h, PCA dose 1ml, locking time 15 min.
89180097|NCT04111328|Experimental|sufentanil and dexmedetomidine subcutaneously|The dose of sufentanil ,dexmedetomidine ,for patient-controlled analgesia is 3.0μg/Kg dissolving in 100ml 0.9%NS.The PCA pump is connected to the deltoid subcutaneously.The parameters were set as background dose 1.5 ml/h, PCA dose 1 ml, locking time 15 min.
89180098|NCT04111328|Experimental|hydromorphone and dexmedetomidine intravenously|The dose of hydromorphone for patient-controlled analgesia is 0.2mg/Kg ,dexmedetomidine ,for patient-controlled analgesia is 3.0μg/Kg dissolving in 100ml 0.9%NS.The PCA pump is connected to the hand vein.The parameters were set as background dose 1.5ml/h, PCA dose 1ml, locking time 15 min.
89369435|NCT03619304|Active Comparator|roasted coffee|oral squamous cell carcinoma cell line with application of roasted coffee
89369436|NCT03619304|Active Comparator|decaffeinated coffee|oral squamous cell carcinoma cell line with application of decaffeinated coffee
89369437|NCT02425462||Cohort 1|Asian patients at least 18 years of age with clinical or surgical diagnosis of endometriosis, and patients with endometriosis associated pelvic pain.
89369438|NCT03700112|Experimental|JUUL Virginia Tobacco flavored 5.0% ENDS|"Administration of JUUL Virginia Tobacco flavored 5.0% ENDS product consumed using 10 puffs delivery method~Administration of JUUL Virginia Tobacco flavored 5.0% ENDS product consumed Ad-libitum delivery method"
89369439|NCT03700112|Experimental|PMI iQOS Heat sticks|"Administration of PMI iQOS Heat sticks - Regular consumed using 10 puffs delivery method~Administration of PMI iQOS Heat sticks - Regular consumed ad-libitum delivery method"
89369440|NCT03700112|Experimental|Reynolds VUSE Solo ENDS - Original|"Administration of Reynolds VUSE Solo ENDS - Original consumed using 10 puffs delivery method~Administration of Reynolds VUSE Solo ENDS - Original consumed using ad-libitum delivery method"
89369441|NCT03700112|Experimental|Imperial MyBlu ENDS - Original|"Administration of Imperial MyBlu ENDS - Original consumed using 10 puffs delivery method~Administration of Imperial MyBlu ENDS - Original consumed using ad-libitum delivery method"
89369442|NCT03700112|Experimental|Altria MarkTen ENDS - Bold Classic|"Administration of Altria MarkTen ENDS - Bold Classic consuming using 10 puffs delivery method~Administration of Altria MarkTen ENDS - Bold Classic consuming using ad-libitum delivery method"
89369443|NCT03700112|Experimental|MLV PHIX ENDS - Original Tobacco|"Administration of MLV PHIX ENDS - Original Tobacco consumed using 10 puffs delivery method~Administration of with MLV PHIX ENDS - Original Tobacco consumed using ad-libitum delivery method"
89369444|NCT03700112|Experimental|NJOY Daily EXTRA ENDS - Rich Tobacco|"Administration of NJOY Daily EXTRA ENDS - Rich Tobacco consumed using 10 puffs delivery method~Administration of NJOY Daily EXTRA ENDS - Rich Tobacco consumed using delivery method and ad-libitum"
88842169|NCT02787655|Active Comparator|Cognitive Training Only Group|Cognitive Training Only Group. For this arm of the intervention, randomized participants followed the same guidelines as the cognitive component of the AE+CT group but did not partake in aerobic exercise. To equalize contact/monitoring of the groups this group met for the same total duration time as the AE+CT group; however, instead of aerobic exercise, progressive whole body stretching and toning exercises
89369445|NCT03700112|Experimental|Altria Marlboro combustible cigarette - Red|Administration of Altria Marlboro combustible cigarette - Red consumed using 10 puffs delivery method Administration of Altria Marlboro combustible cigarette - Red consumed using ad-libitum delivery method
89369446|NCT04482868|Placebo Comparator|open reduction group|
89369447|NCT04482868|Experimental|percutaneous group|
89369448|NCT03452527|Experimental|ICON-1 maintenance therapy|ICON-1 maintenance therapy after initial aflibercept treatment
89369449|NCT03452527|Experimental|ICON-1 combination therapy|ICON-1 combination therapy with aflibercept treatment
89369450|NCT02429908|Other|Post market study of TM-Ardis Interbody|TM-Ardis TLIF MIS or Open single or multi level implant for lumbar fusion
89369451|NCT03226470|Experimental|T512 group|Subjects will receive suppository with T512 at 2 intervals for one month.
89369452|NCT03718351|Active Comparator|transanal endoscopic microsurgery|a TEM tube will be inserted in the rectum. With specialized instruments the adenoma will be dissected en bloc by a full thickness excision, after which the patient will be admitted to the hospital.
89369453|NCT03718351|Experimental|endoscopic submucosal dissection|an endoscope will be inserted into the rectum and the submucosa underneath the lesion will be injected with saline to lift the adenoma. With an endoscopic knife (Insulated Tip Knife, Olympus or Water Jet, Erbe) the lesion will be resected through the submucosal plane in an eb-bloc fashion, after which the patient will be observed for at least 24h in-hospital.
89369454|NCT03713827|Active Comparator|"composite resin, Ceram-x One Universal"|"tooth restoration with nano-ceramic composite resin Ceram-x one Universal"
89369455|NCT03713827|Active Comparator|"glass ionomer cement, Equia Forte"|"Tooth restoration with glass ionomer cement (Glass hybrid restorative system) Equia Forte"
88842170|NCT02798978|Experimental|Part 1: GSK1795091 or Placebo|In Part 1, subjects in sequential cohorts will receive single ascending doses of intravenous (IV) injection of GSK1795091 or matching placebo, with a starting dose of 7 nanogram (ng), on Day 1 until the highest dose is evaluated.
89369456|NCT02429674|Other|TranS-C and IPT-A|12 sessions of weekly outpatient psychotherapy for adolescent depression.
89369457|NCT01373190||Epilepsy Group|Individuals diagnosed with Partial/Focal Onset Epilepsy ICD9CM 345.4 and/or 345.5
89369458|NCT01373190||Control Group|Individuals who do not have the diagnosis of Epilepsy and have no history of seizure disorders
89369459|NCT01311349||1|A listing of all isolates meeting the inclusion criteria will be maintained.
89369460|NCT03028142|Experimental|Lower Dose Nebulised Treatment|1.5 mg nebulised RPL554 twice daily plus 10 mcg tiotropium DPI once daily for 3 days
89369461|NCT03028142|Experimental|Higher Dose Nebulised Treatment|6 mg nebulised RPL554 twice daily plus 10 mcg tiotropium DPI once daily for 3 days
89369462|NCT03028142|Placebo Comparator|Placebo|Nebulised RPL554 matched placebo twice daily plus 10 mcg tiotropium DPI once daily for 3 days
89369463|NCT03188614|Placebo Comparator|Normal saline group|Shock patients who resuscitated with normal saline were enrolled between June, 2015-June.2016.
89369464|NCT03188614|Experimental|Balanced solution group|Shock patients who resuscitated with balanced solution were enrolled after June, 2016.
89369465|NCT02866812|Experimental|patient with endovascular treatment for intracranial aneurysm|
89369466|NCT03713749|Experimental|Robot Esophagectomy (RE)|Patients in the RE group will receive robotic-assisted esophagectomy with standard total two-field lymphadenectomy.
89369467|NCT03713749|No Intervention|Video-assisted thoracoscopic esophagectomy (VATE)|Patients in the VATE group will receive thoracoscopic esophagectomy with standard total two-field lymphadenectomy.
89369468|NCT03182842|Experimental|FreeStyle Libre FGM|Insulin dosing based on FreeStyle Libre FGM glucose values
89369469|NCT03182842|Active Comparator|SMBG - Blinded Sensor - Control|Insulin dosing based on SMBG, FreeStyle Libre FGM will be blinded.
88842171|NCT02798978|Experimental|Part 2 Cohort 1: GSK1795091|In Part 2 Cohort 1, subjects will receive IV injection of GSK1795091 on Day 1, at dose determined in part 1, and second dose on Day 8 (one week apart)
88842172|NCT02798978|Experimental|Part 2 Cohort 2: GSK1795091|In Part 2 Cohort 2, subjects will receive IV injection of GSK1795091 on Day 1, at dose determined in part 1, and a second dose on Day 15 (two weeks apart)
88842173|NCT02898103|Experimental|Active Current then Sham then Active Current|Electrical current will be introduced to the insulated percutaneous lead(s) for 5 minutes; then sham/placebo for 5 minutes; and then active electrical current for the following 2-4 weeks
88842174|NCT02898103|Active Comparator|Sham then Active Current|Sham/placebo will be introduced to the insulated percutaneous lead(s) for 5 minutes; then active electrical current for the following 2-4 weeks
88842175|NCT03005041|Experimental|Test Product 1|Participants will rinse their mouth with 15 mL of the product swishing for 30 seconds.
88842176|NCT03005041|Other|Test Product 2|Participants will rinse their mouth with 15 mL of the water swishing for 30 seconds. Participants then spit out the water.
88842177|NCT03007225|Active Comparator|group 1 Drug eluting beads intervention|Twenty-five patients underwent Chemoembolization with Drug eluting beads. using Drug eluting Doxorubicin hydrochloride (100-150 mg)
89180099|NCT04111328|Experimental|hydromorphone and dexmedetomidine subcutaneously|The dose of hydromorphone for patient-controlled analgesia is 0.2mg/Kg ,dexmedetomidine ,for patient-controlled analgesia is 3.0μg/Kg dissolving in 100ml 0.9%NS.The PCA pump is connected to the deltoid subcutaneously.The parameters were set as background dose 1.5ml/h, PCA dose 1 ml, locking time 15 min.
89180100|NCT00806819|Experimental|nintedanib (BIBF1120) plus pemetrexed|nintedanib (BIBF1120) along with standard therapy of pemetrexed
89180101|NCT00806819|Placebo Comparator|Placebo plus pemetrexed|Pemetrexed standard therapy
89180102|NCT00806819|Experimental|nintedanib (BIBF1120) monotherapy|nintedanib (BIBF1120) monotherapy only for patients who discontinue pemetrexed
89180103|NCT00806819|Active Comparator|pemetrexed monotherapy|pemetrexed monotherapy only for patients who discontinue nintedanib (BIBF1120) or placebo
89180104|NCT00806819|Placebo Comparator|placebo monotherapy|placebo monotherapy only for patients who discontinue pemetrexed
89180105|NCT00801242|Experimental|Degarelix 240 mg / 80 mg|
89180106|NCT04109534|Placebo Comparator|Placebo|Placebo comparator 20 patients aged 18-45 years with a diagnosis of HDM induced allergic asthma and an increase of exhaled NO of 30% after BAP will be randomized to the Placebo Comparator
89180107|NCT04109534|Active Comparator|Verum|PUFAS: 2640 mg of middle-chain and polyunsaturated fatty acids 20 patients aged 18-45 years with a diagnosis of HDM induced allergic asthma and an increase of exhaled NO of 30% after BAP will be randomized to the Active Comparator
89180108|NCT05659940||Healthy people|Healthy participants whose age and gender are consistent with CNV patients
89180109|NCT05659940||CNV patients|Patients who are diagnosed ocular chemical injury coming to Zhongshan Eye Center, Sun Yat-sen University for medical care
88842178|NCT03007225|Active Comparator|group 2 Conventional TACE intervention|Twenty-five patients underwent conventional Chemoembolization (cTACE) using the standard TACE technique
88842179|NCT02799290|No Intervention|CONTROL|No intervention
88842180|NCT02799290|Experimental|ADIPOSE TISSUE EXTRACT|Adipose Tissue extract application
88842181|NCT02799290|Experimental|PLATELET-RICH PLASMA GEL|PLATELET RICH PLASMA GEL APPLICATION
89180110|NCT04108910||Traditional Urine Culture|Patients treated based upon traditional urine culture
89180111|NCT04108910||Guidance PCR/Pooled Sensitivity|Patients treated based upon multiplex UTI PCR/pooled sensitivity results
88842182|NCT02800148|Experimental|Azelaic acid foam|
88842183|NCT02800148|Active Comparator|Finacea Foam|
88842184|NCT02800148|Placebo Comparator|Placebo Foam|
88842185|NCT03008707||Group 1|Patients who undergo Laparoscopic Peritoneal Lavage
88842186|NCT03008707||Group 2|Patients who have a laparoscopically approached sigmoidectomy
88842187|NCT02801006|Experimental|stenfilcon A|Participants will be randomized to wear stenfilcon A lens pair for two weeks during the cross over study.
89180112|NCT05754437|Experimental|Low Level Light Therapy Group|Patients enrolled in the treatment group will undergo Low Level Light therapy using Meibomask (Espansione Marketing S.p.A., Bologna, Italy) for 15 minutes one week (±2 days) before surgery (T0) and one week (±2 days) after surgery (T1).
89180113|NCT05754437|No Intervention|Control group|Patients enrolled in the control group will not receive Low Level Light therapy at any time.
89180114|NCT04377659|Experimental|Intubation/Mechanical Ventilation|Progression of respiratory failure in cohort #1 will be defined as a sustained increase in oxygen requirement or need for intubation/mechanical ventilation
89180115|NCT04377659|Experimental|Respiratory Support|In cohort #2 progression of respiratory failure will be defined as a need for increasing respiratory support (e.g. FiO2 or PEEP)
89180116|NCT04111250|Experimental|Crestal sinus lift using iRasie implant|"Device: iRaise Sinus Lift implant (Maxillent, Herzliya, Israel). Procedure: crestal sinus lift augmentation.~We tested crestal versus lateral approach to the sinus. Crestal approach is made by a novel device (iRaise, implant system). Lateral approach is made conventionally with gold standard procedure (lateral approach).~The iRaise Sinus Lift implant is made of Titanium-6 Aluminum-4 Vanadium alloy, have a surface treated with grit blasting using an apatitic calcium phosphate media, followed by acid etching, and have an internal hexagon connection. Implants have an internal l-shape channel to allow saline and graft passage.~This implants system is made to perform crestal sinus lift procedure at the same time of the implant placement using the same device. After implant site preparation and initial implant placement, the hydraulic system is connected to the implant to allow the injection of saline and then graft the material. Then, the implant, is inserted for its full length."
89180117|NCT04111250|Active Comparator|Lateral sinus lift|"Conventional procedure.~Lateral approach to the sinus was made following the conventional procedure.~A window on the lateral wall of the sinus is performed according to a conventional surgical lateral approach to the sinus cavity. Graft materials is filled inside the sinus cavity. Finally, iSure implants [Maxillent] are placed, and flap is sutured."
89180118|NCT05326139|Active Comparator|Tranexamic acid|Group TA (n=25): TA ( Tranexamic acid, 250mg/2.5 ml inj ) soaked pledgets were placed under the skin flap to cover the osteotomy line
89180119|NCT05326139|Placebo Comparator|Isotonic saline|Group Co (n=25): Isotonic saline ( NaCl, 0.9 %) soaked pledgets were placed under the skin flap to cover the osteotomy line
89180120|NCT04110782||Radium223|
89180121|NCT02605694|Experimental|Arm 1|Duvelisib 25 mg will be administered orally twice daily (BID) during 21-day cycles (Cycles 1-6) followed by 28-day cycles (Cycle 7 and beyond) until disease progression or unacceptable toxicity; and Rituximab (375 mg/m2) will be administered as an intravenous (IV) infusion on Day 1 of Cycles 1-6 (21-day cycles).
89180122|NCT02605694|Active Comparator|Arm 2|"R-CHOP will be administered as follows:~IV infusion on Day 1 of Cycles 1-6 (21-day cycles)~Cyclophosphamide (750 mg/m2)~Doxorubicin hydrochloride (50 mg/m2)~Vincristine sulfate (1.4 mg/m2) (2 mg maximum)~Rituximab (375 mg/m2) Orally on Days 1-5 of Cycles 1-6 (21-day cycles)~Prednisone (100 mg) will be administered."
88842188|NCT02801006|Active Comparator|etafilcon A|Participants will be randomized to wear etafilcon A lens pair for two weeks during the cross over study.
89369470|NCT02800824|Experimental|Budesonide rectal foam|
89369471|NCT02800824|Active Comparator|Uceris rectal foam|
89369472|NCT03695588|Active Comparator|Quadratus lumborum block|Bilateral posterior QLB with 20ml 0.25% L-Bupivacaine.
89369473|NCT03695588|Sham Comparator|Sham QLB|Sham QLB - Ultrasound identification of QLB followed by skin pressure with blunt needle. Patient blinded due to residual spinal anaesthetic block.
89369474|NCT04806360|Experimental|ACRF group|ACRF is a new surgical procedure that previously proposed by our team, it combines the advantages of both the conventional anterior and posterior approach. Eligible patients in this group will receive ACRF surgery.
89369475|NCT04806360|Active Comparator|conventional anterior surgery group|Eligible patients in this group will receive conventional anterior surgery, including anterior cervical discectomy and fusion surgery or anterior cervical corpectomy and fusion surgery.
89369476|NCT04806360|Active Comparator|conventional posterior surgery group|Eligible patients in this group will receive conventional posterior surgery, including laminectomy and fusion surgery or laminoplasty surgery.
89369477|NCT02429752|Experimental|Inspiratory Muscle Training|Subjects will receive 8 weeks of IMT
89369478|NCT03713359|Active Comparator|Trial arm (MRVAC)|"Measles and Rubella combined vaccine (lyophilized) MRVAC produced by POLYVAC is live attenuated measles vaccine. Each vial of 10 doses of measles-rubella combined vaccine is reconstituted with 5.5 mL of water for injection. Each single dose 0.5 mL contains the following components:~Live, attenuated strain AIK-C measles virus not less than 1000 PFU Live, attenuated strain Takahashi rubella virus not less than 1000 PFU Subcutaneous injection"
89369479|NCT03713359|Active Comparator|Control arm|"Measles and Rubella combined vaccine produce by Serum Institute, India (lyophilized) is live attenuated Measles and Rubella vaccines being used in the Vietnam expanded immunization program was used as control arm.~Subcutaneous injection"
89369480|NCT03695432|Experimental|Vaccine|Flubio (A/California/7/2009, A/Texas/50/2012 and B/Massachusetts/2/2012) Vaccine 0,5 ml for every subjects The vaccine will be given intramuscularly
89369481|NCT03695432|Experimental|Probiotic|Lacidofil (Lactobacillus acidophilus Rossel-52 and Lactobacillus rhamnosus Rosell-11 with maltodextrin 211 mg, magnesium stearat 8 mg and ascorbic acid 1 mg) antibiotic
88842189|NCT02790463|No Intervention|Usual Care|Participants recruited in this arm will receive their usual care for gout as they normally would
88842190|NCT02790463|Active Comparator|Intervention|Participants recruited to this arm will receive their usual gout care + pharmacist-led intervention
88842191|NCT02791399|No Intervention|Control|Treatment as usual
88842192|NCT02791399|Experimental|ISOP Intervention|Primary care providers and PACT nurses will participate in the same workshop as those randomized to the control condition (or academic detailing for those unable to attend the workshop). Clinicians randomized to the intervention will additionally collaborate with a nurse care manager (NCM) who will maintain a registry of enrolled patients, track UDT administrations and results, query prescription drug monitoring databases, monitor other evidence of potential problems, and collaborate with expert consultants to provide decision support when patients have evidence of prescription opioid misuse or abuse. The NCM will also meet with patients to discuss methods to reduce opioid adverse effects, prevent misuse, and provide rationale for prescription opioid adherence monitoring.
88842193|NCT02902081|Placebo Comparator|Placebo|Oral placebo administered once prior to subjective drug effects questionnaires and behavioral tasks.
88842194|NCT02902081|Experimental|Cannabidiol|(300 mg, 600 mg, 900 mg) cannabidiol administered once prior to subjective drug effects questionnaires and behavioral tasks.
89180123|NCT02604134|Other|conventional treatment group|The child will receive a prophylaxis and fluoride varnish. Parents will fill out a parent and a child questionnaire.
89180124|NCT02604134|Other|Silver Nitrate group|The child will receive a prophylaxis, then silver nitrate and then fluoride varnish. Parents will fill out a parent and a child questionnaire.
89180125|NCT00800540|Other|AZARGA/COMBIGAN|AZARGA, followed by COMBIGAN, as randomized. Each fixed combination instilled in the study eye, one drop twice daily (9:00 and 21:00), for six weeks, with a 4-week washout period separating the two treatment periods.
89369482|NCT03695432|Placebo Comparator|Placebo Vaccine|Nacl 0,9% 0,5 ml The placebo vaccine will be given intramuscularly
89369483|NCT03695432|Placebo Comparator|Placebo probiotic|capsul
89369484|NCT03715777|Experimental|BoNTA Injection|"Patients diagnosed with chronic pelvic floor pain, without contraindications for the administration of BoNTA.~Name of each active substance (INN or proposed INN if available):~Botulinum toxin type A Clostridium botulinum type A (BoNTA) Pharmaceutical form (use standard terms): Powder and solution for solution for injection Route of administration (relevant to the maximum dose): Intramuscular use Specify total dose : 80 U"
89369485|NCT03695354|Experimental|Whole body vibration plus conventional therapy group|conventional therapy + whole body vibration training for 40 minutes per day, five days per week for two-week period.
89369486|NCT03695354|Active Comparator|conventional training group|conventional therapy (passive range of motion exercise and walking exercise) for 40 minutes per day, five days per week for two-week period.
89369487|NCT03715699|Experimental|Group 1|Patients treated with single glucocorticoid
89369488|NCT03715699|Experimental|Group 2|Patients treated with Leflunomide and glucocorticoid
89369489|NCT02708524|Experimental|Senofilcon C Wearers|Senofilcon C Wearers will wear the Senofilcon C Contact Lenses as daily wear for 30 (-2/+6) days.
89369490|NCT02708524|Active Comparator|Comfilcon A Wearers|Comfilcon A Wearers will wear the Comfilcon A Contact Lens as daily wear for 30 (-2/+6) days.
89369491|NCT02708524|Active Comparator|Lotrafilcon B Wearers|Lotrafilcon B Wearers will wear the Lotrafilcon B Contact Lens as daily wear for 30 (-2/+6) days.
89369492|NCT02708524|Active Comparator|Samfilcon A Wearers|Samfilcon A Wearers will wear the Samfilcon A Contact Lens as daily wear for 30 (-2/+6) days.
89369493|NCT03699800|Experimental|Graphomotor intervention program|The experimental group (EG) intervention comprises a graphomotor intervention program according to a psychomotor approach. The program integrates two group sessions (6-8 children)/week of 30 minutes for 8 weeks (16 sessions).
89369494|NCT03699800|No Intervention|Control Group|The control group (CG) participants will maintain their normal classroom activities. After the study, control group participants will be offered the opportunity to integrate a similar graphomotor intervention program.
89369495|NCT04776408|Active Comparator|Control group_Use Lung recruitment|Use the Lung recruitment,
89369496|NCT04776408|Experimental|Study group_Use Lung recruitment combined inhaled Nitric oxide|Use the Lung recruitment combined inhaled Nitric oxide,
89369497|NCT03695198|Experimental|LY3361237 - Subcutaneous (SC)|LY3361237 administered SC
89369498|NCT03695198|Placebo Comparator|Placebo - SC|Placebo administered SC
89369499|NCT03695198|Experimental|LY3361237 - Intravenous (IV)|LY3361237 administered IV
89369500|NCT03695198|Placebo Comparator|Placebo - IV|Placebo administered IV
88842195|NCT02801942|Experimental|Healthy subjects|Up to 30 mL of blood sample will be collected from healthy subjects. Inguinal lymph node fine needle aspirate biopsy and core biopsy will be performed. Leukocyte subset phenotyping will be carried out on iLN-derived cells by assessing expression of (but not restricted to) the following antigens: CD3, CD4, CD8, CD11c, CD14, CD16, CD19, CD24, CD25, CD38, CD45RA, CD56, Human Leukocyte antigen D related (HLA-DR) and forkhead box P3 protein also called scurfin (FOXP3).
88842196|NCT02801942|Experimental|Subjects with NOT1D|Up to 30 mL of blood sample will be collected from subjects with NOT1D. Inguinal lymph node fine needle aspirate biopsy and core biopsy will be performed. Leukocyte subset phenotyping will be carried out on iLN-derived cells by assessing expression of (but not restricted to) the following antigens: CD3, CD4, CD8, CD11c, CD14, CD16, CD19, CD24, CD25, CD38, CD45RA, CD56, HLA-DR and FOXP3.
88842197|NCT02791945|Experimental|N-acetylcysteine|N-acetylcysteine capsules daily - up to 3200 mg
88842198|NCT02791945|Placebo Comparator|Placebo|Placebo capsules daily - up to 3200 mg
88842199|NCT02793817|Active Comparator|KPI-121 1.0% Ophthalmic Suspension|dosed BID
88842200|NCT02793817|Placebo Comparator|Vehicle of KPI-121 Ophthalmic Suspension|dosed BID
88842201|NCT03007394|Active Comparator|Lorcaserin|10 mg capsule by mouth, twice a day, for 13 weeks
88842202|NCT03007394|Placebo Comparator|Placebo Oral Capsule|10 mg placebo capsule, twice a day, for 13 weeks
88842203|NCT00374192|Experimental|1|Eszopiclone
89369501|NCT02773524|Experimental|Regorafenib|Regorafenib 160mg (4 x 40 mg tablets) orally, once daily on days 1-21 of each 28 day cycle + best supportive care until progression
89369502|NCT02773524|Placebo Comparator|Placebo|Placebo 160mg (4 x 40 mg tablets) orally, once daily on days 1-21 of each 28 day cycle + best supportive care until progression
89369503|NCT02429596|Experimental|Experimental Treatment|AED(s) currently taken (CBZ, VPA, TPM, OXC, LEV, LTG) will be substituted, starting with the morning dose on day 2, with an equivalent formulation available in the market. Namely, a brand product will be switched to a generic, randomly chosen among those available in the market, while maintaining unaltered the dosing regimen and times of administration.Likewise, a generic product will be switched to the brand or another generic.
89369504|NCT02429596|No Intervention|No Experimental Treatment|When the randomized allocation requires continuation on the same product (control), the AED product(s) currently taken will be continued unaltered, with the same dosing regimen and times of administration.
89369505|NCT03418675|Placebo Comparator|Placebo|1 milligram per day for the first week and 1 milligram per day for the final taper week 2 milligrams per day for 10 weeks between taper periods.
89369506|NCT03418675|Experimental|Rexulti|1 milligram per day day for the first week and 1 milligram per day for the final taper week 2 milligrams per day for 10 weeks between taper periods.
89369507|NCT03695120|No Intervention|Full Dose ACEI/ARB or Home Dose Group|This group will receive the full dose of ACEI/ARBs.
89369508|NCT03695120|Active Comparator|No ACEI/ARB Group|This group will not receive the full dose of ACEI/ARBs for the first 72 hours of hospitalization.
89369509|NCT03694964|Experimental|Supplementation with Citrulline|Patients will receive citrulline (ProteoCIT®) 10 mg by day during 45 days
89369510|NCT03694964|Placebo Comparator|Placebo|Patients will receive placebo (one tablet by day) during 45 days
88842204|NCT00374192|Placebo Comparator|2|Placebo
88842205|NCT02806544|Experimental|Tamoxifen|Tamoxifen 20mg by mouth daily
88842206|NCT03008174|Experimental|Intervention|"Early one-way speaking valve (OWSV) assessment by speech language pathologist (SLP) following 12-24 hours after percutaneous tracheostomy procedure.~Second OWSV evaluation with SLP following 48-60 hours from initial percutaneous tracheostomy procedure.~Third OWSV evaluation with SLP following first tracheostomy tube change. Participants may receive additional SLP sessions between second and third sessions per standard of care."
88842207|NCT03008174|No Intervention|Control|"Standard OWSV evaluation with SLP following 48-60 hours from initial percutaneous tracheostomy procedure.~Second OWSV evaluation with SLP following first tracheostomy tube change. Participants may receive additional SLP sessions between first and second sessions per standard of care."
89369511|NCT02421406|Experimental|Internet Behavioral Intervention|Participants receive a 12-week Internet-based eating and activity intervention including multimedia lessons and enhanced self-monitoring of weight loss behaviors with automated feedback
89369512|NCT02421406|Active Comparator|Internet Education Intervention|Participants receive 12 weekly Internet-based weight loss lessons containing information for modification of diet and activity behaviors, but not behavioral strategies for changing these behaviors.
89369513|NCT02653092|Active Comparator|Aim 1-Administration of FFA in an acute model|"Reproduction of the reproductive phenotype of obesity in Normal Weight Women (NWW) by:~1) infusing insulin and free fatty acids (FFAs) in short term experiments and measuring gonadotropin pulsatility and pituitary GnRH response Assessment of the gluco-regulatory and anti-lipolytic actions of insulin with a 2-stage, Hyperinsulinemic, Euglycemic Clamp (HEC) to evaluate both suppression of lipolysis and hepatic glucose production."
89369514|NCT02653092|Experimental|Aim 2-Hyperinsulinemic Euglycemic Clamp after a chronic administration of a diet|"Assessment of the gluco-regulatory and anti-lipolytic actions of insulin with a 2-stage, Hyperinsulinemic, Euglycemic Clamp (HEC) to evaluate both suppression of lipolysis and hepatic glucose production.~Inducing a chronic model of the reprometabolic syndrome by administering a eucaloric diet that is relatively high in pro-inflammatory omega-6 fatty acids and low in anti-inflammatory omega-3 fatty acids (high fat diet; HFD) for one month while monitoring gonadotropin pulsatility and daily urinary reproductive hormone excretion."
89369515|NCT03691454|Experimental|DOS|Docetaxel+Oxaliplatin+S-1
89369516|NCT03691454|Active Comparator|SOX|Oxaliplatin+S-1
89369517|NCT02421484|Experimental|allogeneic mesenchymal stromal cells|This is a Phase 1 dose escalation clinical trial that constitutes 3 dose cohorts with 3 participants per cohort who will receive intravenous doses of allogeneic bone marrow derived allogeneic mesenchymal stromal cells--0.3 million cells/kg, 1.0 million cells/kg, and 3.0 million cells/kg. We will proceed from the lower dose to the next higher dose if there are no safety concerns for each cohort.
89369518|NCT02736318|Experimental|processed osteochondral allograft|Implantation of 1 to 3 osteochondral products in osteochondral lesion of talus.
89369519|NCT03182764||never smokers|Never smokers are those who have never consumed cigarettes in their lifetime.
89369520|NCT03182764||Ex-smokers|Ex-smokers are those who consumed cigarettes previously but do not smoke at the time of the survey.
89369521|NCT03182764||Current smokers|Current smokers are those who, at the time of the survey, consume cigarettes daily or occasionally.
89369522|NCT03691142||Women with Hereditary Haemorrhagic Telangiectasia|Women with Hereditary Haemorrhagic Telangiectasia with at least one full term pregnancy
89002068|NCT06116435|Experimental|PreventT2 + Move group-based classes|Participants will receive a 6-month lifestyle weight management program based on the publicly available Prevent T2 curriculum (formally known as the National Diabetes Prevention Program), integrated with the Move group-based classes. Group classes will be delivered weekly in weeks 1-12, and biweekly in weeks 13-26. Group-based classes will be taught virtually by a trained Registered Dietitian from the Colorado Nutrition Obesity Research Center Clinical Intervention and Translation (CIT) Core.
89002069|NCT06116435|Experimental|PreventT2 + Move group-based classes + Fitness Membership|Participants will receive a 6-month lifestyle weight management program based on the publicly available Prevent T2 curriculum (formally known as the National Diabetes Prevention Program), integrated with the Move group-based classes. Group classes will be delivered weekly in weeks 1-12, and biweekly in weeks 13-26. Group-based classes will be taught virtually by a trained Registered Dietitian from the Colorado Nutrition Obesity Research Center Clinical Intervention and Translation (CIT) Core. Participants will also receive a 6-month membership to the Peloton fitness app.
89180126|NCT00800540|Other|COMBIGAN/AZARGA|COMBIGAN, followed by AZARGA, as randomized. Each fixed combination instilled in the study eye, one drop twice daily (9:00 and 21:00), for six weeks, with a 4-week washout period separating the two treatment periods.
89180127|NCT00800384|Experimental|1|ICD implant without defibrillation testing
89180128|NCT00800384|Active Comparator|2|ICD implant with defibrillation testing
89180129|NCT04108832|Experimental|TCM OA2|TCM OA2 3G BID FOR 8 WEEKS
89180130|NCT04108832|Placebo Comparator|PLACEBO|PLACEBO
89180131|NCT00796328|Experimental|1|
89369523|NCT03699722|Experimental|Education + Activities|12 modules which include the following topics: introduction to the CN and intervention, video about PrEP, PrEP use in combination with other HIV, STI, and pregnancy prevention, identification and strategizing about beliefs regarding PrEP initiation, addressing perceived risk, strategizing about vulnerability factors that may interfere with PrEP uptake, skills building for PrEP uptake, and enhanced referral to a PrEP provider. Up to 4 follow-up phone calls to reinforce strategies. Text messaging for support PrEP adherence.
89369524|NCT03699722|Active Comparator|Information|PrEP information brochures, frequently asked questions and questions to ask provider. Listing of local PrEP providers.
88875239|NCT02540226|Active Comparator|Intravenous tranexamic acid|Patients will receive 1g tranexamic acid in 100mL solution intravenously in the operating room before inflation of the tourniquet. They will again receive the same IV solution in the post-anesthesia care unit, approximately 3 hours after the first solution was given. They will also receive a 75cc topical saline solution approximately 5 minutes before the tourniquet is released.
89180132|NCT02604758|Experimental|Tidal Model|the psychiatric nursing approach based on the Tidal Model
89180133|NCT02604758|No Intervention|control group|The control group received routine treatment and follow-up in the Alcohol and Substance Addiction Treatment Clinic.
89180134|NCT02605382|Experimental|chlorhexidine gluconate|15 ml of solution every 12 hours, twice a day, 30 minutes after brushing, for 14 days
89180135|NCT02605382|Placebo Comparator|placebo|15 ml of solution every 12 hours, twice a day, 30 minutes after brushing, for 14 days
89180136|NCT04114916|Experimental|Apigenin, luteonin, grapefruit extract and citrolive|One capsules a day. It will be consumed at breakfast for eight weeks.
89180137|NCT04114916|Placebo Comparator|maltodextrina|One capsules a day. It will be consumed at breakfast for eight weeks.
89180138|NCT04110860|Experimental|once daily application|the gel is applied to the affected areas once daily for one week followed by a follow-up visit to reassess the case. if complete cure is achieved, stop application. if not, repeat for one more week and then reassess.
89180139|NCT04110860|Experimental|twice daily application|the gel is applied to the affected areas twice daily for one week followed by a follow-up visit to reassess the case. if complete cure is achieved, stop application. if not, repeat for one more week and then reassess.
89180140|NCT04110860|Placebo Comparator|placebo|the gel is applied to the affected areas twice daily for one week followed by a follow-up visit to reassess the case. if complete cure is achieved, stop application. if not, repeat for one more week and then reassess.
89180141|NCT04114760|Active Comparator|Group A : defibrillator ECG to patchy-type ECG|"Group A subject will performing ECG examination to a mock patient in the ambulance.~First ECG performance will be using defibrillator which contain 12-lead ECG checking function. And taking a 15 minutes wash out period. Second ECG performance after wash out period, will be using patchy-type wireless device.~when ECG examination performance ended, survey of patchy-type wireless ECG device usability will be collect."
89180142|NCT04114760|Experimental|Group B : patchy-type ECG to defibrillator ECG|"Group B subject will performing ECG examination to a mock patient in the ambulance.~First ECG performance will be using patchy-type wireless device.~And taking a 15 minutes wash out period. Second ECG performance after wash out period, will be using defibrillator which contain 12-lead ECG checking function.~when ECG examination performance ended, survey of patchy-type wireless ECG device usability will be collect."
89180143|NCT02604836|Experimental|Ibandronate|Participants will receive 150 milligrams (mg) of ibandronate as a film-coated tablet once-monthly.
89180144|NCT00588692|Active Comparator|SphygmoCor Unblinded|The use of the sphygmocor values will determine medication adjustments to optimize HF treatment.
89180145|NCT00588692|Placebo Comparator|SphygmoCor Blinded|Sphygmocor values will be blinded to the investigator.
89180146|NCT02604524|Experimental|Closed-Loop Control (CLC) System|Subjects will use the Closed-Loop Control system in an attempt to maintain blood glucose in a certain range during the day and at night during the trial.
89180147|NCT02604524|Placebo Comparator|Sensor Augmented Pump Therapy Group|Subjects will manage their own glucose levels during the trial.
89180148|NCT04114526|Experimental|Community Health Advisor 4-step Program|
89180149|NCT04110704|Active Comparator|Transvaginal cerclage|
89180150|NCT04110704|No Intervention|Active monitoring|
89180151|NCT04110548|Experimental|HCs on Emotion Regulation|Participants are screened using the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5), Young's online Internet addiction test (YIAT), Beck Depression Inventory (BDI), Beck Anxiety Inventory (BAI), and so on. They are instructed to complete the emotion regulation task on the computer.
89180152|NCT04110548|Experimental|IGDs on Emotion Regulation|Participants are screened using the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5), Young's online Internet addiction test (YIAT), Beck Depression Inventory (BDI), Beck Anxiety Inventory (BAI), and so on.They are instructed to complete the emotion regulation task on the computer.
89180153|NCT04110548|Experimental|IGDs on Craving Regulation|Participants are screened using the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5), Young's online Internet addiction test (YIAT), Beck Depression Inventory (BDI), Beck Anxiety Inventory (BAI), and so on. They are instructed to complete the craving regulation task on the computer.
89180154|NCT05616104||FLEX Vessel Prep followed by angioplasty|Eligible subjects will be treated with the FLEX Vessel Prep system followed by balloon angioplasty.
89369525|NCT03715543|Experimental|Surgical Resection Arm|Surgical Resection of the Greater Splanchnic Nerve
89369526|NCT03690908||IgG4-related orbital inflammation|patients with orbital inflammation and positive IgG4 immunostaining in orbital biopsy
89180155|NCT00915200|Placebo Comparator|Placebo|N-acetylcysteine placebo + silibin placebo
88842208|NCT02809430|Experimental|CPAP intervention|Participants will receive 3 nights of auto-CPAP in order to identify those with OSA using flow resistance detected by the device. After 3 nights, those without apparent OSA or with central apnea, and those who simply do not tolerate CPAP will be excluded from the study. An intensive CPAP adherence protocol (iCAP) will be initiated, including collaborative care with rehabilitation nurses, the study's sleep technologist and overnight respiratory therapists. After the run-in period, the sleep technologist will meet at least twice weekly with CPAP-tolerant participants during their rehabilitation stay for further OSA education and encouragement with a target adherence of 4 hours per night. Participants diagnosed with OSA by the device and tolerant will continue CPAP therapy during rehabilitation and at home for a treatment period of 3 months. Adherence will be downloaded remotely from participant's machines to encourage adherence to treatment and troubleshoot any problems with the device.
89369527|NCT03690908||non IgG4-related orbital inflammation|patients with orbital inflammation and negative IgG4 immunostaining in orbital biopsy
89369528|NCT02429362||Pregnant Women & their stillborn infants|All English speaking female patients who are seen in the Regional One Health perinatal clinics and/or deliver at Regional One Health are the group of study's focus. Likewise, when a delivery results in a stillbirth, the stillborn baby will also be an additional group of our study's focus.
89369529|NCT03718273|Active Comparator|Digoxin|Digoxin 0,25 mg. The initial dose will be based on whether there are factors such as age over 80 years, weight under 60 kg and creatinine clearance <60ml / min,
88842209|NCT03014492|Experimental|Collar Group|Soccer girls that wore the collar device
88842210|NCT03014492|No Intervention|No Collar Group|soccer girls that did not wear the collar
88842211|NCT02928380|Active Comparator|Reference Denture Adhesive|Participants applied reference denture adhesive as a 3 dabs those were applied to upper denture and 2 dabs those were applied to lower denture which were placed in the mouth.
88842212|NCT02928380|Experimental|Test Denture Adhesive|Participants applied test denture adhesive as 3 continuous strips those were applied to upper denture and one continuous strip that was applied to the lower denture, which were placed in the mouth.
88842213|NCT02928380|No Intervention|No Adhesive (Negative Control)|Participants did not apply any denture adhesive in this treatment arm.
88842214|NCT02930174|Active Comparator|Respironics V-60, then Draeger V500|Testing by applying noninvasive positive pressure ventilation (NPPV) via two different bilevel positive airway pressure (BiPAP) devices . Arm one applies the Respironics V-60, then the Drager V-500.
88842215|NCT02930174|Active Comparator|Draeger V500, then Respironics V-60|Testing by applying noninvasive positive pressure ventilation (NPPV) via two different bilevel positive airway pressure (BiPAP) devices . Arm two applies the Drager V-500, then the Respironics V-60.
88842216|NCT02933372|Experimental|Parkinson's Disease Patients|Participants take varenicline for several days and have two Positron Emission Tomography (PET) scans. PET scans are used to estimate how much varenicline is actually in the brain. Safety monitoring with clinical assessments of severity of Parkinson disease (PD) and cognition are performed.
88842217|NCT02933372|Experimental|Healthy Controls|Participants take varenicline for several days and have two Positron Emission Tomography (PET) scans. The PET scans are used to estimate how much varenicline is actually in the brain. Safety monitoring with clinical assessments for presence of Parkinson disease (PD) and cognition are performed.
88842218|NCT02933450|Active Comparator|Patiromer group|Patiromer 25.2 g dose
88842219|NCT02933450|No Intervention|Standard of Care group|Standard of Care
88842220|NCT02902237|Experimental|tTF-NGR|tTF-NGR will be given as 1-hour infusion via central venous access once daily for 5 days with a subsequent rest period of 2 weeks and following cycles with dose escalation of 0.5 mg/m2 upon judgement of tolerability and therapeutic activity. Starting dose will be 1 mg/m2/day. Dose-escalation is stopped before the maximum number of 8 escalation steps if tumor response, tumor progression or a Dose-Limiting Toxicity (DLT) is observed.
88842221|NCT02903407|Active Comparator|Midazolam|IV midazolam will be administered for sedation while patient is mechanically ventilated. Patient will be monitored per standard of care in the CICU using the Richmond Agitation and Sedation Scale (RASS) with a set goal sedation level of RASS 0 to -2. Pain will be monitored based on the Critical-Care Pain Observation Tool (CPOT) assessment with goal less than or equal to 2. Delirium will be evaluated based on the Confusion Assessment Method for the ICU (CAM-ICU) with goal of negative or patient's baseline.
88842222|NCT02903407|Active Comparator|Propofol or Dexmedetomidine|Propofol or Dexmedetomidine per physician discretion will be administered for sedation while patient is mechanically ventilated. Patient will be monitored per standard of care in the CICU using the Richmond Agitation and Sedation Scale (RASS) with a set goal sedation level of RASS 0 to -2. Pain will be monitored based on the Critical-Care Pain Observation Tool (CPOT) assessment with goal less than or equal to 2. Delirium will be evaluated based on the Confusion Assessment Method for the ICU (CAM-ICU) with goal of negative or patient's baseline.
88842223|NCT02811302|Other|Patients monitored by capnography|Capnography and pulse oximetry monitoring data will be collected for up to 48 hours while patients are on the hospital ward. In addition, a 1-month follow up will be completed.
89180156|NCT00915200|Experimental|N-acetylcysteine|N-acetylcysteine active + silibin placebo
89180157|NCT00915200|Experimental|silibin|N-acetylcysteine placebo + silibin active
89180158|NCT00915200|Experimental|N-acetycysteine + silibin|N-acetylcysteine active + silibin active
89180159|NCT00915200|Experimental|N-acetylcysteine + high-dose silibin|N-acetylcysteine active + high-dose silibin active
89369530|NCT03718273|Experimental|Ivabradine|Ivabradine 5 mg, twice a day the first month administered by mouth. If the tolerance is good, the dose will be increased to 7.5 mg on month 2 and will continue until the third month.
89369531|NCT03690830|Experimental|Case group RIF|blood samples, analyzing endometrial cells
89369532|NCT03690830|Experimental|Case group IRPL|blood samples, analyzing endometrial cells
89369533|NCT03690830|Active Comparator|Control group|blood samples, analyzing endometrial cells
89369534|NCT02421640|Experimental|Cisplatin+TIL|Cisplatin concurrent chemoradiotherapy(CCRT) combined with tumor-infiltrating lymphocyte (TIL)
89369535|NCT02421640|Active Comparator|Cisplatin|Cisplatin concurrent chemoradiotherapy(CCRT) only
89369536|NCT01311193|Experimental|light therapy|Morning bright light treatment (at 8000 lux for 40min, daily during 3 weeks)
89369537|NCT02429284||Patients newly diagnosed with CTEPH|Patients newly diagnosed with chronic thromboembolic pulmonary hypertension (CTEPH), WHO Group IV Classification for Pulmonary Hypertension.
89369538|NCT03417505|Experimental|Treated followed by untreated|Patients wear the Hydra-PEG treated scleral lenses for 30 days. After testing and a post contact lens wear washout period, these patients will then wear the untreated lenses for 30 days. In this arm, the intervention (scleral lenses treated with Tangible Hydra-PEG) is administered prior to the control treatment (untreated scleral lenses).
89369539|NCT03417505|Experimental|Untreated followed by treated|Patients wear the untreated scleral lenses for 30 days. After testing and a post contact lens wear washout period, these patients will then wear the Hydra-PEG treated lenses for 30 days. In this arm, the intervention (scleral lenses treated with Tangible Hydra-PEG) is administered after the control treatment (untreated scleral lenses).
88842224|NCT02905981|Experimental|Period 1: Iron Absorption Tests|During 3 consecutive weekly study visits, patients will receive Fer-In- Sol orally 3 milligram iron per kilogram (mg Fe/kg) body weight, Shohl's solution 0.67 millimoles per kilogram (mmol/kg) followed 5 - 15 minutes later by Fer-In- Sol orally 3 mg Fe/kg body weight, and Shohl's solution 0.67 mmol/kg followed 5 - 15 minutes later by Triferic orally 3 mg Fe/kg body weight (respectively). All oral doses will be administered by study personnel at the research center. Blood tests will be conducted following each administration in order to measure iron absorption to see if patients qualify for Period 2.
88842225|NCT02905981|Experimental|Period 2: Dose Titration|Patients who qualified as 'Triferic responders' in Period 1 will participate in Period 2. Patients will be given oral Shohl's solution and Triferic to administer at home 3 times per day, with the dose being titrated higher or lower based on lab results. The initial dose will be the same as Period 1 (Shohl's solution 0.67 mmol/kg followed 5 - 15 minutes later by Triferic orally 3 mg Fe/kg body weight) but may be adjusted during Period 2 based on lab results. Period 2 will involve 5 study visits, scheduled every 4 weeks. At the end of Period 2, blood tests will be performed to determine if patients qualify for Period 3.
88842226|NCT02905981|Experimental|Period 3: Hemoglobin Maintenance|Patients who qualified as 'hemoglobin responders' in Period 2 will participate in Period 3. Patients will continue to take Shohl's solution and Triferic at their titrated dose for an additional six months to confirm that their hemoglobin can be maintained over an extended period of time. The period will be comprised of 3 study visits, scheduled every 8 weeks.
88842227|NCT02907073|Experimental|Healthy Volunteers|At the study visit, healthy subjects will have an initial physical exam, urine pregnancy test (if applicable) and will have catheters placed for i.v. drug administration and blood sampling. Vital signs, and blood samples will be obtained. Subjects will receive an infusion [18F]BF4 over 1 minute and PET imaging will begin. Three (3) PET/CT scanning procedures will be performed over a period of approximately 4 hours with two rest breaks in between. Venous blood samples for clinical laboratory tests will be taken before radiotracer administration and at 1.5 hours post-administration of radiotracer. In addition, venous blood samples will be taken during the PET/CT scans to determine blood pharmacokinetics and metabolite evaluation. Physical exam will be repeated at the end of the study.
89369540|NCT02421562|Experimental|training in hypnoanalgesia|training nurses in hypnoanalgesia to perform painful procedure in children
89369541|NCT02421328|Active Comparator|CPAP first|Infant will be given nasal CPAP for 60 minutes and then put on HHHFNC for another 60 minutes. Ultrasonographic assessment of diaphragmatic dimensions and excursion will be done at the end of the 60 minute periods on nasal CPAP and HHHFNC. After the 2 h study period (2×60 minutes epochs) further respiratory support will be at the discretion of the clinical team
89369542|NCT02421328|Active Comparator|HHHFNC first|Infant will be given HHHFNC for 60 minutes and then switched to nasal CPAP for another 30 minutes. Ultrasonographic assessment of diaphragmatic dimensions and excursion will be done at the end of the 60 minute periods on HHHFNC and nasal CPAP. After the 2 h study period (2×60 minutes epochs) further respiratory support will be at the discretion of the clinical team
89369543|NCT02425150|Experimental|Corneal reshaping/crosslinking (CRXL)|Corneal crosslinking with compression of the cornea using a sutured rigid contact lens during the treatment.
89369544|NCT02425150|Active Comparator|Corneal crosslinking (CXL)|Standard corneal crosslinking using the Dresden protocol.
89369545|NCT02425150|No Intervention|Control group to CRXL|Healthy subjects, age- and sex-matched to the CRXL group.
89369546|NCT02425150|No Intervention|Control group to CXL|Healthy subjects, age- and sex-matched to the CXL group.
89369547|NCT03715387|Experimental|Tacrolimus Treatment|Tacrolimus Topical 0.1% Topical Ointment
89369548|NCT03715387|Placebo Comparator|Control|Patients will be self matched controls with one cheek receiving the study ointment and the other receiving a control ointment (polysporin ointment).
89369549|NCT02425072|Experimental|NovoTTF-100A plus chemotherapy|NovoTTF-100A System with Physician's Choice Chemotherapy
89369550|NCT03715309|Experimental|Revlimd|
88875240|NCT02540226|Experimental|Topical tranexamic acid|Patients will receive 3g tranexamic acid in 75mL solution topically in the operating room, approximately 5 minutes before the tourniquet is released. It will sit for 5 minutes before the solution is suctioned off by the surgeon. They will also receive 2 intravenous saline solutions: one in the operating room before inflation of the tourniquet, and one in the post-anesthesia care unit 3 hours after the first solution was given.
89369551|NCT02429206|Active Comparator|Positive Control|Each volunteer will be asked to self-apply a standard moisturizing cream (Glaxal Base) on one side of their body. Application twice a day during 14 days.
89369552|NCT02429206|Experimental|Experimental Cream|Each volunteer will be asked to self-apply the experimental product (SQIN with CanSATs technology) on the other side of their body. Application twice a day during 14 days.
89369553|NCT03182608|Experimental|Group 1|In the lateral decubitus position, an investigator evaluate the L4-5 interspinous level using an anatomic landmark (Tuffier's line), and then evaluate the L4-5 interspinous level using another anatomic landmark (Tenth rib line). Another investigator evaluate the actual L4-5 interspinous level by noninvasive ultrasonography.
89369554|NCT03182608|Experimental|Group 2|In the lateral decubitus position, an investigator evaluate the L4-5 interspinous level using an anatomic landmark (Tenth rib line), and then evaluate the L4-5 interspinous level using another anatomic landmark (Tuffier's line). Another investigator evaluate the actual L4-5 interspinous level by noninvasive ultrasonography.
89369555|NCT03182530|Active Comparator|ULTRA method group|
89369556|NCT03182530|Active Comparator|standard patent hemostasis group|
89369557|NCT03182530|Experimental|control group|
89369558|NCT03179254|Experimental|Oral hypoglycemic agent continue|Metformin continue on the day of surgery
89369559|NCT03179254|Active Comparator|Oral hypoglycemic agent discontinue|Metformin discontinue on the day of surgery
89369560|NCT02953639|Placebo Comparator|Placebo|Participants received matching Placebo to Basmisanil orally twice daily for 24 weeks.
89369561|NCT02953639|Experimental|Basmisanil 80mg BID|Participants received Basmisanil 80 mg orally twice daily (BID) for 24 weeks.
89369562|NCT02953639|Experimental|Basmisanil 240mg BID|Participants received Basmisanil 240 mg orally twice daily (BID) for 24 weeks.
89369563|NCT04147715|Placebo Comparator|Part 1: Placebo|Participants received a single oral dose of matching placebo in a fasted state on Day 1.
89369564|NCT04147715|Experimental|Part 1: 10 mg S-648414|Participants received a single oral dose of 10 mg S-648414 in a fasted state on Day 1.
89369565|NCT04147715|Experimental|Part 1: 30 mg S-648414|Participants received a single oral dose of 30 mg S-648414 in a fasted state on Day 1.
89369566|NCT04147715|Experimental|Part 1: 100 mg S-648414|Participants received a single oral dose of 100 mg S-648414 in a fasted state on Day 1 followed by a single dose of S-648414 in a fed state (after a high-fat meal) on Day 14.
89369567|NCT04147715|Experimental|Part 1: 250 mg S-648414|Participants received a single oral dose of 250 mg S-648414 in a fasted state on Day 1.
89369568|NCT04147715|Experimental|Part 1: 500 mg S-648414|Participants received a single oral dose of 500 mg S-648414 in a fasted state on Day 1.
89369569|NCT04147715|Experimental|Part 1: 1000 mg S-648414|Participants received a single oral dose of 1000 mg S-648414 in a fasted state on Day 1.
89369570|NCT04147715|Placebo Comparator|Part 2: Placebo + Midazolam|Participants received matching placebo once a day on Days 1 to 14 and a single oral dose of 5 mg midazolam alone on Day -2 and co-administered with the placebo dose on Day 14.
89369571|NCT04147715|Experimental|Part 2: 50 mg S-648414 + Midazolam|Participants received 50 mg S-648414 once a day on Days 1 to 14 and a single oral dose of 5 mg midazolam alone on Day -2 and co-administered with the S-648414 dose on Day 14.
89369572|NCT04147715|Experimental|Part 2: 30 mg S-648414 + Midazolam|Participants received 30 mg S-648414 once a day on Days 1 to 14 and a single oral dose of 5 mg midazolam alone on Day -2 and co-administered with the S-648414 dose on Day 14.
89369573|NCT04147715|Experimental|Part 3: 100 mg S-648414 + Dolutegravir|Participants received 50 mg dolutegravir orally once a day on Days 1 to 7, 100 mg S-648414 orally once a day on Days 15 to 21, and 50 mg dolutegravir co-administered with 100 mg S-648414 orally once a day on Days 22 to 28.
89369574|NCT04147715|Experimental|Part 3: 200 mg S-648414 + Dolutegravir|Participants received 50 mg dolutegravir orally once a day on Days 1 to 7, 200 mg S-648414 orally once a day on Days 15 to 21, and 50 mg dolutegravir co-administered with 200 mg S-648414 orally once a day on Days 22 to 28.
89369575|NCT02420938|Experimental|Rituximab + Urelumab|Participants receive Rituximab 375 mg/m2 by vein weekly for the first 4 weeks (Days 1, 8, 15, 22) then the day prior to each subsequent dose of Urelumab for the 12-week course. Urelumab 8 mg by vein given every 3 weeks for 4 doses, starting Day 2 of the course. Urelumab doses administered approximately 24 hours after the Rituximab doses. Up to two 12-week courses of treatment administered (total of maximum 12 doses of Rituximab and 8 doses of Urelumab).
89369576|NCT02429440|Experimental|Study Arm 1|Intradermal application of peptide vaccine in combination with Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)
89369577|NCT02429440|Active Comparator|Study Arm 2|Intradermal application of peptide vaccine with Montanide ISA-51
89369578|NCT03182452||Pre Phase (no Alarm Advisor)|No Software installed
88819332|NCT02394756|Experimental|Marketed Soft Contact Lens (Test)|Subjects will be randomized to wear each of three contact lens types (Marketed Soft Contact lens, AIR OPTIX® AQUA, or Biofinity®) for a 4-week period with each lens type.
88819333|NCT02394756|Active Comparator|AIR OPTIX® AQUA|Subjects will be randomized to wear each of three contact lens types (Marketed Soft Contact lens, AIR OPTIX® AQUA, or Biofinity®) for a 4-week period with each lens type.
88819334|NCT02394756|Active Comparator|Biofinity®|Subjects will be randomized to wear each of three contact lens types (Marketed Soft Contact lens, AIR OPTIX® AQUA, or Biofinity®) for a 4-week period with each lens type.
88819335|NCT02213900|Experimental|Haloperidol|Randomized patients will receive 0.5mg Haloperidol immediately after surgery and Q8H following the initial dose for a total of 4 days.
88819336|NCT02213900|Placebo Comparator|Placebo|Randomized patients will receive a placebo solution immediately after surgery and Q8H following for a total of 4 days.
88819337|NCT02370888|Experimental|Lenalidomide|"Lenalidomide will be administered for a total of 42 days.~The dose levels of lenalidomide will be as follows:~Dose Level 1: 2.5 mg PO QOD Day 1-21 for 28-day cycle X 2 cycles~Dose Level 2: 2.5 mg PO QD Day 1-21 for 28-day cycle X 2 cycles~Dose Level 3: 5 mg PO QD Day 1-21 for 28-day cycle X 2 cycles~Dose Level 4: 7.5 mg PO QD Day 1-21 for 28-day cycle X 2 cycles"
88819338|NCT05358873|Experimental|Human IgG1 anti-SARS-CoV-2 antibody cocktail|Subjects will receive the Hypromellose-based nasal spray solution containing human IgG1 anti-SARS-CoV-2 antibody cocktail (i.e., applied into both nostrils by spraying two times per nostril) 3 times a day from Day 1 to Day 7. Each day the study products will be self-administered at 8 am, 2 pm, and 8 pm.
89369579|NCT03182452||Post Phase (Alarm Advisor installed)|Software implemented and staff trained (Interventional Phase)
89369580|NCT02429518||Miltefosine|Miltefosine: target of 2.5 mg/kg/day for 28 days
89369581|NCT00708526|Experimental|Phase 1 Recovery|Quick Emergence Device is in place for phase 1 anesthesia recovery
89369582|NCT00708526|Other|Standard of care|Tidal volume and respiratory rate are not changed during phase 1 recovery from anesthesia
89369583|NCT03712735|Active Comparator|Group A|"Bupivacaine 0.08% - fentanyl 2mcg on the following pump settings:~PIEB flow rate = high; interval = 60 min"
89369584|NCT03712735|Experimental|Group B|Bupivacaine 0.08% - fentanyl 2mcg on the following pump settin PIEB flow rate = high; interval = 45 min
89369585|NCT03712735|Experimental|Group C|Bupivacaine 0.08% - fentanyl 2mcg on the following pump settin PIEB flow rate = low; interval = 45 min
89369586|NCT02428816|Experimental|Patients with Parkinson's Disease|Patients with PD will be submitted to an MRI acquisition and to behavioural evaluations in each visits (two visits planned)
88842228|NCT02907073|Experimental|Myeloma patients|For cancer patients undergoing virus treatments, subjects will undergo [18F]BF4-PET/CT imaging at baseline before virus administration and at day 9 following virus treatment. Subjects will be screened by physician specialists within their clinics. Subjects who qualify for the study will return to the clinic within 30 days of screening, have a urine pregnancy test (if applicable) and will have catheters placed for i.v. drug administration. Vital signs will be obtained. All subjects will then receive a single i.v. bolus of [18F]BF4 for injection and PET/CT imaging will begin. Biopsies will be performed to confirm NIS expression in tissue of tumor regions showing uptake of [18F]BF4 in up to three myeloma patients when the site is accessible for biopsy.
89369587|NCT02428816|Experimental|Patients with MSA|Patients with MSA will be submitted to an MRI acquisition and to behavioural evaluations in each visits (two visits planned)
89369588|NCT02428816|Experimental|Controls|30 healthy controls will be submitted to an MRI acquisition and to behavioural evaluations in a sole visit
89369589|NCT03718195|Other|Pediatric formula|"Each child will receive a new formula for a period of seven days. The new formula is a nutritionally complete standard enteral tube feed, with ingredients derived from real food. The formula is a food for special medical purposes for use under medical supervision.~The dietitian will determine the feeding regimen on an individual basis and the enteral formula will be provided via a feeding tube"
89369590|NCT02452554|Experimental|Treatment (lorvotuzumab mertansine)|Patients receive lorvotuzumab mertansine IV over 1-1.5 hours on days 1 and 8. Treatment repeats every 21 days for up to 17 courses in the absence of disease progression or unacceptable toxicity.
89369591|NCT03712501|Experimental|Exercise|Participants will walk for 60 minutes at 60% maximal oxygen uptake on day 1. Participants will return the following day and consume a high fat breakfast and lunch.
89369592|NCT03712501|No Intervention|Control|Participants will rest on day 1. Participants will return the following day where they will consume a high fat breakfast and lunch.
89369593|NCT03182374|Active Comparator|nSTRIDE APS|The nSTRIDE APS Kit is designed to be used for the safe and rapid preparation of APS from a small sample of blood at the patient's point of care. The APS is to be injected intra-articularly for the treatment of knee osteoarthritis and associated symptoms.
89180160|NCT04108754||Diagnosis of AIT|Patients in the neurovascular unit of the Neurological Hospital of Lyon between 01/01/2016 and 30/12/2017 with a probable diagnosis of AIT and having an MRI within 7 days of TIA.
89369594|NCT03182374|Active Comparator|Synvisc-One|Synvisc-One is only intended for intra-articular use by a physician to treat pain associated with osteoarthritis of the knee
88875241|NCT02540772|Experimental|Neuropsychological treatment|The tested treatment is a combination of neuropsychological rehabilitation procedures: learning, episodic memory recall after a delay, selective attention, inhibition of predominant responses and awareness of deficits.
88875242|NCT02540772|No Intervention|No treatment|Patients in the control group only performed the baselines.
88875243|NCT02541864|Experimental|Bismuth quadruple therapy|pantoprazole 40 mg bid for 14 days, bismuth subcitrate 120 mg qid for 14 days, tetracycline 500 mg qid for 14 days, metronidazole 250 mg qid for 14 days
89180161|NCT00588146|Experimental|Pegylated Interferon Alpha2b, then Standard Care|Weekly subcutaneous injection of pegylated interferon alpha2b 1 microgram/kg/week for 6 months, then standard care for 6 months.
89369595|NCT01319682|Active Comparator|Intravenous lidocaine injection group|Patients in Group I (intravenous lidocaine injection group) received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous lidocaine infusion of 2 mg/kg/hr.
89369596|NCT01319682|Placebo Comparator|Placebo control group|Patients in Group C (placebo control group) received normal saline intravenous injection
89369597|NCT03715075||Post-caesarean section group|This single cohort observational study shall recruit women undergoing elective caesarean section within the Simpson's Centre for Reproductive Health (SCRH).
89369598|NCT03182062|Active Comparator|OLA-iHFNC|"Intraoperatively ventilated patients with a tidal volume (VT) of 5-6ml / kg of ideal body weight and respiratory rate to maintain normal carbon dioxide. After intubation, in all patients will be performed an alveolar recruitment maneuver (MRA) and a PEEP titration trial (see Calculation of optimal PEEP). Every 40 minutes will be assessed the need to adjust the level of PEEP by evaluating the dynamic compliance of the respiratory system (Crs). Faced with a decline in Crs> 10% a new MRA and optimal PEEP setting will be assessed.~Postoperatively, high flow oxygen therapy will be individually indicated by evaluating peripheral oxygen saturation."
89369599|NCT03182062|Active Comparator|STD-O2|"Intraoperatively ventilated patients with a tidal volume of 5-6 ml / kg of ideal body weightand respiratory rate to maintain normal carbon dioxide, PEEP 5 cmH2O. In this group no recruitment maneuvers or optimal PEEP setting will be performed.~Postoperatively, standard oxygen therapy."
89369600|NCT01373424||Cervical dystonia|People diagnosed with cervical dystonia
89369601|NCT01373424||Laryngeal dystonia|People diagnosed with laryngeal dystonia
89369602|NCT01373424||Other voice disorders|People diagnosed with a voice disorder other than laryngeal dystonia - enrollment for this group is complete
89369603|NCT01373424||Craniofacial dystonia|People diagnosed with craniofacial dystonia (including blepharospasm, meige syndrome, and oromandibular dystonia)
89369604|NCT01373424||Limb dystonia|People diagnosed with limb dystonia
89369605|NCT01373424||All other isolated dystonias|People diagnosed with any isolated dystonia not listed in descriptions of other cohorts
89369606|NCT01373424||Myoclonus dystonia|People diagnosed with myoclonus dystonia
88842229|NCT02907073|Experimental|Endometrial cancer patients|For cancer patients undergoing virus treatments, subjects will undergo [18F]BF4-PET/CT imaging at baseline before virus administration and at day 9 following virus treatment. Subjects will be screened by physician specialists within their clinics. Subjects who qualify for the study will return to the clinic within 30 days of screening, have a urine pregnancy test (if applicable) and will have catheters placed for i.v. drug administration. Vital signs will be obtained. All subjects will then receive a single i.v. bolus of [18F]BF4 for injection and PET/CT imaging will begin. Biopsies will be performed to confirm NIS expression in tissue of tumor regions showing uptake of [18F]BF4 in up to three endometrial cancer patients when the site is accessible for biopsy.
89369607|NCT01373424||Dopa-responsive dystonia|People diagnosed with dopa-responsive dystonia
89369608|NCT03717883||Healthy subjects|
89369609|NCT03717883||Subjects with ADPKD|
89369610|NCT02424916|Experimental|Autologous somatic cell therapy|Patients treated with melanoma antigens-specific CD8+ T lymphocytes followed by subcutaneous injections of Proleukin.
89369611|NCT04009577|Experimental|Cohort 1 (LEM 5 mg)|"Participants who were taking zolpidem tartrate (ZOL) at least 3 but fewer than 5 nights per week, for each of at least 2 weeks of the 3-week Screening Period, will initially receive LEM 5 mg administered as a tablet, orally for up to 2 weeks.~Participants who meet both criteria for intermittent (Cohort 1) and frequent ZOL use (Cohort 2A and 2B) for 1 week each of the last 2 weeks of the 3-week Screening Period will be assigned to Cohort 1 and also will receive LEM 5mg."
88842230|NCT02812160|Active Comparator|Spatz3 Adjustable Balloon|Spatz3 Adjustable Balloon with Dietary and exercise counselling
88842231|NCT02812160|No Intervention|Control|Dietary and Exercise counselling
88842232|NCT02812238|Experimental|Arm 1|Either NR at 1000mg/day or placebo for one week, followed by a washout period of 2-3 weeks, then a crossover to placebo or NR at 1000mg/day for one additional week. The end point was analyzed at end of each treatment.
88842233|NCT02812238|Experimental|Arm 2|Either NR at 1000mg/day or placebo for one week, followed by a washout period of 2-3 weeks, then a crossover to placebo or NR at 1000mg/day for one additional week. The end point was analyzed at end of each treatment.
88842234|NCT03015649|Experimental|SCOUT device|"The study population consists of 25 - 35 adult surgical patient volunteers who plan to have definitive breast cancer surgery at Memorial Healthcare System (MHS) Hospitals after neoadjuvant treatment.~The investigator will identify subjects who meet inclusion/exclusion criteria, obtain patient's consent and schedule the subject for the SAVI SCOUT Surgical Guidance System procedure. All study participants will receive the same treatment assignment, i.e. lesion localization with the SCOUT device 31 - 365 days prior to surgery. Neoadjuvant treatment decisions will be determined by patient's medical oncologist."
88842235|NCT03015961|Active Comparator|EXPAREL admixed with bupivacaine HCl|EXPAREL 266 mg + bupivacaine HCl
88842236|NCT03015961|Placebo Comparator|Bupivacaine HCl|Bupivacaine HCl
88842237|NCT02814656|Experimental|Cohort 1, AZD8871 300 μg or placebo|In Cohort 1, participants will receive a single dose of AZD8871 300 μg or placebo on Day 1, followed by once daily dosing on Days 5 to 16.
88842238|NCT02814656|Experimental|Cohort 2, AZD8871 600 μg or placebo|In Cohort 2, participants will receive a single dose of AZD8871 600 μg or placebo on Day 1, followed by once daily dosing on Days 5 to 16.
89369612|NCT04009577|Experimental|Cohort 2A (LEM 5 mg)|Participants who were taking ZOL at least 5 nights per week, during, at minimum, the last 2 weeks of the 3-week Screening Period, will initially receive LEM 5 mg administered as a tablet, orally for up to 2 weeks.
89369613|NCT04009577|Experimental|Cohort 2B (LEM 10 mg)|Participants who were taking ZOL at least 5 nights per week, during, at minimum, the last 2 weeks of the 3-week Screening Period, will initially receive LEM 10 mg administered as a tablet, orally for up to 2 weeks.
89369614|NCT03714841|Experimental|CRP value|The patients point of care CRP value is known by the treating physician
89369615|NCT03714841|Active Comparator|CRP value unknown|The patients point of care CRP value is not known by the treating physician
89369616|NCT02176668|Experimental|Cohort1-YH4808 NF 100|7 days repeat administration of YH4808 New Formulation 100mg after meal
89369617|NCT02176668|Experimental|Cohort1-YH4808 OF 200|(Partial cross over design) 7 days repeat administration of YH4808 Old Formulation 200mg after meal, 4 Weeks of wash out period, 7 days repeat administration of YH4808 New Formulation 200mg after meal
89369618|NCT02176668|Experimental|Cohort1-YH4808 NF 200|(Partial cross over design) 7 days repeat administration of YH4808 New Formulation 200mg after meal, 4 Weeks of wash out period, 7 days repeat administration of YH4808 Old Formulation 200mg after meal
89369619|NCT02176668|Experimental|Cohort1-YH4808 NF 400|7 days repeat administration of YH4808 New Formulation 400mg after meal
89369620|NCT02176668|Experimental|Cohort2-YH4808 NF 100|7 days repeat administration of YH4808 New Formulation 100mg before meal
88842239|NCT02814656|Experimental|Cohort 3, AZD8871 900 μg or placebo|In Cohort 3, participants will receive a single dose of AZD8871 900 μg or placebo on Day 1, followed by once daily dosing on Days 5 to 16.
88842240|NCT03018223|Experimental|Conditioning/HCT/GVHD Prophylaxis|"Pre-HCT Conditioning, HCT, GVHD Prophylaxis.~Conditioning regimen: To reduce heterogeneity, two commonly used myeloablative (MAC) and reduced intensity (RIC) regimens are permitted on this trial. Myeloablative conditioning: fludarabine, busulfan. Reduced intensity conditioning: fludarabine, cyclophosphamide, total body irradiation.~Peripheral blood hematopoietic cell transplantation~Graft vs. Host Disease (GVHD) prevention treatment: cyclophosphamide, mycophenolate mofetil, sirolimus.~Growth factor support: G-CSF"
88842241|NCT03018925||Ulcerative Colitis|"The proposed study will include 15 UC anti-TNF naïve patients . We will consider remission when patients have an endoscopic Mayo score ≤1, and activity index score, Mayo= 0 points.~Stool samples will be collected before starting Anti-TNF treatment (M0), and then every 3 months (M1, M2, M3 and M4) to complete the study.~GOLIMUMAB induction with 200mg at week 0, and 100mg at week 2. Under 70kg, the follow up treatment will be 50mg/month, and 100mg/month in patients over 70kg, as clinical practice."
88842242|NCT02814890|Experimental|Ropivacaine and dexmedetomidine|Thoracic paravertebral block is performed using 75mg/20ml ropivacaine + 1μg/kg dexmedetomidine at the end of video-assisted pneumonectomy.
88842243|NCT02814890|Active Comparator|Ropivacaine only|Thoracic paravertebral block is performed using 75mg/20ml ropivacaine at the end of video-assisted pneumonectomy.
88842244|NCT03019783|Placebo Comparator|Remains on baseline HIV regimen|Subjects are enrolled and either kept on their baseline regimen. This is being designated the placebo comparator.
88842245|NCT03019783|Active Comparator|Atazanavir switch|These subjects are switched to an atazanavir-based regimen.
88842246|NCT02815982|Experimental|NOURISH-T|"The intervention aims to increase caregivers' self-efficacy for behavioral change, and facilitate an authoritarian approach to parenting. Behavioral strategies such as self-monitoring, contingency management, and stimulus control are integrated in these sessions. Further, because participatory experiences enhance overall intervention efficacy, these activities are incorporated throughout, including self-assessments, discussions and experiential activities. Homework is assigned between sessions so skills can be practiced. We also focus on the caregivers' relationship with everyone in the family, not just the identified patient or overweight child."
88842247|NCT02815982|Active Comparator|Enhanced Usual Care|Caregivers randomized to the EUC will attend assessment sessions and an initial session moderated by an independent interventionist. The session addresses the role of diet and exercise in pediatric overweight. In addition, EUC caregivers receive nationally available print or web-based brochures on pediatric overweight on 2 occasions during the study so that similar (but not as intensive) information is provided in the intervention and EUC arms of the study. Participants also receive a booster phone call 2 months after the end of the intervention period.
88842248|NCT03019939|Experimental|Prevention (isavuconazole)|Patients receive isavuconazole PO every 8 hours for 6 doses and then Once a day (QD) or IV over 1 hour every 8 hours for 6 doses and then QD for up to 4 days for 12 weeks in the absence of disease progression or unacceptable toxicity.
88842249|NCT03017924|Experimental|Q collar|Subjects that will wear the Q collar during the breacher training
88842250|NCT03017924|No Intervention|No collar|Subjects that will not wear the Q collar during the breacher training
88842251|NCT03020095|Experimental|Ravidasvir,Danoprevir/r,RBV|Participants will receive Ravidasvir 200mg plus Ritonavir boosted Danoprevir 200/200mg,and Ribavirin 1000/1200mg daily for 12 weeks.
88842252|NCT02818244|Active Comparator|Fit Bit Blaze|Fit Bit Blaze Heart Rate Monitoring Device
88842253|NCT02818244|Active Comparator|Garmin Forerunner 235|Garmin Forerunner 235 Heart Rate Monitoring Device
88842254|NCT02818244|Active Comparator|Tom Tom Spark Cardio|Tom Tom Spark Cardio Heart Rate Monitoring Device
88842255|NCT02818244|Active Comparator|Apple Watch|Apple Watch Heart Rate Monitoring Device
88842256|NCT02818244|Active Comparator|Scosche Rhythm +|Scosche Rhythm + Heart Rate Monitoring Device
88842257|NCT02934698|Experimental|Ivacaftor|There is only one arm to this study. The two sisters with Cystic Fibrosis will both receive Ivacaftor for 6 months for their treatment.
88842258|NCT03019796|Experimental|PLACEBO FIRST THEN MEDICATED|Subjects first receive the PLACEBO tablet during 72 hours (full withdrawal). After a week of taking again their medication (MEDICATION TRIAL), they will be tested again. This procedure will be repeated before and after 4 months of aerobic training.
88842259|NCT03019796|Experimental|MEDICATED FIRST THEN PLACEBO|Subjects first receive their antihypertensive MEDICATION tablet (habitual dose prescribed by their primary care doctors). After a week they will take a PLACEBO tablet for 72 hours and will be tested again. This procedure will be repeated before and after 4 months of aerobic training.
88842260|NCT03020719|Experimental|Oral Glutathione|Oral Glutathione oral powder at 65mg/kg/day
89369621|NCT02176668|Experimental|Cohort2-YH4808 NF 200|(Partial cross over design) 7 days repeat administration of YH4808 New Formulation 200mg before meal, 4 Weeks of wash out period, 7 days repeat administration of YH4808 Old Formulation 200mg before meal
89369622|NCT02176668|Experimental|Cohort2-YH4808 OF 200|(Partial cross over design) 7 days repeat administration of YH4808 New Formulation 200mg before meal, 4 Weeks of wash out period, 7 days repeat administration of YH4808 Old Formulation 200mg before meal
88842261|NCT03020719|Placebo Comparator|Placebo|Placebo oral powder at 65mg/kg/day
88842262|NCT03021343|Active Comparator|Colchicine|Colchicine 2 mg 12-24 hours prior to surgery and 1 mg 4 hours before or immediately after surgery and then continued at a dose of 0.5 mg twice daily until hospital discharge. Half the dose was given to patients weighing <70 kg or intolerant to the full dose.
88842263|NCT03021343|No Intervention|No colchicine|In this arm no active medication was administered
88842264|NCT03022435|Other|Group B: 18-30 yo identical twins (LAIV)|Participants to receive FluMist® LAIV by nasal spray.
88842265|NCT03022435|Other|Group B: 18-30 yo identical twins (TIV)|Participants to receive Fluzone® standard TIV
88842266|NCT03022435|Other|Group D: 40-64 yo identical twins (TIV)|Participants to receive Fluzone® standard TIV
88842267|NCT03022435|Other|Group F: 65-100 yo identical twins (TIV)|Participants to receive Fluzone® standard TIV
88842268|NCT03022435|Other|Group F: 65-100 yo identical twins (High-Dose TIV)|Participants to receive High-Dose Fluzone® standard TIV
89369623|NCT02176668|Experimental|Cohort2-YH4808 NF 400|7 days repeat administration of YH4808 New Formulation 400mg before meal
89369624|NCT02176668|Experimental|Cohort3-YH4808 OF 200|"(Partial cross over design)~7 days repeat administration of YH4808 Old Formulation 200mg before bed, 4 Weeks of wash out period, 7 days repeat administration of YH4808 Old Formulation 200mg before dinner~7 days repeat administration of YH4808 Old Formulation 200mg before dinner, 4 Weeks of wash out period, 7 days repeat administration of YH4808 Old Formulation 200mg before bed"
89369625|NCT02176668|Experimental|Cohort3-YH4808 OF 400|"(Partial cross over design)~7 days repeat administration of YH4808 Old Formulation 400mg before bed, 4 Weeks of wash out period, 7 days repeat administration of YH4808 Old Formulation 400mg before dinner~7 days repeat administration of YH4808 Old Formulation 400mg before dinner, 4 Weeks of wash out period, 7 days repeat administration of YH4808 Old Formulation 400mg before bed"
89369626|NCT02424838|Active Comparator|22 gauge with suction|EUS-FNA of pancreatic masses will be performed with a 22 gauge needle using suction.
89369627|NCT02424838|Active Comparator|22 gauge without suction|EUS-FNA of pancreatic masses will be performed with a 22 gauge needle without suction.
89369628|NCT02424838|Active Comparator|25 gauge with suction|EUS-FNA of pancreatic masses will be performed with a 25 gauge needle using suction.
89369629|NCT02424838|Active Comparator|25 gauge without suction|EUS-FNA of pancreatic masses will be performed with a 25 gauge needle without suction.
89369630|NCT03714763|Experimental|Drug treatment|Subjects who show high expression of dopamine D2 receptors in PET-MR imaging.
89369631|NCT03714763|Experimental|Surgery|Subjects who show low expression of dopamine D2 receptors in PET-MR imaging.
89369632|NCT04640532|Experimental|Cohort 1 (R/R MF), Dose Level 1|"TL-895 at 200 mg once a day (QD) continuously starting on Cycle 1 Day 1 in a 28-day cycle.~KRT-232 240mg will be administered orally, once daily (QD), on days 1-7 in a 28-day cycle starting on Cycle 2 Day 1."
88842269|NCT02936648|Experimental|quality improvement intervention|The intervention activities included: assessment, planning, stakeholder engagement, education, ongoing process monitoring, program adaptation, problem identification and problem solving, data audit/feedback, program marketing, network development, among others.
88842270|NCT03023683|Other|Group A: 2-8 yo healthy non-twins|Participants will be given seasonal live, attenuated influenza vaccine (LAIV), FluMist® . Children with no prior influenza vaccine history will receive a second dose of LAIV at least 28 days after the first study dose.
89369633|NCT04640532|Experimental|Cohort 1 (R/R MF), Dose Level 2|"TL-895 at 300 mg once a day (QD) continuously starting on Cycle 1 Day 1 in a 28-day cycle.~KRT-232 at 240mg will be administered orally, once daily (QD), on days 1-7 in a 28-day cycle starting on Cycle 2 Day 1."
88842271|NCT03023683|Other|Group B: 18-49 yo healthy non-twins|Participants will be given seasonal LAIV, FluMist® .
88842272|NCT03020498|Other|Group A: 8-17 yo identical twins|Group A: 8-17 year-old identical twin pairs randomly assigned to Fluzone (trivalent, inactivated influenza vaccine (TIV)) or FluMist (live, attenuated influenza vaccine (LAIV)) within the pair
88842273|NCT03020498|Other|Group B: 8-30 yo non-twin|Group B: 8-30 years old non-twin individuals randomly assigned to Fluzone (trivalent, inactivated influenza vaccine (TIV)) or FluMist (live, attenuated influenza vaccine (LAIV))
89369634|NCT04640532|Experimental|Cohort 2 (R/R MF), Dose Level 1|"TL-895 at 100 mg twice a day (BID) continuously starting on Cycle 1 Day 1 in a 28-day cycle.~KRT-232 at 240mg will be administered orally, once daily (QD), on days 1-7 in a 28-day cycle starting on Cycle 2 Day 1."
89369635|NCT04640532|Experimental|Cohort 2 (R/R MF), Dose Level 2|"TL-895 at 150 mg twice a day (BID) continuously starting on Cycle 1 Day 1 in a 28-day cycle.~KRT-232 at 240mg will be administered orally, once daily (QD), on days 1-7 in a 28-day cycle starting on Cycle 2 Day 1."
89369636|NCT04640532|Experimental|Cohort 3 (JAKi Intolerant MF)|KRT-232 at 240mg will be administered orally, once daily (QD), on days 1-7 in a 28-day cycle.
89399198|NCT03687801|Experimental|Online hearing support|The intervention group will have access to online hearing support for five weeks. The online hearing support will include a program that consists of three elements: 1) reading material; 2) reading instructions and weekly assignments related to the reading material; and 3) online and telephone interaction with a professional.
88842274|NCT03020498|Other|Group C: 70-100 yo non-twin|Group C: 70-100 years old non-twin elderly adults given Fluzone (trivalent, inactivated influenza vaccine (TIV))
89399199|NCT03687801|Active Comparator|Standard care|"The control group will have access to traditional support that the Hearing Organization provides (standard care)."
88842275|NCT03025945|Experimental|nepafenac 0.3%|nepafenac 0.3% ophthalmic solution dosed once daily
88818410|NCT01389284|Experimental|Naproxen Sodium ER (BAYH6689)|1 naproxen sodium extended release (ER) 660 mg tablet and 1 naproxen sodium immediate release (IR) 220 mg placebo tablet initially followed by 1 naproxen sodium IR 220 mg matching placebo tablet at hour 8 (± 15 min), and 1 naproxen sodium IR 220 mg matching placebo tablet at hour 16 (± 15 min)
88818411|NCT01389284|Active Comparator|Naproxen Sodium IR (Aleve, BAYH6689)|1 naproxen sodium ER 660 mg matching placebo tablet and 1 naproxen sodium IR 220 mg tablet initially followed by 1 naproxen sodium IR 220 mg tablet at hour 8 (± 15 min), and 1 naproxen sodium IR 220 mg tablet eight hours at hour 16 (± 15 min)
88842276|NCT03025945|Placebo Comparator|Saline Solution|sterile saline drops with a pH approximately of 7.0 and osmolality of 290 mOsm/kg, dosed at once daily
88842277|NCT02937194|Experimental|Personal oral health instruction + pamphlets distribution|Personal oral health instruction (OHI) for the expectant mothers and their husbands together with oral health education materials on infant's tooth development and eruption, establishment of proper feeding, dietary and toothbrushing habits will be given before baby delivery. Reinforcement of OHI and demonstrations on how to clean the infant's oral cavities and perform toothbrushing will be delivered after the babies are born.
89369637|NCT03712423|Experimental|Patients [89Zr]-Df-CriPec® docetaxel|Day 1 of the Run-in a low dose of [89Zr -Df-CriPec® docetaxel (corresponding to 0.1- 2 mg docetaxel). On Cycle 1 Day 1, the patients will receive unlabelled CriPec® docetaxel of a variable dose up to 60mg/m2 followed < 2 h by a second low dose of [89Zr]-Df-CriPec® docetaxel. On day 1 of each subsequent cycle, patients will only receive unlabelled CriPec® docetaxel . The dose will be the same as was given on Cycle 1 Day 1. For the following patients the dose of unlabelled CriPec® docetaxel combined with the low dose of [89Zr]-Df- CriPec® docetaxel will be variable but never exceed the highest dose of unlabelled CriPec® docetaxel that was determined to be safe in the phase I NAPOLY trial (CT-CL01).
89369638|NCT03717805|Experimental|Intervention group|Participating couples of the intervention group will receive care as usual and will watch the preparatory information movie on oocyte aspiration (POAM) 1-3 days before their oocyte aspiration. Their gynecologist or midwife will empower them to watch the movie when they call them to plan the oocyte aspiration and will send them the secured link to the movie via email.
89369639|NCT03717805|No Intervention|Control group|Participating couples of the control group will receive care as usual (as will participating couples of the intervention group) and will not get access to the preparatory information movie on oocyte aspiration (POAM).
89369640|NCT02421016|Experimental|SYNERGY EES|Bioresorbable polymer everolimus-eluting stent
89369641|NCT02421016|Active Comparator|ABSORB [BVS]|Everolimus-eluting bioresorbable backbone stent
89369642|NCT04620252|Experimental|Chewing calcium supplements|"Participants were given one of 4 different treatments to chew: a negative control group and 3 calcium supplements with different calcium compositions.~Participants were randomized to determine the sequence of exposure to the different treatments."
89369643|NCT04620252|Experimental|Fluoride rinse|Participants rinsed with an over the counter sodium fluoride rinse for 1 min, after having chewed a candy (negative control), a calcium calcium carbonate or a calcium citrate supplement.
89369644|NCT03694886|Active Comparator|Caffeine with small sucrose pill|Participants will be given one dose of 90 milligrams caffeine anhydrous dissolved in 8 ounces of water and a 1 mm sucrose pill to consume in 10 minutes. After 30 minutes post-administration, the cognitive tests will be administered.
89369645|NCT03694886|Active Comparator|Caffeine with large sucrose pill|Participants will be given one dose of 90 milligrams caffeine anhydrous dissolved in 8 ounces of water and a 5 mm sucrose pill to consume in 10 minutes. After 30 minutes post-administration, the cognitive tests will be administered.
89369646|NCT03694886|Placebo Comparator|No caffeine with small sucrose pill|Participants will be given 8 ounces of water and a 1 mm sucrose pill to consume in 10 minutes. After 30 minutes post-administration, the cognitive tests will be administered.
88842278|NCT02937194|Active Comparator|Pamphlets distribution|Pamphlets for adults' and pregnant women's oral health care will be distributed when recruited and information on the babies' oral health care will be distributed before baby delivery.
89369647|NCT03694886|Placebo Comparator|No caffeine with large sucrose pill|Participants will be given 8 ounces of water and a 1 mm sucrose pill to consume in 10 minutes. After 30 minutes post-administration, the cognitive tests will be administered.
89369648|NCT04146467|Experimental|Study Phase I|Subjects will be treated with the Renuvion APR device in the neck and submental region.
89369649|NCT04146467|Experimental|Study Phase II|Subjects will be treated with the Renuvion APR device in the neck and submental region.
89369650|NCT02429128|Active Comparator|Lean PCOS training|14 weeks exercise training
89369651|NCT02429128|Other|Lean healthy controls|14 weeks exercise training
89369652|NCT05602675|Experimental|LY3871801 + Methotrexate (Part 1)|LY3871801 administered orally in combination with methotrexate given orally.
88842279|NCT02937506|Experimental|Propofol|Patients in the treatment arm will be given propofol only when having a colonoscopy.
89369653|NCT05602675|Experimental|LY3871801 + Repaglinide + Drug Cocktail (Part 2)|LY3871801 administered orally in combination with repaglinide given orally and drug cocktail which includes warfarin, dextromethorphan and midazolam administered orally.
89369654|NCT02421250|Experimental|Radical-7 Non-invasive Hgb Monitor|We use the Radical-7 Noninvasive Hgb Monitor device (provided by Masimo Corporation from Irvine USA) to measure hemoglobin levels in patients in the experimental group.
89369655|NCT02421250|No Intervention|Control|We will use standard-of-care for control group and not use the SpHb monitor.
89369656|NCT03714685|Experimental|Firibastat prototype tablet formulations|Firibastat (QGC001) 500 mg modified release prototype tablet formulations or immediate release capsule formulation - 1 tablet or 1 capsule administered per period
89369657|NCT03699566||Healthy volunteers|"Individuals aged 18-65 without chronic disease.~Interventions: Assessment of Respiratory Muscle Strength, Spirometer, Trunk Muscles Endurance Tests"
89369658|NCT03714607|Experimental|Laser|Erbium Yttrium Aluminum Garnet (Er:YAG) laser therapies
89369659|NCT03714607|No Intervention|Control|No intervention
89369660|NCT01374594||Healthy adults|
88842280|NCT02937506|Experimental|Fentanyl Plus Midazolam Only|Patients in the control arm will receive only the standard of care medications, fentanyl and midazolam when having a colonoscopy.
88842281|NCT03026803|Experimental|Oxaliplatin and Capecitabine|21 day cycle with Oxaliplatin 50mg/m2 day 1 and day 8 administered IV, Capecitabine 750 mg/m2 bid p.o. daily from day 1 to day 14
89369661|NCT01374594||Type 2 diabetes|
89369662|NCT03694730|Experimental|Pain-guided Activity Modification|Participants in the Pain guided Activity Modification group will receive an exercise program consisting of progressive patellar tendon loading exercises Outside of physical therapy treatment, these participants will modify activity based on the Pain-Monitoring Model.
88842282|NCT02938052|Experimental|Intervention Arm|"Participants will all undergo a 10-week PP-based health behavior intervention and adherence measurements (baseline and Week 10).~The participants will receive an ActiGraph accelerometer. They will be asked to begin wearing the accelerometer after their initial visit. Participants will wear the ActiGraph for 7 days at baseline and again at 10 weeks."
88842283|NCT03027661|Placebo Comparator|Control Group|Injection of 10 mL of 0.9% sodium chloride into the cervical stroma divided between 3 and 9 o'clock
88842284|NCT03027661|Active Comparator|Study Group|Injection of 10 mL of 0.5% bupivacaine into the cervical stroma divided between 3 and 9 o'clock.
89369663|NCT03694730|Active Comparator|Pain-free Activity Modification|Participants in the Pain-free Activity Modification group will receive an identical exercise program to the Pain-guided Activity Modification group. However, participants will not be allowed to participate in activities that cause patellar tendon pain or excessively load the patellar tendon (e.g. jumping) outside of physical therapy treatment.
89369664|NCT03444181|Experimental|Music lessons|
89369665|NCT03444181|Active Comparator|Training intervention|
89369666|NCT03444181|No Intervention|No intervention|
89369667|NCT01371864||Pediatric Cardiothoracic Team|This group consists of members of the cardiothoracic surgery team: The attending physician, the fellow physician, the nurses, and the physician assistants.
89369668|NCT01371864||Critical Care Team|This group consists of the nurses and physicians who work in the pediatric intensive care unit and the neonatal intensive care unit caring for patients who require cardiothoracic surgery.
89369669|NCT01371864||Subspecialty Team|This group consists of physicians and nurses from pediatric cardiology and pediatric anesthesiology who care for children who require cardiothoracic surgery.
89369670|NCT01371864||Parent|This group consists of the parent or legal guardian of the pediatric patient who requires cardiothoracic surgery.
89369671|NCT03690752|Sham Comparator|weighted|"The weighted group uses the same Alter-G Treadmill as the unweighted group but were not allowed to use the unweighting function of the treadmill.~Intervention: unweighting using Alter-G Anti-Gravity Treadmill"
89369672|NCT03690752|Experimental|unweighted|"The unweighted group uses the same Alter-G Anti-Gravity Treadmill as the weight group but is allowed to adjust their weight using the weight control feature.~Intervention: normal weight using Alter-G Anti-Gravity Treadmill"
89369673|NCT02705716|Experimental|Test Dentifrice|Participants will be instructed to dose a dry toothbrush with a full strip of toothpaste containing 0.454% weight by weight (w/w) stannous fluoride (1100 parts per million [ppm] fluoride). Participants will then brush each of the two selected sensitive test teeth first, followed by the whole mouth thoroughly for at least 1 minute.
89369674|NCT02705716|Placebo Comparator|Control Dentifrice|Participants will be instructed to apply a full brush head of toothpaste containing 0.76% sodium monofluorophosphate (1000ppm fluoride) to a dry toothbrush. Participants will then brush the whole mouth thoroughly for at least 1 minute.
89369675|NCT01374672||Correlative studies|DNA and RNA extracted from biopsy samples are analyzed for methylation changes and transcription changes by ligation-mediated PCR and mass-array genotyping.
89369676|NCT03714529|Experimental|Treatment arm|"The vaccine consists of 500µl of 100µg PD-L1 peptide, dissolved in DMSO and PBS reconstituted with 500 µl Montanide ISA-51.~Patients will be vaccinated Q2W for 10 weeks, and a further 12 weeks if a clinical response is measured."
89369677|NCT04138043|Experimental|GSK2330811 450 mg|Participants will receive a single 450 mg SC dose of GSK2330811, administered as three separate SC injections of 150 milligrams per milliliter [mg/mL]).
89369678|NCT04138043|Placebo Comparator|Placebo|Participants will receive GSK2330811 matching placebo administered as three separate SC injections.
89369679|NCT03116620|Experimental|Chewing evaluation|Children with neuromuscular disorders (NMD) will be participated. Children will be asked to chew a standardized biscuit while video recording. Two physical therapists will assess all video recordings independently and score each video according to the KCPS. The correlation between the KCPS scores of two therapists will be used for interobserver reliability. One therapist will rescore the recordings after an interval of 2 weeks for intraobserver reliability.
88842285|NCT02794207||Participants|One qualitative, semi-structured interview will be conducted. Each interview will last approximately 30-45 minutes and may be audio recorded (if consent is provided). Interviews will consist of several open-ended questions focusing on having the participant reflect upon past experiences with neutropenia management and the impact of the participant's illness and treatment. Several close-ended questions regarding participant's thoughts on potential outcomes will also be included.
88842286|NCT02794207||Caregivers|One qualitative, semi-structured interview will be conducted. Each interview will last approximately 30-45 minutes and may be audio recorded (if consent is provided). Interviews will consist of several open-ended questions focusing on having the participant reflect upon past experiences with neutropenia management and the impact of their child's illness and treatment. Several close-ended questions regarding participant's thoughts on their child's potential outcomes will also be included.
88842287|NCT03022526|Experimental|CSE|intrathecal bupivacaine 2.5mg + fentanyl 15mcg followed by infusion (PCEA): bupivacaine 0.083% with fentanyl 2mcg/mL: basal 8mL/hr, demand 8mL, 2 boluses per hour allowed, total maximum hourly allowance 24mL
89369680|NCT02429050|Active Comparator|intervention|sustained release morphine
89369681|NCT02429050|Placebo Comparator|control|placebo
89369682|NCT04479488||Hospitalized patients|Patient who are suspected or confirmed SARS-CoV2 infection need hospitalization.
89369683|NCT04479488||Non-hospitalized patients|Patient who are suspected or confirmed SARS-CoV2 infection non-hospitalized.
89369684|NCT01311427|Active Comparator|Group education|The control condition received standard group education, which met in small groups two times weekly for 60 minutes over 12 weeks.
89369685|NCT01311427|Experimental|8-form Yang-style Tai chi program|This arm tested a modified 8-form Yang-style Tai chi program in subjects with fibromyalgia. Participants met in small groups two times weekly for 60 minutes over 12 weeks.
89369686|NCT02417142|Experimental|Experimental|Exenatide 2mg subcutaneous injection, once weekly
89369687|NCT02417142|Placebo Comparator|Placebo|Placebo
89369688|NCT03179098|Active Comparator|Control group (GC)|The control group (GC) that will perform the 10 'sustained stretching tractioned by a load proportional to the force captured during a maximal voluntary isometric contraction (MVIC)
88842288|NCT03022526|Active Comparator|Epidural|epidural bupivacaine 0.083% + fentanyl 2mcg/mL (8mL) followed by fentanyl 100mcg (2mL); follwed by infusion (PCEA): bupivacaine 0.083% with fentanyl 2mcg/mL: basal 8mL/hr, demand 8mL, 2 boluses per hour allowed, total maximum hourly allowance 24mL
88842289|NCT02794441|Experimental|Dexamethasone|Dexamethasone 0.6mg/kg (maximum 15mg) PO x 1 dose
88842290|NCT02794441|Placebo Comparator|Placebo|Matched oral solution in same volume per kg as dexamethasone
88842291|NCT02941640|Experimental|Laparoscopic appendectomy. E group.|The securing the base of appendix by Endo-loop.
88842292|NCT02941640|Experimental|Laparoscopic appendectomy. S group.|The securing the base of appendix by stapler.
88842293|NCT02941640|Experimental|Laparoscopic appendectomy. H group.|The securing the base of appendix by Hem-o-lok clip.
88842294|NCT02941640|Experimental|Laparoscopic appendectomy. DS group.|The securing the base of appendix by DS clip.
88842295|NCT02794597|No Intervention|Opioid Medication-Assisted Treatment only|Usual care - Opioid Medication Assisted Treatment
88842296|NCT02794597|Experimental|Intervention|Peer led, behavioral sexual health intervention: Sexual Health Initiative for Navigation and Empowerment (SHINE).
89369689|NCT03179098|Active Comparator|GWM|The modified Weeks Group (GWM) that will carry out the modified Weeks protocol
88842297|NCT02822612||Retinal Disease|Fifteen subjects with retinal disease. Each participant will attend for a single study visit, lasting approximately 1 hour in duration.
88842298|NCT02822612||Glaucoma|Fifteen subjects with glaucoma. Each participant will attend for a single study visit, lasting approximately 1 hour in duration.
88842299|NCT02822612||Strabismus|Fifteen subjects with strabismus. Each participant will attend for a single study visit, lasting approximately 1 hour in duration.
88842300|NCT02822612||Healthy volunteers|Fifteen healthy volunteers. Each participant will attend for a single study visit, lasting approximately 1 hour in duration.
88842301|NCT03028363|Experimental|Olumacostat Glasaretil Gel, 5.0%|Olumacostat Glasaretil Gel, 5.0%, applied twice daily to the face for 12 weeks
88842302|NCT03028363|Placebo Comparator|Olumacostat Glasaretil Gel, Vehicle|Olumacostat Glasaretil Gel, Vehicle, applied twice daily to the face for 12 weeks
88842303|NCT02823080|Active Comparator|cetrotide|study group (24 patients = intervention) received intervention for 3-daysCetrorelix Acetate sc injection (0.25 mg/day) started on Day-0. Serum E2, pain scores and MOD were checked daily. Hematocrit value (Ht%), total leucocytic count (TLC), gastrointestinal (GI) manifestations and ascites grading were re-evaluated on Day-3, 6 and 8.
88842304|NCT02823080|No Intervention|no cetrotide|control group (24 patients) did not receive 3-daysCetrorelix Acetate (no intervention). Serum E2, pain scores and MOD were checked daily. Hematocrit value (Ht%), total leucocytic count (TLC), gastrointestinal (GI) manifestations and ascites grading were re-evaluated on Day-3, 6 and 8.
88842305|NCT03028987|Other|LAIV randomized|Volunteers are past participants who have been identified as HLA DR1501+ or DR0701+ by lab assay results. All participants will be randomized within the twin pair to receive either the seasonal quadrivalent live, attenuated influenza vaccine (LAIV4)/ FluMist® or the seasonal quadrivalent inactivated influenza vaccine (IIV4)/ Fluzone® .
88842306|NCT03028987|Other|IIV4 randomized|Volunteers are past participants who have been identified as HLA DR1501+ or DR0701+ by lab assay results. All participants will be randomized within the twin pair to receive either the seasonal quadrivalent live, attenuated influenza vaccine (LAIV4)/ FluMist® or the seasonal quadrivalent inactivated influenza vaccine (IIV4)/ Fluzone®
88842307|NCT03022916|Active Comparator|Nail Polish + Efinaconazole Solution|One big toe will receive application of Efinaconazole Solution on top of nail polish (without the presence of a top coat or base coat)
88842308|NCT03022916|Placebo Comparator|Nail Polish Only|Both big toes will use nail polish only
88842309|NCT03022916|Active Comparator|Base Coat + Nail Polish + Top Coat + Efinaconazole Solution|One big toe will receive application of Efinaconazole solution on top of nail polish with base coat and top coat.
88842310|NCT03022916|Active Comparator|Nail Polish + Top Coat + Efinaconazole Solution|One big toe will receive application of Efinaconazole solution on top of nail polish with top coat.
88842311|NCT03031795|Experimental|experimental|ketorolac, oral, 20 mg, 1 dose, 45 minutes prior to IUD placement
88842312|NCT03031795|Placebo Comparator|placebo|look alike placebo
88842313|NCT02942654|Experimental|LY900014|Test formulation. 15-U dose of LY900014 administered subcutaneously (SC) in one of two periods.
88842314|NCT02942654|Active Comparator|Insulin Lispro|Reference formulation. 15-U dose of Insulin Lispro administered SC in one of two periods.
89369690|NCT04477928||Study Group|Children receiving routine care at a Sanford facility
88842315|NCT02825966|Other|AUDICOR then LifeVest then AUDICOR|First, assigned to wear AUDICOR device for 15 minutes. Then assigned to wear the WCD, including 6 hours of overnight wear. Total anticipated wear time with WCD is 12-16 hours. Finally, assigned to wear the AUDICOR device for another 15 minutes after finishing the WCD wear.
88842316|NCT03028220|Active Comparator|Real time continuous glucose monitoring|Use of Dexcom G5 continuous glucose monitoring
88842317|NCT03028220|Active Comparator|Flash glucose monitoring|Use of Abbott FreeStyle Libre flash glucose monitoring
88842318|NCT02909959|Active Comparator|Sulforaphane|"Participants will take a sulforaphane supplement 3-8 tablets daily, with dose depending upon body weight. Each tablet contains 125 mg broccoli seed powder and 50 mg broccoli sprout extract, providing approximately 15 µmol sulforaphane.~The weight-based dosing schedule is as follows:~3 tablets (approx. 46.5 µmol SF) if <100 lb; 5 tablets (approx. 77.5 µmol SF) if 100-125 lb; 6 tablets (approx. 93 µmol SF) if 126-175 lb; 7 tablets (approx. 108.5 µmol SF) if 176-199 lb; 8 tablets (approx. 124 µmol SF) if ≥ 200 lb"
88842319|NCT02909959|Placebo Comparator|Placebo|Participants in this arm will take placebo tablets that are identical in shape, size, and color to the sulforaphane tablets. The number of tablets taken per day corresponds to the weight-based schedule described for the sulforaphane arm.
88842320|NCT04333394|Active Comparator|Probiotic|The probiotics capsules contain 7 strains of friendly bacteria (Lactobacillus casei PXN 37, Lactobacillus rhamnosus PXN 54, Streptococcus thermophilus PXN 66, Bifidobacterium breve PXN 25, Lactobacillus acidophilus PXN 35, Bifidobacterium longum PXN 30, Lactobacillus bulgaricus PXN 39)
89369691|NCT01374750|Active Comparator|m-TOR inhibitor free|Immunosuppressive drug
88842321|NCT04333394|Placebo Comparator|Placebo|Placebo capsules have an identical appearance to probiotic capsules and contain microcrystal cellulose.
88842322|NCT00373633|Experimental|Continuous extra-pleural intercostal local anesthesia|intra-operatively placed extrapleural intercostal catheter
88842323|NCT00373633|Active Comparator|Thoracic Epidural|gold standard
88875244|NCT02541864|Active Comparator|Hybrid therapy|(pantoprazole 40 mg bid for 7 days, amoxicillin 1 g bid for 7 days) followed by (pantoprazole 40 mg bid for 7 days, amoxicillin 1 g bid for 7 days, clarithromycin 500 mg bid for 7 days, and metronidazole 500 mg bid for 7 days)
88875245|NCT02541942|Other|Collection of specimen|
88875246|NCT02542410|Active Comparator|Control|Norethindrone acetate 5 mg po daily x 6 months
89369692|NCT01374750|Experimental|Sirolimus|Immunosuppressive drug
88842324|NCT02945150|Experimental|Elbasvir/grazoprevir for HCV+ kidney transplant recipients|"Elbasvir (50mg) / grazoprevir (100mg) (fixed dose combination) treatment for Hepatitis C virus (HCV)-naive recipients who receive a kidney transplant from a deceased, HCV-infected donor~Subjects receive first dose on-call to operating room, and continue daily for 12 weeks. Treatment length is extended to 16 weeks and ribavirin (daily dose 1000 mg for those <75 kg and 1200 mg for those ≥75 kg) if subject receives a kidney from a donor who is infected with HCV containing resistance-associated variants (RAV)."
88842325|NCT02911753|Experimental|Mediterranean Lemonade Consumption|All participants will be asked to consume 32 ounces daily of Mediterranean Lemonade. The beverage will be previously prepared and packaged by study personnel. Participants will receive their beverage supply on a weekly basis for a total of six weeks.
88842326|NCT02911753|Experimental|Green Tea Consumption|All participants will be asked to consume 32 ounces daily of Green Tea. The beverage will be previously prepared and packaged by study personnel. Participants will receive their beverage supply on a weekly basis for a total of six weeks.
88842327|NCT02911753|Placebo Comparator|Flavored Water Consumption|All participants will be asked to consume 32 ounces daily of Flavored Water. The beverage will be previously prepared and packaged by study personnel. Participants will receive their beverage supply on a weekly basis for a total of six weeks.
88842328|NCT02829320|Experimental|GSK1278863|Subjects will receive GSK1278863 once daily orally at a starting dose of 4 milligrams (mg) on Day 1, and continued until the day of Week 4. From Weeks 4 to 24, interruption of treatment or dose adjustments will be made within the maintenance dose range of 1 mg to 24 mg according to the dose adjustment algorithm to achieve and/or maintain Hgb within the target range (10.0 to 12.0 g/dL) based on the Hgb value measured every 4 weeks. Dose changes will be made every 4 weeks. Iron replacement therapy will be given according to the standard starting criteria.
89180162|NCT00588146|Experimental|Standard Care, then Pegylated Interferon Alpha2b|Standard care for 6 months, then weekly subcutaneous injection of pegylated interferon alpha2b 1 microgram/kg/week for 6 months.
89180163|NCT02604602||PPH|
89180164|NCT02604602||non-PPH|
89180165|NCT05653622|Experimental|SIB-DOPA|
89180166|NCT05613764|Experimental|"Control condition with waiting for you message"|This control condition will use the text message that the investigators found to be the best performing in their last mega-study of vaccine text messages to recommend a COVID vaccination.
89180167|NCT05613764|Experimental|Message from local pharmacy team|This condition will use a text message from the participant's local pharmacist recommending a COVID vaccination.
89180168|NCT04110470|Active Comparator|Control Group|Patients will receive standard radiographs post-operative day one or two in hospital, as well as radiographs in clinic at two and six weeks.
89180169|NCT04110470|Experimental|Treatment Group|These patients will not have routine post-operative in hospital radiographs, or radiographs in clinic at two weeks, unless clinically indicated.
89180170|NCT04110002|Experimental|Injury Prevention Program|Those allocated to the injury prevention program will be instructed on the program, the added exercises, and the additional time commitment.
89180171|NCT04110002|No Intervention|Control|The control group will practice and perform with no change to pre-existing years' standard operating practice.
89180172|NCT00795704|Placebo Comparator|Placebo|Control Group
89180173|NCT00795704|Active Comparator|Mulberry Leaf Extract|
89180174|NCT02604368|Experimental|SC411|Omega-3 docosahexaenoic acid, soft gelatin capsule, administered once a day on a per weight basis.
89180175|NCT02604368|Placebo Comparator|Placebo|Soybean oil, soft gelatin capsule, administered once a day on a per weight basis.
89369693|NCT03106792|Experimental|Hairfinity #1|Dosage form: Capsule Frequency: Take 2 capsules by mouth in the morning with a meal. Duration: 90 days
89180176|NCT04108520|Experimental|Intervention Group|Exercises on respiratory muscle, 3 times per week, 1 hour peer day
89180177|NCT04108442|Active Comparator|Traditional|
89180178|NCT04108442|Experimental|Virtual|
89180179|NCT04108598||Adults presenting with SSNHL|Adults presenting with SSNHL to NHS
89180180|NCT05653544||Mitochondrial myopathy|Mitochondrial myopathy, confirmed genetically
89180181|NCT00444457|Experimental|1|
89180182|NCT00444457|Experimental|2|
89180183|NCT00444457|Experimental|3|
89180184|NCT00444457|Active Comparator|4|
89180185|NCT05612360|Experimental|"Control condition with waiting for you message"|This control condition will use the text message that the investigators found to be the best performing in their last mega-study of vaccine text messages to recommend a COVID vaccination.
89180186|NCT05612360|Experimental|Message encouraging vaccination in preparation for the holidays|This condition will use a text message to encourage a COVID vaccination in preparation for the holidays.
89180187|NCT00799058|Active Comparator|dapivirine gel 4789|will be applied by participants once daily for 12-weeks treatment period
89180188|NCT00799058|Active Comparator|dapivirine gel 4759|Will be applied by participants once daily for12-weeks treatment period
89369694|NCT03106792|Experimental|Hairfinity #2|Dosage form: Capsule Frequency: Take 2 capsules by mouth in the morning with a meal. Duration: 90 days
89180189|NCT00799058|Placebo Comparator|HEC-based placebo gel, 2.5g containing no Dapivirine|Will be applied once daily for 12-weeks treatment period
89180190|NCT00725985|Experimental|Cladribine 5.25 mg/kg (ITP)|Cladribine tablets administered as cumulative dose of 0.875 mg/kg over a course of 5 consecutive days at Weeks 1, 5, 9, 13, 48, and 52 resulting in total cladribine dose of 5.25 milligrams per kilograms (mg/kg) during the ITP of 96 weeks or until clinically definite multiple sclerosis (CDMS) conversion, whichever occurred first.
89180191|NCT00725985|Experimental|Cladribine 3.5 mg/kg (ITP)|Cladribine tablets administered as cumulative dose of 0.875 mg/kg over a course of 5 consecutive days at Weeks 1, 5, 48, 52 and placebo matched to cladribine tablets was administered at Week 9 and 13 resulting in total cladribine dose of 3.5 mg/kg during the ITP of 96 weeks or until CDMS conversion, whichever occurred first.
89180192|NCT00725985|Placebo Comparator|Placebo (ITP)|Placebo matched to cladribine tablets administered over a course of 5 consecutive days at Weeks 1, 5, 9, 13, 48 and 52 during the ITP of 96 weeks or until CDMS conversion, whichever occurred first.
89369695|NCT03106792|Experimental|Hairfinity #3|Dosage form: Capsule Frequency: Take 2 capsules by mouth in the morning with a meal. Duration: 90 days
89369696|NCT03106792|Placebo Comparator|Placebo|Dosage form: Capsule Frequency: Take 2 capsules by mouth in the morning with a meal. Duration: 90 days
89369697|NCT03443713|Experimental|Aerobic exercise|Subjects in this arm will complete aerobic exercise at home and at OHSU for the study. Subjects will use a Dexcom G6 CGM.
89369698|NCT03443713|Experimental|Anaerobic exercise|Subjects in this arm will complete anaerobic exercise at home and at OHSU for the study. Subjects will use a Dexcom G6 CGM.
89180193|NCT00725985|Experimental|Cladribine 5.25 mg/kg, Rebif (OLMP)|Participants who received cladribine 5.25 mg/kg and converted to CDMS during ITP entered in open-label maintenance period (OLMP) and received Rebif® new formulation (RNF) subcutaneously at a dose of 44 microgram (mcg) three times a week for up to 96 weeks. Due to trial termination, the OLMP duration was reduced for some participants.
89369699|NCT03443713|Experimental|High intensity interval exercise|Subjects in this arm will complete high intensity interval exercise at home and at OHSU for the study. Subjects will use a Dexcom G6 CGM.
89369700|NCT03106558|Active Comparator|Manual instrument total knee replacement|
89369701|NCT03106558|Active Comparator|Robitic arm total knee replacement|
89369702|NCT03694574|Other|Low schizotypy|Schizotypy score < 14 measured by the German Version of Schizotypal Personality Questionnaire (Klein, Andresen, & Jahn, 1997)
89369703|NCT03694574|Other|High schizotypy|Schizotypy score ≥ 14 measured by the German Version of Schizotypal Personality Questionnaire (Klein, Andresen, & Jahn, 1997)
89369704|NCT01977144|Other|Embryo Transfer with CCS|Patients will have either a single or double embryo transfer with CCS tested embryos
89369705|NCT01977144|No Intervention|Embryo Transfer without CCS|Patients in this group will not have CCS performed on their embryo(s)
89369706|NCT03717649|Active Comparator|Conventional 2-stage venous cannulation|The two-stage venous cannula 36Fr and 51Fr (size) for each of the two stages (91251C, Medtronic)
89369707|NCT03717649|Active Comparator|Conventional 3-stage venous cannula|The standard three-stage cannula (91437C, Medtronic) is 29Fr, 46Fr and 37Fr for each of the three stages.
88842329|NCT03032263|Active Comparator|Direct Laryngoscopy|These patients will be nasally intubated for their procedure via direct laryngoscopy. We will observe and record incidence of Magill forcep use, presence or absence of nasal bleeding, and the grade of laryngeal view. We will also record any general narrative comments from the provider about the ease or difficulty of intubation.
88842330|NCT03032263|Experimental|Video Laryngoscopy|These patients will undergo Video Laryngoscopy for nasal intubation. We will observe and record incidence of Magill forcep use, presence or absence of nasal bleeding, and the grade of laryngeal view. We will also record any general narrative comments from the provider about the ease or difficulty of intubation.
88842331|NCT03032965|Experimental|Adenosine and Isoproterenol|Patients in this group will receive 12-24mg of adenosine for each PV in order to assess dormant PV conduction.
88842332|NCT03032965|Other|Isoproterenol|This group will not receive adenosine during the procedure.
88842333|NCT03030638||Olodaterol|Patients initiating Olodaterol for the first time
89369708|NCT03717649|Experimental|Fenestrated 3-stage venous cannula|The fenestrated three-stage cannula (MC2X, Medtronic) is 29Fr, 29Fr and 29Fr for each of the three stages.
89369709|NCT03182140||Kyleena|Non-interventional, observational, uncontrolled study in women that have chosen Kyleena as their contraceptive method before entering the study
89369710|NCT03694496|Experimental|peer-led theory-based intervention group|2-6 students (depending on the headcount of the grade 2 students of the school) will be selected as peer leaders and they will receive oral health training first. After being trained and qualified, they will deliver oral health talks and workshops to their peers. The peer leaders will be requested to conduct six activities during 6 months, including health talks, workshops, information leaflets, etc.
89369711|NCT03694496|No Intervention|Control group|Participants in the control group will continue their present practice, and no additional interventions will be given except oral health pamphlets delivery. We will record their present practice in detail. As the control group is in different schools, so they will have very low opportunity to get access to the peer-led activities conducted in the intervention group. Contamination will be quite minimum.
89369712|NCT01374828|Experimental|Ketolorac|
89369713|NCT04133519|Active Comparator|Arm 1|Arm 1 is an active behavioral treatment for IBS (Regulora; Gut-Directed Hypnotherapy Software as a Medical Device - SaMD).
89369714|NCT04133519|Active Comparator|Arm 2|Arm 2 is a behavioral treatment (MR-1; Muscle Relaxation, Software as a Medical Device - SaMD)
89369715|NCT05567497|Active Comparator|Trigeminal Nerve Block (TNB)|patients will receive general anesthesia followed 5 ml of 0.25% Bupivacaine for TGB under USG after induction of anesthesia (Block Group).
89369716|NCT05567497|No Intervention|control|patients will receive general anesthesia only (Control Group).
88842334|NCT03030638||Indacaterol|Patients initiating Indacaterol for the first time
88842335|NCT02949518|Experimental|Enhanced Recovery Pathway for Spine|
88842336|NCT02949518|No Intervention|Usual Care|
88842337|NCT02949674|Experimental|Bupivacaine|It will be used bupivacaine in surgical site prior surgery (25 mg). At least 10 minutes before skin incision.
88875247|NCT02542410|Experimental|Experimental|cabergoline 0.5 mg PO twice weekly x 6 months
89369717|NCT03181906|Experimental|Pre-Consultation Medication Reconciliation|Participants underwent medication reconciliation service before their consultation with the attending doctor. A best possible medication history (BPMH) was created and saved as an electronic draft in the electronic medical record system.
89369718|NCT03181906|No Intervention|Control|Participants in the control group proceeded with usual care, where the doctor reviewed the patient's condition and ordered an electronic prescription
89369719|NCT05197764||Children with spastic cerebral palsy|Children between 6 months and 9 years old.
89369720|NCT05197764||Typically developing children|Children between 6 months and 9 years old.
89369721|NCT05197764||Children with an acquired brain injury|Children between 1,5 years and 9 years.
89369722|NCT03714295||Use of interdental brushes|The group use interdental brushes one time each day and wash teeth with a classical brush two times a day
89369723|NCT03714295||No use of interdental brushes|The group wash teeth with a classical brush two times a day
89369724|NCT02424682||HER 2 positive metastatic breast cancer|HER 2 positive metastatic breast cancer treated with Herceptin as per registered indication, until disease progression.
89369725|NCT01373502|Experimental|DES Limus Carbostent Coronary Stent|
89369726|NCT01373502|Active Comparator|Taxus Liberté Coronary Stent|
89369727|NCT03690362|Experimental|Group 1 - Control|Healthy control subjects will be matched by gender, weight, and age to subjects with renal impairment
89369728|NCT03690362|Experimental|Group 2 - Mild Renal Impairment|Mild renal impairment
88842338|NCT02949674|Experimental|Ropivacaine|It will be used ropivacaine in surgical site prior surgery (37.5 mg). At least 10 minutes before skin incision.
88842339|NCT02949674|No Intervention|Control|No application of anesthetic
89369729|NCT03690362|Experimental|Group 3 - Moderate Renal Impairment|Moderate Renal Impairment
89369730|NCT03690362|Experimental|Group 4 - Severe Renal Impairment|Severe Renal Impairment
89369731|NCT03690362|Experimental|Group 5 - ESRD|End Stage Renal Disease undergoing chronic intermittent hemodialysis
89369732|NCT03714217|Experimental|Intervention|Telenutrition counseling
89369733|NCT03746171||Patients with rectosigmoid colonic polyps|Consecutive adult (18-80 yrs) outpatients undergoing colonoscopy in the frame of the FOBT based screening program, in which at least one diminutive (<5 mm) rectosigmoid polyp is detected.
89369734|NCT03717493|Experimental|Affect Regulation Training (ART)|Affect Regulation Training (ART; Berking & Whitley, 2014) is a transdiagnostic, group-based intervention aiming to enhance general affect regulation skills in individuals who meet criteria for mental disorders or are at-risk of developing mental-health problems.
89369735|NCT03717493|No Intervention|Waitlist Control Condition (WLC)|In order to control for the effects of time, we compared changes during ART with changes during WLC. Participants in the WLC condition received no treatment within the study but were offered to participate in ART after completing all assessments.
89369736|NCT04477694||type II diabetic patients|
89369737|NCT04477694||non-diabetic patients|
89369738|NCT03634332|Experimental|PEGPH20 plus Pembrolizumab|All patients will receive treatment with PEGPH20 3 micrograms/kg IV weekly x 3, and pembrolizumab 200 mg IV every 3 weeks, in 3-week cycles.
89369739|NCT03744767|Experimental|Single treatment arm|
88842340|NCT03033511|Experimental|Rovalpituzumab tesirine/dexamethasone|Rovalpituzumab tesirine/dexamethasone every 6 weeks (q6 wk); omitting every third cycle
88842341|NCT03033511|Experimental|Placebo|Placebo q6 wk; omitting every third cycle
89369740|NCT02428972|Experimental|intravenous anesthesia|propofol infusion @ 100-200 mcg/kg/min for maintenance of anesthesia
88842342|NCT03033134|Experimental|BSJ003W|BSJ003W implant group
89369741|NCT02428972|Active Comparator|inhalational anesthesia|sevoflurane MAC between 0.8-1.2 for maintenance of anesthesia
88842343|NCT02951312|Experimental|Glycopyrrolate Inhalation Solution 25mg|Glycopyrrolate Inhalation Solution 25 μg via eFlow nebulizer, once daily
88842344|NCT02951312|Experimental|Glycopyrrolate Inhalation Solution 75mg|Glycopyrrolate Inhalation Solution 75 μg via eFlow nebulizer, once daily
88842345|NCT02951312|Experimental|Glycopyrrolate Inhalation Solution 200mg|Glycopyrrolate Inhalation Solution 200 μg via eFlow nebulizer, once daily
88842346|NCT02951312|Experimental|Glycopyrrolate Inhalation Solution 200mg Jet|Glycopyrrolate Inhalation Solution 200 μg via jet nebulizer, once daily
88842347|NCT02951312|Experimental|Glycopyrrolate Inhalation Solution 500mg|Glycopyrrolate Inhalation Solution 500 μg via eFlow nebulizer, once daily
89369742|NCT03634254||primary caregivers of AAC users in New Taipei City|Satisfaction level of communication quality
89369743|NCT02428660|Other|Controls (no analysis or testing)|MTM alone (i.e. Treatment As Usual)
89369744|NCT02428660|Experimental|Group 1|MTM + software-based drug & gene interaction risk analysis + pharmacogenetic testing
89369745|NCT02428660|Active Comparator|Group 2|MTM + software-based drug & gene interaction risk analysis only
89369746|NCT03694340|Other|Re-programming of cochlear implant|The cochlear implant is programmed with a new MAP based on behavioral measurements of T- and C-levels and used by the participant for 4 months before follow up.
89369747|NCT03699332|Experimental|Intraoperative multi-modality imaging|Patients receive a single intravenous dose of Indium-111-DOTA-Labetuzumab-IRDye800CW. At day 4 or 5 after antibody injection a SPECT/CT scan will be acquired. At day 6 or 7 standard of care cytoreductive surgery will be performed. This will be extended with the use of dual-modality imaging.
89369748|NCT04007159|Experimental|Developmental Serum|The participants will be applied a semi-occlusive adhesive patch containing the developmental serum (0.02 milliliters per centimeters square [mL/cm^2] in an individual cell of the patch) topically to the dorsum, repeatedly for 3 weeks (9 times) in induction phase (48 hours in weekdays and 72 hours in weekends) and for 48 hours (single application) in the challenge phase.
89369749|NCT04007159|Experimental|Developmental Lotion|The participants will be applied a semi-occlusive adhesive patch containing the developmental lotion (0.02 mL/cm^2 in an individual cell of the patch) topically to the dorsum, repeatedly for 3 weeks (9 times) in induction phase (48 hours in weekdays and 72 hours in weekends) and for 48 hours (single application) in the challenge phase.
89399200|NCT03687645|Experimental|Prostate Cancer|Patients with biopsy-proven prostate cancer will be recruited for an additional Hyperpolarised MRI scan prior to any treatment
89369750|NCT04007159|Experimental|Developmental Cream|The participants will be applied a semi-occlusive adhesive patch containing the developmental cream (0.02 mL/cm^2 in an individual cell of the patch) topically to the dorsum, repeatedly for 3 weeks (9 times) in induction phase (48 hours in weekdays and 72 hours in weekends) and for 48 hours (single application) in the challenge phase.
89369751|NCT04007159|Placebo Comparator|Negative Control|The participants will be applied a semi-occlusive adhesive patch containing the 0.9 percent (%) normal saline (0.02 mL/cm^2 in an individual cell of the patch) topically to the dorsum, repeatedly for 3 weeks (9 times) in induction phase (48 hours in weekdays and 72 hours in weekends) and for 48 hours (single application) in the challenge phase.
89369752|NCT04483024|Placebo Comparator|Placebo|Maltodextrin
89369753|NCT04483024|Active Comparator|Glucosamine|Glucosamine hydrochloride
89369754|NCT04483024|Experimental|Collagen hydrolysate|2g of hydrolyzed collagen II
89369755|NCT04483024|Experimental|Collagen hydrolysate + chicken extract|2g of hydrolyzed collagen II with chicken extract
89369756|NCT03690128|Active Comparator|Control Arm - standard EWS procedure|Standard use of the current implement Early Warning System, based on the principles of the National Early Warning Score and with a standard escalation protocol.
89369757|NCT03690128|Active Comparator|Intervention Arm - I-EWS|"Implementation of Individual Early Warning Score (I-EWS) with a systematic clinical assessment with a standard escalation protocol as intervention 7 parameters (Respiration rate, pulse, saturation, systolic blood pressure, consciousness, temperature, Oxygen) are registered , an aggregated score is generated. In the electronic patient journal (Sundhedsplatformen), the nursing staff is asked to reevaluate the aggregated score based on their clinical assessment of the patient. The aggregated score can be upgraded with up to 6 points and downgraded with up to 4.~This new I-EWS score interacts with the standard escalation protocol which defines the observation frequency and relevant clinical actions."
89369758|NCT03119688|Other|Test product|0.09 milliliters (ml) of the cleanser (test product) will be applied on the allocated site on forearm topically.
89369759|NCT03119688|Other|Positive Control|Soap bar (positive control) will be applied on the allocated site on forearm by topical dermal administration of towel moistened with sterile water that had been rubbed onto the 100 g bar of soap for 6 seconds to generate a lather.
88842348|NCT02951312|Experimental|Glycopyrrolate Inhalation Solution1000mg|Glycopyrrolate Inhalation Solution 1000 μg via eFlow nebulizer, once daily
88842349|NCT02951312|Placebo Comparator|Placebo 0.5 mL|Placebo 0.5 mL via jet nebulizer, once daily
88842350|NCT02796625|Experimental|Painful Stimuli|Participants will be exposed to painful heat
88842351|NCT03035929|Experimental|Healthy|"10 Healthy subjects will undergo study procedures at four study visits.~All subjects will undergo the same procedures and interventions."
88842352|NCT02951702|No Intervention|Control|"This will be the historical arm that has not received oral vancomycin but match criteria for high risk"
88842353|NCT02951702|Experimental|Vancomycin Oral|"This arm will receive oral vancomycin 125 mg daily if high risk and determined to be appropriate by an ID physician Intervention type: drug, vancomycin 125 mg daily"
88842354|NCT02911909|Active Comparator|Standard rehabilitation|Patients will receive standard post-operative ACL rehabilitation
88842355|NCT02911909|Experimental|Delfi moderated blood flow restriction|Patients will receive Delfi moderated blood flow post-operative ACL rehabilitation
89369760|NCT03119688|Other|Negative Control|0.09 ml of sterile water (Reference Product) will be applied on the allocated site on forearm topically.
89369761|NCT03119688|Other|No Treatment|An area of the forearm that remained unwashed and was included in the study as a reference for the treated areas.
89369762|NCT03389893|Experimental|Dupilumab w/OLE|"Participants will receive a loading dose of dupilumab (two 300 mg subcutaneous (subcut) injections (total of 600 mgs)) on Day 0, followed by 300 mg dose of dupilumab by subcut injection every 2 weeks (Days 14 and 28).~Open Label Extension (OLE): Participants will begin a 10 week OLE on Day 42, beginning with a loading dose of two subcut administered injections (one 300 mg dose of dupilumab and one dose of placebo, in order to protect prior masking/blind).Participants will then maintain a regimen of 300 mg of dupilumab by subcut injection every two weeks through Day 98.~The subcut injections will be administered in the abdomen (except for the 2 inches (5 cm) around the navel-not allowed), thighs, or upper arms. Injection sites will be rotated with each dose."
88842356|NCT02952872|Experimental|Arm 1|Participants will complete a brief tablet-based intervention created to include the following features: no common factors, no human voice, no animated narrator, and no motivational content.
88842357|NCT02952872|Experimental|Arm 2|Participants will complete a brief tablet-based intervention created to include the following features: no common factors, no human voice, no animated narrator, and motivational content.
88842358|NCT02952872|Experimental|Arm 3|Participants will complete a brief tablet-based intervention created to include the following features: no common factors, no human voice, the presence of an animated narrator, and no motivational content.
89002070|NCT06116435|Experimental|PreventT2 + Move group-based classes + Mental Imagery|Participants will receive a 6-month lifestyle weight management program based on the publicly available Prevent T2 curriculum (formally known as the National Diabetes Prevention Program), integrated with the Move group-based classes. Group classes will be delivered weekly in weeks 1-12, and biweekly in weeks 13-26. Group-based classes will be taught virtually by a trained Registered Dietitian from the Colorado Nutrition Obesity Research Center Clinical Intervention and Translation (CIT) Core. In addition, participants will receive access to online mental guided imagery sessions. Guided positive exercise imagery scripts were developed based on work from Williams et al. and prompt several sensory and emotional experiences.
89369763|NCT03389893|Placebo Comparator|Placebo Comparator w/OLE|"Participants will receive a loading dose of placebo (two placebo subcutaneous (subcut) injections) on Day 0 followed by one dose of placebo by subcut injections every 2 weeks (Days 14 and 28).~Open Label Extension (OLE): Participants will begin a 10 week OLE on Day 42, beginning with a loading dose of dupilumab (two 300 mg subcut injections (total of 600 mgs)-protection of prior masking/blind maintained). Participants will then maintain a regimen of 300 mg of dupilumab by subcut injection every two weeks through Day 98.~The subcut injections will be administered in the abdomen (except for the 2 inches (5 cm) around the navel-not allowed), thighs, or upper arms. Injection sites will be rotated with each dose."
89369764|NCT03178708|Active Comparator|Group A amantadine sulfate|the patients will receive amantadine sulfate infusion using the dose 200 mg slowly I.V 3 hours prior to the surgery
89369765|NCT03178708|Placebo Comparator|Group B ringer lactate|the patients will receive 500 ml ringer lactate infusion slowly i.v 3 hours prior to surgery.
89369766|NCT02424292||Physical activity|Physical activity in a personalised program
89369767|NCT04473872|Active Comparator|Neurodevelopmental treatment program group|"When applying NGT, which is described as a problem solving approach, the treatment program appropriate for their functional levels will be determined for each patient, taking into account the individual needs and wishes of the patient. Principles to be considered while applying the treatment program:~Inhibition of normal / ineffective movements~Facility of normal / effective movements Sensory-motor stimulation~Correct placement of body segments Neurodevelopmental treatment physiotherapy session for 5-days in a week, over 6-week. Each physiotherapy sessions will consist of range of motion exercises, strengthening exercises, exercises such as activities of daily living, mobility and transfer activities."
89369768|NCT04473872|Experimental|diaphragmatic breathing|The group will have a neurodevelopmental treatment program (BOBATH treatment approach) and diaphragmatic breathing exercises. Diaphragmatic breathing; To give the patient a supine position, a pillow is placed under his knees and head. The patient is asked to place his right hand on the upper abdomen and his left hand on the upper part of his chest. The patient is told to take a slow and deep breath through the nose until four counts, and to hold the air in for the time it has inhaled, and then the patient shrinks her lips like a whistle and exhales from using her breath for a long time. Exercises are performed two hours after meals, in short, 2-3 minutes in the beginning, in 10 of the patients, on average 30 minutes per day.
89369769|NCT04473872|Experimental|respiratory muscle training with the THRESHOLD IMT device|The group will have a neurodevelopmental treatment program (BOBATH treatment approach) and respiratory muscle training with the THRESHOLD IMT device. T-IMT is an instrument that provides the same pressure in each breath for the strength and endurance of the inspiratory muscles, regardless of the patient's rapid or slow breathing. This device provides a constant pressure in inspiration with its flow-free one-way valve. It also has an adjustable device pressure. The tool consists of pressure section, mouthpiece and nose clip. During application, constant pressure is applied to the inspiration phase. The training group is started from 40% of MIP and inspiratory muscle training is given. In practice, patients are asked to sit in a loose position on the upper chest and shoulders. After eight breathing cycles, 1-2 respiratory controls are requested
89369770|NCT01373658|Experimental|Yinyi stent|
89399201|NCT03687645|Experimental|Renal Cancer|Patients with biopsy-proven renal cell carcinoma will be recruited for an additional Hyperpolarised MRI scan prior to any treatment
89399202|NCT03687645|Experimental|Breast Cancer|Patients with biopsy-proven breast cancer will be recruited for an additional Hyperpolarised MRI scan prior to any treatment
89399203|NCT03687645|Experimental|Lymphoma|Patients with biopsy-proven lymphoma will be recruited for an additional Hyperpolarised MRI scan prior to any treatment
88842359|NCT02952872|Experimental|Arm 4|Participants will complete a brief tablet-based intervention created to include the following features: no common factors, no human voice, the presence of an animated narrator, and motivational content.
88842360|NCT02952872|Experimental|Arm 5|Participants will complete a brief tablet-based intervention created to include the following features: no common factors, a human voice guiding the intervention, no animated narrator, and no motivational content.
88842361|NCT02952872|Experimental|Arm 6|Participants will complete a brief tablet-based intervention created to include the following features: no common factors, a human voice guiding the intervention, no animated narrator, and the presence of motivational content.
88842362|NCT02952872|Experimental|Arm 7|7. Participants will complete a brief tablet-based intervention created to include the following features: no common factors, a human voice guiding the intervention, an animated narrator guiding the intervention, and no motivational content.
88842363|NCT02952872|Experimental|Arm 8|Participants will complete a brief tablet-based intervention created to include the following features: no common factors, a human voice to guide the intervention, an animated narrator to guide the intervention, and the presence of motivational content.
89369771|NCT04128293|Experimental|Sequence 1 - Treatment ABCD|Participants will receive a single dose of GSK3640254 200 mg (Treatment A- Reference), capsules, orally under moderate fat conditions on Day 1 in first intervention period; followed by GSK3640254 200 mg (Treatment B- Test), tablets, orally under moderate fat conditions on Day 1 in second intervention period; followed by GSK3640254 200 mg (Treatment C- Reference), tablets, orally under fasted conditions on Day 1 in third intervention period; further followed by GSK3640254 200 mg (Treatment D- Test), tablets, orally under high fat conditions on Day 1 in fourth intervention period. There will be at least 7 days wash out period between each dose of study intervention.
88842364|NCT02952872|Experimental|Arm 9|Participants will complete a brief tablet-based intervention created to include the following features: common factors, no human voice, no animated narrator, and no motivational content.
88842365|NCT02952872|Experimental|Arm 10|Participants will complete a brief tablet-based intervention created to include the following features: common factors, no human voice, no animated narrator, and the presence of motivational content.
89369772|NCT04128293|Experimental|Sequence 2 - Treatment BADC|Participants will receive a single dose of GSK3640254 200 mg (Treatment B- Test), tablets, orally under moderate fat conditions on Day 1 in first intervention period; followed by GSK3640254 200 mg (Treatment A- Reference), capsules, orally under moderate fat conditions on Day 1 in second intervention period; followed by GSK3640254 200 mg (Treatment D- Test), tablets, orally under high fat conditions on Day 1 in third intervention period; further followed by GSK3640254 200 mg (Treatment C- Reference), tablets, orally under fasted conditions on Day 1 in fourth intervention period. There will be at least 7 days wash out period between each dose of study intervention.
89369773|NCT04128293|Experimental|Sequence 3 - Treatment CDAB|Participants will receive a single dose of GSK3640254 200 mg (Treatment C- Reference), tablets, orally under fasted conditions on Day 1 in first intervention period; followed by GSK3640254 200 mg (Treatment D- Test), tablets, orally under high fat conditions on Day 1 in second intervention period; followed by GSK3640254 200 mg (Treatment A- Reference), capsules, orally under moderate fat conditions on Day 1 in third intervention period; further followed by GSK3640254 200 mg (Treatment B- Test), tablets, orally under moderate fat conditions on Day 1 in first intervention period. There will be at least 7 days wash out period between each dose of study intervention.
89369774|NCT04128293|Experimental|Sequence 4 - Treatment DCBA|Participants will receive a single dose of GSK3640254 200 mg (Treatment D- Test), tablets, orally under high fat conditions on Day 1 in first intervention period; followed by GSK3640254 200 mg (Treatment C- Reference), tablets, orally under fasted conditions on Day 1 in second intervention period; followed by GSK3640254 200 mg (Treatment B- Test), tablets, orally under moderate fat conditions on Day 1 in third intervention period; further followed by GSK3640254 200 mg (Treatment A- Reference), capsules, orally under moderate fat conditions on Day 1 in first intervention period. There will be at least 7 days wash out period between each dose of study intervention.
89369775|NCT02428582|Active Comparator|bare stent inserted|Standard bare stent will be placed
89369776|NCT02428582|Experimental|Covered stent inserted|Covered stent will be placed
89369777|NCT05197686|Experimental|HFNC|
89369778|NCT05197686|Active Comparator|COT|
89369779|NCT03179020|Experimental|Checklist ICUs|Management of the potential donor guided by the use of an evidence-based checklist. This checklist is based on main recommendations of the Brazilian guideline for the management of potential multiple organ donors.
89369780|NCT03179020|Active Comparator|Usual Care ICUs|Management of the potential donor according usual care.
89369781|NCT02428894||LVAD recipients|
89369782|NCT00787176|Active Comparator|Group A|An intravenous bolus of 1000 mL Lactated Ringers initiated when the patient is positioned for epidural placement. Oxytocin management continued as per protocol.
89369783|NCT00787176|Experimental|Group B|An intravenous bolus of 1000 mL Lactated Ringers. The dose of oxytocin being administered at time of epidural placement will be halved and not increased for 60 minutes until after placement.
88842366|NCT02952872|Experimental|Arm 11|Participants will complete a brief tablet-based intervention created to include the following features: common factors, no human voice, an animated narrator to guide the intervention, and no motivational content.
89369784|NCT00787176|Active Comparator|Group C|The maintenance infusion of 125 mL/hr of Lactated Ringers will be given with no additional fluid bolus. Oxytocin management continued per protocol.
89369785|NCT00787176|Experimental|Group D|The maintenance infusion of 125 mL/hr of Lactated Ringers will be given with no additional fluid bolus. The dose of oxytocin being administered at time of epidural placement was halved and not increased for 60 minutes until after placement.
88842367|NCT02952872|Experimental|Arm 12|Participants will complete a brief tablet-based intervention created to include the following features: common factors, no human voice, an animated narrator to guide the intervention, and the presence of motivational content.
88842368|NCT02952872|Experimental|Arm 13|13. Participants will complete a brief tablet-based intervention created to include the following features: common factors, a human voice to guide the intervention, no animated narrator, and no motivational content.
89369786|NCT02428504||End of life decision|
89369787|NCT03711487|Experimental|Ironing therapy|Stir-fry 500 grams of Foeniculum vulgare seeds until the aroma overflows. Put them into a cotton bag. Ironing therapy put the bag on abdomen after the temperature is suitable, 30 minutes per time, 4 times daily from 12 hours after surgery and last for 2 days. The medicine bag can be heated and reused after it cool down.
89369788|NCT03711487|No Intervention|No intervention|No intervention.
89369789|NCT03633864|Experimental|FMT treatment|FMT treatment arm: Accept fecal microbiota transplantation without changing the ongoing treatment strategy.
89369790|NCT05560555||Retrospective cohort ATTRv and ATTRwt patients enrolled in B3461028 and B3461045 studies in Spain|
89369791|NCT03744689|Active Comparator|Erector Spinae Plane Block|"Erector Spinae Plane Block Group~Block Drug: 0,25% bupivacaine hydrochloride (20ml) will be used for blocks"
89369792|NCT03744689|Sham Comparator|Control Group|Sham block will be done with serum physiologic.
89369793|NCT02424214|Experimental|Ca Ionophore group|Artificial Oocyte activation with Ca Ionophore for 20 min after Intracytoplasmic Sperm Injection
89369794|NCT02424214|Experimental|Strontium Chloride group|Artificial Oocyte activation with Strontium Chloride for 60 min after Intracytoplasmic Sperm Injection
89369795|NCT02424214|No Intervention|Only Intracytoplasmic Sperm Injection|after Intracytoplasmic Sperm Injection Oocytes will cultured and incubated
89369796|NCT05559541|Experimental|AK119+AK104|AK119 and AK104 IV every 2 or every 3 weeks.
89369797|NCT02428426||gastric intestinal metaplasia|patients were diagnosed gastric intestinal metaplasia
89369798|NCT02428426||gastritis|patients were diagnosed non atrophic gastritis
89369799|NCT03691571|Experimental|Esophageal Cooling|Patients randomized to Group A receive the EnsoETM (Attune Medical Esophageal Heat Transfer Device).
89369800|NCT03691571|Active Comparator|Control|Patients randomized to Group B receive standard of care treatment (standard temperature probe monitoring).
89369801|NCT03113916|Experimental|Behavioral|26 weekly behavioral intervention sessions 6 monthly behavioral intervention sessions Sessions focused on diet, physical activity, behavior change
89369802|NCT03113916|No Intervention|Enhanced usual care|Printed materials
89369803|NCT03712111|Experimental|Norepinephrine 6 mcg|Mothers in this group will receive a bolus of Norepinephrine 6 mcg for management of hypotensive episode after spinal anesthesia using Bupivacaine hydrochloride under prophylactic Norepinephrine infusion
89369804|NCT03712111|Active Comparator|Norepinephrine 10 mcg|Mothers in this group will receive a bolus of Norepinephrine 10 mcg for management of hypotensive episode after spinal anesthesia using Bupivacaine hydrochloride under prophylactic Norepinephrine infusion
89369805|NCT02925494|Experimental|Elagolix plus Estradiol/Norethindrone Acetate (E2/NETA)|Elagolix 300 mg twice daily (BID) and E2/NETA (estradiol 1.0 mg/norethindrone acetate 0.5 mg) once daily (QD)
89369806|NCT02925494|Experimental|Elagolix|Elagolix 300 mg BID and placebo for E2/NETA (estradiol 1.0 mg/norethindrone acetate 0.5 mg) QD
89369807|NCT03711409|Experimental|Soft tissue biased manual therapy group|It includes hot pack and muscle release technique of the muscles around the shoulder. The patient receives treatment 45 minutes per times and 2 times per week for 6 weeks.
89369808|NCT03711409|Experimental|Conventional physical therapy group|It includes modality (electrotherapy, ultrasound and low-level laser therapy) and GH joint mobilization. The patient receives treatment 45 minutes per times and 2 times per week for 6 weeks.
89369809|NCT02428348|Experimental|Interview|Interview of epilepsy patients and their family about their opinion on different EEG-cap models in development.
89369810|NCT03744533|Experimental|head-down position treatment|
89180194|NCT00725985|Experimental|Cladribine 3.5 mg/kg, Rebif (OLMP)|Participants who received cladribine 3.5 mg/kg and converted to CDMS during ITP entered in OLMP and received RNF subcutaneously at a dose of 44 mcg three times a week for up to 96 weeks. Due to trial termination, the OLMP duration was reduced for some participants.
89180195|NCT00725985|Experimental|Placebo, Rebif (OLMP)|Participants who received placebo and converted to CDMS during ITP entered in OLMP and received RNF subcutaneously at a dose of 44 mcg three times a week for up to 96 weeks. Due to trial termination, the OLMP duration was reduced for some participants.
89369811|NCT03744533|Active Comparator|guideline-based treatment|
89369812|NCT02420704||Cleavage stage-thin endometrial|Patients transferred with cleavage stage embryo, with endometrial thickness ≤7mm on the day of HCG (human chorionic gonadotropin) administration for fresh cycles, or on the day starting to use progesterone for frozen thawed cycles.
89369813|NCT02420704||Cleavage stage-medium endometrial|Patients transferred with cleavage stage embryo, with endometrial thickness 8-13mm on the day of HCG (human chorionic gonadotropin) administration for fresh cycles, or on the day starting to use progesterone for frozen thawed cycles.
89369814|NCT02420704||Cleavage stage-thick endometrial|Patients transferred with cleavage stage embryo, with endometrial thickness ≥14mm on the day of HCG (human chorionic gonadotropin) administration for fresh cycles, or on the day starting to use progesterone for frozen thawed cycles.
89369815|NCT02420704||Blastocyst stage-thin endometrial|Patients transferred with blastocyst stage embryo, with endometrial thickness ≤7mm on the day of HCG (human chorionic gonadotropin) administration for fresh cycles, or on the day starting to use progesterone for frozen thawed cycles.
89369816|NCT02420704||Blastocyst stage-medium endometrial|Patients transferred with blastocyst stage embryo, with endometrial thickness 8-13mm on the day of HCG (human chorionic gonadotropin) administration for fresh cycles, or on the day starting to use progesterone for frozen thawed cycles.
89369817|NCT02420704||Blastocyst stage-thick endometrial|Patients transferred with blastocyst stage embryo, with endometrial thickness ≥14mm on the day of HCG (human chorionic gonadotropin) administration for fresh cycles, or on the day starting to use progesterone for frozen thawed cycles.
89369818|NCT03744455||End of training|Anesthesia residents at the end of their training who will realize axillary plexus. The satisfaction of the patient will be registered.
89369819|NCT03744455||Begin of training|Anesthesia residents at the begin of their training who will realize axillary plexus. The satisfaction of the patient will be registered.
89369820|NCT03181672|Active Comparator|Stellate ganglion block|Stellate ganglion block
89369821|NCT03181672|Placebo Comparator|control group|Deltoid muscle injection
89369822|NCT05658445||cases|Female with recurrent unexplained abortion
89369823|NCT05658445||control|female with normal labour
89369824|NCT04006145|Experimental|Elobixibat|Elobixibat 5 mg once daily
89369825|NCT04006145|Placebo Comparator|Placebo|Placebo
89369826|NCT03717337|Experimental|Single visit pulp regeneration|Regenerative endodontic procedure not involving placement of intracanal medicament will be done in single visit
89369827|NCT03717337|Active Comparator|Two visit pulp regeneration|Regenerative endodontic procedure involving placing intracanal medicament will be done in two visit
89369828|NCT03689816|Experimental|bone density|bone density
89369829|NCT04362852||Cancer|No intervention
89369830|NCT04362852||Atopic Dermatitis/Eczema|No intervention
89369831|NCT03386773|Experimental|Intervention|Intervention patients will engage in a 16-week program where they will receive regular health promotion messaging about (a) food, nutrition, and diet; and (b) exercise and physical activity. Intervention patients will be asked to track patient generated health data (PGHD) elements related to weight management through a mobile health app loaded on their phones and/or through using a fitness tracker, depending on patient preference, and to share that information with the research team. Patient-reported outcomes (PRO) measures will be collected pre-and-post-intervention. Intervention patients will also be asked to provide answers to patient-reported outcomes measures on a weekly basis.
89369832|NCT03386773|Active Comparator|Control|Control patients will engage in a 16-week program where they will receive regular health promotion messaging about (a) food, nutrition, and diet; and (b) exercise and physical activity. Patient-reported outcomes measures will be collected pre-and-post-intervention.
89369833|NCT04207866|Experimental|Remote AT services|Experimental group will consist of participants who access auditory therapy services from a remote location. Services will be conducted with this group via teleconferencing over the Ontario Health Network.
89369834|NCT04207866|Active Comparator|In House AT|This group will receive auditory therapy services face-to-face at the treatment site.
89369835|NCT04126343|Experimental|Padsevonil|Study participants randomized to this arm will receive assigned doses of padsevonil twice daily. On Day 8 padsevonil will be administered in the morning, and placebo will administered in the evening.
89369836|NCT04126343|Placebo Comparator|Placebo|Study participants randomized to this arm will receive placebo twice daily to maintain the blinding.
89369837|NCT04126343|Active Comparator|Moxifloxacin|Study participants randomized to this arm will receive padsevonil-placebo twice daily. On Day 8 placebo will be administered in the morning, and moxifloxacin will administered in the evening.
89369838|NCT02952313|Other|Latera Implant|All participants have unilateral or bilateral placement of LATERA Nasal Implants.
89369839|NCT03119610|Experimental|Oxytocin nasal spray|Oxytocin (Syntocinon), intranasal, 24IU, 4x a day for 8 weeks, self administered
89369840|NCT03119610|Experimental|Placebo nasal spray|Placebo nasal spray, 4x a day for 8 weeks, self administered
89369841|NCT03689738|Experimental|Potato condition|Potato lunch and dinner meals, and an evening snack containing 100 g potatoes and 5 g RS per meal, providing a total of 300 g/d potatoes, equivalent to roughly two whole potatoes, and 15 g/d RS.
89369842|NCT03689738|Active Comparator|Control condition|Isocaloric, CHO-matched, low-fiber, RS-free lunch and dinner meals, and an evening snack.
89369843|NCT04005755|Experimental|Maxigesic® IV|Acetaminophen 10 mg/ml + ibuprofen 3 mg/ml in 100 ml solution for infusion. The study drug will be administered by injection into a dedicated indwelling venous cannula, infused over 15 minutes. The study drug will be administered every 6 hours (q6h) for a minimum of 48 hours up to at least 5 days, with a maximum of 4 doses within a 24 hour period.
89369844|NCT03699176|Experimental|Vilaprisan|2 treatment periods of 12 weeks without a break
89369845|NCT03699176|Placebo Comparator|Placebo|2 treatment periods of 12 weeks without a break
89369846|NCT03442777|Experimental|Study Arm 1 (on top of standard of care)|"Allevyn® brand silicone adhesive multilayer foam dressings~Patients at risk for pressure ulcer category II, III, IV, Unstageable, and Deep Tissue Injury (DTI) development will receive standard pressure ulcer prevention strategies (as described in the hospital protocol) which include ongoing risk assessment, regular repositioning and skin care.~Skin sites (restricted to sacrum, heel right/left and greater trochanter right/left) will be treated with silicone adhesive multilayer foam dressings by Smith & Nephew (Allevyn® brand)."
89369847|NCT03442777|Experimental|Study Arm 2 (on top of standard of care)|"Mepilex® brand silicone adhesive multilayer foam dressings~Patients at risk for pressure ulcer category II, III, IV, Unstageable, and Deep Tissue Injury (DTI) development will receive standard pressure ulcer prevention strategies (as described in the hospital protocol) which include ongoing risk assessment, regular repositioning and skin care.~Skin sites (restricted to sacrum, heel right/left and greater trochanter right/left) will be treated with silicone adhesive multilayer foam dressings by Mölnlycke Health care (Mepilex® brand)."
89369848|NCT03442777|No Intervention|Study Arm 3 (standard of care)|"Patients at risk for pressure ulcer category II, III, IV, Unstageable, and Deep Tissue Injury (DTI) development will receive standard pressure ulcer prevention strategies (as described in the hospital protocol) which include ongoing risk assessment, regular repositioning and skin care.~No silicone adhesive multilayer foam dressings will be applied on the skin sites of interest for this trial (sacrum, heel right/left, greater trochanter right/left)."
89369849|NCT03746093|Placebo Comparator|Control Group|Participants will consume a bottle of water (330 ml) every day for 12 weeks.
89369850|NCT03746093|Experimental|Non-alcoholic beer|Participants will consume non-alcoholic beer (330 ml) every day for 12 weeks.
89369851|NCT03689348|Placebo Comparator|Placebo|Maltodextrin powder is the placebo ingredient and this is encased in the same pale green capsules as the active ingredient. Participants, if in the placebo group, will consume x3 capsules of placebo per day for 28 days.
89369852|NCT03689348|Experimental|300mg Avena sativa|If in the 300mg of Avena sativa group, participants will consume x2 placebo capsules (described above) and x1 300mg capsule of Avena sativa per day for 28 days.
89369853|NCT03689348|Experimental|600mg Avena sativa|If in the 600mg of Avena sativa group, participants will consume x1 placebo capsule (described above) and x2 300mg capsule of Avena sativa per day for 28 days.
89369854|NCT03689348|Experimental|900mg Avena sativa|If in the 300mg of Avena sativa group, participants will consume x3 300mg capsule of Avena sativa per day for 28 days.
89399204|NCT03692091|Active Comparator|Anterior portal|Injection in to subacromial space from anterior portal
89369855|NCT03689270||Subluxation|Nucleus is hydrodissected until it lilts above the capsular bag, rotated to face the incision then tumbled and emulsification continues from the opposite equator outside in until complete
89369856|NCT03689270||Divide and Conquer|Cataract nucleus is fragmented into 4 pieces then aspirated by ultrasonic vibration
89369857|NCT01375062|No Intervention|tissue from biopsies|
89369858|NCT03401749|No Intervention|Control Group|Usual preadmission surgery instructions (shower the night before).
89369859|NCT03401749|Experimental|Theraworx Group|Usual preadmission surgery instructions (shower the night before) plus theraworx skin wipe system use the night before surgery and 1 hour before surgery.
89369860|NCT03401749|Experimental|CHG Group|Usual preadmission surgery instructions (shower the night before) plus chlorhexidine gluconate (CHG) skin wipe system use the night before surgery and 1 hour before surgery.
89369861|NCT03634176||Group M|both optic nerve sheath diameter (the posterior 3mm of the papilla) before and after received 0.5gr/kg 20% mannitol
89369862|NCT03634176||Group H|both optic nerve sheath diameter (the posterior 3mm of the papilla) before and after received 1.5 ml/kg 7.5% NaCl solution
89369863|NCT03634176||Group P|both optic nerve sheath diameter (the posterior 3mm of the papilla) before and after patients were positioned on reverse Trendelenburg position 30 degrees higher than the feet
89369864|NCT01311583|Active Comparator|usual care plus Teach Back intervention|Trained nurses will provide Teach Back to the intervention group. The nurses' training will focus on the concepts of Teach Back, provide coaching and guidance on how to use it as well as review the principles of conducting research. Role play will be a feature in the education sessions to improve the nurses' comfort level
89369865|NCT01311583|No Intervention|usual care|"All participants will experience the current practice of discharge teaching: daily interaction with the interdisciplinary team members via rounds, counseling on diet and medications with a dietician and pharmacist when referred, view the Heart Failure Discharge Video, and receive a Congestive Heart Failure education package which includes the Heart and Stroke Managing Congestive Heart Failure booklet."
89369866|NCT03029624|Experimental|Treatment Arm|Treatment Arm receives implanted eCoin device and therapy is turned ON.
89369867|NCT02952001||4 mg CLS-TA Suprachoriodal Injection|Those subjects randomized to the CLS-TA 4 mg arm in CLS1001-301 (NCT02595398) and who completed participation without receiving additional therapy. No study drug was administered during this study.
88842369|NCT02952872|Experimental|Arm 14|Participants will complete a brief tablet-based intervention created to include the following features: common factors, a human voice to guide the intervention, no animated narrator, and the presence of motivational content.
89369868|NCT02952001||Sham procedure|Those subjects randomized to the sham procedure arm in CLS1001-301 (NCT02595398) and who completed participation without receiving additional therapy. No study drug was administered during this study.
89369869|NCT05196594||Affected group by transthyretinal amyloidosis with cardiac involvement|collection of stools
89369870|NCT05196594||Affected group by transthyretinal amyloidosis without cardiac involvement|collection of stools
89369871|NCT05196594||healthy control group|collection of stools
88842370|NCT02952872|Experimental|Arm 15|Participants will complete a brief tablet-based intervention created to include the following features: common factors, a human voice to guide the intervention, an animated narrator to guide the intervention, and no motivational content.
88842371|NCT02952872|Experimental|Arm 16|Participants will complete a brief tablet-based intervention created to include the following features: common factors, a human voice to guide the intervention, an animated narrator to guide the intervention, and the presence of motivational content.
88842372|NCT02799667|Active Comparator|Standard Dressing|Women will be randomized to receive the standard dressing (sterile gauze, non absorbent sterile gauze, and a waterproof bandage) at the time of fascial closure in a cesarean delivery.
88842373|NCT02799667|Experimental|Negative Pressure Wound Therapy Dressing|Women will be randomized to receive the Negative Pressure Wound Therapy (NPWT) dressing at the time of fascial closure in a cesarean delivery.
88842374|NCT02914795||non-resuscitated myocardial infarction|diagnostic analysis of platelet function of a matched historical cohort of the ATLANTIS-ACS trial
88842375|NCT02914795||resuscitated myocardial infarction|diagnostic analysis of platelet function of the patient cohort included according to the inclusion criteria
88842376|NCT02953418|Experimental|Radiofrequency ablation|Step-wise endoscopic RFA with the Barrx™ Flex Radiofrequency Ablation System using will be performed in 3 month intervals up to 12 months.
88842377|NCT02915029|Experimental|Education and Lifestyle Coaching|"Education and life style coaching includes:~education about diabetes and kidney disease Coaching /counseling about lifestyle, nutrition and medication adherence"
89369872|NCT01372020|Sham Comparator|control group|
89369873|NCT01372020|Experimental|neuromuscular electrical therapy|
89369874|NCT03744299|Other|Intervention|Patients and caregivers are asked to complete a questionnaire
89369875|NCT01311739|Experimental|10 mg Eligen® B12 (Cyanocobalamin/SNAC)|A single oral dose of Eligen® B12, cyanocobalamin/SNAC (5 mg cyanocobalamin/100 mg SNAC) administered in the fasted state as 2 tablets taken with 50 mL of water resulting in a total dose of 10 mg cyanocobalamin and 200 mg SNAC.
89369876|NCT01311739|Experimental|5 mg Eligen® B12 (Cyanocobalamin/SNAC)|A single oral dose of Eligen® B12, cyanocobalamin/SNAC (5 mg cyanocobalamin/100 mg SNAC) administered in the fasted state as a tablet taken with 50 mL of water resulting in a total dose of 5 mg cyanocobalamin and 100 mg SNAC.
89369877|NCT01311739|Active Comparator|5 mg Oral Cyanocobalamin|A single oral dose of cyanocobalamin alone (5 mg cyanocobalamin, commercial: VITALABS, INC) administered in the fasted state as a tablet taken with 50 mL of water resulting in a total dose of 5 mg cyanocobalamin.
89369878|NCT01311739|Active Comparator|1 mg Intravenous Cyanocobalamin|A single intravenous (IV) dose of cyanocobalamin (1 mg cyanocobalamin) administered in the fasted state. Each subject will receive a 1 mL IV injection of a 1 mg/mL (1000 μg/mL) solution resulting in a total dose of 1 mg cyanocobalamin.
89369879|NCT03744221|Experimental|Corn protein|Corn protein powder
89369880|NCT03744221|Experimental|Bovine plasma protein|Bovine plasma protein powder
89369881|NCT03744221|Active Comparator|control benchmark protein Whey|Whey protein powder
89399205|NCT03692091|Active Comparator|Lateral portal|Injection in to subacromial space from lateral portal
88842378|NCT02915029|No Intervention|Usual care (UC) control arm|once randomize to the Usual Care control group, the participants are left alone and are suggested to contact their providers for health care. The group gets labs and other survey done at 6 and 12 months of the intervention.
88842379|NCT02831660|Experimental|idarucizumab|
88842380|NCT02831816|Experimental|ZP (70% IPA)|Isopropyl alcohol (IPA) 70%
88842381|NCT02831816|Active Comparator|ChloraPrep|Chlorhexidine gluconate (CHG) 2% / Isopropyl alcohol (IPA) 70%
88842382|NCT02831816|Placebo Comparator|ZP Vehicle|ZP without IPA
88842383|NCT02832284|Experimental|iNod System|Multi-center, Prospective, Single-arm Feasibility Study with Salvage.
88842384|NCT03036163|Experimental|Cohort 1|6 male healthy volunteers each of whom received once single oral dose of PBTZ169 - 40 mg (1 capsule)
88842385|NCT03036163|Experimental|Cohort 2|6 male healthy volunteers each of whom received once single oral dose of PBTZ169 - 80 mg (2 capsules)
88842386|NCT03036163|Experimental|Cohort 3|6 male healthy volunteers each of whom received once single oral dose of PBTZ169 - 160 mg (4 capsules)
88842387|NCT03036163|Experimental|Cohort 4|6 male healthy volunteers each of whom received once single oral dose of PBTZ169 - 320 mg (8 capsules)
88842388|NCT03036163|Experimental|Cohort 5|6 male healthy volunteers each of whom received once single oral dose of PBTZ169 - 640 mg (16 capsules)
88842389|NCT03036163|Experimental|Cohort 6|5 male healthy volunteers each of whom received once daily for 14 days 320 mg of PBTZ169 (8 capsules 40 mg)
88842390|NCT03036163|Experimental|Cohort 7|5 male healthy volunteers each of whom received once daily for 14 days 640 mg of PBTZ169 (16 capsules 40 mg)
88842391|NCT02832674|Experimental|Single Treatment|All enrolled subjects will receive a Percutaneous Radiofrequency Single Treatment'
88842392|NCT02973607||Donors|Patients who donated a kidney and took part in the original CRIB-DONOR study.
89369882|NCT05507359|Experimental|Clove Gel|"Group 1: a. The heart rate will be measured using the pulse oximeter before topical application of clove gel.~b. The site where the rubber dam\ matrix band will be applied will be dried, then topically anesthetized with 4.7% (Pain Out Dental Gel, Colgate Palmolive India Ltd, Solan, India) clove gel for 30-60 seconds.~c. During rubber dam clamp\ matrix band application, the pain will be evaluated using the Sounds, Eyes, Motor scale.~d. After the rubber dam clamp\ matrix band application, the child will be asked to choose a face from the Wong-Baker FACES pain rating scale to assess subjective pain.~e. The heart rate will be measured again using the pulse oximeter to evaluate the child's dental anxiety."
88842393|NCT02973607||Controls|Healthy subjects who took part in the original CRIB-DONOR study.
88842394|NCT03034928|Other|Test 1/Control 1, then Control 2/Test 2|Contact lens with investigational coating 1 in right eye, with balafilcon A contact lens in left eye during Period 1, followed by balafilcon A contact lens in right eye, with contact lens with investigational coating 2 in left eye during Period 2. Each lens pair worn contralaterally for approximately 2 hours, with 2 to 8 days between pairs.
88842395|NCT03034928|Other|Test 2/Control 2, then Control 1/Test 1|Contact lens with investigational coating 2 in right eye, with balafilcon A contact lens in left eye during Period 1, followed by balafilcon A contact lens in right eye, with contact lens with investigational coating 1 in left eye during Period 2. Each lens pair worn contralaterally for approximately 2 hours, with 2 to 8 days between pairs.
88842396|NCT03034928|Other|Control 1/Test 1, then Test 2/Control 2|Balafilcon A contact lens in right eye, with contact lens with investigational coating 1 in left eye during Period 1, followed by contact lens with investigational coating 2 in right eye, with balafilcon A contact lens in left eye during Period 2. Each lens pair worn contralaterally for approximately 2 hours, with 2 to 8 days between pairs.
88842397|NCT03034928|Other|Control 2/Test 2, then Test 1/Control 1|Balafilcon A contact lens in right eye, with contact lens with investigational coating 2 in left eye during Period 1, followed by contact lens with investigational coating 1 in right eye, with balafilcon A contact lens in left eye during Period 2. Each lens pair worn contralaterally for approximately 2 hours, with 2 to 8 days between pairs.
88842398|NCT03038815|Experimental|Controll-VACOped-Ortho Tri|All participants are in the control and the two intervention group. The instant change of the ankle joint motion is analyzed. For control, the participants are wearing Sport shoes.This group had the VACOped as the first intervention.
88842399|NCT03038815|Experimental|Controll-Ortho Tri-VACOped|All participants are in the control and the two intervention group. The instant change of the ankle joint motion is analyzed. For control, the participants are wearing Sport shoes.This group had the Ortho Tri first intervention
88842400|NCT02800213|Experimental|Modified Ambu Spur II bag mask first|A health volunteer uses a modified Ambu Spur II bag valve mask with integrated internal handle (experimental device, not yet FDA approved) to deliver 10 breaths per minute for 3 minutes to a manikin (IngMar RespiTrainer manikin model). Volunteer then repeats the procedures using a conventional Ambu Spur II bag valve mask.
88842401|NCT02800213|Active Comparator|Conventional Ambu Spur II bag mask first|A health volunteer uses a conventional Ambu Spur II bag valve mask to deliver 10 breaths per minute for 3 minutes to a manikin (IngMar RespiTrainer manikin model). Volunteer then repeats the procedures using a modified Ambu Spur II bag valve mask.
88842402|NCT02953886|Experimental|Silver Diamine Fluoride (SDF)|Application of Silver Diamine Fluoride (SDF) to root or cervical carious lesions (cavities). Collection of plaque pre- and one month post-SDF application.
88842403|NCT03035318|Active Comparator|DePuy Global® Anchor Peg Glenoid|In the setting of Anatomic Total Shoulder Arthroplasty, this arm uses DePuy Global® Anchor Peg Glenoid Instrumentation to position the glenoid component.
88842404|NCT03035318|Experimental|DePuy Instrumentation with SmartBone™|In the setting of Anatomic Total Shoulder Arthroplasty, this arm uses DePuy Global® Anchor Peg Instrumentation with SmartBone™, to position the glenoid component.
88842405|NCT03035318|Experimental|IRI with SmartBone™|In the setting of Anatomic Total Shoulder Arthroplasty, this arm uses an Intelligent Reusable Instrumentation (IRI), with a SmartBone™, to position the glenoid component.
88842406|NCT03035318|Experimental|RTI with SmartBone™|In the setting of Anatomic Total Shoulder Arthroplasty, this arm uses Real Time Instrumentation (RTI), with a SmartBone™, to position the glenoid component.
88842407|NCT03035318|Experimental|IRI with SmartBase|In the setting of Anatomic Total Shoulder Arthroplasty, this arm uses an Intelligent Reusable Instrumentation (IRI), with a SmartBase™, to position the glenoid component.
88842408|NCT03035708|Experimental|varenicline|1 mg BID (2 capsules BID)
88842409|NCT03035708|Placebo Comparator|Placebo|1 mg BID (2 capsules BID)
88842410|NCT03040154|Experimental|Intervention Arm|Culturally-tailored video that includes parent testimonials, health and mental health clinicians, community-based providers, and church leaders
88842411|NCT03040154|Other|Control Arm|Usual care video publicly available describing the evidence-based parenting intervention
88842412|NCT02916745|Experimental|Photodynamic therapy-Photofrin|Photodynamic therapy (PDT) involves the i.v. injection of 2 mg/kg-porfimer sodium (Photofrin®) followed by illumination of the tumor using a fiber optic device during navigational bronchoscopy. Two days after the injection, a laser light will be applied to the tumor.
88842413|NCT02954198|Active Comparator|Tacrolimus + MMF|Tacrolimus IR BID (5-12ng/mL) + mycophenolate mofetil 1g BID + prednisone x at least 3 months, then converted to Tacrolimus Daily (5 -12ng/mL) + mycophenolate mofetil 1g BID + prednisone x 6 months
88842414|NCT02954198|Active Comparator|Envarsus + Everolimus|Tacrolimus IR BID (5-12ng/mL) + mycophenolate mofetil 1g BID + prednisone x at least 3 months, then converted to Envarsus Daily (2-5ng/mL) + Everolimus Daily (3-8ng/mL) + prednisone x 6 months
88842415|NCT02956070|Experimental|Experimental|35 patients in this group will undergo the whitening procedure using the Dexamethasone acetate intervention.
88842416|NCT02956070|Placebo Comparator|Placebo|35 patients in this group will undergo the whitening procedure using the Potassium Nitrate intervention
88842417|NCT02956616|Experimental|Enhanced Recovery|Postoperative recovery will follow the usual service protocols as if the patient were not in the study with the exception of components of the enhanced recovery protocol (detailed previously), which will include several evidence-based recommendations including early ambulation, early diet initiation, early removal of urinary catheter, early removal of postoperative dressing. Additionally, participants in this group will receive intravenous ketorolac for pain control and Xylitol chewing gum for improvement of postoperative gastrointestinal function.
88842418|NCT02956616|Active Comparator|Routine Perioperative Care|Postoperative recovery will follow the usual service protocols at our institution. Participants in this group may receive intravenous ketorolac (toradol) for pain control
88842419|NCT02809183|Placebo Comparator|Placebo-BID|Administered twice daily (BID) for 14 days
88842420|NCT02809183|Experimental|TRC101 (1.5g BID)|Administered twice daily (BID) for 14 days
89369883|NCT05507359|Active Comparator|Benzocaine Gel|"The heart rate will be measured using the pulse oximeter before topical application of benzocaine gel.~The site where the rubber dam\ matrix band will be applied will be dried, then topically anesthetized with 20% benzocaine gel for 30-60 seconds (Opahl Gel).~During rubber dam clamp\ matrix band application, the pain will be evaluated using the Sounds, Eyes, Motor scale.~After the rubber dam clamp\ matrix band application, the child will be asked to choose a face from the Wong-Baker FACES pain rating scale to assess subjective pain.~The heart rate will be measured again using the pulse oximeter to evaluate the child's dental anxiety."
89369884|NCT05196360|Experimental|MAX-10181|tables
88842421|NCT02809183|Experimental|TRC101 (3g BID)|Administered twice daily (BID) for 14 days
88842422|NCT02809183|Experimental|TRC101 (4.5g BID)|Administered twice daily (BID) for 14 days
88842423|NCT02809183|Experimental|TRC101 (6g QD)|Administered once daily (QD) for 14 days
88842424|NCT02809183|Placebo Comparator|Placebo-QD|Administered once daily (QD) for 14 days
88842425|NCT02958956||Ever User of Pioglitazone|Ever user of pioglitazone was defined as having filled 2 prescriptions for the drug within a 6-month period.
88842426|NCT02958956||Never User of Pioglitazone|Never user of pioglitazone, which included participants receiving no diabetes medications, with fewer than 2 pioglitazone prescription fills in a 6-month period, and with use of diabetes medications other than pioglitazone.
88842427|NCT02833922||Women using Dot to avoid pregnancy|Women living in the United States, ages 18-39 who have not used hormonal birth control or been pregnant in the last three months, who are in a relationship with a male sexual partner, and who wish to use the Dot app to avoid pregnancy for at least one year.
88842428|NCT02917447|Experimental|DESTRESS-WV|Tailored online intervention for PTSD for women Veterans with coach support.
88842429|NCT02917447|Placebo Comparator|Phone Monitoring|Weekly check-in calls from a study coach.
88842430|NCT05829616|Experimental|QLS12004|Subjects will be treated with different dose groups of QLS12004 according to the frequency and periodicity of administration as specified in the protocol, until disease progression or unacceptable toxicity.
88842431|NCT05829590|Experimental|with Artificial intelligence assistant system|Endoscopists would complete the colonoscopy report with the assistance of the artificial intelligence system.
88842432|NCT05829590|No Intervention|without Artificial intelligence assistant system|Endoscopists would complete the colonoscopy report without special prompts.
88842433|NCT05829551|Experimental|RAY1216 dose 1|SAD
88842434|NCT05829551|Experimental|RAY1216 dose 2|SAD
88842435|NCT05829551|Experimental|RAY1216 dose 3|SAD
88842436|NCT05829551|Experimental|RAY1216 dose 4（DDI）|drug-drug interaction
88842437|NCT05829551|Experimental|RAY1216 dose 5|MAD
88842438|NCT05829551|Experimental|RAY1216 dose 6|MAD
88842439|NCT05829551|Experimental|RAY1216 dose 7|MAD
88842440|NCT05829551|Experimental|RAY1216 dose 8|MAD
88842441|NCT05829551|Experimental|RAY1216 dose 9（food effect）|food effect on single dose
88842442|NCT05829551|Experimental|RAY1216 dose 10（food effect）|food effect on single dose
89369885|NCT03712033||TEC4Home Stroke Cohort|"All participants or caregiver involved will be instructed to measure BP per the TEC4Home BP Telemonitoring Protocol. Participants will measure their BP daily, 4x/day, for the first week. After the first week, all weekly BP measurements will be done 3 days/week with 4 measurements a day. All readings must be taken before administration of antihypertensive medications, twice in the morning, 5 minutes apart and twice in the evening, 5 minutes apart.~The TEC4Home telemonitoring nurse will review the BP measurements and contact the participant on a weekly basis until the end of the 6-month monitoring period. The telemonitoring nurse will adjust the antihypertensive medication doses as per the TEC4Home Stroke - Hypertension Management Algorithm."
89369886|NCT04123067|Experimental|Pioglitazone treatment group|oral administration of 45mg Pioglitazone daily for three subsequent days, initiated within 12h of stroke symptom onset
89369887|NCT04123067|Placebo Comparator|Placebo group|Oral administration of placebo daily for three subsequent days, initiated within 12h of stroke symptom onset
89369888|NCT05193006||peritoneal malignant mesothelioma of grade 1|peritoneal malignant mesothelioma of grade 1
89369889|NCT05193006||peritoneal malignant mesothelioma of grade 2|peritoneal malignant mesothelioma of grade 2
89369890|NCT05193006||peritoneal malignant mesothelioma of grade 3|peritoneal malignant mesothelioma of grade 3
89369891|NCT03711955|Experimental|Aerobic training group (AET)|Each AET sessions are to last one hour, with 40 minutes being allocated to the aerobic exercise training component, 10 minutes allocated to warm-ups, 5 minutes allocated to cool-downs, and one 5 minute rest period between the 20 minutes spent on each machine (20 minutes of cycling, 5 minute rest, 20 minutes seated row). The AET program consists of 20 minutes of cycling on the stationary bicycle and 20 minutes of seated row on the kinesis Technogym machine. This is to be preceded by 10 minutes of static stretching during warm up, and 5 minutes of post-exercise recovery (dynamic stretches).
89369892|NCT03711955|Experimental|Instability training group (IRT)|Each IRT sessions are to last one hour, with time being allocated to a 10 minute warm up, consisting of static stretches, a 5 minute cool down, consisting of dynamic stretches, and a series of IRT exercises performed in a circuit setting over the duration of 40 minutes. In the sessions, five resistance exercises will be performed. A linear periodization will occur, in which the training load will progress from high-volume low-intensity to low-volume high-intensity loads over the duration of eight weeks to maximize training adaptations. Additionally, there will be a progressive increase in load/resistance by 1-2 lbs and the degree of instability of each exercise during the course of the eight week program. Unstable devices will be changed from the least unstable to the most unstable device throughout the program, but only when participants showed a considerable decrease in body sway/movement and force production increased when performing exercises.
89369893|NCT05192928|Experimental|All Patients using the Ripple Health Smart Pill Cap|In this single-arm trial, all patients will be using the Ripple Health Smart Pill Cap as a method of medication administration
89369894|NCT01375218|Active Comparator|Plastizote Brace|
89369895|NCT01375218|Active Comparator|Pavlik Brace|
89369896|NCT05196282||UC, Smoker|
89369897|NCT05196282||UC, Smoking cessation|
89369898|NCT05196282||UC, THS user|
89369899|NCT05196282||CD, Smoker|
89369900|NCT05196282||CD, Smoking cessation|
89369901|NCT05196282||CD, THS user|
89369902|NCT03688958|Placebo Comparator|Early Cancer placebo|"The daily supplement of a vegetable colored water solution (drops) for 7 to 35 days in early breast cancer diagnosticated woman.~Placebo: vegetable colored water solution (drops). Evaluate the activity of placebo on tumor size, and molecular tumor response, as well as side effects attenuation"
89369903|NCT03688958|Experimental|Early Cancer Iodine|The daily supplement of an iodine solution (drops, 5 mg/day) for 7 to 35 days in early breast cancer diagnosticated woman
89369904|NCT03688958|Placebo Comparator|Advanced Cancer FEC/TE placebo|"The daily supplement of an vegetable colored water solution (drops) within 4 to 6 cycles of chemotherapy with FEC/TE in advanced breast cancer diagnosticated woman.~Placebo: vegetable colored water solution (drops). Evaluate the adjuvancy of placebo in FEC/TE treatment on tumor size and molecular tumor response, as well as side effects attenuation."
89369905|NCT03688958|Experimental|Advanced Cancer FEC/TE + Iodine|"The daily supplement of an iodine solution (drops, 5 mg/day) within 4 to 6 cycles of chemotherapy with FEC/TE in advanced breast cancer diagnosticated woman Drug: Iodine solution (5 mg/day). Evaluate the adjuvancy of I2 on FEC/TE treatment on tumor size and molecular tumor response, as well as side effects attenuation.~Other Name: evaluating the adjuvancy of iodine supplement in FEC/TE treatment"
89369906|NCT05192616||iCover covered stent|Percutaneous transluminal angioplasty (PTA)
89369907|NCT05196204|Experimental|Trunk-oriented task combined with functional electrical stimulation training group|This group will be formed with participants with spinal cord injury. This group will perform 12 weeks of trunk-oriented task training combined with functional electrical stimulation.
89369908|NCT05196204|Active Comparator|Trunk-oriented task training group|This group will be formed with participants with spinal cord injury. This group will perform 12 weeks of trunk-oriented task training.
89369909|NCT05196204|No Intervention|Control group|Healthy participants will be recruited based on the age and sex of the participants with spinal cord injury to realize clinical, biomechanical and cortical evaluations
88875248|NCT02544984|Placebo Comparator|placebo|The control group will be provided with a placebo medication of similar taste, color, texture, and consistency as the study medication, and will be dispensed once a day on Monday, Wednesday, and Friday.
88875249|NCT02544984|Experimental|azithromycin|Patients will receive azithromycin at a dose of 5 mg/kg to be given once a day on Monday, Wednesday, and Friday. The dosage will be not be adjusted if a new weight is obtained during the trial period.
89369910|NCT03688646|Experimental|Intervention group|Intensive nutrition intervention group receiving standardised oral nutrition supplement provided once daily throughout cancer treatment with 4 session of dietary consultation by designated dietitian for monitoring of diet intake and diet modification to meet patient's requirement
89369911|NCT03688646|No Intervention|Control group|Routine care were given to this group inclusive of 4 session of dietary consultation by designated dietitian for monitoring of diet intake and diet modification to meet patient's requirement and also prescription of oral nutrition supplement where needed. Oral nutrition supplement was not provided
89369912|NCT05196048||No Intervention|No Intervention
88842443|NCT05829538|Experimental|Su Jok|Su Jok Experimental Group (A): In this study, the seed therapy technique was applied using live buckwheat seeds. Hands were used because it was reported in the literature that hands were used for gynecological pain and were more suitable (Şimşek and Alpar, 2022). The acupuncture point, which is the reflection of the painful area, was determined on the women's hands. This point was massaged for a few minutes by the researcher, and then the buckwheat seed was fixed to this point with a bandage and the area where the seed was applied was massaged for 30 minutes. After each application, VAS evaluation was taken from the women. Su Jok was applied to women in the first three days of menstruation for three cycles.
88842444|NCT05829538|Experimental|Massage|Experimental Group (B) classical massage techniques (eufluorage, petrissage, friction, tapotman, vibration) was used. Massage was attempted for a total of 20 minutes, 10 minutes on the back and waist, and 10 minutes on the abdominal region, in the first three days of the three cycles. Massage application was started from the back and waist region. Efflorage, petrissage, friction, vibration, taputman and efflorage for one minute were applied to this area, respectively. Afterwards, three minutes of efflorage, petrissage, friction, and one-minute efflorage were applied to the abdominal region, respectively. Odorless, lubricating gel was used during the application. After each application, VAS evaluation was taken from the women. The women were massaged in the first three days of menstruation for three cycles.
88842445|NCT05829538|No Intervention|Control|VAS evaluation was taken on the first three days during three cycles.
88842446|NCT05829473|Experimental|Breathing Exercise Group|A total of 1 times day diaphragmatic breathing exercise will be made on 3 consecutive days (5 minutes diaphragmatic breathing exercise, 5 minutes relaxation exercise). Diaphragmatic breathing exercises will be performed at least 4 hours after the use of antiemetic drugs in the service. 20 minutes from the diaphragmatic breathing exercise application. Afterward, post-test data will be obtained using the Nausea-Vomiting Severity Evaluation Test During Pregnancy and Pregnancy-Related Anxiety scales. A total of 6 measurements will be made using the scales on the 1st, 2nd, and 3rd days.
88842447|NCT05829473|Experimental|Guided Imagery Group|10 minutes once a day for pregnant women with hyperemesis gravidarum who meet the research criteria the guided imagery compact disc will be played with the computer. A guided imagery compact disc will be watched at least 4 hours after the use of antiemetic drugs in the service.10 minutes once a day for pregnant women with hyperemesis gravidarum who meet the research criteria the guided imagery compact disc will be played with the computer. A guided imagery compact disc will be watched at least 4 hours after the use of antiemetic drugs in the service. Afterward, 20 minutes from the application post-test data will be obtained by using the Nausea-Vomiting Severity Assessment Test in Pregnancy and Pregnancy-Related Anxiety Scale-R2 scales. A total of 6 measurements will be made using the scales on the 1st, 2nd, and 3rd days.
89002071|NCT06116435|Experimental|PreventT2 + Move group-based classes + Mental Imagery + Fitness Membership|Participants will receive a 6-month lifestyle weight management program based on the publicly available Prevent T2 curriculum (formally known as the National Diabetes Prevention Program), integrated with the Move group-based classes. Group classes will be delivered weekly in weeks 1-12, and biweekly in weeks 13-26. Group-based classes will be taught virtually by a trained Registered Dietitian from the Colorado Nutrition Obesity Research Center Clinical Intervention and Translation (CIT) Core. Participants will also receive a 6-month membership to the Peloton fitness app. In addition, participants will receive access to online mental guided imagery sessions. Guided positive exercise imagery scripts were developed based on work from Williams et al. and prompt several sensory and emotional experiences.
89180196|NCT00725985|Experimental|Cladribine 5.25 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU)|Participants who received cladribine 5.25 mg/kg and did not convert to CDMS during ITP, entered in long-term follow-up (LTFU) period. Participants who converted to McDonald multiple sclerosis (MS) during ITP or during LTFU period received open-label cladribine tablets (3.5 mg/kg) during LTFU period. Participants who converted to CDMS during LTFU received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.
89180197|NCT00725985|Experimental|Cladribine 3.5 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU)|Participants who received cladribine 3.5 mg/kg and did not convert to CDMS during ITP, entered in long-term follow-up (LTFU) period. Participants who converted to McDonald multiple sclerosis (MS) during ITP or during LTFU period received open-label cladribine tablets (3.5 mg/kg) during LTFU period. Participants who converted to CDMS during LTFU received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.
89180198|NCT00725985|Experimental|Placebo, Rebif, Cladribine 3.5 mg/kg (LTFU)|Participants who received placebo and did not convert to CDMS during ITP, entered in long-term follow-up (LTFU) period. Participants who converted to McDonald multiple sclerosis (MS) during ITP or during LTFU period received open-label cladribine tablets (3.5 mg/kg) during LTFU period. Participants who converted to CDMS during LTFU received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.
89180199|NCT00725985|Experimental|Cladribine 5.25 mg/kg, Rebif (LTFU)|Participants who received cladribine 5.25 mg/kg and did not convert to CDMS during ITP, entered in LTFU period. Participants who did not convert to McDonald MS during ITP did not receive any treatment during LTFU period. Participants who converted to CDMS during LTFU period received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.
89369913|NCT04080050||RGX-501|Study participants who have received RGX-501 gene therapy in a separate parent trial
89369914|NCT04117607|Experimental|BA1|100 mg (1 injection of 1.0 ml) or maximum tolerated dose (MTD) determined in SAD of Rezafungin administered subcutaneously into the abdomen on Day 1, and 100 mg (250 ml) or MTD of Rezafungin administered via intravenous infusion on Day 22 in an open label manner. n=5.
88842448|NCT05829473|No Intervention|Control Group|No intervention will be made to the pregnant women in the control group, other than their routine daily care. Pre-test data will be obtained by applying the Nausea-Vomiting Severity Evaluation Test During Pregnancy and Pregnancy-Related Anxiety scales at least 4 hours after the use of antiemetic drugs in the service. 20 min from the pre-test data. Afterward, the final test data will be obtained by applying the Nausea-Vomiting Severity Evaluation Test During Pregnancy and Pregnancy-Related Anxiety scales. A total of 6 measurements will be made using the scales on the 1st, 2nd, and 3rd days.
89180200|NCT00725985|Experimental|Cladribine 3.5 mg/kg, Rebif (LTFU)|Participants who received cladribine 3.5 mg/kg and did not convert to CDMS during ITP, entered in LTFU period. Participants who did not convert to McDonald MS during ITP did not receive any treatment during LTFU period. Participants who converted to CDMS during LTFU period received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.
89180201|NCT00725985|Experimental|Placebo, Rebif (LTFU)|Participants who received placebo and did not convert to CDMS during ITP, entered in LTFU period. Participants who did not convert to McDonald MS during ITP did not receive any treatment during LTFU period. Participants who convert to CDMS during LTFU period received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.
88842451|NCT05829382|Active Comparator|DailyColors™ group|"Capsules of 150 mg of the DailyColors™ blend~The investigational product is a capsule containing 150mg of the following phytonutritients:~Item Name Percent of Formula Apple Extract 10.0% Pomegranate Extract 10.0% Tomato Powder 2.5% Beet - Spray Dried 2.5% Olive Extract 7.5% Rosemary Extract 7.5% Green Coffee Bean Extract (C.A) 7.5% Kale - Freeze Dried 2.5% Onion Extract 10.0% Ginger Extract 10.0% Grapefruit Extract 2.5% Carrot - Air Dried 2.5% Grape Skin Extract 17.5% Blueberry Extract 2.5% Currant - Freeze Dried 2.5% Elderberry - Freeze Dried 2.5%"
88842452|NCT05829382|Placebo Comparator|Placebo group|Micro crystalline cellulose will be used as the placebo, which will be produced with similar appearance as the active compound visually and regarding smell and taste.
88842453|NCT05829369|Experimental|Intrinsic foot muscle exercise|This group will perform intrinsic foot muscle strengthening exercises
88842454|NCT05829369|Active Comparator|Minimal Footwear|This group will perform prescribed walking in and daily wear of minimally cushioned footwear
88842455|NCT05829369|Sham Comparator|Control|This group will be given a falls prevention brochure and seated upper extremity and lower extremity active range of motion activities.
88842456|NCT05829304|Active Comparator|Collagen based pulpotomy|"Application of rubber dam for isolation, then a standardized pulpotomy procedure will be performed. Remove pulpal tissues to the orifice level. Haemostasis will be achieved by the application of a wet cotton pellet.~Group I collagen-based Pulpotomy:~After complete haemostasis, collagen based pulpotomy will be applied according to the manufacturer's instructions and gently placed over the pulp stumps to a thickness of 2 mm then the rest of the pulp chamber will be filled with glass ionomer cement.~Tooth will be restored with stainless steel crown."
88842457|NCT05829304|Active Comparator|MTA based pulpotomy|"Application of rubber dam for isolation, then a standardized pulpotomy procedure will be performed. Remove pulpal tissues to the orifice level. Haemostasis will be achieved by the application of a wet cotton pellet.~Group II MTA pulpotomy:~After complete hemostasis, MTA+ Cerkamed will be manipulated to obtain a putty mix. This mix will be placed over the radicular pulp. condensation of the mix with a moistened cotton pellet, followed by application of glass ionomer cement.~Tooth will then be restored with stainless steel crown."
88842458|NCT05829278|Experimental|Acupuncture group|Subjects in the acupuncture group will undergo acupuncture treatment, which is administered 3 times a week for 4 weeks.
88842459|NCT05829278|No Intervention|Waiting list group|No intervention will be provided for the waiting list group and the subjects in this group will be followed during the 4-week observation period.
88842460|NCT05829213|Experimental|"arch-bridge-type reconstruction arm"|"In this arm, patients will receive proximal gastrectomy and arch-bridge-type reconstruction."
88842461|NCT05829200|Other|Asymptomatic Carotid Disease|All individuals who are consented for elective or urgent carotid endarterectomy would be eligible to participate. If patient gives consent, they would undergo an approximately 30-60 minute Transcranial Doppler (TCD)study. We will collect the number of high intensity transient signals (HITS). The patient would undergo surgery regardless of the TCD result.
88842462|NCT05829200|Other|Symtomatic Carotid Disease|All individuals who are consented for elective or urgent carotid endarterectomy would be eligible to participate. If patient gives consent, they would undergo an approximately 30-60 minute Transcranial Doppler (TCD)study. We will collect the number of high intensity transient signals (HITS). The patient would undergo surgery regardless of the TCD result.
88842463|NCT05829161||ASD Group|ASD participants, no intervention
89369915|NCT04117607|Experimental|BA2|100 mg (250 ml) or maximum tolerated dose (MTD) determined in SAD of Rezafungin administered via intravenous infusion on Day 1, and 100 mg (1 injection of 1.0 ml) or MTD of Rezafungin administered subcutaneously into the abdomen on Day 22 in an open label manner. n=5.
89399206|NCT03695991||Study group|Patients will be recruited from out-patient clinics and in-patient sectors of Assiut Urology and Nephrology hospital
88842464|NCT05829161||TD Group|TD participants, no intervention
88842465|NCT05829148|Active Comparator|Dexmedetomidine Group|This Group about 30 patients will receive dexmedetomidine loading dose 1 µg/kg over a period of 15 minutes and maintenance 0.2µg/kg/h throughout the surgery .
88842466|NCT05829148|Active Comparator|Melatonin Group|This Group about 30 patients will receive 10 mg melatonin (2 tablets) one hour before starting of the operation.
88842467|NCT05829148|Active Comparator|Pregabalin Group|This Group about 30 patients will receive oral pregabalin 150 mg one hour before starting of the operation..
88842468|NCT05829148|Placebo Comparator|Control Group|This Group about 30 patients will receive oral starch tablet as a control. Heart rate (HR) and blood pressure values will be recorded at various intervals.
88842469|NCT05829122|Experimental|Sutureless Intrascleral Intraocular Lens Fixation and Modified Iris Cerclage Pupilloplasty|
88842470|NCT05829096|Experimental|Intervention arm|"This is a single arm interventional study.~A patient-level intervention, which includes:~An assessment of existing lifestyle factors (smoking status, physical activity levels, and weight) that may be relevant to shoulder pain;~A brief intervention to support health behaviour change with respect to the target behaviours of smoking cessation, increasing physical activity levels and consuming a healthy diet~Supporting tools for behaviour change, including an activity workbook for goal-setting and a diary for self-monitoring (attached).~The intervention is to be delivered by physiotherapists, integrated within a routine consultation for people with a RC disorder.~A clinician-level implementation toolkit to support the delivery of the clinical intervention, which includes a training package and additional resources e.g. scripts to aid conversations with patients."
89180202|NCT04107974|Experimental|Gastropexy|Percutaneous radiologic guided insertion of G-tube. The skin over the epigastrium is prepared and draped in sterile fashion. Midazolam and fentanyl are administered for conscious sedation. Lidocaine for local analgesia. The stomach is insufflated with air after insertion of an OG or NG tube. Two T-fasteners are inserted into the stomach approximately 4cm apart. A needle is inserted into the stomach and an Amplatz wire is then inserted into the stomach. The tract is dilated with an 18Fr peel away sheath. A 14 Fr balloon retention gastrostomy tube is inserted. The balloon is inflated and bolster set as appropriate. The gastropexy/T-fastener sutures are cut after one week.
89180203|NCT04107974|Experimental|Non-Gastropexy|Percutaneous radiologic guided insertion of G-tube. The skin over the epigastrium is prepared and draped in sterile fashion. Midazolam and fentanyl are administered for conscious sedation. Lidocaine for local analgesia. The stomach is insufflated with air after insertion of an OG or NG tube. A needle is inserted into the stomach and an Amplatz wire is then inserted into the stomach. The tract is dilated with an 18Fr peel away sheath. A 14 Fr balloon retention gastrostomy tube is inserted. The balloon is inflated and bolster set as appropriate.
89180204|NCT04113824|Experimental|trapezius motion style acupuncture treatment|"The MSAT group recieved 3 sessions of MSAT; on second, third, fourth day after hospitalization. A trained doctor of Korean medicine with at least 3 years of clinical experience conducted the MSAT.~The MSAT group were also treated with other Korean medical treatment everyday: acupuncture, chuna, pharmacoacupuncture and Korean herbal medicine."
89180205|NCT04113824|Active Comparator|Korean medical treatment|The control group were received Korean medical treatment everyday after hospitalization: acupuncture, chuna, pharmacoacupuncture and Korean herbal medicine.
89180206|NCT04113980|Experimental|music group|The children in the groups were distracted by listening music 2 minutes before venipuncture, until the process was over.
89180207|NCT04113980|Experimental|kaleidescope group|The children in the groups were distracted by kaleidoscope 2 minutes before the blood collection, until the process was over.
89180208|NCT04113980|Experimental|video group|The children in the groups were distracted by watching cartoon 2 minutes before the blood collection, until the process was over.
89180209|NCT04113980|No Intervention|control group|No intervention was made to children in the control group
89180210|NCT04109768|Experimental|Hands on Nutrition Education|Nutrition and activity intervention to improve behaviors pre to post
89180211|NCT00793910|Active Comparator|Gabapentin|oral medication
89180212|NCT00793910|Placebo Comparator|placebo|
89180213|NCT04113902|Experimental|intervention group|Health education is given intervention group and 12 weeks follow up.
89180214|NCT04113902|No Intervention|control group|Control group takes standard health care and 12 weeks follow up.
89180215|NCT02592525|Experimental|Cluster A|IP-SDM training for health professionals (intervention at 4 months)
89180216|NCT02592525|Experimental|Cluster B|IP-SDM training for health professionals (intervention at 11 months)
89180217|NCT02592525|Experimental|Cluster C|IP-SDM training for health professionals (intervention at 18 months)
89180218|NCT02592525|Experimental|Cluster D|IP-SDM training for health professionals (intervention at 25 months)
89180219|NCT01019941|Other|1st cycle:CKD-810 -> 2nd cycle:Taxotere inj.|
88842471|NCT05829057|Experimental|Arm of P-IL-2|Ia:Subjects will be dosed with single dose of P-IL-2
89180220|NCT01019941|Other|1st cycle:Taxotere inj.-> 2nd cycle:CKD-810|
89180221|NCT04113668|Experimental|Arm A: Single Dose (BMS-986165)|
89180222|NCT04113668|Experimental|Arm B:Diflunisal and Single Dose (BMS-986165)|
89180223|NCT00444145|Experimental|Patients with documented GERD or laryngopharyngeal reflux|Patients who have documented GERD as evidenced by erosive esophagitis or those patients who have newly diagnosed laryngopharyngeal reflux as diagnosed by endoscopy.
89180224|NCT04108286|Experimental|TEST/CONTROL|Eligible subjects that are habitual wearers of spherical soft contact lenses will be randomly assigned to 1 of 2 contralateral lens sequences (Right: TEST/ Left: CONTROL) or (Right: CONTROL/ Left: TEST).
89180225|NCT04108286|Experimental|CONTROL/TEST|Eligible subjects that are habitual wearers of spherical soft contact lenses will be randomly assigned to 1 of 2 contralateral lens sequences (Right: TEST/ Left: CONTROL) or (Right: CONTROL/ Left: TEST).
89180226|NCT04107896|Experimental|Silodosin|8 mg daily by mouth, 12 weeks
89180227|NCT04107896|Active Comparator|Tamsulosin|0.4 mg daily by mouth, 12 weeks
89180228|NCT01024699||XLIF|This group will have the XLIF procedure done.
89180229|NCT01024699||MAS TLIF|This group will have the MAS TLIF procedure done.
89180230|NCT05582720|Active Comparator|Conventional burger group|This arm will consume 2 portions (each 120 g cooked) of conventional burger per week for a 4-week period.
89180231|NCT05582720|Experimental|Vegan burger group|This arm will consume 2 portions (each 120 g cooked) of vegan burger per week for a 4-week period.
89180232|NCT01024777|Active Comparator|High dose cholecalciferol|Patients in the high dose arm will receive 10,000 international units of cholecalciferol daily.
89180233|NCT01024777|Active Comparator|Low dose cholecalciferol|Patients enrolled in the low dose arm will receive up to 1000 international units of cholecalciferol daily.
89180234|NCT04113590|Experimental|Transvaginal cholecystectomy under laparoscopic guidance|The removal of the gallbladder through several small incisions using a camera to see is called laparoscopic cholecystectomy. This study is being done to evaluate whether cholecystectomy can be performed through a natural orifice (the vagina) with minimal laparoscopic assistance (only one abdominal trocar versus four in the routine laparoscopic cholecystectomy).
89399207|NCT03692013|Experimental|nighttime group|patients with nocturnal hypertension taking losartan at nighttime
89369916|NCT04117607|Experimental|MAD1|30 mg (1 injection of 0.3 ml) of Rezafungin administered subcutaneously into the abdomen as three doses, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel), on Days 1, 8, and 15 in a double-blind manner.
89369917|NCT04117607|Experimental|MAD2|60 mg (1 injection of 0.6 ml) of Rezafungin administered subcutaneously into the abdomen as three doses, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel), on Days 1, 8, and 15 in a double-blind manner.
89369918|NCT04117607|Experimental|MAD3|100 mg (1 injection of 1.0 ml) of Rezafungin administered subcutaneously into alternating abdominal quadrants as three doses, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel), on Days 1, 8, and 15 in a double-blind manner.
89369919|NCT04117607|Experimental|MAD4|200 mg (2 injections of 1.0 ml) of Rezafungin administered subcutaneously into alternating abdominal quadrants as three doses, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel), on Days 1, 8, and 15 in a double-blind manner.
89369920|NCT04117607|Experimental|SAD1|1 mg (1 injection of 0.1 ml diluted 1:10 in 5% Dextrose Injection, USP) of Rezafungin administered subcutaneously into the abdomen as a single dose, n=3 (no sentinel dosing), or matching placebo, n=1 (no sentinel dosing), on Day 1 in a double-blind manner.
89369921|NCT04117607|Experimental|SAD2|10 mg (1 injection of 0.1 ml) of Rezafungin administered subcutaneously into the abdomen as a single dose, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel), on Day 1 in a double-blind manner.
89369922|NCT04117607|Experimental|SAD3|30 mg (1 injection of 0.3 ml) of Rezafungin administered subcutaneously into the abdomen as a single dose, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel), on Day 1 in a double-blind manner.
89369923|NCT04117607|Experimental|SAD4|60 mg (1 injection of 0.6 ml) of Rezafungin administered subcutaneously into the abdomen as a single dose, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel), on Day 1 in a double-blind manner.
89369924|NCT04117607|Experimental|SAD5|100 mg (1 injection of 1.0 ml) of Rezafungin administered subcutaneously into alternating abdominal quadrants as a single dose, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel), on Day 1 in a double-blind manner.
89369925|NCT04117607|Experimental|SAD6|200 mg (2 injections of 1.0 ml) of Rezafungin administered subcutaneously into alternating abdominal quadrants as a single dose, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel), on Day 1 in a double-blind manner.
89369926|NCT03657654||Thyroidectomy|Patients that are clinically referred for a thyroidectomy for known or potential cancer.
89369927|NCT03657654||Other surgeries|Patients must be clinically referred for a surgery requiring intubation, but without risk to the laryngeal nerves or dissection adjacent to the larynx
89369928|NCT03688568|Experimental|Imatinib Mesylate Arm|Imatinib Mesylate, given daily orally, 55 mg PO BID, if tolerated for 2 weeks increase to 110 mg/m2 BID, and further increase to 165 and final dosage to 220 mg/m2 bid if tolerated. Can continue for 12 months.
89369929|NCT05192304|Experimental|0.2mg single dose|single dose of TPN-672 0.2mg, 2 subjects
89369930|NCT05192304|Experimental|0.3mg single dose|single dose of TPN-672 0.3mg, 12 subjects（9 for TPN-672, 3 for placebo）
88842472|NCT05829057|Experimental|P-IL-2 plus Anti-PD-1 Monoclonal Antibody|Ib:Subjects will be dosed with dose of P-IL-2 plus Anti-PD-1 Monoclonal Antibody
88842473|NCT05829018|Active Comparator|Dutch South Asian males|males of Dutch South Asian descent, as defined as having 4 grandparents that originally descended from either Surinam, Bangladesh, India, Nepal, Pakistan, Afghanistan, Bhutan or Sri Lanka
89369931|NCT05192304|Experimental|0.4mg single dose|single dose of TPN-672 0.4mg, 12 subjects（9 for TPN-672, 3 for placebo）
89369932|NCT05192304|Experimental|0.5mg single dose|single dose of TPN-672 0.5mg, 12 subjects（9 for TPN-672, 3 for placebo）
89369933|NCT05192304|Experimental|0.6mg single dose|single dose of TPN-672 0.6mg, 12 subjects（9 for TPN-672, 3 for placebo）
89369934|NCT05192304|Experimental|0.7mg single dose|single dose of TPN-672 0.7mg, 12 subjects（9 for TPN-672, 3 for placebo）
89369935|NCT01375296|Experimental|SES|including two types of China-made SES, i.e. Firebird 2 (cobalt-alloy platform with durable polymer coating sirolimus-eluting stent) and Excel (stainless steel platform with biodegradable polymer coating sirolimus-eluting stent).
88842474|NCT05829018|Active Comparator|Dutch South Asian females|females of Dutch South Asian descent, as defined as having 4 grandparents that originally descended from either Surinam, Bangladesh, India, Nepal, Pakistan, Afghanistan, Bhutan or Sri Lanka
89369936|NCT01375296|Other|medicine|
89369937|NCT03527862|No Intervention|Control group|No intervention is performed. Lung ultrasonography is performed within 4 hours after surgery for diagnostic purpose.
89369938|NCT03527862|Experimental|lung ultrasonography group|Lung ultrasonography is performed three times; after tracheal intubation, before surgery end, and within 4 hours after surgery. In this group, respiratory management is performed according to diagnosis.
89369939|NCT04430660|Other|Arm 1|Participants will have there glial acetate metabolism assessed via 13C MRS at baseline and then again 14 days later. Participants will wear blinded continuous glucose monitoring devices for ~4 weeks.
88842475|NCT05829018|Active Comparator|Dutch Europid males|males of Europid descent, as defined as having 4 grandparents from European origin
88842476|NCT05829018|Active Comparator|Dutch Europid females|females of Europid descent, as defined as having 4 grandparents from European origin
88842477|NCT05828862|Experimental|hypotension prediction index guided|patients with hypotension prediction index guidance
88842478|NCT05828862|Active Comparator|no hypotension prediction index guided|patients without hypotension prediction index guidance
88842479|NCT05828797||Shoulder elastography on the hemiplegic side of patients|Patients over the age of 18 who apply to our clinic and have hemiplegia complaints will be evaluated. Patients' age, gender, occupation, habits, disease duration, upper extremity with complaints, dominant upper extremity, additional disease, weight and height values will be recorded. In the physical medicine and rehabilitation department examination of the patients, the patients will be evaluated with the brunnstrom staging used in hemiplegic patients. The elastography of the shoulder on the side with hemiplegia and the elastography of the shoulder on the side without complaints will be examined. Thus, the patient's side with the complaint will be checked by comparing the healthy side.
89369940|NCT03744143|Other|Group A (vaginal technique)|Patients undergoing surgical removal of vaginal endometriotic nodule through vaginal technique
89369941|NCT03744143|Other|Group B (laparoscopic technique)|Patients undergoing surgical removal of vaginal endometriotic nodule through laparoscopic technique. Closure of the vagina with a transverse suture or a longitudinal suture.
89369942|NCT05191992|Experimental|experimental|The group will receive CPR training with the e-learning method and will learn skills with a handmade mannequin.
89002072|NCT06116435|Experimental|PreventT2 + Move group-based classes + Move 1:1 Support|Participants will receive a 6-month lifestyle weight management program based on the publicly available Prevent T2 curriculum (formally known as the National Diabetes Prevention Program), integrated with the Move group-based classes. Group classes will be delivered weekly in weeks 1-12, and biweekly in weeks 13-26. Group-based classes will be taught virtually by a trained Registered Dietitian from the Colorado Nutrition Obesity Research Center Clinical Intervention and Translation (CIT) Core. Participants will also receive Move individualized support sessions. The 1:1 support sessions are designed to help participants adopt the physical activity messages from each Move group-based class into their daily lives.
89369943|NCT03693638|Active Comparator|Single dose (SD)|2,5 ml total anesthetic drug dose (Bupivacaine-fentanyl) were given with 0.2 ml/second rate, and subjects were asked to remain sitted for 90 seconds
89369944|NCT03693638|Active Comparator|Fractionated dose (FD)|1,5 ml of total anesthetic drug dose (Bupivacaine-fentanyl) followed by 1 ml remaining dose after 90 s interval were given
89369945|NCT04112303|Experimental|SOF/VEL|Participants received SOF/VEL (400/100 mg) orally once daily for up to 12 weeks.
89369946|NCT01319838|Experimental|isotretinoin prolongation|Prolonged treatment with isotretinoin, extending standard 6 month duration to 2 years
89369947|NCT03634566|Active Comparator|NAC group|Group NC received NAC 150 mg/kg diluted in 100 ml glucose 5 % over 40 minutes followed by NAC 12.5 mg/kg in 500 ml glucose 5% over 4 hours, followed by NAC 6.25 mg/kg for 2 postoperative days
89369948|NCT03634566|Placebo Comparator|Control group|Group C (Control group) will receive ringer acetate continuous infusion at same rate for 2 days.
89369949|NCT03998189|Experimental|Female Participants|45 female patients will be screened to participate.
89369950|NCT03998189|Experimental|Male Participants|45 male patients will be screened to participate
89369951|NCT01372098|Experimental|NFP + IPV intervention|The protocol for number and timing of visits will be the same for both NFP+IPVI and Standard Care, as follows: weekly for the first four visits, every other week for the remainder of the pregnancy, every week for six weeks in the postpartum and every other week until the infant is 21 months old after which it is once a month for the last three months. We recognize that the intervention might prompt the nurse and mother to alter the regular visit schedule if IPV is present.
89369952|NCT01372098|No Intervention|NFP (standard care)|"The NFP nurses currently receive some training regarding IPV, but it is minimal. Between intake and when the child is 3 months and 12 months old, there is a brief instruction that the nurse assess for IPV. If the client acknowledges current abuse when completing the Abuse Assessment Screen, the nurse should assist her to evaluate threats to personal safety and make referrals as needed. There is a prompt to be mindful of client safety, and to make referrals as needed."
89369953|NCT03688412||Cook lead extraction devices|The Cook lead extraction devices are indicated for use in patients requiring percutaneous removal of CIED leads, indwelling catheters and foreign objects.
89369954|NCT01373892|Active Comparator|Surgery|Slevve vs. Roux-Y
89369955|NCT01373892|No Intervention|Healthy lean volunteers|
89369956|NCT03355872|Experimental|HLX01|
89369957|NCT03355872|Active Comparator|Rituximab|
89369958|NCT03744065|Active Comparator|Lumbar plexus block|Patients randomized to receive an ultrasound-guided lumbar plexus block
89369959|NCT03744065|Experimental|Suprainguinal fascia iliaca block|Patients randomized to receive an ultrasound-guided suprainguinal fascia iliaca block
89369960|NCT05191914|Experimental|chidamide + fulvestrant|
89369961|NCT03688334|Active Comparator|IPF patients|Supplementation of oxygen treatment (40% FiO2) during steady state cardiopulmonary exercise testing
89369962|NCT03688334|Sham Comparator|IPF patients (crossover)|Supplementation of medical air (sham Oxygen) during steady state cardiopulmonary exercise testing
89369963|NCT05191836|Experimental|Pulpotomy in primary mandibular molars by using video game distraction.|
89369964|NCT05191836|Experimental|Pulpotomy in primary mandibular molars by using audio visual distraction.|
89369965|NCT05191836|Other|Pulpotomy in primary mandibular molars without using any type of distraction aids|
89369966|NCT04099277|Experimental|Part A: 10 milligrams (mg) LY3435151|Participants received intravenous (IV) push or IV bolus infusion of 10 mg LY3435151.
89369967|NCT04099277|Experimental|Part B: LY3435151 + Pembrolizumab Dose Escalation|Pembrolizumab was not administered as study was terminated before completion of Part A of the dose escalation period.
89369968|NCT04099277|Experimental|Part C: LY3435151 Dose Expansion|Participants were not enrolled in to this arm, as trial was terminated in dose escalation phase.
89369969|NCT04099277|Experimental|Part D: LY3435151 + Pembrolizumab Dose Expansion|Participants were not enrolled in to this arm, as trial was terminated in dose escalation phase.
89369970|NCT03698786||European males|"This study will involve a cohort of 15 White European men, between the ages of 18-50 years. Participants will be non-smokers, not dieting, and physically well to participate.~Participants will be required to exercise on one occasion."
89369971|NCT03698786||South Asian males|"This study will involve a cohort of 15 South Asian (India, Pakistan, Sri Lanka, Nepal, Bangladesh, Maldives and Bhutan), men, between the ages of 18-50 years. Participants will be non-smokers, not dieting, and physically well to participate.~Participants will be required to exercise on one occasion."
89369972|NCT03743987|Sham Comparator|control group|Apical resection group. Only root resection was applied without any other interventions (like prf or mta)
89369973|NCT03743987|Experimental|MTA group|Root resection was applied and MTA was inserted through the apical foramen
89369974|NCT03743987|Experimental|PRF group|Root resection was applied and PRF was placed to the surgically prepared area
89369975|NCT03743987|Experimental|MTA + PRF group|Root resection was applied. MTA was inserted through the apical foramen and PRF was placed to the surgically prepared area
89369976|NCT05171322||All patients|All patients included were set up with the WARD monitoring devices.
89180235|NCT04106882|Experimental|Arm 1: Metabolic Manipulation via Diet fMRI|All subjects are tested three times, each in a different diet-induced metabolic state: glycolytic (glucose burning), fasting (8 hours no food), and ketotic (fat burning). While having their brains scanned with MRI, subjects are initially tested at rest, and then perform a task. Midway through the session, subjects are removed from the scanner and drink up to 75g glucose. Data analyses quantify network reorganization in response to changing energy constraints (i.e., cognitive demand, fuel).
89180236|NCT04106882|Experimental|Arm 2: Metabolic Manipulation via Ketone Supplement fMRI|All subjects are tested twice, both times in a fasting condition (8 hours no food, unrestricted water). While having their brains scanned with MRI, subjects are initially tested at rest, and then perform a task. Midway through the session, subjects are removed from the scanner and drink either of two fuel sources. In the ketotic (ketone burning) session they will drink a ketone sports drink dosed at 395mg/kg. During the glycolytic (glucose burning) session the same subjects will drink a bolus of glucose, calorie-matched to the ketones. Data analyses quantify network reorganization in response to changing energy constraints (i.e., cognitive demand, fuel).
89180237|NCT04106882|Experimental|Arm 3: Metabolic Manipulation via Ketone Supplement MR/PET|All subjects are tested twice, both times in a fasting condition (8 hours no food, unrestricted water). For both sessions, the investigators will intravenously administer the FDG radioisotope continuously throughout the scan. Thus, PET will map glucose uptake across the brain, while MRS is simultaneously used to measure production of the neurotransmitters glutamine and GABA. While having their brains scanned with MR/PET, subjects are initially tested at rest, and then perform a task. Subjects will drink a ketone sports drink dosed at 395mg/kg. During the glycolytic (glucose burning) session the same subjects will drink a bolus of glucose, calorie-matched to the ketones.
89180238|NCT00725283|Experimental|GSK2130579A Group|Patients with cytologically proven AML, as defined by the World Health Organization classification, who were administered a standard dose of GSK2130579A treatment. Patients received 24 doses of the study treatment over a period of approximately 4 years.
89180239|NCT00444067|Experimental|Spinal Sealant System|Spinal Sealant System
89180240|NCT00444067|Active Comparator|Standard of Care|Standard of care methods as an adjunct to sutured dural repair
89180241|NCT01323283|Active Comparator|Omega-3 supplementation|50 % of all included children will be randomized to this arm and administered capsules containing an omega-3 fatty acid composition.
89180242|NCT01323283|Placebo Comparator|Placebo|50 % of included children will be randomized to this arm and will be administered placebo capsules for the 15 week intervention.
89180243|NCT00789854|Active Comparator|Add-on Quetiapine XR+SSRI/Venlafaxine|"Selective serotonin reuptake inhibitors (SSRI) or Venlafaxine from previous therapy + add-on treatment with quetiapine XR, 300mg tablet once daily (od).~From previous anti-depressant treatment 64% of the patients had SSRI and 35% had Venlafaxine at baseline."
89180244|NCT00789854|Active Comparator|Add-on Lithium+SSRI/Venlafaxine|"Selective serotonin reuptake inhibitors (SSRI) or venlafaxine from previous therapy + add-on treatment with lithium, approximately 900mg tablet once daily (od).~From previous anti-depressant treatment 67% of the patients had SSRI and 33% had Venlafaxine at baseline."
89180245|NCT00789854|Active Comparator|Monotherapy Quetiapine XR|Switch from previous treatment with SSRI or venlafaxine to quetiapine XR monotherapy, 300mg tablet once daily (od)
89180246|NCT00725205||Chronic hepatitis C participants|Untreated chronic hepatitis C (CHC) participants starting Peginterferon alfa-2b (injection pen) and Ribavirin combination therapy as their usual medical treatment according to the approved dosage/regimen were selected for this study.
89180247|NCT01323361|No Intervention|Non-immunosupressed|Normal population
88818412|NCT01389284|Placebo Comparator|Placebo|1 naproxen sodium ER 660 mg matching placebo tablet and 1 naproxen sodium IR 220 mg matching placebo tablet initially followed by 1 naproxen sodium IR 220 mg matching placebo tablet at hour 8 (± 15 min), and 1 naproxen sodium IR 220 mg matching placebo tablet at hour 16 (± 15 min)
88818413|NCT01794143|Active Comparator|Sulfonylurea (glimepiride)|Sulfonylurea
88818414|NCT01794143|Active Comparator|DPP-4 inhibitor|DPP-4 inhibitor (sitagliptin)
88818415|NCT01794143|Active Comparator|GLP-1 receptor agonist|GLP-1 receptor agonist (liraglutide)
88818416|NCT01794143|Active Comparator|Insulin (glargine)|Insulin (glargine), Lantus
88818417|NCT01408862||controls|Healthy volunteers will be asked to donor a 10-80 ml blood through a venous puncture
88818418|NCT01409096|Active Comparator|Pregnenolone|This arm will be given 50mg Pregnenolone twice per day for 2 weeks, then 150mg Pregnenolone twice per day for 2 weeks, then 250mg Pregnenolone twice per day for 8 weeks.
88818419|NCT01409096|Placebo Comparator|Placebo|The arm will be given placebo that matches the Pregnenolone at the same frequency as the Pregnenolone for 12 weeks.
88818420|NCT01547741|Active Comparator|Arm 1: Anthracycline-based chemotherapy|"4 anthracycline-based chemotherapy regimens (Regimens A, B, C, or D).~Regimen A (TAC): 75 mg/m2 docetaxel (T) + 50 mg/m2 doxorubicin (A) + 500 mg/m2 cyclophosphamide (C) IV every 3 weeks for 6 cycles.~Regimen B (AC then WP): 60 mg/m2 doxorubicin (A) + 600 mg/m2 cyclophosphamide (C) every 3 weeks for 4 cycles followed by weekly paclitaxel (WP) 80 mg/m2 IV every week for 12 doses.~Regimen C (DD AC then WP): 60 mg/m2 doxorubicin + 600 mg/m2 cyclophosphamide every 2 weeks for 4 cycles followed by weekly paclitaxel 80 mg/m2 IV every week for 12 doses.~Regimen D (DD AC then DD P): 60 mg/m2 doxorubicin + 600 mg/m2 cyclophosphamide every 2 weeks for 4 cycles followed by paclitaxel (P) 175 mg/m2 IV every 2 weeks for 4 cycles."
88818421|NCT01547741|Active Comparator|Arm 2: docetaxel + cyclophosphamide|TC: 75 mg/m2 docetaxel and 600 mg/m2 cyclophosphamide IV every 3 weeks for 6 cycles
88818422|NCT01410812|Experimental|Suggested Tying|Receive same treatments as control group, but instead of receiving cash they receive 4 iTunes audio novels for their own iPods. Further, they are prompted to try to listen to those novels only when exercising at the gym in order to increase their attendance.
88842480|NCT05828797||Shoulder elastography on the non-hemiplegia side of patients|Patients over the age of 18 who apply to our clinic and have hemiplegia complaints will be evaluated. Patients' age, gender, occupation, habits, disease duration, upper extremity with complaints, dominant upper extremity, additional disease, weight and height values will be recorded. In the physical medicine and rehabilitation department examination of the patients, the patients will be evaluated with the brunnstrom staging used in hemiplegic patients. The elastography of the shoulder on the side with hemiplegia and the elastography of the shoulder on the side without complaints will be examined. Thus, the patient's side with the complaint will be checked by comparing the healthy side.
88842481|NCT05828784|Other|35 consecutive patients|
88842482|NCT05828745|Experimental|CB06-036 Cohort 1|CB06-036 1.5 mg once weekly
88842483|NCT05828745|Placebo Comparator|Placebo Cohort 1|Placebo 1.5 mg once weeky
88842484|NCT05828745|Experimental|CB06-036 Cohort 2|CB06-036 3.0 mg once weekly
88842485|NCT05828745|Placebo Comparator|Placebo Cohort 2|Placebo 3.0 mg once weekly
88842486|NCT05828745|Experimental|CB06-036 Cohort 3|CB06-036 1.5 mg twice-a-week, for 4 weeks
88842487|NCT05828745|Placebo Comparator|Placebo Cohort 3|Placebo 3.0 mg twice-a-week, for 4 weeks
88842488|NCT05828745|Experimental|CB06-036 Cohort 4|CB06-036 3.0 mg once weekly for 4 weeks
88842489|NCT05828745|Placebo Comparator|Placebo Cohort 4|Placebo 3.0 mg once weekly for 4 weeks
88842490|NCT05828732|Experimental|app user group|The participants in this group start using wearable devices to monitor their heart rate and a mobile app to assist with the management of hyperthyroidism after being diagnosed and beginning treatment with anti-thyroid medication.
88842491|NCT05828732|No Intervention|non-user group|The participants in this group begin treatment with anti-thyroid medication after being diagnosed with thyrotoxicosis, but they do not use the wearable devices or mobile app used in this study.
88842492|NCT05828680||Elective cardiac surgery|
88842493|NCT05828628||Patients with a new diagnosis of primary or secondary CNS lymphoma|
88842494|NCT05828576||ECAA patient|ECAA patient recieving conservative treatment
88842495|NCT05828563|Active Comparator|pesticide applicators|This group contain cases
88842496|NCT05828563|Active Comparator|control|control group
88842497|NCT05828498||grup 1|patients who were on a diet and had a Mediterranean Diet Adherence Scale ≥7 were included in the diet group
88842498|NCT05828498||grup 2|As the control group (group 2), 64 patients participated in the study.
88842499|NCT05828485|Experimental|Sequence 1 : AB|6 subjects were given a single dose of MY008211A tablets in the fasting state and, after a 5-day washout period, a single dose of MY008211A tablet was administered after taking a standard high-fat and high-calorie fed.
88842500|NCT05828485|Experimental|Sequence 1 : BA|6 subjects were given a single dose of MY008211A tablet after taking a standard high-fat and high-calorie fed and, after a 5-day washout period, a single dose of MY008211A tablet in the fasting state.
88842501|NCT05828446|Experimental|HCC screening population according to European Association for the Study of the Liver recommendation|
88842502|NCT05828433|Experimental|Epley-Canalith Repositioning|"Step 1: The patient was brought down with the head tilted 45 degrees towards the af-fected canal as in Hallpike test. The neck was extended.~Step 2: The head was rotated 90 degrees towards the unaffected side. The neck was extended.~Step 3: The head and body were rotated by further 90 degrees from the previous positions (now face down). The neck was in neutral position.~Step 4: The patient was brought into a sitting position while having their head turned constantly in the direction of the unaffected side.~Step 5: The head was turn forward and the chin was kept 20° down for a minute"
88842503|NCT05828433|Experimental|Vestibular Rehabilitation Therapy|Habituation exercises Gaze stability exercises and balance training
88842504|NCT05828420|Experimental|The pain effect of listening to white noise on newborn babies|Each baby was listened to white noise 10 minutes before, during and 20 minutes after the painful attempt.
88842505|NCT05828420|Experimental|The pain effect of listening to heart sound on newborn babies|Each baby listened to heart sounds at an average rate of 70 beats 10 minutes before, during and 20 minutes after the painful procedure.
88842506|NCT05828420|Experimental|The pain effect of listening to music on newborn babies|Each baby was listened to the music that the mother listened to the most during pregnancy restriction 10 minutes before, during and after the painful attempt.
88842507|NCT05828394|Experimental|Depithelised Free Gingival Graft, DFGG|The group assignment was communicated through a sealed envelope that was opened just prior to the surgery. The subjects will undergo to a harvesting procedure of a palatal graft using DFGG technique described as following: two horizontal and two vertical incisions will be traced with a 15C blade to delimit the area to be grafted. Along the coronal horizontal incision, the blade will be oriented almost perpendicular to the bone plate and once an adequate soft tissue thickness was obtained, it will be rotated in order to be almost parallel to the superficial surface. The thickness of the graft will be maintained uniform while proceeding apically with the blade. Once the graft is separated, the adipose and glandular tissue as well as the epithelium will be removed extra orally with a new blade. Finally the palate will be sutured with 5-0 monofilament suture and collagen sponges. In this group the palate is suppose to have a secondary intention healing.
88842508|NCT05828394|Experimental|Subepithelial Connective Tissue Graft, SCTG|The group assignment was communicated through a sealed envelope that was opened just prior to the surgery. The subjects will undergo to a harvesting procedure of a palatal graft using SCTG technique described as following: one deep horizontal incision parallel to the gingival margin will be traced at 1.5 mm apical to the gingival margin of the adjacent teeth, according to the palatal pocket depth of the teeth. A deeper incision parallel and deeper to the initial one will be performed. The primary flap will be elevated split-thickness. The horizontal incision will be made almost perpendicular to the underlying bone. Once an adequate soft tissue thickness is obtained, the blade will be rotated in order to be almost parallel to the external surface. The thickness of the graft will be maintained uniform. Finally the palate will be sutured with 5-0 monofilament suture and collagen sponges.In this group the palate is suppose to have a primary intention healing.
88842509|NCT05828381|Experimental|Envafolimab combination with Abraxane and cisplatin|Arm description：Envafolimab:300mg,sc,d1,q3w; for a total of 2 cycles. Chemotherapy： Abraxane + Cisplatin Abraxane :100mg/m2,ivgtt, D1、D8,q3w ,for a total of 2 cycles. Cisplatin : 75 mg/m 2 vigtt D1 , q3w , for a total of 2 cycles.
89369977|NCT03990389|No Intervention|Usual Care Group|"Subjects will undergo screening including Rapid Estimate of Adult Literacy in Medicine (REALM-R) and Edinburgh Postnatal Depression Scale (EPDS) and a few additional questions.~Eligible subjects randomized to usual care will receive monthly reminder phone calls from a research coordinator. Subjects will receive an email with a link to surveys for the purpose of collecting information on depression severity, medication adherence, self-efficacy, side-effect burden, and maternal functioning.~All participants will be asked to participate in a semi-structured debrief interview upon study completion."
89369978|NCT03990389|Experimental|Chabot Care Group|"Subjects will undergo screening including REALM-R and EPDS and a few additional questions.~Eligible subjects randomized to chatbot care will receive monthly reminder phone calls from a research coordinator. Subjects will receive an email with a link to surveys for the purpose of collecting information on depression severity, medication adherence, self-efficacy, side-effect burden, and maternal functioning.~In addition to the above procedures, eligible subjects randomized to chatbot care will receive weekly messages from the chatbot asking them to complete a depression severity measure and side-effect burden assessments. Within week 1 subjects will receive a check-in call from a study coordinator to answer any questions regarding use of the chatbot.~All participants will be asked to participate in a semi-structured debrief interview upon study completion."
89369979|NCT03990389|No Intervention|Provider Subject Cohort|20 provider subjects from each study site will be enrolled to ensure they understand the study and consent to have their patients enrolled in the study
89369980|NCT04037462|Experimental|Lead in Dexamethasone followed by immunotherapy|escalating doses of pretreatment dexamethasone in patients who have failed initial immunotherapy to 1. assess changes in FLT PET uptake 2. assess overall response rates of pretreatment dexamethasone (dose from 1) on subsequent immunotherapy re-challenge
89399208|NCT03692013|Active Comparator|daytime group|patients with nocturnal hypertension taking losartan at daytime
88842510|NCT05828316|Experimental|Intervention group|60 students (30 nursing students in alexandria- 30 nursing students in Saudi). They will participate in resilience based intervention
88842511|NCT05828316|No Intervention|Control group|60 students (30 nursing students in alexandria- 30 nursing students in Saudi). They will not participate in resilience based intervention
88842512|NCT05828264|No Intervention|Control group|children in the control group will be received standard care. Control group children will not receive any distraction techniques.
89180248|NCT00443755|Active Comparator|Insulin Sensitizer Therapy|Two insulin sensitizing drugs will be taken together for 3 months; metformin 1000 mg twice daily plus pioglitazone 45 mg daily.
89180249|NCT00443755|Placebo Comparator|Placebo|Placebo tablets were used to match the active comparator drugs and dosing regimen.
88842513|NCT05828264|Experimental|Quantum Touch|The children in the quantum touch groups will received quantum touch application during the venipuncture procedure by the expert nurse
88842514|NCT05828251|Experimental|Combined Phako-Vitrectomy for FTMH|Study 1: Patient randomized to this arm will receive a combined phako-vitrectomy within two weeks from referall day.
88842515|NCT05828251|Active Comparator|Sequential phako and vitrectomy for FTMH|Study 1: Patients randomized to this arm will receive a standard phacoemulsification as soon as possible. About four weeks after phacoemulsification a vitrectomy is performed.
88842516|NCT05828251|Other|Longstanding FTMH|Study 2: Patients with symptomduration of 3-12 months will be included in this part of the study in a prospective design.
88842517|NCT05828238|Experimental|[18F]SF-DEVD-2|
88842518|NCT05828225|Experimental|Treatment Group|Myasthenia Gravis
88842519|NCT05828212|Experimental|Treatment Group|Recurrent/Refractory Neuromyelitis Optica
88842520|NCT05828199|Active Comparator|Dexmedtomidine group|About 40 patients will receive bolus dose of dexmedetomidine 0.5-1 μg/kg in 100 mL of normal saline over 10 minutes then, continuous infusion dose of dexmedetomidine 0.2 ug/kg/hr.
88842521|NCT05828199|Active Comparator|ketamin group|About 40 patients will receive a ketamine bolus dose (0.3 mg/kg IV slowly), then continuous infusion dose of ketamine (0.2 mg/kg/hr).
88842522|NCT05828121|Experimental|Point1|Receiving treatment
88842523|NCT05828056||BP|100 patients with mood disorders from the psychiatric ward and outpatient services of the Department of Psychiatry, National Taiwan University Hospital
88842524|NCT05827991|Experimental|1565nm Non-ablative Fractional Laser|1565nm Non-ablative Fractional Laser
88842525|NCT05827991|Active Comparator|Minoxidil|Minoxidil for external use
88842526|NCT05827991|Active Comparator|1565nm Non-ablative Fractional Laser combined with Minoxidil for external use|1565nm Non-ablative Fractional Laser combined with Minoxidil for external use
88842527|NCT05827939||SARS-CoV-2 Infection|Participants from individuals with SARS-CoV-2 Infection .
88842528|NCT05827939||SARS-CoV-2 non-infection with vaccination|Participants after the second dose covid19 vaccination from individuals without SARS-CoV-2 infection.
88842529|NCT05827939||SARS-CoV-2 non-infection without vaccination|Participants get covid19 vaccination below 2 dose from individuals without SARS-CoV-2 infection.
88842530|NCT05827913|Experimental|Polylevolactic Acid Injection|Polylevolactic Acid Injection in SD
89180250|NCT00724971|Experimental|Inotuzumab Ozogamicin + Rituximab|
89180251|NCT00443599|Experimental|Insulin|Insulin was infused to target a blood glucose concentration of 80-110 mg/dL
89180252|NCT00443599|Active Comparator|Usual Care|Insulin was infused according to the discretion of the treating clinical team.
88818423|NCT01410812|Experimental|Forced Tying|Receives same treatment as the control group. However, in addition to receiving the cash, they also receive 4 iTunes audio novels for a loaned iPod that they will only have access to at the gym. They are told they may only listen to these novels only when at the gym in order to increase their attendance.
89180253|NCT02604056|Active Comparator|Audit + Feedback|'Usual care' / standard quality improvement supports (including online Audit and Feedback reports for each prescriber in the home)
89180254|NCT02604056|Experimental|Audit + Feedback + Educational Outreach|'Active/full' intervention (featuring Educational Outreach offered to each prescriber and team members in the home)
89180255|NCT04113512|Experimental|Yoga Nasal Irrigation Group|Saline nasal irrigation using neti pot was practiced.
89180256|NCT04113512|No Intervention|Wait list Control group|Group was given usual pain medication. After trial period, they were offered the intervention.
89369981|NCT05194878|Experimental|Neoadjuvant chemotherapy|12 weeks of FOLFOXIRI neuoadjuvantly followed by surgery and adjuvant chemotherapy
88818424|NCT01410812|Experimental|Control|Control group of participants who do not receive any intervention but are weighed at the beginning and end of a 10 week period and receive weekly emails asking them about their exercise. They also receive the equivalent cash value of 4 iTunes audio novels
88818425|NCT01390064|Experimental|Initial Cohort|Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG Subcutaneous administration 5 doses of 300 micrograms
88818426|NCT01390064|Active Comparator|Escalation Cohort|Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG Subcutaneous administration of 5 doses of 500 micrograms
88818427|NCT01390064|Active Comparator|De-escalation Cohort|Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG Subcutaneous administration of 5 doses of 100 micrograms
88818428|NCT01280942|No Intervention|Control|Patients admitted to 4 GHWs designated as controls. Nurses will not be notified when patients on these GHWs satisfy the EWS algorithm. They will also not wear the wireless sensor devices.
88818429|NCT01280942|Experimental|Nurse notification of EWS alert|Patients admitted to 4 GHWs designated as intervention wards at BJH. Nurses will be notified when patients on these wards satisfy the EWS algorithm. Some patients will be asked to wear the wireless remote sensors.
88818430|NCT01472822|Experimental|Omija extract.|
88818431|NCT01472822|Placebo Comparator|Placebo|
88818432|NCT03008486|Active Comparator|DOC - real|Spastic patients with disorders of consciousness receiving the real soft splint
88818433|NCT03008486|Placebo Comparator|DOC - placebo|Spastic patients with disorders of consciousness receiving the placebo soft splint
88818434|NCT03008486|Active Comparator|Stroke - real|Spastic patients stroke receiving the real soft splint
88818435|NCT03008486|Placebo Comparator|Stroke - placebo|Spastic patients stroke receiving the placebo soft splint
88818436|NCT01411592|Active Comparator|Multilink|RBFDPs were inserted using an adhesive bonding system with a phosphonic acid acrylate primer for the zirconia ceramic (Multilink-Automix bonding system [A/B primer and Multilink-Automix] with Metal/Zirconia primer)
88818437|NCT01411592|Active Comparator|Panavia 21 TC|RBFDPs were inserted using a phosphate monomer containing resin (Panavia 21 TC) without any primer
88818438|NCT01473368|Active Comparator|prebiotic (Saccharomyces boulardii)|500 mg, 2 times daily for 14 days
88818439|NCT01473368|Active Comparator|antibiotic (Amoxicillin Clavulanate)|875/125 mg 2 times daily at least 1 hour before meals for 7 days
88818440|NCT01473368|Active Comparator|combination (prebiotic and antibiotic)|Amoxicillin Clavulanate for 7 days (days 1 to 7; 875/125 mg 2 times daily at least 1 hour before meals) in addition to the dietary supplement Saccharomyces boulardii for 14 days (days 1 to 14; 500 mg, 2 times daily).
88818441|NCT01473368|No Intervention|control|
88818442|NCT04351490|Experimental|Group supplementation|
88818443|NCT04351490|No Intervention|Group usual treatment|
88818444|NCT01391312|Active Comparator|botulinum toxin Type A|Botulinum toxin Type A 20U (total dose) injected into the glabellar region on Day 0.
88818445|NCT01391312|Placebo Comparator|placebo (Normal Saline)|Normal Saline (placebo) injected into the glabellar region on Day 0.
88818446|NCT01299935|Experimental|Stress reduction|Stress reduction program utilizing the Transcendental Meditation (TM) technique
88818447|NCT01299935|Active Comparator|health education|health education is taught in a clinical setting using standard AHA recommendations for proper diet, exercise and control of substance usage but without a stress management component.
88818448|NCT05329181|Other|Integrated cognitive behavioral therapy adapted for homeless individuals|Four homeless individuals enrolled in the Treatment First program (a social services program where treatment is offered in conjunction with temporary transitional housing), who had access to stable and sober housing milieus, received the integrated cognitive behavioral treatment.
88818449|NCT01391468|Placebo Comparator|Placebo|cornstarch
88818450|NCT01391468|Experimental|Probiotics|probiotics
88818451|NCT05328869|Experimental|Relaxation group|Jacobson progressive relaxation training will be applied
88818452|NCT05328869|Other|Control group|No intervention will be applied
88818453|NCT01822457|Experimental|Nike FuelBand (NFB)|Patients will receive a Nike Fuel Band to encourage exercise.
88818454|NCT01822457|No Intervention|control|Standard follow-up
88818455|NCT01391858|Active Comparator|pregabalin|pregabalin (lyrica)
88818456|NCT01391858|Placebo Comparator|placebo|placebo
88818457|NCT00103181|Active Comparator|Group 1: WBI|Patients undergo whole breast irradiation (WBI) once daily, 5 days a week for 5-7 weeks.
88842531|NCT05827913|Active Comparator|Fractional Laser|1565nm Non-ablative Fractional Laser treatment in SD
88842532|NCT05827913|Active Comparator|combination treatment|Polylevolactic Acid injection combined with 1565nm Non-ablative Fractional Laser treatment in SD
88842533|NCT05827848|Experimental|Treatment group|Turn on the machine for continuous nerve stimulation
88842534|NCT05827848|No Intervention|control group|Turn off the machine
89180257|NCT04107428|Active Comparator|Somatostatin|
89180258|NCT04107428|Placebo Comparator|Placebo|
88842535|NCT05827835|Experimental|Treatment Group|R/R CD7+Malignant Hematologic Diseases
88842536|NCT05827796|Experimental|Cohort 1: IN10018+ standard chemotherapy (albumin-bound paclitaxel + gemcitabine)|Subjects will be treated with IN10018 25 mg/50 mg/100 mg, once daily, oral+ albumin-bound paclitaxel 125 mg/m2 IV infusion on Days 1 and 8 of each 21-Day Cycle+ gemcitabine 1000 mg/m2 IV infusion on Days 1 and 8 of each 21-Day Cycle.
88842537|NCT05827796|Experimental|Cohort 2: IN10018+ standard chemotherapy (albumin-bound paclitaxel + gemcitabine)+KN046|Subjects will be treated with IN10018 25 mg/50 mg/100 mg, once daily, oral+ albumin-bound paclitaxel 125 mg/m2 IV infusion on Days 2 and 8 of each 21-Day Cycle+ gemcitabine 1000 mg/m2 IV infusion on Days 2 and 9 of each 21-Day Cycle+KN046 5 mg/kg IV infusion on Day 1 of each 21-Day Cycle.
88842538|NCT05827783|Experimental|Bee Buzzy|Bee Buzzy Group: Bee Buzzy was attached to the 3-6-year-old child included in this group by the researcher on the arm of the nurse to perform the phlebotomy procedure. Bee Buzzy reduces pain thanks to its cold wings and vibration. It helps to distract attention during phlebotomy and reduces the feeling of pain and fear. Bee Buzzy was tied 5 cm above the area from which blood will be drawn, and after waiting for 15 seconds, the nurse performed a phlebotomy.
88842539|NCT05827783|Experimental|Puppet Zuzu|While the nurse was going to perform the phlebotomy operation on the 3-6-year-old child included in this group, one of the researchers (no. 2) tried to distract the child by putting the puppet on her hand and making her talk. The puppet used is an easy-to-use and hand-held puppet that will not cause fear in children. The puppet was named 'Zuzu' by researchers.
88842540|NCT05827783|No Intervention|Control|No attempt was made to the 3-6-year-old child included in this group, during the process when the nurse performed the phlebotomy. Routine phlebotomy was performed. Pain and fear of the child during the procedure were evaluated.
88842541|NCT05827770|Experimental|Toripalimab Combined With Temozolomide|Toripalimab Combined With Temozolomide
88842542|NCT05827731|No Intervention|Natural delivery group|The patients in this group were treated with natural delivery
88842543|NCT05827731|Experimental|Cesarean section group|The patients in this group were delivered by cesarean section
88842544|NCT05827692|Experimental|Forest Bath Intervention group A|The intervention consists of 2 sessions of approximately 2 hours duration and fortnightly frequency. In this context, it is guaranteed that patients will receive the care, visits and treatments usually used in people who have presented their clinical situation. The only difference between participating or not in the intervention is the participation in the practice of forest baths and the performance of some additional assessments, i.e. not routinely performed, which are part of this project. The investigators will be responsible for providing an overview of the study to eligible patients interested in participating. Before proceeding to start the intervention, an informed consent will be given to the patients, in which a description of the characteristics of the sessions will be provided.
88842545|NCT05827692|Experimental|Forest Bath Intervention group B|The intervention consists of 2 sessions of approximately 2 hours duration and fortnightly frequency. In this context, it is guaranteed that patients will receive the care, visits and treatments usually used in people who have presented their clinical situation. The only difference between participating or not in the intervention is the participation in the practice of forest baths and the performance of some additional assessments, i.e. not routinely performed, which are part of this project. The investigators will be responsible for providing an overview of the study to eligible patients interested in participating. Before proceeding to start the intervention, an informed consent will be given to the patients, in which a description of the characteristics of the sessions will be provided.
88842546|NCT05827666|Active Comparator|Children|Participants will undergo four metabolic trials in a randomized crossover design, where they will be provided with an isoenergetic (i.e., equal calories) amount of one of the following beverages upon completing a standardized bout of variably intensity exercise: 2% milk, almond 'milk,' soy 'milk,' or rice 'milk.'
88842547|NCT05827666|Active Comparator|Adolescent females|Participants will undergo four metabolic trials in a randomized crossover design, where they will be provided with an isoenergetic (i.e., equal calories) amount of one of the following beverages upon completing a standardized bout of variably intensity exercise: 2% milk, almond 'milk,' soy 'milk,' or rice 'milk.'
88842548|NCT05827666|Active Comparator|Adolescent males|Participants will undergo four metabolic trials in a randomized crossover design, where they will be provided with an isoenergetic (i.e., equal calories) amount of one of the following beverages upon completing a standardized bout of variably intensity exercise: 2% milk, almond 'milk,' soy 'milk,' or rice 'milk.'
89180259|NCT02603978|No Intervention|Wait-list|This arm will receive no intervention for the first 6 months. At the conclusion of the 6-month period, this group will receive a brief alcohol intervention
88842550|NCT05827575|Experimental|taVNS|selected cavum conchae of the two ears for 25hz electrical stimulation
89180260|NCT02603978|Active Comparator|Brief Alcohol Intervention|This arm will receive a brief (2-hour) alcohol intervention based on motivational interviewing
89180261|NCT02603978|Active Comparator|Bystander and Social Norms Intervention|This arm will receive a brief (2-hour) bystander and social norms intervention designed to increase healthy sexual behaviors
89369982|NCT05194878|Active Comparator|Postoperative chemotherapy|surgery followed by 24 weeks of FOLFOX or CapeOX or Cape
89180262|NCT02603978|Active Comparator|Combined Alcohol and Bystander Intervention|This arm will receive a combined (4-hour) alcohol and bystander/social norms intervention to target both alcohol and sexual behavior
89180263|NCT00455143|Experimental|Dexmedetomidine|Participants will be randomized to either dexmedetomidine or placebo which will be started prior to surgery and continued for 24 hours postoperatively. Patients will receive dexmedetomidine until discharge from the PACU.
89369983|NCT03693326|Experimental|PDR001|PDR001 300 mg (fixed dose) intraveneously every 3 weeks
89369984|NCT03988907|Experimental|Part 1|Participants will receive a dose of 5 milligram (mg) risdiplam once daily (QD) for 14 consecutive days
89369985|NCT03988907|Experimental|Part 2|All study participants will receive a single oral dose of 2 mg midazolam on Day 1. On Day 3, the 14-day QD treatment period with risdiplam will begin. The precise dose will be based on the results of Part 1, with single dose administration of 2 mg midazolam again on Day 15 (1 hour after the thirteenth dose of risdiplam)
89369986|NCT03693248|Experimental|Two cycles of neoadjuvant chemotherapy|"Paclitaxel (175mg/m2) and carboplatin (AUC 5.0 or 6.0) IV, D1, every three weeks.~Two cycles of neoadjuvant chemotherapy and four cycles of adjuvant chemotherapy."
89369987|NCT03693248|No Intervention|Three cycles of neoadjuvant chemotherapy|"Paclitaxel (175mg/m2) and carboplatin (AUC 5.0 or 6.0) IV, D1, every three weeks.~Three cycles of neoadjuvant chemotherapy and three cycles of adjuvant chemotherapy."
88842551|NCT05827575|Sham Comparator|sham-taVNS|selected scapha of the two ears for 25hz electrical stimulation
89180264|NCT00455143|Placebo Comparator|Placebo|Participants will be randomized to either dexmedetomidine or placebo which will be started prior to surgery and continued for 24 hours postoperatively or until discharge from the PACU.
89180265|NCT00454987|Experimental|Menitorix Group|Previously primed in infancy with Menitorix™ and Infanrix-IPV™ and boosted with Menitorix™ (Priorix™ co-administered). All UK subjects received a booster dose of Infanrix-IPV™ at 40 to 43 months of age, intramuscularly in the deltoid region.
89180266|NCT00454987|Active Comparator|Meningitec Group|Previously primed in infancy with Meningitec™ and Pediacel™ and boosted with Menitorix™ (Priorix™ co-administered). All UK subjects received a booster dose of Infanrix-IPV™ at 40 to 43 months of age, intramuscularly in the deltoid region.
89369988|NCT03987191|Active Comparator|Standard of Care Transition|Stopping of insulin pump on the day of randomization and starting insulin degludec in 1:1 ratio (same units as total basal insulin on pump) and insulin Aspart for meals and corrections
89369989|NCT03987191|Experimental|Inverstigational Transition|Administration of insulin degludec in 1:1 ratio (same units as total basal insulin on pump) on the day of randomization AND concomitant use of the insulin pump for 48 hours from transition, where insulin pump basal rate will be reduced by 50% during the first 24 hours from transition and by 75% during 24 to 48 hours from transition. Insulin pump will be disconnected after 48 hours from transition
89369990|NCT04098809|Active Comparator|Catheter 16 French|16 French urinary catheter
89369991|NCT04098809|Active Comparator|Catheter 20 French|20 French urinary catheter
89399209|NCT03687489|Experimental|Intervention arm|Participants will be treated with Abdominal Aortic Aneurysm Stent Graft System
88818458|NCT00103181|Experimental|Group 2: PBI|Patients undergo partial-breast irradiation (PBI) twice daily on 5 days over a period of 5-10 days. This may be delivered by intracavitary brachytherapy, MammoSite or other single-entry intracavitary device, or 3-dimensional conformal accelerated partial breast irradiation.
88818459|NCT02201420|Experimental|Tc 99m tilmanocept|Subjects who are enrolled and will receive 50 micrograms tilmanocept radiolabeled with 2 millicuries of Tc 99m and undergo serial SPECT or SPECT/CT imaging.
88818460|NCT02690181|Experimental|GBS NoAdj/GBS NoAdj|Subjects who had received unadjuvanted GBS Trivalent Vaccine in parent study V98_06 (205468 - NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).
88818461|NCT02690181|Experimental|GBS Alum/GBS NoAdj|Subjects who had received GBS Trivalent Vaccine with alum adjuvant in parent study V98_06 (205468 - NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).
88818462|NCT02690181|Experimental|GBS MF59 Full/GBS NoAdj|Subjects who had received GBS Trivalent Vaccine with full dose of MF59 in parent study V98_06 (205468 - NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).
88818463|NCT02690181|Experimental|GBS MF59 Half/GBS NoAdj|Subjects who had received GBS Trivalent Vaccine with half dose of MF59 in parent study V98_06 (205468 - NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).
88818464|NCT02690181|Experimental|Placebo/GBS NoAdj|Subjects who had received placebo in parent study V98_06 (205468 - NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).
88818465|NCT02690181|Experimental|Naive/GBS NoAdj|Healthy non-pregnant female subjects aged 22 through 46 years inclusive on the day of informed consent who had not received any GBS vaccine in the past and who received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).
88818466|NCT01823861|Experimental|Mobile phone-based intervention|Standard care plus automated voice message to support post-abortion contraception use every two weeks for total of three months and direct follow up phone call by family planning counsellor depending on response to voice message.
88818467|NCT01823861|No Intervention|Standard care|Face-to-face post-abortion family planning (PAFP) counselling, follow-up at one or two weeks, clinic phone number, existing 'Hotline' phone number.
88818468|NCT02273063|Experimental|Transcranial Magnetic Stimulation|Stimulation at pulse frequency of 5Hz delivered over L DLPFC. Intensity: 120% of Motor Threshold, 5 Sec Train, 14 Sec Inter-Train Interval, Frequency: 5Hz, Total Pulses: 3000/session. Sessions delivered once/day on weekdays for up to 40 sessions.
88818469|NCT05587257|Experimental|Group 1|six sessions of fractional carbon dioxide laser every 2 weeks will be done for 15 patients with alopecia areata followed immediately by topical application of minoxidil 5%
88818470|NCT05587257|Experimental|Group 2|six sessions of microneedling evry 2 weeks will be done for 15 patients with alopecia areata followed immediately by topical application of minoxidil 5%
88818471|NCT05587257|Experimental|Group 3|15 patient of alopecia areata that will be treated by topical nanominoxidil for 3 months.
88818472|NCT05587257|Active Comparator|Group 4|15 patient of alopecia areata that will be treated by topical minoxidil 5% for 3 months
88818473|NCT05585463||Oncology pediatric patients treated with acupuncture|"Patients in the oncology area of the Sant Joan de Déu Hospital treated at the UOPI (Integrative Pediatric Oncology Unit) from September 2019 to September 2021 have received treatment with acupuncture and intracutaneous Seirin New Pyonex Press Tack®.~Patients in active treatment and survivors are included. Acupuncture treatment can be received in a hospitalization ward, an intensive care unit, a day hospital or an outpatient clinic."
88818474|NCT01825655|Active Comparator|Cetirizine|zyrtec 10mg, oral, one time
88818475|NCT01825655|Placebo Comparator|Sugar pill|Placebo, one pill, one time
88842552|NCT05827562||patients group|". Inclusion criteria:~Patients with RA who fulfilled the 2010 European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) revised criteria for RA (1~Patients having knee effusion .~Exclusion criteria:~Patients with autoimmune diseases other than RA.~Patients or controls with tumors, infections, or other severe organ damage."
89180267|NCT00454987|Active Comparator|Meningitec+Hiberix Group|"Previously primed (according to the routine UK immunisation schedule) with 3 doses of a Meningitec™ conjugate vaccine and a Hiberix™ containing vaccine before the age of 8 months without booster dose at 12 months of age (only for UK). All subjects received a booster dose of Infanrix-IPV™ and Menitorix™ at 40 to 43 months of age, intramuscularly in the deltoid region.~This group was added only at year 2 in UK (Meningitec+Hiberix Group) to comply with UK Hib Catch-up vaccination programme."
88842553|NCT05827562||controls group|healthy subjects
88842554|NCT05827497|Experimental|Group A|baricitinib 2 mg once daily
88842555|NCT05827497|Active Comparator|Group B|methotrexate on 25 mg weekly
88842556|NCT05827471||Tumor group|First diagnosis of colon cancer.
88842557|NCT05827471||Control group|Healthy people.
88842558|NCT05827458||I A|INTENSIVE 3 MONTHS Appropriate local imaging including ultrasound for soft-tissue sarcomas at three-month follow-up A CT scan of the chest was done on a six-monthly basis. CXR at the intervening three-month follow-up.
89180268|NCT00724893||Stage 1 Participants|Participants with CHC receiving PegIFN-2b using Redipen™ formulation (1.5 mcg/kg) once weekly and ribavirin capsules (800-1400 mg) daily according to routine medical practice at participating study sites.
89180269|NCT00724893||Stage 2 Participants|Participants with CHC Genotype 1 receiving PegIFN-2b using Redipen™ formulation (1.5 mcg/kg) once weekly and ribavirin capsules (800-1400 mg) daily according to routine medical practice at participating study sites.
89180270|NCT00789698|Experimental|Lurasidone HC1|
89180271|NCT00789698|Active Comparator|Quetiapine|
89180272|NCT00724815|Experimental|Sumatriptan|NP101 - sumatriptan iontophoretic transdermal patch
89180273|NCT00724815|Placebo Comparator|Placebo|Placebo iontophoretic transdermal patch
89180274|NCT00454909|Experimental|Group A|Subjects aged 10 years (< 11 years) vaccinated with meningococcal vaccine GSK134612.
89180275|NCT00454909|Experimental|Group B|Subjects aged 11 to 25 years vaccinated with meningococcal vaccine GSK134612.
89180276|NCT00454909|Active Comparator|Group C|Subjects aged 11 to 25 years vaccinated with Menactra®.
89180277|NCT00798590|Experimental|GLP-1|
89180278|NCT00798590|Placebo Comparator|Saline|
89180279|NCT05368155|Experimental|ACT and Education Group|The Acceptance and Commitment Training (ACT) and education group will receive the Brief ACT for Pelvic Pain treatment, which will include three weekly, 90-minute group sessions.
88842559|NCT05827458||I B|"INTENSIVE 6 MONTHS~Appropriate local imaging including ultrasound for soft-tissue sarcomas at six month follow-up A CT scan of the chest was done on a six-monthly basis"
88842560|NCT05827458||II A|COST EFFECTIVE 3 MONTHS Appropriate local imaging including ultrasound for soft-tissue sarcomas at three-month follow-up with CXR
88842561|NCT05827458||II B|COST EFFECTIVE 6 MONTHS Appropriate local imaging including ultrasound for soft-tissue sarcomas at six month follow-up with CXR
88842562|NCT05827393|Active Comparator|group A|15 patients with large angle esotropia
88842563|NCT05827393|Active Comparator|group B|15 patients with large angle exotropia
88842564|NCT05827380|Experimental|Training group|Patients assigned to the training group will receive a training targeting on gait adaptability using the C-mill. Subjects are asked to stop any other physical therapy program targeting gait, balance or leg function during the training period. Assessments will take place pre- and post-intervention
88842565|NCT05827380|No Intervention|Waitlist control group|Patients assigned to the waitlist control group will receive standard care for 5 weeks whereafter they will receive the same training as the training group. Assessments will take place pre-intervention, post-waiting period and post-intervention.
88842566|NCT05827315||Thoracic surgery cohort|35 patients undergoing thoracic surgery with lung resection and one lung ventilation under primarily general anaesthesia.
88842567|NCT05827315||Upper gastrointestinal surgery cohort|35 patients undergoing upper gastrointestinal surgery with one lung ventilation under primarily general anaesthesia.
88842568|NCT05827315||Colorectal surgery cohort|35 patients undergoing elective colorectal surgery under primarily general anaesthesia.
89180280|NCT05368155|No Intervention|Enhanced Treatment As Usual|The Enhanced treatment as usual (TAU) condition will receive a letter with treatment resources and encouraged to consult with their VHA primary care clinicians for additional education and treatment options.
89180281|NCT05366673|Experimental|Massage therapy|Patients will receive massage therapy for 10 minutes, once per day from the first day to the seventh day of admission to the intensive care unit.
89180282|NCT05366673|No Intervention|Control group|Patients will maintain usual care.
89180283|NCT01020175|Other|Bone marrow transplantation|Patients received bone marrow transplantation
89180284|NCT01020175|Other|Peripheral blood stem cell transplantation|Patients received filgrastim-mobilized peripheral blood stem cell transplantation
89369992|NCT03122184|Experimental|Positive Psychology + Motivational Interviewing|Participants will complete weekly positive psychology exercises and will systematically set goals related to physical activity. Study trainers will review the positive psychology exercises on the phone each week and will use motivational interviewing techniques to facilitate goal setting.
88842569|NCT05827315||Vascular surgery cohort|35 patients undergoing elective open abdominal aortic surgery under primarily general anaesthesia.
88842570|NCT05827315||Orthopaedic surgery cohort|35 patients undergoing elective primary hip or knee arthroplasty under spinal anaesthesia +/- sedation.
88842571|NCT05827263|Active Comparator|Control group - non-temporomandibular disorders group.|Patients diagnosed with no temporomandibular disorders.
89369993|NCT03122184|Active Comparator|Motivational Interviewing Health Education|Participants will speak on the telephone each week with a study trainer. During these calls, the trainer will provide education about a health behavior (physical activity, medication adherence, diet, stress reduction) and assign an activity related to one health behavior each week. Motivational interviewing techniques will be used throughout to facilitate health behavior changes.
89369994|NCT03745781|Experimental|open-label placebo|open-label placebo
89369995|NCT03745781|No Intervention|treatment as usual|
88842572|NCT05827263|Experimental|Test group - temporomandibular disorders group|Patients diagnosed with mild, moderate, or severe temporomandibular disorders.
88842573|NCT05827250||Neonatal Profile|"LUSS will be obtained twice a week on the following schedule for the duration of each subject's NICU stay.~Day of life (DOL): 7+/-1, 10+/-1, and 14+/-1 Depending on length of stay, within +/-2 days of: DOL 17, 21, 24, 28, 31, 35, 38, 41, 44, 48, 51, 56, and 60."
88842574|NCT05827120||Thrombectomy plus local thrombolysis group|Thrombectomy plus local thrombolysis group - patients treated by mechanical thrombectomy mostly followed by catheter directed thrombolysis (CDT), or by pharmaco-mechanical thrombectomy (PMT) - combination of some form of mechanical disruption of the thrombus in conjunction with chemical lysis. Thrombolysis by alteplase 1mg/hour. Procedure followed by anticoagulation therapy.
89369996|NCT01372176|Experimental|Early Goal-Directed Nutrition|
89369997|NCT01372176|Active Comparator|ASPEN-guidelines|
89369998|NCT04396106|Active Comparator|AT-527 - 550 mg BID|Part A
89369999|NCT04396106|Placebo Comparator|Placebo for 550 mg BID|Part A
88842575|NCT05827120||Local catheter directed thrombolysis alone group|Local catheter directed thrombolysis alone group - patients treated by dedicated catheter for local thrombolysis with side holes placed across the acute thrombus - continuous infusion of alteplase 1mg per hour simultaneously with unfractionated heparine in anticoagulation dosage. Without mechanical or pharmaco-mechanical thrombectomy. Procedure followed by anticoagulation therapy.
88842576|NCT05825846|Experimental|Slow breathing 1 (SB1)|Four second inhale through the nasal + hold two seconds + four second exhale through the mouth + hold for two seconds, repeat (~25 breath cycles within the 5 min intervention)
88842577|NCT05825846|Experimental|Slow breathing 2 (SB2)|Four second inhale through the nose into the diaphragm followed by a two second exhale, repeat (~50 breath cycles within the 5 min intervention)
89370000|NCT04396106|Active Comparator|AT-527 - 1100 mg BID|Part B
89370001|NCT04396106|Placebo Comparator|Placebo for 1100 mg BID|Part B
89370002|NCT03743831|Other|orotracheal intubation direct|
89370003|NCT03743831|Other|orotracheal intubation indirect|
89370004|NCT01373970|Placebo Comparator|Placebo|
88842578|NCT05825495|Active Comparator|Experimental group|Subjects will intragluteally injected with a dose of 150 mg dinalbuphine sebacate at least 12 hours before surgery. During intra- and post-operative period, the pain management will execute following our routine practice.
88842579|NCT05825495|Sham Comparator|Control group|The pain management will peri-operatively execute following our routine practice without dinalbuphine sebacate administration.
88842580|NCT05825443|Experimental|Treatment group|Patients who meet the protocol and sign the informed consent form received 4 cycles of chemotherapy combined with camrelizumab, followed by maintenance with camrelizumab until one year or the disease progressed or unacceptable toxicity. The chemotherapy regimen is decided by the researcher.
89370005|NCT01373970|Active Comparator|PPI + Placebo|PPI followed by cross over to placebo
89370006|NCT03743675|Experimental|Diet-Induced Weight Loss|Subjects in this arm will undergo 6-months of dietary counseling targeting 5-10% weight loss by the end of the intervention period.
89370007|NCT03743675|Experimental|Exercise Training|Subjects in this arm will undergo 6-months of supervised aerobic exercise training (3 days per week, moderate-to-vigorous intensity).
89370008|NCT03743675|Experimental|Diet Plus Exercise|Subjects in this arm will undergo 6-months of dietary counseling targeting 5-10% weight loss by the end of the intervention period. They will simultaneously undergo 6-months of supervised aerobic exercise training (3 days per week, moderate-to-vigorous intensity).
89370009|NCT03743675|No Intervention|Control|Subjects in this group will be asked to maintain their habitual physical activity, and will received counseling regarding a healthy, weight-maintenance diet.
89370010|NCT04050098|Active Comparator|Test: Gemigliptin/Metformin|Fixed Dose Combination Zemimet® SR Tab. 50/1000 mg (Gemigliptin/Metformin Hydrochloride Sustained Release 50/1000 mg)
89370011|NCT04050098|Active Comparator|Reference: Gemigliptin and Metformin|Coadministration of Zemiglo Tablet 50 mg (Gemigliptin 50 mg) and Glucophage XR 1000 mg (Metformin Hydrochloride Prolonged Release 1000 mg)
89370012|NCT03745625|Experimental|HSK3486|First-stage: 1mg/kg/h, 0.4mg/kg/h; Second-stage:Single loading dose: 0.2mg/kg, maintenance dose: 0.35mg/kg/h,
89370013|NCT03745625|Active Comparator|Propofol|First-stage: 5mg/kg/h, 2mg/kg/h; Second-stage:Single load ing dose: 1mg/kg, maintenance dose: 1.75mg/kg/h
89399210|NCT04313283|Experimental|Parents Taking Action|A peer-led intervention, Parents Taking Action is the psychoeducational and child behavior management intervention led by trained Parent Leaders for 12 weeks.
88842581|NCT05824169|Experimental|Low dosage group|2.4x10^14 vg/person of GC101 delivered one-time intrathecally (n=3)
88842582|NCT05824169|Experimental|High dosage group|4.8x10^14 vg/person of GC101 delivered one-time intrathecally (n=3)
88842583|NCT05824104|Experimental|Patients|The intermittent hypoxia protocol refers to four cycles of 5 minutes hypoxia inhaling interval by 5 minutes normoxia, which is performed twice a day (at least 6 hours apart) in 7 days.
88842584|NCT05824052|No Intervention|Group 1|The synovial fluid taken from the patients and not treated in any way.
88842585|NCT05824052|Active Comparator|Group 2|The synovial fluid taken from the patients and injected 10 gamma ozone.
88842586|NCT05824052|Active Comparator|Group 3|The synovial fluid taken from the patients and injected 30 gamma ozone.
88842587|NCT05824039|Experimental|Experimental 1: low dose group|Tea infusion which contain 5 mg of flavonoids, (low dose of flavonoids treatment quantification) oral administration , once daily.
88842588|NCT05824039|Experimental|Experimental 2 : high dose group|Tea infusion which contain 20 mg of flavonoids, ( high dose of flavonoids Treatment quantification) oral administration , once daily .
88842589|NCT05823090|Experimental|Bright light therapy|Eligible participants were provided a light box and an actigraphy wrist-watch and given instructions on the use of each. The light therapy dosing protocol was planned as follows: Weeks 0-2, 50 lux dim red light (DRL) x 15 30 minutes/day; weeks 3-4, 10,000 lux x 15 minutes/day; weeks 5-6, 10,000 lux x 30 minutes/day; weeks 6-8, 10,000 lux x 45 minutes/day. At week 2, the study coordinator dispensed the 10,000 lux BLT unit (and picked up the DRL box) and the actigraphy watch. Participants and their parent/guardian met with 2 study clinicians at the end of each 2-week period. One study clinician, who was blinded to the participant's light box use, conducted a brief interview regarding mood, safety and functioning and side effects. The other study clinician subsequently met with the participant to review safety, side effects and response and made recommendations on duration and timing of light box use based on level of improvement and any barriers to use.
88842590|NCT05822934|Experimental|Carboplatin-gemcitabine|3-4 cycles of Carboplatin-Gemcitabine as a neoadjuvant treatment for Urinary bladder cancer Muscle invasive
88842591|NCT05822934|Active Comparator|cisplatin-gemcitabine|3-4 cycles of Cisplatin -Gemcitabine as a neoadjuvant treatment for Urinary bladder cancer Muscle invasive
88842592|NCT05821972|Experimental|Nebulized dexmedetomidine and ketamine|Pre-operative nebulization of dexmedetomidine and ketamine
89370014|NCT05194020|Experimental|Primary Services|Participants receive 16 hours of Father Factor curricula, 4 hours of The New Playbook curricula, 4 hours of Money Smart curricula over the course of five weeks. Participants also receive on-going job readiness support and post-employment support.
89370015|NCT03698630|Experimental|Dexamethasone|Single dose of 0.3 mg/kg dexamethasone (rounded off to the nearest 2 mg, max. 12 mg) prescribed on day 1
89370016|NCT03698630|Active Comparator|Prednisolone|1 mg/kg prednisolone (rounded off to the nearest 5 mg, max. 40 mg) prescribed daily for three days from day 1
89370017|NCT01375452|Active Comparator|Femara|
88842593|NCT05821972|Active Comparator|Nebulized dexmedetomidine|Pre-operative nebulization of dexmedetomidine
88842594|NCT05821764||The cohort for the TransAc study|Pregnant women followed for their pregnancy in the 3 Gynecology-Obstetrics department participating in the study
88842595|NCT05821439||Premenstrual period|For the premenstrual period evaluation, the participants' 10 days before menstruation will be taken as a reference.
88842596|NCT05821439||Menstrual period|For the evaluation of the menstrual period, the first 3 days when symptoms are seen more will be taken as a reference.
88842597|NCT05821218||back pain group|back pain group
88842598|NCT05812976||PAH Patients|Pulmonary Index of Microcirculatory Resistance (PIMR) and Right Ventricle Index of Microcirculatory Resistance (RV-IMR) measurements during standard-of-care right +/- left heart catheterization at baseline and among those who undergo a standard-of-care right heart catheterization at 6 months.
88842599|NCT05811598|Experimental|repeated red light therapy for 3~4 year-old myopia|0.37mW lighting with wavelength of 650nm for the age of 3~4 years old(including both 3 and 4 years)myopia.
88842600|NCT05811598|Experimental|repeated red light therapy for 5~6 year-old myopia|0.60mW lighting with wavelength of 650nm for the age of 5~6 years old(including both 5 and 6 years)myopia.
88842601|NCT05803616||ILD group|All patients newly diagnosed or relapsing from an ILD could be enrolled in this observational study
88842602|NCT05794178|Experimental|Precision AIM|Education + activity monitor + up to 4 text messages/day, each drawn from one of 3 content libraries and timed based on a person- and context-specific algorithm that will be updated monthly based on incoming data (within a participant-defined availability window)
88842603|NCT05794178|Active Comparator|Random AIM|Education + activity monitor + up to 4 text messages/day, each drawn from one of 3 content libraries and timed at random (within a participant-defined availability window).
88842604|NCT05794178|Active Comparator|No AIM|Education + activity monitor
88842605|NCT05787392||Completed Chamas program|women who participated in Chamas throughout the pandemic
88842606|NCT05787392||Did not complete Chamas program|women who left Chamas during the pandemic
88842607|NCT05787392||Did not participate in Chamas program|women whose communities were randomized to not receive the Chamas intervention
88842608|NCT05774236|Experimental|Cook´s balloon|Silicone 80 mL double-balloon cervical ripening catheter with an adjustable-length malleable stylet
88842609|NCT05774236|Active Comparator|Vaginal dinoprostone|Vaginal delivery system containing 10 mg dinoprostone (Prostaglandin E2) dispersed throughout its matrix and releasing approximately 0.3 mg/hour dinoprostone over a 24-hour period.
89370018|NCT01375452|Experimental|Letrozole|
89370019|NCT03053466|Experimental|Single-Arm|APL-501
89370020|NCT05131308||Detachable embolization coils group|Patients who have an intervention for leak closure with detachable embolization coils
89370021|NCT05131308||Vascular plugs/septal occluders group|Patients who have an intervention for leak closure with vascular plugs/CSO
89370022|NCT05131308||RF Ablation group|Patients who have an intervention for leak closure with Radio Frequency Ablation (RFA)
89370023|NCT03624140|Experimental|Hemoglobin monitoring|3 different techniques will be used for hemoglobine monitoring : hemocue, pulse co-oxymeter (SpHb) and blood measurement
88842610|NCT05764473|Experimental|A (Med/UCLP)|"Following the Mediterranean Diet for six weeks, then following the Ultimate Cholesterol Lowering Plan for six weeks.~Food diaries collected at baseline, week 2, week 4, week 6, week 8, week 10, week 12.~Cardiometabolic risk markers, menopause symptoms and physical activity collected at baseline, week 6, week 12."
88842611|NCT05764473|Experimental|B (ULCP/Med)|"Following the Ultimate Cholesterol Lowering Plan for six weeks, then following the Mediterranean Diet for six weeks.~Food diaries collected at baseline, week 2, week 4, week 6, week 8, week 10, week 12.~Cardiometabolic risk markers, menopause symptoms and physical activity collected at baseline, week 6, week 12."
88842612|NCT05759468|Active Comparator|Investigational Product - MIB 626|The MIB-626 will be a GMP-grade microcrystalline solid NMN mixed with inert excipients (including microcrystalline cellulose) and compressed into tablets at a dose strength of 500 mg per tablet, enabling administration of the 1,000 mg twice daily using two tablets taken twice daily.
88842613|NCT05759468|Placebo Comparator|Placebo|Participants randomized to placebo will receive Matching placebo tablets will be provided by Metro International Biotech, LLC.
88842614|NCT05755698|Experimental|Emotional Awareness and Expression Therapy (EAET)|In this experimental arm, participants are required to attend 8 online sessions, and fill out questionnaires before treatment, immediately after treatment, and at a 3-month follow-up.
88842615|NCT05755269||Observational (blood collection, genotyping, surveys)|Patients complete a survey and undergo collection of a blood sample for PRS genotyping at baseline. Patients receive their PRS results and complete another survey 6 weeks to 6 months after baseline and then complete surveys annually over 10 years on study.
88842616|NCT05748587||Control|24 healthy age and sex-matched controls
88842617|NCT05748587||Patients with acute Ischemic stroke|"24 patients between 50-70 years having neurological symptoms of acute ischemic stroke will be included.~Patients with acute hemorrhagic stroke, Parkinson's disease, dementia, Alzheimer's disease, malignancy, and central nervous system infection will be excluded."
88842618|NCT05748587||Control rats|8 rats will be subjected to a Sham operation and will be injected intramuscularly immediately after the operation with an equivalent 0.9% saline solution. After 24 hours they will be sacrificed.
88842619|NCT05748587||Rats with ischemic stroke|8 rats will be subjected to bilateral common carotid artery occlusion (CCAO) for 30 minutes and will be injected intramuscularly immediately after removing the occlusion with an equivalent 0.9% saline solution. They will be sacrificed after 24 hours of reperfusion.
88842620|NCT05748587||Rats with ischemic stroke + deferoxamine|8 rats will be subjected to bilateral CCAO for 30 minutes and will be injected intramuscularly immediately after removing the occlusion with deferoxamine (200 mg/kg), They will be sacrificed after 24 hours of reperfusion.
88842621|NCT05739019||COVID-19 infection group|Infertile women attending for frozen embryo transfer with a recent past COVID-19 infection
88842622|NCT05739019||Control group|Infertile women attending for frozen embryo transfer without a recent past COVID-19 infection
88842623|NCT05727241||The study cohort (total sample)|All women will undergo ultrasound examination for three-dimensional umbilical cord index.
88842624|NCT05710315|Experimental|ReliZORB|ReliZORB enzyme cartridges will be used with enteral feedings for 5 days
88842625|NCT05710315|Placebo Comparator|Placebo|Placebo enzyme cartridges will be used with enteral feedings for 5 days
88842626|NCT05706389|Experimental|Ca-AKG|Pill format, 500mg/pill, half of daily dose
88842627|NCT05706389|Placebo Comparator|Placebo|Pill format, indistinguishable from active pill
88842628|NCT05706324|Experimental|Low dose|21~65 year old healthy subjects, received low dose of RCVi
88842629|NCT05706324|Experimental|Medium dose|21~65 year old healthy subjects, received medium dose of RCVi
88842630|NCT05706324|Experimental|High dose|21~65 year old healthy subjects, received high dose of RCVi
88842631|NCT05703412|Experimental|Transition-FOCUS mHealth Intervention|"All participants will download the tFOCUS app to their mobile phone. tFOCUS uses EMA to assess variables identified as being salient to treatment engagement and illness self-management. The application delivers algorithm-driven micro interventions to address reported problem(s). Data is transmitted to a clinician dashboard, which can be used for remote monitoring."
88842632|NCT05703412|Active Comparator|Check-In|Control participants will receive the currently recommended best practices of post-discharge care, including follow-up appointments, instructions, referrals and a follow-up check in.
88842633|NCT05694611|Experimental|Preterm neonates|"Diagnostic Test: Brain ultrasound, brain contrast enhanced ultrasound, brain ultrasound elastography To study brain perfusion with brain ultrasound, contrast enhanced ultrasound of the brain and ultrasound-guided shear-wave elastography Drug: Sulfur Hexafluoride To evaluate brain perfusion at term in infants born prematurely~Other Names:~• SonoVue"
88842634|NCT05689385|Experimental|eHealth-based cardiac rehabilitation|Participants receive a 12-wk case manager-led eHealth-based cardiac rehabilitation program with follow-up at 12 week, 6 months and 12 months.
88842635|NCT05689385|No Intervention|Usual care|Participants receive usual care.
88842636|NCT05686954|Experimental|CSO LOW|Participants are given foods enriched with cottonseed oil and instructed on how to substitute study foods into their diet to maintain caloric balance.
88842637|NCT05686954|Experimental|CSO MID|Participants are given foods enriched with cottonseed oil and instructed on how to substitute study foods into their diet to maintain caloric balance.
88842638|NCT05686954|Experimental|CSO HIGH|Participants are given foods enriched with cottonseed oil and instructed on how to substitute study foods into their diet to maintain caloric balance.
88842639|NCT05686954|Active Comparator|CONTROL|Participants are given foods enriched with a mixture of oils and instructed on how to substitute study foods into their diet to maintain caloric balance.
88842640|NCT05678244|Active Comparator|Comparator|"Standard of care + IV acetaminophen:~Baseline fentanyl infusion, with dosage escalations, deescalations, and additional boluses and analgesics (excluding oral or rectal acetaminophen) determined by the patient's physician (this represents standard of care at this institution) with the addition of IV acetaminophen every 4 or 6 hours at weight-appropriate doses based on the patient's gestational age."
89370024|NCT04091087|Experimental|crisaborole ointment|crisaborole ointment
89370025|NCT04091087|Sham Comparator|vehicle ointment|vehicle ointment
89370026|NCT03046836|Experimental|Oxytocin|Each participant will self-administer 40 international units (IU) intranasal Oxytocin
89370027|NCT03046836|Placebo Comparator|Control|Each participant will self-administer matching saline placebo
89370028|NCT03687788|Experimental|Intervention Group|Intervention group received laughter therapy twice a week for six weeks.
89370029|NCT03687788|No Intervention|Control Group|The control group did not take part in the laughter therapy program. This group received the routine care given by the nurses in the center.
89370030|NCT03400033|Experimental|Daprodustat|Subjects randomized to this arm will receive daprodustat tablets titrated doses from 2 to 48 milligrams orally three-times weekly along with saline by IV route for the 52 weeks treatment period.
89370031|NCT03400033|Active Comparator|Epoetin alfa|Subjects randomized to this arm will receive matching placebo tablets to daprodustat orally three-times weekly and Epoetin alfa by IV route for the 52 weeks treatment period.
88842641|NCT05678244|Placebo Comparator|Placebo|"Standard of care + placebo:~Baseline fentanyl infusion, with dosage escalations, deescalations, and additional boluses and analgesics (excluding oral or rectal acetaminophen) determined by the patient's physician (this represents standard of care at this institution) with the addition of an IV saline placebo every 4 or 6 hours at a rate which would mimic their dose of acetaminophen."
89370032|NCT02995902|Experimental|FLT-PET/MRI|
88842642|NCT05677074|Experimental|Tolerance test of fish oil, cod oil, and krill oil|All participants will have their tolerance of three different dietary supplements tested (fish oil, cod oil, and krill oil) using three methods: skin-prick-test, Basophil Histamine Release Assay, and oral provocation.
88842643|NCT05675800|Experimental|Psilocybin Active Dose Treatment A|Psilocybin
88842644|NCT05675800|Experimental|Psilocybin Active Dose Treatment B|Psilocybin
88842645|NCT05675319|Experimental|Arm A (allo SCT)|Allogeneic stem cell transplantation
88842646|NCT05675319|Active Comparator|Arm B (conventional therapy)|"Currently approved triple regimens for first relapse:~carfilzomib/lenalidomide/dexamethasone (KRD) or~elotuzumab/lenalidomide/dexamethasone (ERD) or~daratumumab/bortezomib/dexamethasone DVD) or~daratumumab/lenalidomide/dexamethasone (DRD) or~ixazomib/lenalidomide/dexamethasone (IRD) or~pomalidomide/bortezomib/dexamethasone (PVD) or~carfilzomib/daratumumab/dexamethasone (KDD)~Alternatively, autologous stem cell transplantation may also be performed, if sufficient stem cells are still cryopreserved."
88842647|NCT05650580|Experimental|Dose Escalation and Expansion|Participants with relapsed/Refractory Non-Hodgkin's Lymphoma or Advanced solid tumor will receive TR115 at escalating and expansion dose levels.
88842648|NCT05649345|Experimental|TR64|Daily doses by oral administration on each day of each 28 day cycle. Starting dose is 25mg, with escalation to 400mg, and subsequent dose escalation using a modified Fibonacci algorithm.
88875250|NCT02546388|Experimental|Indium-111 Pentreotide (OctreoScan)|Patients with biopsy-proven extra-cardiac sarcoidosis OR atypical findings on FDG PET and MRI without previous biopsy will be recruited to receive an injection of the FDA-approved radiotracer Indium-111 Pentreotide (OctreoScan). The imaging protocol will consist of imaging at 4 and 24 hours after OctreoScan injection.
89370033|NCT05123820|Experimental|ACT-1014-6470, Midazolam and Omeprazole|"Treatment Period A (Day 1 to Day 2) The plan is that all participants will receive treatment A and then treatment B.~A single oral dose of midazolam 2 mg and a single oral dose of omeprazole 20 mg on Day 1.~Treatment Period B (Day 8 to Day 11)~A single oral dose of 100 mg ACT-1014-6470, a single oral dose of 20 mg omeprazole, and a single oral dose of 2 mg midazolam on Day 8."
89370034|NCT04089761|Experimental|Active Device|Treatment of acute migraine with an active form of Nerivio device
89370035|NCT03118518|Active Comparator|Anti-arrhythmic drug|
89370036|NCT03118518|Experimental|Cryoablation|
89370037|NCT03984305|Experimental|PKG+ Group|"For subjects in the PKG+ Group, participants will wear the PKG watch prior to all study visits in which the study investigator will review and report on the PKG prior to the visit and use the information to guide the discussion with the subject during the clinical assessment.The PKG will be used to determine if the subject is controlled or uncontrolled based on scores provided by the PKG."
89370038|NCT03984305|Placebo Comparator|PKG- Group|For subjects in the PKG- Group (SOC control group), participants will wear the PKG watch prior to all study visits, however the investigator will not have access to the PKG report and will use standard of care to determine clinical treatment plans.
89370039|NCT03397771|Experimental|Litoxetine oral capsules|oral experimental study medication litoxetine
89370040|NCT03397771|Placebo Comparator|Placebo oral capsules|oral comparator
89370041|NCT05009160||Patients with Multiple Sclerosis (PwMS)|PwMS will download the Healios+Me platform App which contains the dreaMS App and will follow the study schedule.
89370042|NCT05009160||Healthy Control Persons (HC)|HC will download the Healios+Me platform App which contains the dreaMS App and will follow the same study schedule as PwMS.
89370043|NCT03711721|Experimental|Food basket|
89370044|NCT03711721|Experimental|Ready-to-Use Therapeutic Food|
89370045|NCT02876835|Experimental|Daprodustat|Participants will receive oral daprodustat once daily.
89370046|NCT02876835|Active Comparator|Darbepoetin alfa|Participants will be administered darbepoetin alfa subcutaneously (SC).
89370047|NCT04086641|Experimental|Foot 1: Crossover Foot, Foot 2: Energy Storing Foot|Participant randomized to crossover foot as first condition, energy storing foot as second condition
89370048|NCT04086641|Experimental|Foot 1: Energy Storing Foot, Foot 2: Crossover Foot|Participant randomized to energy storing foot as first condition, crossover foot as second condition
89370049|NCT03503318|Placebo Comparator|Placebo|Participants will receive an SC injection of placebo matching to TV-46000 at baseline and every 4 weeks (q4w) thereafter. Participants will continue treatment until they experience a relapse event; meet 1 or more of the study discontinuation or withdrawal criteria; or remain relapse-free during the double-blind phase until the study is terminated.
89370050|NCT03503318|Experimental|TV-46000 q1m|Participants will receive an SC injection of TV-46000 at baseline and q4w thereafter. The maximal dose for adult participants is comparable to an oral risperidone dose of 5 milligrams (mg)/day, and the maximal dose for adolescents is comparable to 4 mg/day. Participants will continue treatment until they experience a relapse event; meet 1 or more of the study discontinuation or withdrawal criteria; or remain relapse-free during the double-blind phase until the study is terminated.
89370051|NCT03503318|Experimental|TV-46000 q2m|Participants will receive an SC injection of TV-46000 at baseline and every 8 weeks (q8w) thereafter, and a placebo SC injection 4 weeks after baseline and q8w thereafter. The maximal dose for adult participants is comparable to an oral risperidone dose of 5 mg/day, and the maximal dose for adolescents is comparable to 4 mg/day. Participants will continue treatment until they experience a relapse event; meet 1 or more of the study discontinuation or withdrawal criteria; or remain relapse-free during the double-blind phase until the study is terminated.
89370052|NCT03396913|Experimental|IPL followed by Meibomian Gland Expression (MGX)|Subjects in the experimental arm with receive IPL followed by MGX: IPL pulses will be administered on the skin of the malar region (both cheeks, from tragus to tragus including the nose) and below the lower eyelids. Following IPL therapy, subjects will undergo MGX of both eyelids in both eyes.
88842649|NCT05649332|Experimental|Subjects affected by pressure ulcers|Percentage of subjects whose wounds condition is improved during the four-week treatment with the medical device evaluated by Investigator, according to the pressure ulcers evaluation of PUSH ver. 3.0 score (according to evaluation of the following parameters: length times width, exudate amount and tissue type), performed by the Investigator at 4 weeks after the initiation of treatment, compared to day 0 (baseline).
88842650|NCT05649332|Experimental|Subjects affected by burns|Percentage of subjects whose wounds condition is improved during the four-week treatment with the medical device evaluated by Investigator, according to the evaluation of burn wound VSS score (according to evaluation of the following parameters: vascularity, height/thickness, pliability and pigmentation), performed by the Investigator at 4 weeks after the initiation of treatment, compared to day 0 (baseline).
89370053|NCT03396913|Sham Comparator|Sham IPL followed by MGX|Subjects in the sham comparator arm with receive Sham IPL followed by MGX: Sham IPL pulses will be administered on the skin of the malar region (both cheeks, from tragus to tragus including the nose) and below the lower eyelids. Following Sham IPL therapy, subjects will undergo MGX of both eyelids in both eyes.
89370054|NCT01375920|Active Comparator|Metyrapone, daily medication|500 milligrams Metyrapone to be taken orally twice daily for 3 weeks.
89370055|NCT01375920|Placebo Comparator|placebo|a matched placebo will be given for patients to take twice daily
89370056|NCT03982433|Experimental|Intervention|participants all receive the intervention
88842651|NCT05648812|Active Comparator|Term neonates|"Diagnostic Test: Brain ultrasound, brain contrast enhanced ultrasound, brain ultrasound elastography, cardiac ultrasound To study brain perfusion with brain ultrasound, contrast enhanced ultrasound of the brain and ultrasound-guided shear-wave elastography Drug: Sulfur Hexafluoride To evaluate brain perfusion in infants with no suspected brain pathology using CEUS. Later, different patient groups could be compared to infants with no suspected brain pathology.~Other Names:~• SonoVue"
89180285|NCT01024933|Placebo Comparator|Educational and Behavioral|The Education and Behavioral Contract (Control group) will receive an educational workbook and behavioral contract. Each patient will receive a home blood pressure device for self-monitoring, and will be called every two months.
89180286|NCT01024933|Experimental|PASA group-intervention|The PASA group (Positive Affect/Self-Affirmation/Motivational Interviewing) will receive a positive-affect and self-affirmation intervention with motivational interviewing.These patients will also receive an educational workbook and behavioral contract. This is the intervention.
89370057|NCT03396835|Experimental|INVSENSOR00009 Sensor|All subjects who are enrolled into the test group and participate in data collection receive both the INVSENSOR00009 and the control sensor simultaneously on the forehead.
89370058|NCT01375998||Group 1|
89180287|NCT00481195|Active Comparator|Armodafinil|
89370059|NCT03743597|Experimental|SOCKNLEG|"Group of participant who will conduct the examinations first with the SOCKNLEG compression stockings.~All examinations will be conducted in all participants and with both stockings one after the other."
89370060|NCT03743597|Active Comparator|Sigvaris COTTON|"Group of participant who will conduct the examinations first with the Sigvaris COTTON compression stockings.~All examinations will be conducted in all participants and with both stockings one after the other."
89370061|NCT03683108|Experimental|Resveratrol and Carbossimetyl Beta Glucan|
89370062|NCT03683108|Placebo Comparator|Saline solution|
89180288|NCT00481195|Placebo Comparator|Placebo|
89180289|NCT03604549|Placebo Comparator|Saline|Women in this arm will receive a flush with saline after normal saline Sono HSG.
89180290|NCT03604549|Experimental|Lipiodol UF|Women in this arm will receive a flush with Lipiodol UF after normal saline Sono HSG.
89370063|NCT05137860|No Intervention|Standard Care Group|Each patient will receive their standard chemotherapy treatment for patients with relapsed Acute Lymphoblastic Leukemia based on the HyperCVAD scheme for a period of 12 weeks. Each chemotherapy cycle will be monitored by the health team corresponding to the Hematology service and the principal investigator.
89370064|NCT05137860|Experimental|Bortezomib Treatment Group|Each patient will receive their standard chemotherapy treatment for patients with relapsed Acute Lymphoblastic Leukemia based on the HyperCVAD scheme in combination with Bortezomib for a period of 12 weeks. Each chemotherapy cycle will be monitored by the health team corresponding to the Hematology service and the principal investigator.
89370065|NCT03682952|Experimental|Experimental group|Alprostadil and Beraprost sodium tablets are used to improve the microcirculation of CKD patients.
89370066|NCT03682952|No Intervention|Anemia control group|Anemia patients
89370067|NCT03682952|No Intervention|Control group|Healthy person
88842652|NCT05648812|Experimental|Neonatal asphyxia|"Diagnostic Test: Brain ultrasound, brain contrast enhanced ultrasound, brain ultrasound elastography To study brain perfusion with brain ultrasound, contrast enhanced ultrasound of the brain and ultrasound-guided shear-wave elastography Drug: Sulfur Hexafluoride To evaluate brain perfusion in neonates after birth asphyxia~Other Names:~• SonoVue"
88842653|NCT05648812|Experimental|Neonatal stroke|"Diagnostic Test: Brain contrast enhanced ultrasound, brain ultrasound elastography To study brain perfusion with brain ultrasound, contrast enhanced ultrasound of the brain and ultrasound-guided shear-wave elastography Drug: Sulfur Hexafluoride To evaluate brain perfusion after neonatal stroke~Other Names:~• SonoVue"
88842654|NCT05648812|Experimental|Other neonatal brain pathologies|"Diagnostic Test: Brain ultrasound, brain contrast enhanced ultrasound, brain ultrasound elastography To study brain perfusion with brain ultrasound, contrast enhanced ultrasound of the brain and ultrasound-guided shear-wave elastography Drug: Sulfur Hexafluoride To evaluate brain perfusion in infants with other type (no asphyxia, stroke or preterm birth related) of brain pathology, like hydrocephalus, hemorrhage or central nervous system infection~Other Names:~• SonoVue"
88842655|NCT05648695|Experimental|Non-invasive Neuromodulation|Non-invasive Neuromodulation Intervention with microcurrents: application of 6 electrodes per extremity and an adhesive electrode at C7 level.
88842656|NCT05648695|Placebo Comparator|Placebo Non-invasive Neuromodulation|Intervention with microcurrents: application of 6 electrodes per extremity and an adhesive electrode at C7.
88842657|NCT05644080|Experimental|68Ga/177Lu-PSMA theranostics in recurrent grade 3 and grade 4 glioma|Patients demonstrating a high tumor uptake of 68Ga-PSMA on the diagnostic PET/MRI examination in the screening part of the study are eligible for a standard of 3 cycles, with a possible extension to maximum number of 6 cycles, of 177Lu-PSMA radionuclide therapy sessions. SPECT/CT will be performed after each cycle of treatment for dosimetry calculations, while 68Ga-PSMA PET/MRI, quality-of-life schemes and clinical examinations will be used to monitor therapeutic effects during the therapy cycles and up to 1.5 year after treatment initiation. The main endpoints of the study are progression-free survival and overall survival.
88842658|NCT05641376|Active Comparator|Nebulized Dexmedetomidine|Children will receive a nebulized dexmedetomidine 2 mic/ kg diluted in 3 ml of 0.9% saline 1 h before induction of anaesthesia.
88842659|NCT05641376|Active Comparator|Intravenous Dexmedetomidine|Children will receive intravenous (IV) dexmedetomidine 1mic/kg diluted in 10 ml of 0.9% saline over 10 minutes after anesthesia induction.
88842660|NCT05636527||Thoracic Aortic Disease|"The NEXUS™ Aortic Arch Stent Graft System is indicated for the endovascular treatment of thoracic aortic diseases involving the aortic arch with proximal landing zone in ascending aorta and the Brachiocephalic artery. This includes:~Aneurysm Dissecting aneurysm / dissection and intramural hematoma {IMH) False / Pseudo aneurysm if not infected Residual aneurysm/dissection following ascending aorta open repair Penetrating ulcer, if not infected"
88842661|NCT05634356|Experimental|Experimental|Parents are instructed to say nonsense words in response to infant babbles with a conserved phonological form as infant plays.
88842662|NCT05634356|No Intervention|Control|Parents are instructed to say nonsense words at random times with a conserved phonological form as infant plays.
88842663|NCT05628766||Women diagnosed with primary infertility (n:41)|Women which followed up with infertility of unknown cause.
88842664|NCT05628766||Control group ( n:41)|Healthy women who are not infertile
88842665|NCT05622734|Experimental|VOCALE LBD+|
88842666|NCT05615805|Experimental|3-mL washout with saline based ocular rinse post injection|
88842667|NCT05615805|Experimental|10-mL washout with saline based ocular rinse post injection|
88842668|NCT05615805|Experimental|15-mL washout with saline based ocular rinse post injection|
88842669|NCT05615311|Experimental|Vitamin D group|
88842670|NCT05615311|Placebo Comparator|Control group|
88842671|NCT05607615|Experimental|Experimental|Intravenous administration over at least 4 hours by IV infusion Trappsol Cyclo either 500 mg/kg or 1000 mg/kg every 4 weeks
88842672|NCT05607615|Placebo Comparator|Placebo|Intravenous administration of 0.5N saline over at least 4 hours every 4 weeks
89180291|NCT01027429|Active Comparator|procaine penicillin and gentamicin|Procaine penicillin, 50,000 IU/kg by intramuscular injection plus gentamicin, 5 mg/kg intramuscular injection, both given once daily for 7 days
89180292|NCT01027429|Experimental|Amoxicillin and gentamicin|Oral amoxicillin (80-90 mg/kg) divided twice daily and intramuscular gentamicin, 5 mg/kg once daily, both given for 7 days
89180293|NCT01027429|Experimental|procaine penicillin, gentamicin, and amoxicillin|procaine penicillin, 50,000 IU/kg once daily intramuscular injection plus gentamicin 5 mg/kg once daily intramuscular injection for 2 days, followed by 5 days of oral amoxicillin, 80-90 mg/kg divided in two doses.
89180294|NCT00454363|Experimental|Treatment (pazopanib hydrochloride)|Patients receive pazopanib hydrochloride PO QD on days 1-28. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.
89180295|NCT01020253|Active Comparator|Alendronate medication|
89180296|NCT01020253|Active Comparator|Alfacalcidol medication|
88842673|NCT05597683|Experimental|QL block group|Bilateral transmuscular QL block will be performed under ultrasound-guidance. Twenty mililiter of 0.375% ropivacaine will be injected to each side.
88842674|NCT05597683|No Intervention|Control group|QL block will be not performed.
88842675|NCT05593939|Experimental|Exercise arm|12 week aerobic exercise will be performed in agreement with current guidelines for exercise in older adults from the American College of Sports Medicine. A frequency of 5 days/week, totaling 150-300 min/week, performed at both moderate and vigorous intensities is chosen. This dose has a high level of evidence supporting positive effects on health- and life-span.
88842676|NCT05593939|Experimental|Time restricted feeding|A 12 week fasting/feeding regiment of 16 hours fasting /8 hours feeding each day is chosen. This ratio has been shown to be tolerable in older individuals.
89180297|NCT01020253|No Intervention|Non-medication|
89180298|NCT00454207|Experimental|sildenafil citrate (UK-92,480)|sildenafil citrate 20 mg TID
89180299|NCT01020331|Experimental|ACTIVE|
89180300|NCT01030939|Experimental|Cohort 1: SB-649868|Healthy adult male subjects
89180301|NCT01030939|Experimental|Cohort 2|Healthy adult female subjects
89534804|NCT03333161|Active Comparator|Lower TcCO2|"The investigators will evaluate the effects of attempts to decrease blood carbon dioxide levels within a narrow range of 5 mm Hg (well within the range of usual clinical practice) in a cross-over manner for 24 hours at a time, over a 4-day period, and use Cardiorespiratory Monitoring to evaluate control of breathing.~The investigators will attempt to adjust PCO2 by 5 mm Hg lower than baseline (to minimum of 40 mm Hg), as long as pH is <7.45."
89534805|NCT03229369|Active Comparator|Isolated ACL|Standard Anterior Cruciate Ligament Reconstruction only
88818476|NCT04272489|Experimental|Adaptive Control|The adaptive control system updates the pattern recognition control algorithm by incorporating new EMG data each instance the prosthetic user recalibrates their device.
88818477|NCT04272489|Active Comparator|Non-Adaptive Control|The conventional, non-adaptive control systems resets the pattern recognition control algorithm by deleting old EMG data each instance the prosthetic user recalibrate their device.
88818478|NCT02249663|Experimental|Investigational Test Product|Azelastine hydrochloride and Fluticasone propionate Nasal Spray, 137/50 mcg
88818479|NCT02249663|Active Comparator|Reference Listed Drug|Dymista™ (azelastine hydrochloride/fluticasone propionate) Nasal Spray, 137/50 mcg
88818480|NCT02249663|Placebo Comparator|Placebo|Placebo Nasal Spray
88818481|NCT02692209||FFDM Plus DBT|FFDM Plus DBT images are being evaluated as compared to FFDM alone
88818482|NCT02692209||Full Field Digital Mammography|Fujifilm FFDM alone images are being evaluated as compared to FFDM + DBT
88818485|NCT05328011||overactive bladder syndrome|female patients with overactive bladder syndrome
88818486|NCT05328011||controls|women without overactive bladder syndrome
88818487|NCT01825889|Experimental|Evacetrapib (Participants With Renal Impairment)|Single oral dose of 130 milligrams (mg) evacetrapib on Day 1 to participants with severe renal impairment.
88818488|NCT01825889|Experimental|Evacetrapib (Healthy Participants)|Single oral dose of 130 mg evacetrapib on Day 1 to participants with normal renal function.
88818489|NCT02202746|Experimental|Cohort A: Lucitanib (CO-3810) 10 mg daily|10 mg of lucitanib daily in patients with FGFR1-amplified or 11q-amplified metastatic breast cancer.
88818490|NCT02202746|Experimental|Cohort B: Lucitanib (CO-3810) 15 mg daily|15 mg of lucitanib daily in patients with FGFR1-amplified and 11q-amplified metastatic breast cancer.
88818491|NCT02202746|Experimental|Cohort C: Lucitanib (CO-3810) 10 mg daily|10 mg of lucitanib daily in patients with FGFR1 non-amplified and 11q non-amplified metastatic breast cancer.
88818492|NCT01826513|Experimental|Unblinded Investigational Arm|Participants participated in an unblinded investigational phase of the trial prior to, and separate from, the single-blind cross-over phase of the trial. Data was collected from the his phase to aid the final development of the algorithm before proceeding to algorithm validation (ie. cross-over phase).
88818493|NCT01826513|Active Comparator|Standard AutoSet algorithm|Participants first received therapy with the Standard AutoSet algorithm for one night, and then received therapy with the Modified AutoSet algorithm (an AutoSet device with an algorithm developed for sleep breathing parameters specific to females) the following night.
88818494|NCT01826513|Experimental|Modified AutoSet algorithm|Participants first received therapy with the Modified AutoSet algorithm (an AutoSet device with an algorithm developed for sleep breathing parameters specific to females) for one night, and then received therapy with the standard AutoSet algorithm the following night.
88818495|NCT02692755|Experimental|Palbociclib + Letrozole or Fulvestrant|
88818496|NCT01829399|Experimental|Injected with Bupivacaine|A subcutaneous axillary ring of 10 to 15 mL of 0.25% Bupivacaine with epinephrine 1:200,000 will be injected in the arm 15 minutes prior to tourniquet inflation.
88818497|NCT01829399|Sham Comparator|Injected with saline|A subcutaneous axillary ring of 10 to 15 mL of normal saline will be injected in the arm 15 minutes prior to tourniquet inflation.
88818498|NCT01394510|Experimental|N-acetylcysteine dose study|Subjects will take N-acetylcysteine (NAC) 600 mg twice daily for 2 weeks, then 1200 mg twice daily for an additional 2 weeks. Study procedures will be performed at baseline, after 2 weeks and after 4 weeks.
88818499|NCT05580549||Essential Hypertension|A representative sample of adult patients, with hypertension (ICD-10 diagnose code I10.9) from 2-3 PHCC in Stockholm Region, Sweden. Age 30-85 years old.
88818500|NCT05441865||cognitive trajectory cohort|Th cognitive trajectory cohort, based on CLHLS dataset, will be used to evaluate the influence of cardiovascular risk factors on the cognitive trajectories among cognitively intact older adults
88818501|NCT05441865||neuroiming sample|The neuroiming sample, including cognitively intact older adults with MRI data, will be used to explore the potential mechanism of the cardiovascular risk factors and cognitive function.
88818502|NCT01396226|Experimental|1|A single dose of AZD2927 administered as an iv infusion
88818503|NCT01396226|Placebo Comparator|2|A single dose of placebo administered as an iv infusion
88818504|NCT05327621|Experimental|Pamiparib|Tablets 20mg per os : 40 mg / bid every day in continuous. Patients will be treated with Pamiparib. Cycles are defined in 28-day periods. Disease response will be assessed every 8 weeks (RECIST 1.1). Safety will be assessed continuously.
88818505|NCT02694315||Induction of labor|200 women all are primigravida between 37-42 weeks gestation to whom induction of labor will be carried out in the casualty of Ain Shams University Maternity Hospital. All participants will have an assessment of the cervix by both Bishop score system and transvaginal measurement of cervical length.
88818506|NCT01396382|Experimental|68Ga-DOTATATE PET|Patients will receive a 68Ga-DOTATATE PET scans
88818507|NCT05326841|Experimental|Cholecalciferol group|Participants in this arm take a vitamin D3 dose 5000 international units (IU) daily by mouth for a duration of 12 weeks
88818508|NCT05326841|Placebo Comparator|placebo group|Participants in this arm take a vitamin D3 placebo daily by mouth for a duration of 12 weeks
88818509|NCT05326763|Active Comparator|platelet rich plasma group|Preparing 2 mL of PRP with concentration of 4-6 times the average normal values, 20mL of blood will be first collected from the patient's upper limb cubital vein using an 18G needle.
89370068|NCT01375686||Those at Risk for Type 2 diabetes|All subjects will be at risk for diabetes based on the American Diabetes Association (ADA) Standard of Care Guidelines.
89370069|NCT01372332||Normal subjects|Age-related (+ 5 years of age) and gender-matched normal subjects.
89370070|NCT01372332||Patients with homonymous hemianopia|Patients with homonymous visual field defects
89370071|NCT03682718|Experimental|vaginal misoprostol and intracervical Foley catheter|participants will receive misoprostol by the same dose and method. Transcervical Foley catheter (size 16F, with 30ml balloon capacity) will be passed. The catheter will deﬂated, removed and cervix re-assessed if no spontaneous expulsion occurred at 12 hours post- insertion. A new catheter will be passed for another 12 hours, if the Bishop score is less than 8 this will be considered as failure of induction.
89370072|NCT03682718|Active Comparator|vaginal misoprostol|"Misoprostol group; participants will receive 50 μg intravaginal in the posterior vaginal fornix, 25 μg will be given every 4 hours for another two doses, if a satisfactory Bishop score of 8 not reached, patient will take an overnight rest and she will continue induction by the same doses on the next day-provided that there is no ROMs- (this is according to Ain Shams University Protocol) The maximum dose of Misoprostol is 200 μg.~Oxytocin infusion will not started until 6 hours after the last dose or if there is no adequate contractions obtained."
88842677|NCT05593939|Experimental|Nicotinamide riboside|Previous clinical trials have shown that an nicotinamide riboside dose up to 2 g/day is well tolerated with no treatment-emergent adverse events reported so far and with efficacy on our primary outcome measurement. A dose of 2 g/day NR is therefore chosen and will be split in two: 1 g in the morning and 1 g in the evening.
88842678|NCT05593939|No Intervention|Control|A control group with no intervention.
88842679|NCT05577845|Experimental|Ramosetron|
89180302|NCT01030939|Experimental|Cohort 3|Healthy male elderly subjects
89180303|NCT01030939|Experimental|Cohort 4|Healthy female elderly subjects
89370073|NCT03682640|Experimental|AIDIT protocol|"Treatment as usual with the addition of:~i) Azithromycin Monohydrate, three times a week (≥ 48 h between doses) during 52 weeks. 500 mg if body weight ≥ 30 kg, 250 mg if body weight < 30 kg.~ii) Extra intensive insulin treatment periods for maximum beta-cell rest with Insulin lispro (Sanofi). This treatment will be given i.v. for one episode of 72 hours in the first week after inclusion and s.c. on seven 6-8 h occasions during the study year. The dose will be individually titrated to reach target blood glucose 4.0±0.5 mmol/L.~ii) Dietician support; Extra advice and support from the study dietician within the first week after randomization and after 1.5 and 4 months."
89370074|NCT03682640|No Intervention|Control|Patients will receive treatment as usual (TAU). All patients will receive standard therapeutic treatment consisting of insulin replacement with insulin analogues aiming for normoglycemia from diagnosis. Rapid acting insulin analogue will be administered via insulin pump (continuous subcutaneous infusion) with access to insulin injections in case of malfunction in the pump system.
89370075|NCT03682562||Oral Cancer|Patients diagnosed clinically and histopathologically as having oral cancer.
89370076|NCT03682562||Premalignant Oral Lesions|Patients diagnosed clinically and histopathologically with either leukoplakia or oral lichen planus as stated by modified WHO criteria
89370077|NCT03682562||Normal Subjects|"Patients who give a history of:~No smoking~No alcohol~No systemic disease; and who on conventional oral examination have:~No visible oral lesions on conventional oral examination .~Good oral hygiene."
89370078|NCT03687476|Experimental|VTS-270 (Part A)|VTS-270 200 milligram per milliliter (mg/mL) will be administered intrathecally by lumbar puncture every 2 weeks followed by dose escalation of 100 mg/mL increments up to a maximum tolerable dose of 900 mg/mL. The highest tolerable dose is considered as clinically relevant dose which will be administered throughout the remaining duration of the 20-week treatment period of Part A.
89370079|NCT03687476|Experimental|VTS-270 (Part B)|VTS-270 200 mg/mL will be administered intrathecally by lumbar puncture every 2 weeks in Part B followed by a re-challenge to dose escalation of 100 mg/mL increments up to a maximum tolerable dose of 900 mg/mL. In case of intolerance, the dose should be returned to previously tolerable dose and should be continued throughout the duration of Part B (end of study).
89370080|NCT01376076|Experimental|1|Sequential, Multiple Dose, titration from 1.5mg to 18mg once daily dose of cariprazine
89370081|NCT01376076|Placebo Comparator|2A|Double blind placebo for Days 1-5, Moxifloxacin (400mg) on Day 6, Risperidone 4mg once daily Days 7-15, placebo Days 16-20, Risperidone Days 21-29, placebo Days 30-35
89370082|NCT01376076|Placebo Comparator|2B|Double blind placebo for Days 1-6, Risperidone 4mg once daily Days 7-15, placebo Days 16-20, Risperidone Days 21-29, placebo Days 30-34, Moxifloxacin (400mg) on Day 35
89370083|NCT03687398||control|does not have endometriosis or related diseases and not under any drug therapy does not have any benign or malign disease
88842680|NCT05577845|Active Comparator|Loperamide|
88842681|NCT05540847|Active Comparator|Ultrasound guided interfascial obturator nerve block|In supine position, ultrasound probe will be placed on inguinal region, 2-3 cm below to the inguinal crease. Patients in this group will receive interfascial obturator nerve block under ultrasound guidance.
89180304|NCT00738894|Active Comparator|Medical Management|Antiplatelet medical therapy alone
89180305|NCT00738894|Experimental|Device Closure|PFO closure with study septal occluder device plus antiplatelet medical therapy
89180306|NCT00480493|Experimental|Parent mentor contact|Parent mentor provides face-to-face social support
89180307|NCT00480493|Active Comparator|Control Arm|Parent is given a phone contact
89180308|NCT01027663|No Intervention|Iron Deficiency Anemia|
89180309|NCT01027663|No Intervention|Hereditary Hemochromatosis|
89370084|NCT03687398||patient|has laparoscopically proven endometriosis
89370085|NCT03121950|Experimental|Dance in dementia|examine if participating in a dance class improves mobility and/or cognition in individuals with dementia.
89370086|NCT03121950|Active Comparator|Music and dementia|examine if listening to music improves mobility and/or cognition in individuals with dementia.
89370087|NCT03395353|Experimental|Duloxetine hydrochloride|Duloxetine hydrochloride administered orally.
89370088|NCT03687242|Experimental|SPR001|SPR001 at Dose A
89370089|NCT05760066|Experimental|Resistance Training Preconditioning (PRECON)|"This group will perform:~6 weeks of lower body focused resistance training~2 weeks of locking brace-induced immobilization of a randomized leg~6 weeks of lower body focused resistance training"
89370090|NCT05760066|Active Comparator|Control (CTL)|"This group will perform:~6 weeks of activities of daily living (no training)~2 weeks of locking brace-induced immobilization of a randomized leg~6 weeks of lower body focused resistance training"
89370091|NCT03687164|Experimental|Group Medical Visits|Group visits which will provide aspects of support, empowerment, education and medical care.
89370092|NCT03687164|No Intervention|Usual Care|Usual clinical office visits
89370093|NCT05074758||non-COVID-19 ARDS patients|20 patients with acute respiratory distress syndrome (ARDS) unrelated to COVID-19
89180310|NCT01027663|Active Comparator|Iron Supplements|
89180311|NCT01020409||cardiac surgery with CPB use|Adult patients, who signed the informed consent, intervention: first-time scheduled heart surgery with CPB use.
89370094|NCT05074758||COVID-19 ARDS patients|20 patients with acute respiratory distress syndrome (ARDS) linked to COVID-19
89370095|NCT04082663|Experimental|Dental Mouthpiece|Each participant will be fitted with a maxillary orthotic (mouthpiece). The mouthpiece is fabricated with polyvinyl ethylene acetate which is non-toxic to humans.
89534806|NCT03229369|Experimental|Combined ACL and ALL|Anterior Cruciate Ligament Reconstruction associated with Anterolateral Ligament Reconstruction
89370096|NCT01376154||Subjects prescribed lamivudine tablet|Subjects with hepatitis B virus-induced liver cirrhosis prescribed lamivudine tablet during study period
89370097|NCT01562951|Placebo Comparator|PLACEBO|Treatment with placebo
89370098|NCT01562951|Active Comparator|ADALIMUMAB|Treatment with Adalimumab
89370099|NCT05174364||Epidural Block|Epidural block for the control group will be done before induction of general anesthesia. Patients will be positioned in the sitting position, an 18-gauge Tuohy needle will be inserted into epidural space of Th 11-12 intervertebral space under aseptic condition. In the medial approach, the site of the insertion of the needle is between the spaces created by the vertebral spinous processes. Upon locating the desired spot, lidocaine 1% must be injected into the skin and underlying tissues to decrease the discomfort with the advancement of the epidural needle
88842682|NCT05540847|Experimental|Ultrasound guided subpectineal obturator nerve block|In supine position, the ultrasound probe will be placed on in inguinal region, 1-2 cm below to the inguinal crease to identiy the subpectineal area. Patients in this group will receive subpectineal obturator nerve block under ultrasound guidance.
88842683|NCT05527912|Experimental|Arm I (RCZ WITH CHOP)|Rituximab, Chidamide, Zanubrutinib-induced and CHOP Therapy
88842684|NCT05502588|Active Comparator|Self-Guided Forest Bathing|Forest Bathing intervention without a guide and basic navigational instructions, explanation of forest bathing, and time to return.
88842685|NCT05502588|Experimental|Guided Forest Bathing|Forest Bathing intervention led by a certified Forest Therapy guide.
88842686|NCT05496920|Experimental|Single Arm|Patients will receive both a standard of care PET/CT and a low dose PET/CT
88842687|NCT05492786|Active Comparator|Standard Alert|Standard flu alert
89370100|NCT05174364||Quadratus Lumborum Block|Bilateral QL block type 3 (anterior) for the intervention group will be performed on both sides of the patient after induction of general anesthesia. Patient will be positioned in semi-lateral decubitus and using low-frequency ultrasonography (USG) guidance attached to inferior lumbar region (Petit's triangle) that is consisted of inferior iliac crest and bordered by two muscles such as latissimus dorsi muscle in the posterior, abdominal external oblique muscle in the anterior. The USG will display the Shamrock sign, where the transverse process of vertebrae L4 role as the trunk, erector spinae muscle on the posterior side, psoas major (PM) on the anterior side, and QL muscle on the lateral side. After the visualization of QL and PM muscles, the Contiplex R needle will be directed parallel to the posterior side of the ultrasound probe until the tip of needle is confirmed in the border of QL and PM muscle
89370101|NCT01375842|Experimental|Dose Escalation Cohort: Atezolizumab 0.01 mg/kg|Participants will receive intravenous (IV) infusion of atezolizumab 0.01 milligrams per kilogram (mg/kg) every 3 weeks (q3w) until DLT is reached or up to end of study or treatment discontinuation or death or until initiation of another anti cancer therapy, whichever occurs first.
89370102|NCT01375842|Experimental|Dose Escalation Cohort: Atezolizumab 0.03 mg/kg|Participants will receive IV infusion of atezolizumab 0.03 mg/kg q3w until DLT is reached or up to end of study or treatment discontinuation or death or until initiation of another anti cancer therapy, whichever occurs first.
89370103|NCT01375842|Experimental|Dose Escalation Cohort: Atezolizumab 0.1 mg/kg|Participants will receive IV infusion of atezolizumab 0.1 mg/kg q3w until DLT is reached or up to end of study or treatment discontinuation or death or until initiation of another anti cancer therapy, whichever occurs first.
89370104|NCT01375842|Experimental|Dose Escalation Cohort: Atezolizumab 0.3 mg/kg|Participants will receive IV infusion of atezolizumab 0.3 mg/kg q3w until DLT is reached or up to end of study or treatment discontinuation or death or until initiation of another anti cancer therapy, whichever occurs first.
89534807|NCT03327545|Experimental|Experimental Group 1|Neural mobilization for a total of 12 minutes
89534808|NCT03327545|Experimental|Experimental Group 2|Soft tissue techniques and Stretching right side of the craniocervical for a total of 12 minutes
88842688|NCT05492786|Experimental|High-risk Alert|Flu alert that indicates patient is at high risk for flu and its complications
88842689|NCT05492786|Experimental|High-risk Alert with Risk Factors|Flu alert that indicates patient is at high risk for flu and its complications and presents the factors contributing to this high risk
88842690|NCT05492045|Experimental|Phase 1b Dose escalation of D-1553 combination therapies|Phase 1b will determine maximal tolerated dose and/or recommended phase 2 dose of D-1553 in combination with immunotherapy or targeted therapy in patients with KRAS G12C-mutated locally advanced or metastatic NSCLC.
88842691|NCT05492045|Experimental|Phase 2 of D-1553 combination therapies|Phase 2 will evaluate the efficacy and safety of D-1553 combined with immunotherapy or targeted therapy in patients with KRAS G12C-mutated locally advanced or metastatic NSCLC.
88842692|NCT05491187|Active Comparator|Group B (bupivacaine group)|Drug used: 0.5% hyperbaric bupivacaine heavy (8%dextrose) dose -11mg with volume of 2.2ml single administration, no repetition of intervention
88842693|NCT05491187|Experimental|Group BF(bupivacaine with fentanyl group)|Drug used:- 0.5% hyperbaric bupivacaine heavy (8%dextrose) dose -10mg, 2ml and fentanyl 10mg ,0.2ml with total volume of of 2.2ml single administration, no repetition of intervention
88842694|NCT05480878|Placebo Comparator|Control|"Participants in this arm will receive Placebo with the current DMARDs treatments for rheumatoid arthritis for 12 weeks.~."
88842695|NCT05480878|Experimental|Nitazoxanide|Participants in this arm will receive Nitazoxanide 1 gm/day + DMARDs for 12 weeks.
88842696|NCT05480878|Experimental|Escitalopram|Participants in this arm will receive Escitalopram 10 mg/day + DMARDs for 12 weeks.
88842697|NCT05463289|Other|Diabetic Retinopathy Exam at the point of care|Participants will undergo a point of care diabetic retinopathy eye exam using autonomous AI. Those that test positive will be referred to Eye Care Provider for dilated eye exam.
88842698|NCT05461222|Experimental|Fetal Endoscopic Tracheal Occlusion (FETO)|FETO is performed in-utero and the balloon is removed prior to delivery, and children will have follow-up visits until the age of 2
89370105|NCT01375842|Experimental|Dose Escalation Cohort: Atezolizumab 1 mg/kg|Participants will receive IV infusion of atezolizumab 1 mg/kg q3w until DLT is reached or up to end of study or treatment discontinuation or death or until initiation of another anti cancer therapy, whichever occurs first.
88842699|NCT05448963|Experimental|Robotic mastectomy|Patients receive unilateral or bilateral robot-assisted nipple-sparing mastectomy with or without axillary lymph node dissection
88842700|NCT05430906|Experimental|AK104+chemotherapy|Participants received 3-4 neo-adjuvant cycles of AK104 10mg/kg Q3W then [paclitaxel (135-175 mg/m²) or docetaxel (75 mg/m²)] and [carboplatin (AUC5 or 6) or cisplatin (75mg/m²)] Q3W; followed by surgery
89370106|NCT01375842|Experimental|Dose Escalation Cohort: Atezolizumab 3 mg/kg|Participants will receive IV infusion of atezolizumab 3 mg/kg q3w until DLT is reached or up to end of study or treatment discontinuation or death or until initiation of another anti cancer therapy, whichever occurs first.
89534809|NCT03327545|Placebo Comparator|Control group|Control group
88842701|NCT05419986|Other|Non-opioid users|
88842702|NCT05419986|Other|Active opioid users|
88842703|NCT05414331|No Intervention|Continuation of beta-blocker regimen|Participants will continue with current standard of care on current beta-blocker regimen
88842704|NCT05414331|Experimental|Withdrawing of beta-blockers|Discontinuation of all BB, and medication changes will be made at the 1-month clinic visit. A cardiopulmonary exercise test (CPET) will be performed 1 month after the randomization (2 months after CABG).
88842705|NCT05404256|Experimental|The experimental group|Radical gastrectomy +D2 lymphadenectomy +TissuePatchTM to seal pancreatic tissue surface
88842706|NCT05404256|Other|The control group|Radical gastrectomy +D2 lymphadenectomy
88842707|NCT05403567|Experimental|Bootle Blast Intervention|Children will play the Bootle Blast game at home for 8 continuous weeks.
88842708|NCT05398367|Experimental|Oat Mama Lactation Supplement|Participants will receive a 20 day supply of oat mama lactation supplement for consumption per the manufacturer instructions
88842709|NCT05398367|Experimental|Moringa Supplement|Participants will receive a 20 day supply of moringa supplement for consumption per the manufacturer instructions
88842710|NCT05398367|Experimental|Shatavari Supplement|Participants will receive a 20 day supply of shatavari supplement for consumption per the manufacturer instructions
88842711|NCT05398367|Placebo Comparator|Placebo|Participants will receive a 20 day supply of placebo pills containing a mixture of flour and brown sugar. Participants will consume 2 placebo pills once per day for 20 days.
88842712|NCT05396378||Gestational diabetes|Any parturient who after information agrees to participate in the study. The treatment of the gestational diabetes may be by diet, metformin or insulin according to the hospital's normal protocol.
88842713|NCT05396378||Type II diabetes|Any parturient who after information agrees to participate in the study. The treatment of the diabetes may be by diet, metformin or insulin according to the hospital's normal protocol.
88842714|NCT05383716|Experimental|chemotherapy plus pembrolizumab|Two to four cycles of neoadjuvant chemotherapy in combination with pembrolizumab will be administered before surgery, followed by another one to two cycles of chemotherapy plus pembrolizumab after surgery (4 cycles neoadjuvant/adjuvant chemotherapy in total ) then use pembrolizumab monotherapy for up to 1 year
88842715|NCT05380570||Korean radiation workers|The study population is Korean radiation workers exposed to ionizing radiation in workplaces. Diagnostic medical radiation workers were not included in the study population.
88842716|NCT05378945|Experimental|OC-01|
89370107|NCT01375842|Experimental|Dose Escalation Cohort: Atezolizumab 10 mg/kg|Participants will receive IV infusion of atezolizumab 10 mg/kg q3w until DLT is reached or up to end of study or treatment discontinuation or death or until initiation of another anti cancer therapy, whichever occurs first.
89370108|NCT01375842|Experimental|Dose Escalation Cohort: Atezolizumab 20 mg/kg|Participants will receive IV infusion of atezolizumab 20 mg/kg q3w until DLT is reached or up to end of study or treatment discontinuation or death or until initiation of another anti cancer therapy, whichever occurs first.
89399211|NCT03695835||Adenocarcinoma treated with MyVaccx|MyVaccx combines tumor ablation and immunotherapeutic agents for treatment of late stage cancer disease..
89399212|NCT03691701|Experimental|Strict SBP Target|Home SBP target < 120 mmHg or 90th percentile for age and height (whichever is lower)
89399213|NCT03691701|No Intervention|Usual SBP Target|Usual care, no home SBP target
89399214|NCT03695757|Experimental|Part A) Healthy subjects|Part A) Autologous total IgG 50mg will be administered to the healthy subjects by intramuscular injections, twice a week for 4 weeks (total 8 injections).
88842717|NCT05378945|Placebo Comparator|Placebo|
88842718|NCT05376644|Experimental|HER2 positive breast cancer patients|Maximum (15) evaluable subjects with HER2-positive status in primary tumour before chemo/targeted therapy have to be enrolled in the study. Subjects withdrawn from the study for any reason will be replaced
88842719|NCT05357638|Experimental|Physical Training Group 1 (n=16)|High Intensity Interval Training
88842720|NCT05357638|Experimental|Physical Training Group 2 (n=16)|Continuous Aerobic Training
88842721|NCT05357638|Experimental|Physical Training Group 3 (n=16)|Movement Advice
88842722|NCT05352724|Experimental|Hydration drink A|Water with electrolytes and glucose 625 ml 3 times a week for 4 weeks, during exercise
88842723|NCT05352724|Active Comparator|Hydration drink B|Water with electrolytes and calorie-free sweetener 625 ml 3 times a week for 4 weeks, during exercise
88842724|NCT05352724|Placebo Comparator|Hydration drink C|Water with flavoring and coloring 625 ml 3 times a week for 4 weeks, during exercise
88842725|NCT05347966|Other|Brain Health PRO|
88842726|NCT05334732|Experimental|Sisters Informing Sisters Sessions|The intervention is peer-based and in concert with our theoretical model, builds upon positive role-modeling of the survivor coach to the patient, addresses behavioral expectations/capacities, and uses Motivational Interviewing (MI) techniques. The intervention includes a culturally relevant coach's manual and a patient workbook that will be used to facilitate the coaching sessions.
88842727|NCT05334732|No Intervention|Enhanced Usual Care|Women in the EUC arm will receive usual care that includes standardized information in the public domain (NCI treatment information booklet). This booklet was chosen to provide women with national-level recommendations regarding treatment recommendations.
88842728|NCT05333835|Experimental|HR17031 injection|
88842729|NCT05333835|Active Comparator|INS068 injection|
88842730|NCT05333835|Active Comparator|SHR20004 injection|
88842731|NCT05330377|Experimental|Gilteritinib (Dose Level -1: 40 mg/day)|"Dose escalation for gilteritinib will be conducted according to a BOIN design. Gilteritinib 40 mg/day will be given orally starting day 6 until day 19. CLAG-M chemotherapy will be administered at a fixed dose and schedule as following:~Cladribine (CL) 5 mg/m2 I.V. over 2 hours once per day on days 1 to 5, given first.~Cytarabine (A) 2,000 mg/m2 I.V. over 4 hours once per day on days 1 to 5, given second, 2 hours after cladribine.~Filgrastim (GCSF) 300 mcg S.C. once per day on days 0 to 5, started 24 hours prior to chemotherapy. If WBC is > 20 × 109/L on day 0, the filgrastim dose on day 0 will be omitted.~Mitoxantrone (M) 10 mg/m2 I.V. once per day on days 1 to 3"
88842732|NCT05330377|Experimental|Gilteritinib (Dose Level 1: 80 mg/day)|"Dose escalation for gilteritinib will be conducted according to a BOIN design. Gilteritinib 80 mg/day will be given orally starting day 6 until day 19. CLAG-M chemotherapy will be administered at a fixed dose and schedule as following:~Cladribine (CL) 5 mg/m2 I.V. over 2 hours once per day on days 1 to 5, given first.~Cytarabine (A) 2,000 mg/m2 I.V. over 4 hours once per day on days 1 to 5, given second, 2 hours after cladribine.~Filgrastim (GCSF) 300 mcg S.C. once per day on days 0 to 5, started 24 hours prior to chemotherapy. If WBC is > 20 × 109/L on day 0, the filgrastim dose on day 0 will be omitted.~Mitoxantrone (M) 10 mg/m2 I.V. once per day on days 1 to 3"
88842733|NCT05330377|Experimental|Gilteritinib (Dose Level 2: 120 mg/day)|"Dose escalation for gilteritinib will be conducted according to a BOIN design. Gilteritinib 120 mg/day will be given orally starting day 6 until day 19. CLAG-M chemotherapy will be administered at a fixed dose and schedule as following:~Cladribine (CL) 5 mg/m2 I.V. over 2 hours once per day on days 1 to 5, given first.~Cytarabine (A) 2,000 mg/m2 I.V. over 4 hours once per day on days 1 to 5, given second, 2 hours after cladribine.~Filgrastim (GCSF) 300 mcg S.C. once per day on days 0 to 5, started 24 hours prior to chemotherapy. If WBC is > 20 × 109/L on day 0, the filgrastim dose on day 0 will be omitted.~Mitoxantrone (M) 10 mg/m2 I.V. once per day on days 1 to 3"
88842734|NCT05323435|Experimental|Recombinant Two-Component COVID-19 Vaccine (CHO cell), 20μg|Antigen: NTD-RBD-foldon protein, sodium dihydrogen phosphate, disodium hydrogen phosphate, sucrose, glycine, polysorbate 80 Adjuvant (BFA03): squalene, alpha-tocopherol, polysorbate 80, sodium chloride, potassium chloride, disodium hydrogen phosphate, potassium dihydrogen phosphate (ReCOV for short, 20μg)
88842735|NCT05323435|Experimental|Recombinant Two-Component COVID-19 Vaccine (CHO cell), 40μg|Antigen: NTD-RBD-foldon protein, sodium dihydrogen phosphate, disodium hydrogen phosphate, sucrose, glycine, polysorbate 80 Adjuvant (BFA03): squalene, alpha-tocopherol, polysorbate 80, sodium chloride, potassium chloride, disodium hydrogen phosphate, potassium dihydrogen phosphate (ReCOV for short, 40μg)
88842736|NCT05323435|Active Comparator|COVID-19 Vaccine (Vero Cell), Inactivated|Antigen: inactivated SARS-CoV-2 Virus (19nCoV-CDC-Tan-HB02 strain) Adjuvant: aluminum hydroxide Excipients: disodium hydrogen phosphate, sodium dihydrogen phosphate, sodium chloride
88842737|NCT05322252|Experimental|Simulatenous mifepristone and misoprostol|Participants will receive a dose of 200mg oral mifepristone at time of induction with misoprostol
88842738|NCT05322252|Active Comparator|Misoprostol alone|Participants will have labor induced with misoprostol alone
88842739|NCT05318820|Experimental|HMPL-523-TRR|Three cycle dose: TRR Test product: HMPL-523 Tablets manufactured by Hutchison MediPharma (Suzhou) Co., Ltd.; Reference product: HMPL-523 Tablets manufactured by WuXi STA
88842740|NCT05318820|Experimental|HMPL-523-RTR|Three cycle dose:RTR Test product: HMPL-523 Tablets manufactured by Hutchison MediPharma (Suzhou) Co., Ltd.; Reference product: HMPL-523 Tablets manufactured by WuXi STA
88842741|NCT05318820|Experimental|HMPL-523-RRT|Three cycle dose:RRT Test product: HMPL-523 Tablets manufactured by Hutchison MediPharma (Suzhou) Co., Ltd.; Reference product: HMPL-523 Tablets manufactured by WuXi STA
88842742|NCT05311917|Experimental|home vision therapy|near glasses will be prescribed along with a complete training of the exercises and with a eye exercise form of information about how and how long to do the exercise, by optometrist No 2 (Saeid Abdi).training includes: Voluntary convergence, Bug on string, Eccentric Circles, Jumping vergence , Barrel card, chiastopic fusion, Brock string, push-up These exercises will be done 3 days a week for 20 minutes ( 10 minutes at noon and 10 minutes at night ) for 2 month. Home exercises include eight vision therapy exercises and patients will do two exercises each day at noon and two exercises at night.
88842743|NCT05311917|Experimental|base in prism prescription|base in prism prescription using sheards criterion near prismatic glasses will be prescribed and the amount of prism will be divided between two eyes; and random and aimless eye movements, without convergence and accommodation effects will be prescribed by optometrist No. 2 (Saeid Abdi). patients should complete their checking form for eye exercises.
88842744|NCT05311917|Placebo Comparator|conventional|new near glasses as a conventional treatment with the practice of random and aimless eye movements, without convergence and accommodation effects will be prescribed by optometrist No. 2 (Saeid Abdi). patients should complete the form of their eye training.
88842745|NCT05259423|Experimental|Typical Development, Enriched Education Program|Parents of infants with typical development (i.e, not meeting the eligibility criteria for early intervention services in the state of Delaware) will receive enriched play activity education based on key ingredients evidenced to advance infant development.
88842746|NCT05259423|Active Comparator|Typical Development, Typical Education Program|Parents of infants with typical development (i.e, not meeting the eligibility criteria for early intervention services in the state of Delaware) will receive typical play education based on usual education found in commonly used websites, apps, and books.
88842747|NCT05259423|Experimental|Developmental Delay, Enriched Education Program|Parents of infants with/at risk for developmental delay (i.e, meeting the eligibility criteria for early intervention services in the state of Delaware) will receive enriched play activity education based on key ingredients evidenced to advance infant development.
88842748|NCT05259423|Active Comparator|Developmental Delay, Typical Education Program|Parents of infants with/at risk for developmental delay (i.e, meeting the eligibility criteria for early intervention services in the state of Delaware) will receive typical play education based on usual education found in commonly used websites, apps, and books.
88842749|NCT05251272||Training cohort|Patients were fulfilled diagnosis of compensated cirrhosis based on radiological, histological features of liver cirrhosis and clinical manifestations.
88842750|NCT05251272||Validation cohort|Patients were fulfilled diagnosis of compensated cirrhosis based on radiological, histological features of liver cirrhosis and clinical manifestations.
88842751|NCT05246943||UTMB's Colorectal Surgical Cohort|Subjects who meet the inclusion criteria that will have colorectal surgery at UTMB
88842752|NCT05246904|Active Comparator|audiologist arm|A research audiologist will fit the participant with the hearing devices according to usual clinical best practice procedures.
88842753|NCT05246904|Active Comparator|self-fit arm|Participants will follow manufacturer's printed instructions to complete the self-hearing test using the hearing aids and a provided app to program their hearing aids.
88842754|NCT05241600|Experimental|Mindfulness-Based Childbirth and Parenting (MBCP)|Child-bearers randomized to MBCP participate in the 9-week course with a partner (co-parenting partner or other support person who will be involved in the birth). During the training, mothers receive instruction in formal and informal mindfulness practices, and how these apply to the experience of childbirth and parenting an infant. Each weekly 3-hour class includes demonstration and discussion of a practice to be carried out at home over the coming week.
88842755|NCT05241600|Active Comparator|Treatment as Usual (TAU)|Child-bearers randomized to the treatment as usual comparison group participate (also with a partner) in a non-mindfulness-based childbirth class of their choice from a list provided. To maintain ecological validity of this treatment as usual condition, using an established comparative-effectiveness/pragmatic trial approach, no attempt is made to control the length or contact hours of the class.
88842756|NCT05235334|Experimental|Device user|Participant will engage in treatment with the MySOLIUS device, twice per week for 16 weeks
89534810|NCT03090711|Experimental|TMS|Real transcranial magnetic stimulation (TMS).
88842757|NCT05229016|Experimental|Positive health-related experiences and EQ-5D-5L|Reflecting on positive health-related experiences EQ-5D-5L questionnaire
88842758|NCT05229016|Experimental|Negative health-related experiences and EQ-5D-5L|Reflecting on negative health-related experiences EQ-5D-5L questionnaire
88842759|NCT05229016|No Intervention|Control and EQ-5D-5L|No intervention/ control group EQ-5D-5L questionnaire
88842760|NCT05229016|Experimental|Positive health-related experiences and PROMIS|Reflecting on positive health-related experiences PROMIS Global health v1.2 questionnaire
88842761|NCT05229016|Experimental|Negative health-related experiences and PROMIS|Reflecting on negative health-related experiences PROMIS Global health v1.2 questionnaire
88842762|NCT05229016|No Intervention|Control and PROMIS|No intervention/ control group PROMIS Global health v1.2 questionnaire
88842763|NCT05229016|Experimental|Positive health-related experiences and SF-36|Reflecting on positive health-related experiences SF-36 questionnaire
88842764|NCT05229016|Experimental|Negative health-related experiences and SF-36|Reflecting on negative health-related experiences SF-36 questionnaire
88842765|NCT05229016|No Intervention|Control and SF-36|No intervention/ control group SF-36 questionnaire
88842766|NCT05229016|Experimental|Positive health-related experiences and SNOT-22|Reflecting on positive health-related experiences SNOT-22 questionnaire
89534811|NCT03090711|Sham Comparator|sham TMS|Sham transcranial magnetic stimulation (TMS) as a comparison.
88842767|NCT05229016|Experimental|Negative health-related experiences and SNOT-22|Reflecting on negative health-related experiences SNOT-22 questionnaire
88842768|NCT05229016|No Intervention|Control and SNOT-22|No intervention/ control group SNOT-22 questionnaire
88842769|NCT05229016|Experimental|Positive health-related experiences and RSDI|Reflecting on positive health-related experiences RSDI questionnaire
88842770|NCT05229016|Experimental|Negative health-related experiences and RSDI|Reflecting on negative health-related experiences RSDI questionnaire
88842771|NCT05229016|No Intervention|Control and RSDI|No intervention/ control group RSDI questionnaire
88842772|NCT05229016|Experimental|Positive health-related experiences and mini-RQLQ|Reflecting on positive health-related experiences Mini-RQLQ questionnaire
88842773|NCT05229016|Experimental|Negative health-related experiences and mini-RQLQ|Reflecting on negative health-related experiences Mini-RQLQ questionnaire
88842774|NCT05229016|No Intervention|Control and mini-RQLQ|No intervention/ control group Mini-RQLQ questionnaire
89534812|NCT03090711|Experimental|TMS and tACS|Real transcranial magnetic stimulation (TMS) and real transcranial alternating current stimulation (tACS).
89534813|NCT03090711|Sham Comparator|TMS and sham tACS|Real transcranial magnetic stimulation (TMS) and sham transcranial alternating current stimulation (tACS) as a comparison.
89534814|NCT03231163|Placebo Comparator|No Music|
89534815|NCT03231163|Experimental|Relaxing Classical Music|
89534816|NCT03231163|Experimental|Self-Selected Relaxing Music|
89370109|NCT01375842|Experimental|Expansion Cohort (Atezolizumab)|Participants will receive IV infusion of atezolizumab q3w up to end of study or treatment discontinuation or death or until initiation of another anti cancer therapy, whichever occurs first. The dose which result in total drug exposure less than or equal to (</=) exposures achieved at the MTD or maximum administered dose (MAD), will be selected for expansion cohort.
89370110|NCT03682367|Placebo Comparator|Control|Standard of care use of perioperative analgesia with acetaminophen and opioids that is supplemented with placebo solution. Participants will then be discharged after surgery with postoperative acetaminophen, opioids, and placebo.
89370111|NCT03682367|Experimental|Intervention|Interventional use of perioperative analgesia with acetaminophen and opioids that is supplemented with gabapentin solution. Participants will then be discharged after surgery with postoperative acetaminophen, opioids, and gabapentin.
89370112|NCT03677570||Female athletes|A total of 45 female athletes (15 volleyball, 15 handball, and 15 football players) (average age: 22,26 ± 6,43 / BMI: 21,45 ± 2,39) participated in the study.Trunk muscle endurance of the participants was measured with the McGill core endurance tests and the prone bridge test. Postural stability of the participants was evaluated using Biodex Biosway Portable Balance System (950- 460 USA) device. Sportive performance was tested with the vertical jump test and the hexagonal obstacle test.
89370113|NCT03677570||Healthy Control|15 sedentary females (average age: 24,86 ± 3,02 / BMI: 21,42 ± 1,90) participated in the study.Trunk muscle endurance of the participants was measured with the McGill core endurance tests and the prone bridge test. Postural stability of the participants was evaluated using Biodex Biosway Portable Balance System (950- 460 USA) device. Sportive performance was tested with the vertical jump test and the hexagonal obstacle test.
88842775|NCT05212454|Experimental|capecitabine group|All enrolled cases should be given standard chemotherapy, radiotherapy and endocrine therapy according to the Chinese Society of Clinical Oncology (CSCO) guidelines for the treatment of breast cancer, with the specific regimen decided by the doctor according to the condition. After the completion of standard chemotherapy, capecitabine 1250mg/m2 should be given orally twice a day for 2 weeks of the 3-week treatment course, and the total duration of treatment is 8 courses, which can be given simultaneously with radiotherapy and endocrine therapy. Premenopausal patients may use ovarian suppressants as needed.
88842776|NCT05207189|Experimental|UVT|Biological sling used as a replacement of the synthetic sling.
88842777|NCT05204901|Experimental|Magnetic tracking|This is the only arm of the study. All 12 participants will undergo the insertion of the magnetic-tipped guidewire into their nasogastric tube after its correct placement is confirmed by chest X-ray.
88842778|NCT05168969||Patient carrying a CTNNB1 syndrome|Recruitment of subjects with CTNNB1 syndrome will be done through health care providers, but also by contacting families through social media and specialized databases.
88842779|NCT05145920|Experimental|Pilot testing of an education program promoting effective parenting habit|Parents will receive a series of 5 short videos via Whatsapp
88842780|NCT05140837||cross-sectional study|
88842781|NCT05140837||real-world cohort study|
88842782|NCT05135598|Experimental|Health behavior change intervention|Participants will receive a pedometer, workbook, partner, and 15 weekly phone group meetings.
88842783|NCT05113030||Test group(1st)|PERIODONTAL STATUS OF FEMALE PATIENTS WITH PCOS (NEWLY DIAGNOSED) OF ADOLESCENT AGE GROUP WILL BE ASSESSED
88842784|NCT05113030||Test group(2nd)|PERIODONTAL STATUS OF FEMALE PATIENTS WITH PCOS (NEWLY DIAGNOSED) OF ADULT AGE GROUP WILL BE ASSESSED
88842785|NCT05109598|Experimental|Population I|Population I has 400 subjects aged 3 to 17 who were recruited by this trial.
88842786|NCT05109598|Experimental|Population II|Population II will use 400 subjects aged of 18-59 in the phase III clinical trial in China whose blood has been collected.
88842787|NCT05100485||Training cohort|Training cohort was used to developement the new algorithm for predicting liver decompensation.
88842788|NCT05100485||Validation cohort|Validation cohort was used to test the performance of the new algorithm in predicting liver decompensation.
88842789|NCT05100485||HVPG cohort|HVPG cohort, a cross-section cohort was used to study the diagnostic value of novel score for clinically significant portal hypertension.
88842790|NCT05096845|Experimental|V-01 COVID-19 Vaccine|Intramuscular injection into the lateral deltoid of the upper arm Two doses, one each on Day 0 and 21 (+7 days), respectively.
88842791|NCT05096845|Placebo Comparator|Placebo control|Intramuscular injection into the lateral deltoid of the upper arm Two doses, one each on Day 0 and 21 (+7 days), respectively.
88842792|NCT05091866|Experimental|Treatment (progesterone)|Patients receive progesterone SC QD for up to 24 weeks in the absence of disease progression or unacceptable toxicity.
88842793|NCT05080881|Experimental|Blood draw|All blood draw subjects will have baseline data collected over 15 minutes. The participants with then donate blood. For 15 minutes after the blood donation, the participant will stay in place and will continue to have data collected.
88842794|NCT05079828|Active Comparator|Arm 1|Patients receive first a PET/CT with 68Ga-PSMA-11 and a second PET/CT with 18F-PSMA-1007
88842795|NCT05079828|Active Comparator|Arm 2|Patients receive first a PET/CT with 18F-PSMA-1007 and a second with 68Ga-PSMA-11
88842796|NCT05068492||Training cohort|Training cohort was set to develop the novel non-invasive model for virtual HVPG
88842797|NCT05068492||Validation cohort|Validation cohort was set to validate the novel non-invasive model for virtual HVPG in different people in same environments
88842798|NCT05068492||Test cohort|Test cohort was set to test the novel non-invasive model for virtual HVPG in different environments
88842799|NCT05052892||Training cohort|Patients were fulfilled diagnosis of cirrhosis based on radiological, histological features of liver cirrhosis.
88842800|NCT05052892||Validation cohort|Patients were fulfilled diagnosis of cirrhosis based on radiological, histological features of liver cirrhosis.
88842801|NCT05050474|Experimental|V-01 COVID-19 Vaccine|One dose administrated by intramuscular injection
89370114|NCT03677492|Experimental|Handling Medium Supplemented with Cytochalasin D|
89370115|NCT03677492|No Intervention|Handling Medium as it is.|
89370116|NCT03681353|Experimental|Reduced Use Condition|This arm includes six weeks of mobile contingency management treatment administered via a smart-phone based application (mobile CM), in which participants are provided monetary reinforcement for reducing cannabis use.
89370117|NCT03394885|Experimental|Atezolizumab, Carboplatin, Paclitaxel (+Optional Bevacizumab)|"Atezolizumab administered over 90 (± 15) minutes (for the first infusion, shortening to 60 (± 15) minutes and 30 ± 15) minutes for subsequent infusions as described below) followed by~Paclitaxel 70-80mg/m2 IV administered over approximately one hour followed by~Carboplatin IV administered over 15-30 minutes to achieve an initial target AUC of 5-6 mg/mL/Min (Calvert formula dosing).~(Optional, Physician choice) Bevacizumab IV maintenance administered starting at cycle 5 of chemotherapy over 30-90 minutes. For those who receive bevacizumab, it will be given for a total duration of 16 cycles"
89370118|NCT03682484|Experimental|MA-0211 Single Ascending Dose (fasting conditions)|Successive cohorts of 8 participants (1-7 cohorts) will be started on a fixed single dose of MA-0211 or matching Placebo under fasting conditions. The first two participants will receive either MA-0211 or matching placebo. If no safety issues are observed in the first 24 hours in the first two participants, then the remaining six participants will be dosed.
88842802|NCT05042700|Experimental|Melatonin-Placebo sequence|50% of the included patients will receive 4 weeks of treatment with melatonin, followed by a 4 week wash out period, and then 4 weeks of treatment with placebo. The treatments are blinded.
88842803|NCT05042700|Experimental|Placebo-Melatonin sequence|50% of the included patients will receive 4 weeks of treatment with placebo, followed by a 4 week wash out period, and then 4 weeks of treatment with melatonin. The treatments are blinded.
88842804|NCT05042401|Experimental|Treatment group A|
88842805|NCT05042401|Placebo Comparator|Treatment group B|
88842806|NCT05042401|Experimental|Treatment group C|
88842807|NCT05042401|Placebo Comparator|Treatment group D|
88842808|NCT05039450|Experimental|EFX 28 mg (Main Study)|
88842809|NCT05039450|Experimental|EFX 50 mg (Main Study)|
88842810|NCT05039450|Placebo Comparator|Placebo (Main Study)|
88842811|NCT05039450|Experimental|EFX 50 mg (Cohort D)|
88842812|NCT05039450|Placebo Comparator|Placebo (Cohort D)|
89370119|NCT03682484|Placebo Comparator|Placebo Single Ascending Dose (fasting conditions)|Successive cohorts of 8 participants (1-7 cohorts) will be started on a fixed single dose of MA-0211 or matching Placebo under fasting conditions. The first two participants will receive either MA-0211 or matching placebo. If no safety issues are observed in the first 24 hours in the first two participants, then the remaining six participants will be dosed.
89370120|NCT03682484|Experimental|MA-0211 Single Ascending Dose (food effect)|A single cohort of 8 participants will be started on a fixed single dose of MA-0211, within 30 minutes after the start and 5 minutes after the completion of an US Food and Drug Administration (FDA) high fat breakfast.
89370121|NCT03682484|Experimental|MA-0211 Multiple Ascending Dose|Successive cohorts of 12 participants (1-3 cohorts) will receive oral doses of MA-0211 or matching Placebo for 14 days.
89370122|NCT03682484|Placebo Comparator|Placebo Multiple Ascending Dose|Successive cohorts of 12 participants (1-3 cohorts) will receive oral doses of MA-0211 or matching Placebo for 14 days.
89370123|NCT05168592|Experimental|Imaginal extinction|Conditioned fear will be diminished using imaginal extinction.
89370124|NCT01361373|Active Comparator|DOPAMINE|Sinemet up to 10 mg/kg/day
89370125|NCT01361373|Placebo Comparator|Placebo|placebo
89399215|NCT03695757|Experimental|Part B) Advanced solid tumor|Part B) Autologous total IgG 50mg will be administered to the patients with advanced solid tumor by intramuscular injection, twice a week for 4 weeks (total 8 injections).
89399216|NCT03687255|Experimental|cefepime/AAI101 combination|Cefepime 2 g in combination with AAI101 500 mg q8h (2 hour infusion)
88842813|NCT05028582|Active Comparator|ARQ-154 Foam 0.3%|ARQ-154 Foam 0.3%
88842814|NCT05028582|Placebo Comparator|ARQ-154 Vehicle|ARQ-154 Vehicle
88842815|NCT05010954|Experimental|LXI-15028 50mg group(n=200)|
88842816|NCT05010954|Active Comparator|Lansoprazole 30mg group (n=200)|
88842817|NCT05001724|Experimental|Cohort 1: KN046 plus Lenvatinib RP3D.|Experimental arm: Cohort 1: KN046 5mg/kg every 3 weeks + lenvatinib RP3D every day until progressive disease or unacceptable toxicity.
88842818|NCT05001724|Active Comparator|Docetaxel|Active Comparator: docetaxel 75 mg/m² every 3 weeks until progressive disease or unacceptable toxicity.
88842819|NCT05001022|Experimental|ALG-020572|Subcutaneous injections of ALG-020572 in HV or CHB subjects, up to 7 injections over the course of up to 29 days
88842820|NCT05001022|Placebo Comparator|Placebo|Subcutaneous injections of placebo in HV or CHB subjects, up to 7 injections over the course of up to 29 days
88842821|NCT04996368|Active Comparator|low dose (10mg/kg)|The dose of tranexamic acid varies widely ranging from 10mg/kg to 100mg/kg. We are comparing 10mg/kg to conventional 30mg/kg dose. The result of this study will help us to review our current practice.
88842822|NCT04996368|Active Comparator|high dose or conventional group (30mg/kg)|dose 30mg/kg regularly use in our center as a prophylaxis for prevention of bleeding before open heart surgery
88842823|NCT04994444|Experimental|Preloading|Participants will be started on nicotine patch 3 weeks prior to quit date. At quit date they will use patch and lozenge or gum for 8 weeks.
88842824|NCT04994444|Active Comparator|Standard treatment|Participants will start combination nicotine replacement therapy (patch/gum or patch/lozenge) on their assigned quit date. NRT will be provided for 8 weeks.
88842825|NCT04987892|Active Comparator|Prostatic Lift|Treatment with the UroLift System
88842826|NCT04987892|Active Comparator|Medication|Treatment with Tamsulosin HCl 0.4mg
88842827|NCT04986280||Single Arm|Arm 1 - All patients will undergo PET/CT with 18F-PSMA-1007
88842828|NCT05019222|Experimental|Arm 1) Sevoflurane group|Sevoflurane based inhalation anesthesia
88842829|NCT05019222|Active Comparator|Arm 2) Remimazolam group|Remimazolam based total intravenous anesthesia
88842830|NCT04985318||Registergroup|Patients with acquired Thrombotic Thrombocytopenic Purpura, who have been treated with caplacizumab (Cablivi®)
89370126|NCT03677336|Other|Group l: 1st cycle MVP/placebo OD|"2 cycles of controlled ovarian stimulation, dual triggering, oocyte retrieval (OR) and LPS, with an interval period of 2 to 12 months. The only difference of the second cycle being the other LPS study medication as compared to the first cycle.~1st cycle: Start on day of oocyte retrieval (OR) (=d1): Dydrogesterone Oral Tablet 10 mg 3 times daily + Placebo micronized vaginal progesterone 200 mg capsules 3 times daily, for 8 days.~2nd cycle: Start on day of oocyte retrieval (OR) (=day 1): 'Micronized Progesterone 200 mg intravaginal capsules 3 times daily + placebo 'Dydrogesterone Oral Tablet 10 mg 3 times daily, for 8 days."
88842831|NCT04966663|Experimental|Adjuvant chemo-immunotherapy therapy|"All participants will have blood taken for ctDNA testing.~A cycle is 21 days. Pemetrexed (for participants with non-squamous non-small cell lung cancer), intravenously (by vein) on Day 1 of Cycles 1-4, OR gemcitabine (for all other participants) on Days 1 and 8 of Cycles 1-4.~Cisplatin*, intravenously (by vein) on Day 1 of Cycles 1-4 Nivolumab, intravenously (by vein) on Day 1 of Cycles 1-4~*If cisplatin is not tolerated, carboplatin may be given instead"
88842832|NCT04966663|Other|Observation|"All participants will have blood taken for ctDNA testing.~Participants will be followed as per standard of care every 3 months."
88842833|NCT04960917|Experimental|eHealth literacy workshop|Community members from pre-existing municipality groups will participate in a workshop aimed to raise their ehealth literacy level.
88842834|NCT04957875||urgent endoscopy group|endoscopy <6h after admission
88842835|NCT04957875||early endoscopy group|endoscopy 6-24h after admission
88842836|NCT04927988|Other|Arm 1.|Using of Ringer's Lactated
88842837|NCT04922593|Experimental|LY03010 treatment group|"LY03010 (paliperidone palmitate) is a pharmaceutical equivalent drug product to the listed drug (LD) product INVEGA SUSTENNA. The chemical name is (±)-3-[2-[4-(6-fluoro-1,2-benzisoxazol-3yl)piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4oxo-4Hpyrido[1,2-a]pyrimidin-9-yl hexadecanoate. Its molecular formula is C39H57FN4O4 and its molecular weight is 664.89 g/mol.~LY03010 is white to off-white sterile aqueous extended-release suspension of paliperidone palmitate for IM injection. In LY03010 treatment group, all subjects will receive the first dose of 351 mg IM injection on Day 1 in the deltoid muscle, followed by five (5) monthly dosing of 156 mg IM injection in the gluteal muscle with the last dose on Day 141."
88842838|NCT04922593|Active Comparator|INVEGA SUSTENNA treatment group|"INVEGA SUSTENNA (234 mg, 156 mg) is manufactured by Janssen Pharmaceuticals, Inc and is commercially available. INVEGA SUSTENNA is provided in a prefilled syringe (cyclic-olefin-copolymer) with a plunger stopper and tip cap (bromobutyl rubber).~In SUSTENNA treatment group, all subjects will receive the first dose of 234 mg IM injection in the deltoid muscle on Day 1, and a second dose of 156 mg of IM injection in the deltoid muscle on Day 8, followed by five (5) monthly dosing of 156 mg IM injection in the gluteal muscle with the last dose on Day 148."
88842839|NCT04914000|Experimental|Self Help Materials|Participants will receive a smoking cessation booklet/pamphlet corresponding to their cancer type.
88842840|NCT04902950|Placebo Comparator|Group 1|The solution of saline will be placed into a sterile bowl in the operating area and three lap sponges will be placed in the solution at the beginning of the procedure. Group 1 will undergo application of three normal saline soaked lap sponges to the surgical site. The lap sponges will be removed after three minutes and measurements will be taken for the study.
88842841|NCT04902950|Experimental|Group 2|The solution of Tranexamic Acid (TXA) will be placed into a sterile bowl in the operating area and three lap sponges will be placed in the solution at the beginning of the procedure. Group 2 will undergo application of three (TXA) soaked lap sponges to the surgical site. The lap sponges will be removed after three minutes and measurements will be taken for the study.
88842842|NCT04889118|Experimental|Pembrolizumab+Lenvatinib|Participants receive pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years) PLUS lenvatinib 20 mg via oral capsule daily for up to at least 2 years.
88842843|NCT04889118|Active Comparator|Pembrolizumab+Placebo|Participants receive pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years) PLUS placebo for lenvatinib via oral capsule daily for up to at least 2 years.
88842844|NCT04844125|Experimental|SHR-1209|
88842845|NCT04844125|Placebo Comparator|SHR-1209 Placebo|
88842846|NCT04831138|Experimental|RCC Patients|Patients with locally advanced or metastatic renal cell carcinoma
88842847|NCT04820296|Experimental|Experimental group|Pregnant women in the experimental group will be given 4 sessions Solution-Oriented Approach program, starting at the 32th week of pregnancy. Pregnants in the experimental group will be administered the Wijma Birth Expectation/Experience Scale (W-DEQ-A) and Pregnancy Psychosocial Health Assessment Scale (PPHAS) before the intervention. After the program is completed, a training booklet will be provided for pregnant women and (W-DEQ-A) and PPHAS will be applied again. With pregnant women, 37-40. between gestational weeks, they will be contacted again, face-to-face interview method (W-DEQ-A) and PPHAS again will be evaluated. The pregnant women will inform the researcher by phone after the delivery and the researcher will visit the hospital within the first 24 hours after the delivery to evaluate the mothers' birth fear levels Scale (W-DEQ-B). At the end of the first postpartum week, the postnatal senses of security of the mothers will be evaluated by telephone follow-up counseling.
88842848|NCT04820296|No Intervention|Control group|Pregnant women in the control group will only receive routine care. Pregnant women in the control group will be administered the same scales simultaneously with the experimental group.
89399217|NCT03687255|Active Comparator|piperacillin/tazobactam|Piperacillin 4 g in combination with Tazobactan 500 mg q8h (2 hour infusion)
89399218|NCT03695523|Experimental|PLAY (PhysicaL ActivitY) Policy Intervention|The childcare physical activity policy will be adopted for 8 weeks within participating toddler and preschool classrooms of facilities allocated to the experimental group.
88842849|NCT04819971|Experimental|TTC|
88842850|NCT04800874|Experimental|Cohort 1|Subjects will receive 6 grams of BBP-418 once daily x 90 days, then 12 grams twice daily (BID, a least 8 hours apart) of BBP-418 daily until study completion.
88842851|NCT04800874|Experimental|Cohort 2|Subjects will receive 6 grams of BBP-418 twice daily (BID, at least 8 hours apart) x 90 days, then 12 grams BID of BBP-418 daily until study completion.
88842852|NCT04800874|Experimental|Cohort 3|Subjects will receive 12 grams of BBP-418 twice daily (BID, at least 8 hours apart) x 90 days, then 12 grams BID of BBP-418 daily until study completion.
88842853|NCT04785573|Active Comparator|Intervention group|Participants with metabolic disorders will be subjected to nutritional counsel and the intake of 1 soft gel capsule daily for a total of 3 months.
88842854|NCT04785573|No Intervention|Control group|Participants with metabolic disorders will be subjected to nutritional counsel for a total of 3 months.
88842855|NCT04782050|Experimental|Study arm|
88842856|NCT04772820|Other|Primary Aim|Brief Behavioral Activation coaching will be delivered by telephone and other remote technology by trained coaches. Over 10 sessions, the coaches will help people to find meaningful activities to decrease loneliness, increase physical activity and improve nutrition.
88842857|NCT04727632|Experimental|Treatment: all patients|One session of [18F]FES PET/CT Imaging
88842858|NCT04724148|Experimental|Injecting 1~2mg/kg fentanyl intravenously.|"Measuring HVPG after the preparation of TIPS in patients with portal hypertension;~Measuring HVPG again 5 minutes later after injecting 1~2mg/kg fentanyl intravenously."
88842859|NCT04716244||Gestational diabetes|Women who were diagnosed with gestational diabetes within the least year
88842860|NCT04716244||Pre-eclampsia|Women who were diagnosed with pre-eclampsia within the past year
88842861|NCT04712214|Experimental|Patients with brain tumours candidate for neurosurgery|Patients will be recruited following the inclusion criteria: any patient with a diagnosis of brain tumour, age ranging from 18 with no upper limit, who will agree to the operation and to take part of the present study, will be enrolled. During surgery, multispectral and/or hyper spectral acquisition of images from the surgical field will be performed. Each patient will have an average acquisition of 6 datasets. As each dataset will correspond to an image, this will be divided into many reading regions (from 10 to 20) for a total of approximatively 60 measurements per patient.
88842862|NCT04703803|Experimental|1% lidocaine injection|The intervention group will be submitted to the trigger point injection procedure with 1% lidocaine (the sum of all needled trigger points will have a maximum of 10 ml), in a single intervention
88842863|NCT04703803|No Intervention|Control Group|The control group will receive usual care, defined as the treatment for pain prescribed by their assistant doctors.
88842864|NCT04693221|Sham Comparator|Control|VNS therapy with randomly-set combination of parameters (similar to current practice)
88842865|NCT04693221|Experimental|Experimental|VNS therapy with set combination of parameters chosen based on the lowest phase lag index
88842866|NCT04686383|Experimental|Cohort 1: 20 mg CAL056 mesylate|Patients will receive oral dose of 20 mg CAL056 mesylate once daily under fasting condition in the morning for 28 days during each cycle.
88842867|NCT04686383|Experimental|Cohort 2: 40 mg CAL056 mesylate|Patients will receive oral dose of 40 mg CAL056 mesylate once daily under fasting condition in the morning for 28 days during each cycle.
88842868|NCT04686383|Experimental|Cohort 3: 80 mg CAL056 mesylate|Patients will receive oral dose of 80 mg CAL056 mesylate once daily under fasting condition in the morning for 28 days during each cycle.
88842869|NCT04686383|Experimental|Cohort 4: 120 mg CAL056 mesylate|Patients will receive oral dose of 120 mg CAL056 mesylate once daily under fasting condition in the morning for 28 days during each cycle.
88842870|NCT04686383|Experimental|Cohort 5: 160 mg CAL056 mesylate|Patients will receive oral dose of 160 mg CAL056 mesylate once daily under fasting condition in the morning for 28 days during each cycle.
88842871|NCT04670978|Experimental|albumin-bound paclitaxe combined with bevacizumab biosimilar|albumin-bound paclitaxel, 260mg/m2，ivdrip，D1，once every three weeks bevacizumab biosimilar, 10mg/kg，ivdrip，D1, once every three weeks
88842872|NCT04657835|Experimental|Coronary Artery Bypass Grafting|"Patient with indication of Coronary Artery Bypass Grafting will be included. They will have:~before surgery : cardiac Magnetic Resonance Imaging (MRI), Blood sample~during surgery : Cardiac muscle biopsy~after surgery : Holter-electrocardiogram (ECG), medical examination"
88842873|NCT04639323||Overall eligible participants|Eligible participants whose varix size will be measured by endoscopists and endoscopic ruler will receive standard esophagogastroduodenoscopy
88842874|NCT04639206|Experimental|HOBSCOTCH group|Participants in this study arm will receive the HOBSCOTCH intervention immediately.
88842875|NCT04639206|No Intervention|Wait-listed control|Participants in this study arm will be wait-listed for 6 months and will then receive the HOBSCOTCH intervention.
88842876|NCT04639180|Experimental|Treatment group (Camrelizumab Plus Rivoceranib (Apatinib))|Drug: Camrelizumab; Drug: Rivoceranib (Apatinib)
89534817|NCT03327389|Experimental|Dexmedetomidine (Group D)|Dexmedetomidine infusion during surgery Dexmedetomidine was infused at a rate of 0.4 μg/kg/h starting immediately after anesthetic induction and continued until skin closure
89534818|NCT03327389|Placebo Comparator|Control (Group C)|0.9% NaCl infusion during surgery 0.9% NaCl was infused at a rate of 0.4 μg/kg/h starting immediately after anesthetic induction and continued until skin closure
88842877|NCT04639180|No Intervention|Control group (Active surveillance)|
88842878|NCT04611698|Experimental|Immediate loading group|Visit 1 Implant surgery + Device loading Baseline Visit 2 Followup examination 2 weeks (2/+ 5 days) Visit 3 Followup examination 3 months (± 1 week) Visit 4 Followup examination 6 months (± 1 week) Visit 5 Followup examination 12 months (± 1 month)
88842879|NCT04611698|Experimental|2-week loading group|Visit 1 Implant surgery Baseline Visit 2 Device loading 2 weeks (2/+5 days) Visit 3 Followup examination 3 months (± 1 week) Visit 4 Followup examination 6 months (± 1 week) Visit 5 Followup examination 12 months (± 1 month)
88842880|NCT04607486||CVA and spasticity|Adults with first-ever chronic CVA and leg spasticity
88842881|NCT04607486||CVA without spasticity|Control group
88842882|NCT04607486||healthy subjects|Control group
88875251|NCT02546388|Experimental|Gallium-68 DOTATATE|Patients with biopsy-proven extra-cardiac sarcoidosis OR atypical findings on FDG PET and MRI without previous biopsy will be recruited to receive an injection of the FDA-approved radiotracer Gallium-68 DOTATATE. The imaging protocol will consist of imaging 1 hour after injection for DOTATATE.
89370127|NCT03677336|Other|Group ll: 1st cycle placebo MVP/OD|"2 cycles of controlled ovarian stimulation, dual triggering, oocyte retrieval (OR) and LPS, with an interval period of 2 to 12 months. The only difference of the second cycle being the other LPS study medication as compared to the first cycle.~1st cycle: Start on day of oocyte retrieval (OR) (=day 1): Micronized Progesterone 200 mg intravaginal capsules 3 times daily + placebo Dydrogesterone Oral Tablet 10 mg 3 times daily, for 8 days.~2nd cycle: Start on day of oocyte retrieval (OR) (=day 1): Dydrogesterone Oral Tablet 10 mg 3 times daily + Placebo micronized progesterone 200 mg intravaginal capsules 3 times daily, for 8 days."
89370128|NCT03634995|Experimental|Single Dose|Ascending single doses of BMS-986256
89370129|NCT03634995|Experimental|Multiple Dose|Ascending multiple doses of BMS-986256
89370130|NCT03634995|Experimental|Sequential Dose|Sequential multiple doses of BMS-986256
89370131|NCT01559805|Experimental|Positive Choices|A two-session, individually-focused intervention focusing on engagement in care, disclosure decision-making, and sexual risk reduction, with booster sessions after 1, 3 and 6 months.
89370132|NCT01559805|Active Comparator|Personalized Cognitive Counseling|A one-session, individually-focused risk reduction intervention for MSM that has been selected by the CDC as a DEBI.
89370133|NCT02877927|Experimental|Omadacycline|Omadacycline tablets
89370134|NCT02877927|Active Comparator|Linezolid|Linezolid tablets
89370135|NCT02706886|Placebo Comparator|Part A: SAD: Placebo|A single dose of matching placebo will be administered subcutaneously (SC).
89370136|NCT02706886|Experimental|Part A: SAD: Lumasiran 0.3 mg/kg|A single dose of 0.3 mg/kg lumasiran will be administered SC.
89370137|NCT02706886|Experimental|Part A: SAD: Lumasiran 1.0 mg/kg|A single dose of 1.0 mg/kg lumasiran will be administered SC.
89370138|NCT02706886|Experimental|Part A: SAD: Lumasiran 3.0 mg/kg|A single dose of 3.0 mg/kg lumasiran will be administered SC.
89370139|NCT02706886|Experimental|Part A: SAD: Lumasiran 6.0 mg/kg|A single dose of 6.0 mg/kg lumasiran will be administered SC.
89370140|NCT02706886|Placebo Comparator|Part B: MAD: Placebo|Participants with primary hyperoxaluria type 1 (PH1) will be treated with placebo matching one of the lumasiran dosages in the lumasiran arms (one placebo participant for each lumasiran arm). At Day 85 these placebo treated participants will cross over to their respective Part B lumasiran arms in the Part B: MAD Study Day 85-End of Study Period and will then be treated with lumasiran. The estimated total time on study was up to 546 days.
88842883|NCT04570722|Other|Single arm study|Patients with a history of axillary surgical lymph node procedures (SLNP) presenting for routine radiographic scan will complete baseline measures: bilateral volumetric measurements and self-reported symptoms. Patients will undergo SOC contralateral arm intravenous access attempt. After one failed attempt, ipsilateral intravenous access instead of pedal or neck access will be offered per research protocol. Nursing documentation will reflect the failed venipuncture and categorize a reason for the failed attempt.
88842884|NCT04546360||Overall eligible participants|Eligible participants will receive standard esophagogasrtoduodendoscopy, spleen stiffness measurement and liver stiffness measurement based on two-dimensional shear wave elastography, gallbladder wall thickness, spleen thickness, spleen long diameter and serological examination (platelet count, alanine aminotransferase, aspartate aminotransferase, total bilirubin, creatinine, albumin, prothrombin time, international normalized ratio).
88842885|NCT04531943||TGWSM Using Estrogen|Cohort 1 participants are in the cross-sectional study and will attend two study visits, participating in study activities for up to 12 weeks. Blood samples and rectal mucosal samples will be obtained. This group of participants in Cohort 1 consists of TGWSM currently using feminizing hormone therapy consisting of only estrogen.
88875252|NCT02547012|Experimental|esomeprazole+amox+levo+tetra|esomeprazole 40 mg b.d., amoxicillin 500 mg q.d.s., levofloxacin 500 mg o.d., and tetracycline 500 mg q.d.s.
89370141|NCT02706886|Experimental|Part B: MAD: Lumasiran 1.0 mg/kg qM|Participants with PH1 will be treated with 1.0 mg/kg lumasiran SC once monthly (qM) on Days 1, 29 and 57. The estimated total time on study is up to 546 days. One participant from the Part B: MAD: Placebo arm will cross over to this lumasiran arm at Day 85. For this participant treatment with lumasiran starts at Day 85.
89370142|NCT02706886|Experimental|Part B: MAD: Lumasiran 3.0 mg/kg qM|Participants with PH1 will be treated with 3.0 mg/kg lumasiran SC qM on Days 1, 29 and 57. The estimated total time on study is up to 546 days. One participant from the Part B: MAD: Placebo arm will cross over to this lumasiran arm at Day 85. For this participant treatment with lumasiran starts at Day 85.
89399219|NCT03695523|No Intervention|Control group|Childcare centres will maintain their typical daily programming and standard of care for the duration of the 8-week intervention period.
89399220|NCT03687177|Other|Control group|Nurses from intensive care informed on the prevention of VAP and without visual cue to estimate the angle of elevation of the head of intubated patients
88842886|NCT04531943||TGWSM Using Estrogen plus Progesterone|Cohort 1 participants are in the cross-sectional study and will attend two study visits, participating in study activities for up to 12 weeks. Blood samples and rectal mucosal samples will be obtained. This group of participants in Cohort 1 consists of TGWSM currently using feminizing hormone therapy consisting of estrogen and progesterone.
89370143|NCT02706886|Experimental|Part B: MAD: Lumasiran 3.0 mg/kg q3M|Participants with PH1 will be treated with 3.0 mg/kg lumasiran SC once every three months (q3M) on Days 1 and 85. The estimated total time on study is up to 546 days. One participant from the Part B: MAD: Placebo arm will cross over to this lumasiran arm at Day 85. For this participant treatment with lumasiran starts at Day 85.
89370144|NCT01357707||West Syndrome (idiopathic)|Patients with idiopathic infantile seizures
88842887|NCT04531943||Cisgender MSM|Cohort 1 participants are in the cross-sectional study and will attend two study visits, participating in study activities for up to 12 weeks. Blood samples and rectal mucosal samples will be obtained. This group of participants in Cohort 1 consists of cisgender MSM.
88842888|NCT04531943||TGWSM Initiating Feminizing Hormone Therapy|Cohort 2 participants are in the longitudinal portion of the study and are TGWSM who are planning to initiate feminizing hormone therapy. Individuals in Cohort 2 will participate in study activities for 18 months.
88842889|NCT04530825|No Intervention|Providers|"All eligible providers will be sent questionnaires electronically to their email at baseline and follow-up. Providers will be invited to attend a training session to educate them on the PREVENT tool at baseline~A subset of 5-10 providers will be recruited via email, at the baseline training,or by using snowball-sampling approach within the clinic to participate in qualitative in-depth interviews"
88842890|NCT04530825|No Intervention|Parents|-Semi-structured interviews
88842891|NCT04530825|Active Comparator|Patients - Wait-List Control|"Complete questionnaires at baseline (administered electronically or by mail; accelerometers administered by mail). Following baseline measurement, patients will be randomized and attend their clinic visit. Follow-up measures will be administered immediately following the clinic visit (within 48 hours) and 3-months after the clinic visit electronically and by mail~Up to 10 patients will also take part in semi-structured interviews~A PREVENT action plan (behavior change prescription, community resources, and education) will be provided to the patient via email after the completion of the follow-up measurement."
88842892|NCT04530825|Experimental|Patients - PREVENT tool|"Complete questionnaires at baseline (administered electronically or by mail; accelerometers administered by mail). Following baseline measurement, patients will be randomized and attend their clinic visit. Follow-up measures will be administered immediately following the clinic visit (within 48 hours) and 3-months after the clinic visit electronically and by mail~Up to 10 patients will also take part in semi-structured interviews~At the clinic visit, the provider will use PREVENT tool to discuss risk and deliver a tailored behavioral change plan inclusive of patient-centered community resources. PREVENT will calculate patient's overall risk for developing cardiovascular disease. Physical activity and food intake recommendations are tailored to current weight status and health behaviors using evidence-based recommendations."
88842893|NCT04517565|Experimental|Patients with SWS or high-risk facial port-wine birthmark|All patients with SWS brain involvement (based on previous imaging) or facial port-wine birthmark indicating a high risk for SWS brain involvement will undergo a brain MRI and neuro-psychology testing.
88842894|NCT04516850||Patients tested for COVID-19|The nasopharyngeal swabs taken from patients tested for Covid-19 who resulted infected and non-infected will be analyzed to evaluate the expression of receptors and activating proteases mediating SARS-CoV-2.
88842895|NCT04516850||Patients with mild-moderate and severe SARS-CoV-2 infection|Formalin-fixed paraffin will be analysed to determine the association between polymorphism of the HSD3B1 gene and outcomes in COVID-19 affected patients
88842896|NCT04504383|Experimental|PN-943 450 mg BID|Oral administration of PN-943 450 mg BID
88842897|NCT04504383|Experimental|PN-943 150 mg BID|Oral administration of PN-943 150 mg BID
88842898|NCT04504383|Placebo Comparator|Placebo BID|Oral administration of matching placebo
88842899|NCT04503460|Experimental|Single treatment arm|"All participants who are deemed eligible for inclusion in the study following screening will be enrolled into a single experimental arm which will comprise the following sequential stages:~Baseline sampling; participants only use 'as required' ipratropium bromide when needed (1 week)~Salmeterol xinafoate monotherapy 50 μg twice in the morning and twice in the evening + 'as required' ipratropium bromide when needed (2 weeks)~Washout period; participants only use 'as required' ipratropium bromide when needed (2 weeks)~Salmeterol xinafoate 50 μg / fluticasone propionate 250 μg combination therapy twice in the morning and twice in the evening + 'as required' ipratropium bromide when needed (2 weeks)"
88842900|NCT04500977|Experimental|Training community health promotion leaderss|Community women are trained in leadership and community-based health promotion skills
88875253|NCT02547012|Active Comparator|esomeprazole+amox+levo|esomeprazole 40 mg b.d., amoxicillin 500 mg q.d.s., and levofloxacin 500 mg o.d.
88875254|NCT02547714|Experimental|Secukinumab (AIN457) 300 mg|Participants received secukinumab 300 mg subcutaneously (s.c.) (two 150 mg injections) on Day 1 and at Weeks 1, 2, 3, 4, 8 and 12.
89370145|NCT01318239|Experimental|Standard Chemotherapy with Avastin|
89370146|NCT01318239|Active Comparator|Standard Chemotherapy only|
89399221|NCT03687177|Other|Experimental group|Nurses from intensive care informed on the prevention of VAP with visual cue to estimate the angle of elevation of the head of intubated patients.
89370147|NCT03116932||Part A - high risk MSM|"Part A will consist of a descriptive analysis of the acceptability and knowledge on the topic of PrEP of the individuals that undergo routine HIV testing and counseling in study facilities or through outreach activities.~Part A will be focused only on high risk MSM. For this part of the study, 225 high risk will be interviewed to understand the knowledge and acceptability of PrEP in this population in Puerto Rico."
89370148|NCT01357863||Patients on second line treatment|Patients treated with Lapatinib-capecitabine immediately after first Trastuzumab-containing regimen progression
89370149|NCT01357863||Patients on third or more lines treatment|Patients treated with Lapatinib-capecitabine after 2 or more lines of treatment after first Trastuzumab-containing regimen progression
89370150|NCT02809131|Experimental|Saline irrigation|Saline irrigation
89370151|NCT02809131|Active Comparator|Antibiotic irrigation and PO antibiotics|Antibacterial irrigant (polymyxinB/bacitracin) and postoperative oral antibiotics (cephalexin, clindamycin, or levofloxacin)
89370152|NCT05046054|Active Comparator|transcutaneous electrical nerve stimulation group|Transcutaneous electrical nerve stimulation was givent via two electrodes on the venous cannulation site 20 min before propofol injection
89370153|NCT05046054|Placebo Comparator|control group|No transcutaneous electrical nerve stimulation was not given via two electrodes on the venous cannulation site 20 min before propofol injection
89370154|NCT01354509||Current protocol group|Patients treated with current standards based on physician discretion.
88842902|NCT04436198|Experimental|Treatment group: toric IOL plus capsular tension ring|
88842903|NCT04436198|Active Comparator|Control group: toric IOL only|
88842904|NCT04397419|Experimental|Intervention group|This group is administered a total of 750 ml Red Bull® Energy Drink at defined time-intervals.
88842905|NCT04397419|Placebo Comparator|Placebo group|This group is administered a total of 750 ml still water at defined time-intervals.
88842906|NCT04395196|Active Comparator|High-dose choline supplementation|2 g choline cation
89370155|NCT01354509||Normothermia group|Normothermia protocol, using Hydrogel cooling Pads(Arctic Sun) applied for 96 hrs starting upon admission to the ICU
89370156|NCT03633318||IBM Group|Participants in this arm will have Inclusion Body Myositis (IBM). All patients will have EIM measurements of selected muscles.
89370157|NCT03633318||Control Group|Participants in this arm will be healthy controls. All participants will have EIM measurements of selected muscles.
88842907|NCT04395196|Placebo Comparator|Placebo|Placebo identical to active treatment in appearance, taste, and smell.
88842908|NCT04371900|Experimental|Experimental Group|Mothers randomized to receive a voucher to be used at Planned Parenthood to cover the cost of contraceptives
88842909|NCT04371900|No Intervention|Control Group|Mothers randomized to NOT receive a voucher. Mothers in this arm receive the Planned Parenthood standard of care priced according to the Planned Parenthood sliding scale.
88842910|NCT04371783|Other|Immediate FET group|FET will be performed in the first menstrual cycle following the stimulated IVF cycle
88842911|NCT04371783|Other|Delayed FET group|FET will be performed in the second menstrual cycle following the stimulated IVF cycle
88842912|NCT04368104||Group A|women using any form of minipills
88842913|NCT04368104||Group B|women subjected to office hysteroscopy for different indications but not using any form of hormones or systemic or local hormonal contraception.
89370158|NCT01357941||Prior VTE minor transient risk factor|Pregnant women with a single prior VTE episode that was either unprovoked or associated with a minor transient risk factor - Prophylaxis with fixed-dose LMWH
89370159|NCT01357941||Prior VTE major transient risk factor|Pregnant women with a single prior VTE episode that was provoked by a major transient risk factor - Surveillance
89370160|NCT05009628|Experimental|automated oxygenation with a sitting patient position in the ICU|
89370161|NCT05009628|No Intervention|controlled oxygenation with a lying patient position in the ICU|
89370162|NCT05009628|Experimental|automated oxygenation with the patient lying down in the ICU|
89370163|NCT05009628|Experimental|control oxygenation with the patient in a sitting position in the ICU|
89370164|NCT02784951||Single group|Patients in haemorrhagic shock needing volume replacement and receiving prehospital transfusion of blood products, either red blood cells (RBC), freeze dried plasma (FDP) or whole blood (WB).
89370165|NCT05002062|Sham Comparator|G1 ( Conventional Physical Therapy Program group)|"Patients in G1 underwent conventional physical therapy program continued for 3 months, included (aerobic training 20 minutes, resistive training for 15 minutes and flexibility program for 15 minutes).~The whole treatment session lasted from 50 minutes to one hour, 3 times per week for 3 consecutive months."
89370166|NCT05002062|Active Comparator|G2 ( Computer-based Cognitive Therapy group)|"Patients in G2 underwent Computer-based cognitive training continued for 3 months, included (attention/concentration, memory and reaction behavior training).~The whole treatment session timing lasted 50 minutes to one hour, 3 times per week for 3 consecutive months."
89370167|NCT01442649|Experimental|Arm A : bevacizumab + fluoropyrimidine-based chemotherapy|"Every 2 weeks :~- mFOLFOX6 : Oxaliplatin 85 mg/m2 over 120 mn IV on D1, Folinic Acide 400 mg/m² (racemic) (or 200 mg/m² if L-folinic acid) over 2 h IV on D1, 5-fluoro-uracil 400 mg/m² in bolus IV on D1 and 5-fluoro-uracil 2400 mg/m² in infusion IV over 46 h.~OR~- FOLFIRI : Irinotecan 180 mg/m2 en 90 mn IV on day D1, Folinic acid 400 mg/m² (racemic) (or 200 mg/m² if L-folinic acid) over 2 h IV on D1, 5-fluoro-uracil 400 mg/m² in bolus IV on D1 and 5-fluoro-uracil 2400 mg/m² in infusion IV over 46 h.~AND~Bevacizumab 5 mg/kg IV every 2 weeks."
89399222|NCT03691545|Experimental|Intervention Group|(1) 12 weekly interactive sessions with a health coach to help them set goals and make changes toward becoming physically active and consuming the recommended number of fruits and vegetables.
89399223|NCT03691467|Experimental|immediate implant with hyaluronic acid.|immediate dental implant with topical application of hyaluronic acid.
88842914|NCT04702568|Experimental|BCX9930|Intervention: Drug: BCX9930
89180312|NCT00734994|Experimental|Hyperthermia system, Mitomycin C|Pilot study single arm study to test the safety, tolerability and clinical benefit of regional hyperthermia and mitomycin-C intravesical chemotherapy to treat non-invasive Transitional Cell carcinoma (TCC) of the bladder that has recurred after standard resection and adjuvant therapy.
88842915|NCT04307264||Overall eligible participants|Eligible participants will receive standard esophagogasrtoduodendoscopy, liver stiffness measurement and serological examination (platelet count, alanine aminotransferase, aspartate aminotransferase, total bilirubin, Prothrombin time, albumin).
88842916|NCT04297189|Experimental|Coaching Intervention|Single arm pilot study of coaching intervention
88842917|NCT04294381|Experimental|pilot of SMART-goal-setting health behavior decision tool|participants will be asked to use a decision tool to choose and delineate SMART health behavior goals
88842918|NCT04287283||HBOT|Patients with chronic brain injury or cognitive complaints that have been treated with Hyperbaric oxygen therapy and underwent computerized cognitive tests before and after the treatment
88842919|NCT04283786||General Practitioner|General Practitioners working within primary care in the UK
88842920|NCT04283786||Primary Care Patients|Patients cared for in primary care who started on oral bisphosphonates within the last 24 months for prevention of fragility fractures
88842921|NCT04283786||Secondary Care Clinicians|Clinicians working in secondary care as specialists (e.g. nurses, consultants) involved in the treatment of osteoporosis
88842922|NCT04283786||Secondary Care Patients|Patients cared for in secondary care receiving hospital based (intravenous) bisphosphonate treatments for prevention of fragility fractures who began treatment within the last 24 months
88842923|NCT04283786||Clinical Academics|Clinical academics involved in osteoporosis research
89180313|NCT02593734|No Intervention|Control|No intervention
89180314|NCT02593734|Experimental|Experimental|The intervention is prescription and dispensing by a nurse of oral antipsychotic or antidepressant medication as clinically indicated. The mediations to be selected from include oral olanzapine, risperidone, amitryptaline or fluoxetine at doses prescribed by the treating psychiatrist.
89180315|NCT04088526|Experimental|intervention group|Through the effective intervention of risk factors for death in patients with dialysis, the effect of mortality of peri-dialysis patients was observed.
89399224|NCT03691467|Active Comparator|immediate implant.|immediate dental implant placement with placebo gel
88842924|NCT04283786||Secondary Care Clinicians - Novel Care|Clinicians working in secondary care as specialists (e.g. nurses, consultants) from the osteoporosis service in Nottingham and Sheffield with insight into alternate bisphosphonate treatments
88842925|NCT04283786||Secondary Care Patients - Novel Care|Patients cared for in secondary care receiving alternative bisphosphonate treatments for prevention of fragility fractures who began treatment within the last 24 months at the osteoporosis service in Nottingham or Sheffield
88842926|NCT04283786||Commissioners|Commissioners involved in osteoporosis services
88842927|NCT04259710|Placebo Comparator|Pedometer only|participants will be given a pedometer and instructed how to use it, but will not participate in the goal setting intervention.
88842928|NCT04259710|Active Comparator|Pedometer and intervention|participants will be given a pedometer and participate in a weekly goal setting meeting with the investigator and will receive weekly tips.
89399226|NCT03695289|Experimental|iOTA-SMI|Participants randomized to iOTA-SMI arm will participate in a 16 week interactive obesity treatment approach (iOTA) program approach.
89399227|NCT03695289|Active Comparator|Health Education Control|Participants randomized to the Health Education Control arm will receive monthly in-person health coaching visits for 16 weeks.
89399228|NCT02165540|Experimental|Doula|Patients will have a doula support person during their procedure.
88842929|NCT04259710|Experimental|Pedometer, intervention and implementation intentions|participants will be given a pedometer and participate in the weekly goal setting as above. In addition, 3 times during the intervention they will fill out a form that encourages performance of implementation intentions.
88842930|NCT04228549|No Intervention|Control|Usual care
88875255|NCT02548728|Experimental|Oxytocin|Self administration three times on the first day, then twice daily treatment with intranasal oxytocin spray for 4 days.
89399229|NCT02165540|No Intervention|Routine care/No Doula|Patients will have routine care with clinical staff only.
89399230|NCT02165618|No Intervention|GCT|In a before phase, data on how the GCT operated (i.e. good clinical practice) was gathered.
89399231|NCT02165618|Active Comparator|GCT-RASP|Medication review, based on but not limited to the RASP list
89399232|NCT02165696|Experimental|Manual lymphatic drainage and compression bandaging|Experimental group: 30 minutes and one hour maximum time of manual lymphatic drainage and compression bandaging with multilayer inelastic bandages with low extensibility. It is possible to apply bandages two or three times per week. Also, an elastic bandage is also held in hand fingers with slight compression and other protective bandage is used in skin. The treatment will be carried out for six weeks five days a week
89399233|NCT02165696|Active Comparator|Manual lymphatic drainage|Control group: 30 minutes and one hour maximum time of manual lymphatic drainage. The treatment will be carried out for six weeks five days a week.
89370168|NCT01442649|Experimental|Arm B : cetuximab + fluoropyrimidine-based chemotherapy|"Every 2 weeks :~- mFOLFOX6 : Oxaliplatin 85 mg/m2 over 120 mn IV on D1, Folinic Acide 400 mg/m² (racemic) (or 200 mg/m² if L-folinic acid) over 2 h IV on D1, 5-fluoro-uracil 400 mg/m² in bolus IV on D1 and 5-fluoro-uracil 2400 mg/m² in infusion IV over 46 h.~OR~- FOLFIRI : Irinotecan 180 mg/m2 en 90 mn IV on day D1, Folinic acid 400 mg/m² (racemic) (or 200 mg/m² if L-folinic acid) over 2 h IV on D1, 5-fluoro-uracil 400 mg/m² in bolus IV on D1 and 5-fluoro-uracil 2400 mg/m² in infusion IV over 46 h.~AND~Cetuximab : 500 mg/m² IV every 2 weeks"
88842931|NCT04228549|Experimental|MyPADMGT|Online access to system, with ability to record and study progress with social interaction, diet, physical activity, smoking cessation, blood glucose, blood pressure and weight. Also access to educational content, journal recording, communication to others, setting target levels, contact support as needed.
88842932|NCT04228549|Experimental|MyPADMGT + Nudging|Online access to system, with ability to record and study progress with social interaction, diet, physical activity, smoking cessation, blood glucose, blood pressure and weight. Also access to educational content, journal recording, communication to others, setting target levels, contact support as needed. In addition, nudging support available to help patients make better choices and decisions.
88842933|NCT04169373|Experimental|Study 1: Upadacitinib 15 mg|Participants receive 15 mg upadacitinib orally once a day for 104 weeks. Participants who flare after 104 weeks will receive open-label upadacitinib once daily from the time of flare for 24 weeks (re-treatment).
88842934|NCT04169373|Placebo Comparator|Study 1: Placebo|Participants receive matching placebo for 14 weeks and then switch to receive 15 mg upadacitinib orally once a day for 90 weeks. Participants who flare after 104 weeks will receive open-label upadacitinib once daily from the time of flare for 24 weeks (re-treatment).
88842935|NCT04169373|Experimental|Study 2: Upadacitinib 15 mg|Participants receive 15 mg upadacitinib orally once a day for 104 weeks. Participants who flare after 104 weeks will receive open-label upadacitinib once daily from the time of flare for 24 weeks (re-treatment).
88842936|NCT04169373|Placebo Comparator|Study 2: Placebo|Participants receive matching placebo for 52 weeks and then switch to receive 15 mg upadacitinib orally once a day for 52 weeks. Participants who flare after 104 weeks will receive open-label upadacitinib once daily from the time of flare for 24 weeks (re-treatment).
88842937|NCT04154930|Experimental|Restylane-L Treatment|Restylane-L® injected with optional touch-up at 1 month and optional retreatment at 12 months.
88842938|NCT04154930|No Intervention|No Treatment Control|No treatment control with optional treatment at 12 months.
88842939|NCT04150042|Experimental|Chemotherapy/stem cell treatment|
88842940|NCT04124471|Other|Participants treated with PAP|This is a qualitative study for participants with Down Syndrome who use PAP to treat obstructive sleep apnea syndrome.
88842941|NCT04121520||Observational|At time of consent and within the same day of HVPG measurement, participants will be asked to complete a pre-operative assessment. Relevant statistics will be recorded during the HVPG procedure. Post-operative complication will also be collected and the satisfaction survey will be conducted.
88842942|NCT04093024|Experimental|Double-blind period (DBP) + open-label Nintedanib period (OLNP): Randomised Nintedanib|"This arm shows Nintedanib randomised participants treated orally with Nintedanib in the DBP and OLNP twice daily with a dose interval of approximately 12 hours from one dose to the next dose.~Medication dosage was per administration 50 milligram (mg) [2 capsules with strength 25 mg],75 mg [3 capsules with strength 25 mg], 100 mg [1 capsule with strength 100 mg or 4 capsules with strength 25 mg] or 150 mg [1 capsule with strength 150 mg or 6 capsules with strength 25 mg] based on the participant's weight at baseline (= 0 weeks). The dosage was adjusted at subsequent visits if the participant's weight had changed.~In this arm participants received Nintedanib in both periods (DBP + OLNP). Participants in this arm do not entail participants from the 'randomised to placebo' arms.~DBP: Planned was from first randomised trial drug intake to last blinded drug intake.~OLNP: Planned was from first open-label Nintedanib intake to last open-label Nintedanib intake."
88842943|NCT04093024|Placebo Comparator|DBP+OLNP: Randomised placebo|"Placebo randomised participants were treated orally with a Nintedanib matching placebo soft capsule twice daily in the double-blind period (DBP).~Participants who continued with the open-label Nintedanib period (OLNP) after the DBP switched to active Nintedanib treatment in the OLNP and were treated orally with Nintedanib twice daily.~Medication dosage was per administration 50 milligram (mg) [2 25 mg capsules (cap)],75 mg [3 25 mg cap], 100 mg [1 100 mg or 4 25 mg cap] or 150 mg [1 150 mg or 6 25 mg cap] based on the participant's weight at baseline (= 0 weeks). The dosage was adjusted at subsequent visits if the participant's weight had changed.~The dose interval was approximately 12 hours between one and the next dose.~Here participants received placebo first (DBP) and then Nintedanib (OLNP). DBP: Planned was from first to last randomised blinded drug intake. OLNP: Planned was from first to last open-label Nintedanib intake."
88842944|NCT04091503|Active Comparator|Intranasal Modified Temozolomide 75 mg/M2 per day|75 mg/M2 per day Intranasal Modified Temozolomide administration of within 5 days per week (max: 30 days)
88842945|NCT04091503|Active Comparator|Intranasal Modified Temozolomide 150 mg/M2 per day|150 mg/M2 per day Intranasal Modified Temozolomide administration of within 5 days per week (max: 30 days)
88842946|NCT04091503|Active Comparator|Intranasal Modified Temozolomide 200 mg/M2 per day|200 mg/M2 per day Intranasal Modified Temozolomide administration of within 5 days per week (max: 30 days)
88842947|NCT04085406|Experimental|Active Stimulation|Patients will be randomized in a 1:1 ratio to one of two groups: Active Treatment (active stimulation programmed to the settings found to be optimal during the initial open-label period) and a Control Group (sham stimulation - IPG is set to ON but the voltage is set to 0V).
88842948|NCT04085406|Sham Comparator|Sham Stimulation|Patients will be randomized in a 1:1 ratio to one of two groups: Active Treatment (active stimulation programmed to the settings found to be optimal during the initial open-label phase) and a Control Group (sham stimulation - IPG is set to ON but the voltage is set to 0V).
88842949|NCT04067752|Experimental|High Dialysate Na|high dialysate sodium concentration (138 mEq/L)
89370169|NCT05199792||2x dose of Dotarem|qualifying MRA
89370170|NCT01354587|Active Comparator|Hizentra|Compare IgG levels and site reaction in subjects transitioning from Vivaglobin to Hizentra
89399234|NCT03539588|Active Comparator|Treatment group 1|In this group participants will receive trigger point dry needling with electrical stimulation first and receive trigger point needling by itself second. Only MYOTECH dry needles will be used in this study. However we are not studying the equipment.
88842950|NCT04067752|Active Comparator|Low Dialysate Na|Low dialysate sodium concentration (132 mEq/L)
88842951|NCT04052841|Experimental|MGD-thermal pulsation group|A 12 minutes LIPIFLOW treatment was performed.
88842952|NCT04052841|Experimental|MGD-IPL group|IPL was performed every 3 weeks，3 times in total (0, 3w, 6w).
88842953|NCT04052841|Experimental|MGD-manual warm compresses|Manual warm compresses were performed every 2 weeks，5 times in total (0, 2w, 4w, 6w, 8w).
88842954|NCT04052841|No Intervention|Normal health subject group|Normal health subject without intervention.
88842955|NCT04048941|Experimental|Verum Acupuncture with Movement|Verum acupuncture along radial side of 2nd metacarpal, following by active movement of previously painful body part x 10 minutes.
88842956|NCT04048941|Active Comparator|Verum Acupuncture without Movement|Verum acupuncture along radial side of 2nd metacarpal, following by laying on examination table x 10 minutes.
88842957|NCT04048941|Sham Comparator|Control Acupuncture with Movement|Sham/control acupuncture at acupoint LI4, following by active movement of previously painful body part x 10 minutes.
88842958|NCT04014790|Experimental|RGI-2001|Subjects will be administered RGI 2001 in combination with standard of care treatment
88842959|NCT04009031|Experimental|Bootle Blast|"Bootle Blast is a series of 13 mini-games targeting different upper limb motor therapy goals. Bootle Blast is designed with many of the features of mainstream video games known to be appealing to young people. Game rewards are linked to meeting therapeutic objectives, such as daily play targets that are customizable to each child. Bootle Blast is played through movements of the upper limbs tracked via a low-cost camera/sensor (Microsoft Kinect, no hand-held controls needed). The movements required to play are customizable to each child's range of motion. Some of the mini-games are mixed reality, where children interact and manipulate real-life objects (e.g. musical instruments, coloured building blocks) to play the game. The use of skeletal tracking and mixed reality enables both gross and fine motor skills to be practiced in line with each child's therapy goals and motor abilities."
88842960|NCT03973606|No Intervention|Arab Women health literacy focus groups|Arab women in East Jerusalem will be part of focus groups. During the focus groups, a set of pre-prepared questions will be presented to the participants. The focus groups will be recorded and analyzed verbatim.
88842961|NCT03973606|Experimental|Health literacy workshop|Women from East-Jerusalem and other Arab communities in Israel will be invited to participate in a 4-sessions workshop designed to improve health literacy, self-efficacy when interacting with their physician and increase their cardiovascular health knowledge.
88842962|NCT03969628|Experimental|Multivariate risk assessment group (ICCMS®)|Multivariate risk assessment group (ICCMS®): multivariate caries risk assessment based on International Caries Classification and Management System (ICCMS™) guide
88842963|NCT03969628|Experimental|Simplified risk assessment group (dental caries experience)|Simplified risk assessment group (dental caries experience): simplified caries risk assessment based on dental caries experience (WHO criteria)
88842964|NCT03965234|Experimental|Prevention (cisplatin, metastasectomy)|Patients undergo pulmonary suffusion consisting of cisplatin via infusion. Patients the undergo metastasectomy. Beginning 4-8 weeks, patients with unresectable sarcoma may receive chemotherapy.
88842965|NCT03947723|Experimental|Low power|"These tissue sections will receive radiofrequency ablation to each eyelash follicle at a power of low."
88842966|NCT03947723|Experimental|1 power|These tissue sections will receive radiofrequency ablation to each eyelash follicle at a power of 1.
88842967|NCT03947723|Experimental|1.5 power|These tissue sections will receive radiofrequency ablation to each eyelash follicle at a power of 1.5
88842968|NCT03947723|Experimental|2 power|These tissue sections will receive radiofrequency ablation to each eyelash follicle at a power of 2.
88842969|NCT03921060|No Intervention|Main Study|Up to 100 subjects, both non-CF volunteers and Cystic Fibrosis (CF) patients, will participate in a single study visit that will include a DEXA scan (if not completed as standard of care within 6 months prior to research visit), micro CT, and blood collection.
88842970|NCT03921060|Experimental|Denosomab Sub-study|Approximately 10 subjects with CF that have completed the main study and have results which indicate bone disease are eligible to participate in the sub study. Subjects who consent will receive treatment with denosumab (60 mg/ml via subcutaneous injection in the upper arm, upper thigh, or abdomen every 6 months) for up to 5 years. These subjects will be asked to return every 6 months for injections and annually (+/- 6 months) for up to 5 years for a DEXA scan, micro CT, and blood collection.
88842971|NCT03907891|Experimental|Motivational social support (MSS) from a nurse alone|Participants will receive a 60-minute session of motivational interviewing via videoconference or telephone (at participant discretion) in their home from a trained nurse. The nurse will apply motivational interviewing techniques to explore the patient's thoughts about making a behavior change to attain adequate physical activity (PA). Patients will be encouraged to exercise based on instructions provided by the hospital staff. The patient's ability to take their radial pulse before and after PA will be assessed, and patients will be provided written instructions on the correct manner to take a radial pulse. Patients will receive daily motivational text messages from the nurse for 6 weeks. The texts will be sent via the REDCap automated system. The automated system confirms that texts were sent. The motivational interviewer nurse will confirm by phone that the patient receives her/his first text from the REDCap system.
88875256|NCT02548728|Placebo Comparator|Placebo|Self administration three times on the first day, then twice daily treatment with intranasal spray that does not contain oxytocin for 4 days.
89180316|NCT00798434|Active Comparator|Placebo|Flexible dose regimen of placebo once daily. The dose can be increased after 4 weeks if clinically indicated. Subsequently the dose can be reduced to the original dose if clinically indicated.
89180317|NCT00798434|Active Comparator|Fesoterodine|Flexible dose regimen of fesoterodine fumarate 4mg once daily. The dose can be increased to 8mg once daily after 4 weeks if clinically indicated. Subsequently the dose can be reduced to 4mg if clinically indicated.
89180318|NCT00724503|Experimental|mFOLFOX6 + SIRT|A single injection of SIR-Spheres microspheres into the liver plus systemic chemotherapy consisting of Oxaliplatin + Leucovorin + 5-Fluorouracil (FOLFOX)
89180319|NCT00724503|Active Comparator|mFOLFOX6|Systemic chemotherapy consisting of Oxaliplatin + Leucovorin + 5- Fluorouracil (FOLFOX).
89370171|NCT04995120|Experimental|Induction chemotherapy and Toripalimab|"Induction chemotherapy TP regimen combined with Toripalimab for 3 cycles: Toripalimab 240mg d1, Paclitaxel 175mg/m2 d2 or Nab-Paclitaxel 260mg/m2 d2，Cisplatin 25mg/m2 d2-4 q3w.~Response rate of primary tumor is evaluated using laryngoscopy and head and neck MRI after 3 cycles of induction therapy. If ORR of primary tumor is CR/PR, then chemoradiation is conducted, followed by maintenance therapy of Toripalimab for 8 cycles (6 months). Otherwise, surgery is conducted (laryngeal preservation surgery is preferred), followed by adjuvant radiation/chemoradiation and then maintenance therapy of Toripalimab for 8 cycles."
89370172|NCT03745469||Young-age group|Patient between the age of 18 and 30 years old, with a confirmed diagnosis of chronic mechanical neck pain
89370173|NCT03745469||Middle-age group|Patients between 30 and 60 years old, with a confirmed diagnosis of chronic mechanical neck pain.
89370174|NCT03988998|Experimental|Radiofrequency ablation with radiotherapy|Patients in this arm will receive liver radiotherapy around the primary tumor margin within one month after radiofrequency ablation for hepatocellular carcinoma.
88842972|NCT03907891|Experimental|MSS from nurse with additional significant other support (SOS)|Participants will also receive a 60-minute session of motivational interviewing via videoconference or telephone (at participant discretion) in their home from a trained nurse and text messages from a nurse for 6 weeks, as described in arm 1. In addition, patients will receive daily text messages from their significant other for 6 weeks. Researchers developed the 42 significant other text messages. The motivational interviewing nurse will provide the text messages to the significant other in writing. The order of texts sent from the significant other will be randomized so that we can determine their effectiveness in general. The significant other will be asked to type and send the text message listed for each date to the patient. Study staff will confirm by phone that the patient received the first text from the significant other. Patients will be asked to track the number of text messages from the significant other that they read over the 6-week period using the log provided.
88842973|NCT03907891|Active Comparator|Attention control (AC)|Participants in the AC group will receive a 60-minutes session with a nurse via videoconference or telephone (at participant discretion) viewing of American Heart Association educational videos and and documents regarding IHD. The nurse will additionally provide a written copy of the hospital physical activity instructions, will assess the patient's ability to take their pulse, and provide written instructions on the correct manner to take a radial pulse.
88842974|NCT03862924|Experimental|Active condition|Participants in the active condition will be provided with the Standardized Research Electronic Cigarette (SREC) and will be encouraged to use the SREC whenever they would normally smoke a cigarette.
88842975|NCT03862924|No Intervention|Standard Condition|Participants in this condition will be asked to continue to smoke their usual brand of cigarettes.
88842976|NCT03861156|Experimental|D-0316|Firstly, D-0316 was orally given 75mg for a cycle(21 days), if tolerated, the dose will be increased to 100mg. Otherwise, the dose will be maintained at 75mg.
88842977|NCT03827070|Experimental|Talcum powder & Afatinib|Talcum powder 4 g + Afatinib 0,4 g. Is entered once
88842978|NCT03812718|Active Comparator|ETT Group|"Anesthesia will be induced with fentanyl-citrate (3µg/kg) and propofol (dose determined by automated system based on continuous BIS feedback from the patients). Atracurium besylate 0.5-mg/kg will be given to facilitate placement of airway device. Propofol administration rate will be controlled by a feedback loop facilitated by BIS monitoring using the closed-loop anaesthesia delivery system (CLADS). A BIS value of 50 will be used as the target point for induction and maintenance of GA.~Intraoperative ventilation will be instituted through a polyvinyl chloride (PVC) ETT (Portex, Smiths Medical ASD, Inc, Minneapolis, USA). The size of the tube will be standardized for the male (7.5 mm ID) and the female (6.5 MM ID)."
88842979|NCT03812718|Active Comparator|PLMA Group|Anesthesia will be induced with fentanyl-citrate (3µg/kg) and propofol (dose determined by automated system based on continuous BIS feedback from the patients). Atracurium besylate 0.5-mg/kg will be given to facilitate placement of airway device. Propofol administration rate will be controlled by a feedback loop facilitated by BIS monitoring using the closed-loop anaesthesia delivery system (CLADS). A BIS value of 50 will be used as the target point for induction and maintenance of GA. intraoperative ventilation will be maintained with PLMA (Telefex Medical, Westmeath Ireland) whose size would be selected based on body weight. In patients weighing 30-50 kg PLMA # 3.0, 50-70 kg PLMA # 4.0, and 50-100 kg PLMA # 5.0 will be inserted.
88842980|NCT03811808||MSA patients|patients diagnosed with possible or probable multiple system atrophy
88842981|NCT03752073|Experimental|Trans-cervical cervical balloon|17 F non-latex Foley catheter will be placed and balloon filled with 30 cc of sterile normal saline.
88842982|NCT03752073|Experimental|Hygroscopic cervical dilators|Dilapan-S hygroscopic dilators will be placed into the cervix at the level of the internal os.
88842983|NCT03748303|Experimental|Allo IM cohort|Allopregnanolone 4-18mg IM, weekly, for 12 weeks.
88842984|NCT03736174||Compartment Pressure Testing|Patients who present with symptoms of CECS will be consented and tested per protocol with compartment pressure testing. Concurrently, patients will undergo a high frequency ultrasound to observe any patterns in structure to assist future research in noninvasively diagnosing CECS. Evaluation of ultrasonographic findings will be dependent on tissue density as measured by hypoechoic versus hyperechoic signal as well as muscle compartment thickness at its largest dimension.
88842985|NCT03736174||Control|Control subjects will undergo exercise protocol and ultrasound, but will not have compartment pressure testing completed.
89370175|NCT03988998|Active Comparator|Radiofrequency ablation alone|Patients in this arm will only receive radiofrequency ablation for hepatocellular carcinoma.
89370176|NCT01318785|Active Comparator|Compression ArmsleevesType A|Product A: armsleeves of type SoraLife KKl. 2 according to RAL GZ 387
89370177|NCT01318785|Active Comparator|Compression Armsleeves Type B|Product B: armsleeves of type Elvarex KKl. 2 according to RAL GZ 387
89370178|NCT01376232|Experimental|GSK1278863|100 mg of GSK1278863
89370179|NCT01376232|Experimental|GSK1278863 + food|100 mg of GSK1278863 given with a high fat meal
89370180|NCT01376232|Experimental|GSK1278863 + Gemfibrozil|GSK1278863A 100mg + Gemfibrozil 600mg steady state
89370181|NCT01354665||Group 1|
89370182|NCT01354743|Other|Dysport|Dysport injections into the glabella and orbicularis oculi muscles with dose based on muscle mass
89370183|NCT01361529|Experimental|safty test|FLP,dose escalation,MTD
89370184|NCT05018403|Experimental|AON-D21|Single ascending doses by iv infusion.
89370185|NCT05018403|Placebo Comparator|Placebo|Placebo medication identical in appearance to active.
89370186|NCT04944108|Experimental|Surfactant administration with less invasive surfactant administration (LISA) approach|Participants will be randomized to administer surfactant in a preterm manikin by using the LISA approach (thin catheter)
89370187|NCT04944108|Active Comparator|Surfactant administration with intubation (INSURE) approach|Participants will be randomized to administer surfactant in a preterm manikin by using the INSURE approach (tracheal tube)
89370188|NCT05008575|Experimental|antiCD33 CAR NK cells|After preconditioning with chemotherapy, the antiCD33 CAR NK cells will be evaluated
89370189|NCT03971994|Active Comparator|Young adults|Participants aged between 18 and 40 years old.
89370190|NCT03971994|Active Comparator|Healthy old adults|Participants aged between 65 and 95 years old.
89370191|NCT03971994|Experimental|Patients with Alzheimer's Disease|Participants aged between 65 and 95 years old with a diagnosis of Alzheimer's Disease.
89370192|NCT04069715|Experimental|Farlong NotoGinseng™ (Farlong Ginseng Plus® Panax Notoginseng)|Participants will be instructed to take two capsules once per day in the morning, thirty minutes before a meal. Clinic staff will instruct participants to save all unused and open packages and return them to clinic at each subsequent visit (visit 3, visit 4 and visit 5) for a determination of compliance. If a dose is missed, participants are instructed to take one as soon as they remember that day. Participants will be advised not to exceed two capsules daily.
89370193|NCT04069715|Placebo Comparator|Placebo|Participants will be instructed to take two capsules once per day in the morning, thirty minutes before a meal. Clinic staff will instruct participants to save all unused and open packages and return them to clinic at each subsequent visit (visit 3, visit 4 and visit 5) for a determination of compliance. If a dose is missed, participants are instructed to take one as soon as they remember that day. Participants will be advised not to exceed two capsules daily.
89370194|NCT01319487|Experimental|2304 Eye Drops High Dose|2304 Eye Drops High Dose self-administered in the study eye during the treatment period
89370195|NCT01319487|Experimental|2304 Eye Drops Low Dose|2304 Eye Drops Low Dose self-administered in the study eye during the treatment period
89370196|NCT01319487|Placebo Comparator|Placebo Eye Drops|Placebo Eye Drops self-administered in the study eye during the treatment period
89370197|NCT03681119|Experimental|Advanced Demential Patients|
89370198|NCT03681119|Experimental|Hospice IDT Members|
89370199|NCT03111108|Experimental|Arm 1: EBR/GZR for 8 Weeks|Treatment-naïve participants with stage 0-2 fibrosis (F0-F2) receive FDC of EBR/GZR (50 mg/100 mg) for 8 weeks, with 24 weeks of follow-up.
89370200|NCT03111108|Experimental|Arm 2: EBR/GZR for 12 Weeks|Treatment-naïve participants with F0-F2 stage fibrosis, treatment-naïve participants with F3-F4 stage fibrosis, and treatment-experienced participants with F0-F4 stage fibrosis receive FDC of EBR/GZR (50 mg/100 mg) for 12 weeks, with 24 weeks of follow-up.
88842986|NCT03735004|Experimental|TES 60 Hz DC:AC|Transcranial electrostimulation (TES) with combined direct (DC) and alternating (AC, 60 Hz) current
89370201|NCT03677375|Experimental|Test Subject|All subjects who are enrolled into the test group and participate in data collection receive the noninvasive INVSENSOR00026.
89370202|NCT00702520||Corifollitropin alpha 100 ug|In the base study (P05788, 38833, NCT00702351), participants were pre-treated with daily subcutaneous (SC) injections of 0.1 mg triptorelin started between Day 21 and 24 of the menstrual cycle (mid luteal phase). After suppression of endogenous luteinizing hormone (LH) and follicle stimulating hormone (FSH) was confirmed by estradiol (E2) and progesterone (P) measurements, a single dose of corifollitropin alpha 100 μg was administered in participants weighing <= 60 kg. From stimulation Day 8 onwards, treatment was continued with daily SC of recombinant follicle stimulating hormone (recFSH) injections (maximally 200 IU) up to and including the day of administration of human chorionic gonadotprophin (hCG). No study medications were administered in the present P05783 study (38834, NCT00702520).
88818510|NCT05326763|Active Comparator|dextrose group|4 ml of PRP + 4 ml of 0.9% saline -h 2 ml of 1% lidocaine (10-ml syringe).
88818511|NCT05326763|No Intervention|Placebo (the control group)|
88818512|NCT01412372|Experimental|Placebo|This arm will include those who are randomized to the placebo
88818513|NCT01412372|Experimental|Mesalamine|This arm is for subjects randomized to the study drug, Mesalamine
88818514|NCT05748353||Patients with BRCA pathological variants with breast or ovarian cancers|Patient with pathogenetic mutation of BRCA 1 or 2 gene who have developed breast or ovarian neoplasm
89399235|NCT03539588|Active Comparator|Treatment Group 2|In this group the participants will receive trigger point dry needling first and receive trigger point dry needling with electrical stimulation second. Only MYOTECH dry needles and ESTIM II dual channel stimulator will be used in this study. However we are not studying the equipment.
89399236|NCT03695211|Active Comparator|LM group|LM group use conventional landmark technique, which selects the midpoint of the posterior border of the sternocleidomastoid muscle as the puncture point of superficial cervical plexus block
89399237|NCT03695211|Experimental|GAN Group|This group firstly locate the superficial cervical plexus by ultrasound scanning of the point where the great auricular nerve emerges the posterior border of the sternocleidomastoid muscle (GAN Point). GAN Group apply the precise block technique, selects the GAN Point as the puncture point of superficial cervical plexus block
89399238|NCT02165774|Active Comparator|sacral neuromodulation ON|active sacral neuromodulation (neuromodulator ON)
89399239|NCT02165774|Placebo Comparator|sacral neuromodulation OFF|placebo sacral neuromodulation (neuromodulator OFF)
89370203|NCT00702520||Corifollitropin alpha 150 ug|In the base study (P05788, 38833, NCT00702351), participants were pre-treated with daily SC injections of 0.1 mg triptorelin started between Day 21 and 24 of the menstrual cycle (mid luteal phase). After suppression of endogenous LH and FSH was confirmed by E2 and P measurements, a single dose of corifollitropin alpha 150 μg was administered in participants weighing >= 50 kg. From stimulation Day 8 onwards, treatment was continued with daily SC of recFSH injections (maximally 200 IU) up to and including the day of administration of hCG. No study medications were administered in the present P05783 study (38834, NCT00702520).
89370204|NCT05198856|Experimental|Thalidomide|"The study is divided into two phases:~The first phase is a combination phase (chemotherapy +T) : Oxaliplatin (130mg/m2 iv d1) and capecitabine (1000mg/m2 d1-14 po bid) repeated every 21 days for a total of 4-6 cycles. Thalidomide tablet: 100 mg/d, qn, orally.~The second stage is maintenance stage: Patients who have obtained CR, PR or SD in the first stage enter the maintenance stage and receive maintenance treatment with thalidomide tablets: 100mg/d, qn, orally. Maintained until disease progression or adverse reactions are intolerable."
89370205|NCT04067141|Experimental|somofilcon A, then nelfilcon A|Subjects will bilaterally wear the somofilcon A lenses, then crossover to nelfilcon A lenses after one week of wear. Both lenses will be worn on a daily wear basis for one week.
89370206|NCT04067141|Experimental|nelfilcon A, then somofilcon A|Subjects will bilaterally wear the nelfilcon A lenses, then crossover to somofilcon A lenses after one week of wear. Both lenses will be worn on a daily wear basis for one week.
89370207|NCT03887910|Experimental|Enhanced Intervention|Northwell Health Visits postnatal Nurse Practitioner home visitation program and referrals and developmental toys.
89370208|NCT03887910|Experimental|Intervention|Northwell Health Visits postnatal Nurse Practitioner home visitation program and developmental screening and parent guides only.
89370209|NCT03887910|No Intervention|Control|Usual care with developmental toys.
89370210|NCT03184714|No Intervention|Control|
88842987|NCT03735004|Active Comparator|TES 100 Hz DC:AC|Transcranial electrostimulation (TES) with combined direct (DC) and alternating (AC, 100 Hz) current
88842988|NCT03735004|Sham Comparator|TES with DC current|Transcranial electrostimulation (TES) with direct current (DC) only
88842989|NCT03723473||PAOD patients statin (+)|"Patients with Peripheral Arterial Occlusive Disease (PAOD) and statin treatment.~They will have Magnetic Resonance Imaging (MRI; muscular volume and composition) and gated-P-31 magnetic resonance spectroscopy (MRS) with low-intensity ergometric exercise. It will be performed before surgery (within 48h) and after surgery (first week)"
88842990|NCT03723473||PAOD patients statin (-)|"Patients with Peripheral Arterial Occlusive Disease (PAOD) without statin treatment .~They will have Magnetic Resonance Imaging (MRI ; muscular volume and composition) and gated-P-31 magnetic resonance spectroscopy (MRS) with low-intensity ergometric exercise. It will be performed before surgery (within 48h) and after surgery (first week)"
89370211|NCT03184714|Experimental|Interventional group|NIPPV as treatment of OS
89370212|NCT02876601|Active Comparator|Defibrotide/LPS|"2ng/kg lipopolysaccharide period I: 6.25mg/kg bodyweight defibrotide or placebo (0.9% sodium chloride) period II: vice versa~16 healthy volunteers will receive 2ng/kg bodyweight LPS plus Defibrotide or Placebo 4 healthy volunteers will receive 0.9% saline (NO LPS) plus Defibrotide or Placebo"
89370213|NCT02876601|Placebo Comparator|Placebo/LPS|"2ng/kg lipopolysaccharide period I: 6.25mg/kg bodyweight defibrotide or placebo (0.9% sodium chloride) period II: vice versa~16 healthy volunteers will receive 2ng/kg bodyweight LPS plus Defibrotide or Placebo 4 healthy volunteers will receive 0.9% saline (NO LPS) plus Defibrotide or Placebo"
89370214|NCT02876601|Other|Defibrotide/Placebo|"Placebo (0.9% sodium chloride) period I: 6.25mg/kg bodyweight defibrotide or placebo (0.9% sodium chloride) period II: vice versa~16 healthy volunteers will receive 2ng/kg bodyweight LPS plus Defibrotide or Placebo 4 healthy volunteers will receive 0.9% saline (NO LPS) plus Defibrotide or Placebo"
88842991|NCT03710538|No Intervention|[Placebo + Sedentary]|1) Consumption of 200ml of water (flavored) + breakfast of 90g of carbohydrates (CHO) for men and 80g for women; Sedentary activities throughout the study
88842992|NCT03710538|Experimental|[Snack effect + Sedentary]|2) Consumption of 200ml of soy beverage + 90g of carbohydrate (CHO) breakfast for men and 80g for women; Sedentary activities throughout the study
88842993|NCT03710538|Experimental|[Placebo + Exercise]|3) Consumption of 200ml of water (flavored) + breakfast of 90g of carbohydrates (CHO) for men and 80g for women + physical activity practice (3min walk at 60% VO2max every 30 minutes, x5);
88842994|NCT03710538|Experimental|[Snack + Exercise]|4) Consumption of 200ml of soy beverage + breakfast of 90g of carbohydrate (CHO) breakfast for men and 80g for women + physical activity practice (3min walk at 60% VO2max every 30 minutes, x5).
89180320|NCT00791648|Experimental|statin|"Aim1 intervention: atorvastatin 80mg 1 day prior to open heart surgery and 40mg daily thereafter until hospital discharge.~Aim2 intervention: atorvastatin 80mg the day of cardiac surgery and 40mg on postop day 1."
89370215|NCT02876601|Other|Placebo/Placebo|"Placebo (0.9% sodium chloride) period I: 6.25mg/kg bodyweight defibrotide or placebo (0.9% sodium chloride) period II: vice versa~16 healthy volunteers will receive 2ng/kg bodyweight LPS plus Defibrotide or Placebo 4 healthy volunteers will receive 0.9% saline (NO LPS) plus Defibrotide or Placebo"
88842995|NCT03681314|Active Comparator|Umbilical Cord Milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 10-15 seconds.
88842996|NCT03681314|No Intervention|Immediate Cord Clamping|The umbilical cord is clamped immediately after the delivery.
89370216|NCT04059536||Roxwood Anchoring Catheters|Participants will be treated for an index procedure using Roxwood Medical device(s) as prescribed by the Investigator SOC on Day 0. All devices will be used in accordance with the Instructions for Use (IFU). Participants are to be administered SOC acetylsalicylic acid (ASA) and/or anti-platelet medications orally per physician discretion prior to the index procedure. Administration of an intravenous injection of heparin during the index procedure will also be at the discretion of the Investigator per Institutional SOC.
89370217|NCT03178318|Other|cricothyroid membrane|ultrasound of the neck will identify the position of the upper and lower border of the cricothyroid membrane in extended position.
89370218|NCT03745391|Active Comparator|MULTIMODAL MAGNETIC RESONANCE (MR)|Diagnostic test: Multimodal Neuroimaging Test: MR The group of patients with clinical suspicion of acute stroke and that fulfill the inclusion/exclusion criteria for the study that after randomization be assigned to Multimodal MR, will be directedly transferred to MR. It will be performed a multimodal MR taking into account that after discard an intracerebral haemorrhage and confirm an ischemic lesion if the patient fulfill criteria to receive intravenous alteplase, the test will be paused just to administer the treatment and immediately put again into the machine to complete the MR images. With all the information vascular neurologist will be decide if it is necessary administer endovascular treatment.
89370219|NCT03745391|Active Comparator|MULTIMODAL COMPUTED TOMOGRAPHY (CT)|Diagnostic test: Multimodal Neuroimaging Test: CT The group of patients with clinical suspicion of acute stroke and that fulfill the inclusion/exclusion criteria for the study that after randomization is assigned to Multimodal CT, will be directedly transferred to CT. If the patient fulfill criteria to receive intravenous alteplase after discard an intracerebral haemorrhage the CT will be paused to administer the treatment and immediately will continue with the test. At the end of the test the vascular neurologist will decide if it is necessary administer endovascular treatment.
89370220|NCT03178396|Experimental|Young, intervention|patients ages 18-45, taking melatonin
89370221|NCT03178396|No Intervention|Young, control|patients ages 18-45, usual care
89370222|NCT03178396|Experimental|Older, intervention|patients ages 60 and older, taking melatonin
89370223|NCT03178396|No Intervention|Older, control|patients ages 60 and older, usual care
89370224|NCT03677258|Experimental|Collagen injections|30 females with aging facial problems from 35 to 65 years old prescribed collagen ingection once every 3 weeks, cours of therapy - 3 procedures
89370225|NCT03677258|Active Comparator|Hyaluronic acid injections|30 females with aging facial problems from 35 to 65 years old prescribed hyaluronic acid ingection once every 3 weeks, cours of therapy - 3 procedures
89370226|NCT03682328|Active Comparator|vertebroplasty|Patients will be managed by equipment of vertebroplasty (Osteofix from Tsunami Medical Made in Italy which is composed of a packet of PMMA and ampule of MMA).
89370227|NCT03682328|Active Comparator|kyphoplasty|Patients will be managed by equipment of kyphoplasty (Osteofix from Tsunami Medical Made in Italy which is composed of a packet of PMMA and ampule of MMA).
89370228|NCT01361763|Experimental|Dabigatran|
89370229|NCT01361763|Active Comparator|Antiplatelets|
89370230|NCT02420782|Experimental|ASP6282 single ascending dose (fasted)|Part 1
88842997|NCT03680053|Experimental|PPOS group|Ovarian stimulation will use the progestin-primed ovarian stimulation (PPOS) protocol.Women will receive progesterone (oral duphaston 20mg) daily from Day 3 till the day of ovulation trigger.
88842998|NCT03680053|Active Comparator|Antagonist group|Ovarian stimulation will use the antagonist protocol. Women will receive antagonist (Cetrorelix 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger.
88842999|NCT03673007|Experimental|Treatment Group|Women in this arm of the study receive a voucher which can be used to buy contraception and related services at Planned Parenthood
89180321|NCT00791648|Placebo Comparator|placebo|"Aim 1 control: placebo one day prior to cardiac surgery and daily thereafter until hospital discharge.~Aim 2 control: placebo the day of cardiac surgery and postop day 1."
89370231|NCT02420782|Placebo Comparator|Placebo single ascending dose (fasted)|Part 1
89370232|NCT02420782|Experimental|ASP6282 single dose (fed)|Part 1
89370233|NCT02420782|Placebo Comparator|Placebo single dose (fed)|Part 1
89370234|NCT02420782|Experimental|ASP6282 single dose (fasted)|Part 1 Period 1
89370235|NCT02420782|Experimental|Itraconazole multiple dose and ASP6282 single dose (fasted)|Part 1 Period 2
89370236|NCT02420782|Experimental|ASP6282 multiple ascending dose (nonelderly and elderly)|Part 2. Germany only: once daily dosing, optional twice daily dosing. Midazolam dosing elderly only, exploratory for DDI purpose
89370237|NCT02420782|Placebo Comparator|Placebo multiple ascending dose (nonelderly and elderly)|Part 2. Germany only: once daily dosing, optional twice daily dosing
89370238|NCT02420782|Experimental|ASP6282 and pilocarpine|Part 3
89370239|NCT02420782|Other|Placebo and pilocarpine|Part 3
89370240|NCT03677024|Experimental|SLN arm|"Experimental:~Intra-operative sentinel lymph node (SLN) mapping with indocyanin green injected into the stroma of the cervix.~Full bilateral laparoscopic lymphadenectomy and hysterectomy:~If bilateral SLN are detected, all positive SLN will be removed. Then the surgeons proceeds to a total hysterectomy.~If only unilateral SLN are detected, surgeons will proceed to pelvic lymphadenectomy on the opposite side.~If non SLN are detected, surgeons will proceed to a total hysterectomy, a bilateral salpingo-oophorectomy, a complete and bilateral pelvic lymphadenectomy."
89370241|NCT03677024|No Intervention|Lymphadenectomy arm|Surgeons will proceed to a total hysterectomy, a bilateral salpingo-oophorectomy, a complete and bilateral pelvic lymphadenectomy.
89370242|NCT04054193|Experimental|Fosaprepitant Treatment|Participants received fosaprepitant dimeglumine once daily (QD) for 3 days and were followed for 14 days during the 17-day Cycle 1. Participants also optionally received dexamethasone as background therapy, and a serotonin (5-hydroxytryptamine [5-HT3]) receptor antagonist on Day 1 and optionally on Days 2-3 as background therapy. After completing Cycle 1, participants had the option to continue for up to 2 additional 17-day cycles of the same treatment regimen.
89370243|NCT03394027|Experimental|Arm 1-ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma|Single arm divided in three cohorts, each cohort with a different type of metastatic disease: estrogen receptor (ER) + breast cancer, triple negative breast cancer, and endometrial cancer
89370244|NCT03682172|Experimental|GLP-2 (10pmol/kg/min)|A single four hour intravenous infusion with glucagon-like peptide 2 at a rate of 10pmol/kg/min
89370245|NCT03682172|Experimental|GLP-2 (1pmol/kg/min)|A single four hour intravenous infusion with glucagon-like peptide 2 at a rate of 1pmol/kg/min
88843000|NCT03673007|No Intervention|Control Group|Women in this arm of the study DO NOT receive a voucher for contraceptives. Women in this arm receive the Planned Parenthood standard of care priced according to the Planned Parenthood sliding scale.
89370246|NCT03682172|Experimental|Placebo|A single four hour intravenous infusion with saline water (placebo)
89370247|NCT03184480||SUBJECTS RECEIVING ARNUITY ELLIPTA|Subjects with a diagnosis of asthma bronchial, for which Arnuity is indicated, who are naïve to Arnuity will be included.
89370248|NCT03136107|Experimental|Test product|This arm will include all the test sites on the participants back where test product (Physiogel Daily Defence Protective Day Cream Light) will be applied.
89370249|NCT03136107|Active Comparator|Reference product|This arm will include all the test sites on the participants back where reference product (ISO 24444:2010 P3 standard sunscreen) will be applied.
89370250|NCT03136107|No Intervention|Negative control|This arm will include all the test sites on the participants back which will be left unprotected.
89370251|NCT01376466||patients with acute appendicitis|Patients who have been clinically diagnosed to have acute appendicitis
89370252|NCT03686852|Active Comparator|group A|The main difference between the groups is due to the different dose of r-FSH which will be given to pa-tients after the 7 days of CFA; namely that patients who need additional r-FSH following corifollitropin-alfa will be randomized on day 8 of the stimulation into 3 study groups. In group A, B and C, ovarian stimula-tion with Corifollitropin alfa (Elonva®, MSD) will be used for ovarian stimulation, followed by 50IU (Group A).
89370253|NCT03686852|Active Comparator|groppo B|The main difference between the groups is due to the different dose of r-FSH which will be given to pa-tients after the 7 days of CFA; namely that patients who need additional r-FSH following corifollitropin-alfa will be randomized on day 8 of the stimulation into 3 study groups. In group A, B and C, ovarian stimula-tion with Corifollitropin alfa (Elonva®, MSD) will be used for ovarian stimulation, followed by 150IU (Group B)
88843001|NCT03671902|Other|Lower Body Negative/Positive Pressure|
89370254|NCT03686852|Active Comparator|Group C|The main difference between the groups is due to the different dose of r-FSH which will be given to pa-tients after the 7 days of CFA; namely that patients who need additional r-FSH following corifollitropin-alfa will be randomized on day 8 of the stimulation into 3 study groups. In group A, B and C, ovarian stimula-tion with Corifollitropin alfa (Elonva®, MSD) will be used for ovarian stimulation, followed by 250IU (Group C) of recFSH (Puregon®, MSD).
89370255|NCT03184402|Experimental|DWJ1252|
89370256|NCT03184402|Active Comparator|Gasmotin|
89370257|NCT01318395|Active Comparator|Aliskiren|
89370258|NCT01318395|Placebo Comparator|Placebo|
89370259|NCT01376544|Active Comparator|Assist control ventilation|Assist control ventilation
89370260|NCT01376544|Active Comparator|Pressure support ventilation|
89370261|NCT02329925|Experimental|Tongue Stabilizing Device Treatment|Tongue Stabilizing Device (TSD) is a preformed appliance for OSA that protrudes the tongue and improves upper airway structure and function during sleep.
89370262|NCT03686774|Experimental|Memantine group|Memantine will be given orally for four weeks starting two weeks before surgery. Memantine will be given in increasing doses: 5 mg/day for 3 days; 10 mg/day for 3 days; 15 mg/day for 3 days and 20 mg/day for 5 days.
89370263|NCT03686774|Other|Usual care group|"Concerning the comparator group, patients will be followed in the same way as those in the memantine group except that they will not receive the study treatment."
88843002|NCT03657602|Experimental|Contraceptive Kyleena|Determination of expulsion and discontinuation rates in participants randomly allocated to receive levonorgestrel intrauterine systems Kyleena Intrauterine System
88843003|NCT03657602|Experimental|Contraceptive Mirena|Determination of expulsion and discontinuation rates in participants randomly allocated to receive levonorgestrel intrauterine systems Mirena Intrauterine System
88843004|NCT03633929||KIOS OUD|
88843005|NCT03632369||Optimization Group|The primary objective of this study is to determine an optimized set of scan parameters for HP 129Xe MR diffusion-weighted imaging, HP 129Xe MR ventilation imaging, HP 129Xe Chemical Shift Saturation Recovery (CSSR) and Xenon polarization Transfer Contrast (XTC) MRI that will produce clear, anatomically and clinically relevant images of the lungs in up to 10 healthy participants and up to 10 participants with NSCLC. The primary objective will be completed before moving onto the secondary objective.
89180322|NCT05366595|Active Comparator|Treatment group|who received oral zinc sulfate supplementation on dose doses ranging from 10 mg (infants) to 20 mg (under-five children) of elemental zinc per day, a dosage that is safe in these children
89180323|NCT05366595|No Intervention|Control group|who didn't receive zinc sulfate supplementation.
89180324|NCT02592213|Experimental|Treatment|Treatment of lymphedema with cell-assisted lipotransfer using autologous stromal vascular fraction
89180325|NCT04087239||Pregnant women from >20 weeks gestation|1,200 pregnant women (600 HIV infected mothers and 600 HIV uninfected controls) at least 20 weeks gestation were enrolled from January 2016 to June 2019. Participants are being followed as mother-baby pairs at birth, within 10 days of life 6, 10, 14 24, 48, 72 and 96 weeks of age. At each visit clinical examinations are being used to assess health and the impact of environmental factors. In addition, questionnaires are administered and bio-samples for laboratory tests. The design of the study is non-interventional cohort but participants are being offered advice regarding health and hygiene.
89180326|NCT04113356||ST-Elevation Myocardial Infarction|Patients with acute ST-elevation myocardial infarction treated with primary percutaneous coronary intervention
89180327|NCT04017260|Experimental|open and closed technique|treatment of pilonidal sinus by open and closed approach
89180328|NCT04017260|Experimental|Rhomboid flap technique|treatment of pilonidal sinus by Rhomboid flap
89180329|NCT04017260|Experimental|karydakis technique|treatment of pilonidal sinus by Karydakis
89180330|NCT04017260|Experimental|open technique|treatment of pilonidal sinus by open approach
89180331|NCT00791492|Experimental|Fx-1006A|
89180332|NCT04017338|Experimental|Non Randomized Intervention|"Intervention description: recipients on the wait-list for lung, heart, kidney, and/or pancreas transplants will all receive antiviral treatment in the form of 8 total doses of oral tablets. Lung recipients will also receive donor lungs that are treated with normothermic EVLP (details of both described below).~Drug: All recipients will receive glecaprevir (300mg)/pibrentasvir (120mg) supplied as three tablets per dose 6-12 hours prior to transplant, and for 7 days post-transplant. Other Names: Maviret. Patients will also receive ezetimibe (10mg), supplied as one tablet per dose to be taken at the same time as Maviret tablets (6-12 hours prior to transplant in addition to 7 daily doses post-transplant).~Ex Vivo Lung Perfusion (EVLP): Normothermic EVLP is a method of donor lung preservation, assessment, treatment, and repair of injured organs. This method allows donor lungs to be treated for at least 12h under protective physiological conditions. Other names: Normothermic EVLP."
89180333|NCT04106726|Experimental|Test: Ivermectin cream 1%|Manufactured by Zydus Worldwide DMCC; Apply cream to the affected areas of the face once daily for 12 weeks.
89180334|NCT04106726|Active Comparator|Reference: Soolantra® cream, 1%|Manufactured by Galderma Laboratories, L.P.; Apply cream to the affected areas of the face once daily for 12 weeks.
88818515|NCT05748353||Patients with BRCA pathological variants without diagnosis of cancer|Patient with pathogenetic mutation of BRCA 1 or 2 gene without diagnosis of malignancy and without prophylactic surgery
88818516|NCT05748275||Argos|Biometry measurements first with the Argos device followed by the IOLMaster 700 device.
88818517|NCT05748275||IOLMaster 700|Biometry measurements first with the IOLMaster 700 device followed by the Argos device.
89180335|NCT04106726|Placebo Comparator|Placebo: Placebo for Ivermectin cream 1%|Manufactured by Zydus Worldwide DMCC; Apply to the affected areas of the face once daily for 12 weeks.
89180336|NCT04106336|No Intervention|non cannabis addict|30 non cannabis addict will be control group
89180337|NCT04106336|Active Comparator|cannabis addict|30 cannabis addict will undergo rTMS
89180338|NCT02603354|Active Comparator|3x12 m peroxide gel tooth bleaching 6%|bleaching with 6% hydrogen peroxide 3 times of 12 minutes session for in office bleaching teeth
89180339|NCT02603354|Experimental|1-36 m peroxide gel tooth bleaching 6%|bleaching with 6% hydrogen peroxide 1 time of 36 minutes session for in office bleaching teeth
89180340|NCT00723957|Experimental|Ixabepilone, 32 mg/m^2 + Carboplatin (AUC 6)|
89180341|NCT00723957|Active Comparator|Paclitaxel, 200 mg/m^2 + Carboplatin (AUC 6)|
89180342|NCT04106180|Experimental|SBRT + sintilimab + GM-CSF|
89180343|NCT02603822|Experimental|Healthy Volunteers|Subjects will receive a saccharide solution of 12C mannitol 100 mg, 13C mannitol 100 mg, and lactulose 1 g in 250ml of water at visits 2, 5, and 7 prior to permeability testing. The subjects will also receive Indomethacin capsules prior to visit 5.
89180344|NCT04087005|Experimental|Hominis placental pharmacopuncture|The Hominis placental pharmacopuncture group will receive 10 sessions of Hominis placental pharmacopuncture at 2 sessions/week for 5 weeks. A trained doctor of Korean medicine with at least 2 years clinical experience will administer JHG002 pharmacopuncture with a disposable syringe (0.5ml) directly into the designated sites, using a standardized method.
89370264|NCT02420392|Experimental|Dapagliflozin treatment|Test incretin sensitivity after dapagliflozin treatment in type 2 diabetes patients
88818518|NCT01412918|Experimental|Tinnitus|"Individual with tinnitus. Intervention: inhibitor device demonstration.~The Inhibitor™ Tinnitus Masking Device is a new tinnitus treatment device recently available in the United States for use of temporary relief of tinnitus. The device emits an ultra high frequency sound for 60 seconds via bone conduction when applied to the mastoid. Patients reporting tinnitus will be provided the opportunity to demonstrate the device to observe any changes in their tinnitus. The device may be demonstrated up to 5 times. The investigators will be recording the the degree and duration of change in tinnitus perception following treatment with the Inhibitor™ Tinnitus Masking Device."
88818519|NCT01412918|No Intervention|No tinnitus|Individuals without tinnitus will also be masked with the device.
88818520|NCT02989415||Mechanical Ventilation|Patients undergoing mechanical ventilation during robotic surgery
88818521|NCT01414010|Active Comparator|Prebiotic|
88818522|NCT01414010|Active Comparator|Probiotic|
88818523|NCT01414010|Active Comparator|Antibiotic|
88818524|NCT01414010|No Intervention|Control|Control group, no intervention given.
88818525|NCT01414244|Active Comparator|Glutamine supplementation|Glutamine
88818526|NCT01414244|Placebo Comparator|Placebo|Whey protein powder
88843006|NCT03632369||Delineate Functional vs. non-functional lung tissue|The secondary objective of this study is to delineate functional versus non-functional lung tissue and the effects of radiotherapy. This objective will be explored by performing these five optimized techniques with up to 10 participants with NSCLC at three time points: before radiotherapy begins, at the end of radiotherapy, and at least 10-weeks post-radiation treatment. These results will be correlated with those from PFTs and CT scans performed at corresponding time points.
88843007|NCT03629626|No Intervention|Conventional Perioperative (SP) care|Conventional Perioperative (SP) care
88843008|NCT03629626|Experimental|ERAS protocol|preoperative / intraoperative/ postoperative management
88843009|NCT03625687|Experimental|Treatment with Direct Acting Antiviral for HCV|8 weeks of treatment with HCV Direct Acting Antiviral tablet (Mavyret or Epclusa)
88843010|NCT03574194|Experimental|Methionine-restricted diet|6-10 weeks methionine-restricted diet (MRD) curative intent radiation therapy course of 6 weeks or less.
89180345|NCT04087005|Active Comparator|Transcutaneous electrical nerve stimulation|The control group will receive 2 sessions/week of TENS for 5 weeks. A high-frequency, low-intensity stimulus of 50-100Hz and up to 15mA will be used, such that the patients feel a current but do not feel pain. At each treatment visit, a physiotherapist will administer the treatment to the bilateral temporomandibular joint for 15 minutes. Both centres will use the same TENS device-a BioTron-DX (D.M.C, Osan, South Korea).
89180346|NCT02592057||SOF-based regimens|Adults with chronic HCV infection in India who are being treated with a SOF-based treatment regimen as per the approved prescribing information.
89180347|NCT00723801|Active Comparator|Subjects Randomized to Losartan|Losartan: 100 mg PO QD
89180348|NCT00723801|Active Comparator|Subjects Randomized to Atenolol|Atenolol: 50 mg PO QD
89180349|NCT04086927|No Intervention|Control Group|Patients will not receive compression dressing
89180350|NCT04086927|Experimental|Experimental Group|Patients will receive compression dressing
89180351|NCT00797966|Experimental|1|OPC-34712 + ADT
89180352|NCT00797966|Placebo Comparator|2|Placebo + ADT
89180353|NCT00723489|Experimental|YFV-17D (Right Deltoid)|Participants will be randomized within each atopic dermatitis (AD) severity subgroup or as non-atopic controls to either subcutaneous (SC) or transcutaneous (TC) vaccine administration. In this arm, participants will receive a standard vaccine dose (5.5x10^4 Plaque Forming Units) of YFV-17D administered subcutaneously in the right deltoid and placebo vaccination transcutaneously (then covered with a semi-occlusive dressing) in the left deltoid. The site pharmacist will maintain the blind and an unblinded (i.e., masked) site coordinator will administer assigned treatment: investigators, participants and assessors remain blinded to treatment assignments throughout the duration of the trial.
89180354|NCT00723489|Experimental|YFV-17D (Left Deltoid)|Participants will be randomized within each atopic dermatitis (AD) severity subgroup or as non-atopic controls to either subcutaneous (SC) or transcutaneous (TC) vaccination. In this arm, participants will receive YFV-17D vaccination (1x10^3 Plaque Forming Units) by transcutaneous administration (then covered with a semi-occlusive dressing to optimize YFV-17D absorption) in the left deltoid and placebo by subcutaneous administration in the right deltoid. The site pharmacist will maintain the blind and an unblinded (i.e., masked) site coordinator will administered treatment: investigators, participants and assessors remain blinded to treatment assignments throughout the duration of the trial.
89180355|NCT02591901|Experimental|Uro Vaxom|Uro Vaxom, Once daily for 3 months
89180356|NCT02591901|Placebo Comparator|Placebo|Placebo identical to main drug in shape and form
89180357|NCT05362695|Experimental|Cohort 1: 100 μg IW-3300|100 μg dose of active drug (IW-3300) once daily for 7 days
89180358|NCT05362695|Placebo Comparator|Cohort 1: Placebo|matching placebo once daily for 7 days
89180359|NCT05362695|Experimental|Cohort 2: 300 μg IW-3300|300 μg dose of active drug (IW-3300) once daily for 7 days
89180360|NCT05362695|Placebo Comparator|Cohort 2: Placebo|matching placebo once daily for 7 days
89180361|NCT05362695|Experimental|Cohort 3 (optional): Dose 3|Active drug (IW-3300) once daily for 7 days
89180362|NCT05362695|Placebo Comparator|Cohort 3 (optional): Placebo|Matching placebo once daily for 7 days
89180363|NCT00587990|Experimental|Lower dose mesenchymal stem cell (MSC) injection|Participants will receive lower dose mesenchymal stem cell injections for a total of 2 x 10^7 cells
89180364|NCT00587990|Experimental|Higher dose MSC injection|Participants will receive higher dose of mesenchymal stem cell injections for a total of 2 x 10^8 cells
89180365|NCT00587990|Placebo Comparator|(3) Placebo|Participants will receive placebo injections
89180366|NCT02603744|Experimental|5 million MSC|The patients with POF who underwent intraovarian injection of 5 million mesenchymal stem cells.
89180367|NCT02603744|Experimental|10 million MSC|The patients with POF who underwent intraovarian injection of 10 million mesenchymal stem cells.
89180368|NCT02603744|Experimental|15 million MSC|The patients with POF who underwent intraovarian injection of 15 million mesenchymal stem cells.
89180369|NCT00723255|Experimental|Treatment (bevacizumab, temsirolimus)|Patients receive bevacizumab IV on days 1 and 15 and temsirolimus IV on days 1, 8, 15, and 22.
88843011|NCT03523468|Experimental|uniportal sleeve lobectomy|locally advanced central lung cancer resection by uniportal VATS sleeve lobectomy
88843012|NCT03523468|Active Comparator|open sleeve lobectomy|locally advanced central lung cancer resection by open chest sleeve lobectomy
88843013|NCT03504683|Experimental|Early Time-Restricted Feeding|
88843014|NCT03504683|Experimental|Mid-day Time-Restricted Feeding|
88843015|NCT03504683|Placebo Comparator|Control Schedule|
88843016|NCT03469284|Experimental|Group 1 (lower dose methylene blue, standard of care)|Patients receive lower dose methylene blue PO to swish and spit for 5 minutes every 6 hours then receive standard of care therapy.
88843017|NCT03469284|Experimental|Group 2 (medium dose methylene blue, standard of care)|Patients receive medium dose methylene blue PO to swish and spit for 5 minutes every 6 hours then receive standard of care therapy.
89370265|NCT02420392|No Intervention|Normal glucose tolerance|Test incretin sensitivity in subjects with normal glucose tolerance
89370266|NCT01318551|Experimental|Arm 1|
89370267|NCT01318551|Experimental|Arm 2|
89370268|NCT01318551|Experimental|Arm 3|
89370269|NCT01562795|Experimental|group 1|
89370270|NCT01562795|Experimental|group 2|
89370271|NCT01562795|Experimental|group 3|
89370272|NCT01562795|Other|group 4|
89370273|NCT02424448||Metastatic CRPC|Patients with metastatic prostate cancer post maximal androgen blockade (MAB) with primary or metastatic cancer deposits amenable to biopsy. Patients will have biopsies, blood and urine samples taken.
88843018|NCT03469284|Experimental|Group 3 (higher dose methylene blue, standard of care)|Patients receive higher dose methylene blue PO to swish and spit for 5 minutes every 6 hours then receive standard of care therapy.
88843019|NCT03469284|Active Comparator|Group 4 (standard of care)|Patients receive standard of care therapy.
89370274|NCT01311817|Placebo Comparator|Saline Patch|1mL saline applied to the vaccine patch
89370275|NCT01311817|Experimental|Bacteria plus CT|0.95mL bacterial vector plus 0.05mL cholera toxin
89370276|NCT01354821|Active Comparator|Endovascular therapy branched|Endovascular therapy branched or fenestrated stent-graft
89370277|NCT01354821|Other|Open surgical repair|Open surgical repair or aortic replacement with revascularization of visceral arteries
89370278|NCT05450809||Ambulatory, outpatient Mayo Clinic ECG lab patients|Patients who are undergoing routine clinical evaluation with a 12 lead ECG recording ordered at the Mayo Clinic ECG lab.
89370279|NCT02424136|Other|Entire group|Children aged 2-17 years with suspected peanut allergy who require peanut food challenge to confirm clinical allergy, will be recruited for the study. They will undergo a preceding questionnaire, peanut skin prick testing, spirometry, fraction of exhaled nitric oxide (FeNO) measurement, serum peanut and Ara h2 specific immunoglobulin E (sIgE) antibodies, and collection of blood biomarker prior to food challenge. The primary endpoint will be anaphylaxis at open label peanut challenge, with the primary exposure of interest will be the serum biomarker.
89370280|NCT02916056|Experimental|Azeliragon 5 mg|Azeliragon (TTP488) 5mg orally once daily for 2 years
89370281|NCT03770676|Experimental|Flavour 1|Selenium-fortified biscuits These participants will be assigned to biscuit flavour 1. If possible, there will be an equal number of low, medium and high selenium-status participants. They will consume this flavour of selenium-fortified biscuits for 14 consecutive days at home, providing approximately 60 mcg selenium per day.
88843020|NCT03465072|Experimental|Exercise training|8 Weeks exercise training 3x per week 30-40 minutes per session
88843021|NCT03452150|Experimental|Daily oral dose of D-0316|
88843022|NCT03447340|Experimental|Cafeteria and behavior|Receives cafeteria intervention and behavior intervention
88843023|NCT03447340|Active Comparator|Cafeteria only|Receives only cafeteria intervention
88843024|NCT03425331|Experimental|Nivolumab+Ipilimumab|Nivolumab will be administered once every 2 weeks intravenously Ipilimumab will be administered once every 6 weeks intravenously
88843025|NCT03358797|Experimental|intervention-HPP|Community participants will participate in a group-based lifestyle intervention based on the CDC Diabetes Prevention Program, and adapted to the Arabic language, Arab culture, Mediterranean Diet, and adapted to include empowerment, leadership and emotion regulation.
88843026|NCT03358797|Experimental|CBLI+RT|based on randomization, group that will be assigned to CBLI+RT will receive the CBLI curriculum (as described in the intervention-HPP arm) in addition to the resiliency training
89370282|NCT03770676|Experimental|Flavour 2|Selenium-fortified biscuits These participants will be assigned to biscuit flavour 2. If possible, there will be an equal number of low, medium and high selenium-status participants. They will consume this flavour of selenium-fortified biscuits biscuit for 14 consecutive days at home, providing approximately 60 mcg selenium per day.
88843027|NCT03358797|Experimental|Attention control (CBLI-)|The attention control group will receive the core curriculum of the CBLI (as described in the intervention-HPP arm) only without the resiliency training. The sessions of the resiliency training will be replaced with sessions on health topics that do not contribute to our outcome (increased resiliency) (i.e. breast cancer, osteoporosis)
88843028|NCT03358797|Experimental|Pilot|This group will not be randomized. The group will receive the CBLI content (as described in the intervention-HPP arm) in addition to the resiliency training. The aim of this pilot is to create a resiliency training manual to be implemented in the following groups that will be assigned to receive the CBLI+RT
88843029|NCT03348280||Vitamin D Deficient|Type 2 diabetics with high blood pressure and 25-hydroxyvitamin D levels of <20 ng/ml
88843030|NCT03348280||Vitamin D Sufficient|Type 2 diabetics with high blood pressure and 25-hydroxyvitamin D levels of >30 ng/ml
88843031|NCT03344770|Experimental|Active rESWT|Application of 5,000 pulses of rESWT by a pneumatic generator, with 0.16mJ/mm2 (millijoule per squared millimeter) of energy at a frequency of 20Hz on the most painful spot of the knee. The applications will be given once a week for three weeks.
88843032|NCT03344770|Sham Comparator|Sham rESWT|Application of 5,000 pulses of rESWT by a pneumatic generator, at a frequency of 20Hz on the most painful spot of the knee with 0 mJ/mm2 energy. The applications will also be given once a week for three weeks.
89370283|NCT03770676|Experimental|Flavour 3|Selenium-fortified biscuits These participants will be assigned to biscuit flavour 3. If possible, there will be an equal number of low, medium and high selenium-status participants. They will consume this flavour of selenium-fortified biscuits for 14 consecutive days at home, providing approximately 60 mcg selenium per day.
89370284|NCT03181438|Experimental|TAP Block|"The TAP block will be performed under general anesthesia, according to the technique described below:~The patient will be placed supine with the abdomen exposed between the iliac crest and the costal margin~After skin antisepsis, a high-frequency ultrasound transducer will be placed transversely across the anterior axillary line above the iliac crest~In this region, the abdominal musculature (external oblique, internal oblique and transverse abdomen) is identified, and the transverse abdominal plane of the abdomen~The needle (BD-A-50mm) will be inserted in the technique in plane to the region of the transverse plane of the abdomen, where the solution will be administered.~In this group, will be administered 20 mL of 0.375% ropivacaine"
89370285|NCT03181438|Sham Comparator|Saline Group|"The block will be performed under general anesthesia, according to the technique described below:~The patient will be placed supine with the abdomen exposed between the iliac crest and the costal margin~After skin antisepsis, a high-frequency ultrasound transducer will be placed transversely across the anterior axillary line above the iliac crest~In this region, the abdominal musculature (external oblique, internal oblique and transverse abdomen) is identified, and the transverse abdominal plane of the abdomen~The needle (BD-A-50mm) will be inserted in the technique in plane to the region of the transverse plane of the abdomen, where the solution will be administered.~In this group, will be administered 20 mL of Saline"
89370286|NCT02424058||Neck pain|Patients aged between 18 and 65 years with persistent neck pain for more than 3 months
89370287|NCT02424058||Healthy|Acceptance to participate in the study, no previous neck oain (lifetime-to-date), no spinal surgery or deformity, and no radiological abnormalities detected
89370288|NCT02428114||5 days of filgrastim|Standard of care
89370289|NCT02428114||7 days of filgrastim|Standard of care
89370290|NCT02428114||10 days of filgrastim|Standard of care
89370291|NCT02420158|Experimental|Vagal nerve stimulation|Trans-cutaneous vagal nerve electrical stimulation during 6 months
89370292|NCT01361841|Other|ophtalmic solution,|Travoprost, latanoprost and bimatoprost, ophthalmic solution are topical medications used for controlling the progression of glaucoma or ocular hypertension, by reducing intraocular pressure. they are synthetic prostaglandin F 2α analogue (and prodrug for bimatoprost) that works by increasing the outflow of aqueous fluid from the eyes.
89370293|NCT02420236|Experimental|High-intensity resistance training|Full body, progressive strength training with Theraband® Elastic bands. Three times per week for 12 weeks - 3 weeks with supervised sessions at the clinic, and 9 weeks of home training. Three guided sessions will be offered during the home training period.
88843033|NCT03313115||No Sleep/Wake Protocol Implementation|No implementation of the sleep/wake protocol. A subset of participants in this group will have light and sound levels in the room recorded.
88843034|NCT03313115||Sleep/Wake Protocol Implementation|The sleep/wake protocol will be implemented. A subset of participants in this group will also have light and sound levels in the room recorded.
88843035|NCT03295136|Experimental|Health Promotion Training for Women Employees|Groups of women employees will participate in a 20 session health promotion training course. The course will include health education and health promotion knowledge and skills, as well as leadership and project building skills, including empowerment, change process, recruiting partners and more. The first 15 sessions will be weekly session, while the remaining five will take place every couple of months throughout the following year.
88843036|NCT03270163|Experimental|Experimental|Magnetic and Transcutaneous electrical stimulation of quadriceps
88843037|NCT03214029||Study population|Prospective, observational cohort study of consecutives patients (goal, 2000 patients over 5 months) presenting to the emergency department, in whom serial cTnI measurements are ordered on clinical indication at Hennepin County Medical Center (Minneapolis, MN, USA) to rule-in and rule-out acute myocardial infarction.
88843038|NCT03205293|Experimental|Intervention Group|Female Schoolchildren, their mothers and teachers will be exposed to multiple interventions designed through a participatory approach, integrating the ecological model.
88843039|NCT03205293|No Intervention|Control Group|Regular school curriculum
88843040|NCT03201523|Experimental|Intervention|Community members will be exposed to multiple interventions designed through the participatory approach, integrating the socio-ecological model.
89370294|NCT02420236|Active Comparator|General physical activity|12 weeks of general physical activity - 3 weeks with supervised sessions at the clinic, and 9 weeks of individually adjusted home training. This include circle-training, low-intensity resistance exercises, endurance exercises, ball playing, body awareness, stretching, and relaxation techniques, and similar activities. Neither moderate nor high-intensity resistance exercise is included for participants in this group.Three guided sessions will be offered during the home training period.
89180370|NCT00791258|Experimental|1|Azor tablets and hydrochlorothiazide tablets (if necessary) will be administered for up to 20 weeks
89180371|NCT00808067|Experimental|dabigatran dose 1|dabigatran high dose twice daily
89370295|NCT02583789|Active Comparator|oral treprostinil|Dosing of oral treprostinil will be initiated at 0.125 mg three times daily. Dose escalations of oral treprostinil can occur every 72 hours (three consecutive doses) in 0.125 mg increments. Subjects will be titrated as tolerated to a goal dose of 2mg TID over a 6-week period.
89370296|NCT02583789|Placebo Comparator|Placebo|Placebo mimics oral treprostinil and will be taken three times a day
89370297|NCT01358019|Experimental|LY2523355|
89370298|NCT02428036|Experimental|TBI-1401(HF10) - Cohort 1|Oncolytic virotherapy, intratumoral administrations of TBI-1401(HF10)
89370299|NCT02428036|Experimental|TBI-1401(HF10) - Cohort 2|Oncolytic virotherapy, intratumoral administrations of TBI-1401(HF10)
89370300|NCT01355367|Experimental|Arm 1|
89370301|NCT05759520|Experimental|2-month-old experimental group|Vaccination of 4 doses of experimental vaccine(0,2,4,1 booster dose)
89370302|NCT05759520|Active Comparator|2-month-old control group|Vaccination of 4 doses of control vaccine(0,2,4,1 booster dose)
89370303|NCT05759520|Experimental|3-month-old group|Vaccination of 4 doses of experimental vaccine(0,1,2,1 booster dose)
89370304|NCT02423902|Experimental|Ad-RTS-hIL-12 + Veledimex|Intratumoral injection of Ad-RTS-hIL-12 in combination with veledimex
89370305|NCT02427880|Experimental|Acetazolamide|Each patient receives 250 mg of acetazolamide and 50 mg of hydrochlorothiazide daily for 1 week. Then they are prescribed 40 mg of furosemide daily for 2 weeks.
89370306|NCT02427880|Active Comparator|Furosemide|Each patient is prescribed 40 mg of furosemide and 50 mg of hydrochlorothiazide daily for 1 week. Then they receive 40 mg of furosemide daily for 2 weeks.
89370307|NCT02567643|Experimental|Stereotactic Radiosurgery|
89370308|NCT04789200|Experimental|NX9 oral contrast agent|Subjects will be given a 9% w/w HBGM concentration of NX9 provided as 1.2L of liquid.
89399240|NCT02165852|Experimental|Papillectomy without injection|Conventional snaring mucoal resection without submucosal injection
89399241|NCT02165852|Active Comparator|Papillectomy with injection|Conventional mucosal resction method following injeciton of diluted epinephrine mixture.
88843041|NCT03167489|Experimental|Lifestyle Plus Emotional Regulation|The core intervention will last 5 months. Nutrition content: Mediterranean diet education, social support, self-regulation techniques, and environmental support. Physical activity content: education, guidance in starting a routine, and a walking program with pedometers, weekly physical activity tips and step goals. Emotion regulation content: based on Dialectical Behavior Therapy adapted to binge eating disorders and other ER sources, emphasizing identifying emotions, recognizing the causes of emotions, accepting and tolerating negative emotions, effective self-support and self-compassion, and the ability to manage situations that elicit negative emotions, as well as re-appraisal skills, which are identified as particularly influential on eating behaviors.
88843042|NCT03149211|Active Comparator|Cohort 1|Subjects will receive current standard HAART treatment as the active control group.
88843043|NCT03149211|Experimental|Cohort 2|Subjects will receive UB-421 without HAART treatment by intravenous infusion at 25 mg/kg bi-weekly. After 26-week treatment period, subjects will enter 22-week follow-up period with current standard HAART treatment.
89370309|NCT02423746|Placebo Comparator|Control Group|"The control group will include 3 hearing aid (HA) and 3 cochlear implant (CI) caregiver-child dyads.~Parents in the control group will receive an initial assessment session followed by three behavioral placebo sessions followed by a post-placebo-intervention assessment. All sessions will be delivered in the patients' usual hearing clinics and will last between 60 and 90 minutes. One month post-intervention, participants will complete post-test measures repeating baseline measures, plus acceptability ratings of intervention."
89370310|NCT02423746|Experimental|Intervention Group|"The intervention group will include 3 hearing aid (HA) and 3 cochlear implant (CI) caregiver-child dyads.~Intervention parents receive the initial assessment session followed by the 3-session Family Check Up Behavioral Parenting Training Program (BPT) within one month of baseline assessment followed by a post-intervention assessment. All sessions will be delivered in the patients' usual hearing clinics and will last between 60 and 90 minutes. One month post-intervention, participants will complete post-test measures repeating baseline measures, plus acceptability ratings of intervention."
88843046|NCT03108820|Experimental|TMH Intervention|The multidisciplinary team which develops and carries out the intervention includes a care coordinator who will organize and align recovery resources, a Trauma Surgeon (Dr. Zarzaur), a critical care physician (Dr. Khan), a geriatrician with expertise in collaborative care (Dr. Boustani), and an ICU collaborative care nurse (Dr. Lasiter). Using the Healthy Aging Brain Care monitor, care protocols, specialized software, and specific care protocols, the multidisciplinary team will modulate the intensity and the type of intervention the patient's receive based on the patient's needs. The intervention will last from the time of discharge to 6 months after injury.
88843047|NCT03108820|Active Comparator|Usual Care|Review hospital discharge and rehabilitation plan, identify the primary care physician responsible for the patient care. Patients will receive education on communication skills; caregiver coping skills; and legal and financial advice. Patients randomized to usual care will receive no further interventions.
88843048|NCT03043430|Experimental|Ketamine|Ketamine 100 mg/mL concentration administered in a single 1.0 mg/kg dose with a maximum of 50mg intranasal via mucosal atomization device.
88843049|NCT03043430|Active Comparator|Midazolam|Midazolam 5 mg/mL concentration administered in a single administered in a single 0.3 mg/kg dose with a maximum of 5mg intranasal via mucosal atomization device.
88843050|NCT03035890|Experimental|Radiation Therapy + Immunotherapy|3-5 fraction course of radiation therapy to target lesion concurrent with an immuno-therapeutic agent
89180372|NCT00808067|Experimental|dabigatran dose 2|dabigatran low dose twice daily
89180373|NCT00723021|Experimental|PF-04191834 30mg|
89180374|NCT00723021|Experimental|PF-04191834 100mg|
89180375|NCT00723021|Experimental|PF-04191834 2000mg|
89180376|NCT00723021|Active Comparator|zileuton|
89180377|NCT00723021|Placebo Comparator|placebo|
89180378|NCT02591823||Healthy Controls|Healthy subject who accompanying patients to rheumatology OPD or healthy subjects who are staff at Columbia Asia Hospital,Bangalore.
89180379|NCT02591823||Cases (patients on methotrexate)|Subjects attending the rheumatology OPD of Columbia Asia hospitals bengaluru, who are diagnosed as having Rheumatoid arthritis and fulfill the ACR/ EULAR 2010 classification criteria for rheumatoid arthritis and are started on low dose methotrexate will included as cases
89180380|NCT04309409|Experimental|Nivolumab (Arm A)|"Patients with a risk score of > 0.0 corresponding to high risk of relapse (randomized):~Nivolumab will be applied at a flat dose of 480 mg given as 60-minute iv infusion every 4 weeks for 12 doses over 1 year. Afterwards these patients will receive intense clinical follow up according German Follow up guidelines."
89180381|NCT04309409|No Intervention|Observation, High Risk (Arm B)|"Patients with a risk score of > 0.0 corresponding to high risk of relapse (randomized):~Control group (observation only). These patients will receive intense clinical follow up but no further specific therapy according German Follow up guidelines."
89180382|NCT04309409|No Intervention|Observation, Low Risk (Arm C)|"Patients with a risk score of ≤ 0.0 corresponding to low risk of relapse who are not eligible for randomization:~These patients will receive intense clinical follow up but no further specific therapy according German Follow up guidelines. Documentation of clinical outcome of these patients."
89180383|NCT04086537||BMPR2-mutation carriers|Patients affected by pulmonary arterial hypertension (PAH) with already determined BMPR2 mutation status (hereditary PAH, HPAH) or patients with idiopathic PAH (IPAH) and other forms of PAH who are newly diagnosed within the duration of the study and resulted positive for mutation at the routinely-performed (according to current guidelines) BMPR2 analysis.
89180384|NCT04086537||non-BMPR2 mutation carriers|Patients affected by Pulmonary arterial hypertension (PAH) who resulted negative at the routinely-performed (according to current guidelines) BMPR2 analysis (Idiopathic PAH, IPAH) or patients with Idiopathic PAH (IPAH) and other forms of PAH who are newly diagnosed within the duration of the study and resulted negative for mutation at the routinely-performed (according to current guidelines) BMPR2 analysis.
89180385|NCT04086537||healthy controls|Healthy controls free of heart and lung disease or any comorbidities affecting iron metabolism. This control group will be age and gender matched to non-BMPR2 mutation carriers.
89180386|NCT02608619||PET Imaging|This study will enroll patients who have a clinical diagnosis of a systemic histiocytic disorder, and who are scheduled to undergo confirmatory biopsies of the systemic lesions, that were identified by standard imaging modalities.
88843051|NCT03004261|Experimental|CMV-CTL|The donor derived cytomegalovirus specific T lymphocytes (CMV-CTL) will be transfused to the patients. The patients will receive CMV-CTL cells when they are sero-positive for CMV-DNA 30 days after transplant. The CMV-DNA levels will be monitored weekly for at least 60 days after the transplant. If after the initial dose of CMV-CTL cells the patient develops a viral infection, then they may be eligible to receive one additional injection of CMV-CTLs. If the CMV levels in the blood continue to rise after the dose of T cells then the patient will receive treatment with Ganciclovir or Foscarnet.
88843052|NCT02908061|Active Comparator|Surgery (Usual approach group)|standard surgery
88843053|NCT02908061|Experimental|Surgery + Mesh Placement|prophylactic mesh at the time of standard surgery
88843054|NCT02883972|Experimental|Intervention letter and reminder|Behavioural insights informed invitation letter and SMS/email reminder message
88843055|NCT02883972|Experimental|Intervention letter|Behavioural insights informed invitation letter only
88843056|NCT02883972|Experimental|Control letter and reminder|Control invitation letter and SMS/email reminder message
88843057|NCT02883972|Active Comparator|Control letter|Control invitation letter only
88843058|NCT02856425|Experimental|Colorectal adenocarcinoma (not mismatch repair deficient by either PCR and/or IHC)|
88843059|NCT02856425|Experimental|Gastric or gastroesophageal adenocarcinoma (not mismatch repair deficient by either PCR and/or IHC|
89180387|NCT02591589|Experimental|Normoxic group|To standardize key aspects of ventilator support, tidal volume will be set to 6-8ml/kg and PEEP levels will be set to 0-5cm H2O, allowing flexibility for provider preference. For normoxic oxygenation FiO2 will be set at 0.35 (35%) ideally to maintain PaO2 above 70mmHg (or saturations greater than or equal to 92%), and titrated up if need be to prevent potentially injurious hypoxemia (saturations below 92%). During cardiopulmonary bypass, blended air/ oxygen mixture will be titrated to arterial blood gas analysis with maintenance of PaO2 between 100mmHg and 150mmHg.
88843060|NCT02856425|Experimental|Urothelial cancer|
88843061|NCT02856425|Experimental|Renal Cell cancer (RCC)|
88843062|NCT02856425|Experimental|Mesothelioma (MPM)|
88843063|NCT02856425|Experimental|Cervical Cancer (CC)|
88843064|NCT02856425|Experimental|Hepatocellular (HCC)|
88843065|NCT02856425|Experimental|Thymic Carcinoma (TC)|
88843066|NCT02856425|Experimental|Patients with advanced cancers and high tumor mutational burden (TMB-High)|High tumor mutational burden (TMB-High) on their circulating tumor DNA (ctDNA) as defined by more than twenty mutations per megabase (≥20Mut/Mb) on FoundationOne Liquid CDx assay
88843067|NCT02785952|Experimental|Arm I (nivolumab, ipilimumab)|Patients receive nivolumab IV over 30 minutes on day 1 and ipilimumab IV over 60 minutes on day 1 of every third course (every 42 days). Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
88843068|NCT02785952|Active Comparator|Arm II (nivolumab)|Patients receive nivolumab IV over 30 minutes on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
88843069|NCT02769117|Active Comparator|Ultrasound on fractured bone|An ultrasound technique will be used to record the acoustic response of the fractured bone at each clinical visit until the fracture is healed. The ultrasound probe and a small hydrophone are placed on the exposed portion of the forearm on either sides of the fracture. The ultrasound intensity will be at the safe level according to the FDA regulation. Investigators will conduct the tests on the fracture and on the unaffected (contralateral) bone as the control. Typically this is at 1-, 2-, 4-, and 6- weeks following the fracture.
88843070|NCT02769117|Active Comparator|Ultrasound on contralateral intact bone|An ultrasound technique will be used to record the acoustic response of the intact bone as control at each clinical visit. The ultrasound probe and a small hydrophone are placed on the exposed portion of the forearm or clavicle. The ultrasound intensity will be at the safe level according to the FDA regulation. Investigators will conduct the tests on the fractured forearm/clavicle and on the unaffected (contralateral) forearm/clavicle as the control. Typically this is at 1-, 2-, 4-, and 6- weeks following the fracture.
88843071|NCT02763085|Experimental|Basic Filling Material|Fillings made with a new dental filling material.
89370311|NCT01355445|Active Comparator|Vincristine / Irinotecan|Vincristine, Irinotecan Vincristine :1.5 mg/m² (max 2mg), IV Irinotecan : Irinotecan 50 mg/m²/d, IV
89370312|NCT01355445|Experimental|Vincristine / Irinotecan / Temozolomide|Vincristine, Irinotecan, Temozolomide
88843072|NCT02757573|Experimental|Hypercarbia|Hypercarbia: PaCO2 is elevated from 5 to 7.5 kPa by controlled ventilation.
88843073|NCT02748798|Experimental|Healthy Participants|Participants will inhale investigational gases (HP 3He, HP 129Xe, PFP and SF6) according to the procedure for that intervention. All participants can potentially inhale all the gases. Magnetic resonance imaging will be performed during breath-holds or continuous breathing (gas-dependent) with the appropriate investigational human lung coil (3He Human Lung Coil, 129Xe Small and Large Human Lung Coil, or PFP and SF6 Human Lung Coil), using the 3T Research MRI at the Thunder Bay Regional Health Sciences Centre.
88843074|NCT02748798|Experimental|Lung Disorder Participants|Participants will inhale investigational gases (HP 3He, HP 129Xe, PFP and SF6) according to the procedure for that intervention. All participants can potentially inhale all the gases. Magnetic resonance imaging will be performed during breath-holds or continuous breathing (gas-dependent) with the appropriate investigational human lung coil (3He Human Lung Coil, 129Xe Small and Large Human Lung Coil, or PFP and SF6 Human Lung Coil), using the 3T Research MRI at the Thunder Bay Regional Health Sciences Centre.
88843075|NCT02654236|Placebo Comparator|Placebo|Heavy Drinkers on placebo
88843076|NCT02654236|Experimental|10 mg Obeticholic Acid (OCA)|10 mg Obeticholic Acid (OCA) Study medication will be administered orally, once daily for 4 weeks.
88843077|NCT02654236|No Intervention|Non-drinking Controls|Non-drinking healthy controls
89180388|NCT02591589|Active Comparator|Hyperoxic group|To standardize key aspects of ventilator support, tidal volume will be set to 6-8ml/kg and PEEP levels will be set to 0-5cm H2O, allowing flexibility for provider preference. For hyperoxic oxygenation FiO2 will be set at 1.0 (100%) throughout the intraoperative period, including cardiopulmonary bypass.
88843078|NCT02604563||Arm A: Clonal hematopoiesis|"Complete several self-administered health assessments at baseline and every 6 months until death.~Cognitive assessment, Gait Speed, grip strength, blood pressure, height, and weight will be performed by a member of the research team at baseline and every 6 months until death.~Peripheral blood draw will occur at baseline and no more than every 6 months until death.~Buccal swabs will occur at baseline and repeated as necessary, but not more than every 6 months until death~May be approached about optional bone marrow biopsy"
88843079|NCT02604563||Arm B: No clonal hematopoiesis|"Complete several self-administered health assessments at baseline and every 6 months until death.~Cognitive assessment, Gait Speed, grip strength, blood pressure, height, and weight will be performed by a member of the research team at baseline and every 6 months until death.~Peripheral blood draw will occur at baseline and no more than every 6 months until death.~Buccal swabs will occur at baseline and repeated as necessary, but not more than every 6 months until death~May be approached about optional bone marrow biopsy"
88843080|NCT02604563||Arm C: No clonal hematopoiesis & no follow-up|"Complete several self-administered health assessments at baseline with no further follow-up~Cognitive assessment, Gait Speed, grip strength, blood pressure, height, and weight will be performed by a member of the research team at baseline with no further follow-up~Peripheral blood draw will occur at baseline with no further follow-up~Buccal swabs will occur at baseline with no further follow-up"
88843081|NCT02604563||Arm D: Hip replacement|"Complete several self-administered health assessments at baseline and every 6 months until death.~Cognitive assessment, Gait Speed, grip strength, blood pressure, height, and weight will be performed by a member of the research team at baseline and every 6 months until death.~Participants with or without clonal hematopoiesis who are undergoing hip replacement~Peripheral blood draw will occur at baseline and no more than every 6 months until death.~Buccal swabs will occur at baseline and repeated as necessary, but not more than every 6 months until death~May be approached about optional bone marrow biopsy"
88843082|NCT02604563||Arm E: Trauma|-Blood sample at the time of admission with initial bloodwork. For inpatient participants, weekly follow-up samples will be drawn with morning phlebotomy. A follow-up sample collection will occur 4-7 weeks after discharge.
88843083|NCT02597491|Active Comparator|4 wk assessment + TLC monthly|4 week assessment, 8 weeks of counseling, NRT, monthly follow-up (responders)
88843084|NCT02597491|Active Comparator|4 week assessment + TLC quarterly|4 week assessment, 8 weeks of counseling, NRT, quarterly follow-up (responders)
88843085|NCT02597491|Active Comparator|4 week assessment +TLC + MTM|4 week assessment, 4 weeks counseling, NRT, medication management (nonresponders)
88843086|NCT02597491|Active Comparator|8 week assessment + TLC monthly|8 week assessment, 8 weeks of counseling, NRT, monthly follow-up (responders)
88843087|NCT02597491|Active Comparator|8 week assessment + TLC quarterly|8 week assessment, 8 weeks of counseling, NRT, quarterly follow-up (responders)
88843088|NCT02597491|Active Comparator|8 week assessment + TLC + MTM|8 week assessment, 8 weeks counseling, NRT, medication management (nonresponders)
88843089|NCT02584270|Experimental|Prosthesis + Articulation Therapy|This arm will receive a palatal augmentation prosthesis with standard articulation therapy, and is the study arm.
88843090|NCT02584270|Other|No Prosthesis; Articulation Therapy Only|This arm will not receive a palatal augmentation prosthesis, but will receive standard articulation therapy, and is the control arm.
88843091|NCT02565537|Active Comparator|iDesign WFG LASIK|Wavefront-guided LASIK
88843092|NCT02565537|Active Comparator|Wavelight WFO LASIK|Wavefront-optimized LASIK
88843093|NCT02443727|Experimental|Intranasal oxytocin group|Participants will self-administer a single dose of 24 IU oxytocin (Syntocinon, Novartis; three puffs per nostril, each with 4 IU oxytocin, 6 puffs total).
88843094|NCT02443727|Placebo Comparator|Placebo group|"The placebo is identical to the oxytocin formulation with the exception of the active compound.~Participants will self-administer three puffs per nostril of placebo (6 puffs total)."
89180389|NCT02591667|Experimental|Active treatment|"Patients will first undergo upfront staging laparoscopy with retrieval of tumor tissue for standard pathology.~Two to 4 weeks after initial surgical exploration, patients will receive 4 cycles of FOLFOXIRI + bevacizumab, q2w. The last chemotherapy cycle will be given without bevacizumab.~Five to 7 weeks after the last administration of bevacizumab (i.e., 3 to 5 weeks after completion of chemotherapy), patients will undergo surgery with the intent to perform complete surgical cytoreduction of all peritoneal tumor deposits. Further chemotherapy according to the currently available treatment guidelines, including intraperitoneal hyperthermic chemotherapy in patients where complete surgical cytoreduction has been achieved, will be given at the discretion of the investigator."
89180390|NCT00721227|Active Comparator|Anterior Curve|Reduction Gastroplasty by Gastric Plication on Anterior Curve
89180391|NCT00721227|Active Comparator|Greater Curve|Reduction Gastroplasty by Gastric Plication on Greater Curve
89180392|NCT00807599|Experimental|Stem cell transplant x 1 or x 2|"All patients on this study start with the same treatment, lenalidomide and dexamethasone by mouth. After patients have received 4 cycles of lenalidomide and dexamethasone and are within 2 weeks of completing stem cell collection, they are randomized (like the toss of a coin) to either :~stem cell transplant right after collection~continue lenalidomide and dexamethasone, saving stem cell transplant for a later time."
88843095|NCT02429700|Experimental|PT (Arm 1)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 1 hour on day 1. Treatment repeats every 21 days for 4-6 courses in the absence of disease progression or unacceptable toxicity.
88843096|NCT02429700|Active Comparator|BEP (Arm 2)|"Patients receive bleomycin IM daily for days 1-3, etoposide IV daily for days 1-5, cisplatin IV for days 1-5. Treatment repeats every 21 days for 3 or 4* courses in the absence of disease progression or unacceptable toxicity.~NOTE: *Patients who have good risk will have 3 courses and those who have poor risks will have 4 courses."
88843097|NCT02429687|Experimental|PT (Arm 1)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 1 hour on day 1. Treatment repeats every 21 days for 4-6 courses in the absence of disease progression or unacceptable toxicity.
88843098|NCT02429687|Active Comparator|BEP (Arm 2)|"Patients receive bleomycin IM daily for days 1-3, etoposide IV daily for days 1-5, cisplatin IV for days 1-5. Treatment repeats every 21 days for 3 or 4* courses in the absence of disease progression or unacceptable toxicity.~NOTE: *Patients who have good risk will have 3 courses and those who have poor risks will have 4 courses."
89180393|NCT00807599|Experimental|Continue lenalidomide and dexamethasone|"All patients on this study start with the same treatment, lenalidomide and dexamethasone by mouth. After patients have received 4 cycles of lenalidomide and dexamethasone and are within 2 weeks of completing stem cell collection, they are randomized (like the toss of a coin) to either :~stem cell transplant right after collection~continue lenalidomide and dexamethasone~saving stem cell transplant for a later time."
89180394|NCT00721149|Experimental|NaviStar ThermoCool|
89370313|NCT02420080||Cohort A|"The primary endpoint for subjects in Cohort A is time to progression of AdV disease through Week 24 post initial AdV diagnosis, with progression of AdV disease defined as time to the following outcomes:~Clinical progression to probable or definitive disseminated AdV disease Death"
88809733|NCT01279304||Group 3. High risk|"Surgical strategy is full axillary lymph node dissection after primary systemic treatment and in case of:~a. 4 or more nodes positive: ypN2~or~Surgical strategy is sentinel node procedure only performed prior to primary systemic treatment and in case of:~≤ 2 macrometastases in the sentinel node prior to primary systemic treatment in the presence of risk factors like Grade 3, lymphangioinvasion, tumour size > 3 cm; or~3 macrometastases, 2 macrometastases and 1 micrometastase, 1 macrometastase and 2 micrometastases.~or~Surgical strategy is sentinel node procedure only performed after primary systemic treatment and in case of:~Micrometastases in the post chemo SN, and at least one risk factor~≤ 3 macrometastases in the post chemo SN; or~2 macrometastases and 1 micrometastase, 1 macrometastase and 2 micrometastases"
88809734|NCT01279616|Experimental|Hematopoietic Stem Cell Transplant|Stem cell infusion on Day 0.
88809735|NCT01275638|Placebo Comparator|Prednisolone (20 mg/day) for 10 days.|
88809736|NCT00724568|Experimental|Combination Drug Therapy|Patients will be treated with Velcade at 1.3 mg/m2 on days 1, 4, 8, and 11, Doxil at indicated doses on day 4, Dexamethasone at 20 mg orally on days of Velcade and the day after for all dose levels, and Revlimid at indicated doses on days 1-14 in 3-week cycles for 4-8 cycles. To determine the MTD of the combination of Revlimid, Velcade, dexamethasone, and Doxil, four dose levels are planned.
88809737|NCT01279070|Experimental|REPYFLEC cognitive remediation training|REPYFLEC cognitive remediation as a Problem solving and Cognitive flexibility group training.
88809738|NCT01279070|Active Comparator|Leisure group|"Leisure group is a stimulating activity focused on socialization through group dynamics, board games, coffee and talk."
88809739|NCT01274000|Placebo Comparator|placebo group|
88809740|NCT01274000|Experimental|YM060 low-dose group|
88809741|NCT01274000|Experimental|YM060 middle-dose group|
88809742|NCT01274000|Experimental|YM060 high-dose group|
88809743|NCT04270526|Active Comparator|Active treatment|50 mL 1% lidocaine + 45ml of 0.9% normal saline + 5 mL 8.4% sodium bicarbonate
88809744|NCT04270526|Placebo Comparator|Placebo treatment|50 mL 1% lidocaine + 50ml of 0.9% normal saline
88809745|NCT04274738|Experimental|Mavorixafor and Ibrutinib|Each participants will initially receive mavorixafor at Dose Level 1 (200 mg QD) in combination with ibrutinib 420 mg. Cohort A will comprise the first 6 participants enrolled in the study that complete at least their first cycle at Dose Level 2 (400 mg QD). Cohort A participants will start at Dose Level 1 and be allowed to dose escalate after the first cycle to Dose Level 2, if no DLTs are observed during the first cycle of each participant. Cohort B will comprise the next 6 participants enrolled into the study that complete at least their 1st cycle at Dose Level 3 (600 mg QD). Cohort B participants will start at Dose Level 1 and be allowed to dose escalate up to Dose Levels 2 and 3. Cohort C will comprise the remainder of participants enrolled up to the total of 18. Cohort C participants will start at Dose Level 1 and be allowed to escalate to 400 and 600 mg after each dose level has been deemed safe by participants from Cohort A and B.
88809746|NCT04272320|No Intervention|Group C|
88809747|NCT04272320|Active Comparator|Group TFP|Transversalis fascia plane block, before the surgical procedure.
88809748|NCT01274078|No Intervention|conventional food|Regular eating habits during exercise period
88809749|NCT01274078|Active Comparator|Blueberries|Intervention: Addition of blueberries (150g/day) to regular food during the exercise period on days with exercise
88809750|NCT01277744|Experimental|HIPEC + Cisplatin|HIPEC, technique for combining hyperthermia and chemotherapeutic agents delivered intraoperatively to the peritoneal and retroperitoneal surface via a recirculating perfusion circuit, performed after cytoreductive surgery and lysis of adhesions. Cisplatin 100 mg/M2 per perfusion catheter. The perfusion is continued for 90 minutes after adding the Cisplatin.
88809751|NCT04386200|Experimental|WEB GROUP|Traditional approach integrated with web-based technologies.
88809752|NCT04386200|Other|TRADITIONAL GROUP|Traditional educational approach
88809753|NCT01274156|Active Comparator|shock wave treatment|
88809754|NCT01274156|Sham Comparator|"MEDISPEC Sham"|"MEDISPEC Probe does not deliver energy but creates same noise and sensation of active probe"
88809755|NCT01274234|Experimental|COMBO Stent|COMBO Stent
88843099|NCT02372136|Experimental|Individualized and Optimized Nutrition|Individualized nutrition Optimized nutrition
88843100|NCT02372136|Other|Optimized Nutrition|Optimized nutrition
88843101|NCT02268552|Experimental|branaplam|branaplam Treatment
88843102|NCT02207777|Experimental|Roux-en-Y gastric bypass (RYGB)|Subjects in this group are scheduled to undergo roux-en-Y gastric bypass surgery to obtain approximately 16-18% (with a range of 16-25%) weight loss.
88843103|NCT02207777|Active Comparator|Low-calorie diet|Subjects in this group will participate in a low-calorie diet intervention to obtain approximately 16-18% (with a range of 16-25%) weight loss.
89180395|NCT00788372|Experimental|Fentanyl|Fentanyl transdermal patch will be applied once daily up to 4 weeks in Treatment period 1, releasing at the rate of 12.5 microgram per hour (mcg/hr), maintained for 2 days and for another 48 weeks in Treatment period 2. The dose will be increased as per Investigators' discretion in both treatment periods and the maximum applied dose will be 300 mcg/hr. Total duration of treatment is 52 weeks.
89180396|NCT04086459|Active Comparator|Active repetitive transcranial magnetic stimulation|
89180397|NCT04086459|Sham Comparator|Sham repetitive transcranial magnetic stimulation|
89180398|NCT04086459|No Intervention|No repetitive transcranial magnetic stimulation|
89180399|NCT03953937||ICP cohort|Patients with idiopathic pancreatitis
89180400|NCT05754047||HER2-low|patients with HER2 IHC1+ and HER2 IHC2+/ISH-negative in their pathology
89370314|NCT02420080||Cohort B|The primary endpoint for subjects in Cohort B is time to all-cause mortality through Week 36 post diagnosis of disseminated AdV disease
89370315|NCT01355601|Experimental|Group 1 - Control A|Nutritional beverage containing varying types and levels of carbohydrates
89180401|NCT05754047||HER2-negative|patients with HER2-zero in their pathology
89180402|NCT05754047||HER2-positive|patients with HER2 IHC2+/ISH-positive and HER2 IHC 3+ in their pathology
89180403|NCT03953547||search for antiplatelet resistance|Patients who were hospitalized in the vascular medicine department and who benefited from a search for antiplatelet resistance between April 2014 and November 2017.
89180404|NCT00738582|Experimental|Open Label|Pemetrexed, Cisplatin and MORAb-009 (Amatuximab)
89180405|NCT05753657|Experimental|Treatment arm|treating hyperinsulinemia and hyperglycemia with pioglitazone in patients treated with Alpelisib for metastatic breast cancer
89180406|NCT00720759|Experimental|Arm 1|D-cycloserine + distributed treatment
89180407|NCT00720759|Sham Comparator|Arm 2|D-cycloserine + condensed treatment
89180408|NCT00720759|Placebo Comparator|Arm 3|Placebo + distributed treatment
89180409|NCT00720759|Placebo Comparator|Arm 4|Placebo + condensed treatment
89370316|NCT01355601|Experimental|Group 2 - Experimental A|Nutritional Beverage with varying types and levels of carbohydrates
89370317|NCT04483258|Active Comparator|Sedation with Insufflation|Sedation induction via oxygen mask %8 sevoflurane and reducing %3 concentration after rediotherapy start
88843104|NCT02194829|Experimental|Arm A|Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Patients also receive WEE1 inhibitor AZD1775 PO daily on days 1, 2, 8, 9, 15, and 16.
88843105|NCT02194829|Experimental|Arm B|Patients receive paclitaxel albumin-stabilized nanoparticle formulation, gemcitabine hydrochloride, and WEE1 inhibitor AZD1775 as in Arm A.
88843106|NCT02168400|Experimental|active tDCS|Subjects that are randomly assigned to this arm will receive 10 active transcranial direct current stimulation (tDCS) sessions
88843107|NCT02168400|Sham Comparator|sham tDCS|Subjects randomly assigned to sham-tDCS (transcranial direct current stimulation) will receive very low current stimulation at beginning and end of session, mimicking the feeling of current stimulation in the scalp, but not reaching levels that will stimulate brain function.
88843108|NCT02087046|Other|Stimulation|ANS Totally Implantable Deep Brain Stimulation System
88843109|NCT02010814||PCOS|"Women fulfilling at least two of the three Rotterdam criteria for PCOS, including~Irregular menstrual cycle~Clinical/biochemical hyperandrogenemia~Polycystic ovaries"
88843110|NCT01891994|Experimental|Eltrombopag|Administration of eltrombopag at a dose of 150mg/day for 6 months
88843111|NCT01848028||Fumaric acid esters|Intervention: Drug: conventional systemic: Fumaric acid esters, including Dimethylfumarate, all dosages, frequencies and durations prescribed
88843112|NCT01848028||Methotrexate|Intervention: Drug: conventional systemic: Methotrexate, all dosages, frequencies and durations prescribed
88843113|NCT01848028||Cyclosporine A|Intervention: Drug: conventional systemic: Cyclosporine A, all dosages, frequencies and durations prescribed
88843114|NCT01848028||Efalizumab (withdrawn)|Intervention: Biological: Efalizumab, all dosages, frequencies and durations prescribed
88843115|NCT01848028||Etanercept|Intervention: Biological and biosimilars: Etanercept, all dosages, frequencies and durations prescribed
88843116|NCT01848028||Infliximab|Intervention: Biological and Biosimilars/-identicals: Infliximab, all dosages, frequencies and durations prescribed
88843117|NCT01848028||Adalimumab|Intervention: Biological and Biosimilars: Adalimumab, all dosages, frequencies and durations prescribed
88843118|NCT01848028||Ustekinumab|Intervention: Biological: Ustekinumab, all dosages, frequencies and durations prescribed
88843119|NCT01848028||Golimumab|Intervention: Biological: Golimumab, all dosages, frequencies and durations prescribed
89180410|NCT04017494||Single ventricle|Patients with single ventricle lesions
89180411|NCT00918060|Experimental|gel a|
89180412|NCT00918060|Placebo Comparator|gel b|
89180413|NCT00918411|Experimental|Ramosetron group|oral
89180414|NCT00918411|Placebo Comparator|Placebo group|oral
89180415|NCT04001270||Patients anti leucine rich glioma inactivated-1 encephalitis|Biomarkers from patients with anti-leucine rich glioma inactivated 1 encephalitis (anti LGI1-E) will be studied. This is a non-interventional study involving biological samples (CSF biomarkers) already stored in biobank repositories. All stored samples were collected as part of the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population.
89180416|NCT00720213|Active Comparator|Respironics BiPAP autoSV2, Then Respironics BiPAP autoSV3|Participants will be randomized to receive Respironics BiPAP autoSV2 first and Respironics BiPAP autoSV3 second.
88809756|NCT04385576|Active Comparator|Aerosol Box|Intubation using the Taiwan model Aerosol Box to assess the duration of time needed for successful endotracheal intubation of an airway manikin.
88809757|NCT04385576|Active Comparator|Intubation Box|Intubation using the UMMC model Intubation Box to assess the duration of time needed for successful endotracheal intubation of an airway manikin.
88809758|NCT01274390||Shorter-storage red blood cell units|Red blood cell units stored <= 10 days
88809759|NCT01274390||Longer-storage red blood cell units|Red blood cell units stored >= 21 days
88809760|NCT01277822|Experimental|Losartan/amlodipine Treatment Arm|One combination tablet containing 100 mg losartan potassium and 5 mg amlodipine camsylate, orally, once daily, for 8 weeks. Participants will also receive 2 tablets of placebo for amlodipine 5mg orally, once daily for 8 weeks.
88809761|NCT01277822|Active Comparator|Amlodipine Treatment Arm|2 tablets each containing 5 mg amlodipine, orally, once daily, for 8 weeks. Participants will also receive 1 tablet of placebo for combination losartan/amlodipine orally, once daily for 8 weeks.
88809762|NCT01277666|Placebo Comparator|Placebo|orally administered
88809763|NCT01277666|Experimental|GSK1605786A 500mg once daily|orally administered
88809764|NCT01277666|Experimental|GSK1605786A 500mg twice daily|orally administered
88809765|NCT00249002|Experimental|ABI-007|ABI-007 35 mg/m^2 given intravenously (IV) into the arteriovenous (AV) graft within 96 hours after angioplasty, followed by repeat treatment during weeks 5, 13 and 21
88809766|NCT04386278|Experimental|Intervention 1|Side one: No treatment Side two: OrthoPulse Gen 2 (2RP) for one minute
88809767|NCT04386278|Experimental|Intervention 2|Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (2RP) for one minute
88809768|NCT04386278|Experimental|Intervention 3|Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (2RP) for 5 minutes
88809769|NCT04386278|Experimental|Intervention 4|Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (2RCW) for five minutes
88809770|NCT04386278|Experimental|Intervention 5|Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (3RB 2RL) for one minute
88809771|NCT04386278|Experimental|Intervention 6|Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (3RB 2RL) for five minutes
88809772|NCT04386278|Experimental|Intervention 7|Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (3RB 2RL) for one minute
88809773|NCT04386278|Experimental|Intervention 8|Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (3RB 2RL) for five minutes
88809774|NCT01277042|Experimental|Cervarix Group|Subjects received a 3-dose vaccination course of the Cervarix™ vaccine administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.
88809775|NCT01277042|Active Comparator|Engerix Group|Subjects received a 3-dose vaccination course of the Engerix™-B vaccine administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.
88809776|NCT01274546||"In Office"|These subjects will come into the office to perform the consenting process, and complete all evaluations required at the only visit in the study.
88809777|NCT01274546||"Telephone Arm"|These subjects will be consented over the phone and give a verbal consent to participate. They will complete all aspects of the study over the phone except for the knee society score evaluation and the x-ray.
88809778|NCT00748826||Infliximab -Rheumatoid Arthritis Participants|
88809779|NCT00754130|Experimental|Placebo/MK-0941 20mg|Participants received Placebo during Period 1 and MK-0941 20 mg during Period 2. There was a washout period of at least 8 days between the two treatment periods.
88809780|NCT00754130|Experimental|MK-0941 5mg/Placebo|Participants received MK-0941 5 mg during Period 1 and Placebo during Period 2. There was a washout period of at least 8 days between the two treatment periods.
88809781|NCT00754130|Experimental|MK-0941 5mg/MK-0941 20mg|Participants received MK-0941 5 mg during Period 1 and MK-0941 20 mg during Period 2. There was a washout period of at least 8 days between the two treatment periods.
88809782|NCT00754130|Experimental|Placebo/MK-0941 40mg|Participants received Placebo during Period 1 and MK-0941 40 mg during Period 2. There was a washout period of at least 8 days between the two treatment periods.
88809783|NCT00754130|Experimental|MK-0941 10mg/Placebo|Participants received MK-0941 10 mg during Period 1 and Placebo during Period 2. There was a washout period of at least 8 days between the two treatment periods.
88809784|NCT00754130|Experimental|MK-0941 10mg/MK-0941 40mg|Participants received MK-0941 10 mg during Period 1 and MK-0941 40 mg during Period 2. There was a washout period of at least 8 days between the two treatment periods.
88809785|NCT00246740|Placebo Comparator|Placebo oral tablet|Patients received oral administration of matching placebo pills, twice a day at least 2 days prior to surgery, on the day of surgery, and for the first 3 postoperative days (via a nasogastric tube or orally when patients tolerated it).
88809786|NCT00246740|Experimental|Periostat|Patients received oral administration of 20 mg of doxycycline, twice a day at least 2 days prior to surgery, on the day of surgery, and for the first 3 postoperative days (via a nasogastric tube or orally when patients tolerated it).
88809787|NCT00748982|Experimental|1|
88809788|NCT00748982|Placebo Comparator|2|
88809789|NCT01274858||lung cancer surgery|
88809790|NCT00749606|Experimental|Individual Telephone Intervention|Individually administered weight loss intervention, based on the Diabetes Prevention Program, delivered by telephone in primary care practices.
88809791|NCT00749606|Active Comparator|Group Telephone Intervention|Group education conference calls to deliver the weight loss intervention, based upon the Diabetes Prevention Program, in primary care practices.
88809792|NCT01274936|Experimental|Qishe|
88809793|NCT01274936|Placebo Comparator|Control|Qishe Placebo
88809794|NCT00761930|Placebo Comparator|A|commercially available Fluoride toothpaste
88809795|NCT00761930|Active Comparator|B|fluoride/triclosan/copolymer toothpaste
88809796|NCT00761930|Experimental|C|fluoride/herbal toothpaste
88809797|NCT00245102|Experimental|Arm I|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88809798|NCT01275014|Placebo Comparator|Placebo|
88843120|NCT01848028||Secukinumab|Intervention: Biological: Secukinumab, all dosages, frequencies and durations prescribed
88843121|NCT01848028||Apremilast|Intervention: Small molecule: Apremilast, all dosages, frequencies and durations prescribed
88843122|NCT01848028||Certolizumab|Intervention: Biological: Certolizumab, all dosages, frequencies and durations prescribed
88843123|NCT01848028||Retinoids|Intervention: Drug: conventional systemic: Retinoids, all dosages, frequencies and durations prescribed
88843124|NCT01848028||Leflunomids|Intervention: Drug: conventional systemic: Leflunomids, all dosages, frequencies and durations prescribed
88843125|NCT01848028||systemic PUVA|Intervention: Drug: conventional systemic: systemic PUVA, all dosages, frequencies and durations prescribed
88843126|NCT01848028||Guselkumab|Intervention: Biological: Guselkumab all dosages, frequencies and durations prescribed
89180417|NCT00720213|Experimental|Respironics BiPAP autoSV3, then Respironics BiPAP autoSV2|Participants will be randomized to receive Respironics BiPAP autoSV3 first and Respironics BiPAP autoSV2.
89180418|NCT04086303|Experimental|young handball players|The first group was named young players (n = 19; age = 18.05 ± 2.58 years, body mass index = 22.0 ± 2.21 kg, sport participation ≤ 10 years)
89180419|NCT04086303|Active Comparator|adult handball players|The second group was named old players (n =23; age = 28,91 ± 3.39 years, body mass index = 22.20 ± 2.75 kg, sport participation ≥ 11 years).
89180420|NCT04112966|Experimental|Early Manual Lymph Drainage|14 sessions of manual lymphatic drainage technique in the three months following surgery and received health education on the prevention of lymphedema.
89180421|NCT04112966|Other|Health education for lymphedema prevention|Only the health education for lymphedema prevention.
89180422|NCT04086381|Active Comparator|Intervention|Oral injestion of 20 grams of creatine monohydrate daily
89180423|NCT04086381|Placebo Comparator|Placebo|Oral injestion of 20 grams of cellulose daily
89180424|NCT04107350|Experimental|whole body vibration on|vibration machine on combined with conventional physical therapy
89180425|NCT04107350|Sham Comparator|whole body vibration off|vibration machine off combined with conventional physical therapy
89180426|NCT00810407||rifabutin|Patients administered Rifabutin.
89180427|NCT00720057|Experimental|Naproxen sodium ER (BAYH6689)|single dose (1 tablet) ER Naproxen sodium 660 mg with a full glass of water (240ml) within 1 - 4 hours post dental surgery.
89180428|NCT00720057|Placebo Comparator|Placebo|Single dose (1 tablet) of placebo with a full glass of water (240ml) within 1 - 4 hours post dental surgery.
89180429|NCT00790868|Experimental|D-cycloserine|DCS-augmented CBT
89180430|NCT00790868|Placebo Comparator|Placebo|placebo-augmented CBT
89180431|NCT04024553||bipolar disorder family|Screening priori BD-I/BD-II patients， their relatives with mental illness (including but not limited to BD) and their healthy families.
89180432|NCT04024553||health control|Group-matched non-psychiatric family history health subjects were enrolled, DSM-IV-TR is used for demographic assessment.
89180433|NCT04105556|Experimental|Nursing Care Based on Kolcaba's Comfort Theory|"In this study, nursing care based on Kolcaba's Comfort Theory, which continues throughout the perioperative period, was applied to children and their parents.~Care was given when the child and his / her parents applied to the outpatient clinic for anesthesia consultation on the working day before the operation, and care was continued in the day surgery unit. On the 1st and 3rd days after discharge, the researcher provided tele-monitoring and consultancy services. In addition, communication with the parents was maintained at all times as needed. Care was terminated on the 10th day after discharge. The time of the study was approximately 12-14 days for each child and his / her parents.~Nursing care consists of 3 types of comfort-oriented care interventions. These interventions;~Standard maintenance interventions,~Emotional focused comfort care interventions,~Cognitive and functional comfort care interventions."
89180434|NCT04105556|No Intervention|Routine hospital schedule|"The researcher sincerely answered all questions asked by the control group during the perioperative period.~After the post-discharge post-tests, the control group was given a gift of medal of courage, a story book and a training booklet prepared for the parents after the policlinic control on the 10th postoperative day, and the training was given to the intervention group."
89180435|NCT00719901|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive obatoclax mesylate IV over 3 hours and bortezomib IV on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89180436|NCT03951675||Individuals Living with DMD|90 patients/parents
89180437|NCT03951675||Healthcare Providers to Patients with DMD|40 healthcare providers
89180438|NCT02591277||Harvoni|Adult patients with chronic genotype 1 HCV infection with or without compensated cirrhosis who take Harvoni as part of routine clinical care at a participating clinic/hospital.
88843127|NCT01848028||Brodalumab|Intervention: Biological: Brodalumab, all dosages, frequencies and durations prescribed
88843128|NCT01848028||Tildrakizumab|Intervention: Biological: Tildrakizumab, all dosages, frequencies and durations prescribed
88843129|NCT01848028||Risankizumab|Intervention: Biological: systemic Risankizumab, all dosages, frequencies and durations prescribed
88843130|NCT01848028||Bimekizumab|Intervention: Biological: Bimekizumab, all dosages, frequencies and durations prescribed
88843131|NCT01848028||Tofacitinib|Intervention: JAK-Inhibitor: Tofacitinib, all dosages, frequencies and durations prescribed
88843132|NCT01848028||Upadacitinib|Intervention: JAK-Inhibitor: Upadacitinib, all dosages, frequencies and durations prescribed
88843133|NCT01848028||Baricitinib|Intervention: JAK-Inhibitor: Baricitinib, all dosages, frequencies and durations prescribed
88843134|NCT01848028||Deucravacitinib|Intervention: JAK-Inhibitor: Deucravacitinib, all dosages, frequencies and durations prescribed
88843135|NCT01848028||Ixekizumab|Intervention: Biological: Ixekizumab, all dosages, frequencies and durations prescribed
89180439|NCT02609555|Experimental|TEM perineal Rectopexy|TEM perineal rectopexy: triple repair technique , Perineal rectopexy with a polyprolene mesh assisted by TEM technique, postanal repair to close the postanak space then finally anal cerclage to hold the rectum in place for one month.
89180440|NCT00807365|Experimental|GHRH|Growth Hormone-Releasing Hormone
89180441|NCT02609789|Experimental|Part A: Dose 1|Drug JNJ-55920839 or Placebo administered IV infusion Dose 1.
89180442|NCT02609789|Experimental|Part A: Dose 2|Drug JNJ-55920839 or Placebo administered IV infusion Dose 2.
88843136|NCT01751490|Active Comparator|physiotherapy alone|patients undergoing physiotherapy only
88843137|NCT01751490|Active Comparator|surgery and physiotherpay|patients receiving surgical treatment followed by physiotherapy
88843138|NCT01390038|Experimental|Simpliciti™ Shoulder System|The Simpliciti™ Shoulder System is intended for Total Shoulder Arthroplasty of the shoulder.
88843139|NCT01370460|Experimental|Tranexamic Acid|Topical tranexamic acid (2g/100mL) applied during unilateral total knee arthroplasty.
88843140|NCT01370460|Placebo Comparator|Placebo|100mL 0.9% NS, applied topically
88843141|NCT01008241||Study Group|Convenience sample of adult residents of South Florida
88843142|NCT00965302|Active Comparator|Intensive medical management of Type 2 DM|Intensive medical management of Type II diabetes will include visits every three months for a year with an endocrinologist, with lifestyle counseling, weight management, regular exercise, and glucose control forming the core of the medical therapy.
88843143|NCT00965302|Experimental|Laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy is performed as part of a bariatric surgical program emphasizing healthy dietary choices, regular exercise, and glucose control.
88843144|NCT00621192|Experimental|Meropenem|"These~Participants were subdivided into the following four groups based on Gestational Age (GA) and Postnatal Age (PNA):~Group 1: GA at birth below 32 weeks - PNA <2 weeks; Group 2: GA at birth below 32 weeks - PNA ≥2 weeks and <91 days; Group 3: GA at birth 32 weeks or older - PNA <2 weeks; Group 4: GA at birth 32 weeks or older - PNA ≥2 weeks and <91 days."
88843145|NCT00278200|Experimental|EBV Seronegative|Inactivated EBV-infected vaccine given at Week 0 and Week 4. This arm included all participants who were negative for Epstein-Barr Virus (EBV) at baseline.
88843146|NCT00278200|Experimental|EBV Seropositive|Inactivated EBV-infected vaccine given at Week 0 and Week 4. This arm included all participants who were positive for Epstein-Barr Virus (EBV) at baseline.
88843147|NCT00255346|Experimental|Acute myeloid leukemia (AML)|Dasatinib 70 mg orally twice daily.
88843148|NCT00255346|Experimental|MDS/CMML|Dasatinib 70 mg orally twice daily.
88843149|NCT00255346|Experimental|HES/CEL|Dasatinib 70 mg orally twice daily.
88843150|NCT00255346|Experimental|Primary myelofibrosis (PMF)|Dasatinib 70 mg orally twice daily.
88843151|NCT00255346|Experimental|Systemic Mastocytosis (SM)|Dasatinib 70 mg orally twice daily.
88843152|NCT00114894|Experimental|Safe Sea|
88843153|NCT00114894|Sham Comparator|Placebo|Coppertone® SPF15 (Schering-Plough)
88843154|NCT02834624|Active Comparator|Calfactant|Randomized to receive Infasurf as the surfactant to treat respiratory distress syndrome. Doses 3ml/kg. to be repeated as needed by determination of attending neonatologist.
88843155|NCT02834624|Active Comparator|Poractant Alfa|Randomized to receive Curosurf as the surfactant to treat respiratory distress syndrome. Doses 3ml/kg. to be repeated as needed by determination of attending neonatologist.
88843156|NCT02917603|Experimental|Intervention|These family members and residents will use web conferencing technology to attend their quarterly care conferences
88843157|NCT02917603|No Intervention|Control|These family and residents will receive usual care
89180443|NCT02609789|Experimental|Part A: Dose 3|Drug JNJ-55920839 or Placebo administered IV infusion Dose 3.
89180444|NCT02609789|Experimental|Part A: Dose 4|Drug JNJ-55920839 or Placebo administered IV infusion Dose 4.
88843158|NCT02837744||Axiostat®|Size: 3.5 cm X 3.5 cm
88843159|NCT02918617|Active Comparator|Control toothpaste containing Novamin® technology|Participants will be instructed to apply a full ribbon of toothpaste to a damp toothbrush. Participants will then brush for 2 minutes followed by rinsing with 15 mL of water. Participants will be instructed not to eat or drink for 30 minutes following brushing. Brushing will be performed twice a day (morning and evening).
88843160|NCT02918617|Placebo Comparator|Control toothpaste containing 1500 ppm fluoride as MFP|Participants will be instructed to apply a full ribbon of toothpaste to a damp toothbrush. Participants will then brush for 2 minutes followed by rinsing with 15 mL of water. Participants will be instructed not to eat or drink for 30 minutes following brushing. Brushing will be performed twice a day (morning and evening).
88843161|NCT02918617|Experimental|Test toothpaste with nano-HAP (high concentration)|Participants will be instructed to apply a full ribbon of toothpaste to a damp toothbrush. Participants will then brush for 2 minutes followed by rinsing with 15 mL of water. Participants will be instructed not to eat or drink for 30 minutes following brushing. Brushing will be performed twice a day (morning and evening).
88843162|NCT02918617|Experimental|Test toothpaste with nano-HAP (low concentration)|Participants will be instructed to apply a full ribbon of toothpaste to a damp toothbrush. Participants will then brush for 2 minutes followed by rinsing with 15 mL of water. Participants will be instructed not to eat or drink for 30 minutes following brushing. Brushing will be performed twice a day (morning and evening).
88843163|NCT02918617|Experimental|Test toothpaste with nano-HAP and potassium nitrate (KNO3)|Participants will be instructed to apply a full ribbon of toothpaste to a damp toothbrush. Participants will then brush for 2 minutes followed by rinsing with 15 mL of water. Participants will be instructed not to eat or drink for 30 minutes following brushing. Brushing will be performed twice a day (morning and evening).
88843164|NCT02918617|Placebo Comparator|Control toothpaste without nano-HAP|Participants will be instructed to apply a full ribbon of toothpaste to a damp toothbrush. Participants will then brush for 2 minutes followed by rinsing with 15 mL of water. Participants will be instructed not to eat or drink for 30 minutes following brushing. Brushing will be performed twice a day (morning and evening).
88843165|NCT02918617|Experimental|Test toothpaste with nano-HAP (medium concentration)|Participants will be instructed to apply a full ribbon of toothpaste to a damp toothbrush. Participants will then brush for 2 minutes followed by rinsing with 15 mL of water. Participants will be instructed not to eat or drink for 30 minutes following brushing. Brushing will be performed twice a day (morning and evening).
89180445|NCT02609789|Experimental|Part A: Dose 5|Drug JNJ-55920839 or Placebo administered IV infusion Dose 5.
89180446|NCT02609789|Experimental|Part A: Dose 6|Drug JNJ-55920839 or Placebo subcutaneous injection Dose 6.
89180447|NCT02609789|Experimental|Part B|Participants will receive 6 doses of JNJ-55920839 or placebo (every 2 weeks) as an IV infusion.
89180448|NCT02591355|Experimental|Autologous Platelet Rich Plasma|Autologous Platelet Rich Plasma injection
89180449|NCT02591355|Placebo Comparator|Saline|Saline solution injection
89370318|NCT04483258|Active Comparator|İntravenous sedation|Midazolam+ Ketamine sedation
89370319|NCT02419768|Experimental|Physical Exercise|All patients will receive a circuit-group training including a specific work of balance, posture, gait, fitness, dual tasks and stretching.
89370320|NCT02419768|No Intervention|Control|All patients will not change their physical activities
89370321|NCT01358097||Patients with HPV positive tumors|
89370322|NCT01358097||Patients with HPV negative tumors|
88809799|NCT01275014|Experimental|Dexamethasone|
88809800|NCT00754832|Experimental|1|Period 1 with Ginseng therapy intervention; Washout Period with no drug; Period 2 with placebo
88809801|NCT00754832|Experimental|2|Period 1 with placebo; Washout period with no drug; Period 2 with ginseng therapy intervention
88809802|NCT01275248|Experimental|Ondansetron 0.5 mg|Ondansetron oral tablet 0.5 mg taken twice a day in addition to a serotonin reuptake inhibitor (SRI) for 12 weeks in the core period and for up to 30 months in the extension period.
88809803|NCT01275248|Experimental|Ondansetron 0.75 mg|Ondansetron oral tablet 0.75 mg taken twice a day in addition to a serotonin reuptake inhibitor (SRI) for 12 weeks in the core period and for up to 30 months in the extension period.
88809804|NCT01275248|Placebo Comparator|Placebo|Placebo oral tablet taken twice a day in addition to a serotonin reuptake inhibitor (SRI) for 12 weeks in the core period and for up to 30 months in the extension period.
88809805|NCT00756236|Experimental|M-Group|Patients were randomly assigned to Metoprolol Group. The drug was dispensed in 60ml & 5ml syringes of 0.9% NaCl and 1mg/ml Metoprolol. Investigators and patients were blinded to the group assignment.
88809806|NCT00756236|Experimental|E-Group|Patients were randomly assigned to Esmolol Group. The drug was dispensed in 60ml & 5ml syringes of 0.9% NaCl and 10mg/ml Esmolol. Investigators and patients were blinded to the group assignment.
88809807|NCT00756236|Placebo Comparator|P-Group|Patients were randomly assigned to this group. Patients received 0.9% NaCl only. To maintain the blind, 0.9% NaCl was also dispensed in 60ml & 5ml syringes.
88809808|NCT00762320|Experimental|Low dose Kaletra tablets|Patients will serve as their own controls as they are switched from the baseline treatment with liquid Kaletra to the study intervention treatment with Low Dose Tablet Kaletra (100mg/25mg)
88809809|NCT03807830|Other|One arm feasbility study|
88809810|NCT03807752|Active Comparator|MPH_active|Daily intake at breakfast of supplementary marine protein hydrolysate (MPH). Random sequence of arms.
88809811|NCT03807752|Placebo Comparator|MPH_placebo|Daily intake at breakfast of supplementary placebo. Random sequence of arms.
88809812|NCT03807674|Other|Control group - Healthy teeth|Patients with clinically healthy third molar or premolar teeth with indications for extraction; no clinical signs of pulpitis, no caries, no indications for the replacement of an old filling that is 1 mm from the pulp space as determined on the radiograph; a normal response to the cold test, and no apical radiolucency on the radiograph. For teeth of this group coronal pulpotomy was applied.
88809813|NCT03807674|Experimental|Test group - Teeth with pulpitis|Patients with symptomatic pulpitis resulting from caries; tooth pain defined as sharp, dull, localized or diffuse; pain at night; a symptomatic tooth with a positive response to the cold test and lingering pain; intermittent or continuous episodes of spontaneous pain (with no external stimulus) that could last from a few minutes up to a few hours; no apical radiolucency on the radiograph. For teeth of this group coronal pulpotomy was applied.
88809814|NCT01275404|Experimental|(SMRP) + nurse practitioner information phone calls|Part A will use focus groups to gain feedback and refine the intervention. Part B will consist of a randomized pilot study where 70 men will be randomly assigned to one of two conditions: Sexual Medicine Rehabilitation (SMRP) plus nurse practitioner information phone calls and monitoring (SMRP+I), or SMRP plus the novel psychological intervention of Acceptance and Commitment Therapy for ED (SMRP+ACT-ED).
88809815|NCT01275404|Experimental|SMRP+ACT-ED|Part A will use focus groups to gain feedback and refine the intervention. Part B will consist of a randomized pilot study where 70 men will be randomly assigned to one of two conditions: Sexual Medicine Rehabilitation (SMRP) plus nurse practitioner information phone calls and monitoring (SMRP+I), or SMRP plus the novel psychological intervention of Acceptance and Commitment Therapy for ED (SMRP+ACT-ED).
88809816|NCT03807206||Flashmob 2019|Patients from the following hospitals will receive a questionnaire/structured intereview: Erasmus MC, Franciscus Gasthuis & Vlietland, Ikazia, Haaglanden Medisch Centrum, Albert Schweitzer ziekenhuis, Jeroen Bosch ziekenhuis, Rijnstate ziekenhuis, Amphia ziekenhuis, Tergooi klinieken, Medisch Spectrum Twente, Reinier de Graaf gasthuis. Pending: Maasstad ziekenhuis
88809817|NCT00244712|Experimental|ABC/3TC|The intervention is a regimen containing abacavir/lamivudine + tenofovir/emtricitabine placebo +lopinavir/ritonavir.
88809818|NCT00244712|Active Comparator|TDF/FTC|The intervention is a regimen containing tenofovir/emtricitabine + abacavir/lamivudine placebo + lopinavir/ritonavir.
88809819|NCT00725270|Placebo Comparator|Placebo|Patients will be randomized to placebo
88809820|NCT00725270|Experimental|Mifepristone|Patients will be randomized to mifepristone
88809821|NCT00243932|Experimental|2,700 mg CoQ10|
88809822|NCT00243932|Placebo Comparator|placebo|
88809823|NCT00243932|Experimental|1,800 mg CoQ10|
88809824|NCT01275482|Experimental|isolated contractions caused|The investigators do TFM causing isolated contractions in de muscle fibers containing de latent trigger point.
88809825|NCT01275482|Active Comparator|No isolated contraction caused|The investigators don´t cause contraction during the TFM
88809826|NCT00243386|Active Comparator|1|Standard prophylaxis
88809827|NCT00243386|Experimental|2|PK-driven prophylaxis
88809828|NCT03807284|Experimental|A group psycho-social course|The intervention group received a group psycho-social course, a 2 hour, weekly, eleven week intervention delivered by a health professional working in stroke and usual care.
88809829|NCT03807284|No Intervention|Control Group|Participants in the usual care control group will continue to receive all other services routinely available to them as is usual practice.
88809830|NCT03807362|Experimental|CC-11050 treatment|200mg CC-11050 will be administered twice daily as a pill taken with food (at breakfast and evening meal) for participants with moderate to severe ENL for 10 days, then up to 28 days (during Step 1) and then up to 1 year (during Step 2).
88809831|NCT01275560|Experimental|Metronidazole|3 intakes per day during 10 days
89370323|NCT01358097||Control|
89370324|NCT03178474|Active Comparator|Breast-Fed Group|The infants will be fed with human breast milk by their mother
89370325|NCT03178474|Experimental|TOFER Formula Group|TOFER Infant formula,TOFER®: Infants will be fed by using TOFER® infant formula (Phase I baby formula) from baseline (about 5-14 days) to 13 weeks of age.
89370326|NCT03178474|Experimental|JINLINGGUAN Formula Group|JINLINGGUAN Infant formula,PRO-KIDO™ I-PROTECH®: Infants will be fed by using JINLINGGUAN (PRO-KIDO™ I-PROTECH®) infant formula (Phase I baby formula) from baseline (about 5-14 days) to 13 weeks of age.
89370327|NCT01355757|Experimental|Baxter INFUSOR System|Regional Analgesia INFUSOR system with Patient Control Module for post-operative analgesia
89370328|NCT01355757|Active Comparator|Single Injection of Local Anesthetic|Single injection of 20 ml ropivacaine 0.5%
89370329|NCT02507505|Active Comparator|Regional Anesthesia|Approximately half of the subjects will be randomized to the arm which receives Regional Anesthesia.
89370330|NCT02507505|Active Comparator|General Anesthesia|Approximately half of the subjects will be randomized to the arm which receives General Anesthesia.
89370331|NCT03181360|Active Comparator|Tenecteplase|Tenecteplase + Best standard treatment
89370332|NCT03181360|Other|Control|No tenecteplase + Best standard treatment
89370333|NCT04769856|Experimental|Non-fasting group|
89370334|NCT04769856|Experimental|Fasting group|
88843166|NCT02918617|Experimental|Test cream with nano-HAP (higher concentration)|Participants will be instructed to brush for 2 minutes morning and evening with a full ribbon of standard fluoride toothpaste. After the evening brushing, participants will then insert custom-made trays loaded with a full ribbon of cream. Participants will be instructed to remove the trays after 5 minutes and expectorate the cream. Participants will be instructed not to eat or drink until the next morning following cream use.
88843167|NCT02918617|Placebo Comparator|Control cream without nano-HAP|Participants will be instructed to brush for 2 minutes morning and evening with a full ribbon of standard fluoride toothpaste. After the evening brushing, participants will then insert custom-made trays loaded with a full ribbon of cream. Participants will be instructed to remove the trays after 5 minutes and expectorate the cream. Participants will be instructed not to eat or drink until the next morning following cream use.
88843168|NCT02839772|Active Comparator|Current skin care regimen|Legs/feet washed daily for 3 months with soapy water, soak for 30 mins in 6 litres of water with added sodium hypochlorite (0.0125%), air dried, thin layer of petrolatum jelly applied and Whitfields ointment if required for any fungal infection.
88843169|NCT02839772|Experimental|Current skin regimen plus 2% glycerine|Legs/feet washed daily for 3 months with soapy water, soak for 30 mins in 1 litre of water with added sodium hypochlorite (0.0125%) and 2% glycerine, air dried, thin layer of petrolatum jelly applied and Whitfields ointment if required for any fungal infection.
89180450|NCT05753969|Experimental|MPH / AMPH Treatment|
89180451|NCT05753969|Placebo Comparator|Placebo|
89370335|NCT04275531||regional anesthesia|surgical procedures which will be performed under intrathecal anesthesia without sedation
89370336|NCT04275531||sevoflurane|surgical procedures which will be performed under general anesthesia and sevoflurane will be used for maintenance of anesthesia
89370337|NCT04275531||isoflurane|surgical procedures which will be performed under general anesthesia and isoflurane will be used for maintenance of anesthesia
89370338|NCT04275531||propofol|surgical procedures which will be performed under general anesthesia and propofol infusion will be used for maintenance of anesthesia
89370339|NCT04764864|Active Comparator|Angioembolization|
89370340|NCT04764864|Active Comparator|Preperitoneal Pelvic Packing|
89370341|NCT01355835|Active Comparator|[STNmono]|Conventional stimulation on subthalamic contacts
89370342|NCT01355835|Experimental|[STN+SNr]|Combined subthalamic and nigral stimulation
89370343|NCT04804527|Experimental|Intensified physiotherapy|In addition to usual care physiotherapy patients in the intensified physiotherapy group will receive an extra physiotherapy session of up to 30 minutes on every weekday starting on the first postoperative day. The session will include progressive functional training of basic mobility and walking in the ward delivered by an experienced physiotherapist affiliated with the trial. The aim of this additional session is to improve the functional advances achieved during the earlier physiotherapy session.
89370344|NCT04804527|Active Comparator|Usual care physiotherapy|Patients will receive approximately 30 minutes physiotherapy once daily in the ward delivered by the ward's usual physiotherapists i.e. starting on the first postoperative day and thereafter primarily on weekdays until discharge (a mean of 8.82 days after admission). Usual care physiotherapy is individualized taking the patients ability and previous level of functioning into account and includes 1) progressive functional training of basic mobility e.g. in-out of bed, sit-to-stand and walking including progression in walking aid, stair training if possible, and advices toward better physical functional level, 2) basic bed exercises with progression to standing exercises according to a hand-out training program and recommendations on doing exercises daily and being as physical active as possible during the day.
89370345|NCT03384745|Experimental|M1095 (Sonelokimab) 30mg|M1095, 30 mg, given at Week 0, 2, 4, 8, 12 and every four weeks.
89370346|NCT03384745|Experimental|M1095 (Sonelokimab) 60mg|M1095, 60 mg, given at Week 0, 2, 4, 8, 12 and every four weeks.
89370347|NCT03384745|Experimental|M1095 (Sonelokimab) 120mg - regimen 1|M1095, 120 mg, given at Week 0, 2, 4, 8, 12 and every eight weeks.
89370348|NCT03384745|Experimental|M1095 (Sonelokimab) 120mg - regimen 2|M1095, 120 mg, given at Week 0, 2, 4, 6, 8, 10, 12 and every four weeks.
89370349|NCT03384745|Placebo Comparator|Placebo / M1095 (Sonelokimab) 120mg|Placebo, given at Week 0, 1, 2, 3, 4, 6, 8 and 10, then M1095, 120mg, given at Week 12, 14, 16, and every four weeks.
89370350|NCT03384745|Active Comparator|Secukinumab|Secukinumab, 300mg, given at Week 0, 1, 2, 3, 4, 8, 12 and every four weeks.
89370351|NCT03180814|Active Comparator|Young Group|Healthy young of both sexes between the ages of 18 and 30 years will perform a whole body vibration session
89370352|NCT03180814|Experimental|Elderly Group|Healthy elderly of both sexes between the ages of 60 and 80 years will perform a whole body vibration session
89370353|NCT01361997|Experimental|Chlorhexidine in isopropyl alcohol|This arm is composed of 545 hospitalized patients with suspected blood stream infection, to test 2% chlorhexidine gluconate in 70% isopropyl alcohol.
89370354|NCT01361997|Experimental|Isopropyl alcohol|This arm is composed of 572 hospitalized patients with suspected blood stream infection, to test 70% isopropyl alcohol.
89370355|NCT04750824||Afatinib cohort|Afatinib cohort
88843170|NCT02918773|Experimental|Smartphone otoscope|Participating clinicians randomized to the smartphone otoscope study arm will use a smartphone otoscope for all otic (ear) examinations for a 6-month period.
89370356|NCT04750824||other systemic therapy cohort|other systemic therapy cohort
89370357|NCT01362075|Experimental|Local infiltration analgesia|
89370358|NCT01362075|Active Comparator|Interscalene catheter|
89370359|NCT03180970|Experimental|group 1|This group patients were given dosages of 1.2% Lugol's solution for chromoendoscopy.
89370360|NCT03180970|Experimental|group 2|This group patients were given dosages of 1.0% Lugol's solution for chromoendoscopy.
89370361|NCT03180970|Experimental|group 3|This group patients were given dosages of 0.8% Lugol's solution for chromoendoscopy.
88843171|NCT02918773|Active Comparator|Conventional otoscope|Participating clinicians randomized to the conventional otoscope study arm will use a conventional otoscope for all otic (ear) examinations for a 6-month period.
89370362|NCT03180970|Experimental|group 4|This group patients were given dosages of 0.6% Lugol's solution for chromoendoscopy.
89370363|NCT03180970|Experimental|group 5|This group patients were given dosages of 0.4% Lugol's solution for chromoendoscopy.
89370364|NCT05676528|Experimental|Intervention|Exercise intervention
89370365|NCT01319097|Other|Sorbion Sachet S|Subject will evaluate Sorbion Sachet S dressing for 4 weeks.
89180452|NCT03781427|Active Comparator|Standard care|Cardiac resynchronization therapy: Usual output programming
89180453|NCT03781427|Experimental|High output|Cardiac resynchronization therapy: High output programming
89370366|NCT03631446||Patients administered Picoprep® for bowel cleansing|Patients administered Sodium Picosulfate, Magnesium Oxide and Citric Acid for bowel cleansing
89370367|NCT03178240|Experimental|Intervention|45 minutes seminar on skin cancer prevention and UV-protection in general.
89370368|NCT03178240|No Intervention|Control|The control croup takes part in the survey but does not receive an intervention.
88843172|NCT03040466|Active Comparator|reusable fiberoptic ureteroscope|For this arm, participants will receive the ureteroscopy for their kidney and ureter stones using reusable fiberoptic flexible ureteroscope (URF-P6, Olympus). The surgical method of the ureteroscopy will be a standard fashion same as other arms.
88843173|NCT03040466|Experimental|disposable digital ureteroscope|For this arm, participants will receive the ureteroscopy for their kidney and ureter stones using disposable digital flexible ureteroscope (LithoVue, Boston Scientific). The surgical method of the ureteroscopy will be a standard fashion same as other arms.
88843174|NCT02918851|Experimental|7-day old RBCs|Transfusion of 7-day stored red blood cells: Subjects will be transfused with their own 7-day old red blood cells
89180454|NCT00719355|Experimental|Walking with Poles|Patients were assigned to a 24 week walking with poles program of rehabilitation. The intervention was the additional of poles to the walking program.
89370369|NCT03383887|Placebo Comparator|Placebo|Placebo capsule 30 minutes before sleep
89370370|NCT03383887|Active Comparator|DAW1033D|DAW1033D capsule 30 minutes before sleep
89370371|NCT03184168|Experimental|treatment|[14C]lorlatinib
88843175|NCT02918851|Experimental|28-day old RBCs|Transfusion of 28-day stored red blood cells: Subjects will be transfused with their own 28-day old red blood cells
89370372|NCT04709874|Experimental|Paravertebral block|Patients will receive paravertebral block guided by a nerve stimulator.
88843176|NCT02918851|Experimental|42-day old RBCs|Transfusion of 42-day stored red blood cells: Subjects will be transfused with their own 42-day old red blood cells
88843177|NCT03041636|Experimental|Treatment (ruxolitinib phosphate)|Patients receive ruxolitinib phosphate PO BID. Treatment continues for up to 3 years in the absence of disease progression or unacceptable toxicity. Treatment beyond 3 years may be permitted after discussion with the principal investigator.
89180455|NCT00719355|Active Comparator|Traditional walking program|Patients were assigned to a 24 week traditional walking program.
89370373|NCT04709874|Active Comparator|Suprascapular block|Patients will receive suprascapular block
89370374|NCT01362153|Experimental|001|Golimumab IV infusions of 2 mg/kg golimumab on Days 1 and 85.
89370375|NCT01362153|Experimental|002|Golimumab SC injection of 100 mg every 4 weeks through Week 20
89370376|NCT03184324|Experimental|DWP14012 20mg|DWP14012 20mg, tablet, orally, once daily
89370377|NCT03184324|Experimental|DWP14012 40mg|DWP14012 40mg, tablet, orally, once daily
89370378|NCT03184324|Experimental|DWP14012 80mg|DWP14012 40mg*2, tablet, orally, once daily
89370379|NCT03184324|Active Comparator|Esomerpazole 40mg|Esomerpazole 40mg, tablet, orally, once daily
89370380|NCT02427334|Active Comparator|Dienogest|women will receive oral dienogest 2mg for 14 days starting from the 15th day of menstruation
89370381|NCT02427334|Active Comparator|Fluoxetine|women will receive oral fluoxetine 20mg for 14 days starting from the 15th day of menstruation
89370382|NCT02427334|Placebo Comparator|Placebo|women will receive oral placebo for 14 days starting from the 15th day of menstruation
89370383|NCT03379753|Experimental|Intervention group|Those patients randomized to intervention group will be exposed to the diad of music and positive images in a private hospital room in addition to receiving standard care.
89370384|NCT03379753|No Intervention|Control group|Those patients randomized to control group will receiving standard care in a private hospital room with an un-modified post operative environment.
89370385|NCT03620253|Experimental|Modafinil|Participants will be administered 100 mg modafinil tablets, that will be over-encapsulated, for one week. If the drug is well tolerated, the dosage will be increased to 200 mg for the remaining 7 weeks of the study. Capsules are taken daily in the morning.
89370386|NCT03620253|Placebo Comparator|Placebo|Participants will be administered 100 mg placebo capsule. This capsule will have all the same ingredients as the modafinil tablets, minus the active ingredient. After 1 week, participants' dosage will be increased to 200 mg for the remaining 7 weeks of the study. Capsules are taken daily in the morning.
89370387|NCT03177928|Active Comparator|study group|patients with myeloproliferative neoplasms and reveal cardiac complications by using echocardiogram, intervention by using transthorathic echocardiography for all patients.
89370388|NCT03177928|Active Comparator|control group|patients with hematological disorders including myeloproliferative neoplasms without cardiac affection by using echocardiogram. Intervention will be in the form of using transthorath echocardiography with all patients to reveal any cardiac abnormalities.
89370389|NCT03177928|Active Comparator|control group 2|healthy people from the same age and sex will be investigated using echocardiogram. Intervention will be in the form of using transthorathic echocardiography.
89370390|NCT01355991|Active Comparator|Anticholinergic Agent|
89370391|NCT01355991|Active Comparator|Long Acting Beta 2 Agonist|
89370392|NCT03180658|Experimental|experimental|GTR+CGF+bone graft, CGF
89370393|NCT03180658|Active Comparator|controlled|CGF+bone graft
89370394|NCT01356069|Experimental|SB-APP Psychotherapy|Patients, who signed the informed consent, were randomly assigned to SB-APP in addition to TAU (n=18) or to TAU alone (n=17) groups. The SB-APP group received the usual treatment plus SB-APP (40 weekly sessions) for 10 or 11 months. At the term of the first year (T12) the TAU group continued with the TAU management with supportive weekly session whilst the SB-APP group was carried on with the psychiatric, nurse, educational management without any individual psychological support. The number of sessions performed by the two groups in the first year (T0-T12) was programmed to be almost the same to reduce the number of sessions bias comparing the specific quality of treatments.
89370395|NCT01356069|Active Comparator|TAU treatment|This treatment consisted in a combination of medication, unstructured psychological support focused on socio-relational impairment and rehabilitative interventions provided by nurses and educators. The medication was administered according to the APA guidelines [18] for good clinical practice with regard to BPD.
89370396|NCT03180424|Active Comparator|L Carnitine + Exercise at home|Patients who will receive L Carnitine, in liquid form, at a dosage of 2g per day, in a single intake, in addition to physical exercise advice at home for which a manual will be delivered in the consultation, for 12 weeks.
89370397|NCT03180424|Experimental|L Carnitine + supervised exercise|Patients receiving L Carnitine, in liquid form, at doses of 2g per day, in a single intake, in addition to a supervised physical exercise plan, for 12 weeks.
89180456|NCT05753579|Active Comparator|Control Group|In our study, stabilization exercises were applied to the patients in the control group. The treatment was applied two days a week for five weeks, for a total of ten sessions. After the end of the treatment, stabilization exercises were recommended as a home exercise program until the follow-up evaluation at the third month. A telephone connection was established with the patients once a week and the home program was followed up.Stabilization exercises: It is an approach that is combined with diaphragmatic breathing and activates the passive. The stabilization exercise program was applied in three phases and was progressed in line with the developments in the patients.
89370398|NCT03180424|Placebo Comparator|Placebos + supervised exercise|Patients receiving placebo and supervised exercise plan.
89370399|NCT01319175|Experimental|Training group|
89370400|NCT01358253|Active Comparator|HyperCVAD|"Consolidation:~HyperCVAD(odd courses) alternated with high-dose methotrexate + cytarabine (even courses) every 21 days or later to allow for myelosuppression recovery, for total of 8 courses.~Maintenance:~6-Mercaptopurine+Methotrexate for 24 months. Vincristine+Prednisone for the first 12 months. L-asparaginase in month 3 and 9."
89370401|NCT01358253|Experimental|R-HyperCVAD|"Consolidation:~R-HyperCVAD(odd courses) alternated with high-dose methotrexate + cytarabine (even courses) every 21 days or later to allow for myelosuppression recovery, for total of 8 courses.~Maintenance:~6-Mercaptopurine+Methotrexate for 24 months. Vincristine+Prednisone for the first 12 months. L-asparaginase in month 3 and 9. Rituximab in month 6 and 12."
89370402|NCT03180346|Active Comparator|Single-Use Negative Pressure Wound Therapy|
89370403|NCT03180346|Active Comparator|Standard of Care|
89370404|NCT03180112||case group|Children suffering from Autism Spectrum disorders of variable grades attending to assiut University Children Hospital aged between six months and five years.
89370405|NCT03180112||control group|Healthy children of matching age and sex.
89370406|NCT01356225|Experimental|Intranasal Ketorolac tromethamine|
89370407|NCT01356225|Placebo Comparator|Intranasal placebo|
89370408|NCT03379675|Experimental|Treatment A: JNJ-53718678 500 mg|Participants will receive 500 mg dose of JNJ-53718678 once daily for 7 days.
89370409|NCT03379675|Experimental|Treatment B: JNJ-53718678 80 mg + Placebo|Participants will receive 80 mg dose of JNJ-53718678 along with the matching placebo to the same total volume as for the 500 mg dose once daily for 7 days.
89370410|NCT03379675|Placebo Comparator|Treatment C: Placebo|Participants will receive matching placebo to the same total volume as for the 500 mg dose once daily for 7 days.
89370411|NCT02427412|Active Comparator|IA Tranexamic acid + IV Tranexamic Acid|3 gram of Tranexamic acid diluted into 30 ml Saline Water injected into the knee capsula after ended surgery + 1 g of Tranexamic acid injected intravenous at the start of surgery.
89370412|NCT02427412|Placebo Comparator|IA Saline Water + IV tranexamic Acid|30 ml Saline Water injected into the knee capsula after ended surgery + 1 g of Tranexamic acid injected intravenous at the start of surgery.
89370413|NCT01356303|Experimental|Cisplatin, Docetaxel|Each cycle of chemotherapy administration will be started with docetaxel at dose of 75 mg/m2 in 250 ml of D5W or NS administered as a 1-hour intravenous infusion, followed by cisplatin at dose of 75 mg/m2administered as a 2-hour intravenous infusion every 3 weeks per cycle for 4-6 cycles
88809832|NCT01275560|Active Comparator|Carbosylane|3 intakes per daysduring 10 days
88809833|NCT00762710|Experimental|1 - Prazosin Medication|Following randomization, participants in this arm will receive a 2-week titration of Prazosin followed by 10 weeks of stable dosing of Prazosin. They will also attend study visits at least weekly for 12 weeks and will complete a final follow-up one month after discontinuation of the medication phase of the study at 16 weeks post-randomization.
88809834|NCT00762710|Placebo Comparator|2 - Placebo Medication|Following randomization, participants in this arm will receive a 2-week titration of placebo followed by 10 weeks of stable dosing of placebo. They will also attend study visits at least weekly for 12 weeks and will complete a final follow-up one month after discontinuation of the medication phase of the study at 16 weeks post-randomization.
88809835|NCT03807518|Experimental|Structured Exercise Intervention|The exercise training program was designed to improve physical fitness while the patients are receiving neoadjuvant treatment prior to surgery and for a 6 week period after surgery once patients are deemed fit to return to training.
89180457|NCT05753579|Experimental|Intervention Group|In our study, stabilization exercises and spinal mobilization practices were performed to the patients in the intervention group. The treatment was applied two days a week for five weeks, for a total of ten sessions. After the end of the treatment, stabilization exercises were recommended as a home exercise program until the follow-up evaluation at the third month. A telephone connection was established with the patients once a week and the home program was followed up.Mobilization applications were applied at Maitland IV degree as standard.Three mobilization methods were applied Anterior-Posterior Lumbal Spinal Mobilization Lumbal Spinal Rotational Mobilization Joint Mobilization in Lumbal Flexion Position
89180458|NCT02591433|Experimental|Supportive care (JeffQuit group therapy)|Patients undergo three, 1-hour group therapy sessions held by a JeffQuit practitioner over a 1-month period. Patients receive strategies for managing the psychological, habitual, and physiological components of smoking and help with developing a planned quit date. Patients are also provided with advice on how to switch to cigarette brands with less nicotine and then how to substitute the nicotine patch and gum for cigarettes. The JeffQuit counselor is available for additional individual support as needed.
89180459|NCT04973657|Experimental|VK0214 Active 20mg|20mg QD
89180460|NCT04973657|Experimental|VK0214 Active 40mg|40mg QD
89180461|NCT04973657|Placebo Comparator|Placebo|Placebo QD
89180462|NCT05749601|Active Comparator|Patients without knee osteoarthritis (KOA) grade 0|Patient without knee affection
89180463|NCT05749601|Experimental|Patients with KOA grade I|Kellgren-Lawrence classification (KL) grade I- doubtful narrowing of the joint space and possible osteophytes
88809836|NCT03807518|No Intervention|Standard Oncological Care|This group will receive standard oncological care and will receive no formal education of exercise intervention.
88809837|NCT04384640||Patients seated after Intra-Tympanic injection|
88809838|NCT03807050|Experimental|Astaxanthin|Astaxanthin capsules containing 50 milligram astaxanthin derived from the yeast Phaffia rhodozyma (Xanthophyllomyces dendrorhous)
88809839|NCT00756548|Experimental|1|multi-dose preparation for oral administration prior to colonoscopy
88809840|NCT00756548|Active Comparator|2|multi-dose preparation for oral administration prior to colonoscopy
88809841|NCT00243230|Experimental|Double-Blind - Vicriviroc 30 mg|Vicriviroc 30 mg once daily (QD), orally (PO), plus an open-label optimized antiretroviral therapy (ART) regimen containing a ritonavir-boosted protease inhibitor (PI/r) for 48 weeks.
88809842|NCT00243230|Experimental|Double-Blind - Vicriviroc 20 mg|Vicriviroc 20 mg QD, PO, plus an open-label optimized ART regimen containing a PI/r for 48 weeks.
88809843|NCT00243230|Placebo Comparator|Double-Blind - Placebo|Placebo QD, PO, plus an open-label optimized ART regimen containing a PI/r for 48 weeks.
88809844|NCT00243230|Experimental|Open-label - Vicriviroc 30 mg|Vicriviroc 30 mg once daily (QD), orally (PO), plus an open-label optimized ART regimen containing a ritonavir-boosted protease inhibitor (PI/r) for up to 45 months.
88809845|NCT00243074|Experimental|Treatment (cediranib maleate)|Patients receive oral AZD2171 once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88809846|NCT00241358|Active Comparator|Subcutaneous (SC) Treatment Plan - Donor|"Day 1: Mobilization with 240 mcg/kg SC AMD3100 and leukopheresis~If PBSC collected are not adequate, then donor will again be mobilized with AMD3100 and have leukopheresis collection on day 3."
88809847|NCT00241358|Experimental|Intravenous (IV) Treatment Plan - Donor|"Day -3: Mobilization with 80-480 mcg/kg/day IV AMD3100 and PK analysis~Day 1: Mobilization with 240 mcg/kg/day SC AMD3100 and leukopheresis~If PBSC collected are not adequate, then donor will again be mobilized with AMD3100 and have leukopheresis collection on day 3."
88809848|NCT00241358|Other|Recipients|"Conditioning Regimen~Cyclophosphamide 60mg/kg/day on Days -3 and -2~TBI 550cGy on Day -1~GVHD prophylaxis~*Cyclosporin 3.0mg/kg/day beginning on Day -1 then tapered through Day +100~PBSC transplant on Day 0"
88809849|NCT00241280|Active Comparator|Control|etafilcon A contact lens being worn 7 days/6 nights.
88809850|NCT00241280|Experimental|Test|galyfilcon A contact lens being worn 7 days/6 nights.
88809851|NCT00240500|Experimental|HBV-1 Group|neonates born to HBsAg+ and HBeAg+ mothers who received a 5-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12 and again a booster dose at Month 60)
88809852|NCT00240500|Experimental|HBV-2 Group|neonates born to HBsAg+ and HBeAg+ mothers who received a 4-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12)
88809853|NCT00240500|Experimental|HBV-3 Group|neonates born to HBsAg+ and HBeAg- mothers who received a 5-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12 and again a booster dose at Month 60)
88809854|NCT00240500|Experimental|HBV-4 Group|neonates born to HBsAg+ and HBeAg- mothers who received a 4-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12)
88809855|NCT00240500|Experimental|HBV-5 Group|neonates born to HBsAg- and HBeAg- mothers who received a 5-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12 and again a booster dose at Month 60)
88809856|NCT00240500|Experimental|HBV-6 Group|neonates born to HBsAg- and HBeAg- mothers who received a 4-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12)
88809857|NCT00778310|Experimental|Concerta|The subject will be administered their usual dose of Concerta the morning of the FMRI scan in a double blind fashion
88809858|NCT00778310|Placebo Comparator|Placebo|The subject will be administered a placebo the morning of the FMRI scan in a double blind fashion
88809859|NCT03806426|Experimental|Treatment Group A|Eicosapentaenoic acid free fatty acid (EPA-FFA) 500mg
88809860|NCT03806426|Placebo Comparator|Treatment Group B|Placebo 500mg
88809861|NCT03805646|No Intervention|No Mobile Phone-administered Triage Tool|For each hospital site: Baseline data will be collected for six months.
88809862|NCT03805646|Experimental|Mobile Phone-administered Triage Tool|"For each hospital site: After the first six months of baseline data collection, the mobile phone-administered triage tool (or Mobile Phone-based Triage Tool) will be implemented for a year."
88819339|NCT05358873|Placebo Comparator|Placebo|Subjects will receive the Normal saline solution (0.9% NaCl) nasal spray solution containing human IgG1 anti-SARS-CoV-2 antibody cocktail (i.e., applied into both nostrils by spraying two times per nostril) 3 times a day from Day 1 to Day 7. Each day the study products will be self-administered at 8 am, 2 pm, and 8 pm.
89370414|NCT03184012|Experimental|NuSmile Zirconia crowns|NuSmile Zirconia crowns is an esthetic primary anterior crown used to restore carious primary anterior teeth.
88843178|NCT03042715||Psychological Intervention refinement|"Eight weekly sessions in-person or via telephone~Qualitative interviews~Feedback from 5-10 caregivers to refine the intervention."
89370415|NCT03184012|Experimental|Composite resin strip crowns|Composite resin strip crowns is an esthetic conventional primary anterior crown used to restore carious primary anterior teeth.
89370416|NCT02220309||Anxiety and mood disorders|
89370417|NCT02419534|Active Comparator|Polyethylene glycol|In our study parents will be asked to start at 1g per day if they are less than 1 year of age and 2g per day in divided doses if they are older and will be asked to titrate the does according to the response up to the a maximum does of .5g/kg/day. In titrating the dose parent will be asked to increase the dose every 2 days until the child pass one normal BM per day without significant efforts. They should titrate down or hold treatment if the child developed lose BM or diarrhea. Caregiver will be asked to use placebo ointment by applying 5mm on fingertip to the anal verge area twice a day for the duration of the study.
89370418|NCT02419534|Active Comparator|Polyethylene glycol with Diltiazem|Parents will be instructed to apply 5 mm of ointment on a fingertip at the anal verge twice daily for the duration of the study
89370419|NCT04674852|Other|Marking cN+ nodes|These patients have already undergone neoadjuvant chemotherapy for locally advanced breast cancer with metastasis to the axillary lymph nodes. During standard of care needle-directed I-125 seed localization, the research marker will also be deployed through the same needle. Ultrasound detection of the marker will be compared to conventional biopsy markers and the I-25 seed.
89370420|NCT01362231|Experimental|GS-6624 125mg|
89370421|NCT01362231|Experimental|Experimental: GS-6624 200mg|
89370422|NCT03527316|Experimental|MDMA, Placebo|Cross-over within-subjects design with both treatment conditions, separated by a wash-out phase
89370423|NCT03527316|Experimental|Placebo, MDMA|Cross-over within-subjects design with both treatment conditions, separated by a wash-out phase
89370424|NCT03184246|Experimental|GlideScope|intubation with GlideScope
88843179|NCT02844998|Active Comparator|Dapoxetine 30 mg|Patients who have sedentary life style will treat with Dapoxetine 30 mg (on demand)
88843180|NCT02844998|Experimental|Moderate Running|Patients who have sedentary life style will be advised moderate running which make them breathe somewhat harder than normal for at least 30 minutes for 5 days in a week. (Minimally active category)
88843181|NCT02844998|Sham Comparator|Sham-controlled|Patients who have sedentary life style will be advised those to walk (not running )at most 30 minutes for 5 days in a week. (Inactive category)
88843182|NCT03043105|Experimental|TCP regimen|Thalidomide, cyclophosphamide and prednisone （TCP regimen）would be used for newly-diagnosed symptomatic MCD patients
88843183|NCT02845700|Active Comparator|Perceptual Retraining Treatment (PRT)|"The Perceptual Retraining Treatment will involve systematic presentation of diluted malodors. For each individual, vials on either side of their initial ideographic detection threshold will be presented. During the retraining, participants will be given feedback to shift their bias away from the malodorous target stimuli. For example, in the context of diluted solutions participants will be given the feedback that they are correct when a neutral response is given to solutions that are above the starting threshold (stronger malodor) and incorrect when a target is endorsed that is below the starting threshold (weaker malodor). Each training session will consist of 4 training blocks."
88843184|NCT02845700|Placebo Comparator|Sham Neutral Training (SNT)|Approximately half of the participants will be randomized to the SNT condition designed to control for the effects of time and learning. In the SNT condition, participants will complete the same assessments (including the olfactory bias assessment), as well as a sham training consisting of neutral/neutral odor pairing dilutions, rather than the combat/neutral odor pairings as in the PRT. Following the one-month assessment, they will be given the option to complete the PRT.
88843185|NCT03043885|Experimental|PRF|
88843186|NCT03043885|Experimental|PRF+FDBA|
88843187|NCT03043885|Active Comparator|FDBA|
88843188|NCT03043885|Active Comparator|Blood Clot|
88843189|NCT02810509||Short-term Warfarin-treated cohort|"admission due to AF-related ischemic stroke (known AF or newly detected AF)~for TTR calculation, the number of consecutive INR measurements ≥3 after the 7 days of warfarin adjustment~TTR evaluable days < 90 days"
88843190|NCT02810509||Long-term Warfarin-treated cohort|"admission due to AF-related ischemic stroke (known AF or newly detected AF)~long-term warfarin therapy at least for more than 90 days after the 7 days of warfarin adjustment period~for TTR calculation, the number of consecutive INR measurements ≥3 after the 7 days of warfarin adjustment~TTR evaluable days ≥ 90 days"
88843191|NCT02961062|Experimental|Treatment Sequence 1|
89180464|NCT05749601|Experimental|Patients with KOA grade II|KL grade II - definite osteophytes and possible narrowing of joint space.
89180465|NCT05749601|Experimental|Patients with KOA grade III|KL grade III- definite narrowing of the joint space, significant osteophytosis, and possible bone deformities.
89370425|NCT03184246|Active Comparator|Direct laryngoscopy|intubation with laryngoscope
89370426|NCT01358409|Experimental|Nebivolol|Nebivolol (Bystolic® by Forest/Mylan) is a third-generation beta-blocker; it selectively blocks β1-adrenergic receptors and increases peripheral vasodilation.
89370427|NCT02423590|Active Comparator|Gemcitabine/Carboplatin|"Gemcitabine/carboplatin will be administered as standard 21-day treatment cycles according to normal clinical practice.~Gemcitabine will be given by 30 minute intravenous infusions on Day 1 and Day 8 of each 21-day Cycle.~On Day 1, carboplatin (AUC5) will be given by infusion over 30-60 minutes."
89370428|NCT02423590|Experimental|Gemcitabine/carboplatin + Apatorsen|"Apatorsen (OGX-427) will be administered as an intravenous infusion over 2 hours.~Apatorsen (OGX-427) treatment will begin with a loading dose period prior to the initiation of chemotherapy. Patients will receive three loading doses of 400 mg within a 9-day period with at least 48 hours between infusions and between the last loading dose infusion and Day 1 of initiating chemotherapy. Chemotherapy must be initiated within 7 calendar days once the last loading dose infusion has been completed.~Following the loading dose period, Apatorsen (OGX-427) will be given weekly at a dose of 400 mg by 2 hour intravenous infusions. On days when both chemotherapy and Apatorsen (OGX-427) are given, Apatorsen (OGX-427) should be given first followed by chemotherapy."
88843192|NCT02961062|Placebo Comparator|Treatment Sequence 2|
89370429|NCT01362309|Placebo Comparator|Placebo|Inert filler in matched pill.
89370430|NCT01362309|Active Comparator|d-cycloserine 50 mg|50 mg d-cycloserine.
89370431|NCT03710941|Experimental|REGN2477+REGN1033|Single, sequential, repeat-dose IV or matching placebo
89370432|NCT03710941|Experimental|Placebo|Single, sequential, repeat-dose IV
88809863|NCT03809390|Experimental|Vaginal seeding group|Swabbing infants born by C-section with a gauze incubated in the maternal vagina about an hour before the C-section. The gauze will be extracted prior to the C-section, kept in a sterile container in an incubator (37 ℃), and taken out from the incubator immediately before the swabbing. The infant will be swabbed with the gauze, starting from the lips, followed by the face, thorax, arms, legs, genitals and anal region, and finally the back. The swabbing will take around 15-20 seconds.
89370433|NCT05760768|Experimental|Individualized exercise guidance group|Participants accept individualized exercise guidance. They are also managed continuously through WeChat group chat during prenatal clinical interval.
89370434|NCT05760768|No Intervention|Standard clinic prenatal care (control) group|Participants accept regular routine prenatal care following Chinese standard.
89370435|NCT03710863|Experimental|CM082 Tablet|Code Name: CM082 Tablet Other Name: X-82 Dosage and Administration: 25/50mg BID, P.O., two-week on/two-week off in four-week cycles until disease progression or unacceptable toxicity
89370436|NCT02930889|Experimental|Prostate Artery Embolization|Prostate Artery Embolization is a surgical procedure to relieve symptoms of Benign Prostatic Hyperplasia (BPH). Embolizing particles are injected into a target blood vessel to occlude blood flow.
89370437|NCT02423668||50% Partial adjustment|The prediction error for the first (PE1) and second (PE2) eyes was calculated as the difference between the observed post-operative refraction in spherical equivalent and the predicted post-operative refraction by the IOL Master for the implanted intra-ocular lens. This was obtained for the 3 formulae. Second eye refinement in the intra-ocular lens power selection for the second eye was performed using a theoretical 50% partial adjustment of the PE1. To relate refractive outcomes to pACD values, we performed subgroup analysis based in consecutive 50µm increments in inter-ocular asymmetry of pACD (50-600).
89370438|NCT02423668||No adjustment|The prediction error for the first (PE1) and second (PE2) eyes was calculated as the difference between the observed post-operative refraction in spherical equivalent and the predicted post-operative refraction by the IOL Master for the implanted intra-ocular lens. This was obtained for the 3 formulae. The intra-ocular lens power selection for the second eye was performed irrespective of the first eye prediction error. To relate refractive outcomes to pACD values, we performed subgroup analysis based in consecutive 50µm increments in inter-ocular asymmetry of pACD (50-600).
89002073|NCT06116435|Experimental|PreventT2 + Move group-based classes + Fitness Membership + Move 1:1 Support|Participants will receive a 6-month lifestyle weight management program based on the publicly available Prevent T2 curriculum (formally known as the National Diabetes Prevention Program), integrated with the Move group-based classes. Group classes will be delivered weekly in weeks 1-12, and biweekly in weeks 13-26. Group-based classes will be taught virtually by a trained Registered Dietitian from the Colorado Nutrition Obesity Research Center Clinical Intervention and Translation (CIT) Core. Participants will also receive a 6-month membership to the Peloton fitness app. Participants will also receive Move individualized support sessions. The 1:1 support sessions are designed to help participants adopt the physical activity messages from each Move group-based class into their daily lives.
89370439|NCT02423668||Full adjustment|The prediction error for the first (PE1) and second (PE2) eyes was calculated as the difference between the observed post-operative refraction in spherical equivalent and the predicted post-operative refraction by the IOL Master for the implanted intra-ocular lens. This was obtained for the 3 formulae. Second eye refinement in the intra-ocular lens power selection for the second eye was performed using a theoretical 100% partial adjustment of the PE1. To relate refractive outcomes to pACD values, we performed subgroup analysis based in consecutive 50µm increments in inter-ocular asymmetry of pACD (50-600).
89370440|NCT03178084|Experimental|Maraviroc (UK-427,857) QD + Zidovudine/Lamivudine BID|"Maraviroc (UK-427,857) 300 mg once daily added to Zidovudine/Lamivudine (300 mg/150 mg twice daily).~Following a review of the interim analysis data, the DSMB recommended to terminate the UK-427,857 300 mg QD arm based on pre-specified protocol non-inferiority criteria not being met for the QD arm versus efavirenz"
89370441|NCT03178084|Active Comparator|Efavirenz QD + Zidovudine/Lamivudine BID|Efavirenz (600 mg once daily) added to Zidovudine/Lamivudine (300 mg/150 mg twice daily
89370442|NCT03178084|Experimental|Maraviroc (UK-427,857) BID + Zidovudine/Lamivudine BID|Maraviroc (UK-427,857) 300 mg twice daily added to Zidovudine/Lamivudine (300 mg/150 mg twice daily)
88809864|NCT03809390|No Intervention|Control group|Managed based on the standard practice in the study site
89370443|NCT02875977|Experimental|Experimental Counseling|Patients randomized to this arm receive experimental counseling on the importance of attending PFPT appointments. This includes the standard 2-page educational handout and a 4-minute educational video.
89370444|NCT02875977|Active Comparator|Standard Counseling|Patients randomized to this arm receive standard counseling on the importance of attending PFPT appointments. This includes the standard 2-page educational handout.
89370445|NCT02419222|Experimental|Prism Adaptation|Prism Adaptation Treatment is 20 minutes long, administered 10 consecutive days
89370446|NCT05122572|Experimental|Intravenous Injection|Intravenous with or without Intratumoral RT-01 in the treatment of patients with advanced solid tumors combined with or without Nivolumab in the treatment of patients with advanced solid tumors
89370447|NCT03633006||Pulmonary Nodules|"Subject with pulmonary nodules will be enrolled, provide a blood sample and may be followed up to 2 years for nodule resolution.~A second blood draw will be collected at 12 months."
89370448|NCT03633006||CT Suspicion of Cancer|"Subject with suspicion of lung cancer will provide a blood sample.~Diagnostic information will be collected to confirm the final diagnosis."
89370449|NCT03633006||Pathologically Confirmed Cancer|"Subject has pathologically confirmed lung cancer and is treatment naïve.~Subject will be enrolled and provide a blood sample."
89370450|NCT01356381|Experimental|vildagliptin|
89370451|NCT01356381|Experimental|Placebo|
89370452|NCT03117166|Experimental|Lidocaine|treatment arm
89370453|NCT03117166|Placebo Comparator|Saline|placebo arm
89370454|NCT01356459|Experimental|Intervention|Patients in this arm will have Mepilex dressings applied to their sacrum and heels
88843193|NCT02962934||Non CRRT group|Critically ill patients receiving Ceftolozane-Tazobactam not receiving continuous renal replacement therapy
88843194|NCT02962934||CRRT group|Critically ill patients receiving Ceftolozane-Tazobactam who require continuous renal replacement therapy
88843195|NCT02919007|Experimental|Silk'n HST treatment|Intervention includes treatment with the Silk'n HST on the periorbital areas as instructed in the user's manual. Measure includes the ability to operate the device correctly according to the user manual.
88843196|NCT02811445||High Functioning|Defined by a short physical performance battery score (SPPB) greater than or equal to 11.
88843197|NCT02811445||Low Functioning|Defined by a short physical performance battery score (SPPB) less than or equal to 7.
88843198|NCT02964416|Experimental|Tramadol|Injection Tramadol 100mg diluted in 10 cc syringe (10mg/ml) to be given as 1mg/kg or (1ml/10kg) via intravenous route, once, at the time of dura closure
88843199|NCT02964416|Placebo Comparator|Placebo|0.9% Normal saline in 10 cc syringe,1ml/10kg via intravenous route, once at the time of dura closure
88843200|NCT02812771|Experimental|Efinaconazole|Efinaconazole
88843201|NCT03046225|Experimental|Electrical stimulation|This group received application of transcutaneous electrical nerve stimulation (TENS) associated with conventional physical therapy (continuous passive movement device and exercises).
88843202|NCT03046225|Active Comparator|Physical therapy|This group received only conventional physical therapy (continuous passive movement device and exercises).
88843203|NCT02969876|Other|Study Phase|During this phase participants receive open label vortioxetine for 6 weeks. Participants come to the Depression Clinical & Research Program at the Massachusetts General Hospital for visits once a week. During these visits the participants meet with clinicians and complete cognitive tasks.
88843204|NCT02970032|Active Comparator|Standard heparin dose|The investigators will identify surgical patients placed on fixed dose heparin infusions at their attending surgeon's discretion-the proposed research will not dictate the initiation of the heparin drip intraoperatively. However, the investigators will identify patients already on heparin, evaluate steady state heparin anti-Xa levels and adjust patient's dose if necessary based on steady state anti-Xa levels. Eligible patients will be started on heparin fixed-dose intraoperatively. Steady state anti-Xa levels will be drawn at least 6 hours after initiation of heparin infusion. Goal anti-Xa levels will be 0.1-0.35 IU/mL.
88843205|NCT02970032|Experimental|Real time heparin dose adjustment|Patients with identified out of range levels will receive pharmacist-driven real time heparin dose adjustment and will receive follow-up steady state anti-Xa levels. Anti-Xa level monitoring will be discontinued when in range peak levels are obtained, when heparin infusions are discontinued at surgeon discretion, or when the patient is discharged.
88843206|NCT02813551|Experimental|Torsemide|Torsemide 20 mg daily for 5 days
88843207|NCT02813551|Placebo Comparator|Placebo|Placebo 20 mg daily for 5 days
88843208|NCT02970422||Quartile 1 [Mild]|
88843209|NCT02970422||Quartile 2 [Moderate]|
88843210|NCT02970422||Quartile 3 [Severe]|
88843211|NCT02970422||Quartile 4 [Very Severe]|
88843212|NCT02817763|Active Comparator|Connective tissue graft (CTG)|After local anesthesia, the surgical procedure performed was the trapezoidal-type of Coronally advanced flap (CAF). After the flap was raised, the exposed root surface was gently scaled and planed until it became smooth. Afterward, a thin and small connective tissue graft that was sutured over the root surface. Then, the flap was coronally positioned and sutured to completely cover the graft.
88843213|NCT02817763|Experimental|CTG plus resin composite restoration|After local anesthesia, a sterile rubber dam was placed to isolate the operative field and the coronal zone of the non-carious cervical lesion restoration was performed with a nanocomposite resin, following the manufacturer's instructions. The apical margin of the restoration was place 1 millimeter beyond to the cemento-enamel junction estimation. In the next session, the surgical procedure performed was the trapezoidal-type of CAF. After the trapezoidal-type of CAF flap was raised, a thin and small connective tissue graft that was sutured over the restoration surface. Then, the flap was coronally positioned and sutured to completely cover the graft.
88843214|NCT03049501|Experimental|Caregiving Condition|Participants will receive a computer tablet and have access to web-based skill building sessions, videos from experts, annotated resources and information and tips on caregiving-related topics
88843215|NCT03049501|Placebo Comparator|Nutrition Condition|Participants will receive a computer tablet and have access to web-based training sessions on different topics related to nutrition.
88843216|NCT03050203|Experimental|custom pack|
88843217|NCT03050203|Active Comparator|standard care|
88843218|NCT02970812|Experimental|Electrical Muscle Stimulation|Electrical Muscle Stimulation (EMS) program was consisted of warm-up, warm-down, contraction and relaxation. It was programed to be resemble to actual muscle action of voluntary exercise. To increase energy consumption as high intensity exercise, tripled the contraction duration. EMS group used Program 3 and regulated intensity though channel from 1 to 4.
88843219|NCT02970812|Placebo Comparator|Transcutaneous Electrical Nerve Stimulation|Transcutaneous group used Transcutaneous Electrical Nerve Stimulation (TENS) which is the use of electric current produced to stimulate the sensory nerves to block pain signal. It is programed to applied currents regularly, once a second with a frequency of 1 Hz.
88843220|NCT02846714|Experimental|FLARE intervention|All FLARE participants enrolled will receive the intervention
88843221|NCT02921737|Experimental|Treatment Arm|TAS-102
88843222|NCT02819011|Experimental|MBB AFO Group|This group will be provided with a pair of New Balance 813 shoes plus a custom made MBB AFO for the duration of the study.
88843223|NCT02819011|Active Comparator|No MBB AFO Group|This group will be provided with a pair of New Balance 813 shoes for the duration of the study.
88843224|NCT02846792|Experimental|Treatment (plinabulin, nivolumab)|Patients receive plinabulin IV over 30 minutes and nivolumab IV over 60 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88843225|NCT02850068|Experimental|Geniculate Artery Embolization|Patients in this study will receive the geniculate artery embolization (GAE) procedure. The primary aims will be to determine if geniculate artery embolization (GAE) will reduce pain and disability (resulting from pain, stiffness and difficulty performing daily activities) caused by knee osteoarthritis (OA).
88843226|NCT02819323|Experimental|BLI800 high dose|BLI800 bowel preparation (high dose)
88843227|NCT02819323|Experimental|BLI800 low dose|BLI800 bowel preparation (low dose)
89370455|NCT01356459|No Intervention|Control|Patients in this arm will have standard care
89370456|NCT05189613|Experimental|Severe Asthma+BE|Patients with severe eosinophilic asthma with co-presence of Bronchiectasis (BE) in treatment with Mepolizumab
89370457|NCT05189613|Active Comparator|Severe Asthma without BE|Patients with severe eosinophilic asthma without Bronchiectasis (BE) in treatment with Mepolizumab
89370458|NCT03183700|Other|Control arm 1|The women will receive the usual recall with a new invitation letter with a prefixed appointment.
89370459|NCT03183700|Experimental|Intervention arm 2|Dry one, where FloqSwab, with which perform the sampling is contained and will be preserved after sampling in a tube without preservation solutions
89370460|NCT03183700|Experimental|Intervention arm 3|Wet one in which, after sampling, the FloqSwab, will be dissolved in preservation solutions.
88843228|NCT02819323|Active Comparator|PEG-ELS|PEG based bowel preparation
88843229|NCT03053401|Active Comparator|Adductor Canal block|Adductor Canal Block performed at mid-thigh level to block the saphenous nerve under guidance of a linear ultrasound transducer probe (General Electric; GE). Performed using a 22-gauge 2-inch Stimuplex A needle ( B. Braun Medical Inc., Melsungen, Germany).Solution to be injected will be a combination of Ropivacaine 0.2 % ( 0.5 ml/kg, maximum of 30 ml) and methylprednisolone acetate 1 mg/kg ( maximum of 40 mg ).
88843230|NCT03053401|Active Comparator|Femoral Nerve block|Femoral Nerve Block performed under guidance of a linear ultrasound transducer probe (General Electric;GE).Block will be performed using a 22-gauge 2-inch Stimuplex A needle ( B. Braun Medical Inc., Melsungen, Germany).Solution to be injected will be a combination of Ropivacaine 0.2 % ( 0.5 ml/kg, maximum of 30 ml) and methylprednisolone acetate 1 mg/kg (maximum of 40 mg ).
88843231|NCT02819557|Experimental|Ataluren|Participants will be administered ataluren orally at a dose of 10 milligrams/kilograms (mg/kg) in the morning, 10 mg/kg at midday, and 20 mg/kg in the evening (for a total of 40 mg/kg/day) for up to 52 weeks. Dose will be provided based upon the weight of each participant, which will be assessed every 12 weeks.
88843232|NCT02820181|Experimental|novel tracheostomy bi-ties|those with the novel tracheostomy bi-ties
88843233|NCT02820181|Active Comparator|traditional tracheostomy tie|those with traditional tracheostomy tie
88843234|NCT02860286|Experimental|Open-Label Tazemetostat|Oral Tazemetostat 800mg BID
88843235|NCT03054103|Placebo Comparator|Midazolam alone|Drug: Midazolam titrated 0.5-2.0 mg + normal saline placebo. Midazolam + Normal saline
88843236|NCT03054103|Active Comparator|Midazolam + Ketamine 5 mg|Drug: Midazolam titrated 0.5-2.0 mg + Ketamine 10 MG/ML: 0.5 ML. Midazolam + Ketamine 10 MG/ML: 0.5 ML
88843237|NCT03054103|Active Comparator|Midazolam + Ketamine 10 mg|Drug: Midazolam titrated 0.5-2.0 mg + Ketamine 10 MG/ML: 1 ML. Midazolam + Ketamine 10 MG/ML: 1 ML
89370461|NCT03632928||Migraine patients|"Migraine patients, who do not have any other diseases except from tension type headache.~No intervention, but daily measurements of muscle hardness (Ultrasound Elastography) and tenderness (Pressure pain threshold)"
89370462|NCT01358487|Active Comparator|Online self-help mood management course|Online self-help mood management course based on cognitive behavioral therapy and social cognitive theory, plus automated online follow ups using email reminders and incentives for completing follow-ups
89370463|NCT01358487|Experimental|Online self-help course plus live follow-up if needed|Intervention and automated follow ups with incentives as in the active comparator condition. The experimental procedure is adding live phone follow-ups if participant does not complete online assessment surveys at 1, 3, and 6 months in response to automated emails.
89370464|NCT03302286|Active Comparator|Mannitol Prime|This group will undergo cardiac surgery with heart-lung machine with priming solution of Ringer's acetate 1000 ml, Mannitol 200 ml, Heparin 10000 units and 80 mmol sodium.
89370465|NCT03302286|Active Comparator|NonMannitol Prime|This group will receive a priming solution of Ringer´s acetate 1200 ml, Heparin 10000 units and 80 mmol sodium.
88809865|NCT01212107|Experimental|Part A: 2 mg FGF Receptor QD|"Part A: Dose escalation~2 milligrams (mg) FGF receptor given orally once daily (QD) for a minimum of (1) 28 day cycle.~If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)"
88843238|NCT02860988|Experimental|MCCC Treatment|Participants in this condition received newly-supported reentry services to enhance fatherhood and parenting for individuals with substance use issues. These services focus on responsible parenting, economic stability and mobility, and healthy marriage and relationships.
88843239|NCT02860988|No Intervention|MCCC Comparison|Participants in this condition did not receive reentry services related to responsible parenting, economic stability and mobility, or healthy marriage and relationships.
88843240|NCT02822287|Experimental|2% Acetylcystine Solution|Participants will be orally administered with the clear oral solution containing 2% acetylcysteine (g/mL) in a 100 mL amber glass bottle over 1 minute or less using an oral syringe.
88843241|NCT03043274|Experimental|Cangrelor|Approximately 30 patients in this arm will receive standard STEMI care but will also receive standard dosing of cangrelor at the time of their PCI.
88843242|NCT03043274|No Intervention|No cangrelor|Approximately 30 patients in this arm will receive standard STEMI but will not receive cangrelor at the time of their PCI.
88843243|NCT03054649|Experimental|Cohort 1|Study eye: Primary implantation of HMIOL system with toric optic and no intraoperative optic exchange
88843244|NCT03054649|Experimental|Cohort 2|Fellow eye: Primary implantation of HMIOL system with monofocal optic, followed by intraoperative optic exchange (toric or non-toric optic)
88843245|NCT04333316|Other|large head group|study the postoperative patient's satisfaction
88843246|NCT04333316|Other|dual mobility group|study the postoperative patient's satisfaction
89370466|NCT02419144|Active Comparator|AMI followed by campaigns|Behavioral interventions
89370467|NCT02419144|Active Comparator|Campaigns followed by AMI|Behavioral interventions
88809866|NCT01212107|Experimental|Part A: 4 mg FGF Receptor QD|"Part A: Dose escalation~4 mg FGF receptor given orally QD for a minimum of (1) 28 day cycle.~If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)"
88843247|NCT02975804|Experimental|Interactive computer play (ICP)|The children in the treatment group will receive training on their trunk control using the Tymo in sitting 4 times per week for 20 minutes per session. The treatment will last for 6 weeks. All study children will continue their usual therapies at school.
89370468|NCT01356537||Gaucher's Disease under VPRIV|
89370469|NCT01356615|Experimental|enoxaparin|enoxaparin sodium (Clexane) (40 mg) followed prospectively for 3 months (36 dialyses)
89370470|NCT01356615|Active Comparator|standard unfractionated heparin|standard unfractionated heparin followed prospectively for 3 months (36 dialyses)
89370471|NCT03117322|Experimental|Synbiotic|"Each participant will receive the next:~agave inulin (4 g) in powder~Lactobacillus reuteri DSM 17938 (1 x 10^8 cfu) in 5 drops daily, once a day for four weeks."
89370472|NCT03117322|Experimental|Probiotic|Lactobacillus reuteri DSM 17938 (1 x 10^8 cfu) in 5 drops and maltodextrin (4 g) in powder daily, once a day for four weeks.
89370473|NCT03117322|Experimental|Prebiotic|agave inulin (4 g) in powder and an oil mix (sunflower oil and medium chain triglyceride oil) in 5 drops daily, once a day for four weeks.
89180466|NCT05749601|Experimental|Patients with KOA grade IV|KL grade IV- marked joint space narrowing accompanied by deformities, bone sclerosis, and large osteophytes
89370474|NCT03117322|Placebo Comparator|Placebo|maltodextrin (4 g) in powder and an oil mix (sunflower oil and medium chain triglyceride oil) in 5 drops daily, once a day for four weeks.
89370475|NCT01358565|Active Comparator|Mild and Moderate Hepatic Dysfunction|Patients with mild and moderate hepatic dysfunction
89370476|NCT01358565|Active Comparator|Healthy Volunteers|Healthy volunteers
89370477|NCT02419066||men and women with CD4 >=350|electronic monitoring of ARV adherence in men and women with CD4 >=350
89370478|NCT02419066||pregnant women with CD4 >=350|electronic monitoring of ARV adherence in pregnant women with CD4 >=350
89370479|NCT02419066||men and women with CD4 <200|electronic monitoring of ARV adherence in men and women with CD4 <200
89370480|NCT03620175|Active Comparator|5 Percent TolaSure Topical Gel|
89370481|NCT03620175|Active Comparator|1.5 Percent TolaSure Topical Gel|
88843248|NCT02975804|No Intervention|Standard Therapy|Children in the control group will continue their usual therapy.
88843249|NCT03054805|Experimental|Magnesium oxide and MIYAIRI-BM|"Magnesium oxide 125 mg twice per day for children with weight < 15 kg, 250 mg twice per day for weight <15-30 kg, and 500 mg twice per day for weight > 30 kg for 12 weeks.~MIYAIRI-BM 1 package (1g) divided as 0.5 g twice per day for children with weight < 15 kg, 2 packages divided as 1 g twice per day for weight 15-30 kg, and 3 packages divided as 1.5 g twice per day for weight > 30 kg for 12 weeks."
88843250|NCT03054805|Active Comparator|Magnesium oxide|MIYAIRI-BM 1 package (1g) divided as 0.5 g twice per day for children with weight < 15 kg, 2 packages divided as 1 g twice per day for weight 15-30 kg, and 3 packages divided as 1.5 g twice per day for weight > 30 kg for 12 weeks.
89180467|NCT04016207||Guanfacin regular treatment|
89180468|NCT00590759|Other|GORE TAG® Thoracic Endoprosthesis|
89180469|NCT05753423||Egyptian mothers-children pairs|Egyptian mothers-children pairs attending the Faculty of Dentistry, Ain Shams University will be recruited.
89180470|NCT04030091|Experimental|3 hour pulsatile normal insulin infusion treatment|the pulsatile insulin infusion treatment will be applied for 3 hours once a week with 10 pulses of 3 U of humulin R 100 IU/mL insulin per hour
89370482|NCT03620175|Active Comparator|0.5 Percent TolaSure Topical Gel|
89370483|NCT03620175|Placebo Comparator|Topical Vehicle Gel|
89370484|NCT03180190||patients with ocular toxicity|"Screening for ophthalmic exclusion criteria by slit lamp and fundus examination using both direct and indirect ophthalmoscope Screening for HCQ ocular toxicity by~Perimetry using Octopus perimeter and utilizing 24-2 test strategy,~Electroretinography (ERG) under scotopic and photopic conditions and Spectral domain optical coherence tomography (SD-OCT) genotyping using real time PCR (Taqman discrimination assay) for study frequency of single nucleotide polymorphisms (SNPs) of CYP2C19, CYP1A2, and ABCG2."
89370485|NCT03180190||patients without ocular toxicity|"Screening for ophthalmic exclusion criteria by slit lamp and fundus examination using both direct and indirect ophthalmoscope Screening for HCQ ocular toxicity by~Perimetry using Octopus perimeter and utilizing 24-2 test strategy,~Electroretinography (ERG) under scotopic and photopic conditions and Spectral domain optical coherence tomography (SD-OCT) genotyping using real time PCR (Taqman discrimination assay) for study frequency of single nucleotide polymorphisms (SNPs) of CYP2C19, CYP1A2, and ABCG2."
89370486|NCT01356693|Experimental|Active drug|Bromelin. Extract from Ananas comosus, 3,3g on vehicle (methylparaben, propylparaben, honey from apis mellifera, sodium benzoate, ethylic alcohol, water) 5ml.
89370487|NCT01356693|Placebo Comparator|Placebo|Placebo comparator with the same characteristics of experimental drug, 5ml, single dose.
89370488|NCT03183856|Experimental|Morning walk|200 steps of gait rehabilitation using an end-effector typed gait robot with 5 minute break, 3 times a day for 10 weekdays: the end-effector type gait robot (Morning Walk®, Hyundai Heavy Industry, Republic of Korea)
89370489|NCT03183856|Active Comparator|No Morning walk|200 steps by themselves or with a help of a walker on a even floor at a comfortable pace with 5 minute break, three times a day for 10 weekdays
89370490|NCT03179878|Experimental|SYNB1020|SYNB1020
89370491|NCT03179878|Placebo Comparator|Placebo|100 mL masking solution
89370492|NCT01362387|No Intervention|Group 1|Women assigned to Group 1 will receive the standard post-abortion follow-up currently used at bpas and will be undertaken as usual by staff at the treating clinic
89370493|NCT01362387|Experimental|Group 2|Follow-up after medical abortion using a standard text message, online or telephone questionnaire and a low sensitivity urine pregnancy test.
89370494|NCT04583592|Experimental|Camostat Mesilate|Participants will receive camostat mesilate for 14 days in addition to standard of care treatment.
89370495|NCT04583592|Placebo Comparator|Placebo|Participants will receive placebo for 14 days in addition to standard of care treatment.
89370496|NCT01358643|Other|P90X + Sparkpeople|"For six weeks of the study participants will use the P90X tools and for the other six weeks participants will use Sparkpeople tools.~Sparkpeople is a web based diet and exercise program in which the participant can track their diet and exercise progress and read and post messages to a large online community of others who are also trying to lose weight.~P90X is A DVD based home exercise program that guides the participant through a daily exercise routine."
88843251|NCT03054805|No Intervention|Healthy Children|Healthy Children
88843252|NCT00374738|Experimental|GIFT Intervention|Guided Imagery for Trauma (GIFT)
89370497|NCT01358643|Other|P90X + BodyMedia Fit|"For six weeks participants will use the P90X tools and for the other six weeks participants will use the BodyMedia Fit Device.~P90X is a DVD based home exercise program that guides the participant through a daily exercise routine.~BodyMedia Fit is a program in which the participants wears a small device on their arm that measures their physical activity and allows you to upload detailed physical activity data to a web site to help them track your progress."
89370498|NCT01358643|Other|BodyMedia Fit + Sparkpeople|"For six weeks participants will use the BodyMedia Fit devise and for the other six weeks participants will use the Sparkpeople program.~BodyMedia Fit is a program in which the participants wears a small device on their arm that measures their physical activity and allows you to upload detailed physical activity data to a web site to help them track your progress.~Sparkpeople is A web based diet and exercise program in which the participant can track their diet and exercise progress and read and post messages to a large online community of others who are also trying to lose weight"
88843253|NCT00374738|No Intervention|Music Control|Relaxing Music Audio control; same music used in guided imagery, with no narrative voice.
88843254|NCT02979626||Moderate-to-severe Influenza|"Children 6 weeks to 8 years of age with influenza-like illness and one of the following:~Fever >39~Lower respiratory tract infection~Acute otitis media~Serious extra-pulmonary manifestations (myositis, encephalitis)"
88843255|NCT02979626||Mild Influenza|Children 6 weeks to 8 years of age with influenza-like illness (ILI) without the criteria for moderate-to-severe disease (above)
89370499|NCT03179722|Experimental|Intervention group: Frenchspeaking patients|Intervention: Medication review
89370500|NCT03179722|Experimental|Intervention group: Dutchspeaking patients|Intervention: Medication review Intervention: Dutchspeaking patients are also invited to participate to Additional data collection: questionnaires
89370501|NCT01362465|Experimental|Cardiac Resynchronization Therapy (CRT)|Implanting device to measure delays between paced chambers in heart failure patients.
89370502|NCT03117088|Active Comparator|Checklist ISBAR 3|online-based checklist for standardized handovers
89370503|NCT03117088|Placebo Comparator|Checklist VICUR|comparator Checklist
89370504|NCT01362543|Active Comparator|Stress Management|
89370505|NCT01362543|Active Comparator|Cognitive restructuring|
89370506|NCT02418988|Experimental|TACE plus rAd-p53|TACE plus rAd-p53 artery injection'
89370507|NCT02418988|Active Comparator|TACE|TACE will be applied alone
88843256|NCT02822599|Active Comparator|RiaSTAP|Group 1 will receive an infusion of RiaSTAP after termination of CPB at a dose of 70 mg/kg after randomization to this group.
88843257|NCT02822599|Placebo Comparator|Saline|Group 2 will receive a placebo consisting of Normal Saline 0.9% (NS) after randomization to this group.
88843258|NCT04737421||Group 1 (G1): NobelActive TiUltra implants (3.0, NP, RP, WP)|Subjects will be enrolled into Group 1 and treated with NobelActive TiUltra implants, only if it is driven by the subject's clinical and restorative requirement and standard of care at the enrolling study clinic.
89370508|NCT04579146||HIV-1 patients and treated effectively for more than 12 months|X-ray examination with contrast by a 64-slice CT coronary angiography.
88843259|NCT04737421||Group 2 (G2): NobelParallel CC TiUltra implants (NP, RP; WP)|Subjects will be enrolled into Group 1 and treated with NobelParallel CC TiUltra implants, only if it is driven by the subject's clinical and restorative requirement and standard of care at the enrolling study clinic.
88843260|NCT04737421||Group 3 (G3): NobelReplace CC TiUltra implants (NP, RP)|Subjects will be enrolled into Group 1 and treated with NobelReplace CC TiUltra implants, only if it is driven by the subject's clinical and restorative requirement and standard of care at the enrolling study clinic.
88843261|NCT04737421||Group 4 (G4): Nobel Biocare N1 TiUltra TCC implants (NP, RP)|Subjects will be enrolled into Group 1 and treated with Nobel Biocare N1 TiUltra TCC implants , only if it is driven by the subject's clinical and restorative requirement and standard of care at the enrolling study clinic.
88843262|NCT00373789|Experimental|Botox A|up to two injections of 200 Units of intra-detrusor Botulinum Toxin A , which must be separated by at least eight weeks and no more than 52 weeks
88843263|NCT00373789|Placebo Comparator|Placebo|up to two injections of inactive injection (carrier saline), which must be separated by at least eight weeks and no more than 52 weeks
88843264|NCT03045926|Experimental|Diosmectite (Smecta®)|5 weeks of diosmectite 3g, 3 times daily.
89370509|NCT01356771|Other|Control Group|
89370510|NCT01356771|Other|Tailored Intervention|We will mail three separate pamphlets created specifically for the participant. The information in the pamphlets will be based on answers from the first survey.
89370511|NCT05189301||CHF|CHF for chronic heart failure
89370512|NCT05189301||COPD|COPD for chronic obstructive pulmonary disease
89370513|NCT05189301||control|control for normal controls
89370514|NCT01356927||DMPA|DMPA given at the time of mifepristone for medical abortion
89370515|NCT01356927||Etonogestrel implant|Etonogestrel implant placed at the time of mifepristone for medical abortion
89370516|NCT02703532|Experimental|Stroke Survivors with CARE-CITE Carepartners|Stroke survivors with a carepartner randomized to the CARE-CITE intervention. Participants who have survived a stroke will receive constraint-induced movement therapy (CIMT) while their caregiver participates in an educational program.
89370517|NCT02703532|Experimental|CARE-CITE Education Program Carepartners|Caregivers (someone who assists in the care of stroke survivors) will participate in online CARE-CITE education while their partner (stroke survivor) receives therapy.
89370518|NCT02703532|Active Comparator|Traditional Education Carepartners|Caregivers (someone who assists in the care of stroke survivors) will participate in traditional education while their partner (stroke survivor) receives therapy.
89370519|NCT02703532|Active Comparator|Stroke Survivors with Traditional Education Carepartners|Stroke survivors with a carepartner randomized to receive traditional education. Participants who have survived a stroke will receive constraint-induced movement therapy (CIMT) while their caregiver participates in an educational program.
89370520|NCT03439670|Experimental|Treatment Group 1|Patients enrolled in Treatment Group 1 (experimental group) will receive vamorolone 2.0 mg/kg/day for the duration of the study.
89370521|NCT03439670|Experimental|Treatment Group 2|Patients enrolled in Treatment Group 2 (experimental group) will receive vamorolone at 6.0 mg/kg/day for the duration of the study.
89370522|NCT03439670|Active Comparator|Treatment Group 3|Patients enrolled in Treatment Group 3 (active comparator group) will receive prednisone 0.75 mg/kg/day for 24 weeks followed by 20 weeks of treatment with 2.0 mg/kg/day vamorolone.
89370523|NCT03439670|Active Comparator|Treatment Group 4|Patients enrolled in Treatment Group 4 (active comparator group) will receive prednisone 0.75 mg/kg/day for 24 weeks followed by 20 weeks treatment with 6.0 mg/kg/day vamorolone.
89370524|NCT03439670|Placebo Comparator|Treatment Group 5|Patients enrolled in Treatment Group 5 (placebo comparator group) will receive placebo daily for 24 weeks followed by 20 weeks treatment with 2.0 mg/kg/day vamorolone.
89370525|NCT03439670|Placebo Comparator|Treatment Group 6|Patients enrolled in Treatment Group 6 (placebo comparator group) will receive placebo daily for 24 weeks followed by 20 weeks treatment with 6.0 mg/kg/day vamorolone.
89370526|NCT01357005||Schizophrenia Family|
89370527|NCT02930343|Active Comparator|group 1- MTX+LEF+HCQ|Active Comparator: Combination of Methotrexate (up to 25 mg per week), Leflunomide (20 mg once a day) and Hydroxychloroquine (200-400 mg once at night). All drugs are to be taken orally. Duration of therapy is for 3 months. All patients will receive folic acid (5 mg twice a week) along with methotrexate. Low dose prednisolone (weeks 1-2: 7.5 mg/day, weeks 2-4: 5 mg/day, weeks 4-6: 5 mg on alternate day and then stop) will be given as bridging therapy.
89370528|NCT02930343|Active Comparator|group 2- MTX+SSZ+HCQ|Combination of Methotrexate (up to 25 mg per week), Sulfasalazine (2g per day) and Hydroxychloroquine (200-400 mg once at night). All drugs are to be taken orally. Duration of therapy is for 3 months. All patients will receive folic acid (5 mg twice a week) along with methotrexate. Low dose prednisolone (weeks 1-2: 7.5 mg/day, weeks 2-4: 5 mg/day, weeks 4-6: 5 mg on alternate day and then stop) will be given as bridging therapy.
89370529|NCT03681938||Intensification treatment: Autograft|
89370530|NCT03681938||Standard chemotherapy (without autograft)|
89370531|NCT01362621||Children 6 to less than 12 years of age|
88843265|NCT02928055|Experimental|PNS (3 hr/day)|The PNS (3 hr/day) Group will receive peripheral nerve stimulation treatment for three weeks (3 hours daily) with an Intramuscular Electrical Stimulator following a one week electrode stabilization period.
88843266|NCT02928055|Experimental|PNS (6 hr/day)|The PNS (6 hr/day) Group will receive peripheral nerve stimulation treatment for three weeks (6 hours daily) with an Intramuscular Electrical Stimulator following a one week electrode stabilization period.
88843267|NCT02928055|Experimental|PNS (9 hr/day)|The PNS (9 hr/day) Group will receive peripheral nerve stimulation treatment for three weeks (9 hours daily) with an Intramuscular Electrical Stimulator following a one week electrode stabilization period.
88843268|NCT02983058|Other|PET/SPECT and MRI scans|PET/SPECT scan will be used to evaluate the utility of mGluR5 binding as a biomarker of the CNTNAP2 mutation and related mTOR kinase pathway dysregulation. 30 minutes structural MRI will be obtained to permit co-registration of PET images.
89370532|NCT02703454|Experimental|FIRM-only|Subjects in this arm will be treated with FIRM-guided RF ablation without pulmonary vein isolation (PVI).
89370533|NCT02703454|Active Comparator|Conventional|Subjects in this arm will undergo conventional radio frequency (RF) ablation with confirmation of PVI.
89370534|NCT03686618|No Intervention|Cohort X|no secretin administered. All observations
89370535|NCT03686618|Active Comparator|Cohort 1|32 mcg (<50kg) or 40 mcg (≥50kg) secretin two times a day (40 mcg; q 12 hrs)
89370536|NCT03686618|Active Comparator|Cohort 2|32 mcg (<50kg) or 40 mcg (≥50kg) secretin four times a day (40 mcg; q 6 hrs)
88843269|NCT00373867|Active Comparator|Standard|Standard treatment-based classification physical therapy
88843270|NCT00373867|Active Comparator|Graded exercise|Treatment-based classification physical therapy plus graded exercise
88843271|NCT00373867|Experimental|Graded exposure|Treatment-based classification physical therapy plus graded exposure
89370537|NCT03686618|Active Comparator|Cohort 3|32 mcg (<50kg) or 40 mcg (≥50kg) secretin six times a day (40 mcg; q 4 hrs)
89370538|NCT03103542|Experimental|Recombinant coagulation factor VIII Fc (rFVIIIFc)|Participants will receive rFVIIIFc at a dose of 200 international units (IU)/kilogram (kg) as once daily injections or divided on several injections per day at the discretion of the Investigator, starting at baseline visit up to maximum of 60 Weeks during the ITI Period. Participants who meet the criteria for ITI success will enter a tapering period of 16 weeks where the dose will be tapered down until a prophylactic dose, as judged by the Investigator, is achieved and thereafter a follow-up period of 32 weeks where the patient will continue to receive prophylactic treatment with rFVIIIFc.
89370539|NCT02426866||Patient with Efavirenz exposure|Patient with Efavirenz exposure
89370540|NCT02426866||Patient without Efavirenz exposure|Patient without Efavirenz exposure
89399242|NCT03695133|Experimental|intervention group|"Group-based interventions Group-based interventions include physical activity, sightseeing, picnics, theater, cinema, group educations.~Individual interventions Individual interventions include interventions in the Omaha System Nursing Interventions Scheme that is specific to health problems of elderly women."
89399243|NCT03695133|No Intervention|control group|The control group will not take any intervention, the post-tests will be collected at the end of 12 weeks.
89399244|NCT02165930|Experimental|Treatment A|
89370541|NCT01357083||Major Depression Disorder|This study is analytical cross-sectional and randomized. Two groups of depressed patients and healthy subjects were selected.The individual were submitted to a medical examination, and responded to the Beck depression inventory (BDII-II). Those, who got a score above 20, were included in the depressed group. Among this group, 50 patients were chosen randomly. those who obtained a depressive score below 9, 50 of them were chosen and they were included in the healthy group. The control group was chosen to match to the depressed patients for education, social occasion, occupational and economical situation. All of the subjects were interviewed psychiatrically, and the depression disorder was confirmed on the basis of the DSM criteria. eight out of 50 depressed patients were excluded from the study due to suffering from other psychiatric disorders .
89370542|NCT01358955|Active Comparator|Group cognitive intervention|The cognitive training will be administered twice a week for 12 weeks, located in hospital-based outpatient memory clinics. Each session will last approximately 90 minutes. The cognitive training programs will be offered in group sessions consisted of 5 participants.
89370543|NCT01358955|Active Comparator|Home-based cognitive intervention|The participants will do their homework for 30 minutes every business days for 12 weeks.
89370544|NCT01358955|No Intervention|Wait list Control|They will participate in cognitive intervention after ending this study.
89370545|NCT04960722|Active Comparator|Control|autogenous bone graft
89370546|NCT04960722|Experimental|1.5 mg/g OIF/β-TCP|1.5 mg/g OIF/β-TCP
89370547|NCT04960722|Experimental|2 mg/g OIF/β-TCP|2 mg/g OIF/β-TCP
89370548|NCT04960722|Experimental|3 mg/g OIF/β-TCP|3 mg/g OIF/β-TCP
89370549|NCT02418598|Experimental|Cohort1|The target putamen for AAV-hAADC-2 infusion is identified on MRI image that has been taken prior to the operation, and then subjects will be bilaterally infused with a total volume of 200 µL at a total of 4 sites (2 sites in left putamen, 2 sites in right putamen; 50 µL per site) at a flow rate of 3 µL per minute.
89370550|NCT02418598|Experimental|Cohort2|The target putamen for AAV-hAADC-2 infusion is identified on MRI image that has been taken prior to the operation, and then subjects will be bilaterally infused with a total volume of 600 µL at a total of 4 sites (2 sites in left putamen, 2 sites in right putamen; 150 µL per site) at a flow rate of 3 µL per minute.
89370551|NCT04874922|Experimental|Case group|The case group will first receive standard diabetes training from the hospital. After 28-30. Diabetes training based on Planned Behavior Theory will be given three times between gestational weeks. Each training will take an average of 45 minutes. After that, the data evaluation phase will be started.
89370552|NCT04874922|Other|Control Group|The control group will only receive standart diabetes training from the hospital. Then, only follow-up will be done and the data will be evaluated.
89370553|NCT03686462|Experimental|Virtual reality-based interactive treadmill training|In this group, the subjects will receive virtual reality (VR)-based interactive treadmill training. During the 30-min training session, VR based interaction and feedback will be provided; the foot location will be visualized in the VR screen (semi-immersive condition), the obstacles will be seen in the screen from which subjects has to avoid, gait speed will be visualized, slopes of the treadmill will be changed according to the slope changes in VR and distractors will be added. Dual tasks will also be provided. Subjects in this group will receive a 30min/session, 3 sessions/week for 4 weeks, the total of 12 sessions of VR-based training.
89370554|NCT03686462|Sham Comparator|Treadmill training without VR-based interaction|The subjects in this group will receive the treadmill gait training. Virtual reality environment will be provided during the gait training but no feedback and interaction will be provided. Subjects in this group will receive a 30min/session, 3 sessions/week for 4 weeks, the total of 12 sessions of treadmill-based training.
89370555|NCT02423824|Active Comparator|Insulin Resistance|Adjunctive Liraglutide 1.2-1.8mg/day
89370556|NCT02423824|Active Comparator|Non-Insulin Resistance|Adjunctive Liraglutide 1.2-1.8mg/day
89370557|NCT04548570||approximation of both recti group|
89370558|NCT04548570||non approximation of both recti group|
89370559|NCT02423434||Corneal Confocal Microscopy subjects|
89370560|NCT01012167|Active Comparator|1: galantamine/placebo-oxytocin|Subjects randomized to galantamine will receive galantamine and placebo-oxytocin
89370561|NCT01012167|Active Comparator|2: oxytocin/placebo-galantamine|Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine
89370562|NCT01012167|Placebo Comparator|3: placebo-galantamine /placebo-oxytocin|Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin
89370563|NCT04522518||DD group|160 pairs of children with disabilities 6-12 years of age and their caregivers (n=320)
88843272|NCT02983448|Placebo Comparator|Sham stimulation first|"Sham stimulation delivered at the earlobe (devoid of vagal innervation) is given on first session.~Transcutaneous vagus nerve stimulation delivered at the tragus (vagal innervation) is given on second session."
89370564|NCT04522518||TD group|160 pairs of typically developing children 6-12 years of age and their caregivers (n=320)
88843273|NCT02983448|Active Comparator|Active stimulation first|"Transcutaneous vagus nerve stimulation delivered at the earlobe (vagal innervation) is given on first session.~Sham stimulation delivered at the tragus (devoid of vagal innervation) is given on second session."
89370565|NCT02426710|Experimental|Flutter ablation with intracardiac echocardiography|Atrial flutter ablation will be done using intracardiac echocardiography.
89370566|NCT02426710|Active Comparator|Flutter ablation without intracardiac echocardiography|Atrial flutter ablation will be done without intracardiac echocardiography.
89370567|NCT02426944|Experimental|LAAO group|Patients will be treated interventionally by left atrial appendage occlusion (LAAO). LAAO will be done using Amulet or Watchman device.
88843274|NCT03061513|Active Comparator|Ubiquinol|600mg ubiquinol daily for 24 weeks
88843275|NCT03061513|Placebo Comparator|Placebo|Placebo daily for 24 weeks
89370568|NCT02426944|Experimental|NOAC group|Patients will be treated by novel anticoagulants (NOAC).
89399245|NCT02165930|Experimental|Treatment B|
89399246|NCT03695055|Experimental|Arm 1|Rituximab maintenance
89399247|NCT03695055|Active Comparator|Arm 2|DPP/DCEP-G alternation regimen
88843276|NCT03046472|Experimental|Once a month and once a week.|"Personally meeting once a month of Physical Therapy treatment for Postural Behavior.~In addition exercise group meeting once a week. The intervention program will include physical awareness by using a mirror and practice for good posture, and exercises for flexibility, strength and muscle endurance.~All participants will get 10-15 minutes of exercise for performing every day. The Participants in this group will get also a group exercise meeting once a week That meeting will long 45 minutes and will include the exercise that were given as home work and more.~Total duration 12 weeks/3 months"
88843277|NCT03046472|Active Comparator|Once a month only.|"Personally meeting once a month only for Physical Therapy treatment for Postural Behavior.~The intervention program will include physical awareness by using a mirror and practice for good posture, and exercises for flexibility, strength and muscle endurance.~All participants will get 10-15 minutes of exercise for performing every day. Total duration 12 weeks/3 months"
88843278|NCT02828137||Low NLR group|Neutrophil-to-Lymphocyte (NLR) Ratio < 1.78
88843279|NCT02828137||Intermediate NLR group|1.78 < Neutrophil-to-Lymphocyte (NLR) Ratio < 3.90
88843280|NCT02828137||High NLR group|Neutrophil-to-Lymphocyte (NLR) Ratio > 3.90
88843281|NCT03062605|Active Comparator|Treatment(TX)|. Participants were assigned randomly to one of two treatment groups and continued in parallel for the three-month duration of the study. The first treatment group (TX) rinsed with NaOCL (0.3%) for one minute followed by rinsing with iodine (10%) for one minute
88843282|NCT03062605|Active Comparator|Control (CT)|. Participants were assigned randomly to one of two treatment groups and continued in parallel for the three-month duration of the study. The control group (CT) rinsed with iodine (10%) for minute. The CT group was a positive control. Both of these treatments were done only once at the baseline. The reminder of the three-month study was to obtain saliva samples at specific times to determining microbial levels.
88843283|NCT03062917|Other|Emergency Department|Babies with suspected respiratory tract infection (RTI) in the ED
88843284|NCT03062917|Other|Paediatric Wards|Babies with diagnosed RSV infection admitted to paediatric wards
88843285|NCT03062917|Other|Paediatric Intensive Care|Babies with diagnosed severe RSV infection in PICU requiring mechanical ventilation
88843286|NCT03062917|Other|Health Controls|Babies without respiratory symptoms, attending routine outpatient appointments or undergoing elective surgical procedures
88843287|NCT03062917|Other|Controls in Paediatric Intensive Care|Babies without RSV infection but requiring mechanical ventilation in PICU
88843288|NCT03047174|Experimental|Arm A: Treatment with Mepitel® Film|"Arm A:~Mepitel® Film is a gentle, sterile, transparent, breathable film dressing consisting of polyurethane film coated with a special contact layer. The film dressing is supported with a paper frame for ease of application. Mepitel® Film is an ultra thin, transparent, breathable soft silicone film dressing."
88843289|NCT03047174|Active Comparator|Arm B: Treatment with Standard Care|"Cream: Fatty cream with 2-5% urea is applied to the irradiated skin 3-4 times daily.~Mometasone furoate cream: In addition to the fatty cream with 2-5% urea, mometasone furoate cream (solution 0.1%) is applied to the irradiated skin once daily.~Mometasone furoate cream is used in the treatment of inflammatory skin disorders. In terms of steroid strength, it is more potent than hydrocortisone, and less potent than dexamethasone. It reduces inflammation by causing several effects such as reversing the activation of inflammatory proteins, activating the secretion of anti-inflammatory proteins, stabilizing cell membranes, and decreasing the influx of inflammatory cells. The exact anti-inflammatory mechanism of action is unknown."
88843290|NCT02829307|Experimental|89Zr-GSK3128349|Subjects will receive a single dose of 89Zr-GSK3128349 as an intravenous (IV) infusion over 20 minutes to deliver a dose of 1 mg
88843291|NCT02985710|Other|Sudoscan only|Patients in this arm will only undergoing testing with Sudoscan.
88843292|NCT02985710|Other|Sudoscan Plus|Patients in this arm will get Sudoscan testing as well as a skin biopsy and QSART testing.
88843293|NCT03063385|Experimental|Parental communication intervention|The parental experimental intervention consists of a 60-minute web-based intervention consisting of several modules.
88843294|NCT03063385|Active Comparator|Health promotion control condition.|The Health promotion control condition will be web-based and provide useful information for Puerto Rican parents and youth.
88843295|NCT02986802||Genital herpes treated before third trimester|Women with genital herpes receiving treatment before the 3rd trimester
88843296|NCT02986802||Genital herpes treated only during third trimester|Women with genital herpes receiving treatment during the 3rd trimester
88843297|NCT02986802||Genital herpes untreated|Women with untreated genital herpes
88843298|NCT02986802||Control group|Women (controls) with neither genital herpes nor treatment
88843299|NCT02931565|Experimental|IW-1701|Single 5-mg dose of IW-1701 administered orally
88843300|NCT02931565|Placebo Comparator|Placebo|Matching placebo administered orally
88843301|NCT02986958|Experimental|Checklist|One-page paper-pencil agenda setting checklist involving two activities for older primary care patients and their family companion. The purpose of the checklist is to 1. clarify the role of the family companion during the visit, and 2. to discuss patient health issues to discuss with the primary care provider
88843302|NCT02986958|Placebo Comparator|Usual Care|Care as usual with their primary care provider
89399248|NCT03695055|No Intervention|Arm 3|
89370569|NCT03376321|Experimental|Treatment Arm 1 (pimodivir + Standard-of-Care [SOC] treatment)|Participants will receive pimodivir 600 milligram (mg) orally twice daily for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of pimodivir on Day 1 [evening], dosing will continue until the morning of Day 6) along with SOC treatment. Participants who meet all treatment extension criteria as defined in the protocol may receive an additional 5 day course of same treatment as received at study start. The SOC treatment is determined by investigator based on local practice, may include influenza antivirals and/or supportive care only. The choice to use influenza antivirals as part of SOC should be started no later than the day when participants initially receive pimodivir. An influenza antiviral as part of SOC cannot be changed (example, switching one influenza antiviral for another) during either treatment period or extension phase, with the exception that an influenza antiviral may be discontinued in case of suspected adverse event (AE).
89370570|NCT03376321|Placebo Comparator|Treatment Arm 2 (placebo + SOC treatment)|Participants will receive placebo matching to pimodivir orally twice daily for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of placebo on Day 1 [evening], dosing will continue until morning of Day 6) along with SOC treatment. Participants who meet all treatment extension criteria as defined in protocol may receive an additional 5 day course of same treatment as received at study start. The SOC treatment determined by investigator based on local practice, may include influenza antivirals and/or supportive care only. The choice to use influenza antivirals as part of the SOC should be made before randomization. The influenza antiviral should be started no later than day of first study drug intake. An influenza antiviral as part of the SOC cannot be changed (for example, switching one influenza antiviral for another) during either treatment period/extension phase, with the exception that an influenza antiviral may be discontinued in case of a suspected AE.
89370571|NCT02418520|Experimental|Miswak chewing|Chewing Sticks
89370572|NCT02418520|No Intervention|H.Pylori|Oral H.Pylori
89370573|NCT04437732|Other|Apioc Lens|All subjects will wear either the Apioc-P or Apioc-PT contact lens design
89370574|NCT03183622||ALLO-ASC-DFU treatment|Subjects with ALLO-ASC-DFU treatment in phase 1 clinical trial of ALLO-ASC-BI-101
89370575|NCT05760534|Experimental|Ideal body weight group|
89180471|NCT04030091|Experimental|2 hour pulsatile normal insulin infusion treatment|the pulsatile insulin infusion treatment will be applied for 2 hours once a week with 10 pulses of 3 U of humulin R 100 IU/mL insulin per hour
89370576|NCT05760534|Active Comparator|Total body weight group|
89370577|NCT02418364|Placebo Comparator|placebo reflexology|Placebo reflexology treatment
89370578|NCT02418364|No Intervention|control group|Data will be taken from questionnaires
89370579|NCT02418364|Experimental|reflexology treatment|Reflexology treatment
89370580|NCT01362699|Experimental|JNJ-31001074|
89370581|NCT01362699|Placebo Comparator|Placebo|
89370582|NCT02423512||Anti-TNF Exposure|Inflammatory Bowel Disease (IBD) patients scheduled to start vedolizumab therapy who have been previously exposed to anti-TNF therapy
89370583|NCT02423512||anti-TNF Naive|IBD patients scheduled to start vedolizumab therapy who have not been previously exposed to anti-TNF therapy
89370584|NCT01359033||MINAP cohort|The Myocardial Ischaemia National Audit Project (MINAP) was established in 1999, in response to the national service framework (NSF) for coronary heart disease, to examine the quality of management of heart attacks (myocardial infarction) in hospitals in England and Wales.
89370585|NCT01359033||RIKS-HIA cohort|The Register of Information and Knowledge About Swedish Heart Intensive Care Admissions (RIKS-HIA) has been established to record clinical and treatment information for all patients admitted to the coronary care units in Sweden from 1995.
89370586|NCT03686072|Other|Cataract surgery with goniosynechialysis|
89370587|NCT02423278|Experimental|D4 Lymphadenectomy|"This is the interventional group in which additional para-aortic lymph nodes are dissected meanwhile.~Under this arm, main therapeutic measures are listed as follows:~three-cycle SOX chemo regimen (S-1+Oxaliplatin) as neoadjuvant chemotherapy~radical gastrectomy plus D4 lymphadenectomy~five-cycle SOX chemo as adjuvant chemotherapy~five-year follow-up program to evaluate the prognosis."
89370588|NCT02423278|Experimental|D2 Lymphadenectomy|"This is the control group in which a classic surgical procedure for gastric cancer is performed.~Under this arm, main therapeutic measures are included as follows:~three-cycle SOX chemo regimen (S-1+Oxaliplatin) as neoadjuvant chemotherapy~radical gastrectomy plus D2 lymphadenectomy (Without para-aortic lymph nodes dissection)~five-cycle SOX chemo as adjuvant chemotherapy~five-year follow-up program to evaluate the prognosis."
89370589|NCT01365429|Experimental|EVLP Group|EVLP Group are those recipient lung transplant patients that received donor lungs that had been placed on the XPS™ with Steen Solution™ and undergone ex-vivo lung perfusion before being transplanted.
89370590|NCT01365429|No Intervention|Control Group|Control Group are those recipient lung transplant patients that receive donor lungs via conventional transplant.
89370591|NCT02423356||Echocardiography|All patients will receive 4 echocardiograms and 4 blood draws. The blood draws and echocardiograms will occur at the same visits.
89370592|NCT02950506|Active Comparator|Active tDCS|There will be a total of 14 visits in the study: will complete a screening visit, an initial visit, 10 session visits with active tDCS(transcranial direct current stimulation) andcognitive remediation therapy, and follow--up visits immediately (within 5 days), 1 and 3 months after the last intervention. Subjects will be informed of their group assignment at the end of the study.
89370593|NCT02950506|Sham Comparator|Sham tDCS|There will be a total of 14 visits in the study: will complete a screening visit, an initial visit, 10 session visits with sham tDCS and cognitive remediation therapy, and follow--up visits immediately (within 5 days), 1 and 3 months after the last intervention. Subjects will be informed of their group assignment at the end of the study.
89370594|NCT03183466|Experimental|Patients included in inclusion criteria|
89370595|NCT05189067|Active Comparator|paclitaxel + trastuzumab|"paclitaxel × 12, every week a cycle, trastuzumab × 4, every 3 weeks a cycle; followed by trastuzumab, every 3 weeks a cycle for 9 months.~Paclitaxel i.v. 80mg/m2, trastuzumab i.v. loading dose of 8 mg/kg, followed by 6mg/kg"
89370596|NCT05189067|Experimental|docetaxel + trastuzumab|"(docetaxel + trastuzumab) × 4, every 3 weeks a cycle; followed by trastuzumab, every 3 weeks a cycle for 9 months.~Docetaxel i.v. 100mg/m2, trastuzumab i.v. loading dose of 8 mg/kg, followed by 6mg/kg"
89399249|NCT03694977|Experimental|MCS110/PDR001 combination|
89370597|NCT03374995|Experimental|Group I (topical keratin)|Patients receive topical keratin topically at least BID until the end of radiation therapy (approximately 3-6 weeks).
89370598|NCT03374995|Active Comparator|Group II (standard of care)|Patients receive standard of care as directed by radiation oncologist until the end of radiation therapy (approximately 3-6 weeks).
89370599|NCT02418208||Test retest- 2 visits|Eligible participants will arrive for 2 testing visits a week apart and an optional third visit within 6-12 months.
89370600|NCT02418208||Single Visit|Eligible participants will arrive for a single testing visit
89370601|NCT02828982|Experimental|Powered Ankle Prosthesis|In this condition, the participant is fitted with a powered prosthetic ankle by a certified prosthetist. The ankle is the BiOM which is manufactured by Bionx (which used to be named iWalk). This device was given 510(K) Exempt status by the FDA under (regulation number: 890.3500). Participants will wear the device for 2 weeks.
88843303|NCT02829463||osteoarthritis patients|3.0 Tesla Magnetic resonance imaging was analyzed. It's the documentation from the outpatients and inpatients with osteoarthritis. It's not the intervention the study applied, but the subjects' disease demands.
88843304|NCT02829463||healthy controls|3.0 Tesla Magnetic resonance imaging was analyzed. It's the documentation from the outpatients and inpatients without osteoarthritis. It's not the intervention the study applied, but the subjects' non-osteoarthritis knee symptom demands.
89370602|NCT02828982|Sham Comparator|Dynamic Response Foot|In this arm, participants will wear their clinically prescribed dynamic response foot. This period is 2 weeks long.
89370603|NCT01362777|Experimental|In-Patient Rehabilitation|"Sessions of rehabilitation contains :~Individualized exercise training~Educational activities~Dietary advices"
88843305|NCT03050294|Active Comparator|Control- Atopic Dermatitis|Participants with atopic dermatitis will receive desoximetasone and no calls.
88843306|NCT03050294|Experimental|Atopic Dermatitis Intervention|Participants with atopic dermatitis will receive desoximetasone and will be called twice each day, morning and evening, at predetermined times to go over their use of the medication.
88843307|NCT03050294|Active Comparator|Control- Psoriasis|Participants with psoriasis will receive desoximetasone and no calls.
88843308|NCT03050294|Experimental|Psoriasis Intervention|Participants with psoriasis will receive desoximetasone and will be called twice each day, morning and evening, at predetermined times to go over their use of the medication.
88843309|NCT02831569|Experimental|Loxoprofen sodium/methocarbamol FDC|fixed dose combination (FDC) tablets
88843310|NCT03050918|Active Comparator|Phone Call Group (Intervention Arm)|Follow-up phone call intervention: Patients will receive the first call attempt within 72 hours of hospital discharge with a maximum of 3 call attempts by the study nurse made up until post-discharge day 7. The semi-structured script embedded within the program specific electronic health record Discharge Phone Call Starform is used to guide a conversation to obtain information on potential causes of hospital readmission that can be identified and addressed to improve each patient's transition to outpatient care.
88843311|NCT03050918|No Intervention|Usual Care Group (Control Arm)|Patients assigned to the control group receive standard discharge planning and follow-up per the usual care of their medical providers.
88843312|NCT03065179|Experimental|Nivolumab/Ipilimumab plus SBRT|Induction Dual Immune Checkpoint Inhibition with nivolumab and ipilimumab plus SBRT to 1-2 metastatic sites, followed by nivolumab monotherapy
89370604|NCT01362777|Active Comparator|Educational activities alone|"Out-patient control arm contains only :~-Educational activities"
89370605|NCT02427022|Experimental|Online CTI Training|Services providers in this group received a novel online CTI training. The enhanced course combines depth of knowledge among trainers, skills-based and practical approaches to learning, new technologies, and opportunities for social networking. The course is divided the knowledge, skills, and tools associated with CTI into four two-week modules. The total instruction time for the course was 24 hours.
88843313|NCT02988050|Other|Propofol-dexmedetomidine|Propofol-dexmedetomidine Bupivacaine; Lidocaine (local anaesthetics) Epinephrine (with local anaesthetics for skin infiltration)
88843314|NCT02988050|Other|Propofol-remifentanil|Propofol-remifentanil Bupivacaine; Lidocaine Epinephrine (with local anaesthetics for skin infiltration)
88843315|NCT03065647|No Intervention|Standard Care|Basic Life Support (BLS) and Advanced Cardiovascular Life Support (ACLS) by Emergency Medical Services (EMS) per existing EMS protocols at the scene of the cardiac arrest.
88843316|NCT03065647|Experimental|Expedited Transport|"Intervention: Expedited Transport with Mechanical CPR.~After initial Basic Life Support (BLS) and Advanced Cardiovascular Life Support (ACLS) by Emergency Medical Services (EMS) per existing EMS protocols, patients with refractory cardiac arrest are transported to an ECPR capable emergency department with ongoing mechanical CPR and ACLS for possible initiation of extracorporeal cardiopulmonary resuscitation (ECPR)."
88843317|NCT02988986|Experimental|TAK-228 Plus Tamoxifen|"TAK-228 will be orally administered at 30 mg weekly for 16 weeks.~Tamoxifen will be orally administered at 20 mg daily for 16 weeks."
88843318|NCT02832115|Experimental|Study|40 mg of topical lidocaine and 30 mg of topical nitroglycerine is applied to the wrist overlying radial pulse (centered approximately 1 inch proximal to the radial styloid process) at least 60 minutes before arterial puncture. Immediately prior to sterile preparation of access site, transdermal preparation will be removed in the cath lab.
88843319|NCT02832115|Placebo Comparator|Control|40 mg of topical lidocaine and placebo is applied to the wrist overlying radial pulse (centered approximately 1 inch proximal to the radial styloid process) at least 60 minutes before arterial puncture. Immediately prior to sterile preparation of access site, transdermal preparation will be removed in the cath lab.
89370606|NCT02427022|Active Comparator|Face-to-Face CTI Training|Service providers in the group received 1.5-days of face-to-face CTI training at each study site with one trainer. There were a total of 8 hours of instructor led training per site. Face-to-face training sessions were followed by three assignments with feedback from trainers, and eight 60-minute telephone consultation sessions.
89370607|NCT03711643|Experimental|Optimizing pain management|An experimental group receive a standard pain management and benefit the hypnotic mask (Hypnos pro).
89370608|NCT03711643|Active Comparator|standard pain management|
89370609|NCT02418286||Low Back Pain Participant Registry|Patients with low back pain in traditional Korean medicine rehabilitation clinic
89370610|NCT03133767|Experimental|Lactated ringers solution|Participants in this arm will receive two liters of IV Lactated Ringer's solution during their emergency department stay
89370611|NCT03133767|Experimental|Normal saline solution|Participants in this arm will receive two liters of IV 0.9% sodium chloride solution during their emergency department stay
88843320|NCT02862080|Experimental|no intervention; then no intervention; then cathode tsDCS + Ekso; then Ekso; then cathode tsDCS+Ekso|"Non-invasive transcutaneous spinal direct current stimulation (tsDCS) applies electrical current to the spinal cord via surface electrodes placed on the skin.~Ekso is a type of wearable robotic exoskeleton that provides support to an individual with lower extremity paralysis for standing and walking.~Cathode tsDCS + Ekso will combine the use of cathode tsDCS application followed by a walking session in Ekso. Ekso will consist of a walking session in Ekso with no tsDCS."
88843321|NCT02862080|Experimental|no intervention; then no intervention; then Ekso; then cathode tsDCS + Ekso; then Ekso|"Non-invasive transcutaneous spinal direct current stimulation (tsDCS) applies electrical current to the spinal cord via surface electrodes placed on the skin.~Ekso is a type of wearable robotic exoskeleton that provides support to an individual with lower extremity paralysis for standing and walking.~Cathode tsDCS + Ekso will combine the use of cathode tsDCS application followed by a walking session in Ekso. Ekso will consist of a walking session in Ekso with no tsDCS."
88843322|NCT02862080|Experimental|no intervention; then no intervention; then anode tsDCS + Ekso; then Ekso; then anode tsDCS + Ekso|"Non-invasive transcutaneous spinal direct current stimulation (tsDCS) applies electrical current to the spinal cord via surface electrodes placed on the skin.~Ekso is a type of wearable robotic exoskeleton that provides support to an individual with lower extremity paralysis for standing and walking.~Anode tsDCS + Ekso will combine the use of anode tsDCS application followed by a walking session in Ekso. Ekso will consist of a walking session in Ekso with no tsDCS."
88843323|NCT02862080|Experimental|no intervention; then no intervention; then Ekso; then anode tsDCS + Ekso; then Ekso|"Non-invasive transcutaneous spinal direct current stimulation (tsDCS) applies electrical current to the spinal cord via surface electrodes placed on the skin.~Ekso is a type of wearable robotic exoskeleton that provides support to an individual with lower extremity paralysis for standing and walking.~Anode tsDCS + Ekso will combine the use of anode tsDCS application followed by a walking session in Ekso. Ekso will consist of a walking session in Ekso with no tsDCS."
88843324|NCT03054506|Experimental|CSP01|Subjects in the experimental group will receive CSP01, a non-systemic, orally administered hydrogel capsule, twice a day. CSP01 capsules are taken prior to a meal with water, after which the small particles within the capsules hydrate and expand in the stomach and small intestine. By acting as a bulking agent and possibly reducing colonic transit time through increase of colonic water content, CSP01 may contribute to constipation relief.
88843325|NCT03054506|Active Comparator|Carboxymethylcellulose (CMC)|Subjects in the active control group will receive orally administered 3 capsules of carboxymethylcellulose (CMC) capsules twice a day.
88843326|NCT03054506|Placebo Comparator|Placebo|Matching placebo consists of an inert mixture supplied by Gelesis Inc. in identical-appearing capsules.Subjects in the placebo group will be administered 3 capsules of placebo twice a day.
88843327|NCT03068611|Active Comparator|Standard Web-based Smoking Cessation|A website and text messaging program that is publicly available through BecomeAnEX.com. Participants have access to the website whenever they wish.
88843328|NCT03068611|Experimental|Alcohol-focused Web-Based Smoking Cessation|A modified version of the website and text messaging program that is publicly available through BecomeAnEX.com. This version includes specific information and feedback on alcohol use, allows participants to consider benefits of changing drinking, plans for changing drinking, and strategies. Participants have access to the website whenever they wish.
88843329|NCT02835625|Active Comparator|Digital Breast Tomosynthesis|"Synthetic Mammography (SM) + Digital Breast Tomosynthesis (DBT)~The SM+DBT will be independently read by two radiologists. A consensus meeting will decide whether to recall the woman or not.~Women selected for further assessment (positive screening exam) will be recalled."
88843330|NCT02835625|Active Comparator|Digital mammography|The digital mammograms will be independently read by two radiologists. A consensus meeting will decide whether to recall the woman or not.
88843331|NCT03071887|Experimental|Intervention|Treatment arm - Relaxation Response Resiliency Program (3RP) (this is an open pilot; the treatment arm is the only arm)
88843332|NCT02935699|Experimental|Test Drug|JDP-205 Injection, 10 mg/mL, 1 mL
88843333|NCT02935699|Active Comparator|Control|Diphenhydramine Injection, 50 mg/mL, 1 mL
88843334|NCT04333381|Active Comparator|Common Practice|Patients included in the phase I will receive common practice.
89370612|NCT02422810||No aspirin|Subjects who have not taken aspirin or other blood thinners in the previous 10 days
89370613|NCT02422810||Aspirin Daily|Subjects who have taken aspirin daily for the previous 10 or more days
89370614|NCT02422810||New to aspirin|Subjects newly started on aspirin during their visit
89180472|NCT04030013|Active Comparator|Group education for 2 years|Patients who will receive structured diabetes education in groups , Group 1
89370615|NCT02422966|Experimental|Paracetamol|Paracetamol intravenous solution 15 mg/kg (corresponding to 1.5 ml/kg) per dose every 6 hours for 3 days, for a total amount of 12 doses.
89370616|NCT02422966|Active Comparator|Ibuprofen|Ibuprofen intravenous solution at an initial dose of 10 mg/kg, followed by 5 mg/kg at 24 and 5 mg/kg at 48 h.
89370617|NCT02422888|Experimental|Ticagrelor|Ticagrelor 90 mg twice a day, tablet Duration: 1 year after PCI
89370618|NCT02422888|Active Comparator|Prasugrel|Prasugrel 10 mg once a day, tablet Duration: 1 year after PCI
89370619|NCT01319253||Cayston Only Cohort|This cohort will be on a previously established medication regiment of Cayston inhaled antibiotic alternating regimen every other month.
89370620|NCT01319253||Tobi Only Cohort|This Cohort will be on a previously established medication regiment that includes Tobi inhaled antibiotic regimen alternating every other month.
89180473|NCT04030013|Active Comparator|One to one education for 2 years|Patients who will receive one to one structured diabetes education, Group 2
88843335|NCT04333381|Experimental|Educational and organizational measures|Patients included in the phase II will be attended by emergency nurses that received the educational and organizational intervention.
88843336|NCT03073759|Experimental|dTCS|Patient will receive dTCS with direct current (maximum of 2 mA) stimulation delivered through surface electrodes (TransQE from IOMED®, surface area: 25 cm2) using a Phoresor® II Auto (Model No. PM850, IOMED®, Salt Lake City, Utah 84120, USA) or Sham stimulation.
88843337|NCT03073759|Sham Comparator|Sham|Patients will receive a sham.
88843338|NCT02936479|Experimental|Berinert treatment|
88843339|NCT02841241|Experimental|Esmolol|Esmolol infusion, started without bolus, with slow upward titration to a maximum infusion rate is protocolized, with a target heart rate of 80-90/min
88843340|NCT00374881|Active Comparator|1|Morphine High Dose
88843341|NCT00374881|Placebo Comparator|2|Morphine Low Dose
88843342|NCT00374881|Placebo Comparator|3|Sorbitol Phenylephrine
89180474|NCT04030013|No Intervention|Control group without structured education|Patients who will not receive structured diabetes education, Group 3
89370621|NCT01319253||Cayston and Tobi Cohort|This Cohort will be on a previously established medication regiment that includes Cayston and Tobi inhaled antibiotic alternating every other month
89180475|NCT00734604|Experimental|T(OaD)/S(PRN)/T(PRN)|Tadalafil 5 mg once a day [T(OaD)] for 8 weeks, 1 week washout, sildenafil citrate 100 mg as needed [S(PRN)] for 8 weeks, 1 week washout, tadalafil 20 mg as needed [T(PRN)] for 8 weeks
89180476|NCT00734604|Experimental|T(OaD)/T(PRN)/S(PRN)|Tadalafil 5 mg once a day [T(OaD)] for 8 weeks, 1 week washout, tadalafil 20 mg as needed [T(PRN)] for 8 weeks, 1 week washout, sildenafil citrate 100 mg as needed [S(PRN)] for 8 weeks
89180477|NCT00734604|Experimental|S(PRN)/T(OaD)/T(PRN)|Sildenafil citrate 100 mg as needed [S(PRN)] for 8 weeks, 1 week washout, tadalafil 5 mg once a day [T(OaD)] for 8 weeks, 1 week washout, tadalafil 20 mg as needed [T(PRN)] for 8 weeks
89180478|NCT00734604|Experimental|S(PRN)/T(PRN)/T(OaD)|Sildenafil citrate 100 mg as needed [S(PRN)] for 8 weeks, 1 week washout, tadalafil 20 mg as needed [T(PRN)] for 8 weeks, 1 week washout, tadalafil 5 mg once a day [T(OaD)] for 8 weeks
89180479|NCT00734604|Experimental|T(PRN)/T(OaD)/S(PRN)|Tadalafil 20 mg as needed [T(PRN)] for 8 weeks, 1 week washout, tadalafil 5 mg once a day [T(OaD)] for 8 weeks, 1 week washout, sildenafil citrate 100 mg as needed [S(PRN)] for 8 weeks
89180480|NCT00734604|Experimental|T(PRN)/S(PRN)/T(OaD)|Tadalafil 20 mg as needed [T(PRN)] for 8 weeks, 1 week washout, sildenafil citrate 100 mg as needed [S(PRN)] for 8 weeks, 1 week washout, tadalafil 5 mg once a day [T(OaD)] for 8 weeks
89180481|NCT00590681|Experimental|one|This is an open-label, single arm, multi-center, phase II study involving 48 subjects with newly diagnosed supra-tentorial GBM. Following surgery, subjects with radiographically evaluable disease will receive external beam radiotherapy (59.4 - 60 Gy in 30 - 33 fractions) with daily temozolomide (75 mg/m2). Two to three weeks later, subjects will begin treatment with temozolomide (150-200 mg/m2 daily for five of 28 consecutive days) in conjunction with Avastin (10 mg/kg, every 14 days).
89180482|NCT02607917|Experimental|Mass Media plus clinic intervention.|These geographic areas will receive the media plus clinic intervention over a two year period.
89180483|NCT02607917|Experimental|Media|These geographic areas will receive the media intervention over a two year period.
89180484|NCT02607917|No Intervention|No Intervention|Adjacent states will receive no intervention.
89180485|NCT04088682||All hospitals|"All hospitals will take the treatment quality improvement strategies and tools into implementation.~Intervention: Behavioral: Quality improvement strategies and tools"
89180486|NCT02594982|Other|intervention bundle|An intervention bundle consisting of optimized sedation, pain assessment and treatment, early mobilization and sleep.
89180487|NCT02607839|Placebo Comparator|normal saline|normal saline intravenous infusion
89180488|NCT02607839|Active Comparator|glucose|glucose intravenous infusion
89180489|NCT00727272|Experimental|Quinine Sulfate Caps 324 mg - Fasting|A single dose of quinine sulfate 324 mg administered with 240 mL of room temperature water after an overnight fast of at least 10 hours.
89180490|NCT00727272|Experimental|Quinine Sulphate Tabs 300 mg - Fasting|A single dose of quinine sulphate 300 mg administered with 240 mL of room temperature water after an overnight fast of at least 10 hours.
89180491|NCT00727272|Experimental|Quinine Sulfate Caps 324 mg - Fed|A single dose of quinine sulfate 324 mg administered with 240 mL of room temperature water thirty minutes after the initiation of a standardized, high-fat breakfast.
89180492|NCT00805025|Experimental|AZLI|Participants were evaluated beginning 14 days prior to starting a 28-day course of AZLI (Day 0 to Day 28), followed by post-treatment assessments every 14 days through Day 56, for a total of 70 days of participation in the study.
89180493|NCT00734214|Experimental|0.9% NaCl|
88843343|NCT00374881|Experimental|4|Sorbitol high concentration+Phenylephrine+Morphine
88843344|NCT00374881|Experimental|5|Sorbitol low concentration+Phenylephrine+Morphine
88843345|NCT02865434|Experimental|Group 1 (RA)|Group 1 will receive 50 µg Tc99m-tilmanocept radiolabeled with 10 mCi Tc99m as a single IV injection. Subjects will receive SPECT Imaging (60 Minutes post-injection) and SPECT Imaging (180 Minutes post-injection).
89180494|NCT00734214|Active Comparator|0.45% NaCl|
89180495|NCT03656315|Other|Airway assessment|All patients recruited will be entered into this arm of the study. Airway assessment including Ultrasound scan will be performed
89180496|NCT05247372|Other|The effect of Iyengar yoga practice on patients with multiple sclerosis|
89180497|NCT02607995||low key intervention|for the whole group
89180498|NCT02595216|Experimental|all subjects|"All subjects in this study will receive a single Profound system treatment to the submental area with the profound device; subjects will return to four follow- up visits: 1 week post treatment, 1, 3 and 6 months post treatment.~Prior to treatment, tissue will be treated with injected tumescence or local dermal infiltration solution according to the protocol."
89180499|NCT00787202|Experimental|15 mg BID|
89180500|NCT00787202|Experimental|10 mg BID|
89180501|NCT00787202|Experimental|3 mg BID|
89180502|NCT00787202|Experimental|0.5 mg BID|
89180503|NCT00787202|Placebo Comparator|Placebo|
88843346|NCT02865434|Experimental|Group 2 (RA)|Group 2 will receive 200 µg Tc99m-tilmanocept radiolabeled with 10 mCi Tc99m via IV injection. Subjects will receive SPECT Imaging (60 Minutes post-injection) and SPECT Imaging (180 Minutes post-injection).
88843347|NCT02865434|Experimental|Group 3 (RA)|Group 3 will receive 400 µg Tc99m-tilmanocept radiolabeled with 10 mCi Tc99m via IV injection. Subjects will receive SPECT Imaging (60 Minutes post-injection) and SPECT Imaging (180 Minutes post-injection).
88843348|NCT02865434|Experimental|Group 4 (RA)|Group 4 will receive 50 µg Tc99m-tilmanocept radiolabeled with 5 mCi Tc99m via IV injection. Subjects will receive SPECT Imaging (60 Minutes post-injection) and SPECT Imaging (180 Minutes post-injection).
88843349|NCT02865434|Experimental|Group 5 (RA)|Group 5 will receive 200 µg Tc99m-tilmanocept radiolabeled with 5 mCi Tc99m via IV injection. Subjects will receive SPECT Imaging (60 Minutes post-injection) and SPECT Imaging (180 Minutes post-injection).
88843350|NCT02865434|Experimental|Group 6 (RA)|Group 6 will receive 400 µg Tc99m-tilmanocept radiolabeled with 5 mCi Tc99m via IV injection. Subjects will receive SPECT Imaging (60 Minutes post-injection) and SPECT Imaging (180 Minutes post-injection).
88843351|NCT02865434|Experimental|Group 7 (RA)|Group 7 will receive 50 µg Tc99m-tilmanocept radiolabeled with 1 mCi Tc99m via IV injection. Subjects will receive SPECT Imaging (60 Minutes post-injection) and SPECT Imaging (180 Minutes post-injection).
88843352|NCT02865434|Experimental|Group 8 (RA)|Group 8 will receive 200 µg Tc99m-tilmanocept radiolabeled with 1 mCi Tc99m via IV injection. Subjects will receive SPECT Imaging (60 Minutes post-injection) and SPECT Imaging (180 Minutes post-injection).
88843353|NCT02865434|Experimental|Group 9 (RA)|Group 9 will receive 400 µg Tc99m-tilmanocept radiolabeled with 1 mCi Tc99m via IV injection. Subjects will receive SPECT Imaging (60 Minutes post-injection) and SPECT Imaging (180 Minutes post-injection).
88843354|NCT02865434|Experimental|Group 10 (Healthy Controls)|Group 10 will receive Tc99m-tilmanocept at the MTD via IV injection, Whole body planar SPECT imaging (15 Minutes post-injection) , Whole body planar SPECT imaging (60 minutes post-injection) , Whole body planar SPECT imaging (180 minutes post-injection), and Whole body planar SPECT imaging (18-20 hours post-injection), Planar Image with both Hands in Field of View (60 minutes and 180 minutes post-injection), Blood Collection for PK Testing (15 Mins Before Injection), Blood Collection for PK Testing (after Injection) , Blood Collection for PK Testing (15 minutes post injection) , Blood Collection for PK Testing (60 minutes post injection) , Blood Collection for PK Testing (180 minutes post injection) , and Blood Collection for PK Testing (18-20 hours post injection).
88843355|NCT02865434|Experimental|Group 11 (RA)|Group 11 will receive Tc99m-tilmanocept at the MTD via IV injection, Whole body planar SPECT imaging (15 Minutes post-injection) , Whole body planar SPECT imaging (60 minutes post-injection) , Whole body planar SPECT imaging (180 minutes post-injection), and Whole body planar SPECT imaging (18-20 hours post-injection), Planar Image with both Hands in Field of View (60 minutes and 180 minutes post-injection), Blood Collection for PK Testing (15 Mins Before Injection), Blood Collection for PK Testing (after Injection) , Blood Collection for PK Testing (15 minutes post injection) , Blood Collection for PK Testing (60 minutes post injection) , Blood Collection for PK Testing (180 minutes post injection) , and Blood Collection for PK Testing (18-20 hours post injection).
88843356|NCT00375037|Experimental|Hand hygiene|Hand hygiene promotion
88843357|NCT00375037|Active Comparator|Usual care|usual care
88843358|NCT02841397|Experimental|Test group|All subjects will be enrolled into the test group and will receive Masimo Pulse CO-Oximeter for measurement of various physiological parameters.
88843359|NCT02846233|Active Comparator|Treatment group|Interventions: All prandial insulin injections, usually 3 times daily before meals, will be discontinued. Basal insulin, usually once daily at bed time, will be continued at 80 % of the home dose. Albiglutide OR Dulaglutide AND Empagliflozin will be added to metformin and a basal insulin.
89180504|NCT02609477|Experimental|Istradefylline 40 mg|40 mg istradefylline (1 × 40 mg tablet + 3 × placebo tablets + 3 × placebo capsules)
89180505|NCT02609477|Experimental|Istradefylline 80 mg|80 mg istradefylline (2 × 40 mg tablets + 2 × placebo tablets + 3 × placebo capsules)
89180506|NCT02609477|Experimental|Istradefylline 160 mg|160 mg istradefylline (4 × 40 mg tablets + 3 × placebo capsules)
89180507|NCT02609477|Active Comparator|Phentermine 45 mg|45 mg phentermine (4 x placebo tablets + 3 × 15 mg phentermine hydrochloride capsules)
89180508|NCT02609477|Active Comparator|Phentermine 90 mg|90 mg phentermine (4 × placebo tablets + 3 × 30 mg phentermine hydrochloride capsules)
89180509|NCT02609477|Placebo Comparator|Placebo|Placebo (4 × placebo tablets + 3 × placebo capsules)
89180510|NCT05744999||Patients treated with the reported technique|Two females and 1 male with a mean age of 50 years were diagnosed by CT scan with stage II acute cholecystitis according to the Tokyo guidelines and were operated on within three days of symptom onset
89180511|NCT02592720|Experimental|Cocktail plus FFR guided group|Intracoronary cocktail injection before fractional flow reserve (FFR) measurement. Percutaneous Coronary Intervention (PCI) strategy is decided by FFR value in patients with acute coronary syndrome (ACS).
89180512|NCT02592720|Placebo Comparator|QCA guided group|Percutaneous Coronary Intervention (PCI) strategy is decided by QCA value in patients with acute coronary syndrome (ACS).
89180513|NCT02608073|Experimental|Capecitabine + Cisplatin|Participants with metastatic nasopharyngeal cancer will receive combination treatment with capecitabine (1000 milligrams per meter square [mg/m^2] tablets twice daily [BID] orally) and cisplatin (100 mg/m^2/day intravenous [IV] infusion) for up to 8 cycles.
89180514|NCT02594904|Experimental|G-6-PD normal group|Drug: Yinzhihuang Oral Liquid, dose: 3ml each time, 3 times every day, during the period, measuring bilirubin from skin one time every 24 hours.
89180515|NCT02594904|Experimental|G-6-PD mild deficiency group|Drug: Yinzhihuang Oral Liquid, dose: 3ml each time, 3 times every day, during the period, measuring bilirubin from skin one time every 24 hours.
89370622|NCT03633552|Experimental|12-cycle arm|After completion of chemoradiation, the cases will receive 12 cycles of adjuvant Temozolomide (prescribed as 150 to 200 milligram per square meters body surface per day for the first 5 days of every 28 days).
89370623|NCT03633552|Active Comparator|6-cycle arm|After completion of chemoradiation, the participants will receive 6 cycles of adjuvant Temozolomide (prescribed as 150 to 200 milligram per square meters body surface per day for the first 5 days of every 28 days).
89370624|NCT02426632|Experimental|Session 1: Sequence 1|Participants will sequentially receive 5 milliliter of each 6 JNJ-53718678 formulations (ABCDEF) in a random order, at a dosing interval of 1-2 hours.
89370625|NCT02426632|Experimental|Session 1: Sequence 2|Participants will sequentially receive 5 milliliter of each 6 JNJ-53718678 formulations (ABCDEF) in a random order, at a dosing interval of 1-2 hours.
89370626|NCT02426632|Experimental|Session 1: Sequence 3|Participants will sequentially receive 5 milliliter of each 6 JNJ-53718678 formulations (ABCDEF) in a random order, at a dosing interval of 1-2 hours.
89370627|NCT02426632|Experimental|Session 1: Sequence 4|Participants will sequentially receive 5 milliliter of each 6 JNJ-53718678 formulations (ABCDEF) in a random order, at a dosing interval of 1-2 hours.
89370628|NCT02426632|Experimental|Session 1: Sequence 5|Participants will sequentially receive 5 milliliter of each 6 JNJ-53718678 formulations (ABCDEF) in a random order, at a dosing interval of 1-2 hours.
89370629|NCT02426632|Experimental|Session 1: Sequence 6|Participants will sequentially receive 5 milliliter of each 6 JNJ-53718678 formulations (ABCDEF) in a random order, at a dosing interval of 1-2 hours.
89370630|NCT02426632|Experimental|Session 2: Sequence 7|Participants will receive two best scoring formulations from Session 1 with a varying concentration of sucralose (M1M2M3N1N2N3) sequentially in a random order, at a dosing interval of 1-2 hours.
88843360|NCT02846233|No Intervention|Control group|Interventions: There will not be any change in insulin therapy, and they will continue to have the usual and standard care through the primary care provider. They should not receive SGLT2i and GLP1 RA during the study period.
88843361|NCT02865590|Experimental|Lyophilized Equine Bone Allograft|Sinus Lift with Lyophilized Equine Bone Allograft
88843362|NCT02865590|Active Comparator|deproteinized bovine bone allograft|Sinus lift with deproteinized bovine bone allograft
88843363|NCT02867150|Experimental|Active Device|Active Device: Ward Photonics Photonica Professional Red light therapy system Intervention: Device: Ward Photonics Photonica Professional
88843364|NCT03075085|Active Comparator|Basic WISE strategy|These participants will be asked to implement the basic WISE strategy used in previous studies.
88843365|NCT03075085|Experimental|Enhanced WISE strategy|These participants will be asked to implement the enhanced WISE strategy.
88843366|NCT02867618|Experimental|Carfilzomib + TGR-1202|Oral TGR-1202 will be given PO once daily on Days 1-28 and carfilzomib given intravenously twice a week for 3 consecutive weeks, on days 1, 2, 8, 9, 15, and 16 on the 28-day cycle.
88843367|NCT02868242|Experimental|LDV/SOF|Participants will receive LDV/SOF 90/400 mg fixed dose combination (FDC) (1x 90/400 mg tablet or 4 x 22.5/100 mg tablets based on swallowability assessment during screening) for 12 weeks.
88843368|NCT03075553|Experimental|Treatment (nivolumab)|Patients receive nivolumab IV over 60 minutes on day 1. Treatment repeats every 14 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Patients achieving stable disease, complete response, or partial response receive nivolumab IV over 60 minutes on day 1 of course 9. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
88843369|NCT03076333|Experimental|Single Arm: PET/MR|Each patient will undergo three combined PET/MR scans. The pre-treatment PET, mid-treatment PET and MR, and post-treatment PET are for research purposes and not part of the patient's standard of care (pre-treatment MR and post-treatment MR).
88843370|NCT02869334|Experimental|Auditory remediation with active tDCS|Auditory remediation program paired with active transcranial direct current stimulation (tDCS) for 30 minutes, 2-3 sessions per week
88843371|NCT02869334|Experimental|Auditory remediation with sham tDCS|Auditory remediation program paired with sham transcranial direct current stimulation (tDCS) for 30 minutes, 2-3 sessions per week
88843372|NCT02869334|Sham Comparator|Control (computer games with sham tDCS)|Non-remediation, control computer activities (e.g. games) with sham transcranial direct current stimulation (tDCS) for 30 minutes, 2-3 sessions per week
88843373|NCT03077893|Experimental|Active Group|Treatment with active Provant Therapy System
88843374|NCT03077893|Sham Comparator|Sham Group|Treatment with Inactive (sham) Provant Therapy System
88843375|NCT03054740|Active Comparator|Gebauer Ethyl Chloride|Device: Vapocoolant (Ethyl Chloride Mist Spray)
88843376|NCT03054740|Placebo Comparator|Nature's Tears|Device: Sterile Water
88843377|NCT02997722|Experimental|Ketamine infusion|Assignment to this arm involves receiving a single IV infusion of ketamine 0.5 mg/kg given over 45 minutes.
88843378|NCT02997722|Placebo Comparator|Normal Saline infusion|Assignment to this arm involves receiving an IV infusion of normal saline over the course of 45 minutes.
88843379|NCT03078127|Active Comparator|Sequence A|"In this arm, the interventions were performed in the following order:~Baseline (prior to randomization), Whole body vibration, High Frequency Chest Wall Oscillation (HFCWO, aka Vest or TheVest®), Oscillatory Positive Expiratory Pressure (OPEP) (note this is different than the sequence shown in the example latin square shown in the included protocol, as that was meant to serve as an example -- actual randomization and formulation of the employed latin square / sequence generator was performed following completion of the protocol)"
88843380|NCT03078127|Active Comparator|Sequence B|"In this arm, the interventions were performed in the following order:~Baseline (prior to randomization), HFCWO, OPEP, Whole body vibration (note this is different than the sequence shown in the example latin square shown in the included protocol, as that was meant to serve as an example -- actual randomization and formulation of the employed latin square / sequence generator was performed following completion of the protocol)"
88843381|NCT03078127|Active Comparator|Sequence C|"In this arm, the interventions were performed in the following order:~Baseline (prior to randomization), OPEP, Whole body vibration, HFCWO (note this is different than the sequence shown in the example latin square shown in the included protocol, as that was meant to serve as an example -- actual randomization and formulation of the employed latin square / sequence generator was performed following completion of the protocol)"
89370631|NCT02426632|Experimental|Session 2: Sequence 8|Participants will receive two best scoring formulations from Session 1 with a varying concentration of sucralose (M1M2M3N1N2N3) sequentially in a random order, at a dosing interval of 1-2 hours.
89370632|NCT02426632|Experimental|Session 2: Sequence 9|Participants will receive two best scoring formulations from Session 1 with a varying concentration of sucralose (M1M2M3N1N2N3) sequentially in a random order, at a dosing interval of 1-2 hours.
89370633|NCT02426632|Experimental|Session 2: Sequence 10|Participants will receive two best scoring formulations from Session 1 with a varying concentration of sucralose (M1M2M3N1N2N3) sequentially in a random order, at a dosing interval of 1-2 hours.
89370634|NCT02426632|Experimental|Session 2: Sequence 11|Participants will receive two best scoring formulations from Session 1 with a varying concentration of sucralose (M1M2M3N1N2N3) sequentially in a random order, at a dosing interval of 1-2 hours.
89370635|NCT02426632|Experimental|Session 2: Sequence 12|Participants will receive two best scoring formulations from Session 1 with a varying concentration of sucralose (M1M2M3N1N2N3) sequentially in a random order, at a dosing interval of 1-2 hours.
89370636|NCT03633474|Experimental|N. Lactamica in PBS|Wild-type Neisseria lactamica (strain Y92-1009, sequence type 3493, clonal complex 613) will be used for this human challenge experiment. This strain is identical to that utilised in our previous challenge experiments (>350 volunteers to date).
89370637|NCT03633474|Placebo Comparator|PBS Control|PBS only control. Volunteers randomized to this arm will receive a PBS only solution which contains no bacteria.
89370638|NCT05760456|Experimental|DIDALA|DIDALA is a herbal medicine, produced from dried mulberry leaves. The drug has been approved by the Drug Administration of Vietnam.
89370639|NCT05760456|Active Comparator|METFORMIN|
89370640|NCT02418130|Experimental|UDCA004|UDCA004
89370641|NCT02418130|Placebo Comparator|Placebo of UDCA004|Placebo of UDCA004
89370642|NCT02426788|Experimental|CBT+SMC|"Cognitive behavioural therapy + Standard Medical Care (cognitive-behavioural therapy+SMC):~8 hour-long manual-based CBT sessions with a therapist, weekly or fortnightly."
89370643|NCT02426788|No Intervention|Standard Medical Care (SMC)|Participants assigned to the SMC group (i.e., control group) will receive all the treatment and support they would otherwise receive outside of a research trial.
89370644|NCT03179956|Experimental|Ribociclib|
88843382|NCT03056144|Experimental|Intervention group|The participants will undergo the whole body vibration therapy 1 session per day, 3 days per week for 4 weeks. The whole total whole body therapy session will last 18 minutes with 9 minutes of vibration.
88843383|NCT02943499|Active Comparator|Active Comparator App/Training|This is a standard smoking cessation smartphone app using the latest evidence-based smoking cessation methods and behavior change theory. Subjects will be encouraged to set a quit date of 3 weeks, to allow comparison to experimental arm quit date.
88843384|NCT02943499|Experimental|Experimental App/Training|This is a 3-week smartphone-based training program that trains mindfulness for smoking cessation by helping smokers self-monitor their smoking habits, recognize when and how often they smoke, identify triggers for smoking, and learn methods to become more mindful of triggers, to quit smoking with a target quit date of 3 weeks.
88843385|NCT03000608|Experimental|SAN021 Serum|SAN021 is a serum containing 10% East Indian Sandalwood Oil. It is packaged in an amber glass bottle with a dropper top. The dose is 5 drops per 1% BSA involvement twice daily.
88843386|NCT03000608|Placebo Comparator|SAN021 Placebo|SAN021 Placebo is a serum that does not contain East Indian Sandalwood Oil however, does contain a synthetic sandalwood fragrance. It is packaged in an amber glass bottle with a dropper top. The dose is 5 drops per 1% BSA involvement twice daily.
88843387|NCT02847169|Active Comparator|filcon IV1 toric lens|Participants are randomized to wear filcon IV1 toric lens pair for 1 week during the cross over study.
88843388|NCT02847169|Active Comparator|ocufilcon D toric lens|Participants are randomized to wear ocufilcon D toric lens pair for 1 week during the cross over study.
88843389|NCT03078595||von Willebrand disease type 2 and 3|Examinations (haematologically and periodontally) of von Willebrand disease patients with type 2 and 3 and healthy controls to evaluate whether type 2 and 3 VWD determines an increased susceptibility to gingival bleeding in response to the oral biofilm
88843390|NCT03078595||controls|For each case (VWD) a respective haematologically healthy control is recruited from the gingivitis and periodontitis patients of the Department of Periodontology, Centre for Dentistry and Oral Medicine (Carolinum), Johann Wolfgang Goethe-University Frankfurt/Main. Each control is matched to one of the respective cases for sex, age (±5 years), self-reported smoking status (current smoker/non-smoker), number of remaining teeth (±2 teeth), and periodontal diagnosis (gingivitis, chronic or aggressive periodontitis).
88843391|NCT03108482|Experimental|Co-crystal E-58425 (Tramadol/Celecoxib)|Co-crystal E-58425 (Tramadol/Celecoxib): Two tablets of 100 mg every 12 hours. The total daily dose will be 400 mg of Co-crystal E-58425.
88843392|NCT03108482|Active Comparator|Tramadol (Ultram®)|Tramadol: One tablet of 50 mg every 6 hours. The total daily dose will be 200 mg of tramadol.
88843393|NCT03108482|Active Comparator|Celecoxib (Celebrex®)|Celecoxib: One capsule of 100 mg every 12 hours. The total daily dose will be 200 mg of celecoxib.
88843394|NCT03108482|Placebo Comparator|Placebo|Placebo: One or two tablets of 100 mg every 6 hours.
88843395|NCT03079375|No Intervention|usual care|no pharmaceutical intervention.
89370645|NCT03391765|Experimental|M15-562 ABBV-8E12 2000 mg/M15-563 ABBV-8E12 2000 mg|Intravenous (IV) infusions of 2000 mg ABBV-8E12 at Day 1 and Day 29, then every 28 days for up to 5 years; administered at 300 mg/15 mL and 1000 mg/10 mL strength. Placebo IV infusion was administered on Day 15 in Study M15-563 (to maintain the blind in Study M15-562).
89370646|NCT03391765|Experimental|M15-562 ABBV-8E12 4000 mg/M15-563 ABBV-8E12 4000 mg|Intravenous (IV) infusions of 4000 mg ABBV-8E12 at Day 1 and Day 29, then every 28 days for up to 5 years; administered at 300 mg/15 mL and 1000 mg/10 mL strength. Placebo IV infusion was administered on Day 15 in Study M15-563 (to maintain the blind in Study M15-562).
89370647|NCT03391765|Experimental|M15-562 Placebo/M15-563 ABBV-8E12 2000 mg|Intravenous (IV) infusions of 2000 mg ABBV-8E12 at Day 1, Day 15, and Day 29, then every 28 days for up to 5 years; administered at 300 mg/15 mL and 1000 mg/10 mL strength.
89370648|NCT03391765|Experimental|M15-562 Placebo/M15-563 ABBV-8E12 4000 mg|Intravenous (IV) infusions of 4000 mg ABBV-8E12 at Day 1, Day 15, and Day 29, then every 28 days for up to 5 years; administered at 300 mg/15 mL and 1000 mg/10 mL strength.
89370649|NCT02802228|Experimental|Ifetroban|90 day course of oral ifetroban following intravenous loading dose
89370650|NCT02802228|Placebo Comparator|Placebo|90 day course of placebo following intravenous dose of 5% dextrose in water (D5W)
89370651|NCT02426554|Active Comparator|Group 1|
89370652|NCT02426554|Placebo Comparator|Group 2|
88843396|NCT03079375|Sham Comparator|basic intervention|Medication review
88843397|NCT03079375|Sham Comparator|extended intervention|medication review, medication interview before discharge and follow-up with patient, GP and if relevant pharmacy and nursing home.
89180516|NCT02594904|Experimental|G-6-PD moderate deficiency group|Drug: Yinzhihuang Oral Liquid, dose: 3ml each time, 3 times every day, during the period, measuring bilirubin from skin one time every 24 hours.
89180517|NCT02594904|Experimental|G-6-PD sever deficiency group|Drug: Yinzhihuang Oral Liquid, dose: 3ml each time, 3 times every day, during the period, measuring bilirubin from skin one time every 24 hours.
89180518|NCT02605070|Experimental|Infertility group|Patients referred will be evaluated to participate in the study and then asked to take part.In this visit,the normal protocol for infertility patients will be followed and at least 2 spermiograms and a blood test analyzing the following parameters:FSH, LH,Estradiol,Total testosterone,SHBG, Albumin,Calculation of bioavailable testosterone,Prolactin.If these tests have not been performed,a second baseline visit will be scheduled.Should the patient meet all the inclusion criteria and after the patient has signed an informed consent form agreeing to participate in the study,the physician will prescribe the medication and schedule visits.Before initiating the treatment, they will provide a semen sample.This sample will be sent to the Center for Reproductive Biology,where the sample will be subjected to epigenetic analysis.The patient will be given samples of Bravelle.It is administered subcutaneously.The dose will be 150 IU 3times a week for 3months
89180519|NCT02605070|No Intervention|Fertily group|"Patients who volunteer will be informed of the nature of the study and asked to sign the informed consent form. At least two spermiograms will be performed along with a blood test analyzing the following parameters:FSH,LH,Estradiol,Total testosterone,SHBG,Albumin,Estimation of bioavailable testosterone,Prolactin.~A second baseline visit will be scheduled to evaluate the test results and to check whether these subjects meet all the inclusion criteria for the control group. Those subjects will provide a semen sample which will be stored at -20º C.~Outpatient visit: week twelve: a physical exam will be carried out to identify any adverse reactions. A blood test and a semen sample will also be obtained."
89180520|NCT05572502|Experimental|Vegan diet|All participants will follow a low-fat vegan diet. There are no other study arms or control group.
89180521|NCT02605226|Experimental|Arm I|"Patients receive oral bicalutamide once daily on days 1-28. Patients also receive luteinizing-hormone releasing-hormone (LHRH) agonist treatment intramuscularly (IM) on day 8. Treatment with LHRH agonist repeats every 12 weeks for 24 weeks.~Patients receive cryoablation therapy."
89180522|NCT02605226|Experimental|Arm II|Patients receive androgen ablation as in arm I. Patients receive external beam radiation therapy.
89180523|NCT04033367|Experimental|Dupilumab/Dupilumab|Participants received dupilumab 600 milligrams (mg) (loading dose) injection subcutaneously (SC) on Day 1 followed by dupilumab 300 mg injection SC every 2 weeks (q2w) up to Week 10 in the double-blind (DB) period of 12 weeks. After completion of DB period, participants entered in the open-label extension (OLE) period (Week 12 to 24) and continued to receive dupilumab 300 mg injection SC q2w from Week 12 up to Week 22.
89180524|NCT04033367|Placebo Comparator|Placebo/Dupilumab|Participants received placebo matching to dupilumab injection SC on Day 1 then followed by placebo injection SC q2w up to Week 10 in the DB period of 12 weeks. After completion of DB period, participants entered in the OLE period (Week 12 to 24) and received dupilumab 600 mg (loading dose) at Week 12 followed by dupilumab 300 mg injection SC q2w up to Week 22.
89180525|NCT00733980|Experimental|GSK561679 arm|Double blind GSK561679
89180526|NCT00733980|Placebo Comparator|placebo arm|Double blind placebo
89180527|NCT04088448|Placebo Comparator|Control group|Fluoxetine 20 mg capsule once daily for 12 week plus placebo tablet once daily for 12 weeks
89180528|NCT04088448|Experimental|Metformin group|Fluoxetine 20 mg capsule once daily for 12 week plus Metformin 1000 mg XR tablet once daily for 12 weeks
89180529|NCT00806585|Experimental|MK-0736 0.5 mg|One MK-0736 0.5 mg tablet, orally, once daily for 24 weeks (Phase A). Participant will then be switched to MK-0736 8.0 mg, once daily for an additional 52 weeks (Phase B).
89180530|NCT00806585|Experimental|MK-0736 2.0 mg|One MK-0736 2.0 mg tablet, orally, once daily for 24 weeks (Phase A). Participant will then be switched to MK-0736 8.0 mg, once daily for 52 weeks (Phase B).
89180531|NCT00806585|Experimental|MK-0736 8.0 mg|One MK-0736 8.0 mg tablet, orally, once daily for 24 weeks (Phase A). Participant will continue to receive MK-0736 8.0 mg, once daily for 52 weeks (Phase B).
89180532|NCT00806585|Active Comparator|HCTZ 12.5 mg → MK-0736 8.0 mg|one 12.5 mg hydrochlorothiazide (HCTZ) tablet daily, orally, for 12 weeks. Participant then switched to MK-0736 8.0 mg for 12 weeks (Phase A). Participant will continue to receive MK-0736 8.0 mg, once daily for an additional 52 weeks (Phase B).
89180533|NCT00806585|Placebo Comparator|Placebo|One placebo tablet daily, orally, for 24 weeks (Phase A). Participant will continue to receive placebo, once daily for 52 weeks (Phase B)
89180534|NCT02607761|Experimental|Intervention Group|2 minutes video with information and images on age-related fertility, infertility definitions, infertility risk factors, probabilities of fecundity according to age and cycle.
89180535|NCT02607761|No Intervention|Control|No intervention
89180536|NCT02607761|Active Comparator|Control 1|2 minutes video with same images but information on work-family balance.
89180537|NCT05740553|Experimental|Training First|
89180538|NCT05740553|Experimental|Training Second|
88843398|NCT02871128|Experimental|Natureheme-iron|Subjects receive 2 capsules per day containing either 1000 mg Fe.
89180539|NCT00480025|Experimental|GSK1572932 Group|Patients received up to 13 doses of GSK1572932, 5 doses every 3 weeks followed by 8 doses every 12 weeks.
88843399|NCT02871128|Placebo Comparator|Placebo|Subjects receive 2 capsules per day containing starch placebo of similar appearance.
88843400|NCT02871128|Active Comparator|supplement|Subjects receive 1 capsule per day containing either 100 mg Fe.
88843401|NCT02850601|Experimental|Dexamethasone solution|Dexamethasone 0.5 mg/mL, 5ml TID for 4 weeks
88843402|NCT02850601|Active Comparator|Dexamethasone solution in Mucolox™|Compounded dexamethasone 0.5 mg/mL in Mucolox™, 5ml TID for 4 weeks
89180540|NCT00480025|Placebo Comparator|Placebo Group|Patients received up to 13 doses of placebo, 5 doses every 3 weeks followed by 8 doses every 12 weeks.
89180541|NCT00806351|Experimental|Anidulafungin Arm|Subjects were randomized 2:1 (anidulafungin:caspofunin).
89180542|NCT00806351|Experimental|Caspofungin Arm|Subjects were randomized 2:1 (anidulafungin:caspofunin).
89180543|NCT03589963|No Intervention|Pre-intervention|regular CPNP programming
89180544|NCT03589963|Experimental|Post-intervention|regular CPNP programming plus access to postnatal lactation support
89180545|NCT03995251|Experimental|Standard Medical Treatment +Intramuscular Testosterone + Exerc|Intramuscular Testosterone Undecanoate 1000 Mg (4 ml volume in oily base) will be injected into the upper, outer quadrant of the buttock at 0, 6, 12,16,20, 24 weeks according to manufacturer recommendations
89180546|NCT03995251|Active Comparator|Standard Medical Treatment+Exercise|Standard Medical Treatment +Exercise
89180547|NCT01031017|Placebo Comparator|placebo|group taking placebo
89180548|NCT01031017|Active Comparator|study group|group taking progesterone
89180549|NCT03635177|Experimental|Remote ischemic conditioning|The participant will conduct remote ischemic preconditioning by use of an automated cuff device placed on the upper arm which inflates to 200 mmHg and occludes blood flow. The procedure is conducted on one arm 4 x 5 min per day. Each 5 min occlusion period is interspersed by 5 min.
89180550|NCT03635177|Sham Comparator|Sham occlusion|The participant will conduct a sham procedure of remote ischemic preconditioning by use of an automated cuff device placed on the upper arm which inflates minimally and does not occlude blood flow. The procedure is conducted on one arm 4 x 5 min per day. Each 5 min of sham occlusion is interspersed by 5 min.
89180551|NCT03742531|Active Comparator|low dose group|oxytocin therapy starting with 2mU/min increased by 2 mU/min every 15 minutes. oxytocin will be stopped at the beginning of the active phase of labor.
89180552|NCT03742531|Active Comparator|high dose group|oxytocin therapy starting with 4mU/min increased by 4 mU/min every 15 minutes. oxytocin will be stopped at the beginning of the active phase of labor.
89180553|NCT00733902|Experimental|Tanezumab 10 mg|
89180554|NCT00733902|Experimental|Tanezumab 5 mg|
89180555|NCT00733902|Experimental|Tanezumab 2.5 mg|
89180556|NCT00733902|Placebo Comparator|Placebo|
89180557|NCT01027741|Experimental|Phone Referral|Participants receive phone referral to cancer control and prevention services.
89180558|NCT01027741|Experimental|Tailored Cancer Communication|Participants will receive phone referral to cancer control and prevention services as well as tailored materials in the mail.
89180559|NCT01027741|Experimental|Cancer Control Navigator|Participants will receive phone referral to cancer control and prevention services as well as a personal cancer control navigator.
89180560|NCT01027741|No Intervention|Control|Participants receive only recommendation to talk to health care professional.
89180561|NCT05737355|Experimental|ANKASCIN 568-P Red yeast rice capsules|ANKASCIN 568-P is a fermented product from the red yeast rice fungus <Monascus purpureus NTU 568>. It does not contain Monacolin K, an ingredient that may harm the human body, and is rich in new active ingredients. Take 2 red yeast rice capsules (each containing 440mg ANKASCIN 568-P) every day, and the control group takes 2 placebo capsules (containing equal weight maltodextrin) every day, respectively, at the 0th, 4th , , 12, 24, Collect blood samples for biochemical analysis and record the general body position measurement, blood pressure, blood lipid, blood sugar and other related changes of the subjects, and monitor the liver, kidney, and thyroid functions.
89180562|NCT05737355|Placebo Comparator|Placebo Capsules|Maltodextrin was used as a placebo.
89180563|NCT00914225||Intervention|Cohort 1 is the intervention group who received long-lasting insecticide treated bednets and a water filtration device
89180564|NCT00914225||Comparison|"Cohort 2 is the comparison group included from the control arm of the study, Empiric therapy of helminth coinfection to reduce HIV-1 disease progression ClinicalTrials.gov identifier: NCT00507221~As part of the RCT (NCT00507221), we have enrolled 948 HIV infected ART naïve individuals to compare HIV disease progression in those receiving standard of care versus empiric deworming. Subjects are followed for 24 months and have serial measurements of HIV disease progression, and are evaluated serially for evidence of malaria, diarrhea and other co-morbidities. Participants in this study will have been consented for the collection of data on the frequency of malaria and diarrheal disease, their use of a bednet and water filtration and their compliance with TMP/SMX."
89180565|NCT02608541||Retrospective rib fracture fixation|patients presenting since 2006 with multiple rib fractures or flail chest, managed operatively or non-operatively
89180566|NCT02608541||Prospective rib fracture fixation|patients presenting from October 2015 to October 2017 with multiple rib fractures or flail chest, managed operatively or non-operatively
89180567|NCT00914381|Active Comparator|CRA + CM|Community Reinforcement Approach (CRA) combined with Contingency Management (CM)
89180568|NCT00914381|Active Comparator|TSF + CM|Twelve-Step Facilitation (TSF) combined with Contingency Management (CM)
89180569|NCT00914381|Active Comparator|CRA + VC|Community Reinforcement Approach (CRA) combined with Voucher Control (VC)
89180570|NCT00914381|Active Comparator|TSF + VC|Twelve-Step Facilitation (TSF) combined with Voucher Control (VC)
89180571|NCT02607527|Other|Device Implantation|Transcatheter IRIS placement
89180572|NCT03540017|Experimental|HIPEC|Patient will receive HIPEC in the form of Cisplatin 100mg/m2. 5. HIPEC will be provided at completion of surgical cytoreduction. The chemotherapy will be ordered by the treating gynecologic oncologist. It will be prepared in the chemotherapy pharmacy and delivered to the operating room once the surgeon confirms optimal cytoreduction and eligibility. Patients undergoing bowel resection will be left with bowel in discontinuity during the HIPEC infusion cycle. The abdomen will be temporarily closed with skin staples to prevent spillage of the perfusate. HIPEC will be delivered using the closed technique as has been well described.
89180573|NCT02606747||Diabetes mellitus with DPN|Aged from 40 to 80. Normal cognitive ability. Right handed. Able to walk without any other kinds of central nervous system disorder. Confirmed diabetes with DPN.
89180574|NCT02606747||Diabetes mellitus without DPN|Aged from 40 to 80. Normal cognitive ability. Right handed. Able to walk without any other kinds of central nervous system disorder. Confirmed diabetes without DPN.
89180575|NCT02606981|Experimental|Chlorination|Device: Water chlorination by the Flogenic Primary drinking water source will be outfitted with automatic dosing device supplied with chlorine tablets. The device is called the Flogenic.
89180576|NCT02606981|Placebo Comparator|Control|Active control: Vitamin C dosing into water. Primary drinking water source will be outfitted with automatic dosing device supplied with vitamin C tablets. The device is not commercially available.
89180577|NCT02606435|Experimental|thrombus aspiration with PCI|patient will receive manual thrombus aspiration with percutaneous coronary intervention (PCI)
88843403|NCT02871440|Experimental|Eye drop 1|Omega 3
88843404|NCT02871440|Active Comparator|Eye drop 2|Optive Advanced
88843405|NCT02871440|Active Comparator|Eye drop 3|Optive
88843406|NCT03079531|Experimental|Secukinumab arm|Participants receive secukinumab (7 doses over a 16-week study period).
88843407|NCT03056456|Experimental|LY900014|LY900014 (Treatment B) delivered via an insulin pump as a continuous infusion under the skin, with various intermittent bolus doses immediately before meals over 3-days per period.
88843408|NCT03056456|Active Comparator|Insulin Lispro (Humalog)|Insulin lispro (Treatment A) delivered via an insulin pump as a continuous infusion under the skin, with various intermittent bolus doses immediately before meals over 3-days per period.
88843409|NCT03057704|Active Comparator|Intravenous lidocaine: flushed|Lidocaine injection flushed
88843410|NCT03057704|Experimental|Intravenous lidocaine: tourniquet|Lidocaine injection tourniquet
88843411|NCT02874092|Active Comparator|Rheumatoid Arthritis|-Receiving Methotrexate at stable doses of 10 to 25 mg weekly for at least 12 weeks
88843412|NCT02874092|Active Comparator|Osteoarthritis|-Diagnosis of osteoarthritis made by physician.
88843413|NCT03059810|Experimental|Participating Subjects|Participating Subjects who are habitual soft contact lens wearers, aged 40 to 70 years of age, will be dispensed investigational contact lenses to be worn from 12-16 days, to include a total of 3 visits.
88843414|NCT03062228||Controls|"Healthy, Ghanaian women who have recently delivered a live birth at the Korle Bu Teaching Hospital.~No interventions will be administered."
88843415|NCT02876900|Experimental|Low dose Asenapine maleate patch|Low dose asenapine maleate, transdermal patches will be compared against placebo patches.
88843416|NCT02876900|Experimental|High dose asenapine maleate patch|High dose asenapine maleate, transdermal patches will be compared against placebo patches.
89180578|NCT02606435|Active Comparator|PCI alone|patients will receive percutaneous coronary intervention (PCI) alone including stent implantation
89180579|NCT03518723|Experimental|Non-linear Periodized Resistance Training|"The objective of the Non-linear Periodized Resistance Training (NLPRT) program is to increase muscle strength as well as muscle endurance. The NLPRT program will over the 8 week intervention period target several different aspects of limb muscle function, by alternating the intensity and volume of the exercises.~Progression of exercise is symptom dependent and will be based on Borg CR-10 ratings (dyspnea, muscle fatigue and exertion).~All exercises will be performed using exercise equipment that are available at each included center.~All sessions are supervised and conducted by local professionals using a group format, with approximately 2-4 participants per group."
89180580|NCT03518723|Active Comparator|Resistance Training|"The primary objective of the Resistance training (RT) group is to increase muscular strength. The RT program will be performed in line with current guidelines that are recommended for increasing muscular strength in patients with COPD.~Progression of exercise is performance dependent and will be based on the previous 2 sessions.~All exercises will be performed using exercise equipment that are available at each included center.~All sessions are supervised and conducted by local professionals using a group format, with approximately 2-4 participants per group."
89180581|NCT05752955|Experimental|SMARThealth Pregnancy|"SMART Health Pregnancy is a complex intervention designed to be delivered on top of usual care. It comprises three parts:~(i) A regular screening program focused on women's health during pregnancy and in the year following birth.~(ii) An electronic decision support system (EDSS) (iii) An short messaging service (SMS) appointment reminder system"
89180582|NCT05752955|No Intervention|Active Comparator: Usual Care|Usual antenatal and postnatal care. Women and health workers in the usual care clusters will not receive any additional support beyond that already offered under the local government programs
89180583|NCT00790790|Placebo Comparator|Placebo|Participants randomized to LY545694 placebo were given LY545694 placebo twice daily (BID) oral (po) for 5 weeks.
89180584|NCT00790790|Experimental|LY545694 49 mg|Participants randomized to LY545694 49 milligrams (mg) BID po were first administered LY545694 21 mg BID po at Visit 3. After 1 week of dosing, participants were escalated to LY545694 49 mg BID po at Visit 4. Participants who were intolerant of this dose were titrated back down to 21 mg BID po for the remainder of study treatment.
89370653|NCT03179488|Experimental|Spinal TENS stimulation|"Spinal TENS stimulation: A constant voltage and a symmetric biphasic current of 200 microseg pulse-width at a frequency of 100Hz. The intensity will increase until participants report a strong but comfortable sensation, just below motor threshold."
88843417|NCT02876900|Placebo Comparator|Placebo transdermal patch|Low dose or high dose asenapine maleate transdermal patch will be compared against placebo patches
88843418|NCT03063476|Experimental|Healthy|"Two healthy subjects will be enrolled and each will undergo study procedures at one visit. After screening and consent have been conducted over the phone, subjects will participate in the study procedures. Subjects will arrive in a fasting state (no eat or drink for 8 hours, excluding water). Following collection of blood pressure, height, weight, and a urine and blood sample, subjects will be given an oral bolus of C-13 labeled lysine (5 g) in 50 ml water. This amount of lysine is equivalent to that which is found in a 5oz. serving of beef. Subjects will provide additional urine and blood samples serially post-ingestion. Because blood draws will be collected through an IV, Normal (0.9%) Saline (NS) will be infused at a rate of approximately 10 ml/hr to flush the canula prior to each blood draw.~All subjects will undergo the same procedures and interventions."
88843419|NCT02878382|Other|Conventional MAL-PDT|Conventional topical PDT with Methylaminolevulinate 16% in one half of the scalp with multiple AKs.
89370654|NCT03179488|Sham Comparator|Sham stimulation|The same procedures as experimental group, but but will be applied a sham electrical stimulation increasing the current intensity until sensory perception of the stimulus, and then decreased to zero where it will fix until the end of the stimulation.
89370655|NCT03130257|Active Comparator|Clinic Blood Pressure Measurement|Participants will be asked to check their blood pressure at their clinic once within the subsequent three weeks.
89370656|NCT03130257|Active Comparator|Home Blood Pressure Measurement|Participants will receive a validated upper-arm home blood pressure monitor and asked to take two measurements in the morning and two in the evening for at least 5 days over three weeks.
89370657|NCT03130257|Active Comparator|Kiosk Blood Pressure Measurement|Participants will be asked to use a validated blood pressure kiosk in their clinic or local pharmacy to measure their blood pressure three times on three separate days over three weeks.
89370658|NCT02801448|Placebo Comparator|Placebo|Placebo containing maltodextrine but no active sulforaphane
89370659|NCT02801448|Active Comparator|BSE|Broccoli sprout extract once daily for 12 weeks
89370660|NCT03179332|Experimental|BioChaperone® insulin lispro|Single subcutaneous administration of BioChaperone® insulin lispro
89370661|NCT03179332|Active Comparator|Fiasp®|Single subcutaneous administration of Fiasp® (insulin aspart)
89370662|NCT03179332|Active Comparator|Novorapid®|Single subcutaneous administration of Novorapid® (insulin aspart)
88843420|NCT02878382|Other|Calcipotriol assisted MAL-PDT|Calcipotriol ointment 50 mcg/g applied once a day for 15 consecutive days in one half of the scalp, before Conventional topical PDT
88843421|NCT02880176|Experimental|Financial Incentive|"Financial Incentive to Increase Ambulation: A financial reward is given on a per day basis when subject meets daily step goal, 1/5 chance to win additional monetary prize if patient uploads step count data for at least 75% of study days.~Subjects will use Fitbit Zip to track step counts"
88843422|NCT02880176|No Intervention|Control (Education)|Subjects in this group will receive standard education on the benefits of post-surgery ambulation only Subjects will use Fitbit Zips to track step counts
88843423|NCT02880254|Active Comparator|Kurbo only|use of app plus standard of care
88843424|NCT02880254|Active Comparator|Kurbo plus PHC|use of app, personal health coach and standard of care
88843425|NCT03115580|Active Comparator|Rotational atherectomy|Rotational atherectomy (RA)
88843426|NCT03115580|Active Comparator|CBA/PTCA|Cutting Balloon Angioplasty (CBA) or Percutaneous transluminal coronary angioplasty (PTCA)
88843427|NCT03117140|Active Comparator|Plain Ropivacaine|Plain Ropivacaine 0.75%, (225 mg) total volume 32 cc for interscalene block given pre-operatively
88843428|NCT03117140|Experimental|Ropivacaine + Buprenorphine|A mixture of 0.75% ropivacaine with 300 mcg buprenorphine, total volume 32 cc for interscalene block given pre-operatively
88843429|NCT03117140|Experimental|Ropivacaine + Clonidine|A mixture of 0.75% ropivacaine with 75 mcg clonidine, total volume 32 cc for interscalene block given pre-operatively
89370663|NCT03674177|Experimental|RSV MAT formulation 1 Group|Subjects received a single dose (30 µg) injection of the investigational RSV maternal vaccine (GSK3888550A) at Day 1, intramuscularly into the deltoid region of the non-dominant arm
89370664|NCT03674177|Experimental|RSV MAT formulation 2 Group|Subjects received a single dose (60 µg) injection of the investigational RSV maternal vaccine (GSK3888550A) at Day 1, intramuscularly into the deltoid region of the non-dominant arm
89370665|NCT03674177|Experimental|RSV MAT formulation 3 Group|Subjects received a single dose (120 µg) injection of the investigational RSV maternal vaccine (GSK3888550A) at Day 1, intramuscularly into the deltoid region of the non-dominant arm
89370666|NCT03674177|Placebo Comparator|Control Group|Subjects received a single placebo saline injection at Day 1, intramuscularly into the deltoid region of the non-dominant arm
89370667|NCT03717259|Active Comparator|Open nephrectomy|These patients will undergo an open nephrectomy.
89370668|NCT03717259|Active Comparator|Hand-assisted laparoscopic nephrectomy|These patients will undergo a hand-assisted nephrectomy.
89370669|NCT03717259|Active Comparator|Laparoscopic nephrectomy|These patients will undergo a pure laparoscopic nephrectomy.
89370670|NCT02675790|Active Comparator|Hydroxyurea (Moderate Dose)|The study intervention will include moderate dose hydroxyurea therapy at 20 mg/kg/day (range 17.5 - 26 mg/kg/day) for 36 months.
89370671|NCT02675790|Active Comparator|Hydroxyurea (Low Dose)|The study intervention will include random allocation to low dose hydroxyurea therapy at 10 mg/kg/day (range 7 - 15 mg/kg/day) for 36 months.
89370672|NCT01359189|Experimental|Suspected Primary Prostate Cancer|Patients with suspected prostate cancer will be evaluated for initial proof of concept and feasibility of a scintigraphic rectal probe (ProxiScanTM) utilizing a PSMA receptor radiopharmaceutical (ProstaScint®). To explore the adjunctive benefit/feasibility of PSMA distribution in the normal prostate versus prostate cancer gland utilizing TRUS and CT/SPECT hybrid imaging, biopsy negative patients will be considered as normal controls. This is an exploratory, open label trial and randomization is not required. Subject blinding is not needed and investigator blinding in not possible.
89370673|NCT02417896|Experimental|Spironolactone|The intervention group will receive spironolactone. The drug will be administered orally to cardiac surgical patients by a study investigator (100 mg 12-24 hrs before surgery); subsequently, three further doses of 25 mg are administered orally in the morning of postoperative days 1, 2 and 3.
89370674|NCT02417896|No Intervention|No spironolactone|Cardiac surgical patients requiring cardiopulmonary bypass and aortic cross clamp, randomised not to receive spironolactone will be followed for 10 days after surgery.
89370675|NCT01365663|Experimental|Cohort 1|0.25 mg/kg in Healthy Subjects
89370676|NCT01365663|Experimental|Cohort 2|0.5 mg/kg in Healthy Subjects
89370677|NCT01365663|Experimental|Cohort 3|1.0 mg/kg in Healthy Subjects
89370678|NCT01365663|Experimental|Cohort 4|1.5 mg/kg in Healthy Subjects
89370679|NCT01365663|Experimental|Cohort 5|2.0 mg/kg in Healthy Subjects
89370680|NCT01365663|Placebo Comparator|Saline 0.9%|
89370681|NCT03183544|Experimental|Gallium-68 PSMA-11 prepared using PSMA-11 Sterile Cold Kit|Single injection for diagnostic use only
89370682|NCT04380090|Active Comparator|Drug: Docusate Sodium|Docusate sodium one pill to be taken twice a day by mouth for 28 days
89370683|NCT04380090|Experimental|Drug: Propylene Glycol|One standard dose (17 grams) of propylene glycol by mouth on postoperative day one
89370684|NCT05191563|Experimental|Sequence 1 (Reference-Test)|Period 1: RLD2001-2 + RLD2006, Period2: HCP1904-1
89370685|NCT05191563|Experimental|Sequence 2 (Test-Reference)|Period 1:HCP1904-1, Period 2: RLD2001-2 + RLD2006
89370686|NCT03685994||the patients who will undergo TIPS|
89370687|NCT03711565|Active Comparator|Regular Nasal CPAP using a conventional ventilator|Regular nasal CPAP for management of respiratory distress Patient will have regular nasal CPAP placed via nasal prongs with level of pressure adjusted and level of oxygen adjusted as needed for acceptable oxygenation and ventilation
89370688|NCT03711565|Active Comparator|High Frequency Nasal CPAP|High Frequency Nasal CPAP for management of respiratory distress Patient will be connected to the high frequency device through nasal prongs. The pressure, frequency and amplitude of the pulsations will be adjusted as needed to provide acceptable oxygenation and ventilation
89370689|NCT02418052|Experimental|neck flexion group|Patients who fixed in neck flexion position after MIE
89370690|NCT02418052|No Intervention|control group|Patients without posture intervention after MIE
89370691|NCT03685916|Other|Control|50 grams carbohydrate in the form of rice, 200 milliliters of plain water and 20 grams of garden peas.
89370692|NCT03685916|Experimental|Cumin Rice|50 grams carbohydrate in the form of rice with cumin, 200 milliliters of plain water and 20 grams of garden peas.
89370693|NCT03685916|Experimental|Cumin Drink|50 grams carbohydrate in the form of rice, 200 milliliters of cumin extract in solution and 20 grams of garden peas.
89370694|NCT03685916|Experimental|Cornsilk Rice (Low dose)|50 grams carbohydrate in the form of rice with cornsilk extract (low dose), 200 milliliters of plain water and 20 grams of garden peas.
89370695|NCT03685916|Experimental|Cornsilk Rice (High dose)|50 grams carbohydrate in the form of rice with cornsilk extract (high dose), 200 milliliters of plain water and 20 grams of garden peas.
89370696|NCT03685916|Experimental|Cornsilk Drink (Low dose)|50 grams carbohydrate in the form of rice, 200 milliliters of cornsilk extract (low dose) in solution and 20 grams of garden peas.
89370697|NCT03685916|Experimental|Cornsilk Drink (High dose)|50 grams carbohydrate in the form of rice, 200 milliliters of cornsilk extract (high dose) in solution and 20 grams of garden peas.
89370698|NCT03685916|Experimental|Tamarind Rice|50 grams carbohydrate in the form of rice with Tamarind, 200 milliliters of plain water and 20 grams of garden peas.
89370699|NCT03685916|Experimental|Tamarind Drink|50 grams carbohydrate in the form of rice, 200 milliliters of Tamarind extract in solution and 20 grams of garden peas.
89370700|NCT03116776|Experimental|Walnut Shell Glasses Moxibustion|Use wire to make a glass frame which can fix two walnut shells and moxa roll in front of the eyes, the walnut shell should be soaked in medlar chrysanthemum water and use the moxibustion to treat eye disease.
89370701|NCT03116776|Active Comparator|Sodium hyaluronate eye drops|Commonly used artificial tears in clinical.
88843430|NCT03117140|Experimental|Ropivaciane + Dexamethasone|A mixture of 0.75% ropivacaine with and 8 mg dexamethasone, total volume 32 cc for interscalene block given pre-operatively
88843431|NCT03118466|Experimental|Lenalidomide and MEC chemotherapy|Lenalidomide is taken orally on a daily basis days 1-10. Mitoxantrone, Etoposide, and Cytarabine are administered intravenously on a daily basis for days 4 through 8 of the treatment. There is only one cycle of treatment in this study.
89370702|NCT02505204|Experimental|Clonidine|Will receive bilateral PVB with clonidine.
89370703|NCT02505204|Placebo Comparator|Placebo|Will receive bilateral PVB with placebo.
89370704|NCT01359267|Experimental|Imaging|
89370705|NCT03183232|Experimental|Group A|In this group, the patients will receive under CT Cryosurgery or IRE surgery to control the local tumor
89370706|NCT03183232|Experimental|Group B|In this group, the patients will receive multiple high-activity γδ T cell immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)
89370707|NCT03183232|Experimental|Group C|In this group, the patients will receive multiple high-activity γδ T cell immunotherapies and Cryosurgery or IRE surgery
89370708|NCT01362933||VTE treatment in cancer patient|All patients with cancer present in the clinic, hospital, out patient diagnosed with a VTE during the 6 previous months.
89370709|NCT03681626|Active Comparator|tracheal suction|After a standardized protocol during the thirty minutes before extubation, extubation was performed with a standardized tracheal suction.
89370710|NCT03681626|Experimental|no tracheal suction|After a standardized protocol during the thirty minutes before extubation, extubation was performed without tracheal suction.
89370711|NCT05056714||patients with Nasosinus Polyposis|patients with Nasosinus Polyposis included in the study
89370712|NCT01359345|Experimental|A|The patients with renal failure in whom Gadollinume has being used
89370713|NCT02417584|Experimental|positive airway pressure (PAP)|Treatment with positive airway pressure (PAP)
89370714|NCT01359423|Experimental|long coverage|Primary long full coverage stenting
89370715|NCT01359423|Active Comparator|short spot|primary short spot stenting
89370716|NCT03179566|No Intervention|Usual Care|For the first two weeks, there will be no intervention or changes to the usual discharge instructions
89370717|NCT03179566|Active Comparator|Information Sheet|At discharge, patients will receive an informational sheet detailing options for safe drug disposal
89370718|NCT03179566|Active Comparator|Deterra Drug Deactivation System|At discharge, patients will receive a Deterra Drug Deactivation System.
89370719|NCT01363089|Experimental|Ketorolac tromethamine|
89370720|NCT01363089|Experimental|Oxymetazoline hydrochloride|
89370721|NCT03354637|Active Comparator|ATI-50002 high dose Topical Solution|High dose active
89370722|NCT03354637|Active Comparator|ATI-50002 low dose Topical Solution|low dose active
89370723|NCT03354637|Placebo Comparator|Vehicle Topical Solution|placebo
89370724|NCT03685838|Active Comparator|Compression|Patient will receive Class II above knee compression stockings, and will be asked to wear it for 1 week. This would involve wearing the stocking during daytime but patients will be allowed to take it off at night whilst in bed.
89370725|NCT03685838|No Intervention|No Compression|Patient will not receive any compression stockings.
89370726|NCT02422576|Active Comparator|Control + Product 1|Control product (Thicken Up clear: TUC) + natural ingredient 1 (cinnamon extract)
88843432|NCT03068312|Experimental|Sequence 1: First Ivacaftor (IVA) Then Placebo|Participants received IVA 150 milligram (mg) every 12 hours (q12h) for 8 weeks in treatment period 1 followed by placebo matched to IVA for 8 weeks in treatment period 2. A washout period of 8 weeks was maintained between the 2 treatment periods.
88843433|NCT03068312|Experimental|Sequence 2: First Placebo Then IVA|Participants received placebo matched to IVA for 8 weeks in treatment period 1 followed by IVA 150 mg q12h for 8 weeks in treatment period 2. A washout period of 8 weeks was maintained between the 2 treatment periods.
89370727|NCT02422576|Active Comparator|Control + Product 2|Control product (Thicken Up clear: TUC) + natural ingredient 2 (lemon extract)
89370728|NCT02422576|Active Comparator|Control + Product 3|Control product (Thicken Up clear: TUC) + natural ingredient 3 (lemon extract+eucalyptus extract)
89370729|NCT04053023|Experimental|Participants receiving obeticholic acid and linerixibat|In Part A, participants will be administered one tablet of 10 milligrams (mg) obeticholic acid once daily continuously for 37 days (study Day 1 to study Day 37). Two tablets of 45 mg linerixibat will be administered twice daily from study Day 20 to study Day 37. 1 tablet of 45 mg linerixibat will be administered on Day 38. After evaluation of Part A, if optional part B is conducted, participants will be administered linerixibat and obeticholic acid at an alternative dosing regimen.
88843434|NCT03119168|Experimental|Simethicone solution + Polyethylenglycol|This arm of the study will include the patients assigned to take simethicone solution with their colon preparations ( 4L Polyethyleneglycol)
88843435|NCT03119168|Active Comparator|Polyethylenglycol|This arm of the study will include the patients assigned to take a regular bowel preparation (4L Polyethylenglycol)
88843436|NCT02881112|Experimental|Active Treatment Arm|Treatment with Provant Therapy System
88843437|NCT02881658|Experimental|Plant sterols-enriched soya beverage provided by Vitasoy|Daily consumption of 2g of plant sterols as provided by one pack of 250 ml of plant sterols-enriched soya beverage for consecutive 3 weeks, each pack consumed once with main meal (i.e breakfast, lunch or dinner).
88843438|NCT02881658|Placebo Comparator|Soya beverage provided by Vitasoy|Daily consumption of one pack of 250 ml of soya beverage (without plant sterols) for consecutive 3 weeks, each pack consumed once with main meal (i.e breakfast, lunch or dinner).
88843439|NCT05405972|Experimental|Group Receiving Intervention|"The intervention group receives a link each week connecting them to the videos for both parents and children as well as a communicating/connecting activity. The intervention is self-paced over a 4 week period.~The intervention was titled the Connected Family Series - For Foster Families (CFS-FF) (further referred to as the intervention) and was created/adapted in partnership from the Connected Family Series (CFS) by psychologists at the Karyn Purvis Institute of Childhood Development (KPICD). A letter of support from the KPICD is available in Appendix D. Adaptation was needed as the original intervention was geared toward adoptive families and excluded foster families. This process was done with the original creator (Dr. Jana Hunsley) with members of the research team and fostering community."
88843440|NCT05405972|No Intervention|Control Group|Families in the control group receive no video links during the 4 week period. Families assigned to the control do have the opportunity to participate in the intervention post-data collection and analysis and outside of the research protocol.
88843441|NCT03070730|Other|Atenolol|"In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.~Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.~Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients."
88843442|NCT03070730|Other|Placebos|"In this arm subjects are randomized to placebo tid.~Placebo is used to control the administration effect."
88843443|NCT03070730|Other|Droxidopa|"In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.~Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.~Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients."
88843444|NCT04736498|No Intervention|Control arm|Control group will follow the standard procedure in our centre and will not undergo USG assessment before spinal anaesthesia. The spinal anaesthesia procedure will be standardized. Under strict aseptic precautions spinal anesthesia will be performed at L3-L4 inter-space using a 25 Gauge Quincke spinal needle (B. Braun Medical SA, Melsungen, Germany) in sitting position. 3 ml of hyperbaric bupivacaine 0.5% (15 mg) will be injected with the needle orifice oriented cranially. After injection, patients will be immediately positioned supine. Meanwhile, the non-invasive blood pressure will be measured and recorded every 3 minute for 30 min and then every 5 min throughout surgery and anesthesia.
89370730|NCT01365741|No Intervention|Standard administration of Efient|The test person will ingest Efient in supine position, and remain supine during 2 hours, mimicing the way Efient is used for pre-PCI treatment today
89370731|NCT01365741|Active Comparator|Upright administration of Efient|The test person will ingest Efient in an upright position, and remain supine during 2 hours.
89370732|NCT02426320|Active Comparator|Sedation Interruption Protocol + standard sedation protocol|Nurse directed protocols for administering sedation and/or analgesia, with daily interruption of sedation/analgesia
89370733|NCT02426320|Active Comparator|Standard sedation protocol|Nurse directed protocol for administering sedation and/or analgesia.
89370734|NCT02422732|Other|Children with reading disability|Children with NF1, with reading disability if their performances on reading assessment (Alouette Test) present a delay of at least 18 months, will have Neuropsychological assessments, morphological and functional MRI (fMRI) and genetic analysis
89370735|NCT02422732|Other|Children without reading disability|Children with NF1, without reading disability if their performances on reading assessment (Alouette Test) present a less than 18-month delay, will have Neuropsychological assessments, morphological and functional MRI (fMRI) and genetic analysis.
89370736|NCT03623906|Experimental|Carbon dioxide insufflation colonoscopy|Carbon dioxide insufflation colonoscopy
89370737|NCT03623906|Active Comparator|Air insufflation colonoscopy|Room air insufflation colonoscopy
89370738|NCT05416788|Experimental|Cervical manipulation group|high-velocity, low-amplitude cervical manipulation
89370739|NCT05416788|Sham Comparator|Control group|placebo manipulation, the cervical spine will be tilted and rotated without reaching the end feel or the pump
89370740|NCT01359501|Experimental|Chinese medical treatment|
89370741|NCT01359501|Placebo Comparator|Placebo|
89370742|NCT02422420|Experimental|Individual Incentive|Participants receive a financial incentive every time they attend a class session and goal-based incentives for attending 75% of Core sessions, 75% of Post-Core sessions, separately achieving 5%, 7%, and 10% weight loss during the Core period (i.e. separate financial incentives for each goal reached at any point during the Core period), and 5%, 7%, or 10% weight loss by the end of Post-Core Session 8 (i.e., one financial incentive based on final weight loss).
89370743|NCT02422420|Experimental|Group Incentive|This arm receives the same routine attendance incentives as the Individual Incentive arm. Group goal-based incentives include 5% weight loss by an individual during the Core period and, separately, during the Post-Core period. Financial incentives are also received if the entire DPP group achieves 75% Core session attendance, 75% of Post-Core session attendance, 7% or 10% weight loss from baseline during the Core, and 7% or 10% weight loss from baseline at the end of the Post-Core period.
89370744|NCT02422420|Other|Minimal Incentive|Participants receive the full Diabetes Prevention Program (DPP), but receive a nominal $25 financial incentive for attendance only at the first DPP session and no other incentives for attendance or weight loss.
89370745|NCT03681548|Active Comparator|Reference Product - R|Doxorubicin Hydrochloride Liposome Injection (Sun Pharma); 20 mg/10 mL i.e. 2 mg/mL (50mg/m2 dose). As this is a cross over study, subjects receiving in Cycle 1 the Reference Product (doxorubicin hydrochloride liposome injection SunPharma), will receive in Cycle 2 the Test Product (doxorubicin hydrochloride liposome injection (Ayana); after at least 4 weeks (RT).
89370746|NCT03681548|Experimental|Test Product - T|Doxorubicin Hydrochloride Liposome Injection (Ayana Pharma Ltd); 20 mg/10 mL i.e. 2 mg/mL (50mg/m2 dose). As this is a cross over study, subjects receiving in Cycle 1 the Test Product (doxorubicin hydrochloride liposome injection (Ayana)will receive in Cycle 2 the Reference Product (doxorubicin hydrochloride liposome injection SunPharma); after at least 4 weeks (RT).
89370747|NCT02417506|Experimental|E-OA-07 (Lanconone)|500 mg two capsules to be taken stat at the site
89370748|NCT02417506|Active Comparator|Ibuprofen|200 mg two capsule to be taken stat at the site
88843445|NCT04736498|Experimental|USG arm|In the IVC USG group, USG assessment and volume optimisation using collapsibility index will be done prior to spinal anaesthesia. all patients will be lying supine, for at least 5 min before IVC examination. Ultrasound measurements will be performed using a Sonosite M-Turbo (Sonosite Inc., USA) machine and phased array 5-1 Megahertz transducer (Sonosite Inc.) set to abdominal mode by an M-mode modality through the subcostal view. All IVC measurements will be performed by principal investigator before spinal anaesthesia. Principal investigator should have performed more than 25 scans before the commencement of the study.
88843446|NCT05405348|No Intervention|Control|The control group received routine care (T0)
88843447|NCT05405348|Experimental|Intervention|Same patients, one week after T0, T1 was applied in middialysis. In T1, patients did not consume food at least half an hour before coming to hemodialysis. They also did not consume any food during hemodialysis.
88843448|NCT03121820|Experimental|Memantinol tablets, 20 mg|"Treatment A: a single oral dose of memantin 20 mg film-coated tablet (JSC GEROPHARM, Russia - test)"
88843449|NCT03121820|Active Comparator|Akatinol Memantine® tablets, 20 mg|Treatment B: a single oral dose of memantin 20 mg film-coated tablet (Merz Pharma GmbH & Co. KGaA, Germany - reference)
88843450|NCT03123614|Active Comparator|Loteprednol Etabonate 0.5% Oph Gel|Group 1 will use loteprednol 0.5% gel in both eyes, starting at a frequency of four times per day for the first week and then tapered off based on clinical judgement of the corneal healing response.
88843451|NCT03123614|Active Comparator|Prednisolone acetate 1% Oph Susp|Group 2 will use prednisolone acetate 1% suspension in both eyes, starting at a frequency of four times per day for the first week, then tapered down to a regimen of fluorometholone 0.1% suspension, which will then be tapered off based on clinical judgement of the corneal healing response.
88843452|NCT03123848|Experimental|Darunavir/Cobicistat FDC (Prezcobix)|Participants will receive one darunavir/cobicistat fixed-dose combination (FDC) tablet, containing 800 milligram (mg) of darunavir (DRV) and 150 mg of cobicistat (COBI) in the morning on Day 1.
88843453|NCT03124550|Experimental|Exergame Experience|Participants will use the exergame for 6 weeks, during which time game telemetry data (all interactions with the software) will be automatically logged by the system. The participants will be asked to use the game at least every other day. Caregivers will be sent an email or text message to remind them to use the system if they have not done so within three days. Utilizing two-way text messaging, an experience sampling protocol will be employed: once per week, participants will be sent brief questions probing their level of satisfaction with the exergame and their level of perceived connectedness to the community of other caregivers using the exergame.
88843454|NCT02946073|Placebo Comparator|Placebo|CAM2038 placebo injections
88843455|NCT02946073|Experimental|CAM2038|CAM2038 50 mg/mL q1w at doses of 8 mg, 12 mg, 16 mg, 24 mg, or 32 mg. CAM2038 356 mg/mL q4w at doses of 64 mg, 96 mg, or 128 mg.
89370749|NCT05188911||mCRPC|Patients would be treated with 1000mg abiraterone qd. Patients would be treated with 5mg prednisone bid. Patients would get medical or surgical castration.
89370750|NCT03676946|Experimental|ZKAB001 5mg/kg|Three or six patients will be treated with the dose of 5 mg/kg/time of ZKAB001 IV bi-weekly. DLT will be observed within 28 days after administration.
89370751|NCT03676946|Experimental|ZKAB001 10mg/kg|Three or six patients will be treated with the dose of 5 mg/kg/time of ZKAB001 IV bi-weekly. DLT will be observed within 28 days after administration.
89370752|NCT03676946|Experimental|ZKAB001 15mg/kg|Three or six patients will be treated with the dose of 5 mg/kg/time of ZKAB001 IV bi-weekly. DLT will be observed within 28 days after administration.
89370753|NCT02426242||ICU PATIENTS|Patients with brain-injury
89370754|NCT03352453|Experimental|Rapastinel 450mg|Rapastinel 450 milligram (mg) weekly intravenous (IV) injections.
89370755|NCT03352453|Placebo Comparator|Placebo|Placebo-matching rapastinel weekly IV injections.
89370756|NCT03623438|Experimental|Self-administered acupressure group|Subjects will attend two weekly 120-minute of self-administered acupressure training
89370757|NCT03623438|Active Comparator|Sleep hygiene education (SHE) group|Subjects will attend two weekly 120-minute of sleep hygiene education
89370758|NCT03128931|Experimental|Test Group|The subjects will be enrolled in the test group and will receive the Pediatric SedLine forehead EEG sensor.
89180585|NCT00790790|Experimental|LY545694 105 mg|Participants randomized to LY545694 105 mg BID po were first administered LY545694 21 mg BID po at Visit 3. After 1 week of dosing, participants were escalated to LY545694 49 mg BID po at Visit 4. At Visit 5, participants were titrated to the final dose of LY545694 105 mg BID po. Participants who were intolerant of this dose were titrated back down to LY545694 49 mg BID po for the remainder of study treatment.
89180586|NCT02602964|Experimental|Deep neuromsucular block|Deep neuromuscular block and low pressure pneumoperitoneum
89370759|NCT02417662|Active Comparator|Systemic Anti-Cancer Therapy (SACT) alone|The choice of SACT is determined by the treating clinician and will be supplied from hospital commercial stock, and prepared and administered according to institutional guidelines.
89370760|NCT02417662|Experimental|SACT + Radical Radiotherapy (Conventional RT and SABR)|"SACT followed by radical RT (conventional or SABR) to the primary and SABR to the metastatic sites.~The choice of SACT is determined by the treating clinician and will be supplied from hospital commercial stock, and prepared and administered according to institutional guidelines."
89370761|NCT03676790|Experimental|Group I|(in the first month, continuous ultrasound was applied three times a week and in the second month patients performed only exercise sessions three times a week)
89370762|NCT03676790|Experimental|Group II|(in the first month, pulsed ultrasound was applied three times a week and in the second month patients performed only exercise sessions three times a week)
89370763|NCT03676790|Experimental|Group III|(in the first month, the continuous ultrasound was applied three times a week and in the second month, three times a week, the continuous ultrasound associated with exercises was applied)
89370764|NCT03676790|Experimental|Group IV|(in the first month, the pulsed ultrasound was applied three times a week and in the second month, three times a week, the pulsed ultrasound associated with exercises was applied)
89370765|NCT03676790|Experimental|Group V|(patients received only exercise sessions three times a week for eight weeks)
89370766|NCT01363167|Active Comparator|400 IU Cholecalciferol - Vitamin D|
89370767|NCT01363167|Placebo Comparator|Placebo|Placebo contains Fractionated Coconut Oil
89370768|NCT03710707|Experimental|DNL201 low dose|
89370769|NCT03710707|Experimental|DNL201 high dose|
89370770|NCT03710707|Placebo Comparator|Placebo|
89370771|NCT03107052|Experimental|Fremanezumab 225 mg Monthly|Participants with ECH or CCH who received fremanezumab at 900 mg intravenous (IV) infusion at Week 0 and fremanezumab at 225 mg subcutaneous (SC) injection at Weeks 4 and 8, respectively in the pivotal study TV48125-CNS-30056 or TV48125-CNS-30057, and participants with CCH who received fremanezumab at 675 mg SC injection at Week 0 and placebo SC injection at Weeks 4 and 8, respectively in the pivotal study TV48125-CNS-30057; will receive fremanezumab at 225 mg SC injection monthly (approximately every 4 weeks, administered as single SC injection of fremanezumab at 225 mg [225 mg/1.5 milliliter {mL}] at Week 0 and 36; and 2 placebo SC injections at Weeks 0, 12, 24, and 36 for blinding in participants rolled over from Study TV48125-CNS-30056; fremanezumab at 225 mg as a single SC injection (225 mg/1.5 mL) at Week 0, 12, 24, and 36; 2 SC injections of placebo at Week 0 for blinding in participants rolled over from Study TV48125-CNS-30057) through Week 36 in this study.
89370772|NCT03107052|Experimental|Fremanezumab 675/225 mg Monthly|Participants with CCH who received placebo IV infusion and SC injection at Week 0 and placebo SC injection at Weeks 4 and 8, respectively in the pivotal study TV48125-CNS-30057; will receive fremanezumab 675 mg SC injection as loading dose (administered as 3 SC injections of fremanezumab at 225 mg [225 mg/1.5 mL] at Week 0) followed by monthly (approximately every 4 weeks) fremanezumab at 225 mg SC injection (administered as single SC injection of fremanezumab at 225 mg [225 mg/1.5 mL] at Weeks 12, 24, and 36) through Week 36.
89399250|NCT02172248|Experimental|Sequence ABC|"Treatment A: BI 10773 once daily from day 1 to 5~Treatment B: BI 10773 once daily from day 1 to 4 and metformin twice daily from day 1 to 3 and once in the morning on day 4~Treatment C: metformin twice daily from day 1 to 3 and once in the morning on day 4"
89180587|NCT02602964|No Intervention|Standard neuromuscular block|Standard neuromuscular block and low pressure pneumoperitoneum
89180588|NCT00914888|Experimental|A|Tigecycline
89180589|NCT00914888|Active Comparator|B|Ceftriaxone regimen
89180590|NCT02603198|Active Comparator|mepivacaine chloridrato epinephrine|Side of operation that is going to receive anesthesia with 2% mepivacaine chloridrato with 1:100.000 epinephrine, maximum of 4 cartridges
89180591|NCT02603198|Active Comparator|mepivacaine chloridrato levonordefrin|Side of operation that is going to receive anesthesia with 2% mepivacaine chloridrato with 1:20.000 levonordefrin, maximum of 4 cartridges
89370773|NCT03107052|Experimental|Fremanezumab 675 mg Quarterly|Participants with ECH who received fremanezumab at 675 mg SC injection at Week 0 and placebo SC injection at Weeks 4 and 8, respectively in the pivotal study; or placebo IV infusion and SC injection at Week 0 and placebo SC injection at Weeks 4 and 8, respectively in the pivotal study TV48125-CNS-30056; will receive fremanezumab at 675 mg SC injection quarterly (approximately every 12 weeks, administered as 3 SC injections of fremanezumab at 225 mg [225 mg/1.5 mL] at Weeks 0 an 36; and single placebo SC injections at Weeks 4, 8, 16, 20, 28, and 32 for blinding) through Week 36.
89370774|NCT01359579|Experimental|Subjects with mild renal impairment|
89370775|NCT01359579|Experimental|Subjects with moderate renal impairment|
89370776|NCT01359579|Experimental|Subjects with normal renal function|
89370777|NCT01359579|Experimental|Subjects with severe renal impairment|
89370778|NCT02422654|Experimental|Concentration 1 eliglustat in vehicle A|Single dose of 5 mL solution held in the mouth for 15 seconds with swishing but with no ingestion
89370779|NCT02422654|Experimental|Concentration 1 eliglustat in vehicle B|Single dose of 5 mL solution held in the mouth for 15 seconds with swishing but with no ingestion
88843456|NCT03071744|Other|Lazanda|"Study drug, Lazanda, will be self-administered intranasally during this study. The dose of Lazanda is not predicted from the daily maintenance dose of opioid used to manage persistent cancer pain and must be determined by dose titration. The minimal effective intranasal dose from the radiation therapy simulation will be the dose used as pre-medication prior to any further radiation therapy fractions (up to 10 fractions).~Lazanda should be administered 15 (T-15) minutes prior to laying on the hard surface for each simulation visit. If the response to the titrated Lazanda dose markedly changes, an adjustment of dose may be necessary to ensure that an appropriate dose is maintained as deemed by the investigator."
89370780|NCT02422654|Experimental|Concentration 1 eliglustat in vehicle C|Single dose of 5 mL solution held in the mouth for 15 seconds with swishing but with no ingestion
89370781|NCT02422654|Experimental|Concentration 1 eliglustat in vehicle D|Single dose of 5 mL solution held in the mouth for 15 seconds with swishing but with no ingestion
89180592|NCT04105790|Experimental|Participants|Participants in class-based mental health intervention.
89180593|NCT02602886|Experimental|Exposure and Response Prevention Therapy|
89180594|NCT04105478|Experimental|Un-cemented Comprehensive Nano stemless shoulder arthroplasty|"By using a stemless humeral component stem-related complications can be reduced. Furthermore, the canal preserving design may also facilitate further surgery should the need of a revision prosthesis arise.~Currently, little is known about the results of the stemless design. The initial results have been promising, but as with the stemmed design migration and eventually loosening of the prosthesis can lead to poor results and, in some cases, revision"
89180595|NCT04105478|Active Comparator|Un-cemented Comprehensive stemmed total shoulder arthroplasty|A design with a metal stem in the humeral bone canal is currently regarded as the best treatment option, but complications related to the stem including humeral fractures can have devastating consequences.
89180596|NCT04105322|Experimental|Kinesio Taping on Abdominal Muscles|
88843457|NCT03073148|Experimental|Tangible Boost|Participants will treat their lenses with Tangible Boost after 30 days and again after 60 days.
88843458|NCT03073148|Placebo Comparator|Control|"Participants will treat their lenses with a placebo Tangible Boost kit containing saline after 30 days and again after 60 days."
89180597|NCT04105322|Experimental|Kinesio Taping on Back Muscles|
89180598|NCT04105322|No Intervention|Control|
89180599|NCT00719043|Experimental|A/Indonesia primed-A/turkey Influenza (H5N1)-F1-Placebo Group|Healthy subjects aged 18 years of age or older at the time of enrolment were primed with one dose of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) formulation 1 at Day 0 followed by one booster dose of A/turkey H5N1 vaccine formulation 1 at Day 182 and one dose of placebo (phosphate buffered saline, PBS) at Day 549. Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) and Placebo vaccines were administered intramuscularly in the deltoid region of the non-dominant arm while, A/turkey H5N1 vaccine was administered intramuscularly in the deltoid region of the dominant arm.
89370782|NCT02422654|Experimental|Concentration 1 eliglustat in vehicle E|Single dose of 5 mL solution held in the mouth for 15 seconds with swishing but with no ingestion
89370783|NCT02422654|Experimental|Concentration 2 eliglustat in vehicle A|Single dose of 5 mL liquid formulation held in the mouth for 15 seconds with swishing but with no ingestion
89370784|NCT02422654|Experimental|Concentration 2 eliglustat in vehicle B|Single dose of 5 mL liquid formulation held in the mouth for 15 seconds with swishing but with no ingestion
89370785|NCT02422654|Experimental|Concentration 2 eliglustat in vehicle C|Single dose of 5 mL liquid formulation held in the mouth for 15 seconds with swishing but with no ingestion
89370786|NCT02422654|Experimental|Concentration 2 eliglustat in vehicle D|Single dose of 5 mL liquid formulation held in the mouth for 15 seconds with swishing but with no ingestion
89370787|NCT02422654|Experimental|Concentration 2 eliglustat in vehicle E|Single dose of 5 mL liquid formulation held in the mouth for 15 seconds with swishing but with no ingestion
89370788|NCT02422654|Experimental|Concentration 3 eliglustat in vehicle A|Single dose of 5 mL liquid formulation held in the mouth for 15 seconds with swishing but with no ingestion
89370789|NCT02422654|Experimental|Concentration 3 eliglustat in vehicle B|Single dose of 5 mL liquid formulation held in the mouth for 15 seconds with swishing but with no ingestion
89370790|NCT02422654|Experimental|Concentration 3 eliglustat in vehicle C|Single dose of 5 mL liquid formulation held in the mouth for 15 seconds with swishing but with no ingestion
89370791|NCT02422654|Experimental|Concentration 3 eliglustat in vehicle D|Single dose of 5 mL liquid formulation held in the mouth for 15 seconds with swishing but with no ingestion
89370792|NCT02422654|Experimental|Concentration 3 eliglustat in vehicle E|Single dose of 5 mL liquid formulation held in the mouth for 15 seconds with swishing but with no ingestion
89370793|NCT05668793||Positive group|The positive group is composed of patients with hepatocellular carcinoma of different stages and pathological types.
89399251|NCT02172248|Experimental|Sequence CAB|"Treatment C: metformin twice daily from day 1 to 3 and once in the morning on day 4~Treatment A: BI 10773 once daily from day 1 to 5~Treatment B: BI 10773 once daily from day 1 to 4 and metformin twice daily from day 1 to 3 and once in the morning on day 4"
89399252|NCT02172326|Experimental|Tiotropium inhalation capsules|
89370794|NCT05668793||Negative group|"Patients with other digestive system malignancies (including stomach cancer, esophageal cancer, colorectal cancer, pancreatic cancer, gallbladder/duct cancer, etc.), patients with non-digestive system malignancies (including lung cancer, thyroid cancer, cervical cancer, endometrial cancer, breast cancer, prostate cancer, urothelial cancer, etc.).~Patients with benign liver diseases (such as cirrhosis, hepatitis, fatty liver, liver adenoma, liver cyst, etc.)."
89370795|NCT05188833|Active Comparator|Deep Transcranial Magnetic Stimulation|The treatment will be carried out for 6 weeks, 5 days a week, in total 30 sessions; 20 hz using Brainsway H-7 helmet. It will be applied to the mPFC and ACC simultaneously with a total of 2000 beats at a frequency of 50 beats in each string.
89370796|NCT05188833|Experimental|Deep Transcranial Magnetic Stimulation and Paroxetine|The treatment will be carried out for 6 weeks, 5 days a week, in total 30 sessions; 20 hz using Brainsway H-7 helmet. It will be applied to the mPFC and ACC simultaneously with a total of 2000 beats at a frequency of 50 beats in each string. In addtion to DTMMS, paroxetine will applied.
89370797|NCT05188833|Active Comparator|Paroxetine|Paroxetine is a type of antidepressant known as an SSRI (selective serotonin reuptake inhibitor). It's often used to treat depression in OCD.
89370798|NCT02426164|Active Comparator|Liposomal bupivacaine|Periarticular infiltration of 20cc of liposomal bupivacaine with 20cc of normal saline administered prior to cementation of knee implants
89370799|NCT02426164|Active Comparator|bupivacaine HCl, morphine, epinephrine, methylprednisolone|Periarticular infiltration of 24c of bupivacaine HCl, 0.8cc morphine, 0.3cc epinephrine, and 1cc of methylprednisolone administered prior to cementation of knee implants
88843459|NCT02855281||NSCLC with pleural effusion|The population for selection of potential study participants is comprised of clinical routine patients presenting with (suspected malignant) pleural effusion. These patients must have an indication for pleural puncture. The cause and nature of the pleural effusion at this time point will be unknown in many cases. To establish this, further diagnostic procedures are required. Only patients with confirmed diagnosis of non-small cell lung cancer will be included in the data analysis.
88843460|NCT02946229|Other|MHD Population Ultrasound|Eligible subjects in a convenience population at the site (Maintenance Hemodialysis, MHD) incidentally undergoingnon-invasive cardiac, pulmonary, and abdominal ultrasound scanning on the commercially available GE Vivid S70 system for use in testing feasibility of new algorithms for processing this data.
88843461|NCT03074630|Experimental|Dapagliflozin 10mg and Rosuvastatin 10mg|Rosuvastatin 10mg once daily for 9 weeks, with 5 weeks of once daily Dapagliflozin 10mg added
88843462|NCT03086707|Active Comparator|Cigarette smokers|"Subjects who have smoked at least 20 cigarettes per day for at least the past 5 years.~Subjects will be allowed to use their own brand of non-menthol cigarettes. There will be no smoking restriction after the discharge at Visit 3 and during the 1 day follow-up period."
88843463|NCT03086707|No Intervention|Never smokers|"Subjects who have smoked less than 100 cigarettes throughout their lifetime and no cigarettes in the past 3 years.~Subjects will not be allowed to smoke until discharge at Visit 3."
88843464|NCT03125018|Experimental|Test Subject|All subjects are enrolled into the test group and receive the LNCS ADTX Sensor.
88843465|NCT05404334||Breast Cancer|Patients with histologically proven breast cancer
88843466|NCT05404334||Benign breast disease|Patients with benign breast diseases undergoing surgical resection
88843467|NCT00374972||combined contraceptives|combined contraceptives
88843468|NCT00374972||pregesterone only contraceptives|pregesterone only contraceptives
89370800|NCT03640013|Experimental|Hall Technique|The intervention involves removal from the primary molar and a preformed metal crown is placed using glass ionomer. The subject is then asked to bite until crown is seated. No occlusal adjustment is carried out.
88843469|NCT03088267|Active Comparator|Active Treatment|Double blind amphetamine extended-release oral suspension, 2.5 mg/mL, 6, 7 or 8 mL po QAM
88843470|NCT03088267|Placebo Comparator|Placebo Treatment|Double blind placebo, 6, 7 or 8 mL po QAM
89370801|NCT03640013|Other|Conventional Technique|The procedure involves administering local anesthetic and the intervention involves remoal of caries from the affected primary molar. The tooth is then reshaped and contoured to to enable a preformed metal crown placement. Occlusal and marginal fit is improved by crimping the metal crown to improve fit. The preformed metal crown is cemented with glass ionomer restorative material and occlusion finally checked. The subject is then asked to bite on a cotton roll for two minutes until the cement has set.
89370802|NCT02417428|Experimental|Citrulline|Participants that will be randomized in the first arm will be divided in either citrulline plus HIIT (CIT + HIIT or group A) or citrulline alone (CIT or group B).
89370803|NCT02417428|Placebo Comparator|Placebo|Participants that will be randomized in the second arm will be divided in either placebo plus HIIT (PLA + HIIT or group C) or placebo alone (PLA or group D).
89370804|NCT02417428|Experimental|Exercise|Participant that will be randomized in this arm will have an exercise program (HIIT) added to their respective dietary supplement.
89370805|NCT02417428|Other|Without exercise|Participant that will be randomized in this arm will not have an exercise program.
89370806|NCT02015897|Active Comparator|Physical TherapyB|Group B
89370807|NCT02015897|Placebo Comparator|Physical TherapyA|Group A
89370808|NCT04249674||Patient under a CYP2D6 inhibitor and under Tramadol|
89370809|NCT04249674||Patient not under a CYP2D6 inhibitor but under Tramadol|
89370810|NCT03745157||Patients with Type 2 Diabetes requiring insulin therapy|Patients with type 2 diabetes requiring insulin therapy in Japanese routine clinical practice previously treated with insulin glargine (IGlar)
89370811|NCT02090556||Cohort 1:|RA patients naive of Abatacept and any other biologic agents
89370812|NCT02090556||Cohort 2:|RA patients naive of Abatacept and who previously failed one or more biologic agents
89370813|NCT02426008|Experimental|Culture media with growth factors and Cytokine|Growth factors and Cytokine adding to culture media to detect the deference and monitor the embryological outcome.
88843471|NCT03127358|Experimental|AiCure App|Participants will use a-DOT technology called AiCure (a Smartphone App) to track ingestion of fixed-dose Elbasvir and Grazoprevir, 1 tablet, 50mg-100mg of each drug, respectively, daily for 12 weeks.
88843472|NCT03127358|No Intervention|Treatment As Usual|Participants will receive treatment for ingestion of fixed-dose Elbasvir and Grazoprevir, 1 tablet, 50mg-100mg of each drug, respectively, daily for 12 weeks without using the AiCure app.
88843473|NCT03127358|Active Comparator|AiCure with gamification|Sub-group of participants will use a-DOT technology called AiCure (a Smartphone app) with gaming to track ingestion of fixed-dose Elbasvir and Grazoprevir, 1 tablet, 50mg-100mg of each drug, respectively, daily for 12 weeks. The gaming feature is to test whether competition encourages engagement and helps to increase adherence to the HCV medication.
88843474|NCT03088345|Experimental|Vasopressin, Arginine|Patients randomized to this arm will receive a continuous arginine vasopressin in normal saline carrier infusion immediately following the modified ultrafiltration (MUF) period of their cardiac surgery.
88843475|NCT03088345|Placebo Comparator|Placebo|Patients randomized to this arm will receive a continuous normal saline carrier infusion immediately following the modified ultrafiltration (MUF) period of their cardiac surgery.
88843476|NCT02855437|Active Comparator|Interactive Voice Response|The interactive voice response system (IVR) is an automated telephone system that is used to contact study participants. At enrollment the study coordinator will explain how the IVR works, planned survey schedule, and that participant -initiated calls to IVR are allowed.
88843477|NCT02855437|Active Comparator|RheumPro Smartphone Application|RheumPro is a UAB developed smartphone application to capture patient reported outcomes. At enrollment the study coordinator will explain how RheumPro works, planned survey schedule, and that participant -initiated surveys in RheumPro are allowed.
88843478|NCT03127514|Placebo Comparator|Placebo|Placebo administered by mouth or via feeding tube for 24 weeks: once daily for first 3 weeks and then twice daily for remainder of study if participant tolerating
88843479|NCT03127514|Experimental|AMX0035|AMX0035 administered by mouth or via feeding tube for 24 weeks: once daily for first 3 weeks and then twice daily for remainder of study if participant tolerating
88843480|NCT02858713|Experimental|App as intervention + Enstilar©|Patients prescribed Calcipotriene + Betamethasone Dipropionatecutaneous foam receive the intervention EM with app for smartphone and conventional instruction from a nurse in the consultation.
88843481|NCT02858713|No Intervention|Conventional instructions + Enstilar©|Patients receive conventional instructions from a nurse in the consultation in how to use prescribed Enstilar© with EM.
88843482|NCT00375050|Experimental|Riluzole|
88843483|NCT00375050|Placebo Comparator|Placebo|
88843484|NCT03128372|Experimental|Desaturation|Volunteers undergo oxygen desaturation in order to determine the accuracy of the device over a clinical range of oxygen saturations 70 - 100%.
88843485|NCT02860507|Active Comparator|Neostigmine + Glycopyrrolate|Neostigmine 0.06 mg/kg and Glycopyrrolate 0.04mg/kg iv
88843486|NCT02860507|Experimental|sugammadex|Sugammadex 4mg/kg
88843487|NCT03082196|Experimental|Test varnish|Advantage Anti-Caries Varnish. The active ingredients are Povidone Iodine and Sodium Fluoride .
88843488|NCT03082196|Active Comparator|Standard varnish|The active control varnish will be the same fluoride varnish without iodine with an appropriate FDA approved food dye added to match the color of the test agent. There will be no difference in the treatment and control varnishes except for the povidone iodine.
88843489|NCT03092089|Experimental|Adult patients with high risk STEMI|Adult patients presenting with high-risk STEMI will receive sonothrombolysis with Definity in addition to standard of care (reperfusion therapy with PPCI)
88843490|NCT03134144|Experimental|First without exoskeleton then with exoskeleton|"Subject will perform the conditions as described under model description first without the exoskeleton and then with the exoskeleton."
88843491|NCT03134144|Experimental|First with exoskeleton then without exoskeleton|"Subject will perform the conditions as described under model description first with the exoskeleton and then without the exoskeleton."
88843492|NCT02861131|Experimental|Sugammadex|Sugammadex 2 mg/kg IV once at the end of surgery
88843493|NCT02861131|Active Comparator|Neostigmine|Neostigmine 0.07 mg/kg to a maximum of 5 mg (+ Glycopyrrolate 0.1-0.2 mg per 1 mg of Neostigmine administered) IV once at the end of surgery
88843494|NCT05172206|Active Comparator|Symptom-focused Rehabilitation|Patients in this arm will be referred to a 3-week inpatient comprehensive rehabilitation program. Initially, patients will be classified into one out of three clusters namely: Cluster A (Fatigue), Cluster B (cognition), or Cluster C (physical). The content of the rehabilitation program will be individually adapted according to the patient's most relevant symptom cluster.
88843495|NCT05172206|Other|Usual Care|Patients in this arm do not receive any intervention beyond usual care during the study phase. However, all patients in this group will get the opportunity to also receive a rehabilitation program after the study phase.
88843496|NCT05098886|Experimental|Sequence A|
88843497|NCT05098886|Experimental|Sequence B|
88843498|NCT03093025|Experimental|TS-121 10mg|
88843499|NCT03093025|Experimental|TS-121 50mg|
88843500|NCT03093025|Placebo Comparator|Placebo|
88843501|NCT05098262|Experimental|Sequence A|
88843502|NCT05098262|Experimental|Sequence B|
88843503|NCT02950753|Experimental|Lactated Ringer|Intravenous bolus of Lactated Ringer solution (30ml/kg) via 18ga IV catheter at wide open.
88843504|NCT02950753|Placebo Comparator|Normal Saline|Intravenous bolus of Normal Saline (30ml/kg) via 18ga IV catheter at wide open.
88843505|NCT03082586|Experimental|radiochemotherapy 1|Patients will be treated with radiation therapy 57.2 Gy.
89370814|NCT02426008|Placebo Comparator|In Vitro culture media|culture media to monitor the embryological outcome as control group
88843506|NCT03082586|Experimental|radiochemotherapy 2|Patients will be treated with radiation therapy 64.4 Gy.
88843507|NCT03082586|Experimental|radiochemotherapy 3|Patients will be treated with radiation therapy 71.6 Gy.
88843508|NCT03082586|Experimental|radiochemotherapy 4|Patients will be treated with radiation therapy 78.8 Gy.
88843509|NCT03082586|Experimental|radiochemotherapy 5|Patients will be treated with radiation therapy 86 Gy.
88843510|NCT03082586|Experimental|radiochemotherapy 6|Patients will be treated with radiation therapy 93.2 Gy.
88843511|NCT03086408|Experimental|THRIVE|high flow nasal oxygen
88843512|NCT03086408|Active Comparator|endotracheal tube or supraglottic airway|tracheal intubation or supraglottic airway device
88843513|NCT02951143|Experimental|Single arm|All participants will complete the same experimental events across 6 laboratory sessions.
88843514|NCT02951143|Experimental|0.4 mg/g Concentration|Participants in this arm will experience the 0.4 mg/g Concentration
88843515|NCT02951143|Experimental|1.3 mg/g Concentration|Participants in this arm will experience the 1.3 mg/g Concentration
88843516|NCT02951143|Experimental|2.4 mg/g Concentration|Participants in this arm will experience the 2.4 mg/g Concentration
88843517|NCT02951143|Experimental|5.2 mg/g Concentration|Participants in this arm will experience the 5.2 mg/g Concentration
88843518|NCT02951143|Experimental|15.8 mg/g Concentration|Participants in this arm will experience the 15.8 mg/g Concentration
88843519|NCT05040152|Experimental|Arm I (telephone-based intervention)|Participants receive weekly telephone-based weight loss intervention for 15 weeks, including dietary recommendations tailored to their current weight and weight loss target, home-based aerobic and resistance exercise, and weekly telephone counseling session over 30-45 minutes.
89370815|NCT04050371|Experimental|TRUVADA DOT|one tablet containing 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate as single dose with daily observed therapy performed either via video calling, or at study visit, for a total of 28 to 30 days
88843520|NCT05040152|Active Comparator|Arm II (education brochures)|Participants receive education brochures describing the American Institute for Cancer Research physical activity and dietary guidelines.
88843521|NCT04707404||PEEK|Cranioplasty patients with PEEK.
88843522|NCT04707404||Titanium|Cranioplasty patients with titanium mesh.
88843523|NCT04707092|Experimental|Antibiotic at induction|Patients will receive one single dose of Antibiotic at induction
88843524|NCT04707092|Experimental|Antibiotic one week|Patients will receive one single dose of Antibiotic at induction, plus a 7 day treatment with oral Antibiotic
88843525|NCT04707014|Placebo Comparator|Attention-Distraction techniques|A high-tech distraction technique (Apple®), passive and chosen by the child, either an animated video or his or her favourite music. After standard intravenous sedation, the child is taken to the operating theatre to watch his or her favourite video or music and this is maintained throughout the procedure.
88843526|NCT04707014|Experimental|HIPNOSIS GROUP|A technique of rapid conversational hypnosis, with focus on therapeutic suggestion (guiding the patient into a hypnotic trance), adapted to the child's cognitive development. Induction with hypnotic suggestion focuses and accompanies the child's body sensations and allows their active participation. After standard sedation, therapeutic suggestion is maintained throughout the surgery and in the post-hypnotic period before awakening.
88843527|NCT02867059|Experimental|first dose|The dose used in the first cohort was determined on the basis of the safety and PK data generated in the FIM study (NCT02661373) currently ongoing in United States (US) and will be 150 mg.
88843528|NCT02867059|Experimental|second dose|Depending on the pharmacodynamics data (effect of SJ733 on parasitaemia) obtained from this first cohort, the dose in Cohort 2 may be adjusted but will not exceed 600 mg.
88843529|NCT04985708||Patient with AMICS are likely to benefit from MCS|later
88843530|NCT04985708||Develop and maintain a patient registry of AMICS|later
88843531|NCT04985708||Classify patients based on shock severity.|later
88843532|NCT03088748||Smith & Nephew Journey II PCR TKA|Subjects implanted with a Smith & Nephew Journey II posterior cruciate retaining total knee arthroplasty
88843533|NCT03088748||Smith & Nephew Journey II BCR TKA|Subjects implanted with a Smith & Nephew Journey II posterior bi-cruciate retaining total knee arthroplasty
88843534|NCT02953561|Experimental|Treatment (azacitidine, avelumab)|Patients receive azacitidine SC or IV over 10-40 minutes on days 1-7 or on days 1-5 and 8-9. Patients also receive avelumab IV over 60 minutes on days 1 and 14 for 4 courses (or until complete response) and on day 1 for subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88843535|NCT03090620|Experimental|Physostigmine|Physostigmine 0.02 mg/kg IV bolus (max of 2 mg), which can be repeated at 10 minutes, followed by a 0.02 mg/kg/hr (max of 2 mg/hr) infusion for 4 hours.
88843536|NCT03090620|Experimental|Lorazepam|Lorazepam 0.05 mg/kg IV bolus (max 2 mg), which can be repeated at 10 minutes if inadequate patient response, followed by a Normal Saline infusion for 4 hours.
88843537|NCT04938752|Experimental|Sequence I|
88843538|NCT04938752|Experimental|Sequence II|
88843539|NCT02953873|Other|Conversion Arm|Tacrolimus Extended Release Capsule (goal 5 - 12ng/mL) + Mycophenolate Mofetil ≥500mg twice a day OR Mycophenolate Sodium ≥360mg twice a day+ prednisone ≥ 5mg Daily
88843540|NCT03141242|Active Comparator|ENACT Group Visit|Participants will engage in two 2-hour group visits related to advance care planning, including printed advance care planning resources.
88843541|NCT03141242|Placebo Comparator|Mailed Resources|Participants will receive printed advance care planning resources by mail.
88843542|NCT03095053|Active Comparator|PGT-A group|Next Generation sequencing preimplantation genetic testing for aneuploidy
88843543|NCT03095053|No Intervention|Morphology group|morphological assessment of blastocyst by light microscope
88843544|NCT03098173|Experimental|Early colonoscopy|Performance of prepared colonoscopy within 24 h of arrival
88843545|NCT03098173|Active Comparator|Elective colonoscopy|Performance of prepared colonoscopy between 24 and 96 h after arrival
88843546|NCT03091478|Experimental|Pembrolizumab 200 mg|Pembrolizumab 200 mg every 3 weeks
88843547|NCT02867605|Other|Healthy Controls ages 18-45 with BMI of 19-25 or 30-35|Single Arm study
88843548|NCT03092024|Experimental|SPIN-HAND program|
88843549|NCT03092024|No Intervention|Not Offered the SPIN-HAND program|Treatment as usual
88843550|NCT03092960|Active Comparator|Minimal intensity intervention|Patients assigned to this group will received the Minimal intensity intervention.
89370816|NCT04189536|Experimental|SMS Intervention|All subjects will receive customized text messages twice a day, every day for 9 months that will include reminders to adhere to the individualized medication regimen, reminders to call their clinician for a prescription refill followed by reminders to pick up medication from the pharmacy, and educational reminders about ADHD and its treatment.
89370817|NCT04183764|Experimental|MAX-40279-01|capsule, 5mg and 25mg
89399253|NCT02169596|Other|Coronary Artery Disease|Blood tests to assess platelet function and EndoPAT assessment for endothelial function testing before and after ticagrelor administration (90mg BD)
89399254|NCT02169596|Other|Healthy Normals|Blood tests to assess platelet function and EndoPAT assessment for endothelial function testing before and after ticagrelor administration (90mg BD)
88843551|NCT03092960|Experimental|HOMBRE|Patients assigned to this group will receive the HOMBRE intervention
88843552|NCT02870101|Other|Intervention|Performance of three nucleic acid amplification tests (NAATs) to detect Neisseria gonorrhoeae (NG) and Chlamydia trachomatis (CT) from swabs collected from the pharynx and rectum. Assays include: Nucleic acid amplification test 1 for NG and CT; Nucleic acid amplification test 2 for NG and CT; and, Nucleic acid amplification test 3 for NG and CT.
88843553|NCT03143894|Active Comparator|Active tDCS first|2 mA of active tDCS applied over a 30-minute study session once per day for 5 consecutive days then sham tDCS after washout.
88843554|NCT03143894|Sham Comparator|Sham tDCS first|Stimulation mimicking the tDCS applied only briefly over a 30-minute study session once per day for 5 consecutive days then active tDCS after washout.
88843555|NCT03144518|Experimental|Experimental|Participants in the experimental condition will view a video designed to induce positive affect. This includes 3 short comedy clips (fork handles sketch, the two Ronnie's; A room with a view - faulty towers; Tim Vine Live stand-up extract), uplifting music (Jailhouse Rock - Elvis Presley; Happy Together - The Turtles), jokes and positive imagery. The content of the intervention has been informed by patient and public involvement, focus groups with older adults, and pilot testing.
88843556|NCT03144518|Active Comparator|Active Control|Participants in the control condition will view a video of matched length to the experimental condition video, but not designed to induce mood change. This includes short documentary clips (a pride in pencils; model railways, lecture extract on hydration), neutral music and images.
88843557|NCT03148262|Experimental|The high flow nasal cannula|The Comfort Flo system will be used for the high flow nasal cannula during colonoscopy
88843558|NCT03148262|Placebo Comparator|The standard nasal cannula|The Salter nasal cannula will be used during the colonoscopy
88843559|NCT03099655|Experimental|Attain Stability Quad Lead|Attain Stability Quad Lead (Model 4798) - Single arm study.
88843560|NCT03093272|Experimental|ARN-509 Combined With Docetaxel|"Apalutamide (ARN-509) will be taken orally at home daily~Docetaxel will be administered every 3 weeks intravenously~Prednisone will be taken orally twice daily~Leuprolide Acetate will be administered at the specification of the physician"
88843561|NCT03093662|Experimental|Ventilation with nasal cannula|Non-invasive positive pressure ventilation with nasal cannula.
88843562|NCT03093662|Active Comparator|Ventilation without nasal cannula|Non-invasive positive pressure ventilation without nasal cannula.
88843563|NCT03100123|Active Comparator|Standard of Care Arm|Open-label low-molecular-weight heparin (LMWH) prophylaxis until 37 weeks gestation AND low-dose aspirin daily until delivery.
88843564|NCT03100123|Experimental|Experimental Arm|Open-label low-dose Aspirin 81 mg daily from randomization until delivery.
88843565|NCT04700150|Experimental|interventional group A|2 tai chi session per week during 4 month (M0 to M4)
88843566|NCT04700150|Placebo Comparator|Control group B|2 tai chi session per week during 2 month (M2 to M4)
88843567|NCT03097484|Experimental|Standard therapy plus Aromatherapy|These infants will receive aromatherapy, consisting of Lavender and Chamomile essential oils, in addition to standard care, which includes morphine replacement therapy, infant massage, PT, OT, and music therapy.
88843568|NCT03097484|No Intervention|Standard therapy ALONE|These infants receive standard care ONLY, which includes morphine replacement therapy, infant massage, PT, OT, and music therapy.
88843569|NCT02872909|Active Comparator|low irradiance LED PDT|Ambulight LED portable PDT treatment
88843570|NCT02872909|Active Comparator|conventional higher irradiance LED|Conventional LED hospital based standard PDT treatment
88843571|NCT04695236|Experimental|Study group|Study Group: Intravascular hypothermia therapy group ZOLL Intravascular Temperature Management system, Quattro catheter will be used in study group
88843572|NCT04695236|Placebo Comparator|Control group|"Control group: Without intravascular hypothermia therapy group~ZOLL Intravascular Temperature Management system, Quattro catheter will not be used in control group"
88843573|NCT02957305|Active Comparator|Misoprostol 400 µg|Participants received misoprostol 400 µg: 2 tablets of misoprostol (200µg each) introduced into the vagina, at least 6 hours before the Manual Vacuum Aspiration (MVA) procedure.
88843574|NCT02957305|Experimental|Misoprostol 200 µg|Participants received misoprostol 200 µg: 1 tablet of misoprostol introduced into the vagina, at least 6 hours before the Manual Vacuum Aspiration procedure.
88843575|NCT02873923||Patients with a metastatic soft tissue sarcoma|All patients included in eligible clinical trials of the meta-analysis
88843576|NCT04590092|No Intervention|Control|Study Participants who do not receive a pessary. This group will be given an information pamphlet on pelvic floor (Kegel) exercises in pregnancy and will continue to have standard antenatal care with their maternity provider.
88843577|NCT04590092|Experimental|Pessary|Study Participants who are fitted with a pessary for urinary incontinence. This group will be given an information pamphlet on pelvic floor (Kegel) exercises in pregnancy and pessary use in pregnancy. They will continue to have standard antenatal care with their maternity provider.
88843578|NCT03104647|Experimental|VRP-Clinic|VRP-Clinic software on a virtual reality platform
89399255|NCT02166008|Active Comparator|Repamipide|Rebamipide (100) 1 tab oral tid for 1 year or peptic ulcer occurred
89399256|NCT02166008|Placebo Comparator|placebo|A placebo is a simulated or otherwise medically ineffectual treatment for a disease or other medical condition intended to deceive the recipient. It will be prescribed as the same regimen of Rabamipide.
89370818|NCT04447287|Experimental|ASP8062 in combination with buprenorphine/naloxone|Participants received multiple sublingual doses of buprenorphine/naloxone on days 1 through 26. In the Investigational Period participants were on a stable daily dose of buprenorphine/naloxone on days 5 through 18. After randomization on day 12, participants received a single oral dose of ASP8062 concomitantly with buprenorphine/naloxone. The stable dose of buprenorphine/naloxone was down titrated from days 19 through 26.
89370819|NCT04447287|Placebo Comparator|Placebo ASP8062 in combination with buprenorphine/naloxone|Participants received multiple sublingual doses of buprenorphine/naloxone on days 1 through 26. In the Investigational Period participants were on a stable daily dose of buprenorphine/naloxone on days 5 through 18. After randomization on day 12, participants received a single oral dose of placebo concomitantly with buprenorphine/naloxone. The stable dose of buprenorphine/naloxone was down titrated from days 19 through 26.
89370820|NCT01879319|Experimental|Evolocumab AMD|Participants received evolocumab 420 mg once a month subcutaneously using an automated mini-doser (AMD) (one 3.5 mL injection) for 8 weeks (Day 1, Week 4, and Week 8). Participants self-administered evolocumab in the clinic on Day 1 under supervision and then self-administered in a home setting at Weeks 4 and 8.
89370821|NCT01879319|Experimental|Evolocumab AI/pen|Participants received evolocumab 420 mg once a month subcutaneously using an autoinjector/pen (AI/pen) (three 1.0 mL injections) for 8 weeks (Day 1, Week 4, and Week 8). Participants self-administered evolocumab in the clinic on Day 1 under supervision and then self-administered in a home setting at Weeks 4 and 8.
88843579|NCT03104725|Experimental|Healthy Volunteers|HVs who undergo 2 LPs as inpatients, with 48 hours between LPs and no NAC treatment
89370822|NCT04165122|Experimental|HDIT101 + Valaciclovir placebo|"Group A:~Patients treated with a single i.v. infusion of 2 g HDIT101 for 60 min at the randomization visit and with an episodic Valaciclovir placebo bid for 3 days."
89370823|NCT04165122|Active Comparator|HDIT101 placebo + Valaciclovir|"Group B:~Patients treated with a single i.v. infusion of HDIT101 placebo for 60 min at the randomization visit and with episodic Valaciclovir 500 mg twice daily for 3 days."
89189271|NCT00416455|Experimental|Treatment (diagnostic scans, surgery, chemotherapy, radiation)|Patients receive fludeoxyglucose F 18 (FDG) IV followed 60 minutes later by positron emission tomography (PET)/CT scanning on day 1. Patients also receive ferumoxtran-10 IV over 30-45 minutes on day 1 (or 24-36 hours before MRI) and undergo MRI on day 2. Patients undergo extraperitoneal, laparoscopic, or trans-peritoneal lymphadenectomy with pelvic and abdominal lymph node biopsy within 2 weeks after PET/CT scan. Patients diagnosed with metastatic disease prior to lymph node biopsy proceed directly to primary treatment. Patients with cervical cancer undergo chemoradiotherapy within 4 weeks of PET/CT scan.
89370824|NCT02417350|Experimental|Ketogenic diet first|Starting with ketogenic diet first and then switching to a NFA recommended diet
89370825|NCT02417350|Experimental|NFA recommended diet first|Starting with NFA recommended diet first and then switching to a ketogenic diet
89370826|NCT02422030|Experimental|Group1: TreatmentA+TreatmentB+TreatmentC|TreatmentA: Atorvastatin 40m*1T/day, TreatmentB: Fenofibric acid 135mg*1Cap/day, TreatmentC: Atorvastatin 40m*1T/day and Fenofibric acid 135mg*1Cap/day. Each treatment period was separated by a washout period of at least 8days.
89370827|NCT02422030|Experimental|Group2: TreatmentC+TreatmentA+TreatmentB|TreatmentA: Atorvastatin 40m*1T/day, TreatmentB: Fenofibric acid 135mg*1Cap/day, TreatmentC: Atorvastatin 40m*1T/day and Fenofibric acid 135mg*1Cap/day. Each treatment period was separated by a washout period of at least 8days.
89370828|NCT02422030|Experimental|Group3: TreatmentB+TreatmentC+TreatmentA|TreatmentA: Atorvastatin 40m*1T/day, TreatmentB: Fenofibric acid 135mg*1Cap/day, TreatmentC: Atorvastatin 40m*1T/day and Fenofibric acid 135mg*1Cap/day. Each treatment period was separated by a washout period of at least 8days.
89370829|NCT02422030|Experimental|Group4: TreatmentC+TreatmentB+TreatmentA|TreatmentA: Atorvastatin 40m*1T/day, TreatmentB: Fenofibric acid 135mg*1Cap/day, TreatmentC: Atorvastatin 40m*1T/day and Fenofibric acid 135mg*1Cap/day. Each treatment period was separated by a washout period of at least 8days.
89370830|NCT02422030|Experimental|Group5: TreatmentB+TreatmentA+TreatmentC|TreatmentA: Atorvastatin 40m*1T/day, TreatmentB: Fenofibric acid 135mg*1Cap/day, TreatmentC: Atorvastatin 40m*1T/day and Fenofibric acid 135mg*1Cap/day. Each treatment period was separated by a washout period of at least 8days.
89370831|NCT02422030|Experimental|Group6: TreatmentA+TreatmentC+TreatmentB|TreatmentA: Atorvastatin 40m*1T/day, TreatmentB: Fenofibric acid 135mg*1Cap/day, TreatmentC: Atorvastatin 40m*1T/day and Fenofibric acid 135mg*1Cap/day. Each treatment period was separated by a washout period of at least 8days.
89370832|NCT04159350|Experimental|Rectal Expulsion Device (RED) - Feasibility|Feasibility Phase.
89370833|NCT04159350|Experimental|Rectal Expulsion Device (RED) - Validation|Validation Phase.
89370834|NCT05668715|Experimental|Group 1: Antimuscarinic Naive (AM-N)|None of the women had previously taken anti-muscarinic agents and oral ß3 adrenoreceptor agonist (mirabegron) in this group.
89370835|NCT05668715|Active Comparator|Group 2: Antimuscarinic Refractory (AM-R)|Women with idiopathic OAB refractory to anti-muscarinic agents and oral ß3 adrenoreceptor agonist (mirabegron) when 2 or more were administered for at least 6 weeks each and failure was due to lack of efficacy with or without side effects were included in this group.
89370836|NCT02425930||C3 Depletion|Patients with persistent low-level of complement C3 within the perioperative period would be assigned into this main observational group. After a careful multidisciplinary treatment (MDT) discussion, a radical operation with gastrectomy plus D2 lymphadenectomy would be performed, followed by an adjuvant chemotherapy if required. Generally, SOX chemo regimen (S-1+Oxaliplatin) would be first considered for the candidates.
88843580|NCT03104725|Experimental|PD Patients|Patient undergoes a lumbar puncture (LP) as an inpatient at the NIH Clinical Center to obtain cerebrospinal fluid (CSF) for assays of Cys-DA, 3,4- dihydroxyphenylacetic acid (DOPAC), and related biochemicals. The second LP is done after the patient has taken at least 5 doses of NAC (2 grams orally twice per day).
88843581|NCT03153956|Experimental|Active Treatment Arm|Personally calibrated bio-mechanical device
88843582|NCT03153956|Placebo Comparator|Control Arm|sham-placebo device (similar shoes without bio-mechanical elements).
88843583|NCT02876575|Other|A bipolar instrument for tonsillectomies|A bipolar electrosurgical device that employs RF energy and pressure to ligate vessels interposed between its jaws which can then be transected using the built in knife deployed by the device trigger.
88843584|NCT03154658|Experimental|Sub-serratus regional block|A regional block using of ropivacaine 0.35% (30 mL will be used per side in patients weighing over 60 kg and 20 mL will be used in patients weighing less than 60 kg) will be administered to the injection site deep to the serratus anterior muscle.
88843585|NCT03154658|Active Comparator|Supra-serratus regional block|A regional block using of ropivacaine 0.35% (30 mL will be used per side in patients weighing over 60 kg and 20 mL will be used in patients weighing less than 60 kg) will be administered to the injection site superficial to the serratus anterior muscle.
88843586|NCT03157232|Experimental|Test Group|All subjects are enrolled into the test group and all subjects received both the Rainbow DCI and R1-25 sensor.
88843587|NCT02958787|Experimental|Intervention|Vessel Sparing Radiation Therapy using MRI based treatment planning to limit dose to critical erectile structures
88843588|NCT03098420|Placebo Comparator|Control Group|20 patients. Each patient will receive postoperative bilateral TAP blocks (20mL of ropivacaine) and 1mL of normal saline bilaterally (control) with standard intrathecal bupivacaine and morphine.
89370837|NCT02425930||Non-C3 depletion|Patients with normal plasma values of complement C3 within the perioperative period would be assigned into this control group. Those patients would undergo the same decision making process to determine the final treatment plan.
89370838|NCT03685682|Experimental|VZV seronegative Transplant Patients|recombinant subunit Herpes zoster vaccine
89370839|NCT01365897|Placebo Comparator|Placebo|Control Group
89370840|NCT01365897|Experimental|Modafinil 200mg|Modafinil 200mg taken orally.
89370841|NCT02422108|Experimental|intervention|Denosumab (Prolia) 60 mg s.c.
89370842|NCT03685604|Active Comparator|Cardiothoracic surgery - PI disinfection|
89370843|NCT03685604|Active Comparator|Cardiothoracic surgery - CHX disinfection|
89370844|NCT03685604|Active Comparator|Abdominal surgery - PI disinfection|
89189272|NCT04071210|Experimental|Experimental|Probiotic tablets (containing a mix of Lactobacillus rhamnosus PB01, DSM 14869 and Lactobacillus curvatus EB10, DSM 32307, 1*10(9) CFU) 2 times/day for 12 weeks
89189273|NCT04071210|Placebo Comparator|Placebo Comparator|Placebo tablets 2 times/day for 12 weeks
89370845|NCT03685604|Active Comparator|Abdominal surgery - CHX disinfection|
89370846|NCT03685526|Experimental|Interventional arm|Patients will be treated with Cinenses Lung Volume Reduction Reverser System.
89370847|NCT01359657|Experimental|Arm A: Anti-CXCR4 (BMS-936564)+Lenalidomide+Dexamethasone|
89370848|NCT01359657|Experimental|Arm B: Anti-CXCR4 (BMS-936564)+Bortezomib+Dexamethasone|
89370849|NCT02417116|Placebo Comparator|Control|Minims Saline (Preservative Free) lubricant eye drops - daily for 90 days
89370850|NCT02417116|Active Comparator|Hypromellose - standard treatment|Tear Supplement: Hypromellose 0.3% eye drops - daily for 90 days
88843589|NCT03098420|Active Comparator|2mg Dexamethasone|20 patients. Each patient will receive postoperative bilateral TAP blocks (20mL of 0.5% ropivacaine) with 0.5 mL (2mg) of dexamethasone and 0.5 ml of normal saline split between 2 sides with standard intrathecal bupivacaine and morphine.
88843590|NCT03098420|Active Comparator|4mg Dexamethasone|20 patients. Each patient will receive postoperative bilateral TAP blocks (20mL of 0.5% ropivacaine) with 20mL of 0.5% ropivacaine) and 1 mL (4mg) of dexamethasone between 2 sides with standard intrathecal bupivacaine and morphine.
89370851|NCT02417116|Active Comparator|Combination treatment|Tear Supplement 2: Hylo-Forte 0.2% Sodium Hyaluronate eye drops, Omega 3 nutrition supplement: Omega-3 tablets, Eye bag: TranquilEyes Moist Heat Lid Compresses - Daily for 90 days;
88843591|NCT02876887|Active Comparator|Cocoa|Three servings per day of epicatechin-rich (75 mg daily) cocoa beverages for six months.
88843592|NCT02876887|Placebo Comparator|Placebo|Three servings per day of placebo beverages for six months.
88843593|NCT03158714|Experimental|Couples Connecting Mindfully Curriculum|Receives the Couples Connecting Mindfully curriculum over a 6 week period.
88843594|NCT03158714|Experimental|ELEVATE Curriculum|Receives the ELEVATE curriculum over a 6 week period.
88843595|NCT03158714|No Intervention|Control|No programming is offered.
88843596|NCT03108469|Active Comparator|IONIS-PKKRx (ISIS 546254)|Those randomized to IONIS-PKKRx (ISIS 546254) will receive subcutaneous injections containing 1.00 mL (200mg) weekly for weeks 1-16.
88843597|NCT03108469|Placebo Comparator|Placebo|Those randomized to placebo will receive subcutaneous injections containing 1.00 mL (200mg) weekly for weeks 1-16.
88843598|NCT03159260|Experimental|Theraworx|Subjects will receive two 3 ounce foam dispensers corresponding to their group assignment (Foam A or Foam B) and a 2-week Compliance and Symptom Log. The contents of these two foams will remain blind to the subjects and the data collectors until all 50 subjects complete the study protocol. One of the foams will contain Theraworx/[pH]uel (treatment) and the other will contain a physiologically inert substance (placebo control).
88843599|NCT03159260|Placebo Comparator|Placebo|Subjects will receive two 3 ounce foam dispensers corresponding to their group assignment (Foam A or Foam B) and a 2-week Compliance and Symptom Log. The contents of these two foams will remain blind to the subjects and the data collectors until all 50 subjects complete the study protocol. One of the foams will contain Theraworx/[pH]uel (treatment) and the other will contain a physiologically inert substance (placebo control).
88843600|NCT02878057|Experimental|Advanced Breast Cancer|Patients With HER-2 Negative Advanced Breast Cancer With Chest Wall Metastasis; Dosing regimen: apatinib tablets: 500 mg, Po, QD; 4 weeks as a cycle, continuous treatment until disease progression, death or intolerable toxicity (giving endocrine therapy simultaneously if hormone receptor positive)
88843601|NCT03104738|No Intervention|50% reduction of basal insulin dose|This is the institutional standard of care. The evening before surgery, 20 subjects will reduce their basal insulin dose to 50%.
88843602|NCT03104738|Experimental|25% reduction of basal insulin dose|The evening before surgery, 20 subjects will reduce their basal insulin dose to 25%.
88843603|NCT03162458|Experimental|Anaferon for children|
88843604|NCT03162458|Placebo Comparator|Placebo|
88843605|NCT03163472|Active Comparator|10 ml of lidocaine 2% with epinephrine|patients will receive axillary brachial plexus block with 10 ml of lidocaine 2% with epinephrine.
88843606|NCT03163472|Experimental|30ml of lidocaine 2% with epinephrine|patients will receive axillary brachial plexus block with 30 ml of lidocaine 2% with epinephrine.
88843607|NCT02880475|Experimental|OXN prolonged release tablet 5/2.5mg|The subjects were randomized to receive a single dose of OXN prolonged release tablet 5/2.5mg for one time.
88843608|NCT02880475|Experimental|OXN prolonged release tablet 20/10mg|The subjects were randomized to receive a single dose of OXN prolonged release tablet 20/10 mg for one time.
88843609|NCT04468568||Atosiban|Intravenous Atosiban as main tocolytic agent
88843610|NCT04468568||Terbutaline|Intravenous Terbutaline as main tocolytic agent
88843611|NCT03106844|Experimental|Treatment|All patients in this study will receive Fecal Microbiota Tranplantation
88843612|NCT03168308|Active Comparator|Neostigmine & Glycopyrrolate|Patients randomized to receive Neostigmine w/ Glycopyrrolate
88843613|NCT03168308|Active Comparator|Sugammadex|Patients randomized to receive Sugammadex
88843614|NCT03168542|Experimental|Toric Multifocal Contact Lens|JJVC Investigational Toric Multifocal Contact Lens for Presbyopia
88843615|NCT03168542|Experimental|Multifocal Contact Lens|1-Day Acuvue® Moist Brand Multifocal Contact Lens
89189274|NCT00714324||1|Paper screening
89370852|NCT03685370|Active Comparator|LOS group|Patients randomized to recieve epidural catheter placement with LOS technique, without any Rx control
89370853|NCT03685370|Experimental|X-ray group|Patients randomized for X-ray placement of epidural catheter
89370854|NCT05416398|No Intervention|Control|They will only receive standard medical treatment. In addition to the evaluation parameters applied, no additional information and/or exercise will be recommended other than routine clinical treatment and recommendations.
88809867|NCT01212107|Experimental|Part A: 10 mg FGF Receptor QD|"Part A: Dose escalation~10 mg FGF receptor given orally QD for a minimum of (1) 28 day cycle.~If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)."
88809868|NCT01212107|Experimental|Part A: 10 mg FGF Receptor QD + Phosphate Binders|"Part A: Dose escalation~10 mg FGF receptor + phosphate binders given QD for a minimum of (1) 28 day cycle.~If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)"
88843616|NCT03109015|Active Comparator|Schedule 4/2|
88843617|NCT03109015|Experimental|Schedule 2/1|
88843618|NCT04253756|No Intervention|18-gauge autogard catheter|Standard of care
88843619|NCT04253756|Experimental|20-gauge BD Nexiva Diffusics|Intervention
89189275|NCT00714324||2|Electronic screening
89189276|NCT00714402||a|children with proven of probable invasive bacterial infections
89370855|NCT05416398|Experimental|Aerobic Exercise|Aerobic exercise group; 3 days a week, 45-60 minutes will be carried out in the form of walking and jogging on the treadmill. Initially, warm-up exercises (10 minutes) will perform walking at 35-70% of maximum heart rate (HRmax). Then, aerobic exercises, the resistance and duration of which are increased according to the tolerance of the patient on the treadmill for 30-35 minutes, and at 60-70% of the HRmax, attention will be paid to ensure that the fatigue severity perceived by the patients is within the range of 12-14 according to the Modified Borg scale. Afterwards, the exercise program will be terminated with a cooling period (10 minutes) consisting of walking at a light pace.
89370856|NCT05416398|Experimental|High-İntensity İnterval Training|The high-intensity interval training (HIIT) group, it will be performed as walking or jogging on the treadmill for 4X4 minutes (16 minutes in total) at ≥ 80% of HRmax, three times a week, with each session lasting a total of 38 minutes. Each training session will begin with a 10-minute warm-up period at 70% of HRmax. Between each 4-minute interval and after the last interval, patients will walk at 70% of HRmax for 3 minutes. Patients will check heart rate and target heart rate to control exercise intensity and will aim to reach their individual target heart rate after 1-1.5 minutes of exercise in each interval. The physical therapist, who oversees all training sessions, will check the patients' target heart rates.
89370857|NCT03685292||Group A|Subject(s): A Subgroup
89370858|NCT03685292||Group B|Subject(s): B Subgroup
89370859|NCT03685292||Group C|Subject(s): C Sub Group
89370860|NCT05416164|Experimental|Omission of radiotherapy|
89370861|NCT01363245|Experimental|Hospital phone counseling|multisession telephone counseling by hospital/study's smoking cessation staff
89370862|NCT01363245|Active Comparator|Fax-to-quit|Faxed referral to the state Quitline, which will then perform phone outreach as per Quitline protocol
89370863|NCT03685214|Experimental|0.9% saline|We use 0.9% saline for resuscitation fluid in ICU septic patients
89370864|NCT03685214|Experimental|Balanced Crystalloids|We use acetated Ringer's solution for resuscitation fluid in ICU septic patients
89370865|NCT02425696||group 1|Normal individuals without migraine
89370866|NCT02425696||group 2|Migraineurs
89370867|NCT01359813|No Intervention|Usual treatment|intravenous injection of Human Albumin. 1,5g/kg on first day and 1g/kg on third day
89370868|NCT01359813|Experimental|Human Albumin|1,5g/kg on first day and 1g/kg on third day.
88843620|NCT04706780||ESP block group|Diaphragmatic excursion was measured using M-mode ultrasound during normal breathing, deep breathing and with the sniff manoeuvre.
88843621|NCT03115177|Active Comparator|Cefazolin|All patients will receive standard perioperative antibiotics with 2g of cefazolin within 1 hour of incision. The control group will not receive any further antibiotic treatment.
89370869|NCT03183310|Active Comparator|Chlorpromazine|Administration of an intravenous bolus injection of 10 mg Chlorpromazine to investigate the effect on esophageal sensitivity.
89370870|NCT03183310|Placebo Comparator|Placebo (Saline)|Administration of an intravenous bolus injection of saline (placebo) as the control condition of chlorpromazine in this cross-over study.
89370871|NCT05416008||Group 1: treatment with ETV|"The patients in this group were composed of patients with chronic hepatitis B who firstly take entecavir for the treatment of chronic hepatitis B.~Take Entecavir capsule orally for a long time, once a day, 0.5mg each time."
89370872|NCT05416008||Group 2: treatment with TAF|"The patients in this group were composed of patients with chronic hepatitis B who firstly take Tenofovir alafenamide Fumarate for the treatment of chronic hepatitis B.~Take Tenofovir alafenamide Fumarate tablets orally for a long time, 25mg once a day."
89370873|NCT05416008||Group 3: treatment with TDF|"The patients in this group were composed of patients with chronic hepatitis B who firstly take Tenofovir disoproxil Fumarate for the treatment of chronic hepatitis B.~Tenofovir disoproxil fumarate was orally administered for a long time, once a day, 300mg each time."
89370874|NCT03685058|Active Comparator|The control group|A total of 88 non-cavitated proximal carious lesions treated with standard-of-care preventive measures which include application of 5% sodium fluoride topical varnish (Vanish 5% Sodium Fluoride White Varnish with Tri-Calcium Phosphate, 3M ESPE, St. Paul, MN, U.S.A.), oral hygiene instruction, and dietary counseling applied at initial, six-months follow-up, and 12-months follow-up visits.
89370875|NCT03685058|Experimental|The test group|Intervention: A total of 88 non-cavitated proximal carious lesions treated with light curable resin modified glass ionomer varnish (Vanish™ XT Extended Contact Varnish, 3M ESPE, St. Paul, MN, U.S.A.) at initial and six-months follow-up visits. In addition to, standard-of-care preventive measures, applied at initial, six-months follow-up, and 12-months follow-up visits.
89370876|NCT03178006||obese plus diabetes,|BMI 30-40kg/m2 and diabetes or pre-diabetes
89370877|NCT03178006||obese|BMI 30-40kg/m2
88843622|NCT03115177|Active Comparator|Doxycycline+Cefazolin Group|All patients will receive standard perioperative antibiotics with 2g of cefazolin within 1 hour of incision. The treatment group will receive 100mg of doxycycline IV in addition to cefazolin within 1 hour of incision.
88843623|NCT04201418||Patisiran Prospective Cohort|Patients who are naive to patisiran at study enrollment with the intention to initiate commercial patisiran therapy.
88843624|NCT04201418||Patisiran Mixed Cohort|Patients who are currently on commercial patisiran therapy for less than 12 months at study enrollment.
88843625|NCT04201418||Patisiran Retrospective Cohort|Patients who have been on commercial patisiran therapy for at least 12 months prior to study enrollment, regardless of current treatment status at enrollment.
89189277|NCT00415909|Experimental|TALL-104 + IM|TALL-104 cells and imatinib mesylate (IM) therapy
89189278|NCT00709566|No Intervention|Control|Waiting List control.
89189279|NCT00709566|Active Comparator|Exercise therapy|
89370878|NCT03178006||control|BMI 20-27,5kg/m2
89370879|NCT01365975||Community Intervention Program Population: The Chinese Childre|Community sample of mothers, fathers and offspring from 2 provinces in China who participated in a community public health study in 1994-1996.
89399257|NCT02166086||Endoscopic imaging|Any patient who has undergone advanced imaging procedures for diagnosis and/or treatment of a pancreatico-biliary disorder.
89189280|NCT00709566|Experimental|Combined therapy|Combined Exercise therapy and Manual Therapy
89189281|NCT02573688|Experimental|Interdisciplinary Therapy|The Therapy includes: Physical Exercise (three times week - 180 minutes); Nutrition, Psychology, Physiotherapy (once a week - 60 minutes each one)
89370880|NCT03177850|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m
89370881|NCT03177850|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m.
89370882|NCT01366053||Prostate Cancer|Males who have been diagnosed with Prostate Cancer and are experiencing PSA rise, while taking androgen agonist therapy.
89370883|NCT03102918|Active Comparator|Cannabidiol|Epidiolex
89370884|NCT03102918|Placebo Comparator|Placebo|Placebo
89370885|NCT03676712|Experimental|scoliosis patients|scoliosis patients who have cobb angle over 20 degree wear scoliosis brace for six months
89370886|NCT02421796||NCWS patients|Consecutive adult patients with an irritable bowel syndrome (IBS)-like clinical presentation, according to Rome II criteria, and a definitive diagnosis of NCWS.
89370887|NCT02421796||CD patients|Sex- and age-matched subjects with CD, diagnosed according to standard criteria during the same study period and enrolled as first control group.
89370888|NCT02421796||IBS patients|Sex- and age-matched subjects with IBS unrelated to NCWS or other food 'intolerance', diagnosed according to standard criteria during the same study period and enrolled as second control group.
89370889|NCT03684902|Experimental|xpolration|women who underwent emergency midline laprotomy
89370890|NCT03102762|Experimental|Botulinum Toxin Type A (BTX-A) Group|Experimental: BTX-A Group The treatment group, 35 patients, will be injected with 100 units BTX-A one day following penile colour Doppler assessment.
89370891|NCT03102762|Placebo Comparator|Placebo Group|"Saline Group:~The control group, 35 patients, will be injected with 1 ml normal saline one day following penile colour Doppler assessment."
89370892|NCT03684824|Other|obese group|100 obese patients with BMI between 30 and 35 who are undergoing IVF/ICSI treatment for infertility
89370893|NCT02421874|Experimental|Use of electronic health record / outcomes monitoring|Use of electronic health record / outcomes monitoring via a specified electronic behavioral health information system
89370894|NCT02421874|Active Comparator|education about outcomes monitoring|Care coordination as usual with education about fidelity and outcomes monitoring but no use of EBHIS
89370895|NCT01359891||Cohort 1|"All patients >18 years admitted to the University Hospital Graz, Austria, with positive blood cultures tested in the Microbiology Laboratory, Department of Internal Medicine, Medical University Graz, or the Institute for Hygiene, Microbiology and Environmental Medicine, Medical University Graz, are screened for study inclusion. Patients eligible for the study have to have Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, Enterococcus faecium, Enterococcus faecalis, Streptococcus pneumoniae, Klebsiella pneumoniae or medically relevant fungi / viral pathogens identified as causative pathogen.~The estimated total number of patients included in this first study cohort will be 500."
89180600|NCT00719043|Experimental|A/Indonesia primed-A/turkey Influenza (H5N1)-F2-Placebo Group|Healthy subjects aged 18 years of age or older at the time of enrolment were primed with one dose of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) formulation 2 at Day 0 followed by one booster dose of A/turkey H5N1 vaccine formulation 2 at Day 182 and one dose of placebo (phosphate buffered saline, PBS) at Day 549. Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) and Placebo vaccines were administered intramuscularly in the deltoid region of the non-dominant arm while, A/turkey H5N1 vaccine was administered intramuscularly in the deltoid region of the dominant arm.
89370896|NCT01359891||Cohort 2|"All patients >18 years admitted to the University Hospital Graz, Austria, will be screened for study inclusion if the attending emergency department physicians on the very first visit suspects bacteremia/fungemia/sepsis and consecutively orders blood cultures. Patients will be included in this second cohort if these initially taken blood culture turns positive (n=200) or stays negative (n=50) at the Microbiology Laboratory, Department of Internal Medicine, Medical University Graz. As soon as the number of 50 is reached for the control group enrollment will be stopped for this group.~As soon as the proposed number of 250 patients is reached enrolment for this second cohort will be stopped. Patients enrolled in cohort 2 may also be consecutively enrolled in cohort 1."
89370897|NCT01359891||Validation Cohort|To verify the employed Presage™ST2 assay established in our study laboratory for its intended use, a total number of 70 left over plasma samples obtained from septic patients which have prior been tested for sST2 with the same assay at the Department of Laboratory Medicine, Barmherzige Brueder Linz, Austria, will be retested. This cohort therefore serves as a validation cohort.
88809869|NCT01212107|Experimental|Part A: 8 mg FGF Receptor BID|"Part A: Dose escalation~8 mg of FGF receptor given orally twice a day (BID) for a minimum of (1) 28 day cycle.~If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)"
88843626|NCT02962609|Experimental|Semielevated Side-Lying Position-ESL|Preterm infants feed in the ESL position. In the ESL position, infant's head and trunk were elevated to an angle of 45-60° with the help of a pillow prepared by the researcher from the beds that were previously used in the unit and infants were held in side-lying position as in the breast-feeding position where their right ear faced the ceiling and the other ear faced the arms of the researcher. Their knees and hip were leaned against the researcher's arms and both the head and the neck were held at the same level by the researcher, whereas the chin was held in the flexion posture mildly facing the floor.
88809870|NCT01212107|Experimental|Part A: 10 mg FGF Receptor BID|"Part A: Dose escalation~10 mg FGF receptor given orally BID for a minimum of (1) 28 day cycle.~If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)"
88843627|NCT02962609|Experimental|Semielevated Supine Position-ESU|Before feeding: In the ESU position, the head and the trunk of the infant were elevated to an angle of 45-60° with the help of the same pillow that was prepared by the researcher from the beds previously used in the unit and was used in the experimental group and the infant was laid in supine position in the arms of the researcher. Their head and neck were held at the same level by the researcher, whereas the chin was held in the flexion posture mildly facing the floor.
88843628|NCT02962687|Experimental|Videoconference care management|12-week nurse care management for medically complex Veterans with CI delivered via videoconferencing
88843629|NCT02962687|Active Comparator|Telephone care management|12-week nurse care management for medically complex Veterans with CI delivered via telephone calls
88843630|NCT03174158|Active Comparator|Brief advice|Usual care plus brief telephone advice to quit tobacco delivered by a clinical research coordinator who underwent Tobacco Treatment Specialist core training.
88843631|NCT03174158|Experimental|Text messaging|Patients randomized to the text messaging program are offered a 12-week text messaging. The text messaging intervention will use content from the National Cancer Institute's SmokeFreeTXT library, content for smokers not ready to quit from SmokeFreeTXT and a pilot feasibility study conducted by the PI, and new messages supporting nicotine replacement medication adherence. The text messaging program will be personalized using subject's first name, the telephone number for the Massachusetts General Hospital (MGH) tobacco cessation counseling services and the Massachusetts state quitline. Smokers receiving the intervention will be sent from 0 and 5 text messages per day.
88843632|NCT03174158|Experimental|Mailed nicotine replacement therapy|Subjects randomized to mailed nicotine replacement therapy will be offered a 2 week supply of nicotine replacement therapy mailed to their home address. Daily smokers planning to quit in the next 30 days will be offered nicotine patches (14 or 21 mg patches) and lozenges (2 or 4 mg lozenges) dosed according to package instructions. Non-daily smokers planning to quit will be offered a 2 week allotment of 2 mg lozenges alone. Smokers not planning to quit will be offered one box of lozenges (72 count box of 4 mg or 2 mg lozenges based on time to first cigarette as above per package instructions) to use when they are not smoking during their practice quit attempt.
88843633|NCT03174158|Experimental|Text messaging + mailed NRT|Subjects will be offered both the 12 week text message program and 2 weeks of mailed nicotine replacement therapy.
88843634|NCT04736641||Patients group|Individuals with hip disease and chronic pain on hip
88843635|NCT00422630|Active Comparator|Average American Diet|
88843636|NCT00422630|Active Comparator|The DASH diet|
88843637|NCT00422630|Active Comparator|The Low Glycemic Index Diet|The carbohydrate content of a low GI diet can vary, but many advocates of low GL popular diets suggest a macronutrient profile that is 40% carbohydrate, 30% protein, and 30% fat. These low GL diets are lower in carbohydrate content and higher in protein content than the average American diet. Low GL diets typically contain ample amounts of fruits and vegetables, moderate quantities of nuts, legumes, lean meats, fish, and reduced-fat dairy products, and scant amounts of refined grains, potatoes, and sweets
88843638|NCT03115411|Experimental|Winged stent|Placement of Winged stent for management of biliary obstruction. Stent to be placed for 90 days, with laboratory studies and clinical evaluation during this period to assess for stent potency.
88843639|NCT03176654|Experimental|HVLAT manipulation|An HVLAT manipulation is applied to the site of pain or restriction with the patient in supine. This technique uses both primary levers (pre-manipulation rotation - away (30 ° - 45 °) from the side of pain or limitation) and secondary levers (Side bending - towards coupled with lateral shift - away, and posterior-anterior (PA) shift (extension). This is a bimanual technique. For the applicator hand, the anterolateral portion of the first or second phalanx of the second ray was positioned on the superior joint partner of the target vertebrae using a cradle hold. The other hand is placed on the posterolateral aspect of the occiput (above the ear). While maintaining these positions the clinician performed the thrust with the arc of rotation dependent on the level of the target vertebrae.
88843640|NCT03176654|Sham Comparator|Sham HVLAT manipulation|Subjects in the control group were instructed to lay on a table in the same position as the HVLAT manipulation group. The clinician went through the same basic steps as the HVLAT manipulation, localizing the appropriate vertebral landmarks but without carrying out the final HVLA thrust procedure.
88843641|NCT03115801|Active Comparator|Arm A - immunotherapy alone|"Patients with Renal Cell carcinoma will receive Nivolumab alone Days 1, 15, 29, 43 and 57.~Patients with Urothelial cancer will receive Atezolizumab or Pembrolizumab on Days 1, 22, 43 and 64."
88843642|NCT03115801|Active Comparator|Arm B - Radiation & immunotherapy|Radiation is given to one lesion, 30 Gy in 3 fractions of 10 Gy, every other day. On the day of radiation (Day 1) immunotherapy is administered and repeated on the scheduled days.
88843643|NCT03177512|Experimental|LYNX Mobile App|
88843644|NCT03177512|No Intervention|Control|Participants in this study arm will receive local standard of care for linkage to PrEP and HIV/STI testing.
88843645|NCT03117517|Experimental|Metformin|Drug intervention: Metformin 500 mg tablet twice orally for 3 months
88843646|NCT03117517|Active Comparator|Metformin, pioglitazone|Drugs intervention: Combination of Metformin (1000 mg) and pioglitazone (30 mg) tablets will be given orally for 3 months
89370898|NCT03681002|Other|structured lifestyle program|individual counseling focusing on Lifestyle habits
88843647|NCT02966275|Experimental|Glucagon-only bionic pancreas - glucagon|"Subjects will wear the bionic pancreas that consists of a continuous glucose monitor linked to a smartphone running a hypoglycemia prevention algorithm that doses glucagon from an insulin pump through a subcutaneous infusion set.~Subjects will continue to manage any hypoglycemia that occurs according to the current recommendations of their care provider."
88843648|NCT02966275|Placebo Comparator|Glucagon-only bionic pancreas - placebo|"Subjects will wear the bionic pancreas that consists of a continuous glucose monitor linked to a smartphone running a hypoglycemia prevention algorithm that doses placebo from an insulin pump through a subcutaneous infusion set.~Subjects will continue to manage any hypoglycemia that occurs according to the current recommendations of their care provider."
89189282|NCT00415597|Experimental|ALO-01|Doses given once or twice daily
89370899|NCT03177538|Active Comparator|Corifollitropin alfa and menotropin|Elonva 150 mcg, Merional 150-300 IU
89370900|NCT03177538|Active Comparator|Follitropin alfa and lutropin alfa|Pergoveris 300 IU
89370901|NCT01363323|Experimental|Arm 1|
89370902|NCT01363323|Experimental|Arm 2|
89180601|NCT00719043|Experimental|A/Indonesia primed-A/turkey Influenza (H5N1)-F3-Placebo Group|Healthy subjects aged 18 years of age or older at the time of enrolment were primed with one dose of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) formulation 3 at Day 0, one dose of placebo (phosphate buffered saline, PBS) at Day 182 followed by one booster dose of A/turkey H5N1 vaccine formulation 3 at Day 549. Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) and A/turkey H5N1 vaccines were administered intramuscularly in the deltoid region of the non-dominant arm while, Placebo vaccine was administered intramuscularly in the deltoid region of the dominant arm.
89370903|NCT01363323|Experimental|Arm 3|
89370904|NCT01363323|Placebo Comparator|Arm 4|
89370905|NCT01363323|Active Comparator|Arm 5|
89370906|NCT03183076|Active Comparator|modified adkins diet|modified adkins diet. It consists in the free intake of proteins and fats, and the restriction of carbohydrates that are gradually being installed. Its mechanism of action that induces a state of ketosis.
89370907|NCT03183076|Active Comparator|Pharmacotherapy without diet|It consists in administer only pharmacological treatment withot a special diet, Drug-resistant epilepsy is characterized by the use of antiepileptic drugs and in optimal doses, depending on the type of epilepsy, at least on two consecutive occasions without response to management.
89370908|NCT01360047||Cases|Cases with nonfatal MI or coronary death
89370909|NCT01360047||Controls|Age, sex, and calendar-year matched controls sampled from the original study cohort to be a round number of at least four times the number of cases
89370910|NCT04388553|Experimental|Treatment|lumbar ESP block is performed. Before proceeding to ESP block, the back is cleaned with aseptic technique and draped. 40 mL of 0.25% levobupivacaine (or maximum of 2mg/kg body weight made up to same volume) is injected into the ESP.
89370911|NCT04388553|No Intervention|Control|no regional anaesthesia is performed nor saline is injected into the ESP
89370912|NCT05415852|Active Comparator|fractional CO2 laser|Laser
89370913|NCT05415852|Active Comparator|Pulsed dye laser|Laser
88843649|NCT02967367|Experimental|Jawbone/Withings sleep trackers, Bodymedia Sensewear|2 types of Consumer sleep trackers, including Jawbone and Withings, and one research actigraph (Bodymedia Sensewear) are added to classical polysomnography in order to assess their accuracy to measure sleep parameters in obstructive sleep apnea patients
88843650|NCT05405101|Experimental|Radiofrequency ablation of adrenal aldosterone producing adenoma (s)|Ablation of adrenal aldosterone producing adenoma(s)
89370914|NCT05415852|Active Comparator|Nd Yag|Laser
89370915|NCT05415852|Active Comparator|Q switched Nd Yag|Laser
89370916|NCT03117244|Experimental|Exercise Group|
89370917|NCT03117244|Active Comparator|Exercise and NMES Group|
89370918|NCT03117244|No Intervention|Control Group|
88843651|NCT05405101|Other|Unilateral adrenalectomy for aldosterone producing adenoma(s)|Unilateral adrenalectomy for laldosterone producing adenoma(s)
88843652|NCT03795350|Experimental|TRIMBOW|"Experimental: BDP/FF/GB~4 puffs of 99mTc Radiolabelled Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium Bromide administered via pMDI"
88843653|NCT03118843|Experimental|SOF/VEL/VOX|SOF/VEL/VOX for 12 weeks
88843654|NCT03724370|Experimental|TES+ VHA-SRM|Telehealth monitoring system (TES) will be added to the VA suicide risk management system (VHA-SRM)
88843655|NCT03724370|Active Comparator|VHA-SRM|VHA-SRM will be active comparator
88843656|NCT04736732||COVID-19 positive patients|"Patients who had previous asymptomatic or mild COVID-19 (mild=never required supplemental oxygen during the acute phase of the infection)~Patients who had previous moderate or severe COVID-19 (moderate=required supplemental oxygen by nasal cannula during the acute phase of the infection; severe=required supplemental oxygen by either high-flow nasal cannula, non-invasive positive pressure ventilation or intubation~Patients who had COVID-19 but did not have signs or symptoms related to COVID-19 lasting beyond 4 weeks from the date of COVID-19 symptom-onset or diagnosis"
89370919|NCT01366287|Experimental|Suspension/fasted|
89370920|NCT01366287|Experimental|Tablet/fasted|
88843657|NCT04736732||COVID-19 negative patients|COVID-19 negative control group
88843658|NCT05401513|Experimental|Pilates Group|12-weeks exercise program, twice a week, with Pilates method exercises.
88843659|NCT05401513|No Intervention|Control Group|12-weeks maintaining their normal physical activity routine.
88843660|NCT05365022|No Intervention|Conventional Non-Robotic Assisted Knee Prosthetic Surgery|
88843661|NCT05365022|Active Comparator|ROSA® System Robotic Assisted Knee Prosthetic Surgery|
88843662|NCT03119389|Experimental|Donning Non-Sterile Gloves without HH|In this arm, entire units will be assigned education that hand hygiene before donning non-sterile gloves is NOT necessary. For Aim A, observations will be made on compliance at entry and exit with hand hygiene and glove use. For Aim B, samples will be obtained from the gloves after donning to determine total aerobic colony counts and to identify important hospital pathogens
89189283|NCT04071054||Hemodialysis patients|
89189284|NCT00714480|Other|Group I|Administration of anti-thymocyte globulin post-operative days -6,-4,-2, and 0
89189285|NCT00714480|Other|Group II|Administration of anti-thymoglobulin post-operative days -2, 0, 2 and 4
89370921|NCT01366287|Experimental|Tablet/fed|
89370922|NCT03177382|Experimental|Total neoadjuvant treatment|The interventions of experimental group include 1 cycle of CAPOX before radiotherapy; and then start concurrent chemoradiotherapy with CAPOX regimen (capecitabine: 825mg/m2, bid, 5d/w; oxaliplatin, 130mg/m2, D1, q3w) for 2 cycles followed by 3 cycles of CAPOX 2-3 weeks after the completion of radiotherapy. Intensity modulated radiotherapy (IMRT/VMAT) was used for radiotherapy, and the dose was 50-50.4Gy/25-28f, 1.8-2.0Gy/d, 5f/w. The TME operation will be given 3-4 weeks after the end of the total neoadjuvant treatment.
89534819|NCT03093441|Experimental|Multimodal|Multimodal High-Intensity Interval Training Intervention. This group will train using multimodal exercises for 5 sets of 60 seconds of all out work, followed by 3 minutes of rest. Each session will have the same exercises within each set, but every session will be different than the others for movements utilized. There will be three movements used in each set. The first movement will be a strength movement for 4-6 repetitions. The second movement follows the first immediately and is a faster body weight or light implement power movement for 6-8 repetitions. The third movement follows the second immediately and is a very fast, sprint-like movement for the remainder of the 60 seconds. The intent of each set is to be completed with as much effort as possible across the full 60 seconds.
89370923|NCT03177382|Active Comparator|concurrent chemoradiotherapy group|The interventions of control group is standard preoperative concurrent chemoradiotherapy. The radiotherapy target areas and dosage are the same as group TNT. During radiotherapy, only oral capecitabine will be delivered and capecitabine dose was 825mg/m2, bid, 5d/w. The TME surgery will be performed 6-8 weeks after the end of concurrent chemoradiotherapy. Then, patients will receive another 6 cycles of CAPOX.
89370924|NCT05190861|Experimental|droplet digital PCR method|Pathogen detection by droplet digital PCR method as an adjunct to traditional microbiological assessments including blood culture
89370925|NCT05190861|Active Comparator|blood culture only|Pathogen detection by microbiological assessments including blood culture
89370926|NCT03177304|Experimental|Web based IPT Training|All subjects (trainees) received the web based training, consisting of an on-line tutorial, remote live training via videoconferencing, and access to a post-training web portal
89370927|NCT05760222|Experimental|Acupuncture arm|Intervention with 10 acupuncture sessions twice per week for 4 weeks followed by 2 more sessions once per week
89370928|NCT05760222|No Intervention|Usual care arm|Lifestyle recommendations
89370929|NCT05188443||COVID-19|Patients tested for COVID-19 with current or previous (last 3 years) radiological imaging
88843663|NCT03119389|No Intervention|HH before donning Non-Sterile Gloves|In this arm, entire units will be assigned education that hand hygiene before donning non-sterile gloves IS necessary. For Aim A, observations will be made on compliance at entry and exit with hand hygiene and glove use. For Aim B, samples will be obtained from the gloves after donning to determine total aerobic colony counts and to identify important hospital pathogens
89370930|NCT03106948|Placebo Comparator|Low frequency angioplasty|Subjects who have had 0-1 angioplasty during the 12 months prior to randomization. Subjects will have endoluminal biopsy prior to angioplasty but will not have insertion of the ACT drug delivery catheter
89370931|NCT03106948|Active Comparator|Moderate frequency angioplasty|Subjects who have had 2-3 angioplasties during the 12 months prior to randomization. Subjects will have endoluminal biopsy prior to angioplasty followed by insertion of the ACT drug delivery catheter where ascorbic acid (10.0 µM) will be injected following conventional balloon angioplasty
88843664|NCT02967991|Active Comparator|19 Left|EUS-guided liver biopsy using a19-gauge liver biopsy in the left lobe
88843665|NCT02967991|Experimental|22 Left|EUS-guided liver biopsy using a 22-gauge liver biopsy in the left lobe
88843666|NCT02967991|Active Comparator|19 Right|EUS-guided liver biopsy using a 19-gauge liver biopsy in the right lobe
88843667|NCT02967991|Experimental|22 Right|EUS-guided liver biopsy using a 22-gauge liver biopsy in the right lobe
88843668|NCT03830840||Adult Individuals with Type 2 diabetes|Individuals ≥18 years of Hispanic/Latino heritage with an established diagnosis of type 2 diabetes
88843669|NCT03830840||Adult Family member|Adult family members, ≥18 years, of the individual with type 2 diabetes
88809871|NCT01212107|Experimental|Part A: 14 mg FGF Receptor BID|"Part A: Dose escalation~14 FGF receptor given orally BID for a minimum of (1) 28 day cycle.~If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)"
88843670|NCT03830840||Child family member with diabetes|Child, ≥7 years but <18 years, family member with diabetes
88843671|NCT03830840||Child family member without diabetes|Child, ≥7 years but <18 years, family member without diabetes
88843672|NCT05400421||Device Calibration & Algorithm Training|The data obtained from this group will be used to a) quantify the relationship between PWV measured at the groin versus the thigh for less intrusive future piezo sensor placement and b) train the proposed device for the next cohort.
88843673|NCT05400421||Device & Algorithm Testing|The gold-standard and new device values will be collected from this group to validate the previously trained system.
88843674|NCT02222922|Experimental|PF-06647020 Q3W|Investigational drug infused over 60 minutes once every 21 days.
89370932|NCT03106948|Active Comparator|High frequency angioplasty|High frequency angioplasty defined by 4 or more angioplasties 12 months prior to randomization. Subjects will receive ascorbic acid (10.0 µM) in combination with D-penicillamine (25 µM) will be injected following conventional balloon angioplasty
88843675|NCT02222922|Experimental|Drug-drug interaction (DDI)|PF-06647020 combined with fluconazole
89189286|NCT00714480|Other|Group III|Administration of anti-thymocyte globulin post-operative days 0, 2, 4 and 6
89370933|NCT01366365|Experimental|Arm 1|IV methylnaltrexone (MNTX)
89370934|NCT01366365|Placebo Comparator|Arm 2|placebo
89370935|NCT03177148|Active Comparator|Usual Care|"1-2 pediatric clinicians per practice will be trained in study procedures, current obesity treatment guidelines, and obesity billing and coding via telephone and webinar~NO active enrollment of parents~Secure extraction of HIPAA limited Electronic Health Record (EHR) and billing data from practices for outcomes analyses~At the end of the intervention period, 1-2 pediatric clinicians will be offered the in-person MI training and DVD materials"
88809872|NCT01212107|Experimental|Part A: 18 mg FGF Receptor BID|"Part A: Dose escalation~18 mg FGF receptor given orally BID for a minimum of (1) 28 day cycle.~If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)"
88843676|NCT02222922|Experimental|PF-06647020 Q2W|Investigational drug infused over 60 minutes once every 14 days (28 day cycle)
88843677|NCT02222922|Experimental|PF-06647020 combined with Avelumab|PF-06647020 combined with Avelumab administered by infusion
88843678|NCT03503942|Experimental|Treatment arm|Participants in the treatment arm will receive structured group-based lifestyle interventions with stepwise addition of metformin for selected high-risk participants.
88843679|NCT03503942|No Intervention|Control|Participants in the control arm will receive the current standard of care for pre-diabetes which includes counseling on lifestyle modifications and follow up by primary care physicians.
88843680|NCT03122587|Sham Comparator|Active Sham (Session 1 and Session 2)|Active sham transcranial alternating current stimulation (tACS) during Session 1 and Session 2
88843681|NCT03122587|Experimental|Active Sham (Session 1) and tACS at 10 Hz (Session 2)|Active sham transcranial alternating current stimulation (tACS) during Session 1 and Transcranial Alternating Current Stimulation at 10 Hz during Session 2
89189287|NCT00709800|Experimental|2|
89189288|NCT00709800|Experimental|3|
89370936|NCT03177148|Experimental|Intervention by Clinicians|"Clinicians complete surveys during enrollment and end of the intervention~1-2 clinicians from each practice will receive 2.5 days of in-person MI training, two scored encounters with a standardized patient, and an interactive DVD MI booster training system focusing on pediatric obesity.~Enroll 35 eligible parents per practice~Clinicians give up to 4 in-person, MI sessions to enrolled parents over 2 years.~Dietitians will provide up to 6 telephone counseling sessions.~•Parents will complete surveys after enrollment and at the end of intervention"
89370937|NCT01363557|Experimental|Arm A : Gefitinib + WBRT|Arm A : WBRT and Concurrent Gefitinib followed by Gefitinib Maintenance
89370938|NCT01363557|Experimental|Arm B : Gefitinib|Arm B : Gefitinib alone
89370939|NCT02416336|Experimental|Sentinella intraoperative use|"Standard of care intraoperative protocol~Localize SLN with the Gamma Probe for In vivo count~Optional (time permitting during surgical prep). Image same SLN with Sentinella (Pre-incision)~Surgically remove/excise localized SLN~Ex vivo count - excised SLN with Gamma Probe~In vivo background/roaming count with Gamma Probe~Repeat step 1-5, until no SLNs are found with the Gamma Probe (negative reading)~Sentinella intraoperative imaging protocol~Survey surgical field/Post-excision control with Sentinella for remaining SLNs~If focal uptake seen in step 1, search for these occult SLNs with Gamma Probe and remove localized additional SLNs~Record information on data sheet for each excised SLN with Gamma Probe and Sentinella"
89370940|NCT02425540||patients with unclassified ovarian mass|
89370941|NCT01804296|Experimental|Part 2 Active|Open-label, active repetitive transcranial magnetic stimulation
89370942|NCT01346475|Active Comparator|valacyclovir|
89370943|NCT01346475|Experimental|high dose valacyclovir|
89370944|NCT02416414||Solid Organ Transplant Recipients|Subjects who have received a Solid Organ Transplant.
89370945|NCT02416414||Healthy Controls|Healthy individuals.
89370946|NCT05415306|Experimental|Attention Bias Modification Training|Participants randomized to the ABMT group will undergo active attention bias modification training. The emoji-based ABMT protocol will be adapted from the attention bias modification task from Browning et al., 2012. The stimuli used during the task are pictures of emoji displaying emotional expressions that have valences that are either positive, neutral, or negative. The positive, negative and neutral emojis will be chosen from the outcome of a preliminary rating questionnaire.
89370947|NCT05415306|Sham Comparator|Sham Training|Participants in the sham control group will receive a sham version of the ABMT task. This condition is identical to the active ABM condition except for the location of the probe, which replaces the positive, negative, and neutral stimuli with equal probability. This control procedure is not expected to modify any underlying biases present.
89370948|NCT05415306|Active Comparator|Deep-breathing training|The protocol for the deep breathing practice will be adapted from the procedure outlined in (Cheng et al., 2019). Participants randomized to the deep breathing group will undergo mindful deep breathing practice. Participants will be required to follow an instructional video and perform mindful deep breathing. The video guide will be sent to each participant in the deep breathing group, and they will be instructed to perform the exercise once a day at any time of their choice for the 14-day period.
89370949|NCT05415306|No Intervention|No-intervention control|Participants in the no-intervention control group will not be required to undergo any intervention.
89370950|NCT02425384|Experimental|Intervention Group|This group is provided an activity meter that tracks the amount and intensity of one's physical activity and is linked to a motivational website. On the website, activity data from the activity meter can be viewed after uploading information from the meter to the website. The reward website allots points for participants based on the amount and intensity of physical activity. Points can be redeemed for rewards on the website, such as gift cards and digital badges.
89370951|NCT02425384|Active Comparator|Active Control|This group is provided an activity meter that tracks the amount and intensity of one's physical activity and a copy of the game Dance Dance Revolution (DDR). The activity meter will upload data to a secure server but will not be linked to the motivational website used by the intervention group. DDR is a dancing video game in which players view arrows timed to music on a TV screen and gain points by stepping on the corresponding arrows on a floor mat. Players obtain points in the game by stepping on the correct arrows at the right time to the beat of the music. The points earned with DDR cannot be redeemed for rewards.
89370952|NCT02425384|Placebo Comparator|Passive Control|This group is provided with an activity meter and will be asked to carry it with them as they go about their normal daily activities. Like in the Active Control group, participants in the Passive Control group will not have access to the motivational website. For this group, the activity meter functions solely as a monitor to track their activity levels. No other product or intervention will be introduced to the control group.
89370953|NCT05754060||Saint-Louis Lille Battery (SSLIB)|"Saint-Louis Lille Battery (SSLIB) is composed of three tests studying the speed of cognitive processing and proposed to the subjects on a tactile tablet. These three tasks are:~(a) Reaction time tasks specifically developed for this study b) A digital adaptation of the WAIS-IV code subtest c) A digital version of the Trail Making Test (A and B)"
89370954|NCT03177226|Experimental|Functional TENS stimulation|Short stimulation to identifying Sensory Threshold and Motor Threshold, followed by continuous functional electrical stimulation, throughout the entire self-stimulation phase [from full erection to ejaculation]
88843682|NCT03122587|Experimental|Active Sham (Session 1) and tACS at 40 Hz (Session 2)|Active sham transcranial alternating current stimulation (tACS) during Session 1 and Transcranial Alternating Current Stimulation at 40 Hz during Session 2
89370955|NCT03177226|Sham Comparator|Non-stimulation treatment|Short stimulation to identifying Sensory Threshold and Motor Threshold, followed by continuous non-functional electrical stimulation, throughout the entire self-stimulation phase [from full erection to ejaculation]
89370956|NCT02416960|Experimental|Low Glycemic Index Diet Group|Patients will follow a treatment with a hypocaloric diet with low glycemic index/load for 12 weeks, immediately before the in vitro fertilization cycle.
89189289|NCT00709800|Experimental|4|
88843683|NCT03791138|Experimental|intervention group|Care as usual and an online patient decision aid
88843684|NCT03791138|No Intervention|control group|Care as usual with a standard information leaflet
88843685|NCT05364398|Active Comparator|ACL reconstruction with stump preservation|
88843686|NCT05364398|Active Comparator|ACL reconstruction with stump resection|
89189290|NCT00709800|Placebo Comparator|5|
89189291|NCT00709800|Experimental|1|
88843687|NCT02161146|Experimental|AGN-229666|One drop of AGN-229666 in each eye on Days 1 and 15.
89189292|NCT00714636||ALS|Subjects having either definite or probable ALS by El Escorial Criteria.
89370957|NCT02416960|Active Comparator|Conventional Diet Group|Patients will follow a treatment with a hypocaloric diet with high glycemic index/load for 12 weeks, immediately before the in vitro fertilization cycle.
89370958|NCT02416960|No Intervention|Control Group|Patients will follow their usual diet for 12 weeks, immediately before the in vitro fertilization cycle.
89370959|NCT01338636|Other|Exercise-induced PAH|Open-label ambrisentan
89370960|NCT02416726|Experimental|Peripheral blood|The peripheral blood sample will be extrated with DNA and performed NGS using Illumina Nextseq500 sequencer.
89370961|NCT02416726|Experimental|Primary tumor|The gene testing of the primary tumor tissue diagnosed with nonsquamous NSCLC will be performed with NGS technique using Illumina Nextseq500 sequencer.
89370962|NCT02416726|Experimental|Metastatic lymph node|The gene testing of the metastatic lymph node tissue diagnosed with nonsquamous NSCLC will be performed with NGS technique using Illumina Nextseq500 sequencer.
89370963|NCT02416258|Active Comparator|LP0113 aerosol spray|Calcipotriol (as monohydrate) 50 mcg/g and betamethasone (as dipropionate) 0.5 mg/g, topical
89370964|NCT02416258|Placebo Comparator|Aerosol spray vehicle|No active ingredient, topical
89370965|NCT02416258|Active Comparator|LEO 90100 aerosol foam|Calcipotriol (as monohydrate) 50 mcg/g and betamethasone (as dipropionate) 0.5 mg/g, topical
89370966|NCT02416258|Active Comparator|Betamethasone dipropionate aerosol spray|Betamethasone (as dipropionate) 0.5 mg/g, topical
89370967|NCT02416258|Active Comparator|Calcipotriol aerosol spray|Calcipotriol (as monohydrate) 50 mcg/g, topical
89370968|NCT02416258|Active Comparator|Daivobet® gel|Calcipotriol (as monohydrate) 50 mcg/g and betamethasone (as dipropionate) 0.5 mg/g, topical
89370969|NCT00592254||A|
89370970|NCT02410720|Active Comparator|Instruction leaflet|Patients will receive the Picoprep solution with an instruction leaflet of how to use it and the dietary modifications needed
89370971|NCT02410720|Experimental|Mobile App|Patients will receive Picoprep solution with an instruction leaflet + Picoprep Mobile App which will be downloaded to their smartphones that has the same information plus a reminder utility
89370972|NCT02416570|Active Comparator|Clarithromycin|Clarithromycin 250mg by mouth twice a day for 8 weeks
89370973|NCT02416570|Placebo Comparator|Placebo|Placebo matched capsule one capsule by mouth twice a day for 8 weeks
89370974|NCT03176914|Experimental|Intervention arm|Eleven clusters (Villages) will be randomly selected. A cluster will comprises of 10-15 volunteers selected from a cohort 10-15 households. Educative sessions will be held in each cluster once every fortnight using a participatory methods by a trained Village Health Worker (VHW). A session will focus on one thematic area running for 1-2 hours. Trained volunteers will in turn replicate the session(s) in their cohorts and do home visits to monitor care practices and screen children for various ailment. Health information is collated from each cluster and consolidated by the VHW who reports monthly at the clinic.
88843688|NCT02161146|Placebo Comparator|Vehicle|One drop of Vehicle to AGN-229666 in each eye on Days 1 and 15.
89180602|NCT00719043|Experimental|A/Indonesia primed-Placebo-A/turkey Influenza (H5N1)-F1-Group|Healthy subjects aged 18 years of age or older at the time of enrolment were primed with one dose of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) vaccine formulation 1 at Day 0, one dose of placebo (phosphate buffered saline, PBS) at Day 182 followed by one booster dose of A/turkey H5N1 vaccine formulation 1 at Day 549. Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) and A/turkey H5N1 vaccines were administered intramuscularly in the deltoid region of the non-dominant arm while, Placebo vaccine was administered intramuscularly in the deltoid region of the dominant arm.
89370975|NCT03176914|Active Comparator|Conventional Intervention arm|In the conventional mobilization system, a Village Health Worker facilitates community health programs as the sole source of health education for the entire villages. She does home visits, child growth monitoring and the various components primary health care at village level inclusive of disease surveillance and community case management using the 'supermarket approach' , whereby 3 or more themes are covered in a space of 10- 30 minutes in functions like funerals, village gatherings and other opportune moments. The Village Health worker prepares village monthly reports on all the indicators on community health and submits to the local health centre.
89370976|NCT02416024||No Refractory hypotension group|Patient who did not require more than 200 mcg of phenylephrine to maintain systemic blood pressure during 10 minutes after induction of general anesthesia.
89370977|NCT02416024||Control|Patient who required more than 200 mcg of phenylephrine to maintain systemic blood pressure during 10 minutes after induction of general anesthesia
89370978|NCT00322218|Experimental|Zevalin|"Patients received Zevalin.~Zevalin Therapeutic Regimen:~Day 1: Initial administration of 250 mg/m^2 rituximab, followed immediately by administration of 185 MBq of [111In]-ibritumomab tiuxetan ,in centers where centers where biodistribution imaging or dosimetry had not been required, the first rituximab infusion was given alone.~- Day 7-9: Rituximab 250 mg/m^2, followed immediately by [90Y]-ibritumomab tiuxetan 14.8 MBq/kg given as a slow intravenous push over 10 minutes.~Two treatment days one week apart were followed by a 12-week safety period."
89370979|NCT00322218|No Intervention|Observational|Patients in this arm did not receive any reference therapy; they remained free of any anti-lymphoma therapy and were observed for relapse. This was non-interventional Stage consisting of a longterm follow-up period (until completion of a median observation period of 5 years).
89370980|NCT02410564|Active Comparator|CBTI treatment|cognitive behavioral therapy for insomnia (CBTI) treatment is a validated web based version of CBT-I, which will take place over seven weeks and will include a combination of face-to-face and telephone sessions, and email updates
89399258|NCT02169752|Active Comparator|Ambrisentan|Subjects will be randomly assigned in a 1:1 ration according to the computer generated random numbers to receive either placebo (sugar pill) or ambrisentan.
88843689|NCT02161146|Active Comparator|Olopatadine|One drop of olopatadine in each eye on Days 1 and 15.
88843690|NCT02161146|Other|AGN-229666/Olopatadine|One drop of AGN-229666 in one eye and one drop of olopatadine in the other eye on Days 1 and 15.
88843691|NCT02161146|Other|AGN-229666/Vehicle|One drop of AGN-229666 in one eye and one drop of Vehicle to AGN-229666 in the other eye on Days 1 and 15.
89189293|NCT00714636||Non-ALS|Subjects not having either definite or probable ALS by El Escorial Criteria.
89189294|NCT02574624|Experimental|Intraocular Assistance|Intraocular assistance in patients undergoing standard of care vitreous surgeries
89370981|NCT02410564|Placebo Comparator|Waitlist control condition|No advice regarding sleep will be given to the control group and if participants ask, they will be informed that such advice can be provided in a few weeks if they choose to crossover to the treatment condition at the end of the study.
89370982|NCT05046730|Experimental|Prospective Evaluation of the SFM Device|This is a multicenter, single-arm study in which clinical outcomes prospectively evaluated for a minimum of 100 subjects undergoing ileostomy reversal using the SFM Anastomosis Device
89370983|NCT05046730|Active Comparator|Retrospective Chart Review of Historical Controls|In order to have a sufficient pool of retrospective patients for matching, retrospective data will be collected for a minimum of 300 patients. The historical control cohort will be accrued from the same pool of institutions participating in the prospective study.
89370984|NCT05200494|No Intervention|Flexible Bronchoscopy without Recruiting Maneuver|At the end of the bronchoscopy, no further interventions or ventilator maneuvers will be done.
89370985|NCT05200494|Experimental|Flexible Bronchoscopy with Recruiting Maneuver|At the end of the bronchoscopy, a recruiting maneuver will be applied to the patients. Recruiting Maneuver consists in the application of an airway pressure of 30 cmH2O for a period of 30 seconds.
88843692|NCT03447782|Experimental|NDPH Persistent|"Patients will be evaluated in clinic 1 month after the phone call evaluation. At this time, patients will begin a 3 month trial of low-dose naltrexone (Naltrexone HCL powder compounded to provide 4.5mg once per day orally).~Patients will be evaluated in clinic 3 months after beginning treatment with naltrexone."
88843693|NCT03447782|No Intervention|Healthy Controls|These participants will be in the research study for the initial visit only. They will be evaluated by a physician or nurse practitioner
88843694|NCT03109951|Other|Diabetes group|Type 2 diabetes patients undergoing colonoscopy with preparation with 2L of polyethylene glycol.
88843695|NCT03408704|Experimental|ASP-arm|This group of primary health care centers get the internal education (ASP).
88843696|NCT03408704|No Intervention|Control-arm|No intervention at all.
88843697|NCT03123055|Experimental|B-701 (vofatamab)|B-701 (vofatamab, 25 mg/kg) will be administered via IV infusion on Cycle 0 Day 1 for a single 14-day cycle.
88843698|NCT03123055|Experimental|B-701 (vofatamab) plus pembrolizumab|B-701 (vofatamab, 25 mg/kg [or the recommended Phase 2 dose if different than 25 mg/kg]) plus pembrolizumab (200 mg) will be administered by IV infusion on Cycle 1 Day 1 once every 3 weeks.
88843699|NCT03340532|Placebo Comparator|Sleep hygiene video|Participants will watch a sleep hygiene video
88843700|NCT03340532|Experimental|Information video|The INFORMATION SunSmart video providing basic information about UV risks, including secondary skin cancer and the benefits of SP, as well as specific SP recommendations and steps to integrate SP as part of routine self-care for the healthy cancer survivor
89189295|NCT02575638|Experimental|Treatment population|The study drug, CZ48, is administered orally in capsule form t.i.d. Capsules in 30mg and 50mg of drug are available for dosing. This is a dose escalation study so dosage has not yet been determined. Study drug is take on day 1 - 5 and then no drug on day 6 and 7. This is repeated for 4 weeks, or one course.
88843701|NCT03340532|Experimental|Information + Appearance video|THE INFORMATION + APPEARANCE VIDEO which will include the full information video, along with an additional embedded video segment emphasizing negative appearance consequences of UV exposure.
88843702|NCT03124069|Experimental|F&P Saturn|Participants will be placed on this arm for a total of 14 ± 5 days from Visit 2. Participants will be using the trial nasal mask during this treatment arm.
88843703|NCT02969317|Experimental|Tiotropium + olodaterol fixed-dose combination|Fixed dose combination
88843704|NCT03314168|Active Comparator|Control group|Patients who are randomized in control group will receive the usual care in their respective hospital.
88843705|NCT03314168|Experimental|Single-set group|Patients who are randomized in Single-set (SS) group, will receive 12-week of combined training, twice a week, composed by 10 resistance exercises and 20-25 minutes aerobic exercise at 80-95% of the second ventilatory threshold heart rate in a cycle. One-single set will be performed per exercise at 60-80%1-RM, with 1-1,5min of rest between the exercises.
89189296|NCT02573610|Experimental|DE-108|High concentration / Antibacterial Ophthalmic Solution
89370986|NCT03176992|Active Comparator|Surgicel group|80 patients underwent formal curettage followed by insertion of 4 pieces of Surgicel inside the uterine cavity
88809873|NCT01212107|Experimental|Part A: 24 mg FGF Receptor BID|"Part A: Dose escalation~24 mg FGF receptor given orally BID for a minimum of (1) 28 day cycle.~If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)."
88809874|NCT01212107|Experimental|Part A: 18 mg FGF Receptor BID Extension|"Part A: Dose escalation~18 mg FGF Receptor given orally BID for a minimum of (1) 28 day cycle.~If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)"
88809875|NCT01212107|Experimental|Part A: 16 mg FGF Receptor BID|"Part A: Dose escalation~16 mg FGF Receptor given orally BID for a minimum of (1) 28 day cycle.~If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)"
88809876|NCT01212107|Experimental|Part B: 16 mg FGF Receptor BID|"Part B: Dose determined by part a dose escalation~16 mg FGF Receptor given orally BID for a minimum of (1) 28 day cycle.~If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)"
88809877|NCT03808064|Experimental|Intervention arm|After randomization, the FCHVs in the intervention arm will receive training, health education materials and a recording register. After receiving training, they will educate women of their respective ward on cervical cancer screening and prevention through home visits and maintain records in their service register.
88809878|NCT03808064|No Intervention|Control arm|There won't be any intervention in the control arm.
88809879|NCT04271306|Experimental|Groups 1A & 1B|Volunteers aged 18-45 years will receive doses of Pfs25-IMX313 (10µg)/Matrix-M (50µg) intramuscularly at months 0, 1 and 2
88809880|NCT04271306|Experimental|Groups 2A & 2B|Volunteers aged 18-45 years will receive doses of Pfs25-IMX313 (50µg)/Matrix-M (50µg) intramuscularly at months 0, 1 and 2
88809881|NCT04271306|Experimental|Groups 3A & 3B|Volunteers aged 5-12 years will receive doses of Pfs25-IMX313 (10µg)/Matrix-M (50µg) intramuscularly at months 0, 1 and 2
88809882|NCT04271306|Experimental|Group 3C|Volunteers aged 5-12 years will receive doses of Pfs25-IMX313 (10µg)/Matrix-M (50µg) intramuscularly at months 0, 1 and 6.5
88809883|NCT04271306|Experimental|Groups 4A & 4B|Volunteers aged 5-12 years will receive doses of Pfs25-IMX313 (50µg)/Matrix-M (50µg) intramuscularly at months 0, 1 and 6.5
88809884|NCT04271306|Experimental|Group 4C|Volunteers aged 5-12 years will receive doses of Pfs25-IMX313 (50µg)/Matrix-M (50µg) intramuscularly at months 0 and 1 and a dose of Pfs25-IMX313 (10µg)/Matrix-M (50µg) intramuscularly at month 6.5
88809885|NCT01246895||Experimental|Microfracture with BST-CarGel
88809886|NCT01246895||Control|Microfracture without BST-CarGel
88809887|NCT03800420|Experimental|BBT-401-1S|BBT-401-1S, Oral capsule, QD
88809888|NCT03800420|Placebo Comparator|Placebo|Placebo, Oral capsule, QD
88809889|NCT01299077||Lumbar disc degenerative disease|Triple therapy (MBL+ MYO+ NSAIDs) which prescribed by doctors (Drs) based on disease condition
88809890|NCT03802760||TAVI patients|Patients undergoing transfemoral TAVI
88809891|NCT03802760||MitraClip patients|Patients undergoing MitraClip implantation
88809892|NCT03802760||TricuspidalClip|Patients undergoing TricuspidalClip implantation
88809893|NCT04345484|Experimental|GMT Intervention + Health Lifestyle Program|The intervention group will participate in GMT, a standardized cognitive rehabilitation program which will be given as per the manual and which consists of 9 sessions each 2-hours in duration. They will also participate in the Healthy Lifestyle Program (HLP), which includes physical activity monitoring (step count, calories burned and sleep) with the Garmin vívofit 4 Activity Tracker, and recording and monitoring of goals with the My Goals app. Moreover, participants will be offered an exercise program with weaning to community-based resources and home exercise recommendations for longer-term sustainability.
88809894|NCT04345484|Active Comparator|Health Lifestyle Program|The control group enters directly into the HLP without any other study visits. The HLP includes physical activity monitoring (step count, calories burned and sleep) with the Garmin vívofit 4 Activity Tracker, and recording and monitoring of goals with the My Goals app. Moreover, participants will be offered an exercise program with weaning to community-based resources and home exercise recommendations for longer-term sustainability.
88809895|NCT01247285|Experimental|Investigational Test Product|90 mg Fluoxetine Hydrochloride Capsules (Teva)
88809896|NCT01247285|Active Comparator|Reference Listed Drug|90 mg PROZAC WEEKLY® Capsules (Eli Lilly)
88809897|NCT03806582|Active Comparator|intervention|intervention with norepinephrine to reach a MAP of 85 mmHg for a maximum duration of 1 hour, observation of the effect on right ventricular function
88809898|NCT03806582|No Intervention|control|control group; treatment according to current standards, observation of the effect on right ventricular function
88809899|NCT00779558|Active Comparator|Study drug|Heparin sulfate infusion at 10 units/kg/hour
88809900|NCT00779558|Placebo Comparator|Placebo|Placebo - normal saline infusion
88809901|NCT01300559|Experimental|Treatment Group|Tissuelink device plus Unipolar electrocautery will be used in this arm of the study.
88809902|NCT01300559|No Intervention|No treatment|Unipolar electrocautery without Tissuelink device will be used in this arm of the study.
88809903|NCT03806894||Jewish communities|Ashkenazi, Sephardi, Ethiopian
88809904|NCT03806894||Arab populations|Muslim, Christian, Druze
88809905|NCT01300949|Active Comparator|Glaucoma|154 glaucoma, ocular hypertension and glaucoma suspect patients will have contrast sensitivity measured by Spaeth/Richman Contrast Sensitivity Test (SPARCS) and Pelli-Robson Contrast Sensitivity Chart.
89370987|NCT03176992|No Intervention|Thermal balloon ablation group|80 patients underwent thermal balloon ablation using bipolar radiofrequency electrical energy (Novasure)
88843706|NCT03314168|Experimental|Multiple-sets group|Patients who are randomized in Multiples-set (MS) group, will receive 12-week of combined training, twice a week, composed by 10 resistance exercises and 20-25 minutes aerobic exercise at 80-95% of the second ventilatory threshold heart rate in a cycle. Regarding resistance exercises, three set will be performed per exercise at 60-80%1-RM, with 1-1,5min of rest between sets and the exercises.
88843707|NCT03307226|Experimental|Youth Development Accounts (YDA)|"Youth Development Accounts (YDA)~Youth Development Accounts (YDA) with 1:1 incentive match rate to be used for education and microenterprise development~Financial workshops on asset-building, saving and investing in Income Generating Activities (IGAs) Behavioral: Youth Development Accounts (YDA)"
88843708|NCT03307226|Experimental|YDA + Multiple Family Groups (MFG)|"YDA + Multiple Family Groups (MFG)~Youth Development Accounts (YDA) with 1:1 incentive match rate to be used for education and microenterprise development~Financial workshops on asset-building, saving and investing in Income Generating Activities (IGAs)~Multiple Family Groups sessions focused on strengthening family relationships and mental health"
88843709|NCT03307226|No Intervention|Usual Care|Usual Care consisting of curricula delivered at secondary schools in Uganda including Life Planning Skills, and Adolescent Sexual Reproductive Health
88843710|NCT03124693|Experimental|Test Group|All subjects are enrolled into the test group and all subjects received the Rainbow DCI pulse oximeter sensor.
88843711|NCT03288194|Experimental|Problem-Solving Treatment|Problem-Solving Treatment is a structured, yet flexible, form of cognitive-behavioral psychotherapy intended to increase problem-solving skills.
88843712|NCT03288194|Active Comparator|Time Management|Time Management is a structured, yet flexible, intervention intended to increase creativity.
89180603|NCT00719043|Experimental|A/Indonesia primed-Placebo-A/turkey Influenza (H5N1)-F4-Group|Healthy subjects aged 18 years of age or older at the time of enrolment were primed with one dose of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) formulation 4 at Day 0, one dose of placebo (phosphate buffered saline, PBS) at Day 182 followed by one booster dose of A/turkey H5N1 vaccine formulation 4 at Day 549. Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) and A/turkey H5N1 vaccines were administered intramuscularly in the deltoid region of the non-dominant arm while, Placebo vaccine was administered intramuscularly in the deltoid region of the dominant arm.
88843713|NCT03124771|Experimental|Rainbow Resposable Adhesive Sensors|All subjects are enrolled into the test group and all subjects received the Rainbow Resposable Adhesive Sensors.
88843714|NCT05357300|Active Comparator|Peripheral Nerve Stimulation|Implant of percutaneous leads and impulse generator for peripheral nerve stimulation
88843715|NCT05357300|No Intervention|Best Medical Treatment|Physical therapy and therapy with analgetic medication
88843716|NCT05347082|Experimental|Vitamin D|8000 IU of vitamin D orally, once a day, for four weeks.
88843717|NCT05235139|Experimental|IOL implantation experimental|Experimental arm: Premium monofocal intraocular lens.
88843718|NCT05235139|Active Comparator|IOL implantation active comparator|Comparator arm: EDOF intraocular lens.
88843719|NCT03124927|Experimental|Test Group|All subjects are enrolled into the test group and all subjects receive DCI pulse oximeter sensor.
88843720|NCT03125005|Experimental|Rainbow Universal Pulse Oximeter Sensor|All subjects will be enrolled in the test group and will receive Rainbow Universal Pulse Oximeter Sensor.
88843721|NCT03087578|Experimental|EA|Patients undergoing electroacupuncture weekly for 6 weeks for 30 minutes/session.
88843722|NCT03087578|Active Comparator|Medication|Patients will receive 50 mg of mirabegron daily for 6 weeks. Patients may continue to take this medication after the study if they have improvement in symptoms.
88843723|NCT02971735|Experimental|interactive multimedia module|Subjects allocated to this experimental group will receive an intervention of mobile technology of e-learning (M-TEL) using the interactive multimedia (IM) module consist of integrated text, images, and small game tests (intervention) for 100 minutes. The module is a non-linearity of learning with interaction (student-based choice and pop-up feedback). This context has been adjusted to the same level to that of the PPS module.
88843724|NCT02971735|Active Comparator|Power Point show module|Subjects allocated to this experimental group will receive an intervention of mobile technology of e-learning (M-TEL) using the Power Point show (PPS) module consist of integrated text, images, and audio (intervention) for 100 minutes. The module is a linear learning without interaction. This context has been adjusted to the same level to that of the IM module.
88843725|NCT02907086||colorectal cancer|
88843726|NCT02907086||melanoma|
89189297|NCT02573610|Active Comparator|Levofloxacin 0.5%|Low concentration / Antibacterial Ophthalmic Solution
89189298|NCT02575560||weekly use erolotinib vs history data|Drug: erolotinib erolotinib 1050mg, oral, once a week, continues to disease progression or death or stop by physician
89189299|NCT00710190|Experimental|Rheos Implant|
89189300|NCT00715182|Experimental|TKI258|
89370988|NCT03176992|No Intervention|Endometrial resection group|80 patients underwent transcervical Hysteroscopic endometrial resection
89370989|NCT05328336|Experimental|Experimental: Tislelizumab and Nab Paclitaxel|Experimental: Tislelizumab and Nab Paclitaxel Tislelizumab 200mg IV on day 1 in combination with nab paclitaxel 200mg IV on day 2 every 3 weeks for 3 cycles followed by surgery.
89180604|NCT00719043|Experimental|A/Indonesia primed-Placebo-A/turkey Influenza (H5N1)-F2-Group|Healthy subjects aged 18 years of age or older at the time of enrolment were primed with one dose of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) formulation 2 at Day 0, one dose of placebo (phosphate buffered saline, PBS) at Day 182 followed by one booster dose of A/turkey H5N1 vaccine formulation 2 at Day 549. Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) and A/turkey H5N1 vaccines were administered intramuscularly in the deltoid region of the non-dominant arm while, Placebo vaccine was administered intramuscularly in the deltoid region of the dominant arm.
88843727|NCT05339282|Experimental|The experimental group in acute cholecystitis|"inclusion criteria~among patients with mild acute cholecystitis (grade I by Tokyo guidelines) or moderate acute cholecystitis without evidence of gallbladder perforation(grade II)~cholecystitis with a thickness of 4 mm or more on gallbladder in preoperative imaging~Gallbladder with surrounding organs due to gallbladder inflammation~Patients over 19 years of age~normal saline (Isotonic Sodium Chloride Injection Daihan(50mL/bag)) was used before surgery."
88843728|NCT05339282|Experimental|The controled group in acute cholecystitis|"among patients with mild acute cholecystitis (grade I by Tokyo guidelines) or moderate acute cholecystitis without evidence of gallbladder perforation(grade II)~cholecystitis with a thickness of 4 mm or more on gallbladder in preoperative imaging~Gallbladder with surrounding organs due to gallbladder inflammation~Patients over 19 years of age~First-generation cephalosporin (Cefazolin inj., 1g, Cefazolin sodium, Chong-geun-dang pharm.co.) was used before surgery."
88843729|NCT02975557|Active Comparator|Brimonidine 0.15%|Brimonidine 0.15% eye drops 2 times a day for 12 weeks
88843730|NCT02975557|Active Comparator|Brimonidine 0.075%|Brimonidine 0.075% (1:1 dilution will be performed using 0.15% Alphagan-P solution with Refresh Plus Artificial Tears solution) eye drops 2 times a day for 12 weeks.
88843731|NCT02975557|Placebo Comparator|Placebo|Placebo (Refresh plus Artificial Tear) dispensed in Brimonidine bottles 2 times a day for 12 weeks.
88843732|NCT02642588|Experimental|energy gel|women will be given 22 g of carbohydrates every 45-60 minutes for up to 8 hours or until delivery during the active phase of labor
88843733|NCT02642588|No Intervention|control|women will be given only clear liquids during labor
88843734|NCT04736810|Experimental|AK105 plus Cisplatin, Gemcitabine and Anlotinib Hydrochloride|
89180605|NCT00719043|Placebo Comparator|Naïve Placebo-A/turkey Influenza (H5N1)-F3-Group|Healthy subjects aged 18 years of age or older at the time of vaccination received one dose of placebo (phosphate buffered saline, PBS) at Day 0 followed by two doses of A/turkey H5N1 vaccine formulation 3, one dose administered at Day 182 and the other at Day 549. Placebo vaccine and one dose of A/turkey H5N1 vaccine (Day 549) was administered intramuscularly in the deltoid region of the non-dominant arm while the other dose of A/turkey H5N1 vaccine (Day 182) was administered intramuscularly in the deltoid region of the dominant arm.
89180606|NCT00786422|Experimental|Rivaroxaban (Xarelto, BAY59-7939)|
89180607|NCT00718887|Experimental|Entecavir, 0.5 mg QD|
89180608|NCT00718887|Other|Adefovir, 10 mg QD/Entecavir, 0.5 mg QD|Control
89180609|NCT00786188|Experimental|Brisdelle (paroxetine mesylate)|Eligible subjects will be randomized to receive Brisdelle (paroxetine mesylate) Capsules 7.5 mg.
89180610|NCT00786188|Placebo Comparator|Placebo - Sugar Pill|Eligible subjects will be randomized to receive a sugar pill.
89180611|NCT00790556|Experimental|1|MK8245
89180612|NCT00790556|Placebo Comparator|2|Placebo Comparator
89180613|NCT04112732|Experimental|Multivitamin|1 multivitamin tablet administered by mouth daily for 12 weeks, to be taken with main meal.
88843735|NCT04736810|Experimental|AK105 plus Cisplatin and Gemcitabine|
89180614|NCT04112732|Placebo Comparator|Placebo|1 placebo tablet administered by mouth daily for 12 weeks, to be taken with main meal.
89180615|NCT00733824|Experimental|Cohort 1|"240 µg/kg SC AMD3100 Day -5~10 µg/kg SC G-CSF Day -4 thru Day -1~160 µg/kg IV AMD3100 and 10 µg/kg SC G-CSF Day 1~Pheresis (this will be repeated on Day 2 through Day 4 until target of ≥5X106 CD34+ cell/kg is reached)"
89180616|NCT00733824|Experimental|Cohort 2|"240 µg/kg SC AMD3100 Day -5~10 µg/kg SC G-CSF Day -4 thru Day -1~240 µg/kg IV AMD3100 and 10 µg/kg SC G-CSF Day 1~Pheresis (this will be repeated on Day 2 through Day 4 until target of ≥5X106 CD34+ cell/kg is reached)"
89180617|NCT00733824|Experimental|Cohort 3|"240 µg/kg SC AMD3100 Day -5~10 µg/kg SC G-CSF Day -4 thru Day -1~320 µg/kg IV AMD3100 and 10 µg/kg SC G-CSF Day 1~Pheresis (this will be repeated on Day 2 through Day 4 until target of ≥5X106 CD34+ cell/kg is reached)"
89180618|NCT00733824|Experimental|Cohort 4|"240 µg/kg SC AMD3100 Day -5~10 µg/kg SC G-CSF Day -4 thru Day -1~400 µg/kg IV AMD3100 and 10 µg/kg SC G-CSF Day 1~Pheresis (this will be repeated on Day 2 through Day 4 until target of ≥5X106 CD34+ cell/kg is reached)"
89180619|NCT00733824|Experimental|Phase II|"240 µg/kg SC AMD3100 Day -5~10 µg/kg SC G-CSF Day -4 thru Day -1~MTD as determined in Phase I IV AMD3100 and 10 µg/kg SC G-CSF Day 1~Pheresis (this will be repeated on Day 2 through Day 4 until target of ≥5X106 CD34+ cell/kg is reached)"
89180620|NCT00718809|Experimental|Arm I|Patients receive oral saracatinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88843736|NCT04736810|Experimental|AK105 plus Gemcitabine and Anlotinib Hydrochloride|
88843737|NCT05267990|Active Comparator|coronary artery calcium-guide|"1500 asymptomatic T2DM patients who will receive Coronary artery calcium (CAC) imaging using 256 sliced multi-detector computerized tomography (MDCT) scanner If CAC score >0, Treadmill ECG or Thallium201 Scan would be arranged. If Treadmill ECG or Thallium201 show significant ischemia, further study such as CT angiography or coronary angiography will be arranged.~If CAC score > 100， Aspirin 100mg QD will be suggested to decrease the cardiovascular risk in patients with low risk of bleeding. Previous studies revealed aspirin for patients with CAC score>100 at low bleeding risk indicated net benefit If CAC score > 400，statin therapy will be suggested to control lipidemia aggressively and target LDL level<70 mg/dL"
88843738|NCT05267990|No Intervention|usual care|The investigators will enroll 500 age, gender, risk factor matched T2DM patient from our hospital. The doctor in charge will give usual care according to the Diabetes associate of Taiwan clinical practice guidelines for diabetes care.
88843739|NCT03132571|Experimental|Naltrexone with Bupropion|Oral Naltrexone taken once a day and Oral Bupropion taken once a day for 16 weeks.
88843740|NCT03132571|Placebo Comparator|Placebo with Bupropion|Oral placebo capsule and Oral Bupropion taken once a day for 16 weeks.
89180621|NCT04086069|Experimental|Standard Training+Sit-to-stand trainer|Training using a sit-to-stand trainer device in addition to standard training of standing-up with the help of a physiotherapist
89180622|NCT04086069|No Intervention|Standard Training|Standard training of standing-up with the help of a physiotherapist
89180623|NCT00585039|Experimental|A|levalbuterol nebulization
89180624|NCT04085913|Active Comparator|Current Practice|Thyroid or parathyroid surgery with local injection of lidocaine and epinephrine preincision, as is current practice.
89180625|NCT04085913|Experimental|Bupivicaine HCL|Thyroid or parathyroid surgery with local injection of bupivicaine HCL and Epinephrine preincision.
89180626|NCT04085913|Experimental|Exparel Injection|Thyroid and parathyroid surgery with local injection of lidocaine and epinephrine preincison and Exparel postincision
89180627|NCT00806195|Experimental|MenACWY-CRM197 + Routine Vaccines (Non-Detailed)|"Infants received one vaccination of MenACWY-CRM197 vaccine at 2, 4, 6 and 12 months of age and one vaccination of routine vaccines (according to the local vaccination schedule) - DTaP: 2, 4, 6, 15 months, IPV: 2, 4, 6, months, Hib: 2, 4, 6, 15 months, Pneumococcal conjugate: 2, 4, 6, 12 months, MMR: 12 months.~Routine vaccines given to subjects in these arms will be consistent with the US ACIP recommended vaccines.~Non-Detailed - infants who only provided SAEs (Serious Adverse Events) and medically attended AEs (Adverse Events)."
89180628|NCT00806195|Active Comparator|Routine Vaccines (Non-Detailed)|"Infants received one vaccination of routine vaccines (according to the local vaccination schedule) - DTaP: 2, 4, 6, 15 months, IPV: 2, 4, 6 months, Hib: 2, 4, 6, 15 months, Pneumococcal conjugate: 2, 4, 6, 12 months, MMR: 12 months.~Routine vaccines given to subjects in these arms will be consistent with the US ACIP recommended vaccines.~Non-Detailed - subjects who only provided SAEs and medically attended AEs."
89180629|NCT00806195|Experimental|MenACWY-CRM197 + Routine Vaccines (Detailed)|"Infants received one vaccination of MenACWY-CRM197 vaccine at 2, 4, 6 and 12 months of age and one vaccination of routine vaccines (according to the local vaccination schedule) - DTaP: 2, 4, 6, 15 months, IPV: 2, 4, 6, months, Hib: 2, 4, 6, 15 months, Pneumococcal conjugate: 2, 4, 6, 12 months, MMR, Varicella, Hepatitis A: 12 months. HBV and rotavirus vaccines should be administered according to ACIP guidelines during the first year of life.~Routine vaccines given to subjects in these arms will be consistent with the US ACIP recommended vaccines.~Detailed - subjects who provided Reactogenicity and all AEs for 7 days, SAEs and medically attended AEs."
89180630|NCT00806195|Active Comparator|Routine Vaccines (Detailed)|"Infants received one vaccination of routine vaccines (according to the local vaccination schedule) - DTaP: 2, 4, 6, 15 months, IPV: 2, 4, 6 months, Hib: 2, 4, 6, 15 months, Pneumococcal conjugate: 2, 4, 6, 12 months, MMR, Varicella, and Hepatitis A: 12 months. HBV and rotavirus vaccines should be administered according to ACIP guidelines during the first year of life.~Routine vaccines given to subjects in these arms will be consistent with the US ACIP recommended vaccines.~Detailed - subjects who provided Reactogenicity and all AEs for 7 days, SAEs and medically attended AEs."
89180631|NCT00806195|Experimental|MenACWY-CRM197 + Routine Vaccines (All)|"Infants received one vaccination of MenACWY-CRM197 vaccine at 2, 4, 6 and 12 months of age and one vaccination of routine vaccines (according to the local vaccination schedule) - DTaP: 2, 4, 6, 15 months, IPV: 2, 4, 6, months, Hib: 2, 4, 6, 15 months, Pneumococcal conjugate: 2, 4, 6, 12 months, MMR, Varicella, Hepatitis A: 12 months. HBV and rotavirus vaccines should be administered according to ACIP guidelines during the first year of life.~Routine vaccines given to subjects in these arms will be consistent with the US ACIP recommended vaccines.~All (Detailed and Non-Detailed subjects): Detailed - subjects who provided Reactogenicity and all AEs for 7 days, SAEs and medically attended AEs; Non-Detailed - subjects who only provided SAEs and medically attended AEs."
89180632|NCT00806195|Active Comparator|Routine Vaccines (All)|"Infants received one vaccination of routine vaccines (according to the local vaccination schedule) - DTaP: 2, 4, 6, 15 months, IPV: 2, 4, 6, months, Hib: 2, 4, 6, 15 months, Pneumococcal conjugate: 2, 4, 6, 12 months, MMR, Varicella, and Hepatitis A: 12 months. HBV and rotavirus vaccines should be administered according to ACIP guidelines during the first year of life.~Routine vaccines given to subjects in these arms will be consistent with the US ACIP recommended vaccines.~All (Detailed and Non-Detailed subjects): Detailed - subjects who provided Reactogenicity and all AEs for 7 days, SAEs and medically attended AEs; Non-Detailed - subjects who only provided SAEs and medically attended AEs."
89180633|NCT02922335|Experimental|Multisystemic Therapy - Emerging Adults|Multisystemic Therapy for Emerging Adults (MST-EA) is designed to help emerging adults (ages 18-21) with mental illness who have been in trouble with the law. MST-EA is a treatment program specifically for emerging adults, to increase skills and capacities that can help them reduce their antisocial behavior and help reduce problems caused by mental health illness, and alcohol or drug use when present.
89180634|NCT02922335|Active Comparator|Enhanced Treatment as Usual|With Enhanced Treatment as Usual (E-TAU) emerging adults will get the treatments that they usually receive when they have a mental illness and have been in trouble with the law. They will receive travel vouchers for attending services, a card with an individualized list of contacts when in crisis, and facilitation with identifying need of services and accessing those services.
89180635|NCT05752877|Experimental|Interventional Group|
89189301|NCT04070586||4DCBCT images|4DCBCT images are acquired and assessed offline.
89370990|NCT02410408|Active Comparator|Control|Information package about patient safety certification or how to conduct Root Cause Analysis
89370991|NCT02410408|Experimental|Experimental|Apps: Root Cause Analysis or patient safety ISO certification
89370992|NCT03176680|Experimental|Fluid therapy optimization|Fluid loading to optimize stroke volume after induction.
89370993|NCT03176680|No Intervention|Fluid therapy normalization|No fluid loading after induction.
89370994|NCT02410486||EOS infant / mother with chorio|Infant with EOS (Gram-positive or Gram-negative) and mother with Chorioamnionitis
89370995|NCT02410486||EOS infant / mother without chorio|Infant with EOS (Gram-positive or Gram-negative) and mother without Chorioamnionitis
89370996|NCT02410486||EOS Gram-neg infant / mother with chorio|Infant with Gram-negative EOS and mother with Chorioamnionitis
89370997|NCT02410486||Gram-neg infant / mother without chorio|Infant with Gram-negative EOS and mother without Chorioamnionitis
89370998|NCT02410486||Gram-pos infant / mother with chorio|Infant with Gram-positive EOS and mother with Chorioamnionitis
89370999|NCT02873754|Experimental|STEP UP|STEP UP is an intervention that combines evidence-based telephone cognitive behavioral counseling for smoking cessation, access to nicotine replacement therapy (NRT; including transdermal nicotine patch and either nicotine polacrilex or nicotine lozenge) and bupropion, and intensive mobile contingency management behavioral therapy administered via a smart-phone based application.
89371000|NCT03287414|Experimental|VAY736|Participants received 300 mg VAY736 administered subcutaneously every 4 weeks for 48 weeks on top of current standard-of-care therapy
89371001|NCT03287414|Placebo Comparator|Placebo|Participants received placebo administered subcutaneously every 4 weeks for 48 weeks on top of current standard-of-care therapy
89371002|NCT03174886|Experimental|AADvac1 40 µg|The intervention consists of Axon Peptide 108 coupled to keyhole limpet haemocyanin (KLH) 40 µg/0.30 mL suspension for injection; and aluminium hydroxide Al(OH)3 (containing approx. 0.5 mg Al3+/0.30 mL), administered subcutaneously. The basic immunisation regimen consists of 6 doses administered subcutaneously in 6-week intervals. Subsequently, 5 booster doses are applied in 13-week intervals, for a total of 11 administrations.
89371003|NCT03174886|Experimental|AADvac1 160 µg|The intervention consists of Axon Peptide 108 coupled to KLH 160 µg/0.30 mL suspension for injection; and aluminium hydroxide Al(OH)3 (containing approx. 0.5 mg Al3+/0.30 mL), administered subcutaneously. The basic immunisation regimen consists of 6 doses administered subcutaneously in 6-week intervals. Subsequently, 5 booster doses are applied in 13-week intervals, for a total of 11 administrations.
89371004|NCT02415868||Low pH|Post Menopausal women with vaginal pH of 4.5 or below
89371005|NCT02415868||High pH|Post Menopausal women with vaginal pH of 5.5 or above
89371006|NCT05348460|Other|Ketone - Placebo treatment|Patients will first receive a supplemental drink containing a ketone ester before performing the 31P MRS exercise protocol. After 1-2 weeks, subjects will cross-over and repeat the 31P MRS exercise protocol, this time after receiving the placebo treatment.
89371007|NCT05348460|Other|Placebo - Ketone treatment|Patients will first receive a placebodrink before performing the 31P MRS exercise protocol. After 1-2 weeks, subjects will cross-over and repeat the 31P MRS exercise protocol, this time after receiving the supplemental drink containing a ketone ester.
89371008|NCT02415790|Experimental|Part A: PK of E2027 in healthy adults|Part A consists of 6 sequential cohorts of healthy adults. There will be 8 participants in each cohort, with 6 participants randomized to E2027 and 2 participants to placebo.
89371009|NCT02415790|Experimental|Part B: PK and PD of E2027 in healthy adults|Part B consists of 4 sequential cohorts of healthy adult participants. There will be 8 participants in the 1st cohort, with 6 participants randomized to E2027 and 2 participants to placebo. In the 2nd to 4th cohorts, there will be 7 participants in each cohort, with 6 participants randomized to E2027 and 1 participant to placebo. Participants in the 2nd cohort will then receive placebo/the same dose of E2027 again after their washout period in the fed state for the evaluation of food effect.
89371010|NCT02415790|Experimental|Part C: PK of E2027 in elderly cohorts|In Part C, 1 cohort of 8 healthy elderly participants will be enrolled, with 6 participants randomized to E2027 and 2 participants to placebo.
89371011|NCT02415790|Experimental|Part D: PK of E2027 in healthy Japanese adults|In Part D, there will be 3 cohorts of 7 healthy adult Japanese participants, with 6 participants randomized to E2027 and 1 participant to placebo.
89371012|NCT03644160|Experimental|Intervention Group|Physical activity and behaviour change The intervention group (group A) will receive an 8 week individualised, tailored behaviour change intervention to promote PA and an information booklet about physical activity with a physiotherapist who has training in behaviour change techniques and motivational interviewing. Using a range of behaviour change and self-regulation techniques (eg goal-setting, self-monitoring), participants will be guided towards physical activity maintenance at the end of the 8 weeks. In addition, participants will be signposted to physical activity classes, facilities and resources in the local community. This group will continue with their routine care for their condition throughout the study period.
89371013|NCT03644160|No Intervention|Control Group|The control group (Group B) will receive the same information booklet about physical activity only. This group will continue with their routine care for their condition throughout the study period.
89371014|NCT03669614|Experimental|AR-501 inhaled|Four doses (low, medium, high, top) of inhaled AR-501 will be used.
89371015|NCT03669614|Placebo Comparator|inhaled AR-501 Placebo|Four doses (low, medium, high, top) of inhaled placebo will be used
89371016|NCT02415946|Active Comparator|Sinus floor augmentation (lateral)|Maxillary sinus floor elevation using a lateral approach
89371017|NCT02415946|Experimental|Sinus floor augmentation (transcrestal)|Maxillary sinus floor elevation using a transcrestal approach (Smart Lift technique; Trombelli et al. 2008)
89371018|NCT05200260|Experimental|Upfront cytoreductive surgery with maintenance therapy|Primary debulking surgery with a maximal cytoreduction of complete gross resection within 3 weeks after biopsy, followed by at least 6 cycles of adjuvant chemotherapy and maintenance therapy for patients with CR/PR after platinum-based therapy.
89371019|NCT05200260|Active Comparator|Neoadjuvant chemotherapy with maintenance therapy|Neoadjuvant chemotherapy with 3 cycles of chemotherapy, then followed by interval debulking surgery. The maximal time interval between course 3 chemotherapy and IDS is 6 weeks. And then 3 cycles of adjuvant chemotherapy and maintenance therapy for patients with CR/PR after platinum-based therapy.
89371020|NCT02415634|Experimental|Intervention|Intervention Participants in the experimental group will receive usual care plus the RECAP with ICU therapist follow up after ICU discharge. This will be provided for a period of 3 weeks after intensive care unit discharge.
88843741|NCT02735720||TEVAR group|"Adult patients whose clinician's are managing their thoracic aortic aneurysms or with penetrating aortic ulcers with TEVAR.~Standard work-up examinations for TEVAR will be collected, consisting of computed tomography (CT), echocardiography, blood pressure, heart rate, ECG and blood tests. Prior to the TEVAR procedure, a non-invasive MRI scan and blood samples will be acquired. Intraoperative pressure measurements will be collected during the TEVAR. One year following TEVAR, the subject will undergo a second non-invasive MRI study in addition to the standard clinical imaging follow-up CT-scan. Measurements of blood pressure, heart rate, ECG, and blood testing will also be repeated at follow-up."
88843742|NCT02735720||Non-TEVAR medical treatment group|"Adult patients whose clinician's are managing their thoracic aortic aneurysms or with penetrating aortic ulcers with pharmacological treatment alone.~Patients with stable thoracic aortic aneurysms or with penetrating aortic ulcers not requiring aortic repair are monitored in the outpatient clinic as standard of care. The investigators will collect blood pressures and heart rates in these patients, which are acquired as standard of care. In addition, in this study, these subjects will undergo an ECG, blood testing and one non-invasive MRI scan at baseline. One year after baseline, this group will undergo a second non-invasive MRI study, with subsequent blood pressure and heart rate measurements, ECG and blood testing."
88843743|NCT02374424|Experimental|GA101_DHAP|"Patients receive: GA101-DHAP x 2, restaging, mobilization and collection of peripheral blood stem cells, + GA101-DHAP x 2, restaging with PET and CT and consolidation with BEAM and ASCT in patients in response (CR+PR).~During the treatment period of four cycles, all patients will receive a total of four 28-day courses of chemotherapy."
88843744|NCT03134209|Experimental|Zipper surgical skin closure|Zipper surgical skin closure device applied to the most superficial layer of skin following a joint arthroplasty
88843745|NCT03134209|Active Comparator|Monocryl + Dermabond|Monocryl suture plus Dermabond is a commonly used combination of wound closure techniques today.
89371021|NCT02415634|Active Comparator|Control|Control Patients (Controls) will not receive formal (study-related) rehabilitation interventions and will only receive usual care.
89371022|NCT05579106||Covid-19 patients|Mechanically ventilated and sedated adult patients with proven COVID-19 infection by PCR of nose- or airway sample. The nociception of this patient will be monitored by the nociception level monitor for 8 hours.
89371023|NCT05579106||non-COVID-19 patients|Mechanically ventilated and sedated adult patients not infected with COVID-19 infection. The nociception of this patient will be monitored by the nociception level monitor for 8 hours.
89371024|NCT03684746||Medial Experts|Including doctors- surgeons - consultants
89371025|NCT03684746||Care specialist|including nurses - before/after care staff
89371026|NCT02416648|Experimental|CCC Counseling; baseline and 2 months|Intervention group 1 received 2 CCC Counseling sessions; at baseline and at 2 months. The intervention was a 10 to 15 minute clinic based one on one counseling session between a clinician (counselor) and a HIV positive adult patient (client). Areas covered during the brief counseling included; HIV transmission and prevention, healthy sexual practices, condom use, reduction in multiple sexual partners, beneficial disclosure, and individual risk assessment and reduction strategies.
89371027|NCT02416648|Experimental|CCC Counseling; baseline|Intervention group 2 received a session CCC Counseling session at baseline only. The intervention was a 10 to 15 minute clinic based one on one counseling session between a clinician (counselor) and a HIV positive adult patient (client). Areas covered during the brief counseling included; HIV transmission and prevention, healthy sexual practices, condom use, reduction in multiple sexual partners, beneficial disclosure, and individual risk assessment and reduction strategies.
89371028|NCT02416648|No Intervention|Routine care|The control group received routine clinic care.
89371029|NCT03684668|Experimental|Psychoeducational intervention|The psychoeducational intervention, with the use of meta-universes,consists of three sessions in which techniques based on three of the four sources of self-efficacy described are applied.
89371030|NCT03684668|No Intervention|Control|The control arm will not receive the psychoeducational intervention. Students in this group will complete the questionnaires before the beginning of the intervention and after its end.
89371031|NCT03174964|Experimental|Treatment group|IVIg group
89371032|NCT03174964|No Intervention|Control group|Patients who do not receive any treatment despite a history of Recurrent Implantation Failure problem as controls
89371033|NCT03684434|Experimental|Online MI plus Online CBT|An online motivational interviewing (MI) lesson will first be delivered to clients. The MI lesson is expected to take one hour to complete. No therapist support will be provided during this component of treatment. An 8-week Internet-delivered cognitive behavioural therapy (ICBT) will be then delivered to clients following completion of online MI. Clients will receive weekly support in the form of emails and phone calls from registered social workers, psychologists or supervised graduate students, who have experience delivering ICBT. Therapist will spend approximately 15 minutes per week/per client.
89371034|NCT03684434|Active Comparator|Online CBT|An 8-week Internet-delivered cognitive behavioural therapy (ICBT) will be delivered to clients. Clients will receive weekly support in the form of emails and phone calls from registered social workers, psychologists or supervised graduate students, who have experience delivering ICBT. Therapist will spend approximately 15 minutes per week/per client.
89371035|NCT02416804|Experimental|Buprenorphine|Buprenorphine group : They will apply 3 days after the spine operation.
89180636|NCT05728151|Experimental|For group A|Group A will be inducted as before in addition of giving a peribulbar block up to 5 ml ( according to the volume of the eye ) of Articaine 4 % with adrenaline 1/100000 mixed with 10IU of Hyaluronidase by a single injection technique: a 26/27 gauge needle will be inserted as far laterally as possible in the inferotemporal quadrant. Once the needle is under the globe, it will be directed along the orbital floor, passing the globe equator to a depth controlled by observing the needle/hub junction reaching the plane of the iris. After negative aspiration for blood, with the globe in primary gaze, and start injection and the injected volume will be guided by digital intraocular pressure.
89371036|NCT02416804|Active Comparator|Tramadol|Tramadol group : They will take a pill of tramadol analgesics.
89371037|NCT04933812|Other|Group Social Support Meetings and Facebook Group|Facebook group where community doulas will be providing information on various pregnancy and support topics in addition to 8 possible group Zoom meetings that will include pregnancy-related/reflection topics.
89371038|NCT03684356|Experimental|experimental|immediate implant with socket shield technique
89371039|NCT03684356|Active Comparator|control|immediate implant placement with filling the buccal gap with xenograft
89371040|NCT02416882|Other|Aerobic Exercise vs Sedentary Option|Relative Reinforcing Value of aerobic exercise versus sedentary activity will be determined.
88843746|NCT03134209|Active Comparator|Polyester mesh + Dermabond|The polyester plus Dermabond closure techniques combines the OCA topical skin adhesive with a flexible, self-adhesive polyester mesh that has proven to reduce wound cosure times and have a significant greater skin holding strength than skin staples or subcuticular sutures in one study
89371041|NCT02416882|Other|Resistance Exercise vs Sedentary Option|Relative Reinforcing Value of resistance exercise versus sedentary activity will be determined.
88843747|NCT02596412|Experimental|augmented reality (Mini-Docs) on tablet|• Cerebral-palsied children using the module with augmented reality (Mini-Docs) on tablet during TB injections in addition to regular drug techniques (experimental group)
89371042|NCT04792320|Experimental|Active bamboo charcoal|"Eligible 120 participants (group I),The other 60 eligible controls (group II) will be also randomized into ABC-treatment (A) or no-treatment (B) with a 1:1 ratio. The participants will receive CharXenPlus 4g particles ( containing ABC 2g) thrice daily for 6 months in subgroups IA and IIA.~While the patients in subgroups IB and IIB will not receive any ABC. The subgroups IA and IB will be further randomly subdivided into IAa, IAb, IBa, and IBb subsubgroups.~All the patients will receive probiotics APL-MIX2 (CharXprob) 0.8 g powder once a day in the last 3 months except those in subsubgroups IAb and IBb."
88843748|NCT02596412|No Intervention|Control|Cerebral-palsied children with the usual pain care during TB injections, which combines drug techniques to distractibility techniques (control group)
88843749|NCT03134989|Other|Cochlear implant recipients|Study group is comprised of cochlear implant patients already identified as candidates and undergoing surgery.
88843750|NCT02002130|Placebo Comparator|Placebo GABA and Placebo GAD-alum|"Placebo formulation, Maltodextrin, for Gamma-Amino Butyric Acid (GABA) capsule-identical in appearance and taste, but no active medication will be taken with meals.Number of pills based on body surface area.~Placebo GAD-alum(Glutamic Acid Decarboxylase in alum) injection- identical in appearance but no active medication will be received at baseline and 1 month."
89371043|NCT04792320|Experimental|Probiotics|"Eligible 120 participants (group I),The other 60 eligible controls (group II) will be also randomized into ABC-treatment (A) or no-treatment (B) with a 1:1 ratio. The patients will receive CharXenPlus 4g particles ( containing ABC 2g) thrice daily for 6 months in subgroups IA and IIA.~While the patients in subgroups IB and IIB will not receive any ABC. The subgroups IA and IB will be further randomly subdivided into IAa, IAb, IBa, and IBb subsubgroups.~All the patients will receive probiotics APL-MIX2 (CharXprob) 0.8 g powder once a day in the last 3 months except those in subsubgroups IAb and IBb."
89371044|NCT04792320|Experimental|Active bamboo charcoal+Probiotics|"Eligible 120 participants (group I),The other 60 eligible controls (group II) will be also randomized into ABC-treatment (A) or no-treatment (B) with a 1:1 ratio. The patients will receive CharXenPlus 4g particles ( containing ABC 2g) thrice daily for 6 months in subgroups IA and IIA.~While the patients in subgroups IB and IIB will not receive any ABC. The subgroups IA and IB will be further randomly subdivided into IAa, IAb, IBa, and IBb subsubgroups.~All the patients will receive probiotics APL-MIX2 (CharXprob) 0.8 g powder once a day in the last 3 months except those in subsubgroups IAb and IBb."
88843751|NCT02002130|Active Comparator|GABA and placebo GAD-alum|"Patients will receive the Active GABA (Gamma-Amino Butyric Acid) capsules. Each capsule 250mg. Dosage will be calculated according to body surface area of the child and divided between 2 meals/day. Larger dose taken with larger meal.~Patients will receive the GAD-alum( Glutamic Acid Decarboxylase in alum) placebo at baseline and 1 month."
89371045|NCT04792320|No Intervention|No invervention|"Eligible 120 participants (group I),The other 60 eligible controls (group II) will be also randomized into ABC-treatment (A) or no-treatment (B) with a 1:1 ratio. The patients will receive CharXenPlus 4g particles ( containing ABC 2g) thrice daily for 6 months in subgroups IA and IIA.~While the patients in subgroups IB and IIB will not receive any ABC. The subgroups IA and IB will be further randomly subdivided into IAa, IAb, IBa, and IBb subsubgroups.~All the patients will receive probiotics APL-MIX2 (CharXprob) 0.8 g powder once a day in the last 3 months except those in subsubgroups IAb and IBb."
89371046|NCT03176758|Active Comparator|Spinal block|"Intrathecal 10 mg Heavy Marcaine, 200 mcg Morphine + High volume local anesthesia infiltration Bupivacaine 5mg/ml + adrenaline 5 mcg/ml 3mg/kg ideal body weight diluted with 100cc Normal Saline~+ Total Knee Replacement ( which will not be the intervention of interest)"
89371047|NCT03176758|Active Comparator|General anesthesia|"1-3 mg IV propofol 0.5 mg/kg IV Rocuronium + Fentanyl 2-3 mcg/kg + Morphine 0.1mg/kg IV Maintenance: Volatile anesthetic + High volume local anesthesia infiltration Bupivacaine 5mg/ml + adrenaline 5 mcg/ml 3mg/kg ideal body weight diluted with 100cc Normal Saline~+ Total Knee Replacement ( which will not be the intervention of interest)"
89371048|NCT04203537|Active Comparator|CA-008 36 mg|Single administration (0.3 mg/mL concentration)
89371049|NCT04203537|Active Comparator|CA-008 60 mg|Single administration (0.5 mg/mL concentration)
89371050|NCT04203537|Active Comparator|CA-008 90 mg|Single administration (0.75 mg/mL concentration)
89371051|NCT04203537|Placebo Comparator|Placebo|Single administration
89371052|NCT05565612|Experimental|Probiotic group|"Normodigest Classic~Multi-strain probiotic mixture (15 strains) with a concentration of 7,5 x 10^9 + fructooligosaccharides~1 vial of 10 ml per day for 12 weeks"
89371053|NCT05565612|Placebo Comparator|Placebo group|"Maltodextrin-based placebo~1 vial of 10 ml per day for 12 weeks"
88843752|NCT02002130|Active Comparator|Active Oral GABA and Active GAD-alum Injection|"Patients will receive Oral GABA(Gamma-Amino Butyric Acid) 250mg capsules. Dosage (# of capsules) based on body surface area and divided between 2 meals/day.~Patients will receive a primary (at baseline)injection of recombinant human GAD(Glutamic Acid Decarboxylase) in a standard vaccine formulation with alum, and a booster injection of the same at 1 month after baseline."
89371054|NCT03177070|Experimental|Methylene Blue|Intravenous administration of methylene blue and assessment of ureteric fluorescence intraoperatively.
89371055|NCT03174808|Experimental|Mindfulness-Based Stress Reduction (MBSR)|Participants will attend group sessions led by an instructor experienced in MBSR in an academic setting.
89371056|NCT03680690||Group A|women with normal uterus,detected by hysteroscopy.
89371057|NCT03680690||Group B|Women with detected or corrected uterine cavitary lesions by hysteroscopy.
89371058|NCT05190393||Convex resection group|Patients were used hemivertebra resection procedure on convex side to treat congenital cervical scoliosis.
89371059|NCT05190393||Concave distraction group|Patients were used distraction and lateral opening procedure on concave side to treat congenital cervical scoliosis, without hemivertebra resection.
88843753|NCT03135379|Experimental|Heated gel|Patient undergoes ultrasound study using the intervention of heated ultrasound gel.
89371060|NCT03101592|No Intervention|Standard of care ART dispensing|The standard of care arm will allow ART dispensing based on usual practice at the clinic. Standard of care is anticipated to have variability in how ART is dispensed, although the approach should be consistent with applicable country guidelines at the time of study.
89371061|NCT03101592|Experimental|Three-month ART dispensing|Providers at facilities randomized to three-month ART dispensing will be expected to provide all enrolled patients with a 90-day supply of ART and associated HIV medications (cotrimoxazole and isoniazid if part of country guidelines). All other aspects of care will be as per standard of care for the enrolling clinic.
89371062|NCT03101592|Experimental|Six-month ART dispensing|Providers at facilities randomized to six-month ART dispensing will be expected to provide all enrolled patients with a 180-day supply of ART and associated HIV medications (cotrimoxazole and isoniazid if part of country guidelines). All other aspects of care will be as per standard of care for the enrolling clinic.
88843754|NCT03135379|Placebo Comparator|Room temperature gel|Patient undergoes ultrasound study using the intervention of room temperature gel.
88843755|NCT01306994||Syndrome Group|Individuals with Freeman-Sheldon, Sheldon-Hall, distal arthrogryposis type 1, or distal arthrogryposis type 3
89371063|NCT02410174|Experimental|Stereotactic Body Radiotherapy (SBRT)|Starting dose of 48Gy in 3 fractions, will escalate dose by 2 Gy per fraction (a 6Gy total dose) to a maximum dose of 20Gy x 3 fractions (TD 60 Gy in 3 fractions).
89371064|NCT01360203|No Intervention|Current Care|Patients will receive the current care provided to heart failure patients at each of the study sites
89371065|NCT01360203|Experimental|Care Transition Intervention|Care transition intervention beginning prior to discharge and through six months post-discharge.
89371066|NCT03684200|Experimental|Copenhagen adductor exercise|20 players allocated to the Copenhagen adductor exercise group complete a progressive strengthening programme comprising of the Copenhagen adductor exercise over a period of 6 weeks. They will complete two exercise sessions a week consisting of one set of the Copenhagen adductor exercise. The exercise will be performed on each side. The training load will increase from 5 repetitions in week 1, to 15 repetitions in week 6. The exercise programme is performed at the end of the warm-up of a regular football training session.
89371067|NCT03684200|No Intervention|Control|19 players allocated to the control group will be asked not to perform the Copenhagen adductor exercise or any other specific strength training for the adductor muscles and to continue to play football as usual.
88843756|NCT01306994||Control Group|Healthy individuals
89371068|NCT01366599||Patients enrolled in IHCIS in 2006|Patients enrolled in IHCIS in 2006
89371069|NCT03172000|Active Comparator|Colonoscopy and biopsy|IBD patients
89371070|NCT03172000|No Intervention|Colonoscopic biopsy|Non IBD patients colonoscopic biopsy
89371071|NCT03680612|Experimental|Cefepime 1G - 2G / AAI101 0.5G - 0.75G|cefepime 1 g or cefepime 2 g in combination with AAI101 500 mg or 750 mg
89371072|NCT03680612|Active Comparator|cefepime monotherapy|cefepime 1 g or cefepime 2 g
89371073|NCT01360281|Experimental|ECR|
89371074|NCT01360281|No Intervention|Control|
89371075|NCT01360281|Experimental|NMES|
89371076|NCT02410096|Active Comparator|Oil supplementation verum|30 patients aged 12-44 years with a diagnosis of exercise induced asthma undergo a methacholine challenge and a prick test. After randomization patients will receive in double blind approach ones daily 1190 mg of middle-chain and polyunsaturated fatty acids for four weeks. Before and after supplementation an exercise challenge in a cold chamber will be performed.
89371077|NCT02410096|Placebo Comparator|Oil supplementation placebo|30 patients aged 12-44 years with a diagnosis of exercise induced asthma undergo a methacholine challenge and a prick test. After randomization patients will receive in double blind approach placebo for four weeks. Before and after placebo treatment an exercise challenge in a cold chamber will be performed.
88843757|NCT03135535|Experimental|Avex Footbeat|Subjects will receive a new pair of diabetic shoes with BOA shoelace closure and a pair of AVEX Footbeat insoles, which include a micro-mobile compression pump. The entire system is named 'intervention shoes' for simplicity. They will be instructed to wear the intervention shoes on daily basis for 4 weeks for duration of at least 4 hours per day.
89371078|NCT01366677|Experimental|Yoga Therapy|
89371079|NCT03684122|Experimental|Injection of Umbilical cord derived MSCs|Allogenic Umbilical Cord derived stem cells injected intravenously to enrolled PD patients
89371080|NCT03684122|Experimental|Injection of MSCs differentiated into neural stem cells NSCs|Allogenic Umbilical Cord derived stem cells (MSCs) differentiated into neural stem cells (NSCs) injected intrathecaly and intravenously to enrolled PD patients.
89371081|NCT05188209|Experimental|MRG003|On the first day of every 3 weeks, MRG003 will be administered via intravenous infusion at 2.0 mg/kg calculated based on the actual body weight
89371082|NCT03171922|Experimental|Internet Diet|Internet Diet group have online dietary coach every 2 weeks
89371083|NCT03171922|Experimental|Clinic Diet|clinic visit based weight loss diet program group who have every 2 weeks visit at clinic.
89371084|NCT04046939|Placebo Comparator|placebo BID|Following a 2-4 week placebo run-in, randomized subjects received 1 tablet placebo twice daily for 12 weeks.
89371085|NCT04046939|Active Comparator|37.5 mg BID dexpramipexole|Following a 2-4 week placebo run-in, randomized subjects received 1 tablet of 37.5 mg dexpramipexole twice daily for 12 weeks.
88843758|NCT02979301|Experimental|Tamoxifen 5 mg/day|Women with high background uptake on MBI take 5 mg tam per day for 30 days.
88843759|NCT02979301|Experimental|Tamoxifen 10 mg/day|Women with high background uptake on MBI take 10 mg tam per day for 30 days.
88843760|NCT01930136|Experimental|Calorie restriction (25%)|CR will correspond to a reduction of 25% from the total daily calorie expenditure calculated as Total Daily Energy Expenditure (TDEE) (kcal/d) using the formula from the validated Seven-Day Physical Activity Recall (PAR) Questionnaire (RMR x activity levels).
88843761|NCT01930136|Active Comparator|Ad libitum health diet|
88843762|NCT02979925|Experimental|Active transcutaneous magnetic stimulation|Active transcutaneous magnetic stimulation (TMS) at the target site of nerve damage/injury.
88843763|NCT02979925|Sham Comparator|Sham transcutaneous magnetic stimulation|Sham TMS will consist of the same parameters as active, however, the subject will be shielded from the magnetic field of the coil.
88843764|NCT05171114|Experimental|moderate Scleroderma|Patients with Cochin hand score less than or equal to 16
89371086|NCT04046939|Active Comparator|75 mg BID dexpramipexole|Following a 2-4 week placebo run-in, randomized subjects received 1 tablet of 75 mg dexpramipexole twice daily for 12 weeks.
89371087|NCT04046939|Active Comparator|150 mg BID dexpramipexole|Following a 2-4 week placebo run-in, randomized subjects received 1 tablet of 150 mg dexpramipexole twice daily for 12 weeks.
89371088|NCT05188131|Experimental|Intravenous Infusion of Diclofenac Sodium|Intravenous Infusion of Diclofenac Sodium in healthy subjects.
89371089|NCT05188131|Placebo Comparator|Intravenous Infusion of Placebo|Intravenous Infusion of Placebo (isotonic saline) in healthy subjects.
89371090|NCT03172156||Stage I NSCLC patients after surgery with ctDNA detection|Stage I NSCLC patients;ctDNA detection
89371091|NCT03174496||Children aged 4-7 years|
89371092|NCT03174496||Children and adolescents aged 8-16 years|
89371093|NCT01360359|Experimental|Core Stabilization|"8-week core stabilization program in 3 stage that emphasizes use of specific local trunk stabilizing muscles to restore active control and stability to the trunk.~8-week exercise program, 1-2 sessions/ week, 30-60 minute sessions"
89371094|NCT01360359|Active Comparator|Trunk Motion and Fitness|"8-week exercise program in 3 stages emphasizing spine motion, general trunk flexibility and strengthening and cardiovascular fitness.~8-week exercise program, 1-2 sessions/ week, 30-60 minute sessions"
89371095|NCT02409940|Experimental|Autologus Mesenchymal Stem Cells|This group would get two doses of mesenchymal stem cell (MSCs) infusion, one day pre transplant and 30 days post transplant. These MSCs would be derived from transplant recipient's bone marrow which are cultured in GMP compliant laboratories for 4-6 weeks.
89371096|NCT02409940|Active Comparator|Allogeniec Mesenchymal Stem Cells|This group would get two doses of mesenchymal stem cell (MSCs) infusion, one day pre transplant and 30 days post transplant. These MSCs would be derived from transplant donor's bone marrow which are cultured in GMP compliant laboratories for 4-6 weeks.
89371097|NCT02409940|No Intervention|Control without Mesenchymal Stem Cells|This group would get no stem cell infusion.
88843765|NCT05171114|Experimental|severe Scleroderma|Patients with Cochin hand score greater than 16
88843766|NCT04954651||VAC|Vaccinated subject against Sars-Cov2
88843767|NCT02983825|Experimental|Continuous positive airway pressure (CPAP) level changes|Protocol guided changes in CPAP level from clinical baseline, with responsiveness in V/Q mismatch guiding subsequent changes; limited to a range of -2 to +3 cm H2O from baseline
88843768|NCT01818986|Experimental|arm one|Sipuleucel-T and Stereotactic Ablative Body Radiation (SABR)
88843769|NCT03138577|Other|Dose Cohort 7|5 mL of 2:1 mixture of 1.5% mepivacaine and 0.5% bupivacaine Ultrasound Imaging Bedside Negative Inspiratory Force Meter
88843770|NCT03138577|Other|Dose Cohort 6|10 mL of 2:1 mixture of 1.5% mepivacaine and 0.5% bupivacaine Ultrasound Imaging Bedside Negative Inspiratory Force Meter
88843771|NCT03138577|Other|Dose Cohort 5|15 mL of 2:1 mixture of 1.5% mepivacaine and 0.5% bupivacaine Ultrasound Imaging Bedside Negative Inspiratory Force Meter
88843772|NCT03138577|Other|Dose Cohort 4|20 mL of 2:1 mixture of 1.5% mepivacaine and 0.5% bupivacaine Ultrasound Imaging Bedside Negative Inspiratory Force Meter
88843773|NCT03138577|Other|Dose Cohort 3|Supraclavicular Block: 25 mL of 2:1 mixture of 1.5% mepivacaine and 0.5% bupivacaine Ultrasound Imaging Bedside Negative Inspiratory Force Meter
88843774|NCT03138577|Other|Dose Cohort 2|30 mL of 2:1 mixture of 1.5% mepivacaine and 0.5% bupivacaine Ultrasound Imaging Bedside Negative Inspiratory Force Meter
88843775|NCT03138577|Other|Dose Cohort 1|35 mL of 2:1 mixture of 1.5% mepivacaine and 0.5% bupivacaine Ultrasound Imaging Bedside Negative Inspiratory Force Meter
89180637|NCT05728151|Experimental|Group L|General Anesthesia will be inducted as before in addition of giving a peribulbar block up to 5 ml ( according to the volume of the eye ) of Lidocaine 2%mixed with 10IU of Hyaluronidase by a single injection technique.
89180638|NCT05728151|Experimental|Group M|General Anesthesia will be inducted as before in addition of giving a peribulbar block up to 5 ml (according to the volume of the eye) of Mepivacaine 3% mixed with 10IU of Hyaluronidase by a single injection technique.
89180639|NCT02919137|Experimental|Visible light exposure Red 30 lux|The participants will be exposed to red LED light at a illuminance of 30 lux at eye level for 45 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will perform cognitive tests (verbal fluency task, arithmetic task, word repetition task) during the colored light exposure and hyperventilation and hypoventilation tasks .
89180640|NCT02919137|Experimental|Visible light exposure Red 120 lux|The participants will be exposed to red LED light at a illuminance of 120 lux at eye level for 45 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will perform cognitive tests (verbal fluency task, arithmetic task, word repetition task) during the colored light exposure and hyperventilation and hypoventilation tasks .
89180641|NCT02919137|Experimental|Visible light exposure Blue 30 lux|The participants will be exposed to blue LED light at a illuminance of 30 lux at eye level for 45 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will perform cognitive tests (verbal fluency task, arithmetic task, word repetition task) during the colored light exposure and hyperventilation and hypoventilation tasks .
89180642|NCT02919137|Experimental|Visible light exposure Blue 120 lux|The participants will be exposed to blue LED light at a illuminance of 120 lux at eye level for 45 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will perform cognitive tests (verbal fluency task, arithmetic task, word repetition task) during the colored light exposure and hyperventilation and hypoventilation tasks .
89180643|NCT02919137|Experimental|Visible light exposure Green 30 lux|The participants will be exposed to green LED light at a illuminance of 30 lux at eye level for 45 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will perform cognitive tests (verbal fluency task, arithmetic task, word repetition task) during the colored light exposure and hyperventilation and hypoventilation tasks .
89180644|NCT02919137|Experimental|Visible light exposure Green 120 lux|The participants will be exposed to green LED light at a illuminance of 120 lux at eye level for 45 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will perform cognitive tests (verbal fluency task, arithmetic task, word repetition task) during the colored light exposure and hyperventilation and hypoventilation tasks .
89180645|NCT02919137|Experimental|Visible light exposure White 30 lux|The participants will be exposed to white LED light at a illuminance of 30 lux at eye level for 45 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will perform cognitive tests (verbal fluency task, arithmetic task, word repetition task) during the colored light exposure and hyperventilation and hypoventilation tasks .
89180646|NCT02919137|Experimental|Visible light exposure White 120 lux|The participants will be exposed to white LED light at a illuminance of 120 lux at eye level for 45 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will perform cognitive tests (verbal fluency task, arithmetic task, word repetition task) during the colored light exposure and hyperventilation and hypoventilation tasks .
89180647|NCT00733746|Experimental|Neoadjuvant therapy + Surgery + Adjuvant therapy|As part of neoadjuvant therapy, patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, 15, 29, 36, and 43 and oral erlotinib hydrochloride once daily on days 1-43 in the absence of disease progression or unacceptable toxicity. Within 3-6 weeks after completion of neoadjuvant therapy, patients undergo pancreaticoduodenectomy and patients receive gemcitabine hydrochloride and erlotinib hydrochloride as in neoadjuvant therapy within 5-10 weeks post surgery.
89180648|NCT03422705|Sham Comparator|Standard of care|No intervention - no programming, no medical intervention.
88843776|NCT00913640||PD Group|
88843777|NCT00913640||Control Group|
88843778|NCT03181724|Active Comparator|Decision Aid|Cohort that will receive a decision aid.
88843779|NCT03181724|No Intervention|No Decision Aid (control)|One cohort will not receive the decision aid, and instead will receive only a brochure as standard treatment.
88843780|NCT05113004|Placebo Comparator|Arm 1|"Cohort 1 : Patients with High levels of symptoms and low disease activity receive :~Placebo of Leflunomide 20mg/d Placebo of Mycophenolate mofetil 2000mg/d Placebo of hydroxychloroquine 400mg/d"
89534820|NCT03093441|Active Comparator|Rowing|Multimodal High-Intensity Interval Training Intervention. This group will train using a rowing ergometer for 5 sets of 60 seconds of all out work, followed by 3 minutes of rest (a total of 20 minutes each session). Each training session will be the same across the 12 weeks. The intent of each set is to be completed with as much effort as possible across the full 60 seconds.
88843781|NCT05113004|Other|Arm 2|"Cohort 1 : Patients with High levels of symptoms and low disease activity receive :~Leflunomide 20mg/d hydroxychloroquine 400mg/d Placebo of Mycophenolate mofetil 2000 mg/d"
88843782|NCT05113004|Other|Arm 3|"Cohort 1 : Patients with High levels of symptoms and low disease activity receive :~Placebo of Leflunomide 20mg/d Mycophenolate mofetil 2000mg/d hydroxychloroquine 400mg/d"
88843783|NCT05113004|Placebo Comparator|Arm 4|"Cohorte 2 :Patients with moderate or hight activity, regardless of level of symptoms, they receive :~Placebo of Leflunomide 20mg/d Placebo of Mycophenolate mofetil 2000mg/d Placebo of hydroxychloroquine 400mg/d"
88843784|NCT05113004|Other|Arm 5|"Cohorte 2 :Patients with moderate or hight activity, regardless of level of symptoms, they receive :~Leflunomide 20mg/d hydroxychloroquine 400mg/d Placebo of Mycophenolate mofetil 2000 mg/d"
88843785|NCT05113004|Other|Arm 6|"Cohorte 2 :Patients with moderate or hight activity, regardless of level of symptoms, they receive :~Placebo of Leflunomide 20mg/d Mycophenolate mofetil 2000mg/d hydroxychloroquine 400mg/d"
88843786|NCT04707079|Experimental|Duvelisib|Eligible subjects will be given duvelisib (15mg, 25mg), orally at a dose of 25 mg BID during each 28-day treatment cycle, for up to 12 cycles.
88843787|NCT05092568||covid pregnancy|Pregnant patients with positive polymerase chain reaction assay COVID-19 test results, who were followed up and treated in the pandemic service of Başakşehir Çam and Sakura City Hospital.
88843788|NCT03182582|Active Comparator|Week 1 - Erbium:Yttrium-Aluminum-Garnet Laser Debridement|"During the first treatment, laser debridement will be performed at 200-um until punctate bleeding is visualized. During the second treatment, sharp debridement will be performed via a scalpel/curette until punctate bleeding is visualized.~Tissue biopsies will then be obtained from the wounds prior to the first treatment, immediately after the first treatment, immediately prior to the subsequent treatment, and immediately after the second treatment. These will then be sent to Pathogenius for molecular analysis of wound microflora using polymerase chain reaction and sequencing.~Pain will be assessed during debridement by recording the Numerical Rating Scale for pain assessment."
88843789|NCT03182582|Active Comparator|Week 1 - Scalpel/Curette Debridement|"During the first treatment, sharp debridement will be performed via a scalpel/curette until punctate bleeding is visualized. During the second treatment, laser debridement will be performed at 200-um until punctate bleeding is visualized.~Tissue biopsies will then be obtained from the wounds prior to the first treatment, immediately after the first treatment, immediately prior to the subsequent treatment, and immediately after the second treatment. These will then be sent to Pathogenius for molecular analysis of wound microflora using polymerase chain reaction and sequencing.~Pain will be assessed during debridement by recording the Numerical Rating Scale for pain assessment."
88843790|NCT05081726||Never had delirium|Older people recovering from hip fracture surgery who did not have postoperative delirium
88843791|NCT05081726||Recovered delirium|Older people recovering from hip fracture surgery who experienced delirium which has resolved
88843792|NCT04740229|Experimental|Moderate-intensity flow-based Yoga|The intervention will consist of participants engaging in a progressive series of moderate-intensity, flow-based yoga poses, along with breathing and relaxation, for eight weeks. The intervention will be titrated in terms of supervision, with first two weeks being completely supervised, followed by partial supervision for three weeks, and three weeks of unsupervised sessions. The sessions will be ~50 minutes long, 3 times/week. All supervised sessions will be conducted online through Google Meet (GM), which is a live video interaction platform. Videos will be provided to guide unsupervised sessions. Sessions will be led by a certified yoga instructor. An orientation will be provided in the first week, given that the participants will have no or minimal experience with yoga. The intervention will consist of basic sun salutations of hatha yoga sun salutation A, sun salutation B and flow sequences, and breathing exercises, and relaxation.
88843793|NCT04740229|No Intervention|Waitlist control|Participants in this group will not receive the 8-week intervention during the course of the study, and will be asked to engage in their regular activities. They will be asked to not start any new activities during the study period. After they complete the study, they will be provided with the same intervention (live instruction, feedback and supportive videos).
88843794|NCT02986711|Experimental|Motivational Text Messages|Motivational text messages to help participants stay quit when they leave the hospital.
88843795|NCT02986711|Sham Comparator|Control|Text messages to ask about current smoking status.
88843796|NCT00374569|Experimental|Gymnastics|Gymnasts stand on a computerized dynamic posturography Force Plate and Stability is measured and gymnastic routines performed
88843797|NCT00374569|Experimental|Non Gymnasts|Non Gymnasts stand on a computerized dynamic posturography Force Plate and Stability is measured and gymnastic routines performed
88843798|NCT03141931|Experimental|Supplement|Combination of flaxseed oil, borage oil and fish oil omega-3 fatty acids
88843799|NCT03141931|Placebo Comparator|Placebo|Polyethylene glycol, Oleic acid, Propylene glycol
88843800|NCT03143569|Active Comparator|aPTT nomogram|aPTT guided heparin management
88843801|NCT03143569|Experimental|Anti-factor Xa nomogram|Anti-factor Xa guided heparin management
88843802|NCT04631497||Healthcare workers|The study will cover employees of the Intensive Care Unit - nurses and doctors working with patients with COVID-19 infection. Test takers will be over the age of 18 and under the age of 70, female and male.
88843803|NCT02222688|Experimental|Cirmtuzumab 0.015 - 0.03 mg/kg|Cohort 1: Cirmtuzumab 0.015 mg/kg for two 14-day cycles followed by cirmtuzumab 0.03 mg/kg for two 14-day cycles via intravenous (IV) infusion
88843804|NCT02222688|Experimental|Cirmtuzumab 0.06 - 0.12 - 0.24 mg/kg|Cohort 2: Cirmtuzumab 0.06 mg/kg for one 14-day cycle, followed by cirmtuzumab 0.12 mg/kg for one 14-day cycle, followed by 0.24 mg/kg for two 14-day cycles via IV infusion
89180649|NCT03422705|Experimental|Optimised programming|Optimised pacemaker programming to avoid right ventricular pacing.
89180650|NCT03422705|Experimental|Medical therapy|Lisinopril uptitrated to optimally tolerated dose.
88843805|NCT02222688|Experimental|Cirmtuzumab 0.5 - 1.0 mg/kg|Cohort 3: Cirmtuzumab 0.5 mg/kg for one 14-day cycle, followed by cirmtuzumab 1.0 mg/kg for three 14-day cycles via IV infusion
88843806|NCT02222688|Experimental|Cirmtuzumab 2.0 - 4.0 mg/kg|Cohort 4: Cirmtuzumab 2.0 mg/kg for two 14-day cycles, followed by cirmtuzumab 4.0 mg/kg for two 14-day cycles via IV infusion
88843807|NCT02222688|Experimental|Cirmtuzumab 8 mg/kg|Cohort 5: Cirmtuzumab 8 mg/kg for four 14-day cycles via IV infusion
88843808|NCT02222688|Experimental|Cirmtuzumab 16 mg/kg|Cohort 6: Cirmtuzumab 16 mg/kg for four 14-day cycles (or maximum 2000 mg) via IV infusion
88843809|NCT02222688|Experimental|Cirmtuzumab 20 mg/kg|Cohort 7: Cirmtuzumab 20 mg/kg for four 14-day cycles (or maximum 2000 mg)
88843810|NCT03149887|Experimental|Experimental|Injection of liposomal bupivacaine in surgical field at end of arthroscopic rotator cuff repair.
88843811|NCT03149887|Active Comparator|Control|Injection of inert placebo solution in surgical field at end of arthroscopic rotator cuff repair.
88843812|NCT04759404|Active Comparator|Deep Oscillation Group|Individuals in the deep oscillation group will be treated by the researcher. During the application, individuals will be positioned face down on the stretcher. After the powder is applied to the lumbar region, deep oscillation treatment with a frequency of 80% -100% with a frequency of 145-150 Hz for the first 10 minutes and 55-60 Hz for 5 minutes will be applied with the Physiomed Deep Oscilation device. Each individual will be given a home exercise program (stretching and strengthening for waist, back and abdominal) consisting of stretching and strengthening. Individuals will be asked to come to the center where the research will take place, for a total of six sessions for two weeks, three times a week.
88843813|NCT04759404|Active Comparator|Myofascial Release Group|Individuals in the myofascial relaxation group will be treated by the researcher. During the application, individuals will lie face down on the stretcher. Myofascial release therapy will be applied in the lumbar region and each individual will be given home exercise (stretching and strengthening for waist, back and abdominal). Individuals will be asked to come to the center where the research will be conducted for a total of six sessions for two weeks, three times a week.
88843814|NCT04759404|No Intervention|Control Group|
88843815|NCT02988193|Experimental|optima4BP Medication Management|"optima4BP will provide a monthly medication optimization to the treating physician for review and subsequent implementation. The Treatment Recommendation will consist of:~curated blood pressure (BP) and heart rate (HR) values reported by the patient through the use of home monitoring BP arm cuff;~medication treatment recommendation;~active link to access additional treatment analysis tools."
88843816|NCT02988193|No Intervention|Usual Care Medication Management|Usual care management will follow medication treatment management according to the physician preference. The treating physician will not be provided with a medication optimization recommendation, nor with monthly curated BP and HR values.
88843817|NCT02988349|Active Comparator|Caries-free subjects|Subjects will use Colgate® Sensitive Pro-Relief® toothpaste for 2 weeks,.
88843818|NCT02988349|Experimental|Caries-active subjects|Subjects will use Colgate® Sensitive Pro-Relief® toothpaste for 2 weeks,.
88843819|NCT04541329|Experimental|Tildrakizumab treatment|
88843820|NCT03150043|Other|All Participants|All patients who agree to participate in the study will have the Masimo Rainbow Pulse CO-Oximeter non-invasive hemoglobin monitor placed on their finger during cesarean delivery. A CBC will be drawn immediately prior to delivery and this value will be compared to the values obtained from the monitor. The patients will be separated into quartiles based on total drop in hemoglobin (pre-op to post-op day 1) and the values from the monitor compared between quartiles.
88843821|NCT02159352|Experimental|Group 1: Daclatasvir and Darunavir/Ritonavir|"Treatment A: Daclatasvir oral tablet on specific days~Treatment B: Daclatasvir tablet and Darunavir Tablet/Ritonavir capsule orally on specific days"
88843822|NCT02159352|Experimental|Group 2: Daclatasvir and Lopinavir/Ritonavir|"Treatment C: Daclatasvir oral tablet on specific days~Treatment D: Daclatasvir tablet and Lopinavir/Ritonavir tablet orally on specific days"
88843823|NCT04499833|Experimental|"liver transplant outside the Milan Criteria"|"patients with hepatocellular carcinoma, outside the Milan Criteria, that complied with the proposed HepatoPredictTool, submitted to liver transplant"
88843824|NCT03150199|Experimental|Positive Psychology + Motivational Interviewing|Participants will complete weekly positive psychology exercises and will systematically set goals related to physical activity. Study trainers will review the positive psychology exercises on the phone each week and will use motivational interviewing techniques to facilitate goal setting.
88843825|NCT03150199|Active Comparator|MI-Based Health Education Intervention|Participants will speak on the telephone each week with a study trainer. During these calls, the trainer will provide education about a health behavior related to diabetes health (physical activity, medication adherence, diet) and will use motivational interviewing techniques to facilitate the consideration of behavior change.
88843826|NCT02187744|Experimental|PF-05280014|
88843827|NCT02187744|Active Comparator|Herceptin®|
88843828|NCT03154333|Experimental|diacerein 1% ointment|diacerein 1% ointment will be used for 8 weeks
88843829|NCT03154333|Placebo Comparator|vehicle ointment|vehicle ointment will be used for 8 weeks
88843830|NCT04473625||Breast|Subjects with clinically confirmed breast cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.
89180651|NCT02607293||Subjects undergoing ART treatment with long GnRH-a or GnRH-ant|Subjects undergoing ART treatment with long GnRH-a protocol or GnRH-ant protocol + Gn + human chorionic gonadotropin (hCG) as per routine clinical practice. No visits or intervention(s) additional to the routine practice of the Investigators will be performed during this observational study.
89180652|NCT02607371||Cohort 1 / VKA treatment|A sample of about 200 patients with nonvalvular atrial fibrillation who are treated with VKAs for at least three months at date of study inclusion
89180653|NCT02607371||Cohort 2 / NOAC treatment|A sample of about 200 patients with nonvalvular atrial fibrillation who are treated with NOACs for at least three months at date of study inclusion
88843831|NCT04473625||Lung|Subjects with clinically confirmed lung cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.
88843832|NCT04473625||Colorectal|Subjects with clinically confirmed colorectal cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.
89180654|NCT00718419|Experimental|A: Enzastaurin|
89180655|NCT02590965|Placebo Comparator|Control Group|Placebo is a capsule in the form of 1mg and 5 mg, orally, once daily, 3 weeks on/1week off with best supportive care.
88843833|NCT04473625||Prostate|Subjects with clinically confirmed prostate cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.
88843834|NCT04473625||Bladder|Subjects with clinically confirmed or suspicion of bladder cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.
89180656|NCT02590965|Experimental|Treatment Group|The subjects will receive oral Fruquintinib at fasting state 5mg+best supportive care, once daily for the first 3 consecutive weeks and dose holiday for 1 week according to their dose regimens until the occurrence of disease progression, unacceptable toxicity, or withdrawal of consent
89180657|NCT02591043|Other|Follow-up|Patients have not received a structured follow up examination or evaluation of outcome after surgery. Therefore this study aims at conducting a follow up examination regarding functional outcome, pain and radiologic healing in these patients.
89180658|NCT04085757|Experimental|long interval dinoprostone|A small envelope including two labeled plastic bags (A & B) (each bag containing either 1 dinoprostone tablet(3mg) or 1 identically appearing placebo tablet) will be packaged in sequentially numbered sealed envelopes. In long interval dinoprostone group, bag (A) contains dinoprostone tablet and bag (B) contains placebo tablet. After signing the informed consent, the sequentially numbered sealed envelopes will be opened (according to the sequence of attendance of the patient) by the study nurse. Tablets in bag (A) will be inserted 12 hours before office hysteroscopy and tablets in bag (B) will be inserted 3 hours before office hysteroscopy.
89180659|NCT04085757|Active Comparator|short interval dinoprostone|A small envelope including two labeled plastic bags (A& B) (each bag containing either 1 dinoprostone tablets(3 mg) or 1 identically appearing placebo tablet) will be packaged in sequentially numbered sealed envelopes. In short interval dinoprostone group, bag (A) contains placebo tablet and bag (B) contains dinoprostone tablet. After signing the informed consent, the sequentially numbered sealed envelopes will be opened (according to the sequence of attendance of the patient) by the study nurse. Tablets in bag (A) will be inserted 12 hours before office hysteroscopy and tablets in bag (B) will be inserted 3 hours before office hysteroscopy.
89180660|NCT04085679||MMU active group|Subjects residing in nursing homes where the MMU care model has already been implemented
89180661|NCT04085679||MMU control group|Subjects residing in nursing homes where the MMU care model has not yet been implemented (ED visits performed in case of urgent clinical situations)
89371098|NCT03680534|Experimental|Reciproc Blue|Patients in which root canal from a lower premolar was prepared with the Reciproc Blue technique.
89371099|NCT03680534|Experimental|WaveOne Gold|Patients in which root canal from a lower premolar was prepared with the WaveOne Gold technique.
89371100|NCT03680534|Experimental|XP EndoShaper|Patients in which root canal from a lower premolar was prepared with the XP EndoShaper technique.
89371101|NCT00704782|Experimental|Dimebon|20 mg by mouth 3 times a day
88843835|NCT04473625||Uterine|Subjects with clinically confirmed uterine cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.
88843836|NCT04473625||Kidney/Renal Pelvis|Subjects with clinically confirmed or suspicion of kidney/renal pelvis cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.
88843837|NCT04473625||Ovarian|Subjects with clinically confirmed or suspicion of ovarian cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.
88843838|NCT04473625||Liver|Subjects with clinically confirmed liver cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.
88843839|NCT04473625||Pancreas|Subjects with clinically confirmed or suspicion of pancreatic cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.
88843840|NCT04473625||Stomach|Subjects with clinically confirmed stomach cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.
88843841|NCT04473625||Esophageal|Subjects with clinically confirmed esophageal cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.
88843842|NCT04393441|Active Comparator|Systane® Ultra Multidose|All participants administered 1 to 2 drops of REFRESH PLUS® 3 times daily in each eye for approximately 7 days during a run-in period prior to randomization on Day 1. Participants then administered 1 to 2 drops of Systane® Ultra Multidose in each eye 3 times daily for up to 90 days.
88843843|NCT04393441|Experimental|011516X (New Artificial Tear Formulation)|All participants administered 1 to 2 drops of REFRESH PLUS® 3 times daily in each eye for approximately 7 days during a run-in period prior to randomization on Day 1. Participants then administered 1 to 2 drops of 011516X in each eye 3 times daily for up to 90 days.
88843844|NCT03160027|Experimental|Immediate PBM treatment|This arm will receive photobiomodulation (PBM), delivered with the Vielight Gamma device, once every other day (e.g., Mon, Wed, Fri) for 20 minutes (the device automatically shuts itself off after 20 minutes) for 12 weeks.
88843845|NCT03160027|No Intervention|Delayed PBM treatment|This arm will maintain usual activities for 12 weeks. After the week 12 psychometric and MRI assessment, this arm will receive PBM, delivered with the Vielight Gamma device, once every other day (e.g., Mon, Wed, Fri) for 20 minutes (the device automatically shuts itself off after 20 minutes) for 12 weeks.
88843846|NCT02994979|Experimental|Delirium-prevention group|Multicomponent delirium prevention intervention led by a Certified Nursing Assistant (CNA) adapted for the long-term care setting from the Hospital Elder Life Program.
89399259|NCT02169752|Placebo Comparator|Placebo|Subjects will be randomly assigned in a 1:1 ration according to the computer generated random numbers to receive either placebo (sugar pill) or ambrisentan.
88843847|NCT02994979|Sham Comparator|Usual care group|Usual care plus a sham visit from the intervention CNA
89180662|NCT02590887|Experimental|drink manufactured from lupine peptides|"Beverage drink containing 0.5mg/ml of protein hydrolysate extracted from food grade lupine flour. The drink will be formulated as 200 mL tetra brik subjected to a test of microbiological safety according to the Spanish law (RD 135/2010 of 12 February 2010).~The final beverage shall consist of:~Oily phase: refined sunflower oil 5% w/w of the emulsion~Aqueous phase (water) 95% w/w of the emulsion, containing equal volumes of solution A and B:~Solution A:~Hydrolyzed Lupine (1.17% w/w)~Sucrose (14.03% w/w)~Vanilla flavor (0.42% w/w)~Drinking water (84.38% w/v)~Solution B:~Xanthan gum (0.28% w/w)~Drinking water (99.72% w/v)~The samples will guard and kept by the investigator until the day of delivery to the volunteers.~The duration of treatment 4 weeks, during which the volunteers daily consume the contents of a tetra brik."
89180663|NCT00717249|Experimental|Test Lens|galyfilcon A contact lens with a silver additive
89180664|NCT00717249|Active Comparator|Control Lens|galyfilcon A control contact lens
89180665|NCT04085211||Inflammatory Bowel Disease|Patients with an established diagnosis of ulcerative colitis or Crohn's Disease who require either a flexible sigmoidoscopy or colonoscopy as part of routine care (e.g. surveillance or staging disease activity)
89180666|NCT04085211||Patients with symptoms of gastro-oesophageal reflux disease|Patients with symptoms of gastro-oesophageal reflux disease requiring a gastroscopy as part of routine clinical care.
89180667|NCT04085211||Atrophic gastritis|Patients with known or suspected atrophic gastritis that require a gastroscopy to either confirm the diagnosis or surveillance for pre-cancerous changes.
89180668|NCT04085211||Neuroendocrine Tumours|Patients with an established history of gastric neuroendocrine tumours requiring surveillance
89180669|NCT00727194|Experimental|1|eculizumab
89180670|NCT00727194|Placebo Comparator|2|Placebo
89180671|NCT00717093|Experimental|Active|
89180672|NCT00717093|Placebo Comparator|Placebo|
89180673|NCT02592642|Experimental|Group 1|Self-management Program, Workbook, Video, Pedometer
89180674|NCT02592642|Active Comparator|Group 2|Instructional Workbook, Video, and Pedometer
89180675|NCT02592642|Experimental|Group a|Para-spinal TENS
89180676|NCT02592642|Placebo Comparator|Group b|Para-spinal Placebo TENS
89180677|NCT02592642|Experimental|Group c|Prototype Spinal Stenosis Belt
89180678|NCT02592642|Sham Comparator|Group d|Sham spinal stenosis belt
89180679|NCT00716859|Active Comparator|Timolol|
89180680|NCT00716859|Experimental|latanoprost|
89180681|NCT00589121|Experimental|Cohort A - Chemotherapy|Radiation therapy with neoadjuvant or adjuvant or concurrent or interdigitated chemotherapy followed by surgery followed by, for patients with positive margins, radiation therapy boost
89180682|NCT00589121|Experimental|Cohort B - No Chemotherapy|Radiation therapy followed by surgery followed by, for patients with positive margins, radiation therapy boost
89180683|NCT00590135|Experimental|AORTIC STENOSIS PATIENTS|Atorvastatin (Lipitor) 40mg by mouth daily is administered to patients with aortic stenosis
89180684|NCT00589667|Experimental|Treatment|Patients will receive pemetrexed (500 mg/m2 IV infusion over approximately 10 minutes) followed immediately by gemcitabine (1250 mg/m2 IV infusion given over approximately 30 minutes) on day 1 and day 15 of a 28-day cycle.
88843848|NCT02995915|Experimental|Tele-health Mobile Contingency Management Intervention|This arm includes a proactive tele-health intervention that combines evidence-based telephone cognitive behavioral treatment for alcohol and smoking cessation, a tele-medicine clinic for access to smoking cessation pharmacotherapy (including nicotine replacement therapy and bupropion), and mobile contingency management treatment administered via a smart-phone based application (mobile CM).
88843849|NCT02995915|Active Comparator|Tele-health for Alcohol and Smoking Cessation|This arm includes a proactive tele-health intervention that will provide controls for therapist, medication, time and attention effects. The tele-health intervention provides the same evidence-based telephone CBT for alcohol and smoking cessation, and tele-medicine clinic for access to smoking cessation pharmacotherapy as in the mCM intervention, but does not include mCM. Instead, participants will receive monetary compensation for each assessment, regardless of abstinence.
88843850|NCT04376515|Experimental|HOPE Intervention|HOPE peer-led intervention
89180685|NCT00737568|Experimental|Tenofovir DF|TDF plus placebo to match FTC/TDF
89180686|NCT00737568|Experimental|FTC/TDF|FTC/TDF plus placebo to match TDF
89180687|NCT02607137|Experimental|Health Education|Health information related to physical activity
89180688|NCT02606591|Experimental|Electroencephalograph (EEG) + Testing|Participants complete an electroencephalograph (EEG) cognitive tests, and provide a hair sample shortly after entering the study and again near the end of the school year. Hair sample tested to measure a stress hormone called cortisol.
89180689|NCT00737100|Experimental|Tiotropium Respimat 2.5 mcg|patient to receive low dose tiotropium once daily
89180690|NCT00737100|Experimental|Tiotropium Respimat 5 mcg|patient to receive high dose tiotropium once daily
89180691|NCT00737100|Placebo Comparator|Placebo Respimat|patient to receive placebo once daily
89180692|NCT00732498|Experimental|ESHAP followed by Zevalin and Rituximab|Etoposide, Methylprednisolone, Cytarabine, Cisplatin (ESHAP) infusion X 2 Cycles followed by Rituximab and In-Zevalin or Y-Zevalin.
89180693|NCT03964428||periodontitis|
89180694|NCT03964428||periodontitis with T2DM|
89180695|NCT03964428||control|
89180696|NCT00726882|Other|HCV-infected Participants|"Hepatitis C virus (HCV)-infected participants who received ABT-333 at any dose level or matching placebo in a prior clinical study involving ABT-333.~Participants received no treatment in this follow-up study."
89180697|NCT00790400|Experimental|Everolimus|Study drug was given by continuous oral daily dosing of two 5 mg tablets.
89180698|NCT00790400|Placebo Comparator|Placebo|Placebo was given by continuous oral daily dosing of two 5 mg tablets.
89180699|NCT04087434||Retrospective|retrospective review of 300 records of patients following concussive diagnosis to track recovery and adherence to progressive return to activity recommendations.
89180700|NCT04087434||Prospective|300 prospective patients enrolled following concussive diagnosis to track recovery, clinical diagnosis and brain gauge performance.
89180701|NCT04087434||Control Group|75-100 Healthy Controls recruited by Fort Bragg to assess performance in a healthy population for brain gauge performance.
89371102|NCT03676400|Experimental|NGF-574H|"NGF-574H is hair serum with 5% conditioned media of umbilical cord blood-derived stem cells containing various trophic factors that help alleviate hair loss.~NGF-574H will be directed to use on hair and scalp by subject her/himself at home twice a day (in the morning and evening) for 24 weeks."
89371103|NCT03676400|Placebo Comparator|placebo|Hair serum without conditioned media of umbilical cord blood-derived stem cells will be directed to use on hair and scalp by subject her/himself at home twice a day (in the morning and evening) for 24 weeks.
89371104|NCT01360437|Active Comparator|Prasugrel|
89371105|NCT01360437|Experimental|Ticagrelor|
89371106|NCT04042103|Experimental|Tapinarof (DMVT-505) cream, 1%|Tapinarof (DMVT-505) cream, 1% applied topically once daily
89371107|NCT03172078|Active Comparator|Target-control infusion without bispectral index monitoring|Target-control infusion (TCI) with propofol during advanced endoscopic procedure e.g. endoscopic Ultrasound (EUS), endoscopic retrograde cholangiopancreatogram (ERCP)
89371108|NCT03172078|Active Comparator|Target-control infusion with bispectral index monitoring|Target-control infusion (TCI) with propofol and BIS monitoring during advanced endoscopic procedure e.g. endoscopic Ultrasound (EUS), endoscopic retrograde cholangiopancreatogram (ERCP)
89371109|NCT01363869|Experimental|Green tea extracts 2 gm/day|Green tea extracts 2 gm/day for 14 days
89371110|NCT01363869|Experimental|Green tea extracts 4 gm/day|Green tea extracts 4 gm/day for 14 days
89371111|NCT01363869|Experimental|Green tea extracts 6 gm/day|Green tea extracts 6 gm/day for 14 days
88843851|NCT04376515|No Intervention|Control|Control group- online community without peer leaders
88843852|NCT02997085|Experimental|Live-Action 360° Video Virtual Reality|
89371112|NCT03174730|Experimental|Growth mindset|In addition to SmartQuit (the app), study participants will receive the content in the form on one growth mindset tip (sent in an email) per day starting on the first day of the study. Email exercises will be sent out every 3 days and there are a total of 8 emails.
89371113|NCT03174730|Other|Control|Participants will get SmartQuit, but not the growth mindset intervention.
89371114|NCT03676322|Experimental|Part A: M5049|
89371115|NCT03676322|Placebo Comparator|Part A: Placebo|
89371116|NCT03676322|Experimental|Part B: M5049|
89371117|NCT03676322|Placebo Comparator|Part B: Placebo|
89371118|NCT03676322|Experimental|Part C: M5049|
89371119|NCT02409862|Experimental|Oxytocin Spray|This group will receive the single dose of 24 IU oxytocin, self-administered intranasally (IN). Prior to administration a saliva sampling will be done. Afterwards, they will participate in the Choices Study during EEG and eye tracking recording.
89371120|NCT02409862|Placebo Comparator|Placebo spray|This group will receive the single dose of 24 IU saline, self-administered intranasally (IN). Prior to administration a saliva sampling will be done. Afterwards, they will participate in the Choices Study during EEG and eye tracking recording.
89371121|NCT01366989||Total Ankle Arthroplasty with calcaneal stem|Patients received the TAA with calcaneal stem between 12/6/05 & 11/13/07 at approximately 28 sites.
89371122|NCT02415088|Active Comparator|Interscalene block|block of the plexus brachialis in the interscalene region with local anaesthetics
89371123|NCT02415088|Active Comparator|Selective shoulder block|selective block of the suprascapular nerve and the axillary nerve with local anaesthetics
88809906|NCT01300949|Active Comparator|Controls|125 patients with no eye diseases will have contrast sensitivity measured by Spaeth/Richman Contrast Sensitivity Test (SPARCS) and Pelli-Robson Contrast Sensitivity Chart. This included patients with refractive errors (needing glasses) and nuclear sclerosis (cataract).
88809907|NCT01300949|Active Comparator|Age-Related Macular Degeneration (ARMD)|35 retina patients with age-related macular degeneration (ARMD) will have contrast sensitivity measured by Spaeth/Richman Contrast Sensitivity Test (SPARCS) and Pelli-Robson Contrast Sensitivity Chart.
88809908|NCT01301183|Experimental|Rh IGF-1 + Transdermal estradiol|RhIGF-1 with transdermal 17-beta estradiol
88809909|NCT01301183|Placebo Comparator|Placebo + Transdermal estradiol|Placebo and transdermal 17-beta estradiol
88809910|NCT00758420|Active Comparator|1|Varisolve (polidocanol endovenous mircofoam)
88809911|NCT00758420|Placebo Comparator|2|Agitated saline
88809912|NCT00779870||1|healthy volunteers
88809913|NCT00779870||2|mild asthmatics
88809914|NCT00779870||3|moderately-severe asthmatics
88809915|NCT00779870||4|severe asthmatics
88809916|NCT01213043|Active Comparator|Prolastin-C, 60 mg/kg|60 mg/kg weekly infusion of Prolastin-C for 8 weeks. Subjects were infused with 60 mg/kg Prolastin-C by means of one of two possible treatment sequences: 1) 60 mg/kg weekly infusion of Prolastin-C for 8 weeks followed by 120 mg/kg Prolastin-C for 8 weeks, or 2) 120 mg/kg Prolastin-C for 8 weeks followed by 60 mg/kg weekly infusion of Prolastin-C for 8 weeks (total of 16 weeks).
88809917|NCT01213043|Experimental|Prolastin-C, 120 mg/kg|120 mg/kg weekly infusion of Prolastin-C for 8 weeks. Subjects were infused with 120 mg/kg Prolastin-C by means of one of two possible treatment sequences: 1) 60 mg/kg weekly infusion of Prolastin-C for 8 weeks followed by 120 mg/kg Prolastin-C for 8 weeks, or 2) 120 mg/kg Prolastin-C for 8 weeks followed by 60 mg/kg weekly infusion of Prolastin-C for 8 weeks (total of 16 weeks).
88809918|NCT00758576|Experimental|SN6AD1|AcrySof ReSTOR Model SN6AD1 Intraocular Lens
89371124|NCT01360671|Experimental|Sildenafil|iv sildenafil
89371125|NCT03176602||All patients admitted to the ICU|All patients ≥ 18 years old who had ≥ 24 hours length of stay in the ICU
89371126|NCT03676244|Experimental|immediate implant placement in anterior esthetic zone|extraction of badly broken anterior maxillary teeth with immediate implant placement
89371127|NCT01363947|Experimental|Dose Escalation Cohort (DNIB0600A)|Participants will receive IV infusions of DNIB0600A at doses ranging from 0.2 milligrams/kilogram (mg/kg) to 2.8 mg/kg q3w until dose-limiting toxicity (DLT) is reached, or up to 28 cycles.
89371128|NCT01363947|Experimental|Expansion Cohort (DNIB0600A)|Participants will receive 2.4 mg/kg, by IV infusion, of DNIB0600A q3w for up to 26 cycles.
89371129|NCT02955797|Experimental|Group 1(Meningococcal Vaccine-Naive):MenACYW Conjugate Vaccine|Healthy, meningococcal vaccine naive toddlers aged 12 to 23 months received a single dose of MenACYW Conjugate vaccine on Day 0.
89371130|NCT02955797|Experimental|Group 2 (Meningococcal Vaccine-Naive): Nimenrix®|Healthy, meningococcal vaccine naive toddlers aged 12 to 23 months received a single dose of Nimenrix® vaccine on Day 0.
89371131|NCT02955797|Experimental|Group 3 (MenC-Primed): MenACYW Conjugate Vaccine|Healthy, meningococcal C vaccine primed toddlers aged 12 to 23 months received a single dose of MenACYW Conjugate vaccine on Day 0.
89371132|NCT02955797|Experimental|Group 4 (MenC-Primed): Nimenrix®|Healthy, meningococcal C vaccine primed toddlers aged 12 to 23 months received a single dose of Nimenrix® vaccine on Day 0.
88843853|NCT02997085|Active Comparator|CGI 360° Video Virtual Reality|
88843854|NCT02997085|No Intervention|Waitlist|Participants randomized to the waitlist group will complete all study procedures except the VR exposure. After completion of the study visit, participants in the waitlist condition will be given the option of viewing either the Live-Action 360° 3D HD VVR or the CGI 360° 3D VVR.
88843855|NCT03163303|Experimental|Tobacco Status Project (TSP) + Alcohol Intervention|Tobacco and alcohol intervention on Facebook and 14-day nicotine patch
88843856|NCT03163303|Experimental|Tobacco Status Project Intervention|Tobacco intervention on Facebook and 14-day nicotine patch
88843857|NCT04349995||Amplatzer PFO Occluder|Percutaneous PFO Closure using Amplatzer PFO occluder
88843858|NCT03165175|Experimental|App + treatment as usual|The experimental group will be provided with the prescription drug-abuse education smartphone application in addition to treatment as usual. This educational mobile phone app focuses on helping military members reduce their risk for prescription drug misuse.
89371133|NCT05554068|Experimental|Shingrix|Patients 1-3 years post transplant will receive the Shingrix vaccine in standard dosing and schedule.
89371134|NCT03680378|Experimental|Cefepime 2 gram + AAI101 1 gram|cefepime 2 grams in combination with AAI101 1 gram intravenous infusion
89371135|NCT01319331|Experimental|Alpha-1 Antitrypsin (AAT, Aralast NP)|Alpha-1 Antitrypsin (AAT, Aralast NP) as prescribed for study duration
89371136|NCT04913298|Other|Cytosorb therapy|blood samples are taken before and after the cytokine adsorber at given times
88843859|NCT03165175|No Intervention|Treatment as usual|The control group will be provided with treatment as usual, and will also receive a list of resources for help with prescription drug and other substance abuse issues.
88843860|NCT03000283|Experimental|Conivaptan Treatment Group|All seven patients in this arm will receive conivaptan as described in Interventions.
88843861|NCT03855163|Experimental|Inspection visits|Regulatory tool to ensure enterprise compliance with legal requirements
88843862|NCT03855163|Experimental|Guidance workshops|Regulatory tool applied to inform and advise enterprises on legal requirements and how to realize compliance with such requirements
88843863|NCT03855163|Experimental|Online risk assessment tool|Regulatory tool applied to aid enterprises in conducting written objectives concerning health, environment and safety activities
88843864|NCT03855163|No Intervention|Control group|The Labour Inspection Authority will not preform any intervention activities in enterprises assign to the control group
89180702|NCT00918294|Experimental|QuickOpt|QuickOpt is an optimization algorithm to program the AV, PV and VV delays
89180703|NCT00915512|Experimental|Paliperidone extended-release (ER)|
89371137|NCT02406352|Experimental|Routine colposcopy and MDC with probe|The intervention which consists of obtaining cervical images with the MDC and spectroscopic data with the probe will be applied to all participants who agreed to participate in the study during their visit for a colposcopy exam or treatment with a LEEP procedure. A control biopsy will also be obtained from patients who agree to provide it. The control biopsy is a biopsy of cervical tissue that does not appear to have atypical changes when observed through a standard of care colposcope.
89371138|NCT03822650||Prospective|"Subjects who meet eligibility criteria and enroll in the prospective arm will be assessed every 6 months ± 4 weeks for a period of up to 3 years, according to the Schedule of Assessments.~Subjects in the Prospective arm may also participate in the Retrospective arm."
89371139|NCT03822650||Retrospective|Upon confirmation of eligibility criteria, the site will obtain an Informed Consent/Assent form and release of medical records from the subject/legally authorized representative to allow review of the medical records from the subject's primary care physician and/or specialists to confirm the CLN5 diagnosis and disease course. To facilitate collection of the medical records, a caregiver interview will be completed at initial enrollment then once yearly for up to 3 years.
89371140|NCT02409628|Experimental|EktoTherix|One application of the EktoTherix scaffold to a fresh wound resulting from a full thickness excision of skin cancer.
89371141|NCT03676166|Experimental|0mg THC smoked cannabis|placebo smoked cannabis
89371142|NCT03676166|Experimental|10mg THC smoked cannabis|smoked cannabis containing 10mg THC
89371143|NCT03676166|Experimental|25mg THC smoked cannabis|smoked cannabis containing 25mg THC
89371144|NCT03676166|Experimental|0mg THC vaporized cannabis|placebo vaporized cannabis
89371145|NCT03676166|Experimental|10mg THC vaporized cannabis|vaporized cannabis containing 10mg THC
89371146|NCT03676166|Experimental|25mg THC vaporized cannabis|vaporized cannabis containing 25mg THC
89371147|NCT02406118|Experimental|Transanal total mesorectal excision|Laparoscopy-assisted transanal total mesorectal excision
89371148|NCT03101514|Experimental|Kanglaite group|Kanglaite 200ml is injected once a day from Monday to Friday during radiotherapy.
89371149|NCT02406040|Experimental|High Protein|2.4g protein/kg/d. The macronutrient composition will be 50:15:35 (carbohydrates:fat:protein) during Energy Restriction
89371150|NCT02406040|Experimental|Adequate Protein|1.2g protein/kg/d. The macronutrient composition will be 50:35:15 (carbohydrates:fat:protein) during Energy Restriction
88843865|NCT03164629|Experimental|3D Angiogram + Emboguide|Participants will receive cone-beam CT 3D Emboguide: cone-beam CT with Embolization Guidance software (Emboguide) to identify prostatic arteries and assist endovascular navigation, by projecting a 3D road map of prostatic arteries on live fluoroscopy, in order to differentiate them from non-target vessels.
88843866|NCT03164629|Active Comparator|No 3D Angiogram + Emboguide|Embolization will be guided by a standard of care CT.
88843867|NCT03168295|Experimental|Placebo first and then dapagliflozin|Renal transplant subjects with intact native kidneys with Type 2 Diabetes Mellitus receive dapagliflozin then placebo
88843868|NCT03168295|Active Comparator|Dapagliflozin first then placebo|Renal transplant subjects with intact native kidneys who are non-diabetic receive placebo then dapagliflozin
89180704|NCT02594670|Experimental|DU20 and HT7 combination|combination of two acupoints based on location and Heart meridian, including Baihui (DU20) and Shenmen(HT7).
89180705|NCT02594670|Other|DU20 and SP6 combination|combination of two acupoints based on location and Spleen meridian, including Baihui (DU20) and Sanyinjiao(SP6).
88843869|NCT03168295|Other|Control Group|Subjects who are type 2 diabetes mellitus who have not undergone renal transplant.
88843870|NCT03168841|Experimental|Intervention Group, receiving medication|Enrolled subjects with confirmed onychomycosis will be dispensed topical medication for treatment.
89180706|NCT02594670|Sham Comparator|DU20 and SA combination|combination of local acupoint Baihui (DU20) and a sham acupoint (SA) not belonging to any regular meridian or acupoint.
89180707|NCT02594748|Experimental|Experimental group|Intervention is administered to patients in this Arm. The intervention is self-management education based on the theory of planned behavior(TPB). The intervention of experimental group is individual guide and face to face education based on TPB.
88843871|NCT03822949|Experimental|Experimental: Exposed to Day light|Patients undergoing primary sternotomy cardiac surgery: Patients will be enrolled 10 to 1 days prior to surgery and will receive an intense (bright light, Square One Wake Up Light NatureBright 10,000 LUX) box. The patient will start using the light box prior to surgery every morning from 8.30 to 9.00 AM. Blood /buccal swabs will be collected on the day of enrollment (10 to 1 days prior to surgery) between 7 and 10 AM without any light therapy and on the day of surgery between 7 and 10 AM before anesthesia induction after one week of light therapy.
88843872|NCT03822949|Placebo Comparator|Sham Comparator: Exposed to Room light|Patients undergoing primary sternotomy cardiac surgery: Patients will be enrolled 10 to 1 days prior to surgery and will receive a placebo/control device (dim/night light box). The patient will start using the light box 7 days prior to surgery every morning from 8.30 to 9.00 AM. Blood /buccal swabs will be collected on the day of enrollment (10 to 1 days prior to surgery) between 7 and 10 AM without any light therapy and on the day of surgery between 7 and 10 AM before anesthesia induction after one week of placebo therapy.
88843873|NCT03822949|Experimental|Experimental: ICU Exposed to Day light|Patients undergoing trauma or elective surgery with ICU admission: Light therapy will consist of 30 minutes intense light each morning for 5-10 days. Blood will be drawn before sunrise and after light therapy. Light therapy will be performed by a study nurse to ensure proper use. In addition, endothelial function and activity will be measured using the noninvasive Endo-pat and ActiWatch device. The patient will need to keep the box as close as possible to their eyes and not walk away during the treatment period. This will be facilities by a study nurse.
89180708|NCT02594748|Active Comparator|Comparison group|The comparison group will receive routine care
88843874|NCT03822949|Placebo Comparator|Sham Comparator: ICU Exposed to Room light|Patients undergoing trauma or elective surgery with ICU admission: Light therapy will consist of 30 minutes using a placebo/control device (dim/night light box) each morning for 5-10 days. Blood will be drawn before sunrise and after light therapy. Light therapy will be performed by a study nurse to ensure proper use. In addition, endothelial function and activity will be measured using the noninvasive Endo-pat and ActiWatch device.
89180709|NCT04088214|Experimental|ArtDSTP|Arthroscopic lateral soft tissue release
89180710|NCT00786032||BCI Device|All participants will use the BCI System as a means of communication.
88843875|NCT04068493|Experimental|Dissonance-based obesity intervention|Participants in this arm will receive Enhanced Project Health.
88843876|NCT04068493|No Intervention|Assessment Only|Participants in this arm will only complete the baseline assessment and 2 month assessment. They will not receive Enhanced Project Health.
89180711|NCT02602652|Experimental|a live attenuated chimeric JE vaccine|Children were received JE-CV as a booster dose after vaccinated with SA14-14-2 vaccine as a first dose regimen 12-24 months before.
89180712|NCT02593500|Experimental|Pulmictan+Test (Treatment Sequence AB)|"Treatment period 1:~Budesonide 200 µg (Budesonida Pulmictan® 200 µg: reference product (A)). Pressurized inhalation suspension. Single dose of 600 µg (3 puffs)per treatment period under fasting conditions.~Treatment period 2:~Budesonide 200 µg (test product (B)). Pressurized inhalation suspension. Single dose of 600 µg (3 puffs) per treatment period under fasting conditions."
89371151|NCT02405884|Other|measurement of intraocular pressure|Patients were divided into groups according to the days on which they underwent hemodialysis. Intraocular pressure was measured with a Kowa HA-2 Perkins applanation tonometer. The tonometry included three measurements in the central region of the cornea before and after hemodialysis. In all patients, the measurements were performed three times on the days when hemodialysis sessions were performed, with 24 hours between each session, and the means of the measurements were obtained. All parameters were measured under prior corneal anesthesia with 0.1% proparacaine and 0.25% fluorescein eye drops.
89371152|NCT02405728|Experimental|Peripherally inserted central catheters|Peripherally inserted central catheters (PICCs) - Most commonly used vascular access in hematological patients - Randomization between CICCs and PICCs
89371153|NCT02405728|Active Comparator|Centrally inserted central catheter|Centrally inserted central catheter (CICCs) - New vascular access, with the aim to reduce the complications - Randomization between CICCs and PICCs
89371154|NCT04897698|Placebo Comparator|Placebo|Four capsules containing rice flour will be given to the placebo group daily.
89371155|NCT04897698|Experimental|Single dose|"Two capsules of probiotics and two capsules of placebo daily. Probiotic capsules contains strains of pediococcus (Bacterial family of Lactobacillaceae) and saccharomycetes (kingdom of Fungi and the division Ascomycota) with a concentration of 13 millions cfu/g. Other ingredients (including stabilization) include rice bran, vegetable L-Cystein, magnesium salts from vegetable fatty acids. The capsule shell is made of vegetable HydroxyPropylMetylCellulosa (HPMC). Each capsule has a weight of 0.4 gram.~The placebo is made of rice flour."
88843877|NCT03815227|Experimental|Outpatient birth|Maternity out the same date or the next day of the birth
88843878|NCT04058587|Experimental|Simmitinib tablet|"The core trial period includes 4-weeks Screening stage (28d), 7-days single administration stage, 4-weeks multiple administration stage (28d), 3-days blood collection stage of PK after multiple administration.~The starting dose was set at 1mg/d on toxicology data. Dosing will continue uninterrupted for 28 days in multiple administration stage.~The dose-limiting toxicity (DLT) period assessment will be from the first administration of Simmitinib tablet to the end of the first cycle (35 days)."
88843879|NCT03865615|Experimental|Oxytocin First|Subjects will receive oxytocin prior to their first scanning session, and placebo prior to their second scanning session.
88843880|NCT03865615|Experimental|Placebo First|Subjects will receive placebo prior to their first scanning session, and oxytocin prior to their second scanning session.
88843881|NCT03180385|Experimental|Neurally-Adjusted Ventilatory Assist (NAVA)|Synchronized biphasic non-invasive respiratory support
88843882|NCT03180385|Active Comparator|Biphasic Positive Airway Pressure Support (BiPAP)|Conventional non-invasive respiratory support
88843883|NCT03859297|Experimental|Rumination-Focused CBT|RF-CBT is a manual-based treatment for prevention of depression, includes focus on ruminations, mental habits, concreteness training, and mindfulness.
88843884|NCT03859297|No Intervention|Treatment as Usual|Participants are allowed to continue any therapy outside of the treatment study.
88843885|NCT03859297|Active Comparator|Relaxation-based therapy|RelaxT includes an active comparison treatment that can be used to monitor and modify physiological responses to stress
88843886|NCT03185546|Experimental|Normal Nicotine Content (NNC) cigarette + moderate nicotine e-liquid + tobacco flavors|Participants are provided with normal nicotine content tobacco Spectrum Cigarettes along with moderate nicotine level e-liquid cartridges and can choose from tobacco e-liquid flavors.
88843887|NCT03185546|Experimental|NNC cigarette + low nicotine e-liquid + tobacco flavors|Participants are provided with normal nicotine content tobacco Spectrum Cigarettes along with very low nicotine level e-liquid cartridges and can choose from tobacco e-liquid flavors.
88843888|NCT03185546|Experimental|NNC cigarette + moderate nicotine e-liquid + variety flavors|Participants are provided with normal nicotine content tobacco Spectrum Cigarettes along with moderate nicotine level e-liquid cartridges and can choose from tobacco and non-tobacco e-liquid flavors.
88843889|NCT03185546|Experimental|NNC cigarette + low nicotine e-liquid + variety flavors|Participants are provided with normal nicotine content tobacco Spectrum Cigarettes along with very low or nicotine-free nicotine level e-liquid cartridges and can choose from tobacco and non-tobacco e-liquid flavors
88843890|NCT03185546|Experimental|Very Low Nicotine Content (VLNC) cigarette + moderate nicotine e-liquid + tobacco flavor|Participants are provided with very low nicotine content tobacco Spectrum Cigarettes along with moderate nicotine level e-liquid cartridges and can choose from tobacco e-liquid flavors.
88843891|NCT03185546|Experimental|VLNC cigarette + low nicotine e-liquid +tobacco flavors|Participants are provided with very low nicotine content tobacco Spectrum Cigarettes along with very low or nicotine-free nicotine level e-liquid cartridges and can choose from tobacco e-liquid flavors.
88843892|NCT03185546|Experimental|VLNC cigarette + moderate nicotine e-liquid + variety flavors|Participants are provided with very low nicotine content tobacco Spectrum Cigarettes along with moderate nicotine level e-liquid cartridges and can choose from tobacco and non-tobacco e-liquid flavors.
88843893|NCT03185546|Experimental|VLNC cigarette + low nicotine e-liquid + variety flavors|Participants are provided with very low or nicotine-free nicotine content tobacco Spectrum Cigarettes along with very low nicotine level e-liquid cartridges and can choose from tobacco and non-tobacco e-liquid flavors
88843894|NCT05365009||EPIMAR group|EPIMAR (ARgentina's Autoimmune Mechanism Interstitial Pulmonary Disease) registry was created in 2016 by a group of multidisciplinary specialists with experience in the management of ILD.
88843895|NCT05058482|Experimental|Non-adhesive Liquid Embolic System(NALES)|
88843896|NCT05058482|Active Comparator|Onyx Liquid Embolic System& Marathon Flow Directed Micro Catheter|
88843897|NCT03657511|Other|Educational Interventions to Promote Tobacco Cessation|
88843898|NCT04613882|Experimental|Soft Toric Custom Made contact lenses|Subjects will be randomized to wear Soft Toric custom made contact lenses for 30 minutes in one eye with other eye patched.
88843899|NCT04613882|Active Comparator|Soft Spherical Contact Lenses|Subjects will be randomized to wear soft spherical contact lens for 30 minutes in one eye with other eye patched
88843900|NCT04613882|Active Comparator|Spectacle Correction|Subjects will be randomized to wear spectacle Correction for 30 minutes in one eye with other eye patched.
88843901|NCT03713203|Experimental|Pagetex PDT|"PAGETEX medical device for photodynamic therapy (PDT). Composed of the association: Laser source + optical fiber + diffuser support incorporating luminous textiles + drug photosensitizer (Metvixia®)"
88843902|NCT02186652|Other|Pantoprazole|
88843903|NCT03677791|Experimental|Virtual 360° intervention|counselling in the virtual 360° environment and also counselling in accordance with current practice
88843904|NCT03677791|Active Comparator|Control group|counselling in accordance with current practice
89399260|NCT02172404|Experimental|HandiHaler® vs. MDI|sequence during treatment phase: first Placebo capsule administered via HandiHaler then Ipratropium metered dose inhaler
89399261|NCT02172404|Experimental|MDI vs. HandiHaler®|sequence during treatment phase: first Ipratropium metered dose inhaler then Placebo capsule administered via HandiHaler Ipratropium metered dose inhaler
88843905|NCT06289452|Experimental|IVB102 Treatment Arm（Low dose）|Intraocular injection of a single low dose of IVB102
88843906|NCT06289452|Experimental|IVB102 Treatment Arm（Intermediate dose）|Intraocular injection of a single intermediate dose of IVB102
89371156|NCT04897698|Experimental|Double dose|Four capsules of probiotics daily. Probiotic capsules contains strains of pediococcus (Bacterial family of Lactobacillaceae) and saccharomycetes (kingdom of Fungi and the division Ascomycota) with a concentration of 13 millions cfu/g. Other ingredients (including stabilization) include rice bran, vegetable L-Cystein, magnesium salts from vegetable fatty acids. The capsule shell is made of vegetable HydroxyPropylMetylCellulosa (HPMC). Each capsule has a weight of 0.4 gram.
89371157|NCT02702518|Active Comparator|rhDNase I|rhDNase I 0.1% eye drops 4 times a day for 8 weeks
89371158|NCT02702518|Placebo Comparator|Vehicle|Drug vehicle eye drops 4 times a day for 8 weeks
89371159|NCT04935060|Active Comparator|Usual Care Dementia assessment|Clinicians will conduct the assessment and outcome process as per their usual practice.
89371160|NCT04935060|Experimental|Guide informed dementia assessment|The guide will be used by both clinicians, patients and their companions to inform the approach to the dementia assessment process.
89399262|NCT03538964|Active Comparator|Toric intraocular lens (IOL)|toric intraocular lens for low astigmatism correction
89180713|NCT02593500|Experimental|Test+Pulmictan (treatment sequence BA)|"Treatment period 1:~Budesonide 200 µg (test product (B)). Pressurized inhalation suspension. Single dose of 600 µg (3 puffs) under fasting conditions.~Treatment period 2:~Budesonide 200 µg (Budesonida Pulmictan® 200 µg: reference product (A)). Pressurized inhalation suspension. Single dose of 600 µg (3 puffs) under fasting conditions."
88843907|NCT06289452|Experimental|IVB102 Treatment Arm（High dose）|Intraocular injection of a single high dose of IVB102
88843908|NCT06289426|Experimental|Yoga - Group S|The experimental group will participate in 8 weeks of live online yoga classes, 3 times a week for 60 minutes each session. The yoga program will be designed based on previous evidence and personal experience of yoga experts and researchers.
88843909|NCT06289426|No Intervention|Control - Group L|The control group will be waitlisted and will continue with the usual routine for 8 weeks. They will participate in 8-week yoga classes after the completion of the study.
88843910|NCT06289413||Development of AD/OI after BS.|
88843911|NCT06289348||groupe 1|60 parents of children screened for PKU. Each of them will be assessed using a socio-psychological questionnaire (7 days after the announcement) and the revised event impact scale (7 days, 4 and a half months).
88843912|NCT06289348||groupe 2|25 parents from group 1. This smaller sample of 25 parents will be subjected to non-directive interviews (1 month after the announcement) and to the Stern interview (4 and a half months after the announcement).
88843913|NCT06289348||groupe 3|15 doctors : interview
88843914|NCT06289348||groupe 4|5 midwifes : short interview
88843915|NCT06289335|Active Comparator|Dexmedetomidine|0.3 mcg Kg-1 (actual weight) of dexmedetomidine IV in 20 mL of saline
88843916|NCT06289335|Sham Comparator|Ondansetron|8 mg ondansetron IV in 20 mL saline
88843917|NCT06289309|Experimental|NerveTrend|In operations with NerveTrend mode the i-IONM stimulator will be used to test vagal response at the beginning of surgery, map out and trace the RLNs during surgery by repetitive stimulations, and in case of loss of signal (LOS) it will be used to identify the type and site of neural injury (Type I vs. Type II). Final prognostication of postoperative neral function will be based on vagal stimulation at the end of each lobectomy. In addition, the EMG trending including amplitude and latency changes from initial vagal baseline will be evaluated using the NerveTrend mode at 3 - 5min intervals to assure almost real time EMG tracing and allow for modification of surgical maneuvers in case of occurrence of severe combined events (yellow zone) in order not to end up with the LOS (red zone).
88843918|NCT06289309|Active Comparator|NerveAssure|In operations with NerveAssure mode the i-IONM stimulator will be used to test vagal response at the beginning of surgery, map out and trace the RLNs during surgery by repetitive stimulations, and in case of loss of signal (LOS) it will be used to identify the type and site of neural injury (Type I vs. Type II). Final prognostication of postoperative neral function will be based on vagal stimulation at the end of each lobectomy. In addition, the APS electrode will be placed on the Vagus nerve to allow for Automatic Periodic Stimulation of the Vagus nerve to test the RLN condition throughout the surgery and allow for modification of surgical maneuvers in case of occurrence of severe combined events (yellow zone) in order not to end up with the LOS (red zone).
89180714|NCT02594592||Younger Women|Younger Women (age ≤ 55 years),complete questionaire
89399263|NCT03538964|Sham Comparator|Non toric intraocular lens (IOL)|non toric intraocular lens
89399264|NCT02166164|Experimental|Experiemental pain models|all study participants will be tested with the same experimental pain models: Brief thermal sensitization, Long thermal stimulation, and Heat-pain-detection threshold.
88843919|NCT06289296|Experimental|Fatty acid intake in lean males|Lean males will be studied before and after 7 days daily intake of either Medium-chain fatty acids or Long-chain fatty acids. . After a wash-out period the intervention is repeated in opposite sequence.
88843920|NCT06289296|Experimental|Fatty acid intake in obese males|In obese male participants will be studied before and after 7 days daily intake of either medium-chain fatty acids (MCT) or long-chain fatty acids (LCT). After a wash-out period the intervention is repeated in opposite sequence.
89180715|NCT02594592||Younger Men|Younger Men (age ≤ 55 years),complete questionaire
89180716|NCT02594592||Older Men|Older Men (age > 55 years). complete questionaire
88843921|NCT06289283||Bladder carcinoma of non muscle invasive bladder cancer and muscle invasive bladder cancer.|"Group I: Non-muscle invasive bladder cancer,16 patients, 16 for bladder tissue, and 16 for urine samples. Total 32 samples. (The study will explore the microbiota in urine and in tissue samples, so every patient with bladder cancer will give (2 samples). The control group will give urine sample ( one samble). Recent research showed that microbiota is detecred in the urothelium of normal undividuals and patients with bladder cancer, this microbiota would differ from urine( liquid) microbiota.(References: ) Group II: Muscle invasive bladder cancer, 11 patients. 22 samples 11 for bladder tissue and 11 for urine samples obtained from the same patients. Group III: 11 Normal adults: urine samples from serves as control group of the study.~Total number of participant is 38 individual"
88843922|NCT06289270||1-muscle invasive bladder cancer., 2-Non-muscle invasive invasive. 3- Control.|"Samples: Total number of studied samples: The study will explore the microbiota in urine and in tissue samples, so every patient with bladder cancer will give (2 samples). The control group will give urine sample ( one samble).~Group I: Non-muscle invasive bladder cancer,16 patients, 16 for bladder tissue, and 16 for urine samples. Total 32 samples. (The study will explore the microbiota in urine and in tissue samples, so every patient with bladder cancer will give (2 samples). The control group will give urine sample (1 samble).~Group II: Muscle invasive bladder cancer, 11 patients. 22 samples 11 for bladder tissue and 11 for urine samples obtained from the same patients. Group III: 11 Normal adults: urine samples from serves as control group of the study.~Total number of participants is 38 individuals."
88843923|NCT06289257||Endometriosis|Women with endometriosis
88843924|NCT06289257||Control|Healthy women
88843925|NCT06289205|Active Comparator|Group 1|Group 1 will be regarded as control group and per operative methotrexate infusion will be used by mixing 75 mg of methotrexate into one litre of BSS solution.
88843926|NCT06289205|Experimental|Group 2|Group 2 will be regarded as the study group and will receive 500 µg of intra-silicon oil methotrexate at the end of the surgery and then at 1st, 2nd, 3rd , 4th and 6th post operative weeks.
88843927|NCT06289166|Experimental|Consecutive doses of STSP-0601|
88843928|NCT06289140|Experimental|Pterostilbene cocrystal - gelatin capsule|Participants consuming one gelatin capsule of Pterostilbene cocrystal (ccPT)
88843929|NCT06289140|Experimental|Pterostilbene cocrystal - gastro-resistant capsule|Participants consuming one gastro-resistant capsule of Pterostilbene cocrystal (ccPT)
89180717|NCT02594592||Older Women|Older Women (age > 55 years),complete questionaire
89180718|NCT02594358|Active Comparator|Caffeine 20 mg|Patching plus once daily caffeine for 12 weeks
89180719|NCT02594358|Active Comparator|Caffeine 40 mg|Patching plus once daily caffeine for 12 weeks
89180720|NCT00785486|Other|Midazolam alone|Baseline midazolam and 1-hydroxy-midazolam pharmacokinetics. One day 1 after a fast of at least 10 hours patients received a single oral dose of midazolam 2 mg. Blood was drawn at times sufficient to characterize the pharmacokinetics of midazolam and its main metabolite.
89180721|NCT00785486|Other|Qualaquin (quinine) alone steady state|On the morning of day 9 after taking Qualaquin (quinine) capsules 324 mg orally every 8 hours for the prior 5 days, and following a fast of at least 10 hours all study participants received their usual morning dose of Qualaquin (quinine) 324 mg. Blood was drawn at times sufficient to determine the steady state Cmax and AUC 0-tau for Qualaquin (quinine).
89180722|NCT00785486|Experimental|Midazolam with Qualaquin (quinine)|On day 10 after taking Qualaquin (quinine) for 6 days according to the stated regimen, all participants took their usual dose of Qualaquin (quinine) with an oral dose of midazolam 2 mg. Blood was drawn sufficient to characterize the steady state kinetics of quinine and the kinetics of midazolam and 1-hydroxy-midazolam in the presence of each other.
89180723|NCT00917904|Placebo Comparator|vehicle placebo gel|
89180724|NCT00917904|Experimental|dapivirine gel|
89180725|NCT00589979|Experimental|Lidoderm (Lidocaine 5% Patch)|Lidoderm (lidocaine 5% patch) 10cm X 14cm patches each on the front and back of the index knee every 24 hours (q24h)
89180726|NCT00589979|Placebo Comparator|Placebo Patch|Placebo Patch 10cm X 14cm patches each on the front and back of the index knee every 24 hours (q24h)
89399265|NCT02169908|Other|Occurrence of painful neuropathy|Assessment of neuropathic pain with two devices (Thermotest and von Frey hairs) and with the Neuropathic Pain Symptom Inventory.
88843930|NCT06289140|Active Comparator|Pterostilbene free form|Participants consuming one capsule with Pterostilbene free form (PT)
88843931|NCT06289101|Experimental|text4FATHER|Receipt of twice-weekly texts that include resource links and instructions to support behavior change (e.g., videos, infographics) and start mid-pregnancy and continuing through 2 months of baby's age.
88843932|NCT06289101|No Intervention|Usual care|Usual care that is consistent with typical maternity care in involving fathers-to-be.
88843933|NCT06289075||ICU patients|All ICU patients in different countries worldwide from 2005-2023
88843934|NCT06289062|Experimental|NACI in FIGO ⅠB1 Cervical Cancer|Neoadjuvant chemotherapy plus camrelizumab for ⅠB1 Cervical Cancer. Patients first received one cycle of platinum-based doublet priming chemotherapy. After 3 weeks, participants subsequently received two cycles of the PD-1 inhibitor camrelizumab combined with chemotherapy every 3 weeks. The study will be conducted in two stages: (1) Patients enrolled in the first stage with tumors ≤2 cm and no new lesions after completion of treatment will undergo cone biopsy + pelvic lymphadenectomy or SLN mapping. Those who meet ConCerv criteria will undergo a second TCT, HPV and colposcope 3 months later, and those who do not meet ConCerV criteria will undergo radical cervical surgery. (2) Patients enrolled in the second stage with tumors ≤2 cm and no new lesions underwent cervical biopsy + pelvic lymphadenectomy or SLN mapping; patients with LSIL on biopsy underwent TCT, HPV, and colposcope 3 months later; if biopsy suggests HSIL and above, perform cone biopsy.
88843935|NCT06289036||favorable prognosis|modified Rankin scale (mRS) ≤ 2
88843936|NCT06289036||poor prognosis|modified Rankin scale (mRS) > 2
88843937|NCT06289023|Experimental|HA-WBRT-SIB|Patients with lung cancer and brain metastases undergo HA-WBRT-SIB using image-guided radiotherapy, receiving a total dose of 30-36 Gy delivered in 18-20 fractions to the whole brain (CTV), while the dose to the GTV is boosted to 44 Gy-52 Gy in 18-20 fractions, ﬁve times a week. The optimal mean dose (Dmean) to the bilateral hippocampus should optimally be ≤ 8 Gy, with a mandatory maximum dose (Dmax) to the hippocampus not exceeding 10 Gy; the preferred Dmean to the hippocampus PRV should optimally be ≤ 9 Gy, while the mandatory Dmax to the hippocampus PRV should be ≤ 12 Gy. The HVLT-R immediate recall scores are obtained at baseline and 1, 3, and 6 months after treatment.
88843938|NCT06288997|Active Comparator|Active tACS group|a tACS device with a current level of 15mA with a patented frequency of 77.5Hz.
89180727|NCT02594280||Selective Laser Trabeculoplasty (SLT)SLT|Monitor glaucoma patients that are scheduled to be treated with Selective Laser Trabeculoplasty (SLT) with VEP/PERG. The treatment is not dependent on the study.
89180728|NCT02594280||Trabecular stent bypass microsurgery|Monitor glaucoma patients that are scheduled to be treated with trabecular stent bypass microsurgery with VEP/PERG.The treatment is not dependent on the study.
89180729|NCT02590653|Experimental|Group A|Group A patients will start atorvastatin at a dose of 80 mg/day between 24 and 96 hours after the onset of STEMI
89180730|NCT02590653|Active Comparator|Group K|Group K patients will start atorvastatin at a dose of 20 mg/day between 24 and 96 hours after the onset of STEMI
89180731|NCT02590497|Experimental|Diagnostic (MRI, tumor tissue analysis)|Patients undergo MRI before and after gadolinium contrast administration, including 3D volumetric T1-weighted sequence, FLAIR sequence, diffusion weighted imaging, and perfusion MRI. Tissue samples are also analyzed for the tumor genetic profile.
89180732|NCT00797732|Active Comparator|Active Acupuncture|The active intervention used a three-phase step-up protocol to gradually increase the body areas treated and needling intensity. Acupuncture needles (0.20x25mm) were inserted with a depth of 5-10 mm into predefined points based on a systematic literature review following the STRICTA guideline. Needles were stimulated to obtain the de qi sensation. An electroacupuncture (EA) device was connected at two acupoints. All needles remained in place for 30 minutes. The active acupuncture was administered once every 2 weeks for 24 weeks, starting 2 weeks into CRT and ending at 20 weeks after CRT. [Refs: Lu W, Wayne PM et al. Contemp Clin Trials 2012; 33; 700-711; MacPherson H, Altman DG et al. PLoS Med 2010;7:e1000261]
89180733|NCT00797732|Sham Comparator|Sham Acupuncture|The sham intervention was designed to be maximally inert and minimally invasive, while simulating most aspects of the active protocol. Sham needles (0.12x30mm) were inserted at 14 locations paralleling the same body regions needled in the active group; however, all sham point locations were off the pathways of traditional Chinese medicine acupuncture meridians and points. An identical but deactivated EA device was used following sham protocols previously used. The sham acupuncture was administered once every 2 weeks for 24 weeks, starting 2 weeks into CRT and ending at 20 weeks after CRT. [Refs: Lu W, Wayne PM et al. Contemp Clin Trials 2012; 33; 700-711; Wayne PA, Krebs DE et al. Arch Phys Med Rehabil 2005;86:2248-2255]
89180734|NCT04085055|Active Comparator|22 Gauge FNB Needle - ProCore|The 22 Gauge FNB Needle - ProCore will be used to biopsy solid pancreatic mass lesions.
89180735|NCT04085055|Active Comparator|22 Gauge FNB Needle - Acquire|The 22 Gauge FNB Needle - Acquire will be used to biopsy solid pancreatic mass lesions.
88843939|NCT06288997|Sham Comparator|Sham tACS group|a sham device with no tACS
88843940|NCT06288984|Experimental|active rTMS|
88843941|NCT06288984|Sham Comparator|sham rTMS|
88843942|NCT06288971|Experimental|Children with impairment in EF and in visuo-spatial abilities|Children aged 5 to 13 years old with a diagnosis of Cerebral Palsy, with EF impairment and visuo-spatial difficulties
89180736|NCT04085055|Active Comparator|22 Gauge FNB Needle - SharkCore|The 22 Gauge FNB Needle - SharkCore will be used to biopsy solid pancreatic mass lesions.
89180737|NCT04085055|Active Comparator|22 Gauge FNB needle - EZ Shot 3 Plus|The 22 Gauge FNB Needle - EZ Shot 3 Plus will be used to biopsy solid pancreatic mass lesions.
89180738|NCT03945435||Normal Glucose Tolerance|Blood glucose level of less than 140 mg/dL at the 2 hour timepoint.
89180739|NCT03945435||Impaired Glucose Tolerance|Blood glucose level of greater or equal to 140 mg/dL at the 2 hour timepoint.
89399266|NCT02166320|Active Comparator|Partially covered SEMS|Boston Scientific Ultraflex SEMS
89399267|NCT02166320|Experimental|Fully covered SEMS|Boston Scientific Wallflex Esophageal SEMS.
89399268|NCT02166398|Active Comparator|Amosartan 5/50 tab|Amosartan 5/50 tab given by oral administration
89371161|NCT04482946|Experimental|Assessment of fluid responsiveness|The positive end-expiratory pressure test (PEEP-test) consisted of a transient increase of PEEP from 5 to 20 cm H2O for 120 seconds. The PEEP-test was interrupted if MAP decreased below 55 mm Hg and/or pulse contour cardiac index (PCCI) decreased below 1.5 L/min/m2. Mini-fluid challenge test (mFCT) consisted of rapid infusion of crystalloids 1.5 mL/kg during 120 seconds. Thereafter, all patients received fluid challenge (standard fluid challenge test, sFCT). During the sFCT, patients received 7 mL/kg of crystalloids within 10 minutes. Investigators performed monitoring of mean arterial pressure (MAP), SVV and PPVPiCCO using femoral artery (PiCCO2). Investigators also assessed PVVNK using radial artery and Nihon Kohden patient monitor. HLI (Hamilton G-5, Switzerland) and PVI (Masimo, USA) were assessed non-invasively, using finger probes.
89371162|NCT03683888|Experimental|Healthsnap|50 patients will receive HealthSnap assessment in addition to their current treatment regardless of their participation into the study
89371163|NCT03683888|Active Comparator|Diet|50 patients will receive standard of care dietary counselling in addition to their current treatment regardless of their participation into the study
89371164|NCT03683732||Frenchteenagers|
88843943|NCT06288971|Experimental|Children with impairment in EF and in specific cognitive processes underlying academic skills|Children aged 5 to 13 years old with a diagnosis of Cerebral Palsy, with impairment in EF and in specific cognitive processes underlying academic skills
89371165|NCT03739229|Active Comparator|H7N9 LAIV|H7N9 live influenza vaccine at study entry (dose 1) and four weeks post-dose one (dose 2), subjects will receive two, 0.25 ml intranasal doses of study vaccine (total dose 0.50 ml at each study vaccine administration).
88843944|NCT06288971|Experimental|Children with impairment in EF and in motor planning|Children aged 5 to 13 years old with a diagnosis of Cerebral Palsy, with impairment in EF and in motor planning
88843945|NCT06288971|No Intervention|Typically developing children|Children aged 5 to 13 years old with no clinically documented disorders.
89371166|NCT03739229|Placebo Comparator|Placebo|Lyophilized purified allantoic fluid of chicken embryos with stabilizers at study entry (dose 1) and four weeks post-dose one (dose 2), subjects will receive two, 0.25 ml intranasal doses of placebo (total dose 0.50 ml at each placebo administration).
89371167|NCT03680300|Experimental|Post Facilitating Stretch|Each patient in group A will be given with hot pack along with Tens for 20 mins then the patient will receive post facilitation stretch only, for about one month on daily basis.
89371168|NCT03680300|Experimental|Post Isometric Relaxation|Each patient in group B will receive hot pack along with Tens for 20 mins then the patients will receive post isometric relaxation alone for about one months on daily basis.
89371169|NCT03680300|Experimental|Frictional Massage|Frictional massage will be given to 3rd group
89371170|NCT02414620|Experimental|Dental Vibe|New oscillating device for reduction in pain during dental anesthesia
88843946|NCT06288958||Children with Cerebral Palsy|Children aged 4 to 12 with CP diagnosis
88843947|NCT06288945|Experimental|Study Group|The educational nursing interventions were individually administered to each participant in the study group in two sessions which were conducted after the assessment phase on the day of the eye examination at the ophthalmology outpatient clinic and after the diagnosis of dry eye syndrome.
88843948|NCT06288945|No Intervention|Control Group|The control group was selected first and did not receive the educational program for dry eye syndrome
88843949|NCT06288932|Experimental|Mycophenolate Mofetil (MMF) Treatment|"Patients in this arm will receive Mycophenolate Mofetil (MMF) at a starting dose of 500mg twice daily along with Prednisolone.~The pediatric dose of MMF will be calculated by 30mg/kg/day. Dose adjustment will be based on treatment response, with potential increases to 750mg twice daily or 1g twice daily.~MMF will be administered for a specific duration, as determined by the study design."
88843950|NCT06288932|No Intervention|Standard Treatment Control|Patients in this arm will receive the standard treatment for ITP, which may include corticosteroids (prednisolone) commonly used for ITP management.The treatment regimen will be determined based on current standard guidelines and clinical practice.
88843951|NCT06288841|Placebo Comparator|Ropivacaine injection group|
88843952|NCT06288841|Experimental|Bupivacaine liposomal low-dose group|
88843953|NCT06288841|Experimental|Bupivacaine liposomal medium-dose group|
88843954|NCT06288841|Experimental|Bupivacaine liposomal high-dose group|
88843955|NCT06288828|Experimental|Exercise group|Participants in the intervention group will undergo 150 minutes of moderate aerobic exercise per week for 16 weeks, accompanied by a personalized nutritional plan (1.2 grams of protein per kilogram of ideal body weight per day and a calorie intake of 35 kilocalories per kilogram of ideal body weight per day).
89371171|NCT03680222|No Intervention|Standard method|Standard method recommended by the guide
89371172|NCT03680222|Experimental|Reversed Tracking Method|Reversed Tracking Method
89371173|NCT03176524|Experimental|BioChaperone® glucagon formulation 1|Single subcutaneous fixed doses (50 µg and 1.0 mg)
89371174|NCT03176524|Experimental|BioChaperone® glucagon formulation 2|Single subcutaneous fixed doses (50 µg and 1.0 mg)
89371175|NCT03176524|Active Comparator|GlucaGen® HypoKit®|Single subcutaneous fixed doses (50 µg and 1.0 mg)
89371176|NCT03676088|Experimental|Test group - rhPDGF-BB+MCAT+CTG|Root coverage surgical procedure.The patients were assigned into two treatment groups (test and control). Intervention - The test group recession coverage is treated with modified coronally advanced tunnel with connective tissue graft with recombinant human platelet derived growth factor- BB
89371177|NCT03676088|Active Comparator|Control group - MCAT+CTG|Root coverage surgical procedure.The patients were assigned into two treatment groups (test and control). Intervention - The control group recession coverage is treated with modified coronally advanced tunnel with connective tissue graft alone
89371178|NCT02414464|Experimental|35% hydrogen peroxide|Volunteers of this group will receive a gel with 35% hydrogen peroxide - Whiteness HP 35% for whitening treatment.
89371179|NCT02414464|Experimental|35% hydrogen peroxide with calcium|Volunteers of this group will receive a gel with 35% hydrogen peroxide with calcium - Whiteness HP Blue Calcium 35% for whitening treatment.
89371180|NCT02414464|Experimental|20% hydrogen peroxide with calcium|Volunteers of this group will receive a gel with 35% hydrogen peroxide with calcium - Whiteness HP Blue Calcium 20% for whitening treatment.
89371181|NCT02961582|Experimental|Sacral Neuromodulation|
89371182|NCT02961582|Other|Personalized Conservative Treatment|
89371183|NCT04039503|Experimental|5 mg Tirzepatide|5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.
89371184|NCT04039503|Experimental|10 mg Tirzepatide|10 mg tirzepatide administered SC once a week.
89371185|NCT04039503|Experimental|15 mg Tirzepatide|15 mg tirzepatide administered SC once a week.
89371186|NCT04039503|Placebo Comparator|Placebo|Placebo administered SC once a week.
89371187|NCT02414308|Experimental|Adipose tissue stem cell injection|The stem cell will be harvested by liposuction and injection will be at corpora cavernosa and dorsal penile artery
89371188|NCT02860728|Experimental|Resistance training|Patients with COPD will participate in 4 weeks (12 sessions) of individualized, non-linear, lower body resistance training.
89371189|NCT03679910||Group 1|pancreatic cancer patients (50 patients)
89371190|NCT03679910||Group2|A- Non-pancreatic cancer subjects with benign diseases will be 20 subjects. B- Healthy individuals (control): 20 apparently healthy volunteers after informed consent.
89371191|NCT05418114|No Intervention|Group B|Patients will be given local infiltration with 9 ml (180 mg) of 2% lignocaine only.
89371192|NCT05418114|Active Comparator|Group A|Patients will be given local infiltration with 9 ml (180 mg) of 2% lignocaine + 1 ml (500 mg) of 50% Magnesium sulphate
89371193|NCT03683420|Experimental|Group I (music)|The intervention is a behavioral intervention, which consists of giving patients and caregivers iPods to listen to music for up to 60 minutes while the patient is receiving a chemo infusion. The study consists of a presurvey, active listening period, and a post-survey.
89371194|NCT03683420|No Intervention|Group II (control)|The intervention is a behavioral intervention, which consists of giving patients and caregivers iPods to listen to music for up to 60 minutes while the patient is receiving a chemo infusion. Participants and caregivers in the control condition complete a presurvey and post survey but do not listen to music during infusion session .
89371195|NCT03683264|Other|Vacuum delivery|Deliveries completed using vacuum instrumentation were performed by obstetricians with a minimum of five years' experience in obstetric practice. In terms of analgesia, epidural analgesia was used for intrapartum analgesia. The vacuum was a metal vacuum (Bird's cup 50 mm, 80 kPa) was used to perform fetal extraction. Traction was carried out during contraction, along with maternal push, at a rate of 2-3 tractions per contraction, and without associating Kristeller maneuver. The procedure was abandoned if, after three cup slides or 15 min, fetal extraction had not been successful. Selective episiotomy was carried out in vacuum delivery following Valme's University Hospital clinical practice guideline for instrumental deliveries.
89371196|NCT03683264|Other|Forceps delivery|Deliveries completed using forceps instrumentation were performed by obstetricians with a minimum of five years' experience in obstetric practice. In terms of analgesia, epidural analgesia was used for intrapartum analgesia. The forceps used for the instrumentation was the forceps of Kielland. Traction was carried out during contraction, along with maternal push, at a rate of 2-3 tractions per contraction, and without associating Kristeller maneuver. The procedure was abandoned if, after three cup slides or 15 min, fetal extraction had not been successful. Selective episiotomy was carried out in VD following Valme's University Hospital clinical practice guideline for instrumental deliveries.
89371197|NCT01364025|Experimental|uterosacral ligament suspension|uterosacral ligament suspension colpopexy sutures will be placed bilaterally at the time of hysterectomy
89371198|NCT01364025|No Intervention|hysterectomy alone|
89371199|NCT03225716|Experimental|Ibrutinib + Ulocuplumab|"Ibrutinib administered orally once daily~Ulocuplumab administered intravenously 2-4 times per cycle for Cycles 1-6"
89371200|NCT01367067||Psychometric Questionnaire|Adult inpatients and outpatients with a clinical indication of any part of the body who have been referred to Charité for MR imaging and have filled out a psychometric questionnaire
89371201|NCT01367067||No Psychometric Questionnaire|Adult inpatients and outpatients with a clinical indication of any part of the body who have been referred to Charité for MR imaging and did not fill out a psychometric questionnaire
89371202|NCT03672812|No Intervention|placebo|0,5ml
89371203|NCT03672812|Experimental|liraglutide|0,5ml
89371204|NCT05417880|Active Comparator|Group 1 (Control group)|Continue with current oral anti-hyperglycemic regime
89371205|NCT05417880|Active Comparator|Group 2 (Voreta group)|Empagliflozin 10 mg OD
89371206|NCT05417880|Experimental|Group 3 ( Voreta + SunnyD PRO group )|Empagliflozin 10 mg OD + Vitamin D3 (2000 IU) + Vitamin K2 (100 mcg)
89371207|NCT03679832||Historical Group 1|Patients admitted at UMC between September 2015 and October 2016
89371208|NCT03679832||Historical Group 2|Patients admitted at UMC between November 2016 and up to the beginning of the QIP
89371209|NCT03679832||Nutrition-Focused QIP|Patients admitted at UMC that meet eligibility criteria and prospectively enrolled into QIP including malnutrition screening, nutrition consultation, expedited provision of oral nutritional supplementation (ONS) and encouragement of ONS consumption 30-days post discharge
89399269|NCT02166398|Experimental|UI15AML055MT tab|UI15AML055MT tab given by oral administration
88843956|NCT06288828|Other|Control group|The control group will solely receive nutritional guidance and maintain their sedentary lifestyle. The researchers will compare outcomes between these two groups.
88843957|NCT06288776|Experimental|Interventional Group|Participants will be assessed for their tooth sensitivity (VAS scoring) and after giving herbal based mouthwash sensitivity will be assessed after 3 months
88843958|NCT06288711|Active Comparator|Treatment as usual (TAU)|Participants randomized to TAU will continue to receive standard buprenorphine or methadone maintenance treatment from their current treatment provider and complete follow-up assessments as described above. However, they will not receive posttraumatic stress disorder treatment. Staff will mail participants an emergency naloxone kit containing two naloxone doses with simple instructions, a list of resources and contact information for mental health providers and other relevant resources in their community and assistance contacting any resources of interest.
89180740|NCT05541614|Experimental|Subgingival debridement + Flapless Enamel Matrix Derivative|"Subgingival debridement following a minimally-invasive non-surgical treatment (MINST) approach with flapless application of EMD~Root instrumentation under local anesthesia using mini hand instruments (mini curettes) and ultrasonic instruments with fine tips in the furcation area of mandibular first or second molars with class II buccal furcation defects. EDTA gel will be applied for 2 minutes on the affected root surfaces, followed by rinsing with saline and drying prior to the application of Emdogain® FL. Emdogain® FL has been shown to enhance the early healing of periodontal soft tissue wounds resulting from the instrumentation of periodontal pockets."
89180741|NCT05541614|Active Comparator|Periodontal surgery + Enamel Matrix Derivative|"Periodontal surgery following a minimally-invasive surgical treatment (MIST) protocol with application of EMD~Following local anesthesia, minimal flap elevation on the buccal aspect of first or second molars associated with a grade II furcation defect will be performed.Removal of granulation tissues and root instrumentation with mini hand instruments (mini curettes) and ultrasonic instruments with fine tips in the furcation area will then be carried out. EDTA gel will be applied for 2 minutes on the affected root surfaces, followed by rinsing with saline and drying prior to the application of Emdogain®. Then, the surgical flaps will be positioned and sutured in order to completely cover the defects."
89180742|NCT02590731||Control group|Pfeiffer test 6 or above. No or mild cognitive impairment
89180743|NCT02590731||Cognitivt impaired|Pfeiffer test less than 6. Moderate to severe cognitive impairment.
89180744|NCT02608151|Active Comparator|Touch massage without oil|massage without oil
89180745|NCT02608151|Experimental|touch massage with oil|massage with an oil consisting of 4 vegetable oils (40% sunflower oil, 3% grape seed oil, 1.5% coriander oil, and 57% of rapeseed oil)
89180746|NCT02590575|Other|CO2 removal|
89180747|NCT00736944|Experimental|1|"Induction chemotherapy followed by Radiation therapy plus Cisplatin~Induction chemotherapy:~Abraxane 100 mg/m2 IVPB, Day 1, 8, and 15 of cycles 1, 2, and 3. Cetuximab 400 mg/m2 IVPB, Day 1, cycle 1. Cetuximab 250 mg/m2 IVPB, Day 8 and 15 cycle 1, 2 and 3. Cisplatin 75 mg/m2 IVPB, Day 1, cycles 1, 2, and 3. 5-FU 750 mg/m2 CIVI, Day 1, 2 and 3, cycles 1, 2, and 3.~Post-Induction:~Radiation - Monday-Friday weeks 1-7 with concurrent Cisplatin 100 mg/m2 IVPB on radiation day 1, 22, and 42."
89180748|NCT00736944|Experimental|2|"Induction chemotherapy followed by Radiation therapy plus Cetuximab~Induction chemotherapy:~Abraxane 100 mg/m2 IVPB, Day 1, 8, and 15 of cycles 1, 2, and 3. Cetuximab 400 mg/m2 IVPB, Day 1, cycle 1. Cetuximab 250 mg/m2 IVPB, Day 8 and 15 cycle 1, 2 and 3. Cisplatin 75 mg/m2 IVPB, Day 1, cycles 1, 2, and 3. 5-FU 750 mg/m2 CIVI, Day 1, 2 and 3, cycles 1, 2, and 3.~Post-Induction:~Radiation - Monday-Friday weeks 1-7 with concurrent Cetuximab (for patients who cannot receive cisplatin) will begin (+/- 3 days) before starting radiation therapy at 400 mg/m2 IVPB. Subsequent doses of cetuximab will be given weekly at 250 mg/m2 IVPB"
89180749|NCT03195959||PH-Patients|Patients with mean pulmonary artery pressure >25mmHg and a pulmonary arterial wedge pressure <15mmHg during right heart catheterisation, which are diagnosed as having pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension.
89180750|NCT03195959||Control group|Patients with clinically indicated right heart catheterisation (because of dyspnea or other signs of PH), but had no PH (no elevated mean pulmonary artery pressure (mPAP <20mmHg)).
89180751|NCT02590419|No Intervention|Control Group|Control Group (involvement of BrightMatter™ Plan (BMP)): Patients with temporal lobe epilepsy, who have been identified as candidates for anterior temporal lobe resection (ATLR) will be recruited. All epilepsy patients will have clinical MRI scans that include a diffusion tensor imaging (DTI) protocol. Surgery will be carried out according to usual standard of care, without the use of processing for DTI tractography. Additional clinical scanning with the same protocol will be carried out post-operatively at 6 months. Pre-operative and post-operative (6-month) visual field assessments (Estermann Perimetry and Humphrey Perimetry) will also be carried out . Primary outcomes will be assessed to identify the baseline incidence of visual of postoperative visual field deficits.
89180752|NCT02590419|Experimental|Treatment Arm|Treatment group (involvement of all three products BrightMatter™ Plan (BMP), BrightMatter™ Bridge (BMB), and BrightMatter™ Guide(BMG): A treatment group (prospective enrollment) that uses the interventional technology will be recruited based on the same eligibility criteria as control cohort. All epilepsy patients will have clinical MRI scans that include a DTI protocol. For this treatment group of patients, the BrightMatter system (BMB,BMP, and BMG) will be employed pre-operatively and intra-operatively for planning before and guidance during anterior temporal lobe resection (ATLR). Additional clinical scanning with the same protocol will be carried out post-operatively at 6 months. Pre-operative and post-operative (6-month) visual field assessments (Estermann Perimetry and Humphrey Perimetry) will also be carried out. Primary outcomes will be assessed to evaluate the effect of surgical planning and guidance with DTI tractography on outcomes, by comparison against the control cohort.
89371210|NCT05186883|Experimental|Treatment with allogenic parathyroid cells|Patients with postoperative hypoparathyroidism receiving standard treatment and allogenic parathyroid cells
89371211|NCT05186883|Active Comparator|Control|Patients with postoperative hypoparathyroidism receiving standard treatment
89371212|NCT05007652|Experimental|multiple myeloma cohort (KRN125)|
89371213|NCT05007652|Active Comparator|multiple myeloma cohort (KRN8601)|
89371214|NCT05007652|Experimental|malignant lymphoma cohort|
89371215|NCT03675932|Experimental|Cycling Intervention|Single-arm trial. All participants will receive the same intervention of Rapid Cadence Cycling on a Solo-Rider Spin Bicycle
89371216|NCT01367145|Active Comparator|Omacor|
89371217|NCT01367145|Placebo Comparator|Placebo|
88843959|NCT06288711|Experimental|Prolonged exposure therapy (PE)|In addition to receiving standard buprenorphine- or methadone-maintenance treatment from their current provider and completing scheduled assessments as described above, PE participants will also receive 12 individual sessions of prolonged exposure therapy scheduled weekly over the 12-week treatment period and delivered via a secure and university-supported telemedicine platform. Beginning in study week 1, PE participants will complete weekly 60-minute telemedicine-delivered prolonged exposure therapy sessions provided by doctoral or master's level therapists trained in prolonged exposure therapy.
88843960|NCT06288711|Experimental|Prolonged exposure therapy + attendance contingent financial incentives (PE+)|Participants assigned to the PE+ condition will receive the procedures noted above for the PE group plus financial incentives delivered contingent upon completion of PE sessions.
88843961|NCT06288672|Active Comparator|True avoidance diet|Food patch test-directed avoidance diet for 16 weeks where participant avoids avoid eating the food(s) to which they are allergic
88843962|NCT06288672|Sham Comparator|Sham avoidance diet|Avoidance diet for 16 weeks of randomly selected foods to which the patch testing did not show an allergy
88843963|NCT06288646||Confirmed Lung Cancer|"To be eligible for the lung cancer group:~Aged 50 and over;~Current or former smoker with smoking history ≥ 20 pack-years;~Capacity to give informed consent;~Non-metastatic non-small cell lung cancer, that has not been treated~No history of active cancer in the past 5 years (exceptions include: Ductal carcinoma in situ (DCIS), cervical intraepithelial neoplasia (CIN), non-invasive bladder cancer, non-melanoma skin cancers, Gleason prostate cancer ≤ 6);~Able to provide a breath sample.~To be eligible for a second breath sample:~Same as above, in addition to, and with the exception of criterion 4:~Non-metastatic non-small cell lung cancer, which has undergone surgical resection;~6 months since completion of surgery, radiation, and chemotherapy on primary NSCLC;~CT scan at least 6 months after surgical resection, confirming the absence of lung cancer."
88843964|NCT06288646||Control|"For a participant to be eligible in the study control group:~Aged 50 and over;~Current or former smoker with smoking history ≥ 20 pack-years;~Capacity to give informed consent;~No history of active lung cancer;~No pulmonary nodule(s);~No active cancer in the last 5 years; (Note: DCIS, CIN, non-invasive bladder cancer, non-melanoma skin cancers, Gleason ≤ 6 prostate cancer will be exceptions);~Ability to provide a breath sample."
88843965|NCT06288646||Stable pulmonary nodule|"For a participant to be eligible for admission to the stable lung nodules group:~Aged 50 and over;~Current or former smoker with smoking history ≥ 20 pack-years;~Capacity to give informed consent;~No history of active lung cancer or other active cancer in the past 5 years; (Note: DCIS, CIN, non-invasive bladder cancer, non-melanoma skin cancers, Gleason prostate cancer ≤ 6 or lower will be exceptions);~Presence of one or more stable lung nodules (as determined by the principal investigator);~Ability to provide a breath sample."
88843966|NCT06288620|Experimental|Microwave Ablation|Preoperative US-guided microwave ablation of breast cancer
89371218|NCT03679754|Experimental|Ad-RTS-hIL-12 + veledimex|Intratumoral Ad-RTS-hIL-12 and oral veledimex
89371219|NCT02405572|Active Comparator|Formula 1|infant formula
89371220|NCT02405572|Active Comparator|Formula 2|infant formula
89371221|NCT01319409|Experimental|Anatomic Double-Bundle ACL Reconstruction|Subjects in this arm will undergo anatomic double-bundle ACL reconstruction using an autograft quadriceps tendon with a bone block. The graft will be split into 2 strands, 1 to recreate the posterolateral (PL) bundle, the other to recreate the anteromedial (AM) bundle of the ACL. The bone block will be placed in a single femoral tunnel located in the center of the femoral ACL insertion site. The free ends of the graft will be placed in tunnels located in the centers of the tibial insertions for the PL and AM bundles. The PL bundle will be fixed with the knee in full extension and the AM bundle will be fixed with the knee at 45 degrees of flexion.
89371222|NCT01319409|Active Comparator|Anatomic Single-Bundle ACL Reconstruction|Subjects in this arm will undergo anatomic single-bundle ACL reconstruction using an autograft quadriceps tendon with a bone block. The graft will not be split. The bone block will be placed in a single femoral tunnel located in the center of the femoral ACL insertion site. The free end of the graft will be placed in single tunnel located in the center of the tibial ACL insertion site. The graft will be fixed with the knee at 10 20 20 degrees of flexion.
89371223|NCT02405806|Experimental|low carbohydrate food|"The subjects will be given a diet with moderate, low carbohydrate content for 3 months, or as a single test meal, and this will be evaluated in metabolic parameters, microbiota and biomarkers in serum as described previously.~Intervention: Food: Low carbohydrate food"
89399270|NCT00109538|Experimental|Lonafarnib|Lonafarnib 200 mg twice daily, oral, continuously
89399271|NCT00109538|Placebo Comparator|Placebo|Placebo, BID, oral
88843967|NCT06288581|Experimental|Traditional toothbrush group|Children in this group will use a traditional brush first to clean their teeth then will use U shaped brush later.
88843968|NCT06288581|Experimental|U shaped toothbrush group|children in this group will use a U-shaped brush first to clean their teeth then will use traditional brush later
88843969|NCT06288542|No Intervention|group c|control group . this group will not receive any iv fluids
88843970|NCT06288542|Experimental|group d|Group D will receive 1 mL/kg/h 5% Dextrose infusion, applied preoperatively during fasting until induction of anesthesia
88843971|NCT06288542|Active Comparator|group r|this group will receive 1 mL/kg/h ringer infusion, applied preoperatively during fasting until induction of anesthesia
88843972|NCT06288529||Patients with type 2 diabetes mellitus using SGLT2 inhibitor|
88843973|NCT06288529||Patients with type 2 diabetes mellitus not using SGLT2 inhibitor|
88843974|NCT06288529||Patients with chronic kidney disease mellitus using SGLT2 inhibitor|
88843975|NCT06288529||Patients with chronic kidney disease mellitus not using SGLT2 inhibitor|
88843976|NCT06288503|Experimental|Intervention|Hydrolysed rice protein formula
88843977|NCT06288503|Active Comparator|Control|Cow's milk based extensively hydrolysed formula
88843978|NCT06288490|Experimental|amorphous calcium carbonate|Ten (10) subjects previously diagnosed and chronically treated for primary hypoparathyroidism will be enrolled. The daily CCS intake will be gradually replaced by reduced amount of elemental calcium from ACC. Five (5) subjects will consume the ACC before having a meal and the other five (5) subjects will consume the ACC after having a meal. The safety and the efficacy of the treatment will be closely monitored throughout this phase.
88843979|NCT06288464|Experimental|Intervention|Stoma feeding
88843980|NCT06288425||No rejection, normal biopsy (controls)|Normal biopsy - no acute tubular injury (ATI), rejection or any other pathology
88843981|NCT06288425||Acute kidney injury without evidence of rejection|Biopsy features of acute tubular injury but no evidence of rejection
88843982|NCT06288425||Subclinical Rejection|Biopsy features of injury and inflammation but not meeting current diagnostic criteria for acute or chronic rejection
88843983|NCT06288425||Acute rejection|Biopsy features of T-cell mediated, antibody-mediated, or mixed rejection
88843984|NCT06288425||Isolated vascular rejection|Biopsy features of inflammation in the blood vessels only
88843985|NCT06288425||Isolated glomerulitis|Biopsy features of inflammation in the glomeruli only
88843986|NCT06288425||Chronic (active) rejection|Biopsy features of chronic rejection - T-cell, antibody or mixed types
88843987|NCT06288425||BK virus associated nephropathy (BKVAN)|Biopsy features of SV40 positive staining in tubules to diagnose BKVAN
88843989|NCT06288399||Obesity Group|Adults with diagnosis of obesity and obesity-related comorbidities
89371224|NCT02405806|Active Comparator|standard food|The subjects will be given a diet with standard food as a single test meal, and this will be evaluated in metabolic parameters, microbiota and biomarkers in serum, as described Intervention: Food: Standard food
89371225|NCT03632772|Experimental|Solifenacin 5 mg for 4 weeks|Solifenacin 5 mg once-daily for 4 weeks.
89371226|NCT03632772|Experimental|Mirabegron 50 mg for 4 weeks|Mirabegron 50 mg once-daily for 4 weeks.
89371227|NCT03632772|No Intervention|Control: non treatment|Control: non treatment.
88843990|NCT06288373|Experimental|Camrelizumab combined neoadjuvant chemotherapy plus radical surgery|Patients receive 1 cycle of cisplatin and nab paclitaxel combined neoadjuvant chemotherapy and subsequent 2 cycles of camrelizumab combined neoadjuvant chemotherapy. Based on the tumor size as indicated by MRI, patients who achieve complete response or partial response (CR/PR，RECIST v1.1) will undergo open radical hysterectomy and pelvic lymph node dissection. Patients who show stable disease or progression (SD/PD，v1.1) will proceed directly to concurrent chemoradiotherapy (CCRT).
88843991|NCT06288373|Active Comparator|Concurrent Chemoradiotherapy (CCRT)|Pelvic EBRT + concurrent platinum-containing chemotherapy + brachytherapy
88843992|NCT06288360|Experimental|Neoadjuvant chemotherapy plus camrelizumab (NACI)|Patients first received one cycle of platinum-based doublet priming chemotherapy. After 3 weeks, participants received two cycles of the PD-1 inhibitor camrelizumab combined with chemotherapy every 3 weeks.
88843993|NCT06288334|Experimental|Pediatric patients treated with cetirizine|Pediatric patients who were being treated with cetirizine to fight allergic diseases.
89371228|NCT01360749|Experimental|Lambdalina and placebo|Eligible patients will receive lambdaline (lidocaine cream 40 mg/g) in Left Lower Extremity and placebo in Right Lower Extremity.
89371229|NCT01360749|Experimental|Placebo and lambdalina|Eligible patients will receive placebo in Left Lower Extremity and lambdaline (lidocaine cream 40 mg/g) in Right Lower Extremity.
89371230|NCT02405650||CRIC VAP cohort|"If eligible, the participant will have additional testing at regular annual CRIC Visit. The following will occur:~abdominal and pelvic Magnetic Resonance Imaging (MRI) scan~400 meter walk test for physical fitness"
88843994|NCT06288321|Placebo Comparator|Standard Mydrin-P Group|Subjects allocated to the Standard Mydrin P group will receive standard Mydrin-P (0.5% tropicamide / 0.5% phenylephrine HCl) which is the standard eyedrops used for dilation of pupil before retinopathy of prematurity examination.
89371231|NCT01367223|Experimental|solution of amino acids with glutamine|Group 1 as the experimental group who will be administered a solution of amino acids supplemented with glutamine
89371232|NCT01367223|Other|amino acids solution without glutamine|Group 2:control group will be administered a solution of amino acids (Aminoven Infant® or Vamin®) not supplemented with glutamine
88843995|NCT06288321|Experimental|Microdrop group|Those allocated to the microdrop group will receive microdrop Mydrin-P for pupil dilation before retinopathy of prematurity exam.
89371233|NCT03171532|Active Comparator|4 strand hamstring ACL reconstruction|The hamstring tendons will be harvested by standard technique and the lengths of the Semitendinosus and Gracilis tendons will be measured after clearing all adherent muscle tissue. The ends will be prepared and folded in middle to prepare4-strand graft.
89371234|NCT03171532|Active Comparator|5 strand hamstring ACL reconstruction|The hamstring tendons will be harvested by standard technique and the lengths of the Semitendinosus (ST) and Gracilis (GR) tendons will be measured after clearing all adherent muscle tissue. For 5-strand graft, minimum length of ST and GR in consideration would be 24 cm and 16 cm respectively. For 5-strand group the ST tendon will be be folded twice and sutured on itself to make a three strand graft and then GR tendon will be folded once along with it to make a final 5-strand graft.
89371235|NCT03672656|Experimental|pattern scanning laser system Pascal|
89371236|NCT03672656|Active Comparator|conventional laser|
89371237|NCT03675854|Experimental|Extended Group|3 weeks of antibiotics
89371238|NCT03675854|Active Comparator|Conventional Group|2 weeks of antibiotics
89371239|NCT03171688||Modeling|It is the cohort that will be used for selecting risk factors and models for predicting postoperative nausea and vomiting.
89371240|NCT03171688||Validation|It is the cohort that will be used for validation of risk factors and models selected in the modeling group.
89371241|NCT03672578|Experimental|Loss-frame, text-only, no attribution|Label participants will see is loss-frame, text-only, and with no attribution
89371242|NCT03672578|Experimental|Gain-frame, text-only, no attribution|Label participants will see is gain-frame, text-only, and with no attribution
89371243|NCT03672578|Experimental|Loss-frame, icon, no attribution|Label participants will see is loss-frame, icon, and with no attribution
89371244|NCT03672578|Experimental|Grain-frame, icon, no attribution|Label participants will see is gain-frame, with an icon, and with no attribution
89371245|NCT03672578|Experimental|Loss-frame, icon, attribution|Label participants will see is loss-frame, icon, and with attribution
89371246|NCT03672578|Experimental|Gain-frame, icon, attribution|Label participants will see is grain-frame, icon, and with attribution
89371247|NCT03672578|Experimental|Loss-frame, text-only, attribution|Label participants will see is loss-frame, text-only, and with attribution
89371248|NCT03672578|Experimental|Gain-frame, text-only, attribution|Label participants will see is gain-frame, text-only, and with attribution
89371249|NCT03672578|Placebo Comparator|No label|Participant will not see a label
89371250|NCT02414074|Other|Youth Behavioral Intervention|Teen Intervene Program
89371251|NCT02414074|Other|Parent Education|Everyday Parenting Program
89371252|NCT01367379||Physician of internal medicine in Taipei city hospital|
89371253|NCT02409472|Other|minimal surveillance|Minimal program for colon cancer: Office visit and CEA at 4,8,12,16,20,24,30,36,42,48, and 60 months. Colonoscopy at 12, and 48 months. Liver echography* at 8, and 20 months.
89371254|NCT02409472|Other|intensive surveillance|Intensive program for colon cancer: Office visit, complet blood count (CBC), CEA+ Carbohydrate Antigen (CA) 19.9 at 4,8,12,16,20,24,30,36,42,48, and 60 months. Colonoscopy at 12, 24, 36, 48,and 60 months. Liver echography* at 4,8,12,16,24,36,48, and 60 months. Chest X-ray at 12,24,36,48,and 60 months.
89371255|NCT03679520|Experimental|New programme|A new programme of antenatal parental preparation provided by midwives to groups with 8-16 individuals. It will include 5 sessions á 2 hours and start in gestational week 25.
89371256|NCT03679520|Active Comparator|Regular programme|A regular programme of antenatal parental preparation provided by midwives to groups of 8-16 individuals and encompassing between 5 and 7 hours of antenatal parental preparation.
89371257|NCT02413840|Experimental|Baduanjin qigong group|Doing exercise of Baduanjin qigong under the guidance of medical staff;psychological counseling at the same time.
89371258|NCT02413840|No Intervention|control group|Psychological counseling only.
89371259|NCT01360827|Experimental|Arm 1 (Part 1)|
89371260|NCT01360827|Experimental|Arm 2 (Expansion cohorts -Part 2 and Part 2a)|
89371261|NCT03171610|Experimental|Sufentanil group|Arm Description: PCA with sufentanil (3 mcg/kg), ramosetron (NaseaTM) 0.3 mg and ketorolac 120 mg in a normal saline with a total volume of 100ml
89371262|NCT03171610|Active Comparator|Fentanyl group|PCA with fentanyl (20 mcg/kg), ramosetron (NaseaTM) 0.3 mg and ketorolac 120 mg in a normal saline with a total volume of 100ml
89371263|NCT01364181|Experimental|Udenafil|Udenafil 50mg qd po
89399272|NCT02172482||Symptoms of COPD|Patients with symptoms of COPD receiving Tiotropium bromide 18 micrograms
89399273|NCT02169986|No Intervention|control group|Parents/caregivers will receive the standard of care.
88809919|NCT01213199|Experimental|Differin 0.3%|"Differin® 0.3% Gel~Adapalene 0.3%~Topical to the face, once daily application in the evening for the first four weeks and twice daily application in the morning and in the evening for the following 20 weeks."
88809920|NCT03809702|Active Comparator|Pregabalin group|Group 1: Pregabalin tablet 75 mg orally twice daily for 4 weeks will be given to the subjects in this group along with other routine treatment Here, the intervention is administration of Pregabalin tablet 75 mg
88809921|NCT03809702|Placebo Comparator|Placebo group|Group 2: Placebo tablet twice daily for 4 weeks will be given to the subjects in this group along with other routine treatment
88809922|NCT03806036|Active Comparator|Vitamin D group|50 women will receive 300.000 I.U single dose of VIT D IM injection (Memphis company) , and in the next menstrual cycle induction done by clomiphen citrate 100mg daily for 5 days starting from third day of menstruation and HMG single dose on 8th day
88809923|NCT03806036|Placebo Comparator|Control group|50 women will receive clomiphen citrate 100mg daily for 5 days starting from third day of menstruation and HMG single dose on 8th day
88809924|NCT01213589||Descending thoracic aortic dissection|Patients diagnosed with a descending thoracic aortic dissection and who are amenable to stent-graft operation. The patient had an indication for treatment by either endovascular stent graft implantation for either an acute, sub-acute or chronic Type B dissection.
88809925|NCT03806504|Active Comparator|high PEEP|35 cm/H2O PEEP, 2-3 ml/kg tidal volume,45 seconds, after cardiopulmonary bypass
88809926|NCT03806504|Active Comparator|control group|6 cm/H2O PEEP, 6-8 ml/kg tidal volume, continues, after cardiopulmonary bypass
88809927|NCT01213823||Cases|Potential cases were defined as patients with a diagnosis of severe hepatic injury identified in the acute-care inpatient cohort using ICD-9 codes associated with the case definition of severe liver injury. Case status was validated by a Consultant Gastroenterologist blinded to study drug exposure via medical record review using an apriori algorithm. Only validated cases were included in the analysis (N=69)
88809928|NCT01213823||Controls|Controls were defined as patients without a diagnosis of severe hepatic injury (i.e. with no ICD-9 codes associated with the case definition of severe liver injury) selected at random from the same acute-care inpatient cohort as cases (N=467)
88809929|NCT00780026|Experimental|Strict Glycemic Control|strict glycemic control (80 to 110 mg/dl)
89371264|NCT02409550||113 patients with concomitant asthma and allergic rhinitis|113 patients with concomitant asthma and allergic rhinitis followed up from at least 3 months will be enrolled for the validation process at outpatient clinic of Pediatric Allergology & Pulmonology (PAP) of Respiratory Disease Research Center (RDRC) within the Institute of Biomedicine and Molecular Immunology (IBIM) of the National Research Council (CNR) of Palermo (RDRC-IBIM CNR), Italy.
89371265|NCT02414230||Experimental F 18 T807|
89371266|NCT03679442|Experimental|Healthy individuals|Healthy individuals received intravenous N-acetylcysteine (NAC) treatment to investigate its actions on macrophage activation assessed by the markers soluble CD163 and CD206
89371267|NCT01367535|Experimental|Arm 1|
88843996|NCT06288295||Score development cohort|Patients over 60 years of age admitted to a general medicine department in the investigating center between October 2021 and February 2022
88843997|NCT06288295||Score validation cohort|Patients over 60 years of age admitted to a general medicine department in the investigating center between October 2022 and February 2023
88843998|NCT06288282||Patients with chronic back pain with lumbar, cervical or thoracic spine diagnoses.|
88843999|NCT06288269||Control of Hypertension or/and Type 2 Diabetic|Control disease of HT Control disease of DM2 Control disease of HT plus DM2
88844000|NCT06288269||Uncontrol of Hypertension or/and Type 2 Diabetic|Uncontrol disease of HT Uncontrol disease of DM2 Uncontrol disease of HT plus DM2
88844001|NCT06288256||Adults Undergoing Spine Surgery|Adults Undergoing Spine Surgery on opiods
88844002|NCT06288230|Experimental|vesemnogene lantuparvovec|One-time Intravenous administration of vesemnogene lantuparvovec according to an ascending dose design.
88844003|NCT06288204|Experimental|Conservative Group: Propolis+Royal Jelly|4 capsules a day, providing daily royal jelly in an amount of 100 mg/day plus 500 mg/day of propolis, for 2 months.
88844004|NCT06288204|Experimental|Conservative Group: Royal Jelly|4 capsules a day, providing daily royal jelly in an amount of 100 mg/day, for 2 months.
89371268|NCT01367535|Experimental|Arm 2|
89371269|NCT01367535|Active Comparator|Arm 3|
88844005|NCT06288204|Placebo Comparator|Conservative Group: Placebo|4 capsules a day of placebo.
88844006|NCT06288204|Experimental|Hemodialysis Group: Propolis+Royal Jelly|4 capsules a day, providing daily royal jelly in an amount of 100 mg/day plus 500 mg/day of propolis, for 2 months.
88844007|NCT06288204|Experimental|Hemodialysis Group: Royal Jelly|4 capsules a day, providing daily royal jelly in an amount of 100 mg/day, for 2 months.
88844008|NCT06288204|Placebo Comparator|Hemodialysis Group: Placebo|4 capsules a day of placebo.
88844009|NCT06288204|Experimental|Hyperthension Group: Propolis+Royal Jelly|4 capsules a day, providing daily royal jelly in an amount of 100 mg/day plus 500 mg/day of propolis, for 2 months.
88844010|NCT06288204|Experimental|Hyperthension Group: Royal Jelly|4 capsules a day, providing daily royal jelly in an amount of 100 mg/day, for 2 months.
88844011|NCT06288204|Placebo Comparator|Hyperthension Group: Placebo|4 capsules a day of placebo.
88844012|NCT06288178|Experimental|Types of bread|The three breads (whole wheat bread, buckwheat bread, and cornmeal bread) contained 30 grams of digestible carbohydrates. Participants consumed these breads when they were hungry. Blood glucose was measured with a glucometer at 0 (fasting), 30, 60, 90, and 120 minutes. Anthropometric measurements were measured by BIA method and weight classification (obesity and normal weight) was made.
88844013|NCT06288178|Experimental|Reference bread (White bread)|Control group. Blood glucose comparison of all breads was determined according to white bread. The measurement method used was the same as for the other breads.
89371270|NCT01367535|Placebo Comparator|Arm 4|
89371271|NCT02414776|Experimental|hydroxychloroquine plus hormonal therapy|Add hydroxychloroquine to the current hormonal therapy
89371272|NCT03174418||Cohort A|Patients with bifurcated coronary lesions treated by percutaneous coronary interventions.
89371273|NCT03174418||Cohort B|Patients with untreated bifurcated coronary lesions.
89371274|NCT03679364||LUOTAI group|LUOTAI group treated with LUOTAI with dosage, dosing schedule and duration follows local clinical practice in accordance with the terms of the local marketing authorization: 400mg of LUOTAI injectable lyophilized powder diluted in 250ml of 5% Glucose Solution or 0.9% Normal Saline for included diabetic patients, via slow intravenous infusion, once daily for consecutive 14 days, and followed by 200mg of LUOTAI soft capsules, three times a day for 65 days.
89371275|NCT03679364||Control group|Control group comprises of patients who are not treated with LUOTAI, and follows local clinical practice for ischemic stroke.
89371276|NCT02413762||NGT, no insulin resistance|Individuals with normal glucose tolerance without a diagnosis of IGF, IGT or Diabetes Mellitus. No intervention.
89371277|NCT02413762||IFG/IGT/T2DM|Individuals with a diagnosis of impaired glucose tolerance, impaired fasting glucose or type 2 diabetes mellitus. No intervention.
89371278|NCT02413762||Insulin resistance without IGT|e.g. polycystic ovarian syndrome. No intervention.
89371279|NCT02413762||IGT, no insulin resistance|e.g. T1DM. No intervention.
89371280|NCT02413762||Previous metabolic surgery|Previous metabolic surgery for weight loss or treatment of T2DM. No intervention.
89371281|NCT05187663|Active Comparator|Study group|In the test group, implant surface decontamination was performed with photodynamic therapy.
89002074|NCT06116435|Experimental|PreventT2 + Move group-based classes + Mental Imagery + Move 1:1 Support|Participants will receive a 6-month lifestyle weight management program based on the publicly available Prevent T2 curriculum (formally known as the National Diabetes Prevention Program), integrated with the Move group-based classes. Group classes will be delivered weekly in weeks 1-12, and biweekly in weeks 13-26. Group-based classes will be taught virtually by a trained Registered Dietitian from the Colorado Nutrition Obesity Research Center Clinical Intervention and Translation (CIT) Core. Participants will also receive Move individualized support sessions. The 1:1 support sessions are designed to help participants adopt the physical activity messages from each Move group-based class into their daily lives. In addition, participants will receive access to online mental guided imagery sessions. Guided positive exercise imagery scripts were developed based on work from Williams et al. and prompt several sensory and emotional experiences.
89371282|NCT05187663|Active Comparator|Control group|In the control group, implant surface decontamination was performed with 1% chlorhexidine gel.
89371283|NCT03672422||Acute Recurrent Pancreatitis|At least 2 episodes of acute pancreatitis with complete resolution of pain and a >1 month pain-free interval between episodes.
89002075|NCT06116435|Experimental|PreventT2 + Move group-based classes + Fitness Membership + Mental Imagery + Move 1:1 Support|Participants will receive a 6-month lifestyle weight management program based on the publicly available Prevent T2 curriculum, integrated with the Move group-based classes. Group classes will be delivered weekly in weeks 1-12, and biweekly in weeks 13-26. Group-based classes will be taught virtually by a trained Registered Dietitian. Participants will also receive a 6-month membership to the Peloton fitness app. Participants will also receive Move individualized support sessions. In addition, participants will receive access to online mental guided imagery sessions.
89371284|NCT03672422||Chronic Pancreatitis|"Children with at least:~1) One irreversible structural change* in the pancreas with or without abdominal pain +/- exocrine pancreatic insufficiency +/- diabetes.~*irreversible structural changes:~Ductal calculi, dilated side branches, parenchymal calcifications found in any imaging (abdominal ultrasound (abd US), magnetic resonance imaging/magnetic resonance cholangiopancreatography (MRI/MRCP), computerized tomography (CT), endoscopic retrograde cholangiopancreatography (ERCP), endoscopic US (EUS).~Ductal obstruction or stricture/dilatation/irregularities that are persistent (for >2 months) on any imaging.~Parenchymal atrophy, irregular contour, accentuated lobular architecture, cavities alone are not diagnostic findings for CP.~Surgical or pancreatic biopsy specimen demonstrating histopathologic features compatible with CP (acinar atrophy, fibrosis, protein plugs, infiltration with lymphocytes, plasma cells, macrophages)."
89371285|NCT03171376|Active Comparator|Intraorifice Group|After root canal treatment intraorifice barrier of glass-ionomer cement (Ketac™ Molar, 3M ESPE ) placed 3mm inside canals from root canal orifice.
89371286|NCT03171376|Active Comparator|Base Group|2mm thick base of glass-ionomer cement (Ketac™ Molar, 3M ESPE ) applied uniformly on the floor of the pulp chamber after completion root canal treatment.
89002076|NCT06116357|Other|Health volunteers|Evaluate the CB activity of health volunteers as the control
89002077|NCT06116344||experimental|experimental: patients with a condition
89002078|NCT06116344||control group|control group: patients without condition
89002079|NCT06116331||Participants|Participants will complete 3 online questionnaires at 6 month intervals. At the first two time points they will also be asked to submit 2 at home stool sample tests, to assess fecal calprotectin.
89002080|NCT06116318||MRD negative|c-Kit mutation tested negative
89002081|NCT06116318||MRD L1|MRD detection at low level-1：<0.001%
89002082|NCT06116318||MRD L2|MRD detection at low level-2：0.001%≤c-Kit MRD<0.01%
89002083|NCT06116318||MRD L3|detection at low level-3：0.01%≤c-Kit MRD<0.1%
89002084|NCT06116318||MRD positive|MRD positive：c-Kit MRD≥0.1%
89002085|NCT06116279|Experimental|Insertion of electrode during planned neurosurgery for epilepsy|During the surgical procedure, following exposure of the brain via a craniotomy, the novel electrodes will be inserted into tissue planned for resection. This will be targeted using the existing neuronavigation software that is being used during the surgery and may be augmented by intraoperative ultrasound, also a common adjunct used in these surgeries. Following insertion of the electrode, the cables will be connected to a specialised (portable) amplifier inside the operating theatre and 15 minutes of data will be recoded. The electrodes will then be removed and the surgical resection will then proceed as planned. The content of the recordings will not be available in real-time and will not be used to inform or change the surgical resection plan in any way.
89371287|NCT03171376|Active Comparator|Control Group|Neither intraorifice barrier nor base applied after completion of root canal treatment.
89371288|NCT03171298|Experimental|transanal TME|Laparoscopic Assisted Transanal Total Mesorectal Excision
89371289|NCT03672266||Neurological Disorder|Individuals with neurological disorders such as Autism Spectrum Disorder(s), including those who may also have an ADHD diagnosis, Asperger's Syndrome, Alzheimer's Disease, Fragile X syndrome, Parkinson's disease, Lewy Body Dementia, and/or Frontoparietal Dementia
89371290|NCT03672266||Neurotypical|Healthy individuals with no known neurological disorders
89371291|NCT03675542|Experimental|Study medication|HSP90 inhibitor (CUDC-305)
89371292|NCT03171454|Experimental|Delayed Intrauterine Balloon therapy|In the delayed balloon group,a Foley catheter will be inserted into the uterine cavity 2 weeks after the surgery, the balloon will be inflated with normal saline (from 3ml to 5ml) then deflated, and the procedure repeated three time over 3 minutes or so, then the cavity will be flushed with 10 mls of normal saline solution after via the irrigating channel of the Foley catheter before removal. The whole procedure will be repeated a further 2 weeks later.
89371293|NCT03171454|Experimental|immediate Intrauterine Balloon therapy|At the conclusion of the surgery, in the immediate balloon group: a Foley-catheter will be immediately inserted into the uterine cavity and the balloon will be distended with 5mls of saline under ultrasound guidance and the balloon will stay in situ for 7 days.
89371294|NCT03679286||All subjects|No intervention
89371295|NCT04482712|Placebo Comparator|Placebo|Administration of placebo daily during hospitalization
89371296|NCT04482712|Active Comparator|Rapamycin|Administration of rapamycin (sirolimus) 1mg daily during hospitalization
89371297|NCT03679208|Experimental|Stage 1 Safety cohort|Two injections of the investigational device (KIO014) at 3-month interval in 10 patients and 12-month follow-up to establish long-term safety as primary endpoint.
89371298|NCT03679208|Experimental|Stage 2 Performance (test group)|One injection of the investigational device (KIO014) in 60 patients to evaluate the reduction in pain at 3 months as primary endpoint. Additional follow-up at 6 months.
89371299|NCT03679208|Active Comparator|Stage 2 Performance (control group)|One injection of the control device (Durolane(r)) in 30 patients to evaluate the reduction in pain at 3 months as control endpoint. Additional follow-up at 6 months.
89371300|NCT02409394|Experimental|hetrombopag 7.5mg fasted to fed|Hetrombopag tablet, fasting conditions on day 1; 9 days wash-out; Than subjects will be crossover to have hetrombopag tablet with high fat, high calorie breakfast on day 11.
89371301|NCT02409394|Experimental|hetrombopag 7.5mg fed to fasted|Hetrombopag tablet with high fat, high calorie breakfast on day 1; 9 days wash-out; Than subjects will be crossover to have hetrombopag tablet, under fasting condition on day 11.
89371302|NCT02409004|Experimental|Ataluren|Ataluren 1375 mg powder for oral suspension administered once daily on Days 1 and 11 Rifampin 300 mg capsules administered twice daily on Day 3 to Day 12
89371303|NCT03131895|Experimental|Part 1, Sequence 1 (Regimen A, B)|Dexlansoprazole 30 mg, delayed-release capsule manufactured by TOB (Regimen A [test]), orally, once on Day 1 of Period 1 following a 10 hour fast, followed by minimum of 5 day washout period, followed by dexlansoprazole 30 mg, delayed-release capsule manufactured by TPC (Regimen B [reference]), orally, once on Day 1 of Period 2 following a 10-hour fast.
89371304|NCT03131895|Experimental|Part 1, Sequence 2 (Regimen B, A)|Dexlansoprazole 30 mg, delayed-release capsule manufactured by TPC (Regimen B [reference]), orally, once on Day 1 of Period 1 following a 10 hour fast, followed by minimum of 5 day washout period, followed by dexlansoprazole 30 mg, delayed-release capsule manufactured by TOB (Regimen A [test]), orally, once on Day 1 of Period 2 following a 10-hour fast.
89371305|NCT03131895|Experimental|Part 2, Sequence 3 (Regimen C, D)|Dexlansoprazole 60 mg, delayed-release capsule manufactured by TOB (Regimen C [test]), orally, once on Day 1 of Period 1 following a 10 hour fast, followed by minimum of 5 day washout period, followed by dexlansoprazole 60 mg, delayed-release capsule manufactured by TPC (Regimen D [reference]), orally, once on Day 1 of Period 2 following a 10-hour fast.
89371306|NCT03131895|Experimental|Part 2, Sequence 4 (Regimen D, C)|Dexlansoprazole 60 mg, delayed-release capsule manufactured by TPC (Regimen D [reference]), orally, once on Day 1 of Period 1 following a 10 hour fast, followed by minimum of 5 day washout period, followed by dexlansoprazole 60 mg, delayed-release capsule manufactured by TOB (Regiment C [test]), orally, once on Day 1 of Period 2 following a 10-hour fast.
89371307|NCT03671876|Active Comparator|Intervention plus therapy|"Case group:~A population that suffered a stroke and treated to improve mobility with the Selfit system (25 patients) for twice a week, at least 30 minutes per session, for a period of 3 weeks.~Intervention with the Selfit system include a set of mobility task exercises."
89371308|NCT03671876|No Intervention|Therapy and no intervention|"Control group:~A population that suffered a stroke and is being treated in the hospital without any interventions with the Selfit system."
89371309|NCT04039919|Experimental|Part A: Padsevonil and Ethanol|Subjects will be randomized to receive Padsevonil and Ethanol.
89371310|NCT04039919|Placebo Comparator|Part A: Padsevonil and Ethanol-Placebo|Subjects will be randomized to receive Padsevonil and Ethanol-Placebo.
89371311|NCT04039919|No Intervention|Part A: Ethanol and Ethanol-Placebo|Subjects will be randomized to receive Ethanol and Ethanol-Placebo.
89371312|NCT04039919|No Intervention|Part A: Ethanol-Placebo and Ethanol|Subjects will be randomized to receive Ethanol and Ethanol-Placebo.
89371313|NCT04039919|Experimental|Part B: Padsevonil and Cannabidiol|Subjects will be randomized to receive Padsevonil and Cannabidiol.
89371314|NCT04039919|Placebo Comparator|Part B: Padsevonil-Placebo and Cannabidiol|Subjects will be randomized to receive Padsevonil-Placebo and Cannabidiol.
89371315|NCT02405494|Other|Beverage 1|Liquid foam consisting of 37 ml liquid with 73% overrun (total volume 65 ml).
89371316|NCT02405494|Other|Beverage 2|Liquid foam consisting of 37 ml liquid with 427% overrun (total volume 197 ml).
89371317|NCT02405494|Other|Beverage 3|Liquid foam consisting of 98 ml liquid with 73% overrun (total volume 169 ml).
89371318|NCT02405494|Other|Beverage 4|Liquid foam consisting of 98 ml liquid with 427% overrun (total volume 514 ml).
88809930|NCT00780026|No Intervention|Standard of Care Control|standard of care insulin dosing
89371319|NCT02405494|Other|Beverage 5|Liquid foam consisting of 25 ml liquid with 250% overrun (total volume 88 ml).
89371320|NCT02405494|Other|Beverage 6|Liquid foam consisting of 110 ml liquid with 250% overrun (total volume 385 ml).
89371321|NCT02405494|Other|Beverage 7|68 ml beverage consisting of 68 ml liquid with 0% overrun (total volume 68 ml).
89371322|NCT02405494|Other|Beverage 8|Liquid foam consisting of 68 ml liquid with 500% overrun (total volume 405 ml).
89371323|NCT02405494|Other|Beverage 9|Liquid foam consisting of 68 ml liquid with 250% overrun (total volume 236 ml).
89399274|NCT02169986|Experimental|electronic reminders|In this group, the parents/caregivers will receive two daily electronic reminders in addition to the standard of care.
88809931|NCT01214057|Experimental|Total Intravenous Anesthesia|Total Intravenous Anesthesia (TIVA) with propofol and remifentanyl
88844014|NCT06288165||Coronary Sinus Reducer implantation|Subject after Coronary Sinus Reducer implantation due to chronic disabling refractory angina pectoris (Canadian Cardiovascular Society [CCS] classes 2-4) despite maximally tolerated anti-angina medical therapy. All patients were evaluated by the local Heart Team and considered not amenable to percutaneous or surgical revascularization procedures. After the Heart Team evaluation patients were qualified for the procedure or Coronary Sinus Reducer implantation unless they meet one of the exclusion criteria. Initial patient evaluation (prior to device implantation) consists of past medical history, actual clinical assessment with an evaluation of CCS class, Seattle Angina Questionnaire - 7 items (SAQ-7) scores, 6-min walk distance (6-MWT) test, and echocardiography. First, a follow-up visit is scheduled 1 month after the implantation procedure than the follow-up is planned twice a year.
88844015|NCT06288152|Experimental|Intervention Group|STS plus standard of care
88844016|NCT06288152|No Intervention|Control Group|Standard of care
88844017|NCT06288126||High Risk Group|This group include women at high risk for gestational diabetes (GDM) according to most of the European guidelines. They have one or more of the following criteria: age ≥35 years, overweight or obesity, family history of diabetes, high-risk ethnicities, history of previous GDM or previous macrosomia, and high levels of fasting glycemia during the first trimester screening.
88844018|NCT06288126||Low Risk Group|This group will include women at low risk for GDM according to most of the European guidelines. They have none of the following criteria: age ≥35 years, overweight or obesity, family history of diabetes, high-risk ethnicities, history of previous GDM or previous macrosomia, and high levels of fasting glycemia during the first trimester screening.
88844019|NCT06288100||Observations|"number of patients, sex, age, Bodi Mass Index , Range of Motion ,type of plate & Screws used , Degree of deformity .~Digital radiography (General Electric Healthcare ) functional scores software T-tests, One-way analysis of variance."
88844020|NCT06288087|Other|MG Group|The group trained with VR Based Training with Machine Guidance will be referred as MG group.
88844021|NCT06288087|Other|EG Group|The group trained with VR Based Training with Educators Guidance in Metaverse will be referred as EG group.
88844022|NCT06288074||Severe community-acquired pneumonia|
88844023|NCT06288074||Non-Severe community-acquired pneumonia|
88844024|NCT06288074||Healthy control|
88844025|NCT06288048|Experimental|Deep Dry Needling (DDN), Ischemic Compression, Cold Spray with Stretching + MFT|The intervention protocol in this study will target individuals experiencing Post-needling pain associated with lateral elbow pain. It will comprise a series of treatments including Deep Dry Needling (DDN) focused on the proximal third of the m. Brachioradialis (BR), was conducted with the patient seated and the therapist positioned on the same side as the needle insertion. Following DDN, ischemic compression (IC) will be applied using a sphygmomanometer on the seated subject's arm, along with three applications of cold spray synchronized with m. Brachioradialis (BR) stretching. The intervention will conclude with Mirror Therapy (MFT), where the patient will face a mirror covering the punctured side at a 45-degree angle for proper hand visualization, engaging in hand exercises and wrist movements while observing their reflection.
88844026|NCT06288048|Active Comparator|Deep Dry Needling (DDN), Ischemic Compression, Cold Spray with Stretching|The intervention protocol in this study will target individuals experiencing Post-needling pain associated with lateral elbow pain. It will comprise a series of treatments including Deep Dry Needling (DDN) focused on the proximal third of the m. Brachioradialis (BR), conducted with the patient seated and the therapist positioned on the same side as the needle insertion. Following DDN, ischemic compression (IC) will be applied using a sphygmomanometer on the seated subject's arm, along with three applications of cold spray synchronized with m. Brachioradialis (BR) stretching. The intervention will not conclude with Mirror Therapy (MFT).
88844027|NCT06288022|Experimental|total tubeless mini-PCNL|When finish the mini-PCNL operation, patient not receive placement both ureteral drainage tube (DJ-stent) and nephrostomy tube.
88844028|NCT06288022|Active Comparator|tubeless mini-PCNL|When finish the mini-PCNL operation, patient receive placement ureteral drainage tube (DJ-stent) but not receive nephrostomy tube.
88844029|NCT06288009|Experimental|Layered Closure with Running Locking Suture on Side A|For all participants, one wound side half will be labeled as A and the other side as B. The bottom (subcutaneous) layer of the entire wound will receive the normal stitching. For the upper (cutaneous) layer, Side A will be closed with a running locking suture, and Side B will be closed with a standard running suture.
88844030|NCT06288009|Experimental|Layered Closure with Running Locking Suture on Side B|For all participants, one wound side half will be labeled as A and the other side as B. The bottom (subcutaneous) layer of the entire wound will receive the normal stitching. For the upper (cutaneous) layer, Side B will be closed with a running locking suture, and Side A will be closed with a standard running suture.
88844031|NCT06287996|Experimental|Warm water foot-bath and actigraphy|Warm water foot-bath and actigraphy
88844032|NCT06287996|Active Comparator|actigraphy|actigraphy
88844033|NCT06287983|Experimental|EXERCISE GROUP|The Sample Spondylitis Exercise Program
88844034|NCT06287983|Active Comparator|EXERCISE+ Inspiratory muscle trainer (IMT) GROUP|The Sample Spondylitis Exercise Program Inspiratory muscle training will also be added to the intervention group.
88844035|NCT06287957|Experimental|ML|Patients with mini platform implants to be treated with Labrida Bioclean
88844036|NCT06287957|Experimental|RL|Patients with regular platform implants to be treated with Labrida Bioclean
88844037|NCT06287957|Active Comparator|ME|Patients with mini platform implants to be treated with Air-Flow Devices (EMS Handy 3.0 Perio Premium)
88844038|NCT06287957|Active Comparator|RE|Patients with regular platform implants to be treated with Air-Flow Devices (EMS Handy 3.0 Perio Premium)
89371324|NCT03671798||REM sleep behavior disorder (RBD)|Diagnosis of RBD according to ICSD-3: 1) Sleep talking or complex movement during sleep. 2) Such movement was recorded by video PSG (AV-PSG) during REM sleep or according to history the movements were occurred during REM. 3) REM sleep without atonia (RWA) during PSG monitoring. 4) This abnormal phenomenon cannot be explained by other sleep disorder, psychiatric disease, drug or substance abuse.
89371325|NCT03671798||Controls|Subjects with 1) No RBD symptoms and PSG characteristics. 2) No neurological symptoms or diseases, MRI scan will be employed to exclude brain pathology. 3) No narcolepsy or hypersomnia, ruled out by multiple sleep latency test. 4) No history of mental illnesses or use of antidepressants
89399275|NCT02172560||Premature withdrawal from tiotropium|
89371326|NCT02409160|Experimental|Bariatric Surgery|Standard laparoscopic Roux-en-Y gastric bypass technique resulting in a gastric pouch with a volume of about 25 mL, a 100-cm-long Roux-limb, and a 75-cm-long biliopancreatic limb.
89371327|NCT02409160|No Intervention|Control Group|
89371328|NCT05171595||no myocardial injury|In this study, patients were divided into groups of myocardial injury, where patients had TnT elevations (of 20-64 ng/L with an absolute change of ≥ 5 ng/L, or a hsTnT level ≥65 ng/L, both evaluated as due to ischemic etiology) and a group with no myocardial injury.
89399276|NCT02166554|Placebo Comparator|Control Arm|Standard of care for post-operative adhesion prevention included irrigation of tissues and lavage of all fluids with saline placebo following surgery
88809932|NCT01214057|Active Comparator|Inhaled Anesthesia|Inhaled anesthesia with sevoflurane and remifentanyl.
88809933|NCT03009149|Experimental|AEROBIC EXERCISE|The effects of 12 week aerobic exercise will record
88809934|NCT00780338|Experimental|1|Cohort 1: receives the Assets Getting To Outcomes intervention first. The AGTO intervention includes three types of assistance which are adapted to fit the needs and priorities of the individuals involved, as well as the inner and outer setting: (1) a manual of text and tools; (2) face-to-face training, and (3) onsite technical assistance (TA). These three types of assistance aim to improve the implementation process for each program. Two full-time, Maine-based staff, one with a master's and one with a bachelor's degree, provided AGTO tools, training, and TA to the intervention coalitions and programs during the two year intervention period. The tools are in the Search Institute-published manual, Getting To Outcomes with Developmental Assets: Ten steps to measuring success in youth programs and communities, which all intervention participants received.
88809935|NCT00780338|Active Comparator|2|Cohort 2: receives the Assets Getting To Outcomes intervention second, after Cohort 1 is done receiving the intervention.
88809936|NCT03805958|Experimental|Pre-procedure|Confirmed landmark by ultrasound scan before procedure
88809937|NCT03805958|Active Comparator|Real time|Confirmed landmark by ultrasound scan during procedure
88809938|NCT03809546|Placebo Comparator|Placebo|
88809939|NCT03809546|Active Comparator|7.5 mg THC|
88809940|NCT03809546|Active Comparator|15 mg THC|
88809941|NCT03809312|Active Comparator|Clavulin group with polyps|Group who will receive clavulin after the endoscopic sinus surgery in prophylactic and who have polyps in the surgery
88809942|NCT03809312|Placebo Comparator|Placebo group with polyps|Group who will receive placebo after the endoscopic sinus surgery in prophylactic and who have polyps in the surgery
88809943|NCT03809312|Active Comparator|Clavulin group without polyps|Group who will receive clavulin after the endoscopic sinus surgery in prophylactic and who haven't polyps in the surgery
88809944|NCT03809312|Placebo Comparator|Placebo group without polyps|Group who will receive clavulin after the endoscopic sinus surgery in prophylactic and who haven't polyps in the surgery
88809945|NCT03807986|Experimental|Nanofat grafting and PRP injection|Striae diatensae will be treated by nanofat grafting once every three months for 2 times combined with PRP injection once a month for 6 times.
88809946|NCT03807986|Experimental|Microfat grafting and PRP injection|Striae diatensae will be treated by microfat grafting once every three months for 2 times combined with PRP injection once a month for 6 times.
88809947|NCT03805802|Experimental|active product|Once daily ad libitum consumption of one package of the fiber product 6 weeks (blinded phase). Once daily ad libitum consumption of one package of the fiber product 6 weeks (open phase).
88809948|NCT03805802|Placebo Comparator|reference product|Once daily ad libitum consumption of one package of placebo during 6 weeks (blinded phase). Once daily ad libitum consumption of one package of the fiber product 6 weeks (open phase).
88809949|NCT01247363|Experimental|LY2608204|Oral capsules of LY2608204 given once daily at a starting dose of 160 milligram (mg), which may be titrated in 3 dose escalations to 240 mg, 320 mg and 400 mg, with a 7-day treatment duration at each dose level for up to 28 days total treatment.
88809950|NCT00780494|Experimental|bevacizumab+ carboplatin +capecitabine|Participants receive bevacizumab 15 mg/kg intravenously followed by carboplatin AUC 6 intravenously on Day 1 of a 21-day cycle, concurrently with capecitabine 850 mg/m2 twice-daily by mouth on Cycle Days 1-to-14, followed by a 1-week break.
88809951|NCT03806348|Experimental|Resuturing|Early resuturing of perineal wound dehiscence. Antibiotics: Amoxicillin 500 mg, Clavulanic Acid 125 mg and Metronidazole 400 mg by mouth, every 8 hours, for at least 6 Days.
88809952|NCT03806348|No Intervention|Conservative treatment|Antibiotics: Amoxicillin 500 mg, Clavulanic Acid 125 mg and Metronidazole 400 mg by mouth, every 8 hours, for at least 6 Days.
88809953|NCT00763412|Placebo Comparator|1 Placebo|1 pill before each meal 3-4 times a day for 2 years. All subjects had abnormal glucose tolerance. Subjects were randomized to placebo or drug.
88809954|NCT00763412|Experimental|2. repaglinide|repaglinide 0.5 mg before each meal 3-4 times a day for 2 years. All subjects had abnormal glucose tolerance.Subjects were randomized to placebo or drug.
88809955|NCT01302743|Active Comparator|Metformin|oral extended-release Metformin 1000 mg once a day for 90 days
88809956|NCT01302743|Experimental|Cinnamon Bark|Cinnamon Bark 1000 mg once a day for 90 days
88809957|NCT01302743|Experimental|Cinnulin PF|Cinnulin PF 500 mg once a day for 90 days
88809958|NCT01248221|Experimental|Healthy subjects|The subject will consume the test meal containing [13C]-Spirulina platensis and 99mTc sulfur colloid, after which gastric emptying will be assessed simultaneously by scintigraphy and breath tests. Scintigraphic image acquisition will be obtained upon completion of the meal and at 15, 30, 45, 60, 90, 120, 150, 180, and 240 minute time points. Breath samples will be collected at baseline before the test meal is started and thereafter on the same time schedule as the scintigraphic procedure.
88819340|NCT02214212|Active Comparator|Red Light (RL)|"Intervention/Device:~This patient group will receive 30 minutes of red light daily for a period of 10 days in the morning. Identical baseline and outcome testing will be completed for both arms."
89371329|NCT05171595||Myocardial injury|In this study, patients were divided into groups of myocardial injury, where patients had TnT elevations (of 20-64 ng/L with an absolute change of ≥ 5 ng/L, or a hsTnT level ≥65 ng/L, both evaluated as due to ischemic etiology) and a group with no myocardial injury.
89371330|NCT03174340|Experimental|Exercise + diet|"Exercise intervention:~During the first session a standardized exercise prescription will be discussed with the participant. The exercise program will be of a moderate intensity, at less than 140 heart beats/min (which corresponds to 60% of the calculated maximum heart rate (HRmax) or 50% maximum oxygen volume (VO2max) ). A session of 30 to 60 minutes/week will be organised.~Participants will be instructed to conduct a nonsedentary lifestyle. They will be encouraged to increase their number of steps on a daily basis and perform not more that 45 minutes of continuous exercise per day. Pedometers will be used to measure the compliance and as a positive feedback for motivation.~The participants will return to the exercise laboratory once per week for Actiheart data downloading, number of steps recording, exercise support and counselling, and to perform the supervised group exercise intervention.~This is in addition to the diet (see below, control group)"
89371331|NCT03174340|No Intervention|Diet only|Participants will receive diet counselling according to their characteristics. The usual recommendation is to have a fractioned normocaloric diet (unless the dietician identify a grossly hypercaloric diet), with low fat and increase in fibers content.
89371332|NCT01367613|Experimental|Arm 1|
89371333|NCT03174106|Experimental|Smartphone-Application|"Patients in Smartphone-Application-arm will get Access to the Application Vett, they will be learned how to use it. They will receive feedback based on their goals and tasks in the Application for one year, and they will also receive motivational Notifications through the Application, atleast once a week in the follow-up period. Patients in this arm will also have the possibility to send questions to their supervisor through the Application, in that case they will receive answer within two working days. In addition they will receive usual care which is described below."
89371334|NCT03174106|No Intervention|Control-group|Patients in the control-group will receive usual care consisting of general advice according to a heart-friendly lifestyle and follow-up by their general practitioner.
88844039|NCT06287944|Experimental|Treatment ( Actinium Ac 225-DOTA-Daratumumab)|Patients receive daratumumab IV over 45 minutes followed by indium In 111-DOTA-daratumumab IV over 15 minutes and actinium Ac 225-DOTA-daratumumab IV over ~20-40 minutes on day -15. Patients receive TMLI BID on days -8 to -5, fludarabine IV on days -4 to -2 and melphalan IV on day -2, followed by HCT on day 0. Patients receive GVHD prophylaxis with sirolimus and tacrolimus starting on day -1. Patients also undergo CT during screening, nuclear scan and SPECT scans on study, bone marrow biopsy and aspiration, echocardiography, or MUGA, and blood sample collection during screening and throughout study.
88844040|NCT06287931|Experimental|Ursodoxycholic acid group|Ursodoxycholic acid, 250mg po tid x 6 months
88844041|NCT06287931|Experimental|Bifidobacterium group|Bifidobacteria, 210 mg po tid x 6 months
88844042|NCT06287931|Experimental|Bifidobacterium and ursodeoxycholic acid group|Ursodoxycholic acid, 250mg po tid x 6 months Bifidobacteria, 210 mg po tid x 6 months
88844043|NCT06287918|Experimental|Stage I - dose escalation|Dose escalation of 3HP-2827 in patients with advanced solid tumours.
88844044|NCT06287918|Experimental|Stage II - expansion|Expansion evaluating the recommended dose and schedule of 3HP-2827 identified from Stage I.
89371335|NCT03739151|Other|Behavioral Obesity Treatment|All participants will receive gold-standard behavioral obesity treatment
89371336|NCT01361061||patients with liver cirrhosis|
88844045|NCT06287905|No Intervention|group of antivenom only|Dose of antivenom 1-1 ampoule intramuscular and/ or, 2-1 to 5 Polyvalent anti-scorpion serum ampoules produced by the vaccine & serum institution (VACSERA)in Egypt according to the severity of the case on 200 to 500 ml glucose 5% infusion and assess the patient clinically to repeat the dose after 4 to 6 hours. (Shoreit et al., 2019)
88844046|NCT06287905|Experimental|group of adding prazosin plus standard treatment|1-Dose and administration of prazosin: 30 μg/kg/dose of prazosin will be delivered orally every 6 hours 4 doses, in adults we shouldn't exceed 1 mg per dose. Prazosin will be delivered using a nasogastric tube while securing the patient's airway in the event of vomiting or unconsciousness. Every 30 minutes for the first three hours, every hour for the following six, and then every four hours until improvement, blood pressure, pulse rate, respiration rate, and oxygen saturation will be measured. When pain is the only symptom, prophylaxis shouldn't be given. To avoid the first-dose phenomenon, the patient should remain in a laying position for around 3 hours (even while the case is being examined) (Shoreit et al., 2019).
89399277|NCT02166554|Experimental|Cross-linked Hyaluronan Hydrogel Arm|HyaRegen
89371337|NCT02405182||Patients|ALS patients (as well as patients with other motor neuron diseases such PLS and PMA) will be recruited from ALS clinics under the direction of ALS neurologists who are participating in this study. ALS patients should meet research criteria for possible, probable, probable laboratory-supported, or definite ALS. Patients with a history of CNS disease (e.g. stroke, head injury) or significant psychiatric disease will be ineligible. Patients must be able to undergo a brain MRI for approximately an hour.
88844047|NCT06287879|Experimental|Roxadustat|Subjects were treated with Roxadustat for renal anemia
88844048|NCT06287879|Active Comparator|EPO|Subjects were treated with EPO for renal anemia
89371338|NCT02405182||Controls|Healthy controls who are age and gender matched to patients will be recruited. Controls with a history of CNS disease (e.g. stroke, head injury) or significant psychiatric disease will be ineligible. Controls must be able to undergo a brain MRI for approximately an hour.
89371339|NCT03745001|Experimental|Single dose study part|there will be 7 cohorts of healthy volunteers dosed with single doses of EHP-101 (7 planned dose levels) or with placebo and 1 potential additional cohort (also dosed with single dose of EHP-101 or placebo)
89371340|NCT03745001|Experimental|Multiple dose study part|there will be 3 cohorts of healthy volunteers dosed with multiple doses of EHP-101 (3 planned dose levels) or placebo and 1 potential additional cohort (also dosed with multiple doses of EHP-101 or placebo)
89371341|NCT02405338|Experimental|WT1/PRAME vaccination|
89371342|NCT03738839|Experimental|Direct Bonding|On the individual teeth Conventional bracket placement Use conventional composite
89371343|NCT03738839|Experimental|Indirect bonding|On the dental stone models Indirect bracket placement Use flowable composite Use transfer trays
89371344|NCT03738839|Active Comparator|Quantitative Light-Induced Fluorescence|Use special device and software Determination of the number and effect of caries
89371345|NCT01364337|Active Comparator|DASH diet|
89371346|NCT01364337|Active Comparator|lower carbohydrate DASH diet|
88844049|NCT06287866|No Intervention|Second Intention Wound Healing|
88844050|NCT06287866|Experimental|Pinch Grafting|
88844051|NCT06287853||Partial Thickness Tear|Patient with a diagnosis of a symptomatic primary partial-thickness tear of the supraspinatus and/or infraspinatus tendons amenable to repair.
88844052|NCT06287853||Full Thickness Tear|Patient with a diagnosis of a symptomatic primary full-thickness tear of the supraspinatus and/or infraspinatus tendons amenable to repair.
88844053|NCT06287814||Stage III colorectal cancer patients|MRD assessment by ctDNA analysis Patients will be managed according to current standard-of-care
89002086|NCT06116253|Experimental|Renal Mass Patients|"Patients will be enrolled for 2 MRI visits. These visits will include an approximately 1 hour research MRI scan and a total of between 3 and 5 hours Tc-99m DTPA scan.~In each MRI visit, patients will be scanned for approximately one hour including both standard-of-care clinical sequences and research-based Advanced Diffusion Imaging sequences, on a Prisma 3T MRI scanner. Following the MRI exam or on a day not more than a week after the MRI exam, patients will undergo renal function assessment via Tc-99m DTPA scan and patient's kidneys will be scanned using a gamma camera. Proteinuria will be assessed by standard of care urinalysis of specimens collected at each MRI visit for each patient. Blood test will be performed at each visit to estimate GFR (eGFR) from measurement of serum creatinine."
89371347|NCT02405416|Experimental|IIVCC group|The portal triad and infrahepatic inferior vena cava are dissected and taped with a vessel loop, respectively. During liver parenchymal resection，portal triad and infrahepatic inferior vena cava clampings are performed at the specified transection depth from liver surface successively.
89371348|NCT02405416|Active Comparator|SHVE group|In this group, the portal triad clamping and selective hepatic vascular exclusion of major hepatic veins are used. Different major hepatic veins are occluded by clamping forcep depending on the site of tumors. The clamping timepoints are same as the IIVCC group.
89371349|NCT01361295|Active Comparator|PVI with PVAC gold|Patient for pulmonal vein isolation using the PVAC Gold Catheter. Intervention.
89371350|NCT01361295|Active Comparator|PVI with Cooled-RF|Patient for pulmonal vein isolation using the Cooled-RF catheter.
89371351|NCT02405104|Active Comparator|THA+Klorz|All patients in this arm are treated surgically with a THA and medically with Chlorzoxazone
89371352|NCT02405104|Placebo Comparator|THA+Placebo|All patients in this arm are treated surgically with a THA and medically with placebo
88844056|NCT06287749||Pancreatic Ductal Adenocarcinoma patients|Resectable PDAC patients
88844057|NCT06287736|No Intervention|Conventional Medical Management (CMM). Group1|
88844058|NCT06287736|Active Comparator|Spinal Cord Stimulator (SCS) immediate activation. Group 2|
88844059|NCT06287736|Active Comparator|Spinal Cord Stimulator (SCS) Delayed activation. Group 3|
88844060|NCT06287723||Stage IV colorectal liver metastasis patients|Stage IV colorectal liver metastasis patients treated with curative intent
88844061|NCT06287710||study of diagnostic accuracy|Patients included in this study would have received fluid expansion in all cases, as the prescription of 10 to 20ml/kg fluid expansion by the physician in charge is the main inclusion criterion.
88844062|NCT06287697||Longitudinal study-Thailand|"Cohort 1: 60 children were started at 6-8 months old, and were followed-up at 9-11, 12-14 and 15-17 months old.~Cohort 2: 71 children were started at 12-14 months old, were followed-up 15-17, 18-21 and 21-24 months old."
88844063|NCT06287697||Cross-sectional study-Pakistan|Children aged 6-8, 9-11, 12-14, 15-17, 18-20, 21-23 months, both sexes.
88844064|NCT06287697||Cross-sectional study-Philippines|Children aged 6-8, 9-11, 12-14, 15-17, 18-20, 21-23 months, both sexes.
88844065|NCT06287697||Cross-sectional study-Sri Lanka|Children aged 6-8, 9-11, 12-14, 15-17, 18-20, 21-23 months, both sexes.
88844066|NCT06287697||Cross-sectional study-Vietnam|Children aged 6-8, 9-11, 12-14, 15-17, 18-20, 21-23 months, both sexes.
88844067|NCT06287671||Study cohort|Patients undergoing elective colorectal resection or stoma closure
88844068|NCT06287658|Experimental|Experimental|Kegel exercises and Ba Duan Jin applications will be applied to women in the experimental group online (via Zoom application) in two sessions per week for a total of 8 weeks. Afterwards, women will be asked to perform these practices three days a week for 12 weeks and will be monitored. The research will last a total of 16 weeks.
88844069|NCT06287658|Active Comparator|Control|Women in the control group will be given training on Kegel exercises and Ba Duan Jin applications after the research is completed.
89180753|NCT02606669|Experimental|Intermittent Fasting|"The intervention of interest here is the Intermittent Energy Restriction (IER) or the Intermittent Fasting approach, specifically, the 5:2 diet, where adherence to this dietary intervention consists of fasting for two consecutive days and consuming enough to meet energy requirements for the remaining five non-fasting days. In this study, fasting will be achieved by using a meal replacement product (Optifast®) supplemented by two scoops of protein powder (Propass®) and a multivitamin, making a total of 540kcal (54g protein, 60g carbohydrates) for each fasting day."
88844070|NCT06287632|Experimental|Recruitment and ITP-CPAP|Recruitment maneuver followed by CPAP set to intrathoracic pressure (ITP)
88844071|NCT06287632|Active Comparator|Standard CPAP|CPAP set to home level of CPAP (if known) or CPAP set to standard levels (8-10 cmH20)
88844072|NCT06287632|Placebo Comparator|Atmospheric pressure|Breathing without CPAP
88844073|NCT06287619|Experimental|Intervention Group|Patients randomized to the IV iron group will receive 1000 mg ferric derisomaltose (Monoferric) diluted in 100 mL of 0.9 % sodium chloride solution, via intravenous infusion over 1 hour using an opaque IV bag and tubing for blinding.
88844074|NCT06287619|Placebo Comparator|Control group|Patients randomized to the placebo group will receive 100 mL of 0.9 % sodium chloride solution via intravenous infusion using an opaque IV bag and tubing for blinding.
88844075|NCT06287606|Experimental|CTP0302-A|2 days split-dose
88844076|NCT06287606|Experimental|CTP0302-B|One day dose
88844077|NCT06287606|Active Comparator|Conventional OST|2 days split-dose
88844078|NCT06287593|Other|group A|For patients with negative ctDNA after 3 weeks of neoadjuvant TKI treatment, radical resection surgery will be performed after continuing TKI treatment for 9-12 weeks.
88844079|NCT06287593|Other|group B|For patients with positive ctDNA after 3 weeks of neoadjuvant TKI treatment, radical resection surgery will be performed after continuing TKI treatment for 9-12 weeks.
88844080|NCT06287593|Other|group C|For patients with positive ctDNA after 3 weeks of neoadjuvant TKI treatment, radical resection surgery will be performed after 3 cycles of TKI plus chemotherapy.
88844081|NCT06287593|Other|group D|For patients with positive ctDNA after 3 weeks of neoadjuvant TKI treatment, radical resection surgery will be performed after 3 cycles of sequential neoadjuvant PD-1 blockades plus chemotherapy.
88844082|NCT06287580|Active Comparator|Antihypertensive drug treatment Arm|Participants will take a fixed dose of chlorthalidone (a diuretic, 25 mg orally once daily) for two week, with study visits for laboratory assessment at before and after intervention.
88844083|NCT06287580|Placebo Comparator|Placebo treatment Arm|Participants will receive placebo treatment for two weeks, with study visits for laboratory assessment at before and after intervention.
88844084|NCT06287554||Group A|Group A (n:39) included patients who had been early placed in prone positions within 24 hours of intubation
88844085|NCT06287554||Group B|Group B (n:31) included patients who had not been placed in prone position
89180754|NCT02606669|No Intervention|Control|Diet and Physical Activity advice only. No treatment plan.
88844086|NCT06287541|Experimental|Urine biomarker -Guided without reTURBT|Participants in this arm will proceed without reTURBT.
88844087|NCT06287541|No Intervention|Standard Care with reTURBT|Participants in this arm will receive standard care, which undergo reTURBT
88844088|NCT06287528|Experimental|Dose Level 1|0.5x106 CAR-T cell/kg without lymphodepleting chemotherapy (LDC)
89371353|NCT02405104|Active Comparator|TKA+Klorz|All patients in this arm are treated surgically with a TKA and medically with Chlorzoxazone
89371354|NCT02405104|Placebo Comparator|TKA+Placebo|All patients in this arm are treated surgically with a TKA and medically with placebo
89180755|NCT02603510|Experimental|SAR342434/Humalog|SAR342434 and Humalog will be self-administered subcutaneously via insulin pump. The dose will be individually titrated and administered in a basal and bolus fashion.
89180756|NCT02603510|Experimental|Humalog/SAR342434|Humalog and SAR342434 will be self-administered subcutaneously via insulin pump. The dose will be individually titrated and administered in a basal and bolus fashion.
89371355|NCT01364415|Experimental|Pasireotide LAR|
88844089|NCT06287528|Experimental|Dose Level 2|0.5x106 cells/kg with lymphodepleting chemotherapy (LDC)
88844090|NCT06287528|Experimental|Dose Level 3|1x106 cells/kg with lymphodepleting chemotherapy (LDC)
88844091|NCT06287489|Other|Mediterranean diet phase followed by regular diet phase|Three-month of M phase, one month of washout and three month of R phase
88844092|NCT06287489|Other|Regular diet phase followed by Mediterranean diet phase|Three-month of R phase followed by three month of M phase
89180757|NCT04084977||Sydenam Chorea (SC)|individuals with SC
89180758|NCT04084977||tonsilitis|children with tonsilitis in the past 3 months
88844093|NCT06287476|Experimental|Control Group|This arm consist of only healthy participants (age (+/- 3 years) and sex matched to the COPD group), which will undergo three study visits
88844094|NCT06287476|Experimental|COPD group|This arm consist of only COPD patients, which will undergo three study visits
88844095|NCT06287463|Experimental|DCC-3084 Module A Escalation Phase (ModA Part 1)|Participants will receive DCC-3084 in ModA Part 1, Escalation Phase.
88844096|NCT06287463|Experimental|DCC-3084 Module A Expansion Phase (ModA Part 2)|Participants will receive DCC-3084 in ModA Part 2, Expansion Phase.
88844097|NCT06287450|Experimental|Cohort 1: Dose A in Younger Adults|Single injection of Dose A of IN006 or matching-placebo on Day 0.
88844098|NCT06287450|Experimental|Cohort 1: Dose B in Younger Adults|Single injection of Dose B of IN006 or matching-placebo on Day 0.
88844099|NCT06287450|Experimental|Cohort 1: Dose C in Younger Adults|Single injection of Dose C of IN006 or matching-placebo on Day 0.
88844100|NCT06287450|Experimental|Cohort 1: Dose D in Younger Adults|Single injection of Dose D of IN006 or matching-placebo on Day 0.
88844101|NCT06287450|Experimental|Cohort 1: Dose B in Older Adults|One injection of either Dose B of IN006 or matching-placebo on Day 0. Participants who initially assigned to receive IN006 on Day 0 will be further randomized to receive a second injection of either IN006 or matching-placebo approximately 12 months later.
88844102|NCT06287450|Experimental|Cohort 1: Dose C in Older Adults|One injection of either Dose C of IN006 or matching-placebo on Day 0. Participants who initially assigned to receive IN006 on Day 0 will be further randomized to receive a second injection of either IN006 or matching-placebo approximately 12 months later.
88844103|NCT06287450|Experimental|Cohort 1: Dose D in Older Adults|One injection of either Dose D of IN006 or matching-placebo on Day 0. Participants who initially assigned to receive IN006 on Day 0 will be further randomized to receive a second injection of either IN006 or matching-placebo approximately 12 months later.
88844104|NCT06287437|Experimental|Intervention|The subjects receive sequential once weekly and low frequency subcutaneous injection of HRS 9531
88844105|NCT06287437|Placebo Comparator|Control|The subjects receive low frequency subcutaneous injection of the placebo
88844106|NCT06287424|Experimental|A: 4 tablet per day|"• Group A: Daily use of Aged Garlic Extract product: Take two (2) tablets with a meal twice daily.~The label is:~Garlic extract tablets for research - for research use only Instructions for use: Take (2) tablets immediately after breakfast and (2) tablets immediately after dinner every day.~Storage: Store in a cool, dry place with the lid tightly closed. Expiration date: August 2022 Please return empty bottles and excess tablets as requested."
88844107|NCT06287424|Experimental|B: 6 tablet per day|"• Group B: Daily use of Aged Garlic Extract product: Take three (3) tablets with a meal twice daily.~The label is:~Garlic extract tablets for research - for research use only Instructions for use: Take (3) tablets immediately after breakfast and (3) tablets immediately after dinner every day.~Storage: Store in a cool, dry place with the lid tightly closed. Expiration date: August 2022 Please return empty bottles and excess tablets as requested."
88844108|NCT06287424|Experimental|C: 8 tablet per day|"• Group C: Daily use of Aged Garlic Extract product: Take four (4) tablets with a meal twice daily.~The label is:~Garlic extract tablets for research - for research use only Instructions for use: Take (4) tablets immediately after breakfast and (4) tablets immediately after dinner every day.~Storage: Store in a cool, dry place with the lid tightly closed. Expiration date: August 2022 Please return empty bottles and excess tablets as requested."
88844109|NCT06287424|Placebo Comparator|D: Placebo|"• Group C: Daily use of Aged Garlic Extract product: Take four (4) tablets with a meal twice daily.~The label is:~Garlic extract tablets for research - for research use only Instructions for use: Take (4) tablets immediately after breakfast and (4) tablets immediately after dinner every day.~Storage: Store in a cool, dry place with the lid tightly closed. Expiration date: August 2022 Please return empty bottles and excess tablets as requested."
88844110|NCT06287398|Experimental|Epcoritamab Treatment|Single arm study - All patients undergo same treatment with Epcoritamab for salvage and consolidation phases.
88844111|NCT06287385|Experimental|Formula fed|Goat-milk Based Formula (Stage 3)
88844112|NCT06287372||Group 1: Calafiore cardioplegia|"Patients were randomly assigned to undergo surgery using one of two methods for myocardial protection:~• Group 1: Calafiore intermittent antegrade warm blood cardioplegia (consisting of normothermic pump blood, potassium chloride 2 mEq/ml and magnesium sulfate 50%). This cardioplegic solution was administered at 37 degrees C following application of the aortic cross-clamp and repeated after completion of each distal coronary anastomosis as described previously."
88844113|NCT06287372||Group 2: del Nido cardioplegia|• Group 2: Modified del Nido intermittent antegrade cold blood cardioplegic solution (consisting of 750 ml of lactated Ringer solution, 200 ml of pump blood, 13 ml of sodium bicarbonate 8.4%, 16 ml of mannitol 20%, 4 ml of magnesium sulfate 50%, 13 ml of lidocaine 2% and 13 ml of potassium chloride 2 mEq/ml). This solution was administered as a 1-liter bolus at 3-4 degrees C following application of the aortic cross-clamp, and repeated as a 500 ml bolus if cross-clamp time extended beyond 60 minutes (none of the patients in this study).
88844114|NCT06287346||One-piece|One-piece CeraRoot dental implants
88844115|NCT06287346||Two-piece (TL)|Two-piece CeraRoot TL dental implants
88844116|NCT06287320||NSCLC patients received CRT plus ICIs|"For it's an observational study, locally advanced NSCLC patients received CRT with induction immunotherapy or consolidation immunotherapy will be divided into the group NSCLC patients received CRT plus ICIs."
89180759|NCT04084977||control|children wit no tonsilitis
89371356|NCT03176368|Experimental|Coconut Oil|Through a interventional/cohort design, we propose to study the experience of coconut oil over a three month period, allowing patients to use Biotene© oral lubricant (or another product of their choice) as an alternative to coconut oil if they so prefer.
89371357|NCT03522129|Active Comparator|Active Treatment- CT1812 560 mg|
89371358|NCT03522129|Active Comparator|Active Treatment- CT1812 280 mg|
89371359|NCT03522129|Active Comparator|Active Treatment- CT1812 90 mg|
89371360|NCT03522129|Placebo Comparator|Placebo Comparator - Placebo|
89371361|NCT03176446|Active Comparator|Control Group|The children anesthesia will be traditional technique
89371362|NCT03176446|Active Comparator|Computerized Group|The children anesthesia will be computerized technique
89371363|NCT03176446|Active Comparator|DentalVibe Group|The children anesthesia will be DentalVibe technique
89371364|NCT03176212|Active Comparator|Beverage with milk fat globule membrane|In this arm, subjects consumed a beverage
89371365|NCT03176212|Placebo Comparator|Control|In this arm, subjects consumed a beverage with identical macronutrients
89371366|NCT02408614||Slow-paced walking|Subjects will complete 47 minutes of walking at slow pace.
89371367|NCT02408614||Moderate-paced walking|Subjects will complete 47 minutes of walking at a moderate pace.
89371368|NCT02408614||Interval training|Subjects will complete 40 minutes of walking alternating between a moderate and fast pace.
89371369|NCT03171142|Active Comparator|Heliox group|receive Helium oxygen mixture 21:79 via nasal cannula 2L/min
89371370|NCT03171142|Active Comparator|Air group|receive oxygen 21%via nasal cannula 2L/min
88844117|NCT06287320||NSCLC patients received CRT|"For it's an observational study, locally advanced NSCLC patients received CRT without immunotherapy will be divided into the group NSCLC patients received CRT."
88844118|NCT06287307|Active Comparator|Semaglutide 2.4mg|Patients in this group will receive the active comparator semaglutide 2.4mg. This is a medication which is distributed by an intramuscular injection once weekly.
89371371|NCT04035473|Active Comparator|Sequence A (Oraxol, IV paclitaxel)|"The treatment sequences will be:~A Oraxol (paclitaxel + HM30181) on Days 1, 2, and 3 of Treatment Period 1 followed by IV paclitaxel on Day 1 of Treatment Period 2 B IV paclitaxel on Day 1 of Treatment Period 1 followed by Oraxol on Days 1, 2, and 3 of Treatment Period 2"
89371372|NCT04035473|Active Comparator|Sequence B (IV paclitaxel, Oraxol)|"The treatment sequences will be:~A IV paclitaxel on Day 1 of Treatment Period 1 followed by Oraxol on Days 1, 2, and 3 of Treatment Period 2 B Oraxol (paclitaxel + HM30181) on Days 1, 2, and 3 of Treatment Period 1 followed by IV paclitaxel on Day 1 of Treatment Period 2"
89371373|NCT02405026||HIV infected patients|HIV infected patients with asthma
89371374|NCT02405026||HIV uninfected patients|HIV uninfected patients with asthma
89180760|NCT02594436||Ingenol mebutate gel 0.015 percent|Topical treatment of face or scalp once daily for three consecutive days
88844119|NCT06287307|Placebo Comparator|Placebo|Patients in this group will receive the placebo. This is a placebo which is distributed by an intramuscular injection once weekly.
88844120|NCT06287268||eltrombopag|ATG treatment naïve pediatric patients with AA in routine clinical practice
89180761|NCT02594436||Ingenol mebutate gel 0.05 percent|Topical treatment of trunk or extremities once daily for two consecutive days
89180762|NCT04107194|Experimental|Tailored therapy|"Clarithromycin-sensitive strain (10 day-therapy):~Pantoprazole 40 mg bid (tablet) Amoxicillin 1000 mg bid (tablet) Clarithromycin 500 mg bid (tablet) Metronidazole 500 mg bid (tablet)~Clarithromycin-resistant and tetracycline-sensitive strain (10 day-therapy):~Pantoprazole 40 mg bid (tablet) Tetracycline 125 mg + metronidazole 125 mg + bismuth 140 mg in a single tablet (3 tablets qid)~Clarithromycin- and tetracycline-resistant and levofloxacin-sensitive strain (10 day- therapy):~Pantoprazole 40 mg bid (tablet) Amoxicillin 1000 mg bid (tablet) Levofloxacin 500 mg bid (tablet)~Clarithromycin-, tetracycline- and levofloxacin-resistant strain (10 day-therapy):~Pantoprazole 40 mg bid (tablet) Amoxicillin 1000 mg bid (tablet) Rifabutin 150 mg bid (tablet)"
88844121|NCT06287255|Experimental|Exercise is Medicine Plus|Participants receiving the Exercise is Medicine program along with a smartwatch.
89371375|NCT02405026||HIV infected non-asthmatic patients|HIV infected patients without asthma
89371376|NCT02413528|Sham Comparator|Standard Care with Medication Monitoring|"Patients will be given an inhaler sensor to monitor medication use and a sham version of the mobile app that will not include reminders or incentives.~Intervention: Inhaler sensor"
88844122|NCT06287242|Active Comparator|matched manipulation|For the matched manipulation group, participants with the source of neck pain at the cervical spine determined by the CTDT will receive a cervical manipulation, and participants with the source of neck pain at the thoracic spine determined by the CTDT will receive a thoracic manipulation. The manipulation will be given to the participant's most provocative spinal level as determined by the examiner and side determined by the CTDT. The investigator will be limited to 2 manipulation attempts even if cavitation was not achieved.
88844123|NCT06287242|Active Comparator|unmatched manipulation|For the unmatched manipulation group, participants with the source of neck pain at the cervical spine determined by the CTDT will receive a thoracic manipulation, and participants with the source of neck pain at the thoracic spine found during the CTDT will receive a cervical manipulation. The manipulation will be given to the most hypomobile spinal level determined by the physical therapist and to the most provocative side found during the CTDT. The investigator will be limited to 2 manipulation attempts even if cavitation was not achieved.
89371377|NCT02413528|Experimental|Medication Monitoring and Mobile App|"Patients will be given an inhaler sensor to monitor medication use and a mobile phone application that will send them reminders and provide an opportunity to see their own medication use and win incentives for adherence.~Interventions: Inhaler sensor and mobile application for asthma adherence"
89371378|NCT04032977|Experimental|PN40082|Test device: PN40082 (manufactured by Prollenium Medical Technologies) is a clear, colorless gel in 1.0 mL pre-filled syringes with 25 mg/mL of stabilized hyaluronic acid and lidocaine 0.3% w/w
89371379|NCT04032977|Active Comparator|Restylane Silk|Restylane Silk (manufactured by Q-Med AB for Medicis - A Division of Valeant Pharmaceuticals Corporation North America, LLC ) is a clear, colorless gel in 1.0 mL pre-filled syringes formulated to a concentration of 20 mg/mL of stabilized hyaluronic acid and lidocaine 0.3% w/w.
89371380|NCT02408926|Experimental|Group A|Women will be vaccinated with an acellular pertussis containing vaccine (Boostrix) between 27 and 36 weeks of gestation. Children born from these mothers will be vaccinated according to the official recommendations in Thailand at 2, 4, 6 and 18 months with a hexavalent acellular pertussis containing vaccine (Infanrix hexa).
89371381|NCT02408926|Active Comparator|Group B|Women will be vaccinated with an acellular pertussis containing vaccine (Boostrix) between 27 and 36 weeks of gestation. Children born from these mothers will be vaccinated according to the official recommendations in Thailand at 2, 4, 6 and 18 months with a pentavalent whole cell pertussis containing vaccine (Quinvaxem). OPV (oral poliovirus vaccine) will also be administered at 2, 4, 6 and 18 months.
89371382|NCT04030247|Experimental|Plant Sterol|South Asian participants with moderate cardiovascular disease risk will receive standard of care in addition to the plant sterol supplement to take twice daily for 3 months.
89371383|NCT04481698||Mesoglycan|All patients received the standard post-operative therapy (a recommended oral dose of ketorolac tromethamine of 10 mg every 4-6 hours, not exceeding 40 mg per day and not exceeding 5 post-operative days according to the indications for short-term management of moderate/severe acute post-operative pain and stool softeners) plus mesoglycan (Prisma® 30 mg 2 vials i.m./day for the first 5 post-operative days and then Prisma® 50 mg 1 oral tablet twice/day for an additional 30 days, Mediolanum Farmaceutici, Milan, Italy)
89371384|NCT04481698||Control|standard post-operative therapy (a recommended oral dose of ketorolac tromethamine of 10 mg every 4-6 hours, not exceeding 40 mg per day and not exceeding 5 post-operative days according to the indications for short-term management of moderate/severe acute post-operative pain and stool softeners)
89371385|NCT03738761|Experimental|Amlessa® Arm|Patients allocated to treatment with Amlessa® (starting FDC of perindopril 4mg/amlodipine 5mg) according to their previous antihypertensive therapy and as described in the protocol inclusion criteria.
89371386|NCT03738761|Experimental|Co-Amlessa® Arm|Patients allocated to treatment with Co-Amlessa® (starting FDC perindopril 4mg/indapamide 2,5mg/amlodipine 5mg) according to their previous antihypertensive therapy and as described in the protocol inclusion criteria. Patients on previous perindopril and amlodipine therapy will be automatically assigned to Co-Amlessa® arm.
89371387|NCT02413216|Experimental|TicHelper|In this condition, participants will be provided with a secure username and login information for TicHelper.com. Participants will be asked to log in and use TicHelper.com for 8 weeks as instructed by the program (TicHelper recommends 30-60 minutes of website and therapeutic activity per day). TicHelper.com consists of 3 modules: Education, Assessment, and Intervention. The education module provides information about tic disorders and treatment. The assessment module tracks progress through the program. The intervention module uses interactive activities to teach tic management skills including habit reversal training (HRT). During HRT, patients learn to become more aware of tics and pre-tic sensations and to subsequently interrupt tics. Participants will also learn ways to interact with each other regarding tics, to identify and alter tic-worsening factors, and relaxation strategies to reduce stress.
89371388|NCT02413216|Active Comparator|Internet-Based Resources Condition|Participants who are assigned to the Internet-Based Resources (IBR) condition will receive a collection of materials with inks to the best available online resources about tic disorders and their treatment. The sites that are provided use a variety of online print, video, and animation materials to teach patients about various aspects of chronic tic disorders and their management. Participants will will be asked to explore and use the website information over the course of 8 weeks in any manner they find helpful. Participants will be asked to spend 30-60 minutes per day reviewing and discussing the information provided.
89371389|NCT03671642|Experimental|Perfusion assessment|Q-ICG: quantitative perfusion assessment with FA White light perfusion assessment FA: fluorescence angiography without quantification
89371390|NCT02408224||one arm|patients on Ticagrelor
89371391|NCT03623282|Experimental|Synatura® 15 mL|Synatura syrup single arm
89371392|NCT03738605|Experimental|Laser Group|Microablative Fractional CO2 Laser Therapy (The parameters that will be used are the following: 1) Power: 30 ή 40 watts, 2) Dwell time:1000μs, 3) Spacing 1000 μm, 4) Depth: SmartStak parameter from 1-3 depending on the treatment status, 5) D-pulse mode.)
89371393|NCT03738605|Placebo Comparator|Placebo|Placebo therapy (The parameters that will be used are the following: 1) Power: 0.5 watts, 2) Dwell time:1000μs, 3) Spacing 1000 μm, 4) Depth: SmartStak parameter 1, 5) Smart-pulse mode.
88844124|NCT06287229|Experimental|Phase 1B + Phase 2|Participants found to be eligible to take part in this study, you will be assigned to a study phase (Phase 1B or Phase 2). Up to 10 participants will be enrolled in Phase 1B, and up to 30 will be enrolled in Phase 2. All participants will first receive cytoreductive therapy (inotuzumab ozogamicin, blinatumomab, and either hyper-CVAD or mini-hyper-CVD), followed by lymphodepletion chemotherapy and 1 dose of brexucabtagene autoleucel.
88844125|NCT06287216|Experimental|Mental Hygiene Group|This is the group participating in the mental hygiene challenge that is willing to give informed consent and conduct pre-post as well as daily well-being surveys.
88844126|NCT06287216|Active Comparator|Self-Care Group|Similar to the above, instead of recommending mental hygiene, we will be recommending daily self-care, and offer standard government issued resources, as well as resources from other reputable organizations.
88844127|NCT06287203|Active Comparator|Risk estimates + Psychoeducation|Participants in this condition will complete the prevention program in which individuals receive their personalized risk estimates, followed by psychoeducation about ways to reduce substance use and associated harm.
88844128|NCT06287203|Active Comparator|Risk estimates + Online CBT Modules|Participants in this condition will complete the prevention program in which individuals receive their personalized risk estimates, followed by on-line cognitive behavioral therapy (CBT)-based modules to assist with controlling substance use.
88844129|NCT06287203|Active Comparator|Risk estimates + Genetic Counselor|Participants in this condition will complete the prevention program in which individuals receive their personalized risk estimates, followed by a follow-up appointment with a genetic counselor.
89371394|NCT04482790|Active Comparator|Conventional celluloid matrix|Conventional celluloid matrix technique in management of black triangle
89371395|NCT04482790|Experimental|Bioclear cervical matrix|Bioclear cervical matrix with injection molding technique in management of black triangle
89371396|NCT03738527|Experimental|TXA arm|
89371397|NCT03738527|Placebo Comparator|Placebo arm|
89371398|NCT03738449|Experimental|Group 1|"Period 1: D484~Period 2: CKD-387"
89371399|NCT03738449|Experimental|Group 2|"Period 1: CKD-387~Period 2: D484"
89371400|NCT03174262|Experimental|Ergonomic Computer Workstation Training|
89371401|NCT03174262|No Intervention|Control Group|
88844130|NCT06287203|Other|Waitlist Control - Psychoeducation Only|Participants in this condition will not receive their personalized risk estimates until the end of the study. They will receive psychoeducation about ways to reduce substance use and associated harm at the time that the active conditions receive their estimates and associated follow-up content.
88844131|NCT06287008||OKT|"patients who underwent open kidney transplantation"
88844132|NCT06287008||RAKT|"patients who underwent robot-assisted kidney transplantation"
89371402|NCT02413060|Experimental|Resistance training|Patients of treatment group will undergo resistance training every week sessions
89371403|NCT02413060|Other|Lifestyle counseling|Patients of control group will get the lifestyle counseling every 3 month
89371404|NCT03738371||Team of health professionals|Team of health professionals involved in thrombectomy (including specialized nurses in anesthesiology, anesthesiologists, neuroradiologist and technicians specialized in electro-radiology) will participate to in situ simulation.
88844133|NCT06286904||Sleep position detection|Accuracy of Skiin Garment system for detecting sleep position of pregnant womem.
89371405|NCT03176056|Experimental|Low carbohydrate diet|Low carbohydrate diet limits carbohydrate <=90g/day
89371406|NCT03176056|Active Comparator|Calori restricted diet|Traditional diabetic diet
89371407|NCT02915978|Experimental|Lower Dose Fentanyl|Lower dose Fentanyl delivered via sublingual spray every 4 hours.
88844134|NCT06286527||adult PrEP users|
88844135|NCT06286488|Experimental|Evaluation of immunogenicity and tolerance of quadrivalent influenza vaccine in obese adults|Scientific observations published during the 2009 influenza pandemic have highlighted the more severe course and complications of influenza in obese people. The effect of excessive body fat in humans on the immune response to influenza vaccination is not fully explained by the available studies. Study aim was the evaluation of immunological efficacy and tolerance of QIV in obese adult patients and the relationship between the degree of obesity and immunogenicity of quadrivalent QIV in obese adult patients. Free of charge influenza vaccination was done with a quadrivalent Sanofi Pasteur Vaxigrip Tetra vaccine at a dose of 0.5 ml according to WHO recommendations for 2017/2018 for the northern hemisphere.
89371408|NCT02915978|Experimental|Higher Dose Fentanyl Sublingual Spray|Higher dose Fentanyl delivered via sublingual spray every 4 hours.
89371409|NCT02915978|Placebo Comparator|Placebo|Placebo (matching Fentanyl) delivered via sublingual spray every 4 hours.
89371410|NCT02412904|Other|drug to ovulation induction: rFSH|Patients submitted to IVF that will use rFSH (Puregon®, Organon Ltd., Ireland) for ovarian stimulation
89371411|NCT02412904|Other|drug to ovulation induction :HMG|Patients submitted to IVF that will use hMG (Menopur®, Ferring Pharmaceuticals, Denmark) for ovarian stimulation
88844136|NCT06286488|Experimental|Immunogenicity of QIV in pregnant women, including transplacental transport of antibodies|Many studies confirm the safety of vaccinations against influenza during pregnancy for pregnant women as well for children. Previous studies have assessed the immunological efficacy of a monovalent and trivalent vaccine, but studies assessing the immunological efficacy and tolerability of the tetravalent, inactivated influenza vaccine in pregnant women are missing.The aim of the study is to assess immunogenicity and tolerance of tetravalent, inactivated influenza vaccine in pregnant women, depending on the duration of vaccination (II or III trimester) by assessing the level of antibodies in neonatal umbilical cord blood (transplacental transfer). Free of charge influenza vaccination was done with a quadrivalent Sanofi Pasteur Vaxigrip Tetra vaccine at a dose of 0.5 ml according to WHO recommendations for 2021/2022, 2022/2023 for the northern hemisphere.
88844137|NCT06286436|Experimental|Dual-task training|
88844138|NCT06286410|Experimental|Aniso-A|"Aniso-A~Those found to have anisometropic accommodation response do not focus effectively in their amblyopic eye when looking at the 0.33m (near) targets. Aniso-A response will be determined by their interocular difference in measurements at near (0.33m).~They will be given a prescription for D-28 segment bifocal glasses. The distance section of the glasses will match their current glasses, and the bifocal add will be equivalent to the mean amount they are under accommodating by at 0.33m in their amblyopic eye during the cue conditions with glasses. Bifocals will only be worn during patching. They will wear their own current glasses for all other times. This will be made very clear to parents/caregivers, and written instructions will be given.~The participant will act as their own controls: visual acuity at recruitment will be used to compare to visual acuity during and after the intervention."
88875257|NCT02549040|Experimental|Doravirine fixed sequence treatment|After a minimum 10 hour overnight fast, participants received a single oral dose during each of 5 periods. During Period 1, participants received Treatment B: Doravirine Type 1 dose (150 mg tablet [40% drug loaded granule]). During Period 2, participants received Treatment A: Doravirine 100 mg film coated tablet. During Period 3, participants received Treatment C: Doravirine Type 2 dose (150 mg tablet [30% drug loaded granule]). During Period 4, participants received Treatment D: Doravirine Type 3 dose (150 mg tablet [50% drug loaded granule]. During Period 5, participants received Treatment E: Doravirine Type 4 dose (100 mg tablet [30% drug loaded granule]). Each period was separated by a 14 day washout.
89371412|NCT02412826||Acute pancreatitis|Patients presenting to the hospital with acute pancreatitis that will receive AbStats sensor
89371413|NCT03675230|Active Comparator|3DCRT|This arm will be planned by 3DCRT to the treatment of the Medulloblastoma
89371414|NCT03675230|Experimental|Tomotherapy HD，TOMO|This arm will be planned by TOMO to the treatment of the Medulloblastoma
89371415|NCT02404714||CF/CRMS|"Subject's with a previous cystic fibrosis or cystic fibrosis related metabolic syndrome (CRMS) diagnosis will receive the institution's standard iontophoresis sweat testing (Gibson-Cooke or Wescor Macroduct) to provide a diagnosis.~The patient will also receive a sweat test provided by the new CF Quantum Sweat Test System which includes the same process and principal of operation of iontophoretic stimulation, collection and analysis of sweat compared to the standard. The results of the new sweat test and the standard sweat test will be compared. The new sweat test will not be used to diagnose, treat or mitigate the patient's condition. Results are used only to compare to the standard of care."
89371416|NCT02404714||NON CF/CRMS|"Subject's without a previous cystic fibrosis or cystic fibrosis related metabolic syndrome (CRMS) diagnosis but referred to the sweat test lab on a clinical observation basis by a physician will receive standard iontophoresis sweat testing (Gibson-Cooke or Wescor Macroduct) to provide a diagnosis.~The patient will also receive a sweat test provided by the new CF Quantum Sweat Test System which includes the same process and principal of operation of iontophoretic stimulation, collection and analysis of sweat compared to the standard. The results of the new sweat test and the standard sweat test will be compared. The new sweat test will not be used to diagnose, treat or mitigate the patient's condition. Results are used only to compare to the standard of care."
89371417|NCT03671408||periodontitis|periodontitis patients which were diagnosed based on clinical parameters
88844139|NCT06286410|Experimental|Anti-A|"Anti-A~Those found to have anti-accommodation over-accommodate in their amblyopic eye for the 2m (distance) target. Aniso-A response will be determined by their interocular difference in measurement in the distance (2m).~They will be given a prescription for single vision distance glasses. The distance prescription in their non-amblyopic eye will be the same as their current glasses. The distance prescription in their amblyopic eye will be reduced by the same amount they are over-accommodating by during the cue conditions with glasses. This amended distance prescription will only be worn during patching. They will wear their own current glasses for all other times. This will be made very clear to parents/caregivers, and written instructions will be given.~The participant will act as their own controls: visual acuity at recruitment will be used to compare to visual acuity during and after the intervention."
88844140|NCT06286059|No Intervention|Control group|Patients will receive conventional management including high dose atorvastatin and isotonic (0.9%) saline intravenous (IV) infusion at a rate of 1 ml/kg/hr for 12 hours or reduced to 0.5 ml/kg/hr if the patient's LVEF < 40% or overt heart failure.
88844141|NCT06286059|Experimental|Phentolamine group|In addition to the conventional management, patients will receive phentolamine infusion.
88844142|NCT06285864|Experimental|Interoception-based intervention|The interoception-based intervention group will receive the intervention, which consists of 8 weekly sessions, of 1h30 hour, in groups (4-8 participants in each group).
88844143|NCT06285864|No Intervention|Waiting list|The waiting list group will maintain their treatments as usual and receive the interoception-based intervention, at the end of the study.
88844144|NCT06285448||Patients with Alzheimer's disease|Patients with Alzheimer's disease eligible to receive lecanemab infusions at HealthPartners clinics and their care partners.
88844145|NCT06285032|Experimental|Cognitive Behavioral Therapy (CBT)|Participants will be randomized to the CBT group (N=34). CBT groups will meet for 1 hour via Zoom, for 8 weeks.
88844146|NCT06285032|Experimental|Social Navigation Group|Participants will be randomized to the social navigation group (N=34). Social navigation group will meet for 30 mins via Zoom, for 8 weeks.
88844147|NCT06285032|Experimental|Usual Care Group|Participants will be randomized to the usual care group (N=34). Participants in this group will resume to their usual standard of care for 8 weeks.
88844148|NCT06284421|Experimental|Durometer|This is a single-arm trial in which a Shore durometer will be used to measure the hardness of the uterus after placental delivery during cesarean section.
88844149|NCT06284356||Patients without complications after LSG|
88844150|NCT06284356||Patients with complications after LSG|
88844151|NCT06284356||Control Group|
88844152|NCT06284317|Experimental|Durvalumab|Protocol treatment in the adjuvant phase consists of adjuvant durvalumab
88844153|NCT06284317|No Intervention|Observation|Observation only
88844154|NCT06283823||Retainer with high margins|Thermoformed retainers with modified cutout and high margins in the posterior region of the retainer
88844155|NCT06283823||Retainer with low margins|Thermoformed retainer with conventional festooned cutout and low margins
88844156|NCT06283771|Experimental|EXPERIMENTAL GROUP|The study group will wear heated socks to be developed with wearable technology
88844157|NCT06283771|No Intervention|CONTROL GROUP|The control group will wear socks that look exactly the same as the heated socks developed with wearable technology worn by the study group, but with a closed heating circuit.
88844158|NCT06283706|Experimental|Tryptophan in Adults >60y|Tryptophan levels, up to 7 levels, will be tested in a random order in all subjects
88844159|NCT06283498|Experimental|Device Treatment|20 female patients with overactive bladder symptoms, aged 21 to 80 years old, inclusive from two sites.
88844160|NCT06283472|Experimental|High-Intensity|Participants will receive high-intensity episodic future-thinking cue images, and high-intensity episodic recent-thinking cue images during an MRI decision-making task.
88844161|NCT06283472|Active Comparator|Low-Intensity (Control)|Participants will receive low-intensity episodic future-thinking cue images, and low-intensity episodic recent-thinking cue images during an MRI decision-making task.
88844162|NCT06283459|Experimental|IMNN-101|"Participants will receive a single intramuscular (IM) dose of IMNN-101 on Day 0 in the deltoid muscle.~IMNN-101 is for intramuscular injection only."
88844163|NCT06283407||Poland|People with musculoskeletal conditions from the general population in Poland
89371418|NCT03671408||gingivitis/healthy|gingivitis healthy patients which were diagnosed based on clinical parameters
89371419|NCT03174028|Active Comparator|laparoscopic group|laparoscopic pull-through
88844164|NCT06283407||Spain|People with musculoskeletal conditions from the general population in Spain
88844165|NCT06283368||Benign Thyroid Pathologies|Nodular Goiter Graves Diseases Tocsic Thyroid Nodular Disease
88844166|NCT06283368||Thyroid Cancer Cases|Papillary Thyroid Carcinoma Medullary Thyroid Carcinoma Hurthle Cell Carcinoma Anaplastic Thyroid Carcinoma
89371420|NCT03174028|Sham Comparator|posterior sagittal group|posterior sagittal anorectoplasty
89371421|NCT02701192||Coccygectomy Treatment|Patients undergoing coccygectomy surgical procedure.
88844167|NCT06283225|Experimental|Intervention group|the intervention group has access to the dysmenorrhoea app and its functions in addition to normal regular care.
88844168|NCT06283225|No Intervention|Control group|the intervention group has access to normal regular care only.
88844169|NCT06283212|Experimental|Cohort X|Cohort X will consist of 2 participants and will evaluate ETX101 dose level 1.
89371422|NCT02404480|Experimental|Cohort 1|PTC 596 administered twice daily- Dose level 0.65mg/kg
88844170|NCT06283212|Experimental|Cohort Y|Cohort Y will consist of 2participants and will evaluate ETX101 dose level 2.
88875258|NCT02549508|Experimental|AutoCPAP with SensAwake On, then SenAwake Off|Participants will start AutoCPAP treatment with SensAwake on for 4 weeks. After 4 weeks, the will cross over to SensAwake off for another 4 weeks.
89371423|NCT02404480|Experimental|Cohort 2|PTC 596 administered twice daily-Dose level 1.3mg/kg
89371424|NCT02404480|Experimental|Cohort 3|PTC 596 administered twice daily-2.6mg/kg
89371425|NCT02404480|Experimental|Cohort 4|PTC 596 administered twice daily-Dose level 5.2mg/kg
89371426|NCT02404480|Experimental|Cohort 5|PTC 596 administered twice daily-Dose level 10mg/kg
89371427|NCT02404480|Experimental|Cohort 6|PTC 596 administered twice daily-Dose level 7mg/kg
88875259|NCT02549508|Experimental|AutoCPAP with SensAwake Off, then SensAwake On|Participants will start AutoCPAP treatment with SensAwake Off for 4 weeks. After 4 weeks, the will cross over to SensAwake On for another 4 weeks.
89180763|NCT04107194|Active Comparator|Empiric therapy|"Either one of the two following 10-day regimens (according to physician's decision):~Pantoprazole 40 mg bid (tablet) Amoxicillin 1000 mg bid (tablet) Clarithromycin 500 mg bid (tablet) Metronidazole 500 mg bid (tablet)~Pantoprazole 40 mg bid (tablet) Tetracycline 125 mg + metronidazole 125 mg + bismuth 140 mg in a single tablet (3 tablets qid)"
89180764|NCT03180827|Experimental|ovarian tissue cryopreservation|
89180765|NCT02590263|Experimental|Arm A of Phase 1 portion|ABT-414 administered every other weeks monotherapy
89180766|NCT02590263|Experimental|Phase 2 portion|ABT-414 administered every other weeks in combination with temozolomide
89180767|NCT02590263|Experimental|Arm C of Phase 1 portion|ABT-414 administered every other weeks in combination with radiation and temozolomide
89180768|NCT02590263|Experimental|Arm B of Phase 1 portion|ABT-414 administered every other weeks in combination with radiation and temozolomide
89180769|NCT02603588|Experimental|active acupuncture|intervention: subjects in the active acupuncture group received active sphenopalatine ganglion acupuncture
89180770|NCT02603588|Sham Comparator|sham acupuncture|intervention: subjects in the sham acupuncture group received sham sphenopalatine ganglion acupuncture
89180771|NCT00914303|Experimental|AZD3241|AZD3241 Tablets
89180772|NCT00914303|Experimental|Placebo|Placebo Tablets
89180773|NCT02590185|Experimental|cocktail probe drugs|"A capsule of omeprazole ABBOTT® 10mg~10 mg of an oral liquid formulation of Dextrométhorphane bromhydrate (Drill Pierre FABRE MEDICAMENT® 5mg/5mL, syrup)~1 mg of an injectable solution of Midazolam for oral administration (Midazolam Panpharma® 1mg/mL, injectable solution)~A tablet of fexofenadine Zentiva® 120mg"
89180774|NCT04104698||Study Group (MDD with SIs)|25 Egyptian patients diagnosed with major depression (with suicidal ideations)
89180775|NCT04104698||Control group (MDD without SIs)|25 Egyptian patients diagnosed with major depression (without suicidal ideations)
89180776|NCT00736476|Experimental|1|
89180777|NCT00736476|Placebo Comparator|2|
89180778|NCT02590107|Experimental|Supportive care (Boost Plus, Pro-Stat 101)|Participants receive Boost Plus PO BID or Pro-Stat 101 PO BID beginning one week before scheduled HSCT and continuing until hospital discharge. If participants do not tolerate the Boost Plus or Pro-Stat, they receive a milkshake PO QD as an alternative.
89180779|NCT04104932||Surgical group|Patients with isolated minor rib fractures received surgical stabilization.
89180780|NCT04104932||Conservative group|Patients with isolated minor rib fractures received conservative treatment, such as NSAIDs.
89180781|NCT02606357|Experimental|HOE901|HOE901 administered subcutaneously once a day in the evening, at dinner, or at bedtime with titration based on FPG levels
89180782|NCT04019496||Episodic Migraine|
89371428|NCT02404480|Experimental|Cohort 7 (Bio Marker cohort)|PTC 596 administered twice daily-Dose level 5.2mg/kg
89371429|NCT02412514|Active Comparator|Arm A|Infants assigned to Arm A will receive bOPV at 6, 10, and 14 weeks of age and IPV at 6 weeks of age.
89180783|NCT04019496||Healthy controls|equal to or less than 1 headache day/month
89180784|NCT04104386|Experimental|Disclosure of Telomere Length Arm|Telomere Length results were provided (personal value, means, and standard deviation of the group), and categorized as 'short' telomere length (bottom quartile) and 'not short' (above the bottom quartile) based on age related norms available from research literature.
89180785|NCT04104386|No Intervention|Non-Disclosure|Telomere Length results were not provided.
89371430|NCT02412514|Active Comparator|Arm B|Infants assigned to Arm B will receive bOPV at 10 and 14 weeks of age and IPV at 6 weeks of age.
89371431|NCT02408458|Other|MIROMESH|Single-arm study. MIROMESH will be used in the surgical repair of ventral hernia.
89180786|NCT00715299|Other|Locomotor Training Group|persons who have sustained a stroke within greater than 6 months ago and less than 5 years.
89180787|NCT02602730|Experimental|Break the Chain|Access during the evaluation study period to an Internet smoking cessation intervention that included digital coaching messages sent at prescribed times during the participant's quit process and as needed in response to participant questions or comments.
89180788|NCT02602730|Active Comparator|Clearing the Air PDF|"Control users were e-mailed a copy of the National Cancer Institute's PDF smoking cessation booklet, Clearing the Air."
89180789|NCT00918489|Experimental|Vorinostat|Daily administration of 400mg vorinostat on 28 days (one therapy cycle). Seven days of therapy break between two consecutive cycles.
89180790|NCT04112888|Experimental|Collagen group|"Patients will receive 3 to 5 infiltrations of collagen on the scar once a week.~Patients will receive the conventional treatment of 8 rehabilitation sessions with massage therapy techniques, muscle stretches and fascial work. The rehabilitation sessions will always be carried out by the same physiotherapist specialized in pelvic floor. Two rehabilitation sessions per week during four weeks. The rehabilitation sessions will last 45 minutes."
89180791|NCT04112888|Active Comparator|Control group|Patients will receive the conventional treatment of 8 rehabilitation sessions with massage therapy techniques, muscle stretches and fascial work. The rehabilitation sessions will always be carried out by the same physiotherapist specialized in pelvic floor. Two rehabilitation sessions per week during four weeks. The rehabilitation sessions will last 45 minutes.
89180792|NCT02604992|Experimental|Group 1 (A,B,C)|With a 7-day washout between periods, participants are randomized to receive Treatment A, Treatment B, and then Treatment C.
89180793|NCT02604992|Experimental|Group 2 (B,C,A)|With a 7-day washout between periods, participants are randomized to receive Treatment B, Treatment C, and then Treatment A.
89180794|NCT02604992|Experimental|Group 3 (C,A,B)|With a 7-day washout between periods, participants are randomized to receive Treatment C, Treatment A, and then Treatment B.
89180795|NCT02604992|Experimental|Group 4 (C,B,A)|With a 7-day washout between periods, participants are randomized to receive Treatment C, Treatment B, and then Treatment A.
89180796|NCT02604992|Experimental|Group 5 (A,C,B)|With a 7-day washout between periods, participants are randomized to receive Treatment A, Treatment C, and then Treatment B.
89371432|NCT02404558|Experimental|Sarilumab|Single subcutaneous (SC) dose of sarilumab
89371433|NCT02404558|Active Comparator|Tocilizumab|Single SC dose of tocilizumab
89371434|NCT02404636||Alcoholic hepatitis|Individuals admitted to hospital with acute alcoholic hepatitis, defined as acute onset of jaundice in the context of recent hazardous alcohol use and the absence of other liver disease
89371435|NCT02404636||Hazardous alcohol use|Individuals admitted to hospital for any cause who drink hazardous quantities of alcohol but without evidence of alcoholic hepatitis or advanced liver disease
89371436|NCT04481854|Experimental|Cricoid pressure group|Patients of this group will recieve cricoid pressure during direct laryngoscopy.
89371437|NCT04481854|Experimental|left paratracheal pressure group|Patients of this group will recieve left paratracheal pressure during direct laryngoscopy.
89371438|NCT02408536||Single cohort|Retrospective analysis of all patients diagnosed, from 01/01/2000 to 01/01/2014, with low-grade serous ovarian cancer or invasive recurrence after surgery for borderline serous carcinoma
88844171|NCT06282419|Experimental|Experimental group 1|Fetal images and fetal heart sound recordings will be taken from the pregnant women in experimental group 1 with a mobile phone compatible portable USG device. Fetal USG images of their babies, taken with a portable USG device, and fetal heart sounds will be sent to the prospective fathers in experimental group 1 by the researcher via WhatsApp application twice a week until birth (at least 3 weeks).
88844172|NCT06282419|Placebo Comparator|Experimental group 2|Fetal USG images and fetal heart sounds taken from the internet, which are not of their babies, will be sent to the prospective fathers by the researcher via WhatsApp application twice a week until birth (at least 3 weeks). In the second stage of the research; Breastfeeding videos prepared by the researcher will be sent to fathers in experimental group 2 twice a week for 4 weeks after birth via WhatsApp application.
88844173|NCT06282419|No Intervention|control group|No visual or auditory stimuli were sent.
88844174|NCT06281652|Experimental|Go classes|Subjects randomized to a group intervention with Go lessons once a week for 12 weeks
88844175|NCT06281652|Experimental|Chess classes|Subjects randomized to a group intervention with Chess lessons once a week for 12 weeks
88844176|NCT06281652|Experimental|Go & Chess classes|Subjects randomized to a group intervention with Go and Chess lessons twice a week for 12 weeks
88844177|NCT06281652|No Intervention|Control|Subjects randomized to no intervention for 12 weeks
88844178|NCT06281262||Pregnant women|Singletone pregnancy, gestational age 9+0 - 12+0, history of preeclampsia (PE) or spontaneous preterm birth (PTL = preterm labour) or pPROM (preterm premature rupture of membranes).
88844179|NCT06281158|Experimental|14C-DNL343|
88844181|NCT06280612|Experimental|Live Cat Group|"Before starting the study, the Structured Patient Information Form, Edmonton Symptom Diagnosis Scale, and Oxford Happiness Scale Short Form were applied to the patients. Then, the researcher gave the patients face-to-face, individual information about hand hygiene after contact with a live cat for approximately 15 minutes in the waiting room and offered them a Live Cat Information Brochure. Patients were then asked to spend 20 minutes with a pet at home twice a week for 12 weeks. Edmonton Symptom Diagnosis Scale and Oxford Happiness Scale Short Form were applied to this group of patients three times: before, at the 6th week, and at the end of the 12th week of the study."
88844182|NCT06280612|Experimental|Robotic Cat Group|"Before starting the study, the Structured Patient Information Form, Edmonton Symptom Diagnosis Scale, and Oxford Happiness Scale Short Form were applied to the patients. Then, the researcher gave the patients face-to-face information about the robotic cat Silver and its use for approximately 15 minutes in the waiting room and offered them a Robotic Cat Information Brochure. In each pet therapy application, patients' hand hygiene and cleaning of the Robotic Cat was provided, the robot cat was given to the patients."
88844183|NCT06280612|No Intervention|Control Group|"Before starting the study, the Structured Patient Information Form, Edmonton Symptom Diagnosis Scale, and Oxford Happiness Scale Short Form were applied to the patients. Treatment was given to this group of patients only after informing them about the study, and the patients were followed for only three months. Edmonton Symptom Diagnosis Scale and Oxford Happiness Scale Short FormS were applied to the patients three times: before, at the 6th week, and the end of the 12th week of the research."
89002087|NCT06116240|Experimental|Subjects with advanced hepatocellular carcinoma|TQB2450 injection, 21 days as a treatment cycle. AL2846 capsule, 21 days as a treatment cycle.
89371439|NCT02408302|Active Comparator|oral midazolam|oral midazolam 0.5-0.7 mg/kg maximum 10 mg. one dose only before the invasive procedure.
89371440|NCT02408302|Active Comparator|intranasal midazolam|intranasal midazolam 0.3-0.5 mg/kg maximum 5 mg. one dose only before the invasive procedure
89371441|NCT02408302|Active Comparator|buccal midazolam|buccal midazolam 0.3-0.5 mg/kg maximum 5 mg. one dose only before the invasive procedure
89371442|NCT02404324|Experimental|spectacles|"Esotropia is treated by full optical correction (spectacles prescription) in all children with refractive errors. Special attention is paid to astigmatism up to 0.5 Dptr.~Intervention: Prescription of spectacles"
89371443|NCT03170986|Experimental|Multisectoral Agriculture and Microfinance Arm|
89002088|NCT06116240|Experimental|Advanced gastric adenocarcinoma / gastroesophageal junction adenocarcinoma subjects|TQB2450 injection, 21 days as a treatment cycle. AL2846 capsule, 21 days as a treatment cycle.
89371444|NCT03170986|No Intervention|Control Arm|
89371445|NCT02412358|Active Comparator|Pulsar|Patients use Pulsar toothbrush for plaque removal
89371446|NCT02412358|Active Comparator|Crossaction|Patients use Crossaction toothbrush for plaque removal
89371447|NCT02412358|Active Comparator|Butler|Patients use Butler toothbrush for plaque removal
89371448|NCT03173716|Active Comparator|Intervention Group|DEFINITY contrast will be prepared according to package insert instructions. A dose of 1.5 mL activated DEFINITY diluted in 28.5 of preservative free saline to constitute a total volume of 30 mL will be infused at a rate of 90-120 mL/hr (1.5-2.0 mL/min). RTMPE will be performed.
89371449|NCT03173716|No Intervention|Control Arm|Echocardiograms will be performed without the use of DEFINITY contrast/RTMPE.
89371450|NCT03115372|Experimental|Group I (CRC education)|LHWs undergo training over 3 days and recruit 15 participants from their social network. Participants attend a CRC educational session conducted by an LHW over 90 minutes at month 1 and 3. Participants receive phone calls from the LHW at months 2 and 4 reminding them about CRC screening.
89399278|NCT02170142||No treatment|All subjects studied are normal healthy neonates without a condition. MRI will be used to assess normal brain development.
89371451|NCT03115372|Active Comparator|Group II (CRC brochure)|LHWs undergo training over 3 days and recruit 15 participants from their social network. Participants attend a lecture on healthy nutrition for cardiovascular health presented by a professional health educator at months 1 and 3. After the first meeting, participants receive a brochure on CRC screening. Participants receive phone calls from the LHW at months 2 and 4 regarding changes in their nutritional behavior. Participants may attend an optional post-intervention LHW outreach session on CRC screening.
89371452|NCT03173872|Experimental|One Group Study Arm|One group study arm assesses pre Reiki and post Reiki intervention measures
89371453|NCT02412202|Other|patients who undergo weaning from mechanical ventilation|consecutive mechanically ventilated critical ill patients who fulfil criteria for weaning will be included
89371454|NCT02408146|Experimental|conventional intravenous infusion pump|The first group receives conventional intravenous infusion pump of patient-controlled analgesia.
89371455|NCT02408146|Experimental|parecoxib|The second group has oral celecoxib before surgery, then receives parecoxib sodium intravenously guttae after surgery.
89371456|NCT02408146|Experimental|new intravenous infusion pump|The third group uses new intravenous infusion pump of patient-controlled analgesia after surgery.
89371457|NCT02412124|Experimental|Supportive care (W2W program)|Patients participate in the W2W program for which they are matched with a trained mentor and followed throughout treatment by phone, email, and/or in person.
89371458|NCT04482010|No Intervention|Classic HIV care|Participants diangosed HIV positive at the time of the community-based activities conducted by ARCAD Santé PLUS. They will be referred to the referral centers (CSRéf) for the classic HIV care in the Malian public health system.
89371459|NCT04482010|Other|Community-based HIV care|Participants diagnosed HIV positive at the time of the community-based activities by ARCAD Santé PLUS. They will receive community-based HIV care by the NGO at the gold-mining site.
89371460|NCT03175900|Experimental|Naoan dripping pills for migraine|Drug: Naoan dripping pills, Chinese patent medicine，pill. Patients will receive treatment with Naoan dripping pills for 12 weeks, Fenbid can be taken if headache is unbearable Procedure: MRI scanning（fMRI and DTI）
89371461|NCT03175900|Placebo Comparator|Placebo|Drug: Placebo, pill. Patients will receive treatment with placebo for 12 weeks, Fenbid can be taken if headache is unbearable Procedure: MRI scanning （fMRI and DTI）
89371462|NCT03175666|Experimental|Nant TNBC|avelumab, bevacizumab, capecitabine, cisplatin, cyclophosphamide, 5-fluorouracil, leucovorin, nab-paclitaxel, lovaza, stereotactic body radiation therapy, ALT-803, ETBX-011, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, and haNK.
89371463|NCT03101358|Experimental|SOR007 0.15%|0.15% SOR007 (Uncoated Nanoparticle Paclitaxel) Ointment applied topically twice daily for 28 days
89371464|NCT03101358|Experimental|SOR007 1.0%|1.0% SOR007 (Uncoated Nanoparticle Paclitaxel) Ointment applied topically twice daily for 28 days
89371465|NCT03101358|Experimental|SOR007 2.0%|2.0% SOR007 (Uncoated Nanoparticle Paclitaxel) Ointment applied topically twice daily for 28 days or up to 56 days
89371466|NCT02404246|Experimental|Intervention Arm|Intervention evaluated the feasibility, acceptability, and effectiveness of a structured peer support intervention based on the Certified Peer Specialist Program of the Depression and Bipolar Support Alliance (DBSA).
89371467|NCT02404246|No Intervention|Usual Care|Usual Care
89371468|NCT05236218||Pilot study (n = 10)|10 participants will be recruited to complete the questionnaire (version 1). A research assistant will be present to help support them /answer any questions around the format. Readability and comprehension will be noted. Any changes (if needed) can be implemented to its format before the main data collection.
89371469|NCT05236218||Discrete Choice Experiment Questionnaire (n = 50)|Discrete Choice Experiment (DCE) Patients
89371470|NCT03173794|No Intervention|Usual Care Only|The control group will receive usual care, no CommunityRx-H intervention
89371471|NCT03173794|Experimental|Usual Care and Intervention|The intervention arm will receive the CommunityRx-H intervention, an information-based intervention that provides referrals to community resources
89371472|NCT03171220|Experimental|Neoantigen Reactive T Cells + SHR-1210|Peripheral blood lymphocytes will be collected and neoantigen reactive T cells(NRTs) will be generated in the laboratory;Both Fludarabine 30mg/m2/D and Cyclophosphamide 300mg/m2/D will be i.v. for 3 days before cell infusion; NRTs 0.5~1 x 10^10, will be i.v.Q3 weeks for total 4 doses;programmed cell death-1（PD1） inhibitor SHR-1210,200mg,will be i.v. Q3 weeks for total 4 doses,2 day2 prior to each NRTs infusion;Interleukin-2 (IL-2) will be continuous intravenous infused since the first day of the cell infusion for 5 consecutive days, 4000,000 international unit per day.All Patients will receive a total of 4 cycles of treatment.
88819341|NCT02214212|Experimental|Bright White Light (BWL)|"Intervention/Device:~This patient group will receive 30 minutes of bright white light daily for a period of 10 days in the morning. Identical baseline and outcome testing will be completed for both arms."
88819342|NCT02394600|Experimental|Grastek®|48 participants will receive Grastek® once per day for 120 days. Grastek® is a standardized sublingual immunotherapy (SLIT) tablet containing 2800 BAU of standardized allergen extract from Timothy grass (Phleum pretense). This SLIT product is approved by Health Canada and the Food and Drug Administration (FDA) for the treatment of grass-pollen induced allergic rhinoconjunctivitis (AR) in Canada and the United States respectively.
88819343|NCT02394600|Placebo Comparator|Placebo|48 participants will receive placebo once per day for 120 days.
88819344|NCT02214290|Active Comparator|Caffeine|200 mg caffeine tablet produced by CVS Pharmacy, USA
88819345|NCT02214290|Placebo Comparator|Placebo|Placebo pill produced by NOW FOODS, USA
88819346|NCT02214290|Experimental|L-citrulline|L-citrulline capsule (750 mg) provided by NOW FOODS
88819347|NCT03160911|Experimental|Over-the-scope clip|The patient would receive an esophagogastroduodenoscope to identify the bleeding source. The endoscopist can decided whether to pre inject the ulcer with adrenaline. Then the OTSC is used for haemostasis.
89371473|NCT03170830|Experimental|Healthy control group|Age:45-75 years.Pepole who have normal ECG without the history of cardiovascular disease can be included in the healthy control group.
89371474|NCT03170830|Experimental|unstable angina disease control group|Age:>18 years.Unstable angina patients meet the diagnostic criteria.
89371475|NCT03170830|Experimental|acute myocardial infarction group|Age:>18 years.Acute myocardial infarction patients meet the diagnostic criteria.
89371476|NCT03175822|Experimental|Visual Arts Training|Visual Arts Training
88844184|NCT06280313||Treatment (Splenectomy+Targeted therapy+ Immunotherapy)|Eligible patients with unresectable hepatocellular carcinoma accompanied by cirrhotic hypersplenism were enrolled in the trial, and all participants underwent either open or laparoscopic splenectomy, with or without devascularization around the cardia. Starting two weeks post-surgery, patients began intravenous infusion of PD-1 monoclonal antibody, Tislelizumab, at a dosage of 200mg every three weeks. Three weeks post-surgery, patients commenced oral administration of the targeted therapy, Lenvatinib, with a dosage based on body weight: 8mg (≤60kg) or 12mg (>60kg), once daily.
89371477|NCT03175822|No Intervention|Waitlist Control|Waitlist Control
89371478|NCT04847934|Experimental|Virtual Reality Group|watching the application by wearing virtual glasses to the child during the intramuscular injection
89371479|NCT04847934|Experimental|Manual Pressure Vibration Technique Group|Application of manual pressure vibration technique to the area where the intervention will be made
89371480|NCT04847934|Experimental|Cold Vibration Group|Buzzy, connecting and operating 5 cm above the area to be injected
89371481|NCT04847934|No Intervention|Control Group|Standart care
89371482|NCT03116386|Other|run-in period|"In order to improve the precision of data, the run-in period is dedicated to sensitize the caregivers about the importance of~reporting all the falls occurring during the night~tracking in each resident's file, all informations about the estimate length of time spent on floor after a fall occurring during the night~and also reporting every other events occuring at night as wandering. All the beds will progressively equipped with the Etolya-F ® devices but the Etolya-F ® ddevices will stay off."
89371483|NCT03116386|Sham Comparator|control period|We expect 30 falls will occurr at night during this 6 months period. Etolya-F ® devices will be installed on the bed of all participant residents but with limited fonctionnalities i.e. only the length of absence in the bed will be recorded (difference between time of detection of the beginning of absence in the bed and time where the resident will be found by the caregivers out of his bed).
89371484|NCT03116386|Experimental|Etolya-F ® devices|We also expect 30 falls will occur at night during this 6-month period. Etolya-F ® devices will be used with all their functionalities i.e. permit detection of absence in the bed, activation of a lighting environment when the resident gets up from his bed, transmission of alert to caregivers through the centralized system of sick call if the resident do not return to bed after 15 minutes and recording the time when caregivers will find the resident out of bed, distinguishing between a fall and a night wandering in the room or corridors without a fall
89371485|NCT05200650|Experimental|TumoCure Treatment|Subjects will be treated with a single intra-tumor injection of TumoCure, containing the polymeric delivery system and the Cisplatin hemotherapy agent at a dose of 100mg.
88844185|NCT06280274|Experimental|Treatment|Oral metformin hydrochloride
88844186|NCT06280274|Placebo Comparator|Placebo|Placebo tablet
88844187|NCT06280079|Experimental|Ultra-high-caloric fatty diet|ultra-high-caloric, high-fat, fluid nutritional supplement oral intake of 4 times 35 ml per day in addition to normal food intake, corresponding to +630 kcal and +70g fat per day
88844188|NCT06280079|Placebo Comparator|Placebo|placebo, fluid nutritional supplement oral intake of 4 times 35 ml per day in addition to normal food intake, corresponding to +50 kcal and +3,5g fat per day
88844189|NCT06278766|Experimental|ABBV-552|Participants will receive ABBV-552 on Day 1.
88844190|NCT06278181||Type 2 diabetes|Individuals with type 2 diabetes followed by the diabetes clinic at Limbe hospital
88844191|NCT06278181||Diabetes free|Community controls without diabetes, referred by the patients with diabetes. The unexposed individuals referred should have approximately the same age, be of same sex and health cathment area as the exposed individual
88844192|NCT06276647|Experimental|Patient Education Pamphlet and Partner Sheet|The study intervention consists of a patient education pamphlet and partner sheet (physically and virtually accessible) that will educate and prepare post-partum participants about health conditions (hypertension, diabetes, and depression), important health behaviors , physical and emotional postpartum symptoms, teach self-management skills, enhance social support, and connect post-partum participants with community resources. The education materials will provide simple actions that participants can utilize to address symptoms, realistic time frames for healing, danger signs to look out for and contact their physicians, and a list of resources for specific issues. The patient navigator will spend approximately 20 minutes with participants after enrollment, in the hospital. Following discharge, the patient navigator will contact each patient between 4 and 20 times, by phone and/or text with a research phone, to address questions and link participants to medical and community resources.
89371486|NCT03116542|Experimental|Diagnostic (18F-FLT PET/CT)|"Patients undergo 18F-FLT (3'-18Fluoro-3'-deoxy-L-thymidine) PET/CT (Positron Emission Tomography/Computed Tomography) at baseline. No specific dietary restrictions or hydration are required for FLT-PET scans, however, patients will be urged to drink plenty of water before and after the PET studies. [18F] FLT will be prepared by the cyclotron core facility and assessed for quality control following good manufacturing practice criteria. The radiopharmaceutical will immediately be brought to the Molecular Imaging and Therapy Service Radiopharmacy for dispensation in the PET suite. For each scan, patients will receive approximately up to 370 MBq (target of 10 mCi) [18F] FLT by intravenous infusion."
88844193|NCT06276647|No Intervention|Standard Postpartum Care|These patients will receive Standard postpartum care.
88844194|NCT06275035|Experimental|Experimental arm|Participants in the experimental arm (memantine) will be started on memantine. The starting dose of memantine will be 5mg once daily at bedtime for 1 week, followed by 5mg twice daily for 1 week, and finally increased to the full dose of 10 mg twice daily for 6 months.
88844195|NCT06275035|No Intervention|Standard arm|Participants in the standard arm will continue the standard treatment as planned.
88844196|NCT06273033||Patients who have undergone last-generation CCTA and ICA.|
89180797|NCT02604992|Experimental|Group 6 (B,A,C)|With a 7-day washout between periods, participants are randomized to receive Treatment B, Treatment A, and then Treatment C.
89371487|NCT03632694|Experimental|Health Coaching and Tech Support|"Participants receive tech support for using the Jawbone UP2 activity monitor and smartphone app, and education materials and health coaching to achieve their goals to reduce sedentary time and increase their daily steps."
89371488|NCT03632694|Active Comparator|Tech Support Only|"Participants receive tech support for using the Jawbone UP2 activity monitor and smartphone app and education materials on reducing sedentary behavior."
89371489|NCT03632694|No Intervention|Waitlist Control|"Participants are instructed to maintain their regular activities. Upon completion of the 16-week intervention, participants receive the Jawbone UP2 activity monitor, education materials, and one session of tech support/health coaching."
89371490|NCT03170674|Experimental|FT21039 Product Use Group|Subjects will use the electronic cigarette product (FT21039).
89371491|NCT03170674|Experimental|FT21092 Product Use Group|Subjects will use the electronic cigarette product (FT21092).
88844197|NCT06270160|Experimental|Arm 1: HIVST Alone|Participants will be provided with HIVST instructions and education from peer navigators, who will also emphasize the importance of receiving a confirmatory test irrespective of HIV positive result. Peer navigators will demonstrate how to use an HIVST kit, including how to 1) open the kit, 2) collect the oral fluid samples, and 3) read the results. In addition to HIVST education, participants will be offered optional pre-test counselling and SMS contact information to connect with their peer navigator. If participants do not want post-test counselling, the PN will follow up within two weeks. If the participants report testing positive, then they will be immediately scheduled for confirmatory testing and enrolled in the support programs at MARPI for young people living with HIV.
88844198|NCT06270160|Experimental|Arm 2: HIVST + mHealth|Participants in this arm will be enrolled into the HIVST intervention (as described above) as well as mHealth. The mHealth intervention is a 5-week program that includes a: 1) weekly SMS check-in moderated by the peer navigator; 2) weekly themed informational SMS and accompanying questions to enhance engagement; 3) WhatsApp group multi-media sharing with peer navigators. The peer navigator and coordinator will review group discussions weekly to incentivize engagement; 4) participatory comic books. The investigators are collaborating with the WelTel non-profit agency for a supportive SMS intervention. Weekly 2-way supportive messages will automatically be sent on the same weekday with WelTel software to Arm 2+3 participants, who should respond within 48 hours.
89371492|NCT03170674|Experimental|FT21018 Product Use Group|Subjects will use the electronic cigarette product (FT21018).
89371493|NCT03170674|No Intervention|Abstinence Group|Subjects in the Abstinence Group will not be assigned any products.
89371494|NCT03170596|Experimental|Tazarotene gel arm|The treatment protocol in this arm will consist of night time application of Tazarotene 0.1% gel during the entire study period. (3 months)
89371495|NCT03170596|Active Comparator|Microneedling arm|The treatment protocol in this arm will consist of four sessions of microneedling at monthly intervals. (0, 1, 2, 3 months)
89371496|NCT03170752|Experimental|Intervention group|"The screening intervention Cardiovascular Assessment Screening Program (CASP) to be implemented by NPs in the intervention group has three steps:~Identification of patients (using Eligibility for Heart Health Screening Form, Heart Health Assessment Pamphlet, Tracking Form for Heart Health Screening, Algorithm for NP to Screen);~Screening utilizing appropriate tools (Cardiovascular Screening Checklist, Heart Health Screening Website/App);~Actions to follow up on the screening results (Heart Health Screening Website/App, CV Decision Tree Algorithm)."
89371497|NCT03170752|No Intervention|Control group|The NPs in the control group will be instructed to follow usual practice to screen patients for cardiovascular disease.
88875260|NCT02550132|Experimental|Participants|All volunteers will participate in an experimental session. Participants will be delivered four different spinal manipulations (SMT) at T7 with a rate of force application of about 2200 Newtons/seconds and a preload force of 25 Newtons (N). SMTs will differed in their time to peak force (ms) and peak force (N), respectively fixed as follow for each applied SMT: (1)57 ms / 150 N, (2)80 ms / 200 N, (3)102 ms / 250 N and (4)125 ms / 300 N.
89002089|NCT06116240|Experimental|Advanced non-small cell lung cancer|TQB2450 injection, 21 days as a treatment cycle. AL2846 capsule, 21 days as a treatment cycle.
89180798|NCT00730236|Experimental|AEGR-733|
89180799|NCT04084899||Continuous Positive Airway Pressure|Patient treated with continuous positive airway pressure
89180800|NCT00915824|Experimental|STOPP/START intervention|STOPP/START intervention group
89180801|NCT04084743|Experimental|Virtual reality training and Dual task intervention|Cognitive and motor Dual-task intervention and virtual reality training intervention in patients with Parkinson's disease
89180802|NCT04084743|Active Comparator|Conventional physiotherapy and Dual task intervention|The dual-task intervention without virtual reality training intervention in patients with Parkinson's disease
89371498|NCT03173404|Experimental|Group I|Patients underwent hysteroscopy examination before IVF cycle.
89371499|NCT03173404|No Intervention|Group II|Patients underwent direct IVF cycle without previous hysteroscopy.
89371500|NCT05194176|No Intervention|Control|The control group will receive usual care. Patients will be instructed to perform respiratory exercises 8 times daily for 10 minutes and to extend these exercises 2 times daily with (sitting) physical exercises for an additional 10 minutes. Respiratory exercises include using incentive spirometry and exercises for deep breathing, huffing and coughing. Patients receive a leaflet with the exercises described and the exercises will be performed once daily under supervision of a physiotherapist. The other sessions will be unsupervised.
89371501|NCT05194176|Experimental|Virtual Reality|The intervention group will be instructed to perform the respiratory exercises using the VR-intervention 8 times daily for 10 minutes and to extend these exercises 2 times daily with (sitting) physical exercises for an additional 10 minutes. The respiratory exercises in VR are comparable to the exercises in usual care but performed in a virtual environment and without incentive spirometry. The physical exercises consist of several games through which patients are challenged to reach out to objects while engaging their core. Patients are allowed to continue these exercises or play some relaxation games for up to 30 minutes per session in total. The exercises will be performed once daily under supervision of a physiotherapist. The other sessions will be unsupervised.
89371502|NCT03173638|Experimental|Mesenchymal stem from valladolid (MSV)|Allogenic mesenchymal stem cells from bone marrow
89371503|NCT03175354|Experimental|ALX-101 Gel 1.5% vs. ALX-101 Gel Vehicle|ALX-101 Gel 1.5% applied twice daily for 42 days to one treatment area and ALX-101 Gel Vehicle applied twice daily for 42 days to a second treatment area. Treatments will be randomly assigned to bilateral target areas.
89371504|NCT03175354|Experimental|ALX-101 Gel 5% vs. ALX-101 Gel Vehicle|ALX-101 Gel 5% applied twice daily for 42 days to one treatment area and ALX-101 Gel Vehicle applied twice daily for 42 days to a second treatment area. Treatments will be randomly assigned to bilateral target areas.
89371505|NCT03173326|Experimental|Subarachnoid block|
89371506|NCT03173326|Active Comparator|General anesthesia|
89371507|NCT02411968||111In-Girentuximab DOTA SPECT|Patients >50 years of age with renal tumours ≤4 cm highly suspicious for a malignancy planned to undergo cryotherapy will undergo 111In-Girentuximab DOTA SPECT scanning.
89371508|NCT04481776|Experimental|Breakfast consumption|Participants will be asked to consume a standardised breakfast at home before 09:00 for seven consecutive days. The energy content of the breakfast will be 25% of individual measured resting metabolic rate. Prior to the experimental conditions, the participants will select one wholegrain, high-fibre ready-to-eat cereals (with the option of adding raisins) and fruit juice from a limited selection. Thus, breakfast composition will be controlled within participants, but not between participants to account for individual preferences. To ensure that the correct amount of each breakfast item is consumed, food items will be provided to the participants in pre-packaged containers and the participants will be provided with a marked beaker to measure their milk and juice each morning. The only exception is that parents will be asked to provide the 1.8% milk.
89371509|NCT04481776|Experimental|Breakfast omission|Participants were asked to abstain from all energy-providing nutrients before 10:30 for seven consecutive days.
89371510|NCT02403856|Experimental|Experimental group (Sodium Chloride 0.9%)|Needling and lavage of calcific tendinitis of the rotator cuff followed by the injection of sterile physiological Saline (Sodium Chloride 0.9%) in the subacromial bursae.
89371511|NCT02403856|Active Comparator|Control group (Methylprednisolone Acetate)|Needling and lavage of calcific tendinitis of the rotator cuff followed by the injection of methylprednisolone acetate in the subacromial bursae
89371512|NCT03170284||Bevacizumab|Participants with advanced (stage IIIB/IV) NSCLC other than predominantly squamous cell histology receiving Bevacizumab in accordance with the summary product characteristics (SPC) is observed.
89371513|NCT02411890|Experimental|Adductor canal block|Adductor canal block (active) + Femoral nerve block (sham block)
89371514|NCT02411890|Active Comparator|Femoral nerve block|Femoral nerve block (active) + Adductor canal block (sham block)
89371515|NCT02407912|Experimental|Cisplatin|75 mg of body surface area of ciplatin in distilled water is injected in to the chest through a chesttube.
89371516|NCT02407912|No Intervention|Control|No intervention was applied.
89371517|NCT02411500|Experimental|Formulation A|
89371518|NCT02411500|Experimental|Formulation B|
88844199|NCT06270160|Experimental|Arm 3: HIVST + mHealth + Creating Futures Livelihoods program|In addition to HIVST and mHealth access, participants in Arm 3 will also be in enrolled in an 8-week Creating Futures program. This manualized program was developed with youth in South Africa and adapted for the Kenyan context (manual is appended). Topics within the Creating Futures program include: 1) introduction and situating self; 2) sustainable and social resources; 3) peer group meeting; 4) education and learning; 5) getting and keeping jobs; 6) income generating activities; 7) saving and coping with shocks; 8) reflection and looking ahead. This intervention aims to help participants think about, and plan for, their futures to assist them in making a living in the long term. Each workshop is facilitated by pairs of peer navigators and runs from 2-4 hours.
89371519|NCT02411500|Experimental|Formulation C|
89371520|NCT02411500|Experimental|Formulation D|
89371521|NCT02411500|Experimental|Formulation E|
89371522|NCT02411500|Experimental|Formulation F|
89371523|NCT03170128|Active Comparator|Outpatient Physical Therapy|
88844200|NCT06269848||Junior boxers|Junior category boxers aged 15 to 16 years old
88844201|NCT06269848||Youth boxers|Youth category boxers aged 17 to 18 years old
88844202|NCT06268743|Experimental|High intensity|Participants will perform high-intensity aerobic and strength training exercises.
88844203|NCT06268743|Active Comparator|Moderate Intensity|Participants will perform moderate-intensity aerobic and strength training exercises.
89371524|NCT03170128|Active Comparator|Home Exercises|
89371525|NCT03170050|Experimental|YYD701-2|YYD701-2 Hyaluronic Acid Gel and Lidocaine Hydrochlorid, total dose 1ml, single injection
89371526|NCT03170050|Active Comparator|Restylane Perlane Lidocaine|Restylane Perlane Lidocaine Hyaluronic Acid Gel and Lidocaine Hydrochlorid, total dose 1ml, single injection
89371527|NCT02407834|Experimental|S1 - 0.25% sodium hypochlorite|Brushing with specific brush and neutral soap, three times a day. After, immesion in 0.25% sodium hypochlorite during 20 minutes, once a day. This protocol was used during 7 days.
89371528|NCT02407834|Experimental|S2 - 0.5% sodium hypochlorite|Brushing with specific brush and neutral soap, three times a day. After, immesion in 0.5% sodium hypochlorite during 20 minutes, once a day.This protocol was used during 7 days.
89371529|NCT02407834|Experimental|S3 - 10% Ricinus communis|Brushing with specific brush and neutral soap, three times a day. After, immesion in 10% Ricinus communis solution during 20 minutes, once a day. This protocol was used during 7 days.
89371530|NCT02407834|Placebo Comparator|S4 - saline solution|Brushing with specific brush and neutral soap, three times a day. After, immesion in saline solution during 20 minutes, once a day. This protocol was used during 7 days.
89371531|NCT02407678|Experimental|Treatment|Treated eye undergoes AAV-mediated REP1 gene replacement. AAV vector is delivered by subretinal injection.
89371532|NCT02407678|No Intervention|Control|Untreated eye
89371533|NCT02411266|Placebo Comparator|control|Subjects in this group will undergo sham preconditioning. A blood pressure cuff will be placed around the leg and inflated just lightly to a pressure of 30mmHg, not enough to affect arterial circulation. This will be maintained for 10min followed by 5min of deflation. This will constitute one conditioning cycle. There will be 3 sham conditioning cycles per treatment session.
89371534|NCT02411266|Active Comparator|treatment group|Study personnel will place a blood pressure cuff around the subject's leg and use it to interrupt the circulation to the leg for 10 minutes followed by release of the blood pressure for 5 minutes. This will be repeated for a total of 3 times every 24 to 48 hours up to 14 days. The cuff will be inflated for 10 minutes and then deflated for 5 minutes. There will be 3 cycles of this. The cuff will be inflated to 200mmHg to induce ischemia, confirmed by palpation of pedal pulses.
89371535|NCT02407522|Experimental|black rice group|Each subject in the experimental group will be provided with black rice (50 g/day).According to the clinical requirements, no specific rules are needed for other treatments of the two groups.
89371536|NCT02407522|Placebo Comparator|white rice group|individuals in the control group will be subjected to follow-up. According to the clinical requirements, no specific rules are needed for other treatments of the two groups.
89371537|NCT02411188|Experimental|STEP Program Group|Arm: Intervention: The 12-week STEP Program intervention will include: initial individual consult/goal setting; weekly 90 minute information/interactive sessions; individualized patient centred care; journaling
89371538|NCT02411188|No Intervention|Usual Care Group|The usual care group will follow the routine model of care for post-discharge patients who do not participate in a CRP. Usual care group participants will be given the opportunity/option to participate in the STEP Program in 6 months.
89371539|NCT03169738|Experimental|Nant NSCLC Vaccine|avelumab, bevacizumab, capecitabine, cisplatin, cyclophosphamide, 5-fluorouracil, fulvestrant, leucovorin, nab paclitaxel, nivolumab, lovaza, oxaliplatin, stereotactic body radiation therapy, ALT-803, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, and haNK.
89371540|NCT02407600|Active Comparator|Fosparepitant administered in 1st cycle|Fosaprepitant (Emend) for Injection 150 mg is administered, one time, intravenously on day 1 only, as an infusion with a duration of 30 minutes. It will be initiated approximately 30 minutes prior to the subjects first chemotherapy cycle. An intravenous saline placebo will be administered on day 1 of the second chemotherapy cycle, in the same manor as EMEND for Injection.
89371541|NCT02407600|Sham Comparator|Fosaprepitant administered in 2nd cycle|Subject will receive a saline Placebo intravenously on day 1 of their first chemotherapy cycle. For the subject's second chemotherapy cycle, EMEND for Injection 150 mg is administered, one time, intravenously on day 1, as an infusion with a duration of 30 minutes. It will be initiated approximately 30 minutes prior to the subjects second chemotherapy cycle.
89371542|NCT02403544|Experimental|CCRT Arm|Patients recruited will be treated by concurrent chemoradiotherapy with IGRT and two cytotoxic agents: capecitabine and oxaliplatin. Capecitabine will be taken orally twice a day, from D1 to D14 while oxaliplatin will be given intravenously on D1 and D8, every 21 days. The doses of the two drugs will be escalated alternatively in each level group. The radiation will be given by IGRT and the dose is between 45 to 54Gy, 1.8-3Gy per fraction.
89371543|NCT02411032|Experimental|Reminder control|Customers receive a mailing on a random day, which does not coincide with any of the predictable fresh start events.
89371544|NCT02411032|Experimental|Birthday framed|Customers receive a mailing on the most recent Wednesday before the customers' birthday, and the mailing frames the customers' birthday by emphasizing a fresh start associated with the customers' birthday.
89371545|NCT02411032|Experimental|New Year's framed|Customers receive a mailing on 1/21/15, and the mailing frames the customers' birthday by emphasizing a fresh start associated with the customers' birthday.
89371546|NCT02411032|Experimental|Birthday un-framed|Customers receive a mailing on the most recent Wednesday before the customers' birthday, but the mailing does not frame the customers' birthday.
89371547|NCT02411032|Experimental|New Year's un-framed|Customers receive a mailing on 1/21/15, but the mailing does not frame New Year's.
89371548|NCT02411344|Experimental|Pertuzumab, Trastuzumab, Letrozole|
88844208|NCT06266572|Experimental|Pre-Intervention|Research participants will receive access to a web-based platform designed to provide information about Opioid Use Disorder. Prior to receiving access to this application, research participants will complete online, self-reported surveys assessing stigma, empowerment, and knowledge of opioids.
88844209|NCT06266572|Experimental|Post-Intervention|Research participants will have access to the web-based platform for 7 to 14 days prior to receiving a second, identical series of self-report surveys assessing stigma, empowerment, and knowledge of opioids. Additionally, after using the platform, research participants will complete a measure of system usability.
89002090|NCT06116240|Experimental|Locally advanced or metastatic urothelial cancer|TQB2450 injection, 21 days as a treatment cycle. AL2846 capsule, 21 days as a treatment cycle.
88844211|NCT06263491|Experimental|Cohort A|If participants show that they have no MRD, participants will be in Cohort A and will stop taking pirtobrutinib. Participants will continue to be observed and tested for MRD, and participants will be able to continue receiving the drug if you test positive.
88844212|NCT06263491|Experimental|Cohort B|If participants test positive for MRD at the 24 month time point, participants will be in Cohort B and the participant will continue taking pirtobrutinib.
88844213|NCT06250868||Normal cornea|
88844214|NCT06250738|Experimental|Study population|
88844215|NCT06247098|Experimental|Xenograft - Autogenous 1:4|Sinus grafted with a ratio of Xenograft - Autogenous 1:4
88844216|NCT06247098|Active Comparator|Xenograft alone|Sinus grafted with Xenograft only
88844217|NCT06245499|Experimental|Intervention|Care Partners in the intervention group will be approached and offered care coordination through the Aging Brain Care Virtual program
88844218|NCT06245499|No Intervention|Control|Care partners in the control group will not be approached, but outcomes data will be collected from the EMR for comparison with the intervention group.
88875261|NCT02550210|Experimental|Breast Cancer Locator (BCL)|The Breast Cancer Locator (BCL) uses 3D printing to create a bra-like plastic form that matches the breast surface when the patient is in the supine MRI (and surgical) position. This locator will be constructed pre-operatively, sterilized and provided to the surgeon at the time of procedure.
89002091|NCT06116240|Experimental|Advanced esophageal squamous cell carcinoma|TQB2450 injection, 21 days as a treatment cycle. AL2846 capsule, 21 days as a treatment cycle.
89371549|NCT02407444|Experimental|Physiotherapy treatment & leg cycling|"This group will receive conventional physiotherapy treatments, each session will last 30 minutes. Treatments include muscles strength exercises for upper and lower extremities, static and dynamic balance training in standing ,pain relief techniques and functional training (including transfers, sit to stand, walking and climbing stairs). The treatment program shall be consistent with the patient's problems and the degree of difficulty will rise depending on progress.~In addition this group will have cycling training with leg cycle ergometer for 20 minutes.~This treatment protocol will last for three weeks, five days a week, 50 minutes each session per day."
89371550|NCT02407444|Active Comparator|Physiotherapy treatment & music listening|"This group will receive conventional physiotherapy treatments, each session will last 30 minutes .Treatments include muscles strength exercises for upper and lower extremities, static and dynamic balance training in standing ,pain relief techniques and functional training (including transfers, sit to stand, walking and climbing stairs). The treatment program shall be consistent with the patient's problems and the degree of difficulty will rise depending on progress.~In addition this group will listen to music (while sitting on a chair) for 20 minutes.This treatment protocol will last for three weeks, five days a week, 50 minutes each session per day."
89371551|NCT03657095|Experimental|Esuberaprost|Participants who received esuberaprost during the BPS-314d-MR-PAH-302 double-blind study will receive 2 tablets of 15 μg esuberaprost sodium tablets for oral administration QID for up to 7 months (which will include the 4 weeks of blinded transition).
89371552|NCT03657095|Placebo Comparator|Placebo/Esuberaprost|Participants who received placebo during the BPS-314d-MR-PAH-302 double-blind study will receive 1 esuberaprost tablet and 1 placebo tablet QID during the first 2 weeks of the blinded transition and then receive 2 esuberaprost tablets QID for the rest of the study, for up to 7 months (which will include the other 2 weeks of the total 4-week blinded transition).
89180803|NCT03899597|Experimental|artificial contractions (ARTCON) group|All participating patients in the intervention (ARTCON) group will undergo oxytocin exposure in the form of a continuous intravenous infusion according to dosage guidelines of The Czech Society of Obstetrics and Gynaecology. The exposure will take two hours to complete and should be finished at least one hour before elective caesarean section is performed in order for the assumed effects of physiological stress associated with labor to occur.
89371553|NCT03100344|Experimental|Group 1|Nemolizumab (low dose)
89371554|NCT03100344|Experimental|Group 2|Nemolizumab (medium dose)
89371555|NCT03100344|Experimental|Group 3|Nemolizumab (high dose)
89371556|NCT03100344|Placebo Comparator|Group 4|Nemolizumab placebo
88844219|NCT06239376|Active Comparator|GnRH agonist + Letrzole - Artificial Cycle|"Pre-treatment includes two doses of 3.75 mg GnRH agonist (Diphereline®, Ipsen, France) on days 2-4 of the menstrual cycle and 28 days later, along with daily 2.5 mg Letrozole (Femara®, Novartis, Switzerland) starting from the first agonist injection.~Endometrial preparation in an artificial cycle begins 28 days after the second agonist injection. Patients will take 6 mg/day of oral estradiol valerate (Valiera; Abbott) at least 9 days before initiating progesterone. Endometrial thickness is monitored starting on the 10th day. When it reaches ≥7 mm, 400 mg twice times a day of vaginal progesterone (Cyclogest®, Actavis, UK) is initiated. Embryo transfer aligns with progesterone initiation, taking the embryo's stage into account. Luteal phase support comprises oral estradiol valerate 4 mg/day and vaginal progesterone 400 mg twice times a day until the 7th week of gestational age (GA), followed by progesterone alone at 400 mg twice times a day up to the 12th week of GA."
88875262|NCT02551224|Experimental|Breezhaler, then Ellipta|Half of the patients will be assigned to first receive a single dose of placebo via the Breezhaler® followed by a single dose of placebo via the Ellipta® inhalation device. The evaluation questionnaires after using each device.
89371557|NCT02403700||All study participants|One group observation study
89371558|NCT02407366|Experimental|Icotinib with concurrent radiotherapy|Icotinib (125 mg ,three times daily)with concurrent thoracic radiotherapy(TRT) (66 Gy/33 fractions), followed by maintenance icotinib (125 mg ,Three times daily) until disease progression or unacceptable toxicity.
89371559|NCT02407366|Active Comparator|Chemoradiotherapy|Pemetrexed(500mg/m2) + carboplatin (AUC，5) every 21 days for three cycles with concurrent thoracic radiotherapy(TRT) (66 Gy/33 fractions), followed by consolidation chemotherapy with two cycles of pemetrexed(500mg/m2) + carboplatin (AUC，5) every 21 days.Maintenance pemetrexed(500mg/m2) will be administered after consolidation chemotherapy until disease progression or unacceptable toxicity .
89371560|NCT03738137|Experimental|Narcotrend|After 0.1µg/kg sufentanil is applied, miidazolam is given by non-anaesthetist physicians to achieve moderate levels of sedation as assessed by the Narcotrend index stage C.
89371561|NCT03738137|Experimental|BIS|After 0.1µg/kg sufentanil is applied, midazolam is given by non-anaesthetist physicians to achieve moderate levels of sedation as assessed by bispectral index (BIS; between 70 and 85).
89371562|NCT03738137|Experimental|No monitoring|After 0.1µg/kg sufentanil is applied, midazolam iss given by non-anaesthetist physicians according to patient's tolerance .
89371563|NCT03738137|Experimental|Lidocaine|Only topical anesthesia was applied.
89371564|NCT02410876||Controls|No lower urinary tract symptoms undergoing cystoscopy in anesthesia for stone treatment or microhematuria assessment.
88875263|NCT02551224|Experimental|Ellipta, then Breezhaler|Half of the patients will be assigned to first receive a single dose of placebo via the Ellipta® followed by a single dose of placebo via the Breezhaler® inhalation device. The evaluation questionnaires after using each device.
88875264|NCT02551770|Active Comparator|Test (with Emdogain)|Scaling and root planing with Emdogain
89002092|NCT06116240|Experimental|Non-scaly and non-small cells lung cancer|TQB2450 injection, 21 days as a treatment cycle. AL2846 capsule, 21 days as a treatment cycle. Pemetrexed disodium for injection, 21 days as a treatment cycle. Cisplatin injection, 21 days as a treatment cycle.
89371565|NCT02410876||Spinal cord injury/acontractile|"Patients with traumatic spinal cord injury (SCI) with no (neither spontaneous nor provoked) detrusor activity during the filling phase of urodynamics.~Bladder biopsy 6 weeks after trauma 6 months later urodynamic study and bladder biopsy"
89180804|NCT03899597|Placebo Comparator|standard approach (SA) group|All participating patients in the control (SA) group will undergo placebo exposure in the form of a continuous intravenous infusion. The exposure will take two hours to complete and should be finished at least one hour before elective caesarean section is performed.
89371566|NCT02410876||Spinal cord injury/Detrusor overactivity|"SCI patients with proven detrusor (urodynamics) overactivity during the filling phase.~Bladder biopsy 6 weeks after trauma 6 months later urodynamic study and bladder biopsy"
89371567|NCT02410876||Prostatic obstruction/acontractile|"Low flow to no flow, no measurable detrusor activity on urodynamic evaluation, cystoscopy in line with obstruction.~Bladder biopsy at TURP (transurethral resection prostate) 3 months later urodynamic study and bladder biopsy"
89371568|NCT02410876||Prostatic obstruction/ obstructed|Obstruction according to Schäfer nomogram on urodynamic evaluation. Bladder biopsy at TURP 3 months later urodynamic study and bladder biopsy
89371569|NCT03737279|Experimental|Meditation|"Intervention Group:~Routine care plus twice daily mindful meditation"
88844220|NCT06239376|Active Comparator|Artificial Cycle|The endometrium will be prepared using oral estradiol valerate (Valiera; Abbott) 6 mg/day starting from the 2nd to the 4th day of the menstrual cycle. The endometrial thickness will be monitored from day 10th onwards, and vaginal progesterone (Cyclogest®; Actavis) 400 mg twice times a day will be initiated when endometrial thickness reaches ≥7 mm. Estradiol exposure must last for at least 9 days before progesterone administration. Embryo transfer will be scheduled by the time of the initiation of progesterone and embryo stages. Luteal phase support comprises oral estradiol valerate 4 mg/day and vaginal progesterone 400 mg twice times a day until the 7th week of gestational age (GA), followed by progesterone alone at 400 mg twice times a day up to the 12th week of GA.
89371570|NCT03737279|Active Comparator|Routine care|"Control Group:~Routine care which includes ACOG educational pamphlets on day 1, 2 and 3 after randomization"
89371571|NCT02407210|Experimental|azilsartan group|Once-daily oral administration of 20 or 40 mg tablet before or after breakfast
89371572|NCT02407210|Active Comparator|olmesartan medoxomil group|Once-daily oral administration of 20 or 40 mg tablet before or after breakfast
89371573|NCT03737201|Experimental|ozone|Thirty five molar teeth with deep caries lesion were selected to apply two-visit indirect pulp therapy with ozone. The peripheral demineralized dentin and the superficial necrotic dentin were completely removed, and left some caries at the central part. The cavity was exposed to gaseous ozone for 60 seconds, with an ozone delivery system. The remaining caries dentin was covered with calcium hydroxide base material and cavity sealed with glass ionomer cement to reopen 4 months later.
88844221|NCT06238570|Placebo Comparator|Manual vitrification (using Vitrolife system)|The vitrification of the oocytes will be carried out by an authorized technician according to the manual protocol validated and used routinely.
89371574|NCT03737201|Active Comparator|chlorhexidine digluconate|Thirty five molar teeth with deep caries lesion were selected to apply two-visit indirect pulp therapy with chlorhexidine digluconate. The peripheral demineralized dentin and the superficial necrotic dentin were completely removed, and left some caries at the central part. Following the excavation, 2% chlorhexidine digluconate was applied to the cavity for 60 seconds using a brush. According to the manufacturer instructions, puddled solution was removed with a new brush without dry to leave site moist. The remaining caries dentin was covered with calcium hydroxide base material and cavity sealed with glass ionomer cement.
89371575|NCT03737201|Active Comparator|control|Thirty five molar teeth with deep caries lesion were selected to apply conventional two-visit indirect pulp therapy (control). The peripheral demineralized dentin and the superficial necrotic dentin were completely removed, and left some caries at the central part. The remaining caries dentin was covered with calcium hydroxide base material and cavity sealed with glass ionomer cement.
89371576|NCT02951533|Experimental|Group I: Guselkumab|Participants will receive Guselkumab 100 milligram (mg) administered as 100 milligram per milliliter (mg/mL) solution subcutaneously (SC) by single-use prefilled syringe (PFS) at weeks 0, 4, 12 and 20.
89371577|NCT02951533|Active Comparator|Group II: Fumaric Acid Esters (FAE)|Participants will receive Fumaderm initial/Fumaderm tablets by self administration at week 0. The individual FAE dose representing the optimal efficacy/tolerability ratio needs to be determined for each participant according to local prescription information. To this aim, FAE doses will be slowly increased beginning with increasing doses of Fumderm initial (containing 30 mg dimethylfumarate) over the first 3 weeks. Thereafter, participants will be switched to Fumaderm tablets (containing 120 mg dimethylfumarate) starting with 1 tablet per day. Fumaderm dose may be increased to a maximum of 3*2 tablets per day. The decision to maintain, increase or decrease the FAE dose depends on efficacy, safety and tolerability.
88844222|NCT06238570|Active Comparator|Semi-automatic vitrification of oocytes using the GAVI® automaton (Merck)|The vitrification of the oocytes will be carried out using the GAVI® automaton
88844223|NCT06223126||Oral Contraception-Starter|Women who start taking oral contraception
88844224|NCT06223126||Oral Contraception-Stopper|Women who stop taking oral contraception
88844225|NCT06223126||Oral Contraception-Long-Term User|Women who use oral contraception continuously
89180805|NCT00714285|Experimental|Quadrivalent influenza vaccine GSK 2115160A Group 1|Subjects in this group received 1 full dose of GSK Biologicals' quadrivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0
89180806|NCT00714285|Experimental|Quadrivalent influenza vaccine GSK 2115160A Group 2|Subjects in this group received 1 low dose of GSK Biologicals' quadrivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0
88844226|NCT06215326|Experimental|Moderate-intensity Continuous Training (MICT) Group|MICT plan is containing usual care protocol and additional complete a total of 12 supervised moderate-intensity continuous training sessions in 2-3 weeks.
88844227|NCT06215326|Experimental|High-intensity Interval Training (HIIT) Group|HIIT plan is containing usual care protocol and additional complete a total of 12 supervised high-intensity interval training training sessions in 2-3 weeks.
88844228|NCT06215326|No Intervention|Usual care group|Usual care is including smoking cessation instruction, respiratory exercise, review by a specialist nurse, meeting with the surgeon and anesthetist, and receiving information about preparing for surgery.
88875265|NCT02551770|Other|Control (without Emdogain)|Scaling and root planing without Emdogain
88875266|NCT02553798|Experimental|Glycopyrronium|Glycopyrronium Topical Wipes
88844229|NCT06213831|Experimental|Maximal Use Ruxolitinib 1.5%|Participants will apply ruxolitinib 1.5% cream BID through Week 4 to all pruriginous lesions. At Week 4, participants who have completed 4 weeks of treatment with no safety concerns may enter the optional 4-week treatment extension period, during which all participants will apply ruxolitinib 1.5% cream BID to existing pruriginous lesions.
88844230|NCT06213350||Needs Assessment Participants|
88844231|NCT06213350||Focus Group Participants|
88844232|NCT06211179|Experimental|Sequence ABC|
88844233|NCT06211179|Experimental|Sequence BCA|
88844234|NCT06211179|Experimental|Sequence CAB|
88844235|NCT06209996|Experimental|L4 weight management intervention|A weight management intervention, namely Lose Little, Live Longer (L4), is recently developed to assist overweight cancer survivors in weight loss through lifestyle modification including improved dietary quality and enhanced physical activity levels. Its underlying theoretical framework is principally derived from Social Cognitive Theory (SCT), which have been widely used in health behavioural change interventions.
88844236|NCT06209996|Active Comparator|Active control|A video-based intervention is selected as a low-touch alternative with expected benefits beyond a no treatment control. Participants allocated to the active control arm will receive five educational videos designed to promote a balanced diet and reinforce regular physical activity, weekly through instant messaging.
88844237|NCT06209996|No Intervention|Waitlist|Participants allocated to the waitlist control arm will receive a set of pamphlets with generic, knowledge-based dietary and physical activity information. All pamphlets are developed based on the self-management framework. Participants in this arm will be arranged to attend to the L4 intervention upon completion of the study.
88844238|NCT06209632|Experimental|MT and CCFES group|mirror therapy combined with contralaterally controlled functional electrical stimulation to perform hand exercises
88844239|NCT06209632|Sham Comparator|Sham MT and CCFES group|sham mirror therapy with contralaterally controlled functional electrical stimulation to perform hand exercises
88844240|NCT06209632|Active Comparator|Control group|conventional physiotherapy
88844241|NCT06205485|Active Comparator|FOLFOX OR CAPOX|"FOLFOX= Six cycles of modified FOLFOX consisting of leucovorin, oxaliplatin and bolus fluoruracil (optional), infusional fluorouracil.~CAPOX= Capecitabine twice daily for 14 days and Oxaliplatin on day 1"
88844242|NCT06205485|Active Comparator|ChemoRT|Standard dose of infusional 5-Fluorouracil/capecitabine and radiation
88844243|NCT06205186|Other|Program Users|
88844244|NCT06205082|Experimental|LIT-00814 20mg|Take a fixed dose of LIT-00814 tablets orally once a day in the morning and evening, and take them orally continuously.
88844245|NCT06205082|Experimental|LIT-00814 50mg|Take a fixed dose of LIT-00814 tablets orally once a day in the morning and evening, and take them orally continuously.
88844246|NCT06205082|Experimental|LIT-00814 100mg|Take a fixed dose of LIT-00814 tablets orally once a day in the morning and evening, and take them orally continuously.
88844247|NCT06205082|Experimental|LIT-00814 150mg|Take a fixed dose of LIT-00814 tablets orally once a day in the morning and evening, and take them orally continuously.
88844248|NCT06200896|Experimental|SFM in Obese Patients, When Used to Create a Duodenal-Ileal Anastomosis Post Sleeve Gastrectomy|Duodenal-Ileal Anastomosis Post Sleeve Gastrectomy created with Self Forming Magnets (SFM)
89534821|NCT03093441|No Intervention|Control|Multimodal High-Intensity Interval Training Intervention. This group will be instructed to continue with any activity they were involved in prior to the study and to not begin any new exercise programs during the course of the study. To incentive participation in this group, the control group will be offered the MM-HIIT intervention the following semester at no cost.
88844249|NCT06200896|Experimental|SFM in Obese subjects when Used to Create a Jejuno-Jejunostomy (J-J) Anastomosis|Jejuno-Jejunostomy (J-J) Anastomosis created with Self Forming Magnets (SFM) as part of a Roux-en-Y gastric bypass
88844250|NCT06199635|Experimental|SNAP-S|Self-Forming Magnetic (SFM) Anastomosis Device and Delivery System being used to to Create a Primary Sleeve Gastrectomy Duodenal-Ileal Anastomosis
88844251|NCT06199635|Experimental|SNAP-PS|Self-Forming Magnetic (SFM) Anastomosis Device and Delivery System being used to to Create a Duodenal-ileal Anastomosis years after a Primary Sleeve Gastrectomy)
88844252|NCT06199635|Experimental|J-J|Self-Forming Magnetic (SFM) Anastomosis Device and Delivery System being used to to Create a Jejuno-Jejunostomy in a Roux-en-Y Gastric Bypass
88844253|NCT06196437|Experimental|Acupuncture|Participants will receive acupuncture, five times per day form pre-operation to 3 days after operation. The selected acupoints include RN3,RN4, bilateral ST36,SP6,SP9 and LR3. All acupoints areas have been sterilized before acupuncture. needles (Ф0.30×50mm) will be directly inserted at a depth of 25-30 mm deep. Arrival of Qi by acupuncture and needle retaining for 20 minutes.
88844254|NCT06196437|Sham Comparator|Sham acupuncture|Participants will receive shame acupuncture, five times per day form pre-operation to 3 days after operation. The selected non-acupoints nearby RN3,RN4, bilateral ST36, SP6,SP9 and LR3, All acupoints areas have been sterilized before acupuncture. needles (Ф0.30×50mm) will be directly inserted at a depth of 5 mm deep. Needle retaining for 20 minutes and without needle manipulation.
88844255|NCT06195995|Experimental|Intervention group for gambling addiction|A 40-minute transcranial alternating current stimulus intervention of real stimulus is conducted twice a day (at least 3 hours apart) for a total of 10 days in the intervention group of gambling addiction.
88844256|NCT06193668|Active Comparator|High-fat overnutrition|Lipid overnutrition: 40% higher lipid consumption per day than required over three weeks.
88844257|NCT06193668|Active Comparator|Normocaloric macronutrient-balanced nutrition|Normocaloric, macronutrient-balanced nutrition per day over three weeks
88844258|NCT06193382|Experimental|PCIT Group|Participants in this group will receive the PCIT intervention for up to 5 weeks.
88844259|NCT06193265||Surgery under full endoscopy|A full endoscopic surgery will be performed on patienst with herniated disc
88844260|NCT06193265||Conventional microscopic surgery|A conventional microscopic surgery will be performed on patienst with herniated disc
88844261|NCT06193070|Experimental|Supportive Care (escape room game)|Patients play the virtual misinformation escape room game consisting of 5 puzzles and a final task over 30-45 minutes on study.
89180807|NCT00714285|Active Comparator|Trivalent influenza vaccine GSK 2115160A Group 1|Subjects in this group received 1 low dose of GSK Biologicals' trivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0
89180808|NCT00714285|Active Comparator|Trivalent influenza vaccine GSK 2115160A Group 2|Subjects in this group received 1 full dose of GSK Biologicals' trivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0
89371578|NCT03175042||Pregnant patients with anemia|Pregnant patients meeting Center for Disease Control (CDC) guidelines for anemia during pregnancy will be screened for participation in the study. In the outpatient setting at our institution it is standard of care that these women have complete blood counts (CBCs) drawn every 4-6 weeks. At the time of the routine blood draw, we will place the non invasive monitor on their finger to record the hemoglobin value. We will be comparing the hemoglobin values obtained from the CBC to that obtained from the non-invasive monitor.
89371579|NCT03738059|Placebo Comparator|group I (placebo)|will receive intravenous normal saline (NS)
89371580|NCT03738059|Experimental|group II (Dex 0.5)|will receive intravenous Dex 0.5 mcg/kg
89371581|NCT03738059|Experimental|group III (Dex 0.25)|will receive intravenous Dex 0.25 mcg/kg
89371582|NCT03738059|Experimental|group IV (Dex 0.2)|will receive intravenous Dex 0.2 mcg/kg.
89371583|NCT05233462|Active Comparator|control group|"intrathecal administration of a solution containing~bupivacaine 10 mg~morphine 100 micrograms~sufentanil 3 micrograms"
89371584|NCT05233462|Experimental|individualized group|"intrathecal administration of a solution containing~bupivacaine 0.05 mg per cm of patient's height~morphine 100 micrograms~sufentanil 3 micrograms"
89371585|NCT02700412|Experimental|Epidiolex 100 milligram/milliliter (mg/mL) oral solution|"Participants will receive a CBD starting dose of 5 mg/kg/day in twice daily dosing and titrate by 5 mg/kg/2 weeks up to 25 mg/kg/day. Additional increases in dosing, by 5 mg/kg/day up to a maximum of 50 mg/kg/day, may be instituted at the discretion of the treating Principle Investigator (PI).~If a subject experiences a clinically significant or dose limiting adverse event (AE) or severe adverse event (SAE) attributable to CBD, the investigator will determine if a dose reduction or taper is necessary (decreases will occur in 5 mg/kg/2 week increments or at a rate felt appropriate by the treating PI)."
89371586|NCT03115606|Active Comparator|Videolaryngoscope|Patients intubated with C-Mac D Blade Videolaryngoscope
89371587|NCT03115606|Active Comparator|Fastrach LMA|Patients intubated with Fastrach LMA
89371588|NCT02403466|Experimental|Resident Handoff Bundle|bundle of interventions designed to improve handoff, including: training of residents in teamwork and handoff techniques; redesign of verbal handoff processes; implementation of handoff mnemonic (I-PASS); implementation of structured written / computerized handoff tool; faculty training in handoffs
89371589|NCT02403388||Multiprofessional primary care offices with PRisM|25 multiprofessional primary care offices. Each professional of care of the offices (about 10 FTE / office) have to declare each adverse event that occurs in their office during 18 months.
88819348|NCT03160911|Active Comparator|Conventional endoscopic haemostasis|The patient would receive an esophagogastroduodenoscope to identify the bleeding source. Haemostasis will be performed in the conventional way, either using heater probe, endoscopic clips and/or injection of adrenaline
88875267|NCT02557698|Experimental|Balneum oil bath|Balneum oil bath, bathing every other day for four weeks
88875268|NCT02557698|No Intervention|standard skin cleanser|Usual skin cleanser (non-oil containing), bathing or showering every other day for four weeks
88875269|NCT02560038|Experimental|Combination chemotherapy|Combination chemotherapy consisting of gemcitabine and cisplatin plus paclitaxel on a 21-day cycle.
88875270|NCT02560584|Experimental|Cysview arm|"In this single-arm trial, Cystoscopy in white light followed by blue light (BL) is performed in all applicable patients during 2 study visits; Visit 2 (Surveillance) and Visit 3 (Operating room procedure)~All patients receive instillation of 100 mg hexaminolevulinate hydrochloride as intravesical solution (50 mL) in the bladder prior to cystoscopy. Retention time: 1-3 hours.~Surveillance cystoscopy is performed with the investigational device KARL STORZ D-Light C PDD Flexible Videoscope System"
88875271|NCT02561130|Experimental|Intervention|Drug: insulin glargine - sc injection; Drug: metformin, oral administration; Drug: forxiga, oral administration; Behavioral: lifestyle therapy, diet and exercise
88875272|NCT02561130|No Intervention|Standard Care|Standard glycemic care as informed by the current clinical practice guidelines
88875273|NCT02562066|Experimental|amifampridine phosphate -placebo|Each patient will participate in an open-label unblinded drug escalation/treatment run-in phase for up to 4 weeks until stable dose and frequency of amifampridine phosphate is achieved for 7 days. After this phase, half of the subjects will be randomized to receive amifampridine in Period I and then crossed over to receive placebo in Period II. Each randomized treatment period is 7 days in duration and is separated by a re-stabilization period of approximately two weeks where the subject will be returned to the stable dose administered at the end of the open-label run-in period. Dosing will be between 20 - 80 mg per day and frequency will be between 2-4 times per day.
88875274|NCT02562066|Experimental|placebo - amifampridine phosphate|Each patient will participate in an open-label unblinded drug escalation/treatment run-in phase for up to 4 weeks until stable dose and frequency of amifampridine phosphate is achieved for 7 days. After this phase, half of the subjects will be randomized to receive placebo in Period I and then crossed over to receive amifampridine in Period II. Each randomized treatment period is 7 days in duration and separated by a re-stabilization period of approximately two weeks where the subject will be returned to the stable dose administered at the end of the open-label run-in period. Dosing will be between 20 - 80 mg per day and frequency will be between 2-4 times per day.
89371590|NCT02403388||Multiprofessional primary care offices without PRisM|25 multiprofessional primary care offices. Each professional of care of the offices (about 10 FTE / office) have to declare each adverse event that occurs in their office during 18 months.
89180809|NCT02728115|Experimental|Cellavita HD Lower Dose|Participants assigned to this arm will receive 3 administrations, one every 30 days, of 1x10^6 cells/weight range per administration of Cellavita HD (n= 3) .
89371591|NCT02407288|Active Comparator|active tDCS|patients will received 2 sessions per day for 5 consecutive days. Each session will last 20 minutes. The tDCS device will deliver a direct current of 2mA during 20 minutes. Cathode will be localized in front of the left orbito-frontal on the FP3 point according to the EEG international reference. Anode will be localized in front of the right cerebellum 3 cm below the inion and 1 cm right from the midline
88809959|NCT01248221|Experimental|Dyspeptic subjects|The subject will consume the test meal containing [13C]-Spirulina platensis and 99mTc sulfur colloid, after which gastric emptying will be assessed simultaneously by scintigraphy and breath tests. Scintigraphic image acquisition will be obtained upon completion of the meal and at 15, 30, 45, 60, 90, 120, 150, 180, and 240 minute time points. Breath samples will be collected at baseline before the test meal is started and thereafter on the same time schedule as the scintigraphic procedure.
88809960|NCT00763490|Experimental|Double cord blood transplant|'full intensity, double umbilical cord, stem cell transplant' with 'Flu/Bu4 conditioning regimen'
89371592|NCT02407288|Placebo Comparator|SHAM tDCS|The same procedure will be applied except that the tDCS device will only deliver a current stimulation for the 10 first seconds.
88809961|NCT01214759|Other|Truvada and Raltegravir|Single arm
88809962|NCT03805724||Periodontally healthy subjects|They will be selected from healthy subjects who attend the restorative dental clinic and has clinically healthy gingiva with zero plaque index, gingival index and clinical attachment level & probing depth ≤ 3 mm. Plaque samples will be collected.
88809963|NCT03805724||Chronic Periodontitis|Chronic periodontitis patients having probing depth of ≥3 mm and clinical attachment level ≥ 1 mm. Plaque samples will be collected.
88809964|NCT03805724||Chronic Gingivitis|Gingivitis patients having signs of clinical inflammation with no clinical attachment loss. Plaque samples will be collected
88809965|NCT03806192|Experimental|Group A (psychoeducational counseling sessions via telephone)|Participants attend 5 psychoeducational counseling sessions over 30-60 minutes via telephone.
88809966|NCT03806192|Experimental|Group B (psychoeducational counseling sessions in person)|Participants attend 5 psychoeducational counseling sessions over 30-60 minutes via video teleconference.
88809967|NCT01249625|Active Comparator|N95 Respirator|The investigators are comparing specific N95 respirator against specific medical masks.
88809968|NCT01249625|Active Comparator|Medical/surgical mask|The investigators are comparing medical/surgical masks against the N95 respirator.
88809969|NCT03809468|No Intervention|control|Routine follow up of a clinic visit at 1-2 weeks postop, and 6-8 weeks postop.
88809970|NCT03809468|Experimental|study|phone call follow up instead of clinic visit follow up at 1-2 weeks, followed by 6-8 week clinic follow up
88809971|NCT00759668|Experimental|SN60D3|AcrySof Natural ReSTOR Intraocular Lens (IOL) Model SN60D3
88809972|NCT00759668|Active Comparator|SN60AT|AcrySof Natural Monofocal Intraocular Lens (IOL) Model SN60AT
88809973|NCT00780572|Experimental|Arm 1: ADE Alerts|Arm 1 is a random intervention group in which half of the patients admitted to the VASLCHCS during study time period will be randomly selected. Providers will see ADE alerts for all patient in the randomly selected experimental group
88809974|NCT00780572|No Intervention|Arm 2: Control/No Alerts|The second arm is the control. Alerts will not be displayed for these patients.
88809975|NCT00780962|Experimental|N-Acetylcysteine group|Subjects in this group will receive 3 grams of N-acetylcysteine in 500 cc normal saline (0.9% Sodium Chloride) over 30 minutes prior to contrast administration. After contrast administration, they will receive a continuous infusion of 200 mg N-acetylcysteine per hour. This dose will be administered as an infusion of 67 cc per hour of a solution of 3 grams of N-acetylcysteine in 1000 cc of normal saline. The infusion will be administered for a minimum of two hours and then stopped after 24 hours, or when the patient is discharged from the Emergency Department or the hospital, whichever comes first.
88809976|NCT00780962|Placebo Comparator|0.9% Sodium-chloride group|Subjects in this group will receive 500 cc Normal Saline (0.9% Sodium Chloride) over 30 minutes prior to contrast administration. After contrast administration, they will receive a continuous infusion of 67 cc per hour of normal saline. The infusion will be administered for a minimum of two hours and then stopped after 24 hours, or when the patient is discharged from the Emergency Department or the hospital, whichever comes first.
88809977|NCT04384874|Active Comparator|Silbernagel combined concentric-eccentric program|A graduated rehabilitation program using exercises with concentric and eccentric contractions and progressing to plyometric training. The exercises are performed daily with progression guided by pain symptoms. There is no specificity in prescribed exercise loading.
88809978|NCT04384874|Experimental|SSC6|A multi-stage rehabilitation program with focus on strength and reactive strength targets, as well as running gait re-training. These exercises will be initially carried out 3 days per week for the first 6 weeks with specific load targets prescribed.
88809979|NCT00764738|Active Comparator|Monthly|Ranibizumab injections every month for 12 months.
88809980|NCT00764738|Active Comparator|As Needed|Ranibizumab injections monthly for 4 months then as needed thereafter.
88809981|NCT00781508|Experimental|sildenafil|Effect of oral administration of a single dose of sildenafil 50 mg on left ventricular filling pressures as evaluated 1 hr after sildenafil administration in patients with heart failure
88809982|NCT00781508|Placebo Comparator|placebo|Inactive placebo prepared to mimic the appearance of sildenafil.
88844262|NCT06189612|Experimental|Group1: Clinical reasoning-based physiotherapy + cervical movement control training|Physiotherapeutic treatment is carried out based on the results of a subjective and physical examination performed at the outset. It may thus include various manual therapy treatment approaches targeting the maxillary and/or cervical or thoracic regions and adapted individually to each patient. In addition, one third of each treatment time is used to gradually teach patients the abnormal (positive) tests of the test battery for assessing motor control of the cervical region as a self-exercise for home use. To do this, patients are also given access via a quick response (QR) code to a website where they can find videos and instructions for the exact exercises that are in their home program.
88844263|NCT06189612|Experimental|Group 2: Clinical reasoning-based physiotherapy + orofacial movement control training|Physiotherapeutic treatment is carried out based on the results of a subjective and physical examination performed at the outset. It may thus include various manual therapy treatment approaches targeting the maxillary and/or cervical or thoracic regions and adapted individually to each patient. In addition, one third of each treatment time is used to gradually teach patients the abnormal (positive) tests of the test battery for assessing motor control of the orofacial region as a self-exercise for home use. To do this, patients are also given access via a QR code to a website where they can find videos and instructions for the exact exercises that are in their home program.
88844264|NCT06189612|Active Comparator|Group 3: Clinical reasoning-based physiotherapy + standard exercises|Physiotherapeutic treatment is carried out based on the results of a subjective and physical examination performed at the outset. It may thus include various manual therapy treatment approaches targeting the maxillary and/or cervical or thoracic regions and adapted individually to each patient. In addition, one third of each treatment time is used to gradually teach patients general coordination- and strength exercises for the jaw and the cervical region as a self-exercise for home use. To do this, patients are also given access via a QR code to a website where they can find videos and instructions for the exact exercises that are in their home program.
88844265|NCT06189300|Experimental|Virtual Glasses|Training and consultancy will be provided
88844266|NCT06189300|No Intervention|Control|Standard care will be given
88844267|NCT06185231|Experimental|Percussion Massage Group|Both groups will undergo a progressive exercise program given as Phase-1, Phase-2, and Phase-3 for 6 weeks. The Percussion massage group will receive percussion massage therapy for a total of 5 minutes for each muscle group.The application will be done to the Quadriceps and Hamstring muscle groups before exercise. The device will be used with a soft connection head at 33-40 Hz. A total of 5 minutes of percussion massage will be applied to each muscle group. In the first 2.5 minutes of the massage therapy, the medial side of the focus muscle will be targeted, and in the second 2.5 minutes, the lateral side of the focus muscle will be targeted. Neuromuscular Electrical Stimulation (NMES) will be applied to the Quadriceps muscle group for facilitation and reeducation purposes.
88844268|NCT06185231|Active Comparator|Conventional Group|"Conventional group undergo a progressive exercise program given as Phase-1, Phase-2, and Phase-3 for 6 weeks.~Neuromuscular Electrical Stimulation (NMES) will be applied to the Quadriceps muscle group for facilitation and reeducation purposes.~NMES Parameters:~Electrode placement: will be applied to motor points and the muscle belly to achieve optimal contraction.~Frequency: 50-70 Hz Duration: 20 minutes."
88844269|NCT06181747|Experimental|ADHD group|Participants are required to engage in game training at home for 5 days per week, with each session lasting 20-25 minutes. The game is equipped with anti-addiction measures, limiting the maximum daily game time to 30 minutes. Participants will adjust their game training based on their own abilities, and as the training progresses, the game will adaptively adjust the difficulty level and change levels accordingly.
88844270|NCT06181747|Experimental|healthy control group|Participants are required to engage in game training at home for 5 days per week, with each session lasting 20-25 minutes. The game is equipped with anti-addiction measures, limiting the maximum daily game time to 30 minutes. Participants will adjust their game training based on their own abilities, and as the training progresses, the game will adaptively adjust the difficulty level and change levels accordingly.
88844271|NCT06175403|Experimental|Upper body obesity|Subjects identify with upper body obesity will receive Niacin to lean how fat cells in different regions of the body the response.
88844272|NCT06175403|Experimental|Normal weight|Subjects identify with normal body weight will receive Niacin to lean how fat cells in different regions of the body the response.
88844273|NCT06164691|Experimental|Blue light|This cohort will be exposed to bright (1700 lux) blue (peak 442 nm) light for 4 hours each morning for 3 days prior to and 3 days following each chemotherapy infusion.They will be exposed to bright (1700 lux) blue (peak 442 nm) light for 1 hour each morning during radiation treatments.
88844274|NCT06164691|Experimental|Amber light|This cohort will be exposed to bright (1700 lux) amber (peak 617 nm) light for 4 hours each morning for 3 days prior to and 3 days following each chemotherapy infusion.They will be exposed to bright (1700 lux) amber (peak 617 nm) light for 1 hour each morning during radiation treatments
89180810|NCT02728115|Experimental|Cellavita HD Higher dose|Participants assigned to this arm will receive 3 administrations, one every 30 days, of 2x10^6 cells/weight range per administration of Cellavita HD (n= 3).
88844275|NCT06164691|Active Comparator|Ambient white light|This cohort will be exposed to usual, ambient white lighting of the environment during chemotherapy and radiation treatments.
88844276|NCT06163677||COVID-19 Positive|Laboratory-confirmed COVID-19 illness and at least one patient-reported symptom
89180811|NCT02590029|Experimental|Mindfulness|15 minute mindfulness session
89180812|NCT02590029|Experimental|Suggestion|15 minute therapeutic suggestion session
89180813|NCT02590029|Active Comparator|Psychoeducation|15 minute psychoeducation session
89180814|NCT04084665|Experimental|Intervention|Guselkumab 200mg q4 weekly
89180815|NCT00776984|Experimental|tiotropium 5mcg/day|patient to receive double-blind treatment with either 5mcg/day tiotropium inhalation solution or placebo inhalation solution
89180816|NCT00776984|Experimental|placebo|patient to receive double-blind treatment with either 5mcg/day tiotropium inhalation solution or placebo inhalation solution
89180817|NCT05751239||Bisexual-Biromantic|People that self-identify as bisexual-biromantic
89180818|NCT05751239||Heterosexual-heteroromantic|People that self-identify as heterosexual-heteroromantic
89180819|NCT05751239||Homosexual-homoromantic|People that self-identify as homosexual-homoromantic
89371593|NCT02406898|Experimental|hysteroscopic surgery with morcellation technic|"The hysteroscope with the MH system will be introduced. Resection of fibroids or both will be realized. The procedure will end or when the fibroids will be completely resected.~the procedure may be suspended before complete resection of fibroids or uterine perforation or higher operating time to 90 minutes or amount of liquid used distension than 9 liters or distension fluid deficit of more than one liter ."
89371594|NCT02406898|Active Comparator|conventional hysteroscopy technic with resection.|"The hysteroscope with conventional resection system will be introduced. Resection of fibroids or both will be realized. The procedure will end or when the fibroids will be completely resected.~the procedure may be suspended before complete resection of fibroids or uterine perforation or higher operating time to 90 minutes or amount of liquid used distension than 9 liters or distension fluid deficit of more than one liter (4 )."
88844277|NCT06163677||Influenza Positive|Laboratory-confirmed influenza illness and at least one patient-reported symptom
88844278|NCT06156059|Placebo Comparator|Septic Shock Standard of Care (SOC)|Placebo suspension and capsules
89371595|NCT02351544|Experimental|Botulinum toxin|Patients in this arm will receive botulinum toxin for migraine headaches
89371596|NCT02351544|Experimental|Surgery|Patients in this arm will receive surgery for migraine headaches
88844279|NCT06156059|Active Comparator|Septic shock Oral Bedtime Melatonin (OBM)|100 mg suspension or in capsules OBM
88844280|NCT06156059|Placebo Comparator|Resuscitated Cardiorespiratory Arrest SOC|Placebo suspension and capsules
88844281|NCT06156059|Active Comparator|Resuscitated Cardiorespiratory Arrest OBM|100 mg suspension or in capsules OBM
88844282|NCT06156059|Placebo Comparator|Ischemic Stroke (SOC)|Placebo suspension and capsules
88844283|NCT06156059|Active Comparator|Ischemic stroke (OBM)|100 mg suspension or in capsules OBM
89180820|NCT05751239||Pansexual-panromantic|People that self-identify as pansexual-panromantic
89180821|NCT00714051|Experimental|Fall Prevention Training|The falls prevention training group participated in four weekly training sessions on a custom-built treadmill that produced trip-simulating perturbations (movements). While harnessed overhead to prevent actual falls, the treadmill stopped or moved suddenly. The goal for the participant was to try and prevent a fall. Each week, the level of difficulty of the task was increased.
89180822|NCT00714051|Active Comparator|Attention Control|The attention control group participated in four weekly treadmill walking sessions at a self-selected speed.
89371597|NCT02406976|Experimental|G1- EXERCISE|The group will Participate in an physical exercise program twice a week. This program consists of 20 minutes of aerobic exercises of low intensity (2-4 on the Borg scale) in the rhythm of different songs that encourage their implementation. After these exercises will be performed five minutes of stretching exercises.
89371598|NCT02406976|Experimental|G2- EXERCISE AND LIFESTYLE|"This groups will receive the same intervention of G1 group, associated with the weekly group with a psychologist.~These groups worked techniques of cognitive behavioral therapy based on principles of learning, in order to promote and maintain new healthy behaviors, as well as the reduction or elimination of undesirable conduct."
89371599|NCT02406976|Active Comparator|G3- CONTROL|This group will keep the routine treatment in outpatient of bariatric surgery. This treatment consists of individual consultations and 05 (five) information meetings organized by the multidisciplinary team composed by the surgeon, endocrinologist, psychologist, psychiatrist, nutritionist, physical education teacher, pulmonologist, cardiologist and nurse. The G1 and G2 will also receive this intervention.
88844284|NCT06156059|Placebo Comparator|Hemorraghic stroke (SOC)|Placebo suspension and capsules
88844285|NCT06156059|Active Comparator|Hemorrhagic stroke (OBM)|100 mg suspension or in capsules OBM
88844286|NCT06150716|Experimental|Cohort A: ION356 Dose A|Participants will receive ION356 intrathecally at Dose A in the MAD Period, followed by ION356 Dose A in the LTE Period.
88844287|NCT06150716|Experimental|Cohort B: ION356 Dose B|Participants will receive ION356 intrathecally at Dose B in the MAD Period, followed by ION356 Dose B in the LTE Period.
88844288|NCT06148324|Experimental|Immediate treatment (IT)|Participants randomized to the IT arm will receive the 8-week MENTOR program, followed by an 8-week retention period.
88844289|NCT06148324|Experimental|Delayed treatment (DT)|Participants randomized to the DT arm will have an 8-week waitlist period prior to starting the 8-week MENTOR program, followed by an 8-week retention period.
88844290|NCT06144840|Experimental|MT-7117|
88844291|NCT06144840|Placebo Comparator|Placebo|
88844292|NCT06140784|Sham Comparator|0.76% Sodium Monofluorophosphate Dentifrice|
88844293|NCT06140784|Active Comparator|Marketed 0.454% Stannous Fluoride plus Arginine Dentifrice|
88844294|NCT06140784|Active Comparator|Marketed 0.454% Stannous Fluoride Dentifrice|
88844295|NCT06140784|Active Comparator|0.454% Stannous Fluoride Dentifrice|
88844296|NCT06137170||TAS±BEV-R|Eligible patients who started with trifluridine/tipiracil +/- bevacizumab (TAS+/-Bev) first, followed by regorafenib (R), without other therapies in-between.
88844297|NCT06137170||R-TAS±BEV|Eligible patients who started with regorafenib first, followed by TAS+/-Bev without other therapies in-between.
88844298|NCT06130787|Experimental|All patients|
88844299|NCT06130423|Experimental|Music intervention and NRT|The rhythm of the music sessions will be 2 per week in the first month, 1 per week in the second month and 1 every 15 days in th third month, music intervention will be associated to NRT.
88844300|NCT06130423|Active Comparator|NRT Group|Nicotine Patch, Nicotine Gum as in the intervention group, the physician will adapt the type of NRT according to the patient's smoking profile.
88844301|NCT06128551|Experimental|RMC-6291 and RMC-6236|Dose escalation and Dose expansion
88844302|NCT06126939|Experimental|Denver group|In addition to routine health guidance, one-to-one parent classes were conducted to guide parents to interact with children once a week for 1h each time; A group leader was assigned to supervise the formulation of the intervention plan and ensure the quality of the intervention. The intervention lasted for 3 months
88844303|NCT06126939|No Intervention|Control group|Regular autism related knowledge health education
88844304|NCT06124807|Experimental|LY3305677 Dose 1|Participants will receive LY3305677 subcutaneously (SC).
88844305|NCT06124807|Experimental|LY3305677 Dose 2|Participants will receive LY3305677 SC.
88844306|NCT06124807|Experimental|LY3305677 Dose 3|Participants will receive LY3305677 SC.
88844307|NCT06124807|Placebo Comparator|Placebo|Participants will receive LY3305677 matching placebo.
88809983|NCT03805568|Active Comparator|dexmedetomidine infusion group|dexmedetomidine infusion (loading dose of 1 ㎍/kg over 10 min and continuous infusion of 0.3-0.6 ㎍/kg/h) during the surgery
88809984|NCT03805568|Active Comparator|remifentanil infusion group|remifentanil of 4 ng/ml during induction, followed by remifentanil infusion (1.5~2.5 ng/ml) during the surgery
88809985|NCT00781898|Active Comparator|Depot Naltrexone|
88809986|NCT00781898|Placebo Comparator|Placebo|
88809987|NCT03800732|Experimental|Night workers.|Night workers of the military police of Minas Gerais, Uberlândia, who will participate in the three interventions of the study.
88809988|NCT00765128|Experimental|Ketorolac|90 mg ketorolac in 1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.
88809989|NCT00765128|Placebo Comparator|Placebo|1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.
88809990|NCT00765206|Experimental|Zegerid|Omeprazole 20 mg /sodium bicarbonate 1100 mg over-the-counter (OTC) Capsule
88809991|NCT00765206|Active Comparator|Prilosec|Omeprazole magnesium 20 mg OTC tablet
88809992|NCT05316896|Experimental|Internal perturbation|The people included in this group did 6 internal perturbation exercises with 10 repetitions in each session. The patients performed a total of 60 perturbation exercises in one session. Perturbations were chosen according to the patient's tolerance, from easy to difficult. Treatment protocols of stroke individuals were determined according to their functional levels. 6 of the exercises given below were chosen according to the levels determined at the beginning of the study and were progressed by getting more difficult.
88809993|NCT05316896|Experimental|Eksternal perturbation|The individuals included in this group performed 6 external perturbation exercises with 10 repetitions in each session. The patients performed a total of 60 perturbation exercises in one session. Perturbations were chosen according to the patient's tolerance, from easy to difficult. Treatment protocols of stroke individuals were determined according to their functional levels. 6 of the exercises given below were chosen according to the levels determined at the beginning of the study and were progressed by getting more difficult.
88809994|NCT03809156|Experimental|Combo Riociguat and Ambrisentan Therapy|Riociguat Oral Product and Ambrisentan Oral Product to be given in combination to de novo (untreated) patients.
88809995|NCT03808844|Experimental|HSK3486|0.4mg/kg/0.2 mg/kg
88809996|NCT03808844|Active Comparator|Propofol|2.0mg/kg/1.0mg/kg
88809997|NCT05316428|Experimental|alcohol plus TPN171H|0.5 g/Kg alcohol plus 10 mg TPN171H tablet
88809998|NCT05316428|Experimental|alcohol|0.5 g/kg alcohol
88809999|NCT05316428|Experimental|TPN171H|10 mg TPN171H tablet
88810000|NCT03805178|Experimental|Rejection post-transplant|Treatment with Belatacept and Carfilzomib for subjects who show evidence of antibody-mediated rejection (AMR) following lung transplantation.
88810001|NCT03805178|Experimental|Pre-transplant desensitization|Treatment with Belatacept and Carfilzomib for subjects with elevated human leukocyte antigen (HLA) antibodies prior to lung transplantation.
88810002|NCT05318378|Experimental|student|Twenty fifth-year medical students were asked to participate in the study
88810003|NCT05318378|Active Comparator|senior surgeon|As controls, we asked 3 independent board-certified orthopedic surgeons to participate in the study following the same conditions as described previously.
88810004|NCT01303835|Experimental|Naltrexone|Randomized patients received 4.5 mg low dose naltrexone (LDN) to be taken every night before bed.
88810005|NCT01303835|Placebo Comparator|Placebo|Randomized patients received placebo to be taken every night before bed.
88810006|NCT03805334|Experimental|Touchpoints|Subjects will wear Touchpoints devices on both ankles daily for 10 days. The devices will be worn ~1 hour before bedtime and through the night. They will be removed upon waking in the morning.
88810007|NCT01250717|Experimental|Docetaxel Followed by Radical Prostatectomy|Docetaxel,Dexamethasone,Estramustine,Zoladex,Casodex,Prostatectomy
88810008|NCT03808532|Experimental|High-Risk with Moisturizer|
88810009|NCT03808532|No Intervention|High-Risk without Moisturizer|
88810010|NCT03808376|Experimental|Continuous Glucose Monitoring Device|The Eversense® 180 CGM System
88810011|NCT03009305|Experimental|Lower body negative pressure|Single-arm, lower body negative pressure, continuous positive airway pressure, positive expiratory pressure.
88810012|NCT05744258|Other|IBS patients|
88810013|NCT05744258|Other|Healthy volunteers|
88810014|NCT02189915|Experimental|Creatine monohydrate|
88810015|NCT04385030|Active Comparator|ETCC Active associated with Mirror Therapy (TE)|The study will consist of 12 sessions, being carried out over a period of 1 month, with 3 weekly sessions on consecutive days, where each patient will receive ETCC for 30 minutes concomitantly with ET. Outcome assessments will be performed before the beginning of the protocol on the base (T0) and immediately after the end of the 12 sessions (T1).
88810016|NCT04385030|Sham Comparator|ETCC simulated associated with Mirror Therapy (TE)|The study will consist of 12 sessions, being carried out over a period of 1 month, with 3 weekly sessions on consecutive days, where each patient will receive ETCC for 30 minutes concomitantly with ET. Outcome assessments will be performed before the beginning of the protocol on the base (T0) and immediately after the end of the 12 sessions (T1).
88810017|NCT03804866|Experimental|Arm A: NGR-hTNF+ anthracycline|NGR-hTNF+Pegylated Liposomal Doxorubicin or Doxorubicin
88810018|NCT03804866|Active Comparator|Arm B: anthracycline|Pegylated Liposomal Doxorubicin or Doxorubicin
88810019|NCT01251575|Experimental|Treatment (fludarabine, transplant, immunosuppression)|"CONDITIONING: Patients receive fludarabine phosphate IV over 30 minutes on days -4 to -2. Patients also undergo total-body irradiation on day 0.~TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell transplantation.~IMMUNOSUPPRESSION: Patients receive sirolimus PO QD on days -3 to 180 with taper to day 365; cyclosporine PO BID on days -3 to 150 with taper to day 180; and mycophenolate mofetil PO TID on days 0-30 and then BID to day 100 with taper to day 150."
88844308|NCT06124079|Placebo Comparator|standard care|Standard care currently consists of education materials with the after visit summary (available in MyChart) around opioid use and precautions and disposal information.
88844309|NCT06124079|Experimental|Interactive messaging service|Participants will be randomized to one of 3 specific versions of OPY.
88844310|NCT06120855|Experimental|Regulated cannabis from authorized pharmacies (intervention group)|Multimodal intervention of authorized, regulated cannabis sale in combination with counselling on reducing harms for recreational cannabis users in Swiss pharmacies (intervention group).
88844311|NCT06120855|Active Comparator|Cannabis from the illicit market (control group)|The control group receives no intervention and is expected to continue purchasing cannabis from the illicit market.
88844312|NCT06116578|Active Comparator|A: Pembrolizumab before surgery|Before surgery: Pembrolizumab 200 mg two intravenous (IV) infusions q3w (2 injections: at C1D1 and C1D21)
88844313|NCT06116578|Active Comparator|B: Pembrolizumab + olaparib before surgery|Before surgery: Pembrolizumab 200 mg two IV infusions q3w (2 injections: at C1D1 and C1D21) + concomitant full dose olaparib (300 mg per os b.i.d) during four weeks
88844314|NCT06111508|Experimental|Continuous Glucose Monitoring (CGM) based Titration|The CGM-based titration algorithm will run on the Diabetes Assistant and Amazon Web Services (AWS) platform (DiAs-Cloud). DiAs-Cloud enables the seamless integration of a smart phone application and AWS server architecture to enable data capture, dose computation, review by the clinical team, and communication to study participants. For dose computation the algorithm is comprised of three components; titration glucose level, personalized target, and safety hypoglycemia feature.
88844315|NCT06111508|No Intervention|Standard Self-Monitoring Blood Glucose (SMBG) Titration|The SMBG-based titration algorithm will run on the Diabetes Assistant and Amazon Web Services (AWS) platform (DiAs-Cloud). DiAs-Cloud enables the seamless integration of a smart phone application and AWS server architecture to enable data capture, dose computation, review by the clinical team, and communication to study participants. Participants in the standard SMBG based titration group will wear a blinded CGM during the whole study. The total daily basal insulin dose will be converted 1:1 to Degludec. Algorithm informed dose changes will be made once weekly and checked by study physician.
88844316|NCT06107972|Experimental|Launching! to Adulthood (¡Iniciando! la Adultez) program|
88844317|NCT06106373|Experimental|Pediatric Cochlear Implant Recipient|Pediatric subjects receiving a cochlear implant between the ages of 9 months and under 12 years of age.
89189302|NCT02574468|Active Comparator|DPC+Dexa|forty intact premolars were randomly assigned to 1 of 4 treatment groups (n=10): I) DPC, II) MP, III) DPC+dexamethasone, and IV) MP+dexamethasone. After administration of local anesthesia (3% mepivacaine plain; Septodont, Cedex, France) dental rubber dam was applied and tooth surface disinfected with 2% chlorhexidine gluconate. Occlusal cavity was prepared using high speed diamond fissure bur and buccal pulp horn was mechanically exposed (approximately 1.2 mm in diameter) using a sterile high speed carbide round bur. In MP, depth of penetration to the pulp was 0.5 mm
89371600|NCT02288832|Experimental|Innovative strategy (group A):|these women will undergo routine screening for bacterial vaginosis by analysis of their self-collected vaginal samples with this innovative technique; if the test is found to be positive, an appropriate treatment will be prescribed. The POC (point-of-care) test will be considered positive if: A. vaginae is detected at a threshold > 105.copies per ml and/or G. vaginalis > 105 copies per ml. The women with vaginosis will be screened monthly for recurrences through 28 weeks, and recurrence will be treated.
88844324|NCT06100237|Experimental|Cohort A: Tec-Dara|Participants will receive the recommended dosage combination treatment Tec-Dara.
88844325|NCT06100237|Experimental|Cohort B: Tal-Dara|Dosing and treatment schedule for participants in this group will be determined after Cohort A is completed.
88844327|NCT06098807|Experimental|Familiy Based Treatment|;one session per week during a period of four weeks with high quality content. The sessions will be performed at CAP location in Lund. The treatment will be performed by a clinician at CAP who could be a doctor, psychologist or health counselor - all with cognitive behavioral therapy competence. The sessions will be in group settings, separately for children and parents. In that sense, children will be included in a group with other children and parents will be included in a group with other parents. Each group will have 1-2 therapists leading the program. The theme of the week will be the same for both parent and child group, although the delivery will potentially differ. We expect that a session will last approximately 90 min with a 15-minute coffee break included.
88844328|NCT06091865|Experimental|Odronextamab + CHOP|Part 1, includes dose escalation (Part 1A), and randomized exploration of 2 regimens of odronextamab -cyclophosphamide, doxorubicin, vincristine, prednisone (O-CHOP) dose optimization, (Part 1B).
88844329|NCT06091865|Active Comparator|Rituximab + CHOP|Part 2 is the randomized controlled portion, participants will receive either O-CHOP or R-CHOP.
88844330|NCT06090279|Experimental|OmniFlow Breathing Therapy BioFeeback System|This system is a FDA approved healthcare gaming system that is used for patients who have difficulty breathing and allows the patients to participate in breathing exercises for pulmonary rehab.
88844331|NCT06085729|Experimental|Dose Escalation and Monotherapy Maintenance|Participants will be assigned to a study group and dose level of ADI-PEG20 based on when participant join this study. Up to 2 dose levels of ADI-PEG20 may be tested. Up to 15 participants will be enrolled per dose level.
89371601|NCT02288832|Other|Standard strategy (group B):|This group will be followed according to the usual practices of the physicians seeing them.
89371602|NCT03175588|Experimental|virtual rehabilitation|video based exercise
89371603|NCT03175588|No Intervention|physical Activity|different type of physical Activity
89371604|NCT03175510||patients group|Patients with low back pain (18-65 years)
88844332|NCT06084104|Experimental|Hepatic impairment|Subjects with hepatic impairment
88844333|NCT06084104|Experimental|Healthy Subject|Subjects with normal hepatic function
88844334|NCT06083753|Experimental|PIPE-307 Dose A|
88844335|NCT06083753|Experimental|PIPE-307 Dose B|
88844336|NCT06083753|Placebo Comparator|Placebo|
88844337|NCT06081400|Experimental|Cryoablation|One single cryoablation of the desmoid tumor at Day 0
88844338|NCT06081400|Active Comparator|Medical therapy|"Chemotherapy: at the investigator's discretion: either~methotrexate 30mg/m² + vinblastine 6mg/m² (IV infusion) once/week for 6 months, then every other week from months 7 to 12, or~vinorelbine 90mg/week (per os: 3x30mg, soft capsules) for 12 months."
89371605|NCT02401984||Screening|A Screening tool will be administered to the participants.
89371606|NCT02403232|Experimental|ASCs injection|Autologous adipose-derived stem cells (ASCs) injection with LIPOGEMS system.
89371607|NCT02406820||No Indwelling PAC, Daily Testing|Acutely decompensated heart failure patients undergoing a right heart catheterization for whom a retained indwelling PAC is not clinically indicated and who are registered to twice daily non-invasive hemodynamic monitoring during an isometric handgrip stress test (IHGST).
89371608|NCT02406820||Indwelling PAC, Daily Testing|Acutely decompensated heart failure patients undergoing a right heart catheterization for whom a retained indwelling PAC is clinically indicated and who are registered to three times daily non-invasive hemodynamic monitoring during an isometric handgrip stress test (IHGST).
88844341|NCT06079814|Experimental|experiment group|Patients will wear virtual reality glasses 10 minutes before cystoscopy. The content chosen by the patient (there will be three options) will be watched throughout the procedure.
89371609|NCT02406820||No Indwelling PAC, No Daily Testing|Acutely decompensated heart failure patients undergoing a right heart catheterization for whom a retained indwelling PAC is clinically indicated and who are registered to no daily non-invasive hemodynamic monitoring during an isometric handgrip stress test (IHGST).
89371610|NCT03116308|Experimental|50 mg OPC|Subjects received 50 mg OPC once-daily in the evening for 12 days. On D9 subjects were to receive 50 mg OPC in the evening after a minimum 6 hours fast. On D10 subjects were to receive the QD dose of 50 mg OPC thirty minutes after the start of moderate meal (with a previous 6 hours fast)
89371611|NCT02402998|Experimental|Eltrombopag|Eltrombopag 50 mg/daily.
89371612|NCT03665441|Experimental|Eryaspase plus Chemotherapy|"eryaspase 100 U/kg dosed every 2 weeks in combination with~Gemcitabine plus abraxane (albumin-bound paclitaxel) administered on Days 1, 8, and 15 of each 4 week cycle as follows:~Abraxane (125 mg/m2) IV~Gemcitabine (1000 mg/m2) IV~Or~Irinotecan plus 5-FU plus leucovorin administered on Days 1 and 15 of each 4 week cycle as follows:~Onivyde 70 mg/m2 (irinotecan freebase) IV (recommended dose in patients homozygous for UGT1A1*28 is 50 mg/m2)~Leucovorin 400 mg/m2 IV~5 FU 2400 mg/m2~Or~FOLFIRI: Irinotecan 180 mg/m2 IV~Leucovorin 400 mg/m² IV~5 FU 400 mg/m² IV bolus~5 FU 2400 mg/m² IV continuous infusion over 46 hours immediately following bolus 5 FU"
89371613|NCT03665441|Other|Chemotherapy alone|Standard treatment: Gemcitabine plus abraxane (albumin-bound paclitaxel) administered on Days 1, 8, and 15 of each 4 week cycle Or Irinotecan plus 5-FU plus leucovorin administered on Days 1 and 15 of each 4 week cycle
89371614|NCT03169660|Experimental|Treatment group|Eyes with submacular hemorrhage secondary to exudative age-related macular degeneration and were treated with vascular endothelial growth factor trap-eye.
89371615|NCT02401828|Experimental|Group A - Direct Switch|Direct switch from cART to Dolutegravir mono-therapy at baseline. Dolutegravir single tablet 50mg QD, once a day. Duration = 48 weeks
89371616|NCT02401828|Experimental|Group B - Delayed Switch|Delayed switch from cART to Dolutegravir mono-therapy at week 24 from baseline. Dolutegravir single tablet 50mg QD, once a day. Duration = 48 weeks
88844342|NCT06079814|No Intervention|control group|Standard procedure.
88844343|NCT06069102|Active Comparator|Usual Care Group|Standard of care BP medication will usually be started if a subject's BP consistently exceeds 150/100 mmHg at any point.
88844344|NCT06069102|Experimental|Intervention (Tight Blood Pressure Control) Group|BP medication will be started if a subject's hospital BP consistently exceeds 140/90 mmHg or her home BP consistently exceeds 135/85 mmHg.
88844345|NCT06067555|Active Comparator|Intramuscular (IM) Control|An intramuscular control group, from which no skin biopsies will be taken after vaccination. Only the intramuscular cohort will receive the flu vaccine via standard IM route in the deltoid region of the upper arm.
88844346|NCT06067555|Experimental|ID-2hour|Participants receive intradermal flu vaccination in the upper arm and will have skin biopsy of vaccination site 2 hours after vaccine administration.
88844347|NCT06067555|Experimental|ID-6hour|Participants receive intradermal flu vaccination in the upper arm and will have skin biopsy of vaccination site 6 hours after vaccine administration.
88844348|NCT06067555|Experimental|ID-1day|Participants receive intradermal flu vaccination in the upper arm and will have skin biopsy of vaccination site 1 day after vaccine administration.
88844349|NCT06067555|Experimental|ID-3day|Participants receive intradermal flu vaccination in the upper arm and will have skin biopsy of vaccination site 3 days after vaccine administration.
89002093|NCT06116227|Experimental|Group A: Whole Body Vibration Training plus conventional physical therapy exercise program|30 patients received whole body vibration training on a vibration platform for 12-15 minutes, 3 times per week, plus a traditional physical therapy exercise program in the form of a 60-minute supervised exercise program for 8 weeks.
88844350|NCT06067555|Experimental|ID-28day|Participants receive intradermal flu vaccination in the upper arm and will have skin biopsy of vaccination site 3 days after vaccine administration.
88844351|NCT06067555|Placebo Comparator|Sal-2hour|"A control group in which bacteriostatic saline is injected intradermally in lieu of influenza vaccine. A skin biopsy will be taken from the vaccination site 2 hours after administration."
89371617|NCT02699866|Experimental|BLT Implant Ø 2.9 mm|The Straumann BLT Implants Ø 2.9 mm are available with a length of 10, 12 and 14 mm.
89371618|NCT03663569||subjects with COPD|
89371619|NCT02401438||pregnant women with preterm delivery|5D LB and 2D ultrasounds will be done to pregnant women between 28 and 34 weeks planned for termination of pregnancy for obstetric or medical causes.
89371620|NCT02401516|Active Comparator|Reprogramming Insoles|EG - experimental group. Subjects will be subjected to the use of insoles with the artifact in the postural reprogramming insole that emits a electrogalvanic stream. Volunteers of this research must use the insole for at least 12 hours a day and have usage control through a daily chart.
89371621|NCT02401516|Placebo Comparator|Neutral Insoles|CG - control group. Subjects will be subjected to the use of insoles likewise the ones used by EG, but instead the artifact in the postural reprogramming insole made of metal, will be made of cork.
89371622|NCT03596762|Experimental|160 mg Elinzanetant (BAY3427080)|Participants received 4x40 mg elinzanetant capsules.
89371623|NCT03596762|Experimental|120 mg Elinzanetant (BAY3427080)|Participants received 3x40 mg elinzanetant capsules and 1 placebo capsule.
89371624|NCT03596762|Experimental|80 mg Elinzanetant (BAY3427080)|Participants received 2x40 mg elinzanetant capsules and 2 placebo capsules.
89371625|NCT03596762|Experimental|40 mg Elinzanetant (BAY3427080)|Participants received one 40 mg elinzanetant capsule and 3 placebo capsules.
89371626|NCT03596762|Placebo Comparator|Placebo|Participants received four placebo capsules orally once daily in the evening before bedtime.
89371627|NCT04481386|Experimental|Active arm|Participants with a diagnosis of retinal detachment or vitreous haemorrhage, who are scheduled for vitrectomy surgery with a vitreous substitute
89371628|NCT02401594|Experimental|Group 1: Rivaroxaban treatment|Rivaroxaban active substance plus a placebo of enoxaparin
89371629|NCT02401594|Active Comparator|Grouyp 2: Enoxaparine treatment|Enoxaparin active substance plus a placebo tablet of Rivaroxaban
89371630|NCT02406508|Experimental|Hepatic Delivery System Treatment followed by Sorafenib|"Percutaneous hepatic perfusion with melphalan hydrochloride for injection using the Hepatic Delivery System.~Melphalan hydrochloride is administered at a dose of 3mg/kg ideal body weight once every 6 weeks for a maximum of 3 cycles of treatment.~After the Melphalan/HDS treatment patients will be treated with sorafenib according to the package prescribing information."
89371631|NCT02401360|Experimental|Experimental Group|Oral care regimen
89371632|NCT02401360|Placebo Comparator|Control Group|Toothbrush and toothpaste
89371633|NCT02402686||Tocilizumab for RA in Routine Clinical Practice|Participants from routine clinical practice in Hungary who are receiving treatment for RA with tocilizumab SC according to standard of care and in line with the current summary of product characteristics (SPC)/local labeling and who have no contraindication to tocilizumab therapy as per the local label are eligible for observation.
89371634|NCT03736577|Experimental|NorGeP-NH|"Initially, a three hours lecture on dementia, depression, anxiety and psychosis on the elderly will be held. Both physicians working in the facilities and selected personnel, i.e. specialized nurses, will attend.~Intervention: Drug reviews with NorGeP-NH Physicians in the intervention group will attend a 1-2 hours lecture about psychopharmacology and drug review. They will learn how to do drug reviews with the Norwegian general practice criteria - Nursing homes (NorGeP-NH) and they will do a structured drug review on the participants' drug charts."
89371635|NCT03736577|No Intervention|Control nursing home|"Initially, a three hours lecture on dementia, depression, anxiety and psychosis on the elderly will be held. Both physicians working in the facilities and selected personnel, i.e. specialized nurses, will attend. Physicians will not attend any lecture about drug reviews and they will keep treating participants as usual."
88810020|NCT00782756|Experimental|RT, with temozolomide and bevacizumab|This treatment regimen is novel in that it delivers the initial course of RT over 2 weeks instead of 6 weeks; also, the addition of bevacizumab during and after RT is a new approach.
88810021|NCT04384718||Medea Group|Group of children with Developmental Dyslexia treated with Tachidino protocol at IRCCS Medea
88810022|NCT04384718||Asur Group|Group of children with Developmental Dyslexia treated with Tachidino protocol at Asur Marche
88810023|NCT04384718||Waiting list Group|Group of children with Developmental Dyslexia on a waiting list for treatment with Tachidino protocol at IRCCS Medea or Asur Marche
88810024|NCT01215695|Active Comparator|Control|Patients will be randomly assigned to having their ETT placed with use of a pre-formed stylet provided by the manufacturer of the GVL (control group)
88810025|NCT01215695|Experimental|Intervention|Patients will be randomly assigned to either having their ETT placed with use of flexible, disposable tracheoscope (aScope, Ambu, Denmark) (intervention group).
88810026|NCT05744102|Other|Adult patients having MRI planned at Paul Brousse Hospital|Evaluate new MRI sequences on a population of patients undergoing MRI as part of their usual care
88810027|NCT03808142||Treatment|During a 3-months period all patients with an active myBETAapp account were invited to participate in the study (3-month invitation period=enrollment period). Patients seek more information about the study were able to access a detailed informed consent form via their app providing step-by-step background information. Those patients were wishing to participate in the study were able to provide (electronic) informed consent (ICF).
88810028|NCT01305473||Sepramesh Group|
88810029|NCT00760526|Active Comparator|1|continuous glucose monitoring
88810030|NCT00760526|Active Comparator|2|Standard glucose monitoring with a home glucose meter
89371636|NCT02402608|Active Comparator|dietary supplement|oral essential amino acid (EAA), whey protein and vitamin D mixture (32 g)
89371637|NCT02402608|Placebo Comparator|placebo|placebo consisting of an equicaloric amount of maltodextrin with the same flavour and appearance as for the intervention product
89371638|NCT02401282|Experimental|ABM|Attention bias modification
89371639|NCT02401282|Placebo Comparator|Placebo|Dot-probe task
89371640|NCT03663179|Experimental|Active TMS|Participants will receive 20 sessions of active TMS targeting the left DLPFC.
89371641|NCT03663179|Sham Comparator|Sham TMS|Participants will receive 20 sessions of sham TMS over the left DLPFC.
89371642|NCT03662789|Active Comparator|Iron isomaltoside 1000|"The active drug, iron isomaltoside 1000 will be administered as a single, intravenous infusion of 20 mg/kg body weight (rounded off to the nearest 100 mg) dissolved in 100 ml NaCl as recommended by the drug manufacturer (on-label treatment)."
89371643|NCT03662789|Placebo Comparator|Placebo|Patients allocated to placebo will receive an intravenous infusion of 100 ml NaCl 0.9%
89371644|NCT03115996|Experimental|REGN3918 (Cohorts 1-4 & 6a)|Cohorts 1-4 and 6a will receive sequential ascending doses of REGN3918
89002094|NCT06116227|Experimental|Group B: Conventional Physical Therapy Exercise Program.|30 patients will receive a traditional physical therapy program. The program consists of 60 minutes of supervised exercise stretching exercise to all involved joints followed by strengthening for affected muscles for 8 weeks.
89371645|NCT03115996|Experimental|Placebo (Cohorts 1-4 & 6a)|Cohorts 1-4 and 6a will receive placebo
89371646|NCT03115996|Experimental|REGN3918 (Cohort 5 & 6b)|Cohort 5 and 6b will receive multiple doses of REGN3918
89371647|NCT03115996|Experimental|Placebo (Cohort 5 & 6b)|Cohort 5 and 6b will receive placebo
89371648|NCT02401204||Neonates admitted to QSNICH NICU|All neonates admitted to the QSNICH NICU over a period of one year from March 2015 to March 2016 meeting the inclusion and exclusion criteria will be enrolled in the study. Readmitted neonates will be eligible to be enrolled again into the study.
89371649|NCT03736421||Control Cohort|"This cohort is recruited to help to define what a normal PIVA value should be during a state of presumed euvolemia."
89371650|NCT03736421||Infection Cohort|This cohort are subjects with suspected infection, enriched to contain sepsis patients.
89371651|NCT03736421||Acute Heart Failure|This cohort will have a diagnosis of CFH who are being admitted to the hospital. These patients will be followed during their hospital course.
89371652|NCT02401126|Active Comparator|Nitrate supplementation|Concentrated nitrate-rich beetroot juice
89371653|NCT02401126|Placebo Comparator|Placebo|Nitrate-depleted beetroot juice
89371654|NCT04481932|Experimental|Trastuzumab combined with Pyrotinib and chemotherapy|The dosage of the above drugs can be adjusted according to the adverse reactions of the subjects. The subject continued to use the drug until the full cycle or the disease progressed or the toxicity was intolerable or withdrawn, or the researcher judged that the medication must be terminated.
89371655|NCT03658889||Patients under treatment(s) for GCA|Patients at least 50 years old with Giant Cell Arteritis (GCA) and under treatment(s) for GCA
89371656|NCT03169582|Active Comparator|Avanafil|Clinical evaluation of the two pharmacological interventions (Sildenafil vs Avanafil).
89371657|NCT03169582|Active Comparator|Sildenafil|Clinical evaluation of the two pharmacological interventions (Sildenafil vs Avanafil)
89371658|NCT02406664|Experimental|Obese patients|15 Obese patients (BMI>30) having one of comorbidity (type 2 diabetes, dyslipidemia, or hypertension) and morbid obese patients (BMI>35) accepted for bariatric surgery.
89371659|NCT02406664|No Intervention|Control patients|15 matched controls receiving Intensive medical therapy
89371660|NCT02402374|Experimental|PRP gel|Autologous platelet rich plasma gel
89371661|NCT02402374|Placebo Comparator|Placebo|Saline gel
89371662|NCT02402140|Experimental|1 with pharmaceutical intervention|"Patients allocated to group 1 with pharmaceutical intervention received instructions on the proper use of immunosuppressants as dosage, frequency and administration schedules, importance of immunosuppressive drugs and the risk of rejection.~No more interventions were applied."
88810031|NCT01306175|Experimental|Digoxin alone (Reference)|Tablet, oral administration with 240 mL water
88810032|NCT01306175|Experimental|Digoxin plus BI 10773 (Test)|Tablets, oral administration with 240 mL water
88810033|NCT03804476|Experimental|AER-271|The experimental drug AER-271 will be administered in this Arm. In Part A single ascending doses will be administered by IV bolus infusion of AER-271 formulated in phosphate buffered normal saline over a 30-min period. In Part B multiple ascending doses of AER-271 will be administered by IV 30-min bolus infusion BID for 72 hours. AER-271 will also be administered as an initial bolus dose over 30-min then continuous infusion over 72 hours.
88810034|NCT03804476|Placebo Comparator|Placebo|A placebo control will be administered in this Arm. In Part A phosphate buffered normal saline will be administered over a 30-min period. In Part B multiple doses of phosphate buffered normal saline will be administered by IV 30-min bolus infusion BID for 72 hours. This placebo will also be administered as an initial bolus dose over 30-min then continuous infusion over 72 hours. In both Parts, the volume of placebo administered will be the same as the Experimental Arm.
88810035|NCT01215929|Active Comparator|Dextroamphetamine|
88810036|NCT01215929|Placebo Comparator|Placebo|
88810037|NCT03804398|Experimental|optimal PEEP group|The study group titrate PEEP from 4cmH2O,increased in 2cmH2O steps and hold at each step for 1min,and the static pulmonary compliance(Cst) would be record.Optimal PEEP was determined until the maximal static pulmonary compliance was obtained
88810038|NCT03804398|Active Comparator|PEEP level of 5 cmH2O group|In the control group at PEEP level of 5 cmH2O was established and maintained during the study period
88810039|NCT05744024|Experimental|Virtual Reality Therapy (Intervention group 1)|In addition to the standard wound care procedure, the Virtual Reality Therapy group (intervention group 1) will receive the VR system during the wound care. The VR system consists of Virtual Reality glasses, a controller and a headphone. The application SyncVR Relax & Distract will be used, which will contain various videos for the patient those from to relax and be distracted. This group wears the VR system 10 minutes before the start of the wound care, until 1 minute after the wound care has ended.
88844352|NCT06067555|Placebo Comparator|Sal-6hour|"A control group in which bacteriostatic saline is injected intradermally in lieu of influenza vaccine. A skin biopsy will be taken from the vaccination site 6 hours after administration."
88844353|NCT06067555|Placebo Comparator|Sal-1hour|"A control group in which bacteriostatic saline is injected intradermally in lieu of influenza vaccine. A skin biopsy will be taken from the vaccination site 1 day after administration."
89371663|NCT02402140|No Intervention|2 without pharmaceutical intervention|"Standard following of the Hospital do Rim, without pharmaceutical intervention. This group was just followed by the nurses of the hospital, but without a standardized intervention.~It was not a intervention, it was the control group"
89371664|NCT03655691|Placebo Comparator|Vehicle|Vehicle / Placebo formulation
89371665|NCT03655691|Experimental|Dose 1|lower dose of ET-01
89371666|NCT03655691|Experimental|Dose 2|higher dose of ET-01
89371667|NCT03169504|Experimental|Acupuncture|Patients in this arm will receive acupuncture.
89371668|NCT03169504|Experimental|Conventional drug|Patients will be individually divided into Group A, Group B, Group C and Group D according to GOLD 2017. For Group A, Salbutamol Sulphate Inhalation Aerosol (Ventolin®, GlaxoSmithKline Australia Pty Ltd) will be used. For Group B and Group C, Tiotropium Bromide Powder for Inhalation (Spiriva®, Boehringer Ingelheim International GmbH) will be used. As for Group D, Tiotropium Bromide Powder for Inhalation (Spiriva®, Boehringer Ingelheim International GmbH) or Fluticasone Propionate Powder for Inhalation (Seretide®, Laboratoire GlaxoSmithKline) will be used.
89371669|NCT03169504|Experimental|Acupuncture plus conventional drug|Patients in this arm will receive both acupuncture and conventional drug.
89371670|NCT03169426|Experimental|Beta Blockers Carvedilol Phosphate|"Subjects are going to take beta-blocker (carvedilol, 12.5 mg once) before undergoing remote ischemic conditioning.~Intervention: taking beta-blocker"
89371671|NCT03169426|No Intervention|Control|Subjects are going to undergo remote ischemic conditioning without taking any drug.
89371672|NCT03658811|Experimental|Upper eyelid meibomian gland dysfunction|Patients with symptoms of dry eye disease in spite of previous or current use of currently available over the counter or prescription medications for dry eye and evidence of upper eyelid meibomian gland dysfunction and no prior intense pulsed light treatments or meibomian gland expression treatments
89371673|NCT03115528||Medical Oncology Physicians|Medical oncology physicians are sent the Estimation of Prognosis questionnaire by email.
89371674|NCT03115528||Palliative Care Physicians|Palliative care physicians are sent the Estimation of Prognosis questionnaire by email.
89371675|NCT03732443||Critical Ill Patients|Critically ill patients with a RASS ≥ 3. FAM-CAM and CAM-ICU will be administered.
89371676|NCT03573206|Experimental|Treatment Arm|Cardiva Medical Mid-Bore VVCS for venous femoral access site closure
88844354|NCT06064890|Experimental|Cohort 1 (dose 1)|Initial dose, delivered as a one-time only, intrathalamic administration.
88844355|NCT06064890|Experimental|Cohort 2 (dose 2)|Escalated dose, delivered as a one-time only, intrathalamic administration.
89371677|NCT03169348|Experimental|study group|Hepatitis- C virus with thrombocytopenia
89371678|NCT03172546||Anti-IIa users|Determination of predictors of anticoagulant activity in a prospective cohort of patients using oral anti IIa anticoagulant including analysis of PK-PD genetic polymorphisms
88844356|NCT06060457|Experimental|Fluzone HD + mRNA-1345|Participants will receive Fluzone HD + mRNA-1345 by intramuscular (IM) injection on Day 1 followed by placebo by IM injection on Day 22.
88844357|NCT06060457|Experimental|Fluzone HD Followed by mRNA-1345|Participants will receive Fluzone HD + placebo by IM injection on Day 1 followed by mRNA-1345 by IM injection on Day 22.
89002095|NCT06116214|Active Comparator|Control group|in this group the teeth will be irrigated with 2.5% Sodium Hypochlorite (gold standard)
89371679|NCT03172546||Anti-Xa users|Determination of predictors of anticoagulant activity in a prospective cohort of patients using oral anti Xa anticoagulant including analysis of PK-PD genetic polymorphisms
89371680|NCT03631355|Active Comparator|ACL Reconstruction w/ BTB Autograft + IV TXA|Patients receive a standard arthroscopic ACL reconstruction with a BTB autograft. In addition, these selected patients received two individual doses of intravenous TXA intra-operatively.
89371681|NCT03631355|No Intervention|ACL Reconstruction w/ BTB Autograft, no IV TXA|Patients receive a standard arthroscopic ACL reconstruction with a BTB autograft. In addition, these selected patients did not receive two individual doses of intravenous TXA intra-operatively. Only the consented surgery was performed.
89371682|NCT02411422|Experimental|Intubation using laryngoscope|"Intubation using Macintosh laryngoscope. we will check procedure time according to kind of endotracheal tube, separately.~Two kinds of endotracheal tube will be used~Conventional endotracheal tube~Reinforced endotracheal tube"
89371683|NCT02411422|Experimental|i-gel blind intubation|"i-gel blind intubation means that blind endotracheal intubation will be performed after i-gel insertion.~i-gel will be used as a conduit. we will check procedure time according to kind of endotracheal tube, separately.~Two kinds of endotracheal tube will be used~Conventional endotracheal tube~Reinforced endotracheal tube"
89371684|NCT02411422|Experimental|i-gel bronchoscopic intubation|"i-gel bronchoscopic intubation means that bronchoscopic endotracheal intubation will be performed after i-gel insertion.~i-gel will be used as a conduit. we will check procedure time according to kind of endotracheal tube, separately.~Two kinds of endotracheal tube will be used~Conventional endotracheal tube~Reinforced endotracheal tube"
89371685|NCT03169192||Repeated fractures group|detection of gene mutations of osteogenesis imperfecta in single group of patients with repeated fractures then start treatment with zoledronic acid in doses children less than 5 years ( 0.025 milligram for each kilogram every 3 months for 18 months duration) children more than 5 years ( 0.05 milligram for each kilogram every 6 months for 18 months duration)
88844358|NCT06057441|No Intervention|No noise stimulation|A prolonged fixation (PF) task and memory guided saccade (MGS) task will be performed without noise.
88844359|NCT06057441|Active Comparator|Auditory white noise stimulation|A prolonged fixation (PF) task and memory guided saccade (MGS) task will be performed in auditory white noise.
88844360|NCT06057441|Active Comparator|Visual white pixel noise, 25%|A prolonged fixation (PF) task and memory guided saccade (MGS) task will be performed in visual white pixel noise at 25%.
89371686|NCT05000957|Experimental|"Magic Max Laser Treatment + Colporrhaphy"|"Laser treatment of the vagina, vulva, and paraurethral region with a Magic Max laser. In total, three procedures will be performed with an interval of 4 weeks.~During the procedure, the following sequence of actions will be performed:~st Stage - vaginal processing with a conical mirror handpiece,~nd Stage - vaginal processing with a corner mirror handpiece,~d Stage - external vulva and paraurethral region processing with a switched beam diameter handpiece.~A/R colporrhaphy will be performed 1 month after last laser treatment."
88844361|NCT06057441|Active Comparator|Visual white pixel noise, 50%|A prolonged fixation (PF) task and memory guided saccade (MGS) task will be performed in visual white pixel noise at 50%.
88844362|NCT06054633|Active Comparator|Oral L-arginine|Participants in the intervention arm will receive oral L- arginine tablets, 2 g three times daily
89371687|NCT05000957|Active Comparator|Colporrhaphy (control group 1)|A/R colporrhaphy only will be performed.
89371688|NCT05000957|Other|No Treatment (control group 2)|Any surgery which do not affect condition of vagina, vulva and paraurethral region will be performed.
89371689|NCT04482166|Experimental|Candidates|Training of fiberoptic-guided tracheal intubation through supraglottic airway device to pediatric airway manikin
89371690|NCT03679052|Active Comparator|Group I (Mirtazapine group): (n=100)|
89371691|NCT03679052|Active Comparator|Group II (Clonidine group): (n=100)|
89371692|NCT03679052|Placebo Comparator|Group III (Control group): (n=100)|
89371693|NCT03172312||Total thyroidectomy|Patients need to do total thyroidectomy According to guidelines
89371694|NCT03172312||Hemithyroidectomy|Patients need to do Hemithyroidectomy According to guidelines
89371695|NCT03675074|Experimental|Treatment|A dual path jejunoileal side-to-side anastomosis is endoscopically created using the Neujia device.
89371696|NCT03172390|Experimental|Cohort of patients : ascending aorta dilatation|measure of ascending aorta quality and quantity parameters by 4D Cardiac magnetic resonance
89371697|NCT03678974|Experimental|Exercise|Subjects will receive metabolic testing, exercise prescription, YMCA memberships, and physician based on Intensive Behavioral Therapy for Obesity utilizing CardioCoach app.
89371698|NCT03540914|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
89371699|NCT03540914|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m.
89371700|NCT03671252|Experimental|Experimental: Group 1|Patient will receive FOLFOXIRI regimen every two weeks for 4-6 cycles within 2-3 months.Two weeks after completing 3 and 6 cycles of FOLFOXIRI regimen,patients will have two efficacy evaluations according to RECIST criteria and toxicity evaluation .If the tumor is defined as no progression without severe toxicity at the first efficacy evaluation, the rest of 3 cycles of FOLFOXIRI regimen will be performed.If it is defined as progression of primary tumor or it is defined as progression of primary tumor and MRF(+)at the second efficacy evaluation,patients are assigned into active comparator group. If distant metastasis occurred during chemotherapy, patients are treated according to the guidelines for metastatic colorectal cancer.Chemotherapy is initiated at 3-4 weeks after R0 resection. XELOX regimen is performed post-operatively (about 4-6 cycles). If postoperative pathology confirmed as positive margin, postoperative chemoradiotherapy was given.
89371701|NCT03671252|Active Comparator|Active Comparator:Group 2|The patients are scheduled to receive chemoradiotherapy. After 5 weeks from the end of chemoradiotherapy, patients will have a efficacy evaluation according to RECIST criteria. If the tumor is defined as CR、PR or SD, and the TME operation is conducted within 5-10 weeks after chemoradiotherapy completion. If tumor is defined as progressive disease with the possibility of R0 resection, the operation was also conducted within 5-10 weeks after chemoradiotherapy . If tumor is defined as progressive disease without possibility of R0 resection, the palliative chemotherapy was performed . If distant metastasis occurred during chemoradiotherapy, patients are treated according to the guidelines for metastatic colorectal cancer. Adjuvant chemotherapy of XELOX is performed post-operatively (about 4-6 cycles).
88844363|NCT06054633|Placebo Comparator|Placebo|The control group will receive an identical inert placebo tablet, three times daily
89371702|NCT02400892||PFO|Subjects with a bedside Transthoracic Echocardiogram (TTE) bubble study positive for a PFO
88844364|NCT06048809|Experimental|Test Toothpaste|Participants will be instructed to brush their teeth with the test toothpaste (Sensodyne Repair and Protect containing 1100 parts per million [ppm] fluoride as SnF2) for 1-timed minute twice a day (morning and evening) in their usual manner for 6 weeks. Participants will record each brushing in the diary provided.
88844365|NCT06048809|Active Comparator|Reference Toothpaste|Participants will be instructed to brush their teeth with the reference toothpaste (Colgate Cavity Protection containing 1100 ppm fluoride as sodium monofluorophosphate [SMFP]) for 1-timed minute twice a day (morning and evening) in their usual manner for 6 weeks. Participants will record each brushing in the diary provided.
88844366|NCT06046274|Experimental|Cohort A: pembrolizumab + acasunlimab|Pembrolizumab will be administered in combination with acasunlimab as second-line (2L) or third-line (3L) therapy for dMMR/MSI-H in checkpoint inhibitor (CPI) naïve participants.
88844367|NCT06046274|Experimental|Cohort B: pembrolizumab + acasunlimab|Pembrolizumab will be administered in combination with acasunlimab as 2L or 3L therapy for mismatch repair deficient/ microsatellite instability-high (dMMR/MSI-H) participants who had prior exposure to programmed cell death protein/ programmed death ligand 1 (PD-1/PD-L1) inhibitors.
89371703|NCT02400892||Control|Subjects with a bedside TTE bubble study negative for a PFO
89371704|NCT03629249|Experimental|QAW039 150 mg|QAW039 150 mg once daily orally
89371705|NCT03629249|Experimental|QAW039 450 mg|QAW039 450 mg once daily orally
89371706|NCT03629249|Placebo Comparator|Placebo|Placebo to QAW039 once daily orally
89371707|NCT02396524|Experimental|Hockey FIT program|12-week active phase - exercise and healthy living program (1x/week; 90 minutes/session); 40-week maintenance phase (individualized approach)
89371708|NCT02396524|No Intervention|Usual-care wait-list control|No active intervention (usual care)
89002096|NCT06116214|Experimental|Experimental group|in this group the teeth will be irrigated with 10% V. Nelotica (Herbal irrigant)
88844368|NCT06044571|Active Comparator|Prescriptive|A diet and exercise prescription individually tailored to each participant's multiple chronic health conditions will provide concrete advice with less autonomy, and will minimize risks of physiologic changes due to weight loss (hypoglycemia, hypotension, muscle loss). Licensed, trained professionals- Registered Dietician Nutritionists (RDNs) and Physical Therapists (PTs) will introduce clinical reasoning, knowledge, and experience, assess biological adaptations to weight loss, modify prescriptions based on changing medical needs, and provide real-time and asynchronous guidance. Registered Dietician Nutritionists (RDNs) and Physical Therapists (PTs) will deliver group and individual, live sessions to the home by telemedicine. Sessions will last 60-min (Registered Dietician Nutritionist: 20 min; Physical Therapy: 40 min).
88844369|NCT06044571|Active Comparator|Behavioral|"Health coaches have a bachelor's degree and take a 6-8-week certification program. Health coaches will use a structured manual involving evidence-based behavior change techniques (problem-solving, self-regulation, motivation). Group and individual sessions will be via telemedicine.~Conceptual model targets include:~barrier identification: problem-solving to identify and address barriers to meet goals~self-regulation: a focus on self-monitoring and behavior goals with feedback~autonomous motivation: self-selecting goals, motivational interviewing use, and creating plans; and (d) self-efficacy: learning from group experiences, verbal persuasion, and encouraging pursuit of goals in the face of setbacks."
89002097|NCT06116188||Patients with Mild cognitive impairment|20 study volunteers with a diagnosis of MCI due to AD or early AD or episodic memory decline during the last 6 months from the local memory clinics and by contacting doctors who treat and diagnose memory disorders. Patients with Alzheimer´s dementia - i.e. cognitive impairment severe enough to cause problems in activities of daily living - will not be included in the study due to the study protocol which requires co-operation and the ability to lie still in the PET scanner for approximately 60 minutes.
89180823|NCT00914147|Other|Pulmonary Function Test (PFT)|After signing consent, patients will undergo a complete spirometry test, lung volumes and diffusing capacity (DLCO) measurement utilizing the single-breath breath holding technique, according to the ATS/ERS consensus and standardization. PFT measurements will be reported as absolute values (e.g. liters) and percentage of predicted. The predicted normal values will be calculated according to sex, age, height and race using the Third National Health and Nutrition Examination Survey (NHANES III) reference equation. Predicted values for diffusion capacity will be calculated using the Morris/Polgar equation. DLCO values will be adjusted to anemia (hemoglobin levels)
89180824|NCT02605499|Experimental|UV-C light disinfection|During intervention UV-C light disinfection will be used in hospital patient rooms as an adjunct to routine daily and discharge cleaning.
89180825|NCT02605499|No Intervention|Control|During control period there will be standard discharge and daily room cleaning only, with no UV-C light disinfection.
89180826|NCT04026659|Experimental|Multi-modal exercise programme|The 10-week multi-modal exercise programme will comprise of twice weekly supervised group-based exercise sessions. Each exercise session will last approximately 1 hour and consist of a combination of aerobic, resistance and balance and flexibility exercises.
89180827|NCT05685069||Standardized work-up|A standardized workup procedures including cerebral MRI, long-term rhythm monitoring (3 x 7 days ECG), echocardiography, stroke laboratory, risk factor assessment and noninvasive angiography of the cervical and intracranial arteries will be performed.
89180828|NCT02606513|Experimental|Comparison of CTU vs MRU|CTU is the primary test of choice for the evaluation of the UUT. The performance of MRU will be compared to that of CTU in the same patient population
89180829|NCT04015557|Experimental|Acetaminophen|Adult patients with homocystinuria due to cystathionine beta synthase (CBS) deficiency and controls will receive a single dose of Acetaminophen (1.5g) orally. Blood will be drawn at time 0, 2, 4, 6 and 8 hours after the acetaminophen dose.
89180830|NCT04015557|Experimental|Acetaminophen + N-acetylcysteine|Patients with homocystinuria due to cystathionine beta synthase (CBS) deficiency and controls will receive again a normal dose of acetaminophen (1.5g) orally and one hour later oral N-acetylcysteine (70 mg per kilogram of body weight). Blood will be drawn at time 0, 2, 4, 6 and 8 hours after the acetaminophen dose.
89180831|NCT02702765|Experimental|Wilsons disease|All patients will receive all interventions (galactose elimination capacity test , ultrasound, fibroscan, continuous reaction time test and functional hepatic nitrogen clearance ), except liver biopsy.
89180832|NCT05534282|Experimental|Interaction-focused Music Therapy with Children and Significant Others (INMUT-KB) (exp. group)|Interaction-focused music therapy with children with cancer and their significant others, delivered by trained music therapists
89180833|NCT05534282|Experimental|Music Therapy with Children (MUT-K) (exp. group)|Interaction-focused music therapy with children with cancer without the involvement of significant others, delivered by trained music therapists.
89180834|NCT05534282|Experimental|Interaction-focused Music Therapy with Children and Significant Others (WG-KB) (control group)|Study participants randomized to this group receive the intervention INMUT 10 weeks after the experimental groups.
89180835|NCT02568605|Experimental|Prebiotic Fibre|The intervention group will receive two 8g packets/day of prebiotic fibre to add to 250 ml of water and consume 30 minutes prior to breakfast and dinner.
89180836|NCT02568605|Placebo Comparator|Placebo|The control group will receive two 3g packets/day of maltodextrin to add to 250 ml of water and consume 30 minutes prior to breakfast and dinner.
89180837|NCT02568605|Other|Weight Loss|All participants will be supported through Registered Dietitian visits to achieve approximately 10% weight loss.
89180838|NCT00784784|Experimental|Influenza vaccine|Influenza vaccine, using Fluviral trivalent split virus vaccine
89180839|NCT00784784|Experimental|Antiviral prophylaxis|Zanamivir antiviral prophylaxis
89371709|NCT03671174|Experimental|Prednisone + hydroxychloroquine + anticoagulation|Oral low-dose prednisone PLUS Oral hydroxychloroquine PLUS Oral low-dose aspirin PLUS subcutaneous low-molecular-weight heparin
89371710|NCT03671174|Experimental|Hydroxychloroquine + anticoagulation|Oral hydroxychloroquine PLUS Oral low-dose aspirin PLUS subcutaneous low-molecular-weight heparin
89371711|NCT03671174|Active Comparator|Anticoagulation|Oral low-dose aspirin PLUS subcutaneous low-molecular-weight heparin
89371712|NCT03172234|Active Comparator|amantadine group (Group A)|the patients will receive oral amantadine sulfate using the dose 100 mg 120 minutes prior to the surgery, 5 ml saline IV 5 minutes before intubation.
89371713|NCT03172234|Active Comparator|gabapentin group(Group B)|the patients will receive oral gabapentin using the dose 800 mg 120 minutes prior to surgery,5 ml saline IV 5 minutes before intubation.
89371714|NCT03172234|Placebo Comparator|control group (group C)|the patients will receive placebo oral tablet 120 minutes prior to surgery, IV fentanyl 2µ/kg in 5 ml saline 5 minutes before intubation.
89371715|NCT02396836|Active Comparator|6 step hand hygiene technique|Hand decontamination with alcohol hand rub using the World Health Organisations 6 step technique
89371716|NCT02396836|Experimental|3 step hand hygiene technique|Hand decontamination with alcohol hand rub using the 3 step technique
89371717|NCT03671096|Experimental|Intrastromal TCA Inlay|Implant Intrastromal TCA using femto-second laser surgery It is expected to be carried out once only during the study duration
89371718|NCT03623360||Patients with liver cirrhosis|"The cohort includes patients who encompass the full clinical spectrum of liver function within cirrhosis.~The participants will undergo a full MRI protocol for liver screening including morphological imaging, fibrosis scoring tests based on relaxometry and diffusion maps, and our novel functional technique based on free breathing DCE-MRI."
89371719|NCT03628781|Experimental|mehealth portal with integrated behavioral tools|Patients in this arm will continue to use the mehealth for ADHD web-based software for ADHD care but will also have access to a module that allows parents and teachers to develop and implement behavioral interventions such as daily report cards online.
89371720|NCT03628781|Other|mehealth portal with no integrated behavioral tools|Patients in this arm will continue to use the mehealth for ADHD web-based software for ADHD care but will wait one year before getting access to the behavioral intervention features.
89371721|NCT03670940||COPD patients|COPD patients without bronchiectasis
89371722|NCT03670940||COPD and bronchiectasis patients|COPD patients with bronchiectasis
89371723|NCT02717078|Experimental|LoBAG Diet|Assignment to consume the LoBAG diet (30% carbohydrate, 30% protein, 40% fat; carbohydrates that are low in starch emphasized) for 12 weeks.
88844370|NCT06044571|Experimental|Responders to Prescriptive- Continue Prescriptive|The prescriptive strategy will continue among participants who responded to this intervention well initially, meaning that participants who lost greater than or equal to 2.5 percent (%) of their body weight using the prescriptive intervention. Participants will continue their diet and exercise programs that were initially tailored to them.
89371724|NCT02717078|Active Comparator|Control Diet|Assignment to consume the control diet (50% carbohydrate, 15% protein, 35% fat) for 12 weeks.
88844371|NCT06044571|Experimental|Non-responders to Prescriptive- Switch to Behavioral|Participants who lost less than 2.5 percent (%) of their body weight initially will be randomized to a different type of intervention. One possibility could be that participants switch first-line treatment from a prescriptive strategy to the alternative (behavioral) as participants may need motivation or problem-solving.
89371725|NCT03371251|Experimental|Phase 1b: BOS161721 20, 60, 120 mg|Participants will be randomized to receive a 20 milligram (mg), 60 mg, or 120 mg subcutaneous (SC) dose of BOS161721. Participants may receive a total of 7 SC monthly doses of BOS161721 on Days 0, 30, 60, 90, 120, 150, and 180, followed by safety follow-up visits on at Days 210, 240, and 270.
89371726|NCT03371251|Placebo Comparator|Phase 1b: Placebo 20, 60, 120 mg|Participants will be randomized to receive a 20 mg, 60 mg, or 120 mg SC dose of placebo. Participants may receive a total of 7 SC monthly doses of placebo on Days 0, 30, 60, 90, 120, 150, and 180, followed by safety follow-up visits on at Days 210, 240, and 270.
89371727|NCT03371251|Experimental|Phase 2: BOS161721|Participants will be randomized to receive a 120 mg SC dose of BOS161721 (as determined from Phase 1b of the study). Participants may receive a total of 7 SC monthly doses of BOS161721 on Days 0, 30, 60, 90, 120, 150, and 180, followed by safety follow-up visits on at Days 210, 240, and 270.
89371728|NCT03371251|Placebo Comparator|Phase 2: Placebo|Participants will be randomized to receive a 120 mg SC dose of placebo (as determined from Phase 1b of the study). Participants may receive a total of 7 SC monthly doses of placebo on Days 0, 30, 60, 90, 120, 150, and 180, followed by safety follow-up visits on at Days 210, 240, and 270.
89371729|NCT03370471|Experimental|Healthy Older Adults|"Participants complete all four interventions~Retrieval Practice + Moderate Intensity Exercise: Subjects will engage in 30 minutes of moderate-intensity cycling prior to word learning using Retrieval Practice (active retrieval during learning)~Retrieval Practice + Gentle Stretching: Subject will engage in 30 minutes of gentle upper- and lower- limb stretching prior to word learning using Retrieval Practice (active retrieval during learning)~Study Only + Moderate Intensity Exercise: Subjects will engage in 30 minutes of gentle stretching prior to word learning using Study Only (no active retrieval during learning)~Study Only + Gentle Stretching: Subjects will engage in 30 minutes of gentle stretching prior to word learning using Study Only (no active retrieval during learning)"
89371730|NCT03370471|Experimental|Individuals with Aphasia|"Participants complete all four interventions~Retrieval Practice + Moderate Intensity Exercise: Subjects will engage in 30 minutes of moderate-intensity cycling prior to word learning using Retrieval Practice (active retrieval during learning)~Retrieval Practice + Gentle Stretching: Subject will engage in 30 minutes of gentle upper- and lower- limb stretching prior to word learning using Retrieval Practice (active retrieval during learning)~Study Only + Moderate Intensity Exercise: Subjects will engage in 30 minutes of gentle stretching prior to word learning using Study Only (no active retrieval during learning)~Study Only + Gentle Stretching: Subjects will engage in 30 minutes of gentle stretching prior to word learning using Study Only (no active retrieval during learning)"
88844372|NCT06044571|Experimental|Non-responders to Prescriptive- Combination of Prescriptive and Behavioral|Participants who lost less than 2.5 percent (%) of their body weight early on will be re-randomized to a different type of intervention. One possibility could be that participants will have a combined prescriptive and behavioral intervention- three guideline-advised strategies that may be synergistic in a subset of participants requiring knowledge, and needing goal setting and problem-solving skills. This approach is available in multispecialty, tertiary care obesity clinics.
89180840|NCT00801983|Experimental|A|Subject receives typical keyboard first for 6 months and alternative keyboard second for 6 months
89180841|NCT00801983|Experimental|B|Subject receives alternative keyboard first for 6 months and typical keyboard second for 6 months
89534822|NCT03229447|Active Comparator|E-learning intervention|The E-learning intervention consists of two 20-minute e-learning modules that combine a didactic component with testimonials from respected professionals in the fields of addiction treatment and criminal justice. Module 1 describes the nature of opioid addiction and treatment modalities. Module 2 addresses specific criminal justice concerns of cost, acceptance, usefulness, and diversion, perceived obstacles to providing MAT access as described to us by Ohio criminal justice professionals in formative phase. All courts recruited for the study are exposed to E-Learning.
88844373|NCT06044571|Experimental|Responders to Behavioral- Continue Behavioral|The behavioral strategy will continue among participants who responded to this intervention well initially, meaning that participants who lost greater than or equal to 2.5 percent (%) of their body weight using the behavioral intervention.
88844374|NCT06044571|Experimental|Non-responders to Behavioral- Switch to Prescriptive|Participants who lost less than 2.5 percent (%) of their body weight early on will be re-randomized to a different type of intervention. One possibility could be that participants switch first-line treatment strategy to the alternative (prescriptive) as participants may need knowledge to support adherence.
88844375|NCT06044571|Experimental|Non-responders to Behavioral- Combination of Prescriptive and Behavioral|Participants who lost less than 2.5 percent (%) of their body weight early on will be re-randomized to a different type of intervention. One possibility could be that participants will have a combined prescriptive and behavioral intervention - three guideline-advised strategies that may be synergistic in a subset of participants requiring knowledge, and needing goal setting and problem-solving skills. This approach is available in multispecialty, tertiary care obesity clinics.
88844376|NCT06041867|Experimental|Agaricus bisporus group|Dietary supplement: 10 capsules containing 500 mg Agaricus bisporus powder each
88844377|NCT06041867|Placebo Comparator|Placebo group|Dietary supplement: 10 placebo capsules, capsules that do not contain Agaricus bisporus powder
88844378|NCT06038682||Argatroban anticoagulation|Study subjects in this group will receive Argatroban anticoagulation.
88844379|NCT06038682||Heparin anticoagulation|Study subjects in this group will receive Heparin anticoagulation.
89180842|NCT00914537||1|Human immunodeficiency virus (HIV) positive adult men who have sex with men that are members of KPNC (Kaiser Permanente Northern California) and do not have a current anal cancer diagnosis.
89180843|NCT05490368|Experimental|Bed mattress sensor system|The experimental group uses the new bed mattress sensor system for 6 months.
89180844|NCT05490368|No Intervention|Control Group|In the control group, participants do not use any of the following bedside fall-prevention tools: bed-exit alarm system, ultra low bed, and ripple bed during the same 6-month period.
89180845|NCT04114799|Active Comparator|Group A invasive haemodynamical measurement|No continuous infusion of fluids will be used intraoperatively. A defined amount of fluid (20 ml of Plasmalyte, Baxter) will be used to flush the anesthetics and other drugs only. Fluid bolus will be applied in case of protocol defined hypotension according to the value of systolic pressure variation SPV (Aisys GE). The value of SPV (tidal volume 6 ml/kg) above 8% will be used to predict fluid responsiveness. In case of fluid responsiveness, bolus of 2ml/kg of Plasmalyte will be given within 10 minutes. Boluses will be repeated in hypotensive patients if fluid responsiveness persists. Norepinephrine will be used in hypotensive patients without predicted fluid responsiveness.
89180846|NCT04114799|Experimental|Group B non-invasive haemodynamical measurement|No continuous infusion of fluids will be used intraoperatively. A defined amount of fluid (20 ml of Plasmalyte, Baxter) will be used to flush the anesthetics and other drugs only. Fluid management and the use of norepinephrine will follow a protocol based on the values of cardiac index level, systemic vascular resistance and systolic volume variation (SVV) (ClearSight, Edwards).
89180847|NCT05684991|Experimental|Treatment Group|One capsule of KSM-66 300 mg (contains Ashwagandha extract) two times a day, orally with water
89180848|NCT05684991|Placebo Comparator|Control Group|One capsule of Placebo two times a day, orally with water
89180849|NCT00587288|Experimental|Reslizumab 3 mg/kg|Reslizumab 3 mg/kg intravenous (IV) on Day 0 of each 28-day (+/- 7 days) cycle, for 4 cycles
89180850|NCT00587288|Placebo Comparator|Placebo|Saline placebo IV on Day 0 of each 28-day (+/- 7 days) cycle, for 4 cycles
89180851|NCT00800735|Experimental|Pegylated-interferon alfa-2a plus ribavirin|Participants received pegylated-interferon alfa-2a 180 µg/week subcutaneously plus ribavirin 1000 mg/day orally for patients weighing < 75 kg or 1200 mg/day for patients weighing ≥ 75 kg for 48 weeks.
89180852|NCT05324163|Experimental|X0002 spray group|X0002 spray 17.5mg, twice a day; Celecoxib placebo 200mg, once a day
89180853|NCT05324163|Active Comparator|Celecoxib capsule Group:|X0002 spray placebo 17.5 mg, twice a day; Celecoxib capsule 200mg, once a day
89180854|NCT05324163|Placebo Comparator|The placebo group|X0002 spray placebo 17.5 mg, twice a day; Celecoxib placebo 200mg, once a day
89180855|NCT00730158|Experimental|Arm A|irinotecan+ KD018
89180856|NCT00730158|Experimental|Arm B|irinotecan + placebo
89180857|NCT04104074|Experimental|Radiotherapy Plus Sintilimab|HCC Patients will be received radiotherapy and concurrent Sintilimab (PD-1 inhibitor)treatment.
89180858|NCT04114643|Active Comparator|Prothrombin Complex Concentrate|
89180859|NCT04114643|Active Comparator|Frozen Plasma|
89180860|NCT04114487|No Intervention|control 1|The control 1 group will not be subjected to any application except education.
89180861|NCT04114487|Active Comparator|control 2|The control 2 group will be the control group and will be taken to the balance training in addition to normal education.
89180862|NCT04114487|Experimental|intervention|In theintervention group, dual task balance training will be applied within the scope of cognitive rehabilitation.
89180863|NCT04084587|Experimental|Treated Group|"Group A: 15 patients rehabilitated with Retimax Vision Trainer, 10 consecutive sessions of 8 minutes each, performed twice a week in the best eye.~Exams performed before and after treatment:~BCVA (ETDRS)~Reading speed (MNREAD)~Contrast sensitivity (Pelli-Robson)~Microperimetry and analysis of fixation (OCT-SLO OPTOS)~QoL (VFQ-25)"
88844380|NCT06036147|Experimental|Pathway 1|All interventions: cf-CBT, PST & CM
88844381|NCT06036147|Experimental|Pathway 2|cf-CBT & PST
88844382|NCT06036147|Experimental|Pathway 3|cf-CBT & CM
88844383|NCT06036147|Experimental|Pathway 4|cf-CBT only
88844384|NCT06036147|Experimental|Pathway 5|PST & CM
88844385|NCT06036147|Experimental|Pathway 6|PST only
89399279|NCT02172638|Experimental|FAST-TRACK Group|Patients in this group will be managed according to an specifically designed FAST-TRACK protocol which will include: Preoperatory nutritional management and coaching by surgeon, anesthetist, nutritionist and specifically trained nurse personnel, reduced preoperatory fasting, avoiding use of intraabdominal drainages, specific anesthetic management to reduce intraoperative stress, avoiding use of Nasogastric tube, avoiding the need for major opioid in postoperatory analgesia and use of an standardized postoperatory management protocol directed to obtain an early oral intake and mobilization with a the goal of normal diet and deambulation in the 3rd day after surgery.
88844386|NCT06036147|Experimental|Pathway 7|CM only
88844387|NCT06036147|No Intervention|Pathway 8|No interventions
88844388|NCT06029244|Active Comparator|EyeControl-Pro assisted active intervention arm|The device will be placed on patient's heads. Once the device is properly positioned, patient's will undergo a training session/tutorial lasting 2-3 minutes to orient them to the device usage. Personalized family messages recorded by LARs or others will be played at regular intervals up to 5 times per day (between 08:00-18:00) (8 am to 6 pm). Personalized music/brown noise will be played for 15 minutes every 4 hours, which will be modulated according to your reactions/choices. A study team member will assess patient's mental status by asking thinking and memory questions twice a day (AM and PM). The device will perform the same assessments within 30 minutes of those performed by the study team. The device will be removed at 1800/2000 hrs to ensure adequate sleep. Patient's will be in this study arm for up to 7 days of start of study. The device will be removed on day 7 or sooner if patient's do not need ventilator support and standard care will continue as before device usage.
88844389|NCT06029244|Sham Comparator|Sham Control|The device will be placed on patient's heads. Once the device is properly positioned, patient's will undergo a training session/tutorial lasting 2-3 minutes to orient them to the device usage. Patient's will not receive any of the orientation or family messages and no music will be played through the earphones of the device. A study team member will assess patient's mental status by asking thinking and memory questions twice a day (AM and PM). The device will perform the same assessments within 30 minutes of those performed by the study team. The device will be removed at 1800/2000 hrs to ensure adequate sleep. Patient's will be in this study arm for up to 7 days of start of study. The device will be removed on day 7 or sooner if patient's do not need ventilator support and standard care will continue as before device usage.
89180864|NCT04084587|No Intervention|Control Group|"Group B: 9 patients control group without rehabilitation.~Exams performed twice, at the same time interval elapsed for the treated group:~BCVA (ETDRS)~Reading speed (MNREAD)~Contrast sensitivity (Pelli-Robson)~QoL (VFQ-25)"
89180865|NCT00918372||Extreme fitness|Female competitive long distance runners
89180866|NCT00918372||Control|Age and Risk matched controls
89180867|NCT00784550|Experimental|ADVAIR DISKUS® inhlaer Plus SPIRIVA® HANDIHALER® inhaler|Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID Plus Tiotropium Bromide 18 mcg QD
89180868|NCT00784550|Active Comparator|SPIRIVA® HANDIHALER® inhaler|Tiotropium Bromide 18mcg QD plus Placebo DISKUS BID
89180869|NCT02592564|Experimental|Psychological treatment|Psychological treatment during 9 weeks.
89180870|NCT04008875||Successful weaning/extubation|"Successful weaning will be defined as a patient who completes a planned 30-minute spontaneous breathing trial.~Successful extubation will be defined as a patient who completes a planned 30-minute spontaneous breathing trial and is not reintubated in the first 48 hours after extubation."
89180871|NCT04008875||Failed weaning/extubation|"Failed weaning will be defined as a patient who did not complete a planned 30-minute spontaneous breathing trial.~Failed extubation will be defined as a patient who did not complete a planned 30-minute spontaneous breathing trial, in the first 48 hours after extubation are reintubated, have unplanned non-invasive ventilation (NIV) or who have a tracheostomy."
89180872|NCT05659121|Experimental|EksoGT group|Participants in the intervention group will receive 12 sessions of robotic exoskeleton training incorporated into their conventional physiotherapy session.
89180873|NCT05659121|No Intervention|Control group|Participants in the control group will only undergo outcome measures assessment. They will continue with their conventional physiotherapy and the frequency and type of activity at physiotherapy will be recorded.
89180874|NCT00729690|Experimental|1 Multi-Dose Pregabalin|Group 1 (n=16, multi-dose pregabalin): patients receive pregabalin 150 mg orally 1 hour prior to surgery and then repeat 150 mg doses at 12 and 24 hours after initial dose.
89180875|NCT00729690|Experimental|2 single-dose pregabalin|Group 2 (n=16, single dose pregabalin): patients receive pregabalin 150 mg orally 1 hour prior to surgery, and then placebo doses at 12 and 24 hours after initial dose.
89180876|NCT00729690|Placebo Comparator|3 Placebo|Group 3 (n=16, placebo): patients receive matching placebo at the same 3 time points as Groups 1 and 2.
89180877|NCT04027829|Experimental|Dexmedetomidine|Intravenous infusion of dexmedetomidine for 50 min after surgery at intensive care unit
89180878|NCT02593344|Experimental|endopat|measure of endothelial function with endopat
89180879|NCT00784238|Experimental|Paliperidone|Paliperidone Extended-Release (ER) oral tablet will be administered once daily at a starting dose of 6 milligram (mg) for 24 weeks, wherein dose range will be 3 to 12 mg per day.
89180880|NCT00917982|Other|Vision therapy|
89180881|NCT02589873|Active Comparator|In-Person Diabetes Prevention Program|An in-person group delivery modality of a CDC recognized Diabetes Prevention Program (DPP), delivered by the Young Men's Christian Association (YMCA). This group receives lifestyle coaching in a group setting, meeting weekly for 16 weeks followed by 3 biweekly sessions, and 5 monthly maintenance sessions.
89180882|NCT02589873|Active Comparator|Online Diabetes Prevention Program|An online delivery modality of a CDC recognized Diabetes Prevention Program (DPP), delivered by Canary Health's Virtual Lifestyle Management program. This group completes online learning sessions weekly for 16 weeks followed by 8 monthly maintenance sessions.
89180883|NCT00729612|Experimental|Treatment (nab-paclitaxel, carboplatin)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes and carboplatin IV over 1-2 hours on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
89180884|NCT05684913|Experimental|Zinc granulate group|The patients in this group will receive a chair-side prepared surgical stent from Zn granulates on the palatal wound after FGG surgery.
89371731|NCT03709849|Experimental|experimental group|Intervention, dosage and frequency: drug: Bushen Culuan Decoction 13g tid and Clomiphene Citrate Tablets placebo 50mg qd; Dosage form: Bushen Culuan Decoction is dissolved medicine and Clomiphene Citrate Tablets placebo is tablets; Duration: the medicine will be taken from 5th day of a menstrual cycle, Bushen Culuan Decoction is taken for 14 days while Clomiphene Citrate Tablets placebo being taken for 5 days. Then patients stop taking the medicine until the 5th day of next menstrual cycle. If the patient doesn't have a regular menstrual cycle, the medicine will be taken from 5th day from vaginal bleeding caused by taking progesterone. Each treatment cycle contains 3 menstrual cycle. If the patient regains normal ovulation at the end of the first treatment cycle, she will reach the end of the whole treatment, and if not she will start the second treatment cycle. All treatment will be terminated after 2 treatment cycles.
89371732|NCT03709849|Active Comparator|control group|Intervention, dosage and frequency: drug: Clomiphene Citrate Tablets 50mg qd and Bushen Culuan Decoction placebo 13g tid; Dosage form: Clomiphene Citrate Tablets is tablet and Bushen Culuan Decoction placebo is dissolved medicine; Duration: the medicine will be taken from 5th day of a menstrual cycle, Clomiphene is taken for 5 days while Bushen Culuan Decoction placebo being taken for 14 days while. Then patients stop taking the medicine until the 5th day of next menstrual cycle. If the patient doesn't have a regular menstrual cycle, the medicine will be taken from 5th day from vaginal bleeding caused by taking progesterone. Each treatment cycle contains 3 menstrual cycle. If the patient regains normal ovulation at the end of the first treatment cycle, she will reach the end of the whole treatment, and if not she will start the second treatment cycle. All treatment will be terminated after 2 treatment cycles.
89371733|NCT05343325|Experimental|Low-dose Radiotherapy, Tislelizumab, Combined With Albumin-bound Paclitaxel and Cisplatin|Neoadjuvant therapy will be performed for a total of 2 cycles, with 21 days as a cycle, which includes: ① Low-dose radiotherapy: 1GY/1F, D1, D2, D8, D15, Q3W for two cycles, and the total dose of radiation in the two cycles will be GTV 8 Gy/8 F and GTVnd 8 Gy/8 F; ② Teilizumab: 200 mg D1, Q3W for two cycles; ③ Albumin-bound paclitaxel: 100mg/m2, D1, D8, D15, Q3W for two cycles; ④Cisplatin: 25mg/m2, D1, D8, D15, Q3W for two cycles.
89371734|NCT03709693||SternaLock Blu|All patients will receive SternaLock Blu for closure of full mid-line sternotomy.
89371735|NCT03709615|No Intervention|Wait list|Wait list condition with no active treatment, length of 10 weeks, with weekly measurements.
89371736|NCT03709615|Experimental|Intervention- active treatment|Internet delivered CBT for social anxiety disorder
89371737|NCT03349645|Experimental|AMPION™ 4 mL dose|4 mL intra-articular injection of AMPION™
89534823|NCT03229447|Experimental|Change Team Intervention|Half of the courts exposed to e-learning will be randomly assigned to a change team intervention. The change team will reinforce the information in the modules and provide instrumental assistance in linking courts to MAT providers and financial resources.
89534824|NCT03333083|Experimental|Raltegravir + Lamivudine|
88844390|NCT06024460|Experimental|Non-pharmacological treatment strategy|"Interventions: Non-pharmacological treatment include acupuncture, electroacupuncture, spinal manual therapy, and motion style acupuncture treatment.~Frequency: Not specified (Twice a week recommended) Duration: Eight weeks."
88844391|NCT06024460|Active Comparator|Pharmacological treatment strategy|"Interventions: Active pharmacological treatment involving prescription medication, injection therapy, or other pharmacological interventions.~Frequency: Not specified (Twice a week recommended) Duration: Eight weeks."
88844392|NCT06021457|Experimental|RBT-1|Single IV infusion prior to cardiac surgery
88844393|NCT06021457|Placebo Comparator|Placebo|Single IV infusion prior to cardiac surgery
89534825|NCT03093597|Active Comparator|virgin coconut oil|All subjects will apply virgin coconut oil to a previously randomize section of the skin on the left or right forearm.
89534826|NCT03093597|Active Comparator|virgin jojoba oil|All subjects will apply virgin jojoba oil to a previously randomize section of the skin on the left or right forearm
88844396|NCT06014931|Experimental|Telemedicine ICU Recovery Clinic|scheduled telemedicine study visits 3 weeks and 3 months after hospital discharge or return-to-home if discharged to another facility
88844397|NCT06014931|No Intervention|Standard Recovery Conditions (i.e., Control)|Control group participants will proceed with follow-up as determined by the discharging hospital team and directed to use the provided PICS guide to connect with commonly used resources.
88844398|NCT06012916||Treatment Resistant Depression + Esketamine Treatment|This is a group of individuals with treatment resistant depression receiving Esketamine treatment as prescribed by their physician during outpatient appointments over several weeks at the Interventional Psychiatry outpatient clinic at University of North Carolina at Chapel Hill (UNC). After signing the informed consent, electroencephalogram (EEG) will be recorded before and after Esketamine administration by the attending physician. The participant will perform a cognitive task before and after the Esketamine administration as well as complete self-scored questionnaire regarding depressive symptoms, treatment expectation and Esketamine side-effects. Clinical information like the duration of episode, medication or clinician-rated depression scores will be retrieved from the charting system.
88844399|NCT06008795|Active Comparator|Group 1 - Active - Active|Subjects randomized to Group 1 will receive an active PPF nerve block in Stage 1 followed by an active PPF nerve block in Stage 2 of the Double-Blinded Trial Phase
89534827|NCT03093597|Active Comparator|virgin almond oil|All subjects will apply virgin almond oil to a previously randomize section of the skin on the left or right forearm
88844400|NCT06008795|Other|Group 2 - Placebo - Active|Subjects randomized to Group 2 will receive a placebo PPF-injection in Stage 1 followed by an active PPF nerve block in Stage 2 of the Double-Blinded Trial Phase
88844401|NCT06008795|Placebo Comparator|Group 3 - Placebo - Placebo|Subjects randomized to Group 3 will receive a placebo PPF-injection in Stage 1 followed by a placebo PPF-injection in Stage 2 of the Double-Blinded Trial Phase
88844402|NCT06008470||covid-19|"Inclusion Criteria:~Literacy,~To be between the ages of 18-45,~To study at Kırıkkale University Faculty of Health Sciences~Volunteering to participate in the research,"
88844403|NCT06008470||control|
88844404|NCT06008197|Experimental|Finerenone|
88844405|NCT06008197|Placebo Comparator|Placebo|
89371738|NCT03678896|Experimental|CrewD Program approach|"The aim was to increase education about the disease by using narrative skills through the CrewD Program. The sessions were conducted by two group leaders: a health professional and a literature professor manager of creative writing groups.~Each session had a title, which parallels the classical structured educational approach (active comparator condition), which was known in advance by the subjects: a) Who I am in Diabetes?; b) Nutrition; c) The body where I live; d) Fears; e) Can attention change things?; and f) Roots.~Team leaders directed a discussion of different texts used in the sessions with the participants focusing on their feelings and on how the texts relate to themselves and to their diabetes. Patients were encouraged to participate and freely express their opinion."
89371739|NCT03678896|Active Comparator|Classical structured education|"Each session was 90 minutes long, with a similar internal structure in all of them. Each session included the following topics: a) Chronic Disease; b) Nutrition; c) Exercise; d) Complications; e) Self-management; and f) Diabetic foot. The sessions were held in a large room, in which the seats were arranged in circle. Every session was chaired by two healthcare providers, who worked as group leaders.~There was a different visual presentation in each session, with relevant theoretical information. A board with sheets of paper was available for use in the discussion along with brochures about the disease.~Patients were encouraged to actively participate and take part in group-problem solving. Group leaders guided the discussion by asking questions and encouraging the discussion."
89371740|NCT03349333|Experimental|pralatrexate|Vitamin B12 and folic acid will be taken concurrently with pralatrexate
88844408|NCT05994820|No Intervention|Control|These participants receive no intervention. No chatbot messaging. Usual care.
88844409|NCT05994820|Experimental|Vaccine Campaign|These participants will receive the Happy Baby Programme messages through a WhatsApp Chatbot. All messages will be narrowly focused on vaccine promotion.
89371741|NCT03349099|Active Comparator|Cook Flexor|ureteral access sheath
89371742|NCT03349099|Active Comparator|Boston Scientific Navigator HD|ureteral access sheath
89180885|NCT05684913|Active Comparator|Hemostatic agent group|The patients in this group will receive hemostatic agent sutured on the palatal wound after FGG surgery.
88844410|NCT05994820|Experimental|Vaccine++ Campaign|These participants will receive the Happy Baby Programme messages through a WhatsApp Chatbot. All messages will promote vaccines in conjunction with other health-promotion activities (e.g. nutrition, breastfeeding, etc.).
89180886|NCT04102202|Experimental|BOL-DP-o-05|
89180887|NCT04102202|Placebo Comparator|Placebo|
89180888|NCT02589795|Experimental|Group 1: ID/EP + IM|"0.6 mg DNA-C CN54ENV, intradermally with electroporation, at Weeks 0, 4 and 8. 2 mg DNA-C CN54ENV, intramuscularly without electroporation, at Weeks 0, 4 and 8.~50 µg CN54gp140, intradermally without electroporation, at Week 20."
88844411|NCT05993182|Active Comparator|Group-I|received 5mg of Ephedrine after the first hypotension [ Base line time or starting point is first hypotension]
88844412|NCT05993182|Active Comparator|Group-II|received 10mg of Ephedrine after the first hypotension [ Base line time or starting point is first hypotension]
88844413|NCT05993182|Active Comparator|Group-III|15mg bolus dose of ephedrine IV after the first hypotension [ Base line time or starting point is first hypotension]
88844414|NCT05990920|Experimental|Cohort 1|SNK02 will be administered as an IV infusion weekly for 8 weeks.
88844415|NCT05980299|Experimental|experimental|The experimental arm involves a brief positive interaction around a preferred activity or personal care routine.
88844416|NCT05974189||HFrEF patients treated with at least one GDMT and with vericiguat|"This study will use anonymized real-world data from HealthVerity open and closed Medical and Pharmacy Claims.~Adult patients with a diagnosis of HFrEF and received vericiguat added to at least one guideline directed medical therapy (GDMT), from January 1, 2021 through June 30, 2022 will be included in this retrospective cohort analysis."
88844417|NCT05974189||HFrEF patients treated with at least one GDMT, without vericiguat|"This study will use anonymized real-world data from HealthVerity open and closed Medical and Pharmacy Claims.~Adult patients with a diagnosis of HFrEF and received at least one GDMT (without vericiguat), from January 1, 2021 through June 30, 2022 will be included in this retrospective cohort analysis."
88844418|NCT05973851|Experimental|Major Depressive Disorder EIPT: second-line antidepressant + esketamine nasal spray|"Major depressive disorder randomized to EIPT: Switch to second-line antidepressant + esketamine nasal spray or (es)ketamine infusion. Antidepressant: Compound, brand, dosage, frequency and duration up to the investigator's discretion (in accordance with SmPC).~Esketamine nasal spray: 2 times per week for 4 weeks. Initial dose 28 mg, after that increases can be made with 28 mg per increase (up to 84 mg per week). This decision is up to the investigator's discretion (in accordance with SmPC).~(Es)ketamine infusion: performed twice weekly for 4 weeks. Compound, brand up to the investigator's discretion (in accordance with SmPC)."
88844419|NCT05973851|Active Comparator|Major Depressive Disorder TAU: second-line antidepressant|Subject with major depressive disorder, randomized to TAU: switch to second-line antidepressant. When randomized to second-line anti-depressants, this means participants will receive treatment as usual. The physician has the choice to administer any second-line anti-depressant. More specification is not possible, as this is a choice the physician makes with the participant based on the characteristic and preference of the participant (in line with standard clinical practice).
89180889|NCT02589795|Experimental|Group 2: ID + IM/EP|"0.6 mg DNA-C CN54ENV, intradermally without electroporation, at Weeks 0, 4 and 8.~2 mg DNA-C CN54ENV, intramuscularly with electroporation, at Weeks 0, 4 and 8. 50 µg CN54gp140, intradermally without electroporation, at Week 20."
89180890|NCT02589795|Experimental|Group 3: ID/EP + IM/EP|0.6 mg DNA-C CN54ENV, intradermally with electroporation, at Weeks 0, 4 and 8. 2 mg DNA-C CN54ENV, intramuscularly with electroporation, at Weeks 0, 4 and 8. 50 µg CN54gp140, intradermally without electroporation, at Week 20.
89180891|NCT02602418|Experimental|HIV Positive participants|Intervention; 90 HIV positive participants will be trained. Half the participants will have the Adaptive WM Cogmed training, and half will have the non-adaptive WM Cogmed training.
89180892|NCT02602418|Other|Seronegative particpiants|Intervention; 90 seronegative participants will be trained. Half the participants will have the Adaptive WM Cogmed training, and half will have the non-adaptive WM Cogmed training.
89180893|NCT05325801|Experimental|BMCA and GPRC5D dual target CAR-T cells （OriC321）|
89371743|NCT03348163|Experimental|Switch ART|Switch from current antiretroviral therapy (ART) to bictegravir + tenofovir alafenamide + emtricitabine (B/FTC/TAF) for 48 weeks
89371744|NCT03348163|Active Comparator|Continue Current ART|Continue current antiretroviral therapy (ART) therapy (which is emtricitabine plus tenofovir disoproxil fumarate or tenofovir alafenamide plus 3rd agent) for 48 weeks.
89371745|NCT03347695|Experimental|A new operation|Left Atrial Geometric Volume Reduction, Pulmonary Vein Island Isolation and Left Appendage Base Closure
89371746|NCT03347695|Other|A new operation (Selected pilot study)|Left Atrial Geometric Volume Reduction, Pulmonary Vein Island Isolation and Left Appendage Base Closure
89371747|NCT02892019|Active Comparator|Indacaterol acetate 75 μg o.d.|Indacaterol acetate 75 μg o.d. delivered via Concept1 inhaler
89371748|NCT02892019|Active Comparator|Indacaterol acetate 150 μg o.d.|Indacaterol acetate 150 μg o.d. delivered via Concept1 inhaler
88844420|NCT05973786|Experimental|Bipolar Depression EIPT: Switch to one of the following combinations:|Bipolar Depression randomized to EIPT: Switch to 1. one of the following: escitalopram, sertraline, or venlafaxine plus 2. two of the following: lithium, valproate acid or quetiapine
89180894|NCT00585546|Experimental|LVAD and Clenbuterol|
89180895|NCT00768248|Active Comparator|Active|3-7 days of perineural local anesthetic infusion
89371749|NCT03709537|Experimental|Mental Health Peer Workforce Support|Sites assigned to this group will engage in Co-Learning Collaborative, several trainings, and the creation of Implementation Teams--all part of the intervention and designed to support their peer workforce.
89371750|NCT03709537|No Intervention|Control Group|Sites assigned to this group will continue practice as usual and not receive any additional peer worker training or technical assistance.
89371751|NCT03710629||NSCLC patients with driver genes|NSCLC patients and driver genes
89371752|NCT03710551|Experimental|Experimental Infant Formula|Experimental Infant Formula with a new fat blend plus L. reuteri
89371753|NCT03710551|Active Comparator|Standard Infant Formula|Standard bovine milk-based infant formula.
89371754|NCT03365791|Experimental|PDR001+LAG525|PDR001 300 mg and LAG525 400 mg administered via i.v. infusion over 30 minutes once every 3 weeks (Q3W). LAG525 was given first followed by PDR001.
89371755|NCT03365011|Placebo Comparator|Placebo|"Placebo was defined as 50% nitrogen and 50% oxygen for 40 minutes.~Participants are blinded to the order of interventions administered. Participants have been informed prior to consent that one session will contain the nitrous oxide gas mixture, and the other session will contain the placebo gas mixture."
89371756|NCT03365011|Experimental|Nitrous oxide|"Nitrous oxide treatment was defined as 50% nitrous oxide and 50% oxygen for 40 minutes.~Participants are blinded to the order of interventions administered. Participants have been informed prior to consent that one session will contain the nitrous oxide gas mixture, and the other session will contain the placebo gas mixture."
89371757|NCT03627767|Experimental|PF-04965842 100 mg QD|Double-blind randomized treatment following open label run-in period.
89371758|NCT03627767|Experimental|PF-04965842 200 mg QD|Double-blind randomized treatment following open label run-in period.
89371759|NCT03627767|Placebo Comparator|Placebo QD|Double-blind randomized treatment following open label run-in period.
89371760|NCT03732365|Experimental|Investigational Group|Patients who are randomized to the investigational regimen will receive Ultrasonic Drug Delivery, which includes infusion of up to 2 grams of cefazolin in 100 mL saline followed by external ultrasound in addition to standard of care antibiotic treatment according to the antibiotic package insert instructions for the particular gram-positive pathogen over a period of no more than 14 days as well as standard of care adjunct therapy.
88844421|NCT05973786|Active Comparator|Bipolar Depression TAU: Switch to quetiapine plus lithium or valproate acid or lamotrigine|Bipolar Depression randomized to TAU: Switch to quetiapine plus lithium or valproate acid Compound, brand, dosage, frequency and duration up to the investigator's discretion (in accordance with SmPC).
88844422|NCT05973747|Experimental|Calcium Gluconate|2 grams of calcium gluconate, infused intravenously over 10 minute infusion beginning upon umbilical cord clamping
89180896|NCT00768248|Placebo Comparator|Placebo|3-7 days of perineural normal saline infusion
89180897|NCT04099550|Active Comparator|SMBG with lifestyle intervention|All participants receive a 12-week lifestyle intervention (diet and exercise). The control group was monitored self-monitoring blood glucose (SMBG) at least 2 times a day for initial 1-week.
89180898|NCT04099550|Experimental|RT-CGM with lifestyle intervention|All participants receive a 12-week lifestyle intervention (diet and exercise). The intervention group was monitored initial 1-week with a RT-CGM.
89371761|NCT03732365|Active Comparator|Comparator Group|Patients who are randomized to the comparator regimen will receive antibiotic according to the antibiotic package insert instructions for standard of care for the particular gram-positive pathogen over a period of no more than 14 days as well as standard of care adjunct therapy.
89371762|NCT03627065|Experimental|Parsaclisib|
89371763|NCT05665985|Experimental|Moringa Oliefera|Intervention with Dry Extract of Moringa Oleifera (trade name is Keloreena Ⓡ , registered number in National Food and Drug Registry: 193332021) The dose given is 1000 mg bi in day for 30 days.
89371764|NCT05665985|Placebo Comparator|Placebo|Capsules similar to moringa oliefera, which contain powder, have no pharmacological effect.
89371765|NCT03732287|Experimental|-5 degrees Celsius for 10 seconds|
89371766|NCT03732287|Experimental|-5 degrees Celsius for 20 seconds|
89371767|NCT03732287|Experimental|-10 degrees Celsius for 10 seconds|
89371768|NCT03732287|Experimental|-10 degrees Celsius for 20 seconds|
89371769|NCT05665907||children with vestibular dysfunction with hearing loss|children with vestibular dysfunction with hearing loss
89371770|NCT05665907||children with vestibular dysfunction with normal inner ear function|children with vestibular dysfunction with normal inner ear function
89180899|NCT00918801||Type 1 Diabetes Mellitus|Adolescents ages 13-18 with T1DM
88844423|NCT05973747|Active Comparator|Calcium Chloride|0.5mg calcium chloride, infused intravenously over 10 minute infusion beginning upon umbilical cord clamping
88844424|NCT05967455|Experimental|Cohort 1 Naive DENV1|Dengue-1-Virus-Live-Virus-Human-Challenge (DENV-1-LVHC), two doses (0.5 mL of 6.5 x 10^3 plaque forming units/milliliter (PFU/mL) inoculated subcutaneously on day 1 and day 181.
88844425|NCT05967455|Experimental|Cohort 2 Naive DENV3|Dengue-3-Virus-Live-Virus-Human-Challenge (DENV-3-LVHC), two doses (0.5 mL of 1.4 x 10^3 plaque forming units/milliliter (PFU/mL) inoculated subcutaneously on day 1 and day 181.
88844426|NCT05967455|Experimental|Cohort 3 Returning DENV1|Dengue-1-Virus-Live-Virus-Human-Challenge (DENV-1-LVHC), single dose (0.5 mL of 6.5 x 10^3 plaque forming units/milliliter (PFU/mL) inoculated subcutaneously on day 1.
88844427|NCT05967455|Experimental|Cohort 4 Returning DENV3|Dengue-3-Virus-Live-Virus-Human-Challenge (DENV-3-LVHC), single dose (0.5 mL of 1.4 x 10^3 plaque forming units/milliliter (PFU/mL) inoculated subcutaneously on day 1.
88844428|NCT05958875|Experimental|Schizophrenia early intensified treatment (EIPT): Switch to clozapine|Subject with schizophrenia, randomized to EIPT: Switch to clozapine. Brand, dosage, frequency and duration up to the investigator's discretion
88844429|NCT05958875|Active Comparator|Schizophrenia treatment as usual (TAU): second-line antispychotic|Subject with schizophrenia or related disorder randomized to TAU: switch to second-line antispychotic. Compound, brand, dosage, frequency and duration up to the investigator's discretion (in accordance with SmPC)
88844430|NCT05953688|Experimental|ESK-001 Dose Level 1|ESK-001 administered as an oral tablet
88844431|NCT05953688|Experimental|ESK-001 Dose Level 2|ESK-001 administered as an oral tablet
88844432|NCT05949177|Experimental|Graded Exposure and Mindfulness Meditation|The participants randomized to the GEMM group will complete 1) written exposure and 2) in vivo exposure and will be asked to rate their task specific fears after baseline tests. Tasks identified to be fearful will be used to develop the graded-hierarchy of fearful situations, and these fearful situations will be addressed in the GEMM. Participants will be instructed to watch a 30-min video that provides education on the rationale of cognitive behavioral therapies, specifically the benefits of exposure therapy and mindfulness meditation. Participants randomized into the GEMM group will also complete 5-weeks of Mobile Mindfulness Meditation. Participants randomized into the GEMM group will be guided through 4, 10-minute Mobile Mindfulness Meditation per week (20 total sessions) via the Headspace mobile application where they will learn the fundamentals of mindfulness meditation and how to apply mindfulness meditation to sports rehabilitation.
88844433|NCT05949177|Placebo Comparator|Waitlist Control|Participants will be randomized to a waitlist control group. Participants will receive an email stating that they will receive access to 5-weeks of Headspace after 5-weeks. Participants will be also asked to not change their normal routines or download apps for relaxation, meditation, or sleep during 5-weeks. After completion of the outcome assessments at 5-weeks, participants in this group will receive access to 5-weeks of Headspace.
88844434|NCT05945810|Experimental|sequence A|In cycle 1, subjects in sequence A receive a 50-mg single dose of TLL-018 extended-release tablet on day 1, and once daily for 5 consecutive days from day 3 onwards. After a 3-day washout period, subjects enter the cycle 2 at day 11 when they receive a 20-mg single dose of TLL-018 immediate-release tablet on the morning and another dose 12 hours later at night. From day 13 onward, they continue to receive 20 mg TLL-018 immediate-release tablets twice daily for 5 consecutive days.
88844435|NCT05945810|Experimental|sequence B|In cycle 1, subjects in sequence B receive a 20-mg single dose of TLL-018 immediate-release tablet on the morning on day 1 and another dose 12 hours later at night. From day 3 onward, they continue to receive 20-mg TLL-018 immediate-release tablets twice daily for 5 consecutive days. After 3 days of washout, subjects receive a 50-mg single dose of TLL-018 extended-release tablet on day 11 In cycle 2, and once daily for 5 consecutive days from day 13 onwards.
88844436|NCT05941247|Experimental|Hemay005 60 mg|The participant will receive single administration of Hemay005 tablets at dose of 60 mg on Day 1. Thereafter, those participants will receive Hemay005 tablets at dose of 60 mg for 7 consecutive days, which will be administrated twice daily.
89180900|NCT00918801||Non Controls|Healthy adolescents ages 13-18 without T1DM
88844437|NCT05929807|Experimental|TransCon CNP 100 mcg|TransCon CNP 100 mcg delivered once weekly by subcutaneous injection
88844438|NCT05929066|Experimental|Retatrutide Dose 1|Participants will receive retatrutide subcutaneously (SC).
88844439|NCT05929066|Experimental|Retatrutide Dose 2|Participants will receive retatrutide SC.
89180901|NCT02602028|Experimental|once daily dosage schema of colchicine|The once daily dosage group was prescribed as once daily at 08:00 a.m. (Total 1mg)
88844440|NCT05929066|Experimental|Retatrutide Dose 3|Participants will receive retatrutide SC.
88844441|NCT05929066|Placebo Comparator|Placebo|Participants will receive placebo.
89180902|NCT02602028|Experimental|twice daily dosage schema of colchicine|Twice daily dosage group received the treatment twice daily at 08:00 a.m. and 08:00 p.m. (Total 1mg)
89180903|NCT05684757|Active Comparator|Dietary Advice: Sweet Taste|Participants will be asked to reduce their free sugar intakes to less than 5% TEI. To aid with this, they will be asked to reduce their intakes of foods and drinks high in free sugars, and replace these with foods low in sugars, that remain high in sweet taste, eg. fruit, low-calorie sweetened foods and drinks. The intervention will be provided to participants in written form, in an opaque sealed envelope.
89180904|NCT05684757|Active Comparator|Dietary Advice: Taste|Participants will be asked to reduce their free sugar intakes to less than 5% TEI. To aid with this, they will be asked to reduce their intakes of foods and drinks high in free sugars, and replace these with foods low in sugars, that remain high in taste, eg. nuts, foods and drinks flavoured with herbs and spices. The intervention will be provided to participants in written form, in an opaque sealed envelope.
89371771|NCT02142738|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg, administered as intravenous (IV) infusion on Day 1 of each 21-day cycle for up to 35 cycles.
89534828|NCT03093597|Active Comparator|white petrolatum ointment|All subjects will apply white petrolatum ointment to a previously randomize section of the skin on the left or right forearm.
89534829|NCT03231007||Innovators|Maternity units that implemented the Care Bundle to the highest level (according to an NHS survey in 2015) are categorised as 'Innovators'.
88844442|NCT05911841|Experimental|LY3454738 Dose 1|Participants will receive LY3454738 subcutaneously (SC).
88844443|NCT05911841|Experimental|LY3454738 Dose 2|Participants will receive LY3454738 SC.
89371772|NCT02142738|Active Comparator|Paclitaxel+Carboplatin|Participants receive paclitaxel 200 mg/m^2 and carboplatin Area Under the Curve (AUC) 5 or 6, administered as IV infusion on Day 1 of each 21-day cycle for 4-6 cycles followed by optional pemetrexed 500 mg/m^2 every three weeks (Q3W) maintenance for participants with non-squamous histologies for the remainder of the study or until documented PD or participant discontinuation. If PD occurs, participants may be able to receive pembrolizumab Q3W in a second course of treatment.
89371773|NCT02142738|Active Comparator|Pemetrexed+Carboplatin|Participants receive pemetrexed 500 mg/m^2 and carboplatin AUC 5 or 6, IV infusion on Day 1 of each 21-day cycle for 4-6 cycles; participants with non-squamous histologies may then receive pemetrexed 500 mg/m^2 on Day 1 of each 21-day cycle as maintenance therapy for the remainder of the study or until documented PD or participant discontinuation. If PD occurs, participants may be able to receive pembrolizumab Q3W in a second course of treatment.
89371774|NCT02142738|Active Comparator|Pemetrexed+Cisplatin|Participants receive pemetrexed 500 mg/m^2 and cisplatin 75 mg/m^2, administered as IV infusion on Day 1 of each 21-day cycle for 4-6 cycles followed by optional pemetrexed 500 mg/m^2 Q3W maintenance for the remainder of the study or until documented PD or participant discontinuation. If PD occurs, participants may be able to receive pembrolizumab Q3W in a second course of treatment.
89371775|NCT02142738|Active Comparator|Gemcitabine+Carboplatin|Participants receive gemcitabine 1250 mg/m^2, administered as IV infusion on Days 1 and 8 of each 21-day cycle and carboplatin AUC 5 or 6, administered as IV infusion on Day 1 of a 21-day cycle, for 4-6 cycles or until documented PD or participant discontinuation. If PD occurs, participants may be able to receive pembrolizumab Q3W in a second course of treatment.
89371776|NCT02142738|Active Comparator|Gemcitabine+Cisplatin|Participants receive gemcitabine 1250 mg/m^2, administered as IV infusion on Days 1 and 8 of each 21-day cycle and cisplatin 75 mg/m^2, administered as IV infusion on Day 1 of each 21-day cycle for 4-6 cycles or until documented PD or participant discontinuation. If PD occurs, participants may be able to receive pembrolizumab Q3W in a second course of treatment.
88844444|NCT05911841|Experimental|LY3454738 Dose 3|Participants will receive LY3454738 SC.
88844445|NCT05911841|Placebo Comparator|Placebo|Participants will receive placebo.
89371777|NCT03617861|Experimental|Healthy Controls: Secretin Then Placebo|Healthy subjects first receive human Secretin 0.2 mcg/kg via IV over 1 min on Visit Day 1. After a 1 to 4 week washout period, they received the placebo treatment (normal saline, matching Secretin dose) via IV over 1 min on Visit Day 2.
89371778|NCT03617861|Experimental|Healthy Controls: Placebo Then Secretin|Healthy subjects first receive placebo treatment (normal saline, matching Secretin dose) via IV over 1 min on Visit Day 1. After a 1 to 4 week washout period, they received the human Secretin 0.2 mcg/kg via IV over 1 min on Visit Day 2.
89371779|NCT03617861|Experimental|Functional Dyspepsia: Secretin Then Placebo|Functional Dyspepsia subjects first receive human Secretin 0.2 mcg/kg via IV over 1 min on Visit Day 1. After a 1 to 4 week washout period, they received the placebo treatment (normal saline, matching Secretin dose) via IV over 1 min on Visit Day 2.
88844446|NCT05910268|Experimental|Group 1|Control (month 7-12) then NIATx+ECHO (month 13-36) then Maintenance (month 37-54)
88844447|NCT05910268|Experimental|Group 2|Control (month 7-18) then NIATx+ECHO (month 19-42) then Maintenance (month 43-54)
88844448|NCT05910268|Experimental|Group 3|Control (month 7-24 then NIATx+ECHO (month 25-48) then Maintenance (month 49-54)
88844449|NCT05899452|Experimental|Bubbles|Patient will receive bubble distraction method prior to and during the placement of their IV cannula
89371780|NCT03617861|Experimental|Functional Dyspepsia: Placebo Then Secretin|Functional Dyspepsia subjects first receive placebo treatment (normal saline, matching Secretin dose) via IV over 1 min on Visit Day 1. After a 1 to 4 week washout period, they received the human Secretin 0.2 mcg/kg via IV over 1 min on Visit Day 2.
89371781|NCT03732053|Experimental|GPR Intervention Research group|A total of 135 subjects with AD in the mild or moderate phase participated in the study from which 90 pertain to research group.The intervention implemented to the patients with AD was the Global Postural therapy which lasted about 30-40 min in repeated sessions of 2 meetings per week by making 48 sessions in total during a six month period.
88844450|NCT05899452|Active Comparator|Video|Patient will receive video distraction on an tablet computer prior to and during the placement of their IV cannula
88844451|NCT05899218|Experimental|Photo-Novella|Participants in the photo-novella intervention will be asked to take 12 photographs and write a caption for each photo based on two prompts.
88844452|NCT05899218|Experimental|Digital Storytelling|Participants in the digital storytelling intervention will be asked to create two videos (1-3 minutes each) based on two prompts.
88844453|NCT05896228|Experimental|Iber-KDd Combination Therapy|Prior to Iber-KDd combination therapy, participants will receive Acetaminophen, Diphenhydramine and Montelukast therapy per protocol. Participants will receive up to eight (8) 28-day cycles of combination Iberdomide (I), Carfilzomib (K), Daratumumab (D), and Dexamethasone (d) (Iber-KDd) therapy. Participants will receive Iber-KDd combination therapy for approximately 8 months. In the absence of disease progression, participants will continue on to Iber monotherapy. Participants with disease progression will discontinue study therapy but will continue to be followed for up to three (3) years after conclusion of Iber-KDd combination therapy.
89534830|NCT03231007||Early Adopters|Maternity units that implemented the Care Bundle to the second-highest level (according to an NHS survey in 2015) are categorised as 'Early Adopters'.
89534831|NCT03231007||Late Adopters|Maternity units that implemented the Care Bundle to the third-highest level (according to an NHS survey in 2015) are categorised as 'Late Adopters'.
88844454|NCT05896228|Experimental|Iber Monotherapy|After completion of Iber-KDd combination therapy, and In the absence of disease progression, participants will then receive up to twelve (12) 28-day cycles of Iberdomide (Iber) monotherapy. Participants will receive Iber monotherapy for up to 12 months or until disease progression. Participants will be followed for up to three (3) years after conclusion of Iber monotherapy. Total study participation is up to five (5) years.
88844455|NCT05889741|Experimental|Stellate Ganglion Block|One time administration of a stellate ganglion block
88844456|NCT05889741|Placebo Comparator|Sham SGB|One time administration
89371782|NCT03732053|No Intervention|Control Group|45 subjects of the study belongs to the control group which has not received the same treatment .
88844458|NCT05881226||Patients admitted to hospital/emergency department with neurological diseases|All clinical data, laboratory data and imaging data of patients at baseline and follow-up were collected, as well as blood and tissue samples that did not affect the diagnosis and treatment of patients after obtaining the consent of patients at different time points in the acute and chronic phases.
88844459|NCT05877885|Experimental|Targeted Cognitive Training Intervention|
88844460|NCT05877885|Active Comparator|General Cognitive Training Intervention|
88844461|NCT05877404||Gynecologic Oncologists|Gynecologic Oncologists and gynecologic oncology fellows-in-training from around the world, who are members of the Society of Gynecologic Oncology (SGO).
88844462|NCT05873699|Experimental|Hyperpolarized 13C-Pyruvate Magnetic Resonance Spectroscopic Imaging|"Participants will have the HP-MR scan within the 4 weeks before your scheduled surgery.~Hyperpolarized C-Pyruvate will be injected by vein during the scan. Your vital signs (temperature, blood pressure, heart rate and respiration [breathing]) will be monitored during the scan. The estimated time of the scan is a couple of minutes, but you may be in the room of the MRI for up to 30 minutes for preparation. The entire process of obtaining the MRI (and possible blood draw) may be up to half of a work day (not including your personal travel time)."
88844463|NCT05870787||Swede score colposcopy|Swede score colposcopy: includes application with acetic acid, supplemented with a systematic scoring system (the Swede score) including Lugols iodine, and collection of cervical biopsies.
88844464|NCT05870787||Conventional colposcopy|Conventional colposcopy: includes application with acetic acid and collection of cervical biopsies.
89180905|NCT05684757|Active Comparator|Dietary Advice: No taste|Participants will be asked to reduce their free sugar intakes to less than 5% TEI. To aid with this, they will be asked to reduce their intakes of foods and drinks high in free sugars, and replace these with foods low in sugars, that are low in taste, eg. foods and drinks that are plain-flavoured, wholegrains. The intervention will be provided to participants in written form, in an opaque sealed envelope.
89180906|NCT05486390|Experimental|Intervention|
89180907|NCT05486390|No Intervention|Control|
89180908|NCT04103684|Experimental|Patients will receive steroid pulse therapy|
89180909|NCT04103684|Active Comparator|Patients will receive low dose steroids|
89180910|NCT04084275|Experimental|experimental group|Levine's conservation model was used as the theoretical framework for this study. A literature review was used to determine the contents of the intervention program. A nursing care program which consisted of 8 sessions, the first of which was at the hospital and the others at the homes of puerpera and which were held at different times and lasted 12 weeks in total, based on Levine's Conservation Model was provided to the women in the intervention group. Each session lasted approximately 60-120 minutes, according to the educational and practical contents.The puerpera were given trainings on different subjects based on the module during each session. For these trainings, the investigators prepared, in the light of the literature data, leaflets containing information about breastfeeding, personal hygiene, fatigue, nutrition and pilates exercises
88844469|NCT05861986|Experimental|Risdiplam|Participants will receive risdiplam orally once daily for 72 weeks (Treatment Period). The Treatment Period will be followed by a 1-year Treatment Extension Period for a total study duration of 120 weeks (approximately 2.5 years) for each participant enrolled.
88844470|NCT05855967|Experimental|Ixekizumab|"Participants with moderate to severe plaque psoriasis.~Participants with active psoriatic arthritis.~Ixekizumab will be given by subcutaneous (SC) injection."
88844471|NCT05850520|Experimental|Higher Dose Regimen 1|Higher dose of aflibercept is administered with initial initiation doses intervals, followed by extension of treatment intervals and further adjustment of intervals according to treatment response.
88844472|NCT05850520|Experimental|Higher Dose Regimen 2|Higher dose of aflibercept is administered with initial initiation doses intervals, followed by extension of treatment intervals and further adjustment of intervals according to treatment response.
88844473|NCT05850520|Active Comparator|Standard of care|Aflibercept 2 mg is administered by standard treatment intervals, followed by adjustment of treatment intervals according to treatment response.
88844474|NCT05849077|Experimental|Sat75|FiO2 will be titrated every 30 seconds by 0.2-0.3 to achieve target SpO2 that approximates the 75th percentile SpO2 observed in healthy term newborns. Percentiles are roughly based on Dawson reference curves of healthy term infants after birth.
88844475|NCT05849077|Active Comparator|Sat50|FiO2 will be titrated every 30 seconds by 0.1-0.2 to achieve NRP recommended target SpO2 which approximates the 50th percentile SpO2 observed in healthy term newborns. Percentiles are roughly based on Dawson reference curves of healthy term infants after birth.
88844476|NCT05845905|Active Comparator|RIC group|Patients are treated with remote ischemic conditioning (RIC).
88844477|NCT05845905|Placebo Comparator|Sham RIC group|Patients are treated with sham remote ischemic conditioning (sham-RIC).
89180911|NCT04084275|No Intervention|control group|The puerpera in the control group received only the standard nursing care given after birth. Standard nursing care contain solely breastfeeding training. The puerpera in the control group were visited before they were discharged from the hospital to obtain their contact information and to administer them the pretest. A home visit at the end of postpartum month 3 was also planned and they were administered the posttest. After collecting the posttest data, the trainings given to the women in the intervention group on nutrition, sleep, fatigue and pilates exercises were also given to the women in the control group in consideration of the ethical dimension of the study; they were actively trained on pilates exercises by the investigator and the relevant leaflets were given to them by the end of their trainings.
89371783|NCT03614975|Active Comparator|Flucelvax inactivated influenza vaccine|Participants receiving inactivated Flucelvax influenza vaccine will receive 0.5 mL given intramuscularly
88844479|NCT05839652|Experimental|Study 1|Twenty-five participants will be asked to visit the laboratory on 6 occasions, for an open-label, dose escalation trial to determine the effect of midodrine and droxidopa on supine and seated blood pressure and on symptoms of autonomic dysreflexia and orthostatic hypotension.
88844480|NCT05839652|Experimental|Study 2|Determine the effects of compression garments, midodrine, and droxidopa, compared to placebo, on orthostatic hemodynamics, symptoms of AD and OH and reporting of fatigue and thermal comfort.
88844481|NCT05839054|Experimental|Roller Coasters, group 1|VR audio-visual users with Roller Coasters
89371784|NCT03614975|Active Comparator|Fluzone inactivated influenza vaccine|Participants receiving inactivated Fluzone influenza vaccine will receive 0.5 mL given intramuscularly
89371785|NCT03613649|Experimental|Treatment A|2 g of zoliflodacin administered orally on Day 1 of each dosing period, n=72
89371786|NCT03613649|Experimental|Treatment B|4 g of zoliflodacin administered orally on Day 1 of each dosing period, n=72
89371787|NCT03613649|Placebo Comparator|Treatment C|Placebo for zoliflodacin administered orally on Day 1 of each dosing period, n=72
89371788|NCT03613649|Active Comparator|Treatment D|400 mg of moxifloxacin administered orally on Day 1 of each dosing period, n=72
89371789|NCT04652856|Experimental|Electrical and Sham Electrical Brain Stimulation|Electrical brain stimulation and sham electrical brain stimulation will be administered to all participants.
88844482|NCT05839054|Experimental|Wild Dolphins, group 2|VR audio-visual users with Wild Dolphins
88844483|NCT05839054|No Intervention|group 3|did not use any additional equipment
89371790|NCT03096288|Experimental|Evolocumab|Evolocumab (Repatha) 420 mg s.c. single injection
89371791|NCT03096288|Placebo Comparator|Placebo|0.9% sodium chloride s.c. single injection
88844484|NCT05832905||Experiment (observational) group with Mobile and Wearable-assisted Case Management (MCM)|MCM involves the integration of mobile technology, such as smartphones and wearable devices, to supplement TAU. This approach is designed to provide additional support and monitoring to patients through the use of mobile applications and remote contact with healthcare professionals. In this study, MCM was implemented alongside TAU, with patients receiving pharmacotherapy, CBT, and mobile-assisted case management services. The MCM component consisted of regular contact with case managers via telephone and a dedicated mobile application.
88844485|NCT05832905||Control group (TAU)|TAU refers to the standard care provided to patients with panic disorder, which typically includes a combination of pharmacotherapy and psychological or behavioral treatment. In the context of this study, TAU consisted of pharmacological interventions, such as prescribing anxiolytic or antidepressant medications, and psychological interventions, primarily Cognitive Behavioral Therapy (CBT). The administration of TAU was conducted by qualified healthcare professionals who followed established clinical guidelines and treatment protocols to ensure the appropriate management of panic disorder symptoms.
88844486|NCT05830968|Experimental|Device treatment|Treatment area will include affected areas over the entire face (presence of comedones, pustules, papules, nodules and cysts
88844487|NCT05828849|Experimental|Low SES Population - Intervention|Participants receive the study intervention, composed of navigation, compensation, and personalization for study participants. The intervention will be administered in person to the participants recruited for the study and will be administered by peer navigators who will be trained on Motivational Interviewing (MINT) techniques.
88844488|NCT05828849|No Intervention|Low SES Population - No Intervention|Participants receive no intervention components of navigation, compensation, and personalization. Participants will receive their normal medical care through regular doctor visits without any intervention or personalization.
88844489|NCT05826353|Experimental|K-321|K-321 ophthalmic solution four times daily (QID) for 12 weeks followed by a two-week gradual dose taper phase and 38-week follow-up phase
89371792|NCT03731975|Active Comparator|CTZ Paste|Endodontic treatment with CTZ paste.
89371793|NCT03731975|Experimental|GP Paste|Endodontic treatment with Guedes-Pinto paste.
89371794|NCT05417256|Active Comparator|Tappa Blocker Group|After orotracheal intubation, Tappa endobronchial blocker will be inserted using a broncoscope by an experienced anaesthetist. Time from laryngoscopy to successful placement of the endobronchial blocker will be recorded.
89371795|NCT05417256|Active Comparator|Arndt Blocker Group|After orotracheal intubation, Arndt endobronchial blocker will be inserted using a broncoscope by the experienced anaesthetist. Time from laryngoscopy to successful placement of the endobronchial blocker will be recorded.
89371796|NCT05665829|Active Comparator|Microlaryngeal surgery (MLS)|For traditional MLS under general anesthesia, after intubation with microlaryngeal tube, a laryngoscope will be inserted transorally under direct vision and suspended. Laryngeal lesions are visualized with either microscope or endoscope, and removed with microsurgery instruments and sent for routine section
88844490|NCT05826353|Placebo Comparator|Placebo|Placebo ophthalmic solution QID for 12 weeks followed by a two-week gradual dose taper phase and 38-week follow-up phase
88844491|NCT05823974|Experimental|Flu mRNA_1_1 Group|Eligible Younger Adults (YA) participants receive a single dose of Flu mRNA (GSK4382276A) study intervention formulation 1 administered in Phase 1, at Day 1.
89371797|NCT05665829|Experimental|Awake transnasal laser-assisted surgery (TNLS)|For TNLS, a transnasal channel flexible laryngoscope is used with prior trans-nasal, trans-oral and trans-laryngeal local anesthesia application. A 445nm blue laser is introduced via a working channel of laryngoscope, with a lesion-specific laser setting. Biopsy can be performed by devascularizing and thinning the lesion down to a pedicle, then removed with biopsy forcep. During the operation, patient will receive continuous SpO2 monitoring with regular blood pressure monitoring. Patients are discharged on same day of procedure after close observation for 2 hours in day center.
89371798|NCT03731897|Experimental|prolotherapy|"Experimental: Plantar fasciitis injection with prolotherapy total 5cc. Procedure: Plantar fascia will be injected to the places where it adheres to the bone.~Drug: 5 cc 30% dextrose + 4 cc salin + 1cc 2% lidocaine. This treatment, known as regenerative injection therapy, stimulates tissue repair and reduces pain."
89371799|NCT03731897|Placebo Comparator|control|"Placebo Comparator: Plantar fasciitis injection with 9cc salin + 1 cc 2% lidocaine total 5cc.~Procedure: Plantar fascia will be injected to the places where it adheres to the bone.~Drug: 9 cc salin + 1cc 2% lidocaine. This treatment is safe for Plantar fasciitis injection."
89371800|NCT02072148|Experimental|Low Risk Group I|"Group I:~Complete resection (margins: tonsil >1mm, tongue >3mm, pT1-2, pN0-2B),~No LVI, no PNI, <3 positive nodes.~No ECS, No matted or Level >III,"
89371801|NCT02072148|Experimental|Intermediate Risk Group II|"Group II~Complete resection (margins: tonsil <1mm, tongue <1mm, pT1-2, pN0-2B),~+LVI, +PNI, <3 positive nodes. ≤1mm ECS."
89371802|NCT02072148|Experimental|High Risk Group IIIA|"3+ nodes, no ECS > 1mm~Contralateral or supraclavicular nodes"
89371803|NCT02072148|Experimental|High Risk Group IIIB|"Incomplete surgical resection with + surgical margins~≥ 1 mm ECS~Matted nodes"
89371804|NCT01735812|Experimental|symptomatic UF|
89371805|NCT05451030|Experimental|remote ischemic preconditioning|
89371806|NCT05451030|Sham Comparator|control group|
88844492|NCT05823974|Experimental|Flu mRNA_1_2 Group|Eligible YA participants receive a single dose of Flu mRNA (GSK4382276A) study intervention formulation 2 administered in Phase 1, at Day 1.
88844493|NCT05823974|Experimental|Flu mRNA_1_3 Group|Eligible YA participants receive a single dose of Flu mRNA (GSK4382276A) study intervention formulation 3 administered in Phase 1, at Day 1.
88844494|NCT05823974|Experimental|Flu mRNA_1_4 Group|Eligible YA participants receive a single dose of Flu mRNA (GSK4382276A) study intervention formulation 4 administered in Phase 1, at Day 1.
89371807|NCT03611075|Experimental|Low-Functioning Autism Spectrum Disorder (ASD) Children|Participants will be 5-12 years old, with Intelligence Quotient (IQ) scores between 50-70
89371808|NCT03611075|Experimental|High-Functioning ASD Children|Participants will be 5-12 years old, with IQ scores of 70 or above
89371809|NCT03611075|Experimental|Low-Functioning ASD Adolescents|Participants will be 13-17 years old, with IQ scores between 50-70
88844495|NCT05823974|Experimental|Flu mRNA_1_5 Group|Eligible YA participants receive a single dose of Flu mRNA (GSK4382276A) study intervention formulation 5 administered in Phase 1, at Day 1.
89371810|NCT03611075|Experimental|High-Functioning ASD Adolescents|Participants will be 13-17 years old, with IQ scores of 70 or above
89371811|NCT03611075|Experimental|Low-Functioning ASD Adults|Participants will be 18-45 years old, with IQ scores between 50-70
88844496|NCT05823974|Experimental|Flu mRNA_1_6 Group|Eligible YA participants receive a single dose of Flu mRNA (GSK4382276A) study intervention formulation 6 administered in Phase 1, at Day 1.
88844497|NCT05823974|Experimental|Flu mRNA_1_7 Group|Eligible YA participants receive a single dose of Flu mRNA (GSK4382276A) study intervention formulation 7 administered in Phase 1, at Day 1.
88844498|NCT05823974|Experimental|Flu mRNA_1_8 Group|Eligible YA participants receive a single dose of Flu mRNA (GSK4382276A) study intervention formulation 8 administered in Phase 1, at Day 1.
88844499|NCT05823974|Experimental|Flu mRNA_1_9 Group|Eligible YA participants receive a single dose of Flu mRNA (GSK4382276A) study intervention formulation 9 administered in Phase 1, at Day 1.
88844500|NCT05823974|Experimental|Flu mRNA_1_10 Group|Eligible YA participants receive a single dose of Flu mRNA (GSK4382276A) study intervention formulation 10 administered in Phase 1, at Day 1.
88844501|NCT05823974|Experimental|Flu mRNA_1_11 Group|Eligible YA participants receive a single dose of Flu mRNA (GSK4382276A) study intervention formulation 11 administered in Phase 1, at Day 1.
88844502|NCT05823974|Experimental|Flu mRNA_1_12 Group|Eligible YA participants receive a single dose of Flu mRNA (GSK4382276A) study intervention formulation 12 administered in Phase 1, at Day 1.
89180912|NCT02602184|Experimental|AR/101|Topically treatment with AR/101+Standard of Care once daily for up to 21 days. Daily treatment will include application of AR/101 drug to the wound and coverage with dressing (SoC). Subjects who are scheduled for an elective abdominoplasty at the practice of the principal investigator will have superficial split thickness wounds created on their abdomen according to protocol about 4 weeks prior to their scheduled abdominoplasty. A total of 8 split thickness (5X5 cm, 0.0254 mm in thickness) wounds will be distributed on the abdomen between the umbilicus and the suprapubic hairline. 4 of the wounds will be treated with AR/101.
89371812|NCT03611075|Experimental|High-Functioning ASD Adults|Participants will be 18-45 years old, with IQ scores of 70 or above
89371813|NCT03611075|No Intervention|Typically Developing (TD) Healthy Participant Children|Participants will be 5-12 years old
89371814|NCT03611075|No Intervention|TD Healthy Participant Adolescents|Participants will be 13-17 years old
89371815|NCT03611075|No Intervention|TD Healthy Participant Adults|Participants will be 18-45 years old
89371816|NCT05430204|Active Comparator|one-hour Glucose tolerance test (GCT)|
89371817|NCT05430204|Experimental|CGM screening|
89371819|NCT03095508|Experimental|Angal S (Arm A)|Patients received Angal S, topical spray [Menthol], 0,5 mg + 2 mg (Sandoz d.d., Slovenia), administered as three to five consecutive presses on the actuator button, 6-10 times per day, for a maximum 4 days or until full illness resolution
89371820|NCT03095508|Active Comparator|ANTI-ANGIN® FORMULA (Arm B)|"Patients received ANTI-ANGIN® FORMULA, topical metered spray, 0,12 mg + 0,24 mg (LLC Valeant, Russia) administered as three to five consecutive presses on the actuator button, 6-10 times per day, for a maximum 4 days or until full illness resolution"
89371821|NCT05416866|Experimental|TR group|ultrasound-guided transversus abdominis plane block with 20 ml mixture 0.20% ropivacaine + dexamethasone 5 mg and retrolaminar block with 30-40 ml mixture 0.20% ropivacaine + dexamethasone 5 mg
89371822|NCT05416866|Experimental|TQ group|ultrasound-guided transversus abdominis plane block with 20 ml mixture 0.20% ropivacaine + dexamethasone 5 mg and quadratus lumborum block with 30 ml mixture 0.20% ropivacaine + dexamethasone 5 mg
89371823|NCT03632538||Male|"20 male adult patients after cardiac surgery. Drawing of patients blood for measurement of biomarkers (penKid, adrenomedulin, C-terminal alpha-1 antitrypsin peptide) for AKI before and after cardiac surgery (times: 0, 6, 24, 72, 168 hours)."
89371824|NCT03632538||Female|"20 female adult patients after cardiac surgery. Drawing of patients blood for measurement of biomarkers (penKid, adrenomedulin, C-terminal alpha-1 antitrypsin peptide) for AKI before and after cardiac surgery (times: 0, 6, 24, 72, 168 hours)."
89371825|NCT05416242|Active Comparator|Fixed appliance|Patients in this group will be treated using traditional brackets alone.
89371826|NCT05416242|Experimental|Self-ligaton appliance|Patients in this group will be treated using self-ligating brackets alone.
88844503|NCT05823974|Active Comparator|Control Group|Eligible YA participants receive a single dose of Control 1 administered in Phase 1, at Day 1.
88844504|NCT05823974|Experimental|Flu mRNA_Ph2_1_YA Group|Eligible YA participants receive a single dose of Flu mRNA (GSK4382276A) study intervention formulation 1 administered in Phase 2, at Day 1.
88844505|NCT05823974|Experimental|Flu mRNA_Ph2_2_YA Group|Eligible YA participants receive a single dose of Flu mRNA (GSK4382276A) study intervention formulation 2 administered in Phase 2, at Day 1.
88844506|NCT05823974|Experimental|Flu mRNA_Ph2_3_YA Group|Eligible YA participants receive single dose of Flu mRNA (GSK4382276A) study intervention formulation 3 administered in Phase 2, at Day 1.
89371827|NCT05416242|Experimental|Self-ligaton appliance + piezocision|Patients in this group will be treated using self-ligating brackets associated with piezocision.
89180913|NCT02602184|Placebo Comparator|Placebo|Topically treatment with Placebo + Standard of Care once daily for up to 21 days. Daily treatment will include application of placebo control to the wound and coverage with dressing (SoC). Subjects who are scheduled for an elective abdominoplasty at the practice of the principal investigator will have superficial split thickness wounds created on their abdomen according to protocol about 4 weeks prior to their scheduled abdominoplasty. A total of 8 split thickness (5X5 cm, 0.0254 mm in thickness) wounds will be distributed on the abdomen between the umbilicus and the suprapubic hairline. 4 of the wounds will be treated with Placebo.
89180914|NCT00775268|Experimental|Group A - Participants Scanned at Baseline & After Chemotherapy|Patients undergo 3'-deoxy-3'-[18F] fluorothymidine (FLT) and fluorodeoxyglucose F 18 (FDG) PET/CT scans at baseline, after 2 courses of chemotherapy, and after completion of chemotherapy. Patients with residual FDG-positive mass after completion of therapy may be enrolled in group B.
88844507|NCT05823974|Active Comparator|Control_Ph2_YA Group|Eligible YA participants receive single dose of Control 1 vaccine administered in Phase 2, at Day 1.
88844508|NCT05823974|Experimental|Flu mRNA_Ph2_1_OA Group|Eligible OA participants receive a single dose of Flu mRNA (GSK4382276A) study intervention formulation 4 administered in Phase 2, at Day 1.
88844509|NCT05823974|Experimental|Flu mRNA_Ph2_2_OA Group|Eligible OA participants receive single dose of Flu mRNA (GSK4382276A) study intervention formulation 5 administered in Phase 2, at Day 1.
89371828|NCT00973830|Experimental|Carve-In|Patients in this arm are given the Diabetes Guide and engage in six sessions of brief counseling with a nurse or medical assistant from their clinic. Counseling focuses on behavioral changes patients can make to improve their diabetes.
89371829|NCT00973830|Experimental|Carve-Out|Patients in this arm are given the Diabetes Guide and engage in six sessions of brief counseling over-the-phone with a diabetes health educator stationed in Chicago, IL. Counseling focuses on behavioral changes patients can make to improve their diabetes.
88844510|NCT05823974|Experimental|Flu mRNA_Ph2_3_OA Group|Eligible OA participants receive single dose of Flu mRNA (GSK4382276A) study intervention formulation 6 administered in Phase 2, at Day 1.
89371830|NCT00973830|No Intervention|Control|Patients in this arm receive standard care. They receive no Diabetes Guide or brief counseling sessions
89371831|NCT03607487|Experimental|Cohort 1|INCB054707 at the Cohort 1 dose or placebo.
89371832|NCT03607487|Experimental|Cohort 2|INCB054707 at the Cohort 2 dose or placebo.
89371833|NCT03607487|Experimental|Cohort 3|INCB054707 at the Cohort 3 dose or placebo.
89371834|NCT03731741|Experimental|treatment group|Group I: 29 patients (25 completed the study) that received the study agent (400mg of oral pentoxifylline daily for 6 months.), besides the appropriate weight-based dose of ESA (60-150I.U/kg/wk).
89371835|NCT03731741|No Intervention|control group|Group II: 28 patients (25 completed the study) who did not receive pentoxifylline but they received the appropriate dose of ESA. They were used as a control group and compared to group1 concerning the primary and the secondary outcomes.
89180915|NCT00775268|Experimental|Group B - Participants Scanned in the Evaluation of Residual Masses After Therapy|Patients who have completed treatment in whom FDG-PET shows a remaining tumor mass undergo an FLT PET/CT scan . Patients also undergo a biopsy or fine-needle aspiration, if clinically indicated.
89371836|NCT03736187|Experimental|Cephalexin|Group a will receive cephalexin 1gm before skin incision intravenous
89371837|NCT03736187|Experimental|Cephalexin &metronidazole|Group b will receive cephalexin 1gm intravenous plus 1gm metronidazole rectally before skin incision
89371838|NCT03731663|Experimental|Appetizing Food exposure group|Participants allocated to this group will watch a 3-minute video presenting a series of pictures of appetizing foods eaten in facilities in a tourist destination. An audio of a young adult describing herself eating these foods during a trip to London will be played.
89371839|NCT03731663|Sham Comparator|Control content watching group|Participants allocated to this group will watch a 3-minute video presenting a series of control pictures of tourist attractions in London. An audio of a young adult describing herself visiting these sites during a trip will be played.
89371840|NCT03605693|Active Comparator|Early Psychological Intervention|Those assigned to Early Psychological Intervention will receive Written Exposure Therapy, a 5 session treatment in which participants write about their trauma event in a specified manner.
88844511|NCT05823974|Active Comparator|Control_Ph2_OA Group|Eligible OA participants receive a single dose of Control 2 vaccine administered in Phase 2, at Day 1.
88844512|NCT05817344|Experimental|3-Week Baseline|Participants in this arm are randomized to a 3-week baseline period with repeated weekly assessment after the initial intake. Following the 3-week baseline, participants receive 5 weekly sessions of Written Exposure Therapy - Integrated (WET-I) followed by a 4-week follow-up phase with repeated weekly assessments.
88844513|NCT05817344|Experimental|5-Week Baseline|Participants in this arm are randomized to a 5-week baseline period with repeated weekly assessment after the initial intake. Following the 5-week baseline, participants receive 5 weekly sessions of Written Exposure Therapy - Integrated (WET-I) followed by a 4-week follow-up phase with repeated weekly assessments.
89371841|NCT03605693|No Intervention|Usual care|Those assigned to usual care will complete study assessments but will not be referred to any psychological treatment
89371842|NCT03736109||Group I:|Thirty patients with knee osteoarthritis taking topical Copper-Albumin Complex cream
89180916|NCT00775190|Active Comparator|Ortho tricyclen™|Participant Randomized to Ortho tricyclen 1 tablet by mouth Daily
89371843|NCT03736109||Group II:|Thirty patients with knee osteoarthritis taking oral chondroprotective drugs
88844514|NCT05811403|Experimental|EGCG as a flushing fluid, MTA as a pulp capping material|
88844515|NCT05811403|Experimental|EGCG as a flushing fluid, Premixed BC putty as a pulp capping material|
89371844|NCT03605303|Active Comparator|CONTROL- etafilcon A current molding|1-Day ACUVUE® MOIST
88844516|NCT05811403|Experimental|NaOCl as a flushing fluid, Premixed BC putty as a pulp capping material|
88844517|NCT05811403|Active Comparator|NaOCl as a flushing fluid, MTA as a pulp capping material|
89180917|NCT00775190|Active Comparator|Trinessa™|Participant Randomized to Trinessa 1 tablet by mouth Daily
89371845|NCT03605303|Experimental|TEST- etafilcon A novel molding|Investigational Contact Lens
89371846|NCT03735953|Experimental|Retroflexion arm|Retroflexion in the total colon and slow withdrawal to the rectum and record all visible colon polyps and other colon related diseases
88844518|NCT05810259|Experimental|Mindfulness|Participants will take part in 7 repeating digital mindfulness modules using the Caravan Wellness App.
88844519|NCT05810259|Experimental|Light to Moderate Physical Activity|Participants will take part in 7 repeating light to moderate physical activity digital wellness modules using the Caravan Wellness App.
88844520|NCT05810259|No Intervention|Control|A no intervention group that will not be using the Caravan Wellness App.
88844521|NCT05804175||Post surgical (non-cardiac) PACU patients with anticipated overnight stay.|"In this study investigators will recruit patients that meet the following criteria:~Inclusion Criteria:~≥18 years old undergoing non-cardiac surgery~Post-operative patients admitted to the PACU and expected to stay in the hospital for at least overnight~Receiving supplemental oxygen via face mask in the PACU~On continuous SpO2 saturation monitoring~Receiving standard postoperative of care~Exclusion Criteria:~Requirement for any form of postoperative invasive ventilatory support~Patients receiving only local or topical anesthesia~Day/outpatient surgery~Unable to cooperate with the application of the study device~Surgical/nursing/anesthesia staff suggest no study-related monitoring because of medical situation"
88844522|NCT05801003|Experimental|Study group|Pre-dilation with cutting balloon followed by ASES implantation.
89180918|NCT00479557|Active Comparator|1|arm 1: ACC-001 (Vanutide Cridificar)+ QS-21
89180919|NCT00479557|Active Comparator|2|arm 2: ACC-001
89180920|NCT00479557|Placebo Comparator|3|arm 3: QS-21
89180921|NCT00479557|Placebo Comparator|4|Drug: Phosphate Buffered Saline (PBS)
89371847|NCT03735953|No Intervention|Forward view arm|Colonoscope is slowly withdrawn from the proximal colon to the the rectum have a forward view and record all visible colon polyps and other colon related diseases
89371848|NCT03731507|Experimental|Range of motion in upper extremity|Assessment of shoulder: flexion/extension, abduction/adduction, internal/external rotation, elbow flexion/extension, hip: flexion/extension, abduction/adduction, internal/external rotation, knee: flexion/extension, ankle: dorsal flexion/plantar flexion
89371849|NCT03604523|Active Comparator|Dilation by Balloon|Esophageal dilation by balloon device.
89371850|NCT03604523|Active Comparator|Dilation by Semi-rigid Savary|Esophageal dilation by semi-rigid savary device.
89371851|NCT03621059|Experimental|Behavioral Therapy with TS|habit reversal training (HRT)
89371852|NCT03621059|No Intervention|observational|observational and usual care Pyridoxine(50mg)
89371853|NCT03731429|Experimental|Intervention|Group that receives a 1 mg/kg single bolus of 2% IV lidocaine
89371854|NCT03731429|Placebo Comparator|Placebo|group that receives 0.9% saline solution
89371855|NCT03735641||postoperative|Expanded Pedicled Deltopectoral Flap is a type of surgical flap that has been cut away from surrounding areas for transplantation.The postoperative patients are studied . Tested sensory recovery,skin color and Skin elasticity
89371856|NCT03602339|Experimental|Arm 1_Suspected CNS-lesion|Patients with suspected or confirmed CNS-lesions underwent unenhanced MRI, and contrast-enhanced MRI after gadoterate injection.
89180922|NCT00774800|Experimental|First Humalog+PH20, then Humalog, Humulin-R+PH20, Humulin-R|"Humalog + Recombinant human hyaluronidase PH20 (rHuPH20) (Intervention 1): 24 units (U) of rHuPH20 per unit of Humalog, injected subcutaneously (SC), for up to 3 visits until an appropriate dose was identified.~Humalog alone (Intervention 2): a single SC injection of the appropriate identified dose of Humalog, delivered before a liquid meal.~Humulin-R + rHuPH20 (Intervention 3): 24 U of rHuPH20 per unit of Humulin-R, injected SC, for up to 2 visits until an appropriate dose was identified.~Humulin-R alone (Intervention 4): a single SC injection of the appropriate identified dose of Humulin-R, delivered before a liquid meal.~Appropriate dose of either Humalog or Humulin-R was that at which blood glucose following a liquid meal was <160 milligrams per deciliter (mg/dL) for more than 30 minutes during the first 4 hours after injection and never fell below 60 mg/dL.~All dose finding visits and interventions were separated by 3-10 days."
89371857|NCT03602339|Experimental|Arm 2_Confirmed CNS-lesion|Patients with gadoterate-confirmed CNS-lesions (subgroup of Arm 1) underwent a second unenhanced MRI, and contrast-enhanced MRI after gadobutrol injection.
89371858|NCT03735485|Experimental|Group I|The control group. Participants in this group received only conventional physiotherapy. Number of the participants were 14.
89371859|NCT03735485|Experimental|Group II|The shoulder mobilization group. Participants in this group received conventional physiotherapy and shoulder joint mobilization techniques. Number of the participants were 15.
89371860|NCT03735485|Experimental|Group III|The Proprioceptive Neuromuscular Facilitation (PNF) group. Participants in this group received conventional physiotherapy and PNF exercises. Number of the participants were 15.
89371861|NCT03653429|Active Comparator|Tranexamic acid group|10mg/kg intravenous tranexamic
89371862|NCT03653429|Placebo Comparator|Normal Saline group|10mg/kg intravenous normal saline
89371863|NCT03601715|Active Comparator|Coplanar|Electrode placed side by side on the same aspect of the right tight.
89371864|NCT03601715|Active Comparator|Contraplanar|Electrode placed over opposite aspects of the right tight.
89371865|NCT03601715|Active Comparator|Longitudinal|One electrode is placed at each end of the limb in opposite aspects of the tight.
89371866|NCT03735407|Experimental|C-Scan procedure|Subjects who are at high or at average risk for developing CRC and who are scheduled for optical colonoscopy will undergo C-Scan procedure
89371867|NCT03731117|Experimental|FST|FUROSEMIDE STRESS TEST
88844523|NCT05801003|Active Comparator|Control group|Pre-dilation with a standard balloon (semi-compliant or non-compliant) followed by ASES implantation.
88844524|NCT05797727|Experimental|LifeChamps Platform|Participants will be asked to use the LifeChamps platform and will be provided with the study equipment.
88844525|NCT05797727|Experimental|LifeChamps Platform HCP|Participating Healthcare professionals will be asked to use the LifeChamps Dashboard
88844526|NCT05795699|Experimental|K-321|K-321 ophthalmic solution four times daily (QID) for 12 weeks followed by a two-week gradual dose taper phase and 38-week follow-up phase
88844527|NCT05795699|Placebo Comparator|Placebo|Placebo ophthalmic solution QID for 12 weeks followed by a two-week gradual dose taper phase and 38-week follow-up phase
89371868|NCT03735329|Experimental|Pulse oximetry monitoring|
89371869|NCT03735251||Left Ventricular Diastoic Dysfunction Classification|normal diastole pattern：E/A>1，DT 160~220 ms，S/D >1，AR 0.22-0.32m/sec，E/e'< 8 diastolic dysfunction pattern Impaired relaxation pattern：E/A< 1，DT > 220 ms，S/D > 1，AR 0.21-0.28 m/sec，E/e'<10 Pseudo-normalization pattern：E/A> 1，DT 150~210 ms，S/D < 1，AR ≥0.35m/sec，E/e'≥ 10 Restrictive pattern：E/A ≥ 2，DT < 150 ms，S/D <1，AR ≥0.25m/sec，E/e'≥10
89371870|NCT03735173|Active Comparator|Pegged through SP|Primary anatomic shoulder arthroplasty with implantation of a cemented all-polyethylene pegged glenoid component through a Subscapularis Peel (SP) manipulation.
89371871|NCT03735173|Active Comparator|Pegged through ST|Primary anatomic shoulder arthroplasty with implantation of a cemented all-polyethylene pegged glenoid component through subscapularis tenotomy (ST) manipulation.
89371872|NCT03735173|Active Comparator|Keeled through SP|Primary anatomic shoulder arthroplasty with implantation of a cemented all-polyethylene keeled glenoid component through a Subscapularis Peel (SP) manipulation.
89371873|NCT03735173|Active Comparator|Keeled through ST|Primary anatomic shoulder arthroplasty with implantation of a cemented all-polyethylene keeled glenoid component through subscapularis tenotomy (ST) manipulation.
89371874|NCT05665673||Study Group|Sociodemographic information about the stroke patients included in the study will be obtained and some physical tests will be performed.
89371875|NCT03731039||SURGICAL PROCEDURES ASSOCIATED WITH SLIGHT TISSUE DAMAGE|
89371876|NCT03731039||SURGICAL PROCEDURES ASSOCIATED WITH MODERATE TISSUE DAMAGE|
89371877|NCT03731039||SURGICAL PROCEDURES ASSOCIATED WITH SUBSTANTIAL TISSUE DAMAGE|
89371878|NCT03594227|Active Comparator|400mg BID (Low dose)|ATI-501 low dose - oral administration
89371879|NCT03594227|Active Comparator|600mg BID (Mid dose)|ATI-501 mid dose - oral administration
89371880|NCT03594227|Active Comparator|800mg BID (High dose)|ATI-501 high dose - oral administration
89371881|NCT03594227|Placebo Comparator|Placebo|Placebo - oral administration
89371882|NCT03098550|Experimental|Immunotherapy Combination|TNBC and PAC participants who are deriving clinical benefit will continue to be treated with the nivolumab plus daratumumab combination therapy
89371883|NCT03098550|Experimental|Nivolumab Monotherapy|NSCLC patients who are deriving clinical benefit will be treated with nivolumab monotherapy
89371884|NCT05039190|Active Comparator|Experimental: HBM9161 (680mg )|HBM9161 680mg; First treatment period: Subcutaneous injection, QW for 6 doses; Second treatment period: Subcutaneous injection, QW for 6 doses
89371885|NCT05039190|Placebo Comparator|Placebo Comparator: Placebo|Placebo; First treatment period: Subcutaneous injection, QW for 6 doses; Second treatment period: Subcutaneous injection, QW for 6 doses
89371886|NCT03095118|Experimental|Daratumumab|Subjects will receive daratumumab intravenously at a dose of 16 mg/kg once weekly for 8 weeks followed by once every 2 weeks for 8 additional doses
89371887|NCT02696902|Experimental|MEDI3902 500 mg|Participants will receive a single intravenous (IV) dose of 500 mg MEDI3902.
89371888|NCT02696902|Placebo Comparator|Placebo|Participants will receive a single IV dose of placebo matched to MEDI3902.
89371889|NCT02696902|Experimental|MEDI3902 1500 mg|Participants will receive a single IV dose of 1500 mg MEDI3902.
89371890|NCT05386758|Experimental|Panel A - Severe Renal Impairment Group|Participants with severe renal impairment will receive a single oral 800 mg dose of molnupiravir.
89371891|NCT05386758|Experimental|Panel B - Healthy Control Group|Participants in the healthy mean matched control group will receive a single oral 800 mg dose of molnupiravir.
89371892|NCT01567878||ankylosing spondylitis|It will be held ultrasound exam in enthesis and joints in patients with ankylosing spondylitis and healthy subjects
89371893|NCT01567878||Healthy pelople|It will be held ultrasound exam in enthesis and joints of healthy subjects
89371894|NCT03169114|Active Comparator|Amikacin injection|Antibiotic Non-Operative Management Strategy
89371895|NCT03169114|Active Comparator|Appendicectomy|Surgery Management Strategy
89371896|NCT03169270|Experimental|COPD training group|COPD were required to be clinically stable at the time of study without episodes of exacerbation or oral steroid treatment in the previous four months. All COPD patients were on bronchodilators and inhaled corticosteroids. No patient presented severe co-morbidities. The intervention consists in an 8-week programe of exercise training.
89371897|NCT03169270|Active Comparator|Healthy training group|Healthy sedentary age-matched subjects were recruited from the outpatients' clinics of our hospital. The intervention consists in an 8-week programe of exercise training.
89371898|NCT04602936|Active Comparator|Solriamfetol|All medication will be 37.5 mg encapsulated soriamfetol tablets or matching encapsulated placebo tablets supplied in numbered containers for dispensing to patients. The minimum dose of solriamfetol during the trial will be 37.5 mg/day; the maximum dose will be 150 mg/day. At the Baseline Visit (Visit 0), participants will be instructed to take one capsule of solriamfetol 37.5 mg or matching placebo in the morning for the first 7 days. Thereafter, at Visit 1, solriamfetol or placebo will be increased to 75 mg/day, if tolerated. Beginning on day 15 (Visit 2), solriamfetol or placebo will be increased to 150 mg/day, if tolerated. Study medication dosage may be decreased, or a scheduled increase may not be made, because of side effects. Study medication will be administered as a single daily dose in the morning.
89371899|NCT04602936|Placebo Comparator|Placebo|Placebo (i.e., inactive compound for comparison)
89371900|NCT02396602|Experimental|Intervention|After completing baseline the baseline questionnaire, women randomized to the intervention group will receive an iPad, along with a brief tutorial on iPad navigation, and use the miPlan app for up to 15 minutes. They will complete a post-intervention survey before proceeding to standard of care contraceptive counseling.
89371901|NCT02396602|No Intervention|Control|After completing baseline the baseline questionnaire, women randomized to the control arm will proceed to standard of care contraceptive counseling.
89371902|NCT02694562|Experimental|40um Embozene TANDEM Microspheres|40um Embozene TANDEM Microspheres loaded with Irinotecan (up to 150 mg)
89371903|NCT02874534|Experimental|Behavioral Activation|Treatment will consist of 15 weekly 45-minute sessions. Session 1 provides orientation and psychoeducation on anhedonia, and activity monitoring is introduced. Sessions 2-3 include structured values assessments of 10 life areas to enhance motivation for sustained behavior change and to clarify goals. Following goals clarification, an activity hierarchy is developed, establishing a set of idiographic behavioral targets across life areas prioritized by ease of implementation to scaffold task engagement during the course of treatment.
89371904|NCT02874534|Active Comparator|Mindfulness Treatment|BATA will be compared to mindfulness based cognitive therapy (MBCT), chosen because its mechanisms of action are hypothesized to impact different brain mechanisms than BATA. Mindfulness is nonjudgmentally bringing awareness and acceptance to one's present-moment experience. MBCT will be administered in an individual format. The MBCT protocol will be modeled on the session outlines presented in Wahbeh et al., 2014. Treatment will be compromised of 15 weekly 45-minute sessions.
89371905|NCT02396446||Intervention group|Inpatients at CSMC whose abdominal acoustic sounds will be measured using the AbStats device.
89180923|NCT00439309|Experimental|VascuSeal|Consists of two liquids that when mixed together in situ rapidly cross-link to form a biocompatible absorbable sealant that is tissue adherent. These liquids are sprayed onto tissues using the Dual Liquid Applicator. The formed Sealant remains intact for approximately 2 to 7 days. During this period the Sealant undergoes hydrolysis where it is absorbed into the circulatory system and is excreted through the kidneys.
89371906|NCT02396680||TR006 Subjects|Subjects that have previously been randomised into study TR006
89371907|NCT03115762|Experimental|ASKB1202|Subject to receive one intravenous (i.v.) infusion of ASKB1202
89371908|NCT03115762|Active Comparator|bevacizumab A|Subject to receive one intravenous (i.v.) infusion of bevacizumab sold in China
89371909|NCT03115762|Active Comparator|bevacizumab B|Subject to receive one intravenous (i.v.) infusion of bevacizumab sold in Europe
89371910|NCT03168958|Active Comparator|Methadone Group|Patients in this group will receive 0.4 mg/kg of methadone at induction of anesthesia
89371911|NCT03168958|Sham Comparator|Saline-Control Group|Patients in this group will receive an equal volume of saline as the active comparator group at induction of anesthesia
89371912|NCT02396056|Sham Comparator|Occlusive Membrane (OM)|Five patients will be randomly assigned to the OM group.
89371913|NCT02396056|Experimental|Modified Perforated Membrane (MPM)|Five patients will be randomly assigned to the MPM group.
89371914|NCT02396368|Experimental|Radium 223 and Tasquinimod|"During dose level 1, tasquinimod will start at 0.25mg/day orally with a goal of 0.5mg/day. Dose level 2 will start at 0.25mg/day with a goal of 1mg/day.~Radium-223 will be administered per FDA-approved dosing (six IV injections at a dose of 50kBq/kg of body weight, administered every 4 weeks)."
89371915|NCT03632460|Active Comparator|Dexmedetomidine|1 mcg/kg dexmedetomidine added to 8 ml 0.375% ropivacaine
89371916|NCT03632460|Active Comparator|Dexamethasone|8 mg dexamethasone added to 8 ml 0,375% ropivacaine
89371917|NCT03167632||dental patients|
89371918|NCT02396290|Experimental|fractional CO2 laser with PRP|fractional carbon dioxide laser followed by intradermal injection of platelet rich plasma
89371919|NCT02396290|Active Comparator|fractional CO2 laser with NS|fractional carbon dioxide laser followed by intradermal injection of NS
89371920|NCT01567956|Experimental|Propionyl-L-Carnitine|Modified release tablets containing 500 mg of propionyl-L-carnitine
89371921|NCT01567956|Placebo Comparator|Placebo|Modified release tablets containing inert substances
89534832|NCT03231007||Low Adopters|Maternity units that implemented the Care Bundle to the fourth-highest level (according to an NHS survey in 2015) are categorised as 'Low Adopters'.
89534833|NCT03332927|Experimental|Egg based breakfast foods|Study products delivering two eggs/day, 6 days per week, will be administered for the 4-week treatment period.
88844530|NCT05788393|Experimental|Dexmedetomidine group|This group will receive continuous intraoperative dexmedetomidine IV infusion [1ug/kg dexmedetomidine over 15 min as a loading dose and 0.5ug/kg/h for maintenance].
88844531|NCT05788393|Experimental|Lidocaine group|This group will receive continuous intraoperative lidocaine IV infusion [1.5 mg/kg lidocaine over 15 min as a loading dose and 1.5 mg/kg/h for maintenance].
88844532|NCT05787639|Experimental|Treatment|Stereotactic radiation therapy (SBRT (8GyX3)) will be delivered to gross tumor volume (GTV) +3mm, followed by Pembrolizumab 200 mg IV and Evorpacept 45 mg/kg IV every three weeks x 2 cycles followed by surgical resection of primary tumor and neck dissection.
88844533|NCT05783622|Experimental|Dose Escalation|Subjects will be dosed weekly during each 21-day cycle. Dosage per cohort will increase to determine the maximum tolerable dose.
88844534|NCT05783622|Experimental|Backfill Expansion|Subjects will be dosed weekly during each 21-day cycle. Subjects will be dosed at levels previously declared tolerable.
88844535|NCT05783622|Experimental|Expansion|Subjects will be dosed weekly during each 21-day cycle. Subjects will be dosed at the preliminary recommended Phase 2 dose (RP2D).
88844536|NCT05769946|Placebo Comparator|placebo|Atopic dermatitis patients treated with placebo for 12 week.
88844537|NCT05769946|Experimental|Hemay005 60mg|Atopic dermatitis patients treated with Hemay005 60mg BID for 12 week.
88844538|NCT05769946|Experimental|Hemay006 75mg|Atopic dermatitis patients treated with Hemay005 75mg BID for 12 week.
88844539|NCT05769049|Experimental|REC610|Lyophilized gE antigen: white cake or powder. clear to opalescent, colorless liquid after reconstitution with water for injection BFA01 adjuvant suspension: opalescent white liquid After reconstitution: opalescent white liquid. Each dose (0.5 mL) contains 50 μg of Quillaja Saponin (QS-21), 50 μg of MPL, 1 mg of dioleoyl phosphatidylcholine, and 0.25 mg of cholesterol
89371922|NCT03168724|Experimental|GMT Intervention|Over the course of 9 weeks, there are 2h-group sessions with a therapist.
89371923|NCT03168724|No Intervention|Control|Group not getting the intervention
89371924|NCT03168646|Active Comparator|group 1|wafer group procedure using an arthroscope through portal(radial to extensor carpi ulnaris, debridement of triangular fibro-cartilage complex 3-4 mm is shaved from the dome of the ulna by 2.9 bur.
88844540|NCT05769049|Active Comparator|Shingrix|Lyophilized gE antigen: white cake or powder. clear to opalescent, colorless liquid after reconstitution with water for injection AS01B adjuvant suspension: opalescent, colorless to pale brownish liquid suspension After reconstitution: opalescent, colorless to pale brownish liquid. Each dose (0.5 mL) contains 50 μg of QS-21, 50 μg of MPL, 1 mg of dioleoyl phosphatidylcholine, and 0.25 mg of cholesterol
89371925|NCT03168646|Active Comparator|group 2|ulnar shortening group :this is the most logical technique, dorsoulnar incision is made on the distal one-third of the forearm then a 6 hole 3.5 mm Dcp plate is position,osteotomy using oscillating saw in z-shaped manner.
89371926|NCT03097614|Experimental|TrueTear|The device delivers small electrical currents, activating nerves that stimulate the body's natural tear production system.
89371927|NCT05745766||Canines assessed using 2D images|The 2D-based assessments of the impacted maxillary canine.
88844541|NCT05765097|Experimental|Artificial pancreas group|Using artificial pancreas system (composed of a CGM, a pump and AndroidAPS software) to treat adult patients with diabetes
89534834|NCT03332927|Active Comparator|Non-egg based breakfast foods|Study products delivering non-egg based control breakfast foods will be administered 6 days per week for the 4-week treatment period.
89371928|NCT05745766||Canines assessed using 3D images|The 3D-based assessments of the impacted maxillary canine.
89371929|NCT05745766||Canines assessed intra-operatively or post-operatively|The gold standard-based assessments are based on surgical exposure.
89371930|NCT03168802|Experimental|MRgFUS facet treatment|MRgFUS ablation for facet joint pain once at Lumbar spine
89371931|NCT03168802|Active Comparator|Radiofrequency ablation facet treatment|Radiofrequency ablation for facet joint pain once at Lumbar spine
89371932|NCT05418660||Cohort 1|The cohort includes patients who discontinue the treatment at 24 months and continue the follow-up at least for 3 months
89371933|NCT05418660||Cohort 2|The cohort includes patients who continue the treatment beyond 24 months until unacceptable toxicity or progression.
89371934|NCT03364309|Experimental|Ixekizumab 80mg Q4W|Participants received starting dose of 160 milligrams (mg) Ixekizumab at week 0 followed by 80mg Ixekizumab once every four weeks (Q4W) by subcutaneous injection during induction period.
89371935|NCT03364309|Experimental|Ixekizumab 80mg Q2W|Participants received starting dose of 160mg Ixekizumab at week 0 followed by 80mg Ixekizumab once every two weeks (Q2W) by subcutaneous injection during induction period.
89534835|NCT03229291|Experimental|Low Dose|Topical SM04755 solution (15 mg/mL) applied once per day for 14 days
89534836|NCT03229291|Experimental|Mid Dose|Topical SM04755 solution (45 mg/mL) applied once per day for 14 days
89534837|NCT03229291|Experimental|High Dose|Topical SM04755 solution (90 mg/mL) applied once per day for 14 days
89371936|NCT03364309|Placebo Comparator|Placebo|Participants received placebo every two weeks (Q2W) by subcutaneous (SC)injection during induction period.
89371937|NCT03168178|Active Comparator|Standard Antibiotic Treatment|Standard antibiotic treatment provided to patient. Placenta submitted for pathologic exam. Maternal and neonatal outcomes collected.
89371938|NCT03168178|Experimental|No Antibiotic Treatment|No Antibiotic treatment given. Placenta submitted for pathologic exam. Maternal and neonatal outcomes collected.
89371939|NCT05166096|Experimental|Rho-11 administered in Period 1, oral aspirin administered in Period 2|
89371940|NCT05166096|Experimental|Oral aspirin administered in Period 1, Rho-11 administered in Period 2|
89371941|NCT03168490|Active Comparator|1.5g low gluten friendly bread|1.5g low gluten friendly bread as15g bun/day to be consumed as 250 ml beverages at breakfast for 14 days
89371942|NCT03168490|Active Comparator|3g medium gluten friendly bread|3g medium gluten friendly bread as 30g bun to be consumed as 250 ml beverages at breakfast for 14days
89371943|NCT03168490|Active Comparator|6g high gluten friendly bread|6g high gluten friendly bread as 60g bun to be consumed as 250 ml beverages at breakfast for 14 days
89371944|NCT03168490|Placebo Comparator|Control bread|Placebo control bread as 15g bun to be consumed as 250 ml beverages at breakfast for 14 days
89371945|NCT03168490|Placebo Comparator|Gluten free bread|Gluten bread as 15g bun to be consumed as 250 ml beverages at breakfast for 14 days
89371946|NCT03168412|Experimental|the Accelerated Vaccination Schedule Group|Participants in this arm are aged over 18 years and would receive three doses of Recombinant Hepatitis E Vaccine (Escherichia Coli)(Hecolin®) at 0,7,21 day.
89371947|NCT03168412|Active Comparator|the Standard Vaccination Schedule Group|Participants in this arm are aged over 18 years and would receive three doses of Recombinant Hepatitis E Vaccine (Escherichia Coli)(Hecolin®) at 0,1,6 month.
89371948|NCT05110638|Experimental|SKX-16 (Luliconazole 10% Solution)|
89371949|NCT03167320||LOVIC|Irish patients with low Von Willebrand levels will be have both venous blood sampling and a bleeding score administered at study entry. A DDAVP (1-desamino-8-D-arginine vasopressin) fall off study was organised for those patients in the cohort with no previous fall offs available and no contraindications to DDAVP.
89371950|NCT03700788|Experimental|Clorhexidine|2% Chlorhexidine
89371951|NCT03700788|Active Comparator|Calcium Hydroxide|Calcium Hydroxide
89371952|NCT02395900|Active Comparator|Flaxseed|30 grams Flaxseed powder
89371953|NCT02395900|Placebo Comparator|control|dietary and exercise recommendation
89371954|NCT02921802||Patients who received Revlimid|Among relapsed or refractory multiple myeloma and Myelodysplastic syndrome (MDS) with a deletion 5q cytogenetic abnormality patients, all patients who received Revlimid will be targeted in this surveillance.
89371955|NCT03167398|Experimental|CRE carriers|Fecal Microbiota Transplantation
89371956|NCT03334903|No Intervention|Standard of Care|Standard of care includes one dose of 600 mg gabapentin in the immediate preoperative period (1-2 hours before surgery), then a dose of 600 mg each morning during postoperative admission.
89371957|NCT03334903|Experimental|Postoperative Gabapentin Regimen|Single preoperative dose of 600 mg, as described above, plus an additional postoperative regimen. Patients will take 300 mg gabapentin every 8 hours for 1 week after discharge, then a single nightly dose of 300 mg gabapentin for another month.
89371958|NCT03167476||RLH|This group includes subjects diagnosed with reactive lymphoid hyperplasia.
89371959|NCT03167476||Lymphoma|This group includes subjects diagnosed with lymphoma.
89534838|NCT03229291|Placebo Comparator|Vehicle|Vehicle solution applied once per day for 14 days
88810040|NCT05744024|Experimental|Music Therapy (Intervention group 2)|In addition to the standard wound care procedure, the Music Therapy group (intervention group 2) will be hearing their preferred audio, chosen by patient to be relaxing and to offer distraction, through headphones during wound care. This group wears the headphone with music 10 minutes before the start of the wound care, until 1 minute after the wound care has ended.
88810041|NCT05744024|No Intervention|Care as usual (control group/group 3)|The care as usual group (control group) will receive the care as usual. This group receives neither VRT nor MT during wound care.
88810042|NCT01252277|Experimental|Lovaza™|Lovaza™ (two 1 gram capsules twice daily) for six months
88810043|NCT00767624|Other|antidepressant + desensitization|Combined antidepressant medication (determined by an algorithm) plus desensitization therapy
88810044|NCT00767624|Other|antidepressant + cognitive behavioral|Combined antidepressant medication (determined by algorithm) plus cognitive behavioral therapy
88810045|NCT01216241|Active Comparator|Daptomycin|Daptomycin intravenous 8mg/kg once per day 5-10 days.
88810046|NCT01216241|Placebo Comparator|Saline Placebo|Saline solution
88810047|NCT03807908|Experimental|Intervention Tape|"The intervention includes 3 strips of tape; 2 (1 on each side) placed vertically along the lumbar erectors and 1 horizontally at the posterior superior iliac spine.~Subjects will wear the tape for as long as possible up to 5-7 days."
88810048|NCT03807908|Sham Comparator|Sham Tape|"One strip of tape will be applied horizontally to the thoracolumbar junction.~Subjects will wear the tape for as long as possible up to 5-7 days."
88810049|NCT01216397|Experimental|Linagliptin/Metformin (standard batch)|Fixed dose combination tablet
88810050|NCT01216397|Experimental|Linagliptin/Metformin (side batch)|Fixed dose combination tablet
88810051|NCT04345406|Experimental|ACEIs|ACEIs with conventional treatment for COVID19
88810052|NCT04345406|Experimental|Conventional treatment of COVID19|Conventional treatment of COVID19
88810053|NCT01216943|Experimental|Triple Combination Therapy|One drop of Triple Combination Therapy (bimatoprost/brimonidine tartrate/timolol fixed combination ophthalmic solution) administered to each eye, twice daily for 12 weeks.
88810054|NCT00783614|Active Comparator|1|Start antiretroviral therapy (ART) immediately and initiate aspirin 325mg po daily
88810055|NCT00783614|Placebo Comparator|2|Start antiretroviral therapy (ART) immediately and initiate placebo pill daily
88810056|NCT00783614|Active Comparator|3|Defer antiretroviral therapy (ART) for 1 month and immediately initiate aspirin 325mg po daily
89371960|NCT03167008||idiopathic male infertility|"total of 30 male patients with idiopathic male infertility.~Semen samples will be collected from all patients Semen analysis will be examined after 2-5 days of sexual abstinence based on World Health Organization (WHO) (2010).~blood samples will be taken &the following will be done Serum vitamin D level ,Serum calcium level ,Serum testosterone level ,luteinizing hormone (LH), and follicle-stimulating hormone (FSH), will be measured."
89371961|NCT03167008||fertile male group|"total of 30 fertile male (as control)~Semen samples will be collected,Semen analysis will be examined after 2-5 days of sexual abstinence based on World Health Organization (WHO) (2010).~blood samples will be taken &the following will be done Serum vitamin D level ,Serum calcium level ,Serum testosterone level ,luteinizing hormone (LH), and follicle-stimulating hormone (FSH), will be measured."
89371962|NCT03679026||CVRF|individuals with cardio-vascular risk factors and diseases
89371963|NCT03679026||WCVRF|individuals without cardio-vascular risk factors and diseases
89371964|NCT03168100|Experimental|Study Treatment|Elotuzumab (10 mg Days 1 and 15), lenalidomide (15 mg Days 1-21), and dexamethasone (20 mg days 1, 8, 15, and 22) administered in 28-day cycles which will be alternated every 8 weeks with bortezomib (1.0 mg Days 1, 8, and 15), lenalidomide (15 mg Days 1-21), and dexamethasone (20 mg Days 1, 8, 15, and 22)
89534839|NCT03079635|Active Comparator|Normal Weight|This group will be administered two breakfast beverages with a one- to two-week washout period between beverages. The beverages will be a control or an isocaloric, macronutrient matched breakfast beverage with omega-3 fatty acids.
89534840|NCT03079635|Active Comparator|Overweight and Obese|This group will be administered two breakfast beverages with a one- to two-week washout period between beverages. The beverages will be a control or an isocaloric, macronutrient matched breakfast beverage with omega-3 fatty acids.
89534841|NCT03327311||Bellafill 1 week post-injection|n=2. Histopathology conducted 1 week post-injection
89534842|NCT03327311||Bellafill 1 month post-injection|n=2. Histopathology conducted 1 month post-injection
88844547|NCT05754684|Experimental|Intervention|Quadruple immunotherapy
88844548|NCT05753241||healthy group (HG)|Participants were grouped according to their basic conditions without any intervention
88844549|NCT05753241||allergen immunotherapy group (AIT)|Participants were grouped according to their basic conditions without any intervention
88844550|NCT05753241||allergic rhinitis group (ARG)|Participants were grouped according to their basic conditions without any intervention
88844551|NCT05752981||tr-FNIRS neuromonitor|During shoulder surgery, the tr-fNIRS (time-resolved (tr) functional near infrared spectroscopy (fNIRS) (tr-fNIRS)) neuromonitor will be used to gather data on cerebral oxygenation of multiple brain regions for these patients. No intervention will be administered based on the results of the tr-fNIRS.
88844552|NCT05738486|Experimental|Donanemab Dose Level 1|"Participants will receive donanemab by intravenously (IV) infusion.~Participants will receive placebo at certain intervals to preserve the blind."
88844553|NCT05738486|Experimental|Donanemab Dose Level 2|"Participants will receive donanemab by IV infusion.~Participants will receive placebo at certain intervals to preserve the blind."
88844554|NCT05738486|Experimental|Donanemab Dose Level 3|"Participants will receive donanemab by IV infusion.~Participants will receive placebo at certain intervals to preserve the blind."
88844555|NCT05738486|Experimental|Donanemab Dose Level 4|"Participants will receive donanemab by IV infusion.~Participants will receive placebo at certain intervals to preserve the blind."
89371965|NCT03709381|Experimental|ACTH stim test arm|Cosyntropin 1 mcg IV (low dose) will be given to subjects at t=0 minutes, and Cosyntropin 250 mcg (high dose) IV will be given to subjects at t=60 minutes. (All subjects were in the same arm and had the same protocol).
89371966|NCT01353664|Experimental|Romidepsin|This study is an open-label, single-arm study. The study is divided into the Screening Period, Treatment Period, and Follow-up Period.
89534843|NCT03327311||Bellafill 2 months post-injection|n=2. Histopathology conducted 2 months post-injection
89534844|NCT03327311||Bellafill 3 months post-injection|n=2. Histopathology conducted 3 months post-injection
89534845|NCT03327311||Bellafill 6 months post-injection|n=2. Histopathology conducted 6 months post-injection
89534846|NCT03229213||Cystic Fibrosis|Cystic fibrosis patients will be invited to participate in the study. All participants will complete a questionnaire to assess the level of physical activity prior to evaluation. On the first visit they will perform the cardiopulmonary exercise test (CPET) to evaluate cardiorespiratory responses during exercise. On the second visit an evaluation of the cardiorespiratory responses during the use of interactive video games (Nintendo Wii or Xbox One) will be performed. During interactive games, participants will use an accelerometer to assess the level of physical activity.
89534847|NCT03229213||Healthy|Healthy subjects will be invited to participate in the study. All participants will complete a questionnaire to assess the level of physical activity prior to evaluation. On the first visit they will perform the cardiopulmonary exercise test (CPET) to evaluate cardiorespiratory responses during exercise. On the second visit an evaluation of the cardiorespiratory responses during the use of interactive video games (Nintendo Wii or Xbox One) will be performed. During interactive games, participants will use an accelerometer to assess the level of physical activity.
88844556|NCT05735652||Subjects with localized T1-T2 prostate cancer in China who were injected with SpaceOAR Hydrogel|This observational study aims to evaluate the safety and effectiveness of radiotherapy for subjects with localized T1-T2 prostate cancer in China who were injected with SpaceOAR Hydrogel, via collecting clinical data related to radiotherapy.
88844557|NCT05733182|Active Comparator|3000K|Participants will receive a reading lamp of colour temperature 3000K.
88844558|NCT05733182|Active Comparator|4500K|Participants will receive a reading lamp of colour temperature 4500K.
88844559|NCT05733182|Active Comparator|6500K|Participants will receive a reading lamp of colour temperature 6500K.
88844560|NCT05724654|Experimental|Experimental|Skin roasted peanuts
89180924|NCT00439309|Active Comparator|GELFOAM/THROMBIN|GELFOAM/THROMBIN description - GELFOAM Sterile Compressed Sponge is a medical device intended for application to bleeding surfaces as a hemostatic. It is water-insoluble, off-white, nonelastic, porous, pliable product prepared from purified porcine Skin Gelatin USP Granulates and Water for Injection, USP. It may be cut without fraying and is able to absorb and hold within its interstices, many times its weight of blood and other fluids. Although not necessary, GELFOAM can be used either with or without thrombin to obtain hemostasis.
89180925|NCT00479167|Experimental|Bortezomib and Tositumomab I-131|
89180926|NCT00725712|Experimental|5-days on/9-days off|Dosing for first 5 days in every 14-day period.
89180927|NCT00725712|Experimental|daily dosing|dosed every day
89534848|NCT03327233|Experimental|Intervention group|Implementing the Connecare system to support integrated care for complex patients with an unplanned admission to Assuta Ashdod who are discharged back to the community with an emphasis on Connecare self managment system for the patient and close follow up and coordination of all of the medical, health and social care in the community by a Maccabi integrated care nurse for a period of 3 months post discharge.
88810057|NCT00783614|Placebo Comparator|4|Defer antiretroviral therapy (ART) for 1 month and immediately initiate placebo pill daily
88810058|NCT01252745|Experimental|10.0 mg of TBS-1, 4.0% T.I.D.|TBS-1 syringes pre-filled with 125 μL 4.0% gel to deliver 5.0 mg of Testosterone per nostril (intra-nasal) given t.i.d. at 2100, 0700, and 1300 hours. (total dose 30 mg/day)
88810059|NCT01252745|Experimental|13.5 mg of TBS-1, 4.5% B.I.D|TBS-1 syringes pre-filled with 150 μL 4.5% gel to deliver 6.75 mg of Testosterone per nostril (intra-nasal) given b.i.d. at 2100 and 0700 hours. (total dose 27.0 mg/day)
88810060|NCT01252745|Experimental|11.25 mg of TBS-1, 4.5% T.I.D|TBS-1 syringes pre-filled with 125 μL 4.5% gel to deliver 5.625 mg of Testosterone per nostril (intra-nasal) given t.i.d. at 2100, 0700, and 1300 hours. (total dose 33.75 mg/day)
89180928|NCT02594046|Experimental|stem cell group|stem cell group who apply 1.2 g of allogeneic human adipose derived stem cell component extract on their scalp for 16 weeks
88810061|NCT04278872|Experimental|SJX-653|Participants will receive SJX-653
88810062|NCT04278872|Placebo Comparator|Placebo|Participants will receive placebo
88810063|NCT03807596|Active Comparator|SRP group|Chronic periodontitis patients with type 2 diabetes mellitus recieved Periodontal treatment in the form of scaling & root planing (SRP) alone.
88810064|NCT03807596|Experimental|Hyaluronic acid & SRP group|Chronic periodontitis & type 2 diabetes mellitus patients received Periodontal treatment in the form of scaling & root planing (SRP) with the adjunctive use of hyaluronic acid.
88810065|NCT02147522|Experimental|A Helping Hand (AHH)|Participants receive DHS-PCMH usual care from their respective county health clinic providers plus the AHH intervention provided by study promotoras. AHH intervention includes 6 weekly in-person or via-telephone intervention sessions followed by 3 monthly telephone booster sessions aimed at reducing the burden and strain on patients, families, and care providers by assessing, enhancing, and facilitating patient depression and co-morbid illness self-care management, and activating patient communication with clinic medical providers.
88810066|NCT02147522|No Intervention|Usual Care (UC)|"Participants receive DHS Patient Centered Medical Home (PCMH) clinic team usual care from their respective county health clinic providers.~PCMH model has available DHS medical providers and social workers for depression care and refer patients when indicated to community mental health clinics. Problem-Solving Therapy (PST) is available in some of participating clinics."
88810067|NCT01217411|Active Comparator|Arm I (WBRT or SRS)|Patients with >= 4 brain lesions undergo WBRT as in phase I and patients with =< 3 brain lesions undergo SRS as in phase I.
88810068|NCT01217411|Experimental|Arm II (WBRT or SRS and RO4929097)|Patients with >= 4 brain lesions receive RO4929097 and undergo WBRT as in phase I and patients with =< 3 brain lesions receive RO4929097 and undergo SRS as in phase I.
88810069|NCT05595356|Experimental|Active tDCS|Participants will receive 30 daily sessions of tDCS. Each session lasts 20 minutes, and delivers a current of 2mA.
88810070|NCT05595356|Sham Comparator|Sham tDCS|Participants will receive 30 daily sessions of sham tDCS. Each session lasts 20 minutes, and the sham programming delivers 3 ramps of 30 seconds of active current, the first in the first minute of the session, the second after 10 minutes and the third at the last minute of the session.
88810071|NCT03804086|Experimental|Test Group|Advanced PRF (A-PRF) + nano-crystalline hydroxyapatite bone substitute combined with open flap debridement (OFD).
88810072|NCT03804086|Active Comparator|Control Group|Open flap debridement alone.
88810073|NCT03804242|Experimental|Black Youth M.A.T.T.E.R.|The session topics are as follows: (1) Debunking the Stigma of Mental Health in the Black Community, (2) School to Prison Pipeline, (3) Achievement Gap, (4) Cultural Barrier that Black Students Experience with Teachers, (5) Trauma 101, (6) Trauma 102, (7) Actions of Today, Blueprints for Tomorrow: Youth Organizing to Transform Education film, (8) My Voice Will Be Heard (Part I), and (9) My Voice Will Be Heard (Part II). The intervention will be conducted in 2-hour weekly group sessions.
88810074|NCT03804242|No Intervention|Usual Care|All participants already participate in Youth Justice Coalition's Free LA High School. Those in control condition will participate in educational activities as usual.
88810075|NCT01253525|Experimental|Ramucirumab (IMC-1121B ) and Pacitaxel|Each treatment cycle is 4 weeks (28 days)
88810076|NCT05743712|Experimental|SMART-Wrap|SMART-Wrap is a prototype measurement and feedback software system tailored to Wraparound service model (WSM) for emotional disorders to provide measurement-based care in care coordination for youth behavioral health.
88810077|NCT01247675|Experimental|ACP-001, 0.02 mg hGH/kg/wk|Once weekly subcutaneous injection of ACP-001 equivalent to 0.02 mg hGH/kg/week for 4 weeks
89371967|NCT04952766|Other|immunocompromised and healthy subjects|"Immunocompromised subjects and healthy subjects groups will have collection of biological samples (blood with/without nasopharyngeal swabs) at Month-0, -1, -2, -3, -6, with associated data for the study of the kinetics of antibodies anti COVID-19.~Biological samples :~Serum and plasma from each participant for the purpose of performing the SARS-CoV-2 serologic tests~Nasopharyngeal samples (not mandatory)~Associated data :~Demographic data~Description of clinical manifestations related to vaccination~Description of clinical manifestations related to SARS-CoV-2 infection, if any Blood Fractioning~Serum and plasma aliquoted and stored under 250, 500 and 1000 µL (at -80°C)"
88810078|NCT01247675|Experimental|ACP-001, 0.04 mg hGH/kg/wk|Once weekly subcutaneous injection of ACP-001 equivalent to 0.04 mg hGH/kg/week for 4 weeks
89371968|NCT02395744|Experimental|OPC Treatment|Paclitaxel administration using the OPC for the prevention of restenosis in infrapopliteal de novo and restenotic lesions and occlusions using a novel catheter, the OPC. Subjects will be treated with the endovascular intervention selected by the treating physician in reference vessels ranging from 2mm to 4mm in diameter. Following the achievement of optimal interventional results (≤ 30 percent residual stenosis without stenting and without flow-limiting dissection) the OPC will be placed at the interventional treatment area and paclitaxel will be delivered to the treated segment.
89371969|NCT02400502|Experimental|I-CAT Therapy|Integrated Coping and Awareness Therapy is a six-month intervention designed to examine the physiological, biological, and psychological effects of meditation and mindfulness practice on individuals diagnosed with a psychotic disorder.
89371970|NCT02400268|Experimental|7 days course of antibiotic treatment|Accepted antibiotic indicated for enterobacteriaceae infections, according to sensibility test performed and daily practice protocols or local guidelines.
89371971|NCT02400268|Active Comparator|14 days course of antibiotic treatment|Accepted antibiotic indicated for enterobacteriaceae infections, according to sensibility test performed and daily practice protocols or local guidelines.
89371972|NCT04905186||healthy adults|This is a cross-over study with no intervention.
89371973|NCT02400424|Experimental|SBRT|Study treatment = SBRT for peripheral primary tumor.
89371974|NCT03168568|Experimental|Valsartan/Sacubitril|Valsartan-Sacubitril 50mg/100mg twice daily, titrated to 200mg twice daily p.o. Duration of product administration: 3 months
89371975|NCT03168568|Active Comparator|Valsartan|Valsartan 40mg/80mg twice daily, titrated to 160mg twice daily p.o Duration of product administration: 3 months
88810079|NCT01247675|Experimental|ACP-001, 0.08 mg hGH/kg/wk|Once weekly subcutaneous injection of ACP-001 equivalent to 0.08 mg hGH/kg/week for 4 weeks
89371976|NCT05745610|Experimental|Shen Hai Long Group|
89371977|NCT05745610|Active Comparator|Sheng Jing Group|
89371978|NCT02395588||Guideline based care|"Prior to discharge. Survey data will include descriptive characteristics, depression, heart failure knowledge. After patient education is complete prior to discharge patients will complete a readiness for discharge scale and heart failure self-care survey.~Phone call 48 hours after discharge. Discharge instructions will be reinforced.~Phone call 7 days after discharge. Survey data will include self management, complications, and satisfaction care.~Secondary data 30 days post discharge. The hospital electronic medical record system will be queried to determine if the patient has been readmitted within 30 days of discharge for heart failure or non-heart failure causes."
88844561|NCT05724654|No Intervention|Control|No skin roasted peanuts
89371979|NCT02395354|Other|Placing a self-expanding metallic stent|Placing a self-expanding metallic stent
89371980|NCT02395354|Other|A balloon dilatation|A balloon dilatation
89371981|NCT02400112|Experimental|Vancomycin Powder|If the patient randomizes to the experimental group (vancomycin powder), the patient will receive open fracture care identical to the control group except that, prior to closure, 1 gram of vancomycin powder will be applied locally to the open fracture bed. The traumatic and surgical wounds will be closed over a sterile drain and dressed, and the extremity will be immobilized.
88810080|NCT01247675|Active Comparator|Omnitrope, 0.04 mg hGH/kg/wk|Once daily subcutaneous injection of human Growth Hormone (Omnitrope) equivalent to 0.04 mg hGH/kg/week for 4 weeks
88810081|NCT05310968|Experimental|Tirofiban group|"This group will receive tirofiban and aspirin. Day 1: Tirofiban injected intravenously for 24 hours and aspirin of 100-300 mg. Tirofiban will be injected at 4 ug/kg/ min for the first 30 minutes and 0.1 ug/kg/min for the next 24 hours.~Day 2-90: Aspirin 100mg per day."
88810082|NCT05310968|Placebo Comparator|Tirofiban placebo group|"This group will receive tirofiban placebo and aspirin. Day 1: Tirofiban placebo injected intravenously for 24 hours and aspirin of 100-300 mg. The placebo will be injected at the same rate with Tirofiban group.~Day 2-90: Aspirin 100mg per day."
88810083|NCT03804164|Experimental|Supportive Care (psycho-educational sessions)|Patients participate in a psycho-educational program weekly over 2 hours for 6 weeks.
88810084|NCT01254851|Active Comparator|goal-augmented post-operative care.|Patients in this group will be given a goal number of steps to take on each post-operative day.
88810085|NCT01254851|No Intervention|Usual care|routine post-operative ambulation
88810086|NCT00768716|Experimental|White subjects|2 x 500 mg acetaminophen by mouth once
88810087|NCT00768716|Experimental|Black subjects|2 x 500 mg acetaminophen by mouth once
88810088|NCT05743634|Experimental|Treatment Group|Single injection with YY001 in glabellar lines
88810089|NCT05743634|Active Comparator|Active-Controlled Group|Single injection with BOTOX® in glabellar lines
88810090|NCT05743634|Placebo Comparator|Placebo-Controlled Group|Single injection with placebo in glabellar lines
89371982|NCT02400112|No Intervention|Standard Treatment|If the patient randomizes to the control group (standard treatment), the patient will receive irrigation and debridement of the fracture site and surrounding soft tissues. The fracture will then be stabilized in standard fashion determined by fracture personality. Once stabilized, a sterile drain will be placed in the open fracture bed and the traumatic and surgical wounds will be closed and dressed. The extremity will then be immobilized.
89371983|NCT02694328|Experimental|ALKS 3831|Administered as a coated bilayer tablet
89371984|NCT02694328|Active Comparator|Olanzapine|Administered as a coated bilayer tablet
88844562|NCT05715047|Experimental|CBT for Fatigue Program|"Screening for eligibility will use the Fatigue Symptoms Inventory (FSI) average severity item over the prior week. Scores of ≥4 of 0-10 will be invited to participate. 30 participants will be enrolled and will complete study procedures as outlined:~Baseline questionnaires.~10 intervention sessions.~Questionnaires and surveys 3 and 5 months after enrollment."
88844563|NCT05715047|Active Comparator|Usual Care|"Screening for eligibility will use the Fatigue Symptoms Inventory (FSI) average severity item over the prior week. Scores of ≥4 of 0-10 will be invited to participate. 30 participants will be enrolled and will complete study procedures as outlined:~Baseline questionnaires.~Receive material from the Blood and Marrow Transplant Information Network describing common medical causes of fatigue after HCT and recommendations for management.~Questionnaires and surveys 3 and 5 months after enrollment."
88844564|NCT05712967||PATIENTS WITH MM|patients fulfilling the International Myeloma Working Group (IMWG) diagnostic criteria for MM
88844565|NCT05712967||PATIENTS WITH sMM|patients fulfilling the International Myeloma Working Group (IMWG) diagnostic criteria for SMM
88844566|NCT05712967||Controls|healthy controls
88844567|NCT05712460|Experimental|Group A: Higher dose sisunatovir|higher dose of sisunatovir dosed every 12 hours
88844568|NCT05712460|Experimental|Group B: Lower dose sisunatovir|Lower dose of sisunatovir dosed every 12 hours
88844569|NCT05712460|Placebo Comparator|Group C: Placebo|Placebo for sisunatovir dosed every 12 hours
88844570|NCT05712460|Experimental|Group D: Higher dose of sisunatovir|Higher dose of sisunatovir dosed every 12 hours under fasted conditions
88844571|NCT05712460|Experimental|Group E: sisunatovir palatability|Sisunatovir in 4 vehicles (water, saline, apple juice, infant formula) to assess the palatability of sisunatovir in each vehicle. sisunatovir will not be swallowed, participants will swirl and spit to assess various aspects of the taste.
89371985|NCT04480996||Road traffic accidents with medicines|Road traffic accidents cases reported in the World Health Organization (WHO) and the French pharmacovigilance database of patients treated by Drugs Responsible for Cognitive and Psychomotor Side Effects
89371986|NCT02399878||Patients undergoing surgery|All non-cardiothoracic surgical patients aged 18 years or above receiving general anesthesia at Massachusetts General Hospital between January 2007 and August 2014.
89371987|NCT02395276|Active Comparator|Whole body hypothermia|Children that had an event suspected for hypoxic ischemic brain injury, according to the inclusion criteria, will be randomly allocated for whole body hypothermia therapy. Treatment will be initiated within 6 hours of the event, the child will be dressed with a cooling suit and their temperature will be monitored. Whole body hypothermia will be to 33 +/- 1 °C . Treatment period will be 48 hours with 24 hours warming up period.
88844572|NCT05710744|No Intervention|Family Members of patients in the ICU|Family members will join routine meetings with the physicians treating with their critically ill loved ones.
88844573|NCT05710744|Other|ICU Physicians|Physicians will view a tip sheet containing information about best practices of shared decision making with diverse individuals. Physicians will then conduct routine meetings with families of patients with acute respiratory failure.
88844574|NCT05709652|Experimental|Experimental|Patients subjected to aortic CTA with a gantry revolution time of 0.23 sec
88844575|NCT05709652|Active Comparator|Control|Patients subjected to aortic CTA with a gantry revolution time of 0.28 sec
88844576|NCT05708352|Experimental|Keto-Diet|Intensive 18-week Keto Diet intervention.
88844577|NCT05708352|Placebo Comparator|Standard Anti-Cancer Diet|Standard Anti-Cancer Diet with Dietitian support
88844578|NCT05708235|No Intervention|Arm A: Control Arm|Patients must continue the same standard ET,prescribed as per standard practice, used in the surveillance phase. Changes in ET are not allowed.
88844579|NCT05708235|Experimental|Arm B: Experimental Arm with giredestrant|Giredestrant: 30 mg will be taken orally (PO) once a day (QD) on Days 1 to 28 of each 28-day cycle up to five years or until disease recurrence, unacceptable toxicity, or treatment/study discontinuation (whichever occurs first).
88844580|NCT05708235|Experimental|Arm C: Experimental Arm with giredestrant + abemaciclib|"Giredestrant: 30 mg will be taken PO QD on Days 1to 28 of each 28-day cycle up to five years or until disease recurrence, unacceptable toxicity, or treatment/study discontinuation (whichever occurs first).~Abemaciclib 150mg will be taken PO twice daily (BID) (two intakes for a total daily dose of 300 mg) during each 28-day cycle up to two years or until disease recurrence, unacceptable toxicity, or treatment/study discontinuation (whichever occurs first)."
88844581|NCT05708235|Experimental|Arm D: Experimental Arm with giredestrant + inavolisib|"Giredestrant: 30 mg will be administered PO QD on Days 1-28 of each 28-day cycle up to five years or until disease recurrence, unacceptable toxicity, or treatment/study discontinuation (whichever occurs first).~Inavolisib: 9 mg will be administered PO QD on Days 1-28 of each 28-day cycle up to two years or until disease recurrence, unacceptable toxicity, or treatment/study discontinuation (whichever occurs first)."
88844582|NCT05694247|Experimental|CorNeat KPro|Intraocular implantation of the CorNeat KPro
89371988|NCT02395276|Placebo Comparator|Whole body normothermia|Children that had an event suspected for hypoxic ischemic brain injury, according to the inclusion criteria, will be randomly allocated for normothermia therapy. Treatment will be initiated within 6 hours of the event, the child will be dressed with a cooling suit and their temperature will be monitored. Cooling will be to 36-37 °C . Treatment period will be 72 hrs.
89180929|NCT02594046|Placebo Comparator|placebo group|placebo group who apply a placebo on their scalp for 16 weeks
89371989|NCT02395276|No Intervention|Control|A group of children that underwent a cardiac surgery and was not suspected to have an hypoxic ischemic brain injury. This group will be undergo the similar biomarkers collection as arm 1 and 2. The information will be used to measure the change in biomarkers between surgeries with no HII to those in arm 1+2.
89371990|NCT02395510|Other|Flexible, open label dosing|Flexible dosing 5-20mg
89371991|NCT05745532|Experimental|Experimental|Ten transfusion-dependent β-thalassaemia subjects aged 8-16 years will be reinfused with β-globin-restored autologous hematopoietic stem cells modified with LentiHBBT87Q.
89371992|NCT05745454|Experimental|HER2-E-CART cells|HER2-E-CART cells were intravenously transfused and followed up to 2 years after the last cell transfusion
89371993|NCT02395432|Active Comparator|Totaltrack|OTI with Totaltrack
89371994|NCT02395432|Active Comparator|Macintosh Laryngoscope|OTI with Macintosh Laryngoscope
89371995|NCT02395198||HCV negative or in HCV treatment at T1|This group will be followed up at T2
89371996|NCT02394886|Experimental|ALLO-ASC-DFU|ALLO-ASC-DFU treatment with conventional care
89371997|NCT02400034|Active Comparator|FAST voiding trial method|1) Bladder drained with indwelling foley catheter, then retrograde filled with 300cc sterile water. 2) catheter is removed; 3) Patient voids within 20 minutes (if unable to void after 20 minutes, she will be discharged home with a catheter secondary to voiding dysfunction). 4) The patient will subjectively quantify their FOS via VAS scale. 5) If VAS scale >50 (=50%) the catheter will remain out, patient is discharged home without measuring a PVR 6) If VAS scale is from 0-49 (= 0-49%) a PVR will be checked via bladder scan. If PVR is <500 the patient will be discharged WITHOUT a catheter; If PVR is >500 the patient will be discharged WITH a catheter. If she is discharged with an indwelling foley catheter, she will have an in-office retrograde voiding trial in 2-5 days
89371998|NCT02400034|Active Comparator|Retrograde fill voiding trial method|1) Bladder drained with indwelling foley catheter, then retrograde filled with 300cc sterile water. 2) catheter is removed; 3) Patient voids within 20 minutes (if unable to void after 20 minutes, she will be discharged home with a catheter secondary to voiding dysfunction). 4) The patient will subjectively quantify their FOS via VAS scale (however this information will only be used for research purposes). 5) If she voids >/= 2/3 (200cc) the catheter will remain out as she will have passed her voiding trial. If she voids < 200cc she will be discharged home with a catheter and instructed to follow-up in 2-5 days for an in-office retrograde voiding trial in 2-5 days.
89371999|NCT02399956||Survivors|"Participants will be recruited from the St. Jude Lifetime Cohort (SJLIFE protocol) and the After Completion of Therapy (ACT) Clinic at St. Jude Children's Research Hospital.~Intervention: Survey"
89372000|NCT02399800|Experimental|EUS with Celiac Block|Celiac Block with triamcinolone and bupivicaine Intra Plexus Triamcinolone and Bupivicaine Injection
89372001|NCT02399800|Active Comparator|EUS without Celiac Block|Patients will undergo EUS but no celiac block will be performed
89372002|NCT02399566|Experimental|Experimental|followed classical chemotherapy for 4 cycles, use Erlotinib orally for the maintenance therapy
89372003|NCT02399566|Active Comparator|Comparator|followed classical chemotherapy for 4 cycles, use Pemetrexed interventional for the maintenance therapy
89372004|NCT02399644|Experimental|ACT|Acceptance and Commitment Therapy is a version of Cognitive behavioral Therapy that focuses on acceptance and mindfulness. The aim is to prevent avoidance and control of negative private events such as anxiety or pain. The treatment consists of 7 weekly group sessions, 2 hours a week. The participants are given homework between sessions.
89372005|NCT02399644|Experimental|Physical activity|Participants are going to participate in a training programme including aerobic exercise as well as endurance and strength training for the neck, shoulders, low back, core and leg muscles. The training is group-based and supervised by a physiotherapist two times a week, one hour a time for eight weeks. Home exercises twice a week are also a part of the intervention. It is possible to individually adjust movements and intensity to the participants' capacity if needed.
89372006|NCT02399644|No Intervention|Experience based discussion group|Participants are going to discuss their experiences of long term pain. The discussions is supervised by a heath care professional and is based on beforehand defined subjects, i.e. relations, spare time, economics, occupation. The meetings are hold for 7 weeks, 2 hours a week.
88810091|NCT05743322|Experimental|3D printing arm|A bi-atrial 3D printed model will be manufactured before the procedure
88810092|NCT01218971|Experimental|Medisorb naltrexone 380 mg|Intramuscular (IM) injection administered once every 4 weeks for up to 48 weeks.
88810093|NCT01218971|Experimental|Medisorb naltrexone 190 mg|IM injection administered once every 4 weeks for up to 48 weeks.
88810094|NCT01337687|Experimental|Oxytocin|
88810095|NCT01337687|Placebo Comparator|Placebo|
88810096|NCT04351919|Experimental|HCQ Arm|
88810097|NCT00769808|Experimental|Technolas 217z Excimer Laser|Bausch & Lomb Zyoptix Aspheric Algorithm for LASIK correction of myopia and myopic astigmatism.
88810098|NCT00769886|Experimental|KetoNaph|KetoNaph (ketotifen fumarate 0.025%, naphazoline HCl 0.05%) ophthalmic solution
88810099|NCT00769886|Active Comparator|Naphazoline|Naphazoline HCl 0.05% ophthalmic solution
88810100|NCT00769886|Active Comparator|Ketotifen|Ketotifen fumarate 0.025% ophthalmic solution
88810101|NCT00769886|Placebo Comparator|Vehicle|Vehicle of KetoNaph ophthalmic solution
88810102|NCT00794144|Experimental|1|Olopatadine Hydrochloride Nasal Spray 0.6%
88810103|NCT00794144|Placebo Comparator|2|Olopatadine Hydrochloride Nasal Spray Vehicle
88810104|NCT01309451|Active Comparator|Bevacizumab alone|
88810105|NCT01309451|Active Comparator|Combined group|Bevacizumab plus Ozurdex
88810106|NCT00787904||Surgical Menopause|Pre-menopausal women undergoing total hysterectomy with oophorectomy rendering them post-menopausal
88810107|NCT00787904||Surgical Control|Pre-menopausal women undergoing abdominal surgery but without ovary removal
88810108|NCT00787904||Healthy|Healthy matched pre-menopausal controls
88810109|NCT04351841|Placebo Comparator|control|15 g maltodextrin per day consumed in the morning
88810110|NCT04351841|Experimental|Active|15 g arabinogalactan per day consumed in the morning
88810111|NCT01255865||A1 - up to 1 month|Age group 0 up to 1 month
88810112|NCT01255865||A2 - 1 to 3 months|Age group from 1 month to 3 months
88810113|NCT01255865||A3 - 3 months to 1 year|Age group from 3 months to 1 year
88810114|NCT01255865||B - 1 year to 5 years|Age group from older than 1y and younger than 5 years
89372007|NCT03167164|Experimental|NANT MCC Vaccine|"A combination of agents will be administered to subjects in this study:~avelumab, bevacizumab, capecitabine, cisplatin, cyclophosphamide, 5-fluorouracil, leucovorin, nab-paclitaxel, omega-3-acid ethyl esters, stereotactic body radiation therapy, ALT-803, ETBX-051, ETBX-061, GI-6301, and haNK."
89372008|NCT03167086|Experimental|Single Session Skills-Based Pain Psychology Class|"Empowered Relief (ER): A single-session skills-based approximately 2-hr group intervention for chronic pain."
89372009|NCT03167086|Active Comparator|Cognitive Behavioral Therapy (CBT)|8-week Manualized Pain-CBT Group Intervention will be delivered by PhD-level psychotherapists (3 in total).
89372010|NCT03167086|Active Comparator|Health Education (HE)|The active control treatment arm consists only of Health Education and has no psychological treatment components. It is a 2-hour HE class matched to the single-session psychological experimental arm (ER) on 4 important factors: duration, structure, format and site.
89372011|NCT03334747|Experimental|Treatment arm 1: KAE609 10 mg Single Dose (SD)|KAE609 10 mg once daily (QD) for 1 day
89372012|NCT03334747|Experimental|Treatment arm 2:KAE609 25 mg SD|KAE609 25 mg once daily (QD) for 1 day
88844586|NCT05689047|Experimental|Part A: Safety Run-in Cohort M5717+Pyronaridine|M5717 and pyronaridine once daily in a single day treatment regimen at low dose of 330 milligrams (mg) and 360 mg respectively.
88844587|NCT05689047|Experimental|Part B: Dose escalation cohort; M5717+Pyronaridine|After completion of Part A, if dose will be considered safe and well tolerated, the Internal Data Monitoring Committee (IDMC) will have the option to recommend dose adjustments. M5717 and pyronaridine once daily will be administered in an escalated dose in a single day or 2-day treatment regimen.
88844588|NCT05689047|Active Comparator|Pyronaridine-artesunate|Pyronaridine-artesunate (Pyramax) once daily in a 3-day treatment regimen.
88844589|NCT05682170|Experimental|Acute Myeloid Leukemia|"Phase 1: Dose Escalation- c3 monotherapy and d5+c3 combination~Phase 2: Dose Expansion"
88844590|NCT05677321||Participants with AUD|Drink regularly (i.e., 2 or more drinks per day for at least 3 days per week in the past 12 months)
88844591|NCT05677321||Participants without AUD|Does not drink regularly (less than 2 drinks per day for at least 3 days per week in the past 12 months)
88844592|NCT05676749|Experimental|C-TIL051|C-TIL051 plus IL-15 (NKTR-255) and Pembrolizumab
88844593|NCT05668585|Experimental|Phase 1: Arm A: CFT1946|Approximately 40 subjects with V600 Solid Tumors (non-CNS) (post BRAF inhibitor for NSCLC, CRC, melanoma, ATC)
88844594|NCT05668585|Experimental|Phase 1: Arm B: CFT1946 + trametinib|Approximately 28 subjects with V600 Solid Tumors (non-CNS) (post BRAF inhibitor for NSCLC, CRC, melanoma)
88844595|NCT05668585|Experimental|Phase 2: Arm A1: CFT1946|Approximately 30 subjects with V600 melanoma or NSCLC (post BRAF inhibitor)
88844596|NCT05668585|Experimental|Phase 2: Arm B1: CFT1946 + trametinib|Approximately 20 subjects with V600 melanoma or NSCLC (post BRAF Inhibitor)
88844597|NCT05658458|Experimental|Vericiguat therapy|Adult participants with chronic HFrEF who are naïve to vericiguat and will be prescribed vericiguat as per local label by their treating physician (cardiologists).
88844598|NCT05643495|Experimental|Group A|Participants will receive VX-864 every 12 hours (q12h) for 48 weeks.
89372013|NCT03334747|Experimental|Treatment arm 3:KAE609 10 mg 3 Days|KAE609 10 mg (QD) for 3 days
89372014|NCT03334747|Experimental|Treatment arm 4:KAE609 50 mg SD|KAE609 50 mg once daily (QD) for 1 day
89372015|NCT03334747|Experimental|Treatment arm 5:KAE609 25 mg 3 Days|KAE609 25 mg once daily (QD) for 3 days
89372016|NCT03334747|Experimental|Treatment arm 6:KAE609 75 mg SD|KAE609 75 mg once daily (QD) for 1 day
89372017|NCT03334747|Experimental|Treatment arm 7:KAE609 50 mg 3 Days|KAE609 50 mg once daily (QD) for 3 days
89372018|NCT03334747|Experimental|Treatment arm 8: KAE609 150 mg SD|KAE609 150 mg once daily (QD) for 1 day
89372019|NCT03334747|Active Comparator|Treatment arm 9: Coartem Control|Coartem® control
89372020|NCT02399722|Active Comparator|VAC mono therapy|negative pressure wound therapy alone
89372021|NCT02399722|Active Comparator|WICVAC combined therapy|Polymeric membrane dressing combined with negative pressure wound therapy
89372022|NCT02394652|Experimental|Experimental: Metformin with Standard Chemoradiation|"Metformin: About 1 week prior to the start of chemoradiation, take 850 mg of metformin, orally, once a day for 3 days, followed by 850 mg twice a day and continued for the duration of external radiation.~Chemoradiation: Cisplatin will be given intravenously at 40 mg/m2 week for 5 doses, concomitantly with external beam radiation.~FAZA-PET scan at baseline and after about 1 week of metformin (just prior to the start of chemoradiation)"
89372023|NCT02394652|Active Comparator|Standard Chemoradiation|"Chemoradiation: Cisplatin will be given intravenously at 40 mg/m2 week for 5 doses, concomitantly with external beam radiation.~FAZA-PET scan at baseline and about 1 week later (just prior to the start of chemoradiation)."
89180930|NCT00729378|Experimental|Exercise Intervention|Implementation of intervention program designed to provide skeletal loading through high impact activities. All activities performed by subjects in exercise intervention arm will be assessed by physical activity questionnaire and use of pedometer. Have baseline anthropometric measurements, total body DXA scans and peripheral quantitative computed tomography (pQCT) scans of the tibia and femur.
89372024|NCT02394496|Experimental|ARM 1|Fulvestrant + Placebo Lapatinib
89372025|NCT02394496|Experimental|ARM 2|Fulvestrant + Aromatase Inhibitors + Placebo Lapatinib
89372026|NCT02394496|Experimental|ARM 3|Fulvestrant + Lapatinib
89372027|NCT02394496|Experimental|ARM 4|Fulvestrant + Lapatinib + Aromatase Inhibitors
89372028|NCT03709303||SCD patients|Patients with sickle cell disease who have decided about enrollment in an NIH study of PBSCT or Gene therapy
89372029|NCT03346759|Experimental|Tampon A First|Subjects were provided with 24 Tampax Pearl Regular Tampons (tampon A) to use exclusively for the first of two consecutive menstrual cycles. Subjects were then provided with 24 Playtex Gentle Glide 360 Regular Tampons (tampon B) to use exclusively for the second of two consecutive menstrual cycles. For the third menstrual cycle, subject used tampons of their choosing.
89372030|NCT03346759|Experimental|Tampon B First|Subjects were provided with 24 Playtex Gentle Glide 360 Regular Tampons (tampon B) to use exclusively for the first of two consecutive menstrual cycles. Subjects were then provided with 24 Tampax Pearl Regular Tampons (tampon A) to use exclusively for the second of two consecutive menstrual cycles. For the third menstrual cycle, subject used tampons of their choosing.
89372031|NCT03362671|Experimental|Treatment Group|Participants will be treated with a novel experimental implant supported mandibular advancement oral appliance, which uniquely attaches to orthodontic mini implants (OMIs) in the jaw. Participants will be fitted with OMIs per standard clinical practice prior to treatment with the novel oral appliance.
89372032|NCT01312051||Protocol 1|Healthy, overweight 11 to 17 year old black and white adolescents
89372033|NCT01312051||Protocol 2|Healthy, normal-weight 11 to 17 year old black and white adolescents
89372034|NCT01312051||Protocol 3|Healthy, normal-weight 8 to 12 year old black and white adolescents
89372035|NCT01312051||Protocol 4|Healthy, overweight 11 to 17 year old black and white adolescents
89372036|NCT02394418|Active Comparator|Sevoflurane|Treatment of delirium by inhaled sevoflurane
89372037|NCT02394418|Active Comparator|Propofol|Treatment of delirium by propofol i.v. infusion
89372038|NCT02394418|Active Comparator|Dexmedetomidine|Treatment of delirium by dexmedetomidine i.v. infusion
89372039|NCT06336564|Active Comparator|Control Group|Pelvic floor muscle training
89372040|NCT06336564|Experimental|Intervention Group|Pelvic floor muscle training and microablative radiofrequency
88810115|NCT01255865||C - 5 years to 12 years|Age group from older than 5y and younger than 12 years
88810116|NCT01255865||D - 12 years to 21 years|Age group from older than 12 years and younger than 21 years
88810117|NCT01255865||E - 21 years and older|Age group older than 21 years
88810118|NCT04383704|Experimental|calorie-restricted modified MIND diet|This arm received instruction in modifying the content of their diet to meet MIND pattern guidelines.
88810119|NCT04383704|Active Comparator|calorie-restricted standard control diet|They instructed to calorie-restricted diet alone.
88810120|NCT03803384|Experimental|ESWT Order A and B|First Endurance Shuttle walk test (A) with supplemental Oxygen therapy via auto-regulated oxygen flow rates (FreeO2) to maintain a oxygen saturation of 92% and second Endurance Shuttle walk (B) test with supplemental Oxygen therapy via constant oxygen flow rates
88810121|NCT03803384|Experimental|ESWT Order B and A|First Endurance Shuttle walk test (B) with supplemental Oxygen therapy via constant oxygen flow rates and second Endurance Shuttle walk (A) test with supplemental Oxygen therapy via auto-regulated oxygen flow rates (FreeO2) to maintain a oxygen saturation of 92%
88810122|NCT03803306|Experimental|Vedic Medical Astrology Group (VMA)|
88810123|NCT03803306|Sham Comparator|Placebo vedic medical astrology (PMA)|
88810124|NCT00771056|Experimental|Hydroxychloroquine|Hydroxychloroquine 400 mg po daily for up to one year.
88810125|NCT00795002|Experimental|Arm I|Patients receive alvocidib IV over 1 hour on days 1-3, cytarabine IV continuously over 72 hours on days 6-8, and mitoxantrone hydrochloride IV over 60-120 minutes on day 9.
88810126|NCT00795002|Experimental|Arm II|Patients receive alvocidib IV over 30 minutes followed by alvocidib IV over 4 hours on days 1-3. Patients also receive cytarabine and mitoxantrone hydrochloride as in arm I.
89180931|NCT00729378|No Intervention|Control|Participants in this arm will not take part in exercise intervention. All activities performed by subjects in control arm will be assessed by physical activity questionnaire and use of pedometer. Have baseline anthropometric measurements, total body DXA scans and peripheral quantitative computed tomography (pQCT) scans of the tibia and femur.
89534849|NCT03327233|No Intervention|Matched control group|The control group will be selected from Maccabi's database and will be patients who are matched 1:1 with the intervention sample and live in another community similar to Ashdod in socioeconomic characteristics who undergo the same elective major surgery in other hospitals
88810127|NCT03802838|Active Comparator|Acupuncture|Acupuncture+Amisulpride
89534850|NCT03332849|Experimental|Cohort 1|T1DM: Multiple dose subcutaneous administration
89534851|NCT03332849|Experimental|Cohort 2|T1DM: Multiple dose subcutaneous administration
89372044|NCT06336512|Other|serum zonulin|
89534852|NCT03332849|Experimental|Cohort 3|T2DM: Multiple dose subcutaneous administration
89534853|NCT03332849|Experimental|Cohort 4|T2DM: Multiple dose subcutaneous administration
89534854|NCT03240445|Experimental|Period 1|ODM-203 dosed after food
89534855|NCT03240445|Experimental|Period 2|ODM-203 dosed before food
89534856|NCT03240445|Experimental|Periods 3-6|ODM-203 dosed as a tablet or dispersion
89534857|NCT03230929|Experimental|BIS-PLE|Anesthesiologist attaches the sensors of BIS and PLEM 100 on the forehead of the patient, and monitor the monitor and record the values of BIS, PLEM 100, and neuromuscular monitoring.
89534858|NCT03327155|Experimental|TDF/FTC (300mg/200mg) once daily|Tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) (300mg/200mg) on tablet once daily with food.
88810128|NCT03802838|Other|Amisulpride|Amisulpride only.
88810129|NCT03802682|Experimental|Treatment Sequence AB|Participants will receive a single dose of apalutamide 240 milligram (mg) (4*60 mg tablets) swallowed whole under fasted conditions on Day 1 of Treatment Period 1 (Treatment A [reference]) followed by a single dose of apalutamide 240 mg (4*60 mg tablets) as a dispersed mixture in applesauce under fasted conditions on Day 1 of Treatment Period 2 (Treatment B [test]). Study treatment periods will be separated by a washout interval of at least 42 days and no more than 56 days between doses.
88810130|NCT03802682|Experimental|Treatment Sequence BA|Participants will receive a single dose of apalutamide 240 mg (4*60 mg tablets) as a dispersed mixture in applesauce under fasted conditions on Day 1 of Treatment Period 1 (Treatment B [test]) followed by a single dose of apalutamide 240 mg (4*60 mg tablets) swallowed whole under fasted conditions on Day 1 of Treatment Period 2 (Treatment A [reference]). Study treatment periods will be separated by a washout interval of at least 42 days and no more than 56 days between doses.
88810131|NCT00772304|Experimental|1|Olopatadine 0.6% / Azelastine 137 mcg
88810132|NCT01310231|Active Comparator|Metformin|Metformin plus standard chemotherapy (containing anthracyclines, platinum, taxanes or capecitabine; first or second line).
88810133|NCT01310231|Placebo Comparator|Placebo|Placebo and standard chemotherapy (containing anthracyclines, platinum, taxanes or capecitabine; first or second line).
88810134|NCT00789074|Experimental|Varenicline pre-treatmemt|Participants will use varenicline (1mg BD) 4-weeks prior to quitting
88810135|NCT00789074|Placebo Comparator|Placebo|Participants will use 3 weeks of placebo, followed by 1 week of varenicline, prior to quitting
88810136|NCT01338857|Experimental|Sorafenib (Nexavar)|Sorafenib will be administered orally BID (approximately every 12 hours). Grapefruit juice is not allowed while taking sorafenib. A cycle of therapy is considered to be 28 days and there is no interruption between cycles. Patients may receive up to a total of 12 cycles provided that no off-protocol or off-study criteria are met.
88810137|NCT05742620|Experimental|anlotinib+CAPEOX/SOX|Adjuvant treatment of locally advanced gastric cancer and colorectal cancer
88810138|NCT03802448|Active Comparator|Control group|"composed of fifteen pregnant women who only wore a natural wrist splint during sleeping for 4 weeks.~A neutral wrist splint was worn by all pregnant women in both groups daily at night, only all through the study time (4 weeks). This neutral wrist splint was used to keep the wrist in a straight position (neutral position) and to prevent the extreme wrist motion (flexion and extension) while sleeping"
88810139|NCT03802448|Experimental|Study group|"a myofascial release in addition to wearing a natural wrist splint during sleeping for 4 weeks.~Myofascial wrist retinaculum (Transverse carpal ligament) release.~• Second part; Interosseous membrane and forearm muscles myofascial release (Bilateral thumb pressure technique)."
88810140|NCT01339013|Active Comparator|AnaConDa|
88810141|NCT01339091|Experimental|Dalbavancin|
88810142|NCT01339091|Active Comparator|Vancomycin with possible switch to oral linezolid|
88810143|NCT01257347|Other|Concealment (control)|Clinicians in the control arm will not receive any electronically-monitored medication adherence information (collected via MedSignals pillbox) at the 1-month visit and will be expected to manage hypertension according to their usual care.
88810144|NCT01257347|Experimental|Disclosure (intervention)|"Disclosure of adherence report to clinician:~At clinic visits with patients with uncontrolled hypertension, clinicians in the intervention arm were provided with a quantitative summary of their patients' electronic adherence to antihypertensive medications (collected via MedSignals pillbox)."
88810145|NCT05742542|Experimental|High intensity interval training with high time spent near VO2max|"Participants performed high intensity interval training with high time spent near VO2max three times a week for two weeks.~All training sessions consisted of five times 2 minutes of work and 1 minute of passive recovery. The work intensity was adjusted at 85% and 87% of power output achieved at the end of incremental test for the first and second week, respectively.~The training sessions were performed using cycle ergometer.~Findings were compared to high intensity interval training with low time spent near VO2max, which followed the same exercise frequency, intensity and total duration."
88819349|NCT04685499|Experimental|Telomelysin (OBP-301)|All patients will receive intratumoral injection(s) with OBP-301. If tolerated and no progression is observed, up to twelve injections may be given in each patient.
88844599|NCT05643495|Experimental|Group B|Participants will undergo a liver biopsy done before receiving VX-864 q12h for 48 weeks, and will undergo a second liver biopsy at either Week 24 or Week 48.
89534859|NCT03090555|Experimental|Translational Manipulation|"Participants received an interscalene block on the affected side. Then, a physical therapist performed thrust manipulations on the affected shoulder until full passive physiologic motion was restored. These participants returned to the clinic approximately 3 days later for the first of 6 manual therapy (MT) sessions.~The first clinic treatment session included instruction in a home program of static stretching, resistive exercise, and ice, issue of an illustrated handout and digital video disc detailing the same program, and manual therapy (MT) by a physical therapist that included all indicated grades of non-thrust manipulation. Subsequent clinic treatment sessions included additional MT, progression of the strengthening exercises, and reinforcement of the home program."
88844604|NCT05638581|Active Comparator|LTOWB|Participants randomized to receive (Low Titer O Whole Blood [LTOWB])
88844605|NCT05638581|Active Comparator|Components|Participants randomized to receive the component blood products.
88844606|NCT05630820|Experimental|Bepirovirsen|
88844607|NCT05630820|Placebo Comparator|Placebo|
88844608|NCT05630352|Experimental|Dose level 1|Injection in the muscle at 0-, 8-, and 16-weeks.
88844609|NCT05630352|Experimental|Dose level 2|Injection in the muscle at 0-, 8-, and 16-weeks
88844610|NCT05630352|Experimental|Dose level 3|Infection in the muscle at 0-, 8- and 16- weeks
88844611|NCT05630352|Experimental|Dose level 4|Injection in the muscle at 0-, 8- and 16- weeks
88844612|NCT05625399|Experimental|Nivolumab + Relatlimab FDC SC|
88844613|NCT05625399|Active Comparator|Nivolumab + Relatlimab FDC IV|
88844614|NCT05618535|Sham Comparator|Zero position|All monitoring was done from 9 to 11 a.m., and the whole monitoring process was carried out in a specific and quiet environment at 20-24℃ to avoid other auditory and visual stimuli. After 10min of the relaxed supine position, the blood pressure, heart rate, and blood flow velocity of the middle cerebral artery were measured in the 0° position for 5min.
88844615|NCT05618535|Experimental|30 degrees position|Within 30 seconds after the 0° position measurement completion, the subjects were transferred to the 30° position and rested for 15 minutes under the 30° position. In other words, a washout period of 15 minutes was established between two measurements to ensure the stability of vital signs and avoid confounding effects. The blood pressure, heart rate, and blood flow velocity of the middle cerebral artery were measured again for 5 minutes after the vital signs were stable.
88844616|NCT05618457|Other|Aminoglycoside dose adjustment|Eligible patients will be assessed for attainment of PK/PD target under standard dosing, dose adjustment to attain target will be proposed where appropriate
88844617|NCT05617508|Placebo Comparator|Placebo|Placebo, no active ingredients. Administered in capsule form twice daily for the duration of the trial (12 weeks).
88844618|NCT05617508|Experimental|Dietary Supplement: NR 1000 mg group|Nicotinamide Riboside (NR) 1000mg total daily. Administered in capsule form in doses of 500mg twice daily for the duration of the trial (12 weeks).
88844619|NCT05617508|Experimental|Dietary Supplement: NR dose escalation group|Nicotinamide Riboside (NR) dose escalation group: 1000mg NR daily in doses of 500mg twice daily (week 1 - week 4), 2000mg NR daily in doses of 1000mg twice daily (week 5 - week 8), 3000mg NR daily in doses of 1500mg twice daily (week 9 - week 12).
88844620|NCT05607420|Experimental|Dose finding part|"UCART20x22 tested at several dose levels until the Maximum Tolerated Dose (MTD) and/or the Recommended Phase 2 Dose (RP2D) is identified.~Dose expansion part: UCART20x22 administered at the RP2D determined during the dose finding part"
88819350|NCT04668339|Experimental|Study Group 1, Younger Adult Participants|Participants will receive one dose of ARCT-021 on Day 0, one dose of Placebo (saline) on Day 28 and on Day 208 either one dose of ARCT-021 or one dose of placebo
88844621|NCT05604534||Healthy Adult|Adults 18 years of age or older, in good general health
88844622|NCT05603104|Experimental|Schizophrenia EIPT: Switch to clozapine|Schizophrenia randomized to EIPT: Switch to clozapine. Brand, dosage, frequency and duration up to the investigator's discretion
88844623|NCT05603104|Active Comparator|Schizophrenia TAU: second-line antispychotic|Schizophrenia randomized to TAU: switch to second-line antispychotic. Compound, brand, dosage, frequency and duration up to the investigator's discretion (in accordance with SmPC)
88844624|NCT05603104|Experimental|Major Depressive Disorder EIPT: second-line antidepressant + esketamine nasal spray|"Major depressive disorder randomized to EIPT: Switch to second-line antidepressant + esketamine nasal spray or (es)ketamine infusion. Antidepressant: Compound, brand, dosage, frequency and duration up to the investigator's discretion (in accordance with SmPC).~Esketamine nasal spray: 2 times per week for 4 weeks. Initial dose 28 mg, after that increases can be made with 28 mg per increase (up to 84 mg per week). This decision is up to the investigator's discretion (in accordance with SmPC).~(Es)ketamine infusion: performed twice weekly for 4 weeks. Compound, brand up to the investigator's discretion (in accordance with SmPC)."
88819351|NCT04668339|Experimental|Study Group 2, Younger Adult Participants|Participants will receive one dose of ARCT-021 on Day 0, a second dose of ARCT-021 on Day 28 and on Day 208 either one dose of ARCT-021 or one dose of placebo
88819352|NCT04668339|Experimental|Study Group 3, Younger Adult Participants|Participants will receive one dose of ARCT-021 on Day 0, a second dose of ARCT-021 on Day 28 and on Day 208 either one dose of ARCT-021 or one dose of placebo
89372049|NCT06336473|Experimental|Skin biopsy|
89372050|NCT06336460|Experimental|Pericapsular Nerve Group (PENG) Block|
89372051|NCT06336460|Experimental|Fascia Iliaca Compartment (FIC) Block|
89372052|NCT06336447|Experimental|Group #1: Virtual Reality Headset|Group 1 will be assigned to the Virtual Realtity Headset. Participants will wear the headset for at least 10 minutes prior to the planned procedure. Subjects will receive standard procedure. The VR Headset will be removed 10 minutes after the planned procedure.
89372053|NCT06336447|Active Comparator|Group 2 No Virtual Reality Headset|Group 2 will receive standard care without the use of the Virtuality Reality Headset.
89372054|NCT06336434|Experimental|Q4W Switch|Pregnant people between 10 0/7 and 19 4/7 weeks gestation with HIV-1 viral suppression on oral antiretroviral therapy willing to switch to an every four week (Q4W) CAB LA + RPV LA regimen.
89372055|NCT06336434|Experimental|Q8W Switch|Pregnant people between 10 0/7 and 19 4/7 weeks gestation with HIV-1 viral suppression on oral antiretroviral therapy willing to switch to an every eight week (Q8W) CAB LA + RPV LA regimen.
89372056|NCT06336434|Experimental|Q4W Continuation|Pregnant people 19 4/7 weeks gestation or less with HIV-1 viral suppression who were using every 4 week CAB LA + RPV LA at and since conception and are willing to continue their current CAB LA + RPV LA regimen.
89372057|NCT06336434|Experimental|Q8W Continuation|Pregnant people between 10 0/7 and 19 4/7 weeks gestation with HIV-1 viral suppression who were using every 8 week CAB LA + RPV LA at and since conception and are willing to continue their current CAB LA + RPV LA regimen.
89372058|NCT06336421|Experimental|Experimental Group|virtual reality glasses were used in primiparous pregnant women undergoing cesarean section. The video, in which baby pictures will be shown accompanied by virtual reality music, was prepared by the researcher and a faculty member in the music department. During the cesarean section, the researcher showed the pregnant woman in the experimental group a video accompanied by music and baby pictures using virtual reality glasses for an average of 10 minutes.
89372059|NCT06336421|No Intervention|Control group|"Written consent was obtained from pregnant women who agreed to participate in the study.~10 minutes before cesarean section; A personal information form was filled out to determine the descriptive characteristics of the pregnant women.~The pregnant woman's anxiety level before the procedure was determined using the State Anxiety Scale.~Before the procedure, blood pressure, pulse, respiratory rate and saturation in the patient follow-up form were recorded.~Routine practice was performed during cesarean section.~10 minutes after cesarean section; In order to determine the anxiety level, the parameters in the State Anxiety Scale and the Patient Follow-up Form were measured again and the process was completed."
89372060|NCT06336395|Experimental|Standard risk (SR)|"No anthracycline throughout the treatment.~CNS consolidation using Capizzi type low dose methotrexate (LDMTX) x 2 courses to replace pre-existing high dose methotrexate (HDMTX) 2.5g #3/4"
89372061|NCT06336395|Experimental|Intermediate risk (IR)|Those with CD20 ≥ 20% expression on diagnostic blasts by flow immunophenotyping will receive additional dose of rituximab on day 1 of each delayed intensification (DI) phases: phase III (2 courses) and V (1 course) for total 3 infusions
88844625|NCT05603104|Active Comparator|Major Depressive Disorder TAU: second-line antidepressant|Major depressive disorder randomized to TAU: Switch to second-line antidepressant + esketamine nasal spray or ketamine IV or esketamine IV . Antidepressant: Compound, brand, dosage, frequency and duration up to the investigator's discretion (in accordance with SmPC).
88844626|NCT05603104|Experimental|Bipolar Depression EIPT: Switch to one of the following combinations:|Bipolar Depression randomized to EIPT: Switch to 1. one of the following: escitalopram, sertraline, or venlafaxine plus 2. two of the following: lithium, valproate acid or quetiapine
88844627|NCT05603104|Active Comparator|Bipolar Depression TAU: Switch to quetiapine plus lithium or valproate acid or lamotrigine|Bipolar Depression randomized to TAU: Switch to quetiapine plus lithium or valproate acid Compound, brand, dosage, frequency and duration up to the investigator's discretion (in accordance with SmPC).
88844628|NCT05602701||Patients awaiting TKA|Patients awaiting unilateral total knee arthroplasty due to end-stage knee osteoarthritis.
89180932|NCT05246787|Experimental|Breastfeeding intervention|The baby will be placed on the mother's lap 2 minutes before the procedure. 2 minutes before the heel lance, the mother starts to breastfeed her baby and continues to breastfeed throughout the procedure and until the last touch to baby. If necessary, the researcher may verbally warn the mother in a calm tone to continue breastfeeding throughout the procedure. During the resting period (last 2 minutes) after the blood draw is completed, the baby stays on the mother's lap.
89372062|NCT06336395|Experimental|High risk (HR)|Provisional HR patients will be offered CAR-T cell immunotherapy or HSCT
89372063|NCT06336369||Cases|"Cases: (Gilbert-Syndrom):~Total bilirubin in the blood > 1.2 mg/dL (17.1 μM)~Unconjugated (indirect bilirubin) > 1 mg/dL"
89372064|NCT06336369||Controls|"Controls (non-Gilbert-Syndrom):~Total bilirubin in the blood ≤ 1.2 mg/dL (17.1 μM)~Unconjugated (indirect bilirubin) ≤ 1 mg/dL"
88844629|NCT05600504||Elderly patients over the age of 65|no intervention
89372065|NCT06336356|Experimental|Arm 1: Baxdrostat 2 mg|Participants will receive baxdrostat 2 mg tablet orally once daily.
89180933|NCT05246787|Experimental|Shotblocker intervention|2 minutes before the procedure, the baby will be placed on the mother's lap. ShotBlocker is a small plastic tool that is blunt, short, has many points in contact with the skin, does not contain drugs, is in the shape of a horseshoe, invasive interventions can be applied through the space in the middle. It is positioned on the skin before the invasive procedure. The investigator should make sure that the contact points touch the skin. Shotblocker is pressed firmly for 20 seconds before the intervention, it is pulled from the area and the heel is pierced with the lancet. After Shotblocker is applied to the skin, invasive intervention should be performed within 30 seconds and the protocol should be followed. During the resting period (last 2 minutes) after the heel lance is completed, the baby stays on the mother's lap.
89180934|NCT05246787|Experimental|Breastfeeding and Shotblocker intervention|The baby will be placed on the mother's lap 2 minutes before the procedure. 2 minutes before the heel lance, the mother starts to breastfeed her baby and continues to breastfeed throughout the procedure and until the last touch to baby. The investigator should make sure that the contact points touch the skin. Shotblocker is pressed firmly for 20 seconds before the intervention, it is pulled from the area and the heel is pierced with the lancet. After Shotblocker is applied to the skin, invasive intervention should be performed within 30 seconds and the protocol should be followed. During the resting period (last 2 minutes) after the heel lance is completed, the baby stays on the mother's lap.
88844630|NCT05600504||Elderly patients over the age of 65 undergoing elective non-cardiac surgery|no intervention
88844631|NCT05599490|Experimental|Experimental Treatment|Computerized plasticity-based adaptive cognitive training requiring a total maximum of 50 treatment sessions, up to 5 sessions per week, 42 minutes per session.
89372066|NCT06336356|Placebo Comparator|Arm 2: Placebo|Participants will receive placebo tablet orally once daily.
89372067|NCT06336343|Experimental|Individuals with moderate-to-severe psoriasis|Individuals with moderate-to-severe psoriasis who have failed similar therapies.
89372068|NCT06336330||HFpEF|Adult patients with preserved ejection fraction (HFpEF; EF≥50%) who receive treatment with dapagliflozin in accordance with the local dapagliflozin product label for symptomatic chronic heart failure.
88844632|NCT05598931||Healthy Controls|Subjects will undergo a single MRI session and will then participate in an on-line neuro-navigation session in which various TMS coil positions will be recorded. The brain/head images will be provided to the programmer to permit development of the virtual neuro-navigation algorithm. Data from Yr1 will be used by the programmer as a training sample, and from Yr2 as a test sample.
89372069|NCT06336330||HFmrEF|Adult patients with mildly reduced ejection fraction (HFmrEF; EF 41-49%) who receive treatment with dapagliflozin in accordance with the local dapagliflozin product label for symptomatic chronic heart failure.
88844636|NCT05592275|Experimental|LY3540378 Dose 1|Participants will receive LY3540378 subcutaneously (SC).
88844637|NCT05592275|Experimental|LY3540378 Dose 2|Participants will receive LY3540378 SC.
88844638|NCT05592275|Experimental|LY3540378 Dose 3|Participants will receive LY3540378 SC.
88844639|NCT05592275|Placebo Comparator|Placebo|Participants will be given placebo SC.
89372070|NCT06336330||HFrEF|Adult patients with reduced ejection fraction (HFrEF; EF ≤40%) who receive treatment with dapagliflozin in accordance with the local dapagliflozin product label for symptomatic chronic heart failure.
89372071|NCT06336317|Active Comparator|Vaccination arm|Influenza vaccine (Vaxigrip Tetra Sanofi Pasteur Europe).
89372072|NCT06336317|Placebo Comparator|Placebo arm|Sodium Chloride (Placebo) Solution for infusion, 9mg/ml ATC code: B05BB01
89372073|NCT06336304||Pediatric|
89534860|NCT03090555|Active Comparator|Comparison Group|Participants in the comparison group did not undergo a session of translational manipulation. In order to equalize the number of intervention sessions, members of this group underwent 7 in-clinic sessions of manual therapy (MT). The first clinic treatment session for all study participants included instruction in the home program of static stretching, resistive exercise, and ice, issue of an illustrated handout and digital video disc detailing the same program, and MT by a physical therapist that included all indicated grades of non-thrust manipulation. Subsequent clinic treatment sessions included additional MT, progression of the strengthening exercises, and reinforcement of the home program.
89372074|NCT06336304||Male Adult Obstructive|
89372075|NCT06336304||Male adult incontinence and/or urgency|
89534861|NCT03332693|Active Comparator|No exercise|Volunteers will not participate in exercise
89534862|NCT03332693|Active Comparator|Light exercise|Volunteers will participate in one short exercise
88844644|NCT05574322|Experimental|Training group (PRP)|Participants benefiting from an 8-week muscle strengthening program (PRP)
88844645|NCT05574322|Sham Comparator|Control group|Participants in the control group will be asked to maintain their habits and lifestyle (without training program) for the duration of the study.
88844646|NCT05569265|Experimental|Hemodynamic prediction index based goal directed hemodynamic therapy|Hemodynamic handling will be based hemodynamic prediction index (HPI)
88844647|NCT05569265|No Intervention|No HPI|Patients in the control group will be treated according to standard practice.
89180935|NCT05246787|No Intervention|Control group/ Standard Care|The baby is placed on the mother's lap 2 minutes before the procedure and the mother is provided to hold the baby effectively and graspingly. Standard heel lance procedure is applied. No additional interventions are applied to the baby. During the resting period (last 2 minutes) after the heel lance is completed, the baby stays on the mother's lap.
89180936|NCT00478933|Experimental|ICD Therapy, blood sampling|Blood sampling Defibrillator, Dual Chamber ; Implantable
89180937|NCT04084353||Delivered women|Maternal and perinatal outcomes will be collected prospectively on all patients that deliver in Government Medical College (GMC) Hospital before, during and after the training over the study period (8 months) in order to evaluate the impact of the training.
89180938|NCT04087824|Experimental|AI monitoring colonoscopy|Patients in this group go through colonoscopy under the AI monitoring device.
89180939|NCT00725322|Experimental|Placebo then Botox|
89180940|NCT00725322|Experimental|Botox then Placebo|
89180941|NCT04084197|Experimental|Sequence 1|Period 1 : Fasted state + HIP1402, Period 2 : Fasted state + HIP1801
89372076|NCT06336304||Female adult obstructive|
89372077|NCT06336304||Female adult incontinence and/or urgency|
89372078|NCT06336304||Adults with neurological co-morbidities|
89372079|NCT06336291|Experimental|Arm A|Patients will be treated with L19TNF on Days 1, 3 and 5, and on Days 22, 24 and 26 and Lomustine on Day 1 (in the evening after L19TNF infusion) of a 42-day cycle for up to a maximum of 6 cycles.
89372080|NCT06336291|Experimental|Arm B|Patients will be treated with on Days 1, 3 and 5, and on Days 22, 24 and 26 and Lomustine on Day 1 (in the evening after L19TNF infusion) of a 42-day cycle for up to a maximum of 6 cycles
89372081|NCT06336291|Experimental|Arm C|Patients will be treated with L19TNF on Days 1, 3 and 5, and on Days 22, 24 and 26 and Lomustine on Day 1 (in the evening after L19TNF infusion) of a 42-day cycle for up to a maximum of 6 cycles.
89372082|NCT06336291|Experimental|Arm D|Patients will be treated with L19TNF on Days 1, 3 and 5, and on Days 22, 24 and 26 and Lomustine on Day 1 (in the evening after L19TNF infusion) of a 42-day cycle for up to a maximum of 6 cycles.
89534863|NCT03332693|Active Comparator|Heavy exercise|Volunteers will participate in heavy exercise
89534864|NCT03090867|Active Comparator|Conventional arm|The relative or surrogate will not be encouraged to perform care. The management of the relative or surrogate wi ll not changed from the regular standard of the ICU.
89534865|NCT03090867|Experimental|The relative/surrogate will be encouraged to perform care|"The relative or surrogate will perform at least two cares a week . A manual will be given to the relative or surrogate, explaining the different care he can choose to perform on the patient.~The care proposed are: feeding, mouth care, hair wash, shaving, eye care, hand, foot and face massage.~All care are planned and perform under the supervision or/and in collaboration with a caregiver.~Each care is written down on a collecting sheet."
89372083|NCT06336291|Experimental|Arm E|Patients will be treated with L19TNF on Days 1, 3 and 5, and on Days 22, 24 and 26 and Lomustine on Day 1 (in the evening after L19TNF infusion) of a 42-day cycle for up to a maximum of 6 cycles.
89372084|NCT06336291|Experimental|Arm F|Patients will be treated with L19TNF on Days 1, 3 and 5, and on Days 22, 24 and 26 and Lomustine on Day 1 (in the evening after L19TNF infusion) of a 42-day cycle for up to a maximum of 6 cycles.
89372085|NCT06336278||Knee Osteoarthritis|Patients who have knee pain at least 6 months, 45-75 years old, kellgren-lawrence grade 1-3
89372086|NCT06336278||Control|Subjects who have not knee pain, 45-75 years old
89372087|NCT06336252|Experimental|Arm 1 digital nudging|"In hospital Participants in the intervention group will receive usual hospital care and be provided with a sensor collecting data on physical activity level during hospitalisation AND a monitor placed at their bedside that displays information about their physical activity level, in terms of time spent bedridden, sitting, standing, and walking. This information will be visible to the health personnel, the patients, and their relatives. This feedback system is developed and provided by SENS Innovation.~After discharge The visual feedback system from SENS will be continued after discharge and include an E-sport biking system provided by 4Mvideo. This integrated new system will combine an ergometer bike or sofa bike installed in the patient's own home or nursing home, and data from the sensor that the participants continue to wear after discharge will go into the SENS system, feeding back a visual track of their activities"
88844648|NCT05566262|Experimental|Bodewell Treatment|All patients will be treated with the active product, Bodewell. Bodewell will be applied topically twice a day to all active lesions.
89372088|NCT06336252|No Intervention|Arm 2 usual care|The participants in the non-exposed cohort will receive usual hospital care and be provided with a sensor collecting data on activity level during hospitalisation.
89372089|NCT06336226|Active Comparator|One stage group|The one-stage operation was performed under regional anesthesia. A 5-cm incision at the ante cubital fossa identifies the basilic vein. The incision was extended proximally, and the underlying deep fascia was opened. The basilic vein was mobilized up to its junction with the brachial vein. The median cutaneous nerve of the forearm was carefully dissected and preserved. After side branches were ligated, the basilic vein was tunnelled subcutaneously, with a Roberts' forceps maintaining its axial orientation.An end-to-side arteriovenous anastomosisto the brachial artery was performed
89372090|NCT06336226|Active Comparator|two stage group|"he first stage of the two-stage procedure was performed under local anesthesia by formation of the arteriovenous anastomosis with minimal disturbance of the basilic vein. After 4 to 6 weeks, a flow assessment of the AVF by duplex scanning was made to determine if revision of the anastomosis was necessary at the second stage. The second stage was performed under regional anesthesia. The entire length of the basilic vein was mobilized, asubcutaneous flap was created, and the vein was positioned anterolaterally. Usually, a further 2 weeks was required before the AVF can be used"
89372091|NCT06336213|Experimental|Ampicillin/sulbactam intervention group|If a patient meets dual criteria (presepsin > 519,5 pg/ml at the end of surgery and the absence of presepsin increase after 6 hours after the end of surgery) then switching to ampicillin/sulbactam 3 g every 6 hours at least 72 h after the surgery is done.
89372092|NCT06336213|No Intervention|Cefazolin|If presepsin < 519,5 pg/ml at the end of surgery, cefazolin 2 g every 6 h at least 72 h p/o is continued further
89372093|NCT06336200||Higher Kinesiophobia|"It is a group with a high level of kinesiophobia according to the Tampa kinesiophobia scale."
89372094|NCT06336200||Lower Kinesiophobia|"It is a group with a low level of kinesiophobia according to the Tampa kinesiophobia scale."
88844649|NCT05565885||patients with vascularitis|Two additional 7ml EDTA tubes of blood are taken from the same blood puncture as during routine follow-up at several points in the follow-up
88844650|NCT05561400|Active Comparator|Real tDCS|the participant receives real tDCS to the right cerebellum during behavioral intervention (CILT)
88844651|NCT05561400|Placebo Comparator|Sham tDCS|the participant receives sham tDCS to the right cerebellum during behavioral intervention (CILT)
88844652|NCT05556954||Infected DFU cohort|25 participants that have an infected DFU will be enrolled.
88844653|NCT05556954||Non-infected DFU cohort|75 non-infected participants with DFU will be enrolled.
88844654|NCT05556512|Experimental|Tirzepatide|Participants will receive escalated doses of tirzepatide subcutaneously (SC) up to a maximum tolerated dose.
88844655|NCT05556512|Placebo Comparator|Placebo|Participants will receive tirzepatide matched placebo.
89180942|NCT04084197|Experimental|Sequence 2|Period 1 : Fasted state + HIP1801, Period 2 : Fasted state + HIP1402
89180943|NCT04084197|Experimental|Sequence 3|High fat diet + HIP1402, Period 2 : High fat diet + HIP1801
89180944|NCT04084197|Experimental|Sequence 4|High fat diet + HIP1801, Period 2 : High fat diet + HIP1402
89372095|NCT06336187||RCC (renal cell carcinoma)|Patients with small, incidentally detected, histologically confirmed renal cell carcinoma
89372096|NCT06336174||Surgery Group|Symptomatic intracranial stenosis patients who receive endovascular therapy combined with standard medical treatment
89372097|NCT06336174||Medical group|Symptomatic intracranial stenosis patients who receive standard medical treatment without endovascular therapy
89372098|NCT06336161|Active Comparator|Group A ( Erector Spinae Plane Block)|About 40 patients who will be subjected to Ultrasound-Guided Erector Spinae Plane Block.for Postoperative Pain Management
89372099|NCT06336161|Active Comparator|Group B (Caudal Injection)|About 40 patients who will be subjected to Ultrasound-Guided Caudal Injection in Lumbosacral Spine Surgeries for Postoperative Pain Management
89372100|NCT06336148|Experimental|ACTM-838 Monotherapy|Escalating doses of ACTM-838 in Part 1a followed by expansion in Part 1b at the recommended dose determined in Part 1a
89372105|NCT06336109|Experimental|Knee Pain|Injection to the infrapatellar fat pad.
89372106|NCT06336109|Experimental|Shoulder Pain|Injection to the deltoid muscle.
89372107|NCT06336096|Experimental|Part A|Participants will be randomized to receive a single dose of SUZ in 1 of 6 treatment sequences with 3 dosing periods to assess the relative bioavailability of two tablet formulations and the effect of food on the PK of SUZ. There will be a 14-day washout period between each dosing period.
89372108|NCT06336096|Experimental|Part B|Participants will be randomized to receive a single dose of SUZ formulation in 1 of 2 treatment sequences with 2 dosing periods to assess the relative bioavailability of tablet formulation compared to a suspension of SUZ. There will be a 14-day washout period between each dosing period.
88844656|NCT05554406|Active Comparator|Arm I (cytarabine, daunorubicin)|Patients receive cytarabine IV and daunorubicin IV per standard approach on study. Patients also undergo a bone marrow aspiration and collection of blood throughout the trial.
88844657|NCT05554406|Experimental|Arm II (cytarabine, daunorubicin, venetoclax)|Patients receive cytarabine IV and daunorubicin IV with venetoclax PO on study. Patients also undergo a bone marrow aspiration and collection of blood throughout the trial.
89180945|NCT02593890|Active Comparator|Intervention|Arm A: Participants will be fitted with the THEYA Recovery bra
89180946|NCT02593890|No Intervention|Control|Arm B: Participants will be recommended or fitted with current recommended bra used in each hospital by the Breast Care Nurse Specialist
89180947|NCT02589483|Experimental|Prospective pilot|Patient included prospectivly will be all treated according to study protocol.The rectal anastomosis will be reinforced with HemoPatch.
89372109|NCT06336096|Experimental|Part C|Participants will be randomized to receive a single dose of a pre-determined strength of SUZ in 1 of 2 treatment sequences with 2 dosing periods to assess the relative bioavailability of two tablet formulations of SUZ. There will be a 14-day washout period between each dosing period.
89372110|NCT06336083|Experimental|Doppler ultrasound|First degree relatives of patient with diagnosed Carotid Web will receive an echography doppler of the carotid arteries and answer questionnaires
89180948|NCT00725010||Patients|Participants with newly diagnosed Glioblastoma multiforme who were prescribed temozolomide and radiotherapy as standard care.
89180949|NCT02589561|Active Comparator|face to face fitting|face to face fitting of hearing aids
89372111|NCT06336070|Experimental|Exercise intervention|Two cohorts of both healthy postmenopausal women and women free of postmenopausal breast cancer recurrence. Each of the groups will be split into two different exercise programmes. Both programmes, High Intensity Interval Training (HIIT) programme (metabolic power training) and Muscle Power Intervention (MPI) programme will consist of 8 weeks.
89372112|NCT06336070|No Intervention|Cross-sectional study|Two cohorts of both healthy postmenopausal women and women free of postmenopausal breast cancer recurrence.
89180950|NCT02589561|Experimental|remote fitting|remote fitting of hearing aids
89180951|NCT05684601|Placebo Comparator|rotating drills device|Third molar surgery performed with traditional rotating devices
89180952|NCT05684601|Active Comparator|Piezoelectric device|Third molar surgery performed with piezoelectric surgery device
89180953|NCT05216055|Experimental|Investigational Arm|"The study drug volume, concentration, and dose of treatment arm #1 selected is based on the Principal Investigator's prior experience recommendations by the Food Drug Administration (FDA), and evidence based on prior literature. The final concentration of ropivacaine is 0.375% and final volume of the mixture is 60mL.~Ropivacaine 0.5% HCl, 40 mL (5 mg per mL) (200 mg)~Dexmedetomidine HCl, 0.50 ml (100 ug per mL) (50 ug)~Dexamethasone sodium phosphate, 1 mL (10 mg per mL) (10 mg)~Normal saline 0.9%, 18.5mL"
89180954|NCT05216055|Active Comparator|Liposomal Bupivacaine (Exparel)|"The study drug for patients in the treatment arm #2 will be a mixture of liposomal bupivacaine and bupivacaine 0.25% as follows:~Liposomal bupivacaine, 20 mL (13.3 mg/ml) (266 mg)~Normal saline 0.9%, 40mL The total volume to be injected in each patient will be 60 mL (see below for different treatment arms)."
89180955|NCT02592408|Active Comparator|Pf: ASP|In falciparum patients (Pf): 3 days of artesunate + sulfadoxine/pyrimethamine (ASP)
89180956|NCT02592408|Active Comparator|Pv: ASP + 14DPQ on day 2|In vivax patients (Pv): 3 days of artesunate + sulfadoxine/pyrimethamine (ASP) and 14 days of primaquine (14DPQ) starting on day 2
89180957|NCT02592408|Active Comparator|Pf: ASP + SDPQ|In falciparum patients (Pf): 3 days of artesunate + sulfadoxine/pyrimethamine (ASP) and a single dose of primaquine (SDPQ) on day 2
88844658|NCT05554406|Experimental|Arm III (azacitidine, venetoclax)|Patients receive azacitidine SC or IV and venetoclax PO on study. Patients also undergo a bone marrow aspiration and collection of blood throughout the trial.
88844659|NCT05554406|Experimental|Arm IV (daunorubicin and cytarabine liposome)|Patients receive daunorubicin and cytarabine liposome IV on study. Patients also undergo a bone marrow aspiration and collection of blood throughout the trial.
88844660|NCT05546268|Experimental|Phase 1 Dose Escalation|Patients with NSCLC, SCLC, high-grade neuroendocrine cancer of any primary site, any solid tumors with L-MYC or N-MYC amplification, or DLBCL
88844661|NCT05546268|Experimental|Phase 2 Expansion - NSCLC|Patients with NSCLC with high or low L-MYC or N-MYC expression
88844662|NCT05546268|Experimental|Phase 2 Expansion - SCLC|Patients with SCLC
88844663|NCT05546268|Experimental|Phase 2 Expansion - L-MYC or N-MYC amplified solid tumors|Patients with L-MYC or N-MYC amplified solid tumors
88844664|NCT05543252|Experimental|Minzasolmin (UCB0599) High Dose Arm|Participants will receive a predefined high dosage of minzasolmin (UCB0599) during the Treatment Period.
88844665|NCT05543252|Experimental|Minzasolmin (UCB0599) Low Dose Arm|Participants will receive a predefined low dosage of minzasolmin (UCB0599) during the Treatment Period.
88844666|NCT05540665|Experimental|Daxdilimab Arm 1|Daxdilimab injections over a total of 104 weeks
89180958|NCT02592408|Active Comparator|Pv: ASP + 14DPQ on day 42|In vivax patients (Pv): 3 days of artesunate + sulfadoxine/pyrimethamine (ASP) and 14 days of primaquine (14DPQ) starting on day 42
89180959|NCT00767000|Experimental|MK-0941 10 mg|
89180960|NCT00767000|Experimental|MK-0941 20 mg|
89180961|NCT00767000|Experimental|MK-0941 30 mg|
89180962|NCT00767000|Experimental|MK-0941 40 mg|
88844667|NCT05540665|Experimental|Daxdilimab Arm 2|Daxdilimab injections over a total of 104 weeks
88844668|NCT05540665|Placebo Comparator|Placebo|Placebo injections over a total of 104 weeks
89180963|NCT00767000|Placebo Comparator|Placebo|
89180964|NCT05194449|Experimental|Comfort Talk® App (Cft) Group|Mobile app with elements of relaxation, self-hypnosis, and reframing of distress
89180965|NCT05194449|Placebo Comparator|Placebo Group|Mobile app with white noise choices having the same looks and functionality as the active Comfort Talk® 1st app
89180966|NCT00724932|Experimental|Sugammadex|4.0 mg.kg-1 sugammadex at 1-2 PTC
89180967|NCT00724932|Experimental|Neostigmine|50 µg.kg-1 neostigmine (with atropine in a ratio of 5:1 for neostigmine:atropine) at reappearance of T2
89180968|NCT00766532|Experimental|aromatase inhibitor therapy|aromatase inhibitor therapy for six weeks
89372113|NCT06336057||Patients|Group of patients with narcolepsy type 1.
89372114|NCT06336057||Controls|Group of control patients with Obstructive Sleep Apnea (OSA) corrected by treatments
89372115|NCT06336044|Experimental|Standard patients|Patients treated with the experimental Medical Device
89180969|NCT02602340|Experimental|Behavioral Activation therapy|Participants will complete 10, 90-minute sessions of Behavioral Activation therapy, conducted using a group format. Each group will include 8-12 participants. Behavioral Activation therapy seeks to target behaviors that might maintain or worsen the depression.
88844669|NCT05538182|Experimental|Spectacles|"Based on the refraction results, spectacles will be prescribed at the baseline visit and worn throughout the study. Study participants with newly diagnosed hyperopia at baseline will undergo a reading assessment and near visual acuity check over six months, compared to age-, gender- and school-matched emmetropic controls.~Spectacle compliance will be observed among newly diagnosed hyperopic and newly diagnosed myopic school children in Grades 2 and 4 primary school children, from Mashonaland Central province of Zimbabwe, at six weeks and 14 weeks from spectacle acquisition."
88844670|NCT05538182|No Intervention|No treatment|Age-, gender- and school-matched emmetropic controls will undergo a reading assessment at baseline and at six months.
88844671|NCT05537740|Experimental|Dose escalation - Arm 1A|Dose escalation of BAY3375968 as monotherapy
89180970|NCT02589093|Experimental|Stimulation|Subjects will receive progressive electrical stimulations with an external nerve stimulator over the ulnar nerve, from 0 mA to 30 mA in increments of 5 (2 Hz single twitch mode), for 3 minutes at each intensity. They will be asked to score their pain level (NRS 0-10) every minute. ANI will be recorded constantly.
89372116|NCT06336031|Experimental|Image and video data set shown with BII stimuli.|Participants will undergo this test on two separate days. On each day, participants will be asked to watch a series of videos and images. For this arm of the study, participants will view the BII phobia-related stimuli.
89372117|NCT06336031|Placebo Comparator|Image and video data set shown with neutral stimuli.|Participants will undergo this test on two separate days. On each day, participants will be asked to watch a series of videos and images. For this arm of the study, participants will view the neutral stimuli.
89372118|NCT06336018|Experimental|Mild hepatic impairment: Etavopivat dose 2|Participants will receive a single dose of oral etavopivat.
89372119|NCT06336018|Experimental|Moderate hepatic impairment: Etavopivat dose 2|Participants will receive a single dose of oral etavopivat.
89372120|NCT06336018|Experimental|Healthy matched controls: Etavopivat dose 2|Participants will receive a single dose of oral etavopivat.
88844672|NCT05537740|Experimental|Dose escalation - Arm 1B|Dose escalation of BAY 3375968 in combination with pembrolizumab
88844673|NCT05537740|Experimental|Dose expansion - Arm 2A|BAY3375968 monotherapy-mode-of-action (monotherapy-MoA) expansion in subjects with one of the following tumor types: NSCLC (PD-L1 tumor proportion score [TPS] ≥50%), TNBC (PD-L1 combined positive score [CPS] ≥10), HNSCC (PD-L1 CPS ≥20), or melanoma (no PD-L1 cut-off). The tumors should have primary (ICI-refractory) or secondary (ICI-relapsed) resistance to prior ICI-therapy. The final decision on the enrolled tumor type is at the discretion of the Sponsor.
88844674|NCT05537740|Experimental|Dose expansion - Arm 2B|Disease-specific combination expansion with separate cohorts in 4 ICI-relapsed tumor types (NSCLC, TNBC, HNSCC, and melanoma)
89372121|NCT06336018|Experimental|Severe hepatic impairment: Etavopivat dose 1|Participants will receive a single dose of oral etavopivat.
88844675|NCT05536739|Experimental|Powered Hip Exoskeleton for Stroke Assistance|This study will be conducted on a sample population of stroke subjects (single arm). Each subject will test with each condition of the exoskeleton (repeated measures).
88844676|NCT05536037|Experimental|Prevention (metformin)|Patients receive metformin PO QD on days 1-3 and then PO BID for up to 12 months in the absence of unacceptable toxicity.
89372122|NCT06336018|Experimental|Healthy matched controls: Etavopivat dose 1|Participants will receive a single dose of oral etavopivat.
89372123|NCT06336005|Experimental|NNC6022-0001|Participants will be randomised to NNC6022-0001.
89372124|NCT06336005|Placebo Comparator|Placebo (NNC6022-0001)|Participants will be randomised to placebo.
88844677|NCT05526157||Patients with CKD+T2D in Study period I|In the pre-finerenone approval period (Study period I), 4 new-user cohorts to be identified, based on the first use of any drug in these classes: SGLT2i, GLP-1 RA, sMRA, or nsMRA.
88844678|NCT05526157||Patients with CKD+T2D in Study period II|In the post-finerenone approval period (Study period II), 5 new-user cohorts to be created based on the use of any drug in these classes: SGLT2i, GLP-1 RA, sMRA, finerenone, and other nsMRA).
88844679|NCT05514054|Experimental|Imlunestrant|Imlunestrant administered orally.
89180971|NCT04083807|Experimental|TISSEEL Lyo|Applied once intra-operatively to the study suture line using the DUPLOJECT Fibrin Sealant Preparation and Application System.
89180972|NCT04083807|Active Comparator|Manual compression with surgical gauze pads|Treated once intraoperatively with manual compression using surgical gauze pads at the study suture line.
89180973|NCT02601794|Experimental|App-based Mindfulness Training|12 week mindfulness training delivered remotely through mobile app
89180974|NCT02601794|No Intervention|Waitlist Control|No intervention provided during study period. 12 week mindfulness training will be delivered through mobile app once all study assessments have been completed
89180975|NCT05188989|Experimental|TPN171H 2.5mg group|
89180976|NCT05188989|Experimental|TPN171H 5mg group|
89180977|NCT05188989|Experimental|TPN171H 10mg group|
89372125|NCT06335992|Experimental|Exercise|"The exercise training protocol to be used in this study:~Supervised exercise training (aerobic- and muscle strengthening exercise): 2 times a week for 12 weeks.~Aerobic exercise with ergometer cycling for 30 min, at moderate intensity (60% Wpeak) individually adjusted to level 4-6 on the Borg category ratio-10 scale.~Muscle strengthening exercise will consist of 8-12 strength exercises of the major upper and lower body muscle groups. Each exercise includes three sets with 8-12 repetitions.~Exercise training at home: once a week for 12 weeks."
89372126|NCT06335979|Experimental|Cohort 1|Dose level 1
89180978|NCT05188989|Placebo Comparator|Placebo group|
89372127|NCT06335979|Experimental|Cohort 2|Dose level 2
89372128|NCT06335979|Experimental|Cohort 3|Dose level 3
89372129|NCT06335979|Experimental|Cohort 4|Dose level 4
89180979|NCT00774566|Active Comparator|1|segmental PVI using an irrigated tip catheter
89180980|NCT00774566|Active Comparator|2|PVI using the Cryo-Balloon
89372130|NCT06335979|Experimental|Cohort 5|Dose level 5
88819353|NCT04668339|Placebo Comparator|Study Group 4, Younger Adult Participants|Participants will receive one of Placebo (Saline) on Day 0, one dose of Placebo on Day 28, and one dose of Placebo on Day 208
88819354|NCT04668339|Experimental|Study Group 1, Older Adult Participants|Participants will receive one dose of ARCT-021 on Day 0, one dose of Placebo (saline) on Day 28 and on Day 208 either one dose of ARCT-021 or one dose of placebo
88819355|NCT04668339|Experimental|Study Group 2, Older Adult Participants|Participants will receive one dose of ARCT-021 on Day 0, a second dose of ARCT-021 on Day 28 and on Day 208 either one dose of ARCT-021 or one dose of placebo
88819356|NCT04668339|Experimental|Study Group 3, Older Adult Participants|Participants will receive one dose of ARCT-021 on Day 0, a second dose of ARCT-021 on Day 28 and on Day 208 either one dose of ARCT-021 or one dose of placebo
89180981|NCT02589249|Placebo Comparator|Placebo|placebo
89180982|NCT02589249|Active Comparator|AyuFlex1|AyuFlex1 (500 mg/d)
89180983|NCT02589249|Active Comparator|AyuFlex2|AyuFlex2 (1000 mg/d)
89372131|NCT06335979|Experimental|Cohort 6|Dose level 6
89372132|NCT06335979|Experimental|Cohort 7|Dose level 7
89372133|NCT06335979|Experimental|Cohort 8|Dose level 8
89372134|NCT06335966||Patients with suspected Barrett's Esophagus or at risk for esophageal cancer|Patients who receive primary care in a rural settings and are in need of screening for Barrett's Esophagus or esophageal cancer.
89372135|NCT06335953|Experimental|Intervention|"The intervention consists of the following:~Mailing a deprescribing educational brochure to PLWD and care partners;~PLWD and/or care partners will receive a single telehealth visit in which an embedded clinical pharmacist discusses the benefits and harms of the patient's medications with the patient and care partner in the context of their goals and preferences;~Pharmacist-primary care provider (PCP) communication in which the pharmacist provides tailored deprescribing recommendations designed to be useful and actionable for the PCP."
88819357|NCT04668339|Placebo Comparator|Study Group 4, Older Adult Participants|Participants will receive one dose of Placebo (saline) on Day 0, a second dose of Placebo on Day 28 and a third dose of Placebo on Day 208
88819358|NCT00369603|Experimental|Razadyne ER|galantamine treatment group
88819359|NCT00369603|Experimental|Aricept|Aricept Treatment Group
88819360|NCT01432886|Experimental|1|
88819361|NCT05239455||Healthy adult participants|Performance criteria will be evaluated in healthy adult participants, who receive radiolabeled, autologous infusions of LR-RBC components after being stored for 42 days at 1-6°C.
88819362|NCT01433042|Experimental|capsule endoscopy|
88819363|NCT01551056|Experimental|AC-170 0.24%|
88819364|NCT01551056|Placebo Comparator|AC-170 0%|
88819365|NCT05227131|Experimental|Margetuximab + Tucatinib + Capecitabine|All eligible patients will receive the combination of margetuximab 15 mg/kg by intravenous infusion on Day 1 of each cycle (no loading dose is required), capecitabine at 1000 mg per square meter of body-surface area orally twice daily on days 1 to 14 of each 21-day cycle, and tucatinib 300 mg orally twice daily (every 12 hours) continuously in 21-day cycles.
88819366|NCT05218239|Active Comparator|Routine education group|Routine education, including postpartum lifestyle, Kegel exercise and Knack method.
88819367|NCT05218239|Experimental|Global training group|Global training was added on the basis of routine education.
88819368|NCT01435304|Experimental|Hemobag®|Hemobag® method of returning residual CPB blood (study group)
88819369|NCT01435304|No Intervention|cell saver|Standard method of returning the residual pump volume to the patient as washed, centrifuged cells (control group)
88819370|NCT03024567|Active Comparator|Salt|6 grams sodium chloride per day for 14 days
88819371|NCT03024567|Placebo Comparator|Placebo|6 grams gelatine per day for 14 days
88819372|NCT01499498|Experimental|Sildenafil and Boceprevir|Healthy volunteers
88819373|NCT01436006||CT scan|patient with cancer
89372136|NCT06335953|Active Comparator|Delayed intervention (wait list control)|"The intervention consists of the following:~Mailing a deprescribing educational brochure to PLWD and care partners;~PLWD and/or care partners will receive a single telehealth visit in which an embedded clinical pharmacist discusses the benefits and harms of the patient's medications with the patient and care partner in the context of their goals and preferences;~Pharmacist-primary care provider (PCP) communication in which the pharmacist provides tailored deprescribing recommendations designed to be useful and actionable for the PCP."
89372137|NCT06335940||No videoregulation|"An initial period of 40 days during which we leave the use of video-regulation to the discretion of the regulating physicians (emergency physicians or general practitioners) when they are faced with a call labelled by a medical regulation assistant (ARM) Pediatric dyspnea in a child under 10 years of age or when they themselves judge that the call falls into this category; as is the case in the current practice of the SAMU38."
89372138|NCT06335940||Videoregulation|"A 40-day period during which we will encourage regulating physicians to use video-regulation for every call concerning pediatric dyspnea in a child aged < 10 years."
89372139|NCT06335927|Experimental|HAIC-GEMOX+Cadonilimab+Regorafenib|HAIC-GEMOX: Gemcitabine 1000mg/m2 on Day 1 + Oxaliplatin 85mg/m2 on Day 1, every 3 weeks (Q3W), for up to 6 treatment cycles in combination with Cadonilimab (6mg/kg, D2, Q3W) and Regorafenib (80mg QD, Q3W)
89372140|NCT06335914|Experimental|PSMA and FDG PET Imaging|Participants advanced prostate cancer will undergo PSMA and FDG PET prior to starting their standard of care treatment and during treatment.
89372142|NCT06335888|Experimental|AzaFol first, FDG second|AzaFol PET/CT imaging followed by FDG PET/CT imaging (standard of care)
89372143|NCT06335888|Active Comparator|FDG first, AzaFol second|FDG PET/CT imaging (standard of care) imaging followed by AzaFol PET/CT
89372144|NCT06335875|Experimental|Bipolar Disorder|Participants will follow an intervention consisting of dietary changes and ketone ester supplementation for 90 +/- 10 days. The dietary changes are intended to reduce glycemic spiking and include: not consuming sweets, not consuming soda, replacing 'white' grains with whole grain alternatives, and reserving any fruit consumption for the end of meals. During the same time period, participants will consume the ketone ester supplement, consisting of 19 g Juvenescence Cognitive Switch™ (=12.5 g active C8-KE) diluted in water twice per day.
89372145|NCT06335862|Other|PPT-group|Participants allocated to this study arm will undergo the primary posterior tracheopexy (PPT). This PPT is performed concurrently with the primary OA correction. Afterwards, all patients follow the (same) routine follow-up schedule. This treatment is currently used in some centres.
89372146|NCT06335862|Other|No-PPT-group|Participants allocated to this study arm will undergo the the primary OA correction, without a PPT. Afterwards, all patients follow the (same) routine follow-up schedule. This treatment is also used in some centres.
89372147|NCT06335849|Experimental|Treatment 1 (LYB004 25µg)|Subjects will be enrolled and stratified by age (50-59 years and 60-70 years in a 1:1 ratio) and randomized (2:2:1) to receive 25 μg LYB004, 50 μg LYB004 or SHINGRIX. The two-dose immunization schedule will be adopted, that is, LYB004 or SHINGRIX will be intramuscularly injected on Day 0 and Day 60.
89372148|NCT06335849|Experimental|Treatment 2 (LYB004 50µg)|Subjects will be enrolled and stratified by age (50-59 years and 60-70 years in a 1:1 ratio) and randomized (2:2:1) to receive 25 μg LYB004, 50 μg LYB004 or SHINGRIX. The two-dose immunization schedule will be adopted, that is, LYB004 or SHINGRIX will be intramuscularly injected on Day 0 and Day 60.
89372149|NCT06335849|Active Comparator|Treatment 3 (SHINGRIX)|Subjects will be enrolled and stratified by age (50-59 years and 60-70 years in a 1:1 ratio) and randomized (2:2:1) to receive 25 μg LYB004, 50 μg LYB004 or SHINGRIX. The two-dose immunization schedule will be adopted, that is, LYB004 or SHINGRIX will be intramuscularly injected on Day 0 and Day 60.
89372150|NCT06335836||SI group (social isolation group)|"The LSNS-6 was used for assessing social networks among older Chinese. Lubben suggested using a score of less than 12 as a clinical cutoff point of the LSNS-6 to indicate social isolation, which meant, on average, the respondents had less than two people to perform social integration functions.~0≤LSNS-6≤12"
89372151|NCT06335836||nonSI group (non-social isolation group)|LSNS-6>12
89372152|NCT06335823|Experimental|Active TENS unit|All patients will have the TENS unit applied: 2 pads from channel 1 will be at T10-L1 and the second set of pads will be from S2-S4; 5 minutes prior to the start of the procedure. Patients in this arm will have the TENS unit turned on to a 80 hz preset frequency with 100 mA as the pulse width.
89372153|NCT06335823|Placebo Comparator|Non-active TENS unit|All patients will have the TENS unit applied: 2 pads from channel 1 will be at T10-L1 and the second set of pads will be from S2-S4; 5 minutes prior to the start of the procedure. Patients will not have the TENS unit turned on.
89372154|NCT06335810|Experimental|Social Network Intervention|Participants will complete 3 communication skills sessions with their social network members during weeks 3, 5, and 15.
89372155|NCT06335810|Placebo Comparator|Individual Lifestyle Intervention|Participants will complete standard diabetes prevention program (DPP) based health coaching sessions during weeks 3, 5, and 15.
89372156|NCT06335810|Other|Social Network Member|Social Network Members will complete 3 communication skills sessions with the social network intervention participant during weeks 3, 5, and 15.
88844680|NCT05514054|Active Comparator|Investigator's Choice of Endocrine Therapy|Investigator's choice of tamoxifen, anastrozole, letrozole, or exemestane administered per local approved label.
89180984|NCT02589327|Experimental|Exercise Intervention|Hight intensity resistance training group
89180985|NCT02589327|No Intervention|Control|No-exercise control group
89180986|NCT04103918|Other|Jalucomplex® 2|Jalucomplex® 2 (Linear Hyaluronic Acid) Injection: follow the instruction for use
89372157|NCT06335797|Experimental|SENNA|Group A participants will be prescribed oral senna (Senokot; Atlantis Consumer Healthcare Inc., Bridgewater, NJ) 8.6mg tablets and be instructed to start with two tablets on the morning of Post Operative Day (POD)#1. Participant will continue taking two tablets on the daily. If no bowel movement on the morning of POD#3 participant may take 2 tablets in the morning and another 2 tablets that evening. The same can be replicated on POD#4. If no bowel movement on the morning of POD#5 participant may take magnesium hydroxide (Phillips' Milk of Magnesia; Bayer AG, Leverkusen, Germany) 30 mL by mouth and need to call the urology clinic for further instruction.
89372158|NCT06335797|Experimental|DULCOLAX|Group B participants will be prescribed bisacodyl rectal (Dulcolax Suppository; Sanofi S.A., Paris, France) 1 suppository to be placed rectally on the morning of Post Operative Day (POD)#1. Participant will continue placing a nightly rectal suppository until their first bowel movement. If no bowel movement by the morning of POD#5 participant may take magnesium hydroxide (Phillips' Milk of Magnesia; Bayer AG, Leverkusen, Germany) 30 mL by mouth and need to call the clinic for further instruction.
89372159|NCT06335784|Active Comparator|Sleep Hygiene (SH)|Participants will receive 4 weekly individual sessions of standardized instructions on sleep hygiene, that they will be asked to apply every day for 4 weeks. Each session will consist of providing patients with advice to help their sleep without any CBT-I or other complementary medicine components. They will also have an odorless diffuser being diffused at the end of each weekly individual session and during the night.
89372160|NCT06335784|Experimental|Imagery Rescripting (IR)|Participants will receive 4 weekly individual sessions of IR. The IR technique consists of imagining a negative memory or image as vividly as possible, and of transforming it into a positive one. An odorless diffuser will be presented while imagining the positive imagery generated during IR. During 4 weeks, patients of this group will practice IR at home, every day in bed and have the same odorless diffuser being diffused during the night.
89372161|NCT06335784|Experimental|Targeted Memory Reactivation (TMR)|Participants will receive 4 weekly individual sessions of IR, at the end of which, a chosen odor will be presented while imagining the positive imagery generated during IR. During 4 weeks, patients of this group will practice IR at home every day in bed and have the same odor being diffused during the night.
89372162|NCT06335784|Active Comparator|Odor Alone (OA)|Participants will have a chosen odor diffused during the night for 4 weeks and will receive 4 weekly individual sessions of standardized instructions on sleep hygiene, that they will be asked to apply every day for 4 weeks. The chosen odor will be diffused at the end of each weekly individual session.
89372163|NCT06335771|No Intervention|Lean Individuals|No intervention will be administered.
89372164|NCT06335771|Experimental|Metabolically abnormal obese Individuals (obesity with normoglycemia and abnormal liver fat content)|Participants will undergo a dietary weight loss intervention to achieve 10% weight loss over about 6 months.
89372165|NCT06335771|Experimental|Metabolically normal obese Individuals (obesity with normoglycemia and normal liver fat content)|Participants will undergo a dietary weight loss intervention to achieve 10% weight loss over about 6 months.
89372166|NCT06335771|Experimental|Individuals with Type 2 Diabetes Mellitus|Participants will undergo a dietary weight loss intervention to achieve 10% weight loss over about 6 months.
89372167|NCT06335758||Patients receiving solid oral medication as a standard of care.|Solid oral medication administered via the ReX Remote Digital Nurse.
89372168|NCT06335745|Experimental|Arm 1: PediCARE + Usual Supportive Care Experimental|"Participants will be randomized in a 1:1 ratio and stratified according to treatment group and household material hardship (HMH) severity group and participant parents/guardians will complete:~Remote baseline visit with introduction to PediCARE intervention by central study team~Parent completion of baseline survey.~Receipt of monthly PediCARE resource provisions x 6-months.~Parent completion of 3-month follow-up survey.~Parent completion of 6-month follow up survey and end of intervention period."
89372169|NCT06335745|No Intervention|Arm 2: Usual Supportive Care Arm|"Participants will be randomized in a 1:1 ratio and stratified according to treatment group and HMH severity group and participant parent/guardians will complete:~Remote baseline visit~Parent completion of baseline survey.~Receipt of site-specific routine supportive care x6-month study period~Parent completion of 3-month follow-up survey~Parent completion of 6-month follow-up survey"
89372170|NCT06335719|Experimental|Treatment Group|Treatment group undergoes nerve biopsies during surgery. In addition, patients in the treatment group receive brief electrical stimulation therapy for approximately 10 minutes during the first stage cross-face nerve graft surgery.
89372171|NCT06335719|Experimental|Control Group|Control group undergoes only nerve biopsies during surgery - no brief electrical stimulation.
89372172|NCT06335706||Frequently worn underpants during daytime|It will be divided into two groups based on the type of underwear worn: loose-fit, which includes boxers and tight-fit, which includes all other types.
89372173|NCT06335706||Frequently worn underpants at nighttime|It will be divided into two groups based on the type of underwear worn: loose-fit, which includes boxers or none, and tight-fit, which includes all other types.
89372174|NCT06335693|Experimental|adjuvant hypofractionated radiotherapy|Patients after radical prostatectomy with high-risk pathological factors will receive hypofractionated post-prostatectomy radiotherapy in 15 fractions.
89372175|NCT06335667|Experimental|mpMRI + Diagnostic TURBT|
89372176|NCT06335654||colorectal lesion|
89372177|NCT06335641|Experimental|Treatment arm|Head cooling
89372178|NCT06335628|No Intervention|Group A: Connective Tissue Graft (CTG)|Volumetric changes between groups will be compared by matching intraoral scans before and after surgery (including follow-ups after 5 years) using the engineering software Geo-Magic®.
89372179|NCT06335628|Experimental|Group B: Volume Collagen Matrix Xenograft (VCMX) Geistlich Fibro-Gide®|The CTG (Group A) is the gold-standard for soft tissue augmentation, therefore it is considered the control group in this investigation.
89372180|NCT06335615|Experimental|Intervention|The intervention group follows a one-hour in-person intervention focused on acceptance of stress. Each participant follows this intervention individually.
89372181|NCT06335615|Active Comparator|Control|The control group follows a 20-minute online psychoeducation at home. Each participant follows this intervention individually.
89372182|NCT06335602|Experimental|Laser Acupuncture Treat|Low level laser therapy to acupoints related to operation wound, before and after operation
89372183|NCT06335602|Sham Comparator|Laser Acupuncture Sham|Low level laser therapy(with Sham device) to acupoints related to operation wound, before and after operation
89372184|NCT06335602|Active Comparator|Herbal packing|External application of herbal medicine packing around the operation wound, before and after operation
88819374|NCT04551729|Active Comparator|Fluid restriction|Patient will receive a lifestyle advice to adhere to fluid restriction of 1500cc/day for 3 months.
88819375|NCT04551729|Experimental|Liberal fluid intake|Patient will receive a lifestyle advice for liberal fluid intake for 3 months.
89372185|NCT06335589|Experimental|EBP-Massed|PTSD evidence-based psychotherapies are delivered in a massed format (e.g., intended be delivered at least three times per week).
89372186|NCT06335589|Active Comparator|EBP-TAU|PTSD evidence-based psychotherapies are delivered treatment as usual, which is typically once per week.
89372187|NCT06335576||Gastric cancer patients receiving adjuvant chemotherapy|
89372188|NCT06335563|Experimental|AR glasses-assisted pulmonary nodule puncture localization|Combined with placing positioning marks on the patient's body surface and tracing the needle entry point with the assistance of a CT scan gantry laser. Disinfect the area around the puncture needle point, and use 2% lidocaine for local infiltration anesthesia. The doctor wears augmented reality (AR) glasses, completes the connection between the AR glasses and the puncture target, and clicks on the puncture point plane through the puncture target needle tip. Calibrate the puncture position at any two points. After confirming that the patient has held his breath, quickly puncture the needle into the pleura and advance it to the planned puncture position according to the screen prompts. After the second CT scan is performed to confirm that the puncture needle is positioned at a reasonable position, the positioning hook wire is released and the puncture needle sheath is withdrawn.
89372189|NCT06335563|Active Comparator|CT-guided pulmonary nodule puncture localization|Positioning markers are placed on the patient's surface and the first CT scan is performed. The needle insertion point and needle insertion depth are designed based on the two-dimensional CT scan image and the positioning marks. The location of the needle entry point was traced with the laser assistance of the CT gantry. Disinfect and puncture around the needle point, and use 2% lidocaine for local infiltration anesthesia. According to the designed needle path angle, the needle is first inserted under the skin, and a second CT scan is performed to confirm that the extension line of the puncture needle is within the nodule range. Then the needle is inserted to the target depth, and the third CT scan is performed. After confirming that the puncture needle is positioned at a reasonable position, the positioning hook wire is released and the puncture needle sheath is withdrawn.
89372190|NCT06335550|Other|Robotic mastectomy|All consecutive cases of robotic mastectomy over the study duration
89372191|NCT06335537|Experimental|Urocit-K, then Baking Soda|After being off Urocit-K for two weeks, participants will collect two 24-hour urine tests to document hypocitraturia or low urine pH for calcium oxalate or uric acid stone formers, respectively. Participants will take Urocit-K 30 mEq AM and 30 mEq PM for four-weeks. During the last two days of the four-week drug period, two 24-hour urine collections will be obtained, and the participants will enter another washout period of two weeks before switching over to Baking Soda dissolved in up to 250 mL of water ½ teaspoon (29.5 mEq) in AM and ½ Teaspoon (29.5 mEq) in PM for four weeks. During the last two days of this study arm, two 24-hour urine collections will be obtained. A basic metabolic panel blood test will be obtained at the end of the study arm.
89372192|NCT06335537|Experimental|Baking Soda, then Urocit-K|After being off Urocit-K for two weeks, participants will collect two 24-hour urine tests to document hypocitraturia or low urine pH for calcium oxalate or uric acid stone formers, respectively. Participants will take Baking Soda dissolved in up to 250 mL of water ½ teaspoon (29.5 mEq) in AM and ½ Teaspoon (29.5 mEq) in PM for four weeks. During the last two days of the four-week drug period, two 24-hour urine collections will be obtained, and the participants will enter another washout period of two weeks before switching over to Urocit-K 30 mEq AM and 30 mEq PM for four weeks. During the last two days of this study arm, two 24-hour urine collections will be obtained. A basic metabolic panel blood test will be obtained at the end of the study arm.
88844681|NCT05506384|Experimental|Relaps prevention treatment|The treatment will be administered in an individual format and consist of seven to nine sessions of 45 minutes over a period of seven to nine weeks. The number of sessions can vary to be able to accommodate the fact that participants may have different levels of motivation for changing their primary problem behavior, which is why some participants may require one or two extra sessions at the start of the treatment. The treatment will be offered to participants both in person and via video link to facilitate participation for children and adolescents living further away from the participating clinics.
88844682|NCT05506384|Other|Treatment as usual|The patients in this arm will get treatment as usual at their Child and Adolescent psychiatry clinic.
88844683|NCT05485987|Experimental|Vatiquinone|Participants will receive an oral solution (100 milligrams [mg]/milliliter [mL]) of vatiquinone (15 mg/kilogram [kg] if body weight <13 kg and 200 mg if body weight ≥13 kg) 3 times a day (TID) for 72 weeks.
88844684|NCT05482893|Experimental|Dose Escalation|An accelerated titration design will be employed, and 1 patient will be enrolled initially at each of the lower dose levels: 0.1 mg/kg, 0.3 mg/kg and 1 mg/kg. At Dose Level 4 (3 mg/kg), the standard 3+3 design will be implemented.
88844685|NCT05482893|Experimental|Dose Expansion|Two dose levels will be explored with at least 10 patients in each; the recommended dose for expansion (RDE) from Part A, and another dose level. The RDE may be the MTD or a lower dose level. Additional dose levels and regiments such as, Q2W and/or Q3W dose evaluations may be performed.
88844686|NCT05482893|Experimental|Combination Expansion with Chemotherapy|"Part C, Cohort 1: Patients with m/a GC/GEJ-C, that have progressed under first line (1L) SOC chemotherapy +/- ICI, and are treatment naïve to CLDN18.2 targeting agents and are eligible for second line (2L) treatment. Patients will receive PT886 in combination with Paclitaxel.~Part C, Cohort 2: Patients with m/a PDAC that are treatment naïve for their 1L treatment. Patients will receive PT886 in combination with Gemcitabine plus nab-Paclitaxel (Abraxane).~Patients enrolled in Part C and D of the study must present with ≥ 10% CLDN18.2 positive TC in their tumors."
89180987|NCT05183685|Experimental|Intervention group|The participants will receive alternative telecare consultation and face to face consultation every 14 weeks.
89372193|NCT06335524|Experimental|Caregiver-implemented early developmental intervention (EDI) using finger puppets|Caregivers of infants in the intervention group will receive finger-puppets and additional training pertaining to infant parent interaction and developmentally appropriate infant communication training.
89372194|NCT06335524|Active Comparator|Routine EDI care including Bookworm training|All study participants will receive Bookworm reading intervention training and routine EDI care.
89372195|NCT06335511||Decompression|microsurgical decompression (MiD)
89372196|NCT06335511||Fusion|decompression and instrumented fusion (MiD + F)
89372197|NCT06335498||Wear AFGen1 for at least 7 days|Wear AFGen1 for 7 to 10 days. ECG co-measurement with 12 lead device at start and periodic measurements of ECG with AFGen1 during wear period
89372198|NCT06335498||Misplacement Study Group|Wear AFGen1 device in misplaced position compared to wearing device in standard position as directed by instructions for use
89372199|NCT06335485|Experimental|CBT intervention group|Participants will be asked to wear an activity tracker throughout the duration of the study. In addition, Participants will attend 4 weekly online virtual CBT sessions that will provide information on stress and pain reduction techniques before surgery, and 2 sessions following surgery.
89180988|NCT05183685|Placebo Comparator|Control group|The participants will receive usual face to face consultation every 14 weeks.
89372200|NCT06335485|No Intervention|No CBT group|Participants will be asked to wear an activity tracker throughout the duration of the study.
89372201|NCT06335472|Active Comparator|three nerves pulsed radiofrequency with hydrodissection|suprascapular nerve ,axillary nerve, lateral pectoral nerve pulsed radiofrequency combined with hydrodissection in adesive capsultis
89372202|NCT06335472|Active Comparator|suprascapular nerve pulsed radiofrequency with hydrodissection|suprascapular nerve pulsed radiofrequency combined with hydrodissection
89372203|NCT06335446||Atrial tachycardia- validation phase|The group will consist of patients with AT (whether de novo or occurring post AF ablation) that are undergoing catheter ablation.
89372204|NCT06335433|No Intervention|No Intervention Control|Participants will be asked to maintain their normal lifestyle patterns (i.e. diet and physical activity) and will undergo no other intervention.
89372205|NCT06335433|Experimental|Two Sessions/Week|Participants will complete 6-weeks of supervised isometric handgrip exercise training with a frequency of two sessions/week
89372206|NCT06335433|Experimental|Four Sessions/Week|Participants will complete 6-weeks of supervised isometric handgrip exercise training with a frequency of four sessions/week
89372207|NCT06335420|Active Comparator|Carrot juice|"The cultivation of Yellowstone carrots will be conducted by DanRoots A/S.DanRoots, Organic Vegetables, Bjerringbro, Denmark.Juice is produced and taste corrected by Orskov Food, Denmark in collaboration with Naturfrisk, Ørbæk.~Analysis of carrot juice for falcarinol and falcarindiol content will be done at random from 10 samples leaving the factory and 10 samples collected after 30 days storage at participant's homes for each batch."
89372208|NCT06335420|Placebo Comparator|Placebo juice|Placebo juice is produced from natural flavours and taste corrected by Orskov Food, Denmark in collaboration with Naturfrisk, Ørbæk. The taste is corrected to prevent enabling differentiation between carrot juice and placebo.
89372209|NCT06335407|Other|BXCL501 Dose Range 40µg to 160µg|Participants will receive 40µg on days 1-2. On days 3 and 4, participants will receive 40µg twice per day. On days 5 and 6 participants will receive 40µg in the morning and 80µg in the evening. On days 7-28 participants will receive 80µg in the morning and evening. Dose escalation will follow the above schedule based on tolerability assessed by clinician.
89372210|NCT06335394|Experimental|Single-arm study|NVD003
89372211|NCT06335381|Experimental|MOMs High Touch (MOMs-HT)|Participants randomized to the MOMs-HT arm will receive close clinical and behavioral health monitoring via weekly chats (text or email) using chatbot technology and navigation to timely clinical, behavioral health, and/or social care services by the MOMs team throughout the prenatal and postpartum periods; 12 bi-weekly self-management support telehealth visits with a MOMs care management coordinator (CMC) or registered nurse (RN) during the prenatal period; home blood pressure monitor to measure their blood pressure regularly; Fitbit to track physical activity; and 6-weekly postpartum telehealth visits with navigation to clinical, behavioral, and social services as needed by the MOMs team immediately post-delivery.
89372212|NCT06335381|Active Comparator|MOMs Low Touch (MOMs-LT)|Participants randomized to the MOMs-LT arm will receive close clinical and behavioral health monitoring via weekly chats (text or email) using chatbot technology and navigation to timely clinical, behavioral health, and/or social care services by the MOMs team throughout the prenatal and postpartum periods; 6-weekly postpartum telehealth visits with navigation to clinical, behavioral, and social services as needed by the MOMs team immediately post-delivery; and a Fitbit to track physical activity.
89372213|NCT06335355|Experimental|Treatment group A|
89372214|NCT06335355|Active Comparator|Treatment group B|
89372215|NCT06335355|Active Comparator|Treatment group C|
89372216|NCT06335342||Radiotherapy to head and neck region|Patients treated at European Institute of Oncology with radiotherapy to head and neck region
89372217|NCT06335329|Active Comparator|standard vaping cessation counseling (SOC) + ultrasound (US)|Participants will receive SOC via a publicly available infographic from the Food and Drug Administration). They will also be provided with a discussion of lung US findings
89372218|NCT06335329|No Intervention|Standard vaping cessation counseling (SOC) alone|Participants will receive a SOC alone. They will be kept blinded to their lung point-of-care ultrasound findings and will not be able to visualize the images as the ultrasound is performed.
89372219|NCT06335316|Experimental|Stellate Nerve Block+ routine rehabilitation treatment|The patients were given Nerve block and routine rehabilitation treatment for 10 days.
89372220|NCT06335316|Placebo Comparator|placebo+routine rehabilitation treatment|The patients were given placebo block and routine rehabilitation treatment for 10 days.
89372221|NCT06335303|Experimental|BI 1819479 low dose treatment group|
89372222|NCT06335303|Experimental|BI 1819479 medium dose treatment group|
89372223|NCT06335303|Experimental|BI 1819479 high dose treatment group|
89372224|NCT06335303|Placebo Comparator|Placebo group|
89372225|NCT06335290||Radiotherapy to thoracic region|Collection of data of patients receiving RT to thoracic region
88819376|NCT05201391|Experimental|"Eat Right Now (ERN) mobile application"|Participants in this single-arm trial will receive the ERN app as the intervention.
89002098|NCT06116188||Healthy controls|"We will also recruit 20 cognitively unimpaired controls, matched for age and gender for the patients group.~Inclusion criteria for the cognitively unimpaired group for the present study are:~i) no subjective cognitive complaints ii) CERAD (consortium to establish a registry for Alzheimer´s Disease) test battery at screening visit: CERAD total score within the normal range iii) clinical dementia rating (CDR) = 0, based on an interview with the study volunteer´s spouse or close relative iv) age 55 to 80 years"
89372226|NCT06335277||Total Body Irradiation (TBI)|Patients treated at European Institute of Oncology with Total Body Irradiation (TBI)
89372227|NCT06335264||Case group (HF)|"Clinical signs and/or symptoms of heart failure caused by a structural and/or functional cardiac abnormality, as defined by Bozkurt et al. [2021], diagnosed at the cardiovascular clinic~NT-proBNP levels > 125 pg/L or objective evidence of cardiogenic pulmonary or systemic congestion~One of the following;~i. For HFpEF, LVEF ≥ 50% ii. For HFmrEF, LVEF 41-49% iii. For HFrEF, LVEF ≤ 40%"
89372228|NCT06335264||Control group (non-HF)|"Absence of known clinical heart failure history.~Absence of criteria in the case group."
89372229|NCT06335251||Radiotherapy to limbs|Collection of data of patients receiving RT to limbs
89372230|NCT06335238||Radiotherapy to abdominal-pelvic region|Collection of data of patients receiving RT to abdominal-pelvic region
89372231|NCT06335225|Experimental|Precise nutrition group|
89372232|NCT06335225|Active Comparator|Control group|
89372233|NCT06335212||One group of subjects were recruited.|
89372234|NCT06335199|Experimental|Unilateral tVNS|Electrical stimulation to the vagus nerve area of the outer ear on the left side.
89372235|NCT06335199|Experimental|Bilateral tVNS|Electrical stimulation to the vagus nerve area of the outer ear on both sides.
89002099|NCT06116162|Active Comparator|CO2 fractional laser treatment|One side face was random to receive CO2 fractional laser. After local anesthesia, Acupulse device (LUMENIS, US) was used to perform CO2 fractional laser. The laser was operated in DeepFX mode under the parameters of 20-25 MJ energy intensity, 5% coverage, 300 Hz emission frequency and on the 10 mm spot size without overlap, Superficial mode under the parameters of 80-120 MJ energy intensity, 40-60% coverage, 300 Hz emission frequency, 10 mm spot size without overlap.
89180989|NCT04022018|Experimental|Adaptive radiotherapy group|Concurrent adaptive external volumetric rotational intensity modulated radiotherapy and chemotherapy followed by image-guided adaptive brachytherapy is the treatment strategies of adaptive radiotherapy group patients. CT repositioning will be performed after 15fractions of external radiotherapy, then new target volume will be contoured and new radiotherapy plan will be formulated with the assistance of artificial intelligence program. New radiotherapy plan will be performed from the 17th fraction external radiotherapy.
89372236|NCT06335199|Sham Comparator|Unilateral Sham|Electrical stimulation to the non-vagus nerve area of the outer ear on the left side.
89372237|NCT06335199|Sham Comparator|Bilateral Sham|Electrical stimulation to the non-vagus nerve area of the outer ear on both sides.
89372242|NCT06335160|No Intervention|Control Group|control group (Mesalamine group, n =23) who will receive 1 g mesalamine three times daily for 6 months.
89372243|NCT06335160|Active Comparator|Treatment Group|Treatment group( mebendazole group, n = 23) which will receive the standard treatment for UC plus mebendazole 500 mg twice daily for 6 months
89372244|NCT06335147|Experimental|Serplulimab, mFOLFOX6|Serplulimab，200mg，iv，q2w，d1； mFOLFOX6（Oxaliplatin: 85 mg/m2，LV ：400mg/m2，Fluorouracil： 400mg/m2 d1，2400 mg/m2 continuous intravenous drip for 46-48 hours；q2w）
89372245|NCT06335134|Experimental|Trial Group 1: Metformin and Warfarin administered before and with XW003 treatment|Metformin will be dosed twice daily (0.5 mg per dose) in two periods of 3.5 days for a total of 7 doses before and with XW003 treatment. Single doses of warfarin (2.5 mg per dose) will be given before and with XW003 treatment. The two drugs will be separated by a washout. XW003 will be administered subcutaneously once weekly in escalating doses of 0.3 mg for 4 weeks, 0.6 mg for 4 weeks and 1.2 mg for 4 weeks.
89372246|NCT06335134|Experimental|Trial Group 2: Rosuvastatin and Digoxin administered before and with XW003 treatment|Single doses of rosuvastatin (10 mg per dose) and digoxin (0.25 mg per dose) will be given before and with XW003 treatment. The two drugs will be separated by a washout. XW003 will be administered subcutaneously once weekly in escalating doses of 0.3 mg for 4 weeks, 0.6 mg for 4 weeks and 1.2 mg for 4 weeks.
89372247|NCT06335121|Experimental|Intervention - Aim 2|During the intervention period, PPIL staff will capture PrEP eligible women through an updated electronic flag alert in the patient's electronic medical record. The flag will alert to offer the patient PrEP navigation services and implement adapted POWER Up intervention strategies according to training.
89372248|NCT06335121|No Intervention|Control - Aim 2|PPIL health centers will follow current PrEP navigation procedures using current monitoring system.
89372249|NCT06335108||Control Group|Surgery carried out according to clinical routine under general anaesthesia.
89372250|NCT06335108||Local Anaesthesia Group|Surgery carried out under local tumescent anaesthesia. Procedure
89372251|NCT06335095||Control|Healthy volunteers
89372252|NCT06335095||Disease|
89372253|NCT06335082||Acute Arm|Data will be collected at pre-ablation/baseline and at time of the ablation procedure. Sites should follow the subjects per their standard of care and at a minimum report any acute onset procedure or device-related complications through 30-days post procedure. Data collection will include procedural workflow, procedural outcomes, and acute onset procedure or device-related complications through 30 days.
89372254|NCT06335082||Symptomatic Monitoring Only Arm (SMO)|Data will be collected at pre-ablation/baseline, the ablation procedure, a 3-Month post-ablation office visit and 12-Months post-ablation (monitoring is triggered for symptomatic recurrences only). Data collection will include procedural workflow, procedural outcomes, acute, mid, and late onset procedure or device related complications, and symptomatic recurrence.
89372255|NCT06335082||Full Monitoring Arm (FM)|Data will be collected at pre-ablation/baseline, the ablation procedure, a 3-Month post-ablation office visit, interim continuous monitoring for asymptomatic arrhythmia recurrence at 6- and 12-Months post-ablation as well as monitoring as needed for symptomatic recurrences, and a 12-Month post-ablation office visit. Data collection will include procedural workflow, procedural outcomes, acute, mid, and late onset procedure or device related complications, symptomatic recurrence as well as asymptomatic recurrence.
89372256|NCT06335069|Experimental|Additional 68Ga-FAPI-46 PET/CT and PET/MRI exam|All participating patients will undergo an additional 68Ga-FAPI- 46 PET/CT and 68Ga-FAPI-46 PET/MRI scan prior to their breast cancer treatment.
89372257|NCT06335056|Experimental|ProudMe|The ProudMe condition involves three key components: (a) artificial intelligence (AI)-assisted behavior management system (i.e., ProudMe Tech), (b) ProudMe physical/health education (PE) and lunchroom reform (ProudMe Cafeteria), (c) customized implementation training (ProudMe Training).
89372258|NCT06335056|Active Comparator|Waitlist Control|The waitlist control involves (a) regular physical/health education and lunchroom, (b) professional development training on the importance of quality physical/health education, health eating and foot environment. It does not involve AI-assisted behavior management system.
89372259|NCT06335043|No Intervention|Mental Health Provider|Mental health provider's thoughts on pharmacogenetic testing for treatment planning and changes to treatment planning.
89372260|NCT06335043|Experimental|Patient with Pharmacogenetic Testing|For patient participants who opt-in to pharmacogenetic testing, a report summarizing the pharmacogenetic testing results will be sent to each patient participants' respective mental health provider.
89372261|NCT06335043|No Intervention|Patient without Pharmacogenetic Testing|For patient participants who opt-out to pharmacogenetic testing will be followed to see if treatment course is maintained.
88875275|NCT02562924|Active Comparator|Budesonide rinse group|"1a. Days 0-7: 40 mg prednisone daily, saline sinus rinse 4 times daily, nasal saline spray q 1 hour while awake b. Days 7-91: 8oz saline/budesonide sinus rinse BID (twice daily) c. After day 91: i. In case endoscopy shows any polyps, edema or discharge: Decrease volume to 4 oz budesonide/saline rinse BID. Continue until day 182 ii. In case endoscopy shows no polyps, edema and discharge: Decrease volume to 4 oz budesonide/saline rinse once daily.~Reevaluate at day 119:~In case endoscopy shows any polyps, edema or discharge: Return to the initial regimen as per 1.c.i till day 182.~In case endoscopy shows no polyps, edema and discharge: Continue as per 1.c.ii till day 182."
89180990|NCT04022018|Active Comparator|Control group|Concurrent external volumetric rotational intensity modulated radiotherapy and chemotherapy followed by image-guided adaptive brachytherapy is the treatment strategies of control group patients.
89180991|NCT04084041|Experimental|Device|Device group
89180992|NCT04084041|Active Comparator|Conventional chest physiotherapy|Control group
89180993|NCT00916214|Experimental|Intervention|
89180994|NCT05163483|Experimental|Tucidinostat (chidamide), PD-1 inhibitor （Toripalimab), Bevacizumab|"Tucidinostat (chidamide), 30mg, po., biw, q3w Toripalimab, 240mg, ivgtt., d1, q3w Bevacizumab, 7.5mg/kg, ivgtt., d1, q3w~approximately 2 years"
89180995|NCT05163093||Angle closure glaucoma patients with or without abnormal zonular.|We observe the zonular during surgery, and divide patients into two groups according to their zonular, including with or without abnormal zonular.
89372262|NCT06335017|Active Comparator|group 1 - study group|Candidates will drink a mixture of 60 ml of castor oil and 140 ml of orange juice. 30 minutes later, A 22-French Foley catheter will be inserted above internal cervical os and will be filled with 60 mL of normal saline.
89180996|NCT05163093||Patients with age-related cataract.|We observe the zonular during surgery, and divide patients into two groups according to their zonular, including with or without abnormal zonular.
89372263|NCT06335017|Active Comparator|group 2- control|A foley catheter will be inserted into cervical canal as described above according to the department protocol without ingestion of castor oil.
89372264|NCT06335004||Patients with white matter disease/healthy subjects|Patients with white matter disease due to genetic or acquired causes. MRI with or without intravenous gadolinium will be performed
89372265|NCT06335004||Patients with no white matter disease|Patients undergoing MRI with or without gadolinium for clinical diagnostic purposes, with no known white matter disease.
88844687|NCT05482893|Experimental|Combination Expansion with KEYTRUDA® (pembrolizumab)|"Part D, Cohort 3: Patients with m/a GC/GEJ-C who have progressed under 1L or 2L SOC chemotherapy +/- ICI and are treatment naïve to CLDN18.2 targeting agents. Patients will receive PT886 in combination with KEYTRUDA® (pembrolizumab).~Part D, Cohort 4: 1L treatment of patients with HER2 negative m/a GC/GEJ-C, that are treatment naïve to CLDN18.2 targeting agents. Patients will receive PT886 in combination with SOC chemotherapy and KEYTRUDA® (pembrolizumab).~Part D, Cohort 5: Patients with m/a GC/GEJ-C, that have progressed under 1L SOC chemotherapy, and zolbetuximab, and are treatment naïve to KEYTRUDA® (pembrolizumab) or other ICI therapy for their m/a disease. Patients will receive PT886 in combination with KEYTRUDA® (pembrolizumab).~Patients enrolled in Part C and D of the study must present with ≥ 10% CLDN18.2 positive TC in their tumors."
89372266|NCT06334991|Experimental|CD19 t-haNK with Rituximab|Participants will initially receive a single 3-week cycle of the CD19 thaNK as a single-agent regimen. Following a 1-week safety pause, participants will then receive a single 3-week cycle of CD19 t-haNK in combination with rituximab. Participants will then undergo the first tumor assessment. Participants with no evidence of progressive disease (PD) will be eligible to receive up to 2 additional 3-week cycles of CD19 t-haNK combination with rituximab.
89372267|NCT06334978|Experimental|Intervention Group|Techniques used: the dog technique in flexion, scalene muscle energy technique, Jones' first rib adjustment, first rib trust in posterior subluxation, occipitomastoid thrust, Sutherland's posterior needle-scratch, SBS decompression, semi-direct thrust for the sacrum, Sutherland's sacrum, posterior occipital condyle thrust, SBS equilibration.
89372268|NCT06334978|No Intervention|Control Group|Conventional treatment
89372269|NCT06334965|Experimental|PET-MRI|PET-MRI added in care pathway
89372270|NCT06334952|Other|tDCS - Sham|Patient will be randomized to firstly receive tDCS (10 non consecutive days, 20 minutes twice a day with 20 minutes of break) and then Sham (10 non consecutive days, 20 minutes twice a day with 20 minutes of break).
89372271|NCT06334952|Other|Sham - tDCS|Patient will be randomized to firstly receive Sham (10 non consecutive days, 20 minutes twice a day with 20 minutes of break) and then tDCS (10 non consecutive days, 20 minutes twice a day with 20 minutes of break).
89372272|NCT06334939||EA group|The group that includes patients who develop Emergence agitation after anesthesia and during the recovery period.
89372273|NCT06334939||Non EA Group|The group will include calm patients who do not develop Emergence agitation after anesthesia and during the recovery period.
89372274|NCT06334926||Colon cancer patients|Retrospective data analysis of the subgroup of patients suffering from colon carcinoma
89372275|NCT06334926||Rectal cancer patients|Retrospective data analysis of the subgroup of patients suffering from rectal carcinoma
89372276|NCT06334913||MPN patients|U.K. based adult patients with MPN diagnosis.
89372277|NCT06334900||Anti-GAD encephalitis|This is a non-interventional study involving clinical data. This data are information of medical follow up on patient like diagnosis, symptoms, biological results, cancer, treatments.
89372278|NCT06334887|Experimental|Use of esTOCma|Experimental group will use esTOCma until they finish it (within a preestablished 10-days period).
89372279|NCT06334887|No Intervention|Control group|Control group will do nothing for 10 days.
88844688|NCT05479747|Active Comparator|Ibuprofen (Brufen)|Participants were handed Brufen (Ibuprofen) (Abbott chemical laboratories, Advil, USA) 600 mg 3 times daily for 3 days after meals in tightly sealed envelope with an included written paper contained the instruction for dose administration.
88844689|NCT05479747|Experimental|Trypsin 5 mg Chymotrypsin 5 mg (Ambezim G)|Participants were handed Ambezim G (Trypsin 5 mg Chymotrypsin 5 mg) (Global Napi Pharmaceutical Company, Giza, Egypt) 3 times daily for 3 days one hour before meals in tightly sealed envelope with an included written paper contained the instruction for dose administration.
89180997|NCT00587054|Experimental|Transplant Patients|
89180998|NCT04083729|Active Comparator|Patients with persistent pulmonary hypertension|Patients with persistent pulmonary hypertension after balloon mitral comisseruotomy
89180999|NCT04083729|Active Comparator|Patients without persistent pulmonary hypertension|Patients without persistent pulmonary hypertension after balloon mitral comisseruotomy
89181000|NCT00766142|Experimental|Chemotherapy + Cetuximab|Surgery + Chemotherapy + Cetuximab
89372280|NCT06334874|Active Comparator|intervention|
89372281|NCT06334874|Placebo Comparator|placebo|
89372282|NCT06334861||Fragile patients vaccinated with herpes zoster vaccine|"Patients with immunodeficiency and/or immunosuppression afferent to the U.O.C. Rheumatology, U.O.C. Hematology and Hematopoietic Stem Cell Transplantation, U.O.C. Infectious Diseases and Geriatric Internal Medicine, Travel Clinic and Occupational Health Outpatient Clinic of FPU Agostino Gemelli IRCCS who meet the inclusion criteria will be recruited.~Inclusion Criteria.~Patients with congenital and/or acquired immunodepression;~Age > 18 years;~Signature of informed consent Exclusion criteria.~Persons younger than 18 years of age"
89372283|NCT06334848|Other|treatment of stress urinary incontinence by transobturator tape|patients with stress urinary incontinence are treated by transobturator tape
89372284|NCT06334848|Other|treatment of stress urinary incontinence by mini sling|patients with stress urinary incontinence are treated by mini sling
89372285|NCT06334835||Childhood Acute Lymphoblastic Leukemia patients|Bone marrow mononuclear cells from childhood acute lymphoblastic leukemia of T cells
89372286|NCT06334835||Healthy subjects|Cord blood mononuclear cells from healthy volounteers
89372287|NCT06334822|Experimental|Standard Care + Heartfelt device|In addition to standard care activities, participants have the Heartfelt device at home. During this arm, the device sends alerts and measurement data to the patient, carers and clinicians.
89372288|NCT06334822|Active Comparator|Standard care (control)|In addition to standard care activities, participants have the Heartfelt device at home. During this arm, data is captured without sending health alerts or measurement data to the patient, carers and clinicians.
89372289|NCT06334822|Experimental|Standard Care + Heartfelt device in pharmacy|Participants will follow standard care advice, and have monthly measurements taken at the pharmacy using the Heartfelt device. The pharmacist will receive the measurements and alerts and be able to communicate this to the participant.
89372290|NCT06334809||Cohort A:patients with high risk localized prostate cancer|"Cohort A:150 patients with high risk localized prostate cancer (defined as >cT3 or PSA > 20 ng/mL or presence of ECE or SVIat mpMRI), with tissue available from diagnostic biopsy/prostatectomy undergoing or who underwent curative treatment (prostatectomy/radical radiotherapy) but have not started a FU pathway.~Patients within Cohort A will be followed up with PSA every 3 months for 3 years and early scans. They will also receive a blood sample for ctDNA/CTC before (when feasible) and after radical treatment, 6 months and 12 months (if not progressed), at time of PSA or radiological progression"
89372291|NCT06334809||Cohort B: patients with de novo metastatic hormone sensitive prostate cancer (mHSPC)|Cohort B: 100 patients with de novo metastatic hormone sensitive prostate cancer (mHSPC) with tissue available from diagnostic biopsy of the primary and when possiblepossible, from a metastatic site. Patients must either have not started a standard treatment or have started for not longer than 3 months;Patients within Cohort B will be followed up with PSA and scans every 3 months. They will also receive a blood sample before (when feasible) or after the start of systemic treatment, 6 months and 12 months (if not progressed), at time of PSA or radiological progression
89372292|NCT06334809||Cohort C:Patients with metastatic castration resistant prostate cancer (mCRPC) progressing|Cohort C:100-150 patients with metastatic castration resistant prostate cancer tissue (mCRPC) progressing on a standard treatment with available from biopsy of a metastatic site, and when possiblepossible, from the primary.Patients within Cohort C will be followed up with PSA monthly and scans every 3 month. They will also receive a blood sample for ctDNA/CTC before (when feasible) or after the start of systemic treatment, 6 months and 12 months (if not progressed), at time of PSA or radiological progression.
89372293|NCT06334796|Experimental|Virtual Assistant|Patients answer question with a virtual assistant about their recent visit to the ER.
89372294|NCT06334796|Active Comparator|ChatGPT 3.5|Patients answer question with ChatGPT about their recent visit to the ER.
89372295|NCT06334796|Active Comparator|ChatGPT 4|Patients answer question with ChatGPT about their recent visit to the ER.
89372296|NCT06334783|Experimental|TILs|Biological: TILs Drug: IL-2
89372297|NCT06334770|Experimental|Group( A) ROXOLID IMPLANT|NINE patients were rehabilitated with implant retained maxillary overdenture where four Straumann BLX® ROXOLID implant were inserted opposed by mandibular complete denture.
89372298|NCT06334770|Active Comparator|Group (B) CONVENTIONAL TITANIUM IMPLANT|NINE patients were rehabilitated with implant retained maxillary overdenture where four conventional titanium implants were inserted opposed by mandibular complete denture.
89372299|NCT06334757|Experimental|Serplulimab+Bevacizumab+Pemetrexed+Carboplatin|Using Serplulimab in combination with bevacizumab, carboplatin and pemetrexed to treat patients with EGFR mutated, advanced non-small cell lung cancer (NSCLC) after failure of EGFR tyrosine kinase inhibitors.
88844690|NCT05479747|Active Comparator|Ibuprofen (Brufen) + Trypsin 5 mg Chymotrypsin 5 mg (Ambezim G)|Participants were handed Brufen (Ibuprofen) (Abbott chemical laboratories, Advil, USA) 600 mg 3 times daily for 3 days after meals and Ambezim G (Trypsin 5 mg Chymotrypsin 5 mg) (Global Napi Pharmaceutical Company, Giza, Egypt) 3 times daily for 3 days one hour before meals in tightly sealed envelope with an included written paper contained the instruction for dose administration.
88844691|NCT05479747|Placebo Comparator|Placebo pills (Sugar pills)|Participants were handed postoperatively sugar pills (Placebo pills) (Department of pharmaceutics & industrial pharmacy at Faculty of pharmacy Ain Shams University, Cairo, Egypt) 3 times daily for 3 days in tightly sealed envelope with an included written paper contained the instruction for dose administration.
88844692|NCT05477186|Experimental|Part A: CV0501 Dose Cohort 1 (12 μg)|Enrollment will be staggered, beginning with Group 1a (12 μg, younger adults). Initiation of enrollment in Group 1b (12 μg, older adults) will depend on Safety Review Team (SRT) review of safety data up to Day 8 from a minimum of 10 participants in Group 1a.
88844693|NCT05477186|Experimental|Part A: CV0501 Dose Cohort 2 (25 μg)|For both Group 2a (younger) and Group 2b (older age), initiation of enrollment in the subsequent group at the next dose level for Cohorts 2-5 will depend on SRT review of safety data up to Day 8 from a minimum of 10 participants, from the previous dose level in the same age group.
88844694|NCT05477186|Experimental|Part A: CV0501 Dose Cohort 3 (50 μg)|For both Group 3a (younger) and Group 3b (older age), initiation of enrollment in the subsequent group at the next dose level for Cohorts 2-5 will depend on SRT review of safety data up to Day 8 from a minimum of 10 participants, from the previous dose level in the same age group.
88844695|NCT05477186|Experimental|Part A: CV0501 Dose Cohort 4 (75 μg or 100 μg)|For each of the groups in Cohort 4, Group 4a (younger) and Group 4b (older age),the SRT may recommend a dose specified by the dosing scenarios in the protocol, based on their review of all available safety data. The SRT will use the same approach, independently, to select the dose levels for older participants (Group 4b) and younger participants (Group 4a).
89002100|NCT06116162|Experimental|SVF-gel preparation and filling|The other side face received SVF-gel filling. The autologous fat graft was harvested from the lower abdomen or inner thigh of all subjects. The Coleman fat was was islolated by centrifugation. Then, SVF gel further islolated by using cutting and centrifugation. 22G sharp-tip injector was used to inject the SVF-gel into the dermis of acne scars.
89372300|NCT06334705|Other|participants can take part in any examinations they wish|
89372301|NCT06334692||Cases|Sera from patients with biopsy-proven idiopathic MCD or FSGS who provided consent to store their samples in the certified biobank (Mario Negri Biological Resources Centre - Rare Diseases and Renal Diseases Biobank - CRB). Serum samples will be tested for the levels of anti-nephrin autoantibodies by in-house ELISA and results confirmed by commercial ELISA kits.
89372302|NCT06334692||Controls|Sera from patients with biopsy-proven idiopathic membranous nephropathy who provided consent to store their samples in the certified biobank (Mario Negri Biological Resources Centre - Rare Diseases and Renal Diseases Biobank - CRB). Samples will be tested for the levels of anti-nephrin autoantibodies by in-house ELISA and results confirmed by commercial ELISA kits.
89372303|NCT06334679|Experimental|Group-1 (Clinical Routine (liquid vaseline) and Cold Gel Pack applied group)|"Before the first application of the day, the 12-Item Itching Severity Scale will be applied to evaluate the patient's daily itching. Before each application, itching severity will be evaluated with the Visual Analog Scale (VAS) for Itch at minute 0. Vital signs will be measured and recorded. Cold gel packs placed in a sterile cloth sheath will be placed in full contact with the burn areas and applied for 20 minutes. During the application, the skin will be checked every 30 seconds and 5 minutes, and the application will be interrupted in case of new pain, numbness, redness, pallor, chills, cold sensitivity and skin surface temperature ≤13 degrees Celsius. The temperature of the cold gel packs before and during application will be checked with a Digital Infrared Non-Contact Thermometer. Immediately after the application is completed, a 20-minute VAS for itching will be shown and they will be asked to evaluate the severity of the itching they feel instantly."
89372304|NCT06334679|No Intervention|Group-2: Clinical routine (liquid petroleum jelly) applied group (control)|"Before the first application of the day, the 12-Item Itching Severity Scale will be applied to evaluate the patient's daily itching. Before each application, the Visual Analog Scale (VAS) for Itch will be shown at minute 0 and they will be asked to evaluate the severity of itching they feel immediately. Vital signs will be measured and recorded. Liquid petroleum jelly, which is the routine practice of the clinic, will be applied by clinic nurses. Immediately after the application is completed, a 20-minute VAS for itching will be shown and they will be asked to evaluate the severity of itching they feel immediately."
89372305|NCT06334666|Experimental|Active Comparator: Encourage using pedometer group.|MASLD patient who received pedometer recording and was encouraged to use actively.
89372306|NCT06334666|No Intervention|Placebo comparator: Discourage using pedometer group|MASLD patient who received pedometer recording but without encouraged to use.
89372307|NCT06334653|Placebo Comparator|Placebo|Saline infusion
89372308|NCT06334653|Experimental|Tocilizumab|IL-6 receptor antibody infusion (8 mg/kg body weight, max 800 mg)
89372309|NCT06334640||Subjects with glaucoma and macular degeneration|Adults subjects affected by glaucoma and macular degeneration
89372310|NCT06334640||Healthy volunteers|Adult healthy volunteers without eye disease
89372311|NCT06334627|Experimental|Pre-Primary Intervention|Program consisting of 9 modules focussing on early learning, play, saftey, wellbeing, reading and writing will be delivered approximately every two weeks to groups of 10 parents from the intervention arm.
89372312|NCT06334627|No Intervention|Control|No intervention delivered. Participants will attend any government pre-primary based programmes as standard of care.
89372313|NCT06334614|Experimental|iReach Device group|The iReach Device group will undergo the clinical trial with the device in addition to the normal clinical activity
89372314|NCT06334614|No Intervention|Normal clinical activity group|The Normal clinical activity group will continue their normal clinical activity
89372315|NCT06334601||Obstructive Sleep Apnea|Patients evaluated for sleep disorders, who present an at home-polygraphy with at least one EEG channel (PSG) reporting moderate-to severe obstructive sleep apnea (apnea-hypopnea index >14).
89372316|NCT06334588|Experimental|Suspected or confirmed Autism Spectrum Disorders (ASD)|Patient with ASD or suspected ASD for whom an MRI is requested by the clinician as part of care
89372317|NCT06334588|Experimental|Healthy volunteers over 3 years of age|Healthy Control Children will be recruited specifically for the research
89372318|NCT06334588|No Intervention|Healthy volunteers under 5 years of age|Children who have already undergone an MRI for various medical reasons and whose MRI was normal.
89372319|NCT06334575|Active Comparator|ICS treatment|
89372320|NCT06334575|No Intervention|No ICS treatment|
89002101|NCT06116123|Experimental|Group I (Massage mattress with cube/block system)|
89372321|NCT06334562|Experimental|Sugammadex Sodium group|The dose of Sugammadex Sodium is 2mg/kg
89002102|NCT06116123|No Intervention|Group II (Standard of care)|
89002103|NCT06116084|Active Comparator|Ericksonian hypnosis|An Ericksonian hypnosis session given to patients during a scintigraphic or PET examination, in a conventional manner, i.e. the hypnotherapist (MERM) is close to the patient in the examination room at the time of the session and communicates with him/her without any special device dedicated to this purpose.
89372322|NCT06334562|Active Comparator|Neostigmine group|The dose of Neostigmine is 50 μg/kg
89372323|NCT06334549|Experimental|Ephedrine-Propofol|receive ephedrine 0.15mg/kg (configured concentration 6mg/mL) when MAP was a 20% decrease in baseline blood pressure after both induction of anesthesia and tracheal intubation.
89372324|NCT06334549|Experimental|Phenylephrine-propofol|receive phenylephrine 2.5ug/kg(configured concentration 100ug/mL) when MAP was a 20% decrease in baseline blood pressure after both induction of anesthesia and tracheal intubation.
89372325|NCT06334549|Experimental|Norepinephrine-propofol|receive norepinephrine 0.2ug/kg(configured concentration 8μg/ml) when MAP was a 20% decrease in baseline blood pressure after both induction of anesthesia and tracheal intubation.
89372326|NCT06334549|Active Comparator|Ephedrine-sevoflurane|receive Ephedrine 0.15mg/kg(configured concentration 6mg/mL) when MAP was a 20% decrease in baseline blood pressure after both induction of anesthesia and tracheal intubation.
89372327|NCT06334549|Active Comparator|Phenylephrine-sevoflurane|receive phenylephrine 2.5ug/kg(configured concentration 80ug/mL) when MAP was a 20% decrease in baseline blood pressure after both induction of anesthesia and tracheal intubation.
89372328|NCT06334549|Active Comparator|Norepinephrine-sevoflurane|receive norepinephrine 0.2ug/kg(configured concentration 8ug/mL) when MAP was a 20% decrease in baseline blood pressure after both induction of anesthesia and tracheal intubation.
89372329|NCT06334536||Medical staff|Medical staff who work at the Department of Obstetrics and Gynecology or Women Health Units in Asia and Oceania countries.
89372330|NCT06334523|Experimental|Continuous Tracheal Gas Insufflation|the preterm infant intubated and ventilated with Continuous Tracheal Gas Insufflation
89372331|NCT06334523|No Intervention|standar ventilation|the preterm infant intubated and ventilated by standard ventilation
88844696|NCT05477186|Experimental|Part A: CV0501 Dose Cohort 5 (100 μg, 150 μg or 200 μg)|For each of the groups in Cohort 5, Group 5a (younger) and Group 5b (older age), the SRT may recommend a dose specified by the dosing scenarios in the protocol, based on their review of all available safety data. The SRT will use the same approach, independently, to select the dose levels for older participants (Group 5b) and younger participants (Group 5a).
88844697|NCT05477186|Experimental|Part B: CV0501 Dose Cohort 6 (3 μg)|Part B, designed to comprise 2 single age group cohorts, Group 6a (≥18 to <65 years old) will start based on the first interim analysis of safety and immunogenicity data, provided that the SRT assesses the 12 μg dose to be immunogenic and safe.
88844698|NCT05477186|Experimental|Part B: CV0501 Dose Cohort 7 (6 μg)|Part B, designed to comprise 2 single age group cohorts, Group 7a (≥18 to <65 years old) will start based on the first interim analysis of safety and immunogenicity data, provided that the SRT assesses the 12 μg dose to be immunogenic and safe.
88844699|NCT05476939|Active Comparator|everolimus|"Tablets of 2.5 mg or 10 mg. The prescribed dose is 5 mg/m²/day, orally, once daily. Dose will be capped at 10 mg once daily.~Study treatment will be continued until centrally confirmed disease progression (either radiologically or histologically), unacceptable toxicity, or consent withdrawal.~At the time of centrally confirmed progression, patients will be allowed to switch to the other arm in case no better option is available after considering the results of the molecular profiling. In case of switch (everolimus to ONC201 or vice-versa), the patient will observe a wash-out period before starting:~the second treatment,~or a reirradiation (if applicable). No treatment is allowed during reirradiation. Then, if an additional treatment is needed, the second treatment will be started within one week after the end of the reirradiation."
88844700|NCT05476939|Experimental|ONC201|"Capsules of 125 mg. The prescribed dose is 375 mg/m2, once daily at Day 1 and Day 2 of each week. Dose will be capped at 625 mg per dose. Study treatment will be continued until centrally confirmed disease progression (either radiologically or histologically), unacceptable toxicity, or consent withdrawal.~At the time of centrally confirmed progression, patients will be allowed to switch to the other arm in case no better option is available after considering the results of the molecular profiling. In case of switch (everolimus to ONC201 or vice-versa), the patient will observe a wash-out period before starting:~the second treatment,~or a reirradiation (if applicable). No treatment is allowed during reirradiation. Then, if an additional treatment is needed, the second treatment will be started within one week after the end of the reirradiation."
88844701|NCT05470504|Other|1|open label pegvisomant
88844702|NCT05468489|Experimental|Serplulimab + chemotherapy|Serplulimab + chemotherapy (carboplatin-etoposide)
88844703|NCT05468489|Active Comparator|Atezolizumab + chemotherapy|Atezolizumab + chemotherapy (carboplatin-etoposide)
88844704|NCT05463731|Experimental|Remternetug (IV)|"Participants will receive remternetug intravenously (IV)~Participants will receive remternetug IV during the treatment period, then switch to placebo IV in the extension period."
88844705|NCT05463731|Experimental|Remternetug (SC)|"Participants will receive one of two dosing regimens of remternetug subcutaneously (SC)~Participants will receive remternetug SC during the treatment period, then switch to placebo SC in the extension period."
88844706|NCT05463731|Placebo Comparator|Placebo|"Participants will receive placebo matching remternetug IV or SC.~Participants will receive placebo IV during the treatment period, then switch to remternetug IV in the extension period.~Participants will receive placebo SC during the treatment period, then switch to LY3372993 SC in the extension period."
88844707|NCT05463731|Experimental|Open-Label Addenda Remternetug (IV)|Participants will receive one of three dosing regimens of remternetug IV during the open-label addenda.
89372332|NCT06334510||Approval consistency study|A total of 1050 recipients aged 18-59 years were enrolled in this study. Blood samples were collected before and 30 days after vaccination. Hemagglutination inhibition (HI) antibody to influenza virus was detected in the serum of all recipients to evaluate the inter-batch consistency of the vaccine.
89372333|NCT06334510||Safety and immunogenicity in a larger vaccination cohort aged 3 years and older|3850 recipients were enrolled in an open trial: safety observation after vaccination, follow-up for adverse events (AE) 30 minutes and 0-30 days after vaccination, and SAEs for 6 months after vaccination.
89372334|NCT06334497|Experimental|Letermovir+Valganciclovir|Daily administration of Letermovir plus Valganciclovir
89372335|NCT06334497|Active Comparator|Letermovir Placebo+Valganciclovir|Daily administration of Letermovir placebo plus Valganciclovir
88844708|NCT05463731|Experimental|Open-Label Addenda Remternetug (SC)|Participants will receive one of two dosing regimens of remternetug SC during the open-label addenda.
88844709|NCT05449340|Experimental|BEAUTIFY application|
88844710|NCT05446272|Experimental|NIV-NAVA|
88844711|NCT05446272|Active Comparator|NS- NIPPV|
88844712|NCT05443087|Experimental|Regorafenib - mCRC, GIST, HCC|"3 x 30 = 90 patients~Patients with mCRC, GIST or HCC treated with Regorafenib"
88844713|NCT05443087|Experimental|Everolimus - gepNET|"60 patients~Patients with gepNET treated with Everolimus"
88844714|NCT05443087|Experimental|Sunitinib - pNET, GIST|"2 x 30 = 60 patients~Patients with pNET and GIST, treated with Sunitinib"
88844715|NCT05443087|Experimental|Cabozantinib - HCC|"60 patients~Patients with HCC treated with Cabozantinib"
88844716|NCT05443087|Experimental|Encorafenib - Cetuximab - mCRC|"60 patients~Patients with mCRC treated with the association Encorafenib - Cetuximab"
88844717|NCT05434689|Experimental|Iberdomide, Daratumumab and Dexamethasone (Regimen A)|Iberdomide dosed according to cohort assignment days 1-21. Dexamethasone 40 mg oral or intravenously (20 mg for participants 70 or older) on days 1,8,15 and 22 Darartumumab and hyalurnonidase-fihj 1,800mg/30,000 units subcutaneously on days 1,8,15,22 (cycles 1,2) or on days 1,15 (cycles 3-6)
89002104|NCT06116084|Experimental|Experimental hypnosis|Hypnosis session with headphones and microphones
89002105|NCT06116058|Experimental|Group A: integrated neuromuscular inhibition technique|Group A: patient will receive integrated neuromuscular inhibition technique and conventional physical therapy program for 3 sessions /week over 4 weeks periods
89372336|NCT06334471||prospective study|The prospective study group includes patients aged 19 years or older who have provided written consent for participation, have the capability to consent voluntarily, are eligible for tissue examination and surgical removal for sample collection, and have confirmed or suspected breast cancer for pathological confirmation.
88844718|NCT05434689|Experimental|Iberdomide, Carfilzomib, Daratumumab and Dexamethasone (Regimen B)|Iberdomide dosed according to cohort assignment days 1-21. Dexamethasone 40 mg oral or intravenously (20 mg for participants 70 or older) on days 1,8,15 and 22 Darartumumab and hyalurnonidase-fihj 1,800mg/30,000 units subcutaneously on days 1,8,15,22 (cycles 1,2) or on days 1,15 (cycles 3-6) Carfilzomib dosed intravenously dosed according to cohort assignment on days 1, 8, 15 (Consistent with standard practice, the very first dose of carfilzomib (cycle 1 day 1) must be 20 mg/m^2).
88844719|NCT05431595|Experimental|Group 1|Participants will receive haloperidol by vein every 12 hours (or more often, as needed).
88844720|NCT05431595|Experimental|Group 2|Participants will receive chlorpromazine by vein every 12 hours (or more often, as needed).
88844721|NCT05431595|Experimental|Group 3|Participants will receive valproate by vein every 12 hours.
88844722|NCT05431595|Experimental|Group 4|Participants will receive placebo every by vein every 12 hours.
88844723|NCT05430152|Experimental|Low-Dose Naltrexone|The Low-Dose Naltrexone (LDN) will be provided as a compounded capsule starting at a strength of 1mg/day of naltrexone and increasing up to a maximum of 4.5 mg/day. The compounding pharmacy will compound the needed doses in Capsugel® empty gelatin based capsules using Naltrexone Hydrochloride Tablets and CELLULOSE.
88844724|NCT05430152|Placebo Comparator|Placebo|Matching placebo capsule will be created by compounding pharmacy to look exactly like the LDN doses. The compounding pharmacy will compound the placebo in Capsugel® empty gelatin based capsules using CELLULOSE.
88844725|NCT05421390|No Intervention|≤1 dairy serving/day|Limited dairy intake
88844726|NCT05421390|Experimental|2-3 servings/day reduced-fat|2-3 servings/day of skim milk, fat-free yogurt, and low-fat cheese
88844727|NCT05421390|Experimental|2-3 servings/day regular-fat|2-3 servings/day of regular-fat milk, yogurt, and cheese
88844728|NCT05415787||adult patients with metastatic prostate cancer|
88844729|NCT05411705|Experimental|rhTPO|The study in a 2:1 randomization ratio (110 subjects to rhTPO).
88844730|NCT05411705|Other|Control|The study in a 2:1 randomization ratio (55 subjects to control group).
88844731|NCT05405231|Experimental|Crisis Line Facilitation (CLF)|Crisis Line Facilitation (CLF) is a promising translational strategy designed to increase Military and Veteran's Crisis Line (MVCL) use among NG members during periods of elevated suicidal risk by addressing individual-level barriers.
88844732|NCT05405231|Active Comparator|Passive Implementation|The PI condition includes an educational resource brochure describing the Military and Veteran's Crisis Line (MVCL), including the phone number for the crisis line, as well as other mental health services available to National Guard members.
89534866|NCT03229525|Active Comparator|Trauma Related Expressive Writing|Participants randomized to this condition will complete six sessions during which they will write about their trauma for 20 minutes. The participant will receive instructions to write about the traumatic event that they feel affects them the most. For each session they will be instructed to write about the same event. For the first session, participants will complete psychoeducation and treatment rationale modules. The instructions for writing about the traumatic event will emphasize the importance of exploring their deepest emotions and thoughts at the time of the event, as well as providing detailed information about the event itself. For the remaining five writing sessions participants will be instructed to write about the same event and to focus on providing a detailed description of the part of the event that was most distressing to them, as well as how the event had affected their lives. A researcher will review the writing independently to ensure treatment compliance.
89534867|NCT03229525|Sham Comparator|Neutral Expressive Writing|Participants randomized to this condition will complete six sessions during which they will write about their day, without describing emotions or opinions. Previous research has shown a significant reduction of symptoms with this type of control writing condition in participants with PTSD (Sloan et al., 2011). A researcher will review the writing to ensure compliance.
88844735|NCT05375201|Experimental|VR skateboarding training|specific rehabilitation exercise for improving postural balance
89534868|NCT02492321|Active Comparator|EBI-005|Drug: EBI-005 The investigational drug EBI-005, is an intervention to one of two study arms: 5 mg/mL topical administered 3 times per day
88844736|NCT05374681|Other|Medical treatment alone|Medical treatment without embolization of the MMA.
88844737|NCT05374681|Other|Surgical treatment alone|Surgical treatment without embolization of the MMA.
88844738|NCT05374681|Experimental|Medical treatment associated with an embolization of the MMA|Medical treatment + embolization under local anesthesia or conscious sedation. The embolization will be carried out by femoral or radial arterial guided by pre-embolization cervical CTA. The middle meningeal artery will be catheterized then embolized by cyanoacrylates until the occlusion of the MMA.
88844739|NCT05374681|Experimental|Surgical treatment associated with an embolization of the MMA|Surgical treatment + embolization under local anesthesia or conscious sedation. The embolization will be carried out by femoral or radial arterial guided by pre-embolization cervical CTA. The middle meningeal artery will be catheterized then embolized by cyanoacrylates until the occlusion of the MMA.
88844740|NCT05374603|Experimental|Savolitinib combine with Durvalumab|single-arm
88844741|NCT05373355|Experimental|Cohort 1|TLL018 tablets 1piece,BID
88844742|NCT05373355|Experimental|Cohort 2|TLL018 tablets 3pieces, BID
88844743|NCT05373355|Placebo Comparator|Cohort 3|TLL018 placeboes 3pieces, BID
88844744|NCT05372640|Experimental|Treatment (ZEN003694, abemaciclib)|Patients receive ZEN003694 PO QD on days 1-28 or 5 days on and 2 days off, and abemaciclib PO BID on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo imaging evaluation, blood sample collection and tumor biopsy throughout the study.
88844745|NCT05372419|Experimental|Lebrikizumab|Participants will receive Lebrikizumab subcutaneously (SC).
88844746|NCT05365750||Case|"The COVID-19 case group is a random sample of individuals who are enrolled in KPCO's health plan who are cases or likely cases. These individuals may have positive antibodies to COVID-19."
88844747|NCT05365750||Control|A random stratified sample of the general KPCO membership with similar age, gender, race/ethnicity and co-morbidities as case group
89181001|NCT05152563|Experimental|SC 150 mg of lirentelimab (AK002)|Subjects in this arm will receive 6 monthly doses of 150 mg of lirentelimab (AK002) administered subcutaneously.
89181002|NCT05152563|Experimental|SC 300 mg of lirentelimab (AK002)|Subjects in this arm will receive 6 monthly doses of 300 mg of lirentelimab (AK002) administered subcutaneously.
88844750|NCT05356364|Active Comparator|Perinatal Understanding of Mindful Awareness for Sleep (PUMAS)|PUMAS combines behavioral sleep strategies with elements from mindfulness-based interventions, and is tailored specifically to meet the unique needs of pregnant women. Behavioral sleep strategies include sleep restriction and stimulus control. Mindfulness elements include guided meditations and engaging in mindful activities. PUMAS consists of 6 60-minute sessions with a therapist along with self-monitoring with sleep diaries. All sessions are delivered via telemedicine during pregnancy.
88844751|NCT05356364|Active Comparator|Cognitive Behavioral Therapy for Insomnia (CBTI)|CBTI combines behavioral sleep strategies with cognitive therapy. It is the first-line treatment for insomnia as recommended by the American College of Physicians and the American Academy of Sleep Medicine. Behavioral sleep strategies include sleep restriction and stimulus control. Cognitive therapy includes scheduled worry time and challenging dysfunctional beliefs about sleep. CBTI consists of 6 60-minute sessions with a therapist along with self-monitoring with sleep diaries. All sessions are delivered via telemedicine during pregnancy.
88844752|NCT05348395|Experimental|Experimental diet|The experimental diet will provide 15% of calories from saturated fat and 14% of calories from fructose with a goal of providing 1.25x total energy needs
88844753|NCT05345847|Experimental|1- Active Surveillance|Active surveillance with rescue corticosteroids
88844754|NCT05345847|Active Comparator|2- Early initiation of steroid (Standard)|Early intervention with high-dose steroids
88844755|NCT05330039||Patients with IEM|Collection of biological samples (stool and urine) and health-related data at two timepoints, three to six months apart.
89372337|NCT06334471||Retrospective study|The retrospective study group includes patients who have been histologically confirmed with breast cancer and whose breast cancer tissues collected between 2012 and 2023 are stored in the Samsung Seoul Hospital Human Biobank and available for distribution.
88844756|NCT05330039||Healthy Siblings|Collection of biological samples (stool) and health-related data at two timepoints, three to six months apart.
88844757|NCT05329623|Experimental|Normal hepatic function|Matched healthy participants with normal hepatic function
88844758|NCT05329623|Experimental|Mild hepatic impairment|Mild hepatic impaired participants with Child-Pugh A (score of 5 to 6)
88844759|NCT05329623|Experimental|Moderate hepatic impairment|Moderate hepatic impairment with Child Pugh B (score from 7 to 9)
88844760|NCT05329623|Experimental|Severe hepatic impairment|Severe hepatic impairment with Child Pugh C (score from 10 to 15)
88844761|NCT05328908|Experimental|Arm A: Nivolumab + Relatlimab Fixed-dose Combination (FDC)|
88844762|NCT05328908|Active Comparator|Arm B: Investigator's Choice|Treatment with Regorafenib or TAS-102
88844763|NCT05327127|Experimental|K-001|K-877-ER and CSG452 Once daily (QD)
88844764|NCT05327127|Experimental|K-877-ER|K-877-ER and CSG452 Placebo QD
88844765|NCT05327127|Experimental|CSG452|CSG452 and K-877-ER Placebo QD
88844766|NCT05327127|Placebo Comparator|Placebo|
88844767|NCT05325970||Cohorts Interventions Patients receiving head and neck RT|
88844768|NCT05322408|Experimental|Administer HCW9218|"Administer HCW9218 as monotherapy at assigned dose by SC injection once every 3 weeks. Dose Level~-1 - 0.1 mg/kg~- (start) 0.25 mg/kg~- 0.5 mg/kg~- 0.8 mg/kg~- 1.2 mg/kg"
88844769|NCT05312775|Active Comparator|Single-layer uterine closure|Women will undergo a CD following a standard way with respect to the mode of hysterotomy, non-closure of the peritoneum. The control group will receive a single-layer closure using unlocked continuous running multifilament sutures and the endometrial layer will be included
88844770|NCT05312775|Active Comparator|Double-layer uterine closure|Women will undergo a CD following a standard way with respect to the mode of hysterotomy, non-closure of the peritoneum. In the intervention group, double-layer closure of the uterus will be performed using unlocked multifilament continuous running sutures for both layers and the endometrial layer will be included in the first layer. The second layer is a continuous running suture that imbricates the first layer
88844771|NCT05309317|Experimental|CAUTI-VSG|Preventing Catheter-Associated Urinary Tract Infections with a Virtual Simulation Game
88844772|NCT05309317|Active Comparator|Control group|"Training on CAUTI Prevention"
88844773|NCT05306522|Experimental|Telerehabitation Group|Patients will undergo telerehabilitation based spinal stabilization exercise 3 days per week for 6 weeks.
88844774|NCT05306522|Experimental|Face to face Group|Patients will undergo spinal stabilization exercise 3 days per week for 6 weeks.
88844775|NCT05301556|Experimental|Experimental Product|Food for Special Medical Purpose (FSMP) is a special medical food for patients with tumors
88844776|NCT05301556|Active Comparator|Control Product|Nutrition Emulsion (TPF-T) TPF-T is a tumor-specific enteral nutrition therapy
88844777|NCT05297565|Experimental|Arm A: Subcutaneous Nivolumab|
88844778|NCT05297565|Active Comparator|Arm B: Intravenous Nivolumab|
88844779|NCT05297409||Hyperkalemia patient with Chronic kidney disease|
88844780|NCT05297409||hyperkalemia patient with heart failure|
88844781|NCT05273554|Experimental|Pembrolizumab|by vein over about 30 minutes on Day 1 of each cycle.
88844782|NCT05273554|Experimental|Lenvatinib|2 lenvatinib capsules at the same time by mouth every day while on study.
89372338|NCT06334458|Other|Early diagnosis for Pancreatic Cancers in high-risk asymptomatic subject groups|Early diagnosis for pancreatic cancer in first degree healthy/asymptomatic relatives of patients with exocrine pancreatic cancer (high-risk asymptomatic subject groups)
89372339|NCT06334445||Control group|Wearables/sensors and ePsycHeart App
89372340|NCT06334445||Intervention group|Wearables/sensors and ePsycHeart App and eHealtHeart
89372341|NCT06334432|Other|Phase 1: Schedule A|Schedule A evaluating escalating dose levels of NUV-1511
89372342|NCT06334432|Other|Phase 1: Schedule B|Schedule B evaluating escalating dose levels of NUV-1511
89372343|NCT06334432|Experimental|Phase 2: Tumor Type 1|Tumor type to be selected after Phase 1. Dose Schedules A and B to be further evaluated.
89372344|NCT06334432|Experimental|Phase 2: Tumor Type 2|Tumor type to be selected after Phase 1. Dose level and schedule to be selected after identification of the recommended phase 2 dose (RP2D) in Phase 1.
89372345|NCT06334432|Experimental|Phase 2: All comers|All tumor types allowed per protocol. Dose level and schedule to be selected after identification of the recommended phase 2 dose (RP2D) in Phase 1.
89372346|NCT06334419|Experimental|All Study Participants|Participants received, in random order, a single dose of placebo or Gaboxadol with a two-week washout period between doses. The gaboxadol dosage selected for this study is 10 mg or Placebo as a single dose on each study visit (two at home and two in clinic).
89181003|NCT05152563|Experimental|SC 450 mg of lirentelimab (AK002)|Subjects in this arm will receive 6 monthly doses of 450 mg of lirentelimab (AK002) administered subcutaneously.
89372347|NCT06334406||Cohort A|Patients treated with intravesical instillations for non-invasive bladder cancer
89372348|NCT06334406||Cohort B|Patients treated with radiotherapy (+/- concurrent chemotherapy) for invasive bladder cancer
89534869|NCT02492321|Placebo Comparator|Vehicle|Placebo Comparator: One of two study arms: placebo topical administered 3 times per day
89534870|NCT05024877|Experimental|Hetrombopag treatment group|stanozolol 2mg tid + Hetrombopag (started with 5mg/day and increased by 2.5mg/day every 2 weeks if the platelet count remains less than 20×10e9/L and reduced if the platelet count reaches over than 150×10e9/L, the maximum dosage is 15mg/day)
88844785|NCT05269251||Axillary Brachial Plexus Block|Our study includes 3 groups, 33 patients each who underwent axillary, infraclavicular and interscalene blocks. In the study, which of the axillary, infraclavicular and interscalene blocks will be preferred, will be decided by an experienced anesthesiologist in accordance with the type of surgery to be performed. Demographic data, comorbidities, and smoking will be questioned in each group, arterial blood pressure, heart rate, body temperature, radial artery diameter and flow velocities will be recorded before peripheral nerve block is applied, and tissue oxygenation will be measured with Near Infrared Spectroscopy (NIRS) in the extremities with and without block. Tissue oxygenation, radial artery flow velocity and diameters, body temperature will be measured simultaneously at 0(basal)-5-10-15-20-25 and 30th minutes after the application of the block. test will be applied and the success of the procedure will be determined accordingly.
88844786|NCT05269251||Infraclavicular Brachial Plexus Block|Our study includes 3 groups, 33 patients each who underwent axillary, infraclavicular and interscalene blocks. In the study, which of the axillary, infraclavicular and interscalene blocks will be preferred, will be decided by an experienced anesthesiologist in accordance with the type of surgery to be performed. Demographic data, comorbidities, and smoking will be questioned in each group, arterial blood pressure, heart rate, body temperature, radial artery diameter and flow velocities will be recorded before peripheral nerve block is applied, and tissue oxygenation will be measured with Near Infrared Spectroscopy (NIRS) in the extremities with and without block. Tissue oxygenation, radial artery flow velocity and diameters, body temperature will be measured simultaneously at 0(basal)-5-10-15-20-25 and 30th minutes after the application of the block. test will be applied and the success of the procedure will be determined accordingly.
89002106|NCT06116058|Experimental|Group B :Instrument assissted soft tissue mobilization|Group B : patient will receive Instrument assissted soft tissue mobilization technique and conventional physical therapy program for 3 sessions /week over 4 weeks periods
89181004|NCT05152563|Other|Placebo|Placebo
89372349|NCT06334406||Cohort C|Patients treated with neo-adjuvant chemotherapy for invasive bladder cancer
89372350|NCT06334393|Experimental|VLA1601 Low dose|
89372351|NCT06334393|Experimental|VLA1601 Low dose + CpG 1018®|
89372352|NCT06334393|Experimental|VLA1601 Low dose + 3M-052-AF|
89372353|NCT06334393|Experimental|VLA1601 Medium dose|
89372354|NCT06334393|Experimental|VLA1601 High dose|
89372355|NCT06334380|Active Comparator|Control Group: Virtual Reality Modules Only|Participants will have access to the prehabilitation (preoperative) and rehabilitaiton (postoperative) virtual reality physical therapy modules.
89372356|NCT06334380|Experimental|Intervention Group: Virtual Reality Modules + Live Physical Therapist Support|"Participants will have access to prehabilitation and rehabilitaiton virtual reality physical therapy modules in addition to zoom office hours with the physical therapist so that they may ask questions."
89372357|NCT06334367|Experimental|CD25 treatment|The humanized CD25 antibody was administered at 1 mg/kg iv on days+4 and +7 after HSCT.
89372358|NCT06334367|Other|control group|
89372359|NCT06334354||Breast Cancer Survivor (BCS)|Enrolled participants will be asked to complete a one-time, remote neurocognitive assessment. The neurocognitive assessment will consist of the CogSuite Neurocognitive Battery, an online, remotely deliverable battery of cognitive experimental measures, and a standard battery of remote neuropsychological measures. DNA will be collected via mailed saliva kits to assess Apolipoprotein E (APOE) status.
89534871|NCT03228979|Active Comparator|Structured Semi-Interactive Prevention|The intervention arm will receive a Structured Semi-Interactive Stroke Prevention Package including patient workbook, short messaging services and health education videos for a period of one-year in addition to standard of care as per current guidelines
89534872|NCT03228979|No Intervention|Control group|Patients will receive standard post stroke care for 1 year
89534873|NCT03327077|No Intervention|Control Group|
89534874|NCT03327077|Experimental|Intervention Group|Music group
89534875|NCT03079557|Experimental|Intragastric botulinum toxin type A|Botulinum toxin A (Allergan) injected intragastrically in the antrum
89372360|NCT06334354||Non-cancer Control (NCC)|Enrolled participants will be asked to complete a one-time, remote neurocognitive assessment. The neurocognitive assessment will consist of the CogSuite Neurocognitive Battery, an online, remotely deliverable battery of cognitive experimental measures, and a standard battery of remote neuropsychological measures. DNA will be collected via mailed saliva kits to assess Apolipoprotein E (APOE) status.
89372361|NCT06334341|No Intervention|No intervention|No intervention
89372362|NCT06334341|Experimental|Video|Patient PrEP Video only
88844787|NCT05269251||Interscalene Brachial Plexus Block|Our study includes 3 groups, 33 patients each who underwent axillary, infraclavicular and interscalene blocks. In the study, which of the axillary, infraclavicular and interscalene blocks will be preferred, will be decided by an experienced anesthesiologist in accordance with the type of surgery to be performed. Demographic data, comorbidities, and smoking will be questioned in each group, arterial blood pressure, heart rate, body temperature, radial artery diameter and flow velocities will be recorded before peripheral nerve block is applied, and tissue oxygenation will be measured with Near Infrared Spectroscopy (NIRS) in the extremities with and without block. Tissue oxygenation, radial artery flow velocity and diameters, body temperature will be measured simultaneously at 0(basal)-5-10-15-20-25 and 30th minutes after the application of the block. test will be applied and the success of the procedure will be determined accordingly.
88844788|NCT05264831|Active Comparator|PVI procedure alone|"If the patient presents with AF (= failure of electric cardioversion, approximately 30% of patients), randomization will be carried out according to :~- Group 1: PVI procedure alone in accordance with ESC recommendations"
88844789|NCT05264831|Experimental|PVI procedure combined with substrate modulation|"If the patient presents with AF (= failure of electric cardioversion, approximately 30% of patients), randomization will be carried out according to :~- Group 2: PVI procedure associated with substrate modulation"
88844790|NCT05259527|Experimental|Vitamin D Replacement|Participants will receive prescribed oral vitamin D2 to achieve a serum vitamin D level between 30 ng/mL to 50 ng/mL.
88844791|NCT05259527|Active Comparator|Standard of Care|Participants will receive standard-of-care advice to take over the counter vitamin D.
88844792|NCT05259527|No Intervention|Observation Arm|Observation only
88844793|NCT05257551||Patients with Small Cell Lung Cancer (SCLC)|This protocol will include participants with newly diagnosed extensive stage (stage IV) small cell lung cancer with tissue collected from the primary lung tumor, or metastatic sites outside of the liver or biliary system.
88844794|NCT05256641|Experimental|Group I (acalabrutinib)|Beginning day 90, patients receive acalabrutinib PO QD and then PO BID once no longer on prophylactic antifungal (CYP34A inhibitors) until day 365 in the absence of disease progression or unacceptable toxicity.
88844795|NCT05256641|Experimental|Group II (acalabrutinib)|Beginning day 60, patients receive acalabrutinib PO QD and then PO BID from day 74 if there are no dose reductions until day 365 in the absence of disease progression or unacceptable toxicity.
89372363|NCT06334341|Experimental|Risk Assessment|Patient Risk Assessment only
89372364|NCT06334341|Experimental|Risk Assessment and Video|Patient Risk Assessment and Patient PrEP Video
89372365|NCT06334341|Experimental|Best Practice Alert|Best Practice Alert only
89372366|NCT06334341|Experimental|Best Practice Alert and Video|Best Practice Alert and Patient PrEP Video
88844796|NCT05256641|Experimental|Group III (acalabrutinib)|Beginning anytime between days 28-104, patients receive acalabrutinib PO BID until day 365 in the absence of disease progression or unacceptable toxicity.
88844797|NCT05254834||Cancer Group|Collect Subject Data Collect Blood Specimen
88844798|NCT05254834||Non-cancer Group|Collect Subject Data Collect Blood Specimen One Year Follow Up On Cancer Status
88844799|NCT05252533|Experimental|Cohort 1: Juvenile Psoriatic Arthritis (jPsA)|Participants (aged greater than or equal to [>=] 5 to less than [<] 18 years) will receive ustekinumab at the dose and frequency as prescribed by their treating health care professional (HCP).
88844800|NCT05252533|Experimental|Cohort 2: Pediatric Psoriasis (PsO)|Participants (aged >=6 to <18 years) will receive ustekinumab at the dose and frequency as prescribed by their treating HCP.
88844801|NCT05251753|Experimental|A K-Lock left|A) left side K-Lock with right side suture-based technique
88844802|NCT05251753|Experimental|B K-Lock right|B) right side K-Lock with left side suture-based technique.
88844803|NCT05247216|Experimental|Hemay007 800 mg QD group|Drug: 800mg QD of Hemay007; daily oral administrtion for 12 weeks
89372367|NCT06334341|Experimental|Best Practice Alert and Risk Assessment|Best Practice Alert and Patient Risk Assessment
89372368|NCT06334341|Experimental|Best Practice Alert, Risk Assessment and Video|Best Practice Alert, Patient Risk Assessment, and Patient PrEP Video
89372369|NCT06334341|Experimental|Training|Provider Training
88844804|NCT05247216|Experimental|Hemay007 1200 mg QD group|Drug: 1200mg QD of Hemay007; daily oral administrtion for 12 weeks
88844805|NCT05247216|Experimental|Hemay007 600 mg QD group|Drug: 600mg QD of Hemay007; daily oral administrtion for 12 weeks
88844806|NCT05247216|Placebo Comparator|placebo group|Drug: placebo of Hemay007; daily oral administrtion for 12 weeks
88844807|NCT05242640|Experimental|Mindful attention|16 sessions over 8 weeks (2x/week) of mindful attention audio recordings delivered via headphones
88844808|NCT05242640|Experimental|Exercise|16 sessions over 8 weeks (2x/week) of moderate-intensity treadmill walking
88844809|NCT05242640|Experimental|Exercise with mindful attention|16 sessions over 8 weeks (2x/week) of moderate-intensity treadmill walking utilizing mindful attention audio recordings delivered via headphones
88844810|NCT05242640|No Intervention|No intervention|No intervention sessions
89372370|NCT06334341|Experimental|Training and Video|Provider Training and Patient PrEP Video
89372371|NCT06334341|Experimental|Training and Risk Assessment|Provider Training and Patient Risk Assessment
89372372|NCT06334341|Experimental|Training, Risk Assessment, and Video|Provider Training, Patient Risk Assessment, and Patient PrEP Video
89372373|NCT06334341|Experimental|Training and Best Practice Alert|Provider Training and Best Practice Alert
89372374|NCT06334341|Experimental|Training, Best Practice Alert, and Video|Provider Training, Best Practice Alert, and Patient PrEP Video
89372375|NCT06334341|Experimental|Training, Best Practice Alert, and Risk Assessment|Provider Training, Best Practice Alert, and Patient Risk Assessment
89372376|NCT06334341|Experimental|Training, Best Practice Alert, Risk Assessment, and Video|Provider Training, Best Practice Alert, Patient Risk Assessment, and Patient PrEP Video
89372377|NCT06334328|Experimental|Virtual reality based mindful movement therapy|"Participants will be asked to complete 12 VR-MMT sessions over a 6-week period, with two 30-minute sessions per week.~Each session will be comprised of a guided warm-up (5 min, pre-recorded video played on the computer monitor) followed by a VR module with a head-mounted display (HMD) on (20 min). The VR module includes both structured and freestyle dance/movement guided by the therapist's prompts that are pre-recorded. Sessions will end with a closing routine (5 min, including guided breathing, stretching, and meditation) in order to assist participants to transition back to the real environment."
88844811|NCT05240586|Experimental|pharmacopunture therapy|The physicians will choose the type and volume of pharmacopuncture according to participants' conditions.
88844812|NCT05240586|Active Comparator|acupuncture therapy|The physicians will choose the type and number of acupuncture therapy according to participants' conditions.
88844813|NCT05240586|Active Comparator|physical therapy, medication(prn)|The physicians will choose the type and time of physical therapy according to participants' conditions. According to clinical judgment, clinicians can prescribe analgesics and muscle relaxants if necessary.
88844814|NCT05236114||Cohort 1|Cohort 1 will include patients with early-stage and locally advanced disease (stages I-IIIB) who are candidates for definitive surgical resection.
88844815|NCT05236114||Cohort 2|Cohort 2 will include patients with stage IV disease receiving first line IO (mono/combo) therapy.
89372378|NCT06334315|Experimental|Combined oral contraceptive pill users|Administered a combined oral contraceptive pill containing desogestrel and ethinyl estradiol (Desogen, 0.15mg desogestrel and 0.03mg ethinyl estradiol per active pill) for at least one cycle (21 days) and up to 13 total cycles (one year)
89534876|NCT03230851|Experimental|aspirin 100mg/d therapy|Group1: aspirin 100 mg/d;
89534877|NCT03230851|Experimental|aspirin 100mg/2d therapy|Group2: aspirin ;
89372381|NCT06334289||Frailty group|
88844816|NCT05234177||Participants with stage I-IV colorectal cancer (CRC)|This protocol will include participants with stage I-IV CRC who are scheduled to undergo or have undergone a surgical resection with curative intent.
88844817|NCT05225948|Active Comparator|RIC+Standard medical treatment|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mmHg. RIC will be conducted twice daily during the period of hospitalization. Besides, the patients will be treated with standard medical treatment according to consensus on diagnosis and treatment of cerebral small vessel disease in China 2015, including antiplatelet aggregation and lipid-stabilizing drugs as well as neurotrophic and circulation improving treatment.
88844818|NCT05225948|Placebo Comparator|Sham RIC+Standard medical treatment|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 60 mmHg. RIC will be conducted twice daily during the period of hospitalization. Besides, the patients will be treated with standard medical treatment according to consensus on diagnosis and treatment of cerebral small vessel disease in China 2015, including antiplatelet aggregation and lipid-stabilizing drugs as well as neurotrophic and circulation improving treatment.
88844819|NCT05224440|Experimental|Sponsorship Initiative|TSMV receives a VA certified and volunteer sponsor (1-on-1) approximately 6 months prior to military discharge. Sponsorship continues for approximately 6 months after military discharge.
88844820|NCT05224440|No Intervention|Transition as Usual|TSMVs transition to civilian life as usual.
88844821|NCT05206357|Experimental|Epcoritamab|Participants will receive subcutaneous (SC) epcoritamab in 28 day cycles.
88844822|NCT05203510|Experimental|Treprostinil|"Participants will receive parenteral treprostinil at initial dose of 1.25 nanograms/kilogram/minute (at minimum) either intravenously or subcutaneously. Based on mPAP assessments and after a minimum dose of parenteral treprostinil is reached, at Investigator's (PI's) discretion, participants may transition to oral treprostinil and continue dose uptitration for further reduction of mPAP. Based on Month 12 mPAP assessment, participants may transition from parenteral to oral treprostinil at PI's discretion after completion of Month 12 assessment and continue uptitration for further reduction of mPAP. If minimum dose of parenteral treprostinil is not reached at Month 6/12 at PI's discretion, uptitration of parenteral treprostinil or oral treprostinil transition may occur to maintain normal mPAP.~Treprostinil therapy (parenteral or oral) may continue as tolerated toward goal of further reduction of mPAP until Month 36."
89372382|NCT06334289||Non-frailty group|
89372383|NCT06334276||Fatal drowning|This group of patients have died before 30 days after the drowning incident.
89372384|NCT06334276||Non-fatal drowning|This group of patients have survived until 30 days after the drowning incident.
89372385|NCT06334198|Active Comparator|Active treatment|Naldemedine + tramadol
89372386|NCT06334198|Placebo Comparator|Placebo treatment|Placebo + tramadol
89534878|NCT03230851|Experimental|aspirin 100mg/3d therapy|Groups3: aspirin ;
89534879|NCT03230851|Experimental|aspirin 50mg bid therapy|Groups4: morning 50mg evening 50mg;
89372389|NCT06333197|Experimental|transparotid approch|Patients who diagnosed with extra capsular fracture of mandibular condyle will undergo Retromandibular transparotid approch
89372390|NCT06333197|Experimental|Retroparotid approch|Patients who diagnosed with extra capsular fracture of mandibular condyle will undergo Retromandibular retroparotid approch
89534880|NCT03230851|Experimental|aspirin 75mg/d therapy|Group5: aspirin 75mg / d;
88844823|NCT05196191|Experimental|Viagenex Max|VIAGENEX Max graft will be placed in the incision at the end of surgery prior to closing.
88844824|NCT05196191|Active Comparator|Standard of care|Hibiclens wash will be performed.
89534881|NCT03230851|Experimental|aspirin 50mg/d therapy|Group6: aspirin 50mg / d;
89534882|NCT03230851|Experimental|indobufen 100mg bid therapy|Group7: 100mg bid
89534883|NCT05464433|Experimental|liposomal mitoxantrone hydrochloride|Patients with recurrent and refractory Extranodal Natural Killer/T Cell Lymphoma（NKTCL）will receive sequentially higher doses of liposomal mitoxantrone hydrochloride in combination with tislelizumab for 6 cycles (planned) (28 days per cycle). The initial dose of liposomal mitoxantrone hydrochloride is 16 mg/m2.
89372391|NCT06333041|Experimental|Epidiolex (cannabidiol)|"Oral Epidiolex (cannabidiol) administered twice daily (BID) Week 1: 5 mg/kg/day BID Weeks 2-8: 10 mg/kg/day BID Weeks 9-16: 20 mg/kg/day BID~8-week washout; cross-over to placebo comparator starting on Week 24."
89372392|NCT06333041|Placebo Comparator|Placebo (PBO)|"Week 1: Dose escalate to maximum tolerated placebo dose Weeks 2-16: Maximum tolerated placebo dose~8-week washout; cross-over to Experimental group starting at week 24, following the same dose-escalation as the Experimental arm."
89372393|NCT06332885||Single Group Assignment|Bronchoscopic lung volume reduction with Zephyr Valves
89372394|NCT06332781|Active Comparator|Standard of Care|Standard of care
89372395|NCT06332781|Experimental|Experimental|Gentamicin
89372396|NCT06331429|No Intervention|Control Group|Patients who receive the treatment program, will previously constitute their own control group (waiting list control group).
89372397|NCT06331429|Experimental|Experimental group|Adolescents who receive the treatment program, will previously constitute their own control group (waiting list control group). Thus, diagnostic measures will be obtained in all of them in an initial evaluation (T1), and after 6 weeks of this assessment the treatment program will be started. In the first contact session at 6 weeks after T1 all adolescents will be re-assessed (T2) and after this the treatment program will be started (within an estimated time of 15 days maximum from this second pre-treatment evaluation, the estimated duration of treatment being 6 weeks). After the completion of the serious game, a new asssesment pass will be performed (T3) in order to assess the post-treatment change. Thus, the estimated time between T2 and T3 will be equivalent to that between T1 and T2, being 6 weeks.
89534884|NCT03229135||Group A|Group A (CLcr≥60mL/min) : Teicoplanin was intravenously administered 3 times for moderate infections (skin, soft tissue and respiratory infections) or 6 times for severe infections(endocarditis caused by MRSA or severe pneumonia) at the loading dose of 400 mg at 12h intervals, followed by maintenance dosing 400 mg/d.
89534885|NCT03229135||Group B|Group B (40 mL/min≤CLcr<60mL/min) : Teicoplanin was intravenously administered 3 times at the loading dose of 400 mg at 12h intervals, followed by maintenance dosing 400 mg/d.
89372400|NCT06331052|Experimental|3-D Tractography Vim FUSA|Twenty-four consecutive essential tremor (ET) participants undergoing Vim FUSA using 3-D tractography will be assessed at baseline and Month 3.
89372401|NCT06330558||group A|laparoscopic right adrenalectomy
89372402|NCT06330558||Group B|laparoscopic left adrenalectomy
89372403|NCT06330467|Other|Borderline|Borderline patients
89372404|NCT06330467|Other|Functional Dissociative Crises (FDC)|FDC patients
89372405|NCT06330467|Other|Early psychosis|Early psychosis patients : mental state at risk for psychosis and first psychotic episode
89372406|NCT06330454||Painfull TKA|Pulsed electromagnetic field therapy
89372407|NCT06330441|Experimental|A - chronic pancreatitis|Chronic pancreatitis, due to cystic fibrosis
89372408|NCT06330441|Experimental|B1 - genetic predisposition (STK11, CDKN2A, PRSS1)|Persons with a confirmed diagnosis of Peutz-Jeghers syndrome (STK11 mutation) or familial melanoma syndrome (CDKN2A mutation), hereditary pancreatitis (PRSS1 mutation)
89372409|NCT06330441|Experimental|B2 - genetic predisposition of hereditary syndromes|Persons with a confirmed diagnosis of hereditary syndromes and at the same time with the condition of at least one relative of the first or second degree with a diagnosis of pancreatic ductal adenocarcinoma in family anamnesis; i.e. Lynch syndrome (mut: MLH1, MSH2, MSH6 a PMS2, EPCAM), HBOC (mut: BRCA1, BRCA2, PALB2, ATM), familial adenomatous polyposis (mut: APC), Li-Fraumeni syndrome (mut: TP53)
89372410|NCT06330441|Experimental|C - positive family anamnesis|Persons with positive family anamnesis of pancreatic ductal adenocarcinoma without proven hereditary syndrome
89372411|NCT06330272|Experimental|CPP-ACPF treatment|"To apply the dental mousse, prophylaxis will first be carried out on teeth affected by pumice. The application of Tooth Mousse Plus to the MIH lesion will be carried out under relative isolation and with the aid of a microbrush, the amount of mousse will be a pea grain. The cream will remain on the surface for 1 minute. The application will be carried out once a week, for four consecutive weeks."
89372412|NCT06330168|Experimental|bupivacaine-calcitonin-fentanyl group|thoracic paravertebral block using 20 mL 0.25% bupivacaine, 100 micrograms of fentanyl (2ml), and 100 IU of calcitonin (1ml)
89372413|NCT06330168|Placebo Comparator|bupivacaine-fentanyl group|thoracic paravertebral block using 20 mL 0.25% bupivacaine, 100 micrograms of fentanyl (2ml), and 1 ml saline 0.9%.
89372414|NCT06330038|Experimental|TIVA group|The TIVA group will receive propofol for both induction and maintenance of general anesthesia.
89372415|NCT06330038|Active Comparator|GAS group|The GAS group will receive one or more volatile anesthetics (sevoflurane, desflurane, or isoflurane) for induction and maintenance of anesthesia during the surgery. For GAS group, propofol, midazolam, remimazolam, etomidate, or ketamine can be used with inhalation agents as co-induction agents under the discretion of the attending anesthesiologist.
89372416|NCT06329661|Active Comparator|Cyclosporine ophthalmic solution, 0.1% (VEVYE)|
89372417|NCT06329661|Placebo Comparator|Saline solution, 0.6%|
89372418|NCT06329531||Screen of Cancer Survivorship - Occupational Therapy Services (SOCS-OTS)|You will be asked to complete three questionnaires and a short interview about yourself and how well you are able to complete your daily tasks. The SOCS-OTS, which is a 20-item questionnaire.
89372421|NCT06329219|Experimental|Radiation|Participants in the intervention group each receive a hyperthermia device for water-filtered Infrared-A radiation.
89372422|NCT06329219|No Intervention|Waiting list|Participants in the control group initially receive no therapeutic intervention, but can receive it after the study's last visit for 3 months.
89372423|NCT06329102||Access (Open, laparoscopic, robotic)|Outcomes will be analysed for the different groups
89372424|NCT06329102||Extend of lymphadenectomy described by VAS score|The extend of lymphadenectomy achieved will be described by a visual analogue scale (VAS) after the operation
89372425|NCT06329102||Quality of the specimen|The quality of the specimen will be documented postoperatively by a graded classification system
89372426|NCT06328673|Experimental|Module A Dose Escalation|Patients with advanced solid tumors enrolled in dose escalation cohorts treated with DM919
89372427|NCT06328673|Experimental|Module A Cohort Expansion|Patients with select solid tumor types enrolled in expansion cohorts treated with DM919 at a dose selected from the Module A Escalation arm
89372428|NCT06328673|Experimental|Module B Combination Therapy Dose Escalation|Patients with advanced solid tumors enrolled in dose escalation cohorts treated with DM919 in combination with pembrolizumab
89372429|NCT06328673|Experimental|Module B Combination Therapy Cohort Expansion|Patients with select tumor types enrolled in expansion cohorts treated with DM919 at a dose selected from the Module B Escalation arm, in combination with pembrolizumab
89372430|NCT06327256|Experimental|Dose group 1|Group receiving placebo or dose 1 of BI 3000202
89372431|NCT06327256|Experimental|Dose group 2|Group receiving placebo or dose 2 of BI 3000202
89372432|NCT06327256|Experimental|Dose group 3|Group receiving midazolam, midazolam and dose 3 of BI 3000202 or midazolam and placebo, and only BI 3000202 or only placebo
89372433|NCT06327256|Experimental|Dose group 4|Group receiving midazolam, midazolam and dose 4 of BI 3000202 or midazolam and placebo, and only BI 3000202 or only placebo
89372434|NCT06327126||two-session treatment group|two-session ERCP
89372435|NCT06327126||single-session treatment group|single-session ERCP
89002107|NCT06116058|Active Comparator|Group C:conventional physical therapy|Group C: patient will receive conventional physical therapy only in the form of ( stretch for hamstring ,illiopoaps ,low back muscle and strenghtning for abdominal ,back muscles and side support exercise and quadriped exercise)
89372436|NCT06327061|Experimental|Experimental: Peer education and network support|During sessions 1 and 2, participants will be taught information and skills pertaining to overdose prevention and response. During the 3rd session, participants will trained to talk to their non drug using network members in overdose prevention and response.
89372437|NCT06327061|Active Comparator|comparison: Standard of care of health education|In one session, participants will receive the standard of care for overdose prevention.
88819377|NCT01499654|Experimental|Half-dose radiotracer administration|For this study, researchers would like to administer half of the radiotracer, obtain resting images, administer the remainder of the radiotracer and obtain a second set of resting images. Subjects will be given the same amount of radioactive material that would normally be given for this test; however, it will be administered in two ½ doses.
89372438|NCT06326372||Control group|In the control group, observation will be conducted solely by another anesthesia doctor or assistant participating in the study, and the data will be recorded blindly without being reported to the anesthesia doctor responsible for the surgery. The oxygen therapy administered by the anesthesia doctor in charge and the FiO2 values will be recorded independently and blindly, based solely on the clinician's own assessment, rather than according to the information obtained from ORi. Subsequently, for two days following the surgery, evaluations will be conducted twice daily at the same hours for ward patients using CAM, and for ICU patients using CAM-ICU. If delirium is detected, delirium subtyping will be performed using the Richmond Agitation-Sedation Scale (RASS).
89372439|NCT06326372||ORi+SpO2 group|"In the SpO2+ORi group; It is aimed to maintain SpO2 between %95 and %98, and ORi at 0.00.~Data will be recorded every 10 minutes. After extubation, patients will first be evaluated in the postoperative recovery room. Subsequently, for two days following the surgery, evaluations will be conducted twice daily at the same hours for ward patients using CAM, and for ICU patients using CAM-ICU. If delirium is detected, delirium subtyping will be performed using the Richmond Agitation-Sedation Scale (RASS)."
89372440|NCT06326125|Experimental|TICK-B|active distraction technique as non-pharmacology in treating children's pain and fear during venipuncture procedure.
89372441|NCT06326125|Experimental|TkTx-Cream|as Pharmacological approach will be use in managing children's pain and fear during venipuncture procedure.
89372442|NCT06326125|Experimental|TICK-B and TkTx-C|Pharmacological approache and non-Pharmacological will be use in managing children's pain and fear during venipuncture procedure.
89372443|NCT06326125|No Intervention|Control Group|No intervention will applied in this group
89534886|NCT03229135||Group C|Group C (CLcr<40mL/min) : Teicoplanin was intravenously administered 2 times at the loading dose of 400 mg at 12h intervals, followed by maintenance dosing 200 mg/d.
89534887|NCT03229135||Group D|Group D (standard regimen) : Teicoplanin was intravenously administered 1-3 times at the loading dose of 400 mg at 12h intervals, followed by maintenance dosing 200 mg/d.
89534888|NCT05024565|Experimental|prolonged intravenous infusion of β-lactams Antibiotics|Administer according to the PK/PD optimized regimen with the goal of increasing T>MIC. (1) Carbapenems: Calculate the daily dose according to the creatinine clearance rate and divide it into 3 times. Each time, the dose is injected intravenously at 1/2 dose for 15 minutes, and the remaining 1/2 dose is injected at a constant rate for 3 hours. (2) Cephalosporins: calculate the allowable daily dose according to the creatinine clearance rate, inject at a uniform rate within 24 hours. (3) β-lactams and β-lactamase inhibitor compound: the daily dose is calculated according to the creatinine clearance rate and injected at a uniform rate within 24 hours.
89372448|NCT06322082|Experimental|Pilates and Shock Wave group|30 patients will receive Pilates exercises combined with Low Intensity Extracorporeal Shock Wave Therapy and conventional pelvic floor muscle exercises
89372449|NCT06322082|Experimental|Shock Wave group|30 patients will receive Low Intensity Extracorporeal Shock Wave Therapy and conventional pelvic floor muscle exercises.
89372450|NCT06322082|Experimental|Pilates group|30 patients will receive Pilates exercises and conventional pelvic floor muscle exercises
89372451|NCT06322082|Experimental|control group|30 patients will receive conventional pelvic floor muscle exercises
89372454|NCT06320158||patients who are candidates for hip surgery|cohort of patients who are candidates for hip surgery: completion of scales and questionnaires, venous blood sampling, muscle ultrasound scan
88810146|NCT05742542|Experimental|High intensity interval training with low time spent near VO2max|"Participants performed high intensity interval training with low time spent near VO2max three times a week for two weeks.~All training sessions consisted of ten times 1 minutes of work and 30 seconds of passive recovery. The work intensity was adjusted at 85% and 87% of power output achieved at the end of incremental test for the first and second week, respectively.~The training sessions were performed using cycle ergometer.~Findings were compared to high intensity interval training with high time spent near VO2max, which followed the same exercise frequency, intensity and total duration."
89372455|NCT06320158||healthy subjects|cohort of healthy subjects recruited in 2016-2017 completion of scales, questionnaires and performance of the Short Physical Performance Battery test, venous blood sampling, muscle ultrasound scan
89372456|NCT06320002|Experimental|Fecal ostomy surgery participants receiving the CI-oSurg|This arm will include patients who are undergoing or have undergone fecal ostomy surgery and surgical clinicians caring for the patients who will receive the CI-oSurg intervention.
89372457|NCT06319820|Experimental|Group A: TAR-210|Participants in Group A will have TAR-210 inserted in the bladder on Day 1 and removed after 12 weeks. One TAR-210 will be inserted every 12 weeks over a treatment period of approximately 1 year.
89372458|NCT06319820|Active Comparator|Group B: MMC or Gemcitabine|Participants in Group B will receive intravesical mitomycin C (MMC) or gemcitabine (investigator's choice) once weekly for 4 to 6 induction doses followed by a maintenance phase for a minimum of 6 months and up to 1 year.
89372459|NCT06318403|Experimental|Transdermal estradiol patches|All patients will receive patches with identical labeling from our pharmacy, to be applied twice weekly. In the study group, these will contain 0.025 mg/day of estradiol. In the control group, these will be placebo. These will be applied twice weekly for three months beginning at the time of surgery and extending for three months after surgery.
88810147|NCT04383236|Experimental|ChocBalls|(L. acidophilus containing lozenges, PharmaCare Europe Ltd; West Sussex, RH10 9NQ, UK)
89372460|NCT06318403|Placebo Comparator|Placebo patches|All patients will receive patches with identical labeling from our pharmacy, to be applied twice weekly. In the study group, these will contain 0.025 mg/day of estradiol. In the control group, these will be placebo. These will be applied twice weekly for three months beginning at the time of surgery and extending for three months after surgery.
89372461|NCT06316778|Experimental|Pelvic floor muscle training|
89372462|NCT06316440|Experimental|Noise-canceling Group|Intraoperative intervention with noise-canceling earphones was performed to isolate the noise
89372463|NCT06316440|No Intervention|Control Group|After general anesthesia, the intervention of wearing noise-canceling earphones was not given
89372464|NCT06316297|Experimental|Experimental 1|Two administrations of the Acne mRNA vaccine will be injected in three increasing doses
89372465|NCT06316297|Experimental|Experimental 2|One administration of the Acne mRNA vaccine in three increasing doses and one administration of placebo will be injected
89372466|NCT06316297|Placebo Comparator|Placebo 1|Two administrations of placebo will be injected
88844825|NCT05183867|Experimental|Healthy Minds Program (HMP) app|Participants will receive access to the 4-week HMP Foundations module. The HMP app is a meditation-based smartphone app designed to promote and protect psychological well-being through sustainable skills training. The program is grounded in constituents of psychological well-being identified in empirical literature. HMP provides core content, with instruction administered through a curriculum of guided practices. HMP is based on research on eudaimonic well-being (e.g., environmental mastery, purpose) and brain-based skills that underlie these qualities (e.g., regulation of attention, mental flexibility). The full HMP has guided audio practices that address 4 constituents of well-being: awareness, connection, insight, and purpose. At post-treatment, participants will be given access to additional HMP content to support their continued practice.
89002108|NCT06116045|Experimental|Group A - BZ371A, then Placebo|Participants will first receive topical BZ371A 7.5 mg for daily use for 2 weeks. After a washout period of 2 weeks, they will receive topical Placebo to be used daily for 2 weeks.
89372468|NCT06313047||HCC patients|Each of the patients was given Doxorubicin and followed up for one year.
88844826|NCT05183867|Active Comparator|Psychoeducation app|Participants will receive access to the 4-week HMP Foundations module with guided meditation practices removed. The active control will include only the didactic content included in HMP without the guided meditation practices.
88844827|NCT05183867|No Intervention|Usual Care|Participants will receive access to HMP at the end of the study and will be encouraged to continue with their usual care.
88844828|NCT05181254|Experimental|Health dialogue|Patients > 18 years old seeking primary care for mental illness (depression, anxiety, sleep disorders or stress related problems) will be followed at 12 and 24 months from baseline in a first assessment, and after 5 and 10 years with follow-up in national registers in a later phase. The patient will fill out a web-based questionnaire about lifestyle habits before the visit to the health center and will be called for blood sampling and measurement of blood pressure and BMI. A nurse with special training in the Health Dialogue then meets the patient and provides individually tailored advice based on the patient's unique conditions and the risk profile on the Health Dialogue, such as help with smoking cessation, physical activity on prescription (PaR-S), contact with a dietitian, physiotherapist. A continued contact with a psychologist or physician will be planned if necessary
88844829|NCT05180279|Experimental|Sleep Lab|
88844830|NCT05178238||Patients with high viral load of SARS-CoV-2 in feces|
88844831|NCT05178238||Patients with low viral load of SARS-CoV-2 in feces|
89534889|NCT05024565|No Intervention|short-term intravenous infusion of β-lactams Antibiotics|The daily allowable dose is calculated according to the creatinine clearance rate. The carbapenems, cephalosporins and β-lactamase inhibitor compound preparations are administered in accordance with the dosage and usage required by the instructions, and the injection is generally 30 minutes.
88844833|NCT05130866|Experimental|Cohort A Adults, Dose 40 mg|
88844834|NCT05130866|Experimental|Cohort A Adults, Dose 60 mg|
88844835|NCT05130866|Experimental|Cohort A Adolescents|Starting dose of 30 mg followed by dose escalation to 40 mg and 60 mg.
88844836|NCT05130866|Experimental|Cohort B Active|Dose TBD
88844837|NCT05130866|Placebo Comparator|Cohort B Placebo|
88844838|NCT05124691|Active Comparator|Albendazole|Albendazole 400 mg single dose
88844839|NCT05124691|Experimental|FDCx1. Albendazole and Ivermectin Fixed Dose Coformulation|Single dose of a tablet of FDC 400mg18mg or 400mg9mg. (i) For participants <45 kg of body weight at baseline: FDC of 400mg ALB 9mg IVM. (ii) For participants ≥45 kg of body weight at baseline: FDC of 400mg ALB18mg IVM
88844840|NCT05124691|Experimental|FDCx3. Albendazole and Ivermectin Fixed Dose Coformulation 3 days|Daily dose of a tablet of FDC 400mg18mg or 400mg 9mg for 3 days. (i)For participants <45 kg of body weight at baseline: FDC of 400mg ALB9mg IVM. (ii) For participants ≥45 kg of body weight at baseline: FDC of 400mg ALB 18mg IVM.
88844841|NCT05100771||Experimental group|The experimental group will be made up of patients with focal epilepsy
88844842|NCT05099549|Experimental|Phase 1, Dose Escalation|"It is estimated that approximately 3-6 subjects will be enrolled per cohort in three dose cohorts for a total of 12-18 participants.~SNK01 (fixed dose) will be administered weekly by IV infusion."
88844843|NCT05099549|Experimental|Phase 2a, Expansion Cohort 1 - Metastatic colorectal cancer (EXP-1: mCRC)|SNK01 (fixed dose) will be administered weekly by IV infusion.
88844844|NCT05099549|Experimental|Phase 2a, Expansion Cohort 2 - Head and Neck Squamous Cell Carcinoma (EXP-2: SCCHN)|SNK01 (fixed dose) will be administered weekly by IV infusion.
88844845|NCT05099549|Experimental|Phase 2a, Expansion Cohort 3 - Non-small cell lung cancer (EXP-3: NSCLC)|SNK01 (fixed dose) will be administered weekly by IV infusion.
88844846|NCT05098470|Active Comparator|Metformin|
88844847|NCT05098470|Active Comparator|Insulin Glargine|
88844848|NCT05098470|Experimental|Dorzagliatin|
88844849|NCT05095571|Other|NO-ALS Extension Study High Dose EH301|
88844850|NCT05090163|Active Comparator|PREP group|Control group
88844851|NCT05090163|Experimental|PREP Plus group|Intervention group
89534890|NCT03230617||Intrinsic positive end expiratory pressure > 5|chronic obstructive pulmonary disease patient with intrinsic positive end expiratory pressure more than5
88844853|NCT05075577|Experimental|Phase 1 Cohort 1|600 mg QD EPI-7386 in combination of Enzalutamide120 mg
88844854|NCT05075577|Experimental|Phase 1 Cohort 2|800 mg QD EPI-7386 in combination of Enzalutamide120 mg
88844855|NCT05075577|Experimental|Phase 1 Cohort 3|600 mg BID EPI-7386 in combination of Enzalutamide120 mg
88844856|NCT05075577|Experimental|Phase 1 Cohort 4|RP2D mg EPI-7386 in combination of Enzalutamide160 mg
88844857|NCT05075577|Experimental|Phase 2 Enzalutamide + EPI-7386 (Randomized 2:1)|RP2D mg EPI-7386 in combination of Enzalutamide RP2D mg
88844858|NCT05075577|Active Comparator|Phase 2 Enzalutamide single agent|Enzalutamide 160 mg
88844859|NCT05069220|Experimental|18F-MFBG PET/CT in neuroendocrine malignancies|Each patient receive a single intravenous injection of 18F-MFBG 2-4 MBq/kg and undergo PET/CT scan after 60 min post-injection. Patients with neuroblastoma should have a routine clinical 123I-MIBG scintigraphy (planar and/or SPECT/CT) performed within 6 months prior to the inclusion visit or scheduled within 3 months after the inclusion visit. According to patients' condition and clinical management, part of patients with PPGL and NB will receive 68Ga-DOTATATE PET/CT, comparing with 18F-MFBG PET/CT.
89534891|NCT03230617||Auto positive end expiratory pressure < 5|chronic obstructive pulmonary disease patient with intrinsic positive end expiratory pressure less than5
89534892|NCT03090477|Experimental|Pharmaceutical care and adherence aids|
88844862|NCT05061017|Experimental|Pixatimod (PG545) + Nivolumab|"Pixatimod : 25 mg IV, weekly~Nivolumab: 480 mg IV, Q4 weeks~Cohort 1 (MSS CRC)"
88844863|NCT05061017|Experimental|Pixatimod (PG545) + Nivolumab + cyclophosphamide|"Pixatimod : 25 mg IV, weekly~Nivolumab: 480 mg IV, Q4 weeks~cyclophosphamide: 50 mg PO twice daily (Day 1-Day 7; Day 15-Day 21) with a 7-day drug free interval (Day 8-Day 14 and Day 22-Day 28)~Cohort 2 (PD-1 R/R melanoma) and Cohort 3 (PD-1 R/R NSCLC)"
88844864|NCT05058534||Very preterm infants born between November 30, 2018 and November 30, 2019|Infants born between November 30, 2018 - November 30, 2019, before implementation of the new multiperfusion neonatal system
89372469|NCT06311591|No Intervention|Enhanced Treatment as Usual (ETAU) Historical Control Group|Enhanced Treatment As Usual (ETAU) Historical Control is defined as the treatment provided as part of routine clinical care in the participating EDs during a period of time when Jaspr was not being implemented.
89372470|NCT06311591|Experimental|Jaspr Implementation Group|"This group will receive the enhanced treatment as usual (ETAU) provided as part of routine clinical care at the participating EDs. They will also be considered by their treating team for administration of Jaspr. Jaspr administers a Suicide Status Interview (SSI), Safety Planning, and Lethal means counseling, and allows open access to the Jaspr resource library. They can sign up to receive Jaspr at Home mobile app.~Electronic Health Records (EHR) will be used to assess the outcomes in the 12 months following the index visit."
89372471|NCT06311578|Experimental|Part 1: Dose Escalation|Participants with advanced solid tumors will receive JNJ-87704916 alone and in combination with cetrelimab. Ascending dose levels will be sequentially tested.
89372472|NCT06311578|Experimental|Part 2 Cohort A: Dose Expansion|Participants with relapsed/refractory metastatic non-small cell lung cancer (NSCLC) will receive JNJ-87704916 in combination with cetrelimab at the dose identified in Part 1. Additional cohorts may be added to evaluate additional disease indications, or treatment regimens.
89372473|NCT06304974|Experimental|Experimental Group|Participants receive BL-B01D1 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
89372474|NCT06304974|Experimental|Control group|Participants receive Irinotecan or paclitaxel or docetaxel in the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
89372475|NCT06304610|Experimental|Sample taking and questionnaire|"The participant is invited in the colposcopy waiting room by the study nurse and is asked to follow the study nurse to a separate room. Here the participant is given all the information about the study and sampling. If the participant agrees to participate and signs the consent form, the study nurse registers the participant and then asks her to complete a very short questionnaire. After that, the participant will be asked to take a self-sample.~Then the participant will proceed to her appointment for colposcopy. The doctor will take an endocervical samples, similar to a pap smear, before the actual colposcopy examination begins. Her samples will then be analyzed with the newly developed ELEVATE test and with comparative lab tests (standard HPV DNA detection and protein detection tests) in order to validate the newly developed ELEVATE cervical cancer screening test.~Participation is free and the participant can stop your participation at any time."
89534893|NCT03090477|No Intervention|Control (dispensing of TKI & instruction about administration)|
89534894|NCT03332615|Active Comparator|Clinicians with MI coaching|Clinicians in the intervention arm will be taught Motivational Interviewing via a coaching model in which a didactic session is followed by feedback through review of clinicians' audio-recorded encounters.
89372478|NCT06300294|Experimental|acupressure|acupressure application and Routine care and treatment (filling out the initial hospitalization documents, measuring vital signs, taking an ECG, preparing for the CAG procedure, administering the ordered medications).
89372479|NCT06300294|No Intervention|control|Routine care and treatment (filling out the initial hospitalization documents, measuring vital signs, taking an ECG, preparing for the CAG procedure, administering the ordered medications).
89372480|NCT06299540||Group 1: Individual Physical Activity Intervention|Participants with chronic lymphocytic leukemia (CLL) will be invited to perform physical activity according to a predefined intervention program. This program includes walking and weekly remote adapted physical activity sessions (2 sessions per week, the duration and difficulty of which will be adapted by the adapted physical activity [APA] trainer according to the Participant's abilities).
89372481|NCT06299540||Group 2: Standard of Care|Participants with CLL will continue physical activity according to their lifestyle and the recommendations of the medical team.
89372482|NCT06295848|Experimental|Cardiac Rehabilitation|The CR group will receive training for CVD and HT once a week, along with a rehabilitation program consisting of aerobic, resistance, flexibility and stretching exercises 3 days a week for 6 weeks.
89372483|NCT06295848|No Intervention|Control|Control group will receive treatment for their RA that is considered standard of care treatment (e.g. pharmacotherapy), but will not be participated in the CR program.
88844865|NCT05058534||Very preterm infants born between December 1st, 2019 and December 31st, 2022|Infants born between January 1rst, 2019 - December 31st, 2022, after implementation of the new multiperfusion neonatal system
89181005|NCT00916526|Experimental|bronchial provocation test with mannitol|"Patients referred for evaluation of a chronic cough (without treatment or after stopping inhaled corticosteroids for 2 weeks) will perform a measure of FeNO, a bronchial provocation test with mannitol, will fill out a questionnaire of quality of life for the cough (Leicester Cough Questionnaire) and the intensity of coughing on a 10-cm visual scale.~After 6 weeks after treatment with inhaled corticosteroids patients will perform the same tests."
89181006|NCT00724854||Mono-infected with HCV|Participants infected with Hepatitis C Virus (HCV).
89181007|NCT00724854||Co-infected with HCV and HIV|Participants co-infected with HCV and Human Immunodeficiency Virus (HIV).
89372484|NCT06295692|Experimental|JNJ-77242113- Participants With Generalized Pustular Psoriasis (GPP) or Erythrodermic Psoriasis (EP)|Participants with GPP or EP will receive JNJ-77242113 tablet orally.
89181008|NCT04023734|Experimental|Intervention|A targeted and tailored pharmacist intervention at baseline and at 1-month follow-up.
88810148|NCT04383236|Active Comparator|Oracure oral gel (15 gm, Amun pharmaceutical company, Egypt)|"Each 100 g contains:~Lidocaine HCI 2.0g. Cetylpyridinium chloride 0.1 g."
88810149|NCT01339247|Active Comparator|Paxil CR Reference|Paroxetine Hydrochloride 25 miligrams(mg) tablet with controlled release (Paxil CR), once a day, manufactured by SmithKline Beecham (Cork) Limited - Cidra - Puerto Rico, in Period 1, followed by Paroxetine Hydrochloride 25 mg tablet with controlled release (Paxil CR), once a day, manufactured by GlaxoSmithKline Inc. - Mississauga - Canada, in Period 2
88844866|NCT05058508|Experimental|EXER|"Just Move exercises"
88844867|NCT05058508|Experimental|SOC EXER|Standard of Care Exercise
88844868|NCT05057793|No Intervention|Standard of care|Multilayer, multicomponent compression intended for the treatment of VLU
89372485|NCT06295679||Repatha® with Standard of Care Exposure|Participants with clinically evident ASCVD treated with Repatha® in combination with SOC in a clinical setting. To ensure that the recruitment strategy has as little impact on routine practice as possible, the decision to treat the participant with Repatha® with SOC will be made independently of, and before, enrollment in the study.
89372486|NCT06295679||Standard of Care Exposure|Participants with clinically evident ASCVD treated with SOC alone in a clinical setting. To ensure that the recruitment strategy has as little impact on routine practice as possible, the decision to treat the participant with SOC only will be made independently of, and before, enrollment in the study.
89372487|NCT06293846|Experimental|What I Learned at Home|What I Learned at Home is a self-efficacy behavioral intervention that will help provide the framework of implementation for the BeFIT program in the future. The BeFIT program will be a component of the WILAH framework.
89181009|NCT04023734|Active Comparator|Control group|Usual care based on the Indonesian guideline at baseline and 1-month follow-up.
89181010|NCT04083651|Experimental|Methylnaltrexone Bromide (MNTX)|Participants will receive methylnaltrexone bromide (MNTX) 450 mg (3 tablets of 150 mg each) QD orally. If the initial interim analysis suggests a lack of efficacy, subsequent participants will receive 450 mg MNTX twice daily (BID) or three times daily (TID). Treatment will continue until participant's death or early withdrawal from study or study completion at Day 168.
89372488|NCT06290128|Experimental|Riliprubart Arm|Riliprubart for 24 weeks followed by open-label extension phase with riliprubart for 24 weeks
89372489|NCT06290128|Placebo Comparator|Placebo Arm|Placebo for 24 weeks followed by open-label extension phase with riliprubart for 24 weeks
89372490|NCT06285968|Experimental|Multidimensional Sleep Health Promotion Intervention|"Participants randomized to the intervention arm will receive:~A multi-component multidimensional sleep health promotion intervention that includes virtual sleep health and sleep hygiene education, personalized feedback and establishment of a sleep health plan, behavioral coaching, self-monitoring, supportive accountability, and addressing light and noise in the sleep environment.~Cardiovascular health education materials based on the American Heart Association's Life's Essential 8 framework."
89181011|NCT04083651|Placebo Comparator|Placebo|Participants will receive placebo matching to MNTX until participant's death or early withdrawal from study or study completion at Day 168.
89181012|NCT00728988|Experimental|Atorvastatin Group|
89181013|NCT00728988|Other|Usual Care Group|
89181014|NCT05130957|Experimental|Experimental Group|The pregnant women in the experimental group are given a massage with clove oil.
89372491|NCT06285968|No Intervention|Standard of care|Participants randomized to the control arm will receive standard American Heart Association Life's Essential 8 cardiovascular health education materials.
89181015|NCT05130957|Other|Control Group|The pregnant women in the control group are given a massage without any oil as standard midwifery care
89181016|NCT05129241||Cohort 1|Patients for whom the treating physician has decided to initiate lipid-lowering treatment with the PRALUENT® 2 ml SYDNEY auto-injector, irrespective of participation in the study
89181017|NCT04087746|Active Comparator|AFLIBERCEPT|Intra-vitreal injection of AFLIBERCEPT
89181018|NCT04087746|Active Comparator|RANIBIZUMAB|Intra-vitreal injection of RANIBIZUMAB
89181019|NCT00728754|Experimental|Dental implant Osseotite Prevail|Dental implant with lateralized design
89181020|NCT00728754|Active Comparator|Dental implant Osseotite|Dental implant without the lateralized design
89181021|NCT04083417|Active Comparator|Phenoxymethylpenicillin group|Patients randomized to oral phenoxymethylpenicillin 1000 mg three times daily for ten days
89181022|NCT04083417|Experimental|No antibiotic treatment group|Patients randomized to no antibiotic treatment
89181023|NCT00728130|Experimental|A|A neck dissection of at least the ipsilateral sub-level 1B will be performed in all patients
89372492|NCT06285903|Experimental|Group Densah Bur|patients received dental implant using osseodensification via Densah bur
89372493|NCT06285903|Experimental|Group piezoelectric|patients received dental implant using hydrodynamic piezoelectric sinus lifting
89372494|NCT06285851|Experimental|FeSC Cookie|Iron-yeast complex
89372495|NCT06283992|Experimental|Digital Navigation|Patients in this arm will receive 1:1 digital navigation support which will teach them about the functions of the patient portal and telehealth.
89372496|NCT06283992|No Intervention|Standard of Care|Patients in this arm will receive the standard of care which will be an educational sheet.
89534895|NCT03332615|Placebo Comparator|Wait-list control|After consent, clinicians in the wait-list control arm will complete a survey to self-assess their motivational interviewing skills and burnout.
89534896|NCT03228901|Experimental|Oxytocin|24IU Syntocinon, delivered in a single nose via a nasal spray
89534897|NCT03228901|Placebo Comparator|Placebo|Matched nasal spray
89534898|NCT05024331||Pediatric physicians|"Assigned Interventions~Prediction of the first date of recovery period with given data about chemotherapy of pediatric patients who diagnosed solid tumor at Samsung medical center during 2010-2018~Sees the result of the prediction algorithm.~Change or maintain their prediction values.~Participate in the usability questionnaires."
89534899|NCT03332537|No Intervention|Control|Participants will be provided an online interactive platform to access electronic modules (total of 10) on: IBS-related pain neurophysiology and the brain-gut axis and self-management strategies. There is no additional intervention.
89534900|NCT03332537|Experimental|Personalized IBS Pain SM|Participants will be enrolled in the online platform. After completion of the modules, they will be scheduled for a consultation with a research nurse about their level of peripheral and central sensitivity, self-evaluation of IBS-pain SM, goal setting and self-monitoring of IBS-pain and physical activity. They will be asked to document their pain and all symptom SM behaviors daily for the next 10 weeks. At the 6-week follow-up visit, the researcher will review the online activities of the participant, go over the previously selected goals with the participants. The study nurse will acknowledge accomplishment of goals and assist in problem-identification and solving.
89534901|NCT03228745|Experimental|pre-operative MBSR|Pre-operative MBSR is a condition where individuals will receive a pre-operative 8-week community-based MBSR course, which includes group classes lasting 2.5 hours a week, 45-minutes of home practice 6 days per week, a 1-hour orientation session at the beginning, and a full-day silent retreat at the end. During the orientation, participants will complete the study measures for this study.
88844869|NCT05057793|Active Comparator|Standard of care + geko 12h|Multilayer multicomponent compression intended for the treatment of VLU in conjuction with geko™ therapy 12 hours daily
88844870|NCT05054036|Experimental|MoviPrep|"For MoviPrep, the dose, schedule, and route of administration are as follows:~On the evening prior to the colonoscopy, mix the powder with lukewarm water to a total volume of 32 oz. Drink 8 oz. every 15 minutes until the solution is finished. Drink 16 oz. of clear liquids before bed.~On the morning of the procedure, repeat the above steps and make sure all fluids are consumed at least 2 hours prior to colonoscopy.~Limit food intake to a regular breakfast, light lunch and clear soup or plain yogurt for dinner on the day prior to the colonoscopy (completed at least 1 hour prior to the first MoviPrep dose.~Consume only clear liquids from the start of MoviPrep until after the colonoscopy."
88844871|NCT05054036|Active Comparator|GoLYTELY|"For GoLYTELY, the dose, schedule, and route of administrate are as follows:~On the evening prior to the colonoscopy, mix powder with lukewarm water to a total volume of 4 liters. Drink 2 liters of the solution and store the rest in the refrigerator.~Drink the remaining 2 liters on the morning of the procedure.~Limit food intake to a light breakfast on the day prior to the colonoscopy, followed by only clear liquids until the procedure is complete.~Avoid red and purple liquids."
88844872|NCT05051241|Experimental|Dose escalation Cohort 1|5 mg BID, 14d-on/14d-off
89534902|NCT03228745|No Intervention|treatment-as-usual (TAU)|The individuals in the TAU group will receive their treatment as usual.
89372508|NCT06278363|Experimental|Sexual Nursing Care|"Group 1 patients receive Sexual Nursing Care, involving personalized counseling by a nurse to address sexual dysfunctions post-stroke. The intervention includes partner involvement to foster new intimacy, sexual education, and exercises. Four 45-minute outpatient sessions with the nurse and partner are provided. Any emerging issues requiring diagnostic investigation will be communicated to the referring specialist."
89372509|NCT06278363|Active Comparator|Standard Nursing Care:|"Patients in Group 2 receive a standard nursing care approach. In this group, no specific structured interventions for sexual dysfunctions are provided. Management of sexual dysfunctions occurs based on the clinical case and standard care approach.~Care sessions follow a routine program, without specific interventions for the sexual sphere.~As in Group 1, any emerging issues during treatment that require further diagnostic investigation will be communicated to the referring specialist.~Both groups will be evaluated for the impact of treatment not only quantitatively, through the analysis of the effect of counseling on sexual and relational aspects but also qualitatively, to investigate psychorelational changes and mood impact on the quality of life of the involved couples."
89372510|NCT06278311||Patients|This group will include individuals presenting with digestive and/or non-digestive symptoms or conditions and whose medical evaluation necessitates 'toxin assessment.'
89372511|NCT06278311||Healthy controls|This group will include individuals not presenting with digestive and/or non-digestive symptoms or conditions and who volunteer to provide urine samples for 'toxin assessment.'
89372514|NCT06274047|Experimental|Arm 1|Participants will receive 6 months of standard-of-care androgen deprivation therapy (ADT) and radiation therapy.
89372515|NCT06274047|Experimental|Arm 2|Participants will receive 6 months of apalutamide and radiation therapy.
89372516|NCT06274047|Experimental|Arm 3|Participants will receive 24 months of standard-of-care androgen deprivation therapy (ADT) and radiation therapy.
89372517|NCT06274047|Experimental|Arm 4|Participants will receive 6 months of ADT, apalutamide, and radiation therapy.
89372518|NCT06272981|Experimental|Pulsed Field (PF)/Radiofrequency (RF) Ablation System|Participants with drug refractory symptomatic PAF who are candidates for atrial fibrillation ablation uses PF and RF energy to produce targeted intracardiac lesions for the treatment of atrial fibrillation.
89534903|NCT03090321|Active Comparator|Stand Prompt|Behavioral Intervention Prompt- Participant will receive a notification asking them to stand and walk if they have been sitting for longer than 60 minutes.
89534904|NCT03090321|Active Comparator|Step Prompt|The participant will receive a notification if they are below 5000 steps by 3pm each day asking them to get to 10000 steps.
89534905|NCT03090321|Active Comparator|Cluster Prompt|The participant will receive daily information notifications specific to the activity cluster they fall into based on the activity data collected in phase 1 of the study.
89534906|NCT03090321|Placebo Comparator|Read AHA website|Daily reminder to read the American Heart Association (AHA) website.
89534907|NCT03090321|No Intervention|Baseline monitoring|No feedback is provided to the users. This is the control arm.
88844873|NCT05051241|Experimental|Dose escalation Cohort 2|10 mg BID, 14d-on/14d-off
89534908|NCT03326765|Other|Children|Questionnaires electroencephalogram (EEG) Actigraphy polysomnography
89534909|NCT03326765|Other|Adults|Questionnaires electroencephalogram (EEG) Actigraphy polysomnography
89372528|NCT06268886|Placebo Comparator|Placebo|
89372529|NCT06268886|Experimental|BMS-986446 Dose A|
89372530|NCT06268886|Experimental|BMS-986446 Dose B|
88844874|NCT05051241|Experimental|Dose escalation Cohort 3|20 mg BID, 14d-on/14d-off
89372531|NCT06268860|Experimental|Rocatinlimab Vial|Participants will receive rocatinlimab vial solution SC
89372532|NCT06268860|Experimental|Rocatinlimab Prefilled Syringe|Participants will receive rocatinlimab prefilled syringe solution SC
89372533|NCT06267001|Experimental|Atezolizumab + Tiragolumab|Participants will receive atezolizumab and tiragolumab intravenously (IV).
88844875|NCT05051241|Experimental|Dose escalation Cohort 4|30 mg BID, 14d-on/14d-off
88844876|NCT05051241|Experimental|Dose escalation Cohort 5|40 mg BID, 14d-on/14d-off
88844877|NCT05051241|Experimental|Dose escalation Cohort 6|50 mg BID, 14d-on/14d-off
88844878|NCT05051241|Experimental|Dose escalation Cohort 7|65 mg BID, 14d-on/14d-off
89181024|NCT02588937|Experimental|EntecaBell ODT.|
88844879|NCT05051241|Experimental|Dose escalation Cohort 8|85 mg BID, 14d-on/14d-off
88844880|NCT05051241|Experimental|Dose escalation Cohort 9|85 mg BID, 7d-on/7d-off
88844881|NCT05051241|Experimental|Dose expansion Cohort 10|85 mg BID, 14d-on/14d-off
89181025|NCT02588937|Active Comparator|Baraclude Tab.|
89181026|NCT04083105|Experimental|30% Nitrous Oxide with Midazolam|30 percent nitrous oxide/70 percent oxygen will be administered for 5 minutes prior to intranasal midazolam.
89181027|NCT04083105|Experimental|70% Nitrous Oxide with Midazolam|70 percent nitrous oxide/30 percent oxygen will be administered for 5 minutes prior to intranasal midazolam.
89372534|NCT06267001|Placebo Comparator|Atezolizumab + Placebo|Participants will receive atezolizumab and placebo IV.
89372535|NCT06263738|Active Comparator|Whole Body Hyperthermia|Participants in the heat exposure alone group will receive a single heat session using the Clearlight Sauna Dome lasting up to 140 minutes.
89372536|NCT06263738|Active Comparator|Whole Body Hyperthermia + Cold Water Plunge|Participants in the heat exposure and cold plunge group will receive a single heat session using the Clearlight Sauna Dome lasting up to 140 minutes followed by a cold plunge session lasting up to 10 minutes.
89372537|NCT06258590|Experimental|tVNS|All patients will receive at-home Transcutaneous auricular vagus nerve stimulation (taVNS) and assess the impact on multiple behavioral outcomes associated with ASD and anxiety. This is an open-label trial.
89372538|NCT06256510|Experimental|Midazolam with and without Vepdegestrant|Midazolam administered as a single dose in Period 1 Day 1, and Period 2 Day 1 and Day 15. Vepdegestrant administered once a day for 15 days in Period 2.
89372539|NCT06254612|Experimental|SP-624|Participants to receive two 10 mg capsules of SP-624 once daily for a total daily dose of 20 mg
88844882|NCT05041803|Experimental|CTP-543|Patients who previously completed a qualifying CTP-543 clinical trial
88844883|NCT05041153|Experimental|Treatment (pembrolizumab, lenvatinib)|Patients receive pembrolizumab IV over 30 minutes on day 1 and lenvatinib PO QD, Treatment repeats every 42 days for up to 17 cycles in the absence of disease progression or unacceptable toxicity.
89181028|NCT00735696|Experimental|ramucirumab + paclitaxel + carboplatin|"Participants will receive ramucirumab in combination with paclitaxel and carboplatin until disease progression, the development of an unacceptable toxicity, or other withdrawal criteria, for up to six cycles (3 weeks per cycle).~In the absence of any withdrawal criteria, participants will continue to receive ramucirumab monotherapy every 3 weeks, provided there is ongoing evidence of benefit upon review every 6 weeks."
89372540|NCT06254612|Placebo Comparator|Placebo|Participant to receive 2 matching placebo capsules once daily
89534910|NCT03228823|Active Comparator|Radiofrequency Ablation|Radiofrequency ablation (RFA) will be performed after 3-month observation period. EPS and RFA will be performed using standard techniques and protocols similar to those patients that do not participate in this clinical study. In the event of polymorphic PVCs, all morphologies are to be targeted for ablation
89372547|NCT06240455|Active Comparator|WP1302 400μg|"After screening, eligible subjects will be randomized to treatment at a ratio (stratified by size of goiter [grade 0 or 1; grade 2], WHO classification) of 1:1:1:1 to either any group of MMI with WP1302 at a dose of 400 μg, 800 μg, or 1200 μg, or the group of MMI with placebo.~The study consists of up to 5 periods: a screening period of up to 2 weeks; a WP1302 or placebo titration with MMI period of 12 weeks; a Full dose of WP1302 or placebo with MMI tapering period of 26 weeks; a follow-up period of 4 weeks; and an extended follow-up period of 6 months."
89372548|NCT06240455|Active Comparator|WP1302 800μg|"After screening, eligible subjects will be randomized to treatment at a ratio (stratified by size of goiter [grade 0 or 1; grade 2], WHO classification) of 1:1:1:1 to either any group of MMI with WP1302 at a dose of 400 μg, 800 μg, or 1200 μg, or the group of MMI with placebo.~The study consists of up to 5 periods: a screening period of up to 2 weeks; a WP1302 or placebo titration with MMI period of 12 weeks; a Full dose of WP1302 or placebo with MMI tapering period of 26 weeks; a follow-up period of 4 weeks; and an extended follow-up period of 6 months."
89372549|NCT06240455|Active Comparator|WP1302 1200μg|"After screening, eligible subjects will be randomized to treatment at a ratio (stratified by size of goiter [grade 0 or 1; grade 2], WHO classification) of 1:1:1:1 to either any group of MMI with WP1302 at a dose of 400 μg, 800 μg, or 1200 μg, or the group of MMI with placebo.~The study consists of up to 5 periods: a screening period of up to 2 weeks; a WP1302 or placebo titration with MMI period of 12 weeks; a Full dose of WP1302 or placebo with MMI tapering period of 26 weeks; a follow-up period of 4 weeks; and an extended follow-up period of 6 months."
89372550|NCT06240455|Placebo Comparator|WP1302 Placebo|"After screening, eligible subjects will be randomized to treatment at a ratio (stratified by size of goiter [grade 0 or 1; grade 2], WHO classification) of 1:1:1:1 to either any group of MMI with WP1302 at a dose of 400 μg, 800 μg, or 1200 μg, or the group of MMI with placebo.~The study consists of up to 5 periods: a screening period of up to 2 weeks; a WP1302 or placebo titration with MMI period of 12 weeks; a Full dose of WP1302 or placebo with MMI tapering period of 26 weeks; a follow-up period of 4 weeks; and an extended follow-up period of 6 months."
89534911|NCT03228823|Active Comparator|Antiarrhythmic Drug|Antiarrhythmic drugs (AADs) will be only initiated after 3-month observation period. AAD therapy of choice is amiodarone. Amiodarone loading dose of 10 grams is recommended, followed by maintenance dose of 200-400mg daily to achieve successful PVC suppression. Investigators define successful PVC suppression only if ≥ 80% absolute reduction in PVC burden is achieved after a drug or intervention. Alternatively, sotalol and/or propafenone could be considered at discretion of electrophysiologists (sotalol dose of at least 120mg twice daily, propafenone 150-300mg tid) if there is a significant concern of safety profile of amiodarone.
88844884|NCT05038735|Experimental|Alpelisib plus fulvestrant|Alpelisib 300 mg orally once daily on a continuous dosing schedule, in a 28-day cycle + fulvestrant 500 mg as intramuscular injection on Cycle 1 Day 1 and 15, and on Day 1 on every Cycle thereafter, in a 28 days cycle.
88844885|NCT05038735|Placebo Comparator|Alpelisib-matching placebo plus fulvestrant|Alpelisib-matching placebo orally once daily on a continuous dosing schedule, in a 28-day cycle + fulvestrant 500 mg as intramuscular injection on Cycle 1 Day 1 and 15 and on Day 1 on every Cycle thereafter, in a 28 days cycle. Participants who have disease progression per RECIST v1.1 as assessed by BIRC will have the option to crossover to be treated with alpelisib plus fulvestrant
89534912|NCT03332381|Active Comparator|Attention training technique|
89372553|NCT06234605|Experimental|Monotherapy (Cohort 1)|Participants will receive HC-7366 monotherapy [dose to be determined] daily
89372554|NCT06234605|Experimental|Combination Escalation (Cohort 2)|Participants will receive HC-7366 20 mg plus belzutifan 120 mg daily
89372555|NCT06234605|Experimental|Combination Escalation (Cohort 3)|Participants will receive HC-7366 40 mg plus belzutifan 120 mg daily
89372556|NCT06234605|Experimental|Combination Escalation (Cohort 4)|Participants will receive HC-7366 75 mg plus belzutifan 120 mg daily
89372557|NCT06234605|Experimental|Combination Expansion (Cohort 5)|Participants will receive HC-7366 [dose selected from escalation] plus belzutifan 120 mg daily
89372558|NCT06234605|Experimental|Combination Expansion (Cohort 6)|Participants will receive HC-7366 [dose selected from escalation] plus belzutifan 120 mg daily
88844890|NCT05030428|Experimental|Inclisiran sodium|Subcutaneous injection
88844891|NCT05030428|Placebo Comparator|Placebo|Subcutaneous injection
88844892|NCT05028868||Large artery atherosclerosis(LAA)|
88844893|NCT05028868||Cardiogenic stroke(CS)|
88844894|NCT05028868||Penetrating artery disease(PAD)|
88844895|NCT05028868||Other etiology(OE)|
88844896|NCT05028868||undetermined etiology(UE)|
89002109|NCT06116045|Experimental|Group B - Placebo, then BZ371A|Participants will first receive topical Placebo for daily use for 2 weeks. After a washout period of 2 weeks, they will receive topical BZ371A 7.5 mg to be used daily for 2 weeks.
89372561|NCT06226766|Experimental|Dose escalation/expansion|"The dose escalation phase will utilize single patient accelerated dose titration (ADT) for dose level 1 (1.1 mg/kg , SC, QW) and dose level 2 (2.3 mg/kg, SC, QW), followed by dose level 3 (4.5 mg/kg, SC, QW), dose level 4 (5.6 mg/kg, SC, QW) and dose level 5 (6.7 mg/kg, SC,QW), which will all be enrolled and monitored using the 3+3 design, aimed at determining the MTD/RP2D of JSKN033.~After or during dose escalation, SMC will select 1-2 dose levels to expand with 10-30 additional patients with gastrointestinal tumor with HER2 expression each dose level for further exploration of the efficacy and safety of JSKN033."
89372562|NCT06225167||Protocol Group|Patients will be analyzed during the time frame of February 2020 to February 2023 for the protocol group
89372563|NCT06225167||Non Protocol Group|Patients will be analyzed during the time frame of February 2017 to February 2020 for the non-protocol group.
89534913|NCT03332381|Active Comparator|Mindful self-compassion|
89534914|NCT03090243||Study Group|measurements of IOP before and after virtual colonoscopy
89534915|NCT03079713|Experimental|Vibratory Anesthesia|Following administration of topical anesthetic and betadine, wearable vibrator will be triggered prior to and during the intravitreal injection
89534916|NCT03079713|Sham Comparator|Standard Injection.|Following administration of topical anesthetic and betadine, wearable vibrator will be placed against the lower lid but NOT triggered prior to and during the intravitreal injection
89372568|NCT06222411|Other|Physicians in Methodist Health System (MHS)|All Current physicians who are older than 18 years of age who are literate in English
89534917|NCT03079713|Experimental|Vibratory Anesthesia with Corneal/Conjunctival Sensation Test|Healthy patients not requiring intravitreal injection will be subjected to corneal and conjunctival aesthesiometry with and without the vibrator triggered while in contact with the lower eyelid of a single eye.
89372572|NCT06220604|Experimental|JNJ-77242113|Participants will receive JNJ-77242113 from Week 0 through Week 156 and deucravacitinib matching placebo from Week 0 through Week 24.
89372573|NCT06220604|Placebo Comparator|Placebo|Participants will receive matching placebo for JNJ-77242113 from Week 0 through Week 16, matching placebo for deucravacitinib from Week 0 through Week 24 and JNJ-77242113 from Week 16 through Week 156.
89372574|NCT06220604|Active Comparator|Deucravacitinib|Participants will receive deucravacitinib from Week 0 through Week 24 and matching placebo for JNJ-77242113 from Week 0 through Week 24 and JNJ-77242113 from Week 24 through Week 156.
89372575|NCT06219148|Experimental|Collaborative|"Social workers and music therapists work together, and information collected during music therapy informs social work wellness sessions following a protocol developed during the feasibility study.~There are 3 blocks of activities, identical to the non-collaborative arm:~Weeks 1-2: enrollment, stratification, random assignment~Weeks 3-6: music therapy and social work interventions~Weeks 7-8: social work follow up."
89002110|NCT06116045|Experimental|Group C - BZ371A, then Placebo|Participants will first receive topical BZ371A 5.0 mg for daily use for 2 weeks. After a washout period of 2 weeks, they will receive topical Placebo to be used daily for 2 weeks.
89372576|NCT06219148|Sham Comparator|Non-Collaborative|"Social workers and music therapists operate independently.~There are 3 blocks of activities, identical to the collaborative arm:~Weeks 1-2: enrollment, stratification, random assignment~Weeks 3-6: music therapy and social work interventions~Weeks 7-8: social work follow up."
89372577|NCT06211764|Experimental|Group A: TAR-200|Participants will receive intravesical TAR-200 every 3 weeks during an induction phase and every 12 weeks during a maintenance phase.
89372578|NCT06211764|Active Comparator|Group B: Mitomycin C (MMC) or Gemcitabine|Participants will receive either single agent intravesical MMC or gemcitabine every week during an induction phase and every 4 weeks during a maintenance phase.
89372579|NCT06207162|Experimental|neural fingerprinting of MOUD|Study participants will have one in-person screening (2 hours), 6 in-person visits for fMRI scans conducted biweekly (4 hours), and will be computationally assessed 12 times, once per week for 12 weeks. After participation in the main study, participants will be asked to complete a 15-minute follow up every month for an additional three months
89002111|NCT06116045|Experimental|Gorup D - Placebo, then BZ371A|Participants will first receive topical Placebo for daily use for 2 weeks. After a washout period of 2 weeks, they will receive topical BZ371A 5.0 mg to be used daily for 2 weeks.
89372580|NCT06203977|Active Comparator|REPAIR CKD cohort|Patients will receive open label colchicine 0.3 mg daily for 8 weeks followed, in patients who tolerated the 0.3 mg dose, by forced titration to 0.6 mg daily for 8 weeks.
89372581|NCT06203977|Active Comparator|REPAIR Dialysis cohort|Patients will receive open label colchicine 0.3 mg daily for 8 weeks followed, in patients who tolerated the 0.3 mg dose, by forced titration to 0.6 mg daily for 8 weeks.
89372583|NCT06203171||Group C|Patients with perioperative complications
89372584|NCT06203171||Group non-C|Patients with no perioperative complications
89372585|NCT06200103|Active Comparator|Arm I (177Lu-PSMA-617 standard)|Patients receive 177Lu-PSMA-617 IV over 10-15 minutes on day 1 of each cycle. Cycles repeat every 42 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients receive gallium Ga 68-labeled PSMA-11 IV and undergo PET/CT and a bone scan during screening and on the trial. Patients also undergo SPECT/CT and blood sample collection on the trial.
89372586|NCT06200103|Experimental|Arm II (177Lu-PSMA-617 treatment pause)|Patients receive 177Lu-PSMA-617 IV over 10-15 minutes on day 1 of each cycle. Cycles repeat every 42 days for 5 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo clinical observation until documented first progression. Patients may resume treatment with 77Lu-PSMA-617. Patients receive gallium Ga 68-labeled PSMA-11 IV and undergo PET/CT and a bone scan during screening and on the trial. Patients also undergo SPECT/CT and blood sample collection on the trial.
89372587|NCT06194825|Experimental|Eplontersen|Eplontersen by subcutaneous injection once every 4 weeks
89372588|NCT06194825|Placebo Comparator|placebo|Eplontersen-matching placebo by subcutaneous injection once every 4 weeks
89372589|NCT06194500|Experimental|Carbon-14-Labeled [14C]-LY3549492 - Part A|Carbon-14-Labeled [14C]-LY3549492 administered as oral solution.
89372590|NCT06194500|Experimental|LY3549492 + [14C]-LY3549492 - Part B|LY3549492 administered as oral solution followed 3 hours later by [14C] LY3549492 will be administered as intravenous (IV) infusion.
89372591|NCT06193083||Qualitative study|The study will comprise an initial qualitative phase. Semi-directed individual interviews using a descriptive approach will be carried out (around 25 patients, over an 8-month period).
89372592|NCT06193083||Quantitative study|"Following analysis of the qualitative data, we will then carry out a quantitative study to determine the distribution of the different profiles within this population and the factors influencing the perception of deprescription. The self-administered questionnaires, rPATD and BMQ (medication beliefs questionnaire), potentially supplemented by other items following analysis of the qualitative data, will be administered to 300 patients (over a 12-month period).~The ancillary study will be carried out during this second phase, using a validated self-questionnaire to assess patients' level of literacy."
89372593|NCT06190717|Experimental|Diagnostic Arm|All subjects will have the EchoMark implanted. Subjects will be assessed every 2 weeks (+/- 1 week) (but no more frequently than weekly) with the EchoSure system until fistula maturation occurs and/or permanent access use is achieved.
89372594|NCT06190717|Active Comparator|Standard of Care|Subjects will be evaluated per KDOQI guidelines (with physical examination at approximately 2 weeks (+/- 1 week) and between 4 and 6 weeks (+/- 1 week)). If evaluation yields abnormal findings, subjects will receive a Duplex ultrasound assessment (DUS). All SOC Arm subjects will be followed per the institution's standard of care until fistula maturation occurs and/or permanent access use is achieved but no more frequently than once per month.
89372597|NCT06188520|Experimental|Module 1|AZD8421 monotherapy
89372598|NCT06188520|Experimental|Module 2A_abema|AZD8421 with camizestrant and abemaciclib
89372599|NCT06188520|Experimental|Module 2A_ribo|AZD8421 with camizestrant and ribociclib
89372600|NCT06188520|Experimental|Module 2A_palbo|AZD8421 with camizestrant and palbociclib
89372601|NCT06184568|Active Comparator|Semaglutide|
89372602|NCT06184568|Experimental|IBI362|
89372603|NCT06182085|Placebo Comparator|Placebo|Daily oral administration of 3 capsules in the morning and evening.
89372604|NCT06182085|Experimental|PRI-002, dosage arm 1|Daily oral administration of 3 capsules in the morning and evening, lower dose.
89372605|NCT06182085|Experimental|PRI-002, dosage arm 2|Daily oral administration of 3 capsules in the morning and evening, higher dose.
89372606|NCT06178289|Experimental|3M Cavilon Advanced Skin Protectant|3M Cavilon Advanced Skin Protectant (2,7ml) is a cyanoacrylate based film and will be administered every third day for a study period of 21 days.
89372607|NCT06178289|Active Comparator|Standard nursing home treatment protocol|Usual wound treatment care provided in the nursing home will be administered.
88844897|NCT05028855||sCAS patients|Investigators plan to enroll 850 patients of symptomatic cerebral atherosclerotic stenosis (sCAS) for cerebral autoregulation assessment to explore the relationship between cerebral autoregulation (CA) and stroke recurrence, determine the threshold values of CA parameter for predicting stroke recurrence associated with particular stenosis.
89002112|NCT06116045|Experimental|Group E - BZ371A, then Placebo|Participants will first receive topical BZ371A 2.5 mg for daily use for 2 weeks. After a washout period of 2 weeks, they will receive topical Placebo to be used daily for 2 weeks.
89181029|NCT02593968|Experimental|Treatment|subject were treated 3 periods with Yallaferon®; each period has interval 10 days ; one period included Yallaferon application for every other day for 10 times
89181030|NCT02593968|Placebo Comparator|Plcaebo|subject were treated 3 periods with Yallaferon® Plcaebo; each period has interval 10 days; one period included Yallaferon application for every other day for 10 times
89372608|NCT06174805|Experimental|AXIOS(TM) Stent and Electrocautery Enhanced Delivery System|Patients who meet all the inclusion criteria and none of the exclusion criteria will have a EUS-guided gastroenterostomy (EUS-GE) using the AXIOS(TM) lumen-apposing Metal Stent for the management of symptoms associated with gastric outlet obstruction from malignant unresectable neoplasm
89372609|NCT06173167|Experimental|SpeedCEM Plus luted crowns|crowns delivered with a self-adhesive, self-curing resin cement (SpeedCEM Plus\Ivoclar Vivadent AG)
89372610|NCT06173167|Experimental|ZirCAD Cement cemented crowns|crowns delivered with a resin modified glass ionomer cement (ZirCAD Cement\Ivoclar Vivadent AG)
89372611|NCT06172751||anti-IL-5/IL-5R therapy|Patients initiated anti-IL-5/IL-5R therapy
89372612|NCT06172751||other therapies|Patients initiated other therapies.
89372613|NCT06171529|Placebo Comparator|Placebo - Saline|For patients who randomize to Saline: An unblinded IHTSC Fellow, nurse/PA, or OR staff will use a 3 or 5 cc syringe to draw up the saline. A 23 gauge needle will be used to inject the saline after arthroplasty and prior to closure of the capsule. 2cc of saline will be injected into each patient.
89372614|NCT06171529|Experimental|Treatment - CTM|For patients who randomize to CTM: An unblinded IHTSC Fellow, nurse/PA, or OR staff will use a 3 or 5 cc syringe to draw up the CTM Flow material. A 23, or 20 gauge needle will be used to inject the CTM after arthroplasty and prior to closure of the capsule. To draw up the injection: allow the particulate to settle to the bottom and withdrawal fluid into the 3 or 5 cc syringe. It is ok if some particulate is drawn up into the syringe. 2cc of CTM will be injected into each patient.
89372615|NCT06171399|Experimental|"All Natural descriptor"|"Four edible product packages (gummies, chocolate, mints, cookies) with the product descriptor All Natural."
89372616|NCT06171399|Experimental|"Gluten-free descriptor"|"Four edible product packages (gummies, chocolate, mints, cookies) with the product descriptor Gluten-free"
89372617|NCT06171399|Experimental|"Vegan descriptor"|"Four edible product packages (gummies, chocolate, mints, cookies) with the product descriptor Vegan"
89372618|NCT06171399|Experimental|"100% Organic descriptor"|"Four edible product packages (gummies, chocolate, mints, cookies) with the product descriptor 100% Organic"
89372619|NCT06171399|Experimental|"Handcrafted descriptor"|"Four edible product packages (gummies, chocolate, mints, cookies) with the product descriptor Handcrafted"
89372620|NCT06171399|Experimental|"Made with live resin descriptor"|"Four edible product packages (gummies, chocolate, mints, cookies) with the product descriptor Made with live resin"
89372621|NCT06171399|Experimental|"Fast-acting descriptor"|"Four edible product packages (gummies, chocolate, mints, cookies) with the product descriptor Fast-acting"
89372622|NCT06171399|Experimental|"Relax descriptor"|"Four edible product packages (gummies, chocolate, mints, cookies) with the product descriptor Relax"
89372623|NCT06171399|Experimental|"Energy Boost descriptor"|"Four edible product packages (gummies, chocolate, mints, cookies) with the product descriptor Energy Boost"
89372624|NCT06171399|Experimental|No descriptor (control)|Four edible product packages (gummies, chocolate, mints, cookies) without any product descriptors
89372625|NCT06171178|Experimental|Part 1: ASP1012 Dose Escalation|Participants with previously treated solid tumor types will receive ASP1012 in a 21-day cycle.
89372626|NCT06171178|Experimental|Part 2: ASP1012 Dose Expansion (Monotherapy)|Participants with previously treated melanoma will receive ASP1012 with dose level(s) selected from dose escalation (Part 1) in a 21-day cycle.
89372627|NCT06171178|Experimental|Part 2: ASP1012 + Pembrolizumab Dose Expansion (previously treated solid tumors)|Participants with previously treated solid tumors, will receive ASP1012 in a 21-day cycle. Pembrolizumab will also be administered every three weeks in a 21-day cycle, for up to 3 doses.
89372628|NCT06171178|Experimental|Part 2: ASP1012 + Pembrolizumab Dose Expansion (treatment-naïve melanoma)|Participants with treatment-naïve melanoma will receive ASP1012 in a 21-day cycle. Pembrolizumab will also be administered every three weeks in a 21-day cycle, for up to 3 doses.
89372629|NCT06171178|Experimental|Part 3: ASP1012 Dose Expansion (previously treated gastric cancer)|Participants with previously treated gastric cancer will receive ASP1012 with dose level selected from dose escalation (Part 1) in a 21-day cycle.
89372630|NCT06171178|Experimental|Part 3: ASP1012 Dose Expansion (colorectal cancer [CRC])|Participants with CRC will receive ASP1012 with dose level selected from dose escalation (Part 1) in a 21-day cycle.
89372631|NCT06171178|Experimental|Part 3: ASP1012 Dose Expansion (ovarian cancer)|Participants with ovarian cancer will receive ASP1012 with dose level selected from dose escalation (Part 1) in a 21-day cycle.
89372632|NCT06171178|Experimental|Part 3: ASP1012 Dose Expansion (other solid tumor type)|Participants with other solid tumor type will receive ASP1012 with dose level selected from dose escalation (Part 1) in a 21-day cycle.
89372633|NCT06169982|Experimental|LY3209590|LY3209590 administered subcutaneously (SC)
89534918|NCT03326687|Experimental|Treatment ABAB|Participants will receive anomia treatment in isolation and will perform a physical endurance task in isolation during A phases. They will receive anomia treatment in combination with performing a physical endurance task during B phases.
89372635|NCT06167317|Experimental|Part A: GS-0201 Monotherapy Dose Escalation|Participants will receive escalating doses of GS-0201 monotherapy, until disease progression, or until the participant meets other study drug discontinuation criteria as specified in protocol or up to 105 weeks, whichever occurs first.
89372636|NCT06167317|Experimental|Part B: Cohort B1: GS-0201 Monotherapy Dose Expansion|Participants with selected indications will receive GS-0201 monotherapy at the recommended dose for expansion.
89534919|NCT03326687|Experimental|Treatment BABA|Participants will receive anomia treatment in isolation and will perform a physical endurance task in isolation during A phases. They will receive anomia treatment in combination with performing a physical endurance task during B phases.
88844899|NCT05024318|Active Comparator|SABR plus nephrectomy|Stereotactic Ablative Radiotherapy (SABR) will be prescribed to a dose of 42Gy in 3 fractions. All radiotherapy treatment be completed within 3 weeks.Patients will undergo nephrectomy within 9-12 weeks after the first dose of treatment.
88844900|NCT05024318|Experimental|Pembrolizumab followed by SABR after cycle 1 plus nephrectomy|Pembrolizumab 200 mg (flat dose) will be administered as a 30 minute IV infusion every 21 days for 3 cycles. Patients will receive 1 cycle of pembolizumab prior to SABR followed by an additional 2 cycles of pembrolizumab (1 cycle is 21 days). Patients will undergo nephrectomy 9-12 weeks after commencement of treatment.
89002113|NCT06116045|Experimental|Group F - Placebo, then BZ371A|Participants will first receive topical Placebo for daily use for 2 weeks. After a washout period of 2 weeks, they will receive topical BZ371A 2.5 mg to be used daily for 2 weeks.
89372637|NCT06167317|Experimental|Part B: Cohort B2: GS-0201 Monotherapy Dose Expansion|Participants with selected indications not included in cohort B1 will receive GS-0201 monotherapy at the recommended dose for expansion.
89372638|NCT06167317|Experimental|Part C: Dose Escalation: GS-0201 + Sacituzumab Govitecan (SG)|Participants will receive escalating doses of GS-0201 in combination with SG, until disease progression, or until the participant meets other study drug discontinuation criteria as specified in protocol or up to 105 weeks, whichever occurs first.
89372639|NCT06167317|Experimental|Part D: Cohort D1: Dose Expansion: GS-0201 + SG|Participants with confirmed unresectable locally advanced or metastatic triple negative breast cancer (mTNBC) will receive GS-0201 at the recommended Phase 2 dose (RP2D) in combination with SG.
89372640|NCT06167317|Experimental|Part D: Cohort D2: Dose Expansion: GS-0201 + SG|Participants with confirmed unresectable locally advanced or metastatic HR+/HER2- breast cancer will receive GS-0201 at the recommended Phase 2 dose (RP2D) in combination with SG.
89372641|NCT06166849|Experimental|Experimental Fluoride Application|Two-step system, consisting of Component A (ammonium fluoride solution) and Component B (calcium fluoride application)
89372642|NCT06166849|No Intervention|No Treatment|
89372643|NCT06165211|Experimental|Nature Sound Group|During hemodialysis, 30 minutes with an Mp3 player and headphones (to minimize the effect of surrounding noise). Nature sounds consisting of bird, wind and tree sounds will be played.
89372644|NCT06165211|Placebo Comparator|Routine Care|Patients will watch the program they want on the bedside TV during hemodialysis.
89534920|NCT05024175||CARv3-TEAM-E T cells|"Eligibility to participate on this study if enrolled on study 20-532 and received infusion of CARv3-TEAM-E T~The research study procedures include evaluations and follow up visits: Timepoints of each evaluation and follow up visit- per protocol~Medical History/Physical Exam~Blood Test~Assessment of Disease: CT (Computerized Tomography) scan or PET-CT (Positron Emission Tomography-Computerized Tomography) scans.~Tumor biopsy.~Data Collection~Biobanking"
89534921|NCT03332225|Experimental|Anakinra|Treatment with iv anakinra 200 mg three times daily (every eight hours) for seven days and sc 1ml N/S 0.9% every other day for 15 days
89534922|NCT03332225|Placebo Comparator|IV Placebo|Treatment with iv 1ml N/S 0.9% three times daily (every eight hours) for seven days and sc 1ml N/S 0.9% every other day for 15 days
89372651|NCT06161155|Active Comparator|Whey protein then bovine plasma protein|During the first dietary intervention, the diet is supplemented with whey protein isolate. During the second dietary intervention, the diet is supplemented with bovine plasma protein.
89372652|NCT06161155|Active Comparator|Bovine plasma protein then whey protein|During the first dietary intervention, the diet is supplemented with bovine plasma protein. During the second dietary intervention, the diet is supplemented with whey protein isolate.
89372653|NCT06158113|Experimental|Baricitinib|Participants will be asked to take 4mg of baricitinib by mouth daily for up to 24 weeks.
88844901|NCT05021237|Experimental|Safety Lead In|An interim safety evaluation will be conducted in a minimum of 10 assessable patients who received at least 3 radiation treatments (pulses) with 90 days follow up after radiation OR who experience a dose-limiting toxicity, as defined below. Patients not meeting these requirements will still count towards the overall trial enrollment target, however, the safety lead-in will continue until 10 fully assessable patients are reached (estimate 17 total patients needed for 40% attrition). These patients initially will be enrolled to the base dose-level of 8.5Gy/fraction.
88844902|NCT05007301||Standard of care|Patients who are receiving the geko device as part of standard of care for wound management
89372654|NCT06157060||Patient with hepatocellular carcinoma|Patient with hepatocellular carcinoma who can undergo radical resection
88844903|NCT05006794|Experimental|Part A: GS-9716 Dose-Escalation|Patients will receive escalating doses of GS-9716 to estimate MTD.
88844904|NCT05006794|Experimental|Part A: GS-9716 Dose-Expansion|Patients will receive ≤ MTD of GS-9716.
88844905|NCT05006794|Experimental|Part B (Cohort B1): GS-9716 + docetaxel|Patients will receive escalating doses of GS-9716 in combination with docetaxel.
88844906|NCT05006794|Experimental|Part B (Cohort B4): GS-9716 + sacituzumab govitecan-hziy|Patients will receive escalating doses of GS-9716 in combination with sacituzumab govitecan-hziy.
88844907|NCT05006794|Experimental|Part C (Cohort C1): GS-9716 + docetaxel|Patients will receive ≤ MTD GS-9716 in combination with docetaxel.
88844908|NCT05006794|Experimental|Part C (Cohort C4): GS-9716 + sacituzumab govitecan-hziy|Patients will receive ≤ MTD GS-9716 in combination with sacituzumab govitecan-hziy.
89372655|NCT06155682|Active Comparator|Active rTMS|multiple trains of active transcranial magnetic stimulation in a day (using the active TMS coil), for multiple days
89372656|NCT06155682|Sham Comparator|sham rTMS|multiple trains of sham transcranial magnetic stimulation in a day (using the sham comparator TMS coil), for multiple days
89372657|NCT06150157|Experimental|Dose Escalation (Part 1) and Dose Expansion (Part 2)|In dose escalation (Part 1), participants will receive JNJ-88549968. The dose will be escalated sequentially to determine the recommended phase 2 dose (RP2D) and optimal dosing schedule(s) based on safety, pharmacokinetic, pharmacodynamic, and preliminary assessment of efficacy across several dose regimens. In dose expansion (Part 2), participants will receive JNJ-88549968 at the RP2D regimen(s) determined in dose escalation (Part 1).
89372658|NCT06149520|Experimental|BAY3018250 Dose 1|Participants will receive BAY3018250 Dose 1.
89372659|NCT06149520|Experimental|BAY3018250 Dose 2|Participants will receive BAY3018250 Dose 2.
89372660|NCT06149520|Placebo Comparator|Placebo to BAY3018250|Participants will receive placebo to BAY3018250.
89372663|NCT06147323|Active Comparator|Normal Healthy Diet group|Participants aged 18-65 years in general good health will be following the Eatwell booklet advice*and NICE/NHS guidelines (https://www.nice.org.uk/).
89372664|NCT06147323|Placebo Comparator|Placebo Group|Participants aged 18-65 prediabetics will take 2 capsules/day (750mg Maltodextrin placebo comparator) before each of the two main meals without any advice on the diet to follow.
89372665|NCT06147323|Active Comparator|Seaweed Group|Participants aged 18-65 prediabetics will take 2 seaweeds brown extract capsules/day (information detailed in the safety product sheet, total dose of 700 mg before each of the two main meals. All participants will be advised on product storage and use conditions prior to use to ensure product consistency throughout the period of the study.
89372666|NCT06145074|Experimental|Propranolol|Propranolol will be administered 40 mg twice daily (morning and evening) in 10 days prior to surgery for pancreatic cancer
89372667|NCT06145074|Placebo Comparator|Placebo|Placebo will be administered twice daily (morning and evening) in 10 days prior to surgery for pancreatic cancer.
89372668|NCT06144632|Experimental|Treatment Group|Participants with drug refractory, symptomatic paroxysmal atrial fibrillation will receive PFA /radiofrequency (RF) ablation using THERMOCOOL STSF catheter in conjunction with the TRUPULSE generator per the hospital's standard protocol (at discretion of investigator).
89372669|NCT06143878|Experimental|JNJ-77242113|Participants will receive JNJ-77242113 from Week 0 through Week 156 and deucravacitinib matching placebo from Week 0 through Week 24.
89372670|NCT06143878|Placebo Comparator|Placebo|Participants will receive matching placebo for JNJ-77242113 from Week 0 through Week 16, matching placebo for deucravacitinib from Week 0 through Week 24 and JNJ-77242113 from Week 16 through Week 156.
89372671|NCT06143878|Active Comparator|Deucravacitinib|Participants will receive deucravacitinib from Week 0 through Week 24 and matching placebo for JNJ-77242113 from Week 0 through Week 24 and JNJ-77242113 from Week 24 through Week 156.
89372672|NCT06143670|Experimental|Test Product|Participants will be instructed to brush their teeth with full ribbon of toothpaste (0.454% w/w SnF2) on head of toothbrush provided for at least one (timed) minute twice a day (morning and evening) for 12 weeks.
88844909|NCT04996004|Experimental|Dose Escalation (Ontorpacept+doxorubicin)|In the dose escalation portion of the study, participants with specific subsets of soft tissue sarcomas who have not received more than one prior line of therapy and have not received an anthracycline in any setting will be enrolled in three escalating dose cohorts to characterize the safety and tolerability of Ontorpacept (TTI-621) when administered in combination with doxorubicin for up to six cycles and followed by Ontorpacept (TTI-621) monotherapy
88844910|NCT04996004|Experimental|Dose Expansion Dose Level A (Cohort A)|Participants with high-grade leiomyosarcoma will receive up to six cycles of Ontorpacept (TTI-621) at a pre-specified dose level (Dose Level A) in combination with fixed-dose doxorubicin followed by Ontorpacept (TTI-621) monotherapy to further characterize safety, tolerability, and clinical activity of the treatment regimen.
89372673|NCT06143670|Active Comparator|Negative Control|Participants will be instructed to brush their teeth with full ribbon of toothpaste (0.243% w/w Sodium fluoride) on head of toothbrush provided for at least one (timed) minute twice a day (morning and evening) for 12 weeks.
89372674|NCT06139406|Experimental|Part 1: Dose escalation|Participants will receive one cycle of TCE monotherapy (step up to target dose) with either JNJ-80948543 or JNJ-75348780 followed by initiation of combination therapy with JNJ-87801493 one week later.
89372675|NCT06139406|Experimental|Part 2:Dose expansion|Participants with specific B-cell NHL histologies will receive recommended phase 2 regimen (RP2R) of JNJ-87801493 with TCE as determined in Part 1.
89372676|NCT06131398|Experimental|Group A: AMG 355 monotherapy|Specified dose on specified days
88844911|NCT04996004|Experimental|Dose Expansion Dose Level B (Cohort B)|Participants with high-grade leiomyosarcoma will receive up to six cycles of Ontorpacept (TTI-621) at a pre-specified dose level (Dose Level B) in combination with fixed-dose doxorubicin followed by Ontorpacept (TTI-621) monotherapy to further characterize safety, tolerability, and clinical activity of the treatment regimen.
89372677|NCT06131398|Experimental|Group B: AMG 355 and pembrolizumab|Specified dose on specified days
88844912|NCT04996004|Experimental|Dose Expansion Dose Level C (Cohort C)|Participants with high-grade leiomyosarcoma will receive up to six cycles of Ontorpacept (TTI-621) at a pre-specified dose level (Dose Level C) in combination with fixed-dose doxorubicin followed by Ontorpacept (TTI-621) monotherapy to further characterize safety, tolerability, and clinical activity of the treatment regimen.
89372678|NCT06129279|Experimental|İntervention (EFT) group|"In order to determine the students who meet our study criteria, PİF, DDF, VAS, MSS and Short Form 36 will be applied for the pre-test to female students studying in the relevant departments of KBÜ SBF.~To EFT Group; After the first tests are done, the 1st EFT session will be held, the 2nd EFT session will be held 30 days later, and the final tests will be done 30 days later. During this period, affirmations will be given depending on the need. Each session is planned to last an average of 45 minutes - 1 hour, and duration and affirmations will be arranged according to the woman's individual difficulties, perspective, support systems, past traumas and emotional blockages.~4th Procedure: Preliminary tests will be carried out and then the 1st EFT session will be held.~5. Procedure: After 30 days, the first final tests will be performed and then the second EFT session will be held.~Procedure 6: After 30 days, only the 2nd final tests will be performed."
89372679|NCT06129279|No Intervention|Control group|"In order to determine the students who meet our study criteria, PİF, DDF, VAS, MSS and Short Form 36 will be applied for the pre-test to female students studying in the relevant departments of KBÜ SBF. Students in the control group will receive routine counseling regarding primary dysmenorrhea, and no extra intervention or practice will be performed.~Procedure 1: Preliminary tests will be conducted and then general training for dysmenorrhea will be conducted.~2nd Process: 30 days later, the questions of the students who will take the 1st post-test will be answered.~3rd Procedure: After 30 days, the second final tests will be performed."
89372680|NCT06129266|Experimental|İntervention (Oral care with breastmilk) group|Newborns selected according to the randomization group will receive nursing care, including oral care and feeding, from the same person twice a day, at 09:00 in the morning and 15:00 in the afternoon. Breast milk (BM) will be used for oral care. At each treatment, two ml BM should be dropped onto sterile gauze to clean the cheeks, tongue and palate. Process steps; After hand hygiene is achieved, it will be done using disposable gloves.
89372681|NCT06129266|No Intervention|Routine maintenance group|No intervention will be applied to the control group other than oral care with sterile distilled water, which is routine clinical practice.
89372682|NCT06128538|Experimental|Acupuncture Arm|No control
89372683|NCT06122649|Experimental|Placebo-controlled Treatment Phas|Participants are randomized in a 1:1 ratio to take either apremilast or placebo BID for 16 weeks.
89181031|NCT02591862|Other|Coversin (Nomacopan)|"This is an open label, non-comparator study.~Patient will be given a single ablating dose of 0.57mg/kg per subject followed by daily repeat maintenance doses. The initial repeat dose will be 25% of the ablating dose. If this is insufficient to maintain complement inhibition at ≤10% of baseline (pre-treatment) level after 5 days of treatment the daily dose will be increased by doubling until that level of inhibition is achieved. In the event of 100% inhibition being achieved the dose may be titrated downwards at the PI's discretion until a satisfactory clinical result is obtained. If at any point in treatment complement inhibition falls to less than 50% of baseline a further ablating dose of 0.57mg/kg should be given. Coversin lyophilised powder in each vial was diluted with 0.6 mL water for injection prior to use."
89181032|NCT02588547|Active Comparator|Granisetron 1|Intravenous granisetron 1 mg
89181033|NCT02588547|Active Comparator|Granisetron 0.7|Intravenous granisetron 0.7 mg
89372684|NCT06122649|Experimental|Active Treatment Phase|Participants who received placebo during the placebo-controlled treatment phase will receive apremilast BID for 36 weeks. Participants who took apremilast will continue receiving it BID for 36 weeks.
88844913|NCT04992546|Experimental|SAR444727 5% BID per lesion|During the double-blinded period, 2 target lesions per participant (with difference no greater than 1 point in total sign scores [TSS]) were randomized in 1:1 ratio to receive either SAR44727 Gel 5 percent (%) or matching placebo (i.e., each participant was treated with both SAR444727 5% BID and placebo in parallel). During open-label period, participants applied SAR444727 Gel, 5% twice daily (BID) to the all atopic dermatitis (AD)-affected areas, except the scalp, palms, soles and genitals through Days 15 to 42.
88844914|NCT04992546|Placebo Comparator|Placebo then SAR444727 5% BID per lesion|Multiple topical doses of placebo for 14 days, and PRN473 (SAR444727) for 28 days
88844915|NCT04983862|Experimental|Illuminare-1|
88844916|NCT04982315|Experimental|Standard Acupuncture|Participants randomized to standard acupuncture will receive 8-15 acupuncture treatments over 3 months.
88844917|NCT04982315|Experimental|Enhanced Acupuncture|Participants randomized to enhanced acupuncture will receive 12-21 acupuncture treatments over 6 months.
88844918|NCT04982315|No Intervention|Usual Care|Participants assigned to the usual care arm will not receive acupuncture and will be asked to not get acupuncture over the one-year course of the study.
88844919|NCT04980651|Active Comparator|RIC+Standard medical treatment|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mm Hg. RIC will be conducted twice daily for 7 consecutive days. Additionally, the patients will be treated with standard medical treatment according to the Guidelines for diagnosis and treatment of acute ischemic stroke in China 2014.
88844920|NCT04980651|Placebo Comparator|Sham RIC+Standard medical treatment|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mm Hg. RIC will be conducted twice daily for 7 consecutive days. Additionally, the patients will be treated with standard medical treatment according to the Guidelines for diagnosis and treatment of acute ischemic stroke in China 2014.
88844921|NCT04979104|Experimental|SL Cementless|Since the trial is not comparative, the only arm implies the use of the investigational device (SL cementless femoral stem)
88844922|NCT04978727|Experimental|SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥10 and ≤21 years|"500 mcg (1 mL) SurVaxM emulsion with Montanide ISA 51. Sargramostim dose is 3.33 mcg/kg/dose for patients < 30 kg, and 100 mcg for patients ≥ 30 kg.~Priming Phase: patients will get one dose of SurVaxM combined with Montanide ISA 51 through a subcutaneous injection at the start of the study and every 2 weeks for 6 weeks (for a total of 4 doses). At each SurVaxM/Montanide ISA 51 injection, patients will also get an injection of sargramostim.~Maintenance Phase: the patient will get a SurVaxM/Montanide ISA 51 dose along with a sargramostim dose about every 8 weeks for up to two years.~After finishing study treatment, patients will be followed for up to 3 years following the last dose of SurVaxM/Montanide ISA 51. Patients will be followed in clinic every 3 months during the follow-up."
89181034|NCT02588547|Placebo Comparator|Placebo|intravenous 0.9% Sodium chloride (2 ml)
89181035|NCT00478231|Experimental|1|
89181036|NCT04083261||High daily dose users|Total Cannabinoid Daily Dose greater than 50 mg
89181037|NCT04083261||Control|"Users that represent the median dose between high daily dose users and low daily dose users taking between 11-21 mg"
89181038|NCT04083261||Low daily dose users|Total Cannabinoid Daily Dose less than 10 mg
89181039|NCT05095233|Experimental|Young Adults Culturally Adapted Therapy for Suicidal Prevention|Young Adults Adapted Manual Assisted Psychological Therapy for Suicide Prevention
89181040|NCT05095233|Active Comparator|MINPLAN TOOL|Research has shown that user engagement, rather than the modality of therapy is the key to achieving successful outcomes and given that just 50% and 13% of patients currently have a choice of when and where they receive therapy, self-help tool apps Like MIN PLAN may not only be equally effective as some forms of traditional psychotherapy but also provide a flexible and pragmatic means of increasing patient access, through removing barriers to treatment that do not respond to financial impetus.
89534923|NCT03332225|Experimental|Recombinant human interferon-gamma|Treatment with sc recombinant human interferon-gamma every other day for a total of 15 days and with iv 1ml N/S 0.9% three times daily (every eight hours) for seven days
88844923|NCT04978727|Experimental|SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥1 and <10 years|"500 mcg (1 mL) SurVaxM emulsion with Montanide ISA 51. Sargramostim dose is 3.33 mcg/kg/dose for patients < 30 kg, and 100 mcg for patients ≥ 30 kg.~Priming Phase: patients will get one dose of SurVaxM combined with Montanide ISA 51 through a subcutaneous injection at the start of the study and every 2 weeks for 6 weeks (for a total of 4 doses). At each SurVaxM/Montanide ISA 51 injection, patients will also get an injection of sargramostim.~Maintenance Phase: the patient will get a SurVaxM/Montanide ISA 51 dose along with a sargramostim dose about every 8 weeks for up to two years.~After finishing study treatment, patients will be followed for up to 3 years following the last dose of SurVaxM/Montanide ISA 51. Patients will be followed in clinic every 3 months during the follow-up."
88844924|NCT04978727|Experimental|SurVaxM for patients with non-relapsed DIPG post radiation-therapy ages ≥1 and ≤21 years|"500 mcg (1 mL) SurVaxM emulsion with Montanide ISA 51. Sargramostim dose is 3.33 mcg/kg/dose for patients < 30 kg, and 100 mcg for patients ≥ 30 kg.~Priming Phase: patients will get one dose of SurVaxM combined with Montanide ISA 51 through a subcutaneous injection at the start of the study and every 2 weeks for 6 weeks (for a total of 4 doses). At each SurVaxM/Montanide ISA 51 injection, patients will also get an injection of sargramostim.~Maintenance Phase: the patient will get a SurVaxM/Montanide ISA 51 dose along with a sargramostim dose about every 8 weeks for up to two years.~After finishing study treatment, patients will be followed for up to 3 years following the last dose of SurVaxM/Montanide ISA 51. Patients will be followed in clinic every 3 months during the follow-up."
88844925|NCT04978480||Stroke patients|patients with suspected severe acute stroke
88844926|NCT04968041|Experimental|MI-CBT KNA Program|6-week group intervention using MI and CBT strategies to promote adherence to a ketogenic nutrition program.
88844927|NCT04956081|Experimental|virtual neuro-navigation|The specific area within the L-DLPFC will be identified by a software using MR images. TMS will be administered to the identified area.
88844928|NCT04956081|Experimental|on-line neuro-navigation|The specific area within the L-DLPFC will be identified by a person using MR images. TMS will be administered to the identified area.
88844929|NCT04947384||Patients with moderate mitral valve disease, undergoing interventions|Patients with established WHO-2 diagnosis of PH undergoing open and interventional mitral valve procedures.
88844930|NCT04947384||Patients undergoing mitral valve interventions without pulmonary hypertension|Patients with no PH undergoing open and interventional mitral valve procedures. This group will serve as a control.
88844931|NCT04947384||Patients with precapillary pulmonary hypertension scheduled for right heart catheterization|Patients with established diagnosis of WHO-1-4 groups of PH undergoing right heart catheterization. This group will serve as a control.
88844932|NCT04945330||Gastrointestinal (GI)|Participants with GI cancer.
88844933|NCT04945330||Head and neck (H&N)|Participants with H&N cancer.
88844934|NCT04945330||Lung|Participants with lung cancer.
89372685|NCT06121323|Active Comparator|Lactate infusion|All participants will be randomized to first receive a three-hour intravenous infusion with either a racemic (D/L) mixture of sodium lactate or intravenous isotonic sodium chloride placebo. All participants will then cross over to the converse infusion on the same day.
88844935|NCT04945330||Soft tissue sarcoma (STS)|Participants with STS cancer.
89372686|NCT06121323|Active Comparator|Lactate ingestion|All participants will be randomized to first receive either an orally administered racemic (D/L) mixture of sodium lactate or isocaloric, isovolumic oral placebo (maltodextrin). The oral dose of lactate will be equal to the intravenous dose. All participants will be studied for three hours and then cross over to receive the converse oral administration following additional three hours of observation time on the same day.
89534924|NCT05023941|Active Comparator|Medicine Group|Start orally take Acetazolamide 2 days before entering the hypoxic room.
88844936|NCT04945330||Primary central nervous system (CNS)|Participants with CNS cancer.
88844937|NCT04945330||Melanoma|Participants with Melanoma cancer.
88844938|NCT04945330||Pediatrics|
88844939|NCT04945330||Others|
88844940|NCT04937504|Active Comparator|STAIR-PC Group|Participants in the Skills Training in Affective and Interpersonal Regulation for Primary Care (STAIR-PC) group will complete five (30 minute each) therapist-led sessions in-person or via Telehealth for up to 12 weeks.
88844941|NCT04937504|Experimental|WebSTAIR Group|Participants in the WebSTAIR group will complete 10 self-guided, web-based modules for up to 12 weeks.
88844942|NCT04930393|Active Comparator|PECS II Block|This group will receive an interscalene block in addition to a pectoral nerve block under ultrasound guidance with local anesthetic injected in the plane between the pectoralis minor and serratus anterior muscles
88844943|NCT04930393|Active Comparator|Axillary Ring Block|This group will receive an interscalene block in addition to a ring block with local anesthetic injected subcutaneously along the axilla from anterior to posterior direction.
88844944|NCT04922333|Experimental|Bisphosphonate|Participants in this arm will receive six months of 150 mg once monthly oral risedronate
88844945|NCT04922333|Placebo Comparator|Placebo|Participants in this arm will receive six months of placebo
88844946|NCT04920383|Experimental|Dose Escalation and Expansion|ALPN-202 + pembrolizumab KEYTRUDA®
88844947|NCT04915989|Experimental|GX-19N|Dose A of GX-19N will be intramuscularly administered via Electroporator(EP) on day 1 and day 29. (Optional administration on day 57)
88844948|NCT04908189|Experimental|Deucravacitinib|
88844949|NCT04908189|Placebo Comparator|Placebo|
88844950|NCT04908189|Other|Apremilast|
88844951|NCT04906980|Experimental|JNJ-64281802|Participants will receive 2 initial loading doses of JNJ-64281802 up to Day 2, followed by a maintenance dose on Days 3, 4, and 5.
88844952|NCT04906980|Placebo Comparator|Placebo|Participants will receive oral dose of matching placebo every 8 hour (q8h) and once daily on Day 4 and Day 5.
89372687|NCT06120140|Experimental|Arm A: Enhanced Dermatologic Management|Participants will receive enhanced dermatologic management to reduce dermatologic toxicities in skin and nail with oral doxycycline tablet or minocycline capsule (100 milligrams [mg] twice daily for 12 weeks), clindamycin 1 percent (%) topical lotion, chlorhexidine 4% topical solution, and noncomedogenic skin moisturizer (once daily, sufficient quantity to cover skin) during background anticancer treatment of advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) with amivantamab (1050 mg for body weight less than [<] 80 kilograms [kg] and 1400 mg for body weight greater than or equal to [>=] 80 kg as intravenous [IV] infusion, once weekly for the first 4 weeks and then once every 2 weeks) and lazertinib (240 mg, tablet, once daily) until documented disease progression using Response Evaluation Criteria in Solid Tumors [RECIST] version [v] 1.1).
89372688|NCT06120140|Active Comparator|Arm B: Standard-of-Care Dermatologic Management|Participants will receive standard care for dermatologic management according to local practice to reduce dermatologic toxicities in skin and nail during background anticancer treatment of advanced or metastatic EGFR-mutated NSCLC with amivantamab plus lazertinib.
89372689|NCT06118502|Experimental|Adaptive Randomization 1|This arm includes people who did not respond to 4 weeks of pharmacotherapy (either varenicline or combination NRT). After a 4-week course of pharmacotherapy, participants that are not responding to medication will receive four weeks of the other FDA approved option, either varenicline or combination NRT, with instructions to try to quit again
88844953|NCT04905693|Experimental|Inhaled Treprostinil|Treprostinil inhalation solution (0.6 mg/mL) delivered via an ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath. Inhaled QID and titrated to a target of 15 breaths QID or until the subject reaches their maximum clinically tolerated dose.
88844954|NCT04899310|Experimental|mRNA-3705|Participants in Part 1 will receive a weight based dose of mRNA-3705, administered intravenously (IV), once every 2 weeks (Q2W) or once every 3 weeks (Q3W) for up to 10 doses over approximately 40 weeks. Participants in Part 2 will receive mRNA 3705 at the selected dose level and frequency for up to 12 months.
88844955|NCT04889924|Experimental|Axillary radiotherapy without lymphadenectomy|Axillary radiotherapy (level I and II) + level III and supraclavicular +/- internal mammary chain without lymphadenectomy
88844956|NCT04889924|Active Comparator|Axillary lymph node dissection|Axillary lymph node dissection + radiotherapy level III and supraclavicular +/- internal mammary chain
88844957|NCT04885894||MS Zeposia|Individuals with MS who will begin taking Zeposia as part of standard care.
88844958|NCT04885894||MS High dose efficacy medication|Individuals with MS who will begin taking high dose efficacy oral medication as part of standard of care.
88844959|NCT04885894||Healthy Control|Healthy controls, all of whom will be matched on age, education and gender to the MS groups.
89534925|NCT05023941|Active Comparator|RIPC Group|Start RIPC training twice daily, 6 days before entering the hypoxic room.
89372690|NCT06118502|Experimental|Non-Adaptive Randomization 1|This arm includes people who did not respond to 4 weeks of pharmacotherapy (either varenicline or combination NRT). After a 4-week course of pharmacotherapy, participants that are not responding to the medication will receive four additional weeks of the same medication with instructions to try to quit again
89534926|NCT05023941|Experimental|Rapid RIPC Group|Start RIPC training forth daily, 3 days before entering the hypoxic room.
89534927|NCT05023941|Experimental|Combined Group|Medicine + Rapid RIPC
88844962|NCT04874233|Active Comparator|Active Treatment: HU6 150 mg; N = 20|HU6 is Active Study Drug
88844963|NCT04874233|Active Comparator|Active Treatment: HU6 300 mg; N = 20|HU6 is Active Study Drug
88844964|NCT04874233|Active Comparator|Active Treatment: HU6 450 mg; N = 20|HU6 is Active Study Drug
88844965|NCT04874233|Placebo Comparator|Placebo Comparator Non-active study drug N = 20|Non-active Study Drug
88844966|NCT04874012|Placebo Comparator|Placebo|Participants into the placebo group will receive the same treatment regimen, but with packets of the same appearance and size containing only vehicle.
88844967|NCT04874012|Active Comparator|Taurine|Participants will receive 6 gy taurine divided into twice/day orally administration for 12 weeks.
88844968|NCT04873596|Active Comparator|nebulized dexmedetomidine|parturient will receive nebulized 3ug/kg dexmedetomidine diluted in normal saline (0.9%) solution till total volume of nebulized solution will become 5 ml and will be nebulized by a standard hospital jet nebulizer via mouthpiece, with a continuous flow of 100% oxygen at 6 L/min. for 15 minutes, and the treatment will be stopped when the nebulizer will be began to sputter.
89181041|NCT02588703|Experimental|Cognitive Behavioral Therapy|9-session 2-hour group cognitive behavioral therapy
89534928|NCT05023941|No Intervention|Control Group|Subjects do not receive specific interventions before entering the hypoxic room.
89181042|NCT02588703|Active Comparator|Usual Care|9-session 2-hour group counseling
89181043|NCT02588625|Experimental|Part A - BMS-986020|BMS-986020 or Placebo tablets specified dose on specified days
89181044|NCT02588625|Experimental|Part B - BMS-986020|BMS-986020 or Placebo tablets specified dose on specified days
89181045|NCT02588469|Experimental|Interventional group|Physical activity program coupled with compression socks wearing during 3 months.
89181046|NCT02588469|Active Comparator|control group|Physical activity program without compression socks during 3 months.
89181047|NCT00474175|Placebo Comparator|1|Placebo control
89181048|NCT00474175|Active Comparator|2|10% benzocaine gel formulation
89181049|NCT00474175|Active Comparator|3|20% benzocaine gel formulation
89181050|NCT03002389|Other|All COPD Subjects|"All subjects will be assessed with hyper polarized xenon-129 MRI, pulmonary function test, quality of life measures (BDI, TDI, SGRQ, CRQ, BODE, GOLD), and blood test.~Intervention: All subjects will received Anoro one puff once a day for 30 days first, then 3 day washout, then Arnuity 250 microgram one puff twice a day for 30 days to complete the study."
89181051|NCT02979379||Pain|Individuals with COPD who experience chronic pain (episodes of daily pain for a duration greater than three months)
89181052|NCT02979379||No Pain|Individuals with COPD who do not experience pain on a regular basis.
89181053|NCT04082949|Placebo Comparator|Subgroups:control and initial pocket depths:5-6mm|Control group divided into two subgroups according to initial pocket depths and this subgroup includes initial pocket depths:5-6mm
89181054|NCT04082949|Placebo Comparator|Subgroups:control and initial pocket depths≥7mm|Control group divided into two subgroups according to initial pocket depths and this subgroup includes initial pocket depths higher than 7mm
89181055|NCT04082949|Experimental|Subgroups:AFG and initial pocket depths:5-6mm|AFG group divided into two subgroups according to initial pocket depths and this subgroup includes initial pocket depths:5-6mm
89181056|NCT04082949|Experimental|Subgroups:AFG and initial pocket depths≥7mm|AFG group divided into two subgroups according to initial pocket depths and this subgroup includes initial pocket depths higher than 7mm
89181057|NCT03574129|Experimental|Adolescent transition package|Adolescent transition package
89181058|NCT03574129|No Intervention|Standard of care|Standard of care adolescent services
89181059|NCT03937245||HA-BSI|Patients with HA-BSI treated in an ICU
89181060|NCT01020643|Experimental|controlled sedation using propofol|
89181061|NCT03537391|Experimental|Imaging based staging of high risk PC|"Each individual study patient will be imaged for PC metastasis detection with each different imaging modalities as follows:~Traditional imaging (clinical standard imaging);~Whole-body contrast enhanced computer tomography~Planar bone scintigraphy~Novel imaging (investigational imaging);~SPECT/CT (investigational imaging)~18F-PSMA-PET/CT (investigational imaging)~Whole-body MRI (investigational imaging)~In order to define the true nature of the findings from each different imaging modality, comparison with best valuable comparator (BvC) is made. Consensus reading of all imaging modalities and follow-up data of clinical, imaging, histopathological and laboratory results are used to define BvC."
89181062|NCT03529591|Active Comparator|180 deg selective laser trabeculoplasty|The right eye of a patient is randomized to be treated with either 180 or 360 degrees selective laser trabeculoplasty (SLT). The fellow eye is treated with the opposite treatment, that is, if the right eye is treated with 180 degrees SLT, the left eye is treated with 360 degrees SLT. Intraocular pressure (IOP) response is assessed at 2 weeks, one, three and six months post treatment and compared to the alternative treatment arm, the fellow eye.
89181063|NCT03529591|Active Comparator|360 deg selective laser trabeculoplasty|The right eye of a patient is randomized to be treated with either 180 or 360 degrees selective laser trabeculoplasty (SLT). The fellow eye is treated with the opposite treatment, that is, if the right eye is treated with 180 degrees SLT, the left eye is treated with 360 degrees SLT. Intraocular pressure (IOP) response is assessed at 2 weeks, one, three and six months post treatment and compared to the alternative treatment arm, the fellow eye.
89181064|NCT02588391|Experimental|Active Brain Training|"The children in this arm receive one type of Brain Training with online computer games that actively matches their skill level."
89181065|NCT02588391|Experimental|Passive Brain Training|"The children in this arm receive one type of Brain Training with online computer games that are at a consistent skill level."
89181066|NCT02588391|Other|Cross-over|"Following completion of the 6-month follow-up sessions after completion of Brain Training, each group is allowed to cross-over to the other arm of Brain Training (open-label extension)."
89181067|NCT02588313|Active Comparator|Mango fruit powder 100mg|Mango fruit powder 100mg
89181068|NCT02588313|Active Comparator|Mango fruit powder 300mg|Mango fruit powder 300mg
89181069|NCT02588313|Placebo Comparator|Placebo formulation|Placebo formulation
89181070|NCT02968537|Experimental|Alc-IT (50/50) (morning)|Alc-IT (50/50) (morning): This alcohol-specific inhibition-training (Alc-IT) training group will operate with a Go/NoGo ratio of 50/50 (Houben et al. 2011; 2012): This original version of the Alc-inhibition-training will include 80 alcoholic NoGo trials as well as 80 non-alcoholic Go trials. In order to arrive at the same training length while keeping the number of Alc-NoGo-pairings constant and the Go/NoGo-ratio at 50/50, it will additionally include 80 neutral Go-trials as well as 80 neutral NoGo-trials. It will thus consist of 320 trials and take about 10.5 minutes to be completed. In the morning group, this training will be administered within the first 2 hours after awakening.
89181071|NCT02968537|Experimental|Alc-IT (75/25) (morning)|This version of the alcohol-specific inhibition-training (Alc-IT) will operate with a Go/NoGo-ratio of 75/25. It will equally include 80 Alcoholic NoGo-trials and 80 non-alcoholic Go-trials, but now 160 neutral Go-trials will complete the set. This training will also consist of 320 trials and take about 10.5 minutes. In the morning group, this training will be administered within the first 2 hours after awakening.
89181072|NCT02968537|Placebo Comparator|Control-training (morning)|This group will receive an unspecific inhibition training. this training is of the same length and difficulty as the two Alc-inhibition-trainings. In the morning group, this training will be administered within the first 2 hours after awakening.
89534929|NCT03090399|No Intervention|control group|patients in which standard fluid administration was applied
89534930|NCT03090399|Active Comparator|case group|patients in which fluids were administered according to FloTrac parameters
89372691|NCT06118502|Experimental|Harm Reduction Randomization 2|This arm includes people who did not respond to two 4-week courses of pharmacotherapy (either varenicline or combination NRT or both). After two 4-week courses of pharmacotherapy, participants who are not responding to medication will be randomly assigned to a harm reduction group (e-cigarettes). Participants assigned to the harm reduction group will receive four weeks of e-cigarette product with instructions to switch completely
89372692|NCT06118502|Experimental|Non-Adaptive Randomization 2|This arm includes people who did not respond to two 4-week courses of pharmacotherapy (either varenicline or combination NRT or both sequentially). After two four-week courses of pharmacotherapy, participants that are not responding to the medication will receive four additional weeks of the same medication with instructions to try to quit again.
89372693|NCT06118411|Experimental|Study 1, Period A: Group 1|Participants will receive upadacitinib 15 mg once a day for 48 weeks.
89372694|NCT06118411|Experimental|Study 2, Period A: Group 1|Participants will receive upadacitinib 15 mg once a day for 48 weeks.
89372695|NCT06118411|Placebo Comparator|Study 1, Period A: Group 2|Participants will receive placebo once daily for 48 weeks.
89372696|NCT06118411|Placebo Comparator|Study 2, Period A: Group 2|Participants will receive placebo once a day for 48 weeks.
89372697|NCT06118411|Experimental|Study 1, Period B: Extension Period|Participants will receive upadacitinib 15 mg once daily for 112 weeks.
89372698|NCT06118411|Experimental|Study 2, Period B: Extension Period|Participants will receive upadacitinib 15 mg once daily for 112 weeks.
89372699|NCT06117774|Experimental|Tarlatamab|Participants will receive tarlatamab on Cycle 1 Day 1, 8 and 15, and once every 2 weeks (Q2W) thereafter (cycle is 28 days).
89372700|NCT06117774|Placebo Comparator|Placebo|Participants will receive placebo on Cycle 1 Day 1, 8 and 15, and Q2W thereafter (cycle is 28 days).
89372701|NCT06116786|Experimental|Part 1: JNJ-86974680+Cetrelimab|Participants will receive JNJ-86974680 alone (dose 1, dose 2, dose 3, and dose 4) daily in 4 cohorts and then along with a set dose of cetrelimab.
89372702|NCT06116786|Experimental|Part 2: JNJ-86974680+Cetrelimab+Radiation Therapy (RT)|Participants will receive treatment with the identified safe dose of JNJ-86974680 in combination with cetrelimab from part 1, in conjunction with radiation.
89372703|NCT06107777|Experimental|Pharmacopucture on Acupoints Related to Psychological Stress|"The Pharmacopucture group will recieve Pharmacopucture treatment durling the hospitalization. The mandatory acupoints are (Dan-jung(CV17), Jung-wan(CV12), Gi-hae(CV6), Gwan-won(CV4), Sin-mun(HT7). If needed, they will recieve additional acupoints are (So-hae(HT3), Jung-jeo(TE3), Sam-eumgyo(SP6). A trained doctor of Korean medicine with at least 3 years of clinical experience are going to conduct the pharmacopucture.~The Pharmacopucture group will also be treated with other Korean medical treatment everyday: acupuncture, chuna and Korean herbal medicine."
89372704|NCT06107777|Active Comparator|Korean medical treatment|The control group will receive Korean medical treatment everyday after hospitalization: acupuncture, chuna, pharmacoacupuncture(except on mandatory and additional acupoints) and Korean herbal medicine.
89372705|NCT06106568||EOB-MRI|Adult patients with confirmed diagnosis of pancreatic cancer who had the prescription record of an active treatment preceding the pancreatic cancer diagnosis and with a record of EOB-MRI
89372706|NCT06106568||non-EOB-MRI|Adult patients with confirmed diagnosis of pancreatic cancer who had the prescription record of an active treatment preceding the pancreatic cancer diagnosis and without a record of EOB-MBI
89372707|NCT06106568||EOB-MRI with surgery|Adult patients with confirmed diagnosis of pancreatic cancer who had the prescription record of an active treatment preceding the pancreatic cancer diagnosis and with a record of EOB-MRI and surgery
89372708|NCT06106568||non-EOB-MRI with surgery|Adult patients with confirmed diagnosis of pancreatic cancer who had the prescription record of an active treatment preceding the pancreatic cancer diagnosis and without a record of EOB-MRI but with a record of surgery
89372709|NCT06106568||EOB-MRI without surgery|Adult patients with confirmed diagnosis of pancreatic cancer who had the prescription record of an active treatment preceding the pancreatic cancer diagnosis and with a record of EOB-MRI but without a record of surgery
89372710|NCT06106568||non-EOB-MRI without surgery|Adult patients with confirmed diagnosis of pancreatic cancer who had the prescription record of an active treatment preceding the pancreatic cancer diagnosis and without a record of EOB-MRI or surgery
89372711|NCT06106568||EOB-MRI with an open-close laparotomy|Adult patients with confirmed diagnosis of pancreatic cancer who had the prescription record of an active treatment preceding the pancreatic cancer diagnosis and with a record of EOB-MRI and an open-close laparotomy
88810150|NCT01339247|Active Comparator|Paxil CR Test|Paroxetine Hydrochloride 25 mg tablet with controlled release (Paxil CR), once a day, manufactured by GlaxoSmithKline Inc. - Mississauga - Canada, in Period 1, followed by Paroxetine Hydrochloride 25 miligrams(mg) tablet with controlled release (Paxil CR), once a day, manufactured by SmithKline Beecham (Cork) Limited - Cidra - Puerto Rico, in Period 2
88810151|NCT00772772|Experimental|Vitamin D3|Vitamin D3 30,000 international units orally per week for 8 weeks
88810152|NCT01339403||HIV infected|No study specific intervention, non-interventional trial
88810153|NCT01339403||HIV-uninfected|No study specific intervention, non-interventional trial
88810154|NCT05742464|Experimental|Treatment|
88810155|NCT03802526|Experimental|NVP-1805-R1|"Drug: NVP-1805-R1~1 tablet, oral dosing"
88810156|NCT03802526|Experimental|NVP-1805-R2|"Drug: NVP-1805-R2~1 tablet, oral dosing"
88810157|NCT03802526|Experimental|NVP-1805-R1 and NVP-1805-R2|Drug: NVP-1801-R1 1 tablet and NVP-1801-R2 1 tablet co-administration(oral dosing)
88810158|NCT02197481|Active Comparator|Clamp-Crushing technique|liver transection during hepatectomy by the routine clamp-crushing technical without BiClamp forceps assisted
88810159|NCT02197481|Experimental|BiClamp forceps hepatectomy|The BiClamp forceps, a reusable bipolar sealing instrument for use in open surgery, was uniformly employed in all patients randomized to BiClamp forcep hepatectomy group in the present study.
88810160|NCT00773474|Experimental|Lonafarnib|All registered patients will be treated with Lonafarnib 200 mg PO BID daily on days 1-21 of every 21-day cycle until progression of disease, unacceptable toxicity, or investigator's discretion.
89181073|NCT02968537|Experimental|Alc-IT (50/50) (afternoon)|"Alc-IT (50/50) (afternoon): As in the arm Alc-IT (50/50) (morning), this alcohol-specific inhibition-training (Alc-IT) group will operate with a Go/NoGo ratio of 50/50 (Houben et al. 2011; 2012): This original version of the Alc-inhibition-training will include 80 alcoholic NoGo trials as well as 80 non-alcoholic Go trials. In order to arrive at the same training length while keeping the number of Alc-NoGo-pairings constant and the Go/NoGo-ratio at 50/50, it will additionally include 80 neutral Go-trials as well as 80 neutral NoGo-trials. It will thus consist of 320 trials and take about 10.5 minutes to be completed. In contrast to the In the morning group, this afternoon group will receive the training in the afternoon."
89372712|NCT06106568||non-EOB-MRI with an open-close laparotomy|Adult patients with confirmed diagnosis of pancreatic cancer who had the prescription record of an active treatment preceding the pancreatic cancer diagnosis and without a record of EOB-MRI but with a record of an open-close laparotomy
89372713|NCT06103838|Experimental|18F-fluciclovine PET/CT in Multiple Myeloma|Evaluate 18F-fluciclovine PET/CT in participants with multiple myeloma at Timepoint #1, Timepoint #2 ( after induction treatment (NDMM) or six months (RRMM)) and at Timepoint #3 (the time of progression or 5 years).
89372714|NCT06103526|Active Comparator|Immunonutrition and ERAS|Immunonutrition supplements will be provided to patients in the form of oral supplements given twice daily for 3 days pre-surgery and 3 days post-surgery.
89372715|NCT06103526|No Intervention|ERAS without immunonutrition|Typical ERAS protocol will be followed for patients in that group
89372716|NCT06101095|Experimental|Dupilumab|Subcutaneous injection (SC) as per protocol
89372717|NCT06101095|Placebo Comparator|Placebo|SC injection as per protocol
89372718|NCT06100744|Experimental|Risankizumab|Participants will receive risankizumab for 24 weeks, in Period 1. Participants who respond to the study treatment received in Period 1, will continue to receive the same treatment in Period 2 for another 100 weeks. There will be a 140 day safety follow up after the treatment period.
89372719|NCT06100744|Experimental|Adalimumab|Participants will receive adalimumab for 24 weeks, in Period 1. Participants who respond to the study treatment received in Period 1, will continue to receive the same treatment in Period 2 for another 100 weeks. There will be a 70 day safety follow up after the treatment period.
89534931|NCT03332147|Experimental|Investigational Group|The RHEA device and Patient Monitor Device are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
89534932|NCT03332147|Active Comparator|reference group-Earlysense system|The reference device and Patient Monitor Device are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
89534933|NCT03093519|Experimental|KHK6640|Intravenous administration
89534934|NCT03093519|Placebo Comparator|Placebo|Intravenous administration
88844969|NCT04873596|Active Comparator|nebulized midazolam|parturient will receive nebulized 0.2 mg/kg midazolam diluted in normal saline (0.9%) solution till total volume of nebulized solution will become 5 ml and will be nebulized by a standard hospital jet nebulizer via mouthpiece, with a continuous flow of 100% oxygen at 6 L/min. for 15 minutes, and the treatment will be stopped when the nebulizer will be began to sputter.
88844970|NCT04872543|Experimental|ASTX727 (cedazuridine and decitabine)|Patients who meet the eligibility criteria will be treated with oral ASTX727 (INQOVI) on days 1-5 of each 21-day cycle with Pegfilgrastim support on day 7. A delay in the start of subsequent cycles due to holidays, weather, or other circumstances will be permitted up to 7 days and not considered a protocol deviation. Drug dosing will be interrupted for any Grade 4 adverse events or clinically significant laboratory abnormalities. For Grade 3 or 4 AE, if the AE returns to Grade 1 or baseline, the patient may be re-escalated.
89372724|NCT06095115|Experimental|JNJ-77242113|Adolescent and adult participants will receive JNJ-77242113 from Week 0 through Week 156. At Week 24, adult participants who are psoriasis area and severity index (PASI) 75 or investigator global assessment (IGA) score of 0 or 1 responders (that is, those who achieve an IGA score of 0 or 1 and have >=2-grade improvement from baseline) will be re-randomized either to continue JNJ-77242113 or to placebo (and will be retreated with JNJ-77242113 upon loss of >=50% of their Week 24 PASI improvement). Adult participants identified as both PASI 75 and IGA 0 or 1 score non-responders will continue to receive JNJ-77242113 through Week 52. From Week 52 to Week 156, all adult participants will receive JNJ-77242113. Adolescents will not participate in re-randomization regardless of their PASI score or IGA score at Week 24. Adolescents will continue to receive JNJ-77242113 from Week 0 through Week 156.
89372725|NCT06095115|Experimental|Placebo|Adolescent and adult participants will receive JNJ-77242113 matching placebo from Week 0 to Week 16. Participants will cross-over to receive JNJ-77242113 from Week 16 through Week 156.
89372728|NCT06086275|Experimental|8mg PO buprenorphine|After the open-label period, the participant will receive 8mg PO, then 16mg PO will be administered in the following visit.
89372729|NCT06086275|Experimental|16mg PO buprenorphine|After the open-label period, the participant will receive 16mg PO, then 8mg PO will be administered in the following visit.
89372730|NCT06086275|Experimental|0.15mg IV Dose|The first dose administered will be fixed to an open-label 0.15mg IV dose.
89372731|NCT06083857|Experimental|Amivantamab and Tepotinib Combination|Participants will be given 2 investigational drugs (amivantamab and tepotinib) and come to the clinic for study visits every 4 weeks.
89372732|NCT06082986||Bio-naive Participants With Crohn's Disease (CD)|Participants with CD from inflammatory bowel disease (IBD) database who received ustekinumab from 20 May 2020 to 16 September 2022 in the real-world setting in China will be observed in the study. Only data available per routine clinical practice will be collected within this study.
89372733|NCT06082843|Experimental|Placebo|
89372734|NCT06082843|Experimental|Avenciguat (BI 685509)|This trial contemplates a dose-titration period, depending on dose tolerability.
89372735|NCT06080230|Active Comparator|Psychoeducation Program Group|Participants in the 8-week Program
89372736|NCT06080230|No Intervention|Control Group|Those who do not participate in the 8-week Program
89372737|NCT06077773|Experimental|EP262 50 mg|
89372738|NCT06077773|Experimental|EP262 150 mg|
89372739|NCT06077773|Placebo Comparator|Placebo|
89372740|NCT06072482|Experimental|Group A: Avacopan + Standard of Care (SoC)|Avacopan 30 mg twice daily for 5 years + SoC background immunosuppressive therapy.
89372741|NCT06072482|Experimental|Group B: Avacopan/Placebo + SoC|Avacopan 30 mg twice daily for 1 year, followed by placebo twice daily for 4 years + SoC background immunosuppressive therapy.
89372742|NCT06072482|Placebo Comparator|Group C: Placebo + SoC|Placebo twice daily for 5 years + SoC background immunosuppressive therapy.
89372743|NCT06071767|Experimental|Arm A: Active ChAdV and MVA vaccines, vesatolimod and bnAbs|
89372744|NCT06071767|Placebo Comparator|Arm B: Placebos for vaccines, vesatolimod and bnAbs|
89372745|NCT06067841|Experimental|Administration of BMS-986460|
89534935|NCT03332069|Experimental|Study|50 Gy external beam radiation administered in fractions of 2 Gy 3 Doses of 8 Gy High Dose Rate brachytherapy up to 3 doses of 80mg/m2 of Cisplatin 10 modulated electro-hyperthermia treatments (55 minutes at a maximum of 150W)
89372747|NCT06064370||laparoscopic right adrenalectomy|laparoscopic right adrenalectomy for pheochromocytoma
89372748|NCT06064370||laparoscopic left adrenalectomy|laparoscopic left adrenalectomy for pheochromocytoma
89372749|NCT06062264|Active Comparator|Portal-Based PCP Video Reminder Message|Participants in their arm will receive up to 3 portal-based messages with a video recorded message from their own primary care physician encouraging them to receive the influenza vaccine.
89372750|NCT06062264|Active Comparator|Portal-Based PCP Infographic Reminder Message|Participants in their arm will receive up to 3 portal-based messages with an infographic message with an image of their own primary care physician encouraging them to receive the influenza vaccine.
89372751|NCT06062264|No Intervention|Standard Health System Portal Messages|Participants in this arm will only receive standard-of-care health system portal messages, and will not receive study-based messages.
89372752|NCT06053424|Experimental|AZD7798|"Arm consists of up to 6 sequential panels:~Healthy participant panel 1, Healthy participant panel 2, Healthy participant panel 3, Crohn's disease panel 1, Crohn's disease panel 2, Optional panel"
89534936|NCT03332069|Active Comparator|Control|50 Gy external beam radiation administered in fractions of 2 Gy 3 Doses of 8 Gy High Dose Rate brachytherapy up to 3 doses of 80mg/m2 of Cisplatin
89534937|NCT03090087|Experimental|Healthy person|The purpose is to investigate the effect of A2A adrenoceptor stimulation using the drug regadenoson (Rapiscan) on the diameter of retinal arterioles during hypoxia in vivo.
89534938|NCT03093363|Other|Intervention group|Asthmatic patients with the pharmacist's intervention
89372756|NCT06050928|Experimental|EP262 150 mg|Once daily
89372757|NCT06049017|Experimental|Group 1: JNJ-77242113 Dose-1|Participants will receive JNJ-77242113 Dose-1 tablets orally from Week 0 through Week 28. Participants who complete the Week 28 assessments and have achieved clinical response at Week 28 and who, in the opinion of the investigator, will continue to benefit from treatment with study intervention will continue in the 48-week long term extension (LTE) period and receive the same treatment up to Week 76.
89372758|NCT06049017|Experimental|Group 2: JNJ-77242113 Dose-2|Participants will receive JNJ-77242113 Dose-2 tablets orally from Week 0 through Week 28. Participants who complete the Week 28 assessments and have achieved clinical response at Week 28 and who, in the opinion of the investigator, will continue to benefit from treatment with study intervention will continue in the 48-week LTE period and receive the same treatment up to Week 76.
89372759|NCT06049017|Experimental|Group 3: JNJ-77242113 Dose-3|Participants will receive JNJ-77242113 Dose-3 tablets orally from Week 0 through Week 28. Participants who complete the Week 28 assessments and have achieved clinical response at Week 28 and who, in the opinion of the investigator, will continue to benefit from treatment with study intervention will continue in the 48-week LTE period and receive the same treatment up to Week 76.
89372760|NCT06049017|Experimental|Group 4: Placebo|Participants will receive placebo tablets orally from Week 0 through Week 28. Placebo-treated participants who meet the criteria of inadequate response at Week 16, will receive JNJ-77242113 Dose-3 tablet orally through Week 28. Participants who complete the Week 28 assessments and have achieved clinical response at Week 28 and who, in the opinion of the investigator, will continue to benefit from treatment with study intervention, will continue in the 48-week LTE period and receive the same treatment up to Week 76.
89534939|NCT03093363|Other|Control group|Asthmatic patients without the pharmacist's intervention (only questionnaires)
88844971|NCT04859608|Experimental|Therapeutic drug monitoring|Tailored dosing schedule for eculizumab based on therapeutic drug monitoring
88844972|NCT04859608|No Intervention|Control|Initial eculizumab schedule is continued (real-life arm). No eculizumab dosages are performed in this arm.
88844973|NCT04855630|Experimental|Sleep Only Group|Participants in this group will wear the DREEM 2 headband for 12 weeks.
88844974|NCT04855630|Active Comparator|Exercise Only Group|Participants in this group will workout twice a week for 12 weeks.
88844975|NCT04855630|Active Comparator|Exercise and Sleep Group|Participants in this group will take part in a guided exercise program in additional to wearing the DREEM 2 headband for 12 weeks.
89372764|NCT06038188|No Intervention|Control group|The control group will receive usual care alone
88844976|NCT04854005||Breast Cancer|Patients with cTx/cT1-2cN1 HR+/HER2- tumors who are scheduled to undergo upfront surgery will undergo AUS at the enrolling institution to characterize suspicious-appearing lymph nodes, as is part of routine practice.
88844977|NCT04850105||TEGSEDI-exposed cohort|This cohort consist of patients diagnosed with hATTR-PN who are receiving any dose of commercial TEGSEDI and who have provided written informed consent to be included into the study.
88844978|NCT04850105||TEGSEDI-unexposed cohort|This cohort which will consist of patients diagnosed with hATTR-PN who have not taken any dose of TEGSEDI within 25 weeks prior to enrollment and are eligible for TEGSEDI treatment per applicable product label and who have provided written informed consent to be included into the study.
89372765|NCT06038188|Experimental|SIT LESS Booster|The intervention group will receive usual care in combination with the remote 3-week SIT LESS Booster program.
89372771|NCT06030882|Experimental|Biologic Care Pathway|Care through a biologic care pathway
89372772|NCT06030882|No Intervention|Control|Care as usual
88844981|NCT04824092|Experimental|Tafasitamab plus lenalidomide in addition to R-CHOP|"Patients will receive tafasitamab plus lenalidomide in addition to R-CHOP for six 21-day cycles:~Tafasitamab dose: 12 mg/kg body weight. Each 21-day cycle (cycles 1-6) will comprise of a tafasitamab IV infusion on Day 1, Day 8 and Day 15.~Lenalidomide dose: 25 mg as a starting dose per os (orally) once per day on Days 1-10 of each 21-day cycle~R-CHOP dose: Rituximab (or locally approved biosimilar) 375 mg/m2, IV Day 1 of every 21-day cycle; Cyclophosphamide 750 mg/m2, IV Day 1 of 21-day cycle; Doxorubicin 50 mg/m2, IV Day 1 of 21-day cycle; Vincristine 1.4 mg/m2 (max 2 mg) IV Day 1 of 21-day cycle; Prednisone/prednisolone 100 mg/day, per os, Day 1-5 of every 21-day cycle"
88844982|NCT04824092|Placebo Comparator|Tafasitamab placebo plus lenalidomide placebo in addition to R-CHOP|"Patients will receive tafasitamab placebo plus lenalidomide placebo in addition to R-CHOP for six 21-day cycles:~Tafasitamab placebo: 0.9% saline solution Days 1, 8 and 15 of each 21-day cycle~Lenalidomide placebo: Days 1-10 of each 21-day cycle~R-CHOP dose: Rituximab (or locally approved biosimilar) 375 mg/m2, IV Day 1 of every 21-day cycle; Cyclophosphamide 750 mg/m2, IV Day 1 of 21-day cycle; Doxorubicin 50 mg/m2, IV Day 1 of 21-day cycle; Vincristine 1.4 mg/m2 (max 2 mg) IV Day 1 of 21-day cycle; Prednisone/prednisolone 100 mg/day, per os, Day 1-5 of every 21-day cycle"
89372773|NCT06027840|Experimental|QUIT-C (Concurrent)|Treatment in this arm will emphasize concurrent cessation of cigarettes and e-cigarettes. All participants will receive 12-weeks of varenicline, weekly individual counseling, and access to cessation resources including a guided self-change booklet and links to free text-based support. Counseling and cessation resources will emphasize concurrent cessation.
89372774|NCT06027840|Experimental|QUIT-S (Sequential)|Treatment in this arm will focus on cessation of cigarettes followed sequentially by cessation of e-cigarettes. All participants will receive 12-weeks of varenicline, weekly individual counseling, and access to cessation resources including a guided self-change booklet and links to free text-based support. Counseling and cessation resources will emphasize sequential cessation.
89372775|NCT06025123|Experimental|Early transnasal evaporative cooling with the RhinoChill device|Early transnasal evaporative cooling initiated during ACLS at the scene of the cardiac arrest within 20 minutes from EMS arrival and subsequent hypothermia at 33ºC for 24 hours and fever control for 72 hours at the ICU
89372776|NCT06025123|No Intervention|Standard of care|Standard advanced cardiac life support, subsequent fever control (Normothermia) for 72 hours at ICU
89372777|NCT06024616|Experimental|TARANG arm|"Participants will participate in TARANG and receive the following a total of 14 sessions:~Navigating newly formed relationships (e.g. spousal communication, healthy relationships with in-laws, establishing peer network, and negotiation skills)~Improving women's awareness of sexual reproductive health~Challenging inequitable gender norms to reduce unintended pregnancies.~Life skills education to enable them to have improved social mobility, decision-making, and agency.~The TARANG intervention will be delivered by Vikalp (a registered non-governmental organization implementing the intervention)."
88844988|NCT04813926||Patients diagnosed with PAH|
88844989|NCT04810806|Experimental|Immediate coronary angiography group|Immediate coronary angiography group will routinely receive coronary angiography within 2 hours after randomization.
88844990|NCT04810806|Active Comparator|Delayed coronary angiography group|Delayed coronary angiography group will receive coronary angiography during hospitalization after stabilization of symptoms and signs of heart failure.
88844991|NCT04810078|Experimental|Arm A|
89372778|NCT06024616|No Intervention|Control arm|Participants in the control arm receive standard of care--contraceptive access through community health workers and routine counseling by community health workers
89372779|NCT06023030||Upadacitinib|Participants will receive upadacitinib as prescribed by their physician according to local label.
89372780|NCT06022029|Experimental|Part 1a: Monotherapy Dose Escalation|ONM-501 will be administered as intratumoral injections once per week for three weeks, followed by three weeks without ONM-501 administration. Each dosing cycle will be 21 days.
88844992|NCT04810078|Active Comparator|Arm B|
88844993|NCT04810078|Experimental|Arm C|
88844994|NCT04810078|Experimental|Arm D|
89181074|NCT02968537|Experimental|Alc-IT (75/25) (afternoon)|"As in the arm Alc-IT (75/25) (morning), this version of the alcohol-specific inhibition-training (Alc-IT) will operate with a Go/NoGo-ratio of 75/25. It will equally include 80 Alcoholic NoGo-trials and 80 non-alcoholic Go-trials, but now 160 neutral Go-trials will complete the set. This training will also consist of 320 trials and take about 10.5 minutes. In contrast to the In the morning group, this afternoon group will receive the training in the afternoon."
88844995|NCT04806568|Experimental|PwMS-CogTr|"Adult individuals with Multiple Sclerosis will follow a cognitive training intervention.~Neurological assessment~History of Multiple Sclerosis~Expanded Disability Status Scale (EDSS)~2 types of high-density electroencephalographic recordings~at rest with eyes closed (10 minutes)~event potentials via a multisensory oddball paradigm (45 minutes)~Neuropsychological assessment~MMSE~CDT~GVLT~BVMT~SDMT~Verbal Fluency: Phonemic [ Chi-Sigma-Alpha] and Semantic [Animals-Fruits-Objects]~Digit Span (For-Back-Seq)_WAIS-4GR~SNST~GAT~DASS21~MSIS-29~CRIq~MFIS~EQ-5D-5L~BDI-II~Somatometric assessment~Timed 25-Foot Walk (T25-FW)~3m backwards walk test~Hole Peg Test (9-HPT)~Handgrip Strength Test~Single Leg Stance (SLS)~Four Square Step Test (FSST)~BrainHQ training"
88844996|NCT04806568|No Intervention|PwMS-Con|"Adult individuals with Multiple Sclerosis serving as passive controls.~Neurological assessment~History of Multiple Sclerosis~Expanded Disability Status Scale (EDSS)~2 types of high-density electroencephalographic recordings~at rest with eyes closed (10 minutes)~event potentials via a multisensory oddball paradigm (45 minutes)~Neuropsychological assessment~Mini Mental Status Examination (MMSE)~Clock Drawing Test (CDT)~Greek Verbal Learning Test (GVLT)~Brief Visuospatial Memory Test (BVMT)~Symbol Digit Modalities Test (SDMT)~Verbal Fluency: Phonemic [ Chi-Sigma-Alpha] and Semantic [Animals-Fruits-Objects]~Digit Span (For-Back-Seq)_WAIS-4GR~Stroop Neuropsychological Test (SNST)~The Greek Accentuation Test (GAT)~DASS-21~MSIS-29~CRIq~MFIS~EQ-5D-5L~BDI-II~Somatometric assessment~T25-FW~3m backwards walk test~9-HPT~Handgrip Strength Test~SLS~FSST"
88844997|NCT04806568|No Intervention|Heal-Con|"Healthy adults serving as passive controls.~2 types of high-density electroencephalographic recordings~at rest with eyes closed (10 minutes)~event potentials via a multisensory oddball paradigm (45 minutes)~Neuropsychological assessment~Mini Mental Status Examination (MMSE)~Greek Verbal Learning Test (GVLT)~Brief Visuospatial Memory Test (BVMT)~Symbol Digit Modalities Test (SDMT)~Somatometric assessment~Timed 25-Foot Walk (T25-FW)~3m backwards walk test~Hole Peg Test (9-HPT)~Handgrip Strength Test~Single Leg Stance (SLS)~Four Square Step Test (FSST)"
88844998|NCT04786067|Experimental|Immunosuppression Taper|Patients included in this arm are kidney transplant recipients with stable kidney function currently on or are converting to a Belatacept based immunosuppression regimen. Eligible patients who are deemed immune quiescent after a 3 month monitoring period will undergo sequential withdrawal of immunosuppression medications over a 12 month period from a three drug regimen to a Belatacept only immunosuppression regimen. During the total 15 month period patients will be monitored with monthly clinic visits, blood draws for routine monitoring as well as donor derived cell free DNA and genetic testing through KidneyCare to monitor immune suppression.
88844999|NCT04781543|Experimental|HZN-825 300 mg once daily (QD)|One set of 2 HZN-825 150mg tablets in the morning and one set of 2 placebo tablets in the evening.
88845000|NCT04781543|Experimental|HZN-825 300 mg twice daily (BID)|One set of 2 HZN-825 150mg tablets in the morning and one set of 2 HZN-825 150mg tablets in the evening.
88845001|NCT04781543|Placebo Comparator|Placebo|One set of 2 placebo tablets in the morning and one set of 2 placebo tablets in the evening.
88845002|NCT04751292||Lowlanders|People living at low (<1500 m) altitude
88845003|NCT04751292||Highlanders|People living at high (>2500 m) altitude
88845004|NCT04750902|Active Comparator|0.24% Sodium Fluoride Dentifrice|Toothpaste
89181075|NCT02968537|Placebo Comparator|Control-training (afternoon)|"As in the arm Control-training (morning), this group will receive an unspecific inhibition training. This training is of the same length and difficulty as the two Alc-inhibition-trainings. In contrast to the In the morning group, this afternoon group will receive the training in the afternoon."
89181076|NCT05045391||pulmonary tuberculosis (smear-positive) patients|Patients with pulmonary tuberculosis (smear-positive). Diagnosis of chronic pulmonary aspergillosis among patients with pulmonary tuberculosis (smear-positive)
89181077|NCT05045391||pulmonary tuberculosis (smear-negative) patients|Patients with pulmonary tuberculosis (smear-positive). Diagnosis of chronic pulmonary aspergillosis among patients with pulmonary tuberculosis (smear-negative)
89181078|NCT01031329||Complicated Acute otitis media Group|"This group was divided into 3 sub-groups.~One sub-group includes treatment failure subjects who have had a diagnosis of acute otitis media and showed no clinical improvement within 48-72 hours of antibiotic treatment or reappearance of symptoms within 10 days following the end of antibiotic treatment.~The second sub-group includes subjects with recurrent acute otitis media, who have had new episodes of acute otitis media within the past 6 months or the fourth (or greater) new episode within the past year.~The third sub-group includes subjects with spontaneous otorrhoea if perforation has occurred < 24 hours prior to the visit."
89181079|NCT01020721||Glaucoma|South korean patients with primary congenital glaucoma
89181080|NCT05034939|Active Comparator|FLEX Vessel Prep System followed with PTA (TEST arm)|FLEX Vessel Prep System is used to create circumferential, continuous micro-incisions along the length of the stenosis by performing a retrograde pullback through the lesion. Following FLEX, standard balloon angioplasty is performed with an uncoated PTA balloon sized to meet the reference vessel diameter, according to its corresponding instructions for use. Once advanced to the lesion, the balloon should be inflated according to the site's standard of care.
89181081|NCT05034939|Active Comparator|PTA only (CONTROL arm)|Standard Balloon angioplasty is performed with an uncoated PTA balloon sized to meet the reference vessel diameter, according to its corresponding instructions for use. Once advanced to the lesion, the balloon should be inflated according to the site's standard of care.
89181082|NCT05030649|Experimental|Smart Glasses|The real-time ultrasound image is displayed through head-mounted display Moverio BT-300 (Epson Inc., USA) during the radial arterial cannulation.
89181083|NCT05030649|Active Comparator|Control|The real-time ultrasound image is displayed by the ultrasound machine's monitor during the radial arterial cannulation.
89181084|NCT04082715|Experimental|carbidopa/levodopa+celecoxib|carbidopa/levodopa+celecoxib treatments will be effective.
89181085|NCT04082715|Placebo Comparator|placebo1+celecoxib|A placebo comparator for carbidopa/levodopa+celecoxib .
89181086|NCT04082715|Placebo Comparator|placebo1+placebo2|A placebo comparator for carbidopa/levodopa+celecoxib and placebo1+celecoxib.
89181087|NCT00443209|Experimental|Telcagepant 280 mg/300 mg|Participants receive telcagepant 300 mg soft gel capsules or telcagepant 280 mg tablets, administered orally as a single dose at onset of migraine. If still experiencing a migraine 2 hours after the first dose of telcagepant, participants may take an optional second dose of study drug or non-study rescue medication. Participants may take up to 16 doses (for treatment of up to 8 migraines) of telcagepant per month for up to 18 months.
89181088|NCT00443209|Active Comparator|Rizatriptan 10 mg|Participants receive rizatriptan tablets, administered orally as a single dose at onset of migraine. If still experiencing a migraine 2 hours after the first dose of rizatriptan, participants may take an optional second dose of study drug or non-study rescue medication. Participants may take up to 16 doses (for treatment of up to 8 migraines) of rizatriptan per month for up to 18 months.
89181089|NCT02588235|Experimental|Ezetimibe and Atorvastatin Therapy|Atorvastatin (20 mg/day）plus ezetimibe（10 mg/day）
89181090|NCT02588235|Active Comparator|Atorvastatin Therapy|Atorvastatin (20 mg/day）
89181091|NCT01020955|Active Comparator|NutropinAq and Increlex|NutropinAq (0.15 mg/day for 1 month, 0.3 mg/day for 5 months) and Increlex (15 µg/kg/day for 1 month and 30 µg/kg/day for 5 months).
89181092|NCT01020955|Placebo Comparator|NutropinAq and placebo|NutropinAq (0.15 mg/day for 1 month, 0.3 mg/day for 5 months) and placebo for 6 months.
89181093|NCT01028209|Experimental|Assess [18F] PBR06 and PET imaging|
88845005|NCT04750902|Experimental|1.5% Arginine Dentifrice|Toothpaste
88845006|NCT04750902|Experimental|4.0% Arginine Dentifrice|Toothpaste
88845007|NCT04750902|Experimental|8.0% Arginine Dentifrice|Toothpaste
88845008|NCT04747301|Other|Double-balloon catheter group|Sweeping the membranes by UTAH CVX-RIPE® (Utah Medical Products, Inc, 7043 South 300 West, Midvale, Utah 84047 USA).
89181094|NCT05015985|Active Comparator|MUSIC-CARE Group|"In the Music-Care group, a program of music therapy was administered through a hardware and software provided to the investigative team by the Music-Care Company. The standardized techniques include three sequences in which the relaxing, maintenance and simulating times differ.~Music-Care utilizes the U technique designed to gradually relax the listener. In the current study, music sequences during patients' sessions were based on the mount U, and instrumental musical works were selected for a varying numbers styles (classical, jazz, world music, etc.) and adapted to the patient's style via patient request."
89372781|NCT06022029|Experimental|Part 1b: ONM-501 in Combination with cemiplimab|ONM-501 will be administered as intratumoral injections once per week for three weeks followed by three weeks without ONM-501 administration. Each dosing cycle will be 21 days. The combination agent will be administered according to standard protocol, once every three weeks.
89372782|NCT06022029|Experimental|Part 2: RDE ONM-501 in Combination with cemiplimab in indication-specific expansion cohorts|Once the recommended doses for expansion (RDEs) are determined for ONM-501 + ICI combination or ONM-501 monotherapy, the expansion phase of the study will be initiated. The expansion phase will enroll patients in one to three indication-specific expansion cohorts.
89372783|NCT06021431|Experimental|MORE-VR|"An 8-session version of Mindfulness-Oriented Recovery Enhancement (MORE) delivered by virtual reality. The treatment involves training in mindfulness, reappraisal, and savoring techniques to address OUD.~Participants in this arm will also receive Treatment as usual (TAU) with medications for opioid use disorder (MOUD) such as buprenorphine, methadone, or naltrexone plus any psychological counseling they are already receiving in their standard care."
89372784|NCT06021431|Active Comparator|Treatment as Usual (TAU)|Treatment as usual (TAU) with medications for opioid use disorder (MOUD) such as buprenorphine, methadone, or naltrexone plus any psychological counseling they are already receiving in their standard care.
89372788|NCT06016855|Experimental|Treatment (surgical debulking, 177Lu dotatate)|Patients undergo surgical debulking on day 0 and receive 177Lu dotatate IV over 30 to 40 minutes on day 1 of each cycle. Treatment repeats every 56 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan or MRI throughout the trial, and undergo dotatate PET/CT during screening and on study.
89372789|NCT06016842|Experimental|Elafibranor 80 mg|Participants will take 1 tablet of elafibranor 80 mg per day orally before breakfast with a glass of water at approximately the same time each morning.
89372790|NCT06016842|Placebo Comparator|Placebo|Participants will take 1 placebo tablet per day orally (matching the 80 mg elafibranor sized tablet) before breakfast with a glass of water at approximately the same time each morning.
89372791|NCT06016179|Experimental|Treatment Arm - intracavitary tocilizumab|Four incremental weekly intra-cavitary doses of tocilizumab starting at 0.5μg/mL and increasing to 1.6μg/mL, 5μg/mL and 50μg/mL once a week over four weeks.
89372794|NCT06014086|Experimental|Sequential escalating doses of PH-762.|Escalating doses of PH-762 are to be tested, with an observation period between doses.
89372795|NCT06005285|Experimental|Early Start Denver Model (ESDM)|Early Start Denver Model (ESDM) is a comprehensive model that integrates principles of applied behavior analysis (ABA), relationship-based, developmental, and play-based orientations into an individualized and yet manualized treatment. Core features include the use of naturalistic ABA strategies, sensitivity to typical developmental sequence, caregiver involvement, a focus on interpersonal exchange and positive affect within everyday activities. Providers in the ESDM condition will receive training in caregiver coaching strategies and will be asked to conduct caregiver coaching in the strategies at least monthly.
89372796|NCT06005285|Active Comparator|Treatment as Usual (TAU)|Treatment as usual will vary based on the agency. However, a majority of CBAs use Discrete trial teaching (DTT) based on the Lovaas model.19 DTT involves 10 components described in numerous research publications: capturing child physical and visual attention, adult presentation of the stimuli and instruction (antecedent), child behavior, adult reinforcement, correction procedures, 3-5 second interstimulus interval between trials, behavior-specific praise, and data recording. Most CBAs include caregivers in some way as caregiver involvement is required by most funders. Often, caregivers observe treatment sessions or learn the teaching approach being used with their child. Providers often provide consultation on addressing behavioral concerns.
89181095|NCT05015985|Sham Comparator|CONTROL group|In the control group, a music program from an established playlist with various instrumental music is chosen by the patient and delivered by the same tablet.
89372797|NCT05998863|Experimental|EffCaMgCit|38 meq (760 mg) Ca, 20 meq (243 mg) Mg, and 100 meq total citrate per day; designed to be added to 6 oz water for 1-2 minutes, to be dissolved/suspended before swallowing.
89372798|NCT05998863|Placebo Comparator|Placebo|Each sachet of Placebo will contain microcrystalline cellulose, but no calcium, magnesium or citrate. Placebo will be added to 6 oz water for 1-2 minutes, to be dissolved/suspended before swallowing.
89372799|NCT05998395|Experimental|Ruxolitinib|Ruxolitinib at 5 mg twice a day (BID) for 1 week and then at 10 mg BID for 13-24 weeks and 1 week of 5 mg BID before stopping ruxolitinib.
89372800|NCT05997485||Participants receiving Paxlovid Treatment|Patients administered oral Paxlovid as prescribed according to national Morocco treatment guidelines for Covid.
89372801|NCT05997056|Experimental|neuroendocrine tumors|Patients with well-differentiated neuroendocrine tumors of the gastrointestinal tract, lung, or pancreas.
88845009|NCT04747301|Other|Vaginal insertion Prostaglandin E2 group|Propess® 10mg Vaginal delivery system (Ferring Controlled Therapeutics Ltd., 1 Redwood Place, Peel Park Campus, East Kilbride, Glasgow, G74 5PB, UK) is a vaginal insert containing 10mg of dinoprostone in a timed-release formulation (the medication is released at 0.3 mg/hour).
89372802|NCT05993754|Experimental|Intervention group|Frail and pre-frail elderly people over 65 years of age who underwent elective non-cardiac surgeries who receive non-pharmacological interventions by the nursing team
89372803|NCT05993754|No Intervention|Control group|Frail and pre-frail elderly people over 65 years of age undergoing elective non-cardiac surgeries who will receive traditional care.
89372804|NCT05992805||Volunteer Participants|Volunteer participants being scanned by a qualified clinician using various ultrasound machines.
89372805|NCT05987761|Experimental|PRT Treatment Group|After study participants have completed screenings to meet our inclusion criteria, participants will take part in the pre-intervention MRI brain scan and behavioral assessments and will then be assigned randomly to one of two arms of intervention for 9 weeks. Participants in the PRT Treatment Group will complete an 9-week intervention, PRT for Adolescents, to improve the adolescent's social skills. Following the completion of the 9-week intervention, participants will be asked to complete a second MRI brain imaging session, followed by post-measure appointments in order to assess immediate effects of the intervention.
89372806|NCT05987761|Experimental|Delayed Treatment Group|After study participants have completed screenings to meet our inclusion criteria, participants will take part in the pre-intervention MRI brain scan and behavioral assessments and will then be assigned randomly to one of two arms of intervention for 9 weeks. After 9-weeks without any intervention, participants in the Delayed Treatment Group will be asked to complete a second MRI brain imaging session, followed by post-measure appointments, and will then receive the PRT intervention at the end of the study.
89534940|NCT05009433|Experimental|Pregnant HIIT group|"The high intensity interval training (HIIT) program will be implemented according to the World Health Organization guidelines on physical activity and sedentary behavior (2020) and on the recommendations on physical activity and exercise during pregnancy and postpartum period published by the American College of Obstetricians and Gynecologists (2020). The program will be also based on the High-Intensity Interval Training for Cardiometabolic Disease Prevention report by American College of Sports Medicine (2019). During the study, the participant will be under standard obstetric care on her own. She is obliged to inform her obstetric care provider about participation in the HIIT program and to provide feedback to the project coordinator as to possible recommendations of the obstetric care provider regarding the exercise."
89534941|NCT05009433|Active Comparator|Pregnant MICT group|The moderate intensity continuous training (MICT) program will be implemented based on the World Health Organization guidelines on physical activity and sedentary behavior (2020) and on the recommendations on physical activity and exercise during pregnancy and postpartum period published by the American College of Obstetricians and Gynecologists (2020). During the study, the participant will be under standard obstetric care on her own. She is obliged to inform her obstetric care provider about participation in the MICT program and to provide feedback to the project coordinator as to possible recommendations of the obstetric care provider regarding the exercise.
89534942|NCT05009433|Sham Comparator|Pregnant standard care group|During the study, the participant will be under standard obstetric care on her own. She is obliged to inform her obstetric care provider about participation in the HIIT Mama study and to provide feedback to the project coordinator as to possible contraindications to taking part in the study tests.
89372811|NCT05980143|Experimental|Metacognitive Therapy|MCT will be delivered in accordance with the MCT-PATHWAY treatment manual.
88845010|NCT04742608||Ancillary-correlative (biospecimen collection)|Patients undergo collection of blood samples on the day of surgery following anesthesia but prior to incision and at the first routine blood test following surgery. Patients who undergo remnant ablation after total thyroidectomy with radioactive iodine have an additional blood sample collected. Patients also undergo collection of tissue samples following surgical resection of thyroid nodule or thyroid cancer. Patients' medical records are also reviewed.
88845011|NCT04725396|Experimental|Patients undergoing PVP-assisted MR|PVP is based on CT-scan with millimetric thin slice acquisitions of the facial bone and fibulas. The surgeon defines the exact sites of the intended mandibular osteotomies. A single external subcontracted laboratory (Materialise®) produces the various cutting guides for mandibular resection, flap conformation and the preformed plates for flap osteosynthesis. Flap conformation is entirely performed at the donor site before section of the vascular pedicle (flap still vascularized).
88845012|NCT04725396|Active Comparator|Patients undergoing conventional (i.e. without PVP) MR|Flap modeling and positioning requires one or multiple cuneiform osteotomies. The bone transplant is shaped to restore the contours of the mandibular defect using preoperative imaging studies and the resection specimen. Flap conformation begins at the donor site and is generally completed at the recipient site after fibular pedicle section and before microvascular anastomosis (during ischemia time). The different bone fragments are fixed together and to the native mandible using either titanium miniplates or reconstruction plate and monocortical screws. Regardless of the material used for fixing the fibular flap to the native mandible, the use of a reconstruction plate adapted to the native mandible (or other similar techniques) prior to tumor resection is recommended to guide flap shaping and positioning, and to insure an accurate MR.
88845013|NCT04722991|Experimental|Runcaciguat (BAY1101042)|
88845014|NCT04722991|Placebo Comparator|Placebo|
88875276|NCT02562924|Experimental|MEDIHONEY® rinse alone group|"Days 0-7: Same as 1a;~Days 7-91: 8oz saline sinus rinse followed with 0.5oz of MEDIHONEY® in 50 cc of normal saline.~After day 91:~i. In case endoscopy shows any polyps, edema or discharge: Decrease volume to 4 oz saline rinse followed with the 50cc of the MEDIHONEY®rinse BID. Continue until day 182 ii. In case endoscopy shows no polyps, edema and discharge: Decrease volume to 4 oz saline rinse followed with the 50cc of the MEDIHONEY®rinse once daily. Reevaluate at day 119:~In case endoscopy shows any polyps, edema or discharge: Return to the initial regimen as per 1.c.i till day 182.~In case endoscopy shows no polyps, edema and discharge: Continue as per 1.c.ii till day 182."
89181096|NCT04082793|Experimental|Photobiomodulation group|Low-level laser therapy will be given to the PTMB group along with mandibular mobilization and stabilization exercises
89181097|NCT04082793|Experimental|Sonophoresis group|Ultrasonic massage with diclofenac gel will be given to the sonophoresis group along with mandibular mobilization and stabilization exercises
88845015|NCT04721522||356 case will be enrolled|Pituitary suppression will be achieved by long or antagonist protocol. For long protocol, GnRH agonist will be administered for 10-14 days starting from mid-luteal phase of preceding cycle. After confirmation of down regulation, gonadotropins will be given from second or third day of cycle in a daily dose of (150-300 IU). Gonadotropins therapy will be tailored according to age, BMI, antral follicle count, antimullerian hormone and previous response. In antagonist protocol, gonadotropins will be given from second or third day of cycle in a daily dose of (150-300 IU). GnRH antagonist will be adjusted according to patient response. On the 5th -6th day of stimulation, sonography will be performed and repeated every 1-3 days with regular estradiol assessment. When at least 3 follicles reach ≥ 17 mm in mean diameter, trigger will be given. Oocytes pick up will be performed 34-36 hour after triggering.
89372812|NCT05977127|Experimental|Intradermal vaccination with 20 mcg mRNA vaccine|Participants will receive a single dose of 20 mcg COVID-19 mRNA vaccine (Comirnaty; Pfizer/BioNTech) through the intradermal route using microneedles.
89372813|NCT05977127|Active Comparator|Intramuscular vaccination with 30 mcg mRNA vaccine|Participants will receive a single dose of 30 mcg COVID-19 mRNA vaccine (Comirnaty; Pfizer/BioNTech) through the intramuscular route.
89372814|NCT05977127|Active Comparator|Intramuscular vaccination with 20 mcg mRNA vaccine|Participants will receive a single dose of 20 mcg COVID-19 mRNA vaccine (Comirnaty; Pfizer/BioNTech) through the intramuscular route.
88845016|NCT04715893|Experimental|Ostomy belt group|Participants in this group will receive ostomy belts for eight weeks.
88845017|NCT04690413|Experimental|Persons tested with investigational device|Persons tested with investigational device who previously tested positive or negative for COVID-19 with an emergency use authorized or FDA cleared COVID-19 test
88845018|NCT04682509|Experimental|Study group|All study subjects will receive glecaprevir/pibrentasvir (Mavyret®) 300/120 mg orally x 14 days, starting on POD 0 prior to transplantation of the HCV positive kidney. If HCV RNA is detectable after 2 weeks of therapy, Mavyret® will be continued to complete a full course of 8 weeks per standard of care. Safety monitoring and frequent surveillance for HCV viremia will occur for all subjects throughout the duration of the study. The kidney transplantation procedure and routine post-transplant management will be performed per standard of care.
88845019|NCT04678453|Experimental|Cohort 1 - Low dose SNK01|SNK01 (low dose) administered once every three weeks (Q3W) for four cycles.
88845020|NCT04678453|Experimental|Cohort 2 - Medium dose SNK01|SNK01 (medium dose) administered Q3W for four cycles.
88845021|NCT04678453|Experimental|Cohort 3 - High dose SNK01|SNK01 (high dose) administered Q3W for four cycles.
88845022|NCT04678453|Experimental|Cohort 4 - SNK01 at Maximum Tolerated Dose (MTD) / Recommended Phase 2 Dose (RP2D)|SNK01 (at MTD/RP2D) administered Q3W for four cycles.
88845023|NCT04670432|Experimental|Treatment group|Hydroxyethylrutoside oral tablet twice daily for 8 weeks starting at the time of randomization, in addition to usual care.
88845024|NCT04670432|No Intervention|Control group|Usual care, consisting of anticoagulant treatment and elastic compression therapy for full study duration.
88845025|NCT04658186|Experimental|UCB0599 High Dose Arm|Participants will be randomized to receive a predefined high dosage of UCB0599 during the Treatment Period.
88845026|NCT04658186|Placebo Comparator|Placebo Arm|Participants will be randomized to receive a predefined dosage of Placebo during the Treatment Period.
88845027|NCT04658186|Experimental|UCB0599 Low Dose Arm|Participants will be randomized to receive a predefined low dosage of UCB0599 during the Treatment Period.
88845028|NCT04651088|Placebo Comparator|Metabolic diet|Controlled metabolic diet arm.
88845029|NCT04651088|Active Comparator|Potassium citrate|
88845030|NCT04651088|Active Comparator|Sodium Bicarbonate|
88845031|NCT04651088|Active Comparator|Litholyte arm|
88845032|NCT04651088|Active Comparator|Crystal Lite|
88845033|NCT04651088|Active Comparator|Potassium Bicarbonate|
88845034|NCT04625530|Experimental|ferric carboxymaltose|ferric carboxymaltose 20 mg/kg (with a maximum dose of 1000 mg ferric carboxymaltose in a single Infusion) (Ferinject® 1000 mg/20 ml) will be administered between day -27 and day -7.
88845035|NCT04625530|Experimental|tranexamic acid|tranexamic acid 10mg/kg (Tranexam OrPha 1000 mg/10 ml, OrPha Swiss GmbH, Küsnacht, Switzerland) will be administered 15 -30 minutes prior to surgery followed by infusion of tranexamic acid through syringe pump (1 mg/kg/h) till 4 h postoperatively
88845036|NCT04625530|Experimental|ferric carboxymaltose and tranexamic acid|"ferric carboxymaltose (Ferinject® 1000 mg/20 ml) between day -27 and day~-7 and tranexamic acid (Tranexam OrPha 1000 mg/10 ml) 15-30 minutes prior to surgery followed by Infusion of tranexamic acid through syringe pump (1 mg/kg/h) till 4 h postoperatively will be administered."
88845037|NCT04625530|No Intervention|"no treatment accordingly current standard of care"|"no treatment accordingly current standard of care will be given"
88845038|NCT04617353|Experimental|Plasma|(the treatment of sterno-mediastinitis was carried out using a combined method of air-plasma flow and NO therapy)
88845039|NCT04617353|Other|Standard therapy|(patients who were treated for sterno-mediastinitis according to clinical guidelines, the main method of which is a permanent irrigation and aspiration flow drainage method, as well as a Vacuum Assisted Closure (VAC) system of dressings for vacuum drainage)
88845040|NCT04617080|Active Comparator|SUPRACOR Regular|
88845041|NCT04617080|Experimental|SUPRACOR Strong|
88845042|NCT04616326|Experimental|Galcanezumab|"Galcanezumab administered by SQ injection.~Participants may be eligible for optional open-label extension at the end of the double-blind period."
88845043|NCT04616326|Placebo Comparator|Placebo|"Placebo administered by SQ injection.~Participants may be eligible for optional open-label extension at the end of the double-blind period."
88845044|NCT04616183|Experimental|Arm A (ERK1/2 inhibitor LY3214996, cetuximab)|Patients receive ERK1/2 inhibitor LY3214996 PO QD on days 1-28 and cetuximab IV over 1-2 hours on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89181098|NCT00439231|Experimental|Lenalidomide (Revlimid) subjects|Lenalidomide regimen testing to determine efficacy for CLL/ SLL subjects
89181099|NCT01021189|Experimental|1|AZD1446
89372815|NCT05976217|Experimental|treatment|Venetoclax 100 mg daily for 3 weeks
89372816|NCT05972889|Experimental|Device TENS|
89372817|NCT05972889|Experimental|Device IFC|
89372818|NCT05972889|Sham Comparator|Sham TENS|
89372819|NCT05972889|Sham Comparator|Sham IFC|
89002114|NCT06115954|Experimental|Synchronous Telerehabilitation|"On the basis of telerehabilitation, before starting both synchronous and asynchronous exercise therapy, a comprehensive self-management program will be provided.~Self-management training will be shared online synchronously with the participants in this exercise group. The exercise program will consist of functional exercises focused on trunk stabilization, including warm-up and cool-down periods, 3 times a week for 12 weeks, and will be performed online by the physiotherapist. Exercise training will be completed with a 10-minute warm-up exercise followed by 40-minute trunk stabilization and functional exercises for the upper and lower extremities, followed by a 10-minute cooling-down program consisting of flexibility exercises. Progression in exercise training will be done by increasing the number of repetitions and adding elastic bands to the exercises."
89372820|NCT05972889|No Intervention|Control|Subjects continue with current standard of care only for 4 weeks with the option to crossover to the NexWave Device group for an additional 4 weeks (up to 8 total weeks).
89002115|NCT06115954|Active Comparator|Asynchronous Telerehabilitation|Self-management training will be delivered to the participants in this exercise group via video and they will be asked to watch it. The exercise program will consist of functional exercises focused on trunk stabilization, including warm-up and cool-down periods, 3 times a week for 12 weeks, and will be shared with the participants through videos taken by the physiotherapist. Exercise training will be completed with a 10-minute warm-up exercise followed by 40-minute trunk stabilization and functional exercises for the upper and lower extremities, followed by a 10-minute cooling-down program consisting of flexibility exercises. Participants will be checked weekly by phone to determine exercise tracking. Progression in exercise training will be achieved with new videos that include an increase in the number of repetitions of the participants and the addition of elastic bands to the exercises.
89002116|NCT06115941|Experimental|Incentive spirometer group|"incentive spirometry group patients were directed to start incentive spirometry, 48 hours prior to surgery. They were given an incentive spirometer and were briefed that they should inhale into the mouth piece of spirometer to lift the balls to the roof of tube and hold for five seconds and then exhale. 13 They were asked to perform 10 such breaths for 6 times in a day till surgery under direct supervision of researcher and this was charted in patient file."
89372821|NCT05971693|Experimental|OMNYPULSE Bi-Directional Catheter with TRUPULSE Generator|Participants with symptomatic paroxysmal atrial fibrillation (PAF) will undergo the ablation procedure with OMNYPULSE bi-directional catheter used in combination with the TRUPULSE generator for pulmonary vein isolation (PVI).
89372822|NCT05970120|Experimental|NUVISION NAV Ultrasound Catheter|Participants with five different subgroups (scar-related atrial tachycardia, persistent atrial fibrillation [PsAF], paroxysmal atrial fibrillation [PVF], ventricular tachycardia [VT], and premature ventricular complex [PVC]) will be treated using NUVISION NAV ultrasound catheter per investigator's standard of care and followed until 7 days post-procedure.
89002117|NCT06115941|No Intervention|No Incentive spirometer group|"In group B or no incentive spirometry group patients were not asked to perform incentive spirometry."
89002118|NCT06115928|Experimental|interventional group|Patients will undergo cardiac rehabilitation for 30-minute each sessions, twice a week for one month with virtual reality.
89002119|NCT06115928|No Intervention|control group|Patients will undergo cardiac rehabilitation for 30-minute each sessions, twice a week for one month on standard care (without virtual reality)
89002120|NCT06115876||Pre-Diabetes|Fasting Blood glucose ≥ and <7 5.6mmol/L ≥100 and<126 mg/dL HbA1C 5.7% to 6.4% 2hr Oral Glucose Tolerance Test (OGTT) ≥7.8 and <11.1 mmol/L ≥140 and<200 mg/dL
89002121|NCT06115876||Diabetes|Fasting Blood glucose 7 mmol/L (126mg/dL) or higher HbA1C 6.5% or higher 2hr Oral Glucose Tolerance Test (OGTT) 11.1 mmol/L (200 mg/dL) or higher
89002122|NCT06115863|Active Comparator|placebo group|"Delirium and cognitive functions will be assessed for patients in the control group twice per day for five consecutive days' pre and post conventional nursing care.~The researcher will observe the conventional nursing care provided by CCNs in the study setting which may affect delirium incidence and patients' cognitive functions for 45 minutes twice daily for five consecutive days. These traditional nursing practices may include a close conversation between the nurse and the patient, patient re-orientation, such as providing information about time, date, and location, tactile stimulation during various procedures, and changing patients' positions."
89002123|NCT06115863|Experimental|early cognitive stimulation Interventions group|"Beginning on the first day of the patient's admission to the ICU, the early cognitive stimulation interventions will be implemented for nearly 45 minutes twice daily for five days. One session will be conducted during the morning shift and the other during the evening shift. Each session will include the following:~Cognitive stimulation activities will be administered to patients in the intervention group by a member of his family for 15 minutes twice a day for five consecutive days.~Cognitive training exercises: The researcher will carry out these exercises for a total of 300 minutes over the course of five days, splitting the time between 30 minutes in the morning shift and 30 minutes in the evening shift."
89002124|NCT06115850|No Intervention|No Music intervention|Anxiety assessment questionnaires were administered before the treatment began and after 2 weeks of treatment. Physiological parameters, including heart rate, systolic and diastolic blood pressure, and blood oxygen levels, were monitored before and after 2 weeks of treatment.
89002125|NCT06115850|Experimental|Music intervention|Anxiety assessment questionnaires were administered before the treatment began and after 2 weeks of treatment. Physiological parameters, including heart rate, systolic and diastolic blood pressure, and blood oxygen levels, were monitored before and after 2 weeks of treatment.
89002126|NCT06115824||Cohort A|Cohort A was the cohort of patients who received methotrexate-based chemotherapy alone
89002127|NCT06115824||Cohort B|cohort B was the cohort of patients who received methotrexate-based chemotherapy + orelabrutinib.
89181100|NCT01021189|Placebo Comparator|2|Placebo
89181101|NCT04993755|Experimental|TPN-101, 400 mg/day|
89181102|NCT04993755|Placebo Comparator|Placebo|
89181103|NCT01031485|Active Comparator|Spread with milk peptides and plant sterols|
89181104|NCT01031485|Placebo Comparator|Standard spread|
89181105|NCT00437983|Active Comparator|PS-Omega3|Phosphatidylserine-Omega3, 300mg/day 15 wk
89181106|NCT00437983|Placebo Comparator|Placebo|Cellulose tainted with fishy odor, 3 capsules/day
89372823|NCT05968989|Experimental|Group 1|60 mcg of FluMos-v2 on Day 0 and Week 16
89372824|NCT05968989|Experimental|Group 2|180 mcg of FluMos-v2 on Day 0 and Week16
89002128|NCT06115772||Observational|Participants complete surveys, watch an educational video on HPV vaccination and undergo collection of blood and saliva samples on study. Patients also undergo cervical screening per standard of care and may receive a referral to gynecology if not up to date on anogenital screening.
89002129|NCT06115746|Experimental|iDECIDE|"Participants will…~Receive 4 weekly sessions of the iDECIDE drug curriculum.~Complete assessments and questionnaires, including self-reports of substance use and 4 urinalysis virtual visits.~Be video recorded for quality control."
89002130|NCT06115746|No Intervention|Waitlist Control Group|"Participants will…~Not receive the iDECIDE curriculum during the weekly visits. They can choose to self-enroll in the iDECIDE curriculum at their one-month follow up visit.~Undergo symptom monitoring during the weekly visits.~Complete assessments and questionnaires, including self-reports of substance use and 4 urinalysis virtual visits."
89002131|NCT06115733|Experimental|Capecitabine combined with fuquitinib|"Phase Ⅰb dose exploration trial of fuquinitinib combined with capecitabine (n=6-9) :~Capecitabine: 1000 mg/m² orally, twice a day on days 1-21 of each cycle, 28 days for one treatment cycle.~Fuquinitinib: 1 to 21 days per cycle, orally, once a day, 28 days for a treatment cycle. There are two dose gradients of fuquintinib: 2mg/d, and the initial dose of 3mg/d is 2mg/d. According to the 3+3 dose climbing principle, dose exploration is carried out in the order of 2mg/d→3mg/d, The recommended dose of fuquinitinib combined with capecitabine, as determined in phase I b, continued to enroll 47 patients in the dose-expansion phase trial until the patient became intolerant of toxicity or disease progression."
89002132|NCT06115694|Active Comparator|Experimental group：TCI Articulating Introducer|Tracheal intubation was performed using a TCI core under a visual laryngoscope
89002133|NCT06115694|Placebo Comparator|Control group：GlideRite® Rigid Stylet|Tracheal intubation was performed under a visual laryngoscope using a common tube core
89002134|NCT06115655||malignant patients|The presence of biliary stricture due to malignant diseases, such as cholangiocarcinoma.
89002135|NCT06115655||benign patients|The presence of biliary stricture due to benign diseases, such as inflammation.
89002136|NCT06115629|Experimental|Imaging surveillance|Computed tomography scan every 6 months for 3 years postoperatively. Upper gastrointestinal endoscopy at 12 months postoperatively.
89002137|NCT06115629|No Intervention|Clinical surveillance|Clinical review every 6 months for 3 years postoperatively with further investigation according to symptoms.
89002138|NCT06115616||Exercise|
89002139|NCT06115603|Active Comparator|Cannabigerol|80mg of Cannabigerol daily for 14 days. Cannabigerol is a safe, legal, non-high-inducing cannabinoid obtained from the cannabis plant.
89002140|NCT06115603|Placebo Comparator|Placebo|80mg of placebo daily for 14 days Placebo is made in the form of MCT oil.
89002141|NCT06115590|No Intervention|Low Stress|Reference Group
89002142|NCT06115590|No Intervention|Elevated Stress|Half of the Participants(n=40) with elevated stress (PSS score >13) will be randomly assigned to this group
89002143|NCT06115590|Experimental|Elevated Stress intervention|Half of the Participants(n=40) with High stress (PSS score >13) will be randomly assigned to this group
89002144|NCT06115551|No Intervention|Control|Subjects in the control group will be asked to keep their normal diet during the study period.
89002145|NCT06115551|Experimental|FMD1-ProLon|Subjects in FMD1 groups will be provided and asked to consume a 5-day low calorie fasting-mimicking diet (ProLonTM).
89002146|NCT06115551|Experimental|FMD2-ProMete|Subjects in FMD2 groups will be provided and asked to consume a 5-day low calorie fasting-mimicking diet (ProMeteTM).
89002147|NCT06115512|Experimental|AGA111|AGA111 in autologous blood coagulum (ABC) is locally delivered at the intervertebral space.
89002148|NCT06115512|Placebo Comparator|Placebo|Placebo in ABC is locally delivered at the intervertebral space.
89002149|NCT06115447||Polyglactin group|lung suturing with polyglactin
89002150|NCT06115447||Polypropylene Arm|lung suturing with Polypropylene
89002151|NCT06115434||salvage cystectomy|patients will undergo salvage cystectomy after failure of bladder preservation protocol
89002152|NCT06115434||radical cystectomy|patients who will undergo radical cystectomy without going through bladder preservation
89002153|NCT06115421|Experimental|oral low doses of Roxadustat three times weekly plus iron supplement,|
89002154|NCT06115421|Active Comparator|Erythropoiesis-stimulating agents (ESAs)|
89002155|NCT06115408|Experimental|Drug;Dienogest|2mg pills oral daily
89002156|NCT06115408|Experimental|Drug;N-Acetylcysteine|600 mg/day oral daily
89372825|NCT05968989|Experimental|Group 3|180 mcg of FluMos-v2 on Day 0 and Week16
89002157|NCT06115343|Experimental|Experimental Group|Conscious Awareness application consists of 6 recordings of 30 minutes for 6 weeks.
89002158|NCT06115343|No Intervention|Control Group|Participants in the control group engage in 6 sessions of 30-minute social activity for 6 weeks.
89002159|NCT06115317|Other|Prism followed by sham|
89002160|NCT06115317|Other|Sham followed by prism|
89002161|NCT06115304|Other|Intervention arm|
89002162|NCT06114563|Experimental|Spirulina yogurt|2 cups of yogurt with spirulina each containing 2 g of spirulina
89002163|NCT06114563|Active Comparator|Conventional yogurt|2 cups of conventional yogurt (without spirulina)
89002164|NCT06114394|Experimental|UPV/EHU technique (Aguirre-Zorzano et al 2017)|Harvesting a connective tissue graft from palate by the UPV/EHU technique.
89002165|NCT06114394|Active Comparator|Single incision technique (Huerzeler & Weng 1999)|Harvesting a connective tissue graft from palate by the single incision technique
89002166|NCT06113822||Control Group|Without Anxiety - Normal BMI 15 patient nonanxiety group (HAD scores ranging from 0 to 10) body mass index is normal between 18.5-24.9
89002167|NCT06113822||1st working group|High BMI & Anxiety Normal 19 Patient nonanxiety group (HAD scores ranging from 0 to 10) Those with a high body mass index are between 25 and 29.9.
89002168|NCT06113822||2st working group|Normal BMI & High Anxiety (15 patients) having anxiety group (HAD scores ranging from 11 to 21) body mass index is normal between 18.5-24.9
89002169|NCT06113822||3st working group|High BMI & High Anxiety (19 patients) having anxiety group (HAD scores ranging from 11 to 21) Those with a high body mass index are between 25 and 29.9.
89372826|NCT05965687|Experimental|NBO group|Normobaric Hyperoxia combined with intravenous thrombolysis
89372827|NCT05965687|Placebo Comparator|Control group|Nasal oxygen combined with intravenous thrombolysis
89002170|NCT06113770|Experimental|ready made zirconia|the selected tooth will receive ready made zirconia crown
89002171|NCT06113770|Experimental|pmma crown|the selected tooth will receive cad cam custom made pmma crown
89002172|NCT06112808|Experimental|BCD-263|
89002173|NCT06112808|Active Comparator|Opdivo|
89002174|NCT06111573|Experimental|Vitamin D + Occlusal Splint|Vitamin D is a fat-soluble secosteroid. Vitamin D is very important in muscle and bone metabolism. Vitamin D is a vitamin with some anti-inflammatory and immune-modulating properties.
89002175|NCT06111573|Active Comparator|Diclofenac Sodium + Occlusal Splint|Diclofenac Sodium is a type of NSAID which has been found effective both as an analgesic and in reducing inflammation and is classified as weak and preferentially COX-2 selective.
89002176|NCT06111222|Other|Bilateral implantation of investigational device|Bilateral implantation of investigational device
89002177|NCT06110728|Experimental|Habit Change|Participants randomly assigned to the Habit Change arm will be asked to track behaviors related to their specific goals on a daily basis through the app and will be allowed to engage with the app freely. Outside of using the app, participants will not be asked to engage in any additional activities beyond those typically engaged in for behavioral health treatment (e.g., completion of mental and behavioral health outcome measures).
89002178|NCT06110728|No Intervention|Treatment as Usual|Participants in the TAU arm will continue to engage in their behavioral health treatment as usual and will not be provided access to the habit change app.
89002179|NCT06108193|Experimental|topical minoxidil in Acne Vulgaris|Split face: 2% or 5% topical minoxidil solution applied and no treatment Description: Subjects will apply the 2% or 5% topical minoxidil solution to every inflammatory acne facial lesion on one half of the face and no treatment to every inflammatory acne lesion on the other half of the face twice a day for 4 weeks.
89534943|NCT05009433|Experimental|Nonpregnant HIIT group|"The high intensity interval training (HIIT) program will be implemented according to the World Health Organization guidelines on physical activity and sedentary behavior (2020) and on the High-Intensity Interval Training for Cardiometabolic Disease Prevention report by American College of Sports Medicine (2019).~During the study, the participant will be under standard health care on her own. She is obliged to inform her health care provider about participation in the HIIT Mama study and to provide feedback to the project coordinator as to possible contraindications to exercise or taking part in the study tests."
89002183|NCT06097611|Experimental|Efficacy of early Tranexamic Acid in Pediatric Polytraumatized Patients|
89002184|NCT06097611|Active Comparator|Efficacy of Early Tranexamic Acid in Pediatric Polytraumatized Patients|
89002185|NCT06090617||PA group 1|"conclusive diagnosis of unilateral PA by the four corners criteria:~Biochemical evidence of PA~Lateralization of aldosterone secretion at adrenal venous sampling.~Correction of biochemical values and fall of blood pressure after adrenalectomy.~Immunohistochemical demonstration of CYP11B2 positive nodule(s)"
89372828|NCT05965492|Active Comparator|Bottled pain formulations Group|Participants in this group will use the standard-of-care medication treatment for ambulatory spinal surgery prescribed to them in different bottles for 7 days.
89372829|NCT05965492|Experimental|Multi-Modal regimen Group|Participants in this group will receive the same drugs used during the standard-of-care treatment for ambulatory spinal surgery. However, the drugs will be prescribed using a simple multimodal medication pre-formulated package for 7 days.
89002186|NCT06090617||PA group 2|Presumed diagnosis of bilateral PA, defined as above but without evidence of lateralized aldosterone excess.
89002187|NCT06090617||PH Group|Primary (essential) Hypertension (PH): conclusively ascertained high blood pressure and exclusion of secondary hypertension
89002188|NCT06090617||Non Hypertensive Control Group|comprising patients submitted to surgery but free of hypertension
89372830|NCT05965193|Experimental|NBO group|Normobaric Hyperoxia combined with intravenous thrombolysis
89002189|NCT06089226||Assessment Group|
89002190|NCT06087458|Experimental|Experimental: Low Dose|VOY-101 Low Dose (single dose, IVT)
89002191|NCT06087458|Experimental|Experimental: High Dose|VOY-101 High Dose (single dose, IVT)
89002192|NCT06086028|Experimental|Real time access start arm|"The participants will receive real-time access to their biometric data via the Biostrap API (immediate information condition). After 1 week washout the arms will cross-over, and the delayed access start arm will receive real-time access to their biometrics via the Biostrap API while real time access start arm is blinded to their biometric report until the end of the control period."
89002193|NCT06086028|Experimental|Delayed access start arm|"The participants are blinded to their biometrics until the control period is over (information delayed condition). After 1 week washout the arms will cross-over, and the delayed access start arm will receive real-time access to their biometrics via the Biostrap API while real time access start arm is blinded to their biometric report until the end of the control period."
89002194|NCT06077201|No Intervention|Control|Standard of care course for an individual not participating in center based cardiac rehabilitation. AHA Life's Essential 8 Fact Sheets are provided to promote healthy living.
89002195|NCT06077201|Experimental|HBCR hands-off|Home-based cardiac rehabilitation with mobile application + AHA Life's Essential 8 sheets.
89002196|NCT06077201|Experimental|HBCR interactive|Home-based cardiac rehabilitation with mobile application and periodic video calls with exercise physiologist + AHA Life's Essential 8 sheets.
89002197|NCT06060873||Observational|Patients undergo blood sample collection during screening and throughout the study. Patients whose screening blood samples show elevated miRNA-371 proceed to standard RPLND surgery. Patients whose screening blood samples show normal levels of miRNA-371 undergo standard surveillance followed by standard RPLND surgery at the time of elevated miRNA-371 levels. Patients may also have their medical records reviewed.
89002198|NCT06033911|No Intervention|No App|No intervention. Participants will be given access to a web-based submission portal.
89372831|NCT05965193|Placebo Comparator|Control group|Nasal oxygen combined with intravenous thrombolysis
89372832|NCT05963243||Healthy Volunteers|Healthy adult (18+ years old) volunteers
89372833|NCT05963230||Volunteer Participants|Healthy adult (18+ years old) volunteers
89372834|NCT05963074|Experimental|Cohort 1a: Ibrutinib Lead-in+Fixed Duration Ibrutinib+Venetoclax|Participants will receive ibrutinib 420 milligrams (mg) capsule every day (QD) for a lead-in of 3 cycles (1 cycle = 28 days). From Cycle 4, venetoclax 400 mg tablet dose ramp-up (from 20 to 400 mg over 5 weeks) will begin, and venetoclax 400 mg QD will be administered with ibrutinib 420 mg QD, orally for 12 cycles through Cycle 15.
89372835|NCT05963074|Experimental|Cohort 1b: Ibrutinib Lead-in+Fixed Duration Ibrutinib+Venetoclax|Participants will receive ibrutinib 420 mg capsule QD for a lead-in of 3 cycles (1 cycle = 28 days). From Cycle 4, venetoclax 400 mg tablet dose ramp-up (from 20 to 400 mg over 5 weeks) will begin and ibrutinib dose will be reduced to 280 mg and will be administered QD, venetoclax 400 mg tablets QD will be administered with ibrutinib 280 mg for 12 cycles through Cycle 15.
88845045|NCT04616183|Experimental|Arm B (ERK1/2 inhibitor LY3214996, cetuximab, abemaciclib)|Patients receive ERK1/2 inhibitor LY3214996 and cetuximab as in Arm A. Patients also receive abemaciclib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89372836|NCT05963074|Experimental|Cohort 2a: Continuous Ibrutinib Monotherapy|Participants will receive ibrutinib 420 mg QD (or last tolerated dose) until disease progression (PD) or unacceptable toxicity.
89372837|NCT05963074|Experimental|Cohort 2b: Continuous Ibrutinib Monotherapy|Participants will receive ibrutinib 420 mg QD for 1 cycle (1 cycle = 28 days) followed by Ibrutinib 280 mg QD (or last tolerated dose) and continue until disease progression or unacceptable toxicity.
89372838|NCT05962398||CSL222|Participants who received CSL222 and completed either the study CSL222_2001 (NCT03489291) or CSL222_3001 (NCT03569891) will be followed up from Year 5 after administration of CSL222 in parent study up to Year 15.
89372839|NCT05961709|Experimental|Cemiplimab|Participants will receive cemiplimab by vein over about 30 minutes on Day 1 of each 3-week study cycle, up to 8 cycles.
88845046|NCT04608409|Experimental|Lapatinib - Group 1|Patients in this group will receive Lapatinib (500mg PO BID) and Paclitaxel (80mg/m2).
89372841|NCT05950464|Experimental|Treatment (tuvusertib, BET bromodomain inhibitor ZEN-3694)|Patients receive tuvusertib and BET bromodomain inhibitor ZEN-3694 PO on study. Patients in the dose-escalation phase of the trial also undergo ECG during screening, collection of blood samples on study, and x-ray, CT, or MRI throughout the trial. Patients in the dose-expansion phase of the trial also undergo ECG during screening, biopsies during screening and on study, and x-ray, CT, or MRI, and collection of blood samples throughout the trial.
88845047|NCT04608409|Experimental|Lapatinib - Group 2|Patients in this group will receive Lapatinib (750mg PO BID) and Paclitaxel (80mg/m2).
88845048|NCT04608409|Experimental|Lapatinib - Group 3|Patients in this group will receive Lapatinib (1500mg PO BID) and Paclitaxel (80mg/m2).
88845049|NCT04608409|Experimental|Lapatinib - Group 4|Patients in this group will receive Lapatinib (2000mg PO BID) and Paclitaxel (80mg/m2).
88845050|NCT04604483|Experimental|PTNS|Treatment with PTNS for chronic anal fissure, treatment to be given for 30 minutes during 10 consecutive work Days.
89372842|NCT05947760|Experimental|IV Magnesium Sulfate adjuvant group|Participants in this group will receive standard-of-care procedures intraoperatively and postoperatively along with IV magnesium sulfate for pain control.
89372843|NCT05947760|No Intervention|Control group|Participants in this group will receive standard-of-care procedures intraoperatively and post-operatively for pain control.
89372844|NCT05945927||Participants with HER2-positive Advanced Breast Cancer|Participants will be prospectively followed from the index date (the first treatment of T-DM1) for up to 1 year.
89372845|NCT05944081||Arcadius XP L®|all patients who received a Arcadius XP L® interbody fusion device between 2016 until approx. January 2021 (minimum Follow-up is one year) in the study center
88845051|NCT04595773|Experimental|Aerobic Exercise Training and Education (AET+)|Participants will perform both exercise training and education for 10 weeks
88845052|NCT04595773|Other|Education only (CON)|Participants will perform only education for the first 10 weeks, then cross-over to perform exercise in the second 10 weeks
88845053|NCT04595006|Experimental|Cold Stimulation (CS)|Subjects will undergo a mild cold stimulation of about 14 degrees Celsius by wearing a cooling vest for approximately an hour daily for the next 12 weeks or 3 months.
88845054|NCT04595006|Experimental|Browning Nutraceutical (BN)|Subjects will consume 2000mg of curcumin daily for the next 12 weeks or 3 months.
88845055|NCT04595006|Experimental|Cold Stimulation and Browning Nutraceutical (CSBN)|Subjects will undergo a mild cold stimulation of about 14 degrees Celsius by wearing a cooling vest for approximately an hour and consume 2000mg of curcumin daily for the next 12 weeks or 3 months.
88845056|NCT04570423|Experimental|Cohort 1: ≥12 to <17 years|Participants will receive a SC injection of eflapegrastim after completion of each cycle of chemotherapy up to four cycles of treatment (cycle length may vary and can be up to 28 days or more based on the type of chemotherapy regimen selected).
88845057|NCT04570423|Experimental|Cohort 2: ≥6 to <12 years|Participants will receive a SC injection eflapegrastim after completion of each cycle of chemotherapy up to four cycles of treatment (cycle length may vary and can be up to 28 days or more based on the type of chemotherapy regimen selected).
89372846|NCT05935267||control cohort|control cohort
89372847|NCT05935267||irrigation cohort|irrigation cohort
89372848|NCT05935267||standard cohort|standard cohort
89372849|NCT05923866|Experimental|ONO-2808 Arm|
89372850|NCT05923866|Placebo Comparator|Placebo Arm|
89372851|NCT05920252|Experimental|Digitally enhanced treatment supported by the Vira platform|"Intensive outpatient DBT supported by the Vira platform. The Vira app is installed on the patient's smartphone. The app passively collects data from phone sensors (i.e., measures of physical activity, sleep patterns, mobility, and language patterns reflecting mood states and cognition) that are indicative of risk-relevant behavioral patterns and psychological states. It also prompts users to answer a daily check in question. Mobile sensing data are processed to provide an automated assessment of the user's functioning. Patients will be asked to use Vira for the duration of their intensive outpatient treatment. Patients' use of the Vira app is supported by practitioners, who can schedule just-in-time reminders (i.e., nudges) to arrive in the user's phone at scheduled times to support their behavior change plan and DBT treatment. The Vira Platform therefore integrates mobile sensing, self-report assessment, and just-in-time nudges and notifications into the practitioner's workflow."
89372852|NCT05920252|Active Comparator|Treatment as Usual (TAU)|Intensive outpatient DBT + EARS app (passive data monitoring software)
89534944|NCT05009433|Active Comparator|Nonpregnant MICT group|"The moderate intensity continuous training program will be implemented according to the World Health Organization guidelines on physical activity and sedentary behavior (2020).~During the study, the participant will be under standard health care on her own. She is obliged to inform her health care provider about participation in the HIIT Mama study and to provide feedback to the project coordinator as to possible contraindications to exercise or taking part in the study tests."
89534945|NCT05009433|Sham Comparator|Nonpregnant standard care group|During the study, the participant will be under standard health care on her own. She is obliged to inform her health care provider about participation in the HIIT Mama study and to provide feedback to the project coordinator as to possible contraindications to exercise or taking part in the study tests.
89372855|NCT05913388|Experimental|GB1211 + Pembrolizumab|GB1211 will be administered orally twice a day at 400mg in combination with standard pembrolizumab treatment.
89372856|NCT05913388|Placebo Comparator|Pembrolizumab Monotherapy|Placebo will have the same appearance as GB1211 and administered orally twice a day in combination with standard pembrolizumab treatment.
89372857|NCT05910593||Patient|Patients diagnosed with degenerative cervical myelopathy; will have dexterity measured once with dexterity tool being tested.
89372858|NCT05910593||Healthy|Healthy volunteers will have their dexterity measured at two time points to perform reliability analysis.
89534946|NCT03326609|Experimental|Volume: 2.5 mL|Perineural injection of ropivacaine 10 mg, 2.5 mL. Concentration: Ropivacaine 4 mg/mL.
89534947|NCT03326609|Experimental|Volume: 5 mL|Perineural injection of ropivacaine 10 mg, 5 mL. Concentration: Ropivacaine 2 mg/mL
89372861|NCT05907954|Experimental|darovasertib|IDE196 (darovasertib) oral open label
89534948|NCT03326609|Experimental|Volume: 10 mL|Perineural injection of ropivacaine 10 mg, 10 mL Concentration: Ropivacaine 1 mg/mL
89534949|NCT03326609|Experimental|Volume: 15 mL|Perineural injection of ropivacaine 10 mg, 15mL Concentration: Ropivacaine 0.67 mg/mL
89372864|NCT05902754|Experimental|Sulforaphane tablets|People in the experimental group will be advised to take 2 tablets a day with a meal for 28 days.
89372865|NCT05902754|Placebo Comparator|Placebo tablets|People in the placebo group will be advised to take 2 tablets a day with a meal for 28 days.
88845058|NCT04570423|Experimental|Cohort 3: ≥2 to <6 years|Participants will receive a SC injection eflapegrastim after completion of each cycle of chemotherapy up to four cycles of treatment (cycle length may vary and can be up to 28 days or more based on the type of chemotherapy regimen selected).
88845059|NCT04570423|Experimental|Cohort 4: ≥1 month to <2 years|Participants will receive a SC injection eflapegrastim after completion of each cycle of chemotherapy up to four cycles of treatment (cycle length may vary and can be up to 28 days or more based on the type of chemotherapy regimen selected).
88845060|NCT04568031|Active Comparator|Part I|Cohort C will include healthy participants aged 18 to 55 years. Cohort D will include healthy elderly participants aged ≥ 56 years. In Cohort D, the elderly population is further divided into 2 different age subgroups; aged 56 to 69 years (Subcohort D1) and aged ≥ 70 years (Subcohort D2). At least 30% of participants in Cohort D will be secured for participants with age ≥ 70 years.
89002199|NCT06033911|Placebo Comparator|FoodFlip© App with no nutrition symbol|Intervention control: participants will have access to food information in the shape of a Nutrition Facts table through FoodFlip©. Participants will have access to a submission portal linked to their study ID through the app.
89181107|NCT00783692|Experimental|Vedolizumab|"In the Induction Phase participants received vedolizumab 300 mg, administered by intravenous infusion at Week 0 and Week 2 (Days 1 and 15).~In the Maintenance Phase, participants who demonstrated a clinical response at Week 6 according to protocol-specified criteria were randomized in a 1:1:1 ratio to double-blind treatment with vedolizumab administered every 4 weeks, vedolizumab administered every 8 weeks, or placebo for up to Week 50. Participants who did not demonstrate response at Week 6 of the Induction Phase continued treatment with vedolizumab, administered every 4 weeks during the Maintenance Phase."
89372866|NCT05900336|Experimental|Sodium Naproxen first|Participants take the dose of sodium naproxen during the first menstrual cycle and take the placebo during the second menstrual cycle.
89372867|NCT05900336|Experimental|Placebo first|Participants take the dose of placebo during the first menstrual cycle and take the sodium naproxen during the second menstrual cycle.
89534950|NCT03326609|Experimental|Volume: 20 mL|Perineural injection of ropivacaine 10 mg, 20mL Concentration: Ropivacaine 0.5 mg/mL
89534951|NCT03331913|Active Comparator|intradermal / submucosal injection group|intradermal / submucosal injection at pain area
89372870|NCT05896033|Experimental|Menthol Spectrum Cigarettes and Menthol E-cigarettes|Ppts will be randomly assigned to receive the menthol spectrum cigarettes and Njoy Ace menthol e-cigarettes. Will be used for the duration of the study (8 weeks) starting at the second visit.
89534952|NCT03331913|Experimental|intra-masseter injection group|intra-masseter injection on the ipsilateral of pain involved
89534953|NCT03093285||dysthyoidic female|sexually active, hypothyroidic or hyperthyroidic women of childbearing age
89372871|NCT05896033|Experimental|Menthol Spectrum Cigarettes and Tobacco E-cigarettes|Ppts will be randomly assigned to receive the menthol spectrum cigarettes and Njoy Ace tobacco e-cigarettes. Will be used for the duration of the study (8 weeks) starting at the second visit.
89372872|NCT05896033|Experimental|Non-menthol Spectrum Cigarettes and Menthol E-cigarettes|Ppts will be randomly assigned to receive the non-menthol spectrum cigarettes and Njoy Ace menthol e-cigarettes. Will be used for the duration of the study (8 weeks) starting at the second visit.
89372873|NCT05896033|Experimental|Non-menthol Spectrum Cigarettes and Tobacco E-cigarettes|Ppts will be randomly assigned to receive the non-menthol spectrum cigarettes and Njoy Ace tobacco e-cigarettes. Will be used for the duration of the study (8 weeks) starting at the second visit.
89372874|NCT05894239|Other|Induction Therapy: Phesgo plus Taxane-Based Chemotherapy|Participants will be administered the treatments as outlined in the interventions section.
89372875|NCT05894239|Experimental|Maintenance Therapy: Inavolisib plus Phesgo|Participants will be administered the treatments as outlined in the interventions section.
89372876|NCT05894239|Active Comparator|Maintenance Therapy: Placebo plus Phesgo|Participants will be administered the treatments as outlined in the interventions section.
89534954|NCT02490995|No Intervention|Group A|Information given by the anaesthetist during the consultation
89534955|NCT02490995|Experimental|Group B|Movie + Information given by the anaesthetist during the consultation
89534956|NCT03090009|Active Comparator|Flurbiprofen|Flurbiprofen 100 mg bid.
89534957|NCT03090009|Placebo Comparator|Placebo|Placebo taken bid
89372882|NCT05889832|Experimental|HR, HRV and BR measured with Shen.AI and reference method|
89372883|NCT05882877|Experimental|ARM A: Dose 1 to Dose 1|Participants from parent Rocatinlimab studies ROCKET-Ignite, ROCKET-Horizon, ROCKET-SHUTTLE, or ROCKET-ASTRO who received Dose 1 will be randomized or assigned to receive Dose 1 Every 4 Weeks (Q4W) or Every 8 Weeks (Q8W). Participants from parent Rocatinlimab study ROCKET-VOYAGER who received Dose 1 will be assigned to receive Dose 1 Q4W.
89372884|NCT05882877|Experimental|ARM B: Dose 2 to Dose 2|Participants from parent Rocatinlimab studies ROCKET-Ignite, ROCKET-SHUTTLE, or ROCKET-ASTRO who received Dose 2 will be randomized or assigned to receive Dose 2 Q4W or Q8W.
89372885|NCT05882877|Placebo Comparator|ARM C: Dose 1 or Dose 2 to Placebo|Participants from parent Rocatinlimab studies ROCKET-Ignite or ROCKET-Horizon who received Dose 1 will be randomized to receive placebo Q4W. Participants from parent Rocatinlimab study ROCKET-Ignite who received Dose 2 will be randomized to receive placebo Q4W.
89372886|NCT05882877|Placebo Comparator|ARM D: Placebo to Placebo|Participants from parent Rocatinlimab studies ROCKET- Ignite, ROCKET-Horizon, ROCKET-SHUTTLE, ROCKET-ASTRO, or ROCKET-VOYAGER who received placebo will be randomized or assigned to receive placebo Q4W.
89372887|NCT05882877|Experimental|ARM E: Dose 1, Dose 2, Placebo, or Open-label (OL) to OL Dose 1|"Participants from parent Rocatinlimab studies ROCKET- Ignite, ROCKET-Horizon, ROCKET- SHUTTLE, ROCKET-ASTRO, or ROCKET-VOYAGER who received Dose 1, Dose 2, or placebo will be assigned to receive OL Rocatinlimab Dose 1 Q4W.~Participants who received OL in parent Rocatinlimab study ROCKET- ASTRO will continue to receive OL Rocatinlimab Dose 1 Q4W.~All participants from parent Rocatinlimab study ROCKET-Orbit will be assigned to receive OL Rocatinlimab Dose 1 Q4W."
89372890|NCT05877963|Experimental|Ublituximab|Participants will be transitioned from current anti-CD20 therapy or other DMT to receive ublituximab 450 milligram (mg) or 150 mg intravenous (IV) infusion on Day 1 of Week 1 (W1D1) and ublituximab 450 mg IV infusion at D15 (if applicable) and Week 24.
89372891|NCT05868577|Experimental|corticosteroid injection/ local anesthetic (CSI/LA)|"The PI will then administer the (CSI/LA) injection using an infracalcaneal needle peppering technique as follows:~The hypodermic needle is inserted using infracalcaneal injection approach.~The hypodermic needle is withdrawn while at the same depositing injectate~The hypodermic needle is redirected without emerging from the skin. The PI will perform steps 1-3 standardly 20-25 times."
89372892|NCT05868577|Placebo Comparator|local anesthetic (LA)/Saline injection|"The PI will then administer the (LA/Saline) injection using an infracalcaneal needle peppering technique as follows:~The hypodermic needle is inserted using infracalcaneal injection approach.~The hypodermic needle is withdrawn while at the same depositing injectate~The hypodermic needle is redirected without emerging from the skin. The PI will perform steps 1-3 standardly 20-25 times."
89372893|NCT05866458||Single Arm Cohort|The study population consists of women with newly diagnosed T1-3 node negative breast cancer with no clinical evidence of distant metastatic disease, that have been treated with NAC, BCS and axillary staging surgery with final pathology demonstrating a pCR (defined as absence of residual invasive and in situ breast cancer within the breast or lymph nodes).
89372894|NCT05860803|No Intervention|Control group of standard physician directed care|Subjects will receive pulmonary rehabilitation via standard physician directed care (i.e., 'normal care').
89372895|NCT05860803|Experimental|Home-based specific breathing and respiratory muscle training group|In addition standard of care pulmonary rehabilitation, subjects will participate in an 8-week home-based specific breathing and respiratory muscle training via the LungTrainers Pulmonary Rehabilitation regime (LT-PR).
89372896|NCT05859334|Experimental|Treatment (erdafitinib)|Patients receive erdafitinib PO QD in the absence of disease progression or unacceptable toxicity. Patients also undergo MRI, OCT, and collection of blood samples throughout the trial.
89372897|NCT05856370|Other|Receiving eligible Medtronic Powered Systems, Instruments, and Imaging device(s)|
89181108|NCT00783692|Placebo Comparator|Placebo|In the Induction Phase participants received placebo intravenous infusion at Week 0 and Week 2 (Days 1 and 15). Participants continued to receive placebo during the Maintenance Phase, regardless of treatment response during Induction.
89181109|NCT04992273|Experimental|≥20 kg to <40 kg|SC administration
89181110|NCT04992273|Experimental|≥10 kg to <20 kg|SC administration
89181111|NCT04992273|Experimental|≥5 kg to <10 kg|SC administration
89181112|NCT04992273|Experimental|≥3 kg to <5 kg|SC administration
89181113|NCT02588157|Active Comparator|İnsertion time|handling the device till the glottic visualisation of Macintosh, McGrath MAC X-Blade and Glidescope
89181114|NCT02588157|Active Comparator|intubation time|handling the device till seeing the endotracheal tube entering from the vocal cords Macintosh, McGrath MAC X-Blade and Glidescope
89181115|NCT04082871|Active Comparator|Intervention|"All pharmacist level counseling and education regarding treatment, adherence and self-care activities were delivered to the active group patients only (planned to take 15 minutes). Patient level TRPs (any TRP that could be resolved via patient education and counseling) were resolved directly with the patient by the clinical pharmacist.~A letter with the identified TRPs (prioritized from most important to least important) for each patient in the active group was sent to the patient's psychiatrist by the researcher in sealed envelopes. The psychiatrist either accepted or rejected the recommendations. In case the recommendations were accepted, the psychiatrist implemented the recommended changes. Patients were informed by a phone call by the pharmacist to visit their psychiatrist soon after the recommendations were approved for the changes to be applied.~If the recommendations were rejected, the psychiatrist stated the reason of rejection and discussed it with the pharmacist."
89181116|NCT04082871|Active Comparator|Control|"Control group patients also underwent the baseline interview with the researcher at the psychiatric clinic, TRPs were identified and documented. No intervention was provided by the pharmacist and no letter was sent to the patients' psychiatrists. In case a patient was found to have a life-threatening TRP, the patient was excluded from the study and reported to the psychiatrist due to ethical considerations.~After study completion, all patients in the control group received the MMR service, and a letter with their TRPs and recommendations to resolve them was sent by the pharmacist to their psychologist"
89181117|NCT04959903|Experimental|Adult patients affected by hematological malignancies|Adult patients affected by acute leukemia (AML, ALL or acute leukemia of ambiguous lineage) or myelodysplastic syndrome eligible for a T depleted allogeneic HSCT
89181118|NCT04959903|Experimental|Pediatric patients affected by hematological malignancies|Pediatric patients affected by acute leukemia (AML, ALL or acute leukemia of ambiguous lineage) eligible for a T depleted allogeneic HSCT
89181119|NCT00783224|Placebo Comparator|Mometasone Furoate Placebo (PLAMF)|Placebo to mometasone furoate nasal spray, made to be indistinguishable from mometasone furoate nasal spray
89181120|NCT00783224|Placebo Comparator|Fluticasone Propionate Placebo (PLAFP)|Placebo to fluticasone propionate nasal spray, made to be indistinguishable from fluticasone propionate nasal spray
89181121|NCT00783224|Experimental|Mometasone Furoate (MF)|Mometasone furoate nasal spray 200 μg/day(QD)
89181122|NCT00783224|Active Comparator|Fluticasone Propionate (FP)|Fluticasone Propionate nasal spray 200 μg/day, twice per day (BID)
89181123|NCT00919581||Healthy controls|
89181124|NCT00919581||Subjects with spinal cord injury|
89181125|NCT04102124|Experimental|SHR3680+SHR3162|Participants will receive SHR3680 combined with SHR3162 orally
89181126|NCT04102124|Experimental|SHR3680+SHR3162(Placebo)|Participants will receive SHR3680 combined with SHR3162(Placebo) orally
89181127|NCT04102124|Placebo Comparator|SHR3680(Placebo)+SHR3162(Placebo)|Participants will receive SHR3680(Placebo) combined with SHR3162(Placebo) orally
89181128|NCT04015479|Experimental|Immediate Intervention Group|Participants will complete 10 weeks of twice-weekly whole body resistance training. Peanut protein powder (72g/day) will be provided for daily consumption during the study period
89181129|NCT04015479|Active Comparator|Wait-list Control Group|Participants will complete 10 weeks of twice-weekly whole body resistance training. Peanut protein powder will be provided after the study period
89181130|NCT04082559|Other|Antibiotic treatment|"Patients with active disease will be randomized and will receive a prescription for one of two antibiotic regimens.~Ciprofloxacin 500 mg 2/d + metronidazole 500 mg 2/d for two weeks~Doxycycline 100 mg 2/d + metronidazole 500 mg 2/d for two weeks"
89181131|NCT04082559|Other|Combination therapy (Antibiotics + diet)|"Favorable antibiotics (according to aim 1) for two weeks + Mediterranean diet (MED) for 8 weeks.~Favorable antibiotics (according to aim 1) for two weeks + specific carbohydrate diet (SCD) for 8 weeks."
89181132|NCT04082559|Other|Nutritional prevention|"Patients in clinical remission will be recruited to a dietary prevention study.~Mediterranean diet~Control- based on the American Dietetic Association recommendations for patients with IBD~Personalized nutrition group- based on prior results from study- NCT02858557"
89181133|NCT04082325|Experimental|Part A Lu AF88434 or Placebo|6 cohorts (cohort A1 to A6) with 9 subjects in each cohort. In each cohort 6 subjects will receive single doses of Lu AF88434 and 3 subjects will receive placebo
89181134|NCT04082325|Experimental|Part B1 Lu AF88434 Fed-Fasting-Fasting|4 subjects will receive an identical oral dose of Lu AF88434 in Group B1. The treatment sequence for Group B1 is: Fed-Fasting-Fasting. 14C-spiked dose (Lu AF99723) will be given in the last treatment sequence.
89181135|NCT04082325|Experimental|Part B2 Lu AF88434 Fasting-Fed-Fasting|4 subjects will receive an identical oral dose of Lu AF88434 in Group B2. The treatment sequence for Group B2 is: Fasting-Fed-Fasting. 14C-spiked dose (Lu AF99722) will be given in the last treatment sequence.
89181136|NCT04082325|Experimental|Part B3 Lu AF88434 Fasting-Fasting-Fed|4 subjects will receive an identical oral dose of Lu AF88434 in Group B3. The treatment sequence for Group B3 is: Fasting-Fasting-Fed.
89181137|NCT02587845|Active Comparator|IV group|Intravenous tranexamic acid injection Group IV tranexamic acid group were administered intravenous 10 mg/kg dose of TXA after closing the ITB.
89181138|NCT02587845|Experimental|Topical group|Intra-articular tranexamic acid injection Group Topical tranexamic acid group were administered 2.0 g TXA in 100 ml of normal saline into the hemovac line after closing the ITB.
89372898|NCT05856370|Other|Receiving eligible Advanced Energy device(s)|
89002200|NCT06033911|Active Comparator|FoodFlip© App with 'high-in' nutrition symbol|Intervention: Participants will have access to food information through FoodFlip© with Health Canada's 'high-in' nutrition symbol. ©. Participants will have access to a submission portal linked to their study ID through the app.
89372899|NCT05856370|Other|Receiving eligible device(s) from all other product groups|Robotics and Navigation, Rods and Screws, Interbodies and Biologics, Spinal Tethers, and Other Spinal Hardware device(s)
89534958|NCT02492087|Active Comparator|Tranexamic acid (TXA) Group|Subjects in the TXA group will receive the topical tranexamic acid solution which will be administered intra-operatively, during the caesarean section on the surgical wound and into the intrauterine cavity after the delivery of the baby and the placenta. 60mls of the solution will be applied topically to the placental bed as identified by the surgeon carrying out the surgery by spraying the study solution using a syringe into the uterine cavity. Another 30mls of the solution will be applied to the open incision wound. The surgeon will then proceed to close the first layer of the uterus in the usual manner. The remaining 30mls of the study drug solution is then applied topically on the closed incision wound
89534959|NCT02492087|Sham Comparator|Control Group|Subjects in the Control group will receive topical normal saline solution which will be administered intra-operatively in the same manner as described for the TXA group.
89534960|NCT03093129|Active Comparator|artesunate|Patients will receive 200 mg artesunate (Arinate®) per oral (PO) once daily (OD) for fourteen days prior to their planned surgery and then be followed up for 5 years following surgery.
89534961|NCT03093129|Placebo Comparator|placebo|Patients will receive matching placebo tablets per oral (PO) once daily (OD) for fourteen days prior to their planned surgery and then be followed up for 5 years following surgery.
89534962|NCT02491697|Active Comparator|Capecitabine Monotherapy|"Patients with advanced breast cancer accept capecitabine monotherapy.~Drug: Capecitabine"
89534963|NCT02491697|Experimental|DC-CIK Immunotherapy+Capecitabine|"Biological/Vaccine: DC-CIK DC-CIK immunotherapy combined with capecitabine are used to treat advanced breast cancer.~Drug: Capecitabine"
89534964|NCT03093675|Experimental|TELELAP ALF-X Robotic Surgical System|The patients will undergo surgical procedures using the innovative TELELAP ALF-X robotic system.
89534965|NCT03326453|Experimental|Mini Dental implant|2 mini dental implant of diameter 2.8 mm with length 10 mm will be inserted mandiblular ridge ≥5 mm mesial to the mental foraminato support overdentures for the intervention group.
89534966|NCT03326453|No Intervention|conventional implant|two slandered implant diameter 3.7 mm and length 10 mm will be placed in interforaminal region of mandiblular ridge support overdenture for the compartor group.
89534967|NCT03092973||Epistaxis Group|
89534968|NCT03092973||Control Group|
89534969|NCT03331757|Experimental|Glucose as reference food|Eleven metabolically healthy, normal weight subjects (male: 2, female: 9) after 10-14 hr fast, consumed 50g available carbohydrate from D-glucose, tested three times, in different weeks as reference food along with 300ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first drink.
89534970|NCT03331757|Experimental|Fir honey|Eleven metabolically healthy, normal weight subjects (male: 2, female: 9) after 10-14 hr fast, consumed 50g available carbohydrate from fir honey, tested once, along with 300ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first drink.
89534971|NCT03331757|Experimental|Heather honey|Eleven metabolically healthy, normal weight subjects (male: 2, female: 9) after 10-14 hr fast, consumed 50g available carbohydrate from heather honey, tested once, along with 300ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first drink.
89372914|NCT05830201|Active Comparator|Control Group|Dog will not be in room when child has elbow pins removed
89372915|NCT05830201|Experimental|Therapy Dog Group|The dog will come in a few minutes before to meet with you and your child and ensure ease. The therapy dog will be present throughout the procedure and is able to sit on the exam table if desired.
89534972|NCT03331757|Experimental|Citrus honey|Eleven metabolically healthy, normal weight subjects (male: 2, female: 9) after 10-14 hr fast, consumed 50g available carbohydrate from citrus honey, tested once, along with 300ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first drink.
89534973|NCT03331757|Experimental|Pine honey|Eleven metabolically healthy, normal weight subjects (male: 2, female: 9) after 10-14 hr fast, consumed 50g available carbohydrate from pine honey, tested once, along with 300ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first drink.
89372919|NCT05828641|Active Comparator|Supination-flexion|Supination-flexion maneuver will be applied in the treatment of patients in this group.
89372920|NCT05828641|Active Comparator|Hyperpronation|Hyperpronation maneuver will be applied in the treatment of patients in this group.
89372921|NCT05822752|Active Comparator|Arm 1: Lenvatinib or Sorafenib|Participants will receive Lenvatinib or or Sorafenib, as part of an approximately 2 year treatment period.
89372922|NCT05822752|Experimental|Arm 2: Livmoniplimab Dose A + Budigalimab|Participants will receive Livmoniplimab Dose A in combination with budigalimab, as part of an approximately 2 year treatment period.
89372923|NCT05822752|Experimental|Arm 3: Livmoniplimab Dose B + Budigalimab|Participants will receive Livmoniplimab Dose B in combination with budigalimab, as part of an approximately 2 year treatment period.
89372924|NCT05822635||Subjects with complex pancreaticobiliary disease|All subjects will undergo the intraoperative endoscopy with either the SpyGlass Discover System or the SpyGlass DS Direct Visualization System.
89372927|NCT05819775|Experimental|CSL312|Ages 2-5 years and 6-11 years will have specific subcutaneous dosing schedules
89372928|NCT05817526|Active Comparator|BMAC/ collagen|Bone marrow aspirate concentrate loaded on collagen utilization for filling peri-implant gap around immediate dental implants in the Maxillary esthetic zone
89372929|NCT05817526|Active Comparator|Autograft|Autograft harvested from chin utilization for filling peri-implant gap around immediate dental implants in the Maxillary esthetic zone
89372930|NCT05814614|Active Comparator|electrical stimulation small phase duration|phase duration 200 microseconds, frequency 20 Hertz, 20 minutes
89372931|NCT05814614|Active Comparator|electrical stimulation broad pulse duration|phase duration 1000 microseconds, frequency 8 Hertz, 20 minutes
89372932|NCT05814614|Sham Comparator|electrical stimulation inactive 100Hz|phase duration 200 microseconds, frequency 100 Hertz, 2 seconds active 20 seconds no output, 20 minutes
89372933|NCT05812989|Active Comparator|Social Engage Coaching|Social Engage Coaching involves psychoeducation on the importance of social connections for health as well as structured goal setting and problem solving for increasing social connectedness.
89372934|NCT05812989|Active Comparator|Social Engage Coaching with Connect for Caregivers|Social Engage Coaching involves psychoeducation on the importance of social connections for health as well as structured goal setting and problem solving, guided by use of a digitized prioritization tool, for increasing social connectedness.
89372935|NCT05812040|Other|MRD + HR-MRD|
89372936|NCT05810064||Discharged ED Patients prior to Intervention|Patients aged 65 and older who are in the emergency department and subsequently discharged (not admitted)
89372937|NCT05810064||Discharged ED Patients after Intervention|Patients aged 65 and older who are in the emergency department and subsequently discharged (not admitted)
89372938|NCT05802303|Active Comparator|Transdermal Gel|In the Estradiol gel group patients will be administered transdermal Estradiol gel (17-beta Estradiol gel 0.06%)
89372939|NCT05802303|Other|Oral Estradiol|In the Oral Estradiol group, all women will be given oral Estradiol valerate tablets
89372940|NCT05802134|Experimental|Fruit and Vegetable recipient|For 4 weeks, the individuals will receive supplemental, culturally-appropriate fruits and vegetables (to achieve 8-10 servings per day) supported by intensive education for chronic disease management.
88845061|NCT04568031|Placebo Comparator|Part II|Cohort C will include healthy participants aged 18 to 55 years. Cohort D will include healthy elderly participants aged ≥ 56 years. In Cohort D, the elderly population is further divided into 2 different age subgroups; aged 56 to 69 years (Subcohort D1) and aged ≥ 70 years (Subcohort D2). At least 30% of participants in Cohort D will be secured for participants with age ≥ 70 years.
89372941|NCT05801224|Experimental|Electrical Impedance Tomography|"A total of 60 subjects (cohort 1) will receive an inhaled nitric oxide (iNO) challenge (20 ppm) for 15 min. The investigators will measure ventilation and perfusion distributions using EIT before iNO (OFF1), after 15 min on iNO (ON), and after 15 min washout (OFF2) to confirm baseline stability."
89372942|NCT05801224|Experimental|Electrical Impedance Tomography and Dual-Energy Computed Tomography|In a subset of 10 subjects (cohort 2), EIT and DECT will be performed in a row at the same type of bed and body position. In cohort 2, the measurements will be before nitric oxide (iNO) and during iNO. The OFF-ON fashion for DECT imaging is to minimize the subject's exposure to radiation and reduce the time spent in the CT room.
89372943|NCT05799599|Active Comparator|Stay-Play_Talk Basic Followed by Stay_Play_Talk Basic - (SPT Basic Responders)|After being randomly assigned to the SPT Basic condition, these participants responded and therefore remained in this condition
89372944|NCT05799599|Active Comparator|Stay_Play_Talk Basic Followed by Randomization to Stay_Play_Talk Basic (SPT Basic - SPT BASIC)|After being randomly assigned to the SPT Basic condition, these participants did not respond but were randomized to stay in this condition to examine longer duration in this treatment.
89372945|NCT05799599|Experimental|Stay_Play_Talk Basic Followed by Randomization to Stay_Play_Talk Plus (SPT Basic - SPT Plus)|After being randomly assigned to the SPT Basic condition, these participants did not respond and were randomized to Stay_Play_Talk Plus in the second stage.
89372946|NCT05799599|Experimental|Stay_Play_Talk Plus Followed by Stay_Play_Talk Plus (SPT Plus Responders)|After being randomly assigned to the SPT Plus condition, these participants responded and therefore remained in this condition
89372947|NCT05799599|Experimental|Stay_Play_Talk Plus Followed by Randomization to Stay_Play_Talk Plus (SPT Plus - SPT Plus)|After being randomly assigned to the SPT Plus condition, these participants did not respond and were randomized to Stay_Play_Talk Plus in the second stage.
89372948|NCT05799599|Experimental|Stay_Play_Talk Plus Followed by Randomization to Stay_Play_Talk Advanced (SPT Plus - SPT Advanced)|After being randomly assigned to the SPT Plus condition, these participants did not respond and were randomized to Stay_Play_Talk Advanced condition in the second stage which incorporates direct instruction.
89372949|NCT05798481|Experimental|sodium nitrite and N-acetycysteine mixture|"sodium nitrite 2.5mg + N-acetylcysteine 50mg~Sodium nitrite 5 mg + N-acetylcysteine 50mg"
89372950|NCT05791708||cold agglutinin disease (CAD)|Patient with a diagnosis of CAD as per investigator judgment based on the diagnosis criteria listed in study protocol. In addition, this group includes a cohort of CAD patients treated with sutimlimab
89372951|NCT05791708||cold agglutinin syndrome (CAS)|Patient with a diagnosis of CAS as per investigator judgment based on the diagnosis criteria listed in study protocol
89372952|NCT05791526||Participants Receiving Upadacitinib|Participants receiving upadacitinib for moderate to severe Ulcerative colitis (UC) in real-world practice.
89372953|NCT05790785||Children with Type 1 diabetes|children recruited within 14 weeks of type 1 diabetes diagnosis and followed for 24 months.
89372954|NCT05788289|Experimental|Participants with Mantle Cell Lymphoma|Participants have a diagnosis of Mantle Cell Lymphoma have previously failed or could not tolerate Bruton's tyrosine kinase inhibitors/BTKi
89372955|NCT05786664||Observational (survey, biospecimen collection, record review)|Patients complete surveys, undergo collection of blood samples, and review of medical records on study.
89372956|NCT05784441|Experimental|JNJ-90009530|
88845063|NCT04565665|Experimental|Phase II Arm I (mesenchymal stem cells)|Patients receive MSCs as in the Pilot study.
88845064|NCT04565665|Active Comparator|Phase II Arm II (standard of care)|Patients receive standard of care.
88845065|NCT04565665|Experimental|Pilot study (mesenchymal stem cells)|Patients receive MSCs IV over 1-2 hours on day 1. Patients may receive a second infusion of MSCs within 7 days after the first infusion per physician discretion.
88845066|NCT04557813||IC before start of any treatment|Informed consent (IC) before start of any treatment after diagnosis of NTRK fusion-positive cancer. All data after diagnosis of NTRK fusion-positive cancer are collected prospectively.
89002201|NCT06030284|Experimental|BurstDR-SCS|Subjects implanted with BurstDR-SCS will be included in BurstDR-SCS arm.
89372957|NCT05784402|Experimental|Sequence A: Semaglutide J-Semaglutide C-Semaglutide J|After 6 weeks of run-in dose escalation period participants will orally receive semaglutide J at dose level 1 once daily for 4 weeks followed by semaglutide C once daily for next 4 weeks and thereafter semaglutide J at dose level 3 once daily for next 4 weeks.
89372958|NCT05784402|Experimental|Sequence B: Semaglutide C-Semaglutide J-Semaglutide J|After 6 weeks of run-in dose escalation period participants will orally receive semaglutide C once daily for 4 weeks followed by semaglutide J at dose level 2 once daily for next 4 weeks and thereafter semaglutide J at dose level 4 once daily for next 4 weeks.
89372959|NCT05784402|Experimental|Sequence C: Semglutide J-Semaglutide J-Semaglutide C|After 6 weeks of run-in dose escalation period participants will orally receive semaglutide J at dose level 1 once daily for 4 weeks followed by semaglutide J at dose level 3 once daily for next 4 weeks and thereafter semaglutide C (2x dose) once daily for next 4 weeks.
89372960|NCT05784402|Experimental|Sequence D: Semaglutide J-Semaglutide C-Semaglutide J|After 6 weeks of run-in dose escalation period participants will orally receive semaglutide J at dose level 2 once daily for 4 weeks followed by semaglutide C (2x dose) once daily for next 4 weeks and thereafter semaglutide J at dose level 4 once daily for next 4 weeks.
89372961|NCT05782907|Experimental|Period 1- Open Label Induction Phase|All participants in open label induction phase of Period 1 will receive upadacitinib Dose A for 8 weeks based on body weight.
89372962|NCT05782907|Experimental|Period 1- Double Blind Maintenance Phase|Clinical responders at the end of open label induction phase of Period 1 will be randomly assigned to receive either upadacitinib Dose B or Dose C for 44 weeks based on body weight.
88845067|NCT04557813||IC after start of any treatment|IC after start of any treatment after diagnosis of NTRK fusion-positive cancer. Data after study inclusion are collected prospectively and retrospectively.
89372963|NCT05782907|Experimental|Period 2- Open Label Long Term Extension Phase Arm A|Clinical non-responders outside of US after Period 1 induction phase will receive upadacitinib Dose A daily for 8 week extended induction phase in open label long term extension (OLE) Period 2. Clinical responders from extended induction phase in OLE will receive upadacitinib Dose B daily for up to 252 weeks in OLE period 2.
89372964|NCT05782907|Experimental|Period 2- Open Label Long Term Extension Phase Arm B|Clinical non-responders in US after Period 1 induction phase or clinical responders with loss of response during maintenance phase will receive upadacitinib Dose B daily for up to 260 weeks in OLE Period 2.
89372965|NCT05782907|Experimental|Period 2- Long Term Extension Phase Arm C|Clinical responders who complete Period 1 through Week 52 will receive upadacitinib Dose C daily for up to 260 weeks in OLE Period 2.
89372966|NCT05782179|Experimental|Cohort 1 - Active|Cohort 1 (30 healthy older adult) will receive three injections, each consisting of 50 μg of GBS-NN and 50 μg of GBS NN2 bound to aluminium hydroxide in a 4:1 ratio (investigational medicinal product or placebo).
88845068|NCT04557813||Deceased patients|Patients deceased prior to study inclusion (no IC required). All data are collected retrospectively.
89372967|NCT05782179|Placebo Comparator|Cohort 1 - Placebo|Cohort 1 (30 healthy older adult) will receive three injections, each consisting of 50 μg of GBS-NN and 50 μg of GBS NN2 bound to aluminium hydroxide in a 4:1 ratio (investigational medicinal product or placebo).
89372968|NCT05782179|Experimental|Cohort 2 - Active|Cohort 2 (30 healthy older adult) will receive three injections, each consisting of 125 μg of GBS-NN and 125 μg of GBS NN2 bound to aluminium hydroxide in a 4:1 ratio (investigational medicinal product or placebo).
89372969|NCT05782179|Placebo Comparator|Cohort 2 - Placebo|Cohort 2 (30 healthy older adult) will receive three injections, each consisting of 125 μg of GBS-NN and 125 μg of GBS NN2 bound to aluminium hydroxide in a 4:1 ratio (investigational medicinal product or placebo).
88845069|NCT04551469|Experimental|Treatment Arm|30 minutes of listening to music
89372970|NCT05782179|Experimental|Cohort 3 - Active|Cohort 3 (15 obese and/or diabetic older adults) will receive three injections, each consisting of 50 μg of GBS-NN and 50 μg of GBS NN2 bound to aluminium hydroxide in a 4:1 ratio (investigational medicinal product or placebo).
89372971|NCT05782179|Placebo Comparator|Cohort 3 - Placebo|Cohort 3 (15 obese and/or diabetic older adults) will receive three injections, each consisting of 50 μg of GBS-NN and 50 μg of GBS NN2 bound to aluminium hydroxide in a 4:1 ratio (investigational medicinal product or placebo).
89372972|NCT05782179|Experimental|Cohort 4 - Active|Cohort 4 (15 obese and/or diabetic older adults) will receive three injections, each consisting of 125 μg of GBS-NN and 125 μg of GBS NN2 bound to aluminium hydroxide in a 4:1 ratio (investigational medicinal product or placebo).
88845070|NCT04551469|No Intervention|Standard of Care|actual sounds of the intensive care unit environment
88845071|NCT04550039|Experimental|Body-weight-supported treadmill training|Participants complete prescribed gait training program for at least three weeks or until they discharge.
89181139|NCT04103528|Other|morning group(from 8:00 to 12:00)|
88845072|NCT04550039|Experimental|EksoNR exoskeleton|Participants complete prescribed gait training program for at least three weeks or until they discharge.
88845073|NCT04544124|Experimental|Contingency management for treatment attendance|Participants who receive contingency management in addition to their usual care (treatment-as-usual). These participants are in the 12-week contingency management program which provides incentives for their treatment attendance.
88845074|NCT04544124|No Intervention|Treatment-as-usual|Participants who solely receive their usual care (treatment-as-usual) and do not receive contingency management.
88845075|NCT04533711|Experimental|OA-PCP|Participants assigned to the OA-PCP intervention will receive an initial physical activity (PA) coaching call then, 5 more calls over the course of 12 months. Participants, if they agree, will also receive monthly check-in emails between phone calls.
89181140|NCT04103528|Other|afternoon group(from 14:00 to 18:00)|
89181141|NCT05683431|Experimental|Cognitive Control of Emotion (CCE) Training|"Mobile (iphone/ipad) App with game-like exercises designed to improve Cognitive Control of Emotion (CCE), i.e. the ability to control the influence of emotional information on behavior. Participants do 20 sessions (approximately 30min each), over 4 weeks."
89181142|NCT04103840||Severe alcohol- associated hepatitis|Severe alcohol associated hepatitis as defined by probable/ conformed National Institute on Alcohol Abuse and Alcoholism (NIAAA) criteria
89372973|NCT05782179|Placebo Comparator|Cohort 4 - Placebo|Cohort 4 (15 obese and/or diabetic older adults) will receive three injections, each consisting of 125 μg of GBS-NN and 125 μg of GBS NN2 bound to aluminium hydroxide in a 4:1 ratio (investigational medicinal product or placebo).
89372974|NCT05780099||Cases|patients treated at internal medicine wards
89372976|NCT05773248||Standard care|
89372977|NCT05773248||ERAS|
89372978|NCT05770414|Experimental|Intervention group|Participants assigned to this group will receive the MTC online program after completing the pre-intervention questionnaire.
89372979|NCT05770414|No Intervention|Waitlist control group|Participants assigned to this group will not receive the MTC online program during the study period. At the end of the 8 weeks and after the post-questionnaire is completed, they will have the option to receive the MTC online program if they wish.
89372980|NCT05769348|Active Comparator|Active Unilateral Treatment|Chronic migraine patients will be randomized (Taves method) to receive UNILATERAL high-definition transcranial direct current stimulation (HD-tDCS*) as 20 minute sessions, once daily for 20 days (M-F for 4 weeks).
88845076|NCT04533711|Placebo Comparator|Attention Control|Participants assigned to the Attention Control group will receive the same number of phone calls over the course of 12 months, focused on understanding osteoarthritis (OA) and current information on treatment options. Participants, if they agree, will also receive monthly check-in emails between phone calls.
88845077|NCT04531215|Active Comparator|ultrasound guided Retrolaminar Block|ultrasound guided Retrolaminar Block (RLB) with 20 ml (0.5% Bupivacaine) plus 5 mic/ml Adrenaline (1:200,000) at the level of T4 of the surgical side.
88845078|NCT04531215|Active Comparator|ultrasound guided erector spinae|ultrasound guided Erector Spinae Plane Block (ESPB) with 20 ml (0.5% Bupivacaine) plus 5 mic/ml Adrenaline (1:200,000) at the level of T4 of the surgical side.
88845079|NCT04521803|No Intervention|Arm 1: Standard of care (RIF10)|Dosing of the daily oral RHZE fixed dose combination (FDC) will be according to WHO weight bands
89372981|NCT05769348|Active Comparator|Active Bilateral Treatment|Chronic migraine patients will be randomized (Taves method) to receive BILATERAL high-definition transcranial direct current stimulation (HD-tDCS*) as 20 minute sessions, once daily for 20 days (M-F for 4 weeks).
89372982|NCT05769348|Sham Comparator|Sham Treatment|Chronic migraine patients will be randomized (Taves method) to receive SHAM high-definition transcranial direct current stimulation (HD-tDCS*) as 30-second administrations at the beginning and end of each 20 minute session, once daily for 20 days (M-F for 4 weeks).
89372983|NCT05769348|No Intervention|No Treatment|Episodic Migraine Patients will not receive study treatment. These patients will complete observational study components (Screening visit, baseline visit, MRI and PET scan only).
89372984|NCT05763381|Active Comparator|The Usual Care + PBM Group|Participants that are assigned to this group will receive active treatment with PBM 3 times a week for 3 weeks for a total of 9 treatments.
89372985|NCT05763381|Placebo Comparator|The Usual Care + Sham (Placebo) PBM Group|Participants that are assigned to this group will receive Sham PBM therapy 3 times a week for 3 weeks for a total of 9 treatments. Sham PBM therapy is an inactive harmless treatment that is intended to mimic the active PBM treatment.
89372986|NCT05763017|Experimental|Relative Motion Splint|In the relative motion splint, the metacarpophalangeal joint of the affected finger(s) positioned in approximately 20°-25° more extension/flexion than metacarpophalangeal joint of the adjacent fingers.
89372987|NCT05763017|Active Comparator|Metacarpophalangeal Joint Blocking Splint|In the metacarpophalangeal joint blocking splint, the metacarpophalangeal joint of the affected finger(s) positioned in 0°.
89372988|NCT05759481|Experimental|Propofol|Low-dose propofol infusion at 25 mcg/kg/min
89372989|NCT05759481|Placebo Comparator|Placebo|Same volume of 0.9% normal saline as the study group
89372990|NCT05756764||Patients with obesity on pharmacotherapy|Before initiation of pharmacotherapy (as part of the standard-of-care treatment) and 6 months after initiated medication
89372991|NCT05752487|Experimental|Pulsed Field (PF) /Radiofrequency (RF) Catheter ablation|Participants with drug refractory, paroxysmal atrial fibrillation (PAF) who are candidates for catheter ablation will be enrolled with ablation system which uses THERMOCOOL SMARTTOUCH SF (STSF) catheter and TRUPULSE generator to deliver RF or PF energy during cardiac ablation procedures.
89372992|NCT05752006|Experimental|Crane operators|Individuals employed as crane operators in Port of Koper.
89372993|NCT05752006|Active Comparator|Control subjects|Individuals who spend more than half of their occupation time standing.
89372994|NCT05750823|Experimental|Ruxolitinib Cream|Participants with non-segmental vitiligo with genital involvement will receive ruxolitinib 1.5% cream BID for up to 48 weeks
89372995|NCT05748158|Other|Weight loss|A 37 week behavioral intervention aimed at decreasing energy intake and increasing physical activity.
89372996|NCT05741710|Experimental|Methylone|
89372997|NCT05741710|Placebo Comparator|Placebo|
89372998|NCT05740566|Experimental|Tarlatamab|Participants will receive tarlatamab as an intravenous (IV) infusion.
89372999|NCT05740566|Active Comparator|Standard of Care|Participants will receive treatment per local standard of care (SOC).
89002202|NCT06030284|Experimental|Sham control arm|Subjects implanted with the BurstDR-SCS system will be included in the Sham control arm
89373000|NCT05734105|Experimental|Ripretinib|150 mg QD of ripretinib (3×50 mg tablets) will be dosed continuously in repeated 42-day cycles.
89373001|NCT05734105|Active Comparator|Sunitinib|50 mg QD of sunitinib (4×12.5 mg capsules) will be dosed in 42-day cycles. Sunitinib will be given continuously for 4 weeks with a 2-week break.
89373002|NCT05724199|Experimental|Rocatinlimab Dose 1 + TCS/TCI|Rocatinlimab Dose 1 every 4 weeks (Q4W) for 24 weeks + TCS/TCI + loading dose at Week 2.
89373003|NCT05724199|Experimental|Rocatinlimab Dose 2 + TCS/TCI|Rocatinlimab Dose 2 Q4W for 24 weeks + TCS/TCI + loading dose at Week 2.
89373004|NCT05724199|Placebo Comparator|Placebo + TCS/TCI|Placebo Q4W for 24 weeks + TCS/TCI + loading dose at Week 2.
89002203|NCT06018441||Severe asthma|Participants with severe asthma starting treatment with dupilumab
89002204|NCT06015945|Experimental|Transcutaneous Electrical Acustimulation (TEA)|
89002205|NCT06013930|Experimental|External Qigong|Participants will meet individually with the Qigong practitioner once a week for three weeks for 30-minute segments.
88845080|NCT04521803|Experimental|Arm 2: High-dose RIF (RIF35)|Simulations were performed to determine the dose of RIF required to achieve the most equitable drug exposures across the weight range, 30 to 100 kg. Demographic data of a reference cohort of TB patients (n = 1225), with or without HIV-1 coinfection, recruited in clinical trials conducted in West Africa and South Africa were used for the simulations35-38. An additional 12 250 virtual patients were generated using the weight and height distributions of the 1225 patients to increase the number of patients with a weight close to the boundaries of the weight range. Parameter estimates of the population PK model for RIF were used to simulate (100 replicates) RIF exposures22. Four dosing scenarios were evaluated using the weight-band based dosing with 4-drug FDC tablets and extra RIF tablets with each tablet containing 150 mg or 600 mg RIF. The FDC tablets were assumed to have 20% reduced bioavailability based on data from a clinical trial where the same formulation was used39
89534974|NCT03331757|Experimental|Thyme honey|Eleven metabolically healthy, normal weight subjects (male: 2, female: 9) after 10-14 hr fast, consumed 50g available carbohydrate from thyme honey, tested once, along with 300ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first drink.
89534975|NCT03331757|Experimental|Chestnut honey|Eleven metabolically healthy, normal weight subjects (male: 2, female: 9) after 10-14 hr fast, consumed 50g available carbohydrate from chestnut honey, tested once, along with 300ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first drink.
89373007|NCT05714202|Experimental|Treatment Group A: TAR-200 + Cetrelimab|Participants will receive intravesical TAR-200 once every 3 weeks (Q3W) and cetrelimab.
89373008|NCT05714202|Active Comparator|Treatment Group B: Bacillus Calmette-Guerin (BCG) Vesiculture|Participants will receive intravesical BCG once every week for 6 weeks (induction) and then followed by once every week for 3 weeks starting at Weeks 12, 24, 48, 72, and 96 (maintenance).
89373009|NCT05714202|Experimental|Treatment Group C: TAR-200 Alone|Participants will receive intravesical TAR-200 alone once Q3W.
89534976|NCT05017467|Experimental|vss|Vancouver Scar Scale (VSS) at the one, three and 6 months after surgery
89373012|NCT05713253|Experimental|ELITA System|Each subject will receive a SILK lenticule removal procedure on one eye and a commercially available laser vision correction procedure on their fellow eye (Feasibility Phase). Subjects will receive a lenticule removal procedure on both eyes to reduce or eliminate myopic refractive errors (Pivotal Phase). The second eye treatment will be considered only after the first eye 1-week follow up visit has been completed and safety criteria are met.
89373013|NCT05706285||Erector Spina Plane Block and Intravenous Patient Controlled Analgesia|
89373014|NCT05706285||Intrathecal Morphine and Intravenous Patient Controlled Analgesia|
89373015|NCT05704738|Experimental|Arm A: Dose 1|"Part 1 (Initial Period); Week 0 to Week 24: Rocatinlimab Dose 1 every 4 weeks (Q4W) for 24 weeks with loading dose at Week 2 (+ topical corticosteroids (TCS)/ topical calcineurin inhibitor (TCI) if within combination therapy cohort).~Part 2 (Maintenance Period); Week 24 to Week 52: Part 1 Responders will be rerandomised at Week 24 to Rocatinlimab Dose 1 Q4W or every 8 weeks (Q8W) for 28 weeks (+ TCS/TCI if within combination therapy cohort)."
89373016|NCT05704738|Experimental|Arm B: Dose 2|"Part 1 (Initial Period); Week 0 to Week 24: Rocatinlimab Dose 2 Q4W for 24 weeks with loading dose at Week 2 (+TCS/TCI if within combination therapy cohort).~Part 2 (Maintenance Period); Week 24 to Week 52: Part 1 Responders will be rerandomised at Week 24 to Rocatinlimab Dose 2 Q4W or Q8W for 28 weeks (with TCS/TCI if within combination therapy cohort)."
89373017|NCT05704738|Experimental|Arm C: Placebo|"Part 1 (Initial Period); Week 0 to Week 24: Placebo Q4W for 24 weeks with loading dose at Week 2 (+TCS/TCI if within combination therapy cohort).~Part 2 (Maintenance Period); Week 24 to Week 52: Part 1 Responders will be reassigned at Week 24 with Placebo Q4W for 28 weeks (with TCS/TCI if within combination therapy cohort)."
89373018|NCT05704738|Experimental|Arm D: Open-Label Dose 1|Part 2; Week 24 to Week 52: Part 1 Non-Responders will be reassigned at Week 24 with Rocatinlimab Open-label Dose 1 Q4W for 28 weeks (with TCS/TCI if within combination therapy cohort). Participants in Arms A, B or C Maintenance Period will be reassigned with Rocatinlimab Open-label Dose 1 Q4W (with TCS/TCI if within combination therapy cohort) upon relapse after Week 24.
88845081|NCT04521361|Experimental|Patients with Low extent of disease|Adult men with bone mCRPC having < 6 bone metastases
89373019|NCT05703607|Experimental|SubStudy A (SSA): Group 1|Candidate 1, Dose Level 1, lyophilized, 0, 2 months schedule
89373020|NCT05703607|Experimental|SSA: Group 2|Candidate 1, Dose Level 2, lyophilized, 0, 2 months schedule
89373021|NCT05703607|Experimental|SSA: Group 3|Candidate 1, Dose Level 3, lyophilized, 0, 2 months schedule
89373022|NCT05703607|Experimental|SSA: Group 4|Candidate 1, Dose Level 2, frozen, 0, 2 months schedule
89373023|NCT05703607|Experimental|SSA: Group 5|Candidate 1, Dose Level 2, Frozen, 0, 6 months schedule
89373024|NCT05703607|Experimental|SSA- Group 6|Candidate 2, frozen, 0, 2 months schedule
89373025|NCT05703607|Experimental|SSA: Group 7|Candidate 3, Frozen, 0, 2 months schedule
89373026|NCT05703607|Active Comparator|SSA: Group 8|Shingrix, 0, 2 months schedule
89373027|NCT05703607|Active Comparator|SSA: Group 9|Shingrix, 0, 6 months schedule
88845082|NCT04521361|Experimental|Patients with High extent of disease|Adult men with bone mCRPC having ≥ 6 bone metastases
88845083|NCT04520009|Active Comparator|Activity Restriction|Discharge orders for activity restriction
88845084|NCT04520009|Active Comparator|Activity As Tolerated|Discharge orders written for activity as tolerated
89181143|NCT04103840||Control|Apparently healthy Family controls
89373028|NCT05703607|Experimental|SSA: Group 10|Candidate 1, Dose level 4, lyophilized, 0, 6 months schedule
89373029|NCT05703607|Experimental|SSA: Group 11|Candidate 2, Dose level 2, lyophilized, 0, 2 months schedule
89373030|NCT05703607|Experimental|Substudy B (SSB): Group 1|Selected Vaccine candidate/dose-level/dosing schedule
89373031|NCT05703607|Active Comparator|SSB: Group 2|Shingrix
89373032|NCT05703607|Experimental|SSA: Group 12|Candidate 2, Dose level 3, lyophilized, 0, 2 months schedule
89373033|NCT05703607|Experimental|SSA: Group 13|Candidate 2, Dose level 4, lyophilized, 0, 2 months schedule
89373034|NCT05703607|Active Comparator|SSA: Group 14|Shingrix, 0, 2 months schedule
89373035|NCT05700383|Experimental|GetActive-Fitbit|GetActive-Fitbit is an adaptation of the original GetActive-Fitbit program, a mind-body program for the unique needs of individuals with chronic musculoskeletal pain that incorporates activity skills to help individuals improve all aspects of physical function. The GetActive-Fitbit sessions address mind-body skills (e.g., mindfulness, deep breathing, self-compassion), walking skills (e.g., step goals, quota-based pacing), and skills to change thinking (e.g., identify unhelpful thoughts about pain and activity, challenging thoughts). The format is a 10-week program delivered in-person with weekly group sessions and home practice of skills and walking.
89373036|NCT05700383|Active Comparator|Healthy Living for Pain|Healthy Living for Pain is an active intervention that will be dose, attention, and time matches to the GetActive-Fitbit program. Healthy Living for Pain is an adaptation of the Health Enhancement Program, developed by Dr. Vranceanu and colleagues from Stony Brook, with adjustments for patients with chronic musculoskeletal pain. The Healthy Living for Pain sessions provide educational information on chronic musculoskeletal pain, the role of sleep and nutrition, physical activity, healthcare management, medication use, and social connection. The format is a 10-week program delivered in-person with weekly group sessions and home practice journaling.
89373037|NCT05699174|Active Comparator|Standard of Care PO (oral) antibiotics|An intervention in this study includes randomization of patients with an infected nonunion to standard of care PO (oral) antibiotics for up to 6 weeks post hospitalization. No medications will be provided by the study. Study participants will be prescribed their oral antibiotics by their treating physician and the specific type will depend on their infection diagnosis. Medications will be obtained using health insurance and/or resources available at the treating facility therefore the mode of antibiotics utilized as standard of care will vary across participating sites. Sites will follow their standard of care delivery for antibiotics and the study will defer to this standard.
88845085|NCT04517253|Experimental|Baricitinib|"CANDLE:~Participants with chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE) received an optimized dosage of baricitinib that was determined throughout the dose-adjustment period administered as tablets or oral suspension based on participants weight and estimated glomerular filtration rate (eGFR).~SAVI:~Participants with STING-associated vasculopathy with onset during infancy (SAVI) received an optimized dosage of baricitinib that was determined throughout the dose-adjustment period administered as tablets or oral suspension based on participants weight and estimated glomerular filtration rate (eGFR).~Aicardi-Goutières Syndrome (AGS):~Participants with Aicardi-Goutières Syndrome (AGS) received an optimized dosage of baricitinib that was determined throughout the dose-adjustment period administered as tablets or oral suspension based on participants weight and estimated glomerular filtration rate (eGFR)."
88845086|NCT04513899|Experimental|Community Health Worker/Registered Nurse (CHW/RN)|Nurse-led Community Health Worker (CHW/RN) program delivered DOT for HCV treatment.
88845087|NCT04513899|Active Comparator|Clinic-based Standard of Care (cbSOC)|Standard of care for HCV treatment delivered by a clinic-based MD or clinic-based NP at the clinic site
88845088|NCT04499950|Experimental|SLOW-BWL|All patients will receive the POWER-remote behavioral weight loss intervention (BWL) and have a behavioral coach for the duration of the 6 month study. During months 1-3, the behavioral coach will call weekly. From months 4-6, the behavioral coach will call monthly. At week 9, those who lose <5%, designated slow responders, will continue BWL and initiate Contrave (SLOW-BWL). The SLOW-BWL arm will receive at least 16 weeks of Contrave [as per the Food and Drug Administration (FDA) recommended administration] starting at week 9 and discontinue if ≥5% weight loss is not achieved at month 6.
88845089|NCT04499950|Active Comparator|FAST-BWL|All patients will receive the POWER-remote behavioral weight loss intervention (BWL) and have a behavioral coach for the duration of the 6 month study. During months 1-3, the behavioral coach will call weekly. From months 4-6, the behavioral coach will call monthly. At week 9, those who lose ≥5%, designated fast responders, will continue with BWL alone (FAST-BWL)
88845090|NCT04478279|Experimental|Dose Escalation|This cohort only patients diagnosed with locally advanced or metastatic melanoma, carcinoma or sarcoma of any tumor type who are refractory or intolerant to all available therapies. ST101 will be administered intravenously (IV), initially once per week.
88845091|NCT04478279|Experimental|Dose Expansion HR+ Breast|This cohort must have progressed after 1-2 hormone based therapies. The starting dose of ST101 for Expansion will be derived from the maximum tolerated dose (MTD)/recommended dose for expansion (RDE) and the best dosing schedule determined during Dose Escalation.
88845092|NCT04478279|Experimental|Dose Expansion Melanoma|This cohort must have Melanoma that has progressed after/or on treatment with an immune checkpoint inhibitor (CPI) and have received 1-2 prior lines of therapy for their advanced/metastatic disease. The starting dose of ST101 for Expansion will be derived from the maximum tolerated dose (MTD)/recommended dose for expansion (RDE) and the best dosing schedule determined during Dose Escalation.
89373038|NCT05699174|Active Comparator|Standard of Care Intravenous (IV) antibiotics|An intervention in this study includes randomization of patients with an infected nonunion to intravenous (IV) antibiotics for up to 6 weeks post hospitalization. No medications will be provided by the study. Study participants will be prescribed their IV antibiotics by their treating physician and the specific type will depend on their infection diagnosis. Medications will be obtained using health insurance and/or resources available at the treating facility therefore the mode of antibiotics utilized as standard of care will vary across participating sites. Sites will follow their standard of care delivery for antibiotics and the study will defer to this standard.
89373040|NCT05684796|Active Comparator|Anticoagulation (AC)|Subjects will have their pulmonary embolism treated with anticoagulants alone. There will be no procedure for this group.
89373041|NCT05684796|Active Comparator|Indigo|Subjects will have their pulmonary embolism treated with anticoagulants and mechanical aspiration thrombectomy with the Indigo® Aspiration System.
89373042|NCT05684562||Fontan group|Cardiopulmonary exercise test Pulmonary function test respiratory muscle strength test
89373043|NCT05684562||Control Group|Cardiopulmonary exercise test Pulmonary function test respiratory muscle strength test
89373044|NCT05683691|Experimental|Vanquish System Treatment|
89373045|NCT05682443|Experimental|Arm A: ONC-392 10 mg/kg, Q4W plus lutetium Lu 177 vipivotide tetraxetan 7.4 GBq, Q6W|Arm A receives ONC-392, 10 mg/kg, Q4W, IV infusion for up to 13 doses, plus lutetium Lu 177 vipivotide tetraxetan 7.4 GBq (200 mCi), IV infusion, Q6W for up to 6 doses.
89373046|NCT05682443|Active Comparator|lutetium Lu 177 vipivotide tetraxetan 7.4 GBq, Q6W|lutetium Lu 177 vipivotide tetraxetan 7.4 GBq (200 mCi), IV infusion, Q6W for up to 6 doses.
89373047|NCT05677256|Experimental|IPV-primed Group|Approximately 250 subjects to receive 3 doses of IPV administered at approx. 6, 10, 14 weeks of age and an nOPV2-002 challenge at approx. 18 weeks of age.
89373048|NCT05677256|Active Comparator|bOPV-primed Group|Approximately 250 subjects to receive 3 doses of bOPV administered at approx. 6, 10, 14 weeks of age and an nOPV2-002 challenge at approx. 18 weeks of age.
89373049|NCT05675956|Experimental|High Intensity|The device will be set to 100% intensity for this group.
89373050|NCT05675956|Active Comparator|Low Intensity|The device will be set to 10% intensity in this group
89534977|NCT05017467|Experimental|QuickDASH , VAS|, Quick Disabilities of Arm Shoulder and Hand functional score (QuickDASH) and Visual Analogue Scale (VAS) test was used to determine overall hand function, activities of daily living, work performance, pain, aesthetics, and satisfaction with hand function
89534978|NCT03326375|Experimental|SBRT (Stereotatic body radiotherapy)|Treatment of SBRT in HCC patients who have incomplete response after first TACE
89534979|NCT03326375|No Intervention|TACE (Transarterial chemoembolization)|Treatment of repeated TACE in HCC patients who have incomplete response after first TACE
89534980|NCT03331679|Experimental|2 Wk HIIT|2 weeks of High Intensity Interval Training
89534981|NCT05024019|Experimental|Study group|The study group received nimotuzumab (200mg, weekly, for 6 weeks) combined with concurrent radiotherapy.
89534982|NCT05024019|No Intervention|Control group|The control group received radiotherapy alone.
89373057|NCT05674656|Experimental|Dolutegravir(DTG)/Rilpivirine (RPV)|
89373058|NCT05672771|Experimental|Different Mixed Condition (DM)|Training in both Lexical Decision Span and Category Span in Phase 1 (which are both different from the target task Reading Span in Phase 2).
89373059|NCT05672771|Experimental|Different Single Condition (DS)|Training in the Lexical Decision Span in Phase 1 (which is different from the target task Reading Span in Phase 2).
89373060|NCT05672771|Active Comparator|Same Task (ST) Practice Control|Training in Reading Span task in Phase 1 (which is the same as target task in Phase 2).
89373061|NCT05672771|Placebo Comparator|Non-WM Placebo Control (PC)|Training in a speeded Lexical Decision task only (which has no memory component) in Phase 1 prior to Phase 2 training in WM.
89373062|NCT05667493|Experimental|Eplontersen|Eplontersen will be administered once every month by sub-cutaneous (SC) injection for up to 36 months or 6 months after eplontersen is approved and available in the site's country, whichever occurs first.
89534983|NCT03326297|Experimental|Osteopathy manual therapy|Osteopathy manual therapy applying the following treatment: Technique for the treatment of parasympathetic innervation, Techniques for the treatment of sympathetic innervation of the digestive system, Functional visceral techniques.
89373064|NCT05666570||Avelle NPWT|Avelle Negative Pressure Wound Therapy administered as indicated by the IFU.
89534984|NCT03326297|Active Comparator|Measures to support and education to the family|Measures to support and education to the family that consist on pedagogical intervention in parents, health education.
89534985|NCT03326297|No Intervention|No specific intervention|No specific intervention, prescriptions by pediatrician
89534986|NCT05017077|Experimental|Telemonitoring|To evaluate the feasibility and efficacy of a new model of tele monitoring in pediatric population in advanced heart failure, we will enroll 20 patients in advanced NYHA/Ross class in waiting list for Heart Transplant. An home telemonitoring capable to detect vital parameters as heart rate, body temperature, blood pressure, oxygen saturation, breathe frequency, weight, arrhythmias and cardiac index may offers to physician valuable information able to strictly monitoring the clinical status of patients
89534987|NCT03326219|Other|Aethoxysklerol clarivein during leg amp|Clarivein treatment with Aethoxysklerol in 5 patients during lower or upper leg amputation
89534988|NCT05008731|Experimental|Group 1|botulinum toxin: 100 units (0.5ml) in 1 injection
89373071|NCT05652868|Experimental|Part 1 Dose Escalation|Part 1 patients will receive MYTX-011.
89373072|NCT05652868|Experimental|Part 2 Cohort A|Part 2 Cohort A patients will be randomized to two different dose levels of MYTX-011. Doses to be determined after completion of Part 1.
89373073|NCT05652868|Experimental|Part 2 Cohort B|Part 2 Cohort B patients will receive MYTX-011 at the recommended phase 2 dose.
89373074|NCT05652868|Experimental|Part 2 Cohort C|Part 2 Cohort C patients will receive MYTX-011 at the recommended phase 2 dose.
89373075|NCT05652868|Experimental|Part 2 Cohort D|Part 2 Cohort D patients will receive MYTX-011 at the recommended phase 2 dose.
89373076|NCT05652868|Experimental|Part 2 Cohort E|Part 2 Cohort E patients will receive MYTX-011 at the recommended phase 2 dose.
89373082|NCT05646862|Experimental|Inavolisib + Fulvestrant|Participants will be administered the treatments as outlined in the interventions section.
89373083|NCT05646862|Active Comparator|Alpelisib + Fulvestrant|Participants will be administered the treatments as outlined in the interventions section.
89373084|NCT05646836|Experimental|Arm A: Dose-Escalation and Expansion: XmAb24306+Cevostamab|Participants will receive escalating doses of XmAb24306 with a fixed dose regimen for cevostamab up to the maximum tolerated dose (MTD). After dose escalation has been completed, up to two expansion cohorts each investigating different XmAb24306 doses in combination with cevostamab may be enrolled.
89373085|NCT05646836|Experimental|Arm B: Single-Agent Cevostamab Expansion|Participants will receive cevostamab alone.
89373086|NCT05646420|Experimental|ADPKD patients|"The study will include 90 patients with diagnosis of ADPKD based on renal ultrasonography findings or genetic test.~Specifically, five groups of patients will be identified according to KDIGO classification:~18 subjects with normal or high renal function: eGFR ≥90 ml/min/1.73m2 - CKD G1 stage~18 subjects with mildly decreased renal function: eGFR 89-60 ml/min/1.73m2 - CKD G2 stage~18 subjects with mildly to moderately decreased renal function: eGFR 59 to 45 ml/min/1.73m2 - CKD G3a stage~18 subjects with moderately to severely decreased renal function: eGFR 44 to 30 ml/min/1.73m2 - CKD G3b stage~18 subjects with severely decreased renal function: eGFR 29 to 15 ml/min/1.73m2 - CKD G4 stage."
89373087|NCT05642468|Experimental|10 mg (Arm 1)|10mg tablet A3907 administered orally once daily for 12 weeks.
89181144|NCT02601404||Bioresorbable Scaffold|Patients receiving percutaneous coronary intervention (PCI) for coronary artery disease using Absorb™(Abbott Vascular)
89373088|NCT05642468|Experimental|30 mg (Arm 2)|30mg (3x10 mg tablets) A3907 administered orally once daily for 12 weeks.
88845093|NCT04478279|Experimental|Dose Expansion GBM|Primary (de novo) GBM that has recurred or progressed (per modified RANO criteria) after 1 standard treatment regimen. Standard therapy is defined as maximal surgical resection, radiotherapy, and concomitant temozolomide with radiotherapy or adjuvant chemotherapy with temozolomide. The starting dose of ST101 for Expansion will be derived from the maximum tolerated dose (MTD)/recommended dose for expansion (RDE) and the best dosing schedule determined during Dose Escalation.
89373089|NCT05642468|Experimental|30 mg BID (Arm 3)|30mg (3x10 mg tablets) A3907 administered orally Bi-daily for 12 weeks.
89373090|NCT05642468|Experimental|30 mg BID for CRS (Arm 4)|30mg (3x10 mg tablets) A3907 administered orally Bi-daily for 12 weeks.
89534989|NCT05008731|Placebo Comparator|Group 2|Placebo: 0.5 ml in 1 injection
89534990|NCT03331523|Experimental|Calcipotriene/betamethasone dipropionate|
89373093|NCT05639231|Experimental|INTOMOB intervention|"The intervention will be multilevel, targeting the patients, healthcare professionals (HCPs) and environment, as described under Intervention description."
88845094|NCT04478279|Experimental|Dose Expansion CRPC|CRPC that has progressed after previous treatment with taxanes, abiraterone and enzalutamide/apalutamide. The starting dose of ST101 for Expansion will be derived from the maximum tolerated dose (MTD)/recommended dose for expansion (RDE) and the best dosing schedule determined during Dose Escalation.
88845095|NCT04478279|Experimental|Dose Expansion Recurrent Glioblastoma|Recurrent GBM patients must have completed radiation at least 3 months prior to minimize the inclusion of patients with pseudoprogression. Recurrent GBM patients must have unequivocal radiographic evidence of tumor progression by contrast-enhanced magnetic resonance imaging (MRI) scan within 21 days prior to registration. Patients must be able to delay surgery for 2 - 4 weeks per investigator decision
88845096|NCT04478279|Experimental|Newly Diagnosed Glioblastoma|Newly diagnosed patients with a suboptimal resection or biopsy must be candidates for another surgical resection as determined by neurosurgical evaluation or multidisciplinary team based on the current standard of care that suggests that maximal safe resection is beneficial. Recurrent GBM patients must be candidates for tumor resection
89373094|NCT05639231|No Intervention|Control|"Control procedure in the randomized trial:~Patients will receive standard of care, including physiotherapy if prescribed by the hospital physician and usual mobility recommendations and support by the HCPs.~HCPs will neither complete the e-learning, nor receive the checklist and the oral presentation.~The environment will not be modified in regards to mobility. Already existing information on this topic (e.g., small posters hanging in patient rooms) will not be removed, since it corresponds to current standard of care in some hospitals.~In the pilot study, there will be no control procedure, since the objective is to assess experience and feasibility of the intervention, not its effects."
89373095|NCT05639036|Active Comparator|Control-Free Hand External Ventricular Drain Placement|This group will receive an external ventricular drain placed using the standard free-hand technique
89373096|NCT05639036|Experimental|Intervention - Image Guided External Ventricular Drain Placement Using the NAV3 System|This group will receive an external ventricular drain placed using the assistance of the Stryker NAV3 image guidance system
89373097|NCT05638295|Experimental|Cohort I Arm A (sotorasib, panitumumab)|Patients receive sotorasib PO QD on days 1-28 and panitumumab IV on days 1 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood samples, biopsy, and CT or MRI on study.
88845097|NCT04474613|Experimental|Liquid biopsy|A liquid biopsy is a test will be done on a sample of blood to look for cancer cells
88845098|NCT04471506|Other|study group will receive interval training and diet advices|exercise program in form of a cycling protocol which will be comprised 5 minutes of warming up before exercise initiation and another 5 minutes for cooling down by the end of the exercise session in the form of slow pedaling (50% of PHR). The work interval also will be consisted of 8-12 cycling intervals (60s cycling work interval with 120s of passive rest or low-intensity cycling (70% of PHR) between work intervals that progressively will be reduced until reaching 90s by the end of the exercise program)17.
88845099|NCT04471506|Other|diet recommendations|The control group will receive diet recommendations. The volunteers will follow diet recommendations for 12 weeks
89373098|NCT05638295|Active Comparator|Cohort I Arm B (sotorasib)|Patients receive sotorasib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may cross-over to cohort II. Patients also undergo collection of blood samples, biopsy, and CT or MRI on study.
89373099|NCT05638295|Experimental|Cohort II (sotorasib, panitumumab)|Patients receive combination therapy as in Arm A.
89373100|NCT05633355|Experimental|Rocatinlimab|Rocatinlimab will be administered subcutaneously every 4 weeks (Q4W) for 52 weeks with one additional dose at Week 2.
89373101|NCT05630781|Active Comparator|Control Arm|80 Volunteers who are between the ages of 18-60 and are non-smokers/vapers. 1. Baseline visit with 1 fMRI scans pre- and post-20mg methylphenidate, 4 acute drug administration (6-14 days in randomized order: 1. Placebo + placebo; 2. 20mg suvorexant + Placebo; 3. Placebo + 40mg methylphenidate; 4. 20 mg suvorexant + 40mg methylphenidate max)
89373102|NCT05630781|Experimental|Nicotine Dependence Arm|140 Volunteers who are between the ages of 18-60 and are daily smokers/vapers. Suvorexant at 10 mg single dose, and Suvorexant at 10 mg daily for approximately 7 days.
89373103|NCT05629078|Active Comparator|Toric Intraocular lens|Toric intraocular lens- AT TORBI® 709M, to be implanted bilaterally in the cataract surgery to correct astigmatism at the same time.
89373104|NCT05629078|Active Comparator|Monofocal intraocular lens|Standard monofocals IOLs- Zeiss CT ASPHINA 409/509M, to be implanted bilaterally in the standard NHS cataract surgery without correcting the astigmatism.
89373105|NCT05627557|Experimental|Obinutuzumab (Group A)|Participants in Group A will receive obinutuzumab 1000 milligrams (mg) (or 20 mg/ kilogram [kg] for participants <45 kg) administered by intravenous (IV) infusion on Days 1, 15, 168 (Week 24), and 182 (Week 26).
89534991|NCT03331523|Active Comparator|Taclonex®|
89534992|NCT03331523|Placebo Comparator|Placebo|
89534993|NCT05023863|Active Comparator|Alpha Lipoic Acid Group (intervention group)|35 patients will receive radiation therapy with or without platinum-based chemotherapy in addition to alpha lipoic acid 600 mg tablets twice daily (throughout the radiotherapy period). .
88845100|NCT04453202|Experimental|Cohort 1 Group 1: RSV Vaccine|Participants will receive a single intramuscular (IM) injection of an Ad26-based RSV vaccine on Day 1.
88845101|NCT04453202|Experimental|Cohort 1 Group 2: RSV Vaccine|Participants will receive a single IM injection of an Ad26-based RSV vaccine (low dose 1) on Day 1.
88845102|NCT04453202|Experimental|Cohort 1 Group 3: RSV Vaccine|Participants will receive a single IM injection of an Ad26-based RSV vaccine (low dose 2) on Day 1.
88845103|NCT04453202|Experimental|Cohort 1 Group 4: RSV Vaccine|Participants will receive a single IM injection of an Ad26-based RSV vaccine (low dose 3) on Day 1.
88845104|NCT04453202|Placebo Comparator|Cohort 1 Group 5: Placebo|Participants will receive IM injection of placebo on Day 1.
88845105|NCT04453202|Experimental|Cohort 2 Group 6: RSV Vaccine|Participants will receive a single IM injection of an Ad26-based RSV vaccine on Day 1.
88845106|NCT04453202|Experimental|Cohort 2 Group 7: RSV Vaccine|Participants will receive a single IM injection of an Ad26-based RSV vaccine (high dose 1) on Day 1.
88845107|NCT04453202|Placebo Comparator|Cohort 2 Group 8: Placebo|Participants will receive IM injection of placebo on Day 1.
88845108|NCT04453202|Experimental|Cohort 3 Group 9: RSV Vaccine|Participants will receive a single IM injection of an Ad26-based RSV vaccine on Day 1.
88845109|NCT04453202|Experimental|Cohort 3 Group 10: RSV Vaccine|Participants will receive a single IM injection of an Ad26-based RSV vaccine (high dose 2) on Day 1.
88845110|NCT04453202|Experimental|Cohort 3 Group 11: Placebo|Participants will receive IM injection of placebo on Day 1.
88845111|NCT04420975|Experimental|Treatment (BO-112, nivolumab)|Patients receive BO-112 intratumorally on days 8 and 15 or 1, 8, and 15 and nivolumab IV over 30-60 minutes on day 8 in the absence of disease progression or unacceptable toxicity. Patients also undergo standard of care radiation therapy on days 8-12 for a total of 5 fractions. Patients then undergo standard of care definitive surgical resection on day 26 to 50.
88845112|NCT04416581|Experimental|P-CAB 50mg group|tegoprazan 50 mg + rabeprazole 20mg placebo, once daily.
88845113|NCT04416581|Active Comparator|PPI group|rabeprazole 20mg + tegoprazan 50 mg placebo, once daily.
88845114|NCT04416204|Experimental|Type 2 diabetes|Participants with Type 2 Diabetes received Glycogen loading (GL) and Non-Glycogen loading (NGL) meal in a randomized manner.
88845115|NCT04416204|Experimental|Participants without diabetes|Participants with no Diabetes received Glycogen loading (GL) and Non-Glycogen loading (NGL) meal in a randomized manner.
89373106|NCT05627557|Active Comparator|MMF (Group B)|Participants in Group B will receive oral MMF 600 mg/m^2 twice a day (BID) (target 1200 mg/m2/day in divided doses, maximum 2 g/day) to Week 52.
89373107|NCT05627362|Experimental|Double-Blind Period: Elafibranor 80 mg|Participant will receive two tablets per day (one tablet of elafibranor 80 mg + 1 tablet of placebo matching the 120 mg sized tablet) over the 12 weeks in Double-blind period.
89373108|NCT05627362|Experimental|Double-Blind Period: Elafibranor 120 mg|Participant will receive 2 tablets per day (one tablet of elafibranor 120 mg + 1 tablet of placebo matching the 80 mg sized tablet) over the 12 weeks in Double-blind period.
89373109|NCT05627362|Placebo Comparator|Double-Blind Period: Placebo|Participant will receive 2 placebo tablets per day (one matching the 80 mg sized tablet + one matching the 120 mg sized tablet) over the 12 weeks in Double-blind period.
89373110|NCT05627362|Experimental|Open-Label Extension Period: Elafibranor 120 mg|Participant will receive one tablet per day (elafibranor 120 mg) over the 96 weeks in Open-Label extension period.
89534994|NCT05023863|Placebo Comparator|Control Group|35 Patients will receive radiation therapy with or without platinum-based chemotherapy in addition to placebo tablets twice daily (throughout the radiotherapy period)
89373112|NCT05609825|Experimental|LY3875383 (Part A)|Single-ascending doses of LY3875383 administered subcutaneously (SC).
89373113|NCT05609825|Experimental|LY3875383 (Part B)|Single doses of LY3875383 administered SC.
88845116|NCT04403633|Experimental|Receiving Educational Tool|Patients in this arm will receive the educational tool after the pretest in addition to usual care.
88845117|NCT04403633|No Intervention|Receiving Usual Care|Patients in this arm will receive usual care after the pretest.
88845118|NCT04396236|Experimental|Lasmiditan High Dose|Lasmiditan administered orally with matching placebo to maintain the blind.
88845119|NCT04396236|Experimental|Lasmiditan Mid Dose|Lasmiditan administered orally with matching placebo to maintain the blind.
88845120|NCT04396236|Experimental|Lasmiditan Low Dose|Lasmiditan administered orally with matching placebo to maintain the blind.
88845121|NCT04396236|Placebo Comparator|Placebo|Placebo administered orally.
88845122|NCT04391270|Experimental|web-based intervention group|"Except Library, the participants in this group will also have access to the Intervention sub-section of the website. It will consist of six sessions delivered every two weeks following the same time schedule as the essay delivery in Library."
88845123|NCT04391270|Experimental|blended intervention group|"Except visiting Library and Intervention of the website, the participants in this group will also receive three face-to-face workshops (40 min per session) held at their workplaces."
88845124|NCT04391270|No Intervention|Control group|"The participants in the control group will have access to the Library sub-section of the website. General information of MVPA, health and work productivity will be provided with 18 short essays, which can be downloaded and printed out. The information will be factual and non-personally tailored."
88845125|NCT04375800|Experimental|Doravirine + 2 NRTIs|Participants receive DOR (3.2 mg to 100 mg based on weight) in combination with 2 NRTIs (based on local label) for 96 weeks.
89002206|NCT06013930|Experimental|Mindfulness Meditation|Participants will meet individually with the mindfulness practitioner once a week for three weeks for 30-minute segments.
89373114|NCT05609825|Experimental|LY3875383 (Part C)|Single doses of LY3875383 administered SC.
89373115|NCT05609825|Experimental|LY3875383 (Part D)|Single doses of LY3875383 administered SC.
89373116|NCT05609825|Placebo Comparator|Placebo (Part A)|Placebo administered SC.
89373117|NCT05609825|Placebo Comparator|Placebo (Part B)|Placebo administered SC.
89373118|NCT05609825|Placebo Comparator|Placebo (Part C)|Placebo administered SC.
89373119|NCT05609825|Placebo Comparator|Placebo (Part D)|Placebo administered SC.
89373120|NCT05608148|Experimental|GAIA-102 alone|GAIA-102: 5 x 10^6 cells / dose at a fixed dose, 1 to 3 doses / week for 3 consecutive weeks
89373121|NCT05608148|Experimental|GAIA-102 with Dinutuximab, Filgrastim, Teceleukin combination|GAIA-102: 5 x 10^6 cells / dose at a fixed dose, 1 to 3 doses / week for 3 consecutive weeks Filgrastim: 5 µg/kg/day on Day1-14 Teceleukin: 750,000 units/m2/day on Day29-31 and 1,000,000 units/m2/day on Day 36- 39 Dinutuximab: 17.5mg/m2/day on Day4-7 and Day36-39
89373122|NCT05608148|Experimental|GAIA-102 with Nivolumab combination|GAIA-102: 5 x 10^6 cells / dose at a fixed dose, 3 doses / week for 3 consecutive weeks Nivolumab: 3mg/kg/day(Children) or 240mg/day(Adults) on Day1
89373123|NCT05604131|Active Comparator|Hemorrhagic Myocardial Infarction - Deferiprone|Enrolled patients with CMR confirmed presence of intramyocardial hemorrhage
89373124|NCT05604131|Active Comparator|Non-hemorrhagic Myocardial Infarction - Deferiprone|Enrolled patients with CMR confirmed absence of intramyocardial hemorrhage
89373125|NCT05604131|Placebo Comparator|Hemorrhagic Myocardial Infarction - Placebo|Enrolled patients with CMR confirmed presence of intramyocardial hemorrhage
89373126|NCT05604131|Placebo Comparator|Non-hemorrhagic Myocardial Infarction - Placebo|Enrolled patients with CMR confirmed absence of intramyocardial hemorrhage
89399280|NCT02172638|Active Comparator|Classical management group|Patients assigned to this group will receive the standard management preformed in our center until now. This management includes a preoperatory control exclusively by the surgeon and anesthetist, minimum of 8h fasting previous to surgery, loose use of intraabdominal drainage , systematic use of nasogastric tube whenever rectum resection or omentectomy is performed, Postoperative analgesia following standing Vall d'Hebron protocols for Moderate-severe postoperative pain, which include use of combined analgesia with non opioids drugs and major Opioids, and usual flexible, non standardized postoperatory management with mobilization and oral intake progression depending on perceived evolution by attending surgeon.
89399281|NCT03538886|Active Comparator|Percutaneous coronary intervention (PCI)|Currently, percutaneous coronary intervention (PCI) using balloon and drug eluting stents is the treatment of choice for treatment of a proximal LAD lesion.
89399282|NCT03538886|Experimental|Coronary artery bypass grafting (CABG)|Coronary artery bypass grafting is a well established treatment with documented excellent long-term results for the treatment of proximal LAD lesion.
89373127|NCT05603910|Experimental|Lenvatinib, Pembrolizumab and Hypofractionated (Hypofx) External Beam Radiation Therapy (EBRT) Group|"Participants in this group will receive a combination treatment of Lenvatinib, Pembrolizumab, and Hypofx Pelvic EBRT over a period of approximately 10 to 12 weeks.~Lenvatinib - administered in a 3 plus 3 escalation/de-escalation design. Participants will receive 1 of 4 of the following dose levels:~Dose level 1- 4 mg Dose level 2- 8 mg Dose level 3 (Starting dose) - 12 mg Dose level 4- 16 mg~Pembrolizumab- 200 mg IV will be administered on Day 1, 22 and 43~HypoFx whole pelvic EBRT begins on Day 22 and continues for a total of 16 fractions of radiation given at a dose of 2.5 Gy per fraction for a total dose of 40.0 Gy delivered to the pelvis. A pelvic boost HypoFx EBRT consisting of 7 fractions of radiation given at a dose of 2.5 Gy per fraction that will be delivered to site(s) of gross disease of at least 1.0 cm in size. An additional boost total dose of 17.5 Gy administered will be administered over a period of 1.5 to 2.0 weeks."
89534995|NCT05463809|Experimental|Experimental group: Ropivacaine-controlled analgesia pump|A single injection of 0.375% Ropivacaine 15 milliliters was given into the common peroneal nerve, medial sural cutaneous nerve, and lateral sural cutaneous nerve. Than，a catheter was placed in the gastrocnemius plane, and a 0.125% ropivacaine-controlled analgesic pump was applied.(The formulation was 0.125% ropivacaine at 300 milliliters, with a background dose of 3 milliliters/hours, a patient-controlled analgesia(PCA) dose of 8 milliliters, and a locking time of 25 minutes.）
89373129|NCT05596409|Experimental|Elacestrant|Subjects will take a starting dose of 400 mg of elacestrant dihydrochloride in tablet form once daily for up to 6 months.
89373130|NCT05590793|Experimental|Triptorelin pamoate 22.5 mg 6-month formulation|All enrolled participants will receive one intramuscular (i.m.) injection of containing 22.5 mg 6-month formulation triptorelin pamoate on Day 1.
89373131|NCT05590442||Training cohort|The patients will be divided into the training and validation cohorts with a ratio of 7:3. The training cohort will be used to screen variables and construct the model.
89373132|NCT05590442||Validation cohort|The validation cohort will be used to validate the results obtained using the training cohort.
89373133|NCT05581303|Placebo Comparator|Placebo|Placebo will be administered by subcutaneous injection
89373134|NCT05581303|Experimental|Olpasiran|Olpasiran will be administered by subcutaneous injection
89373135|NCT05563363|Experimental|Home treatment|Home visits by care staff at the same frequency as in hospital
89373136|NCT05563363|Active Comparator|Standard inpatient treatment|Inpatient treatment on hospital ward
89373137|NCT05563246|Experimental|LY3473329 Dose 1|Participants will receive LY3473329 orally.
89373138|NCT05563246|Experimental|LY3473329 Dose 2|Participants will receive LY3473329 orally.
89373139|NCT05563246|Experimental|LY3473329 Dose 3|Participants will receive LY3473329 orally.
89373140|NCT05563246|Placebo Comparator|Placebo|Participants will receive placebo orally.
89373141|NCT05554328|Experimental|Arm I (selumetinib, olaparib)|Patients receive selumetinib PO BID and olaparib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo a tumor biopsy and blood collection during screening and on study, as well as ECHO or MUGA, and CT scans throughout the trial. Patients may undergo bone marrow aspiration or biopsy as clinically indicated.
89373142|NCT05554328|Active Comparator|Arm II (selumetinib)|Patients receive selumetinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who experience progression may elect to cross over to Arm I provided they have not had dose limiting toxicities to monotherapy selumetinib. Patients also undergo a tumor biopsy and blood collection during screening and on study, as well as ECHO or MUGA, and CT scans throughout the trial. Patients may undergo bone marrow aspiration or biopsy as clinically indicated.
89373143|NCT05554224||Severe obesity without liver disease|Patients with severe obesity who did not meet the criteria described in Kleiner et al. (2005) for nonalcoholic steatohepatitis diagnosis (score 0-2).
89373144|NCT05554224||Severe obesity with liver disease without criteria for steatohepatitis|Patients with severe obesity who did not meet the criteria described in Kleiner et al. (2005) for nonalcoholic steatohepatitis diagnosis, but their biopsies presented some liver severity (scores 3 and 4).
88810161|NCT01310855|Active Comparator|Cediranib & Gefitinib|Cediranib maleate 30mg od orally and gefitinib 500mg od orally. Each cycle of treatment lasts 6 weeks. Treatment will continue until confirmation of progression, patient decision or the development of unacceptable toxicity (if there is radiological progression only treatment can continue if the investigator has the opinion that the patient is receiving benefit.
89373145|NCT05554224||Severe obesity with well-defined steatohepatitis and/or cirrhosis|Patients with severe obesity who met the criteria described in Kleiner et al. (2005) for nonalcoholic steatohepatitis diagnosis (score 5-8).
89002207|NCT06013930|Active Comparator|Psychoeducation|In the psychoeducation arm, participants will receive recordings online, once a week for three weeks which will be approximately 30 minutes in length.
89002208|NCT06006221|Experimental|experimental group|After the morning meeting, the initiative group will be given 40 minutes of Qigong relaxation exercise.
89373146|NCT05552963|Experimental|Irreversible Electroporation (IRE) System|Participants with symptomatic drug refractory paroxysmal atrial fibrillation (PAF) and indicated for catheter ablation will be treated with the IRE system which includes multi-electrode circular IRE catheter and the multi-channel IRE generator.
89373147|NCT05552612||Long COVID|Patients with Long COVID
89373148|NCT05552612||Without Long COVID|Patients who do not have Long COVID
89373153|NCT05544227|Experimental|SV-102 Treatment Arm|SV-102 Treatment Arm
89373154|NCT05538897|Experimental|Phase Ib (megestrol acetate, ipatasertib)|Patients receive megestrol acetate PO QD on days 1-28 and ipatasertib PO QD on days 1-21 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo a CT or MRI during screening, on study, and during follow-up. Patients also undergo collection of blood samples throughout the trial.
88845126|NCT04373330|Experimental|Intensive lifestyle intervention|The intensive lifestyle intervention used in HELP PD and that will be used in HELP-VM was a modification of the successful Diabetes Prevention Program (DPP) core curriculum adapted for use in groups. The 16-session core curriculum used in DPP, covering key concepts related to energy balance, nutrition, and physical activity, was expanded to include regular sessions focused on group problem-solving of barriers and issues specific to the members and to incorporate presentations from local community groups on topics relevant to healthy living (exercise resources, etc.) The same intervention will be used in HELP-VM and will target moderate intensity physical activity (goal ≥180 min/wk). A DVD series was developed in HELP PD to standardize this core content, improve fidelity of intervention delivery, and to allow the CHWs to focus on group facilitation and problem-solving. This DVD series will also be used in HELP-VM.
88845127|NCT04373330|No Intervention|Medical Treatment as Usual|Subjects randomized to MTAU will be encouraged to continue engaging in medical treatment as per their usual. The MTAU group will complete baseline and 6-month follow-up assessments, and participants will complete daily symptom self-monitoring on the same schedule as HELP-VM participants.
88845128|NCT04370093|Experimental|Pioglitazone Drug (including Placebo)|45 mg/day- one pioglitazone tablet once daily throughout the 24 weeks of the study
88845129|NCT04370093|Experimental|Weight Loss, Behavioral|Weight loss following the Group Lifestyle Balance Program based on the Diabetes Prevention Program that utilizes cognitive behavioral strategies (goal setting, problem solving, self-monitoring, stimulus control),and provides written education materials to support health and nutrition behavior changes for weight management and disease prevention.
88845130|NCT04370093|Other|Pioglitazone + Weight Loss|Pioglitazone 45 mg/day + Weight Loss following the Group Lifestyle Balance Program based on the Diabetes Prevention Program that utilizes cognitive behavioral strategies (goal setting, problem solving, self-monitoring, stimulus control),and provides written education materials to support health and nutrition behavior changes for weight management and disease prevention.
88845131|NCT04364672|Experimental|Women with stage 1-4 newly diagnosed breast cancer|
88845132|NCT04364256|Active Comparator|Active NMES|"asymmetric biphasic waveforms at 71 pulses per second frequency (Hz), 400 s pulse duration, 5:10s on:off time (50% duty cycle), and 1.5s ramp-up time. Participants will be in control of the muscle stimulator devices at all times and will be instructed to perform all sessions in the supine position. Bilateral NMES will be delivered via asymmetric, biphasic using four cutaneous parallel channels delivered simultaneously using 2x4 or 3x5 self-adhesive electrodes. For the active NMES group, participants will be encouraged to increase the amplitude to a level of moderate discomfort, such as that experienced during conventional exercise, but not to induce pain. At minimum, the amplitude should induce visible muscle contraction."
88845133|NCT04364256|Sham Comparator|Sham NMES|The amplitude of the muscle stimulators for the Sham group will be capped at 15 milliamperes so patients will only feel cutaneous sensation without achieving muscle contraction.
88845134|NCT04349436|Experimental|RP1, intra-tumoral injection, oncolytic virus|RP1 administered as an intra-tumoral injection every 2 weeks.
89181145|NCT04099394|Experimental|Behavioral Health|Ten behavioral health classes.
89181146|NCT04099394|Active Comparator|Health Education|Ten health education classes covering healthy aging.
88845135|NCT04317612|Active Comparator|Active berry product|Once daily consumption over the period of the study
88845136|NCT04317612|Placebo Comparator|Reference product|Once daily consumption over the period of the study
88845137|NCT04317417|Experimental|Condition 1|1) Cognitive Changes after Cancer, 2) Diet, 3) Weight Management, 4) Financial Literacy and 5) Sun Protection
88845138|NCT04317417|Experimental|Condition 2|1) Cognitive Changes after Cancer, 2) Diet, 3) Weight Management, 4) Financial Literacy and 5) Acts of Kindness
88845139|NCT04317417|Experimental|Condition 3|1) Cognitive Changes after Cancer, 2) Diet, 3) Weight Management, 4) Strengths/ Achievable Goals and 5) Sun Protection
88845140|NCT04317417|Experimental|Condition 4|1) Cognitive Changes after Cancer, 2) Diet, 3) Weight Management, 4) Strengths/ Achievable Goals and 5) Acts of Kindness
88845141|NCT04317417|Experimental|Condition 5|1) Cognitive Changes after Cancer, 2) Diet, 3) Positive Reappraisal , 4) Financial Literacy and 5) Sun Protection
88845142|NCT04317417|Experimental|Condition 6|1) Cognitive Changes after Cancer, 2) Diet, 3) Positive Reappraisal , 4) Financial Literacy and 5) Acts of Kindness
88845143|NCT04317417|Experimental|Condition 7|1) Cognitive Changes after Cancer, 2) Diet, 3) Positive Reappraisal , 4) Strengths/ Achievable Goals and 5) Sun Protection
88845144|NCT04317417|Experimental|Condition 8|1) Cognitive Changes after Cancer, 2) Diet, 3) Positive Reappraisal , 4) Strengths/ Achievable Goals and 5) Acts of Kindness
88845145|NCT04317417|Experimental|Condition 9|1) Cognitive Changes after Cancer, 2) Mindfulness, 3) Weight Management, 4) Financial Literacy and 5) Sun Protection
88845146|NCT04317417|Experimental|Condition 10|1) Cognitive Changes after Cancer, 2) Mindfulness, 3) Weight Management, 4) Financial Literacy and 5) Acts of Kindness
88845147|NCT04317417|Experimental|Condition 11|1) Cognitive Changes after Cancer, 2) Mindfulness, 3) Weight Management, 4) Strengths/ Achievable Goals and 5) Sun Protection
88845148|NCT04317417|Experimental|Condition 12|1) Cognitive Changes after Cancer, 2) Mindfulness, 3) Weight Management, 4) Strengths/ Achievable Goals and 5) Acts of Kindness
88845149|NCT04317417|Experimental|Condition 13|1) Cognitive Changes after Cancer, 2) Mindfulness, 3) Positive Reappraisal , 4) Financial Literacy and 5) Sun Protection
88845150|NCT04317417|Experimental|Condition 14|1) Cognitive Changes after Cancer, 2) Mindfulness, 3) Positive Reappraisal , 4) Financial Literacy and 5) Acts of Kindness
88845151|NCT04317417|Experimental|Condition 15|1) Cognitive Changes after Cancer, 2) Mindfulness, 3) Positive Reappraisal , 4) Strengths/ Achievable Goals and 5) Sun Protection
89002209|NCT06006221|No Intervention|control group|No application will be made to the control group. The control group will continue their routine treatment in the clinic.
89181147|NCT00584805|Experimental|Vaccination|Inactivated, Dried, TSI-GSD 104, EEE
89373155|NCT05538897|Active Comparator|Phase II (megestrol acetate)|Arm I: Patients receive megestrol acetate PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo a CT or MRI during screening, on study, and during follow-up. Patients also undergo collection of blood samples throughout the trial.
89373156|NCT05538897|Experimental|Phase II (megestrol acetate, ipatasertib)|Arm II: Patients receive megestrol acetate PO QD on days 1-28 and ipatasertib PO QD on days 1-21 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo a CT or MRI during screening, on study, and during follow-up. Patients also undergo collection of blood samples throughout the trial.
89373157|NCT05535777|Active Comparator|Enhanced Text Reminders with Callback by Person|"Participants in this arm will receive up to 3 R/R messages by text. R/R message will receive a phone call back by a call center agent if they press 1 in response to a question on the original text message. The call center agent's job is to schedule patients for clinical visits. These call center agents will be trained by our faculty and staff and will have the usual HIPAA and other patient confidentiality training."
89373158|NCT05535777|Active Comparator|Enhanced Bidirectional Text Reminders|"Participants in this arm will receive a text message from a call center agent if they press 1 in response to a question on the original text message. The bidirectional texts will have an agent who can answer questions and schedule an appointment through text message back-and-forth conversations with the patient. Bidirectional texts will be exchanged on a HIPAA compliant bidirectional text messaging platform. The patient will use the regular SMS function on their cellphone and the agent will receive and respond to the bidirectional text on the HIPAA compliant platform."
89373159|NCT05535777|No Intervention|Standard Text Reminders|Participants in this arm will receive up to 3 text messages, reminding them about the importance of influenza vaccination. The standard texts will include a clinic call back number and patient portal self-scheduling for patients to schedule their influenza vaccines. The direct scheduling texts includes a direct number to an agent that can help schedule and answer questions on the phone in real time. The texts with a direct number to schedule will link a specified phone number to call and schedule. This number would be answered by a central agent quickly and a patient could schedule their flu shot at any clinic site. This specific phone number would not go through the multiple option menus a patient would normally experience when calling their clinic.
89373160|NCT05530603|Experimental|Intervention|Participants are randomized to interventional arm which is seven-day intervention that requires them to download mobile app to complete educational courses each day. There are pre and post tests to complete and a follow up focus group six month after intervention. The intervention encourages education on mammogram needs.
88845152|NCT04317417|Experimental|Condition 16|1) Cognitive Changes after Cancer, 2) Mindfulness, 3) Positive Reappraisal , 4) Strengths/ Achievable Goals and 5) Acts of Kindness
88845153|NCT04317417|Experimental|Condition 17|1) Positive Events, Capitalizing and Gratitude, 2) Diet, 3) Weight Management, 4) Financial Literacy and 5) Sun Protection
88845154|NCT04317417|Experimental|Condition 18|1) Positive Events, Capitalizing and Gratitude, 2) Diet, 3) Weight Management, 4) Financial Literacy and 5) Acts of Kindness
88845155|NCT04317417|Experimental|Condition 19|1) Positive Events, Capitalizing and Gratitude, 2) Diet, 3) Weight Management, 4) Strengths/ Achievable Goals and 5) Sun Protection
88845156|NCT04317417|Experimental|Condition 20|1) Positive Events, Capitalizing and Gratitude, 2) Diet, 3) Weight Management, 4) Strengths/ Achievable Goals and 5) Acts of Kindness
88845157|NCT04317417|Experimental|Condition 21|1) Positive Events, Capitalizing and Gratitude, 2) Diet, 3) Positive Reappraisal , 4) Financial Literacy and 5) Sun Protection
88845158|NCT04317417|Experimental|Condition 22|1) Positive Events, Capitalizing and Gratitude, 2) Diet, 3) Positive Reappraisal , 4) Financial Literacy and 5) Acts of Kindness
88845159|NCT04317417|Experimental|Condition 23|1) Positive Events, Capitalizing and Gratitude, 2) Diet, 3) Positive Reappraisal , 4) Financial Literacy and 5) Sun Protection
88845160|NCT04317417|Experimental|Condition 24|1) Positive Events, Capitalizing and Gratitude, 2) Diet, 3) Positive Reappraisal , 4) Strengths/ Achievable Goals and 5) Acts of Kindness
88845161|NCT04317417|Experimental|Condition 25|1) Positive Events, Capitalizing and Gratitude, 2) Diet, 3) Positive Reappraisal , 4) Strengths/ Achievable Goals and 5) Acts of Kindness
89181148|NCT00765674|Experimental|Aliskiren / amlodipine|Patients received an aliskiren 150 mg tablet plus an amlodipine 5 mg capsule for 4 weeks and then were force titrated up to aliskiren 300 mg plus amlodipine 10 mg for the remaining 4 weeks of the study. During the 8 weeks, patients also received a placebo tablet and a placebo capsule. Patients took a total of 4 pills each day orally with water in the morning at approximately 8:00 am, except on the morning of a study visit when they took their study medications after all visit procedures and assessments had been completed.
88845162|NCT04317417|Experimental|Condition 26|1) Positive Events, Capitalizing and Gratitude, 2) Mindfulness, 3) Weight Management, 4) Financial Literacy and 5) Acts of Kindness
88845163|NCT04317417|Experimental|Condition 27|1) Positive Events, Capitalizing and Gratitude, 2) Mindfulness, 3) Weight Management, 4) Strengths/ Achievable Goals and 5) Sun Protection
88845164|NCT04317417|Experimental|Condition 28|1) Positive Events, Capitalizing and Gratitude, 2) Mindfulness, 3) Weight Management, 4) Strengths/Achievable Goals and 5) Acts of Kindness
88845165|NCT04317417|Experimental|Condition 29|1) Positive Events, Capitalizing and Gratitude, 2) Mindfulness, 3) Positive Reappraisal , 4) Financial Literacy and 5) Sun Protection
88845166|NCT04317417|Experimental|Condition 30|1) Positive Events, Capitalizing and Gratitude, 2) Mindfulness, 3) Positive Reappraisal , 4) Financial Literacy and 5) Acts of Kindness
88845167|NCT04317417|Experimental|Condition 31|1) Positive Events, Capitalizing and Gratitude, 2) Mindfulness, 3) Positive Reappraisal , 4) Strengths/ Achievable Goals and 5) Sun Protection
88845168|NCT04317417|Experimental|Condition 32|1) Positive Events, Capitalizing and Gratitude, 2) Mindfulness, 3) Positive Reappraisal , 4) Strengths/ Achievable Goals and 5) Acts of Kindness
88845169|NCT04298905|No Intervention|Standard of Care|Individuals randomized to standard of care will receive a standardized adherence education session and provided with a paper-based diary to track appointments and adherence. Instructions will be provided on the importance of daily adherence in the primary health care facility closest to patients' residence, as per standard of care. Directly observed therapy (DOT) is recommended for all patients at patients' nearest clinic. All patients are seen face-to-face monthly for adherence monitoring, monthly symptom reports and laboratory evaluations per standard of care treatment guidelines. All research participants will also receive a clinic visit quality checklist to ensure completeness of standard of care procedures.
89373161|NCT05530603|No Intervention|Control|Participants are randomized to control arm where they are give an education brochure. There are pre and post tests to complete.
89373162|NCT05526846|Experimental|Invervention group|Participants will receive an educational intervention about how to incorporate more plant foods into their diet.
89373163|NCT05518123|Experimental|Rimegepant 75 mg|
89373164|NCT05518123|Placebo Comparator|Placebo|
89373165|NCT05516914|Experimental|LBL-007 & Tislelizumab|LBL-007 Injection; dose A or dose B; Q3W
89373166|NCT05514665||Neonates with perinatal hypoxic-ischemic brain injury|Neonates who are admitted to the Level III Neonatal Intensive Care Unit with a diagnosis of hypoxic ischemic encephalopathy will undergo diffuse optical tomography measurements prior to discharge from Neonatal Intensive Care Unit . Their developmental assessment will be performed at 6 months and 12 months postmenstrual age.
89534996|NCT05463809|Experimental|Control group: oxycodone-controlled analgesia pump|No treatment was given preoperatively, and postoperative oxycodone patient-controlled intravenous analgesia(PCIA). After awakening, intravenous oxycodone was titrated according to numerical rating scale(NRS) score, providing analgesia without background dose of oxycodone patient-controlled intravenous analgesia(PCIA) pump (single dose 1 milligram, locking time 5 minutes, 14 hours limit 12 milligrams)
89373168|NCT05503186|Experimental|Text Message Intervention Study Condition|The intervention is a text message intervention. Text messages will provide guidance on secure storage and disposal of prescription opioids to participants who have been dispensed a prescription opioid. Participants in the intervention study condition will receive a series of text messages that aim to facilitate secure storage and disposal of unused opioid prescriptions.
89373169|NCT05503186|Active Comparator|Control Study Condition|Participants assigned to the control study condition will not receive the text message intervention. Participants assigned to the control study condition will receive a standard of care of treatment which is whatever guidance that is provided to them by their physician and/or pharmacist.
88810162|NCT01310855|Placebo Comparator|Cediranbib & placebo|Cediranib maleate 30mg od orally and placebo 500mg od orally. Each cycle of treatment lasts 6 weeks. Treatment will continue until confirmation of progression, patient decision or the development of unacceptable toxicity (if there is radiological progression only treatment can continue if the investigator has the opinion that the patient is receiving benefit.
89373170|NCT05502679|Active Comparator|Traditional Group|6-week non-weight bearing of the affected lower limb rehabilitation protocol (TG)
89373171|NCT05502679|Experimental|Weight-bearing Group|Immediate lower limb weight bearing to tolerance rehabilitation protocol (WBG)
89373172|NCT05502562||Participants with type 2 diabetes|Adult participants with type 2 diabetes and naive to injectable glucose-lowering treatment.
89373173|NCT05491356|Experimental|Intervention - tPA administered|This group will receive 2mL of intra-catheter tPA during twist drill craniostomy procedure
89373174|NCT05491356|Placebo Comparator|Placebo Control|This group will receive 2mL of intra-catheter saline solution during twist drill craniostomy procedure
89373175|NCT05490238|Experimental|Distal radial access|Distal radial access using 7Fr Glidesheath Slender sheath (Terumo Corp., Japan)
89373176|NCT05490238|Active Comparator|Conventional radial access|Conventional radial access using 7Fr Glidesheath Slender sheath (Terumo Corp., Japan)
89373177|NCT05485961|Experimental|CSL300 (low dose)(Phase 2b)|Intravenous (IV) administration
88810163|NCT00773786|Experimental|Arformoterol|Arformoterol twice daily for 1 week via nebulizer
88810164|NCT00773786|Placebo Comparator|Placebo|Placebo twice daily for 1 week
89373178|NCT05485961|Experimental|CSL300 (medium dose)(Phase 2b)|IV administration
89373179|NCT05485961|Experimental|CSL300 (high dose)(Phase 2b)|IV administration
89373180|NCT05485961|Placebo Comparator|Placebo (Phase 2b)|IV administration
89373181|NCT05485961|Experimental|CSL300 (Phase 3)|IV administration
89373182|NCT05485961|Placebo Comparator|Placebo (Phase 3)|IV administration
89373183|NCT05484622|Experimental|Safety Lead-In Phase: Vorasidenib + Pembrolizumab|Participants will receive vorasidenib orally, once daily (QD) in combination with pembrolizumab 200 mg intravenous (IV) infusion, once every 3 weeks (Q3W) in each 21-day cycle until disease progression, unacceptable toxicity or other discontinuation criteria are met.
89373184|NCT05484622|Experimental|Randomized Perioperative Phase: Vorasidenib + Pembrolizumab|Participants will receive vorasidenib recommended combination dose (RCD) determined in the Safety Lead-in phase, orally, QD from Day 1 to 28 in combination with pembrolizumab 200 mg IV infusion, Q3W on Days 1 and 22 of a 28-day cycle prior to surgery.
89373185|NCT05484622|Experimental|Randomized Perioperative Phase: Vorasidenib Only|Participants will receive vorasidenib orally, QD from Day 1 to 28 of a 28-day cycle prior to surgery.
89373186|NCT05484622|No Intervention|Randomized Perioperative Phase: Untreated Control Group|Participants will not receive any treatment prior to surgery.
89373187|NCT05483907|Experimental|BBT-877|200 mg twice daily (BID)of BBT-877 in patients with IPF, with or without AF approved background therapies (pirfenidone or nintedanib).
89373188|NCT05483907|Placebo Comparator|Placebo|200 mg twice daily (BID)of Placebo in patients with IPF, with or without AF approved background therapies (pirfenidone or nintedanib).
89534997|NCT03331445|Experimental|160 ppm Nitric Oxide|
89373191|NCT05470283|Experimental|OBX-115 plus Acetazolamide|Participants will receive chemotherapy to prepare your body for the study drug combination, then you will receive OBX-115 and acetazolamide.
89373192|NCT05458856|Experimental|Triptorelin embonate|All participants will receive triptorelin embonate 22.5 mg
88810165|NCT03802370|Other|single am|single arm , superiority trial , tunneling technique in connective tissue graft around dental implants
88810166|NCT01312181|Active Comparator|HealthCall +Motivational Interviewing|Patients access HealthCall by calling a toll-free number and putting a four-digit Personal Identification Number (PIN). The HealthCall system will then ask a short script of pre-recorded questions in English or Spanish, on substance use and other variables (e.g., medication adherence, unprotected sex, feeling of physical well-being, stress, etc). The MI session focuses on reduce ambivalence and increase motivation to reduce non-injection drug use (NIDU), gain a commitment to change, if possible, and ultimately to reduce or eliminate NIDU. The intervention includes: a) identifying pros and cons of using and stopping; b) exploring ambivalence about stopping NIDU; c) eliciting change talk
89534998|NCT05008029|Experimental|In situ immobilization|Immobilization without reducing the radius fracture and above-elbow casting.
88845170|NCT04298905|Active Comparator|mHealth intervention|Individuals randomized to the intervention arm will receive the same standardized adherence education, followed by an orientation session to the study intervention. This orientation will include education on basic smartphone operations and use. The CHW will set up appointment reminders for clinic visits as well as daily adherence reminders for submission of the video DOT sessions and symptom reports. A smartphone capable of downloading apps, receiving short message service (SMS) and access wifi and cellular connectivity will be provided to intervention patients. All patients are seen face-to-face monthly for adherence monitoring, monthly symptom reports and laboratory evaluations per standard of care treatment guidelines. All research participants will also receive a clinic visit quality checklist to ensure completeness of standard of care procedures.
89373195|NCT05457556|Experimental|Arm A (halploHCT)|Patients receive a myeloablative conditioning regimen with PTCy or alpha beta T cell depletion at the discretion of the treating provider. Patients then undergo haploHCT on day 0. Patients undergoing myeloablative conditioning regimen with PTCy also receive GVHD prophylaxis on days 3-5. Patients undergo lumbar puncture, bone marrow aspiration, and ECHO or MUGA during screening. Patients also undergo collection of blood throughout the trial.
89373196|NCT05457556|Experimental|Arm B (MUD-HCT)|Patients receive a TBI-based or chemotherapy-based myeloablative conditioning regimen between days -9 and -2, followed by MUD-HCT on day 0. Patients then receive GVHD prophylaxis regimen on days 1-11. Patients undergo lumbar puncture, bone marrow aspiration, and ECHO or MUGA during screening. Patients also undergo collection of blood throughout the trial.
89373197|NCT05457556|Experimental|Arm C (haploHCT)|Patients who only have a haplo donor receive a myeloablative conditioning regimen with PTCy or alpha beta T cell depletion at the discretion of the treating provider. Patients then undergo haploHCT on day 0. Patients undergoing myeloablative conditioning regimen with PTCy also receive GVHD prophylaxis on days 3-5. Patients undergo lumbar puncture, bone marrow aspiration, and ECHO or MUGA during screening. Patients also undergo collection of blood throughout the trial.
89373198|NCT05456685|Experimental|Open Label|On Day 1 of every 3-week cycle (Q3W) for 6 cycles, MIRV will be given at the dosage of 6 mg/kg of adjusted ideal body weight (AIBW) along with carboplatin given at area under the concentration curve (AUC) 5 administered through intravenous (IV) infusion (maximum dosing per National Comprehensive Cancer Network [NCCN] guidelines [NCCN 2021]). Upon completion of carboplatin plus MIRV treatment, single-agent MIRV will be continued at the tolerated dose on Day 1 Q3W in patients with investigator determined stable disease, PR, or CR.
89534999|NCT05008029|Active Comparator|Reduction under general anesthesia|Radius closed reduction under general anesthesia and above-elbow casting. Percutaneous fixation with K-wires, a sugar tong splint immobilization, and a nerve block if needed.
89535000|NCT03331367|Active Comparator|Total Cyrotherapy of the Prostate|Patients who will undergo total cryotherapy of the prostate will be evaluated for immune markers using a blood draw and urine sample collected at three timepoints (baseline, 2-3 weeks post cryotherapy, 3 months post cryotherapy)
89535001|NCT03331367|Active Comparator|Focal Cryotherapy of the Prostate|Patients who will undergo focal cryotherapy of the prostate will be evaluated for immune markers using a blood draw and urine sample collected at three timepoints (baseline, 2-3 weeks post cryotherapy, 3 months post cryotherapy)
88845171|NCT04295759|Experimental|Dose-finding|INCB7839 dosing will begin at 120 mg/m2/dose BID which is equivalent to the adult RP2D (200 mg PO BID) based on a typical adult size of 1.67m2. The INCB7839 dose may be decreased to 80 mg/m2/dose BID if the staring dose is not tolerable. 28 consecutive days (4 weeks) will constitute one course. Patients may continue to receive INCB7839 for 26 courses (approximately 2 years).
88845172|NCT04295486|Experimental|Treatment Once Daily|Participant receives 81 mg aspirin taken once daily beginning the night before surgery and up to 28 days post surgery.
88845173|NCT04295486|Active Comparator|Treatment Twice Daily|Participant receives 81 mg aspirin taken twice daily (one in the morning and one at night) beginning at the night before surgery and up to 28 days post surgery.
88845174|NCT04280523|Experimental|ESR-specific PET Scan|"Specific Aim: To test the hypothesis that among PAH patients, higher lung ESR density associates with a more severe hemodynamic profile and worse 1 year outcomes.~Study Design: Enroll 20 randomly selected subjects from each group (PAH vs. control)"
89373202|NCT05443490|Experimental|Probiotic group|Probiotic mixture
89373203|NCT05443490|Placebo Comparator|Placebo group|Maltodextrine
89373204|NCT05437198||Chronic Obstructive Pulmonary Disease (COPD)|Patients with chronic obstructive pulmonary disease will be recruited from the pulmonology or occupational pathology department. They are either active smokers or ex-smokers. They are over 18 years old
89373205|NCT05437198||NO-Chronic Obstructive Pulmonary Disease|"The no-COPD are controls followed in chi créteil for another pathology. They are between 18 and 30 years old and 45 and 70 years old.~They are either:~Ex-smoker~Active smoker~Non-smoker"
89373206|NCT05436197|Experimental|PLAYshop Intervention|Participants will receive a 60 minute virtual/hybrid physical literacy workshop, an equipment goody-bag with basic play equipment and printed resources, and access to a digital app with an online toolkit and four bi-weekly boosters lessons.
89373207|NCT05436197|No Intervention|Control|Participants will receive the 60 minute virtual/hybrid physical literacy workshop, equipment goody-bag, and access to the digital app after completing the follow-up measures.
89373208|NCT05426733|Experimental|Odevixibat (A4250)|Capsules for oral administration once daily for 104 weeks.
89373209|NCT05425537||Fatal drowning|Fatal drowning incident where the patient died because of the drowning process
89373210|NCT05425537||Non-fatal drowning|Non-fatal drowning incident where the patient was drowning and can be ascertained to have been experiencing either mild, moderate, or severe respiratory impairment immediately after the drowning process ended but survived.
89373211|NCT05421663|Experimental|JNJ-90014496|Participants will receive intravenous (IV) infusion of autologous JNJ-90014496 on Day 1.
89535002|NCT03331367|Active Comparator|Cyberknife SBRT of the Prostate|Patients who will undergo Cyberknife SBRT of the prostate will be evaluated for immune markers using a blood draw and urine sample collected at three timepoints (baseline, 2-3 weeks post Cyberknife, 3 months post Cyberknife)
89373215|NCT05389423|Experimental|1/Dose Escalation|Pomalidomide (escalating doses) + Prednisone, Etoposide, Doxorubicin, Vincristin
89373216|NCT05389423|Experimental|2/Dose Expansion|Pomalidomide (at the MTD) + Prednisone, Etoposide, Doxorubicin, Vincristine and
89373217|NCT05387083|Experimental|Low Dose of TP-05 (lotilaner)|Single Oral Low Dose of TP-05 tablet.
89373218|NCT05387083|Experimental|High Dose of TP-05 (lotilaner)|Single Oral High Dose of TP-05 tablet.
89373219|NCT05387083|Placebo Comparator|Placebo|Single Oral Dose of placebo tablet.
89373220|NCT05386108|Experimental|Phase 1b Cohort 1|Elacestrant 300 mg once daily (QD) + abemaciclib 100 mg twice daily (BID)
89373221|NCT05386108|Experimental|Phase 1b Cohort 2|Elacestrant 400 mg QD + abemaciclib 100 mg BID
89373222|NCT05386108|Experimental|Phase 1b Cohort 3|Elacestrant 400 mg QD + abemaciclib 150 mg BID
89373223|NCT05386108|Experimental|Phase 2|Elacestrant in combination with abemaciclib at the recommended phase 2 dose (RP2D) determined in phase 1b
89373224|NCT05385016|Experimental|Education Arm|Participants will attend weekly two hour small group instruction sessions. All sessions will have an education component, a hands-on nutrition/cooking lesson, and a group exercise session. Two health educators will be present during group sessions with one leading
89373225|NCT05383911|Experimental|Shared Decision Making Toolkit including VR|
89373226|NCT05383911|Experimental|Shared Decision Making Toolkit without VR|
89373227|NCT05383352|Experimental|Sequence RT: Reference Product followed by Test Product|"Cycle 1 (Crossover Phase) Day 1: One dose Onivyde® Reference product + 5-FU/LV.~Cycle 1 (Crossover Phase) Day 15: One dose Onivyde Test product + 5-FU/LV~Cycle 2 Onwards (Extension Phase): Participants who choose to continue treatment after Cycle 1 will receive Onivyde® Reference product on Day 1 and Day 15 of every 28-day cycle in combination with 5-FU/LV"
89373228|NCT05383352|Experimental|Sequence TR: Test Product followed by Reference Product|"Cycle 1 (Crossover Phase) Day 1: One dose Onivyde Test product + 5-FU/LV.~Cycle 1 (Crossover Phase) Day 15: One dose Onivyde® Reference product + 5-FU/LV.~Cycle 2 Onwards (Extension Phase): Participants who choose to continue treatment after Cycle 1 will receive Onivyde® Reference product on Day 1 and Day 15 of every 28-day cycle in combination with 5-FU/LV."
89373229|NCT05382325|Experimental|MK-1484|Participants will receive MK-1484 every 3 weeks (Q3W) or 21-day cycle at escalating dose levels from 0.2-60 mg for up to a total of 35 cycles (up to approximately 24 months).
89373230|NCT05382325|Experimental|MK-1484 + Pembrolizumab|Participants will receive MK-1484 Q3W at escalating dose levels from 10-60 mg plus pembrolizumab 200 mg once every 21-day cycle for up to a total of 35 cycles (up to approximately 24 months).
89373231|NCT05382286|Experimental|Sacituzumab Govitecan-hziy (SG) + Pembrolizumab|"Participants will receive SG 10 mg/kg on Days 1 and 8 of 21-day cycles and pembrolizumab 200 mg on Day 1 of 21-day cycles~Pembrolizumab will be administered for a maximum of 35 cycles."
89373232|NCT05382286|Active Comparator|Pembrolizumab + Treatment of Physician's Choice (TPC)|"Participants will receive pembrolizumab 200 mg on Day 1 of each 21-day cycle (maximum 35 cycles) plus TPC determined prior to randomization from 1 of the 3 allowed regimens:~Paclitaxel 90 mg/m^2 on Days 1, 8, and 15 of 28-day cycles~nab-Paclitaxel 100 mg/m^2 on Days 1, 8, and 15 of 28-day cycles~Gemcitabine 1000 mg/m^2 + carboplatin area under the curve (AUC) 2 on Days 1 and 8 of 21-day cycles"
89373233|NCT05378750|Experimental|Intervention group|"Bio-impedance spectroscopy.~Treatment algorithm for diuretic therapy."
89373234|NCT05378750|No Intervention|Control group|No intervention.
89535003|NCT03331367|Active Comparator|Radical Prostatectomy|Patients who will undergo a radical prostatectomy will be evaluated for immune markers using a blood draw and urine sample collected at three timepoints (baseline, 2-3 weeks post surgery, 3 months post surgery)
89373236|NCT05372614|Experimental|Treatment (neratinib, trastuzumab deruxtecan)|Patients receive neratinib PO QD on days 1-21 (days 8-21 of cycle 1, then days 1-21 in cycles thereafter for PD study) of each cycle and trastuzumab deruxtecan IV over 30-90 minutes on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo blood sample collection, CT scan and echocardiograpahy or MUGA scan throughout study. Additionally, patients may undergo a tissue biopsy at baseline.
89373237|NCT05372393|Active Comparator|Local infiltration anaesthesia in carpal tunnel release|The investigators allocate 59 patients in this arm. It serves as the control group, who receives local infiltration anaesthesia.
89373238|NCT05372393|Experimental|Distal median nerve block with local infiltration anaesthesia in carpal tunnel release|The investigators allocate 59 patients in this arm. It serves as the experimental group, who receives local infiltration anaesthesia and distal median nerve block.
89373239|NCT05368389||Healthdot Patients|This group represents the patient who have undergone a bariatric procedure and had the Healthdot device attached and had data collected from the device for 10 days.
89373240|NCT05368389||Healthdot providers|This group represents the providers or study/hospital staff who were involved in the attachment, recruitment, and enrollment of the Healthdot patients.
89373241|NCT05365633|Other|Empowerment activity-enhanced tobacco cessation assistance|Single arm pilot intervention design to assess feasibility and acceptability
89373242|NCT05361447|Experimental|GAD65 Associated Epilepsy|Subjects diagnosed with GAD65 associated epilepsy, serum high-titer GAD65 positivity, trialed and failed at least 2 anti-seizure medications, at least 4 seizures per month will be started on diazepam.
89373243|NCT05361395|Experimental|Part 1: Dose Exploration Combination Regimen 1|Tarlatamab+Atezolizumab+Carboplatin+Etoposide
89373244|NCT05361395|Experimental|Part 2: Dose Exploration Combination Regimen 2|Tarlatamab+Atezolizumab+Carboplatin+Etoposide
89373245|NCT05361395|Experimental|Part 3: Dose Exploration Combination Regimen 3|Tarlatamab+Atezolizumab+Carboplatin+Etoposide
89373246|NCT05361395|Experimental|Part 4: Dose Expansion|Expansion of Part 1, Part 2, or Part 3 with Atezolizumab
89373247|NCT05361395|Experimental|Part 5: Dose Exploration Maintenance|Tarlatamab+Atezolizumab
89373248|NCT05361395|Experimental|Part 6: Dose Expansion Maintenance|Expansion of Part 5 with Atezolizumab
89373249|NCT05361395|Experimental|Part 7: Dose Expansion|Expansion of Part 1, 2, or 3 with Durvalumab
89373250|NCT05361395|Experimental|Part 8: Dose Expansion Maintenance|Expansion of Part 5 with Durvalumab
89373251|NCT05361395|Experimental|Part 9: Dose Expansion Maintenance|Expansion with Tarlatamab+Durvalumab
89373252|NCT05347550|No Intervention|Control - No graduated compression stockings|In those centres randomised to the control arm, participants will not receive Graduated Compression Stockings (GCS).
89373253|NCT05347550|Experimental|Intervention - The provision of graduated compression stockings|Centres randomised to the intervention arm, which is the current standard of care, will consist of participants receiving Graduated Compression Stockings (GCS). Clinical staff (e.g. theatre support workers) will issue stockings to all patients who are scheduled to undergo short-stay surgery. Participants will be instructed to wear their stockings just before undergoing the surgical procedure and to remove the stockings as soon as they are ambulant (i.e. after the procedure).
89373254|NCT05336214|Experimental|Refer|Practice referral of patients to a virtual CGM initiation service
89373255|NCT05336214|Experimental|Learn|Practice completion of online educational module, American Academy of Family Physicians (AAFP) Transformation in Practice Series (TIPS) on continuous glucose monitoring in primary care
89373256|NCT05336214|Experimental|Learn + Practice Facilitation|Practice completion of online educational module, American Academy of Family Physicians (AAFP) Transformation in Practice Series (TIPS) on continuous glucose monitoring in primary care plus practice facilitation
89373257|NCT05329766|Experimental|A1: First Line - Treatment Naïve Participants|Domvanalimab and zimberelimab once every 4 weeks (Q4W) in addition to FOLFOX chemotherapy by intravenous (IV) infusion once every 2 weeks (Q2W)
89373258|NCT05329766|Experimental|A2: First Line - Treatment Naïve Participants|Zimberelimab Q4W in addition to chemotherapy with FOLFOX administered by IV infusion Q2W
88845175|NCT04280081|Experimental|Selpercatinib|Selpercatinib 160 milligrams (mg) administered orally twice daily (BID).
88845176|NCT04271436|Experimental|PET/CT + PET/MR|-Eligible patients will have imaging assessments (as part of the study) performed at three time-points: pre-treatment, following cycle 1 of treatment, and following cycle 2 of treatment. Baseline FDG PET/CT will be a standard-of-care procedure. If possible, PET/CT imaging will be performed, followed immediately by PET/MR imaging during each imaging session. At minimum, PET/MR should be obtained at least once during each time-point (i.e. either during the FDG or FLT procedure). FDG imaging and FLT imaging should be performed at least 24 hours apart and no more than 7 days apart.
89373259|NCT05329766|Experimental|A3 First Line - Treatment Naïve Participants|"Non-randomized A3 safety run-in cohort: Domvanalimab and zimberelimab co-administered Q4W via IV infusion over 60 minutes in addition to FOLFOX chemotherapy via IV infusion Q2W.~After completion of A3 safety run-in cohort, participants are randomized to the A3 arm. Domvanalimab and zimberelimab co-administered Q4W via IV infusion over 30 minutes, in addition to FOLFOX chemotherapy via IV infusion Q2W"
89373260|NCT05329766|Experimental|A4 First Line - Treatment Naïve Participants|Zimberelimab administered Q4W via IV infusion over 30 minutes, in addition to FOLFOX chemotherapy via IV infusion Q2W
89373261|NCT05329766|Experimental|B1: Second Line or greater Checkpoint Inhibitor Naïve Participants|Domvanalimab and zimberelimab administered once every three weeks (Q3W) by IV infusion
89373262|NCT05329766|Experimental|B2: Second Line or greater Checkpoint Inhibitor Naïve Participants|Quemliclustat Q2W and zimberelimab Q4W administered by IV infusion
89373263|NCT05329766|Experimental|Cohort C1: Second Line or greater - Checkpoint Inhibitor Experienced Participants|Domvanalimab and zimberelimab Q3W administered by IV infusion
89373264|NCT05325866|Experimental|Part 1: Monotherapy Dose Exploration|Participants across multiple primary epithelial solid tumors with centrally determined FGFR2b overexpression and relapsed/refractory unresectable and/or metastatic disease will receive 1 of 2 dose regimens of bemarituzumab to determine recommended Phase 2 dose.
89373265|NCT05325866|Experimental|Part 2: Monotherapy Dose Expansion|Participants across multiple primary epithelial solid tumors with centrally determined FGFR2b overexpression and relapsed/refractory unresectable and/or metastatic disease will receive the dose of bemarituzumab identified as the recommended Phase 2 dose during Part 1.
89373266|NCT05322577|Experimental|Part 1 Cohort A: Bemarituzumab with CAPOX|
88845177|NCT04241835|Experimental|Open label Tazemetostat|"Part 1:~Participants will receive a single oral 800 mg dose on day 1, and twice daily from day 5 to day 14. Participants will return to the clinical study unit on an out-patient basis from day 15 to day 18. A single oral 800 mg dose of tazemetostat will be administered on day 15.~Part 2:~Will begin on day 19 and participants continuing treatment in Part 2 will receive tazemetostat (oral 800 mg dose) tablets to be taken twice daily in repeated 28-day cycles."
88845178|NCT04233762||Female Natural Cycle Group|Females with regular natural menstrual cycle.
89373267|NCT05322577|Experimental|Part 1 Cohort C: Bemarituzumab with CAPOX and Nivolumab|
89373268|NCT05322577|Experimental|Part 1 Cohort D: Bemarituzumab with SOX and Nivolumab|
89373269|NCT05322577|Experimental|Part 2: Bemarituzumab with SOX and Nivolumab.|
89373270|NCT05321147|Experimental|PTCL that express KIR3DL2|lacutamab will be administered every week for 5 weeks then every 2 weeks for 10 administrations then every 4 weeks until disease progression or unacceptable toxicity.
89373271|NCT05319964|Experimental|anti-gravity treadmill|"Patients in all three study groups will receive hot pack, transcutaneous electrical nerve stimulation (TENS), therapeutic ultrasound 3 days a week for 8 weeks.~Participants were provided 30 minutes 30% unweighed BWSTT sessions including a 5 minutes warm - up and cool - down period for each session, 3 days a week, for 8 weeks"
89373272|NCT05319964|Active Comparator|conventional treadmill|"Patients in all three study groups will receive hot pack, transcutaneous electrical nerve stimulation (TENS), therapeutic ultrasound, 3 days a week for 8 weeks.~The moderate-intensity aerobic exercise program will be performed for 30 minutes at an intensity of 65-80% of the maximum heart rate, consisting of a 5-minute warm-up and cool-down period."
88845179|NCT04233762||Female Oral Contraceptive Pill Group|Females taking the combined oral contraceptive pill.
88845180|NCT04233762||Male Group|Males with no history of anabolic steroid use.
88845181|NCT04231565|Active Comparator|TAF group|100 patients would receive treatment of oral Tenofovir alafenamide Fumarate(TAF) 25 mg once per day from baseline to life-long unless the patient achieves HBsAg loss.
88845182|NCT04231565|No Intervention|Observation group|100 patients would not receive treatment from baseline to life-long.
88845183|NCT04199052|No Intervention|Standard of Care|Women assigned to the control arm will receive self-directed (non-Virtual Peer Navigator (PN) supported) treatment as usual at the HIV care service provider of choice following the Ryan White standard of care (i.e., referrals to physical, dental and mental health services; case management; and ancillary services. Annual assessments (e.g., updates on insurance, housing, referrals needed, behavioral assessment [e.g., depression, substance use]) are conducted by a case manager. For women who have fallen out of care and re-engage care, case management begins with an interview and assessment of current needs. Goals are set to create an individual care plan related to medical care, housing, and other resources, as needed. Referrals are made to appropriate services (e.g., primary care, housing, benefits counseling, food, support services) based on the intake assessment. It is important to note that the case management approach is self-guided versus intensive virtual PN assistance.
88845184|NCT04199052|Experimental|LinkPositively Intervention|Women assigned to the LinkPositively intervention arm will have access to all four components of the LinkPositively app. Women will be scheduled for a session with staff to inform them of their assigned virtual Peer Navigator (PN). Staff will train participants on how to download the app, explain the five components, using each component, and contacting their PN. Within the first week after, virtual PNs will complete a one-on-one, in-person or phone intake session with the participant, based on the participant's preference. During this intake session, the PN will conduct a participant needs assessment to connect her to HIV medical care via local health clinics and identify other areas of need, services of need, and assisted referrals (domestic violence services, mental health care, substance abuse treatment, housing and legal support, etc.). PNs will provide trauma-informed emotional and informational support, including guidance on accessing information about referred services.
88845185|NCT04190628|Experimental|Monotherapy Dose Escalation|"A classic 3+3 design will be used to determine MTD and RP2D. Three to six patients per treatment cohort will be assigned to receive sequentially higher oral doses of ABM-1310 on a twice daily schedule (bid) for 28-day cycles, starting at a dose of 25 mg bid. Patients will receive twice daily oral doses of ABM-1310 continuously until disease progression, unacceptable toxicity, or a clinical observation satisfying another withdrawal criterion is met."
88845186|NCT04190628|Experimental|Combination Therapy Dose Escalation|"A classic 3+3 design will guide the dose escalation in Part B. At each dose level, ABM-1310 will be administered in combination with cobimetinib (Cotellic ®) once daily (qd) for the first 21 days of each 28-day treatment cycle. The starting dose of ABM-1310 will be a dose below the MTD that has been demonstrated to be safe in Part A Monotherapy."
88845187|NCT04190628|Experimental|Monotherapy Therapy Dose Expansion-1|- In C-1(Monotherapy - Primary CNS Tumors), continuous twice daily oral doses of ABM-1310 at the recommended phase 2 dose (RP2D) from Part A until disease progression, unacceptable toxicity, or a clinical observation satisfying another withdrawal criterion is met.
88845188|NCT04190628|Experimental|Monotherapy Therapy Dose Expansion-2|- In C-2 (Monotherapy - Advanced or Metastatic Solid Tumors excluding Primary CNS Tumor with or without Brain Metastasis), continuous twice daily oral doses of ABM-1310 at the recommended phase 2 dose (RP2D) from Part A until disease progression, unacceptable toxicity, or a clinical observation satisfying another withdrawal criterion is met.
89002210|NCT05991661|Active Comparator|XKH001 Injection|Cohort 1: 100 mg Q4W (D1, D29, D57) 6subjects Cohort 2: 300 mg Q4W (D1, D29, D57) 6subjects Cohort 3: 600 mg Q4W (D1, D29, D57) 6subjects The Sponsor will discuss with the investigator to decide whether to conduct the 4th to 5th cohorts (e.g., 600 mg Q14D, 600 mg Q8W, and the specific dose regimen will be determined at that time) no later than the completion of the safety assessment for Cohort 3.
89002211|NCT05991661|Placebo Comparator|XKH001 Placebo Injection|Cohort 1: 100 mg Q4W (D1, D29, D57) 6subjects Cohort 2: 300 mg Q4W (D1, D29, D57) 6subjects Cohort 3: 600 mg Q4W (D1, D29, D57) 6subjects The Sponsor will discuss with the investigator to decide whether to conduct the 4th to 5th cohorts (e.g., 600 mg Q14D, 600 mg Q8W, and the specific dose regimen will be determined at that time) no later than the completion of the safety assessment for Cohort 3.
89181149|NCT00765674|Experimental|Aliskiren / hydrochlorothiazide|Patients received an aliskiren 150 mg tablet plus a hydrochlorothiazide 12.5 mg capsule for 4 weeks and then were force titrated up to aliskiren 300 mg plus hydrochlorothiazide 25 mg for the remaining 4 weeks of the study. During the 8 weeks, patients also received a placebo capsule and a placebo tablet. Patients took a total of 4 pills each day orally with water in the morning at approximately 8:00 am, except on the morning of a study visit when they took their study medications after all visit procedures and assessments had been completed.
89373273|NCT05319964|Other|Control|Patients in all three study groups will receive hot pack, transcutaneous electrical nerve stimulation (TENS), therapeutic ultrasound 3 days a week for 8 weeks
88845189|NCT04190628|Experimental|Combination Therapy Dose Expansion-1|- In C-3 (Combination therapy - Advanced/Metastatic Solid Tumors including Primary CNS tumors but excluding Melanoma with Brain metastasis), continuous twice daily oral doses of ABM-1310 at the recommended phase 2 dose (RP2D) from Part B, in combination with cobimetinib (Cotellic®) 60 mg administered the first 21 days of each 28-day treatment cycle until disease progression, unacceptable toxicity, or a clinical observation satisfying another withdrawal criterion is met.
88845190|NCT04190628|Experimental|Combination Therapy Dose Expansion-2|- In C-4 (Combination therapy - Melanoma with Brain Metastasis), continuous twice daily oral doses of ABM-1310 at the recommended phase 2 dose (RP2D) from Part B, in combination with cobimetinib (Cotellic®) 60 mg administered the first 21 days of each 28-day treatment cycle until disease progression, unacceptable toxicity, or a clinical observation satisfying another withdrawal criterion is met.
88845191|NCT04190524|Other|Intervention/Control|Each subject will serve as their own control. The esophagus diameter will be measured on each subject, then cricoid pressure will be applied and the esophagus diameter will again be measured.
89181150|NCT00765674|Experimental|Amlodipine / hydrochlorothiazide|Patients received an amlodipine 5 mg capsule plus a hydrochlorothiazide 12.5 mg capsule for 4 weeks and then were force titrated up to amlodipine 10 mg plus hydrochlorothiazide 25 mg for the remaining 4 weeks of the study. During the 8 weeks, patients also received 2 placebo tablets. Patients took a total of 4 pills each day orally with water in the morning at approximately 8:00 am, except on the morning of a study visit when they took their study medications after all visit procedures and assessments had been completed.
89181151|NCT00765674|Experimental|Aliskiren / amlodipine / hydrochlorothiazide|Patients received an aliskiren 150 mg tablet, a HCTZ 12.5 mg capsule and a placebo capsule for the first 3 days of treatment. Amlodipine 5 mg was then added for the remainder of the first 4 weeks of treatment. At the end of 4 weeks, patients were force titrated up to aliskiren / amlodipine / hydrochlorothiazide 300/10/25 mg for the remaining 4 weeks of the study. During the 8 weeks, patients also received a placebo tablet. Patients took a total of 4 pills each day orally with water in the morning at approximately 8:00 am, except on the morning of a study visit when they took their study medications after all visit procedures and assessments had been completed.
89181152|NCT00765362|Experimental|1|Subjects who are candidates for a total knee replacement and meet the inclusion/exclusion criteria of the study.
89181153|NCT04231929|Experimental|BioPearl™ loaded with doxorubicin|Chemoembolization with doxorubicin-loaded BioPearl™ microspheres
89181154|NCT00586898|Experimental|1|
89181155|NCT02587455|Experimental|Low Dose Radiotherapy Arm|Pembrolizumab and radiotherapy
89181156|NCT02587455|Experimental|High Dose Radiotherapy Arm|Pembrolizumab and radiotherapy
89181157|NCT04099238||Subjects with ischemic stroke|Adult subjects from the UK THIN database who were hospitalized for ischemic stroke between 01-Jul-2016 to 30-Jun-2018
89181158|NCT04099238||NVAF patients with ischemic stroke|Adult subjects from the UK THIN database who were hospitalized for ischemic stroke between 01-Jul-2016 to 30-Jun-2018 and had a diagnosis of NVAF prior to ischemic stroke (Subgroup)
89181159|NCT04099082||Cases|eligible patients with 10% decline in Forced Expiratory Volume (FEV1) at 2 months
89181160|NCT04099082||Controls|eligible patients free of 10% FEV1 decline at 2 months
89181161|NCT00919659|Experimental|parenteral nutrition|25kcal/kg/bw /day via parenteral support
89181162|NCT04099316|Experimental|Older adults|Older adults (Over the 60 years), Subjects did not suffer from musculoskeletal or metabolic diseases.
89181163|NCT04099316|Experimental|Older adults-Control|Older adults (Over the 60 years), Subjects did not suffer from musculoskeletal or metabolic diseases.
89181164|NCT04099316|No Intervention|No intervention|Metabolic diseases, Hypertension (150/90mmHg), Myocardial infarction within 6 months. Fractures within 6 months.
89181165|NCT04098926|Experimental|Accelerated dose-integrated radiotherapy - pN0|Lymph node negative breast cancer
89181166|NCT04098926|Experimental|Accelerated dose-integrated radiotherapy - pN1|Lymph node positive breast cancer
89181167|NCT04101812|Experimental|Experimental group|Experimental group Pegylated liposomal doxorubicin 40mg/m2 iv every 3 weeks, for 3 cycles; PD-1 every 3 weeks, for 3 cycles.
89181168|NCT04101812|Active Comparator|Control group|PD-1 every 3 weeks, for 6 cycles.
89181169|NCT04923867||Supratentorial Procedure Group|Subjects that have undergone a supratentorial procedure with the use of Suturable DuraGen™.
89181170|NCT04923867||Infratentorial Procedure Group|Subjects that have undergone a infratentorial procedure with the use of Suturable DuraGen™.
89181171|NCT04923867||Spinal Procedure Group|Subjects that have undergone a spinal procedure with the use of Suturable DuraGen™.
89181172|NCT02587533|Active Comparator|Hypoxia without dopamine|Target hemoglobin oxygen saturation (SpO2) 80%. No pharmacologic suppression of chemoreflex afferents. Readout: Responses to electrical baroreflex stimulation.
89181173|NCT02587533|Active Comparator|Hypoxia with dopamine|Target hemoglobin oxygen saturation (SpO2) 80%. Counteracting pharmacologic suppression of chemoreflex afferents. Readout: Responses to electrical baroreflex stimulation.
89181174|NCT02587533|Active Comparator|Hyperoxia without dopamine|Nearly complete hemoglobin oxygen saturation. No additional pharmacologic suppression of chemoreflex afferents. Readout: Responses to electrical baroreflex stimulation.
89181175|NCT02587533|Active Comparator|Hyperoxia with dopamine|Nearly complete hemoglobin oxygen saturation. Additional pharmacologic suppression of chemoreflex afferents. Readout: Responses to electrical baroreflex stimulation.
89181176|NCT04916847||children with controlled HIV|Children over 0 days and under 16 years old, with controlled HIV
89181177|NCT04916847||children with hematologic Malignancy treated by conventional chemotherapy|Children over 0 days and under 16 years old, with Hematologic Malignancy treated by conventional chemotherapy
89181178|NCT04916847||Children with inflammatory bowel disease treated by anti-TNF at least 6 weeks|Children over 0 days and under 16 years old, with inflammatory bowel disease treated by anti-TNF
89181179|NCT04916847||Children with idiopathic juvenile arthritis|Children over 0 days and under 16 years old, with idiopathic juvenile arthritis treated by methotrexate:
89181180|NCT04916847||Children treated by renal transplantation|Children over 0 days and under 16 years old, treated by renal transplantation from more than 3 months:
89373274|NCT05308446|Experimental|Arm I (encorafenib, cetuximab, nivolumab)|Patients receive encorafenib PO QD on days 1-28, cetuximab IV on days 1 and 15, and nivolumab IV on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89373275|NCT05308446|Active Comparator|Arm II (encorafenib, cetuximab)|Patients receive encorafenib PO QD on days 1-28 and cetuximab IV on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89373276|NCT05299814|Experimental|Behavior Therapy|8 sessions of an evidence based parenting program to address oppositional behaviors and ADHD symptoms at home. All participants are in this arm.
89373277|NCT05297890|Experimental|Lorlatinib|Drug：Lorlatinib 100mg, oral, Quaque Die (QD), continuous administration in 21 days as a cycle
89373278|NCT05293639|Experimental|Treatment Group|PFA ablation using a circular multi-electrode pulsed electrical field catheter and multichannel generator
89373279|NCT05292586|Experimental|CHF 1535 pMDI|CHF 1535 pMDI 800/24µg TDD
89181181|NCT04916847||Children attending consultation|"Children over 0 days and under 16 years old, without immunodepression or chronic inflammation attending consultation for :~preoperative assessment~-congenital abnormalities of the kidney and urinary tract:~Nephropathies without renal impairment (eDFG > 45mL/min/1.73m2)~Non-inflammatory intestinal (polyposis, Chronic intestinal pseudo-obstruction, short bowel syndrome) or pancreatic (hereditary pancreatitis) pathologies This group of children will be a control group (age matched healthy children, non-immunosuppressed)."
89181182|NCT04912245|Other|Telehealth visit|Patients with either MCI or unrecognized dementia and their care partners (if available) will be approached to participate in a telehealth Advance Care Planning (ACP) visit with a member of the patient's primary care team via either telephone or video. Patients without willing or available care partners are still eligible to participate in the study.
89373280|NCT05292586|Active Comparator|CHF 718 pMDI|CHF 718 pMDI 800µg TDD
89373281|NCT05291039|Active Comparator|Infliximab.|group 1 (n=20): patients will receive IFX,
89373282|NCT05291039|Active Comparator|Adalimumab.|group 2 (n=20): patients will receive ADA
89373283|NCT05287347||Prospective|Blood specimens will be obtained for the model-assigned high risk cohort at each collaborating HCO, over two years of recruitment period. Data of each participant will be electronically followed for observation of outcome measures for up to 3 years.
89373284|NCT05287204||AKI-RRT|Adults admitted to the ICU with AKI requiring CRRT with study enrollment within 48 hours of CRRT initiation.
89373285|NCT05287204||Historical Controls|The controls for the ICU phase will be 41 critically ill adults without AKI-RRT in whom similar measurements of muscle size, quality, and function were collected in a recent prior study [PubMed ID: 33148301]. The controls for the recovery phase will come from an ongoing prospective observational study being performed at the University of Kentucky, which will include outpatient functional assessments performed on 200 ICU survivors (NCT05537298).
89373286|NCT05286801|Experimental|Arm B (atezolizumab, tiragolumab)|Patients receive atezolizumab IV over 30-60 minutes on day 1 and tiragolumab IV over 30-90 minutes on day 1 of each cycle. Treatment repeats every 21 days for up to 5 years in the absence of disease progression or unacceptable toxicity. Patients also undergo standard imaging scans including x-rays, CT, MRI, and/or FDG PET-CT throughout the trial. Patients also undergo blood sample collection on study.
89373287|NCT05286801|Experimental|Part A (atezolizumab, tiragolumab)|Patients receive tiragolumab IV over 30-90 minutes on day 1 of each cycle and atezolizumab IV over 30-60 minutes on day 1 of each cycle starting in cycle 2. Treatment repeats every 21 days for up to 5 years in the absence of disease progression or unacceptable toxicity. Patients undergo standard imaging scans including x-rays, CT, MRI, and/or FDG PET-CT, throughout the trial. Patients also undergo blood sample collection on study.
89373288|NCT05284747|Experimental|Evolocumab + Routine Lipid Management|Participants will receive open-label evolocumab every 2 weeks (Q2W) plus routine lipid management.
89373289|NCT05284747|Active Comparator|Routine Lipid Management|Participants will receive routine lipid management per standard of care (SoC).
89373290|NCT05279092|Active Comparator|Bupivacaine-Liposomal Bupivacaine (B-LB)|Nerve blockade administration will be carried out per standard of care. All patients will receive single injection under ultrasound guidance with adductor canal block comprised of 20 ml 0.25% plain bupivacaine + 10 ml LB (133 mg) with the total volume of 30 ml; 10 ml 0.25% plain bupivacaine + 10 ml LB (133 mg) with the total volume of 20 ml will be administered through an Interspace between the popliteal artery and capsule of the posterior knee (iPACK) block.
89373291|NCT05279092|Experimental|Bupivacaine -Dexamethasone Sodium Phosphate-Methylprednisolone Acetate (B-DEX-MPA)|Nerve blockade administration will be carried out per standard of care. All patients will receive single injection under ultrasound guidance with adductor canal block comprised of 30 ml 0.25% plain bupivacaine + 5 mg DEX (0.5 ml) and 40 mg MPA (1 ml); 20 ml 0.25% plain bupivacaine + 5 mg DEX (0.5 ml) and 40 mg MPA (1 ml) will be administered through an iPACK block.
88845192|NCT04187898|Experimental|Early Phase: Eflapegrastim @ 30mins post TC|"Eflapegrastim (13.2 mg/0.6 mL fixed dose, equivalent to 3.6 mg granulocyte colony-stimulating factor [G-CSF]).~Supplied in prefilled single-use syringes for subcutaneous injection.~Cycle 1: Administered on the same day as TC chemotherapy, 30 minutes from the end of TC administration.~Cycles 2-4: Administered 24 hours after TC chemotherapy administration.~Each cycle is 21 days."
89181183|NCT04870905|Experimental|ICRT arm|
89373292|NCT05273021||participants with substance use problems|"There are 2 subgroups:~Participants without intellectual disabilities~Participants with intellectual disabilities with and without severe mental illness"
89373293|NCT05271747|Active Comparator|AB- Kolicare|Probiotic multi-strain formulation comprising Bifidobacterium longum CECT7894 and Pediococcus pentosaceus CECT8830 in sunflower oil. Probiotic strains have Qualified Presumption of Safety (QPS) status by European Food Safety Authority
89373294|NCT05271747|Active Comparator|Reuteri gotas|Probiotic single-strain formulation comprising Lactobacillus reuteri DSM17938 in sunflower oil and medium-chain triglyceride oil. Probiotic strains have Qualified Presumption of Safety (QPS) status by European Food Safety Authority
89373295|NCT05259839|Experimental|Arm A (ABBV-383 with Pomalidomide and Dexamethasone)|Participants with relapsed or refractory (R/R) multiple myeloma (MM) who meet the criteria outline in the protocol will receive ABBV-383 with Pomalidomide and Dexamethasone.
89373296|NCT05259839|Experimental|Arm B (ABBV-383 with Lenalidomide and Dexamethasone)|Participants with R/R MM who meet the criteria outline in the protocol will receive ABBV-383 with Lenalidomide and Dexamethasone.
89373297|NCT05259839|Experimental|Arm C (ABBV-383 with Daratumumab and Dexamethasone)|Participants with R/R MM who meet the criteria outline in the protocol will receive ABBV-383 with Daratumumab and Dexamethasone.
88845193|NCT04187898|Experimental|Early Phase: Eflapegrastim @ 3 hours post TC|"Eflapegrastim (13.2 mg/0.6 mL fixed dose, equivalent to 3.6 mg G-CSF).~Supplied in prefilled single-use syringes for subcutaneous injection.~Cycle 1: Administered on the same day as TC chemotherapy, 3 hours from the end of TC administration.~Cycles 2-4: Administered 24 hours after TC chemotherapy administration.~Each cycle is 21 days."
89373298|NCT05259839|Experimental|Arm D (ABBV-383 with Nirogacestat)|Participants with R/R MM who meet the criteria outline in the protocol will receive ABBV-383 with Nirogacestat.
89373299|NCT05245058|Experimental|SPH5030 tablets|"Subjects will take SPH5030 tablets orally on an empty stomach once or twice a day.~Each subject will receive only one corresponding dose, and there were five dose groups: 50mg/ d, 100mg/ d, 200mg/ d, 300mg/ d and 400mg/ d."
89535004|NCT05008263||Patients with viral chronic liver disease at primary diagnosis|Patients with primary diagnosis of viral hepatitis B and hepatitis C who was referred for liver biopsy. All patients underwent liver shear wave elastography and dynamic liver scintigraphy evaluating liver physical and functional changes shortly prior to liver biopsy procedure.
89535005|NCT03325907|Experimental|template-guided biopsy|Participants receive transthoracic lung biopsy guided by navigational template.
89373302|NCT05224791||Gastric Bypass|The RYGB connects a limb of the intestine to a much smaller stomach pouch, which prevents the bile from entering the upper part of the stomach and esophagus, thereby effectively bypassing the remaining stomach and first segment of the small intestine.
89373303|NCT05224791||Sleeve Gastrectomy|"The SG is a restrictive procedure in which a partial left gastrectomy of the fundus and body of the stomach is performed in order to create a long tubular sleeve along the lesser curvature. The weight loss and resolution of comorbidities are attributed not only to the restrictive nature of the procedure but also to restriction by the pylorus, decreased ghrelin, increased satiety, increased gastric emptying, and faster small bowel transit times with a component of malabsorption."
89373304|NCT05224349||Group A|Participants with stable oral anti-spasticity treatment for at least 4 weeks prior to study entry
89373305|NCT05224349||Group B|Participants with no anti-spasticity therapy for at least 4 weeks prior to study entry
89373306|NCT05217420|Experimental|Moving Well|Participants will receive weekly calls for 12 weeks (7 weeks before total knee arthroplasty surgery and 5 weeks after surgery) from a peer coach, an exercise program, and mental preparation (through positive thinking) for surgery. Participants will also receive the standard of care for patients undergoing total knee arthroplasty.
89373307|NCT05217420|Active Comparator|Staying Well|Participants will receive weekly calls for 12 weeks (7 weeks before total knee arthroplasty surgery and 5 weeks after surgery) from a research assistant. The calls will be similar in length to those in the experimental arm and will cover various health topics not related to total knee arthroplasty. Participants will also receive the standard of care for patients undergoing total knee arthroplasty.
89373308|NCT05206773|Experimental|Venglustat|Participant will receive venglustat dose once daily up to 12 months
89373309|NCT05206773|Placebo Comparator|Placebo|Participants will receive placebo once daily up to 12 months
88845194|NCT04187898|Experimental|Early Phase: Eflapegrastim @ 5 hours post TC|"Eflapegrastim (13.2 mg/0.6 mL fixed dose, equivalent to 3.6 mg G-CSF).~Supplied in prefilled single-use syringes for subcutaneous injection.~Cycle 1: Administered on the same day as TC chemotherapy, 5 hours from the end of TC administration.~Cycles 2-4: Administered 24 hours after TC chemotherapy administration.~Each cycle is 21 days."
88845195|NCT04187898|Experimental|Expansion Phase: Eflapegrastim @ 30 mins post TC|"Eflapegrastim (13.2 mg/0.6 mL fixed dose, equivalent to 3.6 mg G-CSF).~Supplied in prefilled single-use syringes for subcutaneous injection.~Cycles 1-4: Administered on the same day as TC chemotherapy, 30 minutes following the end of TC administration.~Each cycle is 21 days."
89373312|NCT05191797|Experimental|Treatment (bomedemstat, atezolizumab)|Patients receive bomedemstat PO QD on days 1-21 and atezolizumab IV on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89373313|NCT05188105|Experimental|real tACS|Single session of alpha tACS (12 Hz) at 3 mA over the occipital cortex.
89373314|NCT05188105|Placebo Comparator|sham tACS|Single session of sham tACS over the occipital cortex.
89373315|NCT05187624|Experimental|Part I: Dose Escalation|Participants with newly diagnosed GBM will receive RO7428731, intravenously (IV), up to one year or until disease progression, withdrawal of consent, unacceptable toxicity, or death, whichever occurs first.
89373316|NCT05187624|Experimental|Part II: Dose-Expansion(s)|Participants with newly diagnosed GBM will receive RO7428731, IV, in maximum of two dose expansion cohorts at a dose(s) not exceeding the maximum tolerated dose (MTD) established in Part I.
88845196|NCT04142437||GI|adult patients with gastrointestinal (GI) cancer
88845197|NCT04142437||H&N|adult patients with head and neck (H&N) cancer
89373317|NCT05187624|Experimental|Part III: Safety Run-in|Participants with recurrent GBM will receive RO7428731, IV in a dosing schedule determined in Part I. At the end of the Safety Run-in period, a decision will be made as to whether to open the Dose-Expansion Cohort Part IVA or open a second Safety Run-in Cohort at a lower dose.
89373318|NCT05187624|Experimental|Part IV A: Dose-Expansions Cohort|Participants with recurrent GBM will receive RO7428731, IV at specified doses and dosing schedules.
89373319|NCT05179603|Experimental|Cohort A: (sub study 01) classic Hodgkin lymphoma (cHL)|SAR444245 and pembrolizumab administered every 3 weeks on Day 1 of each cycle (21 days per cycle) for up to 35 cycles.
88845198|NCT04142437||STS|adult patients with soft tissue sarcoma (STS)
88845199|NCT04142437||CNS|adult patients with primary central nervous system (CNS) cancer
88845200|NCT04142437||Lung|adult patients with lung cancer
88845201|NCT04142437||Melanoma|adult patients with melanoma
88845202|NCT04142437||Pediatric|all pediatric patients regardless of tumor type will be enrolled under this cohort
88845203|NCT04142437||other|patients with other tumor types
88845204|NCT04128956|Experimental|Aspirin®|"To show if a combination therapy of rivaroxaban plus Aspirin® is more efficient (superiority testing) as rivaroxaban alone in the prevention of early venous stent thrombosis in patients suffering from post-thrombotic syndrome in the first 6 months following endovascular therapy.~To demonstrate tolerability of combination therapy of Aspirin® plus rivaroxaban in long-term treatment."
88845205|NCT04128956|No Intervention|Control group|Observational study of standard of care anticoagulation (rivarobaban dosis defined in the clinical routine).
88845206|NCT04117087|Experimental|Treatment Phase|KRAS Vaccine Peptide, Nivolumab and Ipilimumab
88845207|NCT04117087|Experimental|Reinduction Treatment Phase|KRAS Vaccine Peptide, Nivolumab and Ipilimumab
88845208|NCT04101357|Experimental|Part 1A - monotherapy dose escalation|BNT411 monotherapy
88845209|NCT04101357|Experimental|Part 1B - combination dose escalation|BNT411 in combination with atezolizumab, carboplatin, and etoposide
88845210|NCT04101357|Experimental|Part 2 - expansion cohorts|BNT411 either as monotherapy or in combination with with atezolizumab, carboplatin, and etoposide
89002212|NCT05979831|Experimental|DS-2325a|"Participants will be randomized to receive a single initial (loading) dose of DS-2325a (Week 1) followed by (maintenance) doses for a total of 12 weeks (Main Phase).~Participants will receive DS-2325 doses for a total of 24 weeks (Extension Phase)."
89002213|NCT05979831|Placebo Comparator|Placebo|Participants will be randomized to receive a single initial loading dose of placebo followed by maintenance doses of placebo for a total of 12 weeks (Main Phase).
89181184|NCT02587689|Experimental|anti-MUC1 CAR T Cells|The subject's T cells will be modified in one or two different ways that will allow the cells to identify and kill the MUC1+ tumor cells.
89181185|NCT04082403|Active Comparator|Pre SALAD education group|Each trainee was asked to intubate a mannequin with a contaminated airway
89373320|NCT05179603|Experimental|Cohort C1: (sub study 03) diffuse large B Cell lymphoma (DLBCL)|SAR444245 administered every 2 weeks on Day 1 of each cycle (14 days per cycle) for up to 52 cycles.
89373321|NCT05178082|Experimental|VP group|Participants are linked to online informative videos on chronic pain produced by the Multidisciplinary Pain Centre (Rigshospitalet, DK). Ten video-modules of 2-6 minutes each. 1. Chronic pain development in Denmark, treatment offered at the Centre. 2. How chronic pain can affect life in all its facets. Chronic complex pain explained. 3. Psychological models used to describe affected life domains. The role of dysfunctional thoughts on e.g. anxiety. 4. The connection between pain and factors that can reduce energy level. 5. Pain interference in the familiar dynamic and relations. 6. Information about how to balance activity and rest - and on daily breathing exercises. 7. The Rules and opportunities when health challenges working life e.g. work relocation. 8. The importance of healthy habits regarding eating, sleep, and self-treating. 9. Selection of medication according to the patient's quality of life. 10. Expected side effects of medication and on measures to counteract side effects.
89399283|NCT03539510|Experimental|HF-ACP Website|The HF-ACP website leads participants through 4 e-learning modules. Each module contains 3 core elements: (1) educational content which provides information and support to help patients complete the module (2) interactive tools for documenting their thoughts and progress and (3) motivational video clips that encourage behavior change by validating participants ambivalence, suggesting strategies to help participants complete the task and to encourage and reassure participants that they can do this.
89535006|NCT02490917|Experimental|ACT™ device|Patients randomized to receive the Adjustable Continence Therapy device ACT™
89535007|NCT02490917|Other|AMS 800 ™ device|Patients randomized to receive the artificial urinary sphincter AMS 800 ™
88845211|NCT04098016|Experimental|Intervention|Participants will receive: 1) tailored behavior change goals, 2) self-monitoring with tailored feedback, and 3) skills training.
88845212|NCT04088396|Experimental|Baricitinib|Baricitinib given orally.
88845213|NCT04088396|Placebo Comparator|Placebo|Placebo given orally.
88845214|NCT04078035|Experimental|Socio-evaluative Speech Stress, then Control|Participants will attend two laboratory sessions. At the first session, participants will complete a socio-evaluative speech task, which is a widely used, highly effective way to investigate stress responses in a laboratory setting. Participants will prepare and deliver a brief, 3-minute speech defending themselves against an alleged transgression (e.g., running a stop sign). The speech will be delivered in front of a video camera, a mirror and an audience (the interviewer and another staff member). Participants will be told that their non-verbal behaviors are being evaluated. At the second session, participants will rest quietly for the same period as the speech task, in the absence of the stressor.
88845215|NCT04078035|Experimental|Control, then Socio-Evaluative Speech Stress|Participants will attend two laboratory sessions. At the first session, participants will rest quietly for 5 minutes. At the second session, participants will complete a socio-evaluative speech task, which is a widely used, highly effective way to investigate stress responses in a laboratory setting. Participants will prepare and deliver a brief, 3-minute speech defending themselves against an alleged transgression (e.g., running a stop sign). The speech will be delivered in front of a video camera, a mirror and an audience (the interviewer and another staff member). Participants will be told that their non-verbal behaviors are being evaluated.
89373322|NCT05178082|Experimental|ER group|Participants will attend a single-session, 2-hour online group class. The program has two main components: didactics and skills acquisition. Participants will learn about pain self-regulation and self-management. The program content includes strategies to empower individuals with chronic non-cancer pain as following: 1) the identification of unhelpful thought patterns in the moment, 2) regulation of cognition and emotion, including thought reframing and mindset, 3) how to decrease physiological hyperarousal using relaxation techniques (binaural relaxation audio file for diaphragmatic breathing and progressive muscle relaxation), and 4) establishing self-soothing actions. At the end of the class, participants will develop a self-tailored plan for implementing these skills/strategies in daily life to use behaviors that modulate attention and counteract helplessness (Darnall et al 2014). The online class will be delivered by a nurse certified in the ER.
89373323|NCT05178082|No Intervention|Control group|Participants in the control group will not receive any of the interventions. This project will not interfere with any current or future pain treatment. After the end of collecting data, the Multidisciplinary Pain Centre will eventually make available the videos that compose VP to all patients.
89373324|NCT05177055|Experimental|n=15, sleep-school 6 weeks|Patients receive treatment as usual in the psychiatric clinic combined with participation in the sleep-school. They have already been given education on sleep regulation and sleep hygiene advice in the first meeting with the sleep-school facilitator.
89373325|NCT05177055|Experimental|n=15, sleep-school 6 weeks and additive bb-glasses|Patients receive treatment as usual in the psychiatric clinic combined with participation in the sleep school and additive treatment with bb-glasses. They have already been given education on sleep regulation and sleep hygiene advice in the first meeting with the sleep-school facilitator.
89373326|NCT05177055|Active Comparator|n=30 Six-week wait list for sleep-school|Patients receive treatment as usual in the psychiatric clinic while they wait for participation in the sleep school. They have already been given education on sleep regulation and sleep hygiene advice in the first meeting with the sleep-school facilitator.
89373327|NCT05166577|Experimental|Nanatinostat in combination with valganciclovir|
89373328|NCT05166577|Experimental|Nanatinostat in combination with valganciclovir and pembrolizumab|
89535008|NCT03325127||Radium-223 concomitant with Abiraterone or Enzalutamide|Approximately 150 medical charts from mCRPC patients within the network will be collected
89373330|NCT05156957|Experimental|intervention group|The study intervention is a brief physiotherapeutic assessment, a brief information on the expected course of the condition, and a brief instruction on self-management, including three exercises for daily self-guided therapy.
89373331|NCT05156957|No Intervention|control group|The control group will receive written information on the expected course of the condition, written instructions on self-management and written instructions on exercises for daily self-guided therapy.
89373332|NCT05145309|Experimental|Potassium Magnesium Citrate (KMgCit) first then Placebo|Patients will be asked to take KMgCit ( Sterling Pharmaceutical Services) first for 4 weeks. The content of each sachet will be dissolved in 250 ml water and will be drunk with breakfast and again with dinner during the KMgCit Phase, to deliver 40 meq K, 20 meq Mg and 74 meq citrate per day. Then, subjects will be asked to take Placebo packaged in an identical sachet by dissolving in 250 ml water and drink it with breakfast and again with dinner for 4 weeks
89373333|NCT05145309|Experimental|Placebo first then KMgCit|Patients will be asked to take Placebo packaged in an identical sachet by dissolving in 250 ml water and drink it with breakfast and again with dinner for 4 weeks. Then, subjects will be asked to take KMgCit (Sterling Pharmaceutical Services, Dupo, IL) after dissolving in 250 ml water and drink it with breakfast and again with dinner for 4 weeks
89373334|NCT05133726|Experimental|Text Message cluster|This arm will receive only daily text message support for six months plus weekly text message over 6 weeks (six information text messages all together)
89373335|NCT05133726|Experimental|Text message with or without peer support|All individuals in this cluster will receive daily text message support for six months plus weekly text message over 6 weeks (six information text messages all together) with some selected members also receiving peer support for six months
88845219|NCT04062669|Experimental|Low dose (Ld-) RG SAM (CNE) group|"In Part 1 of the study, healthy adults, 18 to 40 years of age, will receive one intramuscular injection of RG SAM (CNE) low dose formulation vaccine in one arm and one intramuscular injection of saline solution in the opposite arm at Days 1 and 61).~In Part 2 of the study, healthy adults, 18 to 40 years of age, will receive one intramuscular injection of RG SAM (CNE) low dose formulation vaccine in one arm according to a 0, 2, 6-month schedule (i.e. at Days 1 and 61)"
88845220|NCT04062669|Experimental|Medium dose (Md-) RG SAM (CNE) group|Healthy adults,18 to 40 years of age, will receive one intramuscular injection of RG SAM (CNE) medium dose formulation vaccine in one arm and one intramuscular injection of saline solution in the opposite arm at Day 1.
88845221|NCT04062669|Experimental|Lower dose (Lrd-) RG SAM (CNE) group|Healthy adults, 18 to 40 years of age, will receive one intramuscular injection of RG SAM (CNE) lower dose formulation vaccine in one arm according to a 0, 2, 6-month schedule (i.e. at Days 1 and 61)
88845222|NCT04062669|Experimental|Lowest dose (Ltd-) RG SAM (CNE) group|Healthy adults, 18 to 40 years of age, will receive one intramuscular injection of RG SAM (CNE) lowest dose formulation vaccine in one arm according to a 0, 2, 6-month schedule (i.e. at Days 1 and 61)
88845223|NCT04062669|Placebo Comparator|Saline Placebo group|"In Part 1 of the study, healthy adults, 18 to 40 years of age, will receive two intramuscular injections of saline placebo, one in each arm, according to a 0, 2, 6-month schedule (i.e. at Days 1 and 61).~In Part 2 of the study, healthy adults, 18 to 40 years of age will receive one intramuscular injections of saline placebo in one arm according to a 0, 2, 6-month schedule (i.e. at Days 1 and 61)."
89002214|NCT05978284|Experimental|Part 1: Dose Escalation|"During the dose-escalation, an accelerated titration design (ATD) will be utilized for the first two dose groups (0.03mg and 0.1 mg), and the conventional 3+3 dose escalation method will be used for the subsequent dose groups. The entire duration of 28 days after the first dose of ZG006 is defined as the dose-limiting toxicity (DLT)."
89002215|NCT05978284|Experimental|Part 2: Dose Expansion|Participants will receive the RP2D/MTD identified in Part 1 (dose exploration) of the study.
89181186|NCT04082403|Experimental|Post SALAD education group|Each trainee was asked to intubate a mannequin with a contaminated airway after receiving SALAD training
89002216|NCT05965583|Experimental|BI 1815368 (Reference, R) then BI 1815368 + Itraconazole (Test, T)|
89181187|NCT04862325|No Intervention|Usual care|"Control group will follow the standard preoperative measures Enhanced Recovery After Surgery (ERAS®) established in the protocols of our hospital. Standard preoperative measures: recommendation of nutritional and physical activity and advice to stop smoking and reduce alcohol intake; optimization of preoperative pathologies including anaemia. An information document on ERAS® measures in our center will be attached to all of them."
89181188|NCT04862325|Experimental|Multimodal prehabilitation|Patients following the standard preoperative policies of our institution and the multimodal prehabilitation program
89181189|NCT00919737|Experimental|NPC-08|
89373336|NCT05133726|No Intervention|Control group|This group will only receive usual care plus weekly text message over 6 weeks (six information text messages all together) with provides information about community services
88845224|NCT04062669|Active Comparator|RabAvert group|"In Part 1 of the study, healthy adults, 18 to 40 years of age, will receive one intramuscular injection of RabAvert in one arm and one intramuscular injection of saline solution in the other arm, according to a 0, 2, 6-month schedule (i.e. at Days 1 and 61).~In Part 2 of the study, healthy adults, 18 to 40 years of age, will receive one intramuscular injection of RabAvert in one arm according to a 0, 2, 6-month schedule (i.e. at Days 1 and 61)."
88845225|NCT04059146|Experimental|Pain Education + Exercise|"The goals of the pain education intervention are for patients to 1) address fear of movement and pain catastrophizing specific to AT, 2) learn about the neurophysiology of pain, 3) develop coping skills, and 4) promote exercise participation through pacing. This program enables patients to have a conceptual change in their understanding of what causes pain, gain greater control over the psychological aspects of pain, and reduce the perceived threat of chronic pain.~All participants will receive the same progressive Achilles tendon loading exercise program."
88845226|NCT04059146|Active Comparator|Standard Education + Exercise|"The comparison group will be given education based on standard of care resources that primarily utilize a biomedical model, which assumes that AT pain is primarily caused by tissue damage.~All participants will receive the same progressive Achilles tendon loading exercise program."
89181190|NCT02587611|Experimental|Elemental liquid diet|"Elemental liquid diet (200 kcal/200 mL) is labeled with 100 mg [13C]sodium acetate and healthy subjects drink it within 5 min.~Elemental liquid diet (200 kcal/200 mL) is labeled with 100 mg [13C]sodium acetate and is administered within 15 min using the gastrostomy tube."
89373337|NCT05133440|Experimental|Experimental Arm|Participants will receive two cycles of Radium (Ra-223) dichloride at 55 kBq/kg or 0.00149 mCi/kg or 1.49 uCi/kg every 4 weeks followed 2-3 weeks later by SBRT at a dose of 9 Gy per fraction for 3 fractions (total dose of 27 Gy) to all sites of radiographically apparent metastatic disease. SBRT to the target index lesion(s) should be completed within 30 days after simulation after completion of the 2nd infusion of Radium (Ra-223) dichloride. Specific dose constraints, dosing schedules, and management of SBRT to multiple sites will be at the discretion of the treating Radiation oncologist. The goal is to complete simulation and SBRT within 30 days. Only active or progressive disease is to be treated at the discretion of the treating investigator.
89373338|NCT05133440|Active Comparator|Control Arm:|Participants will receive SBRT at a dose of 9 Gy per fraction for 3 fractions (total dose of 27 Gy) to all sites of radiographically apparent metastatic disease. SBRT fractions can be administered every day or every other day per institutional practice. SBRT should begin within 30 days (+/- 7 days) of randomization. Only active or progressive disease is to be treated at the discretion of the treating investigator.
89373339|NCT05131477|Experimental|KY1005 Dose Level 1|Every 4 weeks
89373340|NCT05131477|Experimental|KY1005 Dose Level 2|Every 4 weeks
89373341|NCT05131477|Experimental|KY1005 Dose Level 3|Every 4 weeks
89373342|NCT05131477|Experimental|KY1005 Dose Level 4|Every 4 weeks
89373343|NCT05131477|Placebo Comparator|Placebo|Every 4 weeks
89373344|NCT05120960|Experimental|Group A|will receive tepotinib alone
89373345|NCT05120960|Experimental|Group B|will receive tepotinib and osimertinib
89373346|NCT05120661|Experimental|Carbohydrate-rich food product (to be determined)|This is a nutritional product, such as bread or cake, containing 50 gram carbohydrates.
89373347|NCT05120661|Experimental|Another carbohydrate-rich food product (to be determined)|This is a nutritional product, such as bread or cake, containing 50 gram carbohydrates.
89373348|NCT05111626|Experimental|Part 1 Safety Lead-in: Bemarituzumab with mFOLFOX6 and Nivolumab|Participants will be administered bemarituzumab at different doses with mFOLFOX6 and nivolumab to determine the recommended phase 3 dose (RP3D) based on occurrence of dose-limiting toxicities (DLTs), and on an evaluation of the overall safety, tolerability, and pharmacokinetics (PK).
89373349|NCT05111626|Experimental|Part 2: Bemarituzumab with chemotherapy (mFOLFOX6 or CAPOX) and Nivolumab|"Participants will be administered bemarituzumab at the RP3D determined from Part 1 in combination with mFOLFOX6 and nivolumab on a 14-day cycle.~Or participants will be administered bemarituzumab in combination with CAPOX and nivolumab on a 21-day cycle."
89373350|NCT05111626|Placebo Comparator|Part 2: Placebo with chemotherapy (mFOLFOX6 or CAPOX) and Nivolumab|"Participants will be administered placebo comparator in combination with mFOLFOX6 and nivolumab on a 14-day cycle.~Or participants will be administered placebo comparator in combination with CAPOX and nivolumab on a 21-day cycle."
89373351|NCT05104567|Experimental|Cohort A (Sub-study 01): 2-3L ESCC Post PD-1/PD-L1|SAR444245 and pembrolizumab are administered every 3 weeks on Day 1 of each cycle (21 days per cycle) for up to 35 cycles.
89373352|NCT05104567|Experimental|Cohort B1 (Sub-study 02): 1-3L GC/GEJ PD1/PD-L1 naïve non-MSI-H CPS ≥1|SAR444245 and pembrolizumab are administered every 3 weeks on Day 1 of each cycle (21 days per cycle) for up to 35 cycles.
88845227|NCT04047862|Experimental|Phase 1|"Cycle 1 (28 Days): A flat dose of ociperlimab as a single agent on Day 1. In the first cycle, 200 mg tislelizumab will be administered on Day 8.~If ociperlamib is tolerated in Cycle 1, participants will receive tislelizumab + ociperlimab sequentially on Day 29 and every 21 days for up to 8 months."
88845228|NCT04047862|Experimental|Phase 1b Cohort 1|Participants with metastatic squamous NSCLC will receive ociperlamib + tislelizumab + paclitaxel/nab-paclitaxel + Carbo once every 3 weeks (Q3W) for 4 to 6 cycles (21 days each) followed by ociperlimab + tislelizumab Q3W)
88845229|NCT04047862|Experimental|Phase 1b Cohort 2|Participants with metastatic squamous NSCLC will receive ociperlimab + tislelizumab + pemetrexed + Cis/Carbo Q3W for 4 to 6 cycles (21 days each) followed by ociperlamib+tislelizumab Q3W)
88845230|NCT04047862|Experimental|Phase 1b Cohort 3|Participants with metastatic NSCLC (PD-L1 positive, [TC] ≥ 1%) will be treated with ociperlimab + tislelizumab
88845231|NCT04047862|Experimental|Phase 1b Cohort 4|Patients with extensive stage SCLC will be treated with ociperlimab + tislelizumab + etoposide + Cis/Carbo Q3W for up to 6 to 8 cycles followed by ociperlamib+tislelizumab Q3W
88845232|NCT04047862|Experimental|Phase 1b Cohort 5|Checkpoint inhibitor (CPI)-experienced NSCLC patients will be treated with ociperlimab plus tislelizumab
88845233|NCT04047862|Experimental|Phase1b Cohort 6|Patients with metastatic ESCC will be treated with ociperlimab + tislelizumab + cisplatin + 5-fluorouracil /paclitaxel Q3W for 6 cycles followed by ociperlamib+tislelizumab Q3W
88845234|NCT04047862|Experimental|Phase1b Cohort 7|Patients with metastatic EAC will be treated with ociperlimab + tislelizumab + cisplatin + 5-fluorouracil or paclitaxel Q3W for 6 cycles followed by ociperlamib+tislelizumab Q3W
88845235|NCT04047862|Experimental|Phase1b Cohort 8|Patients with recurrent or metastatic HNSCC (PD-L1 positive, vCPS≥ 1%) will be treated with ociperlimab + tislelizumab Q3W
88845236|NCT04047862|Experimental|Phase1b Cohort 9|Patients with metastatic G/GEJ carcinoma will be treated with ociperlimab + tislelizumab + [oxalipatin + capecitabine] or [cisplatin + 5-fluorouracil] Q3W for 6 cycles followed by ociperlamib+tislelizumab + capecitabine Q3W
88845237|NCT04047862|Experimental|Phase 1b Cohort10|Patients with metastatic NSCLC (PD-L1 positive, [TC] ≥ 1%) will be treated with tislelizumab in combination with ociperlimab 450mg, 900mg or 1800mg Q3W.
88845238|NCT04042467|Experimental|Greenlight Plus|"Families will receive the Greenlight intervention plus a health information technology (HIT) intervention aimed at supporting family goal-setting and behavior change.~This design allows us to determine if HIT and the asynchronous support it provides between well-child visits can promote additional behavior change and obesity prevention."
88845239|NCT04042467|Active Comparator|Greenlight|During each of the recommended well child visits from 0-24 months, pediatric residents, trained in clear health communication skills and shared goal-setting, will use the Greenlight Toolkit of low literacy, age- specific, parent education booklets to promote healthy family behaviors and obesity prevention.
88845240|NCT04008030|Experimental|Arm A: Nivolumab Monotherapy|
88845241|NCT04008030|Experimental|Arm B: Nivolumab + Ipilimumab Combination|
88845242|NCT04008030|Active Comparator|Arm C: Investigator's Choice Chemotherapy|Participants in Arm C would be allowed to receive Nivolumab + Ipilimumab if they progress
88845243|NCT04005105|Active Comparator|Intensive management|"Baseline mean blood pressure (MAP) and central venous pressure (CVP) will be measured to calculate baseline mean perfusion pressure. Intra-surgical values of ± 25% basal MAP will be maintained and once in the ICU an algorithm corresponding to group~1 based on cardiac index and MPP will be followed for 24 hours."
88845244|NCT04005105|No Intervention|Standard management|MAP during surgery will be maintained > 60 mmHg according to usual protocol. Once in ICU, during the first 24 hours an algorithm corresponding to group 2 based on cardiac index, MAP and CVP will be followed.
88845245|NCT03997981||Breast cancer patients with weekly/biweekly paclitaxel regimen|
88845246|NCT03997981||Breast cancer patients receiving docetaxel regimen|
89181191|NCT02587611|Active Comparator|Standard semi-solid diet|"Standard semi-solid diet (200 kcal/200 mL) is labeled with 100 mg [13C]sodium acetate and healthy subjects drink it within 5 min.~Standard semi-solid diet (200 kcal/200 mL) is labeled with 100 mg [13C]sodium acetate and is administered within 15 min using the gastrostomy tube."
89181192|NCT04848051|Experimental|CRC screening reminder|Participants randomized to the CRC Reminder arm will receive reminder that they are due/overdue for CRC screening
89373353|NCT05104567|Experimental|Cohort B2 (Sub-study 02): 1-3L GC/GEJ PD1/PD-L1 naïve non-MSI-H CPS < 1|SAR444245 and pembrolizumab are administered every 3 weeks on Day 1 of each cycle (21 days per cycle) for up to 35 cycles.
88845247|NCT03997981||Lymphoma patients receiving vincristine regimen|
88845248|NCT03997981||Multiple myeloma patients receiving bortezomib regimen|
88845249|NCT03997981||Colorectal cancer patients receiving oxaliplatin-based regimens|
88845250|NCT03977480|Active Comparator|Hemay007 400 mg BID group|Patients will orally take Hemay007 tablets 400 mg BID for 12 weeks.
88845251|NCT03977480|Active Comparator|Hemay007 800 mg QD group|Patients will orally take Hemay007 tablets 800 mg QD for 12 weeks.
88845252|NCT03977480|Active Comparator|Hemay007 600 mg BID group|Patients will orally take Hemay007 tablets 600 mg BID for 12 weeks.
88845253|NCT03977480|Placebo Comparator|placebo group|Patients will orally take placebo tablets for 12 weeks.
88845254|NCT03976518|Experimental|ATEZOLIZUMAB|Atezolizumab will be administered at a flat dose of 1200 mg by intravenous route. Atezolizumab will be delivered in 250-mL 0.9% NaCl (sodium chloride) intravenous (IV) infusion bags. The administration will be repeated every 3 weeks (21 [± 3] days). The initial dose will be delivered over 60 (± 15) minutes. In case the first infusion is tolerated without any infusion-associated AEs the second infusion may be delivered over 30 (± 10) minutes. If the second 30 minutes infusion is well tolerated all the subsequent infusions may be administered over 30 (± 10) minutes. The treatment will be continued until disease progression, intolerable toxicity, patient refusal or Investigator's decision or any criterion for withdrawal from the trial or trial drug is fulfilled.
88845255|NCT03954067|Experimental|Dose Escalation - cutaneous or subcutaneous lesions|Participants will receive ASP9801 on days 1 and 15 of 28 day cycles to determine the recommended phase 2 dose. After cycle 2, participants who have not met any discontinuation criteria and receiving clinical benefit may be treated on continuous cycles until treatment discontinuation criteria are met.
89181193|NCT04848051|Experimental|CRC Reminder & Short message|Participants randomized to the CRC Reminder & short message arm will receive reminder that they are due/overdue for CRC screening and short message to encourage screening
89373354|NCT05104567|Experimental|Cohort B3 (Sub-study 02): 2-4L GC/GEJ Post PD1/PD-L1 non-MSI-H|SAR444245 and pembrolizumab are administered every 3 weeks on Day 1 of each cycle (21 days per cycle) for up to 35 cycles.
89373355|NCT05104567|Experimental|Cohort C (Sub-study 03): 2-3L HCC Post PD-1/PD-L1|SAR444245 and pembrolizumab are administered every 3 weeks on Day 1 of each cycle (21 days per cycle) for up to 35 cycles.
89373356|NCT05104567|Experimental|Cohort D1 (Sub-study 04): 3-6L CRC non-MSI-H any RAS|SAR444245 and pembrolizumab are administered every 3 weeks on Day 1 of each cycle (21 days per cycle) for up to 35 cycles.
89373357|NCT05104567|Experimental|Cohort D2 (Sub-study 04): 3-6L CRC non-MSI-H RAS wild type|SAR444245 is administered every 3 weeks on Day 1 of each cycle (21 days per cycle) and cetuximab is administered on Day 1, Day 8 and Day 15 of each cycle until progressive disease.
89373358|NCT05101798|Experimental|5-aminolevulinic acid hydrochloride (Gleolan®)|Gleolan® is available in colorless glass vials containing 1.5 g 5-aminolevulinic acid hydrochloride (Gleolan®) Gleolan® is administered orally to patients prior to tumor removal by surgery (20 mg/kg BW).
89373359|NCT05101096|Experimental|Sacituzumab Govitecan-hziy 6 mg, Advanced Solid Tumors|(Phase 1 Cohort A: dose escalation) Japanese participants with advanced solid tumors will receive sacituzumab govitecan-hziy (SG) 6 mg/kg by intravenous (IV) injection on Day 1 and Day 8 of a 21-day cycle until disease progression or unacceptable toxicity.
89373360|NCT05101096|Experimental|Sacituzumab Govitecan-hziy 8 mg, Advanced Solid Tumors|(Phase 1 Cohort A: dose escalation) Japanese participants with advanced solid tumors will receive SG 8 mg/kg by IV injection on Day 1 and Day 8 of a 21-day cycle until disease progression or unacceptable toxicity.
89373361|NCT05101096|Experimental|Sacituzumab Govitecan-hziy 10 mg, Advanced Solid Tumors|(Phase 1 Cohort A: dose escalation) Japanese participants with advanced solid tumors will receive SG 10 mg/kg by IV injection on Day 1 and Day 8 of a 21-day cycle until disease progression or unacceptable toxicity.
89373362|NCT05101096|Experimental|Sacituzumab Govitecan-hziy 6 mg, UGT1A1 Polymorphism|(Phase 1 Cohort B: dose escalation) Japanese participants with UGT1A1 polymorphism will receive SG 6 mg/kg by IV injection on Day 1 and Day 8 of a 21-day cycle until disease progression or unacceptable toxicity.
89373363|NCT05101096|Experimental|Sacituzumab Govitecan-hziy 8 mg, UGT1A1 Polymorphism|(Phase 1 Cohort B: dose escalation) Japanese participants with UGT1A1 polymorphism will receive SG 8 mg/kg by IV injection on Day 1 and Day 8 of a 21-day cycle until disease progression or unacceptable toxicity.
89373364|NCT05101096|Experimental|Sacituzumab Govitecan-hziy 10 mg, UGT1A1 Polymorphism|(Phase 1 Cohort B: dose escalation) Japanese participants with UGT1A1 polymorphism will receive SG 10 mg/kg by IV injection on Day 1 and Day 8 of a 21-day cycle until disease progression or unacceptable toxicity.
89373365|NCT05101096|Experimental|Sacituzumab Govitecan-hziy, Metastatic Triple-negative Breast Cancer (mTNBC)|(Phase 2: dose expansion) Japanese participants with mTNBC will receive SG at the recommended Phase 2 dose (RP2D) on Day 1 and Day 8 of a 21-day cycle until disease progression or unacceptable toxicity.
89373366|NCT05101096|Experimental|Sacituzumab Govitecan-hziy, HR+/HER2- Metastatic Breast Cancer (HR+/HER2- mBC)|(Phase 2) Japanese participants with HR+/HER2- mBC will receive SG at the recommended Phase 2 dose (RP2D) on Day 1 and Day 8 of a 21 day cycle until disease progression or unacceptable toxicity.
89373367|NCT05101096|Experimental|Sacituzumab Govitecan-hziy, Metastatic Urothelial Carcinoma (mUC)|(Phase 2) Japanese participants with mUC will receive SG at the recommended Phase 2 dose (RP2D) on Day 1 and Day 8 of a 21 day cycle until disease progression or unacceptable toxicity.
89373368|NCT05094336|Experimental|Part 1a, Phase 1: AMG 193 Monotherapy Dose Exploration|"Participants with MTAP-null solid tumors will receive escalating doses of AMG 193 to estimate the MTD and/or the RP2D.~A group of these participants in the United States (US) will have the option to take part in a Drug Substance Particle Size (DSPS) assessment. These participants will receive escalating doses of AMG 193 and a dose of a comparator AMG 193 test tablet."
89373369|NCT05094336|Experimental|Part 1c, Phase 1: AMG 193 Monotherapy Dose Expansion|Participants will receive the identified MTD/RP2D of AMG 193 in the following cohort: MTAP-null or lost MTAP expression NSCLC.
89373370|NCT05094336|Experimental|Part 2a, Phase 1: AMG 193 Dose Exploration + Docetaxel|Participants with MTAP-null NSCLC will receive escalating doses of AMG 193 + a fixed dose of docetaxel to estimate the MTD/RP2D of the combination.
89373371|NCT05094336|Experimental|Part 2b, Phase 1: AMG 193 + Docetaxel Dose Expansion|Participants with MTAP-null NSCLC will receive the identified MTD/RP2D of AMG 193 + docetaxel.
89181194|NCT04848051|Experimental|CRC Reminder and Navigation Program|Participants randomized to the CRC reminder and navigation program arm will receive reminder that they are due/overdue for CRC screening and short message to participate in the health navigation program that will connect participants to individually tailored resources and assistance
89373372|NCT05094336|Experimental|Part 3: AMG 193 Phase 2|Participants with MTAP-null solid tumors will receive AMG 193.
89373373|NCT05094336|Experimental|Part 1e, Phase 1: AMG 193 Monotherapy Dose Expansion|Participants will receive the identified selected dose/MTD of AMG 193 in the following cohort: MTAP-null BTC.
89373374|NCT05094336|Experimental|Part 1f, Phase 1: AMG 193 Monotherapy Dose Expansion|"Participants will receive the identified selected dose/MTD of AMG 193 in the following cohort:~MTAP-null head and neck squamous cell carcinoma (HNSCC)"
89373375|NCT05094336|Experimental|Part 1g, Phase 1: AMG 193 Monotherapy Dose Expansion|"Participants will receive the identified selected dose/MTD of AMG 193 in the following cohort:~MTAP-null pancreatic adenocarcinoma"
89373376|NCT05094336|Experimental|Part 1h, Phase 1: AMG 193 Monotherapy Dose Expansion|Participants will receive the identified selected dose/MTD of AMG 193 in the following cohort: MTAP-null or lost MTAP expression solid tumors (other than lymphoma or primary brain tumor).
89373377|NCT05094336|Experimental|Part 1i, Phase 1: AMG 193 Dose Optimization|Participants will receive a randomized dose optimization evaluation of AMG 193.
89373378|NCT05094336|Experimental|Part 1j, Phase 1: AMG 193 DSPS Substudy (US Sites Only)|Participants will receive doses of AMG 193 and comparator AMG 193 test tables at different times in a fasted state.
89373379|NCT05094336|Experimental|Part 1k, Phase 1: AMG 193 Food Effect Substudy (US Sites Only)|Participants will receive AMG 193 once on a fasted state and once after eating a standardized high-fat, high calorie meal.
89181195|NCT04848051|Experimental|CRC Reminder & CRC education|Participants randomized to the CRC reminder and CRC education program arm will receive reminder that they are due/overdue for CRC screening and offered short educational program conducted online
89181196|NCT04847661|Active Comparator|Mefloquine arm|"Mefloquine hydrochloride will be given in a dose of 1100-1650 mg, according to body weight (BW), splitted into two to three doses.~30kg≤BW<45kg: 825mg followed by 275mg after 6-8 hours~45kg≤BW<60kg: 825mg followed by 550mg after 6-8 hours~60kg≤BW: 825mg followed by 550mg after 6-8 hours and then 275mg 6-8 hours after the second dose"
89181197|NCT04847661|Placebo Comparator|Control arm|A similar tablet of non-active gradients was specifically manufactured for the study by EVA Pharma company. The placebo tablets exactly resemble the active treatment mefloquine tablets (the same shape, size and color).
89181198|NCT00919815|Experimental|ciclosporin arm|ciclosporin reducing regimen lasting 24 weeks (additional prednisolone given for the first four weeks)
89181199|NCT00919815|Active Comparator|prednisolone|standard course of prednisolone given in a reducing regimen over 24 weeks
89181200|NCT02587377|Other|Cohort 1|single cohort of patient
89181201|NCT00796991|Active Comparator|Arm A|
89181202|NCT00796991|Active Comparator|Arm B|
89181203|NCT00796991|Active Comparator|Arm C|
89181204|NCT05682183|Active Comparator|Multi-domain Psychoeducation Self-management Programme|Participants will be registered at the care centre and will receive usual care from their care manager who is assigned to them when they register with the centre. Those who are randomised into the intervention arm will undergo 5-sessions of Multi-domain Psychoeducation Self-management Programme over 5 weeks.
89181205|NCT05682183|Active Comparator|Treatment as Usual|Participants will be registered at the care centre and will receive usual care from their care manager who is assigned to them when they register with the centre.
89181206|NCT04082247|Experimental|Experimental group|The education and training of early childhood educators (developed by the researchers) and their intervention on children.
89181207|NCT04082247|No Intervention|Control group|Receive the standard care.
89181208|NCT04112225|Active Comparator|Positive affect condition|Participants use Happify as it is currently available to consumers on the main site, including all engagement elements. Users may access a wide variety of 4-week programs and use them in any way they desire for the entire study period.
89181209|NCT04112225|Sham Comparator|Psychoeducation condition|Participants complete a series of quizzes and polls on Happify designed to engage them in thinking about well-being topics, but without giving any specific instructions for how to promote well-being. Participants gain access to 8 weeks worth of content, but may repeat the content as often as they like in the follow-up period.
89181210|NCT04787211|Experimental|BRII-196 and BRII-198 in adult subjects with severe COVID-19|
89181211|NCT04787211|Experimental|BRII-196 and BRII-198 in adult subjects with mild-moderate COVID-19|
89181212|NCT04787211|Experimental|Placebo in adult subjects with mild-moderate COVID-19|
89181213|NCT04112147|Experimental|Antroquinonol capsule 100mg|Patients will receive 12-week of 50mg BID Antroquinonol
89181214|NCT04112147|Experimental|Antroquinonol capsule 200mg|Patients will receive 12-week of 100mg BID Antroquinonol
89181215|NCT04112147|Placebo Comparator|Placebo oral capsule|Patients will receive 12-week of 50mg BID Antroquinonol placebo
89181216|NCT04081857|Experimental|Sequence 1|Period 1 : Fasted state + HGP1810 Period 2 : Fasted state + HCP1704
89181217|NCT04081857|Experimental|Sequence 2|Period 1 : Fasted state + HCP1704 Period 2 : Fasted state + HGP1810
89181218|NCT02604953||Ocular Hypertension patients|Ocular hypertension patients are recruited from the Wills Eye Hospital Glaucoma Service. Short Duration Transient Visual Evoked Potential (SD- tVEP) and Pattern electroretinogram (PERG) testing will be conducted.
89535009|NCT03325049|Experimental|The health-promoting conversations|In the intervention group, there were 3 health-promoting conversations with each family after the discharge. The health-promoting conversations were held within an approximately 4- to 8-week period with an interval of 2 weeks between conversations. A closing letter was sent 2 to 3 weeks after the final conversation that summarized all of the conversations and that provided further opportunities for reflection.
89181219|NCT02604953||Healthy Controls|Healthy adults are recruited from staff, family and friends of Wills Eye Hospital Glaucoma Research Center. Short Duration Transient Visual Evoked Potential (SD- tVEP) and Pattern electroretinogram (PERG) testing will be conducted.
89181220|NCT02604953||Glaucoma patients|Glaucoma patients are recruited from the Wills Eye Hospital Glaucoma Service. Short Duration Transient Visual Evoked Potential (SD- tVEP) and Pattern electroretinogram (PERG) testing will be conducted.
89181221|NCT04773171|Experimental|CACR Group|Participants of CACR group will attend individual computer-assisted cognitive remediation sessions. Researcher will give instruction in the use of the computerized training programs and assists participants during their training sessions.
89181222|NCT04773171|Active Comparator|TAU Group|Participants of TAU group will attend usual training sessions offered by the training centres with similar intensity and frequency as the CACR training.
89181223|NCT02605109||RiskMERS|Exposed to case-patients
89181224|NCT00914771|Active Comparator|H5N1 pandemic Influenza vaccine 3.75µg|
89181225|NCT00914771|Active Comparator|H5N1 pandemic Influenza vaccine 7.5µg|
89181226|NCT04114331|Experimental|Manual therapy and exercise|"The intervention (3 times a week for 4 weeks, for a total of 12 sessions) consisted primarily of manual therapy (soft tissue and joint mobilization) followed by therapeutic exercises (muscular control and coordination).~Manual therapy:~Joint mobilizations (Grades I-V) to cervical spine, thoracic spine and ribs Soft tissue mobilization to the pectoralis, scaleni, upper traps, thoracolumbar fascia, erector spinae, and suboccipital musculature~Therapeutic exercises:~Strengthening of mid and lower traps, lats, glut med, and glut max. Active & passive stretching of thoracic and lumbar rotation, hip flexors, and plantarflexors.~The treating therapists agreed on a protocol with treatment individualized to each patient."
89181227|NCT02586987|Experimental|Dose escalation: Selumetinib+MEDI4736|"An oral formulation of selumetinib will be administered in combination with an IV dose of MEDI4736. 4 cohorts of double combination (Selumetinib+MEDI4736).~The decision to escalate to the next dose level/cohort will be made by the Safety Review Committee (SRC) following the completion of the dose limiting toxicity (DLT) assessment period for at least 3 evaluable patients in each cohort."
89535010|NCT03325049|Active Comparator|Control Arm|Usual Care
89373380|NCT05085886|Experimental|DepCare Intervention|The clinic (administrators, staff, care managers) will receive quality improvement support and education around depression screening as well as local technical assistance for mental health treatment optimization. The cluster of primary care providers in the intervention arm will receive education and decisional support for optimizing mental health treatment and access to quality improvement/implementation meetings. Eligible patients will receive a tool that facilitates enhanced screening, diagnosis recognition, treatment selection support, psychoeducation, and activation.
89373381|NCT05085886|Active Comparator|Enhanced Usual Care|The clinic (administrators, staff, care managers) will receive quality improvement support and education around depression screening as well as local technical assistance for mental health treatment optimization. The cluster of primary care providers and patients in the active comparator arm will have access to this clinic-level strategy (i.e., the same clinic level intervention as in the DepCare group), but will not receive any provider or patient-level interventions.
89373382|NCT05063565|Experimental|TheraSphere followed by Durvalumab and Tremelimumab|TheraSphere followed by Tremelimumab plus Durvalumab administered once, then repeated administration of Durvalumab monthly up 18 months.
89373383|NCT05061420|Experimental|Cohort A1 (sub study 01) treatment- naïve|Participants with HNSCC, who are treatment-naïve for R/M disease and have a PD-L1 Combined Positive Score (CPS) ≥1, will receive pembrolizumab followed by SAR444245. Both drugs administered by intravenous (IV) infusion on Day 1 of each 21-day treatment cycle for up to 35 cycles.
89373384|NCT05061420|Experimental|Cohort B1: (sub study 04) PD1/PD-L1 and platinum-based treatments|Participants with HNSCC who have received treatment with a PD1/PD-L1-based regimen & platinum-based regimen and have failed no more than 2 regimens for R/M disease, will receive pembrolizumab followed by SAR444244. Both drugs administered IV infusion on Day 1 of each 21-day treatment cycle for up to 35 cycles
89373385|NCT05061420|Experimental|Cohort B2: (sub study 05) cetuximab- naïve|Participants with R/M HNSCC, who are cetuximab-naïve, have received treatment with a platinum-based regimen, and have failed no more than 2 regimens for R/M disease, will receive treatment with cetuximab followed by SAR444245. Cetuximab IV will be given on days 1, 8, and 15 of each 21 day. SAR444245 will be administered by IV infusion on Day 1 of each 21-day treatment cycle. Dosing of both drugs is to continue until disease progression, unacceptable toxicity, or withdrawal of consent.
89373386|NCT05052385||ECP only (aGVHD patients)|Patients treated with ECP and other Standard Of Care treatments (SOC)
89373387|NCT05052385||ECP and Ruxolitinib (aGVHD patients)|Patients treated with ECP and Ruxolitinib
89373388|NCT05052385||Ruxolitinib only (aGVHD patients)|Patients treated with Ruxolitinib and other Standard Of Care treatments (SOC)
89373389|NCT05052385||ECP only (cGVHD patients)|Patients treated with ECP and other Standard Of Care treatments (SOC)
89373390|NCT05052385||ECP and treatment combination (cGVHD patients)|Patients treated with ECP and Ruxolitinib or Ibrutinib
89373391|NCT05052385||Treatment combination only (cGVHD patients)|Patients treated with Ibrutinib and/or Ruxolitinib and other Standard Of Care treatments (SOC)
89373393|NCT05039515|Experimental|IPN60130 high dosage|Oral capsule, swallowed whole or sprinkled onto food, once daily
89373394|NCT05039515|Experimental|IPN60130 low dosage|Oral capsule, swallowed whole or sprinkled onto food, once daily
89373395|NCT05039515|Placebo Comparator|Placebo|Oral capsule, swallowed whole or sprinkled onto food, once daily
89373396|NCT05035030|Experimental|Odevixibat (A4250)|Capsules for oral administration once daily for 72 weeks.
89373397|NCT05033379|Experimental|Control Arm|Instruction about importance of sleep.
89373398|NCT05033379|Experimental|Coaching|Undergo resilience coaching
89373399|NCT05033132|Experimental|Balstilimab|Balstilimab monotherapy: approximately 147 patients.
89373400|NCT05033132|Experimental|Balstilimab + Zalifrelimab|Balstilimab in combination with Zalifrelimab (combination therapy): approximately 30 patients.
89373401|NCT05031416|Experimental|Consumers who smoke at outpatient community mental health clinic|Consumers with serious mental illness who attend outpatient community mental health clinic will participate in a smoking cessation with the LTQ application and nicotine replacement therapy
89373402|NCT05027802|Experimental|Palovarotene Chronic/Flare-Up Regimen|"Chronic treatment: participants will receive 5 mg palovarotene or the dose received during participation in the parent study at the time of transition to Study CLIN-60120-452 or prior to interrupting/stopping palovarotene treatment.~Flare-up treatment: at the time of a flare-up (or substantial high-risk traumatic event likely to lead to a flare-up) participants will receive 20 mg palovarotene for 28 days, followed by 10 mg palovarotene for 56 days."
89373403|NCT05027763|No Intervention|Control Arm|Standard care - patients will not receive specific dietary advice.
89373404|NCT05027763|Experimental|High Fiber/low fat|Patients will receive sample meals and education/support, will be asked to follow this diet for 10 days.
89373405|NCT05027763|Experimental|Fermented|Patients will receive sample meals and education/support, will be asked to follow this diet for 10 days.
89373406|NCT05018650|Experimental|Route 92 Medical Monopoint Reperfusion System|Aspiration thrombectomy with the Route 92 Medical HiPoint 88 and HiPoint 70 Reperfusion Catheters as part of the Monopoint Reperfusion System to treat acute ischemic stroke
89373407|NCT05018650|Active Comparator|Aspiration Predicate|Aspiration thrombectomy with a predicate aspiration device to treat acute ischemic stroke
89373408|NCT05018585|Experimental|Diamyd|Patients will be assigned to receive i) three (3) intralymphatic injections with 4µg Diamyd (rhGAD) on Days 0, 30, and 60 and; ii) oral vitamin D 2000 IU/daily for 4 months (from Day -30 through Day 90)
89373409|NCT05018585|Placebo Comparator|Placebo|Patients will be assigned to receive i) three (3) intralymphatic injections of Placebo for Diamyd (rhGAD) on Days 0, 30, and 60 and; ii) oral vitamin D 2000 IU/daily for 4 months (from Day -30 through Day 90)
89373410|NCT05009069|Experimental|Atezolizumab + Tiragolumab|"Weeks 1-5: Radiotherapy to the pelvis on Days 1-5 every week. Chemotherapy: Capecitabine or fluorouracil (5-FU) 5 days/week during radiotherapy.~Day 1 of Weeks 8, 11 and 14: Atezolizumab plus tiragolumab (Day 1 of each 21-day cycle for 3 cycles)."
89373411|NCT05009069|Other|Atezolizumab|"Weeks 1-5: Radiotherapy to the pelvis on Days 1-5 every week. Chemotherapy: Capecitabine or fluorouracil (5-FU) 5 days/week during radiotherapy.~Day 1 of Weeks 8, 11 and 14: Atezolizumab (Day 1 of each 21-day cycle for 3 cycles)."
89373412|NCT05006729||RURAL cohort study|A longitudinal research project in ten rural counties in Alabama, Kentucky, Louisiana, and Mississippi enrolling approximately 4,600 participants from these communities, examining several different aspects of their health, including heart and lung function.
89373413|NCT05003843|Other|Single Arm|Use of Indigo Aspiration System in patients with obstruction due to DVT
89373414|NCT05001282|Experimental|ELU001|Dose Escalation: Escalating doses of ELU001 Dose Expansion: Recommended Dose for Expansion (or RP2D)
89373415|NCT05001269|Experimental|Open-Label DCR-PHXC|Open-Label monthly subcutaneous injection of DCR-PHXC based on age and weight.
88845256|NCT03954067|Experimental|Dose Escalation - visceral lesions|Participants will receive ASP9801 on days 1 and 15 of 28 day cycles to determine the recommended phase 2 dose. After cycle 2, participants who have not met any discontinuation criteria and receiving clinical benefit may be treated on continuous cycles until treatment discontinuation criteria are met.
89373416|NCT04994717|Experimental|Safety Run-in: Blinatumomab alternating with low-intensity chemotherapy|"The safety run-in will be performed prior to initiating the phase 3 randomized part of the study. This safety run-in is to evaluate the safety and tolerability of blinatumomab alternating with low-intensity chemotherapy.~The safety run-in also evaluates a shorter dose step interval from (4 days instead of 7 days) and a 1-week (instead of 2-week) drug free interval between blinatumomab cycles. Blinatumomab will be infused at a lower dose for 4 days and increase to a higher dose on Day 5 of the infusion for the remainder of the infusion."
89373417|NCT04994717|Experimental|Phase 3: Blinatumomab alternating with low-intensity chemotherapy|Participants will receive blinatumomab alternating with low-intensity chemotherapy.
89373418|NCT04994717|Active Comparator|Phase 3: Standard of care (SOC) chemotherapy|Participants will receive 1 of 2 SOC chemotherapy regimens (GMALL or HyperCVAD) per investigator's choice.
89373419|NCT04987775|Active Comparator|N-Acetyl Cysteine (NAC)|Participants who are randomized to the intervention arm will receive N-Acetyl-L-Cysteine (Free-Form/NAC) 900mg two times a day for 8 weeks after the initiation of the first dose of study drug.
89373420|NCT04987775|Placebo Comparator|Placebo|Participants who are randomized to the placebo arm will take matching placebo two times a day for 8 weeks after the initiation of the first dose of study drug.
89373421|NCT04987307|Experimental|Arm A: Efavaleukin alfa|Efavaleukin alfa Dose 1 administered by SC injection once every two weeks (Q2W)
89373422|NCT04987307|Experimental|Arm B: Efavaleukin alfa|Efavaleukin alfa Dose 2 administered by SC injection Q2W
89373423|NCT04987307|Experimental|Arm C: Efavaleukin alfa|Efavaleukin alfa Dose 3 administered by SC injection Q2W
89373424|NCT04987307|Placebo Comparator|Arm D: Placebo|Placebo Q2W
89373425|NCT04980625|Active Comparator|RIC+Standard medical treatment|RIC+Standard medical treatment Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mm Hg. RIC will be conducted twice daily for 7 consecutive days from thrombolysis. Additionally, the patients will be treated with standard medical treatment according to the Guidelines for diagnosis and treatment of acute ischemic stroke in China 2014.
89373426|NCT04980625|Placebo Comparator|Sham RIC+Standard medical treatment|Sham RIC+Standard medical treatment Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mm Hg. RIC will be conducted twice daily for 7 consecutive days from thrombolysis. Additionally, the patients will be treated with standard medical treatment according to the Guidelines for diagnosis and treatment of acute ischemic stroke in China 2014.
89373427|NCT04974541|Experimental|Cardiac rehabilitation with standard psychosocial care plus Heart Health Yoga|Subjects will participate in 12-weeks of cardiac rehabilitation with standard psychosocial care plus Heart Health Yoga
89373428|NCT04974541|Active Comparator|Cardiac rehabilitation with standard psychosocial care|Subjects will participate in 12-weeks of cardiac rehabilitation with standard psychosocial education component
88845257|NCT03954067|Experimental|Dose Expansion (Monotherapy) - cutaneous or subcutaneous lesions|Participants will receive ASP9801 on days 1 and 15 of 28 day cycles at the dose recommended by the dose escalation phase. After cycle 2, participants who have not met any discontinuation criteria and receiving clinical benefit may be treated on continuous cycles until treatment discontinuation criteria are met.
89373429|NCT04973124|Active Comparator|SEVODEX Group|The SEVODEX group will receive intraoperative dexmedetomidine at a fixed infusion rate of 0.25 mcg/kg/h
88845258|NCT03954067|Experimental|Dose Expansion (Monotherapy) - visceral lesions|Participants will receive ASP9801 on days 1 and 15 of 28 day cycles at the dose recommended by the dose escalation phase. After cycle 2, participants who have not met any discontinuation criteria and receiving clinical benefit may be treated on continuous cycles until treatment discontinuation criteria are met.
88845259|NCT03954067|Experimental|Dose Expansion (Monotherapy Induction) - cutaneous or subcutaneous lesions|Participants will receive ASP9801 on days 1, 8, 15 and 22 of the first 28 day cycle. Participants will receive ASP9801 on days 1 and 15 on the second 28 day cycle at the dose recommended by the dose escalation phase. After cycle 2, participants who have not met any discontinuation criteria and receiving clinical benefit may be treated on continuous cycles until treatment discontinuation criteria are met.
88845260|NCT03954067|Experimental|Dose Expansion (Combination Therapy) - cutaneous or subcutaneous lesions|Participants will receive ASP9801 on days 1 and 15 of 28 day cycles at the dose recommended by the dose escalation phase. Participants will also receive pembrolizumab starting on day 1 and once every 6 weeks. After cycle 2, participants who have not met any discontinuation criteria and receiving clinical benefit may be treated on continuous cycles until treatment discontinuation criteria are met.
88845261|NCT03954067|Experimental|Dose Expansion (Combination Induction Therapy) - cutaneous or subcutaneous lesions|Participants will receive ASP9801 on days 1, 8, 15 and 22 of first 28 day cycle at the dose recommended by the dose escalation phase. Participants will also receive pembrolizumab starting on day 1 and once every 6 weeks. Participants will receive ASP9801 on days 1 and 15 on the second 28 day cycle at the dose recommended by the dose escalation phase. After cycle 2, participants who have not met any discontinuation criteria and receiving clinical benefit may be treated on continuous cycles until treatment discontinuation criteria are met.
88845262|NCT03954067|Experimental|Dose Expansion (Combination Therapy) - visceral lesions|Participants will receive ASP9801 on days 1 and 15 of 28 day cycles at the dose recommended by the dose escalation phase. Participants will also receive pembrolizumab starting on day 1 and once every 6 weeks. After cycle 2, participants who have not met any discontinuation criteria and receiving clinical benefit may be treated on continuous cycles until treatment discontinuation criteria are met.
89373430|NCT04973124|Placebo Comparator|SEVO Group|The SEVO group will not receive dexmedetomidine during surgery.
89373431|NCT04971473|Experimental|rhTSH+Thyroid hormone withdrawal|"rhTSH: rhTSH(0.9 mg) was administered intramuscularly (IM) once daily (qd) for 2 days. Twenty-four hours following the second dose of rhTSH.Oral radioiodine was given 24 hours after the second injection of rhTSH, and scanning was done 48 hours after the radioiodine administration.~Thyroid hormone withdrawal: Patients stop taking thyroid hormone for 14 days, and then monitor the level of thyroid stimulating hormone every week. When TSH>30mU/L, an ablative activity of 131I was administered.and scanning was done 48 hours after the radioiodine administration."
89373432|NCT04969926||Patients with confirmed, suspected or at risk of developing parathyroid disorder|Parathyroid (and related disorders) will be evaluated and their biospecimens collected to define the molecular signature and clinical spectrum of their disorder
89373433|NCT04963296|Experimental|Obinutuzumab|Participants will receive obinutuzumab 1000 milligrams (mg) intravenous (IV) infusions on Day 1 and at Weeks 2, 24 and 26.
88845263|NCT03952624||Control|FNS <= 3
88845264|NCT03952624||Fatigued|FNS >= 4
88845265|NCT03938922|Experimental|Active Treatment|ENT-01 tablet will be taken once daily by mouth.
89181228|NCT02586987|Experimental|Mandatory paired biopsy expansion cohort: Selumetinib+MEDI4736|One or more independent mandatory paired biopsy expansion cohorts for double combination treatment will start after safety and tolerability have been established for the relevant dose. It will be tumour-type specific for double combination, the tumor type will be determined from emerging data.
89373434|NCT04963296|Placebo Comparator|Placebo|Placebo participants will receive obinutuzumab matched placebo on Day 1 and at Weeks 2, 24 and 26.
89373435|NCT04950842|Experimental|JB-101|induced T cell with suppressive function
89373436|NCT04950686|Experimental|Intervention - Media Aware for Young Adults|This arm will receive Media Aware for Young Adults between the pretest and posttest questionnaire. Media Aware for Young Adults is a web-based sexual and relationship health promotion program that uses a media literacy education (MLE) approach. The program is self-paced and includes four modules.
89373437|NCT04950686|Active Comparator|Active Control - Health Aware for Young Adults|This arm will receive Health Aware for Young Adults in between the pretest and posttest questionnaire. Health Aware for Young Adults is a web-based sexual and relationship health promotion program. The program contains the same health content as Media Aware for Young Adults but without the media literacy education components. The program is self-paced and includes four modules.
89373438|NCT04950686|No Intervention|Delayed Intervention Control|Participants in this condition will not receive a sexual or relationship health promotion program until after the 12-month follow-up survey. After that survey is complete, they will receive access to the Media Aware for Young Adults program.
89373439|NCT04949828||Participants on CREON|
89373440|NCT04936542|Other|Sequence 1|Participants will receive one cycle of aboBoNT-A followed by one cycle of onaBoNT-A in the selected overactive upper limb muscles
89373441|NCT04936542|Other|Sequence 2|Participants will receive one cycle of onaBoNT-A followed by one cycle of aboBoNT-A in the selected overactive upper limb muscles
89373442|NCT04935177|Experimental|Imlifidase|Imlifidase, is provided as a freeze-dried powder for concentrate for solution for infusion, 11 mg per vial. After reconstitution with sterile water for injection, the concentrate contains 10 mg/mL imlifidase. Imlifidase is administered intravenously as one infusion of 0.25 mg/kg over 15 minutes generally 24 hours prior to transplantation. A second dose of 0.25 mg/kg may be given if the first imlifidase dose is considered not to have had sufficient effect.
89373443|NCT04935177|Other|Best available treatment|Institution-specific desensitization protocol (i.e. any combination of plasma exchange (PLEX), intravenous IVIg, anti-CD20 antibody, and eculizumab) where appropriate OR remain on wait list for a more compatible organ offer
89373444|NCT04933539|Experimental|Arm 1|Daratumumab SC (Cycles 1-2: Days 1, 8, 15, 22; Cycles 3-6: Days 1, 15; Cycles =7: Days 1 of the 28-day cycle); Carfilzomib IV (Days 1, 8, 15 of the 28-day cycle); Dexamethasone PO/IV (Days 1, 8, 15, 22 of the 28-day cycle)
89373445|NCT04931654|Experimental|Dose Escalation Part A: NSCLC Immuno-oncology (IO) acquired or primary resistance|AZD7789 monotherapy
89373446|NCT04931654|Experimental|Dose Expansion Part B1: NSCLC IO acquired resistance - RP2D level 1|AZD7789 Monotherapy
89373447|NCT04931654|Experimental|Dose Expansion Part B2: NSCLC IO naive, PD-L1 50% or greater - RP2D level 1|AZD7789 Monotherapy
89373448|NCT04931654|Experimental|Dose Expansion Part B3: NSCLC IO acquired resistance - RP2D level 2|AZD7789 Monotherapy
88845266|NCT03921658||Cohort 1 - Cross-sectional (within 2 years of diagnosis)|Individuals diagnosed and treated for ovarian cancer in past two years, will complete 1 study measure
89373449|NCT04931654|Experimental|Dose Expansion Part B4: advanced or metastatic gastric and GEJC IO acquired resistance- RP2D level 1|AZD7789 monotherapy
89373450|NCT04931654|Experimental|Dose Expansion Part B5: NSCLC IO naive, PD-L1 1-49% - RP2D Level 1|AZD7789 monotherapy
89373455|NCT04914897|Experimental|Cohort A1: Non-small cell lung cancer 1rst line therapy with Tumor proportion score > 50%|SAR444245 + pembrolizumab, on day 1 of a 21-day treatment cycle (up 35 cycles).
89373456|NCT04914897|Experimental|Cohort A2: Non-small cell lung cancer 1rst line therapy with Tumor proportion score 1-49%|SAR444245 + pembrolizumab, on day 1 of a 21-day treatment cycle (up 35 cycles).
89373457|NCT04914897|Experimental|Cohort B1: Non-small cell lung cancer 2/3rd line therapy|SAR444245 + pembrolizumab, on day 1 of a 21-day treatment cycle (up 35 cycles).
89373458|NCT04914897|Experimental|Cohort C1: :Mesotheloma 2/3rd line therapy|SAR444245 + pembrolizumab, on day 1 of a 21-day treatment cycle (up 35 cycles).
88845267|NCT03921658||Cohort 2- Prospective (from diagnosis)|Individuals newly diagnosed with ovarian cancer, will complete 3 study measures (baseline/diagnosis, completion of chemotherapy, one year post-diagnosis)
88845268|NCT03906227|Active Comparator|low CD5+ /on maintenance|Subjects in remission with Cluster of Differentiation (CD)19+CD5+ lower than 43% will continue on maintenance immunosuppression (Maintenance Therapy Group)- no randomization.
88845269|NCT03906227|Active Comparator|high CD5/ on maintenance|Subjects in remission with CD19+CD5+ 43% or greater, randomized to continue on maintenance immunosuppression (Maintenance Therapy Group)
89373459|NCT04913129|No Intervention|Control Group|Standard physician-guided medical care after COVID-19
89373460|NCT04913129|Experimental|Interventional (exercise training) Group|8 week home-based exercise training
89373461|NCT04909008|Experimental|Exercise Training|Two sets of exercise testing (before and after) 10 weeks of supervised exercise training (3 sessions per week) at Mayo Clinic Florida.
89373462|NCT04909008|No Intervention|Control Groups|Two sets of exercise testing while continuing with standard medical care in between.
89373463|NCT04907799|Experimental|Daily Caloric Restriction|The daily caloric restriction group will participate in a 2-year, group-based, behavioral weight loss intervention based on a 30% reduction in caloric intake and increased physical activity.
89373464|NCT04907799|Other|Standard Advice Control|The standard advice control group will receive an initial consultation with a registered dietician regarding current clinical recommendations for ADPKD without subsequent counseling sessions.
89373465|NCT04903314|Experimental|Cohort I|Xcopri to be administered to ages 12 to < 18 years not to exceed 400 mg/day.
89373466|NCT04903314|Experimental|Cohort IIa|Xcopri to be administered to ages 6 to < 12 years not to exceed 400 mg/day.
88845270|NCT03906227|Experimental|high CD5 / NO maintenance|Subjects in remission with CD19+CD5+ 43% or greater , randomized to NO maintenance immunosuppression (NO Maintenance Therapy Group)
88845271|NCT03905538|Experimental|[18F]FLT-PET/CT Arm|The experimental [18F]FLT-PET/CT will be completed before initiation of chemotherapy and prior to the third cycle (or month) of chemotherapy. Laboratory analysis and correlative radiology, as directed per clinical care based on the primary diagnosis, are required within 30 days of the baseline [18F]FLT PET/CT. Follow-up will comprise 24 months of standard practice treatment and follow up.
88845272|NCT03898479|Experimental|CTP-543|Patients who previously completed a qualifying CTP-543 clinical trial
88845273|NCT03884439||Infliximab [infliximab biosimilar 3]|Patients with Crohn's Disease or Ulcerative Colitis treated by Infliximab BS
88845274|NCT03874936|Experimental|A; Dexamethasone twice|24mg intravenous Dexamethasone (Dexavital®, Vital Pharma) 4mg/ml just before the operation and repeated after 24 hours.
88845275|NCT03874936|Experimental|B; Dexamethasone once|24mg intravenous Dexamethasone just before the operation and placebo which is 6ml of isotonic sodium chloride (9mg/ml, 'normal' saline) after 24 hours
88845276|NCT03874936|Placebo Comparator|C; Placebo twice|placebo intravenous just before the operation and repeated after 24 hours
88845277|NCT03874858|Experimental|TFR1 stage- Nilotinib|"During TFR1 stage, all patients will be treated with nilotinib 300 mg QD for up to 48 weeks (consolidation period).~Patients with sustained DMR at the end of the consolidation period will enter the TFR1 period and nilotinib will be discontinued.~Patients with loss of MMR will return to the standard nilotinib administration~Patients with ≥ MMR, but without sustained DMR at the end of the consolidation period will be treated with nilotinib 300 mg QD"
88845278|NCT03874858|Experimental|TFR2 stage- Nilotinib+Asciminib|"During the TFR2 stage, participants will be treated with nilotinib and asciminib for up to 96 weeks (reinduction period).~Patients with sustained DMR at the end of reinduction will enter TFR2 and asciminib + nilotinib will be discontinued.~Patients with ≥ MMR, but without sustained DMR, at the end of the reinduction, will be treated with nilotinib monotherapy at 300 mg BID until the end of the TFR2 stage.~Patients with loss of MMR at any time during reinduction or during nilotinib monotherapy will be discontinued from the study."
88845279|NCT03844061|Experimental|MMF + Rituximab + Belimumab|Two infusions of 1000 mg of Rituximab, two weeks apart, weekly subcutaneous injections of 200 mg of Belimumab, and background MMF, 1000 -1500 mg twice daily for 48 weeks.
88845280|NCT03844061|Placebo Comparator|MMF + Placebo + Placebo|Two placebo infusions of normal saline, two weeks apart, weekly saline placebo subcutaneous injections, and background MMF, 1000 -1500 mg twice daily for 48 weeks.
89002217|NCT05965349|Experimental|Group-based MBCT|A telephone-based, 8-week MBCT session including: (1) learning mindfulness skills; (2) practicing mindfulness skills in class and at home; and (3) dialogue and inquiry.
89002218|NCT05956106|Experimental|Metabolic syndrome patients|Dried Mulberry fruit powder is used for preventing symptoms in Metabolic Syndrome patients Dietary intervention: Black Mulberry fruit powder Dosage: 45g per day
89373467|NCT04903314|Experimental|Cohort IIb|Xcopri to be administered to ages 4 to < 6 years not to exceed 400 mg/day.
89373468|NCT04903314|Experimental|Cohort III|Xcopri to be administered to ages 2 to < 4 years not to exceed 400 mg/day.
89373469|NCT04901806|Experimental|Phase 1 Dose Escalation|
89373470|NCT04901806|Experimental|Phase 2 Cohort Expansion|
89373471|NCT04892953|Experimental|Cohort A (oligoprogressive)|Patients undergo LCT consisting of radiation therapy and/or surgery, then receive durvalumab IV over 1 hour on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89373472|NCT04892953|Experimental|Cohort B (polyprogressive)|Patients undergo LCT consisting of radiation therapy and/or surgery, then receive durvalumab IV over 1 hour on day 1. Patients also receive one of the following chemotherapy options: carboplatin and paclitaxel on day 1, carboplatin on day 1 and nab-paclitaxel on days 1, 8, 15, or carboplatin on day 1 and gemcitabine on days 1 and 8. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients with non-squamous histology receive pemetrexed on day 1 every 21 days for cycles 1-4, pemetrexed and durvalumab IV on day 1 every 28 days in the absence of disease progression or unacceptable toxicity.
89373475|NCT04884399|Experimental|CMAB818|0.5 mg by intravitreal injection once on the first day.
89373476|NCT04884399|Active Comparator|Lucentis®|0.5 mg by intravitreal injection once on the first day.
89373477|NCT04879862|Experimental|Locomotion|Participants will receive 160 locomotor training sessions with epidural stimulation. These sessions may occur once a day (stand and step will alternate days) or twice a day (stand and step on the same day) as recommended by the study physician. Participants will train 5 days per week and each session will last between 1 to 1.5 hours.
88845281|NCT03829410|Experimental|Onvansertib + FOLFIRI + Bevacizumab|"Phase 1b: Onvansertib escalating starting dose of 12 mg/m^2 orally Day 1 through Day 5 and Day 15 through Day 19 of each 28-day cycle in combination with FOLFIRI (180 mg/m^2 irinotecan, 400 mg/m^2 leucovorin, 400 mg/m^2 bolus 5-fluorouracil (5-FU), and 2400 mg/m^2 continuous intravenous infusion 5-FU + 5 mg/kg bevacizumab. This Phase 1b portion of the study has been completed.~Phase 2: Onvansertib Recommended Phase 2 Dose (RP2D) of 15 mg/m^2 orally Day 1 through Day 5 and Day 15 through Day 19 of every 28-day cycle in combination with FOLFIRI (180 mg/m^2 irinotecan, 400 mg/m^2 leucovorin, 400 mg/m^2 bolus 5-fluorouracil (5-FU), and 2400 mg/m^2 continuous intravenous infusion 5-FU + 5 mg/kg bevacizumab, with treatment modifications or delays based on unresolved toxicity experienced during a previous cycle."
88845282|NCT03826342|Experimental|Health Check-up for Expectant Moms|Theory-driven and derived from empirical support
88845283|NCT03826342|Active Comparator|Time, attention, and information-matched control|Well-validated
88845284|NCT03818217|Experimental|Coach Pepper group|Pepper is a humanoid socially assistive robot.
88845285|NCT03818217|Other|Tablet group|Tablet training
88845286|NCT03796767|Experimental|Arm A (radiation therapy)|Patients with bone metastases undergo SBR) or hypofractionated radiation per institutional standard of care guidelines at investigator's discretion.
88845287|NCT03796767|Experimental|Arm B (salvage oligometastasectomy)|Patients with nodal metastases undergo salvage oligometastasectomy.
88845288|NCT03796767|Experimental|Arm C (salvage oligometastasectomy, radiation therapy)|Patients with nodal metastases undergo salvage oligometastasectomy. Following recovery, patients undergo SBRT or hypofractionated radiation per institutional standard of care guidelines at investigator's discretion. Within 4 months following completion of salvage therapy (defined as the combination of oligometastasectomy and/or bone radiation) and depending on PSA response as well as previous treatment, patients may receive adjuvant nodal IMRT.
88845289|NCT03786185|Experimental|Adolescents with dyslexia|MusicPlast training
88845290|NCT03786185|Active Comparator|Adolescents without dyslexia|MusicPlast training
89373478|NCT04879862|Experimental|Bladder+Locomotion|Participants will receive 80 sessions of bladder training alone followed by 80 sessions of locomotor training sessions with epidural stimulation. They will be asked to continue with your bladder training once you start locomotor training. Locomotor Training sessions may occur once a day (stand and step will alternate days) or twice a day (stand and step on the same day) as recommended by the study physician. Participants will train 5 days per week and each session will last between 1 to 1.5 hours.
88845291|NCT03786185|Experimental|Young Adults|MusicPlast training
88845292|NCT03786185|Active Comparator|Young Adults Control|MusicPlast Control, in a similar design as MusicPlast
88845293|NCT03786185|Experimental|Seniors|MusicPlast training
88845294|NCT03781986|Experimental|APG-115 monotherapy|APG-115 will be administered in an open label fashion until progression, intolerance, or patient preference.
88845295|NCT03781986|Experimental|APG-115 + Carboplatin [terminated]|APG-115 and Carboplatin will be administered in an open label fashion until progression, intolerance, or patient preference. [Phase 1 was terminated early and this arm was discontinued. An MTD was not established during Phase 1.]
88845296|NCT03761849|Experimental|RO7234292 Q8W|RO4234292 is administered intrathecally every 8 weeks.
88845297|NCT03761849|Experimental|RO7234292 Q16W|RO7234292 is administered intrathecally every 16 weeks. Participants in this arm will also receive placebo at alternate weeks to keep the blind.
88845298|NCT03761849|Placebo Comparator|Placebo|Placebo will be administered every 8 weeks by IT injection.
88845299|NCT03732105|Experimental|Surgery-radiotherapy|Patients in the surgery-radiotherapy group will receive Intensity Modulated Radiation Therapy (IMRT) at a dose of 50Gy/25fraction after surgery. After radiotherapy, patients will be actively monitored.
88845300|NCT03732105|No Intervention|Surgery group|Patients in the surgery group will be actively monitored after randomization.
88845301|NCT03713658|Experimental|Oral Risperidone|Participants will receive 3 milligram (mg) oral risperidone tablets once daily for up to one Week to determine tolerability based on investigator review.
88845302|NCT03713658|Experimental|Paliperidone Palmitate Once Monthly (PP1M)|Participants will receive 50, 75, 100 or 150 mg eq. ([paliperidone palmitate] mg equivalent [to paliperidone]) long acting formulation of paliperidone palmitate once monthly (PP1M) intramuscular injection for 4 months (17 weeks) plus option to continue 3 more months if not stabilized depending on the participant's clinical safety, tolerability and efficacy requirements.
88845303|NCT03713658|Experimental|Paliperidone Palmitate Every 3 Months (PP3M)|Participants will receive 175, 263, 350 or 525 mg eq. ([paliperidone palmitate] mg equivalent [to paliperidone]) long acting formulation of paliperidone palmitate every 3 months (PP3M) intramuscular injection for 24 Weeks.
89181229|NCT02586987|Experimental|Dose escalation: Selumetinib+MEDI4736+tremelimumab|"An oral formulation of selumetinib will be administered in combination with an IV dose of MEDI4736 and an IV dose of tremelimumab.~For triple combination treatment, the starting dose of selumetinib (DL1) will be determined by the SRC based on emerging data from dose escalation cohorts of double combination treatment."
88845308|NCT03704350|Active Comparator|20-24.9 BMI|Participants with a BMI that falls between 20 and 24.9 who will receive the controlled diet
88845309|NCT03704350|Active Comparator|25-29.9 BMI|Participants with a BMI that falls between 25 and 29.9 who will receive the controlled diet
88845310|NCT03704350|Active Comparator|30-34.9 BMI|Participants with a BMI that falls between 30 and 34.9 who will receive the controlled diet
88845311|NCT03704350|Active Comparator|35-39.9 BMI|Participants with a BMI that falls between 35 and 39.9 who will receive the controlled diet
88845312|NCT03704350|Active Comparator|40-44.9 BMI|Participants with a BMI that falls between 40 and 44.9 who will receive the controlled diet
88845313|NCT03704350|Active Comparator|45-50 BMI|Participants with a BMI that falls between 45 and 50 who will receive the controlled diet.
88845314|NCT03669653|Active Comparator|RIC+Standard medical treatment|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mm Hg. RIC will be conducted twice daily for 7 days. Additionally,the patients will be treated with standard medical treatment according to Guidelines for diagnosis and treatment of acute ischemic stroke in China 2014
88845315|NCT03669653|Placebo Comparator|Sham RIC+Standard medical treatment|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 60 mm Hg. RIC will be conducted twice daily for 7 days. Additionally,the patients will be treated with standard medical treatment according to Guidelines for diagnosis and treatment of acute ischemic stroke in China 2014
89181230|NCT02586987|Experimental|Mandatory paired biopsy expansion cohort: triple combination|One or more independent mandatory paired biopsy expansion cohorts for triple combination treatment will start after safety and tolerability have been established for the relevant dose. It will be tumour-type specific for triple combination, the tumor type will be determined from emerging data.
89181231|NCT04007861||Patients with pain|"This will be the group of patients in whom pain is a significant enough problem, that they have been referred to the specialist Pain Management Team. These patients will be identified retrospectively.~Patients seen in Pain Management Clinics between 1st of January 2016 and 31st of December 2018, who have consented to be included in the Pain Management database and have a clinician specified pain diagnosis of pain persistent post-surgical pain following breast cancer treatment will be identified. If these patients have an unclear pain diagnosis, they will not be included."
89181232|NCT04007861||Patients without pain|"This will be the group of patients in whom pain is deemed not to be a significant problem.~Once again, these patients will be identified retrospectively. Appropriately matched patients to the 52 patients in the patients with pain will be identified using records of hospital operating lists by the peri-operative medicine team.~Patients will be matched based upon the following details:~Age (within 5 years of matched case)~Surgical procedure (matched for the following elements:~Surgery to breast tissue (biopsy, lumpectomy, wide-local excision or mastectomy)~+/- Sentinal lymph node biopsy or axillary dissection~+/- Reconstruction~Surgical procedure within 3-months of matched case.~Provided these individuals have not had an appointment with or referral to the Pain Management Team, they will be included in the matched controls."
89181233|NCT04114253||Liver transplant patients|Adult patients undergoing deceased donor liver transplantation.
89181234|NCT02586753|Experimental|Paclitaxel plus Cisplatin with radiotherapy|patients will receive concurrent chemoradiotherapy with drug Paclitaxel plus Cisplatin
89181235|NCT02586753|Experimental|S1 plus Cisplatin with radiotherapy|patients will receive concurrent chemoradiotherapy with drug S1 plus Cisplatin
89181236|NCT00799487|Experimental|1|CONCERTA (methylphenidate HCl) or placebo Optimal Subject Dose (18mg-54mg) once daily during Lab School Day #1 with placebo on Day #2
89181237|NCT00799487|Experimental|2|CONCERTA (methylphenidate HCl) or placebo Optimal Subject Dose (18mg-54mg) once daily during Lab School Day #2 with placebo on Day #1
89181238|NCT00584727|Active Comparator|senofilcon A/alphafilcon A/etafilcon A|First intervention:senofilcon A toric contact lenses Second intervention: alphafilcon A toric contact lenses Third intervention: etafilcon A sphere contact lenses
89181239|NCT00584727|Active Comparator|alphafilcon A/etafilcon A/senofilcon A|First intervention: alphafilcon A toric contact lenses Second intervention: etafilcon A sphere contact lenses Third intervention: senofilcon A toric contact lenses
89181240|NCT00584727|Active Comparator|etafilcon A/senofilcon A/alphafilcon A|First intervention: etafilcon A sphere contact lenses Second intervention:senofilcon A toric contact lenses Third intervention: alphafilcon A toric contact lenses
89181241|NCT00584727|Active Comparator|senofilcon A/etafilcon A/alphafilcon A|First intervention: senofilcon A toric contact lenses Second intervention: etafilcon A sphere contact lenses Third intervention: alphafilcon A toric contact lenses
89181242|NCT00584727|Active Comparator|alphafilcon A/senofilcon A/etafilcon A|First intervention: alphafilcon A toric contact lenses Second intervention: senofilcon A toric contact lenses Third intervention: etafilcon A sphere contact lenses
89181243|NCT00584727|Active Comparator|etafilcon A/alphafilcon A/senofilcon A|First intervention: etafilcon A sphere contact lenses Second intervention: alphafilcon A toric contact lenses Third intervention: senofilcon A toric contact lenses
89181244|NCT04081935|Experimental|Reduce pain and fair|To determine whether the virtual reality as a distracting intervention could reduce pain and fear in school-age children receiving intravenous injections at an emergency department.
89181245|NCT04081935|No Intervention|Compared|Normal treatment
89181246|NCT00799409|Experimental|1|CONCERTA (methylphenidate HCl) / Placebo Optimal Subject Dose (18 mg-54 mg) once daily during Lab School Day #1 and Placebo once daily on Lab School Day #2
89181247|NCT00799409|Experimental|2|Placebo/ CONCERTA (methylphenidate HCl) Placebo once daily on Lab School Day #1 and Optimal Subject Dose (18 mg-54 mg) once daily during Lab School Day #2
89181248|NCT00782210|Experimental|Olodaterol (BI 1744) Low|Low dose inhaled orally once daily from the Respimat inhaler
89181249|NCT00782210|Experimental|Olodaterol (BI 1744) High|High dose inhaled orally once daily from the Respimat inhaler
89181250|NCT00782210|Placebo Comparator|Placebo|Olodaterol (BI1744) placebo inhaled orally once daily from the Respimat inhaler
89181251|NCT04111679|Experimental|Music|During laparoscopic task performance; participants will wear a noise cancelling headphone that plays music that is chosen by the participant.
89181252|NCT04111679|No Intervention|No music|During laparoscopic task performance; participants will wear a noise cancelling headphone that does not play music.
89181253|NCT05678153||passive smokers children group (study group)|children whose parents reported having one or more family members smokes indoors in the presence of the child
89373479|NCT04877041|Experimental|Exercise (Intradialytic Cycling)|Participants will receive a standardized baseline exercise counseling session as per control and then participate in a supervised intradialytic cycling program for 12-weeks
88845316|NCT03667404|Experimental|Resistant Maltodextrin|Resistant maltodextrin (RM) powder 25 g during days 1-7 and 50g during days 8-28, each dose dissolved in 8 oz of water once daily in the morning.
88845317|NCT03667404|Placebo Comparator|Maltodextrin|Maltodextrin 25g for days 1-7 and 50 g for days 8-28, each dose dissolved in 8 oz of water once daily in the morning.
89373480|NCT04877041|No Intervention|Usual Care|Participants will receive a standardized baseline exercise counseling session. Participants in the control group will not undergo formal exercise intervention, but will not be prohibited from participating in exercise outside of hemodialysis. They will be asked to not to participate in intradialytic cycling during the study (16 weeks total).
88845318|NCT03648216|Experimental|Intervention Group|The intervention group will receive a pedometer and HAPA behavioural counseling with the aim of limiting their daily step count to <5000 steps per day, over a one week period. Counseling strategies will be grounded in the HAPA model - specifically, creating an action plan and coping strategies for maximizing their daily sedentary behaviour and minimizing steps taken. Strategies may include: driving to locations more often, refraining from physical activity as much as possible, and/or completing tasks in sedentary postures.
88845319|NCT03648216|No Intervention|Control Group|The control group will not receive any behavioural intervention or instruction.
88845320|NCT03646357|Active Comparator|Betablocker|Patients receiving a betablocker. Any other treatment or management is to be given as per usual care.
89373481|NCT04873934|Experimental|Inclisiran with Usual Care|Inclisiran sodium 300 mg / 1.5 ml (equivalent to 284 mg of inclisiran)
88845321|NCT03646357|Experimental|Non-Betablocker|No betablocker is given to this arm. Any other treatment or management is to be given as per usual care.
88845322|NCT03616028|Experimental|Non-valvular AF adults|Left atrial appendage closure (LAAC) with the CLAAS device will be performed according to the device Instructions for Use, based on TEE, ICE and angiographic guidance, femoral venous access and inter-atrial septum crossing.
88845323|NCT03615235||Recipients of a Kidney Transplant|APOLLO will prospectively assess transplant outcomes in recipients of kidneys from eligible living and deceased donors at all transplant programs in the United States including Puerto Rico.
88845324|NCT03615235||Living Kidney Donors|APOLLO will prospectively assess post-donation renal outcomes in eligible living kidney donors at all transplant programs in the United States including Puerto Rico.
88845325|NCT03594747|Experimental|Tislelizumab + Paclitaxel + Carboplatin|Tislelizumab 200 milligrams (mg) plus paclitaxel 175 mg/m^2 and carboplatin area under the plasma or serum concentration-time curve (AUC) 5 on Day 1 administered intravenously once every 3 weeks until unacceptable toxicity, withdrawal of consent, loss of clinical benefit, or disease progression; paclitaxel and carboplatin were administered for 4 to 6 cycles (each cycle is 21 days)
88845326|NCT03594747|Experimental|Tislelizumab + Nab-paclitaxel + Carboplatin|Tislelizumab 200 mg on Day 1 plus Nab-paclitaxel 100 mg/m^2 on Days 1, 8, and 15 and carboplatin AUC 5 on Day 1 administered intravenously once every 3 weeks until unacceptable toxicity, withdrawal of consent, loss of clinical benefit, or disease progression; Nab-paclitaxel and carboplatin were administered for 4 to 6 cycles (each cycle is 21 days)
88845327|NCT03594747|Active Comparator|Paclitaxel + Carboplatin|Paclitaxel 175 mg/m^2 and carboplatin AUC 5 on Day 1 administered intravenously once every 3 weeks for 4 to 6 cycles (each cycle is 21 days)
88845328|NCT03582163||STN|Patients with Parkinson's disease who have undergone subthalamic nucleus (STN) DBS.
88845329|NCT03582163||GPi|Patients with Parkinson's disease who have undergone GPi (GPi) DBS.
88845330|NCT03566290|Experimental|Open-Label Extension, 3 mg GTx-024|Eligible subjects from G201002
88845331|NCT03556683|Experimental|Hypertonic Saline|Subjects will inhale hypertonic saline before having a Mucociliary Clearance (MCC) scan
88845332|NCT03554603|Experimental|Modified Reporting|"Microbiology laboratory will report Positive urine cultures may represent asymptomatic bacteriuria or urinary tract infection. If urinary tract infection is suspected clinically, please call 777-xxxx (researcher mobile phone) for identification and susceptibility results"
88845333|NCT03554603|No Intervention|Standard Reporting|Microbiology laboratory will report identification and susceptibility results
88845334|NCT03500328|Active Comparator|Early Aggressive Therapy|"Higher efficacy disease-modifying therapy (Early Aggressive Therapy) for treatment of multiple sclerosis~Early Aggressive Therapy choices and maximum allowable doses:~Natalizumab (Tysabri), 300 mg IV every 4 wks~Alemtuzumab (Lemtrada), 12 mg IV daily (QD) for 5 days; 1 year later: 12 mg IV QD for 3 days~Ocrelizumab (Ocrevus), 300 mg IV every 2 wks (for 2 doses) at initiation; then 600 mg IV every 6 mths~Rituximab (Rituxan), 1000 mg IV every 2 wks (for 2 doses); may repeat every 16-24 wks~Cladribine (Mavenclad), 3.5 mg per kg body weight orally divided into 2 yrly treatment courses (1.75 mg per kg body weight each year); each yrly treatment course is divided into 2 treatment cycles; administer cycle dosage as 1 or 2 tablets QD over 4-5 consecutive days~Ofatumumab (Kesimpta), 20 mg SC wkly for wks 0, 1 and 2; 20 mg subcutaneously (SC) monthly starting at wk 4~Ublituximab-xiiy (Briumvi), 150 mg IV (first dose); 450 mg IV 2 wks after first dose; 450 mg IV q 24 wks"
88845335|NCT03500328|Active Comparator|Traditional Therapy|"First-line disease-modifying therapy (Traditional Therapy) for treatment of multiple sclerosis~Traditional Therapy choices and maximum allowable doses:~Glatiramer acetate (Copaxone, Glatopa, and other generics), 20 mg SC daily, or 40 mg SC 3 times a wk~Intramuscular (IM) interferon (Avonex), 30 mcg IM weekly~SC interferon (Betaseron, Extavia, Rebif), 0.25 mg SC every other day (Betaseron, Extavia); 44 mcg SC 3 times a wk (Rebif)~Pegylated interferon (Plegridy), 125 mcg SC every 14 days~Teriflunomide (Aubagio), 14 mg PO QD~Dimethyl fumarate (Tecfidera and generics), 240 mg PO twice a day (BID)~Diroximel fumarate (Vumerity), 462 mg PO BID~Monomethyl fumarate (Bafiertam), 190 mg PO BID~Fingolimod (Gilenya and generics), 0.5 mg PO QD~Siponimod (Mayzent), 1 mg PO QD or 2 mg PO QD~Ozanimod (Zeposia), 0.92 mg PO QD~Ponesimod (Ponvory), 20 mg PO QD~Fingolimod ODT (Tascenso), 0.25 mg PO QD if <=40 kg; 0.5 mg PO QD if > 40 kg"
88845336|NCT03498612|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for up to 18 cycles in the absence of disease progression or unacceptable toxicity.
88845337|NCT03484936|Active Comparator|RIC+Standard medical treatment|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mm Hg. RIC will be conducted twice daily for 7 days. Additionally,the patients will be treated with standard medical treatment according to 2014 chinese guideline for the diagnosis and treatment of intracerebral hemorrhage.
88845338|NCT03484936|Placebo Comparator|Sham RIC+Standard medical treatment|Sham remote ischemic conditioning (Sham RIC) is simulated by the measurement of blood pressure twice daily for 7 days.Additionally,the patients will be treated with standard medical treatment according to 2014 chinese guideline for the diagnosis and treatment of intracerebral hemorrhage.
89373482|NCT04873934|No Intervention|Usual Care|Usual Care Alone
89373483|NCT04867174|Placebo Comparator|Control Arm|No messaging about COVID-19 vaccination
89373484|NCT04867174|Experimental|Emotional message|Participants view an emotional video from the state of California about getting back to normal.
89373485|NCT04867174|Experimental|Safety and effectiveness message|Participants view a video with information about the safety and effectiveness of the COVID-19 vaccines
89373486|NCT04867174|Experimental|Consequences message|Participants view a video with information about the consequences of not getting vaccinated against COVID-19.
89373487|NCT04864886||Healthy volunteers|Control group
89373488|NCT04864886||Patients with atopic dermatitis|Physician-diagnosed atopic dermatitis
89373489|NCT04864886||Patients with primary immunodeficiency|Confirmed by genetic diagnosis or suspected by genetic variant of unconfirmed significance and a history consistent with immunodeficiency
89373490|NCT04864886||Patients with psoriasis|Physician-diagnosed psoriasis
89373491|NCT04863664|Experimental|Intervention/Treatment (LEADR)|Patients will be implanted with a Next Generation ICD Lead and undergo required electrical testing
89373492|NCT04863664|Experimental|Intervention/Treatment (LEADR LBBAP)|Patients will be implanted with a Next Generation ICD Lead in the LBBAP location and undergo required electrical testing
89373493|NCT04856046||Observational (biospecimen collection, medical record review)|Patients undergo collection of blood samples at 4-6 weeks prior to surgery/ablation and at 12 weeks, 6, 12, 18 and 24 months after surgery/ablation. Patients' previously collected tissue samples are analyzed. Patients' medical records are also reviewed at baseline, 4-6 weeks prior to surgery/ablation, 12 weeks, 6, 12, 18 and 24 months after surgery/ablation, and then every 6 months for 3 years.
89373494|NCT04838769|Active Comparator|REZŪM|"Subjects randomized to receive the REZŪM treatment will receive standardized treatment, following the Instruction for Use (IFU). The REZŪM System is intended to relieve symptoms, obstructions, and reduce prostate tissue associated with benign prostatic hyperplasia (BPH). It is indicated for men with a prostate volume ≥ 30 ml. The REZŪM System is also indicated for treatment of prostate with hyperplasia of the central zone and/or a median lobe.~1:1 randomization will occur via the electronic data capture (EDC) system."
89373495|NCT04838769|Active Comparator|Dual Drug Therapy|Subjects assigned to dual drug therapy will be treated with the local formulary preferred choice of commercially available urinary selective alpha blocker and 5-alpha reductase inhibitor. This arm will therefore represent local standard of care.
89373496|NCT04830709||PARPi maintenance cohort (PMC)|patients who received at least one dose of PARPi as 1L MTX after 1L platinum-based CTX
88845339|NCT03473756|Experimental|Rogaratinib + Atezolizumab in Part A|"Part A: Part A is conducted in patients who are cisplatin-ineligible and have had no prior systemic treatment for locally advanced or metastatic disease.~Patients will receive rogaratinib plus atezolizumab combination treatment."
88845340|NCT03444376|Experimental|GX-188E, KEYTRUDA®|GX-188E: 1st day of week 1,2,4,7,13,19, 46/ 2mg KEYTRUDA® : Day 1 q3 weeks/ 200mg
89373497|NCT04830709||Bevacizumab maintenance cohort (BMC)|patients who continue to receive at least one dose of bevacizumab after 1L platinum-based CTX and who have not received PARPi MTX treatment
89373498|NCT04830709||No maintenance cohort (NMC)|patients who never received any 1L MTX treatment (PARPi or bevacizumab)
89373499|NCT04806282||1/All Patients|Documented hearing instability
89373500|NCT04806035|Experimental|Cohort A: TG-1801|"TG-1801 Single Agent~As per protocol v3.0, Cohort A is no longer enrolling."
89373501|NCT04806035|Experimental|Cohort B: TG-1801|TG-1801 Single Agent, escalating doses
89373502|NCT04806035|Experimental|Cohort C: TG-1801 + Ublituximab|"TG-1801 in combination with ublituximab~As per protocol v3.0, ublituximab will be discontinued and the Cohort C is no longer enrolling."
89373503|NCT04791553|Experimental|Normal Hepatic Function|Group 1 single oral dose of 200 mg (2 x 100 mg tablet) cenobamate given to Matching healthy subjects with normal hepatic function
89373504|NCT04791553|Experimental|Hepatic Impairment|Group 2 single oral dose of 200 mg (2 x 100 mg tablet) cenobamate given to subjects with severe hepatic impairment
89373505|NCT04785287|Experimental|Arm I (BMS-986218, SBRT)|Patients receive anti-CTLA4 monoclonal antibody BMS-986218 IV over 30 minutes on day 1. Treatment repeats every 28 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo SBRT on days 36-39 (days 8-11 of cycle 2).
89373506|NCT04785287|Experimental|Arm II (BMS-986218, SBRT, nivolumab)|Patients receive anti-CTLA4 monoclonal antibody BMS-986218 and SBRT as in Arm 1. Beginning cycle 2, patients also receive nivolumab IV over 30 minutes starting on day 1. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
89373507|NCT04773964|Experimental|MET642 high dose|
89373508|NCT04773964|Experimental|MET642 low dose|
89373509|NCT04773964|Placebo Comparator|MET642 Placebo|
89373510|NCT04772989|Experimental|Dose Escalation Q3W Cohorts|Escalating doses of AB308 in combination with zimberelimab (360 mg) will be given every 3 weeks in participants with advanced malignancies.
89373511|NCT04772989|Experimental|Dose Escalation Q4W Cohorts|Escalating doses of AB308 in combination with zimberelimab (480 mg) will be given every 4 weeks in participants with advanced malignancies.
89373512|NCT04772989|Experimental|Dose Escalation Q6W Cohort|Selected dose of AB308 in combination with zimberelimab will be given every 6 weeks in participants with advanced malignancies.
88845341|NCT03437395|Other|Partial Breast Irradiation|All participants will be treated with partial breast irradiation by utilizing 3D conformal external beam irradiation or balloon brachytherapy. This is not a randomized study.
88845342|NCT03417297|Experimental|high intensity focused ultrasound|Initially, 3 patients will be enrolled and followed for 3 months to assess the safety of study intervention which is unilateral MR guides focused ultrasound thalamotomy (anterior nucleus). These data will be reviewed by the Data and Safety Monitoring Committee (DSMC) and the FDA. If approval is granted by the DSMC and FDA, then up to an additional 7 participants will be enrolled.
88845343|NCT03412877|Experimental|1/iTCR|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + Individual Patient TCR-Transduced PBL + high- or low-dose aldesleukin
88845344|NCT03412877|Experimental|2/iTCR + Pembro|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + Individual Patient TCRTransduced PBL + high- or low-dose aldesleukin + pembrolizumab prior to cell administration and 3 additional doses every 3 weeksfollowing cell infusion
88845345|NCT03403361|Experimental|Dual-Energy CT scan|Patients enrolling in this study will undergo additional sequential DECT scan in addition to their routine SECT or DECT scan.
89373513|NCT04772989|Experimental|Dose Expansion Cohort 1|AB308 will be given in combination with zimberelimab at 360 mg or 480 mg Q3W or Q4W, respectively, in participants with in participants with locally advanced or metastatic NSCLC.
89373514|NCT04772989|Experimental|Dose Expansion Cohort 2|AB308 will be given in combination with zimberelimab at 360 mg or 480 mg Q3W or Q4W, respectively, in participants with melanoma.
88845346|NCT03394053||Affected Patient|Person with a clinical diagnosis of a PID; either known or unknown as defined by lab and/or clinical findings on 2 or more occasions that are consistent with a defect in innate or adaptive immunity
89373515|NCT04772989|Experimental|Dose Expansion Cohort 3|AB308 will be given in combination with zimberelimab at 360 mg or 480 mg Q3W or Q4W, respectively, in participants with metastatic gastric, or gastroesophageal junction, or esophageal cancer.
89373516|NCT04772989|Experimental|Dose Expansion Cohort 4|AB308 will be given in combination with zimberelimab at 360 mg or 480 mg Q3W or Q4W, respectively, in participants with cervical cancer.
89373517|NCT04772989|Experimental|Dose Expansion Cohort 5|AB308 will be given in combination with zimberelimab at 360 mg or 480 mg Q3W or Q4W, respectively, in participants with hematological malignancies.
89373518|NCT04769011|Experimental|Clinical, neuropsychological, neurophysiological, and genetic evaluations|Clinical, neuropsychological, neurophysiological, and genetic evaluations
89373519|NCT04767022|Experimental|Genoss® DCB|Paclitaxel Coated PTCA Balloon Catheter
89373520|NCT04767022|Active Comparator|SeQuent® Please NEO|Paclitaxel Coated PTCA Balloon Catheter
89373521|NCT04757636|Experimental|2.0 mg aflibercept with Standard Dosing 2.0 mg OPT-302|"2.0 mg aflibercept intravitreal injection administered at 4-weekly intervals for three treatments, and then at 8-weekly intervals.~2.0 mg OPT-302 intravitreal injection administered at 4-weekly intervals."
89373522|NCT04757636|Experimental|2.0 mg aflibercept with Extended Dosing 2.0 mg OPT-302|"2.0 mg aflibercept intravitreal injection administered at 4-weekly intervals for three treatments, and then at 8-weekly intervals.~2.0 mg OPT-302 intravitreal injection administered at 4-weekly intervals for three treatments, and then at 8-weekly intervals, with sham intravitreal injection administered at visits when OPT-302 is not."
89373523|NCT04757636|Sham Comparator|2.0 mg aflibercept with sham|"2.0 mg aflibercept intravitreal injection administered at 4-weekly intervals for three treatments, and then at 8-weekly intervals.~Sham intravitreal injection administered at 4-weekly intervals."
88845347|NCT03394053||Normal Volunteer|Persons (age 18-75 years) who are not related to another study subject, who do not have a PID, weight >110lbs, no history of viral hepatitis B or C, have a negative HIV screening test
88845348|NCT03394053||Relative of Patient|Biological relatives (age 0-75 years) of a subject who meets affected patient criteria, but who do not have a PID themselves
88845349|NCT03328468|Experimental|Breathing Exercise|
89181254|NCT05678153||non-passive smokers children group (control group)|children whose parents reported not to have one or more family members smokes indoors in the presence of the child
89373524|NCT04757610|Experimental|0.5 mg ranibizumab with Standard Dosing 2.0 mg OPT-302|"0.5 mg ranibizumab intravitreal injection administered at 4-weekly intervals.~2.0 mg OPT-302 intravitreal injection administered at 4-weekly intervals."
89373525|NCT04757610|Experimental|0.5 mg ranibizumab with Extended Dosing 2.0 mg OPT-302|"0.5 mg ranibizumab intravitreal injection administered at 4-weekly intervals.~2.0 mg OPT-302 intravitreal injection administered at 4-weekly intervals for three treatments, and then at 8-weekly intervals, with sham intravitreal injection administered at visits when OPT-302 is not."
89373526|NCT04757610|Sham Comparator|0.5 mg ranibizumab with sham|"0.5 mg ranibizumab intravitreal injection administered at 4-weekly intervals.~Sham intravitreal injection administered at 4-weekly intervals."
89535011|NCT03088761||cuffed tube pressure group|"The pressures of cuffed tracheal tubes will be monitored simultaneously with a cuff manometer and pressure transducer. The measurements will be observed continuously. When the cuff pressure is noted to exceed 15 cmH2O, the cuff will be deflated immediately to less than 15 cmH2O. The time when the correction occurred, the time interval between corrections and the number of corrections during surgery will be recorded.~The baseline cuff pressure will be assessed in the supine position after which time a second measurement will be made in the prone position. A blind investigator will check and record the findings of cuffed tracheal tube."
89535012|NCT03092583|Experimental|Patient group|Subjects must meet the modified New York criteria for AS, or the ASAS criteria for Ax-SpA, and must be naïve of biologic therapy (anti-TNF-α agents) at the time of inclusion, or have received but subsequently discontinued anti-TNF-α therapy at least 3 months before inclusion. A blood sample will be drawn (35 mL) to these patients.
89535013|NCT03092583|Other|Control group|Subjects must be free from any inflammatory or auto-immune disease. A blood sample will be drawn (35 mL) to these controls subjects.
88845350|NCT03291522||Men with azoospermia|Ultrasound-guided rete testis flushing and aspiration
89181255|NCT00920127|Placebo Comparator|Placebo|
89181256|NCT00920127|Active Comparator|AKL1|
89373530|NCT04752722|Experimental|Phase 1|Dose escalation phase
89535014|NCT03325829||Patients with colonic diverticula|No interventional study
89181257|NCT01558115|Experimental|Denosumab - Group #1|Receive active drug for year 1 and year 2 of the study
89181258|NCT01558115|Placebo Comparator|Placebo - Group #2|Receive placebo for year 1 and active drug for year 2 of the study
89373531|NCT04752722|Experimental|Phase 2|"Cohort 1: Recommended Phase 2 dose (RP2D) with eligible BCG-unresponsive NMIBC patients, up to 4 cycles of treatment with EG-70~Cohort 2: RP2D with eligible high-risk NMIBC patients who have been incompletely treated with BCG or are BCG-naïve"
89373532|NCT04724200||Referred from primary care for investigation of suspected heart failure|All patients recruited to the OPERA trial will have been referred from their primary care clinician for investigation of a suspected diagnosis of heart failure.
89373533|NCT04704661|Experimental|Treatment (trastuzumab deruxtecan, ceralasertib)|Patients receive trastuzumab deruxtecan IV over 30-90 minutes on day 1 and ceralasertib PO BID on days 1-7. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. NOTE: During the dose-expansion phase, the first 6 patients in each disease cohort (gastroesophageal cancer [cohort A] and colorectal cancer [cohort B]) receive only trastuzumab deruxtecan for the first cycle, followed by trastuzumab deruxtecan and ceralasertib together in subsequent cycles.
89535015|NCT05016063|Experimental|Dual CD33-CLL1 CAR-T cells|CD33-CLL1 CAR T cells
89535016|NCT03325751||Healthy subjects|
89373536|NCT04700579||TB Cases|"n= 50 (25 HIV positive and 25 HIV negative)~Xpert MTB/RIF Ultra-confirmed TB"
89373537|NCT04700579||Healthy Household Contacts|"n= (25 HIV positive and 25 HIV negative)~Culture negative TB result"
89373538|NCT04700579||Sick controls|"n=50~Diseases: Asthma, Chronic obstructive pulmonary disease (COPD), Cancer, Bronchiectasis (including post-TB) and Pneumonia"
89373539|NCT04700306|Experimental|Sophrology|the patient must make 8 visits with interviews and questionnaires, including 7 visits with a session of sophrology
88810167|NCT01312181|Active Comparator|Motivational Interviewing (MI)|The MI session focuses on reduce ambivalence and increase motivation to reduce non-injection drug use (NIDU), gain a commitment to change, if possible, and ultimately to reduce or eliminate NIDU. The intervention includes: a) identifying pros and cons of using and stopping; b) exploring ambivalence about stopping NIDU; c) eliciting change talk
89373540|NCT04700306|No Intervention|Control|the patient must make 7 visits with interviews and questionnaires
89373541|NCT04691037||CCTA|
89373542|NCT04685135|Experimental|MRTX849|
89373543|NCT04685135|Active Comparator|Docetaxel|
89373544|NCT04654988|Experimental|Immunosuppression|Prednisone: 1 mg/kg daily for 4 weeks followed by gradually tapered dose for 5 months and Azathioprine: 2 mg/kg daily for 12 months
89373545|NCT04654988|Placebo Comparator|Placebo|placebo matching prednisone: 1 mg/kg daily for 4 weeks followed by gradually tapered dose for 5 months and placebo matching azathioprine: 2 mg/kg daily for 12 months
89373546|NCT04623931|Experimental|Treatment (temozolomide, radiation therapy)|Patients receive temozolomide PO daily and radiation therapy over 5 days a week (weekdays only) for 6 weeks. Beginning 28 days after the last dose of radiation therapy, patients receive temozolomide PO for 12 months in the absence of disease progression or unacceptable toxicity.
89373547|NCT04609072||Healthy volunteers|Up to 200,000 men and women aged 30 to 70 years, with no personal history of cancer, and patients or members of participating integrated health care systems.
89535017|NCT03325751||Glaucoma subjects|Patients with primary open-angle-, pseudoexfoliation- or primary angle-closure glaucoma
88810168|NCT01312181|Placebo Comparator|HIV/AIDS health education - DVD control|HIV/AIDS health education - DVD control. The purpose of this condition is to control for clinical attention associated with Motivational Interviewing (MI)participation, and to provide an analogue of standard care, i.e. brief advice but no other intervention.
88810169|NCT03802292|Active Comparator|Single Ascending Dose YQ23|
88810170|NCT03802292|Placebo Comparator|Single Dose Placebo|
88810171|NCT01258049|Experimental|ArTiMist|
88810172|NCT01258049|Active Comparator|Quinine|
88810173|NCT03802136||high concentration of biomarkers|the patients with biomarkers level over the normal max value
88810174|NCT03802136||low concentration of biomarkers|the patients with biomarkers level below the normal max value
88810175|NCT03802214||vedolizumab-UC-naïve to TNF-antagonist|standard vedolizumab induction therapy for ulcerative colitis patients who are naïve to TNF-antagonist therapy
88810176|NCT03802214||vedolizumab-UC- previous TNF-antagonist|standard vedolizumab induction therapy for ulcerative colitis patients with previous TNF-antagonist exposure
88810177|NCT00775346||Polysomnography (PSG) Subjects|Subjects who have been prescribed with needing a polysomnography (PSG) will be enrolled into the study.
88810178|NCT03801980|Experimental|SK-1403|Patients receive SK-1403 three times a week administered by intravenous bolus injection at the end of each hemodialysis for the whole treatment periods (24 weeks), with individual dose adjustment.
88810179|NCT03801980|Placebo Comparator|Placebo|Patients receive Placebo three times a week administered by intravenous bolus injection at the end of each hemodialysis for the whole treatment periods (24 weeks), with individual dose adjustment.
88810180|NCT03801746|Experimental|Vadadustat, Cyclosporine|Part 1: Arm 1: Subjects will receive vadadustat 300 mg alone and vadadustat 300 mg in combination with oral cyclosporine 500 mg in a crossover design
88810181|NCT03801746|Experimental|Vadadustat; Probenecid|Part 1: Arm 2: Subjects will receive vadadustat 300 mg alone and vadadustat 300 mg in combination with oral Probenecid 500 mg Q12h in a fixed sequence design
89373548|NCT04606095|Experimental|Aim 1 - Healthy control|Participants will have three visits for this part along with a run-in observation period. An EEG with Quantitative Sensory Testing (QST) will be performed at visit 1 along with other measures. Additionally, the an MRI will be done at visit 2 along with other measures.
89373549|NCT04606095|Experimental|Aim 1 - Fibromyalgia participant|Participants will have three visits for this part along with a run-in observation period. An EEG with Quantitative Sensory Testing (QST) will be performed at visit 1 along with other measures. Additionally, the an MRI will be done at visit 2 along with other measures.
89373550|NCT04606095|Experimental|Aim 3 - HD-tDCS of M1|There will be two weeks of treatment in which participants will have 5 daily sessions of focused HD-tDCS or Sham per week.
89373551|NCT04606095|Experimental|Aim 3- HD-tDCS of ES|There will be two weeks of treatment in which participants will have 5 daily sessions of focused HD-tDCS or Sham per week.
89373552|NCT04606095|Sham Comparator|Aim 3 - Sham|There will be two weeks of treatment in which participants will have 5 daily sessions of focused HD-tDCS or Sham per week.
88845351|NCT03263091|Experimental|Roxadustat|"Open-label, lead-in: Participants will receive sequential escalating roxadustat doses (1.5 milligrams/kilograms [mg/kg], 2.0 mg/kg and 2.5 mg/kg), three times a week (TIW) based upon their actual weight at the randomization visit to identify the starting dose for double-blind period.~Double-blind: Participants will receive roxadustat 2.5 mg/kg TIW based upon their body weight for a duration of 52 weeks.~Open-label: Participants with high serum erythropoietin levels (>400 milli-international units [mIU]/milliliter [mL] mIU/mL) will receive roxadustat 2.5 mg/kg TIW based upon their body weight for a duration of 52 weeks."
88845352|NCT03263091|Placebo Comparator|Placebo|Double-blind: Participants will receive placebo matching to roxadustat for a duration of 52 weeks.
88845353|NCT03256240|Active Comparator|side-to-side functional end anastomosis|side-to-side functional end anastomosis creation
88845354|NCT03256240|Active Comparator|Kono-S|antimesenteric functional side-to-side handsewn anastomosis, known as the Kono-S anastomosis
89373553|NCT04604509|Experimental|Group I (varenicline, counseling)|Participants receive varenicline PO daily or BID for 6 weeks in the absence of unacceptable toxicity. Participants who quit smoking continue treatment for 6 additional weeks in the absence of unacceptable toxicity. Participants also receive behavioral smoking cessation counseling.
89373554|NCT04604509|Experimental|Group II (NRT, counseling)|Participants receive NRT consisting of a patch, lozenges, or gum daily for 6 weeks in the absence of unacceptable toxicity. Participants who quit smoking continue treatment for 6 additional weeks in the absence of unacceptable toxicity. Participants also receive behavioral smoking cessation counseling.
89373555|NCT04604509|Experimental|Group III (varenicline or NRT, counseling)|Participants continue to receive varenicline as in Group I or NRT as in Group II for 6 additional weeks depending on which group they were assigned to. Participants also receive behavioral smoking cessation counseling.
89373556|NCT04604509|Experimental|Group IV (varenicline or NRT, counseling)|Participants switch to a different therapy and receive varenicline as in Group I or NRT as in Group II for 6 weeks depending on which group they were assigned to. Participants also receive behavioral smoking cessation counseling.
89373557|NCT04604509|Experimental|Group V (higher dose varenicline or NRT, counseling)|Participants receive a higher dose and continue to receive varenicline as in Group I or NRT as in Group II for 6 weeks depending on which group they were assigned to. Participants also receive behavioral smoking cessation counseling.
89373558|NCT04604509|Experimental|Group VI (varenicline or NRT, bupropion, counseling)|Participants continue to receive varenicline as in Group I or NRT as in Group II for 6 weeks depending on which group they were assigned to. Participants also receive bupropion PO daily for 6 weeks and behavioral smoking cessation counseling.
89373559|NCT04604509|Experimental|Group VII (varenicline and NRT, counseling)|Participants receive varenicline as in Group I and NRT as in Group II for 6 weeks. Participants also receive behavioral smoking cessation counseling.
89373560|NCT04595279|Experimental|Smoking sessions|This is the single arm that will go through cigarette smoking sessions
89373561|NCT04595266|Active Comparator|Control|Systemic chemotherapy with FOLFOX6m + monoclonal Ab (anti-EGFR or bevacizumab).
88845355|NCT03237741|Experimental|Treatment Sequence 1: ABC1D1|Single dose of reference capsule GDC-0134 (Treatment A) during Period 1. Single dose of prototype capsule GDC-0134 (Treatment B) during Period 2. Single dose of GDC-0134 prototype capsule administered as GDC-0134-in-applesauce preparation under fasting conditions (Treatment C1) during Period 3. Single dose of GDC-0134 prototype capsule administered under fasting conditions in combination with 20 mg rabeprazole, and following prior administration of rabeprazole once daily for 3 days (Treatment D1) during Period 4. The washout period between doses will be a minimum of 21 days.
88845356|NCT03237741|Experimental|Treatment Sequence 2: ABC2D2|Single dose of reference capsule GDC-0134 (Treatment A) during Period 1. Single dose of prototype capsule GDC-0134 (Treatment B) during Period 2. Single dose of GDC-0134 prototype capsule administered after a high-fat meal (Treatment C2) during Period 3. Single dose of GDC-0134 prototype capsule administered after a high-fat meal in combination with 20 mg rabeprazole, and following prior administration of rabeprazole once daily for 3 days (Treatment D2) during Period 4. The washout period between doses will be a minimum of 21 days.
89373562|NCT04595266|Experimental|Experimental|Systemic chemotherapy with FOLFOX6m + monoclonal Ab (anti-EGFR or bevacizumab) + Intra-arterial liver chemotherapy with LIFEPEARLS-IRINOTECAN (catheterization and infusion of 100 +/- 50 micron microspheres loaded with 100 mg of irinotecan in both liver lobes) cycles 2 and 4.
89373563|NCT04589143|Experimental|Experience group|In this group,participants take agomelatine at a dose of 25-50 mg/d for 8 weeks.
89373564|NCT04589143|Placebo Comparator|Contral group|In this group,participants take a placebo at a dose of 25-50 mg/d for 8 weeks.
89373565|NCT04580420|Experimental|Open-Label DCR-PHXC|Open-Label monthly subcutaneous injection of DCR-PHXC based on age and weight.
89373566|NCT04576988|Experimental|Sotatercept plus background PAH therapy|Sotatercept at a starting dose of 0.3 mg/kg with a target dose of 0.7 mg/kg administered subcutaneously (SC) every 21 days plus background PAH therapy
89373567|NCT04576988|Placebo Comparator|Placebo plus background PAH therapy|Placebo administered (SC) every 21 days plus background PAH therapy
89373568|NCT04575467|Experimental|CBL-514 320 mg|CBL-514 will be administered via injection into the thigh subcutaneous adipose layer.
89373569|NCT04575467|Experimental|CBL-514 480 mg|CBL-514 will be administered via injection into the abdomen subcutaneous adipose layer.
89373570|NCT04575467|Experimental|CBL-514 640 mg|CBL-514 will be administered via injection into the abdomen subcutaneous adipose layer.
89373571|NCT04575467|Experimental|CBL-514 800 mg|CBL-514 will be administered via injection into the abdomen subcutaneous adipose layer.
89373572|NCT04573972|Active Comparator|Regular incentive|During the two-week intervention period, the standard incentive group will earn $2 per day when they meet their step goal, and this reward is earned regardless of whether they walk alone or with others.
89373573|NCT04573972|Experimental|Social Incentive|During the two-week intervention period, he social incentive group will earn $1 per day when they meet their step goal and an additional $1 if they walk 2,000 steps together with another study participant.
89373575|NCT04565990|Experimental|Selexipag|Participants will receive selexipag tablets twice daily with the dose strength corresponding to their individual maximum tolerated dose (iMTD) from the parent study.
89373576|NCT04565951|Experimental|Treatment arm|Participants in this arm will receive the intervention, VA S.A.V.E.
89373577|NCT04565951|Sham Comparator|Sham arm|"Participants in this arm will receive a sham training, not the intervention, consisting of information unrelated to suicide prevention but relevant to transitioning veterans and their loved ones."
89373578|NCT04563520|Experimental|Experimental treatment|"Personalized dose of aPCC-emicizumab will be administered to participants. The max dose allowed for aPCC will be 25 U/kg/dose every 8 hours, for no more than 72 hours without further discussion with the PI. If there is less than a good' response in bleed event response efficacy as stated above at 48 hours or less than moderate for surgical event control, the local PI can consider the use of thrombin generation guided rFVIIa with max dose no more than 90 µg/kg/dose every 8 hours for 72 hours, with wean to occur for no more than 7 total days without further discussion with the PI."
89373579|NCT04557969||1/ Cohort 1|Patients with histologically confirmed or clinical presentation suspicious of GIST
89373580|NCT04547790|Experimental|Psyllium group|Subjects will take psyllium once daily for the first three days, then twice daily starting Day 4 until the end of the study.
89373581|NCT04547790|Experimental|Wheat Dextrin group|Subjects will take wheat dextrin once daily for the first three days, then twice daily starting Day 4 until the end of the study.
89373582|NCT04543331||treatment naïve patients|Patients being the first time treated for nAMD or DME
89373583|NCT04543331||pre-treated patients|Patients already being treated for nAMD or DME
89373584|NCT04526665|Experimental|Elafibranor 80mg|Study subjects will take 1 tablet per day orally before breakfast with a glass of water each morning
89373585|NCT04526665|Placebo Comparator|Placebo|Study subjects will take 1 tablet per day orally before breakfast with a glass of water each morning
89373586|NCT04517851|Experimental|Treatment (elotuzumab)|Patients receive elotuzumab IV over 1-4 hours on days 1, 8, 15, and 22 of cycles 1-2. Beginning in cycle 3, patients receive elotuzumab IV over 1-4 hours on day 1. Treatment repeats every 28 days for up to 36 cycles in the absence of disease progression or unacceptable toxicity.
89373587|NCT04482621|Active Comparator|Decitabine + Standard of Care (SOC)|Study drug Decitabine will be administered via Intravenous injection. Dosage Regimen: 10mg/m^2/day IV day x 5 days (1 cycle only)
89373588|NCT04482621|Placebo Comparator|Standard of Care (SOC) + Placebo|Saline based placebo will be administered via Intravenous injection. Dosage Regimen: 10mg/m^2/day IV day x 5 days (1 cycle only)
89373589|NCT04477603|Experimental|Subjects receiving the Impella ECP|
89373590|NCT04475926||LGMD2E/R4 Cohort|Participants with LGMD2E/R4 will be enrolled in this cohort. Enrollment will be capped according to age as follows: 4 to 7 years age range, 8 to 16 years age range, and ≥17 years age range through the course of the study.
89373591|NCT04475926||LGMD2D/R3 Cohort|Participants with LGMD2D/R3 will be enrolled in this cohort. Enrollment will be capped according to age as follows: 4 to 7 years age range, 8 to 16 years age range, and ≥17 years age range through the course of the study.
89373592|NCT04475926||LGMD2C/R5 Cohort|Participants with LGMD2C/R5 will be enrolled in this cohort. Enrollment will be capped according to age as follows: 4 to 7 years age range, 8 to 16 years age range, and ≥17 years age range through the course of the study.
89373593|NCT04475926||LGMD2A/R1 Cohort|Participants with LGMD2A/R1 will be enrolled in this cohort. Enrollment will be capped according to age as follows: 4 to 7 years age range, 8 to 16 years age range, and ≥17 years age range through the course of the study.
89373594|NCT04458610|Experimental|Treatment (zanubrutinib, rituximab)|See Detailed Description.
89002219|NCT05943496|Experimental|Treatment (tafasitamab, obinutuzumab, acalabrutinib)|Patients receive obinutuzumab IV over a rate titrated up to 400 mg/hour on days 1, 2, 8, and 15 for cycle 1 then on day 1 for cycles 2-6 and tafasitamab IV over 1.5-2 hours on days 1, 4, 8, 15, and 22 for cycle 2, on days 1, 8, 15, and 22 for cycles 3-4, and on days 1 and 15 for cycles 5-7. Patients also receive acalabrutinib PO BID in each cycle. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo blood sample collection and CT throughout the trial. Patients may undergo an ECHO at baseline as clinically indicated and may also undergo bone marrow biopsy and/or aspiration at baseline and/or follow-up
89002220|NCT05938894|Experimental|EFfect-food choices|Participants will complete four online games at least biweekly during the study.
89373595|NCT04449874|Experimental|Arm A: Dose-escalation (Stage I), Dose Expansion (Stage II)|"Participants in Stage I will receive GDC-6036 administered orally once daily (PO QD). The dose will be increased in successive cohorts until a study-specific threshold is reached.~Participants with select solid tumors will be treated with GDC-6036 PO QD in Stage II."
89373596|NCT04449874|Experimental|Arm B: GDC-6036 + Atezolizumab (Stage I and Stage II)|Participants with non-small cell lung cancer will receive GDC-6036 in combination with atezolizumab.
89373597|NCT04449874|Experimental|Arm C: GDC-6036 + Cetuximab (Stage I and Stage II)|Participants with colorectal cancer will receive GDC-6036 in combination with cetuximab.
89373598|NCT04449874|Experimental|Arm D: GDC-6036 + Bevacizumab (Stage I and Stage II)|Participants with solid tumors will receive GDC-6036 in combination with bevacizumab.
89373599|NCT04449874|Experimental|Arm E: GDC-6036 + Erlotinib (Stage I and Stage II)|Participants with non-small cell lung cancer will receive GDC-6036 in combination with erlotinib.
89373600|NCT04449874|Experimental|Arm F: GDC-6036 + GDC-1971 (Stage I and Stage II)|"Participants with solid tumors will receive GDC-6036 in combination with GDC-1971 PO in Stage I.~Participants with select solid tumors will be treated with GDC-6036 in combination with GDC-1971 PO in Stage II."
89373601|NCT04449874|Experimental|Arm G: GDC-6036 + Inavolisib (Stage I and Stage II)|"Participants with solid tumors will receive GDC-6036 in combination with inavolisib PO in Stage I.~Participants with select solid tumors will be treated with GDC-6036 in combination with inavolisib PO in Stage II."
89373602|NCT04446468|Experimental|PEACE|The PEACE intervention will be delivered by a trained mental health staff member, such as a study psychologist, mental health nurse, social worker, or psychiatrist. The intervention consists of three synergistic components that work to support the patient after inpatient psychiatric discharge: 1) Brief educational component, where the patient receives a one-hour, one-on-one, personalized educational session on suicide prevention; 2) Seven regular contacts after discharge, where the study psychologist who delivered the brief educational visit will contact the patient to monitor the patient's symptoms, assess treatment adherence, review their safety plan, and assist the patient with engaging in care, if needed; and 3) Mobile app, which aims to improve the patient's social connectedness and provide additional educational materials on suicide. Patients in this arm will also continue to receive standard post-discharge psychiatric care.
89399284|NCT03539510|No Intervention|Usual Care|"The standard of care for advance care planning at our institution is the Speak Up booklet and the Power of Attorney workbook from the Attorney General's Office - Ontario. Patients randomized to the Control arm will be asked to register on a separate research portal where participants will have electronic access to both of the booklets and a link to the Speak Up online Interactive workbook. There is no specific information on HF or HF treatments. Participants in the control arm will be asked to complete the ACP using the interactive workbook. Participants in the control arm will not receive any additional communication from the research team about their progress."
89002221|NCT05938894|Active Comparator|Control|Participants will complete four online games at least biweekly during the study.
89002222|NCT05932602||Aveir DR Leadless Pacemaker System|This study will utilize real-world data from patients implanted with the Aveir DR Leadless Pacemaker System. No device intervention is required in this study.
89002223|NCT05932602||Dual Chamber Transvenous Pacemaker|This study will utilize real-world data from patients implanted with a dual-chamber transvenous pacemaker as a comparator to the Aveir DR LP system study arm. No device intervention is required in this study.
89002224|NCT05925686|Experimental|Tramadol.|
89002225|NCT05924932||group 1 with Control IQ system|Tandem t:slim X2 with hybrid closed loop system Control IQ, glucose sensor: Dexcom G6
89002226|NCT05924932||Group 2 with SmartGuard system|MiniMed 780G, with hybrid closed loop system SmartGuard, sensor Guardien 4
89002227|NCT05913232|Experimental|H-1337 0.6% Ophthalmic Solution b.i.d.|One drop H-1337 twice daily in the study eye for 28 days
89373603|NCT04446468|Experimental|Control|Those randomized to the control arm will receive standard psychiatric hospital discharge care alone. Current VA standard discharge care includes five core elements. First, patients and their outpatient providers are required to be involved in discharge planning. Second, patients should be offered evidence-based treatments to address their mental health symptoms. Third, the inpatient team should work with the patient to complete a safety plan prior to discharge. Fourth, the inpatient team should arrange two follow-up care visits within 30 days of discharge. Fifth, the inpatient team in conjunction with the SPC assess whether patients are appropriate to be placed on the High Risk for Suicide List. Patients who are placed on the High Risk for Suicide List receive enhanced oversight as outlined in VA policy.
89373604|NCT04445155|Experimental|Modified DECIDE-Provider Arm|2-4 hour workshop for providers to improve perspective-taking, reduce attributional errors, and increase receptivity to parent participation.
89373605|NCT04445155|Experimental|Modified DECIDE-Parent Arm|Up to three parent training sessions designed to help patients effectively ask questions and participate in decisions about care.
89373606|NCT04445155|Other|Provider Subgroup Study|To boost provider recruitment, we sought recommendations from a subgroup of providers. We gave each provider access to the DECIDE online training and the pre- and post-survey.
89373607|NCT04445155|No Intervention|Treatment as Usual|Control arm
89373608|NCT04444921|Active Comparator|Arm A (carboplatin, paclitaxel)|Patients receive paclitaxel IV on days 1, 8, and 15 of each cycle, and carboplatin IV on day 1 of each cycle. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
89373609|NCT04444921|Experimental|Arm B (carboplatin, paclitaxel, nivolumab)|Patients receive nivolumab IV over 30 minutes on days 1 and 15 of cycle 1 and then on day 1 only of subsequent cycles, paclitaxel IV on days 1, 8, and 15 of each cycle, and carboplatin on day 1 of each cycle. Treatment repeats every 28 days for up to 6 cycles for carboplatin and paclitaxel, and up to 2 years for nivolumab in the absence of disease progression or unacceptable toxicity.
89373610|NCT04441008|Experimental|aiTBS arm|aiTBS treatment as lead-in phase to ECT standard of care treatment.
89373611|NCT04441008|Active Comparator|ECT arm|ECT as clinically indicated.
89373612|NCT04439539|Experimental|Cohort 1: Participants Enrolled Prior to Protocol Amendment 5 is in Effect|During the Induction phase, participants will receive JNJ-73763989 subcutaneously along with JNJ-56136379 tablet orally with NA (either tenofovir disoproxil or tenofovir alafenamide tablets orally) treatment. At the start of consolidation phase, participants will be randomized to receive PegIFN-alpha-2a subcutaneously in addition to JNJ-73763989 and JNJ-56136379 with NA in arm 1 and arm 2 (without PegIFN-alpha-2a). According to predefined criteria NA treatment may be continued during the follow up (FU) phase.
89373613|NCT04439539|Experimental|Cohort 2: Participants Enrolled After Protocol Amendment 5 is in Effect|Following implementation of protocol amendment- 5 and 6, all participants will receive JNJ-73763989 subcutaneously along with NA (tenofovir disoproxil tablets orally) for 36 weeks (induction phase). In the consolidation phase, participants will receive PegIFN-alpha-2a subcutaneously in addition to JNJ-73763989 and NA for 12 weeks. According to predefined criteria NA treatment may be continued during the follow up (FU) phase. JNJ-56136379 (JNJ-6379) was discontinued as per amendment 6 of the study.
89373614|NCT04424407|Other|CBT-I|
89373615|NCT04404153|Experimental|Active tDCS|The active tDCS will involve 30-minutes of direct current at intensity of 2 milliamperes (mA).
89373616|NCT04404153|Sham Comparator|Sham tDCS|Sham stimulation consists of the direct current ramped up to 2mA over 30 seconds, ramped down over 30 seconds and stay at 0 current for the remaining application period.
89373619|NCT04394624|Experimental|Ramucirumab + SAR408701|Ramucirumab will be administered intravenously prior to intravenously adminstration of SAR408701 every two 2 weeks.
88845357|NCT03237741|Experimental|Treatment Sequence 3: BAC1D1|Single dose of prototype capsule GDC-0134 (Treatment B) during Period 1. Single dose of reference capsule GDC-0134 (Treatment A) during Period 2. Single dose of GDC-0134 prototype capsule administered as GDC-0134-in-applesauce preparation under fasting conditions (Treatment C1) during Period 3. Single dose of GDC-0134 prototype capsule administered under fasting conditions in combination with 20 mg rabeprazole, and following prior administration of rabeprazole once daily for 3 days (Treatment D1) during Period 4. The washout period between doses will be a minimum of 21 days.
88845358|NCT03237741|Experimental|Treatment Sequence 4: BAC2D2|Single dose of prototype capsule GDC-0134 (Treatment B) during Period 1. Single dose of reference capsule GDC-0134 (Treatment A) during Period 2. Single dose of GDC-0134 prototype capsule administered after a high-fat meal (Treatment C2) during Period 3. Single dose of GDC-0134 prototype capsule administered after a high-fat meal in combination with 20 mg rabeprazole, and following prior administration of rabeprazole once daily for 3 days (Treatment D2) during Period 4. The washout period between doses will be a minimum of 21 days.
89373620|NCT04394624|Experimental|Ramucirumab + pembrolizumab +SAR408701|Participants will be treated with tusamitamab ravtansine and ramucirumab and pembrolizumab to assess the tolerability of the combination
88845363|NCT03211039|Other|Whole Genome Sequencing|Genetic test that looks at all coding and non-coding areas of the genome
88845364|NCT03211039|Other|Whole Exome Sequencing|Genetic test that looks at all coding areas of the genome
88845365|NCT03207867|Experimental|NIR178 + PDR001|Part 1: NIR178 continuously in combination with PDR001 400mg every 4 weeks. The part 1 enrolled 9 different tumor types.
88845366|NCT03207867|Experimental|NIR178 BID Intermittent + PDR001|Part 2: Three different dosing schedules of NIR178 twice daily (BID) including continuous and two intermittent in combination with PDR001
89002228|NCT05913232|Experimental|H-1337 1.0% Ophthalmic Solution b.i.d.|One drop H-1337 twice daily in the study eye for 28 days
89373621|NCT04387084|Experimental|Treatment (STF, PD-1/PD-L1 inhibitor)|Patients undergo STF for 47-48 hours prior to immunotherapy and for 24 hours after immunotherapy with standard of care pembrolizumab given IV over 30 minutes, nivolumab IV over 30 minutes, cemiplimab IV over 30 minutes, avelumab IV over 60 minutes, atezolizumab IV over 60 minutes, or durvalumab IV over 60 minutes on day 3. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
89373624|NCT04369924|Experimental|Unidimensional Measurement-Based Care|Youth and caregivers will complete a symptom rating scale every session. Clinicians will receive feedback reports summarizing these data, including alerts indicating if the youth is on track for positive treatment outcomes. These feedback reports will be used to support clinical decision-making.
89373625|NCT04369924|Experimental|Multidimensional Measurement-Based Care|Youth and caregivers will complete battery of questionnaires covering multiple process and outcome domains every session. Clinicians will receive feedback reports summarizing these data, including alerts indicating if the youth is on track for positive treatment outcomes. These feedback reports will be used to support clinical decision-making.
89373626|NCT04344470|Experimental|Healthy Volunteers|Healthy Volunteers
89373627|NCT04340115||Participants treated with RINVOQ|Participants treated with upadacitinib in accordance with approved local label. Decision to treat with upadacitinib was made prior to offering participation in this study.
88845367|NCT03207867|Experimental|Part 3|Further evaluation of optimal intermittent or continuous schedule of NIR178 in combination with PDR001 (if selected based on results of Part 2). A film-coated tablet of NIR178 was assessed.
88845368|NCT03207867|Experimental|Japanese safety run-in part|Different dosing schedules of NIR178 were explored.
88845369|NCT03207672|Experimental|Schedule 1: E7389-LF|Participants will receive E7389-liposomal formulation (LF) at a starting dose of 1.0 to 2.5 milligrams per meters squared (mg/m^2), administered as an intravenous (IV) infusion on Day 1 of a 21-day cycle (tri-weekly).
88845370|NCT03207672|Experimental|Schedule 2: E7389-LF|Participants will receive E7389-LF at a starting dose of 1.0 to 1.5 mg/m^2, administered as an IV infusion on Day 1 and Day 15 of a 28-day cycle (bi-weekly).
88845371|NCT03142841|No Intervention|Standard Care|Study participants will receive the usual standard care they would receive had they not been enrolled in this study
88845372|NCT03142841|Experimental|Problem Solving Intervention|The intervention consists of a problem-solving intervention and information/tools on the previously developed, evidenced-based Spanish-version of the RESCUE stroke caregiver website to improve stroke caregiver outcomes. The intervention will be conducted via telephone by a trained rehabilitation counselor. The intervention consists of four components: 1. Introduction to the RESCUE website and the problem-solving method; 2. Illustrative example on how to use the problem-solving approach and the RESCUE website to address caregiving problems; 3. Individualized practice exercise to develop a personalized problem-solving plan; and 4. Summary of the problem-solving method.
88845373|NCT03111290|Sham Comparator|Sham|Device: Direct Cortical Stimulation Sham. Trials in which stimulation is not applied. These trials are initiated using a generic trigger generator.
88845374|NCT03111290|Active Comparator|Stimulation|Device: Direct Cortical Stimulation. 150 stimulations with stimulations lasting 5 seconds at different target electrodes at two target frequencies (e.g. 5 Hz and 10 Hz) 2 milliampere in amplitude (Pulse shape - Biphasic square pulse 200 microsecond in duration per phase). Stimulation will be applied concurrently with the task and stimulation trials will be randomly interleaved with sham trials.
88845375|NCT03091075|Experimental|Treatment Group|Oxandrolone
88845376|NCT03091075|Placebo Comparator|Placebo Group|placebo
89373629|NCT04336722|Experimental|Odevixibat (A4250)|Capsules for oral administration once daily for 104 weeks.
89373630|NCT04336722|Placebo Comparator|Placebo|Capsules for oral administration (to match active) once daily for 104 weeks.
89373631|NCT04335591|Experimental|Linzagolix 75 mg|
89373632|NCT04335591|Experimental|Linzagolix 200 mg + Add-back (E2 1 mg / NETA 0.5 mg)|
89373633|NCT04331769|Experimental|Device group: AccuCinch Ventricular Restoration System|Subjects in this arm will receive the AccuCinch Ventricular Restoration System
89373634|NCT04331769|Active Comparator|Control group: Guideline-Directed Medical Therapy|Subjects in this arm will receive guideline-directed medical therapy (GDMT)
89373635|NCT04329845|Active Comparator|open splenectomy for splenic injury in trauma|open splenectomy as a technique for removal of the spleen in case of injury to spleen
89373636|NCT04329845|Active Comparator|laparoscopic splenectomy for splenic injury in trauma|laparoscopic splenectomy as a technique for removal of the spleen in case of injury to spleen
89373637|NCT04324619|Experimental|Immediate|After completing an online learning program about child abuse and its reporting, this group will receive follow-up micro-learning immediately.
89373638|NCT04324619|Experimental|3 month delay|After completing an online learning program about child abuse and its reporting, this group will receive follow-up micro-learning after a delay 3 months.
89373639|NCT04324619|Experimental|6 month delay|After completing an online learning program about child abuse and its reporting, this group will receive follow-up micro-learning after a delay 6 months.
88845377|NCT03089983|Active Comparator|No medication-assisted treatment (control group)|The control group will choose to receive no opioid agonist treatment upon release from prison.
88845378|NCT03089983|Active Comparator|Methadone maintenance treatment (MMT)|Methadone maintenance treatment (MMT) is the standard of care in Malaysia, and participants who choose this arm will receive MMT upon release from prison.
88845379|NCT03089983|Experimental|Buprenorphine/Naloxone|Participants who choose buprenorphine/naloxone will receive an induction phase for 10 days and then move on to receiving it in the community for 6 months. Buprenorphine/naloxone has been authorized and is available for use in Malaysia.
88845380|NCT03089983|Active Comparator|Standard Isoniazid (INH) for 26 weeks|Participants will be randomized to receive INH, the standard of care in Malaysia, for 26 weeks while in prison.
89373640|NCT04324619|Experimental|12 month delay|After completing an online learning program about child abuse and its reporting, this group will receive follow-up micro-learning after a delay 12 months.
89373641|NCT04311931|Experimental|Experimental Creative Dance group|The experimental group intervention will attend the creative dance program. The program integrates 3 sessions / week of 60 minutes on alternated days.
89373642|NCT04311931|No Intervention|Control group|"The control group will maintain the usually daily activities, not attending any exercise program.~After study end, the control group will have the opportunity to participate on an exercise program."
89373643|NCT04300114|Experimental|Maintenance Fluzoparib monotherapy|
89373644|NCT04300114|Placebo Comparator|Maintenance placebo monotherapy|
89373645|NCT04296305|Experimental|Group A (hydromorphone, placebo)|"TREATMENT PHASE I: Patients receive hydromorphone IV over 2 minutes and placebo IV over 15 minutes.~TREATMENT PHASE II: Patients receive hydromorphone IV over 15 minutes and placebo IV over 2 minutes."
88845381|NCT03089983|Experimental|Short-course isoniazid + rifapentine (INH + RIF) for 12 weeks|Participants will be randomized to receive INH + RIF as TB treatment while in prison.
88845382|NCT03040973|Experimental|Capmatinib|Starting dose of study treatment for patients in this protocol should be the same as the dose provided in the parent protocol at the time when the rollover protocol is initiated. Dose modifications are permitted.
88845383|NCT03040973|Experimental|Capmatinib + Nazartinib|Starting dose of the study treatment for patients should be the same as the dose provided in the parent protocol at the time when the rollover protocol is initiated. Dose modifications are permitted.
88845384|NCT03040973|Experimental|Capmatinib + Gefitinib|Starting dose of the study treatment for patients in this protocol should be the same as the dose provided in the parent protocol at the time when the rollover protocol is initiated. Dose modifications are permitted.
88845385|NCT03040973|Experimental|Capmatinib + Osimertinib|Starting dose of the study treatment for patients in this protocol should be the same as the dose provided in the parent protocol at the time when the rollover protocol is initiated. Dose modifications are permitted.
88845386|NCT03024138||Repeat CT|
88845387|NCT03017898|Experimental|Laser coagulation|Treatment of anal fistulae meeting the inclusion criteria
88845388|NCT02990793|Active Comparator|Active MeRT Treatment|Active treatment will consist of 6 seconds a minute for 30 minutes a day, 5 days a week for 5 weeks.
88845389|NCT02990793|Sham Comparator|Sham MeRT Treatment|Sham treatment will consist of 6 seconds a minute for 30 minutes a day, 5 days a week for 5 weeks.
89373646|NCT04296305|Experimental|Group B (hydromorphone, placebo)|"TREATMENT PHASE I: Patients receive hydromorphone IV over 15 minutes and placebo IV over 2 minutes.~TREATMENT PHASE II: Patients receive hydromorphone IV over 2 minutes and placebo IV over 15 minutes."
89373647|NCT04288089|Experimental|Palbociclib + H3B-6545 (Dose Escalation and Dose Expansion)|Participants will receive Palbociclib 75, 100, 125 milligram (mg) capsules or tablets, orally, once daily from Days 1 to 21 followed by 7 days off treatment in 28-day cycles along with H3B-6545 150, 300, 450 mg capsules or tablets, orally, once daily from Days 1 to 28 in 28-day cycles in dose escalation part. Based on MTD or RP2D determined for H3B-6545 in combination with palbociclib in dose escalation part, participants will continue to receive study treatment in dose expansion part until PD, development of unacceptable toxicity, or withdrawal of consent (up to 24 months).
89373648|NCT04284553|Experimental|Base Order Entry Alert|
89373649|NCT04284553|Experimental|Base Open Encounter Alert|
89373650|NCT04284553|Experimental|Order Entry + Follow-up booster Alert|
89373651|NCT04284553|Experimental|Open Encounter + Follow-up booster Alert|
88845394|NCT02955277|Experimental|TECH protocol|TECH protocol - Daily self-training using tablet apps facilitated by weekly group sessions. The self-training will take place independently at participants' home and will include mostly playing puzzle-apps to train different cognitive components. Participants will be requested to play (and log) various apps three to five times a week for 30-60 minutes each time, for a total of 15-25 training sessions. In addition they will use the tablets for a variety of everyday uses. The individual self-training will be accompanied by six weekly sessions (of 60 minutes) in a small group setting (5-6 participants) led by an experienced occupational therapist.
88845395|NCT02955277|Active Comparator|standard care or active standard care|Participants will receive standard occupational therapy with no TECH protocol. or Will receive active standard care: six weekly group sessions (60 minutes) for cognitive training using puzzle games. The setting will includes small groups of 5-6 participants, with no self training at home.
88845396|NCT02951130|Experimental|Milrinone|Milrinone infusion at 0.33µg/kg/min. The dose of the study drug will be increased to 0.66 µg/kg/min if oxygenation index (OI) remains ≥ 10 without any evidence of hypotension (as defined by the protocol) two hours after initiation of study drug. Infusion will be continued until the OI decreases to < 7. The maximum duration of study drug infusion is 72 hours.
88845397|NCT02951130|Placebo Comparator|5% dextrose (D5W)|An equivalent volume of 5% dextrose (D5W) will be used for infants randomized to the placebo arm.
88845398|NCT02926911|Active Comparator|Surgery|DCIS - Surgery +/- radiation choice for endocrine therapy (MMG q 12 months x 5 years usual care for recurrent disease)
88845399|NCT02926911|Experimental|Active Monitoring|DCIS - Choice for endocrine therapy (MMG q 6 months x 5 years GCC for invasive progression)
88845400|NCT02916472|Experimental|CyberCycling - Aerobic Exercise|30-60 mins/week, 3 days/week supervised stationary cycling with exergaming/videogaming for 12 weeks
88845401|NCT02916472|Active Comparator|Control Stretching - Resistance Bands|2 days/week at home for 12 weeks
89373652|NCT04284553|Experimental|Order Entry + Cold State outreach|
89373653|NCT04284553|Experimental|Open Encounter + Cold State outreach|
89373654|NCT04284553|Experimental|Order Entry + Simplified|
89373655|NCT04284553|Experimental|Open Encounter + Simplified|
89373656|NCT04284553|Experimental|Order Entry + Sign-off alert|
89373657|NCT04284553|Experimental|Open Encounter + Sign-off alert|
89373658|NCT04284553|Experimental|Order Entry + Pre-commitment|
89373659|NCT04284553|Experimental|Open Encounter + Pre-commitment|
88845402|NCT02905656|Placebo Comparator|Brief Advice|Participants will receive brief advice to quit smoking, and be provided psycho-education citing health consequences and the positive impact on mortality and morbidity.
89373660|NCT04284553|Experimental|Order Entry + Different Risks|
89373661|NCT04284553|Experimental|Open Encounter + Different Risks|
89373662|NCT04284553|Experimental|Standard Epic Basic Alert|
89373663|NCT04284553|No Intervention|No Alert (Usual Care)|
89373664|NCT04278989|Experimental|Anti-tumor B|1,200 mg three times a day.
89373665|NCT04276441||Non- Atrial Fibrillation (AF) Cohort|Participants without a history of AF will be randomly assigned into the study to either an Apple Watch/iPhone group or an iPhone group only.
89373666|NCT04276441||Atrial Fibrillation (AF) Cohort|Participants with a diagnosis of AF taking a direct oral anti-coagulant (DOAC) for at least 30 days will be randomly assigned to Apple Watch/iPhone group or iPhone group only.
89373667|NCT04269902|Active Comparator|Arm I (delayed V-O)|Treatment begins once 2018 IWCLL indications are met. Patients receive obinutuzumab IV over 4 hours on days 1, 2, 8, and 15 of cycle 1 and on day 1 of cycles 2-6. Patients also receive venetoclax PO QD on days 22-28 of cycle 1 and on days 1-28 of cycles 2-12. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT, collection of blood samples, and bone marrow aspiration throughout the trial.
89373668|NCT04269902|Experimental|Arm II (early V-O)|Treatment begins as soon as eligibility criteria are met. Patients receive obinutuzumab IV over 4 hours on days 1, 2, 8, and 15 of cycle 1 and on day 1 of cycles 2-6. Patients also receive venetoclax PO QD on days 22-28 of cycle 1 and on days 1-28 of cycles 2-12. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT, collection of blood samples, and bone marrow aspiration throughout the trial.
89373669|NCT04267848|Active Comparator|Arm A (platinum doublet, observation)|"INITIAL THERAPY: Patients receive 1 of 4 platinum doublet regimens based on the treating physician's choice of each cycle. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.~CONTINUANCE THERAPY: Patients then undergo observation.~Patients also undergo ECHO as clinically indicated during screening and on the trial. Patients may undergo MRI during screening and as clinically indicated on the trial, as well as CT and blood sample collection throughout the trial.~(CLOSED AS OF UPDATE #7)"
89373670|NCT04267848|Experimental|Arm B (platinum doublet, sequential pembrolizumab)|"INITIAL THERAPY: Patients receive 1 of 4 platinum doublet regimens* based on the treating physician's choice of each cycle and pembrolizumab IV over 25-40 minutes on day 1 of each cycle or for cycles 1 and 3 (patients enrolled after 10/14/2020). Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.~CONTINUANCE THERAPY: Patients then receive pembrolizumab IV over 25-40 minutes on day 1 of each cycle. Treatment repeats every 21 days for 13 cycles or every 6 weeks for 12 cycles (patients enrolled after 10/14/2020) in the absence of disease progression or unacceptable toxicity.~Patients also undergo ECHO as clinically indicated during screening and on the trial. Patients may undergo MRI during screening and as clinically indicated on the trial, as well as CT and blood sample collection throughout the trial."
89373671|NCT04267848|Experimental|Arm C (platinum doublet, combination pembrolizumab)|"INITIAL THERAPY: Patients receive 1 of 4 platinum doublet regimens* based on the treating physician's choice of each cycle and pembrolizumab IV over 25-40 minutes on day 1 of each cycle or for cycles 1 and 3 (patients enrolled after 10/14/2020). Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.~CONTINUANCE THERAPY: Patients then receive pembrolizumab IV over 25-40 minutes on day 1 of each cycle. Treatment repeats every 21 days for 13 cycles or every 6 weeks for 12 cycles (patients enrolled after 10/14/2020) in the absence of disease progression or unacceptable toxicity.~Patients also undergo ECHO as clinically indicated during screening and on the trial. Patients may undergo a MRI during screening and as clinically indicated on the trial, as well as CT and blood sample collection throughout the trial."
88845403|NCT02905656|Experimental|Motivational Interviewing (MI)|Motivational interviewing (MI) is a collaborative conversation style for strengthening a person's own motivation and commitment to change. MI attempts to avoid a confrontational style and, instead, guides participants toward choosing to make a change in their behavior.
88845404|NCT02905656|Experimental|Rate Reduction (RR)|Participants will be informed of the strong medical evidence of systematic reductions in smoking behavior can lead to long-term smoking cessation. This condition will receive Nicotine Replacement Therapy in the form of gum.
89373672|NCT04247243|Experimental|Rapid testing|Abbott ID NOW Strep A testing.
89373673|NCT04247243|Active Comparator|Reference testing|Culture-based testing.
88845405|NCT02905656|Experimental|MI + RR|In this intervention, participants receive both the skills based rate reduction intervention and the more motivationally based MI intervention. This condition will receive Nicotine Replacement Therapy in the form of gum.
88845406|NCT02900651|Experimental|Phase I - All|advanced stage (relapsed/refractory or recurrent/metastatic) malignancy limited to the following malignancies; DLBCL, nasopharyngeal carcinoma, gastric cancer, ovarian cancer, prostate cancer and sarcoma.
89002229|NCT05913232|Experimental|H-1337 1.0% Ophthalmic Solution q.a.m. and H-1337 Placebo q.p.m.|One drop H-1337 every morning and matching placebo every evening in the study eye for 28 days
89373674|NCT04240002|Experimental|Dose Escalation - 2 years to less than 21 years of age|Participants will be administered fludarabine, cytarabine and granulocyte colony-stimulating factor (FLAG) chemotherapy on days -1 to 5 and gilteritinib will be administered once per day on days 8 to 21 at the assigned dose. Participants may receive prophylactic intrathecal cytarabine at the start of the cycle, as per institutional standards. A participant completing 2 cycles (cycle is defined as 28 days) will have the option to participate in long term treatment (LTT) with gilteritinib (for up to 2 years).
88845407|NCT02843529|Experimental|Prodromal AD (MCI)|"Altoida: neuropsychological, MRI, EEG and CSF biomarkers~MCI participants will undergo at baseline and every 6 months a neurological examination and a neuropsychological assessment. Alzheimer disease biomarkers' measurements will be performed at inclusion and at the end of the study (or the conversion)."
88845408|NCT02843529|Experimental|Preclinical AD (cognitively normal)|"Altoida: neuropsychological, MRI, EEG and CSF biomarkers~Cognitively normal participants at risk will undergo at baseline and every 6 months a neurological examination and a neuropsychological assessment. Alzheimer disease biomarkers' measurements will be performed at inclusion and at the end of the study (or the conversion)."
89373675|NCT04240002|Experimental|Dose Escalation - 1 year to less than 2 years of age|Participants will be administered fludarabine, cytarabine and granulocyte colony-stimulating factor (FLAG) chemotherapy on days -1 to 5 and gilteritinib will be administered once per day on days 8 to 21 at the assigned dose. Participants may receive prophylactic intrathecal cytarabine at the start of the cycle, as per institutional standards. A participant completing 2 cycles (cycle is defined as 28 days) will have the option to participate in long term treatment (LTT) with gilteritinib (for up to 2 years).
89373676|NCT04240002|Experimental|Dose Escalation - 6 months to less than 1 year of age|Participants will be administered fludarabine, cytarabine and granulocyte colony-stimulating factor (FLAG) chemotherapy on days -1 to 5 and gilteritinib will be administered once per day on days 8 to 21 at the assigned dose. Participants may receive prophylactic intrathecal cytarabine at the start of the cycle, as per institutional standards. A participant completing 2 cycles (cycle is defined as 28 days) will have the option to participate in long term treatment (LTT) with gilteritinib (for up to 2 years).
89373677|NCT04240002|Experimental|Dose Expansion|Participants will be administered fludarabine, cytarabine and granulocyte colony-stimulating factor (FLAG) chemotherapy on days -1 to 5 and gilteritinib will be administered once per day on days 8 to 21 at the dose determined in dose escalation portion. Participants may receive prophylactic intrathecal cytarabine at the start of the cycle, as per institutional standards. A participant completing 2 cycles (cycle is defined as 28 days) will have the option to participate in long term treatment (LTT) with gilteritinib (for up to 2 years).
89373678|NCT04239157|Experimental|Treatment (canakinumab)|Patients receive canakinumab SC on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89373679|NCT04223778|Experimental|Doravirine/Islatravir (DOR/ISL)|Participants who were previously treated with continuous background antiretroviral therapy (ART) will receive DOR/ISL, a fixed dose combination (FDC) of 100 mg doravirine (DOR)/0.75 mg islatravir (ISL) orally once daily for 96 weeks.
89373680|NCT04223778|Active Comparator|Baseline Background Antiretroviral Therapy (ART)|Participants will receive continuous background ART for 48 weeks and DOR/ISL, a FDC of 100 mg DOR/0.75 mg ISL orally once daily for 48 weeks.
89373681|NCT04214262|Experimental|Arm A (atezolizumab, SBRT)|Patients receive atezolizumab IV over 30-60 minutes on day 1 of each cycle. Treatment repeats every 21 days for 8 cycles in the absence of disease progression or unacceptable toxicity. Starting on day 1 cycle 3, patients also undergo SBRT for 3-8 treatments every 2 days or QD over 1-3 weeks. Patients undergo FDG-PET/CT during screening. Patients undergo blood sample collection and CT scans throughout the trial.
88845409|NCT02839733||Cerebral Palsy|Children and young adults with Cerebral Palsy.
88845410|NCT02839733||Healthy Volunteer|Children and young adults healthy volunteer
88845411|NCT02836262|Experimental|HIT Hip Replacement System (HRS)|Single group assignment with historical controls.
88845412|NCT02825134|Experimental|Transcatheter aortic valve replacement|Transcatheter aortic valve replacement
88845413|NCT02825134|Active Comparator|Surgical aortic valve replacement|Surgical aortic valve replacement
88845414|NCT02818660|Experimental|Synacthen|The patient get Synacthen to stimulate the adrenals to produce cortisol
88845415|NCT02814721|No Intervention|Standard cannulation|The standard cannulation protocol of the center was defined as using 17 gauge needles for the first 3 dialysis sessions, followed by 16 gauge for the next 3, and finally 15 gauge for subsequent sessions.
88845416|NCT02814721|Active Comparator|Ultrasound guided cannulation|The study protocol involved similar up titration of needle size over a 3-week period, except that a pre-cannulation evaluation of the fistula was performed using the Sonic Window ultrasound device. The device was used to evaluate and identify the optimal site of cannulation (image 1). Depending upon the cannulator's preference, real-time guidance could be employed during cannulation (image 2, 3). The cannulations were performed by 4 selected personnel trained in device use and successfully completed a competency evaluation on simulator models and a mature dialysis fistula.
89002230|NCT05913232|Active Comparator|Timolol 0.5% Ophthalmic Solution b.i.d.|One drop Timolol twice daily in the study eye for 28 days
89002231|NCT05895513|Experimental|Pimavanserin|One single dose of pimavanserin (34 mg oral)
89002232|NCT05895513|Placebo Comparator|Placebo|One single dose of matching placebo
89373682|NCT04214262|Active Comparator|Arm B (SBRT)|Beginning 21 days after randomization, patients undergo SBRT for 3-8 treatments every 2 days or QD over 1-3 weeks. Patients undergo FDG-PET/CT during screening. Patients undergo blood sample collection and CT scans throughout the trial.
88845417|NCT02807597|Experimental|Phase I Dose Level 1: LS301|"Patient will undergo surgery 4-24 hours after administration of LS301 (0.05 mg/kg)~Excised tissue will be examined for the presence of LS301 fluorescence using the Cancer Vision Goggles (CVG) to determine if LS301 accumulated in the breast cancer. The investigators will quantify fluorescence intensity in the cancer to establish the feasibility of observing LS301 fluorescence with the imaging system. FDA-approved fluorescence imaging systems may be used to benchmark CVG data."
89373683|NCT04212013|Experimental|Ibrutinib/Rituximab|All subjects meeting eligibility criteria will receive rituximab: 375 mg/m^2 on days 1, 8, 15 and 22 on cycle 1.
88845418|NCT02807597|Experimental|Phase I Dose Level 2: LS301|"Patient will undergo surgery 4-24 hours after administration of LS301 (0.075 mg/kg)~Excised tissue will be examined for the presence of LS301 fluorescence using the Cancer Vision Goggles (CVG) to determine if LS301 accumulated in the breast cancer. The investigators will quantify fluorescence intensity in the cancer to establish the feasibility of observing LS301 fluorescence with the imaging system. FDA-approved fluorescence imaging systems may be used to benchmark CVG data."
89002233|NCT05894538|Experimental|Arm D - Ivermectin 600|"Ivermectin - 7-mg tablets~Participant will be instructed to take a pre-specified number of tablets for 6 consecutive days based on their weight for a daily dose of approximately 400-600 µg/kg."
89373684|NCT04212013|Placebo Comparator|Ibrutinib/Placebo|Ibrutinib capsules (140 mg each) will be dosed at 560 mg once daily on a 28-day cycle on a continuous basis. Placebo capsules will be similarly dosed at 4 capsules daily.
89373685|NCT04207190|Experimental|Treatment (talazoparib, gemtuzumab ozogamicin)|Patients receive talazoparib PO daily on days 1-21 and gemtuzumab ozogamicin IV over 2 hours on days 1, 4, and 7 or day 1 for patients who CR/CRi after cycles 1 or 2. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
89373687|NCT04204941|Experimental|Phase 1b: Open-label Tazemetostat and Phase 3: Tazemetostat + Doxorubicin Arm|"Phase 1b: On cycle 1 day -1, participants will receive a single morning dose of tazemetostat at the assigned dose level. Participants will receive doxorubicin 75 mg/m2 intravenously (IV) on day 1 of each cycle for up to 6 cycles.~Tazemetostat will be escalated from a starting dose of 400 mg twice daily PO to 600 mg twice daily PO to 800 mg twice daily.~Phase 3:~Tazemetostat (800 mg) administered orally twice daily in continuous 21-day cycles during cycles 1-6 and in continuous 28-day cycles during cycle 7 and beyond.~Doxorubicin 75 mg/m2 IV on day 1 of cycles 1-6."
89373688|NCT04204941|Placebo Comparator|Phase 3: Placebo + Doxorubicin Arm|"Placebo administered orally twice daily in continuous 21-day cycles during cycles 1-6 and in continuous 28-day cycles during cycles 7 and beyond.~Doxorubicin 75 mg/m2 IV on day 1 of cycles 1-6."
89373689|NCT04200898|Experimental|Cheetah System|For each subject, surgeons will create an iLEX refractive correction using the investigational Cheetah femtosecond laser and Cheetah patient interface (regular or small diameter designs) on one eye (phase I) and one/both eyes based on refractive correction needs (phases II and III).
89373690|NCT04200534|Experimental|Group I (centralized care strategy)|Participants receive counseling over the phone to help them quit smoking and learn about lung cancer screening over 15-20 minutes for 6-8 sessions over 8 weeks. Participants may also receive nicotine patches.
89373691|NCT04200534|Active Comparator|Group II (usual care)|Participants receive counseling on lung cancer screening and smoking cessation from primary care providers at health care visit.
89373692|NCT04198792||ECPR patients|Patients that is put om ECMO during cardiac arrest
89373693|NCT04198792||ECMO patients, non-ECPR|Patients that is put on ECMO due to circulatory failure but not cardiac arrest
88845419|NCT02807597|Experimental|Phase I Dose Level 3: LS301|"Patient will undergo surgery 4-24 hours after administration of LS301 (0.1 mg/kg)~Excised tissue will be examined for the presence of LS301 fluorescence using the Cancer Vision Goggles (CVG) to determine if LS301 accumulated in the breast cancer. The investigators will quantify fluorescence intensity in the cancer to establish the feasibility of observing LS301 fluorescence with the imaging system. FDA-approved fluorescence imaging systems may be used to benchmark CVG data."
88845420|NCT02807597|Experimental|Phase I Dose Expansion: LS301|"Patient will undergo surgery 4-24 hours after administration of LS301 (dose to be determined in Phase I dose escalation portion)~9 patients will be enrolled (6 invasive ductal carcinoma and 3 DCIS)~Excised tissue will be examined for the presence of LS301 fluorescence using the Cancer Vision Goggles (CVG) to determine if LS301 accumulated in the breast cancer. The investigators will quantify fluorescence intensity in the cancer to establish the feasibility of observing LS301 fluorescence with the imaging system. FDA-approved fluorescence imaging systems may be used to benchmark CVG data."
89373694|NCT04192981|Experimental|Concurrent GDC-0084 with Radiation|GDC-0084 in 3 + 3 dose-escalation in 3 cohorts: 45, 60, 75 mg daily, with a potential de-escalation cohort to 30mg, to determine MTD in combination with whole brain radiation therapy radiation therapy to 30Gy in 10 fractions. Once MTD is determined, 12 additional patients will be treated with GDC-0084 at MTD in combination with whole brain radiation therapy.
89373695|NCT04189458|Experimental|Multimodal exercise program|The experimental group intervention will attend the multimodal exercise program. The program integrates 3 sessions / week of 60 minutes on alternated days. The multimodal exercise program includes exercises promoting simultaneous motor and cognitive stimulation.
88845421|NCT02807597|Experimental|Phase II: LS301|"Patient will undergo surgery 4-24 hours after administration of LS301 (dose to be determined in Phase I portion)~Excised tissue will be examined for the presence of LS301 fluorescence using the Cancer Vision Goggles (CVG) to determine if LS301 accumulated in the breast cancer. The investigators will quantify fluorescence intensity in the cancer to establish the feasibility of observing LS301 fluorescence with the imaging system. FDA-approved fluorescence imaging systems may be used to benchmark CVG data."
89373696|NCT04189458|No Intervention|Control Group|Usual care. After the study, it will be offered the opportunity to integrate a similar exercise program for the control group (CG) participants.
89373697|NCT04185532|Experimental|Rebound ACL brace and physiotherapy|The intervention will be the use of rebound ACL brace for 9 weeks, which initially is locked followed by a gradually increased range of motion. A standardized rehab protocol is applied.
89373698|NCT04185532|Active Comparator|Physiotherapy|A standardized rehab protocol comparable to the experimental group but with no brace
89373699|NCT04174118|Experimental|belcesiran|Healthy volunteers will be administered a single dose of belcesiran.
89373700|NCT04174118|Placebo Comparator|Placebo|Healthy volunteers will be administered a single dose of matching placebo.
89373701|NCT04153292|Experimental|TMVR - Main Cohort|Subjects for whom commercially available surgical or transcatheter treatment options are deemed unsuitable will have transcatheter mitral valve replacement (TMVR).
89373702|NCT04153292|Experimental|TMVR - Failed TEER Registry|Subjects who have had an attempted but failed transcatheter edge-to-edge repair (TEER) procedure will have TMVR.
89373703|NCT04153292|Experimental|TMVR - MAC Registry|Subjects with mitral annular calcification (MAC) will have TMVR.
89373704|NCT04152603|No Intervention|Control Arm|Enrollment rates, parent/LAR-reported trust in research, and parent/LAR-reported experiences of respect during research recruitment before implementation of the BRIEF intervention.
89002234|NCT05894538|Placebo Comparator|Arm D - Placebo|"Placebo - appearance and size matched to active study drug.~Participant will be instructed to take a pre-specified number of tablets for 6 consecutive days based on their weight, matched to active study drug dosing."
88845423|NCT02759679|Other|Lung cancer|Patients with lung cancer
88845424|NCT02759679|Other|Controls|Controls being either healthy or having other lung disease
88845425|NCT02757989|Experimental|Patients with donor|Patients with a matched donor (8/8 at molecular level unrelated donor or matched sibling)
88845426|NCT02757989|No Intervention|Patients without donor|Patients without a matched donor
88845427|NCT02701153|Experimental|Treatment (hypofractionated radiation therapy)|Patients undergo hypofractionated radiation therapy on Monday-Friday for 5 days. Beginning 2-12 weeks after completion of radiation therapy, patients undergo surgery.
89002235|NCT05892614|Experimental|efzofitimod 450 mg|Administered IV infusion
89373705|NCT04152603|Experimental|BRIEF Arm|Enrollment rates, parent/LAR-reported trust in research, and parent/LAR-reported experiences of respect during research recruitment after implementation of the BRIEF intervention.
89373706|NCT04109274|Experimental|Institution-Based Exercise and Self-Management (EXSM)|Eight session of supervised exercise within the cancer institution plus 8 self-management modules focusing on goal setting and action planning for safe and effective exercise strategies (this is based on our team's successful pilot intervention). Four booster sessions will be provided to this group.
89373707|NCT04109274|Experimental|Institution-Based Self-management only (SM)|Eight SM sessions for safe and effective exercise strategies will be provided to this group (described above). Four booster sessions will be provided to this group.
89373708|NCT04109274|No Intervention|Usual care|Participants in this group will receive care as normally provided by their treating oncologist. This can be heterogeneous between different physicians and centres, but usually includes oncologists encouraging their patients to 'stay active'
89373709|NCT04090346|Experimental|Clostridium difficile infection|Clostridium difficile infection (CDI) is due to a toxin-producing bacteria that causes a more severe form of antibiotic associated diarrhea. The disease ranges from mild diarrhea to severe colon inflammation that can even be fatal.
89373710|NCT04057131||Firazyr|Participants with Hereditary angioedema (HAE) receiving treatment with Icatibant acetate (Firazyr) as prescribed by their physician following locally approved prescribing information.
89373711|NCT04052997|Experimental|Camidanlumab Tesirine|Camidanlumab Tesirine is administered as a 30- minute intravenous (IV) infusion on Day 1 of each cycle (every 3 weeks). Camidanlumab Tesirine will be administered at a dose of 45 μg/kg every 3 weeks for 2 cycles, then 30 μg/kg for subsequent cycles.
89373712|NCT04052880|Experimental|Daratumumab with dose-attenuated VRd|SubQ Daratumumab with Dose-Attenuated VRd
89373713|NCT04044690|Experimental|IgPro20|human immunoglobulin G administered subcutaneously
89373714|NCT04044690|Placebo Comparator|Placebo|human albumin solution administered subcutaneously
89373715|NCT04028167|Experimental|Sequential FLOT followed by chemoradiation|Sequential Chemotherapy with Docetaxel, Oxaliplatin, and 5-Fluorouracil/Leucovorin followed by chemoradiation with concurrent carboplatin and paclitaxel
89373716|NCT04004767||TRC-PAD Cohort|Individuals identified as being at an increased risk for memory loss caused by Alzheimer's disease dementia. Determination of risk based on a number of factors including family history, performance on memory tests, genetic tests and biomarker tests.
89373717|NCT03999411|Placebo Comparator|Usual Care|Participants will receive brief advice to adhere to ART brief advice to quit smoking, 6-week supplies of nicotine-replacement therapy (NRT), and self-help materials to quit smoking and adhere to ART.
89373718|NCT03999411|Active Comparator|Smoking cessation only intervention|"Participants in this group will receive the usual care (UC) for adherence to ART, one in-person orientation sessions, 6-week supplies of NRT the Crave-to-Quit app, and two brief follow-up phone calls."
88845428|NCT02693808|Active Comparator|Autologous fat injection|Patients have undergone lateral orbital wall decompression on both sides. Temporal hollowing after surgery will be treated with injection on one side with autologous fat and the other side with long-lasting hyaluronic acid.
88845429|NCT02693808|Active Comparator|Hyaluronic acid injection|Patients have undergone lateral orbital wall decompression on both sides. Temporal hollowing after surgery will be treated with injection on one side with autologous fat and the other side with long-lasting hyaluronic acid.
88845430|NCT02633163|Experimental|Low Dose Mesenchymal Stem Cells (MSCs)|Mesenchymal Stem Cells (MSCs) 1 x 10^6 cells/kg in Plasma-Lyte A solution
88845431|NCT02633163|Experimental|High Dose Mesenchymal Stem Cells (MSCs)|Mesenchymal Stem Cells MSCs 5 x 10^6 cells/kg in Plasma-Lyte A solution
88845432|NCT02633163|Placebo Comparator|Plasma Lyte A Solution|Placebo Infusion (Plasma-Lyte A solution only)
88845433|NCT02605616|Experimental|Active drug AZ compound|AZ compound 800 mg/day for 12 weeks (plus or minus 1 week) in two divided doses morning (400 mg) and evening (400 mg).
89373719|NCT03999411|Experimental|Combined smoking cessation and HIV intervention|Participants in this group will receive everything given in the Smoking Cessation Only arm and will also use the emocha app and will receive a tutorial explaining the app content and features. The study team will explain to participants that the app will help them in tracking dose-by-dose medication adherence by recording a video for themselves taking their medication.
89373720|NCT03983824|Experimental|Treatment (peposertib, mitoxantrone, etoposide, cytarabine)|Patients receive peposertib PO BID on days 2-21, mitoxantrone IV over 15 minutes, etoposide IV over 60 minutes and cytarabine IV over 60 minutes on days 1-5 in the absence of disease progression or unacceptable toxicity.
89373721|NCT03973671||UC patients|"Patients diagnosed with primary or recurrent non-muscle-invasive bladder (NMIBC) cancer.~No experimental intervention will be administered. NMIBC patients will be diagnosed, treated and followed up according to guidelines-based institutional routines.~The clinical (demographic, operative and follow-up) and pathological data of the patients will be collected in a complete anonymous way."
89373722|NCT03969329|Experimental|Etelcalcetide|Patients will receive etelcalcetide in addition to standard of care
89373723|NCT03962543|Experimental|Mirdametinib (PD-0325901)|Mirdametinib (PD-0325901) capsule or dispersible tablet 2 mg/m^2 (maximum dose of 4 mg) by mouth twice daily
89373724|NCT03945773|Experimental|Cohort A|Subjects who radiographically progressed after one prior line by CPI therapy with ipilimumab and nivolumab.
89373725|NCT03945773|Experimental|Cohort B|Subjects who radiographically progressed after one prior line by CPI therapy combined with VEGF-targeted therapy.
89373726|NCT03940989|Experimental|3-Week Camp|Subject will participate in a HABIT-ILE camp format for 6-hours/day, 5 days/week for three weeks.
89373727|NCT03940989|Experimental|15-Week Camp|Subject will participate in a HABIT-ILE camp format for 6-hours/day, one day/week for 15 weeks.
89373728|NCT03940209|No Intervention|Usual care|Medicaid beneficiaries in this arm will have all the usual resources available to them through their health plan including access to a physician network, case management resources, and other educational and health-focused resources and activities.
88845434|NCT02605616|Placebo Comparator|Placebo|Placebo 800 mg/day for 12 weeks (plus or minus 1 week) in two divided doses morning (400 mg) and evening (400 mg).
88845435|NCT02601950|Experimental|Open-label Tazemetostat|All cohorts will receive 800 mg oral Tazemetostat twice a day in continuous 28-day cycles.
88845437|NCT02577835||Hypertensive patients|No intervention. Patients will be sumbitted to standard tests required for hypertension management, including ambulatory blood pressure monitoring, and pharmacologically treated according to recommendations of international guidelines. The registry will include data from subjects fulfilling the inclusion criteria and whose data are contained in existing databases collected by the participating centers and who are regularly followed-up at the center. New subjects can be enrolled for this project, but they must be submitted to ambualtory blood pressure monitoring because it is required for evaluating their hypertension status, according to current recommendations.
89373729|NCT03940209|Experimental|Basic needs navigation|Medicaid beneficiaries in this arm will have all the usual resources available to them through their health plan (usual care) as well as a navigator for 6 months to address any unmet basic needs, provide instrumental and emotional social support, and improve self-management capabilities.
89373730|NCT03937830|Experimental|1/Arm 1|Durvalumab, bevacizumab and tremelimumab
89373731|NCT03937830|Experimental|2/Arm 2|Durvalumab, bevacizumab, tremelimumab and TACE
89373734|NCT03904693|Experimental|FDC therapy + Placebo macitentan + Placebo tadalafil|Subjects to receive FDC macitentan/tadalafil (macitentan 10 mg and tadalafil 40 mg) plus matching placebos for the two other study treatments.
89373735|NCT03904693|Active Comparator|Macitentan mono-therapy + Placebo tadalafil + Placebo FDC|Subjects to receive macitentan 10 mg plus matching placebos for the two other study treatments.
89373736|NCT03904693|Active Comparator|Tadalafil mono-therapy + Placebo macitentan + Placebo FDC|Subjects to receive tadalafil 40 mg (2 x 20 mg) plus matching placebos for the two other study treatments.
88845440|NCT02520609||Healthy volunteers|Healthy volunteers
88845441|NCT02520609||Patients with metabolic syndrome without NAFLD|Patients with metabolic syndrome without NAFLD
89373740|NCT03868020|Experimental|Diagnostic (fluciclovine F18 PET/CT)|Patients receive fluciclovine F18 IV and undergo PET/CT scan over 20-30 minutes.
89373741|NCT03867539|Active Comparator|Control Group; Bupivacaine + opioids|"This is the standard of care arm. This group will receive pre-operative opioid education and standard of care, which consists of an injection of 10cc bupivacaine (plus ~1cc epinephrine and bicarbonate) into the carpal tunnel and overlying skin pre-operatively, and a post operative prescription for opioids (oxycodone/acetaminophen 5/325). Pain scores and medication usage will be tracked for three days post operatively to assess the validity and efficacy of differing pain management strategies."
89373742|NCT03867539|Experimental|Experimental Group: Exparel, no opioids|This group will receive pre-operative opioid education, Exparel injection (liposomal bupivacaine, with bupivacaine, epinephrine and bicarbonate), and would not receive a prescription for opioids. This injection will be administered as 10cc injected in the operative field, consisting of ~5cc of Exparel (liposomal bupivacaine), ~5cc of bupivacaine, and ~1cc epinephrine. Pain scores and medication usage will be tracked for three days post operatively to assess the validity and efficacy of differing pain management strategies.
89373743|NCT03858205|Experimental|Treatment (low-dose radiation therapy)|Patients receive low-dose radiation therapy at consecutive business days 1 and 2 in the absence of disease progression or unacceptable toxicity. Patients with no pain relief may receive additional radiotherapy at 4 weeks following initial radiotherapy.
89373744|NCT03856632|Active Comparator|Risk Factor Modification (RFM)|A structured risk factor modification (RFM) program currently offered to all patients who are overweight or obese undergoing an ablation procedure for atrial fibrillation.The RFM program is already offered through our Center for Atrial Fibrillation and is managed by a nurse practitioner. The RFM program will provide patient teaching and education on weight, fitness,blood pressure control, glucose control, cholesterol, sleep apnea, smoking, and alcohol.
89373745|NCT03856632|Experimental|RFM plus Liraglutide|In addition to RFM, Liraglutide will be administered. Liraglutide is an FDA approved medication used as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management of obese adults with weight-related comorbid conditions.
89373746|NCT03851159|Placebo Comparator|No Intervention: HIV-negative|HIV-negative patients are selected to receive the placebo for the first two weeks of first-line TB treatment.
89373747|NCT03851159|Experimental|Intervention: HIV-|HIV-negative patients are selected to receive the food supplement for the first two weeks of first-line TB treatment.
89373748|NCT03851159|Placebo Comparator|No Intervention: HIV+|HIV-positive patients are selected to receive the placebo for the first two weeks of first-line TB treatment.
88845442|NCT02520609||Patients with NAFLD|Patients with NAFLD
88845443|NCT02476539|Experimental|Hemay022|"Part one: Dose Escalation Group Hemay022 tablets will be taken orally once daily in doses of 50mg, 100mg, 200mg, 300mg,400mg or 500mg daily for 28 days.~Part two: Extension Group Hemay022 tablets will be taken in three dose groups that had been assessed by Part one for 28 days."
88845444|NCT02470780|Experimental|Three-month follow-up|
88845445|NCT02470780|Experimental|Six-month follow-up|
88845446|NCT02467569|Experimental|Hemay020|"Part one: Dose Escalation Group Hemay020 capsules will be taken orally in doses of 25mg, 50mg, 100mg, 200mg or 300mg once daily for 28 days.~Part two: Extension Group Hemay020 capsules will be taken in two dose groups that assessed by Part one for 28 days."
88845447|NCT02455557|Experimental|Treatment (SurVaxM, temozolomide)|Patients receive the first priming dose of SVN53-67/M57-KLH peptide vaccine in emulsion with montanide ISA 51 SC and sargramostim SC within 7-28 days after completion of chemoradiation. Treatment repeats every 2 weeks for a total of 4 doses in the vaccine priming phase and then every 12 weeks during the adjuvant phase in the absence of disease progression or unacceptable toxicity. Patients also receive standard adjuvant temozolomide PO or IV on days 1-5. Treatment repeats every 28 days for 6 courses or more (at the discretion of the investigator) in the absence of disease progression or unacceptable toxicity. Patients may then receive maintenance SVN53-67/M57-KLH peptide vaccine in emulsion with montanide ISA 51 SC and sargramostim SC every 12 weeks in the absence of disease progression or unacceptable toxicity.
88845448|NCT02418832|Other|Men with Azoospermia, sperm cell aspiration and TEFNA|Men between 16-80 with Obstructive and Non-Obstructive Azoospermia; Sperm cell aspiration,TEFNA and Ultrasound Guidance
88845449|NCT02404870|Experimental|Admission 1 or 2|Canagliflozin
88845450|NCT02404870|Placebo Comparator|Admission 2 or 1|Placebo
88845451|NCT02383810|Active Comparator|Elsiglutide 10 mg - target population|Elsiglutide 10 mg once daily as s.c. injection for 4 consecutive days in patients receiving 5-FU based chemotherapy
89002236|NCT05892614|Experimental|efzofitimod 270 mg|Administered IV infusion
89373749|NCT03851159|Experimental|Intervention: HIV+:|HIV-positive patients are selected to receive the food supplement for the first two weeks of first-line TB treatment.
89373750|NCT03835273||Control group|Fifty control participants who have not received upper gastrointestinal surgery.
88845452|NCT02383810|Active Comparator|Elsiglutide 20 mg - target population|Elsiglutide 20 mg once daily as s.c. injection for 4 consecutive days in patients receiving F-FU based chemotherapy
88845453|NCT02383810|Active Comparator|Elsiglutide 40 mg - target population|Elsiglutide 40 mg once daily as s.c. injection for 4 consecutive days in patients receiving 5-FU based chemotherapy
89373751|NCT03835273||Open surgery|Fifty patients who have undergone open removal of oesophagus more than one year ago.
89373752|NCT03832569|Experimental|Pembrolizumab|Pembrolizumab 200 mg IV every 3 weeks over 30 minutes.
89373753|NCT03819764|Active Comparator|Aerobic Exercise & Repetitive Task Practice|"Participants will perform the following:~45 minutes of cycling~45 minutes of upper extremity repetitive arm exercises"
89373754|NCT03819764|Active Comparator|Upper Extremity Repetitive Task Practice Only|"Participants will perform the following:~1. 90 minutes of upper extremity repetitive arm exercises"
89373755|NCT03819049|Experimental|Cohort 1: ExPEC10V (Low Dose)|Participants will be randomized to receive a single intramuscular (IM) injection of low dose ExPEC10V on Day 1.
89373756|NCT03819049|Experimental|Cohort 1: ExPEC10V (Medium dose)|Participants will be randomized to receive a single IM injection of medium dose ExPEC10V on Day 1.
88845454|NCT02383810|Placebo Comparator|Placebo - target population|Placebo once daily as s.c. injection for 4 consecutive days in patients receiving 5-FU based chemotherapy
88845455|NCT02383810|Active Comparator|Elsiglutide 10 mg - additional population|Elsiglutide 10 mg once daily as s.c. injection for 4 consecutive days in patients receiving 5-FU based chemotherapy with monoclonal antibody.
88845456|NCT02383810|Active Comparator|Elsiglutide 20 mg - additional population|Elsiglutide 20 mg once daily as s.c. injection for 4 consecutive days in patients receiving 5-FU based chemotherapy with monoclonal antibody.
89373757|NCT03819049|Experimental|Cohort 1: ExPEC10V (High dose)|Participants will be randomized to receive a single IM injection of high dose ExPEC10V on Day 1.
89373758|NCT03819049|Experimental|Cohort 1: ExPEC4V|Participants will be randomized to receive a single IM injection of ExPEC4V on Day 1.
89373759|NCT03819049|Experimental|Cohort 1: Prevnar 13|Participants will be randomized to receive a single IM injection of Prevnar 13 on Day 1.
89373760|NCT03819049|Experimental|Cohort 2: ExPEC10V|Participants will be randomized to receive a single IM injection of selected dose of ExPEC10V on Day 1. The ExPEC10V dose used in Cohort 2 will be based on the primary analysis (Day 30) results of Cohort 1.
89373761|NCT03819049|Placebo Comparator|Cohort 2: Placebo|Participants will be randomized to receive a single IM injection of matching placebo on Day 1.
89373762|NCT03818035|Experimental|Part 1: Guselkumab|Participants in group 1 (Part 1) will receive 100 milligram (mg) guselkumab subcutaneously (SC) at Weeks 0, 4, 12 and 20.
89373763|NCT03818035|Experimental|Part 2: Guselkumab q8w and Guselkumab q16w|Eligible participants from Part 1 will continue to participate in Part 2. Participants (super responder [SRe]) with a Psoriasis Area and Severity Index (PASI) score = 0 at weeks 20 and 28 will be randomized to guselkumab 100 mg every 8 weeks (q8w) (group 2a) or guselkumab 100 mg q16w (group 2b), at weeks 28 to 60. Group 2b will receive placebo injection at weeks 28, 44 and 60 to keep the comparison double blind. Participants losing control of disease (PASI score >5) during study Part 2 (until week 60), will enter the re-treatment arm (group 2d) and receive guselkumab 100mg q8w (at re-treatment week 0), followed by administration at re-treatment-weeks 8 and 16.
89373764|NCT03818035|Experimental|Part 2: Guselkumab q8w|Participants (Non SRe) in group 2c with a PASI score greater than (>) 0 at week 20 and/or 28 will continue to receive guselkumab 100 mg q8w until week 60.
89373765|NCT03818035|Experimental|Part 3: Guselkumab Withdrawal|Participants from groups 2a and 2b with a PASI score <3 at week 68 will be included in Part 3 (group 3a and 3b) and be withdrawn from guselkumab. Study visits will be conducted every 12 weeks until week 220 (follow-up). Participants with fluctuating disease (PASI score greater than or equal to [>=] 3) at week 68 or PASI >5 (participants losing control of disease) at any visit during part 3 after week 68 will get an opportunity to enter the re-treatment-arm (group 3c) in which participants will receive three guselkumab injections of 100 mg q8w.
88845457|NCT02383810|Active Comparator|Elsiglutide 40 mg - additional population|Elsiglutide 40 mg once daily as s.c. injection for 4 consecutive days in patients receiving 5-FU based chemotherapy with monoclonal antibody.
88845458|NCT02383810|Placebo Comparator|Placebo - additional population|Placebo once daily as s.c. injection for 4 consecutive days in patients receiving 5-FU based chemotherapy with monoclonal antibody.
88845459|NCT02329652|Experimental|Intervention - implant neuroprosthesis|Receives implanted networked neuroprosthetic system for hand, arm, and trunk function. Undergoes functional training and assessment.
88845460|NCT02257853|No Intervention|Control Group|No intervention group
88845461|NCT02257853|Experimental|Intervention|Receives stress reduction intervention introduction with daily practice
88845462|NCT02242968||Healthy Volunteers|Male and Female healthy volunteers between aged 18 and 65 years.
88845463|NCT02215187|Experimental|Problem-Solving Training|PST is a cognitive-behavioral intervention. Delivery of the PST + usual care condition will be administered to caregivers over the course of 6 one-hour per week, telephone calls/sessions that will entail education related to problem-solving skills/problem-solving model and application to caregiving and managing caregiver related problems.
88845464|NCT02215187|Sham Comparator|Attention Control|Attention/social contact control. Health education (non-skill focused).
89373766|NCT03811561|Experimental|Semaglutide|Participants will receive semaglutide once weekly as subcutaneous (s.c., under the skin) injection added to standard of care.
88845465|NCT02194387|Experimental|Supportive care (energy balance interventions)|"TELEPHONE COACHING VS EMAIL COACHING: Participants receive telephone coaching once per week for 16 weeks or 1 email per week for 16 weeks (with follow-up responses if the participant responds) from a coach trained in motivational interviewing.~TEXT MESSAGES: Participants receive daily text messages promoting adherence to diet and exercise recommendations daily 1-3 times per day or no text messages.~SOCIAL NETWORKING: Participants are invited to an online forum for study participants available for 16 weeks or do not receive an invitation for social networking.~SELF-MONITORING: Participants are asked to record their dietary intake 4-7 days per week or 1 day per week on a website or smartphone app."
88845466|NCT02185560||BAY43-9006|NEXAVAR treatment group
89002237|NCT05892614|Placebo Comparator|Placebo|Administered IV infusion
89373767|NCT03811561|Placebo Comparator|Placebo|Participants will receive placebo (semaglutide) once weekly as subcutaneous subcutaneous (s.c., under the skin) injection added to standard of care.
88845467|NCT02181569||Treatment seeking participants with alcohol dependence|Treatment seeking individuals with alcohol dependence who are admitted into a 28-day inpatient treatment program.
89373768|NCT03811015|Experimental|Arm A (cisplatin, IMRT, nivolumab)|Patients receive cisplatin IV over 60 minutes weekly and IMRT 5 days a week for 7 weeks for a total of 35 fractions. Within 4 weeks after completion of concurrent therapy, patients receive nivolumab IV once weekly over 30 minutes every 4 weeks for 12 months in the absence of disease progression or unacceptable toxicity. Patients undergo CT or FDG PET/CT scans throughout the trial. Patients may undergo ECHO as clinically indicated. Additionally, patients undergo blood sample collection during screening.
89373769|NCT03811015|Active Comparator|Arm B (cisplatin, IMRT, observation)|"Patients receive cisplatin IV over 60 minutes weekly and IMRT 5 days a week for 7 weeks for a total of 35 fractions, and then go on observation.~Patients will be offered the option to cross-over to Arm C if they have clearly documented progression within 12 months from the end of cisplatin/radiation therapy. Patients undergo CT or FDG PET/CT scans throughout the trial. Patients may undergo ECHO as clinically indicated. Additionally, patients undergo blood sample collection during screening."
89373770|NCT03811015|Experimental|Arm C (nivolumab)|Patients receive nivolumab IV over 30 minutes every 4 weeks for 12 months in the absence of disease progression or unacceptable toxicity. Patients undergo CT or FDG PET/CT scans throughout the trial. Patients may undergo ECHO as clinically indicated. Additionally, patients undergo blood sample collection during screening.
89373771|NCT03807765|Experimental|Nivolumab followed by stereotactic radiosurgery (SRS)|480 mg Nivolumab will be given intravenously every 4 weeks, followed by SRS the week after the initial dose of Nivolumab.
89373774|NCT03789669|Experimental|Investigational|In phase I the investigators will use the investigational Cheetah femtosecond laser and Cheetah patient interface (PI) on one eye to create a LASIK flap (worst seeing eye should be preferred). Refractive correction via corneal ablation with a commercial excimer laser will be performed at the discretion of the investigator.If refractive correction is performed on the study eye, the fellow eye may receive standard LASIK treatment, otherwise, fellow eye will remain untreated.
89373775|NCT03789669|Active Comparator|Investigational/Control|"In phase II, both eyes of each subject will be treated. The investigators will use the investigational Cheetah femtosecond laser and Cheetah PI on one eye, and commercial iFS femtosecond laser and PI on the other eye to create a LASIK flap on subjects' corneas. Flap parameters (such as flap depth, flap diameter, and hinge angle) should be the same for both eyes. The eye to receive Cheetah flap will be randomized (ratio of 1:1 for right eye and left eye).~Subjects in phase II will undergo refractive correction via corneal ablation on both eyes using a commercial excimer laser for vision correction (same excimer laser system will be used on both eyes)."
89373776|NCT03789669|Active Comparator|Control/Investigational|"In phase II, both eyes of each subject will be treated. The investigators will use the commercial Cheetah femtosecond laser and Cheetah two piece PI on one eye, and commercial Cheetah femtosecond laser and investigational Cheetah one piece PI on the other eye to create a LASIK flap on subjects' corneas. Flap parameters (such as flap depth, flap diameter, and hinge angle) should be the same for both eyes. The eye to receive Cheetah flap will be randomized (ratio of 1:1 for right eye and left eye).~Subjects in phase II will undergo refractive correction via corneal ablation on both eyes using a commercial excimer laser for vision correction (same excimer laser system will be used on both eyes)."
89373777|NCT03783871|Experimental|Single-arm|Subjects will be treated with microwave ablation.
89373778|NCT03765567|Experimental|Intervention Arm|Subjects randomized to the Intervention Arm will receive usual care plus two (2) grams of Vancomycin powder administered topically. In the emergency room prior to surgical intervention, a qualified member of the study team or clinical team member will apply 2 grams of vancomycin powder directly to the open fracture site such that all visible surfaces of the wound are completely and uniformly covered, including bone edges.
88845468|NCT02142803|Experimental|Treatment (TORC1/2 inhibitor INK128, bevacizumab)|Patients receive TORC1/2 inhibitor INK128 PO QD on days 1-28 and bevacizumab IV on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88845471|NCT01962324|Experimental|SIB Dose-Escalation radiotherapy|Simultaneous integrated boost to intraprostatatic tumor and lymph nodes
88845472|NCT01953315|Experimental|Autologous Muscle Progenitor Cells|Autologous MPCs, administered via a single, direct injection into the bladder neck sphincter region
89189303|NCT02574468|Active Comparator|MP+Dexa|forty intact premolars were randomly assigned to 1 of 4 treatment groups (n=10): I) DPC, II) MP, III) DPC+dexamethasone, and IV) MP+dexamethasone. After administration of local anesthesia (3% mepivacaine plain; Septodont, Cedex, France) dental rubber dam was applied and tooth surface disinfected with 2% chlorhexidine gluconate. Occlusal cavity was prepared using high speed diamond fissure bur and buccal pulp horn was mechanically exposed (approximately 1.2 mm in diameter) using a sterile high speed carbide round bur. In MP, depth of penetration to the pulp was 0.5 mm
88845475|NCT01937052||Breast cancer patients|All patients planned to initiate hormonal therapy with either Tamoxifen, Raloxifene (Evista®), Anastrozole (Arimidex®), Letrozole (Femara®) or Exemestane (Aromasin®) are eligible to participate in sample collection and data for patient-reported outcomes/questionnaires.
88845476|NCT01930071|Experimental|PQ Bypass Guide Wire Delivery System|PQ Bypass Guide Wire Delivery System to complete percutaneous Fem-pop bypass
88845477|NCT01897480|Experimental|LY2875358 plus Erlotinib|"Lead In: Approximately 8 weeks of erlotinib 150 milligram (mg) given orally per day.~Randomization: Erlotinib 150 mg given orally per day plus 750 mg LY2875358 given as 1.5 hours intravenous (IV) infusions on Days 1 and 15 of 28-day cycles."
88845478|NCT01897480|Active Comparator|Erlotinib|"Lead In: Approximately 8 weeks of erlotinib 150 mg given orally per day.~Randomization: Continue Erlotinib 150 mg given orally per day, in 28-day cycles."
88845479|NCT01885299||Patients being treated by SRS/SBRT|Patients with a condition being considered for treatment by SRS/SBRT
88845480|NCT01840189|Active Comparator|Cortef|Treatment A is oral hydrocortisone replacement( Cortef 5 mg)with weight-adjusted doses as suggested by Mah et al , will take 2 months
88845481|NCT01840189|Active Comparator|Solu-cortef|This is the treatment B by continuous subcutaneous hydrocortisone infusion. Solu-cortef infusion will be given as Solu-Cortef Act-o-Vial 50mg/ml, , produced by Pfizer. Pump designed for subcutaneous insulin infusion can be used for subcutaneous administration.
88845482|NCT01791855|Experimental|Healthy Volunteers|
88845483|NCT01791855|Experimental|Mild Renal Impairment|
88845484|NCT01791855|Experimental|Moderate renal impairment|
88845485|NCT01791855|Experimental|Severe renal impairment|
88845488|NCT01770821|Active Comparator|Standard physical training & standard nutrition|Standard of care
88845489|NCT01770821|Experimental|Tailored physical training and sipdrink|Tailored physical training and sipdrink (Protein nutridrink, 200 ml x 2)
88845490|NCT01770821|Experimental|Tailored physical training and standard nutrition.|Standard physical training provided by the hospital and standard hospital nutrition
88845491|NCT01770821|Experimental|Standard physical training and sip drink|Standard physical training provided by the hospital and sipdrink (Nutridrink protein, 200 ml x2)
89373779|NCT03765567|No Intervention|Control Arm|Subjects randomized to the Control Arm will receive usual care for open long bone fracture as determined by the treating physician.
88845494|NCT01730131||Control Patients at Risk for PML|Participants with impaired immune function from any cause and considered at risk for PML
88845495|NCT01730131||Healthy Volunteers|Healthy volunteers without impaired immune function
88845496|NCT01730131||PML Patients|Participants with PML
88845497|NCT01721720||Participants with and without ADHD|Participants with and without ADHD
88845498|NCT01676805||1|Patients with a known lymphoid malignancy or precursor disease to a lymphoid malignancy
88845499|NCT01676805||2|Patients without a known lymphoid malignancy or precursor disease to a lymphoid malignancy
88845500|NCT01617395||GEMS cohort|Individuals at risk for developing MS
88845501|NCT01617395||Healthy volunteer cohort|healthy volunteers, ages 18-50, who do not have a known first-degree relative with MS
88845502|NCT01617395||MS patient cohort|MS patients whose first-degree relatives are enrolled in this study
88845504|NCT01508962||Healthy individuals (controls)|
88845505|NCT01508962||Individuals affected with ALS (sporadic or familial)|
89002238|NCT05890599|Experimental|Yoga Therapy|12 week yoga program, one weekly session of 90 minutes each, plus 2 times weekly 30 minutes of self practice.
88845508|NCT01460264||exposed|current daily smokers 100 cigarettes or more during lifetime
88845509|NCT01460264||unexposed|current non-smokers
88845510|NCT01445509|Experimental|Arm 1|Group 1 will receive dasatinib and bevacizumab together at the start of study in a dose escalation fashion
88845511|NCT01445509|Experimental|Arm 2|Group 2 will be randomized as to which agent they receive for cycle one. Cycles 2 and beyond are treated using both agents.
88845512|NCT01445288||1|Pediatric Patients with Central Nervous System Tumors
88845513|NCT01443468||1|Patients within a family with a known TP53 mutation who are positive for that mutation.
88845514|NCT01443468||2|Patients within a family with a known TP53 mutation who are negative for that mutation.
88845515|NCT01443468||3|Unaffected family members.
88845516|NCT01443468||4|Patients who meet clinical LFS criteria but haven't had TP53 testing.
89373780|NCT03765567|No Intervention|Observational Arm|Subjects who otherwise meet the criteria to be included in the study but are not able to provide consent, either themselves or through a Legally Authorized Representative, will be placed in the Observational Arm and receive usual care with no experimental intervention.
89373781|NCT03748641|Experimental|Cohort 1: Participants with mCRPC and HRR Gene Alteration|Participants with L1 metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alteration will receive combination of niraparib 200 milligrams (mg) or matching placebo and abiraterone acetate (AA) 1000 mg plus prednisone 10 mg. In the open label extension (OLE) phase participants earlier receiving the combination of niraparib and AAP may continue to receive open-label combination of niraparib 200 mg and AA 1000 mg plus prednisone 10 mg and those receiving placebo and AAP may cross over depending on the outcome of study to receive open-label combination of niraparib 200 mg and AA 1000 mg plus prednisone 10 mg.
89373782|NCT03748641|Experimental|Cohort 2: Participants with mCRPC and No HRR Gene Alteration|Participants with L1 mCRPC and no HRR Gene alteration will receive combination of niraparib 200 mg or matching placebo and AA 1000 mg plus prednisone 10 mg. In the OLE phase participants earlier receiving the combination of niraparib and AAP may continue to receive open-label combination of niraparib 200 mg and AA 1000 mg plus prednisone 10 mg and those receiving placebo and AAP may cross over depending on the outcome of study to receive open-label combination of niraparib 200 mg and AA 1000 mg plus prednisone 10 mg.
89373783|NCT03748641|Experimental|Cohort 3 (Open-label): Participants with mCRPC|Participants with mCRPC will receive a new formulation of niraparib 200 mg and AA 1000 mg tablets plus prednisone 10 mg.
89373784|NCT03743025|Experimental|Dulaglutide Arm|Participants without a history of DM who are randomized to receive a single injection of dulaglutide (0.75 mg/0.5 mL solution in a single-dose pen) one to three days prior to surgery.
89373785|NCT03743025|Placebo Comparator|Placebo Arm|Participants without a history of DM who are randomized to receive a single injection of a placebo (saline injection of 0.5 mL pre-drawn solution) one to three days prior to surgery.
89373786|NCT03706833|Experimental|Edwards PASCAL System - CLASP IID|Transcatheter mitral valve repair with the Edwards PASCAL System in patients with degenerative mitral regurgitation
89373787|NCT03706833|Active Comparator|Abbott Mitraclip System - CLASP IID|Transcatheter mitral valve repair with the Abbott Mitraclip System in patients with degenerative mitral regurgitation
89373788|NCT03706833|Experimental|Edwards PASCAL System - CLASP IIF|Transcatheter mitral valve repair with the Edwards PASCAL System in patients on guideline directed medical therapy with functional mitral regurgitation
89373789|NCT03706833|Active Comparator|Abbott Mitraclip System - CLASP IIF|Transcatheter mitral valve repair with the Abbott Mitraclip System in patients on guideline directed medical therapy with functional mitral regurgitation
89373790|NCT03706833|Experimental|Edwards PASCAL System - Single-Arm Registry|Transcatheter mitral valve repair with the Edwards PASCAL System in patients with mitral regurgitation who were deemed non-randomizable by a central screening committee (CSC) due to complex anatomical features described in the current MitraClip Instructions for Use (IFU) but were considered suitable for the PASCAL system.
89373791|NCT03697148|Experimental|Diagnostic (mpMRI)|Patients undergo mpMRI within 3 months prior to schedule surgery.
88845517|NCT01443468||5|Patients within a family with an negative/unknown TP53 mutation.
89373792|NCT03674567|Experimental|Part 1a: Monotherapy Dose Escalation|Eligible subjects will be enrolled in sequential cohorts treated with successively higher doses of FLX475 as monotherapy.
88845518|NCT01441089||1/ Patients with cancer, other tumors, or possible genetic tumor|Patients enrolled on IRB approved NIH Intramural Research Program (IRP) therapeutic clinical trials
89373793|NCT03674567|Experimental|Part 1b: Combination Dose Escalation|Eligible subjects will be enrolled in sequential cohorts treated with successively higher doses of FLX475 in combination with pembrolizumab.
89373794|NCT03674567|Experimental|Part 2a: Monotherapy Expansion Cohorts|Eligible subjects will be initially enrolled in Stage 1 of parallel expansion cohorts of FLX475 as monotherapy; additional subjects in each cohort may be enrolled in Stage 2.
89373795|NCT03674567|Experimental|Part 2b: Combination Expansion Cohorts|Eligible subjects will be initially enrolled in Stage 1 of parallel expansion cohorts of FLX475 in combination with pembrolizumab; additional subjects in each cohort may be enrolled in Stage 2.
89373796|NCT03671590|Experimental|Arm 1: TG-1701 Monotherapy|Participants will receive TG-1701 oral daily dose. As per protocol v6.0, participants from this arm will be transitioned to the long-term extension arm to receive TG-1701 monotherapy.
89373797|NCT03671590|Experimental|Arm 2: TG-1701 + Ublituximab + Umbralisib|Participants will receive TG-1701, oral dose in combination with ublituximab, oral dose and umbralisib, fixed IV infusion on specific Days of Cycles 1 and 2, followed by maintenance infusions in Cycles 3 to 6 (Cycle=28 days). As per protocol v6.0, participants from this arm will be transitioned to the long-term extension arm to receive TG-1701 monotherapy.
88845519|NCT01374360||Receiving Soliris or Ultomiris|PNH patients of any age, including minors, that are receiving Soliris or Ultomiris
88845520|NCT01374360||Not receiving Soliris or Ultomiris|PNH patients of any age, including minors, that are not receiving Soliris or Ultomiris
88845521|NCT01273129||Patients|Patients 8 years and older whose seizures are uncontrollable with medication may participate in this study as well as patients with tumor related epilepsy in whom invasive monitoring is indicated.
88845522|NCT01239082|Other|Arm 1|Colonoscopy (one time screening)
88845523|NCT01239082|Other|Arm 2|FIT (annually)
88845528|NCT01146574|Experimental|0.1mg/kg Sotatercept|Approximately 8 subjects will be randomized to receive either a single 0.1 mg/kg subcutaneous dose of sotatercept or matching placebo in a 3:1 ratio
88845529|NCT01146574|Experimental|0.3mg/kg Sotatercept|Dose Group 1: 0.3 mg/kg sotatercept subcutaneous every 28 days
88845530|NCT01146574|Experimental|0.5mg/kg Sotatercept|Dose Group 2: 0.5 mg/kg sotatercept subcutaneous every 28 days
88845531|NCT01146574|Experimental|0.7mg/kg Sotatercept|Dose Group 3: 0.7 mg/kg sotatercept subcutaneous every 28 days
89189304|NCT00710268|Experimental|1|Dose Escalation Study 50, 100, 200, 400 mg
89373798|NCT03671590|Experimental|Arm 3: Long Term Safety Extension - TG-1701 Monotherapy|All the ongoing participants from Arm 1 and 2, will be transitioned to TG-1701 monotherapy in long-term extension period, per protocol version 6.0.
89373799|NCT03625882||Gaucher Disease Participants Treated With VPRIV|Participants with Gaucher disease will be enrolled in this survey, who are in VPRIV treatment-naïve therapy or have been switched from another therapeutic agent for Gaucher disease.
89373800|NCT03604978|Experimental|Cohort A (nivolumab, radiosurgery)|Patients receive nivolumab IV over 30 minutes on day 1. Cycles repeat every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients also undergo multi-fraction stereotactic radiosurgery on days 1, 3, and 5. Patients undergo brain MRI and blood sample collection throughout the study. Patients may also undergo ECHO as clinically indicated.
89373801|NCT03604978|Experimental|Cohort B (nivolumab, ipilimumab, radiosurgery)|Patients receive nivolumab IV over 30 minutes every 2 weeks for 12 doses (6 months) and then every 4 weeks for additional 6 months. Patients also receive ipilimumab IV over 90 minutes on day 1. Treatment with ipilimumab repeats every 6 weeks for 4 doses in the absence of disease progression or unacceptable toxicity. Patients undergo multi-fraction stereotactic radiosurgery on days 1, 3, and 5. Patients undergo brain MRI and blood sample collection throughout the study. Patients may also undergo ECHO as clinically indicated.
89373802|NCT03602599||Healthy-controls Longitudinal Cohort|( Cohort HL ; approximate n=20) includes subjects who will participate in up to 4 study visits across 1 year.
89373803|NCT03602599||Healthy-controls Short-term Cohort|( Cohort HS ; approximate n=80) will participate in a single baseline visit.
89373804|NCT03602599||New Transplant Cohort|( Cohort NT ; approximate n=300) consists of patients who are scheduled to undergo allogeneic HSCT (under another protocol at the NIH).
89373805|NCT03602599||Prior Transplant Cohort|( Cohort PT ; approximate n=100) consists of patients who have already undergone allogeneic HSCT.
89373806|NCT03600701|Experimental|Treatment (atezolizumab, cobimetinib)|Patients receive atezolizumab IV over 30-60 minutes on days 1, and cobimetinib PO QD on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unaccepted toxicity. Patients also undergo a CT scan, MRI, biopsy, and collection of blood throughout the trial.
89373807|NCT03568994|Experimental|ADE 10+3+5 plus Atovaquone (AQ)|Induction I ADE: cytarabine, daunorubicin, etoposide 10+3+5, atovaquone daily
89373808|NCT03568994|Experimental|DA 3+10 with GO plus AQ|Induction I DA: daunorubicin, cytarabine 3+10 with GO: gemtuzumab ozogamicin, atovaquone daily
89373809|NCT03552705|Experimental|Tranexamic Acid|5-day course of standard adult oral tranexamic acid dosage of 1300 mg taken 3 times a day (3900 mg/day) and intravenous tranexamic acid during ACL reconstruction surgery (1 gram of iv TXA just prior to incision and 1 gram of iv TXA just prior to wound closure)
89373810|NCT03552705|Placebo Comparator|Placebo|5-day course of placebo and intravenous saline during ACL reconstruction surgery
89373811|NCT03507413|Active Comparator|INVESTIGATIONAL DRUG|oral metformin treatment with 2000Mg daily: Glucophage 500mg Tablet (2-0-2) daily for 1 year
89373812|NCT03507413|Placebo Comparator|COMPARATIVE DRUG|Placebo matching M90 Oral Tablet treatment twice daily (2-0-2) for 1 year
89373813|NCT03499119|Other|Cohort 1|Subjects with a body weight at Day 1 of less than weight threshold.
89373814|NCT03499119|Other|Cohort 2|Subjects with a body weight at Day 1 of weight threshold or more.
89373815|NCT03492177|Experimental|open label selexipag|The first dose of selexipag (Uptravi) will be administered in the evening of Day 1 and will be based on the body weight. Thereafter selexipag will be administered twice daily (morning and evening). Selexipag will be up-titrated during the first 12 weeks, with weekly increments equal to the starting dose until the participants reach their individual maximum tolerated dose (iMTD) or until a maximum dose corresponding to their baseline weight category is achieved (which will be 8-fold of the corresponding starting dose). Up-titration is followed by a stable maintenance treatment period from Week 12 to Week 16, at the maximum tolerated dose. Thereafter, participants will be treated with selexipag as long as the treatment is beneficial to the participants, as per investigator's decision.
89373816|NCT03482349|Experimental|Total Knee Robotically-Assisted|The intervention is then performed with a new device and surgical procedure. At first the femur and the tibia are fixed to the operating table with a special clamp and the knee bones are exposed with the standard technique; then the surgeon digitizes the shape of the joint and the computer transfers the planned surgical strategy to a dedicated surgical robot. Resections are performed by the surgeon on a constrained guide held by the robot.
89373817|NCT03482349|No Intervention|Total Knee Manual-Executed by Surgeon|Your orthopaedic surgeon will remove the damaged cartilage and bone, and then position the new metal and plastic implants to restore the alignment and function of your knee.
89373818|NCT03473743|Experimental|Phase 1b: Dose Escalation|Two dosing cohorts (erdafitinib and cetrelimab; and erdafitinib, cetrelimab and cisplatin/carboplatin) are explored in Phase 1b of the study. Participants will receive erdafitinib orally followed by cetrelimab intravenously (IV) and carboplatin/cisplatin IV as a part of platinum chemotherapy. The dose levels will be escalated sequentially based on the decisions of the Study Evaluation Team (SET) until the recommended Phase 2 Dose (RP2D) has been identified.
89373819|NCT03473743|Experimental|Phase 2: Dose Expansion|The participants will be randomized in a 1:1 manner to receive either erdafitinib alone (orally) or the identified RP2D of Phase 1b for erdafitinib (orally) in combination with cetrelimab (IV).
89399285|NCT03538730|No Intervention|Attention Control|Similar to previous narrative and memory interventions, parents in the control group will receive instructions from a researcher for 20 minutes on how to engage in child-directed play. Importantly, they will not talk about pain or the past surgery experience.
88810182|NCT03801746|Experimental|Vadadustat and Rifampin|Part 2: Subjects will receive vadadustat 300 mg alone and vadadustat 300 mg in combination with IV rifampin 600 mg in a cross-over design
89373820|NCT03466450|Experimental|Glasdegib and Temozolomide Oral Capsule|"During Phase Ib, Four to six weeks after surgical diagnosis, concurrent with radiotherapy (STUPP) + temozolomide (75mg/m2/day for 42 days) + PF-04449913 (Glasdegib) (3 dose levels will be evaluated: 100mg QD, 150mg QD and 200mg QD, or 75-50mg) will be administered.~During Phase II, Radiation therapy, temozolomide and glasdegib will be administered. This last, as the dose that have been selected previously, based on the Phase Ib results. Glasdegib ( PF-04449913) recommended dose until progresion of disease, unacceptable toxicity, non-compliance, consent withdrawal up to 2 years."
89373821|NCT03463902|Experimental|left IFG anodal|2 mA Stimulation of 10 min, anodal electrode over left IFG, cathodal electrode over right IFG, 30 sec ramp to start and 30 sec ramp to stop
89373822|NCT03463902|Active Comparator|left IFG cathodal|2 mA Stimulation of 10 min, cathodal electrode over left IFG, anodal electrode over right IFG, 30 sec ramp to start and 30 sec ramp to stop
89373823|NCT03463902|Active Comparator|left IPL anodal|2 mA Stimulation of 10 min, anodal electrode over left IPL, cathodal electrode over right IPL, 30 sec ramp to start and 30 sec ramp to stop
89373824|NCT03463902|Active Comparator|left IPL cathodal|2 mA Stimulation of 10 min, anodal electrode over left IFG, cathodal electrode over right IFG, 30 sec ramp to start and 30 sec ramp to stop
88845532|NCT01146574|Placebo Comparator|Placebo|The Placebo to Sotatercept ratio is 1:3 meaning for every 1 patient that receives Placebo, 3 patients will receive Sotatercept.
88845533|NCT01143454||1. Adult index cases and relatives|Enrolled with a known or suspected pathology that may be associated w/cardiovascular dysfunction or risk w/suspected atypical presentation, heritable disorder, or genetic predisposition.
89373825|NCT03463902|Placebo Comparator|Placebo|anodal electrode over left IFG, cathodal electrode over right IFG, stimulation only during 30 sec ramp at beginning and end of 10 min
89373826|NCT03462719|Experimental|Treatment Arm A: Ibrutinib and Venetoclax (I+VEN)|Participants will initially receive ibrutinib (420 mg [milligrams]/day) for 3 cycles. Venetoclax dose ramp up (from 20 to 400 mg over 5 weeks) will begin at Cycle 4 and the combination of ibrutinib and venetoclax will be given for 12 cycles (each cycle is equivalent to 28 days). Participants who subsequently develop progressive disease may enter to Subsequent Therapy Phase to receive single-agent ibrutinib until disease progression or unacceptable toxicity.
89373827|NCT03462719|Active Comparator|Treatment Arm B: Chlorambucil and Obinutuzumab (G-Clb)|Participants will receive chlorambucil and obinutuzumab (G-Clb) for 6 cycles. Participants will receive obinutuzumab, 1000 mg intravenously (IV) on Days 1, 8 and 15 of Cycle 1, and on Day 1 of Cycles 2 to 6 and chlorambucil 0.5 milligrams per kilogram (mg/kg) body weight, on Days 1 and 15 of Cycles 1 to 6. Participants who subsequently develop progressive disease may enter to Subsequent Therapy Phase to receive single-agent ibrutinib until disease progression or unacceptable toxicity.
89373828|NCT03459690|Experimental|Experienced meditators|Meditation ≥ 30 min per day for at least 5 days per week over the past 1 year
89373829|NCT03459690|Experimental|Novice meditators|No meditation practice in the previous year and < 20 entire lifetime hours
89399286|NCT03538730|Experimental|Memory Reframing Intervention|Parents in the intervention group will spend 20 minutes with a researcher and receive instructions about adaptive ways of reminiscing about the in-hospital and post-surgery periods.
89399287|NCT02172716|Experimental|Nonsurgical periodontal treatment|Nonsurgical periodontal treatment will be conducted following a full-mouth approach; no antibiotics or chemical plaque control will be provided.
89399288|NCT03694899|Experimental|one|acetaminophen 650 mg three times/day ibuprofen 600 mg three times/day opioid dose based on use in hospital day prior to discharge
88810183|NCT03801668|Experimental|Nab-P/S-1|Patients in this arm receive chemotherapy with Albumin-bound Paclitaxel plus S-1.
88810184|NCT03801668|Active Comparator|SOX|Patients in this arm receive chemotherapy with Oxaliplatin plus S-1.
88810185|NCT05414006|Experimental|Group E1|S-ketamine was administered intravenously after delivery，patient controlled epidural analgesia（PCEA）was administered postoperatively PCEA formula：（10μg/ml hydromorphone+0.11% ropivacaine) 200ml
88810186|NCT05414006|Experimental|Group E2|S-ketamine was administered intravenously after delivery，patient controlled intravenous analgesia（PCIA) was administered postoperatively PCIA formula：（100μg/ml hydromorphone) 100ml
88810187|NCT05414006|Placebo Comparator|Group C1|placebo was administered intravenously after delivery，patient controlled epidural analgesia（PCEA) was administered postoperatively PCEA formula：（10μg/ml hydromorphone+0.11% ropivacaine) 200ml
88810188|NCT05414006|Placebo Comparator|Group C2|placebo was administered intravenously after delivery，patient controlled intravenous analgesia（PCIA） was administered postoperatively PCIA formula：（100μg/ml hydromorphone) 100ml
88810189|NCT02199041|Experimental|Treatment|"Interventions: cyclophosphamide, thiotepa, fludarabine, melphalan, mesna, granulocyte colony-stimulating factor (G-CSF), mycophenolate mofetil, tacrolimus, methylprednisolone, total lymphoid irradiation, and lymphocyte infusions.~Cells for infusion are prepared using the CliniMACS System."
88845534|NCT01143454||2. Child index case and child relatives|Children over 1 year of age who is affected with diseases/disorders (index cases), or who is a relative of a person who is affected with diseases/disorders.
88845535|NCT01143454||3. Healthy adult volunteers|Healthy adult volunteers must be 18 years of age or older, and must agree to have blood or tissue samples studied, and potentially stored for future research.
88845536|NCT01130818|Experimental|1|single ascending doses
88845537|NCT01130818|Placebo Comparator|2|single dose placebo
88845538|NCT01130818|Experimental|3|single dose, oral solution, 50 mg
88845539|NCT01130818|Experimental|4|single dose, capsules (fasting)
88845540|NCT01130818|Experimental|5|single dose, capsules (fed)
89399289|NCT03687021|No Intervention|endometriosis|tissue biopsy from patients (n=10) with endometriosis
89399290|NCT03687021|No Intervention|without endometriosis|tissue biopsy from patients (n=10) without endometriosis
89002239|NCT05890599|Active Comparator|Health Education|12 week health education program, one weekly session of 90 minutes each, plus 2 times weekly 30 minutes of self practice.
89181259|NCT01294007|Experimental|Study Graft Composite|"AlphaGraft ProFuse Demineralized Bone Scaffold are soaked in PureGen according to Preparation for Use and handling technique. The graft composite is placed on the randomized study side contralateral to the autograft bone graft per surgeon's standard technique for PLF. The wound is closed according to surgeon's standard technique.~Post operative care will be according to the site specific standard of care. An avoidance of heavy physical activity and limitations on working, lifting, bending etc. are common precautions post procedure. The decision to use a post operative orthosis is left to the discretion of the Investigator."
89181260|NCT01294007|Active Comparator|Control Graft Composite|"Contralateral to the study graft composite, placement of posterolateral fusion graft composite containing iliac crest bone (5 cc/level/side) and local autograft composite (equal volume split with study side). Supplemental posterior pedicle screw fixation utilizing Zodiac, Illico or Xenon Spinal Fixation system.~A defined volume of iliac crest bone graft (indicated in table 2) is harvested and combined with 50% of the previously harvest morselized local bone~The graft composite is placed on the randomized control side using standard technique for PLF"
89181261|NCT02606123|Experimental|EPI-506|Part I: Ascending doses of EPI-506 administered orally to define the maximum tolerated dose.
89189305|NCT02575482|Experimental|Single and Multiple ascending dose|Single dose of SUVN-D4010 in healthy male subjects
89189306|NCT02575482|Placebo Comparator|Placebo|Placebo in healthy male subjects
89399291|NCT03687021|Experimental|Intramuscular progesterone|Intramuscular progestin(20mg)
88845543|NCT01065454|Experimental|Riociguat (Adempas, BAY63-2521) up to 2 mg|Participants received riociguat up to 2 mg three times per day (tid) (increasing from 0.5 to 1 to 2 mg).
88845544|NCT01065454|Experimental|Riociguat (Adempas, BAY63-2521) up to 1 mg|Participants received riociguat up to 1 mg tid (increasing from 0.5 to 1 mg).
89399292|NCT03687021|Experimental|vaginal progesterone|vaginal progestin (90mg)
89399293|NCT03687021|Experimental|oral progesterone|oral progestin(40mg)
88845545|NCT01065454|Experimental|Riociguat (Adempas, BAY63-2521) fixed 0.5 mg|Participants received riociguat 0.5 mg tid (fixed dose).
88845546|NCT01065454|Placebo Comparator|Placebo|Participants received placebo tid.
88845547|NCT01011712||1|patients without known or not fully characterized immunodeficiency, who have severe, persistent, or treatment-refractory viral infections
88845548|NCT00837122||Control|Control subjects are nondiabetics ethnically matched to patients
88845549|NCT00837122||T2D|Patients with confirmed T2D who are newly diagnosed or on treatment in Ibadan, Nigeria
88845550|NCT00801372||Pre-existing Fibroblast MCB|Pre-existing fibroblast donors for hESC derivation project
88845551|NCT00495300||1|Related or Unrelated Hematopoietic Stem Cell Transplantation Recipients for the National Marrow Donor Program
89399294|NCT02170454|Active Comparator|rTMS|rTMS on pharyngeal cortical area in healthy subjects
88845552|NCT00445627||Healthy Lean Controls|Cross-sectional analyses of continuous variables (e.g. hormonal measurements, inflammatory markers, lipids, BMI, and body composition measurements) will be compared using ANOVA
89002240|NCT05881590|Experimental|Hybrid pulmonary rehabilitation|
89002241|NCT05878119|Active Comparator|Investigational Product - MIB 626 plus usual physical activity (MIB-626- UPA)|The MIB-626 will be a GMP-grade microcrystalline solid NMN mixed with inert excipients (including microcrystalline cellulose) and compressed into tablets at a dose strength of 500 mg per tablet, enabling administration of the 1,000 mg twice daily using two tablets taken twice daily.
89399295|NCT02170454|Placebo Comparator|Placebo|Sham rTMS on pharyngeal cortical area in healthy subjects
89399296|NCT02174744||numerical scale|
89399297|NCT03694743|Experimental|2Shape rotary system|root canal preparation using 2Shape rotary system in mandibular molars with symptomatic pulpitis
89399298|NCT03694743|Active Comparator|Protaper Next rotary system|root canal preparation using Protaper Next rotary system comparing to 2Shape rotary system in mandibular molars with symptomatic pulpitis
89399299|NCT02172794|Experimental|tiotropium|
89399300|NCT02172794|Active Comparator|salmeterol|
89399301|NCT04173819|Experimental|Group 1|Single Agent, abdominal subcutaneous injection, 10:2 ratio for Ab:placebo
89399302|NCT04173819|Experimental|Group 2|Single agent, abdominal subcutaneous injection 10:2 ratio for Ab:placebo
89399303|NCT04173819|Experimental|Group 3|Single agent intravenous injection 10:2 ratio for Ab:placebo
88845553|NCT00445627||Overweight Obese Controls|Cross-sectional analyses of continuous variables (e.g. hormonal measurements, inflammatory markers, lipids, BMI, and body composition measurements) will be compared using ANOVA
88845554|NCT00445627||Type 1 Diabetes|Cross-sectional analyses of continuous variables (e.g. hormonal measurements, inflammatory markers, lipids, BMI, and body composition measurements) will be compared using ANOVA
88845555|NCT00362843||healthy volunteers|healthy volunteers
88845556|NCT00362843||patients|Patients with Fragile X Syndrome
88845557|NCT00342797||Retinoblastoma cohort|Retinoblastoma patients treated at two hospitals in New York and one hospital in Boston from 1914-2006.
88845558|NCT00341497||Cohort|Persons seen at dental clinics at 6 Veterans Affairs Medical Centers who had clinically visibleoral lesions
89181262|NCT04111913|Experimental|anlotinib and chemoradiotherapy|"anlotinib: 12 mg, po, qd, on day1-14 of a 21 days cycle; anlotinib will be administrated to 2 cycles for induction before the 2 cycles of chemoradiation and anlotinib will be administrated up to 1year or disease progression for maintenance treatment.~EP regimen: cisplatin 50mg/m2, d1, 8, 29, 36; etoposide 50mg/m2, d1~5, d29~33. Radiotherapy program: 2 Gy / time / d, 5 d / week;PTV radiotherapy 60~66Gy/30~33 times/6~7 weeks."
89181263|NCT04081467|Experimental|bed rest condition|Bed rest condition without any additional intervention
89181264|NCT02605265|Active Comparator|Capecitabine Alone|"Concurrent Chemoradiotherapy:~Radiation: 50Gy/25Fx; Capecitabine: 825mg/m2 bid Monday-Friday per week~Chemotherapy in Interval Between CRT and Surgery:~Capecitabine: 1000mg/m2 bid d1-14; Oxaliplatin: 130mg/m2 d1~Surgery:~Scheduled 6-8 weeks after the completion of CRT~Adjuvant Chemotherapy:~Capecitabine: 1000mg/m2 bid d1-14; Oxaliplatin: 130mg/m2 d1; q3w, 5cycles"
89181265|NCT02605265|Experimental|Capecitabine with Irinotecan|"Concurrent Chemoradiotherapy:~Radiation: 50Gy/25Fx; Capecitabine: 625mg/m2 bid Monday-Friday per week; Irinotecan: 80mg/m2 (UGT1A1*28 6/6) or 65mg/m2 (UGT1A1*28 6/7)~Chemotherapy in Interval Between CRT and Surgery:~Capecitabine: 1000mg/m2 bid d1-14; Irinotecan: 200mg/m2 d1~Surgery:~Scheduled 6-8 weeks after the completion of CRT~Adjuvant Chemotherapy:~Capecitabine: 1000mg/m2 bid d1-14; Oxaliplatin: 130mg/m2 d1; q3w, 5cycles"
89181266|NCT02604875||observational|Blood samples will be taken for measuring copeptin levels in healthy subjects.
89181267|NCT04081623||Clinic|This group is undergoing their scheduled visit for Non-Stress Test (NST) or Biophysical Profile (BPP)
89373830|NCT03431350|Experimental|Combination 1:Dose Selection: Niraparib + cetrelimab (Part 1)|Dose regimen 1: The participants will receive niraparib 200 milligram (mg) orally once daily in combination with cetrelimab 240 mg intravenously (IV) once every 2 weeks. Dose regimen 2: The participants will receive niraparib 200 mg orally once daily in combination with cetrelimab 480 mg IV once every 4 weeks in 28-day treatment cycles until disease progression, unacceptable toxicity, death, or the sponsor terminates the study. The safety evaluation team (SET) will determine if an additional cohort is necessary, based on the data from dose regimens 1 and 2. Participants in the Treatment Phase of this combination will be offered the option to enter the Long-term Extension Phase of the study.
89373831|NCT03431350|Experimental|Combination 1:Dose Expansion: Niraparib + cetrelimab (Part 2)|Participants will be assigned to either Cohort 1A (Biomarker [BM] positive [+]) or Cohort 1B (BM negative [-]) and will receive established RP2D of cetrelimab and niraparib, in Part 2 until disease progression, unacceptable toxicity, death, or the sponsor terminates the study. A futility analysis will be performed for the Cohort 1B after 10 BM- participants are enrolled in Part 2. This cohort will be closed if the response is less than predetermined response rate as outlined in the protocol. Participants in the Treatment Phase of this combination will be offered the option to enter the Long-term Extension Phase of the study.
89181268|NCT04081623||Labor and Delivery|This group is in active labor.
89181269|NCT04101500|Placebo Comparator|AECOPD(P+C1)|Placebo Tablets(P) three times a day, one tablet at a time; combined with Compound Ipratropium Bromide Solution(C1) 2.5ml atomized inhalation twice a day.
89181270|NCT04101500|Experimental|AECOPD(C1+C2)|Compound Sodium Chlolate and Aminophylline Tablets(C2) three times a day, one tablet at a time; combined with Compound Ipratropium Bromide Solution(C1) 2.5ml atomized inhalation twice a day.
89181271|NCT04103060|Experimental|Cerdulatinib 0.37% gel|Cerdulatinib 0.37% gel applied topically twice daily
89181272|NCT04103060|Placebo Comparator|Vehicle gel|Vehicle gel applied topically twice daily
89181273|NCT02586441|Experimental|Electroencephalography|"Standard monitoring included electrocardiogram, noninvasive arterial blood pressure, pulse oximetry, and BIS-VISTATM sensor at OR.~Raw EEG in a steady state was collected for 5 minutes.~Anesthesia was induced with intravenous 1% propofol (1.5-2.5 mg/kg) and rocuronium bromide (0.6 mg/kg)~Mechanical ventilation was initiated~Anesthesia was maintained with desflurane at an end-tidal concentration of 6-7 %, with a fraction of inspired oxygen of 0.5 (fresh gas flow; O2 1.5 L/min and air 2.5 L/min).~On completion of the surgery, all anesthetic gases were discontinued and the FiO2 was increased to 1.0.~After extubation, BIS-VISTA TM monitoring was stopped."
89399304|NCT04173819|Experimental|Group 4|Single agent intravenous injection 10:2 ratio for Ab:placebo
89399305|NCT04173819|Experimental|Group 5|Combined agent intravenous injection 10:2 ratio for Ab:placebo
88845559|NCT00317616||Unaffected individuals from families in which the genetic cause of ALS is known|This population would include pre-symptomatic individuals at genetic risk for ALS or a related neurodegenerative disorder (i.e., FTD).
88845560|NCT00271622||healthy volunteers|healthy volunteers
88845561|NCT00271622||individuals at risk|individuals with risk for psychiatric disorders or neurodevelopmental disorders, such as autism spectrum disorders.
88845562|NCT00156767||Bone Marrow Transplant|Patients enrolled in an NCI protocols for bone marrow transplant for breast cancer using prednisone treatment.
88845563|NCT00156767||Cirrhosis|Adults on NIDDK protocol 91-DK-0213 with evidence of chronic liver disease with class A or B cirrhosis secondary to viral hepatitis
88845564|NCT00156767||Critical Care|Patients with a diagnosis of sepsis by the primary clinical provider in the Emergency room of ICU
88845565|NCT00156767||Healthy Volunteer|Healthy adult volunteers
88845566|NCT00156767||Known Adrenal Insufficiency|patients with known diagnosis of Adrenal Insufficiency
88845567|NCT00156767||Nephrotic Syndrome|Adults enrolled in NIDDK protocols with diagnosis of nephrotic syndrome
88845568|NCT00156767||Post Surgical Treatment for Cushings|Patients with transient adrenal insufficiency secondary to successful surgical treatment of cushing's syndrome
89373832|NCT03431350|Experimental|Combination 2: Dose Expansion: Niraparib + AA-P (Part 2)|Participants will be assigned to one of 4 cohorts based on biomarker status - Cohort 2A (BRCA biallelic loss), 2B (other DRD biallelic loss), 2C (BRCA monoallelic loss), or 2D (other DRD monoallelic loss), and will receive niraparib 200 mg once daily in combination with abiraterone acetate 1000 mg (4*250 mg) plus 10 mg prednisone (5 mg twice daily) throughout treatment phase. Participants in the Treatment Phase of this combination will be offered the option to enter the Long-term Extension Phase of the study.
89373833|NCT03431350|Experimental|Combination 3: Niraparib + AA-P|Participants will be assigned to one of three cohorts to receive AA-P with or without niraparib. Participants in the Treatment Phase of this combination will be offered the option to enter the Long-term Extension Phase of the study.
88845569|NCT00136500||Individuals affected with ALS|This population be sporadic or familial ALS.
89181274|NCT04015713||TB HIV-negative|"Patients will receive standard TB treatment and will be followed according to the national procedures.~In addition, plasma samples will be collected at baseline, Week 1, Week 2, Week 4 and Week 8 to measure IL-1Ra, sCD163 and IP-10. Baseline will be the initiation of TB treatment.~All participants will be followed 24 weeks."
89373834|NCT03406247|Experimental|Nivolumab|Patients in cohorts 1 and 1bis will be administered Nivolumab 240 mg every 2 weeks during 3 first months and then 480 mg every 4 weeks during 3 months
89373835|NCT03406247|Experimental|Nivolumab + Ipilimumab|"Patients in cohorts 2 and 2bis will be administered~nivolumab 240 mg every 2 weeks during 6 months~ipilimumab 1mg/kg IV every 6 weeks during 6 months"
89373836|NCT03382106|Experimental|Smoking Cessation Group 1|80 normal smokers will be recruited (defined by Pulmonary Function Tests, questionnaires and interviews), between the ages of 21 and 65 will be studied to assess inflammation and heterogeneity of Perfused Blood Volume prior to and following a 3 month smoking cessation program. In 40 of the 80 subjects during the smoking cessation program, we will provide three times per day Sildenafil 20 milligrams (MG) (Viagra) for the full 3 months of the smoking cessation period. We select a three-month cessation program to maximize the likelihood of compliance with cessation yet providing enough time for a resolution of lung injury to take place. Pulse wave velocity, carotid artery compliance and stiffness and pressure wave reflection will be measured.
89373837|NCT03382106|Placebo Comparator|Smoking Cessation Group 2|80 normal smokers will be recruited (defined by Pulmonary Function Tests, questionnaires and interviews), between the ages of 21 and 65 will be studied to assess inflammation and heterogeneity of Perfused Blood Volume prior to and following a 3 month smoking cessation program. In 40 of the 80 subjects during the smoking cessation program, we will provide three times per day placebo oral tablet for the full 3 months of the smoking cessation period. We select a three-month cessation program to maximize the likelihood of compliance with cessation yet providing enough time for a resolution of lung injury to take place. Pulse wave velocity, carotid artery compliance and stiffness and pressure wave reflection will be measured.
89373838|NCT03382106|Experimental|Non-Smokers Group 1|20 non-smokers will be recruited (defined by Pulmonary Function Tests, questionnaires and interviews) between the ages of 21 and 65 will be studied to compare the heterogeneity of Perfused Blood Volume with that of smokers for a 3 month period of time. We will provide 10 females and 10 males three times per day Sildenafil 20 milligrams (MG) (Viagra) for the full 3 months.
89373839|NCT03382106|No Intervention|Non-Smokers Group 2|20 non-smokers will be recruited (defined by Pulmonary Function Tests, questionnaires and interviews) between the ages of 21 and 65 will be studied to compare the heterogeneity of Perfused Blood Volume with that of smokers for a 3 month period of time. 10 females and 10 males will not receive any medication for the full 3 months.
89373840|NCT03329976||patient|any person about to undergo combined surgery for cataract and ERM
89373841|NCT03329950|Experimental|CDX-1140|Part 1: Eligible patients will receive CDX-1140, based on cohort assigned, in 4 week cycles until progression, intolerance, or two years of treatment.
89373842|NCT03329950|Experimental|CDX-1140 and CDX-301|Part 2: Eligible patients will receive CDX-1140, based on cohort assigned, in 4 week cycles until progression, intolerance or two years of treatment. A fixed dose of CDX-301 is injected once a day for five days before cycles 1 and 2 of CDX-1140.
89373843|NCT03329950|Experimental|CDX-1140 and pembrolizumab|Part 3: Eligible patients will receive CDX-1140, based on cohort assigned, in 3 week cycles until progression, or intolerance, or two years of treatment. A fixed dose of pembrolizumab will also be given in 3 week cycles.
89373844|NCT03329950|Experimental|CDX-1140 and chemotherapy|Part 4: Eligible patients will receive CDX-1140, based on cohort assigned, in 4 week cycles until progression, or intolerance, or two years of treatment. Chemotherapy will also be given according to standard of care.
89373845|NCT03320759|No Intervention|No rehabilitation|
89373846|NCT03320759|Experimental|Rehabilitation|
89373847|NCT03319940|Experimental|Part A|Tarlatamab monotherapy
89189307|NCT02575326|Other|Standard Control|Teens in the control group will receive standard or usual care as provided by their physician.
89373848|NCT03319940|Experimental|Part C|Tarlatamab with Pembrolizumab
89373849|NCT03319940|Experimental|Part D|Tarlatamab with additional CRS mitigation strategies
89373850|NCT03319940|Experimental|Part E|Tarlatamab administration with 24-hour monitoring
89373851|NCT03319940|Experimental|Part F|"Tarlatamab administered in outpatient infusion centers with 8-hour monitoring~Optional wearable digital device substudy (US sites only)"
89373852|NCT03319940|Experimental|Part G|"Tarlatamab additional dosing schedule~Optional wearable digital device substudy (US sites only)"
89373853|NCT03307317||Adult pilots|Healthy adults between the ages of 18-65 years
89373854|NCT03307317||AR infants|Infants with 12 months of age (+/- 2 weeks) with one of the following: observed developmental delay, sibling of a child with autism, premature birth, small for gestational age.
89373855|NCT03307317||TD infants|Healthy infants with 9 months of age (+/- 2 weeks)
89373856|NCT03294460|Experimental|1|Alcohol self-administration (IV ethanol for sessions 1 and oral for session 2)
88845570|NCT00136500||Unaffected individuals from families in which the genetic cause of ALS is known|This population includes pre-symptomatic individuals at genetic risk for ALS or a related neurodegenerative disorder (i.e., FTD).
88845571|NCT00136500||Individuals affected with an ALS-related neurodegenerative disease|This would include FTD, MSP, IBMPFD, etc.
88845572|NCT00136500||Healthy controls|
88845574|NCT00098072|No Intervention|Pilot|Pilot
89373857|NCT03294135|Experimental|Conventional Group|Participants who received primary vaccination in study V48P7 on Days 0, 28 (+10) and 300 (+21) (55 participants) and who received a booster vaccination in study V48P7E1 (NCT00387634) (55 participants). For these participants a second booster vaccination within six months after the annual blood draw was to be administered within the present study only in case their Neutralization Test (NT) titer resulted below 10.
89373858|NCT03294135|Experimental|Accelerated/Rapid Group|Participants who received primary vaccination in study V48P7 on Days 0, 7 (+3) and 21 (+7) (66 participants) and who received a booster vaccination either in study V48P7E1 (NCT00387634) (9 participants) or before enrolment in study V48P7E1 (NCT00387634) (40 participants). For these participants a second booster vaccination within six months after the annual blood draw was to be administered within the present study only in case their NT titer resulted below 10.
89373859|NCT03294135|Experimental|Accelerated Conventional Group|Participants who received primary vaccination in study V48P7 on Days 0, 14 (+3) and 300 (+21) (133 participants) and who received a booster vaccination in study V48P7E1 (NCT00387634) (109 participants). For these participants a second booster vaccination within six months after the annual blood draw was to be administered within the present study only in case their NT titer resulted below 10.
89373860|NCT03288493|Experimental|Phase 1: P-BCMA-101 CAR-T cells|Single ascending dose cohorts, given in a single intravenous infusion of CAR-T cells. Rimiducid may be administered as indicated.
89373861|NCT03288493|Experimental|Phase 1 P-BCMA-101 CAR-T cells (Cohort A)|Single dose given across two intravenous infusions of CAR-T cells. Rimiducid may be administered as indicated.
89373862|NCT03288493|Experimental|Phase 1 P-BCMA-101 CAR-T cells (Cohort B)|Single dose given across three intravenous infusions of CAR-T cells. Rimiducid may be administered as indicated.
89373863|NCT03288493|Experimental|Phase 1 P-BCMA-101 CAR-T cells (Cohort C)|Single dose given across two intravenous infusions of CAR-T cells. Rimiducid may be administered as indicated.
89373864|NCT03288493|Experimental|Phase 1 P-BCMA-101 CAR-T cells with Comb.Therapy (Cohort R)|Single intravenous infusion of CAR-T cells, with combination therapy, beginning one week before CAR-T infusion. Rimiducid may be administered as indicated.
89373865|NCT03288493|Experimental|Phase 1 P-BCMA-101 CAR-T cells with Comb.Therapy (Cohort RP)|Single intravenous infusion of CAR-T cells, with combination therapy, beginning one week before apheresis. Rimiducid may be administered as indicated.
89373866|NCT03288493|Experimental|Phase 1 P-BCMA-101 CAR-T cells with Comb.Therapy (Cohort RIT)|Single intravenous infusion of CAR-T cells, with combination therapy, beginning one week before CAR-T infusion. Rimiducid may be administered as indicated.
89373867|NCT03288493|Experimental|Phase 2: P-BCMA-101 CAR-T Cells|CAR-T cells administered via intravenous infusion as a total dose
89373868|NCT03288207|Other|Group 2 Label: PA monitor with standard remote coaching (SRC)|African American women who are at risk for cardiovascular outcomes in resource-limited communities in the Washington D.C. area.
89373869|NCT03288207|Other|Group 1 Label: PA monitor with remote coaching tailored to place|African American women who are at risk for cardiovascular outcomes in resource-limited communities in the Washington D.C. area.
89373870|NCT03271489|Experimental|Elagolix plus estradiol (E2)/norethindrone acetate (NETA)|Elagolix plus estradiol (E2)/norethindrone acetate (NETA)
89373871|NCT03271489|Placebo Comparator|Placebo|Placebo
88845575|NCT00086567||patients|Patients in first remission from treatment of FIGO stage III/IV primary peritoneal, fallopian tube, or epithelial ovarian carcinoma
88845576|NCT00077909||Group 1|Patients with Infectious Pneumonia
88845577|NCT00077909||Group 2|Patients with Non-Infectious Pneumonia
89373872|NCT03255174|Experimental|EVARREST® Fibrin Sealant Patch|EVARREST Fibrin Sealant Patch is a sterile, bio-absorbable combination product consisting of two constituent parts- a flexible matrix and a coating of biological components (human plasma-derived fibrinogen and thrombin) embedded in a flexible composite patch component.
89373873|NCT03238326|Experimental|Rollover & De-Novo|1-4 mg/day; Start at 0.5 mg/day, titrate and maintain between 1mg/day to max of 4 mg/day
88845578|NCT00055172||Non-sibling relative|18 years of age or older
88845579|NCT00055172||Patients (index cases)|Patients (index cases), 6 months of age or older
88845580|NCT00055172||Siblings|Siblings, 6 months of age or older
89373874|NCT03226197|Experimental|Study group|Ketone ester drink to be administered by nasogastric tube. Initial bolus dose of 25 ml on enrollment. After 1 hour, begin 47 hr infusion at 6 ml per hour.
89373875|NCT03216837|Experimental|Cathodal Transcranial direct current stimulation|Cathodal tDCS
89373876|NCT03216837|Sham Comparator|Sham Transcranial direct current stimulation|Sham
89373877|NCT03212469|Experimental|Patients with head and neck squamous cell carcinoma|
89373878|NCT03212469|Experimental|Patients lung cancer|
89373879|NCT03212469|Experimental|Patients with oesophagus cancer|
89373880|NCT03201965|Active Comparator|CyBorD alone (cyclophosphamide/bortezomib/dexamethasone)|Participants will receive dexamethasone (40 milligrams [mg] orally or intravenous [IV] dose), followed by cyclophosphamide (300 milligram per meter square [mg/m^2] orally or IV dose), then bortezomib (1.3 mg/m^2 subcutaneous injection) weekly on Days 1, 8, 15, 22 in every 28-day cycle for a maximum of 6 cycles.
88845581|NCT00029445||Family members|Family members of individuals with innate control over HIV
88845582|NCT00029445||HIV infection with one of the following HLA types: B*27+, B*35+,B*44+, B*57+, B*58+, and/or A*02.|People living with HIV with specific HLA-types.
88845583|NCT00029445||Long term nonprogressors|Individuals with innate control over HIV
88845584|NCT00025714||Patients|Patients who have agreed to undergo brain surgery to treat drug resistant epilepsy and are enrolled in protocol 11-N-0051 Epilepsy Surgery.
88845585|NCT00024479||suspected or confirmed rheumatic disease|autoimmune, autoinflammatory, or degenerative conditions
88845586|NCT00023023||Adults and children subjects|The NIH and SH components will enroll and follow only adult (age >=18) blood donor or recipient subjects. CNMC will enroll and follow children between the ages of 6 months and 18 years.
88845591|NCT00006150||Affected adults and children|Confirmed or suspected history of a Hyper IgE syndrome
88845592|NCT00006150||Relatives|Family members of subjects with confirmed or suspected history of a Hyper IgE syndrome
89399306|NCT04173819|Experimental|Group 6|Subcutaneous injection combined ratio 1 with loading dose 30:3 ratio of Ab:Placebo
89399307|NCT04173819|Experimental|Group 7|Subcutaneous injection in abdomen combined ratio 2 with loading dose 30:3 ratio of Ab:Placebo
89399308|NCT04173819|Experimental|Group 8|Subcutaneous injection in abdomen combined ratio 3 with loading dose 30:3 ratio of Ab:Placebo
88845596|NCT00001258||1|Patients with schizophrenia spectrum disorder
88845597|NCT00001258||2|normal volunteers
88845598|NCT00001168||Dyslipidemia|Dyslipidemia
88845599|NCT03187418|Experimental|Micropulse trans-scleral CPC|A treatment session of micropulse trans-scleral cyclophotocoagulation in the affected eye, using the MicroPulse® P3 Glaucoma Device (MP3) powered by the CYCLO G6™ Glaucoma Laser System (Iridex, Mountain View, CA, USA).
88845600|NCT03606889|Experimental|Quadratus Lumborum block group|Quadratus Lumborum block group (QL) patients will receive a bilateral Quadratus Lumborum block using Bupivicaine 0.125%
88845601|NCT03606889|Experimental|Transversus abdominis plane block group|Transversus abdominis plane block (TAP) patients will receive a bilateral TAP block using Bupivicaine 0.125%
88845602|NCT03283969|Placebo Comparator|Control Powder|Isocaloric powder
88845603|NCT03283969|Experimental|Freeze Dried Strawberry Powder|Contains freeze dried strawberries
88845604|NCT05363917|Experimental|Natrunix with MTX placebo (+Folate)|Natrunix 400mg, subcutaneous injection with oral MTX placebo (+Folate). This arm will enroll 100 subjects.
88845605|NCT05363917|Active Comparator|Natrunix Placebo with MTX(+Folate)|Natrunix Placebo, subcutaneous injection with oral MTX(+Folate). This arm will enroll 50 subjects.
88845606|NCT03187730|Active Comparator|Intervention Arm|
88845607|NCT03187730|Placebo Comparator|Waitlist Control|
88845608|NCT05363761|Experimental|Ablation Treatment|Neurotronic Infusion Catheter Treatment
88845609|NCT03189134|Experimental|Imaging arm|Up to 5mL of 1:1000 dilute FLUORESCITE will be applied to cardiac tissue prior to imaging with Cellvizio 100 Series System with Confocal Miniprobes
88845610|NCT03261193|Sham Comparator|ITM + Sham QLB|Standard spinal with intrathecal morphine for surgical anesthetic with sham saline block. Saline will be administered as a quadratus lumborum block prior to cesarean section.
88845611|NCT03261193|Experimental|ITM + Bupivacaine QLB|Standard spinal with intrathecal morphine for surgical anesthetic with ql block with bupivacaine local anesthetic. Interventional drug will be administered prior to cesarean section.
88845612|NCT05359705|Experimental|Healthy subjects|Healthy subjects who meet the Inclusion/Exclusion.
88845613|NCT00375661|No Intervention|interferon|
88845614|NCT04736186|Experimental|Loperamide|Loperamide 4 mg, T.I.D. (D1-7) →4 mg, B.I.D. (D8-21)
88845615|NCT04736186|Experimental|Loperamide and gold bifid|Loperamide 4 mg, T.I.D. (D1-7) →4 mg, B.I.D. (D8-21) + gold bifid2g T.I.D.
88845616|NCT04736186|Experimental|Loperamide and Montmorillonite SAN|Loperamide 4 mg, T.I.D. (D1-7) →4 mg, B.I.D. (D8-21) + Montmorillonite SAN 3 g, T.I.D.
88845617|NCT04736186|No Intervention|Non-intervention|Do not intervene and stop diarrhea as needed
88845618|NCT02185794|Placebo Comparator|Placebo (GT 1a, Cohort 1)|Participants with genotype (GT) 1a HCV infection will receive placebo once daily for 3 days under fasted conditions.
88845619|NCT02185794|Experimental|Voxilaprevir 50 mg (GT 1a, Cohort 1)|Participants with GT 1a HCV infection will receive voxilaprevir 50 mg once daily for 3 days under fasted conditions.
88845620|NCT02185794|Experimental|Voxilaprevir 100 mg (GT 1a, Cohort 1)|Participants with GT 1a HCV infection will receive voxilaprevir 100 mg once daily for 3 days under fasted conditions.
88845621|NCT02185794|Experimental|Voxilaprevir 300 mg (GT 1a, Cohort 1)|Participants with GT 1a HCV infection will receive voxilaprevir 300 mg once daily for 3 days under fasted conditions.
88845622|NCT02185794|Placebo Comparator|Placebo (GT 3, Cohort 2)|Participants with GT 3 HCV infection will receive placebo once daily for 3 days under fasted conditions.
88845623|NCT02185794|Experimental|Voxilaprevir 50 mg (GT 3, Cohort 2)|Participants with GT 3 HCV infection will receive voxilaprevir 50 mg once daily for 3 days under fasted conditions.
88845624|NCT02185794|Experimental|Voxilaprevir 100 mg (GT 3, Cohort 2)|Participants with GT 3 HCV infection will receive voxilaprevir 100 mg once daily for 3 days under fasted conditions.
88845625|NCT02185794|Experimental|Voxilaprevir 300 mg (GT 3, Cohort 2)|Participants with GT 3 HCV infection will receive voxilaprevir 300 mg once daily for 3 days under fasted conditions.
88845626|NCT02185794|Placebo Comparator|Placebo (GT 2, Cohort 3)|Participants with GT 2 HCV infection will receive placebo once daily for 3 days under fasted conditions.
88845627|NCT02185794|Experimental|Voxilaprevir 100 mg (GT 2, Cohort 3)|Participants with GT 2 HCV infection will receive voxilaprevir 100 mg once daily for 3 days under fasted conditions.
88845628|NCT02185794|Experimental|Voxilaprevir 100 mg (GT 4, Cohort 4)|Participants with GT 4 HCV infection will receive voxilaprevir 100 mg once daily for 3 days under fasted conditions.
88845629|NCT02185794|Experimental|Voxilaprevir 100 mg (GT 1b, Cohort 5)|Participants with GT 1b HCV infection will receive voxilaprevir 100 mg once daily for 3 days under fasted conditions.
88845630|NCT02185794|Experimental|Voxilaprevir 100 mg Fed (GT 3a, Cohort 6)|Participants with GT 3a HCV infection will receive voxilaprevir 100 mg once daily for 3 days under fed conditions.
88845631|NCT02185794|Experimental|Voxilaprevir 600 mg (Cohorts 7-9)|Participants with genotypes 1a, 1b, 2, 3, or 4 HCV infection will receive voxilaprevir up to 600 mg under fasted or fed conditions for 3 days.
89399309|NCT04173819|Experimental|Group 9|Subcutaneous injection in abdomen combined ratio 2 without loading dose 30:3 ratio of Ab:Placebo
89399310|NCT04173819|Experimental|Group 10|Subcutaneous injection in arm combined ratio 2 without loading dose 30:3 ratio of Ab:Placebo
89373881|NCT03201965|Experimental|CyBorD plus Daratumumab|Participants will receive dexamethasone (20 mg orally or IV dose as premedication and 20 mg on the day after daratumumab dosing) followed by 1800 mg of daratumumab subcutaneously followed by cyclophosphamide (300 mg/m^2 orally or IV dose weekly) and bortezomib (1.3 mg/m^2 subcutaneous injection weekly) on Days 1, 8, 15, 22 in every 28-day cycle for a maximum of 6 cycles. Daratumumab will be administered weekly for the first 8 weeks (2 cycles), then every 2 weeks for 4 cycles (cycles 3-6), and then every 4 weeks until progression of disease or subsequent therapy for a maximum of 2 years.
89373882|NCT03196310|Experimental|PRP|Intra-articular injection of platelet rich plasma.
89373883|NCT03196310|Active Comparator|Corticosteroid|Intra-articular injection of kenalog.
89373884|NCT03196310|Placebo Comparator|Normal Saline|Intra-articular injection of normal saline
89373885|NCT03193619||PTA-UltraScore Focused Force PTA balloon|Treatment with the UltraScore Focused Force PTA balloon will be per the investigational site's standard of care and adhering to the IFU.
89373886|NCT03173937|Experimental|1|CordIn is a cryopreserved stem/progenitor cell-based product of purified CD133+ cells composed of ex vivo expanded allogeneic UCB cells.
89373887|NCT03138291|Experimental|Somnodent|SomnoDent is a custom-made oral appliance for the treatment of mild to moderate obstructive sleep apnea. SomnoDent is worn during sleep to provide Continuous Open Airway Therapy by moving the lower jaw slightly forward. This movement tightens the soft tissue and muscles of the upper airway, which prevents obstructive apneas while sleeping.
89373888|NCT03081806|Experimental|Group A|High dose group: X0002, BID (approximately every 12 hours; n=102); Placebo, BID(approximately every 12 hours; n=102)
89373889|NCT03081806|Placebo Comparator|Group B|Low dose group: X0002, BID (approximately every 12 hours; n=102); Placebo, BID(approximately every 12 hours; n=102)
89373890|NCT03049072||Ion beam therapy|All patients treated with ion beam therapy at MedAustron who consent to the participation in the registry.
89373891|NCT03020212|Active Comparator|Oxygen|Long-term oxygen therapy in patients with chronic obstructive pulmonary disease (COPD)
89373892|NCT03020212|No Intervention|Not oxygen|No intervention ( no therapy with oxygen)
89373893|NCT03006172|Experimental|Stage I Arm A: Inavolisib Single Agent|Participants will receive inavolisib in escalating dose levels with starting dose of 6 milligrams (mg). Participants will receive single dose of inavolisib on Day 1 of Cycle 1 followed by once daily from Day 8 of Cycle 1. (Cycle length: 35 days for Cycle 1 and 28 days for all other cycles). Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
89373894|NCT03006172|Experimental|Stage I Arm B: Inavolisib + Palbociclib + Letrozole|Participants will receive inavolisib in escalating dose levels (starting dose 3 mg) on Days 1-28, palbociclib on Days 1-21, and letrozole on Days 1-28 of each 28-day cycle. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
89373895|NCT03006172|Experimental|Stage I Arm C: Inavolisib + Letrozole|Participants will receive inavolisib in escalating dose levels along with letrozole on Days 1-28 of each 28-day cycle. The starting dose of inavolisib will not exceed the starting dose in Stage I Arm A. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
89373896|NCT03006172|Experimental|Stage II Arm B: Inavolisib + Palbociclib + Letrozole|Participants will receive inavolisib on Days 1-28 in combination with palbociclib on Days 1-21 and letrozole on Days 1-28 of each 28-day cycle. Dose of inavolisib will be decided based on the results of Stage I Arm B. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
89373897|NCT03006172|Experimental|Stage II Arm C: Inavolisib + Letrozole|Participants will receive inavolisib in combination with letrozole on Days 1-28 of each 28-day cycle. Dose of inavolisib will be decided based on the results of Stage I Arm C. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
88845632|NCT02185794|Experimental|Voxilaprevir 100 mg + SOF/VEL 400/100 mg (Group 1, Cohort 10)|Participants with any GT HCV infection received voxilaprevir 100 mg on Day 1 after moderate fat meal and voxilaprevir 100 mg plus sofosbuvir (SOF)/velpatasvir (VEL) (400/100 mg) fixed-dose combination (FDC)on Days 2 and 3 after either a light or moderate-fat meal.
88845633|NCT02185794|Experimental|Voxilaprevir 100 mg + SOF/VEL 400/100 mg (Group 2, Cohort 10)|Participants with any GT HCV infection received voxilaprevir 100 mg on Day 1 and voxilaprevir 100 mg plus SOF/VEL (400/100 mg) FDC on Days 2 and 3 after moderate fat meal.
88845634|NCT04941170|Active Comparator|Group (T)|receive preoperative bilateral ultrasound-guided oblique subcostal transversus abdominis plane block.
89181275|NCT04015713||TB HIV-positive|"Patients will receive standard TB treatment and will be followed according to the national procedures.~In addition, plasma samples will be collected at baseline, Week 1, Week 2, Week 4 and Week 8 to measure IL-1Ra, sCD163 and IP-10. Baseline will be the initiation of TB treatment.~All participants will be followed 24 weeks."
89373898|NCT03006172|Experimental|Stage II Arm D: Inavolisib + Fulvestrant|Participants will receive inavolisib on Days 1-28 in combination with fulvestrant on Day 1 and 15 of Cycle 1 and then on Day 1 from Cycle 2 (cycle length: 28 days). Dose of inavolisib will be decided based on the results of Stage I Arm C. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
89373899|NCT03006172|Experimental|Stage II Arm E: Inavolisib + Palbociclib + Fulvestrant|Participants will receive inavolisib (Days 1-28) in combination with palbociclib (Days 1-21) and fulvestrant (Days 1 and 15 of Cycle 1; Day 1 for subsequent cycles)(Cycle = 28 days). Dose of inavolisib will be determined from the results of Stage I Arm B. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
88845635|NCT04941170|Active Comparator|Group (E)|receive preoperative bilateral ultrasound-guided erector spinae plane block.
88845636|NCT05357911|Experimental|digoxin cohort|
89002242|NCT05878119|Placebo Comparator|Placebo plus usual physical activity (PL-UPA)|Matching placebo tablets will be provided by the study's Sponsor, Metro International Biotech, LLC.
88845637|NCT05355883|Experimental|Remote Ischemic Conditioning (RIC)|"RIC is achieved via blood pressure cuff inflation to at least 20 mmHg above systolic blood pressure to 250 mmHg on the more involved arm. RIC involves 5 cycles of 5 minutes blood pressure cuff inflation followed by alternating 5 minutes of cuff deflation and requires 45 minutes. RIC is performed on visits 2-6.~Intervention~Hand Arm Bimanual Intensive Therapy (HABIT)~Bimanual cup stacking training~Balance training"
89181276|NCT02586363|Active Comparator|Baraclude Tab. 0.5mg, fasting|Single dose Baraclude Tab. 0.5mg, fasting state
88845638|NCT05355883|Sham Comparator|Sham Conditioning|"Sham conditioning is achieved via blood pressure cuff inflation to 25 mmHg on the more involved arm. RIC involves 5 cycles of 5 minutes blood pressure cuff inflation followed by alternating 5 minutes of cuff deflation and requires 45 minutes. RIC is performed on visits 2-6.~Intervention~Hand Arm Bimanual Intensive Therapy (HABIT)~Bimanual cup stacking training~Balance training"
88845639|NCT03374839|Experimental|TIL + IL-2 + Nivolumab|"A first cohort of 3 patients will be done to ensure that the combined treatment (TIL + IL-2 + Nivolumab) would not cause severe autoimmunity pathologies.~For this first cohort, a dose of 0.5 billion of TILs per injection will be administered. After the opinion of the Data and Safety Monitoring Committee (DSMC), the sponsor will make the decision of the second cohort of 8 patients who will receive between 1 and 20 billion of TIL."
88845640|NCT04848272|Placebo Comparator|Saline control|Saline control
88845641|NCT04848272|Experimental|Lanadelumab 30 mg|Lanadelumab 30 mg
88845642|NCT04848272|Experimental|Lanadelumab 100 mg|Lanadelumab 100 mg
88845643|NCT04848272|Experimental|Lanadelumab 300 mg|Lanadelumab 300 mg
88845644|NCT02221674|Experimental|Tapentadol|Tapentadol 4 mg/mL immediate release oral solution, single dose post-operatively.
88845645|NCT04520906|Experimental|single-arm|Subjects will be treated with microwave ablation.
88845646|NCT04736719||Warfarin|Reference group
88845647|NCT04736719||Apixaban|Exposure group
88845648|NCT04736563|Experimental|patients with painful arthritis of the knee|Administration of joints and muscle gel Puressentiel containing of 14 essential oils
88845649|NCT04736797||Patient|Transgender people who seek hormone treatment
88845650|NCT04736797||Control participants|volunteers without gender dysphoria
88845651|NCT04429646|Experimental|LAMax left atrial appendage occluder|Intervention device, LAMax left atrial appendage closure system
88845652|NCT04429646|Active Comparator|Watchman (control)|Intervention device, Watchman® LAA Closure Device
88845653|NCT02221284||Alogliptin|Alogliptin 25 milligram (mg), tablets, orally, once daily, up to 12 months, along with an insulin preparations, with a rapid-acting insulin secretagogue (Glinide), with a SGLT-2 inhibitor, or the other diabetic drugs within 3 months prior to the start of alogliptin treatment or during the alogliptin treatment period in routine medical care.
88845654|NCT04736407||Repositioned|Allocated to sampling performed around a standard clinical repositioning (lateral side to side), or a 10 minute wait period between two serially drawn CSF samples, for each biweekly routine CSF infection surveillance sampling.
88845655|NCT04736407||Non-repositioned|Allocated to sampling performed with a 10 minute wait period between two serially drawn CSF samples, for each biweekly routine CSF infection surveillance sampling
88845656|NCT04736108|Experimental|ADT with Abiraterone and prednisone|All subjects in this arm will receive luteinizing hormone releasing hormone analogue (LHRHa) plus abiraterone acetate and prednisone, as per standard of care. Goserelin 10.8 mg will be used once per 12 weeks. Abiraterone acetate will be administered orally as 1000 mg once daily along with 5 mg of oral prednisone once per day. Subjects will continue to take abiraterone acetate and prednisone for 24 weeks before radical prostatectomy
88845657|NCT03196076|Experimental|Perflutren Lipid Microsphere (Healthy subjects)|Healthy subjects will be imaged using contrast-enhanced ultrasound (perflutren) for image optimization prior to enrolling clinical patients.
88845658|NCT03196076|Experimental|Perflutren Lipid Microsphere (patients with kidney lesions)|Patients with kidney lesions will be imaged using contrast-enhanced ultrasound with perflutren.
88845659|NCT03196076|No Intervention|Controls: No interaction|Patients with kidney lesions will be included as control subjects. These patients will be followed, but will not receive any study intervention.
89181277|NCT02586363|Experimental|Cavir Tab. 0.5mg, fasting|Single dose Cavir Tab. 0.5mg, fasting state
88845660|NCT02971033|Placebo Comparator|placebo|placebo
88845661|NCT02971033|Experimental|20mg/day ezetimibe|20mg/day ezetimibe
88845662|NCT02971033|Experimental|40mg/day ezetimibe|40mg/day ezetimibe
89181278|NCT02586363|Experimental|Cavir Tab. 0.5mg, high fatty meal|Single dose Cavir Tab. 0.5mg, high fatty meal
89181279|NCT00764660|Experimental|SCH 900435|Participants received SCH 900435 12 mg (as three SCH 900435 4 mg tablets) by mouth twice daily for 12 weeks.
89181280|NCT00764660|Placebo Comparator|Placebo|Participants received matching placebo tablets by mouth twice daily for 12 weeks.
89181281|NCT02586285|Active Comparator|S-Adenosyl Methionine Treatment|Patients will be treated with S-Adenosyl Methionine treatment after curative resection.
89181282|NCT02586285|No Intervention|Control group|Patients will be treated without S-Adenosyl Methionine treatment after curative resection.
89181283|NCT00584415|Active Comparator|GP + PVI ablation|This study contains only one arm, which is GP ablation + PV antrum isolation. The intervention (GP ablation + PV isolation) was performed using ThermoCool Navistar catheters in all patients
88845663|NCT05406674|Active Comparator|Arm A|Patients in Arm A are treated with interval cytoreductive surgery (with no more than 1 cm residual disease) and cispaltin-based HIPEC with a dosage of 100 mg/m2
88845664|NCT05406674|Experimental|Arm B|Patients in Arm B are treated with interval cytoreductive surgery (with no more than 1 cm residual disease) and cisplatin- based HIPEC with a dosage of 40 mg/L perfusate.
88845665|NCT05341375|Other|Group C|The general anesthesia was used.In this group, cognitive function was evaluated by MMSE scale on one day before surgery, one day after surgery, and three months after surgery
88845666|NCT05341375|Experimental|Group TA|Group TA received 0.375% ropivacaine 20ml thoracic paravertebral nerve block combined with general anesthesia under ultrasound guidance after anesthesia induction
88845667|NCT05341375|Experimental|Group TE|Group TE received s-ketamine anesthesia induction dose of 0.3 mg/kg on the basis of TA group. Anesthesia maintenance dose of 0.2ug/kg/h was pumped to 30min before the end of the operation
88845668|NCT05341375|Other|Non-surgical controls|Age and sex-matched community people are included for three sessions of MMSE test evaluation for calculation of POCD incidence as normal control to in Z value calculation of POCD incidence to rule out learning effect
88845669|NCT02796001|Active Comparator|RV16 infected volunteers re-challenged with RV16|volunteers re-challenged with RV16
88845670|NCT02796001|Active Comparator|RV infected volunteers re-challenged with RV39|volunteers re-challenged with RV39
88845671|NCT02796001|Other|RV infected not rechallenged|Volunteers who were infected with RV16 and eligible for re-challenge but who were not re-challenged due to voluntary withdrawal (3) or removal for exclusion criteria
88845672|NCT04736264|Active Comparator|Rehabilitation group|"This is the phase 3 of the entire research protocol. Phase 3 will be initiated once the phase 2 (development of rehabilitation module) is completed. A user friendly and inexpensive device and program with minimal usage of low vision aid will be designed and piloted. There are 3 different rehabilitation modules.~A total of 300 primary glaucoma patients will be recruited and randomized using SNOSE: 150 intervention group and 150 non-intervention group. The intervention group will comprised of 150 primary glaucoma patients who will be assigned to different rehabilitation program:~navigation and mobility (50 patients)~physical activities including special exercise (50 patients)~reading (50 patients) There will be no patient who will be involved in more than one rehabilitation program at anytime."
88845673|NCT04736264|No Intervention|Non-rehabilititation group|Group of primary glaucoma patients who are not taught and practiced the new rehabilitation module for navigation, physical activity (exercise) and reading. They will be asked to continue their regular activities and provided with the similar reading material (book) to read daily.
88845674|NCT05406518|Experimental|Intervention|Arm of intervention
88845675|NCT04373252|Experimental|Fecal Microbiota Transplant|All participants will receive two fecal microbiota transplants one week apart. The transplant will occur via antegrade enema and the enema transplant material will be provided by OpenBiome, the product used is FMT Lower Delivery (FMP 30).
88845676|NCT03235687|Experimental|Cohort A|Patients randomized to Cohort A will receive ExoDx Prostate (IntelliScore) test results along with a post-ExoDx Prostate (IntelliScore) test result questionnaire to evaluate impact of test results in the biopsy decision process, utility, ease of understanding and work-flow implementation.
88845677|NCT03235687|No Intervention|Cohort B|Patients randomized to Cohort B will proceed with conventional standard of care.
88845678|NCT03200587|Experimental|Avelumab and cabozantinib, all patients|
88845679|NCT01801189|Experimental|Pregabalin|Single, 300 mg pre-operative oral dose of Pregabalin.
88845680|NCT01801189|Placebo Comparator|Sugar Pill|Single, placebo pre-operative dose.
88845681|NCT04275362||DJO subjects for surgical technique|Subjects who meet the inclusion criteria and receive a DJO Empowr total knee replacement but will not participate in motion data collection
88845682|NCT04275362||DJO subjects for data collection|Subjects who meet the inclusion criteria and consent to be in the study will receive a DJO Empowr total knee replacement and participate in motion data collections at pre-op, and 6 and 12 months post-op. Subjects will also participate in pre-op, 6 month, 1 year, 2 year, 5 year, and 10 year post-op clinical data collections
88845683|NCT04275362||Prospective control subjects|Healthy age matched subjects who did not have any knee osteoarthritis and participated in motion data collections.
89373900|NCT03006172|Experimental|Stage II Arm F: Inavolisib + Palbociclib + Fulvestrant + Metformin|Participants will receive inavolisib (Days 1-28) in combination with palbociclib (Days 1-21), fulvestrant (Days 1 and 15 of Cycle 1; Day 1 for subsequent cycles) and metformin (Days 1-28)(Cycle = 28 days). Dose of inavolisib will be determined from the results of Stage I Arm B. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
88845684|NCT04275362||Stryker TKA subjects|Subjects who met the inclusion criteria and consented to be in a study whereby they received a Stryker Triathlon total knee replacement and participated in motion analysis pre-surgery and 6 and 12 months post-surgery.
88845685|NCT04275362||Biomet TKA subjects|Subjects who met the inclusion criteria and consented to be in a study whereby they received a Biomet Vanguard total knee replacement and participated in motion analysis pre-surgery and 12 months post-surgery.
88845686|NCT04275362||Retrospective control subjects|Healthy age matched subjects who did not have any knee osteoarthritis and participated in motion data collections.
88845687|NCT05406206|Experimental|HAIC combined with Fruquintinib|HAIC with fruquintinib until progression. Fruquintinib should be administrated within 1 week after HAIC.
88845688|NCT00716755|Experimental|Dose Reduction|See Intervention
88845689|NCT05406128|Active Comparator|preoperative group|Erector spina plane block will be applied to preoperative group patients in the preoperative period.
88845690|NCT05406128|Active Comparator|intraoperative group|In the intraoperative group, erector spina plane block will be applied after anesthesia induction.
88845691|NCT05406050|Experimental|TR|Subjects first receive a single-dose of 0.75 μg test eldecalcitol soft capsule (T, produced by Wenzhou Haihe Pharmaceutical Co., Ltd. China) in the first treatment period and to receive the reference (R, produced by Chugai Pharmaceutical Co., Ltd. Japan) in the second treatment period.
88845692|NCT05406050|Experimental|RT|Subjects first receive a single-dose of 0.75 μg reference eldecalcitol soft capsule (R, produced by Chugai Pharmaceutical Co., Ltd. Japan) in the first treatment period and to receive test capsule (T, produced by Wenzhou Haihe Pharmaceutical Co., Ltd. China) in the second treatment period.
88845693|NCT04736095||3D ultrasound for diagnosis of submucous myomas|
88845694|NCT04736095||Hysteroscopy for diagnosis of submucous myoma|
88845695|NCT03199118|Experimental|CAF+SCTG+PRF|The patients suffering from class I or II gingival recession in the intervention group will receive a subepithelial connective tissue graft (SCTG) covered by platelet rich fibrin membrane (PRF) followed by a coronally advanced flap (CAF)
88845696|NCT03199118|Active Comparator|CAF+SCTG|Control group patients with class I or II gingival recession will receive treatment that consists of CAF+SCTG only
89373901|NCT03006172|Experimental|Stage II Arm G: Inavolisib + Trastuzumab + Pertuzumab|Participants will receive inavolisib in combination with trastuzumab and pertuzumab (Days 1-21). Dose of inavolisib will be determined from the results of Stage I Arm A. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
89373902|NCT02997228|Active Comparator|Arm I (bevacizumab, mFOLFOX6)|Patients receive bevacizumab intravenously (IV) over 30-90 minutes on day 1, oxaliplatin IV over 2 hours on day 1 of cycles 1-10, leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV over 46-48 hours on days 1 and 2. Treatment with oxaliplatin repeats every 2 weeks for up to 10 cycles in the absence of disease progression or unacceptable toxicity. Treatment of bevacizumab, leucovorin calcium, and fluorouracil repeat every 2 weeks for up to 48 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT with or without PET or MRI throughout the trial. Patients may also undergo collection of optional blood samples throughout the trial. (CLOSED TO ACCRUAL)
88845697|NCT03202472|Experimental|Diagnostic (radiofrequency-guided localization)|Patients undergo mammogram or ultrasound for image-guided placement of the radiofrequency tag within 30 days of surgery and then undergo radiofrequency-guided localization during surgery.
88845698|NCT04200404|Experimental|Phase Ib arm|arms 1. Phase Ib: advanced or refractory solid tumors;
88845699|NCT04200404|Experimental|Phase II arm|arms 2.Phase II: subjects with tumor of specific types
88845700|NCT04171778|Experimental|Intervention|Subjects in this arm will immediately begin a whole-food, plant-based nutrition program consisting of weekly educational group meetings and prepared meals delivered to the subjects' homes for the first 12 weeks followed by monthly educational group meetings for an additional 6 months.
88845701|NCT04171778|Other|Wait List Control|Subjects in this arm will continue their usual care as directed by their nephrologist for 12 weeks before starting the same whole-food, plant-based nutrition program as the intervention arm subjects.
88845702|NCT04135742|Experimental|active tACS+ Cognitive Training group|"Subjects will receive CCT for a period of 3 months, 24 times, twice a week for 20 minutes each time.~Placement of stimuli electrodes will be: a) active electrode over the left DLPFC (F3), and b) reference electrode over the right parietal region (P4). The exact location of electrodes will be determined by the 10/20 EEG method with EEG cap. Subjects will have 24 tACS sessions for three months, twice a week.The active tACS group will be stimulated with a 2 mA,40Hz current for 20 minutes each time during the stimulation."
88845703|NCT04135742|Sham Comparator|sham tACS+Cognitive Training group|"Subjects will receive CCT for a period of 3 months, 24 times, twice a week for 20 minutes each time.~Placement of stimuli electrodes will be: a) active electrode over the left DLPFC (F3), and b) reference electrode over the right parietal region (P4). The exact location of electrodes will be determined by the 10/20 EEG method with EEG cap. Subjects will have 24 tACS sessions for three months, twice a week.The sham tACS group will have stimulation lasting only 40 seconds though the electrodes will remain in place for 20 min."
88845704|NCT04135742|Sham Comparator|active tACS+ sham Cognitive Training group|"Subjects will watch neutral pictures on iPad for a period of 3 months, 24 times, twice a week for 20 minutes each time.~Placement of stimuli electrodes will be: a) active electrode over the left DLPFC (F3), and b) reference electrode over the right parietal region (P4). The exact location of electrodes will be determined by the 10/20 EEG method with EEG cap. Subjects will have 24 tACS sessions for three months, twice a week.The active tACS group will be stimulated with a 2 mA,40Hz current for 20 minutes each time during the stimulation."
88845705|NCT03202550|Placebo Comparator|Placebo Arm|Two oral placebo pills (microcrystalline cellulose capsules)
88845706|NCT03202550|Active Comparator|Active Drug Arm: Lorazepam and Oxycodone|1 mg of oral lorazepam and 5 mg of oral oxycodone (also encased in microcrystalline cellulose capsules)
88845707|NCT03203564|Active Comparator|Modufolin® for injection, 200, 350 and 500 mg/m2|Three cohorts, 8 subjects will be randomised to Modufolin ® for injection 100 mg
88845708|NCT03203564|Placebo Comparator|0.9% NaCl sterile solution|Three cohorts, 3 subjects will be randomised to placebo
88845709|NCT04123886|Experimental|SCB-313|
88845710|NCT03285542|Active Comparator|DERMABOND GROUP|For the active arm of the study, the arthrotomy (deep layer) is repaired using number 1 Vicryl, the subcutaneous layer will be then closed with simple interrupted knots using number 2-0 braided absorbable sutures (Vicryl), followed by closure of the subcutaneous layer using a STRATAFIX Spiral Knotless Tissue Control Device in addition to DERMABOND PRINEO (Ethicon, Johnson and Johnson, Somerville, New Jersey) system for dermal closure.
88845711|NCT03285542|Placebo Comparator|CONTROL GROUP|For the control arm of the study, the arthrotomy (deep layer) is repaired using number 1 Vicryl, the subcutaneous layer will be then closed with simple interrupted knots using number 2-0 braided absorbable sutures (Vicryl), followed by skin closure with staples
88845712|NCT03207074|Other|All patients|Single study arm. All patients who participate in the study will receive conventional histological diagnosis and diagnosis with the new technology (iKnife)
88845713|NCT04088786|Experimental|Active|Cytoreductive surgery (CRS) followed by study treatment with nanoliposomal irinotecan administered intraperitoneally.
88845714|NCT03207386|Experimental|Youth VIP|Youth VIP is a youth-led set of prevention strategies. Youth and their adult mentors are trained in evidence based sexual assault primary prevention strategies at a three day youth summit. The summit is followed by participation in working groups in which youth and their adult mentors will adapt best practices for sexual assault prevention to the Rapid City community and diffuse these strategies through both their own social networks and more formally in work in Rapid City middle and high schools.
88845715|NCT00392821|Experimental|RAD001 and Sorafenib|RAD001 and Sorafenib
88845716|NCT03208166|Experimental|Ischemic Conditioning|Doctormate device is used daily.
88845717|NCT03208166|Other|Usual Care|Standard medical care.
88845718|NCT04051112|Experimental|SCB-313|
88845719|NCT04708171||Awake mapping under local anesthesia|
88845720|NCT04708171||Asleep mapping under general anesthesia|
88845721|NCT04708171||Resection under general anesthesia without mapping|
88845722|NCT02187042||All patients|Metastatic and/or advanced renal cell carcinoma patients treated with sunitinib in first line and followed by standard care plus call center
88845723|NCT03209882|Experimental|One TILS, one sham, and then five TILS interventions|Participants first received a TILS intervention, followed by a sham session one week later. Then, participants received another five weekly TILS interventions.
89181284|NCT05326022|Experimental|medical therapy group|formed of 20 patients to whom ordinary medical therapy as the pervious groups and placebo shame laser had been applied.
88845724|NCT03209882|Experimental|One sham, then six TILS interventions|Participants first received a sham session, followed by six weekly TILS sessions.
89181285|NCT05326022|Experimental|medical therapy and Microcurrent group|formed of 20 patients to whom the microcurrent therapy had been applied with ordinary medical therapy.
89181286|NCT05326022|Experimental|medical therapy and Low-Level Laser Therapy group|formed of 20 patients to whom the Low Level Laser Therapy had been applied with ordinary medical therapy.
89181287|NCT02586129|Experimental|YH14755|PO, Once Daily, 16 weeks
89181288|NCT02586129|Active Comparator|Metformin|PO, Once Daily, 16 weeks
89181289|NCT02586129|Active Comparator|Rosuvastatin|PO, Once Daily, 16 weeks
89181290|NCT00916604|Experimental|A|3 gradually increasing repeated oral doses of AZD1656 given to 3 groups (6 on active substance in each group)
89181291|NCT00916604|Placebo Comparator|B|Placebo oral suspension given to 3 groups (2 on placebo in each group)
89181292|NCT04081077|Experimental|Regimen 1: Bedaquiline, Pretomanid, Linezolid, Moxifloxacin|Bedaquiline: 400 mg once daily for 2 weeks followed by 200 mg 3 times per week for 22 weeks Pretomanid: 200mg once daily for 24 weeks Moxifloxacin: 400 mg once daily for 24 weeks Linezolid: 600mg daily for 16 weeks then 300mg daily (or 600mg x3/wk) for the remaining 8 weeks or earlier when moderately tolerated
89181293|NCT04081077|Experimental|Regimen 2:Bedaquiline, Pretomanid, Linezolid, Clofazimine|Bedaquiline: 400 mg once daily for 2 weeks followed by 200 mg 3 times per week for 22 weeks Pretomanid: 200mg once daily for 24 weeks Linezolid: 600mg daily for 16 weeks then 300mg daily (or 600mg x3/wk) for the remaining 8 weeks or earlier when moderately tolerated Clofazimine: 50 mg (less than 33 kg), 100 mg (more than 33 kg) for 24 weeks
89181294|NCT04081077|Experimental|Regimen 3: Bedaquiline, Pretomanid, Linezolid|Bedaquiline: 400 mg once daily for 2 weeks followed by 200 mg 3 times per week for 22 weeks Pretomanid: 200mg once daily for 24 weeks Linezolid: 600mg daily for 16 weeks then 300mg daily (or 600mg x3/wk) for the remaining 8 weeks or earlier when moderately tolerated)
89181295|NCT00764504|Experimental|Primary|Primary shoulder
89181296|NCT00764504|Experimental|Revision|Revision shoulder
89181297|NCT00764504|Experimental|Continued Access|Primary shoulder subjects enrolled at a later date in order to collect more data.
89181298|NCT02586051|Experimental|Cohort 1: Single Dose Obinutuzumab|"Desensitization period: Participants will receive obinutuzumab on Day 1 followed by high dose intravenous immunoglobulin (IVIG) on Days 22 and 43 of treatment period.~Transplantation period: Participants who are found to qualify for transplantation and receive a compatible kidney offer after inclusion will receive two additional infusions of obinutuzumab (one at the time of transplantation [within the first 48 hours of the transplantation] and second at Week 24 post-transplantation)."
89181299|NCT02586051|Experimental|Cohort 2: Repeated Dose Obinutuzumab|"Desensitization period: Participants will receive obinutuzumab on Days 1 and 15 followed by high dose IVIG on Days 22 and 43. An additional dose of obinutuzumab may be administered on Day 169 at investigator's discretion.~Transplantation period: Participants who are found to qualify for transplantation and receive a compatible kidney offer after inclusion will receive two additional infusions of obinutuzumab (one at the time of transplantation [within the first 48 hours of the transplantation] and second at Week 24 post-transplantation)."
89181300|NCT02601326|Active Comparator|Laparoscopic ventral mesh Rectopexy|Fixation of the rectum to the sacrum using laparoscopy and mesh
89181301|NCT02601326|Active Comparator|delorme's procedure|excision of excess rectal mucosa under spinal anesthesia then plication of the rectal muscles with vicryl 2/0 sutures
89181302|NCT04101734||Double Lumen Endotracheal Tube|Group of patients intubated with Double Lumen Endotracheal Tube.
89181303|NCT04101734||Double Lumen Video Endotracheal Tube|Group of patients intubated with Double Lumen Video Endotracheal Tube.
89181304|NCT02601638|Experimental|Arm 1|"Demographics and Health History Questionnaire (5-10 minutes to complete)~Pre-Class Laryngectomy Survey (5-10 minutes to complete)~Attend a preoperative counseling session with a speech pathologist. It will take 30-60 minutes~Attend the Total Laryngectomy Preoperative Education Class. Participants will attend within 1-2 weeks of providing written consent and prior to their scheduled surgery. The preoperative education class will take one hour.~Complete the Day of Hospital Discharge Laryngectomy Survey at the time of discharge from the hospital (5-10 minutes to complete)~Perform the day of discharge practicum assessing the minimal competency skills for laryngectomy care prior to discharge from the hospital.~Complete the Laryngectomy Education Study Exit survey. Participants will perform an exit survey at the first clinic appointment after 30 days after hospital discharge (15-30 minutes to complete)"
89181305|NCT00763958|Experimental|Buprenorphine|Active sublingual buprenorphine provided to participants; dose as clinically indicated up to 32 mg daily for up to 3 months
89181306|NCT00763958|Placebo Comparator|Placebo|Placebo sublingual medication provided to individuals randomized to control up to 3 months
89181307|NCT02601482|Experimental|Control (CON)|No exercise intervention.
89181308|NCT02601482|Experimental|Normal Interval Walking (IW-60).|Sixty minutes with repeated cycles of 3 minutes of fast and 3 minutes of slow walking on a treadmill
89373903|NCT02997228|Experimental|Arm II (atezolizumab)|Patients receive atezolizumab IV over 30-60 minutes on day 1. Treatment repeats every 2 weeks for up to 48 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT with or without PET or MRI throughout the trial. Patients may also undergo collection of optional blood samples throughout the trial.
88845725|NCT03290378|Active Comparator|AVE-901 50 mg|
89181309|NCT02601482|Experimental|Time-reduced Interval Walking (IW-45)|Forty-five minutes with repeated cycles of 3 minutes of fast and 1.5 minutes of slow walking on a treadmill
89181310|NCT04101578||Ocular MG|Patients with autoimmune MG whose symptoms restricted to extraocular muscles
89181311|NCT04101578||Generalized MG|Patients not only suffer from extraocular muscles weakness but also from limb weakness, bulbar symptoms, or even respiratory failure
88845726|NCT03290378|Active Comparator|AVE-901 25 mg|
88845727|NCT03290378|Placebo Comparator|Placebo|
89181312|NCT00763256|Active Comparator|A|
88845728|NCT04659967|Experimental|Pre/Post Training (Within subject)|Participants will complete a baseline questionnaire followed by immediate virtual training, and complete a post-training questionnaire. Participants will also be asked to complete a questionnaire 1-month, 3-months, and 6-months post-training.
88845729|NCT02076217||unprotected intercourse 6-14 days prior to contraception|Women who initiate highly effective reversible contraception within 6-14 days of unprotected intercourse.
88845730|NCT03290768|Experimental|Diabetes Management Educational Program|Subjects receive a CGM and activity tracker as part of a educational program to help manage their glucose levels.
88845731|NCT04626661||Health volunteers|The study population will consist, initially, of healthy volunteers. This group was chosen to perform measurements on, to eliminate the effect of critical illness and interventions on the critically ill patients and to better explore the effect of time-since-application of the 5-aminolevulinic acid-patches.
88845732|NCT04626661||Patients admitted to the ICU after neurosurgery|This study population will consist of patients undergoing elective neurosurgery with planned postoperative recovery of at least 24 hours in the intensive care unit or medium care unit. Leiden University Medical Center is a neurosurgical center in which a wide variety of surgeries including tumor resection in the posterior cranial fossa (including vestibular schwannoma) are performed. Clinical experience has shown that this cohort of patients are in general, hemodynamically the most stable patients and receive the least amount of interventions compared to other cohorts of patients in the intensive care unit and medium care unit. For these reasons, the cohort of elective neurosurgical patients would be ideal to investigate the reason of the increased between- and within-subject variability of mitochondrial oxygen tension in the intensive care unit and medium care unit setting.
88845733|NCT04976647|Active Comparator|A arm: HLX10+chemo|Participants receive 300mg HLX10 IV every 3 weeks (Q3W) in combination with carboplaitin (AUC5 or 6) IV Q3W and nab-paclitaxel (260mg/m2) IV Q3W for 4-6 circle.
88845734|NCT04976647|Experimental|B arm: HLX10+HLX07+chemo|Participants receive 300mg HLX10 IV Q3W plus 1500mg HLX07 IV Q3W with chemo.
88845735|NCT04976647|Experimental|C arm: HLX10+HLX07|Participants receive 300mg HLX10 IV Q3W plus 1500mg HLX07 IV Q3W.
88845736|NCT03291080|Experimental|Liquid|Oral liquid formulation of 13-Cis Retinoic Acid - test product.
88845737|NCT03291080|Experimental|Capsule|Isotretinoin capsules (13-CRA extracted per standard of care)- reference product.
88845738|NCT03292562|Active Comparator|Discontinue NCPAP after weaning pressures|After randomization, CPAP pressure will be weaned by 1 every 24hours as long as the subjects continue to meet stability criteria after each wean, until CPAP of 4. If after decrease in CPAP pressure, the subject meets CPAP failure criteria pressure will be increased back to the previous level and after stabilization for 24 hours weaning process will be started again. Once the subject meets stability criteria on CPAP of 4, NCPAP will be stopped and subject will be placed on nasal cannula (NC) according to unit guidelines (max 1 Liter flow, 30% FiO2).
88845739|NCT03292562|Active Comparator|Discontinue NCPAP without weaning pressures|After randomization, once the subject meets stability criteria, NCPAP will be stopped and subject will be placed on nasal cannula (NC) according to unit guidelines (max 1 Liter flow, 30% FiO2).
88845740|NCT04874545|Experimental|Propofol group|Maintenance of anaesthesia will be done using Propofol total intravenous anesthesia (TIVA) 6-12 mg/ kg/h by syringe pump, 100 % O2.
88845741|NCT04874545|Active Comparator|sevoflurane group|Maintenance of anaesthesia will be done using sevoflorane1.5-2%, 100 % O2.
88845742|NCT03216200|Experimental|Experimental|5 Subjects with 20-75% Distal Subungual Onychomycosis (mild to moderate DSO) infection of their big toe (hallux) nail infected by the dermatophytes Trichophyton (T.) rubrum or T. mentagrophytes will be enrolled. All Subjects will receive three 45-minute plasma treatments performed over a week.
88845743|NCT04735939||morning dosing radiotherapy|
88845744|NCT04735939||evening dosing radiotherapy|
89181313|NCT00763256|Placebo Comparator|B|
89181314|NCT02585973|Other|open label, single-arm, Phase 1b|AZD1775 when added to standard of care concomitant chemotherapy (cisplatin) and radiation
89181315|NCT00920283|Experimental|Chrono Carbostent Carbofilm™ Coated Coronary Stent|
88845745|NCT03888092|Experimental|Z650 , Single-arm|Z650 will be administered daily, at dose of 350 mg orally
88845746|NCT04440865|Active Comparator|Arm 1- Standard colonoscopy|Standard colonoscopy is performed
88845747|NCT04440865|Active Comparator|Arm 2- Colonoscopy assisted by Genius|Colonoscopy assisted by Genius artificial intelligence system is performed
88845748|NCT03418064|Experimental|fanfilcon A toric|Subjects who wore fanfilcon A toric contact lens, either as the first or second lens in this cross-over study.
88845749|NCT03418064|Active Comparator|lotrafilcon B|Subjects who wore lotrafilcon B toric contact lens, either as the first or second lens in this cross-over study.
88845750|NCT03181009|Experimental|Group A (300 mg maintenance dose)|After initial therapy with omalizumab Group A subjects will escalate their food flour allergens to 300 mg in 18 weeks.
89181316|NCT00920283|Active Comparator|Driver, Cobalt Alloy Coronary Stent|
89181317|NCT04081311|Experimental|water flosser|patient will be provided with Waterpik Water Flosser and instructed to water floss around the implant once a day, preferably at nighttime
88845751|NCT03181009|Active Comparator|Group B (1200 maintenance dose)|After initial therapy with omalizumab Group B subjects will escalate their food flour allergens to 1200 mg in 18 weeks.
89181318|NCT04081311|Active Comparator|dental floss|patient will be instructed to floss with TePe Bridge and Implant Floss once a day, preferably at nighttime
89181319|NCT04080921|Experimental|Stem cell transplantation|Stem cell transplantation 2 intrathecal administrations of autologous bone marrow mononuclear cells at baseline and 6 months afterward
89181320|NCT00762788|Active Comparator|senofilcon A contact lens|ACUVUE OASYS
89181321|NCT00762788|Active Comparator|lotrafilcon A contact lens|NIGHT&DAY
89181322|NCT00762788|Active Comparator|lotrafilcon B contact lens|O2Optix
89181323|NCT00762788|Active Comparator|balafilcon A contact lens|PureVision
89181324|NCT00762788|Active Comparator|comfilcon A contact lens|Biofinity
89181325|NCT00762788|Active Comparator|etafilcon A contact lens|ACUVUE 2
89181326|NCT04080609|Experimental|Sequential arm|Dorzagliatin was administered single dose; after wash-out, rifampicin was dosed continuously for 9 days, with Dorzagliatin dosed simultaneously on day 8.
88845752|NCT03292952|Experimental|Double-blind KP415|"KP415 (serdexmethylphenidate [SDX] Cl/ d-methylphenidate [d-MPH] HCl) oral capsule:~28/6 mg SDX/d-MPH (molar equivalent to 20 mg d-MPH HCl), 42/9 mg SDX/d-MPH (molar equivalent to 30 mg d-MPH HCl), 56/12 mg SDX/d-MPH (molar equivalent to 40 mg d-MPH HCl)"
88845753|NCT03292952|Placebo Comparator|Double-blind Placebo|Placebo oral capsule
88845754|NCT03292952|Experimental|Open-Label KP415|"KP415 (serdexmethylphenidate [SDX] Cl/ d-methylphenidate [d-MPH] HCl) oral capsule:~28/6 mg SDX/d-MPH (molar equivalent to 20 mg d-MPH HCl), 42/9 mg SDX/d-MPH (molar equivalent to 30 mg d-MPH HCl), 56/12 mg SDX/d-MPH (molar equivalent to 40 mg d-MPH HCl)"
88845755|NCT03296072|Experimental|Test product|Participants will apply a full ribbon of the test product (1.5 grams [g]) containing 0.254% w/w sodium fluoride and 5% KNO3.
88845756|NCT03296072|Active Comparator|Comparator Product|Participants will apply a full ribbon of the comparator product (1.5 g orally) containing 0.454% w/w stannous fluoride.
88845757|NCT03296072|Placebo Comparator|Placebo Product|Participants will apply a full ribbon of the placebo (1.5 g orally) containing 5% KNO3.
88845758|NCT03182725|Placebo Comparator|Placebo|Patient will consume one placebo pill twice a day for one month.
88845759|NCT03182725|Experimental|Ivabradine|Patient will consume one dose of Ivabradine twice a day for one month.
88845760|NCT03216512|Experimental|Noise cancelling headphone first, then sham control headphone|This group will use the noise cancelling headphone during the first experimental session as they complete study assessments. They will then return within a week, for experimental session day 2, to complete the same assessments this time using a sham control headphone.
88845761|NCT03216512|Experimental|Sham control headphone first, then noise cancelling headphone|This group will use the sham control headphone during the first experimental session as they complete study assessments. They will then return within a week for experimental session day 2, to redo the same assessments this time using a noise cancelling headphone.
88845762|NCT03185065|Experimental|Arm A|amantadine, placebo, modafinil, methylphenidate
88845763|NCT03185065|Experimental|Arm B|placebo, methylphenidate, amantadine, modafinil
88845764|NCT03185065|Experimental|Arm C|modafinil, amantadine, methylphenidate, placebo
88845765|NCT03185065|Experimental|Arm D|methylphenidate, modafinil, placebo and amantadine
88845766|NCT03419780|Active Comparator|Single-Unit Blood Transfusion Protocol|In this arm, patients receive a 1 unit pRBC transfusion with the plan for post-transfusion blood count at 4-6 hours post-transfusion and clinical reassessment.
88845767|NCT03419780|Active Comparator|Multiple-Unit Blood Transfusion Protocol|In this arm, patients receive 2 units of pRBCs, followed by 4-6 hour post-transfusion blood count and clinical reassessment.
88845768|NCT05406271|Experimental|Hip Prosthesis with intraoperative fluoroscopy|
88845769|NCT05406271|No Intervention|Hip Prosthesis without intraoperative fluoroscopy|
88845770|NCT04415671|Experimental|Part A- AD-214 SAD in Healthy Volunteers|
88845771|NCT04415671|Placebo Comparator|Part A-Placebo SAD in Healthy Volunteers|
88845772|NCT04415671|Experimental|Part B-AD-214 MAD in Healthy Volunteers|
88845773|NCT04415671|Placebo Comparator|Part B-Placebo MAD in Healthy Volunteers|
88845774|NCT04398199|Experimental|Hypofractionated Radiation Therapy|Hypofractionated radiation therapy will be delivered to all participants. The radiation will be planned in a special way to give the biggest parts of the tumors that are the most difficult to control a little more radiation every day than the lower risk areas.
88845775|NCT05406037||Patients with MM|"Age : from 3 to 75 years old ;~- Specific medical conditions : patient hospitalized in one of the departments of the University Hospital of Lille or Amiens, in whom the diagnosis of mucormycosis will have been made on the criteria below, with compatible clinical and radiological evolution :~conventional mycology data and/or~positive q-PCR and/or~pathology data confirmed by PCR;"
89181327|NCT04080687||Fallers|The patients who had fallen during the 6 months prior to the study onset
89181328|NCT04080687||Non-fallers|The patients who had not fallen during the 6 months prior to the study onset
88845776|NCT05406037||High-risk patients without MM (control group 1)|"Age : from 18 to 75 ;~- Specific medical conditions : patients hospitalized at the University Hospital of Lille or Amiens for whom a diagnosis of candidiasis or invasive aspergillosis has been made according to specific classifications (EORTC/MSG criteria, AspICU criteria)"
88845777|NCT05406037||Patients with another IFI (control group 2)|"Age : from 18 to 75 ;~Specific medical conditions : patients undergoing assessment for haematopoietic stem cell transplantation, considered at risk of invasive fungal infection but for whom the pre-transplant assessment will have excluded an ongoing infection."
88845778|NCT04396249|Experimental|Active tVNS group|The active tVNS group will be stimulated with 10 sessions of active transcutaneous vagal nerve stimulation (tVNS)
88845779|NCT04396249|Sham Comparator|Sham tVNS group|The sham tVNS group will be stimulated with 10 sessions of sham transcutaneous vagal nerve stimulation (tVNS)
88845780|NCT03285061|No Intervention|Standard Disposal Instructions|These patients will receive standard instructions on proper disposal of excess pain medication following orthopedic foot and ankle surgery. They will be asked complete a survey at their 6 post operative follow-up on excess medication disposal.
88845781|NCT03285061|Experimental|At Home Disposal|With patients' prescription for post operative pain medication, a Deterra portable drug deactivation system will be provided, along with instructions on proper use. They will be asked complete a survey at their 6 post operative follow-up on excess medication disposal.
88845782|NCT02219334|Experimental|NoseFrida|If randomized to the NoseFrida group, the NoseFrida/filters will be given along with educational instruction of its use to the parents of patients admitted with bronchiolitis. The NoseFrida will be used by the parent to suction the nares of their infants/toddlers.
88845783|NCT02219334|No Intervention|NeoSucker|The NeoSucker (used for nasal suctioning) is part of the current standard of care for patients with bronchiolitis. The NeoSucker is used for removing nasal secretions by a nurse or respiratory therapist. The NeoSucker is a plastic tube which is used to suction the secretions. The bedside nurse will continue to use the NeoSucker as needed. NoseFrida will not be used for this sub group of patients.
88845784|NCT03285373||patients with NVAF|patients with Non Valvular Atrial Fibrillation
89189308|NCT02575326|Other|Intervention|Teens in the intervention group will receive a provider administered, tailored discussion guide based on motivational interviewing techniques.
88845785|NCT02159040|Active Comparator|Azacitidine|75mg/m2 7days/28 day cycle
88845786|NCT02159040|Experimental|Azacitidine and Deferasirox|azacitidine 75mg/m2 7 days/28 day cycle deferasirox 10 mg/kg/day
89373904|NCT02997228|Experimental|Arm III (atezolizumab, bevacizumab, mFOLFOX6)|Patients receive atezolizumab IV over 30-60 minutes on day 1. Treatment repeats every 2 weeks for up to 48 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive bevacizumab IV over 30-90 minutes on day 1, oxaliplatin IV over 2 hours on day 1 cycles 1-10, leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV over 46-48 hours on day 1. Treatment with oxaliplatin repeats every 2 weeks for up to 10 cycles in the absence of disease progression or unacceptable toxicity. Treatment of bevacizumab, leucovorin calcium, and fluorouracil repeat every 2 weeks for up to 48 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT with or without PET or MRI throughout the trial. Patients may also undergo collection of optional blood samples throughout the trial.
88845787|NCT03285529|Active Comparator|STRATAFIX GROUP|STRATIFIX symmetric PDS Plus #1 will be used to close the capsule following total knee arthroplasty. The subcutaneous layer will be then closed with simple interrupted knots using number 2-0 braided absorbable sutures (Vicryl), followed by closure of the subcutaneous layer using a number 2-0 monofilament absorbable suture with inverted interrupted knots (Monocryl) followed by the use of steri-strips and adhesive
88845788|NCT03285529|Placebo Comparator|CONTROL GROUP|The arthrotomy (deep layer) is repaired using Vicryl #1 followed by closure of the intermediate layer with a 2-0 Vicryl and a subcutaneous layer with a 2-0 Monocryl followed by steri-strips and adhesive, following total knee arthroplasty.
88845789|NCT03189589|Experimental|GSK2269557 500 µg receivers|Randomized healthy subjects will receive single dose of GSK2269557 500 µg via inhalation route via the ELLIPTA DPI.
88845790|NCT03189589|Experimental|GSK2269557 750 µg receivers|Randomized healthy subjects will receive single dose of GSK2269557 750 µg via inhalation route via the ELLIPTA DPI.
88845791|NCT02218008|Experimental|High Dose|
88845792|NCT02218008|Experimental|Low Dose|
88845793|NCT02218008|Placebo Comparator|Placebo|
88845794|NCT03216902|Placebo Comparator|Placebo (Vehicle of DE-126) followed by high dose of DE-126|
88845795|NCT03216902|Experimental|Ultra-low dose 0.0005% DE-126|
88845796|NCT03216902|Experimental|Low dose 0.001% DE-126|
88845797|NCT03216902|Experimental|Medium dose 0.002% DE-126|
88845798|NCT03216902|Experimental|High dose 0.003% DE-126|
88845799|NCT03216902|Active Comparator|0.005% Latanoprost|
88845800|NCT03190213|Experimental|Pembrolizumab, all patients|
88845801|NCT03190993|Active Comparator|Sugar Sweetened Solid Treatment|A solidified food that is made with the SSB syrup concentrate and gelatin. It is equivalent to one 20 oz. soft drink.
88845802|NCT03190993|Active Comparator|Sugar Sweetened Beverage Treatment|20 oz. carbonated sugar sweetened beverage. Added ingredients include: ~2.1g whey protein powder.
88845803|NCT03194503|Active Comparator|Attendings|Study intervention is a VL coaching training for site neonatology attendings. Each site leader/key educator will be trained remotely by expert co-investigators. Site leaders and key educators will train their attendings. The quality of VL coaching skills will be verified by randomly auditing 20% of attending providers at each site for their skill assessment by remote simulation during the transition/post-intervention phase.
88845804|NCT03194503|No Intervention|Trainees|Trainees will be coached as usual by attendings during their supervised intubation events
88845805|NCT03219320|Placebo Comparator|Placebo Oral Capsule|Up to 300 subjects: Placebo
88845806|NCT03219320|Experimental|NYX-2925|Up to 300 subjects: Multiple dose levels of NYX-2925 daily for 28 days
88845807|NCT03194737|Experimental|UroLift System procedure|All eligible,enroled subjects will undergo a UroLift procedure.
88845808|NCT03194737|No Intervention|Retrospective Arm|Chart review will be performed on all invasive BPH surgeries (TURP, Holmium Laser Enucleation of the prostate (HoLEP), etc) performed by the site from June 1, 2015 to December 31, 2015
88845809|NCT01632150|Experimental|Elotuzumab + Thalidomide + Dexamethasone + Cyclophosphamide|
88845810|NCT03421886|Experimental|Aerodentis system|30 patients will be systematically assigned to the treatment group (wearing Aerodentis Device).
88845811|NCT03421886|Active Comparator|Invisalign clear aligner system|15 patients will be systematically assigned to the control group (wearing clear aligners).
88845812|NCT03286465|Experimental|Pediatric phlebotomy tubes|Use of pediatric size tubes for diagnostic blood collection.
88845813|NCT03286465|Active Comparator|Adult phlebotomy tubes|Use of adult size tubes for diagnostic blood collection.
88845814|NCT02185014|Other|Adalimumab|Participants received open-label adalimumab 40 mg by subcutaneous injection every other week for 40 weeks.
88845815|NCT03297944|Experimental|All Participants|All participants received each intervention with alprazolam, zolpidem and placebo.
88845816|NCT04333004|Experimental|Pembrolizumab Combined With Chemotherapy|
89189309|NCT02575248|Experimental|Group A|patients diagnosed laparoscopically with Endometriosis Stage 1 and Stage 2
88845817|NCT03298880|Other|Four VM's|Healthy volunteers undergo repeated VM's - Device: Supine VM VAD, Supine VAD manometer Modified VM VAD, Modified VM Manonmeter
88845818|NCT03219866|Experimental|Nebulizers|Subjects will receive a long-acting B2-agonist (LABA; Brovana, twice daily), corticosteroid (ICS; Pulmicort, twice daily), and a short-acting anti-cholinergic (SAMA; Atrovent, three times a day).
88845819|NCT03219866|Experimental|Dry Powder Inhaler|Subjects will receive a LABA/ICS (Advair Diskus, twice daily) plus a long-acting anticholinergic (LAMA; Spiriva Handihaler, once daily).
88845820|NCT03291379|Experimental|BTG-002814|Single arm: BTG-002814 (vandetanib-eluting radiopaque beads)
88845821|NCT03300674|Active Comparator|Intravenous hydromorphone|Intravenous hydromorphone 1mg. A second dose can be administered at 30 minutes.
88845822|NCT03300674|Active Comparator|Intravenous lidocaine|Intravenous lidocaine 120 mg. A second dose can be administered at 30 minutes
88845823|NCT02184156|Experimental|AMPION™ 4 mL dose|4 mL injection of Ampion
88845824|NCT02184156|Placebo Comparator|Placebo 4 mL dose|4 mL injection of placebo
88845825|NCT03291613|Experimental|Pinpoint App|Tablet application.
88845826|NCT03300752|Experimental|BREATHE Intervention|The patient's primary care provider (PCP) will deliver the active intervention (shared decision-making discussion of asthma control status and treatment) - BREATHE Intervention.
89373905|NCT02990663|Experimental|Bedtime BP Meds|Use of blood pressure lowering medication at bedtime
88845827|NCT03300752|Active Comparator|Control Intervention|The patient's primary care provider (PCP) will deliver the control intervention (discussion of healthy lifestyles).
88845828|NCT04059913|Experimental|Part 1: ESA-Naïve Participants - Low Weight Based Dosing|ESA-naïve participants will receive roxadustat 70 mg TIW for body weight 45 to <60 kg or 100 mg TIW for body weight ≥60 kg.
88845829|NCT04059913|Experimental|Part 1: ESA-Naïve Participants - Standard Weight Based Dosing|ESA naïve participants will receive roxadustat 100 mg TIW for body weight 45 to <60 kg or 120 mg TIW for body weight ≥60 kg.
88845830|NCT04059913|Experimental|Part 1: ESA-Treated Participants - Low Weight Based Dosing|ESA-treated participants will receive roxadustat 70 mg TIW for body weight 45 to <60 kg or 100 mg TIW for body weight ≥60 kg.
88845831|NCT04059913|Experimental|Part 1: ESA-Treated Participants - Standard Weight Based Dosing|ESA treated participants will receive roxadustat 100 mg TIW for body weight 45 to <60 kg or 120 mg TIW for body weight ≥60 kg.
88845832|NCT04059913|Experimental|Part 2: Roxadustat QW|Participants will receive roxadustat once a week (QW). Roxadustat dose will be 2-dose step increase from originally planned week 21 TIW per dose amount.
88845833|NCT04059913|Experimental|Part 2: Roxadustat BIW|Participants will receive roxadustat twice a week (BIW). Roxadustat dose will be 1-dose step increase from originally planned week 21 TIW per dose amount.
89181329|NCT00583947|Other|ARF/LEV|"Cross-over phase: one day active treatment with arformoterol 7.5 microgram per nebulization followed by a 7 day washout. Then a one day active treatment with levalbuterol 0.63 milligram per nebulization.~Open-label phase: Following another 7 day washout, one day treatment with arformoterol 15 micrograms per nebulization."
89373906|NCT02990663|Active Comparator|Morning BP Meds|Use of blood pressure lowering medication in the morning
89373907|NCT02988271|Experimental|Group I (meditation)|Patients watch a pre-recorded instructional meditation video via an iPod meditation app. Patients then complete meditation exercises using the meditation app over 5-15 minutes QD for up to 2 weeks. Patients also complete questionnaires before and after meditation sessions and participate in an interview over 10 minutes.
89373908|NCT02988271|Active Comparator|Group II (waitlist control)|Patients receive supportive care, such as access to social workers, support groups, spiritual care, or other patient services for up to 2 weeks. Patients also complete questionnaires over 15-20 minutes and participate in an interview over 10 minutes.
88845834|NCT04059913|Experimental|Part 2: Roxadustat TIW|Participants will receive roxadustat TIW. Roxadustat dose will continue per dose adjustment guideline.
88845835|NCT02158884|Other|IDEO brace|IDEO brace
88845836|NCT03220412|Experimental|Experimental Condition|Intervention was guns in movies. Participants in this condition viewed a movie with guns, as it was filmed and distributed. The actual scenes in the movie (National Treasure or The Rocketeer) was not edited, but the same scenes were used as the Experimental Condition Intervention is m
88845837|NCT03220412|No Intervention|Control Condition|Participants in this condition viewed a movie without guns. The movie (National Treasure or The Rocketeer) was edited to remove guns from scenes.
88845838|NCT04028557|Experimental|Customized CDS|The customized CDS will be designed and implemented with comprehensive application of known best practice principles in CDS design. The recommendation will be to initiate an evidence-based beta blocker for heart failure.
88845839|NCT04028557|Active Comparator|Commercial CDS|The commercial CDS is available to all institutions using the Epic electronic health record vendor, but violates some CDS design best practices, notably not being tailored to the end users of a given health system. The recommendation will be to initiate an evidence-based beta blocker for heart failure.
88845840|NCT03195517|Experimental|Physical Exercise|"The exercise program was performed at C.U.R.I.A.Mo. Institute of Università degli Studi di Perugia. Twenty-four exercise sessions were provided, carried out twice a week for three months. Each session was supervised by two graduated trainers and two medical doctors with a maximum attendance of 5 patient/group.~Each session lasted 45 minutes divided into 15 minutes of aerobic activity and 30 minutes of weight-bearing and resistance activities.~This latter section was specifically projected for adults and older adults with increased risk of fractures and was intended to improve muscle strength and flexibility, balance and, as a result, to prevent the risk of falls."
88845841|NCT03195517|No Intervention|No additional physical exercise|Usual recommendations for prevention of fractures in adults and elderly.
88845842|NCT04333069|Other|Uncorrected and best corrected visual acuity|Measuring of uncorrected and best corrected visual acuity after phaco emulsification and irrigation aspiration cataract surgery
88845843|NCT03419533||2018 school leavers|South Australian school leavers in 2018 (year 12 in 2017)
88845844|NCT03419533||2019 school leavers|South Australian school leavers in 2019 (year 12 in 2018)
88845845|NCT02158806|Experimental|Aspirin|150 mg capsule once daily for up to 24 weeks
88845846|NCT02158806|Placebo Comparator|Inert capsule|Matching capsule once daily for up to 24 weeks
88845847|NCT03197389|Other|Cohort A1|Cohort A1 will include patients with a triple negative breast tumor. Patients will be treated with one injection of Pembrolizumab (Keytruda®) administered intravenously at 200 mg 10 +/- 4 days before surgery.
88845848|NCT03197389|Other|Cohort A2|Cohort A2 will include patients with ER/PR negative and Her2 positive breast tumor. Patients will be treated with one injection of Pembrolizumab (Keytruda®) administered intravenously at 200 mg 10 +/- 4 days before surgery.
88845849|NCT03197389|Other|Cohort B1|Cohort B1 will include patients with a triple negative breast tumor who received neoadjuvant chemotherapy and who have clear signs of residual tumor on imaging after finishing neoadjuvant chemotherapy (i.e. on imaging estimated residual tumor size of at least 10 mm). Patients will be treated with one injection of Pembrolizumab (Keytruda®) administered intravenously at 200 mg 10 +/- 4 days before surgery.
89181330|NCT00583947|Other|LEV/ARF|"Cross-over phase: one day active treatment with levalbuterol 0.63 milligram per nebulization followed by a 7 day washout. Then a one day active treatment with arformoterol 7.5 micrograms per nebulization.~Open-label phase: Following another 7 day washout, one day treatment with arformoterol 15 micrograms per nebulization."
89181331|NCT00772928|Experimental|Pentacel™ concurrently with Prevnar®|Participants had Pentacel™ concurrently administered with Prevnar®
88845850|NCT03197389|Other|Cohort B2|Cohort B2 will include patients with a ER/PR negative and Her2 positive breast tumor who received neoadjuvant chemotherapy and who have clear signs of residual tumor on imaging after finishing neoadjuvant chemotherapy (i.e. on imaging estimated residual tumor size of at least 10 mm). Patients will be treated with one injection of Pembrolizumab (Keytruda®) administered intravenously at 200 mg 10 +/- 4 days before surgery.
88845851|NCT03197389|Other|Cohort A3|Cohort A3 will include patients with ER positive breast tumor. Patients will be treated with one injection of Pembrolizumab (Keytruda®) administered intravenously at 200 mg 10 +/- 4 days before surgery.
88845852|NCT03197389|Other|Cohort B3|Cohort B3 will include patients with a ER positive breast tumor who received neoadjuvant chemotherapy and who have clear signs of residual tumor on imaging after finishing neoadjuvant chemotherapy (i.e. on imaging estimated residual tumor size of at least 10 mm). Patients will be treated with one injection of Pembrolizumab (Keytruda®) administered intravenously at 200 mg 10 +/- 4 days before surgery.
88845853|NCT02158728||ICD indicated subjects|"Subjects indicated for implantable cardioverter defibrillator (ICD)/ cardiac resynchronization therapy defibrillator (CRT-D) implant, ICD/CRT-D change-out, or indicated for an ICD/CRT-D and undergoing ablation or electrophysiology (EP) study (including Non-Invasive ElectroPhysiology Study [NIPS]).~Enrolled subjects are prepared for the indicated procedure as per investigational center's standard practice. The investigator will determine the best methodology for inducing or simulating SVT within the indicated procedure. Data is recorded by a data acquisition recording system. Recording should begin just before the indicated procedure and continue until completion of the procedure.The recorded data are collected."
88845854|NCT03198871|Experimental|Acetaminophen Injectable Product|Acetaminophen group: Half of subjects enrolled will be randomized to the acetaminophen group
88845855|NCT03198871|Placebo Comparator|Sodium Chloride 0.9%, Intravenous|Sodium Chloride 0.9% group: Half of subjects enrolled will be randomized to the acetaminophen group
88845856|NCT03301298|Experimental|SXC-2023, 50 mg|Single dose of 50 mg, given orally in capsule form.
88845857|NCT03301298|Experimental|SXC-2023, 100 mg|Single dose of 100 mg, given orally in capsule form.
88845858|NCT03301298|Experimental|SXC-2023, 200 mg|Single dose of 200mg, given orally in capsule form.
88845859|NCT03301298|Experimental|SXC-2023, 400 mg|Single dose of 400mg, given orally in capsule form.
88845860|NCT03301298|Experimental|SXC-2023, 800 mg|Single dose of 800mg, given orally in capsule form.
88845861|NCT03301298|Experimental|SXC-2023, 1600 mg|Single dose of 1600 mg, given orally in capsule form.
88845862|NCT03301298|Placebo Comparator|Placebo oral capsule|Placebo comparator, given once orally in matching capsule form.
88845863|NCT02157948|Active Comparator|Denosumab CP2|Participants received 60 mg denosumab manufactured using the current CP2 process subcutaneously once every 6 months for 1 year.
89373909|NCT02951767|Experimental|Cohort 1: Treatment-naive Cisplatin Ineligible Participants|Participants with advanced disease who are treatment-naive for advanced urothelial carcinoma and cisplatin ineligible will receive atezolizumab 1200 mg via IV infusion on Day 1 of 21-day cycles until disease progression per RECIST v1.1 criteria or unmanageable toxicity.
89373910|NCT02949739|Active Comparator|Intensive lifestyle modification|"The investigators will recruit 3,600 South Asian men and women aged 40-70 years with i. central obesity (waist≥100 cm) and/or ii. prediabetes (HbA1c 6.0-6.4%) to the study (Index cases). Recruitment will be from the Indian subcontinent (India, Pakistan, Sri Lanka) and Europe (UK). Index cases will receive either i. intensive lifestyle modification (N=1,800); or ii. usual care (N=1,800).~Intensive lifestyle modification follows clinically accepted, evidence based strategies to achieve >7% reduction in weight through improved diet and increased physical activity, and is delivered as 9 face-face and 13 telephone contact sessions over 12 months.~Index cases will be followed for three years to identify new-onset T2D."
88845864|NCT02157948|Experimental|Denosumab CP4|Participants received 60 mg denosumab manufactured using the new CP4 process subcutaneously once every 6 months for 1 year.
89373911|NCT02949739|No Intervention|Usual Care|"The investigators will recruit 3,600 South Asian men and women aged 40-70 years with i. central obesity (waist≥100 cm) and/or ii. prediabetes (HbA1c 6.0-6.4%) to the study.~Recruitment will be from the Indian subcontinent (India, Pakistan, Sri Lanka) and Europe (UK). Index cases will receive either i. intensive lifestyle modification (N=1,800); or ii. usual care (N=1,800).~Usual care group will comprise one diabetes prevention session and written material."
89373912|NCT02941783||BAY81-8973|Hemophilia A patients who require Factor VIII replacement therapy
89373913|NCT02875548|Experimental|Open-label Tazemetostat|"Participants will continue to receive the same tazemetostat dose and schedule as specified in their antecedent tazemetostat protocol.~For participants on combination therapy, the other therapeutic(s) must have been completed in the antecedent study or be provided by a source other than Epizyme if combination treatment is continued in this clinical rollover study."
89373914|NCT02873715|Active Comparator|Usual Care (UC)|Usual Care will consist of the care typically delivered by the family's primary care provider for children with overweight or obesity. The implementations of UC may vary between providers but typically includes and assessment of the child's weight, help remove barriers to weight loss and introductions of goals for better weight management.
88845865|NCT03302767|Experimental|Psychological and Social Consultation|Psychological and Social Consultation
88845866|NCT03220958|Experimental|Metoclopramide|Metoclopramide 20mg + diphenhydramine 25mg + 100cc normal saline, administered as an intravenous drip
88845867|NCT03220958|Placebo Comparator|Placebo|Normal saline, administered as an intravenous drip
88845868|NCT03420625|Active Comparator|Foot IPC|Intermittent pneumatic compression in the foot using the A-V Impulse™, Covidien®, New Haven, CT, USA
88845869|NCT03420625|Active Comparator|Rapid calf IPC|Intermittent pneumatic compression in the calf using the VenaFlow® Elite, DJO Global, USA
88845870|NCT03420625|Active Comparator|Slow calf IPC|Intermittent pneumatic compression in the calf using the Kendall SCD™ 700, Covidien, Medtronic, USA
88845871|NCT03420625|Active Comparator|Calf NMES|Neuromuscular electrical stimulation in the calf using the DJO,TM, CefarCompex Mi-Theta 500 stimulator
89189310|NCT02575248|Active Comparator|group B|patients diagnosed laparoscopically with Endometriosis Stage 1 and Stage 2
89002243|NCT05878119|Active Comparator|MIB-626 plus standardized, progressive, high intensity, multidimensional exercise (MIB-626-Ex)|The MIB-626 will be a GMP-grade microcrystalline solid NMN mixed with inert excipients (including microcrystalline cellulose) and compressed into tablets at a dose strength of 500 mg per tablet, enabling administration of the 1,000 mg twice daily using two tablets taken twice daily.
89002244|NCT05878119|Placebo Comparator|Standardized, progressive, high intensity, multidimensional exercise plus placebo (PL-Ex)|Matching placebo tablets will be provided by the study's Sponsor, Metro International Biotech, LLC.
89002245|NCT05874622|Experimental|VC005 Tablets Low Dose groups|
89002246|NCT05874622|Experimental|VC005 Tablets Medium Dose groups|
89002247|NCT05874622|Experimental|VC005 Tablets High Dose groups|
89002248|NCT05874622|Experimental|VC005 Tablets Placebo Low Dose groups|
89002249|NCT05874622|Experimental|VC005 Tablets Placebo Medium Dose groups|
89002250|NCT05874622|Experimental|VC005 Tablets Placebo High Dose groups|
89002251|NCT05855798|Active Comparator|control group|Erector spinae plane block with 20 mL 0.5% bupivacaine
89002252|NCT05855798|Active Comparator|magnesium group|Erector spinae plane block with 20 mL 0.5% bupivacaine+150 mg magnesium sulphate
89002253|NCT05855798|Active Comparator|ketamine group|Erector spinae plane block with 20 mL 0.5% bupivacaine+2 mg/kg ketamine
89002254|NCT05852808|Active Comparator|Intra-articular steroid injections|The intra-articular steroid injections are the most common standard of care to treat the lower back pain resulting from FJA.
89002255|NCT05852808|Experimental|Low-dose radiation therapy|LDRT is commonly used as treatment for benign degenerative inflammatory disorders
89002256|NCT05845476|Experimental|SOGI Data Collection Intervention|This single arm is an educational intervention for clinicians. After consent, they provide baseline survey fata, then the training intervention, then a post assessment.
89002257|NCT05841550|Experimental|TG01|"TG01 is a sterile lyophilizate consisting of a mixture of seven peptides. The finished product is a white powder for injection, consisting only of the active substances containing 2.1 mg of peptides (individual peptides comprising 0.3 mg each). The lyophilizate is to be reconstituted with QS-21 for injection before use.~QS-21 is a naturally occurring saponin molecule purified from the South American tree Quillaja saponaria Molina. QS-21 Solution is supplied in a 2 mL CZ resin vial as a sterile, solution in PBS (phosphate buffered saline) at a concentration of 0.5 mg/mL QS-21 (500 mcg/mL) with each vial containing 0.7 mL intended single use only.~The vaccine will be given subcutaneously Treatment consists of 12 doses TG01/QS-21 vaccine given every 2 weeks in the first 12 weeks, followed by every 8 weeks until week 52.~TG01 dose 0.7 mg dose and QS-21 50 ug."
89373915|NCT02873715|Experimental|Family-based treatment (FBT)|Family- Based treatment utilizes behavior change techniques to target family-wide changes in diet and physical activity habits with the goal of promoting weight loss and subsequently healthy weight maintenance in all participants. Participants will have visits between 30 to 60 minutes as frequent as weekly and no longer than monthly over the two year study
89002259|NCT05829239|Experimental|ADI-PEG20|ADI-PEG20 (ADI-PEG20 is arginine deiminase (ADI) conjugated to polyethylene glycol (PEG) of 20,000 molecular weight) will be weekly intramuscularly at a dose of 18 mg/m2 body surface area/week for 8-week.
89002260|NCT05829239|Placebo Comparator|Placebo|Will be weekly intramuscularly for 8-week
89002261|NCT05809856|Experimental|Implantation of autologous GrOwnValve|Implantation of autologous GrOwnValve via minimal-invasive transcatheter technique into patients with high-grade pulmonary valve insufficiency and right ventricular dilatation.
89002262|NCT05800990|Experimental|Dietary A-B Intervention|The Dietary A first, then the Dietary B intervention. Since this is a single blind study, the details of the dietary interventions cannot be released during recruitment stage but will be made public once enrollment closes.
89002263|NCT05800990|Experimental|Dietary B-A Intervention|The Dietary B first, then the Dietary A intervention. Since this is a single blind study, the details of the dietary interventions cannot be released during recruitment stage but will be made public once enrollment closes.
89373916|NCT02849405|Other|Arteriosclerosis|Hyperspectral camera for arteriosclerosis Diagnostic
89002264|NCT05793619|Experimental|Condition 1 : prototypes (816-v1 301) to (816-v1 355) every week|Application on the brown spots of the face for the prototypes (816-v1 301) to (816-v1 355) at D0, D7, D14, D21, D28 and D35
89002265|NCT05793619|Experimental|Condition 2 : prototypes (816-v1 301) to (816-v1 355) every two weeks|Application on the brown spots of the face for the prototypes (816-v1 301) to (816-v1 355) at D0, D14, D28, D42, D56 and D70
89002266|NCT05792722|Other|Prostate Capsule-Sparing Radical Cystectomy|Patients randomized to this arm will receive the prostate capsule-sparing surgery performed in the form of standard simple prostatectomy. Patients will also have a cystectomy with one of the following urinary diversions: ileal conduit, Indiana Pouch, or orthotopic neobladder.
89002267|NCT05792722|Other|Nerve-Sparing Radical Cystectomy|Patients randomized to this arm will receive the nerve-sparing surgery will be performed in the form of the standard nerve-sparing radical prostatectomy. Patients will also have a cystectomy with one of the following urinary diversions: ileal conduit, Indiana Pouch, or orthotopic neobladder.
89373917|NCT02849405|Other|Healthy controls|Hyperspectral camera for healthy control Diagnostic
89373918|NCT02844075|Experimental|pembrolizumab|
89002268|NCT05787314|Experimental|Control Diet|"For the Control Diet, a medical nutrition therapy with calorie and fat content was prepared to ensure weight loss of individuals without considering the glycemic index.~The aim of this diet is to achieve weight loss, but not to focus on the content of carbohydrates. 3) In the macro element distribution of the CD, 50-55% carbohydrates, 10-15% protein and 20-25% fat distribution Other name (CD Group)"
89002269|NCT05729204|Experimental|Hypertonic seawater group|Patients that will receive nasal irrigations with hypertonic (2.3% NaCl) seawater solution containing brown algae (Undaria pinnatifida) and blue-green algae (Spirulina platensis) as well as essential oils of Eucalyptus globulus and Mentha spicata, and Thymus vulgaris extract (Sinomarin® Plus Algae Cold & Flu Relief, Gerolymatos International SA, Krioneri, Greece)
89002270|NCT05729204|No Intervention|control group|Patients that will not perform nasal irrigations
89373919|NCT02839850|Experimental|ATTUNE Cementless RP TKA|Subjects will receive a cementless, rotating platform total knee arthroplasty
89373920|NCT02821741|Experimental|Cymba Conchae|Mild electrical stimulation is applied to the cymba conchae of the left ear, and thermal stimulation is applied to the arms.
88845872|NCT03221192||Subjects participating in CE and CD interviews|Twenty adult subjects from the US and 10 adult subjects from Germany with severe recurrent nasal polyps who have received nasal polyp surgery in the past 10 years prior to screening will be asked to participate in CE and CD interviews
88845873|NCT03221192||Subjects participating in interview and real-time data capture|Ten subjects from the US with severe recurrent nasal polyps who are participating in CE and CD interviews will be asked to complete the real-time data capture app task.
88845874|NCT02182830|Experimental|Empagliflozin|starting dose 10mg; forced titration after 4 weeks 25mg dose
88845875|NCT02182830|Placebo Comparator|Placebo|starting dose 10mg; forced titration after 4 weeks 25mg dose
88845876|NCT03424681|Experimental|Modafinil|Modafinil 300 mg by mouth each day
88845877|NCT03424681|Placebo Comparator|Placebo|Identical looking capsule/number of capsules by mouth each day without active medication
88845878|NCT03305653|Experimental|Current/historical diagnosis of EoE|Subjects with current or historical diagnosis of EoE, or suspected of having EoE will complete the Esophageal String Test (EST) and EndoFLIP
88845879|NCT03431012|Experimental|Virus Agency/Negative Attribute Framing|Participants in this condition, after reading a hypothetical scenario, received health messages describing the pandemic flu and the efficacy of the antivirals using linguistic expressions that assigned transmission to the pandemic flu virus itself (Virus Agency Assignment framing), whilst describing the side effects of the antivirals in terms of chances of experiencing side effects after using them (Negative Framing).
88845880|NCT03431012|Experimental|Human Agency/Negative Attribute Framing|Participants in this arm, after reading a hypothetical scenario, received a health message describing the pandemic flu and the efficacy of the antivirals using linguistic expressions that assigned transmission to humans (Human Agency Assignment framing), whilst describing the side effects of the antivirals in terms of chances of experiencing side effects after using them (Negative Framing health messages).
88845881|NCT03431012|Experimental|Human Agency /Positive Attribute Framing|Participants in this arm, after reading a hypothetical scenario, received a health message describing the pandemic flu and the efficacy of the antivirals using linguistic expressions that assigned transmission to humans (Human Agency Assignment framing), whilst describing the side effects of the antivirals in terms of chances of not experiencing side effects after using them (Positive Framing).
88845882|NCT03431012|Experimental|Virus Agency /Positive Attribute Framing|Participants in this arm, after reading a hypothetical scenario, received a health message describing the pandemic flu and the efficacy of the antivirals using linguistic expressions that assigned transmission to the pandemic flu virus itself (Virus Agency Assignment framing), whilst describing the side effects of the antivirals in terms of chances of not experiencing side effects after using them (Positive Framing).
88845883|NCT03427177|Experimental|Treatment|Participants randomized to the treatment arm of the study will be given the mychoice tool.
88845884|NCT03427177|No Intervention|Control|Participants randomized to the control arm of the study will be given existing literature from the NCI that describes clinical trials (standard information for newly diagnosed cancer patients).
88845885|NCT03302780|Experimental|Sham tDCS and BreEStim|This arm includes a 20-min sham tDCS to the current dominant primary motor cortex (M1), followed by a 20-min BreEStim to the median nerve (160 times) transcutaneously on the current dominant side.
88845886|NCT03302780|Experimental|active tDCS (M1) and BreEStim|This arm includes a 20-min active tDCS to the current dominant primary motor cortex (M1), followed by a 20-min BreEStim to the median nerve (160 times) transcutaneously on the current dominant side.
88845887|NCT04332848|Experimental|(B) Empirical therapy|choose antibiotics according to drug history
88845888|NCT04332848|Active Comparator|(A) Susceptibility testing guided therapy|choose antibiotics according to susceptibility testing
88845889|NCT03305887|Experimental|Barbed suture group|"The deep layer and the intermediate layer will be repaired and closed by using one STRATAFIX™ Symmetric Knotless Tissue suture respectively. STRATAFIX Spiral sutures will be used to close the intradermal layer and the DERMABOND™ Advance™ Skin Closure System, a topical skin adhesive (TSA) will be applied to the skin surface to tissue approximation."
88845890|NCT03305887|Active Comparator|Conventional suture group|VICRYL® Plus sutures will be used to close the deep and the intermediate layers with interrupted suturing manner. STRATAFIX Spiral sutures will be used to close the intradermal layer and the DERMABOND™ Advance™ Skin Closure System, a topical skin adhesive (TSA) will be applied to the skin surface to tissue approximation.
88845891|NCT03221738|Experimental|App-Based Cognitive Behavioral Therapy|12-week Smartphone-delivered CBT for BDD.
88845892|NCT03303404|Experimental|Ambulatory (24-hour) Blood Pressure|
88845893|NCT03224390|Experimental|Encouragement Arm|Women randomized to the encouragement arm will receive an invitation via SMS to try the new digital family planning screening and referral service.
88845894|NCT03224390|No Intervention|Control Arm|Women randomized to the control arm will receive a different set of SMS messages that do NOT include a special encouragement try the new digital family planning screening and referral service.
88845895|NCT03303794|Active Comparator|Bupivicaine|0.25% bupivacaine in patients undergoing total knee arthroplasty
88845896|NCT03303794|Experimental|Bupivicaine + Exparel|0.25% bupivacaine and 1.3 % liposomal Bupivacaine in patients undergoing total knee arthroplasty
88845897|NCT03304106|Experimental|Newly Implanted CI Recipients|Use of AI technology to assist in audiologist's evaluation and programming of new (standard of care-commercial) cochlear implant recipients
88845898|NCT03304106|Experimental|Existing CI recipients|Use of AI technology to assist in audiologist's evaluation and programming of existing cochlear implant recipients
88845899|NCT03305822|Experimental|LY900014|Single, subcutaneous (SC) dose of 15 Units (U) LY900014 in one of two study periods
88845900|NCT03305822|Active Comparator|Insulin Lispro (Humalog)|Single SC dose of 15 U insulin lispro (Humalog) in one of two study periods
88845901|NCT04706702|Experimental|Tele-EF|Tele-EnhanceFitness
88845902|NCT03226652||Patients with clinically suspected sleep disordered breathing (SDB)|Patients referred for Sleep disordered breathing assessment.
88845903|NCT03435614||Critically ill patients|Mechanically ventilated critically ill adults receiving regular opioids for more than 72 hours will be prospectively followed for the emergence of withdrawal symptoms upon weaning of opioids.
88845904|NCT03437564|Experimental|Vortioxetine one 20 mg tablet + two 10 mg tablets|Vortioxetine 20 mg (one 20 mg tablet) on Day 1 in Period 1 in a fasted state + vortioxetine 20 mg (two 10 mg tablets) on Day 1 in Period 2 in a fasted state.
89535018|NCT03092739||Cytological and Histological Samples|Cytological and histological specimens that meet the eligibility criteria will be analyzed only from those participants who have consented to biomarker research, according to local regulations and ethical guidelines. Cytological samples may originate from fine needle aspirations. Pleural effusions or bronchial cytology samples (brushings and washings) may be allowed. Histological samples may originate from core needle biopsies, bronchial biopsies (thoracoscopy or mediastinoscopy) or surgical tissue resections.
88845905|NCT03437564|Experimental|Vortioxetine two 10 mg tablets + one 20 mg tablet|Vortioxetine 20 mg (two 10 mg tablets) on Day 1 in Period 1 in a fasted state + vortioxetine 20 mg (one 20 mg tablet) on Day 1 in Period 2 in a fasted state.
88845906|NCT03438266|Experimental|JUVÉDERM VOLUMA® XC Injectable Gel with Cannula|Participants had 1 cheek treated with JUVÉDERM VOLUMA® XC injectable gel with cannula.
89373921|NCT02821741|Active Comparator|Ear Lobe|Mild electrical stimulation is applied to the earlobe of the left ear, and thermal stimulation is applied to the arms.
89373922|NCT02783274|Other|Actis Total Hip System|The Actis DuoFix Femoral Stem can be used for both a Total and Hemi-hip Replacement
89373923|NCT02752035|Experimental|Dose escalation of ASP2215 given with azacitidine|Subjects will be treated with ASP2215 daily (days 1-28) and azacitidine daily for 7 days (days 1-7).
89373924|NCT02752035|Experimental|Arm A: ASP2215|Subjects will be treated daily each 28-day cycle.
89373925|NCT02752035|Experimental|Arm AC: ASP2215 + azacitidine|Subjects will be treated with ASP2215 daily and azacitidine daily for 7 days (days 1-7) each 28-day cycle.
89373926|NCT02752035|Active Comparator|Arm C: azacitidine|Subjects will be treated with azacitidine for 7 days (days 1-7) each 28-day cycle.
89373927|NCT02737956||AMI patients with treatment of PCI|All the patiets treat with PCI were enrolled and recorded the clinical characteristic and outcomes during the follow-up period.
89373928|NCT02737956||Medication|All the patiets treat with medication (standard secondary prevention) without PCI were enrolled and recorded the clinical characteristic and outcomes during the follow-up period.
89373929|NCT02720068|Experimental|Part A: Favezelimab Dose A|Participants receive favezelimab Dose A intravenous (IV) infusion on Day 1 of each 21-day cycle.
89373930|NCT02720068|Experimental|Part A: Favezelimab Dose B|Participants receive favezelimab Dose B IV infusion on Day 1 of each 21-day cycle.
89373931|NCT02720068|Experimental|Part A: Favezelimab Dose C|Participants receive favezelimab Dose C IV infusion on Day 1 of each 21-day cycle.
88845907|NCT03438266|Other|JUVÉDERM VOLUMA® XC Injectable Gel with Needle|Participants had 1 cheek treated with JUVÉDERM VOLUMA® XC injectable gel with a needle.
88845908|NCT03438578|Experimental|Efficacy Safety Score monitoring|Patients monitored with wireless vital signs and Efficacy Safety Score after discharge from the post-anesthesia care unit to an ordinary ward
88845909|NCT03438578|No Intervention|Regular|Patients receiving standard postoperative care after discharge from the post-anesthesia care unit to an ordinary ward
88845910|NCT03315104|Experimental|FLU-IGIV High Dose|"Participants will receive a single infusion of high dose of FLU-IGIV, administered over approximately 3 hours on Day 1. Participants will also receive standard of care (SOC) antiviral treatment for flu. Administered intravenously at a dose of 450 mL of 65 g/mL FLU-IGIV diluted to 500 mL with normal saline. Participants also received standard of care (SOC) antiviral treatment for flu.~FLU-IGIV: Single dose, sterile liquid formulation for IV administration."
89373932|NCT02720068|Experimental|Part A: Favezelimab Dose D|Participants receive favezelimab Dose D IV infusion on Day 1 of each 21-day cycle.
89373933|NCT02720068|Experimental|Part A: Favezelimab Dose E|Participants receive favezelimab Dose E IV infusion on Day 1 of each 21-day cycle.
89373934|NCT02720068|Experimental|Part A: Favezelimab Dose A+Pembro|Participants receive favezelimab Dose A IV infusion on Day 1 of each 21-day cycle PLUS pembrolizumab IV infusion administered sequentially on Day 1 of each 21-day cycle.
89373935|NCT02720068|Experimental|Part A: Favezelimab Dose B+Pembro|Participants receive favezelimab Dose B IV infusion on Day 1 of each 21-day cycle PLUS pembrolizumab IV infusion administered sequentially on Day 1 of each 21-day cycle.
89373936|NCT02720068|Experimental|Part A: Favezelimab Dose C+Pembro|Participants receive favezelimab Dose C IV infusion on Day 1 of each 21-day cycle PLUS pembrolizumab IV infusion administered sequentially on Day 1 of each 21-day cycle.
89373937|NCT02720068|Experimental|Part A: Favezelimab Dose D+Pembro|Participants receive favezelimab Dose D IV infusion on Day 1 of each 21-day cycle PLUS pembrolizumab IV infusion administered sequentially on Day 1 of each 21-day cycle.
89373938|NCT02720068|Experimental|Part A: Favezelimab Dose E+Pembro|Participants receive favezelimab Dose E IV infusion on Day 1 of each 21-day cycle PLUS pembrolizumab IV infusion administered sequentially on Day 1 of each 21-day cycle.
89373939|NCT02720068|Experimental|Part B: Favezelimab Monotherapy Dose|Participants receive favezelimab monotherapy dose IV infusion on Day 1 of each 21-day cycle.
89373940|NCT02720068|Experimental|Part B: Favezelimab Dose F+Pembro|Participants receive favezelimab Dose F IV infusion on Day 1 of each 21-day cycle PLUS pembrolizumab IV infusion administered sequentially on Day 1 of each 21-day cycle.
89373941|NCT02720068|Experimental|Part B: Favezelimab Dose G+Pembro|Participants receive favezelimab Dose G IV infusion on Day 1 of each 21-day cycle PLUS pembrolizumab IV infusion administered sequentially on Day 1 of each 21-day cycle.
89373942|NCT02720068|Experimental|Part B: Favezelimab Dose H+Pembro|Participants receive favezelimab Dose H IV infusion on Day 1 of each 21-day cycle PLUS pembrolizumab IV infusion administered sequentially on Day 1 of each 21-day cycle.
89535019|NCT03324971|Experimental|Diabetic patients with non-adherence and poly-pharmacy|Medications review. Elimination of all unnecessary prescription to cut down the number of medications to the least possible number.
88845911|NCT03315104|Experimental|FLU-IGIV Low Dose|"Participants will receive a single infusion of low dose of FLU-IGIV, administered over approximately 3 hours on Day 1. Participants will also receive SOC antiviral treatment for flu. Administered intravenously at a dose of 225 mL of 65 g/mL FLU-IGIV diluted to 500 mL with normal saline. Participants also received standard of care (SOC) antiviral treatment for flu.~FLU-IGIV: Single dose, sterile liquid formulation for IV administration."
89002271|NCT05725928|No Intervention|Usual Care|No intervention
88845912|NCT03315104|Placebo Comparator|FLU-IGIV Placebo|"Participants will receive a single infusion of placebo for FLU-IGIV, administered over approximately 3 hours on Day 1. Participants will also receive SOC antiviral treatment for flu. Administered IV as 500 mL of normal saline. Participants also received standard of care (SOC) antiviral treatment for flu.~Placebo for FLU-IGIV: Single dose, normal saline solution for IV administration."
88845913|NCT03228914|Active Comparator|Oxymetazoline|Pledgets will be soaked in 0.05% oxymetazoline solution Two pledgets with the associated medication will be placed into the nasal cavity; one along the floor of the nose and another directed towards the middle meatus.
88845914|NCT03228914|Active Comparator|Epinephrine|Pledgets will be soaked in 1:1000 epinephrine solution Two pledgets with the associated medication will be placed into the nasal cavity; one along the floor of the nose and another directed towards the middle meatus.
89373943|NCT02720068|Experimental|Part B: Favezelimab Dose G+Pembro+mFOLFOX7|Participants receive favezelimab Dose G IV infusion on Day 1 of each 21-day cycle PLUS pembrolizumab IV infusion administered sequentially on Day 1 of each 21-day cycle PLUS mFOLFOX7 (oxaliplatin 85 mg/m^2 IV, leucovorin [calcium folinate] 400 mg/m^2 IV and fluorouracil [5-FU] 2400 mg/m^2 IV over 46 to 48 hours every 2 weeks [Q2W]).
89373944|NCT02720068|Experimental|Part B: Favezelimab Dose G+Pembro+FOLFIRI|Participants receive favezelimab Dose G IV infusion on Day 1 of each 21-day cycle PLUS pembrolizumab IV administered sequentially on Day 1 of each 21-day cycle PLUS FOLFIRI (irinotecan 180 mg/m^2 IV, leucovorin [calcium folinate] 400 mg/m^2 IV and 5-FU 2400 mg/m^2 IV over 46 to 48 hours Q2W).
88845915|NCT03315572||Pediatric subject/caregiver dyads-first interview set|The first interview set will consist of eight pediatric subject/caregiver dyads including pediatric subjects with asthma currently using a maintenance inhaler and his or her caregiver. The pediatric subjects and their caregivers will be asked questions regarding ease of use of ELLIPTA inhaler.
88845916|NCT03315572||Pediatric subject/caregiver dyads-second interview set|The second interview set will consist of eight pediatric subject/caregiver dyads including pediatric subjects with asthma currently using a maintenance inhaler and his or her caregiver. The pediatric subjects and their caregivers will be asked questions regarding ease of use of ELLIPTA inhaler.
88845917|NCT03232580|Experimental|rhAnnexin V-128|All patients received a single i.v injection of 99mTc-rhAnnexin V-128 at Day 0.
88845918|NCT03316976|Experimental|Group 1: Dexlansoprazole 30 mg|Dexlansoprazole 30 mg, delayed-release, capsule, orally, administered as single dose on Day 1.
88845919|NCT03316976|Experimental|Group 2: Dexlansoprazole 60 mg|Dexlansoprazole 60 mg, delayed-release, capsule, orally, administered as single dose on Day 1.
88845920|NCT03317288|Other|SCI subjects|The subject act as his or her own control. Each subject will undergo two procedures, intervention: alternating pressure overlay on top of standard operation room overlay, vs. control: operation room overlay.
89373945|NCT02720068|Experimental|Part B: Favezelimab/Pembrolizumab|Participants receive favezelimab/pembrolizumab (favezelimab and pembrolizumab administered as a co-formulation) IV infusion on Day 1 of each 21-day cycle.
88845921|NCT03317444|Experimental|TRC101|Administered once daily (QD) for 12 weeks
88845922|NCT03317444|Placebo Comparator|Placebo|Administered once daily (QD) for 12 weeks
89373946|NCT02720068|Experimental|Part B: Favezelimab Dose G+Pembro+Lenvatinib|Participants receive favezelimab Dose G IV infusion on Day 1 of each 21 day cycle PLUS pembrolizumab IV infusion administered sequentially on Day 1 of each 21-day cycle PLUS oral lenvatinib (20 mg) each day of 21-day cycle.
89373947|NCT02707042|Other|Group A|Control
89373948|NCT02707042|Other|Group B|Amoxicillin
89373949|NCT02707042|Other|Group C|Azithromycin
89373950|NCT02706639||SVAS group|Children or adults must: be between the ages of 0-85; have clinical features of SVAS; SVAS-like condition; have genetic testing results that imply affected status (SVAS has decreased penetrance)
89373951|NCT02706639||WS group|Children or adults must: be between the ages of 0 and 85; have a presumed or confirmed diagnosis of WS; have a parent/guardian available to provide consent and assist in answering medical questions
89373952|NCT02706639||WS region gene changes|Children or adults must: be between the ages of 0-85; have clinical or research genetic testing that reports gene variation in one or more genes in the WS region (ELN variants alone will be considered in the SVAS category but other changes to the region that include ELN plus other genes may be grouped in this category).
89373953|NCT02706353|Experimental|APX005M + Pembrolizumab|"Dose Escalation Phase:~Starting dose level of APX005M is 0.1 mg injected directly into 1-3 tumors every 3 weeks (Weeks 0, 3, 6, and 9) for up to 4 doses. Tumor site chosen based on volume to be injected.~All participants receive Pembrolizumab at 2 mg/kg by vein 1 time every 3 weeks (Weeks 0, 3, 6, 9, and 12). First dose of Pembrolizumab given 1-2 days before or after first dose of APX005M.~Dose Expansion Phase:~Starting dose level of APX005M is maximum tolerated dose from Dose Escalation Phase.~Participants receive same dosage of Pembrolizumab as in Dose Escalation Phase."
89373954|NCT02682147|Experimental|Hypoxia Administration study group|40 subjects will be recruited to study normoxia oxygen compared to hypoxia oxygen. 20M and 20F subjects will be evaluated under normoxia oxygen with low dose non-contrast CT scans at total lung capacity (TLC) and 20% vital capacity (VC) and then with contrast using dual energy CT scans to evaluate heterogeneity of perfused blood volume (PBV). For the intervention, following the normixia scans, hypoxia administration will be administered by breathing an inspired FIO2 of 15% oxygen and the non-contrast and contrast using DECT scans to evaluate heterogeneity of perfused blood volumen will be completed.
89399311|NCT03539354|Active Comparator|CABG + b-blockers|Standart coronary artery bypass grafting is performed with b-blockers treatment. Continuous ECG during intensive care unit stay, daily ECG, and 24-h Holter monitor recordings will be performed at 7, 14, 21, and 30 days after coronary artery bypass grafting, external loop recorder after discharge from intensive care unit till 30 days after coronary artery bypass grafting.
89373955|NCT02682147|Experimental|Hyperoxia Administration study group|40 subjects will recruited to study normoxia oxygen scans compared to hyperoxia scans. 20M and 20F subjects will be evaluated under normoxia with low dose non-contrast CT scans at TLC and 20% vital capacity (VC) and then with contrast scans using DECT to evaluate heterogeneity of perfused blood volume (PBV). For the intervention, following the normoxia scans, hyperoxia administration will be administered by breathing an inspired FIO2 of 100% oxygen and the non-contrast and contrast using DECT to evaluate heterogeneity of perfused blood volumen will be completed.
88845923|NCT03442868|Experimental|High frequency rTMS|High frequency rTMS will be applied to different neural loci based on the randomized sessions.
88845924|NCT03234374|Experimental|INL-001|3 x 100 mg INL-001 (bupivacaine HCl collagen implants). Total bupivacaine HCl dose 300 mg.
88845925|NCT03234374|Active Comparator|Marcaine 0.25% infiltration|Marcaine 0.25% infiltration (bupivacaine HCl 175 mg).
88845926|NCT04332536|Experimental|Chronic Heart Failure|
88845927|NCT04332536|Active Comparator|Age-matched healthy controls|
88845928|NCT03236168|Other|Intervention Arm|This study consists of a single treatment arm. Patients will receive Ivermectin or where contraindicated (Pregnancy, Breastfeeding, Weight <15kg) Permethrin Cream and Malathion shampoo
88845929|NCT03306589|Experimental|Subjects receiving LPS: Part I and Part II|Eligible subjects will be randomized to receive LPS in a dose-escalation manner ranging from 0.5 nanogram (ng)/kg to 4 ng/kg. Subjects will be hydrated prior to administration of LPS with normal saline at a rate of 250 mL/hour for 4 hours prior to dosing and 8 hours after dosing.
88845930|NCT03306589|Experimental|Subjects receiving GM-CSF: Part I and Part II|Eligible subjects will be randomized to receive GM-CSF in a dose-escalation manner ranging from 5 to 15 microgram (µg)/kg.
88845931|NCT03320096|Experimental|Microfocused ultrasound with visualization|
88845932|NCT03309787||Amulet only|As per usual care participants will receive an eHealth (Amulet + videoconferencing) intervention over a 16 week period of time.
88845933|NCT03309787||Amulet/Fitbit|As per usual care participants will receive an eHealth (Amulet/Fitbit + videoconferencing) intervention over a 16 week period of time.
88845934|NCT03309787||Fitbit only|As per usual care participants will receive an eHealth (Fitbit + videoconferencing) intervention over a 16 week period of time.
88845935|NCT03446846|Experimental|5.0 mg MIN-117|MIN-117 5.0 mg (consisting of two 2.5 mg capsules) orally daily for 6 weeks
88845936|NCT03446846|Experimental|2.5 mg MIN-117|MIN-117 2.5 mg (consisting of one 2.5 mg capsule and one placebo capsule) orally daily for 6 weeks
88845937|NCT03446846|Placebo Comparator|Placebo|Placebo (consisting of two placebo capsules) orally daily for 6 weeks
88845938|NCT03312517|Active Comparator|Suvorexant 10mg|Subjects will receive belsomra 10mg before bedtime. In the middle of the night, subjects will be awakened to auditory awakening tones.
88845939|NCT03312517|Active Comparator|Suvorexant 20mg|Subjects will receive belsomra 20mg before bedtime. In the middle of the night, subjects will be awakened to auditory awakening tones.
88845940|NCT03312517|Sham Comparator|Placebo oral capsule|Subjects will receive placebo before bedtime. In the middle of the night, subjects will be awakened to auditory awakening tones.
88845941|NCT03449342|Experimental|Turoctocog alfa|Previously treated moderate or severe haemophilia A patients will receive routine prophylaxis treatment and treatment of bleeding episodes.
89373956|NCT02682147|Experimental|Sildenafil|40 subjects (20M and 20F) will be recruited to study non-contrast imaging at TLC and 20%VC and with contrast using DECT scans to assess perfused blood volume. For the intervention, the subject will be administered 20 mg of sildenafil and then the same scanning will be repeated one hour after sildenafil administration.
88845942|NCT03312595|Other|Restrata TM Wound Matrix|Prospective, single armed, non-randomized study with direct assignment
88845943|NCT03315559|Experimental|Subjects receiving GSK2269557 in treatment period 1|Eligible subjects will receive IV infusion of [14C] radiolabelled GSK2269557 with a single dose of 10 micrograms (µg) administered as single microtracer, concomitantly with an inhaled nonradiolabelled 1000 µg dose of GSK2269557. There will be a washout of at least 14 days after inhaled and IV dosing before subjects receive treatment 2.
88845944|NCT03315559|Experimental|Subjects receiving GSK2269557 in treatment period 2|Eligible subjects will receive [14C]-GSK2269557 with a single dose of 800 µg, administered as an oral solution.
89373958|NCT02568267|Experimental|NTRK1/2/3-rearranged NSCLC|Oral entrectinib (RXDX-101)
89373959|NCT02568267|Experimental|ROS1-rearranged NSCLC|Oral entrectinib (RXDX-101)
88845945|NCT03239522|Experimental|All participants receiving treatment|Each participant will receive a single 6 milligram (mg) oral dose of daprodustat on Day 1 of period 1. After approximately 1 hour, participants will receive 50 microgram (µg) of [14C]-GSK1278863 by IV infusion over 1 hour. On Day 1 of period 2, each participant will receive 25 mg [14C]-GSK1278863 as an oral solution.
88845946|NCT03315949|Experimental|Same-day dose group|Participants who ingest bowel cleanser on the day of colonoscopy. Participant will ingest the 4L PEG on the day of colonoscopy.
88845947|NCT03315949|Active Comparator|Split-dose group|Participants who ingest bowel cleanser by split dose. 2L PEG will be ingested 1 day before colonoscopy. Remaining 2L bowel cleanser will be ingested on the day of colonoscopy.
88845948|NCT03241862|Experimental|Restylane® Silk|All subjects enrolled in the study will undergo lip rejuvenation treatment with Restylane® Silk.
88845949|NCT04332770||Hypothyroid group|Patients with differentiated thyroid carcinoma underwent total thyroidectomy Patients who are planned to withdraw their levothyroxine for radioactive iodine therapy Biosignals will be monitored continuously using Fitbit devices
89181332|NCT00772928|Experimental|Pentacel™ staggered schedule with Prevnar®|Participants had Pentacel™ given at different times from Prevnar® (using a standardized, staggered schedule).
89181333|NCT00762476|Placebo Comparator|Placebo|
89181334|NCT00762476|Experimental|3804-250A|
89181335|NCT02585661|Active Comparator|Dairy product + Salt 1|Dairy product fortified with enriched Fe-54 salt (1)
89181336|NCT02585661|Experimental|Dairy product + Salt 2|Dairy product fortified with enriched Fe-57 salt (2)
89373960|NCT02568267|Experimental|ALK- or ROS1-rearranged NSCLC|"with CNS-only progression previously treated with crizotinib (NOTE: The ALK-rearranged portion of this arm is now closed to enrollment.)~Oral entrectinib (RXDX-101)"
88845950|NCT04332770||Control group|Patients with differentiated thyroid carcinoma underwent total thyroidectomy Patients who are planned to get rhTSH (not to withdraw their levothyroxine) for radioactive iodine therapy Biosignals will be monitored continuously using Fitbit devices
88845951|NCT03328208|Experimental|Comfort Talk® App Group|Patients will receive a tablet preloaded with the Comfort Talk® app in the dental waiting room on an intent-to-treat basis. They can listen as much or as little as they wish during waiting and during their dental treatment. Upon departure, they will receive a download coupon for the app for home use.
88845952|NCT03328208|Active Comparator|White Noise Group|Patients will receive a tablet preloaded with a white noise app in the dental waiting room on an intent-to-treat basis. They can listen as much or as little as they wish during waiting and during their dental treatment.
88845953|NCT03210337|Experimental|Active|A-101 Topical Solution
88845954|NCT03210337|Placebo Comparator|Vehicle|Vehicle
88845955|NCT03242408|Experimental|Oral testosterone undecanoate, LPCN 1021|Oral testosterone undecanoate, LPCN 1021 150 mg TU three times a day
88845956|NCT03242954|Active Comparator|Adolescents: Consent Condition 1|Autonomous minor consent
88845957|NCT03242954|Active Comparator|Adolescents: Consent Condition 2|Adult permission required
88845958|NCT03242954|Active Comparator|Adolescents: Consent Condition 3|Parental permission required
88845959|NCT03242954|Active Comparator|Parents: Consent Conditions 1-3|Autonomous minor consent, adult permission required, and parental permission required
88845960|NCT03459794|Active Comparator|Ivermectin|Ivermectin will be administered once at 150mcg/kg, orally.
88845961|NCT03459794|Placebo Comparator|Control|An oral placebo will be administered once
88845962|NCT03211117|Experimental|Cohort A (pembrolizumab, surgery, chemoradiation)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment with pembrolizumab repeats every 21 days for up to 17 courses after chemoradiation if no residual disease is found or for up to 35 courses after chemoradiation if residual disease is found. After 3 days, patients undergo surgery. Within 42 days of surgery, patients also receive docetaxel IV over 1 hour Q1W and doxorubicin hydrochloride IV Q1W, and undergo IMRT once daily 5 days per week for 6.5 weeks in the absence of disease progression or unacceptable toxicity.
88845963|NCT03211117|Experimental|Cohort B (pembrolizumab, chemoradiation)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment with pembrolizumab repeats every 21 days for up to 17 courses after chemoradiation if no residual disease is found or for up to 35 courses after chemoradiation if residual disease is found. After 3 days, patients also receive docetaxel IV over 1 hour Q1W and doxorubicin hydrochloride IV Q1W, and undergo IMRT once daily 5 days per week for 6.5 weeks in the absence of disease progression or unacceptable toxicity.
88845964|NCT03436147||Vaginal Assisted Laparoscopic Sacrohysteropexy(VALH)|Patients who were performed vaginal assisted laparoscopic sacrohysteropexy (VALH)
88845965|NCT03436147||Vaginal Hysterectomy and Vaginal vault suspension (VAH+VVS)|Patients who were performed vaginal hysterectomy and vaginal vault suspension(VAH+VVS)
88845966|NCT03245372|Active Comparator|Standard care|Basic intraoperative hemodynamic objectives
88845967|NCT03245372|Experimental|Goal directed therapy|Target value is a cardiac index equal or superior to 2.2 l/min/m2.
88845968|NCT03317431||ventilation|patients undergoing selective operation with general anesthesia(GA) and mechanical ventilation(MV)
88845969|NCT03460652|Experimental|Open-Label KP415|"KP415 (serdexmethylphenidate [SDX] Cl/ d-methylphenidate [d-MPH] HCl) oral capsule:~28/6 mg SDX/d-MPH (molar equivalent to 20 mg d-MPH HCl), 42/9 mg SDX/d-MPH (molar equivalent to 30 mg d-MPH HCl), 56/12 mg SDX/d-MPH (molar equivalent to 40 mg d-MPH HCl)"
88845970|NCT03321097|Experimental|condensed RT group|Training session included 45 minutes RT, followed by 30-minute functional training. The condensed group will receive 4 sessions per week, for 6 weeks.
88845971|NCT03321097|Experimental|distributed RT Group|Training session included 45 minutes RT, followed by 30-minute functional training. The distributed group 2 sessions per week, for 12 weeks.
88845972|NCT03245762|Active Comparator|Intranasal oxytocin|Intervention: 4 IU/day of intranasal oxytocin via a nasal spray device each morning.
88845973|NCT03245762|Placebo Comparator|IN-placebo|Intervention: 4 IU/day of placebo via nasal spray device each morning.
88845974|NCT03321253|Experimental|Nd: YAG laser posterior capsulotomy|Posterior capsulotomy was performed by using Nd: YAG laser and macular pigment optical density, intra ocular pressure, choroidal thickness, macular thickness and anterior chamber parameters were measured before Nd: YAG laser, at 1 week, 1 month and 2 months
88845975|NCT03322657|Active Comparator|Neostigmine with glycopyrrolate|Neostigmine 0. 07 mg/kg with glycopyrrolate 0.01 mg/kg with ceiling dose of 5 mg neostigmine with 1 mg of glycopyrrolate at the end surgery
88845976|NCT03322657|Experimental|Sugammadex|Sugammadex 4 mg/kg at the end surgery
88845977|NCT03247322|Experimental|mHealth Group|Patients in the intervention cohort will have enhanced medication safety monitoring utilizing a Pharmacist-led medication therapy using mHealth application. The application will provide patients a useful tool to conduct self-care monitoring and management, including timely reminders to take medications, automated messages when patients miss multiple medication doses, tracking of medication side effects and reporting trends in blood pressures and glucoses (when applicable).
88845978|NCT03247322|No Intervention|Usual Care Group|Subjects in the control group will receive the usual standard of follow up care for kidney transplant patients.
88845979|NCT04332679|Active Comparator|Group A - control group|20 patients treated by means of a dense PTFE (d-PTFE) titanium-reinforced membrane (Cytoplast Ti-250XL; Osteogenics Biomedical) and simultaneous implants placement (BT SAFE; Biotec srl, Vicenza, Italy).
88845980|NCT04332679|Experimental|Group B - Test group|20 patients treated by means of Ti mesh (Trinon Titanium; Karlsruhe, Germany) and cross-linked collagen membrane (Osseoguard, Zimmer Biomet, Warsaw, IN, USA) and simultaneous implants placement (BT SAFE; Biotec srl, Vicenza, Italy).
88845981|NCT03324451|Experimental|Intervention arm|"The arm that receives TTM Intervention for Insulin Initiation. The intervention contains two parts: (1) individual intervention; (2) insulin injection follow-up management"
89181337|NCT00762164|Active Comparator|1Vytorin 10/80 divided into 4|Vytorin 10/80 divided into 4
89002272|NCT05725928|Experimental|Mobility Technician|Designated mobility technicians (MT) will ambulate hospitalized medical patients up to 3 times daily, 7 days per week, until discharge or a maximum of 10 days. Each day, the MT will visit the patient 4 times or until the patient successfully ambulates 3 times that day. In cases where a PT has provided a recommendation in the patient's chart, the MT will follow the recommendation, if feasible. Otherwise, the MT will execute the standard mobility protocol. The mobility protocol will allow the MT to assist a patient with an appropriate out-of-bed activity based on their 6-clicks score from the immediately preceding session
89373961|NCT02568267|Experimental|NTRK/1/2/3-rearranged mCRC|Oral entrectinib (RXDX-101)
89373962|NCT02568267|Experimental|ROS1-rearranged mCRC|Oral entrectinib (RXDX-101)
89373963|NCT02568267|Experimental|ALK-rearranged mCRC|Oral entrectinib (RXDX-101)
89373964|NCT02568267|Experimental|NTRK1/2/3-rearranged other solid tumor|Oral entrectinib (RXDX-101)
89373965|NCT02568267|Experimental|ROS1-rearranged other solid tumor|Oral entrectinib (RXDX-101)
89373966|NCT02568267|Experimental|ALK-rearranged other solid tumor|Oral entrectinib (RXDX-101)
89373967|NCT02543996||Affected or unaffected cohorts (including genetic carriers or non-carriers as|Affected or unaffected cohorts (including genetic carriers or non-carriers as reference biospecimens)
89373968|NCT02498613|Experimental|Treatment (cediranib maleate, olaparib)|Patients receive cediranib maleate PO QD on day 1. Patients undergoing FMISO scan also receive olaparib PO BID beginning the day after the second FMISO scan and the rest of the patients receive olaparib PO BID beginning day 4 of cycle 1. Cycles repeat every 28 days (35 days for cycle 1) in the absence of disease progression or unacceptable toxicity.
89373969|NCT02489318|Experimental|Apalutamide plus ADT|Participants will receive apalutamide 240 milligram (mg) (4X 60 mg tablets) with ADT.
89373970|NCT02489318|Experimental|Placebo plus ADT|Participants will receive matching Placebo with ADT.
89373971|NCT02368041||InSpectraTM StO2|InSpectraTM StO2 monitor manufactured by Hutchinson Technology Inc. to measure the baseline StO2 level after applying the noninvasive probe to the thenar eminence. After a stable reading is obtained a blood pressure cuff will be inflated 40 mmHg above the obtained systolic pressure and the rate of desaturation (Rdes; % × sec-1) will be recorded. After 3 minutes or once the StO2 level comes to zero, whichever is earlier the cuff pressure will be released instantaneously and the rate of reperfusion (Rres; % × sec-1) will be measured. The measurement will be continued until the StO2 returns to the baseline value.
89373974|NCT02277444|Experimental|Golimumab + Methotrexate|Participants will receive 80 milligram per meter square (mg/m^2) as an intravenous (IV) infusion at Weeks 0, 4, and every 8 weeks thereafter up to Week 244, along with commercial methotrexate (MTX) weekly through Week 28 at the same Body Surface Area (BSA)-based dosage (10 to 30 mg/m^2 per week for participants with BSA less than [<] 1.67 meter square (m^2), or minimum of 15 mg/week for participants with BSA greater than or equal to [>=] 1.67 m^2) as at the time of study entry. At Week 252, participants who meet the criteria for the optional Extended Treatment Period (ETP) may continue treatment with golimumab 80 mg/m^2 every 8 weeks after completion of the Week 252 assessments.
89373975|NCT02257736|Experimental|Group 1: AAP and apalutamide|Participants will receive apalutamide 240 milligram (mg) (4*60 mg tablets) and abiraterone acetate (AA) 1000 mg (4*250 mg tablets) once daily on an empty stomach and 5 mg prednisone (P), AAP, twice daily, until disease progression, unacceptable toxicity or end of treatment, whichever occurs first. After unblinding participants will be offered further treatment as defined in the Open-Label Extension (OLE) or Long-Term Extension (LTE) phase (AAP + open label apalutamide or AAP alone).
89373976|NCT02257736|Placebo Comparator|Group 2: AAP and Placebo|Participants will receive matching Placebo of apalutamide and abiraterone acetate (AA) 1000 mg (4*250 mg tablets) once daily on an empty stomach and 5 mg prednisone (P), AAP, twice daily until disease progression, unacceptable toxicity or end of treatment, whichever occurs first. After unblinding participants will be offered further treatment as defined in the OLE or LTE phase (AAP + open label apalutamide or AAP alone).
89373977|NCT02252172|Active Comparator|Lenalidomide and Dexamethasone (Rd)|Participants will receive Lenalidomide 25 mg capsule orally on Day 1 through Day 21 of each 28-day cycle, Dexamethasone 40 mg orally or intravenously once a week. Study treatment continues until disease progression, unacceptable toxicity, or end of study (maximum up to 7 years after last subject is randomized) whichever comes first.
89373978|NCT02252172|Active Comparator|Daratumumab + Lenalidomide + Dexamethasone (DRd)|Participants will receive Daratumumab 16 milligram per kilogram (mg/kg) by intravenous infusion, once a week for 8 weeks, then once every other week for 16 weeks, thereafter once every 4 weeks, Lenalidomide 25 mg capsule orally on Day 1 through Day 21 of each 28-day cycle, Dexamethasone 40 mg orally or intravenously once a week. Following implementation of protocol amendment 8, participants still receiving treatment with daratumumab IV will have the option to switch to daratumumab SC on Day 1 of any cycle, at the discretion of the investigator. Daratumumab subcutaneous (SC) will be administered by SC injection at a fixed dose of 1800 mg once every 4 weeks until documented progression, unacceptable toxicity, or study completion. Study treatment continues until disease progression, unacceptable toxicity, or end of study (maximum up to 7 years after last subject is randomized) whichever comes first.
89373979|NCT02194738|Experimental|A081105 Arm A (blinded erlotinib hydrochloride)|Blinded patients receive erlotinib hydrochloride PO QD on days 1-21. Treatment repeats every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity. (CLOSED 06/14/17)
89373980|NCT02194738|Placebo Comparator|A081105 Arm B (placebo)|Patients receive placebo PO QD on days 1-21. Treatment repeats every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity. (CLOSED 06/14/17)
89373981|NCT02194738|Experimental|A081105 Arm C (unblinded erlotinib hydrochloride)|Unblinded patients receive erlotinib hydrochloride PO QD on days 1-21. Treatment repeats every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
89002273|NCT05724914||Cardiac Arrest|Out-Of-Hospital Cardiac Arrest
89002274|NCT06319235|Experimental|Investigational arm|DUOFAG® (the investigational medicinal product - IMP) will be administered twice a day for two weeks. DUOFAG® will be sprayed on the surgical wound. The phage titers of each bacteriophage in DUOFAG® is ≥ 10 000 000 PFU/mL (PFU = plaque forming units).
89181338|NCT00762164|Active Comparator|Simvastatin|Simvastatin 20 milligrams
89373982|NCT02194738|Active Comparator|A081105 Arm D (observation)|Patients (including patients previously randomized to placebo) undergo observation at least every 6 months for 2 years.
89373983|NCT02194738|Active Comparator|A081801 Arm A (platinum doublet, observation)|"INITIAL THERAPY: Patients receive 1 of 4 platinum doublet regimens based on the treating physician's choice. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.~CONTINUANCE THERAPY: Patients then undergo observation."
89373984|NCT02194738|Experimental|A081801 Arm B (platinum doublet, sequential pembrolizumab)|"INITIAL THERAPY: Patients receive 1 of 4 platinum doublet regimens based on the treating physician's choice. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.~CONTINUANCE THERAPY: Patients then receive pembrolizumab IV over 25-40 minutes on day 1. Treatment repeats every 21 days for 17 cycles in the absence of disease progression or unacceptable toxicity."
89373985|NCT02194738|Experimental|A081801 Arm C (platinum doublet, combination pembrolizumab)|"INITIAL THERAPY: Patients receive 1 of 4 platinum doublet regimens based on the treating physician's choice and pembrolizumab IV over 25-40 minutes on day 1. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.~CONTINUANCE THERAPY: Patients then receive pembrolizumab IV over 25-40 minutes on day 1. Treatment repeats every 21 days for 13 cycles in the absence of disease progression or unacceptable toxicity."
89373986|NCT02194738|Experimental|E4512 Arm A (crizotinib)|Patients receive crizotinib PO BID on days 1-21. Treatment repeats every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
89373987|NCT02194738|Active Comparator|E4512 Arm B (observation)|Patients undergo observation.
89373988|NCT02194738|Experimental|EA5142 Arm I (nivolumab)|Patients receive nivolumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 4 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and/or PET/CT throughout the trial and blood sample collection during screening and follow-up. Patients may undergo an ECHO as clinically indicated.
89373989|NCT02194738|Active Comparator|EA5142 Arm II (observation)|Patients are followed serially with CT and/or PET/CT imaging for up to 1 year and then during follow-up. Patients also undergo blood sample collection during screening and follow-up. Patients may undergo an ECHO as clinically indicated on study.
89373990|NCT02159833|Experimental|Intervention|Intranasal challenge with food protein or vehicle control
89373993|NCT02116764||Cross Sectional|3 years after Transplant
89373994|NCT02116764||No Transplant|These patients were diagnosed with CGD but have not been transplanted
89373995|NCT02116764||Prospective|Prior to Transplant Conditioning
89373996|NCT02116764||Retrospective|1 year after Transplant
89373997|NCT02108652|Experimental|Cohort 2: Participants With Second-line or Beyond Treatments|Participants with advanced disease who had disease progression during or following treatment with at least one platinum-containing chemotherapy regimen in the metastatic setting will receive atezolizumab 1200 mg via IV infusion on Day 1 of 21-day cycles until loss of clinical benefit or unmanageable toxicity.
89373998|NCT02096211||CERAMAX COC 36mm Acetabular Cup|The CERAMAX 36mm ceramic acetabular bearing insert component is manufactured from high purity, dense alumina matrix composite ceramic.The insert is available in several inner diameter sizes, including 36mm; only 36mm inserts will be utilized in this PAS. The inserts secure to DePuy's Pinnacle acetabular shells by means of an interlocking mechanical taper.
89373999|NCT02076009|Experimental|Daratumumab + lenalidomide + dexamethasone|During each 28-day treatment cycle, participants will receive daratumumab, lenalidomide, and dexamethasone.
89374000|NCT02076009|Active Comparator|Lenalidomide + dexamethasone|During each 28-day treatment cycle, participants will receive lenalidomide and dexamethasone.
89374001|NCT01971528|No Intervention|Stage 1: Health control|pilot study: Establishing the central and peripheral contributing factors to the voluntary muscle strength loss during a fatiguing exercise in young and PD groups.
89374002|NCT01971528|No Intervention|Stage 1: PD subjects|pilot study: Establishing the central and peripheral contributing factors to the voluntary muscle strength loss during a fatiguing exercise in young and PD groups.
89374003|NCT01971528|No Intervention|Stage 2: Health subjects|pilot study: Finding optimal sensory stimulation parameters for PD individuals.
89374004|NCT01971528|No Intervention|Stage 2: PD subjects|pilot study: Finding optimal sensory stimulation parameters for PD individuals.
88845982|NCT03324451|Placebo Comparator|Control arm|The arm that receives usual care from the hospital that hosts the control arm. Participants in the control arm receives regular patient education.
88845983|NCT03324607|Experimental|single arm|glycopyrrolate/formoterol (Bevespi) 2 puffs twice a day taken for two weeks, started after completion of the study XeMRI. A follow up xeMRI occurs at the end of the two weeks of taking the Bevespi in a Pre-post study design.
88845984|NCT03247790|Experimental|Lasmiditan (Period 1)|200 mg Lasmiditan tablet given once orally during migraine attack.
88845985|NCT03247790|Experimental|Lasmiditan (Period 2)|200 mg Lasmiditan tablet given once orally during inter-ictal period.
88845986|NCT03249116|Active Comparator|Control - interaction with a stuffed dog|Active control - interaction with a stuffed dog
88845987|NCT03249116|Experimental|Therapy dog - social|animal-assisted intervention - social interaction only with therapy dog during stress task.
88845988|NCT03249116|Experimental|Therapy dog - Social + physical|animal-assisted intervention - Social interaction and physical interaction with therapy dog during stress task.
88845989|NCT03437863|Experimental|Mobile application|Participants recruited from a self-management course are asked to use (single time) a mobile application to support reflection of personal strengths. The participant borrows an Ipad and uses the application to 1) reflect and identify their strengths by reviewing a list of examples, 2) define personal goals, and 3) link strengths to goals.
88845990|NCT03467048|Experimental|McGrath videolaryngoscopy|Endotracheal intubation using McGrath videolaryngoscopy in an appropriate size (usually blade size 3 or 4)
88845991|NCT03467048|Active Comparator|Direct laryngoscopy|Endotracheal intubation using direct laryngoscopy with an appropriately sized Macintosh blade (usually size 3 or 4)
88845992|NCT03249272|Active Comparator|Hypertrophic cardiomyopathy|
88845993|NCT03249272|Active Comparator|Non-ischemic dilated cardiomyopathy|
88845994|NCT03249272|Active Comparator|Control|
88845995|NCT03249584|Other|OsteoCool™ RF Ablation|Subjects will undergo a single OsteoCool™ RF Ablation procedure.
88845996|NCT02182440|Placebo Comparator|Placebo|1 hour IV infusion once daily for 3 days
88845997|NCT02182440|Experimental|0.4 mg/kg (250 U/kg) recAP|1 hour IV infusion once daily for 3 days
88845998|NCT02182440|Experimental|0.8 mg/kg (500 U/kg) recAP|1 hour IV infusion once daily for 3 days
88845999|NCT02182440|Experimental|1.6 mg/kg (1000 U/kg) recAP|1 hour IV infusion once daily for 3 days
88846000|NCT03255902|Experimental|Families attending parenting classes|Families attended 6 parenting sessions, filled out daily glucose screens, & questionnaires
88846001|NCT03468920|Experimental|Arm 1: IV Acetaminophen group|Patients randomized to Arm 1 will receive IV Acetaminophen 1000mg in 100mL NS once and a PO placebo pill preoperatively
88846002|NCT03468920|Active Comparator|Arm 2: PO Acetaminophen group|Patients randomized to Arm 2 will receive IV normal saline 100mL once and Acetaminophen 1000 mg PO once preoperatively
88846003|NCT03470012|Experimental|Treatment Arm|Investigational tape
88846004|NCT03339206|Experimental|Constituent message with FDA and quitline|Messages about the chemical constituents of cigarette smoke will include text about chemicals in cigarette smoke and health effects of the chemicals, and an image of a person related to the health effect. This arm will also include an FDA logo, and information about the benefits of quitting smoking and the quitline. Each condition has 5 messages that will be repeated 3 times in a counterbalanced order. Study investigators used text developed by investigators associated with our Center for Regulatory Research on Tobacco Communication. Design of these messages was developed by our team.
88846005|NCT03339206|Experimental|Constituent message without FDA and quitline|Messages about the chemical constituents of cigarette smoke will include text about chemicals in cigarette smoke and health effects of the chemicals, and an image of a person related to the health effect. This arm is identical to the arm above, except that it does not include FDA source or quit information. Each condition has 5 messages that will be repeated 3 times in a counterbalanced order. Study investigators used text developed by investigators associated with our Center for Regulatory Research on Tobacco Communication. Design of these messages was developed by our team.
88846006|NCT03339206|Other|Littering message (Control)|Messages about littering cigarettes will include text designed to discourage people from littering their cigarette butts, and an image related to the message. Each condition has 5 messages that will be repeated 3 times in a counterbalanced order. Study investigators used text developed by investigators associated with our Center for Regulatory Research on Tobacco Communication. Design of these messages was developed by our team.
88846007|NCT02181816||Azilsartan/Amlodipine|Azilsartan/Amlodipine combination tablets (20 mg/2.5 mg or 20 mg/5 mg), orally, once daily for up to 12 months. Participants will receive interventions as part of routine medical care.
88846008|NCT03256136|Experimental|Nivolumab Plus Ipilimumab EGFR|Nivolumab administered intravenously every 2 weeks Ipilimumab administered intravenously every 6 weeks
88846009|NCT03256136|Experimental|Nivolumab Plus Ipilimumab ALK|Nivolumab administered intravenously every 2 weeks Ipilimumab administered intravenously every 6 weeks
88846010|NCT03256136|Experimental|Nivolumab + Carboplatin + Pemetrexed with EGFR Chemo naive|Nivolumab administered intravenously every 3 weeks Carboplatin administered intravenously every 3 weeks Pemetrexed administered intravenously every 3 weeks
88846011|NCT03256136|Experimental|Nivolumab + Carboplatin + Pemetrexed ALK Chemo naive|Nivolumab administered intravenously every 3 weeks Carboplatin administered intravenously every 3 weeks Pemetrexed administered intravenously every 3 weeks
88846012|NCT04735328|Other|Intervention|"When clinics join the intervention, leaders will receive leadership training through the Leadership and Organizational Change for Implementation (LOCI) intervention.~Therapists will receive training in evidence-based practices for treatment of Post-Traumatic Stress Symptoms (EMDR and CT-PTSD)."
88846013|NCT03260426|Experimental|Clear Liquid Diet|Clear liquids on postoperative day zero and intestinal rate measured by Abstats
88846014|NCT03260426|Experimental|Regular Solid Diet|Regular diet from postoperative day zero and intestinal rate measured by Abstats
88846015|NCT03340610|Other|Open Label Single Arm Trial|Evaluating the efficacy of Alflibercept Injections in DME Following Treatment With Bevacizumab and Ranibizumab
88846016|NCT03341546||Patient cohort|20 patients referred to Ninewells Hospital radiology department for an anterior-posterior abdomen x-ray examination. All of these patients will have a measurement of their anterior-posterior depth before undergoing their x-ray examination. An estimate of their anterior-posterior depth will then be made from their x-ray image using the computational model.
88846017|NCT03344510|Experimental|Kinetic anesthesia device, then no intervention|In this arm of the crossover study, participants will receive lidocaine injection in conjunction with the kinetic anesthesia device, then will receive an injection without the kinetic anesthesia device intervention
89002275|NCT06319235|Placebo Comparator|Control arm|Placebo (physiological saline solution - 0.9% sodium chloride solution) will be administered twice a day for two weeks. Placebo will be sprayed on the surgical wound.
89181339|NCT02585817|Experimental|Remote CIED Management|Patients with a CIED will undergo remote monitoring with information technology.
89181340|NCT00762086|Active Comparator|Treatment Group|AngioPress Intermittent pneumatic compression (IPC) Device
89181341|NCT00762086|Other|Control Group|Aspirin/Clopidegrol and Standard walking exercises
89181342|NCT04098614|Experimental|Recovery Coach Intervention|"Experimental: Recovery Coach Intervention Participants randomized to the intervention arm are linked to a recovery peer coach while they are in the hospital. Recovery peer coaches are provided to the participant by Faces and Voices of Recovery (FAVOR)~- Greenville. Recovery coaches are Certified Peer Support Specialists (CPSS), individuals who have firsthand experience in successful recovery and are trained in using recovery-oriented tools to help peers overcome addiction. FAVOR offers immediate access to a personal coach, a local center, and assistance to off-site intervention and recovery resources in the community. They provide twice weekly contact with participants."
89181343|NCT04098614|No Intervention|Standard of Care Control|Patients in the control condition receive the current standard of care, which entails a treatment referral with a list of addiction recovery facilities, groups, and resources. It is the patient's responsibility to call a treatment facility or group on the list and thus relies on self-referral. The medical team is not permitted to call a facility or group on behalf of the patient. The physician may counsel the patient on the dangers of substance abuse and addiction, but the extent of counseling is variable and dependent on the individual physician.
89181344|NCT00761774|Experimental|Brivaracetam|Brivaracetam at flexible dosing up to 200mg /day
89181345|NCT00583791|Experimental|Main Cohort|Device closure with the AMPLATZER Muscular VSD Occluder for patients with muscular ventricular septal defects which are hemodynamically significant and are either isolated or present in conjunction with other congenital heart defects.
89181346|NCT04080375|Experimental|dinoprostone 3 mg|patients will take 1 tablet of vaginal dinoprostone 1 hour before the surgery
89181347|NCT04080375|Placebo Comparator|placebo|patients will take 1 tablet of placebo 1 hour before the surgery
89181348|NCT00781274|Experimental|MP-424|
89181349|NCT02585739|Experimental|patient|patient with Cluster headache
89181350|NCT02585739|Other|healthy subject|patient without Cluster headache
89181351|NCT02585583|Other|Radiosurgical thalamotomy|Patients will undergo to radiosurgical thalamotomy by Cyberknife system.
89374005|NCT01971528|Experimental|Stage 3: PD subjects|Investigating the long-term effects of combined sensory stimulating strengthening program on the activation level and central fatigue in PD individuals.
89374006|NCT01971528|No Intervention|Stage 3: PD subjects (Control Subjects)|Investigating the long-term effects of combined sensory stimulating strengthening program on the activation level and central fatigue in PD individuals.
89374007|NCT01946204|Experimental|Treatment Arm A: Apalutamide|
89181352|NCT04103294|Experimental|cowpea variety #1|25g of cowpea daily for days 6-10, 50g of cowpea daily for days 11-15 and then 75g of cowpea daily for days 16-20. The pregnant women will receive 50g of cowpea daily for days 6-10, 100g of cowpea daily for days 11-15 and then 150g of cowpea daily for days 16-20
89181353|NCT04103294|Experimental|cowpea variety #2|25g of cowpea daily for days 6-10, 50g of cowpea daily for days 11-15 and then 75g of cowpea daily for days 16-20. The pregnant women will receive 50g of cowpea daily for days 6-10, 100g of cowpea daily for days 11-15 and then 150g of cowpea daily for days 16-20
89181354|NCT02585505|Active Comparator|Intravenous|stem cells will be injected through intravenously in the subjects
89181355|NCT02585505|Active Comparator|superior pancreaticoduodenal|stem cells
89181356|NCT02585505|Active Comparator|splenic artery|stem cells will be injected through splenic in the subjects
89181357|NCT04080765|Experimental|HIV-ASSIST + DHHS arm|Decision-making support for ARV selection through DHHS guidelines in conjunction with HIV-ASSIST
89181358|NCT04080765|Active Comparator|DHHS-alone arm|Decision-making support for ARV selection through DHHS guidelines alone
89181359|NCT04103372|Active Comparator|Low risk|MR Staged >1mm muscularis preserved and technically feasible to perform local excision. Pathology assessment on sample with confirmation of adenocarcinoma. Sample assessed to be low risk based on PRESERVE Risk Score of 0. (Margin Clear >0mm from the diathermy margin and Sm1/2 or Haggitt 1/2/3) Six monthly follow up from date of surgery.
89181360|NCT04103372|Active Comparator|Moderate Risk - RT&Surveillance|MR Staged >1mm muscularis preserved and technically feasible to perform local excision. Pathology assessment on sample with confirmation of adenocarcinoma. Sample assessed to be low risk based on PRESERVE Risk Score of 1. (Margin positive -0mm to the diathermy margin, or SM3 or Haggitt 4, or LVI) Patient randomized to receive radiotherapy (RT) and regular surveillance, with 3 monthly follow-up from the date of surgery.
89374008|NCT01946204|Placebo Comparator|Treatment Arm B: Placebo|
89374009|NCT01866371||Retinal degeneration|This group will include patients with retinal degeneration and vision abnormalities. The group will participate in retinal imaging procedures including adaptive optics imaging, optical coherence tomography and fundus photography. Vision may be assessed using microperimetry, visual fields, and visual acuity.
89535020|NCT03079245|Other|NICU A - E+, CDS, and PAF|This site was assigned to three interventions, Education Plus (E+), Clinical Decision Support (CDS), and Prescriber Audit and Feedback (PAB).
89374010|NCT01866371||Normal control|This group will include individuals without retinal degeneration. The group will participate in retinal imaging procedures including adaptive optics imaging, optical coherence tomography and fundus photography. Vision may be assessed using microperimetry, visual fields, and visual acuity.
89374011|NCT01792687|Experimental|Treatment|ARN-509 when combined with the approved dose of abiraterone acetate (1,000 mg daily) plus prednisone (5 mg daily).
89374012|NCT01776840|Placebo Comparator|Treatment Arm A|
89374013|NCT01776840|Experimental|Treatment Arm B|
89374014|NCT01754363|Experimental|Attune Primary Total Knee Replacement|"Subjects will receive one of the following Attune total knee implants:~Cruciate retaining fixed bearing (CR FB) Cruciate retaining rotating platform (CR RP) Posterior stabilized fixed bearing (PS FB) Posterior stabilized rotating platform (PS RP)"
89374015|NCT01629108||1|Healthy volunteers aged 5 to 80
89374016|NCT01621594|Experimental|1|Subjects with Clinical indication for a coronary CT angiography exam
89374017|NCT01615029|Experimental|Daratumumab|Participants will receive daratumumab along with Lenalidomide and dexamethasone.
89374018|NCT01391442|Other|family|each family, composed of 4 characters at least, is studied
89374019|NCT01314118|Experimental|001|abiraterone acetate in combination with prednisone Abiraterone acetate will be taken as 4 x 250 mg tablets by mouth (PO) once daily. Prednisone will be taken as 2 x 2.5 mg tablets PO once daily.
89374020|NCT01282021||Region 1|Northern part: Gonder, Gojam, Tigray
89374021|NCT01282021||Region 2|Southern Ethiopia: Bale, Sidamo, Gambela
88846018|NCT03344510|Experimental|No intervention, then kinetic anesthesia device|In this arm of the crossover study, participants will receive lidocaine injection without the kinetic anesthesia device intervention, then will receive an injection in conjunction with the kinetic anesthesia device.
88846019|NCT03264092|Experimental|Wet suction|This arm will include all the patients that will get an endoscopic ultrasound guided fine needle biopsy done with the wet suction technique
88846020|NCT03264092|Experimental|Dry suction|This arm will include all the patients that will get and endoscopic ultrasound guided fine needle biopsy done with the dry suction technique
88846021|NCT03264092|Experimental|Slow pull|This arm will include all the patients that will get an endoscopic ultrasound guided fine needle biopsy done with the slow pull technique
89374022|NCT01282021||Region 3|Northeastern and Southeastern Ethiopia
89374023|NCT01171898|Experimental|Dose Escalation Cohort (Phase 1)|ARN-509 will be administered at a starting dose of 30 milligram per day (mg/day), with escalations to 60 mg, 90 mg, 120 mg, 180 mg, 240 mg, 300 mg, 390 mg, and 480 mg daily. Once Recommended Phase 2 Dose (RP2D) has been selected, Phase 1 participants being treated at the lower dose levels will be allowed to escalate to the RP2D level at the discretion of the primary investigator.
89374024|NCT01171898|Experimental|Non-metastatic CRPC (Phase 2)|Participants with non-metastatic, treatment-naive Castration-Resistant Prostate Cancer (CRPC) with rapidly rising Prostate Specific Antigen (PSA) will be enrolled. ARN-509 will be administered at Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D), determined in Phase 1.
89374025|NCT01171898|Experimental|Treatment-naive metastatic CRPC (Phase 2)|Participants with treatment-naive metastatic CRPC will be enrolled. ARN-509 will be administered at MTD and/or RP2D, determined in Phase 1.
89374026|NCT01171898|Experimental|Post-abiraterone metastatic CRPC (Phase 2)|Participants with metastatic CRPC that are chemotherapy-naive, but have been previously treated with abiraterone will be enrolled. ARN-509 will be administered at MTD and/or RP2D, determined in Phase 1.
89374027|NCT01032083|Active Comparator|Citalopram|An SSRI antidepressant
89374028|NCT01032083|Placebo Comparator|Placebo|
89374029|NCT00980538|Experimental|Etravirine|Etravirine Dosed by weight up to a maximum dose of 200 milligram (mg) bid until switched to an etravirine (ETR)-based treatment regimens (i.e. commercially available and reimbursed, or accessible through another source) or local standard of care, as appropriate.
89374030|NCT00918775||Observational (follow-up)|After metastasectomy, patients are followed up every 6 months for up to 5 years.
89374031|NCT00781612|Experimental|Trastuzumab Emtansine|Participants will receive trastuzumab emtansine either as a single agent or in combination with other anti-cancer therapy (atezolizumab, paclitaxel, trastuzumab and docetaxel). Participants will receive the same dose and schedule on Cycle 1, Day 1 at which it was given at the end of the parent study. Study drug will be administered in 21-day cycles or weekly, depending on the schedule used in the parent study. Participants will receive study treatment until disease progression or unacceptable toxicity.
89374032|NCT00739362|Sham Comparator|1-Sham|Active tDCS stimulation
89374033|NCT00739362|Active Comparator|2-Active|Active tDCS stimulation
89374034|NCT00739362|Sham Comparator|2-Sham|Sham/no-stimulation
89374035|NCT00739362|Active Comparator|3-Active|Active tDCS stimulation
89374036|NCT00739362|Sham Comparator|3-Sham|Sham/no-stimulation
89374037|NCT00598351||Patients|Patients must have the diagnosis of NF2 by established clinical criteria or genetic testing.
89374038|NCT00582296||1|multi-organ follow-up
89374039|NCT00582296||2|control follow-up
89535021|NCT03079245|Other|NICU B - E+ and CDS|This site was assigned to two interventions, Education Plus (E+) and Clinical Decision Support (CDS).
89535022|NCT03079245|Other|NICU C - E+|This site was assigned to one intervention, Education Plus (E+).
88846022|NCT03346850|Active Comparator|nasogastric tube (NGT) feeding|
88846023|NCT03346850|Active Comparator|nasoduodenal tube (NDT) feeding|
88846024|NCT03478904|Experimental|4x40mg Enzalutamide Capsule Followed by 160mg Enzalutamide Liquid|Enzalutamide capsule (Treatment A) followed by enzalutamide liquid (Treatment B)
88846025|NCT03478904|Experimental|160mg Enzalutamide Liquid Followed by 4x40mg Enzalutamide Capsule|Enzalutamide liquid (Treatment B) followed by enzalutamide capsule (Treatment A)
88846026|NCT03478982|Experimental|Staccato Alprazolam 1.0 mg|single dose for inhalation
88846027|NCT03478982|Experimental|Staccato Alprazolam 2.0 mg|single dose for inhalation
88846028|NCT03478982|Placebo Comparator|Placebo|single dose for inhalation
89535023|NCT03079245|No Intervention|NICU D - Usual Care|This site was not introduced to an interdisciplinary intervention.
89535024|NCT03078933|Active Comparator|Standard of Care|Standard of care for diabetic foot ulcer wound care
88846029|NCT03264248|Experimental|E-Scale|E-scale daily bodyweight system coupled with a standardized behavioral treatment weight-loss intervention for overweight or obese wheelchair users
88846030|NCT03270332|Experimental|Albuterol followed by placebo|Participants in this group will receive albuterol first followed by Placebo on the next visit
88846031|NCT03270332|Experimental|Placebo followed by albuterol|Participants in this group will receive placebo first followed by albuterol on the next visit
88846032|NCT03349892|Experimental|Stereotactic Ablation Treatment Arm|This is a single-arm, non-blinded study.
88846033|NCT03483506|Experimental|All subjects|
88846034|NCT03271424|No Intervention|Focus Group Discussions|Focus group discussions (FGD) with young women (n=2 FGDs) and young men (n=2 FGDs) in the study area to determine the best way to offer self-testing to study participants.
88846035|NCT03271424|Active Comparator|In Clinic Observation-Both|10 young women and 10 young men were assigned and conducted BOTH of the HIV self-tests. Participants tried two different self-testing kits, one that is oral fluid based (saliva), Oraquick HIV Self Test, and one that is blood based via a finger prick, Atomo HIV Self Test. Oraquick HIV Self Test and Atomo HIV Self Test - Both
88846036|NCT03271424|Active Comparator|In Clinic Observation-Subject Choice|20 young women and 20 young men were assigned and conducted EITHER of the HIV self-tests. Investigators asked them to choose which test they would prefer to use, one that is oral fluid based (saliva), Oraquick HIV Self Test, or one that requires the use blood via a finger prick, Atomo HIV Self Test. Oraquick HIV Self Test - Choice; Atomo HIV Self Test - choice
88846037|NCT03483896|No Intervention|Control|At the 4 facilities in the control arm, participants received the usual care. During the period from 8:00 - 10:00 AM each day, the control group was taken to a similar sized area indoors (without daylight) for socialization under typical electrical lighting conditions.
88846038|NCT03483896|Active Comparator|Daylight Intervention|At the 4 facilities in the active light intervention arm, staff increased the daylight exposure of participants by taking them to the perimeter zone of a daylit room from 8:00 to 10:00 AM for socialization over a period of 12 weeks. The perimeter zone was defined to be the region of the room within 3 meters from windows. The intervention was administered each day (7 days / week) over the duration of the study.
88846039|NCT02156466|Experimental|MSB0010841 30 mg|
88846040|NCT02156466|Experimental|MSB0010841 60 mg|
88846041|NCT02156466|Experimental|MSB0010841 120 mg|
88846042|NCT02156466|Experimental|MSB0010841 240 mg|
88846043|NCT02156466|Placebo Comparator|Placebo|
88846044|NCT03353246|Experimental|InfraScanner 2000™|All patients entered onto the trial will undergo at least one cranial scanning using the InfraScanner 2000™ within 30 minutes of CT. Patients will be scanned using the InfraScanner 2000™ within 30 minutes of each subsequent CT. Patients will know the results of the CT but not the InfraScanner 2000™. The standard for comparison will be determined as follows. A CT result that is positive for hematoma will be considered a true positive and a CT result that is negative for hematoma will be considered a true negative. In cases where the results of the CT are negative for hematoma and the results of the InfraScanner 2000™ are positive consideration of further follow-up will be given on a case-by-case basis.
88846045|NCT03274856|Other|Treatment Sequence 1|GLWL-01 (450mg) twice a day/ Placebo
88846046|NCT03274856|Other|Treatment Sequence 2|Placebo / GLWL-01 (450mg), twice a day
88846047|NCT02216526|Experimental|Cetaphil® Restoraderm|Cetaphil® Restoraderm Body Wash, once daily for 8 weeks and Cetaphil® Restoraderm Body Moisturizer, twice daily for 8 weeks
88846048|NCT02216526|Experimental|Excipial|Excipial Kids Body Wash, once daily for 8 weeks and Excipial U Lipolotio (4% urea), twice daily for 8 weeks
88846049|NCT02216526|No Intervention|Standard skin care|Usual skin care routine of the nursing home resident
88846050|NCT03355820|Experimental|HPV Group|Healthy Chinese female subjects, including and above 17 years of age at the time of enrollment, who received all three doses of the Cervarix vaccine in the HPV-058 (NCT00996125) primary study.
88846051|NCT03357614|Experimental|Sulopenem|Sulopenem 1000 mg IV once daily for a minimum of 5 days, followed by sulopenem-etzadroxil/probenecid 500 mg PO twice daily to complete 7-10 total days of treatment
88846052|NCT03357614|Active Comparator|Ertapenem|Ertapenem 1000 mg IV once daily for a minimum of 5 days, followed by ciprofloxacin 500 mg PO twice daily or amoxicillin-clavulanate 500 mg PO twice daily to complete 7-10 total days of treatment
88846053|NCT03487718|Active Comparator|Control group|Under the effect of local anesthetic tooth will be extracted then a d-PTFE membrane will be used to cover the socket without any bone graft material to preserve the ridge.
88846054|NCT03487718|Experimental|Test group|Under the effect of local anesthetic tooth extraction will be followed by the collection of about 50 ml of the patient's venous blood, then without adding any anticougulant the blood will be spun to make a plug. The Leukocyte platelet rich fibrin plug + d-PTFE membrane will be used to preserve the ridge.
88846055|NCT03275870|Experimental|Hydroxychloroquine treatment|Hydroxychloroquine 200mg BID for 6 months
88846056|NCT03276494|Other|Intraosseous|Administration of intraosseous hypertonic saline
88846057|NCT02216214|Placebo Comparator|Placebo|Participants received placebo to match mirabegron at an initial dose of 25 mg and may have been increased to 50 mg of matching placebo based on individual participant efficacy, tolerability and investigator discretion. Once a participant had increased dose, they remained on that dose for the remainder of the study unless there were safety reasons that required discontinuation of study drug.
89535025|NCT03078933|Experimental|APT001NitricOxide tx 2x week 6 min+ SOC|APT001 Nitric OxideTherapy 2x week for 6 min. treatment time plus standard of care
88846058|NCT02216214|Experimental|Mirabegron|Participants received mirabegron at an initial dose of 25 mg and may have been increased to 50 mg mirabegron after 4 weeks or 8 weeks based on individual participant efficacy, tolerability and investigator discretion. Once a participant had increased dose, they remained on that dose for the remainder of the study unless there were safety reasons that required discontinuation of study drug.
88846059|NCT03277274|Experimental|Group 1 Mild Hepatic Impairment: TAK-954 0.2 mg|TAK-954 0.2 milligram (mg), intravenous, administered as 60-minute infusion, once on Day 1.
88846060|NCT03277274|Experimental|Group 2 Moderate Hepatic Impairment: TAK-954 0.2 mg|TAK-954 0.2 mg, intravenous, administered as 60-minute infusion, once on Day 1.
88846061|NCT03277274|Experimental|Group 3 Severe Hepatic Impairment: TAK-954 0.2 mg|TAK-954 0.2 mg, intravenous, administered as 60-minute infusion, once on Day 1.
88846062|NCT03277274|Experimental|Group 4 Healthy Participants: TAK-954 0.2 mg|TAK-954 0.2 mg, intravenous, administered as 60-minute infusion, once on Day 1.
88846063|NCT03279458|Experimental|Linshom Respiratory Monitoring Device|Volunteers will breathe through a continuous positive airway pressure (CPAP) face mask fitted with the Linshom device. The volunteers will be instructed to breathe normal through the CPAP mask on room air. The excursions of the thermistor tracings (from valley to peak) will be recorded by the Linshom device and displayed continuously on a laptop monitor in a waveform.
88846064|NCT03279458|Active Comparator|Ventilator|Volunteers will breathe through a continuous positive airway pressure (CPAP) face mask fitted with the Linshom device. The volunteers will be instructed to breathe normal through the CPAP mask on room air.The tidal volume will also be measured by the ventilator and the data downloaded in a Compact Flash card.
88846065|NCT02214186|No Intervention|Liberal Fluid therapy|The liberal group will receive 1500 mL of crystalloid solution during the cesarean section. This is the non-intervention arm once that 1500 ml of crystalloid is the amount usually used during caesarean.
89181361|NCT04103372|Active Comparator|Moderate Risk - Surveillance|MR Staged >1mm muscularis preserved and technically feasible to perform local excision. Pathology assessment on sample with confirmation of adenocarcinoma. Sample assessed to be low risk based on PRESERVE Risk Score of 1. (Margin positive -0mm to the diathermy margin, or SM3 or Haggitt 4, or LVI) Patient randomized to surveillance arm with regular surveillance, with 3 monthly follow-up from the date of surgery.
89181362|NCT04103372|Active Comparator|High Risk|MR Staged >1mm muscularis preserved and technically feasible to perform local excision. Pathology assessment on sample with confirmation of adenocarcinoma. Sample assessed to be low risk based on PRESERVE Risk Score of >2. (Margin positive - 0mm to the diathermy margin, Margin positive/or unassessable due to piecemeal removal - 0mm to the tumour margin, Sm3 or Haggitt 4, Poorly differentiated/mucinous, LVI, T2) Patient is considered for surgery, receives radiotherapy and surveillance, with 3 monthly follow-up from date of surgery.
89181363|NCT04103372|Active Comparator|TME (Total mesorectal excision) Surgery|For patients where it is considered technically feasible to do LE but MR staged<1mm muscularis preserved, or it is considered not feasible to perform a local excision. Patients undergo TME surgery. Pathology assessment on sample with confirmation of adenocarcinoma. Patient receives 6 monthly follow-up from date of surgery.
89181364|NCT00916292|Experimental|Low dose|Four subjects will receive low dose FGF-1
89181365|NCT00916292|Experimental|High Dose|Four subjects will receive high dose FGF-1
89181366|NCT02585427|Experimental|low glycemic index rice with butter|50 g available low glycemic index rice cooked with 48 g butter ( equal 40 g saturated fatty acid)
89181367|NCT02585427|Experimental|low glycemic index rice with olive oil|50 g available low glycemic index rice cooked with 44 g olive oil ( equal 40 g monounsaturated fatty acid)
89181368|NCT02585427|Experimental|low glycemic index rice with grapeseed oil|50 g available low glycemic index rice cooked with 40 g grapeseed oil ( equal 40 g polyunsaturated fatty acid)
89181369|NCT02585427|Experimental|high glycemic index rice with butter|50 g available high glycemic index rice cooked with 48 g butter ( equal 40 g saturated fatty acid)
89181370|NCT02585427|Experimental|high glycemic index rice with olive oil|50 g available high glycemic index rice cooked with 44 g olive oil ( equal 40 g monounsaturated fatty acid)
89181371|NCT02585427|Experimental|high glycemic index rice with grapeseed oil|50 g available high glycemic index rice cooked with 40 g grapeseed oil ( equal 40 g polyunsaturated fatty acid)
89181372|NCT02585193|Other|Weight Watchers Intervention|All participants are enrolled in this single arm of the study. All participants receive the Weight Watchers intervention which consists of weekly group intervention/support meetings in which weight loss behaviors (diet, physical activity) are discussed.
89374041|NCT00286637||Cross-Sectional Study|Subjects will undergo a comprehensive ocular examination at every visit. Frequency of the visits is dictated by the treating physician, disregarding participation in the study. In glaucoma clinic patients are typically scheduled for visits every six months, and the frequency of visits varies according to clinical severity in the retina clinic. No additional research visits are required beyond the clinically dictated schedule.
89374042|NCT00286637||Longitudinal Study|Subjects will undergo a comprehensive ocular examination at every visit. Frequency of the visits is dictated by the treating physician, disregarding participation in the study. In glaucoma clinic patients are typically scheduled for visits every six months, and the frequency of visits varies according to clinical severity in the retina clinic. No additional research visits are required beyond the clinically dictated schedule.
89374043|NCT00286637||Reproducibility Study|Subjects willing to participate in the reproducibility arm of the project will undergo the same comprehensive ocular examination as in the longitudinal and cross-sectional study arms. However, OCT scanning will be repeated up to five times within a single visit. The participants will be requested to repeat the visual field and OCT scanning in up to 5 additional independent visits within a month to minimize the possibility that an actual change in ocular structures has occurred. Duration of each additional visit will be up to 45 minutes.
89374044|NCT00286637||Alzheimer's Disease (AD) Sub-Study|Participants with AD or mild cognitive impairment (MCI) undergo the same comprehensive ocular examination as in the longitudinal and cross-sectional study arms.
89181373|NCT02585271|Other|Transanal decompression tube|Patients undergo placement of the transanal decompression tube as a bridge to surgery
89181374|NCT02585271|Other|Stent|Patients undergo placement of the stent as a bridge to surgery
89181375|NCT05520177|Experimental|601 1.25mg|loading phase (6 months): 601 1.25mg/eye/time, Intravitreal injection, administered once every 4 weeks for 6 consecutive doses
89181376|NCT05520177|Active Comparator|ranibizumab 0.5mg|loading phase (6 months): ranibizumab 0.5mg/eye/time, Intravitreal injection, administered once every 4 weeks for 6 consecutive doses
89181377|NCT02585115||Non-pregnant women with symptoms|Non-pregnant women with one or more symptoms of UTI. All women will make a paired urine sample (first void and midstream void) of the same urine sample.
89181378|NCT00780416|Experimental|TRV/PEG/RBV|
89181379|NCT00780416|Active Comparator|PEG/RBV|
89189311|NCT02575170|Experimental|Amino acid|Intravenous infusion of amino acid solution started approximately one hour prior to spinal anaesthesia after recording the baseline vital parameters. Each patient in experimental group received a total of 200 ml at 2 ml/kg/min.
89374045|NCT00050752||1 / Patients|Patients with known or suspected Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome (HLRCC)
89374046|NCT00050752||2 / Family Members|Family members (related by blood) of patients who have or are suspected of having Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome (HLRCC)
89374047|NCT00050752||3 / Non-Biologic Family Members|Spouses enrolled primarily for linkage analysis (Spouses have been removed from the inclusion criteria for this study. This closed cohort is for spouses previously enrolled on study.)
89374048|NCT00026884||Family Members|Family members (related by blood) of patients who have or are suspected of having a malignant disease or an inherited genitourinary malignant disorder
89374049|NCT00026884||Patients|Patients with biopsy-proven malignant diseases; or patients suspected of having a malignant disease; or patients who have or who are suspected of having an inherited genitourinary malignant disorder
89374050|NCT00026702||All|Subjects at least three years old
89374051|NCT00023049||1|patients with known SNHL and/or peripheral vestibular dysfunction
89374052|NCT00004577||Healthy Volunteer|Any healthy, male or female volunteer 18 years of age and older.
89374054|NCT00001238||Disease Category I|Patients, biologic family members with a suspected or an established diagnosis of an inherited urologic malignancy in which the disease gene is known, including VHL and HPRC
89374055|NCT00001238||Disease Category II|Patients and biologic family members with a suspected or an established diagnosis of an inherited urologic malignancy in which the disease gene is not yet known
89374056|NCT00001238||Disease Category III|Patients and biologic family members with a urologic malignant disease of suspected, but not proven genetic etiology
88846066|NCT02214186|Active Comparator|Restrictive Fluid Therapy|The restrictive group will receive 250 mL of crystalloid solution during cesarean section.
88846067|NCT03492398|Experimental|Cohort A HY209 0.05% gel|single dose of HY209 0.05% gel or single dose of placebo
88846068|NCT03492398|Experimental|Cohort A HY209 0.1% gel|single dose of HY209 0.1% gel or single dose of placebo
88846069|NCT03492398|Experimental|Cohort A HY209 0.3% gel|single dose of HY209 0.3% gel or single dose of placebo
88846070|NCT03492398|Experimental|Cohort A HY209 0.5% gel|single dose of HY209 0.5% gel or single dose of placebo
88846071|NCT03492398|Experimental|Cohort B HY209 0.1% gel|multiple dose of HY209 0.1% gel or multiple dose of placebo
88846072|NCT03492398|Experimental|Cohort B HY209 0.3% gel|multiple dose of HY209 0.3% gel or multiple dose of placebo
88846073|NCT03492398|Experimental|Cohort B HY209 0.5% gel|multiple dose of HY209 0.5% gel or multiple dose of placebo
89399312|NCT03539354|Experimental|CABG + b-blockers + temporary SCS|Before coronary artery bypass grafting in the experimental group, 3 days of temporary spinal cord stimulation is performed than device turned off and coronary artery bypass grafting procedure is made. The device for spinal cord is turned on in intensive care unit for 7 days. Continuous ECG during intensive care unit stay, daily ECG, and 24-h Holter monitor recordings will be performed at 7, 14, 21, and 30 days after coronary artery bypass grafting, external loop recorder after discharge from intensive care unit till 30 days after coronary artery bypass grafting.
89399313|NCT03686943||Elderly|Patient over 75 years seen with the mobile extra hospital geriatric team
89399314|NCT02173028||Optimal beta blocker titration|We will compare the efficacy of two management strategies for beta-blocker up-titration: Standard in-office visits vs. Remote follow-up.
89399315|NCT02173028||Without optimal titration of beta blocker|This analysis will be conducted within the Cardiac Resynchronization Therapy observational study Modular Registry (CRT MORE - ClinicalTrials.gov Identifier: NCT01573091).
89189312|NCT02575170|Placebo Comparator|Ringer's Lactate solution|Intravenous infusion of Ringer's lactate solution started approximately one hour prior to spinal anaesthesia after recording the baseline vital parameters. Each patient in experimental group received a total of 200 ml at 2 ml/kg/min.
89189313|NCT00710502|Experimental|1|Transvaginal NOTES Cholecystectomy (Phase 1)
89399316|NCT02174900|Experimental|G6PD deficient 0.25 mg/kg PQ + AL|G6PD deficient males receiving Artemether-Lumefantrine (AL) + 0.25 mg/kg primaquine
89399317|NCT02174900|Active Comparator|G6PD deficient receiving AL only|G6PD deficient males receiving Artemether-Lumefantrine (AL) combination
89399318|NCT02174900|Active Comparator|G6PD normal 0.25 mg/kg PQ + AL|G6PD normal males receiving Artemether-Lumefantrine (AL) + 0.25 mg/kg primaquine
89399319|NCT02174900|Active Comparator|G6PD normal 0.4 mg/kg PQ + AL|G6PD normal males receiving Artemether-Lumefantrine (AL) + 0.4 mg/kg primaquine
89399320|NCT02174900|Experimental|G6PD-deficient 0.4 mg/kg PQ + AL|G6PD deficient males receiving Artemether-Lumefantrine (AL) + 0.4 mg/kg primaquine
89399321|NCT02170610|Experimental|BIBR 1048 MS capsule|
89399322|NCT02170610|Experimental|BIBR 1048 capsule with pantoprazole|
89399323|NCT02170610|Experimental|BIBR 1048 capsule with food|
89399324|NCT03686865||dental implants|
88846074|NCT04758546|Experimental|Aggressive screening criteria + high minimal ventilatory settings|
88846075|NCT04758546|Experimental|Aggressive screening criteria + low minimal ventilatory settings|
88846076|NCT04758546|Experimental|Conservative screening criteria + high minimal ventilatory settings|
88846077|NCT04758546|Active Comparator|Conservative screening criteria + low minimal ventilatory settings|
88846078|NCT02181504|Experimental|abicipar pegol 2 mg|Abicipar pegol 2 mg administered to the study eye by intravitreal injection at day 1, weeks 4 and 8, followed by a sham procedure at weeks 12 and 16.
88846079|NCT02181504|Experimental|abicipar pegol 1 mg|Abicipar pegol 1 mg administered to the study eye by intravitreal injection at day 1, weeks 4 and 8, followed by a sham procedure at weeks 12 and 16.
88846080|NCT02181504|Active Comparator|ranibizumab 0.5 mg|Ranibizumab (Lucentis®) 0.5 mg administered to the study eye by intravitreal injection every 4 weeks from day 1 through week 16.
88846081|NCT03360110|Active Comparator|Test lens|Subjects randomized to wear pair of test lens either first or second
88846082|NCT03360110|Active Comparator|stenfilcon A lens (control)|Subjects randomized to wear pair of control lens either first or second
89374057|NCT03361423|Active Comparator|treatment of migraine with active device|Treatment of acute migraine with an active form of Nerivio migra-1 device
89374058|NCT03361423|Sham Comparator|treatment of migraine with sham device|Treatment of acute migraine with a sham form of the Nerivio Migra-1 device
89374059|NCT02693002|Active Comparator|Hormone replacement therapy|Estradiol/norethindrone acetate 1mg/0.5 mg by mouth oral daily for 12 weeks
89374060|NCT02693002|Placebo Comparator|Placebo|Inert ingredients by mouth oral daily for 12 weeks
89374061|NCT04480606|Experimental|Home exercise group|47 volunteers over 65 years old who are at home during the social isolation process due to the coronavirus outbreak will be included in home exercise group.
89374062|NCT04480606|No Intervention|Control Group|The control group will be asked to remain isolated as they are and the exercise program will not be implemented.
88846083|NCT02179398|Experimental|Lab-score group|"Patients assessed through the Lab-score determination only: Lab-score ≥3 used as the sole marker for the detection of serious bacterial infection.~(WBC and band counts blinded to the physician in charge of the patient)"
88846084|NCT02179398|Active Comparator|Control group|"Patients assessed through the following classically admitted biomarkers for the detection of serious bacterial infection: WBC count, band count and CRP determination.~(PCT and thus Lab-score blinded to the physician in charge of the patient)."
88846085|NCT02156076|Placebo Comparator|Arm A: Placebo (Matching with BMS-919373)|Placebo (Matching with BMS-919373) 0 mg tablets orally once daily for approximately 28 Days
88846086|NCT02156076|Experimental|Arm B: BMS-919373|BMS-919373 3 mg tablets orally once daily for approximately 28 days
88846087|NCT02156076|Experimental|Arm C: BMS-919373|BMS-919373 5 mg tablets orally once daily for approximately 28 days
89181380|NCT02585037|Experimental|Kinesio Taping for facilitation|To provide the facilitation of muscle activity (G1 group) a Kinesio Taping® bandage will be applied to the muscle starting at its origin up to the location of muscle insertion. Bandage in group G1 will be applied following the protocol proposed by method of technical, which defined the direction of the bandage and an applied tension of 10% to 15% (paper off). With a dynamometer Jamar® pressure the grip strength will be messure in four stages: immediately before placing the Kinesio Taping®, 24 h, 48 h, and 72 h after its application.
89189314|NCT00710502|Active Comparator|2|Laparoscopic Cholecystectomy (Phase 2)
89189315|NCT00710502|Experimental|3|Transvaginal NOTES cholecystectomy (Phase 2)
89374063|NCT05408923|Placebo Comparator|Placebo Group|Patients in this group will be given the placebo (sterile saline).
89374064|NCT05408923|Active Comparator|Irrisept|Patients in this group will be given the study drug (Irrisept).
89374065|NCT03707509|Experimental|Camrelizumab + Gemcitabine + Cisplatin|subject will receive camrelizumab 200mg every 3 weeks, cisplatin 80mg/m2 on Day 1 of each 21 day, at most 6 cycles, gemcitabine 1000mg/m2, Day 1 and Day 8 of each 21 day, maximum 6 cycles
89374066|NCT03707509|Active Comparator|Placebos + Gemcitabine + Cisplatin|subject will receive placebos every 3 weeks, cisplatin 80mg/m2 on Day 1 of each 21 day, at most 6 cycles, gemcitabine 1000mg/m2, Day 1 and Day 8 of each 21 day, maximum 6 cycles
89374067|NCT03710395|Active Comparator|Wild homozygous for ABCG2 c.421C>A|Chronic hypertensive breastfeeding women (18-45 years old) genotyped as wild homozygous for ABCG2 c.421C>A.
89374068|NCT03710395|Experimental|Variant genotypes for ABCG2 c.421C>A|Chronic hypertensive breastfeeding women (18-45 years old) genotyped as heterozygous or mutant homozygous for ABCG2 c.421C>A.
89374069|NCT02399098|Experimental|External focus group|This group will be given instructions on how to focus on the external cue relevant to the task (e.g., focus on the center of the dart board).
89374070|NCT02399098|Experimental|Internal focus group|This group will be instructed how to focus on the arm movements (e.g., feel the bend in your elbow).
89374071|NCT02399098|No Intervention|Control|This group will be given general instructions on throwing techniques (e.g., hold the dart with four fingers and make sure it is in a stable position) but no attentional focus instructions will be given.
89374072|NCT03621007||POMC deficiency obesity|
89374073|NCT03621007||LEPR deficiency obesity|
89374074|NCT03621007||PCSK1 deficiency obesity|
89374075|NCT04889950|Experimental|Tixel Group|Tixel C Group: Screening and baseline visits, Treatment- 3 treatment sessions, followed by 2 Follow up sessions, 1and 3 months after last treatment visit. Subject will be questioned about Discomfort and Pain Questionnaires (self-assessed) and OSDI questionnaire.
89374076|NCT04889950|Active Comparator|LipiFlow|LipiFlow: Screening and baseline visits, Treatment- 1 single treatment session, followed by 2 Follow up sessions, 1and 3 months after the last treatment visit. Subject will be questioned about Discomfort and Pain Questionnaires (self-assessed) and OSDI questionnaire.
89374077|NCT02394262|Experimental|Serial CCTA and atherothrombosis markers|Sequential coronary CT-angiography and assesment of biomarkers involved in atherothrombosis after 1 year follow-up.
89374078|NCT03093870|Experimental|Varlitinib and Capecitabine|
89374079|NCT03093870|Placebo Comparator|Placebo and Capecitabine|
89374080|NCT02394184||patients with bicuspid aortic valve stenosis|
89374081|NCT05744908|Active Comparator|With Hunner's ulcer|Pentosan Polysulfate 100 mg
88846088|NCT02156076|Experimental|Arm D: BMS-919373|BMS-919373 12 mg tablets orally once daily for approximately 28 days
88846089|NCT02213094|Experimental|Nicotinamide 500 mg|Nicotinamide 500 mg by mouth each morning until delivery or 14 days, whichever occurs first.
88846090|NCT02213094|Experimental|Nicotinamide 1000 mg|Nicotinamide 1000 mg by mouth each morning until delivery or 14 days, whichever occurs first.
89374082|NCT05744908|Active Comparator|Without Hunner's ulcer|Pentosan Polysulfate 100 mg
89374083|NCT02394106|Experimental|Ofatumumab|"Drug Name: Ofatumumab~Why: Anti-body/antigen interaction results in cell apoptosis and reduced CD20 positive cell related activities~Procedures: methylprednisolone 2 mg/kg infused in 30' IV diluted in 100 ml of normal saline (NaCl 0,9%); oral paracetamol 15 mg/kg ; cetirizine 0,4 mg/kg IV infused slowly in 5 ml of normal saline (NaCl 0,9%) prior to Ofatumumab infusion to reduce common reactions~Who provides: registered nurse~How: Ofatumumab IV at 12 ml/hour in the first 30'. Thereafter, the infusion rate can be doubled every 30 minutes up to a maximum of 200 ml/hour.~Where: in Hospital~When and how much: once; diluted in 1000 ml of normal saline~Tailoring: 1500 mg/1.73m2~How well: expert nurse would assist administration"
89374084|NCT02394106|Placebo Comparator|Placebo|"Drug Name: Normal Saline (NaCl 0,9%)~Why: standard therapy could not be used as comparator for Ofatumumab, given its toxicity and lack of effectiveness. Moreover, although Rituximab, a chimeric monoclonal anti-CD20 antibody, is increasingly being used as a steroid-sparing treatment option for children with certain forms of INS (those that respond to and are dependent of steroids), this drug does not work in DR-INS and could not be used as a comparator.~Materials and Procedures: The placebo arm will receive the same infusion as the Ofatumumab Arm with the exception of the Ofatumumab."
89374085|NCT01568346|Active Comparator|MRI|MRI
88846091|NCT02155608|Experimental|Active eTNS|Following screening and determination of eligibility, participants at baseline are randomized to receive 4 weeks nightly treatment with active or sham eTNS, followed by one week ongoing blinded assessment following treatment discontinuation. Positive responders will be invited to participate in a 12-month open extension.
89374086|NCT01568346|No Intervention|No MRI|No MRI
89374087|NCT02393872|Experimental|High-risk families component|School-based intervention and counselling sessions.
88846092|NCT02155608|Sham Comparator|Sham eTNS|Following screening and determination of eligibility, participants at baseline are randomized to receive 4 weeks nightly treatment with active or sham eTNS, followed by one week ongoing blinded assessment following treatment discontinuation. Following double-blind phase, interested participants randomized to sham have an option for a 4-week open TNS trial. Positive responders will be invited to participate in a 12-month open extension.
88846093|NCT01629966|Placebo Comparator|Placebo|Dose-matched placebo one per day, oral administration
88846094|NCT01629966|Experimental|Vilazadone 20mg|Vilazodone 20mg once per day, oral administration.
88846095|NCT01629966|Experimental|Vilazodone 40mg|Vilazodone 40mg once per day, oral administration
89374088|NCT02393872|Experimental|All-families component|School-based intervention.
89374089|NCT02393872|No Intervention|Control|Control group.
88846096|NCT03363854|Experimental|Tralokinumab(initial)responders-> Tralokinumab(continuation A)|"Week 0 to 16 (initial period):~Tralokinumab loading SC injection on Day 0 followed by tralokinumab injection regimen A.~Week 16 to 32 (continuation period):~Tralokinumab continuation SC injection regimen A."
88846097|NCT03363854|Experimental|Tralokinumab(initial)responders-> Tralokinumab(continuation B)|"Week 0 to 16 (initial period):~Tralokinumab loading SC injection on Day 0 followed by tralokinumab injection regimen A.~Week 16 to 32 (continuation period):~Tralokinumab continuation SC injection regimen B."
89374090|NCT02558634|Experimental|DBS-on|"Ventral intermediate Nucleus (VIM) Thalamic DBS on~DBS system includes:~Implantable Pulse Generator (IPG)~DBS Lead~DBS Lead Extension Kit"
89374091|NCT02558634|Sham Comparator|DBS-off (sham-stimulation)|"Ventral intermediate Nucleus (VIM) Thalamic DBS off~DBS system includes:~Implantable Pulse Generator (IPG)~DBS Lead~DBS Lead Extension Kit"
89374092|NCT02399176|Experimental|Yoga of minimal intensity|Does Yoga: At least 4 times/week.
89374093|NCT02399332|Experimental|Community Pharmacist Involvement|"Patients would have a complex care plan completed by their clinical team, which will involve chronic disease management nurse and the family physician. This complex care plan would also involve discussion with the patient's community pharmacist who would follow-up with the patient monthly and send a report to the patient's physician. Patients would also continue to receive routine care at the clinic.~The monthly follow-ups with the community pharmacist would involve review of the goals of complex care plan and monitoring clinical targets, medication review and discussing adherence as well as patient education. This follow-up can be completed in person or by telephone. The pharmacist would then send a monthly report to patient's family physician."
89374094|NCT02399332|No Intervention|Usual care|Patients have a complex care plan completed by their clinical team, which will involve the chronic disease management nurse and the family physician and then receive routine care and follow up. They will receive usual care from their community pharmacist.
89374095|NCT05744830|Experimental|Overdenture|Each patient in this group will receive a single implant overdenture.
89374096|NCT05744830|Experimental|Complete Denture|Each patient in this group will receive a removable complete denture without implants.
89374097|NCT03166696||acute cerebral infarction|the registry and follow up of consecutive patients who were admitted and diagnosed with acute cerebral infarction
88846098|NCT03363854|Experimental|Tralokinumab(initial)non-respon-> Tralokinumab(continuation A)|"Week 0 to 16 (initial period):~Tralokinumab loading SC injection on Day 0 followed by tralokinumab injection regimen A.~Week 16 to 32 (continuation period):~Tralokinumab continuation SC injection regimen A."
88846099|NCT03363854|Experimental|Placebo (initial)non-respon-> Tralokinumab(continuation A)|"Week 0 to 16 (initial period):~Placebo loading SC injection on Day 0 followed by placebo injection regimen A.~Week 16 to 32 (continuation period):~Tralokinumab continuation SC injection regimen A."
88846100|NCT03363854|Placebo Comparator|Placebo(initial)responders-> Placebo(continuation A)|"Week 0 to 16 (initial period):~Placebo loading SC injection on Day 0 followed by placebo injection regimen A.~Week 16 to 32 (continuation period):~Placebo continuation SC injection regimen A."
89002276|NCT06319222|No Intervention|Standard of Care Arm|Primary care providers will treat subject per standard of care utilizing the Interactive Care Plan program.
88846101|NCT02177838|Experimental|Treatment (cetuximab, cisplatin, EBRT)|Patients receive cetuximab IV over 60-120 minutes for 3 weeks. Patients then undergo EBRT over 6-7 weeks. Patients achieving response continue weekly doses of cetuximab until radiation therapy is completed. Patients unable to achieve response or progression receive cisplatin IV over 1-2 hours on days 1, 22, and 43 of radiation therapy.
88846102|NCT03369158|Experimental|MySpine|"Patients operated for spinal stabilization through patient specific pedicle screw guide MySpine"
89374098|NCT03166696||acute myocardial infarction|the registry and follow up of consecutive patients who were admitted and diagnosed with acute myocardial infarction
89374099|NCT03106714||Detectable RT-PCR ZIKV|Men and women aged 18 years and above with diagnosis of ZIKV infection
89374100|NCT03106480||HIV and Diabetes Cohort|Participants recruited in the study will have diverse characteristics. Participants will either be HIV infected or HIV negative and among those HIV-infected there will be those on ART and those not on ART. In addition, participants will have other background characteristics like having history of tuberculosis treatment, being malnourished while starting ART, having diabetes at ART initiation etc. Investigators will also be able to examine the effect of immune activation, body composition changes, and other related factors on the risk of diabetes. This diversity of characteristics will help provide adequate data to address study outcomes.
89374101|NCT05232292|Active Comparator|Vaccinated|vaccinated ACS & CHF patients over 65 years
89374102|NCT05232292|No Intervention|Not vaccinated|not vaccinated ACS & CHF patients over 65 years
89374103|NCT02393638|Experimental|study group|Simulation and lecture
89374104|NCT02393638|Active Comparator|control group|Lecture only
89374105|NCT03166852|Experimental|Home-training group|High-intensity training at home 3 times/week for 5 weeks
89374106|NCT02399020|Experimental|SCIT group|Social Cognition and Interaction Training intervention group
89374107|NCT03596736|Experimental|Elbow Hemiarthroplasty|
89374108|NCT03596736|Active Comparator|Total Elbow Arthroplasty|
89374109|NCT05744752|Other|Group A|Control; Placebo 1ml NaCl 0.9% daily for 12 weeks
89374110|NCT05744752|Active Comparator|Group B|Pb Group; Lead acetate 19.5mg/kg b.w daily for 12 weeks
89374111|NCT05744752|Experimental|Group C|Pb + Allium sativum extract; Lead acetate 19.5mg/kg b.w followed by Allium sativum(AS) extract 500 mg/kg b.w daily for 12 weeks
89374112|NCT05744752|Other|Group D|CPb + Moringa oleifera extract; Lead acetate 19.5mg/kg b.w followed by Moringa oleifera extract 400mg/kg b.w daily for 12 weeks
89374113|NCT05744752|Active Comparator|Group E|Allium sativum extract; Allium sativum extract 500mg/kg b.w daily for 12 weeks
89374114|NCT05744752|Experimental|Group F|Moringa oleifera extract; Moringa oleifera extract 400mg/kg b.w daily for 12 weeks
88846103|NCT03369158|Active Comparator|Free hand technique|Patients operated for spinal stabilization through standard free hand technique
88846104|NCT03372434|Experimental|Investigational Lens Device #1|Investigational Intraocular Lens Device #1: Model ZFR00
88846105|NCT03372434|Experimental|Investigational Lens Device #2|Investigational Intraocular Lens Device #1: Model ZYR00
89374115|NCT02398942||Proximal Pole Fracture of the Scaphoid|QuickDASH 6 months after injury CT scan 6 months after injury
89374116|NCT02393404|Experimental|PT-FMT|Functional movement-power training group
89374117|NCT02393404|Experimental|FMT alone|Functional movement training group
89374118|NCT02393404|No Intervention|Control|No intervention control group
89374119|NCT02393482|Active Comparator|Balanced estroprogestins|Women assigned to this arm will assume balanced monophasic estroprogestins (etinil-estradiol 100 mcg/levonorgestrel 20 mcg), one tablet orally daily, for 180 days.
89374120|NCT02393482|Active Comparator|GnRHa|Women assigned to this arm will assume Leuprorelin acetate (3,75 mg/2ml), one intramuscular administration every 28 days. After 45 days of treatment, therapy will be implemented with Tibolone 5 mg, one tablet daily orally, and Calcium carbonate/colecalciferol (500 mg/400 UI), one tablet daily orally. This therapy will be prosecuted for the remaining 135 days of treatment.
89374121|NCT03166774||patient consulting in oncology ervice|Program of support of the sexual health in oncology by questionnaire
89374122|NCT02393560||Gout subjects on stable dose of allopurinol (at least 300mg)|
89374123|NCT03346057|Experimental|Sugammadex 2 mg/kg|Sugammadex 2 mg/kg administered as a single intravenous (IV) dose
89374124|NCT03346057|Experimental|Sugammadex 4 mg/kg|Sugammadex 4 mg/kg administered as a single IV dose
89374125|NCT03346057|Experimental|Sugammadex 16 mg/kg|Sugammadex 16 mg/kg administered as a single IV dose
88846106|NCT03372434|Active Comparator|Control Device|Control TECNIS Multifocal Intraocular Lens Model ZLB00
89374126|NCT03346057|Active Comparator|Neostigmine + Glycopyrrolate|Neostigmine 50 μg/kg (up to 5 mg maximum dose) plus glycopyrrolate 10 μg/kg (up to 1 mg maximum dose) administered as a single IV dose
88846107|NCT03376256|Experimental|Phase A - Thoracic ES with LOR|Patients will receive thoracic epidural anesthesia. The thoracic epidural needle will be introduced until loss of resistance (LOR) is perceived to identify the thoracic epidural space (ES). The Compuflo Epidural Instrument will be used to record pressure readings. The thoracic epidural procedure will then continue per standard of care.
88846108|NCT03376256|Experimental|Phase B - Thoracic ES with Compuflo|Patients will receive thoracic epidural anesthesia. The thoracic epidural needle will be introduced until the Compuflo Epidural Instrument indicates that pressure has decreased. The loss of resistance technique will then be used to identify the thoracic epidural space. The thoracic epidural procedure will then continue per standard of care.
88846109|NCT03283436|Experimental|Superior hypogastric plexus block|Prior to the laparoscopic hysterectomy and any additional procedures, the SHPB will be performed on patients in the treatment arm. The block will contain 10 mL of 0.25% bupivacaine hydrochloride (Bupivacaine; 2.5 mg/mL = 25 mg). The anesthetic works by blocking nerve conduction and the steroid by reducing inflammation. The injection will be performed by tenting the presacral peritoneum, aspirating with a laparoscopic needle-tip syringe to ensure extravascular placement, and injecting the block.
88846110|NCT03283436|No Intervention|No block|Patients in the control arm will undergo the hysterectomy with no intervention.
89374127|NCT02393326|Experimental|Partial pulpotomy with biodentine|Biodentine is gently applied to the pulp stumps
89374128|NCT02393326|Other|Formocresol pulpotomy|A cotton pellet moistened with formocresol (1: 5 Buckley's solution) is placed on the amputated pulp for 5 min.
89374129|NCT03523962|Experimental|First pre-op antiseptic skin solution|The PREPARE trial will compare the most common alcohol-based pre-operative antiseptic skin solutions used during extremity fracture surgery. Participant recruitment will begin with the clinical sites using their assigned pre-operative antiseptic skin solution for all eligible fracture surgeries for a two-month period.
89374130|NCT03523962|Experimental|Crossover - Second pre-op antiseptic skin solution|Once the first intervention phase is completed, each site will crossover to the opposite study solution. Each site will need to develop local procedures to ensure a successful crossover. They will use the second solution for all eligible fracture surgeries for a two-month period, and will then crossover back to the solution in the first intervention phase.
89374131|NCT02398708||Chronic Graft-Versus-Host Disease|This group will have questionnaires, clinical data, a blood sample and a stool sample collected to be compared with the other group.
89374132|NCT02398708||No Chronic Graft-Versus-Host Disease|This group will have questionnaires, clinical data, a blood sample and a stool sample collected to be compared with the other group.
89374133|NCT02398864|Experimental|endobronchial ultrasound bronchoscopy|EBUS with TBNA
89374134|NCT03166306|Experimental|Patients with idiopathic or familial PAH|Ten patients with severe idiopathic or familial PAH will undergo PET-CT imaging with [89Zr]-bevacizumab.
89374135|NCT03166306|Experimental|Patients with exercise associated PAH|Ten patients with exercise associated PAH (EPAH) will undergo PET-CT imaging with [89Zr]-bevacizumab.
89374136|NCT03166306|Active Comparator|Healthy volunteers|Ten individuals with no known cardiopulmonary disease will undergo PET-CT imaging with [89Zr]-bevacizumab.
89374137|NCT02398630|Other|Open Label|"This is a single arm open label study.~Its procedures involve:~Transvaginal Echography~Conventional Virtual Histerosalpingography~Virtual Histerosalpingography by MRI~Blood draw for Antimullerian Hormone Dosing"
89374138|NCT03631914|Active Comparator|Active needle tip tracking|A needle tip tracking system is used when performing an ultrasound guided infraclavicular brachial plexus block.
89374139|NCT03631914|Other|Inactive needle tip tracking|No needle tip tracking system is used when performing an ultrasound guided infraclavicular brachial plexus block.
89374140|NCT02398552|Active Comparator|Sunitinib 50mg/day schedule 4/2|Sunitinib 50mg/day 4 weeks on/2 weeks off per 6 weeks till disease progression or intolerable toxicity.
89374141|NCT02398552|Experimental|Sunitinib 50mg/day schedule 2/1|Sunitinib 50mg/day 2 weeks on/1 week off per 6 weeks till disease progression or intolerable toxicity.
89374142|NCT03345979|Experimental|Treatment Group 1|Regular injections
88846111|NCT03380624|Experimental|Refresh Optive, then Refresh Optive MEGA-3|"Participants first utilized one drop of Refresh Optive in each eye before taking lipid layer thickness measurements occurring at 15 minutes and 1 hour after instillation. After a washout period, they returned to repeat the testing using one drop of Refresh Optive MEGA-3 before taking lipid layer thickness measurements.~."
88846112|NCT03380624|Experimental|Refresh Optive MEGA-3, then Refresh Optive|Participants first utilized one drop of Refresh Optive MEGA-3 in each eye before taking lipid layer thickness measurements occurring at 15 minutes and 1 hour after instillation. After a washout period, they returned to repeat the testing using one drop of Refresh Optive before taking lipid layer thickness measurements.
89374143|NCT03345979|Active Comparator|Treatment Group 2|Regular injections
89374144|NCT04654338|Experimental|Intervention Arm|
89374145|NCT02696434|Active Comparator|PBO NTX + BUP|Placebo naltrexone + buprenorphine
89374146|NCT02696434|Experimental|NTX + BUP|Naltrexone + buprenorphine
88846113|NCT03380780|Experimental|Emicizumab|
88846114|NCT00376064|Experimental|SMS995 + Carbegolin, Somavert + SMS995|
89374147|NCT04615416|Experimental|Emotion Regulation Training via Telehealth|All participants will receive 9 sessions of Emotion Regulation Training delivered via telehealth. These individualized therapy sessions are 1-hour in length and occur semi-weekly over the course of four weeks.
89374148|NCT03345901|Experimental|Pemafibrate|.2 mg pemafibrate orally BID
88846115|NCT03581084|Experimental|N-acetylcysteine|"This study will look at the effects of a medication, called n-acetylcysteine or NAC, on lung function. NAC is already approved for use in people with chronic airway conditions, including asthma. However, it is not known who this medication works best in. We believe this medication will likely have the most benefit in people with asthma that have mucus in their airways or mucus plugging. Initial study procedures will include lung function measurements, a low dose CT scan, a blood draw, and a sputum induction. The CT lung imaging will identify asthmatics with mucus plugs."
88846116|NCT03383588|Active Comparator|bupivacaine 0.25%|standard intrathecal bupivacaine (Marcaine) 0.75% 1.5-1.7 ml, intrathecal morphine (Duramorph) 150mcg plus intrathecal fentanyl 10 mcg + 20 ml subcutaneous bupivacaine (Marcaine) 0.25%
89374149|NCT03345901|Placebo Comparator|Placebo|Placebo pill orally BID
89374150|NCT02393092|Experimental|BVA Only|Study participants in this arm will only receive a Brief Violence Awareness (BVA) intervention.
89374151|NCT02393092|Experimental|BVP Only|Study participants in this arm will only receive a Brief Violence Prevention (BVP) intervention.
89374152|NCT02393092|Experimental|Emerging Leaders plus BVP|Study participants in this arm will participate in the Emerging Leaders: East End curriculum at the Boys and Girls Club of Metro Richmond, Martin Luther King Jr. Middle School site. They will also receive a Brief Violence Prevention (BVP) intervention.
89374153|NCT03166462|No Intervention|Control|"Patients in this arm will proceed through the current standard of care for pre-operative screening performed by either the patient's primary care physician or the pre-operative anesthesia clinic which screens patients prior to total knee or total hip arthroplasty."
89374154|NCT03166462|Experimental|Intervention|Patients in this arm will be referred to the Sleep Medicine clinic at the University of Miami Hospital for additional testing and evaluation for obstructive sleep apnea. If they are successfully diagnosed, they will receive appropriate treatment and any interventions for the peri-operative period as recommended by the pulmonary medicine team.
89374155|NCT03166540|Experimental|low consumers|1 cup of espresso coffee/day at 9.00 A.M. for 1 month
88846117|NCT03383588|Active Comparator|bupivacaine 0.25% + epinephrine|standard intrathecal bupivacaine (Marcaine) 0.75% 1.5-1.7 ml, intrathecal morphine (Duramorph) 150mcg plus intrathecal fentanyl 10 mcg + 20 ml subcutaneous bupivacaine (Marcaine) 0.25% with Epinephrine
89374156|NCT03166540|Experimental|high consumers|3 cup of espresso coffee/day at 9.00 A.M. 12.00 P.M. and 3.00 P.M. for 1 month
88846118|NCT03383588|Placebo Comparator|Saline Solution|standard intrathecal bupivacaine (Marcaine) 0.75% 1.5-1.7 ml, intrathecal morphine (Duramorph) 150mcg plus intrathecal fentanyl 10 mcg + 20 ml subcutaneous NACL 0.9% (placebo)
89374157|NCT03166540|Experimental|medium consumers|1 cup of espresso coffee at 9.00 A.M. + cocoa-based products containing coffee at 12.00 P.M. and 3.00 P.M. for 1 month
89374158|NCT02950831|Experimental|Activity and sleep quality recording|Patients will receive a wrist worn accelerometer and accelerometry will be used to monitor physical activity and sleep quality during standard BurstDR Spinal Cord Stimulation clinical treatment
89374159|NCT03709147|Experimental|FAME arm|"cisplatin 75 mg/mq every three weeks OR carboplatin (CBDCA) at an area under the curve (AUC) of 5 every three weeks, up to a maximum of 4 cycles~pemetrexed 500 mg/mq every three weeks~pembrolizumab 200 mg flat dose every three weeks~metformin hydrochloride up to a daily dosage of 1500 mg~every-three week, 5-day Fasting-mimicking diet (FMD), up to a maximum of 4 cycles"
88846119|NCT03388268|Active Comparator|Oral vancomycin|125mg of oral vancomycin four times per day
88846120|NCT03388268|Placebo Comparator|Placebo|Placebo four times per day
88846121|NCT00422786|Experimental|CAP-232|Continuous IV infusion over 21 days at 0.48 mg/kg/day followed by a 7-day rest period.
88846122|NCT03581474|Other|aScope 3 Large|Bronchoscopic procedure
88846123|NCT03390842|Experimental|TRC101|Administered once daily (QD) for 40 weeks
88846124|NCT03390842|Placebo Comparator|Placebo|Administered once daily (QD) for 40 weeks
88846125|NCT02177136|Experimental|1.5 mg OCA titrating to 3 mg OCA|Participants randomized to 1.5 mg OCA took 1.5 mg OCA daily for 12 weeks during the DB phase. If tolerated, the dose was increased to 3 mg OCA daily for an additional 12 weeks.
88846126|NCT02177136|Experimental|5 mg OCA titrating to 10 mg OCA|Participants randomized to 5 mg OCA took 5 mg OCA daily for 12 weeks during the DB phase. If tolerated, the dose was increased to 10 mg OCA daily for an additional 12 weeks.
88846127|NCT02177136|Experimental|Placebo|Participants randomized to placebo took placebo for 24 weeks during the DB phase.
89374160|NCT03709147|Experimental|MERCY arm|"cisplatin 75 mg/mq every three weeks OR carboplatin (CBDCA) at an area under the curve (AUC) of 5 every three weeks, up to a maximum of 4 cycles~pemetrexed 500 mg/mq every three weeks~pembrolizumab 200 mg flat dose every three weeks~metformin hydrochloride up to a daily dosage of 1500 mg"
89374161|NCT03709147|No Intervention|BORN arm|Standard clinical approach.
89399325|NCT02173106|Experimental|Group A: steroid & Cyclosporin|oral methylprednisolone 0.4mg/kg/d and 3.5~5mg/kg/d cyclosporin for 6 months.
88846128|NCT02177136|Experimental|LTSE OCA Total|Following completion of the DB phase, participants were asked to reconfirm their consent for participation in the LTSE phase (planned as a further 24 months) beginning at 5 or 10 mg OCA, based on the last treatment received during the DB phase. Doses up to 10 mg daily were evaluated. All participants received open-label OCA during the LTSE phase of the study.
88846129|NCT03393494|Experimental|Perrigo active|Test product
89399326|NCT02173106|No Intervention|Group B: no steroid & Cyclosporin|no steroid and cyclosporin and waiting for spontaneous remission for 6 months
88846130|NCT03393494|Active Comparator|Reference active|RLD product
88846131|NCT03393494|Placebo Comparator|Perrigo placebo|placebo product
88846132|NCT03588806|Experimental|Xtampza ER (oxycodone) Treatment|Following baseline assessments, subjects will have their current opioid medication changed to Xtampza ER (oxycodone) for the duration of the study. A standard conversion table will be used to calculate the dose of Xtampza ER that is equivalent to the subject's current opioid medication dosage. Subjects will be converted to 75% of the calculated dose for the first 7-10 days and then to 100% of the calculated dose for the remaining 3 weeks of the study. The Xtampza ER dosage may be modified at the discretion of the PI to ensure the safety of the subject. As per manufacturer recommendations, subjects will be instructed to open the capsules, sprinkle the microspheres onto soft food such as pudding or applesauce, and then consume the food.
88846133|NCT02176356|Other|All Participants|JUVÉDERM® ULTRA XC and/or JUVÉDERM® ULTRA PLUS XC and/or JUVÉDERM® VOLUMA® XC injection into facial areas, volume as determined by the investigator on Day 1 with additional treatment at Day 14 if applicable. LATISSE® 1 drop applied to upper eyelid at the base of the eyelashes once daily in the evening for 17 weeks beginning on Day 1. BOTOX® Cosmetic 20U total dose per treatment to glabellar areas and/or 24U total dose per treatment to crow's feet line areas at Month 3.
88846134|NCT03591068|Experimental|OPN-375 186 mcg BID|
88846135|NCT02210208|Experimental|Mepitel® Ag|A dressing device used for surgical burn wounds with skin graft.
88846136|NCT02210208|Experimental|Mepilex® Transfer Ag|Donor site dressing device in the very same patient.
88846137|NCT03395990|Active Comparator|chloroprocaine|15 ml of 2% chloroprocaine via a femoral nerve block technique
88846138|NCT03395990|Sham Comparator|saline|15 ml of 0.9% saline via a femoral nerve block technique
88846139|NCT00376922|No Intervention|usual care|
88846140|NCT00376922|Experimental|Music therapy|
88846141|NCT02209506|Experimental|Cohort 1A: MLN3126 100 mg Non-Japanese Participants|MLN3126 100 mg, administered orally as tablets once on Day 1, followed by a 7 day washout period, followed by once daily administration for 7 days (Days 9 through 15) in healthy, non-Japanese participants.
89374162|NCT02392858|Other|influenza cohort|"Influenza is a major cause of morbidity and mortality. The investigators' first goal is to evaluate soluble HLA-G5 isoform serum level as a potential marker of greater risk of death from Influenza respiratory illness in adult and pediatric patients hospitalized in reanimation.~1 control group of 30 patients (ancillary study) will be constitued to have reference values of the HLA-G5 marker.~Secondly, the investigators collected respiratory samples in order to study the transcriptomic profiles of influenza-infected patients with severe symptoms."
89374163|NCT02393170|Experimental|self-training using video-games|Participants will receive a video-game console and will be asked to play video-games for one hour a day X 6 days a week for 5 weeks.
89374164|NCT02393170|Active Comparator|traditional self-training|Participants will receive a manual and kit of a traditional self-training program and will be asked to perform the program one hour a day X 6 days a week for 5 weeks.
89374165|NCT03709069|No Intervention|Traditional Group|"Traditional group receives diet from hospital kitchen quantity of which calculated depending on calorie requirement per kg body weight. This diet is same for all burn patients fulfilling the inclusion criteria of the study and it will be labelled as routine diet.~Wounds of patients will be managed by closed dressing to be changed on every third day."
89374166|NCT03709069|Experimental|Albumin Group|Interventional group receiving enteral supplemental albumin 2mg per kg body weight along with routine hospital kitchen diet same as group A and same wound management with closed dressing to be changed on every third day similar to group A.
89374167|NCT02398474|Experimental|iliac crest bone graft with a TFP block|Regional anesthesia (RA) for the upper or lower limb depending on the surgery + general anesthesia (GA) + TFP block
89374168|NCT02398474|Active Comparator|local anesthetic infiltration of the surgical site.|RA for the upper or lower limb depending on the surgery + GA + ropivacaine infiltration of the iliac crest bone
89374169|NCT01311973||Renal Function Group #1|Creatinine clearance > 90 mL/min
89374170|NCT01311973||Renal Function Group #2|Creatinine clearance 60-69 mL/min
89181381|NCT02585037|Experimental|Kinesio Taping for inhibition|For inhibition of muscle activity (G2 group), the Kinesio Taping® bandage will be placed over the muscle starting at the insertion location and ending at the muscle origin. Bandage in group G2 will be applied following the protocol proposed by method of technical, which defined the direction of the bandage and an applied tension of 10% to 15% (paper off). With a dynamometer Jamar® pressure the grip strength will be messure in four stages: immediately before placing the Kinesio Taping®, 24 h, 48 h, and 72 h after its application.
89374171|NCT01311973||Renal Function Group #3|Creatinine clearance 50-59 mL/min
89374172|NCT01311973||Renal Function Group #4|Creatinine clearance 40-49 mL/min
89374173|NCT01311973||Renal Function Group #5|Creatinine clearance 30-39 mL/min
89374174|NCT01311973||Renal Function Group #6|Creatinine clearance 20-29 mL/min
89374175|NCT01311973||Renal Function Group #7|Creatinine clearance < 20 mL/min (not on dialysis)
89374176|NCT02398318|Active Comparator|Bilateral Nucleus Accumbens DBS|6 month period of active bilateral nucleus accumbens DBS
89374177|NCT02398318|Sham Comparator|Sham Bilateral Nucleus Accumbens DBS|6 month period of sham bilateral nucleus accumbens DBS
89374178|NCT03710317|Active Comparator|carbetocin|100 μg carbetocin ampoule will be diluted in 10 mL normal saline and administered slowly (over 30-60 s) intravenously by the anesthetist after the birth of the baby
89374179|NCT03710317|Experimental|Tranexamic acid plus misoprostol|400 μg buccal misoprostol (2 tablets of 200 μg) will be given after spinal anesthesia and few minutes before skin incision in addition to 1 gm tranexamic acid in 100 mL of intravenous solution infusion over 15 min.
89374180|NCT02392780|Experimental|Cannabidiol|
89374181|NCT03710239|Active Comparator|Dilapan-S|Synthetic osmotic dilator
89374182|NCT03710239|Active Comparator|Laminaria|Seaweed-based osmotic dilator
89374183|NCT02393014|Experimental|Low fall risk|low fall risk patients
89374184|NCT02393014|Experimental|Medium fall risk|medium fall risk patients
89374185|NCT02393014|Experimental|High fall risk|high fall risk patients
89374186|NCT04474392||At-Risk (N=180)|"No evidence of inflammatory arthritis on clinical examination AND~At elevated risk for RA based on familial or serologic risk~Familial risk includes having a first degree relatives (FDRs) with RA~Serologic risk includes asymptomatic serum ACPA positivity~There will be 1 study visit per year for 3 years; for a subset of 30 of these participants, there will be an additional 3 quarterly visits in one year.~Study Procedures (Baseline & Follow-up):~Questionnaires~Physical and joint exam~Measurement of participants' height, weight~Blood and sputum collection"
88846142|NCT02209506|Experimental|Cohort 2A: MLN3126 300 mg Non-Japanese Participants|MLN3126 300 mg, administered orally as tablets, orally, once on Day 1, followed by a 7 day washout period, followed by once daily administration for 7 days (Days 9 through 15) in healthy, non-Japanese participants.
88846143|NCT02209506|Experimental|Cohort 3A: MLN3126 800 mg Non-Japanese Participants|MLN3126 800 mg, administered orally as tablets once on Day 1, followed by a 7 day washout period, followed by once daily administration for 7 days (Days 9 through 15) in healthy, non-Japanese participants.
89374187|NCT04474392||Healthy Controls (N=120)|"No history of RA~No FDRs with RA~No systemic use of immunosuppressants for autoimmune disease~Participants will return for 1 follow-up visit, approximately 1 year after their baseline visit.~Study Procedures (Baseline & Follow-up):~Questionnaires~Physical and joint exam~Measurement of participants' height, weight~Blood and sputum collection"
89374188|NCT04474392||RA Diagnosis (N=40)|"Classified RA by 1987 ACR and/or 2010 ACR/EULAR RA classification criteria (confirmed by medical chart review) OR~Diagnosed with RA by a board-certified rheumatologist (confirmed by medical chart review)~Participants will return for 1 follow-up visit, approximately 1 year after their baseline visit.~Study Procedures (Baseline & Follow-up):~Questionnaires~Physical and joint exam~Measurement of participants' height, weight~Blood and sputum collection"
89374189|NCT02392390|Experimental|The study population|"A total of 10 leg ulcer patients will be recruted for this study. All will have the experimental treatment.~Intervention: Topical Dynamic Phototherapy (TDP)"
89374190|NCT02392546|Experimental|Elobixibat 10 mg|elobixibat
88846144|NCT02209506|Experimental|Cohort 4A: MLN3126 TBD Non-Japanese Participants|The MLN3126 dose for this Cohort will be determined based on data collected from Cohort 3A. MLN3126, tablets, administered orally, once on Day 1, followed by a 7 day washout period, followed by once daily administration for 7 days (Days 9 through 15) in healthy, non-Japanese participants.
89374191|NCT02392546|Experimental|Elobixibat 15 mg|elobixibat
89374192|NCT02392546|Experimental|Elobixibat 20 mg|elobixibat
89374193|NCT02392546|Placebo Comparator|Placebo|placebo
89374194|NCT02392702|Active Comparator|C-10355, 25 mg|single oral dose.
89374195|NCT02392702|Active Comparator|C-10358, 25 mg|single oral dose.
88846145|NCT02209506|Experimental|Cohorts 1A - 4A: Matched Placebo Non-Japanese Participants|MLN3126 placebo-matching tablets, administered orally, once on Day 1, followed by a 7 day washout period, followed by once daily administration for 7 days (Days 9 through 15) in healthy, non-Japanese participants.
88846146|NCT02209506|Experimental|Cohort 1B: MLN3126 100 mg Japanese Participants|MLN3126 100 mg, administered orally as tablets, once on Day 1, followed by a 7 day washout period, followed by once daily administration for 7 days (Days 9 though 15) in healthy, Japanese participants.
88846147|NCT02209506|Experimental|Cohort 2B: MLN3126 300 mg Japanese Participants|MLN3126 300 mg, administered orally as tablets, once on Day 1, followed by a 7 day washout period, followed by once daily administration for 7 days (Days 9 through 15) in healthy, Japanese participants.
88846148|NCT02209506|Experimental|Cohort 3B: MLN3126 800 mg Japanese Participants|MLN3126 800 mg, tablets, orally, once on Day 1, followed by a 7 day washout period, followed by MLN3126 800 mg, tablets, orally, once daily for 7 days (Days 9 through 15) in healthy, Japanese participants.
88846149|NCT02209506|Experimental|Cohort 4B: MLN3126 TBD Japanese Participants|The MLN3126 dose for this Cohort will be determined based on data collected from Cohort 3B. MLN3126, tablets, administered orally, once on Day 1, followed by a 7 day washout period, followed by once daily administration for 7 days (Days 9 through 15) in healthy, Japanese participants.
88846150|NCT02209506|Experimental|Cohorts 1B - 4B: Matched Placebo Japanese Participants|MLN3126 placebo-matching tablets, administered orally, once on Day 1, followed by a 7 day washout period, followed by once daily for 7 days (Days 9 through 15) in healthy, Japanese participants.
89374196|NCT02392702|Active Comparator|C-10355 or C-10358, 75 mg|single oral dose.
89374197|NCT02392702|Active Comparator|C-10355 or C-10358, 150 mg|single oral dose.
89374198|NCT02392702|Active Comparator|Kalydeco, 150 mg|single oral dose.
88846151|NCT02153736|No Intervention|Usual Care Group|This group of subjects will receive usual care provided in the medial system and community.
89181382|NCT02585037|Placebo Comparator|Kinesio Taping and Placebo|For the control group (G3 group) the Kinesio Taping® bandage will be placed from the lateral extremity to the medial axis. Bandages in the G3 group will be applied laterally to produce a similar visual effect, which control for the placebo effect, but without tension so that a muscle stimulus will be not generated. With a dynamometer Jamar® pressure the grip strength will be messure in four stages: immediately before placing the Kinesio Taping®, 24 h, 48 h, and 72 h after its application.
89181383|NCT02584881|Experimental|Intervention|A safe opioid prescription protocol will be implemented with these trauma patients
89181384|NCT02584881|No Intervention|Control|Standard care at discharge will be implemented with these trauma patients
89374199|NCT02392702|Active Comparator|C-10355 or C-10358, 300 mg|single oral dose.
89374200|NCT02392468|Experimental|BI 409306 low dose|low dose of BI 409306
89374201|NCT02392468|Experimental|BI 409306 high dose|high dose of BI 409306
89374202|NCT02397928|Experimental|TTFields concomitant to pemetrexed plus cisplatin/carboplatin|Patients will be treated continuously with TTFields, in addition to pemetrexed plus cisplatin/carboplatin
89374203|NCT05744440|Experimental|allogenic NK cells|Enrolled patients will receive prespecified dose of allogenic NK cells
88846152|NCT02153736|Experimental|SPEEDI Intervention|This group will receive and parent and physical therapy provided intervention to increase the infants opportunities for play which will enhance development.
89002277|NCT06319222|Other|Digital Clinic Arm|The Ria Treatment Platform (RTP) application will be downloaded onto the patient's smart phone or tablet.
89374204|NCT03734627||Upper Gastrointestinal Surgery - Transit|
89374205|NCT03734627||Control - Transit|
89374206|NCT03734627||Upper Gastrointestinal Surgery - Gut Function|
89374207|NCT03734627||Control - Gut Function|
89374208|NCT02397850|Experimental|30 min or 50 min|Patients receive either seven 30 minutes or 50 minutes phone calls over 6 months (psychotherapy/continuation treatment)
89374209|NCT03734549||technical success group|Technical success was defined as crossing the CTO and placement of a guidewire in the distal true lumen confirmed by angiography.
89374210|NCT03734549||technical failure group|Technical failure was defined that guidewire could not crossing through the CTO nor reture to the true lumen by angiography.
89374211|NCT03734549||had adverse events group|Patients had one of the adverse events such as all-cause death, nonfatal myocardial infarction, repeat revascularization or amputation.at 12 months after procedures.
89374212|NCT03734549||had no adverse events group|Patients had none adverse events such as all-cause death, nonfatal myocardial infarction, repeat revascularization and amputation at 12 months after procedures
89374213|NCT02397772|Active Comparator|Annual school-based deworming|Pre-school and school children (typically 2-14 years) will receive albendazole treatment from trained school teachers, as part of the ongoing national school-based deworming programme.
89374214|NCT02397772|Experimental|Annual community-based deworming|Standard school-based deworming supplemented by annual community-based deworming (2-99 years). All household members who are not enrolled in school will receive albendazole treatment from trained community health workers.
89374215|NCT02397772|Experimental|Biannual|Biannual school- and community-based deworming (2-99 years). All household members who are not enrolled in school will receive albendazole treatment from trained community health workers
88846153|NCT02175966|Experimental|Arm 1: DCV/ASV/BMS-791325+Sofosbuvir|"Initial Therapy:~Daclatasvir/Asunaprevir/BMS-791325 [30 mg (as the free base)/200 mg/75 mg (as the free base)] film coated Fixed Dose Combination tablet twice daily orally for 4 weeks~Sofosbuvir 400 mg tablet once daily orally for 4 weeks"
88846154|NCT02175966|Experimental|Arm 2: DCV/ASV/BMS-791325 + Sofosbuvir|"Initial Therapy~Daclatasvir/Asunaprevir/BMS-791325 [30 mg (as the free base)/200 mg/75 mg (as the free base)] film coated Fixed Dose Combination tablet twice daily orally for 6 weeks~Sofosbuvir 400 mg tablet once daily orally for 6 weeks"
88846155|NCT02175966|Experimental|Rescue Therapy: Arm 1:DCV/ASV/BMS-791325+RBV±PegIFNα-2a|"Daclatasvir/Asunaprevir/BMS-791325 [30 mg (as the free base)/200 mg/75 mg (as the free base)] film coated Fixed Dose Combination tablet twice daily orally for 12 weeks~Ribavirin 200 mg tablets twice daily (1000 or 1200 mg per day based on weight) orally for 12 weeks~With or without Peginterferon α-2a 180 µg solution for injection subcutaneously once weekly for 12 weeks"
89181385|NCT04098692|Experimental|Single-Arm: Derazantinib (Part 1 and Part 2)|"Part 1: 300 mg Derazantinib oral administration followed by 100 μg [14C]-Derazantinib intravenous microdose~Part 2: 300 mg [14C]-Derazantinib oral administration"
89181386|NCT04080219||Normal|Patients with Oxygen desaturation index <5
89181387|NCT04080219||Sleep-disordered breathing|Patients with Oxygen desaturation index ≥5
89181388|NCT03983096||test group|Patients with invasive breast cancer diagnosed by menstrual histology in 2014-2018 and receiving neoadjuvant chemotherapy, or patients with invasive breast cancer diagnosed by menstrual histology in 2014-2016 and receiving adjuvant chemotherapy. That used Pegylated liposomal doxorubicin for treat.
89181389|NCT03983096||control group|Patients with invasive breast cancer diagnosed by menstrual histology in 2014-2018 and receiving neoadjuvant chemotherapy, or patients with invasive breast cancer diagnosed by menstrual histology in 2014-2016 and receiving adjuvant chemotherapy. That used epirubicin for treat.
89181390|NCT04098536|Experimental|Diesel Exposure|
89181391|NCT04098536|Placebo Comparator|Filtered Air Exposure|
89181392|NCT04079985|Experimental|Experimental Group|"The experimental Group underwent a therapeutic intervention based on sessions of kinesitherapy , which is defined as a set of therapeutic procedures that use movement for the treatment and prevention of diseases of the locomotive apparatus. The experimental group also underwent AAT. We conducted a total of 12 weekly sessions of 60 minutes each with 10 participants."
89181393|NCT04079985|Active Comparator|Control Group|"The Control Group underwent a therapeutic intervention based on sessions of kinesitherapy , which is defined as a set of therapeutic procedures that use movement for the treatment and prevention of diseases of the locomotive apparatus without the presence of the therapy dog."
89181394|NCT04080141||PD+|Subjects with personality disorder
89181395|NCT04080141||PD-|Subjects without personality disorder
89181396|NCT00920517|Active Comparator|1|Participants will receive 1 injection of rDEN2/4delta30(ME) or placebo vaccine on Days 0 and 180
89181397|NCT00920517|Active Comparator|2|Participants will receive 1 injection of rDEN2/4delta30(ME) or placebo vaccine on Days 0 and 120
89181398|NCT02584569|Experimental|TAK-915|TAK-915 100 mg suspension, orally, once on Day 1. Additional TAK-915 dose levels may be incorporated based on dose level review meetings (DLRMs) following approximately every 2 participants and based on prior occupancy, duration of occupancy, safety, tolerability, and available pharmacokinetic (PK) data.
89181399|NCT00761462|Experimental|Ciprofloxacin|Subjects receiving Ciprofloxacin (group followed-up for 5 years)
89181400|NCT00761462|Active Comparator|Non-quinolone antibiotic|Subjects receiving non-quinolone antibiotic (group followed-up for 2 years)
89181401|NCT04101032|Experimental|eBEfree|eBEfree is a ICT-delivery version of BEfree - eBEfree that comprises 12 online sessions, based on mindfulness,values and compassion components for women with Binge Eating.
89181402|NCT04101032|No Intervention|Waiting List|Participants will remain in a waiting list. After 12 weeks, they will be offered the same intervention.
89181403|NCT00761306|Experimental|Vortioxetine|
89181404|NCT02584491|Experimental|Functional gait-related training|16 session, 6-week intensive functional gait-related training intervention based on motor learning principles that includes a motor imagery practice component.
89181405|NCT04079595|Experimental|Open-faced head immonbilization masks|Masks used for immobilization of the head (CIVCO Radiotherapy, Orange City, Iowa) during radiation therapy with openings for the face
89181406|NCT04079595|Active Comparator|Closed-face head immobilization masks|Masks used for immobilization of the head (CIVCO Radiotherapy, Orange City, Iowa) during radiation therapy with the face closed
89181407|NCT00772538|Experimental|tiotropium 5mcg/day|patient to receive double-blind treatment with either 5mcg/day tiotropium inhalation solution or placebo inhalation solution
89181408|NCT00772538|Experimental|placebo|patient to receive double-blind treatment with either 5mcg/day tiotropium inhalation solution or placebo inhalation solution
89181409|NCT04079517|Experimental|Tamoxifen 10mg|Randomised dose of daily oral Tamoxifen 10mg, for 180 days
89181410|NCT04079517|Active Comparator|Tamoxifen 20mg|Randomised dose of daily oral Tamoxifen 20mg, for 180 days
89181411|NCT02584413|Experimental|Arm 1: MRI of brain with gadolinium contrast|-Eligible children whose guardians have consented to their participation will undergo routine clinical brain MRI with gadolinium contrast. The MRI scan will last no more than 45 minutes
89374216|NCT03592745|Experimental|active tVNS + robotic arm therapy|Transcutaneous Vagus Nerve Stimulation (tVNS) will be delivered non-invasively via the ear (targeting the auricular branch of the vagus nerve) during robotic arm therapy sessions lasting ~60 minutes, 3x per week for 3 weeks.
89535026|NCT03078933|Experimental|APT001Nitric Oxide tx 2x week 12 min+SOC|APT001Nitric Oxide Therapy 2x week for 12 min. treatment time plus standard of care
88846156|NCT02175966|Other|Rescue Therapy: Arm 2: Sofosbuvir + RBV + PegIFNα-2a|"Sofosbuvir 400 mg tablet once daily orally for 12 weeks~Ribavirin 200 mg tablets twice daily (1000 or 1200 mg per day based on weight) orally for 12 weeks~Peginterferon α-2a 180 µg solution for injection subcutaneously once weekly for 12 weeks"
89181412|NCT00761150|Experimental|Open-label ABT-712|2 ABT-712 extended-release tablets, twice daily, for up to 3 weeks (open-label period).
88846157|NCT02153346|Other|Arm 1|Intervention 1 & 2 are associated with Arm 1. All patients enrolled in the study will possibly receive both the valuation of lost productivity and work productivity and activity impairment questionnaires, which are outside of the patient's usual care.
88846158|NCT04750512|Experimental|real ESP, placebo TAP|US-guided ESP block + sham US-guided TAP block
88846159|NCT04750512|Active Comparator|real TAP, placebo ESP|sham US-guided ESP block + US-guided TAP block before laparoscopic hernia repair
88846160|NCT02174562|Experimental|Primary Care-Occupational Therapy|PC-OT consists of: 1) primary care physician (PCP) - occupational therapist (OT) collaboration; 2) DM education tailored to cognitive impairment; 3) in-home OT cognitive-functional assessment; and 4) OT-delivered Behavior Activation to increase adherence to medications and other diabetes self-management (DSM) practices (e.g., diet).
88846161|NCT02174562|Placebo Comparator|Enhanced Usual Care|Usual care enhanced with education and controls for attention
88846162|NCT05138406|Experimental|Graded Motor Imagery|Individuals will receive standard rehabilitation and graded motor imagery treatment.
88846163|NCT05138406|Active Comparator|Standard Rehabilitation Group|Standard rehabilitation will be applied.
88846164|NCT02136576|Active Comparator|Sensodyne|There are no specific characteristics for inclusion in this group. Enrollment will be determined randomly.
88846165|NCT02136576|Active Comparator|Crest Cavity Protection & MI Paste Plus|There are no specific characteristics for inclusion in this group. Enrollment will be determined randomly.
88846166|NCT02136576|Active Comparator|Clinpro 5000|There are no specific characteristics for inclusion in this group. Enrollment will be determined randomly.
88846167|NCT03600194|Active Comparator|PowerSleep Stim|In this arm soft audio tones (below 65dB) will be administered by the PowerSleep Stim Device during deep sleep as determined by the functionality of the device.
88846168|NCT03600194|Placebo Comparator|PowerSleep Sham|This PowerSleep Sham device is the same as the PowerSleep Stim device, however, it can be configured in a mode that does not play audio tones
89181413|NCT00761150|Experimental|Double-blind ABT-712|2 ABT-712 extended-release tablets, twice daily, for 4 weeks (double-blind period).
89181414|NCT00761150|Placebo Comparator|Double-blind Placebo|2 placebo tablets, twice daily, for 4 weeks (double-blind period).
88846169|NCT03600194|Active Comparator|Northwestern Stim|The NorthWestern Stim device is set up will function similarly to the PowerSleep prototype. Acoustic stimulation provided by headphones with an audible soft volume that do not result in arousals will be used.
88846170|NCT03600194|Placebo Comparator|Northwestern Sham|The Northwestern Sham device will be the same as the Northwestern Stim set up, however no audio tones will be played.
88846171|NCT03398330|Experimental|Oxycodone Tamper Resistant|Oxycodone Tamper Resistant (OTR) Tablet 40 mg
88846172|NCT03398330|Active Comparator|OXYCONTIN®|OXYCONTIN® Tablet 40 mg
88846173|NCT03398798|Active Comparator|".014 with twin brackets"|".014 dimension CuNiTi orthodontic arch wires and .022 slot Ormco Insignia Metal Twin brackets."
88846174|NCT03398798|Active Comparator|".016 with twin brackets"|".016 dimension CuNiTi orthodontic arch wires and .022 slot Ormco Insignia Metal Twin brackets."
88846175|NCT03398798|Active Comparator|".014 with self-ligating brackets"|".014 dimension CuNiTi orthodontic arch wires and .022 slot Ormco Insignia SL (self-ligating) brackets."
88846176|NCT03398798|Active Comparator|".016 with self-ligating brackets"|".016 dimension CuNiTi orthodontic arch wires and .022 slot Ormco Insignia SL (self-ligating) brackets."
88846177|NCT03400748|Experimental|RF Ablation|Single-arm study where subjects receive RF ablation prior to a scheduled surgical resection.
88846178|NCT03505190|Experimental|RO7062931 0.3mg/kg|Participants will receive subcutaneously (SC) 0.3 milligram per kilogram (mg/kg) of RO7062931.
88846179|NCT03505190|Experimental|RO7062931 1.0mg/kg|Participants will receive subcutaneously (SC) 1.0 milligram per kilogram (mg/kg) of RO7062931.
88846180|NCT03505190|Experimental|RO7062931 2.0mg/kg|Participants will receive subcutaneously (SC) 2.0 milligram per kilogram (mg/kg) of RO7062931.
88846181|NCT03505190|Experimental|RO7062931 4.0mg/kg|Participants will receive subcutaneously (SC) 4.0 milligram per kilogram (mg/kg) of RO7062931.
88846182|NCT03505190|Placebo Comparator|Placebo|Participants will receive matching placebo.
89181415|NCT00760994|Experimental|1 - Experiential Accepatance|Experiential acceptance
89181416|NCT00760994|Active Comparator|2 - Cognitive Restructuring|Cognitive restructuring
89181417|NCT00760994|Placebo Comparator|3 - Control|No-intervention control: Nutrition information
89181418|NCT00583557|Experimental|Belimumab|
88846183|NCT04734704|Experimental|vitiligo patients|Adult patients diagnosed with Vitiligo according to usual criteria
88846184|NCT04734704|Experimental|metastatic melanoma patients under anti-PD-1 who did not develop cutaneous irAEs|metastatic melanoma patients under anti-PD-1 who did not develop Cutaneous Immune-Related Adverse Events (cutaneous irAEs).
88846185|NCT04734704|Experimental|Metastatic melanoma patients under anti-PD-1 who developed vitiligo lesions|patients with metastatic melanoma, under anti-PD-1 who developed vitiligo lesions
88846186|NCT04734704|Experimental|metastatic melanoma patients with vitiligo lesions under anti-PD-1 who discontinued|Metastatic melanoma who developed vitiligo lesions under anti-PD-1 who discontinued the treatment
88846187|NCT03513848|Experimental|Bright Light|
88846188|NCT03513848|Placebo Comparator|Dim Light|
88846189|NCT03402932|Experimental|Auditory Amplified-Visual|This arm is designed to test the contrast between auditory amplified and visual conditions.
88846190|NCT03402932|Experimental|Auditory Amplified-Unamplified|This arm is designed to test the contrast between auditory amplified and unamplified conditions.
88846191|NCT03402932|Experimental|Auditory Unamplified-Visual|This arm is designed to test the contrast between auditory unamplified and visual conditions.
88846192|NCT03402932|Other|Younger control group|This arm is designed to validate the visual version by comparing to the auditory version in a group of younger normal hearing controls.
88846193|NCT03621878|Active Comparator|Control group|Patients in this group had 6 sessions in 2 weeks of Transcutaneous Electric Nerve Stimulation (TENS).
88846194|NCT03621878|Experimental|Tensioner Group|Patients in this group had 6 sessions in 2 weeks of TENS combined with neural mobilization exercises (Tensioner technique).
89181419|NCT00586820|Experimental|BQ-123|BQ-123 will be infused at 300 nmol/min for 20 minutes prior to percutaneous coronary intervention (PCI).
89181420|NCT00586820|Placebo Comparator|Placebo|Subjects randomized to the placebo arm will receive a placebo infusion (saline) for 20 minutes prior to PCI.
89374217|NCT03592745|Sham Comparator|sham tVNS + robotic arm therapy|Sham (placebo) transcutaneous Vagus Nerve Stimulation (tVNS) will be delivered non-invasively via the ear (targeting the auricular branch of the vagus nerve) during robotic arm therapy sessions lasting ~60 minutes, 3x per week for 3 weeks.
89374218|NCT02398162||STP|Scrub Typhus Patients (STP, n=60) Cohort. Blood samples will be collected at baseline (the day of presentation to hospital), 2 weeks later in hospital, 12 weeks after baseline at the clinic visit and 1 year later. Data on clinical presentation and relapses will be recorded. Eschar swab specimens and a non-invasive specimen of the dark crust will be also collected from STP group on the day of enrollment.
88846195|NCT03621878|Experimental|Slider Group|Patients in this group had 6 sessions in 2 weeks of TENS combined with neural mobilization exercises (Slider technique).
88846196|NCT03403712|Experimental|Test group|"intravenous fosnetupitant/ palonosetron (260 mg/0.25 mg) fixed-dose combination, administered as a 30-minute infusion of a 50 mL solution, on Day 1 of each cycle.~Oral dexamethasone will be administered on Day 1 of each cycle (12 mg)"
88846197|NCT03403712|Active Comparator|Control group|"oral netupitant/palonosetron (300 mg/0.50 mg) fixed-dose combination on Day 1 of each cycle.~Oral dexamethasone will be administered on Day 1 of each cycle (12 mg)"
88846198|NCT03404648|Experimental|High Risk Prostate Cancer Patients|Subjects will receive C-11 choline PET Tracer and Gadobutrol prior to the one time Positron emission tomography (PET/MR scanner) imaging and Multiparametric Magnetic resonance imaging (mpMRI).
88846199|NCT03383198|Active Comparator|Liposomal Bupivacaine Left|Liposomal Bupivacaine left injection. Liposomal Bupivacaine is injected on the left, Bupivacaine plus Dexamethasone on the right
88846200|NCT03383198|Active Comparator|Liposomal Bupivacaine Right|Liposomal Bupivacaine right injection. Liposomal Bupivacaine injected on the right, Bupivacaine plus Dexamethasone on the left
88846201|NCT03407612|Active Comparator|CPM|These subjects received a continuous passive motion (CPM) device and were instructed to use it for 4-6 hours daily throughout the first two postoperative weeks following their arthroscopic labral repair. They were provided adequate education on how to operate the device. The subjects recorded their average usage of the CPM, as well as their personal perception of the CPM, at the postoperative 2 day, 7 day, and 14 day marks.
88846202|NCT03407612|No Intervention|No CPM|No CPM was administered to these subjects.
88846203|NCT03408392|Experimental|Test followed by Reference Formulation|Subjects will be randomized to receive single dose of Test formulation (SKF101804: cefixime 200 mg/ 5 mL) on Day 1 of the treatment period 1 and Reference formulation (cefixime 200 mg/5 mL) on Day 1 of the treatment period 2. There will be wash out period of 7-14 days between the two treatment periods.
88846204|NCT03408392|Experimental|Reference followed by Test Formulation|Subjects will be randomized to receive single dose of Reference formulation (cefixime 200 mg/5 mL) on Day 1 of the treatment period 1 and Test formulation (SKF101804: cefixime 200 mg/ 5 mL) on Day 1 of the treatment period 2. There will be wash out period of 7-14 days between the two treatment periods.
88846205|NCT04735484||Case|Participants will attend one data collection appointment wearing form-fitting sports clothing and trainers. Participants will wear infrared markers and wearable devices whilst walking over level ground and on a treadmill. Data will be collected using a motion capture system and the wearable devices themselves. Data collection will take approximately 90 minutes
88846206|NCT04735484||Control|Participants will attend one data collection appointment wearing form-fitting sports clothing and trainers. Participants will wear infrared markers and wearable devices whilst walking over level ground and on a treadmill. Data will be collected using a motion capture system and the wearable devices themselves. Data collection will take approximately 90 minutes
88846207|NCT03413618|Experimental|Experimental: Rivaroxaban + Diosmin + Stockings|treatment of deep vein thrombosis with anticoagulation (rivaroxaban), elastic compression stockings and additional prescription of diosmin
88846208|NCT03413618|Active Comparator|Control: Rivaroxaban + Stockings only|standard treatment of deep vein thrombosis with anticoagulation (rivaroxaban) and elastic compression stockings
88846209|NCT03522350|Active Comparator|EmbryoScope|Standard of care embryo incubator.
88846210|NCT03522350|Experimental|EmbryoScope+|New experimental embryo incubator.
88846211|NCT03523988|Active Comparator|Acetaminophen|Acetaminophen 650mg powder in gel capsule taken by mouth before entering appointment
89181421|NCT04578093|Experimental|Intervention|Will receive adjusts curriculum
89181422|NCT04578093|No Intervention|Control|Will receive unadjusted curriculum
89374219|NCT02398162||STE|Scrub Typhus Exposed (STE, n=80) Cohort. Single blood sample collection.
89374220|NCT02398162||STH|Scrub Typhus Healthy (STH, n=30) Cohort. Single blood sample collection
88810190|NCT00789776|Experimental|Treatment (non-myeloablative transplant)|"CONDITIONING: Patients receive fludarabine IV over 30 minutes on days -6 to -2 and cyclophosphamide IV over 1 hour on days -6 and -5. Patients undergo total-body irradiation on day -1.~DONOR BONE MARROW TRANSPLANTATION: Patients undergo donor bone marrow transplantation on day 0.~POST-TRANSPLANTATION IMMUNOSUPPRESSION: Patients receive cyclophosphamide IV over 1 hour on day 3 and mycophenolate mofetil PO TID on days 4 to 40, followed by a taper until day 84 in the absence of GVHD. Patients also receive tacrolimus IV continuously or IV QD over 1-2 hours or PO BID on days 4 to 84, followed by a taper until day 180 in the absence of GVHD.~NK CELL INFUSION: Patients undergo donor lymphocyte infusion of NK cells on day 7."
89181423|NCT00760838|Experimental|Azithromycin|"Azithromycin 250 mg~1x/day during 5 days 3x/week afterwards"
89374221|NCT03165838|Experimental|Postpartum Visit 3-4 Weeks|Participants will have postpartum visit scheduled 3-4 weeks after birth
89374222|NCT03165838|Experimental|Postpartum Visit 6-8 Weeks|Participants will have postpartum visit scheduled 6-8 weeks after birth
89374223|NCT02398006|Active Comparator|Group 1: a standard arm sling|Group 1: the orthopaedic surgeon will apply a standard arm sling that will be used for four weeks; however, during these weeks, participants will be encouraged to discard the sling when their pain has subsided. After four weeks the same orientations of group 1 will be done to this group.
89374224|NCT02398006|Active Comparator|Group 2: a figure-of-eight bandage|Group 2: a figure-of-eight bandage will be used for four weeks, and every week the participants will return to check and adjust the immobilisation. In this way, the dominant hand can remain free and simple activities will be allowed (writing, keyboarding and other). After four weeks, participants will be encouraged to discard the bandage, but load bearing will not be allowed before osseous consolidation (around 10 weeks).
89374225|NCT03592277|Experimental|TREATMENT with Vitamins C and B1|Patients in the Vitamins C and B1 arm will receive 1.5g of vitamin C in 100mL of 0.9% sodium chloride (normal saline) every six hours for four days or until discharge from the ICU, whichever happens first (seventeen dose maximum). In addition, they will receive 200 mg IV vitamin B1 every 12 hours in 50 mL of normal saline for four days or until ICU discharge (whichever happens first, nine dose maximum).
89374226|NCT03592277|No Intervention|PLACEBO with saline only|Patients in the placebo (control group) arm will receive the 100 mL of 0.9% sodium chloride every six hours and 50 mL of 0.9% sodium chloride every 12 hours to act as placebos for the vitamins C and B1 respectively.
89374227|NCT02398084|Experimental|Chewing of nuts|8 samples (4-5 g) of nuts (cashews or walnuts) on two separate visit days.
89374228|NCT03730805|Experimental|Intervention + open mindset|ASSIST-linked Brief Intervention plus prior induction of deliberative mindset
89374229|NCT03730805|Experimental|Intervention + closed mindset|ASSIST-linked Brief Intervention plus prior induction of closed mindset
89374230|NCT03730805|Experimental|Intervention alone|ASSIST-linked Brief Intervention without prior induction of any mindset
89374231|NCT03730805|Experimental|Control + open mindset|In stead of intervention, a neuropsychological assessment (Raven's Standard Progressive Matrices; SPM; Raven, 1940) with prior induction of an open mindset is conduced.
89374232|NCT03730805|Experimental|Control + closed mindset|In stead of intervention, a neuropsychological assessment (Raven's Standard Progressive Matrices; SPM; Raven, 1940) with prior induction of a closed mindset is conduced.
89374233|NCT03730805|No Intervention|Control alone|In stead of intervention, a neuropsychological assessment (Raven's Standard Progressive Matrices; SPM; Raven, 1940) without prior induction of any mindset is conduced.
89181424|NCT00760838|Placebo Comparator|placebo|"Placebo~1x/day during 5 days 3x/week afterwards"
89181425|NCT00920595|Experimental|1|CEP-9722 alone and in combination therapy with temozolomide.
89181426|NCT00586664|Experimental|Bepreve (Bepotastine Besilate Ophthalmic Solution) 1.5%|
89374234|NCT03167866|Placebo Comparator|control group|DM patients who receive a weekly informational Short Message Service (SMS) by phone for 26 weeks. informational SMS
89374235|NCT03167866|Experimental|test group|DM patients who receive a weekly motivational Short Message Service (SMS) for 26 weeks. motivational SMS
89374236|NCT03734471|Active Comparator|Traditional|
89374237|NCT03734471|Experimental|Reactor Device|
89374238|NCT03106246||New onset T1DM|Newly diagnosed Type I diabetic patients who are hyperglycemic but still C-peptide positive
89374239|NCT03106246||T1DM|Patients with established type I diabetes. they are hyperglycemic but C-peptide negative
89374240|NCT03106246||T2DM|Patients with established type II diabetes.
89374241|NCT03106246||Islet Transplant|Patients who received an islet transplantation for type I diabetes
89374242|NCT03106246||Healthy Volunteers|Normoglycemic healthy volunteers
88810191|NCT04384094||Test subjects|Test subjects according to the inclusion / exclusion criterias.
88810192|NCT03801590|Experimental|CXL on patients with infectious keratitis|the procedure of cross linking(CXL) :combined riboflavin-ultraviolet type A rays (UVA) collagen cross-linking. Radiant energy was 3 milliwatts/cm2 for a 30-minute exposure irradiation of the cornea will be carried out on twenty patients with infectious keratitis .
88810193|NCT03801512|Experimental|Steroid Injections|Inject steroid at neuritis nerve root.
88810194|NCT03801512|Experimental|Acupuncture|Acupuncture at acupoints BL23 to BL26.
88810195|NCT03801512|Experimental|Platelet Rich Plasma Injection|Inject Platelet Rich Plasma at neuritis nerve root.
88810196|NCT03800966|Experimental|Intervention|The intervention leaflets will contain information on the TI's tactics to get young people to smoke.
88810197|NCT03800966|Placebo Comparator|Control|The control leaflets will contain information on the tobacco control in Hong Kong.
89374243|NCT03730727|Active Comparator|Control|A liquid meal replacement shake containing 500 kcal (55% kcals from carb, 30% fat, 15% protein) will be administered at approx. 8 am following an 8-10 hour overnight fast. Postprandial blood glucose responses will be assessed for 2-hours post-ingestion. Two-hours after ingestion of the meal, participants will complete a bout of physical activity (either 30-mins of standing still, 30-mins of walking at a self-selected brisk pace on a treadmill, or 3-sets of circuit-exercises [10 squats, 10 push-ups, 10 lunges, 10 sit-ups]).
89535027|NCT03078933|Experimental|APT001Nitric Oxide tx 4x week 6 min+SOC|APT001 Nitric Oxide Therapy 4x week for 6 min. treatment time plus standard of care
89181427|NCT00586664|Experimental|Bepotastine Besilate Ophthalmic Solution 1.0%|
88846212|NCT03523988|Active Comparator|Ibuprofen|Ibuprofen 400mg powder in gel capsule taken by mouth before entering appointment
89374244|NCT03730727|Experimental|Immediate prior to meal|At approx. 8 am following an 8-10 hour overnight fast, participants will complete a bout of physical activity (either 30-mins of standing still, 30-mins of walking at a self-selected brisk pace on a treadmill, or 3-sets of circuit-exercises [10 squats, 10 push-ups, 10 lunges, 10 sit-ups]). Immediately after completion of this bout, a liquid meal replacement shake containing 500 kcal will be administered. Postprandial blood glucose responses will be assessed for 2-hours post-ingestion.
89374245|NCT03730727|Experimental|Immediate post-meal|A liquid meal replacement shake containing 500 kcal will be administered at approx. 8 am following an 8-10 hour overnight fast. Postprandial blood glucose responses will be assessed for 2-hours post-ingestion. Immediately after ingestion of the meal, participants will complete a bout of physical activity (either 30-mins of standing still, 30-mins of walking at a self-selected brisk pace on a treadmill, or 3-sets of circuit-exercises [10 squats, 10 push-ups, 10 lunges, 10 sit-ups]).
89374246|NCT03730727|Experimental|30-minutes post-meal|A liquid meal replacement shake containing 500 kcal will be administered at approx. 8 am following an 8-10 hour overnight fast. Postprandial blood glucose responses will be assessed for 2-hours post-ingestion. Thirty-minutes after ingestion of the meal, participants will complete a bout of physical activity (either 30-mins of standing still, 30-mins of walking at a self selected brisk pace on a treadmill, or 3-sets of circuit-exercises [10 squats, 10 push-ups, 10 lunges, 10 sit-ups]).
89374247|NCT03115138|Other|Patients with glial tumor|
89374248|NCT05665517|Experimental|Chatbot Little K Nurse|"The CKD chat-based instant messaging support health education system in this study was named Chatbot Little K Nurse and connected to the Line platform to set up a one-to-one line. K stands for kidney. Each group contained three parties: patients with CKD (participants ), Chatbot Little K Nurse (virtual), and an instructor (health teacher) for an enhanced intervention. According to the handbook of CKD health management by the Health Promotion Administration (2018b) and the CKD Clinical Diagnosis and Treatment Guidelines for literature investigation in Taiwan, 350 groups of question-and-answer (Q&A) corpora were formed."
88846213|NCT03523988|Experimental|Acetaminophen and Ibuprofen|Acetaminophen 650mg and Ibuprofen 400mg powder in gel capsule taken by mouth before entering appointment
89181428|NCT00586664|Placebo Comparator|Placebo|
89374249|NCT03106402||Treated with topical NSAID|197 eyes of - patients were treated with topical bromfenac sodium hydrate (Bronuck®, Taejoon Pharm. LTD.) 2times a day starting 1 day before surgery and continued for 2 weeks after surgery.
89374250|NCT03106402||Treated without topical NSAID|147 eyes did not receive topical NSAID after cataract surgery
89374251|NCT03730571|Experimental|AbsorbaSeal 6Fr Vascular Closure Device|Patients whose access site will be closed with the AbsorbaSeal 6Fr Vascular Closure Device
89374252|NCT03106168|Experimental|With periapical granuloma|Patients presenting periapical granuloma in mandibular molar teeth, diagnosed by periapical radiography
89374253|NCT03106168|Experimental|Without periapical granuloma|Patients without periapical granuloma in mandibular molar teeth, diagnosed by periapical radiography
89374254|NCT03734159|Experimental|parasternal block|preoperative parasternal block by ropivacaine injection
89374255|NCT03734159|Placebo Comparator|physiological serum|sodium chloride injection
89374256|NCT02397382|Experimental|Guselkumab and Cytochrome P450 Probe Cocktail|Participants will be administered single dose of Guselkumab 200 milligram (mg) by subcutaneous injection (2*100 mg) on Day 8 and Cytochrome P450 probe cocktail consist of midazolam, warfarin/vitamin K, omeprazole, dextromethorphan and caffeine orally once on Day 1,15 and 36.
89374257|NCT02397304|Experimental|Pre-exercise food|Pre-exercise food provision
89374258|NCT02397304|Experimental|Post-exercise food|Post-exercise food provision
89374259|NCT04869826||Outpatients Complicated Hypertension Clinic|This study population consists of approximately 200 adult male and female participants (≥ 19 years of age; minimum 30% male/female). Participants will be recruited from eligible patients who are referred to the Complicated Hypertension Clinic at the Saint John Regional Hospital (SJRH) as well as non-patient participants who are willing to volunteer to consent to participate in the study.
89374260|NCT03401112|Experimental|IMR-687 50 mg/100 mg|A starting dose of IMR-687 50 mg with dose escalation after 4 or 12 weeks, up to 100 mg was administered to participants. Duration of administration was 16 (Week 17) or 24 weeks (Week 25).
89374261|NCT03401112|Experimental|IMR-687 100 mg/200 mg|A starting dose of IMR-687 100 mg with dose escalation after 4 or 12 weeks, up to 200 mg was administered to participants. Duration of administration was 24 weeks (Week 25).
89374262|NCT03401112|Placebo Comparator|Placebo|Matching placebo was administered for 16 (Week 17) or 24 weeks (Week 25).
89374263|NCT02697916|Active Comparator|ASA 81mg|aspirin 81mg
89374264|NCT02697916|Active Comparator|ASA 325mg|aspirin 325mg
88846214|NCT03525548|Active Comparator|TEZ/IVA|Following a run-in period of 4 weeks with Tezacaftor (TEZ)/Ivacaftor (IVA), participants received TEZ 100 milligram (mg)/IVA 150 mg as fixed-dose combination (FDC) tablet in the morning and IVA 150 mg as mono tablet in the evening for 4 weeks in the triple combination (TC) treatment period.
88846215|NCT03525548|Experimental|VX-445/TEZ/IVA TC|Following a run-in period of 4 weeks with TEZ/IVA, participants received VX-445 200 mg/TEZ 100 mg/IVA 150 mg as FDC tablets in the morning and IVA 150 mg as mono tablet in the evening for 4 weeks in the TC treatment period.
88846216|NCT03528512|Experimental|IN ketamine|Intranasal ketamine 3mg/kg (max 100 mg) + saline 0.03 ml/kg (max 2ml)
88846217|NCT03528512|Active Comparator|IN midazolam and fentanyl|Intranasal midazolam 0.3 mg/kg (max 10 mg) + fentanyl 1.5mcg/kg (max 100 mcg)
88846218|NCT04735250||45° group|Uses the video stylet with 45 degree(The tip of the trachway in 45°-55°) to assist the orotracheal tube passing the oral cavity, oropharynx and advanced into the trachea
88846219|NCT04735250||70° group|Uses the video stylet with 70 degree(The tip of the trachway in 60°-70°) to assist the orotracheal tube passing the oral cavity, oropharynx and advanced into the trachea
89189316|NCT02573454|Experimental|Prosocial Exercise|Participants are provided with the intervention (App Assignment). In this arm, the participants are randomly assigned to the Prosocial Exercise group use a GPS exercise app named Charity Miles, in which users can earn donations for charities based on the miles they walk or run (approximately 25 cents for every mile).
88846220|NCT04735250||90° group|Uses the video stylet with 90 degree(The tip of the trachway in 80°-90°) to assist the orotracheal tube passing the oral cavity, oropharynx and advanced into the trachea
88846221|NCT03531710|Experimental|3 boosters|Subjects will receive 3 doses of UB-311 and 2 doses of placebo.
88846222|NCT03531710|Experimental|3 priming doses followed by 2 boosters|Subjects will receive 5 doses of UB-311.
89374265|NCT04866316||GSH Participants|"Qualitative - Semi-structured focus group discussions with care recipients~Quantitative - Pre-test post-test design using survey-based data collection~Quantitative - Retrospective cohort design with propensity score matched comparators"
88846223|NCT03533036|Experimental|Virtual Reality Intervention|VR headsets consist of a Samsung phone dedicated to playing programs designed by the AppliedVR company. The phone is inserted in the front of the headset and can play videos that can be then viewed by the participant while wearing the headset. Participants in the experimental arm will be fitted with VR headsets prior to first trimester abortion and will wear the headset during the procedure. Participants will be able to choose a program of their preference (ex. guided meditation, beautiful scenery). The patient may remove the VR device at any time during the procedure. After the procedure, investigators will carry out a qualitative interview with the participant and ask about the experience of using the VR headset during first trimester abortion. Patients will also complete surveys evaluating procedure-related anxiety. These will be administered before and after the procedure.
88846224|NCT03533036|No Intervention|Control arm|In the control group, participants will not use virtual reality during the procedure. Patients in the control arm will complete surveys evaluating procedure-related anxiety. These will be administered before and after the procedure.
88846225|NCT02153112|Experimental|Cohort 1, Group 1: 1 Dose|Children 4 to <9 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent virus-like particle (VLP) vaccine, intramuscularly (IM) and 500 µg aluminum hydroxide on Day 1, followed by placebo matching norovirus bivalent VLP vaccine IM on Day 29.
88846226|NCT02153112|Experimental|Cohort 1, Group 1: 2 Doses|Children 4 to <9 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide IM on Days 1 and 29.
88846227|NCT02153112|Experimental|Cohort 1, Group 2: 1 Dose|Children 1 to <4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 29.
88846228|NCT02153112|Experimental|Cohort 1, Group 2: 2 Doses|Children 1 to <4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.
88846229|NCT02153112|Experimental|Cohort 1, Group 2a: 1 Dose|Children 1 to <4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.
88846230|NCT02153112|Experimental|Cohort 1, Group 2a: 2 Doses|Children 1 to <4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.
88846231|NCT02153112|Experimental|Cohort 1, Group 3: 1 Dose|Toddlers 6 months to <1 year of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.
88846232|NCT02153112|Experimental|Cohort 1, Group 3: 2 Doses|Toddlers 6 months to <1 year of age will receive 2 doses either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.
88846233|NCT02153112|Experimental|Cohort 2, Group 4: 2 Doses|Infants 6 weeks to <6 months of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) formulations of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 56, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 112.
88846234|NCT02153112|Experimental|Cohort 2, Group 4: 3 Doses|Infants 6 weeks to <6 months of age received 3 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1, 56 and 112.
88846235|NCT03534986|Experimental|AffloVest The Vest Arm|Devices placed on highest intensity / highest frequency
88846236|NCT03534986|Experimental|AffloVest inCourage Arm|Devices placed on highest intensity / highest frequency
88846237|NCT03534986|Experimental|AffloVest SmartVest Arm|Devices placed on highest intensity / highest frequency
88846238|NCT03536702|Experimental|Creative Writing Workshop|The intervention arm will receive a dedicated workshop for one and a half hours every 2 weeks for 3 months.
89374266|NCT04866316||Policy owners, implementers & care partners, health and social care professionals|"Qualitative - Semi-structured in-depth interview with key policy and programme decision-makers~Qualitative - Semi-structured focus group discussions with health and social care professionals~Qualitative - Participant observations~Quantitative - Longitudinal monitoring of process indicators"
89374267|NCT04762680|Experimental|Phase 2 Cohort -SARS-CoV-2 vaccine Formulation 1|2 injections of SARS-CoV-2 vaccine Formulation 1 at Day 1 and Day 22
89374268|NCT04762680|Experimental|Phase 2 Cohort - SARS-CoV-2 vaccine Formulation 2|2 injections of SARS-CoV-2 vaccine Formulation 2 at Day 1 and Day 22
89374269|NCT04762680|Experimental|Phase 2 Cohort - SARS-CoV-2 vaccine Formulation 3|2 injections of SARS-CoV-2 vaccine Formulation 3 Day 1 and Day 22
88810198|NCT00775658|Active Comparator|olopatadine then placebo|participants received olopatadine 0.2% opthalmic solution 1 drop into each eye at the same time each day for 7 to 10 days followed by 7-10 day washout period. They then received a placebo, normal saline opthalmic solution 1 drop into each eye at the same time each day for 7-10 days
89535028|NCT03078933|Experimental|APT001Nitric Oxide tx 4x week 12 min+SOC|APT001Nitric Oxide Therapy 4x week for 12 min. treatment time plus standard of care
88810199|NCT00775658|Active Comparator|placebo then olopatadine|participants received olopatadine 0.2% opthalmic solution 1 drop into each eye at the same time each day for 7 to 10 days followed by 7-10 day washout period. They then received a placebo, normal saline opthalmic solution 1 drop into each eye at the same time each day for 7-10 days
88810200|NCT02199197|Experimental|Radium Ra 223 Dichloride and Enzalutamide|Radium Ra 223 Dichloride and Enzalutamide administered concurrently for 6 28-day cycles.
88810201|NCT02199197|Active Comparator|Enzalutamide alone|Enzalutamide administered as a single agent for 6 28-day cycles.
88810202|NCT01258985|Active Comparator|Tai Chi|12 weeks of Tai Chi classes
88810203|NCT01258985|Active Comparator|Physical Therapy|6 weeks of individualized Physical Therapy followed by 6 weeks of Supervised Home Exercise
88810204|NCT00799604|Experimental|clevidipine|"Patients were sequentially assigned to one of following three planned dose cohorts for Bolus 1 within the clevidipine arm:~Cohort 1: clevidipine 250 µg (0.5 mL)~Cohort 2: clevidipine 500 µg (1 mL)~Cohort 3: clevidipine 125 µg (0.25 mL or 0.5 mL of a 1:1 solution)"
88810205|NCT03009383|Experimental|A bedside portable endoscopy|
88810206|NCT05721482|Experimental|MIM-DASH|A trained MIM provider and dietitian will deliver the MIM DASH group intervention in eight weekly 1-hour sessions via telehealth.
88810207|NCT05721482|No Intervention|Attention Control|A trained interventionist will deliver the Caregiver Training. Participants in this group will attend eight 1-hour group lessons via telehealth for 8 weeks. We will use Alzheimer's Association caregiver training resources on topics such as Healthy Living for Your Brain and Body: Tips from the Latest Research; Dementia Conversations: Driving, Doctors Visits, Legal and Financial Planning; and Understanding and Responding to Dementia-Related Behavior. Similar to the MIM DASH group, participants will receive educational materials so they can follow along using videoconferencing or phone.
88810208|NCT00791102|Active Comparator|1|Topical ASP-1001
88810209|NCT00791102|Placebo Comparator|2|Placebo for Topical ASP-1001
88810210|NCT01259063|Experimental|Pts who failed or relapsed after intravesical BCG|Phase I: Everolimus will be administered as follows: Dose level 1: 5 mg every other day, Dose level 2: 5 mg daily, Dose level 3: 10 mg daily Phase II: Everolimus will be administered at the dose determined in Phase .Everolimus will be continued for 12 months in the patients who achieve a CR or a Partial Response. Patients demonstrating a CR (by cystoscopy and cytology) or a Partial Response at their Cycle 12 cystoscopy will be observed with serial cystoscopies every 3 months.
88810211|NCT05317052|Experimental|Massage|Massage therapy
88810212|NCT05317052|Experimental|Music|Music therapy
88810213|NCT05317052|No Intervention|Control|Control
88810214|NCT04383470||General population, during COVID pandemic|General population during COVID-19 pandemic. Adults, adolescents, and children aged 6 years or older. People working in health-care, police, fire-, and military-service vs others. People with physical illness vs others. People with mental illness vs others. Different continents, countries, and regions.
88810215|NCT04383470||General population, 6 months after COVID pandemic|General population, 6 months after COVID pandemic Adults, adolescents, and children aged 6 years or older. People working in health-care, police, fire-, and military-service vs others. People with physical illness vs others. People with mental illness vs others. Different continents, countries, and regions.
88810216|NCT04383470||General population, 12 months after COVID pandemic|General population, 12 months after COVID pandemic Adults, adolescents, and children aged 6 years or older. People working in health-care, police, fire-, and military-service vs others. People with physical illness vs others. People with mental illness vs others. Different continents, countries, and regions.
88810217|NCT01312805|Active Comparator|CHICA Control|This arm received CHICA without the asthma module
88810218|NCT01312805|Experimental|CHICA Asthma Module|This arm received the CHICA asthma module
88810219|NCT04383548|Experimental|Hyper immunoglobulins have anti-Corona VS2 immunoglobulin|safe purified hyper immunoglobulins containing anti-Corona VS2 immunoglobulins from plasma collected from COVID19 convalescent patients
88810220|NCT04383392|Experimental|Rate adaptive pacing|Turn on Rate adaptive pacing
88810221|NCT04383392|Active Comparator|No Rate adaptive pacing|Turn off Rate adaptive pacing
88810222|NCT01313507|Experimental|NewGam|Participants received NewGam 200-800 mg/kg intravenously every 3 or 4 weeks for 3 months (5 or 4 total infusions, respectively).
88810223|NCT01313897|Experimental|Velcade for Anti-MM therapy|Day(s) -9,-6,-2 3 doses of Bortezomib at 1.0 mg/m2, i.v.
88810224|NCT01341977|Experimental|Alcon MPDS|Alcon Multi-Purpose Disinfecting Solution (MPDS)
88810225|NCT01341977|Active Comparator|ReNu Fresh Multi-Purpose Solution|ReNu Fresh Multi-Purpose Solution
88810226|NCT02192879|Active Comparator|Thoracic Epidural|
88810227|NCT02192879|Active Comparator|Continuous Paravertebral Catheter|
88810228|NCT02192879|Active Comparator|Patient-Controlled Analgesia|
88810229|NCT04351763|Experimental|Amiodarone|"Amiodarone - administered intravenously~Bolus of 150 mg is given over a minimum of 10 min, with subsequent continuous infusion of 1 mg/min for 6 h, next continuous infusion of 0.5 mg/min for 18 h, then switch to oral administration.~Oral administration~200 to 400 mg/day (adjust dosage based on cardiac response and age) up to discharge."
88810230|NCT04351763|Experimental|Verapamil|"Verapamil - administered intravenously~Bolus of 0.075-0.15 mg/kg (5-10 mg) over at least 3 minutes, then switch to oral administration.~Oral administration~120 to 480 mg/day in divided doses every 6-8 hours (adjust dosage based on cardiac response and age) up to discharge."
88810231|NCT04351763|No Intervention|Usual Care|
88810232|NCT00801398|Experimental|Oxymorphone IR|Open-Label, 2 part ascending-dose multicenter study
88810233|NCT01342523|Experimental|No CIS/No loz/No Email/Lite Website/Brief Booklet|"This arm of the project will address the following question:~How effective is the following intervention?~No CIS calls, No nicotine lozenge, No motivational emails, lite website, brief mailed booklet"
89374270|NCT04762680|Experimental|Supplemental Cohort 1 - Booster Monovalent (D614)-AS03 SARS-CoV-2 vaccine|Participants who were previously vaccinated 4 to < 10 months prior with an authorized mRNA or adenovirus-vector COVID-19 vaccine will receive 1 booster injection of monovalent (D614)-AS03 SARS-CoV-2 vaccine
89374271|NCT04762680|Experimental|Supplemental Cohort 2 - Booster Monovalent (B.1.351)-AS03 SARS-CoV-2 vaccine|Participants who were vaccinated 4 to < 10 months prior with an authorized mRNA or adenovirus-vector COVID-19 vaccine or SARS-Cov-2 vaccine will receive 1 booster injection of monovalent (B.1.351)-AS03 SARS-CoV-2 vaccine
89374272|NCT04762680|Experimental|Supplemental Cohort 2 - Booster Bivalent (D614 + B.1.351)-AS03 SARS-CoV-2 vaccine|Participants who were vaccinated 4 to < 10 months prior with an authorized mRNA or adenovirus-vector COVID-19 vaccine will receive 1 booster injection of bivalent (D614+B.1.351)-AS03 SARS-CoV-2 vaccine
89181429|NCT02584335|Active Comparator|"Lidocaine solution (A)"|"Two sterile gauzes will be dampen with the content of the second syringe (the content of the first syringe is always 20 ml of saline solution and it is the first sterile gauzes administrated always) that will contain 20ml of 0.5% lidocaine dilution when the wound treatment process is assigned to the letter A. The nurse has a third syringe exactly like this second syringe to apply if necessary (process still painful to the patient)."
89374273|NCT04762680|Experimental|Supplemental Cohort 2 - Booster Monovalent (D614)-AS03 SARS-CoV-2 vaccine|Participants who were vaccinated 4 to < 10 months prior with SARS-Cov-2 vaccine will receive 1 booster injection of monovalent (D614)-AS03 SARS-CoV-2 vaccine
89374274|NCT04762680|Active Comparator|Supplemental Comparator for Cohort 1 and 2 Boosters - Monovalent (D614)-AS03 SARS-CoV-2 vaccine|2 injections of monovalent (D614)-AS03 SARS-CoV-2 vaccine at Day 1 and Day 22 in previously unvaccinated, naïve participants
89374275|NCT04762680|Experimental|Cohort 2 - Booster Exploratory 1|Participants who were vaccinated 4 to < 10 months prior with an authorized mRNA COVID-19 vaccine will receive 1 booster injection of monovalent (B.1.351)-AS03 SARS-CoV-2 vaccine
89374276|NCT04762680|Experimental|Cohort 2 - Booster Exploratory 2|Participants who were vaccinated 4 to < 10 months prior with an authorized mRNA COVID-19 vaccine will receive 1 booster injection of monovalent (B.1.351)-AS03 SARS-CoV-2 vaccine
89374277|NCT04762680|Experimental|Cohort 2 - Booster Exploratory 3|Participants who were vaccinated 4 to < 10 months prior with an authorized mRNA COVID-19 vaccine will receive 1 booster injection of monovalent (B.1.351)-AS03 SARS-CoV-2 vaccine
89374278|NCT04762680|Experimental|Cohort 2 - Booster Exploratory 4|Participants who were vaccinated 4 to < 10 months prior with an authorized mRNA COVID-19 vaccine will receive 1 booster injection of monovalent (B.1.351)-AS03 SARS-CoV-2 vaccine
89374279|NCT02392312||ATF-Fresenius S|intravenous
89374280|NCT03115216|Active Comparator|FLA-CEIOL|Femtosecond laser assisted cataract extraction and intraocular lens placement
89374281|NCT03115216|Active Comparator|CEIOL|Clear corneal incision with manual cataract extraction and intraocular lens placement
89374282|NCT01310153|Active Comparator|Prone Positioning|Newly born infant placed in prone position (face up) for the first 30 60 seconds of life after delivery by Cesarean birth.
89374283|NCT01310153|Active Comparator|Supine Positioning|newly born infant placed in supine position (face down) for the first 30 60 seconds of life after delivery by Cesarean birth.
89374284|NCT02392156||rFVIIIFc for hemophilia A|Administered based on the clinical judgment of the Prescribing Physician and according to the local approved drug label
89374285|NCT02392156||non-Fc (fusion protein) replacement products for hemophilia A|Administered based on the clinical judgment of the Prescribing Physician and according to the local approved drug label
89374286|NCT02392156||rFIXFc for hemophilia B|Administered based on the clinical judgment of the Prescribing Physician and according to the local approved drug label
89374287|NCT02392156||non-Fc factor replacement products for hemophilia B|Administered based on the clinical judgment of the Prescribing Physician and according to the local approved drug label
89374288|NCT03115060|Experimental|normal saline|Intravenous fluid used in these patients would be normal saline which would be given intravenously during intraoperative and postoperative period
89374289|NCT03115060|Experimental|ringer lactate|Intravenous fluid used in these patients would be ringer lactate which would be given intravenously during intraoperative and postoperative period
89374290|NCT03115060|Experimental|plasmalyte A|Intravenous fluid used in this arm in patients would be plasmalyte A which would be given intravenously during intraoperative and postoperative period
89374291|NCT01871220|Active Comparator|Divergent Abutment|Divergent Transition Profile
89374292|NCT01871220|Experimental|Concave Abutment|Concave Transition Profile
89374293|NCT03359473|Experimental|Male subjects receiving GSK2881078-Cohort 1|Male subjects between the age of 50 and 75 years will be administered GSK2881078 at a dose of 2 mg once daily by the oral route.
89374294|NCT03359473|Placebo Comparator|Male subjects receiving Placebo-Cohort 1|Male subjects between the age of 50 and 75 years will be administered GSK2881078 matching placebo once daily by the oral route.
89374295|NCT03359473|Experimental|Female subjects receiving GSK2881078-Cohort 2|Post-menopausal female subjects between the age of 50 and 75 years will be administered GSK2881078 at a dose of 1 mg once daily by the oral route.
89374296|NCT03359473|Placebo Comparator|Female subjects receiving Placebo-Cohort 2|Post-menopausal female subjects between the age of 50 and 75 years will be administered GSK2881078 matching placebo once daily by the oral route.
89374297|NCT04831060||Case (patients with stage 3 or 4 periodontitis)|
89535029|NCT03092193|Experimental|Naproxen|20 patients will receive naproxen (one tablet 500 mg) to collected saliva samples for pharmacokinetic and pharmacogenetic studies
88810234|NCT01342523|Experimental|CIS/No loz/No email/Lite Website/Brief booklet|"This arm of the project will address the following question:~Does the following treatment provide efficacy relative to others:~CIS calls, no NRT lozenge, no motivational email, Lite website, Brief mailed booklet"
88810235|NCT01342523|Experimental|no CIS/Loz/No email/lite website/brief booklet|"This arm of the project will address the following question:~Does this combination of services achieve effectiveness compared to others:~No CIS phone counseling, NRT lozenge, no motivational email, lite website, brief mailed booklet"
88810236|NCT01342523|Experimental|No CIS/no loz/email/lite website/brief booklet|"This arm of the project will address the following question:~Does this combination of services lead to greater abstinence:~No CIS counseling calls, no NRT lozenge, motivational emails, lite website, brief mailed booklet."
89374298|NCT04831060||Control (healthy periodontium)|Patients with gingival health on intact or reduced periodontium without a history of periodontitis and requiring surgical care such as dental avulsion or pre-prosthetic periodontal surgeries or aesthetic surgeries
89374299|NCT03632304|No Intervention|Brachial plexus block (infraclavicular)|The standard of care at our institution. Performed by experienced regional anesthetists.
89374300|NCT03632304|Active Comparator|Local anesthesia with minimal sedation|The comparison group. Performed by the operating surgeon.
89374301|NCT02397538|Other|Cohort1|Treatment AB → ABC Treatment A+B (10days) → Treatment A+B+C (6days) Treatment A: Fimasartan Treatment B: Amlodipine Treatment C: Rosuvastatin
89374302|NCT02397538|Other|Cohort2|Treatment C → ABC Treatment C (6days) → Treatment A+B+C (10days) Treatment A: Fimasartan Treatment B: Amlodipine Treatment C: Rosuvastatin
89374303|NCT01429038|Experimental|MSC Liver Transplantation|Patients undergoing a first liver transplantation. Beside receiving standard liver tranplantation care (antibacterial and viral prophylactic treatments as well as a standard immunosuppressive regime i.e. tacrolimus, mycophenolate mofetil and steroids), patients will be infused with 1,5-3,0 10E6 MSC/kg on postoperative day 3+/-2
88846239|NCT03536702|Active Comparator|Independent Writing - Control Group|The control arm will receive a book (i.e., Writing Down Bones by Natalie Goldberg) on creative writing and asked to read and do writing activities for one and a half hours once every two weeks for 3 months.
88846240|NCT03537092|Experimental|Vaginal Film|Each participant who inserted a single use placebo vaginal film (Day 0) is randomized to the timing of Visit 3 (Day 3, 7, 10, or 14)
88846241|NCT02133924|Experimental|Natalizumab with steroids|"For subjects whose GVHD assay is Ann Arbor score 2 or 3, the study treatment will consist of two drugs, prednisone (or methylprednisolone) and natalizumab.~Protocol treatment must start within 3 days of the subject's diagnosis of acute GVHD."
88846242|NCT03624920|Placebo Comparator|THN102 Dosage A|THN102 Dosage A is a Placebo
89374304|NCT01429038|Experimental|MSC Kidney Transplantation|Patients undergoing a first kidney transplantation. Beside receiving standard kidney tranplantation care (antibacterial and viral prophylactic treatments as well as a standard immunosuppressive regime i.e. tacrolimus, mycophenolate mofetil and steroids associated with ant-IL-2 antibodies), patients will be infused with 1,5-3,0 10E6 MSC/kg on postoperative day 3+/-2.
89374305|NCT02396992|Other|Minimal-Massive Intervention|The minimal/basic intervention for a massive number of hospitalized patients.
88846243|NCT03624920|Experimental|THN102 Dosage B|THN102 Dosage B : 200 mg/2 mg THN102 is a combination of modafinil 100mg and flecainide 1 mg daily dosage is 200 mg of modafinil and 2 mg of flecainide
88846244|NCT03624920|Experimental|THN102 Dosage C|THN102 Dosage C : 200 mg/18 mg THN102 is a combination of modafinil 100mg and flecainide 9 mg daily dosage is 200 mg of modafinil and 18 mg of flecainide
88846245|NCT03537404|Active Comparator|Treatment A (Part 1/ Part 2)|Narlaprevir 200 mg once daily with Ritonavir 100 mg once daily for 5 days
89374306|NCT04418778||BEAR intervention group|BEAR Therapeutic group for women who have experienced interpersonal trauma
88846246|NCT03537404|Active Comparator|Treatment B (Part 1)|Tenofovir disoproxil fumarate 300 mg once daily for 5 days
89181430|NCT02584335|Placebo Comparator|"Saline solution (B)"|"Two sterile gauzes will be dampen with the content of the second syringe (the content of the first syringe is always 20 ml of saline solution and it is the first sterile gauzes administrated always) that will contain 20ml of saline solution when the wound treatment process is assigned to the letter B. The nurse has a third syringe exactly like this second syringe to apply if necessary (process still painful to the patient). In this case, the three syringes supplied to the nurse, have saline solution."
89181431|NCT00437281|Placebo Comparator|Placebo|
89374307|NCT04418778||Control Condition|Treatment as usual group, women participating in individual or group therapy but not taking the BEAR group
89399327|NCT03932721|Active Comparator|Evolocumabe|Patients with T2DM treated with the standard of care (SGLT2 inhibitors, maximal statin dose and ideal control of blood glucose and blood pressure) AND evolocumab (anti-PCsk9).
88846247|NCT03537404|Active Comparator|Treatment B (Part 2)|Raltegravir 400 mg twice daily for 5 days
88846248|NCT03537404|Experimental|Treatment C (Part 1)|Narlaprevir 200 mg once daily coadministered with ritonavir 100 mg once daily and Tenofovir disoproxil fumarate 300 mg once daily for 5 days
88846249|NCT03537404|Experimental|Treatment C (Part 2)|Narlaprevir 200 mg once daily coadministered with ritonavir 100 mg once daily and 400 mg raltegravir twice daily for 5 days
88846250|NCT03417752|Experimental|Exposure to firearm safety Public Service Announcement (PSA)|Exposure to the firearm safety PSA (approx. 2.5 minutes long) once per week for 3 weeks.
88846251|NCT03417752|Experimental|Exposure to a mix of PSAs|Exposure to a general health promotion video (approx. 2 minutes long) 1 week post-randomization followed by exposure to firearm safety PSA at 2- and 3-weeks post-randomization.
88846252|NCT03417752|Active Comparator|Active control|Exposure to the general health promotion video once per week for 3 weeks.
88846253|NCT03626714|Experimental|Sustained Release Tacrolimus|All subjects will be treated with a single dose injection of sustained-release Tacrolimus
88846254|NCT04332380|Experimental|Intervention Group|Participants included in the experimental group will receive 500 milliliters of convalescent plasma, distributed in two 250 milliliters transfusions on the first and second day after starting the protocol.
88846255|NCT03538808|Active Comparator|Therapeutic Dose Truth|told therapeutic dose medication + received therapeutic dose medication
88846256|NCT03538808|Placebo Comparator|Therapeutic Dose Deception|told therapeutic dose medication + received placebo
88846257|NCT03538808|Active Comparator|Low Dose Vareniclince Deception|told low dose medication + received therapeutic dose medication
88846258|NCT03538808|Placebo Comparator|Low Dose Placebo Deception|told low dose medication + received placebo
88846259|NCT03540134|Experimental|Intracerebral Infusion of Autologous CSF|All subjects will receive the intracerebral infusion of autologous cerebral spinal fluid (CSF) during their deep brain stimulation (DBS) surgery. The DBS surgery will be performed on the targeted nucleus either bilaterally or unilaterally, as previously determined by a multidisciplinary team of neurology, neurosurgery, and neuropsychology. During unilateral DBS surgery, the targeted nucleus will be infused using convection enhanced delivery (CED). The nondominant side will be infused during a bilateral DBS procedure.
89181432|NCT00437281|Experimental|Pregabalin|
89374308|NCT03589469|Experimental|Loncastuximab tesirine|Participants will receive loncastuximab tesirine as an IV infusion over 30 minutes on Day 1 of each cycle (every 3 weeks) at a dose of 150 μg/kg Q3W for 2 cycles, then 75 μg/kg Q3W for subsequent cycles for up to one year or until disease progression, unacceptable toxicity, or other discontinuation criteria, whichever occurs first.
89374309|NCT03734081|Experimental|Gastric electrical stimulation with type 2 ODC|Safety and feasibility assessment of the ODC system (type 2) capsule during and following gastric electrical stimulation protocol.
89374310|NCT03734081|Experimental|Electrical stimulation with type 2 ODC|Safety and feasibility assessment of the ODC system (type 2) capsule during and following small and large bowel electrical stimulation protocol.
89374311|NCT03734081|Experimental|Electrical stimulation with type 1 ODC|Safety and feasibility assessment of the ODC system (type 1 capsule) during and following small and large electrical stimulation protocol.
89374312|NCT03359395|Active Comparator|Alfentanil|
89374313|NCT03359395|Placebo Comparator|placebo|
89374314|NCT03734003|Experimental|Controllable infrared bioeffect system for cutaneous warts|"Controllable infrared bioeffect system at 44±2℃ for 30 mins on target lesion, at days of 1, 2, 3, 15, 16, 23, 30.~Common warts, plantar warts, and condyloma acuminata"
89374315|NCT03734003|Active Comparator|Liquid nitrogen cryotherapy for cutaneous warts|Liquid nitrogen crytotherapy at days 1, 15, 30.
88846260|NCT02173704|Experimental|Bexsero + Routine Group|Subjects received three doses of Bexsero® vaccine at 2, 4, 6 months followed by a booster dose at 12 months, concomitantly administered with routine vaccines (i.e. combined Infanrix-IPV + Hib® and Prevenar-13® at 2, 4, 6 months of age; Engerix-B® at 6 months of age; Priorix® and Varilrix® at 12 months of age.
88846261|NCT02173704|Active Comparator|Routine Group|Subjects received routine vaccines Infanrix-IPV + Hib® and Prevenar-13® at 2, 4, 6 months of age; Engerix-B® vaccine at 6 months; Priorix® and Varilrix® vaccines at 12 months of age.
88846262|NCT03542474|Experimental|Exercise|6 months of high intensity endurance exercise on a treadmill (3 times per week)
88846263|NCT03543176||UMEC/VI|The subjects in this arm had received, UMEC/VI as 62.5/25 microgram (mcg), which is an approved once-daily single inhaler dual LAMA/LABA therapy, given via Ellipta .
89374316|NCT03730493|Experimental|Pictorial flashcard|In the experimental group researcher explained self-care of PIVC using pictorial flashcard on one to one basis. Patients were explained Do's and Don'ts, they have to keep in mind during self-care. Doubts of the patients were also addressed simultaneously. After this a copy of pictorial flashcard was given to the subjects to be used in future (during PIVC in-situ). Time was noted and kept for observation till 72 hours or removal in between.
89374317|NCT03730493|No Intervention|Comparison Group|In control group, standard care was given as per the hospital protocol.Time was noted and kept for observation till 72 hours or removal in between.
89374318|NCT03730415|Experimental|Viscoelastic (VE) guided transfusion|The intervention made in the VE guided transfusion group is that the VE results will be available to the treating physicians to guide transfusions based on VE results during their burn excision.
89374319|NCT03730415|No Intervention|Standard practice transfusion|The standard practice transfusion group will receive the current standard transfusion practice during their burn excision, which is based solely on physician preference using standard lab values.
89374320|NCT03586427|Experimental|AGN-241751 Dose 1|AGN-241751 Dose 1 administered as 1 tablet taken orally every day
89374321|NCT03586427|Experimental|AGN-241751 Dose 2|AGN-241751 Dose 2 administered as 1 tablet taken orally every day
89374322|NCT03586427|Experimental|AGN-241751 Dose 3|AGN-241751 Dose 3 administered as 1 tablet taken orally every day
89374323|NCT03586427|Experimental|AGN-241751 Dose 4|AGN-241751 Dose 4 administered as 1 tablet taken orally every day
89374324|NCT03586427|Placebo Comparator|Placebo|Placebo administered as 1 tablet taken orally every day
89374325|NCT03733769|Experimental|TQL group|transmuscular quadratus lumborum block as an alternative to lumbar plexus block for peri-operative analgesia in hip Surgery
88810237|NCT01342523|Experimental|No CIS/No loz/No email/Full website/Brief booklet|"This arm of the project will address the following question:~Does this combination of services lead to greater abstinence?~No CIS counseling, no NRT lozenge, no motivational email, full website, brief mailed booklet"
88810238|NCT01342523|Experimental|No CIS/No loz/No email/lite website/full booklet|"This arm seeks to answer the question:~Does this combination of services achieve efficacy compared to others:~No CIS counseling, no NRT lozenge, no motivational email, lite website, full mailed booklet"
88810239|NCT01342523|Experimental|CIS/Loz/No email/Lite website/Brief booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, nicotine lozenge, No motivational emails, lite website, brief mailed booklet"
88810240|NCT01342523|Experimental|CIS/No loz/Emails/Lite Website/Brief booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, No nicotine lozenge, motivational emails, lite website, brief mailed booklet"
88810241|NCT01342523|Experimental|CIS/No loz/no email/full website/brief booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, No nicotine lozenge, No motivational emails, full website, brief mailed booklet"
88810242|NCT01342523|Experimental|CIS/No loz/no email/lite website/full booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, No nicotine lozenge, No motivational emails, lite website, full mailed booklet"
88810243|NCT01342523|Experimental|No CIS/Loz/emails/Lite Website/brief booklet|"This arm of the project will address the following question:~How effective is the following intervention?~No CIS calls, nicotine lozenge, motivational emails, lite website, brief mailed booklet"
88846264|NCT03543176||FLUT/SAL|The subjects in this arm had received, FLUT/SAL as 250/50 mcg, which is an approved twice-daily single inhaler dual therapy ICS/LABA treatment, given via DISKUS.
88846265|NCT02173548|Active Comparator|Anakinra|Anakinra 100 mg given subcutaneously once daily for 12 weeks
88846266|NCT02173548|Placebo Comparator|Placebo|Matching Placebo
89374326|NCT03648983|Active Comparator|Standard LE detection|Arm measurements taken. Patients undergo arm circumference measurement at 4, 10, 16, 22, 28, and 34 months.
88846267|NCT03543878|Experimental|Flicker for 8 Weeks|Participants will receive the Flicker exposure during the entire 8-week treatment period
89374327|NCT03648983|Experimental|Enhanced LE detection|Bioimpedance spectroscopy used along with arm measurements. Patients undergo arm circumference measurement and bioimpedance spectroscopy at 4, 10, 16, 22, 28, and 34 months.
89374328|NCT05666453|Experimental|Treatment group|LIV-GAMMA SN Inj. administration after ABO-incompatible liver transplantation
89374329|NCT05666453|Other|Comparator group|No administration after ABO-incompatible liver transplantation
89374330|NCT05666453|Other|Reference group|No administration after ABO-compatible liver transplantation
89374331|NCT02695420|Placebo Comparator|Placebo BID|Participants will receive placebo BID.
89374332|NCT02695420|Experimental|25 mg Omecamtiv Mecarbil BID|Participants will receive 25 mg omecamtiv mecarbil BID.
89374333|NCT02695420|Experimental|37.5 mg Omecamtiv Mecarbil BID Target Dose|Participants will receive omecamtiv mecarbil 25 mg BID up to Week 4 or Week 8 and 25 mg or 37.5 mg BID after Week 4 or Week 8, based on Week 2 PK.
89374334|NCT02695420|Experimental|50 mg Omecamtiv Mecarbil BID Target Dose|Participants will receive Omecamtiv Mecarbil 25 mg BID up to Week 4 or Week 8 and 25 mg or 50 mg BID after Week 4 or Week 8, based on Week 2 PK.
89374335|NCT03733613||Healthy adults|Subjects will receive pre and post-test, in order to verify the test-retest reliability of the Somatosensory detector
89374336|NCT03358147|Experimental|GP MDI 28.8 μg|GP MDI 14.4 μg per actuation taken as 2 inhalations BID
89374337|NCT03358147|Experimental|GP MDI 14.4 μg|GP MDI 7.2 μg per actuation taken as 2 inhalations BID
89374338|NCT03358147|Experimental|GP MDI 7.2 μg|GP MDI 3.6 μg per actuation taken as 2 inhalations BID
89374339|NCT03358147|Placebo Comparator|Placebo MDI|Taken as 2 inhalations BID
88846268|NCT03543878|Active Comparator|Flicker for 4 Weeks|Participants will receive the Flicker exposure during the second four weeks of the 8-week treatment period
88846269|NCT02173158|Experimental|lomitapide|Maximum tolerated dose of lomitapide (up to 60mg/day) in addition to existing lipid lowering therapy including plasmapheresis or lipid apheresis.
88846270|NCT04501640|Experimental|Mirabegron 25 mg fed/Mirabegron 25 mg fasted|Participants received single dose of 25 mg mirabegron tablet under fed condition orally, on day 1 of period 1 followed by single dose of 25 milligram (mg) mirabegron tablet under fasted condition orally, on day 1 of period 2. A washout period of 10 days was maintained between the mirabegron administrations in each period.
88846271|NCT04501640|Experimental|Mirabegron 25 mg fasted/Mirabegron 25 mg fed|Participants received single dose of 25 mg mirabegron tablet under fasted condition orally, on day 1 of period 1 followed by single dose of 25 mg mirabegron tablet under fed condition orally, on day 1 of period 2. A washout period of 10 days was maintained between the mirabegron administrations in each period.
88846272|NCT04501640|Experimental|Mirabegron 50 mg fed/Mirabegron 50 mg fasted|Participants received single dose of 50 mg mirabegron tablet under fed condition orally, on day 1 of period 1 followed by single dose of 50 mg mirabegron tablet under fasted condition orally, on day 1 of period 2. A washout period of 10 days was maintained between the mirabegron administrations in each period.
89181433|NCT02584023|Placebo Comparator|Control|No intervention during the perioperative period. Perform lung ultrasound twice only for the diagnostic purpose after the endotracheal intubation and and at the end of surgery.
89374340|NCT03358147|Other|Spiriva Respimat 2.5 μg|Open Label Spiriva Respimat 2.5 μg
89374341|NCT03733457|Experimental|TASC Intervention|All participants receive Step 1 of the intervention. Participants who have adherence below or at 68% will step up to Step 2 or Step 3 after the third or fourth month in the study.
89374342|NCT03093402|Experimental|JBT-101: 5 mg Twice Daily|Eligible subjects will receive assigned study treatment of JBT-101 5 mg administered twice daily.
89374343|NCT03093402|Experimental|JBT-101: 20 mg & Placebo|Eligible subjects will receive assigned study treatment of JBT-101 20 mg (A.M. Study Product) and 20 mg Placebo (P.M. Study Product).
89374344|NCT03093402|Experimental|JBT-101: 20 mg Twice Daily|Eligible subjects will receive assigned study treatment of JBT-101 20 mg (A.M. Study Product) and JBT-101 20 mg (P.M. Study Product).
89374345|NCT03093402|Placebo Comparator|Placebo + Placebo|Eligible subjects will receive assigned study treatment of Placebo (A.M.) and Placebo (P.M.) for (JBT-101).
89374346|NCT03585959|Experimental|Fluoroscopic Navigation Arm|An Electromagnetic navigation bronchoscopy (ENB) system which provides enhanced three-dimensional fluoroscopy to improve lesion visibility and to compensate for CT-to-body divergence, with an integrated real-time local registration feature allowing the operator to update the catheter position relative to the target during the procedure.
89374347|NCT02397070|Experimental|Jaw exercise program|
89374348|NCT02397070|Active Comparator|Occlusal splint and counseling|
89374349|NCT02397148|Experimental|patients with sinonasal pathology|Computed Tomography Cone Beam Computed Tomography
89374350|NCT03584789|No Intervention|Standard Practice|The patients in this arm were part of usual care with their dental provider.
88846273|NCT04501640|Experimental|Mirabegron 50 mg fasted/Mirabegron 50 mg fed|Participants received single dose of 50 mg mirabegron under fasted condition orally, on day 1 of period 1 followed by single dose of 50 mg mirabegron tablet under fed condition orally, on day 1 of period 2. A washout period of 10 days was maintained between the mirabegron administrations in each period.
88846274|NCT02152566|Experimental|Diagnostic PSG/PG, PSG w. nasal high flow therapy|All patients recruited will undergo a diagnostic sleep study, either a full in laboratory attended polysomnography (PSG), or an in-home polygraphy (PG). If respiratory insufficiencies with Cheyne-Stokes respiration (CSR) are detected, these patients will undergo an overnight in laboratory attended PSG on a nasal high flow therapy device to test the primary endpoint of this study. Patients without respiratory insufficiencies after the first PSG/PG will take no further part in the trial.
88846275|NCT04758390|Experimental|IMARA intervention arm|Participants randomized to the IMARA arm will receive the IMARA intervention (i.e., the intervention group).
88846276|NCT04758390|Experimental|Health promotion control arm|Participants randomized to the health promotion control arm will receive the health promotion intervention (i.e., the control group).
89374351|NCT03584789|Experimental|Clinical Decision Support|A clinical decision support system designed to assist dentists in providing optimal pain management for patients without resorting to opioids when a non-opioid alternative would suffice. It provides pertinent clinical information to the dentist, including point-of-care access to the Prescription Drug Monitoring Program.
88846277|NCT03632954||ACell Arm|"Cytal® Wound Matrix and/or MicroMatrix®~Cytal® Wound Matrix 1-Layer is composed of porcine-derived extracellular matrix also known as urinary bladder matrix. It is intended for the management of a variety of wounds. The individual device is intended for one time use.~MicroMatrix® is composed of a porcine-derived extracellular matrix known as urinary bladder matrix and is intended for the management of a variety of wounds. The devices are supplied in particle form in masses up to 1000mg. It is intended for one-time use."
88846278|NCT04559282|Experimental|New SP followed by Baha 5 SP followed by single blinded SP|Aided hearing with new Sound Processor followed by aided hearing with the Baha 5 sound processor followed by unaided hearing followed by aided hearing with the new Sound Processor and Baha 5 in a laboratory environment (subject blinded for hearing testing).
88846279|NCT04559282|Experimental|Baha 5 SP followed by the New SP followed by single blinded SP|Aided hearing with Baha 5 sound processor followed by aided hearing with the new Sound Processor followed by unaided hearing followed by aided hearing with the new Sound Processor and Baha 5 in a laboratory environment (subject blinded for hearing testing).
88846280|NCT03633344|Active Comparator|Carbowhite|3 tablets as a single dose (210 mg х 3 = 630 mg) TID (630 mg х 3 = 1,890 mg)
88846281|NCT03633344|Placebo Comparator|Carbowhite placebo|3 tablets as a single dose (210 mg х 3 = 630 mg) TID (630 mg х 3 = 1,890 mg)
88846282|NCT02171130|Experimental|Nasal glucagon|3 mg nasal glucagon powder delivered using a nasal powder dosing device.
88846283|NCT04777214|Active Comparator|Active TMS|There are 10 TMS sessions over 2 consecutive weeks in which 20 minutes (1200 pulses) of 1 Hz active TMS are delivered to a previously determined optimal response site in right frontal lobe.
88846284|NCT04777214|Sham Comparator|Sham TMS|There are 10 TMS sessions over 2 consecutive weeks in which 20 minutes (1200 pulses) of 1 Hz TMS are delivered, however, the coil will be rotated 90 degrees during stimulation.
88846285|NCT04749810||Elizaria®|Eculizumab
89181434|NCT02584023|Active Comparator|Alveolar recruitment|Perform lung ultrasound twice during the perioperative period after the endotracheal intubation and and at the end of surgery. Conduct alveolar recruitment maneuver after first lung ultrasound assessment.
89181435|NCT02602106|Experimental|Intervention group|"The aquatic exercise program included a total of three 50-55 minutes session per week. Pregnant women started at 9 weeks and finished at 38-39 weeks.~Each session included 10 minutes of warm up and 10 minutes of cool down including an specific pelvic floor muscle training. The core section of the session included aerobic and strength moderate exercise in water during 25 to 30 minutes"
89181436|NCT02602106|No Intervention|Control group|Sedentary healthy pregnant women
89181437|NCT02584179|Experimental|Biparametric MRI before biopsy|"Biparametric MRI is a reduced Multiparametric MRI using less scan sequences and no intravenous contrast.~All men will have standard transrectal ultrasound guided biopsies"
88846286|NCT04495712|Active Comparator|Spironolactone|Patients randomized to active therapy with spironolactone
88846287|NCT04495712|Placebo Comparator|placebo|patients randomized to placebo
88846288|NCT04474496||Marshallese adults in the U.S.|Marshallese persons 18 years of age or older currently residing in the United States
88846289|NCT03552536|Experimental|A: MK-8583 100mg|After fasting, a single oral dose of 100 mg MK-8583 in capsule form.
88846290|NCT03552536|Experimental|B: MK-8583 ≤ 150 mg|After fasting, a single oral dose of ≤ 150 mg MK-8583 in capsule form, with the dose based on the results from earlier treatments
88846291|NCT03552536|Experimental|C: MK-8583 ≤ 150 mg|After fasting, a single oral dose of ≤ 150 mg MK-8583 in capsule form, with the dose based on the results from earlier treatments
88846292|NCT03553940|Experimental|Arm 1|A single dose of monovalent live attenuated influenza H3N2 M2SR vaccine (M2SR) administered intranasally on Day 1, and a single dose of licensed quadrivalent influenza vaccine (QIV) administered intramuscularly on Day 92. N=25
88846293|NCT03553940|Placebo Comparator|Arm 2|A single dose of Placebo administered intranasally on Day 1, and a single dose of licensed QIV administered intramuscularly on Day 92. N=25
89181438|NCT04102982|Active Comparator|Microwave ablation plus camrelizumab group|Patients in the group are treated with Microwave ablation in the primary tumor, followed by camrelizumab.
89181439|NCT04102982|Placebo Comparator|Camrelizumab group|Patients in the group are treated with camrelizumab alone.
88846294|NCT04448210|Experimental|Educational website intervention|The intervention is an educational website designed to teach youth (12-17 years) about pediatric clinical trials.
88846295|NCT04448210|No Intervention|Wait-list control|The wait-list control group did not receive the intervention between the pre-test and post-test assessments. After completing the post-test questionnaire, youth in the wait-list control group had the option to receive access to the intervention (DigiKnowIt News).
88846296|NCT03640832|Experimental|Test product|All the participant in this arm will receive the test product (development serum). Test product will be applied twice daily to the freshly cleansed skin in place of the participant's current serum and before applying moisturizer.
88846297|NCT03640832|Active Comparator|Reference product|All the participant in this arm will receive the reference product (Physiogel Calming Relief Anti-Redness Serum). Reference product will be applied twice daily to the freshly cleansed skin in place of the participant's current serum and before applying moisturizer.
88846298|NCT04458818|Experimental|Prolene Mesh Implant|The Group of Patients who were offered Prolene mesh Laryngeal implants for Vocal Cord Medialization.
88846299|NCT04456634|Experimental|AL&RUX|"Oral administration of:~• 20 mg/120 mg artemether-lumefantrine (AL) + 20 mg ruxolitinib phosphate (Rux)"
88846300|NCT04456634|Placebo Comparator|AL& Placebo|20 mg/120 mg artemether-lumefantrine (AL) + Placebo
88846301|NCT04454138||Targeted supratenon's placement of XEN 45|Placement of Xen-45 gelatin microstent in the supra-tenon's space to maximize aqueous outflow, while preventing obstruction, limiting fibrosis of the bleb, and promoting long-term patency.
88846302|NCT04454138||Non-targeted placement of XEN 45|Implantation of the XEN-45 gelatin microstent within the subconjunctival space, avoiding intra-tenon's placement.
88846303|NCT04431908||Outpatients (Drive Thru)|Patients receiving testing through a drive thru location.
88846304|NCT04431908||High Risk Asymptomatics|Asymptomatic patients (residents) in a high risk location.
88846305|NCT03558074|Experimental|Active|ALK4290 800 mg daily
89181440|NCT05468073|Experimental|Treatment|Patient will be treated with low dose of Interleukin 2 (PROLEUKIN ®)
89374352|NCT03584789|Experimental|Clinical Decision Support + Education|Patient education regarding pain management before and after dental extraction, including information about the risks and benefits of various strategies.
89374353|NCT03710005|Experimental|Ascent Intervention Treatment|Interventional treatment arm will receive Ascent dehydrated cell and protein concentrate injection
89374354|NCT03710005|Active Comparator|Standard Treatment|Standard treatment arm will receive a standard Corticosteroid injection
89374355|NCT03733379|Placebo Comparator|Control|Scaling and root planing + Placebos of Metronidazole and Amoxicillin three times a day (TID) for 14 days + placebo lozenges of probiotics two times a day for 90 days.
89374356|NCT03733379|Experimental|Probiotic|Scaling and root planing + Placebos of Metronidazole and Amoxicillin three times a day (TID) for 14 days + lozenges of probiotics two times a day for 90 days.
89374357|NCT03733379|Experimental|Antibiotic|Scaling and root planing + Metronidazole (400 mg/thrice a day,TID) and Amoxicillin (500 mg/ TID) for 14 days + placebo lozenges of probiotics two times a day for 90 days.
89374358|NCT03733379|Experimental|Antibiotic + probiotic|Scaling and root planing + Metronidazole (400 mg/thrice a day,TID) and Amoxicillin (500 mg/ TID) for 14 days + lozenges of probiotics two times a day for 90 days.
89374359|NCT03708991||IVF combined with PGT-A|5000-10000 motile sperm will be added to the oocyte
89374360|NCT03708991||ICSI combined with PGT-A|1 motile sperm will be injected into the oocyte
89374361|NCT05733676|Active Comparator|Resin Infiltration|Resin infiltration of early intervention of caries lesion as a consequences of orthodontic treatment
89374362|NCT05733676|Active Comparator|Casein Phosphopeptide (CPP) - Amorphous Calcium Phosphate (ACP) - Fluoride|Casein Phosphopeptide (CPP) - Amorphous Calcium Phosphate (ACP) - Fluoride early intervention of caries lesion as a consequences of orthodontic treatment
89374363|NCT03343639|Experimental|5 mg Serlopitant Tablets|Serlopitant Tablets
89374364|NCT03343639|Placebo Comparator|Matching Placebo Tablets|Placebo Tablets
89374365|NCT04479748|Other|Dextenza insert|Patient's first eye scheduled for surgery will receive an intracanalicular insertion of DEXTENZA (dexamethasone release profile of QID, TID, BID, QD, over 30 days; study eye).
89374366|NCT04479748|Other|Fellow-eye|The fellow-eye will receive topical prednisolone acetate 1% (tapering schedule of QID, TID, BID, QD over 30 days). The fellow-eye design in n=30 patients (60 eyes) allows for balance in patient baseline demographic and systemic characteristics.
88846306|NCT03558230|Experimental|Vibration|The experimental group will receive the wrist stimulation during standardized Constraint-Induced Movement Therapy.
89181441|NCT05468073|Placebo Comparator|Placebo|Patient will receive sodium chloride solution (NaCl)
89374367|NCT03647267|Active Comparator|Pneumatic Vitreolysis|Participants randomized to the Pneumatic Vitreolysis arm will receive 0.3-mL intraocular injection of C3F8 gas.
89374368|NCT03647267|Placebo Comparator|Observation|Participants randomized to the observation group will receive a sham injection.
89374369|NCT03707353|Experimental|Group 1|Volunteers will receive ChAd63 ME-TRAP vaccination intramuscularly, then MVA ME-TRAP vaccination intramuscularly followed by ChAd63 ME-TRAP vaccination intravenously.
89374370|NCT03707353|Experimental|Group 2|Volunteers will receive ChAd63 ME-TRAP vaccination intramuscularly, then MVA ME-TRAP vaccination intramuscularly followed by MVA ME-TRAP vaccination intravenously.
89374371|NCT03707353|Experimental|Group 3|Volunteers will receive ChAd63 ME-TRAP vaccination intramuscularly, followed by ChAd63 ME-TRAP vaccination intravenously.
89374372|NCT03707353|Experimental|Group 4|Volunteers will receive ChAd63 ME-TRAP vaccination intramuscularly, followed by MVA ME-TRAP vaccination intravenously. 4 weeks after the last vaccine dose, all vaccinated volunteers will undergo malaria challenge by mosquito bite.
89374373|NCT03707353|No Intervention|Group 5|6 Volunteers will receive no vaccinations but will undergo malaria challenge infection by mosquito bite at the same time as groups 1-4.
89374374|NCT03707353|No Intervention|Group 6|6 Volunteers will be used as infectivity controls if any volunteers from Groups 1-4 are rechallenged 5 - 7 months after the initial CHMI.
89374375|NCT03707353|Experimental|Group A|Volunteers will receive ChAd63 ME-TRAP vaccination intramuscularly, then MVA ME-TRAP vaccination intramuscularly followed by MVA ME-TRAP vaccination intravenously.
89374376|NCT05731180|No Intervention|Not trained group (CNT)|Control Group (CNT): 70 Students. The CNT group will only receive an introductory lecture about the SAITI-T study and how to use the website. The CNT subjects will not receive training on lung sounds.
89374377|NCT05731180|Experimental|Trained group for 3 days to identify pathological lung sounds (EXP)|Exposed group (EXP): 70 students. EXP group - subjects will be trained for 3 days to identify pathological lung sounds before assessment/assessments. The EXP subjects additionally have an introductory lecture about the SAITI-T study and how to use the website.
89374378|NCT03708913|Experimental|Open-Label Lateral Hypothalamic DBS Stimulation|Open-label lateral hypothalamic DBS stimulation for 1 year.
89374379|NCT03356977|Experimental|Crisaborole ointment 2%|Subjects will be dosed for 28 days. A thin layer of ointment will be applied to all areas designated for treatment.
89181442|NCT04526847|Experimental|Intervention|"Intermittent energy restricted (IER) group:~IER group will receive 5:2 diet pattern (5 day without energy restriction and 2 days with 75% energy restriction, net weekly energy deficit ~25%)"
88846307|NCT03558230|Placebo Comparator|No Vibration|"The control group will wear the vibration device with no vibration during standardized Constraint-Induced Movement Therapy.~The vibration device is a generic, commercially-available, vibrator, not particularly used for this peripheral skin stimulation purpose."
88846308|NCT03560102|Experimental|MR-HIFU treatment|Patients with breast cancer and scheduled surgical resection (lumpectomy or mastectomy) will be treated with Philips Sonalleve® MR-HIFU Breast Therapy System prior to surgery in a treat& resect model
89181443|NCT04526847|Active Comparator|Calorie Restricted Diet (CER)|"Continuous energy restricted (CER) group:~CER group with a low-calorie diet (daily energy deficit ~25%) over the course of six months."
89181444|NCT04520061|Experimental|Navigation Intervention|The intervention will be delivered via synchronous videoconferencing (real-time delivery and communication between the navigator and the participant) by a trained patient navigator and will consist of 4, 30-minute sessions delivered every week, over the span of one month. The navigation intervention group will also receive a mailed copy of the brochure.
89374380|NCT02690974|Other|LCZ696 (sacubitril / valsartan)|All patients were initiated on either LCZ696 at 24 mg sacubitril / 26 mg valsartan or LCZ696 at 49 mg sacubitril / 51 mg valsartan bid for 2-4 weeks and were up-titrated to the next higher dose for another 2 - 4 weeks as applicable.
89374381|NCT03093324|Experimental|ALKS 8700|Oral capsules, administered orally twice daily.
89181445|NCT04520061|No Intervention|Enhanced Usual Care|Enhanced usual care will consist of an online or mailed health insurance resource guide.
89181446|NCT02584101|Experimental|ACT|ACT therapy
89181447|NCT02584101|Active Comparator|Enhanced Treatment as Usual|Group support
89374382|NCT03093324|Active Comparator|Dimethyl Fumarate|Oral capsules, administered orally twice daily.
88846309|NCT03562988|Other|Vitamin C gummy, Then Vitamin C Caplet|The study consisted of two single-day study periods separated by a 7-day washout. At the first study day, a single oral dose of vitamin C gummy (1007.2mg) was orally administered following a 12 hour fasting period. After a 7 day washout period, a single oral dose of vitamin C caplet (1027.9mg) was orally administered following a 12 hour fasting period.
88846310|NCT03562988|Other|Vitamin C tablet, Then Vitamin C gummy|The study consisted of two single-day study periods separated by a 7-day washout. At the first study day, a single oral dose of vitamin C caplet (1027.9mg) was orally administered following a 12 hour fasting period. After a 7 day washout period, a single oral dose of vitamin C gummy (1007.2mg) was orally administered following a 12 hour fasting period.
88846311|NCT03644108|Experimental|Mucinex® ER 600 mg|Single dose of Mucinex® 600 mg Extended-Release (ER) Bi-Layer tablet taken with 240 mL of water after an overnight fast
88846312|NCT04713956|Experimental|G-CSF+DAC+BF|For patients with RAEB-1, REAB-2 and AML Secondary to MDS undergoing allo- HSCT, Granulocyte Colony-Stimulating Factor (G-CSF)+Decitabine+BF conditioning regimen was G-CSF 5ug/kg/day on days -17 to -10 (when white blood cell is more than 20G/L, stop using G-CSF), Decitabine 20mg/m2/day on days -14 to -10, Busulfan (BU) 3.2 mg/kg/day on days -6 to -3, Fludarabine (FLU) 30mg/m2/ day on days -7 to -3.
88846313|NCT04713956|Active Comparator|G-CSF+DAC+BUCY|For patients with RAEB-1, REAB-2 and AML Secondary to MDS undergoing allo- HSCT, Granulocyte Colony-Stimulating Factor (G-CSF)+Decitabine+BUCY conditioning regimen was G-CSF 5ug/kg/day on days -17 to -10 (when white blood cell is more than 20G/L, stop using G-CSF), Decitabine 20mg/m2/day on days -14 to -10, Busulfan (BU) 3.2 mg/kg/day on days -7 to -4, Cyclophosphamide (CY) 60 mg/kg/day on days -3 to -2.
88846314|NCT03565874|Experimental|Heart Rate Variability Biofeedback|HRVB program conducted over the course of 2 weeks of individual daily exercises for 20 minutes per day.
88846315|NCT03569618|Active Comparator|Game 1|Tablet-based Game 1.
88846316|NCT03569618|Placebo Comparator|Game 2|Tablet-based Game 2.
88846317|NCT04425746|Experimental|Afamelanotide|Subjects visited the clinic on Day 0 (administration of afamelanotide implant and porfimer sodium), Day 2 (photodynamic therapy), and Days 20 and 90 for assessments of adverse events, concomitant medication and the results of evaluation of phototoxicity.
88846318|NCT04425746|Placebo Comparator|Placebo|Subjects visited the clinic on Day 0 (administration of placebo implant and porfimer sodium), Day 2 (photodynamic therapy), and Days 20 and 90 for assessments of adverse events, concomitant medication and the results of evaluation of phototoxicity.
88846319|NCT04402970|Experimental|Inhaled/nebulized dornase alfa|Patient to receive inhaled/nebulized dornase alfa (Pulmozyme) 2.5 mg twice daily in the ventilator circuit for 3 days, along with standard of care for ARDS.
88846320|NCT04402970|No Intervention|Standard of care|Standard of care provided for ARDS.
88846321|NCT04392362|Active Comparator|Intervention group|Method of giving adenosine at 6mg then 12mg repeated twice to abort svt Intervention is giving the drug in a simplified method mixing it with 20 ml saline as a whole flush
88846322|NCT04392362|Active Comparator|Control group|Giving adenosine Ising the recommended AHA two syringe method
88846323|NCT04734782||Protective Mothers (high IGG titers)|Protected group Newborns with congenital heart disease + high titers of anti-RSV IGG in the mother's serum before birth
88846324|NCT04734782||Non-protective mothers (low IGG titers)|Unprotected group Newborn with congenital heart disease + negative anti-RSV IGG titers in the mother's serum before birth.
89374383|NCT03584009|Experimental|Venetoclax + Fulvestrant|Participants were administered Venetoclax 800mg orally once daily (QD) and Fulvestrant 500mg intramuscularly (IM) on Day 1 and 15 of Cycle 1 and Day 1 of subsequent cycles (Cycle length = 28 days).
88846325|NCT04390022|Active Comparator|Ivermectin|Participants on this arm will receive a single, oral dose of ivermectin 400 mcg/kg at the enrolment visit.
88846326|NCT04390022|Placebo Comparator|Placebo|Participants on the arm will receive a single, oral dose of placebo tablets at the enrollment visit.
89181448|NCT02583945|Experimental|kidney treatment bundle (KDIGO)|Consequent postoperative application of a kidney treatment bundle: Protocol based hemodynamic optimization and monitoring, regular screening of creatinine in serum and of urine output, no use of potential nephrotoxic medication and normoglycemia.
89181449|NCT05442255||Chemical Submission|Patients with a suspected chemical submission
89181450|NCT05674773||IBD patients with advanced neoplasia|"IBD patients with advanced neoplasia (high-grade dysplasia or colorectal cancer) treated with:~proctocolectomy~(sub)total colectomy~partial colectomy~endoscopic resection"
89181451|NCT04079205|Experimental|Home rehabilitation using Wearable Device|Home rehabilitation using Wearable Device(exoRehab)
89374384|NCT03584009|Active Comparator|Fulvestrant|Participants were administered Fulvestrant 500mg only IM on Day 1 and 15 of Cycle 1 and Day 1 of subsequent cycles (Cycle length = 28 days).
88846327|NCT03649646||Patients|Patients with hypertension uncontrolled by antihypertensive drug
88846328|NCT04370834|Experimental|Other (tocilizumab)|Patients receive tocilizumab IV over 60 minutes. A second dose may be given if there is sustained or recurrent fever, no decrease or not more than a 1-category improvement on the 7-category ordinal scale (only stabilization or partial improvement following first dose), or a >= 1-category worsening on the 7-category ordinal scale from nadir.
88846329|NCT03570476|Experimental|Treatment (olaparib, radical prostatectomy)|Participants receive olaparib orally twice daily for 90 days in the absence of unacceptable toxicity. Beginning 1 day after last olaparib dose, participants undergo radical prostatectomy.
88846330|NCT03571724|Experimental|Usual Brand (UB) non-mentholated filtered cigarettes|Usual Brand (UB) mentholated filtered cigarettes Usual Brand (UB) non-mentholated filtered cigarettes or to very low nicotine non-mentholated cigarettes
89374385|NCT03709927|Experimental|Therapeutic ZTI-01 6 g IV|intravenous fosfomycin (only antibiotic in phosphonic acid derivative class) 6g
89374386|NCT03709927|Experimental|Supra-therapeutic ZTI-01 12 g IV|intravenous fosfomycin (only antibiotic in phosphonic acid derivative class) 12g
89374387|NCT03709927|Active Comparator|moxifloxacin 400 mg PO|oral moxifloxacin 400mg film coated tablets - Avelox(TM)
89374388|NCT03709927|Placebo Comparator|Placebo IV|IV 0.9% normal saline solution
89374389|NCT05666375|Active Comparator|Percutaneous translumbar permcath|"Local anesthesia in adults and general anesthesia in pediatrics.~The patient under fasting condition is placed prone on angiography table.~Skin preparation and a sterile draping of the operating field.~Puncture site is chosen 1.5 cm above right iliac crest 10 cm lateral to the posterior median line.~Puncture into inferior vena cava is made using 21 gauge 15 cm long needle, inserted at 45 degree angle from the horizontal and advanced medially and superiorly under us then fluoroscopic guidance.~Entry into the IVC is made below the level of the renal veins, immediately anterior to the 3rd lumber vertebra.~Intravascular position of the needle is confirmed by free aspiration of blood and injection of contrast media under fluoroscopy.~A guide wire is introduced through the needle and advanced well into the IVC.~The needle is replaced with a dilator. A catheter of appropriate length is tunneled subcutaneously from the right flank and advanced to the IVC"
89374390|NCT05666375|Active Comparator|Percutaneous transhepatic permcath|"The patient lies in supine position.~The procedure is done under local anesthesia.~Under ultrasound guidance; access by a 21 gauge angiocatheter (15cm) to right or middle hepatic vein through intercostal or subcostal approach.~Entrance of the hepatic veins is confirmed by injection of diluted contrast media (iopromide) under fluoroscopy.~A 0.018-inch guidewire is advanced through the needle and into the right atrium.~Intravascular catheter length is measured and selected in standard fashion.~The initial access needle is exchanged over the guidewire for a coaxial transitional sheath, which permits replacement of the 0.018-inch guidewire with a 0.035-inch guidewire.~The tunneled catheter is inserted over the wire through a peel-away sheath"
89374391|NCT03707275|Experimental|Alexa+ Arm|
89374392|NCT03707275|Other|Standard of Care Arm|
89374393|NCT04167462|Experimental|Arm A:BMS-986165 oral administration|
89374394|NCT04167462|Placebo Comparator|Arm B: Placebo oral administration|
89374395|NCT03733223||experimental group|The patients who were treated with Ateptidase had intracranial haemorrhage adverse reactions
89374396|NCT03733223||control group|The patients who were treated with Ateptidase did not have intracranial haemorrhage adverse reactions.
89374397|NCT03707197|Experimental|Meditation Group|The intervention group will be assigned to a digitally-based meditation intervention (Headspace app- Basic + Stress packs) and asked to use this for at least 10 minutes a day over the course of 8 weeks
89374398|NCT03707197|No Intervention|Wait-list Control Group|Wait-list control group participants will continue their normal activities and not engage in any form of meditation during the study period
89374399|NCT05680441||Healty group|The controls/Healthy group were the individuals with well-maintained oral hygiene without no periodontal disease history or symptoms with a probing pocket depth (PPD) of ≤3 mm and bleeding on probing (BOP) of (+) ≤10.
88846331|NCT03571724|Experimental|Usual Brand (UB) mentholated filtered cigarettes|Subjects will be randomized to continue to smoke Usual Brand (UB) mentholated filtered cigarettes or to very low nicotine mentholated cigarettes
88846332|NCT03572972||Patients prescribed apixaban|
88846333|NCT03572972||Patients prescribed dabigatran|
89181452|NCT04079205|Active Comparator|Control|Standard home rehabilitation program
89181453|NCT04079283||Monotherapy|Patients who has received mono-therapy of immune checkpoint inhibitor.
89374400|NCT05680441||Periodontitis stage 3 grade B|Stage III periodontitis patients had at least 4 interdental sites clinical attachment level (CAL)> 5 mm due to periodontitis, radiographic bone loss reaching to the mid-third of the root or beyond, teeth loss less than 4 teeth due to periodontitis. These patients were graded according to the bone loss%/age index (Grade B, 0.25-1.00).
89374401|NCT05680441||Periodontitis stage 3 grade C|Stage III periodontitis patients had at least 4 interdental sites clinical attachment level (CAL)> 5 mm due to periodontitis, radiographic bone loss reaching to the mid-third of the root or beyond, teeth loss less than 4 teeth due to periodontitis.Since the bone loss (%)/age values were >1.0, all periodontitis patients were considered grade C.
89374402|NCT05680441||Gingivitis|Only generalized gingivitis patients were included in this study. Individuals presenting with a BOP≥30% and PPD≤3 mm without radiographic bone loss and attachment loss were considered to have gingivitis.
89374403|NCT04160520|Experimental|Pramipexole and half-standard dose of morphine|0.25 mg oral tablet of pramipexole in combination with 0.05mg/kg of IV morphine
89374404|NCT04160520|Active Comparator|Standard dose of morphine and placebo|0.1mg/kg of IV morphine in combination with a placebo pill
88846334|NCT03572972||Patients prescribed rivaroxaban|
88846335|NCT03572972||Patients prescribed warfarin|
88846336|NCT03572972||Patients prescribed antiplatelet|
88846337|NCT05314790||control group (CG)|Without intervening Educational Program
88846338|NCT05314790||training group (TG)|Group who has received an Educational Program (EP). The implementation of an EP based on meetings within the Department, coordinated by an outside tutor (outreach visit model). The EP content was defined beforehand by a Scientific Board, on the basis of evidence-based guidelines (EBGs) and an up-to-date literature review, but also with a specific focus on any departures from standard clinical practice recommendations (CPRs) identified at each IM department in phase 1.
88846339|NCT04352660|Active Comparator|Injection group|MMC delivered by preoperative subconjunctival injection
88846340|NCT04352660|Active Comparator|Sponge group|MMC delivered by intraoperative direct scleral application with impregnated cellulose sponges
88846341|NCT03650192|Experimental|INVSENSOR00027 Test group|The subjects will be enrolled into the test group and will receive the INVSENSOR00027 investigational sensor.
88846342|NCT04342130|Experimental|All Participants|People with low back pain who were given and oral dose of 30 mg morphine.
88846343|NCT04338074|Experimental|Tranexamic Acid Treatment|
88846344|NCT04338074|Placebo Comparator|Placebo Treatment|
88846345|NCT03964220||Patients with Asthma|
89374405|NCT03583385|Experimental|First Glucophage XR (Test), Then Glucophage XR (Comparator)|Participants received single oral dose of 750 milligram (mg) Glucophage® XR tablet manufactured by PT Merck Tbk, Jakarta, Indonesia (Test Drug) in treatment period 1 followed by single oral dose of 750 mg Glucophage® XR tablet manufactured by Merck Santé, Semoy, France (Comparator Drug) in treatment period 2 under fasting conditions. The two periods were separated by a 7-day wash-out period.
89374406|NCT03583385|Experimental|First Glucophage XR (Comparator), Then Glucophage XR (Test)|Participants received single oral dose of 750 milligram (mg) Glucophage® XR tablet manufactured by Merck Santé, Semoy, France (Comparator Drug) in treatment period 1 followed by single oral dose of 750 mg Glucophage® XR tablet manufactured by PT Merck Tbk, Jakarta, Indonesia (Test Drug) in treatment period 2 under fasting conditions. The two periods were separated by a 7-day wash-out period.
89374407|NCT03632382|Other|OSA diagnosis with 3D acquisition|OSA diagnosis with 3D acquisition
89374408|NCT05288335|Experimental|Circular cylindrical mirror modulated frame glasses (compact)|Subjects that were randomized to receive the Circular cylindrical mirror modulated frame glasses (compact) throughout the entire course of the study.
89374409|NCT05288335|Experimental|Circular cylindrical mirror modulated frame glasses (strong defocus)|Subjects that were randomized to receive the Circular cylindrical mirror modulated frame glasses (strong defocus) throughout the entire course of the study.
89374410|NCT05288335|Experimental|single vision frame glasses|Subjects that were randomized to receive the single vision frame glasses throughout the entire course of the study.
89374411|NCT04350372|Experimental|MitraClip|Subject will receive MitraClip procedure with MitraClip NT System
88846346|NCT03657134|Experimental|EP Procedure|Patient will continuously wear the CoVa-2 monitoring system until they are discharged. During this period, data from the sensor will be sent to the Gateway and Cloud-based System, and then analyzed retrospectively.
88846347|NCT03327571||Group 1: cHL|Participants diagnosed with high-risk stage IIb-IV cHL, received frontline treatment with chemotherapy with or without radiotherapy between 01 January 2010 and 31 December 2013 from the 13 participating countries will be observed for various treatments received for cHL, associated adverse events and resources used from the date of cHL diagnosis until the date of first documented relapse or disease progression after frontline therapy. Participants will be continue to be observed for overall survival until the date of death or data collection, whichever occurs first.
89374412|NCT03708835|Experimental|Transitional Care Model is applied|Types of interventions that are applied to stroke caregivers and patient based on Transitional Care Model are hospital interview, home visit, telephone interview and web-based training. Multiple interventions including at least three face-to-face interviews at the hospital, distance education via Web and telephone communication for three months,and one home visit within seven days after discharge will be performed in order to increase health literacy levels and caregiving competence of the caregivers and to reduce burnout. In pre-tests and post-tests to be applied to the caregivers. Rate of return to the hospital, risk of pressure sore, and time of access to home health services will be assessed in stroke patients
89374413|NCT03708835|No Intervention|Routine hospital schedule|In the first interview after the admission to the hospital, the pretest will be applied to intervention and control groups and the posttest would be applied to the groups at the end of three months after discharge. After taking the posttest, the website will be made available to the control group.
88846348|NCT03327571||Group 2: RRHL|Participants diagnosed with RRHL, between 01 January 2010 and 31 December 2013 from the 13 participating countries will be observed for various treatments received for RRHL, detailed data on treatment pathways, clinical outcomes, associated adverse events and resources used from the date of RRHL diagnosis until the date death or data collection, whichever occurs first. Participants will be continue to be observed for overall survival until the date of death or data collection, whichever occurs first.
88846349|NCT04332614||Control|A standard marketing message encouraging activation and describing the benefits of myGeisinger
89374414|NCT04792801||Patients with HCC and whose liver transplant plan has been validated|"Prospective inclusion of patients who are candidates for a transplant for CHC at the University Hospital of Lille and Rouen whose transplant project has been validated with a AFP score ≤ 2.~The systematic performance of a PET-CT with FDG and a PET-CT with Choline in all patients. At the end of the entire assessment, the patients will be (or not) registered on the transplant list and, for the patients registered on the list, a follow-up will be carried out at the level of a specialized transplant consultation every 3 months at during which the alphafoetoprotein dosage and abdominal imaging will be updated, until liver transplantation."
89374415|NCT01568502||DSE|Patients, who underwent Dobutamine Stress Echocardiography (DSE)
89374416|NCT01568502||DSCMR|Patients, who underwent Dobutamine Stress Cardiac Magnetic Resonance (DSCMR)
88846350|NCT04332614||Focused on provider communication|A simple message focused on one benefit of myGeisinger: communicating easily with providers
88846351|NCT04332614||Focused on scheduling|A simple message focused on one benefit of myGeisinger: scheduling and managing appointments online
89181454|NCT04079283||Combined therapy|Patients who has received immune checkpoint inhibitor combining chemotherapy.
89374417|NCT03708757|Experimental|Post isometric relaxation - Group I|"Group I will receive post isometric relaxation techniques in order to reduce hamstring spasticity. This technique induces relaxation and decreases spasticity in muscles~Post isometric relaxation (3 sets of 10 repetitions ,1 session in a day, 30 minutes, 4 days a week for 6 weeks.) Stretching Exercises (10 reps 3sets) hold for 2 sec"
89374418|NCT03708757|Active Comparator|Eccentric Muscle contraction - Group II|"Eccentric Muscle contraction lengthens the spastic muscles and enhance joint flexibility.~Hot Pack for (10 MINTS) Eccentric stretching (3 sets of 10 repetitions ,1 session in a day, 30 minutes, 4 days a week for 6 weeks.) Stretching Exercise(10 reps 3sets) hold for 2 sec In both experimental groups PIR and Eccentric stretching is applied on hamstring to"
88846352|NCT04332614||Focused on medical information access|A simple message focused on one benefit of myGeisinger: accessing medical information, like test results
88846353|NCT04332614||Social proof|A message similar to control, but including information about how many other patients are using myGeisinger
89181455|NCT04079049|Experimental|Surgical intervention|Surgical and oncological treatment
89181456|NCT04079049|Active Comparator|Control|Oncological treatment
88846354|NCT04332614||Endowment / decision staging|"A message similar to control, but framing myGeisinger as something that patients already have, and just need to take one more step to activate.~Endowment: Give patients the impression they already have the account, so they value it more.~Decision staging: Break down the process into multiple stages - having an account and activating that account- and giving the impression that they are almost there because the first stage is complete"
88846355|NCT04332757|Experimental|Training Intervention|18-week physical development programme to train both rehabilitative and performance enhancement elements of physical preparation.
88846356|NCT04332757|No Intervention|Usual care control|Usual care acting as a control group.
88846357|NCT00422773|Experimental|Cetuximab+ FOLFOXIRI|Cetuximab and Irinotecan, Oxaliplatin, 5FU and Folinic acid
88846358|NCT04326842||Carotid artery stenosis|Patients with carotid artery stenosis. Procedure: Carotid artery revascularization procedure
88846359|NCT04326842||Control|Patients without carotid artery stenosis
88846360|NCT03329209|Experimental|Vedolizumab 300 mg|Vedolizumab 300 mg, infusion, intravenously over 30-minutes, once on Day 1.
88846361|NCT03661346|Experimental|Esmolol|Patients receiving esmolol when intra-operative MAP > 80 mmHg.
88846362|NCT03661346|Active Comparator|Labetalol|Patients receiving labetalol when intra-operative MAP > 80 mmHg
88846363|NCT03329911|Active Comparator|EU Avastin®|"Drug:EU Avastin® 15 mg/kg IV infusions ,every 3 weeks of a cycle for up to 6 cycles, followed for those with non-progressive disease with maintenance monotherapy with Bevacizumab-EU up to a maximum of 8 months.~Drug: Paclitaxel 200mg/m² via IV infusions, every 3 weeks of a cycle for up to 6 cycles~Drug: Carboplatin AUC 6.0 mg/mL•minute via IV infusions,every 3 weeks of a cycle for up to 6 cycles"
88846364|NCT03329911|Experimental|BAT1706|"BAT1706 15 mg/kg IV infusions ,every 3 weeks of a cycle for up to 6 cycles, followed for those with non-progressive disease with maintenance monotherapy with BAT1706 up to a maximum of 8 months.~Drug: Paclitaxel 200mg/m² via IV infusions, every 3 weeks of a cycle for up to 6 cycles~Drug: Carboplatin AUC 6.0 mg/mL•minute via IV infusions,every 3 weeks of a cycle for up to 6 cycles"
88846365|NCT04322396|Placebo Comparator|Control|"This arm will receive standard care and placebo in 15 days.~Azithromycin placebo:~Day 1-3: 500 mg x 1 Day 4-15: 250 mg x 1~Hydroxychloroquine placebo:~Day 1-15: 200 mg x 2"
88846366|NCT04322396|Active Comparator|Intervention|"This arm will receive standard care and azithromycin and hydroxychloroquine in 15 days.~Azithromycin:~Day 1-3: 500 mg x 1 Day 4-15: 250 mg x 1~Hydroxychloroquine:~Day 1-15: 200 mg x 2"
88846367|NCT03222037|Experimental|TEST/SCR|Subjects who are current soft contact lens wearers between the ages of 18 and 35 will be randomized to the two different treatments (TEST/SCR) sequentially
88846368|NCT03222037|Experimental|SCR/TEST|Subjects who are current soft contact lens wearers between the ages of 18 and 35 will be randomized to the two different treatments (SCR/TEST) sequentially
88846369|NCT03961100|Experimental|Part 1|Participants will be randomly assigned to one of the three treatment sequences (T1T2R, T2RT1, RT1T2). In each treatment sequences, participants will cross-over to three periods taking different formulations of entrectinib. Entrectinib will be administered as a single 600 milligram (mg) oral dose under fed condition in three different formulations. Test formulation 1 (T1): film-coated mini-tablet; Test formulation 2 (T2): film-coated mini-tablet; Reference formulation (R): hard capsule.
88846370|NCT03961100|Experimental|Part 2|Participants will be randomly assigned to one of the two treatment sequences (TR, RT). In each treatment sequences, participants will cross-over to two periods taking different formulations of entrectinib. Entrectinib will be administered as a single 200 mg oral dose under fasted condition in two different formulations. Test formulation (T): hydroxypropyl methylcellulose (HPMC) capsule; Reference formulation (R): hard capsule.
88846371|NCT03222427|Experimental|LY3314814|Single 50 milligram (mg) dose of LY3314814 administered orally
88846372|NCT03222427|Experimental|[13C415N3] LY3314814|Single 100 micrograms (μg) intravenous (IV) dose of [13C415N3] LY3314814 administered as an IV infusion.
88846373|NCT03442699|Experimental|Cognitive Behavioral Therapy|Participants will receive up to 10 daily sessions of cognitive behavioral therapy (depending on length of stay), for about an hour each day. During this time the therapist will work to develop a crisis response plan and build coping skills to prevent future suicidal thoughts and behaviors.
88846374|NCT03954158|Experimental|Crisaborole ointment 2% once daily (QD) vs vehicle QD|intra-participant comparison, treatment will be randomly assigned to target lesion 1 and lesion 2.
88846375|NCT03954158|Experimental|Crisaborole ointment 2% twice daily (BID) vs vehicle BID|Intra-participant comparison, treatment will be randomly assigned to target lesion 1 and lesion 2.
88846376|NCT03222505|Experimental|Treadmill|
88846377|NCT03222505|Experimental|Overground Walking|
88846378|NCT03224299|Experimental|Investigational Product #1 (IP1)|octenidine dihydrochloride in isopropyl alcohol in a single-use applicator - clear
88846379|NCT03224299|Experimental|Investigational Product #2 (IP2)|octenidine dihydrochloride in isopropyl alcohol in a single-use applicator - tinted
88846380|NCT03224299|Active Comparator|Active Control|ChloraPrep® - Hi-Lite Orange® applicator
88846381|NCT03224299|Placebo Comparator|Negative Control|sterile 0.9% saline applied with single use applicator
88846382|NCT03333577|Experimental|Experimental SoundArc study group|all subjects will receive the SoundArc intervention
88846383|NCT03334825|Experimental|Enhanced housing placement assistance|
88846384|NCT03334825|Active Comparator|Standard housing placement assistance|
88846385|NCT03442933|Active Comparator|Road Cycling first, then Mountain Biking|First Intervention (3 hours: Road cycling), followed by a 7 days washout, and the second Intervention (3 hours: Mountain Biking).
88846386|NCT03442933|Active Comparator|Mountain Biking first, then Road Cycling|First Intervention (3 hours: Mountain Biking), followed by a 7 days washout, and the second Intervention (3 hours: Road cycling).
88846387|NCT03444961|Experimental|CAREN system training|CAREN training
88846388|NCT03661814|Experimental|Prevena|This group will receive the negative pressure wound therapy device.
88846389|NCT03661814|No Intervention|Standard of Care|This group will not receive the device and their surgery and clinical course will proceed as if they were not part of the study. They will receive the standard of care wound dressings.
88846390|NCT03335761|Experimental|Amplitude Setting #1|InterStim Therapy will be set to amplitude parameter #1.
89374419|NCT03707119||S4BE|"The intervention consisted of the use of Student 4 Best Evidence blog to teach EBP competence. The section S4BE about has been used to teach the EBP principles and their key steps and the section S4BE topics has been used to teach critical thinking and the clinical practice in rehabilitation for a total of 24 training hours."
89002278|NCT06319209||Preoperative resolved COVID-19|Patients who had a history of SARS-CoV-2 infection prior to surgery underwent limited breast cancer operations in the Breast Surgery Department of our hospital after recovering from SARS-CoV-2 infection between January 2023 and March 2023.
89002279|NCT06319209||Preoperative COVID-19 negative|Patients undergoing limited surgery for breast cancer in our Breast Surgery Department between June and August 2022 had no history of SARS-CoV-2 infection prior to surgery. However, they were diagnosed with COVID-19 after the first tumor evaluation following surgery, which occurred at least 90 days after the surgery.
89002280|NCT06319196|Experimental|Anti-PD-1/LAG-3 (Opdualag/BMS-986213)|
89002281|NCT06319196|Active Comparator|Anti-PD-1 ( Nivolumab)|
89002282|NCT06319183|Experimental|Salbutamol|
89002283|NCT06319170|Experimental|Olanzapine Group A|Single-dose injection
89002284|NCT06319170|Experimental|Olanzapine Group B|Single-dose injection
89002285|NCT06319170|Experimental|Olanzapine Group C|Single-dose injection
89002286|NCT06319157|Experimental|minimal access group|
89002287|NCT06319157|Other|conventional group|
89002288|NCT06319144|Active Comparator|Experimental group|Patients in the experimental group were infused intravenously with 5% dextrose (500 ml/h) in the PACU. The study outcomes were collected at three assessment periods, 0-0.5 h, 0.5-6 h, 6-24 h, after anesthesia by an independent investigator.
89002289|NCT06319144|Active Comparator|Control group|Patients in the control group were infused intravenously with 0.9% Normal Saline (500 ml/h) in the PACU. The study outcomes were collected at three assessment periods, 0-0.5 h, 0.5-6 h, 6-24 h, after anesthesia by an independent investigator.
89002290|NCT06319118|Placebo Comparator|Placebo Comparator: placebo|control group patients, 40 cases
89002291|NCT06319118|Experimental|Experimental: dihydroergotine mesylate sustained-release tablets|treatment group patients, 80 cases
89535030|NCT03092193|Experimental|Naproxen-esomeprazole|20 patients will receive after one month of first collection (with naproxen 500 mg), naproxen-esomeprazole (one tablet 500mg+20mg) to collected saliva samples for pharmacokinetic and pharmacogenetic studies
89002293|NCT06319079|Experimental|Super 1.000 Mamá|Breastfeeding mothers who breastfeed their children during the first four months postpartum will receive a fortified powder milk product formulated and designed specifically for this population.
89002294|NCT06319079|Sham Comparator|Leche comercial|Breastfeeding mothers who breastfeed their children during the first four months postpartum will receive commercial powder milk.
89002295|NCT06319066|Experimental|CFO with W1|The therapists will propose the orthotic wedges after examining the foot angles following the foot assessment from the study of Root, the forefoot angle will be determined for both the forefoot and rearfoot wedges. Previous studies recommended the posting at 60% of the measured forefoot angle, up to a maximum of 8 degrees, for extrinsic forefoot varus wedge and the posting at 50% of the measured forefoot angle, up to a maximum of 6 degrees, for extrinsic rearfoot varus wedge. After the posting, all participants will be asked to test the provided foot orthoses within their footwear. If any disturbance has been found during testing, the adjustment will be performed.
89002296|NCT06319066|Experimental|CFO with W2|The therapists will propose the orthotic wedges after examining the foot angles following the foot assessment from the study of Monaghan et al., the forefoot will be posted at 50% of the measured forefoot angle, and the rearfoot will be posted at 20% of the measured rearfoot angle. After the posting, all participants will be asked to test the provided foot orthoses within their footwear. If any disturbance has been found during testing, the adjustment will be performed.
89002297|NCT06319066|Active Comparator|CFO without wedge|The 3-quarter-length CFO will be made from thermoplastic material (rigid foot orthoses) which consists of four layers i.e. two layers of 0.5-mm polyvinyl chloride (PVC), one layer of 1.5-mm thick fiber to increase strength of foot orthoses in the bottom layers as well as one layer of 1.2-mm genuine leather in the upper layer to increase comfort. It incorporates a heat-molding process to adjust individual foot shape in prone position. The materials will be set within approximately three minutes.
89002298|NCT06319053|Experimental|Laparoscopy|Adult study participants who are planned to undergo intraperitoneal laparoscopic surgery
89374420|NCT03708679||Group F|Patients with menstrual cycle between 8-12 days were called Group F (Follicular phase)
89374421|NCT03708679||Group L|Patients with menstrual cycle between 20-24 were called Group L (Luteal phase)
89374422|NCT02949973|Experimental|Voclosporin|Voclosporin, oral, 23.7 mg twice daily (BID)
89374423|NCT05175937||APP group|Patient wearing ICD with Bluetooth® technology and smartphone APP based remote monitoring
89002299|NCT06319040||Study Group 1|15 patients who underwent isolated ACLR
89002300|NCT06319040||Study Group 2|15 patients who underwent ACLR with additional intervention
89002301|NCT06319040||Control Group|15 healthy individuals
89002302|NCT06319027|Experimental|Diagnostic (DSC-MRI, fluciclovine F18 PET, MR spectroscopy)|Patients receive a gadolinium-based contrast agent and undergo DSC-MRI scans at 4 and 8 weeks after completion of SOC radiation therapy. Patients with evidence of disease progression then undergo MR spectroscopy or receive fluciclovine F18 IV and undergo PET scan within 12 weeks of SOC radiation therapy completion.
89002303|NCT06319014|Experimental|AE Group|"The AE group will exercise on aerobic machines (i.e. treadmill, elliptical, bicycle)~All exercise participants will be prescribed exercise that meets guidelines of the American College of Obstetricians and Gynecologists (ACOG), American College of Sports Medicine (ACSM), and the American Heart Association (AHA); 150 minutes per week, moderate intensity (60-80% aerobic capacity, Rating of Perceived Exertion, RPE, 12-15) per week. These limits are the same as those that generated previous positive findings for our preliminary data."
89181457|NCT04078971|Experimental|Ketogenic diet|Ketogenic diet: less than 30 g/day of carbohydrate. Subjects can eat beef, veal, poultry, fish, raw and cooked vegetables without restriction, cold cuts such as dried beef, eggs and seasoned cheese (parmesan), ketogenic pasta (selected with a ketogenic ratio of 4:1), fruits with the lowest glycemic index (blueberry, raspberry), raw nuts and seeds, ghee butter, plant oils and fats from avocado, coconut and olives
89374424|NCT05175937||Bedside transmitter group|Patient wearing ICD monitored remotely through a bedside transmitter
89181458|NCT04078971|Active Comparator|Western diet|The western diet (WD) is composed mainly of whole cereals (spelt, rye, oat) and pseudo-cereals (buckwheat, quinoa, amaranth), whole grain pasta, potatoes, meet, fish, vegetables, fruit, legumes, olive oil, milk and red wine (at most 1 glass per day). It ensure a constant energy and macronutrient balance: protein 1.8g x Kg-1 x body weight-1 x day-1, (30%), fats 20-25% and carbohydrate 50-55%.
89374425|NCT04152252||Baseline|No CPR feedback during CPR
89374426|NCT04152252||Real-time feedback|Real-time feedback on chest compression depth, chest compression rate and recoil available to EMS while performing CPR. Feedback is delivered as visual text, numeric and graphical presentations on the defibrillator with audio tones for rate.
89374427|NCT04152252||Post-event debriefing|Structured oral post-event debriefing based on objective performance data from the resuscitation attempt. The debriefing is conducted as hot/immediate self-directed debriefing session with a maximum length of 10 minutes.
89374428|NCT05420922||Systemic therapy|ICIs (PD1 or PDL-1)+TKIs (Lenvatinib or Sorafenib)
89374429|NCT05420922||Local treatment|local treatment include: TACE, HAIC, RF Ablation, Microwave Ablation, Radiotherapy, etc.
89374430|NCT05420922||Triple therapy|"Systemic therapy plus Local treatment:~ICIs (PD1 or PDL-1)+TKIs (Lenvatinib or Sorafenib) plus local treatment (TACE, HAIC, RF Ablation, Microwave Ablation, Radiotherapy, etc)"
89181459|NCT02596269|Experimental|Nefopam(NF) group|Received i.v. PCA with the same volume of solution containing 1250 µg fentanyl plus 120 mg of nefopam in normal saline (fentanyl 12.5 µg/ml and nefopam 1.2 mg/ml).
89374431|NCT05283096||Patients with chronic inflammatory rheumatic disease|
89374432|NCT02948959|Placebo Comparator|Placebo|Placebo (for Dupilumab), subcutaneous (SC) injection every 2 weeks (q2w) for 52 weeks in combination with stable-dose background therapy of medium-dose inhaled corticosteroids (ICS) with a second controller medication (i.e., long-acting β2 agonist [LABA], long acting muscarinic antagonist [LAMA], leukotriene receptor antagonist [LTRA] or methylxanthines) or high-dose ICS alone or high-dose ICS with second controller medication. Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication. Participants were followed up for 12 weeks after last dose (i.e. up to Week 64).
89374433|NCT02948959|Experimental|Dupilumab|Dupilumab 200 milligrams (mg) (in 1.14 milliliters [mL] for >30 kilograms [kg] bodyweight [BW]) or 100 mg (in 0.67 mL for less than or equal to (<=) 30 kg BW), SC injection q2w for 52 weeks in combination with stable-dose background therapy of medium-dose ICS with a second controller medication (i.e., LABA, LAMA, LTRA] or methylxanthines) or high-dose ICS alone or high-dose ICS with second controller medication. Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication. Participants were followed up for 12 weeks after last dose (i.e. up to Week 64).
89374434|NCT03582215|Experimental|Part 1: Cream|"Part 1: Cream~Ingredients: 2% Avobenzone; 10% Octocrylene; 2% Ecamsule"
89374435|NCT03582215|Experimental|Part 1: Lotion|"Part 1: Lotion~Ingredients: 3% Avobenzone; 4% Oxybenzone; 6% Octocrylene"
89374436|NCT03582215|Experimental|Part 1: Spray 1|"Part 1: Spray 1~Ingredients: 3% Avobenzone; 6% Oxybenzone; 2.35% Octocrylene; 15% Homosalate; 5% Octisalate"
89374437|NCT03582215|Experimental|Part 1: Spray 2|"Part 1: Spray 2~Ingredients: 3% Avobenzone; 5% Oxybenzone; 10% Octocrylene"
89374438|NCT03582215|Experimental|Part 2: Lotion|"Part 2: Lotion~Ingredients: 3% Avobenzone; 4% Oxybenzone; 6% Octocrylene"
89374439|NCT03582215|Experimental|Part 2: Aerosol Spray|"Part 2: Aerosol Spray~Ingredients: 3% Avobenzone; 6% Oxybenzone; 10% Octocrylene; 15% Homosalate; 5% Octisalate"
89374440|NCT03582215|Experimental|Part 2: Nonaerosol Spray|"Part 2: Nonaerosol Spray~Ingredients: 3% Avobenzone; 10% Octocrylene; 10% Homosalate; 5% Octisalate; 7.5% Octinoxate"
89374441|NCT03582215|Experimental|Part 2: Pump Spray|"Part 2: Pump Spray~Ingredients: 3% Avobenzone; 10% Homosalate; 5% Octisalate; 7.5% Octinoxate"
89374442|NCT03089580|Experimental|Intense Pulsed Light Treatment|Participants will have one eye randomized to receive the intense pulsed light (IPL) therapy treatment while their other eye will receive the sham treatment. Participants will receive approximately 15 light spots to areas around the eye, lower eyelid, cheek, side of the nose and temple. The energy level will be based on skin type. IPL will be administered 4 times throughout the study.
89374443|NCT03089580|Placebo Comparator|Sham Treatment|Participants will have the other eye randomized to receive a sham treatment. The sham treatment will be conducted by placing the intense pulsed light (IPL) device to approximately 15 areas around the eye, lower eyelid, cheek, side of nose and temple without delivery of the light. The sham treatment will mimic the IPL treatment but no light will be delivered. Sham treatment will be administered 4 times throughout the study.
89374444|NCT05420610||Patients with major burn.|Adult patients (age > 18 years) suffered from major burn which defined as total burned surface area (TBSA) > 20% with at least second degree burn depth were admitted to the intensive care unit (ICU) of the Burn Center at a tertiary medical center were retrospectively reviewed.
89374445|NCT05420532|Experimental|Exergaming Group|A video game-based physical activity training will be applied under a physiotherapist supervision for 1 days/week for 8 weeks.
89181460|NCT02596269|Placebo Comparator|Saline(SF) group|Received i.v. PCA with 100 ml solution containing 1250 µg of fentanyl in normal saline (12.5 µg/ml),
89374446|NCT01568580|Experimental|test drug|GreenGene
89374447|NCT05175859||Early tracheostomy|Tracheostomy time before day 10 following endotracheal airway management and invasive ventilation.
89374448|NCT05175859||Late tracheostomy|Tracheostomy time after day 11 following endotracheal airway management and invasive ventilation.
89374449|NCT04107870|Experimental|Virtual Reality Exposure Therapy|Female adolescents aged 13 to 18 are proposed virtual reality exposure therapy sessions, accompanied by a cognitive and behavioral therapy (CBT) therapist, to work on their body representations
89374450|NCT04107870|Active Comparator|Psychomotor Therapy|Psychomotor therapy sessions are proposed to female adolescents aged 13 to 18 years, ac-companied by a psychomotor therapist, to work on their body representations.
89374451|NCT05175703|Other|the infrainguinal arteries disease group|Actual patient group with any atherosclerotic change in the infrainguinal arteries
89374452|NCT04102800|Other|Treatment|Benralizumab 30mg by subcutaneous injection, 18 months treatment for the first 75 participants enrolled, 12 months treatment for participants 76-150
89374453|NCT03632226||1|Healthy Volunteers
89374454|NCT05682703||EBV virus infector|QPCR/EBV antibody, diagnosed as EBV infection patient
89374455|NCT05682703||nasopharyngeal carcinoma patients|Patients diagnosed as nasopharyngeal carcinoma by pathological diagnosis (2018 WHO standard)
89374456|NCT05682703||Healthy people|healthy people with no history of nasopharynx related diseases or other known diseases that may affect blood lipid/protein metabolism
88846391|NCT03335761|Experimental|Amplitude Setting #2|InterStim Therapy will be set to amplitude parameter #2.
88846392|NCT03335761|Experimental|Amplitude Setting #3|InterStim Therapy will be set to amplitude parameter #3.
88846393|NCT03662282|Experimental|Drug - Omegaven®|Therapy with Omegaven® will be initiated at the goal dose of 0.5-1/kg/day. The default is over 24 hours, but shorter intervals may be considered if a program of total parenteral nutrition cycling is recommended. Omegaven® will be infused intravenously through either a central or peripheral catheter.
88846394|NCT03336853|Experimental|HybenX ®|1 cc of mixture of hydroxybenzenesulfonic acid (37%) and hydroxymethoxybenzene acids (23%), sulfuric acid (28%), and water (12%) for 20 sec
88846395|NCT03336853|Placebo Comparator|Control|5 cc of sterile saline water for 20 sec
88846396|NCT03954626|Experimental|RTH258|Intravitreal injection
88846397|NCT04332835|Experimental|Intervention Group|Participants included in the experimental group will receive 500 milliliters of convalescent plasma, distributed in two 250 milliliters transfusions on the first and second day after starting the protocol. Simultaneously, they will receive the standard therapy defined by institutional protocol.
88846398|NCT04332835|Active Comparator|Control Group|Participants included in the control group will receive standard therapy defined by institutional protocol.
88846399|NCT03662360|No Intervention|GROUP A - control group|16 patients who respect the inclusion criteria, treated with psychotropic drugs Pro Re Nata.
88846400|NCT03662360|Experimental|GROUP B - aromatherapy group|16 patients included in the inclusion criteria, treated with psychotropic drugs Pro Re Nata and, in a complementary way, with diffusion aromatherapy
88846401|NCT03225001|Experimental|Failing surgical valve|Patients with a failing surgical bioprosthetic valve in the aortic position demonstrating stenosis and/or insufficiency will be treated with Edwards SAPIEN XT transcatheter valve.
88846402|NCT03225313|Placebo Comparator|control group|normal saline will be injected in the rectus sheath
88846403|NCT03225313|Active Comparator|Rectus block group|bupivicaine will be injected in the rectus sheath
88846404|NCT03225313|Experimental|Field block group|bupivicaine will be injected locally in a circular fashion surrounding the site of the hernia
89374457|NCT05664919|Experimental|Drug group|3500 participants will use SA58 Nasal Spray in drug group.
88846405|NCT03949244|Active Comparator|Latanoprost 0.005%|Latanoprost 0.005% drops to the nailfold.
88846406|NCT03949244|Experimental|Latanoprost bunod 0.024%|Latanoprost bunod 0.024% drops to the nailfold.
89374458|NCT05664919|No Intervention|Blank control group|3500 participants won't be given medication in blank control group.
88846407|NCT03949244|Placebo Comparator|Normal saline 0.9%|Normal saline 0.9% to the nailfold.
88846408|NCT03225859|Experimental|Self-Management Program|Patients in this arm will receive the therapist assisted self-management intervention following completion of trauma-focused therapy for PTSD.
88846409|NCT05313932|Experimental|Sleep deprivation|Two hours of sleep deprivation (Six hours of sleep)
88846410|NCT05313932|No Intervention|No intervention|No sleep deprivation (Eight hours of sleep)
88846411|NCT03948386|Active Comparator|isobaric bupivacaine|"Isobaric bupivacaine 12.5 mg (2.5 cc of 0.5%) for ≤ 74 height and 15 mg (3 cc) for > 74 height"
89374459|NCT05175079|Experimental|Accupressure group|"acupressure band apply to P6 (nei guan) point which located three fingers below the skin wrinkles of the anterior wrist.~Acupressure band wear 3 times daily before breakfast, lunch and dinner for at least 10 minutes"
89374460|NCT05175079|Placebo Comparator|Control group|
89399328|NCT03932721|No Intervention|Control|Patients with T2DM treated exclusive with the standard of care (SGLT2 inhibitors, maximal statin dose and ideal control of blood glucose and blood pressure).
89399329|NCT00106340|Experimental|Vildagliptin|
89399330|NCT00106340|Active Comparator|Glimepiride|
88846412|NCT03948386|Active Comparator|hyperbaric bupivacaine|"hyperbaric bupivacaine 10.25 mg (1.5 cc 0.75%) for ≤ 74 height and 13.125 mg (1.75 cc) for > 74 height"
88846413|NCT03948386|Active Comparator|isobaric mepivacaine|"isobaric mepivacaine 52.5 mg (3.5 cc of 1.5%) for ≤ 74 height and 60 mg (4 cc) for > 74 height"
88846414|NCT03445195|Experimental|Sulbactam-ETX2514 (ETX2514SUL) + Imipenem/Cilastatin|
88846415|NCT03445195|Placebo Comparator|Placebo + Imipenem/Cilastatin|
88846416|NCT04289714|Experimental|R-DOT|Remote Directly Observed Therapy
88846417|NCT04289714|Experimental|Haillie|Smartinhaler Haillie
88846418|NCT04289714|Experimental|Rafi-tone/INCA|Rafi-tone with Flo-tone /INCA
88846419|NCT04277936|Experimental|Levetiracetam (LEV) 500 mg|Participants will take their first dose of 500 mg LEV. After a two hour time window, the participants will complete MRI study. After MRI, patients will begin a 2-week intervention with 250 mg BID oral LEV.
88846420|NCT03666026|No Intervention|Standard of care control|Participants in this group will not receive any MyChart influenza vaccination reminders
88846421|NCT03666026|Experimental|1 MyChart R/R|Participants in this group will receive up to 1 influenza reminder recall notice via their MyChart account
88846422|NCT03666026|Experimental|2 MyChart R/R|Participants in this group will receive up to 2 influenza reminder recall notices via their MyChart account
88846423|NCT03666026|Experimental|3 MyChart R/R|Participants in this group will receive up to 3 influenza reminder recall notices via their MyChart account
88846424|NCT03936608|Experimental|Individualized RV-LV Pacing Offset|
88846425|NCT03936608|Active Comparator|No RV-LV Pacing Offset|
88846426|NCT03670160|Active Comparator|Phenobarbital|Phenobarbital loading dose 20mg/kg in 2 divided doses, then 5 mg/kg/day divided every 12 hours. Phenobarbital continued throughout the infants hospitalization.
88846427|NCT03670160|Active Comparator|Clonidine|Clonidine 5 mcg/kg/day divided every 3 hours. Clonidine will be continued to achieve control of NAS symptoms. Clonidine may be weaned after successful discontinuation of oral morphine sulfate. Infants will not be discharged on clonidine.
88846428|NCT03672032|Active Comparator|Fork-tip Needle|
88810244|NCT01342523|Experimental|No CIS/Loz/No emails/lite website/full booklet|"This arm of the project will address the following question:~How effective is the following intervention?~No CIS calls, nicotine lozenge, No motivational emails, lite website, full mailed booklet"
88810245|NCT01342523|Experimental|No CIS/Loz/No emails/full website/brief booklet|"This arm of the project will address the following question:~How effective is the following intervention?~No CIS calls, nicotine lozenge, No motivational emails, full website, brief mailed booklet"
88846429|NCT03672032|Active Comparator|Franseen Needle|
88846430|NCT03446053|Experimental|N-Rephasin® SAL200|Forty subjects will be randomly assigned to receive either N-Rephasin® SAL200 injection or a placebo administered by a 60-min intravenous infusion. Within each group, 8 subjects (6 active and 2 placebo) will receive a single dose of 6 mg/kg, followed by multiple ascending dose of 3, 6, 9, and 12 mg/kg/day.
88846431|NCT03446053|Placebo Comparator|INT200-Placebo|Saline
88846432|NCT00375895|Experimental|Ciclosporin|
88846433|NCT05314322|Experimental|High frequency group|Deep brain stimulation's parameter: Frequency adjusted to 130Hz, with other parameters fixed
88846434|NCT05314322|Experimental|Low frequency group|Deep brain stimulation's parameter: Frequency adjusted to 60Hz, with other parameters fixed
88846435|NCT03338803||Patients with a written prescription for linagliptin|
88846436|NCT05314244|Experimental|pylorus resecting group|The patients who underwent pylorus resecting pancreaticoduodenectomy for periampullary tumors
88846437|NCT05314244|No Intervention|pylorus preserving group|The patients who underwent pylorus preserving pancreaticoduodenectomy for periampullary tumors
88846438|NCT03452371|Active Comparator|Enhanced Traditional Care|Participants in this arm will receive usual care to help with smoking cessation offered to all patients who are smokers and some additional resources they can access for support.
88846439|NCT03452371|Experimental|Patient Navigation Intervention|Participants in this arm will meet with the trained patient navigator either in-person if she is available, or by telephone. They will receive up to ten hours of patient navigation over three months.
88846440|NCT03906968|Experimental|SinuSonic Device|SinuSonic Device used twice a day for four to six weeks.
88846441|NCT05314634|Experimental|concurrent exercise group, CE|Participants conduct 5-min warm up, 12-min aerobic exercise, 13-min resistance exercise, and 5-min cool down.
88846442|NCT05314634|Experimental|aerobic exercise group, AE|Participants conduct 5-min warm up, 25-min aerobic exercise, and 5-min cool down.
88846443|NCT05314634|No Intervention|reading control group, RC|Participants conduct reading for 35 minutes.
88846444|NCT04206800|No Intervention|Routine care|Routine care is normally having men abstain from ejaculation from 2 to 5 days prior to the scheduled oocyte retrieval date. Men in the routine care arm will abstain from ejaculation greater than 48 hours before providing a semen sample the day of the scheduled oocyte retrieval.
88846445|NCT04206800|Experimental|Ejaculatory abstinence less than 24 hours|Males will ejaculate within 24 hours of the scheduled oocyte retrieval date.
88846446|NCT03689504|Active Comparator|Standard of Care|The standard of care is an intensive individualized home-based nutrition education program, together with a home food ration and micronutrient supplement, delivered by frontline workers for 6 months.
88846447|NCT03689504|Experimental|Home Garden Intervention|This arm adds an 8 month individualized home-based family garden intervention to the existing standard of care (home-based nutrition education)
88846448|NCT03455491|Experimental|XC221 100 mg|"XC221 100 mg orally.~1 tablet of XC221 100 mg +1 tablet of Placebo 100 mg (in total 2 tablets) once daily during 3 days of treatment period"
88846449|NCT03455491|Experimental|XC221 200 mg|XC221 200 mg orally. 2 tablets of XC221 100 mg once daily during 3 days of treatment period
89399331|NCT02255786|Experimental|ACT Parent Group|Participants will complete a total of five Acceptance and Commitment Therapy - Parent Group Sessions First four are held weekly, last session held one month from 4th session.
88846450|NCT03455491|Placebo Comparator|Placebo|Placebo orally. 2 tablets of Placebo 100 mg once daily during 3 days of treatment period
89399332|NCT02255786|No Intervention|Treatment as Usual|Treatment as usual-Control
88846451|NCT03349567|Experimental|Audit-and-feedback|The experimental arm will consist of Emergency Department providers who do receive the intervention.
88846452|NCT03349567|No Intervention|Control|The control arm will consist of providers who do not receive the intervention.
88846453|NCT03691844|Experimental|AMZ001 + Placebo|on the target knee
88846454|NCT03691844|Experimental|AMZ001|on the target knee
88846455|NCT03691844|Placebo Comparator|Placebo|on the target knee
88846456|NCT03691844|Active Comparator|Comparator|Diclofenac gel on the target knee
88846457|NCT03456427|Other|All Study Participants|All subjects will undergo standard of care imaging on one breast. The other breast will be imaged using Patient-Assisted Compression (PAC), followed by Technologist-controlled (TC) Compression.
89374461|NCT03323346|Experimental|Disulfiram with copper|"Patients will take one pill of disulfiram (Antabus) daily at a dose of 400 mg continually during the treatment phase (from day 0 till End of treatment Visit). In case of intolerance, lower dose up to 200 mg per day is allowed. Patients will take disulfiram after their evening meal.~Patients will avoid alcohol and other disulfiram-drug interactions will be considered.~Copper supplementation will be given separately from disulfiram; in the morning with patients´breakfast. Patients will take one pill of copper dietary supplement (for instance Copper Star, STARLIFE) corresponding to 2 mg of elementary copper."
88846458|NCT04195880|Experimental|Experimental VA Community Living Centers|Eight VA CLCs selected to receive the INTERACT intervention
88846459|NCT04195880|No Intervention|Control VA Community Living Centers|Eight CLCs, matched to experiment CLCs, based on size, location to VAMC, and hospitalization rates, did not receive the intervention and continued care as usual
88846460|NCT03352609|Experimental|Active rTMS|5 sessions of rTMS delivered with MagPro (MagVenture) double blind rTMS system delivered at 110% of resting motor threshold with 3000 pulses of 10hz stimulation (5s on, 10s off) per session.
89374462|NCT05628571|Placebo Comparator|Fluoride toothpaste|Participants will brush their teeth with a commercially available Fluoride toothpaste (1450 ppm F) and a commercially available adult soft bristle toothbrush
88846461|NCT03352609|Sham Comparator|Sham|5 session of sham rTMS delivered with Magpro (MagVenture) double blind rTMS system to mimic active intervention.
88846462|NCT04191668|Other|PSG and NightOwl|Default patient recruitment During the study, for each execution day, all patients that have been scheduled for a PSG will be presented with an informed consent. All recruited patients shall be a part of the study during which they wear the NightOwl Sensor while undergoing the PSG exam.
88846463|NCT03354325|Active Comparator|Scheduled PCP follow-up|Parents of children randomized to scheduled follow up will be instructed to follow up with their primary care physician (PCP) within 4 days of discharge regardless of improvement and/or symptom resolution. Research coordinators will verify that the child has a scheduled follow up appointment prior to discharge.
88846464|NCT03354325|Experimental|As needed PCP follow-up|At the time of hospital discharge, parents will be instructed that the child does not need to automatically follow up with his/her primary care physician (PCP). Rather, the child should follow up on an as needed basis: if the child does not improve or if new concerns arise.
88846465|NCT03892460|Experimental|Treatment|Neuromuscular electrical stimulation
88846466|NCT03892460|No Intervention|Control|No treatment control
88846467|NCT03232645|Other|Rhythmia HDx and DirectSense technology|"Subjects will undergo ablation treatment of the pulmonary veins with the Rhythmia HDx mapping system with DirectSense technology. Subjects indicated for ablation treatment of de-novo PAF will be selected based on the inclusion/exclusion criteria and if deemed to be eligible for participation, will be asked to sign the Informed Consent Form.~For all enrolled subjects who undergo the ablation procedure, the subjects will be treated with the commercial Rhythmia HDx System with commercially available Software Version 2.0 with DirectSense technology (or any commercially available updates that are released during the course of the study); the IntellaMap Orion mapping catheter and the IntellaNav MiFi OI ablation catheter."
88810246|NCT01342523|Experimental|no CIS/no loz/emails/full website/brief booklet|"This arm of the project will address the following question:~How effective is the following intervention?~No CIS calls, no nicotine lozenge, motivational emails, full website, brief mailed booklet"
88846468|NCT00377936|Active Comparator|1|Gemcitabine
88846469|NCT00377936|Experimental|2|EndoTag-1 + Gemcitabine
88846470|NCT00377936|Experimental|3|EndoTag-1 + Gemcitabine
88846471|NCT00377936|Experimental|4|EndoTag-1 + Gemcitabine
89374463|NCT05628571|Experimental|Zinc toothpaste|Participants will brush their teeth with a toothpaste containing amine base, zinc lactate and fluoride (1400 ppm F) and a commercially available adult soft bristle toothbrush
89374464|NCT05255016|Sham Comparator|Standard of care + Sham CXL + Artificial Tears|Standard-of-care treatment and Sham CXL and administration of artificial tears.
88846472|NCT03457909|Experimental|DS-MCE|outpatients who have esophagus symptoms will take DS-MCE and conventional endoscopy examination examination successively.
88846473|NCT03696758|Experimental|Sildenafil followed by Metoprolol|Young adults born premature, recruited either from the National Lung Project Cohort or the general public, will undergo Cardiac Magnetic Resonance Imaging before and after medication administration. This will occur twice, on two separate visits. Subjects will be given sildenafil in between imaging scans at one visit, and will receive intravenous metoprolol in between scans at next visit. There will be a minimum period of 12 hours between drug interventions to ensure adequate drug wash-out. Subjects will also undergo pulmonary function testing and electrocardiogram.
89181461|NCT00741039|Experimental|1,|Patients > or = to 65 years of age with a diagnosis of prostate, lung, and/or breast cancer will be immunized with the inactivated influenza vaccine (0.5 ml intramuscularly) and/or the 23 valent pneumococcal vaccine (0.5 ml subcutaneously or intramuscularly).
89374465|NCT05255016|Experimental|Standard of care + CXL + Riboflavin 0.25% TE Solution|Standard of care treatment and the experimental combination product. The PXL Platinum 330 Illumination System is a portable electronic medical device. The device's light emitting diode (LED) is used to deliver a metered dose of UV-A light to a targeted treatment area for illuminating the cornea during corneal collagen CXL. The riboflavin solution is an isotonic (0.9%) sodium chloride solution containing 0.25% riboflavin, 1% hydroxypropylmethylcellulose, and 0.007% benzalkonium chloride, adjusted to a pH of 7.0, and packaged in 2 mL sterile syringes for topical ophthalmic use.
89374466|NCT05610397||1 level STALIF® C Ti|25 patients who have a 1 level implant with STALIF® C Ti
89374467|NCT05610397||1 level STALIF® C FLX|25 patients who have a 1 level implant with STALIF® C FLX
88810247|NCT01342523|Experimental|no CIS/no loz/emails/lite web/full booklet|"This arm of the project will address the following question:~How effective is the following intervention?~No CIS calls, no nicotine lozenge, motivational emails, lite website, full mailed booklet"
88810248|NCT01342523|Experimental|no CIS/no loz/no email/full website/full booklet|"This arm of the project will address the following question:~How effective is the following intervention?~No CIS calls, no nicotine lozenge, No motivational emails, full website, full mailed booklet"
88810249|NCT01342523|Experimental|CIS/loz/emails/lite website/brief booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, nicotine lozenge, motivational emails, lite website, brief mailed booklet"
88846474|NCT03696758|Experimental|Metoprolol followed by Sildenafil|Young adults born premature, recruited either from the National Lung Project Cohort or the general public, will undergo Cardiac Magnetic Resonance Imaging before and after medication administration. This will occur twice, on two separate visits. Subjects will be given metoprolol in between imaging scans at one visit, and will receive intravenous sildenafil in between scans at next visit. There will be a minimum period of 12 hours between drug interventions to ensure adequate drug wash-out. Subjects will also undergo pulmonary function testing and electrocardiogram.
89374468|NCT05610397||1 level STALIF® M Ti|25 patients who have a 1 level implant with STALIF® M Ti
88846475|NCT03461965|Experimental|Education with 3D printed model|The experimental group will be educated on MMS with a standardized script in addition to a 3D MMS model
88846476|NCT03461965|Active Comparator|Verbal Counselling|Participants in the control group will be educated on MMS according to the current standard of care, verbal counselling, with a standardized script
88846477|NCT03702608|Other|EluNIR 38mm|
88846478|NCT03233737|Experimental|Stage II: One spray CTY-5339-A, then one spray CTY-5339-CB|A single spray of CTY-5339-A Anesthetic Spray (14.0% benzocaine and 2.0% tetracaine HCl) tested over a 60 minute session, followed by a 4-14 day washout period, followed by a single spray of CTY-5339-CB Anesthetic Spray (14.0% benzocaine) tested over a 60 minute session. Used in Stage II of the study only.
88846479|NCT03233737|Active Comparator|Stage II: One spray of CTY-5339-CB, then one spray CTY-5339-A|A single spray of CTY-5339-CB Anesthetic Spray (14.0% benzocaine) tested over a 60 minute session, followed by a 4-14 day washout period, followed by a single spray of CTY-5339-A Anesthetic Spray (14.0% benzocaine and 2.0% tetracaine HCl) tested over a 60 minute session. Used in Stage II of the study only.
88846480|NCT03233737|Experimental|Stage I: One spray CTY-5339-A|Metered spray bottle with ≈200 uL total spray volume. Contains the active ingredients: 14.0% Benzocaine (USP = 28 mg) and 2.0% Tetracaine Hydrochloride (USP = 4 mg). Administered in a single anesthetic spray. Tested over a 60 minute session. Used in Stage I of the study only.
88846481|NCT03233737|Active Comparator|Stage I: One spray CTY-5339-CB|Metered spray bottle with ≈200 uL total spray volume. Contains the active ingredient: 14.0% Benzocaine (USP = 28 mg). Administered in a single anesthetic spray. Tested over a 60 minute session. Used in Stage I of the study only.
89374469|NCT05610397||1 level STALIF® M FLX|25 patients who have a 1 level implant with STALIF® M FLX
88846482|NCT03233737|Placebo Comparator|Stage I: One spray CTY-5339-P|Metered spray bottle with ≈200 uL total spray volume. Contains no active ingredient (placebo: vehicle control). Administered in a single anesthetic spray. Tested over a 60 minute session. Used in Stage I of the study only.
88846483|NCT05440747||Newly diagnosed CML-CP patients|Treat with TKI (Imatinib or Flumatinib or Nilotinb or Dasatinib).
88846484|NCT05440747||Patients with suboptimal response|"Treat with original TKI~Treat with original TKI combined with interferon/thymosin;~Replace other TKI ;~Replace other TKI and combined with interferon/thymosin."
88846485|NCT04144088|Active Comparator|Wu Ling San|"Drug : Wu Ling San Extract Granules Sun-Ten"
88846486|NCT04144088|Active Comparator|Yin-Chen Wu Ling San|"Drug : Yin-Chen-Wu-Ling-San Extract Power SUN-TEN"
88846487|NCT04144088|Placebo Comparator|Placebo|Drug : 1/10 Wu Ling San
88846488|NCT03462745|Experimental|Cannulation with AccuVein AV 300|The AccuVein AV300 device helps in venepuncture and intravenous (IV) cannulation. It uses infrared light that can be absorbed by the blood hemoglobin so that veins location is clearly viewed on the skin's surface.
88846489|NCT03462745|No Intervention|Standard insertion|Intravenous cannulation is an invasive procedure of inserting an intravenous catheter blindly through the skin, into the lumen of a peripheral vein.
89374470|NCT05610397||2 level STALIF® C Ti|25 patients who have a 2 level implant with STALIF® C Ti
89374471|NCT05610397||2 level STALIF® C FLX|25 patients who have a 2 level implant with STALIF® C FLX
89374472|NCT05610397||2 level STALIF® M Ti|25 patients who have a 2 level implant with STALIF® M Ti
89374473|NCT05610397||2 level STALIF® M FLX|25 patients who have a 2 level implant with STALIF® M FLX
89374474|NCT05598450|Experimental|schizophrenia patients with auditory hallucinations|For schizophrenia patients with auditory hallucinations, rTMS+MEG for implementation intervention
89374475|NCT03645395|Experimental|MT-3724 10 mcg/kg-LEN|MT-3724 10 mcg/kg/dose IV for 6 doses over 12 days (M-W-F X 2 weeks on Days 1, 3, 5, 8, 10, and 12) of each 28 day cycle in combination with LEN. If the treatment with MT-3724 is continued beyond Cycle 2, then MT-3724 will be administered weekly (Days 1, 3, 5, 8, 10, and 12) of each 28-day cycle
89374476|NCT03645395|Experimental|MT-3724 25 mcg/kg-LEN 3x a week|MT-3724 25 mcg/kg/dose IV for 6 doses over 12 days (M-W-F X 2 weeks on Days 1, 3, 5, 8, 10, and 12) of each 28 day cycle in combination with LEN. If the treatment with MT-3724 is continued beyond Cycle 2, then MT-3724 will be administered weekly Days 1, 3, 5, 8, 10, and 12) of each 28-day cycle
89374477|NCT03645395|Experimental|MT-3724 20 mcg/kg-LEN 3x a week|MT-3724 20 mcg/kg/dose IV for 6 doses over 12 days (M-W-F X 2 weeks on Days 1, 3, 5, 8, 10, and 12) of each 28 day cycle in combination with LEN. If the treatment with MT-3724 is continued beyond Cycle 2 , then MT-3724 will be administered weekly (Days 1, 3, 5, 8, 10, and 12) of each 28-day cycle
89374478|NCT03645395|Experimental|MT-3724 25 mcg/kg-LEN 2x a week|MT-3724 25 mcg/kg dose IV for 4 doses (days 1, 5, 8 and 12 during cycles 1 and 2) of each 28 day cycle in combination with LEN and weekly during cycles 3 and beyond (days 1, 8, 15 and 22).
88810250|NCT01342523|Experimental|CIS/loz/no email/full website/brief booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, nicotine lozenge, No motivational emails, full website, brief mailed booklet"
88810251|NCT01342523|Experimental|CIS/loz/no email/lite website/full booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, nicotine lozenge, No motivational emails, lite website, full mailed booklet"
88810252|NCT01342523|Experimental|CIS/no loz/emails/full website/brief booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, no nicotine lozenge, motivational emails, full website, brief mailed booklet"
88810253|NCT01342523|Experimental|CIS/no loz/emails/lite website/full booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, no nicotine lozenge, motivational emails, lite website, full mailed booklet"
89374479|NCT03645395|Experimental|MT-3724 50 mcg/kg-LEN|MT-3724 50 mcg/kg dose IV for 4 doses (days 1, 5, 8 and 12 during cycles 1 and 2) of each 28 day cycle in combination with LEN and weekly during cycles 3 and beyond (days 1, 8, 15 and 22).
89374480|NCT04074018|Experimental|Experimental group|Self-rehabilitation guided program with investigator PMR specialist
89374481|NCT04074018|Active Comparator|Control group|Conventional rehabilitation with a speech therapist or physiotherapist specialized in facial rehabilitation
88846490|NCT03711578|Experimental|Tenalisib|Participants receive Tenalisib 800 mg BID in 28-Days Cycle for 8 Cycles
89374482|NCT03342469|Experimental|ADHD- Artificial food coloring, then placebo|Participants first received 225 mg of the six most common artificial food colors (Red 40, Red 3, Yellow 5, Yellow 6, Blue 1, and Blue 2) mixed in chocolate cookies and consumed consecutively over three days (Monday, Tuesday, Wednesday). After a 4-day washout period, they then received placebo of chocolate cookies and consumed them over three days.
89374483|NCT03342469|Experimental|ADHD - Placebo, then artificial food coloring|Participants first received placebo of chocolate cookies and consumed them over three days. After a 4-day washout period, they then received 225 mg of the six most common artificial food colors (Red 40, Red 3, Yellow 5, Yellow 6, Blue 1, and Blue 2) mixed in chocolate cookies and consumed consecutively over three days (Monday, Tuesday, Wednesday).
89374484|NCT03342469|Experimental|Controls- Artificial food coloring, then placebo|Participants first received 225 mg of the six most common artificial food colors (Red 40, Red 3, Yellow 5, Yellow 6, Blue 1, and Blue 2) mixed in chocolate cookies and consumed consecutively over three days (Monday, Tuesday, Wednesday). After a 4-day washout period, they then received placebo of chocolate cookies and consumed them over three days.
89374485|NCT03342469|Experimental|Controls - Placebo, then artificial food coloring|Participants first received placebo of chocolate cookies and consumed them over three days. After a 4-day washout period, they then received 225 mg of the six most common artificial food colors (Red 40, Red 3, Yellow 5, Yellow 6, Blue 1, and Blue 2) mixed in chocolate cookies and consumed consecutively over three days (Monday, Tuesday, Wednesday).
89374486|NCT05178888|Experimental|Dose Escalation|Dose escalation of MRTX849 and palbociclib to determine maximum tolerated dose in combination.
88846491|NCT03463915|Active Comparator|Bladder instillation WITH triamcinolone acetonide|Six weekly bladder instillations of standard cocktail plus triamcinolone acetonide. Standard cocktail= heparin (10,000 units), 2% viscous lidocaine (10 mL), 8.4% sodium bicarbonate (15 mL of 1 mEq/mL), and 0.5% bupivacaine (10 mL of 5 mg/mL) plus triamcinolone acetonide (1 vial, 40 milligrams (mg)/1 milliliters (mL).
88846492|NCT03463915|Placebo Comparator|Bladder instillation WITHOUT triamcinolone acetonide|Six weekly bladder instillations of standard cocktail without triamcinolone acetonide. Standard cocktail= heparin (10,000 units), 2% viscous lidocaine (10 mL), 8.4% sodium bicarbonate (15 mL of 1 mEq/mL), and 0.5% bupivacaine (10 mL of 5 mg/mL).
88846493|NCT04147442|Experimental|Music program fine-tuned and standard|The fine-tuned program and the standard program will be compared within the same instrument as a hearing aid can have up to 4 different listening programs in it.
88846494|NCT03237871|Experimental|Survey and informational text messages|Text-message survey and informational text messages
88846495|NCT04146272|Active Comparator|Moderate Hearing loss current Mermaid first, then new|Participants were randomized to wear the current Mermaid hearing aid that uses the current feedback cancellation first for 10 days. Then they wore the new Mermaid Hearing aid for another 10 days.
88846496|NCT04146272|Active Comparator|Moderate Hearing loss new Mermaid first, then current|Participants were randomized to wear the new Mermaid hearing aid that uses the new feedback cancellation first for 10 days. Then they wore the current Mermaid Hearing aid for another 10 days.
88846497|NCT04146272|Active Comparator|Severe hearing loss current Power first, then new|Participants were randomized to wear the current power hearing aid that uses the current feedback cancellation first for 10 days. Then they wore the new power Hearing aid for another 10 days.
88846498|NCT04146272|Active Comparator|Severe hearing loss new Power first, then current|Participants were randomized to wear the new power hearing aid that uses the new feedback cancellation first for 10 days. Then they wore the current power Hearing aid for another 10 days.
88846499|NCT03473665|Active Comparator|Indomethacin|Indomethacin Extended Release Oral Tablet 75mg by mouth, every 12 hours for 6 weeks
89374487|NCT05178888|Experimental|Dose Expansion|Expansion cohorts may be implemented to ensure sufficient safety experience, pharmacokinetic data and early evidence of clinical activity of MRTX in combination with palbociclib.
88846500|NCT03473665|Active Comparator|Diclofenac|Diclofenac Delayed Release Oral Tablet 75mg by mouth, every 12 hours for 6 weeks
88846501|NCT03473665|Active Comparator|Meloxicam|Meloxicam tablet 7.5mg by mouth, every 12 hours for 6 weeks
88846502|NCT03473665|Active Comparator|Celecoxib|Celecoxib 200mg capsule by mouth, every 12 hours for 6 weeks
88846503|NCT03863210|Experimental|Participants who received informations about lifestyle change|
88846504|NCT03239665|Active Comparator|Pharmacist-led Intervention (PHARM)|In the PHARM intervention group, participants will be given a 60-minute formal presentation on vaccine-preventable diseases to address knowledge and beliefs related to zoster, pneumonia, and influenza and to address barriers to receiving vaccination. In several studies, it has been demonstrated that those who believe it is wise to receive vaccinations and those that have discussed vaccination with their healthcare provider are more likely to receive a vaccine.
89399333|NCT03538496|Active Comparator|ultrasound guided erector spinae plane block|ultrasound guided erector spinae plane block with 20 ml %0.25 bupivacaine
89374488|NCT03581825|Experimental|Test/Control|Myopic subjects who are habitual soft contact lens wearers between the ages of 40 and 70 years of age, will be randomized to sequence Test/Control. Alternative Spherical lenses will be used if optimization cannot be achieved with the Multifocal lenses.
89374489|NCT03581825|Experimental|Control/Test|Myopic subjects who are habitual soft contact lens wearers between the ages of 40 and 70 years of age, will be randomized to sequence Control/Test. Alternative Spherical lenses will be used if optimization cannot be achieved with the Multifocal lenses.
89374490|NCT03342001|Experimental|Treatment group, open label|calcitonin nasal spray, 200 mcg daily
89374491|NCT03730025|Experimental|Auscultation plus NeoTapAS|Pediatric resident responsible for HR assessment will estimate the HR by listening to the praecordium with a stethoscope. When using NeoTapAS, he/she will simultaneously tap the same pace on the screen of an iPad with the NeoTapAS app installed and will verbally communicate the HR displayed on the screen.
89374492|NCT03730025|Active Comparator|Auscultation without NeoTapAS|Pediatric resident responsible for HR assessment will mentally calculate the HR based on auscultation (by counting the number of beats in 6 seconds and multiplying by 10) and will verbally communicate the calculated HR.
89374493|NCT03341923|Other|DT1MF, then AMMF|Delefilcon A multifocal contact lenses, followed by etafilcon A multifocal contact lenses. Each product worn in both eyes for 14 +/- 3 days.
89374494|NCT03341923|Other|AMMF, then DT1MF|Etafilcon A multifocal contact lenses, followed by delefilcon A multifocal contact lenses. Each product worn in both eyes for 14 +/- 3 days.
89374495|NCT03579719|Experimental|Balovaptan + Itraconzole|Dosing in Period 1 was separated by at least a 7 day washout period before dosing starts in Period 2. Participants received the study drugs in 2 periods over a total of 37 days.
89374496|NCT03631602|Experimental|Arm 1|posaconazole oral suspension
89374497|NCT03631602|Active Comparator|Arm 2|itraconazole oral solution
89374498|NCT03732989|Active Comparator|Control group: Non-interactive toy prototype|30 children will be given the same toy as participants in the experimental group, but without the interactive features (haptic feedback).
88846505|NCT03239665|Experimental|Peer-led Intervention (PEER)|A pharmacist will train the peer educators about vaccine-preventable diseases over the course of two didactic sessions. Following this training, a third session will be held to train the peer educators on the script that they will deliver to participants. The script will include the key learning points to be taught by the peer educators to participants about vaccine preventable diseases and vaccination. The script will also include role-play exercises. In the role-play exercises, 3 vaccination-related scenarios (one for each disease- zoster, pneumonia, and influenza) will be delivered to illustrate situations participants might encounter when interacting with healthcare providers or friends/family.
88846506|NCT03717506|Experimental|Test product|GDC 268 Lotion applied topically as directed.
89374499|NCT03732989|Experimental|Experimental: Interactive toy prototype|30 children will be given the same toy as participants in the control group, but with the interactive features (haptic feedback).
89374500|NCT03341533|Experimental|Ice packs plus usual post-op analgesia|Ice pack applied to the abdomen and maintained continuously for the first 12 hours post-operatively. Standard standard post-operative analgesia orders will be followed in addition to use of ice.
89374501|NCT03341533|Active Comparator|Usual post-op analgesia|Standard post-operative analgesia only, no ice use.
89374502|NCT03732911|Experimental|Intervention|Intervention arm
89374503|NCT03631524|No Intervention|Conventional therapy|The control arm will be subject to the same assessments as the treatment arm at the start and end of the two week period. They will receive standard care in the ward including physiotherapy as prescribed by the managing team
89374504|NCT03631524|Experimental|Intervention arm|The treatment arm will be given up to 1 hour of physiotherapist-prescribed resistive training exercises administered via a telerehabilitation device per day in addition to standard therapy for a total of 10 sessions over a 2 week period. They will be evaluated for motor strength, activity of daily living performance, mood and perceived level of health.
89374505|NCT03729791|Experimental|actual tDCS|2mA direct current, 20 minutes per session, 2 sessions per day with at least 3hours interval between sessions, a total of 10 tDCS sessions
89374506|NCT03729791|Active Comparator|sham tDCS|sham direct current, 20 minutes per session, 2 sessions per day with at least 3hours interval between sessions, a total of 10 tDCS sessions
89374507|NCT03708445|Experimental|Bile duct stenosis|This arm includes patients with bile duct stenosis. Endobiliary brushing cytology specimens will be obtained with endoscopic retrograde cholangiopancreatography (ERCP) of patients with bile duct stenosis. Cytology staining will be performed in the cytology specimens.
89374508|NCT02688088|Active Comparator|Drug Cocktail - Period 1|Single dose of drug cocktail: 100 milligram (mg) caffeine,10 mg warfarin, 30 mg dextromethorphan, and 0.2 mg midazolam administered orally on Day 1 in Period 1.
89374509|NCT02688088|Experimental|200 mg Abemaciclib + Drug Cocktail - Period 2|200 mg Abemaciclib administered orally every 12 hours (Q12H) on Days 1 - 12 in Period 2 with a single dose of drug cocktail: 100 mgcaffeine,10 mg warfarin, 30 mg dextromethorphan, and 0.2 mg midazolam administered orally on Day 8 in Period 2.
89374510|NCT02688088|Experimental|200 mg Abemaciclib - Period 3|200 mg Abemaciclib administered orally Q12H on Days 13 to 28 in Period 3. Participants may continue to receive abemaciclib until discontinuation criteria are met.
89374511|NCT02688088|Experimental|200 mg Abemaciclib - Period 4|200 mg Abemaciclib administered orally Q12H on Days 1 to 28 in Period 4. Participants may continue to receive abemaciclib until discontinuation criteria are met.
88846507|NCT03717506|Active Comparator|Reference Product|Clindamycin Phosphate Lotion, 1% applied topically as directed.
88846508|NCT03717506|Placebo Comparator|Placebo|GDC Vehicle lotion applied topically as directed.
88846509|NCT03861338|Experimental|sublocade|Sublocade buprenorphine extended-release (BXR) injection, 300 mg and 100 mg
88846510|NCT03851744|Active Comparator|Sea Level|Carbohydrate metabolism measured at SL
88846511|NCT03851744|Experimental|High Altitude|Carbohydrate metabolism measured at HA
88846512|NCT00377780|Experimental|1|Myocet + docetaxel + trastuzumab
89374512|NCT02688088|Experimental|Safety Extension Period|200 mg Abemaciclib administered orally Q12H on Days 1 to 28 onwards in extension period. Participants may continue to receive abemaciclib until discontinuation criteria are met.
89374513|NCT05598216||Fasting state|based on the sampling time and the serum's aspect
89374514|NCT05598216||non-fasting state|based on the sampling time and the serum's aspect
89374515|NCT03641651|Experimental|Technology arm|4 Weeks intervention of intensive rehabilitation using rehabilitation technology, 3-5 h per day, within a 5d week in-or outpatient setting.
89374516|NCT04728204|Experimental|Intervention group|8 module, 8 week long internet-based intervention for reducing burden of depression
89374517|NCT04728204|No Intervention|Control group|Participants randomized to the control group will be instructed to wait until the intervention group finishes the treatment and that they will be able to use the same intervention afterwards.
89374518|NCT03341299|Experimental|LY900014 Before Meal|Individualized dose of LY900014 administered subcutaneously (SC) immediately before meal in one of four study periods.
89374519|NCT03341299|Experimental|LY900014 After Meal|Individualized dose of LY900014 administered SC 20 minutes after start of meal in one of four study periods.
89374520|NCT03341299|Active Comparator|Insulin Lispro (Humalog) Before Meal|Individualized dose of insulin lispro administered SC immediately before meal in one of four study periods.
89374521|NCT03341299|Active Comparator|Insulin Lispro (Humalog) After Meal|Individualized dose of insulin lispro administered SC 20 minutes after start of meal in one of four study periods.
88846513|NCT03242941|Experimental|Persistent and Paroxtmal AF Patients|Patients with either paroxymal or persistent AF already referred to the center for Pulmonary Vein Ablation will be stimulated delivering a novel dual-stage pacing protocol to terminate atrial fibrillation usinf a ring of electrodes positioned on the septum.
88846514|NCT03719300|Experimental|Single Arm BC-819|inodiftagene vixteplasmid
88846515|NCT00376519|Experimental|Transplant with Treg Cells|Patients receive preparative therapy with Fludarabine, cyclophosphamide, total body irradiation and Treg infusion followed by umbilical cord blood transplantation.
89374522|NCT05653960||Subjects who undergo EMR or ESD|Subjects who undergo EMR or ESD for colorectal lesions
89374523|NCT05666219|Experimental|Treatment group|Patients receiving Injection Aminophylline
89374524|NCT02949271|Active Comparator|Programmed Intermittent Epidural Bolus|Epidural catheters will be placed at the L3/4 or L4/5 interspace with 4 cm of catheter being left in the epidural space. Epidural analgesia will be initiated and maintained with a solution of ropivacaine 0.1% with fentanyl 2 mcg/ml. After the initial epidural loading dose of 20 mL is administered in incremental fashion, patients will receive either 6 mL every 45 minutes in the PIEB arm (first bolus 30 minutes after epidural initiation). All study participants will be provided with PCEA set to 8mL boluses with a 10-minute lockout period. The maximum amount of PCEA analgesia will be set to a 1-hour maximum of 45mL.
88846516|NCT03719378|No Intervention|Traditional Fluid|"NPO Clears and Food after midnight.~2 Liters of lactated ringers administered by anesthesia intraoperatively.~Postoperatively - 2 Liters of Crystalloid while in PACU and Inpatient Room for a Total of 4 Liters of Crystalloid within 24 hours. (Patient will receive 500 milliliters while in PACU and 1500 milliliters while in their Inpatient Room, for a total of 2 Liters).~Normal diet postoperatively."
88846517|NCT03719378|Experimental|Oral Fluid|"Pre Operative Oral Fluids (Patients encouraged to drink a minimum of 60 ounces of clear liquid per day for the 3 days prior to procedure.)~NPO Food/Milk: none beginning 8 hours prior to procedure time.~Pre Operative Oral Fluids (Patients are asked to drink 10 ounces of clear liquid 4 hours prior to their scheduled procedure time.)~Preoperative holding area, IV is started in the patient with Lactated Ringers IV fluid at a rate of 75ml/hr. IV fluids will be stopped and hep-locked in the PACU when the patient is taking PO fluid; the total amount of IV fluids is not to exceed 500ml total.~PO fluid protocol: a minimum of 60 ounces of liquid per day for 3 days."
88846518|NCT03368053|Experimental|GSKSB732461 Group|Healthy HIV uninfected volunteers who participated in study PRO HIV-002 between February 2003 and February 2005 and who were vaccinated with at least 3 doses of the GSKSB732461 vaccine candidate in the PRO-HIV-002 study.
89374525|NCT02949271|Active Comparator|Continuous Epidural Infusion|Epidural catheters will be placed at the L3/4 or L4/5 interspace with 4 cm of catheter being left in the epidural space. Epidural analgesia will be initiated and maintained with a solution of ropivacaine 0.1% with fentanyl 2 mcg/ml. After the initial epidural loading dose of 20 mL is administered in incremental fashion, patients will receive 8mL/hr of continuous infusion beginning immediately after the loading dose for the maintenance of analgesia in the CEI arm. All study participants will be provided with PCEA set to 8mL boluses with a10-minute lockout period. The maximum amount of PCEA analgesia will be set to a 1-hour maximum of 45mL.
89374526|NCT03732755|Experimental|Active|PoNS Treatment will consist of three stages: an in-clinic training program, a home training program, and an extended home training program. During all stages of the study, subjects will complete three training sessions per day, morning, afternoon and evening, 6 days per week.
89374527|NCT03706807|Experimental|Mindfulness-Based Intervention|"This group will be included in the eight-week mindfulness program following the Mindfulness-Based Health Promotion (MBHP) protocol. The group will have a weekly meeting of an hour and thirty minutes for eight weeks to perform the mindfulness-based interventions accompanied by plus four one-hour meetings through a maintenance group after conclusion of the program, totaling 16 hours. The training will be lead by a certified instructor and he will introduce practices such as mindfulness in breathing, body scan, mindful walking, mindful movements and 3-minutes of mindfulness and the concepts of first and second suffering and the Hi-Thanks-Bye."
88846519|NCT03719612|Experimental|DEFINITY®|Each patient will undergo an unenhanced ultrasound examination and a DEFINITY® contrast-enhanced ultrasound
89374528|NCT03706807|Active Comparator|Cognitive Stimulation|The basic workshop is considered a cognitive stimulation and the participants will receive an hour and thirty minutes class once a week during four months. The abilities learned at the workshop will be basic computer functions from development of the psychomotricity involving the use of mouse, keyboard, MS paint, photo gallery and PowerPoint presentations to surf on the internet, learn how to play online games and use social networks. The activities of the workshop are elaborated according to the development of each class and is participants.
89374529|NCT03706807|No Intervention|Naïve|It's a waiting list group which will receive no intervention.
89374530|NCT03640559|Placebo Comparator|Placebo|the group were having the administration of Placebo (saline 2.4 mL/kg IP)
88846520|NCT04706611|Experimental|Irritable Bowel Syndrome|Fecal Microbiota Transplantation will be performed.
88846521|NCT04706611|Experimental|Constipation|Fecal Microbiota Transplantation will be performed.
88846522|NCT04706611|Experimental|Clostridium Difficile Infection|Fecal Microbiota Transplantation will be performed.
88846523|NCT04706611|Experimental|Functional Dyspepsia|Fecal Microbiota Transplantation will be performed.
88846524|NCT04706611|Experimental|Parkinson's Disease|Fecal Microbiota Transplantation will be performed.
88846525|NCT04706611|Experimental|Metabolic Syndrome|Fecal Microbiota Transplantation will be performed.
89374531|NCT03640559|Experimental|Seroguard|the group were having the administration of Seroguard 0.41 g/L solution, 2.4 mL/kg IP
89374532|NCT03339583|Experimental|zopiclone first group|underwent the medication therapy (zopiclone) for the first two weeks followed by brief behavioral therapy
89374533|NCT03339583|Experimental|BBT-I first group|received two-week brief behavioral therapy followed by medication therapy (zopiclone).
89374534|NCT03639779|Experimental|Sodium thiosulfate|50 ml vials of sodium thiosulfate (250mg/ml) will be used for treatment.
89374535|NCT03639779|Placebo Comparator|Saline solution|30 ml vials of sodium chloride 0.9% will be used for the control treatment.
89374536|NCT05239195|Active Comparator|Video Laryngoscope Group|For patients assigned to the video laryngoscope group, the operator will use a video laryngoscope on the first laryngoscopy attempt. A video laryngoscope will be defined as a laryngoscope with a camera and a video screen. Trial protocol will not dictate the brand of video laryngoscope.
88846526|NCT04706611|Experimental|Non-Alcoholic Fatty Liver Disease|Fecal Microbiota Transplantation will be performed.
88846527|NCT04706611|Experimental|Autism Spectrum Disorder|Fecal Microbiota Transplantation will be performed.
88846528|NCT04706611|Experimental|Radiation Enteritis|Fecal Microbiota Transplantation will be performed.
89374537|NCT05239195|Active Comparator|Direct Laryngoscope Group|For patients assigned to the direct laryngoscope group, the operator will use a direct laryngoscope on the first laryngoscopy attempt. A direct laryngoscope will be defined as a laryngoscope without a camera or a video screen. Trial protocol will not dictate the brand of direct laryngoscope or the blade shape.
89374538|NCT03575975||Mobile-bearing ankle prosthesis user|Users of the Stryker Scandinavian Total Ankle Replacement (STAR) mobile-bearing prosthesis.
89374539|NCT03575975||Control|Healthy individual age- and gender-matched to a participant in the mobile-bearing prosthesis user group.
88846529|NCT04706611|Experimental|Atopic Dermatitis|Fecal Microbiota Transplantation will be performed.
88846530|NCT04706611|Experimental|Food Allergic|Fecal Microbiota Transplantation will be performed.
88846531|NCT04706611|Experimental|Graft-versus-Host Disease|Fecal Microbiota Transplantation will be performed.
88846532|NCT04706611|Experimental|Obesity|Fecal Microbiota Transplantation will be performed.
89374540|NCT03575975||Fixed-bearing ankle prosthesis user|Users of the INBONE II Total Ankle Replacement fixed-bearing prosthesis.
89374541|NCT05174923||Age Range 45 to </= 60|
89374542|NCT05174923||Age Range 61 to </= 75|
89374543|NCT05174923||Age >/= 76|
89374544|NCT03636893|Experimental|FLOT Chemotherapy regimen|"A total of four preoperative and four postoperative cycles of FLOT chemotherapy administered~A cycle consists of Day 1 5-fluorouracil(5-FU) 2600mg/M2 administered via an intravenous peripherally inserted central venous catheter(PICC) for 24 hour Leucovorin 200mg/M2 intravenous Oxaliplatin 85mg/ M2 intravenous Docetaxel 50mg/M2 intravenous~Repeated every 15th day"
89374545|NCT03636893|Active Comparator|SOX Chemotherapy regimen|"Three preoperative cycles and three postoperative cycles of SOX chemotherapy administered~A cycle consist of Day 1: Oxaliplatin 130mg/M2 intravenous Day 1-14 Tegafur gimeracil oteracil potassium capsule 80mg/M2 oral (twice daily)~Repeated every 21st day"
89374546|NCT05174689|Other|EIA wih house dust mite|Patients with EIA and house-dust mite allergy and an eNO > 30 ppb
89374547|NCT05174689|Other|EIA without sensitization|Patients with EIA without allergic sensitization and an eNO < 20 ppb
89374548|NCT05174689|Other|Healthy controls|Healthy controls without allergic sensitization or known asthma
89374549|NCT03729635|Experimental|PIFB performed to treat PSP|Pectoral-intercostal fascial plane block (PIFB) is performed on patients with severe post-sternotomy pain (PSP) after coronary artery bypass graft surgery (CABG).
89374550|NCT05581693|Experimental|A (L04RD1 -> L04TD2)|Administration of 1 tablet of L04RD1, and taking 7-day wash-out period, and then administration of 1 tablet of L04TD2
88846533|NCT04706611|Experimental|Diabetes mellitus|Fecal Microbiota Transplantation will be performed.
88846534|NCT04706611|Experimental|Multi-Drug Resistant Infection|Fecal Microbiota Transplantation will be performed.
88846535|NCT04706611|Experimental|Hepatic Encephalopathy|Fecal Microbiota Transplantation will be performed.
88846536|NCT04706611|Experimental|Enteric Dysbacteriosis|Fecal Microbiota Transplantation will be performed.
88846537|NCT04706611|Experimental|Multiple Sclerosis|Fecal Microbiota Transplantation will be performed.
88846538|NCT04706611|Experimental|Pseudomembranous Enteritis|Fecal Microbiota Transplantation will be performed.
88846539|NCT04706611|Experimental|Acute Pancreatitis|Fecal Microbiota Transplantation will be performed.
88846540|NCT04706611|Experimental|Chronic Fatigue Syndrome|Fecal Microbiota Transplantation will be performed.
88846541|NCT04706611|Experimental|Acute-on-chronic Liver Failure with HBV Infection|Fecal Microbiota Transplantation will be performed.
88846542|NCT04706611|Experimental|Alcoholic Liver Disease|Fecal Microbiota Transplantation will be performed.
88846543|NCT04706611|Experimental|Anorexia|Fecal Microbiota Transplantation will be performed.
88846544|NCT04706611|Experimental|Decompensated Cirrhosis|Fecal Microbiota Transplantation will be performed.
88846545|NCT04706611|Experimental|Henoch-Schonlein Purpura|Fecal Microbiota Transplantation will be performed.
88846546|NCT04706611|Experimental|Autoimmune Liver Disease|Fecal Microbiota Transplantation will be performed.
88846547|NCT04706611|Experimental|Systemic Lupus Erythematosus|Fecal Microbiota Transplantation will be performed.
88846548|NCT04706611|Experimental|IgG4-Related Disease|Fecal Microbiota Transplantation will be performed.
88846549|NCT04706611|Experimental|Celiac Disease|Fecal Microbiota Transplantation will be performed.
89374551|NCT05581693|Experimental|B (L04TD2 -> L04RD1)|Administration of 1 tablet of L04TD2, and taking 7-day wash-out period, and then administration of 1 tablet of L04RD1
89374552|NCT05568121|Experimental|A (L04RD1 -> L04TD1)|Administration of 1 tablet of L04RD1, and taking 7-day wash-out period, and then administration of 1 tablet of L04TD1
89374553|NCT05568121|Experimental|B (L04TD1 -> L04RD1)|Administration of 1 tablet of L04TD1, and taking 7-day wash-out period, and then administration of 1 tablet of L04RD1
89374554|NCT01353586|Experimental|nMARQ™ System|The nMARQ™ System (Circular and Crescent Mapping and Ablation Catheters as well as the Multi-Channel Radiofrequency Generator) as part of the Multi-Electrode Irrigated Pulmonary Vein (PV) Isolation System will serve as a treatment method for subjects undergoing radiofrequency catheter ablation for drug refractory, symptomatic Paroxysmal Atrial Fibrillation (PAF). The study later included a Subpopulation Neurological Assessments (SNA) substudy which is a prospective, non-randomized, controlled, acute assessment to compare subjects treated with the nMARQ™ System against control subjects treated with the NAVISTAR® THERMOCOOL® Irrigated Tip Catheter.
89374555|NCT05173441|Experimental|High Dose Group|Standard of care (SOC)+high dose COVID-HIG. COVID-HIG will be administered via intravenous infusion. once a day, for three consecutive days (Day 0, day 1, and Day 2). And it could be administered again for 1-2 days according to the clinical improvement of subjects, and the total number of infusions should not exceed5 times.
89374556|NCT05173441|Experimental|Low Dose Group|Standard of care (SOC)+low dose COVID-HIG. COVID-HIG will be administered via intravenous infusion. once a day, for three consecutive days (Day 0, day 1, and Day 2). And it could be administered again for 1-2 days according to the clinical improvement of subjects, and the total number of infusions should not exceed5 times.
89374557|NCT05173441|Placebo Comparator|Control Group|Standard of care (SOC)+placebo (0.9% sodium chloride). Placebo will be administered via intravenous infusion. once a day, for three consecutive days (Day 0, day 1, and Day 2). And it could be administered again for 1-2 days according to the clinical improvement of subjects, and the total number of infusions should not exceed5 times.
89374558|NCT05682469|Experimental|VR group|VR cognitive training receives eight gardening activities. The cognitive elements including attention, working memory, processing speed, and executive function incorporated training.
89374559|NCT05682469|Active Comparator|control group|The control group is performing traditional cognitive training program.
89374560|NCT05226949||Cases|"54 newborns with neonatal HSV infection.~Interventions:~Diagnostic test and disease pathogenesis: Host RNA expression profiling by RNA sequencing and proteomic analyses. Cases will be randomly assigned to a Discovery Cohort (identification of diagnostic RNA and proteomic profiles)."
89374561|NCT05226949||Controls|"108 newborns without infection.~Interventions:~Diagnostic test and disease pathogenesis: Host RNA expression profiling by RNA sequencing and proteomic analyses. Controls will be randomly assigned to a Discovery Cohort (identification of diagnostic RNA and proteomic profiles)."
89374562|NCT03706651||Exposed group, during Tele-expertise|Infants hospitalized in health facilities performing tele-expertise
89374563|NCT03706651||Exposed group, Prior Tele-expertise|Infants hospitalized in health facilities performing Tele-expertise prior implementation of Tele-expertise
89374564|NCT05682313|Experimental|Elastography arm|single arm that includes all patient who have consented for ultrasound elastography
89374565|NCT03708133|Experimental|Test Treatment + Reference Treatment|"Male and female subjects with Chagas' disease will be give treatment follow below Crossover Sequence:~Test treatment~Reference treatment"
89374566|NCT03708133|Experimental|Reference Treatment + Test Treatment|"Male and female subjects with Chagas' disease will be give treatment follow below Crossover Sequence:~Reference treatment~Test treatment"
89374567|NCT05075161|Experimental|Pirfenidone|Patients randomized to Pirfernidone Group will receive tables of 267 mg
89374568|NCT05075161|Placebo Comparator|Placebo|Patients randomized to Placebo Group will receive 5 ml of Water
89374569|NCT05073055|Active Comparator|Group SA|Group 1 (SE) (n = 35): patients undergoing spinal anesthesia of patients in our hospital to do unilateral inguinal hernia operation. Block application and the times when the sensory block reaches the T10 level are recorded. Surgery is allowed in patients who develop sensory block at the T10 level. During our study, no changes will be made to the procedure described above, which is standardized during our study, only patient data will be recorded observationally. Patients who do not have sufficient sensory block to start the procedure despite waiting 10 minutes will be registered and excluded from the study and additional anesthesia will be applied.
89374570|NCT05073055|Active Comparator|Group ESP+TA|Group 2 (Errector spina block + TA) (n = 35): 2% lidocaine hydrochloride (10 mg / ml) 15 ml, 0.5% bupivacaine hydrochloride (20 mg / ml) 15 ml, serum 8.4% Sodium Bicarbonate 5 ml to be used for each patient before the operation in order to apply the erectile spina block block with tumescent anesthesia. Adding adrenaline tartrate (5 μg / mL) to 5 ml with saline, a total of 40 ml of mixture was prepared. Hydrodissection was achieved using a 5 cm, 21G peripheral nerve block needle just below the erector spina muscle on the Transverse Process of L1. Afterwards, a unilateral injection of 15 ml at T12 and L1 levels was applied to each segment with the needle directed at two different angles from the same insertion point.
89374571|NCT05518357|Experimental|LILRB4 STAR-T|LILRB4 STAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of STAR-T cells, subjects receive fludarabine at dose 25-30mg/m2/day and cyclophosphamide treatment at dose 250-300mg/m2 for 3 days and take a rest for 2 days before infusion. STAR-T cells will be intravenously infused with a escalated dose of 1E6#3E6#1E7 cells/kg
89374572|NCT05095831||Suspicion of solid neoplastic lesion|Patients with high suspicion of solid pancreas neoplasia: carcinoma, intrapapillary mucinous neoplasia (IPMN), neuroendocrine tumor, lymphoma, or intrapancreatic metastasis; based on CT/MR.
89374573|NCT05095831||Suspicion of a solid inflammatory lesion|Patients with high suspicion of solid inflammatory lesions: acute, chronic, or autoimmune pancreatitis; based on CT/MR.
89374574|NCT05095831||Control group|Patients without a history of any type of solid or hematologic malignancy, hepato-pancreato-biliary disease (including fatty liver and pancreas disease), tobacco/alcohol habits, or morbid obesity with bariatric surgery criteria; who require EUS evaluation (e.g., suspicious of a subepithelial lesion in the context of chronic dyspepsia).
89374575|NCT03638869|Placebo Comparator|Arm 1|100 mL Ocean Spray® Diet Cranberry Juice
89374576|NCT03638869|Experimental|Arm 2|REL-1017 25 mg in 100 mL of Ocean Spray® Diet Cranberry Juice
88846550|NCT04706611|Experimental|Protein-losing Enteropathy|Fecal Microbiota Transplantation will be performed.
88846551|NCT04706611|Experimental|Asperger Syndrome|Fecal Microbiota Transplantation will be performed.
89374577|NCT03638869|Experimental|Arm 3|REL-1017 50 mg in 100 mL of Ocean Spray® Diet Cranberry Juice
89374578|NCT03638869|Experimental|Arm 4|REL-1017 75 mg in 100 mL of Ocean Spray® Diet Cranberry Juice
89374579|NCT03708055|Experimental|Prevention (weight bearing exercise program)|Participants undergo a weight bearing exercise program in a group 2 days a week and at home 5 days a week for 8 weeks.
89374580|NCT03091920|Experimental|IW-1973 QD/QD|On Days 1-14: IW-1973 40 mg taken once daily (QD) in morning (AM) and placebo taken QD at night (PM).
89374581|NCT03091920|Experimental|IW-1973 BID (Twice Daily)/QD|On Days 1-7: IW-1973 20 mg taken in AM and IW-1973 20 mg taken in PM. On Days 8-14: IW-1973 40 mg taken QD in AM and placebo taken QD in PM.
89374582|NCT03091920|Placebo Comparator|Placebo|On Days 1-14: Placebo taken in AM and in PM.
89374583|NCT03338569|Sham Comparator|Placebo|Placebo designed to mimic intervention
89374584|NCT03338569|Active Comparator|Intervention|6000 mg per day Vitamin C supplement
89374585|NCT03338023|Experimental|LY2963016 + Insulin Lispro|Participants received 100 units per milliliter (U/mL) LY2963016 administered subcutaneously (SC) once daily (QD) and 100 U/mL premeal insulin lispro administered SC thrice-daily (TID) within 15 minutes before meals or immediately after the meal.
89374586|NCT03338023|Active Comparator|Lantus® + Insulin Lispro|Participants received 100 U/mL Lantus® administered SC QD and 100 U/mL premeal insulin lispro administered SC thrice-daily (TID) within 15 minutes before meals or immediately after the meal.
89374587|NCT03337477|Experimental|ZS+insulin+glucose|ZS will be administered in addition to insulin and glucose. Insulin and glucose is the current standard of care to treat serum potassium ≥5.8mmol/L.
89374588|NCT03337477|Placebo Comparator|Placebo+insulin+glucose|Placebo will be administered in addition to insulin and glucose. Insulin and glucose is the current standard of care to treat serum potassium ≥5.8mmol/L.
89374589|NCT02687542|Placebo Comparator|Placebo|Placebo
89374590|NCT02687542|Experimental|PF-06649751 low dose (1 mg QD)|PF-06649751 low dose level (1 mg QD)
88846552|NCT04706611|Experimental|Rheumatoid arthritis|Fecal Microbiota Transplantation will be performed.
88846553|NCT04706611|Experimental|Ulcerative colitis|Fecal Microbiota Transplantation will be performed.
88846554|NCT04706611|Experimental|Crohn's disease|Fecal Microbiota Transplantation will be performed.
88846555|NCT04706611|Experimental|Psoriasis|Fecal Microbiota Transplantation will be performed.
88846556|NCT04706611|Experimental|Ankylosing spondylitis|Fecal Microbiota Transplantation will be performed.
88846557|NCT04706611|Experimental|Immune checkpoint inhibition-related colitis|Fecal Microbiota Transplantation will be performed.
89374591|NCT02687542|Experimental|PF-06649751 middle dose 1 (3 mg QD)|PF-06649751 lower middle dose 1 (3 mg QD)
89374592|NCT02687542|Experimental|PF-06649751 middle dose 2 (7 mg QD)|PF-06649751 higher middle dose 2 (7 mg QD)
89374593|NCT02687542|Experimental|PF-06649751 high dose (15 mg QD)|PF-06649751 high dose (15 mg QD)
89374594|NCT03707899|Experimental|Group I (JLP-1401)|JLP-1401(Telmisartan 80 mg, amlodipine 5 mg, rosuvastatin 5 mg)
89374595|NCT03707899|Active Comparator|Group II (Telmisartan/Amlodipine, Rosuvastatin)|Twinsta(Telmisartan 80 mg, amlodipine 5 mg) and Crestor(rosuvastatin 5 mg)
89374596|NCT05054569|Experimental|10-week eHealth intervention|Weekly video conference groups led by a trained facilitator
89374597|NCT05682001||DC group|Anterior lens capsule tissues from DC patients
89374598|NCT05682001||ARC group|Anterior lens capsule tissues from ARC patients
89374599|NCT05682001||NC group|anterior lens capsules collected from three age-matched transparent crystals of cadaveric eyes
89374600|NCT03336619|Active Comparator|Nitazoxanide|Two Nitazoxanide 300 mg tablets orally twice daily (b.i.d.) for 5 days
89374601|NCT03336619|Placebo Comparator|Placebo|Two Placebo tablets orally twice daily (b.i.d.) for 5 days
89374602|NCT03114904|Other|"Usual weaning management"|
89374603|NCT03114904|Other|Introduction to H2 for the discontinuation of therapeutics|
89374604|NCT03706339|Placebo Comparator|normal saline arm group|they received 110 ml saline infusion or placebo (110 normal salines) by slow intravenous injection at an approximate rate of 1 mL per min plus Throughout the operation irrigation was done by120 ml saline
89374605|NCT03706339|Active Comparator|intravenous tranexamic acid group|1 gm tranexamic acid (2 ampoules of Capron 500 mg /5 ml; Cairo, Egypt) intravenous just before skin incision plus100 ml normal saline IV just before skin incision plus topical application of 120 ml normal saline applied on the pelvic bed after Cesarean hysterectomy
88810254|NCT01342523|Experimental|CIS/no loz/no email/full website/full booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, no nicotine lozenge, No motivational emails, full website, full mailed booklet"
88810255|NCT01342523|Experimental|No CIS/loz/emails/full website/brief booklet|"This arm of the project will address the following question:~How effective is the following intervention?~No CIS calls, nicotine lozenge, motivational emails, full website, brief mailed booklet"
88846558|NCT04706611|Experimental|Autoimmune enteropathy|Fecal Microbiota Transplantation will be performed.
88846559|NCT04706611|Experimental|Drug-induced diarrhea|Fecal Microbiota Transplantation will be performed.
88846560|NCT03373591|Experimental|Liposomal Bupivacaine TAP block|Patients will be randomized to receive an intraoperative transverse abdominis peritoneal (TAP) block with liposomal bupivacaine (LB). The solution used to perform the TAP block with LB will comprise of 20mL of liposomal bupivacaine solution, 30mL of 0.25% bupivacaine, and 100mL of normal saline.
88846561|NCT03373591|Active Comparator|Regular Bupivacaine TAP block|Patients will be randomized to receive an intraoperative transverse abdominis peritoneal (TAP) block with regular bupivacaine (RB).The solution used to perform the TAP block with RB will comprise of 50mL of 0.25% bupivacaine and 100mL of normal saline.
88846562|NCT03373591|No Intervention|No TAP block|Patients will be randomized to receive no TAP block as a control group.
88846563|NCT03720938|No Intervention|Control Group|Physically inactive children who did not play AVGs.
89374606|NCT03706339|Experimental|Topical tranexamic acid group|2 gm topical tranexamic acid ( 4 ampoules of Capron 500 mg/5 ml applied typically) in 100 ml normal saline applied on the placental bed after Cesarean section plus110 ml normal saline IV just before skin incision
89374607|NCT03739476|Experimental|Interventional|Quetiapine 25 milligrams 1 hour after surgery and each 12 hours for 3 days
89374608|NCT03739476|Placebo Comparator|control|Placebo 1 hour after surgery and each 12 hours for 3 days
89374609|NCT05000268|Active Comparator|Painful Healthcare Workers with COVID-19|Healthcare workers who have had COVID-19 infection in the past and are now in pain without COVID-19 infection
89374610|NCT05000268|Active Comparator|Painful Health Care Workers without COVID-19|Healthcare workers with past and present pain without COVID-19 infection
89374611|NCT03639558|Active Comparator|Haloperidol + Promethazine + Chlorpromazine|Haloperidol + Promethazine + Chlorpromazine are all psychiatric drugs that have been well tested. The combination of these 3 drugs, however, have never been randomised.
89374612|NCT03639558|Experimental|Haloperidol + Promethazine|Haloperidol + Promethazine are both psychiatric drugs with antipsychotic and calming properties.
89374613|NCT03506646|Experimental|Beetroot juice-Placebo|Subjects will be tested on two different days. The first day will be beetroot juice and the second day will be a placebo. Testing will take place approximately one hour after intake. There will be a 14 day washout period between testing days.
89374614|NCT03506646|Experimental|Placebo-Beetroot juice|Subjects will be tested on two different days. The first day will be a placebo and the second day will be beetroot juice. Testing will take place approximately one hour after intake. There will be a 14 day washout period between testing days.
89374615|NCT01353508|Experimental|LCZ696 to Valsartan - Heart Failure (HF) cohort|Participants in this arm received Valsartan 160 mg twice daily (bid) during open-label run-in, LCZ696 200 mg bid double blind treatment during period 1, Valsartan 160 mg bid during wash-out, and Valsartan 160 mg bid double blind treatment during period 2.
88810256|NCT01342523|Experimental|No CIS/loz/emails/lite website/full booklet|"This arm of the project will address the following question:~How effective is the following intervention?~No CIS calls, nicotine lozenge, motivational emails, lite website, full mailed booklet"
88846564|NCT03720938|Experimental|Intervention Group|Physically inactive children who played alternately Nintendo Wii® active video games for 50-60 min, 3 days a week, 12 weeks, in laboratory environment.
88846565|NCT03374683|Experimental|RR Digital Tool|Participants in the RR digital tool were provided with a link to the web-based intervention (https://outsideplay.ca) to complete within one week.
88846566|NCT03374683|Active Comparator|RR In-Person Workshop|Participants in the in-person workshop attended the 45-90 minute in-person workshop.
89374616|NCT01353508|Experimental|Valsartan to LCZ696 - HF Cohort|Participants in this arm received Valsartan 160 mg twice daily bid during open-label run-in, Valsartan 160 mg bid during period 1, Valsartan 160 mg bid during wash-out, and LCZ696 200 mg bid double blind treatment during period 2.
89374617|NCT01353508|Experimental|LCZ696 to Valsartan - Hypertension (HTN) cohort|Participants in this arm received Valsartan 320 mg once daily (qd) during open-label run-in, LCZ696 400 mg qd double blind treatment during period 1, Valsartan 320 mg qd during wash-out, and Valsartan 320 mg qd double blind treatment during period 2.
89374618|NCT01353508|Experimental|Valsartan to LCZ696 - HTN cohort|Participants in this arm received Valsartan 320 mg qd during open-label run-in, Valsartan 320 mg qd during period 1, Valsartan 320 mg qd during wash-out, and LCZ696 400 qd bid double blind treatment during period 2.
89374619|NCT05470855|Experimental|Experimental Group in Protective effect study|22500 subjects including 7500 subjects aged 1-3 years with no history of varicella vaccination,7500 subjects aged 4-6 years with a history of 1 dose of varicella vaccine,7500 subjects aged 7-12 years with a history of 1 dose of varicella vaccine will receive one dose of varicella vaccine.
89374620|NCT05470855|No Intervention|Control Group in Protective effect study|22500 subjects including 7500 subjects aged 1-3 years with no history of varicella vaccination,7500 subjects aged 4-6 years with a history of 1 dose of varicella vaccine,7500 subjects aged 7-12 years with a history of 1 dose of varicella vaccine.
89374621|NCT05470855|Experimental|Safety group|30000 subjects from study 1 will be enrolled to conduct safety observation study,all adverse events of all subjects will be collected.
89374622|NCT05470855|Experimental|Etiological study group|Herpes fluid collected from varicella cases in study 1 will be used to conduct etiological study on the pathogenic strains of varicella cases.
89374623|NCT01568268|Experimental|Palonsetron|
89374624|NCT01568268|Placebo Comparator|Placebo|
89374625|NCT03636269|Active Comparator|CR845 0.5mcg/kg|IV CR845 0.5 mcg/kg administered after each dialysis session (3 times/week)
89374626|NCT03636269|Placebo Comparator|Placebo|IV Placebo administered after each dialysis session (3 times/week)
89374627|NCT05598060|Experimental|neoadjuvant stereotactic body radiation therapy followed by hepatectomy|Experimental: Phase1(Cohort 1): neoadjuvant stereotactic body radiation therapy (24Gy/3Fr) followed by hepatectomy Experimental: Phase1(Cohort 2): neoadjuvant stereotactic body radiation therapy (30Gy/3Fr) followed by hepatectomy Experimental: Phase1(Cohort 3): neoadjuvant stereotactic body radiation therapy (36Gy/3Fr) followed by hepatectomy
89374628|NCT03114982|Experimental|Low potency of NBP608|Single dose 0.5mL of low potency of NBP608 by subcutaneous injection into the outer aspect of the upper arm or the anterolateral thigh
88810257|NCT01342523|Experimental|No CIS/loz/no emails/full website/full booklet|"This arm of the project will address the following question:~How effective is the following intervention?~No CIS calls, nicotine lozenge, No motivational emails, full website, full mailed booklet"
88810258|NCT01342523|Experimental|no CIS/no loz/emails/full website/full booklet|"This arm of the project will address the following question:~How effective is the following intervention?~No CIS calls, no nicotine lozenge, motivational emails, full website, full mailed booklet"
88810259|NCT01342523|Experimental|CIS/loz/emails/full website/brief booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, nicotine lozenge, motivational emails, full website, brief mailed booklet"
88846567|NCT03374683|Sham Comparator|Position Statement on Active Outdoor Play|Participants in the control condition were provided with a web link to the Position Statement on Active Outdoor Play, which includes information on research and recommendations for action.
89374629|NCT03114982|Experimental|Middle potency of NBP608|Single dose 0.5mL of middle potency of NBP608 by subcutaneous injection into the outer aspect of the upper arm or the anterolateral thigh
89374630|NCT03114982|Experimental|High potency of NBP608|Single dose 0.5mL of high potency of NBP608 by subcutaneous injection into the outer aspect of the upper arm or the anterolateral thigh
89374631|NCT03114982|Active Comparator|Varivax|Single dose 0.5mL of Varivax by subcutaneous injection into the outer aspect of the upper arm or the anterolateral thigh
89374632|NCT04919707|Experimental|Older Adolescent Soccer Players|10 male, 10 female soccer players, grades 11-12, age 16-18 Neurocognitive measures, physical measures, header session, MRI
89374633|NCT04919707|Experimental|Younger Adolescent Soccer Players|10 male, 10 female soccer players, grades 6-7, age 12-13 Neurocognitive measures, physical measures, header session, MRI
89374634|NCT03166072|Active Comparator|Low-vision rehabilitation program|Participants and their care givers in Low-vision rehabilitation program will undergo a standardized interview to measure HRQoL using the time trade-off method (TTO), depression using the Patient Health Questionnaire (PHQ-9), anxiety using Generalized Anxiety Disorder (GAD-7) and Veterans Affairs Low Vision Visual Functioning Questionnaire (VA LV VFQ-48) at the first study visit and after Low-vision rehabilitation program.
89374635|NCT03166072|Placebo Comparator|No Intervention|Participants and their care givers will undergo a standardized interview to measure HRQoL using the time trade-off method (TTO), depression using the Patient Health Questionnaire (PHQ-9), anxiety using Generalized Anxiety Disorder (GAD-7) and Veterans Affairs Low Vision Visual Functioning Questionnaire (VA LV VFQ-48) at the first study visit and will continue to receive treatment as usual.
88846568|NCT03480685|Other|IVUS Imaging vs. OCT Imaging|A vessel segment will be imaged with intravascular ultrasound (IVUS). The same vessel segment will be imaged with optical coherence tomography (OCT).
88846569|NCT03378973|Experimental|High dose dexmedetomidine|Patients will receive dexmedetomidine 0.5 mcg/kg/hr plus propofol 50 mcg/kg/min
88846570|NCT03378973|Active Comparator|Low dose dexmedetomidine|Patients will receive dexmedetomidine 1.0 mcg/kg/hr plus propofol 25 mcg/kg/min
88846571|NCT03380845|Active Comparator|Fraxel Restore on one side of the face|"Fraxel Restore on one side of the face~Fraxel Restore: acne scar correction~Randomized treatment with Fraxel Restore on one side of the face, and Fractora on the opposite side of the face - the study is a randomized,single-center, split-face study in subjects seeking acne scar correction. Subjects were treated with Fraxel on one side of the face and Fractora on the other side of the face. The side of the face for each device was randomly assigned."
88846572|NCT03380845|Active Comparator|Fractora on the other side of the face|"Fractora on the other side of the face~Fractora: acne scar correction~Randomized treatment with Fraxel Restore on one side of the face, and Fractora on the opposite side of the face - the study is a randomized,single-center, split-face study in subjects seeking acne scar correction. Subjects were treated with Fraxel on one side of the face and Fractora on the other side of the face. The side of the face for each device was randomly assigned."
88846573|NCT04121078|Experimental|Sequence AB: TAK-906 25 mg + TAK-906 25 mg and Rifampin 600 mg|TAK-906 25 milligram (mg) (Treatment A), capsule, orally, once on Day 1 of Study Period 1, followed by a washout period of at least 7 days, further followed by rifampin 600 mg, infusion, once, intravenously over 30 minutes along with TAK-906 25 mg (Treatment B), capsule, orally, once immediately after the end of infusion on Day 1 of Study Period 2.
88846574|NCT04121078|Experimental|Sequence BA: TAK-906 25 mg and Rifampin 600 mg + TAK-906 25 mg|Rifampin 600 mg, infusion, once, intravenously over 30 minutes along with TAK-906 25 mg (Treatment B), capsule, orally, once immediately after the end of infusion on Day 1 of Study Period 1 followed by a washout period of at least 7 days, further followed by TAK-906 25 mg (Treatment A), capsule, orally, once on Day 1 of Study Period 2.
89374636|NCT04911361|Active Comparator|Topical loteprednol suspension in both eyes|25 subjects will be randomized to receive treatment loteprednol etabonate 0.5% suspension QID for 2 weeks.
89374637|NCT04911361|Experimental|Lower eyelid canaliculi DEXTENZA insertion (study group)|25 subjects will be randomized to receive treatment of OTX-DED
89374638|NCT03166150|Experimental|Multi-modal rehabilitation program|12 weeks of various exercises
89374639|NCT03166150|Active Comparator|Pelvic Floor Physical therapy|12 weeks of standard pelvic floor physical therapy
89374640|NCT04906993|Experimental|camrelizumab combined with famitinib malate|
89374641|NCT04906993|Active Comparator|platinum-based chemotherapy|
89374642|NCT03165760|No Intervention|control group|Vt = 8 ml/kg of PBW and PEEP = 4 cm H2O
89374643|NCT03165760|Experimental|protective ventilation group|Vt = 6ml/kg of PBW, PEEP = 10 and RM if disconnected
89374644|NCT02685202|Experimental|Mandibular advancement splint|An oral appliance which is standard of care in treating mild or moderate obstructive sleep apnea by repositioning the mandible in a forward position
89374645|NCT03087786|Experimental|Nicotine Bitartrate 4mg Lozenge|Nicotine Bitartrate Lozenge 4mg. Take 1 lozenge every 1-2 hours, as needed for 21 days
89374646|NCT03087786|Active Comparator|Nicotine Polacrilex 4mg Lozenge|Nicotine Polacrilex Lozenge 4mg. Take 1 lozenge every 1-2 hours, as needed for 21 days
89374647|NCT03635957|Experimental|Pegloticase With Methotrexate (MTX)|"Run-In Period: oral MTX at a dose of 15 mg weekly for 4 weeks prior to the first dose of pegloticase.~Pegloticase + Immunomodulator (IMM) Period: pegloticase 8 mg administered intravenously (IV) every 2 weeks from Day 1 through the Week 50 Visit for a total of 26 infusions. MTX 15 mg weekly on the same day each week, within 1 to 3 days prior to each pegloticase infusion and one additional weekly dose after the last infusion."
89374648|NCT05241067|Placebo Comparator|Normal saline|Placebo (Dose: equal volume saline) + Standard of care
89374649|NCT05241067|Active Comparator|Centhaquine|Centhaquine (Dose: 0.01 mg/kg) + Standard of care
89374650|NCT03732599|Active Comparator|Standard DALK|Standard (with the use of a blade) deep anterior lamellar keratoplasty (DALK), which is a partial thickness corneal transplant, which has been shown to be a safe and effective procedure.
89374651|NCT03732599|Active Comparator|IE-DALK (femtosecond)|Femtosecond deep anterior lamellar keratoplasty (DALK). The femotosecond laser technology allows for the creation of precise and reproducible corneal incisions.
89374652|NCT05681767|Experimental|Intervention group|Motivational multicomponent lifestyle intervention + treatment as usual
89374653|NCT05681767|Other|Control group|Treatment as usual
89374654|NCT01310309||EXecutive Registry|A prospective controlled registry to analyze the clinical efficacy and safety at mid and long-term follow-up in patients with MVD treated with the XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS).
89374655|NCT01353274||Patients with hypertension|
89374656|NCT03729479|Experimental|Experimental: DASH diet|Participants will be taught to follow a DASH diet (low-sodium and low-fat meal plan, which includes whole grains, fat-free or low-fat dairy products, vegetables, fruits, poultry, fish, and nuts, with processed, high-sodium, regular-fat, and sugar-added foods restricted).
89374657|NCT03729479|Experimental|Experimental: very low carbohydrate, ketogenic diet|Participants will be taught to follow a very low-carbohydrate, ketogenic diet (non-starchy vegetables, nuts, seeds, meat, fish, and natural fats such as avocado, olive oil, and butter, with starchy and sugary foods restricted).
89374658|NCT03729479|Experimental|Experimental: DASH diet and extra support|"Participants will be taught to follow a DASH diet (low-sodium and low-fat meal plan, which includes whole grains, fat-free or low-fat dairy products, vegetables, fruits, poultry, fish, and nuts, with processed, high-sodium, regular-fat, and sugar-added foods restricted).~They will also be given training in positive affect, mindfulness, health information seeking and sharing, and cooking practices and behavior."
88846575|NCT03248947|Other|Pharmacy opioid use disorder care|A single-arm study to evaluate the feasibility and acceptability of transitioning office-based buprenorphine treatment of adult patients with opioid use disorder from physicians to pharmacists.
88846576|NCT04114058|Active Comparator|Liposomal Bupivicaine|Following hip arthroscopy, local field infiltration with liposomal bupivicaine will be performed for adjunct pain control
88846577|NCT04114058|Active Comparator|fascia iliaca blockade|Preoperatively before hip arthroscopy, a fascia iliaca blockade will be performed for adjunct pain control
88846578|NCT03480919|Experimental|Shen Men acupuncture|Single acupuncture needles will be placed bilaterally onto the patient's Shen Men acupuncture point in the ear for a duration of 20 minutes.
88846579|NCT03480919|Sham Comparator|Sham acupuncture|Single acupuncture needles will be placed bilaterally onto a sham location in the ear for a duration of 20 minutes.
88846580|NCT03480919|Placebo Comparator|Simulated acupuncture|Acupuncture will be simulated with a paper clip.
88846581|NCT03817580|Experimental|Project X 26ml|3.15 % w/v CHG (chlorhexidine gluconate) / 70% v/v IPA (isopropyl alcohol) contained within a saturated at use swabstick. 26ml volume. Single use.
89374659|NCT03729479|Experimental|Experimental: very low carb, ketogenic diet and extra support|"Participants will be taught to follow a very low-carbohydrate, ketogenic diet (non-starchy vegetables, nuts, seeds, meat, fish, and natural fats such as avocado, olive oil, and butter, with starchy and sugary foods restricted).~They will also be given training in positive affect, mindfulness, health information seeking and sharing, and cooking practices and behavior."
89374660|NCT05221255|Sham Comparator|Sham Therapy|Patients will receive 12 sessions of biofeedback-assisted pelvic floor muscle relaxation plus non-real magnetic stimulation.
89374661|NCT05221255|Experimental|Spinal magnetic stimulation|Patients will receive 12 sessions of biofeedback-assisted pelvic floor muscle relaxation followed by real spinal magnetic stimulation.
89374662|NCT04893343||Neonatal infection with antibiotics|In-patient neonates with ICD-10 infectious disease diagnosis, treated with antibiotics
89374663|NCT04893343||Neonatal infection without antibiotics|In-patient neonates with ICD-10 infectious disease diagnosis, treated without antibiotics
89374664|NCT03165682||Group 1|Twenty-five patients with Systemic Lupus Erythematosus with prominent fatigue symptoms ( inclusion criterion: FSS of at least 4)
88846582|NCT03817580|Experimental|Project X 5.1ml|3.15 % w/v CHG (chlorhexidine gluconate) / 70% v/v IPA (isopropyl alcohol) contained within a saturated at use swabstick. 5.1ml volume. Single use.
88846583|NCT03817580|Active Comparator|Prevantics Maxi Swabstick|3.15 % w/v CHG (chlorhexidine gluconate) / 70% v/v IPA (isopropyl alcohol). Swabstick. 5.1ml volume. Single use.
88846584|NCT03862040|Experimental|Cefiderocol|All participants were receiving standard of care (SOC) antibiotic treatment for pneumonia. Forty hours after the start of SOC treatment, participants will be administered 2 g doses of cefiderocol (or renally adjusted doses) infused intravenously over 3 hours, every 8 hours (or every 6 hours for participants with augmented renal function), for an expected minimum of 3 doses and up to a total of 6 doses in participants with normal renal function and participants with mild or moderate renal impairment, and for an expected minimum of 6 doses and up to a total of 9 doses in participants with severe renal impairment.
88846585|NCT03482713|Experimental|Gefapixant 45 mg|Participants will receive a gefapixant 45 mg film-coated tablet BID for 28 days.
89374665|NCT03165682||Group 2|Twenty-five patients with Systemic Lupus Erythematosus without subjectively enhanced fatiguability
89374666|NCT03165682||Group 3|Twenty-five age, sex and educationally matched controls among the health worker.
89374667|NCT04831021|Experimental|Patients issued from dialysis units (clinic)|
89374668|NCT02690194|Placebo Comparator|Placebo Group|"Pre-Placebo therapy~Blood pressure, pulse, and respiration rate~State-Trait Anxiety Inventory~PLACEBO THERAPY SESSION~Post-Placebo therapy/Pre-procedure~Blood pressure, pulse, and respiration rate~State-Trait Anxiety Inventory~PROCEDURE~Post-procedure -Rate pain level of procedure"
88846586|NCT03482713|Placebo Comparator|Placebo|Participants will receive a film-coated placebo tablet matching gefapixant BID for 28 days.
89181462|NCT00741039|Experimental|2|MSKCC employee volunteer controls > or = to 65 years of age without a cancer diagnosis will be immunized with the inactivated influenza vaccine (0.5 ml intramuscularly) and/or PPV23 vaccine (Pneumovax), (0.5 ml subcutaneously or intramuscularly).
89181463|NCT02595801||Exposed|Exposure to surgery prior to completion of Early Development Instrument
89181464|NCT02595801||Reference|No exposure to surgery prior to completion of Early Development Instrument
89181465|NCT04019769|Experimental|1|All patients will receive L-glutamine 10-30mg daily based on weight for 3 months
89181466|NCT02583555|Active Comparator|Active patient support|Interview followed by frequent telephone support Questionnaire every 3 months
89181467|NCT02583555|No Intervention|Controls|Questionnaire every 3 months
89181468|NCT02583321|Active Comparator|Period with endotracheal tubes not allowing SSD|During this period of the DEMETER study (NCT02515617), patients will be intubated with standard endotracheal tubes not allowing Subglottic Secretions
89181469|NCT02583321|Experimental|Period with endotracheal tubes allowing SSD|During this period of the DEMETER study (NCT02515617), patients will be intubated with specific endotracheal tubes allowing Subglottic Secretions Drainage
89181470|NCT04454229|Experimental|Direct oral antibiotic challenge|Direct oral antibiotic (penicillin) challenge in patients with PEN-Fast less than 3.
89181471|NCT04454229|Active Comparator|Standard of care|Standard of care: skin testing and, if negative, oral challenge.
89181472|NCT04436055||All participants|All participants including cannabis users, other drug users, and non-drug users.
89181473|NCT02583165|Experimental|Monotherapy arm|MEDI1873
89181474|NCT00772382|Experimental|MCI-196|
89181475|NCT02582931|Experimental|Arm 1: MRI-guided SBRT|"Radiotherapy will consist of stereotactic body therapy, to be given over five fractions, delivered once daily or once every other day for a period of one to two weeks, for a total of five treatments.~Patients will be planned for an initial dose of 35Gy to the planning target volume (PTV), with dose adaptation and reduction allowed based on safety constraints that are generally accepted, up to a maximum allowed total dose of 50Gy in five fractions to the PTV.~All patients will undergo both CT and MRI simulation in positioning appropriate for the specific treatment site"
89181476|NCT04102748|Active Comparator|Conventional|
89181477|NCT04102748|Active Comparator|I-incision|
89181478|NCT04102748|Active Comparator|M-flap|
89181479|NCT04078659|Experimental|Propofol infusion|Patients received intravenous Propofol infusion
88846587|NCT00376831|Active Comparator|0|fentanyl
89181480|NCT04078659|Experimental|Magnesium Sulfate infusion|Patients received intravenous Magnesium Sulfate infusion
89181481|NCT02583009|Experimental|PAC-14028 cream 0.1%|PAC-14028 cream 0.1%, Twice daily for 4 weeks
89181482|NCT02583009|Experimental|PAC-14028 cream 0.3%|PAC-14028 cream 0.3%, Twice daily for 4 weeks
89374669|NCT02690194|Experimental|Experimental (Buddhify) Group|"Pre-Buddhify therapy~Blood pressure, pulse, and respiration rate~State-Trait Anxiety Inventory~BUDDHIFY THERAPY SESSION~Post-Buddhify therapy/Pre-procedure~Blood pressure, pulse, and respiration rate~State-Trait Anxiety Inventory~PROCEDURE~Post-procedure -Rate pain level of procedure"
88846588|NCT00376831|Active Comparator|1|ketamine
89374670|NCT02690194|No Intervention|Control Group|"Pre-Procedure~Blood pressure, pulse, and respiration rate~State-Trait Anxiety Inventory~PROCEDURE~Post-procedure -Rate pain level of procedure"
88846589|NCT03857750||Elderly (>80 years)|Patients planned for elective surgery above 80 years
89399334|NCT03538496|Active Comparator|ultrasound guided paravertebral block|ultrasound guided paravertebral block with 20 ml %0.25 bupivacaine
88846590|NCT03857750||Younger (18-40 years)|Patients planned for elective surgery between 18-40 years
88846591|NCT03491917||DBT plus S-View|Breast images utilizing DBT plus S-View
88846592|NCT03491917||FFDM alone|Breast images using FFDM alone only
89181483|NCT02583009|Experimental|PAC-14028 cream 1.0%|PAC-14028 cream 1.0%, Twice daily for 4 weeks
89181484|NCT02583009|Placebo Comparator|PAC-14028 cream vehicle|PAC-14028 cream vehicle, Twice daily for 4 weeks
89181485|NCT00798707|Experimental|Desvenlafaxine succinate sustained-release 25 mg|
89181486|NCT00798707|Experimental|Desvenlafaxine succinate sustained-release 50 mg|
89181487|NCT00798707|Placebo Comparator|Placebo|
89181488|NCT02582853||Patients diagnosed with GBS|"Patients will undergo a lumbar puncture as a part of the diagnostic procedure as soon as they are suspected to be suffering from GBS on clinical grounds with blood test. The procedure and a blood test will be repeated after 6 months.~Lumbar puncture Blood sample"
89181489|NCT02582853||Symptomatic controls|Controls include patients with unspecified neurological symptoms or diseases who will undergo a lumbar puncture at the Department of Neurology at Aarhus University Hospital as part of their diagnostic work up irrespective of this study. We expect to include 40 symptomatic controls.
89181490|NCT00760214|Experimental|Azilsartan Medoxomil 40 mg QD|
89181491|NCT00760214|Experimental|Azilsartan Medoxomil 80 mg QD|
89181492|NCT00760214|Active Comparator|Ramipril 10 mg QD|
89181493|NCT04078425|Experimental|HF with preserved EF|50patients of heart failure with preserved ejection fration will receive anti.failure treatment(lanoxin,beta blocker,diuretics) for one month with follow up echocardiography before and after
89181494|NCT04078425|Experimental|HF with preserved EF recive eplernone|50 patients with heart failure with preserved ejection frationnwill receive traditional anti-failure treatment in addition to aldosterone antagonist (Eplernone) with follow up echocardiography and aldosterone level before and after
89181495|NCT04098380|Active Comparator|Small bite|The needle bites will be applied with a bite width of 5 mm and inter-suture spacing of 5 mm
89181496|NCT04098380|Active Comparator|Large bite|The needle bites will be applied with a width of 10 mm and inter-suture spacing of 10 mm
89181497|NCT02582541|Active Comparator|SEMS alone|Endoscopic retrograde cholangiopancreatography (ERCP) was performed under standard operating conditions with a duodenoscope (TJF 260V, Olympus, Tokyo, Japan) to confirm the length of the biliary stricture, diameter, and position. An uncovered self expanding metallic stent (SEMS) (Wallstent, Boston Scientific, USA) would be placed across the biliary stricture.
89374671|NCT04986163|Active Comparator|non-invasive analgesia monitoring with ANSPEC-PRO monitor and MEDASENSE monitor|non-invasive analgesia monitoring with ANSPEC-PRO monitor and MEDASENSE monitor: the monitoring will be done in different periods. In each period the two monitors will monitoring the pain in a serial way. Period 1: awake patient, Period 2: sedated patient with propofol, Period 3 : monitoring during standardized pain stimulus; Period 4: monitoring during surgery
88846593|NCT03828422||patients with essential thrombocythemia|"essential thrombocythemia with JAK2 V617F positive mutation~patients from the Department of Haematology at University Medical Centre Ljubljana, Slovenia, who were diagnosed with JAK2 V617F positive ET between 2011 and 2014~no personal history of clinically manifest atherosclerotic vascular disease (myocardial infarction, angina pectoris, peripheral arterial disease, aortic disease, transient ischemic attack or ischemic stroke)~all signed the informed consent~examined twice, the first time in the years 2014-2015 and for the second time in the years 2018-2019~blood for laboratory tests~imaging and functional examination: ultrasound examination, EndoPat plethysmography, coronary artery calcium scanning"
88846594|NCT03828422||control group|"the control group is selected among healthy employees of the University Medical Centre Ljubljana and their relatives~they are matched with the patient group for age and sex distribution and classical risk factors for cardiovascular disease~no personal history of clinically manifest atherosclerotic vascular disease (myocardial infarction, angina pectoris, peripheral arterial disease, aortic disease, transient ischemic attack or ischemic stroke)~all signed the informed consent~blood for laboratory tests~examined twice, the first time in the years 2014-2015 and for the second time the in years 2018-2019~imaging and functional examination: ultrasound examination, EndoPat plethysmography, coronary artery calcium scanning"
88846595|NCT03254719|Other|Treatment Arm|All participants enrolled in the study will receive chiropractic care consistent with the usual chiropractic procedures for the management of chronic low back pain at the Iowa City VA Health Care System. Participants will also complete study assessments as described in outcomes.
89374672|NCT04986163|Active Comparator|non-invasive analgesia monitoring with ANSPEC-PRO monitor and MEDSTORM monitor|non invasive analgesia monitoring with ANSPEC-PRO and MEDSTORM the monitoring will be done in different periods. In each period the two monitors will monitoring the pain in a serial way. Period 1: awake patient, Period 2: sedated patient with propofol, Period 3 : monitoring during standardized pain stimulus; Period 4: monitoring during surgery
89374673|NCT04986163|Active Comparator|non-invasive analgesia monitoring with MEDSTORM and MEDASENSE|non-invasive analgesia monitoring with MEDSTORM and MEDASENSE the monitoring will be done in different periods. In each period the two monitors will monitoring the pain in a serial way. Period 1: awake patient, Period 2: sedated patient with propofol, Period 3 : monitoring during standardized pain stimulus; Period 4: monitoring during surgery
89374674|NCT02684344|Experimental|Tamsulosin Group|"Subjects will receive:~0.4mg tamsulosin by mouth nightly for 3 doses prior to the day of surgery and for 2 doses following surgery~education about signs and symptoms of urinary retention"
89374675|NCT02684344|Active Comparator|Education Group|"Subjects will receive:~1) education about signs and symptoms of urinary retention"
89374676|NCT02683876||Subjects with malodor|individuals with self-reported odor issues suspected to be associated with microbial imbalance on or inside the body and inefficient metabolism as evidenced from other laboratory tests
89374677|NCT02683876||Healthy control|individuals not complaining of uncontrollable or unpredictable malodor episodes
89374678|NCT03974100|Experimental|GP2411|60 mg /mL subcutaneous injection every 6 months
88846596|NCT04084028|Experimental|Active Cooking +meal kits and recipes|"Participants will attend a weekly 2-hour cooking class to learn how to prepare meals. Participants cook and sample the meal at the end of class and the chef will walk them through a sensory exercise. At the end of each class, participants will be provided with the recipe for the next class and asked to create a timeline for the various steps of preparation. Participants will bring this timeline to class and discuss as a group before preparing the meal.~Following 6 weeks of cooking classes, participants will receive 6 weeks of home-delivered meal kits. Following 6 weeks of meal kits, participants will received 6 weeks of recipes. Both the meal kits and recipes will accommodate major dietary needs (vegan, gluten-free, etc.)"
89189317|NCT02573454|Active Comparator|Personal Exercise|Participants are provided with the intervention (App Assignment). In this arm, the participants are randomly assigned to the Personal Exercise group use a traditional GPS exercise app named Nike + Running, in which users can track the mileage that they walk or run (i.e., there is no opportunity to earn donations for charity through exercise behaviour).
89374679|NCT03974100|Active Comparator|EU authorized Prolia|60 mg /mL subcutaneous injection every 6 months
89374680|NCT02689804|Other|Normal-BMI|Women with normal BMI will receive the first emergency contraception (EC) dose and complete pharmacokinetics (PK) assessments; then return to the clinic after at least 8 days to receive the second study drug and complete the same assessments. The study drugs Levonorgestrel (LNG-EC) and Ulipristal Acetate (UPA-EC) will be given in random order.
89374681|NCT02689804|Other|Obese-BMI|Women with obese BMI will receive the first emergency contraception (EC) dose and complete pharmacokinetics (PK) assessments; then return to the clinic after at least 8 days to receive the second study drug and complete the same assessments. The study drugs Levonorgestrel (LNG-EC) and Ulipristal Acetate (UPA-EC) will be given in random order.
89374682|NCT02946931||Prizbind® for Intravenous Solution|Patients treated with dabigatran etexilate who have uncontrolled bleeding or require emergency surgery or procedures.
89374683|NCT04360369|Active Comparator|Goldmann Applanation Tonometer|Measurement of IOP with Goldmann Applanation Tonometer. All subjects will participate in this arm.
89374684|NCT04360369|Active Comparator|ORA G3 and ic100|Measurement of IOP with Ocular Response Analyzer G3 and ic100 tonometers. All subjects will participate in this arm.
89374685|NCT04360369|Experimental|Tono-Vera Tonometer|Measurement of IOP with Tono-Vera Tonometer. All subjects will participate in this arm.
89374686|NCT04765969||Severe COPD patients|GOLD C and D group patients
89374687|NCT03959202|Experimental|Intervention|Based on the self-efficacy theory, participants in the intervention arm will receive personalized, circadian-based activity guidelines, a 2-hour in person education session, real time physical activity self-monitoring, interactive prompts, biweekly phone consultation with the research team, and financial incentives for achieving weekly physical activity goal.
89399335|NCT03694665|Other|Morbidly anesthetized obese|Morbidly obese patients undergoing bariatric surgery (single-arm study) will receive a Lung recruitment maneuver to treat atelectasis..
89374688|NCT03959202|Placebo Comparator|Control|The control group will receive general education on physical activity for older adults and continue daily activity and healthcare routine. Participants in this group will also receive a Go4Life program book from the National Institute on Aging.
89374689|NCT05597670|Other|group A|Patients in this group will receive a traditional therapeutic knee rehabilitation program in the form of mini-squatting exercise (up to 45 degree knee flexion measured by a universal goniometer) , strengthening of hip abductors and external rotators
89374690|NCT05597670|Experimental|group B|Patients in this group will receive the same program as group (A) plus proximal stabilization exercise
89374691|NCT03165370||Insomnia|those with unsatisfactory sleep quantity and/or quality (difficulty with sleep induction, awakenings during the night, early morning awakening, total sleep time, and overall quality of sleep), complaint of a minimum frequency (at least three times a week) and duration (1 month), marked distress caused by the sleep problem and/or interference with ordinary activities of daily living
89374692|NCT04353271|Experimental|Hydroxychloroquine|Subjects in this arm will receive the study drug
89374693|NCT04353271|Placebo Comparator|Placebo|Subjects in this arm will take placebo for 6 days
89374694|NCT01374568|Active Comparator|sitagliptin|Sitagliptin
89374695|NCT01374568|Placebo Comparator|Placebo|Placebo
89374696|NCT03706183||Study Group|The IMA levels will be determined and the association of the IMA and Hearing thresholds will be evaluated.
89374697|NCT03706183||Control Group|The IMA levels will be determined.
89374698|NCT03706105|Experimental|Intervention - Cardiac Rehabilitation|
89374699|NCT03114826||Renal cell carcinoma in renal transplant patients|
89374700|NCT01312441|Experimental|Ergocalciferol|Ergocalciferol 50,000 IU by mouth once weekly for 6 months
89374701|NCT01312441|Placebo Comparator|Placebo|Placebo by mouth once weekly for 6 months
89374702|NCT02682784|Experimental|Oxytocin/Cocaine User|Individuals who meet criteria for cocaine use disorder and are randomized to oxytocin.
89374703|NCT02682784|Active Comparator|Placebo/Cocaine User|Individuals who meet criteria for cocaine use disorder and are randomized to placebo.
89374704|NCT02682784|Experimental|Oxytocin/Control|Healthy controls who are randomized to oxytocin.
89374705|NCT02682784|Active Comparator|Placebo/Control|Healthy controls who are randomized to placebo.
89374706|NCT03165604|Active Comparator|Normal weight|30 normal weight children will receive 2 types of information: standard information and positive information regarding a water drink before physical exercise
89374707|NCT03165604|Active Comparator|Over weight|30 over weight children will receive 2 types of information: standard information and positive information regarding a water drink before physical exercise
89374708|NCT03164902|Experimental|Digital Medicine Arm|Subjects enrolled in this single arm study will be directed to use digital medicine versions of their hepatitis C therapy for the duration of therapy.
89374709|NCT03164746|Active Comparator|DRY group|Dry sheet therapeutic body wraps will be conducted through twice-a-week sessions for a 3-month duration. Sessions take place in the same quiet room and they usually last 45 minutes each up to 1 hour depending on the patient's response. During sessions, the patient wearied a bathing suit. Sessions were conducted under the supervision of an occupational therapist and involved at least two members of the patient's care team.
89374710|NCT03164746|Experimental|WET Group|Wet sheet therapeutic body wraps will be conducted through twice-a-week sessions for a 3-month duration. Sessions take place in the same quiet room and they usually last 45 minutes each up to 1 hour depending on the patient's response. During sessions, the patient wearied a bathing suit. Sessions were conducted under the supervision of an occupational therapist and involved at least two members of the patient's care team.
89374711|NCT05367895||Exposure group 1|Adults (≥ 18 years of age) registered in the E-SUS or SIVEP-gripe RWD source data from August 16th, 2021 through April 21st, 2022 and received a three-dose homologous vaccination with CoronaVac. Specifically, ≥14 days after receipt of the third vaccine dose using a homologous regimen with CoronaVac.
89374712|NCT05367895||Exposure group 2|Adults (≥ 18 years of age) registered in the E-SUS or SIVEP-gripe RWD source data from August 16th, 2021 through April 21st, 2022, who received a two-dose vaccination with CoronaVac and did not receive any booster vaccine. Specifically, ≥14 days after receipt of the second vaccine dose and before the third dose of CoronaVac.
89374713|NCT05367895||Exposure group 3|Adults (≥ 18 years of age) registered in the E-SUS or SIVEP-gripe RWD source data from August 16th, 2021 through April 21st, 2022, who received only one dose vaccination with CoronaVac and did not receive any other vaccine dose. Specifically, ≥14 days after receipt of the first vaccine dose and before the second dose of CoronaVac.
89374714|NCT05367895||Non-Exposure group|Adults (≥ 18 years of age) registered in the E-SUS or SIVEP-gripe RWD source data from August 16th, 2021 through April 21st, 2022, who were not vaccinated. No history of vaccination for any type of COVID-19 vaccine, or <14 days after receipt of the first vaccine of CoronaVac.
89374715|NCT03165448||Self-reported questions|All the participants will enroll the same study protocol, without any exceptions: pre-operative patient's self-reported questioning, post-operative doctor's questioning, 4-6 weeks patients retesting.
89374716|NCT05354245|Experimental|Fibre mixture group|Use of a fibre mixture (3 times daily, 5 grams per gift, total of 15 grams per day) during 12 weeks
89374717|NCT05354245|Placebo Comparator|Placebo group|Use of a placebo (maltodextrin, isocaloric manner, 3 times daily) during 12 weeks.
89374718|NCT05464888|Experimental|+Short AAT|Children aged 4-8 y.o. willing to receive an oral exam, a toothbrush cleaning, simulated radiographs and be a study participant - 75 experimental patients who will be interacting with the dog prior to their oral exam.
89374719|NCT05464888|Experimental|+Long AAT|Children aged 4-8 y.o. willing to receive an oral exam, a toothbrush cleaning, simulated radiographs and be a study participant - 75 experimental patients who will be interacting with the dog throughout their entire visit.
89374720|NCT05464888|Active Comparator|Active control; NO dog|Children aged 4-8 y.o. willing to receive an oral exam, a toothbrush cleaning, simulated radiographs and be a study participant - 75 control patients who will not be interacting with the dog during their visit and will color a dog picture for 3 minutes instead.
89374721|NCT03165214|Active Comparator|coil group|micro coils
89189318|NCT00715260||UP Patients on HD|Uremic Pruritus (UP) patients maintained on hemodialysis (HD)
89374722|NCT03165214|Experimental|glue group|hystoacryl mixed with lipidol
89374723|NCT03705949|Active Comparator|Study group|Sodium Hyaluronate 0.1% drops
89374724|NCT03705949|Active Comparator|Control group|Sodium Hyaluronate 0.2% drops
88846597|NCT04084028|Active Comparator|Active cooking only|Participants will attend a weekly 2-hour cooking class to learn how to prepare meals. Participants cook and sample the meal at the end of class and the chef will walk them through a sensory exercise. At the end of each class, participants will be provided with the recipe for the next class and asked to create a timeline for the various steps of preparation. Participants will bring this timeline to class and discuss as a group before preparing the meal. Unlike the previous arm, no further instruction will be given once cooking classes end.
88846598|NCT04084028|Active Comparator|Meal Kits only|Participants will receive weekly meal kit deliveries for 6 weeks. Following 6 weeks of meal kit deliveries, students will receive emails at the beginning of each week providing them with 5 healthy recipes.
88846599|NCT04084028|No Intervention|Control|Participants will receive no interventions.
88846600|NCT03387319|Experimental|Racialized Stressful Event Recall|Participants in this study are recall a stressful event related to race.
88846601|NCT03387319|Experimental|Non-racialized Stressful Event Recall|Participants in this study arm recall a stressful event unrelated to race.
88846602|NCT03852524|Experimental|Study Arm|The study arm will receive subcutaneous methylnaltrexone (0.15mg/kg rounded to 8 or 12 mg) before surgery and then daily, for the following three days after surgery (four doses).
88846603|NCT03852524|Placebo Comparator|Placebo Arm|The placebo arm will receive subcutaneous placebo before surgery and then daily, for the following three days after surgery (four doses).
88846604|NCT03388645|Experimental|Low Dose 10^6.3 PFU of RSV A2|Single intranasal dose of 10^6.3 plaque forming units (PFU) of respiratory syncytial virus A2 (RSV A2) using a nasal atomizer on Day 0
88846605|NCT03388645|Experimental|High Dose 10^7 PFU of RSV A2|Single intranasal dose of 10^7 plaque forming units (PFU) of respiratory syncytial virus A2 (RSV A2) using a nasal atomizer on Day 0
88846606|NCT04081610|Experimental|Lagricel® Ofteno Multidose|Lagricel® Ofteno Multidose 0.4% hyaluronate. Ophthalmic solution. Laboratorios Sophia
88846607|NCT04081610|Active Comparator|Lagricel® Ofteno Single dose|Lagricel® Ofteno single dose. 0.4% hyaluronate. Ophthalmic solution. Laboratorios Sophia
88846608|NCT03390907|Experimental|Hybrid APC|Hybrid APC ( Erbe Hybrid APC) design for ablation of abnormal tissue in GI tract.
88846609|NCT04713878|Active Comparator|Group 1|Intubated without comorbidity
88846610|NCT04713878|Active Comparator|Group 2|Intubated with comorbidity
88846611|NCT04713878|Active Comparator|Group 3|No intubated
88846612|NCT03840278|Experimental|Bihormonal iLet first, then Insulin-Only iLet|"Each sequence of the study will use the iLet Bionic Pancreas. The iLet is an autonomous infusion pump controlled by the bionic pancreas control algorithm that calculates and doses insulin and/or dasiglucagon based on glucose values received by the Dexcom G5 Continuous Glucose Monitor (CGM).~For this sequence, participants first used the bihormonal iLet bionic pancreas for 1 week. They then used the insulin-only iLet bionic pancreas for 1 week."
88846613|NCT03840278|Experimental|Insulin-Only iLet first, then Bihormonal iLet|"Each sequence of the study will use the iLet Bionic Pancreas. The iLet is an autonomous infusion pump controlled by the bionic pancreas control algorithm that calculates and doses insulin and/or dasiglucagon based on glucose values received by the Dexcom G5 Continuous Glucose Monitor (CGM).~For this sequence, participants first used the insulin-only iLet bionic pancreas for 1 week. They then used the bihormonal iLet bionic pancreas for 1 week."
88846614|NCT04735783|Experimental|Very low-energy, viscous placebo breakfast|Participants will consumed a viscous breakfast meal from a standard bowl with a standard spoon. The volume of the meal will be 5 mL/kg body mass, consisting of 15% (0.75 mL/kg body mass) low-energy flavoured squash, with the remainder made up of tap water. To thicken the solution and increase the perception of energy intake, 0.1 g/kg xanthan gum (a soluble fibre often used as a low-energy thickening agent) will be added and the mixture will be blended thoroughly. An additional 3 mL/kg tap water will be consumed as a drink alongside the meal in this trial.
88846615|NCT04735783|Active Comparator|Typical, whole-food breakfast|Participants will consume a standardised meal consisting of puffed rice cereal, semi-skimmed milk, white bread, seedless strawberry jam, and apple juice. This meal will provide 20% of estimated energy requirements, determined by multiplying estimated resting metabolic rate by a physical activity level of 1.6. A measured volume of tap water will be consumed alongside this meal, in order to match total water content of the typical whole-food breakfast to the very low-energy, viscous placebo breakfast.
88846616|NCT04735783|Active Comparator|Water-only control|Participants will consume 8 mL/kg body mass of plain tap water to match the total water content of the typical whole-food breakfast and the very low-energy, viscous placebo breakfast.
88846617|NCT03838874|Active Comparator|Low-Dose Bupivacaine|Subjects in this group will be given 10mg of Low-Dose Bupivacaine, which is within standard of care for spinal anesthesia during TKA or THA.
88846618|NCT03838874|Active Comparator|Mepivacaine|Subjects in this group will be given 70mg of Mepivacaine, which is within standard of care for spinal anesthesia during TKA or THA.
88846619|NCT04332302|Experimental|Power training group|Participants will be enrolled in a resistance training program.
88846620|NCT04332302|No Intervention|Control group|Participants will be doing their normal life.
88846621|NCT03815240|Other|no dressing (A)|No dressing will be applied at sacrum before 3.5 hours loading period in supine position
88846622|NCT03815240|Active Comparator|Mepilex (B)|'Mepilex® Border Sacrum' dressing will be applied at sacrum before 3.5 hours loading period in supine position
88846623|NCT03815240|Active Comparator|Allevyn (C)|'ALLEVYN Life Sacrum' dressing will be applied at sacrum before 3.5 hours loading period in supine position
89374725|NCT03162484|Experimental|Physical activity intervention group|"The intervention consisted in doing physical activities two to four times per week, each session last 60 minutes. The program includes different activities: swimming, paddle tennis, football and aerobic exercises into the swimming-pool.~Each session starts with a warm up. The main part of the session is divided into two sections. The first section includes different exercises to improve balance, mobility and coordination. The second section is comprised of communicative and cooperative games. The session finishes with a cool-down."
89374726|NCT03162484|No Intervention|Control group|People in control group did not receive any physical activity program.
89374727|NCT04693039|Experimental|FLZ-150mg|Drug：Phenlarmide；Dosage：150mg；
89374728|NCT04693039|Experimental|FLZ-300mg|Drug：Phenlarmide；Dosage：300mg；
89374729|NCT04693039|Experimental|FLZ-600mg|Drug：Phenlarmide；Dosage：600mg；
89374730|NCT04693039|Experimental|FLZ-900mg|Drug：Phenlarmide；Dosage：900mg；
89374731|NCT04693039|Placebo Comparator|Placebo-150mg|Drug：Placebo；Dosage：150mg；
89374732|NCT04693039|Placebo Comparator|Placebo-300mg|Drug：Placebo；Dosage：300mg；
89374733|NCT04693039|Placebo Comparator|Placebo-600mg|Drug：Placebo；Dosage：600mg；
89374734|NCT04693039|Placebo Comparator|Placebo-900mg|Drug：Placebo；Dosage：900mg；
89374735|NCT03162562|Experimental|Oregovomab plus Poly ICLC (Hiltonol)|Oregovomab Solution, 2 mg IV, every three weeks (weeks 0, 3, 6, and 9) and then once at week 16 plus poly ICLC Suspension, 2 mg IM, 30 minutes post-oregovomab infusion and 48 hours post-oregovomab infusion (total 10 doses)
89374736|NCT03162718|Other|single arm|exercise
89374737|NCT03705871|Experimental|Differential Expansion Group|The experimental group will be comprised 24 patients treated with a rapid maxillary expansion using the expander with differential opening. The expander is composed by two screws, one posteriorly and the other anteriorly positioned on the palate.
89374738|NCT03705871|Active Comparator|Fan-Fype Expander Group|The active comparator group will be comprised by 24 patients treated with rapid maxillary expansion using the the fan-type expander. The expander is composed by one screw anteriorly positioned on the palate.
89374739|NCT03164590|Active Comparator|ketamine|
89374740|NCT03164590|Active Comparator|dexmedetomidine|
89374741|NCT03164590|Placebo Comparator|bupivacaine|
89374742|NCT05119075|Experimental|Dopaminergic ON-drug state first, dopaminergic OFF-drug state second|"The following examinations and assessments will be performed at visit 3 on regular treatment in dopaminergic ON-drug state and at visit 4 in dopaminergic OFF-drug state (overnight withdrawal of all antiparkinsonian drugs):~MRI assessment,~Cognitive, neuropsychiatric and neurological assessment,~Robot-induced hallucinations through sensorimotor stimulation."
89374743|NCT05119075|Experimental|Dopaminergic OFF-drug state first, dopaminergic ON-drug state second|"The following examinations and assessments will be performed at visit 3 in dopaminergic OFF-drug state (overnight withdrawal of all antiparkinsonian drugs) and at visit 4 on regular treatment in dopaminergic ON-drug state:~MRI assessment,~Cognitive, neuropsychiatric and neurological assessment,~Robot-induced hallucinations through sensorimotor stimulation."
89374744|NCT04440046|Experimental|Real manual therapy|Real manual therapy directed to the thoracic spine and glenohumeral joint added to a therapeutic exercise program
89374745|NCT04440046|Sham Comparator|Sham thoracic manual therapy|Sham manual therapy directed to the thoracic spine with real manual therapy directed to the glenohumeral joint added to the same therapeutic exercise program performed in the real manual therapy group
89374746|NCT04440046|Sham Comparator|Sham manual therapy|Sham manual therapy directed to the thoracic spine and glenohumeral joint added to the same therapeutic exercise program performed in the real manual therapy group
89374747|NCT05309707||Patients with aortic arch pathologies treated by branch stent graft systems|Patients with aortic arch pathologies treated by branch stent graft systems (Nexus stent-graft system®, Relay Branch® or Zenith arch branch graft®), with proximal landing at zone 0.
89374748|NCT03387852|Experimental|SAR440340|Participants received 2 injections of SAR440340 300 milligram (mg) along with 1 injection of dupilumab placebo, subcutaneous (SC) once every 2 weeks (Q2W) for 12 weeks.
89374749|NCT03387852|Active Comparator|Dupilumab|Participants received 1 injection of dupilumab 300 mg along with 2 injections of SAR440340 placebo, SC Q2W for 12 weeks.
89374750|NCT03387852|Experimental|SAR440340 + Dupilumab|Participants received 2 injections of SAR440340 300 mg along with 1 injection of dupilumab 300 mg, SC Q2W for 12 weeks.
89374751|NCT03387852|Placebo Comparator|Placebo|Participants received 2 SC injections of SAR440340 placebo along with 1 SC injection of dupilumab placebo Q2W for 12 weeks.
89374752|NCT02679274|Placebo Comparator|Placebo|Placebo injection (saline) to be received on weeks 0, 1, 4, 5, 8 and 9.
89374753|NCT02679274|Experimental|Testosterone|Testosterone Enanthate injections (25mg/injection females; 100mg/injection males) to be received on weeks 0, 1, 4, 5, 8 and 9.
89374754|NCT04674319|Experimental|Brain engagement while using compesatory modes for walking|Brain engagemnent (recruitment of attention) is measured during four walking conditions
89374755|NCT05162833|Experimental|Maintenance group|"Subjects that completed the clinical study Evaluation of the TheraNova Neuromodulation System for the Treatment of Overactive Bladder Symptoms that were in the active treatment group will be offered to extend treatment for 3 months."
89374756|NCT01312285|Placebo Comparator|Placebo|
89374757|NCT01312285|Experimental|Resonator Device|
89374758|NCT04961437||Patients with de novo acute respiratory failure|"The following tests will be performed as part of the research (these tests are usually performed as part of routine care but not routinely and comprehensively):~A diaphragmatic ultrasound in the half-seated position. Diaphragmatic excursion and thickening fraction will be measured in the right hemi-diaphragm.~A 10-minute reference acquisition. They will be performed at inclusion, H2, H4 and H48."
89374759|NCT05309473|Experimental|Subjects Who Received Acoustic Stimulation|Following 40 hours of deprivation participants will sleep for approximately a four hour recovery sleep period and receive acoustic stimulation via the Philips SmartSleep during slow-wave sleep. They will then sleep for second night of four hour recovery sleep and receive acoustic stimulation via the Philips Smart Sleep device during slow-wave sleep again.
89374760|NCT05309473|Sham Comparator|Subjects Who Received Sham (no Acoustic Stimulation)|Following 40 hours of deprivation participants will sleep for approximately a four hour recovery sleep period and receive Sham (no acoustic stimulation) via the Philips SmartSleep during slow-wave sleep. They will then sleep for second night of four hour recovery sleep and receive Sham (no acoustic stimulation) via the Philips Smart Sleep device during slow-wave sleep again.
89374761|NCT03620929|Experimental|Experiment group|Having estrogen(Estradiol Valerate) after hysteroscopic adhesiolysis three months, all patients in this group will be treated with hormone therapy for 3 cycles; each cycle consists of estradiol 4mg per day for 21 days with addition of progestogen in the form of dydrogesterone 10mg per day for the last 7 days;
89374762|NCT03620929|No Intervention|Control group|Control group without estrogen treatment. A second-look hysteroscopy and ultrasound assessment of the endometrium will be carried out 4 weeks after the surgery, and again at 8 weeks after the surgery.
89374763|NCT04537741|Experimental|NSTEMI scheduled for angiography|
89374764|NCT05177497|Experimental|treatment arm|
89374765|NCT04969861|Experimental|BEMPEG + Pembrolizumab|Bempegaldesleukin plus pembrolizumab every 3 weeks (q3w) for up to 35 cycles (approximately 2 years).
89374766|NCT04969861|Active Comparator|Pembrolizumab Monotherapy|Pembrolizumab monotherapy q3w for up to 35 cycles (approximately 2 years).
89374767|NCT04967521|Experimental|Abemaciclib|Abemaciclib will be administered 200mg orally twice a day. Each cycle is 28 days.
89374768|NCT04967521|Placebo Comparator|Placebo Arm|Patients will be randomized 1:1 and will receive placebo if they are randomized to the placebo arm of the study. Each cycle is 28 days.
89374769|NCT05308849|Other|Pediatric Peritonitis|Patient (from 3 to 17 years-old) treated for appendicular peritonitis. It includes surgical treatment (appendicectomy, peritoneal toilet) and antibiotherapy according to French recommendation.
89374770|NCT02678416|Experimental|IV Acetaminophen|All participants receive IV acetaminophen as one of 4 interventions in random sequence
89374771|NCT02678416|Experimental|Oral Acetaminophen|All participants receive oral acetaminophen as one of 4 interventions in random sequence
88846624|NCT03815240|Active Comparator|Optifaom (D)|'Optifoam® Gentle Sacrum' Dressing will be applied at sacrum before 3.5 hours loading period in supine position
88846625|NCT04071392||Post-Essure Group|"Healthy women with history of Essure hysteroscopic permanent contraception.~Eligible participants will then undergo the HSG imaging study - a standard radiological imaging study to determine that the fallopian tubes are open and free of disease. It also checks the uterine cavity for any abnormalities."
88846626|NCT04071392||Control Group|"Healthy women with no history of permanent contraception.~Eligible participants will then undergo the HSG imaging study - a standard radiological imaging study to determine that the fallopian tubes are open and free of disease. It also checks the uterine cavity for any abnormalities."
88846627|NCT04045964|Experimental|Motivational advice and free NRT|
88846628|NCT04045964|Active Comparator|Quitline referral|
88846629|NCT03941912|Experimental|Erchonia EVRL|635 nanometers (nm) and 405 nm dual-diode laser application
88846630|NCT04048460|Experimental|eAudiology|Participants will receive bilateral, behind-the-ear hearing aids as part of this study. The intervention will involve e-Audiology sessions following the initial hearing aid fitting and orientation. E-Audiology sessions will consist of hearing aid follow-up programming, troubleshooting, HAT assistance, and general help with hearing devices. E-Audiology sessions will take place over the course of approximately 6 weeks.
88846631|NCT04016324|Other|Basic evaluation|Subjects with overactive bladder will go through InterStim basic evaluation with the commercially approved foramen needle and basic evaluation kit.
88846632|NCT04039412|Active Comparator|(1) Hybrid regimen|omeprazole 20mg bid, and amoxicillin 1gm bid in the 1st week, then clarithromycin 500mg bid, omeprazole 20mg bid, amoxicillin 1gm bid, and metronidazole 500mg tid in the 2nd week.
89181498|NCT02582541|Experimental|SEMS plus radiofrequency ablation|Endoscopic retrograde cholangiopancreatography (ERCP) would be performed under standard operating conditions to confirm the length of the biliary stricture, diameter, and position. The Habib EndoHBP catheter (Emcision, London, United Kingdom) was placed through the biliary stricture under fluoroscopic guidance. The RFA energy can be delivered repetitively at different tumor sites within one procedure, according to the stricture size. After the RFA application is completed, SEMS (Wallstent, Boston Scientific, USA) can be deployed.
89181499|NCT00638391||1|all patients treated with Anastrozole
89374772|NCT02678416|Experimental|Placebo|All participants receive placebo as one of 4 interventions in random sequence
89374773|NCT02678416|Experimental|Morphine|All participants receive morphine as one of 4 interventions in random sequence
89374774|NCT03164668|Other|Usual cigs; menthol e-cig then tobacco e-cigs|Participants can continue to smoke their usual cigarettes. For the first month of study they receive menthol flavored e-cigarettes and for the second month they receive tobacco flavored e-cigarettes
88810260|NCT01342523|Experimental|CIS/loz/emails/lite website/full booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, nicotine lozenge, motivational emails, lite website, full mailed booklet"
88810261|NCT01342523|Experimental|No CIS/loz/emails/full website/full booklet|"This arm of the project will address the following question:~How effective is the following intervention?~No CIS calls, nicotine lozenge, motivational emails, full website, full mailed booklet"
88846633|NCT04039412|Active Comparator|(2) Reverse hybrid regimen|clarithromycin 500mg bid, omeprazole 20mg bid, amoxicillin 1gm bid, and metronidazole 500mg tid for 1 week, followed by omeprazole 20mg bid, and amoxicillin 1gm bid in the 2nd week.
89374775|NCT03164668|Other|Usual cigs; tobacco e-cig then menthol e-cigs|Participants can continue to smoke their usual cigarettes. For the first month of study they receive tobacco flavored e-cigarettes and for the second month they receive menthol flavored e-cigarettes
89374776|NCT03164668|Other|avoid menthol cigs; menthol e-cig then tobacco e-cigs|Participants avoid smoking menthol cigarettes. For the first month of study they receive menthol flavored e-cigarettes and for the second month they receive tobacco flavored e-cigarettes
89374777|NCT03164668|Other|avoid menthol cigs; tobacco e-cig then menthol e-cigs|Participants avoid smoking menthol cigarettes. For the first month of study they receive tobacco flavored e-cigarettes and for the second month they receive menthol flavored e-cigarettes
89374778|NCT03164512|Placebo Comparator|Placebo|Placebo oral and vapor
89374779|NCT03164512|Experimental|Vaporized High Cannabidiol Cannabis|Cannabis containing approximately 100mg cannabidiol and 5mg delta-9-THC
88810262|NCT01342523|Experimental|CIS/no loz/emails/full website/full booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, no nicotine lozenge, motivational emails, full website, full mailed booklet"
88810263|NCT01342523|Experimental|CIS/Loz/no Emails/Full Website/Full Booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, nicotine lozenge, No motivational emails, full website, full mailed booklet"
89374780|NCT03164512|Experimental|Vaporized Cannabidiol|100mg cannabidiol in vapor
88846634|NCT04039412|Active Comparator|(3) Levofloxacin quadruple regimen|levofloxacin 250mg QD, omeprazole 40mg QD, nitazoxanide 500mg bid, and doxycycline 100mg QD for 10 days. (LOAD)
88846635|NCT04036838|Experimental|Indication for H.pylori testing|Walk in basis: Symptomatic patients of H.pylori infection will be enrolled for this study if all acceptance criteria are met. Patients will undergo C13 Urea Breath Test in addition to at least 2 other diagnostic tools from one obtained biopsy as comparison.
88846636|NCT03831854|Active Comparator|lamotrigine|Patient will receive 300 mg of oral lamotrigine with small sips of water to reduce the psychologic side effects (measured by four key items of Brief Psychiatric Rating Scale: conceptual disorganization, hallucinatory behavior, suspiciousness, and unusual thought content) of intraoperative ketamine use.
88846637|NCT03831854|Placebo Comparator|Placebo|Patient will receive oral Placebo with small sips of water, to reduce the psychologic side effects (measured by four key items of Brief Psychiatric Rating Scale: conceptual disorganization, hallucinatory behavior, suspiciousness, and unusual thought content) of intraoperative ketamine use.
88846638|NCT03806270||Midazolam|"Demizolam, once on the operation day, usually ordered 15 minutes before strabismus operation by another anesthesiologist who is charged to perform anesthesia who is not related with the trial.The maximum dose of 0.5 mg/kg midazolam is given orally with cherry juice of maximum 5 ml. in Yeditepe University Hospital to the pediatric patients by the anesthesiologists.~In all groups patients are not selected to the groups and premedication and doses are not given by the investigator, they grouped according to the premedication given by the anesthesiologists, after the operation retrospectively."
88846639|NCT03806270||Midazolam&Hydroxyzine dihydrochloride1/2|"Midazolam and Hydroxyzine dihydrochloride, once on the operation day, usually ordered 15 minutes before strabismus operation by another anesthesiologist who is charged to perform anesthesia who is not related with the trial.The maximum dose of 0.5 mg/kg midazolam is given orally with hydroxyzine dihydrochloride (dose of 0.5 mg/kg) in Yeditepe University Hospital to the pediatric patients by the anesthesiologists.~In all groups patients are not selected to the groups and premedication doses are not given by the investigator, they grouped according to the premedication given by the anesthesiologists, after the operation retrospectively."
88846640|NCT03806270||Midazolam&Hydroxyzine dihydrochloride|"Midazolam and Hydroxyzine dihydrochloride, once on the operation day, usually ordered 15 minutes before strabismus operation by another anesthesiologist who is charged to perform anesthesia who is not related with the trial.The maximum dose of 0.5 mg/kg midazolam is given orally with the maximum dose of 1mg/kg hydroxyzine dihydrochloride in Yeditepe University Hospital to the pediatric patients by the anesthesiologists.~In all groups patients are not selected to the groups and premedication doses are not given by the investigator, they grouped according to the premedication given by the anesthesiologists, after the operation retrospectively."
89181500|NCT02583867|Experimental|Exercise|Participants will complete an exercise dose of 15 kilocalories per kilogram of bodyweight per week (KKW). This is equivalent to approximately 150 minutes/week of aerobic exercise. This dose will be completed in at least 3 sessions per week for 12 weeks.
89374781|NCT03164512|Experimental|Oral Cannabidiol|100mg oral cannabidiol
89374782|NCT03164200|Experimental|High fat breakfast|45% fat 35% Carbohydrate 20% protein
89374783|NCT03164200|Experimental|Higher carbohydrate breakfast|60% carbohydrate 20% fat 20% protein
89374784|NCT02680834|Experimental|Dual Action Pneumatic Compression Device|ACTitouch dual action pneumatic compression system used daily during wakeful hours for up to 16 weeks.
89374785|NCT02680834|Active Comparator|Multi-layer bandaging|PROFORE or Coban 2 to be worn 24 hours daily for up to 16 weeks.
89374786|NCT03343704|Experimental|Group A - patients with uncontrolled or life-threatening bleeding|
89374787|NCT03343704|Experimental|Group B - patients not bleeding but requiring emergency surgery or invasive procedure|
89374788|NCT03840642|Active Comparator|Mirror Me|Parents randomized to the Mirror Me condition will complete the 4 Mirror Me modules over a period of 5 weeks (~1 per week plus a week to practice). They will be provided with a visual guide for how to access the website. At 5 weeks, they will complete a remote parent-child interaction. Then they will be told their condition and to continue to use the website and practice what they have learned with their children.
89535031|NCT05015907|Experimental|Selective supraclavicular nerve block|After induction of anesthesia, the anesthesiologist sterilizes the skin of the area to be punctured. In the test group, an Ultrasound-guided selective supraclavicular nerve block is performed using 0.5% Ropivacaine 0.1mL/kg (Maximum dose: 5mL).
88810264|NCT01342523|Experimental|CIS/Loz/Emails/Full Website/Full Booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, nicotine lozenge, motivational emails, full website, full mailed booklet"
88810265|NCT01261559|No Intervention|Standard CT|Women assigned to undergo CT using the standard dose reduction methods (including bismuth shielding and tube current modulation) but without the Chrysalis device.
88810266|NCT01261559|Experimental|Chrysalis CT|Women assigned to undergo CT using the standard dose reduction methods (including bismuth shielding and tube current modulation) plus application of the Chrysalis device for breast displacement.
88810267|NCT01342757|Experimental|Arm I|"Patients receive vorinostat once daily on days -7 to -1 (course 1 only) and days 8-14 and 22-28 and temozolomide on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Patients undergo magnetic resonance spectroscopic imaging at baseline and at approximately 1 and 8 weeks on treatment. Patients also undergo a survey administration of Inventory of Depression Symptomatology Self-Reported (IDS-SR) assessment at baseline and periodically during study."
88810268|NCT02199743|Active Comparator|Lurasidone|Lurasidone 40mg po qhs with food x 1 week; Lurasidone 80mg po qhs with food x 3 weeks
88810269|NCT02199743|Active Comparator|Haloperidol|Haloperidol 4mg po qhs with food x 1 week; Haloperidol 8mg po qhs with food x 3 weeks.
88810270|NCT02199743|Active Comparator|Perphenazine|Perphenazine 16mg po qhs with food x 1 week; Perphenazine 32mg po qhs with food x 3 weeks.
88810271|NCT01315145|Active Comparator|Percutaneous Lumbar Decompression|Patients receiving percutaneous decompression using the mild® Device Kit.
88810272|NCT01315145|Active Comparator|Lumbar Epidural Steroid Injection|Injection of epidural steroids into the lumbar spine
88810273|NCT01316315|Experimental|Active|N6022 - 5 mg
88810274|NCT01316315|Placebo Comparator|Placebo|Placebo
88810275|NCT00776594|Experimental|Group 1|Androgen Deprivation Therapy Plus Bevacizumab
88810276|NCT00776594|Experimental|Group 2|Androgen Deprivation Therapy Alone
88810277|NCT01262105|No Intervention|No device|
88810278|NCT01262105|Experimental|Device deployed|
88810279|NCT00777062|Experimental|1|VIVITROL (Naltrexone extended-release injectable suspension), 380 mg injection at the start of weeks 2 and 6
88810280|NCT00777062|Placebo Comparator|2|Placebo injection, 380 mg injection at the start of weeks 2 and 6.
88810281|NCT01264601|Experimental|Single Dose|This arm will receive TIV as 2 doses, the first of which will be normal saline administered at approximately 10% of the total age appropriate dose volume, followed 30 minutes later by the full age appropriate dose. For children receiving a 0.25ml dose, a 20%/80% split will be used for ease of administration in drawing up the dose.
88810282|NCT01264601|Experimental|Graded Challenge|Subjects in this arm will receive TIV by standard 10%/90% 2-step graded challenge split of the age appropriate dose, separated by 30 minutes. For children receiving a 0.25ml dose, a 20%/80% split will be used for ease of administration in drawing up the dose.
88810283|NCT01317095|Active Comparator|Wire closure is the intervention|Patients will have their sternum closed using stainless steel wires.
88810284|NCT01317095|Active Comparator|Rigid fixation|Patients will have their sternum closed by rigid fixation using Starnalock plates.
88810285|NCT01345721|Experimental|MenACWY (2 primary + 1 booster dose)|Subjects who had previously received two primary doses of MenACWY-CRM vaccine (at 6-8 months and 12 months of age) in parent study, were administered one booster dose of the same vaccine in this extension study.
88810286|NCT01345721|Experimental|MenACWY (1 primary + 1 booster dose)|Subjects who had previously received one primary dose of MenACWY-CRM vaccine (at 12 months of age) in parent study, were administered one booster dose of the same vaccine in this extension study.
88810287|NCT01345721|Experimental|MenC (1 primary dose)+MenACWY (1 booster dose)|Subjects who had previously received one primary dose of the comparator MenC vaccine (at 12 months of age) in parent study, were administered one booster dose MenACWY-CRM vaccine in this extension study.
88810288|NCT01346267|Experimental|Arm I- Real Acupressure bands|Patients wear Sea-Band acupressure wristbands on each wrist beginning approximately 30 minutes prior to the first cisplatin-containing chemotherapy course and continually for 24 hours after the last chemotherapy dose (acute phase), and for a maximum of 7 days or until the next chemotherapy course starts (delayed phase). Patients are allowed to take bands off intermittently (up to 4 times a day, for no more than 15 minutes each time) to relieve pressure or to bathe. Patients also receive standard of care anti-emetic prophylaxis comprising granisetron, ondansetron, or dexamethasone during chemotherapy according to institutional or physician preference.
88810289|NCT01346267|Sham Comparator|Arm II- Placebo Acupressure Bands|Patients wear placebo wristbands on each wrist and receive standard of care anti-emetic prophylaxis during chemotherapy as patients in arm I.
88810290|NCT01318577|Experimental|Investigational Solution|Hydrogen peroxide system for cleaning, protein removal, disinfecting and storing of contact lenses.
88810291|NCT01318577|Active Comparator|Clear Care Solution|Hydrogen peroxide system for cleaning, protein removal, disinfecting and storing of contact lenses
88810292|NCT01318733|Experimental|CD07805/47 Gel 0.5%|
88810293|NCT01318967|Placebo Comparator|PAH|PAH measure of renal blood flow is first performed on subjects prior to administration of furosemide
88810294|NCT01318967|Active Comparator|MRI after furosemide|After the PAH measurement is complete, subjects receive 20 mg furosemide and undergo BOLD MRI to estimate renal blood flow
88810295|NCT01319045|Experimental|Iloprost|Participants will be administered iloprost at 5 mcg/dose x 6 doses daily for 3 months.
88810296|NCT01267019|Experimental|Arm 1: vivo augmentation|social cognitive training with in vivo augmentation
88846641|NCT03828734|Experimental|TMS to frontal cortex followed by TMS to parietal cortex|Participants will receive TMS while performing a cognitive control task. In their first stimulation session, the TMS coil will be placed over the frontal cortex on the scalp. In their second session, the TMS coil will be placed over the parietal cortex on the scalp. During every session, subjects receive Theta TMS, Alpha TMS, and Arrhythmic TMS.
88846642|NCT03828734|Experimental|TMS to parietal cortex followed by TMS to frontal cortex|Participants will receive TMS while performing a cognitive control task. In their first stimulation session, the TMS coil will be placed over the parietal cortex on the scalp. In their second session, the TMS coil will be placed over the frontal cortex on the scalp. During every session, subjects receive Theta TMS, Alpha TMS, and Arrhythmic TMS.
88846643|NCT04033640|Other|G6PD Diagnostic Testing|"Participants provided whole blood samples as well as finger-stick capillary blood samples.~At the clinic site, study staff performed the SD Biosensor STANDARD G6PD test and the POC HemoCue hemoglobin test on finger stick blood samples.~At the reference laboratories, G6PD activity was measured from whole blood samples using the SD Biosensor STANDARD G6PD test and the Pointe Scientific G6PD reference assay and hemoglobin was measured using the HemoCue hemoglobin test and by a complete blood count (CBC) using an automated hematology analyzer (Manaus site only)."
88846644|NCT04033640|No Intervention|Health Workers|Participants were trained on use of the SD Biosensor STANDARD G6PD test by members of the study team with extensive experience with G6PD diagnostics and the STANDARD G6PD test. Health worker participants were surveyed to assess label and packing comprehension as well as results interpretation.
88846645|NCT03497845|Experimental|a VN with AS03 Adjuvant, then gf/WA with AS03 Adjuvant|Single dose of Vietnam (VN) (H5N1) vaccine with AS03 Adjuvant (Dose 1 = Day 1), followed by single dose of gf/Washington (WA) (H5N8) vaccine with AS03 Adjuvant (Dose 2 = Day 22).
88846646|NCT03497845|Experimental|b IN with AS03 Adjuvant, then gf/WA with AS03 Adjuvant|Single dose of IN (H5N1) vaccine with AS03 Adjuvant (Dose 1 = Day 1), followed by single dose of gf/WA (H5N8) vaccine with AS03 Adjuvant (Dose 2 = Day 22).
88846647|NCT03497845|Experimental|c dk/BANG with AS03 Adjuvant, then gf/WA with AS03 Adjuvant|Single dose of dk/Bangladesh (BANG) (H5N1) vaccine with AS03 Adjuvant (Dose 1 = Day 1), followed by single dose of gf/WA (H5N8) vaccine with AS03 Adjuvant (Dose 2 = Day 22).
88846648|NCT03497845|Experimental|d gf/WA with AS03 Adjuvant, then IN with AS03 Adjuvant|Single dose of gf/WA (H5N8) vaccine with AS03 Adjuvant (Dose 1 = Day 1), followed by single dose of IN (H5N1) vaccine with AS03 Adjuvant (Dose 2 = Day 22).
88846649|NCT03497845|Experimental|e dk/BANG with AS03 Adjuvant, then bhg/QL with AS03 Adjuvant|Two doses of dk/BANG (H5N1) vaccine with AS03 Adjuvant (Dose1 = Day 1; Dose 2 = Day 22), followed by single dose of bhg/Qinghai Lake(QL) (H5N1) vaccine with AS03 Adjuvant (Day 142).
88846650|NCT03497845|Experimental|f gf/WA with AS03 Adjuvant, then bhg/QL with AS03 Adjuvant|Two doses of gf/WA (H5N3) vaccine with AS03 Adjuvant (Dose 1 = Day 1; Dose 2 = Day 22), followed by single dose of bhg/QL (H5N1) vaccine with AS03 Adjuvant (Day 142)
88846651|NCT03497845|Experimental|g VN with MF59 Adjuvant, then gf/WA with MF59 Adjuvant|Single dose of VN (H5N1) vaccine with MF59 Adjuvant (Dose 1 = Day 1), followed by single dose of gf/WA (H5N8) vaccine with MF59 Adjuvant (Dose 2 = Day 22).
88846652|NCT03497845|Experimental|h IN with MF59 Adjuvant, then gf/WA with MF59 Adjuvant|Single dose of IN (H5N1) vaccine with MF59 Adjuvant (Dose 1 = Day 1), followed by single dose of gf/WA (H5N8) vaccine with MF59 Adjuvant (Dose 2 = Day 22).
89535032|NCT05015907|Active Comparator|Control|The nerve block is not performed in the control group.
88846653|NCT03497845|Experimental|i dk/BANG with MF59 Adjuvant, then gf/WA with MF59 Adjuvant|Single dose of dk/BANG (H5N1) vaccine with MF59 Adjuvant (Dose 1 = Day 1), followed by single dose of gf/WA (H5N8) vaccine with MF59 Adjuvant (Dose 2 = Day 22).
88846654|NCT03497845|Experimental|j gf/WA with MF59 Adjuvant, then IN with MF59 Adjuvant|Single dose of gf/WA (H5N8) vaccine with MF59 Adjuvant (Dose 1 = Day 1), followed by single dose of IN (H5N1) vaccine with MF59 Adjuvant (Dose 2 = Day 22).
88846655|NCT03497845|Experimental|k dk/BANG with MF59 Adjuvant, then bhg/QL with MF59 Adjuvant|Two doses of dk/BANG (H5N1) vaccine with MF59 Adjuvant (Dose 1 = Day 1; Dose 2 = Day 22); followed by single dose of bhg/QL (H5N1) vaccine with MF59 Adjuvant (Day 142).
88846656|NCT03497845|Experimental|l gf/WA with MF59 Adjuvant, then bhg/QL with MF59 Adjuvant|Two doses of gf/WA (H5N8) vaccine with MF59 Adjuvant (Dose 1 = Day 1; Dose 2 = Day 22), followed by single dose of bhg/QL (H5N1) vaccine with MF59 Adjuvant (Day 142).
88846657|NCT04036292|Active Comparator|OC-01 Low Dose, 0.6 mg/mL|OC-01 (varenicline) nasal spray, 0.6 mg/ML
88846658|NCT04036292|Active Comparator|OC-01 High Dose, 1.2 mg/mL|OC-01 (varenicline) nasal spray, 1.2 mg/ML
88846659|NCT04036292|Placebo Comparator|Placebo (vehicle) nasal spray|Placebo (vehicle) nasal spray
88846660|NCT03501043|Experimental|Dysport|Subjects will receive 1000 to 1500 units of Dysport to be distributed on the basis of clinical indication to ankle plantar flexors (gastrocnemius and soleus), knee extensors and flexors, tibialis posterior and long toe flexors for one injection.
88846661|NCT00377390||Cockroach sensitive|
88846662|NCT00377390||Control (cockroach insensitive)|
88846663|NCT03261973|Other|DV8 esophageal deviation tool|This is a non-randomized one arm study.
88846664|NCT03820388|Experimental|Propofol Group|Propofol 2 mg/kg
88846665|NCT03820388|Experimental|Etomidate Group|Etomidate 0.3 mg/kg
88846666|NCT03820388|Experimental|Propofol plus Etomidate Group|Propofol 1 mg/kg plus Etomidate 0.15 mg/kg
88846667|NCT03264157|Experimental|BPL HRIG + RabAvert|20 IU/kg dose HRIG + active rabies vaccine
88846668|NCT03264157|Active Comparator|Comparator HyperRab + RabAvert|20 IU/kg dose HRIG + active rabies vaccine
88846669|NCT03820544|Experimental|SEMS|Patients undergo Endoscopic Retrograde Cholangiopancreatography (ERCP) with Self Expanding Metal Stents (SEMS) placement before standard of care surgical resection.
88846670|NCT03820544|Active Comparator|Standard of care surgical resection|Patients undergo standard of care surgical resection.
88846671|NCT03400579|Experimental|Remote Ischemic Conditioning|RIC procedure (i.e., four cycles of alternating 5-min inflation and 5-min deflation) administered by the autoRIC® device
88846672|NCT03801044||PD patients|All PD patients treated in out unit were enrolled.
88846673|NCT04029584|Experimental|Fluvastatin Alone First, Then Fluvastatin +IV Rifampin 600 mg|"The effect of rifampin on the pharmacokinetics of fluvastatin will be studied in healthy volunteers with or without hepatic induction in a randomized, unblinded, crossover clinical trial.~For uninduced periods, subjects will be randomized to receive one oral dose of fluvastatin (Lescol®) 20mg capsule first. Separated by one day of washout, they then receive one oral dose of fluvastatin (Lescol®) 20mg capsule immediately following a 30-min intravenous infusion of rifampin 600mg in 10ml Normal Saline.~Before starting hepatic induced period, subjects will have a washout for greater than one week.~To induce hepatic enzyme and transporter, Subjects will be pretreated with 5 days with 600mg oral rifampin. Subjects will be then randomized first to receive a single dose of fluvastatin 20mg. Separated by one day of washout, subject will then receive one oral dose of fluvastatin 20mg immediately after a 30-min IV infusion of rifampin 600mg."
88846674|NCT04029584|Experimental|Fluvastatin +IV Rifampin 600 mg First, Then Fluvastatin Alone|"The effect of rifampin on the disposition of fluvastatin will be studied in healthy volunteers with or without hepatic induction in a randomized, unblinded, crossover clinical trial.~For uninduced periods, subjects will be randomized to first receive one oral dose of fluvastatin (Lescol®) 20mg capsule immediately following a 30-min intravenous infusion of rifampin 600mg in 10ml Normal Saline.Separated by one day of washout, subjects will be then receive a single dose of fluvastatin (Lescol®) 20mg capsule.~Before starting induction periods, subjects will have a washout greater than one week.~To induce hepatic enzyme and transporter, subjects will be pretreated with 5 days with 600mg oral rifampin. subjects will be randomized to receive first one oral dose of fluvastatin 20mg immediately after a 30-min IV infusion of rifampin 600mg. Separated by one day of washout, subject will then receive one oral dose of fluvastatin 20mg."
88846675|NCT04028960|Placebo Comparator|Placebo|No active drug
88846676|NCT04028960|Experimental|Humulin-R|Insulin
88846677|NCT03401671|Experimental|Japanese|Healthy subjects of Japanese descent will receive a single dose of 300 milligrams (mg) lanadelumab subcutaneous (SC) injection in the abdomen.
88846678|NCT03401671|Experimental|Non-Hispanic Caucasians|Healthy Non-Hispanic Caucasian subjects will receive a single dose of 300 mg lanadelumab SC injection in the abdomen
88846679|NCT04023578|Experimental|Rheo Knee XC|Amputee subjects currently using either magneto-rehologic or hydraulic MPKs are fitted with the Rheo Knee XC, a magneto-rheologic MPK.
88846680|NCT03502915|Experimental|Nitrous Oxide|Patients will receive nitrous oxide during the version procedure.
88846681|NCT03502915|Placebo Comparator|Oxygen|Patients will receive placebo (100% oxygen) during the version procedure.
88846682|NCT03506347|Active Comparator|Vancomycin 15mg/kg IV|Will receive 15mg/kg based on actual body weight (maximum of 2g) of vancomycin via the systemic route at a rate of 15mg/kg as per hospital guidelines. Systemic IV vancomycin is given via a forearm vein, given over an infusion timed to finish immediately prior to surgery.
88846683|NCT03506347|Experimental|Vancomycin 500mg Intraosseous|Will have the limb exsanguinated and an above knee tourniquet inflated to 300 mmHg. Immediately following tourniquet inflation, Group B will receive 500mg of vancomycin, via an EZ-IO intraosseous cannula. The vancomycin would be administered in 150ml of saline solution. The intraosseous cannula would be placed into the epiphysis of the proximal tibia. The tourniquet will be left inflated for 10 minutes following completion of the IORA injection then deflated.
88846684|NCT04210232|Experimental|TECNIS® TORIC II Intraocular Lens (IOL)|Subjects will be implanted with the TECNIS Toric II IOL in one or both eyes qualified for study inclusion
88846685|NCT04019990|Other|Wheelchair basketball and ambulant basketball players|13 players from the North Cyprus wheelchair Basketball Team and 15 players from the Koop Bank Basketball Men's Team voluntarily will participate in the study. Subjects will include to study if they fulfil criteria. Athletes will involve in 8 weeks Thrower's Ten exercise program. After 8. Weeks and 12. Weeks assessments will be repeated.
88846686|NCT03266419|Experimental|Deep NMB using rocuronium|The abdomen is insufflated to 13 mmHg pneumoperitoneum with deep NMB (post tetanic count 1-2) during operation
88846687|NCT03266419|Active Comparator|Moderate NMB using rocuronium|The abdomen is insufflated to 13 mmHg pneumoperitoneum with moderate NMB (train of four 1-2) during operation
88846688|NCT03270943|Experimental|Mindful Self-Compassion (MFY)|An 8-week mindfulness self-compassion course for teens. 6 monthly continuation sessions will occur following completion of the 8-week course.
88846689|NCT03270943|Active Comparator|Healthy Lifestyles (HLG)|An 8-week healthy lifestyles course for teens. 6 monthly continuation sessions will occur following completion of the 8-week course.
88846690|NCT03800030|Experimental|Theta-gamma, Delta-beta, Sham|"Every participant will receive Theta-gamma tACS, Delta-beta tACS, and Sham tACS on separate sessions during performance of a computerized task.~Sequence: Theta-gamma tACS, then Delta-beta tACS, then Sham tACS"
88846691|NCT03800030|Experimental|Theta-gamma, Sham, Delta-beta|"Every participant will receive Theta-gamma tACS, Delta-beta tACS, and Sham tACS on separate sessions during performance of a computerized task.~Sequence: Theta-gamma tACS, then Sham tACS, then Delta-beta tACS"
88846692|NCT03800030|Experimental|Delta-beta, Theta-gamma, Sham tACS|"Every participant will receive Theta-gamma tACS, Delta-beta tACS, and Sham tACS on separate sessions during performance of a computerized task.~Sequence: Delta-beta tACS, then Theta-gamma tACS, then Sham tACS"
88846693|NCT03800030|Experimental|Delta-beta, Sham, Theta-gamma tACS|"Every participant will receive Theta-gamma tACS, Delta-beta tACS, and Sham tACS on separate sessions during performance of a computerized task.~Sequence: Delta-beta tACS, then Sham tACS, then Theta-gamma tACS"
88846694|NCT03800030|Experimental|Sham, Delta-beta, Theta-gamma tACS|"Every participant will receive Theta-gamma tACS, Delta-beta tACS, and Sham tACS on separate sessions during performance of a computerized task.~Sequence: Sham tACS, then Delta-beta tACS, then Theta-gamma tACS"
88846695|NCT03800030|Experimental|Sham, Theta-gamma, Delta-beta tACS|"Every participant will receive Theta-gamma tACS, Delta-beta tACS, and Sham tACS on separate sessions during performance of a computerized task.~Sequence: Sham tACS, then Theta-gamma tACS, then Delta-beta tACS"
89181501|NCT02583633|Active Comparator|Group one have received Transdermal nitroglycerin|transdermal GTN (Schwarz Pharma AG, Monheim, FRG) were prescribed and placed on the patient forearm. Each patch contained 37.4 mg of glyceryl trinitrate which was released in blood stream (10mg/24hour). After one hour of the first patch application, the uterine contractions were evaluated.
88846696|NCT03799484|Other|Topical Anesthesia|2.5% Lidocaine/2.5% Prilocaine Cream will be applied to one side of the forehead and Petrolatum Ointment to the other prior to administration of Botulinum Toxin Type A Injection
88846697|NCT03799484|Other|Petrolatum|Petrolatum Ointment will be applied to one side of the forehead and 2.5% Lidocaine/2.5% Prilocaine Cream to the other side prior to administration of Botulinum Toxin Type A Injection
88846698|NCT04012970|Experimental|A - Intervention then control|Intervention (30 minutes spinal mobilisations) received in first session, then control (30 minutes lying still) received in second session.
88846699|NCT04012970|Experimental|B - Control then intervention|Control (30 minutes lying still) received in first session, then intervention (30 minutes spinal mobilisations) received in second session.
89181502|NCT02583633|Active Comparator|Group two have received nifedipine|"For the nifedipine group, nifedipine 5mg softgel (Daana Pharma Co., Tabriz, Iran) was prescribed. In this group, the order of medicine prescription was as below;~One softgel every 20 min (4 doses)~Two softgel every 6 hr (4 doses)~One softgel every 6 hr (4 doses)~One softgel every 8 hr (3 doses) Likewise, the uterine contractions were checked every one hour and if the contraction didn't subside or there was any change in dilation and effacement, the treatment were stopped and another tocolytic were applied."
89181503|NCT04447833|Experimental|Mesenchymal Stromal Stem Cell Treatment|Infusion of allogeneic bone marrow derived mesenchymal stromal stem cells (MSC). First three patients receive a singe dose of 1x10^6 MSC/kg dose, next six patients receive a single dose of 2x10^6 MSC/kg.
88846700|NCT03508687|Experimental|Group 1: 300 mg Gemcabene daily week 12-24|Patients took Gemcabene 300mg daily for weeks 1-12. After 12 weeks, at visit T4, patients were randomized 1:1 according to pre-generated randomization code. This arm received 300mg Gemcabene daily for 12 weeks total, starting at week 12.
88846701|NCT03508687|Experimental|Group 2: 600mg Gemcabene daily week 12-24|Patients took Gemcabene 300mg daily for weeks 1-12. After 12 weeks, at visit T4, patients were randomized 1:1 according to pre-generated randomization code. This arm received 600mg Gemcabene daily for 12 weeks total, starting at week 12.
88846702|NCT03999944|Other|Sequence 1|"FRESCA Airbox Flow Generator set to fixed pressure first, then FRESCA Airbox Generator set to auto-adjusting pressure.~Second intervention within 1 - 10 days of first intervention."
88846703|NCT03999944|Other|Sequence 2|"FRESCA Airbox Flow Generator set to auto-adjusting pressure first, then FRESCA Airbox Generator set to fixed pressure.~Second intervention within 1 - 10 days of first intervention."
88846704|NCT03273283|Experimental|Intervention|Patients received a brief intervention on alcohol use. This brief intervention was a little chat based on motivational techniques to enhance motivation to reduce alcohol use or to initiate treatment. Patients were referred to specialized treatment when indicated.
88846705|NCT03273283|No Intervention|Control|Informative leaflets regarding alcohol use
88846706|NCT04290494||CNSR I (2007 to 2008)|"For this group following patients will be analysed:~The overall AIS patients aged 18 to 80 years who arrived at hospital within 7 days of symptom onset (Patient group A)~Thereof: IVT eligible patients:~AIS patients who arrived at hospital within 2 hours (patient group B) and 3.5 hours (patient group B') of symptom onset and with no documented absolute contraindications to IVT treatment~Thereof: IV rtPA treated patients:~IVT eligible patients who arrived at hospital within 2 hours of symptom onset and received IV rtPA within 3 hours of symptom onset (patient group C) and those who arrived at hospital within 3.5 hours of symptom onset and received IV rtPA within 4.5 hours of symptom onset (patient group C')"
88846707|NCT04290494||CNSR II (2012 to 2013)|"For this group following patients will be analysed:~The overall AIS patients aged 18 to 80 years who arrived at hospital within 7 days of symptom onset (Patient group A)~Thereof: IVT eligible patients:~AIS patients who arrived at hospital within 2 hours (patient group B) and 3.5 hours (patient group B') of symptom onset and with no documented absolute contraindications to IVT treatment~Thereof: IV rtPA treated patients:~IVT eligible patients who arrived at hospital within 2 hours of symptom onset and received IV rtPA within 3 hours of symptom onset (patient group C) and those who arrived at hospital within 3.5 hours of symptom onset and received IV rtPA within 4.5 hours of symptom onset (patient group C')"
88846708|NCT04290494||CNSR III (2015 to 2017)|"For this group following patients will be analysed:~The overall AIS patients aged 18 to 80 years who arrived at hospital within 7 days of symptom onset (Patient group A)~Thereof: IVT eligible patients:~AIS patients who arrived at hospital within 2 hours (patient group B) and 3.5 hours (patient group B') of symptom onset and with no documented absolute contraindications to IVT treatment~Thereof: IV rtPA treated patients:~IVT eligible patients who arrived at hospital within 2 hours of symptom onset and received IV rtPA within 3 hours of symptom onset (patient group C) and those who arrived at hospital within 3.5 hours of symptom onset and received IV rtPA within 4.5 hours of symptom onset (patient group C')"
88846709|NCT04005404|Experimental|intertrochanteric femoral fractures|geriatric patients with intertrochanteric femoral fracture who have consented to the study intervention
88846710|NCT04005404|Experimental|neck femur fractures|geriatric patients with neck of femur fracture who have consented to the study intervention
88846711|NCT04005404|Experimental|subtrochanteric femoral fractures|geriatric patients with subtrochanteric femoral fracture who have consented to the study intervention
88846712|NCT03232892|Experimental|Trametinib 2.0mg PO daily|Trametinib 2.0mg PO daily in 28-day cycles. A maximum of two trametinib dose level reductions are allowed (1.5mg and 1mg) in the case of adverse reactions.
88846713|NCT03787472|Experimental|Test/Control|Hyperopic subjects that are habitual soft contact lens wearers and have presbyopia will be randomized into one the sequence (Test/Control).
89181504|NCT04078503||Case|All patients aspected to stay in ICU for at least 3 days who will develop delirium
89181505|NCT04078503||Control|All patients aspected to stay in ICU for at least 3 days who will not develop delirium (1:1 matched with the controls with a propensity score method).
89181506|NCT02582385||Amyotrophic lateral sclerosis (ALS)|Archived/residual histopathology sections and paraffin blocks, retrieved entirely from residual autopsy material from patients who died with an amyotrophic lateral sclerosis.
89181507|NCT02582385||Control|Archived/residual histopathology sections and paraffin blocks, retrieved entirely from residual autopsy material from one non-ALS case.
89181508|NCT04186689||children in fully food secure households (G1)|preschool children live in a fully food secure household have at least a carious tooth that needs treatment under local anesthesia other than extraction without any previous dental treatment experience.
88846714|NCT03787472|Experimental|Control/Test|Hyperopic subjects that are habitual soft contact lens wearers and have presbyopia will be randomized into the sequence (Control/Test).
89181509|NCT04186689||children in marginally food secure households (G2)|preschool children live in a marginally food secure household have at least a carious tooth that needs treatment under local anesthesia other than extraction without any previous dental treatment experience.
89181510|NCT04186689||children in food insecure households (G3)|preschool children live in a food-insecure household have at least a carious tooth that needs treatment under local anesthesia other than extraction without any previous dental treatment experience.
89181511|NCT00638469|Other|left/right|left or right body side
89181512|NCT02689011|Experimental|Group F|Femoral nerve Block Group
89181513|NCT02689011|Active Comparator|Group E|Epidural Group
89181514|NCT02582307|Experimental|Hyoscine butylbromide|Hyoscine butylbromide 10mg oral single dose
89181515|NCT02582307|Active Comparator|Acetaminophen|Acetaminophen 15mg/kg oral single dose (maximum 1000mg)
89181516|NCT02689245|Experimental|Tenofovir + Fecal Microbiota Transplantation (FMT)|
89181517|NCT02689245|Active Comparator|Tenofovir|
89181518|NCT04187001||Judges|Professionals that assess the content validity of the exercise protocol
89181519|NCT04187001||Target population|People that assess the exercise protocol for cultural adaptation
89181520|NCT00802841|Experimental|Nilotinib|Participants received 400 mg nilotinib twice daily (BID).
89181521|NCT00802841|Active Comparator|Imatinib|Participants received 600 mg imatinib once daily (QD).
89181522|NCT00772148|Experimental|LCP-Tacro|LCP - Tacro™ tablets, once daily (LifeCycle Pharma A/S, Hørsholm DK)
89374789|NCT03840642|Experimental|Mirror Me Plus Remote Coaching|Parents randomized to the Mirror Me plus remote coaching condition will complete the 4 Mirror Me modules over a period of 5 weeks (~1 per week plus a week to practice). They will be provided with a visual guide for how to access the website. At 5 weeks, they will complete a remote parent-child interaction. Then all parents in this condition will be told about the opportunity to participate in remote video teleconferences once per week for 5 weeks. Trained therapists will provide feedback to parents as they use the RIT techniques with their child at home. All sessions will follow a similar format including a discussion of accomplishments and challenges, parent practice with feedback, problem solving, and planning for the next week. Sessions will be recorded for data collection and therapist coaching fidelity. Participants will have access to Mirror Me for the duration of the research study.
89374790|NCT02680756|Experimental|Oral ferric iron compound|30 mg capsules to be taken orally twice a day for 52 weeks
89374791|NCT02680756|Active Comparator|Intravenous iron|Administered as per the local summary of product characteristics (SPC)
89374792|NCT03631836|Experimental|Combinaton monoclonal therapeutic antibody and bevacizumab|Determine the safety profile and tolerability of monoclonal therapeutic antibody given in combination with a fixed dose of bevacizumab in patients with recurrent glioblastoma in terms of Dose-Limiting Toxicities
89374793|NCT03162094|Experimental|AVX-012 Opthalmic Solution Low dose|"Phase I: AVX-012 ophthalmic solution Low dose administration three times per day (TID) for 7 days~Phase II: If the low dose of AVX012 is selected on phase I, AVX-012 ophthalmic solution Low dose administration three times per day (TID) and two times per day (BID) for 28 days"
89374794|NCT03162094|Experimental|AVX-012 Opthalmic Solution High dose|"Phase I: AVX-012 ophthalmic solution High dose administration three times per day (TID) for 7 days~Phase II: If the high dose of AVX012 is selected on phase I, AVX-012 ophthalmic solution High dose administration three times per day (TID) and two times per day (BID) for 28 days"
89374795|NCT03162094|Placebo Comparator|Placebo (Vehicle) Opthalmic Solution|"Phase I: Placebo ophthalmic solution administration three times per day (TID) for 7 days~Phase II: Placebo ophthalmic solution administration three times per day (TID) and two times per day (BID) for 28 days"
89374796|NCT03670862||stroke|Ischemic stroke patients with sympton onset in 24 hours
89374797|NCT03674918||persons with arterial hypertension|patients referred to consultation cardiology for hypertension. They get a 24 h blood pressure monitoring to define the exact mean arterial blood pressure
89374798|NCT03086460|Experimental|Treatment A|"Treatment A, CHF 1531 pMDI:~CHF 1531 pMDI 6 μg total daily dose (TDD):~1 inhalation of CHF 1531 pMDI 3 μg/actuation plus 1 inhalation of CHF 1531 matched Placebo BID."
88810297|NCT01267019|Active Comparator|Arm 2: social cognitive|social cognitive training
88810298|NCT01267019|Active Comparator|Arm 3: non-social skills|non-social skills training
88810299|NCT01348607|Experimental|Arm I - methylphenidate hydrochloride|Patients receive oral methylphenidate extended-release once daily for 7-42 days in the absence of unacceptable toxicity.
88810300|NCT01348607|Experimental|Arm II -modafinil|Patients receive oral modafinil once daily for 7-42 days in the absence of unacceptable toxicity.
88810301|NCT01348607|Placebo Comparator|Arm III placebo|Patients receive oral placebo once daily for 7-42 days in the absence of unacceptable toxicity.
88810302|NCT06214650|Experimental|Radiofrequency group|"All participants will be receive two interventions:~A weekly session for 10 weeks with radiofrequency. It will be use the protocol of INDIBA. Each session will last 30 minutes.~Participants will do an homely exercise protocol. This protocol will practise for 3 days at week."
88810303|NCT06214650|Active Comparator|Control group|"All participants will be receive two interventions:~A weekly session for 10 weeks with radiofrequency. It will be use INDIBA without intensity such as a placebo. Each session will last 30 minutes.~Participants will do an homely exercise protocol. This protocol will practise for 3 days at week."
88810304|NCT06214637|Placebo Comparator|Placebo|It will be administered for a period of 30 days, once a day before bed, with a 15-day wash-out interval. The placebo, a drug without active substance, that will be administered to research participants will be the biotherapeutic vehicle, that is, 30% alcohol (v/v), which is commonly used as a vehicle for homeopathic medicines.
89181523|NCT00772148|Active Comparator|Prograf (tacrolimus)|Prograf® capsules, twice daily (Astellas Pharma US, Deerfield IL)
89181524|NCT02582229|Experimental|Interventionnal|The intervention will be performed under general anesthesia with tracheal intubation. Endomina will be introduced into the stomach over guide wires and then fixed to the endoscope. The procedure will include the placement of 4-6 transmural anterior-posterior sutures after argon plasma coagulation of the tissue opposition areas in order to ensure persistence of the pouch reduction. Patient will be kept overnight after the procedure.
89181525|NCT02689089|Other|3HP|The interrupted time series design aims to collect data at multiple time points before (standard regimen) and after the introduction of the new 3HP regimen (interruption) to detect if a significant increase in the number of completions has occurred with the new regimen
89181526|NCT00638547|Experimental|Intent-to-Treat|All patients who have received at least one dose of Laronidase.
89181527|NCT02605889|Experimental|Group A|Laser acupuncture
89181528|NCT02605889|Sham Comparator|Group B|Simulation Laser acupuncture
89181529|NCT00759902|Other|1|Treatment A (test product) followed by Treatment B (reference product)
88846715|NCT03778190|Experimental|Magnet|The physician will attempt to remove the corneal foreign body using an eye magnet for these patients.
88846716|NCT03510481|Experimental|Experimental arm 1: Dosing interval 0, 8, 16, and 54 weeks|Participants received 3 doses of PfSPZ Vaccine (9 x 10^5) via direct venous inoculation (DVI) at 0, 8, 16 weeks and a 4th dose at 38 weeks post 3rd vaccination. Oral antimalarial treatment with artemether 20mg/lumefantrine 120mg (AL) given orally with food with 4 tablets taken as a single initial dose, then 4 tabs again after 8hrs, then 4 tabs twice daily for the following two days for a total of 24 tabs, 2 weeks prior to 3rd and 4th injection.
88846717|NCT03510481|Experimental|Experimental arm 2: Dosing interval 0, 1, 4, and 42 weeks|Participants received 3 doses of PfSPZ Vaccine (9 x 10^5) via direct venous inoculation (DVI) at 0, 1, 4 weeks and a 4th dose at 38 weeks post 3rd vaccination. Oral antimalarial treatment with artemether 20mg/lumefantrine 120mg (AL) given orally with food with 4 tablets taken as a single initial dose, then 4 tabs again after 8hrs, then 4 tabs twice daily for the following two days for a total of 24 tabs, 2 weeks prior to 3rd and 4th injection.
88846718|NCT03510481|Placebo Comparator|Placebo comparator 3a: Dosing interval 0, 8, 16, and 54 weeks|Control for Arm 1. Participants received 3 doses of placebo saline injection via direct venous inoculation (DVI) at 0, 8, 16 weeks and a 4th dose at 38 weeks post 3rd injection. Oral antimalarial treatment with artemether 20mg/lumefantrine 120mg (AL) given orally with food with 4 tablets taken as a single initial dose, then 4 tabs again after 8hrs, then 4 tabs twice daily for the following two days for a total of 24 tabs, 2 weeks prior to 3rd and 4th injection.
88846719|NCT03510481|Placebo Comparator|Placebo comparator 3b: Dosing interval 0, 1, 4, and 42 weeks|Control for Arm 2. Participants received 3 doses of placebo saline injection via direct venous inoculation (DVI) at 0, 1, 4 weeks and a 4th dose at 38 weeks post 3rd injection. Oral antimalarial treatment with artemether 20mg/lumefantrine 120mg (AL) given orally with food with 4 tablets taken as a single initial dose, then 4 tabs again after 8hrs, then 4 tabs twice daily for the following two days for a total of 24 tabs, 2 weeks prior to 3rd and 4th injection.
88846720|NCT03172520|Experimental|Facial Nerve Monitoring with APS electrode|The investigators will use the Facial Nerve Monitor along with the automatic periodic stimulating(APS) electrode during parotidectomy surgery.
88846721|NCT03109418|Placebo Comparator|Control Group|OSA patients will receive standard inhaled anesthesia with normal saline infusion
88846722|NCT03109418|Active Comparator|Ketamine Group|OSA patients receiving standard inhaled anesthesia combined with a low-dose ketamine infusion.
88846723|NCT03404167|Experimental|Zoliflodacin|4 g (2 sachets of 2 g) of zoliflodacin orally in the morning of Day 1 after 8 hours of fasting, n=8
88846724|NCT03771560|Experimental|Open-label|In this open-label trial, all subjects will receive the twice daily dose of folinic acid. Folinic acid will be delivered in pill form at a weight-based dose.
89181530|NCT00759902|Other|2|Treatment B (reference product) followed by Treatment A (test product)
89181531|NCT04077957|Experimental|Group 1. Experimental|Etanercept 50mg per week plus conventional synthetic DMARDs(csDMARDs, methotrexate 10mg per week, sulfasalazine 2.25g per day, hydroxychloroquine 0.2g per day) for 4 weeks when in high disease activity; etanercept 50mg per week plus csDMARDs for 2 weeks and continue with csDMARDs only for 2 weeks when in low disease activity; csDMARDs only for 4 weeks when in disease remission status.
89181532|NCT04077957|Active Comparator|Group 2. Positive Control|Etanercept 50mg per week for first 12 weeks; etanercept 50mg per ten days for second 12 weeks; etanercept 25mg per week for next 12 weeks; etanercept 25mg per two week for next 12 weeks.
89181533|NCT04114019||Stress urinary incontinence|Women suffering from stress urinary incontinence
89181534|NCT04102670|Experimental|Treatment|Subjects will receive a combination of Ultherapy, Xeomin, Beletero Balance, Dilute Radiesse and Neocutis MicroFirm Face and Neck Cream
89181535|NCT04114097|Experimental|Betamethasone-17-valerat + placebo ointment|"Atopic dermatitis patients: topical treatment with twice daily full-body ointment containing corticosteroid (Betnovate, betamethasone dipropionate ointment 0.1%) and placebo"
89374799|NCT03086460|Experimental|Treatment B|"Treatment B, CHF 1531 pMDI:~CHF 1531 pMDI 12 μg TDD:~1 inhalation of CHF 1531 pMDI 6 μg/actuation plus 1 inhalation of CHF 1531 matched Placebo BID."
89374800|NCT03086460|Experimental|Treatment C|"Treatment C, CHF 1531 pMDI:~CHF 1531 pMDI 24 μg TDD: 2 inhalations of CHF 1531 pMDI 6 μg/actuation BID."
89374801|NCT03086460|Experimental|Treatment D|"Treatment D, CHF 1531 pMDI~CHF 1531 pMDI 48 μg TDD: 2 inhalations of CHF 1531 pMDI 12 μg/actuation BID."
89374802|NCT03086460|Experimental|Treatment E|"Treatment E, Matched placebo~Placebo: 2 inhalations of CHF 1531 pMDI matched Placebo BID."
89374803|NCT03086460|Active Comparator|Treatment F|"Treatment F, Formoterol fumarate inhalation solution (IS)~Perforomist® IS (active comparator, open-label) 40 μg TDD: 1 inhalation, 20 μg/ 2 mL vial, 1 vial BID."
89374804|NCT02674490|Experimental|A-tDCS & SALT|A-tDCS (1 mA) plus Speech and Language Treatment (SALT) for 15 sessions (20-minutes per each 45-minute treatment session) over the course of 3 weeks. The electrical current will be administered to a pre-specified region of the brain. The stimulation will be delivered at an intensity of 1mA for a maximum of 20 minutes. SALT will be a computer-delivered naming + picture matching task .
89374805|NCT02674490|Sham Comparator|Sham-tDCS & SALT|Sham-tDCS plus SALT for 15 sessions (20-minutes per each 45-minute treatment session) over the course of 3 weeks. Current will be administered in a ramp-like fashion, but after the ramping, the intensity will drop to 0 mA. SALT will be a computer delivered oral naming + picture naming task.
89374806|NCT03162250|Experimental|DSTA4637S low dose level + SOC|DSTA4637S low dose level intravenous (IV) infusion will be administered within 24 hours of randomization on Day 1 and then every 7 days up to 6 doses of study drug in addition to anti-staphylococcal SOC antibiotics.
89374807|NCT03162250|Experimental|DSTA4637S intermediate dose level+ SOC|DSTA4637S intermediate dose level IV infusion will be administered within 24 hours of randomization on Day 1 and then every 7 days up to 6 doses of study drug in addition to anti-staphylococcal SOC antibiotics.
89374808|NCT03162250|Experimental|DSTA4637S high dose level+ SOC|DSTA4637S high dose level IV infusion will be administered within 24 hours of randomization on Day 1 and then every 7 days up to 6 doses of study drug in addition to anti-staphylococcal SOC antibiotics.
89374809|NCT03162250|Placebo Comparator|Placebo + SOC|Placebo matched to DSTA4637S IV infusion will be administered within 24 hours of randomization on Day 1 and then every 7 days up to 6 doses of study drug in addition to anti-staphylococcal SOC antibiotics.
89374810|NCT03670706|Active Comparator|Group A|Exercise training, then crossover to analgesic optimisation
89374811|NCT03670706|Active Comparator|Group B|Analgesic optimisation, then crossover to exercise training
89374812|NCT03670706|No Intervention|Group C|Control group
89374813|NCT03114280|Experimental|TPF2|docetaxel (T), cisplatin (P), 5 Fluorouracil (F) and pembrolizumab every 21 days followed by radiotherapy (RT) combined with carboplatin
89374814|NCT03678818|Experimental|Handling Medium Supplemented with Latrunculin A|
89374815|NCT03678818|No Intervention|Handling Medium as it is.|
89374816|NCT03163654|Active Comparator|Experimental group|Surgery 1: The tunnel technique for covering multiple gingival recessions. Graft: porcine-derived acellular dermal collagen matrix (PADM, mucoderm® ).
89374817|NCT03163654|Active Comparator|Control group|Surgery 2: The tunnel technique for covering multiple gingival recessions. Graft: connective tissue graft
89374818|NCT03678662|Experimental|hyperalgesia expectation|In this group the subjects will be told that the 3 minutes wall squat will have pain-enhancing effects.
89374819|NCT03678662|Experimental|hypoalgesia expectation|In this group the subjects will be told that the 3 minutes wall squat will have pain-diminishing effects.
89374820|NCT03678662|Active Comparator|Neutral|In this group the subjects expectations are not manipulated
89374821|NCT03163810|Experimental|Erchonia Verju and EVRL Laser|"The Erchonia Verju Laser has 6 diodes that each emit 17 milliwatts (mW) 532 nanometers (nm) of green laser light.~The Erchonia EVRL Laser emits 635 nanometers (nm) red light and 405 nm blue light simultaneously"
89374822|NCT03163888||Navigation TKR group|TKR performed under computer navigation without violating distal femur bone marrow.
89181536|NCT04114097|Active Comparator|Tacrolimus ointment|"Atopic dermatitis patients: topical treatment with twice daily full-body ointment containing calcineurin inhibitor (Protopic, tacrolimus ointment 0.1%)"
88846725|NCT03404401|Experimental|BLI4700 Bowel Preparation|
89374823|NCT03163888||Conventional TKR group|TKR performed under conventional distal femur cutting juts with violation of distal femur bone marrow.
89374824|NCT03164044||Patients with drug allergy|Patients with drug allergy to antibiotics or NSAIDs
89374825|NCT03674762|Experimental|dental implants|microgrooved dental implants submerged
89374826|NCT03674762|Experimental|dentale implants|microgrooved dental implants nonsubmerged
89374827|NCT03678584|Experimental|Handling Medium Supplemented with Chaetoglobosin A|
89374828|NCT03678584|No Intervention|handling Medium as it is.|
89374829|NCT03623516||Thyroid cancer|All subjects living in the Marne or Ardennes Departments of France and who were diagnosed with papillary thyroid cancer between 1975 and 2014.
89374830|NCT02600234|Experimental|Treatment with Inter-Atrial Shunt Device|Once all study criteria have been met, if randomized to this arm, patients will receive the IASD implant.
89374831|NCT02600234|Placebo Comparator|Control|Once all study criteria have been met, if randomized to this arm, patients will not receive the implant. They will undergo an intracardiac echo only, with the option to crossover at 1 year.
89374832|NCT02677714|Experimental|Patients with breast cancer receiving chemotherapy|After reconstitution and radiolabeling, 99mTc-rhAnnexin V-128 was administered as a single intravenous bolus of 350 MBq +/- 10% at baseline, after the 2nd cycle, after the 4th cycle and 12 weeks after AC chemotherapy.
89374833|NCT03670550|Experimental|Knee Brace|"ACL-reconstruction patients will be issued an Ossur Rebound ACL Brace at the time of enrollment in the study, prior to surgery. They will use this brace throughout their rehab and physical therapy.~Dynamic X-ray imaging of the knee will take place prior to surgery, and again upon clearance from physical therapy 7-9 months after surgery. The injured knee will be imaged with and without the brace, and the contralateral limb will be imaged for use as a control."
89374834|NCT03161678|Active Comparator|Wild-Type Genotype|Research subjects with wild type CES1 genotypes will be studied before and after oral ingestion of clopidogrel (75 mg/d for 8 days) and ticagrelor (90 mg twice daily for 8 days) treatment.
89374835|NCT03161678|Experimental|Carriers of the CES1 G143E Mutation|Research subjects who carry the CES1 G143E allele (rs71647871) will be studied before and after oral ingestion of clopidogrel (75 mg/d for 8 days) and ticagrelor (90 mg twice daily for 8 days) treatment.
88846726|NCT03404401|Active Comparator|FDA Approved Bowel Preparation|
88846727|NCT03767738|Experimental|Intravitreal Aflibercept Injection (IAI)|Cohort 1 - Initial patients Cohort 2 - Additional patients
88846728|NCT03989570|Experimental|Group I (A group)|31 patients Will undergo ESP block with 40 ml bupivacine 0.25% (20 ml on each side), and TAP block with 40 ml saline 0.9% (20 ml on each side).
89181537|NCT00772070|Experimental|Previously received TetraMenD|Participants previously received one dose of a Meningococcal vaccine, TetraMenD in Study 603-02.
89002304|NCT06319014|Experimental|RE Group|"The RE group will perform 12-15 repetitions of 10-12 resistance exercises in a circuit, for 3 sets, with a rest period of 30-60 seconds between sets as needed.[172] Seated isokinetic exercise using resistance machines will target all major muscle groups. Light dumbbells and resistance bands will be used if the participant is unable to lift the minimal load on machines. Core exercises will be performed at the end of the session (i.e. seated side bends)~All exercise participants will be prescribed exercise that meets guidelines of the American College of Obstetricians and Gynecologists (ACOG), American College of Sports Medicine (ACSM), and the American Heart Association (AHA); 150 minutes per week, moderate intensity (60-80% aerobic capacity, Rating of Perceived Exertion, RPE, 12-15) per week. These limits are the same as those that generated previous positive findings for our preliminary data."
89002305|NCT06319014|Experimental|AERE Group|"AERE group will alternate between AE exercise and RE; for this group, RE exercises will consist of 1 set of 12-15 repetitions of 4 resistance exercises, then 5 minutes of AE, then repeat this cycle with different exercises.~All exercise participants will be prescribed exercise that meets guidelines of the American College of Obstetricians and Gynecologists (ACOG), American College of Sports Medicine (ACSM), and the American Heart Association (AHA); 150 minutes per week, moderate intensity (60-80% aerobic capacity, Rating of Perceived Exertion, RPE, 12-15) per week. These limits are the same as those that generated previous positive findings for our preliminary data."
89002306|NCT06319014|No Intervention|Control|The Control group will participate in weekly sessions that focus on stretching, breathing, and healthy lifestyle.
89002307|NCT06319001|Experimental|Positive stress education (PSE)|This intervention will consist of standardized information about the relationships between expectations and the stress response. Using the CATS as a theoretical framework, the participants will be explained that when people face stressors, i.e., pain, heat, and cold water, the expectations about handling the situation will influence both the experience (e.g., pain) and the physiological stress response.
89002308|NCT06319001|Sham Comparator|Neutral control|To control for the PSE intervention, the participants will receive 15 min of neutral information about the effects of physical exercise on cardiovascular fitness.
89002309|NCT06318988||conservative|compression therapy, and oral or topical venoactive drugs
89002310|NCT06318988||invasive|sclerotherapy, foamsclerotherapy, open surgery, endovenous thermal ablation
89002311|NCT06318975|Placebo Comparator|Brief Alcohol Intervention|Those assigned to the BAI condition receive the standard BAI, which we have conducted since 2010, during the 4th week of Technical Training, the last week of enforced abstinence. This BAI has become the de-facto standard of care and is part of USAF Training. The BAI is a group-based, one-hour session which includes the following components: Interactive discussion of the positives and negatives of drinking during training and heavy vs. moderate drinking; Discussion of USAF rules on alcohol use and penalties for violations; Discussion of impact of alcohol on military readiness; effects of alcohol and hangover on performance; Review of standard drinks, blood alcohol levels and tolerance; and normative feedback on the Airmen's drinking level compared to others. We will engage in a conversation about whether they have observed concerning patterns of alcohol misuse among other USAF personnel, and how to handle this, along with harm reduction and alcohol refusal strategies.
89002312|NCT06318975|Experimental|BAI + Texting|Those assigned to this arm will receive the same BAI as the other arm with the addition of automated text messages. All messages are pre-written, the timing is pre-planned - all Airmen receive the same content at the same time. Airmen will receive 1-3 daily text messages per day two weeks before they are allowed off base following 12 weeks of enforced abstinence and will continue for the 4 weeks. All Airmen randomized to the text message arm will be directed to enroll into the supplemental program, specifying the first date when they will be able to go off base so that messages are timed appropriately. Messages sent before time off base reinforce the BAI content and provide additional, actionable advice on reducing or avoiding alcohol in more detail and specificity than time allows for during the BAI; messages sent after the first weekend off base will provide probes for reflection on Airman's behavior during the weekend. Messages are designed to maintain or enhance skill building.
89002313|NCT06318962|Experimental|Digital Therapeutic|BCBT Delivery via digital app
89002314|NCT06318962|No Intervention|Treatment as Usual|
89002315|NCT06318949|Experimental|experimental arm|
89002316|NCT06318936||Older adults with RSV infection|Adults aged ≥60 years attending primary care with acute respiratory tract infecion
89002317|NCT06318910|Experimental|CFO with W1|The therapists will propose the orthotic wedges after examining the foot angles following the foot assessment from the study of Root, the forefoot angle will be determined for both the forefoot and rearfoot wedges. Previous studies recommended the posting at 60% of the measured forefoot angle, up to a maximum of 8 degrees, for extrinsic forefoot varus wedge and the posting at 50% of the measured forefoot angle, up to a maximum of 6 degrees, for extrinsic rearfoot varus wedge. After the posting, all participants will be asked to test the provided foot orthoses within their footwear. If any disturbance has been found during testing, the adjustment will be performed.
89002318|NCT06318910|Experimental|CFO with W2|The therapists will propose the orthotic wedges after examining the foot angles following the foot assessment from the study of Monaghan et al., the forefoot will be posted at 50% of the measured forefoot angle, and the rearfoot will be posted at 20% of the measured rearfoot angle. After the posting, all participants will be asked to test the provided foot orthoses within their footwear. If any disturbance has been found during testing, the adjustment will be performed.
89181538|NCT00772070|Experimental|Meningococcal vaccine-naїve|Participants have never received a Meningococcal vaccine in the past.
89181539|NCT00796757|Experimental|1|
89181540|NCT00759356|Other|1|Treatment A (test product) followed by Treatment B (reference product)
89374836|NCT03161678|Experimental|Carriers of CES1 Functional Mutation|Research subjects who carry a CES1 mutation of potential functional impact (to be determined...studies ongoing) will be studied before and after oral ingestion of clopidogrel (75 mg/d for 8 days) and ticagrelor (90 mg twice daily for 8 days) treatment.
89374837|NCT03114670|Experimental|CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells|Patients will receive a full dose CART infusion at day 0.
88810305|NCT06214637|Experimental|Melissa officinalis 6 CH|It will be administered for a period of 30 days, once a day before bed, with a 15-day wash-out interval. This concentration that will be administered to research participants will be the biotherapeutic vehicle, that is, 30% alcohol (v/v), which is commonly used as a vehicle for homeopathic medicines.
89374838|NCT03674684||hydroxyethyl starch|Patients who received hydroxyethyl starch
89374839|NCT03674684||gelatin|Patients who received gelatin
89374840|NCT03674684||crystalloids|Patients who received crystalloids
89374841|NCT05596656||allergic type 1 DM children|45 cases were considered allergic based on written questionnaire taken by the resident. Diagnosis of atopy was confirmed by skin prick testing
89374842|NCT05596656||Non-allergic type 1 DM children|Forty-five Non-allergic type 1 DM children were selected as age and sex matched control group.
89374843|NCT03678272|Active Comparator|HERNIOPLASTY WITH PANAVALE MESH|Preformed polypropylene mesh.
89374844|NCT03678272|Active Comparator|HERNIOPLASTY WITH PARIETEX PROGRIP MESH|Mesh consisting of mono lament polyester with a resorbable polylactic acid (PLA) microgrip technology.
89374845|NCT03678272|Active Comparator|HERNIOPLASTY WITH ADHESIX MESH|Self-adhesive mesh.
89374846|NCT03678272|Active Comparator|HERNIOPLASTY WITH TIMESH MESH|Titaniumized polypropylene mesh.
89374847|NCT03632070||Stroke|Patients with ischemic or hemorrhagic stroke who were admitted to Samsung Medical Center and transferred to the Department of Physical and Rehabilitation Medicine
89374848|NCT03674606|Experimental|Routine low-dose aspirin|Subjects shall receive standard antenatal care as well as taking oral low-dose aspirin from the eligibility visit until 36-week gestation once daily, as prescribed by the research clinician. Fetal Medicine Foundation screening test results from the recruitment visit shall not be disclosed to the participants in this arm.
89374849|NCT03674606|No Intervention|No aspirin|No low-dose aspirin will be prescribed. Fetal Medicine Foundation screening test results from the recruitment visit shall not be disclosed to the participants in this arm.
88810306|NCT06214637|Experimental|Melissa officinalis 9 CH|It will be administered for a period of 30 days, once a day before bed, with a 15-day wash-out interval. This concentration that will be administered to research participants will be the biotherapeutic vehicle, that is, 30% alcohol (v/v), which is commonly used as a vehicle for homeopathic medicines.
89002319|NCT06318910|Active Comparator|CFO without wedge|The 3-quarter-length CFO will be made from thermoplastic material (rigid foot orthoses) which consists of four layers i.e. two layers of 0.5-mm polyvinyl chloride (PVC), one layer of 1.5-mm thick fiber to increase strength of foot orthoses in the bottom layers as well as one layer of 1.2-mm genuine leather in the upper layer to increase comfort. It incorporates a heat-molding process to adjust individual foot shape in prone position. The materials will be set within approximately three minutes.
89374850|NCT03674606|Active Comparator|Test-indicated low-dose aspirin|The Fetal Medicine Foundation screening test will be used to determine whether a subject is at high risk of developing any pre-eclampsia until 42-week gestation. Participants with risk > 1:8 must start low-dose aspirin treatment immediately. Participants with a risk < 1:8 will be excluded.
89374851|NCT02677324|Experimental|ABT199|ABT199 will be administered daily, with 28 consecutive days defined as a treatment cycle for a maximum for 26 cycles
89374852|NCT03670238|Experimental|Orogastric intubation|Orogastric intubation using a polyurethane enteral tube followed by fixation of the tube tip to a superior molar.
89374853|NCT03670238|Active Comparator|Nasogastric intubation|Nasogastric intubation using a polyurethane enteral tube followed by fixation of the tube to the patient face.
89374854|NCT03674450|Experimental|Interventional|
89374855|NCT03114748|Experimental|EEG|2 scalp electroencephalographic (EEG) recording will be acquired in ON and OFF DBS conditions
89374856|NCT03114748|Experimental|DBS ON and OFF|DBS is turned ON and OFF in the 2 EEG sections
89374857|NCT02461784||Case|Male subjects with IBD diagnosis currently taking methotrexate (MTX) as treatment for their disease.
89374858|NCT02461784||Control|Male subjects with IBD diagnosis not exposed to methotrexate (MTX) as treatment for their disease.
88810307|NCT06214637|Experimental|Melissa officinalis 12 CH|It will be administered for a period of 30 days, once a day before bed, with a 15-day wash-out interval. This concentration that will be administered to research participants will be the biotherapeutic vehicle, that is, 30% alcohol (v/v), which is commonly used as a vehicle for homeopathic medicines.
88810308|NCT06214585|Experimental|Intermittent Heat & cold Therapy|There will be one group that will be receiving warm water application on the mother's back and then receiving ice pack application on the same region.
88810309|NCT06214585|Experimental|Heat- Only Therapy|This group of mothers will receive a warm application by hot water bag only on her back
88810310|NCT06214585|No Intervention|Control Group|This group will receive just standard care as hospital protocol
88810311|NCT06214572|Active Comparator|Systemic therapy|"Participants will receive one of the following Gemcitabine-based systemic therapy alone:~Gemcitabine plus cisplatin:~Gemcitabine 1000mg/m2 and Cisplatin 25 mg/m2, each administered on Days 1 and 8 every 3 weeks (q3w)~Gemcitabine plus oxaliplatin:~Gemcitabine 1000 mg/m2 and oxaliplatin 100 mg/m2 IV infusion on days 1 and 8 q2w.~Gemcitabine plus cisplatin plus Durvalumab:~Durvalumab 1500 mg via intravenous (IV) infusion q4w, starting on Cycle 1 in combination with cisplatin 25 mg/m2 and gemcitabine 1000 mg/m2 each administered on Days 1 and 8, q3w.~Gemcitabine plus cisplatin plus nab-paclitaxel:~Gemcitabine 800 mg/m2, cisplatin, 25 mg/m2, and nab-paclitaxel 100 mg/m2, on days 1 and 8, q3w.~duration: 3 months"
88810312|NCT06214572|Active Comparator|RT (Radiation therapy)|"Participants will receive radiation therapy in addition to systemic therapy Hypofractionated external image guided radiation to a dose of 40-55Gy in 10 sessions (up to 60Gy in 15 sessions) over 2-3 weeks.~This is followed by systemic therapy as in the Systemic therapy arm"
88810313|NCT06214533|Experimental|Never block|"Prior to the end of the laparoscopic surgery and any additional procedures, the bilateral celiac plexus block will be performed by the surgeon after identification of the aorta at the superior border of body of pancreas. A 22-gauge spinal needle will be inserted into the retroperitoneal fat on either side of the aorta under direct vision. Needle aspiration will be performed to exclude entry into vessels before administration of the interventional drug.~The block will contain 20 mL of 0.5% ropivacaine hydrochloride + 1:400000 adrenaline.~Intervention: Drug: 20 mL of 0.5% Ropivacaine"
88810314|NCT06214533|Placebo Comparator|Placebo block|"Patients in the control arm will undergo the celiac plexus block procedure as well. The block will contain 20 ml of 0.9% normal saline + 1:400000 adrenaline.~Intervention: Drug: 20 mL of 0.9% normal saline"
88810315|NCT06214520|Experimental|Intervention|Intervention Group
89374859|NCT03161782|Experimental|PNF Stretching group|Each subject in PNF Stretching group will receive a treatment protocol consisting of PNF stretching, cold therapy and exercise.
89374860|NCT03161782|Experimental|Static Stretching group|Each subject in Static Stretching group will receive a treatment protocol consisting of static stretching, cold therapy and exercise.
89374861|NCT03670082|Experimental|Group 1: Fasting condition in Period I|Subjects will be in fasting condition in Period I and in a fed condition in Period II.
89374862|NCT03670082|Experimental|Group 2: Fed condition in Period I|Subjects will be in fed condition in Period I and in fasting condition in Period II.
89374863|NCT02443220|Experimental|distal-proximal group|"TEAS (transcutaneous electric acupoint stimulation) on Danzhong and Hegu"
89374864|NCT02443220|Active Comparator|regional group|"TEAS (transcutaneous electric acupoint stimulation) on Danzhong and Juque"
89374865|NCT02443220|Sham Comparator|control group|"no TEAS (transcutaneous electric acupoint stimulation) on Danzhong and Hegu ."
89374866|NCT03163966|Experimental|CR6086 30 mg|CR6086 30 mg bid for 12 weeks as add-on to methotrexate (MTX) once weekly. MTX uptitrated to stable dosing as per standard guidelines
89374867|NCT03163966|Experimental|CR6086 90 mg|CR6086 90 mg bid for 12 weeks as add-on to MTX once weekly. MTX uptitrated to stable dosing as per standard guidelines
89181541|NCT00759356|Other|2|Treatment B (reference product) followed by Treatment A (test product)
89374868|NCT03163966|Experimental|CR6086 180 mg|CR6086 180 mg bid for 12 weeks as add-on to MTX once weekly. MTX uptitrated to stable dosing as per standard guidelines
89374869|NCT03163966|Experimental|Placebo|CR6086 matching placebo bid for 12 weeks as add-on to MTX once weekly. MTX uptitrated to stable dosing as per standard guidelines
89374870|NCT03678116|Placebo Comparator|Sugar Pill (Placebo)|Taken with 8oz of water after baseline REE and hemodynamic measurements have been taken. One of three interventions to be consumed by the subjects. One week washout period required between treatments.
89374871|NCT03678116|Experimental|Caffeine (plus Teacrine and Cayenne)|Taken with 8oz of water after baseline REE and hemodynamic measurements have been taken. One of three interventions to be consumed by the subjects. One week washout period required between treatments.
89374872|NCT03678116|Experimental|Caffeine (plus Teacrine)|Taken with 8oz of water after baseline REE and hemodynamic measurements have been taken. One of three interventions to be consumed by the subjects. One week washout period required between treatments.
89374873|NCT03163498||ACTIVE|Participating in this group will be 30 active hypertension patients who exercise at least 3 times a week for at least 30 minutes
89374874|NCT03163498||INACTIVE|Participating in this group will be 30 inactive hypertension patients who do not exercise.
89374875|NCT03768648|Experimental|patient|RRMS diagnosis according to McDonald criteria (Polman et al.,2005);
89374876|NCT03768648|Active Comparator|Control|40 Healthy controls (HC)
89374877|NCT03678038|Experimental|rotator interval injection|patient received ultrasound-guided steroid injection via rotator interval
89374878|NCT03678038|Active Comparator|posterior recess injection|patient received ultrasound-guided steroid injection via posterior recess
89374879|NCT03163420|Placebo Comparator|Placebo|placebo
89374880|NCT03163420|Experimental|Diclofenac potassium|Diclofenac potassium 50 mg
89374881|NCT04744272|Active Comparator|Intervention|Participants randomised to the intervention arm will be provided with access to the digital web-based application (app) myAsthma.
89374882|NCT04744272|No Intervention|Control|Participants randomised to the control arm will continue with standard care processes
89374883|NCT03677960|Experimental|Dose 1 - Multiple Ascending Dose(MAD)|Multiple Doses of Topical ABI-1968 cream applied by the Investigator in the clinic
88810316|NCT06214520|Active Comparator|Control 1|Control group 1
89181542|NCT04101266|Active Comparator|Interscalene nerve block|preoperative interscalene nerve block to be applied with ultrasound guidance.
89374884|NCT03677960|Experimental|Dose 2 - Multiple Ascending Dose(MAD)|Multiple Doses of Topical ABI-1968 cream applied by the Investigator in the clinic
89374885|NCT03677960|Experimental|Dose 3 - Multiple Ascending Dose(MAD)|Multiple Doses of Topical ABI-1968 cream applied by the Investigator in the clinic
89374886|NCT04440436|Experimental|IM19 CAR-T cells|IM19 CAR-T cells be administrated in two dose level
89374887|NCT01568814|Placebo Comparator|High volume PEG|Patients who are scheduled colonoscopy ingest high volume PEG(4L) for bowel preparation.
89374888|NCT01568814|Active Comparator|Low volume PEG with low residual meals|Patients who are scheduled colonoscopy ingest low volume PEG(2L) and have a prepackaged low residual meals for bowel preparation.
89374889|NCT05405686|Active Comparator|Control arm|In the control group, 225 IU of recombinant FSH will be administered in a fixed antagonist protocol.
89374890|NCT05405686|Experimental|Study arm|In the study group, 225 IU of recombinant FSH plus 112,5 IU of recombinant LH will be administered.
89374891|NCT04711122||Role of prophylactic antibiotics in childscore A|Role of prophylaxis against infections in progression of cirrhotic patients with childscore A
89374892|NCT05272696|Experimental|Experimental|"All enrolled patients will receive two cycles of chemotherapy consisting of nab-paclitaxel (260 mg/m² on days 1), cisplatin (75 mg/m² on days 1), and Pembrolizumab (200 mg on days 1). Each cycle is repeated every 21 days.~After induction therapy, patients with PR but the maximum diameter of tumor > 3cm or SD or PD can receive surgery directly. After surgery, adjuvant CRT will be given for patients with high-risk factors.~After induction therapy, patients with PR and maximum tumor diameter ≤ 3cm or CR evaluated by MDT after 2 courses induction therapy can receive CRT. Evaluation was performed 3 months after CRT. After MDT discussion, patients with high-risk factors need maintenance treatment."
89374893|NCT05563116||People living with HIV (PLHIV)|"Adults over 18 living with HIV. Participants were referred to one of our two study centers for cardiovascular assessment as part of their routine care.~PLHIV are at intermediate cardiovascular risk, they present at least one cardiovascular risk factor without established cardiovascular disease.~NB: all tests performed are part of routine care for cardiac prevention in France (no study specific interventions were performed.)"
89374894|NCT05563116||HIV negative subjects|"Adults over 18 without HIV infection. Participants were referred to one of our two study centers for cardiovascular assessment as part of their routine care.~HIV- subjects are at intermediate cardiovascular risk, they present at least one cardiovascular risk factor without established cardiovascular disease.~NB: all tests performed are part of routine care for cardiac prevention in France (no study specific interventions were performed.)"
89374895|NCT03520946|Experimental|Arm A (ramucirumab + TAS102)|Patients randomized to arm A will receive ramucirumab 8 mg/kg iv over 60 min on d1+15, q4w and TAS102 35mg/m2 p.o. twice daily (BID) d1-5 and 8-12, q4w until progression or intolerance or completion of 6 cycles.
89374896|NCT03520946|Active Comparator|Arm B (TAS102 only)|Patients randomized to arm B will receive TAS102 35mg/m2 p.o. twice daily (BID) d1-5 and 8-12, q4w until progression, intolerance or completion of 6 cycles.
89374897|NCT03677726|Experimental|Mindfulness Based Therapy for Insomnia|The mindfulness-based intervention consists of eight 2-hour sessions covering various mindfulness techniques (e.g. mindfulness of breath, body and movement, senses and informal practice, and empathy and compassion) that pertain to people with sleep problems and insomnia. Participants will be provided handouts for the information covered during these talks and discussions.
89374898|NCT03677726|Active Comparator|Sleep Hygiene Education Exercise Program|The Sleep Hygiene Education and Exercise Program has known relationships with good sleep quality. It will comprise of eight weekly 2-hour sessions. Each session will introduce a concept related to sleep and sleep hygiene. The facilitator will provide the theory and rationale behind the concept, and encourage participants to share and discuss their experiences related to the concept. The session will end with the participants evaluating how to implement the specific concept in their daily lives, and its potential implications for their sleep. Participants will be provided with a manual that outlines the concept and how they intend to apply it to their daily lives.
88810317|NCT06214520|No Intervention|Control 2|Control group 2
89002320|NCT06318897|Experimental|Pathologic Complete Response|If a participant's tissue shows a pathological complete response to treatment, participants will receive up to 13 cycles of pembrolizumab alone. Pathological complete response means that the study team cannot find any evidence of cancer in the breast or lymph node tissue sample that was removed during the participants surgery, after the participant completes the 4 cycles of carboplatin, pembrolizumab and paclitaxel.
89181543|NCT04101266|Active Comparator|suprascapular and infraclavicular nerve block|preoperative suprascapular and infraclavicular nerve block to be with ultrasound guidance
89374899|NCT03674060|Experimental|SYO-1644 100mg|SYO-1644 tablet, PO, 1 100mg tablet
89374900|NCT03674060|Experimental|SYO-1644 150mg|SYO-1644 tablet, PO, 1 100mg tablet and 1 50mg tablet
89374901|NCT03674060|Experimental|SYO-1644 200mg|SYO-1644 tablet, PO, 2 100mg tablet
89374902|NCT03674060|Active Comparator|Nexavar|Nexavar 200mg/tablet, PO, 1 tablet
89374903|NCT02049632|Experimental|Omission of axillary clearance|No axillary lymph node dissection after sentinel node biopsy and sentinel node micrometastases
89374904|NCT03163576|Experimental|study group|patients received niacin 750 mg twice daily up to 2000 mg in addition to usual phosphate binders .
89374905|NCT03163576|Active Comparator|control group|patients received usual phosphate binders .
89374906|NCT01971008|Experimental|Elastic abdominal binder, then placebo binder|"Patients in this arm will be invited to wear an elastic abdominal binder (Abdosyncro Abdominalbandage, Syncro Med GmbH) for 2 hours on day 1 and a placebo binder (Clima Care Body warmer, Bort Medical) for 2 hours on day 3, after wash-out on day 2"
89374907|NCT01971008|Experimental|Placebo binder, then elastic abdominal binder|"Patients in this arm will be invited to wear a placebo binder (Clima Care Body warmer, Bort Medical) for 2 hours on day 1 and an elastic abdominal binder (Abdosyncro Abdominalbandage, Syncro Med GmbH) for 2 hours on day 3, after wash-out on day 2"
88810318|NCT06214507||Prospective|
88810319|NCT06214507||Retrospective only|
89002321|NCT06318897|Experimental|Non-Pathologic Complete Response|If a participant's tissue does not show a pathological complete response, the participant will receive 4 cycles of pembrolizumab plus 2 other drugs (doxorubicin and cyclophosphamide), followed by 9 cycles of pembrolizumab alone.
89002322|NCT06318871|Experimental|Dose Level 0: CIML NK + N-803|"Participants will be enrolled in a staggered fashion into a 3+3 dose de-escalation design per protocol to establish a maximum tolerated dose (MTD) of CIML NK Cells. Dose will start at Dose Level 0.~Baseline visit.~Day -7: Apheresis for autologous NK cell collection.~Days -6 through -2: Predetermined dose of standard of care lymphodepleting chemotherapy per protocol.~Days 0: Predetermined dose of CIML NK Cell Therapy infusion 1x daily administered in-clinic or hospital.~Days 1, 7, 14, 35, 56, 77, and 98: Predetermined dose of N-803 1x daily.~Day 28 and then ever 2-3 months: CT/MRI/PET~In-clinic visit every 3 months with CT, MRI, or PET scan.~End of Treatment: in-clinic visit~Follow Up: every 4 months in-clinic, by telephone, or remotely.~If 2 or more out of 5 participants experience dose-limiting toxicities (DLTs), subsequent dose will be de-escalated to Dose Level -1."
89002323|NCT06318871|Experimental|Dose Level -1: CIML NK + N-803|"Participants will complete:~Baseline visit.~Day -7: Apheresis for autologous NK cell collection.~Days -6 through -2: Predetermined dose of standard of care lymphodepleting chemotherapy per protocol.~Days 0: Predetermined dose of CIML NK Cell Therapy infusion 1x daily administered in-clinic or hospital.~Days 1, 7, 14, 35, 56, 77, and 98: Predetermined dose of N-803 1x daily.~Day 28 and then ever 2-3 months: CT/MRI/PET~In-clinic visit every 3 months with CT, MRI, or PET scan.~End of Treatment: in-clinic visit~Follow Up: every 4 months in-clinic, by phone, or remotely.~If 1 or less DLTs are observed, this will be the maximum tolerated dose. If 2 or more DLTs are observed, accrual will stop."
89002324|NCT06318858|Experimental|Group 1 daily iron supplementation|"12.5 mg daily iron syrup supplementation from 6-9 months old, followed by 12.5 mg weekly iron syrup supplementation from 9-12 months old.~Infants aged 6-9 months will receive two iron syrup bottles. One bottle aims for ingestion every Monday of the week, and one bottle aims for ingestion on other days of the week.~At ages 9-12 months, infants will receive an iron syrup bottle that aims for ingestion every Monday of the week."
89002325|NCT06318858|Other|Group 2 weekly iron supplementation|"12.5 mg weekly iron syrup supplementation from 6-12 months old. Infants aged 6-9 months will receive an iron syrup bottle that aims for ingestion every Monday of the week and a placebo bottle that aims for ingestion on other days of the week.~At ages 9-12 months, infants will receive an iron syrup bottle that aims for ingestion every Monday of the week."
89002326|NCT06318845|Experimental|Sequence A|DHP2302R1 75 mg once daily for 7 days, followed by 2 weeks of washout period; then DHP2302R2 50 mg once daily for 7 days, followed by 2 weeks of washout period; then DHP2302R1 75 mg+DHP2302R2 50 mg once daily for 7 days
89002327|NCT06318845|Experimental|Seqeunce B|DHP2302R1 75 mg once daily for 7 days, followed by 2 weeks of washout period; then DHP2302R1 75 mg+DHP2302R2 50 mg once daily for 7 days, followed by 2 weeks of washout period; then DHP2302R2 50 mg once daily for 7 days
89002328|NCT06318845|Experimental|Sequence C|DHP2302R2 50 mg once daily for 7 days, followed by 2 weeks of washout period; then DHP2302R1 75 mg+DHP2302R2 50 mg once daily for 7 days, followed by 2 weeks of washout period; then DHP2302R1 75 mg once daily for 7 days
89002329|NCT06318845|Experimental|Sequence D|DHP2302R2 50 mg once daily for 7 days, followed by 2 weeks of washout period; then DHP2302R1 75 mg once daily for 7 days, followed by 2 weeks of washout period; then DHP2302R1 75 mg+DHP2302R2 50 mg once daily for 7 days
89002330|NCT06318845|Experimental|Seqeunce E|DHP2302R1 75 mg+DHP2302R2 50 mg once daily for 7 days, followed by 2 weeks of washout period; then DHP2302R2 50 mg once daily for 7 days, followed by 2 weeks of washout period; then DHP2302R1 75 mg once daily for 7 days
89002331|NCT06318845|Experimental|Seqeunce F|DHP2302R1 75 mg+DHP2302R2 50 mg once daily for 7 days, followed by 2 weeks of washout period; then DHP2302R1 75 mg once daily for 7 days, followed by 2 weeks of washout period; then DHP2302R2 50 mg once daily for 7 days
89374908|NCT04058912||PATİENCE GROUP|"To be in the range of 18-40 years~Patients with an operation indication with >=5 cm endometrioma~Symptomatic patients due to endometrioma (dysmenorrhea, dyspareunia, chronic pelvic pain, etc.)~Patients who will be followed for IVF cycle due to infertility"
89374909|NCT04058912||PATİENCE-CONTROL GROUP|"To be in the range of 18-40 years~Patients with operation plan due to non-endometrioma ovarian pathologies~Symptomatic patients with benign ovarian pathology (such as chronic pelvic pain, compression, syphilomas, dysmenorrhea, dyspareunia, etc.)~Asymptomatic, despite a 6-month follow-up period, increase in cyst size or become symptomatic"
89374910|NCT02781870|Other|No-fixation|These patients will be randomized during the operation, at the time of mesh placement to receive the 3D ENDOLAP visible without fixation.
89374911|NCT02781870|Experimental|LiquiBand Fix glue fixation|"These patients will be randomized during the operation, at the time of mesh placement to receive the 3D ENDOLAP visible with LiquiBand® Fix 8™ glue fixation.~Patients will be operated in a standard procedure to receive the 3D ENDOLAP visible with LiquiBand® Fix 8™ glue fixation."
89374912|NCT03673982|Experimental|iCASK Group|Materials and support to aid transitions.
89374913|NCT04759846|Experimental|Group with normal hepatic function|Normal hepatic function
89374914|NCT04759846|Experimental|Group with moderate hepatic impairment|Moderate hepatic impairment (Child-Pugh Class B)
89374915|NCT04759846|Experimental|Group with severe impairment|Severe impairment (Child-Pugh Class C)
89374916|NCT01810718|Experimental|Nilotinib|"3 patients (pts) will receive Nilotinib 200 mg daily dose. If no dose-limiting toxicity, the next 3 pts will be treated with next dose of Nilotinib 300 mg daily dose.~Doses will not be escalated beyond 600 or below 200 mg/die. The dose estimated as the MTD in phase I will be used for phase II."
89374917|NCT01776164||Patient with FRDA|Patients affected by Friedreich's ataxia
89374918|NCT01776164||Healthy controls|Healthy volunteers age- and gender-matched with no neurological disease identified.
89374919|NCT01383798|Placebo Comparator|Placebo|Red capsule (50 mg) lactose
89374920|NCT01383798|Experimental|Ferrous sulfate|
88810320|NCT06214468|Other|Tylenol and Nicotinamide Riboside|
88810321|NCT06214468|Active Comparator|Tylenol Only|
89374921|NCT01644578|Other|Real-time imaging for MRI-guided procedures|Real-time imaging for improvement of workflow in MRI-guided procedures
89374922|NCT03673904||Prediabetics|Ages ranging from 18 to 60 years old,males and females were included . A fasting blood glucose level (100 to 125 mg/dL). or A 2-hour blood glucose level (140 to 199 mg/dL) .or Hb A1C 5.7% to 6.4%.
89374923|NCT03673904||Newly diagnosed type 2 diabetes|Ages ranging from 18 to 60 years old,males and females were included Newly diagnosed type 2 diabetes: (maximum within one month from diagnosis) A fasting blood glucose level >126 mg/dl A 2-hour blood glucose level > 200 mg/d Hb A1C > 6.5%
89374924|NCT01374178|Experimental|LY2963016|A single 0.5-unit per kilogram (U/kg) dose of LY2963016 will be administered subcutaneously.
89374925|NCT01374178|Active Comparator|Lantus|A single 0.5-U/kg dose of Lantus will be administered subcutaneously.
89374926|NCT03673592||Euploid embryos analyzed by PGT-A|Embryos with a normal chromosome copy number. This embryos will be transferred to the uterus.
88846729|NCT03989570|Active Comparator|Group II (B group)|31patients Will undergo TAP block with 40 ml bupivacine 0.25% (20 ml on each side), and ESP block with 40 ml saline 0.9% (20 ml on each side).
88846730|NCT03989570|Placebo Comparator|Group III (C group)|31 patients anesthetized with the protocol followed by Minia University Hospital
88846731|NCT03273673|Experimental|Biofeedback Intervention|The 6-week biofeedback training program is focused on altering loading and movement asymmetry during biweekly sessions on non-consecutive days (12 sessions). The biofeedback training program will provide sensory (visual and tactile) feedback to the subject to heighten awareness of asymmetrical movement strategies (e.g. load shift, movement asymmetry) during a squat. The two exercises that will be completed during the biofeedback training program will be a visual feedback squat and a resisted squat (tactile feedback). Each of these tasks will be completed 30 (3 sets of 10 repetitions) times per session. We will provide a 20 second rest between trials, and a 10 minute break between the visual and tactile feedback exercises to decrease the effect of fatigue.
88846732|NCT03273673|No Intervention|Control|The 6-week attention control group program will focus on providing educational information to the participants related to the clinical and sports expectations as they are released to return to sport. These participants will be asked to meet 6 times during the 6-week intervention time period. Three of these visits will be completed in person and three will be completed using an online educational module (6 sessions). The online sessions will be completed in week 1, week 3, and week 5 while the in person sessions will be completed during week 2, week 4, and week 6.
88846733|NCT04331990|Active Comparator|Standard Physical Therapy|Control group for the study. Intervention in the form of warm-up and strengthening, stretching and neuromuscular control exercises.
88846734|NCT04331990|Experimental|Intermittent Mechanical Traction|Standard care in addition to intermittent mechanical distraction of the knee joint.
88846735|NCT04331990|Experimental|Continuous Mechanical Traction|Standard care in addition to continuous mechanical distraction of the knee joint
88846736|NCT03512041|Experimental|RLIC - 5 Cycles|Remote Limb Ischemic Conditioning (RLIC) is achieved via blood pressure cuff inflation to 20 mmHg above systolic blood pressure on the non-dominant arm. 5 Cycles of RLIC requires 45 minutes and involves 5 cycles of 5 minutes blood pressure cuff inflation followed by alternating 5 minutes of cuff deflation. RLIC is performed on visits 1-7.
88846737|NCT03512041|Experimental|RLIC - 4 Cycles|RLIC is achieved via blood pressure cuff inflation to 20 mmHg above systolic blood pressure on the non-dominant arm. 4 Cycles of RLIC requires 35 minutes and involves 4 cycles of 5 minutes blood pressure cuff inflation followed by alternating 5 minutes of cuff deflation. RLIC is performed on visits 1-7.
88846738|NCT03512041|Experimental|RLIC - 3 Cycles|RLIC is achieved via blood pressure cuff inflation to 20 mmHg above systolic blood pressure on the non-dominant arm. 3 Cycles of RLIC requires 25 minutes and involves 3 cycles of 5 minutes blood pressure cuff inflation followed by alternating 5 minutes of cuff deflation. RLIC is performed on visits 1-7.
89181544|NCT04113941|Experimental|Neuronox®|Neuronox® total 100U, inject 5U/0.5mL per site, 20 sites
89181545|NCT04113941|Placebo Comparator|Placebo|Normal saline, same volume with Experimental arm
89374927|NCT03673592||Low-grade mosaic embryos (PGT-A)|Embryos with a lower aneuploidy percentage (<50%). This embryos will be considered for transfer to the uterus.
89374928|NCT03673592||High-grade mosaic embryos (PGT-A)|Embryos with a high aneuploidy percentage (50-70%). This embryos will be discarded for transfer.
89374929|NCT03673592||Aneuploid embryos analyzed by PGT-A|Embryos with an abnormal number of chromosomes. This embryos will be discarded for transfer.
89374930|NCT03161314|Experimental|(Sub-project 1)PHP / (Sub-project 3)Strengthening|
89374931|NCT03161314|Active Comparator|(Sub-project 1)Normal healthy / (Sub-project 3)Stretching|(Sub-project 3) Conservative physical therapy treatment with stretching exercise
89374932|NCT03163108|No Intervention|RMC only|routine manual control (RMC) of the fraction of inspired oxygen (FIO2)
89374933|NCT03163108|Active Comparator|CLAC slow|"routine manual control (RMC) + Closed-loop automatic oxygen control (CLAC) with 180sec WAIT-Interval (slow algorithm) of the fraction of inspired oxygen (FIO2)"
89374934|NCT03163108|Experimental|CLAC fast|"routine manual control (RMC) + Closed-loop automatic oxygen control (CLAC) with 30sec WAIT-Interval (fast algorithm) of the fraction of inspired oxygen (FIO2)"
89374935|NCT03161392||Ductal lesion|Subjects with a ductal lesion detected on ultrasonography.
89374936|NCT03161392||No ductal lesion|Subjects without a ductal lesion detected on ultrasonography
89374937|NCT03161470|Active Comparator|Standard Repositioning|Participants randomly selected for this treatment arm will undergo standard BPPV treatments (canalith repositioning procedure) without the mechanical chair.
89374938|NCT03161470|Experimental|Mechanical Chair Repositioning|Participants randomly selected for this treatment arm will undergo standard BPPV treatments (canalith repositioning procedure) with the mechanical chair.
89374939|NCT03161470|Sham Comparator|Sham Treatment|Participants randomly selected for the sham arm will undergo be strapped into the mechanical chair as for the treatment arm but will only undergo the test positions for BPPV-the Dix-Hallpike maneuver. No BPPV repositioning treatment will be completed at the first encounter. At the follow-up visit, standard BPPV treatments (canalith repositioning procedure) will be completed.
89374940|NCT03161548|Experimental|Induction chemotherapy|Induction chemotherapy will be given every 21 days, with the DCU regimen, followed by tongue conservation surgery, and postoperative CCRT as indicated.
89181546|NCT04102592|Experimental|Intervention Group|Participants in this arm receive Lesu (baby wrap) treated with 0.5% permethrin
89181547|NCT04102592|Placebo Comparator|Control Group|Participants in this arm receive Lesu (baby wrap) soaked with water only to mimic re-treatment and mask allotment
89374941|NCT03025542|Experimental|Treatment Arm 1|Subjects randomized in this arm will receive a combination of Bimekizumab and Placebo injections.
89374942|NCT03025542|Experimental|Treatment Arm 2|Subjects randomized in this arm will receive Bimekizumab injections.
89374943|NCT03114436||Consented deceased organ donors|Includes neurological determination of death (DND) and by circulatory determination of death (DCD).
89374944|NCT03673514|Active Comparator|THA Posterior Approach|The posterior approach to the hip has been described by many authors and yields good results. Implants used were Quadra®-H stem and Versacup® hip system, Medacta, Switzerland, with metal on polyethylene bearing. All implants were non-cemented.
89181548|NCT04113473|Experimental|Yoga Group|Experimental group received individualised yoga therapy twice a week for an hour for 12-weeks.
89181549|NCT04113473|No Intervention|Control Group|Control group were given education session and continued on usual care for 12-weeks.
89374945|NCT03673514|Active Comparator|THA Direct anterior approach|The modified Hueter approach, based on the Smith-Peterson approach, was performed for the direct anterior minimally invasive surgery. This approach could have some advantages as it is a muscle sparing approach, hence yielding a faster recovery. A traction table was used for DAA as surgeons were trained to use this method. No intra-operative fluoroscopy was used for implant confirmation.Implants used were Quadra®-H stem and Versacup® hip system, Medacta, Switzerland, with metal on polyethylene bearing. All implants were non-cemented.
89374946|NCT03161236|Experimental|home exercise program|• The exercise group will follow a home exercise protocol for eight weeks: that involves standing on one foot, walking, and doing wall squats.
89374947|NCT03161236|Active Comparator|non exercise group|• The non-exercise group will continue with their usual life style
89374948|NCT03673436||Patients with low back pain|Cohort of 200 low back pain patients, 18 years+, who have been undergoing a lumbar spinal fusion
89374949|NCT03114514|Experimental|PRP injection|A PRP-injection will be performed three times during the course of treatment
89374950|NCT03673358|Experimental|Intervention - CBT|Participants in this arm will receive cognitive behavioural therapy. Participants will have the choice of completing six real-time telephone or video-delivered CBT sessions with a therapist OR complete online modules with asynchronous feedback with a dedicated therapist in addition to standard of care for their fracture injury.
89374951|NCT03673358|No Intervention|No intervention- - control|Participants in the control arm of the study will receive standard of care treatment for their fracture(s) but will not receive any Cognitive Behavioral Therapy.
89374952|NCT03114358|Experimental|Early carbapenems de-escalation|De-escalation carbapenems within 24 hours or no later than 72 hours of prescription by Infectious disease specialist (early de-escalation).
89374953|NCT03114358|No Intervention|Late carbapenems de-escalation|De-escalation followed the hospital policy in which carbapenems were evaluated by ID specialist at 72 hours of admission (late de-escalation). De-escalation may occurred earlier depends upon the decision of the primary care team
89374954|NCT03669692|Active Comparator|Control|Patients in the control group will be assigned to a free diet (ad libitum), according to the Spanish Association of Urology lifestyle recommendations for patients with LUTS
89374955|NCT03669692|Experimental|Caloric Restriction|"Patients in the experimental group will be assigned to intermittent caloric restriction, based on an early time restricted eating, with a 16/8 fasting/feeding scheme.~The patients in this group will have a RC progressive scheme until achieve a maximum of 5 days a week of fasting."
89374956|NCT03161002||wild genotype|Through next generation sequencing, distinguish wild genotype of ticagrelor
89374957|NCT03161002||mutant genotype|Through next generation sequencing, distinguish mutant genotype of ticagrelor
89374958|NCT03669848||Pulse CO-oximetry|Measuring blood Carbon Monoxide levels with Pulse CO-oximetry (SpCO) Measurements are taken with a noninvasive method by placing a sensor on a patient, usually on the fingertip.
89374959|NCT05746312|Experimental|Multiple-baseline study|All participants in this study received the same protocol. First, we had a baseline control period (no intervention) during which we assessed state anxiety levels every two minutes. Subsequently, we administered the intervention and continued to assess state anxiety at two minute intervals. Participants were randomized to baseline periods that varied in length (10,12,14, or 16 minutes of baseline).
89374960|NCT03673280|Placebo Comparator|Classical spinal anesthesia|Patients allocated to this group will receive spinal anesthesia with bupivacaine 12.5mg, Fentanyl 20mcg and Morphine 80mcg + placebo quadratus lumborum block.
89374961|NCT03673280|Experimental|Spinal anaesthesia with block|Patients allocated to this group will receive spinal anesthesia with bupivacaine 12.5mg, Fentanyl 20mcg + quadratus lumborum block.
89374962|NCT03673280|Experimental|Classical anaesthesia plus block|Patients allocated to this group will receive spinal anesthesia with bupivacaine 12.5mg, Fentanyl 20mcg and Morphine 80mcg + quadratus lumborum block.
89374963|NCT04612062|Experimental|Healthy Subjects (Part A)|CEE321 0.2% (3 mg/cm2) topical cream b.i.d.
89374964|NCT04612062|Experimental|Atopic Dermatitis (Part B)|CEE321 0.2% (3 mg/cm2) topical cream b.i.d.
88810322|NCT06214455|Active Comparator|low sugar diet and 10-12 hour eating window|A) Eat a low sugar diet, 10-12 hour eating window for four weeks
88810323|NCT06214455|Active Comparator|Eat a low sugar diet, 8 hour eating window and fasting|B) Eat a low sugar diet, 8 hour eating window and fasting (one 36-60 hour water fast per week) for four weeks
88810324|NCT06214442||Physically active eumenorrheic women with regular menstrual cycle|Women who practice physical exercise and have regular menstruation ranging from 25 to 38 days.
88810325|NCT06214442||Sedentary eumenorrheic women with regular menstrual cycle|Women who do not practice physical exercise and have regular menstruation ranging from 25 to 38 days.
88810326|NCT06214442||Physically active women using hormonal contraceptives|Physically active women using oral hormonal contraception combined with estrogen and progesterone within the last six months.
89374965|NCT03167788|Experimental|Intervention|Cross-matched allogeneic stored red cells will be rejuvenated using rejuvesol® Red Blood Cell Processing Solution (Citra Labs, MA, a Zimmer Biomet Company, IN, USA) with washing and re-suspension in an additive solution prior to transfusion. The rejuvenated red cells will then be administered to the patient as per standard practice and according to established institutional protocols. A maximum of 6 rejuvenated red cell units will be transfused within any 24 hour period.
89374966|NCT03167788|Active Comparator|Control|Standard care i.e. Cross-matched allogeneic stored non-rejuvenated, unwashed red cells will be administered to the patient as per standard practice and according to established institutional protocols.
89374967|NCT03673202||UC monitoring patients|Patients undergoing investigative cystoscopy for the detection of urothelial carcinoma as part of a standard-of-care schedule of investigations. All patients will have urine samples taken and analyzed for urine cytology and Cxbladder. No results for any tests under evaluation in this study are provided to the clinician for diagnostic purposes.
89374968|NCT01383642||individuals age >=70|
89374969|NCT03167944|Experimental|Conventional electrocautery|
89374970|NCT03167944|Experimental|Low thermal electrosurgery system|
89374971|NCT03036254|Experimental|HBOT intervention|The multiplace HBOT unit at Asaf Harofeh. The inside looks like an airplane, with comfortable chairs for 11 subjects and the nurse who stays throughout the session. The HBOT protocol is 90 minutes, 5 times/week, 60 sessions, 100% oxygen at 2 ATA with 5 minute air breaks every 30 minutes.
88846739|NCT03512041|Sham Comparator|Sham Conditioning|Sham conditioning is achieved via blood pressure cuff inflation to 10 mmHg under diastolic blood pressure on the non-dominant arm. Sham conditioning requires 45 minutes and involves 5 cycles of 5 minutes blood pressure cuff inflation followed by alternating 5 minutes of cuff deflation. Sham conditioning is performed on visits 1-7.
89374972|NCT03036254|Sham Comparator|Sham intervention|Except for pressure, all the conditions of the HBOT intervention are provided in the sham intervention (nurse measures vitals and asks about health before entering the chamber, time in the chamber, number of sessions per week and overall, nurse in the chamber at all times, mask on the face, etc.).
89374973|NCT03631212|No Intervention|Waitlist control|Wait-list control group
89374974|NCT03631212|Experimental|Flexiquit|Digital ACT-based intervention for smoking cessation
89374975|NCT03162874|Placebo Comparator|PLACEBO|
89374976|NCT03162874|Experimental|PXT002331 - 10mg|
89374977|NCT03162874|Experimental|PXT002331 - 30mg|
89374978|NCT03672890||Pre-Telestroke|Retrospective collection of defined metrics for all ischemic stroke patients admitted to the participating ASRH 2 years prior to implementation of an inpatient telestroke service.
89181550|NCT00721734|Experimental|Carfilzomib|"Carfilzomib, 15 mg/m², was administered intravenously (IV) on Days 1, 2, 8, 9, 15, and 16 of repeated 28-day cycles for a maximum of 12 cycles.~If the 15 mg/m² dose was tolerated the dose could be increased to 20 mg/m² starting at Cycle 2. If 20 mg/m² was tolerated, an additional dose escalation to 27 mg/m² was allowed at Cycle 3 or at subsequent cycles."
89374979|NCT03672890||Post-Telestroke|Prospective collection of defined metrics for all ischemic stroke patients admitted to the participating ASRH after implementation of an inpatient telestroke service.
89374980|NCT05420220|Experimental|KN046+Axitinib|Eligible subjects will receive KN046 5 mg/kg Q3W IV in combination with Axitinib 5 mg bid po, until progressive disease as judged by the investigator per RECIST v1.1
89374981|NCT03022370|Experimental|Stepping Stones and Creating Futures|Participants receive the Stepping Stones and Creating Futures intervention, comprising of 21 participatory/inter-active sessions, delivered by a trained facilitators. Each session last approximately 3 hours. Sessions are delivered twice a week. Sessions are primarily single sex, with 20 participants per group.
89374982|NCT03022370|No Intervention|Wait-list control|Participants receive no intervention until after final data collection occurs, at which point they will be offered Stepping Stones and Creating Futures.
89374983|NCT03631758|Experimental|Experimental: Evidence + PDA|Evidence-based information on mammography such as blog posts, plain language evidence summaries and web resource ratings (quality-appraised online resources), plus a blog post on PDAs and the relevant decision aid from the Portal database
89374984|NCT03631758|Experimental|Evidence only|The same evidence-based information as group 1 (Evidence + PDA), but without the PDA to quantify the effect of accessing evidence through the Portal alone
89181551|NCT04113551||Cohort T1: Methylphenidate (MPH) (Concerta)|Analysis of data will be performed for participants who have had first exposure of MPH (Concerta) and who were never exposed to MPH (Ritalin) between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure.
89374985|NCT03631758|Sham Comparator|Attention control|Information on how to distinguish high from low-quality health information, not specific to cancer screening or PDAs
89374986|NCT02642562|No Intervention|Standard care|Participants in this arm will receive their usual care
89374987|NCT02642562|Experimental|Standard care plus IV iron infusion|"Iron to be administered as iron (III) isomaltoside 1000 / ferric derisomaltose.~Infused over a minimum of 15 mins for doses up to and including 1000mg, and a minimum of 30 mins for doses >1000mg~Where Hb ≥10 g/dL, dosage according to body weight is as follows:~Body weight <50 kg: 20 mg/kg; Body weight 50 to <70 kg: 1000 mg; Body weight ≥70 kg: 20 mg/kg up to a maximum of 1500 mg.~Where Hb <10 g/dL, dosage according to body weight is as follows:~Body weight <50 kg: 20 mg/kg; Body weight 50 to <70 kg: 20 mg/kg; Body weight ≥70 kg: 20 mg/kg up to a maximum of 2000 mg."
89374988|NCT03623204||Patients with bariatric surgery for obesity|
89374989|NCT04601610|Experimental|Cohort 1|Subjects who have not received first-line system treatment previously;
89374990|NCT04601610|Experimental|Cohort 2|Subjects who have received at least first-line system treatment
89374991|NCT02490306|Experimental|Hemorrhagic stroke|"Patient group A is defined as patients that are diagnosed with hemorrhagic stroke.~Interventions: Strokefinder MD100 measurement"
89374992|NCT02490306|Experimental|Ischemic stroke|"Patient group B is defined as patients that are diagnosed with ischemic stroke.~Interventions: Strokefinder MD100 measurement"
89374993|NCT02490306|Experimental|Stroke mimics|"Patient group C is defined as patients with stroke mimics, i.e. with initially suspected stroke but not diagnosed with stroke.~Interventions: Strokefinder MD100 measurement"
89374994|NCT03668912|Experimental|Guided participation group|
89374995|NCT03668912|No Intervention|Usual care group|
88846740|NCT03053960||Diagnostic (helical CT, PET/CT, MRI, CBCT)|Patients undergo helical (Computed Tomography) CT,(Positron Emission Tomography and Computed Tomography) PET/CT, (Magnetic Resonance Imaging) MRI, and (Cone-Beam Computed Tomography) CBCT scans. Patients also undergo therapeutic conventional surgical resection of tumor.
88846741|NCT05313386|Experimental|Cohort 1- 120 Micrograms|"120 Micrograms film or Placebo film are given to patients in 3:1 ratio respectively.~Repeat doses may be administered in increments of 120 μg every 3 to 6 hours post first dose (StartD) only if the RASS score remains ≥ +1. For subjects 65 years and older, repeat doses may start in increments of 60 μg every 3 to 6 hours post first dose only if RASS is still ≥+1."
88846742|NCT05313386|Experimental|Cohort 2- 180 Micrograms|"180 Micrograms film or Placebo film are given to patients in 3:1 ratio respectively.~Repeat doses may be administered in increments of 120 μg every 3 to 6 hours post first dose (StartD) only if the RASS score remains ≥ +1. For subjects 65 years and older, repeat doses may start in increments of 60 μg every 3 to 6 hours post first dose only if RASS is still ≥+1."
88846743|NCT05313386|Experimental|Cohort 3- 240 Micrograms|"Two 120 Micrograms films or two Placebo films are given to patients in 3:1 ratio respectively.~Repeat doses may be administered in increments of 120 μg every 3 to 6 hours post first dose (StartD) only if the RASS score remains ≥ +1. For subjects 65 years and older, repeat doses may start in increments of 60 μg every 3 to 6 hours post first dose only if RASS is still ≥+1."
88846744|NCT05313386|Experimental|Cohort 4- 300 Micrograms|"One 120 Micrograms film and one 180 Micrograms film or two Placebo films are given to patients in 3:1 ratio respectively.~Repeat doses may be administered in increments of 120 μg every 3 to 6 hours post first dose (StartD) only if the RASS score remains ≥ +1. For subjects 65 years and older, repeat doses may start in increments of 60 μg every 3 to 6 hours post first dose only if RASS is still ≥+1."
88846745|NCT03274999|Experimental|TrueTear™ Intranasal then Extranasal Application|TrueTear™ device, intranasal (test) application, for approximately 3 minutes on Day 0 followed by TrueTear™ device, extranasal (control) application, for approximately 3 minutes on Day 14.
88846746|NCT03274999|Experimental|TrueTear™ Extranasal then Intranasal Application|TrueTear™ device, extranasal (control) application, for approximately 3 minutes on Day 0 followed by TrueTear™ device, intranasal (test) application, for approximately 3 minutes on Day 14.
88846747|NCT04018664|Placebo Comparator|Placebo|"Placebo~150 mL flavored beverage"
88846748|NCT04018664|Experimental|90 mg nalbuphine HCl solution|"90 mg nalbuphine HCl solution~9 mL × 10 mg/mL hydromorphone HCl + 141 mL flavored beverage"
88846749|NCT04018664|Experimental|120 mg nalbuphine HCl solution|"120 mg nalbuphine HCl solution~12 mL × 10 mg/mL hydromorphone HCl + 138 mL flavored beverage"
88846750|NCT04018664|Experimental|150 mg nalbuphine HCl solution|"150 mg nalbuphine HCl solution~15 mL × 10 mg/mL hydromorphone HCl + 135 mL flavored beverage"
88846751|NCT04018664|Experimental|180 mg nalbuphine HCl solution|"180 mg nalbuphine HCl solution~18 mL × 10 mg/mL hydromorphone HCl + 132 mL flavored beverage"
88846752|NCT04018664|Experimental|270 mg nalbuphine HCl solution|"270 mg nalbuphine HCl solution~27 mL × 10 mg/mL hydromorphone HCl + 123 mL flavored beverage"
88846753|NCT04018664|Experimental|Up to 405 mg nalbuphine HCl solution|"Up to 405 mg nalbuphine HCl solution~Up to 40.5 mL × 10 mg/mL hydromorphone HCl + at least 109.5 mL flavored beverage"
88846754|NCT04018664|Experimental|Up to 540 mg nalbuphine HCl solution|"Up to 540 mg nalbuphine HCl solution~Up to 54 mL × 10 mg/mL hydromorphone HCl + at least 96 mL flavored beverage"
89374996|NCT01382004|Active Comparator|Penicillin-G-Benzathine|penicillin-G-Benzathine : 50,000 UI/Kg single dose(maximum 2.4 million units IM)
89374997|NCT01382004|Experimental|Azithromycin|Azithromycin: 30 mg/kg single dose (Maximum: 2.000 mg.)
89374998|NCT03669224|Experimental|Nano Care Gold|Silver and Gold nano particles suspended in 70 % isopropyl alcohol. It will be used for cavity pre-treatment. This arm will be compared with no intervention (negative control).
89374999|NCT03669224|Active Comparator|Chlorhexidine|2% chlorhexidine gluconate solution will be applied to prepared cavity followed by adhesive system then resin composite. This arm will be compared with no intervention (negative control).
89375000|NCT04584528|Other|EHR-embedded Individualized Pain Plan (IPP)|The EHR embedded IPP will be made accessible to patients and ED providers at each study site.
89375001|NCT03669458|Experimental|Arm 1: BTK intervention with SPUR/DCB|Below the knee peripheral intervention using SPUR/DCB.
89375002|NCT03669458|Experimental|Arm 2: BTK intervention using SPUR Only|Below the knee peripheral intervention using SPUR only.
89375003|NCT03669458|Experimental|ARM 3: BTK intervention using DCB Only|Below the knee peripheral intervention using DCB only.
89375004|NCT01381848|Experimental|001|Doripenem Type=exact number unit=mg/kg number=5 form=solution for injection route=intravenous use once on Day 1 for patients <8 weeks CA.,Doripenem Type=exact number unit=mg/kg number=8 form=solution for injection route=intravenous use once on Day 1 for patients >=8 weeks CA.
89375005|NCT03668834|Active Comparator|Dermabrasion with NCES|Intervention-Dermabrasion with autologous non cultured epidermal cell suspension Recipient site preparation using dermabrasion followed by autologous non cultured epidermal cell suspension technique of 1 stable vitiligo patch of each of the 36 patients.
89375006|NCT03668834|Active Comparator|Dermaroller with NCES|Intervention-Dermaroller with autologous non cultured epidermal cell suspension Recipient site preparation using dermaroller system followed by autologous non cultured epidermal cell suspension technique of 1 stable vitiligo patch of each of the 36 patients.
89375007|NCT03668834|Active Comparator|Liquid nitrogen induced blister with NCES|Liquid nitrogen induced blister with autologous non cultured epidermal cell suspension Recipient site preparation using liquid nitrogen induced blister followed by autologous non cultured epidermal cell suspension technique of 1 stable vitiligo patch of each of the 36 patients.
89375008|NCT04546620|Active Comparator|Arm A Control|6 cycles of standard R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone) immunochemotherapy every 21 days.
88846755|NCT03763058|Other|Music intervention|The music intervention is administered via a smartphone- (and computer-) based application called Music Care.
89375009|NCT04546620|Experimental|Arm B Experimental|1 cycle of standard R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone) immunochemotherapy followed by 5 cycles of R-CHOP + acalabrutinib taken twice daily for 21 day cycles.
89375010|NCT03021668|Experimental|Prevena Peel & Place Dressing for wound closure|In the participants randomized to this arm the surgical site will be closed using Prevena Peel & Place Dressing.
89375011|NCT03021668|Placebo Comparator|Standard closure of the wound|In the participants randomized to this arm the surgical site will be closed using the standard closure technique.
89375012|NCT03668756||Computer-Assisted Navigation TKA|the patients who were received CAS TKA in one limb
89375013|NCT03668756||Conventional TKA|the patients who were received conventional TKA in one limb
89375014|NCT03669380||conservative treatment|Conservative treatment consisted of bowel rest, intravenous fluid therapy, nutritional support, strict blood pressure control, anticoagulation (with or without antiplatelet) and close observation
89375015|NCT03669380||Interventional and surgical treatment|Interventional and surgical treatment
89375016|NCT03669068||Elective endoscopy|Patients undergoing gastrointestinal endoscopy unrelated to anticoagulant-induced gastrointestinal bleeding.
89375017|NCT03669068||Gastrointestinal bleeding|Patients with anticoagulant-induced gastrointestinal bleeding will be analyzed separately
89375018|NCT03668678|Experimental|iGrow Readers Curriculum|The iGrow Readers nutrition and physical activity curriculum was implemented in early-childhood classrooms assigned to the IGrow Readers intervention group.
89375019|NCT03668678|No Intervention|Standard Curriculum|The standard curriculum was provided within early-childhood classrooms assigned to the control group.
89375020|NCT03668990|Other|persons with Multiple Sclerosis (MS)|"25 persons with MS Persons perform funtional-oriented upper limb movments while wearing IMUs (Xsens, MVN Studio). This is a full-body human measurement system based on inertial sensors, biomechanical models and sensor fusion algorithms applied in neurological patients for measuring upper limb movements.~Funcitonal-oriented upper limb movements are performed at two different test days."
89375021|NCT03668990|Other|stroke patients|"25 stroke patients Persons perform funtional-oriented upper limb movments while wearing IMUs (Xsens, MVN Studio). This is a full-body human measurement system based on inertial sensors, biomechanical models and sensor fusion algorithms applied in neurological patients for measuring upper limb movements.~Funcitonal-oriented upper limb movements are performed at two different test days."
88846756|NCT03031340|Placebo Comparator|Placebo|
88846757|NCT03031340|Experimental|Pregabalin|
88846758|NCT03760796|Experimental|Corrie Health Digital Platform group|Receives the Corrie Health intervention plus the standard of care
88846759|NCT03405259|Experimental|Super Seal® Desensitizer|Professionally Applied
88846760|NCT03405259|Sham Comparator|Acclean® Fluoride Varnish|Professionally Applied
88846761|NCT03513757|Active Comparator|propofol|Each patient will receive 1 mg/kg lidocaine followed by 2 mg/kg propofol IV once prior to continuous propofol infusion for MRI sedation at 200 mcg/kg/min. Dose will be increased by 50 mcg/kg/min up to 300 mcg/kg/min for movement and decreased to 150 mcg/kg/min if no movement after 30 minutes. Additional 1 mg/kg propofol bolus administered at time of each movement. Study to be terminated if movement persists despite above interventions.
88846762|NCT03513757|Experimental|propofol dexmedetomidine|Each patient will receive: 1 mg/kg lidocaine, 2 mg/kg propofol, 4 mcg/kg glycopyrrolate and single dose dexmedetomidine administered prior to scan. Dexmedetomidine dose is dependent on expected duration of scan and will be equal to 1 mcg/kg/hour x duration of scan in hours. 1 mg/kg propofol will be administered for movement up to 2 times. For continued movement after that, begin propofol infusion at 150 mcg/kg/min. Study to be terminated if movement persists despite above interventions.
88846763|NCT03760640|Experimental|LY900014|Participants received 100 units per milliliter (U/mL) of LY900014 administered via continuous subcutaneous insulin infusion (CSII) by the Medtronic MiniMed 670G insulin pump.
89375022|NCT03668990|Other|Healthy controls|"50 healthy controls Persons perform funtional-oriented upper limb movments while wearing IMUs (Xsens, MVN Studio). This is a full-body human measurement system based on inertial sensors, biomechanical models and sensor fusion algorithms applied in neurological patients for measuring upper limb movements.~Funcitonal-oriented upper limb movements are performed at two different test days."
89375023|NCT03668210||Patients with contralateral ACL after Ligamentoplasty|"Athletic patients who have consulted in Sports Medicine Department at the Rennes University Hospital, victims of an ACL rupture during sports activity and who declared a contralateral ACL after the ligamentoplasty.~Isokinetic evaluation."
89375024|NCT03668210||Patients without contralateral ACL rupture|"Athletic patients who have consulted in Sports Medicine Department at Rennes University Hospital, without ACL rupture.~Isokinetic evaluation."
89375025|NCT03020888|Experimental|Magseed and Sentimag|"Magseed marker deployed to mark a breast lesion under imaging guidance up to 30 days prior to surgery.~Marker located during surgery using the Sentimag system, and removed with the lesion."
89375026|NCT03668522||children|age<=17
89375027|NCT03668522||adult|age>17
89375028|NCT03668132||Left damage|Have the ischemic brain damage and the location of the damage ,and in the left brain
89375029|NCT03668132||Right damage|Have the ischemic brain damage and the location of the damage ,and in the right brain
89375030|NCT03668132||Normal control|Not have the ischemic brain damage
88846764|NCT03760640|Active Comparator|Insulin Lispro (Humalog)|Participants received 100 U/mL of Insulin lispro (Humalog) administered via CSII by the Medtronic MiniMed 670G insulin pump.
88846765|NCT03407053|Active Comparator|Ultra-processed diet then unprocessed diet|Participants assigned to this arm will consume ultra-processed diet for two weeks followed by unprocessed diet for two weeks
88846766|NCT03407053|Active Comparator|Unprocessed diet then ultra-processed diet|Participants assigned to this arm will consume unprocessed diet for two weeks followed by ultra-processed diet for two weeks
89181552|NCT04113551||Cohort T2: MPH (Ritalin)|Analysis of data will be performed for participants who have had first exposure of MPH (Ritalin) and who were never exposed to MPH (Concerta) between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure.
89375031|NCT02250300|Experimental|MLN9708 Phase II matched sibling|Phase II Patients will be enrolled in two independent cohorts of matched sibling and matched unrelated donor transplants. Four doses of MLN9708 will be administered on days 1, 8, 15, & 22 starting on day +60 to +90 post allogeneic HCT.
89375032|NCT02250300|Experimental|MLN9708 Phase II matched unrelated|Phase II Patients will be enrolled in two independent cohorts of matched sibling and matched unrelated donor transplants. Four doses of MLN9708 will be administered on days 1, 8, 15, & 22 starting on day +60 to +90 post allogeneic HCT.
89375033|NCT02250300|Experimental|MLN9708 Phase I (2.3 mg)|Phase I Four doses of MLN9708 will be administered on days 1, 8, 15, & 22 orally based on a dose escalation schema.
89375034|NCT02250300|Experimental|MLN9708 Phase I (3.0 mg)|Phase I Four doses of MLN9708 will be administered on days 1, 8, 15, & 22 orally based on a dose escalation schema.
89375035|NCT02250300|Experimental|MLN9708 Phase I (4.0 mg)|Phase I Four doses of MLN9708 will be administered on days 1, 8, 15, & 22 orally based on a dose escalation schema.
89375036|NCT04403490|Experimental|HABIT-ILE|Hand and arm bimanual intensive therapy including lower extremities
89375037|NCT04403490|Active Comparator|Conventional intervention|Conventional physical and occupational therapy
89375038|NCT03020966|Experimental|Oral Tylenol|Patient group receiving 1000mg of oral acetaminophen and an intravenous placebo
89375039|NCT03020966|Experimental|Intravenous Tylenol|Patient group receiving 1000mg of intravenous acetaminophen and an oral placebo
89181553|NCT04113551||Cohort T3: MPH (Concerta and Ritalin)|Analysis of data will be performed for participants who have had exposure to Concerta and Ritalin during the time in the cohort between 1 January 2013 and 30 September 2018 and has continuous observation of at least 30 days prior to the exposures.
88846767|NCT03756506|Active Comparator|Novel Microbicidal Liquid Polymer|"All pins and wire sites will be cleaned daily while hospitalized. Basic pin care will be performed once daily by hospital nursing staff prior to discharge. Following discharge from the hospital, the pin care protocol will be continued by research participant's caregiver.Research participants will be instructed to notify the Principal Investigator if they observe any signs or symptoms of infection. These include redness around pin site, discharge,tenderness in the soft tissue, loosening of the pin, nausea, vomiting, fever or chills.~Step 1: Brush the pin sites with saline using an ordinary soft toothbrush or gauze with sterile gloves Step 2: If following Step 1, debris remains, use forceps (tweezers) to gently remove debris. Step 3: Apply product with Q-tip on clean dry wound around (extending approximately one inch around pin site) and on the pin. The Polymer will be applied daily while in the hospital and then at a minimum of at least three times a week until pin removal."
88846768|NCT03756506|No Intervention|Control group: no Novel Microbicidal Liquid Polymer|"The usual care of pin track sites will be followed as outlined belowAll pins and wire sites will be cleaned daily while hospitalized. Basic pin care will be performed once daily by hospital nursing staff prior to discharge. Following discharge from the hospital, the pin care protocol will be continued by research participant's caregiver.~Research participants will be instructed to notify the Principal Investigator if they observe any signs or symptoms of infection. These include redness around pin site, discharge, tenderness in the soft tissue, loosening of the pin, nausea, vomiting, fever or chills.~Research participants will be instructed that the approach to pin care should occur in a step-wise fashion. Step 1: Brush the pin sites with saline using an ordinary soft toothbrush or gauze with sterile gloves Step 2: If following Step 1, debris remains, use forceps (tweezers) to gently remove debris."
88846769|NCT03275623|Active Comparator|Antibiotic treatment|Standard prenatal care with treatment for any urine culture with growth of 1- 100,000 CFU of any organism.
88846770|NCT03275623|Active Comparator|No antibiotic treatment|Standard prenatal care without treatment for any urine culture with growth of 1- 100,000 CFU of any organism.
88846771|NCT04735237|Experimental|Autogenous fat injection|Fat will first be harvested from the abdomen, then injected into the lip
89181554|NCT04113551||Cohort T4: Atomoxetine (ATO)|Analysis of data will be performed for participants who have had first exposure of ATO between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure.
89375040|NCT01381770|Experimental|Platelet-derived repairing factors|
89375041|NCT01383564|Active Comparator|CPAP group|CPAP group
89375042|NCT01383564|Placebo Comparator|non CPAP group|non CPAP group
89375043|NCT03020576|Active Comparator|Conventional Therapy|Participants randomized to this arm will receive conventional based therapy to their affected upper limb dose matched with the Robotic Therapy group. These interventions are aimed at increasing range of motion, strength and function at the shoulder, elbow, wrist and hand.
89375044|NCT03020576|Experimental|Robotic Therapy|Participants randomized to this arm will receive robotic based therapy using the Amadeo Hand Robot device to improve range of motion, strength, and coordination to the wrist and hand.
89375045|NCT00892866|Other|Ancillary-Correlative (biomarkers in cervical cancer)|Patients undergo liquid-based cytology specimen sample collection for analysis of CA-IX, p16, Ki-67, and MCM2 expression via IHC and for the presence of high risk HPV DNA and HPV genotyping.
89375046|NCT03667976|No Intervention|Control Group|All participants in the control group will receive a study pedometer and a physical activity logbook. Participants will also receive the Canadian Society of Exercise Physiology/ParticipACTION physical activity guidelines for adults ages 18 to 64.
89399336|NCT03538418|Experimental|WAT group|The WAT group will receive a 3-month WAT-based exercise training programme, which includes 12 weekly exercise training sessions (an hour each) in addition to 2 face-to-face sessions followed by weekly to monthly telephone sessions offering support on dealing with technical issues and BCTs (7 session in total). The WAT group will be left to use the WAT on their own for 3 months during the follow-up period.
89375047|NCT03667976|Experimental|Intervention Group|All participants in the intervention group will receive a study pedometer and a physical activity logbook. Participants will also receive the South Asian women Together in a Health Initiative (SATHI) intervention which consists of a gender and culturally specific South Asian physical activity education booklet and video and 2) a matched peer. Peers will encourage physical activity and provide motivation and suggestions for incorporating physical activity into daily life of a South Asian woman based on Bandura's Self-Efficacy construct. Peer contact will occur via telephone, text/email messaging or in person at least once weekly and more often as determined by participants.
89375048|NCT04051268|Experimental|Vi-DT TCV Batch 1|1 dose of 0.5 ml of Vi-DT TCV vaccine batch 1
89375049|NCT04051268|Experimental|Vi-DT TCV Batch 2|1 dose of 0.5 ml of Vi-DT TCV vaccine batch 2
88846772|NCT04735237|Active Comparator|Surgical revision with orbicularis oris muscle reconstruction|
88846773|NCT03756038|Experimental|Drug: Oral Lorazepam (1mg)|Lorazepam (Ativan) is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety or anxiety associated with depressive symptoms.
88846774|NCT03756038|Placebo Comparator|Drug: Oral Placebo|
88846775|NCT03276637|Experimental|Healthy Active-Duty Airmen Cohort|Whole exome sequencing (WES) will be performed on 75 ostensibly healthy, active-duty Airmen (patient-participants) who receive medical care in military Primary Care, Internal Medicine and/or Family Practice settings who in their baseline survey expressed interest in receiving WES. Military healthcare providers who have received brief genomics training will return results to the patient-participants and the WES reports will be permanently integrated into their electronic medical record.
88846776|NCT03754556||Women with IUD|Women with an intrauterine device (IUD) and electronic health records in the Kaiser Permanente Northern California (KPNC), Kaiser Permanente Southern California (KPSC), Kaiser Permanente Washington (KPWA) and the Regenstrief Institute (RI) databases.
88846777|NCT03276871|Active Comparator|Balloon Dissection|Patients will undergo laparoscopic TEP inguinal hernia repair and creation of the extraperitoneal space will be performed with a balloon dissection technique using the Spacemaker Balloon Dissector.
88846778|NCT03276871|Experimental|Telescopic Dissection|Patients will undergo laparoscopic TEP inguinal hernia repair and creation of the extraperitoneal space will be performed with a telescopic dissection technique.
89181555|NCT04113551||Cohort T5: Guanfacine (GFC)|Analysis of data will be performed for participants who have had first exposure of GFC between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure.
89181556|NCT04113551||Cohort T6: MPH (Concerta and Ritalin), ATO, or GFC|Analysis of data will be performed for participants who had have MPH (Concerta or Ritalin), ATO, or GFC first exposure between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure. These are all exposures to any study drug(s) among the participants with an exposure to at least one of the study drugs.
89181557|NCT04113551||Cohort T7: MPH (Concerta or Ritalin)|Analysis of data will be performed for participants who had have MPH (Concerta or Ritalin) first exposure between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior. These are the first exposure to any MPH among the participants with who had some exposure to MPH.
88846779|NCT03521089|Active Comparator|Active tDCS|Active tDCS uses the Soterix Medical 1x1 Low Intensity Transcranial Electrical Stimulator (tES) Model 2001. The active tDCS intervention include stimulation for 15 minutes at 1mA. The cathode electrode will be placed over the right dorsolateral prefrontal cortex with reference electrode (anode) over the left dorsolateral prefrontal cortex. Both electrodes are covered by saline-soaked sponges that are held against the scalp by a pair of large, adjustable head straps. Treatment sessions will last for 15 minutes. 5 consecutive treatment sessions will be completed within 1 week.
88846780|NCT03521089|Sham Comparator|Sham tDCS|Sham tDCS uses the Soterix Medical 1x1 Low Intensity Transcranial Electrical Stimulator (tES) Model 2001. The sham tDCS intervention lasts for 15 minutes. The cathode electrode will be placed over the right dorsolateral prefrontal cortex with reference electrode (anode) over the left dorsolateral prefrontal cortex. Both electrodes are covered by saline-soaked sponges that are held against the scalp by a pair of large, adjustable head straps. Treatment sessions will last for 15 minutes. 5 consecutive treatment sessions will be completed within 1 week.
89181558|NCT04113551||Cohort T8: MPH (Concerta) All Exposures|Analysis of data will be performed for participants who have had all exposures of MPH (Concerta) and were never exposed to MPH (Ritalin) between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure.
89181559|NCT04113551||Cohort T9: MPH (Ritalin) All Exposures|Analysis of data will be performed for participants who have had all exposures of MPH (Ritalin) and were never exposed to MPH (Concerta) between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure.
89181560|NCT04113551||Cohort T10: ATO All Exposures|Analysis of data will be performed for participants who have had all exposures of ATO between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure.
88846781|NCT03410797|Other|Voice Disorder Requiring Voice Therapy|Individuals with a voice disorder such as muscle tension dysphonia (MTD), vocal fold atrophy or vocal fold lesions recommended for voice therapy as treatment.
89375050|NCT04051268|Experimental|Vi-DT TCV Batch 3|1 dose of 0.5 ml of Vi-DT TCV vaccine batch 3
89375051|NCT04051268|Active Comparator|PQed Typhoid Conjugate Vaccine (subjects 6 mo-45 yo)|1 dose of 0.5 ml of PQed TCV Vaccine
89375052|NCT04051268|Active Comparator|Vi Polysaccharide Vaccine (subjects 46-60 years old)|1 dose of 0.5 ml of Vi Polysaccharide Vaccine
88846782|NCT03410953|Experimental|Fendrix|"The primary immunisation consists of 4 separate 0.5 ml doses of FENDRIX administered at the following schedule:~1 month, 2 months and 6 months from the date of the first dose. Once initiated, the primary course of vaccination at 0, 1, 2 and 6 months should be completed with Fendrix, and not with other commercially available HBV vaccine"
88846783|NCT03521479|Experimental|Group A|Treated with 2% Squaric Acid Dibutyl Ester (SADBE) on day 0 and with 2% SADBE on the visits at week 3, week 6, week 9, and month 8.
88846784|NCT03521479|Experimental|Group B|Treated with 2% Squaric Acid Dibutyl Ester (SADBE) on day 0 and with 0.5% SADBE on the visits at week 3, week 6, week 9, and month 8.
88846785|NCT03521479|Active Comparator|Group C|Treated with 2% Squaric Acid Dibutyl Ester (SADBE) on day 0, month 3, and month 6.
88846786|NCT03521479|Active Comparator|Group D|Treated with 2% Squaric Acid Dibutyl Ester (SADBE) on day 0 and month 6.
89375053|NCT05420298|Experimental|cervical mobilization|session will include3-5 repetitions of muscle energy technique in combination of facet joint mobilization of unilateral antro-posterior glide and extension repetitions
89375054|NCT05420298|Active Comparator|cervical manipulation|patients will receive high velocity low amplitude thrust
88846787|NCT01495988|Active Comparator|Vemurafenib/Cobimetinib|Vemurafenib will be given at a dose of 960 mg, orally, 2X a day to all patients. Cobimetinib will be given at a dose of 60mg, orally, 1X a day to all patients for 21 days, then 7 days off, in a 28 day treatment cycle. Patients will be assessed for toxicity every 4 weeks and be restaged for tumor response/progression every 8 weeks until week 48, then every 12 weeks thereafter. Patients will be followed until disease progression.
88846788|NCT01495988|Experimental|Vemurafenib/Cobimetinib + Bevacizumab|Vemurafenib will be given at a dose of 960 mg, orally, 2X a day to all patients. Cobimetinib will be given at a dose of 60mg, orally, 1X a day to all patients for 21 days, then 7 days off, in a 28 day treatment cycle. Bevacizumab will be administered at the MTD (determined by phase Ib safety lead-in), intravenously, every 2 weeks. Patients will be assessed for toxicity every 4 weeks and be restaged for tumor response/progression every 8 weeks until week 48, then every 12 weeks thereafter. Patients will be followed until disease progression.
88846789|NCT01495988|Active Comparator|Vemurafenib|Vemurafenib will be given at a dose of 960 mg p.o. BID to all patients. Patients will be assessed for toxicity every 3 or 6 weeks (depending on the specific toxicity) and be restaged for tumor response/progression every 6 weeks until week 48, then every 12 weeks thereafter. Patients will be followed until disease progression.
88846790|NCT01495988|Experimental|Vemurafenib + Bevacizumab|Vemurafenib will be given at a dose of 960 mg p.o. BID to all patients. Patients assigned to the combination arm will also receive bevacizumab 15 mg/kg every IV every 3 weeks. Patients will be assessed for toxicity every 3 or 6 weeks (depending on the specific toxicity) and be restaged for tumor response/progression every 6 weeks until week 48, then every 12 weeks thereafter. Patients will be followed until disease progression.
88846791|NCT02934932|Experimental|Brexpiprazole 2mg|Subjects will be titrated to this dose of brexpiprazole for 6 weeks.
88846792|NCT02934932|Experimental|Brexpiprazole 4mg|Subjects will be titrated to this dose of brexpiprazole for 6 weeks.
88846793|NCT02934932|Placebo Comparator|Placebo|Subjects will be titrated to this dose of placebo for 6 weeks.
88846794|NCT03415243|Experimental|Treatment A Group|Participants will receive a single dose (1 sachet) of the investigational product (Acetaminophen 650mg+Dextromethorphan 20mg+Phenylephrine 10mg).
88846795|NCT03415243|Experimental|Treatment B Group|Participants will receive a single dose (2 caplets) of the investigational product (Acetaminophen 325mg+Dextromethorphan 10mg+Phenylephrine 5mg).
88846796|NCT02892500|Experimental|bupivacaine hydrochloride and betamethasone sodium phosphate|When the patient has been randomized to either group, a licensed provider under the direction of the PI, will utilize the ultrasound to identify the inferior tibiofibular ligament (syndesmotic ligament). This provider that performs the injection will not be involved in any follow-up visits or return to play review. When appropriate positioning is confirmed the area will be injected with a mixture of 5 ml of 0.25 % bupivacaine hydrochloride and 2 ml of 3 mg/ml betamethasone sodium phosphate (Celestone® Soluspan®) (BTM)
89002332|NCT06318832|Experimental|Internet Delivered Cognitive Behavioural Therapy (ICBT)|ICBT: Participants will receive the 10-week tailored ICBT Wellbeing program consisting of 1) education about how taking on the role of care-partner can impact emotional and cognitive wellbeing through introduction to the CBT model; 2) structured problem solving; 3) cognitive therapy and thought challenging to manage one's wellbeing and impact of caregiving; 4) building communication and intimacy; 5) physical symptoms of depression (i.e., hypo-arousal), anxiety/anger (i.e., hyper-arousal); practicing behavioural activation and controlled relaxation; 6) overdoing-underdoing cycle of activity levels and issues around the fear avoidance of social, physical, and cognitive activities; practicing activity pacing and gradually tackling avoidance; 7) occurrence of setbacks in thought, physical, behavioural, and cognitive symptoms; signs of setbacks and creating setback plans.
89375055|NCT03017612|Experimental|Single Arm Study|Evaluating the safety and effectiveness of the raindrop near vision inlay implanted in bilateral pseudophakic subjects
89375056|NCT03635099|Placebo Comparator|Part I - Placebo (fasted)|Part I - Placebo matching BI 730357 taken orally once daily as a film-coated tablet in the morning while fasted for 12 weeks in period 1 followed by the same treatment for 12 weeks in period 2 (total treatment period of 24 weeks). Participants who failed to achieve a Psoriasis Area Severity Index score (PASI) 75 response at Week 12 were switched to a 200 mg dose, participants switching dose were imputed as failure for records after week 12, under original randomized treatment arm.
88846797|NCT02892500|Active Comparator|bupivacaine hydrochloride|When the patient has been randomized to either group, a licensed provider under the direction of the PI, will utilize the ultrasound to identify the inferior tibiofibular ligament (syndesmotic ligament). This provider that performs the injection will not be involved in any follow-up visits or return to play review. When appropriate positioning is confirmed, the area will be injected with 5ml of bupivacaine hydrochloride.
89375057|NCT03635099|Experimental|Part I - BI 25 mg (fasted)|Part I - 25 milligram (mg) BI 730357 taken orally once daily as a film-coated tablet in the morning while fasted for 12 weeks in period 1 followed by the same treatment for 12 weeks in period 2 (total treatment period of 24 weeks). Participants who failed to achieve a Psoriasis Area Severity Index score (PASI) 50 response at Week 12 were switched to a 50 mg dose, participants switching dose were imputed as failure for records after week 12, under original randomized treatment arm.
89375058|NCT03635099|Experimental|Part I - BI 50 mg (fasted)|Part I - 50 milligram (mg) BI 730357 taken orally once daily as a film-coated tablet in the morning while fasted for 12 weeks in period 1 followed by the same treatment for 12 weeks in period 2 (total treatment period of 24 weeks). Participants who failed to achieve a Psoriasis Area Severity Index score (PASI) 50 response at Week 12 were switched to a 100 mg dose, participants switching dose were imputed as failure for records after week 12, under original randomized treatment arm.
89375059|NCT03635099|Experimental|Part I - BI 100 mg (fasted)|Part I - 100 milligram (mg) BI 730357 taken orally once daily as a film-coated tablet in the morning while fasted for 12 weeks in period 1 followed by the same treatment for 12 weeks in period 2 (total treatment period of 24 weeks). Participants who failed to achieve a Psoriasis Area Severity Index score (PASI) 50 response at Week 12 were switched to a 200 mg dose, participants switching dose were imputed as failure for records after week 12, under original randomized treatment arm.
89375060|NCT03635099|Experimental|Part I - BI 200 mg (fasted)|Part I - 200 milligram (mg) BI 730357 taken orally once daily as a film-coated tablet in the morning while fasted for 12 weeks in period 1 followed by the same treatment for 12 weeks in period 2 (total treatment period of 24 weeks).
89375061|NCT03635099|Placebo Comparator|Part II - Placebo (fed)|Part II - 4 film-coated tablets of matching Placebo were taken orally in the morning with a meal and 2 film-coated tablets of matching Placebo were taken orally in the evening with a meal for 12 weeks.
88846798|NCT02904356|Experimental|Brainsway H-coil for rTMS|Brainsway H-coil for repetitive transcranial magnetic stimulation: High-frequency rTMS will be administered to the medial prefrontal cortex for 3 weeks.
88846799|NCT03418051|No Intervention|Control|Control group that will receive no intervention throughout the duration of the study (2-weeks).
88846800|NCT03418051|Experimental|Joint Mobilization|Participants will receive 6, 5-minute treatment sessions over 2-weeks. Each session will consist of 2, 2-minute bouts of Grade III anterior-to-posterior talocrural joint mobilization with 1-minute between sets. Mobilizations will be large-amplitude, 1-s rhythmic oscillations from the mid- to end range of arthrokinematic motion.
88846801|NCT03418051|Experimental|Massage|Participants will receive 6, 5-minute treatment sessions over 2-weeks. Each session will consist of 2, 2-minute bouts of plantar massage bouts with 1-minute between sets. The massage will be a combination of petrissage and effleurage to the entire plantar surface.
88846802|NCT02818946|Other|MRI|Patients who have undergone mammography, breast sonography, and planning to have a contrast-enhanced breast MRI for evaluation of nipple discharge.
88846803|NCT00378404|Experimental|1|
88846804|NCT01440452|Experimental|Group A|For 3 weeks, you will need to come to the International Center for Spinal Cord Injury at Kennedy Krieger Institute (ICSCI) one (1) time per week during which you will perform FES cycling for 1 hour each.
88846805|NCT01440452|Experimental|Group B|For 3 weeks, you will need to come to the ICSCI three (3) times per week during which you will perform FES cycling for 1 hour each.
88846806|NCT01440452|Experimental|Group C|For 3 weeks, you will need to come to the ICSCI five (5) times per week during which you will perform FES cycling for 1 hour each.
88846807|NCT01440452|Experimental|Group D|For 3 weeks, you will need to come to the ICSCI three (3) times per week during which you will perform cycling without FES for 1 hour each.
88846808|NCT03742154|Experimental|Varenicline Group|50 participants will be enrolled in this group. They will receive a sample of varenicline to use for up to 4-weeks. They are receiving 40 - 0.5mg pills of varenicline, with instructions for titration.
88846809|NCT03742154|No Intervention|Control Group|49 participants will be enrolled in this group.
88846810|NCT03284359|Experimental|Pre-Consent Nudge Bundle|Arm 1 will be administered a novel pre-consent nudge bundle which incorporates several behavioral economic interventions within a brief survey. Participants will subsequently be asked by the same research personnel to participate in a simulated randomized control trial (RCT) comparing two mechanical ventilation weaning protocols among mechanically ventilated patients. Participants will receive the standard consent form followed by a risk assessment and demographic survey.
88846811|NCT03284359|No Intervention|Standard Consent|Arm 2 will serve as the control arm. Participants will be approached by the research personnel to participate in a simulated RCT comparing two mechanical ventilation weaning protocols among mechanically ventilated patients. Participants will receive a standard consent form as detailed in the Study Instruments section. Following the consent process participants will conduct the same risk assessment survey and demographic survey.
88846812|NCT05313230||CITRASAFE|Patient underwent CITRASATE dialysis session
89375062|NCT03635099|Experimental|Part II - BI 400 mg once daily (fed)|Part II - 4 film-coated tablets of 100 milligram (mg) BI 730357 (400 mg in total) were taken orally in the morning with a meal and 2 film-coated tablets of matching Placebo were taken orally in the evening with a meal for 12 weeks.
89375063|NCT03635099|Experimental|Part II - BI 200 mg twice daily, 400 mg total (fed)|Part II - 2 film-coated tablets of 100 milligram (mg) BI 730357 were taken orally with a meal in the morning and evening (twice daily; total daily dosage: 400 mg) for 12 weeks.
88846813|NCT03738020|Experimental|HA IDF|
88846814|NCT03738020|Active Comparator|Restylane|
89181561|NCT04113551||Cohort T11: GFC All Exposures|Analysis of data will be performed for participants who have had all exposures of GFC between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure.
89375064|NCT03667898|Experimental|Active needle tip tracking|A needle tip tracking system is used when performing an ultrasound guided lumbar plexus block.
89375065|NCT03667898|Other|Inactive needle tip tracking|No needle tip tracking system is used when performing an ultrasound guided lumbar plexus block.
89375066|NCT03668444|Experimental|TXS- Supportive Text Group|Participants randomized to this arm (TXS) of the study will receive care as usual within the Drug Treatment Court (DTC) system plus supportive daily text messages which will be delivered at specific times each day for 30 days and will be signed by the judge for their specific DTC. (TXS) Group receives text messages for drug treatment compliance.
89375067|NCT03668444|Placebo Comparator|TAU- Treatment As Usual Group|Participants randomized to the (TAU) arm of the study will continue to participate in court-ordered treatments as usual with no additional intervention. Participants will receive motivational text messages for 30-days.
89375068|NCT03668366|Experimental|S-1 arm|The patients in the S-1 arm will receive IMRT (66-70.4Gy to GTV, 57-60.8Gy to CTV1, 54-56Gy to CTV2, given in 30-32 fractions). During the IMRT course, S-1 will be administered orally according to body surface area (BSA<1.25m2, 30mg; BSA: 1.25-1.5m2, 40mg; BSA>1.5m2, 50mg) twice per day for 30-32 days. The dose modifications of S-1 will not be permitted during concurrent chemotherapy unless progression of the disease, toxicities of grade 4 or patient's refusal.
89375069|NCT03668288||PID patients|Adults with primary or secondary immunodeficiency for whom human immunoglobulin-assisted recombinant human hyaluronidase treatment is initiated
89375070|NCT04595786|Active Comparator|TXA group|The TXA group will receives Tranexamic acid intraoperative.
89375071|NCT04595786|Placebo Comparator|Placebo group|The TXA group will receives 0.9% saline intraoperative.
89375072|NCT04584164|No Intervention|Control arm|This arm involves patients applying the basic hygiene rules (with mouthwashes) without the sialendoscopy method.
89375073|NCT04584164|Experimental|Sialendoscopy arm|This arm involves patients applying the hygiene rule and benifiting in addition a sialendoscopy treatment with a local injection of corticostéroïdes (at the end of the procedure) in the treatment for Xerostomia.
89375074|NCT01383408|Sham Comparator|healthy individual|healthy individual with no lung disease and no history of cancer including lung cancer
89375075|NCT01383408|Experimental|lung cancer|patients with histologically confirmed lung cancer, but no history of other cancer
89375076|NCT01383408|Experimental|breast cancer|patients with histologically confirmed breast cancer, but no history of other cancer
89375077|NCT01383408|Experimental|ovarian cancer|patients with histologically confirmed ovarian cancer, but no history of other cancer
89375078|NCT05419752|Experimental|endo sequence bioceramic sealer|obturation using Endo-sequence BC sealer
88846815|NCT02734940|Active Comparator|Unrestricted Fentanyl|"Will receive injection of sterile saline (2cc) in lower back area (to minimize participant bias) and unrestricted amount of intraoperative opioids (fentanyl) at the discretion of the Anesthesiologist.~Both groups will receive General Anesthesia with volatile agents and single dose of iv Tylenol intraoperatively. Both groups of patients will be transported to Intensive Care Unit (ICU) on Dexmedetomidine (dose range 0.25 - 0.7 mcg/kg/hr). Dose titration is based on sedation level and hemodynamic goals set by Cardiac Anesthesiologist."
88846816|NCT02734940|Experimental|Lidocaine, Dexmedetomidine and Ketamine|Will receive pre-operative spinal duramorph (4mcg/kg up to max dose of 300mcg), intra-operative intravenous (iv) infusion of Ketamine (0.4 mg/kg/hr), Lidocaine (20 mcg/kg/min) and Dexmedetomidine (0.25 mcg/kg/hr) started after induction of General Anesthesia and maintained through the Cardiopulmonary Bypass (CPB) towards the end of surgery. At this point all infusions will be turned off except Dexmedetomidine. The total intraoperative fentanyl dose will be limited to <250mcg (or 3mcg/kg) and total midazolam to ≤ 2mg in the study group.
88846817|NCT00378092|Experimental|Risperidone Long-Acting Injection (RLAI) (Period 1)|Participants will receive 25 milligram (mg) to 50 mg of RLAI intramuscularly (into the muscle) which will be tapered and discontinued over a period of up to 6 weeks. Participants will be followed-up until their first disease relapse or maximum of 36 months.
89181562|NCT04113551||Cohort T12:MPH(Concerta and Ritalin),ATO,orGFC All Exposures|Analysis of data will be performed for participants who have had all exposures of MPH (Concerta or Ritalin), ATO, or GFC between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure. These are all exposures to any study drug(s) among the participants with an exposure to at least one of the study drugs.
89375079|NCT05419752|Experimental|MTA fill apex calcium silicate base sealer|obturation using calcium-silicates based MTA fill-apex sealer
89375080|NCT05419752|Experimental|AH plus resin sealer|obturation using AH Plus sealer
89375081|NCT03634085|Experimental|Cohort A|"Ascending doses of BDM-2 in Bottle (50 mg - 3600 mg); oral suspension or placebo will be orally administered and will be investigated, alternately dosed in Cohort A of 8 healthy male subjects under fasted conditions. For each dose, 6 subjects will receive active treatment and 2 subjects will receive placebo. Subjects will be randomized in such a way that for each dose different subjects receive placebo.~The last session for the subjects in Cohort A will be under fed conditions where the same treatment allocation as in the session of the selected dose (administered under fasted conditions) will be used."
89375082|NCT03634085|Experimental|Cohort B|Ascending doses of BDM-2 in Bottle (50 mg - 3600 mg); oral suspension or placebo will be orally administered and will be investigated, alternately dosed in Cohort B of 8 healthy male subjects under fasted conditions. For each dose, 6 subjects will receive active treatment and 2 subjects will receive placebo. Subjects will be randomized in such a way that for each dose different subjects receive placebo.
89375083|NCT05419596||Major Urologic Surgery Group|Elder patients who undergo major urologic surgery will be investigated for the change in genomic protein that are related to cognition. These proteins are APOE, phosphatidyl-inositol-binding clathrin assembly protein, CR1 (complement receptor 1) , ATP-binding cassette transporter, IL6, Triggering receptor expressed on myeloid cells2 (TREM2)
89375084|NCT04373148||COVID-19|Participants diagnosed with COVID-19
89375085|NCT04373148||Controls|Participants not diagnosed with COVID-19
88846818|NCT00378092|Experimental|Oral risperidone and RLAI (Period 2)|Participants who will experience a disease relapse, will receive RLAI 25 mg, 37.5 mg, or 50 mg, every 2 weeks as an intramuscular injection in the gluteus (a muscle) for up to 24 months. Supplementation with oral risperidone 1 mg or 2 mg or 3 mg will be administered for 21 days from the first dose of RLAI (until RLAI injections becomes effective) and then taper off over the next 5 days. Thereafter, oral risperidone can be administered at the discretion of the Investigator if additional antipsychotic medication will be required due to acute exacerbation of symptoms between visits.
88846819|NCT01347632|Other|BV pre treatment|Open Label Study. All participants had BV and took metronidazole 500 mg po BID for 7 days.
88846820|NCT02679560|Active Comparator|Liposomal Bupivacaine|In patients with femur or hip fractures, a fascia iliaca compartment block using liposomal bupivacaine will be administered
88846821|NCT02679560|Placebo Comparator|Ropivacaine HCL|In patients with femur or hip fractures, a fascia iliaca block using using 0.2% ropivacaine will be administered
88846822|NCT00378248|Experimental|Combined psychotherapy|18 weeks day hospital treatment followed by long-term outpatient combined group- and individual psychotherapy
88846823|NCT00378248|Active Comparator|Outpatient individual psychotherapy|Eclectic individual psychotherapy in outpatient private practice
88846824|NCT03734822|Other|CF|Cystic fibrosis patients undergoing general anesthesia.
88846825|NCT02671136|Other|CWC with HBO|Conventional Wound Therapies (CWC) with adjunctive Hyperbaric Oxygen Therapy
88846826|NCT02671136|Other|CWC without HBO|Conventional Wound Therapies (CWC) without adjunctive Hyperbaric Oxygen Therapy
88846827|NCT03728348||Subject aged 45-49 with Average CRC Risk|Subject aged 45-49 with average risk for development of CRC.
88846828|NCT02665988|Experimental|Real tDCS|Those receiving experimental treatment will receive real tDCS during 20-minute periods over the course of 10 sessions. The treatment will be delivered by trained clinical personnel.
88846829|NCT02665988|Placebo Comparator|Sham tDCS|Those receiving sham tDCS will receive active tDCS during 20-minute periods over the course of 10 sessions. The treatment will be delivered by trained clinical personnel.
88846830|NCT03726164|Active Comparator|Remote Conditioning group|Patients will receive a standard remote ischaemia preconditioning protocol comprising a blood pressure cuff placed on arm and inflated to 200mmHg for 5 minutes and then deflated for 5 minutes, a cycle repeated three times, prior to the PCI procedure.
88846831|NCT03726164|Placebo Comparator|Control Group|Patients will receive a standard sham remote ischaemia preconditioning protocol with an un-inflated cuff be placed on the arm in this group of patients for 30 minutes. This is the sham intervention for this group.
88846832|NCT03723980|Active Comparator|Control Group or Group I or Calcium hydroxide Group|
88846833|NCT03723980|Experimental|Experimental Group or Group II or Propolis Group|
88846834|NCT02660528|Experimental|Tocilizumab|Tocilizumab 162 mg sc q2weeks x 4 doses
88846835|NCT02633540|Experimental|IMRT Radiation|All subjects will be treated using IMRT with the standard fractionation for T1a glottic cancer at Fox Chase Cancer Center: 63 Gy in 28 fractions; 6 for T1a and 65.25 Gy in 29 fractions; 33 for T2a. Treatment will be followed by functional assessments performed at months 1,3,6,12,and 24.
88846836|NCT01240304|Experimental|Gemcitabine, radiation therapy, surgery|
88846837|NCT02614586|Experimental|Placebo + TAK-058 + Ondansetron|TAK-058 placebo-matching solution, orally, along with ondansetron placebo-matching capsule, orally, on Day 1 of first intervention period (2 days), followed by 1 week washout period, further followed by TAK-058 150 milligram (mg), solution, orally along with ondansetron placebo-matching capsule orally, on Day 1 of second intervention period (2 days), followed by 1 week washout period, further followed by ondansetron 16 mg, capsule, orally along with TAK-058 placebo-matching solution, orally, on Day 1 of third intervention period (2 days).
88846838|NCT02614586|Experimental|TAK-058 + Placebo + Ondansetron|TAK-058 150 mg, solution, orally along with ondansetron placebo-matching capsule orally, on Day 1 of first intervention period (2 days), followed by 1 week washout period, further followed by TAK-058 placebo-matching solution, orally, along with ondansetron placebo-matching capsule, orally, on Day 1 of second intervention period (2 days), followed by 1 week washout period, further followed by ondansetron 16 mg, capsule, orally, along with TAK-058 placebo-matching solution, orally, on Day 1 of third intervention period (2 days).
88846839|NCT02614586|Experimental|Ondansetron + Placebo + TAK-058|Ondansetron 16 mg, capsule, orally, along with TAK-058 placebo-matching solution, orally, on Day 1 of first intervention period (2 days), followed by 1 week washout period, further followed by TAK-058 placebo-matching solution, orally, along with ondansetron placebo-matching capsule, orally, on Day 1 of second intervention period (2 days), followed by 1 week washout period, further followed by TAK-058 150 mg, solution, orally, along with ondansetron placebo-matching capsule, orally, on Day 1 of third intervention period (2 days).
88846840|NCT02614586|Experimental|Placebo + Ondansetron + TAK-058|TAK-058 placebo-matching solution, orally, along with ondansetron placebo-matching capsule, orally, on Day 1 of first intervention period (2 days), followed by 1 week washout period, further followed by ondansetron 16 mg, capsule, orally, along with TAK-058 placebo-matching solution, orally, on Day 1 of second intervention period (2 days), followed by 1 week washout period, further followed by TAK-058 150 mg, solution, orally, along with ondansetron placebo-matching capsule, orally, on Day 1 of third intervention period (2 days).
88846841|NCT02614586|Experimental|TAK-058 + Ondansetron + Placebo|TAK-058 150 mg, solution, orally along with ondansetron placebo-matching capsule orally, on Day 1 of first intervention period (2 days), followed by 1 week washout period, further followed by ondansetron 16 mg, capsule, orally, along with TAK-058 placebo-matching solution, orally, on Day 1 of second intervention period (2 days), followed by 1 week washout period, further followed by TAK-058 placebo-matching solution, orally, along with ondansetron placebo-matching capsule, orally, on Day 1 of third intervention period (2 days).
89181563|NCT04113551||Cohort T13: MPH (Concerta or Ritalin) All Exposures|Analysis of data will be performed for participants who have had all exposures of MPH (Concerta or Ritalin) between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure. These are all exposures to any MPH (Concerta or Ritalin) among the participants with an exposure to MPH (Concerta or Ritalin).
89375086|NCT01381614||Occurance of severe adverse event claims in subjects|Presence or absence of common severe treatment related adverse events (based on existence of claims) in patients with metastatic RCC. Common severe adverse event defined as Grade 3 or higher with >=5% frequency of occurance as reported in product label.
89375087|NCT03729323|Experimental|Experimental: Motivational Interviewing|INTERVENTION GROUP: In this group, Diabetics and Hypertensives will attend two Nursing Consultation sessions based on the assumptions and techniques of Motivational Interviewing with a certified nurse with specific 20-hour theoretical and practical training for this approach style.
89375088|NCT03729323|Active Comparator|Nursing Consultation|CONTROL GROUP: In this group, Diabetics and Hypertensives will attend two conventional nursing consultation sessions aimed at self-care, with a untrained nurse for the use of motivational interviewing, based on the recommendations of the Primary Care Strategy Notebooks for the care of chronic conditions in Diabetes Mellitus and Arterial Hypertension and the SSC-GHC Institutional Protocol for SAH and DM2 Patient Care.
89375089|NCT01381536|Experimental|GSK1550188 1mg/kg or 10mg/kg|one shot IV
88810327|NCT06214442||Sedentary women who use hormonal contraception|Sedentary women using oral hormonal contraception combined with estrogen and progesterone within the last six months.
88810328|NCT06214429||Carotid Atherosclerotic Plaque Stenosis >50%|Main cohort, composed by subjects with carotid stenosis above 50% confirmed by at least methods (eg. Doppler ultrasound peak systolic velocity > 140cm/s and MRI residual lumen measurement).
88810329|NCT06214416|Active Comparator|Abstention|These participants will be encouraged to totally avoid alcohol consumption.
88810330|NCT06214416|Active Comparator|Mediterranean alcohol-drinking pattern|These participants will be encouraged to change their pattern of consumption to a more Mediterranean way, which includes 5 aspects: moderate alcohol consumption (maximum of 2 drinks/day for women and 4 drinks/day for men), spread consumption throughout the week, drink with meals and never with an empty stomach, prefer wine and mainly red wine, as well as completely avoid episodes of binge-drinking.
88810331|NCT06214416|No Intervention|Control of abstainers|This group will include all participants who consume less than 3 alcohol drinks a week at the time of recruitment.
88810332|NCT06214416|No Intervention|Control of drinkers|This group will include all participants who don't want to change their alcohol-drinking pattern.
88810333|NCT06214403|Experimental|MET-2|Participants randomized to the intervention will receive MET-2 daily for 10 days. MET-2 capsules are administered orally at 0.5 g per capsule, containing 3.1 x 10^5-10^11 colony forming units (CFU). An initial loading dose of 10 MET-2 capsules/day will be taken for 2 days (5 grams total). For the following 8 days, participants will take a maintenance dose of 3 MET-2 capsules/day (1.5 grams total).
88810334|NCT06214403|Placebo Comparator|Placebo|Participants randomized to the placebo will receive microcrystalline cellulose in a capsule, identical in appearance to MET-2 but not containing live bacteria. Participants will take the placebo in the same dosing schedule as the MET-2 arm: 10 capsules daily for 2 days, followed by 3 capsules daily for 8 days.
88810335|NCT06214390|Active Comparator|Single strategy|A single strategy based only on urine output
88810336|NCT06214390|Experimental|Combined strategy|A strategy based on combined criteria (urine output + urinary parameters)
88810337|NCT06214377|Experimental|Active Transcranial Direct Current Stimulation and dopaminergic medication|Active Transcranial Direct Current Stimulation (atDCS) will be applied over the Primary Motor Cortex (M1) contralateral to pain if it is unilateral, or always on the left M1 if pain is bilateral. It will consist of 1 session of 20 minutes of conventional stimulation (anode over M1) at 2 mA. It will be applied in the OFF state (i.e., >12h after the last medication intake). Lately, patients will take its usual dopaminergic medication.
88810338|NCT06214377|Sham Comparator|: Sham Transcranial Direct Current Stimulation and dopaminergic medication|Sham Transcranial Direct Current (s-tDCS) will be applied over the Primary Motor Cortex with the same procedure, during 1 session of 20 minutes of conventional stimulation. It will be applied in the OFF state (i.e., >12h after the last medication intake). Lately, patients will take its usual dopaminergic medication.
88810339|NCT06214364|Active Comparator|Active transcranial direct current stimulation|"Active Anodal Transcranial Direct Current Stimulation (a-tDCS) will be applied over the Primary Motor Cortex of the affected or most affected hemisphere during 10 20 minute-sessions at 2 miliamps.~The tDCS stimulator device will be used by an experienced physical therapist by a saline-soak pair of surface electrodes. The anode electrode will be placed over C3 (EEG 10/20 system) and the cathode electrode over the contralateral supraorbital area (Fp2), in order to enhance the excitability of M1.~While the tDCS stimulation is administered, virtual reality upper limb exercises will be conducted. Virtual reality program will continue for another 20 minutes after the tDCS stimulation."
88810340|NCT06214364|Sham Comparator|Sham Transcranial Direct Current Stimulation|"Sham Transcranial Direct Current (s-tDCS) will be applied over the Primary Motor Cortex during 10 sessions of 20 minutes.~The electrodes will be placed in the same positioned as for M1 stimulation in the experimental group, but the current will only be applied ramping for 30 seconds in the beginning and at the end of the procedure to secure the blinding.~While the sham tDCS stimulation is administered, virtual reality upper limb exercises will be conducted. Virtual reality program will continue for another 20 minutes after the sham tDCS stimulation."
88810341|NCT06214351|Experimental|Experimental Group|"A mobile application will be installed on the smartphones of the pregnant women in the experimental group.~The mobile application will be installed on the phones of the pregnant women in the experimental group. (The mobile application will be downloaded from the Play Store for Android users and from the App Store for iOS users). Information about the application will be provided and any questions from the pregnant women will be answered. Pregnant women will be free to access the application at any time during the study."
88810342|NCT06214351|No Intervention|Control Group:|Pregnant women in the control group will receive routine antenatal care. Routine antenatal care will be provided to pregnant women in the control group.
88810343|NCT06214312||Spontaneous ventilation|Anesthetized Children ventilated with a laryngeal mask airway in spontaneous ventilation with a positive end expiratory pressure of 5cmH2O.
88810344|NCT06214312||Pressure support ventilation|Anesthetized Children ventilated with a laryngeal mask airway in pressure support ventilation with a positive end expiratory pressure of 5cmH2O, maximum pressure not exceeding 15cmH2O.
89375090|NCT02676778|Experimental|E7777|Participants with relapsed or refractory peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL) will receive 9 μg/kg/day of E7777, administered by intravenous drip infusion in 60 minutes (± 10 min) for Days 1 through 5 of each cycle in maximum of 8 cycles. Every cycle consists of 3 weeks.
89375091|NCT03160924|Active Comparator|Enhanced Recovery After Surgery (ERAS)|"In this arm, the ERAS perioperative care program will be applied.~Preoperative counselling by surgeon, dietician and physiotherapist~Preoperative carbohydrate-loaded drink 800ml 12.5% Carbohydrate drink 8h before surgery 400ml 12.5% Carbohydrate drink 4h before surgery (Omit 4h drink if patient has DM)~Fluid restriction, avoid opioids, use of Cox-II inhibitors as analgesics~Avoid use of drains~Early resumption of diet~Early mobilisation with physiotherapist~Dietary counselling by dietician~Early discharge if fulfil discharge criteria.~Discharge criteria:~Adequate pain control with oral analgesics Ability to tolerate soft diet Passage of flatus Mobilization~Patients will be called by doctors every day after discharge to monitor their clinical status. There will be a low threshold for readmitting patients. Patients will also be given a hotline to call if they feel unwell. They will be seen in clinic on post-operative D7 and D14."
89375092|NCT03160924|No Intervention|Conventional perioperative program|"In this arm, the conventional preoperative program will be applied.~No preoperative counselling~No Preoperative carbohydrate-loaded drink~Routine anaesthesia, no specific protocol on fluid restriction, opioids will be used as usual. Tramadol would be used as postoperative pain control.~Routine use of drains~Diet will be resumed when there is flatus clinically~Mobilisation as per patient's wish~Dietary counselling by dietician~Discharge if fulfil discharge criteria.~Discharge criteria:~Adequate pain control with oral analgesics Ability to tolerate soft diet Passage of flatus Mobilization~Patients will be seen in clinic on post-operative D14."
88846842|NCT02614586|Experimental|Ondansetron + TAK-058 + Placebo|Ondansetron 16 mg, capsule, orally along with TAK-058 placebo-matching solution, orally, on Day 1 of first intervention period (2 days), followed by 1 week washout period, further followed by TAK-058 150 mg, solution, orally, along with ondansetron placebo-matching capsule, orally, on Day 1 of second intervention period (2 days), followed by 1 week washout period, further followed by TAK-058 placebo-matching solution, orally, along with ondansetron placebo-matching capsule, orally, on Day 1 of third intervention period (2 days).
88846843|NCT01211756|Experimental|Oxytocin|20 IU of intranasal oxytocin twice per day for the first week, 40 IU of intranasal oxytocin twice per day for the following 3 weeks, one week wash out, 4 week placebo trial.
88846844|NCT01211756|Placebo Comparator|Placebo|Four week placebo trial, one week wash out, 20 IU of intranasal oxytocin twice per day for one week, 40 IU of intranasal oxytocin twice per day for 3 weeks.
88846845|NCT03591458|Experimental|Amitriptyline|Participants will be initiated on 25 mg Amitriptyline daily for two weeks during the Titration Period. Amitriptyline dose will be increased to 50 mg daily for 8 weeks during the Intervention Period. Finally, the dose of Amitriptyline will be reduced to 25 mg daily during the two week Taper Period.
88846846|NCT03591458|Placebo Comparator|Placebo|Participants will be initiated on a daily Placebo capsule matching the 25 mg Amitriptyline during the Titration Period. The daily dose will be changed to the Placebo capsule matching the 50 mg Amitriptyline for 8 weeks during the Intervention Period. Finally, the daily dose will be changed back to the Placebo capsule matching the 25 mg Amitriptyline during the two week Taper period.
88846847|NCT03565328|Experimental|Nicotinamide Riboside in patients with stable heart failure|Nicotinamide Riboside (NR) will be started at 500 mg daily (250 mg BID) then increased at two weekly intervals by 250 mg/dose (BID) (500 mg/day) to a final dose of 1000 mg PO BID (2000 mg/day) in patients with stable, systolic heart failure.
88846848|NCT03534362|Active Comparator|Nasopore Group|Nasopore group will receive frontal drill out procedure as indicated with Kenalog-soaked Nasopore stent intervention applied to the post-operative outflow tract.
88846849|NCT03534362|Active Comparator|Propel Stent Group|Propel stent group will receive frontal drill out procedure as indicated followed by Propel stent placement intervention applied to the post-operative outflow tract.
88846850|NCT01206296|Experimental|Intraperitoneal Gemcitabine|Intraperitoneal Gemcitabine
88846851|NCT02593682|Experimental|Suvorexant Group|In this arm, subjects will receive 10 mg suvorexant 2 hours before a one-minute 35% CO2 challenge.
88846852|NCT02593682|Placebo Comparator|Placebo Group|In this arm, subjects will receive a placebo, compounded to look identical to the study drug, 2 hours before a one-minute 35% CO2 challenge.
88846853|NCT02461550|Experimental|IRE procedure|The IRE procedure will be performed in the operating room at the time of scheduled clinical resection of colorectal lung metastases by the surgeon with guidance from the Interventional Radiologist.
88846854|NCT01200602|Experimental|Arm A|Patients receive oral megestrol acetate 1-2 times daily for 4 weeks.
88846855|NCT01200602|Active Comparator|Arm B|Patients have clinical observation for weight loss and gain for 4 weeks.
88846856|NCT01194908|Experimental|Arm A|Patients treated with decitabine and LBH589
88846857|NCT01184456|Experimental|GanedenBC30, GBI-30, PTA-6086|
88846858|NCT01184456|Placebo Comparator|Placebo|
88846859|NCT01163084|Experimental|Arm I (leuprolide acetate, goserelin acetate, vismodegib)|Patients receive LHRH analogue comprising leuprolide acetate IM or goserelin acetate SC on day 1 and vismodegib PO QD on days 1-28. Treatment repeats every 28 days for up to 16 weeks in the absence of disease progression or unacceptable toxicity.
88846860|NCT01163084|Active Comparator|Arm II (leuprolide acetate, goserelin acetate)|Patients receive LHRH analogue comprising leuprolide acetate or goserelin acetate as in Arm I. Treatment repeats every 28 days for up to 16 weeks in the absence of disease progression or unacceptable toxicity.
88846861|NCT01162382|Experimental|Transcranial Magnetic Stimulation|Open-label transcranial magnetic stimulation
88846862|NCT01155518|Experimental|testosterone|intramuscular injections every 2 weeks
88846863|NCT01155518|Experimental|clomiphene|oral drug thrice a week
88846864|NCT01155518|Placebo Comparator|placebo for testosterone|placebo for testosterone arm
88846865|NCT01155518|Placebo Comparator|placebo for clomiphene|oral placebo for clomiphene arm
88846866|NCT01155518|No Intervention|eugonadal obese|obese men with normal testosterone level
88846867|NCT01155518|No Intervention|lean|healthy lean men (control)
88846868|NCT03490916|Experimental|Acetazolamide normal dose|One (1) dose of 250mg of Acetazolamide
88846869|NCT03490916|Placebo Comparator|Placebo|One (1) dose of placebo
89375093|NCT01381458||COPD patients receiving pharmacotherapy|COPD patients age 40 years and older receiving pharmacotherapy to treat their COPD and an index event of COPD hospitalization or ER visit.
88846870|NCT03333746|Experimental|Treatment (lenalidomide, nivolumab)|Patients receive lenalidomide PO on days 1-21 and nivolumab IV over 1 hour on days 1 and 14. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89375094|NCT03162640||P|for cannabis
89375095|NCT03162640||C|for the control group
89375096|NCT05419440|Active Comparator|laparoscopic drainage of appendicular abscess|laparoscopic drainage of appendicular abscess laparoscopy drainage of pus ,excision of appendix and putting a drain
89375097|NCT05419440|No Intervention|interventional radiology for management of appendicular abscess|insertion of a drain or pig tail under sonar or ct guided
89375098|NCT05746156|Experimental|lymphatic map|Lymphatic mapping will be performed
89375099|NCT05179486||Observational (biospecimen collection, questionnaire)|Participants complete a questionnaire over 20 minutes. Participants also undergo collection of blood and leftover tissue samples.
88846871|NCT01139996|Experimental|Transdermal Clonidine/Oral Clonidine|An oral loading dose of Clonidine 0.3 mg and placement of a Clonidine Transdermal system at a dose of 0.3 mg/day (Catapres TTS-3), with patch overlay, followed by a final dose of Clonidine 0.3 mg after 12 hours
88846872|NCT01139996|Placebo Comparator|Comparator|Placebo group will receive a placebo oral tablet and the overlay patch only and in 12 hours they will receive a second and final placebo tablet
88846873|NCT02417870|Experimental|aldesleukin|
88846874|NCT01131884|Active Comparator|Fosamax|Fosamax at 70 mgs q weekly by mouth for the duration of the study.
88846875|NCT01131884|Placebo Comparator|Placebo Sugar Pill|Double blind study using Fosamax versus placebo. Placebo is an inactive drug.
88846876|NCT01139294|No Intervention|standard IV therapy|control arm of the study
88846877|NCT01139294|Experimental|Hylenex|1ml subcutaneous with initiation of intravenous fluids then every 24 hours with a maximum dose of 3 injections in 72 hours
88846878|NCT02402036|Experimental|Regorafenib|Regorafenib 120 mg orally daily for 21 days out of a 28 day cycle
88846879|NCT02389712|Active Comparator|Lamotrigine|Subjects on this arm will be randomized to Lamotrigine.
89375100|NCT05419206||COVID-19 cases with anticytokine therapy|Considering the use of anti-cytokines in these patients, it was found that 53 received tocilizumab, 27 received anakinra, and 10 received both. CMV DNA was positive in 38 (22.7%) of the patients included in the study. CMV positivity was found to be significantly higher in 90 patients (31.11%) compared to 77 patients (16.88%) who did not receive anti-cytokine treatment (p:0.033)
89375101|NCT05419206||COVID-19 cases without anticytokine therapy|MV positivity was found to be significantly higher in 90 patients (31.11%) compared to 77 patients (16.88%) who did not receive anti-cytokine treatment (p:0.033)
89375102|NCT05746000|Other|Control Group|Participants in the control group will attend three standard diet counselling.
89375103|NCT05746000|Other|Intervention Group|Participants in the intervention group will attend three individual diet counselling and will be educated about sugar calculation (sugar exchange).
88846880|NCT02389712|Active Comparator|Fluoxetine|Subjects on this arm will be randomized to Fluoxetine.
88846881|NCT00378950|Active Comparator|1|Participants will receive a 1-hour education session about CHF, symptom recognition, diet, exercise, and daily check ups.
88846882|NCT00378950|Experimental|2|Participants will receive a 1-hour education session about CHF, symptom recognition, diet, exercise, and daily check ups, as well as additional information on diuretic self adjustment. This group will then get several follow-up phone calls over the course of the year to reinforce these topics and help them master the knowledge and encourage behavior and lifestyle changes to align with these topics.
88846883|NCT03530917|Experimental|Single Ascending Dose (SAD): Placebo|In SAD Cohorts 1-4, there will be eight participants in total receiving placebo, two in each cohort.
88846884|NCT03530917|Experimental|SAD: Cohort 1|Eight participants will be administered 40mg RO7020531 orally on Day 1.
88846885|NCT03530917|Experimental|SAD: Cohort 2|Eight participants will be administered 100mg RO7020531 orally on Day 1.
88846886|NCT03530917|Experimental|SAD: Cohort 3|Eight participants will be administered 140mg RO7020531 orally on Day 1.
88846887|NCT03530917|Experimental|SAD: Cohort 4|Eight participants will be administered 170mg RO7020531 orally on Day 1.
88846888|NCT03530917|Experimental|Multiple Ascending Dose (MAD): Placebo|In MAD Cohorts 1-3, there will be six participants in total receiving placebo, two in each cohort.
88846889|NCT03530917|Experimental|MAD: Cohort 1|Eight participants will be administered 100mg RO7020531 orally on Day 1 and every other day (QOD) for 14 days.
88846890|NCT03530917|Experimental|MAD: Cohorts 2 and 3|Sixteen participants will be administered 150mg RO7020531 orally on Day 1 and every other day (QOD) for 14 days.
89375104|NCT03162406|Experimental|Vitamin D|Procedure: SRP Dietary Supplement: Vitamin D3 Oral supplementation 25000 IU once per week for 6 months Other Name: Cholecalciferol
89375105|NCT03162406|Placebo Comparator|Placebo|Procedure: SRP Dietary Supplement: Placebo Oral supplementation once per week for 6 months
89375106|NCT02946385|Experimental|ABCWY_ 0_2 Group|Subjects who received 2 doses of MenABCWY vaccine at Month 0 and Month 2 in study V102_15 (NCT02212457), and will receive 1 dose of MenABCWY in this extension study
89375107|NCT02946385|Experimental|ABCWY_0_2_6 Group|Subjects who received 3 doses of MenABCWY vaccine at Month 0, Month 2 and Month 6 in study V102_15 (NCT02212457), and will receive 1 dose of MenABCWY in this extension study
89375108|NCT02946385|Experimental|B_0_2 Group|Subjects who received 2 doses of rMenB+OMV vaccine at Month 0 and Month 2 in study V102_15 (NCT02212457), and will receive 1 dose of rMenB+OMV in this extension study
89375109|NCT02946385|Experimental|ABCWY_ 0_6 Group|Subjects who received 2 doses of MenABCWY vaccine at Month 0 and Month 6 in study V102_15 (NCT02212457), and will receive 1 dose of MenABCWY in this extension study
89375110|NCT02946385|Active Comparator|ABCWY Naive Group|Subjects who are meningococcal vaccine-naive and of similar age to subjects enrolled from the parent study (NCT02212457), and will receive 2 doses of MenABCWY in this extension study
89375111|NCT02946385|Active Comparator|rMenB+OMV Naive Group|Subjects who are meningococcal vaccine-naive and of similar age to subjects enrolled from the parent study (NCT02212457), and will receive 2 doses of rMenB+OMV in this extension study
89375112|NCT05177341||Amputees with acceptable phantom sensation|
89375113|NCT05177341||Amputees with no phantom sensation|
89375114|NCT05177341||Control group|
89375115|NCT05308771|Experimental|Epidural anesthesia using VPC syringe|Epidural anesthesia detection using VPC syringe
89375116|NCT05676190|Experimental|CIK combined with chemotherapy group|Combination of CIK cells and chemotherapy
89375117|NCT05676190|Experimental|CIK combined immunotherapy group|Combination of CIK cells and immunotherapy
89375118|NCT05676190|Experimental|CIK combined targeted therapy group|Combination of CIK cells and targeted therapy
89375119|NCT05676190|Experimental|CIK in combination with other therapies|CIK in combination with any two or three of these (i.e., chemotherapy, immunotherapy, and targeted therapy) treatments
89375120|NCT04917211|Experimental|virtual reality mask|During the prior anesthesia consultation, the patient is informed of the possibility within the framework of the study of benefiting from analgesia with disconnection by a virtual reality mask, associated with local anesthesia. The patient will be explained that in the event of pain despite the virtual reality mask and local anesthesia, administration of remifentanil will be possible
89375121|NCT02694718|Experimental|Capecitabine+Oxaliplatin|Eligible participants received capecitabine 1000 milligrams per square meter (mg/m^2) on Days 1-14, and 825 mg/m^2 on Days 22-35 and 43-56 twice a day (bid) orally, along with oxaliplatin as a 2-hour intravenous (iv) infusion of 130 mg/m^2/once a day (d) on Day 1 and 50 mg/m^2/d on Days 22, 29, 43 and 50 prior to radiotherapy. Participants received radiation therapy having a fraction dose of 1.8 gray (Gy)/day, 5 days a week, for five consecutive weeks starting on Day 22 of the treatment period. Participants, who completed the treatment period, underwent surgery at Week 14.
89375122|NCT04378153|Experimental|HS-Discontinue (Study A)|Discontinuation of current hypertonic saline (HS) therapy in Study A
89375123|NCT04378153|Active Comparator|HS-Continue (Study A)|Continuation of current hypertonic saline (HS) therapy in Study A
89181564|NCT04113551||Cohort T14: MPH (Concerta and Ritalin) All Exposures|Analysis of data will be performed for participants who have had all exposures of MPH (Concerta and Ritalin) between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure. These are all exposures to any MPH (Concerta or Ritalin) among the participants with an exposure to MPH (Concerta) during the study period and to an exposure to MPH (Ritalin) during the study period.
89375124|NCT04378153|Experimental|Dnase-Discontinue (Study B)|Discontinuation of current dornase alfa (dnase) therapy in Study B
89375125|NCT04378153|Active Comparator|Dnase-Continue (Study B)|Continuation of current dornase alfa (dnase) therapy in Study B
89375126|NCT03106090|No Intervention|No SCP Control|Patients returning for early follow-up who did not receive SCP.
89375127|NCT03106090|No Intervention|SOC SCP Control|Patients returning for early follow-up who received a standard of care SCP.
89375128|NCT03106090|Experimental|eSCP Intervention|"Patients currently receiving treatment who will be enrolled to receive an enhanced SCP (eSCP) with additional information beyond ASCO guidelines tailored to patient concerns and preferences."
89375129|NCT03161080|Experimental|Dry Eye Neovis|20 Patients with dry eye syndrome receiving Neovis Total Multi Eyedrops
89375130|NCT03161080|Experimental|Dry Eye Vismed|20 Patients with dry eye syndrome receiving Vismed Multi Eyedrops
89375131|NCT03161080|Experimental|Dry Eye Hydrabak|20 Patients with dry eye syndrome receiving Hydrabak Eyedrops
89375132|NCT04923139||Japanese VTE patients including Ca-VTE patients|Include a large number of adult VTE patients (including Ca-VTE patients) prescribed rivaroxaban who visited facilities covered by the MDV database
89181565|NCT02592954|Experimental|Jojoba oil with broccoli sprout extract|500nmol of broccoli sprout extract in 1ml of jojoba oil will be applied to the same arm every night under saran wrap for 1 week
89181566|NCT02592954|Placebo Comparator|Jojoba oil|1ml of jojoba oil will be applied to the same arm every night under saran wrap for 1 week
88846891|NCT02365688|Other|Initial bolus pre-incision|Initial pre-incision bolus of 500 cc of fluids with hemodynamic response recorded
89181567|NCT02605343||NeuroIDgenetix-guided Pain Management|The medical provider for the NeuroIDgenetix-guided group will make post-operative pain management recommendations based on test results. Patient outcomes, narcotic consumption, opioid-related adverse effects, time to mobilization, number of adverse drug events and number of hospital and/or medical visits will be measured throughout the study.
89375133|NCT04891627||Healthy control groups|individuals with clinically healthy gingiva BOP score less than 10% and PD≤3mm
89375134|NCT04891627||Periodontitis group|interdental AL ≥5 mm
89375135|NCT04891627||Periodontitis with diabetes group|HbA1c ≥6.5%
89375136|NCT04365829|Experimental|Virtual reality|
89375137|NCT04692688|Experimental|APX3330|Five 120 mg tablets will be taken by mouth as follows: 3 tablets every morning and 2 tablets every evening.
89375138|NCT04692688|Placebo Comparator|Placebo|Five 120 mg tablets will be taken by mouth as follows: 3 tablets every morning and 2 tablets every evening.
89375139|NCT05681221|Active Comparator|LSTR in necrotic primary second molar using TAP|Triple antibiotic paste (TAP) is considered the gold standard in LSTR. It is a combination of ciprofloxacin, metronidazole and minocycline. Many anaerobic bacteria are resistant to ciprofloxacin. Hence, it is often used with metronidazole in treating mixed infections to compensate for its limited scope. Therefore, TAP can affect gram-negative, gram-positive, and anaerobic bacteria, and this combination can be effective against odontogenic microorganisms.
88846892|NCT05600348|Experimental|0 oz Pork|Participants receive 0 oz pork and 6 oz 50:50 blend of chicken and beef per day
88846893|NCT05600348|Experimental|3 oz Pork|Participants receive 3 oz pork and 3 oz 50:50 blend of chicken and beef per day
88846894|NCT05600348|Experimental|6 oz Pork|Participants receive 6 oz pork and 0 oz 50:50 blend of chicken and beef per day
88846895|NCT02369744|Active Comparator|Silodosin|Subjects in the Silodosin Group will be given silodosin 8 mg tablets, one tablet to be taken PO each day for two weeks.
88846896|NCT02369744|Active Comparator|Tamsulosin|Subjects in the Tamsulosin Group will be given tamsulosin 0.4 mg tablets, one tablet to be taken PO each day for two weeks.
88846897|NCT03577171|Experimental|ABI-H0731 + SOC ETV|Participants with cHBV who are currently not being treated will receive ABI-H0731 along with SOC ETV tablets orally for 24 weeks. Eligible participants may enter a separate extension study after Week 24 to continue open-label ABI-H0731 for up to an additional year if necessary.
88846898|NCT03577171|Experimental|Placebo + SOC ETV|Participants with cHBV who are currently not being treated will receive matching placebo along with SOC ETV tablets orally for 24 weeks. Eligible participants may enter a separate extension study after Week 24 to start treatment on open-label ABI-H0731 for up to a year if necessary.
88846899|NCT02367170|Experimental|IMST Intervention group|IMST will be conducted 5 days per week by study staff using a threshold inspiratory muscle training device (Respironics model 735). Prior to training, the tracheal cuff pressure is assessed to ensure no air leakage and appropriate inflation. The IMST training takes approximately 15 minutes to complete. To perform IMST, FiO2 is increased for 2 minutes prior to each training bout to maintain oxygen saturation more than 92%.
88846900|NCT02367170|Sham Comparator|SHAM group|SHAM training will also be conducted five days per week with an identical training device that has been modified by removing the valve leaflet, which essentially removes all inspiratory loading by the device. The modified SHAM device makes a whistling sound during inspiration, which enhances the sham effect. For SHAM treatment, supplemental oxygen FiO2 will be increased for two minute prior to each bout.
88846901|NCT01104116|Experimental|PET/CT imaging|Surgical patients will undergo [18F]-FDG PET/CT imaging
88846902|NCT03579433|Experimental|ORA with VerifEye+|First surgical eye randomly assigned to Acrysof® IQ Toric IOL and ORA with VerifEye+ or Acrysof® IQ Toric IOL and Barrett Toric Calculator, with the second surgical eye (fellow eye) assigned to the alternative group.
88846903|NCT03579433|Active Comparator|Barrett Toric Calculator|First surgical eye randomly assigned to Acrysof® IQ Toric IOL and ORA with VerifEye+ or Acrysof® IQ Toric IOL and Barrett Toric Calculator, with the second surgical eye (fellow eye) assigned to the alternative group.
88846904|NCT03534427|No Intervention|Control group|No exercise intervention
88846905|NCT03534427|Experimental|Jump rope exercise intervention|The jump rope exercise program was performed for 50 minutes with 5 minutes of warm-up and cool-down per day, 5 times a week for 12 weeks. The program consisted of various main jump rope exercises (1 line 2 jump, jumping feet together, running jumping, open side jump, open back and forth jump, rock paper scissor jump). The warm-up and cool down consisted of static stretching, walking, and jogging. Intensity of exercise was gradually increased from 40-50% heart rate reserve (HRR) in weeks 1-4 and to 60-70% HRR in weeks 9-12. Each training session was supervised by the researchers. Every subject wore a heart rate monitor during the whole training session in order to maintain the designated training intensity.
88846906|NCT02340728|Experimental|ERCP with SEMS plus radiofrequency ablation|Endoscopic retrograde cholangiopancreatogram (ERCP) is performed under standard conditions with cannulation of the bile duct, and demonstration on a cholangiogram the location, diameter and length of the biliary stricture. The HabibTM EndoHBP probe (EMcision, London, United Kingdom) is advanced through the working channel of a side viewing endoscope over a 0.035in guidewire, and positioned across the occluded SEMS under fluoroscopy. 7-10W are usually delivered for 90 seconds with a standard high frequency generator, followed by a 1 minute resting period. Sequential applications of RFA are applied along the entire length of the stricture with an overlap of 1cm.
88846907|NCT02340728|Active Comparator|ERCP with SEMS alone (standard of care)|Endoscopic retrograde cholangiopancreatogram (ERCP) is performed under standard conditions with cannulation of the bile duct, and demonstration on a cholangiogram the location, diameter and length of the biliary stricture. The HabibTM EndoHBP probe (EMcision, London, United Kingdom) is advanced through the working channel of a side viewing endoscope over a 0.035in guidewire, and positioned across the occluded SEMS under fluoroscopy. 7-10W are usually delivered for 90 seconds with a standard high frequency generator, followed by a 1 minute resting period.
88846908|NCT00376909|Experimental|Intervention|Series of telephone support calls from a trained prevention care manager
88846909|NCT00376909|No Intervention|Usual Care|Usual care
88846910|NCT01078844|Placebo Comparator|Placebo|Treatment as usual plus placebo
88846911|NCT01078844|Active Comparator|memantine|Treatment as usual plus memantine
88846912|NCT00422851||1|Normal tympanic membrane
88846913|NCT00422851||2|tympanosclerosis
88846914|NCT00422851||3|dimeric (atrophic)
88846915|NCT01072526|Active Comparator|Intervention|Subjects will receive Euphrasia-based homeopathic therapy (Artificial Tears) in combination with cyclosporin solution (Restasis) .
88846916|NCT01072526|Placebo Comparator|Control|Subjects will receive placebo in combination with cyclosporin solution (Restasis) .
88846917|NCT03536923|Experimental|Leva Arm|Subjects will use the leva device twice daily to perform pelvic floor muscle exercises
88846918|NCT05312840|Other|Routine dose group|Routine dose group: Every three weeks as a cycle. On the first day of each cycle, Gemcitabine 1000mg / m2, Cisplatin 75mg / m2, Carboplatin auc5 were injected intravenously, and Gemcitabine 1000mg / m2 and Cindilimab 200mg were injected intravenously on the eighth day. After 4 or 6 cycles of treatment, if there is no disease progression, continue to use Cindilimab 200mg every three weeks until the disease progresses.
89375140|NCT05681221|Experimental|LSTR in necrotic primary second molar using nano silver particles and calcium hydroxide|Nano silver particles have a strong anti-bacterial properties due to its ability to target the bacteria on different cellular levels. Calcium hydroxide has been used for so long as an intra canal medication in odontogenic infections due to its strong alkalinity that gives it its anti bacterial properties. This combination might be a future alternative to antibiotics, in an attempt to decrease the bacterial antibiotic resistance and antibiotics use.
89375141|NCT04303507|Experimental|Chloroquine or Hydroxychloroquine|"In Asia, the participant will receive chloroquine.~In Europe, the participant will receive hydroxychloroquine~Specific drug allocation will be determined by country prior to activation based upon factors such as inventory availability and importation requirements"
89375142|NCT04303507|Placebo Comparator|Placebo|
89375143|NCT04296643|Experimental|Medical Mask|Medical Mask worn when providing care to patient with febrile respiratory illness
89375144|NCT04296643|Active Comparator|N95 respirator|N95 respirator worn when providing care to patient with febrile respiratory illness
89375145|NCT03202537|Experimental|dexlansoprazole|dexlansoprazole 90mg per day (60mg am, 30mg pm dosing) for 4 weeks
89375146|NCT02944513|Experimental|Experimental|Subjects will receive the Quell device
89375147|NCT02944513|No Intervention|Control|Subjects will not receive the Quell device
89375148|NCT03638557|Experimental|Intervention|"The intervention package consists of the following;~Balanced Nutrition and Clean and Healthy Lifestyle Behavior Education for the boarding school students (once a week with the duration of 30-60 minutes. 3 weeks are delivered by trained teachers, and 1 week by research team.~Nutritious lunch, for 7 days a week. With the total of 220 days. The lunch menu is designed to meet 30% of the students RDA, which consists of 635-777 Kcal and 18-22 grams of protein"
89375149|NCT04289935|Experimental|single arm|"Unicentric histologically confirmed invasive luminal B, HER2- enriched, triple negative breast cancer + Clipping + Neoadjuvant chemotherapy~rCR / near-rCR in MRI~Registration~US-guided VAB~Breast conserving surgery / mastectomy~Pathology examination 1. Preoperative VAB, 2. Surgical specimen"
89375150|NCT04235413|Experimental|Real-Time Incentives Group|Each participant will be randomized using a blocking procedure (SNAP participant or not). The intervention will last 6 months and consist of receiving real-time financial incentives at the point of purchase for eligible fruits and vegetables purchases.
89375151|NCT04235413|No Intervention|Control Group|No intervention administered. Each participant will be randomized using a blocking procedure (SNAP participant or not).
89375152|NCT04762537|Active Comparator|Standard Induction Method|The Standard Method (13-day long) includes 5-days of buprenorphine taper followed by 7-day washout period
89375153|NCT04762537|Experimental|Rapid Induction Method|The Rapid Method includes one day of buprenorphine followed by a day of washout and 3-4 days of oral naltrexone titration with adjunctive medications
89375154|NCT04755673|Experimental|Experimental: Atrantil (Medical Food)|All participants in the trial will take two capsules of Atrantil three times a day for 28 days.
89375155|NCT03620851||elderly patients (≥70 yo) vs. younger patients (<70 yo)|elderly patients (≥ 70 yo) and younger patients (< 70 yo)
89375156|NCT04920643|Experimental|High-Exchange Ultrafiltration|Subzero-Balance Simple Modified Ultrafiltration (60ml/kg/hour)
89375157|NCT04920643|Active Comparator|Low-Exchange Ultrafiltraiton|Subzero-Balance Simple Modified Ultrafiltration (6ml/kg/hour)
89375158|NCT03631134|Experimental|SGLT2i treatment|The patients who are using basal insulin therapy with or without oral hypoglycemic drugs will be added SGLT2 inhibitor treatment
89375159|NCT01381380|Other|single-arm studies|Manual therapy for one group
88846919|NCT05312840|Other|Low dose group|Low dose group: Every three weeks as a cycle. Gemcitabine 750mg / m2, Cisplatin 56mg / m2 or Carboplatin auc3 were injected intravenously on the first day of each cycle 75. On the eighth day, Gemcitabine 750mg / m2 and Cindilimab 200mg were injected intravenously. After 4 or 6 cycles of treatment, if there is no disease progression, continue to use Cindilimab 200mg every three weeks until the disease progresses.
89375160|NCT04909645|Experimental|Clearsight (finger cuff)|
89375161|NCT04011618|Placebo Comparator|Placebo|16 patients to receive 1 homologated placebo capsule (calcined magnesia 500 mg) every 12 hours along 12 weeks
89375162|NCT04011618|Experimental|Ellagic acid|16 patients to receive 1 homologated intervention capsule (ellagic acid 500 mg) every 12 hours along 12 weeks
89375163|NCT04153279|Experimental|CMV-TCR-T cells|The patients will receive one dose of CMV-TCR-T.The dosage ranges from 0.1×10^6 to 1×10^6 TCR+T/Kg.
89375164|NCT04138615|Experimental|Morphine|Morphine will be administered intravenously
89375165|NCT04138615|Placebo Comparator|Placebo|Saline will be administered intravenously
89375166|NCT01381302||Parkinson|Early onset of disease
89375167|NCT01383330|Experimental|Megace|800mg
89375168|NCT01383330|Active Comparator|DW-ES(A)|625mg
89375169|NCT01383330|Active Comparator|DW-ES(B)|625mg
89375170|NCT03018938|Experimental|Insulin Analog Mid Mixture|Insulin analog mid mixture given subcutaneously (SC).
89375171|NCT03018938|Experimental|Basal Insulin Analog|Basal insulin analog given SC.
89375172|NCT03631368|Experimental|Botox|
89375173|NCT02943577|Experimental|Rapastinel 450 mg|Rapastinel 450 mg weekly intravenous (IV) injections. Each participant will continue to take the same dose of antidepressant therapy the participant was receiving prior to entering this study throughout treatment.
89375174|NCT02943577|Placebo Comparator|Placebo|Placebo-matching rapastinel weekly IV injections. Each participant will continue to take the same dose of antidepressant therapy the participant was receiving prior to entering this study throughout treatment.
89375175|NCT03174535||Exposure group|The exposure group was the patients who were treated with Qilong capsules (QLC). The willingness of the patients and the objective judgment of the clinician were comprehensively considered to decide whether to use QLC for intervention. Patients who chose to use QLC for intervention would take it immediately after being deemed eligible for enrollment. The recommended dosage of QLC was 0.4g each time, 3 times a day. The course of treatment was 12 weeks. QLC was produced by Jining Huaneng Pharmaceutical Factory Co., Ltd. All participants in the exposure groups received the standard level of CT provided by clinicians according to the clinical diagnosis and treatment guidelines for IS, including antiplatelet aggregation drugs, antihypertensive drugs, hypoglycemic drugs, and lipid-lowering drugs.
89375176|NCT03174535||Non-exposure group|The non-exposure group was the patients who did not take QLC. All participants in the non-exposure groups received the standard level of CT provided by clinicians according to the clinical diagnosis and treatment guidelines for IS, including antiplatelet aggregation drugs, antihypertensive drugs, hypoglycemic drugs, and lipid-lowering drugs.
88846920|NCT00376129|Experimental|I|
88846921|NCT02307188|Experimental|Basket Catheter|The Constellation Full Contact Mapping Catheter (multipolar catheter) to be utilized for collection of atrial electrograms.
88846922|NCT01035944|Experimental|HemCon Operating Room|The HemCon dressing is the intervention for the HemCon Operating Room arm. The first sub-study will evaluate the use of HemCon dressings in the operating room setting. 20 patients will be treated with HemCon dressings following a debridement, and 20 patients will be treated with gauze dressings following a debridement.
88846923|NCT01035944|Active Comparator|Control Operating Room|The first sub-study will evaluate the use of HemCon dressings in the operating room setting. 20 patients will be treated with HemCon dressings following a debridement, and 20 patients will be treated with gauze dressings following a debridement.
88846924|NCT01035944|Experimental|HemCon Bedside|The intervention for the HemCon Beside arm is the HemCon Dressing. The other sub-study will evaluate the use of HemCon dressings compared to control dressings in bedside debridement. In this sub-study, 20 patients will be treated with HemCon dressings following a debridement, and 20 patients will be treated with gauze dressings following a debridement.
88846925|NCT01035944|Active Comparator|Control Bedside.|The other sub-study will evaluate the use of HemCon dressings compared to control dressings in bedside debridement. In this sub-study, 20 patients will be treated with HemCon dressings following a debridement, and 20 patients will be treated with gauze dressings following a debridement.
88846926|NCT03582553|Experimental|150 mg dose|Blood will be drawn at at 0, 2, 3, 3.5, 4, 4.5, 6, 8,12, and 24 hours to measure serum naringenin concentrations in response to a single 150 mg oral dose of an extract of Citrus sinensis (sweet orange) containing naringenin and its precursor naringin.
88846927|NCT03582553|Experimental|300 mg dose|Blood will be drawn at at 0, and 4 hours to measure serum naringenin concentrations in response to a single 300 mg oral dose of an extract of Citrus sinensis (sweet orange) containing naringenin and its precursor naringin.
88846928|NCT03582553|Experimental|600 mg dose|Blood will be drawn at at 0, 2, 3, 3.5, 4, 4.5, 6, 8,12, and 24 hours to measure serum naringenin concentrations in response to a single 600 mg oral dose of an extract of Citrus sinensis (sweet orange) containing naringenin and its precursor naringin.
88846929|NCT03582553|Experimental|900 mg dose|Blood will be drawn at at 0, and 4 hours to measure serum naringenin concentrations in response to a single 900 mg oral dose of an extract of Citrus sinensis (sweet orange) containing naringenin and its precursor naringin.
88846930|NCT03582553|Placebo Comparator|Placebo|Subjects in the first cohort will receive 150 mg and 300 mg ascending doses of naringenin and subjects in the second cohort will receive 600 mg and 900 mg ascending doses of naringenin. Each cohort will also have a placebo group.
88846931|NCT01025492|Active Comparator|Trilipix|Trilipix (fenofibric acid) 135 mg tablet orally, once daily for 12 weeks
88846932|NCT01025492|Placebo Comparator|Placebo|Matching placebo tablet orally, once daily for 12 weeks
89375177|NCT04776499|Experimental|Healthy volunteers receiving propylthiouracil, riociguat, and perphenazine|Eight healthy volunteers will be included. Up to 15 healthy volunteers will be screened to reach the goal of 8 exposed volunteers. Sex is not expected to have an impact on the short-term evaluation of the potential drug-drug interactions. Therefore female and male participants will be included in an undefined proportion.
88846933|NCT04331834|Experimental|Pre-exposure prophylaxis of SARS-CoV-2|Participants will receive hydroxychloroquine 400 mg daily during the first 4 days, followed by 400 mg weekly during 6 months
88846934|NCT04331834|Placebo Comparator|Control group with placebo|Participants will receive placebo 400 mg daily during the first 4 days, followed by 400 mg weekly during 6 months
88846935|NCT04735159|Active Comparator|Study group-SCS Impanted|30 patients with chronic pain (at least 6 months) with pre- and post-surgery evaluation (imaging and clinical evaluation) implanted with Precision SpectraTM for the validation study and for the construction of the predictive model.
88846936|NCT04735159|No Intervention|Comparator-chronic pain|20 patients with chronic pain (at least 6 months) with degenerative spine pain. Non-specific low-back pain, nociceptive pain / mixed neuropathic. This will be the comparator group
89375178|NCT03668054|Experimental|Bevacizumab (Lumiere®)|Dosage form: intravitreal single dose vial. Dosage: 0.05ml (1.25 mg) Frequency: monthly injections (up to 6 doses)
89375179|NCT03623048|Experimental|Propolis extract|intervention
88846937|NCT04735159|No Intervention|Control-healthy volunteers|10 volunteers without pain or related disease, age less than 25 years, to establish a control group whose pattern is used as a comparator with chronic pain groups. This is the control group
88846938|NCT02202044|Experimental|Intravesical BCG and EMDA/MMC|Patients are assigned one course of treatment per week for 6 weeks of Intravesical Intravesical BCG and EMDA/MMC
88846939|NCT03538795|Experimental|iTBS&eCIMT|Participants will first receive baseline testing followed by a no-treatment control period. Participants will then be tested again, receive the combination therapy, i.e., iTBS&eCIMT, and then receive post-treatment testing.
88846940|NCT01023620|Experimental|Pioglitazone|10 male patients with lipodystrophy taking daily Pioglitazone 45 mg
88846941|NCT01023620|Sham Comparator|Observation/Comparison|10 male patients with lipodystrophy not taking daily Pioglitazone
88846942|NCT03595579|Experimental|AXS-05|
88846943|NCT03595579|Active Comparator|Bupropion|
88846944|NCT02200328|Experimental|Metronidazole|Metronidazole tablets 500mg orally or IV , 3 times a day for a maximum of 14 days
88846945|NCT02200328|Placebo Comparator|Placebo|Placebo(Corn starch pill) orally 3 times a day for a maximum of 14 days
88846946|NCT04327843|Experimental|CAE + LAI|Customized Adherence Enhancement (CAE) + Long-Acting Injectable Antipsychotic (LAI)
88846947|NCT02147834|Active Comparator|Ranolazine|"Ranolazine 500mg tablet~500mg tablet two times per day for 7 days then,~500mg tablet (1000mg) two times per day for 15 weeks"
88846948|NCT02147834|Placebo Comparator|Sugar pill|"Sugar pill that looks like the drug ranolazine 500mg tablet~500mg tablet two times per day for 7 days then,~500mg tablet (1000mg) two times per day for 15 weeks"
88846949|NCT04343287|Active Comparator|BRM421 Ophthalmic Solution|A topical solution of BRIM421 ophthalmic drops
89375180|NCT03623048|Experimental|Pomegranate extract|intervention
89375181|NCT03623048|Active Comparator|Chlorhexidine|comparator
88846950|NCT04343287|Placebo Comparator|Placebo|A vehicle ophthalmic drops
88846951|NCT04369885|Experimental|Home Telemedicine Device|This arm will receive the intervention of the home telemedicine device for three months.
88846952|NCT00979550|Experimental|Aldara cream|Imiquimod (Aldara cream) will be applied nightly for four weeks after standard of care laser treatment for port wine stain.
89375182|NCT03623048|Placebo Comparator|Saline|comparator
88846953|NCT00979550|Placebo Comparator|non-medicated petroleum cream|Non-medicated petroleum cream will be applied nightly for four weeks after standard of care laser treatment for port wine stain.
88846954|NCT04394845|Experimental|[18F]GTP1|Participants will receive a single bolus injection of radioligand [18F]GTP1 intravenously (IV).
88846955|NCT00966992|No Intervention|Arm 1 (No Zometa)|Women will complete their standard chemoradiation treatment protocol and end of treatment PET scan at about 3 months from completion of radiation. All interventions on this arm are standard of care.
88846956|NCT00966992|Experimental|Arm 2 (Zometa)|Women will complete their standard chemoradiation treatment protocol and end of treatment PET scan at about 3 months from completion of radiation. Women randomized to zoledronic acid will receive 4 mg intravenously (IV) with their first dose chemotherapy and 3, 6 and 9 months after completion of radiation (total of 4 doses) along with scheduled follow-up dual-energy X-ray absorptiometry (DEXA) and biomarker studies.
88846957|NCT02099318|Active Comparator|Active SRP cases|SRP cases: After patients have provided written informed consent, the CT and/or MRI images obtained as part of routine preoperative care will be used to construct the model that the neurosurgeons will use in the SRP. No new or additional images will be obtained as part of this study, and the SRP modeling will rely on neuroimaging conducted as part of standard preoperative assessment. For SRP cases, prior to performing surgery, surgeons will plan and rehearse patient-specific cerebral aneurysm surgery. Similarly to the CT/MRI studies, the SRP will be available for the surgeons during the surgery for evaluation of optional surgery approaches.
88846958|NCT02099318|Placebo Comparator|Control cases|Control cases: The control group will be randomly selected according to a predetermined alternating sequence of consecutive prospectively video recorded aneurysm cases. Informed consent from all patients in both the control and SRP groups will be obtained.
88846959|NCT04418947|No Intervention|No intervention|
88846960|NCT04418947|Active Comparator|MPM control letter|
89375183|NCT01312597|Experimental|Fruit beverage|
89375184|NCT01312597|Experimental|Control beverage|
89375185|NCT03016598|Experimental|Oxytocin|Patients in methadone maintenance treatment (MMT) programs are required to come in every day for their methadone. Additionally they are required to come in weekly for psycho- educational/therapy groups, biweekly random urine screenings, and monthly individual therapy sessions. The investigators will piggy-back off this existing structure and randomize Veterans with stimulant use disorders and receiving MMT for co-occurring opioid use disorder (OUD) to receive either oxytocin or placebo, to be administered twice daily for six weeks while in the MMT program.
89375186|NCT03016598|Placebo Comparator|Placebo|Patients in MMT programs are required to come in every day for their methadone. Additionally they are required to come in weekly for psycho- educational/therapy groups, biweekly random urine screenings, and monthly individual therapy sessions. The investigators will piggy-back off this existing structure and randomize Veterans with stimulant use disorders and receiving MMT for co-occurring OUD to receive either oxytocin or placebo, to be administered twice daily for six weeks while in the MMT program.
89375187|NCT03667664|Other|Prevention of loss of autonomy|Lifestyle counseling for elderly people about physical exercises and nutrition in a preventive way
89375188|NCT04052737|Active Comparator|Normal Saline|Patients will receive the best available standard of care. In control group, 3 doses of equal volume of normal saline will be administered as an IV bolus over 1 minutes every 3 hours ± 1 hour on day 1, the same dosing regimen will be repeated every month for 6 months post randomization.
89375189|NCT04052737|Experimental|PMZ-1620 (sovateltide)|Patients will receive the best available standard of care. In PMZ group, 3 doses of PMZ-1620, at 0.3 μg/kg body weight will be administered as an intravenous bolus over 1 minute every 3 hours ± 1 hour on day 1 (total dose/day: 0.9 µg/kg body weight), the same dosing regimen will be repeated every month for 6 months post randomization.
88846961|NCT04418947|Experimental|MPM intervention letter|
89375190|NCT03017846|Experimental|Cantharidin Treatment|Subjects with lesions treated with topical cantharidin every 3 weeks up to 12 weeks.
89375191|NCT04691869|No Intervention|Control|Patients will be randomized into a control group and study group. The control group will receive an informational discussion with the nurse-practitioner regarding steps to reduce the risk for osteoporosis, as well as an informational handout in their discharge papers.
89375192|NCT04691869|Experimental|Interventional|The study group will undergo the QUS (performed by a member of the study team) and receive the same informational discussion and handouts, with the addition of a QUS screening to take to their follow-up appointment. The QUS screening will come with a half-page description, describing the screening and what their results mean. A discussion lead by the nurse-practitioner, who is a member of the study staff, regarding the results will happen prior to discharge.
89375193|NCT03667118|Experimental|Food Supplement|Infants who received the active food supplement powder
89375194|NCT03667118|Placebo Comparator|Placebo|Infants who received the placebo powder
88846962|NCT04418947|Active Comparator|Mailed control letter|
88846963|NCT04418947|Experimental|Mailed intervention letter|
88846964|NCT00970736||1|20 healthy participants between 60 and 80 years of age. Ten men and 10 women.
88846965|NCT02074904|Experimental|Topiramate|up to 200mg/day orally (over 8 weeks during which the dosage is gradually increased up to 200 mg orally and then maintained, and 1 week of medication taper)
88846966|NCT02074904|Placebo Comparator|Placebo|placebo
88846967|NCT03542305|Experimental|Mild|Mild renal impairment
88846968|NCT03542305|Experimental|Moderate|Moderate renal impairment
88846969|NCT03542305|Experimental|Severe|Severe renal impairment
88846970|NCT03542305|Other|Normal|Normal renal function
88846971|NCT02057276|Active Comparator|Active rTMS|Participants will receive daily active rTMS with occupational therapy immediately following rTMS for 10 consecutive weekdays.
88846972|NCT02057276|Sham Comparator|Sham rTMS|Participants will receive daily sham rTMS with occupational therapy immediately following rTMS for 10 consecutive weekdays.
89181568|NCT02605343||Historical Control|The retrospective chart review will utilize patient outcomes from patients meeting the study inclusion/exclusion criteria. The medical provider for the control group will not have received the NeuroIDgenetix Test Panel results and would have made post-operative pain management recommendations per standard of care.
89181569|NCT00914615|Experimental|SBRT for liver mets from colorectal cancer|
89181570|NCT00798317|Experimental|Ocriplasmin 125µg|125µg of ocriplasmin intravitreal injection
89181571|NCT00798317|Placebo Comparator|Placebo|Intravitreal injection of placebo
89181572|NCT04113629|Other|Sofosbuvir/Daclatasvir|standard DAA therapy: 12 or 24 weeks of sofosbuvir/daclatasvir
89181573|NCT00779402|Experimental|Sipuleucel-T|Subjects received infusion of Sipuleucel-T, at 2-week intervals, for a total of 3 infusions.
89181574|NCT00779402|Placebo Comparator|Control|Subjects received infusion of control (autologous cellular product consisting of antigen presenting cells (APCs) prepared in the absence of PA2024 antigen) at 2-week intervals, for a total of 3 infusions.
89181575|NCT00771914|Experimental|Placebo, Lovaza, Aspirin, Both Aspirin and Lovaza|First Placebo, then 4 grams of Lovaza, then 81mg of Aspirin, then both 4 grams of Lovaza and 81 mg of Aspirin
89181576|NCT00771914|Experimental|Aspirin, Lovaza, Both Aspirin and Lovaza, Placebo|First 81mg of Aspirin, then 4 grams of Lovaza, then both 81mg of Aspirin and 4 grams of Lovaza, then placebo
89375195|NCT02857855|Experimental|80% fraction of inspired oxygen|80% fraction of inspired oxygen delivered either by a nonrebreathing facemask with a reservoir with oxygen flow of 14 l/min and air flow of 2 l/min or by a respirator for first 6 postoperative hours
89181577|NCT00771914|Experimental|Lovaza, Both Aspirin and Lovaza, Placebo, Aspirin|First 4 grams of Lovaza, then both 81mg of Aspirin and 4 grams of Lovaza, then placebo, then 81mg of Aspirin
89181578|NCT00771914|Experimental|Both Aspirin and Lovaza, Placebo, Lovaza, Aspirin|First both 81mg of Aspirin and 4 grams of Lovaza, then placebo, then 4 grams of Lovaza, then 81mg of Aspirin
89181579|NCT04078893|No Intervention|control group|
89181580|NCT04078893|Experimental|on need group|
89181581|NCT04078893|Experimental|communication group|
89181582|NCT04347759|Other|System with coaching messages|A telephone-computer interface IVR system to report symtopms and to receive coaching messages based on symptom severity.
89181583|NCT00779324|Experimental|Amantadine|Amantadine 100 mg every morning and Noon
89181584|NCT00779324|Placebo Comparator|Placebo|Placebo tablets
89181585|NCT04078347||Successful Paravertebral block|Pinprick test was evaluated at 20 min after Paravertebral block. Pinprick sensation was assessed using a 22-gauge short bevel needle from T2 to T10 at midclavicular line bilaterally . Pinprick response was recorded quantitatively as 1 (sensation) or 0 (no sensation/numb). Successful block was defined as the pinprick score was 0 at 20 min after block. Otherwise, it was defined as a failed block.
89375196|NCT02857855|Active Comparator|28% fraction of inspired oxygen|28% fraction of inspired oxygen delivered either by a Venturi facemask or by a respirator for first 6 postoperative hours
89375197|NCT03666728|Experimental|SHR-1210+BP102|Subjects receive SHR-1210 200 mg and BP102 15 mg/kg in day 1 intravenously every 3 weeks, until disease progression or unacceptable toxicity.
89375198|NCT03666871|Experimental|Arm 1|Arm 1 (n=20) will be pretreated with cyclophosphamide 1 g/m2 and will receive a single intravenous infusion of 0.5 to 4x1010 ex vivo expanded autologous CD4+ T cells that have been transduced with a zinc finger nuclease designed to cleave CCR5.
89375199|NCT03666871|Active Comparator|Arm 2|Arm 2 (n=10) will be pretreated with cyclophosphamide 1 g/m2 and will receive a single intravenous infusion of 0.5 to 4x1010 ex vivo expanded autologous CD4+ T cells that have not been modified by zinc finger nucleases.
89181586|NCT04078347||Failed Paravertebral block|Pinprick test was evaluated at 20 min after Paravertebral block. Pinprick sensation was assessed using a 22-gauge short bevel needle from T2 to T10 at midclavicular line bilaterally . Pinprick response was recorded quantitatively as 1 (sensation) or 0 (no sensation/numb). Successful block was defined as the pinprick score was 0 at 20 min after block. Otherwise, it was defined as a failed block.
89181587|NCT00779246|Active Comparator|1|Active surveillance cultures (ASC) (via nasal swabs) will be performed for all patients admitted to the medical intensive care unit (ICU) during the designated study period. All patients will be placed in contact isolation until nasal swabs return negative; otherwise will remain in isolation.
89181588|NCT00779246|Active Comparator|2|Chlorhexidine gluconate (CHG) cloths will be used to bathe patients daily instead of standard soap and water. Active surveillance cultures (ASC) will also be used in this arm, but results will be blinded and not used to determine whether patients should be in contact isolation.
89181589|NCT04078113|Experimental|Experimental group|Every patient will be subjected to a measured stimulus with a power selected in phase 1 (X mA) and pupillary dilatation will be measured by pupillometry. In those patients showing pupillary size variation over the limit for insufficient analgesia estimated in phase 1 for tracheal suction, additional analgesia will be provided before tracheal suction. In those patients without pain detected by pupillometry, additional anlagesia won´t be provided. In both cases Pupillometry, BPS and ESCID will be measured during tracheal suction to determine whether the patient is in pain or not.
89181590|NCT04078113|No Intervention|Control group|"Before tracheal suction and due to medical decision, analgesia following current clinical practice would be administered prophylactically.~Pupillometry, BPS and ESCID will be measured during tracheal suction to determinate whether the patient is in pain or not."
89181591|NCT04097990|Other|healthy participants|healthy participants
89181592|NCT04097990|Other|hypertriglyceridemia without prior pancreatit|
89181593|NCT04097990|Other|hypertriglyceridemia and at least one case of|
89181594|NCT04186533|Experimental|Default Intervention|Participants in the default condition were presented with a pre-filled online shopping cart containing a combination of groceries that meet macro- and micronutrient requirements for their gender and age, and told that they are free to delete, add, and exchange any item they wish to finalize their selections.
89375200|NCT03014180|Experimental|"In-Clinic LVAT"|All subject prior to study enrollment has been implanted with a CRT-D device. During follow-ups, under the supervision of the physician, the algorithm embeded in the device is activated with a password. The feature is deactivated at the end of each follow-up.
89375201|NCT03638401|No Intervention|Standard treatment|
89375202|NCT03638401|Active Comparator|Intervention arm|
89375203|NCT04747873|Experimental|e-CBT|12 weekly sessions with approximately 30 slides and interactive content, delivered through OPTT designed to mirror in-person standard CBT. Participants go through the content and complete homework at the end of the session. Homework is submitted through OPTT and reviewed by the therapist assigned to the participant, who will provide personalized feedback within three days of submission. Therapists have access to pre-designed session-specific feedback templates to use as a basic structure to write their feedback. By doing so, the time needed to respond to each patient is reduced and therefore the number of patients each therapist can handle increases. On average, developing this feedback takes a therapist 15-20 minutes per patient. In addition to the weekly feedback, participants have the option to message their therapist through the platform throughout the week regarding any questions or concerns they may have.
89375204|NCT04747873|Experimental|e-CBT + Stepped Care|"1 - Participant will receive message from assigned care provider on OPTT who check-in with them about strategies and techniques they have discussed and remind them of weekly homework due date.~2.- Participant will receive phone call from therapist who will check-in on them, remind them of therapy strategies, and verbally remind them of weekly homework due date.~3 - Participant will receive phone call from assigned care provider who will check-in on them, remind them of some therapy strategies and techniques and weekly session due date, and provide CBT summary of previously reviewed CBT concepts.~4 - articipant will receive video call (Microsoft Teams) from their therapist who will check-in on them, remind them of weekly session due date, and provide CBT content support to participant.~5 - Participant will receive CBT sessions in live video call (Microsoft Teams) with research psychiatrist involved in care."
89375205|NCT03667040|No Intervention|Control Group|75 participants will take part in three visits (baseline, 30days and 60days)
89375206|NCT03667040|Active Comparator|Intervention|75 participants will take complete a baseline visit and then participate in the intervention. They will use the application, the JOOL app for 30 days. Then complete surveys at 30days and 60days after the interventions
89375207|NCT03666650|Other|Rotem|
89375208|NCT03011840|No Intervention|Pre intervention|"In the first part planned over 2months (Jan - Feb), feedback forms will be collected from patients at the end of minor OT procedure. The number of postponement or rescheduling of cases will be noted.~Postponement or rescheduling of case is defined as an event when the patient who is called for his turn in minor OT is deferred for any amount of time in account of starvation not adequate, investigations not brought, medications not taken as prescribed."
89181595|NCT04186533|Active Comparator|Nutrition Education|Participants in the nutrition education condition were instructed to read brief nutrition education handouts before online grocery shopping.
89375209|NCT03011840|Experimental|Post Intervention|In the intervention phase, the patient information leaflet (PIL) will be handed over to all patients planned for procedure in the minor OT complex. This leaflet will be handed over by the attending doctor in the Head neck OPD. The checklist pertaining to counselling at the Head neck OPD will be ticked after they are carried out. The patient will be instructed to read leaflet carefully and carry the leaflet on the day of Minor OT procedure. In the minor OT the discharge checklist in the PIL would be carried out by all concerned including the surgical, anesthesia and nursing team. The impact of use of PIL will be assessed by noting the number of postponement or rescheduling of cases.
89375210|NCT03666572|Active Comparator|B. infantis alone (Bif) in SAM infants|B. infantis alone (Bif) in Severe Acute Malnourished infants
89375211|NCT03666572|Active Comparator|B. infantis + prebiotic Lacto-N-neotetraose [LNnT]|B. infantis + prebiotic Lacto-N-neotetraose [LNnT] (Bif+prebiotic) in Severe Acute Malnourished infants
89375212|NCT03666572|Placebo Comparator|Placebo (Lactose)|Placebo (Lactose) in Severe Acute Malnourished infants
89375213|NCT03666572|Active Comparator|B. infantis alone (Bif) in Not SAM Infants|B. infantis alone (Bif) in not Severe Acute Malnourished infants
89375214|NCT03667508|Experimental|Rapid Maxillary Expansion|Patients will undergo Rapid Maxillary Expansion using a rapid maxillary expanding device, i.e. a Hyrax expander (modified by McNamra).
89375215|NCT03667508|Active Comparator|Slow Maxillary Expansion|Patients will undergo Slow Maxillary Expansion using a slow maxillary expanding device, i.e. a removable appliance with a central screw.
88810347|NCT06214247|Experimental|Test Group|During PCI, percutaneous transluminal coronary angioplasty is performed on the target lesion using the Wedge NC Scoring Balloon Dilatation Catheter in the test group, subsequently completing the remaining procedure.
88810348|NCT06214247|Experimental|Control Group|During PCI, percutaneous transluminal coronary angioplasty is performed on the target lesion using a similar product(Scoring Balloon Dilatation Catheter) on the market in the control group, subsequently completing the remaining procedure.
88810349|NCT06214234|Other|Early band ligation|Patients with liver cirrhosis present with variceal bleeding underwent band ligation within 12 hours of presentation
88810350|NCT06214234|Other|Delayed band ligation|Patients with liver cirrhosis present with variceal bleeding underwent band ligation within more than 12 hours of presentation
88810351|NCT06214195|Experimental|treatment group|Provide preventive treatment with Shengmai San
88810352|NCT06214195|No Intervention|control group|No preventive intervention
88810353|NCT06214169|Other|Plain Lignocaine group|Group of participants receiving only plain lignocaine for IVRA
88810354|NCT06214169|Other|Cisatracurium group|Group of participants receiving plain lignocaine and cisatracurium combined for IVRA
88810355|NCT06214117|Experimental|Group R|Induction of anesthesia:Anesthesia will induced with remimazolam at 0.3-0.5 mg/kg; Maintenance of anaesthesia:Remimazolam will infuse initially at a rate of 2 mg/kg/h (1-3 mg/kg/h).
88810356|NCT06214117|Placebo Comparator|Group S|Induction of anesthesia:Anesthesia will induced with 8% sevoflurane in 100% oxygen at flow rate of 6 L/min; Maintenance of anaesthesia:Anesthesia depth was maintained at 1-1.5 MAC by sevoflurane.
88810357|NCT06214104|Experimental|acupressure|Acupressure Massage; It will be applied to BL 60 and K3 areas. The application will be applied in successive pressures with the thumb on each point for an average of 45-60 seconds.
88810358|NCT06214104|Experimental|fetal position|The fetal position will be given with the newborn in the right side position, with the arms and legs joined in the midline.
88810359|NCT06214104|No Intervention|Control group|no intervention
89375216|NCT02942485|Experimental|Metronidazole|Patients will be given rectal metronidazole (Flagyl) 500 mg/dose for children weighing 10-14,9 kg, 1000 mg/dose for those weighing 15-29,9 kg and 1500 mg/dose for those weighing 30-44,9 kg. Suppositories will not be halved. Patients will be given 1 dose/day for 3 days.
89375217|NCT02942485|Active Comparator|Tinidazole|Patients will be treated with a standard regimen of oral tinidazole (Fasigyn) at a single dose of 50 mg/kg, maximum 2 g/dose
89375218|NCT03666962||case group|According to the scores of MGLS, compliance was divided into three groups: A score of 0 indicated high compliance; a score of 1 or 2 illustrated intermediate compliance; and a score of 3 or 4 indicated low compliance.
88846973|NCT04420273|Experimental|SSE educational intervention|Women participants receive a SSE brochure and three monthly reminders to perform SSE. In the second month, women select goals for SSE.
88846974|NCT04420273|Active Comparator|Active control: Healthy Living|Women participants receive a Healthy Living brochure and three monthly reminders to perform the following activities of healthy living: get quality sleep, walk briskly for 30 min, eat 5 servings of fruits and vegetables a day. In the second month, women select goals for healthy living.
89375219|NCT03666962||control group|According to the scores of MGLS, compliance was divided into three groups: A score of 0 indicated high compliance; a score of 1 or 2 illustrated intermediate compliance; and a score of 3 or 4 indicated low compliance.
89375220|NCT03666494|Active Comparator|Control Arm|As part of the patient's anesthetic induction, they will receive propofol and fentanyl.
89375221|NCT03666494|Active Comparator|Ketamine Arm|As part of the patient's anesthetic induction, they will receive propofol, fentanyl, as well as ketamine hydrochloride.
89375222|NCT03622970|Experimental|VGBT with Nintendo® Wii and LMC games|"VGBT with Nintendo® Wii and LMC games:~In order to improve the elbow and shoulder functions, Tennis and boxing, the games of Nintendo Wii® Fit WiiSports package that includes shoulder and elbow movements will be used for VGBT with Nintendo® Wii and Leap Motion Controller (LMC) games. In both of the games, the activities are carried out by providing feedback in the context of remote control and sound and vibration notifications."
89375223|NCT03622970|Active Comparator|NDT-based upper limb rehabilitation|"NDT-based upper limb rehabilitation:~NDT-based upper limb rehabilitation aims to facilitate normal movement for upper extremity activities such as getting dressed and eating etc by using real materials (clothes, spoons, pencils, buttons, rope, etc.). The target activities were practised with the materials such as velcro cylinders, skill cubes, exercise bands, screw sets, therapeutic putty, and tripled coordination tools."
89375224|NCT03666884|Active Comparator|dry eye patients 1|dry eye patients treated for 1 month and patient symptoms after 1 month
89375225|NCT03666884|Active Comparator|dry eye patients 2|dry eye patients treated for 1 month and patient symptoms after 1 month
89375226|NCT04057664||Multidisciplinary Group Therapy|Multidisciplinary group therapy for women with chronic pelvic or belly pain
89375227|NCT02942407|Experimental|apixaban|apixaban 5 mg twice daily (apixaban 2.5 mg twice daily for selected patients)
89375228|NCT02942407|Experimental|warfarin|warfarin daily dose adjusted to target International Normalized Ration(INR) of 2-3
89375229|NCT03666806|Experimental|Influenza vaccine|Influenza vaccine: An inactivated influenza vaccine (split virion) shall be used during the study. The product information is attached as an appendix to the proposal. Brief description of the type of influenza vaccine to be used for the study, mechanism of action, dose justification, efficacy, safety and its use in the population.
89375230|NCT03666806|Placebo Comparator|Normal saline|Placebo: Placebo will be normal saline which shall be prepared by the pharmacist for injection by the immunization nurse in a similar syringe as the investigational product.
89375231|NCT03638089|Experimental|Intervention Group|This group will receive up to six sessions of fall-recovery training over the course of 2-3 weeks.
89375232|NCT02921035||Relapsing Multiple Sclerosis (RMS) group|Subjects diagnosed with RMS who are prescribed Rebif (Interferon beta-1a)
89375233|NCT03009344|Experimental|Tazemetostat 800 mg|Participants will receive oral tazemetostat at a starting dose of 800 milligrams (mg) as a single dose (Cycle 0) and 800 mg twice a day as continuous dosing (Cycle 1 and later) (Cycle 0 duration=4 days) (Cycle 1 and later duration= 28 days).
89375234|NCT03322423|Active Comparator|Test 1 Multifocal/Test 2 Multifocal OR Test 2 Alternative|Subjects who are habitual soft contact lens wearers, at least 40 years of age and no more than 70 years of age, will wear Test 1 Multifocal then Test 2 Multifocal OR Test 2 Alternative (based on lens optimization- subject's lens power), for approximately 8-12 days of wear with an approximately 4-8 day washout period.
89375235|NCT03322423|Active Comparator|Test 2 Multifocal OR Test 2 Alternative/Test 1 Multifocal|Subjects who are habitual soft contact lens wearers, at least 40 years of age and no more than 70 years of age, will wear Test 2 Multifocal OR Test 2 Alternative (based on lens optimization- subject's lens power) then Test 1 Multifocal, for approximately 8-12 days of wear with an approximately 4-8 day washout period.
89375236|NCT03007472|Experimental|CI532/N7 study group|All subjects will receive a CI532 cochlear implant (intervention) and be fit with the CP1000 sound processor
89375237|NCT03321721|No Intervention|conservative|patient fulfilling entry criteria will be randomized to the conservative arm - no suturing
89375238|NCT03321721|Active Comparator|suture|patient fulfilling entry criteria will be randomized to the suture arm for repair with nylon suture material
89375239|NCT04621981|Experimental|Sodium Bicarbonate Ringer's Solution|Intravenous drip, 500~1000ml per time. Infusion speed: 15ml/kg/h or according to guidelines or department routine.
89375240|NCT04621981|Active Comparator|Normal Saline|"Intravenous drip, 500~1000ml per time. Dosage depends on age、weight and symptoms.~Infusion speed: According to the department process or clinician's decision."
89375241|NCT03015116|Active Comparator|Usual Care|Participants will complete 6 weeks of stretching and cryotherapy
88846975|NCT05572892||Adult patients hospitalised in the Neurology Department of Caen University Hospital|Measurement of walking dependency according to the FAC scale (in the first week after stroke by physiotherapists, at 6 weeks, 12 weeks and 6 months by telephone).
88846976|NCT05554796|Experimental|Endoscopic classic stapedotomy|This groups contains 30 patients and will undergo classic stapedotomy
88846977|NCT05554796|Experimental|Endoscopic reversal stapedotomy|This groups contains 30 patients and will undergo reversal stapedotomy
88846978|NCT00929474|Experimental|QuickOpt|
88846979|NCT00929474|Active Comparator|Control|
88810360|NCT06214078|Experimental|NMN group|Patients in this group will take nicotinamide mononucleotide capsules orally twice daily for 8 weeks, one capsule per time, each actually containing 250mg of nicotinamide mononucleotide.
89181596|NCT02581761|Experimental|Cytotec treatment group|patient with pregnancy of unkown location will receive cytotec 800 mcg per vaginal
89181597|NCT02581761|Placebo Comparator|Placebo treatment group|patient with pregnancy of unkown location will receive suppository which contain Whitepsol H-15 with no active material (Cytotec).
89181598|NCT04101344|Experimental|Fiber-blend|All participants will receive a two fiber-blend snack and then a four fiber-blend snack. Stool, blood, and urine will be monitored for changes throughout the study.
89181599|NCT00771758|Experimental|001|tapentadol IR 50 or 75 mg capsule every 4 - 6 hr as needed for up to 10 days maximum daily dose 450 mg
88810361|NCT06214078|Placebo Comparator|placebo group|Patients in this group will receive 1 placebo capsule orally twice daily for 8 weeks.
88810362|NCT06214065|Experimental|ASD: excitatory, then inhibitory, then sham rTMS|Participants in this group will undergo fMRI pre- and post- rTMS. Each will receive an excitatory, inhibitory and sham rTMS to the right temporoparietal junction (TPJ) on mentalizing task-related (MTR) activity over 4 study visits.
89181600|NCT00771758|Experimental|002|oxycodone IR 5 or 10 mg capsule every 4 - 6 hr as needed for up to 10 days maximum daily dose 60 mg
89181601|NCT00771758|Placebo Comparator|003|placebo 1 capsule every 4 - 6 hr as needed for up to 10 days
89181602|NCT05293821||Positive test subjects|documented medical history of HIV, HBV or HCV. A combination of 2 or 3 conditions is acceptable.
89181603|NCT05293821||Control|no documented medical history of HIV, HBV or HCV and are considered normal.
88810363|NCT06214065|Experimental|Typically Developing (TD): excitatory, then inhibitory, then sham rTMS|Participants in this group will undergo fMRI pre- and post- rTMS. Each will receive an excitatory, inhibitory and sham rTMS to the right temporoparietal junction (TPJ) on mentalizing task-related (MTR) activity over 4 study visits.
88810364|NCT06214052|Experimental|VH4524184|Participants will receive VH4524184.
88810365|NCT06214052|Placebo Comparator|Placebo|Participants will receive Placebo matching VH4524184.
88810366|NCT06214039|Active Comparator|One session therapy|One session exposure therapy followed by 4 weeks of internet-delivered self-help with therapist support on demand
88810367|NCT06214039|Experimental|One session therapy - divided into 3|Three session exposure therapy followed by 4 weeks of internet-delivered self-help with therapist support on demand
88810368|NCT06213987|Experimental|Tretinoin|Apply 1 gram of tretinoin cream to the axillary region before bedtime once every other day during the first two weeks, and then once daily after that, total duration of 8 weeks.
88810369|NCT06213987|Placebo Comparator|Cream based|Apply 1 gram of cream based to the axillary region on the opposing side before bedtime once every other day during the first two weeks, and then once daily after that, total duration of 8 weeks.
88810370|NCT06213974||All Participants|Participants who have received maribavir treatment for the approved indication after marketing authorization (de novo participants) and before marketing authorization (legacy participants) under expanded access type of program or compassionate use in the real-world setting. Data will be collected prospectively and/or retrospectively from the medical records during this observational period of 16 weeks.
88810371|NCT06213948|Experimental|Healthy|
88810372|NCT06213948|Experimental|Functional Dyspepsia|
88810373|NCT06213935|Active Comparator|group A|will receive a norepinephrine bolus at 0.05 μg/kg, followed by norepinephrine infusion at a rate of 0.05 μg/kg.min
88810374|NCT06213935|Active Comparator|Group B|will receive 10 mg tablets of midodrine 1 hour before spinal anesthesia.
88810375|NCT06213922||Adolescent|
88810376|NCT06213909||eosinophil group|Based on the histopathologic phenotype of the patient's skin, the inflammatory cells infiltrating within and around the blisters were predominantly eosinophils
88810377|NCT06213909||neutrophil group|Based on the histopathologic phenotype of the patient's skin, the inflammatory cells infiltrating within and around the blisters were predominantly neutrophil
88810378|NCT06213909||lymphocyte group|Based on the histopathologic phenotype of the patient's skin, the inflammatory cells infiltrating within and around the blisters were predominantly lymphocyte
88810379|NCT06213870||MRI group|"MRI Images were acquired on a 3T Siemens Prisma scanner (Siemens AG, Munich, Germany).Image sequences and typical parameter ranges were diffusion tensor imaging (repetition time [TR], 5200ms; echo time [TE], 80 ms; 4mm slice thickness; 40 slices) by using SE-EPI sequence; T1 imaging (TR, 240 ms; TE, 2.47 ms; 5 mm slice thickness; 17 slices) by using SE sequence;T2 imaging (TR, 4480 ms; TE, 99 ms; 4 mm slice thickness; 24 slices) by using FSE sequence; FLAIR imaging (TR, 8500 ms; TE, 95 ms; 5 mm slice thickness; 21 slices) by using IR sequence; time-of-flight magnetic resonance angiography images (TR, 20 ms; TE, 3 ms; 0.55 mm slice thickness; 40 slices) by using 3D-TOF sequence;~In the MRI group, patients with FVH-DWI mismatch were considered to have EVT indications and were treated with EVT, while patients without FVH-DWI mismatch were treated with medication."
88810380|NCT06213870||Perfusion group|"The protocol of CT Perfusion was as follows: 100 mm coverage in the z-axis, tube voltage, 80 kV; tube current, 120 mA; section thickness, 5 mm. Twenty-four consecutive spiral acquisitions with 0.28 seconds of rotation time and 1.70 seconds of inter scan delay time were performed.~Patients in the perfusion group were treated with EVT when there exist perfusion mismatch(defined as regional cerebral blood flow (<30%) was < 70 ml with mismatch ratio ≥ 1.8 and mismatch volume ≥ 15 ml), and were treated with medication when there was no perfusion mismatch."
88810381|NCT06213857|Experimental|A (silymarin)|silymarin capsules (140 mg\day) for 6 months + mesalamine
88810382|NCT06213857|No Intervention|B (No silymarin)|mesalamine only
88810383|NCT06213844|Placebo Comparator|Placebo|Single dose of Placebo administered subcutaneously on Day 1
88810384|NCT06213844|Experimental|IBI3002|Single dose of IBI3002 (Dosage 1, Dosage 2, Dosage 3, Dosage 4, Dosage 5, Dosage 6) administered subcutaneously on Day 1
88810385|NCT06213805|Experimental|Minimally invasive microsclerostomy|
88810386|NCT06213727|Experimental|Trial drug group 1|lowe-dose ZKY001 eye drops
88810387|NCT06213727|Experimental|Trial drug group 2|Medium-dose ZKY001 eye drops
88810388|NCT06213727|Placebo Comparator|control group|ZKY001 simulated eye drops
88846980|NCT02043860|Experimental|Total Marrow Irradiation|Escalating doses of total marrow irradiation (3Gy, 6Gy, 9Gy, or 12Gy) with standard high dose melphalan prior to autologous stem cell rescue.
88846981|NCT03606187|Experimental|Test Arm|Subjects randomized to this arm will receive test treatment
88846982|NCT03606187|Active Comparator|Control Arm|Subjects randomized to this arm will receive control treatment
88846983|NCT01974284|Experimental|percutaneous ethanol ablation|The experimental group of the study is comprised of patients that will undergo percutaneous ethanol ablation for the management of papillary thyroid microcarcinoma.
89375242|NCT03015116|Experimental|PBM 10 Watts|Participants will complete 6 weeks of stretching and cryotherapy, plus 9 treatments of PBM (810/980 nm continuous wave, 10 Watts power) over 3 weeks
89375243|NCT03015116|Experimental|PBM 25 Watts|Participants will complete 6 weeks of stretching and cryotherapy, plus 9 treatments of PBM (810/980 nm continuous wave, 25 Watts power) over 3 weeks
88846984|NCT03543085|Experimental|Ultrahigh Frequency (500 KHz) Stimulation|This study is a prospective, single-arm, open label, single center to confirm the effectiveness and safety of an ultrahigh frequency spinal cord stimulation in patients with chronic back pain or lower limb pain.
88846985|NCT03606343|Experimental|Open Trial|Group based treatment targeting academic executive functioning skills such as organization, planning, and study skills. Likely to be 7 90-minute sessions attended weekly by parents and teens
88846986|NCT00869414|Active Comparator|insulin glargine only in morning|Morning only administration of insulin glargine
88846987|NCT00869414|Active Comparator|insulin glargine only at evening|Evening only administration of insulin glargine
88846988|NCT00869414|Active Comparator|split dose insulin glargine|Split dose administration of insulin glargine, half dose in morning, half dose in evening
88846989|NCT04734769||Cycles of embryo transfer from patients with at least one euploid embryo (no rebiopsy group)|Collect retrospectively clinical data on reproductive outcomes
88846990|NCT04734769||Rebiopsy group:|Collect retrospectively clinical data on reproductive outcomes
88846991|NCT04536571|Experimental|Test Contact lens|Subjects will be randomized to wear test lenses for 30 minutes, and then cross-over to control lenses.
88846992|NCT04536571|Active Comparator|Control Contact lens|Subjects will be randomized to wear control lenses for 30 minutes, and then cross-over to test lenses.
88846993|NCT00843986|Placebo Comparator|Placebo|Matching loading dose and continuous intravenous infusion for 48 hours
89181604|NCT02581371|Experimental|Cerebrolysin infusion|Cerebrolysin, solution for injection, 10 ml vials. Two 10-day courses of 50 ml of investigational drug + 50 ml of sodium chloride 0.9% iv slowly drip infusions daily, separated with a 7-day interval
89181605|NCT02581371|Placebo Comparator|Placebo infusion|Sodium chloride 0.9%, solution for infusion, 100 ml. Two 10-day courses of 100 ml of sodium chloride 0.9% iv slowly drip daily, separated with a 7-day interval.
89181606|NCT02688465|Experimental|Apomorphine pump|
89375244|NCT03667430|Experimental|Normal weight subjects|Healthy normal weight (BMI 20-25) men 18-35 year. Intervention: The participants will take placebo or silica powder with specified doses administrated in vials and with instructions to mix with water as; Placebo (microcrystalline cellulose) day 1-5 Porous silica 1gx3 daily for day 6-9 Porous silica 2gx3 daily for day 10-14 Porous silica 3gx3 daily for day 15-21 Total study time 21 days
88846994|NCT00843986|Experimental|Conivaptan|20mg loading dose followed by a 20mg/ day continuous intravenous infusion for 48 hours
88846995|NCT05514158|Experimental|RC48 combind with RC98|
88846996|NCT01965782|Experimental|[^14C]-LY3023703|Single oral dose of 15 mg LY3023703, containing approximately 100 µCi [^14C] labeled drug, administered as an oral solution.
88846997|NCT03608839|Experimental|0,01ml dexamethasone solution|One intravitreous injection of 0,01 ml dexamethasone solution 4 mg/ml.
88846998|NCT03608839|Experimental|0,03 ml dexamethasone solution|One intravitreous injection of 0,03 ml dexamethasone solution 4 mg/ml.
88846999|NCT03608839|Experimental|0,05 ml dexamethasone solution|One intravitreous injection of 0,05 ml dexamethasone solution 4 mg/ml.
88847000|NCT05503160|Active Comparator|Intervention|With validated questionnaires, patient reported outcome monitoring data on quality of life, distress and therapy-adherence are collected. In case of pathologic values, the attending breast center gets advised to intervene according to individual requirements.
88847001|NCT05503160|No Intervention|Control|Standard of care
88847002|NCT03544879|Experimental|Yoga|The yoga intervention consisted of 2x weekly 60-minute sessions for 10 weeks. Yoga consists of postures, breathing exercises, movement, and meditation/concentration..
88847003|NCT03544879|Active Comparator|Health Education|The health education comparison intervention consisted of once weekly, 90-minute health information workshops conducted in group format. Sessions generally consisted of a 60-minute lecture followed by 30 minutes of questions and discussion.
88847004|NCT05486468|Experimental|Treatment Arm|This group will receive two YUTIQ implants at day 1.
88847005|NCT05486468|Sham Comparator|Control Arm|This group will receive two sham injections at day 1.
88847006|NCT00845702|Experimental|Dotarem|Each subject will receive one injection of Dotarem 0.2 ml/kg.
89181607|NCT04186611|Experimental|Early daily occupational therapy intervention|A daily occupational therapy intervention is performed with the patients included. The intervention will consist of assessment as well as early positioning and/or rehabilitation in activities of daily living.
89181608|NCT02688543|Experimental|RF treatment|Patients treated with radio frequency of the genicular nerves
89181609|NCT00758498|Experimental|1|armodafinil - dosage of 50 mg/day
89181610|NCT00758498|Experimental|2|armodafinil - dosage of 150 mg/day
89181611|NCT00758498|Placebo Comparator|3|matching placebo
89181612|NCT00798161|Experimental|BI 1356 + metformin|BI 1356 low dose + metformin 500 mg, twice daily
89181613|NCT00798161|Placebo Comparator|matching placebo|matching placebo
89181614|NCT00798161|Experimental|BI 1356+ Metformin|BI 1356 low dose + metformin 1000 mg, twice daily
89181615|NCT00798161|Active Comparator|Metformin|Metformin 500 mg, twice daily
89181616|NCT00798161|Active Comparator|metformin|Metformin 1000 mg, twice daily
89399337|NCT03538418|No Intervention|Control group|The control group will receive a 3-month exercise training programme without a WAT, which also includes 12 weekly exercise training sessions (an hour each) in addition to 7 face-to-face and telephone sessions offering support for BCTs.
89375245|NCT03667430|Experimental|Subjects with obesity|Obese otherwise healthy men (BMI 30-45) 18-35 year Intervention: The participants will take placebo or silica powder with specified doses administrated in vials and with instructions to mix with water as; Placebo (microcrystalline cellulose) day 1-5 Porous silica 1gx3 daily for day 6-9 Porous silica 2gx3 daily for day 10-14 Porous silica 3gx3 daily for day 15-21 The dose of Silica 3gx3 for additional 10 weeks Total study time 84 days
89375246|NCT03667352|Experimental|Scalp & TAP Block (Group T)|Group T received 0.2% Ropivacaine + clonidine 1µg/kg mixture, for ipsilateral scalp block (10ml),TAP block under USG guidance (20ml) and intravenous saline 0.1ml/kg/hr (sham infusion) for continuous infusion.
88847007|NCT00845702|Other|Time Of Flight Magnetic Resonance Angiography|Each subject undergo a TOF MRA
88847008|NCT03610399|Other|Primaquine Regular Dose Unsupervised|This is the regular primaquine dose Brazil without directly observed therapy.
88847009|NCT03610399|Active Comparator|Primaquine Regular Dose Supervised|This is the regular primaquine dose in Brazil but with directly observed therapy.
88847010|NCT03610399|Active Comparator|Primaquine Double Dose Unsupervised|This is the double total primaquine dose (14 days) in Brazil with directly observed therapy.
88847011|NCT00843830|Experimental|Treatment Arm|Participants will receive tumoral irradiation and dendritic cell vaccination.
88847012|NCT03610633|Experimental|Oxytocin/alcohol use disorder|Participants will receive 24 IU of oxytocin prior to completing fMRI scanning procedures.
88847013|NCT03610633|Placebo Comparator|Placebo/Alcohol use disorder|Participants will receive placebo (saline solution) prior to completing fMRI scanning procedures.
88847014|NCT00832520|Experimental|Remeron (Mirtazapine)|Mirtazapine 15 mg orally at bed time for 8 weeks
88847015|NCT03545893|Active Comparator|Ibuprofen|
88847016|NCT03545893|Active Comparator|Ibuprofen + Oxycodone|
88847017|NCT03551821|Experimental|ATI-50002 Topical Solution|ATI-50002 Topical Solution
88847018|NCT04734691|Experimental|Experimental Arm|
88847019|NCT04734691|Active Comparator|Control Arm|
88847020|NCT00843050|Experimental|P276-00|P276-00: All patients will receive P276-00 185 mg/m2/day as intravenous infusion over 30 minutes in 200 ml of 5% dextrose from day 1 to day 5 in each 21 days cycle for minimum 6 and maximum 12 cycles or until there is progression of disease or unacceptable toxicity
88847021|NCT04658797|Active Comparator|Single Vision Spectacle for Vision correction|Single Vision Spectacle
88847022|NCT04658797|Experimental|somofilcon A Daily disposable contact lenses|Daily disposable contact lenses
88847023|NCT01954160|Other|Early Symplicity Renal Denervation|Subjects undergo Symplicity Renal Denervation within 2 weeks of baseline visit will follow usual care after week 13 visit
88847024|NCT01954160|Other|Late Symplicity Renal Denervation|Subjects following usual care until week 13 visit will then undergo Symplicity Renal Denervation within 2 weeks of Week 13 visit
88847025|NCT03552289|Active Comparator|Cook Enforcer balloon catheter|The Enforcer balloon will be used in the treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistula.
88847026|NCT03552289|Active Comparator|Conventional angioplasty balloon catheters|Commercially available angioplasty balloon devices will be used in the treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistula.
88847027|NCT03615001|Experimental|Urodynamics Arm|
89181617|NCT00798161|Experimental|BI 1356|BI 1356 high dose, once daily
88847028|NCT01877564|Experimental|Group 1 - Metformin|oral metformin at 500 mg twice a day for 14-21 days followed by surgery
88847029|NCT01877564|No Intervention|Group 2 - No treatment|
88847030|NCT03615079|Other|Cognitive Behavioral Therapy (CBT) program|
88847031|NCT03556579|Experimental|Test/Control|For Visit 1, subjects will be randomly assigned to 1 of 2 contralateral lens sequences (Right: Test, Left: Control) OR (Right: Control, Left: Test). Then for visit 2, subjects will be randomly assigned to the same 1 of 2 contralateral lens sequences again.
88847032|NCT03556579|Experimental|Control/Test|For Visit 1, subjects will be randomly assigned to 1 of 2 contralateral lens sequences (Right: Test, Left: Control) OR (Right: Control, Left: Test). Then for visit 2, subjects will be randomly assigned to the same 1 of 2 contralateral lens sequences again.
88847033|NCT00835328|Experimental|Exendin (9-39) 0.02 mg/kg/hr|Cohort 1: Participants will be administered 0.02 mg/kg/hr of Exendin (9-39) and vehicle (normal saline), via continuous intravenous infusion, over 9 hours on two separate days in random order, with 3 hours of follow-up after the last dose is administered or until blood glucose is < 70 mg/dL (whichever comes first). Glucose infusion rates (GIR) will be titrated three hours prior to infusions to keep blood glucose in the range of 70-90 mg/dL. During both infusions, blood glucose will be measured every 30 minutes.
88847034|NCT00835328|Experimental|Exendin (9-39) 0.04 mg/kg/hr|Cohort 2: Participants will be administered 0.04 mg/kg/hr of Exendin (9-39) and vehicle (normal saline), via continuous intravenous infusion, over 9 hours on two separate days in random order, with 3 hours of follow-up after the last dose is administered or until blood glucose is < 70 mg/dL (whichever comes first). Glucose infusion rates (GIR) will be titrated three hours prior to infusions to keep blood glucose in the range of 70-90 mg/dL. During both infusions, blood glucose will be measured every 30 minutes.
88847035|NCT00835328|Experimental|Exendin (9-39) 0.10 mg/kg/hr|Cohort 3: Participants will be administered 0.10 mg/kg/hr of Exendin (9-39) and vehicle (normal saline), via continuous intravenous infusion, over 6 hours on two separate days in random order, with 3 hours of follow-up after the last dose is administered or until blood glucose is < 70 mg/dL (whichever comes first). Glucose infusion rates (GIR) will be titrated three hours prior to infusions to keep blood glucose in the range of 70-90 mg/dL. During both infusions, blood glucose will be measured every 30 minutes.
88847036|NCT00835328|Experimental|Exendin (9-39) 0.20 mg/kg/hr|Cohort 4: Participants will be administered 0.20 mg/kg/hr of Exendin (9-39) and vehicle (normal saline), via continuous intravenous infusion, over 9 hours on two separate days in random order, with 3 hours of follow-up after the last dose is administered or until blood glucose is < 70 mg/dL (whichever comes first). Glucose infusion rates (GIR) will be titrated three hours prior to infusions to keep blood glucose in the range of 70-90 mg/dL. During both infusions, blood glucose will be measured every 30 minutes.
88847037|NCT00832598|Experimental|PET imaging|We will perform [18F]FACBC PET and [18F]FLT PET imaging on 30 patients with gliomas scheduled for treatment with pathway inhibitor agents such as receptor tyrosine kinase inhibitors, antibodies (e.g., bevacizumab), VEGF-Trap, etc.
89375247|NCT03667352|Active Comparator|Intravenous Fentanyl (Group C)|Group C received saline, for ipsilateral scalp block (10ml) and TAP block under USG guidance (20ml) and I.V fentanyl 1 µg/kg/hr as analgesic.
88847038|NCT04499599|Active Comparator|Fast Group|Subjects will be asked to consume a standardized ready-to-eat dinner meal before 5 pm on day 1. Subjects will fast overnight for approximately 19 hours.
88847039|NCT04499599|Placebo Comparator|Breakfast Group|Subjects will be asked to consume a standardized ready-to-eat dinner meal before 5 pm on day 1. Subjects will fast overnight for approximately 15 hours and then consume a breakfast bar on day 2.
88847040|NCT04499599|Experimental|Fast Bar Group|Subjects will be asked to consume a standardized ready-to-eat dinner meal before 5 pm on day 1. Subjects will fast overnight for approximately 15 hours and then consume a Fast Bar on day 2.
88847041|NCT04512703||Healthy Group|Healthy male and female volunteers. Subjects older than 21 years of age. Subjects to wear the µCor device for up to 30 days.
88847042|NCT04512703||Arrhythmia Monitoring Group|Patients with a clinical indication for outpatient cardiac monitoring. Subjects older than 21 years of age. Subjects to wear the µCor device for up to 90 days.
88847043|NCT04512703||Front Position Devices|All devices placed in the front position
88847044|NCT04512703||Side Position Devices|All devices placed in the side position
88847045|NCT01889420|Experimental|Combination therapy|Pomalidomide: 1 tablet orally, daily for 21 days of a 28 day cycle (dose per cohort) Everolimus: 1 tablet orally for 21 days of a 28 day cycle (dose as per cohort) Dexamethasone 40 mg (20 mg >75yrs) orally, days 1, 8,15, 22 of a 28 day cycle
88847046|NCT03557125|Active Comparator|Receives QL Block|If the subject has been randomized to the block group, a subcutaneous lidocaine skin wheel placed will be placed followed by a quadratus lumborum regional block with 40 ml, 0.25% ropivacaine deposited deep to the transversus abdominus apnoneurosis and superficial to the fascia transversalis with direct ultrasound guidance. Local anesthetic will be injected in 5 ml aliquots with aspiration for blood performed before and after the injection of each aliquot. Local anesthetic injection will also be observed with real time ultrasound guidance.
88847047|NCT03557125|Placebo Comparator|Receives Saline Skin Wheel No Block|"The skin will be cleaned with chlorhexidine. If the subject has been randomized to the no block group, a subcutaneous saline skin wheel will be placed and the procedure would end at this point."
88847048|NCT03616171|Experimental|Interventional Group|"Intervention Group (SLEEP-Extend intervention): The SLEEP-Extend intervention consists of two components:~One education session (5-10 minutes) consisting of strategies for sleep hygiene which is the routine for going to sleep (an investigator-developed brochure and information based on recommendations from the American Academy of Sleep Medicine and the National Sleep Foundation will be given and reviewed with the subject)~Instructions on extending time in bed by at least one hour but can be up to 2 hours total per night for 4 weeks which can be accomplished by either going to bed earlier or staying in bed later (subject will decide what works best for them)."
88847049|NCT03616171|Other|Control Group|Control group: consists of One educational session (5-10 minutes) consisting of safety practices used for an urban environment (a safety brochure and safety information will be given and reviewed with the subject)
88847050|NCT03558061|Experimental|Active|ALK4290 800 mg daily
89375248|NCT03666338|Active Comparator|Early, goal-directed mobilization|Early goal-directed mobilization with (1) SOMS algorithm and (2) facilitator
89375249|NCT03666338|No Intervention|Standard of Care|Standard of Care regarding mobilization
88847051|NCT01881932|No Intervention|Standard Care|Patients will be stratified based on cancer type (breast cancer vs colorectal cancer). In standard care arm, patients will not receive additional therapy for CIPN. Patient will complete a weekly questionnaire during the study to determine severity of nerve pain symptoms. Each week record the total amount of chemotherapy received in the past week. Record how much chemotherapy received all together. Each week patient will have blood drawn (about 1 teaspoon) to check nerve growth factors levels. All patients will follow the same chemotherapy dose reduction algorithm. No concomitant anti-neuropathy medication is allowed.
88847052|NCT01881932|Experimental|Acupuncture|Patients will be stratified based on cancer type (breast cancer vs colorectal cancer). The patients will be randomly assigned to receive acupuncture until the end of their chemotherapy. Patient will complete a weekly questionnaire during the study to determine severity of nerve pain symptoms. Each week record the total amount of chemotherapy received in the past week. Record how much chemotherapy received all together. Each week patient will have blood drawn (about 1 teaspoon) to check nerve growth factors levels. All patients will follow the same chemotherapy dose reduction algorithm. No concomitant anti-neuropathy medication is allowed. In standard care arm, patients will not receive additional therapy for CIPN.
89181618|NCT02688231|Experimental|High intensity group|
89181619|NCT02688231|Experimental|Low intensity group|
89181620|NCT02688231|Active Comparator|Control group - conventional treatment|
89181621|NCT02581683|Experimental|Magnesium|Participants in this arm will receive magnesium sulfate + ropivacaine via adductor canal block
89375250|NCT03665948|Experimental|Ketogenic Diet (KD)|Group consuming very low carbohydrate ketogenic diet. The ketogenic diet model was energetically normalized (covered the estimated energy expenditure) and assumed coverage of the daily energy requirement up to 5% of energy from carbohydrates. Proteins were administered in the amount of 1.7 g per kilogram of body mass. The remaining energy needs were covered with fats (fats covered more than 75% of the daily energy requirement). Each of the subjects in this group received 10-day menus.
89375251|NCT03665948|Active Comparator|Low-Glycemic Index Diet (CHO-LGI)|Group consuming carbohydrate, low-glycemic index diet. The carbohydrate diet model with a low glycemic index was energetically normalized (covered the estimated energy expenditure) and assumed coverage of the daily energy requirement of 25% of fat. Proteins were administered in the amount of 1.7 g per kilogram of body mass. The remaining energy needs were covered with carbohydrates (carbohydrates covered about ~55% of the daily energy requirement). The glycemic index of individual meals as well as the daily diet was calculated in accordance with the appropriate recommendations. Each of the subjects in this group received 10-day menus.
89375252|NCT03665870|Experimental|Intervention Arm|Hypoglycemia Education: Participants will receive educational support to prevent repeat episodes of hypoglycemia.
89181622|NCT02581683|Active Comparator|Non-magnesium|Participants in this arm will receive ropivacaine via adductor canal block
89181623|NCT02581683|Sham Comparator|Sham|Participants in this arm will receive a sham adductor canal block
89181624|NCT02688075||Canagliflozin Plus or Minus(+/-) Other Antihyperglycemic Agent|Participants who are receiving Canagliflozin +/- other antihyperglycemic agent (AHA) as per usual clinical practice will be observed for effectiveness, safety and PRO.
89181625|NCT04076709|No Intervention|Standard Care|
89181626|NCT04076709|Experimental|Goal directed anesthesia|Deep neuromuscular blockade (post tetanic count 1-2 twitches) and nociception guided anaesthesia
89181627|NCT04111523|Experimental|SY-007 dose 1|The study will be intiated in healthy subjects at a 1mg dose. Six subjects will be envolved in this study, and the proportion of subjects injected SY-007 to placebo is 2:1.
89181628|NCT04111523|Experimental|SY-007 dose 2|The study will be intiated in healthy subjects at a 4mg dose. Twelve subjects will be envolved in this study, and the proportion of subjects injected SY-007 to placebo is 5:1.
89181629|NCT04111523|Experimental|SY-007 dose 3|The study will be intiated in healthy subjects at a 10mg dose. Twelve subjects will be envolved in this study, and the proportion of subjects injected SY-007 to placebo is 5:1.
89181630|NCT04111523|Experimental|SY-007 dose 4|The study will be intiated in healthy subjects at a 20mg dose. Twelve subjects will be envolved in this study, and the proportion of subjects injected SY-007 to placebo is 5:1.
89181631|NCT04111523|Experimental|SY-007 dose 5|The study will be intiated in healthy subjects at a 30mg dose. Twelve subjects will be envolved in this study, and the proportion of subjects injected SY-007 to placebo is 5:1.
89181632|NCT04111523|Experimental|SY-007 dose 6|The study will be intiated in healthy subjects at a 45mg dose. Twelve subjects will be envolved in this study, and the proportion of subjects injected SY-007 to placebo is 5:1.
89181633|NCT00638781|Active Comparator|1|Desmoteplase 62.5 µg/kg BW i.v. bolus
89181634|NCT00638781|Active Comparator|2|Desmoteplase 90 µg/kg BW i.v. bolus
89181635|NCT00638781|Active Comparator|3|Desmoteplase 125 µg/kg BW i.v. bolus
89181636|NCT00638781|Placebo Comparator|4|Placebo i.v. bolus
89181637|NCT04115423||Tocilizumab initiators|Patients over 18 years of age with a diagnosis of RA (ICD-10 codes: M05-06) and receiving tocilizumab at least once from January 2013 to December 2018. Tocilizumab initiators are required to have no record of tocilizumab within 1 year prior to the first prescription of tocilizumab.
89181638|NCT04115423||Tumor necrosis factor inhibitors (TNFi) users|Patients over 18 years of age with a diagnosis of RA (ICD-10 codes: M05-06) and receiving TNFi at least once from January 2013 to December 2018. TNFi users will be patients who had no record of tocilizumab and given specific TNFi during 1 year before the first prescription of TNFi.
89181639|NCT04113005|Experimental|Desmopressin|Aim to evaluate the safety and tolerability of Desmopressin in CRPC subjects starting Docetaxel treatment.
89181640|NCT00588341|Experimental|Treatment|
89181641|NCT00914693|Experimental|Arm 1|
89181642|NCT00915083|Experimental|Amrubicin 40mg/m^2|Amrubicin 40mg/m^2 given as a 5 minute IV infusion on Days 1, 2 & 3 of a 21 day cycle
89181643|NCT00802529|Experimental|Steroid (Methylprednisolone)|Steroid (Methylprednisolone)
89181644|NCT00802529|Active Comparator|Gentamicin|Gentamicin
89181645|NCT02605811|Experimental|temozolomide|temozolomide oral 150mg/m2 d1-5/28d for 12 cycles
89181646|NCT02605811|Active Comparator|prophylaxis cranial radiotherapy|prophylaxis cranial radiotherapy,25-30Gy/10Fra
89181647|NCT00758264|Experimental|Group A|Meningococcal vaccine GSK134612 co-administered with pneumococcal vaccine GSK1024850A.
89181648|NCT00758264|Active Comparator|Group B|Pneumococcal vaccine GSK1024850A followed one month later by meningococcal vaccine GSK134612.
89181649|NCT00758264|Active Comparator|Group C|Meningococcal vaccine GSK134612 followed one month later by pneumococcal vaccine GSK1024850A.
89181650|NCT04027517|Experimental|JTZ-951|Oral doses once daily
89181651|NCT04027517|Active Comparator|Darbepoetin Alfa|Intravenous doses of Darbepoetin Alfa administered once weekly
89181652|NCT02601092|Experimental|Mini Gastric Bypass|"The mini gastric bypass procedure was first developed by Dr Robert Rutledge from the USA in 1997, as a modification of the standard Billroth II procedure. A mini gastric bypass creates a long narrow tube of the stomach along its right border (the lesser curvature). A loop of the small gut is brought up and hooked to this tube at about 180 cm from the start of the intestine.~No drugs or devices will be used."
89181653|NCT02601092|Active Comparator|Roux-en-Y Gastric Bypass|"This variant is the most commonly employed gastric bypass technique, and is by far the most commonly performed bariatric procedure in the United States. The small intestine is divided approximately 45 cm (18 in) below the lower stomach outlet and is re-arranged into a Y-configuration, enabling outflow of food from the small upper stomach pouch via a Roux limb. In the proximal version, the Y-intersection is formed near the upper (proximal) end of the small intestine. The Roux limb is constructed using 80-150 cm (31-59 in) of the small intestine, preserving the rest (and the majority) of it for absorbing nutrients.~No drugs or devices will be used."
89181654|NCT02605655|Experimental|AMP-1915|Instant noodles contained AMP-1915 2 g/pc with meal, 1 pc/day for 3 months.
89181655|NCT02605655|Placebo Comparator|Placebo|Instant noodles with the same sharp and color as Experimental noodles with meal, 1 pc/day for 3 months.
89181656|NCT00588731|Experimental|Cannabidiol|
89181657|NCT00588731|Placebo Comparator|Placebo|
89181658|NCT04111367|Experimental|Genotype 2 and 6 Subjects|Genotype 2 and 6 Subjects will receive oral tablets of Seraprevir 200mg twice a day along with oral tablet of sofosbuvir 400 mg,once a day from Day 1 up to Week 12
89181659|NCT04111367|Experimental|Genotype 3 Subjects|Genotype 3 Subjects will receive oral tablets of Seraprevir 200mg twice a day along with oral tablet of sofosbuvir 400 mg,once a day from Day 1 up to Week 24
89181660|NCT05629949|Experimental|QL1701+Docetaxel|Participants received intravenous infusion of QL1701 with docetaxel. The initial load dose of QL1701 was 8mg/kg, followed by 6mg/kg every three weeks; The recommended dose of docetaxel is 75mg/m2, given once every 3 weeks for a treatment cycle of 3 weeks.
89181661|NCT05629949|Active Comparator|Herceptin®+Docetaxel|Participants received intravenous infusion of Herceptin® with docetaxel. The initial load dose of Herceptin® was 8mg/kg, followed by 6mg/kg every three weeks; The recommended dose of docetaxel is 75mg/m2, given once every 3 weeks for a treatment cycle of 3 weeks.
89181662|NCT04111445|Experimental|ADG116|
88847053|NCT01881932|Active Comparator|Sham Acupuncture|Patients will be stratified based on cancer type (breast cancer vs colorectal cancer). The patients will be randomly assigned to receive sham acupuncture until the end of their chemotherapy while following the same chemotherapy dose reduction algorithm. No concomitant anti-neuropathy medication is allowed. Patient will complete a weekly questionnaire during the study to determine severity of nerve pain symptoms. Each week record the total amount of chemotherapy received in the past week. Record how much chemotherapy received all together. Each week patient will have blood drawn (about 1 teaspoon) to check nerve growth factors levels.
88847054|NCT03617419|Other|VScan Access R2 Ultrasound System|"Pre-market: Vscan Access R2 Ultrasound System~The following post-market products will be used on label:~GE Corometrics 170 Series Fetal Monitor - as a reference for value of fetal heart rate GE Voluson P8 Ultrasound System - for verification of fetal location during measurement"
88847055|NCT00379106|Active Comparator|Group1|
88847056|NCT00379106|Experimental|Group 2|
88847057|NCT03619135|Experimental|Use of Buzzy Device|The Buzzy device was used for IV access for this arm.
88847058|NCT03619135|Placebo Comparator|Control|No Buzzy device was used - standard IV access for this arm.
88847059|NCT04706312|Experimental|hAMSCs injection|hAMSCs were injected via venous in the dorsum of hand.
88847060|NCT00379184||A|Osteoarthritis patients scheduled for Total Knee Arthroplasty.
89181663|NCT04112771||Penehyclidine group|Penehyclindine hydrochloride was administered before anesthesia induction.
89181664|NCT04112771||Placebo group|Penehyclindine hydrochloride was not administered before anesthesia induction.
89181665|NCT02605577|Experimental|experimental group|"group of late preterm infants following new systemic nutritional management protocol during hospital stay,which including specific enteral and parenteral nutritional protocol and complication monitor, such as hyperglycemia,hypoglycemia,infection,hyperbilirubinemia and anemia(the intervention refers to thisnew systemic nutritional management protocol )"
89181666|NCT02605577|No Intervention|control group|group of late preterm infants using current nutritional management protocol during hospital stay
89181667|NCT05629481|Experimental|CO2 laser group|Participants in the CO2 laser group underwent three vaginal fractional CO2 laser (AcuPulse, Lumenis, Yokneam Illit, Israel) treatment sessions with 4-6 weeks intervals.
89181668|NCT05629481|Sham Comparator|Sham group|Participants in the sham group underwent three sham treatment sessions with 4-6 weeks intervals.
89181669|NCT04112927||OSA Participants|"Inclusion Criteria: 1) age between 18 to 70 years; 2) suspected of OSA and referred to full PSG study by a doctor.~Exclusion Criteria: 1) being diagnosed with a chronic respiratory disease including pulmonary fibrosis, emphysema, respiratory infectious disease, nocturnal asthma, obstructive pulmonary lung disease, pulmonary hypertension, congestive heart failure, sleep related hypoventilation and neuromuscular disorders; 2) having insomnia or restless leg; 3) drug addiction; and 4) under the current, direct supervision of the PI of this study."
89181670|NCT04112927||Healthy Controls|"Inclusion Criteria: 1) age between 18 to 70 years; 2) non-snorer, and being free of any sleep disorders.~Exclusion Criteria: same as the OSA Participants. All participants must not have any cold or any other respiratory illness at the time of recording.~Illiterate participants may still participate in the study; however, there must be a witness who is not involved in the study (i.e. PI, Co-PI, study coordinator, research assistants (RA)/students, etc.) present to witness the consent process between the participant and the individual obtaining consent."
89181671|NCT04109573|Experimental|Anorectal function post anal laser|"Intervention:~Device: laser"
89181672|NCT04112615||Patients and/or carers|Patients and/or their nominated carers come in to give feedback on the device and the system as a whole, from usability to design.
89181673|NCT04112615||Healthcare professionals|Healthcare professionals come in to give feedback on the device and the system, from what results they would like to see and their concerns about patients using it.
89181676|NCT05628233|No Intervention|Study Arm A (control arm)|Subjects receiving cisplatin-based chemotherapy without receiving SENS-401. This control arm will provide natural history data, particularly the incidence and the time to onset of hearing impairment due to ototoxicity.
88847061|NCT00379184||B|Osteoarthritis patients not scheduled for Total Knee Arthroplasty.
88847062|NCT00379184||C|Healthy volunteers
88847063|NCT03559933|Experimental|PEPNS System|The pdSTIM lead will be temporarily inserted near the right and left phrenic nerves and connected to the PEPNS system console in order to stimulate the phrenic nerves and activate the diaphragm on the patients until extubated/removed from mechanical ventilation or until 48 hours has elapsed, whichever comes first.
88847064|NCT00379262|Experimental|1A|Concurrent-Adjuvant CRT using P-PF regimen and conventional fractionation radiotherapy
88847065|NCT00379262|Experimental|1B|Concurrent-Adjuvant CRT using P-PF regimen and accelerated fractionation radiotherapy
88847066|NCT00379262|Experimental|2A|Induction-Concurrent CRT using PF-P regimen and conventional fractionation radiotherapy
89181677|NCT05628233|Experimental|Study Arm B (treatment arm)|Subjects receiving 43.5 mg of oral SENS-401 b.i.d for up to 23 weeks. This arm will provide data on the potential protective effects of SENS-401 on cisplatin induced ototoxicity.
88847067|NCT00379262|Experimental|2B|Induction-Concurrent CRT using PF-P regimen and accelerated fractionation radiotherapy
88847068|NCT00379262|Experimental|3A|Induction-Concurrent CRT using PX-P regimen and conventional fractionation radiotherapy
88847069|NCT00379262|Experimental|3B|Induction-Concurrent CRT using PX-P regimen and accelerated fractionation radiotherapy
88847070|NCT03620383|Experimental|Heat|Distal topical heat application
88847071|NCT03620383|No Intervention|No Heat|Inactive heat pack to blind the investigator.
88847072|NCT00793520|Experimental|1|Twice daily oral administration of milnacipran for 5 weeks, placebo for 2 weeks, and crossover to placebo for 5 weeks.
88847073|NCT00793520|Experimental|2|Twice daily oral administration of placebo for 5 weeks, placebo for 2 weeks, and crossover to milnacipran for 5 weeks.
88847074|NCT03621085|Experimental|Ketamine|Subjects will receive up to 20 mg Ketamine Hydrochloride while the effects of this drug on tolerance to a hemorrhagic insult will be assessed.
88847075|NCT03621085|Placebo Comparator|Placebo|Subjects will receive placebo while the effects of this drug on tolerance to a hemorrhagic insult will be assessed.
88847076|NCT00795236|No Intervention|Observational|Observe to determine free-running versus entrained status.
88847077|NCT00795236|Experimental|Melatonin|Subjects with free-running rhythms will take melatonin.
88847078|NCT04490863|Experimental|Test subjects|All subjects are enrolled and receive Rad-67 Pulse oximeter & DCI Mini sensor for measurement of hemoglobin.
88847079|NCT00790478|Placebo Comparator|Placebo|Placebo -- lactose pill.
88847080|NCT00790478|Active Comparator|Melatonin|Melatonin
88847081|NCT04490239|Experimental|Experimental Arm|"Subjects will be administered heparin sodium (porcine) bottled in a nasal sprayer with a volume per spray of 0.1 mL.~Acute phase:~On day 1, each subject will be administered 0.1 mL per nostril of 5000 U/mL heparin sodium (porcine), for a total dose of 1000 U. Vital signs, blood work, and follow-up clinical observation will be used to detect adverse effects.~On day 2, each subject will be administered 0.1 mL per nostril of 10000 U/mL heparin sodium (porcine), for a total dose of 2000 U. Vital signs, blood work, and follow-up clinical observation will be used to detect adverse effects.~Chronic phase:~The highest acute dose that has no impact on aPTT or INR will be used for the chronic phase of this study. Each subject will be administered a daily dose for fourteen days. The first and last dose will be administered in the clinic; all other doses will be self-administered by subjects at home at the same time of day using a dosing diary to keep records."
88847082|NCT00791336|Experimental|Nelfinavir|
88847083|NCT03621787|Experimental|Single arm study: implant insertion|Participants in trial will be within a single study arm. All participants will have a placebo subcutaneous implant inserted with the device being studied. The implant accuracy will be assess through palpation and ultrasound depth measurements. The implant will then be removed. Safety will be assessed by measuring bruising and bleeding. A follow-up questionnaire will assess bruising and infection risk. A final visit will assess bruising and infection risk by a physician.
88847084|NCT00787124||1|< 28 weeks gestation, < 30 days of age, < 3 previous transfusions
88847085|NCT00787124||2|< 28 weeks gestation, >=30 days of age, >= 3 previous transfusions
88847086|NCT03562663|Experimental|Active tDCS|Participants in this group received 20 minutes of active 2 mA transcranial direct current stimulation over the motor cortex of the affected arm prior to robotic intervention.
88847087|NCT03562663|Sham Comparator|Sham tDCS|Participants in this group received 20 minutes of sham 2 mA transcranial direct current stimulation over the motor cortex of the affected arm prior to robotic training.
88847088|NCT00771602|Experimental|Rituximab|Group 1: 375 mg/m^2 IV Rituximab Alone
88847089|NCT00771602|Experimental|Alemtuzumab|Group 2: 30 mg SQ Alemtuzumab Alone
88847090|NCT00771602|Experimental|Rituximab + Alemtuzumab|Group 3: 375 mg/m^2 Rituximab + 30 mg SQ Alemtuzumab
88847091|NCT04332146|Experimental|Mindfulness-based intervention|
88847092|NCT04332146|Active Comparator|Booklet-based psychoeducation group|
88847093|NCT03623035||Lumbar Plexus block Group|This group includes participants that received Lumbar Plexus blocks (LPB) as the regional analgesic technique in a direct anterior approach (DAA) Total Hip Arthroplasty.
88847094|NCT05277818||Patient with medical device DIVA®|Adult patient, operated for at least 12 months, having had surgery for a degenerative or traumatic mono-segmental lumbar disc herniation, without any other associated pathology, operated with DIVA® implant
88847095|NCT05277818||Patient without medical device DIVA®|Adult patient, operated for at least 12 months, having had surgery for a degenerative or traumatic mono-segmental lumbar disc herniation, without any other associated pathology, operated without DIVA® implant
88847096|NCT05246384|Experimental|Part I (dose escalation) RP7214 + Azacitidine|Participants will receive RP7214 orally in combination with Azacitidine in a 28-day cycle. The dose levels will be escalated until MTD/a recommended Phase 2 dose (RP2D) has been identified.
88847097|NCT05246384|Experimental|Part II (dose expansion) RP7214 + Azacitidine|Participants will receive RP7214 orally at the MTD/RP2D in combination with Azacitidine in a 28-day cycle.
88847098|NCT03626623|Placebo Comparator|Standard of Care (SOC)|The usual care a licensed health care provider would give patients to treat diabetic foot ulcers or wounds.
88847099|NCT03626623|Active Comparator|Cytal Wound Matrix 1-Layer|The application of the Cytal Wound Matrix 1-Layer device according to the Cytal Wound Matrix 1-Layer instructions for use (IFU).
89181678|NCT04109261||Palbociclib treatment|
89181679|NCT04109339|No Intervention|group 1 with no oxytocin|
89375253|NCT03006458|Experimental|comfilcon A|"Participants were randomized to wear comfilcon A toric lenses for two weeks during the cross over study.~The final optical design of comfilcon A contact lens was optimized to improve the quality and two further studies (CV-18-10 and CV-18-11) were conducted after completion of this study to evaluate the modified optical design."
89375254|NCT03006458|Active Comparator|omafilcon B|Participants were randomized to wear omafilcon B toric lenses for two weeks during the cross over study.
89375255|NCT04056104|Experimental|SpO2 and PIx Measurement|Non-invasive measurements of oxygenation (SpO2) and perfusion (PIx) will be measured with pulse oximeters
89375256|NCT03320941|Experimental|LIK066 2.5 mg|Eligible patients randomized to this arm will receive LIK066 2.5 mg orally daily for 12 weeks.
88847100|NCT05149742|Experimental|Cases: Patients with severe to profound hearing loss|Patients aged between 45 to 64 years with severe to profound bilateral post-lingual sensorineural hearing loss with a maximum intelligibility of 70% (disyllabic words) in free-field silence with hearing aids at 60 dB SPL
88847101|NCT05149742|Active Comparator|Controls: 90 matched subjects with normal hearing|Healthy controls aged between 45 to 64 years with normal hearing on pure-tone audiometry (as function of ISO 7029 reference)
88847102|NCT01804166|Other|IBD patients with HSTCL|Subjects with Inflammatory Bowel Disease with a diagnosis of Hepatosplenic T-cell lymphoma
88847103|NCT04459585|Experimental|Dabigatran + Quizartinib|Participants who will receive a single oral dose of 150mg dabigatran etexilate on Day 1 of Period 1 and then will receive a single oral dose of 60mg quizartinib 2 hours prior to the administration of a single oral dose of 150mg dabigatran etexilate on the morning of Day 5 of Period 2.
88847104|NCT05080556|Active Comparator|Arm 1 (control) - standard dosing carboplatin|Arm 1 (Standard Dosing): Carboplatin AUC5 based on nuclear medicine renal clearance.
88847105|NCT05080556|Experimental|Arm 2 (experimental) - adaptive therapy carboplatin according to CA125|Arm 2 (Adaptive Therapy): Carboplatin dose will be calculated according to the CA125 value.
89375257|NCT03320941|Experimental|LIK066 10 mg|Eligible patients randomized to this arm will receive LIK066 10 mg orally daily for 12 weeks.
89375258|NCT03320941|Experimental|LIK066 25 mg|Eligible patients randomized to this arm will receive LIK066 25 mg orally daily for 12 weeks.
89375259|NCT03320941|Experimental|LIK066 50 mg|Eligible patients randomized to this arm will receive LIK066 50 mg orally daily for 12 weeks.
89375260|NCT03320941|Placebo Comparator|Placebo|Eligible patient randomized to this arm will receive LIK066 matching placebo orally daily for 12 weeks.
88847106|NCT00746018|Experimental|1|The patients will already be undergoing a total hysterectomy with removal of the tubes and ovaries for a specific indication diagnosed or defined by their surgeon. If the patient is suitable to proceed by the surgeon, then he/she will perform a right salpingooophorectomy with the LigaSure devices.
88847107|NCT01797380|Placebo Comparator|Sugar Pill|Placebo
88847108|NCT01797380|Active Comparator|Active Drug|Escitalopram tablet, 10mg, daily, 9 weeks.
88847109|NCT03571555||Young people with perinatally acquired HIV|Residential interventions (camps) and community based support (clubs)
88847110|NCT03571555||Caregivers of young people with perinatally acquired HIV|Community based support (clubs)
88847111|NCT00737594|Placebo Comparator|Placebo TID|Participants receive matching placebo capsules three times daily (TID)
89375261|NCT03005288|Experimental|BYM338 10 mg/kg|Bimagrumab (BYM338) 10 mg/kg up to maximum 1200 mg, every 4 weeks until week 44 (12 doses)
89375262|NCT03005288|Placebo Comparator|Placebo|Placebo, every 4 weeks until week 44 (12 doses)
88847112|NCT00737594|Experimental|12 mcg TID|Participants receive 12 mcg Cobiprostone TID
88847113|NCT00737594|Experimental|18 mcg TID|Participants receive 18 mcg Cobiprostone TID
88847114|NCT00732680|Experimental|Botulinum Toxin Type A|Treatment will be in the form of 10 Units of Botulinum Toxin Type A injected into the dilator nasalis muscle on each side of the nose.
88847115|NCT04441255|Experimental|TAK-788 160 mg Fasted + TAK-788 160 mg Fed|TAK-788 160 milligram (mg), capsule, orally, once on Day 1 of Period 1 under fasted conditions (Treatment A), followed by 10 days washout period, followed by TAK-788 160 mg, capsule, orally, once on Day 1 of Period 2 under fed conditions (Treatment B).
88847116|NCT04441255|Experimental|TAK-788 160 mg Fed + TAK-788 160 mg Fasted|TAK-788 160 mg, capsule, orally, once on Day 1 of Period 1 under fed conditions (Treatment B), followed by 10 days washout period, followed by TAK-788 160 mg, capsule, orally, once on Day 1 of Period 2 under fasted conditions (Treatment A).
88847117|NCT00726830|Experimental|Arm I: Opioid rotation to oral methadone|Participants are switched from their current opioid medication (oxycodone or morphine) to methadone. Participants receive oral methadone 2-3 times daily for 4 weeks.
89181680|NCT04109339|Experimental|group 2 with oxytocin 10 U IM + oxytocin 10 U IV|
89181681|NCT04109339|Experimental|group 3 with oxytocin 20 U IM + oxytocin 0 U IV|
89375263|NCT04055246|Experimental|Prebiotic|Participants receive prebiotics containing fiber bar to consume 2x daily for 1 week.
89375264|NCT04055246|Placebo Comparator|Placebo|Participants receive placebo bar containing no added prebiotics to consume 2x daily for 1 week.
89375265|NCT03533816|Experimental|EAGD T-cell infusion (Phase I)|Peripheral blood is collected by leukapheresis from the donor, expanded and activated on CliniMACS-Prodigy, further depleted of alpha beta T-cells using the CliniMACS Alpha Beta T-Cell Depletion System, which leaves a gamma delta T-cell rich product. This product is then infused into the recipient at either 1, 3, or 10 x 1,000,000 cells/kg concentrations depending upon the cohort.
89375266|NCT03533816|Experimental|EAGD T-cell infusion (Expansion)|Peripheral blood is collected by leukapheresis from the donor, expanded and activated on CliniMACS-Prodigy, further depleted of alpha beta T-cells using the CliniMACS Alpha Beta T-Cell Depletion System, which leaves a gamma delta T-cell rich product. This product is then infused into the recipient at the maximum tolerated dose as determined from Phase I.
89375267|NCT03666260|Experimental|Quadratus Lumborum Block arm|
89375268|NCT03666260|Active Comparator|Femoral block arm|
89375269|NCT03665714|Experimental|Impact Oral|"Preoperatively:~1 bottle each time (250ml/bottle), 3 times per day, equivalent to approximately 1060.5kcal per day.~Postoperatively:~Patient should receive:~1 bottle (250 ml each) per day of test product on D 1 and D 2 post surgery, corresponding to 353.5Kcal.~2 bottles (250 ml each) per day of test product on D 3 and D 4 post surgery, corresponding to 707Kcal.~3 bottles (250 ml each) per day of test product on D 5, D 6 and D 7 post surgery, corresponding to 1060.5 kcal.~At the discretion of the authorized investigator/nutritionist, the amount of study products, can be increased to meet the daily caloric goal: 1500Kcal."
89375270|NCT03665714|Active Comparator|Enteral nutrition Emulsion(TPF-T)|"Preoperatively:~272ml each time, 3 times per day, equivalent to approximately 1060.5kcal per day.~Postoperatively:~Patient should receive:~272ml of control product on D 1 and D 2 post surgery, corresponding to 353.5Kcal.~544ml of control product on D 3 and D 4 post surgery, corresponding to 707Kcal.~816ml of control product on D 5, D 6 and D 7 post surgery, corresponding to 1060.5 kcal.~At the discretion of the authorized investigator/nutritionist, the amount of study products, can be increased to meet the daily caloric goal: 1500Kcal."
88847118|NCT00726830|Experimental|Arm II: Opioid rotation to another long-acting strong opioid|Participants currently receiving oxycodone are switched to sustained-release (SR) morphine. Participants currently receiving morphine are switched to SR oxycodone. Participants receive either oral SR morphine or oxycodone 2-3 times daily for 4 weeks.
88847119|NCT03628885|No Intervention|General Vaccine Information|Brief (47 second) animated informational video about vaccines recommended for all young adolescents.
88847120|NCT03628885|Experimental|Top Concern Tailored Intervention|"Intervention includes the General Vaccine Information video plus a brief (< 50 sec) animated video address the parent's top ranked question or concern from the provided list of possible concerns: 1. I need more information about the vaccine; 2. My child is too young; 3. I am concerned about the long-term health effects or safety of the vaccine; 4. My child's health care provider did not recommend it or said my child could wait; 5. The vaccine is not required for school; 6. Other / none of the above. For those indicating #6, they will receive the same video as those indicating #1 (need more information)."
88847121|NCT03628885|Experimental|All Concerns Tailored Intervention|"Intervention includes the General Vaccine Information video plus one or more brief (< 50 sec) animated videos that address all of the parent's indicated question or concern from the provided list of possible concerns: 1. I need more information about the vaccine; 2. My child is too young; 3. I am concerned about the long-term health effects or safety of the vaccine; 4. My child's health care provider did not recommend it or said my child could wait; 5. The vaccine is not required for school; 6. Other / none of the above."
88847122|NCT00691652|Experimental|Oral Clofarabine + Rituximab in Relapsed B Cell NHL|"Phase I: Oral Clofarabine x 14 days for up to 8 cycles at assigned dose level below (1 cycle equals 14 days on drug, 14 days off).~Rituximab weekly for 4 weeks than monthly for up to 8 cycles on day 1 of cycle 375 mg/m2 IV~Dose Level 1: 2 mg Dose Level 2: 4 mg Dose Level 3: 6 mg~Phase II:~Oral Clofarabine x 14 days for up to 8 cycles (Dose determined from phase I) AND Rituximab weekly for 4 weeks than monthly for up to 8 cycles on day 1 of cycle 375 mg/m2 IV"
89375271|NCT03003494||Spiolto® Respimat®|consented COPD patients who will be treated with Spiolto® Respimat® according to the approved SmPC
89375272|NCT03559699|Experimental|AG-348|Participants received AG-348 tablets, administered orally, at a starting dose of 5 milligrams (mg), twice daily (BID), followed by two sequential dose level increases to 20 mg and 50 mg BID, for a period of 16 weeks in Part 1. This was followed by optimized dose BID, as determined by the investigator in Part 1, for a period of 24 weeks in Part 2.
89181682|NCT04109339|Experimental|group 4 with oxytocin 0 U IM + oxytocin 20 U IV|
89181683|NCT05628077||PAIN|
89375273|NCT03928639||Cohort 1|All patients undergoing consultation for structural and valve interventional procedures are invited to participate in this registry protocol.
89375274|NCT04324645||Active Symptom Monitoring via Noona|Participants will undergo a single training session on how to use the Noona software no more than 4-12 weeks before starting therapy. They can start using the software immediately after the training session. Patients will be invited to complete either the Chest Radiotherapy (if radiotherapy alone), Chemotherapy-18 (if chemoradiation therapy), or Bone Radiotherapy (if other) module at baseline, every other week throughout therapy, and during follow up for 90-days. Patients will be encouraged by the treatment team to complete the baseline symptom report prior to starting any therapy and to complete the reports during therapy and in follow up. Patients will also complete the EORTC QLQ-C30 and the NCCN Distress Thermometer at baseline (no more than 12 weeks before starting therapy), within 1 week of completing therapy, and at 90-days follow up. Patients will be encouraged to use Noona's other features beyond invited modules and PRO inventories, such as the diary during the study
89375275|NCT02449681|Experimental|TH-4000 (Tarloxotinib)|TH-4000 150 mg/m2 will be administered by IV infusion over 60 minutes on Days 1, 8, 15 and 22 of each 28-day cycle until progressive disease (PD) or unacceptable toxicity.
89375276|NCT02573233|Placebo Comparator|Placebo|Placebo (for dupilumab), 2 subcutaneous injections on Day 1 (Week 1) as a loading dose followed by a single injection q2w from Week 2 to Week 14, added to stable inhaled corticosteroid/ long-acting beta-agonist (ICS/LABA) therapy. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication.
89375277|NCT02573233|Experimental|Dupilumab|Dupilumab, 2 subcutaneous injections on Day 1 as a loading dose for a total of 600 mg, followed by a single 300 mg injection q2w from Week 2 to Week 14, added to stable ICS/LABA therapy. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication.
88847123|NCT00691574|Active Comparator|2|Subjects will sit in front of a fluorescent bright light box while completing plasma samples to test for melatonin suppression in blood. This will be completed by both the SMS patient group and the control group of elderly individuals.
88847124|NCT00691574|Experimental|1|Subjects will take up to 3 mg of melatonin daily and will complete frequent (every 2-4 weeks) of saliva and/or plasma sampling to test for a change in the timing of the body clock in response to the melatonin.
88847125|NCT03630679||Preterm|born at <37 weeks of gestation
88847126|NCT03630679||Full term Term|born at >/= 37 weeks of gestation
88847127|NCT03631927||Patient|Patients admitted to participating ICUs on the specified dates
88847128|NCT00685880|Experimental|Prolotherapy group|Subjects randomized to this arm will receive injection(s) of 10% dextrose solution in the affected thumb joint.
88847129|NCT00685880|Active Comparator|Corticosteroid Group|Subjects randomized to this arm will receive injection(s) of betamethasone solution in the affected thumb joint.
88847130|NCT00681044|Experimental|SCT with melphalan conditioning|Mobilization with Filgrastim Stem Cell Transplant Melphalan Conditioning Stem Cell infusion
88847131|NCT03632083|Active Comparator|Hy-Care Contact Lens Solution|Each subject will wear fanfilcon A soft contact lens in one eye and comfilcon A soft contact lens in the other eye with each lens having been soaked overnight in the Hy-Care contact lens solution.
88847132|NCT03632083|Active Comparator|Lite Contact Lens Solution|Each subject will wear fanfilcon A soft contact lens in one eye and comfilcon A soft contact lens in the other eye with each lens having been soaked overnight in the Lite contact lens solution.
88847133|NCT05010980||retrospective|For the retrospective part of the study, the existing echocardiographic database will be used to retrieve data. The database query includes the last 2 years.
88847134|NCT05010980||prospective|For the prospective part of the study, patients will be included who have the clinical indication for cmr and scintigraphy due to suspected cardiac amyloidosis and fulfill the inclusion criteria.
88847135|NCT03633487|Experimental|Mucinex® 1200 mg|Mucinex® 1200 mg Extended-Release (ER) Bi-Layer tablet (single dose)
88847136|NCT04929002||McArdle Disease|
88847137|NCT04929002||Pompe disease|
88847138|NCT04929002||Controls|
88847139|NCT03574441|Active Comparator|TegadermTM only|
89181684|NCT05628077||NO PAIN|
89181685|NCT04109495|Other|Smart phone application(NOOM)|
89375278|NCT03867487|Experimental|Study intervention|Empagliflozin 10 mg will be taken daily
89375279|NCT03867487|Placebo Comparator|Control arm|Placebo oral tablet will be taken daily
89375280|NCT01381224||Observation of biomechanical effects post injection|Observation of effects on gait, lumbar spine range of motion and pain symptoms immediately following injection and at two weeks post injection.
89375281|NCT04127539|Experimental|Intervention|Will start a Strong & Steady group exercise programme immediately after baseline testing.
89375282|NCT01381146|Experimental|Impact of Crime Modules|5 session/1 week modules of a restorative justice inspired victim impact group intervention
89375283|NCT01381146|Other|TAU|treatment as usual -- participants have access to all other jail programs and services
89375284|NCT01569048|Active Comparator|remifentanil|
88847140|NCT03574441|Active Comparator|Dressing with TegadermTM plus Steri-StripTM bands|
89375285|NCT01569048|Experimental|dexmedetomidine|
88847141|NCT03574441|Experimental|Dressing with TegadermTM plus catheter support pad.|
88847142|NCT00671606|Experimental|Intraoperative Lymphatic Mapping|Intraoperative sentinel lymph node identification (lymphatic mapping)
88847143|NCT01756586|Active Comparator|Control|Plain bupivacaine
88847144|NCT01756586|Experimental|Experimental|Bupivacaine with Dexamethasone
88847145|NCT03636061|Active Comparator|OC-01 Low Dose, 0.12 mg/mL|OC-01 (varenicline) nasal spray, Low Dose, 0.12 mg/mL
88847146|NCT03636061|Active Comparator|OC-01 Mid Dose, 0.6 mg/mL|OC-01 (varenicline) nasal spray Mid dose, 0.6 mg/mL
88847147|NCT03636061|Active Comparator|OC-01 High Dose, 1.2 mg/mL|OC-01 (varenicline) nasal spray High dose, 1.2 mg/mL
88847148|NCT03636061|Placebo Comparator|Placebo|Placebo (vehicle) nasal spray
88847149|NCT04404907||Males who never deliberately tan|Males responded to an anonymous online survey that they never deliberately tan
88847150|NCT04404907||Males who ever deliberately tan|Males responded to an anonymous online survey that they had ever deliberately tan
88847151|NCT00661466|Experimental|1|Either three or four 5x5-cm bupivacaine sponges implanted at 2 sites within the surgical field (1) over the abdominal viscera and under the fascia prior to closing the fascia and (2) in the subcutaneous tissue just under the skin incision.
88847152|NCT00661466|Placebo Comparator|2|Either three or four 5x5-cm placebo sponges implanted at 2 sites within the surgical field (1) over the abdominal viscera and under the fascia prior to closing the fascia and (2) in the subcutaneous tissue just under the skin incision.
88847153|NCT04403113|Experimental|Study Group (SG)|feeding and oral motor intervention strategies+structured neck and trunk stabilization exercises+caregiver training related to feeding (Study Group)
88847154|NCT04403113|Placebo Comparator|Control Group (CG).|feeding and oral motor intervention strategies+caregiver training related to feeding (Control Group)
89181686|NCT04109495|Other|Non-user|
89181687|NCT04109417|Experimental|osteotomy filled with PRP-gel and covered with PRP-biomembrane|the defect was filled with the previously activated autologous Platelet-rich plasma (PRP) gel and its supernatant. The site was then externally covered with the prepared bio-membrane composed of activated PRP which acted as an adjunct to the mucoperiosteal flap to stimulate tissue regeneration
89375286|NCT03941574|Experimental|HLX10|
89375287|NCT03799705||History of VACTERL or congenital malformations|1) Adults with VACTERL association; 2) adults with a history of congenital malformations resembling VACTERL association; 3) gravid and non-gravid women with a history of recurrent miscarriage, their surviving offspring, and the biological father of offspring; 4) newly diagnosed VACTERL patients identified by healthcare providers.
89375288|NCT01384344|Active Comparator|witness|no mnesic complaint
89375289|NCT01384344|Experimental|Alzheimer disease with apathy|Alzheimer's disease according to criteria of NINCDS-ADRDA with apathy
89375290|NCT01384344|Experimental|Alzheimer's disease without apathy|Alzheimer's disease according to criteria of NINCDS-ADRDA without apathy
89375291|NCT01384266||Subjects undergoing Cataract Surgery|Subjects undergoing routine cataract surgery
89375292|NCT03935880|Active Comparator|Cartiva Hemiarthroplasty|Cartiva implant
89375293|NCT03935880|Active Comparator|Cheilectomy|Bone spur removal
89375294|NCT05304234|Active Comparator|Ultrasound + AFP|Screening by abdominal ultrasound + serum AFP testing at 0, 6 and 12 months
89375295|NCT05304234|Active Comparator|aMRI + AFP|Screening by abbreviated MRI of the abdomen + serum AFP testing at 0, 6 and 12 months
89375296|NCT04008420||Adults who are scheduled to undergo robotic esophagectomy|Adults who are scheduled to undergo robotic esophagectomy
89002333|NCT06318832|Active Comparator|ICBT and Therapist Guidance (TG)|ICBT Therapist Guidance: Weekly Guidance will be provided by a Guide who is a registered social worker with a Master's in Social Work. The Guide will spend ~15 -20 mins. per week/per participant. Weekly interaction will consist of: 1) assist participants practice skills, reinforce progress, engage with the program; 2) guide participants to learn material, highlight lesson content, answer questions, and problem solve on how to apply skills; 3) provide support through warmth and concern; 4) monitor symptoms and risk management.
89002334|NCT06318832|Active Comparator|ICBT and Peer Support (PS)|ICBT Focused Peer Group Discussion: The focused discussion will take the form of a group based virtual session of approximately 6-8 participants in each group The Groups will be moderated by a Spinal Cord Injury Ontario Client Services team member once every two weeks for the duration of the 10-week program.
89002335|NCT06318832|Active Comparator|ICBT and Booster (B)|"ICBT~Booster sessions: Participants allocated to receive booster sessions will have access to a booster module at 16 weeks post enrollment. The booster module will include online materials that review core skills such as thought challenging, deep breathing, behavioural activation, and graded exposure. The module will also discuss how to maintain motivation and continue to practice skills regularly. The Booster module will also include a Do-It-Yourself Guide for participants to print and practice the skills they have learned throughout the course."
89002336|NCT06318832|Active Comparator|ICBT+TG+PS|ICBT and TG and PS
89375297|NCT01380912||breast cancer|"Patients operated with mastectomy and axillary dissection, who are randomised to injection of methylprednisoloneacetate in the cavity~Patients operated with mastectomy and axillary dissection, who are randomised to injection of saline solution in the cavity~Patients operated with mastectomy and Sentinel Node Operation, who are randomised to injection of methylprednisoloneacetate in the cavity~Patients operated with mastectomy and Sentinel Node Operation, who are randomised to injection of saline solution in the cavity"
89375298|NCT03315793|Experimental|Duloxetine Hydrochloride|Duloxetine hydrochloride given orally.
89181688|NCT04109417|Sham Comparator|osteotomy site left empty|osteotomy site following the surgical intervention was left empty
89181689|NCT00757172|Other|Docetaxel + Cisplatin + Panitumumab + RT|Patients received docetaxel (40 mg/m^2), cisplatin (40 mg/m^2) and panitumumab (6 mg/kg) on weeks 1, 3, 5, 7, and 9 with radiotherapy (RT) (5040 cGy, 180 cGy/day x 28 days) beginning week 5. Resection was planned after completing chemotherapy (CRT).
89375299|NCT03315793|Placebo Comparator|Placebo|Placebo given orally.
89375300|NCT01569204|Active Comparator|BrECAPP|modified BEACOPP by omitting Bleomycin and adding Brentuximab Vedotin
89375301|NCT01569204|Active Comparator|BrECADD|modified BEACOPP by omitting Bleomycin, Procarbazine and Prednisone and adding Brentuximab Vedotin, Dacarbazine and Dexamethasone
89181690|NCT04097678|Experimental|Retained Sponge Group|Just prior to imaging, the surgeon will purposely place a sponge in the wound. Two radiographs will be taken of the spine (AP and Lateral views).
89181691|NCT04097678|No Intervention|No Retained Sponge Group|No sponge will be placed in the wound. Two radiographs will be taken of the spine (AP and Lateral views).
89375302|NCT02676466|Experimental|Fish oil Active|This group will receive the Omega-3 fish oil which will be administered at a dose of 1.4 grams per day for the first six months. Based on tolerability and inflammation level, dose may either continue at 1.4 grams per day or be increased to 2.8 grams per day for the remaining six month.
89375303|NCT02676466|Placebo Comparator|Fish oil Placebo|This group will receive a placebo which will be matching to the Omega-3 fish oil. The placebo corn oil are obtained in gel caps and they have identical shape, color, taste and weight. The doses will be administered at doses corresponding to the Omega-3 fish oil.
89375304|NCT02676466|Active Comparator|Losartan Active|This group will receive the Losartan which will be administered at a starting dose of 25 milligrams per day. Based on tolerability, losartan will continue at a dose of either 25 milligrams per day or 50 milligrams per day for the first six months. Based on continued tolerability and inflammation level, dose may either continue at 25 or 50 milligrams per day or be increased to 100 milligrams per day for the remaining six months.
89375305|NCT02676466|Placebo Comparator|Losartan Placebo|This group will receive a placebo which will be matching to the losartan. The placebo cellulose based capsule are obtained in 25 mg and 50 mg capsules. The shell capsules are cellulose based. Placebo and LO have identical shape, color, taste and weight. the doses will be administered at doses corresponding to the losartan.
89181692|NCT00797225|Placebo Comparator|Placebo|Participants received placebo tablets once a day and placebo intramuscular injection once a month for 12 weeks. At the end of 12 weeks participants were re-randomized to receive one of the two doses of elagolix (150 mg or 250 mg) for 12 weeks.
89181693|NCT00797225|Experimental|Elagolix 150 mg|Participants received elagolix 150 mg tablets once a day and placebo intramuscular injection once a month for 12 weeks. At the end of 12 weeks participants continued to receive elagolix 150 mg for an additional 12 weeks.
89375306|NCT02676466|Active Comparator|Fish oil Active + Losartan Active|"This group will receive both the Losartan and Omega-3 fish oil. Losartan will be administered at a starting dose of 25 milligrams per day. Based on tolerability, losartan will continue at a dose of either 25 milligrams per day or 50 milligrams per day for the first six months. Based on continued tolerability and inflammation level, dose may either continue at 25 or 50 milligrams per day or be increased to 100 milligrams per day for the remaining six months.~Omega-3 fish oil will be administered at a dose of 1.4 grams per day for the first six months. Based on tolerability and inflammation level, dose may either continue at 1.4 grams per day or be increased to 2.8 grams per day for the remaining six month."
89375307|NCT02676466|Other|Fish oil Active + Losartan Placebo|"This group will receive the Omega-3 fish oil which will be administered at a dose of 1.4 grams per day for the first six months. Based on tolerability and inflammation level, dose may either continue at 1.4 grams per day or be increased to 2.8 grams per day for the remaining six month.~In addition, this group will receive a placebo which will be matching to the losartan. The placebo cellulose based capsule are obtained in 25 mg and 50 mg capsules. The shell capsules are cellulose based. Placebo and LO have identical shape, color, taste and weight. the doses will be administered at doses corresponding to the losartan."
89375308|NCT02676466|Other|Fish oil Placebo + Losartan Active|"This group will receive a placebo which will be matching to the Omega-3 fish oil. The placebo corn oil are obtained in gel caps and they have identical shape, color, taste and weight. The doses will be administered at doses corresponding to the Omega-3 fish oil.~In addition, this group will receive the Losartan which will be administered at a starting dose of 25 milligrams per day. Based on tolerability, losartan will continue at a dose of either 25 milligrams per day or 50 milligrams per day for the first six months. Based on continued tolerability and inflammation level, dose may either continue at 25 or 50 milligrams per day or be increased to 100 milligrams per day for the remaining six months."
89375309|NCT02676466|Other|Fish oil Placebo + Losartan Placebo|This group will receive a placebo which will be matching to both the omega-3 fish oil and losartan which will be administered at doses corresponding to doses administered for omega-3 fish oil and losartan throughout the 12 month study.
89375310|NCT03350269|Experimental|Intervention|Kidney transplant recipient candidates who are informed that their living donor candidates can receive reimbursement for lost wages incurred during the evaluation, donation surgery and recuperation
89375311|NCT03350269|No Intervention|Control|Kidney transplant recipient candidates who receive standard of care (donors are not offered wage reimbursement)
89375312|NCT01383252|Experimental|Water method|Water infusion in lieu of air insufflation for screening and surveillance colonoscopy
89375313|NCT01383252|Active Comparator|Air method|Air insufflation for screening and surveillance colonoscopy
89375314|NCT01380756|Experimental|Arm 1- Dose Escalation|The dose escalation will be conducted in 2 parts. Group 1 will consist of 8 cohorts and Group 2 will consist of 5 cohorts. The dose escalation is aimed at determining the maximum tolerated dose (MTD) of AMG 900.
88847155|NCT00639626|Experimental|Levemir|
88847156|NCT01718444|Experimental|Group A (No PIES)|"Subjects randomized to this group will receive clomiphene citrate (CC) without using progestin throughout their treatment course.~CC 50 mg oral for 5 days (Days 3-7)~If no ovulation, CC 100 mg for 5 days (Days 12-16)~If no ovulation, CC 150 mg for 5 days (Day 21-25)~Exit study if no response to 150 mg CC, or if no pregnancy after 5 ovulatory cycles"
88847157|NCT01718444|Active Comparator|Group B (PIES Group)|"Women randomized to this group will receive progestin to induce endometrial shedding before starting any doses of clomiphene citrate (CC)~Progestin 10 mg oral for 10 days to induce endometrial shedding (PIES)~CC 50 mg oral for 5 days (Day 3-7)~If no ovulation, progestin 10 mg for 10 days to induce endometrial shedding (starting on CD28) and CC 100 mg x 5 days, starting on day 3 of induced menses~If no ovulation, progestin 10 mg for 10 days to induce endometrial shedding, and CC 150 mg for 5 days~Exit study if no response to 150 mg CC, or if no pregnancy after 5 ovulatory cycles"
89375315|NCT01380756|Experimental|Arm 2- Dose Expansion|The dose expansion part of the study will begin after completion of the dose escalation phase and will consist of 20 subjects with acute myelogenous leukemia.
89375316|NCT04439890|Experimental|Anlotinib hydrochloride capsule + chemotherapy|Anlotinib hydrochloride capsule 12mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21) + Carboplatin injection (AUC 5mg/mL/min, intravenous drip, on Day 1) + Pemetrexed disodium f Injection (500mg / m2, intravenous drip, on Day 1).
88847158|NCT00641108|Experimental|ADAM SPECT|Participants with depression will undergo ADAM SPECT scans and cognitive behavioral therapy.
88847159|NCT00641108|Active Comparator|Control|Healthy subjects without depression will undergo ADAM SPECT scans.
88847160|NCT00638222|Active Comparator|All Study Participants|All enrolled participants were randomized to receive Carvedilol or Placebo in a 2-way crossover design. Each intervention was administered over 8 weeks before switching to the alternative intervention. The study was terminated early, and data were not unblinded so participants cannot be reported separately.
88847161|NCT00634322|Experimental|A|HDMTX-LV with glucarpidase
88847162|NCT00634322|Active Comparator|B|HDMTX-LV with placebo
88847163|NCT00634322|Experimental|C|compassionate use group to treat or prevent life threatening toxicity in the event of delayed elimination of MTX and/or renal impairment
88847164|NCT01705106|Experimental|Treatment (capecitabine, celecoxib)|Patients receive celecoxib PO BID for 7 days (course 0) and then on days 1-21 of course 1 and all subsequent courses. Patients also receive capecitabine PO BID on days 1-14 beginning in course 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
88847165|NCT00626444|Experimental|1|Intravenous vitamin C
89002337|NCT06318832|Active Comparator|ICBT+TG+B|ICBT and TG and B
89002338|NCT06318832|Active Comparator|ICBT+PS+B|ICBT and PS and B
89002339|NCT06318832|Active Comparator|ICT+TG+PS+B|ICBT and TG and PS and B
89181694|NCT00797225|Experimental|Elagolix 250 mg|Participants received elagolix 250 mg tablets once a day and placebo intramuscular injection once a month for 12 weeks. At the end of 12 weeks participants continued to receive elagolix 250 mg for an additional 12 weeks.
89375317|NCT04439890|Placebo Comparator|Placebo + chemotherapy|Placebo given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21) + Carboplatin injection (AUC 5mg/mL/min, intravenous drip, on Day 1) + Pemetrexed disodium f Injection (500mg / m2, intravenous drip, on Day 1).
89375318|NCT03695497|Experimental|Direct anterior approach|total hip arthroplasty with direct anterior approach
89375319|NCT03695497|Experimental|Direct Lateral Approach|total hip arthroplasty with direct lateral approach
89375320|NCT02324725|Experimental|Naltrexone Intervention|Eligible participants receive up to three monthly injections of 380 mg of naltrexone contained in dissolvable polymer microspheres and administered by deep intramuscular injection and slowly released over a period of approximately 4 weeks.
89375321|NCT03633695|Experimental|IC-8 IOL Group|A monofocal IOL (TECNIS ZCB00, ZCT150 or ZCT225 or AcrySof IQ SA60WF, SA6AT3 or SA6AT4) implanted in the first eye. The AcuFocus IC-8 IOL implanted in the second eye.
89375322|NCT03633695|Active Comparator|Control Group|A monofocal IOL (TECNIS ZCB00, ZCT150 or ZCT225 or AcrySof IQ SA60WF, SA6AT3 or SA6AT4) bilaterally implanted.
89375323|NCT01380678|Active Comparator|bevacizumab|intralesional bevacizumab injection
89375324|NCT01380678|Active Comparator|Topical antihistamine and vasoconstrictor|combination of topical antazoline HCl 0.05% and tetrahydrozoline HCl 0.04%
88847166|NCT00624650|Active Comparator|Modified FACTT (control)|The investigators control arm consists of a simplified algorithm for conservative management of fluids in patients with ALI, as to be published by the ARDSnet group, based on the protocol used in the FACTT trial. The protocol calls for strict adherence to ARDSnet ventilation, our weaning protocol and use of only select vasoactive, beta-adrenergic drugs as it is felt that variation in these treatments could seriously confound our results. Albuterol administration will not be permitted in the either arm except for life threatening bronchospasm not responsive to ipratropium. Ipratropium may be administered at the treating physician's discretion for bronchospasm. PiCCO's will be placed in each control patient and data recorded twice daily. The treating physician's will be blinded to this data.
88847167|NCT00624650|Experimental|EVLW|"When EVLW exceeds 9 ml/kg PBW the algorithmic treatment is begun and continued until EVLW ≤9 ml/kg PBW or extubation whichever comes first as tolerated (see figure 6). Furosemide and volume contraction are initiated when sufficient volumetric preload (GEDI) is available to enact volume contraction as a means to decrease measured EVLW without causing concomitant hypoperfusion. Fluid administration is also guided by changes in EVLW. An increase in EVLW > 2ml/kg PBW as a result of fluid administration curtails any further fluid administration until the next scheduled measurement.~Our ultimate treatment goal is to maximally lower EVLW towards the normal range - thus improving lung mechanics and gas exchange - without causing concomitant hemodynamic compromise and end-organ injury. By doing so we feel this algorithmic, goal directed, therapeutic approach should improve outcome."
88847168|NCT03965533|Placebo Comparator|Part A: Placebo IV- Caucasian Participants|Caucasian male participants were administered a single IV infusion of 0.9% weight by volume (w/v) saline placebo.
88847169|NCT03965533|Experimental|Part A: GSK2831781 450 mg IV- Caucasian Participants|Caucasian male participants were administered a single IV infusion of GSK2831781 at a dose of 450 milligram (mg), diluted in 0.9% w/v saline.
88847170|NCT03965533|Placebo Comparator|Part A: Placebo IV- Japanese Participants|Japanese male participants were administered a single IV infusion of 0.9% w/v saline placebo.
88847171|NCT03965533|Experimental|Part A: GSK2831781 450 mg IV- Japanese Participants|Japanese male participants were administered a single IV infusion of GSK2831781 at a dose of 450 mg, diluted in 0.9% w/v saline.
88847172|NCT03965533|Placebo Comparator|Part B: Placebo SC|Caucasian male participants were administered three SC injections of 0.9% w/v saline placebo.
88847173|NCT03965533|Experimental|Part B: GSK2831781 150 mg SC|Caucasian male participants were administered a single SC injection of a unit dose strength of 150 mg per milliliter (mL) of GSK2831781, diluted in 0.9% w/v saline. Participants also received 2 dummy injections of 0.9% w/v saline placebo SC to maintain the blinding.
89375325|NCT02213809|Experimental|Case method education in COPD|Two hours of case method education in COPD are given two times within 3 months to the general practitioners at nine primary health care centers. The education covers examination, including interpretation av spirometry, and treatment of patients with COPD. The learning outcomes are predefined and are the same in both arms. The same person will teach at both times of education.
89375326|NCT02213809|Active Comparator|Traditional education in COPD|Two hours of traditional education in COPD are given two times within 3 months to the general practitioners at nine primary health care centers.The education covers examination, including interpretation av spirometry, and treatment of patients with COPD. The learning outcomes are predefined and are the same in both arms. The same person will teach at both times of education.
89375327|NCT03314233|Experimental|DING intervention|Delayed Cord Clamping
89375328|NCT02675998|Experimental|3mg BID|Tenapanor, 3mg BID (6mg total)
89375329|NCT02675998|Experimental|10mg BID|Tenapanor, 10mg BID (20mg total)
89375330|NCT02675998|Experimental|Dose Titration|Tenapanor, patients start at 30mg BID and can down titrate weekly to 20, 15, 10, and 3mg BID, sequentially based on a GI tolerability question
89375331|NCT02675998|Placebo Comparator|Placebo|Placebo
89375332|NCT01384188|Experimental|E1|ONO-5334
89375333|NCT01384188|Experimental|E2|ONO-5334
89375334|NCT04588519|Experimental|Active Transcutaneous Auricular Neurostimulation|Transcutaneous Auricular Neurostimulation programmed to a pulse width of 250ms; channel 1: 5 Hz, mean intensity 0.3±0.2 mA; channel 2: 100 Hz, mean intensity 0.6±0.2 mA
89375335|NCT05666063||Study Group|Patients who underwent ambulatory urodynamic studies due to lower urinary tract symptoms
89375336|NCT01380600|Other|single arm; Dose escalation|Dose escalation 1e6 pfu/kg bw, 1e7 pfu/kg bw, 3e7 pfu/kg bw of Recombinant Vaccinia GM-CSF JX-594
89375337|NCT03264118|Active Comparator|Control|Decontamination of furcation defect with scaling and root planing only.
89375338|NCT03264118|Experimental|Antimicrobial Photodynamic Therapy|Decontamination of furcation defect with scaling and root planing complemented by antimicrobial photodynamic therapy.
89375339|NCT03539406|Experimental|NK-cells without preparative regimen|NK-cells without preparative regimen
88847174|NCT03965533|Experimental|Part B: GSK2831781 450 mg SC|Caucasian male participants were administered three SC injections of a unit dose strength of 150 mg per mL of GSK2831781 to achieve a dose of 450 mg.
88847175|NCT01693484|Experimental|ICG administered|The ICG dose (10 mg/4cc per image capture) will be administered in its entirety via push injection through IV access established for standard surgical procedure, followed by 10 cc Normal Saline bolus. This ICG dose will be administered twice, 1X prior to anesthesia, and 1X after the tourniquet on operative extremity has been removed for at least 15 minutes.
89181695|NCT00797225|Other|Leuprorelin|Participants received placebo tablets once a day and leuprorelin acetate 1-month depot 3.75 mg intramuscular injection once a month for 12 weeks. At the end of 12 weeks participants were re-randomized to receive one of the two doses of elagolix (150 mg or 250 mg) for 12 weeks.
88847176|NCT03637699|Other|Intervention|Subjects randomized to the intervention group will be complete five weeks of positive psychology exercises, one exercise per week, during the intervention phase (weeks 1-5) of the study.
88847177|NCT03637699|Other|Waitlist Control|Subjects randomized to the waitlist control group will complete five weeks of positive psychology exercises, one exercise per week, during the extension phase (weeks 6-10) of the study.
88847178|NCT01690910|Active Comparator|Front Wheeled Walker|The Front Wheeled Walker is a standard walker that is used to assist patients while walking.
88847179|NCT01690910|Active Comparator|Rifton Gait Trainer|The Rifton Gait Trainer is used to assist patients while walking. It includes a harness to support the patient and prevent falls.
88847180|NCT00613886|Experimental|Comparison for patients of lumbar drain and shunt surgery|"Subjective comparisons made for patients - before and after external lumbar drain, before and after shunt surgery.~Device: Programmable Shunt Insertion (Codman Medtronic)~Behavioral: Assessments in physical therapy, occupational therapy, and speech therapy~Follow-up testing to be administered by trained physician assistant in the outpatient setting on an approximately monthly basis: 10m walk, timed up-and-go, mini-mental status exam, 9-hole grooved pegboard, motor visual perception test (MVPT), modified rankin score (MRS)"
88847181|NCT03947983|Experimental|Intervention Group|The intervention group will receive a sensor-controlled digital game (SCDG) app and weight monitoring and physical activity sensors
88847182|NCT03947983|Active Comparator|Control group|The control group will receive only the weight monitoring and physical activity sensors
88847183|NCT00610532|Experimental|A|intravenous phenytoin alone
88847184|NCT00610532|Experimental|B|intravenous phenytoin plus probenecid
88847185|NCT04713722||MDD/childhood adversity group|subjects with current MDD who experienced childhood adversity
88847186|NCT04713722||rMDD/ childhood adversity|subjects with a history of MDD who experienced childhood adversity
88847187|NCT04713722||MDD|subjects in a current episode of MDD, with no history of childhood adversity
88847188|NCT04713722||Healthy Control|healthy control subjects, with no history of childhood adversity
88847189|NCT01669148|Active Comparator|Conventional + Tomosynthesis|conventional (2D) imaging plus tomosynthesis (3D) imaging first then tomosynthesis alone 1 month later.
88847190|NCT01669148|Active Comparator|Tomosynthesis alone|tomosynthesis (3D) imaging alone first then conventional (2D) imaging plus tomosyntheis 1 month later.
88847191|NCT03638323||LOOP group|Speech therapy consultation for patients with Alzheimer's disease
88847192|NCT03642457|Active Comparator|Serratus Plane Group|Patients randomized to the group will receive a total 20cc of solution consisting of 0.5% bupivacaine with 133mg of liposomal bupivacaine injected in the serratus plane with the help of an ultrasound.
88847193|NCT03642457|Placebo Comparator|Placebo Group|Patients randomized to the group will receive a total 20cc of 133mg liposomal bupivacaine injected prior to skin closure at the incision site as per surgeon's practice.
88847194|NCT00378716|Active Comparator|Group 1|5-FU + Leucovorin
88847195|NCT00378716|Experimental|Group 2|Uracil/Ftorarur + leucovorin
88847196|NCT03644095|Experimental|Mucinex® SE 600 mg (extended-release)|Single dose of Mucinex® SE extended-release 600 mg bi-layer tablet taken with 240 mL of water after an overnight fast
88847197|NCT03644095|Active Comparator|Vicks Cough Syrup 200 mg|Vicks Cough Syrup for Chesty Coughs 200 mg every 4 hours taken with 240 mL of water after an overnight fast
88847198|NCT01633814|Experimental|Transdermal estradiol|Transdermal estradiol, delivery rate 100 µg day-1
88847199|NCT01633814|Placebo Comparator|Placebo|placebo patch.
88847200|NCT04332133|Active Comparator|group 1|group 1 of DME which treated by SML
88847201|NCT04332133|Active Comparator|group 2|Group 2 of DME which treated by intravitreal injection of Ranibizumab
89375340|NCT03539406|Experimental|NK-cells with preparative regimen|NK-cells with preparative regimen
88847202|NCT04332133|No Intervention|group 3|control group of diabetic patients received no treatment
88847203|NCT04713943|Experimental|>Your< Iron Syrup|
88847204|NCT04713943|Other|Placebo|
88847205|NCT04713865||PFA slightly jailed by proximal SFA stent(100 pts)|
88847206|NCT04713865||PFA moderately jailed by proximal SFA stent(100 pts)|
88847207|NCT04713865||PFA totally jailed by proximal SFA stent (100pts)|
88847208|NCT04714099|Experimental|Topical CsA|Group A received topical CsA 0.05% for 3 months
88847209|NCT04714099|Placebo Comparator|Control|Placebo group
88847210|NCT04566770|Experimental|MID A|20 participants(18-49), Ad5-nCoV , two doses, Intramuscular administration
88847211|NCT04566770|Placebo Comparator|MID B|10 participants(18-49), Ad5-nCoV-placebo , two doses, Intramuscular administration
88847212|NCT04566770|Experimental|MIN A|100 participants(6-17), Ad5-nCoV , two doses, Intramuscular administration
88847213|NCT04566770|Placebo Comparator|MIN B|50 participants(6-17), Ad5-nCoV-placebo , two doses, Intramuscular administration
88847214|NCT04566770|Experimental|OLD A|100 participants(56 years of age and above), Ad5-nCoV , two doses(Low dose), Intramuscular administration
88847215|NCT04566770|Experimental|OLD B|100 participants(56 years of age and above), Ad5-nCoV , two doses(Middle dose), Intramuscular administration
88847216|NCT04566770|Placebo Comparator|OLD C|50 participants(56 years of age and above), Ad5-nCoV-placebo , two doses, Intramuscular administration
88847217|NCT04566770|Experimental|EBOV A|34 participants, Ad5-nCoV , two doses, Intramuscular administration
88847218|NCT04566770|Placebo Comparator|EBOV B|17 participants, Ad5-nCoV , two doses, Intramuscular administration
88847219|NCT04350307|Active Comparator|22-Gauge Arm|Patient undergoing epidural injection in this arm will get 22-gauge Quincke needle
89375341|NCT03064048|Active Comparator|Neo-ASA|During this arm the participant will receive a lozenge with nitric oxide as a dietary supplement twice daily.
88847220|NCT04350307|Active Comparator|25-Gauge Arm|Patient undergoing epidural injection in this arm will get 25-gauge Quincke needle
88847221|NCT04348357|Active Comparator|Traditional Visit|Patients come to the office for a traditional postoperative visit
88847222|NCT04348357|Experimental|Tele-medicine|Patients receive postoperative care via telemedicine
88847223|NCT04342663|Experimental|Fluvoxamine|Start fluvoxamine 100mg capsules, three times daily. May reduce dose (or start at reduced dose) for tolerability reasons. Will be followed in the RCT for approximately 15 days.
88847224|NCT04342663|Placebo Comparator|Placebo|Start placebo one capsule, three times daily. May reduce dose (or start at reduced dose) for tolerability reasons. Will be followed in RCT for approximately 15 days.
88847225|NCT00589550|Experimental|Peginterferon alfa-2b|Peginterferon alfa-2b will be administered SC on day 1 of each week of therapy. This will most likely be a Monday or a Tuesday. Sorafenib will be initiated on day 15 (start of week 3) of the first course and continued daily without breaks.
89375342|NCT03064048|Placebo Comparator|Placebo|During this arm the participant will receive a lozenge which will not contain nitric oxide as a dietary supplement twice daily.
88847226|NCT01636466|Experimental|Everolimus conversion|Subjects who have previously undergone a kidney transplant and are in late stage renal allograft failure will be randomized to take everolimus 0.75 mg twice daily after discontinuing current calcineurin inhibitor. Subjects will be weaned off of all other immunosuppression medicines when dialysis starts.
88847227|NCT01636466|No Intervention|Control|Subjects who have previously undergone a kidney transplant and are in late stage renal allograft failure will be randomized to continue on current immunosuppressive regimen. Subjects will be weaned off of all immunosuppression medicines when dialysis starts.
88847228|NCT00583466|Active Comparator|1 Normal saline arm|Polypectomy with normal saline injected for submucosal cushion creation
88847229|NCT00583466|Active Comparator|2 HPMC arm|Polypectomy after injection of hydroxypropyl methylcellulose (HPMC) to create submucosal cushion
88847230|NCT00583466|Experimental|3 Blood arm|Polypectomy after injection of autologous blood
88847231|NCT00568802|Experimental|Hydroxyurea|
88847232|NCT00568802|Placebo Comparator|Placebo|
88847233|NCT00576524|Experimental|Sham Device first, ITD next|Subjects will be randomized to recieve sham device first, ITD next after washout of 7 days.
88847234|NCT00576524|Experimental|ITD first, sham device next|Subjects will be randomized to receive ITD first, sham device next, after washout of 7 days.
88847235|NCT03949621|Active Comparator|Group A: Vedolizumab SC PFS|Vedolizumab SC 108 mg, injection, subcutaneously using a PFS, once on Day 1.
88847236|NCT03949621|Experimental|Group B: Vedolizumab SC Investigational Device|Vedolizumab SC 108 mg, injection, subcutaneously using an investigational device, once on Day 1.
88847237|NCT04474730|Active Comparator|Watch Only|
88847238|NCT04474730|Experimental|Watch+App|
88847239|NCT05313919||1. Coronary microcirculatory disease|
88847240|NCT05313919||2. Epicardial vasospastic angina|
88847241|NCT05313919||3. Microvessel vasospastic angina|
88847242|NCT05313919||4. Non-cardiac disorder|
88847243|NCT04429880|Experimental|Oxytocin|Oxytocin 17 micrograms infusion over 10 minutes
88847244|NCT03645811|Experimental|Implementation of music therapy|"For the music therapy, lecturers specializing in music therapy were consulted and accordingly a mahur maqam, an instrumental piece of traditional Turkish music played on the saz, was chosen. The mahur maqam has a descending scale, which has a relaxing impact as it moves along a 1-2 octave sound spectrum. It elicits feelings of joy and positivity, and immediately draws the attention of the listener, helping keep the mind clear. The mahur maqam belongs to the rast maqam family. Rast maqams are usually evocative of feelings of peacefulness, surrender, tranquility, trust, and mystical sentiments."
88847245|NCT03645811|Experimental|Implementation of EFT|"The EFT application protocol was explained to the students with the help of the image in the picture for 5 minutes. The method was applied through the investigator tapping on their bodies and the students repeating the steps for three sessions. Each of the treatment sessions was approximately three minutes, resulting in a nine-minute treatment for intervention. Each EFT session was performed by following the steps below.~The content of each EFT session was as follows:~Preparation~Tapping Series~The Nine Gamut Sequence and Eye Movements"
88847246|NCT03645811|No Intervention|Control|For the control group, 15 minutes of free time was given.
88847247|NCT05600738|Experimental|Treatment|
88847248|NCT04706078||thick-gingiva group|After insertion of the probe into the facial aspect of the sulcus, the peri-implant biotype can be categorized as thick-gingiva (outline if the probe cannot be seen through the gingival)
88847249|NCT04706078||thin-gingiva group|After insertion of the probe into the facial aspect of the sulcus, the peri-implant biotype can be categorized as thin-gingiva (outline of the probe can be seen through the gingival)
88847250|NCT01692158|Experimental|Teste|Enoxalow (Heparin, Low-Molecular-Weight) - Blau Farmacêutica S/A.
88847251|NCT01692158|Active Comparator|Comparador|Clexane (Heparin, Low-Molecular-Weight)- Sanofi-Aventis
88847252|NCT01570634|Experimental|Open Label CASAD|Treatment with CASAD for 14 days
88847253|NCT03928327|Experimental|Part 1, Treatment Sequence AB|TAK-788 20 mg, capsule, at Hour 0 on Day 1 followed by an overnight fast (Treatment A). Following Treatment A, participants received itraconazole 200 mg solution, orally, once daily (QD) on Days 1 to Day 14 and a single oral dose of TAK-788 20 mg capsule was coadministered on Day 5 (Treatment B). There was a washout period of 7 days between the two treatments.
89375343|NCT05231434|Active Comparator|Control protocol|The control protocol will consist of an initial 10 minutes of rest, followed by 90 minutes of aerobic activity and 60 minutes of the final recovery. Hydration will not be allowed throughout the protocol
89375344|NCT05231434|Experimental|Hydration protocol|The control protocol will consist of an initial 10 minutes of rest, followed by 90 minutes of aerobic activity and 60 minutes of the final recovery. In this protocol, volunteers will be hydrated with mineral water from the 15th minute of exercise until the end of recovery
89375345|NCT03113812|Experimental|ABvac40|
89375346|NCT03113812|Placebo Comparator|Placebo|
89375347|NCT04605874|Experimental|2 cigarillos per pack|After a 5-day period of smoking their own preferred brand of cigarillos, participants will begin a 15-day experimental period when they will be randomized to receive 2 cigarillos per pack.
89375348|NCT04605874|Experimental|4 cigarillos per pack|After a 5-day period of smoking their own preferred brand of cigarillos, participants will begin a 15-day experimental period when they will be randomized to receive 4 cigarillos per pack.
88847254|NCT03928327|Experimental|Part 2, Treatment Sequence CD|TAK-788 160 mg, orally, at Hour 0 on Day 1 following an overnight fast (Treatment C). Following Treatment C, participants received rifampin 600 mg as capsules, orally, once daily (QD) on Days 1 to 13 and TAK-788 160 mg as capsules, orally was coadministered on Day 7 (Treatment D). There was a washout period of 7 days between the two treatments.
89375349|NCT02674204|Experimental|Study Agent|One atorvastatin 20 mg oral capsule per day
89375350|NCT02674204|Placebo Comparator|Control|One matching placebo daily
89375351|NCT05675644|Experimental|Dose finding|Drospirenone-only pill single-dose ranging from 16mg to 32mg
89375352|NCT05675644|Experimental|Primary ovulation inhibition testing|Drospirenone-only pill single-dose at dose determined by dose finding arm
89375353|NCT03113890|Experimental|Assay Guided Group (AGG)|These patients will undergo a cheek swab to collect DNA for the Genecept assay. Study doctors will receive the Genecept report prior to patient discharge and use it to guide psychoeducation and medication management.
89375354|NCT03113890|Other|Treatment as Usual (TAU)|Thus this group will serve as the control group for the outcomes related to Genecept-guided decision making. These patients will undergo a cheek swab to collect DNA for the Genecept assay. Study doctors will receive the Genecept report at the 12-week follow up visit (12 weeks after patient discharge) and will use it to guide psychoeducation. The Study Doctors will not receive the report during the patient's inpatient stay (treatment as usual, TAU). Clinicians will receive the assay report for patients in the treatment-as-usual group at the 3-month followup period.
89375355|NCT02579044|Other|Everolimus and Lonafarnib|Single arm. Phase I: Lonafarnib with escalating doses of everolimus to determine MTD Phase II: Lonafarnib plus everolimus at MTD (efficacy assessment)
89375356|NCT04461106|Active Comparator|Social Marketing Campaign|Select egg hubs will receive social marketing campaign which aims to raise awareness about the benefits of eggs - 'why eggs': increasing the value of eggs from a consumer perspective and encourage consumption of eggs by children (<5yrs) and pregnant/lactating women.
88847255|NCT01055756|Experimental|Test (Cloratadd D)|Loratadine + Pseudoephedrine sulfate Test
88847256|NCT01055756|Active Comparator|Comparator (Claritin D)|Loratadine + Pseudoephedrine Comparator
88847257|NCT03648853|Experimental|intervention|all participants receive the same intervention
89189319|NCT00710658|Experimental|1|Patients had access to the Internet support system WebChoice that allowed them to monitor symptoms over time, and provided access to evidence-based self-management options tailored to their reported symptoms as well as to a communication area where patients could ask questions to a clinical nurse specialist in cancer care and exchange experiences with other cancer patients.
89375357|NCT04461106|No Intervention|No Social Marketing Campaign|Other egg hugs will not receive social marketing campaign.
89375358|NCT02941627|Experimental|Neuro Cochlear Implant System study group|All patients will receive a Neuro Zti implant and fitted with Neuro One sound processor
89375359|NCT03525379|Experimental|Resveratrol|1) Resveratrol- (Transmax) trans- resveratrol (Biotivia Longevity Bioceuticals, LLC, New York, USA) in cellulose capsules. One capsule will be taken orally 2 times per day (BID) for 8 weeks.
89375360|NCT03525379|Placebo Comparator|Placebo|2) Placebo- 500mg (Biotivia Longevity Bioceuticals, LLC, New York, USA) in cellulose capsules. One capsule will be taken orally 2 times per day (BID) for 8 weeks.
89375361|NCT03638245||Abnormal CTG|This group includes pregnancies that showed abnormalities in CTG.
89375362|NCT03638245||Normal CTG|This group includes pregnancies that showed no abnormalities in CTG.
89375363|NCT04763707||Group 1 : Hepatocellular carcinoma HCC patients with HCV|40 HCV-related liver cirrhosis patients with HCC on top (Group 1).
89375364|NCT04763707||Group 2 : Cirrhotic patients with HCV|30 HCV-related liver cirrhosis patients(Group 2).
89375365|NCT04763707||Group 3 : Healthy control|20 healthy volunteers will be included as controls(Group 3).
89375366|NCT03521934|Experimental|Sotagliflozin|Sotagliflozin 200 mg tablet once daily, with possible up-titration in the first 8 months to 400 mg, for up to 21.2 months.
89375367|NCT03521934|Placebo Comparator|Placebo|Matching placebo to sotagliflozin 200 mg once daily, with possible up-titration in the first 8 months to matching placebo to sotagliflozin 400 mg, for up to 21.6 months.
89375368|NCT03434353|Experimental|Group 1: Inarigivir Soproxil 50 mg + TAF|Viremic participants will be administered inarigivir soproxil 50 mg (2 x 25 mg capsules) once daily orally 1 hour before or 1 hour after a meal plus TAF 25 mg tablet once daily orally with food for 12 weeks followed by TAF 25 mg tablet once daily orally with food for 36 weeks.
88847258|NCT00652574|Experimental|Dasatinib|Dasatinib = BMS-354825, Sprycel
88847259|NCT03649867|Other|Semi-structured interview|Each female patient who attended the Survive & Thrive course designed for survivors of interpersonal trauma who meets the inclusion criteria will be invited to take part in a semi-structured interview. This interview will explore their experience of this psychoeducational course.
88847260|NCT01550510|Experimental|Ascorbic Acid + Irinotecan|Ascorbic Acid (50-100g, 3x weekly) with 350mg/m2 irinotecan once a week every 3 weeks
88847261|NCT01550510|Active Comparator|Standard of Care (irinotecan alone)|350mg/m2 irinotecan once a week every 3 weeks
88847262|NCT04333225|Experimental|Hydroxychloroquine|Subjects who chose to enter the HCQ arm received a loading dose of 800 mg HCQ on day 1 followed by two 200 mg tablets once a week for a total of 7 weeks
88847263|NCT04333225|No Intervention|Control|Subjects who declined taking HCQ were considered as controls
88847264|NCT00566462|Experimental|perampanel|
89375369|NCT03434353|Experimental|Group 2: TAF|Viremic participants will be administered TAF 25 mg tablet once daily orally with food for 48 weeks.
89375370|NCT03434353|Experimental|Group 3: Inarigivir Soproxil 200 mg + TAF|Viremic participants will be administered inarigivir soproxil 200 mg (2 x 100 mg tablets) once daily orally 1 hour before or 1 hour after a meal plus TAF 25 mg tablet once daily orally with food for 12 weeks followed by TAF 25 mg tablet once daily orally with food for 36 weeks
88847265|NCT00566462|Placebo Comparator|1|
88847266|NCT00556400|Active Comparator|Lo-ovral|1 tablet of lo-ovral is administered twice a day
89375371|NCT03434353|Experimental|Group 4: Inarigivir Soproxil 100 mg + commercially available NUCs|Virally suppressed participants receiving commercially available nucleoside/nucleotide (NUC) will be administered inarigivir soproxil 100 mg tablet once daily orally 1 hour before or 1 hour after a meal for 12 weeks. Participants will continue commercially available NUCs for 48 weeks.
89375372|NCT03434353|Experimental|Group 5: Inarigivir Soproxil 400 mg + TAF|Viremic participants will be administered inarigivir soproxil 400 mg (2 x 200 mg tablets) once daily orally 1 hour before or 1 hour after a meal plus TAF 25 mg tablet once daily orally with food for 12 weeks followed TAF 25 mg tablet once daily orally with food for 36 weeks.
89375373|NCT03374137||obinutuzumab|Participants with follicular lymphoma or previously untreated chronic lymphocytic leukemia will be treated with obinutuzumab.
89375374|NCT03415776|Experimental|Twice weekly|Two sessions of hemodialysis per week
89375375|NCT03415776|Experimental|Thrice weekly|Three sessions of hemodialysis per week
89375376|NCT02914184|Experimental|Liq_A Group|All subjects will receive two doses of PCV-free HRV liquid formulation lot A, at 6 and 12 weeks of age
89375377|NCT02914184|Experimental|Liq_B Group|All subjects will receive two doses of PCV-free HRV liquid formulation lot B, at 6 and 12 weeks of age
89375378|NCT02914184|Experimental|Liq_C Group|All subjects will receive two doses of PCV-free HRV liquid formulation lot C, at 6 and 12 weeks of age
89375379|NCT02914184|Active Comparator|Lyo Group|All subjects will receive two doses of currently licensed lyophilised HRV vaccine, at 6 and 12 weeks of age
89375380|NCT01380522|Experimental|A|Subjects received kali product under fed conditions
89375381|NCT01380522|Active Comparator|B|Subjects received Searle product under fed conditions
89375382|NCT03611712|Experimental|CCRT-PG2 arm|Astragalus Polysaccharides 500 mg
89375383|NCT03611712|No Intervention|CCRT alone arm|
89375384|NCT03633227|Experimental|Obeticholic Acid (OCA)|Participants will initiate treatment with OCA 5 milligrams (mg) tablets orally once weekly. At Week 12, if there are no safety concerns, the dose will be up-titrated to OCA 5 mg twice weekly. Every 6 weeks thereafter, based on tolerability assessments, further up-titration of dose will be considered. At each titration visit, the participants will start the higher dose regimen no earlier than 2 days after the prior dose. The maximum dose titration will be OCA 10 mg twice weekly at least 3 days apart. The minimum treatment duration will be 48-weeks. Participants, who complete their 48-week treatment, can continue the treatment until all randomized participants complete their 48-week treatment period and the database for that period is locked (total duration: approximately up to 3 years).
89181696|NCT05277285|No Intervention|Standard Treatment|The standard treatment includes the application of mechanical ventilation and / or support with the administration of inotropes and / or extracorporeal oxygenation (ECMO) and the intravenous administration of fluids and dexamethasone. The administration of any other immunosuppressive therapy, including tocilizumab and / or antimicrobials at the discretion of the therapists, is permitted.
88847267|NCT00556400|Placebo Comparator|sugar pill|Sugar pill was provided as a placebo
88847268|NCT03918811|Experimental|Positive Pressure Extubation Technique|ETT is removed in PSV 15/10 mode and without endotracheal suction.
89189320|NCT00710658|No Intervention|2|The control group receiving usual care
89375385|NCT03633227|Placebo Comparator|Placebo|Participants will receive OCA matching placebo orally once weekly or twice weekly for the duration of at least 48-weeks. Participants, who complete their 48-week treatment, can continue the treatment until all randomized participants complete their 48-week treatment period and the database for that period is locked (total duration: approximately up to 3 years).
88847269|NCT03918811|Active Comparator|Traditional Extubation Technique|ETT is removed with continuous endotracheal suction
89375386|NCT03665324||Veteran athletes with Supraventricular arrhythmias|Subjects who consulted in the Sports Medicine Department between January 1, 2010 and January 1, 2017 Veteran athletes (age> 35 years) with documented paroxysmal supraventricular arrhythmias.
89375387|NCT03665324||Veteran athletes without supraventricular arrhythmia|Subjects who consulted in the Sports Medicine Department between January 1, 2010 and January 1, 2017 Veteran athletes (age> 35 years) without documented supraventricular arrhythmia.
89375388|NCT03665246|Experimental|Intervention (iMBC/ECD + C-PrES)|The intervention group of women/children dyads who consent will receive 14 sessions of the Integrated Mothers and Babies Course/Early Childhood Development (iMBC/ECD) curriculum in addition to the C-PrES curriculum. Upon completion of 14 sessions, women will continue to receive MNCHN and ECD messages and group-based iMBC booster sessions every 3 months.
89375389|NCT03665246|No Intervention|Control (C-PrES)|The control group of women/children dyads who consent will have exposure to 14 sessions of the C-PrES curriculum which promotes the adoption of key MNCHN behaviors (e.g. newborn care, exclusive breastfeeding, etc.). Upon completion of 14 sessions, women will continue to receive MNCHN and ECD messages.
88847270|NCT00521924|Experimental|Infliximab + basic treatment|3 mg/kg infliximab plus basic treatment
88847271|NCT00521924|Active Comparator|Basic treatment (DMARDs)|Rheumatoid Arthritis basic therapy (disease modifying anti-rheumatic drugs [DMARDs])
88847272|NCT03927781|Experimental|Pregabalin 300mg|300mg pregabalin, PO, once, 1 hr before surgery
88847273|NCT01553240|Experimental|TMS and fMRI|"functional MRI~single and paired pulse TMS (to identify the difference of motor excitability between patients and healthy controls)"
88847274|NCT03907579|Experimental|Inflatable colon educational module|Participants attend a brief educational presentation in an inflatable colon, focused on colorectal cancer prevention and screening. Participants also receive a copy of the study information sheet and may receive written educational materials to take home. Participants complete a pre-test and a post-test to assess changes in knowledge and intention to get screened for colorectal cancer.
88847275|NCT01545518|Experimental|all subjects|IVIG
89189321|NCT00710736|Experimental|ARRY-334543 + capecitabine|
88847276|NCT04320823|Experimental|Experimental Group|Plasma collection using a modified version (version 1.3.90) of NexSys PCS embedded software installed on current FDA-cleared NexSys PCS device hardware (PCS-300-US), with the new plasma collection feature enabled.
88847277|NCT04320823|Active Comparator|Control Group|Plasma collection using a modified version (version 1.3.90) of NexSys® PCS embedded software installed on current FDA-cleared NexSy PCS device hardware (PCS-300-US), with the new plasma collection feature disabled.
88847278|NCT01539590|Experimental|BB3|Daily intravenous administration of 2 mg/kg BB3 for four (4) days
88847279|NCT01539590|Placebo Comparator|Normal Saline|Daily intravenous administration for four (4) days
88847280|NCT00380042|Active Comparator|Active Stimulation|
88847281|NCT00380042|Sham Comparator|Sham|
88847282|NCT04313647|Experimental|1X level|Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (2.0*10^8 nano vesicles/3 ml)
88847283|NCT04313647|Experimental|2X level|Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (4.0*10^8 nano vesicles/3 ml)
88847284|NCT04313647|Experimental|4X level|Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (8.0*10^8 nano vesicles/3 ml)
88847285|NCT04313647|Experimental|6X level|Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (12.0*10^8 nano vesicles/3 ml)
88847286|NCT04313647|Experimental|8X level|Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (16.0*10^8 nano vesicles/3 ml)
88847287|NCT00537446|Active Comparator|High-level ventilation|Each subject will spend 2 hours receiving high-level noninvasive ventilation.
88847288|NCT00537446|Active Comparator|Low-level ventilation|Each subject will receive 2 hours of low-level noninvasive positive pressure ventilation.
88847289|NCT01526408|Placebo Comparator|Placebo Arm|Treatment with 3 months of placebo
88847290|NCT01526408|Active Comparator|Active Arm|Treatment with 3 months of active drug
88847291|NCT03660787|Placebo Comparator|Placebo, 1.5 mL/kg|each subject received the placebo at the dose of 1.5 mL/kg of body weight;
88847292|NCT03660787|Placebo Comparator|Placebo, 2.4 mL/kg|each subject received the placebo at the dose of 2.4 mL/kg of body weight;
88847293|NCT03660787|Experimental|Seroguard, 1.5 mL/kg|each subject received the test drug at the dose of 1.5 mL/kg of body weight;
88847294|NCT03660787|Experimental|Seroguard, 2.4 mL/kg|each subject received the test drug at the dose of 2.4 mL/kg of body weight.
88847295|NCT04713644||Burst Suppression|Patients who present burst suppression after standardized propofol administration during anesthetic induction
88847296|NCT04713644||No Burst Suppression|Patients who did not present burst suppression after standardized propofol administration during anesthetic induction
88847297|NCT03926065|Experimental|Standard Palatability and Standard Portion Size|Vegetables with Standard Palatability and Standard Portion Size
88847298|NCT03926065|Experimental|Standard Palatability and Larger Portion Size|Vegetables with Standard Palatability and Larger Portion Size
88847299|NCT03926065|Experimental|Enhanced Palatability and Standard Portion Size|Vegetables with Enhanced Palatability and Standard Portion Size
88847300|NCT03926065|Experimental|Enhanced Palatability and Larger Portion Size|Vegetables with Enhanced Palatability and Larger Portion Size
88847301|NCT03663283|Experimental|Liposomal Bupivacaine|Administered utilizing ultrasound guidance by an anesthesiologist. Study patients will receive 10ml (133 mg) of liposomal bupivacaine mixed with 7.5ml of 0.5% plain bupivacaine and 7.5ml of 0.25% bupivacaine. Further, 8 mg (2 ml) IV dexamethasone will be administered concomitantly at the time of the block.
88847302|NCT03663283|Active Comparator|Plain Bupivacaine|Peripheral nerve blocks will be performed with ultrasound guidance by an anesthesiologist. Standard bupivacaine hydrochloride will be utilized. 25 ml of 0.5% bupivacaine for peripheral nerve block will be utilized. Further, 8 mg (2 ml) IV dexamethasone will be administered concomitantly at the time of the block.
88847303|NCT00422929||chronic otitis media with effusion (OME)|history of chronic effusion (3 months if both ears, 6 months if one ear, or 3 episodes of effusion each lasting for 2 months or longer)
88847304|NCT00422929||recurrent AOM|recurrent acute otitis media (3 episodes in 6 months or 4 episodes in 1 year)
88847305|NCT00422929||no OM|no history of significant otitis media (i.e., does not meet criteria for chronic OME or recurrent AOM)
88847306|NCT03909763|Experimental|Berberine plus danazol|Berberine plus danazol group
88847307|NCT00484718|Active Comparator|A|
89181697|NCT05277285|Experimental|One intravenous 12.5 gr STS - Treatment Group 1|Patients will receive standard treatment and one intravenous (iv)12.5 gr STS in 60 minutes continuous intravenous infusion. STS is dissolved in a final volume of 100ml N/S 0.9% w/v,
89181698|NCT05277285|Experimental|Three intravenous doses of 12.5 gr STS - Treatment Group 2|Patients will receive standard treatment and three intravenous doses of 12.5 g STS. STS is dissolved in a final volume of 100ml N/S 0.9% w/v. Each dose will be given in 60 minutes of continuous intravenous infusion with 48 hours intervals between each dose.
89181699|NCT04069143|Experimental|Part 1|
89181700|NCT04069143|Experimental|Part 2|
88847308|NCT00484718|Active Comparator|B|
88847309|NCT00484718|Placebo Comparator|C|
88847310|NCT03665155|Experimental|89Zr-daratumumab|"Three patients will be administered 2 mCi of 89Zr-daratumumab in a total of 50 mg of daratumumab antibody. Administered activity (1 to 5 mCi) of radioactivity and total amount of administered antibody (3 to 50 mg) will be adjusted in subsequent patients in order to maximize image quality.~Patients in phase I will have up to 4 PET/CT scans, multiple blood draws, whole-body counts, and safety monitoring to determine pharmacokinetics, radiation dosimetry, and safety of 89Zr-DFO-daratumumab for PET/CT imaging. Phase II (total of 21-24 patients). After pharmacokinetics and radiation dosimetry are determined in phase I, additional patients will be enrolled in phase II."
88847311|NCT00477230|Experimental|1|Single ablation procedure with Endoscopic Ablation System
88847312|NCT00477230|Active Comparator|2|Medication
88847313|NCT03901105|Experimental|Flortaucipir PET Scan|No study drug will be administered. Scans previously acquired from Study I8D-MC-AZES (NCT02245737, Eli Lilly and Company sponsor) will be read by independent, blinded readers.
89375390|NCT03297372|Experimental|IOL Implantation experimental|Implantation of Micropure 1.2.3. in one of the eyes of the study subject
89375391|NCT02913326|Experimental|Dabigatran etexilate|
89375392|NCT02913326|Active Comparator|Warfarin|
89375393|NCT01384110|Experimental|Brown Seaweed Lemon Tea|Single administration of lemon tea containing 500 mg of brown seaweed powder and 50 g of sucrose
88847314|NCT00448682|Experimental|FUdR + Leucovorin + Oxaliplatin + Docetaxel (Taxotere)|"Treatment will be administered on an outpatient basis. Chemotherapy will be administered weekly, 3 out of 4 weeks, on days 1, 8 and 15:~Day 1 and Day 15 Chemotherapy Administration: Patients will be administered oxaliplatin (85 mg/m2) and docetaxel (25 mg/m2) followed by FUdR/Leucovorin (110 mg/kg//500 mg/m2) on Day 1 and Day 15 of each cycle.~Day 8 Chemotherapy Administration On Day 8, treatment will consist of docetaxel (25 mg/m2) followed by FUdR/Leucovorin (110mg/kg//500mg/m2).~There will be no treatment delivered week 4 (Day 22). For the purpose of this study, one cycle equals four weeks. There will be a maximum of 6 cycles."
88847315|NCT04713488|Experimental|Sputnik Light Vaccine|solution for intramuscular injection Composition for 1 dose (0.5 ml): Active substance: recombinant serotype 26 adenoviral particles containing the SARS-CoV-2 S protein gene, in the amount of (1.0±0.5) x 10*11 particles per dose.
88847316|NCT03675451|Experimental|Interventional|"Injection of study drug followed by PET/CT imaging.~Optional but recommended 68Ga-PSMA-HBED-CC (5±2mCi) injection and PET/CT scan (1 to 3 hours after the injection) will also be performed prior to radical prostatectomy depending on subject's availability and compliance.~Followed by prostatectomy"
88847317|NCT03870152|Experimental|EC treatment (Intervention Arm)|Patients in the intervention arm will receive up to three rounds of EC treatment (no more than one round annually) to all their HGLs identified at baseline. Follow-up is the same as for Control Arm patients: a bronchoscopy surveillance visit at 6, 12, 24, and at 36 months post-randomisation; with further bronchoscopy surveillance visits at 18 and/or at 30 months post-randomisation (dependent on lesion appearance).
88847318|NCT03870152|No Intervention|AFB Surveillance (Control Arm)|Patients randomised to the surveillance (Control Arm) will have: bronchoscopy surveillance at 6, 12, 24, and at 36 months post-randomisation; with further bronchoscopy surveillance visits at 18 and/or at 30 months post-randomisation (dependent on lesion appearance).
88847319|NCT00380120|Experimental|1|Tailoring the duration of anticoagulation according to the ultrasound persistence of residual vein thrombosis
88847320|NCT00380120|Active Comparator|2|Administering a fixed duration of anticoagulation (i.e., discontinue it at the time of randomization in patients with secondary DVT, and prolong it for 3 additional months in patients with idiopathic DVT)
88847321|NCT03675685|Experimental|CCH (Collagenase clostridium histolyticum)|
88847322|NCT03677089|Experimental|ECHO Cohort|Sites undergo 12 ECHO Autism telehealth clinics. Clusters of two sites each will initiate intervention with 3 months between the start of each cluster.
88847323|NCT03677245|Experimental|Balance Biking|Strider Balance Bike riding for 5 days following the Strider Learn to Ride Curriculum
88847324|NCT00383630|Experimental|Group 1|Intramyocardial injection of bone marrow mononuclear cells + LVAD
88847325|NCT00383630|Experimental|Group 2|Intramyocardial injection of CD34+ selected bone marrow mononuclear cells + LVAD
88847326|NCT00383630|Other|Group 3|LVAD alone
88847327|NCT04285411|Experimental|ARMS SpO2 70-100%|Comparison to Reference CO-Oximetry
88847328|NCT00368654|Active Comparator|A|Monotherapy with Raptiva alone
88847329|NCT00368654|Experimental|B|Combination therapy with both Raptiva and Methotrexate
88847330|NCT00368654|Experimental|C|Continue Raptiva, discontinue methotrexate
88847331|NCT00368654|Experimental|D|Continue combination therapy with both Raptiva and Methotrexate
88847332|NCT03888469|Other|DDT2, then 1DAVM|Verofilcon A contact lenses worn first, with etafilcon A contact lenses worn second, as randomized. Each product was worn bilaterally (in both eyes) for 8 -1/+2 days in a daily disposable modality.
88847333|NCT03888469|Other|1DAVM, then DDT2|Etafilcon A contact lenses worn first, with verofilcon A contact lenses worn second, as randomized. Each product was worn bilaterally (in both eyes) for 8 -1/+2 days in a daily disposable modality.
89375394|NCT01384110|Placebo Comparator|Placebo lemon tea|Single administration of placebo lemon tea containing 50 g of sucrose
89375395|NCT03666182||Whole Sample|Female, Caucasian participants aged 18-65 years.
88847334|NCT04283773||Malignant ovarian germ cell tumors ( MOGCTs).|22 cases of malignant ovarian germ cell tumors ; include Dysgerminoma , yolk sac tumor and immature teratomas will be treated by anti P16 antibody and Ki67 antibody.
88847335|NCT04283773||Mature cystic teratomas.|20 cases of mature teratomas will be treated by anti P16 antibody .
88847336|NCT04283773||Normally apparent ovaries.|20 cases of normally apparent ovaries will be treated by anti P16 antibody .
88847337|NCT00329732|Active Comparator|Lidocaine/Bupivicaine|
88847338|NCT00329732|Placebo Comparator|saline|matching volume of saline injected
88847339|NCT03438500|Experimental|Active Shockwave Therapy|Patients in this group receive shockwave therapy.
88847340|NCT04281901|Experimental|PVRP treated participants|Participants will receive PVRP in the chronically inflamed radical cavity at the baseline evaluation (day 0) and 1 month later (1. follow-up). There will be 2 additional follow-ups with a 1-month interval.
89181701|NCT04069143|Experimental|Part 3|
89189322|NCT00715416|Experimental|1|primary nitinol stent placement of superficial femoral artery lesions
89375396|NCT01384032|Experimental|Low fat diet|Subjects were asked to consume a low fat diet for 8 weeks. Composition: 28% energy from fat, 8% energy from saturated fat, 55% energy from carbohydrate. Subjects were provided with low fat spread, cooking oil and snacks and asked to consume these in place of normally eaten equivalent foods. Subjects were asked to consume two extra portions of carbohydrate per day (e.g. two slices of bread, equivalent to 35g carbohydrate) and to consume low fat dairy products. Subjects also consumed 2g control oil per day during this period. Control oil comprised palm olein and soybean oil.
89399338|NCT02174978|Experimental|Group 1: 10 µg FMP012 adjuvanted AS01B|FMP012 with AS01B adjuvant system: 10 µg FMP012 antigen reconstituted with 500 µL AS01B adjuvant to equal 0.5 mL final volume. Doses administered intramuscular at week 0, 4, 8, and 24. On week week 27, there is a P falciparum Controlled Human Malaria Infection (CHMI) challenge.
89375397|NCT01384032|Experimental|High saturated fat diet|Subjects were asked to consume a high saturated fat diet for 8 weeks. Composition: 38% energy from fat, 18% energy from saturated fat, 45% energy from carbohydrate. Subjects were provided with spread, cooking oil and snacks and asked to consume these in place of normally eaten equivalent foods. Subjects were asked to consume one less portion of carbohydrate per day (e.g. one slice of bread and to consume full fat dairy products. Subjects also consumed 2g control oil per day during this period. Control oil comprised palm olein and soybean oil.
89375398|NCT01384032|Experimental|High saturated fat plus DHA diet|Subjects were asked to consume a high saturated fat diet for 8 weeks. Composition: 38% energy from fat, 18% energy from saturated fat, 45% energy from carbohydrate. Subjects were provided with spread, cooking oil and snacks and asked to consume these in place of normally eaten equivalent foods. Subjects were asked to consume one less portion of carbohydrate per day (e.g. one slice of bread and to consume full fat dairy products. Subjects also consumed 6g DHA-rich oil per day during this period providing 3g DHA.
88847341|NCT04281901|Active Comparator|Standardly treated participants|Participants will receive standard conservative measures for the chronically inflamed radical cavity at the baseline evaluation (day 0), 1 month later (1. follow-up), 2 months later (2. follow-up) and 3 months later (3. follow-up).
88847342|NCT04280653|Experimental|NDE L68 StableFit® punctal plug|Each study subject that qualifies at the baseline visit will receive an NDE L68 StableFit® punctal plug in the lower punctum in one of their eyes. All study plugs will remain in the study subject's lower punctum for a period of 28 + 4 days after insertion
88847343|NCT03679975|Experimental|Subjects with ALS|Subjects with a diagnosis of probable or definite ALS in accordance with the Revised El-Escorial Criteria were administered a single dose of the Riluzole Oral Soluble Film (ROSF) 50 mg.
88847344|NCT03887299|Placebo Comparator|Standard Wound Care|Wound dressing and care as per our current practice. Compression dressing consisting of gauze, tefla and adhesive tape will be placed intraoperatively. Dressing will be removed after 24 hours from surgery completion and subjects will have an absorption pad with overlying garments for the remaining postoperative days until standard postoperative visit for wound check.
89181702|NCT04033731||Controls|Participants will include 15 healthy men and women aged 18-40 years, right-hand dominant, Native English speakers, with normal or corrected-to-normal vision.
89181703|NCT04110665|Active Comparator|Paracetamol+ ketoprofene and Tramadol|Paracetamol per os 1g every 6 hours and ketoprofene 100 mg per os every 12 hours were systematically administered. Tramadol 100 mg per os every 6 hours was added when pain was > 3/10 on a numeric ranking scale (0 no pain, 10 worst pain).
89375399|NCT03665558|No Intervention|Aortic dP/dt in sinus rhythm|Left ventricular and aortic dP/dt values were recorded at baseline condition while patients are on sinus rhythm.
88847345|NCT03887299|Active Comparator|CHG Wound Care|ReliaTect™ Post-Op Dressing will be applied as per the manufacturer's instructions intraoperatively. The dressing will be in place until the postoperative clinic visit on postoperative day 7.
88847346|NCT00244010|Other|1|
88847347|NCT03684265|Experimental|Test to Reference|
88847348|NCT03684265|Experimental|Reference to Test|
89375400|NCT03665558|Active Comparator|Aortic dP/dt during DDD pacing|Patients will be their own control. Aortic and ventricular pressures will be recorded under temporary DDD pacing again and these data collected at every pacing steps will be compared to the pressures recorded at baseline condition.
89375401|NCT01382862|No Intervention|Regular Care|Regular care for suspected stroke in Berlin consists of an ambulance with paramedics only, and neither computed tomography (CT) nor point-of-care diagnostics. In Berlin, emergency physicians are involved in prehospital care only in cases of special medical emergencies such as severe instability of vital parameters or loss of consciousness.
88847349|NCT00218036|Experimental|1|Modafinil 200mg / Methadone Maintenance (1.2mg/kg)
88847350|NCT00218036|Experimental|2|Modafinil 400mg/ Methadone Maintenance (1.2mg/kg)
88847351|NCT00218036|Experimental|3|Citalopram 20/ Methadone Maintenance 1.2mg/kg
88847352|NCT00218036|Experimental|4|Citalopram 40/ Methadone Maintenance 1.2 mg/kg
88847353|NCT00218036|Placebo Comparator|5|Placebo given to methadone-maintained subjects (1.2mg/kg) for the duration of the 12-week study
89399339|NCT02174978|Experimental|Group 2: 30 µg FMP012 adjuvanted AS01B|FMP012 with AS01B adjuvant system: 30 µg FMP012 antigen reconstituted with 500 µL AS01B adjuvant to equal 0.5 mL final volume administered intramuscular at week 2, 6, 10, and 24. On week week 27, there is a challenge with P falciparum Controlled Human Malaria Infection (CHMI).
88847354|NCT03848221|Experimental|Systane Complete|Subjects in this group will use Systane Complete before, during, and after contact lens use.
89181704|NCT04110665|Active Comparator|Paracetamol+ ketoprofene+ Nefopam and Tramadol|Paracetamol per os 1g every 6 hours and ketoprofene 100 mg per os every 12 hours and Nefopam 120 mg intravenously were systematically administered. Tramadol 100 mg per os every 6 hours was added when pain was > 3/10 on a numeric ranking scale (0 no pain, 10 worst pain).
88810389|NCT06213714|Experimental|5G Tele-Robotic-Assisted PCI|VRS100 Robotic Console System, was developed by Shenzhen Raysight Intelligent Medical Technology Co., Ltd., will be used for 5G Tele-Robotic-Assisted Percutaneous Coronary Intervention in this study.
88810390|NCT06213701|Experimental|Healthy Minds Program (HMP) app|Participants will receive access to the 4-week HMP Foundations module. The HMP app is a meditation-based smartphone app designed to promote and protect psychological well-being through sustainable skills training. The program is grounded in constituents of psychological well-being identified in empirical literature. HMP provides core content, with instruction administered through a curriculum of guided practices. HMP is based on research on eudaimonic well-being (e.g., environmental mastery, purpose) and brain-based skills that underlie these qualities (e.g., regulation of attention, mental flexibility). The full HMP has guided audio practices that address 4 constituents of well-being: awareness, connection, insight, and purpose. At post-treatment, participants will be given access to additional HMP content to support their continued practice.
89181705|NCT04110665|Active Comparator|Paracetamol+ ketoprofene and morphine|Paracetamol per os 1g every 6 hours and ketoprofene 100 mg per os every 12 hours were systematically administered. Opioid immediate release (morphine 10 mg) per os every 6 hours was added when pain was > 3/10 on a numeric ranking scale (0 no pain, 10 worst pain).
89189323|NCT00715416|Active Comparator|2|balloon angioplasty of superficial artery lesions with secondary stent placement in case of >30% residual stenosis after the procedure
88847355|NCT03848221|Active Comparator|Sensitive Eyes Rewetting Drops|Subjects in this group will use Sensitive Eyes Rewetting Drops before, during, and after contact lens use.
89375402|NCT01382862|Active Comparator|Stroke Emergency Unit Mobile (STEMO)|The STEMO is equipped with a CT-scanner, a point-of-care laboratory and the infrastructure for tele-radiological as well as videoconferencing support. STEMO is operated by a team of experienced neurologists (n=6, half-time positions, with additional formal training in emergency medicine according to the requirements of the Berlin Medical Board), paramedics of the fire brigade (n=3, two years formal training in emergency care) and radiology technicians (n=3, three years formal training in radiology assistance and three months formal training in emergency care).
89375403|NCT03665168||Patients in the palliative stage|Adult patients in various settings will be included (General Practioners practices, home care facilities, general and academic hospitals, hospices) and with any underlying life-limiting disease.
89375404|NCT03630978||Liver resection|
89375405|NCT03665480|Experimental|G-CSF treatment|In G-CSF treatment group, all participants are treated with G-CSF at the dose of 5ug/kg per day until neutrophil higher than 0.5 g/L or 14 days from day three after induction therapy. MRD is monitored at day 14 and 28 with flow cytometry and quantity PCR if a fusion gene is available.
89375406|NCT03665480|No Intervention|G-CSF-free|In G-CSF-free group, no participants with newly diagnosed AML are treated with G-CSF after induction therapy.
89375407|NCT03725891|Active Comparator|Aspirin 162 mg|Aspirin 81mg tow tablet once a day from recruitment until 37 weeks or labor whichever comes first
89375408|NCT03725891|Active Comparator|Aspirin 81 mg plus placebo|Aspirin 81mg one tablet once a day from recruitment until 37 weeks or labor whichever comes first plus placebo one tablet once a day from recruitment until 37 weeks or labor whichever comes first
89375409|NCT01383876|Active Comparator|Collar|Hard cervical collar placed in the operating room after surgery. The collar will be removed/exchanged for bathing, grooming, and dressing changes only. It will remain in place for 12 weeks.
89375410|NCT01383876|Experimental|No Collar|Have a hard cervical collar placed in the operating room after surgery. This will remain in place for 1 to 2 days and be discontinued prior to discharge.
89375411|NCT03751163|Active Comparator|Study|Tranexamic acid 250 mg po bid 12 weeks 4% Hydroquinone cream qhs 12 weeks sunscreen spf 30 qam 24 weeks
88847356|NCT03848221|No Intervention|No Treatment|Subjects in this group will not be allowed to use artificial tears or rewetting drops during the study.
88847357|NCT05314699|Experimental|resistance-aerobic exercise group, RA|Participants conduct 5-min warm up, 13-min resistance exercise, 12-min aerobic exercise, and 5-min cool down.
88847358|NCT05314699|Experimental|aerobic-resistance exercise group, AR|Participants conduct 5-min warm up, 12-min aerobic exercise, 13-min resistance exercise, and 5-min cool down.
88847359|NCT05314699|No Intervention|reading control group, RC|Participants conduct reading for 35 minutes.
88847360|NCT04271761||Current adult recipients of Cochlear Carina System|Adults who are current recipients of the Cochlear Carina System. Participants will attend one scheduled visit where several acoustic measurements will be taken that do not require active participation by the participant.
88847361|NCT00233090|Experimental|Modafinil|single dose of 200 mg. a day of modafinil for four weeks
88847362|NCT00233090|Placebo Comparator|Placebo|
88847363|NCT04266925|Experimental|3 referees|Three referees were present on the field during these youth soccer matches.
88847364|NCT04266925|Active Comparator|1 referee|One referee was present on the field during these youth soccer matches.
89375412|NCT03751163|Placebo Comparator|Control|Placebo po bid 12 weeks 4% Hydroquinone cream qhs 12 weeks sunscreen spf 30 qam 24 weeks
88847365|NCT05182502|Experimental|Tixel treatment arm|subjects will receive 3 monthly treatments with the Tixel device
88847366|NCT04247581|Other|Cohort 1|This will include subjects with no known history of AF and are in normal sinus rhythm at time of screening
88847367|NCT04247581|Other|Cohort 2|This will include subjects with known persistent or permanent AF who are in AF at the time of screening
88847368|NCT02921906|Experimental|Neonatal diabetes|People with neonatal diabetes due to mutations in the KCNJ11 gene who are treated with sulphonylureas and not on insulin.
89181706|NCT04110665|Active Comparator|Paracetamol+ ketoprofene+Opioid delayed release and morphine|Paracetamol per os 1g every 6 hours and ketoprofene 100 mg per os every 12 hours and 20 mg of opioid delayed release (Oxycodone) were systematically administered. Opioid immediate release (morphine 10 mg) per os every 6 hours was added when pain was > 3/10 on a numeric ranking scale (0 no pain, 10 worst pain).
89181707|NCT04077333|Experimental|MISA group|minimal invasive surfactant administration group
89375413|NCT01379430|Experimental|Group 1|Intramuscular arm
88847369|NCT02921906|Active Comparator|Non-diabetic controls|People without diabetes.
88847370|NCT02921906|Active Comparator|Controls with Type 2 Diabetes|People with Type 2 diabetes who are treated with sulphonylurea medication.
88847371|NCT04243369|Other|Experimental - Collaboration Live software|
88847372|NCT03849937|Experimental|Intervention|Three nursing homes will receive the training and three control nursing homes will complete assessments, but not receive the training.
88847373|NCT03849937|Active Comparator|Waitlist Control|After the intervention group takes the training, the waitlist control group will crossover and take the training.
88847374|NCT00177866|Active Comparator|A Placebo or Celebrex|either placebo PO BID for the first eight weeks or Celebrex 200 mg PO BID for the first eight weeks
88847375|NCT00177866|Placebo Comparator|B Placebo or Celebrex|either placebo PO BID for the last eight weeks or Celebrex 200 mg PO BID for the last eight weeks
88847376|NCT00089414|Experimental|1|Treatment arm # 1 consists of the continuous administration of Yasmin oral contraceptive (a combination of 30 µg of ethinyl estradiol and 3 mg of drospirenone) for 15 weeks starting on day 2 to 5 of the first menstrual cycle.
88847377|NCT00089414|Active Comparator|2|Treatment arm # 2 (interrupted Yasmin administration) will be identical to arm # 1 with the exception that the continuous administration of Yasmin will be interrupted by the substitution of placebo for Yasmin for one week during weeks 3, 8, and 14 of the study. The women participating in this treatment arm will experience episodes of menstruation after Yasmin withdrawal (when they are on placebo).
89181708|NCT04077333|No Intervention|EISA group|conventional treatment: endotracheal intubation surfactant administration group
89181709|NCT00778700|Placebo Comparator|Vehicle Cream|Vehicle cream, applied topically, once daily from Day 1 to Week 12.
88847378|NCT00089414|Active Comparator|3|Yasmin oral contraceptive; CDB 2914 progesterone antagonist. Treatment arm # 3 is identical to treatment arm # 1 with the exception that the continuous administration of Yasmin will also include the administration of progesterone antagonist CDB-2914 during weeks 3, 8, and 14. Menses is anticipated to occur within 2-3 days of CDB-2914 administration. Women in treatment arms # 3 and # 1 will be exposed to continuous levels of Yasmin, but due to the local effects of the progesterone antagonist on the endometrium, women in arm # 3 will experience menses.
88847379|NCT00075608|Experimental|2nd Stem Cell Transplant|Mobilization with filgrastim autologous stem cell transplantation with melphalan conditioning stem cell infusion
88847380|NCT03704467|Experimental|Part A: Carboplatin + M6620 + Avelumab|
88847381|NCT03705481|Other|Remote treatment of PCI.|5 sequential subjects presenting for remote PCI who have signed informed consent.
89181710|NCT00778700|Experimental|Ruxolitinib Phosphate 0.5% Cream|Ruxolitinib phosphate 0.5% cream, applied topically, once daily from Day 1 to Week 12.
88847382|NCT05177900|Active Comparator|Biphasic pulse without interphase gap|
88847383|NCT05177900|Experimental|Biphasic pulse with interphase gap|
88847384|NCT02145260|Active Comparator|Lower dialysate sodium|Dialysate sodium concentration of 138 mmol/L
88847385|NCT02145260|Experimental|Higher dialysate sodium|Dialysate sodium concentration of 142 mmol/L
88847386|NCT01795586|Experimental|Dose Escalation|Every patient will receive eribulin and carboplatin. Each cycle is 21 days (or 3 weeks). Eribulin and carboplatin will be given intravenously on days 1 and 8 of each cycle.
88847387|NCT03707041|Experimental|P218 1000 mg (Oral Capsules) - Cohort 1|Two administrations of 1000 mg P218 (capsules p.o.), 48 hours apart
88847388|NCT03707041|Placebo Comparator|P218 Placebo Oral Capsules - Cohort 1|Two administrations of P218 placebo (capsules p.o.), 48 hours apart
88847389|NCT03707041|Experimental|P218 1000 mg (Oral Capsules) - Cohort 2|One administration of 1000 mg P218 (capsules p.o.), 2 hours after PfSPZ Challenge and one administration of 1000 mg P218 (capsules p.o.), 48 hours after first administration.
88847390|NCT03707041|Placebo Comparator|P218 Placebo Oral Capsules - Cohort 2|One administration of P218 placebo (capsules p.o.), 2 hours after PfSPZ Challenge and one administration of P218 placebo (capsules p.o.,) 48 hours after first administration.
88847391|NCT03707041|Experimental|P218 100 mg (Oral Capsules) - Cohort 3|One administration of 100 mg P218 (capsules p.o.), 2 hours after PfSPZ Challenge and one administration of 100 mg P218 (capsules p.o.), 48 hours after first administration.
88847392|NCT03707041|Active Comparator|P218 Placebo Oral Capsule - Cohort 3|One administration of P218 placebo (capsules p.o.), 2 hours after PfSPZ Challenge and one administration of P218 placebo (capsules p.o.), 48 hours after first administration.
88847393|NCT03879044|Experimental|Transcranial Direct Current Stimulation|Active tDCS for 30 minutes before their scheduled work hours at least 3x/week for two consecutive weeks.
88847394|NCT02212574|Other|Chemotherapy|"Chemotherapy Cycle A Lomustine (CCNU) is given by mouth on Day 1. Vincristine is given directly into a vein (IV) over one minute or using a minibag over several minutes by some institutions on Days 1, 8, and 15. Cisplatin is given directly into a vein over 8 hours on Day 1. This cycle lasts 42 days.~Chemotherapy Cycle B Cyclophosphamide is given into a vein over 1 hour on Days 1 and 2. MESNA, a drug to protect the bladder from the effects of cyclophosphamide, will be given 15 minutes before each dose of cyclophosphamide and repeated at 3 and 6 hours. Vincristine is given directly into a vein directly into the vein (IV) over one minute or using a minibag over several minutes by some institutions on Days 1 and 8.This cycle lasts 28 days"
88847395|NCT03708367|Experimental|Study Group: LipiFlow Treatment at PreOp|Study subjects that meet all inclusion and exclusion criteria will be randomized to receive LipiFlow Thermal Pulsation System treatment at preoperative visit before bilateral implantation with commercially-available Symfony Intraocular Lens
88847396|NCT03708367|Other|Control Group|Study subjects that meet all inclusion and exclusion criteria will be randomized to not receive the LipiFlow Thermal Pulsation System treatment at a preoperative visit before bilaterally implanted with the commercially available Symfony Intraocular Lens. Control Group will receive LipiFlow treatment as cross-over group at 3 months postoperative visit.
88847397|NCT03862027|Experimental|Esophageal Balloon catheter|All patients will have an esophageal balloon catheter inserted into their nare while upright (head of bed > 30 degrees) to a depth slightly more than the estimated distance from the lower sternum to the back of the ear (typically around 60 cm). Gastric positioning will be confirmed with abdominal compression testing and the catheter then retracted 10 - 20 cm into the lower esophagus. Placement will be confirmed with the presence of cardiac oscillations on the esophageal probe. The probe will then be secured to the patient's nasal opening using tape.
88847398|NCT03856255|Experimental|Micro-Tech Endoscopic Gauge|Use of the device during screening or surveillance colonoscopy
89181711|NCT00778700|Experimental|Ruxolitinib Phosphate 1.0% Cream|Ruxolitinib phosphate 1.0% cream, applied topically, once daily from Day 1 to Week 12.
89181712|NCT00778700|Experimental|Ruxolitinib Phosphate 1.5% Cream|Ruxolitinib phosphate 1.5% cream, applied topically, once daily from Day 1 to Week 12.
89181713|NCT04077489|Other|MT|Macular thickness
89181714|NCT00793403||1|As per routine clinical care
89181715|NCT02687763|Experimental|Open Label|Open Label. Two 0.5-mL doses of ProQuad® will be given by intramuscular injection at least 30 days but no more than 365 days apart..
89181716|NCT04110899|Experimental|Different paratracheal force|Esophageal occlusion is assessed by inserting an esophageal stethoscope under different paratracheal forces.
89181717|NCT04100876||primary ITP patients .|60 primary ITP patients .
89181718|NCT04100876||healthy subjects .|30 healthy age and sex matched control subjects .
89181719|NCT02581293|Experimental|Only visceral peritoneum will be closed|Group1: Only visceral peritoneum will be closed
89181720|NCT02581293|Experimental|Only parietal peritoneum will be closed|Group 2: Only parietal peritoneum will be closed
89181721|NCT02581293|Experimental|Both of them will be closed|Group 3: Both of them will be closed
89181722|NCT02581293|Experimental|None of them will be closed|Group 4: None of them will be closed
89181723|NCT04109105||NHS-PEG coated collagen patch cohort|Patients diagnosed of colon adenocarcinoma that have ileocolic anastomosis after undergoing a laparoscopic right hemicolectomy surgery.
88847399|NCT04298918|Experimental|Dose Escalation Phase|Participants received venetoclax in combination with a fixed dose of trastuzumab emtansine.
89375414|NCT01379430|Experimental|Group 2|Intradermal arm
89375415|NCT01380444|Active Comparator|1|Gamma3 Intramedullary Nails
89375416|NCT01380444|Active Comparator|2|Sliding Hip Screws
89375417|NCT03639545|Active Comparator|*empagliflozin*|empagliflozin 25 mg daily for 12 weeks, once daily, by mouth
88847400|NCT04298918|Experimental|Dose Expansion Phase|Participants were to receive venetoclax at the Phase II Recommended Dose (RP2D) in combination with trastuzumab emtansine.
88847401|NCT04298918|Experimental|Randomized Phase II Arm 1|Participants were to receive trastuzumab emtansine + placebo.
89375418|NCT03639545|Active Comparator|*metformin*|metformin 2000 mg daily for 12 weeks, once daily, by mouth
89375419|NCT03639545|Active Comparator|*empagliflozin/metformin*|empagliflozin 25 mg daily and metformin 2000 mg daily for 12 weeks, by mouth
89375420|NCT03639545|Placebo Comparator|*placebo*|placebo for 12 weeks, once daily with water, by mouth
89375421|NCT03181386|Experimental|Rivaroxaban|As the rivaroxaban is ingested 1x/day, the interval between a maximum peak concentration and the other peak is 24 hours. Therefore, the surgery will be performed between two peaks of maximum drug concentration, knowing that the maximum peak concentration is an average of two hours after ingestion. So the surgical procedure should be scheduled 14 hours (2 hours+ 12 hours) after the last medication intake.
89375422|NCT03181386|Experimental|Dabigatran and Apixaban|As dabigatran and apixaban are taken 2x/day, the interval between two peak concentration is 12 hours.Taking into account the first two hours of maximum peak concentration and half the interval between two peaks (2 hours + 6 hours = 8 hours), the surgical procedure must be programmed eight hours after the last intake of medication.
89375423|NCT03181386|Active Comparator|Warfarin|The control group will consist of patients on chronic use of warfarin. The operation will be scheduled at any time, provided that the patient has INR value between 2.0 and 3.0 and test performed in maximum 15 days before surgery.
89375424|NCT02912468|Placebo Comparator|Placebo|Placebo (for dupilumab), 1 subcutaneous (SC) injection every 2 weeks (q2w) from Day 1 of Week 0 up to Week 24 added to background therapy of intranasal mometasone furoate nasal spray (MFNS) at stable dose.
89375425|NCT02912468|Experimental|Dupilumab 300 mg|Dupilumab 300 mg SC injection q2w from Day 1 of Week 0 up to Week 24 added to background therapy of intranasal MFNS at stable dose.
89375426|NCT03725813|Experimental|Person-centred inpatient care|Person-centred inpatient care
89375427|NCT04835298||Myotonic dystrophy type 1|adult patients with myotonic dystrophy type 1
89375428|NCT03639467|Experimental|Anlotinib plus gemcitabine/cisplatin|"In the phase Ib portion, patients received dose escalation of anlotinb (from 8mg to 12mg orally once daily on days 1-14 of a 21-day) in combination with fixed dose of gemcitabine (1000mg/m2 intravenously on days 1 and 8) and cisplatin (80mg/m2 intravenously on day 1) every 3 weeks.~In the phase II portion, patients received anlotinb at recommended phase II dose determined in the phase Ib portion, in combination with fixed dose of gemcitabine and cisplatin every 3 weeks.~The combination of anlotinib plus gemcitabine / cisplatin was repeated every 3 weeks for up to six cycles. Patients with disease control (defined as a complete response, a partial response, or stable disease) continue to receive anlotinb until disease progression or unacceptable toxic effects, whichever occurred first."
89375429|NCT01379352||High MELD group|Preoperative MELD score greater than 20
89375430|NCT01379352||Low MELD group|Preoperative MELD score lesser than 20
89375431|NCT03729167|Experimental|Scaling and root planing|Teeth that have been given a prognosis of hopeless and treatment planned for extraction will be scaled and root planed with various non-surgical instruments prior to extraction. The teeth will then be photographed and assessed for remaining hard accretion deposits to determine the effectiveness of the instruments.
89375432|NCT01382706|Experimental|Treatment|Patients receive docetaxel IV over 1 hour on day 1 and lapatinib ditosylate PO QD on days 1-21. Courses repeat every 21 days until disease progression or unacceptable toxicity.
88847402|NCT04298918|Experimental|Randomized Phase II Arm 2|Participants were to receive trastuzumab emtansine + venetoclax.
88847403|NCT03714919|Experimental|Non-opiod pain relief|Subjects will receive preoperative oral dextromethorphan & acetaminophen and intraoperative intravenous dexmedetomidine & ketamine.
89375433|NCT03725735|Experimental|CBT for PG with emotion regulation|A new treatment protocol for problem gamblers, CBT for problem gambling with emotion regulation, has a focus on emotion regulation, a component that has been lacking in current published research.
89375434|NCT03665402|Active Comparator|Rapid metabolizer (Standard treatment)|Standard isoniazid dose regimen (300 mg qd)
89375435|NCT03665402|Active Comparator|Slow metabolizer (Standard treatment)|Standard isoniazid dose regimen (300 mg qd)
89375436|NCT03665402|Experimental|Slow metabolizer (PGx treatment)|Decreased isoniazid dose regimen (200 mg qd)
89375437|NCT01380288|Active Comparator|without white matter change|
89375438|NCT01380288|Active Comparator|with white matter change group|
89375439|NCT03110484|Experimental|Pemetrexed+Tarceva|D1 Pemetrexed 500 mg/m2 IV+ D1-21 Erlotinib 100mg once daily
89375440|NCT03110328|Experimental|mk3475 200mg|Pembrolizumab (MK-3475) 200 mg every 3 weeks (Q3W) Open-label
89375441|NCT04438499|Experimental|Subjects Indicated for a UDS study|The investigational device, i.e. the eSense catheter will be used in all the subjects to assess primary and exploratory objectives. It is a single arm study with no comparative, placebo, sham or control arm.
89375442|NCT01562015|Experimental|Ganetespib|Ganetespib IV infusion once per week for three consecutive weeks followed by a 1 week dose-free interval
89375443|NCT03751085|Experimental|AW frame|AW frame biopsy
88847404|NCT03863522|Other|Fine Needle Aspiration|Participants will receive fine needle aspiration (FNA) later read by the cytopathologist and the cartridge. All patients will receive standard of care (Ultrasound-guided core needle biopsy and diagnosis).
88847405|NCT04223635|Experimental|Hepatic impaired|Participants with moderate hepatic impairment who will receive a single oral dose of pexidartinib.
88847406|NCT04223635|Experimental|Healthy controls|Sex-, age-, and weight-matched healthy participants who will receive a single oral dose of pexidartinib.
88847407|NCT04232137|Experimental|Coffee ceremony|Antenatal care patients will be told on their first antenatal care visit that a postpartum coffee ceremony will be organized for them and up to 4 relatives
89375444|NCT03729089|Experimental|Modified Biophysical Profile scan|Participants randomized to intervention group (modified biophysical profile scanning) will receive scans starting from 34 weeks at enrollment then every 3 weeks thereafter until 40 weeks of amenorrhea.
88847408|NCT04232137|No Intervention|NO Coffee ceremony|Antenatal care patients will be told that they will NOT receive a postpartum coffee ceremony, as is the current status quo
88847409|NCT04204057|Experimental|Tenalisib|Patients receive Tenalisib 800 mg BID, Orally in 28-Day cycle for 7 cycles
88847410|NCT00000884|Experimental|1|Participants will undergo treatment intramuscularly
88847411|NCT00000884|Experimental|2|Participants will undergo treatment orally
88847412|NCT00000884|Experimental|3|Participants will undergo treatment intranasally
88847413|NCT00000884|Experimental|4|Participants will undergo treatment intrarectally
88847414|NCT00000884|Experimental|5|Participants will undergo treatment intravaginally
88847415|NCT00000884|Experimental|6|Participants will undergo treatment intranasally and intramuscularly
88847416|NCT00000884|Experimental|7|Participants will undergo treatment intrarectally and intramuscularly
88847417|NCT04331600|Experimental|CHLOROQUINE|Standard of care + chloroquine phosphate + telemedical approach.
88847418|NCT04331600|Other|CONTROL GROUP|Standard of care + telemedical approach.
88847419|NCT03844321|Experimental|Mindfulness-Based Cognitive Therapy|8 sessions of online mindfulness-based cognitive therapy
88847420|NCT03844321|Experimental|Brief Mindfulness|3 sessions of online mindfulness therapy
88847421|NCT04331678|No Intervention|Usual Care|Participants will be complete survey at enrollment and then again in 3 months.
89375445|NCT03729089|No Intervention|Current standard of care|The participants randomized to this control group will receive the current standard of care recommended by World Health Organization implemented by the attending Doctor. they may receive the modified biophysical profile scanning or not but at non specified time during their pregnancy.
89375446|NCT00002874|Experimental|Bicalutamide|Radiation therapy + bicalutamide
89375447|NCT00002874|Placebo Comparator|Placebo|Radiation therapy + placebo
89375448|NCT03001076|Experimental|bempedoic acid|bempedoic acid 180 mg tablet taken orally, daily. Patients remain on ongoing ezetimibe therapy (study provided)
89375449|NCT03001076|Placebo Comparator|placebo|Matching placebo tablet taken orally, daily. Patients remain on ongoing ezetimibe therapy (study provided)
88847422|NCT04331678|Active Comparator|Active|"Participants in the App group will receive usual care and complete survey at enrollment and then again in 3 months.~In addition, they will be asked to download the study app to their mobile device and use it at least once per week during the 3-month study period."
88847423|NCT05440682|Experimental|CP group|Pre- post-cranioplasty and 6 months follow-up MRI assessment. Each MRI session lasts about 60 minutes and will measure Diffusion Tensor Imaging, Tractography and resting state fMRI
88847424|NCT04332991|Active Comparator|Hydroxychlorquine|Participants assigned to the hydroxychloroquine arm will receive hydroxychloroquine sulfate 400 mg twice daily on the day of enrollment, then 200 mg twice daily for the next 4 days for a 5 day total course.
89375450|NCT03555305|Experimental|Insulin Glargine|Participants received 0.5 units per kilogram (U/kg) of Insulin Glargine subcutaneously (SC).
88847425|NCT04332991|Placebo Comparator|Placebo|Participants randomized to the control group will receive a dose of placebo enterally twice daily for 5 days (a total of 10 doses). The placebo pills will be as similar as possible to the hydroxychloroquine pills to ensure blinding.
88847426|NCT03719677|Experimental|Habit development intervention|Treatment includes occupational therapy evaluation and consultation to address any deficits in physical function, safety, social participation and/or life roles. After the occupational therapy evaluation, the therapist delivers education on physical activity and dietary recommendations and habit development techniques, and uses behavioral skills training to develop habit plans, as well as prompts/cues, environmental modifications, and reminder text messages to reinforce engagement in the plan. The intervention is delivered through 3 face to face sessions, 9 tele coaching calls, and text messages.
88847427|NCT03831451|Experimental|Stroke Preparedness Intervention|The stroke preparedness educational intervention was designed with input from the community where it is being tested. It will be delivered in-person by a research team member. The intervention focuses on recognizing stroke symptoms and the importance of calling 911.
88847428|NCT03831451|Active Comparator|Healthy lifestyle intervention|The Healthy lifestyle stroke risk reduction educational intervention is based on patient materials from the American Heart Association. It will be delivered in-person by a research team member. The intervention focuses on stroke risk reduction.
89181724|NCT02687997|Experimental|Diagnostic|Patients enrolled in lung cancer screening subjected to a sleep study.
88847429|NCT03721549|Experimental|Moderate Dose Inoculum|Moderate dose of Norwalk GI.1 Virus, 3.6x10^5 genome copies
88847430|NCT03721549|Experimental|Higher Dose Inoculum|Higher dose of Norwalk GI.1 Virus, 1x10^6 genome copies
88847431|NCT00000254|Sham Comparator|0% isoflurane|
89181725|NCT02687997|No Intervention|Contro|Patients enrolled in lung cancer screening not included in the diagnostic intervention arm
89181726|NCT04109183|Experimental|Active Comparator: FNC 2 mg+ TDF+EFV|
89181727|NCT04109183|Experimental|Active Comparator: FNC 3 mg+ TDF+EFV|
88847432|NCT00000254|Active Comparator|0.2% isoflurane|
88847433|NCT00000254|Active Comparator|0.4% isoflurane|
88847434|NCT00000254|Active Comparator|0.6% isoflurane|
88847435|NCT03834025|Experimental|Phase 1 Condition 1, Phase 2 Condition 1|Providers assigned to this condition will be sent recruitment materials that are 'recruitment as usual' (Phase 1 Condition 1). These materials will not include prosocial messaging and will not include an additional mention of financial support available for participation. If they enroll, in Phase 2 of the study these participants will be in condition 1.
89181728|NCT04109183|Experimental|Active Comparator: FNC 4 mg+ TDF+EFV|
89181729|NCT04109183|Experimental|Postive Comparator: 3TC+ TDF+EFV|
89181730|NCT04055883|Experimental|DA-1229 5mg|Oral administration of DA-1229 5mg tablet once a day
89181731|NCT04055883|Experimental|DA-1229 10mg|Oral administration of DA-1229 10mg tablet once a day
89181732|NCT04055883|Placebo Comparator|DA-1229 Placebo|Oral administration of DA-1229 Placebo tablet once a day
89375451|NCT03555305|Active Comparator|Lantus|Participants received 0.5 U/Kg of Lantus subcutaneously.
89375452|NCT01310387|Experimental|active pain management|active pain management (APM) by specialized nurses for cancer pain
88847436|NCT03834025|Experimental|Phase 1 Condition 1, Phase 2 Condition 2|Providers assigned to this condition will be sent recruitment materials that are 'recruitment as usual' (Phase 1 Condition 1). These materials will not include prosocial messaging and will not include an additional mention of financial support available for participation. If they enroll, in Phase 2 of the study these participants will be in condition 2.
88847437|NCT03834025|Experimental|Phase 1 Condition 1, Phase 2 Condition 3|Providers assigned to this condition will be sent recruitment materials that are 'recruitment as usual' (Phase 1 Condition 1). These materials will not include prosocial messaging and will not include an additional mention of financial support available for participation. If they enroll, in Phase 2 of the study these participants will be in condition 3.
88847438|NCT03834025|Experimental|Phase 1 Condition 2, Phase 2 Condition 1|Providers assigned to this condition will be sent recruitment materials that include additional mention of financial support available for participation, but will not include prosocial messaging (Phase 1 Condition 2). If they enroll, in Phase 2 of the study these participants will be in condition 1.
89375453|NCT03725579|Experimental|mepivacaine hydrochloride|2% Mepivacaine hydrochloride with 1:100,000 epinephrine anaesthetic solution. Each patient received two inferior alveolar nerve block injections of the tested anesthetic solution by using a side loading aspirating syringe and 27-gauge long needle
89375454|NCT03725579|Active Comparator|articaine hydrochloride|4 % Articaine hydrochloride with 1:100,000 epinephrine anaesthetic solution. Each patient received two inferior alveolar nerve block injections of the tested anesthetic solution by using a side loading aspirating syringe and 27-gauge long needle
89375455|NCT03728855|No Intervention|Standard care|Based on an (electronic) order placed by a physician, nurses collect medication and provide patients with the ordered medication in a timely matter. Nurses document the administration either in an electronic medical record or on paper.
89375456|NCT03728855|Experimental|Self-administration of medication (SAM)|During SAM medication is stocked at the patient's bedside. When medication is scheduled to be administered, patients collect those form their own stock, administer, and document the administration by themselves. Once daily nurses check whether patients succeeded in administration for all prescriptions of the last 24 hours. Each day, patients are qualified for SAM. In the case patients do not meet the criteria of SAM, they will be excluded from SAM.
89375457|NCT03553823|Experimental|secukinumab|20 subjects with plaque psoriasis with an inadequate response to ustekinumab self-administered 300 mg secukinumab as two 150-mg s.c. injections at Baseline, Weeks 1, 2, 3, 4 and then every 4 weeks until Week 12 inclusive
89375458|NCT03553823|Active Comparator|Guselkumab|20 subjects with plaque psoriasis with an inadequate response to ustekinumab self-administered guselkumab as 100 mg s.c. injections at Baseline, Weeks 4, and 12.
89399340|NCT02174978|Other|Infectivity control|Non-immunized infectivity control challenged with P falciparum Controlled Human Malaria Infection (CHMI)
88847439|NCT03834025|Experimental|Phase 1 Condition 2, Phase 2 Condition 2|Providers assigned to this condition will be sent recruitment materials that include additional mention of financial support available for participation, but will not include prosocial messaging (Phase 1 Condition 2). If they enroll, in Phase 2 of the study these participants will be in condition 2.
88847440|NCT03834025|Experimental|Phase 1 Condition 2, Phase 2 Condition 3|Providers assigned to this condition will be sent recruitment materials that include additional mention of financial support available for participation, but will not include prosocial messaging (Phase 1 Condition 2). If they enroll, in Phase 2 of the study these participants will be in condition 3.
88847441|NCT03834025|Experimental|Phase 1 Condition 3, Phase 2 Condition 1|Providers assigned to this condition will be sent recruitment materials that include prosocial messaging, but do not include an additional mention of financial support available for participation (Phase 1 Condition 3). If they enroll, in Phase 2 of the study these participants will be in condition 1.
88847442|NCT03834025|Experimental|Phase 1 Condition 3, Phase 2 Condition 2|Providers assigned to this condition will be sent recruitment materials that include prosocial messaging, but do not include an additional mention of financial support available for participation (Phase 1 Condition 3). If they enroll, in Phase 2 of the study these participants will be in condition 2.
88847443|NCT03834025|Experimental|Phase 1 Condition 3, Phase 2 Condition 3|Providers assigned to this condition will be sent recruitment materials that include prosocial messaging, but do not include an additional mention of financial support available for participation (Phase 1 Condition 3). If they enroll, in Phase 2 of the study these participants will be in condition 3.
88847444|NCT03834025|Experimental|Phase 1 Condition 4, Phase 2 Condition 1|Providers assigned to this condition will be sent recruitment materials that include prosocial messaging and an additional mention of financial support available for participation (Phase 1 Condition 4). If they enroll, in Phase 2 of the study these participants will be in condition 1.
88847445|NCT03834025|Experimental|Phase 1 Condition 4, Phase 2 Condition 2|Providers assigned to this condition will be sent recruitment materials that include prosocial messaging and an additional mention of financial support available for participation (Phase 1 Condition 4). If they enroll, in Phase 2 of the study these participants will be in condition 2.
88847446|NCT03834025|Experimental|Phase 1 Condition 4, Phase 2 Condition 3|Providers assigned to this condition will be sent recruitment materials that include prosocial messaging and an additional mention of financial support available for participation (Phase 1 Condition 4). If they enroll, in Phase 2 of the study these participants will be in condition 3.
89181733|NCT04244565||Self-directed clinical learning|examining the effect of Self-directed clinical learning model as compared to the traditional models to improve nurses' Airway management competencies and minimize airway related incidents.
89181734|NCT04036695|Experimental|Reveal LINQ insertable cardiac monitoring system|In this all study, participants will have the option to undergo an insertion procedure of the Reveal LINQ insertable cardiac monitoring system on a dialysis or non-dialysis treatment day at University Hospital. The implantable loop recorder will be monitored at least once a week for up to 12 months.
89399341|NCT03694587|Active Comparator|Test IMP|
89399342|NCT03694587|Active Comparator|Reference IMP|
89399343|NCT03539276|No Intervention|Pre-intervention|Usual care
88847447|NCT03748771|Experimental|ApneaLink Air|Half of the participants will undergo HST no greater than one week prior to their in-laboratory PSG, while the other half will undergo HST no greater than one week following their in laboratory PSG. All participants will also undergo their HST concurrent to their in-laboratory PSG. The rational for splitting participants in these two groups is to equally distribute the effects of the first night evenly, in which the sleep architecture including reduced total rapid eye movement (REM) sleep time can vary during the first ever sleep study. As the HST will be compared to the in-lab PSG, we would like to evenly distribute this effect by having two groups of ten participants.
88847448|NCT05228912||BNT162b2 mRNA|Group of patients of any age, any sex, that will receive a complete scheme of approved BNT162b2 mRNA vaccination , assigned by a local government vaccination campaign. It can also include patients that receive a third or fourth boost.
88847449|NCT05228912||mRNA-1273|Group of patients of any age, any sex, that will receive a complete scheme of approved mRNA-1273 vaccination, assigned by a local government vaccination campaign. It can also include patients that receive a third or fourth boost.
88847450|NCT05228912||ChAdOx1-S|Group of patients of any age, any sex, that will receive a complete scheme of approved ChAdOx1-S vaccination, assigned by a local government vaccination campaign. It can also include patients that receive a third or fourth boost.
88847451|NCT05228912||Ad26.COV2|Group of patients of any age, any sex, that will receive a complete scheme of approved Ad26.COV2 vaccination, assigned by a local government vaccination campaign. It can also include patients that receive a third or fourth boost.
88847452|NCT05228912||Ad5-nCoV|Group of patients of any age, any sex, that will receive a complete scheme of approved Ad5-nCoV vaccination, assigned by a local government vaccination campaign. It can also include patients that receive a third or fourth boost.
88847453|NCT05228912||Gam-COVID-Vac|Group of patients of any age, any sex, that will receive a complete scheme of approved Gam-COVID-Vac vaccination, assigned by a local government vaccination campaign. It can also include patients that receive a third or fourth boost.
88847454|NCT05228912||Coronavac|Group of patients of any age, any sex, that will receive a complete scheme of approved Coronavac vaccination, assigned by a local government vaccination campaign. It can also include patients that receive a third or fourth boost.
88847455|NCT03836989|Experimental|High-volt electrical stimulation|"Plan to use a monophasic waveform having 100µmsec pulse duration, at 35 Hz using tolerated voltage to generate a contraction a total of 20 minutes.~The stimulation will have 10 seconds on time, 30 seconds off time and 2 second ramp up and down. Electrical stimulation will be produced with the Orthostim 3 device (VQ Ortho Care). The cathode will be placed on the ipsilateral muscle to stimulate and the anode over the ipsilateral mastoid region.~Four facial muscles will be stimulated: 1)frontalis, 2) orbicularis oculi, 3) zygomaticus major, and 4) orbicularis oris.~The voltage is turned up by the participant until he or she can see twitches or as high as tolerated. Ten contractions in each muscle group will be performed or 5 minutes per muscle if no contraction is achieved."
88847456|NCT03836989|Placebo Comparator|Subsensory electrical stimulation|"Plan to use the same device and settings to provide placebo treatment by delivering minimal electricity. The settings will be the same as the intervention except the voltage will be subsensory. ie. below the minimum at which patients feels any effect of the current.~The voltage is turned down two clicks from the voltage at which the participant can first notice any electricity or at the minimal setting."
88847457|NCT03811951|Experimental|Smokers|All participants receive both Novolin R (experimental drug) and 14% NaCl (Sodium Chloride) solution (placebo), to be administered in randomly assigned order on two separate testing sessions. During administration of either Novolin R or 14% NaCl, participants will receive 1 spray in each nostril every 3 minutes for a total of 6 sprays. The nasal spray bottle delivers 0.1 ml of liquid per spray. Since the concentration of insulin in Novolin R is 100 IU/mL, six sprays will deliver a 60 IU dose.
88847458|NCT03811951|Experimental|Non-Smokers|All participants receive both Novolin R (experimental drug) and 14% NaCl solution (placebo), to be administered in randomly assigned order on two separate testing sessions. During administration of either Novolin R or 14% NaCl, participants will receive 1 spray in each nostril every 3 minutes for a total of 6 sprays. The nasal spray bottle delivers 0.1 ml of liquid per spray. Since the concentration of insulin in Novolin R is 100 IU/mL, six sprays will deliver a 60 IU dose.
88847459|NCT04816526|Experimental|Descartes 08|
88847460|NCT04332289||PHH patients|Patients following Roux-en-Y gastric bypass surgery (≥1 year ago) with confirmed post-prandial hyperinsulinemic hypoglycemia
88847461|NCT04332289||Healthy controls|Non-PHH, non-surgical healthy individuals
88847462|NCT03816709|Other|Therapeutic ultrasound treatment|All subjects received a therapeutic ultrasound treatment with the Chattanooga Intelect Legend XT machine with the following parameters: 3 MHz, 1.0 W/cm2, 15 minute treatment time.
89181735|NCT00793325||Somatropin|Patients administered Somatropin.
89399344|NCT03539276|Experimental|Post-intervention|One 90-minute interdisciplinary knowledge exchange including the provision of a validated list of appropriate and inappropriate medications for severe dementia long-term care residents.
88847463|NCT05218148|Experimental|Group A|Group A: SOX regimen (oxaliplatin + Seggio) ) + sintilimab + trastuzumab; 3 cycles of treatment, followed by D2 radical resection, and 5 cycles of adjuvant chemotherapy with the original regimen after surgery
88847464|NCT05218148|Active Comparator|Group B|Group B: SOX regimen, 3 cycles of treatment, followed by D2 radical resection, and 5 cycles of adjuvant chemotherapy with the original regimen after surgery
88847465|NCT04183231|Experimental|Anti-caries varnish|topical dental varnish, 10% PVP-I, 2.5% NaF, topical application to teeth, 0.4 ml, single application
88847466|NCT03890419|Active Comparator|Control Group|Control Group participants will be exposed to full spectrum light during the study.
88847467|NCT03890419|Experimental|Green light Group|Green light Group participants will be exposed to green light during the study.
88847468|NCT03890419|Experimental|Blue light Group|Blue light Group participants will be exposed to blue light during the study.
88847469|NCT03907033|Active Comparator|Standard Bupivacaine|Patients in the control group will receive 0.25% bupivacaine hydrochloride (bupivacaine HCl). 10cc will be injected bilaterally into each uterosacral ligament prior to the colpotomy incision. After entry into the posterior cul-de-sac, an additional 10cc of will be injected bilaterally into the deeper uterosacral ligaments.
89189324|NCT00715494|No Intervention|Group 1 - Control|Patients (Controls) will not receive formal (study-related) rehabilitation interventions and will only receive usual care.
88847470|NCT03907033|Experimental|Liposomal Bupivacaine|Patients in the study group will receive a mixture of 0.5% bupivacaine HCl and liposomal bupivacaine in 1:1 ratio. 10cc of the mixture will be injected bilaterally into each uterosacral ligament prior to the colpotomy incision. After entry into the posterior cul-de-sac, an additional 10cc will be injected bilaterally into the deeper uterosacral ligaments
88847471|NCT03818815|Active Comparator|Drug: OP0201 + Antibiotics|OP0201 20mg per day+oral Amoxicillin-clavulanate in two divided doses for 10 days
89375459|NCT05422716|Experimental|Surgically implanted epidural stimulation for spasticity|"The epidural stimulation (ES) group will undergo the research protocol for epidural stimulator surgical implant followed by mapping studies to identify targeted stimulation configurations for spasticity. In each subsequent 6 months we will enroll cohorts of (n=5) voluntary research participants to allow for the final cohort to complete their 6 month follow up with a remaining 3 months for final data analyses and dissemination for the grant period.~Spinal cord epidural stimulation is administered by a multi-electrode array implanted in the epidural space over the dorsum of the spinal cord."
89375460|NCT05422716|Experimental|Surgically implanted Intrathecal baclofen pump, the standard of care control group|"Individuals randomized to the baclofen pump (BP) group will continue with their clinical surgical and maintenance plan while also participating in all of the outcomes (assessments).~The Baclofen pump will be surgically implanted by a member of the clinical SCI medical team."
89375461|NCT03728777|Placebo Comparator|Placebo|
89375462|NCT03728777|Experimental|Resveratrol|Over the counter supplement
89375463|NCT05422404|Experimental|Chronic GERD patient reciving Anti-Reflux Mucosal Ablation|150 chronic GERD patients will be enrolled from our outpatient clinic. The inclusion criteria are as following: 20-75 years of age, history of GERD over 1 year, who had received daily PPIs or H2 antagonists over 6 month for GERD treatment, and having persistent typical GERD symptoms (acid reflux sensation or heartburn) or atypical GERD symptoms (hoarseness, cough, acid related chest pain, laryngitis) when off PPI or H2 antagonists therapy, defective gastroesophageal Defective junction reciving Anti-Reflux Mucosal Ablation.
89375464|NCT05422404|Active Comparator|Chronic GERD patient reciving Anti-Reflux Mucosectomy|150 chronic GERD patients will be enrolled from our outpatient clinic. The inclusion criteria are as following: 20-75 years of age, history of GERD over 1 year, who had received daily PPIs or H2 antagonists over 6 month for GERD treatment, and having persistent typical GERD symptoms (acid reflux sensation or heartburn) or atypical GERD symptoms (hoarseness, cough, acid related chest pain, laryngitis) when off PPI or H2 antagonists therapy, defective gastroesophageal Defective junction reciving Anti-Reflux Mucosectomy
88810391|NCT06213701|Active Comparator|Psychoeducation app|Participants will receive access to the 4-week HMP Foundations module with guided meditation practices removed. The active control will include only the didactic content included in HMP without the guided meditation practices.
88810392|NCT06213701|No Intervention|Usual Care|Participants will receive access to HMP at the end of the study and will be encouraged to continue with their usual care.
88810393|NCT06213688|Other|Cases|Patients with atopic dermatitis or psoriasis
88810394|NCT06213688|Other|Controls|Patients have consulted or been hospitalized for dermatological reasons without psoriasis or atopic dermatitis
88810395|NCT06213662|Experimental|experimental group|"Botulinum toxin type A for injection (Hengli National Drug approval number S10970037) 100U, diluted with~1 ml.9% sodium chloride solution for reserve use.Each patient was injected with 90U"
88810396|NCT06213610|Other|Sequence TR|25 subjects assigned to the sequence TR will receive a single oral dose of the test product Perindopril 8 mg tablet, marked as T in the sequence, in Period 1 and a single oral dose of the reference product Prestarium® A 10 mg tablet, marked as R in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
88810397|NCT06213610|Other|Sequence RT|25 subjects assigned to the sequence RT will receive a single oral dose of the reference product Prestarium® A 10 mg tablet, marked as R in the sequence, in Period 1 and a single oral dose of the test product Perindopril 8 mg tablet, marked as T in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
88810398|NCT06213584|Experimental|mulligan mobilization|Mulligan mobilization techniques
88810399|NCT06213584|Experimental|pnf|Proprioceptive neuromuscular fasciliation techniques
88810400|NCT06213584|Experimental|conservative rehabilitation|Conservative rehabilitation
88810401|NCT06213558|Active Comparator|Evaluation of rectangular archwire on maxillary canine retraction|Evaluation of rectangular archwire on maxillary canine retraction
88810402|NCT06213558|Active Comparator|Evaluation of square archwire on maxillary canine retraction|Evaluation of square archwire on maxillary canine retraction
88810403|NCT06213545|Experimental|In-Clinic interpretation|After doing patch test, patient come to Siriraj hospital to interpret the results at 48 hr and 72 hr.
88810404|NCT06213545|Experimental|Photo interpretation|After doing patch test, patient take a photo to Siriraj hospital by LINE application to interpret the results at 48 hr, 72 hr and 7 days
88810405|NCT06213532|Other|Beta testing (CONNECTing to LungCare, feedback)|Participants interact with the CONNECTing to LungCare intervention and provide feedback in support of intervention refinement.
88810406|NCT06213532|Experimental|Feasibility trial, Group I (CONNECTing to LungCare)|Participants receive the CONNECTing to LungCare intervention, including education about the benefits and risks of LCS and the importance of shared decision making, computerized assessments of the participant's smoking status, readiness to quit and concerns about quitting, and video segments tailored to the participant's responses to assessment questions, prior to their primary care appointment. Participants and their providers receive a tailored summary of the participant's concerns and barriers to quitting to enhance motivation for smoking cessation and shared decision-making discussions. Participants then receive up to 3 follow-up phone calls over 10-15 minutes each encouraging them to follow up with their provider, to complete the shared decision-making conversation, obtain LCS if appropriate, and access smoking cessation resources. Participants may also receive brief, tailored follow-up text messages that include links to video segments or cessation resources 1-3 times weekly.
88810407|NCT06213532|Active Comparator|Feasibility trial, Group II (usual care)|Participants receive usual care from their provider at their primary care appointment.
89181736|NCT02537847|Experimental|Sitafloxacin group|The first third days of treatment was open label and all patients were given intravenous carbapenems. After day 3, the patients were randomized to either sitafloxacin group or ertapenem group by the use of a computer-generated random number allocation schedule and block size of four. The patients were allocated to the sitafloxacin group or ertapenem group using the sealed envelope method.
88847472|NCT03818815|Placebo Comparator|Placebo Comparator: Placebo +Antibiotics|Placebo 0 mg per day+oral Amoxicillin-clavulanate in two divided doses for 10 days
88847473|NCT00001964|Experimental|single arm|ATG 40 mg/kg/d for 4 d; CsA 2 weeks after at 12 mg/kg/d for 6 months. MMF starting on first day of ATG at 600 mg/m2 twice daily for 18 months
88847474|NCT00001964|Experimental|single arm 2|ATG at 40 mg/kg/day for 4 days; MMF at 600 mg/m2 twice daily for 18 months and CsA at 12 mg/kg/day for 6 months starting 2 weeks after ATG and MMF
88847475|NCT03801265|Active Comparator|Lumbar Plexus block|0.5% ropivacaine 100 mg (20 ml) will be injected
88847476|NCT03801265|Experimental|Quadratus Lumborum type 3 block|0.5% ropivacaine 100 mg (20 ml) will be injected
88847477|NCT03950167||Hyperemesis gravidarum|pregnant women before 14 weeks of pregnancy diagnosed with hyperemesis gravidarum will be assessed in terms of gallbladder functions and serum cholecystokinin levels after a fatty meal.
88847478|NCT03950167||Healthy pregnant women|Healthy pregnant women before 14 weeks of pregnancy without hyperemesis gravidarum will be assessed in terms of gallbladder functions and serum cholecystokinin levels after a fatty meal.
88847479|NCT00000308|Experimental|1|15 mg of d-amphetamine for first 8 weeks of study and 30 mg for the second 8 weeks
88847480|NCT00000308|Experimental|2|30 mg of d-amphetamine for first 8 weeks of study and 60 mg for the second 8 weeks
88847481|NCT00000308|Experimental|3|placebo
88847482|NCT03968965|Experimental|3D MvIGS|One, two and three-level posterior spine fusion surgery using bilateral pedicle screw instrumentation under 3D MvIGS intraoperative navigation guidance.
88847483|NCT03968965|Other|2D Fluoroscopy|One, two and three-level posterior spine fusion surgery using bilateral pedicle screw instrumentation under 2D fluoroscopy.
88847484|NCT00000320|Active Comparator|1; liquid formulation|liquid formulation
88847485|NCT00000320|Active Comparator|2; tablet formulation|tablet formulation
88847486|NCT03978403|Experimental|ABDC|"A: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a Sled coater packaged in foil pouches; B: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a MACAP coater packaged in foil cups; C: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a miniMac coater packaged in foil cups; D: Zolmitriptan nasal 2.5 mg/0.1 mL single dose"
88847487|NCT03978403|Experimental|BCAD|"A: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a Sled coater packaged in foil pouches; B: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a MACAP coater packaged in foil cups; C: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a miniMac coater packaged in foil cups; D: Zolmitriptan nasal 2.5 mg/0.1 mL single dose"
88847488|NCT03978403|Experimental|CDBA|"A: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a Sled coater packaged in foil pouches; B: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a MACAP coater packaged in foil cups; C: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a miniMac coater packaged in foil cups; D: Zolmitriptan nasal 2.5 mg/0.1 mL single dose"
88847489|NCT03978403|Experimental|DACB|"A: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a Sled coater packaged in foil pouches; B: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a MACAP coater packaged in foil cups; C: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a miniMac coater packaged in foil cups; D: Zolmitriptan nasal 2.5 mg/0.1 mL single dose"
89181737|NCT02537847|Active Comparator|control group|Intervention was prescribed ertapenem for patients.
88847490|NCT03979807||Subjects with Chronic obstructive pulmonary disease|
88847491|NCT00001082|Experimental|1|Participants will receive adefovir dipivoxil and L-carnitine
88847492|NCT00001082|Experimental|2|Participants will receive adefovir dipivoxil placebo and L-carnitine.
88847493|NCT04169113|Active Comparator|Group 1 - Hip Arthroscopy|Will be prescribed 60 opiate tablets in addition to other routine post-operative pain medication regimens.
88847494|NCT04169113|Active Comparator|Group 2 - Hip Arthroscopy|Will be prescribed 30 opiate tablets in addition to other routine post-operative pain medication regimens.
88847495|NCT00380276|Other|Open Label Arm|Treatment is open-label
88847496|NCT04149925||AEON Endostapler|Stapling performed by AEON Endostapler
88847497|NCT04149925||Echelon Flex Powered Stapler|Stapling performed by Echelon Flex Powered Stapler
88847498|NCT03799783|Experimental|Dexmedetomidine|2 mcg/Kg iv dexmedetomidine (this dose may be repeated up to 2 times) followed by 1-2 mcg/Kg/hour iv continuous infusion
88847499|NCT04713566|Experimental|Group A|will be using Salvadora Persica oral rinse
88847500|NCT04713566|Experimental|Group B|will be using Commercial Phenolic mouthwash.
88847501|NCT04085341|Experimental|GB-102 Dose 1 (1 mg)|Participants will receive intravitreal (IVT) GB-102 (1 mg) in the study eye at Baseline.
89181738|NCT04076553|Active Comparator|CBT + ICT|"Participants randomized to the ICT condition will complete a computerized ICT training at home during the first 4 weeks of treatment and ICT boosters following their treatment sessions during weeks 5-12."
89189325|NCT00715494|Experimental|Group 2 - Intervention|Participants in the experimental group will receive a focused set of interdisciplinary home-based interventions over a 12 week period.
89189326|NCT00620542|Experimental|Rosuvastatin 20 mg|Rosuvastatin 20 mg distributed in 2-week run-in period
89181739|NCT04076553|Sham Comparator|CBT + sham|"Participants randomized to the sham condition will complete a computerized sham ICT training at home during the first 4 weeks of treatment and sham ICT boosters following their treatment sessions during weeks 5-12. The shame will contain the same proportion of food as non-food but no inhibitory training component."
89181740|NCT04077645|Experimental|Sun salutations|Sun salutations, breathing exercises, and relaxation, at a low to moderate intensity, for 30 minutes.
88847502|NCT04085341|Experimental|GB-102 Dose 2 (2 mg)|Participants will receive intravitreal (IVT) GB-102 (2 mg) in the study eye at Baseline.
88847503|NCT04103515||Subjects implanted with PCR TKA|Subjects who have been implanted with a Zimmer-Biomet Posterior Cruciate Retaining total knee arthroplasty
88847504|NCT04103515||Subjects implanted with PS TKA|Subjects who have been implanted with a Zimmer-Biomet Posterior Stabilizing total knee arthroplasty
88847505|NCT05075018||Healthcare Workers with COVID-19 Infection|Healthcare workers who have been diagnosed with COVID-19 in the past and currently do not have COVID-19 disease constitute this group
88847506|NCT05075018||Healthcare Workers without COVID-19 Infection|Healthcare workers who have not been diagnosed with COVID-19 in the past and currently do not have COVID-19 disease constitute this group
88847507|NCT03782701|Active Comparator|Lumify Eye Drop|Participants will be randomized to receive a single drop of Lumify to either the left or right eye.
88847508|NCT03782701|Active Comparator|Saline Solution Eye Drop|Participants will be randomized to receive a single drop of sterile balanced saline solution to either the left or right eye.
88847509|NCT05314387||SMR TT Hybrid Glenoid without Cementless Finned Short Stem|Patients implanted with SMR TT Hybrid Glenoid without Cementless Finned Short Stem
88847510|NCT05314387||SMR TT Hybrid Glenoid with Cementless Finned Short Stem|Patients implanted with SMR TT Hybrid Glenoid with Cementless Finned Short Stem
88847511|NCT04143373|Experimental|Warm saline|this site was irrigated during impacted mandibular third molar surgery, with normal saline of 37 ± 1 ° C as for the experimental side.
88847512|NCT04143373|No Intervention|Room temperature saline|this site was irrigated during impacted mandibular third molar surgery, with normal saline of 25 ± 2 ° C as for the control side.
88847513|NCT03789175|Other|Nicotinamide riboside (NR) in Li-Fraumeni syndrome|Nicotinamide riboside (NR) to be initiated at week 0 at dose of 250 mg twice a day. At Week 1, NR will be titrated to 500 mg twice a day. At Week 6, NR will be titrated to 750 mg twice a day. At Week 7, NR will be titrated to 1000 mg twice a day or as tolerated until end of week 12. At week 12, if participant responds to primary endpoint, participant will washout of NR at week 18 then restart NR at week 24 until week 30. If there is not response to NR treatment at week 12, the participant may continue taking NR at a tolerated dose until week 24 and the primary endpoint will be re-measured. If participant has a positive response to NR treatment at week 24, then the participant will washout of NR until week 30, at which time the primary endpoint will be re-measured to ensure return to baseline. If there is no response to continued NR treatment at week 24, the study will be ended.
88847514|NCT04130425|Experimental|Healthy Individuals|Subject will be measured for forearm rotation while wearing the custom orthoses Hely & Weber MTC Fracture Brace, thermoplastic orthosis, and delta cast orthosis.
88847515|NCT00000434|Experimental|1|Fit and Strong! is a multi-component exercise and health education program that incorporates flexibility, aerobic conditioning, strength training, and group discussion/problem solving for lifestyle change.
88847516|NCT00001214||Group 1|Patients with pancytopenia
88847517|NCT04131517|Experimental|Oral contraceptive|Participants will receive oral contraceptive in Period 2 of Sequence A and Period 1 of Sequence B of Part 1 and Part 2.
88847518|NCT04131517|Experimental|Oral contraceptive + padsevonil|Participants will receive padsevonil + oral contraceptive in Period 1 of Sequence A and Period 2 of Sequence B of Part 1 and Part 2.
88847519|NCT03782233|Experimental|deep neuromuscular blockade group (Group D)|Patients undergoing elective laparoscopic surgery for gastrectomy will be randomized to receive deep neuromuscular blockade (post-tetanic count = 1-2) using high dose rocuronium.
88847520|NCT03782233|Other|moderate neuromuscular blockade group (Group M)|Patients undergoing elective laparoscopic surgery for gastrectomy will be randomized to receive moderate neuromuscular blockade (train-of-four count = 1-2) using moderate dose rocuronium.
88847521|NCT00380666|Other|PET/CT defined target|Target defined by use of fluoro-deoxy-glucose (FDG)-PET/CT scan for planning af stereotactic radiotherapy.
88847522|NCT04714021|Experimental|Single steep arm- CO2 insufflation|PEG will be performed by single step technique and CO2 will be insufflated during the endoscopy
88847523|NCT04714021|Active Comparator|Single steep arm- air insufflation|PEG will be performed by single step technique and air will be insufflated during the endoscopy
88847524|NCT04714021|Experimental|Pull technique arm- CO2 insufflation|PEG will be performed by pull technique and CO2 will be insufflated during the endoscopy
88847525|NCT04714021|Active Comparator|Pull technique arm- air insufflation|PEG will be performed by pull technique and air will be insufflated during the endoscopy
89181741|NCT04077645|Active Comparator|Aerobic exercise|Walking on a treadmill at low to moderate intensity for 30 minutes.
89375465|NCT03000686|Experimental|Treatment sequence AB|Subjects will receive GSK2586881 in period 1 and saline placebo in period 2. There will be a washout period of 3-14 days between two treatments
89375466|NCT03000686|Experimental|Treatment sequence BA|Subjects will receive saline placebo in period 1 and GSK2586881 in period 2. There will be a washout period of 3-14 days between two treatments
89375467|NCT02646228||molecular profiling, patient derived cells|
89375468|NCT01382628||Preulcerative plantar foot lesion|An area on the plantar foot, usually at the location of a bony prominence, that presents with erythema, significant hyperkeratosis, or thin, shiny skin.
89375469|NCT01382628||Plantar ulcer no history of amputation|Plantar ulceration without a history of amputation or require an amputation.
89375470|NCT01382628||Plantar ulcer and digital amputation|Plantar ulceration who will be undergoing a digital amputation.
89375471|NCT01382628||Plantar ulcer and transmet amputation|Plantar ulceration who will be undergoing a transmetatarsal amputation.
89375472|NCT01382628||Plantar ulceration and choparts|Plantar ulceration who will be undergoing Chopart's or more proximal amputation.
89375473|NCT04701138|Experimental|Dietary Supplement|All subjects will receive the intervention (SPM Active Supplement)
89375474|NCT01382550||VTE subjects|"subjects with a recent (<3 months) first VTE event undergoing long-lasting OAT or 12-month OAT~Exclusion criteria: missing data during the follow-up; contraindications to or lack of compliance to oral anticoagulation (OAT), lack of informed consent; history of previous VTE event; indication for continuous oral anticoagulation (e.g., an artificial heart valve or chronic atrial fibrillation); events occurring during pregnancy, malignancy, puerperium, oral contraceptive intake, hormone replacement therapy; deficiencies of Prot. C and Prot S or combined inhibitor deficiencies."
88847526|NCT00000512|Experimental|Niacin-Colestipol Group|Colestipol was begun at a dose of 5 g three times a day with meals and increased to 10 g three times a day after 10 days, unless side effects delayed the increase. Psyllium hydrophic mucilloid (Metamucil) was provided if dietary bran was insufficient to control constipation. Niacin was started at 125 mg twice a day and gradually increased to 500 mg four times a day (with meals and at bedtime) at one month and 1 g four times a day at two months. If the LDL cholesterol level did not fall below 3.1 mmol per liter (120 mg per deciliter) after three months, the dose of niacin was increased to 1.5 g (three tablets) four times a day, but no further.
88847527|NCT00000512|Experimental|Lovastatin-Colestipol Group|Colestipol was given as described above. Lovastatin was begun at a dose of 20 mg twice a day (in the morning and at bedtime). If the LDL cholesterol level did not fall below 3.1 mmol per liter after three months, the dose of lovastatin was increased to 40 mg twice a day.
88847528|NCT00000512|Placebo Comparator|Conventional-Therapy Group|Patients assigned to conventional therapy (the control regimen) received placebos for colestipol and for lovastatin, given as described above, unless their base-line LDL cholesterol level exceeded the 90th percentile for age. We felt obliged to provide such patients (43 percent of the group) with colestipol instead of its placebo. For purposes of blinding, the lovastatin placebo dose for a patient assigned to conventional therapy was doubled each time the lovastatin dose was doubled for a patient assigned to receive lovastatin and colestipol.
89181742|NCT04077645|Other|Seated rest (attentional control)|Watching educational videos for 30 minutes.
89375475|NCT01380132|Experimental|Anal injection of Nasha Dx|
89375476|NCT02493660|Experimental|InSpace implantation|Arthroscopic InSpace (Sub-acromial tissue spacer system) implantation
89375477|NCT02493660|Active Comparator|Tendon Repair|Arthroscopic partial repair of rotator cuff
89375478|NCT01382472|Experimental|Rosuvastatin|40 mg rosuvastatin pre PCI and daily during hospital stay
89375479|NCT01382472|Other|Historical data (KOMPIS)|Patients from the KOMPIS trial (n=44) will be used as historical controls. They received no statins omn the first day. Low dose simvastatin during hospital stay.
89375480|NCT05421468|Active Comparator|Pre-Iftar (Breaking the fast)|To take thyroxine at breaking of fast with sip of water then wait 30-60 miuntes to eat iftar (breakfast).
89375481|NCT05421468|Experimental|Pre-Fajr (Starting the fast)|To take thyroxine immediately before start of fast at predawn time regardless of last meal time.
89375482|NCT03552029|Experimental|Part 1 - Quizartinib + Milademetan|Participants with relapsed/refractory FLT3-ITD Mutant AML receive quizartinib + milademetan at increasing and/or decreasing doses and schedules
89375483|NCT03552029|Experimental|Part 2 - Cohort 1|Participants with relapsed/refractory FLT3-ITD Mutant AML receive the recommended dose of quizartinib + milademetan determined by Part 1
89375484|NCT03552029|Experimental|Part 2 - Cohort 2|Participants with newly diagnosed FLT3-ITD Mutant AML unfit for chemotherapy receive the recommended dose of quizartinib + milademetan determined by Part 1
89375485|NCT03725423|Experimental|experimental group|Oral administration of 250mg of apatinib daily, with or without chemotherapy
89375486|NCT06171646|Experimental|Experimental, Breathing Group|Breathing exercises were applied to the participants.
89375487|NCT06171646|No Intervention|No Intervention: Standard care|Participants received standard care.
89375488|NCT06171620|Other|Control group (SOC)|Standard of care
89375489|NCT06171620|Experimental|Intervention Group (VR)|Standard of care with addition of the Virtual reality headset
89375490|NCT06171607|Experimental|Diagnostic (contrast agent, CEUS)|Patients receive a contrast tracer (Lumason or DEFINITY) IV and then undergo CEUS scan over 60-90 minutes.
89375491|NCT06171594|Active Comparator|Active chlorhexidine|"Arm Description 2: Antibacterial CHX Mouthwash Arm~This arm involves participants who have been randomly assigned to receive an antibacterial CHX mouthwash containing 0.2% CHX (Corsodyl Mint, GlaxoSmithKline, UK). Similar to Arm 1, the intervention period spans seven days, during which participants will rinse their mouth with 10 mL of antibacterial CHX mouthwash twice daily. The active CHX mouthwash and the placebo mouthwash are indistinguishable in taste, appearance, color, texture, and smell. Participants in this arm will follow the rinse regimen for 7 days, taking the final tube the morning before their next visit (Visit 2 - 8). After the completion of Visit 8, each participant will undergo a washout period of 12 weeks before starting the 7-day reverse order of the given product administration as part of the crossover design."
88847529|NCT03777865|Experimental|13vPnC provided as a 0.5-mL dose in a prefilled syringe|All subjects receive a single dose (0.5mL) of 13vPnC
88847530|NCT04109443|Experimental|Young Men & Media Program group|Participants randomized to the Young Men and Media Program group will have access to the online sexual health media literacy materials. They will also complete three assessments at baseline, post-intervention, and a 3 month follow-up.
88847531|NCT04109443|Active Comparator|Control group|Participants randomized to the control group will have access to available websites (such as by the CDC) that provide information about sexual health and preventing sexually transmitted infections including HIV. They will complete three assessments at baseline, post-intervention, and a 3 month follow-up.
88847532|NCT04107493|Active Comparator|Portable oxygen cylinder|Continuous flow oxygen cylinders will be used as a comparison.
89375492|NCT06171594|Placebo Comparator|Placebo Chlorhexidine|"Arm Description 1: Placebo CHX Mouthwash Arm~This arm involves participants who have been randomly assigned to receive a placebo CHX mouthwash. The intervention period spans seven days, during which participants in this arm will rinse their mouth with 10 mL of CHX placebo mouthwash (ultrapure mint-flavoured water) twice daily. The placebo mouthwash is designed to be identical in taste, appearance, colour, texture, and smell to the active mouthwash, ensuring blinding during the study. Participants in this arm will follow the rinse regimen for 7 days, taking the final tube the morning before their next visit (Visit 2 - 8). After the completion of Visit 8, each participant will undergo a washout period of 12 weeks before starting the 7-day reverse order of the given product administration as part of the crossover design."
89375493|NCT06171516|Experimental|Internet-based Cognitive Behavioral Therapy|10 guided therapy sessions (once-weekly) with each session lasting 20 minutes.
88847533|NCT04107493|Experimental|Mobi™ Portable Oxygen Concentrator|Mobi™ is indicated for patients who require supplemental oxygen, including COPD patients. It provides supplemental, high oxygen concentration to these patients. It is available via prescription only and may be used in the home, institution, and hospital settings, as well as travel environments
88847534|NCT03231397|Other|Control Group|"Six control subjects (three males and three females) with known atherosclerosis by standard clinical criteria without aneurysmal disease.~To assess AAA rupture risk by PET-CTA scans, participants will undergo PET-CT scan using 11C-PBR28 and 18F-fludeoxyglucose (FDG) tracer. Participants will have a blood draw for genetic testing, pregnancy testing if female and creatinine testing."
88847535|NCT03231397|Other|Small AAA's|"Six subjects (three males and three females) with small AAAs (diameter 3.0-4.5cm).~To assess AAA rupture risk by PET-CTA scans, participants will undergo PET-CT scan using 11C-PBR28 and 18F-fludeoxyglucose (FDG) tracer. Participants will have a blood draw for genetic testing, pregnancy testing if female and creatinine testing."
88847536|NCT03231397|Other|Rapidly expanding AAA's|"Six subjects (three males and three females) with rapidly expanding AAAs (>0.5cm over 6 months and/or >1.0cm over 12 months).~To assess AAA rupture risk by PET-CTA scans, participants will undergo PET-CT scan using 11C-PBR28 and 18F-fludeoxyglucose (FDG) tracer. Participants will have a blood draw for genetic testing, pregnancy testing if female and creatinine testing."
88847537|NCT03231397|Other|AAA's undergoing treatment|"Six subjects (three males, AAA >5.5cm and three females, AAA >5.0cm) with AAAs that are indicated for treatment.~To assess AAA rupture risk by PET-CTA scans, participants will undergo PET-CT scan using 11C-PBR28 and 18F-fludeoxyglucose (FDG) tracer. Participants will have a blood draw for genetic testing, pregnancy testing if female and creatinine testing."
88847538|NCT03189433|Active Comparator|Ryanodex + Standard of Care|Ryanodex (dantrolene sodium) 50 mg/mL suspension to be administered as a rapid IV push of 2.5 mg/kg, added to Standard of Care (SOC). SOC is defined as efficient body cooling by physical methods and supportive measures [ice packs, evaporative cooling(application of room temperature water via mist with use of a fan], benzodiazepines to ameliorate shivering, IV fluids, respiratory support, and other treatments deemed necessary to treat complications or comorbidities]. Administer a single dose of Ryanodex. If a subject does not show an adequate clinical response within 10 - 30 minutes post-dose, a second IV bolus dose of 2.5 mg/kg may be administered.
88847539|NCT03189433|No Intervention|Standard of Care only (SOC)|Standard of Care is defined as efficient body cooling by physical methods and supportive methods and supportive measures[ice packs, evaporative cooling (application of room temperature water via mist with use of a fan], benzodiazepines to ameliorate shivering, IV fluids, respiratory support, and other treatments deemed necessary to treat complications or comorbidities].
88847540|NCT03776539|Experimental|ELX-02|Drug: ELX-02
88847541|NCT03774745|Experimental|Progesterone|"Micronized progesterone 200mg oral capsules starting 24 hours after mifepristone 200mg ingestion (day 1).~Progesterone treatment days 2-4: two capsules twice daily orally. Progesterone treatment days 5-15, 16 or 17: two capsules once daily orally."
88847542|NCT03774745|Placebo Comparator|Placebo oral capsule|Placebo capsules starting 24 hours after mifepristone 200mg ingestion (day 1). Placebo treatment days 2-4: two capsules twice daily orally. Placebo treatment days 5-15, 16 or 17: two capsules once daily orally.
89181743|NCT02687841|Experimental|AST-120 and PTX|AST-120 2g 4 times a day for 5 days then AST-120 2g 3 times a day for 5 days Pentapentoxifylline 400mg QD for 10 days
89375494|NCT06171438||Acute kidney injury (AKI)|Donors with AKI (acute kidney injury) defined based on the results of creatinine increase and diuresis decrease before organ harvest.
89375495|NCT06171438||no-AKI|Donors without AKI (acute kidney injury) defined based on the results of creatinine increase and diuresis decrease before organ harvest.
89375496|NCT06171438||delayed graft function (DGF)|Donors and the paired recipients in whom the organ was transplanted in IKEM (Institute for Clinical and Experimental Medicine) who developed delayed graft function (DGF) defined as dialysis in the 1st week after transplantation.
89375497|NCT06171438||no-DGF|Donors and the paired recipients in whom the organ was transplanted in IKEM (Institute for Clinical and Experimental Medicine) with immediate graft function (no-DGF).
89375498|NCT06171438||Recipient IFTA|Donors and the paired recipients in whom the organ was transplanted in IKEM with 3-month protocol biopsy histology finding of IFTA≥2.
89375499|NCT06171438||Recipient no-IFTA|Donors and the paired recipients in whom the was transplanted in IKEM with 3-month protocol biopsy histology finding of IFTA<2.
89375500|NCT06171360||Metastatic HR-positive HER2-negative breast cancer|"Patients with metastatic HR+ HER2- BC starting a first line treatment with a CDK4/6 inhibitor (palbociclib, ribociclib, abemaciclib).~Investigators will regularly collect blood and fecal samples for correlative translational research."
89375501|NCT06171360||Early HR-positive HER2-negative breast cancer at high risk of relapse|"Patients with early HR+ HER2- BC at high risk of relapse, starting adjuvant treatment with a CDK4/6 inhibitor (abemaciclib, ribociclib).~Investigators will regularly collect blood and fecal samples for correlative translational research."
89375502|NCT06171347|Experimental|Experimental group|Patients in the experimental group will receive oral cold spray (tap water) in the postoperative period.
89375503|NCT06171347|No Intervention|Control group|Patients in the control group will not be intervened in the postoperative period except for standard care for thirst management.
89375504|NCT06171334|Experimental|RIC|
89375505|NCT06171321|No Intervention|Group 1: Patients testing negative for ctDNA treated using standard of care treatment|Postoperative ctDNA-negative patients receive oral Teysuno (S-1) for adjuvant therapy。
89375506|NCT06171321|Experimental|Group 2: Patients with a positive ctDNA test are treated with an escalation strategy|Postoperative ctDNA-positive patients receive intravenous combined oral Teysuno (S-1) for adjuvant therapy。
89375507|NCT06171308|Active Comparator|The study group(using the moxibustion)|"The study group was treated with traditional Chinese moxibustion and western medicine. The control group was treated with blank moxibustion and western medicine.~The study group: Using the moxibustion, select specific 3 groups of acupoints. Select a group of acupuncture points every day, in the moxibustion treatment for 20 minutes, 4 weeks for a course of treatment.~The control group: Using the moxibustion with blank patch, select specific 3 groups of acupoints. Select a group of acupuncture points every day, in the moxibustion treatment for 20 minutes, 4 weeks for a course of treatment.~The treatment period is 4 weeks, which is a course of treatment, and the observation period is 8 weeks."
89375508|NCT06171308|Placebo Comparator|The control group(using the moxibustion with blank patch)|"The study group was treated with traditional Chinese moxibustion and western medicine. The control group was treated with blank moxibustion and western medicine.~The study group: Using the moxibustion, select specific 3 groups of acupoints. Select a group of acupuncture points every day, in the moxibustion treatment for 20 minutes, 4 weeks for a course of treatment.~The control group: Using the moxibustion with blank patch, select specific 3 groups of acupoints. Select a group of acupuncture points every day, in the moxibustion treatment for 20 minutes, 4 weeks for a course of treatment.~The treatment period is 4 weeks, which is a course of treatment, and the observation period is 8 weeks."
89375509|NCT06171295|Other|PK of Levobupivacain|Newborns who received epidural anesthesia with Levobupivacain
89375510|NCT06171282|Experimental|Experimental: R130 Treatment Group|Every 7-14 days,1-2 ml R130 （concentration of 1x10^8 plaque-forming Units/mL,PFU/mL）will be injected intratumoral in patients with relapsed/refractory bone and soft tissue tumors.
89375511|NCT06171243||PK/PDLido|Patients over 50 years old, with neuropathic pain who are hospitalized at UC-Christus Clinical Hospital, will be candidates for recruitment to the study.
89375512|NCT06171217|Experimental|Original Cohort|The original REACH cohort continuing study treatment per the protocol schedule of evaluations.
89375513|NCT06171217|Experimental|New Cohort|Newly enrolled REACH participants consent, 3 months screening, and treatment per the protocol schedule of evaluations
89375514|NCT06171139|Experimental|Stage 1: Tool Development|Participants will participate in a semi-structured qualitative interview either by phone, video conference or in-person. A trained interviewer will interview eligible, consenting participants using a semi-structured interview guide to meet objectives. The interview guide is based on The Patient Education Materials Assessment Tool (PEMAT) and the COM-B (capability (C), opportunity (O), and motivation (M))/Behaviour Change Wheel (BCW) framework and will be used to determine an implementation strategy. The interview will be audio-recorded, transcribed verbatim, and analyzed.
89375515|NCT06171139|Experimental|Stage 1: Tool Implementation (Pilot Study)|Participants will receive the tumor genetic pre-test counseling tool informed by results and themes identified in Stage 1. Participants will receive the non-therapeutic intervention, a pre-TGT counseling tool, and complete pre- and post-intervention surveys and a attend a brief post-intervention interview.
89375516|NCT06171126|Placebo Comparator|Placebo|Own faeces instilled to the small intestine during gastroscopy
89375517|NCT06171126|Experimental|Arm A|90g of faeces from Donor A is instilled to the small intestine during gastroscopy
89375518|NCT06171126|Experimental|Arm B|90g of faeces from Donor B is instilled to the small intestine during gastroscopy
89375519|NCT06171126|Experimental|Arm C|90g of faeces from Donor C is instilled to the small intestine during gastroscopy
89375520|NCT06171087|Active Comparator|Domperidon|Participants recieve 10mg of Domperidon, 45 minutes before the start of the experiment
89375521|NCT06171087|Placebo Comparator|Placebo|Participants recieve a placebo pill, 45 minutes before the start of the experiment
89375522|NCT06171074|Experimental|CM310|CM310, Subcutaneous injection
89375523|NCT06171061|Experimental|Experimental group|basic medication + Yangxinshi tablet
89375524|NCT06171061|Other|Control group|basic medication.
88847543|NCT03769207|Other|Ambulatory ECG|
89375525|NCT06171048|Experimental|Group A|CM310 injection, Subcutaneous
89375526|NCT06171048|Experimental|Group B|CM310 injection, Subcutaneous
89375527|NCT06171009|Active Comparator|Pain Coping Information|
89375528|NCT06171009|Experimental|Mindful Pain Management|
88847544|NCT02973464||Valganciclovir 900mg a day|Valganciclovir 900mg tablet by mouth begin within 10 days after renal transplant，once a day till to Day 100 posttransplant.
89181744|NCT02687841|Active Comparator|PTX|Pentapentoxifylline 400mg QD for 10 days
89181745|NCT04076475|Experimental|electrical stimulation|receive daily NMES for 30 min/session for 10 days.
89375529|NCT06170996|Experimental|Internet-Assisted behavioral parent training (IA-BPT)|Internet-Assisted behavioral parent training in group format, 8 sessions over 2 months, delivered by systematically trained and supervised psychologists.
89375530|NCT06170996|No Intervention|General clinical care (GCC)|General clinical care for 2 months, delivered by experienced child psychiatrists, including medication treatment and examinations, crisis-interventions, parent counselling and support.
89375531|NCT06170983|Experimental|Pilot Cohort for Skin Inflammation|Testing skin inflammation
89375532|NCT06170983|Experimental|Azithromycin and Artificial Skin Inflammation|Investigating tissue PK of Azithromycin in artificially inflamed tissue
89375533|NCT06170983|Experimental|Azithromycin and Skin Infection|Investigating tissue PK of Azithromycin in actually infected tissue
89375534|NCT06170957|Experimental|Experimental group|For the experimental group; A modified pacifier will be given to the newborn during the heel blood collection procedure.
89375535|NCT06170957|No Intervention|Control group|For the control group; The newborn will not be given a modified pacifier during the heel blood collection procedure.
89375536|NCT06170931|Active Comparator|A knee of a patient with osteoarthritis of both knees|Posterior cruciate ligament protective approach in patients with knee osteoarthritis
89375537|NCT06170931|Active Comparator|The other knee of a patient with osteoarthritis in both knees|Posterior cruciate ligament transection approach in patients with knee osteoarthritis
89375538|NCT06170918|Experimental|remimazolam|Remimazolam is given for anesthesia induction. The initial dosage is 0.4mg/kg, and the interval dosage is 0.02mg/kg.
89375539|NCT06170892|Experimental|Kangaroo method|The newborns were placed in the kangaroo position in a single session, and the variables were identified before, during and after the application of the technique.
89375540|NCT06170866|Experimental|Social support for physical activity|Socially supported (peer, family and group) physical activity group.
89375541|NCT06170853|Experimental|Augmented reality glasses group|Three days a week (12 weeks in total), each session will be 60 minutes in total, and moderate exercise will be done with AR glasses.
89375542|NCT06170853|No Intervention|Control group|No intervention/application will be made to the children who will be included in the control group.
89375543|NCT06170827|Experimental|AIO-001 (Formulation A)|400 milligram (mg) of 100 milligrams per milliliter (mg/ml) AIO-001 Subcutaneous (SC) injection will be administered.
89375544|NCT06170827|Experimental|AIO-001 (Formulation B)|400 mg of 182 mg/ml AIO-001 SC injection will be administered.
88847545|NCT02973464||Valganciclovir 450mg a day|Valgancigclovir 450 mg tablet by mouth begin within 10 days after renal transplant，once a day till to Day 100 posttransplant.
88847546|NCT02973464||Ganciclovir|Ganciclovir 5mg/kg fluids by intravenous after renal transplant，once a day for the first 14 days；and than sequential Ganciclovir 1g tablet by mouth，third a day till to Day 100 posttransplant.
88847547|NCT03766165|Experimental|Intervention|Job announcements plus educational sessions, mentoring, behavioral economic text messages, and a start-up grant.
88847548|NCT03766165|Other|Control|Job announcements only
88847549|NCT03109873|Experimental|Arm I (EBRT, metformin hydrochloride)|Patients undergo External Beam Radiation Therapy (EBRT). Beginning 1 week prior to start of EBRT, patients receive metformin hydrochloride PO QD for 3 days and BID thereafter until 2 weeks after completion of EBRT.
89181746|NCT04076475|Sham Comparator|Control|receive similar electrical stimulation (ES) procedure as those in the intervention group but with ES machine power off.
89181747|NCT05121441|Experimental|ARD-101|Dose 200 mg of ARD-101, twice daily for 28 days
89181748|NCT05121441|Placebo Comparator|Placebo Comparator|Placebo arm matching active arm ARD-101, 200 mg BID
89375545|NCT06170775|Experimental|Sodiumhexametaphosphate|
89375546|NCT06170775|Active Comparator|MTA|
89375547|NCT06170762|Experimental|Sodiumhexametaphosphate|
89375548|NCT06170762|Active Comparator|MTA|
89375549|NCT06170710|Experimental|RT+ cisplatin+Anti-PD-1 antibody|Concurrent cisplatin-RT followed by PD-1 antibody
89375550|NCT06170710|Active Comparator|RT+ cisplatin|Concurrent cisplatin-RT
89375551|NCT06170684||complete remission|
89375552|NCT06170684||non-complete remission|
89375553|NCT06170658|Experimental|Test Lenses, Then Control Lenses|Participants will wear the Test Lenses in both eyes for one week and then cross over to the Control Lenses in both eyes for one week.
89375554|NCT06170658|Experimental|Control Lenses, Then Test Lenses|Participants will wear the Control Lenses in both eyes for one week and then cross over to the Test Lenses in both eyes for one week.
89375555|NCT06170593|Experimental|Treatment group|Participants will receive injections of 1% triamcinolone into at least 1 and up to 3 facial inflammatory acne lesions. Participants will return to clinic at 24, 48, 72 hours, 7 days, and 14 days following injection for follow up assessment and photography.
89375556|NCT06170580||Participants with carotid artery stenosis|
89375557|NCT06170580||Healthy controls|Participants without carotid artery stenosis
89375558|NCT06170541|Experimental|UHR-CT (Ultra-High-Resolution Computed Tomography-Aquilion Precision)|Participants in this arm undergo CT scans using the Ultra-High-Resolution CT imaging modality.
89375559|NCT06170541|Active Comparator|CR-CT (Conventional Resolution Computed Tomography)|Participants in this arm receive CT scans using the Conventional Resolution CT imaging modality.
89375560|NCT06170528|Other|Mild ADRA and their caregivers|Deployed the AURA_ALZ system at Home
89375561|NCT06170515|Other|BGM Evaluation|
89375562|NCT06170515|Other|HbA1c evaluation|
89375563|NCT06170502|Experimental|mobile application development and implementation|"The aim of the project is to develop and evaluate the effectiveness of a mobile application (AkilMobil) that prevents parents who continue to use drugs for their children at home after their child is discharged from the hospital. The research is a randomized controlled experimental study. In the study, The Form for Determining the Educational Needs of Parents Administering Medicines at Home, Introductory Information Form, Parental Drug Preparation Information Evaluation Form, Parent Evaluation Form in Suspension Drug Administration, Capsule Drug Application Parent Evaluation Form, developed by the researchers in line with the literature, Tablet Pharmaceutical Application Parent Evaluation Form, Mobile Application Usability Questionnaire, AkilMobil Expert Opinion Evaluation Form and STAI State Anxiety Inventory developed by Spielberger et al. will be used."
88847550|NCT03109873|Placebo Comparator|Arm II (EBRT, placebo)|Patients undergo External Beam Radiation Therapy (EBRT). Beginning 1 week prior to start of EBRT, patients receive placebo PO QD for 3 days and BID thereafter until 2 weeks after completion of EBRT.
88847551|NCT04713254|Experimental|Lu AG06466|
88847552|NCT04092907|Experimental|HBM9036 0.25% Ophthalmic Solution|HBM9036, Ophthalmic Solution, twice a day, in the morning and evening
88847553|NCT04092907|Placebo Comparator|Placebo Ophthalmic Solution|placebo, Ophthalmic Solution, twice a day, in the morning and evening
88847554|NCT04086433||Arm A - Echelon Stapler|"Excised gastric tissue specimens will be resected with the Echelon Stapler (Ethicon, size: 60mm, Echelon) and evaluated for burst pressure and staple malformation"
88847555|NCT04086433||Arm B - Titan Stapler|"Excised gastric tissue specimens will be resected with the Titan SGS Stapler (Standard Bariatrics, Titan) and evaluated for burst pressure and staple malformation"
88847556|NCT04710212||Induction Chemotherapy for Acute Leukemia|Receiving induction chemotherapy for acute leukemia, and receiving fluoroquinolone (FQ) prophylaxis.
88847557|NCT04710212||Hematopoietic stem cell transplantation (HCT)|Undergoing hematopoietic stem cell transplantation (HCT), and receiving fluoroquinolone (FQ) prophylaxis.
88847558|NCT03764449|Experimental|Cohort 1|Participants received the study drug at dose level A in 2 periods. There was a minimum of a 14-day wash out period between Day 1 of Period 1 and Day 1 of Period 2.
88847559|NCT03764449|Experimental|Cohort 2|Participants received the study drug at dose level B in 2 periods. There was a minimum of a 14-day wash out period between Day 1 of Period 1 and Day 1 of Period 2.
88847560|NCT04084015|Experimental|Early axillary Impella®|Early placement of axillary Impella® for LV unloading and LV recovery in patients with VA ECMO
88847561|NCT03061279|Experimental|Fixation by Acutrak headless screw|
88847562|NCT03061279|Active Comparator|Fixation by headed screws, plates and or wire|DePuy-Synthes Cannulated Cancellous Screws, DePuy-Synthes Cancellous Screws, DePuy-Synthes Cortical Screws, DePuy-Synthes 1/3 Tubular Plate, DePuy-Synthes LC-DCP Plate, DePuy-Synthes Pre-contoured Plate, and/or 18g Wire.
88847563|NCT03763747|Experimental|Scoreflex NC Scoring PTCA Catheter|Single arm with investigational Scoreflex NC Scoring PTCA catheters
88847564|NCT03758365|Experimental|MC2-01 Cream|Single application of MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%) cream
88847565|NCT03758365|Active Comparator|Clobetasol propionate 0.05% lotion|Single application of Clobetasol propionate 0.05%,
88847566|NCT03758365|Active Comparator|Betamethasone dipropionate 0.05% cream|Single application of Betamethasone dipropionate 0.05%,
88847567|NCT03758365|Active Comparator|Triamcinolone acetonide 0.1% cream|Single application of Triamcinolone acetonide 0.1%,
88847568|NCT03758365|Active Comparator|Hydrocortisone Butyrate 0.1% cream|Single application of Hydrocortisone Butyrate 0.1% Cream
88847569|NCT03758365|Active Comparator|Desonide 0.05% cream|Single application of Desonide 0.05%
88847570|NCT03758365|Placebo Comparator|Vehicle cream|Single application of Vehicle
88847571|NCT03757039|Experimental|Multifocal Contact Lenses|Multifocal soft contact lenses according to the subject's prescription and fitted using the Alcon multifocal fitting guide. Lenses were worn bilaterally (in both eyes) for up to 3 hours, 1 day only.
88847572|NCT03757039|Active Comparator|PAL Spectacles|Progressive addition lens spectacles according to the subject's habitual prescription, with testing up to 3 hours, 1 day only.
88847573|NCT00381212|Experimental|1|AGS-004 immunotherapeutic injections.
88847574|NCT04072237|Experimental|Study Population|MarzAA (Coagulation Factor VIIa variant) 18 µg/kg intravenously (Stage 1) followed by MarzAA 30 µg/kg subcutaneously (SC) (Stage 2), MarzAA 45 µg/kg SC (Stage 3), MarzAA 60 µg/kg SC (Stage 4), MarzAA 2x30 µg/kg SC (Stage 5), MarzAA 90 µg/kg SC (Stage 6), MarzAA 120 µg/kg SC (Stage 7), MarzAA 2×60 µg/kg SC (Stage 8), MarzAA 3x60 µg/kg SC (Stage 9)
89189327|NCT00620542|Active Comparator|Atorvastatin 40 mg|Atorvastatin 40 mg distributed in 2-week run-in period
89189328|NCT00620542|Experimental|Rosuvastatin 40 mg|Rosuvastatin 40 mg distributed in core 2-year study
88847575|NCT00381290|Active Comparator|1|Participants will follow an exercise regimen
88847576|NCT00381290|Active Comparator|2|Participants will follow a calorie-restricted diet
88847577|NCT00381290|Active Comparator|3|Participants will follow a calorie-restricted diet and an exercise regimen
88847578|NCT03743311||Surgical treatment of Hemmorhoid|Patients after surgical treatment (Instrumental Invasive Surgical Procedures or Thrombectomy, Hemorrhoidectomy etc.)
88847579|NCT03743311||Conservative treatment of Hemmorhoid|Patients taken conservative treatment (Detralex)
88847580|NCT03743311||Combined treatment of Hemmorhoid|Combined treatment patients (surgery and conservative treatment)
88847581|NCT04714177|Experimental|Edaravone Dexborneol|Edaravone Dexborneol injection
88847582|NCT04714177|Placebo Comparator|Placebo|Edaravone Dexborneol matching injection
88847583|NCT03740659|Experimental|Levofloxacin + Dexamethasone|"Levofloxacin 5 mg/ml + Dexamethasone 1 mg/ml (30 μl administered twice before Limbal paracentesis).~Limbal paracentesis will be performed prior to cataract surgery."
88847584|NCT03740659|Active Comparator|Levofloxacin|"Levofloxacin 5 mg/ml (30 μl administered twice before Limbal paracentesis).~Limbal paracentesis will be performed prior to cataract surgery."
88847585|NCT03740659|Active Comparator|Dexamethasone|"Dexamethasone 1.14 mg/ml (26 μl administered twice before Limbal paracentesis).~Limbal paracentesis will be performed prior to cataract surgery."
88847586|NCT03738163|Other|Epaderm Cream|This is an open, non randomised single arm study.
88847587|NCT02757547|Placebo Comparator|Transcranial magnetic stimulation - Placebo Arm|A placebo TMS coil is used.
88847588|NCT02757547|Active Comparator|Transcranial magnetic stimulation - Active Arm|An active TMS coil is used.
88847589|NCT02721277|Experimental|SMOFlipid|Subjects with cholestasis will receive 3 G/kg/day of intravenous SMOFlipid daily until parenteral nutrition (PN) is discontinued. In addition, the following monitoring for effects of SMOFlipid will be performed: total days of parenteral nutrition, maximum conjugated bilirubin, time to resolution of bilirubin, time to liver transplant, time to death, positive blood cultures, rates of increase in weight, length, and head circumference, time dependent changes in liver function tests, including triglycerides, and length of hospital stay.
88847590|NCT03733483|Experimental|Sleep Deprivation|
88847591|NCT05752370|Experimental|High flow oxygen|High flow nasal oxygen
88847592|NCT05752370|Active Comparator|Usual care|room air or normal flow oxygen
88847593|NCT00378547|Placebo Comparator|Paracetamol|Oral paracetamol 1 g + placebo + placebo
88847594|NCT00378547|Experimental|Paracetamol + Pregabalin|Oral paracetamol 1g + oral pregabalin 300 mg + placebo
88847595|NCT00378547|Experimental|Paracetamol + pregabalin + dexamethasone|Oral paracetamol 1g + oral pregabalin 300 mg + IV dexamethasone 8 mg
88847596|NCT02658877|Experimental|Omalizumab|
88847597|NCT02658877|Placebo Comparator|Placebo|
88847598|NCT02589145|Experimental|Lenalidomide + Vorinostat/Gem/Bu/Mel + AutoSCT|"Vorinostat and lenalidomide administered orally at the same time within 1 hour before the daily dose of chemotherapy.~Gemcitabine administered as a loading dose of 75 mg/m2 followed by infusion on days -8 and -3.~Busulfan test dose administered as outpatient before admission, or as inpatient on day -10. The test dose of 32 mg/m2 based on actual body weight. Doses of days -6 and -5 subsequently adjusted to target an AUC of 4,000 microMol.min-1.~Melphalan administered at 60 mg/m2 on days -3 and -2.~Patients with CD20+ tumors receive rituximab 375 mg/m2 on day -9 in the AM as an inpatient.~Dexamethasone 8 mg by vein twice a day from day -8 to day -2. Caphosol oral rinses 30 mL four times a day used from day -8. Oral glutamine, 15 g four times a day, swished, gargled and swallowed started on day -8.~Pyridoxine 100 mg by vein or mouth three times a day from day -1. Enoxaparin 40 mg subcutaneously daily from admission until platelet count drops below 50,000/mm3."
88847599|NCT02568007|No Intervention|No Cyproheptadine treatment|Patients will receive standard of care behavior and nutritional interventions. They will not receive cyproheptadine.
89181749|NCT04011267|Experimental|Intervention Group|Patients in the intervention group will perform foot-related exercises described in the SOPeD software three times/week at home via web-software. In the follow-up period, patients will follow the same schedule set by the project till the end of the study.
89181750|NCT04011267|No Intervention|Control Group|Participants in the control group will not receive any specific intervention in addition to the treatment recommended by the health professionals team (doctors, nurses, podiatrists), which includes pharmacological treatment, and self-care recommendations and foot care by international consensus.
89181751|NCT00778622|Experimental|A1|Normal Weight by Body Weight Index
89181752|NCT00778622|Experimental|A2|Overweight by Body Weight Index
89181753|NCT00778622|Experimental|A3|Obese by Body Weight Index
89181754|NCT00915980||Patients without diabetes undergoing gastric bypass|
89181755|NCT00777920|Experimental|Ambrisentan|Participants will receive ambrisentan 2.5 mg, 5 mg or 10 mg tablet orally once daily until such time as the investigator or participant chooses to stop ambrisentan treatment, ambrisentan becomes commercially available, or the sponsor stops the study.
88847600|NCT02568007|Experimental|Continuous Cyproheptadine|Patients will receive standard of care behavior and nutritional interventions. They will receive cyproheptadine every day for a total of two months. Standard dose of 0.25 mg/kg divided BID will be used.
88847601|NCT02568007|Experimental|Cycled Cyproheptadine|Patients will receive standard of care behavior and nutritional interventions. They will receive cyproheptadine every day for two weeks cycled with no cyproheptadine given for two weeks for a total of two months. Patients on cycled dosing will be given cyproheptadine for two weeks, then no medication for two weeks; repeating this cycle for the two month duration of study
88847602|NCT02549755|Other|Radiotherapy treatment monitoring of hepatocellular carcinoma|All patients enrolled in the trial will undergo 3 PET/CT studies using 11C-acetate at the injected radiotracer. The patients will be imaged prior to their radiation therapy and at 1 and 3 months following the completion of their radiation therapy. They will also undergo an MRI scan of the liver at each of those time points.
88847603|NCT04024501|Experimental|Treatment 1|During this treatment period, healthy participants will receive 1 x 12 mg verinurad ER8 capsule formulation in fasted state.
88847604|NCT04024501|Experimental|Treatment 2|During this treatment period, healthy participants will receive 2 x 6 mg verinurad A-capsule formulation in fasted state.
88847605|NCT04024501|Experimental|Treatment 3|During this treatment period, healthy participants will receive 2 x 6 mg verinurad A-capsule formulation in fed state.
88847606|NCT04024501|Experimental|Treatment 4|During this treatment period, healthy participants will receive 2 x 6 mg verinurad B-capsule formulation in fasted state.
88847607|NCT04024501|Experimental|Treatment 5|During this treatment period, healthy participants will receive 2 x 6 mg verinurad B-capsule formulation in fed state.
88847608|NCT05717348|Experimental|Part 1 dose escalation|ES014 doses will be escalated in patients with advanced solid tumors.
88847609|NCT05717348|Experimental|Part 2 dose expansion|Part 2 of the study will consist of 4 expansion cohorts at the recommended optimal biological dose determined in Part 1 dose escalation.
88847610|NCT05709626|Active Comparator|No aspirin (Prasugrel monotherapy)|To start prasugrel monotherapy before primary percutaneous coronary intervention (PCI).
88847611|NCT05709626|Active Comparator|12-month DAPT|To start dual antiplatelet therapy with prasugrel and aspirin for 12 months before primary percutaneous coronary intervention (PCI).
88847612|NCT05707364||Practices Engaged for Pre-Visit Lab Clinic Workflow|Providers and patients/ at the designated practice sites
88847613|NCT03538015|Experimental|Carvedilol 3.125 mg|After enrollment, participants will be placed on continuous glucose monitoring (CGM). One week after CGM placement, participants will undergo the first hypoglycemic clamp study to obtain baseline measures of hypoglycemia frequency, hypoglycemia awareness scores and hormone responses. Following the initial clamp procedure, participants will receive 4 weeks of low-dose carvedilol treatment. After 4 weeks of treatment, the participants will undergo a second hypoglycemic clamp session.
89181756|NCT04236141|Experimental|Polatuzumab Vedotin plus BR|
89181757|NCT04236141|Active Comparator|Placebo plus BR|
89181758|NCT02601248|Experimental|Theliatinib|Theliatinib investigational product once a day (QD) will be orally administrated on a 28-day cycle There are 5 dose cohorts,including120mg/160mg/200mg/220mg/300mg, QD in the dose escalation stage .
89181759|NCT00916682||Cystic Fibrosis|
89181760|NCT04097522|Active Comparator|real neurofeedback|Participants receive neurofeedback from a region of the brain thought to be associated with increasing pain resilience
89181761|NCT04097522|Sham Comparator|sham neurofeedback|Participants receive neurofeedback from a region of the brain thought to be unrelated with increasing pain resilience
89181762|NCT04233099||Healthy Subjects|20 Healthy subjects in a good state of health comparable by age and sex with the other selected groups
88847614|NCT03538015|Experimental|Carvedilol 2.5 mg|After enrollment, participants will be placed on continuous glucose monitoring (CGM). One week after CGM placement, participants will undergo the first hypoglycemic clamp study to obtain baseline measures of hypoglycemia frequency, hypoglycemia awareness scores and hormone responses. Following the initial clamp procedure, participants will receive 4 weeks of low-dose carvedilol treatment. After 4 weeks of treatment, the participants will undergo a second hypoglycemic clamp session.
88847615|NCT03538015|Placebo Comparator|Placebo capsule|After enrollment, participants will be placed on continuous glucose monitoring (CGM). One week after CGM placement, participants will undergo the first hypoglycemic clamp study to obtain baseline measures of hypoglycemia frequency, hypoglycemia awareness scores and hormone responses. Following the initial clamp procedure, participants will receive 4 weeks of placebo treatment. After 4 weeks of treatment, the participants will undergo a second hypoglycemic clamp session.
88847616|NCT05752214||Group A|
88847617|NCT03342157|Experimental|High-dose|8.6/50 mg of senna/docusate, oral, twice daily
88847618|NCT03342157|Experimental|Low-dose|8.6/50 mg of senna/docusate, oral, once daily
88847619|NCT04331210|Active Comparator|Group 1|Using diclofenac sodium suppository 50 mg immediately after suturing and then every 8 hours
88847620|NCT04331210|Active Comparator|Group 2|Using diclofenac sodium tablets 50 mg every 8 hours after birth
88847621|NCT04016077|Experimental|PF-06651600 Moderate Hepatic Impairment|This arm includes participants with moderate hepatic impairment who will receive oral doses of PF-06651600 30 mg on Day 1 through Day 10.
88847622|NCT04016077|Experimental|PF-06651600 Healthy participants|This arm includes healthy adult participants who will receive oral doses of PF-06651600 30 mg on Day 1 through Day 10.
88847623|NCT04016077|Experimental|PF-06651600 Mild Hepatic Impairment|"This arm is in Part 2 which will be conducted if the decision criterion to proceed to Part 2 is met.~The arm includes participants with mild hepatic impairment who will receive oral doses of PF-06651600 30 mg on Day 1 through Day 10."
88847624|NCT04021771|Other|Group A (Intervention Group)|Participants will have at least three study visits. The first visit (T1) will consist of a baseline test, during which participants will complete a simulated encounter with a standardized patient (SP) to establish a baseline score. Participants in Group A will be given access to the online interactive module and will have the opportunity to have video-based DP sessions with the SPs. The second visit (T2) will be scheduled 4-8 weeks after T1 and will consist of another simulated encounter with the SP. Group A will return for a third visit (T3) to provide information about the decay of learned skills and if performance on the task is maintained by a single intervention.
88847625|NCT04021771|Other|Group B (Control Group)|Participants will have at least three study visits. The first visit (T1) will consist of a baseline test, during which participants will complete a simulated encounter with a standardized patient (SP) to establish a baseline score. The second visit (T2) will be scheduled 4-8 weeks after T1 and will consist of another simulated encounter with the SP; following this session, participants in Group B will be introduced to the intervention. Group B will return for a third visit (T3) to provide information on how the curriculum impacts their score.
88847626|NCT05701436|Experimental|the test group|The test group received postoperative conventional treatment combined with precise transarterial chemoembolization based on 3D-HDRA results. Precise transarterial chemoembolization at 1-month intervals for 4 months after surgery.
89535033|NCT05015595|Active Comparator|Memantine|"For thirty-two-week double-blind up-titration treatment period (from T0 to T4) each patient will receive a daily administration of Memantine up to 20mg/day.~Subsequently, each patient will undergone to a double-blind down-titration treatment period for eight-weeks (from T4 to T5). At T4, the dose of Memantine will be reduced at 10mg/day due to safety reasons before the end of treatment (T5)."
88847627|NCT05701436|Active Comparator|the control group|The control group received postoperative conventional treatment combined with Empirical transarterial chemoembolization. Empirical transarterial chemoembolization at 1-month intervals for 4 months after surgery.
88847628|NCT02487277|Experimental|Combination therapy with 1 week Run-In|"PEGPH20: 3ug/kg on Days 1 and 4~1 cycle = 28 days~PEGPH20: 3ug/kg on Days 1, 8, 15~Gemcitabine: 1000mg/m^2 on Days 1, 8, 15~Nab-paclitaxel: 125mg/m^2 on Days 1, 8, 15"
88847629|NCT02487277|Experimental|Combination therapy alone|"1 cycle = 28 days~PEGPH20: 3ug/kg on Days 1, 8, 15~Gemcitabine: 1000mg/m^2 on Days 1, 8, 15~Nab-paclitaxel: 125mg/m^2 on Days 1, 8, 15"
88847630|NCT02436265|Sham Comparator|Group 1 Ropivacaine|Group 1 Ropivacaine Intervention: Each patient will receive a caudal with 1ml/kg of 0.2% ropivacaine
88847631|NCT02436265|Active Comparator|Group 2 Ropivacaine and Dexamethasone|Group 2 Ropivacaine/dexamethasone Intervention: Each patient will receive a caudal with 1ml/kg of 0.2% ropivacaine and 0.1mg/kg of intravenous dexamethasone immediately after caudal placement
88847632|NCT04016623|Experimental|1-day toric test contact lens|Each subject will wear the 1-day toric test (Test) lens in one eye and 1-day toric control (Control) contact lens in the other eye. Patient will wear as an unmatched pair, per predetermined randomization schedule (to determine which eye receives the Test or Control contact lens).
88847633|NCT04016623|Active Comparator|1-day toric control contact lens|Each subject will wear the 1-day toric test (Test) lens in one eye and 1-day toric control (Control) contact lens in the other eye. Patient will wear as an unmatched pair, per predetermined randomization schedule (to determine which eye receives the Test or Control contact lens).
88847634|NCT05751746||Control|Control group with participants who do not get magnesium sulfate administration.
88847635|NCT05751746||Magnesium group|Intervention group with participants who get magnesium sulfate administration.
89181763|NCT04233099||Amyotrophic Lateral Sclerosis with Bulbar onset|20 subjects affected by Amyotrophic Lateral Sclerosis with Bulbar onset, comparable by age and sex with the other selected groups
89181764|NCT04233099||Amyotrophic Lateral Sclerosis with Spinal onset|20 subjects affected by Amyotrophic Lateral Sclerosis with Spinal onset, comparable by age and sex with the other selected groups
89181765|NCT04233099||Parkinson's Disease|20 subjects affected by Parkinson's Disease comparable by age and sex with the other selected groups
89535034|NCT05015595|Placebo Comparator|Placebo|"For thirty-two-week double-blind up-titration treatment period (from T0 to T4) each patient will receive a daily administration of placebo 20 mg/day.~Subsequently, each patient will undergone to a double-blind down-titration treatment period for eight-weeks (from T4 to T5). At T4, the dose of Placebo will be reduced at 10mg/day, following the study protocol, before the end of treatment (T5)."
88847636|NCT03316105|Active Comparator|Transcutaneous electrical nerve stimulation (TENS) stimulation|During this TENS unit stimulation arm, subjects will have a narrow tube (about the diameter of a telephone cord) placed into the subjects small intestine by the study physician and trained technician. The technician will use a small amount of fluoroscopy (radiation) to make sure the tube is placed in the proper position. About one hour after the tube has been placed subjects will be given a breakfast meal. The narrow tube (GDM) will take pressure readings after being placed. After four hours, subjects will again be given a second meal. Fifteen minutes of electrical stimulation will be given to subjects fifteen minutes before ingestion of lunch. After ingestion of lunch, 60 minutes of the electrical stimulation will be applied. When the test is done, the tube will be removed.
88847637|NCT03316105|Sham Comparator|No TENS stimulation|During this no TENS unit stimulation arm, subjects will have a narrow tube (about the diameter of a telephone cord) placed into the subjects small intestine by the study physician and trained technician. The technician will use a small amount of fluoroscopy (radiation) to make sure the tube is placed in the proper position. About one hour after the tube has been placed subjects will be given a breakfast meal. The narrow tube (GDM) will record stomach pressure readings after being placed. After four hours, subjects will again be given a second meal. The TENS unit stimulation will be placed but no electrical stimulation will be given. When the test is done, the tube will be removed.
88847638|NCT03277183|Placebo Comparator|Low dose erythropoietin|Subjects randomized to this arm will receive low-dose of EPO administered thrice weekly
88847639|NCT03277183|Experimental|High dose erythropoietin|Subjects randomized to this arm will receive the same cumulative dose of EPO administered as a high-dose of EPO every 2 weeks
88847640|NCT01525927|Active Comparator|Chemotherapy non-responders|Patients treated with three cycles neoadjuvant chemotherapy who do not exhibit response to chemotherapy are then allocated to recieve standard dose and schedule radiotherapy.
88847641|NCT01525927|Experimental|Chemotherapy responders|Patients who respond to chemotherapy are treated with reduced dose radiotherapy.
88847642|NCT04013737||Patients and Public|Exploration of patient and public engagement with antibiotic decision making in secondary care. Prospective evaluation of a co-designed intervention to support enhanced knowledge and understanding of infections and their management.
88847643|NCT04013737||Prescribers|Quantitative evaluation of the impact of using a clinical decision support system to support antibiotic decision making.
88847644|NCT05670470|Experimental|CTP0303|
88847645|NCT05670470|Active Comparator|Orafang Tab|
88847646|NCT04011631|Experimental|Patients with cardiac surgery|All patients undergoing cardiac surgery at the Ziekenhuis Oost-Limburg, meeting all inclusion and no exclusion criteria, are asked to participate in the investigation.
88847647|NCT05751512|Experimental|MRG003|MRG003 will be administrated via intravenous infusion at 2.3 mg/kg once on Day 1 of every 3 weeks (21-day cycle).
88847648|NCT05751512|Active Comparator|cetuximab/ methotrexate|cetuximab (400 mg/m2 for the first week and 250 mg/m2 for subsequent weeks, QW) or methotrexate (40 mg/m2, IV, QW)
88847649|NCT02373865|Experimental|Arm A|Patients receiving Sitagliptin 100 mg+ Glimepiride-placebo (adapted dosage)
88847650|NCT02373865|Active Comparator|Arm B|Glimepiride (adapted dosage) + Sitagliptin 100 mg Placebo
88847651|NCT02360059|Experimental|Metformin Group|"Participants take 1,000 mg Metformin by mouth twice daily for 12 weeks during Paclitaxel treatment.~Adaptation phase begins 12 days prior to the start of the Paclitaxel therapy. During this phase, study medication dose starts at 500 mg daily for 5 days, followed by 500 mg twice daily for 5 days, followed by the desired dose of 1,000 mg twice daily for 2 days. Participants reach required study medication dose of 2,000 mg daily 2 days prior to commencement of Paclitaxel therapy and continue this dose for remainder of intervention.~Questionnaires completed about numbness and/or symptoms about 2 weeks before start of Paclitaxel, 1 -2 days before Paclitaxel, every week while taking Paclitaxel, and at end of study visit. At week 12, questionnaire completed regarding satisfaction with Paclitaxel.~Three sensory and fine-motor tests completed 2 weeks before Paclitaxel, every 3 weeks while taking Paclitaxel, and at end of study visit."
88847652|NCT02360059|Placebo Comparator|Placebo Group|"Participants take placebo by mouth twice daily starting 12 days before, and 12 weeks during Paclitaxel treatment.~Questionnaires completed about numbness and/or symptoms about 2 weeks before start of Paclitaxel, 1 -2 days before Paclitaxel, every week while taking Paclitaxel, and at end of study visit. At week 12, questionnaire completed regarding satisfaction with Paclitaxel.~Three sensory and fine-motor tests completed 2 weeks before Paclitaxel, every 3 weeks while taking Paclitaxel, and at end of study visit."
88847653|NCT04006795|Experimental|Developmental Serum|All participants in induction phase will be topically applied 2 semi-occlusive patch (Monday) containing developmental serum (0.02milliliters per centimeter square[mL/cm^2] in an individual cell of patch) at 2 sites on the dorsum for 24 hours, post patch removal(Tuesday), sites will be cleaned, developmental serum will be re-applied and 1 of the 2 sites will be irradiated with 2.5 Joules per centimeters square(J/cm^2) ultraviolet(UV) A radiation,then with 0.3 minimal erythemal doses(MEDs) of UVA+UVB radiation. 24 hours post irradiation (Wednesday), sites will be assessed and duplicate patches applied as on Monday for 24 hours. Irradiation on Thursday similar to Tuesday and assessment post 24 hour irradiation on Friday. Same process repeated for 3 weeks. In challenge phase all participants will be applied 2 semi-occlusive patches at 2 naive sites for 24 hours, post which 1 site will be irradiated (same as induction phase). Assessment will be after 24, 48 and 72 hours of irradiation
88847654|NCT04006795|Experimental|Developmental Lotion|All participants in induction phase will be topically applied 2 semi-occlusive patch (Monday) containing developmental lotion (0.02mL/cm^2 in an individual cell of patch) at 2 sites on the dorsum for 24 hours, post patch removal(Tuesday), sites will be cleaned, developmental lotion will be re-applied and 1 of the 2 sites will be irradiated with 2.5J/cm^2 UVA radiation, then with 0.3 MEDs of UVA+UVB radiation. 24 hours post irradiation (Wednesday), sites will be assessed and duplicate patches applied as on Monday for 24 hours. Irradiation on Thursday similar to Tuesday and assessment post 24 hour irradiation on Friday. Same process repeated for 3 weeks. In challenge phase all participants will be applied 2 semi-occlusive patches at 2 naive sites for 24 hours, post which 1 site will be irradiated (same as induction phase). Assessment will be after 24, 48 and 72 hours of irradiation
89181766|NCT04233099||Alzheimer's Disease|20 subjects affected by Alzheimer's Disease comparable by age and sex with the other selected groups
89189329|NCT00620542|Active Comparator|Atorvastatin 80 mg|Atorvastatin 80 mg distributed in core 2-year study
89189330|NCT03912792||XLHED Patients|
88847655|NCT04006795|Experimental|Developmental Cream|All participants in induction phase will be topically applied 2 semi-occlusive patch (Monday) containing developmental cream (0.02mL/cm^2 in an individual cell of patch) at 2 sites on the dorsum for 24 hours, post patch removal(Tuesday), sites will be cleaned, developmental cream will be re-applied and 1 of the 2 sites will be irradiated with 2.5J/cm^2 UVA radiation, then with 0.3 MEDs of UVA+UVB radiation. 24 hours post irradiation (Wednesday), sites will be assessed and duplicate patches applied as on Monday for 24 hours. Irradiation on Thursday similar to Tuesday and assessment post 24 hour irradiation on Friday. Same process repeated for 3 weeks. In challenge phase all participants will be applied 2 semi-occlusive patches at 2 naive sites for 24 hours, post which 1 site will be irradiated (same as induction phase). Assessment will be after 24, 48 and 72 hours of irradiation
88847656|NCT04006795|Placebo Comparator|Negative Control|All participants in induction phase will be topically applied 2 semi-occlusive patch (Monday) containing 0.9 percent normal saline (0.02mL/cm^2 in an individual cell of patch) at 2 sites on the dorsum for 24 hours, post patch removal(Tuesday), sites will be cleaned, normal saline will be re-applied and 1 of the 2 sites will be irradiated with 2.5J/cm^2 UVA radiation, then with 0.3 MEDs of UVA+UVB radiation. 24 hours post irradiation (Wednesday), sites will be assessed and duplicate patches applied as on Monday for 24 hours. Irradiation on Thursday similar to Tuesday and assessment post 24 hour irradiation on Friday. Same process repeated for 3 weeks. In challenge phase all participants will be applied 2 semi-occlusive patches at 2 naive sites for 24 hours, post which 1 site will be irradiated (same as induction phase). Assessment will be after 24, 48 and 72 hours of irradiation
88847657|NCT05665790|Experimental|radiotherapy|
88847658|NCT05665790|Experimental|palliative surgery|
88847659|NCT05665790|No Intervention|no primary leison treatment|
88847660|NCT01500109|Experimental|Ofirmev®|Oral inert cherry syrup will be administered preoperatively as placebo for oral acetaminophen. Ofirmev® will be administered in the operating room once intravenous access is established. Patients will receive standardized dose of local anesthetic (Lidocaine 0.5% with Epinephrine) infiltration by the surgeon before surgical incision as well as at the completion of surgery with Bupivacaine 0.25% with Epinephrine. Postoperatively patients will receive Ofirmev® every 6 hours as well as placebo oral cherry elixir every 6 hours and morphine as needed for 24 hours.
89189331|NCT03912792||Healthy Controls|
88847661|NCT01500109|Active Comparator|Oral acetaminophen|Patients will receive oral acetaminophen cherry elixir preoperatively. After intravenous access is obtained intraoperatively patients will receive placebo for Ofirmev® (saline). Patients will receive standardized dose of local anesthetic (Lidocaine 0.5% with Epinephrine) infiltration by the surgeon prior to surgical incision as wel as at the completion of surgery with Bupivacaine 0.25% with Epinephrine. Postoperatively patient will receive oral acetaminophen every six hours and intravenous placebo (normal saline) for intravenous acetaminophen. Intravenous morphine will be administered as needed for 24 hours.
88847662|NCT01500109|Placebo Comparator|Opioid only|This group will receive placebo oral cherry elixir prior to going to the operating room and placebo Ofirmev® after securing intravenous access in the operating room with redosing every six hours. They will receive local anesthetic (Lidocaine 0.5% with Epinephrine) infiltration by the surgeon prior to incision as well as at the completion of surgery with Bupivicaine 0.25% with Epinephrine. Postoperatively they will receive only Morphine prn for pain control.
88847663|NCT02350777|Experimental|active infection and/or organ compromise or GVHD.|This protocol includes two single-arm phase II trials to assess the efficacy and confirm the safety of administration of TCD stem cell boost or bone marrow (BM) HPC (M) boost from the original donor for patients with poor graft function after allogeneic hematopoietic stem cell transplantation.
88847664|NCT02350777|Experimental|active infection, active or controlled GVHD &/or organ compro|This protocol includes two single-arm phase II trials to assess the efficacy and confirm the safety of administration of TCD stem cell boost or bone marrow (BM) HPC (M) boost from the original donor for patients with poor graft function after allogeneic hematopoietic stem cell transplantation.
88847665|NCT01482325|Experimental|Subjects requiring blood pressure monitoring|Any subject (neonate-adult) requiring hospital or clinic blood pressure monitoring
88847666|NCT00002528|Experimental|Surgery w/ axillary clearance, tamox|Either a total mastectomy with axillary clearance, or a lesser procedure (quadrantectomy or lumpectomy with radiotherapy to the conserved breast) with axillary lymph node dissection, and tamoxifen (20 mg) given after surgery for the duration of 5 years or until relapse.
88847667|NCT00002528|Experimental|Surgery w/o axillary clearance, tamox|Either a total mastectomy without axillary clearance, or a lesser procedure (quadrantectomy or lumpectomy with radiotherapy to the conserved breast) without axillary lymph node dissection, and tamoxifen (20 mg) given after surgery for the duration of 5 years or until relapse.
88847668|NCT02341495|Experimental|Drug Treatment|Deferasirox (20mg/kg/day)on days 1-7 of protocol, repeated every four weeks for 8 cycles given PO Cholecalciferol(4,000 units/day), on days 1-7 of protocol, repeated every four weeks for 8 cycles given PO Azacitidine (75mg/m2 subcutaneous or IV administration) on days 1-7 of protocol, repeated every four weeks for 8 cycles given either subcutaneously or IV
88847669|NCT02320825|Experimental|single-fraction SRS (24 Gy)|single-fraction (24Gy) SRS within eight weeks of having undergone spinal decompression surgery.
88847670|NCT02320825|Experimental|high-dose hypofractionated SRS (27 Gy in 3 fractions)|hypofractionated (3 fractions of 9Gy, total dose of 27Gy) SRS within eight weeks of having undergone spinal decompression surgery.
88847671|NCT01477177|Experimental|Polar Wand Treatment|Cryotherapy device utilizing carbon dioxide (room temperature gas) for treatment of GI neoplasia
88847672|NCT05655884|Experimental|Music Listening Application|"Children in this group; 15 minutes before going to the surgery, the child's favorite and chosen music piece will be loaded onto the mp3 player and played by the researcher (who has received music therapy training) via the creatone music pillow for 15 minutes."
89189332|NCT00711048|Experimental|1|30 mg, oral, single dose
89189333|NCT00711048|Experimental|2|95 mg, oral, single dose
89189334|NCT00711048|Placebo Comparator|3|Oral solution, single dose
89189335|NCT04070742|Experimental|FMX-101|
89189336|NCT04269876|Experimental|Marine Lipid Oil concentrate|Dietary Supplement: Marine Lipid oil concentrate softgel and dietary supplement capsules
89189337|NCT04269876|Placebo Comparator|Placebo|Placebo softgels with Placebo capsules
89375564|NCT06170424||experimental gourp|The patients who used the autologous skin cell suspension combined with skin grafting.
89375565|NCT06170424||Control group|The patients who used split-thickness skin grafting.
89375566|NCT06170411|Experimental|Experimental Group|1-hour trigeminal nerve stimulation with the Elexir (program1), as acute treatment of an early stage migraine attack
88847673|NCT05655884|Experimental|Foot Reflexology Practice|Children in this group; Before going to the surgery, foot reflexology will be applied by the researcher (who has received reflexology training), only to the left foot, for 10 minutes.
89375567|NCT06170411|Sham Comparator|Control Group|1-hour trigeminal nerve stimulation with the sham device, as acute treatment of an early stage migraine attack
89375568|NCT06170359||Group 1: those who did not take pregabalin (n:45)|
88847674|NCT05655884|No Intervention|Control Group|Children in this group will not be subjected to any non-pharmacological application to reduce nausea, pain and anxiety before and after surgery. They will receive routine perioperative care administered in the clinic.
88847675|NCT04005391|Experimental|Postpartum Contraceptives offered to Intervention Clusters|"Women will have postpartum contraceptive options (condoms vive amor, birth control pills segura plus, injectable cyclofem, contraceptive implant jadelle) offered to them at their routine forty day postpartum visit after routine care is provided, first."
88847676|NCT04005391|No Intervention|Routine Care offered to Control Clusters|Women will receive routine postpartum care
88847677|NCT00378781|Experimental|Arm I|Minocycline hydrochloride + Edetate Calcium Disodium (M-EDTA) flush solution into CVC once daily.
88847678|NCT00378781|Experimental|Arm II|Heparin flush solution into CVC once daily.
88847679|NCT05750888|Experimental|Experimental group 1|A novel-designed intrinsic foot muscle-strengthening exerciser using 3D printing techniques will be used in the experimental group.
88847680|NCT05750888|Sham Comparator|Experimental group 2|A regular exercise program will be provided in this group.
88847681|NCT05750888|No Intervention|Control group|There is no exercise or other intervention in this group.
88847682|NCT03990415|Experimental|Stay Strong, Stay Healthy Group|The Stay Strong, Stay Healthy strength training group will meet two times per week for an hour, for eight consecutive weeks. This class provides participants a structured program to learn and progress through strength training exercises designed to increase overall fitness, flexibility, and balance.
88847683|NCT03990415|Active Comparator|Walking Group|The walking group will meet two times per week for an hour, for eight consecutive weeks. This class provides participants a structured walking program to help delineate the effects of the strength training program and exercise in general.
88847684|NCT03990415|No Intervention|Delayed Start Group|The delayed start group will not make any changes to their sedentary lifestyle and will be encouraged to not begin any exercise programs throughout the duration of the study.
88847685|NCT00002570|Active Comparator|Fluorouracil and folinic acid|
88847686|NCT00002570|No Intervention|Observation|
88847687|NCT04002973|Experimental|INVSENSOR00037|All subjects who are enrolled into the test group and participate in data collection receive the noninvasive INVSENSOR00037.
89189338|NCT04069806|Experimental|Preoperative oral carbohydrate load|6 hours for solid food and 2 hours for liquids + oral carbohydrate preparation 2 hours prior to surgery.
89189339|NCT04069806|No Intervention|Standard preoperative fasting|6 hours for solid food and 2 hours for liquids.
88847688|NCT03977935|No Intervention|The first-generation MCCG group|"The patients swallowed the first-generation MCCG with a small amount of water in the left lateral decubitus position. Once the capsule reached the stomach after investigating the esophagus, it was lifted away from the posterior wall, rotated and advanced to the fundus and cardiac regions, and then to the gastric body, angulus, antrum and pylorus. After finishing the stomach examination twice, the endoscopist controlled the capsule to face the pylorus and drag it close to the pylorus. The capsule would enter the duodenal bulb and was held stationary to investigate the duodenal bulb using the 360-degree automatic scanning mode. In the descending part of duodenum, the endoscopist tried to control the capsule to view the major papilla. After passing through the duodenum, the capsule started to complete the small-bowel examination with the small-bowel mode. The magnetic steering time for passing through the pylorus was not allowed more than 15 min."
88847689|NCT03977935|Experimental|The second-generation MCCG group|All process in this study were the same except that the second-generation capsule (Ankon Navicam-2) was used in the experimental group.
89375569|NCT06170359||Group 2: those who took pregabalin (n:45)|
89375570|NCT06170307||COVID-19 group|Patients diagnosed with SARS-CoV-2 Omicron variant infection by SARS-CoV-2 RT-PCR test within 3 months who came to our hospital for echocardiography were included in the case group .
89375571|NCT06170307||Control group|Healthy participants were confirmed free of COVID-19 disease by reverse transcriptase-polymerase chain reaction (RT-PCR) testing and computed tomography (CT) imaging.
89375572|NCT06170294|Experimental|TCR-MAGE-A4 T-Cells|The subjects enrolled will be sequentially assigned to the corresponding dose level.
89375573|NCT06170268||Not Applicable/Open Label Registry|ALZ-NET is a growing network of sites that follow participants over time with an expandable platform, allowing for the collection of real-world data from enrolled patients being evaluated for or receiving any novel FDA-approved Alzheimer's disease therapies. ALZ-NET is treatment agnostic. Drug treatment dosage, frequency and duration will be guided by FDA label and clinician judgment as part of treatment and patient management.
89375574|NCT06170255|Experimental|Depression treatment|Participants receive behavioral therapy for depression
89375575|NCT06170242|Experimental|EDP-323 Arm A|Subjects will take EDP-323 Dose 1 orally for 5 days
89375576|NCT06170242|Experimental|EDP-323 Arm B|Subjects will take EDP-323 Dose 2 orally for 5 days
89375577|NCT06170242|Placebo Comparator|Placebo Arm C|Subjects will take matching placebo orally for 5 days
89189340|NCT00851344|Active Comparator|GSK835726 (10mg)|10mg oral dose
89189341|NCT00851344|Active Comparator|GSK835726 (50mg)|50mg oral dose
89189342|NCT00851344|Active Comparator|GSK835726 (100mg)|50mg oral dose
89375578|NCT06170177||Patients underwent radical cystectomy|
89375579|NCT06170138|Experimental|Ampli-01, 3 mg, nicotine pouch|Subjects will report to the study site for a screening visit followed by 3 visits with a single IP use (Visits 2 to 4) on separate days.There will be at least 1 day between Visits 2, 3 and 4, respectively, where the subjects are allowed ad libitum use of their own nicotine product of choice. Each visit will last one day.
89002340|NCT06318806|Active Comparator|Exposure and Response Prevention|ERP will be delivered in accordance with published guidelines and protocols that employ inhibitory learning principles. Following the creation of a hierarchy of feared situations, patients are encouraged to confront their fears (both during and in-between treatment sessions) while abstaining from engaging in compulsions and other neutralizing strategies (i.e., response prevention). Exercises consist of exposure in vivo (i.e., exposure in real life situations) and/or imaginal exposure that are initially conducted in sessions under the therapist's guidance, and then as daily homework designed by the therapist in collaboration with the patient. In accordance with an inhibitory learning model, rather than focusing on habituation to anxiety, exercises aim to maximize outcomes through expectancy violation, deepened extinction, elimination of safety behaviors during exposure, exposure in multiple contexts, and affect labeling during exposure.
89002341|NCT06318806|Experimental|Inference-based Cognitive Behavioral Therapy|CBT will be delivered in accordance with published guidelines and protocols that target the dysfunctional reasoning giving rise to obsessional doubts. The first learning point in I-CBT is that the compulsions, anxiety and discomfort are driven by an initial obsessional doubt. The principal focus of treatment is to show that the doubt is 100% irrelevant in the here and now. To this end the reasoning narrative is identified, including the reasoning distortions contained therein, giving undue credibility to the obsessional doubt. The selective nature of the doubt is underlined by showing the client how under most everyday circumstances his/her reasoning is entirely different from the obsessional situation. This stage also educates the client in the thematic nature of the obsessional doubt and how personal themes dictate the idiosyncratic nature of the person's obsession. The final stage of therapy consists of training the client in the proper use of the senses.
89002342|NCT06318741|Active Comparator|hospital exercise group|According to the Cardiopulmonary exercise test (KPET) test in Group 1 (medium intensity continuous exercise group), 50 minutes (5 minutes warm-up, 40 minutes exercise, 5 minutes exercise, 5 minutes warm-up, 40 minutes exercise, 5 minutes) for 8 weeks, 3 days a week, at an exercise intensity of 50-60% of the VO2 max level recorded individually in the patients. Aerobic exercise therapy will be organized to be applied on a treadmill (in the form of a minute cool-down).
89002343|NCT06318741|Placebo Comparator|home exercise group|For the home exercise group, walking for 50 minutes, 3 days a week, with an intensity of 12-13 Rate of perceived exertion (RPE) according to the Modified Borg scale will be recommended for 8 weeks.
89002344|NCT06318728||High Performance Triathletes Groups|Triathletes who have been practicing the sport for more than 2 years, can maintain a running pace in triathlon competition below 4 minutes and 10 seconds per kilometer for men and 4 minutes and 30 seconds per kilometer for women, and have a weekly running volume exceeding 35 kilometers.
89002345|NCT06318728||Low Performance Triathletes Groups|Triathletes who have completed at least 2 races, maintain a running pace in triathlon competition above 4 minutes and 50 seconds per kilometer for men and 5 minutes and 10 seconds per kilometer for women, and have a weekly running volume below 30 kilometers.
89002346|NCT06318728||Control Group|Physically active individuals, aged between 17 and 52 years, who do not engage in regular running.
89002347|NCT06318715|Experimental|modified deep extubation|This modified deep extubation (mDE) occurs while the patient is still anaesthetized but at a lower dose of anaesthetic gas than previously described, and balanced with long acting opioids to attenuate the airway reaction.
89002348|NCT06318715|Experimental|standard awake extubation|awake extubation (AE) is still considered the standard practice.
89002349|NCT06318676|Experimental|Group A: Participants with severe renal impairment|
89002350|NCT06318676|Experimental|Group B: Participants with End Stage Renal Disease|
89002351|NCT06318676|Experimental|Group C: Participants with normal renal function|
89002352|NCT06318650|Experimental|Allogenic Demineralized Dentin Matrix|Following atraumatic tooth extraction, curettes will be used to remove granulation tissues, and the socket will be irrigated with sterile normal saline.Then the socket will be filled with Allogeneic Dentin Matrix (that has been prepared before) to the crestal level of then bone followed by placement of a collagen membrane to cover the socket. Suturing technique will be a criss-cross horizontal mattress to ensure that most of the grafting material is covered.
89002353|NCT06318650|Active Comparator|Demineralized Freeze-Dried Bone Allograft|Following atraumatic tooth extraction, curettes will be used to remove granulation tissues, and the socket will be irrigated with sterile normal saline.Then the socket will be filled with Demineralized freeze-dried bone allograft (DFDBA) to the crestal level of then bone followed by placement of a collagen membrane to cover the socket. Suturing technique will be a criss-cross horizontal mattress to ensure that most of the grafting material is covered.
89189343|NCT00851344|Active Comparator|Cetirizine 10mg|10mg cetirizine as active comparator
89375580|NCT06170138|Experimental|Ampli-01, 6 mg, nicotine pouch|Subjects will report to the study site for a screening visit followed by 3 visits with a single IP use (Visits 2 to 4) on separate days.There will be at least 1 day between Visits 2, 3 and 4, respectively, where the subjects are allowed ad libitum use of their own nicotine product of choice. Each visit will last one day.
89375581|NCT06170138|Active Comparator|ZYN Cool Mint Mini Dry, 6 mg nicotine /pouch|Subjects will report to the study site for a screening visit followed by 3 visits with a single IP use (Visits 2 to 4) on separate days.There will be at least 1 day between Visits 2, 3 and 4, respectively, where the subjects are allowed ad libitum use of their own nicotine product of choice. Each visit will last one day.
89375582|NCT06170112||Spinal Orthosis|There are pressure forces applied by the design of the spinal orthosis in changing the biomechanics of the scoliotic spine. In the design of the spinal orthosis designed with the 3-point principle, there is a corrective lateral force applied to the main curvature area and two support forces opposing this force. There are breathing spaces in the back area.
89375583|NCT06170099|Experimental|Laser group|
89375584|NCT06170099|Active Comparator|control group|
89375585|NCT06170073||Poor sleepers|With a total score of Pittsburgh Sleep Quality Index (PSQI) > 5.
89375586|NCT06170073||Good sleepers|With a total score of Pittsburgh Sleep Quality Index (PSQI) ≤ 5.
89375587|NCT06170034||TIA patients|
89399345|NCT03694509|Experimental|Breakfast tea with full fat milk|Black breakfast tea (200ml) with full fat milk (50ml) - The volume of milk added to the tea is at the discretion of the patient but the remaining milk must be consumed afterwards.
89399346|NCT03694509|Active Comparator|Water|Water 250ml
89399347|NCT02175056|Experimental|HL2351|1, 2, 4, 8, 12 mg/kg (SC) / Single-Dose
89375588|NCT06170008|Experimental|Second-degree burn wounds covered with silicone film sheet group|After routine clinical treatment of second-degree burn wounds, the innermost layer is covered with physical microstructure-modified transparent silicone film sheet , and the outer dressing is changed every 3 to 4 days to observe and record the wounds, and the innermost dressing is changed weekly or as necessary and the number of times is recorded to observe the wound healing rate, dressing transparency, dressing-wound adhesion, pain level, wound infection rate and incidence of adverse reactions.
89375589|NCT06170008|Active Comparator|Second-degree burn wounds covered with decellularized pig skin group|After routine clinical treatment of second-degree burn wounds, the innermost layer was covered with decellularized pig skin, the outer dressing was changed every 3 to 4 days, the wounds were observed and recorded, and the innermost dressing was changed weekly or as necessary and the number of times was recorded to observe the wound healing rate, dressing transparency, dressing-wound adhesion, pain level, wound infection rate and incidence of adverse reactions.
89375590|NCT06170008|Experimental|Post-operative skin grafting wounds covered with silicone film sheet group|After skin grafting, the innermost layer is covered with physical microstructure-modified transparent silicone film sheet , and the outer dressing is changed every 3 to 4 days to observe and record the wound. The innermost layer is changed weekly or as necessary and the number of times is recorded to observe the wound healing rate, transparency of the dressing, adhesion of the dressing to the wound, pain, wound infection rate and incidence of adverse reactions.
89375591|NCT06170008|Active Comparator|Post-operative skin grafting wounds covered with vaseline gauze group|After skin grafting, the innermost layer was covered with vaseline gauze, and the outer layer was changed every 3 to 4 days to observe and record the wound. The innermost layer was changed weekly or as necessary and the number of times was recorded to observe the wound healing rate, transparency of the dressing, adhesion of the dressing to the wound, pain, wound infection rate and incidence of adverse reactions.
89375592|NCT06169956||Participants receiving neoadjuvant nivolumab in combination with platinum-based chemotherapy|
89375593|NCT06169930||high-risk|
89375594|NCT06169930||low-risk|
89375595|NCT06169917|Experimental|Healthy participants|"Participants should be aged 18-40, in good health, capable of informed consent, without major medical/psychiatric conditions (e.g., heart disease, diabetes, autoimmune disorders, infectious diseases, major depressive disorder), chronic pain, respiratory issues, or ongoing acute pain, qualify. Exclusions: inability to follow instructions (e.g., language issues), recent alcohol/drug/analgesic use (<24h), caffeine intake (>100mg <8h), or scar tissue/general reduced sensitivity in test areas.~Participants undergo three interventions. The heat stimulation intervention is performed twice. During one heat stimulation intervention, participants receive the 'resonance frequency breathing' intervention. During the other heat stimulation intervention, participants receive the 'natural frequency breathing' intervention. The order of the breathing interventions is counterbalanced across participants."
88847690|NCT03985657|Active Comparator|Baseline Sleep Study|Baseline sleep polysomnography will involve the collection of electroencephalogram, electromyogram, electrocardiogram, airflow, heart rate, blood pressure, and pleural pressure during sleep with no CPAP. Participants in this arm would switch to CPAP within one week of the study.
89375596|NCT06169891|Experimental|SSGJ-613 200 mg|SSGJ-613 200 mg subcutaneous (s.c) once. The s.c. injection could be administered into the abdomen or thigh. Randomized patients will receive one s.c. injection of SSGJ-613 and placebo matching compound betamethasone injection (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1. The i.m. injection is recommended to be administered deeply into the gluteal muscle.
89375597|NCT06169891|Active Comparator|Compound Betamethasone Injection 1 mL|Compound betamethasone injection 1 mL intramuscularly (i.m) once. The i.m. injection is recommended to be administered deeply into the gluteal muscle. Randomized patients will receive compound betamethasone injection 1 mL i.m. once and placebo matching SSGJ-613 s.c. once, on Day 1.
89375598|NCT06169878|Experimental|experimental group|After total hip hip replacement surgery, the abduction apparatus, which provides abduction in the lower extremities and can be adjusted according to the height and weight of the patients, was used while lying and walking.
89375599|NCT06169878|No Intervention|control group|Pillows routinely used in the field were used to ensure abduction after total hip replacement surgery.
89375600|NCT06169839|Active Comparator|Skill training with Low Realism Simulation|the theoretical part of the TYD and OED training with Participation Certificate, the curriculum of which is created by the Ministry of Health, will be explained (by the Researcher). (2 hours) Skill training with Low Realism Simulation (1 hour) Basic CPR Manikin (classical training provided by the Ministry of Health),
89375601|NCT06169839|Experimental|Skills training with High Reality Simulation|the theoretical part of the TYD and OED training with Participation Certificate, the curriculum of which is created by the Ministry of Health, will be explained (by the Researcher). (2 hours) Skills training with High Reality Simulation (1 hour) SimMan® 3G (Laerdal medical)
89375602|NCT06169839|Experimental|Skill training will be given with Virtual Reality Application Supported Simulation|the theoretical part of the TYD and OED training with Participation Certificate, the curriculum of which is created by the Ministry of Health, will be explained (by the Researcher). (2 hours) Skill training will be given with Virtual Reality Application Supported Simulation (1 hour) and application training will be given with 3D MedSim.
89399348|NCT02175056|Placebo Comparator|Placebo|1, 2, 4, 8, 12 mg/kg (SC) / Single-Dose
89399349|NCT02175056|Active Comparator|Kineret(Anakinra)|100 mg (SC) / Single-Dose
88847691|NCT03985657|Experimental|CPAP Sleep Study|Participants will be treated with continuous positive airway pressure to relieve sleep-disordered breathing. Participants in this arm would switch to Baseline study within one week of the study.
88847692|NCT02249377|Experimental|Platelets-Rich-Plasma Group|Patients will be asked to stop taking any type of anti-inflammatory medication from 7 days before the procedure to 2 weeks after and fasting for 3 hours before the procedure. At the moment of the procedure, the radiology team will draw 60ml of venous blood from the patient, the blood will be processed with different components of the PRP kit and centrifuged in the SmartPrep PRP machine, to obtain the PRP. The patient is then scanned prone using a linear 14 or 9 megahertz (MHz) transducer. A 20 Gauge spinal needle is usually employed for purposes of aspiration. Sterile saline will be used to confirm needle placement in the cyst in lieu of lidocaine and then inject the PRP by the radiologist.
89189344|NCT00851344|Placebo Comparator|placebo|placebo tablet
89375603|NCT06169813|Active Comparator|Control (Quit-Line Referral)|Participants will receive referral to the existing South African Quitline. Participants will receive information to contact the Quitline if participants so choose, in addition to ecological momentary assessment (EMA) texting orientation.
89375604|NCT06169813|Experimental|Nicotine Replacement Therapy (NRT)|In addition to phone counseling + ecological momentary intervention (EMI) texting, participants will receive combination NRT (daily patches and lozenges).
89375605|NCT06169813|Experimental|Electronic Cigarette (EC)|"In conjunction with phone counseling + EMI texting, participants will receive the VUSE Solo EC."
89375606|NCT06169527||Participants with AD treated with dupilumab|Patients ≥6 years of age in whom dupilumab therapy was initiated to treat their AD according to French-specific prescribing information.
88847693|NCT02249377|Active Comparator|Corticosteroid group:|Patients will be asked to stop taking any kind of anti-inflammatory medication from 7 days before the procedure to 2 weeks after but fasting in this group won't be required. An ultrasound guided aspiration and triamcinolone (40 mg) diluted with lidocaine without epinephrine and ropivacaine will be used to anesthetize the tissues down to the cyst (including within the cyst for steroid injections). A compression bandage will be placed locally for 7 days. Investigators will monitor any side effect from the injection and treat the patients per standard care - this can include prescription of analgesics.
88847694|NCT05750654|Experimental|Small Tube Group|
88847695|NCT05750654|Active Comparator|Standard Tube Group|
89375607|NCT06169462||Pericapsular nerve group (PENG) block|Patients who underwent PENG in Hip surgery under spinal anesthesia will be evaluated retrospectively in terms of opioid consumption and NRS scores.
89375608|NCT06169462||Suprainguinal fascia compartment block (SIFCB) + PENG|Patients who underwent PENG+SIFCB in Hip surgery under spinal anesthesia will be evaluated retrospectively in terms of opioid consumption and NRS scores.
89375609|NCT06168812|Experimental|Cohort 1|Participants in this cohort will receive glipizide for up to 4 months and participate in continuous glucose monitoring for as long as they are receiving the drug.
88847696|NCT02239627|Active Comparator|Steroid|Epidural steroid injection
88847697|NCT02239627|Experimental|Clonidine|Epidural clonidine injection
88847698|NCT05750576|Experimental|Chlorhexidine-impregnated dressings|
88847699|NCT05750576|Placebo Comparator|Non impregnated dressings|
88847700|NCT00002594|Experimental|Ablative chemo followed by autologous bone marrow (ABM) rescue|Autologous bone marrow and/or peripheral blood stem cells (PBSC) are harvested. Patients then receive intensive cyclophosphamide IV over 1 hour on days -8 to -5 and melphalan IV over 15 minutes on days -4 to -2. Bone marrow is reinfused on day 0. PBSC are reinfused on day 0 if used alone or on day 1 if used after autologous bone marrow transplantation (ABMT). Sargramostim (GM-CSF) is administered IV over 2 hours daily beginning 4 hours after ABMT and continuing until blood counts recover.
89375610|NCT06168812|No Intervention|Cohort 2a|Participants in this cohort will include people who have received various types of treatment for their hyperglycemia and pancreatic cancer. People's medical records will be reviewed to compare the effects of glipizide with the effects of other standard medications used to treat hyperglycemia.
88847701|NCT02234011|Experimental|Ketamine/Placebo|Participants in this group will receive 5 sprays (10 mg each) of intranasal ketamine for the first treatment visit, then receive 5 sprays of placebo (saline solution) at the second treatment visit two weeks later.
89375611|NCT06168812|No Intervention|Cohort 2b|Participants in this cohort will complete a questionnaire about their use of hyperglycemia medications. Participants from Cohort 2a will take part in this group.
89375612|NCT06164626|Experimental|Experimental: Group 1|15 patients who will only have their first teeth or second molars extracted.
88847702|NCT02234011|Experimental|Placebo/Ketamine|Participants in this group will receive 5 sprays of placebo (saline solution) for the first treatment visit, then receive 5 sprays (10 mg each) of intranasal ketamine at the second treatment visit two weeks later.
88847703|NCT02198833|Experimental|Micro-Patterned Foley Catheter|Procedures: Foley Catheter Insertion, Device Specific Adverse Event Assessment, Urine Cultures, Foley Catheter Tip Culture, Scanning Electron Microscopy
88847704|NCT02198833|Active Comparator|Standard-of-Care Foley Catheter|Procedures: Foley Catheter Insertion, Device Specific Adverse Event Assessment, Urine Cultures, Foley Catheter Tip Culture, Scanning Electron Microscopy
88847705|NCT02177773|Experimental|Ga-68 DOTA-TOC PET/CT|Patients receive Gallium Ga 68-DOTA-TOC IV over 1-2 minutes. Within 55-70 minutes, patients then undergo either a PET/CT scan lasting 30-40 minutes or a PET/MRI scan lasting 50 minutes.
88847706|NCT02144155|Experimental|Oxytocin: 24 IU - 168 IU|Oxytocin twice daily for 3 weeks
88847707|NCT02144155|Sham Comparator|Vehicle placebo|Placebo for 3 weeks
88847708|NCT00002618|Active Comparator|Regimen A|Patients begin radiotherapy (5 days a week for 4.5 weeks) to residual tumor on day 1 of maintenance.
88847709|NCT00002618|Active Comparator|Regimen B|Patients receive whole brain irradiation (5 days a week for 3.1 weeks) beginning on day 1 of maintenance. Patients are followed monthly for 6 months, every 3 months for 18 months, every 6 months for 3 years, and annually thereafter.
88847710|NCT02145169|Experimental|Nitrous Oxide arm|Patients will receive a 50/50 mixture of Oxygen and Nitrous oxide via non breather mask
88847711|NCT00002624|Experimental|Radiotherapy + surgery|"Patients begin radiotherapy 2-8 weeks postoperatively. Patients with complete resection undergo radiotherapy 5 days a week for 5.6 weeks. Patients with incomplete resection undergo radiotherapy 5 days a week for 6.6 weeks.~Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter."
88847712|NCT02047747|Experimental|dacomitinib|Dacomitinib 45 mg will be administered orally daily. Treatment cycles will consist of 28 days.
89189345|NCT00855478|Experimental|1|Cypher drug-eluting stent
89375613|NCT06164626|Experimental|Experimental:Group 2|15 patients who will have only their first or second molars extracted and will receive infrared laser treatment
89375614|NCT06164626|Experimental|Experimental: Group 3|15 patients who will have their first or second molars extracted and will receive a graft with scaffold biomaterial
89375615|NCT06164626|Experimental|Experimental:Group 4|15 patients who will have their first or second molars extracted and will receive a graft with scaffold biomaterial and infrared laser treatment
89375616|NCT06164210|Experimental|Traditional Sensory Integration Intervention Group|"Conventional Sensory Integration Intervention Based on Sensory Processing Theory, sensory integration intervention increases a childs ability to process and integrate sensory information and thus create more organized and adaptive behaviors. Sensory-enriched environments use fun interactive games and activities. Sensory integration intervention is carried out by creating an intervention program to create, understand, and eliminate the deficiency of the sensory process.~A conventional sensory integration intervention two sessions (per sessions 45 minutes) a week, was planned for 18-35-month-old infants at risk of ASD in both groups participating in the study. Session planning and activity selection were based on TSP-2 results. In particular, the occupational therapist supported the infant&amp;#39;s active participation in the activities."
89375617|NCT06164210|Active Comparator|Snoezelen-Based Occupational Therapy Group|Snoezelen- Based Occupational Therapy Intervention Different from sensory integration interventions, Snoezelen interventions are environments with all sensory stimuli, such as auditory, visual, tactile, gustatory, olfactory, and vestibular stimuli, in the same environment and where therapeutic guidance and commands are not given to the individual. These interventions aim to reduce agitation, depression, and aggression in individuals and increase daily living activities, functional performance, and well-being. Psychiatric clinics, schools, rehabilitation centers, and occupational therapy clinics are some places where it is used. Some materials found in Snoezelen rooms are bubble tubes, fiber optic light cables, projectors, vibrating massagers, light tactile stimulation materials, aromatic scent emitting devices, music sets, and relaxing music and swings.
89375618|NCT06164197|Experimental|Lokomat|
89375619|NCT06164197|Experimental|Balance Trainer|
89375620|NCT06162585||Observation of Participants exposed 1.2E11gc/eye of MCO-010|This is a long-term follow-up observational study of participants who previously received 1.2E11gc/eye of MCO-010. No investigational product will be administered in this study.
89375621|NCT06162585||Observation of Participants exposed to 0.9E11gc/eye of MCO-010|This is a long-term follow-up observational study of participants who previously received 0.9E11gc/eye of MCO-010 No investigational product will be administered in this study.
89375622|NCT06161207|Experimental|3D-4K-ICG|Indocyanine Green Tracer Using in 3D plus Ultra High Resolution Laparoscopic Gastrectomy with Lymph Node Dissection
89375623|NCT06161207|Experimental|4K-ICG|Indocyanine Green Tracer Using in Ultra High Resolution Laparoscopic Gastrectomy with Lymph Node Dissection
89375624|NCT06161207|Placebo Comparator|3D|3D Laparoscopic Gastrectomy with Lymph Node Dissection
89375625|NCT06160999|Experimental|Religious Conference|Clusters will have religious conference.
89375626|NCT06160999|No Intervention|Religious Conference control|Clusters will have not religious conference. Clusters' background characteristics matched to the Conference arm.
88847713|NCT05750186|Experimental|Abdominal Massage Group|"At the first encounter with the patient; Patient Information Form, Gastrointestinal Symptom Rating Scale, General Comfort Scale and Functional Independence Scale will be applied.~From the morning of the first day, abdominal massage will be applied to the patients 2 times a day, in the morning and in the evening, for 3 days (15 minutes).~Then, applying abdominal massage to the patients in the experimental group. After each massage application, the patient's bowel sounds/movements will be listened to.~Medicines such as laxatives, suppositories and enemas will not be given to the experimental group and Bristol Stool Scale will be filled in for patients who defecate within this period.~In order to evaluate the abdominal massage and its effect on the comfort level of the patients, the Gastrointestinal Symptom Rating Scale, General Comfort Scale and Functional Independence Scale will be applied again at the end of the 3rd day after the application of abdominal massage."
89375627|NCT06160999|Experimental|Vaccine-in-a-van|"Clusters will have deployment of a mobile vaccine clinic (vaccine-in-a-van)."
89375628|NCT06160999|No Intervention|Vaccine-in-a-van control|"Clusters will not have a deployment of a mobile vaccine clinic (vaccine-in-a-van). Clusters' background characteristics matched to the Van arm."
89375629|NCT06159894|Active Comparator|Treatment with LA CAB + RPV and follow-up at Specialist-Care centers (Specialist-Care arm).|Treatment with LA CAB + RPV and follow-up at Specialist-Care centers (Specialist-Care arm).
89375630|NCT06159894|Experimental|Treatment with LA CAB + RPV and follow-up in Polyvalent Day Hospital units (Day Hospital arm).|Treatment with LA CAB + RPV and follow-up in Polyvalent Day Hospital units (Day Hospital arm).
89375631|NCT06159868|Experimental|Intervention|Structured and individualised physiotherapy in combination with optimised nutrition delivered by s specialist critical care rehabilitation team
89375632|NCT06159868|Active Comparator|Control|Standard ward based care
89002354|NCT06318637|Active Comparator|Control Group|Participants in the control group will follow their typical daily activities with their baby throughout the study, including their typical bathing, skincare, and sleep practices.
89002355|NCT06318637|Experimental|Interventional Group (Wash/Shampoo and Lotion)|Participants in the intervention group will use the provided wash/shampoo, and face and body lotion for their baby. At Baseline, participants caregivers in the intervention group will be provided with instructions for institution of a daily bedtime routine for their infant, which includes a massage with a moisturizing lotion.
89189346|NCT00711126|Experimental|Arm 1|HVTs
89375633|NCT06159569|Experimental|Population treated with LACRIACT|20 patients affected by dry eye who met the inclusion and exclusion criteria.. It is optional for the Investigator to recruit a sub-group of patients (maximum number 10 of 20 recruited patients) with regular soft contact lens that will be analysed separately.
89375634|NCT06159426|Experimental|Expert group|The stimulation will be applied by an expert therapist.
89375635|NCT06159426|Active Comparator|Non-expert group|This group will receive the same stimulation as the expert group but in this case it will be applied by a therapist not specialized in therapy.
89375636|NCT06157788||Operated group|Patients were male individuals with anterior glenohumeral instability, who underwent preoperative fMRI, then surgical stabilization by 2 specialized shoulder surgeons, followed by a new fMRI one year postoperatively.
89399350|NCT02173184|Placebo Comparator|Placebo|Placebo vehicle (0.9% NaCl solution)
89375637|NCT06157788||Control Group|The control group consisted in healthy volunteers with no history of shoulder injury, instability, or hyperlaxity, the latter defined as more than 85° of external rotation elbow against waist, or hyperabduction over 105°, who had undergone fMRI at baseline.
89375638|NCT06155383|Active Comparator|XELOX (capecitabine + oxaliplatin)|capecitabine with oxaliplatin arm
89375639|NCT06155383|Experimental|Disitamab Vedotin + Toripalimab|Disitamab Vedotin with Toripalimab arm
89375640|NCT06155383|Experimental|Disitamab Vedotin + Toripalimab + XELOX|Disitamab Vedotin + Toripalimab + XELOX arm
89375641|NCT06154772|Experimental|Color Therapy|Balancing body chakras with colors. Colors are applied to the body's chakras for 10-15 minutes.
89375642|NCT06154772|No Intervention|Control Group|Routine maintenance will be applied
89375643|NCT06153212|Experimental|PTFE Mesh Membrane|A reinforced PTFE Mesh membrane will be used to cover the bone graft.
89375644|NCT06153212|Active Comparator|Collagen membrane|A collagen membrane will be used to cover the bone graft.
88847714|NCT05750186|No Intervention|Control Group|"Patients who did not defecate within the first 3 days after surgery will constitute the control group.~At the first encounter with the patient; A Patient Information Form, Gastrointestinal Symptom Rating Scale (GSS), General Comfort Scale (GAS) and Functional Independence Scale (FIM) will be administered.~From the first encounter, patients will be given medications that are in line with their clinical routine, such as laxatives, suppositories and enemas, according to the doctor's request.~Intestinal sounds/movements of the patients will be listened to 6 times, 2 times a day for 3 days.~Bristol Stool Scale will be filled in for patients who defecate within this period.~At the end of the 3-day follow-up of the patients, Gastrointestinal Symptom Rating Scale, General Comfort Scale and Functional Independence Scale will be applied again and the first stool of the patients who defecate will be evaluated with the Bristol Stool Scale."
88847715|NCT00002642|Experimental|chemoradiotherapy followed by surgery|chemoradiotherapy followed by surgery and post-surgery boost chemotherapy
88847716|NCT03983941|Active Comparator|FNB-AC + Sciatic nerve block|Patients will receive up to 20 mL of 0.2% ropivacaine for FNB-AC and up to 20 mL of 0.2% ropivacaine for sciatic nerve block under ultrasound guidance.
88847717|NCT03983941|Experimental|FNB-AC + IPACK|Patients will receive up to 20 mL of 0.2% ropivacaine for FNB-AC and up to 20 mL of 0.2% ropivacaine for posterior knee capsular infiltration under ultrasound guidance (IPACK)
88847718|NCT01434511|Experimental|OBI-1|
88847719|NCT02973074|Other|OLEOvital|30mg iron are being administered orally twice a day for a period of 4 Weeks it is a granulated powder which is taken orally and then solved with saliva, without taking water
88847720|NCT05750108|Active Comparator|Active Transcutaneous Vagal Nerve Stimulation|
88847721|NCT05750108|Sham Comparator|Sham Transcutaneous Vagal Nerve Stimulation|
88847722|NCT02020837|Experimental|Lymphaticovenous Micro-Anastomosis|
89375645|NCT06153069|Experimental|Short-Course Regimen|The short-course regimen consists of two periods of 8-17 weeks. During the first 8 weeks, the regimen consists of rifampicin (R), isoniazid (H), pyrazinamide (Z), and ethambutol (E). Then based on the presence of radiological manifestations, patients will be in divided into two sub-groups: with-radiological-lesions patients (with_R) and without-radiological-lesions patients (without_R). The regimen for with_R patients consists of rifampicin and isoniazid for an additional 9 weeks. Without_R patients will not undergo further continuation treatment, with a total treatment duration of 8 weeks. The regimen will be extended to 26 weeks if no culture conversion at the end of 8 weeks or the tuberculosis cavity is not closed at the end of treatment.
89375646|NCT06153069|Active Comparator|Standardized Regimen|The standard treatment regimen consists of rifampicin (R), isoniazid (H), pyrazinamide (Z), and ethambutol (E) for 8 weeks, followed by rifampicin and isoniazid for an additional 18 weeks.
89375647|NCT06152263||Atrophic or Cancerous|In each image, the color values of atrophic or cancerous will be quantified using the International Commission on Illumination 1976 (L∗, a∗, b∗) color space. Histological microvascular density in biopsy or resected specimens will be evaluated using CD31 immunostaining. Color differences at the atrophic border and cancerous border, defined as Euclidean distances of color values between the atrophic and non-atrophic mucosa, as well as cancerous and non-cancerous mucosa, will be calculated according to mucosal microvascular density.
89375648|NCT06152263||Non-atrophic or Non-cancerous|In each image, the color values of non-atrophic or non-cancerous will be quantified using the International Commission on Illumination 1976 (L∗, a∗, b∗) color space. Histological microvascular density in biopsy or resected specimens will be evaluated using CD31 immunostaining. Color differences at the atrophic border and cancerous border, defined as Euclidean distances of color values between the atrophic and non-atrophic mucosa, as well as cancerous and non-cancerous mucosa, will be calculated according to mucosal microvascular density.
89375649|NCT06149403|Experimental|OTL-203|Eligible subjects randomized to Arm 1 will receive an intravenous (IV) infusion of OTL-203 gene therapy. Subjects will receive conditioning regimen with busulfan and fludarabine prior to OTL-203 infusion.
89375650|NCT06149403|Active Comparator|Allo-HSCT|Eligible subjects randomized to Arm 2 will receive allogeneic hematopoietic stem cell transplantation. Subjects will receive conditioning regimen with busulfan and fludarabine prior to allo-HSCT.
89375651|NCT06147583|Experimental|Insulin pump fault simulation|Collection of patients data during outpatient use of AID (automated insulin delivery); Inpatient simulation of insulin pump faults by suspension of insulin administration.
89375652|NCT06113458|Active Comparator|Standard and One-time Training|Patient level: Standard, automatic reminders Clinic level: One-time training
89002356|NCT06318624|Experimental|Intervention Group|Movement with Motion technique of Mulligan Concept to the ankle joint and taping will be performed on the participants in the Intervention Group.
89375653|NCT06113458|Experimental|Standard and Practice Facilitation|Patient level: Standard, automatic reminders Clinic level: Regular, ongoing coaching
89189347|NCT00711126|Experimental|Arm 2|HVTs
89375654|NCT06113458|Experimental|High-intensity and One-time Training|Patient level: Personalized feedback Clinic level: One-time training
89375655|NCT06113458|Experimental|High-intensity and Practice Facilitation|Patient level: Personalized feedback Clinic level: Regular, ongoing coaching
89375656|NCT06109571|Experimental|Group 1: mHealth Implementation|First 2 sites begin enrollment. Research participants will be asked to complete weekly-check-in, 4 research surveys and engage in content available in the Connections app and with peer mentors over the course of a year.
88847723|NCT02006407|Other|Primary Brain Tumor|Patients receiving standard cranial radiotherapy will undergo (1) Magnetic Resonance Imaging (MRI) with Diffusion Tensor Imaging (DTI) and (2) Neuro-cognitive testing (CogState-a computerized software testing system that offers various cognitive assessments based on traditional expansive neurocognitive tests) at four timepoints (Baseline, 3 weeks, 6 weeks and 6 months).
88847724|NCT04331054|Active Comparator|1: Usual practice|arm will be follow during 30 days
88847725|NCT04331054|Experimental|2: Usual practice + SYMBICORT RAPIHALER|Usual practice + SYMBICORT RAPIHALER 200/6 µg ( 2 puffs bid during 30 days)
88847726|NCT02973308|Other|Treadmill-Test operator A|Randomised to motorised treadmill group A for inter reliability, observer A will perform both exercise tests
88847727|NCT02973308|Other|Treadmill-Test operator B|Randomised to motorised treadmill group B for intra reliability, observer A will perform one exercise test, followed by observed B
88847728|NCT02973308|Other|Cycle-Test operator A|Randomised to cycle group B for inter reliability, observer A will perform both exercise tests
88847729|NCT02973308|Other|Cycle-Test operator B|Randomised to cycle group B for intra reliability, observer A will perform one exercise test, followed by observed B
88847730|NCT01426555|Active Comparator|FES Rowing|Group 1 - FES-Rowing Exercise for entire study period
88847731|NCT01426555|Experimental|FES Rowing + Zoledronic acid|Group 2 - FES-Rowing Exercise for entire study period plus Zoledronic Acid 5mg administered by i.v. infusion one-time at the end of observation period
88847732|NCT01434745|Placebo Comparator|Placebo|placebo
88847733|NCT01434745|Experimental|Simvastatin|0.5 mg/kg body weight/day
88847734|NCT05595902||Young older adults|≥65-<75 years of age
88847735|NCT05595902||Older adults|≥75-<90 years of age
88847736|NCT05595902||≥90 years old|
88847737|NCT01401049|Experimental|Fospropofol|To compare the incidence and intensity of pain on injection that is caused by propofol (lipid emulsion) versus the test drug fospropofol. A third arm will also be included using a current standard (propofol plus lidocaine) as a methodological control.
88847738|NCT01401049|Active Comparator|Propofol/Lidocaine|The purpose of this study is to compare the incidence and intensity of possible pain on injection as well as patient satisfaction caused by propofol (a lipid based medication); Lusedra (a water based medication); and the drug combination of propofol with lidocaine (a local anesthetic commonly used with propofol injection).
88847739|NCT01402531|Experimental|Submucosal Bevacizumab|200mg Bevacizumab, submucosal injection
88847740|NCT01971853|Placebo Comparator|oral placebo|an Ibuprofen and Acetaminophen Placebo will be added to a Demerol-Vistaril regimen
88847741|NCT01971853|Active Comparator|Oral Analgesics|5 mg/kg ibuprofen + 15 mg/kg acetaminophen will be added to a Demerol-Vistaril regimen
88847742|NCT00002678|Active Comparator|Melphan plus prednisone|melphalan plus prednisone qd x 4 28 day cycles x 12 cycles; No treatment after stable response.
88847743|NCT00002678|Active Comparator|Melphan, prednisone pluse dexamethasone|melphalan plus prednisone qd x 4 28 day cycles x 12 cycles; dexamethasone qd x 4 q 28 days after non-progression
88847744|NCT01397695|Experimental|bevacizumab|
88847745|NCT01982383|Experimental|Micropulse Laser Treatment|Patient's randomized to ML treatment would be treated with the following settings: 200 micron spot size, 0.2 second duration, 15% duty cycle, and 300 milliWatt power. Their eyes would be dilated prior to treatment with standard mydriatic medications, including Tropicamide and Phenylephrine
88847746|NCT01982383|Placebo Comparator|No Treatment|Patients randomized to this treatment arm, will not receive treatment for CSC. They will continue to be observed at month 1 and month 3. If any worsening of pathology is found during the follow up visits, the patient will be removed from the study and given appropriate standard of care by the attending
88847747|NCT05600647|Experimental|Electromagnetic Field therapy with an exercise program|The magnetic field is generated through a mattress that is connected to the device. The maximum program, program 4, for 20 minutes with an intensity of 35 microtesla (level 10) and 50-60 Hz. Every patient is lying on the mattress in a supine position. In addition to exercise training program included postural correction strengthening exercises, stretching, proprioception and balance training
88847748|NCT05600647|Active Comparator|exercise program|Every patients will practice the exercise training program alone. the program included postural correction, strengthening exercises, stretching, proprioception and balance training
88847749|NCT01356667|Active Comparator|Treatment-As-Usual|Substance Abuse treatment typically received
88847750|NCT01356667|Experimental|DARTNA|12-week DARTNA program
89189348|NCT00711126|Experimental|Arm 3|HVTs
89375657|NCT06109571|Experimental|Group 2: mHealth Implementation|Next 2 sites begin enrollment 6 months after Group 1. Research participants will be asked to complete weekly-check-in, 4 research surveys and engage in content available in the Connections app and with peer mentors over the course of a year.
89375658|NCT06109571|Experimental|Group 3: mHealth Implementation|Next 2 sites begin enrollment 6 months after Group 2. Research participants will be asked to complete weekly-check-in, 4 research surveys and engage in content available in the Connections app and with peer mentors over the course of a year.
89375659|NCT06109571|Experimental|Group 4: mHealth Implementation|Next 2 sites begin enrollment 6 months after Group 3. Research participants will be asked to complete weekly-check-in, 4 research surveys and engage in content available in the Connections app and with peer mentors over the course of a year.
88847751|NCT02972918||Levosimendan|At least 12 hours before surgery: Infusion of levosimendan (0,1 mcg/kg/min). 24 hours of infusion without a bolus.
88847752|NCT05600491|Experimental|Early TMZ chemotherapy|Patients were treated with standard concomitant radiochemotherapy regimen (Stupp) plus early postsurgical temozolomide.
88847753|NCT05749484||NCRT+TME|Neoadjuvant chemoradiotherapy (NCRT) and total mesorectal excision (TME) Interventions
88847754|NCT05600413|Experimental|L-Citrulline|L-Citrulline: 6 grams/day
88847755|NCT05600413|Placebo Comparator|Placebo|Crystalline Cellulose
88847756|NCT01934647|Experimental|1 mg MK-8892|Participants will receive a single oral dose of 1 mg MK-8892.
88847757|NCT01934647|Experimental|4 mg MK-8892|Participants will receive a single oral dose of 4 mg MK-8892.
88847758|NCT01934647|Experimental|8 mg MK-8892|Participants will receive a single oral dose of 8 mg MK-8892.
88847759|NCT05440526|Active Comparator|Herbst Group|• Group I: Include ten young adult orthodontic patients who are treated by using fixed orthodontic appliances followed by the type IV Herbst appliance (mini plate anchored appliance). The age of patients will be (18-20y).
88847760|NCT05440526|Active Comparator|TFBC Group|• Group II: Include ten young adult orthodontic patients who are treated by using fixed orthodontic appliances followed by the Twin Force Bite Corrector appliance (dentally anchored appliance). The age of patients will be (18-20y).
88847761|NCT01354951|Experimental|Prostate Biopsy, Focal Brachytherapy , Assessment of QOL|This is a non-randomized, Phase II study examining the tolerance profile (primary endpoint) as well as the secondary endpoints of QOL changes, efficacy and the correlation of post-treatment MRI findings with post-treatment biopsy outcomes in men with early stage low volume prostate cancer treated with focal brachytherapy.
88847762|NCT00379561|Experimental|Intervention PSA-PAH1|Determination of the therapeutic activity of different concentrations of PSA-PAH1 at increasing doses of per gram of prostate.
88847763|NCT01350583|Experimental|Sodium Bicarbonate Therapy|Dose Escalation
88847764|NCT01890577||Study population|Single cohort of dialysis patients
88847765|NCT00002708|Experimental|Arm 1|Whole brain radiation therapy (WBRT) to 37.5 Gy/15 fractions/2.5 Gy once daily, 5 days/week followed by radiosurgery to all metastases
88847766|NCT00002708|Active Comparator|Arm 2|WBRT to 37.5 Gy/15 fractions/2.5 Gy once daily, 5 days/week
89375660|NCT06107751|Active Comparator|Ramped position group|This position will be achieved by elevation of the shoulders and the head elevation till achieving alignment of sternal notch and external auditory meatus
88847767|NCT01315873|Experimental|Bortezomib and Bendamustine|
88847768|NCT01895959|Other|Euflexxa|EUFLEXXA® is a hyaluronate hydrogel produced from bacteria, in a phosphate-buffered saline solution. It is given as a three week treatment regimen. It involves injecting of 2cc or 20mg intra-articularly once per week.
88847769|NCT01303003|Experimental|Treatment Arm 1|Bilateral TAP block consisting of 40cc. 0.125% bupivicaine + 0.5cc. dexamethasone (2mg.) per side.
88847770|NCT01303003|Active Comparator|Treatment Arm 2|Bilateral TAP block of 40cc. of 0.125% bupivicaine + 0.5cc. sterile saline per side
88847771|NCT01256281|Experimental|Femoral Nerve Block|Patients enrolled will receive ultrasound guided FNB in addition to standard care. If subjects are experiencing pain in both lower extremities, both extremities will be blocked; if subjects are experiencing pain in one lower extremity, only the affected extremity will be blocked.
88847772|NCT05313061|Active Comparator|MTX continue|Group will continue MTX after vaccination
88847773|NCT05313061|Experimental|MTX 1 week hold|Group will continue MTX for 1 week after vaccination
89189349|NCT00711126|Experimental|Arm 4|HVTs
88847774|NCT01821859|Experimental|Abraxane/Bevacizumab|"Bevacizumab will be infused at a dose of 10 mg/kg in 100 mL normal saline over 30 minutes ± 10 minutes. It is given first, prior to the Abraxane infusion.~Abraxane will be infused at a dose of 220 mg/m² in 20 mL normal saline per 100 mg vial over 30 minutes. This will follow the Bevacizumab infusion."
88847775|NCT05749328|Experimental|Carbohydrate group|Fasting at 20:00 on the eve of surgery, give 800ml of carbohydrate drink, the patient drinks freely, no more than 200ml per hour, to 3h before surgery, give carbohydrate drink again, according to 5ml/kg calculated dose, maximum 400ml, drink within 30 minutes.
88847776|NCT05749328|No Intervention|Contral group|Fasting at 20:00 on the eve of surgery, fasting at 24:00, until the induction of anesthesia on the day of surgery
88847777|NCT05600023|Experimental|Nitrofurantoin|
88847778|NCT05600023|Experimental|Double antibiotic paste|
88847779|NCT05600023|No Intervention|Control|
88847780|NCT05566184|Experimental|Modified pacifier|In the experimental group, a modified pacifier will be given to the child during the procedure and the data will be collected.
88847781|NCT05566184|No Intervention|Without modified pacifier|Data will be collected without giving the child in the control group a modified pacifier during the procedure.
88847782|NCT01194427|Experimental|Vorinostat and Tamoxifen|Vorinostat and tamoxifen are taken for about 14 days prior to definitive surgery.
88847783|NCT05749250|Experimental|Cavitation therapy|Subjects treated with cavitation energy
89189350|NCT00711126|Experimental|Arm 5|HVTs
89189351|NCT00711126|Experimental|Arm 6|HVTs
89375661|NCT06107751|Sham Comparator|Sniffing position group|This position will be achieved by placing a 7 cm pillow under the occiput.
89375662|NCT06105918|Experimental|Treatment (EBRT, 177Lu-rhPSMA-10.1)|Patients undergo EBRT followed by 177Lu-rhPSMA-10.1 IV on study. Patients also receive rhPSMA-7.3 IV with PET/CT at screening and undergo SPECT-CT and collection of blood samples on study.
88847784|NCT05749250|No Intervention|Control|Control subjects not treated with cavitation energy
88847785|NCT05599555||Unvaccinated blood donors|Blood donors who were unvaccinated with any COVID-19 vaccine by study recruitment
88847786|NCT05599555||Blood donors vaccinated with BNT162b2|Blood donors who were vaccinated with one or more doses of the mRNA vaccine Comirnaty (BNT162b2 mRNA, BioNTech/Fosun-Pharma, Mainz, Germany/Shanghai, China) by study recruitment.
88847787|NCT05599555||Blood donors vaccinated with CoronaVac|Blood donors who were vaccinated with one or more doses of the inactivated CoronaVac (Sinovac life Sciences, Beijing, China) vaccine by study recruitment.
88847788|NCT04706455|Active Comparator|sodium hyaluronate 0.1%|First preoperative Biometry of the eye at the IOL Master® will be measured. Then, corneal topography will be measure at the Oculus pentacam®. Afterwards, sodium hyaluronate 0.1% will be installed and biometry and corneal topography will be repeated after 5 minutes.
88847789|NCT04706455|Active Comparator|sodium hyaluronate 0.3%|First preoperative Biometry of the eye at the IOL Master® will be measured. Then,corneal topography will be measure at the Oculus pentacam®. Afterwards, sodium hyaluronate 0.3% will be installed and biometry and corneal topography will be repeated after 5 minutes.
88847790|NCT00002744|Experimental|Arm I|Therapy defined in description.
88847791|NCT00002744|Experimental|Arm 2|Therapy defined in description.
88847792|NCT00002744|Experimental|Arm 3|Therapy defined in description.
88847793|NCT00002744|Experimental|Arm 4|Therapy defined in description.
89375663|NCT06100588|Experimental|MT + DN|"4 treatment sessions of 20 minutes manual therapy will be given over 4 weeks (1session/week). The techniques will be tailored to the patients needs, and will exclude 'High Velocity Low Amplitude' manipulations.~In addition, a maximum of 4 muscles will be treated by means of dry needling in at least 3 sessions, based on the pain pattern of the patient."
89375664|NCT06100588|Active Comparator|MT alone|4 treatment sessions of 20 minutes manual therapy will be given over 4 weeks (1session/week). The techniques will be tailored to the patients needs, and will exclude 'High Velocity Low Amplitude' manipulations.
89375665|NCT06099769|Experimental|Enzalutamide|Enzalutamide 160 mg/day, continuous daily dosing in a 21-day cycle
89375666|NCT06099769|Experimental|Enzalutamide with Mifepristone|Enzalutamide 120mg/day and mifepristone 300mg/day, continuous daily dosing in a 21-day cycle
89375667|NCT06099769|Active Comparator|Chemotherapy:Carboplatin, Paclitaxel, Eribulin or Capecitabine (TPC)|"The treating physician must select from one of the following regimens.~Eribulin 1.4 mg/m2 IV Day 1 and Day 8 in a 21-day cycle~Capecitabine 1000-1250 mg/m2 twice daily, orally Day 1-14 in a 21-day cycle~Paclitaxel 80 mg/m2 IV Day 1, Day 8 in a 21-day cycle~Carboplatin AUC 6 IV Day 1 in a 21-day cycle~Carboplatin AUC 2 IV Day 1, Day 8 and Day 15 in a 21-day cycle~Patients randomized to TPC may be offered crossover to enzalutamide plus mifepristone treatment at the time of disease progression if they continue to meet eligibility criteria."
88847794|NCT01788475|Active Comparator|Dexamethasone implant up to every 3 Mo.|"Ozurdex (dexamethasone) 0.7 mg implant will be performed on Day 0. All patients will be evaluated monthly thereafter.~Intervention: One month following initial implantation/sham, patients will be evaluated for focal or grid laser treatment if the investigator feels the patient will benefit.~Re-implantation of Ozurdex (dexamethasone) may occur at any time > 3 months following last injection in group 1 if any of the following conditions are met:~Increase of > 50 microns from the best previous CRT measurement~Recurrence of intraretinal cystic edema~Persistent intraretinal cystic edema"
88847795|NCT01788475|Active Comparator|Dexamethasone implant up to every 6 Mo.|"Ozurdex (dexamethasone) 0.7 mg implant will be performed on Day 0. All patients will be evaluated monthly thereafter.~Intervention: One month following initial implantation/sham, patients will be evaluated for focal or grid laser treatment if the investigator feels the patient will benefit.~Re-implantation of Ozurdex (dexamethasone) may occur at any time >6 months following last injection in group 2 if any of the following conditions are met:~Increase of > 50 microns from the best previous CRT measurement~Recurrence of intraretinal cystic edema~Persistent intraretinal cystic edema"
88847796|NCT01788475|Sham Comparator|Sham Implant|"Sham Procedure will be performed on Day 0. All patients will be evaluated monthly thereafter.~Intervention: One month following initial implantation/sham, patients will be evaluated for focal or grid laser treatment if the investigator feels the patient will benefit. Also, at 13 months, patients in the sham group will be eligible for Ozurdex (dexamethasone) 0.7 mg implantation if initial inclusion/exclusion criteria are met. These patients would follow re-implantation guidelines of group 2.~Sham implantation may occur at any time > 6 months following last sham injection in group 3 if any of the following conditions are met:~Increase of > 50 microns from the best previous CRT measurement~Recurrence of intraretinal cystic edema~Persistent intraretinal cystic edema"
88847797|NCT01183897|Experimental|3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic|This phase II study of the anti-GD2 murine IgG3 monoclonal antibody 3F8 combined with granulocyte-macrophage colony stimulating factor (GM-CSF) will assess response in of primary refractory neuroblastoma in bone marrow (i.e., incomplete response to standard treatment).
89375668|NCT06090448|Other|University of Bath - Clinical group 1|Participants will be Assistive Technology Users (clinical group 1) and the study will be conducted remotely at their homes. The device will be sent via post to their address.
88847798|NCT00381914|Experimental|1|400 IU / day vitamin D
88847799|NCT00381914|Experimental|2|800 IU / day vitamin D
88847800|NCT00381914|Experimental|3|1200 IU / day vitamin D
88847801|NCT00423007|Experimental|Bromfenac|Ophthalmic Solution
88847802|NCT00423007|Placebo Comparator|Placebo|Vehicle ophthalmic solution
88847803|NCT00002756|Experimental|Chemo (Reduced Induction) No BMT (Open February 2004)|
88847804|NCT05599477|Experimental|Endoscopic sutured gastroplasty|
89002357|NCT06318624|Sham Comparator|Sham Group|Movement with Motion technique of Mulligan Concept to the ankle joint with lower amplitude and taping with minimal tension will be performed on the participants in the Sham Group.
89002358|NCT06318611||Case group|Children and adolescents diagnosed with type 1 diabetes aged between 6 to 18 years
88847805|NCT01183429|Experimental|3F8 and 13-cis-retinoic acid|This phase II, open-label, single arm trial assesses the anti-NB activity of high-dose 3F8 (80 mg/m2/day), which is used in cycles 1-2, with return to standard 3F8 dosage (20 mg/m2/day) in subsequent cycles. Clinical results will be compared to those in the predecessor trials which used only the standard 3F8 dosage. Starting with A(8), patients no longer receive high dose 3F8 but receive only standard dose 3F8 (20mg/m2/day) for all cycles.
88847806|NCT01157533|Experimental|Vancomycin Loading|Loading dose 30 mg/kg via central or peripheral intravenous infusion. Subsequent doses of vancomycin (15 mg/kg) are considered standard of care.
88847807|NCT01760941|Experimental|Treatment (radiation therapy)|"This is a survey study to evaluate the feasibility and effectiveness of an affordable, $400 flat rate, same-day consultation, simulation, and delivery of a single fraction of palliative radiation therapy for patients with symptomatic bony metastatic disease who are currently enrolled in hospice. Treatment planning and delivery of palliative radiotherapy will utilize standard of care techniques. A physician survey of feasibility will be conducted on the treatment day. Patient surveys will conducted on the day of treatment and at 2 weeks, 4 weeks, 2 months, 3 months, 4 months, 5 months, and 6 months after treatment."
88847808|NCT05749016|Experimental|Study group|Eligible patients received inetetamab with pertuzumab and paclitaxel/carboplatin (TCbIP) regimen every three weeks for a maximum of 6 cycles, followed by surgery.
88847809|NCT01756573|Active Comparator|Bupivacaine|Control
88847810|NCT01756573|Experimental|Bupivacaine with Dexamethasone|Dexamethasone will be mixed with bupivacaine
88847811|NCT01756573|Active Comparator|Intravenous Dexamethasone|Dexamethasone will be given intravenously
88847812|NCT01126801|Experimental|Estradiol|
88847813|NCT01126801|Placebo Comparator|Placebo control|
88847814|NCT00002762||Patient interviewing + blood sampling|"Patients were interviewed at the time of the primary cancer surgery to determine the menstrual history. Blood sampling occurred within 1 day of surgery, and serum samples were shipped frozen to a central laboratory (Mayo Medical Laboratory, Rochester, MN) for E2, Pg, and LH determinations. Serum hormone levels, menstrual cycle length, and day of last menses were used to determine the menstrual phase at which surgery occurred.~Patients were observed every 6 months for the first year postregistration and annually for the next 2 to 10 years postregistration for adjuvant therapy information, disease recurrence, and death."
88847815|NCT01727167|Placebo Comparator|Control Group|This group will breath room air for one hour per day over the course of the three days immediately prior to surgery.
88847816|NCT01727167|Experimental|CO group|This group will breath 200 ppm of CO for one hour per day over the course of the three days immediately prior to surgery.
88847817|NCT05748938|Experimental|RD14-01 treated group|Subjects who meet the enrollment conditions will receive intravenous infusion of anti--ROR1 CAR-T Cells after lymphodepleting therapy.
88847818|NCT01702909|Experimental|Interleukin-2|Interleukin-2
88847819|NCT00002768|Experimental|Autologous stem cell transplantation|Patients receive consolidation chemotherapy followed by autologous stem cell transplantation
88847820|NCT00002774|Experimental|Tirapazamine + cisplatin + 5-FU|2 cycles of induction chemotherapy (tirapazamine, cisplatin, and 5-fluorouracil [5-FU]) followed by simultaneous chemoradiotherapy (tirapazamine, cisplatin, and 5-FU)
88847821|NCT00002774|Active Comparator|Cisplatin + 5-FU|2 cycles of induction chemotherapy (cisplatin + 5-fluorouracil [5-FU]) followed by simultaneous chemoradiotherapy (cisplatin + 5-FU)
88847822|NCT01692691|Experimental|Dacarbazine, carmustine, neulasta|Dacarbazine IV - Day 1; Carmustine IV - Day 2; Neulasta SC - Day 3
88847823|NCT05748860||Adult patients commencing on VA-ECMO|The study population is adult patients on VA-ECMO for cardiogenic shock or cardiac arrest that are or will be enrolled in the national ECMO registry (EXCEL).
89181767|NCT04097444|Experimental|Step 1 (CAPOXIRI+ BEV)|"Induction therapy is followed by the maintenance therapy.~[Induction treatment: CAPOXIRI+BEV] Administered for 6 cycles (a maximum of 8 cycles). BEV: 7.5mg/kg (d.i.v.) oxaliplatin (OX): 100/130 mg/sq.m (d.i.v.) irinotecan (IRI):150/180/200mg/sq.m (d.i.v.) CAP 1,600 mg/sq.m /day (p.o. day1-15) Administered every 3 weeks. OX/IRI dose is applied according to the progress of Step 1.~[Maintenance treatment: 5-fluorouracil (FU)/Levofolinate calcium (LV)+BEV or CAP+BEV] The following 5-FU/LV+BEV therapy will be repeated in 2-week cycles, or the following CAP+BEV therapy will be repeated in 3-week cycles (Physician's choice). No change in treatment regimen will be permitted after the selection of maintenance therapy (5-FU/LV+BEV or CAP+ BEV).~5-FU/LV+BEV: BEV:5mg/kg (d.i.v.) l-LV:200mg/sq.m (d.i.v.) 5-FU:3,200mg/sq.m (c.i.v.) Administered every 2 weeks.~CAP+BEV: BEV: 7.5mg/kg (d.i.v.) CAP 1,600 mg/sq.m /day (po. day1-15) Administered every 3 weeks."
89535035|NCT05023239|Sham Comparator|control group|patients will receive sham block by 10 ml of normal saline (5 mL in each side) as a control.
88847824|NCT01127503|Experimental|Metyrosine|
88847825|NCT01127503|Placebo Comparator|Placebo|
88847826|NCT01122511|Experimental|700 ug dexamethasone and ranibizumab|Intravitreal injection of 700 ug dexamethasone and ranibizumab into study eye
88847827|NCT01122511|Active Comparator|ranibizumab and sham|Intravitreal injection of ranibizumab and Sham into study eye
88847828|NCT05535218|Other|Single Arm|Single Arm treatment
88847829|NCT05531708|Experimental|Anti-mesothelin CAR-T cells|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by investigational treatment, anti-mesothelin CAR-T cells.
88847830|NCT01663285|Experimental|Neoadjuvant Gemcitabine and Cisplatin|Cisplatin 70 mg/m2 through IV for 60 minutes on day 1 of each cycle. Gemcitabine 1,000 mg/m2 IV for 30 minutes on days 1 and 8 during each cycle. Treatment is expected to continue for up to 4 cycles. Chemotherapy will be followed by radical nephroureterectomy within 6 weeks (+/- 2 weeks) from the last date of chemotherapy.
88847831|NCT01673425|Experimental|Live Attenuated Influenza Vaccine|Single intervention study- all participants will receive LAIV instead of injectable flu vaccine.
88847832|NCT05599087|Experimental|Acellular system|Regenerative Endodontic Procedure (REP) the acellular system derived from umbilical cord-derived mesenchymal stem cells encapsulated in a platelet-poor plasma-derived biomaterial.
88847833|NCT05748704|Experimental|Short-term modified fasting|The STMF regimen consists of a low-calorie diet lasting five days and aimed at providing between 800 and 1,000 kcal/day (tentatively 10% carbohydrates, 15% proteins, 75% lipids).
89002359|NCT06318611||Control group|Children and adolescents without type 1 diabetes between the ages of 6 and 18.
89002360|NCT06318572|Experimental|Psychological intervention|
88847834|NCT05598307|Active Comparator|magnesium bolus|A bolus dose of magnesium of 40 mg/kg will be administered within 10 minutes preoperatively diluted in 100 mL of saline. Followingly, normal saline will be administered at a rate of 20 mL/h
88847835|NCT05598307|Active Comparator|magnesium bolus and magnesium infusion|A bolus dose of magnesium of 40 mg/kg will be administered within 10 minutes preoperatively diluted in 100 mL of saline. Followingly, 10 mg/kg/h of magnesium will be administered intraoperatively diluted in a 60 mL syringe and administered at a rate of 20 mL/h
89375669|NCT06090448|Other|Portsmouth Hospital Unit (PHU) - Clinical groups 2,3 & 4|"Three clinical groups will be recruited in Arm 2: 40 with mild-to-moderate motor neurodisabilities without communication assistive technology needs, 40 healthy participants and 20 who do not have the ability to ear rumble.~Participants will be required to attend two in-person visits at the Queen Alexandra Hospital at the beginning and end of the study. This is in addition to completing the home procedure using the Earswitch device at home."
89375670|NCT06079593|Experimental|Gasless Surgery|
88847836|NCT05598307|Placebo Comparator|placebo|100 mL of normal saline will be administered within 10 minutes preoperatively. Followingly, normal saline will be administered at a rate of 20 mL/h
88847837|NCT05747612|Other|Patients with Bipolar Disorder|
88847838|NCT01090141|Active Comparator|Subjects recieving 100 mg of Micafungin|
88847839|NCT01090141|Active Comparator|Subjects recieving 300 mg of Micafungin|
88847840|NCT05597293|Active Comparator|FreeStyle Libe 2|Participants in this group will wear the FreeStyle Libre 2 device
88847841|NCT05597293|Active Comparator|FreeStyle Libre pro iQ|Participants in this arm will wear the FreeStyle Libre pro iQ device
88847842|NCT05597059||Shortness of breath|
88847843|NCT05597059||Extremity pathologies|
88847844|NCT05597059||Abdominal pain|
88847845|NCT05597059||Urological pathologies|
88847846|NCT05597059||Chest pain|
88847847|NCT05597059||Back pain|
88847848|NCT01048723|Experimental|RAD001 Administration|RAD001 was administered orally as once daily dose of 10 mg PO daily x 2 weeks (14 X 10 mg tablets) continuously from study day 1 until the end of therapy (2 weeks later) or unacceptable toxicity.
88847849|NCT05513612|Experimental|Autologous CAR-T cells|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by investigational treatment, CAR-T cells. CAR-T cells targeted CD19/BCMA/CD123/CD7 are autologous genetically modified T cells.
88847850|NCT05596045|Experimental|ASC10|Participants will be randomized to receive 200, 400 and 800 mg ASC10 BID for 5.5 days
88847851|NCT05596045|Placebo Comparator|Placebo|Participants will be randomized to receive placebo
88847852|NCT05594407|Active Comparator|dexmedetomidine-ketamine-lidocaine (DKL) group|combination of dexmedetomidine, ketamine and lidocaine in one syringe
88847853|NCT05594407|Active Comparator|remifentanil group|syringe of remifentanil
88847854|NCT04706377|Active Comparator|Active treatment group|Patients were given oral dispersible tablet with 1000μg of vitamin B12 daily for 12 months.
88847855|NCT04706377|Placebo Comparator|Placebo group|Patients were given placebo tablet similar to the tablet given to the active group once a day for 12 months.
88847856|NCT04706299|Active Comparator|No Mask|Will not wear a mask
88847857|NCT04706299|Experimental|Surgical mask|Will wear a surgical nose and face covering
88847858|NCT04450004|Experimental|Vaccine (3.75 µg) unadjuvanted|• Group 1: 3.75 µg of the Coronavirus-Like Particle COVID-19 Vaccine
88847859|NCT04450004|Experimental|Vaccine (3.75 µg) adjuvanted with CpG 1018|• Group 2: 3.75 µg of the Coronavirus-Like Particle COVID-19 Vaccine adjuvanted with CpG 1018
88847860|NCT04450004|Experimental|Vaccine (3.75 µg) adjuvanted with AS03|• Group 3: 3.75 µg of the Coronavirus-Like Particle COVID-19 Vaccine adjuvanted with AS03
88847861|NCT04450004|Experimental|Vaccine (7.5 µg) unadjuvanted|• Group 4: 7.5 µg of the Coronavirus-Like Particle COVID-19 Vaccine unadjuvanted
88847862|NCT04450004|Experimental|Vaccine (7.5 µg) adjuvanted with CpG 1018|• Group 5: 7.5 µg of the Coronavirus-Like Particle COVID-19 Vaccine adjuvanted with CpG 1018
88847863|NCT04450004|Experimental|Vaccine (7.5 µg) adjuvanted with AS03|• Group 6: 7.5 µg of the Coronavirus-Like Particle COVID-19 Vaccine adjuvanted with AS03
88847864|NCT04450004|Experimental|Vaccine (15 µg) unadjuvanted|• Group 7: 15 µg of the Coronavirus-Like Particle COVID-19 Vaccine unadjuvanted
88847865|NCT04450004|Experimental|Vaccine (15 µg) adjuvanted with CpG 1018|• Group 8: 15 µg of the Coronavirus-Like Particle COVID-19 Vaccine adjuvanted with CpG 1018
88847866|NCT04450004|Experimental|Vaccine (15 µg) adjuvanted with AS03|• Group 9: 15 µg of the Coronavirus-Like Particle COVID-19 Vaccine adjuvanted with AS03
89375671|NCT06079593|Active Comparator|Standard surgery with gas tamponade|
89375672|NCT06073314||Original cohort|This cohort will have a maximum of 10 minutes of quantitative MRI sequences added on to the end of the clinical standard MRI scan
88847867|NCT01583647|Experimental|MK-0524A 1 g/20 mg (Panel A)|Single oral dose of 1 tablet of MK-0524A. Each tablet contained Extended Release (ER) Niacin 1g and laropiprant 20 mg
88847868|NCT01583647|Experimental|MK-0524A 2 g/40 mg (Panel B)|Single oral dose of 2 tablets of MK-0524A. Each tablet contained Extended Release (ER) Niacin 1g and laropiprant 20 mg
88847869|NCT05745428||First group with aortic dissection|19 patients admitted to our Department of Cardiovascular Sciences with a radiological diagnosis of AD within 14 days of the onset of symptoms
88847870|NCT05745428||Control Group|19 healthy outpatient or inpatient controls at our Department with another diagnosis and no evidence of AD, matched for demographic and clinical characteristics.
88847871|NCT04403516|Experimental|DEXTENZA Group|Patients with Pterygium DEXTENZA Group
88847872|NCT04403516|Experimental|Topical Prednisolone Acetate 1% Group|Patients with Pterygium Topical Prednisolone Acetate 1% Group
88847873|NCT01555489|Experimental|Ascorbic Acid, Gemcitabine & Erlotinib|Ascorbic Acid (50-100g, 3x weekly) Standard Chemotherapy of Gemcitabine and Erlotinib for Pancreatic Cancer
88847874|NCT01035073|Experimental|Duloxetine|
88847875|NCT05236868|Experimental|Seltorexant|Participants will receive a single oral dose of seltorexant. At 2 hours after oral dosing, participants will receive 14C-seltorexant as an intravenous (IV) infusion over 15 minutes.
88847876|NCT01561495|Experimental|All Participants|Proton Radiotherapy
88847877|NCT04330976|Experimental|Nutrition and physical activity intervention|
88847878|NCT04330976|Other|Control|
88847879|NCT04331743|Experimental|PLM60|"Three dose levels will be tested according to the 3 + 3 dose-escalation design.The dose-limiting toxicity (DLT) will be assessed from the first administration of PLM60 to the end of the first cycle (28 days)."
88847880|NCT05296759|Active Comparator|botulinum toxin A injection|botulinum toxin A injection
88847881|NCT05296759|Active Comparator|gabapentin|gabapentin
88847882|NCT05296759|Active Comparator|duloxetine|duloxetine
88847883|NCT05546047|Active Comparator|Treatment with Acthar gel|Group 1 - (17 patients) Acthar gel 80 units 2 times a week alone for 12 months of therapy.
88847884|NCT05546047|Active Comparator|Treatment with combination Acthar gel and Tacrolimus therapy|Group 2 - (17 patients) Acthar get 80 units 2 times a week plus oral Tacrolimus 1.0 mg two times a day titrated to trough Tacrolimus levels between 4-6 ng/ml
88847885|NCT05743556|Experimental|HILT group|Therapy of muscle hypertonus by Hight intensive laser applied on cervical muscles.
88847886|NCT05743556|Active Comparator|TRT group|Muscle hypertonus of the cervical area treated by Target radio frequency current.
88847887|NCT05743556|No Intervention|Control group|Group of patients with muscle cervical hyper tone without any therapy.
88847888|NCT05234762|Experimental|ES-481|Week 1 - 25 mg qd (2 x 25 mg capsule in the mornings Days 1 to 7 in Treatment Period 1 and Days 44 to 50 in Treatment Period 2) Week 2 - 50 mg bid (2 x 25 mg capsule in the mornings and 2 x 25 mg capsules in the evening on Days 8 to 14 in Treatment Period 1 and Days 51 to 57 in Treatment Period 2) Week 3 - 75 mg bid (2 x 25 mg capsule in the mornings and 2 x 25 mg capsules in the evening on Days 15 to 21 in Treatment Period 1 and Days 58 to 64 in Treatment Period 2) Week 4 - 75 mg bid (2 x 25 mg capsule in the mornings and 2 x 25 mg capsules in the evening on Days 22 to 28 in Treatment Period 1 and Days 65 to 71 in Treatment Period 2)
88847889|NCT05234762|Placebo Comparator|Placebo|Placebo will be dosed at the same quantity and frequency as ES-481 just as Placebo HPMC capsules
88847890|NCT01532635|Experimental|Allogeneic HSCT Using Two Related Donors|"CONDITIONING: Patients undergo TBI BID on days -9 to -6, undergo DLI on day -6, and receive cyclophosphamide IV over 2 hours on days -3 and -2.~TRANSPLANTATION: Patients undergo CD34+ selected allogeneic HSCT on day 0.~GVHD PROPHYLAXIS: Patients receive tacrolimus IV or PO beginning on day -1 with taper beginning on day 42 and mycophenolate mofetil IV or PO BID on days -1 to 28."
88847891|NCT01085773|No Intervention|Standard written information on exercise|The Control group got the diabetes outpatients clinics standard written information on exercise as a part of the treatment for Type 2 Diabetes and were, like other Type 2 Diabetes patients in the clinic, advised at inclusion to be physically active.
88847892|NCT01085773|Experimental|Exercise on Prescription|In Denmark, Exercise on Prescription have focused on individual behavioral change and an exercise program for 16 weeks. The physical training consisted of both aerobic and strength training and took place in supervised groups
88847893|NCT01085773|Experimental|Nordic Walking|Nordic Walking is a fitness type of walking; incorporating the use of specially designed walking sticks. Nordic Walking focuses on aerobic training where the additional activity of the arms increases a person's oxygen uptake and energy expenditure.
88847894|NCT05295511|Experimental|Team Handball 1|Team handball group participants were instructed to perform one weekly 60-min recreational team handball training sessions for 16 weeks.
88847895|NCT05295511|Experimental|Team Handball 2|Team handball group participants were instructed to perform two weekly 60-min recreational team handball training sessions for 16 weeks.
88847896|NCT05295511|Experimental|Team Handball 3|Team handball group participants were instructed to perform three weekly 60-min recreational team handball training sessions for 16 weeks.
88847897|NCT05295511|No Intervention|Control Group|The control group participants were instructed to keep their regular daily physical activity for 16 weeks.
88847898|NCT00986947|Experimental|IvIg with Rituximab|
88847899|NCT00559897|Experimental|3'-deoxy-3'-[18F]FLT PET & zoledronic acid|"Patient should receive the dose of zoledronic acid within 48 hours of the first FLT PET scan. The second FLT PET scan will be done 6-8 days after the dose of zoledronic acid~Single photon emission computed tomography. Patient should receive the dose of zoledronic acid within 48 hrs of the first '3'-deoxy-3'-[18F]FLT PET scan. The second FLT PET scan will be done 6-8 days after the dose of zoledronic acid."
88847900|NCT00979147|Experimental|Modular Metal Tibial Baseplate|Patients who were randomized to receive the modular polished tibial baseplate/XLK TKA
88847901|NCT00979147|Active Comparator|All Polyethylene Tibial Baseplate|Patients who were randomized to receive the nonmodular APT/GVF TKA design.
88847902|NCT00539617|Experimental|Tarceva and FOLFOX|"COMBINATION THERAPY PHASE: Patients receive erlotinib hydrochloride orally (PO) once daily (QD) on days 1-56. Patients also receive FOLFOX6 therapy comprising oxaliplatin intravenously (IV) over 2 hours, leucovorin calcium IV over 2 hours, and fluorouracil IV over 46-48 hours on days 1, 15, 29, and 43. Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity. Patients with stable disease or no evidence of disease after course 2 or subsequent courses continue on to maintenance phase.~MAINTENANCE PHASE: Patients receive erlotinib hydrochloride PO QD on days 1-42. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity."
88847903|NCT05182580|Experimental|Intervention Group|Autonomous AI results are used to evaluate if the participant needs to see the retina specialist (positive result) or not (negative result).
88847904|NCT05182580|No Intervention|Control Group|All participants see the retina specialist irrespective of the results of their autonomous AI evaluation.
88847905|NCT05467514|Experimental|Liraglutide|Application of liraglutide 1.8 mg subcutaneous daily for 6 months to evaluate subclinical atherosclerosis, by means of carotid doppler US, lipid profile in patients with type 1 diabetes mellitus
88847906|NCT00976339|Experimental|Cholecalciferol 20,000 IU|Participants will receive Cholecalciferol 20,000 IU (2 capsules) weekly for one year.
88847907|NCT00976339|Experimental|Cholecalciferol 30,000 IU|Participants will receive Cholecalciferol 30,000 IU (3 capsules) weekly for one year.
88847908|NCT05456828|Experimental|ASKG712|Single or multiple ascending dose of ASKG712 by intravitreal injection
88847909|NCT04579640|No Intervention|Control|Standard of care (national recommendation of 400 IU/day vitamin D)
88847910|NCT04579640|Experimental|Intervention: Lower-dose vitamin D|Offer of a daily dose of 800 IU (20 micrograms) cholecalciferol to individuals with 25-hydroxyvitamin D level <75 nmol/L
88847911|NCT04579640|Experimental|Intervention: Higher-dose vitamin D|Offer of a daily dose of 3200 IU (80 micrograms) cholecalciferol to individuals with 25-hydroxyvitamin D level <75 nmol/L
88847912|NCT00517075|Experimental|A|high frequency rTMS to the left infero-parietal lobe, active/sham condition randomized (2:1), double-blind
88847913|NCT00517075|Active Comparator|B|Active high frequency rTMS to the left dorsolateral prefrontal cortex
88847914|NCT00517075|Sham Comparator|C|Sham (placebo) high frequency rTMS to the left dorsolateral prefrontal cortex or left infero-parietal lobe, active/sham condition randomized (2:1), double-blind
88847915|NCT00517075|Experimental|Open cross over high frequency rTMS|Following the randomization phase with three arms, subjects who did not respond, have the possibility of receiving open active treatment to the target that they did not receive treatment to in the randomization phase. (i.e. randomized to IPL --> open phase DLPFC and vice versa)
88847916|NCT04579172|Experimental|Group A|Circular isthmic-cervical sutures
88847917|NCT04579172|Experimental|Group B|Resection of the infiltrated part of anterior uterine wall
88847918|NCT00523939|Experimental|Lymphomatous|Subjects with Lymphomatous Meningitis
88847919|NCT00523939|Experimental|Leukemic|Subjects with Leukemic Meningitis
88847920|NCT00954187|Experimental|Gabapentin|Neurontin
88847921|NCT00954187|Experimental|Pregabalin|Lyrica
88847922|NCT04802018|Experimental|Monitored group|Monitoring of vital signs and following with the conventional telephone protocol
88847923|NCT04802018|No Intervention|Control group|Conventional telephone follow-up by health staff
88847924|NCT00947791|Experimental|Ketamine/Midazolam|Patients receive both treatment conditions (ketamine and midazolam) in a single arm, crossover design. Patients are randomized to ketamine-midazolam. Each treatment occurs as a single intravenous infusion on one treatment day. The two treatment conditions occur 2 weeks apart.
88847925|NCT00947791|Experimental|Midazolam/Ketamine|Patients receive both treatment conditions (ketamine and midazolam) in a single arm, crossover design. Patients are randomized to midazolam-ketamine. Each treatment occurs as a single intravenous infusion on one treatment day. The two treatment conditions occur 2 weeks apart.
88847926|NCT05139992||Observational Cohort|Previously unvaccinated persons with sickle cell disease who are scheduled to receive their initial COVID-19 vaccine series.
88847927|NCT00504985||Fatigue in Emergency Center Patients|
88847928|NCT05136326|Experimental|Catartic: chemoradiotherapy plus temozolomide|"External-beam radiation: 50.4 GY (45 Gy in 25 fractions + Boost 5.4 Gy in 3 fractions over 5 weeks) in association with:~Capecitabine 825 mg/sqm/bid per os (p.o.) 5 days/week for 5 weeks plus Temozolomide 75 mg/sqm p.o. 5 days/week for 5 weeks."
88847929|NCT00379015|Experimental|HER2 over-expressing primary breast cancer group|"Patients receive epirubicin hydrochloride and cyclophosphamide in week 1-3. Treatment with epirubicin hydrochloride and cyclophosphamide repeats every 3 weeks for 4 courses. Patients then receive docetaxel in week 13 and trastuzumab (Herceptin®) in weeks 13-15. Treatment with docetaxel and trastuzumab repeats every 3 weeks for 4 courses.~Patients then undergo appropriate surgery. After surgery, patients with hormone receptor-positive disease receive trastuzumab once weekly and either tamoxifen with or without a luteinizing hormone-releasing hormone agonist or an aromatase inhibitor. Treatment continues for 40 weeks."
88847930|NCT05447000|Experimental|Mindfullness Based Stress Reduction|Mindfullness Based Stress Reduction (MBSR) therapy
88847931|NCT05447000|Experimental|Deep Relaxation Exercises|Deep Relaxation Exercises therapy
88847932|NCT05447000|Other|Control|Control
88847933|NCT00930787|Experimental|Strattice Reconstructive Tissue Matrix|Use of Strattice Reconstructive Tissue Matrix to support hernia repair
88847934|NCT00930787|Active Comparator|Proceed Surgical Mesh|Use of Proceed Surgical Mesh to support hernia repair
88847935|NCT00382382|Other|Children with Autism|A diffusion tensor imaging (DTI) will be done to examine the integrity of the white matter pathways in high functioning austistic children.
88847936|NCT00382382|Other|Healthy Volunteers|A diffusion tensor imaging (DTI) will be done to examine the integrity of the white matter pathways in healthy volunteers.
88847937|NCT05438030|Experimental|Paired cardiac MRI and echocardiographic measurements|
88847938|NCT05352061|Experimental|Cognitive Behavioral Therapy (CBT) for Syndemic and Adherence Factors Group|Participants in this group will receive the CBT for Syndemics and Adherence Factors intervention for a total of 14 sessions over 4 months.
88847939|NCT00911053|No Intervention|Baseline|
88847940|NCT00911053|Experimental|Melatonin|Subjects will be administered melatonin.
88847941|NCT00911053|Experimental|Light|
88847942|NCT00911053|Experimental|Regular Sleep Schedule|
88847943|NCT00911053|No Intervention|Longitudinal Monitoring|Optional longitudinal study, an extension of the first study stage, for subjects whose rhythms are not clearly free-running.
88847944|NCT04755530|Active Comparator|Regular whole milk|Substitution of a part of the habitual diet with 400 g/day of regular whole milk
88847945|NCT04755530|Experimental|Yogurt with live bacteria|Substitution of a part of the habitual diet with 400 g/day of yogurt with life bacteria
88847946|NCT04755530|Experimental|Yogurt with inactivated bacteria|Substitution of a part of the habitual diet with 400 g/day of yogurt with inactivated bacteria
88847947|NCT04755530|Experimental|Acidified whole milk|Substitution of a part of the habitual diet with 400 g/day of acidified whole milk
89375673|NCT06073314||Reproducibility cohort|This group will be invited back for a second MRI scan to test reproducibility of quantitative scans and the machine learning algorithms developed to interpret them.
88847948|NCT04330508||Group A|Chronic hepatitis C without Cirrhosis
89181768|NCT04097444|Experimental|Step 2 Arm A (FOLFOXIRI+ BEV)|"Induction therapy is followed by the maintenance therapy.~[Induction treatment: FOLFOXIRI+BEV] Administered for 8 cycles (a maximum of 12 cycles). BEV: 5mg/kg (d.i.v.) OX: 85 mg/sq.m (d.i.v.) IRI:165mg/sq.m (d.i.v.) LV:200mg/sq.m (d.i.v.) 5-FU:3,200mg/sq.m (c.i.v.) Administered every 2 weeks.~[Maintenance treatment: 5-FU/LV+BEV or CAP+BEV] The following 5-FU/LV+BEV therapy will be repeated in 2-week cycles, or the following CAP+BEV therapy will be repeated in 3-week cycles (Physician's choice). No change in treatment regimen will be permitted after the selection of maintenance therapy (5-FU/LV+BEV or CAP+ BEV).~5-FU/LV+BEV: BEV:5mg/kg (d.i.v.) LV:200mg/sq.m (d.i.v.) 5-FU:3,200mg/sq.m (c.i.v.) Administered every 2 weeks.~CAP+BEV: BEV: 7.5mg/kg (d.i.v.) CAP 1,600 mg/sq.m /day (po. Day1-15) Administered every 3 weeks."
89375674|NCT06072196||Novel hormonal therapy cohort|Patients initiating novel hormonal therapy (abiraterone, apalutamide or enzalutamide) for mCSPC
88847949|NCT04330508||Chronic hepatitis C with Cirrhosis|
88847950|NCT04330508||Healthy Volunteers|
89375675|NCT06067451|Experimental|SMART GOAL Arm|"The participants randomized to the study group will receive the SGSP, consisting of the SMART Goal Selection Guide (SGSG) and Weekly Goal Monitoring Tool (WGMT), which will be used in tandem.~The study group participants will also be asked to summarize the information discussed during the visit, and then will receive the SMART (Specific, Measurable, Attainable, Realistic, Time sensitive) Goal Setting Protocol (SGSP)."
88847952|NCT05423912|Experimental|Mild Cognitive Impairment (MCI) Participant|All participants will be asked to complete the quantitative endpoint measures at baseline and 4 and 8 weeks after the end of the course. These measures will be administered verbally by a study staff member by phone (20-30 minutes) or Zoom call to ensure survey questions are clear and participants' questions are answered. These quantitative measures will assess the effect of the program on participants' sense of mastery or control over caregiving tasks as well as their emotional well-being and communication. In addition, qualitative semi-structured interviews will be conducted following program participation. These interviews will focus on participants' perceptions of the effect of the program on them but will also seek information that might help to further strengthen the program
88847953|NCT05423912|Experimental|Person living with MCI participant|All participants will be asked to complete the quantitative endpoint measures at baseline and 4 and 8 weeks after the end of the course. These measures will be administered verbally by a study staff member by phone (20-30 minutes) or Zoom call to ensure survey questions are clear and participants' questions are answered. These quantitative measures will assess the effect of the program on participants' sense of mastery or control over caregiving tasks as well as their emotional well-being and communication. In addition, qualitative semi-structured interviews will be conducted following program participation. These interviews will focus on participants' perceptions of the effect of the program on them but will also seek information that might help to further strengthen the program.
88847954|NCT05097170||1|patients under the age of 65
88847955|NCT05097170||2|patients above the age of 65
88847956|NCT04330352|Experimental|"Mindfulness-based STOP touching your face intervention"|"Eligibility participants who are allocated to the intervention group will be required to find a time to monitor and record their behavior of hand-to-face contacts, including the frequency and length (in second) of face-touching in any of the mucosal area (eyes, nose, mouth) and nonmucosal area (ears, cheeks, chin, neck, forehead, hair) during a 60-minute period. Then, they will receive the online mindfulness-based STOP touching your face program. Each participant will be required to practice this technique until they feel confident and natural. The systematic review showed the efficacy of single session of brief MBIs, the average length was 15 minutes, ranged from less than 5 to 25 min. Thus, the requirement practice time will be at least 15 minutes (excluding the time of reading the text and the first time of listening to the audio). Later (at least 1-hour interval), they will be asked to self-monitor and report their one-hour face-touching behavior again."
88847957|NCT04330352|No Intervention|Contron information intervention|"Participants who allocate to the control group will only receive information to thank them and encourage them to complete the study. They will receive STOP touching your face program after the end of this study. The repeat measurement of the face-touching behavior will be in at least 1-hour interval."
88847958|NCT04713410|Experimental|Group A|Steroids will be given for short duration of time i-e 12 weeks
88847959|NCT04713410|Active Comparator|Group B|Steroid will be given for longer duration i-e 20 weeks
88847960|NCT04713332|Active Comparator|vitamin E|Oral intake of Vitamin E treatment will be given on a daily basis in a single-blind manner one day before the first day of RT and continued for 8 weeks. Patients in the group receiving 500 IU of d-alpha-tocopherol capsules orally (3 times daily).
88847961|NCT04713332|Active Comparator|Hydrogen rich water|Oral intake of HRW (2 ppm) treatment will be given on a daily basis in a single-blind manner one day before the first day of RT and continued for 8 weeks. The group of patients receiving Hydrogen water took an amount of 250 ml orally 3 times a day.
88847962|NCT04713332|Placebo Comparator|placebo|Oral intake of placebo will be given on a daily basis in a single-blind manner one day before the first day of RT and continued for 8 weeks. The placebo group received 3 soft gel placebo capsules containing gelatin three times a day.
88847963|NCT05087186|Experimental|Intervention|Group sessions with psychological therapists
88847964|NCT00476827|Active Comparator|Bevacizumab / Capecitabine|Bevacizumab 15 mg/kg every 3 weeks in combination with Capecitabine (Xeloda), 2 weeks on and 1 week off on a every 3 week cycle.
88847965|NCT00476827|Active Comparator|Bevacizumab / Docetaxel|Docetaxel (taxotere) 35mg/m² IV over 60 min days 1, 8, and 15 in combination with avastin 10 mg/kg on days 1 and 15 of a 28-day cycle.
88847966|NCT00476827|Active Comparator|Bevacizumab /Irinotecan (Camptosar®, CPT-11)|CPT-11 (Irinotecan, Camptosar) - Patients being treated with an enzyme inducing antiepileptic drug (EIAED) will receive 340 mg/m² IV; others will receive 125 mg/m² IV 90 min on days 1 and 15, in combination with avastin 10 mg/kg on days 1 and 15 of a 28-day cycle.
89375676|NCT06067451|No Intervention|Standard of Care Arm|"Participants randomized to this group will receive standard of care.~At the end of each visit, the participants in the standard of care (SOC) group will be asked to provide a summary of topics discussed and what they plan to improve on from now and their next visit:"
89375677|NCT06061302|Experimental|Immediate yoga group|20 participants randomized to immediate yoga intervention group will participate together in a weekly 40-minute guided mindful yoga intervention for a total of 12 consecutive weeks. After each session, participants will be asked to complete the Edmonton Symptom Assessment System (ESAS-r) through MyDataHelps app. At the end of each session, participants will be asked additional questions via MyDataHelps such as completion of yoga session on-site or remotely, the length of time they participated in the session, any additional yoga sessions during the past week, and comments regarding the session/intervention. These participants will also complete health-related quality of life (HRQOL) assessment (EORTC QLQ-C30) at baseline, 6 weeks, and 12 weeks during active yoga intervention.
89375678|NCT06061302|Active Comparator|Waitlist yoga group (delayed yoga intervention group)|20 participants randomized to this group will start the yoga intervention at week 13 and participate in 12 consecutive weeks of weekly 40 minute guided mindful yoga. Participants in this group will complete ESAS-r every 3 weeks and EORTC QLQ-C30 every 6 weeks for the first 12 weeks. These participants will also complete HRQOL assessment (EORTC QLQ-C30) at baseline, 6 weeks, and 12 weeks during active yoga intervention, weeks 13-24.
89375679|NCT06055556|Experimental|Partial Heart Transplantation|Participants will receive a partial heart transplantation to replace the pulmonary valve with fresh donor graft(s). This is an investigational procedure. This means this procedure is not done as a routine treatment for patients with congenital heart defects. Partial heart transplantation involves surgical replacement of the semilunar heart valve with the heart valve and supporting blood vessels and tissue from an organ donor. No other parts of the heart are transplanted besides the heart valve, blood vessel, and tissue surrounding the valve.
89375680|NCT06050668|Experimental|Essential Amino Acid Supplementation|Subjects randomized to intervention arm of this study will receive essential amino acid (EAA)-based oral nutrition supplementation in addition to standard of care postoperative nutrition. Subjects will take 1 scoop (26.7g) of supplement twice daily for 6 weeks after injury. Supplementation will begin within 72 hours of hospital admission. The EAA-based supplement used in this clinical trial is MEND™ Repair and Recover®.
89375681|NCT06050668|No Intervention|Standard of Care Postoperative Nutrition|Subjects randomized to the control arm of this study will receive no intervention. They will receive standard of care postoperative nutrition.
89375682|NCT06047041|Active Comparator|EIS Only|EIS Only (active comparator) condition schools involve technical assistance to support the implementation EIS.
89375683|NCT06047041|Experimental|EIS + ECHO|"EIS + ECHO (experimental) condition involves all of the activities included in the EIS Only condition and will include enhanced implementation supports. Enhanced implementation supports involve 1) monthly collaborative learning ECHO sessions for school student support team staff to support implementation of EIS and evidence-based mental and behavioral health practices and 2) individual school teams will also receive follow-up supports to promote the implementation strategies presented during ECHO sessions."
89375684|NCT06040268|Experimental|Advair HFA (salmeterol 126 ug/fluticasone 270 ug) twice daily for up to 7 days|Participants will inhale salmeterol 126 ug and fluticasone 270 ug twice daily for up to 7 days
89375685|NCT06040268|Placebo Comparator|Placebo|Participants will inhale placebo (same puff number) twice daily for up to 7 days
89375686|NCT06023732|Experimental|Baseline 7 days|Behavioral activation and emotion-focused interventions Baseline randomized length 7-14 days
89375687|NCT06023732|Experimental|Baseline 8 days|Behavioral activation and emotion-focused interventions Baseline randomized length 7-14 days
89375688|NCT06023732|Experimental|Baseline 9 days|Behavioral activation and emotion-focused interventions Baseline randomized length 7-14 days
89375689|NCT06023732|Experimental|Baseline 10 days|Behavioral activation and emotion-focused interventions Baseline randomized length 7-14 days
89375690|NCT06023732|Experimental|Baseline 11 days|Behavioral activation and emotion-focused interventions Baseline randomized length 7-14 days
89375691|NCT06023732|Experimental|Baseline 12 days|Behavioral activation and emotion-focused interventions Baseline randomized length 7-14 days
89375692|NCT06023732|Experimental|Baseline 13 days|Behavioral activation and emotion-focused interventions Baseline randomized length 7-14 days
88847967|NCT00476827|Active Comparator|Bevacizumab / Paclitaxel|Paclitaxel (Taxol)90 mg/m2 IV over 60-90 min days 1, 8, and 15, in combination with avastin 10 mg/kg on days 1 and 15 of a 28-day cycle.
89375693|NCT06023732|Experimental|Baseline 14 days|Behavioral activation and emotion-focused interventions Baseline randomized length 7-14 days
89375694|NCT06011317|Experimental|Part A: Healthy Volunteer (Ages ≥ 18 to < 60 years) Single Ascending Dose|Single oral ascending dose in healthy volunteers ages ≥ 18 to < 60 years
89375695|NCT06011317|Experimental|Part B: Healthy Volunteer (Ages ≥ 18 to < 60 years) Multiple Ascending Doses|Multiple oral ascending doses in healthy volunteers ages ≥ 18 to < 60 years
89375696|NCT06011317|Experimental|Part D: Healthy Volunteer Food Effect and Relative Bioavailability|Crossover food effect (fed versus fasted) single oral dose in healthy volunteers and relative bioavailability of liquid versus solid formulation
89399351|NCT02173184|Experimental|Gynevac|Gynevac suspension for injection, a vaccine containing Lactobacillus strains 15, 34, 79, 84, 127 inactivated by formaldehyde in 0.9% NaCl solution
88847968|NCT00476827|Active Comparator|Bevacizumab /Vinorelbine Tartrate|Vinorelbine Tartrate (Navelbine®) 25 mg/m² IV over 10 min days 1, 8 and 15 in combination with avastin 10 mg/kg IV on days 1 and 15 of a 28-day cycle.
89002361|NCT06318572|Placebo Comparator|Placebo|
89375697|NCT06008054|Experimental|SI-B003 or BL-B01D1 + SI-B003|Participants received SI-B003 or BL-B01D1 + SI-B003 therapy in the first cycle (3 weeks). Participants who had a clinical benefit could receive additional cycles of additional treatment. Administration will be discontinued because of disease progression or intolerable toxicity or for other reasons.
89375698|NCT06006169|Experimental|Study treatment|Participants receive BL-B01D1, SI-B003 or BL-B01D1 + SI-B003 therapy in the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. Administration will be discontinued because of disease progression or intolerable toxicity or for other reasons.
89375699|NCT06005857|Experimental|Experimental group|The group will receive standard hand therapy program + rehabilitation program sustained by the use of a digital application.
89375700|NCT06005857|Active Comparator|Control group|The control group will receive a standard hand therapy program + paper-based (standard) rehabilitation program.
89375701|NCT05999565|Experimental|Motor Imagery Training|"Motor Imagery Training Motor Imagery Training will be applied only to the 2nd group, under the supervision of a physiotherapist, twice a week for 8 weeks, for 20 minutes each session. The treatment duration for the 2nd group will be planned to be a total of 50 minutes, including both motor imagery and motor control exercises. Motor imagery sessions will take place in a quiet environment, with individuals comfortably seated.~Lateralization Training Kinesthetic Imagery Visual Imagery Mirror-Image Active Exercise: Between weeks 6 and 8 of motor imagery training, the active exercises (Stretching Exercises, Active Exercises, and Endurance Exercises) will be actively performed in front of a mirror"
89375702|NCT05999565|Experimental|Motor Control Exercise|"Stretching Exercises: Stretching exercises will be applied to the cervical muscles, pectoral muscles, back, and shoulder muscles. Individuals will be asked to perform flexion, extension, lateral flexion, and rotational normal joint movements in the cervical region, and hold the end position for a few seconds. All stretching exercises will be performed for 15 repetitions.~Active Exercises: To strengthen the cervical muscle groups, individuals will be taught how to use a mild to moderate resistance theraband for cervical flexion, extension, and lateral flexion, without compromising the chin tuck movement. Each movement will be performed for 10 repetitions, with 5-second rest intervals between exercises.~Endurance Exercises: Before starting the endurance exercises, individuals will be taught the contraction of deep cervical flexors to gain automatic postural stabilization, and they will be instructed to maintain this movement in every exercise and activity."
89375703|NCT05991700|Experimental|Concentrated grape powder|
89375704|NCT05991700|Placebo Comparator|Placebo|
89375705|NCT05977270|Experimental|Lifebloom One intervention|
89535036|NCT05023239|Experimental|UG-SZM Group|The patients will be receive bilateral Ultrasound-Guided Suprazygomatic Maxillary (UG-SZM) Nerve Blocks 10 mL of a local anesthetic mixture composed of 0.25% plain bupivacaine
89535037|NCT05015517|Active Comparator|ESPB Group|This group will receive ultrasound-guided erector spinae plane block and subarachnoid block.
88847969|NCT00476827|Active Comparator|Bevacizumab / Gemcitabine|Gemcitabine (difluorodeoxycytidine, dFdC) 1000 mg/m2 IV on days 1 and 8 in combination with avastin 15 mg/kg IV on day 1 of a 21-day treatment cycle.
89375709|NCT05967780|Active Comparator|Group A: Patients with FHP receiving standard cardiac rehabilitation|Consenting participants in this group will receive a standard cardiac rehabilitation protocol.
89375710|NCT05967780|Experimental|Group B: Patients with FHP receiving standard cardiac rehabilitation + therapeutic exercises|The participants who give consent will receive standard cardiac rehabilitation protocol (as Group A) with therapeutic exercise in the intervention group.
89375711|NCT05967780|Active Comparator|Group C: Patients without FHP receiving standard cardiac rehabilitation|The participants without forward head posture will be included in this group and will receive same standard cardiac rehabilitation as the participants in group A.
88847970|NCT05084300|Experimental|Pain Neuroscience Education|Pain neuroscience education in addition medical treatment. Pain neuroscience education can be defined as an educational session or sessions describing the neurobiology and neurophysiology of pain, and pain processing by the nervous system.
88847971|NCT05084300|Other|Usual care|The control group is treated with usual medication for fibromyalgia, anxiolytics, antidepressants, analgesics, ... Depending on the medical needs and criteria of patients´s primary care physician.
88847972|NCT00901303|Other|Early Stage Disease|Group A
88847973|NCT00901303|Other|Advance Stage Disease|Group B
88847974|NCT05083676|Experimental|Acceset Intervention|The qualified participants (seekers) will be randomly allocated into two arms. Arm 1 (n = 50) seekers will engage with the Acceset platform for a period of 3 weeks, together with befrienders (n = 30) and moderators (n = 30). Both seekers and befrienders will be monitored using a questionnaire battery listed (including help seeking behaviors beyond the Acceset platform) at 4 time points: baseline (before the intervention), 3 weeks (the end of the intervention), 6 weeks and 9 weeks (to measure carry over effects).
89375712|NCT05967416|Experimental|SIRPant-M (90×10^6 cells)|SIRPant-M Monotherapy
89375713|NCT05967416|Experimental|SIRPant-M (90×10^6 cells) coupled with focal XRT|SIRPant-M coupled with 2.5 Gy of focal XRT administered within 24 hours after the first ITI and within 3 hours before to 24 hours after the second and third ITI
89375714|NCT05967416|Experimental|SIRPant-M (300×10^6 cells)|SIRPant-M Monotherapy
89375715|NCT05967416|Experimental|SIRPant-M (300×10^6 cells) coupled with focal XRT|SIRPant-M coupled with 2.5 Gy of focal XRT administered within 24 hours after the first ITI and within 3 hours before to 24 hours after the second and third ITI
89375716|NCT05966649|Experimental|Synbiotics|Oral synbiotic (food supplement) containing 8 probiotic Lactobacillus strains, the prebiotics inulin, fructooligosaccharides (FOS) and D-mannose.
89375717|NCT05966649|Placebo Comparator|Placebo|Matching placebo
89375718|NCT05950113|Experimental|Treatment (CART-BCMA/CS1)|Patients undergo leukapheresis on 35 to 21 days before Infusion Day (I-Day -35 to I-Day -21) and receive cyclophosphamide IV over 60 minutes and fludarabine IV over 30 minutes on I-Days -5, -4, and -3. Patients then receive CART-BCMA/CS1 IV on I-Day-0 on study. Patients undergo ECHO, ECG and MRI during screening. Patients undergo bone marrow biopsy and/or bone marrow aspirate screening, between I-Day -28 to I-Day -5, I-Day 30, and at 1 year post CART-BCMA/CS1 infusion. Patients also undergo FDG PET/CT during screening, between I-Day -28 to I-Day -5, I-Day 90 and I-Day 180 and every 3 months thereafter.
89375719|NCT05946837|Experimental|Pneumatic Compression Therapy (PCT)|
89375720|NCT05946590|Other|Frenotomy|Frenotomy performed by a health care professional
89375721|NCT05944419|Active Comparator|V3 Implant MIS Iberica|Implant with triangular neck macro design
88847975|NCT05083676|Active Comparator|waitlist for Acceset intervention|Arm 2 (n = 50) a control group will be placed on a waitlist for Acceset intervention. These individuals will be age and gender matched with the intervention group (i.e., arm 1). Their mental well-being, as well as their help seeking behavior, at the same time points and via the same questionnaire battery will be compared with those in arm 1.
88847976|NCT00459121|Experimental|Zactima, Paclitaxel, Carboplatin|"Zactima- 100 mg orally daily, starting on day 1 of cycle 1. Paclitaxel- 200mg/m2 IV, every 3 weeks starting on day 1 of cycle 1. Carboplatin AUC6 IV, every 3 weeks starting on day 1 of cycle 1 Duration of each cycle: 21 days. The last dose of zactima will be on the first day of the last cycle.~Neoadjuvant Surgery: Surgical resection of the tumor will be performed after the resolution of all the adverse effects from the last cycle of treatment but no earlier than 3 weeks after the last cycle of treatment."
88847977|NCT04696796|Experimental|BasIQ-4 Surgical Knife|Following the administration of 10 ml of 1% lidocaine, mediolateral episiotomy will be preformed with BasIQ-4 Surgical Knife according to computer generated randomization.
88847978|NCT04696796|Active Comparator|Episiotomy Scissors|Following the administration of 10 ml of 1% lidocaine, mediolateral episiotomy will be preformed with episiotomy scissors according to computer generated randomization.
88847979|NCT00432445|Experimental|Proton Beam Radiation Therapy|Radiation given daily for 5 days in a row each week (except for Saturdays, Sundays, and holidays). The whole treatment will take about 4-6 weeks. Ophthalmic examination under anesthesia including dilated eye exam, ocular fundus photography (Ret-Cam), ocular echography and neuro-radiologic assessment (as deemed necessary)
88847980|NCT05061680|Active Comparator|short sphincterotomy +Short duration papillary large balloon dilation|Patients with short sphincterotomy
88847981|NCT05061680|Active Comparator|full sphincterotomy + short duration papillary balloon dilation|Patients with full lenght sphincterotomy
88847982|NCT05061680|Active Comparator|previous sphincterotomy + short duration papillary balloon dilation|Patients with previous sphincterotomy
88847983|NCT05347303|Experimental|Experimental group|The experimental group (EG) after taking initial measurements and signing their informed consent will be subjected to an 8-week intervention plan with 2 sessions per week where they will receive 1 MTOH and 1 Foam roller on discontinuous days. MTOH consists of first evaluating the structures that have restrictions, whether soft tissues or joints, to later be treated with a specific manual technique. For this, evaluation methods based on Kaltenborn are used when it comes to joints and Pilat when focusing on soft tissues. Interventions will not exceed 20 minutes per subject. For the foam roller, subjects will perform slides on the instrument using their body weight on the following muscles: quadriceps, hamstrings, gastrocnemius, and tensor fascia lata, for 60 seconds with 3 repetitions for each. Each repetition will have a rest period of 30 seconds, this will be done on both lower limbs.
88847984|NCT05347303|Active Comparator|Control group|After taking measurements, they will perform 2 foam roller sessions per week following the same indications expressed in the experimental group.
88847985|NCT05343403||Family Integrated Care|During the intervention period, Family Integrated Care (FICare) will be implemented on the neonatal wards of the participating hospitals. Families that are included during this intervention period will participate in Family Centred Rounds (FCR), while being supported by the principles of FICare. FICare incorporates psychological, educational, communication, and environmental strategies to support parents and to prepare them emotionally, cognitively, and physically to care autonomously for their infant at the time of discharge. In FCR, parents actively participate in the medical rounds and decisions are made based on shared-decision making. Not only are parents informed about the clinical condition of their child, they can ask questions and share their own valuable information on their child. Such information can include the overall wellbeing but also specific medical information.
89375722|NCT05944419|Active Comparator|C1 Implant MIS Iberica|Implant with circular neck macro design
89375723|NCT05940129|Experimental|Web-based Intervention Arm (WC-SHE)|Women in computerized WC-SHE arm receives education on healthy relationships the danger assessment and tailored safety planning and list of resources. The intervention also includes assessments of strengths and safety strategies. In addition, husbands and in-laws receive one-on-one health education session that includes topics related to maternal and child health and safety
89375724|NCT05940129|Experimental|WC-SHE +Economic Empowerment|Women in economic empowerment arm receive computerized WC-SHE and are connected with self-help groups. Husbands are also engaged in economic empowerment activities that involve individual psychoeducation, working with spouses in self-help group activities and participating in government economic or vocational training programs. In addition, husbands and in-laws participate in individual sessions on topics related to maternal and child health and safety
89375725|NCT05940129|Experimental|WC-SHE + Enhanced Family Psychoeducation and Advocacy Support Intervention|Women in this arm receive computerized WC-SHE, advocacy and support by a support committee of professionals based on women's priorities and needs, and phone call support by women community resource persons. Husbands and in-laws participate in individual and group sessions that cover topics such as stress, healthy relationships, healthy communication within families and impact of domestic violence on children.
89375726|NCT05934890|Experimental|Walvax PCV13-TT|"Primary Vaccination: A total of approximately 300 infants 6-8 weeks of age will be enrolled and assigned randomly to receive at 2, 4, and 12-15 months of age 1 dose of PCV13-TT. Standard EPI vaccines will be administered concomitantly.~Booster Vaccination: At 12-15 months of age (8 to 11 months after the 2nd dose of the primary series), infants will receive a booster dose of PCV13-TT."
88847986|NCT05343403||Standard Neonatal Care|In the control period, standard neonatal care (SNC) will be provided. Medical rounds will be held between healthcare professionals, and parents are not (structurally) participating during these rounds. Parents are updated daily by the nurses, and (usually) weekly by their attending physician. Care for the infants is provided mostly by the nurses. Parents usually have (unlimited) access to the ward, but are not supported by the concept of FICare. As such, they do not receive education and are not structurally supported by veteran parents. Healthcare professionals stimulate parents to participate in daily care (such as feedings or skin-to-skin care), but do not receive structural education on how to incorporate parents as equal partners into the care team.
88847987|NCT04691024|Experimental|Treatment Group|Remotely Exercises 3 times a week, 8 weeks remotely (with video) spinal stabilization exercises
88847988|NCT04691024|Other|Control Group|Face to Face Exercises 3 times a week, 8 weeks face to face (in clinic) spinal stabilization exercises
88847989|NCT00904423|Experimental|Vitamin D|
88847990|NCT04689698|Experimental|experimental group|
88847991|NCT00904189|No Intervention|Standard of care radiation therapy|Standard of care given for treatment of cancer. Subjects receiving incidental radiation dose to fingernails.
88847992|NCT05328895|Experimental|taVNS group|taVNS was applied using a Huatuo stimulator (SDZIIB) developed by Suzhou manufacture of Medical Device and Material. Stimulation parameters was 1 mA of electrical current at a frequency of 30 Hz with pulse duration ≤ 1 ms, for 30min, administered twice daily. The two electrodes were placed on the cymba conchae and concha around the left ear. Participants received betahistine mesylate tablet (Merislon, Eisai Co., Ltd., China) with the treatment of 6 mg 3 times a day.
88847993|NCT05328895|Placebo Comparator|Control Group|tnVNS was applied using a Huatuo stimulator (SDZIIB) developed by Suzhou manufacture of Medical Device and Material. Stimulation parameters was 1 mA of electrical current at a frequency of 30 Hz with pulse duration ≤ 1 ms, for 30min, administered twice daily. The two electrodes were placed on the antihelix around the left ear. Participants received betahistine mesylate tablet (Merislon, Eisai Co., Ltd., China) with the treatment of 6 mg 3 times a day.
88847994|NCT00399841|Active Comparator|1|Stimulation will occur at the T7 followed by T8 during the trial implant period
88847995|NCT00399841|Active Comparator|2|Stimulation will occur at the T8 followed by T7 during the trial implant period
88847996|NCT00387673|Experimental|Arm 1|6 weeks of upper extremity training for 3 sessions/week, as follows: a) somatosensory stimulation of the median, ulnar and radial nerves at the level of the wrist (2 hours/session);
89375727|NCT05934890|Active Comparator|Pfizer PCV13|"Primary Vaccination: A total of approximately 300 infants 6-8 weeks of age will be enrolled and assigned randomly to receive at 2, 4, and 12-15 months of age 1 dose of PCV13. Standard EPI vaccines will be administered concomitantly.~Booster Vaccination: At 12-15 months of age (8 to 11 months after the 2nd dose of the primary series), infants will receive a booster dose of PCV13."
88847997|NCT00387673|Active Comparator|Arm 2|a 6-week period of 2 hours somatosensory stimulation of the hand, without training
88847998|NCT00387673|Placebo Comparator|Arm 3|a 6-week period of 2 hours sham somatosensory stimulation of the hand, followed by 1 hour of activity-based training
88847999|NCT04669808|Experimental|Cohort A: STP705 30 μg dose|Cohort A: STP705 30 μg dose, localized injection, given once a week for 6 weeks
88848000|NCT04669808|Experimental|Cohort B: STP705 60 μg dose|Cohort B: STP705 60 μg dose, localized injection, given once a week for 6 weeks
88848001|NCT04669808|Experimental|Cohort C: STP705 90 μg dose|Cohort C: STP705 90 μg dose, localized injection, given once a week for 6 weeks
88848002|NCT04669808|Experimental|Cohort D: STP705 120 μg dose|Cohort D: STP705 120 μg dose, localized injection, given once a week for 6 weeks
88848003|NCT04669808|Experimental|Cohort E: STP705 180 μg dose|Cohort E: STP705 180 μg dose, localized injection, given once a week for 6 weeks
88848004|NCT04669808|Experimental|Cohort F: STP705 240 μg dose|Cohort F: STP705 240 μg dose, localized injection, given once a week for 6 weeks
88848005|NCT04669808|Experimental|Cohort G: STP705 320 μg dose|Cohort G: STP705 320 μg dose, localized injection, given once a week for 6 weeks
88848006|NCT00879619|Experimental|Chemotherapy and enzyme inhibitor|Patients receive docetaxel IV over 60 minutes on day 1, prednisone PO BID on days 1-21, and sunitinib malate PO QD on days 2-15. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive sunitinib malate PO QD on days 1-28. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.
88848007|NCT05040698|Experimental|Open Label Fostamatinib|Open label Fostamatinib 100mg dose adjusted by the Principal Investigator after week 1
88848008|NCT00878605|Experimental|Cyclo-Z (minimally effective)|3mg CHP plus 20mg zinc containing gel capsule;
88848009|NCT00878605|Experimental|Cyclo-Z (maximally effective)|9mg CHP plus 20mg zinc containing gel capsule;
88848010|NCT00878605|Experimental|Cyclo-Z (not additionally effective)|15mg CHP plus 20mg zinc containing gel capsule
88848011|NCT00878605|Placebo Comparator|Placebo (for CHP)|Placebo capsules containing no zinc or CHP
88848012|NCT00353275|Other|1|Strict glycemic control with a blood glucose target range of 80-110 mg/dL
88848013|NCT00353275|Other|2|Conventional glycemic control with blood glucose target range of 110-140 mg/dL
88848014|NCT00822679|Experimental|1: Eszopiclone|Subjects receive Eszopiclone for three consecutive nights to observe changes in sleep measures, and inflammatory and coagulation factors
88848015|NCT00822679|Placebo Comparator|2: Placebo|Subjects given placebo for 3 consecutive nights to observe changes in sleep measures, and inflammatory and coagulation factors
88848016|NCT04652180|Experimental|Robot-assisted thoracic approach in Ivor Lewis esophagectomy|Robot-assisted thoracic approach in Ivor Lewis esophagectomy with gastric conduit formation. Abdominal approach will be performed by laparoscopy.
89375728|NCT05934084|No Intervention|Control Arm (C)|Patients in the control arm will not receive any Survivorship Care Plan (SCP) or intervention and will be followed-up according to the best clinical practice, with questionnaires self-administration at 6 and 12 months from randomization.
89535038|NCT05015517|Active Comparator|FIB Group|This group will receive supra-inguinal fascia iliaca block and subarachnoid block .
88848017|NCT04652180|Active Comparator|Open transthoracic approach in Ivor Lewis esophagectomy|Traditional open transthoracic esophagectomy with gastric conduit formation. Abdominal approach will be performed by laparoscopy.
88848018|NCT00322855||Chart Review|patients diagnosed with soft tissue sarcoma
88848019|NCT05034614|Other|Pap smears using the Papette|Papette brush used to collect a Pap smear sample as standard of care.
88848020|NCT05034614|Other|Pap smears using the traditional spatula/cytology brush|Spatula/cytology brush used to collect a Pap smear sample as standard of care.
88848021|NCT00323635|Experimental|Tolterodine|Tolterodine 4 mg q.d. X 8 weeks
88848022|NCT00323635|Placebo Comparator|Placebo|A capsule of identical to tolterodine in taste, smell and appearance that contains no tolterodine
88848023|NCT00314353|Experimental|1|
88848024|NCT00314353|Experimental|2|
89375729|NCT05934084|Experimental|Experimental Arm (E)|Patients in the experimental arm will follow the planned intervention (Survivorship Care Plan (SCP), nutritional plan, physical activity indication) for 6 months.
88848026|NCT00279409|Active Comparator|aripiprazole|"This treatment arm (also called the combination arm) consists of parent training plus continued treatment on a stimulant (that is tolerated but has not yet decreased ADHD symptoms enough to meet our criterion of response), plus augmentation with aripiprazole. Aripiprazole pills are taken once daily over a period of 8 weeks, with patients evaluated on a weekly basis. Dosing will start at 2.5 mg and will be titrated up to 5 mg by week 1, and up to 10 mg by week 2 and for the remainder of the trial."
88848027|NCT00279409|Placebo Comparator|Sugar pill|"This treatment arm (also called the simple treatment arm) will consist of parent training plus continued treatment on a stimulant (that is tolerated but has not yet decreased ADHD symptoms enough to meet our criterion of response), plus a placebo matching aripiprazole. Placebo pills are taken once daily over a period of 8 weeks, with patients evaluated on a weekly basis."
88848028|NCT00253981|Experimental|Infrared Light Therapy|Intervention: The use of infrared light therapy for the treatment of tibial fracture. The treatment was assigned three times a week for four weeks.
88848029|NCT00253981|Placebo Comparator|Standard of Care|Standard of care was characterized by the use of standard medical treatment to include medication.
88848030|NCT05235919|Experimental|repetitive transcranial magnetic stimulation (rTMS)|Participants will receive 15 rTMS sessions for 3 weeks.
88848031|NCT05235919|Sham Comparator|Sham|Participants will receive 15 sessions of sham stimulation for 3 weeks.
88848032|NCT00804349|No Intervention|Control|Patients will receive standard medical therapy for heart failure only and will not receive Autotitrating Positive Airway Pressure therapy.
88848033|NCT00804349|Active Comparator|Autotitrating Positive Airway Pressure|Patients will receive Autotitrating Positive Airway Pressure therapy in addition to standard medical care for heart failure.
88848034|NCT00178477|Experimental|Breath-holding|MRI with breath-holding
88848035|NCT02973373|Experimental|MRI with HF-NIV|Intervention: Acquisition of MRI with High-Frequency non-invasive ventilation (HF-NIV)
88848036|NCT02973373|Active Comparator|MRI without HF-NIV|Intervention: MRI without High-Frequency non-invasive ventilation (HF-NIV)
88848037|NCT00801931|Experimental|A: Full Intensity with TBI|Patients will start their pre-conditioning regimen on Day -8. Fractionated total body irradiation (TBI) will be administered twice daily for 3 days on Days -8, -7, and -6. Patients will receive Thiotepa on Days -5 and-4, Cyclophosphamide on Days -3 and -2 and- rabbit antithymocyte globulin on Days -4, -3, -2 and -1.The double cord blood infusion will be performed on Day 0. GM-CSF hematopoietic growth factor will start on Day 0. GVHD prophylaxis will consist of tacrolimus/mycophenolate mofetil (MMF).
88848038|NCT00801931|Experimental|B: Full intensity without TBI|Patients will start their pre-conditioning regimen on Day -9. Patients will receive busulfan twice daily on Days - 8, -7, -6, and -5 and Melphalan on Days -4, -3 and -2 and rabbit antithymocyte globulin on Days -4, -3, -2 and -1 with double cord blood infusion on Day 0. Granulocyte-macrophage colony-stimulating factor (GM-CSF) hematopoietic growth factor will start on Day 0. GVHD prophylaxis will consist of tacrolimus/MMF.
88848039|NCT00801931|Experimental|C: Moderate Intensity|Patients will start their GVHD prophylaxis with Tacrolimus on Day -8. Patients will receive busulfan twice daily on Days -8, -7, -6, and -5; fludarabine on Days -7, -6, -5, -4, -3 and -2 and alemtuzumab on Days -5, -4, -3, -2, and -1. The double cord blood infusion will be performed on Day 0. GVHD prophylaxis will consist of tacrolimus/MMF.
88848040|NCT00801931|Experimental|D: Reduced Intensity|Patients will start their GVHD prophylaxis with Tacrolimus on Day -6. Patients will receive busulfan twice daily on Days -6, and-5; fludarabine on Days -6, -5, -4, -3 and -2 and rabbit antithymocyte globulin on Days -4, -3, -2, and -1. The double cord blood infusion will be performed on Day 0. GVHD prophylaxis will consist of tacrolimus/MMF.
88848041|NCT00801931|Experimental|E: Fanconi's Anemia|Patients will start their pre-conditioning regimen on Day -6. Patients will receive TBI as a single fraction on Day -6. Patients will receive fludarabine and cyclophosphamide on Days - 5, -4, -3, and -2 and horse antithymocyte globulin on Days -5, -4, -3, -2 and -1. The double cord blood infusion will be performed on Day 0. GVHD prophylaxis will consist of tacrolimus/MMF.
88848042|NCT00801931|Experimental|F: Regimen for non-malignant diseases|Patients will begin fosphenytoin or phenytoin prophylaxis on Day -10. Patients will receive busulfan on days -9, -8, -7 and -6, cyclophosphamide on days -5, -4, -3, and -2 and rabbit antithymocyte globulin on days -4, -3, -2 and -1. The double cord blood infusion will be performed on Day 0. GVHD prophylaxis will consist of tacrolimus/MMF.
88848043|NCT00382850|Active Comparator|open nissen fundoplication|open repair through surgical midline incision
88848044|NCT00382850|Active Comparator|laparoscopic nissen fundoplication|use of laparoscope to do repair
88848045|NCT05348642|Experimental|Experimental group receiving pasteurized Akkermansia muciniphila|pasteurized Akkermansia muciniphila - daily oral dose
88848046|NCT05348642|Placebo Comparator|Control group|Control group receiving placebo, identical to verum regarding the form, size, taste, color and intake.
89535039|NCT05015829||Classical low-flow low-gradient aortic stenosis|LVEF<50% SVi < 35.0 mL/m2 Aortic mean gradient < 40 mmHg AVA < 1.0 cm2.
89375730|NCT05924841|Experimental|Study treatment|Participants received BL-B01D1 monotherapy, SI-B003 monotherapy or BL-B01D1 plus SI-B003 dual therapy in the first cycle (3 weeks). Participants who had a clinical benefit could receive additional cycles of additional treatment. Administration will be discontinued because of disease progression or intolerable toxicity or for other reasons.
88848047|NCT00780481|Experimental|Bradykinin|Patients will have flow mediated vasodilation and radial artery tonometry performed. They will then receive 0, 10, 20, 40 ng/100cc/min of intrabrachial bradykinin. Strain gauge plethysmography and blood sampling at each dose will be done to evaluate t-PA release. Blood will also be drawn for other biomarkers.
88848048|NCT04278326|Experimental|Experimental|"Patients infected by oncogenic HPV and presented a high grade cervical dysplasia or a cervical cancer~Patients with cervical or vaginal cancer~All patients"
88848049|NCT00019747|Experimental|Arm 1 - Thalidomide once daily|Patients receive oral thalidomide 100 mg at bedtime once daily for 4 weeks, then progresses to 200 mg at bedtime for 4 weeks, then progresses to 300 mg at bedtime (maintenance dose).
88848050|NCT00019747|Placebo Comparator|Arm 2 - Placebo once daily|Patients receive oral placebo once daily.
88848051|NCT02970799|Experimental|Intranasal then Extranasal Application|Intranasal Neurostimulator applied intranasally (active) followed by extranasal application on Day 1. Participants were randomized to determine the intranasal and extranasal sequence for Days 15 and 29.
88848052|NCT02970799|Experimental|Extranasal then Intranasal Application|Intranasal Neurostimulator applied extranasally (control) followed by intranasal application on Day 1. Participants were randomized to determine the intranasal and extranasal sequence at Days 15 and 29.
88848053|NCT00759577|Other|Home titration|Patients were given drug to self titrate
88848054|NCT05338112||Patients with active pemphigus lesions|
88848055|NCT04610918||Cases - Pediatric Intestinal Failure Patients|DXA BIA Skin fold measurements Strength tests Physical activity monitoring
88848056|NCT04610918||Controls|BIA Skin fold measurements Strength tests Physical activity monitoring
88848057|NCT00748579|Experimental|Cohort 1|0.5 hour loading dose followed by 1.0 hour maintenance dose of CK-1827452
88848058|NCT00748579|Experimental|Cohort 2|≤ 1.0 hour loading dose followed by 1.0 hour maintenance dose of CK-1827452
88848059|NCT04524962|Experimental|Descartes 30|
88848060|NCT00746239|Active Comparator|1|Subjects will be randomly assigned to receive either Ramelteon and Escitalopram OR Placebo and Escitalopram.
88848061|NCT00746239|Placebo Comparator|2|Subjects will be randomly assigned to receive either Ramelteon and Escitalopram OR Placebo and Escitalopram.
88848062|NCT04977674|Experimental|A: Visit 1) Naltrexone + Ketamine, Visit 2) Placebo + Ketamine|"Participants randomly assigned to arm A:~VISIT 1) Naltrexone 50mg before the administration of ketamine 0.5mg/kg.~VISIT 2) Placebo before the administration of ketamine 0.5mg/kg.~Study visits are separated by 14-28 days."
88848063|NCT04977674|Experimental|B: Visit 1) Placebo + Ketamine, Visit 2) Naltrexone + Ketamine|"Participants randomly assigned to arm B:~VISIT 1) Placebo before the administration of ketamine 0.5mg/kg.~VISIT 2) Naltrexone 50mg before the administration of ketamine 0.5mg/kg.~Study visits are separated by 14-28 days."
88848064|NCT04963790|Experimental|Tailored COVID-19 vaccine messaging|Based on the created segments of hesitant participants (reflecting age, language, education level, rurality, sex, gender, ethnicity, and attitudes or reasons for vaccine hesitancy) in the intervention group, a series of tailored messages that are meaningful to the recipients in the different segments will be created and sent to address the factors influencing the willingness to be vaccinated and persuade them to get the COVID-19 vaccine.
88848065|NCT04963790|Active Comparator|Other health-related messaging|Patients assigned to the control group will receive health messages unrelated to COVID-19.
88848066|NCT04960124|Experimental|Part 1: Cohort 1 (JNJ-42847922)|Participants with normal hepatic function will receive Dose 1 of JNJ-42847922 on Day 1.
88848067|NCT04960124|Experimental|Part 1: Cohort 2 (JNJ-42847922)|Participants with mild hepatic impairment will receive Dose 1 of JNJ-42847922 on Day 1.
88848068|NCT04960124|Experimental|Part 1: Cohort 3 (JNJ-42847922)|Participants with moderate hepatic impairment will receive Dose 2 of JNJ-42847922 on Day 1.
88848069|NCT04960124|Experimental|Part 2: Cohort 4 (Optional) (JNJ-42847922)|Participants with moderate hepatic impairment will receive Dose 1 (depending on the results of Cohort 3) of JNJ-42847922 on Day 1.
88848070|NCT04960124|Experimental|Part 2: Cohort 5 (Optional) (JNJ-42847922)|Participants with severe hepatic impairment will receive Dose 2 or Dose 3 (depending on the results of Part 1) of JNJ-42847922 on Day 1.
89399352|NCT03694431|Active Comparator|Standard HBPC|Patients and caregivers in standard HBPC will continue to receive usual care from the palliative care team which includes home visits
89375731|NCT05920720|Experimental|Self-guided Personalized Treatment|Women who endorse significant DE will complete two weeks of smart-phone self-monitoring to identify target problems and will be sent two self-guided modules of personalized treatment directly to their smart-phones.
89375732|NCT05888792|No Intervention|Single vision lens group|Subjects in single vision lens group will receive a pair of single vision lenses for the first year of study. They will then receive a pair of DG2 lenses for the second year of the study.
89375733|NCT05888792|Experimental|DG2 lens group|Subjects in DG2 lens group will receive a pair of DG2 lenses over the 2-year study.
89375734|NCT05883826|Experimental|PLISSIT Group|Nursing students in this group will be given sexual health training. The training will last for 4 weeks. The training is 16 hours in total. During the training, students will learn the PLISSIT model and evaluate cases involving using this model. Questionnaire will be applied before the training, immediately after the training and 3 months after the training.
89375735|NCT05883826|No Intervention|Control group|Nursing students in this group will not be subjected to any application and will continue their routine nursing lessons. The questionnaire will be administered to the control group before the training given to the experimental group, immediately after the training and 3 months after the training.
89375736|NCT05882110|Experimental|Patients with a body surface wound of 30% TBSA or more and requiring at least 2 weeks to repair|
89375737|NCT05870150|Experimental|ST19|Healthy volunteers will be challenged with Salmonella Typhimurium ST19
89375738|NCT05870150|Experimental|ST313|Healthy volunteers will be challenged with Salmonella Typhimurium ST313
89375739|NCT05866419|Experimental|ThecaFlex DRx Port and Catheter System|Subjects who meet all of the inclusion and none of the exclusion would be eligible to receive the ThecaFlex DRx Port and Catheter System.
88810408|NCT06213519|Experimental|SOX+sintilimab+HIPEC|Patient will receive SOX regimen (oxaliplatin 100mg/m2, d1, S-1 BSA<1.25m2 40mg, twice a day; 1.25m2 ≤ BSA < 1.5m2 50mg, twice a day; BSA ≥ 1.5m2 60mg, twice a day; d1-14) chemotherapy combined with sintilimab (200mg, d1), once every three weeks. In the first cycle, HIPEC (paclitaxel 80 mg/m2, d1-d3) will be administrated, and HIPEC or intraperitoneal chemotherapy (paclitaxel 80 mg/m2, d1) will be administrated in the second and third cycles according to the patient's condition. Then, another 3-cycle SOX regimen of systemic chemotherapy. After the end of 6 cycles, maintain treatment with a combination of S-1 and sintilimab until disease progression or intolerable toxicity.
88810409|NCT06213506|Experimental|Adults_Dose C Group|Adults 18-50 years of age, part of the safety cohort, randomized to receive 2 doses of the iNTS-GMMA Dose C vaccine at Day 1 and Day 57.
88810410|NCT06213506|Active Comparator|Adults_Control Group|Adults 18-50 years of age, part of the safety cohort, randomized to receive 1 dose of the MenACWY vaccine at Day 1 and 1 dose of Placebo at Day 57.
88810411|NCT06213506|Experimental|Children_Dose B Group|Children 24-59 months of age, part of the safety cohort, randomized to receive 2 doses of the iNTS-GMMA Dose B vaccine at Day 1 and Day 57.
88810412|NCT06213506|Active Comparator|Children_Control B Group|Children 24-59 months of age, part of the safety cohort, randomized to receive 2 doses of the MenACWY vaccine at Day 1 and Day 57.
88810413|NCT06213506|Experimental|Children_Dose C Group|Children 24-59 months of age, part of the safety cohort, randomized to receive 2 doses of the iNTS-GMMA Dose C vaccine at Day 1 and Day 57.
88810414|NCT06213506|Active Comparator|Children_Control C Group|Children 24-59 months of age, part of the safety cohort, randomized to receive 2 doses of the MenACWY vaccine at Day 1 and Day 57.
88810415|NCT06213506|Experimental|Infants_9M_Dose A Group|Infants 9 months of age, part of the safety cohort, randomized to receive 3 doses of the iNTS-GMMA Dose A vaccine at Day 1, Day 85 and Day 169. These infants also receive an Expanded Program on Immunization (EPI) vaccination with Measles and Rubella Vaccine (MR-VAC) and Yellow Fever (YF) vaccine at 28 days after the first study intervention administration occurring at Day 1, at the local EPI vaccination centers, and not part of the current clinical trial.
88810416|NCT06213506|Active Comparator|Infants_9M_Control A Group|Infants 9 months of age, part of the safety cohort, randomized to receive 2 doses of the MenACWY vaccine at Day 1 and Day 85 and 1 dose of the DTPaHBV-IPV+Hib vaccine at Day 169. These infants also receive an EPI vaccination with Measles and Rubella Vaccine (MR-VAC) and Yellow Fever (YF) vaccine at 28 days after the first study intervention administration occurring at Day 1, at the local EPI vaccination centers, and not part of the current clinical trial.
88810417|NCT06213506|Experimental|Infants_9M_Dose B Group|Infants 9 months of age, part of the safety cohort, randomized to receive 3 doses of the iNTS-GMMA Dose B vaccine at Day 1, Day 85 and Day 169. These infants also receive an EPI vaccination with Measles and Rubella Vaccine (MR-VAC) and Yellow Fever (YF) vaccine at 28 days after the first study intervention administration occurring at Day 1, at the local EPI vaccination centers, and not part of the current clinical trial.
89375740|NCT05859009|Active Comparator|EUS-Guided Therapy of glue and coil + Non-selective Beta Blockers (Propanolol)|Participants in this arm will receive a daily oral dose of a non-selective beta blocker (Propanolol) and undergo EUS-guided therapy of glue and coil as described in Arms 1 and 2. Participants will be monitored for side effects, complications, and efficacy of both the medication and the procedure.
89375741|NCT05859009|Active Comparator|EUS-Guided Therapy of Glue and Coil|Participants in this arm will undergo endoscopic ultrasound (EUS) to identify and target gastric varices. Under EUS guidance, a combination of glue and coil will be used to occlude the gastric varices. Participants will be monitored for complications and efficacy of the procedure
88848071|NCT00402883|Experimental|Intervention|Induction treatment included: carboplatin AUC=5, pemetrexed 500 mg/m2, and bevacizumab 15 mg/kg each administered intravenously weeks 1 and 4. Radiation was administered concurrently at a dose of 1.8 Gy/d weeks 1 to 7 to a total of 61.2 Gy per institutional guidelines. Consolidative therapy, following an 8-week break from chemoradiotherapy, included carboplatin AUC=6, pemetrexed 500 mg/m2, and bevacizumab 15 mg/kg each administered intravenously on week 16, repeated weeks 19 and 22. Folic acid (350 to 1,000 ug or equivalent) supplementation was administered orally beginning 1 to 2 weeks before the first dose of pemetrexed and continued daily until the patient discontinued study therapy. Vitamin B12(1,000ug) was administered by intramuscular injection 1 to 2 weeks before the first dose of study therapy and repeated every 9 weeks until the patient discontinued therapy.
88848072|NCT04940312||Usual Care Group|Individuals with heart failure receiving standard medical care
88848073|NCT04940312||Intervention Group 1 (pedometer-monitoring only)|Individuals with heart failure receiving a pedometer for measurement of daily step count
88848074|NCT04940312||Intervention Group 2 (app-based coaching)|Individuals with heart failure receiving an individualized, app-based physical activity coaching on the basis of pedometer-based assessment of daily step count
89375742|NCT05859009|Active Comparator|Non-Selective Beta Blockers (Propanolol)|Participants in this arm will receive a daily oral dose of a non-selective beta blocker (such as propranolol) for the duration of the study. Participants will be monitored for side effects and efficacy of the medication.
88848075|NCT04939844|Experimental|NDMM ineligible for transplant|"All participants will receive isatuximab in combination with bortezomib, lenalidomide and dexamethasone for 2 cycles, followed by isatuximab in combination with bortezomib and lenalidomide for 6 cycles, followed by isatuximab in combination with lenalidomide for 10 cycles, followed by continuous lenalidomide until disease progression. The cycle duration is 28 days.~Isatuximab will be administered IV at a dose of 10 mg/kg~on D1, D8, D15 and D22 during Cycle 1~on D1 and D15 during Cycles 2-18~Bortezomib will be administered SC at a dose of 1,3mg/m2~-on D1, D8 and D15 during Cycles 1-8~Lenalidomide will be administered PO at a dose of 25mg/day (15 mg/day in participants with GFR <30mL/minute/1.73m2)~-on D1 to D21 during all Cycles.~Dexamethasone will be administered PO at a dose of 20 mg -on D1, D8, D15 and D22 during Cycles 1 and 2"
88848076|NCT04936568|No Intervention|control|standard oncology care
88848077|NCT04936568|Experimental|intervention|standardized referral to outpatient palliative care by oncologists
88848078|NCT05295212|No Intervention|Cohort A|MRD revealed negative
89375743|NCT05849129|Experimental|Intravenous Vitamin C|1g/kg IVC administered twice weekly for 6 months.
89375744|NCT05849129|Placebo Comparator|Normal Saline|Equivalent volume normal saline administered twice weekly for 6 months.
88848079|NCT05295212|Experimental|Cohort B|MRD revealed positive
89375745|NCT05849012|Experimental|Low Sulfur Diet|Participants in this group will follow a low sulfur diet. This diet decreases the amount of animal products (including meat, dairy, and eggs) as well as sulfur additives in the diet. The main types of foods in the low sulfur diet include fruits, vegetables, whole grains, nuts, seeds, and soy products.
89375746|NCT05849012|Active Comparator|Usual Diet|Participants in this group will follow a standard of care usual diet for 8 weeks.
89375747|NCT05846659|Experimental|Experimental Arm|PULSAR-ICI + IMSA101
89375748|NCT05846659|Active Comparator|Control Arm|PULSAR-ICI
89375749|NCT05828342||Pediatric Patients|Patients under the age of 18 who were operated under general anesthesia and intubated with a cuffed endotracheal tube between 15 July 2022 and 15 October 2022 in the pediatric operating room.
89375750|NCT05816590|Experimental|Meds@HOME Intervention|
89375751|NCT05816590|No Intervention|Control Group|
89375752|NCT05814536|Experimental|AB-218|AB-218 for the treatment of adult patients with advanced cholangiocarcinoma, chondrosarcoma and other solid tumors with IDH1 mutation.
89375753|NCT05812911|Active Comparator|Standard oxygen therapy|Patients will receive standard oxygen. First attempt device in usual care.
89375754|NCT05812911|Experimental|High-Flow nasal cannula therapy (HFNO)|Patient will receive HFNO using a humidification system or via the high-flow interface of the ICU ventilator.
89375755|NCT05812911|Experimental|Noninvasive ventilation therapy (NIV)|Between NIV sessions, patients will receive HFNO with the same modalities than the HFNO group.
89375756|NCT05803785|Experimental|BBC1501 1.25ug|Cohort 1; open-label, non-randomized, single administration
89375757|NCT05803785|Experimental|BBC1501 2.5ug|Cohort 2; open-label, non-randomized, single administration
89375758|NCT05803785|Experimental|BBC1501 5ug|Cohort 3; open-label, non-randomized, single administration
89375759|NCT05798104|Experimental|Collaborative nurse-pharmacist counseling|Collaborative nurse-pharmacist counseling - At the interventional appointment, study participants will first complete a modified Okere-Reiner pre-survey assessing patient perceptions of confidence and knowledge in their biologic therapy. Subsequently, a pharmacist will perform a refresher medication counseling, detailing indication, dosing, storage, and side effects. Upon completion of this counseling, an infusion nurse will then provide education demonstrating proper self-administration to the patient. The patient will then self-administer the medication with coaching and direct observation from the nurse. Afterwards, the patient will complete the Okere-Reiner post-survey to determine the effectiveness of the counseling session at improving perceived confidence and knowledge. Patients will complete both the pre-and post-surveys with direct entry to REDCap on an institution iPad during the study intervention visit.
89375760|NCT05790837|Experimental|Computer prompt + Education (CP+E)|"The intervention group consists of the implementation of the desktop application Stand up for your Health® following the model proposed by the Guide to Physical Activity at Work plus education through an information leaflet"
88848080|NCT05287178|Experimental|DBT Skills + Parent Training|The DBT Skills +PT group intervention integrates DBT Skills, Parent Management Training (PMT), and Emotion Coaching (EC). Each session includes a mindfulness practice, homework review to discuss use of skills previously learned, didactics to learn a new set of DBT and PT skills, and assignment of homework. The DBT Skills portions cover the four modules of traditional DBT Skills: Mindfulness, Emotion Regulation, Distress Tolerance (including skills specifically focused on managing difficulties with addiction), and Interpersonal Effectiveness. PT skills include both PMT and EC components such as: praise, use of parental attention to reward positive behavior, reward systems, effective commands and consequences, psychoeducation on children's emotional development, teaching children to label emotions, validating children's emotions, and handling children's negative emotions, and fostering positive emotions.
88848081|NCT04328948|Experimental|Chemoradiation therapy with elective nodal irradiation|Chemoradiotherapy consists of 5-FU (1,000 mg / m2, day1-4, day29-32), CDDP (75 mg /m2, day1, 29) and radiotherapy (50.4 Gy/28Fr)
88848082|NCT04328948|Active Comparator|Chemoradiation therapy with involved field irradiation|Chemoradiotherapy consists of 5-FU (700 mg /m2, day1-4, day29-32), CDDP (70 mg /m2, day1,29) and radiotherapy (60 Gy/30Fr)
88848083|NCT05286320|Experimental|Target-/Immuno-therapy for advanced HCC w PVTT Lenvatinib/Pembrolizumab plus SBRT combinations|Five-fraction SBRT (week 4-week 5) to PVTT and connected HCC tumor in 2 weeks Lenvatinib 12/8 mg/day for 96 weeks (no lenvatinib from 7 day before SBRT to 7 days after SBRT) Pembrolizumab 200 mg q 3 week x 32 cycles
88848084|NCT00728845|Experimental|Hydroxychloroquine, Carboplatin, Paclitaxel, Bevacizumab|Cohort 1: Bevacizumab Eligible Patients All on Day 1 Paclitaxel 200mg/m2 IV over 3 hours Carboplatin AUC= 6 IV over 15-30 min Bevacizumab 15 mg/kg IV over 90 min for PLUS Hydroxychloroquine 200 mg PO BID Cycles every 3 weeks for 4-6 Cycles
88848085|NCT00728845|Experimental|Hydroxychloroquine, Carboplatin, Paclitaxel|Cohort 2: Bevacizumab Ineligible Patients All on Day 1 Paclitaxel 200mg/m2 IV over 3 hours Carboplatin AUC= 6 IV over 15-30 min PLUS Hydroxychloroquine 200 mg PO BID Cycles every 3 weeks for 4-6 Cycles
88848086|NCT04306016|Experimental|Sensory stimulation|Participants allocated to the intervention group will receive a model-based sensory stimulation intervention, which is aimed at providing visual and auditory stimulation to ICU patients with additional support from family caregivers.
88848087|NCT04306016|No Intervention|Usual care|Participants in the control group will receive usual care routine that they are receiving or planning to receive. The registered ICU nurses will provide the same nursing care as previously, including but not limiting to the use of sedation, analgesia, spontaneous breathing trial, indwelling catheter, feeding, and bowel care.
88848088|NCT00726037|Experimental|1|Three doses of Ontak 9 mcg/Kg IV over 30 minutes every other day for 1 week
89181769|NCT04097444|Experimental|Step 2 Arm B (CAPOXIRI+ BEV)|"Induction therapy is followed by the maintenance therapy.~[Induction treatment: CAPOXIRI+BEV] Administered for 6 cycles (a maximum of 8 cycles). BEV: 7.5mg/kg (d.i.v.) OX: 100/130 mg/sq.m (d.i.v.) IRI:150/180/200mg/sq.m (d.i.v.) CAP 1,600 mg/sq.m /day (p.o. day1-15) Administered every 3 weeks. Regarding to OX/IRI dose, RD will be confirmed at Step 1.~[Maintenance treatment: 5-FU/LV+BEV or CAP+BEV] The following 5-FU/LV+BEV therapy will be repeated in 2-week cycles, or the following CAP+BEV therapy will be repeated in 3-week cycles (Physician's choice). No change in treatment regimen will be permitted after the selection of maintenance therapy (5-FU/LV+BEV or CAP+ BEV).~5-FU/LV+BEV: BEV:5mg/kg (d.i.v.) l-LV:200mg/sq.m (d.i.v.) 5-FU:3,200mg/sq.m (c.i.v.) Administered every 2 weeks.~CAP+BEV: BEV: 7.5mg/kg (d.i.v.) CAP 1,600 mg/sq.m /day (po. day1-15) Administered every 3 weeks."
89181770|NCT04097288|Experimental|Single dose citalopram|A blinded single dose 40 mg citalopram is administered three hours before urethral pressure reflectometry and anal acoustic reflectometry measurements
89181771|NCT04097288|Active Comparator|Single dose reboxetine|A blinded single dose 8 mg reboxetine is administered two hours before urethral pressure reflectometry and anal acoustic reflectometry measurements
89181772|NCT04097288|Placebo Comparator|Single dose placebo citalopram|A blinded single dose visually identical placebo pill to citalopram is administered three hours before urethral pressure reflectometry and anal acoustic reflectometry measurements
89375761|NCT05790837|No Intervention|Only Education (OE)|The control group will receive only education through an information leaflet also following the guidelines of the Work Physical Activity Guide on indications to control the time sitting at work.
88848089|NCT04890860|Experimental|Adults patients undergoing mitral and / or tricuspid valve surgery with cardiopulmonary bypass.|
88848090|NCT04928053|Experimental|phenotypic data and a blood prelevment|
88848091|NCT00703885|Active Comparator|1|"0.25 mg alprazolam PO (liquid) will be administered 1 hour prior to fMRI scan.~One-time, single dose.~Note that subjects receive all 3 treatments in randomized order (cross-over study), approximately 7-10 days apart."
89375762|NCT05776927|Experimental|QVM149|"QVM149 (Indacaterol as acetate 150 µg / glycopyrronium as bromide 50 µg / mometasone furoate 160 µg ) od delivered via Breezhaler® and Placebo to Salmeterol Xinafoate 50 μg~/ Fluticasone Propionate 500 μg bid delivered via Girohaler®"
89375763|NCT05776927|Active Comparator|Salmeterol Xinafoate / Fluticasone Propionate Arm|Salmeterol Xinafoate 50 μg / Fluticasone Propionate 500 μg bid delivered via Girohaler® and Placebo to QVM149 (Indacaterol as acetate 150 µg / glycopyrronium as bromide 50 µg / mometasone furoate 160 µg ) od delivered via Breezhaler®.
89375764|NCT05759039|Active Comparator|MPFL-R|Medial patellofemoral ligament reconstruction
89375765|NCT05759039|Active Comparator|MPFL-R + TTO|Medial patellofemoral ligament reconstruction with concomitant tibial tubercle osteotomy
89375766|NCT05746247|Active Comparator|Patients without a primary care physician within the UPHS health system|Pilot 1 is examining ways to get patients without a primary care physician within the UPHS health system to schedule a visit with a lipid specialist for a formal evaluation of FH.
89375767|NCT05746247|Active Comparator|Patients with a primary care physician within the UPHS health system|Pilot 2 is examining ways to increase physician referrals to preventive cardiology, and increase patient visits with a lipid specialist for a formal evaluation of FH.
89375768|NCT05741944|Experimental|Care with the use of PERSARC (intervention)|Patients in the intervention condition receive usual care with PERSARC added at two points in the decision making process. First, PERSARC will be used in multidisciplinary tumour boards (MTB) by STS professionals to guide treatment advice. Second, PERSARC will be used in patient consultations where the oncological/orthopaedic surgeon informs the patient about his/her diagnosis and discusses the benefits and harms of all relevant treatment options.
89375769|NCT05741944|Sham Comparator|standard care (control)|All patients in the control condition receive standard care
89375770|NCT05729659|Experimental|Sideritis Scardica (SidTea+) extract|Sideritis Scardica (SidTea+) extract will be administered to participants in this arm.
89375771|NCT05729659|Placebo Comparator|Placebo|Placebo will be administered to participants in this arm.
89375772|NCT05717192|Active Comparator|InterVapor®-System|The intervention to be tested is bronchoscopic lung volume reduction (BTVA) using thermal ablation (InterVapor®, Uptake Medical, California, USA). This is performed in addition to standard conservative therapy in accordance with the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines. The intervention can consist of a maximum of two partial interventions
89375773|NCT05717192|No Intervention|Standard of care|Standard conservative therapy in accordance with the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines without the use of a BTVA (patient-specific documentation of therapeutic measures).
89375774|NCT05714345|Experimental|Lymphodepletion with ALLO-647, fludarabine, and cyclophosphamide|ALLO-501A CAR T cells infused following lymphodepletion
89375775|NCT05714345|Experimental|Lymphodepletion with fludarabine and cyclophosphamide|ALLO-501A CAR T cells infused following lymphodepletion
88848092|NCT00703885|Active Comparator|2|"1 mg alprazolam PO (liquid) will be administered 1 hour prior to fMRI scan~One-time, single dose.~Note that subjects receive all 3 treatments in randomized order (cross-over study), approximately 7-10 days apart."
89375776|NCT05700552|Experimental|Intervention Group|In the intervention group, after cesarean delivery in the operating room, maternal vital signs and the newborn's 1st and 5th minute Apgar Score will be evaluated. After the newborn baby is aspirated if necessary, dried with a green cover under the radiant warmer, tied the diaper, and put on a hat, the newborn with an Apgar Score ≥7 and vital signs stable will be wrapped in pre-warmed operating room covers. After providing a suitable environment, the newborn whose body temperature is stabilized will be placed in the prone position without any covering and clothing on the chest area of the mother, and the ALPS value will be applied for about 3 minutes due to the application of hospital procedures, the intramuscular injection will be applied and the ALPS score will be evaluated again after the injection.
89375777|NCT05700552|No Intervention|Control group|The routine procedure of the institution where the study will be performed will be applied to the newborn baby after cesarean section in the control group. Within the scope of this procedure, after the baby is born, the umbilical cord is cut, mouth and nose aspiration is performed under the radiant heater in the operating room, they are dried, and the Apgar Score is evaluated at the 1st and 5th minutes by the midwife. The newborn is wrapped in pre-heated operating room covers, and after being shown to the mother, anthropometric measurements (height, body weight, head circumference) are taken and taken to the delivery room for the administration of vitamin K, hepatitis B vaccine, and the first examination of the baby. The first ALPS value will be recorded in the delivery room in the baby care area, the intramuscular injection will be applied and the ALPS score will be evaluated again after the injection.
89375778|NCT05687071|Experimental|ETC-1002 180mg|
89375779|NCT05683340|Experimental|ETC-1002 180mg|
89375780|NCT05683340|Placebo Comparator|Placebo|
89375781|NCT05676931|Experimental|A1: Domvanalimab + Zimberelimab|Domvanalimab and Zimberelimab, both administered by IV infusion
89375782|NCT05676931|Experimental|A2: Domvanalimab + Zimberelimab|Domvanalimab and Zimberelimab, both administered by IV infusion
89375783|NCT05676931|Experimental|A3: Quemliclustat + Zimberelimab|Quemliclustat and Zimberelimab, both administered by IV infusion
89375784|NCT05676931|Experimental|B1: Quemliclustat + Zimberelimab + Platinum Doublet Chemotherapy|Quemliclustat, zimberelimab, and platinum doublet chemotherapy, all administered by IV infusion
89375785|NCT05676931|Experimental|B2: Domvanalimab + Zimberelimab + Platinum Doublet Chemotherapy|Domvanalimab, Zimberelimab, and platinum doublet chemotherapy, all administered by IV infusion
88848093|NCT00703885|Placebo Comparator|Placebo|"Inactive ingredient in liquid matching appearance and volume of the two active alprazolam dose comparators.~Note that subjects receive all 3 treatments in randomized order (cross-over study), approximately 7-10 days apart."
89375786|NCT05676931|Experimental|B3: Domvanalimab + Quemliclustat + Zimberelimab + Platinum Doublet Chemotherapy|Domvanalimab, Quemliclustat, Zimberelimab, and platinum doublet chemotherapy, all administered by IV infusion
89375787|NCT05676931|Experimental|C1: Quemliclustat + Zimberelimab + Docetaxel|Quemliclustat, Zimberelimab, and Docetaxel, all administered by IV infusion
89375788|NCT05676931|Experimental|C2: Domvanalimab + Zimberelimab + Docetaxel|Domvanalimab, Zimberelimab, and Docetaxel, all administered by IV infusion
89375789|NCT05662943||Type 1 Macular Neovascularization and Polypoidal Choroidal Vasculopathy|Patients with type 1 macular neovascularization and polypoidal choroidal vasculopathy who underwent continuous aflibercept injections with tolerating subfoveal retinal fluid more than 6 months
88848094|NCT04330586|Experimental|Ciclesonide|Ciclesonide 320ug oral inhalation q12h for 14 days
88848095|NCT04330586|No Intervention|Control|Standard care without ciclesonide
88848096|NCT04508036||Study Group|Premature newborns born before 32nd gestational week and weighing less than 1500 grams.
88848097|NCT04857866|Experimental|Single Ascending Dose - XmAb27564 Subcutaneous injection of Dose A, B, C, D, E or F|
88848098|NCT04857866|Placebo Comparator|Single Ascending Dose - Placebo Subcutaneous injection of placebo|
89375790|NCT05659381|Experimental|HIPEC|Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Cisplatin 100 mg/m2 IP over 90 minutes at 42 degrees C
89375791|NCT05659381|Active Comparator|No HIPEC|No treatment
89375792|NCT05641662|Experimental|Exergame group|"Patients will be introduced to the exergame and the exergame will be installed following a protocol either by the patients themselves or an instructor of the study.~Patients will be advised to exergame daily based on their activity monitor reading at baseline and based on their current activity level and preferences.~During the 3 months of active intervention patients will receive feedback on their activity level and data will also be shared with the coach who will use it to adapt the gaming advice. A clear exergaming goal will be set together by patient and coach. In the first month, they will receive weekly feedback on their performance based on the readings from the activity monitor and the reading from the exergame. In the rest of the active study team the frequency of the contact with the coach will be personalized."
89375793|NCT05641662|No Intervention|Control group|Patients will receive a protocol-based activity advice (one time) from the HF team (nurse, cardiologist and/or physiotherapist) that corresponds to the intervention group in terms of time and effort. Participants in the control group are encouraged to decrease their sedentary behaviour to the same extent as the intervention group, and if possible be physical active 30 minutes for 5 days a week.
89375794|NCT05620979|Active Comparator|Active Navigation|Active navigation with the study-based financial navigator scheduling four check-in meetings throughout the study with the participant. All participants will complete an assessment at baseline, 3 months and 6 months and be invited to participate in an optional interview after the 6-month assessment.
89375795|NCT05620979|Active Comparator|Ad Hoc Navigation|Ad hoc navigation in which participant is provided study-based financial navigator to contact as needed. All participants will complete an assessment at baseline, 3 months and 6 months and be invited to participate in an optional interview after the 6-month assessment.
89375796|NCT05620979|Active Comparator|No study-based Navigation|No access to a study-based financial navigator, but access to a national hotline through the Leukemia & Lymphoma Society. All participants will complete an assessment at baseline, 3 months and 6 months and be invited to participate in an optional interview after the 6-month assessment.
88848099|NCT04495400||Percutaneous Screw Fixation|Patients who have had a Percutaneous Screw fixation procedure.
88848100|NCT04495400||Open Fixation|Patients who have had an Open Fixation procedure.
89375797|NCT05616767|Experimental|Training on self-screening and HPV vaccination administration|teaching SMM in Tanzania to conduct self-exams for oropharyngeal hrHPV-associated cancers using cellphone-mediated oral selfies, and administering the HPV vaccination series (with 2 and 6-8 month follow-up) to those who request it
89375798|NCT05614648|Active Comparator|Clonidine Micropellets Injection|Clonidine Micropellets single dose injection into the lumbar epidural space
89375799|NCT05614648|Sham Comparator|Sham Insertion|Sham Control non-epidural needle placement
89375800|NCT05613413|Experimental|Single|"All subjects will receive carbozantinib 40mg PO once daily Days 1-21 Q3W and pembrolizumab 200mg IV infusion Q3W or 400mg IV infusion Q6W per the treating physician's discretion as maintenance therapy following 4 cycles of induction therapy with disease control~Note: Cabozantinib should be stopped at least 3 weeks prior to elective surgery. Do not administer cabozantinib for at least 2 weeks after major surgery and until complete wound healing."
89375801|NCT05610839|Experimental|AEBT website with check-ins|Participants will complete the 8-module intervention of Acceptance-enhanced behavior therapy (AEBT) and will receive weekly check-ins. Acceptance-enhanced behavior therapy is a manualized treatment approach created by Woods and Twohig 2008 that provides both Acceptance and Commitment Therapy and Habit Reversal Therapy.
89375802|NCT05610839|Active Comparator|AEBT website without check-ins|Participants will complete the 8-module intervention of Acceptance-enhanced behavior therapy (AEBT) but will not receive weekly check-ins. Acceptance-enhanced behavior therapy is a manualized treatment approach created by Woods and Twohig 2008 that provides both Acceptance and Commitment Therapy and Habit Reversal Therapy.
88848101|NCT02973451|Active Comparator|Laparoscopic|Laparoscopic Guided Transversus Abdominis Plane Block using Bupivacaine
88848102|NCT02973451|Active Comparator|local|Trocar Site Infiltration of Bupivacaine
88848103|NCT00668785|Experimental|Ranibizumab|Ranibizumab is being used off-label to test the safety and efficacy of its use in Diabetic Macular Edema post panretinal photocoagulation. Ranibizumab 0.5mg at baseline and then again at 30 days and/or 60 days after PRP as deemed appropriate by the Investigator.
88848104|NCT04847804||Positive case|The sample will be tested by microfluidic device and shows positive
88848105|NCT04847804||Negative control|The sample will be tested by microfluidic device and shows negative
88848106|NCT00655057|Active Comparator|1|Healthy participants will undergo TRODAT-1 SPECT imaging.
88848107|NCT00655057|Experimental|2|Participants with depression will undergo TRODAT-1 SPECT imaging and treatment with s-citalopram.
88848108|NCT00655057|Active Comparator|3|Participants with depression will undergo TRODAT-1 SPECT imaging and treatment with cognitive behavioral therapy.
88848109|NCT04358432|Experimental|AK102 450 mg|Participants received AK102 450 mg subcutaneous injection once every 4 weeks (Q4W) for 12 weeks
88848110|NCT04358432|Experimental|AK102 300 mg|Participants received AK102 300 mg subcutaneous injection once every 4 weeks (Q4W) for 12 weeks
88848111|NCT04358432|Experimental|AK102 150 mg|Participants received AK102 150 mg subcutaneous injection once every 2 weeks (Q2W) for 12 weeks
88848112|NCT04358432|Experimental|AK102 75 mg|Participants received AK102 75 mg subcutaneous injection once every 2 weeks (Q2W) for 12 weeks
88848113|NCT04358432|Placebo Comparator|Placebo Q4W|Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for 12 weeks
88848114|NCT04358432|Placebo Comparator|Placebo Q2W|Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks
88848115|NCT00635167|Experimental|Contrast Enhanced Transrectal Ultrasound (TRUS)|
88848116|NCT04353830|Experimental|Phase Ia Dose-Escalation Stage:IBI939|Participants will be treated with escalating doses of IBI939 to determine the MTD.
88848117|NCT04353830|Experimental|Phase Ia Dose-Escalation Stage:IBI939+ Sintilimab|Participants will be treated with escalating doses of IBI939 in combination with a fixed dose of Sintilimab to determine the MTD.
88848118|NCT04353830|Experimental|Phase Ib Expansion Stage:IBI939+ Sintilimab|Participants will be enrolled in the expansion stage to better characterize the safety, tolerability, PK variability, and preliminary efficacy of IBI939 in combination with Sintilimab in different cancer types.
88848119|NCT00630487|Placebo Comparator|Placebo|
88848120|NCT00630487|Active Comparator|Verum|
88848121|NCT03659240|Experimental|Cranberry beverage|
88848122|NCT03659240|Placebo Comparator|Placebo beverage|
88848123|NCT00379327|Experimental|Real Accupuncture|Acupuncture with a real needle that punctures the skin versus acupuncture needle that does not puncture the skin.
88848124|NCT00379327|Placebo Comparator|Non-puncturing Acupuncture|Acupuncture needle that touches but does not puncture the skin
88848125|NCT00000253|Active Comparator|Placebo + 10% N2O|0% N2O inhaled during psychomotor testing, 10% N2O inhaled during psycho motor testing, then subject's choice of the 2.
88848126|NCT00000253|Active Comparator|Placebo + 20% N2O|Placebo inhaled during psychomotor testing, 20% N2O inhaled during psychomotor testing, then subject's choice of the 2.
88848127|NCT00000253|Active Comparator|Placebo + 30% N2O|Placebo inhaled during psychomotor testing, 30% N2O inhaled during psychomotor testing, then subject's choice of the 2.
88848128|NCT00000253|Active Comparator|Placebo + 40% N2O|Placebo inhaled during psychomotor testing, 40% N2O inhaled during psychomotor testing, then subject's choice of the 2.
89181773|NCT04097288|Placebo Comparator|Single dose placebo reboxetine|A blinded single dose visually identical placebo pill to reboxetine is administered two hours before urethral pressure reflectometry and anal acoustic reflectometry measurements
88848129|NCT00000259|Placebo Comparator|Placebo|Subject inhales no drug (100% oxygen)
88848130|NCT00000259|Active Comparator|0.3% sevoflurane|
88848131|NCT00000259|Active Comparator|0.6% sevoflurane|
88848132|NCT00000259|Active Comparator|15% Nitrous oxide|
88848133|NCT00000259|Active Comparator|30% Nitrous oxide|
89181774|NCT04076007|Active Comparator|Active|Nitrate rich beetroot juice (7.5 mmol nitrate in 250mls beetroot juice) once daily.
89375803|NCT05608824|Experimental|Musculoskeletal injury|Shear wave elastography and microvascular flow imaging.
89375804|NCT05606731|Experimental|Intervention Group|"The study's intervention is a parenting/caregiver training program that includes 1-month of weekly in-person sessions plus multi-media interactive text messaging. The weekly 1-hour-in-person sessions will be coupled with four interactive messages per week for a period of 4 weeks total, followed by booster text messages after completing the 4-week program."
89375805|NCT05606731|No Intervention|Usual Care|"Usual care for caregivers of 2- to-5-year-olds will include the Women Infant and Children services : (1) monthly vouchers for nutritious food; (2) individual nutrition counseling at least twice per year; (3) nutrition education two times per year (1:1 counseling or online health education modules); and (4) referrals to family services."
89375806|NCT05606289|Experimental|CIT officers|Police officers randomized to the experimental group will receive a 40-hour CIT training curriculum.
89375807|NCT05606289|No Intervention|Non-CIT officers|Police officers randomized to the no-intervention group will not receive the 40-hour CIT training curriculum.
89375808|NCT05595187|Experimental|Tricuspid repair|Tricuspid repair techniques included suture placement and the type of prosthetic annuloplasty with specified the use of an approved rigid, incomplete, nonplanar, and undersized (ranging 26, 28, or 30, 32, 34 mm) ring.
89375809|NCT05595187|No Intervention|Blank control|
89375810|NCT05588674|Experimental|Probiotic Supplement|1 billion CFU per capsule of a multistrain probiotic formulation including one Bifidobacterium and two Lactobacilli strains with maltodextrin as a carrier
89375811|NCT05588674|Placebo Comparator|Placebo capsule|418mg maltodextrin
89375812|NCT05584553||ToggleLoc 2.9 mm soft tissue device|Patients who already received the ToggleLoc 2.9 mm soft tissue device in the shoulder. No additional surgery will be performed.
89375813|NCT05584553||JuggerLoc soft tissue device|Patients who already received the JuggerLoc soft tissue device in the shoulder. No additional surgery will be performed.
89375814|NCT05581810|Experimental|Cognitive Behavioural Therapy (CBT)|11 weekly sessions of cognitive behavioural therapy (CBT) delivered over videoconference
89375815|NCT05581810|Active Comparator|Cognitive Rehabilitation|11 weekly sessions of traditional cognitive rehabilitation delivered over videoconference
88848134|NCT00000265||Low anxiety|
88848135|NCT00000265||Moderate anxiety|
88848136|NCT00000265||High anxiety|
88848137|NCT04331665|Experimental|Ruxolitinib to prevent COVID-19 pneumonia|All participants will receive ruxolitinib at at 10 mg, twice a day, for 14 days, followed by 5 mg, twice a day, for 2 days and 5 mg, once daily, for 1 day.
88848138|NCT00379405|Experimental|A|Saquinavir (Invirase): 2 capsules (500 mg) / 12 hours
88848139|NCT00379405|No Intervention|2|IP o NNUCS + 2 NUCS as a HAART therapy .
88848140|NCT04321538||Failed Vision Screen Cohort|This cohort represents the entire group of study participants- children who were referred to Yale New Haven Hospital and Yale Medicine for a failed vision screen by either their primary care provider or their school.
88848141|NCT00379483|Experimental|Arm 1|
88848142|NCT00607477|Active Comparator|1|Minoxidil
88848143|NCT00607477|Active Comparator|2|Hydralazine
89002362|NCT06318559|Experimental|3D group|"in Group 3D, an intrafascial nerve-sparing (NS) technique will be performed on the side of the lesion; contralaterally an intra-, inter- or extra-fascial NS technique will be performed. After removal of the prostate, virtual images of the prostate will be projected into the lodge using AI software and will be displayed thanks to the Tile-Pro. The virtual 3D model will allow identifying the extracapsular extension of the tumor lesion, projected at the level of the preserved neurovascular bundle.~A first selective excisional biopsy at the level of the suspected ECE on the NVB will be sent for extemporaneous histological examination. Under 3D AR guidance, a second selective biopsy will then be performed on the NVB at the same level as the first, however involving a larger and thicker layer of tissue. the biopsies will be sent for extemporaneous histological examination. In case of positivity, the entire NVB will be removed"
89002363|NCT06318559|Active Comparator|no3D group|"For the no-3D group, the intra-, inter- or extra-fascial NS technique during robotic prostatectomy will be performed according to the clinical indication.~At the end of the demolitive phase a selective biopsu was performed in a cognitive fashion accordin with the information provided by MRI images.~Reconstructive phase was performed according to our previously described total anatomical reconstruction (TAR) technique for both arms."
89002364|NCT06318546|Active Comparator|Control|This group will undergo spinal anesthesia using fentanyl (50 microgram) as adjuvant to intrathecal bupivacaine
89002365|NCT06318546|Active Comparator|Dexmedetomidine|This group will undergo spinal anesthesia using dexmedetomidine (10mg) as adjuvant to intrathecal bupivacaine
89002366|NCT06318494|Experimental|Patients suffering from ankle instability|
89002367|NCT06318494|Active Comparator|Healthy volunteer subjects not affected by ankle pathology|
89002368|NCT06318481|Experimental|Treatment Group|Patients will be provided ticagrelor twice daily for first 30 days after primary PCI.
89002369|NCT06318481|Active Comparator|Control Group|Patients will be provided clopidogrel twice daily for first 30 days after primary PCI.
89002370|NCT06318468|Experimental|Humanoid diagrams training program|The experimental group will receive the nursing health assessment teaching for 50 minutes and discussion using humanoid diagrams for 40 minutes to learn comprehensive nursing assessment.
89002371|NCT06318468|Active Comparator|comparison group|The comparison group will receive health assessment teaching for 50 minutes and discussion using case discussion for 40 minutes to learn comprehensive nursing assessment.
89002372|NCT06318455|Experimental|breathing exercise group|breathing exercise group: make breathing exercise for 12 weeks
89002373|NCT06318455|No Intervention|control group|control group: continue standart treartment
89002374|NCT06318442|Experimental|Once daily semaglutide|Once daily semaglutide 3 mg (uptitrated to 3 mg twice daily after two days).
89002375|NCT06318442|Active Comparator|- Metformin|Metformin modified release tablets (500mg once daily for the first two days, then 500 mg twice daily).
89002376|NCT06318442|Placebo Comparator|Placebo|Placebo tablets
89002377|NCT06318429|Experimental|stretching exercise group|stretching exercise group
89002378|NCT06318429|No Intervention|control group|control group
89002381|NCT06318390|Experimental|Keto5 XOGenius Beverage|Keto5 XOGenius Beverage contains natural ingredients that are high in the Ketone β-OHB content and has anti-inflammatory and antioxidant properties
89002382|NCT06318377|Experimental|Peanut Consumption|Peanuts are rich in polyphenols and also have anti-inflammatory and antioxidant properties.
89002383|NCT06318377|No Intervention|Non-peanut consumption|The non-peanut consumption will simply not be consuming any additional supplements in their diet
89002384|NCT06318364||Patients staying in the PACU|Patients staying in the PACU
89002385|NCT06318351||Transcutaneous Electrical Acupoint Stimulation|The effect of Transcutaneous Electrical Acupoint Stimulation on postoperative vision was observed according to anesthesiologist's habit of using or not using it.
89002386|NCT06318338|Experimental|Virtual Reality Program|This is a single arm study. All participants will participate in the study intervention, which involves experiencing a virtual reality program.
89002387|NCT06318325||gymnasts|gymnasts ages 9-16 years. All participants are of competitive level, each participating in at least four competitions per year
89002388|NCT06318312|Experimental|11% FiO2|Hypoxic exposure: fraction of oxygen inspired (FiO2) = 11% (~5100 m, ~16735 ft)
89002389|NCT06318312|Experimental|13% FiO2|Hypoxic exposure: fraction of oxygen inspired (FiO2) = 13% (~3800 m, ~12470 ft)
89002390|NCT06318312|Experimental|15% FiO2|Hypoxic exposure: fraction of oxygen inspired (FiO2) = 15% (~2750 m, ~9000 ft)
89375816|NCT05579587||LPR Patients|Adults with a confirmed diagnosis of LPR with HEMII-pH (≥2 LPR events in 24 hr period), Esophageal manometry and Laryngoscopy undergoing endoscopic transoral incisionless fundoplication (TIF).
89002391|NCT06318312|Placebo Comparator|PLA / 21% FiO2|Hypoxic exposure / placebo condition: fraction of oxygen inspired (FiO2) = 21% (sea level)
89181775|NCT04076007|Placebo Comparator|Placebo|Nitrate depleted beetroot juice (0.002 mmol nitrate in 250 ml beetroot juice) once daily.
89181776|NCT03995901|Experimental|FCR001|FCR001 is a cryopreserved allogeneic stem cell therapy derived from mobilized peripheral blood of the kidney donor that is delivered as a single dose with a non- myeloablative conditioning regimen. FCR001 contains the donor's CD34+ cells, facilitating cells, and αβ T cells.
89181777|NCT03995901|No Intervention|Control|"Standard induction therapy followed by a maintenance regimen of tacrolimus, mycophenolate, and +/- corticosteroids after kidney transplant.~Control donors are not followed beyond randomization."
89375817|NCT05577364|Experimental|Selinexor in Combination With R-CHOP|"Patients with untreated EBV-positive diffuse large B-cell lymphoma will receive sequentially higher doses of selinexor in combination with R-CHOP regimen from the second cycle of R-CHOP (3 weeks per cycle).The initial dose of selinexor is 40mg qw po.~After 8 cycles of induction therapy, if the response is assessed as complete remission (CR), maintenance therapy with selinexor will be conducted."
89375818|NCT05564663|Experimental|PTSD Coach App + Brief Support|PTSD Coach App + Brief Support will include brief instruction and support for the use of the PTSD Coach App developed by the study team. The PTSD Coach App incorporates evidence-based assessment, psychoeducation, and self-management strategies for PTSD symptoms that are customizable to the user.
88848144|NCT03603314|Experimental|29 mg dose group|Patients will receive the study drug (SENS-401) in the form of tablets by mouth, twice a day, during the first 4 weeks after randomization.
88848145|NCT03603314|Experimental|43.5 mg dose group|Patients will receive the study drug (SENS-401) in the form of tablets by mouth, twice a day, during the first 4 weeks after randomization.
88848146|NCT03603314|Placebo Comparator|placebo oral tablet|Patients will receive the study drug (placebo) in the form of tablets by mouth, twice a day, during the first 4 weeks after randomization.
88848147|NCT04423861|Experimental|nitazoxanide BID|Patients will receive nitazoxanide 600 mg BID for 7 days.
88848148|NCT04423861|Placebo Comparator|Placebo|Patients will receive matching placebo BID for 7 days.
88848149|NCT04418869|Experimental|Exercise|All subject will perform three different exercise bouts and one control session.
88848150|NCT04330196|Experimental|Glucose condition|In the experimental condition patients ingest 200ml of water containing 75g of glucose
88848151|NCT04330196|Placebo Comparator|Control condition|In the control condition patients ingest 200ml of water sweetened with 700mg of aspartame
88848152|NCT00000271|Experimental|Desipramine|Participants were treated with desipramine, up to 300 mg per day. All patients received weekly individual manual-guided relapse prevention therapy.
88848153|NCT00000271|Placebo Comparator|Placebo|Participants were treated with matching placebo. All patients received weekly individual manual-guided relapse prevention therapy.
88848154|NCT00599131|Experimental|Chemotherapy/Radiation/Surgery|"Patients will undergo induction chemotherapy with (TPF): Docetaxel (Taxotere) 75 mg/m2 and cisplatin 100 mg/m2 on day 1, and 5-FU 750 mg/m2 days 1-4.~On day 20 patients will receive a single dose of cetuximab (C-225) 400 mg/m2.~Depending upon disease response, patients will undergo salvage laryngectomy followed by radiation therapy and chemotherapy."
88848155|NCT04302350|Experimental|Group75|According to preoperative 3D-CTBA evaluation of bronchial and vascular structure of pulmonary nodules and pulmonary segments, the target segmental bronchus, arteries and intra-segment veins were accurately identified and dissected by ligation or stapler cutting. After that, the anesthesiologist began to make preparations for the lung inflation. The portable nitrous oxide concentration detector (TD600-SH-B-N2O) was installed to detect N2O concentration (vol%), and then adjusted the anesthesia machine to the manual control mode. The flow of the selected gas mixture was set to 8L/min (Group75 set to N2O:O2=6:2). When the N2O concentration detector reached the predetermined gas concentration, and then the collapsed lung was re-expanded completely with controlled airway pressure under 20 cmH2O (1cm H2O=0.098 kPa) by the anesthesiologist. This procedure took approximately 1 min, and then FiO2=1.0 was performed after the initiation of the OLV.
88848156|NCT04302350|Experimental|Group50|According to preoperative 3D-CTBA evaluation of bronchial and vascular structure of pulmonary nodules and pulmonary segments, the target segmental bronchus, arteries and intra-segment veins were accurately identified and dissected by ligation or stapler cutting. After that, the anesthesiologist began to make preparations for the lung inflation. The portable nitrous oxide concentration detector (TD600-SH-B-N2O) was installed to detect N2O concentration (vol%), and then adjusted the anesthesia machine to the manual control mode. The flow of the selected gas mixture was set to 8L/min (Group50 set to N2O:O2=4:4). When the N2O concentration detector reached the predetermined gas concentration, and then the collapsed lung was re-expanded completely with controlled airway pressure under 20 cmH2O (1cm H2O=0.098 kPa) by the anesthesiologist. This procedure took approximately 1 min, and then FiO2=1.0 was performed after the initiation of the OLV.
88848157|NCT04302350|Active Comparator|Group0|According to preoperative 3D-CTBA evaluation of bronchial and vascular structure of pulmonary nodules and pulmonary segments, the target segmental bronchus, arteries and intra-segment veins were accurately identified and dissected by ligation or stapler cutting. After that, the anesthesiologist began to make preparations for the lung inflation. The portable nitrous oxide concentration detector (TD600-SH-B-N2O) was installed to detect N2O concentration (vol%), and then adjusted the anesthesia machine to the manual control mode. The flow of the selected gas mixture was set to 8L/min (Group0 set to O2=8). When the N2O concentration detector reached the predetermined gas concentration, and then the collapsed lung was re-expanded completely with controlled airway pressure under 20 cmH2O (1cm H2O=0.098 kPa) by the anesthesiologist. This procedure took approximately 1 min, and then FiO2=1.0 was performed after the initiation of the OLV.
88848158|NCT00584935|Experimental|Rituximab|The Rituximab dose is 1000 mg (1gm) given as an IV infusion every two weeks for 2 doses (Days 1 and 15).
88848159|NCT04297358|Experimental|Stroke patients|40 consecutive sessions of hyperbaric oxygen will be administered at a pressure of 2 absolute atmosphere (ATA) to 10 patients. If there are drop outs, recruitment will be continued until a total of 10 patients with at least 30 sessions.
88848160|NCT04384939|Experimental|Double-J ureteral stent|Pediatric patient with an uropathy or kidney graft need the insertion of Double-J ureteral stent in a routine care
88848161|NCT04246723|Experimental|Cohort A (Narlaprevir + Ritonavir + Sofosbuvir for 12 weeks)|"All of enrolled patients receive equal study therapy with Narlaprevir 200 mg Once a day (QD)/Ritonavir 100 mg QD/Sofosbuvir 400 mg QD orally for 12 weeks. Narlaprevir should be taken with ritonavir and food and should be taken at approximately the same morning time each day.~Sofosbuvir can be taken with or without meals."
88848162|NCT04246723|Experimental|Cohort B (Narlaprevir + Ritonavir + Sofosbuvir for 8 weeks)|"All of enrolled patients receive equal study therapy with Narlaprevir 200 mg QD (once daily)/Ritonavir 100 mg QD/Sofosbuvir 400 mg QD orally for 8 weeks. Narlaprevir should be taken with ritonavir and food and should be taken at approximately the same morning time each day.~Sofosbuvir can be taken with or without meals."
89181778|NCT04076085|Active Comparator|Unsupported Upper extremity exercise|Specially designed unsupported Arm exercises will be done for the population with a rating of somewhat hard 13-14 (Original scale) will be used as a guideline for intensity
89375819|NCT05564663|Active Comparator|Enhanced Usual Care (EUC)|EUC will include brief psychoeducation regarding PTSD and alcohol use disorder (AUD) and resources for PTSD-related mental health treatment.
89375820|NCT05548452|Experimental|Intestinal Microbiota Transplant capsules|Capsules will be provided twice during the trial
89375821|NCT05548452|Placebo Comparator|Placebo capsules|Capsules will be provided twice during the trial
89375822|NCT05548426|Experimental|Linezolid 10 Day|Oral linezolid 600mg, taken twice a day for 10 days
89375823|NCT05548426|Active Comparator|Benzathine Penicillin G|Single intramuscular injection of 2.4 million units of benzathine penicillin G
89375824|NCT05534529|Experimental|Rezafungin|It is IMP.
89375825|NCT05525676|Experimental|Brief Relationship Checkup (BRC)|Couples in the experimental condition will participate in three joint sessions of the Brief Relationship Checkup (BRC; Cordova 2014; Cigrang et al., 2016). This program has been tested in Air Force Primary Care but has not been explored in Veterans with ongoing mental health issues and has not been compared to an active treatment.
88848163|NCT04415996|Experimental|HVLA L3/4 Group|"In each participant, blind assessors will perform pre-intervention measurements of dislocation of center of pressure (CoP), plantar pressure mean and plantar contact area in a baropodometric pressure platform.~Next, the investigator will perform the HVLA technique in L3/L4 joint articulation.~Then, the same measurements before described will be repeated, by the assessors 1 minute after the intervention."
89375826|NCT05525676|Active Comparator|Co-Located Collaborative Care (CCC)|The comparison condition will be three sessions of Co-Located Collaborative Care (CCC) offered to the Screened Veteran only. This reflects the current standard of care in VA Primary Care Mental Health.
89375827|NCT05524298||Elderly Patients With Low Grade Non-Hodgkin Lymphoma|"Elderly Patients With Low Grade Non-Hodgkin Lymphoma Treated With Immunotherapy Or Immunochemotherapy And/Or Radiotherapy.~Assess QoL (quality of life) at baseline, at the end of treatment and after 1 year from the start of the therapy."
89375828|NCT05521815|Active Comparator|Study group|The group that are going to receive the coma arousal therapy program
89375829|NCT05521815|Placebo Comparator|Control group|This group will receive only traditional treatment program
88848164|NCT04415996|Sham Comparator|Control Group|"In each participant, blind assessors will perform pre-intervention measurements of dislocation of center of pressure (CoP), plantar pressure mean and plantar contact area in a baropodometric pressure platform.~Next, the investigator will perform a Sham technique. Then, the same measurements before described will be repeated, by the assessors 1 minute after the intervention."
89375830|NCT05514197|Experimental|Vitamin C arm|Intravenous loading of 5g ascorbic acid before incision of wound
89375831|NCT05514197|Placebo Comparator|Control arm|Intravenous loading of the same volume Normal saline as experimental arm
89375832|NCT05513313||Jynneos vaccine with out other vaccines|Allocated to Jynneos without any need for additional indicated/required vaccines intervention. JYNNEOS (Smallpox and Monkeypox Vaccine, Live, Nonreplicating) suspension for subcutaneous injection. Administer two doses (0.5 mL each) 4 weeks apart. Each dose (0.5 mL) is supplied in a singledose vial.
89375833|NCT05513313||Jynneos vaccine with other vaccines at dose 1|Allocated to Jynneos with concomitant vaccines given at time of first dose of Jynneos intervention.
89375834|NCT05513313||Jynneos vaccine with other vaccines at dose 2|Allocated to Jynneos with concomitant vaccines given at time of second dose of Jynneos.
89375835|NCT05511909|Experimental|opioid stepwise taper + buspirone|up to 45mg/day buspirone during the opioid stepwise taper
89375836|NCT05511909|Active Comparator|opioid stepwise taper + lofexidine|up to 2.16mg/day lofexidine during the opioid stepwise taper
89375837|NCT05511909|Placebo Comparator|opioid stepwise taper + placebo|placebo during the opioid stepwise taper
89375838|NCT05496075|Experimental|Orlistat group|Orlistat was administered orally on the basis of lifestyle guidance.
89375839|NCT05496075|Placebo Comparator|control group|Orlistat placebo was administered orally on the basis of lifestyle guidance.
89375840|NCT05494905|Experimental|Virtual Reality (VR)|
89375841|NCT05494905|Active Comparator|Functional Strength Training (FST)|
89375842|NCT05493735|Placebo Comparator|Control|Lubricating jelly (placebo) will be placed in the vagina to the level of the pessary, five minutes prior to pessary removal.
89375843|NCT05493735|Experimental|Experimental|Lidocaine jelly will be placed in the vagina to the level of the pessary, five minutes prior to the pessary removal.
89375844|NCT05486585|Experimental|Children and Adolescents|30 children aged 8-12 years old and their parents, 30 adolescents aged 13-17 years old and their parents
89375845|NCT05480722|Experimental|Salt Sensitivity Assessment|1 week high salt diet and 1 week low salt diet
89375846|NCT05480722|Experimental|Functional Magnetic Resonance Imaging|Hypertonic saline infusion perturbation with and without NKCC2 antagonism (furosemide) to examine sodium sensing mechanisms
89375847|NCT05480124|Sham Comparator|Sham stimulation treatment|Sham stimulation during a computerized task and electroencephalogram (EEG) recording.
89375848|NCT05480124|Experimental|tACS brain stimulation treatment|tACS brain stimulation during a computerized task and EEG recording. Participants will receive tACS using individualized peak Phase-amplitude coupling (PAC) frequency pairs determined in Session 1.
89375849|NCT05474027|Experimental|Patients Receiving Tranexamic Acid with Avoidance of Hypotensive Anesthesia|
89375850|NCT05469815|Experimental|Lost Children Society Game|Online therapeutic role-playing session
89375851|NCT05465239|Experimental|SurePace Powered Walker User|"Before any formal experiments are conducted, participants will be given an opportunity to train with the new powered walker for a pre-defined period of time to eliminate the confounding effects of being unfamiliar with using the device. (See the description of UVA's facilities and Protection of Human Subjects document for additional discussion of safety measures/protocols and Institutional Review Board procedures.) Experiments will consist of one-hour sessions (with adequate rest periods between trials and time for evaluations) in which participants will be asked to walk at a self-selected (comfortable) walking speed through a pre-defined 8 m x 4 m oval course."
89375852|NCT05447858|Active Comparator|Managerial support in using systematic work environment evaluation and adjustment (SWEA)|Managerial support in using SWEA and the Prehab guide to enhance employees' work situation. Individual work adaptations are adaptations to everyone´s ability in the physical, organisational, and social work environment that aim to enable an employee with reduced ability to perform the normal work, continue working, or plan for a sustainable return to work. The Prehab guide contains a self-assessment test for the employee based on the requirements of the work and one's own ability that can be used in the dialogue with the manager. It also contains suggestions for activities to create a healthier workplace, such as discovering early signals of stress or pain, creating a caring workplace culture and boundaries, regular contact with an employee that is on sick-leave, clear and established safety procedures and routines for the work environmental work, routines for cooperation with other parties, and to learn from one's own and colleague's experiences in an open, permissive climate.
89375853|NCT05447858|Experimental|Neck-specific exercise in addition to SWEA|NSEs will be performed based on a well-structured framework of evidence-based exercises for facilitation of deep neck muscles, improved interaction between the different muscle layers of the neck, increased neck muscle endurance, and improved postural control [15, 30]. To ensure that the exercises are learned and performed correctly, the participant will meet with a physiotherapist a total of four times, once during weeks 2, 3, 4, and 7 (week 1=first visit for a clinical examination due to law) for instruction, guidance, and support. In addition to photos, videos, and text regarding the exercises, the digital support (web-based program at the support and treatment platform Inera via 1177 managed by the County Councils) also contains information about why it is important to exercise the neck muscles, factors that may cause neck pain, how relapses can be handled, ergonomic advice related to the neck, and an exercise diary.
89375854|NCT05445284|Experimental|Group education sessions for parents plus usual diabetes care|"≥3 in-person/virtual one-hour group education sessions for parents plus usual diabetes care, every 3 months for 12 months and ≥3 check-in virtual 15-20 minute sessions in-between the group sessions. Each group session (3-8 parents per group) will be facilitated by a diabetes social worker and will consist of parent-driven discussions on topics relevant to adolescence and transition care. Each one-hour session will commence with an ice-breaker activity and then move to a parent-driven, facilitator-mediated discussion. The group session content will be guided by the needs of the participants; however, the facilitator will actively promote discussion on adolescent- and transition-related topics. The group discussion will end with participants setting goals for their next session."
89375855|NCT05445284|Other|Usual diabetes care|Usual diabetes care, every 3 months for 12 months, which consists of visits with their diabetes care physician. In addition, as per usual care, individual sessions and meetings related to transition care with the diabetes social worker will be provided to parents, as needed.
89375856|NCT05444517|Active Comparator|Interscalene Block|Patients randomized to receive an interscalene block.
89375857|NCT05444517|Experimental|Infraclavicular-Anterior Supraescapular Nerve Blocks|Patients randomized to receive a combined infraclavicular plus anterior suprascapular nerve blocks.
89375858|NCT05443178|Experimental|Cohort 1|100 mg Nivaquine and 4 Tabl Rimstar peroral once daily before breakfast for 14 days
88848165|NCT04181203|Active Comparator|SRT + 6 months of LHRHa|"Treatment with LHRHa will start 4 weeks before the first RT fraction (i.e Day 1 of Week 1 of treatment period.) The total duration of the LHRHa treatment is 6 months.~SRT will start 4 weeks after the first administration of LHRHa (i.e Day 1 of Week 5 of treatment period.). The total duration of SRT is 6.5 weeks."
88848166|NCT04181203|Experimental|SRT + 6 months of LHRHa + 6 months of Apalutamide|"Treatment with LHRHa will start 4 weeks before the first RT fraction (i.e Day 1 of Week 1 of treatment period.) The total duration of the LHRHa treatment is 6 months.~Treatment with apalutamide (240 mg PO daily) should start the same day as the first LHRHa administration, for 6 months.~SRT will start 4 weeks after the first administration of LHRHa (i.e Day 1 of Week 5 of treatment period.). The total duration of SRT is 6.5 weeks."
88848167|NCT03521102|Experimental|Acetaminophen 1000mg IV|NRS pain score will be obtained at baseline, 15, 30, 45, 60, 90, 120, and 180 minutes following completion of intervention. Adverse events will be recorded every 15 minutes for the duration of the study protocol. Participants will be reassessed for the need of additional pain control at 60 minutes.
88848168|NCT03521102|Active Comparator|Hydromorphone 0.5mg IV|NRS pain score will be checked at 5 minutes and every 15 minutes thereafter for 120 minutes. Adverse events will be recorded every 15 minutes for the duration of the study protocol. The need for additional pain control will be assessed at 60 minutes.
88848169|NCT05440591|Active Comparator|Metformin|Metformin XR 500 mg tablets - up-to twice daily orally.
88848170|NCT05440591|Experimental|Dapagliflozin|Dapagliflozin 10 mg tablets - once daily
89375859|NCT05443178|Experimental|Cohort 2|200 mg Chloroquine and 4 Tabl Rimstar peroral once daily before breakfast for 14 days
88848171|NCT05440591|Experimental|MetforminXR 500/Dapagliflozin 5mg|MetforminXR 500/Dapagliflozin 5mg , tablets- once daily
88848172|NCT04099303|Experimental|Vaccine 1A|Subjects received one dose of DTaP aged 4 to 6 years.
88848173|NCT04099303|Active Comparator|Vaccine 1B|Subjects received one dose of DT aged 4 to 6 years.
88848174|NCT04099303|Experimental|Vaccine 2A|Subjects received one dose of DTcP aged 18 to 24 months.
88848175|NCT04099303|Active Comparator|Vaccine 2B|Subjects received one dose of DTaP aged 18 to 24 months.
88848176|NCT04099303|Experimental|Vaccine 3A|Subjects received three doses of DTcP at 3,4,5 months of age.
88848177|NCT04099303|Active Comparator|Vaccine 3B|Subjects received three doses of DTaP at 3,4,5 months of age.
88848178|NCT04099303|Active Comparator|Vaccine 3C|Subjects received three doses of DTaP-IPV-Hib at 3,4,5 months of age.
88848179|NCT04099303|Experimental|Vaccine 4A|Subjects received three doses of DTcP at 2,3,4 months of age.
88848180|NCT04099303|Active Comparator|Vaccine 4B|Subjects received three doses of DTaP-IPV-Hib at 2,3,4 months of age.
88848181|NCT04099303|Experimental|Vaccine 4C|Subjects received three doses of DTcP at 2,4,6 months of age.
88848182|NCT00379951|Experimental|1|Arm 1: ertapenem sodium
88848183|NCT00000331|Experimental|Test Drug|Test drug to prevent heroine withdrawal
88848184|NCT00000331|Placebo Comparator|Placebo Pill|Placebo drug
88848185|NCT03492476|Experimental|Circaid|Compression sleeve on the day associated with the night wearing of the system of contention circaid®
88848186|NCT03492476|Active Comparator|Reference treatment|Compression sleeve during the day associated with a possible treatment with it during the night, according to the recommendations of the HAS
88848187|NCT04712708|Active Comparator|Control Group|Eighteen children with spastic CP will receive especially designed physical therapy program based on Neuro-Developmental treatment (NDT) approach with emphasis on exercise encourage independent standing, stretches exercises, strengthening exercises, approximation, enhancement and facilitation of gait patterning and ankle ROM exercises for one hour for 24 sessions
88848188|NCT04712708|Experimental|Study Group|ighteen children with spastic CP will receive the same program that the control group received in addition to especially designed exercises using rebound therapy (Mini Trampoline) that include push up exercise, standing, squatting, single limb squatting, kneeling position, catching and throwing a ball over head in kneeling position, catching and throwing a ball over head in standing position, kicking the ball, broad jumping with assistance, jumping in place, for 1 hour three times per week for three successive months.
88848189|NCT04022785|Experimental|Treatment (BRD4 Inhibitor PLX51107, azacitidine)|Patients receive PLX51107 PO QD on days 1-21 and azacitidine SC or IV over 15 minutes on days 8-14 and 22-28. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
88848190|NCT06316830|Experimental|High Maintenance Daily Dose (24mg)|The experimental intervention is a high daily maintenance dose of buprenorphine (24 mg) plus any usual clinical care the participant receives at the clinic. This high daily dose is the upper limit of the FDA-approved dose range 35-37 and was selected based on preclinical studies, clinician anecdotes, case reports, and retrospective analyses suggesting improved effectiveness of higher buprenorphine doses among patients with a history of fentanyl use. Underlying pharmacodynamic principles support that the 24 mg daily dose of buprenorphine is likely to be well-tolerated, safe, and better control cravings among people with a history of fentanyl use.
88848191|NCT06316830|Active Comparator|Standard Maintenance Daily Dose (16mg)|The control intervention is the FDA-recommended target daily maintenance dose of buprenorphine (16 mg) plus any usual clinical care the participant receives at the clinic.
88848192|NCT06316804|Experimental|Video Intervention 1|The video intervention #1 will involve videos of patients describing personal narratives of mental illness, treatment and recovery, and will be delivered over 4 weeks (with two booster sessions in week 6 and 12). Assessments will be completed over 12 months from date of randomization.
88848193|NCT06316804|Active Comparator|Video Intervention 2|The video intervention #2 will involve videos of patients describing personal narratives of mental illness, treatment and recovery, and will be delivered over 4 weeks (with two booster sessions in week 6 and 12). Assessments will be completed over 12 months from date of randomization.
88848194|NCT06316804|Placebo Comparator|Waitlist Video Intervention 3|After the completion of the 6-month waitlist period, the experimental video intervention will be provided. The intervention will involve videos of patients describing personal narratives of mental illness, treatment and recovery, and will be delivered over 4 weeks (with two booster sessions in week 6 and 12). The intervention offered after the waitlist period will follow video intervention 1 (experimental arm).
88848195|NCT06316791|Experimental|Single dose of CNCT19|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered before the investigational treatment, CNCT19.
88848196|NCT06316739|Experimental|Immediate intervention neighborhood|According to the trial's wait-list controlled design, the Ganchero intervention will be implemented sequentially in two geographically and socially distinct Bronx neighborhoods with large migrant Puerto Rican populations. In Cycle I, the intervention will be implemented with Gancheros and their clients in neighborhood A, while participants in neighborhood B receive standard access to harm reduction through a local Syringe Services Program (SSP).
89375860|NCT05443178|Experimental|Cohort 3|300 mg Chloroquine and 4 Tabl Rimstar peroral once daily before breakfast for 14 days
88848197|NCT06316739|Experimental|Delayed intervention neighborhood|In Cycle II, the Ganchero intervention will be implemented with Gancheros and their clients in neighborhood B, while participants in neighborhood A receive standard access to harm reduction through a local Syringe Services Program (SSP).
88848198|NCT06316726|Active Comparator|intervention A|full bed silicone mattress plus other measures
88848199|NCT06316726|No Intervention|intervention B|full bed silicone mattress plus usual care
88848200|NCT06316713|Experimental|One MORE (Spanish Adaptation)|
88848201|NCT06316713|No Intervention|Waitlist Control|
88848202|NCT06316700|Active Comparator|Nutritional Powder Supplement|A foundational nutritional supplement consisting of vitamins, minerals, probiotics, prebiotics, and whole food ingredients
88848203|NCT06316700|Placebo Comparator|Placebo|Maltodextrin + Flavoring
89375861|NCT05443178|Experimental|Dose extension group|Dose escalation: XX mg Chloroquine (depending on results) and 4 Tabl Rimstar peroral once daily before breakfast for 14 days
89375862|NCT05436184||Cincinnati IMPRINT birth cohort|mother-infant pairs enrolled at or after week 34 in pregnancy and followed over three flu seasons, up to four years of age.
88848206|NCT06316661||HFpEF|patients with HFpEF
88848207|NCT06316661||healthy volunteers|healthy volunteers matched for age and sex
89535040|NCT05015829||Paradoxical low-flow low-gradient aortic stenosis|LVEF>50% SVi < 35.0 mL/m2 Aortic mean gradient < 40 mmHg AVA < 1.0 cm2.
89535041|NCT05015673|Experimental|SEP-363856 25mg|SEP-363856 25 mg given orally
89399353|NCT03694431|Experimental|Tech-supported HBPC|Patients and caregivers in tech-supported HBPC will receive synchronous video visits with a provider (physician or nurse practitioner) while the nurse is in the patient's home. Home visits by the palliative care team will be determined based on patients/caregivers' needs.
89399354|NCT02170766|Experimental|BIBR 1048 low1|"Two treatments of one single dose of BIBR 1048 12.5 mg without or with Pantoprazole~BIBR 1048 12.5 mg without Pantoprazole~BIBR 1048 12.5 mg with 40 mg Pantoprazole (bid)"
88848208|NCT06316648|Active Comparator|control group|At 00:00 the night before the surgery, the researcher told the patients in the control group that they could have fruit juice/water if they wanted and waited for 10 minutes. The researcher then initiated the restriction process by informing the patients that they could no longer have food/water. Fasting, thirst, blood glucose and nausea-vomiting evaluations applied to the patients in the intervention group were also performed on the patients in the control group at the same hours. IV fluid therapy was not administered to both groups before surgical intervention.
88848209|NCT06316648|Experimental|whey intake|Since whey powder contains 73.45 grams of carbohydrate per 100 grams, whey was given to the patients in this study, unlike OCS (Oral Carbohydrate Solution), as it met the requirement in the ERAS protocol that at least 45 g of oral carbohydrate solution can be given two hours before surgery. It was prepared at the bedside by the first investigator for the patients in the oral whey intervention group by mixing 54 grams of 70% demineralized whey powder taken from the herbalist into 600 ml of drinking water six hours before the surgery, and the patients were given 400 ml six hours before the surgery and 200 ml two hours before the surgery. They were given ml and allowed to drink. Before the surgery, the patients' hunger, thirst, blood glucose and nausea and vomiting levels were evaluated.
89399355|NCT02170766|Experimental|BIBR 1048 low2|"Two treatments of one single dose of BIBR 1048 25 mg without or with Pantoprazole~BIBR 1048 25 mg without Pantoprazole~BIBR 1048 25 mg with 40 mg Pantoprazole (bid)"
88848211|NCT06316622|Experimental|volunteer person|meausered by ultrasound
88848212|NCT06316609||participants from birth cohort with AD|The association between maternal whole blood and serum levels of Emerging Contaminants (ECs) including Per- and Polyfluoroalkyl Substances (PFASs), Organophosphate Flame Retardants (OPFRs), and Microplastics during pregnancy and the incidence of atopic dermatitis in their offspring.
88848213|NCT06316609||participants from birth cohort without AD|The association between maternal whole blood and serum levels of Emerging Contaminants (ECs) including Per- and Polyfluoroalkyl Substances (PFASs), Organophosphate Flame Retardants (OPFRs), and Microplastics during pregnancy and the reduced incidence of atopic dermatitis in their offspring.
88848214|NCT06316596|Active Comparator|NEWBORN BORN AFTER EPIDURAL ANESTHESIA|Group epidural, 0.5% buvasin® will be applied epidural space in the lateral position after monitoring. The patient will be placed in the supine position and surgery will begin when the T5 spinal level is achieved. Pregnant heart rate, blood pressure and saturation values will be recorded at intervals and iv ephedrine will be administered when there is a 25% or more drop in blood pressure. When there is a 25% or more decrease in heart rate, iv atropine will be administered. A NIRS probe (infant,saturation sensor, Invos , Tullamore, Ireland) and pulse will be attached to the newborn by another anesthetist and the measurements will be recorded. Blood pressure will be taken from the umbilical vein. APGAR(activity,pulse,grimace,appearance,respiration), heart rate, SpO2 and umbilical vein saturation values of the newborn will be recorded. NIRS and spO2 values of the newborn will be checked intermittently.
88848215|NCT06316596|Active Comparator|NEWBORN BORN AFTER SPINAL ANESTHESIA|Group spinal, 0.5% buvasin® heavy will be applied spinal space in the lateral position after monitoring. Surgery will begin when the patient is placed in the supine position and T5 spinal level is achieved. Pregnant heart rate, blood pressure, and saturation values are recorded at regular intervals, and when there is a 25% or more drop in blood pressure, the patient will be given iv ephedrine. When there is a 25% or more drop in heart rate, iv atropine will be administered. A NIRS probe (infant,saturation sensor, Invos , Tullamore, Ireland) and pulse will be attached to the newborn by another anesthetist and the measurements will be recorded. Blood pressure will be taken from the umbilical vein. The newborn's APGAR(activity,pulse,grimace,appearance,respiration), heart rate, SpO2 and umbilical venous saturation values will be recorded. NIRS and spO2 values will be checked intermittently.
88848216|NCT06316583|Experimental|dry-needling trigger points treatment (TrP-DN)|Firstly, use pressure techniques to diagnose trigger points on the rectus abdominis and oblique muscles, which typically present as distinct tender points and palpable muscle tension bands. Deep pressure on these points may induce referred pain. Procedure: Begin by disinfecting the treatment sites. Use a traditional acupuncture needle (0.35×50mm) to repeatedly stimulate the designated point until muscle soreness and localized twitching are felt. If participants experience lower back pain, trigger points on the back can also be targeted, located bilaterally from the twelfth thoracic vertebra to the third lumbar vertebra
88848217|NCT06316583|Experimental|acupuncture group|Acupuncturists use acupuncture point needling for treating PD, focusing primarily on key acupoints from the Foot Taiyin Spleen Meridian, Conception Vessel, Foot Taiyang Bladder Meridian, Foot Yangming Stomach Meridian, and Foot Shaoyin Kidney Meridian. Commonly selected points include Taichong, Xuehai, Zusanli, Yanglingquan, Guanyuan, Uterus, and Sanyinjiao. After routine disinfection, a #32 fine needle is quickly inserted and retained for 30 minutes per session
88848218|NCT06316583|Sham Comparator|placebo control group|Subjects undergo the same diagnostic and therapeutic procedures as the TrP-DN group but using a 'sham' needling technique. The sham needling is administered by the same expert as the real needling, with retention time and treatment frequency matching those of the genuine needling group. A retractable sham needle apparatus is used without piercing the skin.
88848219|NCT06316557|Experimental|rTMS group|5Hz rTMS in lesion contralateral cerebellar hemisphere
88848220|NCT06316557|Placebo Comparator|control group|shame rTMS in lesion contralateral cerebellar hemisphere
88848221|NCT06316479|Experimental|Treatment group|All participants will receive PTMC Dermal Filler.
88848222|NCT06316466||the high Lp (a) groups and the low Lp (a) groups|The cut-off value for Lp (a) was determined based on one-year survival rates after diagnosis. Patients were then categorized into the high and low Lp (a) groups.
88848223|NCT06316466||the low Lp (a) groups|The cut-off value for Lp (a) was determined based on one-year survival rates after diagnosis. Patients were then categorized into the high and low Lp (a) groups.
88848226|NCT06316414||Severe asthmatics with history of food anaphylaxis|Omalizumab will be administered i.m. with doses ranging from 150 mg every 28 days to 600 mg every 14 days, according to EMA dosing range table.
88848227|NCT06316401||Patients underwent endoscopic submucosal dissection under spinal anesthesia|"We collected data on all consecutive patients who underwent ESD for recto-sigmoid laterally spreading tumors (LSTs) >35 mm under SA.~SA was carried out in a sitting position, following a strictly aseptic technique. After recognition of L2-L3 intervertebral space through landmark technique, a 25 Gauge needle was inserted and the correct positioning was confirmed by detecting free flow of cerebrospinal fluid. Subsequently, 10-12 mg of hyperbaric bupivacaine + sufentanil 2 mcg according to the decision of the anesthetist was administered intrathecally without barbotage.~Subsequently, the patient underwent ESD of the colorectal lesion."
88848228|NCT06316362|Other|control group|The first group constitutes the control group that was administered the standard treatment protocol for carbamazepine toxicity.
88848229|NCT06316362|Active Comparator|SMOF lipid treated group|The second group received the SMOF lipid infusion in addition to the standard protocol.
88848230|NCT06316336|Experimental|Generic Alfuzosin Hydrochloride 10 mg|Generic Alfuzosin Hydrochloride 10 mg (test drug)
88848231|NCT06316336|Active Comparator|Xatral® XL 10 mg|Xatral® XL 10 mg (Alfuzosin Hydrochloride 10 mg (reference drug))
88848232|NCT06316323|Experimental|Group A|Silver Diamine Fluoride
88848233|NCT06316323|Experimental|Group B|Sodium Fluoride Varnish
88848237|NCT06316284||Chronic kidney disease group|Patients with stage 3-5 CKD (eGFR CKD-EPI <60 mL/min/1.73 m2)
88848238|NCT06316284||Healthy controls|Healthy normotensive patients (eGFR CKD-EPI >90 mL/min/1.73 m2, BP <140/90 mmHg)
88848239|NCT06316284||Hypertensive Group|Hypertensive patients without CKD (eGFR CKD-EPI >90 mL/min/1.73 m2, BP >140/90 mmHg)
88848240|NCT06316271||Normotensive Group|BP less than or equal to 129/84 mmHg
88848241|NCT06316271||Prehypertensive Group|BP 130-139/85-89 mmHg
88848242|NCT06316271||Hypertensive Group|BP 140-150/90-100 mmHg
88848243|NCT06316258|Experimental|Compassion focused therapy group|6 week compassion focused therapy group for adults with ABI
88848244|NCT06316232|Active Comparator|STIM ON plus/MED ON plus|"Patients were evaluated in two following morning sessions under different treatment conditions:~STIM ON plus (intervention 1)~MED ON plus (intervention 2)"
88848245|NCT06316232|Active Comparator|MED ON plus/STIM ON plus|"Patients were evaluated in two following morning sessions under different treatment conditions:~MED ON plus (intervention 2)~STIM ON plus (intervention 1)"
89375863|NCT05432466|Experimental|ACER-002 (celiprolol) 200 mg BID|"ACER-002 200 mg twice daily (BID) (after titration):~200 mg morning and 200 mg evening: 400 mg total daily dose~Titration:~Day 1 to Month 1 - 100 mg once daily (QD) evening: 100 mg total daily dose Month 2 to Month 3 - 100 mg morning and 100 mg evening: 200 mg total daily dose Month 3 to Month 4 - 100 mg morning and 200 mg evening: 300 mg total daily dose Month 4 to End of Treatment Period (BID) - 200 mg morning and 200 mg evening: 400 mg total daily dose"
89375864|NCT05432466|Experimental|Placebo BID|Placebo twice daily (BID) Placebo given orally to mimic ACER-002 (celiprolol) administration
89375865|NCT05403749|Experimental|IBI302 dose 2 group|Drug: Aflibercept 8mg/eye;Intraocular injection
89375866|NCT05403749|Active Comparator|Aflibercept|Drug: Aflibercept 2mg/eye;Intraocular injection
89375867|NCT05403749|Experimental|IBI302 dose 1 group|Drug: Aflibercept 6.4mg/eye;Intraocular injection
89375868|NCT05400122|Experimental|Experimental Infusion|"Preparative Regimen Administration:~Fludarabine will be given at a dose of 30mg/m2 intravenously daily~Cyclophosphamide will be given at a dose of 500mg/m2 intravenously daily~Investigational Agent Administration:~NK Cell Product will be given per institutional standard of care (at a rate no faster than 250mL per hour or 3-4 ml per minute) as two doses by intravenous infusion on Days 0 (+2 days acceptable) and 14 (+/- 3 days acceptable)~IL-2 will be administered at a flat dose of 2.2 million IU subcutaneously starting on the same day as the first NK cell infusion and will be administered three times weekly (dose level 1) or twice weekly (dose level -1) for up to four weeks total~Vactosertib will be administered at a dose of 200mg twice daily for 5 consecutive days per week, for up to four weeks total."
88848252|NCT06316141|Experimental|Experimental Group A|Aqua Jogging Group
88848253|NCT06316141|Experimental|Experimental Group B|Land based Jogging Group
88848254|NCT06316115|No Intervention|Wound debridement of patients with diabetic foot ulcers|No Intervention: The patient's pain and anxiety will be evaluated by a nurse independent of the research before and during the debridement procedure, without any intervention to the patients
88848255|NCT06316115|Experimental|Patients with diabetic foot ulcers using stress balls during wound debridement|Intervention Group: Patients in this group participating in the study will be given a stress ball and asked to use it before the debridement procedure, and each patient will be debrided by the same person throughout the procedure. The patient's pain and anxiety will be evaluated by a nurse independent of the research before and after the debridement procedure.
88848256|NCT06316089|Experimental|PrEPared For Release|Intervention arm
88848257|NCT06316089|No Intervention|Standard of Care|Control arm
88848258|NCT06316076|Experimental|CD19-CAR-DNT cells|8-24 patients are planned to be enrolled in the dose-escalation trial and 12-24 patients in the dose-expansion trial.
88848259|NCT06316063|Experimental|Apnoeic oxygenation with High-flow nasal oxygen|In the apnoeic oxygenation group the HFNO is used for pre-oxygenation,100 % O2, 40 L/min during 3 min. Thereafter, anaesthesia is induced by intravenous Propofol and Remifentanil. Rocuronium for full neuromuscular blockade is administered and a jaw thrust is used to keep an open airway. The airway will be kept patent throughout the procedure using a suspension laryngoscope, placed by the ENT surgeon. During apnoea oxygen will be increased to 70 L/min, 100% O2. Apnoea will be discontinued if any of the criteria SpO2 < 90%, PaCO2 >11 kPa, pH <7.15 or arrhythmias with haemodynamic effects occur.
89181779|NCT04076085|Active Comparator|Lower extremity exercise|Specially designed Lower extremity exercises will be done for the population with a rating of somewhat hard 13-14 (Original scale) will be used as a guideline for intensity
88848260|NCT06316063|Active Comparator|Mechanical ventilation|In the mechanical ventilation group pre-oxygenation is performed by a tight-fitting facemask, 100 % O2, for three minutes. After anaesthesia induction and full neuromuscular blockade, tracheal intubation is performed and mechanical ventilation is started.
88848261|NCT06316050|Active Comparator|humeral retroversion 0º|will be carried out with patients operated with reverse shoulder arthroplasty (at 0º and 30º of humeral retroversion) included consecutively in Terrassa Hospital
88848262|NCT06316050|No Intervention|humeral retroversion 30º|will be carried out with patients operated with reverse shoulder arthroplasty (at 0º and 30º of humeral retroversion) included consecutively in Terrassa Hospital
88848263|NCT06316024|No Intervention|Nothing Per Os group|The participants do not drink anything approximately 6-8 hours after surgery.
88848264|NCT06316024|Experimental|water group|The participants drink 240 ml water approximately 6-8 hours after surgery.
88848265|NCT06316024|Experimental|juice/sport drink group|The participants drink 240 ml juice/sport drink approximately 6-8 hours after surgery.
88848266|NCT06316024|Experimental|chewing gum group|The participants start chewing gum approximately 6-8 hours after surgery.
88848267|NCT06316011||Training and testing cohort|
88848268|NCT06316011||External validation cohort|
88848269|NCT06315998||Training and testing cohort|
88848270|NCT06315998||External validation cohort|
88848271|NCT06315946|Experimental|Pixie® skin tag|A skin tag is selected and treated with the test device Pixie® skin tag according to the instructions for use.
88848272|NCT06315946|Active Comparator|Wortie® skin tag remover|A skin tag is selected and treated with the comparator Wortie® skin tag remover.
88848273|NCT06315933||Unexposed|Children unexposed to general anesthesia before school age (<=6y)
89375869|NCT05398250|Active Comparator|Safety Planning Intervention Tailored for Autistic Individuals|The Safety Planning Intervention Tailored for Autistic individuals (SPI-A) is a brief collaborative intervention that results in an individually tailored plan designed to lower the short-term risk of suicide in autistic youth.
88848274|NCT06315933||Singly exposed|Children singly exposed to general anesthesia before school age (<=6y)
88848275|NCT06315933||Multiply exposed|Children multiply exposed to general anesthesia before school age (<=6y)
88848276|NCT06315920|Experimental|Parecoxib|40mg of IV Parecoxib
88848277|NCT06315920|Active Comparator|Morphine|5 mg of IV Morphine
88848278|NCT06315894|Experimental|Experimental|People with post-COVID syndrome following the intervention
88848279|NCT06315894|No Intervention|Control|People with post-COVID syndrome not following the intervention
88848280|NCT06315881|Experimental|PHASE I ARM I (low FBN R/S ONP)|Participants insert low free-base nicotine (FBN) R/S ONP product over 30 minutes and insert usual brand of ST over 30 minutes or smoke usual brand of cigarette over 5 minutes during each study visit for 5 visits over up to 3 months. Patients also undergo blood sample collection throughout study.
88848281|NCT06315881|Experimental|PHASE I ARM II (low FBN > 99% S ONP)|Participants insert low FBN > 99% S ONP product over 30 minutes and insert usual brand of ST over 30 minutes or smoke usual brand of cigarette over 5 minutes during each study visit for 5 visits over up to 3 months. Patients also undergo blood sample collection throughout study.
88848282|NCT06315881|Experimental|PHASE I ARM III (high FBN R/S ONP)|Participants insert high R/S ONP product over 30 minutes and insert usual brand of ST over 30 minutes or smoke usual brand of cigarette over 5 minutes during each study visit for 5 visits over up to 3 months. Patients also undergo blood sample collection throughout study.
88848283|NCT06315881|Experimental|PHASE I ARM IV (high FBN > 99% ONP)|Participants insert high FBN > 99% S ONP product over 30 minutes and insert usual brand of ST over 30 minutes or smoke usual brand of cigarette over 5 minutes during each study visit for 5 visits over up to 3 months. Patients also undergo blood sample collection throughout study.
88848284|NCT06315881|Experimental|PHASE I ARM V (Usual brand ST or cigarette)|Participants insert usual brand of ST over 30 minutes or smoke usual brand of cigarette over 5 minutes. Patients also undergo blood sample collection at 0, 5, 15, 30, 60, and 90 minutes.
89181780|NCT04076085|No Intervention|Control|Here no active intervention will be given only standard care as prescribed by the hospital will be given
89535042|NCT05015673|Experimental|SEP-363856 50mg|SEP-363856 50mg given orally
89181781|NCT02581059|Experimental|Regorafenib + Ginseng|Regorafenib will be administered 160 mg once daily for the first 21 days of each 28-day cycle. Subjects will receive 1,000 mg ginseng orally twice daily every day for 4 weeks (2 cycles).
89181782|NCT02581059|Active Comparator|Regorafenib Only|Regorafenib will be administered 160 mg once daily for the first 21 days of each 28-day cycle for 2 cycles.
89181783|NCT05247957|Experimental|NKG2DL-specific CAR-NK cells|Experimental: NKG2DL-specific CAR-NK cells, 2 infusions on Day 0 and Day 7 After preconditioning with chemotherapy, NKG2DL-specific CAR-NK cells will be evaluated
89181784|NCT02581605||Osteotomy Arm|Patients due to undergo an osteotomy around the knee. To improve the accuracy of this operation we propose the use of a custom-made 'cutting block' tailored for each individual patient.
89181785|NCT02581605||Partial Knee Replacement Arm|Patients due to undergo a partial knee replacement. To improve the accuracy of this operation we propose the use of a custom-made 'cutting block' tailored for each individual patient.
89181786|NCT00796445|Experimental|MAGE-A3 Group|Patients who received up to 13 doses of recMAGE-A3 + AS15 ASCI. Study products were administered as intramuscular (IM) injections in the deltoid or the lateral region of the thigh (not in anatomical regions where lymph nodes had been excised): 5 doses of ASCI product at 3-week intervals, followed by 8 doses of ASCI product at 12-week intervals.
89181787|NCT00796445|Placebo Comparator|Placebo Group|Patients who received up to 13 doses of placebo. Study products were administered as intramuscular (IM) injections in the deltoid or the lateral region of the thigh (not in anatomical regions where lymph nodes had been excised): 5 doses of placebo at 3-week intervals, followed by 8 doses of placebo at 12-week intervals.
89181788|NCT04075773|Experimental|Religious Prompt|Participants will be provided a writing prompt that describes their self-reported drinking, then asks them to write for 5 to 10 minutes about how that drinking is associated with their self-reported religious identity. After completing that writing assignment, participants will be shown their response, and asked to spend 5 to 10 minutes describing how their drinking behaviors in the next month might change.
89181789|NCT04075773|Sham Comparator|Age Prompt|Participants will be provided a writing prompt that describes their self-reported drinking, then asks them to write for 5 to 10 minutes about how that drinking is associated with their self-reported age. After completing that writing assignment, participants will be shown their response, and asked to spend 5 to 10 minutes describing how their drinking behaviors in the next month might change.
89181790|NCT04075851||Hashimoto or Grave's disease patients in treatment|Draw 10 ml venous blood
88810418|NCT06213506|Active Comparator|Infants_9M_Control B Group|Infants 9 months of age, part of the safety cohort, randomized to receive 2 doses of the MenACWY vaccine at Day 1 and Day 85 and 1 dose of the DTPaHBV-IPV+Hib vaccine at Day 169. These infants also receive an EPI vaccination with Measles and Rubella Vaccine (MR-VAC) and Yellow Fever (YF) vaccine at 28 days after the first study intervention administration occurring at Day 1, at the local EPI vaccination centers, and not part of the current clinical trial.
89181791|NCT04075851||Hashimoto or Grave's disease patients on initial treatment|10 ml of venous blood was extracted every month for three months
89181792|NCT04075851||Pregnant woman with Hashimoto or Grave's disease|10 ml venous blood was extracted every month to postpartum for 6 months
89181793|NCT04075851||Healthy crowd|Draw 10 ml venous blood
89181794|NCT04108871|Experimental|Transperineal Prostate Biopsy|The biopsy needed is inserted to the prostate through the perineal skin, with the assistance of an access system device known as PrecisionPoint. It utilises a single access needle cannula mounted directly on to the ultrasound probe, which acts as an access point traversing through the perineal skin. 4 - 5 cores are obtained from the anterior, mid and posterior zone of each side of the prostate.
89181795|NCT04108871|Active Comparator|Transrectal Prostate Biopsy|The biopsy needle penetrates through the bowel (rectum) to the prostate to obtain 12 cores of prostate tissues from the lateral and medial base, midzone and apex of each side of the prostate (1 core each).
89181796|NCT02580513|No Intervention|Control|3 days with normal circadian alignment.
89181797|NCT02580513|Experimental|Circadian Misalignment|3.5 days in which the subjects will undergo a maximal circadian misalignment of 12 hours by means of a midday nap during the second day, and a subsequent start of a new normal wake period, shifted 12 hours.
89375870|NCT05398250|Active Comparator|Safety Planning Intervention Tailored for Autistic Individuals Plus Structured Follow-Up Contacts|The Safety Planning Intervention Tailored for Autistic individuals plus structured follow-up contacts (SPI-A+) is a multi-component intervention comprised of SPI-A and structured follow-up consisting of at least 2 brief contacts.
89535043|NCT05015673|Placebo Comparator|Placebo|Placebo given orally
88848285|NCT06315881|Experimental|PHASE II ARM I (low FBN R/S ONP)|"WASHOUT PERIOD: Participants use usual brand of ST or cigarettes for 1 week.~CONTROL WEEK: Participants continue regular use of ST or cigarettes for 1 week and receive a text with a link to daily diary surveys to record tobacco use.~Participants insert low FBN R/S ONP for 4 weeks. Participants also attend 2 study visits and undergo oral mucosa sample collection."
88848286|NCT06315881|Experimental|PHASE II ARM II (low FBN > 99% S ONP)|"WASHOUT PERIOD: Participants use usual brand of ST or cigarettes for 1 week.~CONTROL WEEK: Participants continue regular use of ST or cigarettes for 1 week and receive a text with a link to daily diary surveys to record tobacco use.~Participants insert to low FBN > 99% S ONP product for 4 weeks. Participants also attend 2 study visits and undergo oral mucosa sample collection."
88848287|NCT06315881|Experimental|PHASE II ARM III (high R/S ONP)|"WASHOUT PERIOD: Participants use usual brand of ST or cigarettes for 1 week.~CONTROL WEEK: Participants continue regular use of ST or cigarettes for 1 week and receive a text with a link to daily diary surveys to record tobacco use.~Participants insert to high R/S ONP product for 4 weeks. Participants also attend 2 study visits and undergo oral mucosa sample collection."
88848288|NCT06315881|Experimental|PHASE II ARM IV (high FBN > 99% ONP)|"WASHOUT PERIOD: Participants use usual brand of ST or cigarettes for 1 week.~CONTROL WEEK: Participants continue regular use of ST or cigarettes for 1 week and receive a text with a link to daily diary surveys to record tobacco use.~Participants insert high FBN > 99% S ONP product for 4 weeks. Participants also attend 2 study visits and undergo oral mucosa sample collection."
88848289|NCT06315855|Experimental|Telehealth Intervention (THI) arm|"The THI is a 6-month intervention. Participants randomized to THI arm will engage in 6,1-hour virtual sessions with trained study personnel. Modules contain a 1) participant check-in, 2) content designed to build oral health literacy and self-efficacy, 3) and goal-setting.~Coaches will use a facilitation guide, layered with motivational interviewing to conduct telehealth sessions. Participants will also receive biweekly text messages aligned with module content. Post-intervention follow-up will occur at 6- and 12-month post-randomization."
88848290|NCT06315855|No Intervention|Usual Care (UC) arm|This group will receive biweekly text messages on general health behaviors as a retention strategy. This arm will receive no other outside interventions. The Dental Resource directory will be provided to all participants.
88848291|NCT06315842|Experimental|Levels of Diagnostic and Therapeutic Intervention tool|Medical doctors assigned to this group will incorporate a Levels of Diagnostic and Therapeutic Intervention tool into their clinical practice
88848292|NCT06315842|Active Comparator|Usual clinical practice|Medical doctors assigned to this group will continue their clinical practice as usual
88848293|NCT06315829||Confirmed Epileptic Spasms (Positive Class)|Participants diagnosed with infantile spasms based upon historical data and supportive electroencephalography data (i.e. hypsarrhythmia or modified hypsarrhythmia background).
88848294|NCT06315829||Epileptic Spasm Mimics (Negative Class)|Participants diagnosed with non-epileptic movements (e.g. Sandifer syndrome, shuddering attacks, stretching, stereotypy, startle reflex, writhing movements, jitteriness, sleep myoclonus) based upon historical data and supportive electroencephalography data (when available).
88848295|NCT06315829||Awake and Alert (Negative Class)|Participants exhibiting spontaneous, subtle movements in the awake and alert state.
88848296|NCT06315816|Experimental|Experimantal|The children will ask to choose a three-dimensional cartoon from the list to watch during the procedure, it will run, the mobile phone will placed into the virtual reality glasses, and the children wear the VR glasses and start watching the cartoon. During the procedure, the children's parents and the researcher will present, and the children watch the cartoon through virtual reality glasses. After the procedure, the virtual reality glasses will removed, and ten minutes after the procedure will completed, the CFS and the CAS-S will apply as a post-test.
88848297|NCT06315816|No Intervention|Control|No intervention
88848298|NCT06315803|Experimental|Xplane ultrasound group|The lumbar interforamen puncture was performed under the guidance of Xplane ultrasound with a X6-1 volume transducer probe (frequency range 1-6MHz, center frequency 3.2MHz).
88848299|NCT06315803|No Intervention|radiography group|The lumbar interforamen puncture was performed under the guidance of radiography with Mobile X-ray Image System (Arcadis Orbic 3D, Siemens, Germany) .
88848300|NCT06315790|Placebo Comparator|Isotonic saline|
88848301|NCT06315790|Active Comparator|Botulinum toxin A|
88848302|NCT06315777|Experimental|normal cumulus cell oocytes complex|women with normal ovarian reserve will be utilized and analyse the cumulus cell as a baseline
88848303|NCT06315764|Experimental|Aerobic training|Each patient in this study did 20 minutes of peddler aerobic training, with the first 5 minutes serving as a warm-up with intensity set at 60 - 65 percent of maximal heart rate, followed by another 10 minutes of peddler training with intensity gradually increased up to 70 - 75 percent, and the last 5 minutes serving as a cooling down with intensity set at 60 - 65 percent of maximal heart rate. After the warm-up and at the end of each training phase, the participants' heart rates were monitored. Finally, if the individual experienced pain, fainting, or shortness of breath, the training was promptly terminated
88848304|NCT06315764|Experimental|Reflexology|"This group consisted of twenty female patients suffering from hypertension who received the same drugs as group (A) as well as reflexology three times per week for eight weeks .~Following four weeks of treatment (post-1) and additional four weeks of treatment (post-2) the post evaluation was used (post-2).Before and after the foot reflexology, blood pressure was checked twice. Around 20 minutes is spent on foot reflexology ."
88848305|NCT06315751|Experimental|Gemlapodect|Escalating doses of NOE-105 capsules
88848306|NCT06315751|Placebo Comparator|Placebo|Escalating doses of matching placebo
88848307|NCT06315738|Other|Cohort 1 - lower dose active + SOC treatment vs. SOC alone in higher weight range|Infants with birth weight ≥1000 g and ≤3000 g; 0.5 mL/kg of ST266, QD, + Standard of Care (SOC) treatment (n=6); SOC (n=3)
88848308|NCT06315738|Other|Cohort 2 - higher dose active + SOC treatment vs. SOC alone in higher weight range|Infants with birth weight ≥1000 g and ≤3000 g; 1.0 mL/kg of ST266, QD; + Standard of Care (SOC) treatment (n=6); SOC (n=3)
88848309|NCT06315738|Other|Cohort 3 - lower dose active + SOC treatment vs. SOC alone in lower weight range|Infants with birth weight ≥800 g and ≤999 g; 0.5 mL/kg of ST266, QD; + Standard of Care (SOC) treatment (n=6); SOC (n=3)
88848310|NCT06315738|Other|Cohort 4 - higher dose active + SOC treatment vs. SOC alone in lower weight range|Infants with birth weight ≥800 g and ≤999 g; 1.0 mL/kg of ST266, QD; + Standard of Care (SOC) treatment (n=6); SOC (n=3)
88848311|NCT06315712|Experimental|Respiratory muscle training group|Received inspiratory muscle training plus pulmonary rehabilitation program. Powerbreathe device was used for the exercise of the inspiratory muscle strength. Strengthening the inspiratory muscles with the Powerbreathe is similar to weightlifting to strengthen other muscles in the body.
89181798|NCT03939819|Experimental|ViSiGi® 3D suction calibration device|"The ViSiGi® 3D is the first calibration system specifically intended for use during sleeve gastrectomy.ViSiGi 3D®is a non-sterile, single patient use device. The device comprises a tube with a closed, rounded tip, and holes at the distal end. The proximal end of ViSiGi 3D® includes an integral suction regulator and vented On/Off valve.~Advantages of ViSiGi® 3D device include simplification of sleeve calibration in addition to suctioning the stomach and performing leak tests all with one device making operative steps simpler for both the anesthesiology team and surgeons. Since it is single patient use it does not require reprocessing."
89181799|NCT03939819|Active Comparator|Esophagogastroduodenoscopy (EGD) calibration|Gastroscope, similar to The ViSiGi device, have suction, calibration, and leak testing capabilities.
89181800|NCT04219449||study group|Diagnosed beta-thalassemia patients at Assiut University Hospital.
89181801|NCT04209855|Experimental|mirvetuximab soravtansine (MIRV; IMGN853)|MIRV 6 mg/kg adjusted ideal body weight (AIBW) every 3 weeks (Q3W)
89181802|NCT04209855|Active Comparator|Investigator's choice of chemotherapy|"Paclitaxel (Pac; 80 mg/m2) administered once per week (QW) within a 4-week cycle~Pegylated liposomal doxorubicin (PLD; 40 mg/m2) administered every 4 weeks (Q4W)~Topotecan (Topo; 4 mg/m2) administered either on Days 1, 8, and 15 every 4 weeks or for 5 consecutive days (1.25 mg/m2 Days 1-5) every 3 weeks (Q3W)"
89181803|NCT04075929|Other|4x8 min|4x8-min intervals with 2-min recovery periods. The same accumulated duration of these three interval groups means that the total interval time is the same for each group: 4x8-min = 32 min
89181804|NCT04075929|Other|4x(8x40/20s)|4x(12x40/20-sec) intervals with 2-min recovery periods The same accumulated duration of these three interval groups means that the total interval time is the same for each group:4x(12x40/20-sec) = 32 min if the 20-sec recovery is not included in the total time of HIT
89181805|NCT04075929|Other|4x(12x40/20s)|4x(8x40/20-sec) intervals with 2-min recovery periods The same accumulated duration of these three interval groups means that the total interval time is the same for each group: 4x(8x40/20-sec) = 32 min if the 20-sec recovery is included in the total time of HIT
89181806|NCT00756938|Experimental|Losartan potassium 0.1 to 1.4 mg/kg|Open-label losartan at starting dose of 0.1 mg/kg/day with uptitration at Weeks 3, 6, or 9 to the next highest dose level if blood pressure goal not achieved
89181807|NCT00756938|Experimental|Losartan potassium 0.3 to 1.4 mg/kg|Open-label losartan at starting dose of 0.3 mg/kg/day with uptitration at Weeks 3, 6, or 9 to the next highest dose level if blood pressure goal not achieved
89181808|NCT00756938|Experimental|Losartan potassium 0.7 to 1.4 mg/kg|Open-label losartan at starting dose of 0.7 mg/kg/day with uptitration at Weeks 3, 6, or 9 to the next highest dose level if blood pressure goal not achieved
89181809|NCT04076865|Experimental|EMLA|
89181810|NCT00796367|Placebo Comparator|Placebo|Placebo
89181811|NCT00796367|Experimental|VI-0521 Mid|7.5 mg phentermine and 46 mg topiramate
89181812|NCT00796367|Experimental|VI-0521 Top|15 mg phentermine and 92 mg topiramate
89535044|NCT05015361|Experimental|Treatment group A/B|Treatment group A: Remimazolam Tosilate Treatment group B: Remimazolam Tosilate
88848312|NCT06315712|Experimental|Pulmonary rehabilitation group|Received pulmonary rehabilitation program for five sessions per week for 8 weeks. Four resistive exercises, aerobic exercise, and deep breathing exercises, aerobic conditioning exercises on the treadmill. All exercises were performed using variable resistance machines.
88848313|NCT06315699|Experimental|Clemastine|Clemastine，tablet，0.15mg/kg/d，two months
88848314|NCT06315699|Placebo Comparator|fructose|
89375871|NCT05395104|Experimental|Cefiderocol Plus Midazolam|A total of 2 doses of midazolam and 45 doses of cefiderocol was administered to each participant per specified dosing schedule.
89375872|NCT05389462|Experimental|Part 1: Dose Escalation, ADCT-601 Combination Therapy|In Part 1 (dose escalation), participants with selected sarcoma indications will receive escalating doses of ADCT-601 in combination with gemcitabine.
89375873|NCT05389462|Experimental|Part 1: Dose Escalation, ADCT-601 Monotherapy|In Part 1 (dose escalation), participants with sarcoma indications (regardless of AXL gene amplification status), non-small-cell lung cancer (NSCLC) (regardless of AXL gene amplification status), and solid tumors with AXL gene amplification, will receive ADCT-601 monotherapy.
89375874|NCT05389462|Experimental|Part 2: Dose Expansion, ADCT-601 Combination Therapy|"In Part 2 (dose expansion), participants with selected sarcoma indications will receive ADCT-601 in combination with gemcitabine.~Participants will be split into 2 groups:~Group 1: Participants without gemcitabine in prior lines of therapy~Group 2: Participants with gemcitabine containing regimen in prior lines of therapy"
89375875|NCT05389462|Experimental|Part 2: Dose Expansion, ADCT-601 Monotherapy|In Part 2 (dose expansion), participants with a selected indication will receive ADCT-601 monotherapy.
89375876|NCT05380713|Experimental|Radiation+Drug (Arm A)|sub-ablative radiation plus low dose cyclophosphamide followed by surgery and adjuvant immunotherapy
89375877|NCT05380713|Experimental|Radiation alone (Arm B)|sub-ablative radiation alone followed by surgery and adjuvant immunotherapy
89375878|NCT05365776|Experimental|Arm 1: Graded Exposure Therapy|
89375879|NCT05365776|Active Comparator|Arm 2: Prescribed Aerobic Exercise|
89375880|NCT05365776|Active Comparator|Arm 3: Enhanced usual care|
89375881|NCT05359445|Experimental|Dose-Finding Escalation/De-escalation (Phase Ia) and Extension Part (Phase Ib)|"Dose-Finding Escalation/De-escalation of IMA401 (Phase Ia)~IMA401 monotherapy extension cohort following the determination of the recommended dose for extension (RDE) (Phase Ib)"
89375882|NCT05351788|Experimental|SKB264+KL-A167|Participants received SKB264 followed by KL-A167
89375883|NCT05351788|Experimental|SKB264+KL-A167+ Carboplatin or Cisplatin (EGFR wide type)|Participants received SKB264 followed by KL-A167 with Carboplatin or Cisplatin
89375884|NCT05351788|Experimental|SKB264+KL-A167+ Carboplatin or Cisplatin (EGFR mutation)|Participants received SKB264 followed by KL-A167 with Carboplatin or Cisplatin
89002392|NCT06318286|Experimental|Lenvatinib, Pemetrexed, Cisplatin/Carboplatin, and Pembrolizumab|In induction treatment, study interventions include oral lenvatinib, 8 mg quaque die (QD), and pembrolizumab, 200 mg, carboplatin (AUC 5 mg/mL/min) or cisplatin (75 mg/m2), and pemetrexed, 500 mg/m2 all given by intravenous (IV) infusion on Day 1 of a 21-day cycle. Lenvatinib, pembrolizumab, carboplatin/cisplatin, and pemetrexed combination treatment will be given for 4-6 cycles, after which participants may receive maintenance treatment with Lenvatinib, 20 mg QD, and pembrolizumab, 200 mg. Lenvatinib and Pembrolizumab may be given for up to a total of 35 cycles.
89002393|NCT06318273|Experimental|Part 1: ABBV-969 Dose Escalation|Participants will receive escalating doses of ABBV-969.
89002394|NCT06318273|Experimental|Part 2 A: ABBV-969 Dose Expansion|Participants will receive dose A of ABBV-969 from part 1.
89002395|NCT06318273|Experimental|Part 2 B: ABBV-969 Dose Expansion|Participants will receive dose B of ABBV-969 from part 1.
89002396|NCT06318260|Experimental|ATTRwt|Dobutamine (Dobutrex®) infusion.
89002397|NCT06318247|Sham Comparator|Control group|Tooth extraction of third molars
89375885|NCT05350319||Patients planning for total or reverse shoulder arthroplasty|Adult patients who are planning to undergo a total or reverse shoulder arthroplasty
89375886|NCT05350319||Retrospective group of patients who have already undergone preoperative planning|Retrospective cohort of patients who have undergone preoperative planning with a conventional shoulder CT for total or reverse shoulder arthroplasty.
89375887|NCT05350254|Experimental|Stratified Maintenance Care|"All participating patients will receive pragmatic chiropractic care for the initial 3 weeks (6 visits) and home exercise recommendations.~Participants in the Stratified Maintenance Care group will be classified based on the MAINTAIN instrument into: not a candidate, good candidate, and very good candidate for maintenance care:~Participants showing a good response to the initial care and classified as not a candidate or a good candidate for maintenance care will be given home exercise recommendations. Return for further manual treatment will be recommended if they have a relapse or exacerbation of symptoms (symptom-guided care).~Participants classified as having a good response to the initial care and very good candidates for maintenance care, will have visits with tapering manual treatments and home exercise recommendations. They will then be recommended maintenance care with pre-planned visits at 4-12 week intervals (aiming at increasing the interval as soon as possible)."
89375888|NCT05350254|Active Comparator|Standard Chiropractic Care|"All participating patients will receive pragmatic chiropractic care for the initial 3 weeks (6 visits) and home exercise recommendations.~In the Standard chiropractic care group, participating patients will receive a standard (pragmatic) chiropractic care in which treatment will be provided based on the clinician's judgement and home exercise recommendations. This may or may not include maintenance care depending on the clinicians' standard operating procedures. All treatments provided will be recorded. Return for further treatment will be recommended if they have a relapse or exacerbation of symptoms (symptom-based)."
89375889|NCT05327491|Experimental|Treatment Sequence ABC|"Participants will be administered sotorasib orally in the following order:~Period 1 - as 1 tablet (test 1) Period 2 - as 2 tablets (reference) Period 3 - as 1 tablet (test 2)"
89375890|NCT05327491|Experimental|Treatment Sequence BAC|"Participants will be administered sotorasib orally in the following order:~Period 1 - as 2 tablets (reference) Period 2 - as 1 tablet (test 1) Period 3 - as 1 tablet (test 2)"
89375891|NCT05322239|Experimental|Intermittent Theta Burst Stimulation|TBS. A Magventure MagPro 100X stimulator with a B65 figure-8 coil will be used for the TBS sessions. On each of the 3 stimulation days, 5 iTBS sessions will be administered at 30 min intervals.
89002398|NCT06318247|Experimental|GBR group|Tooth extraction of third molars with site preservation using bio-oss (0.5g, Small granule) and bio-guide (25*25mm size). The bone graft material used in the surgical procedure was provided by Geistlich Pharma AG.
89375892|NCT05322239|Experimental|Continuous Theta Burst Stimulation|TBS. A Magventure MagPro 100X stimulator with a B65 figure-8 coil will be used for the TBS sessions. On each of the 3 stimulation days, 5 cTBS sessions will be administered at 30 min intervals.
89375893|NCT05321199|Experimental|Control patients|Closed Envelope for group A (control); patients receiving no tranexamic acid. With Double-Blind Study in which the participants and observers are unaware of who receives tranexamic acid. The total blood loss (TBL), intraoperative blood loss (IBL), postoperative blood loss (PBL), hemoglobin (HGB) levels and Hematocrit value (Hct) on preoperatively (pre-op) and postoperatively, and amount of allogenic blood transfusion were recorded. Furthermore, the general information was also compared between groups.
89375894|NCT05321199|Experimental|Case patients|Closed Envelope for group B (case); patients receiving tranexamic acid intravenously and topically. With Double-Blind Study in which the participants and observers are unaware of who receives tranexamic acid. The total blood loss (TBL), intraoperative blood loss (IBL), postoperative blood loss (PBL), hemoglobin (HGB) levels and Hematocrit value (Hct) on preoperatively (pre-op) and postoperatively, and amount of allogenic blood transfusion were recorded. Furthermore, the general information was also compared between groups.
89375895|NCT05320029|Experimental|Disposable Powered Articulating Endoscopic Linear Cutter Stapler|Disposable Powered Articulating Endoscopic Linear Cutter Stapler
89375896|NCT05320029|Active Comparator|ECHELON Flex Powered Articulating Endoscopic Linear Cutters|ECHELON Flex Powered Articulating Endoscopic Linear Cutters
89375897|NCT05307263|Active Comparator|Atherectomy plus DCB|
89375898|NCT05307263|Active Comparator|DCB|
89375899|NCT05301920|Experimental|Experimental Group|N=20 60Hz pulse electrical stimulation The clinical trial device performs a personal electrical stimulation around the trigeminal nerves for 4weeks (6 times/week), 20 minutes each time.
89375900|NCT05300282|Experimental|phase I|patients will receive the BEGEV regimen plus Atezolizumab in order to determine MTD of the last one drug.
89375901|NCT05300282|Active Comparator|phase IIb - arm A|patients will receive the BEGEV regimen followed by ASCT for patients achieving CR.
89375902|NCT05300282|Experimental|phase IIb - arm B|patients will receive combination treatment with Atezolizumab (at dose obtained from phase I) and BEGEV regimen followed for patients reaching CR by ASCT plus a consolidation with 6 doses of atezolizumab at 1200 mg every 4 weeks.
89375903|NCT05299892|Experimental|Children with Hearing Loss|Participants age 5-12 with hearing loss who will be fit with study hearing aids and tested on speech perception in unaided and aided condition.
88848315|NCT06315686|Experimental|Experimental group|Eligible patients with advanced non-small cell lung cancer with leptomeningeal metastasis were treated with vormetinib combined with OMMAYA lateral ventricle chemotherapy (pemetrexed).
88848316|NCT06315673||Patient|Individuals with diagnosis of definite, probable, probable laboratory-supported, or possible ALS by revised El Escorial research criteria [2], primary lateral sclerosis (PLS), or progressive muscular atrophy (PMA).
88848317|NCT06315673||Control|Individuals with no neurological or orthopedic problems that affects their speech or handwriting AND age-matched to the existing patient cohort.
88848318|NCT06315660|Experimental|TAU+VR|
89375904|NCT05298410|Experimental|Limitless|Participants will be instructed to take Limitless capsules for 30 days starting with the first dose to be administered in clinic on Visit 2 (Day 1, Baseline). The last dose will occur in clinic on Visit 3 (Day 30). Participants will be instructed to take two capsules two hours with water after breakfast, and two capsules two hours after dinner. Do not take food after evening dose before bed. (i.e. no snacking or desserts.). If a dose is missed participants are instructed to skip that dose. Participants will be advised not to exceed four capsules daily.
89375905|NCT05281276|Experimental|chidamide (20 mg) BIW in combination with celecoxib (CC)|"Chidamide: The dosing schedule is four/six tablets (20 mg) BIW, taken at 30 min after breakfast. The interval between two doses in each week should not be less than 3 days.~Celecoxib: The dosing schedule is one capsule (200 mg) daily taken at 30 min after breakfast.~A treatment cycle is defined as a period of 4 weeks (28 days)"
89375906|NCT05281276|Experimental|chidamide(30 mg) BIW in combination with celecoxib (CC)|"Chidamide: The dosing schedule is four/six tablets (30 mg) BIW, taken at 30 min after breakfast. The interval between two doses in each week should not be less than 3 days.~Celecoxib: The dosing schedule is one capsule (200 mg) daily taken at 30 min after breakfast.~A treatment cycle is defined as a period of 4 weeks (28 days)"
88848319|NCT06315660|Active Comparator|TAU|
88848320|NCT06315647|Active Comparator|Patients enrolled for double guide wire technique.|
88848321|NCT06315647|Active Comparator|Patients enrolled for trans - pancreatic sphincterotomy technique.|
88848322|NCT06315647|Active Comparator|Patients enrolled for needle knife precut technique or fistulotomy technique.|
88848323|NCT06315634|Active Comparator|Heavy Bupivacaine plus normal saline|2.5 ml of 0.5% hyperbaric Bupivacaine plus 0.5 ml 0.9 % saline
88848324|NCT06315634|Experimental|Heavy Bupivacaine plus dexmedetomidine|2.5 ml of 0.5% hyperbaric Bupivacaine plus 5 micrograms dexmedetomidine in 0.5 ml 0.9 % saline
88848325|NCT06315634|Experimental|Heavy Bupivacaine plus midazolam|2.5 ml of 0.5% hyperbaric Bupivacaine plus 2 milligrams midazolam in 0.5 ml 0.9 % saline
88848326|NCT06315621|Active Comparator|Physical impression|
88848327|NCT06315621|Experimental|Scanning using intraoral scanner without markers|
88848328|NCT06315621|Experimental|Scanning using Intraoral scanner with markers|
89375907|NCT05280938|Experimental|MAAP Intervention|The MAAP intervention is an 8-week adapted mindfulness intervention based upon Kabat-Zinn's MBSR. The intervention includes spirituality, self-empowerment, interdependence, and story-telling which are salient to AAW. Session topics include Tasting Your Life, Seeing and Believing, The Scent of Roses, When Life Hurts, Hearing Your Own Cries, Embracing Inner Peace, Holding on, Welcoming Stillness. Each session will include an introduction, opening mindfulness practice, class responses to the previous week, review guidelines for class, guided individual reflection, group go-around/discussion, yoga, abdominal breathing, body scan, conclusion, and home practice. Face to face sessions 1, 4, 8 will be in a quiet room to allow group sitting or free floor space. Sessions 2, 3, 5, 6, are virtual on the zoom app. Participants receive practice links and a program workbook. Program attendance, type/amount of practice (weekly logs), and changes in mindfulness will be included in data analysis.
89375908|NCT05280938|Active Comparator|Educational Program|"The Education Program (attention control group) will be an 8-week educational program matched in duration and frequency to the MAAP intervention. Session topics are:1) Perineum and Incision Care, 2) Safe Sexual Practices, 3) Understanding Infant Feeding Methods, 4) How to Communicate Effectively with your Child's Health Care Providers, 5) Healthy Eating, 6) Infant Changing and Baths, 7) Infant Safety at Home, and 8) Utilizing Support from Family and the Community.~Sessions will be given in groups by the same expert clinicians/educators for all cohorts. Subject receipt of the attention control will be monitored by attendance. Control group instructor will not include content on stress reduction or methods (yoga, meditation, etc.) taught in the MAAPI intervention. Classes will be given in the same setting as the MAAPI intervention, at the same time but on a different evening, to avoid crossover of effects."
89375909|NCT05280769|Experimental|Use of oral nicotine pouch - 2 mg|On four separate occasions, participants will come to the research center and be asked to use a nicotine pouch or smokeless tobacco provided by the study team two separate times. The nicotine pouches or smokeless tobacco contain different amounts of nicotine. Participants will not know the concentration of nicotine in the nicotine pouch, but they will know the concentration and brand of the smokeless tobacco (it will be their usual brand). All participants will complete all four study conditions. Sessions will be ordered by Latin-square. Participants will not be assigned to arms based on session order and session order will not be recorded as it is not relevant to the study outcomes.
89375910|NCT05280769|Experimental|Use of oral nicotine pouch - 4 mg|On four separate occasions, participants will come to the research center and be asked to use a nicotine pouch or smokeless tobacco provided by the study team two separate times. The nicotine pouches or smokeless tobacco contain different amounts of nicotine. Participants will not know the concentration of nicotine in the nicotine pouch, but they will know the concentration and brand of the smokeless tobacco (it will be their usual brand). All participants will complete all four study conditions. Sessions will be ordered by Latin-square. Participants will not be assigned to arms based on session order and session order will not be recorded as it is not relevant to the study outcomes.
89375911|NCT05280769|Experimental|Use of oral nicotine pouch - 8 mg|On four separate occasions, participants will come to the research center and be asked to use a nicotine pouch or smokeless tobacco provided by the study team two separate times. The nicotine pouches or smokeless tobacco contain different amounts of nicotine. Participants will not know the concentration of nicotine in the nicotine pouch, but they will know the concentration and brand of the smokeless tobacco (it will be their usual brand). All participants will complete all four study conditions. Sessions will be ordered by Latin-square. Participants will not be assigned to arms based on session order and session order will not be recorded as it is not relevant to the study outcomes.
89375912|NCT05280769|Active Comparator|Use of smokeless tobacco|On four separate occasions, participants will come to the research center and be asked to use a nicotine pouch or smokeless tobacco provided by the study team two separate times. The nicotine pouches or smokeless tobacco contain different amounts of nicotine. Participants will not know the concentration of nicotine in the nicotine pouch, but they will know the concentration and brand of the smokeless tobacco (it will be their usual brand). All participants will complete all four study conditions. Sessions will be ordered by Latin-square. Participants will not be assigned to arms based on session order and session order will not be recorded as it is not relevant to the study outcomes.
89375913|NCT05279040||Cystic Fibrosis Patients|Participants diagnosed with cystic fibrosis who will be initiating Trikafta treatment
89375914|NCT05278234|Experimental|Intervention arm|Participants will engage in a 7-week multicomponent chronic pain self-management program.
89399356|NCT02170766|Experimental|BIBR 1048 medium|"Two treatments of one single dose of BIBR 1048 50 mg without or with Pantoprazole~BIBR 1048 50 mg without Pantoprazole~BIBR 1048 50 mg with 40 mg Pantoprazole (bid)"
88848329|NCT06315608|Experimental|MRG-001 (0.01 mL/kg)|MRG-001 will be subcutaneously administered at 0.01 mL/kg 3 times per week every other day for two weeks per month (Day 0, 2, 4, 7, 9, 11). This cycle will be repeated 3 months in total.
88848330|NCT06315582|Active Comparator|Study Intervention A (control group)|Hysteroscopic septoplasty utilizing bipolar electrosurgery
88848331|NCT06315582|Experimental|Study Intervention B (study group)|Hysteroscopic septoplasty utilizing scissors without electrosurgery followed by hysteroscopic morcellation of residual tissue
88848332|NCT06315569|Experimental|Group A (two 3000m runs 24 hours apart)|Run a second 3000m run 24 hours after completing the first 3000m run
88848333|NCT06315569|Experimental|Group B (two 3000m runs 48 hours apart)|Run a second 3000m run 48 hours after completing the first 3000m run
88848334|NCT06315556||Premature infants diagnosed with ROP|Premature infants diagnosed with retinopathy of prematurity (ROP) and treated with aflibercept 0.4 mg using the Eylea 40 mg/mL prefilled syringe (PFS) in combination with the PICLEO paediatric dosing device (PDD) after marketing authorisation in UK and included in the National Neonatal Research Database (NNRD).
88848335|NCT06315543|Experimental|Adequate drinking water intervention group|increase drinking water by 1650mL per day (3 bottles of 550mL bottled water) on the basis of original drinking water
88848336|NCT06315543|No Intervention|Water intake observation group|maintain original water intake
88848337|NCT06315530|Experimental|Experimental: SOC+Telitacicept arm|Telitacicept 160mg once a week for 48 week as an add-on treatment regimen. SOC treatment includes aspirin and/or vitamin K antagonists (VKA) and/or low molecular weight heparin.
88848338|NCT06315530|Active Comparator|Experimental: SOC arm|SOC treatment includes aspirin and/or vitamin K antagonists (VKA) and/or low molecular weight heparin.
89375915|NCT05278234|No Intervention|Usual care control arm|After completing the 12 month telephone survey, control group participants will be given access to the online program, a wearable physical activity tracker to use and keep, and will be invited to attend a workshop that provides key intervention content and individualized goal-setting guidance.
89375916|NCT05269628|Experimental|Cannabidiol (CBD)|"Epidiolex® doses will be 0.5 mL twice daily during the first seven days of active treatment and 1 mL twice daily (b.i.d.) for the remaining days of treatment.~PLUS Placebo Tetrahydrocannabinol (TCH) capsules which contain no active ingredients. Matching placebo capsules will be taken twice per day in the same schedule and manner as active dronabinol."
89375917|NCT05269628|Active Comparator|Tetrahydrocannabinol (THC)|"The drug dose will be 2.5 mg b.i.d. during the first seven days of active treatment, and 5 mg b.i.d. for the following days of active treatment.~PLUS Placebo CBD (A matching placebo oral solution to Epidiolex® will be used that consists of all of the excipients in the active solution without the cannabidiol component). The placebo will be dosed in the same schedule and manner as active Epidiolex®."
89375918|NCT05269628|Active Comparator|CBD + THC|"Epidiolex® (CBD) doses will be 0.5 mL twice daily during the first seven days of active treatment and 1 mL twice daily (b.i.d.) for the remaining days of treatment.~The THC dose will be 2.5 mg b.i.d. during the first seven days of active treatment, and 5 mg b.i.d. for the following days of active treatment."
89375919|NCT05269628|Placebo Comparator|Placebo CBD + Placebo THC|"Placebo CBD (A matching placebo oral solution to Epidiolex® will be used that consists of all of the excipients in the active solution without the cannabidiol component). The placebo will be dosed in the same schedule and manner as the active CBD.~Placebo Tetrahydrocannabinol (TCH) capsules which contain no active ingredients. Matching placebo capsules will be taken twice per day in the same schedule and manner as active drug."
89375920|NCT05261490|Experimental|Phase 1: Dose Escalation|"In the Phase 1 (dose escalation):~Cycle 1 for dose levels 1 and 2, maplirpacept (PF-07901801) will be administered on Day 1, Day 8, Day 15 and Day 22 in combination with PLD on Day 1 of 28-day cycle. Beginning with Cycle 2 at dose levels 1 and 2, maplirpacept (PF-07901801) will be administered on Day 1 and Day 15 in combination with PLD on Day 1 of 28-day cycles. For Phase 1, dose level 3, maplirpacept (PF-07901801) will be administered on Day 1 and Day 15 in combination with PLD on Day 1 of 28-day cycles. Dose level 3 will be biweekly regimen from the start."
89375921|NCT05261490|Experimental|Phase 2: Dose Expansion|"In the Phase 2 (dose expansion):~maplirpacept (PF-07901801) will be administered with selected dose from the escalation phase by intravenous infusion on Days 1, 8, 15 and 22 in Cycle 1, and then on Days 1 and 15 in subsequent cycles in combination with Pegylated Liposomal Doxorubicin 40 mg/m2 by intravenous infusion on Day 1 of each 28-day cycle."
89375922|NCT05254795|No Intervention|Usual care recipients|
89375923|NCT05254795|Experimental|Molecular tumor board intervention|
89375924|NCT05241210|Experimental|Testing of degree of mucosal inspection|AI provides real-time feedback related to circumferential views during endoscope removal
89375925|NCT05241210|Experimental|Testing of clearing of fecal debris|AI provides real-time feedback related to removal of remaining fecal debris
89375926|NCT05237882|Experimental|Children and Adolescents|6 children aged 8-12 years old, 6 adolescents aged 13-17 years old, fulfilling inclusion criteria will be included
89375927|NCT05225623|Experimental|Intervention|16-week behavioural weight loss classes
89375928|NCT05225623|Other|Waitlist Control|Participants in this arm will receive their treatment as usual for Psoriatic Arthritis and receive BWLT after the intervention group.
89375929|NCT05214105||Patients with sickle cell anemia|Prospective longitudinal study of patients with sickle cell anemia
89375930|NCT05212272||PET-MRI In High-Grade Glioma Patients Undergoing Chemoradiation|PET scan and MRI scan of the brain, blood draw, and 1-hour of memory testing.
89375931|NCT05209347|No Intervention|NoCDO|Participants will be evaluated without a CDO
89375932|NCT05209347|Experimental|CDO-A|The first study CDO will be designated CDO-A
89375933|NCT05209347|Experimental|CDO-B|The second study CDO will be designated CDO-B
89375934|NCT05183737|Active Comparator|Microcapsules with turmeric and propolis|Participants will receive microcapsules containing 0.250 milligrams of turmeric 95% curcumin and 0.250 milligrams of green propolis
89375935|NCT05183737|Placebo Comparator|Placebo Group|Participants will receive microcapsules containing arabic gum and cornstarch with the same weight and characteristics as the intersecting microcapsules
88848339|NCT06315517|Experimental|Conventional lactose-free milk first|Participants will consume conventional lactose-free milk first, then each of the other milk types in random order
88848340|NCT06315517|Experimental|Non-conventional (A2) lactose-free milk first|Participants will consume non-conventional (A2) lactose-free milk first, then each of the other milk types in random order
88848341|NCT06315517|Experimental|Non-conventional (A2) milk first|Participants will consume non-conventional (A2) milk first, then each of the other milk types in random order
88848342|NCT06315491|Experimental|CBX-12 - 125mg/m2 q21d|125mg/m2 CBX-12 administered by intravenous (IV) infusion every 21 days. Treatment will continue until there is evidence of progressive disease (PD) or development of unacceptable toxicity.
88848343|NCT06315491|Experimental|CBX-12 - 100mg/m2 q21d|100mg/m2 CBX-12 administered by intravenous (IV) infusion every 21 days. Treatment will continue until there is evidence of progressive disease (PD) or development of unacceptable toxicity.
88848344|NCT06315478|Active Comparator|Triple regimen(Group A)|
88848345|NCT06315478|Active Comparator|Quadruple regimen (Group B)|
88848346|NCT06315478|Active Comparator|Hybrid regimen (Group C)|
89375936|NCT05180799|Experimental|BA3071|Conditionally active biologic (CAB) antibody that binds to CTLA-4
89375937|NCT05180799|Experimental|Combination Therapy|Conditionally active biologic (CAB) antibody that binds to CTLA-4 with PD-1 inhibitor
89535045|NCT05015361|Active Comparator|Treatment group C|Treatment group C: Propofol Injection.
88848347|NCT06315465|Experimental|Modified Atkin's diet with standard of care arm|Group I will receive Modified Atkin's Diet with standard of care whereas Group II will receive standard of care alone. Children randomized into Group I, initial workup for Modified Atkin's Diet will be done in the form of Electrocardiogram, Renal Function Tests, Liver Function Tests, Complete Blood Counts, Lipid profile, Urine calcium creatinine ratio and Ultrasound Pelvis for nephrocalcinosis. If pre KD work up is normal, then Modified Atkin's Diet will be initiated in the ratio of 1:1.Urine ketones will be checked daily using ketone dipsticks. Telephonic contacts will be made in regular intervals every week to further ensure compliance at home, and to ensure proper understanding and confidence of parents. Those children who are unable to tolerate taking adequate ketogenic diet therapy requiring discontinuation of therapy, will be considered as deviates. First follow-up will be at 4 weeks of treatment initiation, followed by at 8, 12, 16, 20 and 24 weeks.
88848348|NCT06315465|Other|Standard of care arm|"Standard of care intervention plan will be devised for each subject based on the principles of -~Behavioral therapy~Behavioral modification techniques~Psycho education~Cognitive behavioral therapy~Activity based interventions like eye contact exercises, attention enhancement exercises, self-help skills~Speech therapy~Parental training~Occupational therapy~Sensory integration therapy~Pharmacotherapy - Anti-psychotic medications~The parents of the children will be called telephonically every weekly to check for any issues and reinforcement to ensure appropriate regular behavioural intervention to be provided to the child.~Physical follow up - 4, 8, 12, 16, 20, 24 weeks~Follow up assessments - 12 weeks (3 months) & 24 weeks (6 months)"
88848349|NCT06315439||pancreatic solid lesions|
88848350|NCT06315413|Experimental|Composite plug|Tooth extraction will be done a-traumatically followed by socket curettage and cleaning followed by xenograft filling for the socket and coverage with injected flowable composite plug which will then be stabilized using 5.0 polypropylene suture material with a figure of eight suture.
88848351|NCT06315413|Active Comparator|Exposed d-PTFE|Tooth extraction will be done a-traumatically followed by socket curettage and cleaning followed by xenograft filling for the socket and coverage with d-PTFE membrane which will be left exposed intentionally and secured using 5.0 polypropylene suture material with a figure of eight suture.
88848352|NCT06315400|Experimental|Ingavirin®, capsules, 60 mg|Ingavirin® will be administered once a day (60 mg/day) for 5 days on top of standard therapy.
88848353|NCT06315400|Placebo Comparator|Placebo|Placebo will be administered once a day for 5 days on top of standard therapy.
88848354|NCT06315387|Experimental|4-MUST, 128 mg|Single dose: 1 tablet (128 mg). Multiple dose: 1 tablet (128 mg) 3 times a day for 3 days (first dose on an empty stomach, second and third two hours after meals), once in the morning on an empty stomach on day 4.
88848355|NCT06315387|Experimental|4-MUST, 256 mg|Single dose: 2 tablets (256 mg). Multiple dose: 2 tablets (256 mg) 3 times a day for 3 days (the first intake of the drug on an empty stomach, the second and third - two hours after a meal), once in the morning on an empty stomach on the 4th day.
88848356|NCT06315387|Experimental|4-MUST, 384 mg|Single dose: 3 tablets (384 mg). Multiple dose: 3 tablets (384 mg) 3 times a day for 3 days (the first intake of the drug on an empty stomach, the second and third - two hours after a meal), once in the morning on an empty stomach on the 4th day.
88848357|NCT06315322|Experimental|Brivaracetam arm|Subjects in this arm will receive various brivaracetam doses as oral solution or film-coated tablet twice per day.
88848358|NCT06315309|Experimental|phase II single arm study of 2 step ATG dosing in prevention of aGVHD.|The primary outcome for the study is rate of GRFS at one-year post transplant. When accounting for competing risks, any death, relapse, Grade III-IV acute GVHD and cGVHD requiring systemic therapy are competing risks. The reported one year GRFS with the use of standard of care GVHD prevention regimen in MA HSCT (Tac/MTX) was 35%. (El-Jurdi 2023) We hypothesize that with 2 step ATG/Tac/Mini MTX regimen, we can achieve a one year GRFS of 60%.
88848359|NCT06315296|Experimental|Arm I (txt4fasting)|Patients follow a time-restricted diet, receive interactive positive reinforcement messages, and record food intake using the txt4fasting platform daily for 30 days. Patients receive counseling calls twice weekly in weeks 1 and 2 then once weekly in weeks 3 and 4. Patients then undergo SRS on study. Patients also undergo blood sample collection and brain MRI throughout study.
88848360|NCT06315296|Active Comparator|Arm II (attention control)|Patients receive text messages about healthy eating habits and food suggestions twice daily and record food intake using txt4fasting program for 30 days. Patients then undergo SRS on study. Patients also undergo blood sample collection and brain MRI throughout study.
88848361|NCT06315283|Active Comparator|Oral olanzapine|
88848362|NCT06315283|Experimental|TV-44749|
88848363|NCT06315257|Experimental|pBI-11 DNA plus TA-HPV via Skin Scarification|Participants will receive pBI-11 DNA and TA-HPV via Skin Scarification
89375938|NCT05179460||Clean Cohort|Clean cohort refers to cohort of participants who had their first documented exposure to pentosan polysulfate sodium (PPS; Elmiron) on or after 22 May 2018 and who are assumed to have had shorter exposure (the earliest available data based on the linked database between the IRIS registry and Komodo database in this study).
88848364|NCT06315257|Experimental|pBI-11 DNA plus TA-HPV via IM Injection|Participants will receive pBI-11 DNA and TA-HPV via IM Injection
89181813|NCT02580825|Active Comparator|Biofeedback gait retraining|The intervention program will take four weeks while in each week their will be two exercise sessions and a total of 8 sessions. Each session length is about 9 minutes. Each session will include a continuous exercise in which the patient will do walking, walking pace and running (3 minutes each section). During the meeting, participant will receive biofeedback that will displayed on a computer screen that shows the forces that develop in the knee joint so that the patient can see graphically the forces that develop around the knee joint and will be guided / try to reduce the values of the graph by changing the intensity of his landing on the tracks. In all training the time that the biofeedback is shown will be reduced.
89375939|NCT05179460||Overall Cohort|Overall cohort refers to cohort of participants who had their first documented exposure to PPS (Elmiron) any time beginning 01 January 2015 and who are assumed to have relatively longer exposure (the earliest available data based on the linked database between the intelligent research in sight (IRIS) registry and Komodo database in this study).
89375940|NCT05179460||Interstitial Cystitis (IC) Cohort|IC cohort refers to cohort of participants who had at least one IC diagnosis beginning 01 January 2015 and had no documented exposure to PPS based on the records from the Komodo database (the earliest available data based on the linked database between the IRIS registry and Komodo database in this study).
89375941|NCT05178784||Active Stimulation|Adults exposed to active external Combined Occipital and Trigeminal Nerve Stimulation (eCOT-NS) stimulation during the 8-week blinded treatment phase of the MOOD Clinical Trial (NCT04279522) who enrolled in this EEG substudy
89375942|NCT05178784||Sham Stimulation|Adults exposed to sham external Combined Occipital and Trigeminal Nerve Stimulation (eCOT-NS) stimulation during the 8-week blinded treatment phase of the MOOD Clinical Trial (NCT04279522) who enrolled in this EEG substudy
89375943|NCT05176210|Experimental|SAD portion - Cohort 1 (25mg)|An eligible subject will receive a single dose of 25 mg of PS1 or Placebo tablets in a fed condition on Day 1 and be followed for 7 days.
89375944|NCT05176210|Experimental|SAD portion - Cohort 2 (50mg)|An eligible subject will receive a single dose of 50 mg of PS1 or Placebo tablets in a fed condition on Day 1 and be followed for 7 days.
89375945|NCT05176210|Experimental|SAD portion - Cohort 3 (75mg)|An eligible subject will receive a single dose of 75 mg of PS1 or Placebo tablets in a fed condition on Day 1 and be followed for 7 days.
89375946|NCT05176210|Experimental|FE portion - Cohort 4 (50mg)|An eligible subject will receive a single dose of 50 mg PS1 or Placebo tablets in a fasted condition on Day 1 and be followed for 7 days.
89375947|NCT05176210|Experimental|MAD portion - Cohort 5 (25mg)|An eligible subject will receive 25 mg PS1 or Placebo tablets once daily in a fed condition for 14 days and be followed for additional 7 days.
89375948|NCT05176210|Experimental|MAD portion - Cohort 6 (50mg)|An eligible subject will receive 50 mg PS1 or Placebo tablets once daily in a fed condition for 14 days and be followed for additional 7 days.
89375949|NCT05176210|Experimental|MAD portion - Cohort 7 (25mg)|An eligible subject will receive 25 mg PS1 or Placebo tablets once daily in a fed condition for 28 days and be followed for additional 7 days.
89375950|NCT05176210|Experimental|MAD portion - Cohort 8 (50mg)|An eligible subject will receive 25 mg PS1 or Placebo tablets once daily in a fed condition for 28 days and be followed for additional 7 days.
89375951|NCT05172180||The control group|The control group consisted of 54 patients who received Ringer's solution at an average daily dose of 8.1 ml/kg/day as the main infusion solution from the time of transfer to the intensive care unit
88848365|NCT06315244|Experimental|%5 Dextrose Injection Group|Participants in this arm will receive an ultrasound-guided injection of 5% dextrose solution into the sacrotuberous ligament and the sensory innervation area of the perforating cutaneous nerve. The intervention aims to alleviate symptoms of chronic coccydynia by reducing nerve entrapment. Participants will continue their existing physical therapy/medical treatment regimen throughout the study.
88848366|NCT06315244|Placebo Comparator|Placebo Injection Group|Participants in this arm will receive an ultrasound-guided injection of a placebo solution (saline) into the same anatomical region as the experimental group. This arm serves as a control to evaluate the efficacy of the dextrose injection in treating chronic coccydynia symptoms. Participants will continue their existing physical therapy/medical treatment regimen throughout the study.
88848367|NCT06315231|Experimental|Group of edaravone dexborneol sublingual tablet|Patients will receive edaravone dexborneol sublingual tablet twice daily of 12 weeks.
89181814|NCT02580825|Active Comparator|Exercise|The control group will receive the same training program: four weeks while in each week their will be two exercise sessions and a total of 8 sessions. Each session length is about 9 minutes. Each session will include a continuous exercise in which the patient will do walking, walking pace and running (3 minutes each section). This group will not provide the biofeedback.
89181815|NCT00770588|Experimental|gefitinib|Gefitinib (Iressa® 250 mg) 1 tablet daily
89181816|NCT00770588|Placebo Comparator|placebo|placebo 1 tablet daily
89181817|NCT02604719|Experimental|tanexamic acid and Ethamsylate|10 ml of the study drugs (1 gm Tranexamic acid and 1 gm Ethamsylate ) slowly (over 30-60 sec ) in the 2 minutes after birth
89181818|NCT02604719|Placebo Comparator|placebo|10 ml normal saline will be administered intravenously just after birth
89375952|NCT05172180||The test group|Fifty one patients in the test group received the balanced succinate-containing crystalloid solution Reamberin (meglumine sodium succinate) at an average daily dose of 8.3 ml/kg/day for the same purpose
89375953|NCT05167201|Experimental|Nasal High Flow|"The Nasal High Flow device is an integrated flow generator that delivers warmed and humidified air to spontaneously breathing patients through a variety of patient interfaces.~Flow rates up to 60 litres/minute are available to the user, depending on the patient interface and mode of operation."
89535046|NCT01375075|Experimental|30 milligrams (mg) LY2484595|Administered orally once daily for 12 weeks
88848368|NCT06315231|Placebo Comparator|Placebo|Patients will receive placebo twice daily of 12 weeks.
88848369|NCT06315192|Experimental|Stroke Alarm use|The patients are provided with Stroke Alarm and instructed to use it in accordance with the IFU for a 3 months period.
88848370|NCT06315166|Other|Single Arm|Open(self-controlled) split-face design study. Thirty participants will undergo the treatments on one side of the face (buccal area). Treatments will be randomized with combination antibiotic/ FRF therapy.
88848371|NCT06315153||symptomatic group|An ischemic stroke was defined as occurring if the patient developed clinical symptoms related to neurological deficits and/or new infarcted lesions were detected on magnetic resonance imaging, and patients who developed ischemic strokes were classified in the symptomatic group.
88848372|NCT06315153||asymptomatic group|Patients without an ischemic stroke were classified in the asymptomatic group.
88848373|NCT06315140||Record of contamination from the Ford Motor plant|Have lived, for at least 2 consecutive years, in an area identified as having past or current contamination from the Ford Motor plant
88848374|NCT06315140||No record of contamination from the Ford Motor plant|Have lived, at least for 2 consecutive years, in an area with no record of current or past contamination from the Ford Motor plant
88848375|NCT06315127|Experimental|Human Donor Milk|All infants in this group will receive pasteurized donor milk from Rogers Hixon Ontario Human Milk Bank if they need extra feeding.
88848376|NCT06315127|Active Comparator|Formula supplement|All infants in this group will receive formula which is the standard of care if they need extra feeding.
88848377|NCT06315114|Experimental|Lighthouse MBT Parenting Program (LPP)|The experimental group is a manualized transdiagnostic mentalization-based parenting intervention (Lighthouse MBT Parenting Program). This is a 12-week parenting group intervention (weekly session of 2 hours) with one preperatory initial individual session (1 hour) before the group commence.
88848378|NCT06315114|Active Comparator|Care as usual (CAU)|1-2 next of kin sessions (called 'Familiesamtale') is considered the care as usual offered to parents in adult mental health service in the Capital Region of Denmark.
88848379|NCT06315101||Lenvatinib combined with Chinese Herbal Medicine|
88848380|NCT06315088|Experimental|Einkorn Diet|Healthy adult volunteers (not suffering from chronic pathologies) and non-smokers, having an omnivorous diet, and agreeing to change their eating habits for 3 months (reducing meat consumption by half and replacing it with einkorn).
88848381|NCT06315075|Experimental|DBT-A|Single group uncontrolled study. All participants will receive DBT-A
88848382|NCT06315049|Experimental|Music therapy group|It is formed from all the participants in the study. They participated in the music therapy sessions.
88848383|NCT06315036|Experimental|Developmental gymnastics (DG)|Developmental gymnastics group of participants
88848384|NCT06315036|No Intervention|Control (CG)|Control group of participants
89181819|NCT03788343|Experimental|Phenylalanine|"Capsules containing 250 mg Phenylalanine (Phe). The daily dose will be chosen according to gender and weight at the time of T1 and will be divided in 3 separate doses. The assigned dose of the IMP will be kept throughout the whole study and weight fluctuations will not be considered.~Female~<60 kg: 1500 mg per day (divided in 3 doses): 250 mg 2-2-2-0~≥60 kg: 2000 mg per day (divided in 3 doses): 250 mg 2-2-4-0~Male~<60 kg: 2500 mg per day (divided in 3 doses): 250 mg 4-2-4-0~≥60 kg: 3000 mg per day (divided in 3 doses): 250 mg 4-4-4-0~Phe capsules can be ingested before, during or after a meal or together with other amino acid supplements. The last capsule of the given intervention period will be timed to be ingested with the last meal before the study visit.~Patients will take Phe for 4 weeks."
89181820|NCT03788343|Placebo Comparator|Placebo|"Capsules containing 250mg Placebo. Placebo capsules will be administered in identical manner to Phe capsules.~Patients will take the Placebo for 4 weeks."
89181821|NCT02604797|Experimental|Nalbuphine|Nalbuphine group: nalbuphine 100 mg, ramosetron 0.3mg, background dose 1ml/h,patient-controlled analgesia(PCA) 1ml/time, lockout time 10 min, flurbiprofen axetil 50mg 6h after operation.
89181822|NCT02604797|Experimental|Sufentanil|Sufentanil group: sufentanil 100ug, ramosetron 0.3mg, background dose 1ml/h, PCA 1ml/time, lockout time 10 min, flurbiprofen axetil 50mg 6h after operation.
89181823|NCT04107233|Experimental|Intervention|Audit and feedback directed at family physicians, including reports a one-on-one meeting.
89181824|NCT04107233|No Intervention|Control|Usual care; may receive the intervention at the end of the study if successful
89181825|NCT00777608|Experimental|Donepezil 5-10 mg|There will be a 14 day period when all participants will receive placebo, followed by 5 mg donepezil, once daily for 14 days then titrated to 10 mg donepezil once daily for 70 days. Participants may then receive open-label donepezil for an additional 24 weeks.
89181826|NCT00777608|Placebo Comparator|Placebo|There will be a 14 day period when all participants will receive placebo. Participants will take placebo capsules orally, once daily for 84 days. Participants may then receive open-label donepezil for an additional 24 weeks.
89535047|NCT01375075|Experimental|100 mg LY2484595|Administered orally once daily for 12 weeks
88848387|NCT06315010|Experimental|Repotrectinib|Repotrectinib 160 mg orally (PO) every day (QD) for 14 days, and 160 mg twice a day (BID) thereafter.
88848388|NCT06314997|Experimental|RAS unmutated CTCs HER positive|
88848389|NCT06314997|Experimental|CTCs|
88848390|NCT06314997|Experimental|RAS unmutated CTCs HER negative|
88848391|NCT06314984|Active Comparator|Group I A (Conventional neddle syringe)|The injection was done in the mandible by the conventional needle syringe [Inferior Alveolar Nerve Block].
88848392|NCT06314984|Active Comparator|Group I B (Conventional needle syringe)|The injection was done in the maxilla by the conventional needle syringe [Infiltration].
88848393|NCT06314984|Experimental|Group II A (Comfort-in Jet Injector)|The injection was done in the mandible by the needleless Comfort-in jet injector [Inferior Alveolar Nerve Block].
88848394|NCT06314984|Experimental|Group II B (Comfort-in Jet Injector)|The injection was done in the maxilla by the needleless Comfort-in jet injector [Infiltration].
88848395|NCT06314971||T1 Colorectal Cancer, With Recurrence (Training)|Survivors of T1 colorectal cancer who developed recurrent colorectal cancer within 36 months from primary tumor treatment, in the first cohort
89375954|NCT05165498||Patients undergoing elective thoracic surgery, abdominal surgery, or having rib fractures|Patients undergoing elective thoracic surgery, abdominal surgery, or having rib fractures who will have placed a thoracic epidural catheter to manage their perioperative analgesia.
89375955|NCT05156112|Experimental|PAP Treatment on SARRTP Unit|Veterans will receive Positive Airway Pressure device while on the 28-day SARRTP Unit.
89002399|NCT06318234||After neoadjuvant therapy for rectal cancer|(1) Pathologically confirmed as rectal adenocarcinoma, with baseline clinical staging of T3~4 and/or N+; (2) No distant metastasis; (3) Not receiving chemotherapy or any other anti-tumor treatment before enrollment; (4) Has not received immunotherapy before enrollment and is able to adhere to the protocol during the study period (neoadjuvant therapy of short-term radiotherapy sequential chemotherapy combined with immunotherapy); (5) After neoadjuvant therapy, 18F-FAPI and 18F-FDG PET/MRI imaging were performed within 7 days before surgery, and the two scans were collected over two days; (6) Patient age ≥ 18 years old; (7) The patient voluntarily participates and signs an informed consent form.
89375956|NCT05156112|No Intervention|Waitlist Control|Veterans will not receive PAP device until after 3-month Follow Up.
89375957|NCT05154487|Experimental|Apelisib and Fulvestrant|alpelisib 300mg orally daily of each 28-day cycle fulvestrant 500mg IM on Day 1 and Day 15 of Cycle 1, then 500mg IM on Day 1 of each 28-day cycle.
89375958|NCT05140122||Primary caregivers of individuals with Dravet Syndrome|
89375959|NCT05099822|Experimental|Administration of CC-97489|
89375960|NCT05099822|Experimental|Administration of Placebo|
89375961|NCT05086393|Experimental|Duloxetine|Patients randomized to the experimental arm of the study will receive 30 mg of duloxetine and will be advised to consume the medication orally (per os [PO]) daily starting one week prior to surgery and to continue until 6 weeks following surgery. The dose of 30 mg was selected as that has been used as that is the largest starting dose used in other RCTs without requiring a preceding adjustment period at a lower dosage.
89181827|NCT03905031|Experimental|InfraScanner 2000|All participants entered into the study will undergo at least one cranial scanning using the InfraScanner 2000 within 4 hours before or after CT scan. Patients will know the results of the CT scan but not of the InfraScanner 2000. A CT result that is positive for hematoma will be considered a true positive and a CT result that is negative for hematoma will be considered a true negative.
89181828|NCT00792935|Experimental|MK-0941|
89375962|NCT05086393|Placebo Comparator|Control|Patients randomized to the control arm will receive PO-matched placebo tablets and advised to consume their medication similar to the treatment arm. Both groups of patients will receive their medications from the pharmacy at Rush Medical Center, which will be responsible for providing patients with the appropriate regimen. All patients will receive the same postoperative multimodal analgesic regimen that is normally administered as part of conventional care to patients undergoing TKA at Rush University Medical Center.
89375963|NCT05079568|Experimental|Active VR Group|"Subjects will be provided an Oculus Go VR headset pre-loaded with a menu of virtual reality programs which have been designed specifically to treat both acute and chronic pain. Subjects are required to use the VR headset at home four times daily, prior to breakfast, lunch, dinner, and bedtime. Each session will last approximately 15 minutes."
89375964|NCT05079568|Sham Comparator|Sham VR Group|Subjects will be provided an Oculus Go VR headset pre-loaded two-dimensional nature video. Subjects are required to use the VR headset at home four times daily, prior to breakfast, lunch, dinner, and bedtime. Each session will last approximately 15 minutes.
89375965|NCT05077033|Experimental|Intratumoral phIL12 gene electrotransfer|
89375966|NCT05072080|Experimental|Group 1|Group 1 - PXVX0317 lot A (Lot 104)
89375967|NCT05072080|Experimental|Group 2|Group 2 - PXVX0317 lot B (Lot 105)
89375968|NCT05072080|Experimental|Group 3|Group 3 - PXVX0317 lot C (Lot 106)
89375969|NCT05072080|Placebo Comparator|Group 4|Group 4 - Placebo
89375970|NCT05068791|Experimental|Psilocybin|Participants in the Psilocybin condition will receive .36 mg/kg of psilocybin.
89375971|NCT05068791|Active Comparator|Active Placebo|Participants in the Active Placebo condition will receive 2.6 mg/kg of dextromethorphan (DXM).
89375972|NCT05066555||Advanced-stage Hodgkin Lymphoma patients (1)|All patients will be accrued by investigators from the 19 best recruiting centers in the FIL-Rouge clinical trial. Patients had undergone to ABVD-based upfront treatment in FIL-Rouge trial (Comparator arm).
89002400|NCT06318221|Experimental|immunonutrition (intervention group)|Immunonutrition enteral products was given to the patients in the intervention group
89002401|NCT06318221|Active Comparator|standard (control group)|Standard enteral products was given to patients in the control group.
89002402|NCT06318195|Experimental|Condensed Internet delivered prolonged exposure (CIPE)|Condensed Internet delivered prolonged exposure (CIPE) for three weeks with therapist support.
89375973|NCT05066555||Advanced-stage Hodgkin Lymphoma patients (2)|All patients will be accrued by investigators from the 19 best recruiting centers in the FIL-Rouge clinical trial. Patients had undergone to ABVD-based upfront treatment in FIL-Rouge trial (Experimental arm).
89375974|NCT05063929|Experimental|Fruits|Participants will receive 2 cup eq fruits per day
89375975|NCT05063929|Other|Fruit restriction|Participants will receive 1/2 cup eq fruits per day
89181829|NCT00792935|Active Comparator|Glimepiride|
89375976|NCT05059639|Experimental|Almond (2 ounces)|Consume 2 ounces almond daily for 8 weeks
89375977|NCT05059639|Active Comparator|Pretzel|Consume comparative amount of pretzel for 8 weeks
89002403|NCT06318182|Experimental|Training group|Group receiving training based on SIMTEKEP program
89002404|NCT06318182|No Intervention|Control group|The group that did not receive training based on the SIMTEKEP program
89375978|NCT05047523|Experimental|ALXN1840|ALXN1840 will be administered at one of two starting doses, with incremental dose increases permitted.
89375979|NCT05047523|Active Comparator|Standard of Care|Participants will receive their current therapy or initiate Standard of Care therapy.
89375980|NCT05042362|Experimental|Elinzanetant (BAY3427080)|Participants will receive 120 mg elinzanetant orally once daily for 26 weeks.
89375981|NCT05042362|Placebo Comparator|Placebo + elinzanetant|Participants will receive matching placebo orally once daily for 12 weeks, followed by elinzanetant 120 mg for 14 weeks.
89375982|NCT04983940|Experimental|Jatenzo Arm|Participants in this group will receive Jatenzo for 26 consecutive weeks.
89375983|NCT04981730|Experimental|Web-based intervention|Participants in the intervention will receive both the standardized usual care and guided web-based, individually-tailored childbirth and parenting intervention program, consisting of training sessions plus weekly email, message, or video-conference contact from their assigned nurse specialist.
89375984|NCT04981730|No Intervention|Control|Participants in the control group will receive attention from the research nurse and the standardized usual care.
88848396|NCT06314971||T1 Colorectal Cancer, Without Recurrence (Training)|Survivors of T1 colorectal cancer who did not develop recurrent colorectal cancer within 36 months from primary tumor treatment, in the first cohort
88848397|NCT06314971||T1 Colorectal Cancer, With Recurrence (Validation)|Survivors of T1 colorectal cancer who developed recurrent colorectal cancer within 36 months from primary tumor treatment, in the second cohort
88848398|NCT06314971||T1 Colorectal Cancer, Without Recurrence (Validation)|Survivors of T1 colorectal cancer who did not develop recurrent colorectal cancer within 36 months from primary tumor treatment, in the second cohort
88848399|NCT06314958||Stage II/III Colorectal Cancer, with Recurrence (Training)|Stage II/III Colorectal Cancer patients who received treatment with surgery and adjuvant chemotherapy, and experienced recurrence within five years.
88848400|NCT06314958||Stage II/III Colorectal Cancer, without Recurrence (Training)|Stage II/III Colorectal Cancer patients who received treatment with surgery and adjuvant chemotherapy, and did not experience recurrence within five years.
88848401|NCT06314958||Stage II/III Colorectal Cancer, with Recurrence (Validation)|Stage II/III Colorectal Cancer patients who received treatment with surgery and adjuvant chemotherapy, and experienced recurrence within five years.
88848402|NCT06314958||Stage II/III Colorectal Cancer, without Recurrence (Validation)|Stage II/III Colorectal Cancer patients who received treatment with surgery and adjuvant chemotherapy, and did not experience recurrence within five years.
88848403|NCT06314932|Experimental|High UPF|Group starting with the Mediterranean diet (MD) high in ultra-processed foods (UPF)
88848404|NCT06314932|Active Comparator|Low UPF|Group starting with the Mediterranean diet (MD) low in ultra-processed foods (UPF)
88848405|NCT06314880|Experimental|18-50 years old|60 people per age group
88848406|NCT06314880|Experimental|6-17 years old|60 people per age group
88848407|NCT06314880|Experimental|2-5 years old|60 people per age group
88848408|NCT06314880|Experimental|6-23 months old|60 people per age group
88848409|NCT06314880|Experimental|3-5 months old|60 people per age group
88848410|NCT06314867|Experimental|Experimental group 1|lot 1
88848411|NCT06314867|Experimental|Experimental group 2|lot 2
88848412|NCT06314867|Experimental|Experimental group 3|lot 3
88848413|NCT06314854|Experimental|Experimental Group|During the cannulation process, the experimental group will listen to the sound of flowing water throughout the process through the researcher's smartphone. The experimental and control groups will be administered VAS before, during and after each cannulation, and the State and Trait Anxiety Scale will be administered before the dialysis session and after the 12th first session.
88848414|NCT06314854|No Intervention|Control Group|The control group will be provided with standard care and no intervention will be made. A total of 12 sessions will be followed in both groups.
88848415|NCT06314828|Experimental|RJMty19 (CD19-CAR-DNT Cells)|The trial is divided into two parts: Part A is a dose escalation trial with four dose groups (5×10^6 CAR+ cells/kg, 1×10^7 CAR+ cells/kg, 2×10^7 CAR+ cells/kg and 4×10^7 CAR+ cells/kg at day 0), with 8-24 patients planned to be enrolled. Part B is a dose-expansion trial in which 3~6 patients will receive RJMty19 infusions at RP2D dose levels.
88848416|NCT06314802||Learning curve of Surgeon I|
88848417|NCT06314802||Learning curve of Surgeon II|
88848418|NCT06314802||Learning curve of Surgeon III|
88848419|NCT06314802||Learning curve of Surgeon IV|
88848420|NCT06314789|Experimental|Lung ultrasound for newborns|In the study, both LUS imaging and scoring will be performed in the delivery room within the first 30 minutes and lUS score evaluation will be performed at postnatal 2nd, 6th and 24th hours in the intensive care unit for inpatients and in the maternal ward for maternal patients.
88848421|NCT06314776|Active Comparator|Pre-Usual physiotherapy|Pre-intervention (GMFM, Test 10M, Test Time Up and Go)
88848422|NCT06314776|Active Comparator|Usual physiotherapy without Whole-Body Vibration|Two days a week of physical therapy (mobilizations, manual therapy, stretching, respiratory techniques)
88848423|NCT06314776|Active Comparator|Post-Usual physiotherapy|Post-intervention (GMFM, Test 10M, Test Time Up and Go)
88848424|NCT06314763|Experimental|Single dose rivaroxaban 20 mg and steady-state sotorasib 960 mg|To assess the pharmacokinetics of single dose rivaroxaban in presence and absence of 960 mg sotorasib at pharmacokinetic steady-state. Samples will be taken pre-dose (t=0) and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, and 48 hours post ingestion.
88848425|NCT06314750||Well T-downstage|After receiving neoadjuvant therapy, the postoperative pathological stage of patients with primary cT4 rectal cancer was pT2 or less.
88848426|NCT06314750||Poor T-downstage|After receiving neoadjuvant therapy, the postoperative pathological stage of patients with primary cT4 rectal cancer was pT3 or above.
88848427|NCT06314737||Neoadjuvant therapy group|The primary tumor received neoadjuvant therapy before surgical treatment.
88848428|NCT06314737||Surgical treatment group|The primary tumor did not receive neoadjuvant therapy before surgical treatment.
89375985|NCT04980248|Experimental|ALXN1850|Three experimental cohorts will be administered 3 dosages (low, medium, high) of ALXN1850, respectively, via IV infusion and/or SC over multiple administration intervals.
89375986|NCT04979806|Experimental|Cefepime-zidebactam (FEP-ZID)|
89375987|NCT04979806|Active Comparator|Meropenem|
89375988|NCT04967807|Other|Cohort A - Symptomatic|Those with clinical findings suggestive of myocarditis/myocardial injury after COVID-19 vaccination
89375989|NCT04967807|Other|Cohort B - Asymptomatic|Those without signs or symptoms suggestive of myocarditis after COVID-19 vaccination
89375990|NCT04966910|Experimental|Stay Connected|Menu-driven set of strategies to combat loneliness, anxiety and depression in older adults
89375991|NCT04966910|Active Comparator|Treatment as usual|Treatment as usual in these practice settings typically includes regular check-in calls and offering resources and referrals
89375992|NCT04959188||Bereaved family caregivers|Bereaved family caregivers (parents or spouses/partners) of individuals who died from complications associated with dyskeratosis congenita or a related telomere biology disorder.
89375993|NCT04959188||Caregivers|Family and/or caregivers of individuals with dyskeratosis congenita or a related telomere biology disorder.
89375994|NCT04959188||Patients|Individuals with dyskeratosis congenita or a related telomere biology disorder.
88848429|NCT06314724|Experimental|Varicella vaccine group|Participants will receive a single dose of investigational varicella vaccine on Day 0.
88848430|NCT06314724|Active Comparator|Varivax|Participants will receive a single dose of Varivax on Day 0.
88848431|NCT06314711|Experimental|Post-operative ex vivo 3D ultrasound|3D ultrasound of surgical specimen
88848432|NCT06314698|Experimental|Narlumosbart|120 mg SC Q4W, up to 2 years.
88848433|NCT06314698|Active Comparator|Denosumab|120 mg SC Q4W, up to 2 years.
88848434|NCT06314685|Experimental|6~11 months old|For children aged 6-11 months, they was randomly assigned in a 1:1 ratio to the experimental group and control group, and basic immunization was performed following a 0,1-month schedule. And the experimental group received one dose of booster immunization at 18 months old;
88848435|NCT06314685|Experimental|12~23 months old|For infants aged 12-23 months, they was randomly assigned in a 1:1:1 ratio to the two-dose experimental group, one-dose experimental group, and two-dose control group. For the 12-23 month-olds in the two-dose group, they received two doses of immunization according to a 0, 1-month schedule; while those in the one-dose group receive a single dose of immunization.
88848436|NCT06314685|Experimental|2~5 years old|For children aged 2-5 years, they were randomly assigned in a 1:1 ratio to the experimental group and control group and received a single dose of immunization.
88848437|NCT06314672|Experimental|Phase I (interview, discussion, review, AEP, education)|Community members, clinic staff, and providers undergo in-depth interview for intervention development on study. Researchers review baseline data on referral patterns and accrual of racial and ethnic minorities to clinical trials in each clinic site. Providers, clinical staff, and research team participate in implementation discussion. AEP strategies developed and initiated in one OSUCCC/James clinic. Providers and community members participate in educational sessions on study. (Year 1)
88848438|NCT06314672|Experimental|Phase II (AEP, education, interviews)|Participants participate in the AEP in the remaining clinics at OSUCCC/James and community clinics on study. Community members and providers participate in culturally tailored educational activities. Providers, patients, and community members participate in interviews to explore current barriers to referral and participation on study. (Years 2-4)
88848439|NCT06314672|Experimental|Phase III (interview)|Providers, clinic staff, patients, and community members participate in interviews to explore current barriers to referral and participation. (Year 5)
88848440|NCT06314659|Experimental|Experimental group|Group A and C Meningococcal Polysaccharide Conjugate Vaccine
88848441|NCT06314659|Active Comparator|Active control group|Group A and C Meningococcal Polysaccharide Conjugate Vaccine (producted by Yunnan Walvax Biotechnology Co., Ltd) for primary immunization; Group A and C Meningococcal Polysaccharide Conjugate Vaccine (producted by Chengdu Olymvax Biopharmaceutical Inc.) for booster immunization.
89181830|NCT03904563|Experimental|Bevacizumab|All patients received four cycles of weekly docetaxel (25mg/㎡) and nedaplatin (25mg/㎡)(DP), each of 1 day's duration, combined with split-course thoracic radiotherapy, with one-month break.Then every patients are treated with Bevacizumab 1-2 months later.The recommended dose for intravenous infusion is 15mg/kg body weight, which is given every 3 weeks for up to 1 year.
89181831|NCT00770510|Experimental|Eszopiclone 1 mg|
89375995|NCT04958122|Experimental|Cefixime|Oral cefixime 400mg, taken twice a day for 10 days
89375996|NCT04958122|Active Comparator|Benzathine Penicillin G|Single intramuscular injection of 2.4 million units of benzathine penicillin G
89375997|NCT04951492|Experimental|Treatment (Olaparib)|Patients receive olaparib orally (PO) twice daily (BID). Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89375998|NCT04948112|Experimental|Real-time (rt) CGMS with SMBG|Real time continuous glucose monitoring plus self-monitored blood glucose
89375999|NCT04948112|Active Comparator|SMBG with blinded CGM|Self monitored blood glucose with blinded continuous glucose monitoring
89376000|NCT04927975|Experimental|Dose A of Upadacitinib|Participants in this group will receive dose A of upadacitinib orally once daily (QD) for 52 weeks.
89376001|NCT04927975|Experimental|Dose B of Upadacitinib|Participants in this group will receive dose B of upadacitinib orally QD for 52 weeks.
89376002|NCT04927975|Experimental|Dose C of Upadacitinib|Participants in this group will receive dose C of upadacitinib orally QD for 52 weeks.
89376003|NCT04927975|Experimental|Placebo Followed by Dose A of Upadacitinib|Participants in this group will receive placebo for 24 weeks followed by dose A of upadacitinib orally QD for 28 weeks.
89376004|NCT04927975|Experimental|Placebo Followed by Dose B of Upadacitinib|Participants in this group will receive placebo for 24 weeks followed by dose B of upadacitinib orally QD for 28 weeks.
89376005|NCT04926831|Experimental|Cohort A|Participants with NSCLC with MET exon 14 skipping mutations, irrespective of MET gene copy number (GCN) will take 400 mg tablet orally twice per day
89376006|NCT04926831|Experimental|Cohort B|Participants with NSCLC with high level MET amplification will take 400 mg tablet orally twice per day
89376007|NCT04922463|No Intervention|Control group|
89376008|NCT04922463|Experimental|1x PLASOMA|
89376009|NCT04922463|Experimental|2x PLASOMA|
89376010|NCT04900038|Experimental|GSK3640254 100 mg + Dolutegravir (DTG) 50 mg|Participants with human immunodeficiency virus type 1 (HIV-1) orally received low dose (100 mg) GSK3640254 tablet blinded and 50 mg DTG unblinded. Each participant received one tablet per day of each intervention up to Week 24.
89376011|NCT04900038|Experimental|GSK3640254 150 mg + DTG 50 mg|Participants with HIV-1 orally received medium dose (150 mg) GSK3640254 tablet blinded and 50 mg DTG unblinded. Each participant received one tablet per day of each intervention up to Week 24.
89376012|NCT04900038|Experimental|GSK3640254 200 mg + DTG 50 mg|Participants with HIV-1 orally received high dose (200 mg) GSK3640254 tablet blinded and 50 mg DTG unblinded. Each participant received one tablet per day of each intervention up to Week 24.
89376013|NCT04900038|Active Comparator|DTG 50 mg + Lamivudine (3TC) 300 mg|Participants with HIV-1 orally received unblinded 50 mg DTG one tablet and blinded 300 mg 3TC. Each participant received one capsule per day of each intervention up to Week 24.
89376014|NCT04880642|Experimental|C21|50 mg capsules, oral administration twice daily,for 14 days
89376015|NCT04880642|Placebo Comparator|Placebo|placebo capsules, oral administration twice daily,for 14 days
89181832|NCT00770510|Experimental|Eszopiclone 2 mg|
88848444|NCT06314607||Group 1|"Patients already included in the first ONCONEUROTEK (retrospective) study and followed up in the participating center : at their next hospitalization or consultation at Pitié Salpêtrière, they will be given an information note and a consent form (NIFC) informing them of the ONCONEUROTEK 2 study.~(This population concerns all patients in the relevant departments with a last news date < 2 years)"
89376016|NCT04880434|Experimental|Brexucabtagene autoleucel (KTE-X19)|Participants with relapsed/refractory mantle cell lymphoma will receive conditioning chemotherapy consisting of fludarabine 30 mg/m^2/day and cyclophosphamide 500 mg/m^2/day intravenous (IV) infusion for 3 days followed by a single infusion of brexucabtagene autoleucel (KTE-X19) at a targeted dose of 2 x 10^6 anti-CD19 chimeric antigen receptor (CAR) T cells/kg, with a maximum flat dose of 2 x 10^8 anti-CD19 CAR T cells for participants ≥ 100 kg on Day 0 in Cohort 3.
89376017|NCT04877535|Experimental|Intervention|ML will be used to create a report card for each patient that summarizes the preoperative assessment and intraoperative data. Report card data will be made available to providers through multiple methods: integration into electronic health records workflows, electronic health records notifications, mobile device notifications, and print outs in the paper chart
89376018|NCT04877535|No Intervention|Pre-intervention|The standard of care. The report card will be electronically generated (to determine eligibility) but it will not be visible to clinicians.
88848445|NCT06314607||Group 2|"Patients included prospectively : Patients who may be included in this study will be informed of its objectives and procedures by the doctor in charge of their follow-up, during a consultation visit or routine hospitalization, by means of an information note.~(This population concerns around 1,000 patients per year, i.e. around 10,000 patients over 10 years)"
88848446|NCT06314607||Group 3|"This group concerns patients already included in the ONCONEUROTEK study (retrospective) but not currently being followed at the Pitié Salpêtrière hospital. Specifically, patients who are known to the investigators to still be alive. In this case, an information note and a non-opposition form (NINO) will be sent to them by mail to :~inform them of the regulatory update under the Loi Jardé and the RGPD~and collect their non-opposition to the re-use of their data and samples.~If no reply is received within one month, the patient will be deemed not to have objected to the re-use of his or her data and samples in the ONCONEUROTEK 2 study.~(This population concerns all patients in the relevant departments with a last news date > 2 years)"
88848447|NCT06314594|No Intervention|control|Conventional treatment
88848448|NCT06314594|Experimental|intervention|Using paradigms based on transfer learning and semi-supervised learning, using multiple learning methods, transformer image classification algorithms and other mathematical methods, an early warning model and stepped treatment model for adolescent scoliosis were developed and verified, and a cost-effectiveness analysis was conducted at the same time.
88848449|NCT06314581||BPPV|
88848450|NCT06314555||Women under 37 weeks of gestation age|A woman with suspected preeclampsia and with inclusion criteria receives a blood sample, according to the department's usual practices, to analyse the values of sFlt-1 and PlGF and the usual vascular-renal sample. The woman gave her verbal consent to participate in the study. The Roche Elecsys® immunoassay sFlt-1/PlGF ratio was used to measure the two markers in the patients' blood.
89181833|NCT00770510|Experimental|Eszopiclone 3 mg|
89181834|NCT00770510|Placebo Comparator|Placebo|
89181835|NCT00770510|Active Comparator|Zolpidem Tartrate 10 mg|
89181836|NCT02580747|Experimental|anti-meso CAR T cells|"Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.~Patients receive anti-meso-CAR retroviral vector-transduced autologous-derived T cells on days 0, 1, 2 in the absence of disease progression or unacceptable toxicity."
89376019|NCT04873856|Experimental|Intervention group|"Intervention contains:~individual nutritional plan~regular contact~friendly reminder/informal caregiver and~weight dairy."
89376020|NCT04873856|No Intervention|Control Group|Standard of care
89535048|NCT01375075|Experimental|500 mg LY2484595|Administered orally once daily for 12 weeks
89376021|NCT04865588|Active Comparator|rotational atherectomy + cutting balloon|angioplasty with rotational atherectomy followed by cutting balloon
89376022|NCT04865588|Active Comparator|rotational atherectomy + plain old balloon|angioplasty with rotational atherectomy followed by plain old balloon
89376023|NCT04850599|Experimental|Treatment (isatuximab, carfilzomib, pomalidomide)|Patients receive isatuximab IV over 30-60 minutes on days 1, 8, 15, and 22 of cycle 1, and days 1 and 15 of subsequent cycles, carfilzomib IV over 10 to 30 minutes on days 1, 8, 15, and pomalidomide PO QD on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89376024|NCT04847739|Experimental|Standard of Care Treatment + AVB-114|Subjects receive the standard of care treatment (seton placement) prior to Day 0, when it is removed and the AVB-114 study treatment is inserted.
89376025|NCT04847739|Active Comparator|Standard of Care Treatment|Subjects receive the standard of care treatment (seton placement) prior to Day 0, when it is removed and then replaced.
89376026|NCT04838249||Female Control|"n = 20; Inclusion criteria~informed consent, if <18 years from all legal guardians only for part B (patients will participate in all other study parts): weight stable (± 5%) for last 3 months BMI ≤ 30 kg/m² Exclusion criteria severe medical impairments (e.g., uncontrolled cardiovascular disease, severe heart failure, uncontrolled hypertension, cerebral insult, active malign disease, etc.) only for part B (patients will participate in all other study parts): Insufficiently controlled endocrine disorders Chronic pulmonary disorders Diagnosed gastrointestinal diseases History of HIV infection or ongoing chronic infection only for part D (patients will participate in all other study parts): Contraindication against performance of an MRI scan (i.e., presence of metal in body, tattoos in head/neck region, claustrophobia etc.)"
89376027|NCT04838249||Male Control|"n = 20; Inclusion criteria~informed consent, if <18 years from all legal guardians only for part B (patients will participate in all other study parts): weight stable (± 5%) for last 3 months BMI ≤ 30 kg/m² Exclusion criteria severe medical impairments (e.g., uncontrolled cardiovascular disease, severe heart failure, uncontrolled hypertension, cerebral insult, active malign disease, etc.) only for part B (patients will participate in all other study parts): Insufficiently controlled endocrine disorders Chronic pulmonary disorders Diagnosed gastrointestinal diseases History of HIV infection or ongoing chronic infection only for part D (patients will participate in all other study parts): Contraindication against performance of an MRI scan (i.e., presence of metal in body, tattoos in head/neck region, claustrophobia etc.)"
89376028|NCT04838249||Female cross-sex hormone therapy|"n = 20; Inclusion criteria~transsexual patients undergoing cross-sex hormone therapy informed consent, if <18 years from all legal guardians only for part B (patients will participate in all other study parts): weight stable (± 5%) for last 3 months BMI ≤ 30 kg/m²~Exclusion criteria~severe medical impairments (e.g., uncontrolled cardiovascular disease, etc.) self-initiated cross-sex hormone therapy before study start only for part B (patients will participate in all other study parts): Insufficiently controlled endocrine disorders Chronic pulmonary disorders Diagnosed gastrointestinal diseases History of HIV infection or ongoing chronic infection only for part D (patients will participate in all other study parts): Contraindication against performance of an MRI scan"
89399357|NCT02170766|Experimental|BIBR 1048 high|"Two treatments of one single dose of BIBR 1048 100 mg without or with Pantoprazole~BIBR 1048 100 mg without Pantoprazole~BIBR 1048 100 mg with 40 mg Pantoprazole (bid)"
89399358|NCT04156659|Experimental|Tisagenlecleucel|"All patients eligible for treatment with tisagenlecleucel will receive a single dose of tisagenlecleucel.~For subjects ≤ 50 kg, tisagenlecleucel will be administered as a single infusion of 0.2 to 5.0 x 10^6 CAR positive viable T cells per kg body weight.~For subjects > 50 kg, tisagenlecleucel will be administered as a single infusion of 0.1 to 2.5 x 10^8 CAR positive viable T cells."
89535049|NCT01375075|Placebo Comparator|Placebo|Administered orally once daily for 12 weeks
88848451|NCT06314555||Women above 37 weeks of gestation age|A woman with suspected preeclampsia and with inclusion criteria receives a blood sample, according to the department's usual practices, to analyse the values of sFlt-1 and PlGF and the usual vascular-renal sample. The woman gave her verbal consent to participate in the study. The Roche Elecsys® immunoassay sFlt-1/PlGF ratio was used to measure the two markers in the patients' blood.
88848452|NCT06314529||BRL-101|All patients who have received BRL-101
88848453|NCT06314516||Body Composition|Radiologic assessment of fat and muscle components of body composition at presentation and following initial treatment for esophageal cancer.
88848454|NCT06314503|Experimental|WEAKID|Six treatments over the course of two weeks with the WEAKID system
88848455|NCT06314490|Experimental|Open label|
88848456|NCT06314477|Active Comparator|Conservative treatment|Subjects allocated to this arm will receive hygienic and dietary measures counselling
88848457|NCT06314477|Experimental|CPAP treatment|Subjects allocated to this arm will receive treatment with continuous positive airway pressure (CPAP)
89181837|NCT04077177|No Intervention|Assessment Only|
88848458|NCT06314464|Experimental|Praxis|Fifteen SMs with post-acute mTBI and residual dizziness/imbalance complaints from the Center for the Intrepid's Special Operations Performance and Recovery (SPaR) Program will receive 4 weeks of Praxis intervention (45 minutes, 5 days per week)
88848459|NCT06314464|Active Comparator|Control|Fifteen SMs without dizziness/imbalance complaints from the Center for the Intrepid's Special Operations Performance and Recovery (SPaR) Program will receive 4 weeks of supervised cardiovascular activity (45 minutes, 5 days per week)
88848460|NCT06314438|Experimental|Family Care Project workbook|Caregivers will be administered the Family Care Project workbook.
89181838|NCT04077177|Experimental|Intervention|
89181839|NCT04077255|Experimental|anti-EGFR|Participants will receive GC-1118 in combination with weekly paclitaxel.
89181840|NCT00770432|Active Comparator|Polyethylene glycol 3350 powder for solution|MiraLAX® (polyethylene glycol 3350 powder for solution)
89376029|NCT04838249||Male cross-sex hormone therapy|"n = 20; Inclusion criteria~transsexual patients undergoing cross-sex hormone therapy informed consent, if <18 years from all legal guardians only for part B (patients will participate in all other study parts): weight stable (± 5%) for last 3 months BMI ≤ 30 kg/m²~Exclusion criteria~severe medical impairments (e.g., uncontrolled cardiovascular disease, etc.) self-initiated cross-sex hormone therapy before study start only for part B (patients will participate in all other study parts): Insufficiently controlled endocrine disorders Chronic pulmonary disorders Diagnosed gastrointestinal diseases History of HIV infection or ongoing chronic infection only for part D (patients will participate in all other study parts): Contraindication against performance of an MRI scan"
89376030|NCT04831580|Active Comparator|Open radical hysterectomy|
89376031|NCT04831580|Experimental|Robotic radical hysterectomy|
89376032|NCT04826640||Pregnant women who receive COVID-19 vaccine|Pregnant women who receive COVID-19 vaccine
89376033|NCT04824638|Experimental|Group 1: SARS-CoV-2 naive participants|participants without antecedent of SARS-CoV-2 infection
89376034|NCT04824638|Experimental|Group 2: Previously SARS CoV-2 infected participants|participants with antecedent of SARS-CoV-2 infection (more than 5 months)
89376035|NCT04820023|Experimental|BBT-176|
89376036|NCT04817891|Experimental|Experimental: HD-tDCS|Maximum 4 milliAmp (mA) per channel of HD-tDCS treatment for 20 minutes, for 10 sessions. Total mA dose determined by individualized computational models.
89376037|NCT04809805|Experimental|Dose escalation of BAY2666605|Approximately 7 or 8 dose levels are planned.
89376038|NCT04809805|Experimental|Dose expansion of BAY2666605|Participants will receive BAY 2666605 at the dose and regimen declared safe in the dose escalation part.
89376039|NCT04803604|Experimental|Basic social support + communication + Ottawa guide + 1 monthly follow up call|3 in-person/telephone weekly sessions on providing social support, tips for good communication, decision support tools, and a single monthly follow-up call
89376040|NCT04803604|Experimental|Basic social support + communication + Ottawa guide + monthly follow up calls for 24 weeks|3 in-person/telephone weekly sessions on providing social support, tips for good communication, decision support tools, and monthly follow-up calls for 6 months
89376041|NCT04803604|Experimental|Basic social support + communication + 1 monthly follow up call|2 in-person/telephone weekly sessions on providing social support, tips for good communication, and a single monthly follow-up call
89376042|NCT04803604|Experimental|Basic social support + communication + monthly follow up calls for 24 weeks|2 in-person/telephone weekly sessions on providing social support, tips for good communication, and monthly follow-up calls for 6 months
89376043|NCT04803604|Experimental|Basic social support + Ottawa guide + 1 monthly follow up call|2 in-person/telephone weekly sessions on 1 coaching session on providing social support, decision support tools, and a single monthly follow-up call
89376044|NCT04803604|Experimental|Basic social support + Ottawa guide + monthly follow up calls for 24 weeks|2 in-person/telephone weekly sessions on providing social support, decision support tools, and monthly follow-up calls for 6 months
89376045|NCT04803604|Experimental|Basic social support + 1 monthly follow up call|1 in-person/telephone weekly sessions on providing social support and a single monthly follow-up call
89376046|NCT04803604|Experimental|Basic social support + monthly follow up calls for 24 weeks|1 in-person/telephone weekly sessions on providing social support and monthly follow-up calls for 6 months
88848461|NCT06314425|Experimental|Immediate loading of ceramic implants|Tooth/teeth are extracted with minimally invasive approach using piezo surgery and when necessary sectioning after local anesthesia (Articaine 40 mg/mL with epinephrine 10 μg/mL; or Lidocaine 20mg/ml with 10 ug/ml). Extraction sockets are thoroughly degranulated to remove all remnants of soft tissue and residual restorations or material which may have extended beyond the tooth apex. After copious irrigation, the socket condition is recorded, which includes, thickness and location of buccal/facial crestal alveolar bone.
89376047|NCT04803604|Experimental|Advanced social support + communication + Ottawa guide + 1 monthly follow up call|5 in-person/telephone weekly sessions on providing social support, tips for good communication, decision support tools, and a single monthly follow-up call
89376048|NCT04803604|Experimental|Advanced social support + communication + Ottawa guide + monthly follow up calls for 24 weeks|5 in-person/telephone weekly sessions on providing social support, tips for good communication, decision support tools, and monthly follow-up calls for 6
89376049|NCT04803604|Experimental|Advanced social support + communication + 1 monthly follow up call|4 in-person/telephone weekly sessions on providing social support, tips for good communication, and a single monthly follow-up call
89376050|NCT04803604|Experimental|Advanced social support + communication + monthly follow up calls for 24 weeks|4 in-person/telephone weekly sessions on providing social support, tips for good communication, and monthly follow-up calls for 6 months
89376051|NCT04803604|Experimental|Advanced social support + Ottawa guide + 1 monthly follow up call|4 in-person/telephone weekly sessions on providing social support, decision support tools, and a single monthly follow-up call
89376052|NCT04803604|Experimental|Advanced social support + Ottawa guide + monthly follow up calls for 24 weeks|4 in-person/telephone weekly sessions on providing social support, decision support tools, and monthly follow-up calls for 6 months
89376053|NCT04803604|Experimental|Advanced social support + 1 monthly follow up call|3 in-person/telephone weekly sessions on providing social support, and a single monthly follow-up call
89376054|NCT04803604|Experimental|Advanced social support + monthly follow up calls for 24 weeks|3 in-person/telephone weekly sessions on providing social support, and monthly follow-up calls for 6 months
89399359|NCT03538340|Active Comparator|Control Arm|Control Arm: Surgery without intercostal Cryoanalgesia + Standard of Care (thoracic epidural)
89399360|NCT03538340|Experimental|Study Arm|Study Arm: Surgery with intercostal Cryoanalgesia + Standard of Care (thoracic epidural)
88848462|NCT06314412|Experimental|Patients with Multiple Sclerosis|Patients with Multiple Sclerosis
88848463|NCT06314386|Other|Exposed|Clinics are considered exposed after intensive SAIA-TB intervention, implementation phase, and maintenance phase.
88848464|NCT06314386|No Intervention|Unexposed|Clinics are considered unexposed prior to the initiation of SAIA-TB in their clinic
88848465|NCT06314373|Experimental|Dose Escalation|Dose Escalation:Participants will receive escalating doses of HSK39775
89376055|NCT04784052|Experimental|Depleted Stem Cell Transplant with JSP-191 Conditioning|Participants will receive an infusion of donor stem cells which have been depleted of αβ+T cells using the CliniMACS System device. Before the stem cell transplant, they will receive a reduced-intensity preparative regimen containing JSP191 in combination with rATG, cyclophosphamide, fludarabine and rituximab.
89376056|NCT04781153|Experimental|Immediate intervention (A)|Subjects will receive the full mouth disinfection treatment protocol (scaling and rootplaning of all periodontal pockets with adjunctive use of chlorhexidine mouthwash) immediately after baseline.
89376057|NCT04781153|Experimental|Delayed intervention (B)|"Subjects will receive a full mouth disinfection treatment protocol (scaling and rootplaning of all periodontal pockets with adjunctive use of chlorhexidine mouthwash) 3-4 weeks after baseline. The delayed intervention will enable the study team to explore the effect of the participants change in behavior due to participation in a research project, and furthermore how change in oral hygiene habits might affect the lung function."
89376058|NCT04770259|No Intervention|Control|The control group will have a nursing evaluation and then follow the surgeon's instructions in the current standard way until de surgery day. In that day the RN will be evaluate again these group. Then, this group will be followed within the hospital and the first, second and third month after discharge.
89376059|NCT04770259|Experimental|Intervention|The intervention group will have a nursing evaluation and then will attend an evaluation by geriatarics team, kinesiology and nutrition, where a plan of physical cardiovascular, nutritional and metabolic prehabilitation is delivered. On the day of surgery, the RN will evaluate this group again. Then, this group will be followed within the hospital and the first, second and third month after discharge.
89376060|NCT04760405|Experimental|Tai Chi Easy Intervention|Tai Chi Easy: TCE is a standardized protocol used in several prior studies. TCE has been manualized and has a formal training program for instructors. The protocol is taught as a series of repeated and simple-to-learn movements. Patients will receive two 30-minute small group training sessions (Via Zoom) within 7 days of their scheduled transplant. After the training has been completed the participant will be provided with written (via manual) and electronic (DVD, MP3 file download) materials to continue with self-direct practice throughout the duration of the study.
89376061|NCT04754139|Experimental|WeChat mobile mini-application|WeChat mini-application will increase knowledge base about sexual health through interactive health education and counseling support on HIV/STI prevention as well as PrEP initiation and/or adherence management.
89376062|NCT04749888|Experimental|Targeted nurse-led home visiting|The intervention group will receive 25-29 home visits during pregnancy and the first 2 years of life conducted by child health nurses. The frequency of home visits will be determined by nurses based on the needs of the families. The content of each home visit is individually tailored to the mother's needs, skills, strengths, and capacity using parenting education materials.
89376063|NCT04749888|No Intervention|Control group|The control group will receive existing maternal and child health services (usual care) except for the targeted nurse-led home visits.
89376064|NCT04749524||Newborns|Otoacoustic Emissions to be measured with and without suppression noise
89376065|NCT04749524||Newborns failing initial hearing screening test|Otoacoustic Emissions to be measured with and without suppression noise
89376066|NCT04749524||Adults with normal hearing|Otoacoustic Emissions to be measured with and without suppression noise
88848466|NCT06314373|Experimental|Cohort Expansion|Cohort Expansion:Participants will receive HSK39775 at the identified RP2D
89376067|NCT04749524||Adults with hearing loss|Otoacoustic Emissions to be measured with and without suppression noise
88848467|NCT06314360||Subjects with Patellofemoral Pain|Demographic data, pain information, limb dominancy will be collected. Then, functional status will be assessed with Kujala Patellofemoral Pain Form; foot posture will be evaluated with Foot Posture Index; plantar pressure and postural balance values will be collected with the K-Invent K-Plates device.
88848468|NCT06314360||Healthy Control Subjects|Demographic data, limb dominancy will be collected. Then, functional status will be assessed with Kujala Patellofemoral Pain Form; foot posture will be evaluated with Foot Posture Index; plantar pressure and postural balance values will be collected with the K-Invent K-Plates device.
88848469|NCT06314334|Experimental|Group A (synchronous treatment group)|Patients received 4 cycles of Sintilimab combined with pegaspargase therapy, with each cycle lasting 3 weeks, for a total of 4 cycles. Concurrently, they received radiotherapy treatment (IMRT, 50-56Gy, starting within 21 days after the first Sintilimab treatment).
88848470|NCT06314334|Experimental|Group B (sequential treatment group)|Patients received 4 cycles of the PGEMOX regimen chemotherapy. Each cycle lasted 3 weeks, with sequential radiotherapy (IMRT, 50-56Gy) administered within 4 weeks after the last chemotherapy cycle.
88848471|NCT06314334|Experimental|Group C (sandwiched radiotherapy group)|Patients received 2 cycles of the GELAD regimen chemotherapy initially, with each cycle lasting 3 weeks. After the second cycle of chemotherapy, radiotherapy (IMRT, 50-56Gy) was administered within 4 weeks. Following the completion of radiotherapy, they received an additional 2 cycles of the GELAD regimen chemotherapy.
89535050|NCT01375075|Active Comparator|10 mg Atorvastatin|Administered orally once daily for 12 weeks
89535051|NCT01375075|Experimental|100 mg LY2484595 + 10 mg Atorvastatin|Administered orally once daily for 12 weeks
89181841|NCT00770432|Placebo Comparator|Placebo|MALTRIN 500® M500 (maltodextrin 500)
89181842|NCT00792701|Experimental|Arm II|Beginning within 84 days after surgery, patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and cisplatin IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
89376068|NCT04715048|Experimental|Onabotulinumtoxin A|8-10 units of Botox will be injected in the glabellar lines in one side of the face in 3 different locations. This injection will happen once.
89376069|NCT04715048|Experimental|Prabotulinumtoxin A|8-10 units of Jeuveau will be injected in the glabellar lines in the other side of the face in 3 different locations. This injection will happen once.
89535052|NCT05022381|Other|Preoperative and Postoperative Pain Level|The preoperative pain level, hip function and quality of life of patients who underwent radiofrequency thermocoagulation to the articular branches of the femoral and obturatory nerve in chronic hip pain will be compared with the postoperative pain level, hip function and quality of life of these patients.
88848475|NCT06314256|Active Comparator|Injectable PRF|i-PRF is produced by cenrifugation of patients own blood. Injection of 0.1-0.2 ml per interdental papilla 2 times with 3-week interval.
88848476|NCT06314256|Active Comparator|Hyaluronic Acid|"Teosyal® Global Action PureSense. Composition: Cross-linked hyaluronic acid (HA): 25 mg/ml Lidocaine; 0,3%, (injection).~Injection of 0.1-0.2 ml per interdental papilla 2 times with 3-week interval."
88848477|NCT06314243|Experimental|Pumpkin Seed Oil group|"Group 1 (Pumpkin Seed Oil group): consists of 28 patients who will receive one capsule containing 1010 mg PSO once daily for 12 weeks,  Ronkin®, KMT PHARMA, Egypt. "
88848478|NCT06314243|No Intervention|Control group|Group 2 (Control group): consists of 28 patients who will not receive the intervention.
88848479|NCT06314035|Experimental|Experimental Group|Participants in experimental group will receive a COPD Decision Support Tool (PDA intervention).
88848480|NCT06314035|Placebo Comparator|Attention Control Placebo Group|Participants in the attention control placebo group will receive a general health coaching intervention. Dose and time similar to experimental group.
88848481|NCT06314022|No Intervention|Control group|which receives the standard information given in writing,
88848482|NCT06314022|Experimental|APP group|Group which receives the standard information together with the mobile application individually adapted to the scheduled colonoscopy appointment and the type of laxative.
88848483|NCT06313008|Experimental|Empagliflozin|Eligible subjects were randomly and equally assigned to the empagliflozin add-on group (empagliflozin 10 mg/ day).
88848484|NCT06313008|Experimental|Vildagliptin|60 patients recieved vildagliptin as add-on group (vildagliptin 50 mg/day as the initial dose).
88848485|NCT06312930|Experimental|Real TPS group|"Healthy adults aged 18-65 years old will receive one single session of real TPS on the primary motor cortex.~Before and after TPS, participants will perform two visuomotor tasks (a simple reaction time task and a nine-hole peg test).~The stimulation target on the primary motor cortex will be determined by transcranial magnetic stimulation (TMS). Measurements of the resting motor threshold by TMS will be conducted for each participant before the real TPS session."
88848486|NCT06312930|Sham Comparator|Sham TPS group|"Sham stimulation comprises TPS on the vertex as the control region (sham control).~Stimulation duration, intensity, as well as pre- and post stimulation assessments are the same as in the experimental arm.~In this cross-over study, the order of the real and sham stimulation conditions will be randomized and separated by 24 hours."
88848487|NCT06312735|Experimental|Intervention group|Four-week, at-home VR intervention with a recommended daily use of 10-30 minutes
88848488|NCT06312735|No Intervention|Control group|No intervention, patient is a waiting-list control
88848489|NCT06312683|Experimental|All Participants|550 mg Rifaximin (Xifaxan) twice a day x 365 days
88848490|NCT06312553|Experimental|Experimental: Remotely delivered Mindfulness-Based Diabetes Education with remote patient monitoring|"The Mindfulness-Based Diabetes Education (MBDE) program will be delivered in 8, 2-hour weekly sessions, then 2 booster sessions, total duration of 6 months. MBDE will be delivered over Zoom with content delivered by the interventionist per the program manual. Participants will be provided with a tablet and WIFI hotspot. Sessions will be video-recorded and made available to participants in case of missed sessions.~Once randomized, participants will receive a glucometer and test strips; supplies will be delivered to their homes within 7 days of randomization. Study team will review the use of the device. Participants will be instructed to monitor blood glucose 4 times a day. Data collected will be transmitted electronically to the remote patient monitoring system and monitored from 8 a.m. to 5 p.m. on weekdays. Data summaries will be reviewed bimonthly, and clinical summaries will be sent to clinicians."
88848491|NCT06312553|Active Comparator|Standard Diabetes Self Management Education|Standard DSME will be delivered by a certified diabetes educator in four biweekly sessions of 2 hours duration; topics will include healthy eating, physical activity, medication usage, self-monitoring, preventing and managing complications, healthy coping, and problem solving.18 Standard DSME will be delivered in groups of 8-12 participants via Zoom.
88848492|NCT06312319|Experimental|Respiratory training added to orofacial exercises|Home-based respiratory training of the inspiratory and expiratory muscles using a device added to standard treatment including orofacial exercises.
88848493|NCT06312319|Active Comparator|Orofacial exercises|Standard treatment including orofacial exercises.
89376070|NCT04701151|Experimental|Intervention|"Study Subjects randomized to the interventional arm will be assigned to BCG induction therapy once-weekly for 6 weeks and subsequent 1 year of maintenance (6+3x3) of which dwell-time during the first of the 6 induction instillations is 2 hours.~If side effects are registered before the second and all further instillations, Study Subject in the intervention arm will be reduced in dwell-time according to the grading of side effects as given by the study algorithm."
88848496|NCT06312150|Other|Patients with tumour (age 0-20 years)|Patients affected by Wilms' tumour, Ewing's Sarcoma, Osteosarcoma, Soft tissue sarcomas, Carcinomas, Neuroblastoma age between 0-20 years
88848497|NCT06312150|Other|Patients with tumour (age 0-75 years)|Patients affected by Ewing's Sarcoma, Neuroblastoma, Paediatric leukaemia, Breast, lung, colon and ovarian cancers between 0-75 years
88848498|NCT06312150|Other|Control Patients group|Patients underwent their diagnostic pathway, which made it possible to exclude the presence of any ongoing pathological process
88848499|NCT06312098||no-remote ischemic preconditioning group|patients who did not receive remote ischemic preconditioning
88848500|NCT06312098||paired remote ischemic preconditioning group|patients who receive remote ischemic preconditioning
88848501|NCT06311253|Experimental|Trial group|
88848502|NCT06311253|Active Comparator|Control group|
89376071|NCT04701151|Active Comparator|Control|The Study Subjects will be treated according to guidelines with BCG instillation therapy once weekly for 6 weeks and subsequent 1 year of maintenance therapy (6+3x3) with 2 hours of dwelltime.
88848504|NCT06311136|Experimental|Intervention group|"Participants complete a valence-specific ecological momentary intervention twice daily over 14 consecutive days.~The ecological momentary intervention is presented as the Positive Everyday Affect Knowledge (PEAK) diary and includes valence-specific emotion regulation strategy instructions. Participants receive reminders to complete surveys on their strongest emotions since the last assessment. Depending on the valence of this emotion, they receive instructions on how to use the strategy savoring (for positive emotions) or reappraisal (for negative emotions)."
88848505|NCT06311136|No Intervention|Monitoring-only control group|"Participants complete a valence-specific ecological momentary assessment twice daily over 14 consecutive days.~The ecological momentary assessment is presented as the Positive Everyday Affect Knowledge (PEAK) diary, and only involves monitoring participants' emotional experiences and regulation. Participants receive reminders to complete surveys on their strongest emotions since the last assessment. Depending on the valence of this emotion (positive versus negative), they are asked about their emotion regulation strategies."
88848506|NCT06310824|Experimental|MAB-22|Single subcutaneous injection on Day 1
88848507|NCT06310824|Active Comparator|EU-Prolia®|Single subcutaneous injection on Day 1
88848508|NCT06310824|Active Comparator|US-Prolia®|Single subcutaneous injection on Day 1
88848509|NCT06310733|Experimental|LGG (ATCC 53103)|A suspension of freeze-dried LGG ATCC53103 in excipients in an aqueous solution supplied in a 10-mL dark bottle with a delivery cap.
88848510|NCT06310733|Placebo Comparator|Placebo|An identical aqueous solution in appearance and taste but without LGG.
88848511|NCT06310421||Screening group|The patient enrollment takes place at the Neonatology Unit of the Institute for Maternal and Child Health Burlo Garofolo and at the Pediatrics Unit of the Gorizia-Monfalcone Hospital, which are the only two birth centers in the area of the Giuliano-Isontina University Health Authority
88848512|NCT06310382|Experimental|GH55 GROUP|
88848513|NCT06310356|Experimental|continuous glucose monitoring|continuous use of realtime-continuous glucose monitoring with Freestyle Libre 3
88848514|NCT06310356|Active Comparator|self monitoring of blood glucose with glucometer|self monitoring of blood glucose with glucometer, at least 2 days per week if treated with lifestyle and daily if additional treatment with insulin is started
89376072|NCT04685590|Experimental|Treatment|Dasatinib (D) is given as (1) 100mg capsule daily for 2 consecutive days (Sprycel®, Bristol Myers Squibb). Quercetin (Q) will be given as (4) 250 mg capsules daily (total 1000 mg daily) for the same 2 consecutive days (Thorne Research). Both are administered orally.
88848517|NCT06309355|Experimental|Active dose|The intervention is YR001 ointment on a range of body surface area for multiple topical administration
88848518|NCT06309355|Experimental|Placebo dose|The intervention is Placebo on a range of body surface area for multiple topical administration
88848519|NCT06309186||Midwives|The study involves a convenience sample of midwives registered with the two Orders of the Midwifery Profession in Friuli-Venezia Giulia Region (Italy)
88848520|NCT06309147|Experimental|50 mg Active|50mg BID
88848521|NCT06309147|Experimental|100mg Active|100mg BID
88848522|NCT06309147|Placebo Comparator|Matching Placebo|50 and 100 mg matching placebo
88848523|NCT06309121|Placebo Comparator|Active control|Participants in this arm will receive the usual treatment for obesity at our hospital, based on lifestyle changes (encouraging a healthy diet and physical activity) for 3 months. Participants will receive a daily dose of placebo for these 3 months, then given the option to receive a daily dose of probiotic ABB C3 for 3 more months.
88848524|NCT06309121|Experimental|Treatment|Participants in this arm will receive the usual treatment for obesity at our hospital, based on lifestyle changes (encouraging a healthy diet and physical activity) for 3 months. Participants will receive a daily dose of postbiotic blend (ABB C3) for these 3 months, then given the option to receive a daily dose of probiotic ABB C3 for 3 more months.
88848525|NCT06308497|Experimental|Trial Group|Patients within this group will undergo probiotic supplementation in addition to standard treatment
88848526|NCT06308497|Active Comparator|Control Group|Patients within this group will undergo standard treatment
88848527|NCT06305754|Experimental|MK-2870|Participants receive 4 mg/kg MK-2870 via intravenous (IV) infusion every 2 weeks (Days 1, 15, and 29 of every 6-week cycle) until discontinuation criteria is met.
88848528|NCT06305754|Active Comparator|Pemetrexed Plus Carboplatin|Participants receive, via IV infusion, 500 mg/m2 pemetrexed every 3 weeks (Days 1 and 22 of every 6-week cycle) plus area under the curve (AUC) 5 mg/mL*min carboplatin every 3 weeks (Days 1 and 22 of every 6-week cycle for 4 doses), then 500 mg/m2 pemetrexed every 3 weeks until discontinuation criteria is met.
88848529|NCT06304844||diabetic without MAFLD|patients with type 2 DM but has no evidence of MAFLD
88848530|NCT06304844||diabetic with MAFLD (high hepatic involvement)|patients with type 2 DM and have evidence of MAFLD (according to abdominal ultrasonography) and have high controlled attenuation parameter and liver stiffness measurement in Fibroscan
88848531|NCT06304844||diabetic with MAFLD (low hepatic involvement)|patients with type 2 DM and have evidence of MAFLD (according to abdominal ultrasonography) and have low controlled attenuation parameter and liver stffiness measurement in Fibroscan
88848532|NCT06304064|Experimental|Allogeneic Cardiosphere-Derived Cells (CAP-1002)|All participants who were randomized to the Usual Care Treatment Group and completed 12 months of follow-up in the HOPE-Duchenne trial (NCT02485938), will receive CAP-1002 intravenous infusion on Day 1 and at Month 3 in the current study.
88848533|NCT06303609|Experimental|Radiofrequency group|Once a week, for 8 weeks, patient will undergo monopolar non-ablative radiofrequency application by a trained researcher.
88848534|NCT06303609|Active Comparator|Sham group|Once a week, for 8 weeks, patient will undergo monopolar non-ablative radiofrequency application by a trained researcher, but the radiofrequency device will not emit the radiofrequency wave.
88848535|NCT06303349|Experimental|experimental arm|"Patients with subarachnoid hemorrhage, whether aneurysmal or non-aneurysmal, who were admitted to the neuro-resuscitation unit within four days of onset.~Diagnosis was based on clinical presentation and confirmed by brain imaging"
89376073|NCT04685590|Placebo Comparator|Placebo|Matching placebo capsules following the same administration protocol as the experimental treatment - administered once daily (1st dose of each cycle will be given, supervised, at the clinic visit; the 2nd dose will be taken at home) for 2 consecutive days followed by a 13-day (+/- 2 day) no-drug period for 12 consecutive weeks for 6 rounds of administration.
89376074|NCT04648202|Experimental|FS120|Open-label study where FS120 will be administered as monotherapy or in combination with pembrolizumab in dose escalation and expansion cohorts
89376075|NCT04644172|Experimental|Immediate Treatment|The treatment will have 3 components. The first component, Speed of Processing Training, is a computer game. Participants identify targets on the screen as rapidly as possible. The second component is training following shaping principles on simulated instrumental activities of daily living (IADL), such as making a telephone call or generating a shopping list, in the treatment setting. Shaping involves progressively increasingly the complexity of a task in incremental steps as a participant gains mastery. Frequent, positive feedback is another important aspect of shaping. The third component is a set of psychological techniques that will help participants apply the improvements from the game to carrying out tasks that rely on thinking in their daily
89376076|NCT04644172|Other|Delayed Treatment|Participants in this arm will receive testing on the same schedule as the Immediate Treatment up to six-month followup. Delayed Treatment participants will not receive any treatment from the study during this period but will permitted to receive any healthcare that is available on a clinical basis. After six-month followup, participants in this arm will be crossed over to receive the experimental treatment.
89376077|NCT04634240|Experimental|Complete Revascularization|Routine PCI (percutaneous coronary intervention) of all suitable coronary artery stenoses of ≥70% in vessels ≥2.5mm in diameter.
89376078|NCT04634240|No Intervention|Medical Therapy Alone|No revascularization of coronary artery lesions.
89376079|NCT04631484|Experimental|Cytoflavin ((Inosine + Nicotinamide + Riboflavin + Succinic Acid)|Patients will receive treatment with the study drug, 20 ml twice a day IV, dissolved in 200 ml of 0.9% NS, for 10 days;patients will stay in the hospital for the the entire period of therapy. Observation of patients and assessment of the main parameters of the efficacy and safety will continue for 14 days.
89376080|NCT04631484|Placebo Comparator|Placebo|Patients will receive 20 ml placebo (0.9% sodium chloride solution) twice a day IV, dissolved in 200 ml of 0.9% NS, for 10 days; patients will stay in the hospital for the the entire period of therapy. Observation of patients and assessment of the main parameters of the efficacy and safety will continue for 14 days.
89376081|NCT04630418|Experimental|NanoSilk Cosmo|Participants will receive a 30 mL jar of NanoSilk Cosmo
89376082|NCT04578535|Experimental|Part 1 Schedule A: TA 1 (Low TDL HYQVIA)|Participants received a subcutaneous (SC) infusion of HYQVIA 0.1 g/kg (1/4 of TDL) on Day 1 and 8, 0.2 g/kg (1/2 of TDL) on Day 15, 0.3 g/kg (3/4 of TDL) on Day 29 followed by 0.4 g/kg (full TDL) on Day 50 in Ramp-Up dosing manner.
89376083|NCT04578535|Experimental|Part 2 Schedule A: TA 4 (High TDL HYQVIA)|Participants received a SC infusion of HYQVIA 0.25 g/kg (1/4 of TDL) on Day 1 and 8, 0.5 g/kg (1/2 of TDL) on Day 15, 0.75 g/kg (3/4 of TDL) on Day 29 followed by 1.0 g/kg (full TDL) on Day 50 in Ramp-Up dosing manner.
89376084|NCT04578535|Experimental|Part 1 Schedule B: TA 2 (Low TDL HYQVIA)|Participants received a SC infusion of HYQVIA 0.2 g/kg (1/2 of TDL) on Day 1 and 15, followed by 0.4 g/kg (full TDL) on Day 29 and 57 in Ramp-Up dosing manner.
89376085|NCT04578535|Experimental|Part 2 Schedule B: TA 5 (High TDL HYQVIA)|Participants received a SC infusion of HYQVIA 0.5 g/kg (1/2 of TDL) on Day 1 and 15, followed by 1.0 g/kg (full TDL) on Day 29 and 57 in Ramp-Up dosing manner.
89376086|NCT04578535|Experimental|Part 1 Schedule C: TA 3 (Low TDL HYQVIA)|Participants received a SC infusion of HYQVIA 0.4 g/kg (full TDL) SC infusion on Day 1, 29 and 57 without Ramp-Up dosing manner.
89376087|NCT04578535|Experimental|Part 2 Schedule C: TA 6 (High TDL HYQVIA)|Participants received a SC infusion of HYQVIA 1.0 g/kg (full TDL) SC infusion on Day 1, 29 and 57 without Ramp-Up dosing manner.
89376088|NCT04577573|Active Comparator|No cognitive feedback|Perform task without cognitive feedback.
89376089|NCT04577573|Active Comparator|Intermediate feedback.|Perform task with intermediate feedback.
89376090|NCT04577573|Experimental|Enhanced feedback|Perform task with virtual reality and/or haptic feedback.
89376091|NCT04574362|Active Comparator|Rimegepant 75mg|One 75mg oral disintegration tablet
88848536|NCT06303284|Experimental|Teriparatide|20 µg subcutaneous Teriparatide injection once daily for 3 months in the post-operative ankle fracture population.
88848537|NCT06303284|Sham Comparator|placebo|20 µg subcutaneous saline placebo injection once daily for 3 months in the post-operative ankle fracture population.
89376092|NCT04574362|Placebo Comparator|Placebo|Matching placebo
89376093|NCT04566887|Experimental|Acalabrutinib with R-CHOP chemotherapy|Acalabrutinib 100mg twice per day orally with standard of care R-CHOP chemotherapy by IV every 21 days for a maximum of six cycles.
88848538|NCT06302712|Experimental|Intervention|
88848539|NCT06302712|No Intervention|TAU|
89376094|NCT04564027|Experimental|Cohort A|Eligible participants (ATM altered AST), will receive oral dose of Ceralasertib as monotherapy.
89376095|NCT04564027|Experimental|Cohort B|Eligible participants (ATM altered mCRPC), will receive oral dose of Ceralasertib as monotherapy.
88848542|NCT06297577|Experimental|Albumin Platelet Rich Fibrin (Alb-PRF)|For the production of Alb-PRF membrane, two 10 ml vacuum plastic tubes will be centrifuged at 700 g for 8 minutes. After centrifugation, the upper layer (yellow layer) shows the liquid plasma layer. The most upper layer of platelet-poor plasma (PPP) will be collected in a syringe and then will be heated in a heat block device at 75°C for 10 minutes to create denatured albumin (albumin gel). After heating, the albumin gel will be cooled to room temperature for approximately 10 minutes. An injectable albumin gel was then prepared. The liquid platelet-rich layer (liquid-PRF), including the buffy coat layer with accumulated platelets, leukocytes and growth factors, will be collected in a separate syringe and will be reserved at room temperature (20°C). The albumin gel and liquid PRF will be then thoroughly mixed by utilizing a female-female luer lock connector
88848543|NCT06297577|Active Comparator|Platelet Rich Fibrin (PRF)|Cubital venous blood will be drawn from the patient w into 10 ml vacuum tubes and immediately will be centrifuged at 700g for 8 minutes, then will be allowed to rest for 5 minutes in PRF dish. The PRF'clot' still in gel condition will be removed from the tube, cleaned of red blood cells and then placed in intrabony defect .
89376096|NCT04562896|No Intervention|No Device|Participants will be evaluated without a CDO.
89376097|NCT04562896|Experimental|CDO-A|The first design variant will be designated CDO-A
89376098|NCT04562896|Experimental|CDO-B|The second design variant will be designated CDO-B
89376099|NCT04562896|Experimental|CDO-C|The third design variant will be designated CDO-C
89376100|NCT04562688|Experimental|Arm A|Participants assigned to Arm A will engage in CICADAS app only for the first 16 weeks of the intervention period. After the completion of the first intervention period and the mid-intervention assessment (V3) visit, these participants will then be assigned to the PEERS only group for the second 16 weeks of the intervention period. Participants will be asked to attend weekly 1-hour group sessions led by a PEERS clinician.
89376101|NCT04562688|Experimental|Arm B|Participants assigned to Arm B will engage in PEERS + CICADAS for the first 16 weeks of the intervention period. After the completion of the first intervention period and the mid-intervention assessment (V3) visit, these participants will then be assigned to No-Contact (no active intervention) for the second 16 weeks of the intervention period.
89376102|NCT04562688|Experimental|Arm C|Participants assigned to Arm C will engage in PEERS + Active Comparator for the first 16 weeks of the intervention period. After the completion of the first intervention period and the mid-intervention assessment (V3) visit, these participants will then be assigned to No-Contact (no active intervention) for the second 16 weeks of the intervention period.
88848544|NCT06296433|Experimental|VR rehabilitation treatment|Daily use of VR rehabilitation program independently at home for a period of 3 weeks. Each daily session is 20 minutes.
88848545|NCT06296433|Placebo Comparator|VR control treatment|Daily watching 2D video independently at home using VR headset for a period of 20 minutes.
88848546|NCT06296277||Intraoperative mechanical ventilation|Patients subjected to invasive mechanical ventilation (IMV) during general anesthesia for surgery
88848547|NCT06294223|Experimental|Measurement of Upper Extremity Muscle Oxygenation|Measuring muscle oxygenation with fatigue protocol.
88848548|NCT06293963|Experimental|Numerical label|
88848549|NCT06293963|Experimental|Interpretive text-only label|
88848550|NCT06293963|Experimental|Interpretive magnifying glass icon label|
88848551|NCT06293963|Experimental|Separated interpretive magnifying glass icon label|
88848552|NCT06293937|Experimental|Numerical label|
88848553|NCT06293937|Experimental|Interpretive text-only label|
88848554|NCT06293937|Experimental|Interpretive magnifying glass icon label|
88848555|NCT06293937|Experimental|Separated interpretive magnifying glass icon label|
88848556|NCT06289725||patients with genotype B|
88848557|NCT06289725||patients with genotype C|
88848558|NCT06288867|Active Comparator|Labral Repair|Labral tears will be repaired with suture anchors.
88848559|NCT06288867|Active Comparator|Labral Debridement|Labral Debridement will be done by electrocautery
88848560|NCT06288477|Active Comparator|full-strength FC|Formocresol pulpotomy is one of the most common procedure in cases of mechanical and carious exposure in primary teeth.
88848561|NCT06288477|Experimental|Neo-Putty®|Neo-Putty® as dressing agents in pulpotomized primary molars. NeoPUTTY® is composed of extremely fine inorganic tricalcium/dicalcium silicate powders in a water-free organic liquid and contains tantalum oxide as the radiopacifying agent.
88848562|NCT06288451|Experimental|Low dose oral calcitriol|
88848563|NCT06288451|Active Comparator|Usual care|
88848564|NCT06286280|Experimental|Cytosorb group|Use of hemoadsorber for removal of cytokines. Participants undergoing cardiac surgery will be treated using a hemoadsorption device (CytoSorb) within the cardiopulmonary Bypass circuit (=Intervention)
88848565|NCT06286280|No Intervention|Control group|Participants undergoing cardiac surgery will be treated according to Standard of care (no hemoadsorption advice installed in the CPB circuit)
88848566|NCT06285357|No Intervention|control|
88848567|NCT06285357|Experimental|treatment|
88848568|NCT06285240|Experimental|MK-1167|Participants receive 6 mg MK-1167 oral loading doses once daily (QD) Days 1 to 7, followed by 3 mg MK-1167 oral maintenance doses QD Days 8 to 21. Participants also receive 10 mg oral Donepezil on Days -3 to 21.
88848569|NCT06285240|Placebo Comparator|Placebo|Participants receive placebo to MK-1167 oral QD from Days 1 to 21. Participants also receive 10 mg oral Donepezil QD on Days -3 to 21
88848570|NCT06283784|Experimental|Yovis Capsules|YOVIS, the Investigational Food Supplement (IFS), is an oral formulation (capsules) containing definite mix of live probiotics already marketed by Alfa-Sigma as food supplement since September 2017. it is administered to 50 patients 10 consecutive days (1 capsule once daily) with a drop of water, preferably without food.
88848571|NCT06283784|Placebo Comparator|Placebo|Placebo is an oral formulation of inert capsules. it is administered to 50 patients 10 consecutive days (1 capsule once daily) with a drop of water, preferably without food.
88848572|NCT06278285|Other|whole blood in a GLP1|Oxytocyne assay in a GLP1 analogue or non-analogue patient population
88848573|NCT06278285|Other|whole blood in non analague patient population|Oxytocyne assay in a GLP1 analogue or non-analogue patient population
89376103|NCT04551521|Experimental|BRAF V600E/K|
89376104|NCT04551521|Experimental|ERBB2|
89376105|NCT04551521|Experimental|ALK|
89376106|NCT04551521|Experimental|AKT/PTEN|
89376107|NCT04551521|Experimental|PI3K|
89376108|NCT04551521|Experimental|MAPK|
89376109|NCT04551521|Experimental|Immune evasion|
89376110|NCT04545762|Experimental|Treatment Regimen|"Apheresis (1 day): Autologous lymphocytes/ mononuclear cell collection will be collected through standard apheresis procedures as per University of California, San Francisco (UCSF) institutional practices~CAR-T cell manufacturing (estimated ~13-14 days)~Lymphodepleting chemotherapy: 3 days of immunosuppressive chemotherapy. Cyclophosphamide given at a dose of 300 mg/m2/IV and fludarabine given at 30 mg/m2 /IV on days -5, -4, and -3.~CAR-T cell infusion (1 day): The infusion of CAR-T cells targeting CD19 will occur over 5-30 minutes."
89376111|NCT04536584|Experimental|Arm A: personalized coaching for physical activities|This arm consists of providing patients with a personalized coaching focused on exercise and physical activity, with or without connected watch.
89535053|NCT00706433|Active Comparator|ALA 1000 seconds|Aminolevulinic acid HCL (ALA) applied to the entire facial area 45 minutes prior to BLUE light treatment for 1000 seconds (16 minutes and 40 seconds)
88848574|NCT06278025||patients with dysphagia (study)|In the modified barium swallowing study, liquid in the amount of 5 ml was used because it is the optimal amount to monitor physiological events during swallowing . The Penetration Aspiration Scale (PAS) was used to determine the dysphagia severity. The PAS is an 8-point scale describing the degree and nature of laryngeal penetration and aspiration, where a score of 1 refer to 'No penetration or aspiration- No entry of material into the airway', and 8 refer to 'Airway aspiration- Material enters the trachea with no attempt to clear'. According to the MBSS, patients who received a PAS score of 1 were included in the group without dysphagia (control group), and those received a PAS score between 2 and 8 were included in the group with dysphagia (study group).
89376112|NCT04536584|Active Comparator|Arm B: standard supportive approach|The standard supportive approach will consist in recommendations made during visits with the oncologist. The delivery of post-treatment care by oncologists and their team systematically provide exercise advice patients including recommendations for strength training and aerobic activity.
89376113|NCT04522973|Other|Within group four condition comparison|On four separate occasions, participants will come to the research center and complete one of the four conditions. All participants will complete all four study conditions. Sessions will be ordered by Latin-square. Participants will not be assigned to arms based on session order and session order will not be recorded as it is not relevant to the study outcomes.
89376114|NCT04521608|Experimental|Intervention- Home Pulmonary Rehabilitation|Participants enrolled in the intervention arm will be offered a Home-based pulmonary rehabilitation program with health coaching.
89376115|NCT04521608|No Intervention|Control- Choice|This arm receives the standard of care which includes the choice of PR at a facility or through telehealth. Center based PR involves attending a medical center gym where they can do exercises and receive disease specific education. Telehealth PR is delivered virtually through the computer or telephone.
89376116|NCT04484077|Experimental|hCT-MSC infusion|A single, intravenous infusion of hCT-MSCs. Targeted dose is 2x10^6 cells/kg with a maximum dose of 10 x 10^7 cells/kg.
89376117|NCT04477785||Clinical Observation|In PPMI Clinical up to 4,500 participants will be enrolled and followed longitudinally once identified, over the course of 5-8 years.
89376118|NCT04470908|Experimental|Zanubrutinib + Rifabutin|"Day 1: zanubrutinib~Days 3 to 10: rifabutin~Day 11: zanubrutinib and rifabutin"
89376119|NCT04458038|Experimental|intervention arm|
89376120|NCT04451044|Experimental|physiologically-guided arm|Physiologically-guided PCI using the Philips SyncVision system for determining the PCI strategy
88848575|NCT06278025||patients without dysphagia (control)|In the modified barium swallowing study, liquid in the amount of 5 ml was used because it is the optimal amount to monitor physiological events during swallowing . The Penetration Aspiration Scale (PAS) was used to determine the dysphagia severity. The PAS is an 8-point scale describing the degree and nature of laryngeal penetration and aspiration, where a score of 1 refer to 'No penetration or aspiration- No entry of material into the airway', and 8 refer to 'Airway aspiration- Material enters the trachea with no attempt to clear'. According to the MBSS, patients who received a PAS score of 1 were included in the group without dysphagia (control group), and those received a PAS score between 2 and 8 were included in the group with dysphagia (study group).
88848576|NCT06277596|Experimental|Supervise clinical Pilates group|Clinical Pilates exercises will be performed 10 repetitions, 3 days a week, for 6 weeks, under the supervision of a physiotherapist. The exercise program will be progressed as basic stabilization exercises in the first 3 weeks, advanced stabilization exercises in the last 3 weeks, as recommended in the literature, and a 30-second rest will be given between sets.
88848577|NCT06277596|Active Comparator|Clinical Pilates as home exercise|The same exercises will be shown to the home exercise group and it will be ensured that they are performed correctly. Patients will be given an illustrated and descriptive exercise program brochure containing information about exercise position, number of repetitions, contraction duration, rest time between sets, frequency, and an exercise diary for exercise tracking. In the 3rd week, new exercises will be shown to individuals. It will be applied 10 times, 3 days a week, for 6 weeks. The exercise program will be progressed as basic stabilization exercises in the first 3 weeks, advanced stabilization exercises in the last 3 weeks, as recommended in the literature, and a 30-second rest will be given between sets.
89376121|NCT04451044|Active Comparator|angiographically-guided arm|Standard of care angiographically-guided PCI for determining the PCI strategy
89376122|NCT04439149|Experimental|Treatment (GSK2636771)|Patients receive PI3K-beta inhibitor GSK2636771 PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89376123|NCT04419766|Experimental|intervention|Community of Tambai: Indoors and outdoors spraying with IR3535 (3-(N-acetyl-N-butyl) aminopropionic acid ethyl ester)
88848578|NCT06273397|Active Comparator|Furosemide alone|Active comparator arm with intravenous furosemide dosing based on glomerular filtration rate (protocol).
88848579|NCT06273397|Experimental|Acetazolamide plus Furosemide|Experimental arm number 1 corresponds to oral acetazolamide 250mg (once daily) in combination with furosemide according to the protocol.
88848580|NCT06273397|Experimental|Metolazone plus Furosemide|Experimental arm number 2 corresponds to oral metolazone 2.5mg (once daily) in combination with furosemide according to the protocol.
89376124|NCT04419766|No Intervention|Control|Community of Micheu 1: Without spraying.
89376125|NCT04417530|Experimental|Cohort 1 AU-011 & Laser|Low dose of AU-011 + 1 laser application
89376126|NCT04417530|Experimental|Cohort 2 AU-011 & Laser|Medium dose of AU-011 + 1 laser application
89376127|NCT04417530|Experimental|Cohort 3 AU-011 & Laser|Medium dose of AU-011 + 2 laser applications
89376128|NCT04417530|Experimental|Cohort 4 AU-011 & Laser|Highest tolerated dose of AU-011/laser applications from Cohorts 1 to 3 administered weekly for 2 treatments
89376129|NCT04417530|Experimental|Cohort 5 AU-011 & Laser|AU-011/laser applications from Cohorts 1 to 3 administered weekly for 3 treatments. Up to 2 cycles of this regimen may be administered and subjects have the option of receiving a third cycle of treatment.
89376130|NCT04417530|Experimental|Cohort 6 AU-011 & Laser|High dose of AU-011/laser applications administered weekly for 3 treatments and up to 3 cycles of treatment.
89376131|NCT04416633|Other|Durvalumab|Single arm, Durvalumab , IV
89376132|NCT04413266|Active Comparator|Curcumin for CKD|Administration of 3 capsules with 500mg of curcumin and piperine per day, for 12 weeks
89181843|NCT03772353|Experimental|Dalpiciclib combined with Pyrotinib and Endocrine therapy|"Data from phase Ib showed the triplet of pyrotinib, SHR6390, and letrozole had an acceptable safety profile and encouraging efficacy, potentially offering a chemotherapy-sparing treatment option for patients with HER2-positive/HR-positive MBC. Based on DLTs and clinical efficacy, pyrotinib 320mg/d, SHR6390 125mg/d, and letrozole 2.5mg/d was declared as RP2D. The pharmacokinetic analysis had not yielded conclusive results and would involve more samples in phase II trial.~Dalpiciclib combined with Pyrotinib and Endocrine therapy (treatment of physician's choice: letrozole or fulvestrant) ER+/HER2+ metastatic breast cancer patients eligible for first- or second-line treatment were enrolled to receive dalpiciclib combined with pyrotinib and endocrine therapy (treatment of physician's choice: letrozole or fulvestrant)"
88848583|NCT06271434|Experimental|Supplemented|"(n = 15), who will receive one capsule of a supplement called THYROX (Atlantic krill oil) four times a day. The daily content of krill oil is 2000 mg, including omega-3 fatty acids 350 mg, EPA - 240 mg, DHA - 110 mg, phospholipids - 800 mg, astaxanthin 200 mg.~The supplementation period will be six weeks. Intervention: Drug: THYROX (Atlantic krill oil)."
88848584|NCT06271434|Experimental|Control|receiving placebo Intervention: Drug: Placebo
88848585|NCT06270680|Experimental|Supplement Group|The group receiving the carotenoid supplement.
88848586|NCT06270680|Placebo Comparator|Placebo Group|The group receiving the placebo.
88848587|NCT06265727|Experimental|Part A Dose Escalation - CRB-701 Dose Level 1|CRB-701 Dose level 1, intravenous infusion over 30 mins, Dose schedule 1
88848588|NCT06265727|Experimental|Part A Dose Escalation - CRB-701 Dose Level 2|CRB-701 Dose Level 2, intravenous infusion over 30 mins, Dose schedule 1
88848589|NCT06265727|Experimental|Part A Dose Escalation - CRB-701 Dose Level 3|CRB-701 Dose Level 3, intravenous infusion over 30 mins, dose schedule 1
88848590|NCT06265727|Experimental|Part A Dose Escalation - CRB-701 Dose Level 4|CRB-701 Dose Level 4, intravenous infusion over 30 mins, dose schedule 1
88848591|NCT06265727|Experimental|Part B Dose Optimization: CRB-701 High dose|Selected high dose of CRB-701, intravenous infusion over 30 mins, dose schedule 1
88848592|NCT06265727|Experimental|Part B Dose Optimization: CRB-701 low dose|Selected Low dose of CRB-701, intravenous infusion over 30 mins, once every three weeks
88848593|NCT06265727|Experimental|Part C Dose Expansion - Cohort 1|Recommended Phase 2 dose and schedule of CRB-701, intravenous infusion over 30 mins
88848594|NCT06265727|Experimental|Part C Dose Expansion - Cohort 2|Recommended Phase 2 dose and schedule of CRB-701, intravenous infusion over 30 mins
88848595|NCT06265727|Experimental|Part C Dose Expansion - Cohort 3|Recommended Phase 2 dose of CRB-701 and schedule, intravenous infusion over 30 mins
88848596|NCT06265727|Experimental|Part C Dose Expansion - Cohort 4|Recommended Phase 2 dose of CRB-701 and schedule, intravenous infusion over 30 mins
88848597|NCT06265727|Experimental|Part C Dose Expansion - Cohort 5|Recommended Phase 2 dose of CRB-701 and schedule, intravenous infusion over 30 mins
88848598|NCT06264804||progressive suction loss group|Progressive suction loss occurs during the SMILE procedure
88848599|NCT06264804||Normal group|There was no progressive suction during the SMILE procedure
88848600|NCT06264128|Experimental|CPAP v TPAP|Participants will compare CPAP to 2 different levels of TPAP, then will compare 2 levels of TPAP against each other by breathing on each pair of therapies for a minute or so, then deciding which is more comfortable or if they are equivalent.
88848601|NCT06262464|Experimental|Prevention|6 group, online sessions over two weeks. A prevention program using cognitive and behavioral strategies to reduce OCD risk factors and related symptoms.
88848602|NCT06262464|No Intervention|Control|Treatment as Usual
88848603|NCT06255379|Experimental|Fuquinitinib +Tegafur Gimeracil Oteracil|
88848604|NCT06252701|Experimental|Intervention diet then regular diet|4 weeks eating a diet low in ultra-processed foods in diet followed by 4 weeks of eating the participant's regular diet.
88848605|NCT06252701|Experimental|Regular diet then intervention diet|4 weeks of eating the participant's regular diet followed by 4 weeks of eating a diet low in ultra-processed foods.
88848606|NCT06252285|Experimental|Group 1 RSVt Vaccine|Participants will receive 2 intranasal administrations of RSVt vaccine
88848607|NCT06252285|Placebo Comparator|Group 2 Control|Participants will receive 2 intranasal administrations of placebo
88848608|NCT06251323|Experimental|Wave 1 - Clinic 1|A multi-level, multi-component, customized, standardized, technology enabled, person-centered, and team-based care practice transformation strategy, delivered during Year 1.
88848609|NCT06251323|Experimental|Wave 2 - Clinic 1|A multi-level, multi-component, customized, standardized, technology enabled, person-centered, and team-based care practice transformation strategy, delivered during Year 2.
88848610|NCT06251323|Active Comparator|Wave 1 - Clinic 2|A multi-level, multi-component, customized, standardized, technology enabled, person-centered, and team-based care practice transformation strategy, delivered during Year 2.
88848611|NCT06251323|Active Comparator|Wave 2 - Clinic 2|A multi-level, multi-component, customized, standardized, technology enabled, person-centered, and team-based care practice transformation strategy, delivered during Year 3.
88848612|NCT06248918|Experimental|Intervention Group|Participants will receive an exercise plan, activity tracker, and physical activity coaching program based Social Cognitive Theory.
88848613|NCT06248918|No Intervention|Control Group|The control group will not take any intervention but take a standard care, the post-tests will be collected at the end of 12 weeks.
88848614|NCT06238362|Experimental|TPAP - Experimental Therapy|Experimental therapy in which pressure is reduced during inspiration and the reduction is carried through part of expiration such that the pressure is increased near the end of expiration.
88848615|NCT06238362|Active Comparator|CPAP - Traditional OSA Therapy|Standard OSA therapy to which the TPAP therapy will be compared for efficacy.
88848620|NCT06235229|Experimental|GC012F|GC012F will be administered in one infusion
88848621|NCT06234267|Experimental|Dietary Quality|Receive daily text messages for promoting dietary quality.
88848622|NCT06234267|Experimental|Physical Activity|Receive daily text messages for promoting physical activity.
88848623|NCT06234267|Experimental|Sleep Hygiene|Receive daily text messages for promoting sleep hygiene.
88848624|NCT06234007|Experimental|SCRT followed by fruquintinib plus adebrelimab and CAPOX|
89376133|NCT04413266|Placebo Comparator|Placebo for CKD|Administration of 3 capsules with 500mg of placebo (maize starch) per day, for 12 weeks
89376134|NCT04399876|Experimental|Surgery Cohort|"Participant eligibility for intervention and selection of lesion for device placement~- Surgery Cohort will undergo percutaneous placement of several microdevices in a selected tumor(s) prior to surgery. The microdevice in the surgery cohort will dwell in the tumor tissue for approximately 48 hours to allow time for tissue effects of the drugs in the microdevice reservoirs.~Placement of at least 1, and up to 6, microdevices depending on the number of lesions, size and accessibility~Extirpative surgery will proceed according to standard-of-care procedures. The microdevice(s) will be removed surgically along with surrounding tumor tissue.~Standard of care treatment and follow-up of clinical course"
89181844|NCT05559983|Experimental|OSP:rTTHc Cholera Conjugate Vaccine|2 doses @0.5 mL of test vaccine administered intramuscularly in deltoid region at 4 weeks apart
89535054|NCT00706433|Active Comparator|ALA 500 seconds|Aminolevulinic acid HCL (ALA) applied to the entire facial area 45 minutes prior to BLUE light treatment for 500 seconds (8 minutes and 20 seconds)
88848625|NCT06227169|Experimental|Community mental health clinician training cohort 1|In this stepped wedge design, cohorts of community-based clinicians receive a training in how to conduct an evidence-based cognitive behavioral intervention in suicide prevention for justice-involved youth. There are 15 clinicians in each training cohort.
88848626|NCT06227169|Experimental|Community mental health clinician training cohort 2|In this stepped wedge design, cohorts of community-based clinicians receive a training in how to conduct an evidence-based cognitive behavioral intervention in suicide prevention for justice-involved youth. There are 15 clinicians in each training cohort.
88848627|NCT06227169|Experimental|Community mental health clinician training cohort 3|In this stepped wedge design, cohorts of community-based clinicians receive a training in how to conduct an evidence-based cognitive behavioral intervention in suicide prevention for justice-involved youth. There are 15 clinicians in each training cohort.
88848628|NCT06225804|Experimental|ABSK112|"During the escalation part, the administration of oral ABSK112 will be guided by Bayesian optimal interval (BOIN) design based on safety data collected until a maximum tolerated dose (MTD) has been identified. The first dose level will be administered as QD, and different dosing frequencies (e.g., BID) may be explored in subsequent doses depending on emerging safety and pharmacokinetic data.~A separate food effect cohort may be conducted.~In expansion part, patients will be treated at the selected RDE dose level."
88848629|NCT06224751||Near logMAR letter acuity|Comparison of measurements made with the trial computerised test to the trial gold standard printed test
88848630|NCT06224751||Near logMAR word acuity|Comparison of measurements made with the trial computerised test to the trial gold standard printed test
88848631|NCT06224751||Letter Contrast Sensitivity|Comparison of measurements made with the trial computerised test to the trial gold standard printed test
88848632|NCT06224751||Vanishing Optotype Sloan letters|Comparison of measurements made with the trial computerised test to the trial gold standard printed test
88848633|NCT06224751||Auckland Optotypes/Auckland Vanishing Optotypes|Comparison of measurements made with the trial computerised test to the trial gold standard printed test
88848634|NCT06224751||Low contrast letter acuity|Comparison of measurements made with the trial computerised test to the trial gold standard printed test
88848635|NCT06224751||Red Green Stereoacuity|Comparison of measurements made with the trial computerised test to the trial gold standard printed test
88848636|NCT06223256|Experimental|NBL-028|Patients will be treated with NBL-028 at starting dose of 0.01 mg/kg in dose escalation stage. In dose expansion stage, patients will be treated with NBL-028 at the recommended dose or multiple doses (if necessary) determined in the dose escalation stage.
88848637|NCT06219915|Experimental|Carbidopa Monotherapy and Carbidopa-Levodopa|Participants will begin by taking 25mg of Carbidopa monotherapy three times per day (TID) for 3 days. On day four, participants will begin taking 1 tablet of Carbidopa-Levodopa (25/100mg) TID in addition to the Carbidopa monotherapy. On day seven, participants will increase to 1.5 tablets of Carbidopa-Levodopa (25/100mg) TID while maintaining 25mg Carbidopa monotherapy TID. The intervention will end after ten days of supplementation.
88848638|NCT06219915|Placebo Comparator|Placebo|Participants will begin by taking a 25mg placebo tablet three times per day (TID) for 3 days. On day four, participants will begin taking a separate placebo tablet TID in addition to the original placebo. On day seven, participants will increase to 1.5 tablets of the second placebo TID while maintaining 25mg original placebo TID. The intervention will end after ten days of supplementation.
88848639|NCT06216470|Experimental|VIR-3434|VIR-3434 300 mg subcutaneous injection every 4 weeks*48 weeks
88848640|NCT06210230|Placebo Comparator|Control group|
88848641|NCT06210230|Experimental|Intervention group|
88848642|NCT06209580|Experimental|Arm 1|AMT-253 Dose Escalation
88848643|NCT06209580|Experimental|Arm 2|AMT-253 Dose Expansion
88848644|NCT06208787|Experimental|Experimental group|Individuals assigned to this group will receive the experimental neurofeedback training
88848645|NCT06208787|Sham Comparator|Control group|Individuals assigned to this group will receive the sham neurofeedback training
88848646|NCT06208124|Experimental|IMM-6-415|Dose Escalation and Dose Expansion
88848647|NCT06206616||Celiac Disease Children|Pediatric patients affected by newly diagnosed CD according to the European Society for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) criteria will be evaluated before the start of gluten-free diet and after 6 months of gluten-free diet.
88848648|NCT06204081|Experimental|persons with Parkinson's Disease, Hoehn & Yahr stage 4, FOG|This group tests first without the use of cues (CSO evaluates gait pattern, but does not adjust), and then with cues.
88848649|NCT06203990|Experimental|Barre class|Barre is an exercise modality that combines elements of classical ballet with strength training. Barre involves high repetitions of low impact, isometric movements, requires little to no equipment, and is highly modifiable for different fitness levels. Barre is traditionally performed in a class setting, which promotes increased social interaction and builds community. Furthermore, interventions with dance elements exhibit high adherence rates (often > 80%).The exercises in a barre class are also performed holding on to a fixed barre or on the floor, which may address people with PD's fear of falling.
88848650|NCT06200506|Experimental|Transabdominal radiofrequency application|"Tecartherapy equipment (Capenergy CM500) specially designed for Uro-Gynecological Physiotherapy will be used.~A transabdominal radiofrequency application will be performed, with a suprapubic active plate and a passive plate at the sacral level.~Patient position: Supine position. Sessions:9 Duration: 20 minutes Total intervention: 3 weeks Frequency: 3 times a week sessions will be held three times a week for three weeks"
89376135|NCT04399876|Experimental|Ex-Vivo Cohort|"Each participant will undergo a screening process to determine their eligibility for microdevice placement, consisting of the following items:~Routine standard of care for radical prostatectomy.~Placement of implantable microdevice with multiple miniature drug reservoirs but no drug in prostate that have been removed~Ex vivo image guided removal using retrieval device~Standard of Care Treatment and follow-up of clinical course"
89376136|NCT04399837|Experimental|Spesolimab SC low dose|
88848651|NCT06200506|Experimental|Intracavitary radiofrequency application|"Tecartherapy equipment (Capenergy CM500) specially designed for Uro-Gynecological Physiotherapy will be used.~An intracavitary vaginal radiofrequency application will be performed, with an active intracavitary head and with a fixed plate at the sacral level.~Patient position: Supine position. Sessions:9 Duration: 20 minutes Total intervention: 3 weeks Frequency: 3 times a week sessions will be held three times a week for three weeks"
89376137|NCT04399837|Experimental|Spesolimab SC medium dose|
89376138|NCT04399837|Experimental|Spesolimab SC high dose|
89376139|NCT04399837|Placebo Comparator|Placebo|
89376140|NCT04391803|Experimental|Pipeline™ Flex Embolization Device with Shield Technology™|This is a prospective, single-arm study in which subjects have consented and deployment of the Pipeline™ Flex Embolization Device with Shield Technology™ is attempted.
89376141|NCT04388930||Kidney transplant live-donor|Participants that will be a planned live renal transplant donor
89376142|NCT04388930||Kidney transplant recipient|Renal transplant recipient on the waiting list to have or will have had an ABO-blood group compatible live-donor or cadaveric transplant
89376143|NCT04368013||Experimental|The difference from the standard of care is extended sample collection and study related procedures during the study.
89376144|NCT04365413|Experimental|Imaging of Tumor or Lymph node|"Tumors and/or lymph nodes of patients scheduled for standard of care surgery will be imaged using the MSOT device before and after surgery.~The temperature of their skin prior to and after MSOT imaging will also be measured."
88848652|NCT06200506|No Intervention|Control Group|Not treatment received
88848653|NCT06197685|Experimental|Cognitive Rehabilitation + Aerobic Exercise with Virtual Reality (VR)|In the cognitive rehabilitation and aerobic exercise with VR condition, participants will complete a supervised, aerobic exercise training program (AET) integrated with virtual reality (Ideally Designed Exercise to Accelerate Learning/memory; IDEAL) three days per week over a 12 week period. For seven weeks, participants will only complete IDEAL. For weeks 8-12, participants will complete the Kessler Foundation modified story Memory Technique (KF-mSMT®), a memory retraining program on 2 of the 3 days per week.
89376145|NCT04364269|Experimental|VIT-2763 Once a day (QD)|"Participants will be assigned to receive VIT-2763 once a day (QD) in a total daily dose of 60 mg or 120 mg depending on their body weight.~The study medication (VIT-2763 and/or matching placebo) will be administered for all participants twice a day to maintain the blind."
89376146|NCT04364269|Experimental|VIT-2763 Twice a day (BID)|Participants will be assigned to receive VIT-2763 Twice a day (BID) in a total daily dose of 60 mg or 120 mg depending on their body weight.
89376147|NCT04364269|Placebo Comparator|Placebo|Participants will be assigned to receive Placebo, Twice a day.
89376148|NCT04358874|Experimental|Active follow-up|Participants randomized to the active follow-up arm will have follow-up visits in the AKI follow-up clinic every 4 weeks after discharge for a total of 90 days after discharge
88848654|NCT06197685|Experimental|Cognitive Rehabilitation + Stretching and Toning|In the cognitive rehabilitation and stretching and toning (S/T) exercise condition, participants will complete 12 weeks of supervised S/T activities 3 days per week over the 12 week period. For seven weeks, participants will only complete S/T. During weeks 8-12, participants will complete the Kessler Foundation modified story Memory Technique (KF-mSMT®), a memory retraining program on 2 of the 3 days per week.
88848655|NCT06194903|Experimental|Cellphones treated with isopropyl alcohol wipes|
88848656|NCT06194903|Experimental|Cellphones treated with UVC box|
89376149|NCT04358874|Active Comparator|Usual follow-up|Participants randomized to the usual follow-up arm will be called at home 4 weeks after the baseline visit to collect information on primary and secondary outcomes.
89376150|NCT04337970|Experimental|Phase Ib, Dose Level 1|3-6 participants
89376151|NCT04337970|Experimental|Phase Ib, Dose Level 2|3-6 participants
89376152|NCT04337970|Experimental|Phase Ib, Dose Level 3|3-6 participants
89376153|NCT04337970|Experimental|Phase II, Dose Expansion|Optimal Simon 2-stage Design (14 participants initially, if MTD is tolerated well then accrual will go up to 25 participants)
89376154|NCT04318080|Experimental|Cohort 1|Participants with relapsed or refractory Classical Hodgkin Lymphoma (cHL) who have failed to achieve a response or progressed after autologous hematopoietic stem cell transplantation (HSCT)
89376155|NCT04318080|Experimental|Cohort 2|Participants with relapsed or refractory cHL who have received at least 1 prior systemic regimen and are not candidates for autologous or allogeneic HSCT
89376156|NCT04316962|Experimental|Complex rehabilitation|See intervention described elsewhere.
89376157|NCT04309721|Experimental|Perampanel|immediate enteral administration of Perampanel, 12 mg
89376158|NCT04309721|Placebo Comparator|Placebo|immediate enteral administration of placebo
89376159|NCT04299945|Experimental|Dietary nitrate supplementation|The dietary nitrate supplement will be a concentrated, nitrate-rich beetroot juice (70 ml providing ∼400mg nitrate per serving)
89376160|NCT04299945|Placebo Comparator|Placebo|The placebo will be a concentrated, nitrate-depleted beetroot juice (70 ml with trace amounts of nitrate)
89376161|NCT04299048|Experimental|PF-06946860|subcutaneous injection
89376162|NCT04254549|Experimental|Intervention Treatment|Subjects diagnosed with gastroparesis will receive Rifaximin
89376163|NCT04254549|Placebo Comparator|Placebo Group|Subjects diagnosed with gastroparesis will receive a placebo
89376164|NCT04227288|Experimental|Enstilar Foam|Eligible subjects will be provided twice daily daily Enstilar Foam (calcipotriene and betamethasone dipropionate).
89376165|NCT04210206|Experimental|Diet|
89376166|NCT04210206|No Intervention|Control|
89376167|NCT04179981|Other|Conservative care (control arm)|Eligible OVS patients will receive conservative care/usual care with education about sleep apnea and sleep hygiene via handouts and video instructions. This is the control arm.
89376168|NCT04179981|Active Comparator|PAP therapy arm|PAP Therapy will be provided to eligible patients with OVS. This is the active therapy arm.
89376169|NCT04156919|Experimental|Playful condition|Children in the playful and non-playful conditions will receive the fooya! intervention but will be varied in the psychological state of playfulness. Children in the playful condition will play a health game called fooya! Drawing on the playfulness literature, we will manipulate four dimensions of play. First, to manipulate the voluntariness of tasks, children in the playful condition will be asked/invited to participate in the study. Second, to manipulate adult presence, there will be little to no teacher involvement in the playful condition. Third, to manipulate the timing of the activity, children in the playful condition will be given an option to play anytime, including after school hours. Fourth, to manipulate the goal perception, the children in the playful condition will be told that their activity is not graded-i.e., autotelic.
88848659|NCT06178016|Experimental|Experimental Group|Participants in this group will have the Bystander Intervention Program for Dating Violence. The aim of this program, which will be prepared taking into account the needs of the country and institutions, is to provide knowledge and skills to safely intervene in dating violence. The program will be implemented at a convenient time for the experimental group of students within the 2023-2024 Spring semester academic calendar, taking into account the 1st-grade course schedule of Istanbul University-Cerrahpaşa Florence Nightingale Faculty of Nursing.
88848660|NCT06178016|No Intervention|Control Group|The control group will not participate in the Bystander Intervention Program for Dating Violence, an interview consisting of one session is planned considering for the placebo effect. The control group students will be given a single 60-minute information session on dating violence and the students will be expected to fill out the scales to be filled out within the scope of the research at the pre-test and post-test times. At the end of the study, the Bystander Intervention Program for Dating Violence will be carried out with the voluntary participants in the control group, taking into account the ethics.
88848661|NCT06176209||Post traumatic neck pain (i.e. whiplash)|"To be considered eligible for inclusion participants must meet the following criteria:~Inclusion criteria: 18-60 years of age, post-traumatic neck pain of a musculoskeletal nature without fractures or slippage of vertebrae acquired within the last 72 hours in connection an accident. Participants must be able to read and speak Danish.~Exclusion criteria: Previous pain discomfort after similar accidents, existing chronic back pain at the time of the accident, diagnosed with concussion after the accident, suspected or known spinal pathology, including confirmed fracture or slippage of vertebrae at the time of the accident, previous back or neck surgery, spinal cord injuries, severe psychiatric history (e.g., schizophrenia and depression), trauma patients or existing rheumatological or neurological disorders."
88848662|NCT06175715|Active Comparator|Regional anesthesia for carotid endarterectomy in patients with acute stage of ischemic stroke.|
88848663|NCT06175715|Active Comparator|General anesthesia for carotid endarterectomy in patients with acute stage of ischemic stroke.|
88848664|NCT06175065|Experimental|RLS-0071|Doses of RLS-0071, will be administered Q8H, three times a day, for at least 3 days and up to 5 days
88848665|NCT06175065|Placebo Comparator|Placebo|Doses of Placebo for RLS-0071, will be administered Q8H, three times a day, for at least 3 days and up to 5 days
89376170|NCT04156919|Experimental|Non-playful condition|As mentioned earlier, we will manipulate four dimensions of play. First, participation will be mandatory for children in the non-playful condition. Second, teacher presence will be more salient in this condition. Third, children in the non-playful condition will participate during school hours. Fourth, the children in the non-playful condition will be told that their activity is graded.
89376171|NCT04156919|Active Comparator|Control condition|Children in the control condition will play a video game unrelated to diet and lifestyle called Wordsearch.
89376172|NCT04134091|Experimental|Treatment A|LPCN 1144 Formulation A
89376173|NCT04134091|Experimental|Treatment B|LPCN 1144 Formulation B
89376174|NCT04134091|Placebo Comparator|Treatment C|Placebo
89376175|NCT04115644|Placebo Comparator|Group 1 (control)|will receive an injection of 5 cc 0.25% Marcaine without epinephrine
89376176|NCT04115644|Experimental|Group 2 (ketorolac)|will receive an injection of 3 cc 0.25% Marcaine without epinephrine and 2 cc ketorolac 30 mg/ml
89376177|NCT04115644|Other|Group 3 (kenalog)|Pt will receive an injection of 4 cc 0.25% Marcaine without epinephrine and 1 cc triamcinolone. Group 3 is standard of care
89376178|NCT04114123||Longitudinal|The researchers will be evaluating baseline indicators of wanting salience and liking between 2 and 6 month olds, with the goal of following up with these families at 24 months and beyond by reviewing the dyads' medical charts. The researchers will also examine direct and indirect associations between reward-driven eating, and maternal and infant characteristics and infant weight-for-length.
89376179|NCT04114123||Cross-sectional|The researchers will as the mother to answer questionnaires and participate in up to two video taped behavioral protocols when the infant is 6 months old.
89399361|NCT03694119|Active Comparator|Phenelzine|Following tyramine challenging in Period 1, eligible subjects randomly assigned to Phenelzine arm are receiving Phenelzine placebo BID plus ozanimod placebo QD from Days 11 to 31, then receiving Phenelzine 15mg BID plus ozanimod placebo QD from Days 32 to 38. Subjects receive second tyramine challenge from Day 39 to up to Day 49
89376180|NCT04113382|Experimental|Participants aged 2 to <4 years: CLENPIQ|"CLENPIQ administered using split-dose method and consists of two separate doses: the first dose (½ bottle [approximately 80 mL]) one day before colonoscopy between 5:00 PM and 9:00 PM, and the second dose (½ bottle [approximately 80 mL]) the next day, at least 5 hours prior but no more than 9 hours prior to the colonoscopy. Following each dose, participants will consume 50 mL/kg of clear liquids, up to a limit of 1,000 mL."
88848666|NCT06173323|Experimental|Basic social support + communication + patient psychoeducation|2 in-person/telephone weekly sessions on providing social support and tips for good communication for caregiver participants and 2 sessions of social support, decision aids, and tips for good communication for patient participants and a single monthly follow-up call for both participants.
88848667|NCT06173323|Experimental|Basic social support + communication|2 in-person/telephone weekly sessions on providing social support and tips for good communication for caregiver participants and a single monthly follow-up call for caregiver participant
88848668|NCT06173323|Experimental|Basic social support + patient psychoeducation|1 in-person/telephone weekly sessions on providing social support for caregiver participants and 2 sessions of social support, decision aids, and tips for good communication for patient participants and a single monthly follow-up call for both participants.
88848669|NCT06173323|Experimental|Basic social support|1 in-person/telephone weekly sessions on providing social support for caregiver participants a single monthly follow-up call for the caregiver participant.
88848670|NCT06173323|Experimental|Advanced social support + communication+ patient psychoeducation|4 in-person/telephone weekly sessions on providing social support and tips for good communication for caregiver participants and 2 sessions of social support, decision aids, and tips for good communication for patient participants and a single monthly follow-up call for both participants.
88848671|NCT06173323|Experimental|Advanced social support + communication|4 in-person/telephone weekly sessions on providing social support and tips for good communication for caregiver participants and a single monthly follow-up call for caregiver participant
88848672|NCT06173323|Experimental|Advanced social support + patient psychoeducation|3 in-person/telephone weekly sessions on providing social support for caregiver participants and 2 sessions of social support, decision aids, and tips for good communication for patient participants and a single monthly follow-up call for both participants.
88848673|NCT06173323|Experimental|Advanced social support|3 in-person/telephone weekly sessions on providing social support for caregiver participants and a single monthly follow-up call for caregiver participant
88848674|NCT06173115|Active Comparator|Double Perclose device|Double Perclose device ( Perclose Proglide system, Abbott Vascular) was used for large bore arteriotomy site closure during TF-TAVR procedures
88848675|NCT06173115|Experimental|Single Perclose device|Single Perclose device ( Perclose Proglide system, Abbott Vascular) was used for large bore arteriotomy site closure during TF-TAVR procedures
89181845|NCT05559983|Experimental|OSP:rTTHc Cholera Conjugate Vaccine with Aluminum phosphate adjuvant|2 doses @0.5 mL of test vaccine administered intramuscularly in deltoid region at 4 weeks apart
89181846|NCT05559983|Placebo Comparator|Placebo|2 doses @0.5 mL of Sterile 0.9% sodium chloride administered intramuscularly in deltoid region at 4 weeks apart
89181847|NCT02580669|Experimental|Progressive Multiple Sclerosis|22 patients with Progressive Multiple Sclerosis will be included and they get an Neuropsychological assessment, a Neurologic consultation and MRIs (with vasoreactivity testing)
88848679|NCT06157840|Experimental|mHealth application|Study participants, while being stabilized on buprenorphine, will download and engage with the developed mHealth application, completing daily electronic sleep diaries for the next 6 weeks. Each week, they will be asked to complete a short assessment of their experiences from the previous week and their current insomnia severity.
88848680|NCT06157840|Experimental|Control Group|Participants in the control group will receive a simplified version of the app with sleep hygiene (SH) instructions and will be required to complete daily electronic sleep diaries for the next 6 weeks. The SH condition will utilize the same application and entail the same daily and weekly logs, but with the didactic material replaced by detailed education about SH strategies. Each week, participants will be asked to complete a brief assessment of their experiences from the previous week and their current insomnia severity.
88848681|NCT06151535|Experimental|ELAPR002f Injectable Gel|Participants will receive 3 treatment sessions 1 month apart of ELAPR002f injectable gel and will be followed for 4 months.
89399362|NCT03694119|Placebo Comparator|Placebo|Following tyramine challenging in Period 1, eligible subjects randomly assigned to Placebo arm are receiving Phenelzine placebo BID plus ozanimod placebo QD from Days 11 to 38. Subjects receive second tyramine challenge from Day 39 to up to Day 49
88848683|NCT06145906||Paroxysmal AF group|AF that terminates spontaneously or with intervention within 7 days of onset
88848684|NCT06145906||Persistent AF group|AF that is continuously sustained beyond 7 days, including episodes terminated by cardioversion (drugs or electrical cardioversion) after ≥7 days
88848685|NCT06138548|Experimental|Subchondral Insufficiency|Those who have subchondral insufficiency with tibial or femoral overload in the knee.
88848686|NCT06137183|Experimental|Vixarelimab Dose Regimen 1|Participants will receive vixarelimab subcutaneously (SC) during the induction period and the optional ATE period.
88848687|NCT06137183|Experimental|Vixarelimab Dose Regimen 2|Participants will receive vixarelimab SC during the induction period and the optional ATE period.
88848688|NCT06137183|Placebo Comparator|Placebo|Participants will receive placebo SC during the induction period and vixarelimab SC during the optional ATE period.
88848689|NCT06134492|Experimental|Treatment group|Aciclovir therapy
88848690|NCT06134492|No Intervention|Comparison group|No study-specific treatment measures
88848691|NCT06133907|Experimental|Samples Without DNA|Patients who came to the pneumoallergology department of the CHU de Nice since January 2014 for an allergological workup and with tryptasemia was ≥ 8ng/ml (at least once in patient history).
89181848|NCT02580669|Experimental|Multiple Sclerosis, Relapsing-Remitting|22 patients with Multiple Sclerosis, Relapsing-Remitting will be included and they get an Neuropsychological assessment, a Neurologic consultation and MRIs (with vasoreactivity testing)
89181849|NCT02580669|Experimental|Healthy volunteers (22 patients)|22 healthy volunteers will be included and they get an Neuropsychological assessment and MRIs (with vasoreactivity testing)
89376181|NCT04113382|Active Comparator|Participants aged 2 to <4 years: MIRALAX|MIRALAX 3.4 to 4.9 g/kg up to a maximum of 238 g is reconstituted with non-carbonated, clear beverage, or water and administered in increments of 4 ounce (oz) for every 30 minutes, one day before colonoscopy between 5:00 PM and 9:00 PM. Following dosing, participants will consume 50 mL/kg of clear liquids, up to a limit of 1,000 mL total weight-based maximum.
89181850|NCT00777296|Experimental|Cohort 1 - 280 mg ARIKACE™|Subjects in this cohort will receive 280 mg of ARIKACE™
89181851|NCT00777296|Placebo Comparator|Cohort 1 - Placebo|Subjects in this arm of cohort 1 will receive matching placebo
89181852|NCT00777296|Experimental|Cohort 2 - 560 mg ARIKACE™|Subjects in this cohort will receive 560 mg of ARIKACE™
89181853|NCT00777296|Placebo Comparator|Cohort 2 - Placebo|Subjects in this arm of cohort 2 will receive matching placebo
89181854|NCT05186805|Experimental|tapinarof cream|Tapinarof (DMVT-505) cream, 1% applied topically once daily
89535055|NCT00706433|Placebo Comparator|Vehicle 1000 seconds|Vehicle (VEH) applied to the entire facial area 45 minutes prior to BLUE light treatment for 1000 seconds (16 minutes and 40 seconds)
88848692|NCT06132503|Experimental|Phase 1 Single Arm Multicenter Study to Assess the Safety and Tolerability of LP-284|The Phase 1a dose escalation portion of the study will identify the maximum tolerated dose (MTD) and/or optimal dose(s) of LP-284 as the RP2D, based on all available safety, PK, PD, and/or preliminary efficacy data. Phase 1b will consist of the dose expansion portion in a separate cohort(s) of patients to further evaluate the safety of LP-284 at the RP2D and obtain preliminary estimates of clinical activity of LP-284 in patients with DLBCL and MCL.
88848695|NCT06128044|Experimental|Dose Escalation of CB-012|Part A (Dose Escalation) of CB-012 with increasing doses using a 3+3 design, during which the MTD and/or RDE will be identified.
88848696|NCT06128044|Experimental|Dose Expansion of CB-012|Part B (Dose Expansion) - participants will be enrolled to receive CB-012 at the RDE and/or MTD determined in Part A in order to the determine the RP2D.
88848697|NCT06125795||Chronic Lymphocytic Leukemia (CLL) Participants|Participants will receive oral treatments for CLL in accordance with approved local label.
88848698|NCT06120881|Experimental|Experimental|1350mg metformin twice per day
88848699|NCT06120881|Active Comparator|Active Comparator|1000mg metformin twice per day
88848700|NCT06115070|Experimental|Thrombolysis group|intravenous alteplase (0.9 mg/kg; maximum dose, 90mg; 10% administered as a 1-minute bolus, the remaining infused over 1 hour;
88848701|NCT06115070|No Intervention|Control group|according to guideline
88848702|NCT06112535|Experimental|TORS with Versius|
88848703|NCT06112522|Experimental|Experimental : 5 Day treatment course 1 with Tirbanibulin Ointment 1%|Subjects will be given one study kit containing single-dose packets of Tirbanibulin Ointment 1% and instructed to topically apply to the treatment area once daily for 5 consecutive days. Subjects with unresolved lesion at d28 or d56 or d72 or d84 will be given an additional study kit containing single-dose packets of Tirbanibulin Ointment 1% and instructed to topically apply to the treatment area once daily for 5 consecutive days.
88848704|NCT06108336|Experimental|Cerebellar Stimulation|TMS will be administered to the cerebellum on half the trials of a sequence-demanding task, and on half the trials of a non-sequence-demanding task. Task order will be counterbalanced.
88848705|NCT06108336|Active Comparator|Occipital Stimulation|TMS will be administered to an occipital control region on half the trials of a sequence-demanding task, and on half the trials of a non-sequence-demanding task. Task order will be counterbalanced.
88848706|NCT06104319|Experimental|GSK4532990 Dose 1|Participants will receive GSK4532990 Dose 1
88848707|NCT06104319|Experimental|GSK4532990 Dose 2|Participants will receive GSK4532990 Dose 2
88848708|NCT06104319|Experimental|GSK4532990 Dose 3|Participants will receive GSK4532990 Dose 3
88848709|NCT06104319|Experimental|GSK4532990 Dose 4|Participants will receive GSK4532990 Dose 4
89376182|NCT04113382|Experimental|Participants aged 4 to <9 years: CLENPIQ|"CLENPIQ administered using split-dose method and consists of two separate doses: the first dose (1 bottle [approximately 160 mL]) one day before colonoscopy between 5:00 PM and 9:00 PM, and the second dose (½ bottle [approximately 80 mL]) the next day, at least 5 hours prior but no more than 9 hours prior to the colonoscopy. Following each dose, participants will consume 50 mL/kg of clear liquids, up to a limit of 1,000 mL total weight-based maximum."
89376183|NCT04113382|Active Comparator|Participants aged 4 to <9 years: MIRALAX|MIRALAX 3.4 to 4.9 g/kg up to a maximum of 238 g is reconstituted with non-carbonated, clear beverage, or water and administered in increments of 8 oz for every 30 minutes one day before colonoscopy between 5:00 PM and 9:00 PM. Following dosing, participants will consume 50 mL/kg of clear liquids, up to a limit of 1,000 mL total weight-based maximum.
88848712|NCT06100393|Other|Investigational pre-processing algorithm/Standard of Care pre-processing algorithm|
88848713|NCT06098469|Experimental|Neurofeedback|10 neurofeedback sessions + depressive rating scales
88848714|NCT06098235|Placebo Comparator|Usual diet advice|
88848715|NCT06098235|Active Comparator|ORIENT diet intervention|
88848716|NCT06097364|Experimental|Odronextamab + Chemotherapy|Part 1 of the study includes ordonextamab dose escalation for participants with previously untreated FL and relapsed/refractory FL (Part 1A only) followed by a randomized exploration of 2 regimens of odronextamab (O) and cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) with the objective of dose optimization (Part 1B) in previously untreated patients with FL.
88848717|NCT06097364|Active Comparator|Rituximab + Chemotherapy|In Part 2 only, participants will be randomized 1:1:1 to receive rituximab (R) with chemotherapy (CHOP), followed by rituximab monotherapy maintenance.
88848718|NCT06097364|Experimental|Odronextamab + Chemotherapy + Maintenance|In Part 2, participants will be randomized 1:1:1 to receive odronextamab with chemotherapy [CHOP, or cyclophosphamide, vincristine, and prednisone (CVP)], followed by odronextamab monotherapy maintenance.
89399363|NCT03694119|Experimental|ozanimod|Following tyramine challenging in Period 1, eligible subjects randomly assigned to ozanimod arm are receiving Phenelzine placebo BID plus ozanimod 1.84mg QD from Days 11 to 38, including dose escalation days. Subjects receive second tyramine challenge from Day 39 to up to Day 49
88848719|NCT06097364|Experimental|Odronextamab + Chemotherapy + No maintenance|In Part 2, participants will be randomized 1:1:1 to receive odronextamab with chemotherapy (CHOP, or CVP) without maintenance.
88848720|NCT06084884|Experimental|AZD5851|Subjects will receive AZD5851 following 3 consecutive doses of lymphodepleting chemotherapy (fludarabine and cyclophosphamide).
88848721|NCT06081829|Experimental|Open-Label Ivosidenib|250 mg Tablets
89535056|NCT00706433|Placebo Comparator|Vehicle 500 seconds|Vehicle (VEH) applied to the entire facial area 45 minutes prior to BLUE light treatment for 500 seconds (8 minutes 20 seconds)
88848725|NCT06077149|Experimental|Long-term care facility residents|Licensed RSV vaccine IM x 1. Specific product to be determined availability at the facility as SOC
88848726|NCT06077149|Active Comparator|community dwelling adults|Licensed RSV vaccine IM x1. The proportion of specific products will be matched to the LTCF cohort
88848727|NCT06071143|Experimental|KDSTEM Inj.|"Low dose : Urine derived stem cells 1.0x10^8 cells~High dose : Urine derived stem cells 3.0x10^8 cells"
88848728|NCT06067828|Active Comparator|BGF MDI|Pressurized MDI fixed combination product of Budesonide 160 μg, Glycopyrronium 7.2 μg, and Formoterol Fumarate 4.8 μg per actuation.
88848729|NCT06067828|Active Comparator|BFF MDI|Pressurized MDI fixed combination product of Budesonide 160 μg and Formoterol Fumarate 4.8 μg per actuation.
88848730|NCT06067828|Placebo Comparator|Placebo|Placebo as pressurized inhalation suspension.
89181855|NCT04106609|Experimental|Exercise Group|Patients will complete a 60-minute exercise session once per week for 12 weeks. The exercise sessions will be individualized to the patient's needs and fitness level by a trainer. A patient will work with the same trainer throughout the study, who will plan the patient's individualized exercise regimen, and who will provide one-on-one supervision for the duration of each 60-minute session. Each 60-minute session will include cardiovascular, strength, and flexibility training. The intensity level for the aerobic exercise ranges from 30-45% of the individual's predicted VO2max, controlled by heart monitors and lasting 30 min. Strength training will involve a full body workout, with emphasis on all major muscle groups and employing machines, free weights, and resistance tubing. Patients will complete 3 sets of 10 repetitions for each strength exercise. Flexibility training will involve static stretching of all major muscle groups for 15-20 seconds at the completion of each workout.
89181856|NCT04106609|Active Comparator|Control Group|The control group will receive the current standard of care, which includes a resource guide with various options available to the cancer survivor. Within this guide are tips for healthy eating and pictures of standard exercises to improve fitness.
89181857|NCT02603549||Surgery or Blood Patch|
89181858|NCT05084547||Case|Subjects with Bronchiectasis
89181859|NCT05084547||Control|Healthy Controls
89181860|NCT04097132||ischemic stroke patients|all patient admitted with acute ischemic stroke either their ECG was AF or sinus rythm
89181861|NCT04076163|No Intervention|control group|group of students participating to a face-to-face learning
89181862|NCT04076163|Other|intervention group|group of students using serious game
88848739|NCT06064851|Experimental|Baseline Followed by Active tAN|First Menstruation (baseline/no active tAN) followed by Second Menstruation (active tAN)
88848740|NCT06064487|Experimental|septic AKI patients|80 patients with sepsis associated AKI stage 1 or 2 according to KDIGO definition
88848741|NCT06059157|Experimental|Single Arm|Single Arm
88848742|NCT06058130|Active Comparator|Anticoagulation alone|Rivaroxaban 20mg once daily or 15mg once daily / Dabigatran 110mg twice daily or 150mg twice daily
88848743|NCT06058130|Experimental|Anticoagulation combined with antiplatelet therapy|Rivaroxaban 20mg once daily or 15mg once daily or 10mg once daily / dabigatran 110mg twice daily or 150mg twice daily+ aspirin 100mg once daily / clopidogrel 75mg once daily / ticagrelor 90mg twice daily / cilostazol 100mg twice daily
88848744|NCT06057467|Experimental|Early initiation of anticoagulation|"For patients with NIHSS 0-3, anticoagulation therapy will be initiated within 0-3 days of onset.~For patients with NIHSS 4-8, anticoagulation therapy will be initiated within 4-6 days of onset."
88848745|NCT06057467|Active Comparator|Late initiation of anticoagulation|"For patients with NIHSS 0-3, anticoagulation therapy will be initiated within 4-12 days of onset.~For patients with NIHSS 4-8, anticoagulation therapy will be initiated within 7-12 days of onset."
89181863|NCT00756470|Experimental|Neoadjuvant Lapatinib plus Chemotherapy|"Four cycles of Lapatinib and Paclitaxel followed by 4 cycles of Lapatinib plus 5-Fluorouracil, Cyclophosphamide, Epirubicin (FEC75). Cycle is 21 days.~Lapatinib alone at 1,000 mg orally once daily for a 2-week run-in period, followed by initiation of chemotherapy with 2 combination regimens of 4 cycles each.~Week 3 Paclitaxel 80 mg/m^2 weekly for 4 cycles (12 weeks) administered on Day 1, Day 8, and Day 15) of each cycle combined with Lapatinib 750 mg orally once daily.~Week 15, second combination treatment consisting of Lapatinib (1,000 mg orally once daily) combined with FEC75 (5-FU 500 mg/m^2, Epirubicin 75 mg/m^2, and Cyclophosphamide 500 mg/m^2 every 3 weeks for 4 cycles)."
89181864|NCT00792623|Experimental|Varilrix Group|Subjects with autologous peripheral stem cell/bone marrow transplants, who received 2 doses of Varilrix vaccine subcutaneously in the deltiod region of the non-dominant upper arm, at 4.5 and 6.5 months post-transplantation.
89181865|NCT03862599|Sham Comparator|Standard care + sham ESWT|Cialis and Vacuum pump + sham Extra-corporeal shockwave therapy (ESWT)
89181866|NCT03862599|Active Comparator|Standard care + active ESWT|Cialis and Vacuum pump + active Extra-corporeal shockwave therapy (ESWT)
89181867|NCT04106921|Experimental|Universal Health Coverage Mode|The NGOs Muso and Medic Mobile have partnered to develop Universal Health Coverage Mode, a smartphone app tool that provides visual cues to help CHWs track the quantity of household visits they have conducted at each household in a given month.
89181868|NCT04106921|No Intervention|Work as usual|For the control arm, all households within the CHW's household list in the app will have the same appearance. There will be no visual differentiation between households on the list to indicate the frequency of home visits.
89181869|NCT05052567|Experimental|CEND-1|CEND-1+paclitaxel (albumin-bound type)+gemcitabine
89181870|NCT00756314|Experimental|Personalized contraceptive counseling|All 123 allocated women for the intervention group received personalized counseling (face-to-face) and the contraceptive method chosen for free by a specialized trained doctor in family planning.
89376184|NCT04099823|Other|MR brain|"Participants will be asked to complete a MRI screening form to check for the presence of metallic implants and materials. People with pacemakers, aneurysm clips, and cochlear implants, or metal/foreign objects in their eyes cannot have an MRI and will not be able to participate in the study.~Pre-menopausal females will be asked if they think they may be pregnant. If yes, a urine pregnancy test will be performed.~Those who meet eligibility criteria for the study and have agreed to participate will be taken to the MRI suite when MR imaging of the brain will be performed."
89376185|NCT04078568|Active Comparator|the standard group|"IVIG 2g/kg once, given within 12 to 24 hours;~Aspirin 30 mg/kg in oral per day (given in 3 divided doses), then 3 to 5 mg/kg per day when fever subsides for 3 days and C-reactive protein (CRP) is normal. Aspirin will be continued for at least 6 weeks after onset of illness."
89376186|NCT04078568|Experimental|the standard+prednisolone group|"IVIG 2g/kg once, given within 12 to 24 hours;~Aspirin 30 mg/kg in oral per day (given in 3 divided doses), then 3 to 5 mg/kg per day when fever subsides for 3 days and CRP is normal. Aspirin will be continued for at least 6 weeks after onset of illness.~Intravenous methylprednisolone 1.6 mg/kg per day (given in 2 divided doses) for 3 days, then changed to oral prednisolone 2 mg/kg when fever subsides for 3 days . If CRP is normal, the oral dose will be reduced every 5 days from 2 mg/kg to 1 mg/kg to 0.5 mg/kg (tapered over 15 days). Then prednisolone will be discontinued."
89376187|NCT04064723|Active Comparator|Stem components|Randomization between two stem components. LCU or Corail stem.
89376188|NCT04064723|Active Comparator|Cup components|Randomization between two cup components. DeltaTT or Pinnacle cup.
89376189|NCT04064528|Active Comparator|Young|Young adults will be given a 10 g oral bolus of amino acids.
89376190|NCT04064528|Experimental|Older Adults|Older adults will be given a 10 g oral bolus of amino acids.
89376191|NCT04057456|Placebo Comparator|Placebo diet and placebo capsules|Participants taking the placebo diet and capsules
89376192|NCT04057456|Active Comparator|Placebo diet and Nabilone capsules|Capsules will be 0.5mg nabilone. Participants will take up to 8 capsules per day for a maximum dose of 4mg of nabilone per day.
89376193|NCT04057456|Active Comparator|Anti-inflammatory diet and placebo capsules|This meal plan will eliminate foods that have been established as pro-inflammatory (e.g. processed foods, refined sugars, refined wheat products, etc.) as well as foods that are commonly associated with even mild intolerances (e.g. cow's milk) and those that negatively impact cardiovascular health (e.g. hydrogenated oils, alcohol, coffee, refined sugars and wheat, trans fats, processed foods). In their place, the meal plan will consist of foods with established anti-inflammatory properties (e.g. (Oily fish, lean poultry, dark leafy greens, cruciferous vegetables, nuts, whole grains, most kinds of berries, etc).
89376194|NCT04057456|Active Comparator|Anti-inflammatory diet and Nabilone capsules|"Capsules will be 0.5mg nabilone. Participants will take up to 8 capsules per day for a maximum dose of 4mg of nabilone per day.~This meal plan will eliminate foods that have been established as pro-inflammatory (e.g. processed foods, refined sugars, refined wheat products, etc.) as well as foods that are commonly associated with even mild intolerances (e.g. cow's milk) and those that negatively impact cardiovascular health (e.g. hydrogenated oils, alcohol, coffee, refined sugars and wheat, trans fats, processed foods). In their place, the meal plan will consist of foods with established anti-inflammatory properties (e.g. (Oily fish, lean poultry, dark leafy greens, cruciferous vegetables, nuts, whole grains, most kinds of berries, etc)."
89376195|NCT04026386|Experimental|Center Based or In-Home Early Intervention Program|
89376196|NCT04010539|Experimental|Participants receiving Gepotidacin|Participants will receive Gepotidacin orally at the study site during the Baseline (Day 1) visit followed by self-administration of a second oral dose as an outpatient 10 to 12 hours after the first dose.
89376197|NCT04010539|Active Comparator|Participants receiving Ceftriaxone plus Azithromycin|Participants will receive a single IM dose of Ceftriaxone plus a single oral dose of Azithromycin at the study site during the Baseline (Day 1) visit.
89376198|NCT03999333|Experimental|Virtual Reality|Every participant is provided with a VR headset
89376199|NCT03977194|Active Comparator|Arm A : standard treatment|Carboplatine + paclitaxel (4 cycles of 28 days)
89376200|NCT03977194|Experimental|Arm B : standard treatment + immunotherapy|Carboplatine + paclitaxel (4 cycles of 28 days) + atezolizumab (every 21 days) until progression or toxicity
89376201|NCT03962959|Experimental|Excitatory TBS|Excitatory TBS
89376202|NCT03962959|Experimental|Inhibitory TBS|Inhibitory TBS
89376203|NCT03962959|Placebo Comparator|Sham TBS|Sham TBS
89376204|NCT03942887|Active Comparator|Rituximab|Patients will be intravenously treated with Rituximab 1000mg (or biosimilar) in the first week and receive a 2nd dosage of 1000mg 14 days later. Before every infusion of Rituximab patients will receive intravenous methylprednisolone 100mg together with oral acetaminophen 1000 mg and and intravenous Tavegil 2 mg.
89376205|NCT03942887|Active Comparator|Rituximab plus low-dose cyclophosphamide|5.1.2. Cyclophosphamide Patients will be intravenously treated with a total of 6 infusions of cyclophosphamide 500mg every 2 weeks. Before every infusion of cyclophosphamide patients will receive intravenous granisetron to prevent nausea.
89376206|NCT03924830|Active Comparator|Bulk without Surface Sealant|53 teeth will receive restorations using Bulk fill restoration without surface sealant
89376207|NCT03924830|Experimental|Bulk with Biscover|53 teeth will receive restorations using Bulk fill restoration with Biscover surface sealant
89376208|NCT03924830|Experimental|Bulk with Permaseal|53 teeth will receive restorations using Bulk fill restoration with Permaseal surface sealant
89376209|NCT03900689||Health Services Research - Part 1 Survey|Participants will be asked to complete a series of surveys. This will be preferentially completed on the same day of the visit but may be completed at a subsequent visit, over the telephone or taken home and sent back to the clinic.
89376210|NCT03900689||Health Services Research - Part 2 - Focus Group|Patients identified in Part 1 will be offered participation in the focus groups in Part 2. All patients enrolled in Part 1 will be considered for participation in Part 2. Approximately 30 total patients will be invited to participate. Patients who agree to be contacted will receive a telephone call or contacted in clinic and invited to participate in the Part 2 focus group.
88848749|NCT06055946||Symmcora® Long bidirectional|Symmcora® Long-term bidirectional barbed suture for vesicourethral anastomosis in patients undergoing robotic assisted radical prostatectomy.
88848750|NCT06055075|Experimental|Dose Exploration Phase: Forimtamig (Dose 1) + Carfilzomib|Participants will receive Dose 1 of forimtamig, subcutaneous (SC) injection in combination with carfilzomib, intravenous (IV) infusion until disease progression.
88848751|NCT06055075|Experimental|Dose Exploration Phase: Forimtamig (Dose 2) + Carfilzomib|Participants will receive Dose 2 of forimtamig, SC injection in combination with carfilzomib, IV infusion until disease progression.
88848752|NCT06055075|Experimental|Dose Exploration Phase: Forimtamig (Dose 3) + Carfilzomib|Participants will receive Dose 3 of forimtamig, SC injection in combination with carfilzomib, IV infusion until disease progression.
88848753|NCT06055075|Experimental|Dose Exploration Phase: Forimtamig (Dose 1) + Daratumumab|Participants will receive Dose 1 of forimtamig, SC injection in combination with daratumumab, SC injection until disease progression.
88848754|NCT06055075|Experimental|Dose Exploration Phase: Forimtamig (Dose 2) + Daratumumab|Participants will receive Dose 2 of forimtamig, SC injection in combination with daratumumab, SC injection until disease progression.
88848755|NCT06055075|Experimental|Dose Exploration Phase: Forimtamig (Dose 3) + Daratumumab|Participants will receive Dose 3 of forimtamig, SC injection in combination with daratumumab, SC injection until disease progression.
88848756|NCT06055075|Experimental|Dose Expansion Phase: Forimtamig|Participants will receive forimtamig, SC injection at a fixed dose determined during dose exploration phase until disease progression or completion of 12 months of treatment, whichever occurs first.
89376211|NCT03866460||Hearing evaluation DPOAE|Post IA hearing evaluation will be allowed up until 9 months after IA completion (or roughly one year from initiation of treatment). After completion of standard treatment for RB that included IA carboplatin.
88848757|NCT06055075|Experimental|Dose Expansion Phase: Forimtamig + Carfilzomib|Participants will receive forimtamig, SC injection at a fixed dose determined during dose exploration phase in combination with carfilzomib, IV infusion until disease progression.
88848758|NCT06055075|Experimental|Dose Expansion Phase: Forimtamig + Daratumumab|Participants will receive forimtamig, SC injection at a fixed dose determined during dose exploration phase in combination with daratumumab, SC injection until disease progression.
88848759|NCT06054477|Experimental|Phase 1 Dose Escalation|ALE.C04 single agent: Three planned doses of ALE.C04 and ALE.C04 in combination with pembrolizumab. Once a certain dose level of ALE.C04 is considered safe and well tolerated, the first cohort of patients receiving ALE.C04 at a lower dose level combined with pembrolizumab will be initiated
88848760|NCT06054477|Experimental|Phase 1 Recommended Dose for Expansion|One dose of ALE.C04 will be considered (dose identified from Phase 1 Dose Escalation part) Two ALE.C04 dose levels (higher or lower) will be considered for the combination with pembrolizumab
88848761|NCT06054477|Active Comparator|Phase 2 Randomized Combination part|ALE.C04 at RP2D combined to pembrolizumab compared to pembrolizumab monotherapy
88848762|NCT06054477|Experimental|Phase 2 Randomized Monotherapy part|ALE.C04 monotherapy (DL1 Q3W) ALE.C04 monotherapy (DL2 Q3W)
88848763|NCT06051708||AKI group|patients who are hospitalized and develop acute kidney injury after 48 hours from admission
88848764|NCT06051708||no AKI group|patients who are hospitalized and do not develop acute kidney injury after 48 hours from admission till discharge
89535057|NCT05021445|Experimental|plates based exercise|This will consists of 12 elderly participants who receive intervention protocol of Plates- based exercises program in which total 12-sessions will be given for thrice a week for four weeks for 50-minutes.
88848766|NCT06050356|Experimental|Arm 1 (phase 1a)|H107e
89376212|NCT03831503|Experimental|Cohort A - 0.5mg|Participants (n=6 per cohort) will be administered 1 injection (Day 0) of INO-A002 at 0.5 mg DNA/dose. Inoculation will be administered as 0.5 ml IM injection followed by electroporation with the CELLECTRA® 2000 device.
89376213|NCT03831503|Experimental|Cohort B - 1mg|Participants (n=6 per cohort) will be administered 1 injection (Day 0) of INO-A002 at 1 mg DNA/dose. Inoculation will be administered as 1 ml IM injection followed by electroporation with the CELLECTRA® 2000 device.
89376214|NCT03831503|Experimental|Cohort C - 2mg|Participants (n=6 per cohort) will be administered 2 injections (Day 0 and Day 3) of INO-A002 at 2 mg DNA/dose. Inoculation will be administered as 1 ml IM injection followed by electroporation with the CELLECTRA® 2000 device.
88848767|NCT06050356|Experimental|Arm 2 (phase 1a)|CAF®10b
88848768|NCT06050356|Experimental|Arm 3 (phase 1a)|H107e/CAF®10b - low adjuvant dose
88848769|NCT06050356|Experimental|Arm 4a (phase 1a)|H107e/CAF®10b - full adjuvant dose - low dose intranasal H107e
88848770|NCT06050356|Experimental|Arm 4b (phase 1a)|H107e/CAF®10b - full adjuvant dose - full dose intranasal H107e
88848771|NCT06050356|Experimental|Arm 1 (phase 1b)|H107e/CAF®10b
89376215|NCT03831503|Experimental|Cohort D - 4mg|Participants (n=6 per cohort) will be administered 2 injections (Day 0 and Day 3) of INO-A002 at 4 mg DNA/dose. Inoculation will be administered as 1 ml IM injection followed by electroporation with the CELLECTRA® 2000 device.
88848772|NCT06050356|Experimental|Arm 2 (phase 1b)|H107e/CAF®10b + BCG
88848773|NCT06050356|Active Comparator|Arm 3 (phase 1b)|BCG
88848774|NCT06050356|Placebo Comparator|Arm 4 (phase 1b)|Placebo
88848775|NCT06045364|Experimental|Glycopyrrolate|During induction of anesthesia, 0.2mg Glycopyrrolate was given intravenously to participants.
88848776|NCT06045364|Active Comparator|Anisodamine Group|During induction of anesthesia,10mg of Anisodamine was given intramuscular injection
88848777|NCT06041646|Other|Active Treatment - 180 mcg of Igalmi (dexmedetomidine)|An initial dose of 180 µg of Igalmi as needed for the treatment of agitation over a period of 7 days. In the event of persistent or recurrent agitation, investigators may choose to repeat dose at 90 μg after the 2-hour time point in the absence of dose-limiting adverse events or safety concerns. A maximum of 2 repeat doses will be allowed in a 24-hour period.
89376216|NCT03831503|Experimental|Cohort E - 4mg Side Port|Participants (n=6 per cohort) will be administered 2 injections (Day 0 and Day 3) of INO-A002 at 4 mg DNA/dose. Inoculation will be administered as 1 ml IM injection followed by electroporation with the CELLECTRA® 2000 device with Side Port needle.
89376217|NCT03800017|Experimental|Hyperoxia|During exercise on visit 4, participants in both groups (i.e., ILD patients and controls) will breathe supplemental oxygen (i.e., 60% oxygen) during constant-load exercise.
89376218|NCT03800017|Placebo Comparator|Healthy Controls|During exercise on visit 3, participants in both groups (i.e., ILD patients and controls) will breathe ambient air (i.e., 20.93% oxygen) during constant-load exercise.
89376219|NCT03785405|Experimental|sacubitril/valsartan|single arm, open label sacubitril/valsartan
89376220|NCT03773523|Experimental|Experimental: active tDCS|Subjects that are randomly assigned to this arm will undergo 5 sessions of tDCS.
89376221|NCT03773523|Sham Comparator|Sham Comparator: sham tDCS|Subjects randomly assigned to sham-tDCS will receive very low current stimulation at the beginning and end of the session, mimicking the feeling of current stimulation in the scalp, but not reaching levels that will stimulate brain function. There will be a total of 5 sham tDCS sessions.
89376222|NCT03699241|Placebo Comparator|Group 1|HIV-Uninfected participants
89376223|NCT03699241|Placebo Comparator|Group 2|HIV-Uninfected participants
89376224|NCT03699241|Placebo Comparator|Group 3|HIV-Uninfected participants
89376225|NCT03699241|Placebo Comparator|Group 4|HIV-Uninfected participants
89376226|NCT03699241|Placebo Comparator|Group 5|HIV-Uninfected participants
89376227|NCT03673462|Experimental|Group 1: MenACYW Conjugate Vaccine|Healthy infants aged greater than equal to (>=) 42 to less than equal to (<=) 89 days (at the time of enrollment) received MenACYW Conjugate Vaccine at the age of Months 2, 4, 6, and 12 along with Pentacel® (DTaP-IPV/Hib vaccine) at 2, 4, and 6 months of age; PREVNAR 13® (pneumococcal 13-valent conjugate vaccine; PCV13) at 2, 4, 6, and 12 months of age; RotaTeq® (rotavirus vaccine) at 2, 4, and 6 months of age; ENGERIX-B® (hepatitis B vaccine) at 2 and 6 months of age; and M-M-R® II (measles, mumps, and rubella vaccine) and VARIVAX® (varicella vaccine) at 12 months of age.
89376228|NCT03673462|Active Comparator|Group 2: MENVEO®|Healthy infants aged >= 42 to <= 89 days (at the time of enrollment) received MENVEO® Conjugate Vaccine at the age of Months 2, 4, 6, and 12 along with Pentacel® (DTaP-IPV/Hib vaccine) at 2, 4, and 6 months of age; PREVNAR 13® (PCV13) at 2, 4, 6, and 12 months of age; RotaTeq® (rotavirus vaccine) at 2, 4, and 6 months of age; ENGERIX-B® (hepatitis B vaccine) at 2 and 6 months of age; and M-M-R® II (measles, mumps, and rubella vaccine) and VARIVAX® (varicella vaccine) at 12 months of age.
89376229|NCT03611725|Active Comparator|Distal radial artery|"After subcutaneous injection of lidocaine, the distal radial artery around the bony surface area is punctured with a 20-gauge venipuncture catheter needle or steel needle according to the operator's discretion. After successful puncture, flexible, straight plastic 0.025 mini-guidewire is inserted through the hole of the puncture needle. Then, Radifocus® introducer sheath (Terumo, Tokyo, Japan) is inserted into the distal radial artery."
88810419|NCT06213506|Experimental|Infants_9M_Dose C Group|Infants 9 months of age, part of the safety cohort, randomized to receive 3 doses of the iNTS-GMMA Dose C vaccine at Day 1, Day 85 and Day 169. These infants also receive an EPI vaccination with Measles and Rubella Vaccine (MR-VAC) and Yellow Fever (YF) vaccine at 28 days after the first study intervention administration occurring at Day 1, at the local EPI vaccination centers, and not part of the current clinical trial.
88848778|NCT06036641||Colorectal surgery|Individuals scheduled for colorectal surgery in the HDTL position
89376230|NCT03611725|Placebo Comparator|Radial artery|"After subcutaneous injection of lidocaine, the radial artery is punctured with a 20-gauge venipuncture catheter needle or steel needle according to the operator's discretion. After successful puncture, flexible, straight plastic 0.025 mini-guidewire is inserted through the hole of the puncture needle. Then, Radifocus® introducer sheath (Terumo, Tokyo, Japan) is inserted into the radial artery."
89376231|NCT03590327|No Intervention|Apathy +, rTMS -|This arm will be followed without intervention
89376232|NCT03590327|Active Comparator|rTMS|This group will be randomized to receive rTMS treatment
89376233|NCT03590327|Sham Comparator|Sham|This group will be randomized to receive sham treatment
89376234|NCT03583684|Experimental|Pivotal Response Treatment Program (PRT-P)|The Pivotal Response Treatment Program (PRT-P) will consist of 3 parent-only sessions (60-90 min) and 13 family sessions with the parent and child (60-90 min). These 16 sessions are once per week over a 16 week period.
89376235|NCT03583684|No Intervention|Delayed Treatment Group (DTG)|Child continues stable treatments as usual in the community.
89376236|NCT03522831|Active Comparator|Salbutamol meter-dose inhaler|Inhalation of 400 μg salbutamol
89376237|NCT03522831|Placebo Comparator|Placebo meter-dose inhaler|Inhalation of 400 μg placebo
89376238|NCT03517787|Experimental|FES+TE|Participants receiving Functional electrical stimulation (FES) combined with therapeutic exercise (TE)
89376239|NCT03517787|Active Comparator|TE|Participants receiving only therapeutic exercise
89376240|NCT03517787|Other|REF-FES+TE|Healthy adults (reference group REF) that participate only in 1 session and receive FES and therapeutic exercise
89376241|NCT03517787|Other|REF-TE|Healthy adults that participate only in 1 session and receive only therapeutic exercise
89376242|NCT03478852||Single Arm|Single arm open enrollment of patients with standard of care treatment and evaluation
89376243|NCT03464292||Vehicle Patch|Control patch will be the same topical solution but will not contain capsaicin. The patch will applied to the hand for 30 - 60 min. Patients will be instructed to not touch or wash their hands during the course of the study to minimize spreading of the patch to other areas of the body. Subsequently, the patch will be immediately removed.
89376244|NCT03464292||Capsaicin Patch 8% or 0.1% Capsaicin Cream|8% capsaicin topical patch or 0.1% capsaicin cream. The patch will applied to the hand for 30 - 60 min. The cream will be applied similarly on a 3 cm2 area of the arm. Patients will be instructed to not touch or wash their hands during the course of the study to minimize spreading of the patch to other areas of the body. Subsequently, the patch will be immediately removed.
89376245|NCT03434717|Experimental|Control (high distress)|Control group receiving care as usual
89376246|NCT03434717|Experimental|Individualised rehabilitation|"Patients with high distress receive the intervention individualized rehabilitation including evaluation of individual needs and based on that physical, psychological or social interventions to promote rehabilitation."
89376247|NCT03434717|Experimental|Control group (low distress)|Control group receiving care as usual
89376248|NCT03432364|Experimental|ST-400 Investigational product|ST-400 Investigational product is composed of autologous CD34+ hematopoietic stem/progenitor cells that are genetically modified ex vivo at the erythroid-specific enhancer of the BCL11A gene
89376249|NCT03408665|Experimental|SBRT|Stereotaxic Body Radiation Therapy administred in 3 to 6 fractions.
89376250|NCT03406624||Spinal fusion with modic changes|Patients scheduled for surgery with lumbar spinal fusion with procedures involving moderate to extensive removal of the disc, and with modic changes seen on MRI at the actual level for surgery
89376251|NCT03406624||Spinal fusion without modic changes|Patients scheduled for surgery with lumbar spinal fusion with procedures involving moderate to extensive removal of the disc, but with no modic changes seen on MRI at the actual level for surgery
89376252|NCT03406624||Disc herniation surgery with modic changes|Patients scheduled for disc herniation surgery, and with modic changes seen on MRI at the actual level for surgery
89376253|NCT03406624||Disc herniation surgery without modic changes|Patients scheduled for disc herniation surgery, but with no modic changes seen on MRI at the actual level for surgery
89376254|NCT03348969|Experimental|Intervention|Neoadjuvant Mitomycin C
89376255|NCT03348969|Active Comparator|Control|Adjuvant Mitomycin C
89181871|NCT00756314|No Intervention|Control|All 123 women allocated to control group received a standard care available at IMIP.Standard care is comprised of educational group counseling by specialized nursing staff in family planning discussing about contraceptive methods and side effects
88848779|NCT06034210|Experimental|ZOLES insoles|Participants allocated to the intervention group will receive customised 3D-printed insoles (Zoles ApS, Espergærde, DK-3060, Denmark) to mitigate running-related pain and discomfort. Being a pragmatic trial, all participants are permitted to continue or initiate any usual care of their choice.
88848780|NCT06034210|No Intervention|Do-as-usual|"Participants allocated to the control group are a do-as-usual comparator. This implies, that the participants can treat and prevent running-related pain and discomfort in any way they wish, except using the Zoles 3D-printed insoles."
88848781|NCT06031441|Experimental|Dose Escalation Cohort|Participants in successive cohorts will receive escalating doses of RO7566802, as an intravenous (IV) infusion on Day 1 of each 21-day cycle followed by RO7566802 in combination with a fixed dose of atezolizumab, as an IV infusion on Day 1 of each 21-day cycle until disease progression or unacceptable toxicity.
88848782|NCT06031441|Experimental|Dose Expansion Cohort|Participants with select solid tumors will receive a recommended dose of RO7566802, determined in Dose Escalation phase, as an IV infusion in combination with a fixed dose of atezolizumab, as an IV infusion on Day 1 of each 21-day cycle until disease progression or unacceptable toxicity.
88848783|NCT06029179|Active Comparator|Group A|30 patients will receive sodium zirconium cyclosilicate (SZC)
88848784|NCT06029179|Active Comparator|Group B|30 patients will receive sodium polystyrene sulfonate
88848785|NCT06023368|Experimental|Sterile Vapocoolant Spray|Num vapocoolant spray will be administered as a single use canister around the port
88848786|NCT06023368|Active Comparator|EMLA Cream|Numbing (EMLA) cream will be applied around the port.
89535058|NCT05021445|Active Comparator|conventional treatment|this will consists of 12 elderly participants who will receive intervention protocol of Conventional balance training exercises in which total 12-sessions will be given for thrice a week for four weeks for 50-minutes.
88848789|NCT06016088|Experimental|RSP-1502|"Cohorts 1-4 will receive RSP-1502 (300 mg tobramycin plus an ascending dose of CaEDTA).~Cohort 5 will receive 300 mg tobramycin + CaEDTA at the MTD."
88848790|NCT06016088|Active Comparator|Active Control|• Tobramycin Inhalation Solution 300 mg.
88848791|NCT06014983|Active Comparator|Ferrous fumarate|24 mg elemental iron/day
88848792|NCT06014983|Experimental|Ferrous bisglycinate|24 mg elemental iron/day
89376256|NCT03343184|Active Comparator|SEE and incremental restoration|50 teeth will receive restorations using SEE Strategy and Incremental Restoration
88848794|NCT06008756|Experimental|MK-0616|Participants receive MK-0616 20 mg once daily.
88848795|NCT06008756|Placebo Comparator|Placebo|Participants receive placebo once daily.
88848796|NCT06008236|Experimental|Experimental Group|Researcher will be applied progressive muscle relaxation and deep breathing exercises to the students in the experimental group. This practice will be applied to students once a week for six weeks. It will be ensured that the environment is quiet, at room temperature and dim. Students will take their places in chairs at an equal distance from each other. The researcher will be located in a place where his voice is heard by all students, and computers and speakers will be used for music. In addition, black eye patches will be distributed to students to use while exercising before starting the exercises. The muscle groups that are desired to be contracted and relaxed will be as follows (hands, arms, muscles in the face, tongue, head and neck muscles, shoulders, waist, abdominal leg muscles, and feet). At the same time, Lily's Theme which was selected by using the literature and expert opinion, will be played to the students together with the exercises.
88848797|NCT06008236|No Intervention|Control Group|No intervention will be applied to the control group. They will be expected to refill the scales at the end of six weeks and on the eighth week for follow-up purposes.
88848798|NCT06004336|Experimental|Radiation therapy (Control Arm)|Participants will be asked to receive radiation therapy and be randomly assigned to receive pembrolizumab or not after that.
88848799|NCT06004336|Experimental|Radiation Therapy and Pembrolizumab|Participants will be asked to receive radiation therapy and be randomly assigned to receive pembrolizumab or not after that.
88848800|NCT06002243|Experimental|Intervention|Participant receiving echocardiography screening.
88848801|NCT06001827|Experimental|Treatment Arm|Treated with SelfWrap Bioabsorbable Perivascular Wrap during AVF creation surgery
88848802|NCT06001827|Sham Comparator|Control Arm|AVF creation surgery without any intervention (untreated AVF control, or standard of care)
88848803|NCT06000592|Experimental|transcutaneous spinal stimulation|
88848804|NCT06000202|Experimental|Laser Arm|Non-ablative thermal-only Er:YAG laser (Fotona Dynamis) treatment using R11 and PS03 handpieces
88848805|NCT06000202|Sham Comparator|Sham Arm|The same procedure is applied but with a sham handpiece.
88848806|NCT05992311|Experimental|Montelukast Group|Montelukast two capsules of 20 mg (40 mg total) taken by mouth once daily for ten weeks
88848807|NCT05992311|Placebo Comparator|Placebo Group|Microcrystalline cellulose two capsules taken by mouth once daily for ten weeks
88848808|NCT05989373|Experimental|nerve stimulation|The test in currently used to search for a nerv compression
88848809|NCT05989308|No Intervention|Usual Care|Care as usual
89376257|NCT03343184|Experimental|SEE and bulk restoration|50 teeth will receive restorations using SEE Strategy and Bulk Fill Restoration
89376258|NCT03343184|Experimental|SET and incremental restoration|50 teeth will receive restorations using SET Strategy and Incremental Restoration
89376259|NCT03343184|Experimental|SET and bulk restoration|50 teeth will receive restorations using SET Strategy and Bulk Fill Restoration
89399364|NCT02178254|Experimental|Sequence 3|N=10 subjects receive 3grams oral sachet of Monurol in Period 1; 1.0gram of Intravenous (IV) ZTI-01 for Period 2 (1-hour infusion); and 8.0 grams IV ZTI-01 for Period 3.
89376260|NCT03307785|Experimental|Part A: TSR-042 and niraparib 200 mg QD|Patients will receive TSR-042 500 milligram (mg), intravenous (IV) infusion on Day 1 of every cycle (every 3 weeks [Q3W]) for 4 cycles (each cycle is 21 days); followed by TSR-042 1000 mg, IV infusion on Day 1 of every other cycle (every 6 weeks [Q6W]) beginning on Day 1 of Cycle 5 along with niraparib 200 mg, once daily (QD), orally on Days 1 to 21 repeated Q3W.
89376261|NCT03307785|Experimental|Part A: TSR-042 and niraparib 300 mg QD|Patients will receive TSR-042 500 mg, IV infusion on Day 1 of every cycle (Q3W) for 4 cycles (each cycle is 21 days); followed by TSR-042 1000 mg, IV infusion on Day 1 of every other cycle (Q6W) beginning on Day 1 of Cycle 5 along with niraparib 300 mg, QD, orally on Days 1 to 21 repeated Q3W.
89376262|NCT03307785|Experimental|Part B: TSR-042 and carboplatin-paclitaxel|Patients will receive TSR-042 500 mg, IV infusion on Day 1 of every cycle (Q3W) for 4 cycles (each cycle is 21 days); followed by TSR-042 1000 mg, IV infusion on Day 1 of every other cycle (Q6W) beginning on Day 1 of Cycle 5 along with carboplatin, IV infusion on Day 1 Q3W and paclitaxel 175 milligram per square meter (mg/m^2), IV infusion on Day 1 Q3W administered for 4 to 6 cycles.
89376263|NCT03307785|Experimental|Part C: TSR-042, niraparib 200 mg QD and bevacizumab|Patients will receive TSR-042 500 mg, IV infusion on Day 1 of every cycle (Q3W) for 4 cycles (each cycle is 21 days); followed by TSR-042 1000 mg, IV infusion on Day 1 of every other cycle (Q6W) beginning on Day 1 of Cycle 5 along with niraparib 200 mg administered orally on Days 1 to 21 repeated Q3W and bevacizumab 15 mg/kilogram (kg), IV infusion on Day 1 of every 21-day cycle Q3W for up to 15 months.
89376264|NCT03307785|Experimental|Part C: TSR-042, niraparib 300 mg QD and bevacizumab|Patients will receive TSR-042 500 mg, IV infusion on Day 1 of every cycle (Q3W) for 4 cycles (each cycle is 21 days); followed by TSR-042 1000 mg, IV infusion on Day 1 of every other cycle (Q6W) beginning on Day 1 of Cycle 5 along with niraparib 300 mg administered orally on Days 1 to 21 repeated Q3W and bevacizumab 15 mg/kg, IV infusion on Day 1 of every 21-day cycle Q3W for up to 15 months.
89376265|NCT03307785|Experimental|Part D: TSR-042, carboplatin-paclitaxel and bevacizumab|Patients will receive TSR-042 500 mg, IV infusion on Day 1 of every cycle (Q3W) for 4 cycles (each cycle is 21 days); followed by TSR-042 1000 mg, IV infusion on Day 1 of every other cycle (Q6W) beginning on Day 1 of Cycle 5 along with carboplatin, IV infusion on Day 1 Q3W and paclitaxel 175 mg/m^2, IV infusion on Day 1 Q3W administered for 4 to 6 cycles; and bevacizumab 15 mg/kg, IV infusion on Day 1 of every 21-day cycle Q3W for up to 15 months.
89376266|NCT03307785|Experimental|Part E: TSR-042 and carboplatin-pemetrexed|Patients will receive TSR-042 500 mg, IV infusion on Day 1 of every cycle (Q3W) along with carboplatin, IV infusion on Day 1 Q3W and pemetrexed 500 mg/m^2, IV infusion on Day 1 Q3W (with vitamin supplementation) administered for 6 cycles (each cycle is 21 days).
89376267|NCT03307785|Experimental|Part F: TSR-042, TSR-022, and carboplatin-pemetrexed|Patients will receive TSR-042 500 mg, IV infusion on Day 1 of every cycle (Q3W); and TSR-022 900 mg, IV infusion on Day 1 Q3W along with carboplatin, IV infusion on Day 1 Q3W administered for 5 cycles (each cycle is 21 days); and pemetrexed 500 mg/m^2, IV infusion on Day 1 Q3W (with vitamin supplementation).
89376268|NCT03307785|Experimental|Part G: TSR-042 and carboplatin-nab-paclitaxel|Patients will receive TSR-042 500 mg, IV infusion on Day 1 of every cycle (Q3W) along with carboplatin, IV infusion on Day 1 Q3W for 4 to 6 cycles (each cycle is 21 days) and nab-paclitaxel 100 mg/m^2, IV infusion on Days 1, 8 and 15 (every week [Q1W]) of every 3 week cycle for 4 to 6 cycles.
89376269|NCT03307785|Experimental|Part H: TSR-042, TSR-022, and carboplatin-nab-paclitaxel|Patients will receive TSR-042 500 mg, IV infusion on Day 1 of every cycle (Q3W); followed by TSR-022 900 mg, IV infusion on Day 1 Q3W along with carboplatin, IV infusion on Day 1 Q3W for 4 to 6 cycles (each cycle is 21 days) and nab-paclitaxel 100 mg/m^2, IV infusion on Days 1, 8 and 15 (Q1W) of every 3 week cycle for 4 to 6 cycles.
88848810|NCT05989308|Experimental|Preferred Modality|Text or email message to guardian with proxy information. If the guardian has no personal MyChart access, before sending proxy information to set up access to their child's MyChart, the investigators will message the guardian up to two times with information enabling them to access their personal MyChart.
88848811|NCT05989308|Experimental|Patient Portal|Patient portal message (MyChart) to guardian with proxy information. If the guardian has no personal MyChart access, before sending proxy information to set up access to their child's MyChart, the investigators will message the guardian up to two times with information enabling them to access their personal MyChart.
88848812|NCT05981209|Experimental|Treatment (elotuzumab, CC-92480, dexamethasone)|Patients receive elotuzumab IV on days 1, 8, 15, and 22 of cycles 1 and 2 and then on day 1 of each subsequent cycle. Patients also receive CC-92480 PO on days 1-21 of each cycle and dexamethasone IV or PO on days 1, 8, 15, and 22 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients may undergo an ECHO during screening and undergo MRI, CT, or x-ray imaging during screening and on study as clinically indicated. Patients also undergo blood sample collection as well as bone marrow biopsy and aspiration during screening and on study.
88848813|NCT05978388|Experimental|Analysis of coronary CT angiography and CAC scoring at the time of catheter ablation|Based on the results of the coronary CT angiography and CAC scoring in the intervention group, relevant anti-ischemic and multimodality treatment will be initiated according to clinical guidelines.
88848814|NCT05978388|No Intervention|No analysis of coronary CT angiography and CAC scoring at the time of catheter ablation|Patients in the control group will follow the current standard of care prior to ablation.
88848815|NCT05976633|Experimental|Consumption of 1 of 3 rice products|This arm will provide 1 of the 3 randomly assigned rice products to the participant and there will be a minimum of three days separating each visit.
88848816|NCT05976633|Experimental|Consumption of 2 of 3 rice products|This arm will provide the consumption of the second randomly assigned rice product. There will be a minimum of three days separating each visit.
88848817|NCT05976633|Experimental|Consumption of 3 of 3 rice products|This arm will provide the third consumption of the randomly assigned rice product. There will be a minimum of three days separating each visit.
88848818|NCT05976633|Active Comparator|Consumption of the control rice product|This arm will provide the white rice control product.
88848819|NCT05976633|Experimental|Consumption of 1 of 3 rice products with different preparation method|This arm will provide the blends product via a different cooking method (microwave).
89376270|NCT03307785|Experimental|Part I: TSR-042, TSR-022, and carboplatin-paclitaxel|Patients will receive TSR-042 500 mg, IV infusion on Day 1 of every cycle (Q3W); followed by TSR-022 900 mg, IV infusion on Day 1 Q3W along with carboplatin, IV infusion on Day 1 Q3W and paclitaxel 175 mg/m^2, IV infusion on Day 1 Q3W for 4 to 6 cycles (each cycle is 21 days).
89376271|NCT03292484|Experimental|Treatment Pathway 1, 2, 3, 4, 5|Subjects will be assigned to one of five treatment pathways when first enrolled into ARC008, which is dependent on the treatment received (AR101 or placebo) during the parent study and their tolerance of this treatment regimen (e.g., daily or non-daily schedule).
89376272|NCT03267381||Arm 1a|Stage III melanoma diagnosis (biopsy-proven lymph node positive (this is either clinically palpable or enlarged nodes detected by imaging, which are then biopsied and have macroscopic disease).
89376273|NCT03267381||Arm 1b|Stage III after sentinel node biopsy (microscopic disease diagnosed on sentinel node biopsy).
89376274|NCT03267381||Arm 2|Stage IV- will need to stratify by current treatment with immunotherapy, targeted therapy, none
89376275|NCT03267134|Experimental|Hydrus Microstent|Hydrus Microstent implanted in the eye per the supplied Hydrus Microstent Instructions for Use and associated training. Only one eye (study eye) will be implanted.
89376276|NCT03244124|Active Comparator|SET (Self-Etching)|50 teeth will receive restorations using Self-Etching Application Strategy
89376277|NCT03244124|Experimental|SEE (Selective Enamel Etching)|50 teeth will receive restorations using Enamel Etching Application Strategy
88848820|NCT05967728|Experimental|Remote Ischemic Conditioning (RIC)|"For the CSVD patients, each RIC session consists of 4 cycles of inflating a blood-pressure cuff around an upper arm to reduce blood flow to that limb for approximately 5 minutes, after which it is deflated for around 5 minutes to restore normal blood flow. The procedure will use the RIC auto-control device with a cuff that inflates to a pressure of up to 200 mmHg. The patients will use the device once daily for a total of 60 days.~For the MSU patients in the non-randomized component of the study, the device cuff will inflate around a limb to reduce blood flow for approximately 5 minutes, after which it will deflate for around 5 minutes to restore normal blood flow. This cycle will repeat (for a maximum of 6 cycles) until the patient is transferred to the hospital for further management."
88848821|NCT05967728|Sham Comparator|Sham RIC|For the CSVD patients randomized to sham, each RIC session consists of 4 cycles of inflating a blood-pressure cuff around an upper arm to 30mmHg for approximately 5 minutes, after which it is deflated for around 5 minutes. The procedure will use the same RIC device as the treatment arm, just randomized to run the sham protocol. The patients will use the device once daily for a total of 30 days. After 30 days, they will cross over to true RIC as described above, once daily for the remaining 30 days, accomplished by remote reprogramming of their device protocols.
88848822|NCT05963217|Experimental|Experimental: Dose Level 1 to 3|0.3 to 3 x 10^6 autologous CD19-CAR-T cells/kg per patient will be administered intravenously after a conditioning chemotherapy with cyclophosphamide and fludarabine.
88848823|NCT05956886|Experimental|sleep chatbot intervention|Using CBT-I principles, participants will receive a four-week intervention delivered through a chatbot. The self-administered intervention is comprised of personalized behavioral prescriptions based on stimulus control principles and sleep schedule modification goals using sleep efficiency (SE) criteria. Participants are allowed to self-adjust expectations and make realistic decisions on sleep schedules. Other CBT-I components will be used as on-demand content. The chatbot will facilitate sleep goal setting with the participant, communicate weekly behavioral prescription and CBT-I educational modules, collect sleep diary and provide adaptive feedback and reactive services (e.g. Q&A conversations) 24/7.
89376278|NCT03244124|Experimental|ERDry (Etch&Rinse Dry)|50 teeth will receive restorations using Etch&Rinse Dry Application Strategy, leaving dentin dry (but not overdry)
89376279|NCT03244124|Experimental|ERWet (Etch&Rinse Wet)|50 teeth will receive restorations using Etch&Rinse Wet Application Strategy, leaving dentin wet
88848824|NCT05953636|Other|pre-dialytic|25 patients will receive oral protein nutritional supplement (ONS) (Fresubin protein powder 25mg/5scoops per hemodialysis session) for 6 weeks 1 hour before the start of the session (pre-dialytic).
89181872|NCT04108793|Experimental|Intervention Arm|The Intervention group will be given a program of progressive balance and lower limb strengthening exercises twice a week for 3 months. All exercises will include 5 minutes warm-up exercises. The lower limb extensor muscle groups (hip & knee extensors and ankle plantar flexors) will be targeted with exercises designed to enhance postural control (i.e. balance) and muscle strength. The balance exercises include standing with a decreased base of support, forwards and sideways stepping/walking, and graded reaching activities in standing. Strengthening exercises will include sit-to-stand, forward and lateral step-ups onto a small block, semi squats and heel raises in standing. Standard principles governing frequency, volume, duration, intensity and progression of exercise will be applied. Cueing strategies will be used to reduce freezing. T
89181873|NCT04108793|No Intervention|Control Arm|The control arm will receive the usual standard postoperative rehabilitation after a bipolar hemiarthroplasty/ total hip arthroplasty which will include in hospital rehabilitation and a maximum of 5 visits postoperatively
89376280|NCT03235804|No Intervention|Control Group|Those assigned to the Control group will be asked to maintain their usual dietary intake over 12 weeks. Participants' usual dietary intake is expected to reflect the North American dietary pattern (i.e. ~15% of total energy intake coming from protein, ~50% from carbohydrate and ~35% from fat).
89376281|NCT03235804|Experimental|Powdered Meal Replacement Group|Those assigned to the Powdered Meal Replacement group will be asked to maintain their usual dietary intake and consume a powdered meal replacement composed of soy protein, honey and yogurt twice daily (in two snacks) over 12 weeks. The addition of the nutritional supplement to a North American Dietary Pattern (described on the CON group diet) will result in a diet composed of, approximately, 22% of protein, 48% of carbohydrate and 30% of fat of total energy intake. The amount of protein is considered higher than the North American dietary pattern (i.e. 15%); however, still within the Acceptable Macronutrient Distribution Range (AMDR) recommended by the Dietary Guidelines for Americans (10-35%).
89376282|NCT03217188|Experimental|fractionated full dose re-irradiation|
89376283|NCT03217188|Experimental|hypofractionated palliative re-irradiation|
89399365|NCT02178254|Experimental|Sequence 1|N=10 subjects receive 1.0gram of Intravenous (IV) ZTI-01 for Period 1 (1-hour infusion); 8.0 grams IV ZTI-01 for Period 2 (1-hour infusion); and 3grams oral sachet of Monurol in Period 3.
88848825|NCT05953636|Other|intra-dialytic|25 patients will receive oral protein nutritional supplement (ONS) for 6 weeks 2 hours after the start of the session (intra-dialytic).
88848826|NCT05953636|Other|inter-dialytic|25 patients will receive oral protein nutritional supplement (ONS) for 6 weeks in non-dialysis days (inter-dialytic).
88848827|NCT05952856|Experimental|MK-0616|Participants will receive 20 mg of MK-0616 orally once daily (QD) for up to 52 weeks.
88848828|NCT05952856|Placebo Comparator|Placebo|Participants will receive MK-0616-matching placebo orally QD for up to 52 weeks.
88848829|NCT05952570|Experimental|protein supplement|50 patients will receive oral protein nutritional supplement (Fresubin protein powder 25mg/5scoops per hemodialysis session) for 3 months
88848830|NCT05952570|Placebo Comparator|control|50 patients will receive a routine nutrition regimen for 3 months. (control group)
88848831|NCT05952544||control group|include patients who were on low protein diet only
88848832|NCT05952544||interventional group|include patients who consumed KA/EAA plus very low protein diet
89535059|NCT05015205|Experimental|MET Group|Post isometric relaxation technique MET was applied in two muscle groups; Lumbar Extensors (Erector Spinae) and Hip Flexors (Iliopsoas). The exercises were performed 3 times per week for 4 weeks.
88848834|NCT05949580||People with RRMS|Participants with relapsing-remitting multiple sclerosis (RRMS) will have to complete various questionnaire from which data will be collected for patient-reported outcomes (PROs) using the icompanion patient app and the HCPs will complete various questionnaires using the icompanion HCP portal.
88848835|NCT05947890|Experimental|1.1a - Adolescents and adults without HIV and negative interferon-gamma release assay|Participants will receive MTBVAC as a 0.1 mL intradermal (ID) injection, in the upper arm once at Week 0.
88848836|NCT05947890|Experimental|1.1b - Adolescents and adults without HIV and negative interferon-gamma release assay|Participants will receive BCG as a 0.1 mL intradermal (ID) injection, in the upper arm once at Week 0.
89181874|NCT00727506|Experimental|BIBW 2992|BIBW 2992 once daily
89181875|NCT00727506|Active Comparator|TMZ|TMZ 21/28 days
89181876|NCT00727506|Experimental|BIBW 2992 plus TMZ|BIBW 2992 once daily plus TMZ 21/28 days
89181877|NCT04108715|Active Comparator|ESPB GROUP|Erector spina plane block group
89181878|NCT04108715|Active Comparator|SAPB group|Deep Serratus anterior plane block group
89181879|NCT03982706||MRI-US Fusion|patients undergoing MRI targeted prostate biopsy
89181880|NCT03982706||Focal|patients undergoing focal treatment for localized prostate cancer (HIFU, NanoKnife, Cryotherapy)
89181881|NCT00789815|Active Comparator|BIS-guided propofol infusion|In the study group, induction was started using alfentanil 4~5μg/kg bolus following repeated propofol boluses (0.5~1.5 mg/kg) until the BIS level reached 70. During maintenance, propofol infusion (3~12 mg/kg/hour) was given using a syringe pump (Injectomat Agilia, Fresenius Kabi, France), which was titrated to keep the BIS level between 65 and 75.
89181882|NCT00789815|Active Comparator|Clinical-judged midazolam administration|In the control group, induction was started using alfentanil 4~5μg/kg bolus following 2 mg midazolam bolus. After 2 minutes, if the patient was not well sedated, midazolam boluses were repeat by increments of 2 mg/2min until conscious sedation was achieved
89181883|NCT02592174|Other|HIV subjects|"Evaluation of health-related quality of life and collection of social and demographic informations at the inclusion visit.~Neurocognitive assessment with neuropsychologist and walking speed, grasp force and one leg stand assessments at the neurocognitive visit.~Two substudies will be proposed:~cerebral images sub-study (80 patients in the centers of Montpellier and the centers of Nîmes)~sub-study on immune activating markers with sample's collection (plasma), 85 patients in the centers of Montpellier and the centers of Nîmes."
89181884|NCT04019730|Experimental|low carbohydrate diet|less than 10 En% carbohydrates
89181885|NCT04019730|Experimental|high carbohydrate diet|more than 50 En%carbohydrates
89181886|NCT05042583|Experimental|experimental group|The experimental group was injected with 0.5% ropivacaine 6ml
89181887|NCT05042583|Placebo Comparator|Control group|control group was injected with 6ml normal saline.
89181888|NCT00721578||1|
89181889|NCT00789737|Experimental|Welchol|Welchol 625mg tablets
89181890|NCT00789737|Placebo Comparator|placebo|placebo
89181891|NCT03854721|Experimental|VAX014|Intravesical VAX014 (dose: 3.33x10^10 - 9.0x10^11 recombinant bacterial minicells (rBMCs)), given once per week for Weeks 1-6
89181892|NCT02592252|Experimental|Microfinance + gender training|Microfinance + 10 sessions of participatory gender training
89181893|NCT02592252|Experimental|Microfinance only|Receive microfinance only
89181894|NCT02592252|Experimental|Gender training only|10 sessions of participatory gender training for women and their male partners
89399366|NCT02178254|Experimental|Sequence 2|N=10 subjects receive 8.0 grams IV ZTI-01 for Period 1(1-hour infusion); 3grams oral sachet of Monurol in Period 2 and 1.0gram of IV ZTI-01 for Period 3 (1-hour infusion)
89181895|NCT02592252|No Intervention|No intervention|No microfinance or participatory gender training
89181896|NCT04019574|Experimental|CR845 0.5 mcg/kg IV (Therapeutic Dose)|
89181897|NCT04019574|Experimental|CR845 3 mcg/kg IV (Supratherapeutic Dose)|
89181898|NCT04019574|Placebo Comparator|Placebo IV|
89181899|NCT04019574|Active Comparator|Moxifloxacin 400 mg|
89399367|NCT02173262|Other|G-CSF|Participants will receive a daily injection of G-CSF while on chemotherapy for prevention of febrile neutropenia.
89399368|NCT02173262|Other|Ciprofloxacin|Participants will receive Ciprofloxacin 500 mg twice a day by mouth for 10 days of each cycle during chemotherapy for prevention of febrile neutropenia.
89399369|NCT02175134|No Intervention|conventional diagnostic flow arm|Perform the laparoscopic biopsy as a discretion of attending physician's decision
88848837|NCT05947890|Experimental|1.2a - Adolescents and adults without HIV and positive interferon-gamma release assay|Participants will receive MTBVAC as a 0.1 mL intradermal (ID) injection, in the upper arm once at Week 0.
88848838|NCT05947890|Experimental|1.2b - Adolescents and adults without HIV and positive interferon-gamma release assay|Participants will receive BCG as a 0.1 mL intradermal (ID) injection, in the upper arm once at Week 0.
88848839|NCT05947890|Experimental|2.1 a- Adolescents and adults with well-controlled HIV and negative interferon-gamma release assay|Participants will receive MTBVAC as a 0.1 mL intradermal (ID) injection, in the upper arm once at Week 0.
89376284|NCT03199040|Experimental|Neoantigen DNA vaccine + Durvalumab|"The first neoantigen DNA vaccine injection will take place following the completion of standard of care therapy. The day of the first vaccine injection will be referred to as Day 1~The schedule of vaccination is Day 1, Day 29 ± 7, Day 57 ± 7, Day 85 ± 7, Day 113 ± 7, and Day 141 ± 7 with at least 21 days between injection days~For patients who are randomized to the neoantigen DNA vaccine plus durvalumab arm, the neoantigen-specific T cell response will be assessed prior to Day 85. If a neoantigen-specific T cell response is present, durvalumab will be started on Day 85, and will be administered Q4W at a dose of 1500 mg over the course of 60 minutes. If a neoantigen-specific T cell response is not present, these patients will be replaced but may continue to receive the neoantigen DNA vaccine on study. They will not be transferred to the vaccine-only arm."
88848840|NCT05947890|Experimental|2.1.b - Adolescents and adults with well-controlled HIV and negative interferon-gamma release assay|Participants will receive BCG as a 0.1 mL intradermal (ID) injection, in the upper arm once at Week 0.
88848841|NCT05947890|Experimental|2.2 a- Adolescents and adults with well-controlled HIV and positive interferon-gamma release assay|Participants will receive MTBVAC as a 0.1 mL intradermal (ID) injection, in the upper arm once at Week 0.
88848842|NCT05947890|Experimental|2.2 b- Adolescents and adults with well-controlled HIV and positive interferon-gamma release assay|Participants will receive BCG as a 0.1 mL intradermal (ID) injection, in the upper arm once at Week 0.
88848843|NCT05947890|Experimental|3.1 a- Adults with well-controlled HIV and negative interferon-gamma release assay|Participants will receive MTBVAC as a 0.1 mL intradermal (ID) injection, in the upper arm once at Week 0.
88848844|NCT05947890|Experimental|3.1 b- Adults with well-controlled HIV and negative interferon-gamma release assay|Participants will receive BCG as a 0.1 mL intradermal (ID) injection, in the upper arm once at Week 0.
88848845|NCT05947890|Experimental|3.2 a- Adults with well-controlled HIV and positive interferon-gamma release assay|Participants will receive MTBVAC as a 0.1 mL intradermal (ID) injection, in the upper arm once at Week 0.
88848846|NCT05947890|Experimental|3.2 b- Adults with well-controlled HIV and positive interferon-gamma release assay|Participants will receive BCG as a 0.1 mL intradermal (ID) injection, in the upper arm once at Week 0.
88848847|NCT05945212|Experimental|Vibration|Stroke patients in subacute rehabilitation phase will be included. In addition of a subacute post-stroke standard rehabilitation program, they will have a vibration program.
88848848|NCT05945212|Sham Comparator|no vibration|In addition of a subacute post-stroke standard rehabilitation program, they will have a sham vibration program.
88848849|NCT05943990|Experimental|GSK3845097|Eligible participants will be leukapheresed to manufacture engineered T-cells. Participants will then receive high dose of GSK3845097 after completing lymphodepleting chemotherapy. The first study participant receiving GSK3845097 will receive the total assigned dose as 2 separate infusions 7 days apart, in aliquots of 30% (first infusion) and 70% (second infusion) of the total target dose , respectively. Based on the dose limiting toxicities reported in the first participant, then all subsequent participants treated with GSK3845097 will receive the full dose as a single, i.e., one-time, infusion.
88848850|NCT05938023|Experimental|ATL1102 25mg|ATL1102 25mg administered subcutaneously once weekly
88848851|NCT05938023|Experimental|ATL1102 50mg|ATL1102 50mg administered subcutaneously once weekly
88848852|NCT05938023|Placebo Comparator|Placebo|Placebo is administered subcutaneously once weekly
88848853|NCT05934526|Placebo Comparator|Placebo|Placebo inhaled orally twice daily (BID) up to 48 weeks
88848854|NCT05934526|Experimental|Seralutinib 90 mg|Seralutinib inhaled orally BID up to 48 weeks
88848855|NCT05928806|Experimental|Arm A (botensilimab and balstilimab)|Arm A subjects will receive 2 cycles of induction treatment with each cycle lasting 6 weeks. Cycle 1 will consist of botensilimab 75mg IV in combination with balstilimab 450mg IV on Day 1 and Day 22. Cycle 2 will consist of balstilimab 450mg IV ONLY on Day 1 and Day 22. Botensilimab will NOT be given in Cycle 2. Subjects will receive 7 cycles of maintenance treatment with each cycle lasting 12 weeks. Cycles 3 and 4 will consist of botensilimab 75mg IV on Day 1 in combination with balstilimab 450mg IV on Day 1, 22, 43 and 64. Cycles 5-9 will consist of balstilimab alone 450 mg IV on Day 1, 22, 43 and 64.
88848856|NCT05928806|Active Comparator|Arm B (ipilimumab and nivolumab)|Arm B subjects will receive 2 cycles of induction treatment with each cycle lasting 6 weeks. Cycle 1 and 2 will consist of ipilimumab 1 mg/kg IV and nivolumab 3 mg/kg on Day 1 and 22. Subjects will receive 7 cycles of maintenance treatment with each cycle lasting 12 weeks. Nivolumab 480mg IV will be given on Day 1, 29 and 57 of each cycle (every 4 weeks).
88848857|NCT05924243|Experimental|RO7486967 Arm|Participants will receive RO07486967 for approximately 28 days with 14 days of follow up after the last dose.
88848858|NCT05924243|Placebo Comparator|Placebo|Matching placebo
88848859|NCT05919680|Experimental|Part A-800 mg NST-6179|up to 12 subjects
88848860|NCT05919680|Experimental|Part A matched NST-6179 placebo|up to 6 subjects
89181900|NCT04106765||: epileptic LGI1-antibody patients|"Patients affected by LGI1 antibody encephalitis presenting epileptic seizures as a first symptom~Evaluated items:~Number of seizures~Type of seizures~Presence of EEG abnormalities~Presence of IRM abnormalities~Time before cognitive disorders"
88848861|NCT05919680|Experimental|Part B- 1200mg NST-6179|up to 12 subjects
88848862|NCT05919680|Experimental|Part B matched NST-6179 placebo|up to 6 subjects
88848863|NCT05913908|Experimental|Treatment|Treatment with the DUO Transcatheter Tricuspid Coaptation Valve System (DUO System)
88848864|NCT05904470|Experimental|Bemnifosbuvir and Ruzasvir|"Bemnifosbuvir (BEM; AT-527) Tablets~Ruzasvir (RZR; AT-038) Capsules"
88848865|NCT05900076||Patient group|This group corresponds to patients who have just suffered a miscarriage and are undergoing curettage for the evacuation of the product of conception.
89181901|NCT04106765||cognitive LGI1-antibody patients|"Patients affected by LGI1 antibody encephalitis presenting cognitive disorders as a first symptom~Evaluated items:~Presence of EEG abnormalities~Presence of IRM abnormalities~Time before epileptic seizures"
89181902|NCT02593266|Experimental|Intervention Group|weekly sessions of PIP for depression.
89181903|NCT02593266|No Intervention|Waiting list control group|This is treatment as usual.
89181904|NCT04106687|Active Comparator|Caudal Block|After preoxygenation for three minutes, anesthesia would be induced with 8% sevoflurane inhalation in 50% oxygen and % 50 air ; 1ug/kg fentanyl and 3 mg/kg propofol is administered intravenously. Then laryngeal mask is inserted when conditions are satisfactory ultrasound guided caudal block wil performe with bupivacaine 1 ml/kg as 0.25%.
89181905|NCT04106687|Active Comparator|Sacral Erector Spinae Block|After preoxygenation for three minutes, anesthesia would be induced with 8% sevoflurane inhalation in 50% oxygen and % 50 air ; 1ug/kg fentanyl and 3 mg/kg propofol is administered intravenously. Then laryngeal mask is inserted when conditions are satisfactory ultrasound guided sacral erector spinae block wil performe with bupivacaine 1 ml/kg as 0.25%.
88848871|NCT05878457|Experimental|Repetitive transcranial magnetic stimulation|All participants will receive accelerated, high-dose repetitive transcranial magnetic stimulation (rTMS) at the medial prefrontal cortex (mPFC) delivered in runs of 600 pulses, twelve times per day, for three treatment days (contiguous or non-contiguous) within a seven-day period.
88848872|NCT05877547|Experimental|Efinopegdutide 4mg|Efinopegdutide administered by subcutaneous (SC) injection once weekly for 52 weeks in a dose-escalation regimen of 2 mg for 4 weeks and 4mg for 48 weeks.
88848873|NCT05877547|Experimental|Efinopegdutide 7mg|Efinopegdutide administered by SC injection once weekly for 52 weeks in a dose-escalation regimen of 2 mg for 4 weeks, 4 mg for 4 weeks, and 7 mg for 44 weeks.
88848874|NCT05877547|Experimental|Efinopegdutide 10mg|Efinopegdutide administered by SC injection once weekly for 52 weeks in a dose-escalation regimen of 2 mg for 4 weeks, 4 mg for 4 weeks, 7 mg for 4 weeks, and 10 mg for 40 weeks.
88848875|NCT05877547|Placebo Comparator|Placebo|Placebo administered by SC injection once weekly for 52 weeks
88848876|NCT05877547|Active Comparator|Semaglutide 2.4 mg|Semaglutide administered by SC injection once weekly for 52 weeks in a dose-escalation regimen of 0.25 mg for 4 weeks, 0.5 mg for 4 weeks, 1.0 mg for 4 weeks, 1.7 mg for 4 weeks, and 2.4 mg for 36 weeks.
88848877|NCT05875974|Experimental|JZP258|Participants will self-administer an oral dose of JZP258 (XYWAV) as per label and titrate to an optimal dosage for each participant.
88848878|NCT05868733|Experimental|Cohort 1A|Healthy Adults, 18-70yrs
88848879|NCT05868733|Experimental|Cohort 2A|HIV-infected Adults, 18-50yrs
88848880|NCT05868733|Experimental|Cohort 3A|Adolescents, 12 17yrs
88848881|NCT05868733|Experimental|Cohort 4A|Children, 6-11yrs
88848882|NCT05868733|Experimental|Cohort 5A|Children, 18mos-5yrs
88848883|NCT05868733|Experimental|Cohort 1B|Healthy Adults, 18-70yrs
88848884|NCT05868733|Experimental|Cohort 2B|HIV-infected Adults,18-50yrs
88848885|NCT05868733|Experimental|Cohort 3B|Adolescents, 12 17yrs
88848886|NCT05868733|Experimental|Cohort 4B|Children, 6-11yrs
88848887|NCT05868733|Experimental|Cohort 5B|Children, 18mos-5yrs
88848888|NCT05862584|Experimental|Main Cohort|Cohort of patients with inflammatory rheumatism (rheumatoid arthritis or spondyloarthritis diagnosed according to ACR/EULAR 2010 or ASAS), over 18 years of age, and with stable chronic inflammatory rheumatism under biological treatment
88848889|NCT05858164|Experimental|Dose Escalation|Participants will take BAY2862789 oral doses.
88848890|NCT05858164|Experimental|Dose Expansion|Participants will take BAY2862789 oral doses. Dose Expansion starts after Dose Escalation.
88848891|NCT05856890|Experimental|Group 1a: HepB mAb19 1 mg/kg, IV|Single intravenous infusion of HepB mAb19, dosed at 1 mg/kg.
88848892|NCT05856890|Experimental|Group 2a: HepB mAb19 3 mg/kg, IV|Single intravenous infusion of HepB mAb19, dosed at 3 mg/kg.
88848893|NCT05856890|Experimental|Group 3a: HepB mAb19 10 mg/kg, IV|Single intravenous infusion of HepB mAb19, dosed at 10 mg/kg.
88848894|NCT05856890|Experimental|Group 4a: HepB mAb19 30 mg/kg, IV|Single intravenous infusion of HepB mAb19, dosed at 30 mg/kg.
88848895|NCT05856890|Experimental|Group 5: Maximum tolerated dose, IV|Single intravenous infusion of HepB mAb19, dosed at the MTD
88848896|NCT05856890|Placebo Comparator|Group 1b: Placebo 1 mg/kg, IV|Single intravenous infusion of placebo - normal saline, dosed at 1 mg/kg.
88848897|NCT05856890|Placebo Comparator|Group 2b: Placebo 3 mg/kg, IV|Single intravenous infusion of placebo - normal saline, dosed at 3 mg/kg.
88848898|NCT05856890|Placebo Comparator|Group 3b: Placebo 10 mg/kg, IV|Single intravenous infusion of placebo - normal saline, dosed at 10 mg/kg.
88848899|NCT05856890|Placebo Comparator|Group 4b: Placebo 30 mg/kg, IV|Single intravenous infusion of placebo - normal saline, dosed at 30 mg/kg.
88848900|NCT05856786||Ocular parameters|Patients aged 19 years or more who are scheduled to undergo refractive surgery will be included in the study. OCT will be performed at baseline (before surgery), 1 day after surgery and 1 week after surgery. Each patient will be tested 3 times.
88848901|NCT05854563||Bronchoscopy subjects, current or former smokers|Bronchoscopy subjects >=21 yo, current or former smokers
88848902|NCT05854563||Bronchoscopy subjects, never smokers|Bronchoscopy subjects >=21 yo, never smokers
88848903|NCT05844293|Other|Cohort 1|6 subjects injected with 25 mg dose of FXI-GalNAc-siRNA 2 subjects with Saline
88848904|NCT05844293|Other|Cohort 2|6 subjects injected with 50 mg dose of FXI-GalNAc-siRNA 2 subjects with Saline
88848905|NCT05844293|Other|Cohort 3|6 subjects injected with 100 mg dose of FXI-GalNAc-siRNA 2 subjects with Saline
88848906|NCT05844293|Other|Cohort 4|6 subjects injected with 200 mg dose of FXI-GalNAc-siRNA 2 subjects with Saline
88848907|NCT05844293|Other|Cohort 5|6 subjects injected with 400 mg dose of FXI-GalNAc-siRNA 2 subjects with Saline
88848908|NCT05832489|Experimental|Group A|Adult patients with ADHD (ADHD-P) receive a placebo or 25 mg of methylphenidate 45min before the first and second imaging sessions (MRI+EEG)
89535060|NCT05015205|Experimental|Control Group|Postural Correction Exercises was applied to one group. Exercises performed included stretching and strengthening exercises. The exercises were performed 3 times per week for 4 weeks.
89376285|NCT03199040|Experimental|Neoantigen DNA vaccine|"The first neoantigen DNA vaccine injection will take place following the completion of standard of care therapy. The day of the first vaccine injection will be referred to as Day 1~The schedule of vaccination is Day 1, Day 29 ± 7, Day 57 ± 7, Day 85 ± 7, Day 113 ± 7, and Day 141 ± 7 with at least 21 days between injection days"
89376286|NCT03198702|Experimental|Toxin group|The babies receive a botulinum toxin type A injection at the age of 12 months
89376287|NCT03198702|Sham Comparator|Sham group|The babies receive a simulated injection procedure at the age of 12 months
89376288|NCT03159897|Experimental|Comparator arm|Patients will receive 2 courses of standard ABVD (ABVD-28, d1, d15, cycles of 28 days) and then proceed to interim PET/CT evaluation. Those with a PET-2-negative scan (score 1-3 on 5PS) will continue with additional 4 ABVD courses while those with a PET-2-positive (score 4-5) scan will be diverted towards an intensification phase with either escalated BEACOPP or HDT plus ASCR, according to the preference of the centre. Upon completion of treatment, patients will be categorized for response (Lugano2014) by comparing actual PET/CT imaging with baseline, whether 6 ABVD cycles or ABVDx2 + intensification phase with BEACOPP or HDT/ASCR. A salvage rescue program will be planned for patients with Stable (<PR) or Progressive Disease. ISRT 30 Gy will be delivered to complete responders (5PS score 1-2-3) on the initial bulky site(s), to focal rests in case of CR scoring 3 on 5PS with a residual size ≥ 2.5 cm and to focal rests uptakes in the event of PR scoring 4 or 5, whichever is the size.
89376289|NCT03159897|Experimental|Experimental arm|Dose-dense and dose-intense ABVD regimen (ABVD DD-DI: intercycle 21 days, d1, d11; doxorubicin 35 mg/m2 DD 1 and 11) is given in cycles 1 to 4 and dose-dense ABVD (ABVD DD: intercycle 21 days, D1 and D11; conventional doxorubicin dose, e.g. 25 mg/m2 DD 1 and 11) is given as cycles 5 and 6). The treatment is not PET-adapted, and only patients with no response or progressive disease at interim FDG-PET as defined by the Lugano Classification (e.g., score 4 or 5 on 5PS with no significant change or with increased uptake matched with baseline and/or new FDG-avid foci consistent with lymphoma) will be diverted to salvage therapy. ISRT 30 Gy will be delivered to responder patients (DS=3), on focal PET-positive rests with a residual size ≥ 2.5 cm and on patients in PR with uptake scoring 4 or 5, whichever is the size.
89376290|NCT03113981|Experimental|ACTISURF-CERAFIT|Total hip arthroplasty (CERAFIT) grafted by PolyNass
89376291|NCT03113981|Active Comparator|CERAFIT|Total hip arthroplasty (CERAFIT) with HydroxyApatite (HA) no grafted by PolyNass
89376292|NCT03102866|Active Comparator|Arm I (usual care)|Patients receive usual care for 6 weeks during radiation therapy and for 12 weeks after completion of radiation therapy.
89376293|NCT03102866|Experimental|Arm II (aerobic and strength training exercise)|Patients undergo a supervised aerobic and strength training exercise session over 40-60 minutes 3 times weekly for 6 weeks during radiation therapy and for 12 weeks after completion of radiation therapy.
89535061|NCT03087825|Sham Comparator|spontaneous breathing|preoxygenation through spontaneous breathing of 100% oxygen gas flow with or without an inward air leak
89376294|NCT03096886|Experimental|Early CCBT|"Intervention: Computer-Augmented Cognitive Behavioral Therapy~Half of participants presenting with MDD will be randomized to receive 8 weeks of Computer-Augmented Cognitive Behavior Therapy (CCBT) immediately after completing pre-treatment assessments; imaging data will be collected pre- and post-treatment."
89376295|NCT03096886|Experimental|Late CCBT|"Intervention: Waitlist followed by Computer-Augmented Cognitive Behavioral Therapy~Half of participants presenting with MDD will be randomized to be waitlisted for up to 4 weeks and will receive CCBT within 4 weeks; imaging data will also be collected pre--treatment, following waitlist, and post-treatment of CCBT.~This arm will serve as the equivalent of a placebo comparator arm during the waitlist; and then as an experimental arm when receiving 8 weeks of CCBT treatment."
89376296|NCT03096886|No Intervention|Matched Comparison|"No Intervention: Matched Comparison~Healthy controls will act as a matched comparator. Participants will complete pre-treatment assessments and imaging."
89376297|NCT03079999|Experimental|Aspirin|Patients on the experimental arm will receive blinded aspirin. Pediatric subjects who weigh less than 110 lbs will take 81mg aspirin twice a day. All other subjects will take 325mg aspirin twice a day.
89376298|NCT03079999|Placebo Comparator|Placebo|Patients on the placebo arm will receive blinded placebo and take it twice a day.
89376299|NCT02977403|Sham Comparator|AB Control|Control condition - the probe is equally likely to replace the food picture and the neutral picture. There is no correlation between picture type and probe location, and no training of attention should occur.
89376300|NCT02977403|Experimental|AB Retraining|Active treatment - the probe always replaces the neutral picture. There is a perfect correlation between picture type and probe location.
89376301|NCT02977403|Other|Booster Training|3 months after the randomized program is completed, each subject can elect to use open-label attention bias retraining for 2 weeks
89376302|NCT02977403|Active Comparator|Booster Training - active comparator|3 months after the randomized program is completed, each subject can elect to use open-label attention bias retraining for 2 weeks
89376303|NCT02949726|Other|Cancer-treated patients receiving NIRFLI|"Near-infrared Fluorescence Lymphatic Imaging (NIRFLI) using Indocyanine Green (ICG) is used to visualize lymphatic vessel anatomy and function."
89376304|NCT02948686|Active Comparator|SET (Self-Etching)|55 teeth will receive restorations using Self-Etching Application Strategy
89376305|NCT02948686|Experimental|SEE (Selective Enamel Etching)|55 teeth will receive restorations using Enamel Etching Application Strategy
89376306|NCT02948686|Experimental|SETT (Self-Etching, more time)|55 teeth will receive restorations using Self Etching with Extended time Application Strategy
89376307|NCT02948686|Experimental|SETL (Self-Etching, more layers)|55 teeth will receive restorations using Self Etching with Extended layers number Strategy
89399370|NCT02175134|Experimental|two-step algorithm-based approach|"Perform the laparoscopic biopsy as a discretion of attending physician's decision, but if the below conditions are met, do not perform the laparoscopic biopsy.~Blood ELISPOT >= 6 spots or ascites adenosine deaminase > 20 IU/L, and~Ascites ELISPOT/Blood ELISPOT rato > 3"
89399371|NCT03537638|Experimental|Multicomponent Intervention|Rheumatologist and internist receive a multicomponent intervention
88848909|NCT05832489|Experimental|Group B|Adult patients with attention deficit due to/emphasized by mood disorders (ADHD-HD) receive a placebo or 25 mg of methylphenidate 45min before the first and second imaging sessions (MRI+EEG)
89399372|NCT03537638|No Intervention|Control|Rheumatologist and internist provide the usual care
89376308|NCT02904577||Training and validation cohort|"One cohort: from this cohort 2/3 of patients will be randomly separated after registration in training sample, to develop a prognostic model, and 1/3 in test sample, to validate the prognostic score obtained from the prognostic model.~The training cohort aims to develop a prognostic model and a resulting score, on the basis of clinical, biochemical and blood count parameters, in patients with non-follicular indolent lymphomas.~Intervention: any treatment, watch and wait policy included~The validation cohort is aims to assess the prognostic score on a collected set of data in parallel but independently of the sample training.~Intervention: any treatment, watch and wait policy included"
89376309|NCT02879409|Experimental|Treatment arm 1|"75 Type 2 diabetic patients with a gender balance who will have the intervention if/when their FBG >140mg/dl~Intervention: intensify treatment until their FBG is <90mg/dl, using whatever treatment is clinically appropriate for them using different interventions (Metformin, Gliclazide, Sitagliptin, Dapagliflozin, Liraglutide, Pioglitazone, human insulin), and only intensify it further if their FPG rises to >140mg/dl again."
89376310|NCT02879409|Experimental|Treatment arm 2|"75 Type 2 diabetic patients with a gender balance who will have the intervention if/when their FBG >115mg/dl~Intervention: intensify treatment until FBG is <=115 mg/dl and intensify further if >115 mg/dl again, using what ever clinical treatment is necessary (Metformin, Gliclazide, Sitagliptin, Dapagliflozin, Liraglutide, Pioglitazone, human insulin)."
89376311|NCT02840149|Other|68Ga-DOTATATE PET/CT|68Ga-DOTATATE PET/CT scan performed on Neuro-endocrine tumor patients
89376312|NCT02713438|Experimental|Individual Planning|"Participants are filling in the planning forms, referring to their individual physical activity. Both members of the dyad form their own, interdependent plans.~The following behavior change techniques (BCT) are included in the planning intervention protocol: action planning, barrier identification, prompting self-talk, relapse prevention/coping planning. Applications of all BCT included references to planning."
89376313|NCT02713438|Experimental|Dyadic Planning|"Participants are filling in the planning forms jointly. Planning refers to physical activity of only one person in the dyad, the child. The parent is actively participating in forming plans by the child.~The following BCT are included in the planning intervention protocol: action planning, barrier identification, prompting self-talk, relapse prevention/coping planning. Applications of all BCT included references to planning."
88848910|NCT05832489|Experimental|Group C|Adult Healthy controls receive a placebo or 25 mg of methylphenidate 45min before the first and second imaging sessions (MRI+EEG)
89376314|NCT02713438|Experimental|Collaborative Planning|"Participants are filling in the planning forms jointly. Planning refers to physical activity of both persons in the dyad (child and parent). Physical activity may be performed jointly by both persons in the dyad.~The following BCT are included in the planning intervention protocol: action planning, barrier identification, prompting self-talk, relapse prevention/coping planning. Applications of all BCT included references to planning."
89376315|NCT02713438|Active Comparator|Education|The education group received extended physical activity and healthy nutrition education program. The education includes: (1) the guidelines for physical activity and healthy nutrition, tailored to age and health status of the participant, (2) the examples of exercises and their metabolic equivalent; (3) information about healthy body mass and body composition.
89376316|NCT02700620|Experimental|Treatment group|Internet-delivered CBT
89376317|NCT02700620|No Intervention|Control group|Waitlist control
88848911|NCT05831124|Experimental|Low dose multivalent pneumococcal conjugate vaccine formulation A|Stage 1 - Participants will be randomized to receive a single injection.
89376318|NCT02664753|Experimental|L-Carnitine group|"Patients in the experimental arm will receive 10 days of intravenous L-carnitine treatment followed by 46 days of oral L-Carnitine treatment.~Intervention: 56 days of weight-adjusted L-Carnitine treatment"
89376319|NCT02664753|Placebo Comparator|Placebo then open group|"Patients in the placebo arm will receive 10 days of intravenous isotonic saline in a fashion analogous to the experimental arm (they study is thus blinded for the first 10 days and then open there afterwards).~Intervention: 10 days of intravenous placebo (isotonic saline)"
88848912|NCT05831124|Experimental|Low dose multivalent pneumococcal conjugate vaccine formulation B|Stage 2 - Participants will be randomized to receive a single injection.
88848913|NCT05831124|Active Comparator|Low dose of multivalent pneumococcal conjugate vaccine control|Primary control - Stages 1 and 2 - Participants will be randomized to receive a single injection.
88848914|NCT05831124|Active Comparator|Standard dose multivalent pneumococcal conjugate vaccine control|Control - Stages 1 and 2 - Participants will be randomized to receive a single injection.
88848915|NCT05825079|Experimental|Weight-Bearing Feedback Delivered to Mobile Phone|The weight-bearing tracking system is attached to the patient's crutch and calculates how much weight is being put on the crutch. Feedback of this data can be delivered to the patient through a mobile phone application. For Arm A of the study, feedback is delivered to the patient's paired mobile phone, providing them information on how much weight they are exerting on their crutch/injured lower extremity.
88848916|NCT05825079|Active Comparator|No Weight-Bearing Feedback|The weight-bearing tracking system is attached to the patient's crutch and calculates how much weight is being put on the crutch. For Arm B, no feedback about weight-bearing status is delivered to the patient.
89376320|NCT02621398|Experimental|Treatment (paclitaxel, carboplatin, radiation, pembrolizumab)|Patients receive paclitaxel IV over 1 hour and carboplatin IV over 30 minutes on days 1, 8, 15, 22, 29, and 36. Patients undergo 3D CRT or IMRT QD 5 days a week for 6 weeks. Beginning 2-6 weeks after, 2 weeks before the end, or at the start of chemotherapy and radiation therapy, patients also receive pembrolizumab IV over 30 minutes on day 1. Treatment with pembrolizumab repeats every 21 days for up to 18 courses in the absence of disease progression or unacceptable toxicity.
88848917|NCT05820633|Experimental|ultra hypo fractionation radiation therapy (UHF)|5 radiation treatments (5 Gy per fraction) to the prostate, seminal vesicle and pelvic nodes given every other day over 2 weeks for a total of 25 Gy.
88848918|NCT05820633|Active Comparator|standard of care fractionation (SOC)|20-25 radiation treatments (range: 1,8 to 2,15 Gy per fraction) to the prostate, seminal vesicle and pelvic nodes given in 20-25 working day treatments over 4-5 weeks for a total of 43 Gy to 46 Gy.
88848919|NCT05818150|Experimental|Genicular artery embolization with Embosphere Microspheres|"Device: Embosphere Microspheres~Embolic Agent: Embosphere Microspheres"
88848920|NCT05818150|Active Comparator|Corticosteroid Injection of the knee|Drug: Corticosteroid injection
89376321|NCT02609750|Experimental|Structured care & workplace intervention|Through a flow chart the investigators in detail specify the medical and work place interventions (all according to evidence-based guidelines). Red, yellow and blue flags, and motivational factors are identified in a screening investigation. The aim of the screening is to individually tailor the rehabilitation interventions. Physiotherapy interventions are based on a bio-psychosocial and cognitive behavioural therapy perspective. Behavioural medicine treatment principles include careful examination and treatments such as advice to stay active, instructions, OMI, OMT, MDT. The investigators apply interventions based on ergonomics, motivational factors and work place changes according to Convergence Dialogue Meetings (CDM).
89376322|NCT02609750|Active Comparator|Treatment as Usual|Patients follows the PHCs standard schedule and procedures including the so called rehabilitation guarantee
89376323|NCT02525029|Experimental|Arm 1: Phase 1 Dose Level -2: 125 USP hCG/875 pg EGF/m^2|"Standard of care immunosuppression, plus Pregnyl® (hCG supplementation) at assigned dose subcutaneously every other day for up to 5 doses of Pregnyl®; however dose levels -1 and -2 will be used only if dose level 1 proves too toxic.~Individual patient dose reductions: If a patient has a toxicity, the patient can drop down one dose level for the next injection and continue treatment."
89376324|NCT02525029|Experimental|Arm 1: Phase I Dose Level -1: 250 USP hCG/1,750 pg EGF/m^2|"Standard of care immunosuppression, plus Pregnyl® (hCG supplementation) at assigned dose subcutaneously every other day for up to 5 doses of Pregnyl®; however dose levels -1 and -2 will be used only if dose level 1 proves too toxic.~Individual patient dose reductions: If a patient has a toxicity, the patient can drop down one dose level for the next injection and continue treatment."
89376325|NCT02525029|Experimental|Arm 1: Phase 1 Dose Level 1 500 USP hCG/3,500 pg EGF/m^2|"Standard of care immunosuppression, plus Pregnyl® (hCG supplementation) at assigned dose subcutaneously every other day for up to 5 doses of Pregnyl®; however dose levels -1 and -2 will be used only if dose level 1 proves too toxic.~The 1st 2 patients will be enrolled in dose level 1. The next cohort of 2 patients will not begin treatment until all patients in the current cohort have reached day 21 in order to assess for dose limiting toxicity (DLT).~Individual patient dose reductions: If a patient has a toxicity, the patient can drop down one dose level for the next injection and continue treatment."
89399373|NCT04150653||AAA patients|"All patients enrolled in phase 1 will undergo:~Multiphase scan CT~Non-invasive vascular ultrasound elastography by ultrasound (NIVE)"
89399374|NCT02175290||Spinocerebellar Ataxia 3 Yemenite Jews patients|
89399375|NCT03690687||Group I. Primary anastomosis|Resection of the small bowel to place primary anastomosis into small intestine or transverse colon during relaparotomy.
88848921|NCT05813704|Experimental|Coronary Crossing System|Subjects in experimental group will be treated with the Coronary Crossing System manufactured by Shanghai Microport Rhythm Co. Ltd.
88848922|NCT05812781|Experimental|Cohort 1|
88848923|NCT05812781|Experimental|Cohort 2|
88848924|NCT05810961|Experimental|efgartigimod IV|patients receiving infusions of efgartigimod
88848925|NCT05810961|Experimental|placebo|patients receiving infusions of placebo
88848926|NCT05807256||pregnant patients with systemic rheumatological diseases|pregnant patients with systemic rheumatological diseases undergoing assisted fertilization techniques
88848927|NCT05803824|Experimental|group A: Baduanjin Qigong exercise plus selected exercise|"Baduanjin exercise 3 times each week, 30- 60 minutes each time for 12 weeks. The whole set of Baduanjin exercise consists of 9 postures: (1) ready position, (2) holding the hands high with palms up. (3) posing like an archer shooting on left and right sides, (4) holding one arm aloft . (5) looking backwards to prevent sickness and strain, (6) swinging the head and lowering the body t. (7) moving the hands down the back and legs and touching the feet . (8) thrusting the fists and making the eyes glare . and (9) raising and lowering the heels .~Puls Selected Exercise Program~balance exercises is composed of three phases, including warm-up, balance training and cool down.~Resisted Exercises were given according to the standardized Oxford technique of progressive resistance exercises ."
88848928|NCT05803824|Experimental|group B: patients will receive Baduanjin Qigong exercise only|the subjects will receive Baduanjin exercise 3 times each week, 30- 60 minutes each time for 12 weeks. Baduanjin exercise 3 times each week, 30- 60 minutes each time for 12 weeks. The whole set of Baduanjin exercise consists of 9 postures: (1) ready position, (2) holding the hands high with palms up. (3) posing like an archer shooting on left and right sides, (4) holding one arm aloft . (5) looking backwards to prevent sickness and strain, (6) swinging the head and lowering the body t. (7) moving the hands down the back and legs and touching the feet . (8) thrusting the fists and making the eyes glare . and (9) raising and lowering the heels .
88848929|NCT05803824|Experimental|Patients at group C: patients will receive selected exercise program|"Selected Exercise Program: Patients will receive~balance exercises is composed of three phases, including warm-up, balance training and cool down.~Resisted Exercises were given according to the standardized Oxford technique of progressive resistance exercises ."
88848930|NCT05793476|Experimental|Fotona Dynamis Er:YAG Laser System Arm|Non-ablative thermal-only Er:YAG laser treatment using R11 and PS03 handpieces
88848931|NCT05793476|Sham Comparator|Fotona Dynamis Er:YAG Laser System with Sham handpience|The same procedure is applied but with a sham handpiece.
88848932|NCT05791513|Experimental|Using the MAP-Knee Tool|The treating clinician will use the MAP-Knee Tool together with the adolescent. The tool includes four separate components: 1) a tool for diagnosing the most common types of non-traumatic knee pain (SMILE), 2) credible explanations of the aetiology and pathogenesis specific to the diagnosis based on multiple methods with an iterative design, 3) a presentation of prognostic factors based on an individual participant data meta-analysis(19), and 4) an option grid that presents the users of the tool with pros and cons of commonly used management options based on a systematic literature search of systematic and narrative reviews within non-traumatic adolescent knee pain. An overarching focus of all components was to support shared decision-making and base decisions on all three pillars of evidence-based medicine: patient values, clinical expertise, and relevant research. Therefore, the tool should not provide the users with definitive answers simply based on available evidence.
89376326|NCT02525029|Experimental|Arm 1: Phase 1 Dose Level 2 1,000 USP hCG/7,000 pg EGF/m^2|"Standard of care immunosuppression, plus Pregnyl® (hCG supplementation) at assigned dose subcutaneously every other day for up to 5 doses of Pregnyl®; however dose levels -1 and -2 will be used only if dose level 1 proves too toxic.~The 1st 2 patients will be enrolled in dose level 1. The next cohort of 2 patients will not begin treatment until all patients in the current cohort have reached day 21 in order to assess for dose limiting toxicity (DLT).~Individual patient dose reductions: If a patient has a toxicity, the patient can drop down one dose level for the next injection and continue treatment."
89376327|NCT02525029|Experimental|Arm 1: Phase 1 Dose Level 3 2,000 USP hCG/14,000 pg EGF/m^2|"Standard of care immunosuppression, plus Pregnyl® (hCG supplementation) at assigned dose subcutaneously every other day for up to 5 doses of Pregnyl®; however dose levels -1 and -2 will be used only if dose level 1 proves too toxic.~The 1st 2 patients will be enrolled in dose level 1. The next cohort of 2 patients will not begin treatment until all patients in the current cohort have reached day 21 in order to assess for dose limiting toxicity (DLT).~Individual patient dose reductions: If a patient has a toxicity, the patient can drop down one dose level for the next injection and continue treatment."
89376328|NCT02525029|Experimental|Arm 2A: Phase 1 Dose Level -2: 125 USP hCG/875 pg EGF/m^2|"Standard of care immunosuppression, plus Pregnyl® (hCG supplementation) at assigned dose subcutaneously every other day for up to 7 doses of Pregnyl®; however dose levels -1 and -2 will be used only if dose level 1 proves too toxic.~The 1st 2 patients will be enrolled in dose level 1. The next cohort of 2 patients will not begin treatment until all patients in the current cohort has reached day 21 to assess for dose limiting toxicity (DLT).~Individual patient dose reductions: If a patient has a toxicity, the patient can drop down one dose level for the next injection and continue treatment."
89376329|NCT02525029|Experimental|Arm 2A: Phase I Dose Level -1: 250 USP hCG/1,750 pg EGF/m^2|"Standard of care immunosuppression, plus Pregnyl® (hCG supplementation) at assigned dose subcutaneously every other day for up to 7 doses of Pregnyl®; however dose levels -1 and -2 will be used only if dose level 1 proves too toxic.~The 1st 2 patients will be enrolled in dose level 1. The next cohort of 2 patients will not begin treatment until all patients in the current cohort has reached day 21 to assess for dose limiting toxicity (DLT).~Individual patient dose reductions: If a patient has a toxicity, the patient can drop down one dose level for the next injection and continue treatment."
89376330|NCT02525029|Experimental|Arm 2A: Phase 1 Dose Level 1 500 USP hCG/3,500 pg EGF/m^2|"Standard of care immunosuppression, plus Pregnyl® (hCG supplementation) at assigned dose subcutaneously every other day for up to 7 doses of Pregnyl®; however dose levels -1 and -2 will be used only if dose level 1 proves too toxic.~The 1st 2 patients will be enrolled in dose level 1. The next cohort of 2 patients will not begin treatment until all patients in the current cohort has reached day 21 to assess for dose limiting toxicity (DLT).~Individual patient dose reductions: If a patient has a toxicity, the patient can drop down one dose level for the next injection and continue treatment."
89376331|NCT02525029|Experimental|Arm 2A: Phase 1 Dose Level 2 1,000 USP hCG/7,000 pg EGF/m^2|"Standard of care immunosuppression, plus Pregnyl® (hCG supplementation) at assigned dose subcutaneously every other day for up to 7 doses of Pregnyl®; however dose levels -1 and -2 will be used only if dose level 1 proves too toxic.~The 1st 2 patients will be enrolled in dose level 1. The next cohort of 2 patients will not begin treatment until all patients in the current cohort has reached day 21 to assess for dose limiting toxicity (DLT).~Individual patient dose reductions: If a patient has a toxicity, the patient can drop down one dose level for the next injection and continue treatment."
89181906|NCT05374122|Experimental|DSOC + AI-biopsy guidance|"This group is comprised by patients with suggestive malignant biliary lesions assessed by DSOC for biopsy. In this group, the investigators aim to use as a complement tool an AI model for the detection of features suggestive of malignancy to perform the biopsy on the detecting bounding box signal.~A further follow-up of 6 months is necessary for a confirming diagnosis of neoplastic lesions."
89376332|NCT02525029|Experimental|Arm 2A: Phase 1 Dose Level 3 2,000 USP hCG/14,000 pg EGF/m^2|"Standard of care immunosuppression, plus Pregnyl® (hCG supplementation) at assigned dose subcutaneously every other day for up to 7 doses of Pregnyl®; however dose levels -1 and -2 will be used only if dose level 1 proves too toxic.~The 1st 2 patients will be enrolled in dose level 1. The next cohort of 2 patients will not begin treatment until all patients in the current cohort has reached day 21 to assess for dose limiting toxicity (DLT).~Individual patient dose reductions: If a patient has a toxicity, the patient can drop down one dose level for the next injection and continue treatment."
89399376|NCT03690687||Group II. Delayed anastomosis|Resection of the small intestine to place delayed anastomosis. After the closure of the afferent and efferent loops of the small intestine, anastomosis was not applied. A decompression probe was introduced into the upper small intestine. In 24-36 hours, delayed anastomosis was placed into the small intestine or transverse colon during the planned relaparotomy with arrested postoperative peritonitis.
89181907|NCT05374122|Active Comparator|DSOC biopsy without AI guidance|This group is comprised by patients with suggestive malignant biliary lesions assessed by DSOC for biopsy without AI guidance. A further follow-up of 6 months is necessary for a confirming diagnosis of neoplastic lesions.
89181908|NCT02581449|Experimental|omega-3 group|omega-3 soft gelatin capsules 1000 mg (500mg EPA+250mg DHA)once daily for four months
89181909|NCT02581449|Placebo Comparator|placebo group|empty soft gelatin capsules with matched size, color and shape once daily for four months
89181910|NCT04110977|Experimental|Standard Care supported by a Reminder App (Arm A)|Treatment with Standard Care supported by a Reminder App, starting at the beginning of radiotherapy.
89181911|NCT04110977|Active Comparator|Standard Care alone (Arm B)|Treatment with Standard Care alone, starting at the beginning of radiotherapy.
88848933|NCT05791513|Active Comparator|Not using the MAP-Knee Tool|The treating clinician will not use the MAP-Knee Tool in the consultation and will conduct the consultation as per usual practice.
89376333|NCT02525029|Experimental|Arm 2B: Phase 1 Dose Level -2: 125 USP hCG/875 pg EGF/m^2|"Standard of care immunosuppression, plus Pregnyl® (hCG supplementation) at assigned dose subcutaneously every other day for up to 7 doses of Pregnyl®; however dose levels -1 and -2 will be used only if dose level 1 proves too toxic.~The 1st 2 patients will be enrolled in dose level 1. The next cohort of 2 patients will not begin treatment until all patients in the current cohort has reached day 21 to assess for dose limiting toxicity (DLT).~Individual patient dose reductions: If a patient has a toxicity, the patient can drop down one dose level for the next injection and continue treatment."
89376334|NCT02525029|Experimental|Arm 2B: Phase I Dose Level -1: 250 USP hCG/1,750 pg EGF/m^2|"Standard of care immunosuppression, plus Pregnyl® (hCG supplementation) at assigned dose subcutaneously every other day for up to 7 doses of Pregnyl®; however dose levels -1 and -2 will be used only if dose level 1 proves too toxic.~The 1st 2 patients will be enrolled in dose level 1. The next cohort of 2 patients will not begin treatment until all patients in the current cohort has reached day 21 to assess for dose limiting toxicity (DLT).~Individual patient dose reductions: If a patient has a toxicity, the patient can drop down one dose level for the next injection and continue treatment."
89376335|NCT02525029|Experimental|Arm 2B: Phase 1 Dose Level 1 500 USP hCG/3,500 pg EGF/m^2|"Standard of care immunosuppression, plus Pregnyl® (hCG supplementation) at assigned dose subcutaneously every other day for up to 7 doses of Pregnyl®; however dose levels -1 and -2 will be used only if dose level 1 proves too toxic.~The 1st 2 patients will be enrolled in dose level 1. The next cohort of 2 patients will not begin treatment until all patients in the current cohort has reached day 21 to assess for dose limiting toxicity (DLT).~Individual patient dose reductions: If a patient has a toxicity, the patient can drop down one dose level for the next injection and continue treatment."
89376336|NCT02525029|Experimental|Arm 2B: Phase 1 Dose Level 2 1,000 USP hCG/7,000 pg EGF/m^2|"Standard of care immunosuppression, plus Pregnyl® (hCG supplementation) at assigned dose subcutaneously every other day for up to 7 doses of Pregnyl®; however dose levels -1 and -2 will be used only if dose level 1 proves too toxic.~The 1st 2 patients will be enrolled in dose level 1. The next cohort of 2 patients will not begin treatment until all patients in the current cohort has reached day 21 to assess for dose limiting toxicity (DLT).~Individual patient dose reductions: If a patient has a toxicity, the patient can drop down one dose level for the next injection and continue treatment."
89376337|NCT02525029|Experimental|Arm 2B: Phase 1 Dose Level 3 2,000 USP hCG/14,000 pg EGF/m^2|"Standard of care immunosuppression, plus Pregnyl® (hCG supplementation) at assigned dose subcutaneously every other day for up to 7 doses of Pregnyl®; however dose levels -1 and -2 will be used only if dose level 1 proves too toxic.~The 1st 2 patients will be enrolled in dose level 1. The next cohort of 2 patients will not begin treatment until all patients in the current cohort has reached day 21 to assess for dose limiting toxicity (DLT).~Individual patient dose reductions: If a patient has a toxicity, the patient can drop down one dose level for the next injection and continue treatment."
89399377|NCT03690687||Group III. Enterostomy|Resection of the small intestine with enterostomy. In case there was no postoperative peritonitis relief and was organ dysfunction progression, anastomosis was not placed. The surgery was completed with enterostomy to perform open abdomen.
89399378|NCT02173418|Experimental|Ropivacaine|Phrenic nerve block with Ropivacaine
89399379|NCT02173418|Placebo Comparator|Placebo|Phrenic nerve block with Sodium chloride
89181912|NCT04086498|Experimental|ketogenic-mediterranean diet with phytoextracts|The KEMEPHY diet (Paoli et al., 2011) is a mediterranean calorie-controlled ketogenic protocol (about 900 Kcal/day) with the use of some phytoextracts. During this protocol subjects are allowed to eat with no limits green leafy vegetables, cruciferous, zucchini, cucumbers and eggplants. The quantity of meat, eggs and fish was limited to once a day (120g of meat or 200g of fish or 1 egg). Moreover, subjects daily consumed four food supplements and liquid herbal extracts. Food supplements are high proteins (19g/portion) and very low carbohydrate (3.5g/portion) formulas simulating the aspect and taste of common carbohydrate rich foods added with dry phytoextracts (Lodi et al., 2016).
88848939|NCT05786443|Experimental|Empagliflozin|Participants with end-stage kidney disease (ESRD) initiating hemodialysis will receive Empagliflozin 10 mg daily for 12 weeks.
88848940|NCT05786443|Placebo Comparator|Placebo|Participants with ESRD initiating hemodialysis will receive Empagliflozin-matching placebo daily for 12 weeks.
88848941|NCT05785611|Experimental|Radiographic Part (Study A) Filgotinib|Participants will receive filgotinib 200 mg or placebo to match filgotinib. Participants will receive blinded treatment until Week 16. After that participants with an age under 65 and without certain health risks will enter open label period and will receive filgotinib 200 mg until Week 52. Participants reaching an Ankylosing Spondylitis Disease Activity Score (ASDAS) <2.1 at weeks 40 and 52, will enter dose de-escalation phase and will be randomized to filgotinib 200 or 100 mg until Week 104. Participants, with an age of 65 or above or with certain health risks, will enter open label period until Week 104 and will receive 100 or 200 mg filgotinib a day, depending on their axSpA symptoms. The maximum duration of treatment period will be up to Week 104.
88848942|NCT05785611|Experimental|Non-radiographic Part (Study B) Filgotinib|Participants will receive filgotinib 200 mg or placebo to match filgotinib. Participants will receive blinded treatment until Week 16. After that participants with an age under 65 and without certain health risks will enter open label period and will receive filgotinib 200 mg until Week 52. Participants reaching an ASDAS <2.1 at weeks 40 and 52, will enter dose de-escalation phase and will be randomized to filgotinib 200 or 100 mg until Week 104. Participants, with an age of 65 or above or with certain health risks, will enter open label period until Week 104 and will receive 100 or 200 mg filgotinib a day, depending on their axSpA symptoms. The maximum duration of treatment period will be up to Week 104.
88848943|NCT05781191||Employees|
88848944|NCT05781152|Other|Anti-tumor necrosis factor (TNF)|Patients newly diagnosed with pediatric-onset Crohn's disease starting anti-TNF therapy within 6 months of diagnosis
89376338|NCT02525029|Experimental|Arm 2B: Phase 1 Dose Level 4 3,500 USP hCG/24,500 pg EGF/m^2|"Standard of care immunosuppression, plus Pregnyl® (hCG supplementation) at assigned dose subcutaneously every other day for up to 7 doses of Pregnyl®; however dose levels -1 and -2 will be used only if dose level 1 proves too toxic.~The 1st 2 patients will be enrolled in dose level 1. The next cohort of 2 patients will not begin treatment until all patients in the current cohort has reached day 21 to assess for dose limiting toxicity (DLT).~Individual patient dose reductions: If a patient has a toxicity, the patient can drop down one dose level for the next injection and continue treatment."
89376339|NCT02525029|Experimental|Arm 2B: Phase 1 Dose Level 5 5,000 USP hCG/35,000 pg EGF/m^2|"Standard of care immunosuppression, plus Pregnyl® (hCG supplementation) at assigned dose subcutaneously every other day for up to 7 doses of Pregnyl®; however dose levels -1 and -2 will be used only if dose level 1 proves too toxic.~The 1st 2 patients will be enrolled in dose level 1. The next cohort of 2 patients will not begin treatment until all patients in the current cohort has reached day 21 to assess for dose limiting toxicity (DLT).~Individual patient dose reductions: If a patient has a toxicity, the patient can drop down one dose level for the next injection and continue treatment."
89376340|NCT02525029|Experimental|Arm 1: Phase 2 MTD|After completion of the dose finding trial for each arm, the final doses will be carried forward into a two-stage phase II extension trial to confirm safety and make a preliminary determination of the activity level for Arm 1 and Arm 2. If the phase I trial enrolls fewer than 13 patients at the MTD, we will employ Simon's Minmax two-stage design with the possibility to discontinue after the 1st stage if the response rate is low
89376341|NCT02525029|Experimental|Arm 2A: MTD|After completion of the dose finding trial for each arm, the final doses will be carried forward into a two-stage phase II extension trial to confirm safety and make a preliminary determination of the activity level for Arm 1 and Arm 2. If the phase I trial enrolls fewer than 13 patients at the MTD, we will employ Simon's Minmax two-stage design with the possibility to discontinue after the 1st stage if the response rate is low
89376342|NCT02525029|Experimental|Arm 2B: MTD|After completion of the dose finding trial for each arm, the final doses will be carried forward into a two-stage phase II extension trial to confirm safety and make a preliminary determination of the activity level for Arm 1 and Arm 2. If the phase I trial enrolls fewer than 13 patients at the MTD, we will employ Simon's Minmax two-stage design with the possibility to discontinue after the 1st stage if the response rate is low
89376343|NCT02455479|Other|Cohort 1: 100µg|Subjects will receive 100µg dAd5GNE vaccine or placebo at weeks 0, 4, 8, 12, 16 and 20.
89376344|NCT02455479|Other|Cohort 2: 316 µg|Subjects will receive 316 µg dAd5GNE vaccine or placebo at weeks 0, 4, 8, 12, 16 and 20.
89376345|NCT02455479|Other|Cohort 3: 1000µg|Subjects will receive 1000 µg dAd5GNE vaccine or placebo at weeks 0, 4, 8, 12, 16 and 20.
89376346|NCT02427620|Experimental|Treatment (ibrutinib, rituximab, consolidation chemotherapy)|"PART I (IBRUTINIB PLUS RITUXIMAB): Patients receive ibrutinib PO QD on days 1-28 and rituximab IV over 6-8 hours on days 1, 8, 15, and 22 of cycle 1 and then over 4 hours on day 1 of cycles 3-12. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity or until patients achieve complete response.~PART II (CONSOLIDATION THERAPY): Patients receive rituximab IV over 6 hours on day 1; dexamethasone PO or IV on days 1-4; cyclophosphamide IV over 3 hours BID on days 2-4; doxorubicin hydrochloride IV over 15-30 minutes on day 5; and vincristine sulfate IV over 15-30 minutes on day 5 of cycles 1, 3, 5, and 7. Patients also receive rituximab IV over 6 hours on day 1; methotrexate IV over 24 hours on day 2; and cytarabine IV over 2 hours BID on days 3 and 4 of cycles 2, 4, 6, and 8. Treatment repeats every 28 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity."
88848945|NCT05778474||Healthy participants|At least 10 healthy participants aged from 18 to 60 years old with symmetric walking at visual analysis. Participants will be excluded if pregnant, if they present with pharmacologic therapies which could affect balance and walking, and if they suffered from (or presently present with) orthopedic or neurologic conditions potentially impairing walking.
89376347|NCT02408549|Experimental|Lacosamide|"Start dose~SP0982 completers at V1:~LCM 10 mg/kg/day for pediatric subjects weighing <30 kg~LCM 8 mg/kg/day for pediatric subjects weighing ≥ 30kg to <50 kg~LCM 400 mg/day (200 mg bid) for adult subjects (≥18 years of age) or pediatric subjects weighing ≥50 kg~SP0982 Baseline failures at V1:~LCM 2 mg/kg/day for pediatric subjects weighing <50 kg~LCM 100 mg/day (50 mg bid) for adult subjects (≥18 years of age) or pediatric subjects weighing ≥50 kg~Oral solution (pediatric subjects <50 kg):~Minimum LCM dose: 4 mg/kg/day~Maximum LCM dose: 12 mg/kg/day~Tablets (pediatric subjects ≥50kg):~Minimum LCM dose: 200 mg/day~Minimum LCM dose: 600 mg/day~Tablets (adult subjects):~Minimum LCM dose: 200 mg/day~Maximum LCM dose: 800 mg/day"
88848946|NCT05778474||Pathologic group|At least 15 participants with various orthopaedic or neurologic conditions (for example, post-stroke hemiparesis, Parkinson's disease, multiple sclerosis, unilateral amputation, surgical orthopedic interventions) will be enrolled. Participants will present a unilateral motor impairment, not preventing passive oscillation of the upper limbs.
88848947|NCT05774262|Active Comparator|Group A - PACEMAKER|"Group A, n=50 patients aged 18-75 years with indications for elective PM implantation according to the 2021 ESC guidelines for cardiac pacing due to paroxysmal or persistent AVB with a positive results of atropine test.~Group A is early elective pacemaker implantation (PM) strategy in functional AVB."
89376348|NCT02378558|Experimental|Investigational Device|All patients will undergo breast localization and excision of a lesion using the MagneMark system. The radiologist will insert the MagneMarker clip into the area of concern using the MagneJector device. The surgeon will then locate the MagneMaker clip using the MagneProbe. The clip and breast tissue of concern will then be removed.
89376349|NCT02265601|Experimental|computer-based decision aid|"Making Your Wishes Known: Planning Your Medical Future- Offers tailored education, values clarification exercises, and a sophisticated decision aid that translates an individual's goals and preferences into a specific medical plan that can be implemented by a health care team."
89376350|NCT02265601|Active Comparator|standard care|paper/pencil living will form
89376351|NCT01837277|Experimental|Dolutegravir|Intervention: Patients will receive ART regimen based on investigational drug Dolutegravir 50 mg QD + TDF 300 mg QD+ 3TC 150 mg BID
89376352|NCT01837277|Active Comparator|Efavirenz|Intervention: Patients who received ART regimen based efavirenz (EFV 600 mg QD +TDF 300 mg QD+ 3TC 300 mg QD) for one year, befor the use of DTG as SOC for first-line therapy (historic controls)
89376353|NCT01827605|Experimental|Arm A RIT|Infusion of 90Y Ibritumomab Tiuxetan if the patient has less than 25% BM infiltration at the pre-consolidation restaging (0.4 mCi/kg if platelets ≥150,000/mmc, 0.3 mCi/kg if platelets are between 100.000 and 150,000/mmc). Zevalin® will be delivered as per indications and should thus be provided at expenses following regular supplies procedures.
89376354|NCT01827605|Experimental|ARM B ASCT|BEAM conditioning regimen (or in alternative FEAM regimen with fotemustine to replace BCNU) and reinfusion of CD34+ cells of ≥ 2x106/Kg CD34+ day 0 (optimal dose to reinfuse 4x106/Kg CD34+). G-CSF 5 mcg/Kg from day 2 until ANC>1500/mmc. Patients who failed mobilization will directly proceed to rituximab maintenance
89376355|NCT01778647|Experimental|Stimulants plus Lovaza|Usual dose of stimulant plus Lovaza (prescription Omega-3 fatty acids) at a dose of 1800 mg daily.
89376356|NCT01778647|Placebo Comparator|Stimulants plus placebo|Usual dose of stimulants plus placebo(corn oil), which will be given to the patients by MMC's pharmacy.
89376357|NCT01658878|Experimental|Non-infected: Nivolumab|Nivolumab intravenous solution on specific days
89376358|NCT01658878|Experimental|HCV-infected: Nivolumab|Nivolumab intravenous solution on specific days
89376359|NCT01658878|Experimental|HBV-infected: Nivolumab|Nivolumab intravenous solution on specific days
89376360|NCT01658878|Experimental|Nivolumab|Nivolumab intravenous solution on specific days
89376361|NCT01658878|Active Comparator|Sorafenib|Sorafenib tablets on specific days
89376362|NCT01658878|Experimental|Nivolumab plus Ipilimumab Combination|Nivolumab intravenous solution + Ipilimumab intravenous solution on specific days
89376363|NCT01658878|Experimental|Child-Pugh B|Nivolumab intravenous solution on specific days
88848948|NCT05774262|Active Comparator|Group B - CARDIONEUROABLATION|"Group B, n=50 patients aged 18-75 years with indications for elective PM implantation according to the 2021 ESC guidelines for cardiac pacing due to paroxysmal or persistent AVB with a positive results of atropine test.~Group B will undergo strategy of postponed/deferred PM implantation in functional AVB. Patients wil be implanted and monitored with ILR (in case of severe symptomatic AVB always the emergency system will be called). After cardiovascular autonomic testing (CAT), electrophysiological study (EPS), extra cardiac vagal nerve stimulation (ECVS) and cardioneuroablation will be performed. If CNA is succesful, pacemaker implantation will be cancelled. If CNA is unsuccessful, second session of CNA will be planned. In case of inefficient second attempt, patients will be referred for PM implantation. They will cross-over to PACEMAKER arm."
89002405|NCT06318156|Experimental|Group1(lumbar disc herniation)|A well-trained physician donned the Finger TPS tactile pressure measurement system (Finger TPS II, BTLETG03, USA), methodically applying a consistent 60N force with a single thumb vertically downward on the acupoints of the L1 to L5 spinal segments, in accordance with the human cutaneous nerve segment map. Additionally, environmental conditions were meticulously controlled-temperature maintained between 20°C to 25°C, relative humidity at 50% to 60%, with gentle indoor lighting, quiet, and stable airflow. The MESH T-1000 Smart medical infrared thermograph, produced by Wuhan Gewu Optoelectronics Technology Co., Ltd., was utilized to assess the surface temperature of the patient's pressure-sensitive acupoint areas.
89376364|NCT01658878|Experimental|Nivolumab plus Cabozantinib Combination|Nivolumab intravenous solution + cabozantinib oral tablets on specific days
88848951|NCT05761600||Art Therapist|Professionally qualified and HCPC registered Arts Therapists delivering group arts therapy in the community settings in the UK
88848952|NCT05761600||People with a Learning Disability|Adults (18 years+) currently attending an art therapy group who have a learning disability and can consent and communicate in a way that supports meaningful engagement in the study.
89376365|NCT01658878|Experimental|Nivolumab plus Ipilimumab plus Cabozantinib|Nivolumab intravenous solution + Ipilimumab intravenous solution + cabozantinib oral tablets on specific days
89376366|NCT01628406||Patients treated at the neurosurgery department|Patients treated at the neurosurgery department
89376367|NCT01624285|Experimental|Arm I (sorafenib tosylate)|Patients receive sorafenib tosylate PO BID.
89376368|NCT01624285|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID.
89376369|NCT01523002|Active Comparator|Arm A: metoprolol and pyronaridine-artesunate 90-day redosing|Subjects will take 1 day of metoprolol followed by a 7 day wash out period, then 2 days of pyronaridine-artesunate followed by 1 day of pyronaridine-artesunate + metoprolol, followed by a 87 day follow-up period. Subjects will then receive pyronaridine-artesunate once daily for 3 days followed by a 40 day follow-up period.
89376370|NCT01523002|Active Comparator|Arm B: pyronaridine-artesunate 60-day redosing|Subjects will take pyronaridine-artesunate once daily for 3 days, followed by a 57 day follow-up period. Subjects will then take pyronaridine-artesunate once daily for 3 days followed by a 40 day follow-up period.
89376371|NCT01491269|Experimental|Internet delivered CBT|Internet delivered cognitive behavioral intervention, 8 weeks treatment.
89376372|NCT01491269|No Intervention|No intervention|Waitlist
89376373|NCT01471106|Experimental|Group 1: Dasatinib 40 mg|Dasatinib 40 mg by mouth once a day for 3 months (+/- 7 days), At the end of the 3 months (+/- 7 days) participants undergo a repeat FNA and blood collection for the same marker analyses.
89376374|NCT01471106|No Intervention|Group 3: No Dasatinib|No treatment control group. At the end of the 3 months (+/- 7 days) participants undergo a repeat FNA and blood collection for the same marker analyses.
89376375|NCT01471106|Experimental|Group 2: Dasatinib 80 mg|Dasatinib 80 mg by mouth once a day for 3 months (+/- 7 days). At the end of the 3 months (+/- 7 days) participants undergo a repeat FNA and blood collection for the same marker analyses.
89376376|NCT01431807|Experimental|SYR-472 group|(long-term monotherapy or long-term combination therapy with anti-diabetic drugs)
89376377|NCT01402258|Experimental|Tailored Internet-delivered CBT|Behavioral: Tailored Internet-delivered CBT
89376378|NCT00639171||1|Subjects with suspicious breast lesions that warrant further evaluation will be followed to determination and confirmation of diagnosis.
89376379|NCT00639171||2|Normal subjects used to evaluate software and to develop and optimize MR sequences will be examined.
89376380|NCT00580203||1|Patients with head and neck cancers
89376381|NCT00493792|Other|1|Stryker Orthopaedics N2Vac Polyethylene when used with a Triathlon Posterior Stabilized total knee system. This is a fixed- bearing knee intended for use in patients undergoing cemented total knee arthroplasty.
88848953|NCT05761600||Identified Support Person|Person who is well-known to the person with a learning disability (e.g. NHS staff, paid support staff or family members who are carers) who provides practical and/or emotional support to the person with a learning disability attending the art therapy group
89376382|NCT00493792|Other|2|X3 Polyethylene when used with a Triathlon Posterior Stabilized total knee system. This is a fixed- bearing knee intended for use in patients undergoing cemented total knee arthroplasty.
89376383|NCT00489307|Active Comparator|Dexamethasone|"Dexamethasone 4 mg orally two times a day for 14 days.~On day 15 [ ± 3 days], all patients receive dexamethasone 4 mg orally twice a day for 7 days, and then the dose of dexamethasone tapered to 2 mg orally twice a day between days 22 to 28."
89376384|NCT00489307|Placebo Comparator|Placebo|"Placebo by mouth (PO) twice daily for 14 days.~On day 15 [ ± 3 days], all patients receive dexamethasone 4 mg orally twice a day for 7 days, and then the dose of dexamethasone tapered to 2 mg orally twice a day between days 22 to 28."
89376385|NCT00421356||Transfemoral Power Knee group|Transfemoral amputees who used the power assisted Ossur Power Knee who used the knee daily without adjustments for at least 90 days prior to the study.
89376386|NCT00421356||Transfemoral C-Leg knee group|Transfemoral amputees who used the stance control Otto Bock C-Leg who used the knee daily without adjustments for at least 90 days prior to the study.
89376387|NCT00421356||Transfemoral Mauch knee group|Transfemoral amputees who used the mechanical fluid controlled Mauch Swing and Stance Knee who used the knee daily without adjustments for at least 90 days prior to the study.
89376388|NCT00421356||Non amputee control group|Healthy, non-amputee control group
89376389|NCT03521141|Other|Guideline-Based Care (GBC)|GBC participants are 1) referred to the state quitline, 2) provided the NCI Clearing the Air smoking cessation program, and 3) asked to talk to their healthcare provider about potential lung cancer screening (LCS). Medication assignment is guided by standard guidelines and a conversation between the study tobacco counselor and the participant. Groups 1 and 2 also receive GBC counseling.
89376390|NCT03521141|Active Comparator|Nicotine Metabolite Ratio (PC-NMR)|Group 1, nicotine metabolism. Medication is guided by nicotine metabolism.
89376391|NCT03521141|Active Comparator|Respiragene (PC-Respiragene)|Group 2, genetically-informed lung cancer risk score. Medication assignment is guided by standard guidelines and a conversation between the study nurse and the participant.
89376392|NCT03728621|Experimental|Individual-based lifestyle intervention|Promotion of normocaloric & balanced diet and physical activity
89376393|NCT03728621|Experimental|Group-based lifestyle intervention|Promotion of normocaloric & balanced diet and physical activity
89376394|NCT03722147|Experimental|AK105|AK105 200 mg intravenously (IV) every-2-weeks (Q2W)
89376395|NCT03722069|Other|Low sodium diet|22 patients were randomized to receive 3 g/day of dietary sodium chloride and a limit of fluid intake of 1000 ml/day.
89376396|NCT03722069|Other|Normal sodium diet|22 patients were randomized to receive 7 g/day of dietary sodium chloride and a limit of fluid intake of 1000 ml/day.
89376397|NCT03725267|Experimental|Melatonin|Patients will receive 1 pill each day with 30 mg of Melatonin during polymyxin B treatment for a maximum of 14 days.
89376398|NCT03725267|Placebo Comparator|Placebo|Patients will receive 1 pill each day with Placebo during polymyxin B treatment for a maximum of 14 days.
89376399|NCT02997176|Experimental|Group A (control, normal hepatic function)|
89376400|NCT02997176|Experimental|Group B (mild hepatic dysfunction)|
88848954|NCT05745285|Experimental|LLS Program and Usual Care Group|Participants in the LLS Program and Usual Care condition will receive LLS services such as information, services, and financial aid so that patients can have better access to healthcare and better quality of life. Participants will also receive the standard care. Participants will be in this group for 6 months.
88848955|NCT05745285|No Intervention|Usual Care Group|Participants will receive the standard care. Participants will be in this group for 6 months.
88848956|NCT05742906|Other|Group A: Adults treated with SIS 1.0 Cor TRICUSPID ECM Valve|Adults (>/= 21 years of age) treated with the SIS 1.0 Cor TRICUSPID ECM Valve
89376401|NCT02997176|Experimental|Group C (moderate hepatic dysfunction)|
89376402|NCT02997176|Experimental|Group D (severe hepatic dysfunction)|
88848957|NCT05742906|Other|Group B: Pediatrics treated with SIS 1.0 Cor TRICUSPID ECM Valve|Pediatrics (<21 years of age) treated with SIS 1.0 Cor TRICUSPID ECM Valve
88848958|NCT05742906|Other|Group C: Adults treated with SIS 2.0 Cor TRICUSPID ECM Valve|Adults (>/= 21 years of age) treated with the SIS 2.0 Cor TRICUSPID ECM Valve
88848959|NCT05742906|Other|Group D: Pediatrics treated with SIS 2.0 Cor TRICUSPID ECM Valve|Pediatrics (<21 years of age) treated with SIS 2.0 Cor TRICUSPID ECM Valve
89376403|NCT03000452|Experimental|Administration of Daratumumab (DARA) plus Durvalumab (DURVA)|"Subjects will also receive IV DURVA at 1500 mg on Day 2 (Cycle 1) and on Day 1 (Cycles ≥ 2) of each 28-day treatment cycle.~Subjects will receive intravenous (IV) DARA at 16 mg/kg on the same dosing schedule (weekly [QW], every 2 weeks [Q2W], or every 4 weeks [Q4W] of each 28-day treatment cycle) received during their last prior therapy containing DARA at the time of DARA progression"
89376404|NCT03664856|Experimental|experimental group|Subject suffering from a locally advanced or metastatic cancer therefore falling under palliative care as defined by the definition of the French Society of Support and Palliative Care An interview will be performed
89376405|NCT03664310|Experimental|FSET Anxiety and Sleep Treatment|The FSET Anxiety and Sleep Treatment (FAST) is a brief, 45-minute computerized intervention that can be accessed by any device connected to the Internet. The majority of the information is delivered via text. The program contains some interactive features such as quizzes, which direct participants to content, personalized to the individual user (for example screenshots, see Figure 2). FAST contains four modules: motivation, psychoeducation, behavioral tools, and behavior change.
89376406|NCT03664310|Active Comparator|Control|The control condition is the Physical Health Education Treatment (PHET) used in several of our laboratory's prior studies (Schmidt, Capron, Raines, & Allan, 2014). PHET is also a 45-minute computerized intervention, including audio and visual features as well as comprehension quizzes.
89376407|NCT04056416|Experimental|HIIT Exercise Program|Exercise on a MedBIKE 3 times a week for 8 weeks with pre- and post-CPET testing, questionnaires and qualitative interviews.
89376408|NCT03663686|Placebo Comparator|25mg single doses|Intervention Drug: 25mg Litapiprant Tablet administered orally once daily Intervention Drug: Matching Placebo Tablet administered orally once daily
88848960|NCT05741983|Experimental|AMIC®|Bone Marrow Stimulation (Microfracture) with Chondro-Gide®
88848961|NCT05741983|Active Comparator|Microfracture (MFx)|Microfracture alone
88848962|NCT05740371|Other|Argatroban|
89376409|NCT03663686|Placebo Comparator|50mg single doses|Intervention Drug: 50mg Litapiprant Tablet administered orally once daily Intervention Drug: Matching Placebo Tablet administered orally once daily
88848963|NCT05736731|Experimental|A2530|Patients receive Preconditioning Lymphodepletion (PCLD) Regimen followed by a single dose of A2B530 intravenously on day 0
88848964|NCT05735600|Experimental|Virtual|This group will participate in weekly virtual group sessions facilitated by a culturally similar and trained health educator (Promotora). The virtual modules will be on a platform such as Zoom and will last approximately 90 minutes each. Each module will last 60 minutes with the following three components: 1) 15-minute video on behavior change-related module objective, 2) 15-minute vignette/story depicting a family implementing behavior change, and 3) 15-minute discussion on creating goals and overcoming barriers for behavior change pertaining to the module. The remaining 15-minutes will ask participants to share what worked well towards achieving goals set in the prior module
88848965|NCT05735600|Active Comparator|Traditional|This group will get the same educational materials in writing (slides with information from video, written story, and instructions on goal setting and overcoming barriers) and receive a phone call from one of the researchers each week (5 weeks in a row) to provide an opportunity to respond questions, comments, and provide guidance about following the recommendations of the written material
88848966|NCT05733819|Active Comparator|Walking without personalized rhythmic auditory stimulation|Subjects will complete a 6MWT without any auditory cues
88848967|NCT05733819|Experimental|Walking with personalized rhythmic auditory stimulation|Subjects will complete a 6MWT with personalized rhythmic auditory cues
88848968|NCT05726136|Experimental|acetated Ringers|The circulatory effect of a bolus infusion with 4 ml/kg body weight of acetated Ringers will be studied. If cardiac output increase with 10% a second bolus will be infused and further studied.
88848969|NCT05726136|Experimental|albumin 5%|The circulatory effect of a bolus infusion with 4 ml/kg body weight of Albumin 5% will be studied. If cardiac output increases with 10% a second bolus will be infused and further studied.
88848970|NCT05726136|Experimental|albumin 20%|The circulatory effect of a bolus infusion with 1 ml/kg body weight of Albumin 20% will be studied. If cardiac output increase with 10% a second bolus will be infused and further studied.
88848971|NCT05714774|Experimental|Patients with localized prostate cancer|Patients with localized prostate cancer for which focal treatment, hemi-ablation or total ablation of the prostate is indicated will be treated by HIFU applied by FocalOne device.
88848972|NCT05714085|Experimental|Vericiguat|2.5 mg or 5 mg or 10 mg vericiguat administered orally once daily in tablet form for 52 weeks; or 0.2 mg/mL or 1 mg/mL vericiguat administered orally once daily in suspension form for 52 weeks
88848973|NCT05714085|Placebo Comparator|Placebo|Placebo for vericiguat administered orally once daily in tablet form for 52 weeks, or administered orally once daily in suspension form for 52 weeks
89002406|NCT06318156|Experimental|Group2 (healthy control)|A well-trained physician donned the Finger TPS tactile pressure measurement system (Finger TPS II, BTLETG03, USA), methodically applying a consistent 60N force with a single thumb vertically downward on the acupoints of the L1 to L5 spinal segments, in accordance with the human cutaneous nerve segment map. Additionally, environmental conditions were meticulously controlled-temperature maintained between 20°C to 25°C, relative humidity at 50% to 60%, with gentle indoor lighting, quiet, and stable airflow. The MESH T-1000 Smart medical infrared thermograph, produced by Wuhan Gewu Optoelectronics Technology Co., Ltd., was utilized to assess the surface temperature of the patient's pressure-sensitive acupoint areas.
89002407|NCT06318143|No Intervention|Education|provision of information about task sharing
89376410|NCT03663686|Placebo Comparator|100mg single doses|Intervention Drug: 100mg Litapiprant Tablet administered orally once daily Intervention Drug: Matching Placebo Tablet administered orally once daily
88848978|NCT05709574|Experimental|Tadalafil + chemotherapy|Subjects will receive Tadalafil monotherapy for 2 weeks followed by Tadalafil in combination with neoadjuvant FLOT chemotherapy for 8 weeks in the window between their cancer diagnosis and surgical intervention.
88848979|NCT05699642|Experimental|Tai chi + wearable|48 virtual tai chi classes on Zoom over 6 months plus assigned home practice of tai chi 3x a week plus daily use of a Fitbit fitness tracker will be required for this group.
88848980|NCT05699642|No Intervention|Enhanced usual care|Printed educational materials based on existing resources (e.g., AHA; Centers for Disease Control and Prevention) will be shared with subjects in this group.
88848981|NCT05694780|Experimental|Experimental|Women in the intervention group will receive standard obstetric care plus the STEP intervention which is a 8-week program based on sleep hygiene education and cognitive-behavioral training.
88848982|NCT05694780|No Intervention|Control|Women in the control group will receive standard obstetric care.
88848983|NCT05677152|Active Comparator|Zoledronic Acid|zoledronic acid 5 mg (Aclasta®) administered as single intravenous infusion (100 ml): Verum
88848984|NCT05677152|Placebo Comparator|physiological saline solution 0.9%|Sodium chloride (physiological saline solution 0.9%) administered as single intravenous infusion (100 ml): Placebo
88848985|NCT05659953|Experimental|LMT503|Subjects receiving LMT503 orally
88848986|NCT05659953|Placebo Comparator|Placebo|Subjects receiving Matched Placebo orally
88848987|NCT05658276||With LV Unloading|"Adults (18+) who are in cardiogenic shock and being treated with mechanical circulatory support (veno-arterial ECMO) inserted peripherally. The patients in this group will also have an additional device, such as an Impella or an intra-aortic balloon pump (IABP) for left ventricular unloading. The decision whether or not to unload the patient will be purely clinical.~Data will be collected from the patient's chart and entered into a secure database. A standard complete transthoracic echocardiogram will be completed at enrollment and then again 7 days from enrollment (+/- 2 days). Additional blood tests will be ordered for the 7 days after enrollment. All tests will be ordered on Day 1 (patient on ECMO, prior to any LV unloading) and additionally as follows:~Troponin: Daily for 7 days~NT-proBNP: Daily for 7 days~PCO2 gap (in blood gas analysis): Every 6 hours for 3 days~Lactate (in blood gas analysis): Every 12 hours for 3 days~cBIN1: Twice in 7 days"
89376411|NCT03663686|Placebo Comparator|200mg single doses|Intervention Drug: 200mg Litapiprant Tablet administered orally once daily Intervention Drug: Matching Placebo Tablet administered orally once daily
89376412|NCT03663686|Placebo Comparator|400mg single doses|Intervention Drug: 400mg Litapiprant Tablet administered orally once daily Intervention Drug: Matching Placebo Tablet administered orally once daily
89376413|NCT03663686|Placebo Comparator|600mg single doses|Intervention Drug: 600mg Litapiprant Tablet administered orally once daily Intervention Drug: Matching Placebo Tablet administered orally once daily
89376414|NCT03663686|Placebo Comparator|800mg single doses|Intervention Drug: 800mg Litapiprant Tablet administered orally once daily Intervention Drug: Matching Placebo Tablet administered orally once daily
89376415|NCT01373164|Experimental|Phase 1b: 80 mg Galunisertib + Gemcitabine|"Cohort 1: 40 mg Galunisertib was administered orally twice daily (BID) for 14 days followed by 14 days of rest (28 day cycle).~Gemcitabine at a dose of 1000 mg/m^2 was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks."
89376416|NCT01373164|Experimental|Phase 1b: 160 mg Galunisertib + Gemcitabine|"Cohort 2: 80 mg Galunisertib was administered orally twice daily for 14 days followed by 14 days of rest (28 day cycle).~Gemcitabine at a dose of 1000 mg/m^2 was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks."
89376417|NCT01373164|Experimental|Phase 1b: 300 mg Galunisertib + Gemcitabine|"Cohort 3: 150 mg Galunisertib was administered orally twice daily for 14 days followed by 14 days of rest (28 day cycle).~Gemcitabine at a dose of 1000 mg/m^2 was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks."
89376418|NCT01373164|Experimental|Phase 2: Recommended dose of Galunisertib + Gemcitabine|"Galunisertib recommended dose (300 mg) determined from phase 1, administered orally twice daily for 14 days followed by 14 days of rest (28 day cycle).~Gemcitabine at a dose of 1000 mg/m^2 was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks."
89376419|NCT01373164|Experimental|Phase 2: Placebo + Gemcitabine|"Placebo administered orally twice daily for 14 days followed 14 days of rest (28 day cycle).~Gemcitabine at a dose of 1000 mg/m^2 was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks."
89376420|NCT04349332|Active Comparator|Helmet non invasive ventilation (NIV)|Patients randomized to the intervention group will be extubated to helmet NIV.
89376421|NCT04349332|No Intervention|Control invasive mechanical ventilation|Patients randomized to the control group will continue invasive mechanical ventilation. Once weaning criteria are met, patients will undergo a spontaneous breathing trial for 30 minutes. If the spontaneous breathing trial is successful, then the patient will be extubated.
89376422|NCT02999984|Experimental|Gene Therapy|Infusion of autologous cryopreserved EFS-ADA LV CD34+ cells
89376423|NCT03664154|Experimental|Stress and Feeding (SAFE)|The SAFE intervention is grounded in a general theory of guided participation (GP) that posits learning will be facilitated by an emotionally regulated state of the mother. Efforts to help mothers manage stress will better position them to learn and attend to feeding their infants. GP links the two components: stress management (SM) and guided feeding (GF). SM provides skills to manage perceived stress and regulate emotion. GF provides education with skill building to help mothers become more sensitive and responsive to their infant. SAFE is delivered through a secure, password-protected responsive website with practice opportunities.
89376424|NCT03664700||LMA Protector|The LMA Protector will be used
89376425|NCT03550313|Experimental|Group 1 - Coadministration|Multivalent pneumococcal conjugate vaccine coadministered with Prevnar 13
89376426|NCT03550313|Experimental|Group 2 - Staggered Administration|Multivalent pneumococcal conjugate vaccine given 1 month after Prevnar 13
88848988|NCT05658276||Without LV Unloading|"Adults (18+) who are in cardiogenic shock and being treated with mechanical circulatory support (veno-arterial ECMO) inserted peripherally. The patients in this group will not have any LV unloading device in addition to the ECMO support. The decision not to do LV unloading will be purely clinical.~Data will be collected from the patient's chart and entered into a secure database. A standard complete transthoracic echocardiogram will be completed at enrollment and then again 7 days from enrollment (+/- 2 days). Additional blood tests will be ordered for the 7 days after enrollment. All tests will be ordered on Day 1 (patient on ECMO, prior to any LV unloading) and additionally as follows:~Troponin: Daily for 7 days~NT-proBNP: Daily for 7 days~PCO2 gap (in blood gas analysis): Every 6 hours for 3 days~Lactate (in blood gas analysis): Every 12 hours for 3 days~cBIN1: Twice in 7 days"
88848989|NCT05657613|Experimental|CYP450 Cocktail and Transporter Substrates with Pacritinib|This is the first part of the study which is an open-label, single-center, 1-way DDI study designed to assess the effect of pacritinib 200 mg BID at steady state on the systemic exposure of a cocktail of cytochrome P450 (caffeine, midazolam, and omeprazole) and transporter substrates (digoxin, rosuvastatin, and metformin) in 18 healthy male subjects.
88848990|NCT05657613|Experimental|CYP450 3A4 inducer (Bosentan) with Pacritinib|The second part of the study comprises of 2 arms. This is the first arm Days 1 through 14: An oral dose of pacritinib 200 mg (2 × 100 mg capsules) BID (approximately 12 hours apart) Days 8 through 14: An oral dose of bosentan 125 mg BID (approximately 12 hours apart) All the doses will be administered with approximately 240 mL of water.
88848991|NCT05657613|Experimental|CYP450 3A4 inhibitor (Fluconazole) with Pacritinib|"This is the second arm of Part 2 of the study:~Days 1 through 14: An oral dose of pacritinib 200 mg (2 × 100 mg capsules) BID (approximately 12 hours apart) Days 8 through 14: An oral dose of fluconazole 200 mg QD"
89002408|NCT06318143|Experimental|TASSH|replicable evidence-based task-sharing strategy,TAsk-Strengthening Strategy for Hemoglobinopathies (TASSH)
89376427|NCT03550313|Active Comparator|Group 3 - Control with Supplemental Dose|Prevnar 13 with a single dose of multivalent pneumococcal conjugate vaccine
89376428|NCT03312907|Placebo Comparator|Belimumab + Placebo|Eligible subjects will receive Belimumab 200 milligrams (mg) to be administered subcutaneously (SC) on Day 1 and then weekly (i.e., every 7 days) through Week 52. Subjects will also receive rituximab-placebo to be administered by intravenous (IV) infusions at Weeks 4 and 6 in double blind manner. Subjects will receive standard therapy excluding Immunosuppressants and including anti-malarials, non-steroidal anti-inflammatory drugs (NSAIDs), and/or corticosteroids tapered down to prednisone equivalent of less than or equal to (<=) 5 mg/day until Week 104. Subjects will not receive treatment after 52 weeks and will be in observation until Week 104.
89376429|NCT03312907|Experimental|Belimumab + Rituximab|Eligible subjects will receive Belimumab 200 mg to be administered SC on Day 1 and then weekly (i.e., every 7 days) through Week 52. Subjects will also receive rituximab 1000 mg to be administered by IV infusions at Weeks 4 and 6 in double blind manner. Subjects will receive standard therapy excluding Immunosuppressants and including anti-malarials, NSAIDs, and/or corticosteroids tapered down to prednisone equivalent of <= 5 mg/day until Week 104. Subjects will not receive treatment after 52 weeks and will be in observation until Week 104.
89376430|NCT03312907|Other|Belimumab + Standard therapy|Eligible subjects will receive open-label Belimumab 200 mg administered SC on Day 1 and then weekly (i.e., every 7 days) until Week 104. Subjects will also receive standard therapy including immunosuppressant, anti-malarials, NSAIDs, and/or corticosteroids tapered down to prednisone equivalent of <= 5 mg/day until Week 104.
89376431|NCT02999672|Experimental|Cohort 1 (UBC)|First six participants with locally advanced (unresectable and not treatable with curative intent) or metastatic UBC will initially receive Regimen A (trastuzumab emtansine at a dose of 2.4 mg/kg qw). An iDMC will assess the safety among the first six participants and decide whether dose will be switched to Regimen B (trastuzumab emtansine at a dose of 3.6 mg/kg q3w).
89376432|NCT02999672|Experimental|Cohort 2 (Pancreatic cancer/cholangiocarcinoma)|First six participants with metastatic pancreatic cancer/cholangiocarcinoma will receive Regimen A (trastuzumab emtansine at a dose of 2.4 mg/kg qw). An iDMC will assess the safety among the first six participants and decide whether dose will be switched to Regimen B (trastuzumab emtansine at a dose of 3.6 mg/kg q3w).
89376433|NCT03664622|Experimental|group K|patients with a ketamine infusion intraoperative
89376434|NCT03664622|Experimental|group M|patients with a Morphine infusion intraoperative
89376435|NCT05276869||group A|from 3 to 7 years included 36 patients
89376436|NCT05276869||group B|from 8 to 16 years included 17 patients
89376437|NCT01911676|Experimental|PF-03463275 Active Dose #1|Active dose between 40mg
89376438|NCT01911676|Experimental|PF-03463275 Active Dose #2|Active dose between 60mg
89376439|NCT01911676|Placebo Comparator|Placebo|Placebo- no active dose of PF-03463275.
89376440|NCT03663998|Active Comparator|A|CN54ENV IM EP 400 g
89376441|NCT03663998|Active Comparator|B|CN54ENV IM EP 1000 g
89376442|NCT03663998|Active Comparator|C|CN54ENV IM EP 4000 g
89376443|NCT03663998|Active Comparator|D|CN54ENV ID EP 600 g
89376444|NCT03663998|Active Comparator|E|CN54ENV ID EP 1200 g
89376445|NCT03663998|Active Comparator|F|CN54ENV ID EP 1800 g
89376446|NCT03663998|Active Comparator|G|"CN54ENV IM1 EP~+ pIL-12 (500 g)"
89376447|NCT03663998|Active Comparator|H|"CN54ENV IM1 EP~+ pIL-12 (1500 g)"
89376448|NCT03663998|Active Comparator|I|"CN54ENV IM1 EP~+ ID2 EP"
89376449|NCT01793233||Ancillary-Correlative (menstrual diary, biomarker analysis)|Patients complete a menstrual diary to document vaginal bleeding and undergo blood sample collections at baseline, the 3rd course of chemotherapy, at the end of chemotherapy, and at 6 and 12 months post-treatment.
88848992|NCT05656261||Adults of African or sub-Saharan ancestry|The study focuses on those who are at risk of having the APOL1 renal risk variants, which homozygous or compound heterozygous variants have been shown to lead to Chronic Kidney Disease in some of the population. Those who are found to have this mutations are of African or sub-Saharan ancestry. This study will include those aged 18-90 of this population.
88848993|NCT05654103|Active Comparator|surgAVF|Participant will undergo fistula creation through surgical means, which requires undergoing general anesthesia and opening the skin to create the fistula.
88848994|NCT05654103|Active Comparator|endoAVF|Participant will undergo fistula creation through endovascular surgical means, which does not require general anesthesia and is created by using a device that goes through the skin to create the fistula. The two devices that are currently FDA approved and used to create the endoAVF are the WavelinQ™ EndoAVF System and the Ellipsys® Vascular Access System.
89376450|NCT04051658|Experimental|Anodal-tDCS & PT|Anodal transcranial direct current stimulation (tDCS) will be applied for 20 mins before conventional physical therapy (about 1 hour). Anodal on the motor area (M1) of the affected hemisphere, Cathodal on the contralateral supraorbital area. The current intensity is fixed at 1.5 mA and the current will flow continuously. The physical therapist will give an intervention program base on the same basic conventional physical therapy treatment. The scope of intervention is administered to improve motor functions and cerebral hemodynamic.
89376451|NCT04051658|Experimental|Cathodal-tDCS & PT|Cathodal transcranial direct current stimulation (tDCS) will be applied for 20 mins before conventional physical therapy (about 1 hour). Anodal on the supraorbital area of the affected hemisphere, Cathodal on the primary motor area (M1) of the unaffected hemisphere. The current intensity is fixed at 1.5 mA and the current will flow continuously. The physical therapist will give an intervention program base on the same basic conventional physical therapy treatment. The scope of intervention is administered to improve motor functions and cerebral hemodynamic.
89376452|NCT04051658|Experimental|Dual-tDCS & PT|Dual transcranial direct current stimulation (tDCS) will be applied over C3-C4 or the motor area (M1) for 20 mins before conventional physical therapy (about 1 hour). Anodal on the affected hemisphere, Cathodal on the unaffected hemisphere. The current intensity is fixed at 1.5 mA and the current will flow continuously. The physical therapist will give an intervention program base on the same basic conventional physical therapy treatment. The scope of intervention is administered to improve motor functions and cerebral hemodynamic.
89376453|NCT04051658|Sham Comparator|Sham-tDCS & PT|Dual transcranial direct current stimulation (tDCS) in sham mode will be applied over C3-C4 or the motor area (M1) for 20 mins before conventional physical therapy (about 1 hour). Anodal on the affected hemisphere, Cathodal on the unaffected hemisphere. The physical therapist will give an intervention program base on the same basic conventional physical therapy treatment. The scope of intervention is administered to improve motor functions and cerebral hemodynamic .
89376454|NCT05276713||Tucidinostat-based therapy|30 mg tucidinostat was given orally(as six 5 mg tablets per day) twice a week (either, Monday and Thursday, Tuesday and Friday, or Wednesday and Saturday) for 4 consecutive weeks in a 4-week cycle.The endocrine drugs combined with tucidinostat were given based on previous treatment.Patients received tucidinostat-based treatment until disease progression or intolerable adverse events.
89376455|NCT05276635|Other|Control (EFT)|had a form of Emotional Freedom Techniques (EFT) adapted for use with insomnia (EFT-I)
89376456|NCT05276635|Active Comparator|Sleep Hygiene Education (SHE) intervention group|received a Sleep Hygiene Education (SHE) intervention
89376457|NCT04056182|Experimental|Lofexidine|Lofexidine prescribed as three 0.18mg tablets taken orally 4 times daily at 4-to 6-hour intervals for 2-10 days for the management of opioid withdrawal symptoms prior to receiving Vivitrol.
89376458|NCT04269304||Observational|Intermediate Age-Related Macular Degeneration Patients
89376459|NCT03573323|Experimental|Ixekizumab|"A starting dose of 160 milligram (mg) of ixekizumab was given as 2 subcutaneous (SC) injections at Week 0. During the Induction Period, ixekizumab 80 mg was given every 2 weeks (Q2W) at Weeks 2, 4, 6, 8, 10, and 12. During the Extension Period, ixekizumab 80 mg was given as 1 SC injection (Q4W) every 4 weeks at Weeks 16 and 20.~The Post Treatment Follow Up Period was for safety monitoring following the last treatment period."
89376460|NCT03573323|Experimental|Guselkumab|"During the Induction Period, guselkumab 100 mg was given as 1 SC injection at Weeks 0, 4 and 12. 1 placebo injection (to maintain the blind) was given at Weeks 0, 2, 6, 8, and 10. During the Extension Period, guselkumab 100 mg was given at Week 20. 1 placebo injection (to maintain the blind) was given at Week 16.~The Post Treatment Follow Up Period was for safety monitoring following the last treatment period."
89376461|NCT01895842|Experimental|Ruxolitinib|"Part 1: Dose of ruxolitinib received will depend when patient joined study. The first group of patients receive the lowest dose of ruxolitinib. Starting dose level for Part 1, 5 mg by mouth twice a day for a 28 day cycle. The second group of patients receive the lowest dose of ruxolitinib for 1 cycle and if no intolerable side effects are seen, the dose will increase to the next higher dose for Cycles 2 and beyond. The third group of patients receive the higher dose taken by the second group for 1 cycle and if no intolerable side effects are seen, the dose will be increased for Cycles 2 and beyond. The fourth group of patients take the higher dose taken by the third group for 1 cycle and if no intolerable side effects are seen, the dose will increase to the next higher dose for Cycles 2 and beyond.~If patients enrolled in Part 2, they will receive ruxolitinib at the highest dose that was tolerated in Part 1."
89376462|NCT04058054|Experimental|KeraStat® Cream|KeraStat® Cream is a non-sterile, non-implantable wound dressing intended to provide a moist environment in the management of a variety of partial thickness dermal wounds.
89376463|NCT04058054|Experimental|KeraStat® Gel|KeraStat® Gel is a sterile, non-implantable water-based gelatinous (hydrogel) wound dressing intended to act as a protective covering in the management of a variety of partial thickness dermal wounds.
89376464|NCT04058054|Experimental|Biafine|Wound dressing for management of partial and full thickness wounds.
89376465|NCT04058054|Active Comparator|Histamine|Histamine is provided as a solution of histamine base (6.0 mg/mL).
89376466|NCT04058054|Sham Comparator|Saline|Saline (sterile) is provided as a 0.9% NaCl solution.
89376467|NCT03306043|Experimental|Subjects who received mepolizumab|Subjects who were part of study 200622 and were randomized to receive either placebo or mepolizumab will be enrolled in this study as per study eligibility criteria. In this study, subjects will receive 300 mg of mepolizumab SC (three 100 mg SC injections) every 4 Weeks for a total of 5 doses during 20-Week treatment period.
89376468|NCT01728220|Active Comparator|Inhaled NO @ 0.003 mg/kg/ ideal body weight (IBW)/hr (Part A)|Inhaled NO using 3.0 mg/L [2440 ppm] NO minicylinder delivered via INOpulse® DS-C device
89376469|NCT01728220|Active Comparator|Inhaled NO @ 0.010 mg/kg/IBW/hr (Part A)|Inhaled NO using 3.0 mg/L [2440 ppm] NO minicylinder delivered via INOpulse® DS-C device
89376470|NCT01728220|Active Comparator|Inhaled NO @ 0.015 mg/kg/IBW/hr (Part A)|Inhaled NO using 6.0 mg/L [4880 ppm] NO minicylinder delivered via INOpulse® DS-C device
89376471|NCT01728220|Placebo Comparator|Placebo random @ 0.003, 0.010 or 0.015 mg/kg/IBW/hr (Part A)|Placebo using 99.999% N2 minicylinder delivered via INOpulse® DS-C device
89376472|NCT01728220|Active Comparator|Inhaled NO @ 0.030 mg/kg IBW/hr (Part B)|Inhaled NO using 6.0 mg/L [4880 ppm] NO minicylinder delivered via INOpulse® DS-C device
89376473|NCT01728220|Active Comparator|Inhaled NO @ 0.075 mg/kg IBW/hr (Part B)|Inhaled NO using 6.0 mg/L [4880 ppm] NO minicylinder delivered via INOpulse® DS-C device
89376474|NCT01728220|Active Comparator|Placebo random @ 0.030 or 0.075 mg/kg/IBW (Part B)|Placebo using 99.999% N2 minicylinder delivered via INOpulse® DS-C device
89376475|NCT04057430|Active Comparator|String floss|
89376476|NCT04057430|Experimental|Gumchucks floss|
89376477|NCT04498286||Amsterdam MS Cohort|
89376478|NCT01313533|Active Comparator|Lactated Ringers Solution with Arginine|100 ml of LRS with arginine
89376479|NCT01313533|Placebo Comparator|Lactated Ringers Solution|Lactated ringers solution
89376480|NCT03663842|Experimental|Neural tissue management|Myofascial release technique; Hip joint mobilization technique; Cross-fiber friction over the sacroiliac joints; Neural mobilization to improve sciatic nerve excursion.
89376481|NCT03725189|Experimental|PPG Group|Testing of PPG device in healthy adult population doing cardiovascular exercise
89376482|NCT04479904|Experimental|famitinib|
89376483|NCT03725111|Experimental|arterio venous leg ulcers|
88849001|NCT05651282|Experimental|Progesterone Challenge Test|10-day course of medroxyprogesterone acetate (Provera) 10 mg per os (po) daily.
89376484|NCT01069172|Experimental|FS Laser Surgery|For femtosecond laser-assisted cataract surgery group (FS Laser Surgery), subjects will receive capsulotomy, lens segmentation and, at investigator discretion, lens softening using the femtosecond laser device. If necessary, ultrasound (U/S) phacoemulsification will also be applied to facilitate removal of the crystalline lens during cataract surgery.
89376485|NCT01069172|Active Comparator|CCC Surgery|For the continuous curvilinear capsulorhexis (CCC) group (CCC Surgery), subjects will receive the standard of care for CCC and U/S phacoemulsification surgery to facilitate removal of the crystalline lens during cataract surgery.
89376486|NCT03724955|Experimental|Treatment Group|The treatment group will receive Estradiol 2 mg oral daily for 6 months. Medication will be mailed to patient. All study drugs will be dispensed by the Investigational Drug Pharmacy.
89376487|NCT03724955|Placebo Comparator|Placebo Group|The placebo group will receive placebo oral daily for 6 months. Medication will be mailed to patient. Placebo will be dispensed by the Investigational Drug Pharmacy.
89376488|NCT04220008|Experimental|Treatment (busulfan, vorinostat, gemcitabine, clofarabine)|"Patients receive a low-level test dose of busulfan IV over up to 1 hour on days -15 to -9, vorinostat PO QD on days -8 to -4, gemcitabine IV over about 90 minutes on days -7 and -5, clofarabine IV over about 1 hour and high-dose busulfan IV over 3 hours on days -7 to -4. Patients with CD20 positive (+) lymphoma also receive rituximab IV over 3 to 6 hours on days -15, -8, 1, and 8. Patients undergo HSCT on day 0. Patients then receive cyclophosphamide IV over 2 hours on days 3 and 4. Beginning day 5, patients receive standard of care tacrolimus IV over 24 hours and mycophenolate mofetil IV over 2 hours TID until they can be tolerated PO. Once tolerated PO, patients receive tacrolimus PO BID for 6 months and mycophenolate mofetil PO TID for up to 30 days in the absence of disease progression or unacceptable toxicity. After 30 days, patients who develop GVHD continue treatment with mycophenolate mofetil at physician's discretion"
89376489|NCT03721991|Active Comparator|GABA|gamma Amino butyric acid (GABA) food supplement with 6 g per day
89376490|NCT03721991|Placebo Comparator|PLACEBO|Matching placebo capsules to GABA
89376491|NCT02911688|Placebo Comparator|placebo|Safflower oil, taken in 2 capsules every 12 hours for a total of 4 doses
89376492|NCT02911688|Active Comparator|gamma tocopherol|gamma tocopherol 1400 mg, taken as 2 700 mg capsules every 12 hours for a total of 4 doses
89376493|NCT05580250|Experimental|Part A: Single Dose LY3526318|LY3526318 administered orally in three study periods.
89376494|NCT05580250|Placebo Comparator|Part A: Single Dose Placebo|Placebo administered orally in three study periods.
89376495|NCT05580250|Experimental|Part B: Multiple Dose LY3526318|LY3526318 administered orally.
89376496|NCT05580250|Placebo Comparator|Part B: Multiple Dose Placebo|Placebo administered orally.
89376497|NCT05580250|Experimental|Part C: Iohexol + Simvastatin + Metformin + LY3526318|Iohexol administered intravenously (IV) and simvastatin, metformin, and LY3526318 administered orally.
89376498|NCT03663374|Experimental|Odelepan|One tablet once daily
89376499|NCT03663374|Placebo Comparator|Placebo|One tablet once daily
88849002|NCT05649046|Other|patients|
88849003|NCT05648929|Active Comparator|the conventional expander Mentor CPX4 (MENTOR)|"intraindividual comparison of two differentially rough tissue expanders~Arm description: women undergoing prophylactic bilateral NSME and simultaneous tissue-expander based reconstruction with conventionally textured expander with surface roughness 60µM Ra"
88849004|NCT05648929|Active Comparator|the expander SmoothSilk(Motiva) with reduced surface roughness|"intraindividual comparison of two differentially rough tissue expanders~Arm description: women undergoing prophylactic bilateral NSME and simultaneous tissue-expander based reconstruction with reduced textured expander with surface roughness 4µM Ra"
88849005|NCT05646758|Experimental|TQB2934 injection|"intravenous injection. 0.09mg, 0.36 mg, 1mg, 2mg, 3mg, 5mg, 6mg, 10mg, 12mg, 16mg, 20mg each time.~once a week in Cycle 1-3. once every 2 weeks in Cycle 4-6. if reach PR and above remission after 6 cycles of administration, once every 4 weeks,28 days as a treatment cycle."
88849006|NCT05626439|Experimental|Treatment Sequence AB|Study participants randomized into this arm will receive single dose of Staccato alprazolam followed by single dose of oral alprazolam at pre-specified time points in the sequence AB.
88849007|NCT05626439|Experimental|Treatment Sequence BA|Study participants randomized into this arm will receive single dose of oral alprazolam followed by single dose of Staccato alprazolam at pre-specified time points in the sequence BA.
89181913|NCT04086498|Active Comparator|Ketogenic Diet|The KD is a protocol in which all foods containing carbohydrate are excluded, whereas meat, eggs, fish, ham, green leafy vegetables, cruciferous, zucchini, cucumbers and eggplants can be eat without any limit. This protocol allows the use of oil, lemon juice (2 tbs/day), spices and aromatic herbs with a limitation of the use of saturated fats like butter, margarine and lard. Coffee, tea and herbal tea could be sweetened with sweeteners
89181914|NCT04086498|Active Comparator|Mediterranean Diet|The MD is a balanced calorie-controlled diet. The calorie intake was 1200 Kcal/day of which 15% were proteins, 60% carbohydrates and 25% fat. In this protocol was highlighted the use of the typical ingredients of the mediterranean tradition, such as extravirgin olive oil, vegetables, fruits, fish, lean meat and whole grain cereals.
89376500|NCT03431948|Experimental|SBRT with Nivolumab and Urelumab|Patients will receive stereotactic body radiation therapy (SBRT) in combination with nivolumab and urelumab.
89376501|NCT03431948|Experimental|SBRT with Nivolumab and Cabiralizumab|Patients will receive stereotactic body radiation therapy (SBRT) in combination with nivolumab and cabiralizumab .
89181915|NCT00792467|Experimental|ITF2357|"Patients received the following therapy cycle~ITF2357, 50 mg every 6 hours, per os, days 1 - 3;~Mechlorethamine, 6 mg/sqm, intravenously , day 4. Therapy was administered every 21 days as long as there was no evidence of progressive disease or unacceptable toxicity, but in any case for a maximum of 12 cycles.~The mean number of complete treatment cycles received by patients was 5.25, with a minimum of 1 cycle and a maximum of 12 cycles."
89181916|NCT00585468|Experimental|Myfortic - Fed State|Mycophenolate sodium taken with a meal.
88849008|NCT05619744|Experimental|Part 1: RO7616789 QW: Dose Escalation|Participants will receive a fixed dose of RO7616789 intravenously once weekly (QW) per dose level on Day 1, 8, and 15 of each 21-day cycle. In case of toxicity, step-up (single or double) dosing may be explored.
89181917|NCT00585468|Experimental|Myfortic - Fasting State|Mycophenolate sodium taken separately from food by 2 hours.
89181918|NCT02604641|Placebo Comparator|Placebo group|0 mg CoQ10 daily
89181919|NCT02604641|Active Comparator|Quvital LD group|50 mg CoQ10 daily
89181920|NCT02604641|Active Comparator|Quvital HD group|150 mg CoQ10 daily
89181921|NCT04087356||RMD+ Patients|Age-related macular degeneration patients with reticular macular disease
89181922|NCT04087356||RMD- Patients|Age-related macular degeneration patients without reticular macular disease
89181923|NCT05600387|Experimental|Empagliflozin group|subjects in Empagliflozin group take 10mg Empagliflozin 10mg per day
89181924|NCT05600387|No Intervention|Control group|subjects in Control group will not receive Empagliflozin or other sglt-2 inhibitors
89181925|NCT04087044|Experimental|Vestibular dysfunction|66 patients: 30 patients with surgically confirmed unilateral loss, 15 patients with absent ice water calorics and resulting from vestibular neuritis and 21 patients with vestibular migraine
89181926|NCT04087044|Other|Control|120 aged matched controls
89181927|NCT00724152|Experimental|Arm 1/Cognitive Behavioral Therapy|Participants randomly assigned to this experimental group received six weeks of tinnitus education plus cognitive behavioral therapy. Cognitive behavioral therapy for tinnitus participants addressed cognitive and behavioral skills targeting the management of tinnitus and the negative impacts of tinnitus. Long-term self-efficacy and self-sufficiency were emphasized. The major components of CBT for tinnitus included identification of individual responses and beliefs about tinnitus and hearing loss, re-conceptualization of the tinnitus experience as one in which the patient has personal control, presentation of skills to modify cognitions and change behaviors, and reinforcement of skills via goals setting, homework and activities. Skills related to attention control, sleep hygiene, relaxation training are provided. Tinnitus education also included causes, treatments, current research, etc.
89181928|NCT00724152|Active Comparator|Arm 2/Tinnitus Education|Participants randomly assigned to this group received six weeks of tinnitus education. Tinnitus education and skills related to attention control, sleep hygiene and relaxation training such as imagery techniques were provided. Tinnitus education included causes, treatments, current research, epidemiological information, basic anatomy of the ear and brain, and support resources.
89181929|NCT00724152|No Intervention|Arm 3/Standard Care|Participants randomly assigned to this control group received only standard care. Standard care involves audiological measurement and brief education during the standard care appointment.
89181930|NCT02591940||Aortic Coarctation|interventional treatment in heart catheter (stenting/angioplasty) surgical repair of coarctation
89181931|NCT02591940||Aortic Valve Disease|surgical repair in aortic valve disease (reconstruction/valve replacement)
89181932|NCT00721110|Active Comparator|Lidocaine|Intravenous Lidocaine Group - Lidocaine is administered intravenously throughout surgery and during the 24 hours following surgery
89376502|NCT02670928|Active Comparator|Active group of patients|Active group of patients underwent program of active lifestyle management (healthy nutrition, physical exercises, psychological counselling and classes on diabetes) in first 12 weeks of the study.
89376503|NCT02670928|Experimental|Control group of patients|Control group pf patients were being monitored for the same criteria as active group but did not take part in the lifestyle change management program.
89181933|NCT00721110|Placebo Comparator|Placebo|A lidocaine placebo is administered intravenously throughout surgery and during the 24 hours after surgery.
89181934|NCT00721110|Active Comparator|Ketamine|Intravenous Ketamine Group - Ketamine is administered intravenously throughout surgery and during the 24 hours following surgery
89181935|NCT00721110|Active Comparator|ketamine + Lidocaine|both ketamine and Lidocaine are administered intravenously throughout surgery and during the 24 hours after surgery.
88849009|NCT05619744|Experimental|Part 2: RO7616789 Q3W: Dose Escalation|Participants will receive a fixed dose of RO7616789, at a dose determined in Part 1, intravenously once every 3 weeks (Q3W) on Day 1 of each 21-day cycle. In case of toxicity, step-up (single or double) dosing may be explored.
89181936|NCT04076631||Hepatocellular Carcinoma|Patients with hepatocellular carcinoma undergo open hepatectomy.
89181937|NCT02580279|Experimental|EGCG group|EGCG (purity≥95% by high pressure liquid chromatography; from Ningbo HEP Biotech Co., Ltd) is dissolved in 0.9% saline solution;The solution is sprayed three times a day at 0.05 ml/cm2 to the whole radiation field until two weeks after radiation completion; Patients who developed grade Ⅱ radiation-induced dermatitis have the option to either withdraw from the study or to continue with EGCG. Patients are follow general good skin care practices during radiation therapy, such as not applying water soaks to relieve itching or pain, not vigorously rubbing the irradiated area, or not erasing ink marks; patting the skin dry with a soft towel; avoiding exposure to the sun; and wearing loose and cotton clothes. They are advised not to use deodorant, lotion, cream, make up, perfume or any other product on the area during the course of radiation therapy.
89181938|NCT02580279|Placebo Comparator|placebo|The placebo is 0.9% saline solution.Patients are also to follow general good skin care practices which is same as the EGCG group.
89181939|NCT02592096|Experimental|0.1% Pazufloxacin Mesilate Ear Drops|10 drips for ear dropping, 10 minutes for ear bath
89181940|NCT02592096|Experimental|0.3% Pazufloxacin Mesilate Ear Drops|10 drips for ear dropping, 10 minutes for ear bath
89181941|NCT02592096|Experimental|0.5% Pazufloxacin Mesilate Ear Drops|10 drips for ear dropping, 10 minutes for ear bath
89181942|NCT02592096|Active Comparator|Pazufloxacin mesilate injection|0.3g, 30 minutes for ventricular injection
89181943|NCT00791999|Experimental|CDP870 100mg|200mg CDP870 given at Week0, 2, 4 and thereafter 100mg CDP870 given every 2 weeks
89181944|NCT00791999|Experimental|CDP870 200mg|400mg CDP870 given at Week0, 2, 4 and thereafter 200mg CDP870 given every 2 weeks
89181945|NCT00791999|Experimental|CDP870 400mg|400mg CDP870 given every 2 weeks
89181946|NCT00791999|Placebo Comparator|Placebo|Placebo given every 2 weeks
88849010|NCT05619744|Experimental|Part 3: Dose Expansion|Based on emerging data from Part 1 and 2, one or more dosing regimens will be further investigated in Part 3.
89181947|NCT04085484||Infants born between 1 Feb 2010 and 18 Feb 2012|Infants born between 1 February 2010 and 18 February 2012, before the concentrated PN regime was implemented (Original PN group: n = 81).
89181948|NCT04085484||Infants born between 19 Feb 2012 and 30 Sep 2013|Infants born between 19 February 2012 and 30 September 2013, after the concentrated PN regime was implemented (Concentrated PN group: n = 53).
89181949|NCT04033263|Placebo Comparator|Placebo mouth rinse|Placebo: Deionized water (serving as negative control)
89181950|NCT04033263|Active Comparator|Elmex mouth rinse|Commercial mouth rinse used as gold standard in erosion studies: elmex® Erosion Protection solution (which contains 800 ppm Sn2+, as SnCl2, and 500 ppm F-, as NaF and AmF)
88849011|NCT05612035|Experimental|MK-5475|Participants with PH-COPD will receive 380 µg of MK-5475 as an oral inhalation once daily for 24 weeks (base period) and thereafter for 18 months (optional extension period).
89181951|NCT04033263|Active Comparator|Fluoride mouth rinse|Fluoride solution similar to many other commercial mouth rinses containing sodium fluoride (NaF at 500 ppm F-)
89181952|NCT04033263|Experimental|Plant extract A|Plant Extract A
89181953|NCT04033263|Experimental|Plant extract A with fluoride|Plant Extract A + Fluoride
89181954|NCT04033263|Experimental|Plant extract B|Plant extract B
89181955|NCT04033263|Experimental|Plant extract B with fluoride|Plant Extract B + Fluoride
89181956|NCT04033263|Experimental|Plant extract C|Plant extract C
89181957|NCT04033263|Experimental|Plant extract C with fluoride|Plant Extract C + Fluoride
89181958|NCT04075227|Experimental|0.2% loteprednol etabonate|This group was treated with subconjunctival 5-FU injection and topical 0.2% loteprednol etabonate every 4-6 hours for 4 weeks. After that, the regimen was gradually decreased until cessation at 3 months.
89181959|NCT04075227|Active Comparator|0.1% dexamethasone|This group was treated with subconjunctival 5-FU injection and topical 0.1% dexamethasone (CD-oph) every 4-6 hours for 4 weeks. After that, the regimen was gradually decreased until cessation at 3 months.
89181960|NCT03499821|Experimental|Study population|EDOF ICL implanted into both eyes of eligible subjects.
89181961|NCT00585078|Experimental|CAPOX|Participants self-administered capecitabine 1,000 mg/m2 orally twice daily (total daily dose 2,000 mg/m2), days 1-14 in 21-day cycles. Only 500 mg tablets were used, and doses were rounded to the nearest dose that could be administered with 500 mg tablets. Oxaliplatin 130 mg/m2 was administered intravenously on day 1 every 21 (±2) days. Treatment continued until tumor progression or toxicity requiring discontinuation of therapy.
89181962|NCT00720876|Experimental|Vorinostat and Rituximab|Vorinostat by mouth two times (2X) per day for two weeks followed by one week of rest. Rituximab intravenously once every three weeks .
89181963|NCT00723840||Crohn's Disease Participants|"Participants with Crohn's Disease for at least 6 months, who have a Crohn's Disease Activity Index (CDAI) score >= 150. The CDAI score evaluates Crohn's disease symptoms - a score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.~These participants have active disease despite drug therapy."
89181964|NCT00789581|Experimental|Doxorubicin/cyclophosphamide, ixabepilone|Doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 administered for 4 cycles of 21 days each, followed by ixabepilone at 40 mg/m2 given for 4 cycles of 21 days each.
89181965|NCT00789581|Active Comparator|Doxorubicin/cyclophosphamide, paclitaxel|Doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 administered for 4 cycles of 21 days each, followed by paclitaxel at 80 mg/m2 weekly for 12 weeks.
89181966|NCT04075071|Experimental|TCIT-U|Four teachers from two Head Start classrooms will be assigned to Teacher-Child Interaction Training - Universal (TCIT-U). TCIT-U occurs in two phases (6 weeks per phase): Child-Directed Interaction (CDI; focusing on relationship building) and Teacher-Directed Interaction (TDI; focusing on managing behavior problems). The TCIT-U Trainer (a licensed clinical child psychologist) will provide teachers with group didactic sessions (6 hours per phase) and individualized live coaching in their classrooms (20 minutes, once per week). Strategies include the use of PRIDE skills (Praise, Reflection, Imitation, Behavior Description, and Enthusiasm) or specific verbalizations that promote warm, responsive interactions, as well as classroom-appropriate behavior modification strategies which include using effective commands, prompts, natural consequences, differential social attention, and a modified time-out appropriate for use in a classroom.
89181967|NCT04075071|No Intervention|Usual Care|Four teachers from 2 PreK Counts classrooms will be assigned to the Usual Care (UC) group. They will continue their existing behavioral management strategies and techniques. Teachers will report on specific training in and use of other behavior management and social-emotional learning programs at baseline. At the conclusion of the study, UC teachers and staff will be offered didactic training in TCIT-U principles and strategies.
89181968|NCT00717756|Experimental|Lenalidomide|
89181969|NCT00915629|Experimental|Probiotic|Dietary supplement
89535062|NCT03087825|Active Comparator|pressure support ventilation|preoxygenation through non invasive pressure support ventilation of 100% oxygen gas flow (inspiratory trigger sensitivity set at -2 l.min-1, the positive inspiratory support set at +6 cmH2O, the PEEP set at +5 cmH2O and the maximal airway pressure was limited at 15 cmH2O.) with or without an inward air leak
88849012|NCT05612035|Placebo Comparator|Placebo|Participants with PH-COPD will receive matching placebo as an oral inhalation once daily for 24 weeks (base period) and then 380 µg of MK-5475 as an oral inhalation once daily for 18 months (optional extension period).
89181970|NCT04111289|Active Comparator|Patient received upstream high bolus dose of tirofiban|"After consenting for primary PCI ,the patient will be assigned to one arm ( either upstream high bolus dose IV before going to cath lab or selective downstream administration according to operator discretion )~Administration of tirofiban (25 ug/kg bolus and 0.15 ug/kg/min maintenance infusion)~Randomization will be performed by Microsoft Excel where random order will be generated for the study population"
89181971|NCT04111289|Active Comparator|Patients did not receive upstream high bolus dose of tirofiban|Patient receive tirofiban downstream selectively according to operator discretion
88849013|NCT05605678||All Eligible Participants|All Participants diagnosed with severe HemA with or without inhibitors, moderately severe to severe HemB, or HemB with inhibitors will be enrolled and continue to receive their usual hemophilia treatment regimen under SOC therapy. Bleeding episodes and treatment data will be collected during the prospective follow up period in a diary. No intervention will be administered as part of this study.
88849014|NCT05601726|Experimental|Single Administration Dose (SAD) of ABD-3001|Dose escalation of 6 doses level using a 3+3 design.
88849015|NCT05601726|Experimental|Multiple Administration Dose (MAD) of ABD-3001|Dose escalation of 3 doses level for a full cycle of treatment (28 days).
88849016|NCT05600426|Active Comparator|Immunosuppressive Therapy|Patient will receive standard immunosuppressive therapy combination of drugs: horse anti-thymocyte globulin (ATG) and cyclosporine.
88849017|NCT05600426|Active Comparator|Matched Unrelated Stem Cell Transplant|Patient will under go matched unrelated donor transplant of hematopoietic stem cells as their therapy using fludarabine, cyclophosphamide, rabbit anti-thymocyte globulin (ATG), and low-dose total body irradiation (TBI) as preparative regimen and cyclosporine and methotrexate for graft versus host disease (GVHD) prevention.
89376504|NCT03662516|Other|Sequence 1|In Treatment Sequence 1, Period 1 Day 1, subjects will be dosed with a single administration of OC in the form of 1 PORTIA (EE and LN) or equivalent tablet, orally. OC (EE and LN) PK will then be assessed at pre dose and over 48 hours after OC dosing. Period 1 will be immediately followed by Period 2 with no washout. The 48 hours post-OC dose PK sample for Period 1 must be collected prior to receiving the first dose of PF 04965842 in Period 2. In Period 2, subjects will be dosed with 200 mg PF 04965842 PO QD for 9 days followed by administration of a single dose of OC oral tablet immediately after administration of a 200 mg dose of PF-04965842 on the morning of Day 10. OC PK in Period 2 will be assessed at pre dose and over 48 hours after OC dosing. Dosing with 200 mg PF 04965842 PO QD will continue until Day 11.
89376505|NCT03662516|Other|Sequence 2|In Treatment Sequence 2, Period 1, subjects will be dosed with 200 mg PF 04965842 PO QD for 9 days followed by administration of a single dose of OC oral tablet immediately after administration of a 200 mg dose of PF-04965842 on the morning of Day 10. OC PK will be assessed at pre dose and over 48 hours following OC dosing. Dosing with 200 mg PF 04965842 PO QD will continue until Day 11. Subjects will then undergo a washout period of at least 10 days (Day -1 of Period 2 starts 10 days after Day 12 of Period 1). In Period 2 subjects will be dosed with a single OC administration on Day 1. OC PK will then be assessed at pre dose and over 48 hours after OC dose.
89376506|NCT01061684||NAFLD|pediatric patients with non-alcoholic fatty liver disease (NAFLD).
89399380|NCT03686709|Experimental|SIR-Spheres Therapy Selection|Patient selected for SIR-spheres radioembolization therapy using standard of care selection. Infusion of the therapy dose will be monitored using external detectors placed on the delivery system as well as the points on the patient. Blood draws will be collected before, during, and after the therapy infusion to monitor radiation levels in the blood. Following therapy, the patient will undergo standard of care bremsstrahlung SPECT imaging as well post-infusion PET/CT. A final blood draw will take place in conjunction with PET/CT imaging.
89535063|NCT03240055|Experimental|Group SE|21 patients received spinal anesthesia first. After confirmation of the level (T4-T6) of the sensory anesthesia, the sequential administration of etomidate was conducted
88849018|NCT05589974||Acute|Patients with acute first attack CSC with subretinal fluid (SRF) on OCT and symptom duration under 4 months.
88849019|NCT05589974||Chronic|Patients with chronic CSC, i.e. symptoms and SRF for more than 4 months.
88849020|NCT05589714||Younger Age Cohort|"Participants ages ≥ 4 years and < 8 years old will be designated as the Younger Age Cohort.~Participants in this cohort will not be assigned a Vision Cohort.~Registry/Screening Visit and Natural History Study Visits will have an abbreviated testing schedule, detailed in the Schedule of Study Visits and Procedures table."
88849021|NCT05589714||Vision Cohort 1|Participants who are aged ≥ 8 years old will be designated into a Vision Cohort based on data in the better eye, at the Registry/Screening Visit. Criteria that must be met in the better eye* at the Registry/Screening Visit: visual acuity ETDRS letter score of 54 or more (approximate Snellen equivalent 20/80 or better) and visual field** diameter 10 degrees or more in every meridian of the central field
88849022|NCT05589714||Vision Cohort 2|Participants who are aged ≥ 8 years old will be designated into a Vision Cohort based on data in the better eye, at the Registry/Screening Visit. Criteria that must be met in the better eye* at the Registry/Screening Visit: visual acuity ETDRS letter score of 19-53 (approximate Snellen equivalent 20/100 to 20/400) or visual acuity ETDRS letter score of 54 or more (approximate Snellen equivalent 20/80 or better) and visual field** diameter less than 10 degrees in any meridian of the central field
88849023|NCT05589714||Vision Cohort 3|Participants who are aged ≥ 8 years old will be designated into a Vision Cohort based on data in the better eye, at the Registry/Screening Visit. Criteria that must be met in the better eye* at the Registry/Screening Visit: visual acuity ETDRS letter score of 18 or less (approximate Snellen equivalent 20/500 or worse)
88849024|NCT05581004|Experimental|Phase Ia: Dose Escalation|Participants in successive cohorts will receive escalating doses of RO7502175, as an intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression or unacceptable toxicity.
88849025|NCT05581004|Experimental|Phase Ia: Expansion|Participants with select solid tumors will receive a recommended dose of RO7502175, determined in Phase Ia Dose Escalation phase as an IV infusion on Day 1 of each 21-day cycle until disease progression or unacceptable toxicity.
88849026|NCT05581004|Experimental|Phase Ib: Dose Escalation|Participants in successive cohorts will receive escalating doses of RO7502175, as an IV infusion, in combination with a fixed dose of atezolizumab, as an IV infusion on Day 1 of each 21-day cycle until disease progression or unacceptable toxicity.
88849027|NCT05581004|Experimental|Phase Ib: Expansion|Participants with select solid tumors will receive a recommended dose of RO7502175, determined in Phase Ib Dose Escalation phase, as an IV infusion, in combination with a fixed dose of atezolizumab, as an IV infusion on Day 1 of each 21-day cycle until disease progression or unacceptable toxicity.
88849028|NCT05574712|Experimental|Open-Label Treatment Group|Participants will be treated with neoadjuvant therapy for a total of 3 months (12 weeks) prior to prostatectomy. Therapy will consist of leuprolide acetate, abiraterone acetate, and belzutifan.
88849029|NCT05572424|Experimental|Adaptated Physical Activity + pedometer watch|Follow an Adapted Physical Activity program during 12 weeks and wear a pedometer watch during 1 year
88849030|NCT05572424|No Intervention|Control group|Usual care
89376507|NCT04978168|Experimental|Implementation Core|During baseline Exploration, staff organizational surveys are collected. During Preparation, staff focus groups conduct needs assessment with system mapping of linkage points for screening, assessment, and referral, and the agencies/staff involved in these activities. During Implementation, sites use facilitated local change teams (LCT) provided with a core set implementation strategies to facilitate linkages between probation agencies and local community treatment providers. The LCTs identify barriers to change, approaches to overcome barriers, do goal selection using SMART (specific, measurable, achievable, relevant, timely) goals and evidence for medications, address stigma, and clarify needs/expectations/roles of probation officers and treatment providers, then choose and implement goals and strategies. Sustainability Phase: Facilitators work with LCTs for 12 months using a written action plan based on goal selection.
88849033|NCT05560659|No Intervention|Stereotactic ablative body radiotherapy (SABR) alone|1-3 fractions of SABR to all sites of disease
88849034|NCT05560659|Experimental|SABR plus 2 cycles of 177Lu-PSMA|cycles of 177Lu-PSMA with 1-3 fractions of SABR to all sites of disease between cycle 1 and 2
88849035|NCT05560607|Experimental|Intervention/ Drug|Investigation of the knockdown of hepatic HSD17B13 mRNA expression, PK, safety, and tolerability following multiple dose administration of AZD7503 in male participants and female participants of non-childbearing potential with NAFLD or NASH
88849036|NCT05552183|Experimental|Moderate Hepatic Impairment|Subjects with moderate hepatic impairment based on Child-Pugh Class B score of 7-9 will receive 14 days of 200 mg BID pacritinib.
88849037|NCT05552183|Experimental|Severe Hepatic Impairment|Subjects with severe hepatic impairment based on Child-Pugh Class C score of 10-15 will receive 14 days of 200 mg BID pacritinib.
88849038|NCT05552183|Experimental|Normal Hepatic Function|Healthy subjects who have normal hepatic function with age (± 10 years; ≥ 18 years old and ≤ 85 years old), BMI (±20%), and sex, matching with the moderate and severe hepatic impairment cohorts will receive 14 days of 200 mg BID pacritinib.
88849039|NCT05549219|Experimental|10 mg/kg GLM101|GLM101 IV infusions, given weekly
88849040|NCT05549219|Experimental|20 mg/kg GLM101|GLM101 IV infusions, given weekly
88849041|NCT05549219|Experimental|30 mg/kg GLM101|GLM101 IV infusions, given weekly
88849042|NCT05548296|Experimental|OncoSignature Positive Tumors|In Arm 1, participants with an OncoSignature Positive test will enter a Phase 2 Simon 2-Stage Study that will assess the efficacy of ACR-368 as monotherapy in each of the 3 cohorts of participants (ovarian, endometrial, and urothelial).
88849043|NCT05548296|Experimental|OncoSignature Negative or Unevaluable test|In Arm 2, participants with an OncoSignature Negative will receive the combination of ACR-368 and ultralow Dose Gemcitabine (ULDG). The Phase 1b/2 portion will only enroll participants with OncoSignature Negative tumors. Unevaluable tumors will not be able to participate. A Phase 1b Study will assess the safety of the combination of ACR-368 and escalating doses of ULDG in participants with any of the 3 tumor types (ovarian, endometrial, and urothelial). The Phase 1b Study will determine the recommended Phase 2 dose (RP2D) of ULDG. When determined, a Phase 2 Exploratory Study will be initiated to assess the efficacy and safety of the combination of ACR-368 and the RP2D of ULDG in each of the 3 cohorts of participants (ovarian, endometrial, and urothelial).
88849044|NCT05545865|Placebo Comparator|Low Flavanol Cocoa Powder|12 g of Low Flavanol Cocoa Powder (30 mg of cocoa flavanols) provided as a beverage mixed in water
88849045|NCT05545865|Experimental|High Flavanol Cocoa Powder|High Flavanol Cocoa Powder (435 mg of flavanols) will be provided as a beverage mixed in water.
88849046|NCT05545865|Experimental|Two Servings of Vine to Bar Chocolate|Two servings (60g, 6 pieces) of Vine to Bar Chocolate providing both cocoa flavanols and Chardonnay marc.
88849047|NCT05545865|Experimental|One Serving of Vine to Bar Chocolate|A single serving (30g, 3 pieces) of Vine to Bar Chocolate providing both cocoa flavanols and Chardonnay marc.
88849048|NCT05545865|Experimental|Vine to Bar Chocolate covered Almonds|11 pieces (45g) of Vine to Bar Chocolate providing both cocoa flavanols and Chardonnay marc, with almonds
88849049|NCT05544201|Experimental|40 Hz HD-tACS|The stimulation parameters of HD-tACS include: 20 minutes at 40 Hz, 2 milliamps.
89376508|NCT04978168|Experimental|Randomized Trial of Peer Support Specialist Model|After Core implementation is complete, half of adult participants in probation who consent will be randomly assigned to a Peer Support Specialist (PSS) condition. PSS are assigned to adults diagnosed with OUD within 6 months of entry into probation, in addition to treatment as usual. PSS establish linkages to community providers (medical, mental health, substance use treatment); educate about recovery support services, transportation assistance, MOUD; provide experiential, non-clinical support to individuals with SUD; share skills, offer support for setting goals and navigating the recovery process); and provide referrals and support for treatment, housing, employment, drug court, and probation.
88849050|NCT05544201|Active Comparator|HD-tDCS|The stimulation parameters of HD-tDCS include: 20 minutes at 2 milliamps, 20 seconds fade-in and 20 seconds fade-out.
88849051|NCT05544201|Sham Comparator|Sham HD-tCS|In sham condition, the stimulation only last for 30 seconds with the electrodes left in place for a further 20 minutes. This procedure mimics the transient skin sensation of tingling induced by active HD-tACS and HD-tDCS without producing any sustainable effects.
88849052|NCT05535764|Experimental|Treatment: All Patients|A 3+3 dose de-escalation design will be used to determine the recommended phase 2 dose,while ensuring the safety and tolerability of the treatment. In this trial, the dose determined to be the maximum tolerated dose will be the recommended phase 2 dose and will be utilized in the cohort expansion.
88849053|NCT05534984|Experimental|Arm A|
88849054|NCT05534984|Placebo Comparator|Arm B|
88849055|NCT05534984|Experimental|Arm C|
88849056|NCT05532423|Experimental|Metabolic Syndrome Older Adult|Participants with metabolic syndrome will be drinking nitrate rich beetroot juice from the James White Beet It company. Participants will drink one dose of 140mL beetroot juice for two visits of either a nitrate rich juice or a nitrate depleted placebo drink. Both drinks taste and smell the same, just with the active component removed. Following these visits, participants will drink 70ml of nitrate rich beetroot juice daily for 4 weeks to investigate long term effects of the juice on study outcomes.
89002409|NCT06318130|Active Comparator|Lumenless lead|Lumenless leads used are fixed helix pacing leads (SelectSecure 3830 pacing lead from Medtronic) during the LBBP procedure.
88849057|NCT05532423|Experimental|Metabolic Syndrome Older Adult - Placebo juice condition|Participants with metabolic syndrome will be drinking nitrate rich beetroot juice from the James White Beet It company. Participants will drink one dose of 140mL beetroot juice for two visits of either a nitrate rich juice or a nitrate depleted placebo drink. Both drinks taste and smell the same, just with the active component removed. Following these visits, participants will drink 70ml of nitrate rich beetroot juice daily for 4 weeks to investigate long term effects of the juice on study outcomes.
88849058|NCT05525741|Experimental|Vitiligo Group|If the subject consents and they meet all the criteria a 20 ml blood sample will be taken.
88849059|NCT05525741|Other|Volunteers Group|If the subject consents and they meet all the criteria a 20 ml blood sample will be taken.
88849060|NCT05523167|Experimental|EFG PH20 SC|participants receiving efgartigimod PH20 SC on top of background treatment
88849061|NCT05523167|Placebo Comparator|PBO PH20 SC|participants receiving placebo PH20 SC on top of background treatment
88849062|NCT05521412|Experimental|Experimental: Treatment Arm|In this single-arm study, patients will receive doses of [161 Tb]Tb PSMA I&T on Day 1 of every 6 week Cycle. The dose of [161 Tb]Tb PSMA I&T will vary in dose-escalation. Up to 6 Cycles will be given.
88849063|NCT05521321|Experimental|Receives the Stanford Cannabis Prevention and Awareness curriculum|Stanford Cannabis Prevention and Awareness curriculum administered
88849064|NCT05521321|No Intervention|Does not receive Stanford Cannabis Prevention and Awareness curriculum|Receives another curriculum or no cannabis prevention curriculum
88849065|NCT05509777|Experimental|Mirikizumab Dose 1|Mirikizumab administered intravenously (IV) or subcutaneously (SC) in participants that weigh greater than (>) 40 kilograms (kg).
88849066|NCT05509777|Experimental|Mirikizumab Dose 2|"Mirikizumab administered IV or SC in participants that weigh >20 kg to less than or equal to (≤) 40 kg.~Dosing is based on assessments of the participant's weight and appropriate weight class."
88849067|NCT05509777|Experimental|Mirikizumab Dose 3|"Mirikizumab administered IV or SC in participants that weigh greater than or equal to (≥)10 kg to less than or equal to ≤20 kg.~Dosing is based on assessments of the participant's weight and appropriate weight class."
88849068|NCT05508867|Experimental|Favezelimab/Pembrolizumab|Participants will receive coformulated favezelimab/pembrolizumab (800 mg/200 mg) by intravenous (IV) infusion on Day 1, then every three weeks (Q3W), for up to 35 infusions.
88849069|NCT05508867|Active Comparator|Chemotherapy (Bendamustine or Gemcitabine)|Participants will receive physician's choice of EITHER bendamustine by IV infusion at a dose between 90 and 120 mg/m^2 on Day 1 and Day 2 of either a 3- or 4-week cycle for up to 6 cycles OR gemcitabine by IV infusion at a dose between 800 and 1200 mg/m^2 on Day 1 and Day 8 of a 3-week cycle for up to 6 cycles.
88849070|NCT05505201|Experimental|Active stimulation group|Fifteen sessions of inhibitory repetitive transcranial magnetic stimulation (rTMS) treatment at 1 Hz frequency will be applied to the contralesional primary motor cortex (hand region). The application will be performed with Neurosoft-Neuro MS / D device. 120% of the resting motor threshold will be used in the stimulation. One session of stimulation will last for a total of 30 minutes and a total of 1800 pulses in the form of 1 Hz stimulation.
88849071|NCT05505201|Sham Comparator|Sham stimulation group|Fifteen sessions of sham repetitive transcranial magnetic stimulation (rTMS) treatment will be applied to the contralesional primary motor cortex (hand region). The application will be performed with Neurosoft-Neuro MS / D device. The probe of the device will be held in an upright position and stimulation will be performed at the 10% of the resting motor threshold.
88849072|NCT05500339|Experimental|mHealth App|The mHealth App designed for the support of the first 1000 days of life is provided to pregnant women. Specific contents are presented to the user according to the current trimester of pregnancy or the post-partum period following a scheduled routine; all contents are always available for free consultation during the entire period of use. Links to relevant institutional websites are also reported for any further reading. The app has a frequently asked question (FAQ) section, and a calendar function with the possibility to set appointments and reminders. App contents and topics include information about health prevention behaviors such as vaccination during pregnancy, weight increment during pregnancy, abstinence from smoke and alcohol consumption habits, adherence to child routine vaccination schedule.
88849073|NCT05500339|Sham Comparator|Standard care.|Pregnant women receive standard supportive and educational methods.
88849074|NCT05487235|Experimental|Dose-finding Stage: GDC-1971|Participants will receive GDC-1971 tablet or capsule at assigned dose, orally once daily (QD) on Days 1-21 of each cycle, along with atezolizumab 1200 milligrams (mg) intravenous (IV) infusion once every 3 weeks (Q3W), until unacceptable toxicity or loss of clinical benefit. A subset of participants will participate in evaluations regarding tablet versus (vs) capsule formulations.
88849075|NCT05487235|Experimental|Expansion Stage: GDC-1971|Participants will receive GDC-1971 orally at the assigned dose QD on Days 1-21 of each cycle and atezolizumab 1200 mg IV on Day 1 of each cycle until unacceptable toxicity or loss of clinical benefit. A subset of participants will participate in evaluations regarding tablet vs capsule formulation, the effect of food and acid-reducing agents on GDC-1971.
88849076|NCT05483933|Experimental|Pegylated Liposomal Doxorubicin + SL-172154 (SIRPα-Fc-CD40L)|Pegylated Liposomal Doxorubicin (PLD) will be administered via intravenous administration + SL-172154 (SIRPα-Fc-CD40L) will be administered via intravenous administration.
88849077|NCT05483933|Experimental|Mirvetuximab + SL-172154 (SIRPα-Fc-CD40L)|Mirvetuximab (MIRV) will be administered via intravenous administration + SL-172154 (SIRPα-Fc-CD40L) will be administered via intravenous administration
89376509|NCT04978168|Active Comparator|Randomized to Treatment as Usual|After Core Implementation is complete, half of adult participants in probation who consent will be randomly assigned to continue with usual care.
88849078|NCT05469412|Experimental|Interventional group|Standard management combined with distraction by using technology (Tablets/iPads).
89376510|NCT04057508|Active Comparator|Stimulation protocol|Each subject will be blinded and underwent 3 phases of stimulation (actives (2) and sham (1) comparators) in a randomized order .
89376511|NCT04057508|Sham Comparator|Sham stimulation protocol|Each subject will be blinded and underwent 3 phases of stimulation (actives (2) and sham (1) comparators) in a randomized order.
89376512|NCT04887077|Experimental|Kiplin intervention|Kiplin intervention composed of the access to a mobile app and to telecoaching sessions. The number of teleocaching sessions per week will decrease over 3 months.
88849079|NCT05469412|Active Comparator|Control group|Standard management combined with pharmacological intervention (oral midazolam 0.5 mg/kg) administered at least 30 min before surgery (maximum 20mg).
88849080|NCT05454449||symptomatic group|Individuals with patellar tendon pain last for 3 months Individuals age between 18-40 years old Victorian Institute of Sport Assessment (VISA) Questionnaire score ≦80
88849081|NCT05454449||asymptomatic group|Individuals without any lower extremity pain in past 3 months Individuals age between 18-40 years old Victorian Institute of Sport Assessment (VISA) Questionnaire score >80
88849082|NCT05442840|No Intervention|Control Arm|The participants in this arm will receive standard of care from their physician as they would have been doing previously. This still may involve blood work, referrals to other health providers (except pharmacist) and medication adjustments driven by the pharmacist.
88849083|NCT05442840|Active Comparator|Pharmacist Intervention Arm|The participants in this arm will receive standard of care from their physician in addition to pharmacist intervention. The pharmacist or pharmD intern leads the diabetes care for the patient typically, conducting a medication review, recommending medication changes, frequent follow up and requesting blood work and providing referrals to other health care providers as needed,which is standard care
88849084|NCT05425966|Experimental|CLS-R-FUERTE|Active program participation in: a remote school clinician training and comprehensive psychosocial intervention designed to improve attention and behavior in Mexican school-aged youth (grades 1-5). via school clinician training by a clinical research team to lead parent skill groups, child skill groups, and teacher consultation in a behavioral classroom management system.
88849085|NCT05421741|Active Comparator|Intramedullary Nail|Traditional standard of care intramedullary (IM) nail
88849086|NCT05421741|Active Comparator|Antibiotic Coated Intramedullary Nail|Intramedullary Nail coated with 2 grams of vancomycin and 560 mg gentamicin liquid.
88849087|NCT05421013|Experimental|STP705 30ug|STP705 will be administered once weekly for 6 weeks
88849088|NCT05421013|Experimental|STP705 60ug|STP705 will be administered once weekly for 6 weeks
88849089|NCT05421013|Experimental|STP705 90ug|STP705 will be administered once weekly for 6 weeks
89376513|NCT04887077|Active Comparator|face-to-face supervised PA (usual care at the University Hospital of Clermont-Ferrand, France)|three-month program of face-to-face adapted physical activity, three sessions a week, for a total of 36 sessions.
88849090|NCT05418153||Synergy IOL|Patients implanted with the Synergy IOL in both eyes.
88849091|NCT05404958|Experimental|Intervention clinics that implement the Systems Analysis and Improvement Approach|Mombasa County public health staff will facilitate SAIA
88849092|NCT05404958|No Intervention|Usual procedures|
88849093|NCT05398341||Prospective Cohort|There will be a prospective cohort for all subjects scheduled to undergo ACL surgery with the BEAR Implant that are willing to provide consent.
88849094|NCT05398341||Retrospective Cohort|A retrospective cohort will be available for all subjects treated with the BEAR Implant at each participating site. There is no control group.
88849095|NCT05397223|Experimental|Part 1: mRNA-1345|Participants will receive single intramuscular (IM) injection of mRNA-1345 on Day 1.
88849096|NCT05397223|Experimental|Part 1: mRNA-1647 2-Dose|Participants will receive single IM injection of mRNA-1647 on Days 1 and 57.
88849097|NCT05397223|Experimental|Part 1: mRNA-1647 3-Dose|Participants will receive single IM injection of mRNA-1647 on Days 1, 57, and 169.
88849098|NCT05397223|Experimental|Part 2: mRNA-1273|Participants will receive single IM injection of mRNA-1273 on Day 1
88849099|NCT05397223|Experimental|Part 2: mRNA-1010|Participants will receive single IM injection of mRNA-1010 on Day 1.
88849100|NCT05397223|Active Comparator|Part 2: FLUAD®|Participants will receive single IM injection of FLUAD® on Day 1.
88849101|NCT05377255|Other|Arm 1 Interventional Therapy|Subjects will first receive 4 doses of 4 mg each (total: 16 mg) of naloxone through the AP003 device (Arm 1) before the washout period.
88849102|NCT05377255|Other|Arm 2 Reference Therapy|Subjects will first receive 2 doses of 4 mg each (total: 8 mg) of the naloxone through the NARCAN Nasal Spray device (reference therapy, Arm 2) before the washout period.
89376514|NCT03728543|Experimental|Children 0-2yo|Children 0-2 years old with oncological diseases who need an MRI under general anesthesia, will receive sugammadex 2mg/kg IV
88849103|NCT05376150|Experimental|XEN1101 10 mg|During the double blind treatment period (42 days), subjects will take 1 capsule of XEN1101 10 mg, orally with food, per day
88849104|NCT05376150|Experimental|XEN1101 20 mg|During the double blind treatment period (42 days), subjects will take 1 capsule of XEN1101 20 mg, orally with food, per day
88849105|NCT05376150|Placebo Comparator|placebo|During the double blind treatment period (42 days), subjects will take 1 capsule of placebo, orally with food, per day
88849106|NCT05364229|Experimental|MR-guided Tumour Boost with SBRT|MR-guided radiotherapy boost to MRI visible tumour
88849107|NCT05361915|Experimental|Abivertinib - Abiraterone-naive|Abiraterone-naive: Abivertinib 200 mg by mouth twice daily with abiraterone 1000 mg by mouth daily.
88849108|NCT05361915|Experimental|Abivertinib - Abiraterone-progressing|Abiraterone-progressing: Abivertinib 200 mg by mouth twice daily with abiraterone 1000 mg by mouth daily.
88849109|NCT05355454|Experimental|STYLAGE® XXL Treatment Group|"Subjects randomized (5:1 ratio) to receive an initial treatment with STYLAGE® XXL Crosslinked Hyaluronic Acid Gel up to 8mL, based on the PI's assessment, in combination with the aesthetic goal of the subject, then an optional touch-up treatment session 4 weeks later, up to 4mL.~Subjects will also be offered an optional retreatment at week 72 after initial treatment, up to 8mL."
88849110|NCT05355454|Other|No-Treatment Control Group, then Delayed Treatment with STYLAGE® XXL|"No-Treatment for the first 6-month, then subjects will receive a delayed treatment with STYLAGE® XXL Crosslinked Hyaluronic Acid Gel up to 8mL, based on the PI's assessment, in combination with the aesthetic goal of the subject, then an optional touch-up treatment session 4 weeks later, up to 4mL.~Subjects will also be offered an optional retreatment at week 72 after initial treatment, up to 8mL."
88849111|NCT05348785|Experimental|BIIB122 225 mg|"Participants will receive BIIB122, 225 mg tablets, by mouth, once daily (QD) for up to a minimum of 48 weeks and a maximum of 144 weeks.~Participants who received BIIB122 and completed the ET visit of study 283PD302 (NCT05418673) will continue to receive BIIB122, 225 mg tablets, by mouth, QD for up to a minimum of 48 weeks and a maximum of 144 weeks."
88849112|NCT05348785|Placebo Comparator|BIIB122 Matching Placebo|"Participants will receive BIIB122 matching placebo tablets, by mouth, QD for up to a minimum of 48 weeks and a maximum of 144 weeks.~Participants who received placebo and completed the ET visit of study 283PD302 (NCT05418673) will continue to receive BIIB122 matching placebo tablets, by mouth, QD for up to a minimum of 48 weeks and a maximum of 144 weeks."
88849113|NCT05347849|Experimental|BPL-003 arm|
88849114|NCT05347849|Placebo Comparator|Placebo arm|
88849115|NCT05347563||Group A|group A: Patient < 18 years old admitted to a continuous monitoring unit - resuscitation for acute respiratory failure regardless of the ventilation modality and benefiting from TIE monitoring
88849116|NCT05347563||Group B (reference)|Group B (reference): Patient under general anesthesia with mechanical ventilation without respiratory pathology.
88849117|NCT05330234|Other|Therapists|Single arm study. Participants are members of the therapy team at Imperial College Healthcare NHS Trust's stroke wards.
88849118|NCT05329376|Experimental|Group A|12 weeks of daily interactions with Smart Speaker EchoDot 3rd Gen (Amazon Echo®).
88849119|NCT05329376|Other|Group B|12 weeks of maintenance of usual care.
88849120|NCT05328986||COVID|Patients who have had a confirmed diagnosis of COVID-19.
88849121|NCT05325593|Experimental|romiplostim plus dexamethasone (ROM + DEX)|"Dexamethasone 40 mg daily x 4 days only in the first cycle and subcutaneous romiplostim weekly for up to 12 months~Romiplostim:~The starting dose should be 3 mcg/kg/week. It could be start during de 4 days of dexamethasone.~Patients will weekly receive dose increases of romiplostim in increments of 1 mcg/kg up to a maximum dose of 10 mcg/kg in an attempt to reach a target platelet count higher than 50x109/L.~Otherwise, if platelets are lower than 50x109/L treatment with romiplostim will go on until Day 365 since randomization."
88849122|NCT05325593|Active Comparator|Dexamethasone (DEX)|Dexamethasone 40 mg daily x 4 days for up to 3 cycles every 14 to 28 days
88849123|NCT05325203|Experimental|JS002 150mg Q2W for 24 weeks|40 patients will be enrolled in this arm
88849124|NCT05325203|Placebo Comparator|placebo 150mg Q2W for 24 weeks|20 patients will be enrolled in this arm
88849125|NCT05325203|Experimental|JS002 450mg Q4W for 24 weeks|40 patients will be enrolled in this arm
88849126|NCT05325203|Placebo Comparator|placebo 450mg Q4W for 24 weeks|20 patients will be enrolled in this arm
88849127|NCT05309915|Other|Cohort 1|Dose 3mg of STP707 (8 subjects) + placebo (2 subjects) randomized
88849128|NCT05309915|Other|Cohort 2|Dose 6mg of STP707 (8 subjects) + placebo (2 subjects) randomized
88849129|NCT05309915|Other|Cohort 3|Dose 12mg of STP707 (8 subjects) + placebo (2 subjects) randomized
89376515|NCT03728543|Active Comparator|Children 2-18yo|Children 2-18 years old with oncological diseases who need an MRI under general anesthesia, will receive sugammadex 2mg/kg IV
88849130|NCT05309915|Other|Cohort 4|Dose 24mg of STP707 (8 subjects) + placebo (2 subjects) randomized
88849131|NCT05307679|Experimental|Basmisanil|Participants will receive oral basmisanil twice daily (BID) on the first day of treatment, then three times per day (TID) until the end of Part 1 of the trial (Day 365) or the end of Part 2 (Day 1095)
89376516|NCT03728465|Experimental|Treatment Phase|"Treatment phase is divided into the Induction Phase and Maintenance Phase. During the induction phase patients are treated with 1 mg/kg nivolumab and 3 mg/kg ipilimumab, during the maintenance phase with nivolumab 3 mg/kg only ."
88849132|NCT05307679|Placebo Comparator|Placebo|Participants will receive oral placebo BID on the first day of treatment, then TID until the end of Part 1 of the trial (Day 365).
89002410|NCT06318130|Active Comparator|Stylet-driven leads|Stylet-driven leads used are extendable helix pacing leads (Biotronik Solia S60 lead from Biotronik or Tendril STS pacing lead from St. Jude Medical) during the LBBP procedure.
89002411|NCT06318104|Active Comparator|Tegoprazan Group|Tegoprazan 50 mg BID for 14 days, amoxicillin 1gr BID for 14 days, clarithromycin 500 mg BID for 14 days
89376517|NCT03253952||Traumatic Spinal Cord Injury|Observational study - monitoring immune response and heart rate variability
89376518|NCT03253952||Traumatic Spine Fracture, Control Group|Observational study - monitoring immune response and heart rate variability acting as a control group.
89535064|NCT03240055|Placebo Comparator|Group E|27 patients without spinal anesthesia in this group received sequential administration of etomidate
89535065|NCT03087201|Experimental|nabiximols, oromucosal spray|1-12 puffs nabiximols / day, Duration of treatment: 13 weeks
88849133|NCT05307133|Other|Pre menopausal women undergoing sleeve gastreexctomy for morbid obesity|After the indication for sleeve gastrectomy has been retained by the multidisciplinary committee eligible patients will be contacted and offered to participate in the BARIAXYTOCINE study. At the time of the first outpatient visit (V1), body densitometry and blood sample for estradiol, leptin and oxytocin will be done. Patients will undergo surgery within one month and 6 months after surgery they will undergo the same work-up (V2).
88849134|NCT05303532|Experimental|Durvalumab|Participants will receive durvalumab.
88849135|NCT05300087|Experimental|Test Group|Albuterol Sulfate Inhalation Aerosol
88849136|NCT05300087|Active Comparator|Reference Group|Proair HFA (albuterol sulfate) Inhalation Aerosol
88849137|NCT05296473|Experimental|ADHD Therapy|
88849138|NCT05296473|Active Comparator|Control Therapy|
88849139|NCT05291234|Experimental|Stage A: ABBV-916|Participants will receive ABBV-916 for 24 weeks. Participants at the end of 24 weeks will have the option of participating in the 2-year Extension Period.
88849140|NCT05291234|Placebo Comparator|Stage A: Placebo for ABBV-916|Participants will receive Placebo for 24 weeks. Participants at the end of 24 weeks will have the option of participating in the 2-year Extension Period.
88849141|NCT05291234|Experimental|Stage B: ABBV-916 Dose A|Participants will receive ABBV-916 Dose A for 24 weeks. Participants at the end of 24 weeks will have the option of participating in the 2-year Extension Period.
88849142|NCT05291234|Placebo Comparator|Stage B: Placebo for ABBV-916|Participants will receive Placebo for 24 weeks. Participants at the end of 24 weeks will have the option of participating in the 2-year Extension Period.
89535066|NCT03087201|Placebo Comparator|placebo, oromucosal spray|1-12 puffs placebo / day, Duration of treatment: 13 weeks
88849143|NCT05291234|Experimental|Stage B: ABBV-916 Dose B|Participants will receive ABBV-916 Dose B for 24 weeks. Participants at the end of 24 weeks will have the option of participating in the 2-year Extension Period.
88849144|NCT05282316|Active Comparator|EVOO polyphenols enriched|Fifteen subjects with metabolic syndrome will be randomly enrolled each year (3 years of study planned), to the addition of 40 ml daily of healthy polyphenols enriched EVOO to their mediterranean diet for the duration of six months
88849145|NCT05282316|Placebo Comparator|EVOO standard|Fifteen subjects with metabolic syndrome will be randomly enrolled each year (3 years of study planned), to the addition of 40 ml daily of standard EVOO to their mediterranean diet for the duration of six months
88849146|NCT05280314|Experimental|Cohort A - Melanoma|"Cutaneous resectable Stage III melanoma.~Neoadjuvant Treatment (3 cycles): Subcutaneous IO102-IO103 (IO102 85 μg and IO103 85 μg) and intravenous Pembrolizumab KEYTRUDA® 200mg Q3W.~Post-surgery Treatment (15 cycles): Subcutaneous IO102-IO103 (IO102 85 μg and IO103 85 μg) and intravenous Pembrolizumab KEYTRUDA® 200mg Q3W."
88849147|NCT05280314|Experimental|Cohort B - SCCHN|"Stage III or IVA resectable locoregionally advanced Squamous cell carcinoma of the head and neck (SCCHN) of the oral cavity, oropharynx (HPV-negative), hypopharynx, or larynx~Neoadjuvant Treatment (2-3 cycles): Subcutaneous IO102-IO103 (IO102 85 μg and IO103 85 μg) and intravenous Pembrolizumab KEYTRUDA® 200mg Q3W Post-surgery Treatment (15 cycles): Subcutaneous IO102-IO103 (IO102 85 μg and IO103 85 μg) and intravenous Pembrolizumab KEYTRUDA® 200mg Q3W."
88849148|NCT05280314|Experimental|Cohort C|Cutaneous resectable Stage III melanoma. Neoadjuvant Treatment (3 cycles): Subcutaneous IO102-IO103 (IO102 85 μg and IO103 85 μg) and intravenous Pembrolizumab KEYTRUDA® 200mg Q3W (Arm A) versus intravenous Pembrolizumab KEYTRUDA® 200mg Q3W alone (Arm B) Post-surgery Treatment (15 cycles): Subcutaneous IO102-IO103 (IO102 85 μg and IO103 85 μg) and intravenous Pembrolizumab KEYTRUDA® 200mg Q3W (Arm A) versus Pembrolizumab KEYTRUDA® 200mg Q3W alone (Arm B)
88849149|NCT05263206|Experimental|Dupilumab|Loading dose administered subcutaneous (SC), followed by SC once every 2 weeks (Q2W) on top of non-sedative antihistamine and moisturizer
88849150|NCT05263206|Placebo Comparator|Placebo|Loading dose administered SC, followed by SC Q2W on top of non-sedative antihistamine and moisturizer
88849151|NCT05262556|Experimental|NP-101 (TQ Formula) + Nivolumab + Ipilimumab|
89535067|NCT03230539|Experimental|UPA IUS 20 μg|This is a proof-of-concept study utilizing a randomized dose-finding, parallel design to assess the effects of an IUS delivering Cu and 5, 20, or 40 μg of UPA over 12 weeks.
88849152|NCT05261009|Experimental|Peri-capsular Nerve Group (PENG)|Those subjects assigned to the PENG treatment arm will receive a PENG block using 20mL of 0.2% ropivacaine with 1:400,000 epinephrine dosed in 5mL increments with negative aspiration beforehand and between each aliquot.
89002412|NCT06318104|Active Comparator|Esomeprazole Group|Esomeprazole 40 mg BID for 14 days, amoxicillin 1gr BID for 14 days, clarithromycin 500 mg BID for 14 days
88849153|NCT05261009|Active Comparator|Lumbar Plexus Block (LPB)|Those subjects assigned to the LPB treatment arm will receive a stimulation-based LPB dosed with 20cc of 0.2% ropivacaine with 1:400,000 dilution epinephrine dosed in 5mL increments with negative aspiration beforehand and between each aliquot.
88849154|NCT05255211|Experimental|Remimazolam|IV Remimazolam tosilate 0.3mg/kg
88849155|NCT05255211|Active Comparator|propofol|IV propofol 1.2~2.5mg/kg
88849156|NCT05255211|Placebo Comparator|saline|IV saline solution 10ml
88849157|NCT05252195||Participants|Participants with Multiple Sclerosis who meet eligibility criteria.
88849158|NCT05250037||Screening (spirometry measurements)|Patients undergo home spirometry measurements with a portable handheld spirometer and complete questionnaires weekly, a nasal swab for viral polymerase chain reaction (PCR) surveillance bi-weekly, and undergo blood collection and nasal swabs every 3 months for up to 2 years.
88849159|NCT05238116|Experimental|PC945|PC945 dose, administered via nebulizer, twice daily
88849160|NCT05238116|Placebo Comparator|Placebo|PC945-placebo administered via nebulizer, twice daily
88849161|NCT05228002|Active Comparator|Standard|"The monitoring criteria used will be the same as those usually used at the Nice University Hospital, according to the protocol of the department.~For patients in the standard group, the biomarker results will be masked and then revealed afterwards for statistical analysis."
88849162|NCT05228002|Experimental|Biomarkers|"The monitoring decision will be made based on the ratio calculation:~Ratio < 38: Classic monitoring with one prenatal visit per month 38 ≤ Ratio ≤ 85: Close outpatient monitoring Ratio > 85: Inpatient monitoring in Pathological Pregnancy"
88849163|NCT05223192|Experimental|Intervention group|Participants in this group will receive the ocean disc music therapy entrainment intervention
88849164|NCT05223192|No Intervention|Control group|Participants in this group will not receive any intervention
88849165|NCT05222087|Active Comparator|Arm 1: SoC systemic therapy|
88849166|NCT05222087|Experimental|Arm 2: radiotherapy to lung primary, delivered before cycle three of SoC systemic therapy|
88849167|NCT05219058||Patients undergoing abdominoperineal excision|
88849168|NCT05219058||Patient undergoing pelvic exenteration|
89181972|NCT04108637|Experimental|penicillin allergy assessment pathway|"Those in the PAAP intervention arm will complete stage 2&3 of the PAAP pathway:~Stage-2 assessed for skin testing (ST) and ST done or straight to stage 3~Stage-3 oral challenge test (OCT) All completing PAAP will receive a letter from the immunology clinic giving the results of the test. Also, patients who have tested negative will receive the Post-test Intervention Booklet and Patient Intervention Card Materials.~Additionally, all participants in the PAAP arm will be called by the trial team at days 4-6 and 28-30 post testing to collect safety data. During the call at days 28-30 patients will complete the patient questionnaire on allergy beliefs.~Practices will be informed of the test result and instructed to update the participant's electronic health records accordingly."
89181973|NCT04108637|No Intervention|Control Arm|The usual care arm receive no intervention but will be followed up as per intervention arm with monitoring of any symptoms following an antibiotic prescription.
89181974|NCT05674539|Active Comparator|fludarabine and busulfan|fludarabine (30 mg/m^2/day, days -6 to days -2, the total dase is 150 mg/m^2) and busulfan (3.2 mg/kg/day, days -3 to days -2, the total dose is 6.4 mg/kg)
89181975|NCT05674539|Experimental|fludarabine and melphalan|fludarabine (30 mg/m^2/day, days -6 to days -2, the total dose is 150 mg/m^2) and melphalan (70 mg/m^2/day, days -3 to days -2, the total dose is 140 mg/m^2)
89181976|NCT04108559|Experimental|Kinesiologic Tape Group|After the routine impacted third molar surgery, the kinesiologic tape will be prepared individually for each patient; it will be cut into three equal strips (approximately 1.6 cm in width) and placed between the clavicle and the tragus-commissura line. Kinesiologic tape will be removed on the second postoperative day, and all sutures on will be removed on 7. postoperative day.
89181977|NCT04108559|Experimental|Surgical Drain Group|After routine impacted third molar surgery, plastic non-customised drain tube (2-cm long, 2-mm diameter) will be inserted into a vertical incision between the first and second molars and sutured to the vestibular mucosa.
89181978|NCT04108559|Placebo Comparator|Control Group|Routine third molar extraction will be performed. No extra procedures will be done after surgery.
88849169|NCT05218707||Group A|An appropriate size oropharyngeal airway (GUEDEL) will be inserted immediately after removal of LMA and time will be noted. (Size will be chosen by placing the flange at the corner of the mouth and tip at the angle of the jaw).
88849170|NCT05218707||Group B|In Group B No oropharyngeal airway (GUEDEL) will be inserted.
88849171|NCT05218655|Experimental|Vatiquinone|Participants will receive vatiquinone oral solution (100 milligrams [mg]/milliliter [mL]), up to 400 mg, administered orally or via feeding tube 3 times daily (TID).
88849172|NCT05208086||Patients|"Cycle1 day1: collection of 24h urine and an urine sample from miction the day of the visit.~Cycle 2 day1:collection of 24h urine and an urine sample from miction the day of the visit Cycle 4 day 1: collection of 24h urine and an urine sample from miction the day of the visit."
88849173|NCT05200988|Experimental|Induction with heckpoint inhibition followed by consolidative chemoradiation|Checkpoint inhibition and chemoradiation
88849174|NCT05199688|Experimental|Cohort 1: Participants with body weight ≥10kg to <20kg|Satralizumab will be administered SC Q6W in a cohort of at least 2 evaluable patients
88849175|NCT05199688|Experimental|Cohort 2 Participants with body weight ≥20kg to <40kg|Satralizumab will be administered SC at Weeks 0, 2, 4, and Q4W thereafter.
88849176|NCT05199688|Experimental|Cohort 3 Participants with body weight ≥40kg|Satralizumab will be administered SC at Weeks 0, 2, 4, and Q4W thereafter.
88849177|NCT05197036||LEGION Porous CR with Hydroxyapatite|Patients who have already received or a due to receive a Porous Tibia + LEGION Porous CR with HA femoral component (max 175 subjects)
88849178|NCT05197036||LEGION Porous CR without Hydroxyapatite|Patients who have already received or a due to receive a Porous Tibia + LEGION Porous CR without HA femoral component (max 175 subjects)
89181979|NCT00717522|Experimental|Pomalidomide|7 mg pomalidomide taken orally once daily (QD) on days 1 through 21 of each 28-day cycle
89376519|NCT03728387|Experimental|osteoarthritis and clinical pilates exercise|34 volunteer individuals who will be randomly choosen among 84 individuals will be given a 6-week exercise training program. According to this 6 week program, individuals will be admitted to the exercise training program for 45-60 minutes with a physiotherapist for 3 days in a week. The exercise program will consist of a warm-up, a strength training and a cool-down section.
89376520|NCT03662984|Active Comparator|Ciprofibrate|1dd100mg at breakfast
89376521|NCT03662984|Placebo Comparator|Placebo|1dd0mg at breakfast
89376522|NCT03724799|Experimental|single arm|Intravenous low level laser therapy
89376523|NCT03728231||Fifty patients with RA.|"-CBC with assessment of NLR and PLR. Immumological tests (RF, ANA, anti-ds DNA).~Functional Performance Tests:(12)~Fatigue severity scale (13).~Short-Form Health Survey 36 (SF-36) (14).~the short version of the International Physical activity Questionnaire (s-IPAQ) (15).~frequency intensity time (FIT) index of kasari (16). :* Disease activity Score(DAS)(17)"
89376524|NCT03728231||Fifty patients with SLE.|"CBC with assessment of NLR and PLR. Immumological tests (RF, ANA, anti-ds DNA).~Functional Performance Tests:(12)~Fatigue severity scale (13).~Short-Form Health Survey 36 (SF-36) (14).~the short version of the International Physical activity Questionnaire (s-IPAQ) (15).~frequency intensity time (FIT) index of kasari (16). :* SLE Disease activity Index(SLEDAI)(18)"
88849179|NCT05169567|Experimental|Arm A: Abemaciclib plus Fulvestrant|Abemaciclib administered orally in combination with fulvestrant administered intramuscularly (IM).
88849180|NCT05169567|Active Comparator|Arm B: Placebo plus Fulvestrant|Placebo administered orally in combination with fulvestrant administered IM.
88849181|NCT05162014||Pooled Empagliflozin|Patients with type 2 diabetes mellitus (T2DM) and new initiators of empagliflozin on a background of metformin, between 1-Aug-2014 and the latest data-cut available in IBM MarketScan Commercial Claims and Encounters (CCAE)/ Medicare Supplemental (MDCR) 30-Sep-2020 and Optum Clinformatics® Data Mart (CDM) 31-Mar-202, who were enrolled for a minimum of 6 months in the US claims databases before index treatment initiation
88849182|NCT05162014||Pooled Sulfonylureas (SUs)|Patients with type 2 diabetes mellitus (T2DM) and new initiators of Sulfonylureas (SUs) on a background of metformin, between 1-Aug-2014 and the latest data-cut available in IBM MarketScan Commercial Claims and Encounters (CCAE)/ Medicare Supplemental (MDCR) 30-Sep-2020 and Optum Clinformatics® Data Mart (CDM) 31-Mar-202, who were enrolled for a minimum of 6 months in the US claims databases before index treatment initiation
88849183|NCT05155267||Chronic Kidney disease participants (CKD)_HD|CKD submitted to hemodialysis (HD)
88849184|NCT05155267||Chronic Kidney disease participants (CKD)_PD|CKD non-submitted to hemodialysis (pre-dialysis:PD)
89376525|NCT03728231||Fifty apparently healthy controls|"CBC with assessment of NLR and PLR. Immumological tests (RF, ANA, anti-ds DNA).~Functional Performance Tests:(12)~Fatigue severity scale (13).~Short-Form Health Survey 36 (SF-36) (14).~the short version of the International Physical activity Questionnaire (s-IPAQ) (15).~frequency intensity time (FIT) index of kasari (16)."
89376526|NCT03724721|Experimental|pneumothorax drainage|Pneumothorax drainage with vacuum bottle plus intercostal catheter
89376527|NCT03305809|Placebo Comparator|Placebo|Participants received placebo administered orally once a day (QD).
88849185|NCT05155267||Controls|Healthy participants
88849186|NCT05144854|Experimental|ONO-4538 + ipilimumab + chemotherapy|
88849187|NCT05144854|Active Comparator|Chemotherapy|
88849188|NCT05144789|Active Comparator|Active TBS-DLPFC|The active group will receive theta-burst TMS stimulation.
88849189|NCT05144789|Active Comparator|Active TBS-DMPFC|The active group will receive theta-burst TMS stimulation.
88849190|NCT05144789|Sham Comparator|Sham Comparator: Sham TBS-DLPFC or DMPFC|The sham group will receive sham theta-burst TMS stimulation.
88849191|NCT05139069|Experimental|Trauma-Informed Pre-Exposure Prophylaxis Implementation Toolkit|The Toolkit to be developed in the proposed study includes components from the women-specific Pre-Exposure Prophylaxis care continuum theoretical model and implementation challenges, and is adapted to identify and provide care to women experiencing intimate partner violence. Overall, the Toolkit is designed to create culturally-congruent, intimate partner violence-informed clinical settings; and equip clinical staff with the knowledge and skills they need to address HIV prevention for African American women; and integrate intimate partner violence into Pre-Exposure Prophylaxis care services.
89002413|NCT06318091|Active Comparator|platelet poor plasma gel group|in this group, plasma gel will be injected intradermally in the dark circles.
89376528|NCT03305809|Experimental|10 milligram (mg) LY3154207|Participants received 10 mg LY3154207 administered orally QD.
89002414|NCT06318091|Active Comparator|nanofat group|in this group, nanofat will be injected intradermally and subcutaneously in the dark circles
89002415|NCT06318078|Experimental|Intervention|570 children will be allocated to the intervention arm and children in this arm will be assessed using the eCHIS digital tool.
89376529|NCT03305809|Experimental|30 mg LY3154207|Participants received 30 mg LY3154207 administered orally QD.
89376530|NCT03305809|Experimental|75 mg LY3154207|Participants received 75 mg LY3154207 administered orally QD.
89376531|NCT05231356||2|group 1 with positive signs group 2 with negative signs
89376532|NCT02994056|Experimental|SOF/VEL+ RBV|SOF/VEL FDC plus RBV for 12 weeks
89376533|NCT03728153|Experimental|20mg dose|Fluoxetine 20 MG Oral Tablet
89376534|NCT04934488|Experimental|Immediate Treatment|The experimental (immediate workshop) group will receive the online workshop at baseline (T1). The experimental group will also receive care as usual from their healthcare providers.
89376535|NCT04934488|Other|Waitlist Control|The waitlist control group will receive care from usual healthcare providers and will receive the intervention at the conclusion of the study period (T2, 12 weeks after enrollment).
89376536|NCT04056806|Experimental|Group A|receiving terlipressin 2mg bolus on enrollment followed by 1mg per 6 hours. Both Terlipressin infusion and Ceftriaxone continue till 48 hours after endoscopic therapy
89376537|NCT04056806|Active Comparator|Gruoup B|receiving terlipressin 2mg bolus instituted on enrollment followed by 1mg per 6 hours. Ceftriaxone 1gm intravenously dose of ceftriaxone 1gm at 24 h interval. Both Terlipressin infusion and Ceftriaxone continue till 5 days after endoscopic therapy.
88849192|NCT05138965||using the mCP|When the secretion reducing or the wound suture being removed, two pieces of 5cm×7cm-12p sterile gauzes will be crimped by the long side as the center of the reel,and be made as cylindrical gauze rolls with about D=1.5cm. After cleaning the wound, the cylindrical gauze rolls with its surface covered by alginates dressing will be placed above the vaginal wound with the help of endoscope.Itself tension of the rolls pressuring on the wound and the deep tissue can promote the wound healing. The rolls will be placed on about 5-6 hours every time, 2 times a day, for 7 days.Then observing the wound, if necessary, the method will be executed for another 7 days.
89376538|NCT03724643|Experimental|Protocolized Wean|Respiratory therapist determined extubation readiness based on: patent and protected airway; adequate secretion clearance; suction requirement ≤ every 2 hours; FiO2 < 50% and PEEP = 5; and hemodynamic stability without circulatory support. The SBT included CPAP = 5 mmHg at FiO2 ≤ 0.4. Patients were assessed after 3-minutes for appropriateness to continue (SaO2 ≥ 92%; no arrhythmia; RSBI < 105 breaths/min/L). Respiratory distress signs included RR > 30 breaths/min, SaO2< 90%, HR > 140 beats/min, or a sustained change in HR of >20%, systolic BP >200 mmHg or <80 mmHg, or agitation, anxiety, or diaphoresis without other cause. The SBT lasted 120 min in accordance with prior studies. Upon SBT completion, the RSBI was re-measured and an ABG was obtained.
88849193|NCT05138965||no using the mCP|When the secretion reducing or the wound suture bing removed, only alginates dressing will be placed above the vaginal wound with the help of endoscope, without any pressure, being placed about 5-6 hours every time, 2 times a day, for 7 days.
88849194|NCT05135988||Children in vital distress|
88849195|NCT05135988||Health care givers|Experts in vital distress care Non experts in vital distress care
89376539|NCT03724643|No Intervention|Usual Care|In the UC group, the SBT type and extubation decision was determined by the attending intensivist on service based upon neurologic status, airway competence (gag, cough, suction requirements), and negative inspiratory force (NIF) or RSBI measurements.
88849196|NCT05132361|Experimental|SELUTION SLR™ 018 DEB|Treatment with Selution SLR drug eluting balloon to apply long term (>90 days) local treatment with sirolimus
88849197|NCT05132361|Active Comparator|Plain (Uncoated) Balloon Angioplasty (PTA)|Opening artery only by dilatation with an temporary inserted and inflated balloon.
88849198|NCT05122767|Experimental|Single Arm in 4 groups|There will be four groups. Group 1a and Group 1b will provide semi-intensive PK data and safety monitoring to allow for comparison of twice-daily dolutegravir exposures together with HP vs. when DTG is given alone. Group 2a and Group 2b will provide semi-intensive PK data and safety monitoring for either twice-daily or once-daily dolutegravir together with HIV vs when DTG is given alone. All groups will provide safety and tolerability data, HIV virologic outcome data, and information about dolutegravir and rifapentine PK.
88849199|NCT05118490|Experimental|Group 1: People living with HIV infection without active TB|
88849200|NCT05118490|Experimental|Group 2: HIV-negative household contacts of adults with rifampicin-sensitive pulmonary TB|
88849201|NCT05117242|Experimental|Arm A|Treatment with acasunlimab once every 21 days for the first 2 cycles and then every 42 days in subsequent cycles
88849202|NCT05117242|Experimental|Arm B|Treatment with acasunlimab + pembrolizumab once every 21 days
89181980|NCT04128189|Active Comparator|Transplanted subject|In addition to receiving standard dose (2) of Shingrix prior to transplantation, participant may receive a 3rd dose several months after transplantation if they meet criteria related to no rejection.
88849203|NCT05117242|Experimental|Arm C|Treatment with acasunlimab+ pembrolizumab once every 42 days
88849204|NCT05113251|Experimental|Arm A|Trastuzumab deruxtecan
88849205|NCT05113251|Experimental|Arm B|T-DXd, followed by THP
89181981|NCT04128189|Sham Comparator|Non-Transplanted subject|Receives standard Shingrix dose (2), but not transplanted within 16 month time frame post-dose, so does not receive additional Shingrix dose.
89181982|NCT05014659|Experimental|Creatine monohydrate|Participants received 4 x 5g doses of creatine monohydrate (powdered form) for 5 days, followed by 1 x 5g doses of creatine monohydrate (powdered form) for 23 days.
89181983|NCT05014659|Placebo Comparator|Placebo|Participants received 4 x 5g doses of placebo (powdered Maltodextrin) for 5 days, followed by 1 x 5g doses of placebo (powdered Maltodextrin) for 23 days.
89181984|NCT00791921|Experimental|CDP870 200mg|400mg CDP870 given at Week0, 2, 4 and thereafter 200mg CDP870 given every 2weeks
89376540|NCT04056884|Active Comparator|SIBS intervention|SIBS intervention is a 5-session group intervention for siblings and parents of children with chronic illness. Sessions 1-3 are delivered in one day, and sessions 4-5 are delivered in one day one week later.
89376541|NCT04056884|No Intervention|Waitlist|Waitlist is 12 week of no intervention/usual care
89376542|NCT04057118|Experimental|SKI-O-703 100 mg|
89376543|NCT04057118|Experimental|SKI-O-703 200 mg|
89376544|NCT04057118|Experimental|SKI-O-703 400 mg|
88849206|NCT05113251|Active Comparator|Arm C|doxorubicin and cyclophosphamide, followed by THP
89002416|NCT06318078|No Intervention|Control|570 children will be allocated to the intervention arm and children in this arm will be assessed using the standard care and paper based tools.
89376545|NCT04057118|Placebo Comparator|Placebo|
89002417|NCT06318039|Experimental|Novel program|Rehabilitation using a novel program.
89376546|NCT03548051|Experimental|FMT group|100 grams of thawed processed stool diluted into 250 ml of saline and delivered by retention enema given 1-3 hours after loperamide 4 mg po x 1, n=108
89376547|NCT03548051|Experimental|Placebo group|250 ml of saline delivered by retention enema given 1-3 hours after loperamide 4 mg po x 1; if no improvement followed by FMT (100 grams of thawed processed stool diluted into 250 ml of saline and delivered by retention enema given 1-3 hours after loperamide 4 mg po x 1) x 2, n=54
89376548|NCT03728075|No Intervention|Control group|standard protocol for cardiac rehabilitation
89376549|NCT03728075|Experimental|Intervention group|standard protocol for cardiac rehabilitation plus neuromuscular electrical stimulation (NMES)
89376550|NCT03305731|Experimental|Activating Behavior for Lasting Engagement|Participants will engage in the ABLE intervention.
89376551|NCT03305575|Experimental|Chloroprocaine|Patients assigned to chlorprocaine will receive a single spinal injection of 40 mg of chloroprocaine PF. (other name: pure Nesacaine MPF 3% in a total volume of 2ml)
89376552|NCT03305575|Active Comparator|Bupivacaine|Patients assigned to bupivacaine will receive a single spinal injection of 7.5 mg of bupivacaine. (other name: pure Sensorcaine 0.75% diluted with normal saline to a total volume of 2ml).
89376553|NCT04916782||Observational group|
89376554|NCT02993822|Experimental|Orvepitant 10mg|Orvepitant 10mg tablet, once daily for 12 weeks
89376555|NCT02993822|Experimental|Orvepitant 20mg|Orvepitant 20mg tablet, once daily for 12 weeks
89376556|NCT02993822|Experimental|Orvepitant 30mg|Orvepitant 30mg tablet, once daily for 12 weeks
89376557|NCT02993822|Placebo Comparator|Placebo|Placebo to match tablet, once daily for 12 weeks
88810420|NCT06213506|Active Comparator|Infants_9M_Control C Group|Infants 9 months of age, part of the safety cohort, randomized to receive 2 doses of the MenACWY vaccine at Day 1 and Day 85 and 1 dose of the DTPaHBV-IPV+Hib vaccine at Day 169. These infants also receive an EPI vaccination with Measles and Rubella Vaccine (MR-VAC) and Yellow Fever (YF) vaccine at 28 days after the first study intervention administration occurring at Day 1, at the local EPI vaccination centers, and not part of the current clinical trial.
88849207|NCT05111561|Experimental|Treatment (ZEN-3694, binimetinib)|Patients receive ZEN-3694 PO QD and binimetinib PO BID on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. During the dose expansion phase, patients will have two mandatory biopsies - one before beginning the study and the second at day 15 of cycle 1. The study biopsy takes small pieces of cancer tissue from patient's body to look for markers (substances made by, on, or in tumor cells) related to how the study treatment works. Patients also undergo collection of blood samples at screening and on study and undergo CT or MRI throughout the trial.
88849208|NCT05098717||UIP patients|Patients with pulmonary fibrosis and UIP pattern undergoing mechanical ventilation for acute respiratory failure
88849209|NCT05098717||ARDS patients|Patients with ARDS undergoing mechanical ventilation for acute respiratory failure
88849210|NCT05095519|Experimental|18F-DCFPyL|Patients will undergo PET/CT imaging following intravenous administration of 18F-DCFPyL
88849211|NCT05087914|Experimental|Carbidopa-Levodopa (100mg/25mg) + Naproxen (250mg)|"The study drug, Carbidopa-Levodopa, is an FDA-approved medicine traditionally used for the treatment of Parkinson's disease. The study drug will be used for an un-approved or un-labeled use: potentially managing pain in post-surgical patients. Carbidopa/Levodopa is an artificially made version of a naturally occurring hormone that helps regulate brain activity (Levodopa), combined with an artificially made version of a naturally occurring molecule that inhibits the breakdown of Levodopa (Carbidopa).~Naproxen (250mg): Participants will receive one capsule TID, throughout the 5 days of the treatment period. Naproxen will be prescribed for active and control group."
88849212|NCT05087914|Placebo Comparator|Placebo + Naproxen (250mg)|"Placebo:Participants will receive 1 the capsules on a three-times a day schedule for 5 days. A placebo looks like the study drug but is an inactive substance that has no medication. Researchers use a placebo to see if the study drug works better or is safer than not taking anything.~Naproxen (250mg): Participants will receive one capsule TID, throughout the 5 days of the treatment period. Naproxen will be prescribed for active and control group."
88849213|NCT05087303|Active Comparator|Hub and Spoke|
88849214|NCT05087303|Active Comparator|Direct to Consumer|
89181985|NCT00791921|Placebo Comparator|Placebo|Placebo of CDP870
89376558|NCT04846972||Control group|After inclusion, patients will receive standard care. Women allocated in this group will have the standard care.
89376559|NCT04846972||FASTRACS intervention group|Women allocated in the FASTRACS intervention group will follow a structured care pathway comprising three successive steps (end of chemotherapy interview with a nurse, transitional visit with their GP, pre-RTW visit with their OP), plus one optional step (late visit with an OP- RTW to work coordinator). Four tools will be used during the intervention (RTW guide or checklist for the patient, the GP, the OP and the employer).
89376560|NCT02391844|Other|Oxycodone|Xartemis XR - Oxycodone with Acetaminophen Extended Release Tablet
89376561|NCT05675254||EP with ASMs|Epilepsy patients who administered Anti-seizure Medications(ASMs)
89376562|NCT05675254||EP without ASMs|Epilepsy patients who were not administered ASMs
89376563|NCT05675254||No EP|Non-epileptic children and had never taken any ASMs
89376564|NCT03663296|Experimental|Interventional|Additional 30 minutes of self-directed learning and practice using the mobile application, after conventional training session
89376565|NCT03663296|No Intervention|Control|Conventional training session which includes didactic teaching and low-fidelity simulation session involving trainer's demonstration, followed by hands-on practice
89376566|NCT03285854||Children with CKD stage 3-5 and dialysis|Children of all ages with an eGFR <60ml/min/1.73m2, including those on dialysis
89376567|NCT03285854||Healthy age and gender matched children|"All children <18 years~Normal renal function (eGFR 90-120ml/min/1.73m2 [calculated by Schwartz formula] in children >1 year and serum creatinine <35μMol/L in children <1 year)~Weight, height and BMI within 2 SD of normal using WHO growth charts In order to make this study as 'real-life' as possible, free-living UK children on their usual diet and dietary supplementation (including Ca and Vit D), if any, will be included, but analysis will account for medication doses and blood levels."
89376568|NCT03663140||Group 1-Health periodontal|This group created by individuals with healthy periodontal tissues. Periodontal status/peri-implant was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions.
88810421|NCT06213506|Experimental|Infants_6W_Dose A Group|Infants 6 weeks of age, part of the safety cohort, randomized to receive 3 doses of the iNTS-GMMA Dose A vaccine at Day 1, Day 57 (during the Priming phase) and at Day 232 (during the Booster phase). These infants also receive an EPI vaccination with Measles and Rubella Vaccine (MR-VAC) and Yellow Fever (YF) vaccine at 28 days after the third study intervention administration occurring at Day 232, at the local EPI vaccination centers, and not part of the current clinical trial.
89002418|NCT06318039|Active Comparator|Traditional program|Rehabilitation using a traditional program
89181986|NCT04111055|Experimental|Closed-loop group|The MAP of the patient will be managed by the CLV system to avoid hypotension. The MAP target selected in the closed-loop system will be the patient's MAP target ( same target as patient's MAP value preoperatively). Then the closed-loop system will have to adjust norepinephrine infusion rate to keep that MAP value within 10% of patient's target.
89181987|NCT02580123|Experimental|Experimental group|Received the intervention program.
89181988|NCT02580123|No Intervention|Control group|received the standard care
89181989|NCT04106843|Experimental|Treatment (177Lu-DOTATATE)|Patients receive 177Lu-DOTATATE IV over 30 minutes every 8-16 weeks. Treatment continues for up to 52 weeks in the absence of disease progression or unacceptable toxicity.
89181990|NCT04106453|Experimental|navigated microwave ablation|microwave ablation is performed laparoscopically with navigation
88849216|NCT05067257|Experimental|Resiniferatoxin|15 mcg, 20 mcg, or 25 mcg in 2mL injected once into the epidural space
88849217|NCT05067257|Placebo Comparator|Placebo|2mL injected once into the epidural space
88849218|NCT05067257|No Intervention|Concurrent Control|No intervention
88849219|NCT05061823|Experimental|Bintrafusp alfa|
88849220|NCT05058651|Experimental|Arm I (atezolizumab, platinum drug, etoposide)|During induction phase, patients receive atezolizumab IV over 30-60 minutes on day 1 of each cycle, carboplatin IV over 30 minutes or cisplatin IV over 60 minutes on day 1 of each cycle, and etoposide IV on days 1-3 of each cycle. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. During maintenance phase, patients receive atezolizumab IV over 30-60 minutes on day 1 of each cycle. Treatment repeats every 21 days for up to 17 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT scan and/or MRI throughout the trial and blood sample collection on study.
88849221|NCT05058651|Experimental|Arm II (atezolizumab, platinum drug, etoposide, observation)|During induction phase, patients receive atezolizumab IV over 30-60 minutes on day 1 of each cycle, carboplatin IV over 30 minutes or cisplatin IV over 60 minutes on day 1 of each cycle, and etoposide IV on days 1-3 of each cycle. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo observation for 1 year. Patients also undergo CT scan and/or MRI throughout the trial and blood sample collection on study.
88849222|NCT05058651|Active Comparator|Arm III (platinum drug, etoposide, observation)|During induction phase, patients receive carboplatin IV over 30 minutes or cisplatin IV over 60 minutes on day 1 of each cycle and etoposide IV on days 1-3 of each cycle. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo observation for 1 year. Patients also undergo CT scan and/or MRI throughout the trial and blood sample collection on study.
88849223|NCT05051033|Active Comparator|Surgical mitral valve repair|Patients who are randomized to the surgical arm will undergo mitral surgery.
88849224|NCT05051033|Active Comparator|Transcatheter edge-to-edge repair|In the transcatheter edge-to-edge repair arm, patients will be treated with a commercially-approved edge-to-edge mitral repair device.
88849225|NCT05048238|Experimental|Tofacinitib|10 participants receiving 11 mg of Tofacitinib administered orally and daily, from Day 2 to Day 26
88849226|NCT05044429|Experimental|Intravenous Lidocaine|
88849227|NCT05044429|Active Comparator|Transversus abdominis plane (TAP) block|
88849228|NCT05044429|Active Comparator|Quadratus Lumborum (QL) Block|
88849229|NCT05039619|Experimental|Blinded Obinutuzumab|Participants will receive obinutuzumab 1000 milligrams (mg) intravenous (IV) infusions on Day 1, Day 14, Week 24, Week 26 and Week 52. Participants with a body weight of 45 kg or more will receive the 1000 mg dose. Participants with a body weight below 45 kg will receive a weight adjusted dose of 20 mg/kilogram (kg).
88849230|NCT05039619|Placebo Comparator|Placebo|Placebo participants will receive obinutuzumab matched placebo on Day 1, Day 14, Week 24, Week 26 and Week 52.
88849231|NCT05039619|Experimental|Open-Label Obinutuzumab|Younger participants aged 5 to <12 will receive obinutuzumab 1000 mg IV infusions on Days 1, 14, Week 24, Week 26 and Week 52.
88849232|NCT05038462|Active Comparator|Maternal supplementation with Lactoferrin and DHA|The intervention consists in the maternal oral administration of 1000mg of Lactoferrin and 1000mg of DHA daily
88849233|NCT05038462|Placebo Comparator|Placebo|Product with the same physical appearance and taste as the main intervention but without therapeutic effect
88849234|NCT05037149|Experimental|Part 1: Arm A|Cohort 1: STP707 3 mg dose IV infusion, administered on D1,D8,D15,D22 of a 28-Day cycle. If the patient is deriving clinical benefit from the agent it maybe continued and administered on D1,D8, D15 and D22 for each successive cycle.
88849235|NCT05037149|Experimental|Part 1: Arm B|Cohort 2: STP707 6 mg dose IV infusion, administered on D1,D8,D15,D22 of a 28-Day cycle. If the patient is deriving clinical benefit from the agent it maybe continued and administered on D1,D8, D15 and D22 for each successive cycle.
88849236|NCT05037149|Experimental|Part 1: Arm C|Cohort 3: STP707 12 mg dose IV infusion, administered on D1,D8,D15,D22 of a 28-Day cycle. If the patient is deriving clinical benefit from the agent it maybe continued and administered on D1,D8, D15 and D22 for each successive cycle.
88849237|NCT05037149|Experimental|Part 1: Arm D|Cohort 4: STP707 24 mg dose IV infusion, administered on D1,D8,D15,D22 of a 28-Day cycle. If the patient is deriving clinical benefit from the agent it maybe continued and administered on D1,D8, D15 and D22 for each successive cycle.
88849238|NCT05037149|Experimental|Part 1: Arm E|Cohort A: STP707 36 mg dose IV infusion, administered on D1,D8,D15,D22 of a 28-Day cycle. If the patient is deriving clinical benefit from the agent it maybe continued and administered on D1,D8, D15 and D22 for each successive cycle.
88849239|NCT05037149|Experimental|Part 1: Arm F|Cohort 5: STP707 48 mg dose IV infusion, administered on D1,D8,D15,D22 of a 28-Day cycle. If the patient is deriving clinical benefit from the agent it maybe continued and administered on D1,D8, D15 and D22 for each successive cycle.
89181991|NCT04106453|Active Comparator|ultrasound guided microwave ablation|microwave ablation is performed laparoscopically with ultrasound guidance
89181992|NCT03475953|Experimental|Phase 1 : Regorafenib + Avelumab|Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
89181993|NCT03475953|Experimental|Phase 2 : cohort A Regorafenib + Avelumab|Treatment by Avelumab + Regorafenib Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
89181994|NCT03475953|Experimental|Phase 2 : cohort B Regorafenib + Avelumab|Treatment by Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
89181995|NCT03475953|Experimental|Phase 2 : cohort C Regorafenib + Avelumab|Treatment by Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
89535068|NCT03230539|Experimental|UPA IUS 5 μg|This is a proof-of-concept study utilizing a randomized dose-finding, parallel design to assess the effects of an IUS delivering Cu and 5, 20, or 40 μg of UPA over 12 weeks
88849252|NCT05008055|Experimental|Capivasertib monotherapy|Participants with R/R FL, R/R MZL, and R/R MCL will receive capivasertib orally until progression of disease (PD) or unacceptable toxicity.
88849253|NCT04997252|Experimental|high-risk and oligometastatic prostate cance|Neoadjuvant therapy with apalutamide in combination with luteinizing hormone-releasing hormone analogues
88849254|NCT04994522|Experimental|Belzutifan in Participants with ESRD|Participants with ESRD will receive a single dose of belzutifan 120 mg orally on Day 1 of a 4-day treatment period (Period 1), followed by a ≥7 day washout period. Participants receive another single dose of belzutifan 120 mg orally on Day 1 of a 4-day treatment period (Period 2).
88849255|NCT04994522|Experimental|Belzutifan in Healthy Participants|Participants in the healthy matched control group will receive a single dose of belzutifan 120 mg orally on Day 1 of a 4-day treatment period (Period 1).
88849256|NCT04994457||Adults with Glaucoma or Suspected Glaucoma|Adults with Glaucoma or Suspected Glaucoma, who have previously had standard automated perimetry (SAP) and will receive virtual reality visual field (VRVF) as part of the standard of care
88849257|NCT04994457||Visual Field Naive Adults|Visual Field Naive Adults will receive SAP and VRVF
88849258|NCT04994457||Children with Glaucoma or Suspected Glaucoma|Children with Glaucoma or Suspected Glaucoma, who have previously had SAP and will receive VRVF as part of the standard of care
88849259|NCT04994457||Visual Field Naive Children|Visual Field Naive Children will receive SAP and VRVF
88849260|NCT04994457||Remote Care Arm|Glaucoma or Suspected Glaucoma participants, who have previously had SAP and will receive VRVF at their home
88849261|NCT04994457||Ptosis Arm|Patients diagnosed with Ptosis, brow ptosis, or dermatochalasis, will receive a specialized version of VRVF and SAP, specifically to detect ptosis
88849262|NCT04963270|Experimental|Satralizumab|Participants will receive Satralizumab at Weeks 0, 2, 4, and Q4W thereafter. Adolescent patients who first enter the study in the OLE period will receive satralizumab SC loading doses at Week 0, 2, and 4 in the OLE, followed by maintenance doses Q4W thereafter and will remain on stable background therapy until Week 24 of the OLE.
88849263|NCT04963270|Placebo Comparator|Placebo|Participants will receive placebo at Weeks 0, 2, 4, and Q4W thereafter
88849264|NCT04959123|Active Comparator|Ropivacaine|"Patients receive 0.5 mg/kg of actual weight of ropivacaine; the appropriate dose of ropivacaine is drawn from an ampoule of 0.5% ropivacaine, i.e., 5 mg/mL (example for a 75 kg individual: 7.5 mL in each syringe) In the Ropivacaine only group, there is no adrenaline, the syringe loaded with ropivacaine is supplemented to 20 mL with a 0.9% sodium chloride solution"
88849265|NCT04959123|Experimental|Ropivacaine + Epinephrine|"Patients receive 0.5 mg/kg of actual weight of ropivacaine; the appropriate dose of ropivacaine is drawn from an ampoule of 0.5% ropivacaine, i.e., 5 mg/mL (example for a 75 kg individual: 7.5 mLn each syringe) In the ropivacaine + epinephrine group, 0.1 mL of a 1 mg/mL ampoule of epinephrine is added to each syringe before making up to 20 mL (i.e., 100 µg of epinephrine for 20 mL of final solution, i.e., 5 µg/mL, i.e., 1 : 200000)."
88849266|NCT04953780|Experimental|Calaspargase pegol-mknl dose level 1|"Induction Phase (It usually lasts 29 days):~The subject will take Cytarabine 3000 mg/m2 in an IV every 12 hours on days 1, 3, 5 for 6 doses.~The subject will take Idarubicin 12 mg/m2 for three doses in an IV after the first, third, and fifth High-dose Cytarabine.~The subject will take a dose of 750 U/m2 of Calaspargase pegol-mknl in an IV after the last (6th) dose of High-dose Cytarabine every 21 days ( per cycle).~Consolidation Phase ( One cycle of consolidation lasts 4-8 weeks):~The subject will take Cytarabine 3000 mg/m2 in an IV every 12 hours on days 1, 3, 5 for 6 doses.~The subject will take a dose of 750 U/m2 of Calaspargase pegol-mknl in an IV after the last (6th) dose of High-dose Cytarabine.~A single cycle of consolidation may last between 4-8 weeks in duration."
88849267|NCT04953780|Experimental|Calaspargase pegol-mknl dose level 2|"Induction Phase (It usually lasts 29 days):~The subject will take Cytarabine 3000 mg/m2 in an IV every 12 hours on days 1, 3, 5 for 6 doses.~The subject will take Idarubicin 12 mg/m2 for three doses in an IV after the first, third, and fifth High-dose Cytarabine.~The subject will take a dose of 1,000 U/m2 of Calaspargase pegol-mknl in an IV after the last (6th) dose of High-dose Cytarabine every 21 days ( per cycle).~Consolidation Phase ( One cycle of consolidation lasts 4-8 weeks):~The subject will take Cytarabine 3000 mg/m2 in an IV every 12 hours on days 1, 3, 5 for 6 doses.~The subject will take a dose of 1,000 U/m2 of Calaspargase pegol-mknl in an IV after the last (6th) dose of High-dose Cytarabine(every 21 days ( per cycle).~A single cycle of consolidation may last between 4-8 weeks in duration."
89002422|NCT06317974|Experimental|Intervention group|Breastfeeding education was given to the intervention group based on the health belief model.
89002423|NCT06317974|No Intervention|control group|The control group received standard care.
89002424|NCT06317935|Other|ArmeoSenso|ArmeoSenso virtual reality application will be applied to group A in the 0-3 weeks of the study and to group B in the 3-6 weeks.
89002425|NCT06317935|Other|Traditional rehabilitation|Traditional rehabilitation (physiotherapy and occupational therapy) approaches will continue to be applied to groups A and B at all stages of the research.
89376569|NCT03663140||Group 2- Healthy peri-implant|This group created by individuals with healthy peri-implant tissues. Periodontal status/peri-implant was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions.
89376570|NCT03663140||group 3- Gingivitis|This group created by individuals with gingivitis. Periodontal/peri-implant status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions.
89376571|NCT03663140||Group 4-Peri-implant Mucositis|This group created by individuals with peri-implant mucositis. Periodontal/peri-implant status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions.
89376572|NCT03663140||Group 5-Periodontitis|This group created by individuals with periodontitis. Periodontal/peri-implant status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions.
89376573|NCT03663140||Group 6-Periimplantitis|This group created by individuals with peri-implantitis. Periodontal/peri-implant status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions.
89376574|NCT02391922|No Intervention|No first aid course, No dipatch instruction|Participants' first aid skills are tested in two scenarios without prior first aid course and no dispatch instructions during the scenarios
89376575|NCT02391922|Active Comparator|First aid course, No dispatch instructions|Participants' first aid skills are tested in two scenarios 4 to 5 months after receiving a first aid course and no dispatch instructions during the scenarios
89376576|NCT02391922|Active Comparator|First aid course, dispatch instructions|Participants' first aid skills are tested in two scenarios 4 to 5 months after receiving a first aid course and they are given instructions from emergency dispatch by phone during the test scenarios
89376577|NCT02391922|Active Comparator|No first aid course, dispatch instructions|Participants' first aid skills are tested in two scenarios without prior first aid course, and they are given instructions from emergency dispatch by phone during the test scenarios
89376578|NCT04056728|Experimental|Eupenta Inj.|
88849268|NCT04953780|Experimental|Calaspargase pegol-mknl dose level 3|"Induction Phase (It usually lasts 29 days):~The subject will take Cytarabine 3000 mg/m2 in an IV every 12 hours on days 1, 3, 5 for 6 doses.~The subject will take Idarubicin 12 mg/m2 for three doses in an IV after the first, third, and fifth High- dose Cytarabine.~The subject will take a dose of 1,500 U/m2 of Calaspargase pegol-mknl in an IV after the last (6th) dose of High-dose Cytarabine every 21 days ( per cycle).~Consolidation Phase ( One cycle of consolidation lasts 4-8 weeks):~The subject will take Cytarabine 3000 mg/m2 in an IV every 12 hours on days 1, 3, 5 for 6 doses.~The subject will take a dose of 1,500 U/m2 of Calaspargase pegol-mknl in an IV after the last (6th) dose of High-dose Cytarabine.~A single cycle of consolidation may last between 4-8 weeks in duration."
88849269|NCT04953780|Experimental|Calaspargase pegol-mknl dose level 4|"Induction Phase (It usually lasts 29 days):~The subject will take Cytarabine 3000 mg/m2 in an IV every 12 hours on days 1, 3, 5 for 6 doses.~The subject will take Idarubicin 12 mg/m2 for three doses in an IV after the first, third, and fifth High-dose Cytarabine.~The subject will take a dose of 2,000 U/m2 of Calaspargase pegol-mknl in an IV after the last (6th) dose of High-dose Cytarabine every 21 days ( per cycle).~Consolidation Phase ( One cycle of consolidation lasts 4-8 weeks):~The subject will take Cytarabine 3000 mg/m2 in an IV every 12 hours on days 1, 3, 5 for 6 doses.~The subject will take a dose of 2,000 U/m2 of Calaspargase pegol-mknl in an IV after the last (6th) dose of High-dose Cytarabine per cycle.~A single cycle of consolidation may last between 4-8 weeks in duration."
89376579|NCT04056338||Delirium|Patients with delirium as assessed by the bedside nurse using Confusion Assessment Method for the ICU.
89376580|NCT04056338||Non-delirium|Patients without delirium.
89376581|NCT02391766|Active Comparator|empowerment group|empowerment intervention by us for us guides
89376582|NCT02391766|Placebo Comparator|no treatment group|dementia patients treatment as usual
89376583|NCT04056260|Experimental|ICG injection|ICG 0.5mg/ml x 0.5ml x 4 sites
89376584|NCT05675020|Experimental|Parent-Adolescent Dyad|"Each parent-adolescent dyad will receive the intervention (educational program delivered via a 45-minute presentation via Zoom).~The educational program will promote healthy lifestyle knowledge and behaviors through education evidenced by the CDC, WHO, and the American Academy of Pediatrics. Educational sessions will include the importance of healthy lifestyle modifications in the adolescent population with a mental health condition(s), lifestyle recommendations versus reality, nutrition, physical activity, screen time, and sleep recommendations and guidelines. The educational presentation will include 5-10 minutes of education regarding recommendations versus reality for nutrition, PA, screen time, and sleep, 20-25 minutes of education regarding ways to improve healthy lifestyle knowledge and behaviors, 10 minutes for questions and discussion."
88849270|NCT04951453||Aneurysmal subarachnoid haemorrhage|Patients with SAH (see eligibility criteria below). Planned enrollment: 50 patients.
88849271|NCT04951453||Intracerebral haemorrhage|Patients with ICH (see eligibility criteria below). Planned enrollment: 50 patients.
88849272|NCT04951453||Traumatic Brain Injury|Patients with TBI (see eligibility criteria below). Planned enrollment: 50 patients.
88849273|NCT04945460|Placebo Comparator|Placebo|Delivered subcutaneously (SC) every 3 weeks (Q3W) for 24 weeks in the placebo-controlled treatment period. After completion of the placebo-controlled treatment period, placebo participants will enter into 1 of the 2 sotatercept dose groups in an extension period.
88849274|NCT04945460|Experimental|Sotatercept 0.3 mg/kg|Participants will receive sotatercept SC at a dose level of 0.3 mg/kg Q3W for 24 weeks in the placebo-controlled treatment period. After completion of the placebo-controlled treatment period, participants will continue to receive sotatercept SC at a dose level of 0.3 mg/kg Q3W in an extension period for up to 18 months.
88849275|NCT04945460|Experimental|Sotatercept 0.3 mg/kg, escalating to 0.7 mg.kg|Sotatercept SC at a starting dose level of 0.3 mg/kg for 3 dosing visits (Q3W), then escalating to 0.7 mg/kg SC on the fourth dosing visit and Q3W for the remainder of the 24-week treatment Period.
88849276|NCT04945460|Experimental|Extension Period: Placebo Crossed Over to Sotatercept 0.3 mg/kg|After the placebo-controlled treatment period, placebo participants will cross over to receive sotatercept SC at a dose of 0.3 mg/kg Q3W for up to 18 months in an extension period.
88849277|NCT04945460|Experimental|Extension Period: Placebo Crossed Over to Sotatercept 0.3 mg/kg, escalating to 0.7 mg.kg|After the placebo-controlled treatment period, placebo participants will cross over to receive sotatercept SC at a starting dose level of 0.3 mg/kg for 3 dosing visits (Q3W), then escalating to 0.7 mg/kg SC on the fourth dosing visit and then Q3W for up to 18 months in an extension period.
88849278|NCT04939935|Experimental|Intervention|"Participants randomised to the intervention group receive Metformin XR plus standard of care for 104 weeks.~Dosage will depend on individual participant's level of tolerance to Metformin XR as well as their estimated glomerular filtration rate (eGFR). The dosage will be between 1000-2000mg/day."
88849279|NCT04939935|Placebo Comparator|Control|Participants randomised to the control group receive placebo plus standard of care for 104 weeks.
89535069|NCT03230539|Experimental|UPA IUS 40 μg|This is a proof-of-concept study utilizing a randomized dose-finding, parallel design to assess the effects of an IUS delivering Cu and 5, 20, or 40 μg of UPA over 12 weeks
88849282|NCT04896775|Experimental|NiteCAPP CARES|Cognitive Behavioral Treatment-Insomnia. Web-based intervention that will include 4 weekly sessions and 4 bimonthly boosters. Each session is to be completed individually by CG (with PWD to extent able) in a single sitting (less than 45 mins). Each session should be completed in 7 days with next session released only after prior one completed. Session 1 focuses on sleep education, sleep hygiene, and stimulus control. Session 2 focuses on sleep compression, relaxation, and problem solving. Session 3 focuses on coping and stress management and cognitive therapy. Session 4 focuses on a review of skills and plan for maintenance of behavior change.
88849283|NCT04896775|Experimental|NiteCAPP SHARES|Sleep Hygiene and Related Education. Web-based intervention that will include 4 weekly sessions and 4 bimonthly boosters. Each session is to be completed individually by CG (with PWD to extent able) in a single sitting (less than 45 mins). Each session should be completed in 7 days with next session released only after prior one completed. Session 1 focuses on expanded sleep education and sleep hygiene. Session 2 focuses insomnia education and sleep hygiene support. Session 3 focuses on targeted sleep education and sleep in dementia. Session 4 focuses on a review of skills and plan for maintenance of behavior change. Boosters review skills, encourage practice, and troubleshoot issues.
88849284|NCT04896281|Experimental|phenylalanine-free diet|phenylalanine-free diet for patients with hyperphenylalaninemia
88849285|NCT04881916||Sample Collection|"Participation In:~Initial data completion: Telephone collection of information on disease, treatment and testing~Medical record collection: Collection of medical records regarding cancer, testing, and treatment history~Archival tissue collection: Collection of tumor from prior standard of care procedure~Saliva collection: Saliva collection with at home kit~Follow up data completion: Telephone collection of medical condition every 3-6 months up to 2 years."
88849286|NCT04875429|Experimental|Aortic abdominal aneurysm|
88849287|NCT04862663|Experimental|Capivasertib Plus Palbociclib and Fulvestrant|Capivasertib Plus Palbociclib and Fulvestrant (Ph 1b)
88849288|NCT04862663|Experimental|Capivasertib Plus Ribociclib and Fulvestrant|Capivasertib Plus Ribociclib and Fulvestrant (Ph 1b)
88849289|NCT04862663|Experimental|Capivasertib Plus Abemaciclib and Fulvestrant|Capivasertib Plus Abemaciclib and Fulvestrant (Ph 1b)
88849290|NCT04862663|Experimental|Capivasertib Plus Fulvestrant and Investigator's choice of CDK4/6i (palbociclib or ribociclib)|Capivasertib Plus Fulvestrant and Investigator's choice of CDK4/6i (palbociclib or ribociclib) (Ph III)
88849291|NCT04862663|Active Comparator|Fulvestrant and Investigator's choice of CDK4/6i (palbociclib or ribociclib)|Fulvestrant and investigator's choice of CDK4/6i (palbociclib or ribociclib) (Ph III)
88849292|NCT04844983|Experimental|Part 1: Arm A|STP705 30 μg dose, intralesional injection, given once a week for 6 weeks.
88849293|NCT04844983|Experimental|Part 1: Arm B|STP705 60 μg dose, intralesional injection, given once a week for 6 weeks.
88849294|NCT04844983|Experimental|Part 1: Arm C|STP705 90 μg dose, intralesional injection, given once a week for 6 weeks.
88849295|NCT04844983|Other|Part 1: Arm D|Placebo (normal saline), intralesional injection, given once a week for 6 weeks.
88849296|NCT04844983|Experimental|Part 2: Arm A, B or C|STP705 selected dose 1, intralesional injection, given once a week for 6 weeks.
88849297|NCT04844983|Experimental|Part 2: Arm A or B or C|STP705 selected dose 2, intralesional injection, given once a week for 6 weeks.
88849298|NCT04844983|Other|Part 2: Arm D|Placebo (normal saline), intralesional injection, given once a week for 6 weeks.
89002426|NCT06317909|Other|single arm|It is an exploratory study. All participants will undergo allergen challenge.
89002427|NCT06317896||Patient with hepatocellular carcinoma|Patient with hepatocellular carcinoma who can undergo radical resection
88849299|NCT04843059|Other|the resident memory T-cell infiltrate in perilesional vitiligo skin|"To compare the resident memory T-cell infiltrate in perilesional vitiligo skin after 6 months of treatment with OMP and UVB, between three groups of patients suffering from non-segmental vitiligo, using flow cytometric analysis.~First group will include patients with a long-lasting disease (more than 2 years) and no new or growing lesions for at least 2 years: Old vitiligo with Old lesions~The second group will include patients with a long-lasting disease (more than 2 years) and with at least one new lesion developed in the last 6 months: Old vitiligo with new lesions~The third one will include patients developing, for the first-time, vitiligo lesions with all the lesions no older than 6 months: New vitiligo"
88849300|NCT04841785||CKD4/5|Patients with chronic kidney disease stage G4-G5 without dialysis or with a kidney transplant
88849301|NCT04841785||Dialysis|Patients on hemodialysis and peritoneal dialysis
88849302|NCT04841785||Kidney transplant|Patients with a kidney transplant at least 6 weeks after transplantation
88849303|NCT04840264|Experimental|A (First-Line Therapy)|Docetaxel 25 mg/square metre, ivdrip 60 min, D1, D8, D15; Oxaliplatin 85 mg/square metre, ivdrip 180 min, D1, D15; 5Fu 1200 mg/square metre, civ 24 hours, D1, D8, D15; Repeat every 4 weeks.
88849304|NCT04840264|Experimental|B (Second-Line Therapy)|Docetaxel 25 mg/square metre, ivdrip 60 min, D1, D8, D15; Oxaliplatin 85 mg/square metre, ivdrip 180 min, D1, D15; 5Fu 1200 mg/square metre, civ 24 hours, D1, D8, D15; Repeat every 4 weeks.
88849305|NCT04840264|Experimental|C (Third- or Later-Line Therapy)|Docetaxel 25 mg/square metre, ivdrip 60 min, D1, D8, D15; Oxaliplatin 85 mg/square metre, ivdrip 180 min, D1, D15; 5Fu 1200 mg/square metre, civ 24 hours, D1, D8, D15; Repeat every 4 weeks.
88849306|NCT04837196|Experimental|Phase 1 ASP7517 Monotherapy Dose Escalation|Participants will receive ASP7517 on Day 1 of each 28-day cycle for up to 6 doses.
88849307|NCT04837196|Experimental|Phase 1 ASP7517 + Pembrolizumab Dose Escalation|Participants will receive ASP7517 on Day 1 of each 28-day cycle for up to 6 doses in combination with up to 4 doses of pembrolizumab administered every 6 weeks starting from Cycle 1 Day 1. Pembrolizumab monotherapy may be extended up to a total of 17 doses for qualifying participants.
88849308|NCT04837196|Experimental|Phase 2 ASP7517 Monotherapy Dose Expansion|Participants will receive RP2D of ASP7517 on Day 1 of each 28-day cycle for up to 6 doses
88849309|NCT04837196|Experimental|Phase 2 ASP7517 + Pembrolizumab Dose Expansion|Participants will receive RP2D of ASP7517 on Day 1 of each 28-day cycle for up to 6 doses in combination with up to 4 doses of pembrolizumab administered every 6 weeks. Pembrolizumab monotherapy may be extended up to a total of 17 doses for qualifying participants.
88849310|NCT04835441|Experimental|ALPN-101 (acazicolcept)|
88849311|NCT04835441|Placebo Comparator|Placebo|
88849312|NCT04829136|Experimental|Arm I (enteral nutrition) [Discontinued in January 2024]|Patients receive enteral nutrition via nasoenteric feeding tube starting on day 1 until hospital discharge.
88849313|NCT04829136|Active Comparator|Arm II (standard of care) [Discontinued in January 2024]|Patients receive standard of care nutritional support.
88849314|NCT04829136|Experimental|Supportive care (Fiber) [Current study activity]|Patients receive fiber supplementation PO or enterally starting 14 days prior to day 1 of conditioning chemotherapy and continuing until discharge from the hospital. Stool will be collected at different time points throughout the study. Patients may also undergo blood sample collection throughout the study.
88849315|NCT04827745|Experimental|Subjects with R/R CD19-positive MPAL|"Cohort A: Evaluate the efficacy of blinatumomab to achieve the best morphologic response after the first two cycles of therapy in subjects with morphologic R/R CD19-positive MPAL~The treatment of blinatumomab consists of induction, consolidation and maintenance therapy~Subject will receive study drug blinatumomab by continuous IV infusion (CIV)~Each treatment cycle consists of 28 days of blinatumomab CIV followed by a 14±3 days treatment-free interval for induction, 28±3 days treatment-free interval for consolidation, and 56±3 days treatment-free interval for maintenance~The initial dose of blinatumomab is 9 mcg/day for 7 days. The target dose for rest of treatment is 28 mcg/day"
88849316|NCT04827745|Experimental|Subjects with CD19-positive MPAL in CR/CRh/CRi/CRp and detectable MRD|"Cohort B: Evaluate the efficacy of blinatumomab to achieve MRD-negativity in subjects with CD19-positive MPAL in CR, or CRh, or CRi or CRp after receiving at least one chemotherapy block of standard ALL or AML treatment with MRD-positivity at a level of ≥ 0.1% using an assay with a minimum sensitivity of 0.01%~The treatment of blinatumomab consists of induction, consolidation and maintenance therapy~Subject will receive study drug blinatumomab by continuous IV infusion (CIV)~Each treatment cycle consists of 28 days of blinatumomab CIV followed by a 14±3 days treatment-free interval for induction, 28±3 days treatment-free interval for consolidation, and 56±3 days treatment-free interval for maintenance.~The dose of blinatumomab is 28 mcg/day"
89181996|NCT03475953|Experimental|Phase 2 : cohort D Regorafenib + Avelumab|Treatment by Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
89181997|NCT03475953|Experimental|Phase 2 : cohort E Regorafenib + Avelumab|Treatment by Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
88849317|NCT04819477|Other|Cate Plots|after being asked about current referral practices and assessment of benefits and risks of lung cancer screening, all respondents will receive the Fact box after which they will be randomized into two equal groups. The first group (Arm 1) receives a Cates plot and then another survey about assessment of benefits and risks of lung cancer screening and potential change in referral behavior.
89002428|NCT06317883||CORALS|Children aged 3-6 years
89181998|NCT03475953|Experimental|Phase 2 : cohort F Regorafenib + Avelumab|Treatment by Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
89181999|NCT03475953|Experimental|Phase 2 : cohort G Regorafenib + Avelumab|Treatment by Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
88849318|NCT04819477|Other|Fact box only|after being asked about current referral practices and assessment of benefits and risks of lung cancer screening, all respondents will receive the Fact box after which they will be randomized into two equal groups. The second group (Arm 2) receives then a survey about assessment of benefits and risks of lung cancer screening and potential change in referral behavior
88849319|NCT04819113|Experimental|Nimenrix|Nimenrix
88849320|NCT04811196|Experimental|Metronomic dosing|"This Arm is an open-label, non-randomized, phase 1 study of metronomic dosing of selinexor in patients with locally advanced or metastatic MPNST, ESS, LMS. Up to seven dose levels of Selinexor will be investigated.~Patients will undergo 3+3 based dose escalation to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of Selinexor.~Escalating doses of selinexor will be given starting with 2.5 mg (taken orally 4 days in a row followed by 3 days break from treatment, repeating this weekly as part of a 28-day cycle). The first dose for the first 2 patients at each dose level will be staggered by 7 days. Minimum number of patients treated in this trial arm is 18 patients, and maximum 36 patients.~Schedule:~Selinexor flat dosing with dose levels (DLs) of 2.5mg (DL1), 5mg (DL2), 7.5mg (DL3), 10mg (DL4), 12.5mg (DL5), 15mg (DL6), 17.5mg (DL7). A DL-1 (1.25 mg) is also incorporated."
88849321|NCT04811196|Experimental|Split dosing|The second arm of the study is an open-label, non randomized, phase 1b study of selinexor in patients with any histological subtype of STS administered orally one day per week, 40mg in the morning, 20mg in the afternoon and 20mg at night as part of a 28 day cycle. Twenty patients will be accrued to this arm.
88849322|NCT04811092|Placebo Comparator|Placebo plus background PAH therapy|Administered subcutaneously (SC) every 21 days plus background PAH therapy
88849323|NCT04811092|Experimental|Sotatercept plus background PAH therapy|Administered at a starting dose of 0.3 mg/kg, with a target dose of 0.7 mg/kg, subcutaneously (SC) every 21 days plus background PAH therapy
88849324|NCT04805164|Experimental|Innovative strategy|usual medical and surgical care with corticotomy and use of a bone substitute (Cerament-G) delivering gentamicin locally (± skin and soft-tissue/muscle flap) and antibiotic therapy.
88849325|NCT04805164|Active Comparator|Reference strategy|Medico-surgical usual care with corticotomy (± skin and soft-tissue/muscle flap), and antibiotic therapy.
88849326|NCT04803734|Experimental|Test Group|Albuterol Sulfate inhalation aerosol
88849327|NCT04803734|Active Comparator|Reference Group|Proair HFA (albuterol sulfate) Inhalation Aerosol
88849328|NCT04801797|Experimental|Standard of Care (Conventional Induction)|"Randomized participants will receive cytarabine and idarubicin [or daunorubicin) per standard of care as follows:~Induction: cytarabine on days 1-7 and idarubicin (or daunorubicin) on days 1-3 of induction.~Second Induction (if needed): Cytarabine on days 1-5 and idarubicin (or daunorubicin) on days 1-2 of re-induction.~Consolidation (if needed): If < 60 years, cytarabine days 1,3,5 of consolidation cycles, and if ≥60 years, cytarabine days 1-5 of consolidation cycles~Those with secondary or therapy-related AML can receive liposomal daunorubicin and cytarabine (Vyxeos) per standard of care as follows:~Induction: Liposomal daunorubicin and cytarabine (Vyxeos) on Days 1,3, 5 of induction.~Second Induction (if needed): Liposomal daunorubicin and cytarabine (Vyxeos) on days 1,3 of re-induction Consolidation (if needed): liposomal daunorubicin and cytarabine (Vyxeos) on days 1,3 of consolidation cycles"
88849329|NCT04801797|Experimental|Investigational (Venetoclax and Azacitidine)|Participants will receive azacitidine on days 1-7 and venetoclax daily for up to (3) three 28-day study cycles and evaluated for response or benefit. If benefit/response is achieved, azacitidine on days 1-7 and venetoclax on days 1-28 (or less if deemed necessary per protocol) will be given in repeating 28-day cycles until benefit/response is no longer achieved or until patient proceeds to transplantation.
88849330|NCT04790370|Active Comparator|Anticoagulation|Low-molecular weight heparin (LMWH) or unfractionated heparin (UFH)
88849331|NCT04790370|Active Comparator|Anticoagulation and EkoSonicTM Endovascular System|Low-molecular weight heparin (LMWH) or unfractionated heparin (UFH) and EkoSonicTM Endovascular System [ultrasound-facilitated catheter-directed delivery of thrombolytic: 2 mg bolus/catheter + 1 mg/hour/catheter for 7 hours (total of 9 or 18 mg]
88849332|NCT04785300|Experimental|Dasatinib plus Quercetin Treatment Goup|Subjects with MCI or Alzheimer's disease will take Dasatinib and Quercetin by mouth at the same times for 2 days out of every 15 days for 6 cycles lasting for a total of 77 days (12 concurrent doses of each agent).
88849333|NCT04785144|Experimental|Arm 1A|50 mcg of mRNA-1273.351 administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 in participants who received two vaccinations of mRNA-1273 in DMID Protocol 20-0003 (NCT04283461). N=30.
88849334|NCT04785144|Experimental|Arm 1B|25 mcg of mRNA-1273 and 25 mcg of mRNA-1273.351 administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 in participants who received two vaccinations of mRNA-1273 in DMID Protocol 20-0003 (NCT04283461). N=30.
88849335|NCT04785144|Experimental|Arm 2A|100 mcg mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29, and 50 mcg mRNA-1273.351 administered through 0.5 mL intramuscular injection in the deltoid on Day 57 in COVID-19 naïve participants. N=15
88849336|NCT04785144|Experimental|Arm 2B|50 mcg mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29, and 50 mcg mRNA-1273.351 administered through 0.5 mL intramuscular injection in the deltoid on Day 57 in COVID-19 naïve participants. N=15
88849337|NCT04785144|Experimental|Arm 2C|100 mcg mRNA-1273.351 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in COVID-19 naïve participants. N=20
88849338|NCT04785144|Experimental|Arm 2D|50 mcg mRNA-1273.351 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in COVID-19 naïve participants. N=20
88849339|NCT04785144|Experimental|Arm 2E|100 mcg mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1, and 100 mcg mRNA-1273.351 administered through 0.5 mL intramuscular injection in the deltoid on Day 29 in COVID-19 naïve participants. N=20
89002429|NCT06317870|Experimental|PENG group|Pericapsular nerve group block
89002430|NCT06317870|Active Comparator|ITM group|intrathecal morphine injection
89182000|NCT03475953|Experimental|Phase 2 : cohort H Regorafenib + Avelumab|Treatment by Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
89376585|NCT05674864|Placebo Comparator|Group 1 (Control Group)|consists of 46 patients who will receive Amoxicillin 1 gm three times daily plus Lansoprazole 30 mg three times daily plus Placebo 1 capsule three times daily for 14 days.
89376586|NCT05674864|Active Comparator|Group 2 (Linex ® group)|consists of 46 patients who will receive Amoxicillin 1 gm three times daily plus Lansoprazole 30 mg three times daily plus Linex ® capsule (which contains Bifidobacterium Infants, Enterococcus Feacium, and Lactobacillus Acidophilus) 1 capsule three times daily for 14 days.
88849340|NCT04785144|Experimental|Arm 2F|50 mcg mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1, and 50 mcg mRNA-1273.351 administered through 0.5 mL intramuscular injection in the deltoid on Day 29 in COVID-19 naïve participants. N=20
89376587|NCT02391688|Experimental|Treatment A|"Oral intake of:~caffeine 50 mg dextromethorphan 10 mg omeprazole 10 mg flurbiprofen 10 mg midazolam 1 mg"
88849341|NCT04785144|Experimental|Arm 2G|50 mcg of mRNA-1273 and 50 mcg of mRNA-1273.351 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in COVID-19 naïve participants. N=20
88849342|NCT04785144|Experimental|Arm 2H|25 mcg of mRNA-1273 and 25 mcg of mRNA-1273.351 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in COVID-19 naïve participants. N=20
89376588|NCT02391688|Experimental|Treatment B|"Oral intake of:~fexofenadine 25 mg"
89376589|NCT02391688|Experimental|Treatment C|"Oral intake of:~bupropion 20 mg"
89376590|NCT02391688|Experimental|Treatment D|"Oral Intake of Geneva cocktail (A+B+C):~caffeine 50 mg dextromethorphan 10 mg omeprazole 10 mg flurbiprofen 10 mg midazolam 1 mg fexofenadine 25 mg bupropion 20 mg"
88849343|NCT04781036|No Intervention|Normal feet|"Swab their feet to analyze foot microbiome via 16s DNA sequencing~Collect their socks to analyze metabolomics via gas chromatography"
88849344|NCT04781036|Experimental|Foot odor without pitted keratolysis|"Swab their feet to analyze foot microbiome via 16s DNA sequencing~Collect their socks to analyze metabolomics via gas chromatography~Apply 4% chlorhexidine for 2 weeks~Re-evaluate their feet at time of treatment finish and 1 months after treatment finish. The forementioned methods (swab and collect their socks) will be applied on their feet again.~The microbiome and metabolomics will be analyzed to evaluate the difference of microbe and substances after treatment."
88849345|NCT04781036|Experimental|Foot odor with pitted keratolysis|"Swab their feet to analyze foot microbiome via 16s DNA sequencing~Collect their socks to analyze metabolomics via gas chromatography~Apply 4% chlorhexidine for 2 weeks~Re-evaluate their feet at time of treatment finish and 1 months after treatment finish. The forementioned methods (swab and collect their socks) will be applied on their feet again.~The microbiome and metabolomics will be analyzed to evaluate the difference of microbe and substances after treatment."
88849346|NCT04772898|Experimental|Children with Autism Spectrum Disorders|Children with autism spectrum disorder will receive a 6 week (once per week) hippotherapy protocol. During the hippotherapy session, the researchers will monitor the heart rate variability of the horse and the rider. Both horse and rider will wear an electrode strap around the upper thorax. Heart rate recordings will be started simultaneously at the beginning of the HPOT session. To assess movement coupling between the horse and rider, five tri-axial inertial sensors (OPAL, APDM, Inc, Portland, OR) will be used. The sensors will collect actively synchronized tri-axial accelerometer and gyroscope data. One inertial sensor will be placed dorsal at the rider's pelvis, one frontal at the top of the forehead, and one frontal at the top of the sternum. The sensors on the horse will be fixed on the back of the horse on the spine level between T8 and T10 and on the head.
88849347|NCT04772898|Active Comparator|Children with typical development|Children with autism spectrum disorder and with typical development will receive a 6 week (once per week) hippotherapy protocol. During the hippotherapy session, the researchers will monitor the heart rate variability of the horse and the rider. Both horse and rider will wear an electrode strap around the upper thorax. Heart rate recordings will be started simultaneously at the beginning of the HPOT session. To assess movement coupling between the horse and rider, five tri-axial inertial sensors (OPAL, APDM, Inc, Portland, OR) will be used. The sensors will collect actively synchronized tri-axial accelerometer and gyroscope data. One inertial sensor will be placed dorsal at the rider's pelvis, one frontal at the top of the forehead, and one frontal at the top of the sternum. The sensors on the horse will be fixed on the back of the horse on the spine level between T8 and T10 and on the head.
88849348|NCT04769505|Experimental|Intervention group|Participants receive a digital mindfulness-based intervention (MBI) + treatment as usual.
88849349|NCT04769505|No Intervention|Wait list control group|Participants receive treatment as usual during the intervention period. They are provided with the digital mindfulness-based intervention (MBI) after the intervention period. The waitlist control group receives the same intervention as the intervention group, with the exception of using not using the exercises via the software on the smartphone, but receiving the exercises as audio files.
88849350|NCT04767802|Experimental|PTG-300|Evaluate PTG-300's efficacy and safety in subjects with PV and baseline elevated hematocrit.
89376591|NCT04117360||Dentofacial Disharmony Patients|Dentofacial disharmony patients who are seeking jaw surgery in UNC oral and maxillofacial surgery department and are seen in UNC orthodontic dentofacial disharmony clinic.
89376592|NCT02391454|Other|Group A|usual care
89376593|NCT02391454|Experimental|Group B|usual care + RunKeeper app
89376594|NCT01068860|Experimental|Canakinumab 150 mg + Metformin|Eligible participants received a single subcutaneous injection Canakinumab 150 mg.Patients must have had documented diagnosis of Type 2 Diabetes Mellitus and be on a stable dose of Metformin (Met) monotherapy treatment at least 1000 mg/day for 3 months prior to screening
89376595|NCT01068860|Placebo Comparator|Placebo + Metformin|Eligible participants received a single subcutaneous injection of Placebo to Canakinumab. Patients must have had documented diagnosis of Type 2 Diabetes Mellitus and be on a stable dose of Metformin (Met) monotherapy treatment at least 1000 mg/day for 3 months prior to screening
89376596|NCT01068860|Experimental|Canakinumab 150 mg + Metforimin + Sulfonylurea|Eligible participants received a single subcutaneous injection of Canakinumab 150 mg.Patients must have had documented diagnosis of Type 2 Diabetes Mellitus and be on a stable dose of Metformin (Met) at least 1000 mg/day , and a Sulfonylurea (Sulfonyl), at least 1/2 the maximally labeled dose combination therapy, for 3 months prior to screening.
88849354|NCT04756960|Experimental|CHF6001|single dose of CHF6001 dry-powder inhaler (DPI) co-administered with an intravenous microdose of [14^C]-labelled CHF6001
88849355|NCT04755283|Experimental|Abelacimab (MAA868)|"Treatment group 1: Abelacimab middle dose subcutaneous (s.c.) monthly~Treatment group 2: Abelacimab high dose subcutaneous (s.c.) monthly~Extension Treatment Group: Abelacimab high dose subcutaneous (s.c.) monthly"
88849356|NCT04755283|Active Comparator|Rivaroxaban|"Treatment group 3: Rivaroxaban 20 mg by mouth; orally (p.o.) once per day with the evening meal~Patients with a Creatinine Clearance (CrCl) ≤50 ml/min by the Cockcroft-Gault equation will have a dose adaptation to rivaroxaban 15 mg p.o. daily."
88849357|NCT04752267|Experimental|Diagnostic (18F-FMAU, PET/CT, mpMRI)|Patients receive 18F-FMAU intravenously (IV) and undergo a PET/CT scan over 60 minutes. Patients then undergo standard of care mpMRI over approximately 45 minutes.
88849358|NCT04749043|Active Comparator|Virtual Reality then Nitrous Oxide|30 minute exposure to virtual reality, 5 minute washout period, then 30 minute exposure to nitrous oxide
88849359|NCT04749043|Active Comparator|Nitrous Oxide then Virtual Reality|30 minute exposure to nitrous oxide, 5 minute washout period, then 30 minute exposure to virtual reality
88849360|NCT04742595|Experimental|Treatment (SARS-COV-2 specific cytotoxic T cells)|Patients receive SARS-COV-2 specific cytotoxic T lymphocytes IV over 30 minutes on day 1. Treatment may repeat every 14 days at investigators' discretion if patient fails to respond, the infection reoccurs, until the viral load becomes negative or until complete resolution of clinical and radiological signs.
88849361|NCT04740918|Active Comparator|Arm A: Trastuzumab Emtansine and Placebo|Placebo matched to atezolizumab followed by trastuzumab emtansine 3.6 milligrams per kilogram (mg/kg) intravenous (IV) infusion on Day 1 Cycle 1 and thereafter on Day 1 of each 21-day cycle until disease progression, unmanageable toxicity, or study termination by the sponsor.
88849362|NCT04740918|Experimental|Arm B: Trastuzumab Emtansine and Atezolizumab|Atezolizumab 1200 mg IV infusion followed by trastuzumab emtansine 3.6 mg/kg IV infusion on Day 1 Cycle 1 and thereafter on Day 1 of each 21-day cycle until disease progression, unmanageable toxicity, or study termination by the Sponsor.
88849363|NCT04732221|Experimental|Phase 2 Cohort MK-5475 380 µg|Participants receive MK-5475 380 µg via oral inhalation once daily for 12 week base period and for optional 24 month extension period.
88849364|NCT04732221|Experimental|Phase 2 Cohort MK-5475 100 µg|Participants receive MK-5475 100 µg via oral inhalation once daily for 12 week base period and for optional 24 month extension period.
88849365|NCT04732221|Experimental|Phase 2 Cohort MK-5475 32 µg|Participants receive MK-5475 32 µg via oral inhalation once daily for 12 week base period and for optional 24 month extension period.
88849366|NCT04732221|Placebo Comparator|Phase 2 Cohort Placebo|Participants receive placebo via oral inhalation once daily for 12 week base period, and one of the MK-5475 doses (380, 100, or 32 µg) for the optional 24 month extension period.
88849367|NCT04732221|Experimental|Phase 3 Cohort MK-5475|Participants receive one of 3 MK-5475 doses (380, 100 or 32 µg) to be selected at end of the Phase 2 Cohort, administered via oral inhalation once daily for 12-week base period and up to 60 months in the extension period
88849368|NCT04732221|Placebo Comparator|Phase 3 Cohort Placebo|Participants receive placebo via oral inhalation once daily for 12 week base period and up to 60 months in the extension period.
88849369|NCT04731688|Experimental|Weight Maintenance Group|Individuals in this group will receive all aspects of the Provider Directed Group plus a comprehensive behavioral fat mass loss intervention with food provision. Individuals in this group will be provided foods to eat to support weight maintenance and loss of body fat throughout pregnancy. They will be asked to attend two behavioral counseling sessions at the beginning of the study to help learn the program and set goals. They will return for brief visits with a lifestyle counselor every two weeks until 20 weeks gestation and at least once a month until delivery. Individuals will be provided a scale to help keep track of weight during pregnancy.
88849370|NCT04731688|No Intervention|Provider Directed Group|Individuals in this group will receive what is standard practice by their prenatal care providers during pregnancy. In addition, individuals in this group will be asked to attend a brief session at the time of randomization to familiarize with the study and what is expected. They will also be provided with materials describing healthy behaviors in pregnancy.
88849371|NCT04729231|Active Comparator|Nasalis Sling Flap|
88849372|NCT04729231|Active Comparator|Lobed transposition flap|
88849373|NCT04725058|Experimental|Medical Group Visit|Participants receive obesity management in a group setting let by endocrinologist and nutritionist.
88849374|NCT04725058|Experimental|Dietitian-Led Visit|Participant receives obesity management in an individual setting lead by registered dietitian.
88849375|NCT04705766||COVID-19 Negative|Control group to measure progression of AKI/kidney injury overtime
88849376|NCT04705766||COVID-19 Positive|Study group to assess AKI trajectory/progression and associated risk factors of kidney injury with SARS-CoV-2 infection
88849377|NCT04702581|Experimental|PCV alone|Administration of 6 cycles of PCV chemotherapy alone.
88849378|NCT04702581|Active Comparator|RT + PCV|Radiotherapy followed by administration of PCV chemotherapy.
88849379|NCT04647747|Other|Self measurement of peripheral saturation|Participant will be equipped with a pulse oximeter and perform saturation measurements.
88849380|NCT04647253|Experimental|AGENT DCB|Agent DCB is a Monorail Percutaneous Transluminal Coronary Angioplasty (PTCA) balloon catheter with a semi-compliant balloon coated with a formulation of paclitaxel (drug) and an excipient, Acetyl-Tri-n-butyl citrate (ATBC). The balloon catheter platform is based on the commercially available BSC Emerge™ PTCA balloon catheter system (K130391).
88849381|NCT04647253|Active Comparator|Commercially available, PTCA Dilation Catheter|
88849382|NCT04643470|Experimental|Zanubrutinib Low Dose|Participants will receive zanubrutinib 40 mg twice daily (BID) for 72 weeks
88849383|NCT04643470|Experimental|Zanubrutinib High Dose|Participants will receive zanubrutinib 160 mg twice daily (BID) for 72 weeks
89182001|NCT03475953|Experimental|Phase 2 : cohort I Regorafenib + Avelumab|Treatment by Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
89376597|NCT01068860|Placebo Comparator|Placebo + Metforimin + Sulfonylurea|Eligible participants received a single subcutaneous injection of Placebo to Canakinumab.Patients must have had documented diagnosis of Type 2 Diabetes Mellitus and be on a stable dose of Metformin (Met) at least 1000 mg/day , and a Sulfonylurea (Sulfonyl), at least 1/2 the maximally labeled dose combination therapy, for 3 months prior to screening.
89376598|NCT01068860|Experimental|Canakinumab 150 mg + Met + Sulfonyl + Thiazolidinedione|Eligible participants received a single subcutaneous injection of Canakinumab 150 mg.Patients must have had documented diagnosis of Type 2 Diabetes Mellitus and be on a stable dose of Metformin (Met) at least 1000 mg/day , and a Sulfonylurea (Sulfonyl), at least 1/2 the maximally labeled dose, and a Thiazolidinedione (Thiaz)at least 1/2 the maximally labeled dose combination therapy, for 3 months prior to screening.
89376599|NCT01068860|Placebo Comparator|Placebo + Met + Sulfonyl + Thiazolidinedione|Eligible participants received a single subcutaneous injection of Placebo to Canakinumab. Patients must have had documented diagnosis of Type 2 Diabetes Mellitus and be on a stable dose of Metformin (Met) at least 1000 mg/day , and a Sulfonylurea (Sulfonyl), at least 1/2 the maximally labeled dose, and a Thiazolidinedione (Thiaz)at least 1/2 the maximally labeled dose combination therapy, for 3 months prior to screening.
89376600|NCT01068860|Experimental|Canakinumab 150 mg + Insulin|Eligible participants received a single subcutaneous injection of Canakinumab 150 mg. Patients must have had documented diagnosis of Type 2 Diabetes Mellitus for 3 months prior to screening and be on a stable dose of Insulin, 2 insulin injections per day for a total daily dose of less than 100 U with or without Metformin (Met)for 3 months prior to screening
89376601|NCT01068860|Placebo Comparator|Placebo + Insulin|Eligible participants received a single subcutaneous injection of Placebo to Canakinumab. Patients must have had documented diagnosis of Type 2 Diabetes Mellitus for 3 months prior to screening and be on a stable dose of Insulin, 2 insulin injections per day for a total daily dose of less than 100 U with or without Metformin (Met)for 3 months prior to screening
89376602|NCT01068860|Experimental|Canakinumab 150 mg in patients with IGT|Eligible participants received a single subcutaneous injection of Canakinumab 150 mg. Patients must have had Impaired Glucose Tolerance (IGT) as defined by the World Health Organization (WHO) criteria confirmed at screening visit.
89376603|NCT01068860|Placebo Comparator|Placebo in patients with IGT|Eligible participants received a single subcutaneous injection of Placebo to Canakinumab. Patients must have had Impaired Glucose Tolerance (IGT) as defined by the World Health Organization (WHO) criteria confirmed at screening visit.
88849384|NCT04643470|Experimental|Zanubrutinib Medium Dose|Participants will receive zanubrutinib 160 mg once daily (QD) for 72 weeks
89376604|NCT03662594|Other|ECMO tube|
89376605|NCT04056572|Experimental|TQ-B3139|TQ-B3139 tablet 600mg administered orally, twice daily.
89376606|NCT04056650|Active Comparator|Single caffeinated beverage/supplement|
89376607|NCT04056650|Active Comparator|Combination caffeine and L-theanine|
88849385|NCT04643470|Experimental|Placebo|Participants will receive placebo to match zanubrutinib for 72 weeks
88849386|NCT04625153|Experimental|RC18 160mg|RC18 160mg is injected subcutaneously once a week for 48 times.
88849387|NCT04625153|Experimental|RC18 240mg|RC18 240mg is injected subcutaneously once a week for 48 times.
88849388|NCT04623554|Active Comparator|Intervention arm|Prehabilitation program
88849389|NCT04623554|No Intervention|Control arm|Usual care
88849390|NCT04613648||Group A|Painful and stiff hemiplegic side shoulders of stroke patients
88849391|NCT04613648||Group B|Asymptomatic non-hemiplegic side shoulders of stroke patients
88849392|NCT04613648||Group C|Non-dominant side shoulders of healthy volunteers
89376608|NCT03662438|Other|Study Participants|"This is a self-controlled study where participants will serve as their own controls. All participants will be enrolled into a 10 week home-based physiotherapy program which will include a total of 2 home visits by a physiotherapist at the start and midpoint of the program. Participants will also receive weekly telephone calls by a research coordinator to provide encouragement for patient on the programme and enquire about compliance to the home exercise regimen and safety (e.g. falls and healthcare utilisation).~Patients will also be prescribed a lightweight portable oxygen concentrator to facilitate exercise therapy and mobility in the community. They will receive familiarisation and training in its usage as part of the home-based physiotherapy program."
88849393|NCT04612751|Experimental|Cohort 1|Datopotamab deruxtecan (Dato-DXd) + Durvalumab in NSCLC participants who are either treatment-naïve or have received only 1 prior line of systemic chemotherapy without concomitant ICI therapy
88849394|NCT04612751|Experimental|Cohort 2|Datopotamab deruxtecan (Dato-DXd) + Durvalumab in NSCLC participants who are either treatment-naïve or have received only 1 prior line of systemic chemotherapy without concomitant ICI therapy
88849395|NCT04612751|Experimental|Cohort 3|Datopotamab deruxtecan (Dato-DXd) + Durvalumab + Carboplatin in NSCLC participants who are either treatment-naïve or have received only 1 prior line of systemic chemotherapy without concomitant ICI therapy
88849396|NCT04612751|Experimental|Cohort 4|Datopotamab deruxtecan (Dato-DXd) + Durvalumab + Carboplatin in NSCLC participants who are either treatment-naïve or have received only 1 prior line of systemic chemotherapy without concomitant ICI therapy
88849397|NCT04612751|Experimental|Cohort 5|Datopotamab deruxtecan (Dato-DXd) + AZD2936 in participants with treatment-naïve NSCLC
88849398|NCT04612751|Experimental|Cohort 6|Datopotamab deruxtecan (Dato-DXd) + AZD2936 in participants with treatment-naïve NSCLC
88849399|NCT04612751|Experimental|Cohort 7|Datopotamab deruxtecan (Dato-DXd) + AZD2936 + Carboplatin in participants with treatment-naïve NSCLC
88849400|NCT04612751|Experimental|Cohort 8|Datopotamab deruxtecan (Dato-DXd) + AZD2936 + Carboplatin in participants with treatment-naïve NSCLC
88849401|NCT04612751|Experimental|Cohort 9|Datopotamab deruxtecan (Dato-DXd) + MEDI5752 + Carboplatin in participants with treatment-naïve NSCLC
88849402|NCT04612751|Experimental|Cohort 10|Datopotamab deruxtecan (Dato-DXd) + MEDI5752 + Carboplatin in participants with treatment-naïve NSCLC
88849403|NCT04612751|Experimental|Cohort 11|Datopotamab deruxtecan (Dato-DXd) + MEDI5752 in participants with treatment-naïve NSCLC
88849404|NCT04612751|Experimental|Cohort 12|Datopotamab deruxtecan (Dato-DXd) + AZD7789 in participants with CPI acquired resistant NSCLC
88849405|NCT04612751|Experimental|Cohort 13|Datopotamab deruxtecan (Dato-DXd) + AZD7789 in participants with CPI acquired resistant NSCLC
88849406|NCT04612751|Experimental|Cohort 14|Datopotamab deruxtecan (Dato-DXd) + AZD7789 in participants with treatment-naïve NSCLC
88849407|NCT04607174|Other|Pathologic group|At least 20 participants with various neurologic or orthopaedic conditions (for example, hemiparesis post-stroke, multiple sclerosis, traumatic knee injuries, knee osteoarthritis) will be enrolled.
88849408|NCT04586010|Experimental|Fenebrutinib|Participants will receive oral fenebrutinib with teriflunomide-matching placebo.
88849409|NCT04586010|Active Comparator|Teriflunomide|Participants will receive oral teriflunomide with fenebrutinib-matching placebo in a blinded fashion.
88849410|NCT04568460|Experimental|Intervention Group Sessions|Intervention group sessions will be delivered by lay health counselors. The sessions will reflect principles of co-learning, participatory design, and empowerment to promote engagement of young people in critical thinking and problem solving - including modeling, roleplaying, and interactive activities.
88849411|NCT04568460|No Intervention|Standard of Care|This is the standard of care arm. Participants newly diagnosed with HIV will get a referral to the local primary health care setting of their choice for further management, including ART.
88849412|NCT04563013|Sham Comparator|Sham taVNS|The participants under conventional radiotherapy were applied with sham taVNS at the left tragus with the power off for 30min. The intervention would last until to the end of conventional radiotherapy.
88849413|NCT04563013|Active Comparator|taVNS|"For taVNS group, the electrodes were attached to the tragus of left ear after skin preparation with an alcohol pad. The stimulation current was a single-phase rectangular pulse with the following stimulation parameters: duty circle: 60 s on periods and 10 s off periods; frequency: 30 Hz; pulse width: 200 μs; pulse amplitude of 0.5 mA to 1.5 mA; stimulation time:30 min."
88849414|NCT04560166|Experimental|Naxitamab and GM-CSF in combination with irinotecan and temozolomide|"A treatment cycle is 21 days. The patients will receive irinotecan 50 mg/m2/day IV and temozolomide 100 mg/m2/day orally (both on Days 1-5) in combination with naxitamab 2.25 mg/kg/day IV (Days 2, 4, 8 and 10) (total 9 mg/kg per cycle), and GM-CSF 250 ug/m2/day sc, (Days 6-10).~Patients will receive up to 18 IT cycles after enrollment. Naxitamab and GM-CSF will be given for at least 8 cycles."
88849415|NCT04538742|Experimental|Module 1- T-DXd and Durvalumab|T-DXd and Durvalumab
88849416|NCT04538742|Experimental|Module 2- T-DXd and Pertuzumab|T-DXd and Pertuzumab
88849417|NCT04538742|Experimental|Module 3- T-DXd and Paclitaxel|T-DXd and Paclitaxel (Arm not initiated in Part 2)
88849418|NCT04538742|Experimental|Module 4- T-DXd and Durvalumab and Paclitaxel|T-DXd and Durvalumab and Paclitaxel (Arm not initiated in Part 1 and Part 2)
88849419|NCT04538742|Experimental|Module 0- T-DXd|T-DXd
88849420|NCT04538742|Experimental|Module 5 - T-DXd and Tucatanib|T-DXd and tucatinib (Arm not initiated in Part 2)
88849421|NCT04538742|Experimental|Module 6 - T-DXd and Tucatinib|T-DXd and tucatinib in patients with active brain metastases (Part 2 Only) (Arm not initiated)
88849422|NCT04538742|Experimental|Module 7 - T-DXd|T-DXd monotherapy in patients with active brain metastases (Part 2 Only)
88849423|NCT04538417|Other|Residual Limb Pain in affected amputated limb|Patient has residual limb pain in amputated limb and is scheduled to receive standard of care treatment of cooled radiofrequency ablation.
88849424|NCT04528992|Experimental|Physical Therapy with BFR|Participants will begin BFR therapy as early as 2 weeks after surgery. The initial 2 weeks after surgery, or prior to initiation of BFR will consist of the physical therapy following the surgeon's postoperative protocol.
88849425|NCT04528992|Active Comparator|Physical Therapy without BFR|Participants will undergo standard physical therapy following the surgeon's postoperative protocol.
88849426|NCT04482270|Experimental|Fezolinetant: Mild Hepatic Impairment|Participants will receive a single oral dose of fezolinetant under fasting conditions on Day 1.
88849427|NCT04482270|Experimental|Fezolinetant: Moderate Hepatic Impairment|Participants will receive a single oral dose of fezolinetant under fasting conditions on Day 1.
88849428|NCT04482270|Experimental|Fezolinetant: Normal Hepatic Function|Participants will receive a single oral dose of fezolinetant under fasting conditions on Day 1.
88849429|NCT04476849|Experimental|Fezolinetant: Mild renal impairment|Participants will receive a single oral dose of fezolinetant under fasting conditions on Day 1.
88849430|NCT04476849|Experimental|Fezolinetant: Moderate renal impairment|Participants will receive a single oral dose of fezolinetant under fasting conditions on Day 1.
88849431|NCT04476849|Experimental|Fezolinetant: Severe renal impairment|Participants will receive a single oral dose of fezolinetant under fasting conditions on Day 1.
88849432|NCT04476849|Experimental|Fezolinetant: Normal renal function|Participants will receive a single oral dose of fezolinetant under fasting conditions on Day 1.
88849433|NCT04472598|Experimental|Navitoclax + Ruxolitinib|Participants will receive Navitoclax in combination with Ruxolitinib
88849434|NCT04472598|Active Comparator|Placebo for Navitoclax + Ruxolitinib|Participants will receive placebo for Navitoclax and Ruxolitinib
88849435|NCT04471909|Experimental|Chronic Dissection|
88849436|NCT04471909|Experimental|Aneurysm|
88849437|NCT04471909|Experimental|Penetrating Aortic Ulcer and/or Intramural Hematoma|
88849438|NCT04431258|Experimental|Arm A) ABTL0812 + FOLFIRINOX|"FOLFIRINOX will be dosed according to the standard following regimen:~oxaliplatin 85 mg/m2, administered as 2-hour iv infusion~leucovorin 400 mg/m2, administered as 2-hour iv infusion~irinotecan 180 mg/m2, administered as 1.5-hour iv infusion~fluorouracil 2400 mg/m2, administered as 46-hour iv infusion every 2 weeks (=1 cycle) until disease progression or unacceptable toxicities.~ABTL0812 will be administered daily at its RP2D. ABTL0812 will be administered as single agent during a run-in period of one week before starting the first cycle of FOLFIRINOX, then daily during chemotherapy cycles. Also, ABTL0812 will be maintained once chemotherapy is discontinued, if ABTL0812 is tolerated and if the patient is in response or stable disease."
88849439|NCT04431258|Experimental|Arm B) PLACEBO + FOLFIRINOX|"FOLFIRINOX will be dosed according to the standard following regimen:~oxaliplatin 85 mg/m2, administered as 2-hour iv infusion~leucovorin 400 mg/m2, administered as 2-hour iv infusion~irinotecan 180 mg/m2, administered as 1.5-hour iv infusion~fluorouracil 2400 mg/m2, administered as 46-hour iv infusion every 2 weeks (=1 cycle) until disease progression or unacceptable toxicities.~Placebo will be administered at the same volume than ABTL0812 in arm A) FOLFIRINOX, then daily during chemotherapy cycles. Also, placebo will be maintained once chemotherapy is discontinued."
88849440|NCT04430790|Experimental|Doxapram|Blinded doxapram (2mg/ml, in glucose 5%) loading dose of 2.0 to 2.5 mg/kg administered in 5 to 10 minutes, followed by a continuous infusion of 0.5 - 1.0 mg/kg/hr ('www.kinderformularium.nl') as long as needed. Therapy is down titrated or stopped based on the patients' respiratory condition. If endotracheal intubation is needed study drug is stopped. After extubation study drug may be restarted. Switch to gastro-enteral administration is allowed if no iv-access is needed for other reasons.
88849441|NCT04430790|Placebo Comparator|Placebo|Placebo (glucose 5%) will also be administered with a loading dose and continuous infusion (in equal amounts of fluid as in experimental arm) by intravenous or gastro-intestinal infusion. The treatment protocol will be equal to the protocol in the doxapram arm.
88849442|NCT04429607|Active Comparator|Erbium:YAG Laser|Solitary lesions will be randomized to a group, thus, a patient may receive all three treatments, each on different lesions. Patients will undergo two total treatment sessions at 2-6 week intervals.
88849443|NCT04429607|Active Comparator|PDL plus Nd:YAG|Solitary lesions will be randomized to a group, thus, a patient may receive all three treatments, each on different lesions. Patients will undergo two total treatment sessions at 2-6 week intervals.
88849444|NCT04429607|Active Comparator|ED&C treatment|Solitary lesions will be randomized to a group, thus, a patient may receive all three treatments, each on different lesions. Patients will undergo two total treatment sessions at 2-6 week intervals.
88849445|NCT04382898|Experimental|Part 1 (mCRPC) - dose titration|"BNT112 monotherapy~Enrollment into this arm is completed."
88849446|NCT04382898|Experimental|Part 2 Arm 1A (mCRPC) - expansion cohort|"BNT112 in combination with cemiplimab~Enrollment into this arm is completed."
88849447|NCT04382898|Experimental|Part 2 Arm 1B [1] (mCRPC) - expansion cohort|"BNT112 monotherapy~Enrollment into this arm is completed."
88849448|NCT04382898|Experimental|Part 2 Arm 2 (LPC) - expansion cohort|BNT112 in combination with cemiplimab
88849449|NCT04382898|Experimental|Part 2 Arm 3 (LPC) - expansion cohort|BNT112 monotherapy
88849450|NCT04382898|Experimental|Part 2 Arm 1B [2] (mCRPC) - expansion cohort|"Following progression after BNT112 monotherapy, patients in Arm 1b have the option to be treated with cemiplimab monotherapy~Enrollment into this arm is completed."
88849451|NCT04372238|Experimental|RAPIDS intervention|Participants randomized to receive the RAPIDS intervention will receive a fentanyl specific behavioral intervention and a brief behavioral intervention to increase willingness to use fentanyl test strips and engage in overdose risk reduction behaviors, in addition to standard OEND.
88849452|NCT04372238|Active Comparator|Standard OEND|In the control arm participants will receive standard overdose education and naloxone distribution (OEND).
88849453|NCT04360252|Experimental|Gracie Diet|Patients will have a nutritional consultation and will follow the Gracie diet for a month.
88849454|NCT04351113|Experimental|MITO-AO|Healthy older adult subjects ages 65-75 will take the supplement MITO-AO during a 5 day bed rest and will be assessed for vascular function independent of metabolism with passive leg movement (PLM), skeletal muscle bioenergetics independent of vascular constraints (i.e. blood flow and O2 supply) with phosphorous magnetic resonance spectroscopy (31P-MRS), and skeletal muscle bioenergetics under normal blood flow and O2 supply.
88849455|NCT04351113|Experimental|PB-125|Healthy older adult subjects ages 65-75 will take the supplement PB-125 during a 5 day bed rest and will be assessed for vascular function independent of metabolism with passive leg movement (PLM), skeletal muscle bioenergetics independent of vascular constraints (i.e. blood flow and O2 supply) with phosphorous magnetic resonance spectroscopy (P-MRS), and skeletal muscle bioenergetics under normal blood flow and O2 supply.
89376609|NCT03661658|Active Comparator|Inferior alveolar nerve lateralization with implant placement|
89376610|NCT03661658|Experimental|Using short dental implant with atrophic mandible|
89376611|NCT03661580|Experimental|Behavioural Activation|Participants in this arm receive 6 x weekly 1:1 sessions of BA delivered by a trained drugs and alcohol worker at the CDAT service. At the end of the 6-week intervention period participants will be referred back to their usual caseworker at the CDAT service, though they will be offered two BA booster sessions with their BA worker at 2-3 weeks and 4-5 weeks post-treatment. All participants in this arm will continue to have access to Treatment as Usual (i.e. prescribing) as required throughout the intervention period.
89376612|NCT03661580|Active Comparator|Treatment as Usual|Participants in this arm will receive no change to the care they usually receive at the CDAT service.
89376613|NCT03661502|Experimental|variable tidal volume ventilation (VVV)|the intervention is using a ventilation mode with variable tidal volume. The average tidal volume is 6 ml/kg and respiratory rate adapted to reach an end tidalCO2 concentration between 30 and 50 mmHg. Lung recruitment is given when dynamic lung compliance drops below 40. No drug is given. No other treatment or intervention is given.
89376614|NCT03661502|Experimental|Pressure controlled ventilation (PCV)|the intervention is using ventilation mode with constant pressure and constant tidal volume. The tidal volume is 6 ml/kg and respiratory rate is adapted to reach end tidal CO2 concentrations between 30 and 50 mmHg. Lung recruitment is given when dynamic lung compliance drops below 40. No drug is given. No other treatment or intervention is given.
89376615|NCT02989610|Experimental|Omnidirectional followed by directional DBS|Omnidirectional DBS is used for the first 3 months in all subjects, unless not tolerated. Directional DBS is used for months 3-6 in all subjects with a directional DBS lead. Primary endpoint is based on double-blind testing of omnidirectional vs. directional DBS in randomized order at 3-month follow-up visit.
89376616|NCT01372774|Active Comparator|Arm I - WBRT|Patients undergo whole brain radiotherapy (WBRT) once a day, 5 days a week, for approximately 3 weeks. Patient observation/follow up occurs at week 12 and months 6, 9, 12, 16 and 24 post registration/randomization. Event monitoring occurs every 6 months until 5 years post registration/randomization.
88849456|NCT04351113|Placebo Comparator|Placebo|Healthy older adult subjects ages 65-75 will take placebo during a 5 day bed rest and will be assessed for vascular function independent of metabolism with passive leg movement (PLM), skeletal muscle bioenergetics independent of vascular constraints (i.e. blood flow and O2 supply) with phosphorous magnetic resonance spectroscopy (P-MRS), and skeletal muscle bioenergetics under normal blood flow and O2 supply.
88849457|NCT04349644|Experimental|SENSE Theatre|A peer-mediated, theatre-based intervention designed to improve social cognition and behavior.
88849458|NCT04349644|No Intervention|Waitlist Control Group|This group will not receive the intervention during the testing phase of the intervention but will eventually receive the theatre intervention.
89376617|NCT01372774|Experimental|Arm II - SRS|Patients undergo stereotactic radiosurgery (SRS) using a gamma knife or a linear accelerator procedure. Patient observation/follow up occurs at week 12 and months 6, 9, 12, 16 and 24 post registration/randomization. Event monitoring occurs every 6 months until 5 years post registration/randomization.
89376618|NCT04055402|Experimental|EMA group|Participate in the baseline survey, 2-week ecological momentary assessments and a 1-month follow-up survey
89376619|NCT04055402|Active Comparator|Control group|Participate in the baseline survey,and a 1-month follow-up survey
89182002|NCT03475953|Experimental|Phase 2 : cohort A' Regorafenib low-dose + Avelumab|Treatment by Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
89182003|NCT03475953|Experimental|Phase 2 : cohort J Regorafenib + Avelumab|Treatment by Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
88849459|NCT04333290|Experimental|Single Arm: Healthy subjects|The PET radiotracer Myeliviz ([11C]MeDAS) will be administered to healthy subjects twice and PET scans will be obtained each time. This will allow assessment of the PET image quality, PET scan reproducibility and radiotracer distribution.
88849460|NCT04316585|Experimental|Participants receiving GSK2982772 960 mg|Participants will receive GSK2982772 960 mg oral tablets once daily for 12 weeks.
88849461|NCT04316585|Placebo Comparator|Participants receiving placebo|Participants will receive GSK2982772 matching placebo oral tablets once daily for 12 weeks.
88849462|NCT04298450|Experimental|Active SMS Intervention|Participants assigned to the experimental arm will receive the active SMS intervention. Participants in the active intervention group who consent to participate will be asked to complete a web-based survey. Based on survey findings, purposive sampling will be used to select a subsample of 12 to 20 participants for qualitative interviews.
88849463|NCT04298450|Sham Comparator|Sham SMS|Participants assigned to the sham comparator will receive the sham SMS intervention. They will not be re-contacted.
88849464|NCT04283461|Experimental|Arm 1|25 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants from 18-55 years of age. N=15 (4 sentinel, 11 non-sentinel)
88849465|NCT04283461|Experimental|Arm 10|50 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants from 18-55 years of age. N=15.
88849466|NCT04283461|Experimental|Arm 11|50 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants from 56-70 years of age. N=10.
89182004|NCT03475953|Experimental|Phase 2 : cohort K Regorafenib + Avelumab|Treatment by Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
89182005|NCT03475953|Experimental|Phase 2 : cohort L Regorafenib + Avelumab|Treatment by Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
89376620|NCT04055480|Active Comparator|Closed-loop using standard rapid-acting insulin|"Unsupervised home use of day and night hybrid closed loop insulin delivery system (CamAPS FX) for 8 weeks using standard rapid-acting insulin~The CamAPS FX closed-loop system comprises~Dana insulin pump (Diabecare, Sooil, Seoul, South Korea) Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA) An Android smartphone hosting CamAPS FX Application with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump Glooko/Diasend cloud upload system to monitor CGM/insulin data."
89376621|NCT04055480|Experimental|Closed-loop using faster insulin aspart|"Unsupervised home use of day and night hybrid closed loop insulin delivery system (CamAPS FX) for 8 weeks using faster insulin aspart~The CamAPS FX closed-loop system comprises~Dana insulin pump (Diabecare, Sooil, Seoul, South Korea) Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA) An Android smartphone hosting CamAPS FX Application with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump Glooko/Diasend cloud upload system to monitor CGM/insulin data."
89376622|NCT03660800|Experimental|CTAP101 Capsules 450mcg/weekly fasted|
89376623|NCT03660800|Experimental|CTAP101 Capsules 900mcg/weekly fasted|
89376624|NCT03660800|Experimental|CTAP101 Capsules 1800mcg/weekly fasted|
89376625|NCT03660800|Experimental|CTAP101 Capsules 900mcg/weekly fed|
89376626|NCT03158090||Surgical treatment|The subject was received transnasal butterfly surgery.
89376627|NCT03158090||Drug therapy|The subject was received drug treatment including somatostatin analogues such as sandostatin and lanreotide, dopamine receptor agonists and GH receptor antagonists.
89376628|NCT03158090||Radiotherapeutics|he subject was received radiotherapy methods including radiotherapy, linear accelerator X knife, gamma knife and so on.
89376629|NCT02670538|Experimental|Cariprazine 3.0 mg|Following a 7 to 14 days screening/washout period, cariprazine 1.5 milligrams (mg) capsule, one per day, orally for 2 weeks increased to cariprazine 3.0 mg capsule, one per day orally beginning on Day 15 for 4 weeks.
89376630|NCT02670538|Experimental|Cariprazine 1.5 mg|Following a 7 to 14 days screening/washout period, cariprazine 1.5 mg capsule, one per day, orally for 6 weeks.
89376631|NCT02670538|Placebo Comparator|Placebo|Following a 7 to 14 days screening/washout period, matching placebo capsule, one per day, orally for 6 weeks.
89376632|NCT03131414||Irritable bowel syndrome|"A total of 2000 patients with IBS who have met Rome IV criteria are 13 years of age or older will be consented and recruited for this study.~IBS patients will be categorized into diarrhea predominant IBS (IBS-D), constipation predominant IBS (IBS-C) or alternating constipation and diarrhea (IBS-A) or unclassified IBS (IBS-U). A detailed diet history will be obtained and gastrointestinal microbiome will be evaluated."
89376633|NCT03131414||Ulcerative colitis|"2000 CD and 2000 UC cases over the age of 4 years will be enrolled.~Montreal Classification will be used for adult UC patients, and the Paris classification for pediatric UC. The research coordinator will conduct a chart review to confirm date of diagnosis and maximal phenotype at time of enrolment. A detailed diet history will be obtained and gastrointestinal microbiome will be evaluated."
88849467|NCT04283461|Experimental|Arm 12|50 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants 71 years of age or older. N=10.
88849468|NCT04283461|Experimental|Arm 13|10 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants from 18-55 years of age. N=15.
88849469|NCT04283461|Experimental|Arm 14|Optional third mRNA-1273 vaccination sub-study. 100 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle after Day 209 in participants from Arm 1,4,7,10, 11, and 12 from 18 years of age or older. N=70.
88849470|NCT04283461|Experimental|Arm 15|Optional third mRNA-1273 vaccination sub-study. 100 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle no later than Day 394 in participants from Arm 2,3,5 and 8 from 18 years of age or older. N=50.
88849471|NCT04283461|Experimental|Arm 2|100 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants from 18-55 years of age. N=15 (4 sentinel, 11 non-sentinel).
88849472|NCT04283461|Experimental|Arm 3|250 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants from 18-55 years of age. N=15 (4 sentinel, 11 non-sentinel).
88849473|NCT04283461|Experimental|Arm 4|25 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants from 56-70 years of age. N=10.
88849474|NCT04283461|Experimental|Arm 5|100 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants from 56-70 years of age. N=10.
88849475|NCT04283461|Experimental|Arm 6|250 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants from 56-70 years of age. N=10.
89376634|NCT03131414||Crohn's disease|"2000 CD cases over the age of 4 years will be enrolled.~Montreal Classification will be used for adult CD patients, and the Paris classification for pediatric CD. The research coordinator will conduct a chart review to confirm date of diagnosis and maximal phenotype at time of enrolment. A detailed diet history will be obtained and gastrointestinal microbiome will be evaluated."
89376635|NCT03131414||Healthy control|"A total of 2000 healthy family members, relative or friends of cohort participants over the age of 4 will be consented and recruited for this study.~Each control that agrees to participate will undergo an initial screening questionnaire to confirm that they are healthy and have no gastrointestinal symptoms using the ROME IV Questionnaire. A detailed diet history will be obtained and gastrointestinal microbiome will be evaluated."
89376636|NCT03114592|No Intervention|Standard Care|"Complete a survey asking about kidney function and participant demographics.~Receive a one-month follow-up call (one month after hospital discharge date) and complete a phone survey about patient kidney function after discharge"
89376637|NCT03114592|Experimental|mHealth Tool|"Complete a survey asking about kidney function and participant demographics.~Review a 15-20 minute educational tool on a tablet about kidney health~Receive a one-month follow-up call (one month after hospital discharge date) and complete a phone survey about patient kidney function after discharge"
89376638|NCT03547583|Experimental|Vericiguat up to 10 mg|Subjects will receive vericiguat (BAY1021189) for 24 weeks, starting at 2.5 mg once daily at randomization and up-titrated to 5 mg at week 2, to 10 mg at week 4, with sham titration at week 6.
88849476|NCT04283461|Experimental|Arm 7|25 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants 71 years of age or older. N=10.
88849477|NCT04283461|Experimental|Arm 8|100 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants 71 years of age or older. N=10.
88849478|NCT04283461|Experimental|Arm 9|250 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants 71 years of age or older. N=10.
89376639|NCT03547583|Experimental|Vericiguat up to 15 mg|Subjects will receive vericiguat (BAY1021189) for 24 weeks, starting at 2.5 mg once daily at randomization and up-titrated to 5 mg at week 2, to 10 mg at week 4, and to 15 mg at week 6.
89376640|NCT03547583|Placebo Comparator|Placebo|Subject will receive placebo for 24 weeks, once daily, starting sham up-titration at weeks 2, 4, and 6.
89376641|NCT02391298|Experimental|Mindfulness Meditation|All participants will complete baseline assessments of variables of interest (i.e., levels of mindfulness, contrast sensitivity, cognitive inhibition, and emotional regulation skills). Participants will then undergo 8 weeks of self-directed mindfulness training with re-assessments of variables of interest completed at week 4 and week 8. All participants will be given access to meditation recordings and asked to practice the exercises in a progressive manner from mindfulness of breath to a loving/kindness meditation (each exercise twice per week). Participants will be asked at the end of study for feedback on the acceptability of the program.
89376642|NCT02391532|Active Comparator|L. reuteri DSM 17938/ATCC PTA|L. reuteri DSM 17938/ATCC PTA lozenges twice daily for 12 weeks
89376643|NCT02391532|Placebo Comparator|Placebo|Placebo lozenges twice daily for 12 weeks
89376644|NCT03114202|Experimental|Intervention group|Intensive nutritional counseling: once they are admitted to the study and once a week during radiotherapy
89376645|NCT03114202|Other|Control group|Standard care: when there is demand, usually 1 to 2 times during radiotherapy
89376646|NCT03727763|Experimental|FIVC group|Irinotecan 180mg/m2 iv gtt (14 days per course) leucovorin 400mg/m2 iv gtt (14 days per course) 5-fluorouracil 400mg/m2 iv (14 days per course) 5-fluorouracil 2400 mg/m2 46h (14 days per course) vemurafenib 960mg po bid cetuximab 500mg/m2 iv gtt (14 days per course)
89376647|NCT02391220|Active Comparator|Symbiotic|LCA symbiotic fermented milk, 180 g pot, twice daily.
89376648|NCT02391220|Placebo Comparator|Placebo|heat-treated fermented milk, 180 g pot, twice daily.
89376649|NCT03724565||Endoscopic procedural area|air quality check of endoscopic procedural room
88849479|NCT04260854|Active Comparator|Bupivacaine HCl|Immediately prior to surgical wound closure, participants randomized to the bupivacaine arm will be injected with bupivacaine HCl along the closure site.
88849480|NCT04260854|Placebo Comparator|Saline|Immediately prior to surgical wound closure, participants randomized to saline, will receive saline injections along the closure site.
88849481|NCT04257474||Assessing Health Services Utilization Model (HSUM)|150 women with a high lifetime breast cancer risk will be recruited from mammography and primary care clinics. Researchers will assess HSUM factors influencing screening breast MRI utilization. Results will identify participant-level HSUM factors significantly associated with screening outcomes.
88849482|NCT04257474||Qualitative Interviews|Researchers will randomly select 30 participants from group 1 and will use semi-structured qualitive interviews exploring factors impacting utilization of screening breast MRI
88849483|NCT04242771|Experimental|Experimental group|Participants will utilize a daily sleep program available within a widely used smartphone app, which includes seven soundtracks (10-15min each) for guided mindfulness practice at bedtime. Techniques include breathing exercises, mental imagery, awareness of body and mind, and muscle and body relaxation.
88849484|NCT04242446|Experimental|Bimekizumab dosing regimen 1|Subjects participating in the study will receive assigned bimekizumab dosing regimen 1 during the Treatment Period.
88849485|NCT04242446|Experimental|Bimekizumab dosing regimen 2|Subjects participating in the study will receive assigned bimekizumab dosing regimen 2 during the Treatment Period.
88849486|NCT04242446|Experimental|Bimekizumab dosing regimen 3|Subjects participating in the study will receive assigned bimekizumab dosing regimen 3 during the Treatment Period.
88849487|NCT04242446|Placebo Comparator|Placebo Group|Subjects randomized to this arm will receive placebo during the Initial Treatment Period and bimekizumab during the Maintenance Treatment Period.
88849488|NCT04236700||beach workers|"Workers must undergo clinical examinations of the upper and lower lips, performed by previously calibrated researchers, through semi-technical inspection and palpation maneuvers, in order to identify injuries. Photo cameras can be used to improve the visibility of the lips using the image enhancement feature, to confirm the diagnosis. The clinical examination will include: dryness, atrophy, scaly lesions, lip swelling, erythema, ulcerations, cloudy demarcations between the vermilion of the lip and skin, demarcated folds along the lip, white spots or plaques, crusts, stained or pale areas.~They should be evaluated with the application of a previously validated questionnaire containing information related to personal data, information on occupation and health was completed according to the responses of the volunteers. The OHIP-14 quality of life questionnaire will be applied together"
89376650|NCT03724565||Recovery area for patients|air quality check of recovery area for patients in endoscopic unit
89376651|NCT03724565||Cleansing area for equipments|air quality check of cleansing area for equipments in endoscopic unit
89376652|NCT02670382|Experimental|EPA intervention|Subjects randomized to receive 3000 mg EPA/day, provided as EPA 750 mg/capsule will be instructed to take 2 capsules by mouth in the morning and 2 in the evening with meals for 10 weeks.
89376653|NCT02670382|Experimental|DHA intervention|Subjects randomized to 3000 mg DHA/day provided as DHA 750 mg/capsule will instructed to take 2 capsules by mouth in the morning and 2 in the evening with meals for 10 weeks.
88849489|NCT04195763||Participants with Pediatric-onset HPP|Adult participants diagnosed with pediatric-onset HPP, newly prescribed treatment with asfotase alfa, and registered in the patient support program managed by OneSource.
88849490|NCT04189146|Other|Inner Engineering Intervention|The intervention investigators propose for the study includes an Online Course with 7 modules, or a 10 hours long course, and a 1-2 day In-Person Course, in which participants will learn a simple 21 minute practice called Shambhavi Mahamudra Kriya, also known as Shambhavi Kriya.
88849491|NCT04184089|Experimental|Control group|High flow rate of 5 L/min and FiO2 of 40%
88849492|NCT04184089|Experimental|Group 1|Nasal cannula at flow rate of 15 L/min and FiO2 of 40%
88849493|NCT04184089|Experimental|Group 2|Nasal cannula at flow rate of 60 L/min and FiO2 of 40%
88849494|NCT04180215|Experimental|Ph I, Group 1 and Group 2|Patients with HPV 16+ HNSCC or Non-HNSCC who had tumor progression or recurrence on standard of care therapy.
89182006|NCT03475953|Experimental|Phase 2 : cohort M Regorafenib + Avelumab|Treatment by Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
89182007|NCT03475953|Experimental|Phase 2 : cohort N Regorafenib + Avelumab|Treatment by Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
89182008|NCT03475953|Experimental|Phase 2 : cohort O Regorafenib + Avelumab|Treatment by Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
89182009|NCT03475953|Experimental|Phase 2 : cohort P Regorafenib + Avelumab|Treatment by Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
89182010|NCT04106375|Experimental|Intervention Group|Women with a history of depression and no other mental health disorders undergoing Mindfulness Based Cognitive Therapy.
89182011|NCT04106375|No Intervention|Control|Healthy women with no prior history of depression or other mental health disorders as a control group for time-repetition effects on brain activity and task performance
89182012|NCT04108325|Experimental|YY-20394|YY-20394 tablets will be given daily for 28 days in 28-day cycles until there appears evidence of progressive disease, intolerable toxicity, or the subject discontinues from the study treatment for other reasons.
89182013|NCT00582933|Experimental|1|25 research participants with HLA Identical Related Donor using PBSC, 6 with BMT
89182014|NCT00582933|Experimental|2|70 research participants with HLA-Matched Unrelated Donor using PBSC, 17 with BMT
89182015|NCT00582933|Experimental|3|25 research participants with HLA-Mismatched Related Donor using PBSC, no BMT
89182016|NCT00791765|Experimental|Placebo BIW/Etanercept 50 mg BIW|Participants received placebo subcutaneous injections twice per week (BIW) for the first 12 weeks of the study. From Week 12 to Week 24, participants received etanercept 50 mg BIW.
89182017|NCT00791765|Experimental|Etanercept 50 mg BIW/Etanercept 50 mg QW|Participants received etanercept 50 mg by subcutaneous injection twice per week (BIW) for the first 12 weeks of the study. From Week 12 to Week 24, participants received etanercept 50 mg once per week (QW) and placebo once per week.
89182018|NCT03450603||stable COPD|Chronic obstructive pulmonary disease (COPD) was confirmed if the patient had a baseline post-bronchodilator FEV1 less than 80% of the reference value and forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC) quotient of less than 70%.Select patients with COPD without acute attack within three months．
89182019|NCT03450603||exacerbation of COPD|Exacerbation was defined as an event in the natural course of the disease characterized by a change in the patient's baseline dyspnea, cough, and/or sputum that was beyond normal day to day variations and may have warranted a change in regular medication in a patient with underlying COPD.
89182020|NCT00789191|Experimental|Comb|Combination therapy of insulin detemir once daily plus sitagliptin added to subject's own pre-trial metformin treatment
89182021|NCT00789191|Active Comparator|Sita|Monotherapy of sitagliptin once daily added to subject's own pre-trial metformin and/or sulphonylurea (SU) treatment
89182022|NCT03646149||Housing Skills Training Group|Homeless Veterans with serious mental illness who are inpatient at the VA Greater Los Angeles Domiciliary or enrolled in a VA Supported Housing (VASH) program and participating in a Housing Skills Training Group as part of routine clinical care.
89182023|NCT04967235|Active Comparator|Conventional Exercise-based Cardiac Rehabilitation|This interventional arm consists of a conventional exercise-based cardiac rehabilitation, composed of initial rest, warm-up, treadmill aerobic exercise, orthostatic passive recovery, and supine passive recovery.
89182024|NCT04967235|Experimental|Dance-Based Cardiac Rehabilitation|This interventional arm consists of a new dance-based cardiac rehabilitation, composed of initial rest, warm-up, dance therapy, orthostatic passive recovery and supine passive recovery.
89182025|NCT02579577||Decision making cohort|Any people identified as being important within the network of care for children with life-limiting illnesses.
88849495|NCT04180215|Experimental|Ph I, Group 3 and Group 4|Patients with HPV 16+ HNSCC or Non-HNSCC who had tumor progression or recurrence on standard of care therapy.
88849496|NCT04180215|Experimental|Ph II, Group B|Patients with HPV 16+ HNSCC who are eligible to receive immune checkpoint inhibitor as part of standard of care.
89182026|NCT05016843|Experimental|CBT, 8 weeks and access to forum.|
89182027|NCT05016843|Experimental|CBT, 16 weeks and access to forum.|
89182028|NCT05016843|Experimental|CBT, 8 weeks and no access to forum.|
89182029|NCT05016843|Experimental|CBT, 16 weeks and no access to forum.|
89182030|NCT05016843|Experimental|Psychodynamic therapy, 8 weeks and access to forum.|
89182031|NCT05016843|Experimental|Psychodynamic therapy, 16 weeks and access to forum.|
89182032|NCT05016843|Experimental|Psychodynamic therapy, 8 weeks and no access to forum.|
89182033|NCT05016843|Experimental|Psychodynamic therapy, 16 weeks and no access to forum.|
89182034|NCT05016843|Experimental|Waitlist, 8 weeks and access to forum.|
89182035|NCT05016843|Experimental|Waitlist, 16 weeks and access to forum.|
89182036|NCT05016843|Experimental|Waitlist, 8 weeks and no access to forum.|
89182037|NCT05016843|Experimental|Waitlist, 16 weeks and no access to forum.|
88849497|NCT04180215|Experimental|Ph II, Group E|Patients with HPV 16+ HNSCC who are eligible to receive pembrolizumab as part of 1L standard of care.
88849498|NCT04180215|Experimental|Ph II, Group F|Patients with HPV 16+ cancers who had tumor progression or recurrence on standard of care therapy and who are eligible to receive pembrolizumab as part of 2L+ standard of care..
88849499|NCT04180215|Experimental|Ph I, sub-study|Patients with HPV 16+ HNSCC who had tumor progression or recurrence on standard of care therapy
88849500|NCT04162938|Experimental|Patient-Centered Electronic App Group|Patients assigned to the intervention group will receive individualized reports regarding patients' HCV disease progress/liver fibrosis staging by a Fibrosis-4 score using the personalized HCV educational app. The individualized report will also include comprehensive knowledge to fill the gap on general HCV information, natural history of the disease, and care and treatment, if there is any, as well as level of interest in receiving HCV care based on patients' response to the short survey questionnaires on the tablet. Patients will also receive the investigators' HCV program pamphlet regarding HCV infection and disease progression, treatment, as well as information regarding clinics available for HCV care in Baltimore. Patients will receive standard of care, routine HCV LTC services from the investigators' ED HCV LTC program staff.
88849501|NCT04162938|No Intervention|Reference Group|Patients assigned to the reference group will receive the investigators' current 'static' standard of care HCV program pamphlet regarding HCV infection and disease progression, treatment, as well as information regarding clinics available for HCV care in Baltimore City. Patients will also receive standard of care, routine HCV LTC services from the investigators' ED HCV LTC program staff.
88849502|NCT04142632||long term evaluation of hypospadias surgery|
88849503|NCT04131270|Experimental|Planning + Education|"3 education sessions + 1 planning session (integrated into the 3rd education session); delivered face-to-face over 3 weeks (after the baseline measurement), individually.~Planning: The planning materials and forms have sections: (a) instructions of what should be included in a good plan (the when, where, and how components), (b) formulating action and coping plans. Action plans (referring to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties) will be formed. After forming the plans individually, experimenters will discuss the plans with the participants."
88849504|NCT04131270|Active Comparator|Education|"3 education sessions; delivered face-to-face over 3 weeks (after the baseline measurement), individually.~The education includes extended physical activity and sedentary behavior education using participant-educator discussions and printed materials."
88849505|NCT04114656|Placebo Comparator|Participants receiving Placebo|All participants will receive a single dose of placebo in either one or two of the three study periods, as per the randomization schedule.
88849506|NCT04114656|Experimental|Participants receiving GSK3858279|All participants will receive a single dose of GSK3858279 in either one or two of the three study periods, as per the randomization schedule.
89182038|NCT04108013|Experimental|SHR-1210+Carboplatin+Paclitaxel-albumin|Subject will receive SHR-1210 200mg every 3 weeks, carboplatin AUC 5 on Day 1 of each 21 day, Paclitaxel-albumin 130mg/m2 on Day 1 and Day 8 of each 21 day, 2 cycles.
89182039|NCT04108013|Active Comparator|Carboplatin+Paclitaxel-albumin|Subject will receive carboplatin AUC 5 on Day 1 of each 21 day, Paclitaxel-albumin 130mg/m2 on Day 1 and Day 8 of each 21 day, 2 cycles.
89182040|NCT04105985|Experimental|Kovanaze Nasal Spray (endodontics)|Adults (>18 years) who require non-surgical root canal treatment in maxillary anterior teeth
89182041|NCT04105985|Active Comparator|Articaine Injections (endodontics)|Adults (>18 years) who require non-surgical root canal treatment in maxillary anterior teeth
89182042|NCT04074213||Haematologic malignancies with clozapine|Cases reported in the World Health Organization (WHO) database of patients treated by Clozapine, with a chronology compatible with the drug toxicity
89182043|NCT04110587|Placebo Comparator|arthroscopy|Temporomandibular joint arthroscopy is performed under general anesthesia by the same expert temporomandibular joint arthroscopy surgeon. Lysis and Lavage is performed in the upper joint space in all cases. Ringer's lactate is use as irrigation fluid. All participants receive Amoxicillin / Clavulanic Acid, 1g I.V. and Dexamethasone, 4 mg I.V. (Intraoperative); as well as Amoxicillin / clavulanic acid, 500/125 mg / 8h / 5 days by mouth; Diclofenac 100 mg / 12h / 5 days by mouth; and Metamizol 575 mg / 8h by mouth (Post-operatively). Soft diet and a home exercise program are implemented in all patients after 24 hours post-operative.
89182044|NCT04110587|Active Comparator|arthroscopy plus hyaluronic Acid|Temporomandibular joint arthroscopy is performed under general anesthesia by the same expert temporomandibular joint arthroscopy surgeon. Lysis and Lavage is performed in the upper joint space in all cases. Ringer's lactate is use as irrigation fluid. All participants receive Amoxicillin / Clavulanic Acid, 1g I.V. and Dexamethasone, 4 mg I.V. (Intraoperative); as well as Amoxicillin / clavulanic acid, 500/125 mg / 8h / 5 days by mouth; Diclofenac 100 mg / 12h / 5 days by mouth; and Metamizol 575 mg / 8h by mouth (Post-operatively). Soft diet and a home exercise program are implemented in all patients after 24 hours post-operative. An hyaluronic acid injection of 1 mL (Durolane®, 20 mg / mL, Zambon, Barcelona, Spain) at the end of arthroscopy that was only performed in this arm.
89182045|NCT03625869|No Intervention|Control|This is the actual control group receiving conventional therapy, ie. percutaneous coronary intervention.
89182046|NCT03625869|Experimental|PICSO|This arm will be treated with Pressure controlled intermittent Coronary Sinus Occlusion (PiCSO) in addition to conventional therapy (percutaneous coronary intervention).
89182047|NCT03386253|Experimental|active tDCS|Participants receive active tDCS for five consecutive days before attempting to quit smoking
89182048|NCT03386253|Sham Comparator|sham tDCS|Participants receive sham tDCS for five consecutive days before attempting to quit smoking
88849507|NCT04103034|Experimental|BT200 0.18mg|Subjects will receive a single subcutaneous dose of BT200 0.18mg
89182049|NCT04074915|Placebo Comparator|Placebo rinse|Normal saline
88849508|NCT04103034|Experimental|BT200 0.6mg|Subjects will receive a single subcutaneous dose of BT200 0.6mg
88849509|NCT04103034|Experimental|BT200 1.8mg|Subjects will receive a single subcutaneous dose of BT200 1.8mg
88849510|NCT04103034|Experimental|BT200 6.0mg|Subjects will receive a single subcutaneous dose of BT200 6.0mg
88849511|NCT04103034|Experimental|BT200 12.0mg|Subjects will receive a single subcutaneous dose of BT200 12.0mg
88849512|NCT04103034|Experimental|BT200 24.0mg|Subjects will receive a single subcutaneous dose of BT200 24.0mg
88849513|NCT04103034|Experimental|BT200 24.0mg rep|Subjects will receive a single subcutaneous (SC) dose of BT200 24.0mg by gradual SC infusion
88849514|NCT04103034|Placebo Comparator|Placebo SAD|Subjects will receive a single subcutaneous dose of placebo
88849515|NCT04103034|Experimental|BT200 loading dose 12.0mg, maintenance doses of 12.0 mg|Subjects will receive an initial subcutaneous loading doses of BT200 12.0mg followed by 4 weekly (every 7 days) maintenance doses of BT200 12.0mg
88849516|NCT04103034|Experimental|BT200 loading doses 24.0mg, maintenance doses of 24.0 mg|Subjects will receive an initial subcutaneous loading dose of BT200 24mg followed by 4 weekly (every 7 days) maintenance doses of BT200 24mg
88849517|NCT04103034|Placebo Comparator|Placebo MAD|Subjects will receive an initial subcutaneous loading dose of Placebo followed by 4 weekly (every 7 days) maintenance doses of placebo
88849518|NCT04103034|Experimental|BT200 48.0mg + desmopressin challenge|Subjects will receive a single subcutaneous dose of BT200 48.0mg followed by IV infusion (over 30 min) of 0.3µg/kg desmopressin administered 24 hours after single dose of BT200
89182050|NCT04074915|Experimental|Chlorhexidine mouth rinse|Chlorhexidine mouth rinse
88849519|NCT04103034|Placebo Comparator|Placebo + desmopressin challenge dose|Subjects will receive a single subcutaneous dose of placebo followed by IV infusion (over 30 min of 0.3µg/kg desmopressin administered 24 hours after single dose of placebo
88849520|NCT04103034|Placebo Comparator|Placebo infusion|Subjects will receive a single IV dose of placebo administered over 24 hours
88849521|NCT04103034|Experimental|BT200 36.0mg|Subjects will receive a single subcutaneous (SC) dose of BT200 36.0mg by gradual SC infusion
88849522|NCT04103034|Experimental|BT200 48.0 mg|Subjects will receive a single subcutaneous dose (SC) of BT200 48.0mg by gradual SC infusion
88849523|NCT04103034|Experimental|BT200 18.0 mg|Subjects will receive a single subcutaneous (SC) dose of BT200 18.0mg by gradual SC infusion
88849524|NCT04103034|Experimental|BT200 24mg IV infusion|Subjects will receive a single IV dose of BT200 24mg administered over 24 hours
88849525|NCT04101084|Experimental|Rocking chair therapy|Rocking sessions in a safe rocking chair for 2 hours daily for six weeks
88849526|NCT04096586|Active Comparator|Red juice|Subjects consume 8 fl oz of red juice daily for 8 weeks
88849527|NCT04096586|Experimental|Watermelon juice|Subjects consume 8 fl oz of watermelon juice daily for 8 weeks
88849528|NCT04095442|Active Comparator|Cepacol|
88849529|NCT04095442|Sham Comparator|Tom's Natural Mouthwash|
88849530|NCT04090424|Experimental|NovoSorb BTM|Application of NovoSorb BTM to study lesions
88849531|NCT04090424|Active Comparator|Standard of Care|Application of the institution's standard of care to study lesions.
88849532|NCT04075266|Experimental|Cohort 1|Participants with a body weight from >/= 25 kg to < 40 kg (with at least 2 participants with a body weight from >/= 25 kg to </= 35 kg) will receive 300 milligram (mg) ocrelizumab
88849533|NCT04075266|Experimental|Cohort 2|Participants with a body weight >/= 40 kg (with at least 2 participants with a body weight >/= 40 kg but </= 50 kg) will receive 600 mg ocrelizumab
88849534|NCT04075266|Experimental|Cohort 3 (optional)|Based on PK, PD, safety, and tolerability data analyses of Cohorts 1 and 2, additional participants with a body weight from >/= 25 kg to < 40 kg may be enrolled and receive another dose level of ocrelizumab
88849535|NCT04075266|Experimental|Cohort 4 (optional)|Based on PK, PD, safety, and tolerability data analyses of Cohorts 1 and 2, additional participants with a body weight >/= 40 kg may be enrolled and receive another dose level of ocrelizumab
89182051|NCT04074915|Experimental|Test group|Chamomile mouth rinse
89182052|NCT05673525|Experimental|Treatment Group|
89182053|NCT02579733|Active Comparator|Azathioprine|Azathioprine (1.5mg/kg) po for 1 year
89182054|NCT02579733|Placebo Comparator|Sugar pill|Placebo drug identical to azathioprine (1.5mg/kg) po for 1 year
89182055|NCT03326193|Experimental|Participants receiving niraparib+ bevacizumab|Participants will be administered bevacizumab 15 milligram per kilogram (mg/kg) via a 30 minute (min) intravenous (IV) infusion on Day 1 of each 21-day cycle. Niraparib will be administered orally once a day continuously throughout each 21-day cycle (84-day cycle after amendment 2). On Day 1 of each cycle, niraparib will be administered upon completion of bevacizumab infusion. The starting dose of niraparib will be based on the participant's Baseline actual body weight or platelet count.
89182056|NCT02517099|Active Comparator|Pathological phenotype|Regular inhaled steroids- Beclometasone dipropionate 200mcg bd for 4 months OR antibiotic therapy- Co- amoxiclav (0.3ml/kg bd) or Azithromycin (10mg/kg od) for 4 weeks
89182057|NCT02517099|Active Comparator|Clinical guidelines|The children will be treated as directed by their Consultant Paediatrician. The treatment may include- regular inhaled steroids- beclometasone dipropionate 200mcg bd for 4 months OR antibiotic therapy- Co-amoxiclav (0.3ml/kg bd) or Azithromycin (10mg/kg od) for 4 weeks
89182058|NCT04073199|Active Comparator|Long Lever Group|This arm receive the protocolized treatment along with the long passive stretch of the Teres Major in Long Lever with the patient in supine position.
88849536|NCT04024462|Active Comparator|Arm A: Pertuzumab IV + Trastuzumab IV + Chemotherapy|Participants will receive 8 cycles of neoadjuvant chemotherapy: 4 cycles of doxorubicin plus cyclophosphamide (AC) once every 3 weeks (Q3W) followed by docetaxel Q3W for 4 cycles. Pertuzumab and trastuzumab will be given intravenously (IV) for 4 cycles Q3W concurrently with the taxane component of chemotherapy. After completing their neoadjuvant therapy, participants will undergo surgery. Thereafter, participants will receive an additional 14 cycles of pertuzumab IV and trastuzumab IV for a total of 18 cycles.
88849537|NCT04024462|Experimental|Arm B: Pertuzumab and Trastuzumab FDC SC + Chemotherapy|Participants will receive 8 cycles of neoadjuvant chemotherapy: 4 cycles of AC Q3W followed by docetaxel Q3W for 4 cycles. The pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) will be given subcutaneously (SC) for 4 cycles (Q3W) concurrently with the taxane component of chemotherapy. After completing their neoadjuvant therapy, participants will undergo surgery. Thereafter, participants will receive an additional 14 cycles of the PH FDC SC for a total of 18 cycles.
88849538|NCT04015869|Active Comparator|allopregnanolone|allopregnanolone
88849539|NCT04015869|Placebo Comparator|placebo|placebo
88849540|NCT04002661|Active Comparator|Arm 1 - Active|Participants will take flibanserin 100mg orally every night for approximately 3 months.
88849541|NCT04002661|Placebo Comparator|Arm 2 - Placebo|Participants will take a placebo orally every night for approximately 3 months.
88849542|NCT03971266|Experimental|Prevention (Fitbit, PRO diary)|Patients participant in movement assessment during 2 clinical trial visits. Patients also wear a Fitbit to track movements and complete a smartphone based PRO diary over 5-10 minutes to measure physical function, fatigue, sleep disturbance, social isolation, appetite, and body weight for up to 180 days.
88849543|NCT03957928|Active Comparator|Low fat cookies|Subjects consume 100 kcal of low fat cookies daily for 12 weeks.
88849544|NCT03957928|Experimental|Mango fruit|Subjects consume 100 kcal of mango fruit daily for 12 weeks.
88849545|NCT03956602|Active Comparator|Pretzels|Subjects consume pretzels to examine postprandial response
88849546|NCT03956602|Experimental|Brazil nuts|Subjects consume Brazil nuts to examine postprandial response
88849547|NCT03956602|Active Comparator|Potato chips|Subjects consume potato chips to examine postprandial response
88849548|NCT03956602|Experimental|Mixed nuts|Subjects consume mixed nuts to examine postprandial response
88849549|NCT03956602|Active Comparator|White bread|Subjects consume white bread to examine postprandial response
88849550|NCT03956602|Experimental|Dried mango|Subjects consume dried mango to examine postprandial response
88849551|NCT03956602|Experimental|Mango fruit|Subjects consume fresh mango to examine postprandial response
88849552|NCT03933800|Experimental|High flow nasal cannula (HFNC)|High flow nasal cannula therapy
88849553|NCT03933800|Active Comparator|Continuous positive airway pressure (CPAP)|Continuous positive airway pressure therapy
88849554|NCT03927105|Experimental|Nivolumab + Cabiralizumab|Nivolumab 240mg IV + Cabiralizumab 4mg/kg on day 1 of every 14 day cycle.
88849555|NCT03921047||Ancillary-correlative (next generation sequencing)|Patents undergo collection of blood samples before, on day 100, and 1 year after HSCT. Donors undergo collection of blood at the time of HSCT for RNA-based next generation sequencing of TCRA and TCRB genes.
88849556|NCT03909347|Experimental|PLAN (intervention)|Group 1 will receive the study intervention during the 6 months of the study, after the first baseline questionnaire. The intervention is as follows: participants will be asked to take part in a one-time, one-hour education in participants' home or any community location that is most convenient for the participants by a trained community health worker. An educational resource that participants can read at home will be provided at the end of education session. Participants' community health worker will call the participants monthly to identify barriers to dementia care and help participants and participants' elder with making an appointment or transportation to the health care facility, when participants request for assistance.
88849557|NCT03909347|Active Comparator|Standard of care (control)|Group 2 will receive a signs and treatment of dementia pamphlet by the Alzheimer's Association and will be referred to the elder's primary physician.
88849558|NCT03907410|Experimental|Arm 1: Incentives, plus reminders & feedback (IRF)|"There will be a run-in period to determine eligibility for randomization and collect baseline adherence data (Month 0).~During the Experiment period (Months 1-3), Arm 1 will receive the IRF intervention.~During the Observation period (Months 4-6), all the arms will have continued daily ICS monitoring to assess enduring effects of each arm - no IRF."
88849559|NCT03907410|Active Comparator|Arm 2: Reminders & feedback ONLY|"There will be a run-in period to determine eligibility for randomization and collect baseline adherence data (Month 0).~During the Experiment period (Months 1-3), Arm 2 will receive ONLY reminders and feedback, without nominal financial incentives.~During the Observation period (Months 4-6), all three arms will have continued daily ICS monitoring to assess enduring effects of each arm - no IRF."
88849560|NCT03907410|No Intervention|Arm 3 (Control)|"There will be a run-in period to determine eligibility for randomization and collect baseline adherence data (Month 0).~During the Experiment period (Months 1-3), Arm 3 will not receive any component of the IRF intervention.~During the Observation period (Months 4-6), all three arms will have continued daily ICS monitoring to assess enduring effects of each arm - no IRF."
88849561|NCT03878706||GLP1 and SGLT2i group|60 patients treated with a combination of liraglutide and empagliflozin. All subjects will undergo an echocardiographic study in order to estimate GLS as well as the twisting-untwisting of the left ventricle using speckle tracking imaging. PWV, AIx, SBPao and PPao with Arteriograph, Mobilograph and Complior, and perfused boundary region (PBR) of sublingual vessels using a high-resolution camera with Sideview Darkfield Imaging technique (Microscan, Glucockeck). PBR consists the cell-free space which is formed from the separation of red blood cells from plasma at the surface of the endothelial glycocalyx. Oxidative stress markers, vascular cell adhesion molecule (VCAM)-1, intercellular adhesion molecule (ICAM)-1, thrombomodulin, nitrites and nitrates, N-terminal pro B-type natriuretic peptide (NT-proBNP), growth differentiation factor (GDF)-15, blood glucose, glycosylated hemoglobin (HbA1c) and a full lipidemic profile will be measured before and at 6 and 12 months of treatment.
88875277|NCT02562924|Experimental|MEDIHONEY® and budesonide rinse group|"Days 0-7: Same as 1a.;~Days 7-91: 8oz saline/budesonide sinus rinse followed by 0.5oz of MEDIHONEY® in 50 cc of normal saline BID.~After day 91:~i. In case endoscopy shows any polyps, edema or discharge: Decrease volume to 4 oz budesonide/saline rinse followed with 50cc of the MEDIHONEY® rinse BID. Continue with this regimen till day 182.~ii. In case endoscopy shows no polyps, edema and discharge: Decrease volume to 4 oz budesonide/saline rinse followed with 50cc of the MEDIHONEY® rinse once a day.~Reevaluate at day 119:~In case endoscopy shows any polyps, edema or discharge: Return to the initial regimen as per 3.c.i till day 182.~In case endoscopy shows no polyps, edema and discharge: Continue as per 3.c.ii till day 182."
89376654|NCT02670382|Placebo Comparator|Placebo|3000 mg high oleic acid sunflower oil/day; 750 mg high oleic acid sunflower oil/capsule; subjects instructed to take 2 capsules by mouth in the morning and 2 in the evening with meals during 4 week long lead-in phase.
89376655|NCT01310621|No Intervention|No Lavage|Neonate randomized to this group will be managed as per the standard protocol in the neonatal ward. The evaluation of respiratory distress will be done using Downe's score at hourly intervals till 24 hrs, followed by 2 hourly intervals till 72 hrs and finally 4 hourly intervals till resolution of clinical distress.
89376656|NCT01310621|Experimental|Surfactant Lavage|The diluted surfactant is instilled into endotracheal tube over a period of 15 to 20 seconds. Once the instillation is complete, 5 manual breaths will be provided and infant will be repositioned supine. The suction catheter will be inserted and advanced to a position approximately 5mm past the end of endotracheal tube. Suction will be activated for no more than 10 seconds and would be temporarily halted earlier if the oxygen saturation value falls by > 5% of the prelavage value. The same shall be resumed once prelavage oxygen saturation has been restored. The infant's bed will now be moved back to horizontal position. Once the neonate is STABLE, suctioning will be again repeated. The total retrieved volume is measured and recorded.This procedure will be done in both right and left lateral decubitus position
88849562|NCT03878706||GLP1 group|60 patients treated with liraglutide. All subjects will undergo an echocardiographic study in order to estimate GLS as well as the twisting-untwisting of the left ventricle using speckle tracking imaging. PWV, AIx, SBPao and PPao with Arteriograph, Mobilograph and Complior, and perfused boundary region (PBR) of sublingual vessels using a high-resolution camera with Sideview Darkfield Imaging technique (Microscan, Glucockeck). PBR consists the cell-free space which is formed from the separation of red blood cells from plasma at the surface of the endothelial glycocalyx. Oxidative stress markers, vascular cell adhesion molecule (VCAM)-1, intercellular adhesion molecule (ICAM)-1, thrombomodulin, nitrites and nitrates, N-terminal pro B-type natriuretic peptide (NT-proBNP), growth differentiation factor (GDF)-15, blood glucose, glycosylated hemoglobin (HbA1c) and a full lipidemic profile will be measured before and at 6 and 12 months of treatment.
89376657|NCT02991482|Experimental|Pembrolizumab arm|Pembrolizumab is administrated at 200 mg fixed dose i.v. on day 1 of every 3 week cycle for a maximum or 2 years (expected maximum of 36 doses), or until progression of disease determined according to RECIST 1.1 criteria or lack of tolerability, or until the patient declines further treatment.
89376658|NCT02991482|Active Comparator|Standard chemotherapy arm|"Gemcitabine (i.v. 1000 mg/m2) or vinorelbine (i.v. 30 mg/m2, or p.o 60/80 mg/m2) chemotherapy will be chosen on a per patient basis and delivered according to local standards. Chemotherapy will be administered on days 1 and 8 of every 3-week cycle. A maximum number of treatment cycles is not mandated.~Patients randomised to the control arm will be allowed to cross over to receive pembrolizumab at progression, if cross-over criteria are met. Pembrolizumab administration will follow the same schedule as for patients in the experimental arm, i.e. 200 mg fixed dose i.v. on day 1 of every 3-week cycle for a maximum of 2 years or until trial termination."
89376659|NCT03660644|Experimental|WhatsApp, Pedometer and Step Diary|Pedometer, step diary and WhatsApp following pulmonary rehabilitation
89376660|NCT03660644|No Intervention|Control|Usual care following pulmonary rehabilitation.
89376661|NCT02674750|Experimental|Group A|Group A: MYC translocation+ and/or MYC gene copy number gain by FISH
89376662|NCT02674750|Experimental|Group B|Group B: MYC expression in > 40% of tumor cells by IHC
89376663|NCT02674750|Experimental|Group C|Group C: MYC translocation- by FISH, and MYC expression in < 40% of tumor cells, and no MYC gene copy number gain by FISH
89376664|NCT03998566|Experimental|TraceIT Tissue Spacer|
89376665|NCT02389192|Experimental|OPEN|healthy volunteers between the ages of 18-50 to receive a one-time infusion of Zmapp at a dose of 50mg/kg.
89376666|NCT05672758||Sprint-Trained Athletes|Highly trained track sprinters at the national or international level aged 18-35 years with sport experience 5-10 years; structured periodized training
89376667|NCT05672758||Endurance-Trained Athletes|Highly trained long-distance runners and triathletes at the national or international level aged 18-35 years with sport experience 5-10 years; structured periodized training
89376668|NCT05672758||Amateur/Recreational Athletes (Controls)|Individuals participating in amateur non-professional sport aged 18-35 years with activity experience 5-10 years; unstructured non-periodized training
88849563|NCT03878706||SGLT2i group|60 patients treated with empagliflozin. All subjects will undergo an echocardiographic study in order to estimate GLS as well as the twisting-untwisting of the left ventricle using speckle tracking imaging. PWV, AIx, SBPao and PPao with Arteriograph, Mobilograph and Complior, and perfused boundary region (PBR) of sublingual vessels using a high-resolution camera with Sideview Darkfield Imaging technique (Microscan, Glucockeck). PBR consists the cell-free space which is formed from the separation of red blood cells from plasma at the surface of the endothelial glycocalyx. Oxidative stress markers, vascular cell adhesion molecule (VCAM)-1, intercellular adhesion molecule (ICAM)-1, thrombomodulin, nitrites and nitrates, N-terminal pro B-type natriuretic peptide (NT-proBNP), growth differentiation factor (GDF)-15, blood glucose, glycosylated hemoglobin (HbA1c) and a full lipidemic profile will be measured before and at 6 and 12 months of treatment.
89182059|NCT04073199|Active Comparator|Short Lever Group|This arm receive the protocolized treatment along with the short lever stretch according to the Orthopaedic Manual Therapy of the Teres Major.
89376669|NCT02391376|Experimental|moist heat pack group|Three sessions of 15 minutes of superficial heat through a moist heat pack on the lower back of healthy subjects
89376670|NCT02391376|Experimental|seed pack group|Three sessions of 15 minutes of superficial heat through a seed pack on the lower back of healthy subjects
89376671|NCT02391376|Experimental|gel pack group|Three sessions of 15 minutes of superficial heat through a gel pack on the lower back of healthy subjects
89376672|NCT02388412||Vulnerable plaque in optical coherence tomogrpahy|OCT-derived vulnerable plaque is defined as composite of thin-cap fibrous atheroma (cap thickness in optical coherence tomography < 60um), prominent macrophage, or prominent microvessels.
89376673|NCT02388412||Non-vulnerable plaque in Optical coherence tomogrpahy|OCT-derived vulnerable plaque is defined as composite of thin-cap fibrous atheroma (cap thickness in optical coherence tomography < 60um), prominent macrophage, or prominent microvessels. OCT-derived non-vulnerable plaque is defined as a plaque without any of the findings
89376674|NCT02391142|Experimental|cardiac sympathetic nerve block|lidocaine or ropivacaine epidural injection
88849564|NCT03878706||Control group|60 patients treated with insulin and metformin.All subjects will undergo an echocardiographic study in order to estimate GLS as well as the twisting-untwisting of the left ventricle using speckle tracking imaging. PWV, AIx, SBPao and PPao with Arteriograph, Mobilograph and Complior, and perfused boundary region (PBR) of subglottic vessels using a high-resolution camera with Sideview Darkfield Imaging technique (Microscan, Glucockeck). PBR consists the cell-free space which is formed from the separation of red blood cells from plasma at the surface of the endothelial glycocalyx. Oxidative stress markers, vascular cell adhesion molecule (VCAM)-1, intercellular adhesion molecule (ICAM)-1, thrombomodulin, nitrites and nitrates, N-terminal pro B-type natriuretic peptide (NT-proBNP), growth differentiation factor (GDF)-15, blood glucose, glycosylated hemoglobin (HbA1c) and a full lipidemic profile will be measured before and at 6 and 12 months of treatment.
88849565|NCT03877926|Experimental|AV7909 Lot 1|Participants meeting the entry criteria will be randomized 2:2:2:1 to one of four study groups. Groups 1 to 3 will each receive one of the three consecutively manufactured lots of AV7909, per the study visit schedule.
88849566|NCT03877926|Experimental|AV7909 Lot 2|Participants meeting the entry criteria will be randomized 2:2:2:1 to one of four study groups. Groups 1 to 3 will each receive one of the three consecutively manufactured lots of AV7909, per the study visit schedule.
88849567|NCT03877926|Experimental|AV7909 Lot 3|Participants meeting the entry criteria will be randomized 2:2:2:1 to one of four study groups. Groups 1 to 3 will each receive one of the three consecutively manufactured lots of AV7909, per the study visit schedule.
88849568|NCT03877926|Active Comparator|BioThrax|Participants meeting the entry criteria will be randomized 2:2:2:1 to one of four study groups. In Group 4, one lot of BioThrax® vaccine will be administered, per the study visit schedule.
88849569|NCT03874052|Experimental|Treatment (ruxolitinib, venetoclax)|Patients receive ruxolitinib PO BID and venetoclax PO QD on days 1-28. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients may receive additional cycles of ruxolitinib and venetoclax at the discretion of the sponsor-investigator.
88849570|NCT03873844|Experimental|CI Cognitive Therapy|The treatment will have 2 components. The first component, Speed of Processing Training, is a computer game. Participants identify targets on the screen as rapidly as possible. The second component is a set of psychological techniques that will help participants apply the improvements from the game to carrying out tasks that rely on thinking in their daily life.
89182060|NCT04073199|No Intervention|Control Group|only receive the protocolized physiotherapy treatment for the Subacromial syndrome that is applied in the Rehabilitation Service, without the addition of any additional stretch technique.
88849571|NCT03847636|Active Comparator|Familial Adenomatous Polyposis (FAP)|Individuals with duodenal adenomas (DAs) and FAP with Spigelman class 2,3 or 4, treated with cryoballoon ablation (intervention)
88849572|NCT03847636|Active Comparator|Sporadic duodenal adenomas|Individuals with at least 1 sporadic duodenal adenoma (DA) between 1-5 cm in maximum diameter, treated with cryoballoon ablation (intervention)
88849573|NCT03829722|Experimental|Nivolumab, Carboplatin/Paclitaxel, Radiotherapy|Therapy will continue for 21 weeks total. This includes 4 doses of of nivolumab (240mg/m2) before and concurrent with RT/carboplatin/paclitaxel and 4 adjuvant nivolumab doses (480mg/m2) after the end of RT.
88849574|NCT03766334|Experimental|Diabetes Diet+Highland Barley Diet|Diabetes Diet+Highland Barley Diet(20g, thrice-daily)
88849575|NCT03766334|No Intervention|Diabetes Diet|only Diabetes Diet
88849576|NCT03764098|Experimental|Guanfacine ER|Guanfacine extended release (6mg/day ER). Administered orally twice daily at 8:00 AM and 8:00 PM while titrating to the full dose. Titration schedule: Days 1-3 1mg/day; 0.5mg/dose, Days 4-6 2mg/day; 1mg/dose, Days 7-9 3mg/day; 1.5mg/dose, Days 10-12 4mg/day; 2mg/dose; Days 13-15 5mg/day; 2.5mg/dose and Days 16-23 6mg/day; 3mg/dose. Once at steady state, administration is orally once per day at 8:00 PM.
88849577|NCT03764098|Placebo Comparator|Placebo|Administered orally twice a day at 8:00 AM and 8:00 PM Days 1-23, then orally once a day at 8:00 PM.
88849578|NCT03757585|Experimental|Omega-3 Fatty Acids + Inositol|Subjects will be treated with 1020mg QAM + 1020mg QPM of omega-3 fatty acids and inositol based on weight (subjects under 25kg: 1000mg QD; Subjects weighing 25kg or more: 2000mg QD).
88849579|NCT03757585|Experimental|N-acetylcysteine|Subjects will be treated with N-acetylcysteine capsules (subjects ages 5-12: 1800mg QD; subjects ages 13-17: 2400 mg QD) or effervescent tablets (subjects ages 5-12: 1800mg QD; subjects ages 13-17: 2700 mg QD) based on age.
88849580|NCT03755336|Experimental|Slipping Perturbations|The intervention involves exposing participants to a series of 12 unannounced slip perturbations while walking overground. These perturbations will be delivered at 3 different times within the gait cycle - early phase, middle phase, and late phase.
88849581|NCT03732677|Experimental|Arm 1|Chemotherapy + Durvalumab
88849582|NCT03732677|Active Comparator|Arm 2|Chemotherapy alone
88849583|NCT03724435||Pancreatic Cancer Participants|No intervention will be administered. Assessments are performed as standard of care.
88849584|NCT03705416||Endoscopic sleeve gastroplasty|All obese patients who will be undergoing an endoscopic sleeve gastroplasty (ESG). As part of the standard of care this patients will have a preoperative gastroscopy with wireless pH monitoring. Then after the endoscopic sleeve gastroplasty patients will be followed up regarding GERD symptoms for 5 years. As part of the standard of care a follow up endoscopy will be done at year 1 and wireless pH monitoring will be performed
89376675|NCT02391142|No Intervention|non-cardiac sympathetic nerve block|
89376676|NCT02391064|Experimental|Patient|MS Relapsing-remitting under interferon beta-1b treatment in inclusion, Secondary progressive and Primary progressive MS forms
89376677|NCT02391064|Experimental|Control|healthy subject
89376678|NCT02987972|Experimental|V114 Lot 1|Infants will receive a 0.5 mL intramuscular injection of V114 Lot 1 at 2, 4, 6, and 12-15 months of age (Study Day 1, Month 2, Month 4, and Month 10-13)
89376679|NCT02987972|Experimental|V114 Lot 2|Infants will receive a 0.5 mL intramuscular injection of V114 Lot 2 at 2, 4, 6, and 12-15 months of age (Study Day 1, Month 2, Month 4, and Month 10-13)
89376680|NCT02987972|Active Comparator|Prevnar 13™|Infants will receive a 0.5 mL intramuscular injection of Prevnar 13™ at 2, 4, 6, and 12-15 months of age (Study Day 1, Month 2, Month 4, and Month 10-13)
89376681|NCT04479202|Experimental|berberine group (B group)|Patients in the B group were given berberine hydrochloride tables 0.3g tid orally or tube feed daily, until the 14th day of the study. Other treatments include general support therapy, oxygen therapy, antiviral drugs, in combination with antibiotics and small doses of glucocorticoids if necessary, nutritional and organ function support.
89376682|NCT04479202|Sham Comparator|control group (C group)|Patients in the C group were given montmorilonite orally if they presence of diarrhea. The other treatments were the same as in B group.
89376683|NCT02388256|Experimental|Acupuncture|Manual and electroacupuncture
88849585|NCT03705416||Surgery (VSG or RYGBP)|All obese patients who will be undergoing either a vertical sleeve gastrectomy or a Roux-en-Y gastric bypass. As part of the standard of care this patients will have a preoperative gastroscopy with wireless pH monitoring. Then after the surgical procedure patients will be followed up regarding GERD symptoms for 5 years. As part of the standard of care a follow up endoscopy will be done at year 1 and wireless pH monitoring will be performed
88849586|NCT03700801|Experimental|Triple combination therapy group|triple combination therapy group: Triple oral hypoglycemic therapy based on metformin 0.5mg twice a day, dapagliflozin 10mg per day plus saxagliptin 5mg per day.
88849587|NCT03700801|Active Comparator|Premixed insulin therapy group|premixed insulin therapy group: The initial total dose is 0.3U-0.5U/Kg, twice a day, subcutaneous injection before breakfast and dinner, adjusted according to the blood glucose level detected by the blood glucose meter
88849588|NCT03691870|Active Comparator|standard Trans-Arterial Embolization (TAE)|"The standard TAE, without TVE, is used in patient allocated standard treatment.~The arterial approach will consist of at least one attempted catheterization for trans-arterial injection of liquid embolic.~Patients incompletely treated at the time of the final embolization procedure are adjudicated a failure to reach the primary outcome and can be treated using alternative standard options (including surgery, radiation therapy, conservative management). In addition, patients of the control group can also be offered TVE, if still feasible, once the TAE has been adjudicated to be a failure.~If the operator deems, on the table, for a trans-arterial injection to be too dangerous, no arterial injection is necessary. Treatment, where indicated, can be completed through other means."
88875278|NCT02563860|Experimental|Open label|"Treatment with Lovastatin, dose escalating trial according to the following schedule:~10 mg daily for 8 week 20 mg daily for 8 weeks 40 mg daily for 16 weeks."
88875279|NCT02564016|Active Comparator|Capped Epidural|Group 1 (control) will have the epidural catheter capped and left in place.
88875280|NCT02564016|Experimental|Normal Saline Infusion|Group 2 (treatment) will have an epidural infusion initiated with preservative-free normal saline at a continuous rate of 4ml/hour
89182061|NCT02473263|No Intervention|Conventional|No antibiotic administration and no hemodynamic target are required
89376684|NCT02388256|Active Comparator|Enhanced recovery program after surgery|Enhanced recovery program after surgery
89376685|NCT01372618|Experimental|SOM 230/Pasireotide|Treatment with SOM230 600mcg twice daily for 20 days.
89376686|NCT03304873|Experimental|Retapamulin|Thin layer of ointment applied twice a day for five days. Study drug will be applied to the nares and peri-rectal area twice a day for 5 consecutive days.
89376687|NCT03304873|Placebo Comparator|Placebo|The placebo used will be a triple purified pharmaceutical grade white petrolatum
89376688|NCT02669758|Experimental|ALKS 3831|Olanzapine + samidorphan; administered as a coated bilayer tablet.
89376689|NCT02987660|Experimental|LASIK with EX500|Topography Guided LASIK with WaveLight EX500 excimer laser system in bilateral surgery
89376690|NCT02987660|Active Comparator|SMILE with VisuMax|Small incision lenticular extraction (SMILE) with VisuMax laser in bilateral surgery
89376691|NCT04528069|Experimental|PanOptix Toric Trifocal IOL|PanOptix Toric Trifocal IOL implanted in the capsular bag in the posterior chamber following cataract surgery and intended for long-term use over the lifetime of the cataract patient. Both eyes will be implanted (bilateral implantation).
89376692|NCT03661268|Experimental|Septic shock|Patients (at least 18 years of age, no more than 75 years old) with refractory hypotension secondary to sepsis who, at the discretion of treating physicians, required fluid challenge in the presence of pulmonary artery catheter. Refractory hypotension was defined as need of vasopressors to maintain systolic blood pressure (SBP) no less than 90 mmHg despite adequate fluid resuscitation.
89376693|NCT03660566|Experimental|Test - Implant with L-PRF|Patients requiring single implants placement in the esthetic area of maxilla will receive the implant placement with the use of Leucocyte- and Platelet-rich fibrin (L-PRF) membranes.
89376694|NCT03660566|Active Comparator|Control - Implant without L-PRF|Patients requiring single implants placement in the esthetic area of maxilla will receive the implant placement only.
89376695|NCT04526509|Experimental|Substudy 1: Cohort 1 - GSK3901961 in previously treated metastatic NSCLC|Eligible participants will be leukapheresed to manufacture engineered T-cells. Participants will then receive GSK3901961, as intravenous (IV) infusion after completing lymphodepleting chemotherapy.
89376696|NCT04526509|Experimental|Substudy 1: Cohort 2 - GSK3901961 in previously treated advanced SS or MRCLS|Eligible participants will be leukapheresed to manufacture engineered T-cells. Participants will then receive GSK3901961, as IV infusion after completing lymphodepleting chemotherapy.
89376697|NCT04526509|Experimental|Substudy 2: GSK3845097 in previously treated advanced SS or MRCLS|Eligible participants will be leukapheresed to manufacture engineered T-cells. Participants will then receive GSK3845097, as IV infusion after completing lymphodepleting chemotherapy.
89376698|NCT04526509|Experimental|Substudy 3: GSK4427296 in previously treated advanced SS or MRCLS|Eligible participants will be leukapheresed to manufacture engineered T-cells. Participants will then receive GSK4427296, as IV infusion after completing lymphodepleting chemotherapy.
88849589|NCT03691870|Experimental|Trans-Venous Embolization (TVE) (+/- Arterial) strategy|"The experimental treatment is an attempt to completely occlude the AVM using venous catheterization and retrograde EVOH injection during the final session. TAE can be performed to prepare for final TVE during the same or one previous preparatory session, or TAE can be used to rescue an incomplete TVE. In some patients, balloon catheterization is used trans-arterially to assist TVE.~It will be permissible to perform more than one treatment session when deemed necessary (occasionally to treat an AVM through the trans-venous route requires a two-stage approach, with a single trans-arterial attempt to decrease AVM filling prior to the definitive trans-venous approach, and this will be permitted).~The trans-venous strategy will consist of at least one transvenous injection of ethyl vinyl alcohol (EVOH), with the choice of delivery microcatheters and other technical details left to the individual operator's discretion)."
88849590|NCT03683251|Experimental|PDS Implant Cohort 1 (US only)|"Participants with PDS implant from Study GX28228 treated with refill-exchanges of 100 mg/mL ranibizumab Q24W. Participants will switch to an every 12 weeks (Q12W) visit schedule from Week 168 to Week 240.~Eligible participants from Study GX28228 will be enrolled upon completion of their final visit."
88849591|NCT03683251|Experimental|PDS Implant Cohort 2 (US only)|"Participants with PDS implant from Study GR40548 treated with refill-exchanges of 100 mg/mL ranibizumab Q24W. Participants will switch to an every 12 weeks (Q12W) visit schedule from Week 144 to Week 240.~Eligible participants from Study GR40548 will be enrolled upon completion of their final visit."
88849592|NCT03683251|Experimental|PDS Implant Cohort 3 (US only)|"Participants in the intravitreal ranibizumab arm of Study GX28228 who will receive the PDS implant upon study entry and refill-exchanges of 100 mg/mL ranibizumab Q24W. Participants will switch to an every 12 weeks (Q12W) visit schedule from Week 168 to Week 240.~Eligible participants from Study GX28228 will be enrolled upon completion of their final visit."
88849593|NCT03683251|Experimental|PDS Implant Cohort 4 (US only)|"Participants in the intravitreal ranibizumab arm of Study GR40548 who will receive the PDS implant upon study entry and refill-exchanges of 100 mg/mL ranibizumab Q24W. Participants will switch to an every 12 weeks (Q12W) visit schedule from Week 144 to Week 240.~Eligible participants from Study GR40548 will be enrolled upon completion of their final visit."
88849594|NCT03683251|Experimental|PDS Implant Cohort 5 (ex-US only)|Participants from Study WR42221 who completed Week 24 but were not eligible to be randomized within WR42221 and who will be treated with refill-exchanges of ranibizumab 100 mg/mL Q24W
88849595|NCT03683251|Experimental|PDS Implant Cohort 6 (ex-US only)|Participants from Study WR42221 randomized to the Q24W arm, who will continue to be treated with refill-exchanges of ranibizumab 100 mg/mL Q24W
88849596|NCT03683251|Experimental|PDS Implant Cohort 7 (ex-US only)|Participants from Study WR42221 randomized to the Q36W arm, who will continue to be treated with refill-exchanges of ranibizumab 100 mg/mL Q36W
88849597|NCT03674437||Breast Cancer Survivors|Each main cohort has 2 sub-groups: One sub-group in each main cohort will complete the traditional neurocognitive assessments and the Cogsuite Assessment at the MSK Counseling Center, and the other sub-group will complete the Cogsuite Assessment off-site, on their own computers, in a quiet space that is free of distractions.
88849598|NCT03674437||Healthy Controls|Each main cohort has 2 sub-groups: One sub-group in each main cohort will complete the traditional neurocognitive assessments and the Cogsuite Assessment at the MSK Counseling Center, and the other sub-group will complete the Cogsuite Assessment off-site, on their own computers, in a quiet space that is free of distractions.
89376699|NCT03660410||Yanomamis|Yanomami Indians, Anamnesis and oral clinical examination
89376700|NCT03660410||Macuxi|Macuxi Indians, Anamnesis and oral clinical examination
89376701|NCT03660410||Wapixana|Wapixana Indians, Anamnesis and oral clinical examination
89376702|NCT03303469|Experimental|FMISO PET imaging post TACE and Stereotactic body radiation therapy (SBRT)|FMISO imaging at baseline, post-TACE and post-SBRT
89376703|NCT02990000|No Intervention|Pragmatic Match|Randomly assigned, by a case-assigning administrator, to naturalistic treatment with a pragmatically matched provider (control group)
89376704|NCT02990000|Experimental|Scientific Match|Randomly assigned, by a case-assigning administrator, to naturalistic treatment with a scientifically matched provider (experimental group)
89376705|NCT04521127|Active Comparator|Kinesio Taping Group|Kinesio taping will be applied to trapezius muscle
89376706|NCT04521127|Active Comparator|Dry needling Group|Dry needling will be applied to trigger point on trapezius muscle
88849599|NCT03674437||Healthy 21-25 year olds|Healthy participants between the ages of 21 and 25 will be administered the Cogsuite Battery remotely. These participants will not be matched to any other groups and will not be asked for their full medical histories. They will only complete the assessment only once.
89376707|NCT04521127|No Intervention|Control Group|Control group will not receive any additional intervention
89376708|NCT03660254|Experimental|one group has exercise intervention|tai chi exercise intervention，two times a week and each time costs one hour
89376709|NCT03660254|No Intervention|no intervention|no intervention
89376710|NCT03660176|Active Comparator|routine management|Children in the control group receive no additional treatment
88849600|NCT03671018|Experimental|Dose Finding|Participants will receive mosunetuzumab in combination with polatuzumab vedotin. Dose finding will be guided by the observed incidence of dose-limiting toxicities (DLTs) at each dose level.
88849601|NCT03671018|Experimental|Mosunetuzumab + Polatuzumab Vedotin 2L+ R/R FL|Participants with at least one line of prior therapy (2L+) and that have relapsed or refractory (R/R) follicular lymphoma (FL) will receive mosunetuzumab + polatuzumab vedotin.
88849602|NCT03671018|Experimental|Mosunetuzumab + Polatuzumab Vedotin 2L+R/R DLBCL|2L+ participants with R/R diffuse large B-cell lymphoma will receive mosunetuzumab + polatuzumab vedotin.
88849603|NCT03671018|Experimental|Mosunetuzumab SC + Polatuzumab Vedotin 3L+R/R MCL|Participants with at least 2 lines of prior therapy (3L+) will receive subcutaneous (SC) mosunetuzumab + polatuzumab vedotin.
88849604|NCT03671018|Experimental|Mosunetuzumab SC + Polatuzumab Vedotin 2L+R/R DLBCL|2L+ participants with R/R DLBCL will receive SC mosunetuzumab and polatuzumab vedotin.
88849605|NCT03670966|Experimental|Treatment (211At-BC8-B10, chemotherapy, TBI, MMF, G-CSF)|"PREPARATIVE REGIMEN: Patients receive astatine At 211 anti-CD45 monoclonal antibody BC8-B10 infusion over 6-8 hours on day -8, fludarabine IV over 30 minutes on days -6 to -2, and cyclophosphamide IV over 1 hour on days -6 and -5. Patients also undergo TBI on day -1.~TRANSPLANT: Patients undergo PBSC or bone marrow transplant on day 0.~GVHD PROPHYLAXIS: Patients receive cyclophosphamide IV over 1-2 hours on days 3-4, mycophenolate mofetil IV or PO TID on days 5-35, and tacrolimus IV over 1-2 hours (changed to PO once tolerated) on days 5-180 with taper beginning on day 84 per physician discretion. Patients also begin G-CSF IV or SC on day 5 to continue until ANC > 1000/mm^3 x 3 days.~Patients undergo bone marrow biopsy and aspiration and blood sample collection throughout the study."
88849606|NCT03642626||ARM A: Refractory/relapsed B-cell acute lymphoblastic leukemia (ALL)|
89376711|NCT03660176|Experimental|EXP GROUP|children receiving butyrate enemas + routine management butyrate enemas every day before Curative surgery
89376712|NCT04056026|Experimental|Fecal Microbiota Transplant|The patient will undergo fecal microbiota transplant. The 600cc of donor stool will be transplanted by colonoscopy.
89376713|NCT03661190|Other|Grammatical Reasoning|This group will complete a short-term Intensive Grammatical Reasoning cognitive task delivered online by Wesnes Cognition Ltd (START). Participants will be encouraged to complete the START training once a day for six-weeks.
89376714|NCT03661190|Other|Control - Card Pairs|The control group will complete a basic picture-matching task that will provide the same level of engagement, but without the learning effects.
89376715|NCT03660020|Sham Comparator|local anaesthetic group|
88849607|NCT03642626||ARM B: Yescarta for Refractory diffuse large B cell lymphoma (DLBCL)|
88849608|NCT03642626||ARM C: Kymriah for Refractory diffuse large B cell lymphoma (DLBCL)|
88849609|NCT03642626||Arm D: Tecartus CAR-T product for Mantle Cell Leukemia (MCL)|
88849610|NCT03642626||Arm E: Breyanzi for relapsed or refractory large B-cell lymphoma (RLBCL)|
88849611|NCT03642626||Arm F: Abecma for relapsed or refractory multiple myeloma|
88849612|NCT03642626||Arm G: Tecartus B-cell acute lymphoblastic leukemia (ALL)|
89376716|NCT03660020|Active Comparator|hyalorounidase group|
88849613|NCT03641755|Experimental|Dose Level -1: Sapacitabine (100 mg) + Olaparib (300 mg)|"Olaparib will be administered orally twice daily for each 28-day cycle~Sapacitabine will be administered orally once daily on days 1 - 5 and 8 - 12 of every 28-day cycle"
88849614|NCT03641755|Experimental|Dose Level 1: Sapacitabine (150 mg) + Olaparib (300 mg)|"Olaparib will be administered orally twice daily for each 28-day cycle~Sapacitabine will be administered orally once daily on days 1 - 5 and 8 - 12 of every 28-day cycle"
88849615|NCT03641755|Experimental|Dose Level 2: Sapacitabine (200 mg) + Olaparib (300 mg)|"Olaparib will be administered orally twice daily for each 28-day cycle~Sapacitabine will be administered orally once daily on days 1 - 5 and 8 - 12 of every 28-day cycle"
88849616|NCT03641755|Experimental|Dose Level 3: Sapacitabine (250 mg) + Olaparib (300 mg)|"Olaparib will be administered orally twice daily for each 28-day cycle~Sapacitabine will be administered orally once daily on days 1 - 5 and 8 - 12 of every 28-day cycle"
89376717|NCT03661112||All of Us Research Program (AoURP) consortium members|
89376718|NCT03659942||Experimental group|New child arriving in detention CAST questionnaire will be performed
89376719|NCT03659864|Sham Comparator|Exposure 1|filtered air
89376720|NCT03659864|Experimental|Exposure 2|nanoparticle 1 (either DEP or s-GO depending on group)
89376721|NCT03659864|Experimental|Exposure 3|nanoparticle 2 (either CB or us-GO depending on group)
89376722|NCT04055714|Experimental|Treatment arm|Balloon dilation of the Eustachian Tube(s) with Acclarent Aera Balloon
89376723|NCT03661034|Experimental|Cohort 1, Arm A|Dosing 1 hour session per day with GammaSense Stimulation System (non-invasive, non-significant risk)
89376724|NCT03661034|Experimental|Cohort 1, Arm B|Dosing 1 hour session twice per day with GammaSense Stimulation System (non-invasive, non-significant risk)
88849617|NCT03624946|Experimental|Zika Virus Immune Globulin (ZIKV-IG)|Single dose of 50 mL Zika Virus Immune Globulin (ZIKV-IG) will be administered intravenously over 33 minutes.
88849618|NCT03624946|Placebo Comparator|Placebo (Saline Solution)|Single dose of 50 mL placebo will be administered intravenously over 33 minutes.
88849619|NCT03600324|Experimental|Low Intensity/Low Frequency|Participants will be assigned T-REV with low intensity (30% of perceived effort) and low frequency (exercises performed 1x/day)
88849620|NCT03600324|Experimental|Low Intensity/ High Frequency|Participants will be assigned T-REV with low intensity (30% of perceived effort) and high frequency (exercises performed 2x/day)
88849621|NCT03600324|Experimental|High Intensity/Low Frequency|Participants will be assigned T-REV with high intensity (70% of perceived effort) and low frequency (exercises performed 1x/day)
88849622|NCT03600324|Experimental|High Intensity/High Frequency|Participants will be assigned T-REV with high intensity (70% of perceived effort) and high frequency (exercises performed 2x/day)
88849623|NCT03599245|Experimental|Ocrelizumab|Participants will receive a single 600-mg infusion of Ocrelizumab every 24 weeks up to Week 72 of this study.
88849624|NCT03596073|Experimental|Topical Calcipotriene Ointment|-Topical Calcipotriene Ointment will be administered by the participants to their upper extremities twice a day for the period between core biopsy and surgical removal of their breast lesion
88849625|NCT03596073|Placebo Comparator|Topical Vaseline|-Topical Vaseline will be administered by the participants to their upper extremities twice a day for the period between core biopsy and surgical removal of their breast lesion
88849626|NCT03588754|Experimental|Propranolol|Propranolol extended release (160mg/day). Administered orally once daily at 10:00PM. Titration schedule Days 1-3 60mg, Days 4-7 80mg, Days 8-11 120mg, and Days 12-14 160mg until steady state.
88849627|NCT03588754|Placebo Comparator|Placebo|Administered orally once daily at 10:00PM
88849628|NCT03582176|Placebo Comparator|Lactose Placebo|Lactose Placebo by mouth twice per day
88849629|NCT03582176|Active Comparator|Ketotifen Fumarate - 2mg|Ketotifen Fumarate 2 mg by mouth twice per day
88849630|NCT03582176|Active Comparator|Ketotifen Fumarate - 5mg|Ketotifen Fumarate 5 mg by mouth twice per day
88849631|NCT03574207|Other|Arm A: Stimulation then Sham|All procedures are identical in both arms with the exception of the order of stimulation administration. In Arm A, transcranial magnetic stimulation (TMS) will be applied in the first week of participation, and sham stimulation will be applied in the second week of participation.
88849632|NCT03574207|Other|Arm B: Sham then Stimulation|All procedures are identical in both arms with the exception of the order of stimulation administration. In Arm B, sham stimulation will be applied in the first week of participation, and transcranial magnetic stimulation (TMS) will be applied in the second week of participation.
88849633|NCT03568266||Biospecimen Collection|Buccal swabs of prospective participants' saliva will be collected when participant achieves complete remission (during regular clinical visit) from their asparaginase treatment.
88849634|NCT03556332|Experimental|Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab & HCT|After receiving four 28-day cycles of Dara-CRd, eligible patients will then undergo HCT with high dose melphalan conditioning. Sixty to ninety days after HCT, patients will receive another 4 cycles of Dara-CRd.
88849635|NCT03551626|Experimental|Dabrafenib and trametinib combination therapy|Subjects received dabrafenib (150 mg twice daily) and trametinib (2 mg once daily) orally for up to 12 months.
88849636|NCT03539783||PARDS|Children <18 years of age with PARDS and expected duration of hospitalization seven days or greater.
88849637|NCT03539783||Control|Children <18 years of age without PARDS or other lung disease and expected duration of hospitalization 7 days or greater.
88849638|NCT03525925|Experimental|Treatment (ibrutinib, nivolumab)|Participants receive ibrutinib PO daily for 15 days. After 7 days receiving ibrutinib, participants receive nivolumab IV over 60 minutes on days 1 and 15. Courses with nivolumab repeat every 28 days in the absence of disease progression or unaccepted toxicity.
88849639|NCT03524092|Placebo Comparator|Maintenance Period: Miri Induction Responder (IR) - Placebo (PBO) Subcutaneous (SC)|Participants who were responders to blinded mirikizumab (miri) at Week 12 in induction study (LUCENT-1) randomized to withdraw from mirikizumab and start receiving PBO SC every 4 weeks (Q4W) from Week 0 of maintenance study (LUCENT-2) until Week 40 or until loss of response was confirmed.
88849640|NCT03524092|Experimental|Maintenance Period: Miri IR - 200 Milligram (mg) Miri SC|Participants who were responders to blinded mirikizumab at Week 12 in induction study (LUCENT-1) randomized to continue to receive 200 mg mirikizumab SC Q4W from Week 0 of LUCENT-2 until Week 40 or until loss of response was confirmed.
88849641|NCT03524092|Other|Maintenance Period: PBO IR - PBO SC|Participants who were responders to blinded placebo at Week 12 in induction study (LUCENT-1) continue to receive blinded placebo SC Q4W from Week 0 of LUCENT-2 until Week 40 or until loss of response was confirmed.
88849642|NCT03524092|Other|Loss of Response (LOR) Rescue Period:LOR Cohort-300 mg Miri IV|Participants who received PBO SC or 200 mg mirikizumab SC Q4W during maintenance period and experienced a loss of response at or after Week 12, received rescue therapy with open label 300 mg mirikizumab intravenous (IV) Q4W for 3 doses.
88849643|NCT03524092|Other|Extended Induction: Induction Nonresponders - 300mg Miri IV|Participants who were nonresponders to blinded mirikizumab or placebo in induction study (LUCENT-1), received additional 3 doses of open label 300 mg mirikizumab IV Q4W during extended induction period from Week 0 of LUCENT-2 until Week 12.
88849644|NCT03524092|Other|Open Label Maintenance: Delayed Responders - 200 mg Miri SC|Participants who initially did not respond to induction study (LUCENT-1), but responded to extended induction therapy at Week 12 of LUCENT-2 (delayed responders), received 200 mg mirikizumab SC Q4W during open label maintenance period from Week 12 until Week 40.
88849645|NCT03490864|Experimental|Meal timing + Melatonin|This arm will consist of imposing a minimum overnight fasting period of 12 hours and a maximum of 16 hours (with exception of water and other non-caloric beverages), beginning 3 hours before their habitual bed time. This arm will also include a 1mg melatonin supplementation given daily during the intervention.
88849646|NCT03490864|Experimental|Meal timing + Placebo|This arm will consist of imposing a minimum overnight fasting period of 12 hours and a maximum of 16 hours (with exception of water and other non-caloric beverages), beginning 3 hours before their habitual bed time. This arm will also include a melatonin placebo (lactose) supplementation given daily during the intervention.
89376725|NCT03661034|Experimental|Cohort 2, Arm C|Dosing 1 hour session every other day or one 2 hour session per day, depending on Interim Analysis outcomes with GammaSense Stimulation System (non-invasive, non-significant risk)
89376726|NCT03661034|Experimental|Cohort 2, Arm D|Dosing 30 minute session twice per day or 120 minute session twice per day, depending on Interim Analysis outcomes with GammaSense Stimulation System (non-invasive, non-significant risk)
89376727|NCT03659786|Experimental|CC-Test diagnosis and Day 3 transfer|Patients undergo the standard ART treatment, as prescribed by the treating physician, with standard morphology based scoring of the embryos + the extra cumulus cell based diagnosis and transfer of the best embryo based on morphology and CC diagnosis on day 3 of embryo growth (cleavage stage embryo)
89376728|NCT03659786|No Intervention|Day 3 transfer control group|Patients undergo the standard ART treatment, as prescribed by the treating physician, with standard morphology based scoring of the embryos and transfer of the best embryo based on day 3 of embryo growth (cleavage stage embryo)
89376729|NCT03659786|No Intervention|Day 5 transfer control group|Patients undergo the standard ART treatment, as prescribed by the treating physician, with standard morphology based scoring of the embryos and transfer of the best embryo based on day 5 of embryo growth (blastocyst stage embryo)
89376730|NCT03659708|Experimental|Lyon-VTE score|"300 adult pregnant women with a personal history of VTE and/or known thrombophilia, will be randomly included in this group and their VTE risk during pregnancy will be managed according to the Lyon-VTE score :~The Lyon score classifies patients into 3 risk categories and directs the preventive LMWH prescription:~A score strictly less than 3 indicates a moderate thrombotic risk: the patient does not receive LMWH in ante-partum;~A score between 3 and 5 indicates a high thrombotic risk: a preventive dose LMWH is introduced in the third trimester (from the beginning of the 7th month);~A score greater than or equal to 6 indicates a very high thrombotic risk: LMWH at a preventive dose is prescribed throughout the ante-partum.~All patients receive an elasto-compression prescription and daily physical activity is recommended throughout pregnancy (except obstetric contraindication).~All patients also receive systematic preventive LMWH treatment postpartum for 6 weeks."
89376731|NCT03659708|Experimental|recommendations currently available|300 adult pregnant women with a personal history of VTE and/or known thrombophilia, will be randomly included in this group and their VTE risk during pregnancy will be managed according to the last ACCP guidelines or UK guidelines or Canadian recommendations or French recommendations, according to the habits of the center.
89376732|NCT03659630|Experimental|Intervention group|The intervention group receives the MyCompass intervention, an automated self-help intervention for mild to moderate mental ill-health.
89376733|NCT03659630|Placebo Comparator|Comparison group|The control group receives a brief email each week, describing the most common mental health issues.
89376734|NCT03659552|Experimental|Temporary diaphragmatic pacing|There is no comparator for this study. Single site and all patients are in the treatment allocated group of temporary diaphragmatic pacing with the LIVE Catheter which is inserted via the left jugular vein.
89376735|NCT03659474|Experimental|cryotherapy by compression|maximum dynamic intermittent compression, programmed to maintain a temperature at 1 ° C
89376736|NCT03659474|Experimental|ice pack|the ankle joint was surrounded by three plastic bags containing crushed ice.
88849647|NCT03490864|Experimental|Melatonin|This arm will continue to eat at their habitual meal times, and maintain their average habitual caloric and macronutrient intake. No extended overnight fasting will be imposed. This arm will include a 1mg melatonin supplementation given daily during the intervention.
88849648|NCT03490864|Placebo Comparator|Placebo|This arm will continue to eat at their habitual meal times, and maintain their average habitual caloric and macronutrient intake. No extended overnight fasting will be imposed. This arm will also include a melatonin placebo (lactose) supplementation given daily during the intervention
88849649|NCT03485794||Diagnostic (biospecimen collection)|Patients undergo collection of blood for metabolic profiling via LC/Q-TOF/MS.
88849650|NCT03475121|Experimental|Low Risk Patients|Patients with IRSS stage I, pT1, pT2 and pT3 stage will not receive adjuvant therapy
89376737|NCT03659474|Experimental|cold water immersion|articulation of the ankle submerged in cold water at approximately 10 ° C, being controlled by the thermal camera.
89376738|NCT03659396|Experimental|individualized Tai Chi|patient received individualized Tai Chi program training.
89376739|NCT03659396|Active Comparator|Entire Tai Chi|patient received Entire Tai Chi program training.
89376740|NCT03659396|Placebo Comparator|home-based program|patient received home-based program training.
88849651|NCT03475121|Experimental|Higher Risk Patients|Patients with IRSS stage I, pT3b, pT3c, pT3d will receive 6 cycles of adjuvant chemotherapy plus 6 doses of intrathecal topotecan
88849652|NCT03475121|Experimental|Stage II Patients|Patients with Stage II (pT4) will receive 6 cycles of adjuvant chemotherapy plus 6 doses of intrathecal topotecan and orbital radiotherapy
88849653|NCT03475121|Experimental|Patients with buphthalmus|Patients with buphthalmus (cT3c, cT3e) will receive 2 cycles of neo-adjuvant chemotherapy plus 6 doses of intrathecal topotecan followed by secondary enucleation and 6 cycles of adjuvant chemotherapy.
88849654|NCT03448042|Experimental|Dose Escalation|Participants will be assigned sequentially to escalating doses of runimotamab up to the maximum tolerated dose (MTD).
88849655|NCT03448042|Experimental|Dose Expansion|Participants will receive runimotamab based on the MTD or maximum allowed dose (MAD) identified during dose escalation.
89376741|NCT03662048|Active Comparator|intervention at 1 month + usual care|Parents will send the study team photographs of their infant sleeping during the night at ages 1 and 2 months.
89376742|NCT03662048|Placebo Comparator|usual care|Parents will send the study team photographs of their infant sleeping during the night only at at age 2 months.
88849656|NCT03422822|Experimental|Abrocitinib 100 mg|Abrocitinib 100 mg QD PO
88849657|NCT03422822|Experimental|Abrocitinib 200 mg|Abrocitinib 200 mg QD PO
88849658|NCT03421353|Experimental|Arm A1|Patients will receive AZD9150 every two weeks (Q2W) + durvalumab every four weeks (Q4W). There will be a 1 week AZD9150 lead-in prior to durvalumab dosing.
89376743|NCT04055870||Undergone EUS-guided liver biopsy at MDMC|Undergone EUS-guided liver biopsy at MDMC
89376744|NCT03660956|Experimental|Exercise and back counselling group|
89376745|NCT03660956|Active Comparator|Back counselling group|
89376746|NCT03659318|Experimental|Robot|TKA is done with robotic-assisted manner. Final implantation of implants is done by surgeons, same as the conventional way. Robotic-assisted TKA for this arm.
89376747|NCT03659318|Active Comparator|Conventional|TKA is done with conventional instruments. Conventional TKA for this arm.
89376748|NCT03661892|Experimental|Treatment (Syndros)|All patients start on Syndros at 4.2 mg po BID for 3 days, if tolerated without side effects the dose is increased to 8.4 mg QAM and 4.2 mg QPM for an additional 3 days. If the patient continues to tolerate the medication, the dose will be increased to 8.4 mg BID for the rest of the study period (total of 8wks).
89376749|NCT03658850|Active Comparator|Intervention|the experimental group will receive one tablet of hydrochlorothiazide in the presentation of 50mg or equivalent enteral solution every 12h (total of 100mg per day) enterally for 3 days.
89376750|NCT03658850|Placebo Comparator|Control|placebo group will receive one tablet or equivalent volume of enteral solution of inert substance
89376751|NCT03659162||neutropenic cancer patient recieving azoles .|neutropenic cancer patients that undergoing chemotherapy with prophylaxis with azoles and exhibit recurrent fungal infection so appropriate clinical specimen will taken for isolation & identification of causative agent & it's antimicrobial profile then identification of the mechanism of resistance by invitro technique then confirmed by real time pcr.
89376752|NCT01068626|Active Comparator|Rosuvastatin|
89376753|NCT01068626|Placebo Comparator|Placebo for Rosuvastatin|
88849659|NCT03421353|Experimental|Arm A2|Patients will receive AZD9150 once weekly (QW) + durvalumab every three weeks (Q3W) + Cisplatin on Day 1 + 5-flourouracil (5-FU) on Days 1 to 4. This regimen will be repeated every 3 weeks for up to 18 weeks. There will be a 1 week AZD9150 + chemotherapy lead-in prior to durvalumab dosing.
89376754|NCT03060668|Experimental|Study Group|"Caloric needs will be determined by indirect calorimetry. Patients in this group will receive 2.0 to 2.2 grams/kg/day of protein.~Nutritional therapy will be initiated in the first 24 hours after admission.~Nutritional formula will be Peptamen Intense (1.0 kcal/ml, 93 g/L protein (Nestle Health Care)."
88849660|NCT03421353|Experimental|Arm A3|Depending on the results of Arm A2, Arm A3 may not be conducted. If Arm A3 is conducted, patients will receive AZD9150 every two weeks (Q2W) + durvalumab every three weeks (Q3W) + cisplatin on Day 1 + 5-flourouracil (5-FU) over Days 1 to 4. This regimen will be repeated every 3 weeks for up to 18 weeks. There will be a 1 week AZD9150 + chemotherapy lead-in prior to durvalumab dosing.
88849661|NCT03421353|Experimental|Arm A4|"Patients will receive AZD9150 every two weeks (Q2W) + durvalumab every three weeks (Q3W) + gemcitabine on Days 1 and 8. This regimen will be repeated every 3 weeks. In addition, the following will be added to the regimen:~For cisplatin-eligible patients: cisplatin on Day 1 (every 3 weeks for up to 12-18 weeks); or~For cisplatin ineligible patients: carboplatin on Day 1 and Day 8 (every 3 weeks for up to 12-18 weeks)~There will be a 1 week AZD9150 + chemotherapy lead-in prior to durvalumab dosing."
88849662|NCT03421353|Experimental|Arm A5|Patients will receive AZD9150 every two weeks (Q2W) plus durvalumab every three weeks (Q3W) plus carboplatin on Day 1 plus nab-paclitaxel on Days 1, 8, and 15 (every 3 weeks for up to 12-18 weeks). There will be a 1 week AZD9150 + chemotherapy lead-in prior to durvalumab dosing.
88849663|NCT03421353|Experimental|Arm D: AZD9150 SC|Part D will compare the single and steady state pharmacokinetics of AZD9150 given subcutaneously (SC) QW to AZD9150 given by IV QW in combination with durvalumab 1500 mg Q4W. Patients will be randomly assigned to either SC or IV AZD9150.
88849664|NCT03421353|Experimental|Arm D: AZD9150 IV|Part D will compare the single and steady state pharmacokinetics of AZD9150 given subcutaneously (SC) QW to AZD9150 given by IV QW in combination with durvalumab 1500 mg Q4W. Patients will be randomly assigned to either SC or IV AZD9150.
88849665|NCT03418038|Experimental|Arm A (ascorbic acid, combination chemotherapy)|Patients receive ascorbic acid IV on days 1, 3, 5, 8, 10, 12, 15, 17, and 19, and rituximab intravenously IV, ifosfamide IV, carboplatin IV and etoposide IV on days 1-3. Patients who achieve MR or SD after 2 cycles may receive rituximab IV or PO, cisplatin IV or PO, cytarabine IV or PO, and dexamethasone IV or PO. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
88849666|NCT03418038|Active Comparator|Arm B (placebo, combination chemotherapy)|Patients receive placebo (normal saline) IV on days 1, 3, 5, 8, 10, 12, 15, 17, and 19, and rituximab intravenously IV, ifosfamide IV, carboplatin IV and etoposide IV on days 1-3. Patients who achieve MR or SD after 2 cycles may receive rituximab IV or PO, cisplatin IV or PO, cytarabine IV or PO, and dexamethasone IV or PO. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
88875281|NCT02566044|Experimental|CQBW276|"Cohorts 1 and 2 will enroll 8 patients each (6:2 QBW276 and placebo, respectively).~Cohort 1: dose is 3 mg bid (6 mg daily) QBW276 or placebo for 7 days. Cohort 2: dose and frequency will be confirmed after cohort 1 is complete. The duration is 14 days.~Cohort 3: dose and frequency will be confirmed after cohort 2 is complete. The duration is approximately 4 months. Patients will be randomized to one of two treatment sequences: QBW276 in Period 1 and Placebo in Period 2 or Placebo in Period 1 and QBW276 in Period 2. Twenty four patients are required to complete cohort 3."
89376755|NCT03060668|Active Comparator|Control Group|"Patients in this group will receive 25 Kcal/kg/day and 1.4 to 1.5 grams/kg/day of protein.~Nutritional formula in this group will be Novasource senior (Nestle Health Care).~Nutritional therapy will be initiated in the first 24 hours after admission."
89376756|NCT02921750|Experimental|Dressing Exufiber®Gelling Fibre Dressing|will receive dressing Exufiber®
89376757|NCT02921750|Active Comparator|Dressing Aquacel®ExtraHydrofiber®Dressing with Strengthenin|Will receive Aquacel®Extra™
89376758|NCT03659006|Experimental|Biological Collection|Blood sampling on catheter and CSF sampling from VDE, multimodal MRI at D42 and D365, Neurological and neuropsychological evaluation at one year
89376759|NCT03657836|Experimental|Dietary supplement and antibiotics|Participants will take a supplement of 1 sachet (20 mg) dissolved in 200 ml of warm water (36-37 °C) once a day for 60 days accompanied with the standard antibiotic therapy (cefuroxime and ceftriaxone) up to 7 days.
89376760|NCT03657836|Other|Antibiotics only|Participants will take the prescribed antibiotic therapy (cefuroxime and ceftriaxone) up to 7 days.
89376761|NCT03622502|Experimental|Dexmedetomidine|Dexmedetomidine was infused before end of surgery and remifentanil was maintained at predetermined effect-site concentration during the emergence period
89376762|NCT03622502|Active Comparator|Remifentanil|Normal saline was infused before end of surgery and remifentanil was maintained at predetermined effect-site concentration during the emergence period
89376763|NCT03658382|No Intervention|Telephone Results Disclosure|
89376764|NCT03658382|Experimental|Virtual Visit Results Disclosure|
89376765|NCT04401566|Experimental|Internal Myofascial Release Group|Internal myofascial trigger point release therapy consists of 30 minutes massage directly to the pelvic floor musculature by vaginally. Patients were instructed in internal myofascial release techniques. Experienced pelvic health physiotherapist (A.B.) to use her fingers with a lubricated glove when the finger could easily reach internal trigger points and follows these steps: (a) finding internal and external trigger points associated with pelvic muscles, especially around sensitive areas of the vagina, anus, and/or pelvic floor; (b) releasing with the fingers the trigger point associated pelvic muscle tension by carefully pressing on the trigger point. Releasing pelvic muscle tension includes applying varying amounts of pressure, sometimes gradually stroking and strumming the muscle region while systematically contracting and relaxing the affected muscles to aid in a trigger point release.
89376766|NCT04401566|Experimental|External Myofascial Release Group|Eksternal myofascial trigger point release therapy consists of 30 minutes massage to the abdominal wall, gluteal area and abductors, and hamstring muscles. Pain in trigger points may exist at both locations of muscle insertion as well as in the belly and the lower extremity of the muscle.
89376767|NCT04401566|Other|Control Group|The Control group will have a video about exercises recommended in pelvic pain for 30 minutes. A physiotherapist will teach and show the exercises for pelvic pain. The home exercise for pelvic pain contains diaphragm breathing, pelvic floor muscle stretching, and releasing.
89376768|NCT04397354|Active Comparator|Group 1|intracochlear dexamethasone application during cochlear implantation
89376769|NCT04397354|Active Comparator|Group 2|intratympanic dexamethasone application during cochlear implantation
89376770|NCT04397354|Sham Comparator|Group 3|No drugs during cochlear implantation
89376771|NCT02970344|Experimental|Diabetes Coping Skills training (DCST)|Twelve sessions are delivered over 6 months using a faded contact model involving 6 weekly sessions, 3 biweekly sessions and 3 monthly sessions.
89376772|NCT02970344|No Intervention|Diabetes Education|one 60 minute diabetes education session.
89376773|NCT03658226|Experimental|Therapy|Psychodynamic Interpersonal Therapy (PIT)
88849667|NCT03418038|Experimental|Arm C (ascorbic acid and combination chemotherapy)|Patients receive ascorbic acid IV on days 1, 3, 5, 8, 10, 12, 15, 17, and 19. Patients also receive ifosfamide, carboplatin, and etoposide IV or PO, or cisplatin, cytarabine, and dexamethasone IV or PO, or gemcitabine hydrochloride, dexamethasone, and cisplatin IV or PO, or gemcitabine hydrochloride and oxaliplatin IV or PO, or oxaliplatin, cytarabine, and dexamethasone IV or PO according to standard regimen schedule. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients who achieve MR or SD after 2 cycles may switch to an alternative chemotherapy regimen.
88849668|NCT03418038|Experimental|Arm D (ascorbic acid)|Patients receive ascorbic acid IV TIW. Treatments repeat every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
88849669|NCT03415308||Patient Focus Groups|Identify patient preferences for constructs, and related outcomes, that reflect the expression of implicit bias in clinical encounters. I
88849670|NCT03415308||Stakeholders Cognitive Interviews|Investigators will conduct a series of semi-structured interviews.
88849671|NCT03415308||Pilot Testing of Implicit Bias Training|Refined intervention emerging from Aim 2. T
88849672|NCT03374800|Placebo Comparator|Placebo (0.9% saline)|Withholding Stress ulcer prophylaxis (intravenous 0.9% saline as placebo)
88849673|NCT03374800|Active Comparator|Stress Ulcer Prophylaxis (Pantoprazole)|pantoprazole 40mg powder for injection reconstituted with 0.9% saline
88849674|NCT03361020||Hodgkin Lymphoma|Participants will be survivors of Hodgkin Lymphoma (HL) who were treated with thoracic radiation during the course of their HL, who meet eligibility criteria, and who consent to this study.
89376774|NCT04387916|Experimental|KC1036|Patients take a single dose of KC1036 for the pharmacokinetic study, then off for 5 days before the first cycle begins. In the subsequent treatment cycles, KC1036 are given orally once daily, 21 days as a cycle.
89376775|NCT03657758|Active Comparator|EPA and statin therapy group|After randomization, patients with combination therapy start EPA (1800mg/day) and high dose rosuvastatin (10mg/day) for ９ months.
89376776|NCT03657758|Active Comparator|High dose statin therapy group|After randomization, patients with high dose statin therapy start high dose rosuvastatin (10mg/day) for ９ months.
89376777|NCT03657758|No Intervention|low dose statin therapy group|After randomization, patients with low dose statin therapy take low dose rosuvastatin (5mg/day) for ９ months.
88849675|NCT03361020||Control Group|The Comparison or control group members will be recruited from healthy parents, sibling, relative or friends who accompany the participant for follow-up at SJCRH and who meet eligibility criteria.
88849676|NCT03354910|No Intervention|Usual Care|All enrolled patients will receive Usual Care for transplant candidates at our two centers, which includes individual meetings with transplant providers, attendance at a patient group education session in the transplant center (focused on the specifics of the transplant experience), and a transplant education binder.
88875282|NCT02566044|Placebo Comparator|Placebo|"Cohorts 1 and 2 will enroll 8 patients each (6:2 QBW276 and placebo, respectively).~Cohort 1: dose is 3 mg bid (6 mg daily) QBW276 or placebo for 7 days. Cohort 2: dose and frequency will be confirmed after cohort 1 is complete. The duration is 14 days.~Cohort 3: dose and frequency will be confirmed after cohort 2 is complete. The duration is approximately 4 months. Patients will be randomized to one of two treatment sequences: QBW276 in Period 1 and Placebo in Period 2 or Placebo in Period 1 and QBW276 in Period 2. Twenty four patients are required to complete cohort 3."
89376778|NCT02920970|Active Comparator|narafilcon A|Participants are randomized to wear narafilcon A lens pair for one week during the cross over study.
89376779|NCT02920970|Active Comparator|stenfilcon A|Participants are randomized to wear stenfilcon A lens pair for one week during the cross over study.
89376780|NCT03658148||Study Group|Neonates (≤31 days) who underwent cardiac surgery with cardiopulmonary bypass for congenital heart disease (CHD) between 2008-2017.
89376781|NCT01068158|Experimental|0.5% Ivermectin Cream|Up to 4 ounces of topical Ivermectin Cream applied to hair and scalp on day 1
89376782|NCT01068158|Placebo Comparator|Vehicle control|Up to 4 ounces of topical control applied to hair and scalp on day 1.
89376783|NCT03303079|Experimental|TEV-48125 (675/225/225 mg) group|TEV-48125 will be subcutaneously administered once monthly for 3 months (675/225/225 mg).
89376784|NCT03303079|Experimental|TEV-48125 (675 mg/placebo/placebo) group|TEV-48125 or placebo will be subcutaneously administered once monthly for 3 months (675 mg/ placebo/placebo).
89376785|NCT03303079|Placebo Comparator|Placebo group|Placebo will be subcutaneously administered once monthly for 3 months (placebo/placebo/placebo).
89376786|NCT01067846|Experimental|DCS and Cognitive Behavioral Therapy|Subjects will receive 250 mg of Seromycin or D-cycloserine (DCS) prior to computerized cognitive behavioral therapy.
88849677|NCT03354910|Active Comparator|Usual Care (UC) + House Calls (HC)|Patients and their invited guests will be scheduled for one House Call. A house call is meeting done at a patient's home with transplant health educators facilitating a discussion on topics related to living kidney donation. Patients and guests also receive an information packet containing several brochures providing information about the living donation process, common concerns and misperceptions, and donation resources and information about our transplant center (e.g., copy of our quarterly newsletter, contact information). Patients in the group will also receive Usual Care, the regular education on living donation, provided as part of their routine transplant care.
88849678|NCT03354910|Experimental|UC + HC + Peer Mentorship|Patients in this condition will receive the Usual Care and the House Calls intervention as described previously. In addition, participants will receive access to a Peer Mentor trained by the National Kidney Foundation following their House Call.
88849679|NCT03328650||Proximal Humerus Fracture Patients|As part of their routine care, patients who have experienced a proximal humerus fracture that requires operative fixation will receive the A.L.P.S® Proximal Humerus Plating System. This study is an observational, prospective study that monitors the patient's pain, functional ability, and patient-reported outcomes.
88849680|NCT03316391||Pre-eclampsia|Patients in hospital for pre-eclampsia at the Hopital Femme-Mère-Enfant
88849681|NCT03315936|Placebo Comparator|Placebo matching BI 894416 (SRD Part)|Single Rising Dose (SRD) Part
88849682|NCT03315936|Experimental|BI 894416 3 milligram (mg)|SRD Part
88849683|NCT03315936|Experimental|BI 894416 10 mg|SRD Part
88849684|NCT03315936|Experimental|BI 894416 20 mg|SRD Part
88849685|NCT03315936|Experimental|BI 894416 30 mg|SRD Part
88849686|NCT03315936|Experimental|BI 894416 40 mg|SRD Part
88849687|NCT03315936|Experimental|BI 894416 54 mg|SRD Part
88849688|NCT03315936|Experimental|BI 894416 70 mg|SRD Part
88849689|NCT03315936|Experimental|BI 894416 10mg tb / 10mg PfOS / 40mg tb|"BI 894416 10 mg tablet (tb) / BI 894416 10 mg powder for oral solution (PfOS) / BI 894416 4*10 mg tablets.~Relative bioavailability (rel BA) part"
88849690|NCT03315936|Experimental|BI 894416 10mg PfOS / 10mg tb / 40mg tb|"BI 894416 10 mg powder for oral solution (PfOS) / BI 894416 10 mg tablet (tb) / BI 894416 4*10 mg tablets.~Relative bioavailability (rel BA) part."
88849691|NCT03291028||Patients treated with immune check point blocker|Patients who were treated with immune checkpoint inhibitor targeting PD1 and developed metastatic lesion later
88849692|NCT03291028||Patients treated with targeted/ observational therapy|Patients who were not treated with immune checkpoint inhihibitor and developed metastatic lesion following other targeted therapy
88849693|NCT03290677|Experimental|CT-guided Percutaneous Cryoablation of Lung Tumor|"Image-guided core needle biopsy to confirm cancer will be perform~Patients will undergo cryoablation as a standard procedure~cryoablation will be performed with a three-cycle freeze-thaw phase protocol~Non-contrast CT images will be obtained in 3 to 5 minutes intervals to visualize the evolving ablation zone"
88849694|NCT03286322|Experimental|manual therapy cervical spine|
88849695|NCT03286322|Sham Comparator|control group|
88849696|NCT03285841||Cervical Sites|Imaging complete cervix from endocervical canal to transformation zone to ectocervix.
88849697|NCT03285841||Vulvar sites|Imaging vulvar lesions
88849698|NCT03274492|Experimental|R-CHP plus Vincristine Placebo plus Polatuzumab Vedotin|Participants will receive polatuzumab vedotin 1.8 milligrams per kilogram (mg/kg) intravenously (IV), placebo for vincristine IV, rituximab 375 milligrams per square meter (mg/m^2) IV, cyclophosphamide 750 mg/m^2 IV, and doxorubicin 50 mg/m^2 IV on Day 1 and prednisone 100 milligrams per day (mg/day) orally (PO) on Days 1-5 of every 21-day cycle for 6 cycles. Rituximab 375 mg/m^2 IV will be administered as monotherapy in Cycles 7 and 8.
88849699|NCT03274492|Placebo Comparator|R-CHOP plus Polatuzumab Vedotin Placebo|Participants will receive placebo for polatuzumab vedotin, rituximab 375 mg/m^2 IV, cyclophosphamide 750 mg/m^2 IV, doxorubicin 50 mg/m^2 IV, and vincristine 1.4 mg/m^2 IV (maximum 2 milligrams per dose [mg/dose]) on Day 1 and prednisone 100 mg/day PO on Days 1-5 of every 21-day cycle for 6 cycles. Rituximab 375 mg/m^2 IV will be administered as monotherapy in Cycles 7 and 8.
88849700|NCT03271372|Experimental|Arm I (avelumab)|Patients receive avelumab IV over 1 hour once every 15 days for the first 120 days (Induction Phase 1), once every 30 days for the next 120 days (Induction Phase 2), and then once every 120 days (Maintenance Phase) for a maximum of 720 days (approximately 24 months or 2 years total) in the absence of disease progression or unacceptable toxicity.
88849701|NCT03271372|Placebo Comparator|Arm II (placebo)|Patients receive placebo IV over 1 hour once every 15 days for the first 120 days (Induction Phase 1), once every 30 days for the next 120 days (Induction Phase 2), and then once every 120 days (Maintenance Phase) for a maximum of 720 days (approximately 24 months or 2 years total) in the absence of disease progression or unacceptable toxicity.
89376787|NCT01067846|Placebo Comparator|Placebo and Cognitive Behavioral Therapy|Subjects will receive a 250 mg identical looking placebo pill prior to computerized cognitive behavioral therapy.
89376788|NCT03657680||ATQ Group|Convenience sample of patients from Porto Alegre (RS, Brazil) who were experiencing unilateral hip osteoarthritis and were submitted to THA in referral hospitals at least five months previously to data collection. The volunteers were submitted to an evaluation of pain, range of motion, muscular strength and functional capacity.
89376789|NCT03657680||Control Group|The control group was composed of asymptomatic individuals from the community. The volunteers were submitted to an evaluation of pain, range of motion, muscular strength and functional capacity.
88849702|NCT03268850|Experimental|LW-A|The Lost Wages A (LW-A) arm will be composed of kidney transplant patients meeting the inclusion criteria. This arm allows for possible wage reimbursement of living donor lost wages up to a certain amount. This will also include standard of care.
89376790|NCT03658070|Experimental|XY0206-12.5mg|Drug:XY0206;Dosage form:Tablet;Dosage：12.5mg;Include single dose treatment and multiple dose phase
88849703|NCT03268850|Experimental|LW-B|The Lost Wages B (LW-B) arm will be composed of kidney transplant patients meeting the inclusion criteria. This arm allows for possible wage reimbursement of living donor lost wages up to a different amount. This will also include standard of care.
88849704|NCT03253289|Experimental|Meclizine 100 mg|Meclizine 50 mg will be taken by the patient orally twice daily for a total of 28 days(up to 35 days).
88849705|NCT03242031|Experimental|1 session|
88849706|NCT03242031|Active Comparator|4 sessions|
88849707|NCT03241550|Experimental|isavuconazonium sulfate IV cohort 1: 1 to < 6 years of age|Patients will receive an intravenous (IV) loading regimen of isavuconazonium sulfate, which consists of a dose every 8 hours (+/- 2 hours) on days 1 and 2, followed by once daily IV maintenance dosing for up to 26 additional days (for a maximum of 28 days of dosing).
88849708|NCT03241550|Experimental|isavuconazonium sulfate IV cohort 2: 6 to < 12 years of age|Patients will receive an IV loading regimen of isavuconazonium sulfate, which consists of a dose every 8 hours (+/- 2 hours) on days 1 and 2, followed by once daily IV maintenance dosing for up to 26 additional days (for a maximum of 28 days of dosing).
88849709|NCT03241550|Experimental|isavuconazonium sulfate IV cohort 3: 12 to < 18 years of age|Patients will receive an IV loading regimen of isavuconazonium sulfate, which consists of a dose every 8 hours (+/- 2 hours) on days 1 and 2, followed by once daily IV maintenance dosing for up to 26 additional days (for a maximum of 28 days of dosing).
88849710|NCT03241550|Experimental|isavuconazonium sulfate oral cohort 4: 6 to < 12 years of age|Patients will receive a loading regimen of isavuconazonium sulfate by oral administration, comprising one dose every 8 hours (+/- 2 hours) on days 1 and 2 (a total of six doses), followed by once daily oral maintenance dosing for up to 26 additional days (for a maximum of 28 days of dosing).
88849711|NCT03241550|Experimental|isavuconazonium sulfate oral cohort 5: 12 to < 18 years of age|Patients will receive a loading regimen of isavuconazonium sulfate by oral administration, comprising one dose every 8 hours (+/- 2 hours) on days 1 and 2 (a total of six doses), followed by once daily oral maintenance dosing for up to 26 additional days (for a maximum of 28 days of dosing).
89376791|NCT03658070|Experimental|XY0206-25mg|Drug:XY0206;Dosage form:Tablet;Dosage：25mg;Include single dose treatment and multiple dose phase
89376792|NCT03658070|Experimental|XY0206-37.5mg|Drug:XY0206;Dosage form:Tablet;Dosage：37.5mg;Include single dose treatment and multiple dose phase
89376793|NCT03658070|Experimental|XY0206-50mg|Drug:XY0206;Dosage form:Tablet;Dosage：50mg;Include single dose treatment and multiple dose phase
89376794|NCT03658070|Experimental|XY0206-75mg|Drug:XY0206;Dosage form:Tablet;Dosage：75mg;Include single dose treatment and multiple dose phase
89376795|NCT03658070|Experimental|XY0206-100mg|Drug:XY0206;Dosage form:Tablet;Dosage：100mg;Include single dose treatment and multiple dose phase
89376796|NCT03657914|Experimental|Inflatable mediastinal mirror|Patients with especially esophageal squamous cell carcinoma ( ESCC ) who meet the inclusion criteria and do not meet the exclusion criteria will undergo radical resection of single-hole inflatable mediastinal mirror synchronization with laparoscopic esophageal carcinoma, and will be followed up until 3 years after discharging from the hospital.
89376797|NCT03657524|Experimental|Resuscitation patients|
89376798|NCT03657524|Active Comparator|healthy volunteers|
89376799|NCT03311659|Experimental|dTpa group|Healthy female and male subjects with age 4 years and above and who received a single dose of Boostrix vaccine at Day 1.
88849712|NCT03223753|Active Comparator|Arm I (tracking device, limited version of device)|Patients receive educational handouts about physical activity and are encouraged to increase physical activity to at least 420 minutes per week. Patients wear physical activity tracking device daily and upload data at least once a week to the device app/website. Patients also access the limited version of device app/website to get basic information related to their physical activity for 6 months.
88875283|NCT02566590|Experimental|Control|Participants will complete bed rest but will receive a non-protein placebo supplement
88875284|NCT02566590|Experimental|NMES + PRO|Participants will receive daily treatment with neuromuscular electrical stimulation (NMES) and daily supplements of a protein drink.
88875285|NCT02568852|Active Comparator|group 1|Laparoscopic cholecystectomy in general anaesthesia
89376800|NCT03874234|Experimental|Part A: Subjects receiving GSK3186899 + placebo in Cohort 1|Subjects will receive 3 single ascending oral doses (SAD) of GSK3186899 and 1 dose of placebo as spray dried powder, under fasted conditions on Day 1 of cohort 1 in each of the four treatment periods. In each treatment period GSK3186899 and placebo will be administered in a 3:1 ratio. A wash out period of at least 10 days will be maintained between each treatment period.
89376801|NCT03874234|Experimental|Part A: Subjects receiving GSK3186899 + placebo in Cohort 2|Subjects will receive 3 SAD of GSK3186899 and 1 dose of placebo as spray dried powder, under fasted conditions on Day 1 of cohort 2 in each of the four treatment periods. In each treatment period GSK3186899 and placebo will be administered in a 3:1 ratio. A wash out period of at least 10 days will be maintained between each treatment period.
89376802|NCT03874234|Experimental|Part A: Subjects receiving GSK3186899 in Cohort 3|Subjects will receive GSK3186899 orally, under fasted condition and fed conditions on Day 1 of cohort 3 in each of the two treatment periods. There will be a wash out period of at least 10 days between each treatment period. A dose level will be determined based on the effect of food on the safety, tolerability and PK of a single dose of GSK3186899, with dose level selected from Cohorts 1 and 2.
89376803|NCT03874234|Experimental|Part B: Subjects receiving GSK3186899|Subjects will receive GSK3186899, orally, twice daily (BID) on Days 1 to 10. Subjects will receive each dose after either fed or fasted conditions. Part B will be initiated based on the review of all safety, tolerability and PK data from Part A.
89376804|NCT03874234|Placebo Comparator|Part B: Subjects receiving placebo|Subjects will receive placebo, orally, BID on Days 1 to 10. Subjects will receive each dose after either fed or fasted conditions. Part B will be initiated based on the review of all safety, tolerability and PK data from Part A.
88849713|NCT03223753|Experimental|Arm II (tracking device, interactive-reward based device)|Patients receive educational handouts about physical activity and are encouraged to increase physical activity to at least 420 minutes per week. Patients wear physical activity tracking device daily and upload data at least once a week to the device app/website. Patients also access the full version of the interactive-reward based device app/website to see their activity, earn activity points, see other's activity, and interact with other patients for 6 months.
88849714|NCT03170206|Experimental|Binimetinib Combine with Palbociclib Phase 1|"Palbociclib will be administered orally once daily~Patients will be dosed with palbociclib for three weeks out of every four weeks per cycle~Binimetinib will be administered orally twice daily~Patients will be dosed with Binimetinib continuously through the four weeks per cycle"
88849715|NCT03167203|Experimental|hESC-RPE cells|Participants previously enrolled into an Astellas Institute for Regenerative Medicine (AIRM) sponsored clinical trial and treated with Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial (hESC-RPE) cells
88849716|NCT03160339|Experimental|PXVX0047 treatment group|Subjects will receive PXVX0047 vaccine and Teva Placebo-to-Match
88849717|NCT03160339|Active Comparator|Teva Ad4/Ad7 treatment group|Subjects will receive Teva Ad4/Ad7 vaccine and PXVX0047 Placebo-to-Match
88849718|NCT03132415|Experimental|Get Connected|Get Connected is a brief intervention focused on resolving ambivalence about HIV prevention behaviors, increasing self-efficacy for change, and enhancing motivation moving toward action.
88849719|NCT03132415|Active Comparator|HIV Test Locator|Participants randomized to the control condition will receive the Get Connected testing site locator. Given the availability of search engines to locate HIV/STI testing sites, the test locator condition may be considered usual care.
88849720|NCT03126331|Experimental|Cohort I: Intermittent Nivolumab|Nivolumab monotherapy. Participants who have initial 10% or greater tumor burden reduction will discontinue nivolumab until they experience a pre-specified disease progression at which time nivolumab will be restarted
88849721|NCT03126331|Experimental|Cohort II: combination ipilimumab/nivolumab|"Combination of ipilimumab/nivolumab for previously untreated intermediate and poor risk mRCC~Includes participants treated front-line ipilimumab/nivolumab. Participants with treatment-naïve mRCC who receive up to four doses of induction ipilimumab/nivolumab and 24 weeks (+/- 8 weeks; minimum 3 infusions) of maintenance nivolumab and achieve stable disease (SD), complete response (CR), or partial response (PR) will be eligible for inclusion. Participants who achieve SD will continue with nivolumab maintenance per standard of care while those who achieve a PR or CR will enter an observation period off therapy. Upon disease progression, participants will be re-challenged with combination ipilimumab/nivolumab."
88849722|NCT03100903|Experimental|BI 655130 low dose SC|Subject received single low dose BI 655130 solution as subcutaneous (SC) injection on day 1.
88849723|NCT03100903|Experimental|BI 655130 high dose SC|Subject received single high dose BI 655130 solution as subcutaneous (SC) injection on day 1.
88849724|NCT03100903|Experimental|BI 655130 high dose IV|Subject received single high dose BI 655130 solution as 30 minutes intravenous (IV) infusion on day 1.
88849725|NCT03098355|Experimental|4SCAR19/22 T cells and interleukin-2|Patients with resistant or refractory B cell acute lymphoblastic leukemia (ALL) or non-hodgkin's lymphoma (NHL) will receive CAR-T cells at a total dose of 0.5-5x10^6/kg and regular subcutaneous injection of interleukin-2 every other day for 2 weeks and then rest for 2 weeks for up to 6 months after their serum interleukin-6 levels returned to normal range from day 28 after CAR-T cell infusion.
88849726|NCT03090646|No Intervention|Standard of Care|Participants in the control arm will be instructed to attend required follow-up as is standard of care, but will not receive a financial incentive.
89376805|NCT03657446|Experimental|Treatment sequence ABC|Period A: clazosentan Period B: placebo Period C: placebo + moxifloxacin
89376806|NCT03657446|Experimental|Treatment sequence ACB|Period A: clazosentan Period B: placebo Period C: placebo + moxifloxacinn
89376807|NCT03657446|Experimental|Treatment sequence BAC|Period A: clazosentan Period B: placebo Period C: placebo + moxifloxacin
89376808|NCT03657446|Experimental|Treatment sequence BCA|Period A: clazosentan Period B: placebo Period C: placebo + moxifloxacin
89376809|NCT03657446|Experimental|Treatment sequence CBA|Period A: clazosentan Period B: placebo Period C: placebo + moxifloxacin
89376810|NCT03657446|Experimental|Treatment sequence CAB|Period A: clazosentan Period B: placebo Period C: placebo + moxifloxacin
89376811|NCT05276323|Experimental|Medihoney Derma Cream|Intervention group: Medihoney Derma Cream will be applied topically, twice a day, on all affected areas in the body for two weeks. Then, follow-up for two more weeks, overall participating for 4 weeks in the trial.
89376812|NCT05276323|Active Comparator|Hydrocortisone 1% cream|control group: Hydrocortisone 1% cream will be applied topically, twice a day, on all affected areas in the body for two weeks. Then, follow-up for two more weeks, overall participating for 4 weeks in the trial.
89376813|NCT02727452|Experimental|immediate mother-skin-to-skin contact(SSC)|The immediate mother-SSC begins directly after birth (still during the C-section)
89376814|NCT02727452|Active Comparator|immediate father-SSC|The immediate father-SSC begins directly after birth (still during C-section)
89376815|NCT02727452|Other|Routine care;mother-SSC after 30 minutes|After birth (still during C-section) the newborn gets routine care of a midwife close to the mother. SSC with mother after 30 minutes
89376816|NCT05276245|Experimental|Program Group|This structured protocol was a 10-day nature-based program with high level of nature engagement and involvement of multiple sensory processes. The program was held in lunch breaks between 12:00 noon and 2:00 p.m. Each session consisted of 30 minutes in the Eco Garden of The Education University of Hong Kong. Activities of this program included walking, ecological photography, sketching butterflies, planting vegetables, drinking herbal tea, observing birds, and taking a nap in nature. Each activity corresponded to specific sensory pathways. For example, butterfly sketching is focused on the use of visual sense, whereas drinking herbal tea involved sense of taste, smell, and touch. Trainers with master's degrees in environmental education and rich experience in guiding ecological tours provided instructions and guidance to participants during the activities. Participants were also asked to pay attention to their surroundings and focus on their five senses during participation.
89376817|NCT05276245|No Intervention|Waitlist control group|Participants who were randomly assigned to the waitlist control group were instructed to spend their usual half-hour lunch break in the office for consecutive 10 weekdays. Also, the waitlist control group was told to wait for at least three months before they took part in the structured protocol of nature contact.
89376818|NCT05275777|Experimental|ADG106 combined with dose dense Doxorubicin and Cyclophosphamide (Phase Ib)|Intravenous ADG106 + 2 weekly doxorubicin and cyclophosphamide
89376819|NCT05275777|Experimental|ADG106 combined with Paclitaxel (Phase Ib)|Intravenous ADG106 + weekly paclitaxel
89376820|NCT05275777|Experimental|ADG106 combined with dose dense Doxorubicin and Cyclophosphamide follow by Paclitaxel (Phase II)|Intravenous ADG106 combined with two weekly doxorubicin and cyclophosphamide followed intravenous ADG106 combined with weekly paclitaxel
89376821|NCT02985398|Experimental|ALD403 (Eptinezumab) Dose Level 1|ALD403 (Eptinezumab) Dose Level 1 (IV)
89376822|NCT04744714||GDM group|questionnaire survey and clinical follow-up
88849727|NCT03090646|Experimental|Financial Incentive|Up to three gift cards to a major online retailer will be mailed to participants assigned to the intervention arm after complete (i.e. all components addressed) and timely (i.e. within the policy-defined follow-up period) submission of follow-up data at each 6-month, 1-year, and 2-year follow-up visit.
88849728|NCT03068741|Active Comparator|Comparison 1: Prehospital Ceftriaxone|1g of Ceftriaxone will be administered by immediate intramuscular (IM) injection. The drug is provided in a sterile and completely covered vial as a white, odourless powder
88849729|NCT03068741|Placebo Comparator|Comparison 1: Placebo|The placebo is provided in a sterile and completely covered vial.
88849730|NCT03068741|Experimental|Comparison 2: Liberal fluids|Paramedics will administer up to 2 litres of intravenous 0.9% saline solution to all participants in this arm regardless of blood pressure, reassessing for signs of volume overload after each 250ml.
89376823|NCT04744714||non-GDM group|questionnaire survey and clinical follow-up
89376824|NCT05275621|Experimental|Subjects requiring PICC|Subjects requiring a PICC. Positioning is first tried under Virtual Reality distraction. If failure (movements or discomfort) standard procedural sedation is applied. No kind of physical restraint is allowed.
89376825|NCT03310723|Active Comparator|Standard Face Mask Preoxygenation|Tidal volume breathing for via a face mask set at 100% oxygen and a rate of 15L/min.
89376826|NCT03310723|Experimental|Optiflow Preoxygenation|Tidal volume breathing with the OptiFlow system applied at 100% oxygen and a flow rate of 30-70L/min.
89376827|NCT02760290|Experimental|Extraperitoneal group|Extraperitoneal cesarean section will perform after rectus sheat incision and carefully bladder dissecting.
89376828|NCT02760290|Active Comparator|Intraperitoneal group|Conventional transperitoneal cesarean will perform
89376829|NCT05672212|Experimental|ANI (Analgesia/Nociception Index) monitoring|
88849731|NCT03068741|Active Comparator|Comparison 2: Conservative fluids|Paramedics will administer 0.9% saline solution to participants who have systolic blood pressure <90mmHg, and will only continue the infusion until the systolic blood pressure is >=100mmHg.
88849732|NCT03049618|Experimental|Treatment (pembrolizumab, sEphB4-HSA)|Patients receive pembrolizumab IV over 30 minutes on day 1 and recombinant EphB4-HSA fusion protein IV over 30 minutes on days 1, 8, and 15. Courses repeat every 3 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity.
88849733|NCT03032172|Experimental|Risdiplam|Participants will receive multiple doses of risdiplam orally once daily for 24 months. After 24-month treatment, participants will be offered the opportunity to enter the open-label extension (OLE) phase for 3 years.
89182062|NCT02473263|Active Comparator|Aggressive|Antibiotics (Ceftriaxone or piperacillin tazobactam) administration, hemodynamic optimization and opotherapy (norepinephrine, hydrocortisone) when required should be performed in the first 60 minutes after contact with the patient
89376830|NCT05672212|Active Comparator|Standard monitoring|
89376831|NCT05275309|Experimental|Children <= 1 years old|Pediatric patients <= 1 years old of age scheduled for surgery in the prone position
89376832|NCT02388022||degenerative disc disease|Patients who have had a transforaminal lumbar interbody fusion at 1-2 contiguous levels with the CALIBER® expandable spacer and have completed at least 2 year follow-up.
88849734|NCT02994459||Metabolically Normal Obese (likely insulin sensitive)|i) BMI ≥30.0 but <45.0 kg/m2; maximum body circumference <165 cm to ensure subjects fit into the PET/CT and MR scanners; iii) fasting blood glucose: <100 mg/dl; iv) blood glucose 2 h after an OGTT: <140 mg/dl; v) HbA1c <5.7 %; vi) fasting insulin: <20 µU/mL.
88849735|NCT02994459||Metabolically Abnormal Obese (likely insulin resistant)|i) BMI ≥30.0 but <45.0 kg/m2; maximum body circumference <165 cm to ensure subjects fit into the PET/CT and MR scanners; iii) fasting blood glucose: ≥100 mg/dl or blood glucose 2 h after an OGTT: ≥140 or fasting insulin: >20 µU/mL.
88849736|NCT02994459||Metabolically Normal Lean|i) BMI ≥18.5 but <25.0 kg/m2; ii) maximum body circumference <165 cm to ensure subjects fit into the PET/CT and MR scanners; iii) fasting blood glucose: <100 mg/dl; iv) blood glucose 2 h after an OGTT: <140 mg/dl; v) HbA1c <5.7 %; vi) fasting insulin: <20 µU/mL.
88849737|NCT02994459||Metabolically Abnormal Lean|i) BMI ≥18.5 but <25.0 kg/m2; ii) maximum body circumference <165 cm to ensure subjects fit into the PET/CT and MR scanners; iii) iii) fasting blood glucose: ≥100 mg/dl or blood glucose 2 h after an OGTT: ≥140 or fasting insulin: >20 µU/mL.
88849738|NCT02992951|Experimental|DACC-Coated Post-Operative Dressing|DACC-Coated Post-Operative Dressing
88849739|NCT02992951|No Intervention|Non-DACC coated Occlusive Post-operative Film Dressing|Non-DACC coated Occlusive Post-operative Film Dressing
88849740|NCT02970318|Experimental|Acalabrutinib (ACP-196)|Acalabrutinib (ACP-196) Monotherapy
88849741|NCT02970318|Active Comparator|Rituximab Plus Idelalisib or Bendamustine|Investigator's Choice of Rituximab Plus Idelalisib or Bendamustine
88849742|NCT02950961|Other|Arm 1: Mixed Methods Implementation Evaluation|The investigators used mixed methods to evaluate the implementation in two VA Women's Practice Based Research Network (PBRN) sites, describing services and patterns of care utilized by patients prior to seeing a care manager, and then 30, 60, 180, and 365 days post initiation of care with the care manager. Investigators also evaluated facilitators and barriers to implementation of this collaborative care model.
88849743|NCT02945631|Experimental|Reduced Dose Radiation|All patients will receive daily radiation treatment with intensity-modulated radiotherapy (IMRT) - PTV56 and PTV50.4. Treatment will be given 5 days per week and will not routinely be delivered on Saturday, Sunday or major holidays unless a treatment is missed during the week due to technical and/or medical reasons. No more than 5 treatments should be given per week.
88849744|NCT02852824|Experimental|BI 655130 (spesolimab)|
88849745|NCT02852824|Placebo Comparator|Placebo|
88849746|NCT02786277|Experimental|Recommended|Those whose uplift score represents a probability of benefit greater than 0.5 will generate an alert, while those whose uplift score represents a probability of benefit less than 0.5 will not generate an alert.
88849747|NCT02786277|Experimental|Anti-recommended|Those whose uplift score represents a probability of benefit greater than 0.5 will not generate an alert, while those whose uplift score represents a probability of benefit less than 0.5 will generate an alert.
88849748|NCT02782949|Experimental|Arm I (curcumin)|Patients receive curcumin PO BID for 180 days in the absence of unacceptable toxicity.
88849749|NCT02782949|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID for 180 days in the absence of unacceptable toxicity.
88849750|NCT02771730|Experimental|Vaccine A|Receive Ad4-mgag three times at 0,2,and 6 months with a boost at 8months
88849751|NCT02771730|Experimental|Vaccine B|Receive Ad4-EnvC150 three times at 0,2,and 6 months with a boost at 8 months
88849752|NCT02771730|Experimental|Vaccine A & B|Receive both Ad4-mgag and Ad4-EnvC150 three times at 0,2,and 6 months with a boost at 8 months
89376833|NCT02725892||lungcancer patients|Men or women diagnosed with lung cancer all types and stages confirmed over 12 months of recruitment period by a pathologist
89376834|NCT05275153|Experimental|Home based cognitive rehabilitation program|The intervention was conducted for 30 minutes each time, 3 times a week for 8 weeks, a total of 24 times.
89376835|NCT05275153|No Intervention|No intervention|In the control group, natural cognitive changes with the passage of time were observed.
89376836|NCT02390674|Active Comparator|Ciclosporin|Single intravenous administration of ciclosporin (2.5mg per kilogram body weight) immediately prior to reperfusion during primary percutaneous coronary intervention. Ciclosporin is dissolved in saline (maximum concentration 2.5mg per millilitre)
88849753|NCT02771730|Placebo Comparator|Placebo|Receive placebo three times at 0,2,and 6 months with a boost at 8 months
88849754|NCT02771730|Experimental|Vaccine A & B (previously received study vaccine)|People who have previously had a study vaccine: Receive both Ad4-mgag and Ad4-EnvC150 three times at 0,2,and 6 months with a boost at 8 months
88849755|NCT02762006|Experimental|Durvalumab + Tremelimumab with Nephrectomy|"Following systemic therapy, patients will undergo nephrectomy. Adjuvant therapy will be administered within 4-6 weeks of surgery. Subsequent follow-up will then be completed to assess adverse event resolution and long-term outcomes.~Cohort 1: Durvalumab x 1 dose (n=6)~Cohort 2: Durvalumab + Tremelimumab x 1 dose (n=6)~Cohort 2a: Durvalumab + Tremelimumab x 1 dose (n=12)~Cohort 3: Durvalumab + Tremelimumab x 1 dose (n=9)~Cohorts 1 and 2: Adjuvant dosing of Durvalumab x 1 beginning 2-8 weeks after surgery.~Cohort 2a: Durvalumab monotherapy until 1 year after nephrectomy.~Cohort 3: Adjuvant dosing of durvalumab + tremelimumab x 1 beginning 2-8 weeks after surgery, then durvalumab monotherapy until 1 year after nephrectomy."
88849756|NCT02734823||Ancillary-Correlative (ovary imaging, hormonal analysis)|Patients undergo transvaginal ultrasound for antral follicles analysis and collection of serum for ovarian reserve markers and hormonal analysis before TKI therapy and at 12, 24, and 48 weeks.
88849757|NCT02679352|Experimental|SMR stemless|Patients requiring a primary anatomic or reverse shoulder arthroplasty, due to symptomatic painful degenerative joint diseases with good bone stock
88849758|NCT02618434|Experimental|Low dose SPN-810 (18 mg)|Oral
88849759|NCT02618434|Experimental|High dose SPN-810 (36 mg)|Oral
88849760|NCT02618434|Placebo Comparator|Placebo|Oral
88849761|NCT02605538|Active Comparator|Cystic Fibrosis|Vaccination with Twinrix (TM), 3 doses within 6 months according to the manufacturer's instruction. The response will be studied in a time frame of 6 months.
89376837|NCT02390674|Placebo Comparator|Saline|Single intravenous administration of placebo (saline) immediately prior to reperfusion during primary percutaneous coronary intervention
89376838|NCT03657290|Active Comparator|Treatment A|vadadustat 3 X 150 mg Tablets in fasted subjects
89376839|NCT03657290|Active Comparator|Treatment B|Vadadustat 1 X 450 mg Tablets in fasted subjects
89376840|NCT03657290|Active Comparator|Treatment C|vadadustat 1 X 450 mg Tablets in fed subjects
88875286|NCT02568852|Active Comparator|group 2|Laparoscopic cholecystectomy in combined anaesthesia (Spino epidural).
88849762|NCT02605538|Active Comparator|Healthy volunteers|Vaccination with Twinrix (TM), 3 doses within 6 months according to the manufacturer's instruction. The response will be studied in a time frame of 6 months.
88849763|NCT02593825|Experimental|START-Play intervention|Intervention incorporating cognitive factors and focusing on self-initiated movement toward achievement of skill in sitting and reaching to increase problem-solving skills, which will then improve overall developmental outcomes. Visits to home by physical therapist twice weekly with parent training, for 3 months.
88849764|NCT02593825|Active Comparator|Business as Usual|Early motor intervention provided as standard treatment in the home for infants with motor dysfunction who are just beginning to sit. Dosage and content of intervention may vary from infant to infant and geographically.
88849765|NCT02574442||Initial Colposcopy Visit|Women with a scheduled colposcopy and biopsy appointment at the Women's Clinic at Vancouver General Hospital
88849766|NCT02559856|Active Comparator|Apixaban|10 mg PO twice-a-day for 1 week, then 5 mg PO, twice daily for 3 or 6 months of treatment.
88849767|NCT02559856|Active Comparator|Rivaroxaban|15 mg PO twice-a-day for 3 weeks, then 20 mg PO once daily for 3 or 6 months of treatment.
88849768|NCT02537548|Experimental|Treatment (RPLND)|Patients undergo RPLND.
88849769|NCT02483312|Experimental|IL-12|A single dose of IL-12, given intravenously.
88849770|NCT02443623|Experimental|Single Arm Vaccinated with ACAM2000|"To vaccinate plasma donors with the ACAM2000 smallpox vaccine thereby inducing an immune response resulting in high anti-vaccinia antibody titers. The collection of donor plasma will be used in the manufacturing of Vaccinia Immune Globulin Intravenous (VIGIV).~To ensure the safety of plasma donors vaccinated with ACAM2000 through the implementation of risk factor screening procedures and the collection of post-vaccination safety data."
88849771|NCT02411448|Experimental|Ramucirumab + Erlotinib|"Part A: 10 milligrams per kilogram (mg/kg) ramucirumab administered every 2 weeks intravenously (IV) in combination with 150 mg erlotinib daily orally.~Participants may continue to receive treatment until discontinuation criteria are met.~Part B: 10 mg/kg ramucirumab administered every 2 weeks IV in combination with 150 mg erlotinib daily orally. Participants may continue to receive treatment until discontinuation criteria are met."
88849772|NCT02411448|Placebo Comparator|Placebo + Erlotinib|"Part B: Placebo administered every 2 weeks IV in combination with 150 mg erlotinib daily orally.~Participants may continue to receive treatment until discontinuation criteria are met."
88849773|NCT02411448|Experimental|Ramucirumab + Gefitinib or Osimertinib|"Part C: 10 mg/kg ramucirumab administered every 2 weeks intravenously (IV) + 250 mg Gefitinib or 80 mg Osimertinib daily orally.~Ramucirumab and gefitinib administered during period 1.~Ramucirumab and osimertinib administered during period 2."
89002431|NCT06317857|Experimental|Centio Forte (Ivoclar).|"A new class of bioactive alkasite restorative materials has been released in the market. They're composed of three main filler types: salinized inert barium aluminium silicate glass, calcium barium aluminium fluorosilicate glass similar to glass-ionomers, and calcium fluorosilicate glass or alkasite glass. Cention N (Ivoclar Vivadent) was the first available material in the material in the form of powder/liquid, later on, Cention forte was released which is the modified capsulated form with a special adhesive system Marovic et al. (2022).~Cention has the ability to remineralize hard dental tissues through calcium and fluoride release and can also neutralize bacterial acids through hydroxide ions release Par et al. (2020)."
89002432|NCT06317857|Active Comparator|Highly viscous glass ionomer|"Glass-ionomer restorations (GI) are widely used in restorative dentistry. One of their advantages is their chemical adhesion to tooth structure. They also possess a fluoride-releasing property and biocompatibility. Although GIs are commonly used, they have some disadvantages. The most intractable problem with the conventional GIs is probably their lack of strength and toughness. In order to improve the mechanical properties of conventional GICs, reinforced GIs were developed. These reinforced GIs or now commonly known as highly viscous GIs provide improved mechanical properties and wear resistance, easier application allowing their use in posterior stress bearing cavity preparations Bakhadher et al.~(2019)."
88849776|NCT02339155|Experimental|Anthrax Vaccine Adsorbed|Subjects will be administered subcutaneous (SC) 0.5 mL AVA doses on Days 1, 15, and 29 (0, 2, and 4 weeks).
88849777|NCT02339155|Experimental|AVA + Raxibacumab|Subjects will be administered SC 0.5 mL AVA doses on Days 1, 15, and 29 (0, 2, and 4 weeks), with the first AVA dose administered immediately after completion of a single intravenous (IV) infusion 40 milligram (mg)/kilogram (kg) raxibacumab dose. Subjects will be premedicated with 25-50 mg of diphenhydramine up to 1 hour prior to the raxibacumab infusion to reduce the risk of infusion reactions.
88849778|NCT02301286|Experimental|Aspirin|Patients treated with acetylsalicylic acid 80 mg once daily for 5 years. Patients will be stratified according to the admission of adjuvant chemotherapy.
88849779|NCT02301286|Placebo Comparator|Placebo|Patients treated with placebo. Patients will be stratified according to the admission of adjuvant chemotherapy.
88849780|NCT02293811|Other|biopsy|"We will use colonic biopsies performed in the gastroenterology after obtaining consent from the patient and the agreement of the committee for the protection of persons. 5 biopsy will be performed for all patients except those with colon cancer for xhich we realize only 3 colonic biopsy (1 in healthy area and 2 in cancerous area )~To obtain statistically significant results we will establish the following six study groups, as far as possible matched for age and sex:~healthy patients;~patients with colonic Crohn disease in acute phase;~patients with colonic Crohn disease in chronic phase;~patients with ulcerative colitis in acute phase;~patients with ulcerative colitis in chronic phase;~patients with colon cancer"
88849781|NCT02246621|Experimental|Abemaciclib + NSAI|150 milligrams (mg) Abemaciclib orally every 12 hours plus either 1 mg anastrozole or 2.5 mg letrozole orally once daily for 28 days (28 day cycles).
88849782|NCT02246621|Placebo Comparator|Placebo + NSAI|Placebo orally every 12 hours plus either 1 mg anastrozole or 2.5 mg letrozole orally once daily for 28 days (28 day cycles).
88849783|NCT02216838|Experimental|botulinum toxin A|This study is randomized, which means the subject will be randomly assigned (like a flip of a coin) to receive botox on the right or left side of the face and saline injections on the other side. Only one side of the face will receive botox injections.
88875287|NCT02569632|Experimental|Open Label: MenB-FHbp|Trumenba Meningococcal Group B Vaccine (Wyeth/Pfizer Pharmaceuticals)
89182063|NCT03222609|Experimental|Navitoclax + ruxolitinib|Participants will be administered navitoclax once daily (QD) at various doses and a dose greater than or equal to 10 mg of ruxolitinib twice daily (BID).
89376841|NCT02390830|Experimental|Intervention|Participants in the intervention group received at least 25-45' of balance treatment. The balance treatments were aimed at improving participants' control of the position and movement of the center of mass and body segments during static, dynamic and transitional tasks.
89376842|NCT02390830|Active Comparator|Control|Participants in the control group were treated to reduce limitations at body function and activity levels, while treatment for balance disorders was restricted to a maximum of 10' per session. Treatment mainly focused on increasing range of joints motion, reducing of muscle contractures and strength training.
89376843|NCT02387944||Cardiopulmonary bypass|Children with congenital heart defect undergoing surgery on cardiopulmonary bypass
89376844|NCT02387944||cardiac catheterism|Children with congenital heart defect undergoing cardiac catheterism
89376845|NCT02613728|Active Comparator|Standard of Care Arm|Standard enhanced care following minimally invasive colorectal cancer surgery
89376846|NCT02613728|Experimental|Intervention (RecoverMI) Arm|Routine care with Accelerated Recovery Plan, Early Discharge, and Telemedicine following minimally invasive colorectal cancer surgery
89376847|NCT02390596|Experimental|Anakinra|
89376848|NCT02663674|Placebo Comparator|Group 1|A single dose of Fluconazole placebo (2 capsules) administered orally once daily for 42 days starting on Day 1. N=500
89376849|NCT02663674|Experimental|Group 2|400 mg of Fluconazole (2 capsules of 200 mg) administered orally once daily for 42 days starting on Day 1. N=500
89182064|NCT03222609|Experimental|Navitoclax|Participants will be administered various doses of navitoclax once daily (QD)
89376850|NCT02908880|Experimental|MANTA vascular closure device|Open label, single arm study using the MANTA device, developed by Essential Medical, Inc. MANTA is a vascular closure device (VCD) intended for use in catheterization laboratories following percutaneous cardiac or peripheral procedures that use the retrograde common femoral artery access route for large bore (10-18F) interventional devices.
89376851|NCT03657212|Active Comparator|Nap/5mg Zolpidem|The research involves oral administration of zolpidem (ZOL, 5mg) or placebo during sleep with EEG recording. This study will employ a within-subject, crossover design, in which every subject experiences each of the following study conditions: Nap/5mg, Nap/placebo, plus an adaptation nap to be scheduled one week prior to the first experimental day. One condition will be tested per week, with condition order counterbalanced. Each subject will have 2 visits (plus an adaptation nap), each separated by 5-7 days (although this may be extended based on participant availability) to ensure that the drug is completely eliminated from the body. The order of drug conditions will be randomized and counterbalanced. During the experimental phase, each drug condition will include one day in the sleep lab, two encoding test sessions, and one retrieval test session. Multiple subjects will be in the experimental phase concurrently, and multiple subjects will be tested on each day.
89399381|NCT03686709|Experimental|TheraSpheres Therapy Selection|Patient selected for TheraSpheres radioembolization therapy using standard of care selection. Infusion of the therapy dose will be monitored using external detectors placed on the delivery system as well as the points on the patient. Blood draws will be collected before, during, and after the therapy infusion to monitor radiation levels in the blood. Following therapy, the patient will undergo standard of care bremsstrahlung SPECT imaging as well post-infusion PET/CT. A final blood draw will take place in conjunction with PET/CT imaging.
89399382|NCT02173496||Colour contrast sensitivity|Colour contrast sensitivity
89182065|NCT02578485|Experimental|AVideogame|Session with active video game lasting 60 minutes performing heart rate measurements every 10 minutes and evaluating the perceived exertion.
89376852|NCT03657212|Placebo Comparator|Nap/Placebo|The research involves oral administration of zolpidem (ZOL, 5mg) or placebo during sleep with EEG recording. This study will employ a within-subject, crossover design, in which every subject experiences each of the following study conditions: Nap/5mg, Nap/placebo, plus an adaptation nap to be scheduled one week prior to the first experimental day. One condition will be tested per week, with condition order counterbalanced. Each subject will have 2 visits (plus an adaptation nap), each separated by 5-7 days (although this may be extended based on participant availability) to ensure that the drug is completely eliminated from the body. The order of drug conditions will be randomized and counterbalanced. During the experimental phase, each drug condition will include one day in the sleep lab, two encoding test sessions, and one retrieval test session. Multiple subjects will be in the experimental phase concurrently, and multiple subjects will be tested on each day.
89376853|NCT03310411|Experimental|Lasmiditan + Sumatriptan (A)|Single oral dose of 200 milligram (mg) lasmiditan tablet and single oral dose of 100 mg sumatriptan tablet in one of four treatment periods.
89376854|NCT03310411|Experimental|Lasmiditan + Placebo (B)|Single oral dose of 200 mg lasmiditan tablet and single oral dose of placebo tablet in one of four treatment periods.
89376855|NCT03310411|Active Comparator|Sumatriptan + Placebo (C)|Single oral dose of 100 mg sumatriptan tablet and single oral dose of placebo tablet in one of four treatment periods.
89376856|NCT03310411|Placebo Comparator|Placebo + Placebo (D)|Oral doses of placebo tablets in one of four treatment periods.
89376857|NCT03301831|Experimental|Resourcefulness Training Intervention|The intervention arm will receive an intervention that includes: a face-to-face session for teaching social (help-seeking) and personal (self-help) resourcefulness skills; ongoing access to video vignettes of caregivers of technology-dependent children describing resourcefulness skill application in daily life; 4 weeks of skills' reinforcement using daily journal writing; weekly phone calls for the first 4 weeks; and booster sessions at 2 and 4 months post enrollment.
89376858|NCT03301831|No Intervention|Attention Control|The Attention Control arm will receive weekly phone calls for the first 4 weeks and at 2 and 4 months post enrollment plus any usual care.
89376859|NCT02909504|Other|Lithium|Eligible patients will receive lithium 300 mg twice daily and titrated in 300 mg increments every 7 days as tolerated to levels > 0.6 mEq/L
89376860|NCT02505230|Experimental|Meal Order 1|"[P,P+S,HVP,LVP]~For the PASTA (P) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) and no vegetables.~For the PASTA+SIDE (P+S) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) with a side of mixed zucchini and squash (cut in 1/2 inch half-moon slices).~For the HIGH-VOLUME PASTA (HVP) condition, participants view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) mixed with zucchini and squash (cut in 1/2 inch half-moon slices).~For the LOW-VOLUME PASTA (LVP) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) mixed with grated zucchini and squash (chopped in food processor)."
89376861|NCT02505230|Experimental|Meal Order 2|"[P+S,HVP,LVP,P]~For the PASTA+SIDE (P+S) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) with a side of mixed zucchini and squash (cut in 1/2 inch half-moon slices).~For the HIGH-VOLUME PASTA (HVP) condition, participants view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) mixed with zucchini and squash (cut in 1/2 inch half-moon slices).~For the LOW-VOLUME PASTA (LVP) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) mixed with grated zucchini and squash (chopped in food processor).~For the PASTA (P) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) and no vegetables."
89376862|NCT02505230|Experimental|Meal Order 3|"[HVP,LVP,P,P+S]~For the HIGH-VOLUME PASTA (HVP) condition, participants view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) mixed with zucchini and squash (cut in 1/2 inch half-moon slices).~For the LOW-VOLUME PASTA (LVP) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) mixed with grated zucchini and squash (chopped in food processor).~For the PASTA (P) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) and no vegetables.~For the PASTA+SIDE (P+S) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) with a side of mixed zucchini and squash (cut in 1/2 inch half-moon slices)."
89376863|NCT02505230|Experimental|Meal Order 4|"[LVP,P,P+S,HVP]~For the LOW-VOLUME PASTA (LVP) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) mixed with grated zucchini and squash (chopped in food processor).~For the PASTA (P) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) and no vegetables.~For the PASTA+SIDE (P+S) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) with a side of mixed zucchini and squash (cut in 1/2 inch half-moon slices).~For the HIGH-VOLUME PASTA (HVP) condition, participants view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) mixed with zucchini and squash (cut in 1/2 inch half-moon slices)."
89376864|NCT02390206||Botulinum toxin type A (BoNT-A) injection Naïve|Subjects naïve to BoNT-A treatment. Investigators follow their individual injection protocol for treatment with BoNT-A (modalities of administration in accordance with local Summary of Product Characteristics and locally agreed therapeutic guidelines).
89376865|NCT02390440|Experimental|EXPAREL|single dose, 266mg (20mL) of EXPAREL injected to slowly infiltrate the soft tissue around the site of fracture
89399383|NCT02173574|Experimental|Open-Label Single Arm Cohort|
88849784|NCT02216838|Placebo Comparator|Saline Control|This study is randomized, which means the subject will be randomly assigned (like a flip of a coin) to receive botox on the right or left side of the face and saline injections on the other side. Only one side of the face will receive botox injections.
88849785|NCT02142946||RIS MS patients|Radiologically Isolated Syndrome (RIS) MS patients
88849786|NCT02142946||CIS MS patients|Clinically Isolated Syndrome (CIS) patients during a stable phase
88849787|NCT02142946||RRMS patients|Relapsing-remitting (RR) MS patients during a stable phase
88849788|NCT02142946||SPMS Patients|Secondary progressive MS patients (SPMS)
88849789|NCT02142946||PPMS Patients|Primary progressive MS patients (PPMS)
88849790|NCT02142946||Controls|Age and gender matched controls
88849791|NCT02142946||CI Patients|Cochlear Implant patients pre- and post-operatively
88849792|NCT02142946||UVL Patients|Unilateral vestibular loss patients in acute and compensated state
88849793|NCT02142946||Chronic UVL|Chronic unilateral vestibular loss patients
88849794|NCT02142946||Phobic|Phobic vertigo patients
88849795|NCT02081378|Experimental|Asciminib in CML patients|Dose escalation study estimated the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) of asciminib in adult patients with chronic myeloid leukemia (CML).
88849796|NCT02081378|Experimental|Asciminib+Nilotinib in CML patients|Dose escalation study estimated the MTD and/or RDE of asciminib in combination with Nilotinib in adult CML patients
88849797|NCT02081378|Experimental|Asciminib in Ph+ ALL patients|Dose escalation study estimated the MTD and/or RDE of asciminib in adult patients with Ph positive ALL patients
88849798|NCT02081378|Experimental|Asciminib+Imatinib in CML patients|Dose escalation study to estimate the MTD and/or RDE of asciminib in combination with imatinib in adult CML patients
88849799|NCT02081378|Experimental|Asciminib+dasatinib in CML patients|Dose escalation study estimated the MTD and/or RDE of asciminib in combination with dasatinib in adult CML patients
88849800|NCT02061358|Experimental|Cohort 1 - 3 mg UV-4B|Subjects receiving UV-4B 3 mg oral solution or placebo
88849801|NCT02061358|Experimental|Cohort 2 - 10 mg UV-4B|Subjects receiving UV-4B 10 mg oral solution or placebo
88849802|NCT02061358|Experimental|Cohort 3- 30 mg UV-4B|Subjects receiving UV-4B 30 mg oral solution or placebo
88849803|NCT02061358|Experimental|Cohort 4 - 90 mg UV-4B|Subjects receiving UV-4B 90 mg oral solution or placebo
88849804|NCT02061358|Experimental|Cohort 5 - 180 mg UV-4B|Subjects receiving UV-4B 180 mg oral solution or placebo
88849805|NCT02061358|Experimental|Cohort 6 - 360 mg UV-4B|Subjects receiving UV-4B 360 mg oral solution or placebo
88849806|NCT02061358|Experimental|Cohort 7 - 720 mg UV-4B|Subjects receiving UV-4B 720 mg oral solution or placebo
88849807|NCT02061358|Experimental|Cohort 8 - 1000 mg UV-4B|Subjects receiving UV-4B 1000 mg oral solution or placebo
88849808|NCT02034955|Experimental|Post-Operative adaptive radiotherapy|All Patients enrolled in this study will have additional scans (Cone-Beam CT, MRI) daily during their treatment. This extra imaging will help us see any changes that might have occurred during radiation treatment and update the treatment plan to include these changes before patient treatment is continued.
88849809|NCT02022215|Experimental|ME1111 Solution, Low strength|
88849810|NCT02022215|Experimental|ME1111 Solution, High strength|
88849811|NCT02022215|Placebo Comparator|Matching Vehicle Solution|
88849812|NCT02019004|Active Comparator|Onabotulinum Toxin A|One side of the face will be randomized to receive Onabotulinum Toxin A injections in the forehead and glabellar region of the face.
88849813|NCT02019004|Active Comparator|Incobotulinum Toxin A|The other side of the face will be randomized to receive Incobotulinum Toxin A injections in the glabellar and forehead region of the face.
88849814|NCT02000089|Active Comparator|Familial pancreas cancer relatives|"High Risk Group 2 (familial pancreatic cancer relatives):~> 55 years old or 10 years younger than the age of youngest relative with pancreatic cancer, and~come from a family with 2 or more members with a history of pancreatic cancer (2 of which have a first-degree relationship consistent with familial pancreatic cancer), and~have a first-degree relationship with at least one of the relatives with pancreatic cancer.~If there are 2 or more affected blood relatives, at least 1 must be a first-degree relative of the individual being screened"
88849815|NCT02000089|Active Comparator|Group 1 germline mutation carrier|"High Risk Group 3 (Group 1 germline mutation carriers with an associated with an estimated lifetime risk of pancreatic cancer of ~10% or higher):~a. > 50 years old or 10 years younger than the age of the youngest relative affected, if pancreatic cancer is in family, and b. The Patient is a carrier of a confirmed BRCA2, ATM or PALB2 mutation, regardless of family history of pancreatic cancer. b.> Individual is a carrier of a confirmed FAMMM (p16/CDKN2A) mutation, age 40 years or older, regardless of family history of pancreas cancer."
88849816|NCT02000089|Active Comparator|Group 2 germline mutation carrier|"High Risk Group 4 (Group 2 germline mutation carriers with an associated with an estimated lifetime risk of pancreatic cancer of ~5%):~> 50 years old or 10 years younger than the age of the youngest relative with pancreatic cancer, and~The patient is a carrier of a confirmed BRCA1 or HNPCC (hereditary non-polyposis colorectal cancer or Lynch syndrome, hMLH1, hMSH2, PMS1, hMSH6, EpCAM) gene mutation, and there is > 1 pancreatic cancer in the family, one of whom is a first- or second-degree relative of the subject to be screened."
88875288|NCT02570022|Experimental|Liposomal bupivacaine|Patients in this group received local infiltration of Liposomal bupivacaine before the end of surgery.
88849817|NCT02000089|Active Comparator|Hereditary pancreatitis|High risk group 5 (hereditary pancreatitis) with confirmed gene mutations that predispose to chronic pancreatitis, such as PRSS1, PRSS2, CTRC) and age 50 years or older (these patients have an estimated lifetime risk for pancreatic cancer of 40%) or twenty-years since their first attack of pancreatitis, whichever age is younger.
88875289|NCT02570022|Active Comparator|Inter-scalene nerve block|Patients in this group received preoperative ultrasound guided inter-scalene nerve blocks by senior anesthesiologist using ropivicaine.
88849818|NCT02000089|Active Comparator|Peutz-Jeghers Syndrome|"At least 30 years old, and~at least 2 of 3 criteria diagnostic of Peutz-Jeghers syndrome (characteristic intestinal hamartomatous polyps, mucocutaneous melanin deposition, or family history of Peutz-Jeghers syndrome), or,~known STK11 gene mutation carrier"
88849819|NCT02000089|Active Comparator|Negative control|"are undergoing routine EGD or Colonoscopy; or Endoscopic Ultrasound (EUS) and/or Endoscopic Retrograde Cholangiopancreatography (ERCP) for non-pancreatic indications as part of their standard medical care, and~have no clinical or radiologic suspicion of pancreatic disease (chronic pancreatitis or pancreatic cancer)"
88849820|NCT02000089|Active Comparator|Chronic Pancreatitis|"are undergoing EUS and/or ERCP for evaluation and/or treatment of suspected or proven chronic pancreatitis as part of their standard medical care, and,~have no clinical or radiologic suspicion of pancreatic cancer"
88849821|NCT02000089|Active Comparator|Pancreas cancer|a. are undergoing EUS and/or ERCP for evaluation and/or treatment of suspected or proven pancreatic ductal adenocarcinoma (based on clinical and radiologic evidence)
88849822|NCT02000089|Active Comparator|Pancreas cyst, IPMN evaluation|are undergoing EUS and/or ERCP for evaluation and/or treatment of suspected or proven pancreatic cancer precursor, intraductal papillary mucinous neoplasm (based on clinical presentation and radiologic or prior EUS or radiologic evidence of a dilated main pancreatic duct and/or pancreatic cystic lesion communicating with the pancreatic ductal system).
88849823|NCT01979406|Active Comparator|AVA|Anthrax Vaccine Adsorbed (0.5 mL) as the placebo control on Days 1, 15 and 29
88849824|NCT01979406|Experimental|Ad4-PA-1|"Given at 10^9, 10^10 and 10^11 vp~Ad4-PA at Day 1 + oral placebo on Day 15 + AVA boost at Day 29"
88849825|NCT01979406|Experimental|Ad4-PA-2|"Given at 10^9, 10^10 and 10^11 vp~Ad4-PA at Days 1, 15 and 29"
88849826|NCT01979406|Experimental|Ad4-PA-3|"Ad4 given at 10^9, 10^10 and 10^11 vp~Ad4 PA-GPI at Day 1 + AVA boost at Day 15 + placebo on Day 29"
88849827|NCT01979406|Experimental|Ad4-PA-GPI-1|"Given at 10^9, 10^10 and 10^11 viral particles~Ad4 PA-GPI at Day 1 + oral placebo on Day 29 + AVA boost at Day 15"
88849828|NCT01979406|Experimental|Ad4 PA-GPI-2|"Given at 10^9, 10^10 and 10^11 viral particles~Ad4 PA-GPI at Day 1 + placebo on Day 15 + AVA boost at Day 29"
88849829|NCT01979406|Experimental|Ad4-PA-GPI -3|"Given at 10^9, 10^10 and 10^11 viral particles~Ad4-PA-GPI at Days 1, 15 and 29"
88849830|NCT01976260|Active Comparator|Fractional Radiofrequency|Subjects will be randomly assigned to receive fractional radiofrequency treatment to either the right or left side of the face and the contralateral side will receive 1550-nm fractional photothermolysis. Subjects will receive treatments at baseline, week 4, and week 8 for a total of three treatments. Follow up visits will take place at week 16, two months following the last treatment visit.
88849831|NCT01976260|Active Comparator|1550-nm Fractional Photothermolysis|Subjects will be randomly assigned to receive fractional radiofrequency treatment to either the right or left side of the face and the contralateral side will receive 1550-nm fractional photothermolysis. Subjects will receive treatments at baseline, week 4, and week 8 for a total of three treatments. Follow up visits will take place at week 16, two months following the last treatment visit.
88849832|NCT01976247|Active Comparator|Noninvasive Cryolipolysis Device|The Zeltiq System is a noninvasive (not breaking the skin) device that reduces fat by freezing fat cells until they break apart.
88849833|NCT01976247|Active Comparator|High Intensity Focused Ultrasound Device|The LipoSonix System is a noninvasive ultrasound device, which can be used to selectively target and destroy fat tissue located deep under the skin.
88849834|NCT01841034||Conceptio|Any patient receipt within the framework of the coverage(care) of an infertility in the pole ORG, whatever is the étiologie and the type of treatment proposing and presenting during at least two spermogrammes an oligospermie and\or an asthénospermie. The necessity of realizing 2 spermogrammes different to determine the pathological character of the values of a spermogramme takes into account the personal variability of the results.
88849835|NCT01802346|Experimental|Arm I (low-calorie diet)|Patients eat a special low-calorie diet during 3 days prior to chemotherapy, during the 12 weeks of chemotherapy, and 2 days after chemotherapy. Patients are provided with all meals and all food to be consumed and maintain a diary of the food consumed and appropriate amounts.
88849836|NCT01802346|Active Comparator|Arm II (normal diet)|Patients eat a normal diet and receive dietary advice which may include consultation with a nutritionist. Patients maintain a diary of the food consumed and appropriate amounts.
88849837|NCT01802242|Experimental|Active Radiation Treatment (Cohort 2)|
88849838|NCT01802242|Other|Prior Radiation Treatment (Control Cohort)|Patients who received 78Gy RT to the prostate gland 3-4.5 years prior to enrollment. This group will not be receiving any active treatment
88849839|NCT01770743|Experimental|AV7909 (Day 0 and 14)|Route of administration: Intramuscular Dose: 0.5 mL Schedule: Day 0 and Day 14
88849840|NCT01770743|Experimental|AV7909 (Day 0 and 28)|Route of administration: Intramuscular Dose: 0.5 mL Schedule: Day 0 and Day 28
88849841|NCT01770743|Experimental|AV7909 (Day 0, 14, and 28)|Route of administration: Intramuscular Dose: 0.5 mL Schedule: Day 0, Day 14,and Day 28
88849842|NCT01770743|Experimental|AV7909 Reduced Dose|Route of administration: Intramuscular Dose: 0.25 mL Schedule: Day 0, Day 14,and Day 28
88849843|NCT01770743|Active Comparator|BioThrax|Route of administration: Intramuscular Dose: 0.5 mL Schedule: Day 0, Day 14,and Day 28
88849844|NCT01759771|Experimental|Arm 1|4,000 IU of VD3 for one year
88849845|NCT01759771|Placebo Comparator|Arm 2|placebo for one year
88849846|NCT01753115|Experimental|BioThrax + Ciprofloxacin PK|"BioThrax: route of administration/schedule- 0.5 mL subcutaneous (SC) injection / 0-2-4 week schedule.~Ciprofloxacin: 500 mg twice a day (Days 1-6, 19-21, 33-35, 40-48)."
88849847|NCT01753115|Experimental|BioThrax + Ciprofloxacin no PK|"BioThrax: route of administration/schedule- 0.5 mL subcutaneous (SC) injection / 0-2-4 week schedule.~Ciprofloxacin: 500 mg twice a day (Days 1-6, 19-21, 33-35, 40-48)."
88849848|NCT01753115|Experimental|BioThrax only|BioThrax: route of administration/schedule- 0.5 mL subcutaneous (SC) injection / 0-2-4 week schedule.
88849849|NCT01736618||S-ICD System Implant Attempt|All participants undergo an S-ICD System Implant attempt.
88849850|NCT01591356|Experimental|Treatment (EphA2-targeting DOPC-encapsulated siRNA)|Patients receive EphA2-targeting DOPC-encapsulated siRNA IV over 120 minutes on days 1 and 4. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
88849851|NCT01540929||Study Group|DoD Smallpox Screening Form 600 (2 part format)
89376866|NCT02387866|Experimental|50 mg AG-221 tablet|50 mg AG-221 tablet given by mouth with 240 mL of non-carbonated, room temperature water, under fasted conditions
89376867|NCT02387866|Experimental|100 mg AG-221 tablet|100 mg AG-221 tablet given by mouth with 240 mL of non-carbonated, room temperature water, under fasted conditions
89376868|NCT02387866|Experimental|300 mg AG-221 tablet|300 mg AG-221 tablet given by mouth with 240 mL of non-carbonated, room temperature water, under fasted conditions
89376869|NCT02199691|Experimental|Group 1: MenACYW Conjugate Vaccine|Healthy, meningococcal-vaccine naïve participants aged 10 to 17 years received a single dose of MenACYW Conjugate vaccine on Day 0.
89376870|NCT02199691|Active Comparator|Group 2: MENVEO® Vaccine|Healthy, meningococcal-vaccine naïve participants aged 10 to 17 years received a single dose of MENVEO® vaccine on Day 0.
89376871|NCT02199691|Experimental|Group 3: MenACYW Conjugate Vaccine+Tdap+HPV|Healthy, meningococcal-vaccine naïve participants aged 10 to 17 years received a single dose of MenACYW Conjugate vaccine, Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Tdap), and Dose 1 of HPV Vaccine on Day 0. HPV Vaccine Dose 2 and Dose 3 were given at 2 and 6 months, respectively, after Dose 1 given on Day 0.
89376872|NCT02199691|Active Comparator|Group 4: Tdap+HPV|Healthy, meningococcal-vaccine naïve participants aged 10 to 17 years received a single dose of Tdap and Dose 1 of HPV Vaccine on Day 0. HPV Vaccine Dose 2 and Dose 3 were given at 2 and 6 months, respectively, after Dose 1 given on Day 0.
89376873|NCT05671978|Placebo Comparator|neutral position|intubation was performed in the neutral position
89376874|NCT05671978|Experimental|back-up head elevated position|he trachea was intubated in the back-up head elevated position
89376875|NCT02390128||mothers and babies|pregnant mothers (UK resident) and their babies (observational, not an intervention)
89376876|NCT03105856|Active Comparator|CERVARIX|hrHPV-based screening and HPV16/18 L1 VLP AS04 vaccine (Cervarix®) group according to a two-dose schedule (0-12 months)
89376877|NCT03105856|Active Comparator|GARDASIL|hrHPV-based screening and Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) (Gardasil®) vaccine group according to a two-dose schedule (0-12 months)
88849852|NCT01534819||Protocol B, abdominal arm, revision group|AAA subjects with previously implanted commercial endografts for the treatment of graft migration and/or Type Ia endoleak
88849853|NCT01534819||Protocol B, abdominal arm, primary group|AAA subjects at the time of initial endograft implantation either to prevent endograft migration and Type Ia endoleak, or to treat Type Ia endoleak evident at the time of implantation.
88849854|NCT01534819||Protocol B, thoracic arm, revision group|TAA subjects with previously implanted commercial endografts for the treatment of migration and/or Type Ia and/or Type Ib endoleak at the proximal or distal attachment site
88849855|NCT01534819||Protocol B, thoracic arm, primary group|TAA subjects at the time of initial endograft implantation either to prevent endograft migration and Type I endoleak, or to treat Type Ia and/or Ib endoleak at the proximal or distal attachment site evident at the time of implantation
89376878|NCT03105856|No Intervention|CONTROL GROUP|Control group who will receive only hrHPV-based screening.
89376879|NCT03299881|Experimental|Treatment|The Transcutaneous Nerve Stimulator (TENS) Elira wearable patch system will be applied to varying locations on the T6/T7 dermatone for 30 minutes three times a day after meals. Subjects will be instructed to follow a 1200 calorie healthy diet and record any changes in appetite.
89376880|NCT03299881|Active Comparator|Control|Open label diet and exercise counseling only. Subjects will be instructed to follow a healthy 1200 calorie diet and record any changes in appetite.
88849856|NCT01534819||Protocol B, advanced disease arm, revision group|Advanced disease subjects with previously implanted commercial endografts for the treatment of migration and/or Type Ia and/or Type Ib endoleak at the proximal or distal attachment site
88849857|NCT01534819||Protocol B, advanced disease arm, primary group|Advanced disease subjects at the time of initial endograft implantation either to prevent endograft migration and Type I endoleak, or to treat Type Ia and/or Ib endoleak at the proximal or distal attachment site evident at the time of implantation.
88849858|NCT01534819||Protocol C, abdominal arm, short neck, primary group|Planned use of Heli-FX™ in conjunction with the Endurant II/IIs endograft in AAA subjects with short proximal necks (≥ 4 mm and < 10 mm) in primary group.
88849859|NCT01500551|Experimental|Tofacitinib|All patients will be in tofacitinib treatment group.
88849860|NCT01416012|Experimental|Group Kinect|Use of the available Kinect games on the Xbox to train balance and gait
88849861|NCT01416012|Active Comparator|Physical Therapy Standard|This group consists of the usual physical therapy rehabilitation with a special emphasis on lower and upper limb and balance reinforcement.
88849862|NCT01416012|Experimental|Group Nintendo|Use of video games available Balance and Gait training in Individualized training sessions.
88849863|NCT01416012|Experimental|Group Xbox Kinect (MK)|The NW group consists of the use of Nintendo Wii games that targeted upper and lower limbs as well as balance reinforcement
88849864|NCT01395082||Entire registry group|Participants with potential myopericarditis cases referred to the Registry
88849865|NCT01372566|Experimental|Platelet Rich Plasma|Concentrated blood platelets from subject will be injected multiple times into the superficial layer of either their arm (Part 1) or one side of their upper face and cheek (Part 2).
88849866|NCT01372566|Placebo Comparator|Sterile Saline|Sterile saline will be injected multiple times into the superficial layer of either their arm (Part 1) or one side of their upper face and cheek (Part 2)that has not been injected with PRP.
88849867|NCT01351545||Unlicensed CBU|The cohort includes recipients of any age receiving unlicensed cryopreserved cord blood units (CBUs) for designated indications.
89376881|NCT02389972||CML patients treated with dasatinib|Cohort of chronic myeloid leukemia patients treated with second-line dasatinib (Sprycel)
89376882|NCT03105934|Experimental|Pulmonary Arterial Hypertension|Patients with Pulmonary Arterial Hypertension
89376883|NCT03299101|Experimental|Prehabilitation|Prospective sample of patients anticipating cardiothoracic surgery.
88849868|NCT01263691|Active Comparator|BioThrax|BioThrax, 0.5 mL AVA per dose
88849869|NCT01263691|Experimental|AV7909 Formulation 1|0.5 mL AVA + 0.5 mg CPG 7909 per 0.5 mL dose
88849870|NCT01263691|Experimental|AV7909 Formulation 2|0.5 mL AVA + 0.25 mg CPG 7909 per 0.5 mL dose
89376884|NCT02663128|Experimental|Lanabecestat Reference Fasted|Lanabecestat: 50 mg administered once PO in each of 3 treatment periods.
88849871|NCT01263691|Experimental|AV7909 Formulation 3|0.25 mL AVA + 0.5 mg CPG 7909 per 0.5 mL dose
88849872|NCT01263691|Experimental|AV7909 Formulation 4|0.25 mL AVA + 0.25 mg CPG 7909 per 0.5 mL dose
88849873|NCT01263691|Placebo Comparator|Control|Saline control
88849874|NCT01216293|Placebo Comparator|Placebo|Placebo-matching capsules, orally, once daily for up to 26 weeks. Participants had the option to participate in the calcium absorption sub study to receive calcium isotope 42 calcium (42 Ca) 3 milligram (mg), intravenously and 44 calcium (44 Ca) 8 mg, orally, once on Day-1 and Week 26.
88849875|NCT01216293|Experimental|Dexlansoprazole 60 mg|Dexlansoprazole 60 mg, capsules, orally, once daily for up to 26 weeks. Participants had the option to participate in the calcium absorption sub study to receive calcium isotope 42 Ca 3 mg, intravenously and 44 Ca 8 mg, orally, once on Day-1 and Week 26.
88849876|NCT01216293|Active Comparator|Esomeprazole 40mg|Esomeprazole 40 mg, capsules, orally, once daily for up to 26 weeks. Participants had the option to participate in the calcium absorption sub study to receive calcium isotope 42 Ca 3 mg, intravenously and 44 Ca 8 mg, orally, once on Day-1 and Week 26.
88849877|NCT01199783|Experimental|Daptomycin|Infusion of Daptomycin (6 mg/kg bodyweight) once daily
88849878|NCT01199783|Active Comparator|Vancomycin|Vancomycin once daily (effective blood-plasma concentration of 15 mg/l)
88849879|NCT01184222|Active Comparator|Arm Active SENGO|The patients will be hospitalised and managed by medication withdrawal and active GONS, surgically temporarily implanted.
88849880|NCT01184222|Placebo Comparator|Arm sham SENGO|The patients will be hospitalised and managed by medication withdrawal and sham GONS, surgically temporarily implanted.
88849881|NCT01052415|No Intervention|Standard care|Service providers and HIV patients, offered intervention at the end of study
88849882|NCT01052415|Experimental|Intervention|Behavioral: Cognitive-behavioral, small group format sessions delivered in Chinese to service providers and HIV patients.
88849883|NCT01006798|Experimental|Cohort 1|three vaccinations of 10^7vp Ad4-H5-Vtn or placebo
88849884|NCT01006798|Experimental|Cohort 2|three vaccinations of the 10^8vp Ad4-H5-Vtn or placebo
88849885|NCT01006798|Experimental|Cohort 3|three vaccinations of 10^9 Ad4-H5-Vtn or placebo
88849886|NCT01006798|Experimental|Cohort 4|three vaccinations of 10^10 Ad4-H5-Vtn or placebo
88849887|NCT01006798|Experimental|Cohort 5|three vaccinations of 10^11 Ad4-H5-Vtn or placebo
88849888|NCT00927719||ACAM2000® vaccinia vaccine Cohort|Participants had received ACAM2000®, vaccinia virus Smallpox vaccine.
88849889|NCT00877656|Experimental|CD4|Open label treatment arm
88849890|NCT00845650|Experimental|AIGIV 3.5 mg/kg (Cohort A)|AIGIV containing 3.5 mg/kg anti-PA IgG as a single intravenous infusion.
88849891|NCT00845650|Other|Gamunex 90 mg/kg (Cohort A)|Gamunex 90 mg/kg total IgG as a single intravenous infusion.
88849892|NCT00845650|Experimental|AIGIV 7.0 mg/kg (Cohort B)|AIGIV containing 7.0 mg/kg anti-PA IgG as a single intravenous infusion.
88849893|NCT00845650|Other|Gamunex 180 mg/kg (Cohort B)|Gamunex 180 mg/kg total IgG as a single intravenous infusion.
88849894|NCT00845650|Experimental|AIGIV 14.0 mg/kg (Cohort C)|AIGIV containing 14.0 mg/kg anti-PA IgG as a single intravenous infusion.
88849895|NCT00845650|Other|Gamunex 360 mg/kg (Cohort C)|Gamunex 360 mg/kg total IgG as a single intravenous infusion.
88849896|NCT00831402|Other|Arm without iodized vitamin (VITAMIN OLIGOBS PREGNANCY)|50 women will be studied in the absence of iodized supplémentation(natural history of function thyroïdienne in the course of the pregnancy and in the post partum)
88849897|NCT00831402|Active Comparator|Arm with iodized vitamin|The 50 women will be follow up with a supplémentation iodized by vitamins of pregnancy strengthened in iodin everything in the course of the pregnancy and during the 3 months post partum (Oligobs Maxiode, 150 mcg / of iodizes, is 2cp a day)
88849898|NCT00789607|Active Comparator|MRI-guided FM|
88849899|NCT00789607|Active Comparator|TRUS-guided FM|
88849900|NCT00636519|Experimental|Stage A|Botulism Antitoxin Bivalent (Equine) Types A and B Vs. Placebo
88849901|NCT00636519|Experimental|Stage B|Botulism Antitoxin Heptavalent (Equine) Types A-G Vs. Placebo
88849902|NCT00353483||Tissue, blood, and bone marrow (optional) collection|"Undergo neoadjuvant systemic therapy~initial surgery for sentinel lymph node biopsy/portacath placement~definitive cancer surgery (if applicable)~when portacath is removed (1 year, if available)~if metastatic disease develops or is present in accessible sites, a sample may be collected at the time of specimen collection for diagnosis~Undergo Adjuvant Systemic Therapy~initial surgery for a sentinel lymph node biopsy/portacath placement~when portacath is removed (1 year, if available)~If metastatic disease develops or is present in accessible sites, a sample may be collected at the time of specimen collection for diagnosis.~Undergone neoadjuvant systemic therapy~during definitive cancer surgery/portacath removal (if available)~if metastatic disease develops or is present in accessible sites, a sample may be collected at the time of specimen collection for diagnosis"
88849903|NCT00309985|Experimental|Androgen-Deprivation Therapy and Docetaxel|Patients receive androgen-deprivation therapy (including luteinizing hormone-releasing hormone [LHRH] agonist therapy, LHRH antagonist therapy, or surgical castration). Patients also receive docetaxel IV over 1 hour on day 1. Treatment with docetaxel repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
88849904|NCT00309985|Active Comparator|Androgen-Deprivation Therapy alone|Patients receive androgen-deprivation therapy (including luteinizing hormone-releasing hormone [LHRH] agonist therapy, LHRH antagonist therapy, or surgical castration) alone.
88849905|NCT00188708|Experimental|hypoxia measurement|Patients undergoing or planning to receive combined anti-androgen (Casodex) and radiotherapy
88849906|NCT00053482|Experimental|Group 1: ACAM2000|Participants will receive dose 1 of the ACAM2000 smallpox vaccine
88849907|NCT00053482|Experimental|Group 2: ACAM2000|Participants will receive dose 2 of the ACAM2000 smallpox vaccine
88849908|NCT00053482|Experimental|Group 3: ACAM2000|Participants will receive dose 3 of the ACAM2000 smallpox vaccine
88849909|NCT00053482|Experimental|Group 4: ACAM2000|Participants will receive dose 4 of the ACAM2000 smallpox vaccine
88849910|NCT00053482|Active Comparator|Group 5: Dryvax®|Participants will receive dose 1 of Dryvax® smallpox vaccine.
88849911|NCT04246970|No Intervention|Control group|Conventional medical care
88849912|NCT04246970|Experimental|Prehabilitation group|Conventional medical care and 8 weeks of a Prehabilitation supervised program
88849913|NCT04246970|Experimental|Prehabilitation and posttransplant training group|Conventional medical care, 8 weeks of a Prehabilitation supervised program and a posttransplant training program.
88849914|NCT00000373|Active Comparator|olanzapine + fluoxetine|The specific aim was to determine whether combined treatment with fluoxetine plus olanzapine would be more effective than fluoxetine plus placebo in treating OCD subjects who were partial or nonresponders to a prospective, 8-week, open-label trial of fluoxetine.
88849915|NCT00000373|Placebo Comparator|placebo + fluoxetine|The specific aim was to determine whether combined treatment with fluoxetine plus olanzapine would be more effective than fluoxetine plus placebo in treating OCD subjects who were partial or nonresponders to a prospective, 8-week, open-label trial of fluoxetine.
88849916|NCT03367364|Active Comparator|Patient education bundle (PEB)|A charge nurse will intervene in real-time via an EHR-triggered alert when there is documentation that a dose of VTE prophylaxis medication is not given for any reason. The charge nurse will speak to the bedside nurse and one of them will provide the patient with the education bundle including one-on-one personalized discussion, supplemented by a 2-page paper handout and patient education video.
88849917|NCT03367364|Placebo Comparator|Nurse feedback and coaching (NFC)|Nurse leadership (i.e. managers, directors) will provide data to all nurses on their personal clinical effectiveness with the proportion of doses of VTE prophylaxis administered. The data will have comparisons to their nurse peers on the same floor. Coaching for nurses will include one-on-one conversations with bedside nurses with lower performance than their peers.
88849918|NCT00000385|Experimental|1|Lithium 600 mg to 2700 mg per day
88849919|NCT00000385|Placebo Comparator|2|Matching placebo
89002433|NCT06317844|Experimental|Gratitude Writing|In the gratitude writing condition, participants will write continuously for 5 minutes about someone they are grateful for.
89002434|NCT06317844|Placebo Comparator|Neutral Writing|Participants in the neutral writing condition will write continuously for 5 minutes about how they got to the research laboratory.
88875290|NCT02572752|Experimental|Treatment T (Test)|Nintedanib, 1 capsule, oral with 240 mL of water
88875291|NCT02572752|Experimental|Treatment R - 1 (Reference)|Nintedanib, 2 capsules, oral with 240 mL of water
88875292|NCT02572752|Experimental|Treatment R - 2 (Reference)|Nintedanib, 2 capsules, oral with 240 mL of water
89002435|NCT06317818|Experimental|"MSCs group"|One local injection of MSCs (3*10^7 cells) after endoscopic dilatation of the stricture
89002436|NCT06317818|Placebo Comparator|"control group"|One local injection of the placebo (cell-free cell suspension solution devoid of cells) after endoscopic dilatation of the stricture
89002437|NCT06317805|Experimental|Initial triple therapy|Assigned treatment: double oral (background therapy consisting of 1 endothelin receptor antagonist ERA and 1 phosphodiesterase type-5 inhibitor PDE-5i) with subcutaneous (SC)/intravenous (IV) treprostinil on top
89002438|NCT06317805|Active Comparator|• Initial double therapy|double oral (background therapy consisting of 1 endothelin receptor antagonist ERA and 1 phosphodiesterase type-5 inhibitor PDE-5i)
89002439|NCT06317792|Experimental|Online exergaming-based physiotherapy intervention group|The training tasks consist of a set of 10 pieces of training (20 min per session, five sessions every week, for 8 weeks)
89002440|NCT06317792|No Intervention|Online exergaming-based physiotherapy observation group|Observation only
89182066|NCT02578485|Active Comparator|SVideogame|Session with active video sedentary lasting 60 minutes performing heart rate measurements every 10 minutes and evaluating the perceived exertion.
89182067|NCT02578485|Placebo Comparator|EMIntensity|Session with walk on a treadmill with moderate intensity lasting 60 minutes performing heart rate measurements every 10 minutes and evaluating the perceived exertion.
88817060|NCT02917473|Experimental|Intervention group|"Education and counseling as commonly delivered to the patients in clinical practice and written advice for their first-degree relatives.~In addition to oral counseling to the patient, written advice will be provided to patients for their relatives focusing on sun protection, self-skin examination, medical skin examination, increased risk of melanoma for first-degree relatives, who should also be informed orally by the patients to protect themselves from UV radiation, perform self-skin examination and ask their GP or dermatologist to perform annual skin examinations."
88817061|NCT02916004|Other|Measurement of NFR and PDR|Diagnostic intervention: excite NFR and PDR in comparison to behavior pain scale (BPS)
88817062|NCT02905838|Active Comparator|Anatomic e.max Abutment|Implant-supported single crown was fabricated using a prefabricated stock abutment made of yttrium oxide partially stabilized tetragonal zirconia polycrystalline (Y-TZP) (Anatomic IPS e.max Abutment, straight, color M1, Ivoclar, Liechtenstein) and pressed ceramic (fluorapatite glass-ceramic, IPS e.max ZirPress, Ivoclar, Liechtenstein) using the cut-back technique and hand veneered with a thin layer of fluorapatite veneering ceramic (fluorapatite veneering ceramic, IPS e.max Ceram, Ivoclar, Liechtenstein).
88817063|NCT02905838|Active Comparator|CAD/CAM CARES Abutment|Implant-supported single crown was fabricated using an individualized CAD/CAM abutment made of Y-TZP (CARES® Abutment, Institut Straumann AG, Basel, Switzerland) and hand build-up veneering ceramic technique (fluorapatite veneering ceramic, IPS e.max Ceram, Ivoclar, Liechtenstein).
88817064|NCT02889159|Other|Candida albicans antigen|useful in measuring the capacity of a person to manifest a delayed-type hypersensitivity response
88817065|NCT02889159|Other|histamine phosphate|useful to assess type I IgE-mediated hypersensitivity reactions
88817066|NCT02889159|Other|imiquimod 5% cream|direct stimulator of TLR-7, a key component of the innate immune response with downstream signaling effects involving the adaptive immune response
88817067|NCT02889159|Other|tape stripping|to create alterations in key inflammatory mediators involved in both the innate and adaptive immune responses
88817068|NCT02889159|No Intervention|Control|control sample from both sun exposed and non-sun exposed skin
88817069|NCT02841280|Experimental|Chlorthalidone|Subjects with stage 4 chronic kidney disease (CKD) and poorly controlled hypertension confirmed by 24 hour ambulatory blood pressure monitoring will be randomized into two groups, one receiving placebo and one receiving a diuretic called chlorthalidone (12.5 mg at randomization). Doubling of the dose of the diuretic (up to 50 mg) or placebo will occur every 4 weeks if required by home blood pressure (BP) results.
88817070|NCT02841280|Placebo Comparator|Placebo|Subjects with stage 4 CKD and poorly controlled hypertension confirmed by 24 hour ambulatory blood pressure monitoring will be randomized into two groups, one receiving placebo and one receiving a diuretic called chlorthalidone (12.5 mg at randomization). Doubling of the dose of the diuretic (up to 50 mg) or placebo will occur every 4 weeks if required by home BP results.
88817071|NCT02813356||naloxegol|patients exposed to naloxegol
88817072|NCT02813356||non-PAMORA|patients exposed to non-peripherally acting mu-opioid antagonist
88817073|NCT02760329||Chronic airways disease|Patients with suspected or primary diagnosis of asthma or COPD
88817074|NCT02723500|Other|MRI at baseline and over time|Patients with chronic lung disease will undergo pulmonary function tests, hyperpolarized Xenon MRI at each visit.
88817075|NCT02678182|No Intervention|A1: Surveillance|Patients in this Arm will follow current UK standard of care for this setting and will be reviewed every 4 weeks
88817076|NCT02678182|Experimental|Arm A2: Capecitabine Maintenance|1250 mg/M2/DAY on days 1-21
88817077|NCT02678182|Experimental|Arm A3: MEDI4736 (Durvalumab) - No longer open to recruitment|IV treatment on day 1 +15, on a 28 day cycle.
88817078|NCT02678182|Active Comparator|Arm B1: Trastuzumab Maintenance|6mg/kg on day 1 every 21 days
88817079|NCT02678182|Experimental|Arm A4: Rucaparib - No longer open to recruitment|600mg PO twice daily
88817080|NCT02678182|Experimental|Arm A5: Capecitabine and Ramucirumab - No longer open to recruitment|capecitabine 1250 mg/m2/day PO in two divided doses continuously from days 1-21 of each 21 day cycle (see section 12) and ramucirumab 8mg/kg IV day 1 and day 8
88817081|NCT02644070|Experimental|alveolar bone preservation with mp3|Extraction sockets grafted with corticocancellous porcine bone and collagen (MP3, Osteobiol, Coazze, Italy) with graft particle size between 600 and 1000 µm and a collagen membrane (Evolution, Osteobiol, Coazze, Italy) used to stabilize the biomaterial into the socket.
88817082|NCT02644070|Experimental|alveolar bone preservation with apatos|Extraction sockets grafted with cortical porcine bone with particle size between 600 and 1000 µm (Apatos, Osteobiol, Coazze, Italy ) and a collagen membrane (Evolution, Osteobiol, Coazze, Italy) used to stabilize the biomaterial into the socket.
88817083|NCT02644070|No Intervention|NO_graft|extraction sockets with spontaneous healing
88817084|NCT02620865|Experimental|Treatment (anti-CD3 x anti-EGFR BATs)|Patients receive one of the following standard chemotherapy regimens at the discretion of the treating physician: gemcitabine hydrochloride IV over 30 minutes; gemcitabine hydrochloride IV over 30 minutes and paclitaxel albumin-stabilized nanoparticle formulation IV over 30-40 minutes; oxaliplatin IV over 2 hours, fluorouracil IV over 46 hours and leucovorin calcium IV over 2 hours; or fluorouracil IV over 46 hours, leucovorin calcium IV over 2 hours, irinotecan hydrochloride IV, and oxaliplatin IV over 2 hours. Approximately 2 weeks after standard chemotherapy completion, patients receive anti-CD3 x anti-EGFR-bispecific antibody armed activated T-cells IV over 5-30 minutes twice weekly for 4 weeks. Patients also receive aldesleukin SC and sargramostim SC on day -3 before the first anti-CD3 x anti-EGFR-bispecific antibody armed activated T-cells infusion and continuing twice weekly until the final infusion.
88817085|NCT02531425|Experimental|IT-pIL12-EP|intratumoral injection of plasmid-IL12 following immediately by electroporation
88817086|NCT02526498|Experimental|Treatment (APBI using HDR brachytherapy)|Within 1-5 days after balloon placement, patients undergo APBI using HDR brachytherapy over 15-60 minutes for 2-3 days.
88817087|NCT02509988|Experimental|Intervention (study nutritional drink)|"Study nutritional drink comes in the form of a sachet to mix with water & take twice a day (once in the morning and once in the evening).~The drink will be taken before the participant becomes pregnant (for up to 1 year) and throughout pregnancy."
89376885|NCT02663128|Experimental|Lanabecestat Test Fasted|Lanabecestat: 50 mg administered once PO in each of 3 treatment periods.
89376886|NCT02663128|Experimental|Lanabecestat Test Non Fasted|Lanabecestat: 50 mg administered once PO in each of 3 treatment periods.
89376887|NCT02389582|Experimental|Dabigatran|Dabigatran 150mg twice a day for five days
89376888|NCT02389582|Active Comparator|Enoxaparin|Enoxaparin 1mg/kg/day twice a day for five days
89376889|NCT03298867|Active Comparator|Teprotumumab 20 mg/kg|Approximately 38 participants will receive 8 infusions of teprotumumab q3W for a total of 21 weeks. Teprotumumab 10 mg/kg will be administered on Day 1 and teprotumumab 20 mg/kg will be administered q3W for the remaining 7 infusions.
89376890|NCT03298867|Placebo Comparator|Placebo|Approximately 38 participants will receive 8 infusions of placebo q3W for a total of 21 weeks.
89376891|NCT02906930|Experimental|3 mg oral semaglutide|
89376892|NCT02906930|Experimental|7 mg oral semaglutide|
89376893|NCT02906930|Experimental|14 mg oral semaglutide|
89376894|NCT02906930|Placebo Comparator|Placebo|
89376895|NCT02389426|Experimental|Patients with Multiple Sclerosis|One examination with TCD baseline and with NIRS baseline, and a second examination with TCD after bosentan administration and with NIRS after bosentan administration will be performed; The examination will be repeated only in the patients with MS (i.e. not in control subjects) 4 h after the oral intake of one tablet 62.5 mg bosentan (Tracleer®) (when peak plasma concentrations are expected).
89376896|NCT02389426|Experimental|Healthy controls|Only one examination with TCD baseline and NIRS baseline will be performed, without administration of bosentan.
89376897|NCT05274841|Other|Identified support needs|Identified need of either support from a psychologist, nurse, doctor, socialworker or a combination of theese.
89182068|NCT02578485|Placebo Comparator|EISVideogame|Session with walk on a treadmill with intensity similar reached in session with VGA and lasting 60 minutes performing heart rate and perceived exertion measurements every 10 minutes.
89376898|NCT02389660|Experimental|Blended CBT|Internet based blended depression treatment combines individual face-to-face cognitive behavioural therapy (CBT) with CBT delivered through an Internet based treatment platform with mobile phone components. The core components of the CBT treatment are: (1) psycho-education, (2) cognitive restructuring, (3) behavioural activation, and (4) relapse prevention. These will be delivered over 13 sessions (6 online and 7 face-to-face, session sequence - alternate, online platform - Moodbuster).
89376899|NCT02389660|Active Comparator|Treatment as usual|Treatment as usual (TAU) will be defined as the routine care CBT that subjects receive when they are diagnosed with depression in the setting of recruitment. We will not interfere with treatment as usual but we will monitor carefully which health care services are utilized by usual care patients using patient records and through self-report (including TIC-P measurements).
89376900|NCT04580407|Experimental|TAK-672|TAK-672 will be administered at an initial dose of 200 U/kg with intravenous infusion at a rate of 1-2 mL/min. Subsequent doses will be determined based on the post-infusion factor VIII activity (FVIII:C) achieved after the most recent dose given, the target FVIII:C, and pFVIII inhibitor titer (when available)
89182069|NCT02578485|Sham Comparator|Control|Participants remained for 60 minutes at rest performing heart rate measurements every 10 minutes and evaluating the perceived exertion.
89376901|NCT02389504|Active Comparator|Standard Physical Therapy Protocol|Regular Physical Therapy Protocol. Standard treadmill running, monitoring heart rate
89376902|NCT02389504|Experimental|Exertion Physical Therapy Protocol|Exertional Physical Therapy Protocol. Dynamic exertion protocol includes the treadmill running aspect, but also incorporates other exercises that involve lateral movement (e.g., side lunges, lateral speed training exercises) as well as planar changes (e.g., burpees, squat thrusts) . Recovery on these exercises is measured based on time subjects are able to tolerate the exertion without symptom increase. Across all exertion protocols additional measures of subjective physical effort and objective measurement of heart rate are taken.
89376903|NCT05256589|Experimental|SARS_CoV_2 Antigen Rapid Test|"The same group of patients participate in two arms of the study:~One arm is for obtaining performance data of the Sona Saliva C-19 Rapid self test and the comparator arm is to obtain data from the primary care route using approved RT-PCR testing."
89399384|NCT03932331|Experimental|Acalabrutinib|Acalabrutinib will be orally administered until disease progression or unacceptable toxicity.
89376904|NCT02387320|Experimental|Self-Care Toolkit|Women randomized to self-care toolkit group will receive a toolkit which includes a spiral-bound instruction manual, a section of the manual that can be used as a journal, a portable mp3 player with 8 audiofile tracks with guided meditations to reduce stress and anxiety, and two acupressure wristbands to help prevent nausea.
89376905|NCT02387320|No Intervention|Standard Care|Women randomized to the standard care group will be informed that they will continue to receive standard of care as delivered by the SAMMC Oncology Department. The research team will inform women randomized to standard care that they will receive the self-care toolkit at their two week post-operative visit and will be able to use it subsequently if they choose to.
89376906|NCT05255497|Experimental|Biodex Balance Group|This group performed exercises using the biodex balance system
89376907|NCT05255497|No Intervention|Control Group|This group was informed about diabetes self-management.
89399385|NCT02178488|Active Comparator|Cholecalciferol|150 patients with MRSA resistent Cholecalciferol 4000 international units (IU)/day for 12 month
89399386|NCT02178488|Placebo Comparator|Sugarpill|150 patients with MRSA resistent Placebo daily 12 month
89182070|NCT04074369||Pulmonary Tuberculosis Suspects|Individuals with suspected TB infection
89182071|NCT00437203|Experimental|1|
89182072|NCT04072653|Experimental|Observation group( SLNB is spared)|In the second stage, sentinel lymph node biopsy will be spared in the patients with negative preoperative axillary assessment.
89399387|NCT03686631|No Intervention|Passive Arm|This arm uses a passive tracking device to assess the number of times a patient uses their prescribed incentive spirometer.
89376908|NCT02389348|Experimental|combination OZ439 and DSM265|"Subjects will receive 1800 P falciparum infected red blood cells. Development of parasitemia will be monitored by quantitative PCR. When the parasitemia reached the threshold of 1000 p/ml subjects will receive a single oral dose of OZ439 and DSM265.~Subsequent doses in subsequent cohort(s) will be determined following a review of observed OZ439 and DSM265 safety, and pharmacokinetic and pharmacodynamic interaction outcomes as well as the activity of the drugs as defined by parasite clearance kinetics."
89376909|NCT05255341|Experimental|roll pedicle connective tissue graft with bovine bone|"sulcular incisions were performed on the buccal and lingual aspects of the teeth to be extracted~Atraumatic extraction was made by periotome.~After tooth extraction the soft tissue was reflected at least 4 mm beyond the alveolar crest margin and the socket was filled with bovine derived xenograft and covered with roll pedicle connective tissue graft as a barrier membrane.~This pedicle is rolled under the buccal mucosa.The palatal connective tissue pedicle graft was outlined by full thickness incision along the oblique incision line, and parallel incision given from the mesial line angle of target place and reflected coronally up to the crest of the ridge defect. then a partial thickness incision was made extending beyond the line angles of adjacent incisors and mucogingival junction, leaving the periosteum on the bone.~the pedicle graft was rolled from the apical end and secured with interrupted sutures to the labial flap."
89376910|NCT02389270||Healthy children|Healthy children without lower urinary tract diseases, history of urinary tract infection, chronic diseases, anomalies of urinary or genital tract, and remarkable clinical examination.
89376911|NCT03656978|Active Comparator|Dynamic|Keep moving the probe for needle tip visualization during the puncture procedure.
89376912|NCT03656978|Placebo Comparator|Regular-triangle|Needle access along the hypotenuse of the regular triangle formed by the vascular depth and puncture point.
89376913|NCT02383108|Active Comparator|Standard of Care group (SOC)|triple anti-retroviral therapy including 2 NRTIs + boosted PI/NNRTI
89376914|NCT02383108|Experimental|DTG+DRV/r|NRTI-sparing regimen: Once daily integrase inhibitor (INSTI) + darunavir/ritonavir (DRV/r)
89376915|NCT02157662||No coronary disease and risk factors >=3|
89376916|NCT02157662||Coronary disease and risk factors 0-1|Diffuse coronary atherosclerosis extended to more than 5 of the 16 segments according to the American Heart Association classification38 and 0-1 risk factor (reported by the subject or documented at the MDCT) with the exclusion of patients with type 1 or type 2 diabetes mellitus as single risk factor.
89376917|NCT02157662||No coronary disease and risk factors 0-1|
89376918|NCT02157662||Coronary disease and risk factors >=3|Subjects with diffuse coronary atherosclerosis extended to more than 5 of the 16 segments according to the American Heart Association classification38 and 3 or more risk factors (reported by the subject or documented at the MDCT) with the exclusion of patients with type 1 or type 2 diabetes mellitus as single risk factor
89376919|NCT02383186|Active Comparator|Dermal Suturing Only Wound Closure|The side assigned to dermal suturing only will be closed with a single layer of deep absorbable sutures. The method will be buried vertical mattress or set-back suturing at the surgeons discretion.
89376920|NCT02383186|Active Comparator|Layered Cutaneous Wound Closure|The side assigned to layered closure is closed with 5-0 fast acting gut.
89376921|NCT03656822||Routine imaging such as CT or MRI|Subjects will undergo routine pre-operative imaging and will be randomized into 3 groups for data visualization. This group will receive data visualization using routine clinical imaging,
89376922|NCT03656822||Routine imaging (CT or MRI) with a 3D printed model|Subjects will undergo routine pre-operative imaging and will be randomized into 3 groups for data visualization. This group will receive data visualization using routine clinical imaging with a 3D printed anatomical mode
89376923|NCT03656822||Routine imaging (CT or MRI) with a VR model|Subjects will undergo routine pre-operative imaging and will be randomized into 3 groups for data visualization. This group will receive data visualization using routine clinical imaging with a 3D VR anatomical model
89376924|NCT02387242|Experimental|Group 1|10mg/kg Rifampicin
89376925|NCT02387242|Experimental|Group 2|20mg/kg Rifampicin
89376926|NCT02387242|Experimental|Group 3|30mg/kg Rifampicin
89376927|NCT03656588|Active Comparator|a. Standard iodine scrub, 3% hydrogen peroxide prep, follow by|
89376928|NCT03656588|Active Comparator|b. Iodine scrub and ChloraPrep alone|
89376929|NCT02387086|Experimental|A:gefitinib and thalidomide/aspirin|intervention: drug: gefitinib and thalidomide/aspirin: gefitinib will be administered at 250mg QD continuously; thalidomide will be administered at 100mg QD at night continuously; aspirin will be administered at 100mg QD continuously;
89376930|NCT02387086|Placebo Comparator|B:Placebo|intervention: drug: gefitinib and placebo/aspirin: gefitinib will be administered at 250mg QD continuously; placebo will be given to patients in the same way as the thalidomide; aspirin will be administered at 100mg QD continuously;
89376931|NCT02383030|Experimental|Fulvestrant|In Arm A maintenance Fulvestrant will be given until disease progression, unacceptable toxicity or refused of patient to the treatment.
89376932|NCT02383030|No Intervention|No intervention|Patients will be randomized to receive fulvestrant (experimental arm) or no treatment
89376933|NCT02383264||feeding intolerance|Development of feeding intolerance, defined as enteral feeding withholding for at least 1 day due to the onset ofgastrointestinal clinical symptoms
89376934|NCT02383264||normal feeding tolerance|no evidence of feeding intolerance during the hospitalization
89376935|NCT02382952|Experimental|Differential Dissector|For patients in the study device group, blunt dissection will be performed with the Differential Dissector whenever the surgeon believes its use is appropriate.
89376936|NCT02382952|Active Comparator|Standard Dissection Method|For patients in the control group, blunt dissection will be performed by standard method.
89376937|NCT02388958||Women with GDM|
89376938|NCT02388958||Women without GDM|
89376939|NCT02386930|Experimental|Behavrioal Lifestyle modification|
89376940|NCT02386930|No Intervention|Control|
89376941|NCT02389114|Active Comparator|Low Protein Preload|The subjects consumed soybean curd preload containing low protein content.
89376942|NCT02389114|Experimental|Low Protein with Polydextrose Preload|The subjects consumed soybean curd preload containing low protein content and polydextrose.
89376943|NCT02389114|Experimental|High Protein Preload|The subjects consumed soybean curd preload containing high protein content.
89182073|NCT00753272|Experimental|FluNG Group|subjects received 2 doses (1 dose per season) of FluNG vaccine during the Northern Hemisphere (NH) vaccination periods. One dose at Day 0 of the Year 1 and one dose at Day 0 of the Year 2 (= Day 365 Year 1).
89376944|NCT02389114|Experimental|High Protein with Polydextrose Preload|The subjects consumed soybean curd preload containing high protein content and polydextrose.
89376945|NCT02386852|Experimental|Placebo|Study subjects received, in a double blind fashion, placebo pills identical to the drug (ginseng: group 1; ginkgo biloba: group 2).
89376946|NCT02386852|Experimental|Ginseng|Participants in the ginseng group received a medium, and higher dose of ginseng in addition to placebo capsules.
89376947|NCT02386852|Experimental|Ginkgo Biloba|Participants in the ginkgo biloba group received a medium, and higher dose of ginkgo in addition to placebo capsules.
89376948|NCT02388802|Experimental|Uterine transplant|10 patients will be appropriately selected to undergo oocyte retrieval and freezing. Subsequently deceased donor allograft excision will take place prior to uterine transplantation. Immunosuppressive agents will be used to optimise graft success until successful In-vitro fertilisation and subsequent delivery by Caesarean Section
89376949|NCT02386696|Experimental|Ultrasound findings|"Thoracic ultrasound examinations in the following conditions:~Apnea;~Spontaneous regular breathing;~Valsalva maneuver, during which each subject will be asked for performing three forced expirations with closed glottis after one forced inspiration;~Muller maneuver, during which each subject will be asked for performing three forced inspirations after one forced expiration;~Hyperventilation."
89376950|NCT05358964|Experimental|African American Family Health History Education Program|The AAFHHEP arm is an intervention to increase utilization of FHH and increase preventative screening. This tool will be culturally tailored by African Americans for African Americans.
89376951|NCT05358964|Active Comparator|Genetic Alliance: Does it run in the family|The Genetic Alliance Does it run in the family is an existing family health history tool kit generalized to all racial groups. This tool is widely available via the internet.
89376952|NCT02382874|Experimental|AD-MSC|The patients with FSGS who underwent intravenous injection of AD-MSC.
89376953|NCT02382718|Experimental|FAST fish mCyp c 1|"Subcutaneous injections of investigational medicinal product mCyp c 1 formulated in a solution (suspension) with aluminium.~Up-dosing (build-up) phase: each subject will receive 10 injections of active or placebo treatment. The first three injections will be given on the first day. For those on active treatment the dosing will begin at 6ng and conclude on week 8 with the administration of 60μg.~Maintenance phase: the maintenance dose of 60μg will be repeated once at two weeks and then monthly for a period of four months (four monthly injections)."
89376954|NCT02382718|Placebo Comparator|Placebo|Subcutaneous injections of exactly the same dosage, frequency and duration as Active Arm but all injections will be performed with placebo (has the same composition as the active drug suspension but no allergen mCyp c 1 is added).
89376955|NCT02382484|Experimental|Treatment|"The study was a single arm, unblinded, treatment only study. Each patient served as his or her own control.~Treatment delivered by a dual chamber pacing system (BackBeat Medical) which was able to generate stimulating patterns with characteristics that are different than the common pacemaker.~The study was limited to hypertensive patients who were also already scheduled to undergo an invasive electrophysiology procedure."
89376956|NCT02382562|Experimental|Brief Behavioral Activation Intervention|All eligible participants will undergo the Brief Behavioral Activation Intervention.
89376957|NCT02386306|Experimental|Treatment Cohort 1|Each study participant will be administered with one 1mg dose capsule per day of GC021109 for 28 days.
89376958|NCT02386306|Placebo Comparator|Placebo Cohort 1|Patients receiving placebo as part of each cohort will be dosed with a comparable capsule to those in the treatment arm of each cohort.
89376959|NCT02386306|Experimental|Treatment Cohort 2|Each study participant will be administered with one dose per day of GC021109 for 28 days. Dose levels will be determined following a review of cohort 1 safety data through day 14
89376960|NCT02386306|Placebo Comparator|Placebo Cohort 2|Patients receiving placebo as part of each cohort will be dosed with a comparable capsule to those in the treatment arm of each cohort.
89376961|NCT02386306|Experimental|Treatment Cohort 3|Each study participant will be administered with one dose per day of GC021109 for 28 days. Dose levels will be determined following a review of cohort 2 safety data through day 14
89376962|NCT02386306|Placebo Comparator|Placebo Cohort 3|Patients receiving placebo as part of each cohort will be dosed with a comparable capsule to those in the treatment arm of each cohort.
89002441|NCT06317766|Experimental|Part 1 Pre-Clinical Procedure|"1 healthy adult (male or female)~18-75 years of age, who are scheduled to undergo an abdominoplasty (where abdominal skin will be excised) will be recruited.~Informed consent will be obtained by a delegated member of the study staff prior to the day of surgery.~On the day of the scheduled procedure, the laser device will be applied to the skin that will be removed as part of the surgery. The treatment will be completed after induction and prior to prepping for the surgical procedure."
89376963|NCT02382172|Experimental|Social Cognition and Interaction Training for Autism (SCIT-A)|The measures the investigators are giving assess participants' initial level of social deficits and the extent to which the therapy did or did not help their social skills. The research team will compare the level of difficulty that participants first reported with their subjective evaluation of their experience in the group sessions to determine whether the program is clinically useful for further development. The investigators will also have the participants complete eye tracking paradigms to assess possible changes in social functioning after completing the Social Cognition and Interaction Training for Autism (SCIT-A) program.
89376964|NCT02382172|Other|Treatment As Usual (TAU)|Continuation of services being given upon study entry.
88849923|NCT00000829|Experimental|1|Patients receiving intramuscular heptavalent pneumococcal conjugate vaccine
88849924|NCT00000829|Placebo Comparator|2|Patients receiving placebo vaccine
88849925|NCT03282344|Experimental|participants ≥18 years old NKTR-214 and Nivolumab|NKTR-214 0.006mg/kg and nivolumab 360mg will be administered intravenously on day 1 of week 1 of cycle one and every 3 weeks (±3 days) thereafter.
89399388|NCT03686631|Experimental|Smartphone Arm|This arm uses a smartphone connected device and smartphone application to remind and encourage patients to use the spirometer as well as track the number of times they utilize the spirometer.
88849926|NCT03282344|Experimental|participants 12 - 17 years old NKTR-214 0.006mg/kg and Nivo|NKTR-214 0.006mg/kg and nivolumab 360mg will be administered intravenously on day 1 of week 1 of cycle one and every 3 weeks (±3 days) thereafter.
88849927|NCT03889093|Other|Yttrium-90|This single arm study is to evaluate immunologic changes following the treatment of primary or secondary malignancies of the liver utilizing beta-emitting, Yttrium-90.
88849928|NCT00000439|Active Comparator|sodium valproate|sodium valproate was added on treatment as usual and dose monitored by blood level measurements
88849929|NCT00000439|Placebo Comparator|placebo|Placebo comparator was added on treatment as usual and dose monitored by blood level measurements
88875293|NCT02574858|Experimental|QRH-886620|The first three subjects will squirt via syringe into their mouths (po) 4.2 mg (2.1ml) mg of reconstituted (with 5 ml of 0.9% saline) QRH-882260 heptapeptide (~100 µM concentration). They will be asked to wait 5 minutes and then drink at least 4-8oz of tap water. The remaining seven subjects will receive (squirted via syringe into their mouths) 1mg (5ml) of reconstituted (with 5ml of 0.9% saline) QRH-882260 heptapeptide (~100 µM concentration).
88875294|NCT02577042|Experimental|Raltegravir + Atorvastatin|Switching the PI by raltegravir, plus Kivexa or Truvada, for 24 weeks. After that, atorvastatin, 20mg/day, will be added for 48 weeks
89182074|NCT00753272|Active Comparator|Fluarix Group|subjects received 2 doses (1 dose per season) of Fluarix™ vaccine during the Northern Hemisphere (NH) vaccination periods. One dose at Day 0 of the Year 1 and one dose at Day 0 of the Year 2 (= Day 365 Year 1).
89182075|NCT02419287|Experimental|crizotinib|250mg BID
89376965|NCT02983604|Experimental|GS-5829 + exemestane (Phase 1b)|Participants will be sequentially enrolled at progressively higher dose levels of GS-5829 (up to 9 mg) in combination with exemestane and may continue with treatment until disease progression, unacceptable toxicity, withdrawal of consent, or death, whichever comes first.
89376966|NCT02983604|Experimental|GS-5829 + fulvestrant (Phase 1b)|Participants will be sequentially enrolled at progressively higher dose levels of GS-5829 (up to 9 mg) in combination with fulvestrant and may continue with treatment until disease progression, unacceptable toxicity, withdrawal of consent, or death, whichever comes first.
89376967|NCT02983604|Experimental|GS-5829 + fulvestrant (Phase 2)|Participants will receive GS-5829 (dose determined from Phase 1b) + fulvestrant until disease progression, unacceptable toxicity, withdrawal of consent, or death, whichever comes first.
88849930|NCT00002912|Experimental|Arm I|Patients undergo induction therapy consisting of etoposide IV and mitoxantrone IV on days 1-5. Patients then receive PSC-833 IV over 124 hours beginning on day 2. A second course is administered no sooner than 21 days from the start of the first course if the marrow is hypocellular after the first course. Patients with persistent disease after 2 induction courses are removed from the study. Patients receive a total of 3 courses of etoposide/mitoxantrone. Patients who achieve complete remission after 1 induction course receive 2 courses of etoposide/mitoxantrone with PSC-833 as consolidation, beginning within 4 weeks of attainment of complete remission. Patients who achieve complete remission after 2 induction courses receive 1 course of etoposide/mitoxantrone with PSC-833 as consolidation. Cohorts of 3-6 patients receive escalating doses of PSC-833 until the maximum tolerated dose is determined. Patients are followed every 6 months.
88849931|NCT03731845|Experimental|patient|
88849932|NCT00002924||Source of patient samples|The CALGB conducted a phase III study (CALGB 9583) in which 260 men with AiPC were randomly assigned to antiandrogen withdrawal together with simultaneous ketoconazole and hydrocortisone versus antiandrogen withdrawal alone, followed by sequential ketoconazole and hydrocortisone. Metastatic disease with progression despite castrate levels of testosterone, prior antiandrogen therapy for a minimum of 4 weeks, and a minimum PSA level of 5 ng/mL were required; treatment with sequential antiandrogens was allowed. No prior chemotherapy was allowed. Bone marrow biopsies were obtained from 164 patients enrolled on CALGB 9583 and from 20 patients enrolled on CALGB chemotherapy trials (CALGB 9480, 9680, 9780).
88849933|NCT00000451|Experimental|1|Naltrexone plus Sertraline
88849934|NCT00000451|Experimental|2|Naltrexone alone
88849935|NCT04169672|Experimental|Surufatinib & Toripalimab|Surufatinib 250mg will be taken orally once daily continuously through a 21-day cycle of study treatment. Toripalimab 240mg will be intravenously administered on Day 1 of each cycle.
88849936|NCT04169672|Experimental|Surufatinib|Surufatinib 300mg will be taken orally once daily continuously through a 21-day cycle of study treatment.
89376968|NCT02983604|Active Comparator|Fulvestrant (Phase 2)|Participants will receive fulvestrant alone until disease progression, unacceptable toxicity, withdrawal of consent, or death, whichever comes first.
89376969|NCT02386618|Other|Local residual neoplasia|Patients with local residual neoplasia in 3 months after endoscopic resection of colorectal lateral spreading tumors diagnosed endoscopically and/or histologically
89376970|NCT02386384||Control|Normal fertile
88849937|NCT00380419|Experimental|1|Participants will receive 16 sessions of interpersonal psychotherapy
88849938|NCT00000511|Placebo Comparator|Potassium, Magnesium, Calcium, The 3 together, Placebo|Parallel study design, 4 treatment groups
88849939|NCT03344731|Experimental|Experimental Group|Patient with any form ob brain damage
89376971|NCT02386384||Implantation Failure|Failure to conceive
88849940|NCT03344731|Other|Control Group|Healthy volounteers
88849941|NCT03321799|Active Comparator|Sterile Antimicrobial Dressings|Control group, current hospital standard. AQUACEL is left in place for 7 days unless it becomes saturated over 50%, which requires a premature dressing change.
88849942|NCT03321799|Experimental|Negative pressure wound therapy (NPWT)|"Experimental group. Negative pressure wound therapy bandage applied intra-operatively by a physician on the treatment team.~The dressing will be removed after 7 days postoperatively, or if the battery power stops earlier."
88849943|NCT03278119||Sleep Apnea|"Overall 56~both male and female~age group 55 to 75 years, having mild to severe obstructive sleep apnea~in good general health with no significant comorbidities~Located for the most part in boroughs of New York City"
88849944|NCT03278119||No Sleep Apnea|"Overall 56~both male and female~age group 55 to 75 years, without OSA~in good general health with no significant comorbidities~Located for the most part in boroughs of New York City"
88849945|NCT03015896|Experimental|Treatment (lenalidomide, nivolumab)|Patients receive lenalidomide PO on days 1-21 and nivolumab IV over 60 minutes on days 1 and 15 of courses 1-4 and on day 1 of courses 5-12. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88849946|NCT02994836|Active Comparator|Anti-TNF|Infliximab (Infusion 5mg/kg milligram(s)/Kilogram-Intravenous use) or Adalimumab (Subcutaneus 40 mg milligram(s)-subcutaneus)
88849947|NCT02994836|Placebo Comparator|Anti-TNF discontinuation (Placebo)|Physiological saline solution (Infusion-Intravenous use) or Physiological saline solution (Injection-subcutaneous use)
88849948|NCT02973529|Experimental|Absorb|Randomization to implantation of Absorb BVS in bifurcation lesion
88849949|NCT02973529|Experimental|Desolve|Randomization to implantation of Desolve BRS in bifurcation lesion
88849950|NCT04329416|Other|Predicted depth of insertion|The predicted insertion depth of the DLT was calculated using the formula [0.249 x (BH) 0.916] before induction of anesthesia using an application on the smartphone
88849951|NCT04329338|No Intervention|Gut and vaginal sample collection|Gut and vaginal samples were collected for Nugent score, and 16S rRNA metagenomics communities.
88849952|NCT04329338|Experimental|Gut and Vaginal sample after Lactobacillus|Seven women diagnosed with BV by Nugent score (7-10) provided vaginal and gut sample after 14 days oral intake of 3 grams (2.5X108 cfu/g) of Lactobacillus pentosus KCA1
88849953|NCT00002942|Active Comparator|Peripheral Blood Progenitor Cells|
88849954|NCT00002942|Experimental|Autologous Bone Marrow Collection|
88849955|NCT00000955|Other|A|All eligible study participants
88849956|NCT02789384|Experimental|Procedure/Surgery|Newly obtained biopsy if applicable and blood samples collection according to the usual medical practices.
88849957|NCT04048304|Experimental|short antibiotic therapy|3 weeks of antibiotic therapy with no implant left in place 6 weeks of antibiotic therapy with implant left in place
88849958|NCT04048304|Active Comparator|long antibiotic therapy|6 weeks of antibiotic therapy with no implant in place 12 weeks of antibiotic therapy with implant left in place
88849959|NCT04009148||Successful Cascade Testing|Genetic counselor contacts relatives and offers participation in study. Relative accepts and genetic testing in performed.
88849960|NCT04009148||Relative Declines Genetic Testing|Genetic counselor contacts relatives and offers participation in study. Relative declines and genetic testing is not performed.
88849961|NCT02594293|No Intervention|Controlled Group|Discontinue the NA treatment and follow up for 96 weeks
88849962|NCT02594293|Experimental|Pegasys 48 weeks|Discontinue the NA treatment ,PegIFN alfa-2a 180 μg by week for 48 weeks and follow up for 48 weeks
88849963|NCT02749058|Other|Capsulectomy|Procedure: Capsulectomy in Direct Anterior Total Hip Arthroplasty
88849964|NCT02749058|Other|Capsulotomy|Procedure: Capsulotomy in Direct Anterior Total Hip Arthroplasty
88849965|NCT02686892||Group|Spanish territory population of 46,439,864 inhabitants
88849966|NCT02686892||Cohort|Incident cases diagnosed with IBD over 12 months in the Spanish territory
88849967|NCT02341807|Experimental|Cohort 1: AAV2-hCHM Dose 1|Single, unilateral subretinal administration of a single low dose range of AAV2-hCHM.
88849968|NCT02341807|Experimental|Cohort 2: AAV2-hCHM Dose 2|Single, unilateral subretinal administration of a single high dose range of AAV2-hCHM.
88849969|NCT02341807|Experimental|Cohort 3 (Expansion Cohort): AAV2-hCHM Dose 2|Single, unilateral subretinal administration of a single high dose range of AAV2-hCHM.
88849970|NCT00380185||1|Subjects with no hemodynamically significant disease (NHSD) of the coronary or peripheral arteries
88849971|NCT00380185||2|Subjects with coronary artery disease only
88849972|NCT00380185||3|Subjects with both coronary artery disease and peripheral arterial disease
88849973|NCT00380497|Experimental|Pico-Salax|
88849974|NCT00380497|Active Comparator|PEGlyte|
88849975|NCT04331431|Other|spinal cord tumors|
88849976|NCT04925713|Experimental|IFx-Hu2.0 (plasmid DNA) 0.1 mg/lesion|One hundred (100) patients will receive 0.1 mg of IFx-Hu2.0 injected intratumorally in a single lesion at a single time point and be followed-up 28 days thereafter.
88849977|NCT00380731|Experimental|1|Participants will receive immediate cognitive behavioral therapy
88849978|NCT00380731|Experimental|2|Participants will receive cognitive behavioral therapy with a 16-week delayed start
88849979|NCT00380809|Active Comparator|Rotational Atherectomy + PES|Elective lesion preparation with rotational atherectomy priot to stent implantation
88849980|NCT00380809|Active Comparator|Standard Treatment (PES without Rotational Atherectomy)|Stenting without prior rotational atherectomy, usually preceeded with balloon dilatation
89376972|NCT02386384||Recurrent Pregnancy Loss|2 or more unexplained miscarriages
89376973|NCT03656432|Experimental|CPP-ACP paste|MI Paste represents an alternative remineralizing agent that prevents the early demineralization, it is capable of stabilizing calcium phosphate, maintaining the supersaturation of these ions in the oral environment by binding with them and transport them in the form of amorphous calcium phosphate. They can enhance remineralization, decrease demineralization or even both in an acid challenge to teeth surfaces.
89376974|NCT03656432|Experimental|CPP-ACP containing fluoride|MI paste plus contains fluoride 0.2% (900 ppm) that is very similar to the amount of fluoride in the toothpaste binds to the tooth surfaces and plaque and provides biocompatible calcium, phosphate and fluoride in a localized way. So, it provides all the ions needed to build fluorapatite crystals that are more resistant to the acid attack compared to hydroxyapatite
89376975|NCT03656432|Active Comparator|toothpaste contains fluoride|Fluoridated Toothpaste are the most significant and worldwide spread forms of caries control used globally as the greater acceptability of toothpaste makes its regular use more likely, thereby improving effectiveness
89376976|NCT02386462|Experimental|Dexmedetomidine|After an injection of pre-determined bolus dose of dexmedetomidine over 10 min, anaesthesia was induced with propofol 2.0 mg/kg. The modified Dixon's up-and-down method was used to determine the bolus dose of dexmedetomidine, starting from 1.0μg/kg (step size; 0.1μg/kg).
89376977|NCT03656276||Group A: Oncologists (wait list control)|Oncologists will be wait-listed for training on the Tool to improve Participation In Clinical Trials (ToPIC)
89376978|NCT03656276||Group B: Oncologists (training)|Oncologists will receive immediate training on the Tool to improve Participation In Clinical Trials (ToPIC)
89376979|NCT02382328|Experimental|alpha lipoic acid|600mg/24 oral pills alpha lipoic acid 28 days before and 120 days after carpal tunnel release.
89376980|NCT02382328|Placebo Comparator|Placebo|Oral pills of mangensium inactivated 28 days before and 120 days after carpal tunnel release.
89376981|NCT03656198|Experimental|Vaccine group|Three dose primary course of Rabivax-S. Dosing and administration of the vaccine (Rabivax-S) will be according to the package insert, following the schedule for pre-exposure prophylaxis via the intramuscular route; that is, 1 mL by intramuscular injection in the deltoid area of the arm on Day 0, Day 7 and Day 21.
89182076|NCT00437125|Experimental|Duloxetine|Participants received duloxetine 30 milligram (mg) orally once daily (QD) for 1 week, followed by duloxetine 60 mg orally QD for 11 weeks
89376982|NCT03656198|Placebo Comparator|Control group|The intervention (placebo) in the control group is at least one dose (1 mL by intramuscular injection) of a three dose primary course (on days 0, 7 and 21) of vaccine diluent (sterile water for injection).
89376983|NCT02382250||Catheterization Group|These are patients recruited from Bellevue Hospital and NYU Hospital Cardiac Catheterization Laboratories
89376984|NCT02388490|Experimental|Brentuximab vedotin|Brentuximab vedotin is an antibody-drug conjugate (ADC) composed of the anti-CD30 chimeric immunoglobulin G1 (IgG1) monoclonal antibody cAC10 and the potent antimicrotubule drug monomethyl auristatin E connected by a protease-cleavable linker. cAC10 binds to the CD30 antigen, which has a very low expression on normal cells but is found on some tumor cells.
89376985|NCT02386540|Experimental|Health Coaching|Patients randomized to the experimental arm receive six months of post-ED health coaching from the Alameda County Health Coach Program (ACHCP) in addition to usual care in the emergency department at enrollment.
88849981|NCT00001981||Patients with acromegaly|Patients with acromegaly
89376986|NCT02386540|No Intervention|Usual Care|Patients randomized to the control arm receive usual care in the emergency department at enrollment.
89376987|NCT02377414|Experimental|Cohort 1: Retosiban/placebo|Each subject in cohort 1 will receive an intravenous (IV) bolus infusion of 6 milligrams (mg) retosiban or placebo over 5 minutes, followed by a continuous infusion of 6 milligram per hour (mg/h) retosiban or placebo for 24 h. At 24 h of dosing, an additional 6 mg retosiban or placebo will be administered over 5 minutes followed by a 12 mg/h infusion over the next 24 h, for a total time of infusion of 48 h. Subjects administered with placebo will receive an equal volume of normal saline as an IV bolus as well as an equal rate of continuous infusion of normal saline as of retosiban.
89376988|NCT02377414|Experimental|Cohort 2: Retosiban|Each subject in cohort 2 will receive a bolus infusion of 6 mg retosiban over 5 minutes, followed by a continuous infusion of 6 mg/h retosiban for 24 h. At 24 h of dosing, an additional 6 mg retosiban will be administered over 5 minutes followed by a 12 mg/h infusion over the next 24 h, for a total time of infusion of 48 h.
89376989|NCT02377336|Experimental|GS-6615|GS-6615 30 mg (5 x 6 mg) on Day 1, followed by 6 mg twice daily
88849982|NCT04716907||Case : COVID-19 positive patients|patients hospitalized for COVID-19 infection
88849983|NCT04716907||Control : COVID-19 negative patients|patients hospitalized for other reasons
89182077|NCT03173001||Patients with colorectal cancer|Patients hospitalized with colorectal cancer at the Department of Coloproctology of Republican Oncology Research Center.
89376990|NCT02377336|Placebo Comparator|Placebo|Placebo to match GS-6615 (5 tablets) on Day 1, followed by placebo to match GS-6615 twice daily
89376991|NCT02381938|Experimental|Intervention|6-month intervention to increase physical activity and improve other health related behaviors
89376992|NCT02381938|Other|Control|6-month intervention to educate and improve financial health
89399389|NCT02173652|Experimental|BI 1356, high dose|Treatment A: 7 days of BI 1356 treatment given once daily
89399390|NCT02173652|Active Comparator|BI 1356, low dose|Treatment B: 7 days of BI 1356 treatment given twice daily
88875295|NCT02577042|Active Comparator|PI-based regimen + Atorvastatin|Continue with the same PI-based regimen, plus Kivexa or Truvada, for 24 weeks. After that, atorvastatin, 20mg/day, will be added for 48 weeks.
88849984|NCT02335424|Experimental|Pembrolizumab|Participants received pembrolizumab 200 mg by IV infusion on Day 1 of each 21-day cycle (Q3W) for up to 2 years. Eligible participants who stopped the initial course of pembrolizumab due to complete response (CR) or completed initial course of pembrolizumab and had stable disease but progressed after discontinuation, initiated a second course of pembrolizumab at the investigator's discretion for up to an additional year.
88849985|NCT00001621||1|Pulmonary Patients
88849986|NCT03868046||Patients treated with ICIs.|All enrolled patients must have been diagnosed with a cancer potentially treatable with ipilimumab, nivolumab, pembrolizumab, atezolizumab or avelumab, alone or in combination, per standard protocol.
88849987|NCT02973295|Experimental|Group Silymarin|Silymarin 2x200 mg 8 weeks (2x2 caps) Silymarin 2x100 mg 16 weeks (2x1 caps)
88849988|NCT02973295|Placebo Comparator|Group Placebo|2x2 placebo caps 8 weeks 2x1 placebo caps 16 weeks
88849989|NCT04329884|Active Comparator|Intra-articular corticosteroid injections|The hip and groin areas will be prepped and draped in the usual sterile fashion with ChloraPrep. Preprocedural vital signs will be performed and will be in the nursing chart for review. Radiology guidance will be used to guide needle placement within the affected hip to administer lidocaine and a corticosteroid intra-articularly.
88849990|NCT04329884|Active Comparator|Cooled radiofrequency ablation|The hip and groin areas will be prepped and draped in the usual sterile fashion with ChloraPrep. Preprocedural vital signs will be performed and will be in the nursing chart for review. The HALYARD* COOLIEF* SINERGY* Cooled Radiofrequency Probe (sterile, single use) is inserted through a COOLIEF* SINERGY* Introducer used with fluoroscopy guidance in the AP view to visualize the hip joint and sensory nerve areas over the acetabulum (femoral) and ischium (obturator) where the cooled radiofrequency ablation will be applied to create a focal thermal lesion to encompass and denervate the targeted nerves.
88849991|NCT00001627||Group 1|Normal Volunteers and patients.
88849992|NCT00002485||Stratum 1|Not Enrolled / No IRB Applied
88849993|NCT00002485||Stratum 2|Not Enrolled / IRB Approved
88849994|NCT03836378|Experimental|Deep Cleaning and Intervention|One side of the participant's mouth will receive a deep cleaning in addition to the placement of a BioXclude™ membrane in the deep pocket sites. The participant will then be followed for 9 months with routine care.
88849995|NCT03836378|No Intervention|Deep Cleaning Only|One side of the participant's mouth will receive deep cleaning (scaling and root planning) only. The participant will then be followed for 9 months with routine care.
88849996|NCT03833804|Experimental|NLP (natural language processing) pre-screen|Automated processing of clinical notes collected during routine care in first 24 hours of hospital admission to identify individuals at-risk for substance misuse to receive standard-of-care full screening and assessment, brief intervention, or referral to treatment (SBIRT) intervention.
88849997|NCT04713397||LLD group|Patients who have functional scoliosis due to structural LLD
89376993|NCT02662582|Experimental|CK-2127107 1000 mg, then placebo|Participants received CK-2127107 500 milligram (mg), orally, twice daily for 2 weeks in treatment period 1 followed by matching placebo orally, twice daily for 2 weeks in treatment period 2. A washout period of 2 weeks was maintained between the two treatment periods.
89376994|NCT02662582|Experimental|Placebo, then CK-212710 1000 mg|Participants received matching placebo orally, twice daily for 2 weeks in treatment period 1 followed by CK-2127107 500 mg in treatment period 2. A washout period of 2 weeks was maintained between the two treatment periods.
89376995|NCT02382094|Experimental|Arm AA(anti-androgen)|Bicalutamide 150 mg per os daily + if needed Tamoxifen 10 mg against breast tenderness/gynecomasti.
89376996|NCT02382094|Other|Arm TAB (Total androgen blockade)|Bicalutamide 50 mg orally daily + Goserelin 3.6 mg subcutaneously every 28±2 days + if needed Tamoxifen 10 mg against breast tenderness/gynecomasti.
89376997|NCT04439500|Experimental|Real World Strategy Training|Group intervention including education and strategy training to manage everyday functional difficulties.
89376998|NCT04439500|Active Comparator|Psychosocial Education|Group sessions including education on brain health.
89376999|NCT02386150|Experimental|Group 1: 10 μg|10 μg RVEc is to be administered given in the volar surface of the forearm by ID injection (in alternate arms for each vaccination unless there is a medical reason not to alternate arms) with a needle and syringe (ID adapter may be used) (0.1 mL/dose). There are 4 doses planned for this group: 1 primary dose on Days 0, 28, and 106, and a booster dose on Day 365 (1 year).
89399391|NCT03694041|Experimental|SAD: APX-115|Experimental: APX-115 SAD group
89399392|NCT03694041|Placebo Comparator|SAD: Placebo|Experimental: Placebo group
89399393|NCT03694041|Experimental|MAD: APX-115|Experimental: APX-115 MAD group
88849998|NCT04713397||LLD concurrent with AIS|Patients who have structural LLD concurrent with AIS
88849999|NCT03805412|Active Comparator|DEXCOM G6 RT-CGM|These participants will wear blinded continuous glucose monitoring for 10 days at baseline and 14 weeks. They will also complete real-time continuous glucose monitoring (RT-CGM) for 10 days at 2 weeks and 6 weeks. They will receive Nutrition and exercise counseling at week 2 and 6. They will also receive additional training on continuous glucose monitoring.
88850000|NCT03805412|No Intervention|Blinded CGM|These participants will have blinded continuous glucose monitoring(CGM) at the baseline and last 14 weeks. They will not wear continuous glucose monitoring at the interim appointments. They will receive 2 session of nutrition and exercise counseling at week 2 and 6.
88850001|NCT05752513|Placebo Comparator|Group 1|18 pregnant women scheduled for classical cesarean hysterectomy for placenta accreta
89182078|NCT03173001||Population|The control group includes residents of Tashkent city without any complaints from gastrointestinal tract matched by gender and age to the patients with colorectal cancer.
89182079|NCT03173001||Patients with CRC without metastases|Patients hospitalized with colorectal cancer at the Department of Coloproctology of Republican Oncology Research Center.
88850002|NCT05752513|Experimental|Group 2|18 pregnant women scheduled for bladder last cesarean hysterectomy
88850003|NCT03805022|Experimental|Arm A|"Control-Arm phase III high-risk CINSARC:~Patients will be treated by doxorubicin (60 or 75mg/m² day or 20- or 25 mg/m² per day from day1 to day 3) + ifosfamide (7,5-9 g/m² over 3 days with mesna and G-CSF) or dacarbazine (100 mg/m² 1 day or 450 mg/m² 2 days) as per local practices of a 21-days cycle for up to 3 cycles in neoadjuvant setting Neoadjuvant chemotherapy will be followed by surgery. If indicated, radiotherapy could be prescribed at the discretion of the investigator (in neoadjuvant or adjuvant setting)."
88850004|NCT03805022|Experimental|Arm B|"Experimental-Arm phase III high-risk CINSARC:~Patients will be treated by doxorubicin (60 or 75mg/m² day or 20 or 25 mg/m² per day from day1 to day 3) + ifosfamide (7,5-9 g/m² over 3 days with mesna and G-CSF) or dacarbazine (100 mg/m² 1 day or 450 mg/m² 2 days) as per local practices of a 21-days cycle for up to 6 cycles in neoadjuvant setting Neoadjuvant chemotherapy will be followed by surgery. If indicated, radiotherapy could be prescribed at the discretion of the investigator (in neoadjuvant or adjuvant setting)."
88850005|NCT03805022|Experimental|Prospective cohort|Patients will be treated at the discretion of the investigator
88850006|NCT05752435|Active Comparator|BLEOMYCIN|COMPARISON OF THERAPEUTIC EFFICACY BETWEEN INTRALESIONAL BLEOMYCIN AND CRYOTHERAPY IN PLANTAR WARTS
88850007|NCT05752435|Active Comparator|CRYOTHERAPY|COMPARISON OF THERAPEUTIC EFFICACY BETWEEN INTRALESIONAL BLEOMYCIN AND CRYOTHERAPY IN PLANTAR WARTS
88850008|NCT05752357||single arm, observational arm|Patients who received surgery will routinely followed up by pre-op CTC, post-op CTC until 6 months after surgery.
88850009|NCT00003056|Active Comparator|Unselected peripheral blood haemopoietic stem cells (PBSC)|Unselected PBSC together with control graft versus host disease (GVHD) prophylaxis - Control
88850010|NCT00003056|Experimental|CD34+ cells isolated from PBSC|CD34+ cells isolated from PBSC using the Isolex 300i system together with cyclosporine
88850011|NCT01719458||Alcohol|Subjects diagnosed with alcohol dependence
88850012|NCT01719458||Obese|Subjects diagnosed with obesity
88850013|NCT01719458||Healthy|Subjects deemed to be medically healthy
88850014|NCT01568918|Experimental|Tamsulosin|Participants randomized to this arm will receive 0.4 mg/day tamsulosin hydrochloride from 5 days prior to the operation until hospital discharge.
88850015|NCT01568918|Placebo Comparator|Placebo|Participants randomized to this arm will receive a daily placebo capsule matching the active study drug from 5 days prior to the operation until hospital discharge.
88850016|NCT02973139|Active Comparator|Thoracoscopy group|Patients randomized to the Thoracoscopy group will undergo medical thoracoscopy.
88850017|NCT02973139|Active Comparator|Fibrinolytic group|Patients randomized to the Fibrinolytic group will receive intrapleural therapy of combined tissue plasminogen activator (tPA) and human recombinant deoxyribonuclease (DNase)
88850018|NCT01334450|Active Comparator|High Frequency TMS to prefrontal cortex|
88850019|NCT01334450|Active Comparator|Low Frequency TMS to Prefrontal cortex|
88850020|NCT01334450|Sham Comparator|Sham TMS on Prefrontal Cortex|
88850021|NCT00003092|Experimental|Paclitaxel|"Patients receive a single dose of IV paclitaxel over 3 hours. Additional cycles of paclitaxel will be given at the discretion of the physician.~Patients are followed for second malignancies, disease progression, and survival."
88850022|NCT00003098|Experimental|fat reduction increased fiber|Patients are randomized to dietary fat reduction with increased fiber). All patient must successfully complete a dietary run-in phase for 4 weeks before randomization. During the run-in phase, patients are asked to maintain a food record for days 7-14. Patients undergo radioisotopic infusion study of sex steroid metabolism on days 14, 21, and 28. Patients are given 3 prepackaged meals a day for 12 weeks. Patients must maintain a record of all food eaten and return all food containers to the center for documentation. Patients undergo radioisotopic infusion study of sex steroid metabolism on days 70, 77, and 84. At the end of the 12 weeks, patients meet with the dietitian for 30 minutes to receive instructions on maintaining a low fat, high fiber diet for the second phase of the study.
88850023|NCT00003098|Experimental|fat reduction without increased fiber|Patients are randomized to dietary fat reduction without increased fiber). All patient must successfully complete a dietary run-in phase for 4 weeks before randomization. During the run-in phase, patients are asked to maintain a food record for days 7-14. Patients undergo radioisotopic infusion study of sex steroid metabolism on days 14, 21, and 28. Patients are given 3 prepackaged meals a day for 12 weeks. Patients must maintain a record of all food eaten and return all food containers to the center for documentation. Patients undergo radioisotopic infusion study of sex steroid metabolism on days 70, 77, and 84. At the end of the 12 weeks, patients meet with the dietitian for 30 minutes to receive instructions on maintaining a low fat, high fiber diet for the second phase of the study.
88850024|NCT04712630|Experimental|NIPSA without grafting biomaterial|A single horizontal or oblique apical incision will be made in the mucosa located on the bony cortex, far from the marginal tissues and apically to the edge of the bony crest delimiting the defect. The tissue coronal to the incision will be raised full thickness, trying to maintain the preoperative papillae architecture intact. The granulation tissue and epithelium of the pocket will be eliminated. The affected root will be scaled and planed, and calculus eliminated. Once the defect will be debrided, the enamel matrix derivates will be applied. Then the incision line will be sutured by a double suture line to facilitate closing without tension: The first with internal horizontal mattress sutures to approximate the connective tissue of both edges of the mucosal incision, and the second with single interrupted sutures.
88850025|NCT04712630|Active Comparator|NIPSA with grafting biomaterial|A single horizontal or oblique apical incision will be made in the mucosa located on the bony cortex, far from the marginal tissues and apically to the edge of the bony crest delimiting the defect. The tissue coronal to the incision will be raised full thickness, trying to maintain the preoperative papillae architecture intact. The granulation tissue and epithelium of the pocket will be eliminated. The affected root will be scaled and planed, and calculus eliminated. Once the defect will be debrided, the enamel matrix derivates will be applied and the bone defect will be filled with a composite of xenograft and enamel matrix derivates. Then the incision line will be sutured by a double suture line to facilitate closing without tension: The first with internal horizontal mattress sutures to approximate the connective tissue of both edges of the mucosal incision, and the second with single interrupted sutures.
88850026|NCT05751889|Experimental|Serious Game Intervention|Provided with a single session serious game intervention regarding HCV and safe sexual practice.
89377000|NCT02386150|Experimental|Group 2: 20 μg|20 μg RVEc is to be administered given in the volar surface of the forearm by ID injection (in alternate arms for each vaccination unless there is a medical reason not to alternate arms) with a needle and syringe (ID adapter may be used) (0.1 mL/dose). There are 4 doses planned for this group: 1 primary dose on Days 0, 28, and 106, and a booster dose on Day 365 (1 year).
89377001|NCT02908100|Placebo Comparator|Placebo|Participants received matching placebo to GDC-0853 orally starting on Day 1 and ending at Week 48, in combination with background standard of care therapy.
88850027|NCT05751889|Active Comparator|Traditional Health Education|Provided with a single session of traditional online healthcare education regarding HCV and safe sexual practice.
89377002|NCT02908100|Experimental|GDC-0853 (150mg) QD|Participants received GDC-0853 (150mg) orally once daily (QD) starting on Day 1 and ending at Week 48, in combination with background standard of care therapy.
89377003|NCT02908100|Experimental|GDC-0853 (200mg) BID|Participants received GDC-0853 (200mg) orally twice daily (BID) starting on Day 1 and ending at Week 48, in combination with background standard of care therapy.
88810422|NCT06213506|Active Comparator|Infants_6W_Control A Group|Infants 6 weeks of age, part of the safety cohort, randomized to receive 3 doses of the MenACWY vaccine at Day 1, Day 57 (during the Priming phase) and at Day 232 (during the Booster phase). To allow completion of the vaccination schedule a fourth dose of the MenACWY vaccine is administered after the trial ends, as per the licensed indication and in private vaccination settings. These infants also receive an EPI vaccination with Measles and Rubella Vaccine (MR-VAC) and Yellow Fever (YF) vaccine at 28 days after the third study intervention administration occurring at Day 232, at the local EPI vaccination centers, and not part of the current clinical trial.
88850028|NCT00002527|Experimental|Aspirin|325 mg/day PO
88850029|NCT00002527|Placebo Comparator|Placebo|
89377004|NCT02377180|Experimental|Part 1|Intramuscular injection of capsaicin for the study of pain and hyperalgesia
89399394|NCT03694041|Placebo Comparator|MAD: Placebo|Experimental: Placebo group
89377005|NCT02377180|Active Comparator|Part 2|Pain arising from supraspinatus muscle vs. pain arising from trapezius muscle. Nerve block is only expected to be effective in the former.
89377006|NCT02377180|Active Comparator|Part 3|Suprascapular nerve block vs. intramuscular local anesthetic against pain arising from the supraspinatus muscle.
88850030|NCT02973217|Experimental|imILT|Immunostimulating Interstitial Laser Thermotherapy (imILT)
88850031|NCT00381589|Experimental|A|Random assignment to investigational spray
88850032|NCT00383474|Experimental|Arm I|Patients will receive an infusion of bortezomib twice a week for 2 weeks. They will also receive tipifarnib by mouth twice a day for 2 weeks.
89377007|NCT02377024|Experimental|TF 600mg|TF 600mg/day
89377008|NCT02377024|Experimental|TF 1200mg|TF 1200mg/day
88850033|NCT04331197|Active Comparator|Clomiphene Citrate-High BMI women|Clomid 50 mg, 2 tablets orally every day from day 2-5 of the period for 5 days
88850034|NCT04331197|Active Comparator|Letrozole-High BMI women|Femara 2.5 mg, 2 tablets orally every day from day 2-5 of the period for 5 days
88850035|NCT05751733|Experimental|Experimental group|Subjects received Apatinib mesylate
89377009|NCT02377024|Placebo Comparator|placebo|placebo
89377010|NCT02377102|No Intervention|Observational|Patients will be asked to continue for 12 weeks of nonoperative medical management without physical therapy. At 12 weeks they will be reevaluated regarding the need for total knee arthroplasty.
88850036|NCT05751733|Active Comparator|Control group|Subjects received TKI second-line therapy such as Sunitinib, Imatinib plus, Dasatinib, and Reveratinib.
88850037|NCT00002798|Experimental|Arm I (combination chemotherapy)|"Patients receive treatment as in induction therapy, plus G-CSF SC beginning on day 16 and continuing until blood counts recover. If CSF is clear by day 10 of induction, patients receive cytarabine IT on days 0, 10, and 35. If CSF is not clear, patients receive triple intrathecal therapy (TIT; cytarabine, hydrocortisone, methotrexate) on days 0 and 10.~See Detailed Description"
88850038|NCT00002798|Experimental|Arm II (combination chemotherapy)|"Patients receive fludarabine IV over 24 hours on days 0 and 1, cytarabine IV over 72 hours on days 2-4, and idarubicin IV over 15 minutes on days 0-2. G-CSF begins on day 6 and continues until blood counts recover. Patients also receive TIT on days -1 and 7, if CSF is not clear on day 10 of induction. Patients on both arms are reassessed on day 35. Those patients with M1 marrow proceed to intensification; all others are removed from the study.~Intensification: See Detailed Description"
88850039|NCT00002798|Experimental|Arm III (combination chemotherapy, aldesleukin)|Patients receive interleukin-2 IV continuously on days 1-4 and 9-18.
88850040|NCT00002798|Active Comparator|Arm IV (combination chemotherapy)|No further treatment
88850041|NCT00002798|Experimental|Arm V (combination chemotherapy, radiotherapy)|Patients undergo radiotherapy to the chloroma 5 days a week for 2 weeks.
89377011|NCT02377102|Active Comparator|Physical Therapy|Patients will be provided a prescription for 12 weeks of physical therapy at a location of their choice. No set protocol will be issued to allow for adjustments based on patient activity level and the therapist's professional choice. The physical therapy techniques, consisting of active and passive physiological and accessory movements and soft tissue mobilization, active range of motion exercises, muscle strengthening, muscle stretching, and exercises such as riding a stationary bicycle will be applied at the discretion of the treating physical therapist primarily to the knee and surrounding structures.
89377012|NCT03656120|Experimental|0.2mg group|Participants are taking 0.2mg thienorphine hydrochloride table once a day for 12 weeks.
89377013|NCT03656120|Experimental|0.5mg group|Participants are taking 0.5mg thienorphine hydrochloride table once a day for 12 weeks.
89377014|NCT03656120|Placebo Comparator|placebo control group|Participants only taking placebo once a day for 12 weeks.
89377015|NCT04341298|Experimental|Avulux® device|Subjects will be instructed to use the glasses for four weeks. They will be instructed to put the glasses on at the first signs or symptoms consistent with the onset of a migraine attack or at the first onset of aura and keep the glasses on until their headache has resolved.
89399395|NCT03694041|Active Comparator|Food effect - Fasting condition|Experimental: APX-115 under fasting condition
88850042|NCT00003134|Experimental|Arm I: irinotecan|"Patients receive irinotecan IV over 90 minutes on days 1, 8, 15, and 22. This is followed by a 2 week rest and continues for a maximum of 6 courses. Patients who received prior nitrosoureas, also receive reduced starting doses of irinotecan. The dosages may be increased once per patient after the first course if toxic effects are acceptable.~Patients are followed every 3 months for the first year, every 6 months for the next 4 years, then annually until death."
88850043|NCT00003134|Experimental|Arm II: irinotecan|"Patients receive irinotecan on day 1 every 3 weeks for up to 12 courses. Patients who received prior nitrosoureas receive reduced starting doses of irinotecan. The dosages may be increased once per patient after the first course if toxic effects are acceptable.~Patients are followed every 3 months for the first year, every 6 months for the next 4 years, then annually until death."
88850044|NCT00002804|Experimental|Chemotherapy Regimen|Induction (Weeks 1-6) Vincristine sulfate (1.5 mg/m2) day 1, Ifosfamide (3 grams/m2) days 1-3, Doxorubicin (30 mg/m2) days 1-2, filgrastim day 4. Weeks 2 and 3 - Vincristine sulfate (1.5 mg/m2) IV day 1, week 5 no chemotherapy. Evaluate for response. Local Control (Weeks 7-13) Conventional surgery and radiation therapy. Vincristine sulfate (1.5 mg/m2) IV day 1, Ifosfamide (3 grams/m2) days 1-3, Doxorubicin (30 mg/m2) days 1-2, filgrastim day 4. Treatment continues per protocol.
88850045|NCT00003140|Experimental|Arm I|Patients receive oral letrozole once daily.
88850046|NCT00003140|Placebo Comparator|Arm II|Patients receive oral placebo once daily.
88850047|NCT00002551|Experimental|Bolus 5-FU, Pelvic XRT + PVI 5-FU, Bolus 5-FU|Bolus 5-FU (fluorouracil) (500mg/m2/day on days 1-5, 29-33), Pelvic XRT + PVI 5-FU, Bolus 5-FU (450mg/m2/day for 5 days beginning 28 days after RT, for 2 cycles on days 1-5 of a 28 days cycle).
88850048|NCT00002551|Experimental|PVI 5-FU+Pelvic XRT+PVI 5-FU+PVI 5-FU|5-FU (fluorouracil) 300mg/m2/day for 42 days followed by 2 week interruption, Day 57 through XRT will receive 225mg/m2/day of 5-FU followed by 1 month interruption, 4 weeks after completion of XRT 1 8wk cycle of 5-FU 300mg/m2/day.
88850049|NCT00002551|Experimental|Bol 5-FU+LV+LEV+Pel XRT+Bol 5-FU+LV Bol 5-FU + LV + LEV|5-FU (fluorouracil) 425/mg/m2/day Days 1-5,29-33; LV (leucovorin calcium) 20mg/m2/day Days 1-5,29-33; LEV (levamisole hydrochloride) 150mg/day (50mg TID) for 3 days every 14 days starting after each course of 5-FU. During RT: 5-FU and LV 4 days on wk 1 and wk 5 of RT. LV 20 mg/m2/day IV bolus within 2hrs after completion of that day's radiation therapy, for four days in each cycle. Followed immediately by 5- FU 400 mg/m2/day IV bolus. Treatment will be given on days 57 - 60 and 85 - 88.Treatment post-RT-chemotherapy 28 days after completion of RT consist of 5 days of chemotherapy in 28 day cycles. 5-FU, 380 mg/m2/day on days 1 - 5 and LV given at a dose of 20 mg/m2/day on days 1 - 5 with the 5-FU given immediately after the LV. For 2 post-radiation cycles on days 1 - 5 of a 28 day cycle. Levamisole will be given orally at a dose of 150 mg/day (50 mg tid) for 3 days every 14 days during the 1st 3 days of each cycle of 5-FU, and again 14 days after starting each course of 5-FU.
88850050|NCT00002816|Experimental|EARLY # CNS RELAPSE with BM DONOR|Induction (Etoposide, Ifosfamide with Mesna Uroprotection,Ifosfamide, Dexamethasone, Vincristine sulfate, PEG, ITT (methotrexate, cytosine arabinoside and therapeutic hydrocortisone), and leucovorin calcium then Intensification (4 courses of 6 weeks, ITT, dexamethasone, vincristine, methotrexate, leucovorin, 6-Thioguanine, cytarabine (Ara-C), Etoposide, pegaspargase, Ifosfamide with Mesna) and Idarubicin and CXRT.
88850051|NCT00002816|Experimental|LATE CNS RELAPSE with/without BM DONOR, TESTICULAR or OCULAR|Induction (Etoposide, Ifosfamide with Mesna Uroprotection,Ifosfamide, Dexamethasone, Vincristine sulfate, pegaspargase, ITT (methotrexate, cytosine arabinoside and therapeutic hydrocortisone), and leucovorin calcium then Intensification (4 courses of 6 weeks, ITT, dexamethasone, vincristine, methotrexate, leucovorin, 6-Thioguanine, cytarabine (Ara-C), Etoposide, PEG, Ifosfamide with Mesna) and Idarubicin), and Maintenance (4 x 12 courses) of ITT, Vincristine, Methotrexate, T-thioguanine.
88850052|NCT05751499||CASE GROUP|"Both male & Female patients~Age group 18-60 Years~Diagnosed with nonspecific low back pain in acute/flared stage"
88850053|NCT05751499||CONTROL GROUP|MALE AND FEMALE AGE GROUP 18 TO 60 YEARS NOT SUFFERING FROM LOW BACK PAIN
88850054|NCT05751421|Experimental|primary total knee replacement + Zynrelef|Patients undergoing primary total knee replacement with Extended Relief Bupivacaine and Meloxicam (Zynrelef)
88850055|NCT05751421|Active Comparator|primary total knee replacement + adductor canal block (ACB)|Patients undergoing primary total knee replacement with routine adductor canal block
88850056|NCT00003416|Experimental|treatment|"Ind:~dexamethasone 40 mg/d PO D1-4,9-12,17-20 q35 days x 3 cycles~SC Collection:~cyclophosphamide 1.5gm/m2 IV q3 hrs x 2 mesna 3 gm/m2 conIV start with cyclo GCSF 5mcg/kg/d SQ start 1 day after cyclo until WBC > 50,000/mcg~Trans (x2):~melphalan 100 mg/m2/d IV D-1,-2 PBSC infusion D0~Maint:~interferon 3 million units/m2 SQ 3x/wk"
89377016|NCT04341298|Sham Comparator|Control/sham device|Subjects will be instructed to use the glasses for four weeks. They will be instructed to put the glasses on at the first signs or symptoms consistent with the onset of a migraine attack or at the first onset of aura and keep the glasses on until their headache has resolved.
89377017|NCT02166242|Experimental|experimental|patients pathologic diagnosis advanced non-small cell lung cancer who had received more than two lines standard treatment, according to NCCN Non-small cell lung cancer guideline, there were no standard treatment scheme for these patients. Approximately 40 patients will be included in the study, patients will received oral ethaselen dispersible tablet, 600 mg bid dose, patients may quit the study whenever they would like or investigator evaluate that progression disease has developed, or any grade of SAE developed during the study.
88850057|NCT00002569|Active Comparator|Radiation therapy (RT) alone|Radiation therapy (RT) alone - External Beam RT 59.4 Gy (1.8 Gy x 33 fractions, 5 days a week) to MR defined tumor volume.
88850058|NCT00002569|Experimental|Intensive pre-treatment chemotherapy and radiation therapy|Intensive pre-treatment chemotherapy (Day 1 CCNU 130 mg/m2 p.o., Day 8 - Vincristine 1.4 mg/m2 i.v., Days 8-21 - Procarbazine 75 mg/m2 p.o., Day 29 - Vincristine 1.4 mg/m2 i.v.) followed by radiation therapy (External Beam RT 59.4 Gy (1.8 Gy x 33 fractions, 5 days a week) to MR defined tumor volume).
88850059|NCT05720767|Experimental|Part A - Itraconazole|HMPL-523 will be supplied as 100 and 150 mg tablets and will be administered PO as a single dose of 400 mg (combination of 2 of 150 mg tablets and 1 of 100 mg tablet) on two separate occasions (Day 1 and Day 10) in Part A. Itraconazole will be supplied as 100 mg capsules and will be administered as doses of 200 mg (2 × 100 mg) PO BID on Day 6 and 200 mg PO QD on Days 7 to 14 in Part A.
88850060|NCT05720767|Experimental|Part B - Rifampin|HMPL-523 will be supplied as 100 and 150 mg tablets and will be administered PO as a single dose of 700 mg (combination of 4 of 150 mg tablets and 1 of 100 mg tablet) on two separate occasions (Day 1 and Day 13) in Part B. Rifampin will be supplied as 300 mg capsules and will be administered as doses of 600 mg (2 × 300 mg) PO QD on Days 6 to 17 in Part B.
88850061|NCT00003170|Experimental|glutamine|Beginning the first or second day of radiotherapy, patients receive oral glutamine twice daily, including the days that they do not receive radiotherapy. Patients continue on treatment throughout radiotherapy and continue 2 weeks postradiotherapy or until grade 3 diarrhea occurs. Patients are followed weekly for 4 weeks, then at 12 months, and then at 24 months after radiotherapy.
88850062|NCT00003170|Placebo Comparator|placebo|Beginning the first or second day of radiotherapy, patients receive placebo twice daily, including the days that they do not receive radiotherapy. Patients continue on treatment throughout radiotherapy and continue 2 weeks postradiotherapy or until grade 3 diarrhea occurs. Patients are followed weekly for 4 weeks, then at 12 months, and then at 24 months after radiotherapy.
88850063|NCT05751031||European Pregnancy and Paediatric Infections Cohort Collaboration (EPPICC)|Pregnant women living with HIV and their infants from 9 European cohorts and studies within the European Pregnancy and Paediatric Infections Cohort Collaboration (EPPICC)
88850064|NCT00002852|Active Comparator|Arm I (surgery, observation)|Patients receive no further therapy.
88850065|NCT00002852|Experimental|Arm II (surgery, chemotherapy)|Patients receive adjuvant therapy comprising paclitaxel IV over 3 hours followed by carboplatin IV over 1-2 hours on day 1. Treatment continues every 3 weeks for 4 courses.
88850066|NCT05750719||Women with early triple negative breast cancer who received neoadjuvant chemotherapy.|
88850067|NCT00002575|Experimental|Conventional surgery|"Patients undergo open laparotomy and colectomy. A standard incision is made through the abdominal wall and the abdominal cavity is explored. A right or left colectomy or a sigmoid resection is performed.~Patients may be entered on adjuvant chemotherapy trials after surgery provided the subsequent trial does not include radiotherapy and allows entry of patients from both arms.~Quality of life is assessed at baseline and on days 2 and 14 after surgery, at 2 months, and then at 18 months. (closed as of 4/30/99)~Patients are followed every 3 months for 1 year, every 6 months for 4 years, and then annually for 3 years."
89377018|NCT03656042|Experimental|G-CSF|Subjects in the treatment group will receive Filgrastim (75mcg/0.3ml, NEUPOGEN®), 10 mic/kg/day, by sc, for 5 continuous days for the first week, rest for 11 weeks. Filgrastim will be given 12-weekly ( 12 weeks/cycle ) for 2 cycles.
89377019|NCT03656042|No Intervention|No-treatment|No-treatment group is used to control evaluation bias and potential time effect.
89377020|NCT02381860|Placebo Comparator|Placebo|The PLA supplement consisted of a commercially available, less than 5% fruit, cordial (Protein - Trace, Carbohydrate 260 mg•mL-1, Sodium 0.02 mg•mL-1, Fibre-Trace and Anthocyanins-Trace for colour), mixed with water, whey protein isolate (Arla Foods Ltd., Leeds, UK) and maltodextrin (MyProtein Ltd., Northwich, UK) until matched for carbohydrate and calorie content of the MC.
89377021|NCT02381860|Active Comparator|60mL of cherry concentrate with 100ml water|One bolus of 60mL of tart Montmorency cherry (MC) juice mixed with 100mL of water. Independent analysis of MC (Atlas Biosciences, 2010) provided the following compositional data; Fat 0.028 mg•mL-1, Protein 31.47 mg•mL-1, Carbohydrate 669.4 mg•mL-1, Cholesterol < 0.01 mg•mL-1, Sodium 0.691 mg•mL-1, Calcium 0.137 mg•mL-1 and Iron 0.026 mg•mL-1. Additionally, according to the manufacturers guidelines (Cherry Active, Hanworth, UK),
89377022|NCT03655964|Experimental|Olmesartan|20 patients randomly allocated to single-blind antihypertensive therapy with olmesartan (20 mg/day)
88850068|NCT00002575|Experimental|Laparoscopic-assisted colectomy|"Patients undergo a laparoscopic-assisted colectomy. A small infraumbilical incision is made through the abdominal skin and the abdominal cavity is insufflated with CO2 to allow access and visualization. The abdominal cavity is explored. If advanced local disease is identified, a celiotomy and colectomy are performed. Otherwise, a right or left colectomy or sigmoid resection is performed using laparoscopic-assisted techniques.~Patients may be entered on adjuvant chemotherapy trials after surgery provided the subsequent trial does not include radiotherapy and allows entry of patients from both arms.~Quality of life is assessed at baseline and on days 2 and 14 after surgery, at 2 months, and then at 18 months. (closed as of 4/30/99)~Patients are followed every 3 months for 1 year, every 6 months for 4 years, and then annually for 3 years."
88850069|NCT00002864|Active Comparator|Octreotide|
88850070|NCT00002864|Active Comparator|Tamoxifen|
88850071|NCT00002587|Experimental|Arm I|"Patients receive paclitaxel IV over 3 hours on day 1 followed 2-6 hours later by topotecan IV continuously on days 1-14. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of topotecan and paclitaxel until the maximum tolerated dose (MTD) of each drug is determined. The MTD is defined as the highest dose preceding that at which 2 of 6 patients experience dose-limiting toxicity."
88850072|NCT05750641||diet group|those who removed milk and dairy products under the advice of a dietician without medical treatment.
88850073|NCT05750641||free-diet group|According to current standard algorithms and guidelines, appropriate treatment for FD types was arranged for the patient group who preferred to receive a free diet.
89182080|NCT03173001||Patients with CRC with metastases|Patients hospitalized with colorectal cancer at the Department of Coloproctology of Republican Oncology Research Center.
89182081|NCT03173001||Patients with CRC before operation|Patients hospitalized with colorectal cancer before operation at the Department of Coloproctology of Republican Oncology Research Center.
89182082|NCT03173001||Patients with CRC after operation|Patients hospitalized with colorectal cancer after operation at the Department of Coloproctology of Republican Oncology Research Center.
89182083|NCT03173001||Patients with CRC before chemotherapy|Patients hospitalized with colorectal cancer before operation and chemotherapy at the Department of Chemotherapy of Republican Oncology Research Center.
89182084|NCT03173001||Patients with CRC after chemotherapy|Patients hospitalized with colorectal cancer after operation and chemotherapy at the Department of Chemotherapy of Republican Oncology Research Center.
89182085|NCT02578407|Experimental|Accommodative/Vergence Therapy|Accommodative/Vergence Therapy. No drug involved.
89182086|NCT03511027|Experimental|Intervention (SME + Karie Device)|Patients randomly assigned to receive SME+Karie will 1) undergo Screening for Self Medication Readiness to determine self-management capacity, 2) will receive self-medication education (SME) by a study Occupational Therapist, and 3) receive a 5-day self-medication performance assessment by an Registered Nurse prior to discharge. In addition, this group will receive orientation to the Karie Automated Medication Delivery by the study Occupational Therapist. The participants in the intervention arm will use the Karie device for all applicable medications for the study duration.
89182087|NCT03511027|Active Comparator|Control (SME only)|"West Park has a Self-Medication Education Program policy in place which seeks to establish independent medication self-medication capacity during the inpatient stay. Eligibility criteria for SME include a need to manage medications independently at home; stabilized on medication (as per pharmacist/physician discretion); and mild-moderate cognitive/physical impairments (as per an OT assessment). During SME participants receive training by an Occupational Therapist, followed by a 5-day self-medication performance assessment by an Registered Nurse prior to discharge. Participants in the SME group will fill prescriptions as usual for the duration of study."
89182088|NCT02578329|Experimental|Med Diet|Intensively advised Mediterranean diet
89182089|NCT02578329|Active Comparator|Low Fat diet|usual low-fat dietary advice
89182090|NCT01028287|Active Comparator|ACTH-16 units|Patients with nephrotic range proteinuria randomized to this group will receive 16 units ACTHargel sub-cutaneously every day.
89182091|NCT01028287|Active Comparator|ACTH-32 units|Patients with nephrotic range proteinuria randomized to this group will receive 32 units ACTHargel sub-cutaneously every day.
89182092|NCT02578173||AVERT PLUS|The AVERT PLUS will be used on the first 10 patients enrolled in the study. The AVERT PLUS is a contrast monitoring system which is used to precisely measure the volume of contrast delivered to the patient.
89182093|NCT02578173||Non device group|The second group of 10 patients will undergo the scheduled angiography using the standard method of measuring contrast dye delivery.
89182094|NCT01028365||No treatment|Study participants will not be asked to make any changes to their daily lifestyle or existing health care routine. Participants also will not be asked to take any medications or change their diet.
89182095|NCT04698135||morbid obesity|Patients with morbid obesity
89182096|NCT04698135||Metabolically healthy obesity|Patients with metabolically healthy obesity
89182097|NCT04698135||Healthy volunteers|Healthy volunteers
89182098|NCT01028443|Active Comparator|Cyclosporine A 2%|
89182099|NCT01028443|Placebo Comparator|Artificial tears|
89377023|NCT03655964|Experimental|Nebivolol|20 patients randomly allocated to single-blind antihypertensive therapy with nebivolol (5 mg/day)
88850074|NCT00002593|Active Comparator|5-FU/Leucovorin/Levamisole|levamisole hydrochloride: 50 mg every 8 hours x 3 days, PO, repeat every 14 days for 6 months; leucovorin calcium: 20 mg/m^2/day, IV, Days 1-5 of each cycle; 5-fluorouracil: 425 mg/m^2/day, IV, Days 1-5 of each cycle;
88850075|NCT00002593|Active Comparator|Infusional 5-FU + Levamisole|levamisole hydrochloride : 50 mg every 8 hours x 3 days, PO, repeat every 14 days for 6 months; 5-fluorouracil: 250 mg/m^2/day, continuous infusion, daily for 56 days x 3 cycles of 8 weeks.
88850076|NCT00002882|Experimental|IFN-A Therapy Schedule A|Schedule A: IV Interferon alfa-2b (IFN-A) induction 5 times a week for 4 weeks followed by subcutaneous IFN-A maintenance 3 times a week for 48 weeks.
89182100|NCT04096976||Hospital survival|
89182101|NCT04096976||No hospital survival|
89377024|NCT03655964|Experimental|No antihypertensive treatment|20 patients randomly allocated to receive no antihypertensive therapy during the acute stage of ischemic stroke
89377025|NCT02385994|Experimental|enLighten Laser Treatment|Melasma, Cohort I or Lentigines, Cohort II will be treated with dual-pulse duration, dual-wavelength 532nm KTP/1064nm Nd:YAG laser.
89377026|NCT02385994|No Intervention|Control|Melasma subjects randomized to non-treatment will receive no treatments.
89377027|NCT02381236|Experimental|G-202|G-202 administered by intravenous infusion on 3 consecutive days of a 28-day cycle
89182102|NCT03116997|Experimental|Neuromuscular blockade reversed with neostigmine/gly|
89377028|NCT02982590|Active Comparator|warfarin sodium|warfarin daily, dosage according to INR monitor. Aim INR 2-3
89377029|NCT02982590|Experimental|apixaban|Apixaban 5 MG Oral Tablet [ELIQUIS] will be given for randomly selected patients for 3 months.
89377030|NCT02381548|Experimental|Treatment (belinostat, WEE1 inhibitor AZD1775)|Patients receive belinostat IV over 30-90 minutes QD on days 1-5 and 8-12 and WEE1 inhibitor AZD1775 PO QD on days 1-5 and 8-12. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Responding patients with CR, CRi, CRc, or CRm and do not go on to have stem cell transplant may only continue treatment for 3-4 additional courses after response.
89377031|NCT02381314|Experimental|enoblituzumab plus ipilimumab|Enoblituzumab: Fc-optimized, humanized monoclonal antibody. Ipilimumab: Yervoy; recombinant, fully humanized IgG-1 CTLA-4 blocking antibody approved by the US Food and Drug Administration and the European Medicines Agency for the treatment of unresectable or metastatic melanoma.
89377032|NCT02345408|Experimental|CCX872-B|150 mg once or twice daily given orally for at least 12 weeks
89377033|NCT03622268||Indirect calorimetry measurement|Using indirect calorimetry for measure resting energy expenditure
89377034|NCT02386072||1. patients diagnosed with OAB taking mirabegron|patients diagnosed with OAB whose physician has decided to prescribe mirabegron as part of routine clinical practice
89377035|NCT02386072||2. patients diagnosed with OAB taking an antimuscarinic|patients diagnosed with OAB whose physician has decided to prescribe an antimuscarinic as part of routine clinical practice
89377036|NCT03655730|Experimental|intervention arm|follow weekly psychotherapeutic individual sessions following the IPT method during one year.
89377037|NCT03655730|Experimental|usual care arm|continue with the standard follow-up provided by the Mission Locale, including periodic meetings with a referee
89377038|NCT03656900|Experimental|BA9/BA46|
89377039|NCT03656900|Experimental|BA46/BA9|
89377040|NCT03622190||Cohort 1|Music students who are free of pain, PRMDs and/or MSK problems at baseline data collection
88817088|NCT02509988|Active Comparator|Control (standard nutritional drink)|"Standard nutritional drink comes in the form of a sachet to mix with water & take twice a day (once in the morning and once in the evening).~The drink will be taken before the participant becomes pregnant (for up to 1 year) and throughout pregnancy."
88850077|NCT00002882|Experimental|IFN-A Therapy Schedule B|Schedule B: Subcutaneous IFN-A 3 times a week for 52 weeks.
89182103|NCT03116997|Active Comparator|Neuromuscular blockade reversed with sugammadex|
89182104|NCT02600780|Active Comparator|Allopurinol|Allopurinol 300mg Tablets once daily for 90 days
89182105|NCT02600780|Experimental|Febuxostat|Febuxostat 40mg Tablets once daily for 90 days
89182106|NCT00582309|Active Comparator|Glucommander|Glucommander-Guided Intravenous Insulin Infusion
89182107|NCT00582309|Active Comparator|Standard|Standard Intravenous Insulin Infusion Algorithm consists of four levels (Algorithm 1-3 and a doubling of the insulin rate). Most patients begin in algorithm 1, where the insulin rate varies from 0.2 units per hour for BG in the range 70-109 mg/dl up to 6 units/hr for BG > 360 mg/dl. If algorithm 1 fails to bring the patient's BG into target range in 2 hrs, then the patient is moved up to algorithm 2, where the insulin rate varies from 0.5 to 12 units/hr; and if that fails, the patient moved up to algorithm 3, where insulin rate varies from 1 to 16 units/hr depending on the latest BG. Algorithm failure is a blood glucose outside the target range for 2 hrs, and the blood glucose does not decrease by at least 60 mg/dl within 1 hr. If algorithm 3 fails, the insulin rate is doubled.
89377041|NCT03622190||Cohort 2|Music students who aren't free of pain, PRMDs and/or MSK problems at baseline data collection
89377042|NCT03655496|No Intervention|Control group|Subject to standard care.
89377043|NCT03655496|Experimental|Intervention group|Exposed to the home-based tool.
89377044|NCT04439422|Experimental|SAINT|
89377045|NCT04439422|Active Comparator|Self-help material|
89377046|NCT02381470|Experimental|Faropenem|Faropenem 600mg (with amoxicillin/clavulanic acid, 500mg/125mg) given three times daily for 7 days PLUS Rifampicin 10mg/kg once daily alone for the first 2 days then standard combination therapy (rifampicin, isoniazid, pyrazinamide, ethambutol, adjusted for body weight) for the following 5 days
89377047|NCT02381470|Experimental|Cefadroxil|Cefadroxil 1g (with amoxicillin/clavulanic acid, 500mg/125mg) given twice daily for 7 days PLUS Rifampicin 10mg/kg once daily alone for the first 2 days then standard combination therapy (rifampicin, isoniazid, pyrazinamide, ethambutol, adjusted for body weight) for the following 5 days
89399396|NCT03694041|Active Comparator|Food effect - fed condition|Experimental: APX-115 under fed condition
89377048|NCT02381470|Active Comparator|Control|Rifampicin 10mg/kg once daily alone for the first 2 days then standard combination therapy (rifampicin, isoniazid, pyrazinamide, ethambutol, adjusted for body weight) for the following 5 days
89377049|NCT02381158|Experimental|Nebulized Beclomethasone dipropionate|Nebulized Beclomethasone dipropionate applied for 12 weeks with a dose of 400 µg twice a day (total dose 800 µg).
88850078|NCT00002882|Experimental|Adjuvant Biochemotherapy|Cisplatin IV Days 1-4; Vinblastine IVPB Days 1-4; Dacarbazine (DTIC) IVPB on Day 1; IFN-A is given subcutaneously on days 1-5; IL-2 continuous infusion for 96 hours on Days 1-4. Each course repeated every 21 days for 4 courses.
88850079|NCT05750563|Placebo Comparator|Placebo|"Investigational food supplement placebo will be administered according to the same schedule provided for the active product:~From day 1 to day 4: 1 tablet three times a day, before meals (breakfast, lunch and dinner)~From day 5 to day 7: 1 tablet twice a day, before breakfast and dinner~From day 8 to day 62: 1 tablet once a day, before breakfast"
88850080|NCT05750563|Experimental|Experimental|"The dosage will be the following:~From day 1 to day 4: 1 tablet three times a day, before meals (breakfast, lunch and dinner)~From day 5 to day 7: 1 tablet twice a day, before breakfast and dinner~From day 8 to day 62: 1 tablet once a day, before breakfast"
89377050|NCT04241536|Other|No arm|This is an epidemiologic study. No arms are considered.
88850081|NCT00003440|Experimental|Arm A (paclitaxel)|Patients receive paclitaxel intravenously (IV) over 3 hours every 3 weeks.
88850082|NCT00003440|Active Comparator|Arm B (paclitaxel)|Patients receive paclitaxel IV over 1 hour weekly.
88850083|NCT00003440|Experimental|Arm C (paclitaxel, trastuzumab)|Patients receive paclitaxel as in Arm I. Patients also receive trastuzumab IV weekly.
88850084|NCT00003440|Active Comparator|Arm D (paclitaxel, trastuzumab)|Patients receive paclitaxel as in Arm II and trastuzumab as in Arm III.
88850085|NCT00003440|Experimental|Am E (paclitaxel, trastuzumab)|Patients receive paclitaxel and trastuzumab as in Arm C.
88850086|NCT00003440|Active Comparator|Arm F (paclitaxel, trastuzumab)|Patients receive paclitaxel and trastuzumab as in Arm D.
88850087|NCT00003200|Experimental|Taxotere|"After the screening procedures confirm participation in the research study:~Taxotere-Administered weekly for 1 hour (6 doses)~Radiation Therapy (XRT) -5 days a week for 6 weeks~Exam under anesthesia~Neck Dissection (if indicated)"
88850088|NCT05750485||Pupilometric evaluation under procedural sedation with propofol|
88850089|NCT05750407|Experimental|Evidence based home visiting with lifestyle modules|Three lifestyle change modules will be discussed with clients: healthy eating, activity, and tracking diet and weight
88850090|NCT05750251||Ptosis patient|Undergo conventional ptosis correction surgery, including levator muscle resection surgery and Müller's muscle-conjuctival resection surgery
88850091|NCT05750251||Eyelid retraction patient|Undergo conventional ptosis correction surgery, including full-thickness anterior blepharotomy surgery
88850092|NCT00002611|Active Comparator|Stratum 1|Stage I favorable histology (FH) Wilms' tumor, under 24 months of age, and tumor weight less than 550 g: After conventional surgery (nephrectomy), patients receive regimen EE-4A comprising dactinomycin (DACT) IV weekly on weeks 0, 3, 6, 9, 12, 15, and 18 and vincristine sulfate (VCR) IV weekly on weeks 1-10, 12, 15, and 18.
88850093|NCT00002611|Active Comparator|Stratum 2|Stage I FH Wilms' tumor and age 24 months and over or tumor weight at least 550 g; stage I focal anaplastic (FA) or diffuse anaplastic (DA) Wilms' tumor: Patients receive regimen EE-4A comprising dactinomycin (DACT) IV weekly on weeks 0, 3, 6, 9, 12, 15, and 18 and vincristine sulfate (VCR) IV weekly on weeks 1-10, 12, 15, and 18.
88850094|NCT00002611|Active Comparator|Stratum 3|Stage II FH Wilms' tumor: Patients receive regimen EE-4A comprising dactinomycin (DACT) IV weekly on weeks 0, 3, 6, 9, 12, 15, and 18 and vincristine sulfate (VCR) IV weekly on weeks 1-10, 12, 15, and 18.
88850095|NCT00002611|Active Comparator|Stratum 4|Stage III FH Wilms' tumor; stage II or III FA Wilms' tumor: After conventional surgery (nephrectomy), patients receive regimen DD-4A comprising dactinomycin DACT IV weekly on weeks 0, 6, 12, 18, and 24; doxorubicin hydrochloride IV weekly on weeks 3, 9, 15, and 21; and vincristine sulfate VCR IV weekly on weeks 1-10, 12, 15, 18, 21, and 24. Patients also undergo abdominal radiation therapy.
88850096|NCT00002611|Active Comparator|Stratum 5|Stage IV FH or FA Wilms' tumor: patients receive regimen DD-4A comprising dactinomycin DACT IV weekly on weeks 0, 6, 12, 18, and 24; doxorubicin hydrochloride IV weekly on weeks 3, 9, 15, and 21; and vincristine sulfate VCR IV weekly on weeks 1-10, 12, 15, 18, 21, and 24. Patients also undergo abdominal radiation therapy, and whole lung radiation therapy (at the discretion of the investigator).
89377051|NCT02385682||ST-segment elevation AMI|ST-segment elevation acute myocardial infarction teated with percutaneous coronary intervention
89377052|NCT02385682||Non-ST-segment elevation AMI|Non-ST-segment elevation acute myocardial infarction teated with percutaneous coronary intervention
89377053|NCT02385838|Experimental|5-Color Nutrition Label (5-CNL)|The 5-CNL front-of-pack nutrition labeling is affixed on the front-of-pack of foodstuffs of the experimental web-based supermarket
89377054|NCT02385838|Experimental|Mutiple Traffic Lights (MTL)|The MTL front-of-pack nutrition labeling is affixed on the front-of-pack of foodstuffs of the experimental web-based supermarket
89377055|NCT02385838|Experimental|Guidelines Daily Amounts (GDA)|The GDA front-of-pack nutrition labeling is affixed on the front-of-pack of foodstuffs of the experimental web-based supermarket
89377056|NCT02385838|Experimental|Green Tick (Tick)|The Tick front-of-pack nutrition labeling is affixed on the front-of-pack of foodstuffs of the experimental web-based supermarket
89399397|NCT03694041|Placebo Comparator|Drug Interaction - metabolic probe|Experimental: metabolic probe
89377057|NCT02385838|No Intervention|No label|No front-of-pack nutrition labeling is affixed on the front-of-pack of foodstuffs of the experimental web-based supermarket
89377058|NCT02381080|Experimental|Part 1: Ibrutinib+Erythromycin+Voriconazole|Participants will receive oral treatment in six, 28-days cycles. In Cycle 1, participants will take ibrutinib 560 milligram (mg) (4*140 mg capsules) once daily (QD) from Days 1- 4; on Days 5-11 ibrutinib 140 mg capsule QD in combination with erythromycin 500 mg tablet 3 times daily (TID); on Days 12-13 ibrutinib 140 mg capsule QD; on Days 14-18 ibrutinib 560 mg (4*140 mg capsules) QD; on Days 19-25 ibrutinib 140 mg capsule QD in combination with voriconazole 200 mg tablet twice daily (BD); on Days 26-27 ibrutinib 140 mg capsule orally QD; and on Day 28 and in subsequent treatment Cycles (2-6) participants will continue oral treatment with ibrutinib 420 mg or 560 mg QD (depending on the subtype of B-cell malignancy).
89377059|NCT02381080|Experimental|Part 2: Ibrutinib+ Erythromycin+Voriconazole|Participants will receive oral treatment in six, 28-days cycles. In Cycle 1, participants will take ibrutinib 560 mg (4*140 mg capsules) QD from Days 1- 4; on Days 5-18 ibrutinib 560 mg (4*140 mg capsules) QD in combination with either erythromycin 500 mg tablet TID (Group 1) or voriconazole 200 mg tablet BD (Group 2); on Day 19 and in subsequent treatment Cycles (2-6) participants will continue oral treatment with ibrutinib 420 mg or 560 mg QD (depending on the subtype of B-cell malignancy).
89377060|NCT04724824|Experimental|Brain-Computer Interface controlled robotic feedback|
89377061|NCT04724824|Sham Comparator|Sham Brain-Computer Interface controlled robotic feedback|
89377062|NCT02385760|Experimental|Active|CTX-4430 oral capsule, 100 mg, once-daily for 12 weeks
89377063|NCT02385760|Placebo Comparator|Placebo|Placebo: identical oral capsule, without active ingredient, once-daily for 12 weeks
89377064|NCT04694248|Experimental|Anticoagulant plus antiplatelet therapy|For anticoagulant, it is rivaroxaban 20mg once a day for 6 months. For antiplatelet therapy, it is aspirin 100mg once a day indefinitely.
89377065|NCT02376478||TNF-alpha inhibitors|TNF-alpha Inhibitors: patients with psoriasis or inflammatory bowel diseases under TNF-alpha inhibitor monotherapy
89377066|NCT02376478||Purine/folic acid analogues|Purine/folic acid analogues: patients with psoriasis or inflammatory bowel diseases receiving monotherapy with purine or folic acid analogues, such as azathioprin, 6-mercaptopurine, or methotrexate
88817089|NCT02505477|Experimental|N-acetylcysteine|Patients in this group will receive N-acetylcysteine (NAC) 1200mg orally twice daily (total daily dose 2400mg), for eight weeks. Each individual tablet contains 300mg NAC, therefore patients will take two tablets by mouth each morning and two tablets by mouth each evening. Manufacturer: Jarrow Industries, Inc.; Brand name: N-A-C Sustain
89377067|NCT02376478||Combination therapy|Combination therapy: patients with psoriasis or inflammatory bowel diseases receiving combination therapy with TNF-alpha blocker plus purine or folic acid analogues
89377068|NCT02376478||Alternative/no medication|Alternative/no medication: patients with psoriasis or inflammatory bowel diseases receiving alternate therapy, such as phototherapy, fumaric acid, mesalazine, or no medication
89377069|NCT02385448|Experimental|Dienogest|
89377070|NCT02385448|Active Comparator|Combined oral contraceptive pills|
89377071|NCT02376712||Pre-renal AKI|"Three definitions of pre-renal AKI will be used separately:~Hemodynamic instability (any sign of tissue hypoperfusion) on AKI identification, and AKI recovery in 24-72 hours following hemodynamic stabilization.~AKI recovery in less than 72 hours after AKI identification.~Decreased renal blood flow measured by transesophageal echocardiography (TEE)."
89377072|NCT02376712||Renal AKI|"Three definitions of renal AKI will be used separately:~Hemodynamically stable at AKI identification; or hemodynamically instability (any sign of tissue hypoperfusion) on AKI identification, and AKI persistence in 24-72 hours following hemodynamic stabilization.~AKI persistence 72 hours after AKI identification.~Normal or increased renal blood flow measured by TEE."
89399398|NCT02173730|Experimental|BIBR 1048 MS without Pantoprazole|150 mg BIBR 1048 MS capsules administered twice daily over 6 days and once in the morning of the seventh day
88817090|NCT02505477|Placebo Comparator|Placebo|Patients in this group will receive placebo tablets indistinguishable from NAC tablets, with the same protocol as NAC: two placebo tablets by mouth each morning, and two placebo tablets by mouth each evening. Manufacturer: Jarrow Industries, Inc.; Brand name: N-A-C Sustain
88817091|NCT02484885|Other|Healthy Volunteers|Healthy volunteers will undergo pulmonary function tests, hyperpolarized Xenon MRI at each visit.
88817092|NCT02483403|Other|Healthy Volunteers|Healthy elderly volunteers will undergo pulmonary function tests, hyperpolarized Helium-3 MRI at each visit.
88817093|NCT02446093|Experimental|Test Arm|CAN-2409 + prodrug (valacylovir or acyclovir) in combination with neoadjuvant chemoradiation or SBRT + Surgery
88817094|NCT02446093|Active Comparator|Control Arm|Neoadjuvant chemoradiation or SBRT + Surgery
88817381|NCT02250521|Experimental|McGrath Mac intubations|All 100 patients will be intubated using the McGRATH® MAC video laryngoscope, either through direct or indirect vision laryngoscopy. The liquid crystal display (LCD) monitor of the McGRATH™ MAC was initially covered; if the anesthesiologist visualized a modified C-L grade 1-3 view, the patient was intubated utilizing this direct view. If the anesthesiologist observed a modified C-L grade 4 view during their initial direct view, the patient was intubated using the indirect method. If intubation via direct laryngoscopy was unsuccessful on the first attempt, the patient was intubated using the indirect view. If both methods of laryngoscopy were unsuccessful, the rescue intubation technique was performed at the discretion of the anesthesiologist.
89377073|NCT02376634|Active Comparator|Hypnosis|"The hypnosis group will receive a semi-structured intervention by primary investigator. The intervention is somewhat individualized based on the recipients personal characteristics (e.g., age, gender, medical history). The intervention will begin with an induction phase during which the participant is guided to relax and to focus their attention on one stimuli. The intervention will then proceed with a suggestion phase. Suggestions used in this phase will all be directed toward decreasing the patient's anxiety and post-operative pain. Patients will be taught self-hypnosis to decrease distress and reframe painful experiences."
89377074|NCT02376634|No Intervention|Control|This group will receive the standard of care of Nationwide Children's Hospital.
89377075|NCT02376400|Experimental|Group 1|Participants will receive MVA-BN-filo/ Ad26.ZEBOV (Day 1 /Day 29) or Placebo (Day 1/Day 29).
89377076|NCT02376400|Experimental|Group 2|Participants will receive MVA-BN-filo/Ad26.ZEBOV (Day 1 /Day 57) or placebo ( Day 1/Day 57).
89377077|NCT02376400|Experimental|Group 3|Participants will receive Ad26.ZEBOV/ MVA-BN-filo (Day 1/Day 29) or placebo (Day 1/Day 29).
89377078|NCT02376400|Experimental|Group 4|Participants will receive Ad26.ZEBOV/ MVA-BN-filo (Day 1/Day 57) or placebo (Day 1/Day 57).
89377079|NCT03106012|Experimental|Hsyterolaparoscopy|Subjected to bath diagnostic hystroscopy and laparoscopy
89377080|NCT02385370|Active Comparator|using standard method of applying MMC|applying MMC 0.02 % soaked sponges under conjunctival space for 1 to 3 minutes
89377081|NCT02385370|Active Comparator|intratendon injection of MMC|intratendon injection of 0.1 cc MMC 0.01% at the beginning of the procedure
89377082|NCT02376556||Blepharoplasty|patients undergoing upper eyelid blepharoplasty
89377083|NCT02376556||blepharoplasty and muller muscle resection|patients undergoing a combined blepharoplasty and muller muscle resection surgery
89377084|NCT02385058|Experimental|Mebendazole + Quinfamide|Participants will receive mebendazole 600 milligram (mg) and quinfamide 200 mg tablets orally once starting on Day 1 and 21 in both Phase 1 and 2.
89377085|NCT02385058|Experimental|Mebendazole + Quinfamide + Placebo|Participants will receive mebendazole 600 mg and quinfamide 200 mg tablets orally once starting on Day 1 in Phase 1 and placebo tablets orally once starting on Day 21 in Phase 2.
89377086|NCT02376088||GA1|subjects from coastal areas who initiated Methimazole treatment for the first time on enrollment
89377087|NCT02376088||GA2|subjects from coastal areas who were under Methimazole treatment and with an elevated TH level
88810423|NCT06213506|Experimental|Infants_6W_Dose B Group|Infants 6 weeks of age, part of the safety cohort, randomized to receive 3 doses of the iNTS-GMMA Dose B vaccine at Day 1, Day 57 (during the Priming phase) and at Day 232 (during the Booster phase). These infants also receive an EPI vaccination with Measles and Rubella Vaccine (MR-VAC) and Yellow Fever (YF) vaccine at 28 days after the third study intervention administration occurring at Day 232, at the local EPI vaccination centers, and not part of the current clinical trial.
88817124|NCT01348919|Experimental|CEP-18770 Dose A|Participants will receive CEP-18770 Dose A intravenously (IV) on Days 1, 8, and 15 in each 28-day cycle. In addition, participants will receive a fixed dose of 25 mg oral lenalidomide on Days 1 through 21 and a fixed dose of 40 mg oral dexamethasone on Days 1, 8, 15, and 22 of each 28-day cycle.
88817125|NCT01348919|Experimental|CEP-18770 Dose B|Participants will receive CEP-18770 Dose B IV on Days 1, 8, and 15 in each 28-day cycle. In addition, participants will receive a fixed dose of 25 mg oral lenalidomide on Days 1 through 21 and a fixed dose of 40 mg oral dexamethasone on Days 1, 8, 15, and 22 of each 28-day cycle.
88817126|NCT01348919|Experimental|CEP-18770 Dose C|Participants will receive CEP-18770 Dose C IV on Days 1, 8, and 15 in each 28-day cycle. In addition, participants will receive a fixed dose of 25 mg oral lenalidomide on Days 1 through 21 and a fixed dose of 40 mg oral dexamethasone on Days 1, 8, 15, and 22 of each 28-day cycle.
88817127|NCT01341054|Experimental|mouthwash with Chamomilla extract 1%|The Chamomile recutita mouthwash 1% was administered two times daily for 30 days.
88817128|NCT01341054|Experimental|mouthwash with Chamomilla extract 2%|The Chamomile recutita mouthwash 2% was administered two times daily for 30 days.
88817129|NCT01341054|Active Comparator|standard oral care protocol|The standard protocol at the unit, which comprises mouthwash with chlorhexidine 0,12%; oral hygiene teaching. In case the toothbrush cannot be used due to gingival or oral mucosa bleeding, gauze is used to replace it.
88817130|NCT01341054|Experimental|mouthwash with Chamomilla extract 0.5%|The Chamomile recutita mouthwash 0.5% was administered two times daily for 30 days, starting on the first day of chemotherapy.
89377088|NCT02376088||GA3|subjects from coastal areas who were under Methimazole treatment and with a normal TH level
89377089|NCT02376088||GB1|subjects from non-coastal areas who initiated Methimazole treatment for the first time on enrollment
89377090|NCT02376088||GB2|subjects from non-coastal areas who were under Methimazole treatment and with an elevated TH level
89377091|NCT02376088||GB3|subjects from non-coastal areas who were under Methimazole treatment and with a normal TH level
89377092|NCT02376088||NC|age-matched healthy checkup subjects
89377093|NCT03310021|Experimental|Cohort 1|Apixaban + low dose andexanet
89377094|NCT03310021|Experimental|Cohort 2|Rivaroxaban + high dose andexanet
89377095|NCT03310021|Experimental|Cohort 3|Edoxaban + high dose andexanet
89377096|NCT03310021|Experimental|Cohort 4|Edoxaban + high dose andexanet
89377097|NCT03310021|Experimental|Cohort 5|Apixaban + low dose andexanet
89377098|NCT03310021|Experimental|Cohort 6|Apixaban + high dose andexanet
89377099|NCT03310021|Experimental|Cohort 7|Edoxaban + low dose andexanet
89377100|NCT03310021|Experimental|Cohort 8|Apixaban + low dose andexanet
89377101|NCT03310021|Experimental|Cohort 9|Rivaroxaban + low dose andexanet
89377102|NCT03310021|Experimental|Cohort 10|Edoxaban + low dose andexanet
89377103|NCT04630717|Active Comparator|control group|normal discussion before general anesthesia induction
89377104|NCT04630717|Active Comparator|Hypnosis group|hypnosis session before general anesthesia induction
89377105|NCT03333109|Experimental|AMG334 70 mg|AMG334 70 mg: one pre-filled syringe containing 70 mg of erenumab plus one pre-filled syringe of identical placebo administered subcutaneous every 28 days
89377106|NCT03333109|Experimental|AMG334 140 mg|AMG334 140 mg: two pre-filled syringe containing 70 mg each of erenumab administered subcutaneous every 28 days
89377107|NCT03333109|Placebo Comparator|Placebo|Two pre-filled syringes containing placebo identical in appearance to erenumab
89377108|NCT02940223|Experimental|Group I (ethyl icosapentate, physical activity)|Patients receive ethyl icosapentate PO BID for 8 weeks. Patients complete resistance exercises 3 days per week and undergo walking program at least 5 days per week for 8 weeks. After 8 weeks, patients may optionally continue to receive ethyl icosapentate, complete resistance exercises, and undergo walking program for 4 weeks.
89377109|NCT02940223|Experimental|Group II (placebo, physical activity)|Patients receive placebo PO BID for 8 weeks. Patients complete resistance exercises 3 days per week and undergo walking program at least 5 days per week for 8 weeks. After 8 weeks, patients may optionally receive ethyl icosapentate, complete resistance exercises, and undergo walking program for 4 weeks as in Group I.
88850097|NCT00002611|Active Comparator|Stratum 6|Stage V FH, FA, or DA Wilms' tumor: After bilateral conventional surgery (biopsy), patients with FH receive chemotherapy as in stratum 1 (dactinomycin IV weeks 0, 3, 6, 9, 12, 15, and 18 and vincristine sulfate IV weeks 1-10, 12, 15, and 18) or 4 (dactinomycin IV weeks 0, 6, 12, 18, and 24; doxorubicin hydrochloride IV weeks 3, 9, 15, and 21; and vincristine sulfate VCR IV weeks 1-10, 12, 15, 18, 21, and 24). Patients with FA or DA receive chemotherapy as in stratum 7 (vincristine sulfate VCR IV weeks 1, 2, 4-8, 10-13, 18, and 24; cyclophosphamide sulfate (CTX) IV over 1 hour on days 1-3 of weeks 6, 12, 18, and 24 and on days 1-5 of weeks 3, 9, 15, and 21; doxorubicin hydrochloride IV (beginning after CTX infusion) weeks 0, 6, 12, 18, and 24; and etoposide (VP-16) IV over 1 hour (beginning after CTX infusion) on days 1-5 of weeks 3, 9, 15, and 21. Filgrastim (G-CSF) is administered subcutaneously (SC) beginning 24 hours after completion of chemotherapy.
88850098|NCT00002611|Active Comparator|Stratum 7|Stages I-IV clear cell sarcoma): After conventional surgery (nephrectomy), patients receive vincristine sulfate VCR IV weekly on weeks 1, 2, 4-8, 10-13, 18, and 24; cyclophosphamide sulfate (CTX) IV over 1 hour on days 1-3 of weeks 6, 12, 18, and 24 and on days 1-5 of weeks 3, 9, 15, and 21; doxorubicin hydrochloride IV (beginning after CTX infusion) weekly on weeks 0, 6, 12, 18, and 24; and etoposide (VP-16) IV over 1 hour (beginning after CTX infusion) on days 1-5 of weeks 3, 9, 15, and 21. Filgrastim (G-CSF) is administered subcutaneously (SC) beginning 24 hours after completion of chemotherapy and continuing until blood counts recover. Patients also undergo abdominal radiotherapy and whole lung radiotherapy (if pulmonary metastases are present).
88875296|NCT02577510|Experimental|Nerve Stimulation- Xylocaine injection|Anesthesia of the lateral femoral cutaneous nerve using local anesthetic will be randomly assigned on the right or left side to receive nerve stimulation-xylocaine or ultrasound guided -xylocaine injections in all patients. One patient will therefore have both nerve stimulation AND ultrasound guided injections, only the side of the injection will be randomly assigned to one of the two modalities. Once one technique has been used to freeze one side, the other side will be frozen using the other technique.
89182108|NCT00582309|Active Comparator|Simple|Simple Calculated Intravenous Insulin Infusion consists of an initial insulin infusion rate varying from 0.5 units per hour for BG in the target range 80-120 mg/dl up to 8 units/hour for BG > 400 mg/dl. After the initial insulin rate and if BG is still > 120 mg/dl, then the insulin rate is increased by 1-2 units every 1 hour until BG is in the target range. If BG is still >120 mg/dl in 2 hours, then the insulin rate is doubled.
89377110|NCT02940223|Experimental|Group III (placebo, stretching exercises)|Patients receive placebo PO BID for 8 weeks. Patients meet with an exercise specialist during the first week to learn different stretching exercises and complete the stretching exercises 3 days per week for 8 weeks. After 8 weeks, patients may optionally receive ethyl icosapentate, complete resistance exercises, and undergo walking program for 4 weeks as in Group I.
89377111|NCT01312831|Experimental|Oral Eligen® B12|Eligen® B12 1000 μg oral tablet taken in the fasted state as a single tablet with 50 mL water. Each dose self-administered daily, for 90 days, after an overnight fast and 1 hour before the morning meal.
89377112|NCT01312831|Active Comparator|IM B12|Commercially available 1000 μg cyanocobalamin administered IM as 1 mL from a vial containing 1000 μg/mL drug administered by study personnel, in the research clinic, in the morning, in the fasted state and at least 1 hour prior to the morning meal on study Days 1, 3, 7, 10, 14, 21, 30, 60 and 90.
89377113|NCT01312987|Experimental|Nutrition intervention|Receives a month's supply of the nutrition supplement, Plumpy'doz®, in addition to food voucher for each month. Participants were also allowed to attend monthly educational sessions.
89377114|NCT01312987|No Intervention|Control|Receives food vouchers each month.
88850099|NCT00002611|Active Comparator|Stratum 8|Stages II-IV DA Wilms' tumor: After conventional surgery (nephrectomy), Patients receive treatment as in stratum 7 (patients receive vincristine sulfate VCR IV weekly on weeks 1, 2, 4-8, 10-13, 18, and 24; cyclophosphamide sulfate (CTX) IV over 1 hour on days 1-3 of weeks 6, 12, 18, and 24 and on days 1-5 of weeks 3, 9, 15, and 21; doxorubicin hydrochloride IV (beginning after CTX infusion) weekly on weeks 0, 6, 12, 18, and 24; and etoposide (VP-16) IV over 1 hour (beginning after CTX infusion) on days 1-5 of weeks 3, 9, 15, and 21. Filgrastim (G-CSF) is administered subcutaneously (SC) beginning 24 hours after completion of chemotherapy and continuing until blood counts recover. Patients also undergo abdominal radiotherapy and whole lung radiotherapy (if pulmonary metastases are present).
88850100|NCT00002611|Active Comparator|Stratum 9|Stages I-IV rhabdoid tumor: After conventional surgery (nephrectomy), patients receive carboplatin IV on days 1-2 and VP-16 IV over 1 hour (beginning after carboplatin infusion) on days 1-3 of weeks 0, 3, 9, 12, 18, and 21 and CTX IV over 1 hour on days 1-5 of weeks 6, 15, and 24. Filgrastim G-CSF is administered as on stratum 7. Patients also undergo radiation therapy. After completion of chemotherapy, patients undergo second-look conventional surgery (laparotomy) and conventional surgery (partial nephrectomy or wedge excision if feasible). After conventional surgery (second-look surgery), patients without persistent or residual disease resume chemotherapy.
88850101|NCT00003950|Experimental|CPT-11 with Cyclosporine|Each cycle lasts 6 weeks. Administration of cyclosporine and CPT-11 weekly for 4 weeks followed by a 2 week 'rest' period with no drug given. Cyclosporine is given by IV infusion at a dose of 5 mg/kg. CPT-11 is given by IV infusion at a dose of 60 mg/m2.
88850102|NCT00003452|Experimental|Antineoplastons|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
88850103|NCT00003968|Experimental|Arm I|Patients receive bryostatin 1 IV over 1 hour on days 1, 8, and 15. Treatment continues every 4 weeks in the absence of unacceptable toxicity or disease progresssion.
88850104|NCT00003494|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
88850105|NCT00003500|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
88850106|NCT00003512|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
88850107|NCT05664061|Experimental|Fluticasone propionate 100 mcg and Salmeterol 50 mcg inhalation powder/Respirent Pharmaceuticals|Test (T)
88850108|NCT05664061|Active Comparator|ADVAIR DISKUS® 100/50 mcg inhalation powder pre-dispensed/GSK|Reference (R)
88850109|NCT05664061|Placebo Comparator|Placebo|Placebo
89377115|NCT04431193|Experimental|Oxytocin 4 picogram/millilitre|Oxytocin infused to maintain serum concentration of 4 picogram/millilitre
89377116|NCT04431193|Experimental|Oxytocin 16 picogram/millilitre|Oxytocin infused to maintain serum concentration of 16 picogram/millilitre
88850110|NCT00003248|Experimental|Arm I|"Patients receive fludarabine and chimeric anti-CD20 monoclonal antibody IDEC-C2B8 (rituximab) induction. Rituximab is administered IV over 4 hours on day 1, on day 3, and over 1 hour on day 5 of week 1. Subsequent doses are given over 1 hour on day 1 every 4 weeks for a total of 6 courses. Fludarabine IV is administered over 10-30 minutes daily for 5 days during weeks 1, 5, 9, 13, 17, and 21 for a total of 6 courses. Following the sixth course of fludarabine, patients undergo clinical staging and are then observed for an additional 2 months, after which they undergo repeat clinical staging, including bone marrow aspiration. Patients achieving a complete or partial response or stable disease then proceed to consolidation therapy consisting of weekly intravenous infusions of rituximab once weekly for 4 weeks.~Patients are followed every 3 months for 1 year, and then every 6 months thereafter."
89377117|NCT04431193|Experimental|Oxytocin 64 picogram/millilitre|Oxytocin infused to maintain serum concentration of 64 picogram/millilitre
89377118|NCT04431193|Experimental|Oxytocin 256 picogram/millilitre|Oxytocin infused to maintain serum concentration of 256 picogram/millilitre
89377119|NCT03295201|Experimental|Pulmonary rehabilitation+exercise group|Active cycle of breathing techniques (ACBT) and postural exercise program
88850111|NCT00003248|Experimental|Arm II|Patients receive fludarabine induction. Patients receive fludarabine IV over 10-30 minutes daily for 5 days during weeks 1, 5, 9, 13, 17, and 21 for a total of 6 courses. Patients then proceed as in arm I. Patients are followed every 3 months for 1 year, and then every 6 months thereafter.
88850112|NCT00003992|Experimental|Arm I|Patients receive paclitaxel IV over 3 hours immediately followed by trastuzumab (Herceptin) IV over 30-90 minutes on day 1. Paclitaxel repeats every 3 weeks for 4 courses and trastuzumab (Herceptin) repeats weekly for 10 courses. At 3 weeks following paclitaxel and trastuzumab (Herceptin), patients receive doxorubicin IV and cyclophosphamide IV over 1 hour every 3 weeks for 4 courses. Following chemotherapy, estrogen receptor (ER) positive and/or progesterone receptor (PR) positive patients receive oral tamoxifen twice daily for 5 years.
89182109|NCT00443053|Active Comparator|Fondaparinux 2.5mg|
89182110|NCT00443053|Placebo Comparator|Placebo|
89182111|NCT01977183|Experimental|Elderly adults with MSPrebiotic|30 g of MSPrebiotic (potato resistant starch) per day taken with 1 glass (approximately 250 mL) of non-heated fluid or non-heated semi-solid food. If the participant is taking any medications, they will be advised to either take the product 2 hours before or 2 hours after any medications.
89377120|NCT03295201|Active Comparator|Pulmonary rehabilitation group|Active cycle of breathing techniques (ACBT)
89377121|NCT03293485|Experimental|Imipenem+Cilastatin/Relebactam|Participants with cIAI or cUTI will receive imipenem+cilastatin/relebactam intravenous (IV) infusion once every 6 hours for 5 to 14 days
89377122|NCT03309943|Experimental|Propranolol|Propranolol Capsule: 40 mg IR, administered 2x at separate laboratory sessions
89377123|NCT03309943|Placebo Comparator|Placebo|Placebo Capsule: No active ingredients, administered 2x at separate laboratory sessions
89377124|NCT01313065|Experimental|VX15/2503|VX15/2503 monoclonal antibody at a concentration of 0.3 mg/kg - 20 mg/kg to be administered intravenously on a weekly dosing cycle.
89377125|NCT01732627|Experimental|Group 1: MenACYW Conjugate Vaccine|Adult participants aged greater than or equal to (≥) 56 years received a single dose of Meningococcal Polysaccharide (Serogroups A, C, Y, and W 135) Tetanus Toxoid (MenACYW) Conjugate vaccine on Day 0.
89377126|NCT01732627|Active Comparator|Group 2: Menomune® A/C/Y/W 135 vaccine|Adult participants aged ≥56 years received a single dose of Meningococcal Polysaccharide Vaccine, Groups A, C, Y, and W 135 Combined (Menomune®) vaccine on Day 0.
89377127|NCT03307837|Active Comparator|CA-008 Cohort 1 0.5 mg|Intra-operative, local administration
89377128|NCT03307837|Active Comparator|CA-008 Cohort 2 1 mg|Intra-operative, local administration
89377129|NCT03307837|Active Comparator|CA-008 Cohort 3 2 mg|Intra-operative, local administration
89377130|NCT03307837|Active Comparator|CA-008 Cohort 4 3 mg|Intra-operative, local administration
89377131|NCT03307837|Active Comparator|CA-008 Cohort 5 4.2 mg|Intra-operative, local administration
89377132|NCT03307837|Placebo Comparator|Placebo|Intra-operative, local administration of saline (equivalent volume in active comparator arm)
89377133|NCT05065255||Patients|Adult subjects with neurogenic or non-neurogenic urinary tract disorders, newly initiated to ASI, and users of the SpeediCath line of catheters.
88850113|NCT00003992|Experimental|Arm II|Patients receive same therapy as in Arm I, except for additional trastuzumab (Herceptin) IV weekly beginning within 3 weeks following completion of chemotherapy and local therapy and continuing for 1 year. ER and/or PR positive patients receive tamoxifen as in Arm I but may be concurrent with trastuzumab (Herceptin). Following completion of doxorubicin and cyclophosphamide, post lumpectomy and post mastectomy patients may receive local radiotherapy daily for 5-6 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
88850114|NCT00003524|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
88850115|NCT00003530|Experimental|Antineoplaston Therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
88850116|NCT00003254|Experimental|776C85 + 5-FU|776C85, 10mg/m2/dose, PO, Days 1-28 (BID), q 5 wk; 5-FU, 1.0mg/m2/dose, PO, Days 1-28 (BID), q 5 wk.
88850117|NCT05749549|Experimental|BR1733|25-1200 mg QD or BID
88850118|NCT05749471||Patients with chronic venous disease|Consecutive patients with chronic venous disease (CVD) that will be diagnosed, staged according to the CEAP (Clinical-Etiology-Anatomy-Pathophysiology) classification of CVD. ASEX (Arizona Sexual Experience) questionnaire will be administered to CVD patients at time 0 of study inclusion and after treatment of CVD at intervals of 6 months and 12 months after treatment.
88850119|NCT00381667|Experimental|GW642444M 12.5|
88850120|NCT00381667|Experimental|GW642444M 100mcg|
88850121|NCT00381667|Experimental|GW642444M 400mcg|
88850122|NCT00381667|Experimental|GW642444H 100mcg|
88850123|NCT00381667|Experimental|Placebo|
89182112|NCT01977183|Placebo Comparator|Elderly adults with Placebo|30 g of corn starch per day taken with 1 glass (approximately 250 mL) of non-heated fluid or or non-heated semi-solid food. If the participant is taking any medications, they will be advised to either take the product 2 hours before or 2 hours after any medications.
89377134|NCT04296799|Experimental|Single Ascending Dose|The study will consist of 6 cohorts (1 cohort per dose level) of 8 subjects (6 subjects receiving the study drug and 2 receiving matching placebo), for a total of 48 subjects.
89377135|NCT04296799|Experimental|Multiple Ascending Dose|The study will consist of 3 cohorts (1 cohort per dose level) of 8 subjects. Six subjects will receive study drug and 2 subjects will receive matching placebo, daily for 14 consecutive days, for a total of 24 subjects (18 study drug; 6 placebo).
89377136|NCT03637933|Active Comparator|India ink tattooing|Experimental group includes patients undergone to preoperative endoscopic tattooing with Sterile Carbon Particle Suspension.
89377137|NCT03637933|Experimental|Sterile Carbon Particle Suspension tattooing|Control group includes patients undergone to preoperative endoscopic tattooing with India Ink.
89377138|NCT03331315|Active Comparator|Ketorolac|Patients receiving scheduled ketorolac postoperatively
89377139|NCT03331315|Experimental|Celecoxib|Patients receiving celebrex preoperative and postoperatively for 7 days
89377140|NCT03329989|Experimental|EN3835 Active|EN3835 0.84mg (Collagenase Clostridium Histolyticum)
89377141|NCT03287869|Experimental|Brexpiprazole|Brexpiprazole was administered in participants orally with flexible dosing from 2 mg/day from Days 1 to 3 regardless of treatment assignment in the previous double-blind trial, followed by titration to 3 mg/day on Day 4. Participants may have been titrated (or re-titrated) to a higher dose of brexpiprazole, up to a maximum of 4 mg/day, based on treatment response and at the investigator's discretion anytime at Day 7 or thereafter. Participants who were unable to tolerate their current dose could have been titrated down to a minimum of 2 mg/day any time after Day 4.
89377142|NCT02661490|Experimental|Arm 1: NoV Vaccine Formulation A _1-Dose|Participants ≥ 60 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, intramuscularly (IM), on Day 1, followed by norovirus (NoV) GI.1 (15 μg)/GII.4 (50 μg) bivalent virus-like particle (VLP) vaccine (Formulation A), IM, on Day 29.
89377143|NCT02661490|Experimental|Arm 2: NoV Vaccine Formulation A _2-Dose|Participants ≥ 60 years of age, 2-dose regimen: Norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine (Formulation A), IM, on Days 1 and 29.
89377144|NCT02661490|Experimental|Arm 3: NoV Vaccine Formulation B_1-Dose|Participants ≥ 60 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, IM on Day 1, followed by norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine with 15 μg monophosphoryl lipid A (MPL) (Formulation B), IM, on Day 29.
88850124|NCT00004010|Experimental|BEACOPP therapy|"Patients receive 4 cycles of BEACOPP therapy. Drugs utilized in this regimen include Bleomycin (B), Etoposide (E), Doxorubicin (A), Cyclophosphamide (C), Vincristine (O), Prednisone (P) and Procarbazine (P). Each cycle lasts 21 days and is characterized by intravenous pulses of Etoposide (Days 0-2), Doxorubicin (Day 0), Cyclophosphamide (Day 0), Bleomycin (Day 7), Vincristine (Day 7). Seven days of oral procarbazine (Days 0-6) and 14 days of oral prednisone (Days 0-13) are given during each cycle.~Growth factor support with Filgrastim (G-CSF) is given by subcutaneous injection daily beginning Day 8. Response will then be determined and stratification for further treatment."
88850125|NCT05646979|Experimental|Experimental group|EFT application will be applied to the women in the experimental group who will have a cesarean section at 32-38 weeks of gestation.
89377145|NCT02661490|Experimental|Arm 4: NoV Vaccine Formulation B_2-Dose|Participants ≥ 60 years of age, 2-dose regimen: Norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine with 15 μg MPL (Formulation B), IM, on Days 1 and 29.
88850126|NCT05646979|No Intervention|Control group|Women in the control group who will have a cesarean section at 32-38 weeks of gestation will not be interfered with.
88850127|NCT05749315|Active Comparator|Group A|Group A Speech Language Delayed Children
88850128|NCT05749315|Active Comparator|Group B|Group B Speech Language Delayed Children
88850129|NCT00003278|Experimental|radiation + dexamethasone|"Patients undergo whole-brain radiotherapy (WBRT) daily 5 days a week for 4.5 weeks. Beginning 30 days after WBRT is completed, patients receive high-dose dexamethasone IV on days 1-5 during course 1 and on day 1 only during all subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Patients are followed at 1 month after radiotherapy, every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter."
88850130|NCT05749237|Active Comparator|Active group|children older than 10 years with a diagnosis of allergic asthma respiratory and relaxation exercises
88850131|NCT05749237|Placebo Comparator|Placebo group|children older than 10 years with a diagnosis of allergic asthma only relaxation exercises
88850132|NCT00384254|No Intervention|1|Usual Care Control: Patients receive treatment as usual
88850133|NCT00384254|Experimental|2|"5 A Intervention Condition: Patients in this condition receive all five A components (Ask, Advise, Assess, Assist, Arrange) recommended in the Clinical Practice Guideline: Treating Tobacco Use and Dependence."
88850134|NCT00384254|Experimental|3|"3 A Condition: Patients receive Ask, Advise, Arrange intervention consisting of the first two A components recommended by the Clinical Practice Guideline: Treating tobacco Use and Dependence, plus Fax-to-Quit referral to a tobacco quit line."
89377146|NCT02661490|Experimental|Arm 5: NoV Vaccine Formulation A_1-Dose|Participants 18 to 49 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, IM, on Day 1, followed by norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine (Formulation A), IM, on Day 29.
88850135|NCT00002677|Experimental|Arm I|Patients receive oral tributyrin every 8 hours for 3 weeks. Treatment continues every 4 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve stable disease may receive additional courses at the discretion of the protocol chairperson. Cohorts of 3-6 patients receive escalating doses of tributyrin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity.
88850136|NCT05749003|Experimental|sensorimotor training program group|participants will receive Sensorimotor training exercise plus conventional physical therapy program of exercise.
88850137|NCT05749003|Other|Control group|participants will receive conventional physical therapy program of exercise.
89377147|NCT03287791|Experimental|Generic Azelaic Acid Foam|A thin layer of generic azelaic acid, 15% topical foam was to be gently massaged into the entire facial area twice daily, once in the morning and once in the evening, for 12 weeks. Contact with the mouth, eyes, and other mucous membranes was to be avoided. Hands were to be washed following application of study drug. Participants were instructed not to bathe, shower, wash, or swim for at least 4 hours after application of study drug. Participants were provided with mild cleanser, a towel, sunscreen, and moisturizing lotion to be used on treated areas while participating in the study.
89399399|NCT02173730|Experimental|BIBR 1048 MS with Pantoprazole|150 mg BIBR 1048 MS capsules administered twice daily over 6 days and once in the morning of the seventh day together with Pantoprazole. Pantoprazole administration (40 mg bid) started two days before administration og BIBR 1048 and ended in the morning of the seventh day.
89399400|NCT03686553||infected, with SSI|patients with SSI
88850138|NCT00003566|Experimental|video-thorascopy + surgery|Patients will undergo ipsilateral video-thorascopic evaluation. Patients may undergo surgery at the discretion of the surgeon and treating physicians.
88850139|NCT05748925|Active Comparator|study group|study group: will receive SGLT2i as add on drug or replace another drug according to the patient clinical situation, Dapagliflozin 10 mg will be used once daily with or without food for one ye
88850140|NCT05748925|Active Comparator|control group|Control group: will receive placebo as add on drug once daily with or without food for one year.
88850141|NCT05617651|Active Comparator|A group|"Period 1 : Ilaprazole 10mg 2Tab, one a day~Period 2 : Ilaprazole 20mg 1Tab, one a day~Period 3 : Ilaprazole 10mg 2Tab, one a day"
88850142|NCT05617651|Active Comparator|B group|"Period 1 : Ilaprazole 20mg 1Tab, one a day~Period 2 : Ilaprazole 10mg 2Tab, one a day~Period 3 : Ilaprazole 20mg 1Tab, one a day"
88850143|NCT05748691||Pre-implementation group|Clinical use of hs-cTnI in patients with suspected acute coronary syndrome
88850144|NCT05748691||Post-implementation group|Clinical use of hs-cTnT in patients with suspected acute coronary syndrome
88850145|NCT00004070|Experimental|IL-12 Injection 3mg/ml [Phase I]|The dosing schedule will consist of eight injections 3 mg/ml of formulated plasmid over a seven week period.
88850146|NCT00004070|Experimental|IL-12 Injection 6mg/ml [Phase I]|The dosing schedule will consist of eight injections 6mg/ml of formulated plasmid over a seven week period.
88850147|NCT00004070|Experimental|IL-12 Injection MTD [Phase II]|The dosing schedule will consist of eight injections over a seven week period of formulated plasmid at the MTD established in the phase I portion.
88850148|NCT00002707|Experimental|Group 2|doxorubicin and cyclophosphamide plus Taxotere prior to surgery plus tamoxifen
89399401|NCT03686553||non-infected|patients without SSI
89377148|NCT03287791|Active Comparator|Finacea® (Azelaic Acid) Foam|A thin layer of Finacea (azelaic acid), 15% topical foam was to be gently massaged into the entire facial area twice daily, once in the morning and once in the evening, for 12 weeks. Contact with the mouth, eyes, and other mucous membranes was to be avoided. Hands were to be washed following application of study drug. Participants were instructed not to bathe, shower, wash, or swim for at least 4 hours after application of study drug. Participants were provided with mild cleanser, a towel, sunscreen, and moisturizing lotion to be used on treated areas while participating in the study.
89377149|NCT03287791|Placebo Comparator|Vehicle Foam|A thin layer of the vehicle topical foam was to be gently massaged into the entire facial area twice daily, once in the morning and once in the evening, for 12 weeks. Contact with the mouth, eyes, and other mucous membranes was to be avoided. Hands were to be washed following application of study drug. Participants were instructed not to bathe, shower, wash, or swim for at least 4 hours after application of study drug. Participants were provided with mild cleanser, a towel, sunscreen, and moisturizing lotion to be used on treated areas while participating in the study.
89377150|NCT02381002|Experimental|Weight reduction|weight reduction program for 6 months
89377151|NCT03287635|Experimental|Acthar gel 80 U/ml|Patients who continue to experience clinically significant symptoms of dry eye disease even after utilizing traditional methods of treatment for dry eye including but not limited to artificial tears, warm compresses, topical anti-inflammatories like cyclosporine and/or lifitegrast. Patients will receive repository corticotropin intramuscular injections 80 u/ml 2-3 times weekly for up to 3 months as judged by the investigator.
89377152|NCT02380924|Active Comparator|DSP loaded RBC using EryDex System|Autologous RBC loaded with DSP using the EDS process, and treated RBC are infused to the subject.
89377153|NCT02380924|Sham Comparator|Sham treated RBC using the EryDex System|Autologous RBC are treated with buffer using the EDS process, and treated RBC are infused to the subject.
88850149|NCT00002707|Experimental|Group 3|doxorubicin and cyclophosphamide followed by surgery followed by taxotere plus tamoxifen
88850150|NCT00002707|Active Comparator|Group 1|doxorubicin and cyclophosphamide plus tamoxifen
88850151|NCT05747365||Case group|Patients with thyroid cancer diagnosis within 5 years before study enrollment
88850152|NCT05747365||Control group|Patients without clinical diagnosis of thyroid disease
88850153|NCT00002725|Experimental|Arm I|Single-Agent Chemotherapy/Differentiation Therapy. Bryostatin 1, BRYO, NSC-339555.
88850154|NCT04609423|Experimental|Cod liver oil|supplementation for 6 months
88850155|NCT04609423|Placebo Comparator|Corn oil (placebo)|supplementation for 6 months
88850156|NCT05745571|Other|Patients with acute coronary syndrome|30 patients admitted to our hospital with the diagnosis of STEMI-type ACS and ejection fraction ≤ 35% on echocardiographic evaluation
88850157|NCT05745571|Other|Patients with non-ischaemic dilated cardiomyopathy|30 patients with non-ischaemic dilated cardiomyopathy and ejection fraction ≤35% on echocardiographic evaluation
88850158|NCT05745571|Other|Patients diagnosed with STEMI-type ACS|Patients diagnosed with STEMI-type ACS and ejection fraction > 50% on echocardiographic evaluation
89377154|NCT04051918|Experimental|Socially Assistive Robot Intervention|Piano training intervention led by a semi-autonomous socially assistive robot
89377155|NCT04051918|Active Comparator|Content Only Intervention|Piano training intervention using the same curriculum displayed on a computer monitor, without the socially assistive robot tutor.
89377156|NCT03694405|Experimental|Group 1A|3 doses prior MenC , randomized to receive MenACWY-CRM (Menveo)
89377157|NCT03694405|Experimental|Group 1B|3 doses prior MenC, randomized to receive MenACWY-DT (Menactra)
89377158|NCT03694405|Experimental|Group 1C|3 doses prior MenC, randomized to receive MenACWY-TT (Nimenrix)
88850159|NCT05745571|Other|Controls|Controls with normal left ventricular contractile function
88850160|NCT05592769|Experimental|HealthBeacon Injection Care Management System (ICMS) Arm|All participants enrolled will be recruited to this study arm and provided with access to the HealthBeacon ICMS.
88850161|NCT05744947||Recruited patient .|Patient previsouly recruited in the DISCO Registry (Study of the Prevalence Fibromuscular Dysplasia in Patient With Haematoma or Spontaneous Coronary Artery Dissection. (DISCO trial - NCT02799186)) with cardiac rehabilitation following the management of acute coronary syndrome
88850162|NCT00003620|Experimental|Treatment (flavopiridol)|"Patients registered before 9/15/2000 receive flavopiridol IV continuously on days 1-3. Treatment repeats every 14 days for a total of 12 courses in the absence of disease progression or unacceptable toxicity.~Patients registered after 9/15/2000 receive flavopiridol IV over 1 hour daily on days 1-3. Treatment repeats every 3 weeks for a total of 8 courses in the absence of disease progression or unacceptable toxicity."
88850163|NCT05743465||Ponatinib Cohort|Participants will be classified into the cohorts based on the TKI (ponatinib, bosutinib, and others [imatinib, dasatinib, or nilotinib]) drug used on index date, stratified by prior TKI use. Participants with a ponatinib prescription identified as the index drug prior TKI use will be stratified in this cohort.
88850164|NCT05743465||Bosutinib Cohort|Participants will be classified into the cohorts based on the TKI (ponatinib, bosutinib, and others [imatinib, dasatinib, or nilotinib]) drug used on index date, stratified by prior TKI use. Participants without ponatinib use and with bosutinib identified as the index drug prior TKI use will be stratified in this cohort.
89377159|NCT03694405|Experimental|Group 2A|2 doses prior MenC, randomized to receive MenACWY-CRM (Menveo)
89377160|NCT03694405|Experimental|Group 2B|2 doses prior MenC, randomized to receive MenACWY-DT (Menactra)
89377161|NCT03694405|Experimental|Group 2C|2 doses prior MenC, randomized to receive MenACWY-TT (Nimenrix)
89377162|NCT03694405|Experimental|Group 3A|1 dose prior MenC, randomized to receive MenACWY-CRM (Menveo)
89377163|NCT03694405|Experimental|Group 3B|1 dose prior MenC, randomized to receive MenACWY-DT (Menactra)
89377164|NCT03694405|Experimental|Group 3C|1 dose prior MenC, randomized to receive MenACWY-TT (Nimenrix)
89377165|NCT03287089|Active Comparator|Nitrofurantoin|Receives twice daily 100mg nitrofurantoin for 5 days following catheter removal
89377166|NCT03287089|Placebo Comparator|Placebo|Receives twice daily matching placebo for 5 days following catheter removal
89377167|NCT02380768|Experimental|Ambu AuraGain|Subjects will receive the Ambu AuraGain size 1.5 or 2.0 based on manufacturer guidelines
89377168|NCT02380768|Active Comparator|LMA Supreme|Subjects will receive the Ambu AuraGain size 1.5 or 2.0 based on manufacturer guidelines
89377169|NCT02384980|No Intervention|Walk Group|This group of patients are part of the walk group. They will be encouraged to walk and will receive standard care, defined as conservative (non-surgical) management of signs and symptoms, including prescriptive medications to improve circulation and manage pain, determined by their attending physician on a case by case basis.
89377170|NCT02384980|Experimental|FES + Walk Group|This group of patients will participate in Functional Electrical Stimulation (FES) and exercise. This group will receive functional electrical stimulation as an intervention. The FES device will stimulate (activate) the calf and shin leg muscles of both legs while the patient is walking. This group will also receive standard care, defined as conservative (non-surgical) management of signs and symptoms, including prescriptive medications to improve circulation and manage pain, determined by their attending physician on a case by case basis.
89377171|NCT02385136|Experimental|WBRT plus TMZ arm|whole brain radiotherapy (WBRT) concomitantly with temozolomide (TMZ)
89377172|NCT02385136|No Intervention|WBRT|whole brain radiotherapy (WBRT)
89377173|NCT02380534|Experimental|active procedure|High cardiovascular risk patients will undergo H.E.L.P. apheresis.
89377174|NCT02375932|Experimental|Pre-Visit Tool|Patients whose primary care physicians are allocated to the intervention arm will receive a secure electronic message shortly after scheduling an appointment with their provider asking them to complete a pre-visit prioritization survey using the kp.org patient portal
89377175|NCT02375932|Active Comparator|Usual Care Control|Patients whose primary care physicians are allocated to the control arm will continue with usual care
89377176|NCT03113188|Experimental|CBP501, CDDP, Nivolumab|CBP501, Cisplatin and Nivolumab Administered Every 3 Weeks in Patients with Advanced Refractory Tumors
89377177|NCT02376322|Experimental|Radiotherapy in bone metastases|The purpose of this one armed, phase II trial is to determine the efficacy and safety profile of a hypofractionated radiotherapy regimen, 16 Gy in 2 fractions with an interval of one week, for the palliation of complicated bone metastases in patients with poor performance status.
89377178|NCT02375776|Experimental|Intervention|Download and use mobile health application - CORA- Device:smartphones for 12 weeks.
89377179|NCT02375776|No Intervention|Control|Usual Care - The control group will not use the study's mobile health application during the study.
88850165|NCT05743465||Other TKI Cohort|Participants will be classified into the cohorts based on the TKI (ponatinib, bosutinib, and others [imatinib, dasatinib, or nilotinib]) drug used on index date, stratified by prior TKI use. Participants without ponatinib or bosutinib use and with imatinib, dasatinib, or nilotinib identified as the index drug after prior TKI use will be stratified in this cohort.
88850166|NCT00003350|Experimental|Arm I (paclitaxel)|"Patients receive paclitaxel over 3 hours by intravenous infusion. Treatment course repeats every 2 weeks. Patients are evaluated every third course.~Patients in both arms continue treatment if there is no disease progression or unacceptable toxicity. Patients with complete response continue on study treatment for 2 courses beyond documented complete response.~Quality of life is assessed before, during, and after treatment."
88850167|NCT00003350|Experimental|Arm II (pegylated liposomal doxorubicin hydrochloride)|"Patients receive doxorubicin HCL liposome over 30-60 minutes by intravenous infusion. Treatment course is repeated every 3 weeks. Patients are evaluated before every odd course.~Patients in both arms continue treatment if there is no disease progression or unacceptable toxicity. Patients with complete response continue on study treatment for 2 courses beyond documented complete response.~Quality of life is assessed before, during, and after treatment."
88850168|NCT00004136|Experimental|Heat Therapy|
88850169|NCT00004142|Experimental|Radiofrequency Ablation + HAI of Floxuridine/5-FU|Radiofrequency Ablation Combined With Post-Ablation Hepatic Arterial Infusion (HAI) of Floxuridine Alternating With 5-Fluorouracil (5-FU)
88850170|NCT00004148|Experimental|Arm I|Patients receive rV-B7.1 intralesionally every 4 weeks for 8 weeks (weeks 0, 4, and 8). Treatment continues every 12 weeks in the absence of unacceptable toxicity or disease progression for up to 2 courses. Cohorts of 6-8 patients receive escalating doses of vaccine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 or 3 of 8 patients experience dose limiting toxicities.
88850171|NCT04207424|Experimental|Embolization|Patients undergoing embolization of the gastro-epiploic arcade
89377180|NCT02376244|Experimental|High intensity interval training (HIIT)|"Patients will undergo a 15-minute warm-up, followed by a 24-minute conditioning phase, and a 10-minute cool-down. The conditioning phase will include a combination of aerobic exercise (e.g. cycling or walking) and resistance exercise (e.g. squats, bicep curls). Patients will complete 5 intervals of 3 minutes with 2 minute rest periods interspersed. The intensity will correspond to 16-17 on the Borg 6-20 Rating of perceived exertion scale.~Patients will exercise once a week for 8 weeks."
89377181|NCT02376244|Active Comparator|Standard Care|"Patients assigned to this group will participate in usual standard care of cardiac rehabilitation.~Commonly, patients will undergo a 15-minute warm-up, followed by a 24-minute conditioning phase, and a 10-minute cool-down. The conditioning phase will include a combination of aerobic exercise (e.g. cycling or walking) and resistance exercise (e.g. squats, bicep curls). Patients will complete 5 intervals of 3 minutes with 2 minute rest periods interspersed. The intensity will correspond to 11-15 on the Borg 6-20 Rating of perceived exertion scale.~Patients will exercise once a week for 8 weeks."
89377182|NCT03286543|Experimental|Treatment Group (SPRINT Beta System)|Subjects in the treatment group will have up to 2 leads placed in their leg that underwent total knee replacement, will use the SPRINT Beta System, and will receive electrical stimulation in addition to the standard of care.
89377183|NCT03286543|No Intervention|Control Group|Subjects in the control group will receive the standard of care.
88850172|NCT04191122|Active Comparator|COPESS and Treatment as usual|"COPES is a brief (4 + 1 sessions, 50 minutes) psychotherapy based on psychodynamic and cognitive analytic principles that was developed to help those struggling with SH and depression. COPES is designed to be brief and accessible, and involves working collaboratively with a client to try and identify patterns or conflicts in emotional experiences and interpersonal relationships, linked to depressed mood and acts of SH. The therapist works with the client to build a shared map or understanding of these experiences. A goal of therapy is to work towards a small number of specific exits, representing helpful steps the client might make to improve their difficulties. Therapy would take place either in the participant's home or in a community setting (e.g. health centre or clinic) depending on preference.~Safety for the therapist and/or mobility for the patient will be reviewed throughout the recruitment period. Participants in the COPES arm of the trial will also receive TAU."
88850173|NCT04191122|No Intervention|Treatment as usual only|The control group will receive Treatment-as usual (TAU), defined as the standard care provided to individuals struggling with self-harm (SH) as detailed within the 'Managing SH in primary care' NICE guidelines. These include: an initial comprehensive psychosocial assessment of skills and risks; co-production of a care and risk management care plan, which should include harm reduction plans, the need for between 3 and 12 sessions of psychological intervention as well as treatment for associated mental health conditions. Primary care practices in the control arm will be asked to provide information on what constitutes TAU within their organisation. This trial may enhance TAU as researchers will provide details of NICE guidance to GP practices that may not currently be following these guidelines. We will collect data regarding the acceptability of TAU for SH offered by GPs within both treatment arms.
88850174|NCT00382135|Placebo Comparator|1|placebo tablet
88850175|NCT00382135|Active Comparator|2|20 mg tadalafil tablet
88850176|NCT00004154|Experimental|Fenretinide|Fenretinide (4-HPR) 200 mg orally every day for 12 months taken 25 out of every 28 days.
88850177|NCT00004154|Placebo Comparator|Placebo|Placebo orally every day for 12 months, taken 25 out of every 28 days.
88850178|NCT04133324||Main group|One groupe in the study
88850179|NCT00004160|Experimental|Dose 1 Gemcitabine|Patients receive paclitaxel IV over 1 hour and gemcitabine IV over 30 minutes beginning 2 hours into paclitaxel infusion on day 1 of weeks 6, 9, and 12.
88850180|NCT00004160|Experimental|Dose 2 Gemcitabine|Patients receive paclitaxel IV over 1 hour and gemcitabine IV over 30 minutes beginning 2 hours into paclitaxel infusion on day 1 of weeks 6, 9, and 12.
89182113|NCT01977183|Experimental|General adult population with MSPrebiotic|30 g of MSPrebiotic (potato resistant starch) per day taken with 1 glass (approximately 250 mL) of non-heated fluid. If the participant is taking any medications, they will be advised to either take the product 2 hours before or 2 hours after any medications.
89182114|NCT01977183|Placebo Comparator|General adult population with Placebo|30 g of corn starch per day taken with 1 glass (approximately 250 mL) of non-heated fluid. If the participant is taking any medications, they will be advised to either take the product 2 hours before or 2 hours after any medications.
89182115|NCT00720798|Experimental|Tocilizumab|Participants received tocilizumab 8 mg/kg intravenously every 4 weeks till the end of the study (up to 7 years, 7 months). In addition, participants may have also received disease-modifying anti-rheumatic drugs, non-steroidal anti-inflammatory drugs, and oral corticosteroids at the discretion of the investigator.
89182116|NCT01816971|Experimental|Treatment (dexamethasone, carfilzomib, lenalidomide)|"INDUCTION THERAPY: Patients receive dexamethasone IV or PO QD on days 1, 8, 15 and 22; carfilzomib IV over 10-30 minutes on days 1, 2, 8, 9, 15, and 16; and lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity..~TRANSPLANT: Patients undergo autologous stem cell transplant.~CONSOLIDATION THERAPY: Patients receive dexamethasone, carfilzomib, and lenalidomide as in induction. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive dexamethasone and lenalidomide as in induction therapy and carfilzomib IV over 30 minutes on days 1, 2, 15, and 16. Treatment repeats every 28 days for 10 courses in the absence of disease progression or unacceptable toxicity."
89182117|NCT03995095|No Intervention|Control group|Group of participants that received usual psychological attention.
89182118|NCT03995095|Experimental|Experimental group|Group of participants that received usual psychological attention plus attention of spiritual needs following the Kibo protocol (intervention).
89182119|NCT03995329|Other|healthy non smokers|"Healthy non smokers males, aged 18-55years,receiving no medications~Intervention: the use of an IQOS Examination of pulmonary function, exhaled CO, blood pressure, heart rate and O2 saturation immediatly after IQOS"
89182120|NCT03489187||VTTS as standard of care|VTTS as standard of care.
89182121|NCT04936893|Experimental|HeadSpace Mobile App|Mindfulness practice
89182122|NCT04936893|Active Comparator|Lumosity Mobile App|Cognitive games
88850181|NCT00004160|Experimental|Dose 3 Gemcitabine|Patients receive paclitaxel IV over 1 hour and gemcitabine IV over 30 minutes beginning 2 hours into paclitaxel infusion on day 1 of weeks 6, 9, and 12.
88850182|NCT00004160|Experimental|Dose 4 Gemcitabine|Patients receive paclitaxel IV over 1 hour and gemcitabine IV over 30 minutes beginning 2 hours into paclitaxel infusion on day 1 of weeks 6, 9, and 12.
88850183|NCT00004160|Experimental|Dose 5 Gemcitabine|Patients receive paclitaxel IV over 1 hour and gemcitabine IV over 30 minutes beginning 2 hours into paclitaxel infusion on day 1 of weeks 6, 9, and 12.
88850184|NCT05562115|Experimental|Patients treated for an ocular malformation linked to a PAX6 mutation.|
88850185|NCT05562037|No Intervention|Treatment as usual|"Patients referred to CR or PR are initially telephoned by a RN,RC or RA who describes the program and schedules the initial intake evaluation. The intake evaluation reflects usual care practices at both BMC and Fairview Hospital. The purpose of this initial session is to obtain the data required to design an individualized effective and safe rehabilitation program. It is performed by a RN, RC, or RA and includes performing a medical history, physical examination, and testing.~Reminder telephone calls are placed prior to the initial intake and formal reassessments visits."
89182123|NCT01021267|Experimental|Saw palmetto berry extract|Saw palmetto berry extract, organic saw palmetto, ethanolic extract 96%
88850186|NCT05562037|Active Comparator|Stepped Care|"The SC arm will be offered Center Based Rehabilitation (CBR) and subsequently stepped up to transportation-subsidized CBR, home-based TR, and CHW-supported home-based TR based on prespecified non-response criteria/poor adherence.~Standard of Care. Patients meeting a non-response criterion will be stepped up to transportation-subsidized CBR.~Step 1. Transportation-Subsidized CBR. Step 2. Home-Based TR. Step 3. CHW-Supported Home-Based TR."
88850187|NCT05509543|Active Comparator|A group|"Period 1 : Ilaprazole 10mg 2Tab, one a day~Period 2 : Ilaprazole 20mg 1Tab, one a day"
88850188|NCT05509543|Active Comparator|B group|"Period 1 : Ilaprazole 20mg 1Tab, one a day~Period 2 : Ilaprazole 10mg 2Tab, one a day"
88850189|NCT00003674|Experimental|dalteparin + standard therapy|Patients receive dalteparin by subcutaneous injection once daily plus standard therapy. Treatment continues for 1 year in the absence of disease progression and unacceptable toxicity. Quality of life is assessed before treatment, then every month for the first year, and then every 3 months for 2 years. Patients are followed monthly for 1 year, then every 3 months for 2 years.
88850190|NCT00003674|Active Comparator|standard therapy|Patients receive standard therapy alone. Treatment continues for 1 year in the absence of disease progression and unacceptable toxicity. Quality of life is assessed before treatment, then every month for the first year, and then every 3 months for 2 years. Patients are followed monthly for 1 year, then every 3 months for 2 years.
88850191|NCT00002779|Experimental|fludarabine + octreotide|Patients receive fludarabine IV over 10-30 minutes on days 1-5. Patients not currently receiving octreotide, receive a test dose of octreotide subcutaneously on day 1 during course 1 only and then receive octreotide intramuscularly monthly on day 1. Treatment repeats every 28 days for 4-6 courses. Patients then receive octreotide alone for 6-8 courses. Some patients may then receive another 12 courses of octreotide alone, for a total of 2 years of treatment. Patients are followed every 3 months for 5 years or until disease progression.
88850192|NCT00004184|Experimental|Arm I|Patients receive human anti-idiotypic monoclonal antibody vaccine (4B5) in sargramostim (GM-CSF) subcutaneously (SQ) on days 0, 14, 28, and 42. Patients receive GM-CSF alone SQ at vaccination site on days 2, 3, and 4 following immunization.
88850193|NCT00004184|Experimental|Arm II|Patients receive 4B5 plus alum SQ on days 0, 14, 28, and 42. Cohorts of 5 patients receive treatment every 2 weeks for up to 4 courses in the absence of unacceptable toxicity.
88850194|NCT00384566|Experimental|1|
88850195|NCT00384566|Active Comparator|2|
88850196|NCT00384644||1|sepsis, septic shock ptients
88850197|NCT00384644||2|cardiogenic shock patients
88850198|NCT00004190|Experimental|gemcitabine + oxaliplatin|Patients receive gemcitabine IV over 30 minutes on days 1 and 8 immediately followed by oxaliplatin IV over 2 hours on day 1. Treatment repeats every 3 weeks. Patients achieving stable disease, partial response, or regressive disease continue with therapy. Patients achieving complete response for two consecutive evaluations receive an additional 2 courses of therapy. Phase I (closed as of 7/5/00): Cohorts of 3-6 patients receive escalating doses of gemcitabine and oxaliplatin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose limiting toxicity. Phase II: Patients receive the MTD of gemcitabine and oxaliplatin as in phase I. Patients are followed every 3 months for 1 year, and then every 6 months for 4 years.
88850199|NCT00004196|Experimental|AI|Patients with metastasis in a single sentinel node with no evidence of extracapsular extension and no metastatic disease in nonsentinel nodes are randomized to 1 of 2 treatment arms. Patients receive adjuvant high-dose interferon alfa-2b IV 5 days a week for 4 weeks, then subcutaneously 3 times a week for 48 weeks
88850200|NCT00004196|Experimental|Arm AII|Patients with metastasis in a single sentinel node with no evidence of extracapsular extension and no metastatic disease in nonsentinel nodes are randomized to 1 of 2 treatment arms. Observational arm: Patients with metastases in more than one sentinel node with evidence of extracapsular extension or metastasis in any nonsentinel node receive adjuvant high-dose interferon alfa-2b as in arm AI.
88850201|NCT00004196|Experimental|Arm BI|Patients with positive sentinel node(s) by PCR analysis are randomized to one of three treatment arms. Patients undergo observation. Patients are followed every 3 months for 2 years, every 4 months for 1 year, every 6 months for 2 years, and then annually thereafter.
88850202|NCT00004196|Experimental|Arm B II|Patients with positive sentinel node(s) by PCR analysis are randomized to one of three treatment arms. Patients undergo lymph node dissection. Patients are followed every 3 months for 2 years, every 4 months for 1 year, every 6 months for 2 years, and then annually thereafter.
88850203|NCT00004196|Experimental|Arm BIII|"Patients with positive sentinel node(s) by PCR analysis are randomized to one of three treatment arms. Patients undergo lymph node dissection followed by adjuvant high-dose interferon alfa-2b IV 5 days a week for 4 weeks.~Patients are followed every 3 months for 2 years, every 4 months for 1 year, every 6 months for 2 years, and then annually thereafter."
89377184|NCT02380378||Myeloproliferative Neoplasms|Patients diagnosed with Myeloproliferative Neoplasms based on WHO 2008 criteria.
88850204|NCT00381979|Experimental|1|set
88850205|NCT05500807|Other|Open Label Emicizumab|Emicizumab prophylaxis
88850206|NCT00003686|Active Comparator|Pilocarpine|
88850207|NCT00003686|Placebo Comparator|Placebo|
88850208|NCT05495035|Experimental|Olverembatinib + APG-2575 combinational therapy|"Period 1: Olverembatinib alone period (2 weeks):~Period 2: olverembatinib in combination with APG-2575 and dexamethasone (4 weeks):"
88850209|NCT00004856|Experimental|Treatment: Herceptin|Patients receive a loading dose of trastuzumab (Herceptin) IV over 90 minutes on day 1 of week 1. For all subsequent doses, patients receive trastuzumab IV over 30 minutes weekly. Treatment may continue for more than 1 year in the absence of unacceptable toxicity or disease progression.
88850210|NCT04438057|No Intervention|Standard of Care|Patient will receive standard of care therapy.
88850211|NCT04438057|Active Comparator|Treatment Arm|Patient will receive convalescent plasma
89182124|NCT04072965|Experimental|Cross eduacation of balance|10 females with Chronic Ankle Instability will receive balance training for the non affected side for a six weeks
89377185|NCT02380846|Other|Rice|Control session - white rice (equivalent to 50g available carbohydrates)
88850212|NCT04600375|Other|Verbal Consultation, then Written Action Plan|"CONTROL GROUP~Survey A~Routine clinic visit~Verbal consultation only~Survey B~Verbal consultation AND Written Action Plan~Survey C"
88850213|NCT04600375|Experimental|Experimental: Written Action Plan|"INTERVENTION GROUP~Survey A~Routine clinic visit~Verbal consultation AND Written Action Plan~Survey C"
88850214|NCT00004208|Active Comparator|Arm A: ATG + CSA|"Treatment consists of 15 mg/kg ATG (Mérieux; horse antithymocyte globulin; i.e. 1.5 vial/10 kg of body weight/day) given over 8-12 hours for 5 consecutive days.~Cyclosporine A (CSA) will be administered orally in a dose of 2.5 mg/kg bid starting day 1 and continued through day 180."
88850215|NCT00004208|Other|Arm B: Supportive care|Patients randomized to this arm will be treated as outpatients.
88850216|NCT04403425||Emergency laparotomy, obstruction|Patients undergoing emergency laparotomy for intestinal obstruction in need of intraoperative Noradrenaline infusion to maintain predefined normotension.
88850217|NCT04403425||Emergency laparotomy, perforation|Patients undergoing emergency laparotomy for perforated ventricle or intestine in need of intraoperative Noradrenaline infusion to maintain predefined normotension.
88850218|NCT00004862|Experimental|Arm I|Patients receive augmerosen IV continuously on days 1-10 and filgrastim (G-CSF) subcutaneously beginning on day 5 and continuing until blood counts recover. Patients receive fludarabine IV over 30 minutes followed 3.5 hours later by cytarabine IV over 4 hours on days 6-10. Patients who achieve complete response (CR) receive a second course beginning 4 weeks after completion of the first course. Patients who achieve CR and have a matched sibling or unrelated bone marrow donor may undergo allogeneic bone marrow transplantation. Cohorts of 3-6 patients receive escalating doses of fludarabine and cytarabine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity.
88850219|NCT05492071|Experimental|Local Vibration Application Following Flow-Mediated Dilation Application|Flow mediated dilatation will be induced via 5 min cuff inflation below left elbow at suprasystolic pressures (50mmHg above preapplication systolic pressure). Vibration is applied with a commercially available vibration plate to forearm at 20 hz and 3 mm of vertical amplitude for 5 minutes, 30 minutes after termination of FMD.
88850220|NCT05492071|Experimental|Flow-Mediated Dilation Application|Flow mediated dilatation will be induced via 5 min cuff inflation below left elbow at suprasystolic pressures (50mmHg above preapplication systolic pressure).
88850221|NCT00003704|Experimental|capecitabine + radiation|This is a dose-escalation study of capecitabine. Patients receive oral capecitabine twice a day 7 days a week for 6 weeks with concurrent radiotherapy. Radiotherapy is initiated on the same day as the initiation of capecitabine and is administered 5 days a week for 5.5-6 weeks. Cohorts of 3-6 patients receive escalating doses of capecitabine until the maximum tolerated dose (MTD) is reached. The MTD is defined as the dose at which 2 of 3 or 6 patients experience dose-limiting toxicity. Patients are followed every 3 months for 2 years and then every 6 months for 1 year.
88850222|NCT05232097|Experimental|Behavioral therapy|Behavioral therapy consisting of diaphragmatic breathing exercises and physiotherapy to relax tensed abdominal and thoracic muscles
88850223|NCT05485675|Active Comparator|Stand & Move at Work|Given an evidence-based workplace program to reduce sedentary behavior and increase standing and moving using a web-based platform. The web platform has a toolkit with strategies and guides for the worksite Champions to address changes at the environmental, social, and cultural levels.
88850224|NCT05485675|Experimental|Stand & Move at Work+|This arm will receive access to the same web-based platform and toolkit as the other arm. Additionally, worksites in this arm will be assigned and expert facilitator who will meet regularly with the worksite Champions to assist with implementation.
88850225|NCT05230927||Chronic Heart Failure|
88850226|NCT05230927||Chronic Obstructive Pulmonary Disease|
88850227|NCT00004244|Experimental|Arm I|"Patients receive interleukin-12 subcutaneously (SC) twice a week and interferon alfa SC three times a week every week for 4 weeks. Treatment continues in the absence of unacceptable toxicity or disease progression.~Cohorts of 3-6 patients receive escalating doses of interleukin-12 and interferon alfa until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose limiting toxicities.~Patients receive interleukin-12 SC twice a week for 2 weeks, followed by treatment with interleukin-12 in combination with interferon alfa as described above."
88850228|NCT00004244|Experimental|Arm II|"Patients receive interleukin-12 subcutaneously (SC) twice a week and interferon alfa SC three times a week every week for 4 weeks. Treatment continues in the absence of unacceptable toxicity or disease progression.~Cohorts of 3-6 patients receive escalating doses of interleukin-12 and interferon alfa until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose limiting toxicities.~Patients receive interferon alfa SC three times a week for 2 weeks, followed by treatment with interleukin-12 in combination with interferon alfa as described above."
88850229|NCT00004244|Experimental|Arm III|"Patients receive interleukin-12 subcutaneously (SC) twice a week and interferon alfa SC three times a week every week for 4 weeks. Treatment continues in the absence of unacceptable toxicity or disease progression.~Cohorts of 3-6 patients receive escalating doses of interleukin-12 and interferon alfa until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose limiting toxicities.~Patients receive treatment with interleukin-12 in combination with interferon alfa at the MTD as described above."
88850230|NCT04812847||Gram negative infection, MDR present|Neonates with one or more gram-negative bacterial isolates with MDR characteristics during their clinical course in the Neonatal Intensive Care Unit of the study hospital.
88850231|NCT04812847||Gram negative infection, MDR absent|Neonates with one or more gram-negative bacterial isolates with no MDR characteristics during their clinical course in the Neonatal Intensive Care Unit of the study hospital.
89377186|NCT02380846|Active Comparator|Rice with chicken|Treatment 1 - White rice and steamed chicken breast (25g protein)
89377187|NCT02380846|Active Comparator|Rice with fish|Treatment 2 - White rice and steamed fish (25g protein)
89377188|NCT02380846|Active Comparator|Rice with egg white|Treatment 3 - White rice and egg white (25g protein)
89377189|NCT02380846|Active Comparator|Rice with beancurd|Treatment 4 - White rice and steamed beancurd (25g protein)
89377190|NCT02380222||ASM|
89377191|NCT02380222||SM-AHNMD|
89377192|NCT02380222||MCL|
89377193|NCT02380222||SSM|
89377194|NCT02380222||ISM|
88850232|NCT00382525||Patients with Cardiac Rhythm Management device|Patients receiving a Medtronic Cardiac Rhythm Device, worldwide
88850233|NCT00004262|Experimental|Treatment (motexafin gadolinium, radiotherapy, radiosurgery)|Within 5 weeks following surgery, patients receive daily external beam radiotherapy five days a week for 5 weeks. Within 2 weeks following completion of radiotherapy, patients receive gadolinium texaphyrin IV over 2 hours followed 3 hours later by stereotactic radiosurgery. Patients undergoing surgical debulking of tumor prior to external beam radiotherapy receive gadolinium texaphyrin IV over 2 hours, 3 hours prior to surgery in addition to the dose prior to stereotactic radiosurgery.
88850234|NCT00003746|Active Comparator|CDA day|CDA:0.14 mg/kg/day Bolus s.c. (standard) days 1-5
88850235|NCT00003746|Active Comparator|CDA week|CDA:0.14 mg/kg/week Bolus s.c. weeks 1-5
88850236|NCT02973152|Active Comparator|Thyroplasty|This medialisation/augmentation technique is a static technique, performed under local anaesthesia that aims to improve the positioning of the paralysed vocal fold. It uses a silastic implant readily available in different sizes according to size of larynx and gender of the patient. The correct size can be determined intraoperatively by using a measuring device while listening and visualising the larynx with flexible fiberoptic scope simultaneously.
88850237|NCT02973152|Active Comparator|Reinnervation|For laryngeal reinnervation, ansa cervicalis to recurrent laryngeal nerve repair technique will be used. In this technique, the functioning ansa cervicalis nerve that overlies the internal jugular vein and the distal stump of injured recurrent laryngeal nerve (RLN) will be identified and anastomosed without tension (Crumley RL. Teflon versus thyroplasty versus nerve transfer: a comparison. The Annals of otology, rhinology, and laryngology. 1990;99(10 Pt 1):759-63).
88850238|NCT04092842|Experimental|Group intervention: Silicone prothesis|Breast cancer conservative surgery will be performed by removing the tumor according to the usual technique and then the defect generated will be filled with a silicone prosthesis of the same size. Said prosthesis will be covered with fat and subcutaneous cellular tissue and then the skin will be closed.
88850239|NCT04092842|Active Comparator|Group control: Usual surgical technique|Breast cancer conservative surgery will be performed according to the usual surgical technique, that is, removing the tumor and covering the defect by mobilizing the breast tissue and then closing the skin.
88850240|NCT04712786||Group|27 patients, Group 1 consisted of patients with pseudophakic rhegmatogoneous retinal detachment who underwent pars plana vitrectomy and 12% perflouropropane (C3F8) gas tamponade and 20 patients Group 2 consisted of patients with epiretinal membrane or vitreous hemorrhage who underwent PPV without any tamponade
89377195|NCT03306433|Experimental|UDMA-K18|UDMA-K18 smooth surface sealant
89377196|NCT03306433|Placebo Comparator|UDMA-control|UDMA smooth surface sealant without K18
88850241|NCT02972684|No Intervention|Conventional coagulation management|management of perioperative haemorrhage following cardiac surgery using conventional blood coagulation tests.
88850242|NCT02972684|Experimental|Thrombo-elastometry POC testing|management of perioperative haemorrhage following cardiac surgery using the thrombo-elastometry point of care test.
89182125|NCT04072965|Experimental|Traditional training|10 females with Chronic Ankle Instability will receive balance training for the affected side for a six weeks
89182126|NCT04072965|No Intervention|control|balance of 15 females with Chronic Ankle Instability will be assessed before and after six weeks of no intervention
89377197|NCT03306433|No Intervention|Negative control|No intervention to provide baseline
89377198|NCT02380144|Experimental|Orange Fruit - Orange Juice|"Sequence of test foods during the intervention period:~1st: Orange fruit; 2nd: Orange juice"
89377199|NCT02380144|Experimental|Orange Juice - Orange Fruit|"Sequence of test foods during the intervention period:~1st: Orange juice; 2nd: Orange fruit"
89377200|NCT02384902|Experimental|low GI|low GI: participants were asked to consume low GI foods (GI<55) in abundant, medium GI in moderate and high GI (GI>70) rarely.
89377201|NCT02384902|Experimental|low GL|low GL: participants were asked to consume low GI foods and the amount of carbohydrate was controlled.
89377202|NCT02384902|Experimental|conventional diet|conventional diet: all carbohydrate were treated as the same.
89377203|NCT02940691|Experimental|Grazoprevir/elbasvir|Grazoprevir/elbasvir (100mg/50mg) daily taken orally for 12 weeks.
89377204|NCT02379832||Cases|Nulliparous women recruited at diagnosis of preeclampsia No intervention, only observation of biochemical and ultrasonographic markers at recruitment and at delivery N= 45
89377205|NCT02379832||Control|Nulliparous women recruited at the beginning of pregnancy. No intervention, only observation of biochemical and ultrasonographic markers at recruitment (1st trimester), 3 other times during pregnancy (2nd and 3rd trimester) and at delivery N= 45
89377206|NCT02379910|Experimental|SAD 1|AM1030-CREAM
89377207|NCT02379910|Experimental|SAD 2|AM1030-CREAM
89377208|NCT02379910|Experimental|SAD 3|AM1030-CREAM
89377209|NCT02379910|Experimental|MAD 1|AM1030-CREAM
89377210|NCT02379910|Experimental|MAD 2|AM1030-CREAM
89377211|NCT04949269|Experimental|Part A|
89377212|NCT04949269|Experimental|Part B|
89377213|NCT04949269|Experimental|Part C|
89377214|NCT04949269|Experimental|Part D|
89377215|NCT02380066|Experimental|Anyu Peibo 0.4g per day|Anyu Peibo Capsule, oral, 0.2g twice per day
89377216|NCT02380066|Experimental|Anyu Peibo 0.8g per day|Anyu Peibo Capsule, oral, 0.4g twice per day
89377217|NCT02380066|Experimental|Anyu Peibo 1.2g per day|Anyu Peibo Capsule, oral, 0.6g twice per day
89377218|NCT02380066|Experimental|Anyu Peibo 1.6g per day|Anyu Peibo Capsule, oral, 0.8g twice per day
89377219|NCT02380066|Placebo Comparator|Placebo|Placebo,oral, twice per day
88850243|NCT02972762|Active Comparator|L Group|The participants in L Group will receive Lumbar plexus and sciatic nerve block with ropivacaine before anesthesia induction.The investigator use Diprivan TCI target-controlled infusion during anesthesia induction period, target effect-site concentration is set at 4.0g / kg. After reaching the target concentration, sufentanil 0.2g / kg is administrated, Laryngeal mask will be placed into participant's mouth at 2 min after sufentanil is given. Anesthesia will be maintained with remifentanil TCI target-controlled infusion and Diprivan BIS close-loop target controlled infusion,BIS ranges from 50 to 60.The values of BP,P,PetCO2 will be controled in proper site. each participant will be given postoperative analgesia pump to release postoperative pain.
89377220|NCT04938271|Experimental|Healables Wearable Microcurrent Electroceutical HEAL-122 with e-Textile Sports Sleeve|Subjects activate electroceutical at home for 60 minutes (+/- 20 minutes) daily, 5 times per week, for 4 weeks
89377221|NCT02379754|Experimental|Gentamicin treated|"Installation of gentamicin in the middle ear 6 weeks prior to surgery + rehabilitation exercises before and after both treatment and surgery.~Rehabilitation exercises are not considered to be an intervention since their benign impact on vestibular/postural compensation is well documented, and exclusion from exercises would not be approved by the ethical board."
89377222|NCT02379754|No Intervention|Non-gentamicin|Rehabilitation exercises before and after surgery. Rehabilitation exercises are not considered to be an intervention since their benign impact on vestibular/postural compensation is well documented, and exclusion from exercises would not be approved by the ethical board.
89377223|NCT02375620|Experimental|PEG-somatropin: Low dose|0.1 mg/(kg.w), once per week for 52 weeks.
89377224|NCT02375620|Experimental|PEG-somatropin: High dose|0.2 mg/(kg.w), once per week for 52 weeks.
89377225|NCT04911673|Experimental|Music group|"Participants listened a song with headphones that lasts 29 minutes and 32 seconds for four days (three days before menstruation and the first day of menstruation). The song was composed by Juan Martin Saavedra.~In the first month, music group was filled the State Anxiety Inventory (SAI) between 10 and 20th of the menstruation that SAI consists of 20 statements that ask people to describe how they generally feel. In the second month, pain scores were measured on the first day of menstruation using a visual analogue scale (VAS) of 10 cm (0 no pain at all, and 10 the worst possible pain) and Trait Anxiety Inventory (TAI) was filled to assess the anxiety.In the third month, after the participants were listening the music in three days before menstruation and the first day of menstruation (during four days), pain scores were measured on the first day of menstruation using VAS and TAI was filled to assess the anxiety."
89377226|NCT04911673|Experimental|Chocolate group|Participants ate 40 mg of dark chocolate with 60% cocoa per day for four days (three days before menstruation and the first day of menstruation) that was given by researchers to them. In the first month, chocolate group was filled the SAI to assess state anxiety between 10 and 20th of the menstruation.In the second month, pain scores were measured on the first day of menstruation using VAS and TAI was filled to assess the trait anxiety.In the third month, after the participants were eating 40 mg of dark chocolate per day in three days before menstruation and the first day of menstruation (during four days/total 160 mg), pain scores were measured on the first day of menstruation using VAS and TAI was filled to assess the anxiety.
89377227|NCT04911673|No Intervention|Control group|Control group had no intervention. In the first month, control group was filled the SAI to assess state anxiety between 10 and 20th of the menstruation. In the second month, pain scores were measured on the first day of menstruation using VAS and TAI was filled to assess the trait anxiety. In the third month, pain scores were measured on the first day of menstruation using VAS and TAI was filled to assess the anxiety.
89377228|NCT01313377|Experimental|ARM A: Gemox 85|Adjuvant chemotherapy for six months with gemcitabine - oxaliplatin 85mg / m² ( GEMOX 85)
89377229|NCT01313377|Other|ARM B:|Observation until progression or death
89377230|NCT02375542||Cardiac Reoperation|Patients who have previously undergone a cardiac operation with the use of BioGlue and are now undergoing a reoperation
89377231|NCT02384746|Experimental|Combination Treatment|Fulvestrant (500mg) + MLN9708 (2.3, 3, and 4mg)
88850244|NCT02972762|Active Comparator|D Group|The participant in L Group will receive Lumbar plexus and sciatic nerve block with ropivacaine before anesthesia induction.The investigator use Diprivan TCI target-controlled infusion during anesthesia induction period, target effect-site concentration is set at 4.0g / kg. After reaching the target concentration, sufentanil 0.2g / kg is administrated, Laryngeal mask will be placed into participant's mouth at 2 min after sufentanil is given. Anesthesia will be maintained with remifentanil TCI target-controlled infusion and Diprivan BIS close-loop target controlled infusion,BIS ranges from 35 to 45.The values of BP,P,PetCO2 will be controled in proper site. The investigator use postoperative analgesia pump to control postoperative pain for each participant.
88850245|NCT00005006|Active Comparator|1|Alendronate alone
88850246|NCT00005006|Active Comparator|2|Teriparatide daily plus alendronate
88850247|NCT00005006|Active Comparator|3|Teriparatide cyclically plus alendronate
89377232|NCT02375386|Experimental|Spinal manipulation|Participants will receive a lumbar SMT technique previously described in the literature and commonly utilized for the treatment of low back pain . The SMT will be performed four times (two times on each side) in a 5-minute period. In addition, the following will be performed: Functional MRI (fMRI), Behavioral: Pain Sensitivity Testing, Questionnaires,Behavioral: Physical Impairment.
89377233|NCT02375386|Sham Comparator|Therapeutic touch|"Participants in this group will lie prone. The therapist will place both hands in contact with the participants' pelvis across the top of the posterior aspect of the sacrum and ilia and apply a downward force to keep the pelvis in contact with the table. This group accounts for effects of time and personal contact. The amount of hands-on contact will be equivalent between groups. Both groups will be given the same verbal instructions regarding the techniques performed. In addition, the following will be performed: Functional MRI (fMRI), Behavioral: Pain Sensitivity Testing, Questionnaires,Behavioral: Physical Impairment."
89377234|NCT03113344||Children with the usage of anti-infective drugs|
89377235|NCT03112954|Experimental|Buccal-relaxant formula|The buccal-relaxant formula used in this study contained 8 floral essences from native and non-native plants commonly grown in Brazil, developed at the Mater Gaia Institute. Each patient received a small amber glass bottle containing the floral remedy and was instructed to use four drops sublingually 4 times a day for 22 days.
89377236|NCT03112954|Experimental|Placebo|Each patient received a small amber glass bottle containing the placebo, and was instructed to use four drops sublingually 4 times a day for 22 days.
89377237|NCT03113266|Experimental|humanized anti-PD-1monoclonal antibody|humanized anti-PD-1 monoclonal antibody is to be injected intravenously 3mg/kg Q2w until disease progresses or unacceptable tolerability occurs
89377238|NCT02375230|Placebo Comparator|Control|"Control group~Health care provider randomized to the control group will receive a copy of the NRP text pages discussing MR SOPA at every shift for self-study. They will be encouraged by the educator to study these pages for five minutes at every shift. The educator will be there to answer questions if they arise."
89377239|NCT02375230|Active Comparator|MR SOPA|"Health care provider randomized to the MR SOPA group will receive MR SOPA training provided by a qualified educator on every shift. This training will be five minutes long and will consist of each MR SOPA step. These corrective steps will be demonstrated and practiced on a low-fidelity neonatal mannequin. Each participant will receive five minutes of training at the start of each shift.~The educator will teach mask adjustment, and airway reposition. If either of these first steps is unsuccessful the participant will learn about mouth and nose suction, open mouth and increase of airway pressure. All participants will also learn and practice alternative airways placement including intubation and laryngeal mask airway placement."
89377240|NCT02384590|Experimental|CCBT + Care Manager Arm|Patients will be given a tablet device with unlimited data. The device will be pre-installed with a pain and mood diary app that will prompt them to enter their pain severity (0-10), pain location, and mood (0-10), once a day. They will also be registered on to the Beating the Blues website and asked to use the tablet device to complete eight 1-hour Beating the Blues CBT sessions, over the next 3-months. They will also be introduced to a care manager who will contact them on a weekly basis by telephone and throughout the week by email or text, for one-month and then as needed for two additional months. At the conclusion of 3 months participants will only have care manager support upon request but are free to continue using the Beating the Blues program for as long as they like.
88850248|NCT00003812|Experimental|chemotherapy + radiation therapy|Patients receive topotecan IV on days 1-5 and paclitaxel IV over 3 hours on day 1. Filgrastim (G-CSF) is administered subcutaneously every day starting on day 6 until blood counts recover. The course is repeated once beginning on day 22. After restaging, patients begin thoracic radiotherapy daily, five days per week, for 6-7 weeks. On the same day that radiotherapy begins, patients receive carboplatin IV over 1 hour (day 43) and etoposide IV over 1 hour daily for 3 days (days 43-45). The consolidation chemotherapy is repeated every 21 days for a total of 3 courses. Patients with stable or responding disease undergo prophylactic cranial irradiation. Patients are followed at least every 3 months for 2 years, every 6 months for 3 years, and then at least every year.
88850249|NCT00003824|Experimental|cipro|ciprofloxacin
88850250|NCT00003824|Experimental|ceph|cephalexin
88850251|NCT04791319|Placebo Comparator|Group 1: Placebo|Participants will receive subcutaneous (SC) placebo once a week (qw) through Week 15. At Week 16, participants will crossover to receive SC bermekimab Dose 2 qw through Week 31.
88850252|NCT04791319|Experimental|Group 2: Bermekimab|Participant will receive SC bermekimab Dose 1 qw from Week 0 through Week 31.
88850253|NCT04791319|Experimental|Group 3: Bermekimab|Participants will receive SC bermekimab Dose 2 qw from Week 0 through Week 15. At Week 16, participants who achieve an eczema area and severity index (EASI)-75 response (responders) will be rerandomized either to continue to receive bermekimab Dose 2 qw, or to receive bermekimab Dose 1 qw, through Week 31 and participants who do not achieve an EASI-75 response (non responders) will continue to receive bermekimab Dose 2 qw through Week 31.
88850254|NCT04791319|Active Comparator|Group 4: Dupilumab|Participants will receive a loading dose of SC dupilumab Dose 1 at Week 0, SC placebo every two week (q2w) from Week 1 through Week 15 and then dupilumab Dose 2 q2w from Week 2 through Week 14. At Week 16, participants who achieve EASI-75 response (dupilumab responders) will continue on dupilumab Dose 2 q2w through Week 30 and placebo q2w from Week 17 through Week 31. Participants who do not achieve an EASI-75 response (dupilumab non-responders) will receive placebo qw from Week 16 through Week 18 (washout period) and bermekimab Dose 2 qw from Week 19 through Week 31.
89377241|NCT02384590|No Intervention|Treatment As Usual|Similar to the treatment arm, patients will be given a tablet device with unlimited data that comes pre-loaded with a pain and mood diary app. The app will prompt the usual care patients to complete diary data daily. No other activities are required as part of the study but the patients are free to use the tablet as much as they like for their own leisure. At the end of 3-months, patients who continue to report depressive or anxiety symptoms are invited to cross-over to the treatment arm where they will be registered for the Beating the Blues program and given care manger support.
89399402|NCT03686475|Experimental|Biodentine pulpotomy|Biodentine (Septodont, France) Pulpotomy for primary molars Clinical and radiographic evaluation Follow up at 1,3,6 and 12 months
88850255|NCT00005030|Experimental|SCH 66336|Starting dose of preoperative oral SCH 66336 100 mg twice daily for 7-14 days prior to exploratory laparotomy and/or resection of hepatic metastases with surgery between days 8-15.
88850256|NCT00005030|No Intervention|No Treatment|Patients randomized to no treatment may undergo surgery at any time within 15 days of randomization.
88850257|NCT05196373|Experimental|Part 1: Group 1|10ug Intrascar injection
88850258|NCT05196373|Experimental|Part 1: Group 2|20ug Intrascar injection
88850259|NCT05196373|Experimental|Part 1: Group 3|40ug Intrascar injection
88850260|NCT05196373|Experimental|Part 1: Group 4|60ug Intrascar injection
88850261|NCT05196373|Experimental|Part 1: Group 5|80ug Intrascar injection
88850262|NCT05196373|Experimental|Part 1: Group 6|100ug Intrascar injection
88850263|NCT00005036|Experimental|Arm I (irinotecan)|Patients receive irinotecan IV over 90 minutes on day 1. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.
89377242|NCT02384278|Experimental|Internet-based CBT for alcohol problems|A 12-week internet-based cognitive behavior treatment (CBT) and relapse prevention program. The subjects will have access to a psychologist guiding them through the program.
88850264|NCT00005036|Experimental|Arm II (oxalipatin, fluorouracil, leucovorin calcium)|Patients receive oxaliplatin IV over 2 hours on day 1, leucovorin calcium IV over 2 hours on days 1 and 2, and fluorouracil IV bolus followed by IV infusion over 22 hours on days 1 and 2. Treatment repeats every 2 weeks in the absence of disease progression or unacceptable toxicity.
88850265|NCT05454007|Experimental|Individuals with Stroke|In this single group, proof-of-principle design, all eligible participants will be assigned to a single group. These are individuals with stroke who meet inclusion and exclusion criteria. They will each undergo the same assessments and participate in a single walking training session.
88850266|NCT00003854|Experimental|Surgery + radiotherapy + adjuvant therapy|"Patients undergo bilateral anterior iliac crest bone marrow aspiration to test for presence of micrometastases. Patients then undergo breast-conserving therapy comprising segmental mastectomy and sentinel lymph node dissection (SLND) with planned postoperative whole-breast radiotherapy and systemic adjuvant therapy. The SLND comprises ipsilateral axillary sentinel node identification and histopathology.~Patients with no sentinel node identified intraoperatively and patients with sentinel node metastasis identified by hematoxylin and eosin (H&E) who choose not to be registered to ACOSOG-Z0011 undergo axillary lymph node dissection involving removal of at least level I and II nodes.~All patients undergo whole-breast radiotherapy (excluding a supraclavicular field) 5 days a week for a maximum of 8 weeks.~Patients are followed at 30 days; at 6, 12, 18, 24, 30, and 36 months; and then annually until 10 years after surgery."
88850267|NCT05450107|Experimental|Intervention|The intervention group is offered surgical treatment of the shaft fracture of the fifth metatarsal bone with ORIF. Depending on the type of shaft fracture this will be either lag screw fixation or plate fixation. After surgery a period of cast immobilisation with gradual increase of weight bearing will commence
88850268|NCT05450107|Active Comparator|Control|The control group (conservative treatment), will receive a period of cast immobilisation, with a gradual increase in weight bearing by protocol.
88850269|NCT05449639|Experimental|Main group|A second no-random open interventional pilot study sponsored by Relief srl. The primary objectives of the study were to assess the safety and reproducibility of the implantation of the magnetic endo-urethral sphincter, if the procedure was well tolerated by the patients, and if possible irritation symptoms due to the device presence emerged in patients with severe stress urinary incontinence where standard medical treatments failed. The device will be implanted by endoscopic procedure by a standard resectoscope. Up to 20 patients of both gender affected by severe stress urinary incontinence will be involved in the study by means of prospective enrollment.
88850270|NCT05444569|Experimental|LY3537021 + Liraglutide (Part A)|Liraglutide administered subcutaneously (SC) followed by liraglutide in combination with LY3537021 given SC.
89377243|NCT02379598||Amino acid based formula|
88850271|NCT05444569|Experimental|Liraglutide + Placebo (Part A)|Liraglutide administered SC followed by liraglutide in combination with placebo given SC.
88850272|NCT05444569|Experimental|LY3537021 + Liraglutide & Placebo + Liraglutide (Part B)|"LY3537021 administered SC followed by liraglutide administered SC in treatment period 1.~Placebo administered SC followed by liraglutide administered SC in treatment period 2."
88850273|NCT05444569|Experimental|Placebo + Liraglutide & LY3537021 + Liraglutide Part B)|"Placebo administered SC followed by liraglutide administered SC in treatment period 1.~LY3537021 administered SC followed by liraglutide administered SC in treatment period 2."
88850274|NCT04756765|Experimental|Talazoparib Arm|Talazoparib 1 mg/day for 24 cycles (28 days per cycle), continuing until withdrawn or discontinued, eg, until RECIST 1.1 progression or unacceptable toxicity.
88850275|NCT00004466|Experimental|Atorvastatin|
89182127|NCT04072731||thyroid cancer|the thyroid cancer was determined by the the Pathology Department based on the pathological evidence.
89182128|NCT04072731||the adjacent thyroid tissues|the adjacent thyroid tissues was collected from the tissue that 3 centimeters from the thyroid cancer.
88850276|NCT00004466|Placebo Comparator|Placebo|
88850277|NCT00385346|Experimental|A 1|Expressive writing
88850278|NCT00005060|Active Comparator|Taxotere-Cisplatin-5FU preoperatively|TCF preoperatively
88850279|NCT00005060|Active Comparator|Immediate surgery followed by TCF|Surgery followed by Taxotere-Cisplatin-5FU
89377244|NCT02379598||Whey protein formula|
89377245|NCT02379676|Experimental|Ticagrelor|Ticagrelor 90mg twice daily
88850280|NCT04723927||Older adults|The data for motor function and gait pattern analysis was obtained.
88850281|NCT04717297|Experimental|Tailored Medication Management Remote Intervention Treatment Arm|Participants receive a total of three visits (one evaluation/pre-treatment visit and 2 treatment visits) that last 75 minutes each over 4 weeks. Sessions/visits are spaced 1 week apart and will be delivered remotely.
88850282|NCT04717297|Sham Comparator|Waitlist Attention Control Arm|The attention control group will receive two, 75-minute attention visits with a trained research assistant. Upon completion of waitlist period, the participants in the waitlist group will be offered the intervention in person.
89377246|NCT02379676|Active Comparator|Clopidogrel|Clopidogrel 75mg once daily
89377247|NCT02379364|Experimental|Intervention group|Diacutaneous Fibrolysis treatment
89377248|NCT02379130|Experimental|Family Nurture Intervention Group|Children in the FNI group will continue to attend any intervention programs that they are already enrolled in. In addition, they will be asked to attend 1 clinic visit per week for 6 weeks over the course of 12 weeks. During each visit, the mother-child will meet with trained Nurture Specialists. The Nurture Specialists will facilitate and encourage the mother and child to engage in nurturing and calming activities, including sustained touch, vocal soothing, and an odor cloth exchange. FNI families will be asked to participate in a 6 month post-enrollment follow-up visit and a 12 month post-enrollment follow-up visit.
88850283|NCT04717297|Experimental|Tailored Medication Management In-Person Intervention Treatment Arm|Participants receive a total of three visits (one evaluation/pre-treatment visit and 2 treatment visits) that last 75 minutes each over 4 weeks. Sessions/visits are spaced 1 week apart and will be delivered in-person.
88850284|NCT00005066|Experimental|Arm A|O6-BG as an intravenous infusion (through your vein) over 1 hour followed 1 hour later by BCNU intravenously over 15 minutes. chemotherapy every 6 weeks.
89377249|NCT02379130|Active Comparator|Play and Nutrition Intervention Group|Children in the PNI group will continue to attend any intervention programs that they are already enrolled in. They will be asked to attend 1 clinic visit per week for 6 weeks over the course of 12 weeks to meet with clinical personnel who will collect measures regarding the child's behavior and development. At each visit, study staff will meet with mothers to facilitate a lesson plan on appropriate play and nutrition. NPI families will be asked to participate in a 6 month post-enrollment follow-up visit and a 12 month post-enrollment follow-up visit.
89377250|NCT02379286||14 to 17 years old French teenager|14 to 17 years old French teenager representative of French population from whom parental consent to particpare to the study has been given
89377251|NCT04439812||R=0|Patients without positive margins after gastrectomy for gastric cancer
88850285|NCT00005072|Experimental|Leuvectin|Leuvectin
88850286|NCT05138653|Experimental|Single Ascending Dose (SAD) Cohorts 1-3|In Cohorts 1 and 2, all participants will receive treatment with up to 3 single oral doses of CVL-354 and/or 1 single oral dose of placebo in a 4-period crossover design. The starting dose of CVL-354 will be 0.5 mg. Participants will be randomized to 1 of 4 treatment sequences. Cohort 3 may be used to evaluate additional doses or evaluate food effect, depending on the results from Cohorts 1 and 2.
88850287|NCT05138653|Experimental|Multiple Ascending Dose (MAD) Cohorts 1-5|All participants will receive treatment with multiple oral doses of CVL-354 (dose and regimen to be determined) or matching placebo for 14 days.
88850288|NCT05133895||Tocilizumab monotherapy|"Patients with a definite or possible diagnosis of CP at acute active stage were enrolled for this study. Clinical diagnostic criteria consist of: (1) imaging findings show perivascular soft tissue density mass surrounding thoracic aorta, abdominal aorta or iliac arteries; (2) histopathological findings show fibrous tissue with chronic inflammatory infiltrate comprised of lymphocytes, plasma cells and macrophages (Neutrophils and granulomas are rare). Patients who satisfied (1) but without histopathological examination were perceived as possible CP. Secondary forms of CP related to drugs, infections, malignancies, Erdheim-Chester disease or other autoimmune diseases were excluded.~Patients enrolled received intravenous infusions of TCZ (8 mg/kg) at inclusion and then every 4 weeks for at least 3 months."
89377252|NCT04439812||R=1|Patients with positive margins after gastrectomy for gastric cancer
89377253|NCT02375308|Experimental|Hypnotherapeutic Treatment|HDT (Hypnotherapeutic Treatment of Depression) focuses on the hypnotic activation and strengthening of individual resources, the use of regression techniques to rebuild positive and negative experiences and the development of positive imaginations for the future.
89377254|NCT02375308|Experimental|Cognitive Behavioral Treatment|ACDT (Activation-focussed Cognitive Treatment of Depression) focuses on psychoeducation, behavior activation, the use of cognitive techniques, and the improvement of social skills.
89377255|NCT02375074|Experimental|Supported Employment|Supported Employment (SE), focusing on competitive employment in real-life settings without long-lasting preceding training.
89377256|NCT02375074|Experimental|Traditional Vocational Rehabilitation|Traditional Vocational Rehabilitation (TVR), offering training and preparation for the labor market in a sheltered environment.
89377257|NCT02375152|Experimental|Surgical Intervention|
89377258|NCT03113032|Experimental|Exercise group 1|This group of patients will receive the P-SEC exercise intervention protocol on their 'surgical' leg in addition to their normal pre-surgical care.
89377259|NCT03113032|Experimental|Exercise group 2|This group of patients will receive the P-SEC exercise intervention protocol on their 'non-surgical' leg in addition to their normal pre-surgical care.
89377260|NCT03113032|Active Comparator|Control group|This group of patients will not receive the P-SEC protocol but will follow normal pre-surgical care along with the other two groups of patients.
88850289|NCT00003926|Experimental|Solid/brain tumor patients (1-18 years)|Patients with solid tumor or brain tumor in the 1-18 years old stratum.
88850290|NCT00003926|Experimental|Solid/brain tumor patients (19-45 years)|Patients with solid tumor or brain tumor in the 19-45 years old stratum.
88850291|NCT05122819|Experimental|Group A|Intraligamentary Injection by Jet Injector
88850292|NCT05122819|Experimental|Group B|Intraligamentary Injection by regular Dental Anesthesia Syringe
88850293|NCT05122819|Active Comparator|Group C|Inferior Alveolar Nerve Block
88850294|NCT00005090|Active Comparator|ABVD x 5 + ABVD x 3|Patients receive 5 28-day cycles of ABVD (doxorubicin 25 mg/m^2, bleomycin 10 U/m^2, vinblastine 6 mg/m^2, dacarbazine 375 mg/m^2 all on days 1 and 15). Patients with no disease progression are then randomized to either 3 more cycles of ABVD or 1 more cycle of ABVD + high-dose therapy + stem cell transplant.
88850295|NCT00005090|Experimental|ABVD x 5 + ABVD x 1 + HDT + PBSCT|Patients receive 5 28-day cycles of ABVD (doxorubicin 25 mg/m^2, bleomycin 10 U/m^2, vinblastine 6 mg/m^2, dacarbazine 375 mg/m^2 all on days 1 and 15). Patients with no disease progression are then randomized to either 3 more cycles of ABVD or 1 more cycle of ABVD + high-dose therapy + stem cell transplant. Patients randomized to the transplant arm have 2 x 10^6 CD34+ blood mononuclear cells/kg of actual body weight collected at day -7. High dose therapy consists of BCNU 150/m^2 on days -6 to -4, etoposide 60 mg/kg on day -4, and cyclophosphamide 100 mg/kg on day -2. Peripheral blood stem cells are infused on day 0.
88850296|NCT00005096|Experimental|Docetaxel|Docetaxel given via iv at determined dose once a week for 4 weeks
88850297|NCT00004604|Experimental|CEA RNA-pulsed DC cancer vaccine|carcinoembryonic antigen RNA-pulsed dendritic cells
88850298|NCT04648579|Experimental|Hillrom|The intervention involves an automated vital signs document system consisting of a mobile medical device for measuring vital signs (CSM / Hillrom) that collects and analyzes data acquired at the bedside to be sent to a remote data processing point (Digital Control Station), using Hillrom Connecta software.
88850299|NCT04648579|Active Comparator|Control|Hospital usual care.
88850300|NCT04624321|Experimental|Access to tool|Access to the digital tool. They use the tool at their own and do the different themes that are available. They are recommended to use it at least every other week.
88850301|NCT04624321|Placebo Comparator|Usual care|They are followed by their ordinary healthcare provider.
88850302|NCT05396755|Experimental|interventional|The intervention group undergoes scheduled invasive evaluation of the biliary tract with endoscopic retrograde cholangiography (ERC) with biliary interventions (i.e. therapeutic ERC) every 8 weeks for 6 months.
88850303|NCT05396755|No Intervention|control|The control group receives non-interventional standard of care.
88850304|NCT05091853|Active Comparator|Self-adhesive mesh|
88850305|NCT05091853|Active Comparator|Self-gripping mesh|
88850306|NCT04607551|Experimental|Prone positionning|
88850307|NCT04607551|Active Comparator|Supine position|
88850308|NCT04599361||Patients with CHD|"outpatient cardiology practices, hospitals with a cardiology department and hospitals with a cardiology and heart surgery department (n=20) in Germany Patients with chronic coronary heart disease and 2- or 3-vessel or main-vessel disease who are being treated at one of the recruitment sites with a promptly planned intervention for myocardial revascularization who are insured with pre-specified German health insurance companies (BARMER or TK)~Patients will receive questionnaires."
88850309|NCT04592731|Experimental|Gel containing Acetylated Natural Nucleotides|
88850310|NCT04592731|Placebo Comparator|Vehicle Gel|
88850311|NCT00005576|Experimental|Treatment (monoclonal antibody Ch14.18, aldesleukin)|Patients receive MOAB IV over 5 hours on days 7-10 during courses 2 and 4 and on days 3-6 during courses 1, 3, and 5; sargramostim (GM-CSF) IV over 2 hours or subcutaneously daily on days 0-13 during courses 1, 3, and 5; interleukin-2 IV continuously on days 0-3 and 7-10 during courses 2 and 4; and oral isotretinoin twice daily on days 14-27 during courses 2 and 4 and on days 10-23 during courses 3 and 5. Treatment repeats every 24-32 days for 5 courses in the absence of unacceptable toxicity.
88850312|NCT04713163||Health care or laboratory-based workers|Healthy individuals about to receive any approved COVID-19 vaccine
88850313|NCT04713163||Outpatients|Outpatients about to receive any approved COVID-19 vaccine
88850314|NCT04712929||Homogenous oral leukoplakia|"uniform, flat, thin, smooth/ wrinkled/corrugated surface throughout the white lesion.~Tab Fluconazole 100 mg as a mouthwash ( tablet dissolved in 10 ml of drinking water and used as a mouth rinse for 2 minute and swallowed) once a day for 14 days"
88850315|NCT04712929||Non-Homogenous oral leukoplakia|mixture of red and white lesions with a irregularly speckled/ nodular/ verrucous surface Tab Fluconazole 100 mg as a mouthwash ( tablet dissolved in 10 ml of drinking water and used as a mouth rinse for 2 minute and swallowed) once a day for 14 days
88850316|NCT04712929||Control group|30 healthy controls ( age and sex matched) would also be recruited from patients who are reporting for other routine dental problems.
88850317|NCT05082961|Other|X-ray photon therapy + biological samples|
88850318|NCT05082961|Other|Protontherapy + biological samples|
88850319|NCT00423254|Experimental|Low Dose Cohort|
88850320|NCT00423254|Experimental|High Dose Cohort|
88850321|NCT04552015|Other|volunteers|two different types of diagnostic tools (TST vs microneedle) will be used to screen for latent TB infection
88850322|NCT00005594|Experimental|ISIS 2503|All patients will begin treatment at a dose of 6 mg/kg/day of ISIS 2503. ISIS 2503 at the assigned dose will be given as a continuous i.v. infusion over the first 14 days of a 21-day treatment cycle. No drug will be administered during the third week of each treatment cycle.
88850323|NCT00005624|Experimental|CI-994 Treatment|Patients receive CI-994 orally daily. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients are followed for 30 days and then every 2 months.
88850324|NCT00382915||1|Smokers with schizophrenia
88850325|NCT00382915||2|Smokers with bipolar disorder
88850326|NCT00382915||3|Smokers without any mental illness
88850327|NCT00385502|Experimental|EcoNail™|econazole 5%/SEPA® 18% nail lacquer
88850328|NCT00005648|Experimental|001|Gemcitabine with R115777 R115777 200 mg oral twice daily at 12-hour intervals throughout the study coadministered with gemcitabine 1000 mg/m2 iv every week for the first 7 weeks followed by 1 week rest and then every 3 out of 4 weeks thereafter for up to 5 years
89377261|NCT03105544|Experimental|Intervention|Simulation-based training: Virtual-reality simulation training on the Medaphor Scantrainer Transabdominal Simulator until expert level is reached. Then training on a physical mannikin until an average OSAUS-score of 3 or more is attained.
89377262|NCT03105544|No Intervention|Control|No intervention.
89377263|NCT03105622|Experimental|Running+screen|Running on a treadmill at 60% VO2peak for 30 minutes while watching television.
89377264|NCT03105622|Experimental|Running+music|Running on a treadmill at 60% VO2peak for 30 minutes while listening to music.
89377265|NCT03105622|Experimental|Running without stimulus (control condition)|Running on a treadmill at 60% VO2peak for 30 minutes with no other stimuli.
89377266|NCT02374996||APIGT|Bipolar subjects treated with antipsychotics and having impaired glucose tolerance
88850329|NCT00005648|Placebo Comparator|002|Gemcitabine with Placebo Placebo oral twice daily at 12-hour intervals throughout the study coadministered with gemcitabine 1000 mg/m2 iv every week for the first 7 weeks followed by 1 week rest and then every 3 out of 4 weeks thereafter for up to 5 years
89377267|NCT02374996||APNGT|Bipolar subjects treated with antipsychotics and having normal glucose tolerance
89377268|NCT02374996||LINGT|Bipolar subjects treated with lithium and having normal glucose tolerance
89377269|NCT02374762||Hemodialysis Patients with AVF|Hemodialysis patients that use an arteriovenous fistula (AVF) to receive their dialysis treatments will be invited to have their AVF recorded by a digital camera for one minute prior to cannulation.
89377270|NCT02378896|Experimental|CBT + Personalized Computer Program|Cognitive Behavioral Therapy (CBT), consisting of Exposure and Ritual Prevention Therapy and training with a personalized computerized inhibitory training program
88850330|NCT00382447|Experimental|1|Standard nebulizer versus standard breath actuated nebulizer
88850331|NCT04504747||RH+|Prospective blood and biopsie analyses
88850332|NCT04504747||HER2+|Prospective blood and biopsie analyses
88850333|NCT04504747||TN|Prospective blood and biopsie analyses
89377271|NCT02378818|Other|Schizophrenia patients|35 patients, Age between 18 and 65 years, with a diagnosis of schizophrenia and unchanged psychotropic treatment for at least three months before inclusion.
89377272|NCT02378818|Other|Healthy volunteers (schizophrenia)|35 healthy volunteers
89182129|NCT03478267||Fetal heart rate 110-130 bpm|Pregnancies in which the fetal baseline heart rate is between 110 beats per minute and 130 beats per minute.
89182130|NCT03478267||Fetal heart rate 140-160 bpm|Pregnancies in which the fetal baseline heart rate is between 140 beats per minute and 160 beats per minute.
89377273|NCT02378818|Other|Depressive patients|
89377274|NCT02378818|Other|Healthy volunteers (depression)|
88850334|NCT00386282|Other|mifepristone-misoprostol treatment|200 mg mifepristone followed by 800 mcg buccal misoprostol 24-48 hours after the mifepristone
88850335|NCT05323903|No Intervention|Control Group|Postpartum Hemorrhage and Its Management course
88850336|NCT05323903|Experimental|Intervention Group 1- Telesimulation|Postpartum Hemorrhage and Its Management course, Telesimulation application
88850337|NCT05323903|Experimental|Intervention Group 2- Kahoot|Postpartum Hemorrhage and Its Management course, Kahoot game
89377275|NCT02374684|Experimental|Methosulide|Methosulide, oral administration
88850338|NCT05323903|Experimental|Intervention Group 3-Telesimulation and Kahoot|Postpartum Hemorrhage and Its Management course, Telesimulation application and Kahoot game
88850339|NCT04452955|Experimental|PRL3-zumab|All patients will receive PRL3-zumab until clinical progression per RECIST v1.1 and iRECIST criteria, or unacceptable toxicity, or withdraws consent.
88850340|NCT05305573|Experimental|COVID-19 Vaccine HIPRA 40 ug/dose|
88850341|NCT05305573|Active Comparator|Comirnaty (Pfizer-BioNtech) 30 ug/dose concentrate for dispersion for injection|
88850342|NCT04447807|Experimental|Group A: Metacognitive Training Intervention|"Participants of this group will undergo Metacognitive Training (MCT) in group format for the duration of 9 weeks. The intervention will be held once a week, with an estimated duration of 1-2 hours. The MCT intervention focuses on rehabilitating Social Cognition and teaching skills of interpersonal relations, as well as functional remediation aspects.~We estimate a total of 26 participants in this group."
89377276|NCT02374684|Placebo Comparator|Placebo|Placebo, oral administration
89377277|NCT02374528|Experimental|Negative pressure wound therapy|Negative pressure wound therapy (NPWT) is the application of suction (negative pressure) to wounds with skin grafting.
89377278|NCT02374528|Active Comparator|standard pressure bolster dressing|This method is traditional used in skin grafting wound.
89377279|NCT02378740|Placebo Comparator|Placebo|Placebo (.9 sterile normal saline) administered IV
88850343|NCT04447807|Experimental|Group B: Treatment as Usual|Participants of this group will continue to receive medical attention in the Bipolar Disorder Program -PROMAN- part of the University of São Paulo Medical School, although they will not be part taking in any group rehabilitation format We estimate a total of 26 participants in this group.
88850344|NCT00005774|Experimental|Early surfactant group|
89182131|NCT04086420|Experimental|Mindfulness|Delivered through an audio-recording consisting of a single meditation exercise that lasted for 30 minutes
89377280|NCT02378740|Active Comparator|Ketamine|"The study drug (either ketamine or saline) will be administered from the beginning of anesthesia through the commencement of wound closure to provide the following dose of ketamine:~0.5 mg/kg loading dose 8.3 mcg/kg/min (0.5 mg/kg/hr) infusion"
89377281|NCT02383732|Experimental|Treatment|Pediatric subjects between the age of 4-12 years with autistic spectrum disorder and elopement will begin the Elopement Prevention and Safety Training (EPST) program. EPST includes up to 12 120-minute weekly sessions delivered over approximately 12-14 weeks. EPST is a modular treatment, with three components: 1) Universal Safety Measures (USM), 2) Proximity training, and 3) Check-in training. All participants receive the USM module in the first two sessions. They then receive either the Proximity training or Check-in training module depending on the type of elopement exhibited by the child (i.e., bolting vs. wandering).
89399403|NCT03686475|Active Comparator|MTA pulpotomy|"MTA (Angelus- Londrina, Brazil) Pulpotomy for primary molars . it is fine hydrophilic powder consisting of tricalcium silicate, tricalicum aluminate, tricalcium oxide, silicate oxide and bismuth oxide11.~It is currently being used in pulpotomy of primary molars with a high rate of success.~Clinical and radiographic evaluation. Follow up at 1,3,6 and 12 months"
88850345|NCT00005774|Active Comparator|Standard Practice group|
88850346|NCT00005786|Experimental|Treatment (arsenic trioxide)|Patients receive arsenic trioxide IV over 1-4 hours on days 1-5. Treatment repeats every 21 days for a maximum of 6 courses in the absence of unacceptable toxicity or disease progression. Patients with responding or stable disease may receive 6 additional courses.
88850347|NCT00005792|Experimental|MTV|Melphalan Topotecan Etoposide VP-16 Phosphate autologous stem cell transplant
88850348|NCT00005798|Other|CTC Conditioning Regimen|Cyclophosphamide Thiotepa Carboplatin
88850349|NCT00005810|Experimental|Estramustine + docetaxel + carboplatin+ filgrastim|Patients receive oral estramustine 3 times daily on days 1-5. Patients receive docetaxel IV over 1 hour followed by carboplatin IV over 1 hour on day 2. Filgrastim (G-CSF) SC is administered beginning on day 6 and continuing until hematopoietic recovery. Treatment continues every 21 days in the absence of unacceptable toxicity or disease progression. Patients are followed every 3 months for a maximum of 2 years.
88850350|NCT05303623|Experimental|Conventional Physiotherapy|"In the intensive care unit and who had mechanical ventilation for more than 48 hours and who were extubated. Medical, physical and respiratory examination in this group Physical Function Test in Intensive Care (PFIT), maximum inspiratory mouth pressure and maximum expiratory mouth pressure, Medical Research Council Muscle Strength Test and diaphragmatic function with B mode and M mode ultrasonographic assessment.~In this group will apply only conventional physiotherapy. Conventional physiotherapy to contain breathing and,thoracal expansion exercises, bronchial hygiene techniques and gradual mobilization. Conventional physiotherapy apply for 5 days after extubation period 1 time a day."
88850351|NCT05303623|Experimental|Conventional Physiotherapy + inspiratory muscle training|"Physical ,medical and respiratory examination in this group Physical Function Test in Intensive Care (PFIT), maximum inspiratory mouth pressure and maximum expiratory mouth pressure, Medical Research Council Muscle Strength Test and diaphragmatic function with B mode and M mode ultrasonographic assessment. In this group, inspiratory muscle training will be applied in addition to conventional physiotherapy.~Inspiratory muscle training apply for 5 days after extubation period. Inspiratory muscle training will be given with a threshold loading by giving resistance at 30-40% of the maximum inspiratory pressure measurement obtained. The subjects in this group will be given inspiratory muscle training 4 sets with 6-10 breaths per set, 1-2 minutes between each set once a day in addition to conventional physiotherapy."
88850352|NCT05303623|Experimental|Healthy Subject|In the group consisting of healthy volunteers, which will be taken to determine the normative values of the outcome measurements for diaphragmatic tissue Doppler imaging and ultrasonographic evaluation, 2 sessions a day with a threshold-loaded inspiratory muscle training device, starting at 30% of the MIP value, 5 days a week for 4 weeks. Inspiratory muscle training will be performed in 4 sets, 6-8 breaths in each set and 2 minutes rest between sets. In the second evaluation to be made after the inspiratory muscle training, the above-mentioned evaluations and measurements will be repeated.
88850353|NCT00385970|Active Comparator|1|UFT+LV Group: The group treated with UFT and LV
88850354|NCT00385970|Experimental|2|UFT+PSK Group: The group treated with of UFT and PSK
89377282|NCT02383732|Active Comparator|Waitlist Control|Pediatric subjects between the age of 4-12 years with autistic spectrum disorder and elopement will be assigned to the Waitlist Control group. The subjects will be offered the intervention after completion of the 12-week waiting period. The subjects will then begin the Elopement Prevention and Safety Training (EPST) program. EPST includes up to 12 120-minute weekly sessions delivered over approximately 12-14 weeks. EPST is a modular treatment, with three components: 1) Universal Safety Measures (USM), 2) Proximity training, and 3) Check-in training. All participants receive the USM module in the first two sessions. They then receive either the Proximity training or Check-in training module depending on the type of elopement exhibited by the child (i.e., bolting vs. wandering).
89182132|NCT04086420|Active Comparator|Heart-Rate|Given a heart rate monitor and instructed to use it to determine the intensity of their exercise
89182133|NCT00756002|Experimental|Ramelteon 4 mg QD|
88850355|NCT05006677||non-vitamin K antagonist oral anticoagulants (NOACs)|
88850356|NCT05006677||vitamin K antagonists (VKAs)|
88850357|NCT05006677||antiplatelet agents|
88850358|NCT05006677||non-antithrombotic therapy|
89377283|NCT01411267|Experimental|ALL AC220 @ 25mg/m2/day (Dose Level 1)|The starting dose is Dose Level 1 at 25 mg/m2/day. Dose escalation will proceed from level 1 to 2 to 3, and so on, assuming the maximum tolerated dose is not exceeded. Patients will received etoposide and cytarabine on Days 1-5, and AC220 on Day 7 through 28. IT Methotrexate will be given to patients with ALL on Day 0, dose assigned by age.
88850359|NCT00386048||Standard of Care Observation Group|This group is randomized to continue their current medical management strategies for pain as recommended/prescribed by health care providers. Primary and secondary outcomes are collected at the same time intervals as the biopsychosocial intervention group.
89182134|NCT00756002|Placebo Comparator|Placebo QD|
89377284|NCT01411267|Experimental|AML AC220 @ 25mg/m2/day (Dose Level 1)|The starting dose is Dose Level 1 at 25 mg/m2/day. Dose escalation will proceed from level 1 to 2 to 3, and so on, assuming the maximum tolerated dose is not exceeded. Patients will received etoposide and cytarabine on Days 1-5, and AC220 on Day 7 through 28. IT cytarabine will be given to patients with AML on Day 0, dose assigned by age.
89377285|NCT01411267|Experimental|ALL AC220 @ 40mg/m2/day (Dose Level 2)|Dose escalation will proceed from level 1 to level 2 for AC220 at 40mg/m2/day, assuming the maximum tolerated dose is not exceeded. Patients will received etoposide and cytarabine on Days 1-5, and AC220 on Day 7 through 28. IT Methotrexate will be given to patients with ALL on Day 0, dose assigned by age.
89377286|NCT01411267|Experimental|ALL AC220 @ 60mg/m2/day (Dose Level 3)|Dose escalation will proceed from level 2 to 3 for AC220 at 60mg/m2/day, assuming the maximum tolerated dose is not exceeded. Patients will received etoposide and cytarabine on Days 1-5, and AC220 on Day 7 through 28. IT Methotrexate will be given to patients with ALL on Day 0, dose assigned by age. If toxicity at Dose Level 3 would allow further escalation, but demonstrated sufficient AC220 activity, no further dose escalation will be required.
89399404|NCT02175446|Experimental|Experimental1|"Bevacizumab and eribulin~In this study all patients will receive:~Eribulin 1.23 mg/m2 on days 1, 8 every 3 weeks intravenously~Bevacizumab 15 mg/kg every 3 weeks intravenously or Bevacizumab 10 mg/kg every 2 weeks intravenously"
88850360|NCT00386048||Biopsychosocial Intervention Group|This group continues all standard of care procedures for managing pain and adds to this additional cognitive-behavioral treatment (CBT) strategies for managing pain. The intervention explicitly frames the CBT strategies as added, complimentary pain management methods to add to the standard of care treatment.
88850361|NCT04421443|Active Comparator|3 days before intervention|Participants have to complete a pre-treatment assessment (baseline) for 3 days.
88850362|NCT04421443|Active Comparator|5 days before intervention|Participants have to complete a pre-treatment assessment (baseline) for 5 days.
88850363|NCT04421443|Active Comparator|8 days before intervention|Participants have to complete a pre-treatment assessment (baseline) for 8 days.
88850364|NCT04399993|Experimental|Intervention Protocol in Diaphragm|"In each volunteer, after a brief questionnaire, it will be measured the center of gravity and the range of movement of the lumbar spine before the technique.~Each volunteer will stay in supine position with arms along their body, in which their legs may be either extended or flexed.~Next, the researcher will perform the intervention protocol in Diaphragm. Then, all the measurements described before, will be repeated by the assessor right after the technique."
88850365|NCT04399993|Sham Comparator|Sham Technique|"In each volunteer, after a brief questionnaire, it will be measured the center of gravity and the range of movement of the lumbar spine before the technique.~Each volunteer will stay in supine position with arms along their body, in which their legs may be either extended or flexed.~Next, the researcher will perform the Sham technique. Then, all the measurements described before, will be repeated by the assessor right after the technique."
88850366|NCT05293093|Experimental|Wheelchair Skills Training Program intervention study|A one-group pretest-posttest design study will be conducted, consisting of three phases (3- or 5-week baseline phase, 4-week training phase, 4-week retention phase)
88850367|NCT04568330|Other|Best support care (BSC)|Interventions for comparison group (group C) who received BSC alone were (1) informed of potential presentations of HFSR, (2) asked for wearing waterproof gloves before execute household or work with water, (3) provided the method of contacting with healthcare specialists for confirming early diagnosis of HFSR, and (4) asked for self-report when they occurred symptoms of HFSR.
88850368|NCT04568330|Experimental|BSC plus moisture cream|The A group with BCS plus moisturizing cream received the interventions as the comparison group, was given the moisturizing cream (dimethicone, fragrance free, Aveeno, United States) for 9 times and was instructed how to use the cream. The education of usage included (1) using the cream twice a day from 3 days before starting sorafenib and each week post starting sorafenib, (2) scooping out nut-sized cream with a unique spoon each time, (3) gently applied the cream evenly on symmetrical palms below wrists and symmetrical soles below ankles each time, (4) wore unique cotton gloves immediately after the appalment of cream for 30 minutes each time.
88850369|NCT04568330|Active Comparator|10% urea-based cream|The B group with BCS plus 10% urea-based cream had the similar interventions as the A group with BCS plus moisturizing cream except being given the cream container with different component (10% urea; Sipharr, Taiwan). The outlook of the containers with the two kinds of cream was the same. All the cream looks white and grey.
88850370|NCT04569890|Experimental|CZP|Certolizumab pegol: subcutaneous CZP at 200mg twice a week.
89182135|NCT04017403|Experimental|Probiotic group|The probiotic group was treated with Bifidobacterium tripleis,one day before surgery to the sixth day after surgerythe drug is taken orally, 4 capsules at a time, 2 times a day.
89182136|NCT04017403|Placebo Comparator|Placebo group|The control group was given the same package of placebo,one day before surgery to the sixth day after surgery. The drug is taken orally, 4 capsules at a time, 2 times a day.
89377287|NCT01411267|Experimental|ALL AC220 @ 90mg/m2/day (Dose Level 4)|If the study dose of 60 mg/m2/day at Dose Level 3 is well tolerated but does not show sufficient AC220 activity, the study may proceed to Dose Level 4 at 90 mg/m2/day. Patients will received etoposide and cytarabine on Days 1-5, and AC220 on Day 7 through 28. IT Methotrexate will be given to patients with ALL on Day 0, dose assigned by age. If toxicity at Dose Level 4 would allow further escalation, but demonstrated sufficient AC220 activity, no further dose escalation will be required.
89377288|NCT01411267|Experimental|ALL AC220 @ 130 mg/m2/day (Dose Level 5)|If the study dose of 90 mg/m2/day at Dose Level 4 is well tolerated but does not show sufficient AC220 activity, the study may proceed to Dose Level 5 at 130 mg/m2/day. Patients will received etoposide and cytarabine on Days 1-5, and AC220 on Day 7 through 28. IT Methotrexate will be given to patients with ALL on Day 0, dose assigned by age. Dose Level 5 is the highest dose for this study.
89377289|NCT01411267|Experimental|AML AC220 @ 40mg/m2/day (Dose Level 2)|Dose escalation will proceed from level 1 to level 2 for AC220 at 40mg/m2/day, assuming the maximum tolerated dose is not exceeded. Patients will received etoposide and cytarabine on Days 1-5, and AC220 on Day 7 through 28. IT cytarabine will be given to patients with AML on Day 0, dose assigned by age.
89377290|NCT01411267|Experimental|AML AC220 @ 60mg/m2/day (Dose Level 3)|Dose escalation will proceed from level 2 to 3 for AC220 at 60mg/m2/day, assuming the maximum tolerated dose is not exceeded. Patients will received etoposide and cytarabine on Days 1-5, and AC220 on Day 7 through 28. IT cytarabine will be given to patients with AML on Day 0, dose assigned by age. If toxicity at Dose Level 3 would allow further escalation, but demonstrated sufficient AC220 activity, no further dose escalation will be required.
89377291|NCT01411267|Experimental|AML AC220 @ 90mg/m2/day (Dose Level 4)|If the study dose of 60 mg/m2/day at Dose Level 3 is well tolerated but does not show sufficient AC220 activity, the study may proceed to Dose Level 4 at 90 mg/m2/day. Patients will received etoposide and cytarabine on Days 1-5, and AC220 on Day 7 through 28. IT cytarabine will be given to patients with AML on Day 0, dose assigned by age. If toxicity at Dose Level 4 would allow further escalation, but demonstrated sufficient AC220 activity, no further dose escalation will be required.
89377292|NCT01411267|Experimental|AML AC220 @ 130mg/m2/day (Dose Level 5)|If the study dose of 90 mg/m2/day at Dose Level 4 is well tolerated but does not show sufficient AC220 activity, the study may proceed to Dose Level 5 at 130 mg/m2/day. Patients will received etoposide and cytarabine on Days 1-5, and AC220 on Day 7 through 28. IT cytarabine will be given to patients with AML on Day 0, dose assigned by age. Dose Level 5 is the highest dose for this study.
89377293|NCT02378584|Other|natural cycle|Ultrasound controls and endocrine blood test to asses the day of ovulation for embryo transfer
89377294|NCT02378584|Active Comparator|hormonal cycle|Ultrasound controls and endocrine blood test to asses the endometrium thickness for embryo transfer
89377295|NCT03113110|Other|Empagliflozin Arm|Posttransplant Diabetes Mellitus (PTDM) patients after kidney transplantation receiving Empagliflozin 10 MG [Jardiance]
89377296|NCT02661880|Experimental|listening to preferred music choices|All patients will be invited to complete the McGill Quality of Life Questionnaire - Revised (McGill QOL-R) upon admission to the unit. The Questionnaire will not be part of the permanent medical record and the participants will remain anonymous. Afterwards participants will be asked if they would like to listen to music during their stay in the hospital. Music will be selected according to their choices from an i-Tunes playlist. Participants will be invited to listen to music at their own discretion. Prior to discharge from the hospital or after 3 days all willing participants will be again invited to complete the McGill QOL-R questionnaire.
89377297|NCT03306277|Experimental|Onasemnogene Abeparvovec-xioi|One-time Intravenous administration of onasemnogene abeparvovec-xioi at the therapeutic dose.
88850371|NCT04569890|Active Comparator|GC+HCQ|"Hydroxychloroquine: HCQ at 200mg daily, and if tolerated, escalated to 400 mg daily.~Glucocorticoid: continuous usage GC at 10mg a day from Week 0 to Week 52.~At 24 week, non-responders (ΔDAS28<0.6) will switch to the other group. Participants switched to CZP group will taper their dose of GC gradually, if they have an improvement in disease activity (two successive DAS28<2.6). If participants have a disease flare (increased DAS28>0.6) during a reduction in corticosteroid dose, then they will resume their previous dose. Weekly step-down GC scheme: 10mg-7.5mg-5mg-2.5mg-0mg."
88850372|NCT04569500|Experimental|PETAL program|Patients with total laryngectomy and their close relatives, benefiting from the therapeutic education program PETAL
88850373|NCT04569500|No Intervention|Usual care|Patients with total laryngectomy and their close relatives, benefiting from the usual care
88850374|NCT04485637|Other|Communication with basic table|Blood pressure communication showing a basic table representing only the normal range of blood pressure readings
88850375|NCT04485637|Other|Communication with enhanced table|Communication showing an enhanced table (Fig 1B) with more reference information for interpreting blood pressure readings, including how combinations of diastolic and systolic blood pressure reflect normal, elevated and hypertension ranges (adapted from the American Heart Association)
88850376|NCT04485637|Other|Communication with enhanced graph|Communication showing an enhanced graph (adapted from Blood Pressure UK) for interpreting blood pressure readings, showing the same color-coded ranges as the enhanced table, with diastolic blood pressure on the x-axis and systolic blood pressure on the y-axis
89377298|NCT02383888|Placebo Comparator|Matching placebo for each dose groups|
89377299|NCT02383888|Experimental|BI 425809 Active dose group 1|
89377300|NCT02383888|Experimental|BI 425809 Active dose group 2|
89377301|NCT02383888|Experimental|Bi 425809 Active dose group 3|
89377302|NCT04664569||Cohort of bacterial meningitis in children|
89377303|NCT02378194|Placebo Comparator|Placebo group|
89377304|NCT02378194|Experimental|HD-003 (800mg/day)|
89377305|NCT02378194|Experimental|HD-003 (1600mg/day)|
89377306|NCT00579709|Experimental|1|Thymus Tissue for Transplantation
89377307|NCT02374294|Experimental|Epiflo|After the surgery, but before the application of dressing to the surgical site the kit containing the investigation device (and four cannula) is opened. The EPIFLO cannula (sterile package) is opened and applied to the surgical site and sealed with the dressings per protocol. The EPIFLO device is connected to the cannula after making sure the switch is in the ON position.The EPIFLO device is mounted on the patient's body in a convenient location using the Pouch and Arm band provided. At Treatment Visit 3 (Postoperative day #14, +/- 1 day) a new device is given and the old one disposed of. Intermittent dressing changes will take place as needed.
89377308|NCT02374294|No Intervention|Standard of Care|After the surgery, but before the application of dressing to the surgical site if upon opening, the kit contains only a weighted block, then, the regular wound dressing protocol, standard of care, will be followed. Intermittent dressing changes will take place as needed.
89377309|NCT02374216|Other|Dental implants|Evaluation of the failure rate of all dental implants, of any brand, inserted between September 1st 2014 and August 31st 2017
89377310|NCT02383498|Experimental|Vaccine|Radiation + GI-6301 Vaccine + Actigraph
89377311|NCT02383498|Placebo Comparator|Placebo|Radiation + GI-6301 Placebo + Actigraph
89377312|NCT02378350|Active Comparator|ESRD patients receiving HD treatment|no investigational drug involved. Only observe therapy treatment
89377313|NCT02378350|Experimental|ESRD patients receiving PD treatment|no investigational drug involved. Only observe therapy treatment
89377314|NCT02383654|Other|Compassionate Treatment|ALS patients are received Intravenous and intracerebral implantation of Autologous Adipose-Tissue Derived Stem Cells (ADSCs), Rehabilitation.
89377315|NCT02378116|No Intervention|Control|On the control group is done MRI scans of the brain, and patients can be elected for monitoring and/or bicycle stress test to test for neurohormones.
89377316|NCT02378116|Active Comparator|Surgical Closure|During open heart surgery, the surgeon closes the left atrial appendage. The research group recommend a double closure with both a ligation and suture, but a single suture is also accepted.
89377317|NCT02377960|Active Comparator|Usual care (Reference group)|Treatment is leaded by treating physician according to national guide lines with no study-specific medication or clinical appointment protocol.
89377318|NCT02377960|Experimental|An IMB model-based initiation of medication|"In addition to usual care, participants allocated to intervention group will receive~An IMB model-based initiation of medication i.e. a nine-point check list to be fulfilled by physician and patient together when ordering the antihypertensive medication for the first time"
89377319|NCT02377960|Experimental|Tailored SMS-text message support|"Tailored SMS-text message support for the first 12 months of medication. At the beginning (2 weeks), text messages are send on daily basis and focused on medications-reminders and coping with potential side-effects of medication.~After that, text messages will be sent less often and the focus will change to keeping up with medication and reminding of importance of performing adequate home BP self-monitoring, achieving the BP target and attending clinical appointments."
88850377|NCT04569812|Experimental|Standard CPR|After Informed Consent Document (ICD) signature, participants were randomised (to the Standard CPR group) to perform standard CPR (30:2) in a flowchart-assisted resuscitation for 5min in a manikin model
89377320|NCT02377804|Experimental|Experimental intervention|The experimental intervention will consist of 3 sessions, one per week, of 45min of physical therapy including mobilizations of the scapular region, manual therapies targeted to decrease muscle tone, neuromodulatory techniques for spasticity and proprioceptive exercises for the upper extremity. In addition, during this intervention patients will also receive deep dry needling with disposable stainless steel needles (0.3mm x 50mm) that will be inserted into the skin over taut bands of the spastic musculature of the shoulder area: upper trapezius, subscapularis, infraspinatus, and pectoralis mayor
88850378|NCT04569812|Experimental|Chest compressions only|After ICD signature, participants were randomised (to the CC only CPR group) to perform chest compressions only in a flowchart-assisted resuscitation for 5min in a manikin model
88850379|NCT04569656|Experimental|treatment|6 week treatment with Stick pack 30 ml containing PHGG 5 gr e Hyaluronic Acid 200 mg
88850380|NCT04569578|Experimental|Policy|The policy will be implemented on preschool level.
88850381|NCT04569578|No Intervention|Regular practice|The control preschool will continue their regular practice.
88850382|NCT04569188|Experimental|convalescent plasma|Cohort of elderly patients treated with convalescent plasma
88850383|NCT04568876|Active Comparator|PEA Group|Normast® MPS (mPEA and umPEA 300mg + 600mg) oral suspension: 2700mg/die in 3 doses for 28 days, in add-on to standard therapy
89377321|NCT02377804|Active Comparator|Control intervention|The control intervention will consist of 3 sessions, one per week, of 45min of physical therapy including mobilizations of the scapular region, manual therapies targeted to decrease muscle tone, neuromodulatory techniques for spasticity and proprioceptive exercises for the upper extremity.
89377322|NCT02373748|Experimental|BioGaming YuGo System|
88850384|NCT04568876|Other|Control Group|Standard therapy only
88850385|NCT04375657|Experimental|TRIIM Treatment|
88850386|NCT04375657|Active Comparator|Active Control|
88850387|NCT02210468|Experimental|APIC-CF 4cc,|APIC-CF 4cc, once at first day
88850388|NCT02210468|Experimental|APIC-CF, 2cc|APIC-CF, 2cc, one at first day
88850389|NCT02210468|Placebo Comparator|Saline|
88850390|NCT04265287||Pediatric patients with severe pneumonia|Pediatric patients admitted to PICU due to severe pneumonia
88850391|NCT02210546|Experimental|Magnetic Resonance Imaging (MRI)|Patients will undergo MRI yearly
88850392|NCT02210546|Other|Mammography (Mx) + ultrasonography (US)|Patients will undergo yearly two-view (Mx) and breast US
88850393|NCT02210624|Experimental|Single arm|"Experimental: HYNR-CS inj.~Treatment group with HYNR-CS inj."
89182137|NCT00717366|Experimental|MIRCERA Group 1: Intermediate-Conversion-Factor Group|Participants will receive methoxy polyethylene glycol-epoetin beta (MIRCERA) IV injection at a starting dose based on an intermediate conversion factor from their previous Erythropoiesis-stimulating Agent (ESA) dose (4 * previous weekly epoetin dose [international units {IU}]/250 or 4 * previous weekly darbepoetin alfa dose [micrograms {mcg}]/1.1) once every 4 weeks for 20 weeks. Participants who will complete the 20 weeks of treatment with hemoglobin (Hb) level within ± 1 grams per deciliter (g/dL) of their baseline Hb level and within the target range of 10-12 g/dL will enter an optional 52-weeks safety extension period. During this period, the participants will continue to receive MIRCERA IV injection once every 4 weeks.
89182138|NCT00717366|Experimental|MIRCERA Group 2: High-Conversion-Factor Group|Participants will receive MIRCERA IV injection based on a high conversion factor from their previous ESA dose (4 * previous weekly epoetin dose [IU]/125 or 4 * previous weekly darbepoetin alfa dose [mcg]/0.55) once every 4 weeks for 20 weeks. Participants who will complete the 20 weeks of treatment with Hb within ± 1 g/dL of their baseline Hb and within the target range of 10-12 g/dL will enter an optional 52-weeks safety extension period. During this period, the participants will continue to receive MIRCERA IV injection once every 4 weeks.
89182139|NCT02939989|Experimental|Glecaprevir/Pibrentasvir + SOF + RBV for 12 weeks|Participants without cirrhosis who had non-genotype 3 infection and were naïve to protease inhibitor (PI) and/or nonstructural viral protein 5A inhibitor (NS5Ai) prior to participation in AbbVie HCV parent study received daily treatment with glecaprevir/pibrentasvir (GLE/PIB) 300 mg/120 mg plus sofosbuvir (SOF) 400 mg plus twice-daily weight-based ribavirin (RBV) 600 mg - 1200 mg daily total for 12 weeks.
89182140|NCT02939989|Experimental|Glecaprevir/Pibrentasvir + SOF + RBV for 16 weeks|Participants with genotype 3, and/or compensated cirrhosis, and/or experience with PI and/or NS5Ai prior to participation in Abbvie HCV parent study received daily treatment with GLE/PIB 300 mg/120 mg plus SOF 400 mg plus twice-daily weight-based RBV 600 mg - 1200 mg daily total for 16 weeks.
89182141|NCT04096742|Experimental|Altreno|tretinoin 0.05% lotion (Altreno)
89182142|NCT04096742|Sham Comparator|Vehicle|Vehicle lotion not containing tretinoin
89182143|NCT04085640|Experimental|Obturator nerve block with Ropivacaine|Obturator nerve block will be performed before general anesthesia as descripted by Nielsen (RAPM, 2019). A linear transducer will be oriented in the transverse plane and placed in the inguinal crease. The tail of the transducer will be tilted distal in order to visualize the pectineus muscle (medial to the femoral vessels) at its insertion at the superior pubic ramus superficial to the external obturator muscle. An 80 mm nerve block needlewill be inserted in-plane from the lateral end of the transducer and advanced until the tip of the needle will be inside the interfascial plane between the pectineus and the obturator externus muscles. 20 milliliters of ropivacaine 2 mg/mL will be injected in the interfacial plane between the pectineus and external obturator muscles.
89182144|NCT04085640|Sham Comparator|Obturator nerve block with isotonic salin|The same procedure will be performed and 20 milliliters of isotonic saline will be injected in the interfacial plane between the pectineus and external obturator muscles
89182145|NCT02600858|Experimental|"Training off medication"|"Participants will train on the upper limb feeding task before taking their first daily dose of standard dopamine medication for Parkinson's disease, i.e. while off dopamine replacement medication"
89182146|NCT02600858|Other|"Training on medication"|"Participants will train on the upper limb feeding task after taking their first daily dose of standard dopamine medication for Parkinson's disease, i.e. while on dopamine replacement medication"
89182147|NCT03994315|Experimental|B. infantis EVC001 + LNT (3 g/L then 8 g/L)|Infants will receive a once-daily oral feeding of B. infantis EVC001 (8.0 x 10^9 CFU) mixed with infant formula for 28 consecutive days. Group 1 [B. infantis + LNT (3 g/L then 8 g/L)] will also receive two dose-escalated concentrations of the prebiotic supplement (LNT) mixed with their infant formula for every formula preparation during the 28-day supplementation period. They will receive a concentration of 3 g/L for 2 weeks followed by 8 g/L for the next 2 weeks, without a washout period in between.
89182148|NCT03994315|Experimental|B. infantis EVC001 + LNT (6 g/L then 12 g/L)|Infants will receive a once-daily oral feeding of B. infantis EVC001 (8.0 x 10^9 CFU) mixed with infant formula for 28 consecutive days. Group 2 [B. infantis + LNT (6 g/L then 12 g/L)] will also receive two dose-escalated concentrations of the prebiotic supplement (LNT) mixed with their infant formula for every formula preparation during the 28-day supplementation period. They will receive a concentration of 6 g/L for 2 weeks followed by 12 g/L for the next 2 weeks, without a washout period in between.
89182149|NCT03994315|Active Comparator|B. infantis EVC001 alone|Infants will receive a once-daily oral feeding of B. infantis EVC001 (8.0 x 10^9 CFU) mixed with infant formula for 28 consecutive days.
89182150|NCT02590926||Patients|"patients with stable angina and/or documented ischemia presenting with:~An angiographic stenosis of more than 50% and less than 90% of the left main~Any proximal descending anterior with a stenosis of more than 50% and less than 90%~Two or three vessel disease with a stenosis of more than 50% and less than 90% and a left ventricle ejection fraction less than 40%~Single remaining patent coronary artery with stenosis >50% and less than 90%"
89182151|NCT04100642|Active Comparator|1% Hemay808 apply to 25%BSA|8 subjects use 1% Hemay808
89182152|NCT04100642|Experimental|3% Hemay808 apply to 25%BSA|8 subjects use 3% Hemay808
89182153|NCT04100642|Experimental|3% Hemay808 apply to 55%BSA|6 subjects use 3% Hemay808
89182154|NCT04100642|Experimental|7% Hemay808 apply to 25%BSA|8 subjects use 7% Hemay808
89182155|NCT04100642|Placebo Comparator|placebo apply to 25%BSA|6 subjects use placebo apply to 25%BSA
88850394|NCT04569110||Pleural infection|Patients with clinically confirmed ongoing pleural infection.
88850395|NCT04569110||Negative control|Patients without pleural infection.
89377323|NCT02373904|Experimental|Photodynamic Bone Stabilization System (PBSS)|The PBSS is comprised of an inflatable, thin walled polyethylene terephthalate (PET; Dacron™) balloon mounted on an insertion catheter. This balloon catheter system is designed to deliver the monomer cement to the fracture site via the medullary canal of the bone.
89377324|NCT02372032|Experimental|PLD combined with ozone|Patients diagnosed as lumbar disc herniation undergoing percutaneous lumbar discectomy combined with ozone therapy.
89377325|NCT02372032|Active Comparator|pure PLD|Patients diagnosed as lumbar disc herniation undergoing percutaneous lumbar discectomy(PLD).
89377326|NCT03105232||Group A|Morphin, Hydromorfon, Oxycodon
89377327|NCT03105232||Group B|Buprenorfin
89377328|NCT03105232||Group C|Fentanyl
89377329|NCT03105232||Group D|Opioid rotation
89377330|NCT03130959|Experimental|Module A|
89377331|NCT03130959|Experimental|Module B|
89377332|NCT02371954|Experimental|Health Promotion|Happy Older Latinos are Active (HOLA) is multicomponent health promotion intervention led by a community health worker (CHW). First component is a social and physical activation session. Participants meet individually with CHW for 30 minutes once at week 1, then again at week 8 (the midway point). Second component is a moderate intensity group walk. Groups will consist of 6 participants and will meet for one hour, 3 times a week, for 16 weeks. Third component is pleasant events scheduling during cool down phase of the group walk.
89377333|NCT02371954|Active Comparator|Psychoeducation|Participants will be given a fotonovela and will meet once a month after they receive the fotonovela to discuss their thoughts on the materials they received. These discussion groups will last one hour and will consist of 10 participants.
89377334|NCT02373670|Experimental|Parent Mentor|Parent mentors using positive deviance findings to promote healthy behaviors
88850396|NCT04567472|Experimental|Online HEADS: UP|HEADS: UP online is a group-based mindfulness course with an accompanying text-based manual. HEADS: UP comprises 9 x 2.5 hour mindfulness sessions, which incorporate a 30-minute break. A 6-hour silent retreat is offered in week 7. A follow-up session will be offered 6 - 8 weeks after the end of the course. Course materials include accessible information packs delivered weekly, electronically, and CD/audio resources to complement the sessions. The accompanying text-based manual will be delivered 'up front' (hard copy and electronic). A summary email and reminder of personal practice will be sent to participants after each session, including links to audio resources complementing class-based sessions. Signposting to other resources and media, including sites with downloadable voice files e.g. Mindfulness Scotland will be included.
89377335|NCT02373670|Active Comparator|Education|Community health workers providing health education to promote healthy behaviors
89377336|NCT01367769||Thrombosis|"Patients with acute, idiopathic or provoked, unilateral proximal DVT (involving the popliteal vein or further proximal veins) and SVT of the lower-extremity detected with duplex ultrasound.~Age and sex matched controls (volunteers)"
89377337|NCT02373592|Placebo Comparator|Thermometry-only group|"Subjects will be provided with a TempStat (foot thermometer), a device that captures a thermal image of feet.~Some alarm signs have been pre-specified: 1) thermal image shows yellow spots in any area of feet for two consecutive days, 2) thermal image shows different colors in contralateral areas of the feet for two consecutive days or, 3) a dermal lesion. In any of these three scenarios, subjects will be instructed to contact the study nurse by phone. (See Detailed Description for more detail on the actions after an alarm sign has been observed)"
89377338|NCT02373592|Experimental|Thermometry plus SMS and voice messaging|"Thermometry-related intervention activities will be the same as those established for the thermometry-only group. In addition, this group will receive reminders to use the TempStat (two messages) and promote foot care (six messages). The content of these eight messages has been developed and validated through both SMS and voice messaging.~During the first two weeks of the intervention, only reminders to use the TempStat will be sent, daily, Monday to Friday, both via SMS and voice messaging.~Hereafter, for the remaining 76 weeks, patients will only receive two messages per week, one SMS and one voice message, alternating content (reminders to use TempStat and promotion of foot care)."
88850397|NCT04330573||Chronic Non-Specific Neck Pain|Patients with chronic non-specific neck pain. No interventions
88850398|NCT04330573||Control/Healthy Group|Volunteers without pain. No interventions.
88850399|NCT04567316|Experimental|[14C]-radiolabelled BI 1358894|[14C]-radiolabelled BI 1358894 (part 1)
88850400|NCT04567316|Experimental|BI 1358894|BI 1358894 (part 2)
88850401|NCT04569422||ephedrine drop|
89377339|NCT01370031|Experimental|Clenil® Modulite® via AeroChamber Plus™|Clenil® Modulite® administered via AeroChamber Plus™ spacer
89377340|NCT01370031|Active Comparator|Clenil® Modulite® via Volumatic™|Clenil® Modulite® administered via Volumatic™ spacer
88850402|NCT04568720||Shanghai General Hospital|
88850403|NCT02210702|Experimental|Ethinyl Estradiol 35mcg/Noethindrone 1mg|21 day supply of Ethinyl Estradiol 35mcg/Norethindrone 1mg will be taken beginning at Week 3 postpartum
89182156|NCT04100642|Placebo Comparator|placebo apply to 55%BSA|2 subjects use placebo apply to 55%BSA
89377341|NCT01370031|Experimental|Clenil® Modulite® via AeroChamber Plus™ plus charcoal block|Clenil® Modulite® administered via AeroChamber Plus™ spacer plus charcoal block
89377342|NCT01370031|Active Comparator|Clenil® Modulite® via Volumatic™ plus charcoal block|Clenil® Modulite® administered via Volumatic™ spacer plus charcoal block
89377343|NCT02373514|Active Comparator|Paracetamol|Intravenous 1 gm paracetamol in 100 ml saline with rapid infusion
89377344|NCT02373514|Active Comparator|Dexketoprofen|Intravenous 50 mg dexketoprofen in 100 ml saline with rapid infusion
89377345|NCT01364493|Experimental|Trastuzumab+Capecitabine+Oxaliplatin|"Trastuzumab will be administered at a loading dose of 8 mg/kg (on day 1) followed by 6mg/kg i.v. infusion every 3 weeks.~Capecitabine 2000mg/m2d, d1-14; q3w, Oxaliplatin 130mg/m2 d1; q3w, 6 cycles"
88850404|NCT02210702|Experimental|Ethinyl Estradiol 20mcg/Norethindrone 1mg|21 day supply of Ethinyl Estradiol 20mcg/Norethindrone 1mg will be taken beginning at Week 3 postpartum
88850405|NCT02210702|No Intervention|No hormonal contraception|Women choosing copper IUD, spermicides, barrier methods, or sterilization (tubal ligation or partner vasectomy).
88850406|NCT04568096|Active Comparator|Aerosolized All-Trans Retinoic acid plus oral Tamoxifen|The infected patients will receive Aerosolized All-Trans Retinoic Acid in gradual in 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled All-Trans Retinoic Acid therapy plus tamoxifen 20mg orally once daily. for 14 days
88850407|NCT04568096|Placebo Comparator|The standard therapy|The infected patients will receive the standard therapy for COVID-19 for 14 days
88850408|NCT04568018||1 cohort|"Patients with mild ARDS, who are on spontaneous breathing.~Patients who receive surfactant-BL through a mesh-nebulizer combined with the standard COVID-19 therapy, oxygen therapy according to the following scheme: inhalation of surfactant emulsion at 150 mg every 12 hours on the 1st, 2nd, 3rd, 4th and 5th days of the treatment period, inclusive."
88850409|NCT04568018||2 cohort|"Patients with moderate ARDS, who are on spontaneous breathing.~Patients who receive surfactant-BL through a mesh-nebulizer combined with the standard COVID-19 therapy, oxygen therapy according to the following scheme: inhalation of surfactant emulsion at 150 mg every 12 hours on the 1st, 2nd, 3rd, 4th and 5th days of the treatment period, inclusive."
88850410|NCT04568018||3 cohort|"Patients with mild ARDS, receiving NIV and high-flow oxygen therapy.~Patients who receive surfactant-BL through a mesh-nebulizer combined with the standard COVID-19 therapy, oxygen therapy, NIV and high-flow oxygen therapy according to the following scheme: inhalation of surfactant emulsion at 150 mg every 12 hours on the 1st, 2nd, 3rd, 4th and 5th days of the treatment period, inclusive."
88850411|NCT04568018||4 cohort|"Patients with moderate ARDS, receiving NIV and high-flow oxygen therapy.~Patients who receive surfactant-BL through a mesh-nebulizer combined with the standard COVID-19 therapy, oxygen therapy, NIV and high-flow oxygen therapy according to the following scheme: inhalation of surfactant emulsion at 150 mg every 12 hours on the 1st, 2nd, 3rd, 4th and 5th days of the treatment period, inclusive."
88850412|NCT04334317|Experimental|Sentinel Cohort: TAK-071 7.5 mg (Healthy Participants)|A single dose of TAK-071 ≤ 7.5 milligrams (mg), tablet, orally, on Day 1.
88850413|NCT04334317|Experimental|Sentinel Cohort: Placebo (Healthy Participants)|A single dose of TAK-071 placebo-matching mg, tablet, orally, on Day 1.
88850414|NCT04334317|Experimental|TAK-071 + Placebo (PD Participants)|TAK-071 tablets, orally, once daily for up to first 6 weeks in Period 1, followed by ≥3 weeks washout period, followed by TAK-071 placebo-matching tablets, orally, once daily for up to next 6 weeks in Period 2.
88850415|NCT04334317|Experimental|Placebo + TAK-071 (PD Participants)|TAK-071 placebo-matching tablets, orally, once daily for up to first 6 weeks in Period 1, followed by ≥3 weeks washout period, followed by TAK-071 tablets, orally, once daily for up to next 6 weeks in Period 2.
88850416|NCT02210390|Experimental|Intervention|Psycho-education Sessions will be offered weekly basis
88850417|NCT02210390|No Intervention|Control|"Patients who will be randomized to the treatment as usual arm will receive routine care"
88850418|NCT02278172|Active Comparator|Vitamin D3 3000IU (75μg)|Treatment solution delivered via oral spray once daily for 12-weeks
88850419|NCT02278172|Placebo Comparator|Placebo|Placebo solution delivered via oral spray once daily for 12-weeks
88850420|NCT04971031|Experimental|Reproxalap Ophthalmic Solution (0.25%) administered 7 times over two consecutive days.|
88850421|NCT04971031|Placebo Comparator|Vehicle Ophthalmic Solution administered 7 times over two consecutive days.|
88850422|NCT04566614||Biliary Tract Cohort|Patients with suspected biliary tract cancer will be offered ctDNA to support a diagnosis in patients with suspected early stage, locally advanced and advanced disease. This includes patients with tumours that are technically challenging to access with invasive biopsy or due to limitations in endoscopic ultrasound due to the COVID-19 pandemic. Patients with histological diagnosis will not be eligible for this study. Patients with suspected cancer will have ctDNA result (positive or negative) discussed at MDT in conjunction with PREVAIL-imaging risk stratification pathway to risk stratify in terms of cancer risk (low, intermediate and high risk), serum tumour markers and patient presentation which will dictate the appropriate treatment. Those with metastatic disease will have their treatment decision based on ctDNA result, radiology and patient characteristics after discussion between the treating clinician and patient
89182157|NCT01031719|Experimental|Group A: High Risk Population|Each subject will receive two doses of the assigned vaccine, the first on Study Day 1, and the second on Study Day 22
89182158|NCT01031719|Experimental|Group B: High Risk Subjects|Each subject will receive two doses of the assigned vaccine, the first on Study Day 1, and the second on Study Day 22
89377346|NCT02371798|Experimental|Double dose of Gadopentetate dimeglumine|Subjects with a clinical diagnosis of unilateral Meniere Disease (MD) will undergo 3T MR imaging with a double dose of intravenous (IV) gadolinium contrast injection: 0.2 mmol/kg of Gd-DTPA (Magnevist)
89377347|NCT01370109||Penn Site|Patients with renal cell cancer newly undergoing therapy with the oral tyrosine kinase inhibitor sunitinib will be recrutied and observed over a period of approximately 33 weeks, with additional follow-up at 1 and 2 years.
89377348|NCT01370109||Vanderbilt University Medical Center|Patients with renal cell cancer newly undergoing therapy with the oral tyrosine kinase inhibitor sunitinib will be recrutied and observed over a period of approximately 33 weeks.
89377349|NCT01370109||Case Medical Center|Patients with renal cell cancer newly undergoing therapy with the oral tyrosine kinase inhibitor sunitinib will be recrutied and observed over a period of approximately 33 weeks.
89377350|NCT01370109||University of Wisconsin at Madison|Patients with renal cell cancer newly undergoing therapy with the oral tyrosine kinase inhibitor sunitinib will be recrutied and observed over a period of approximately 33 weeks.
89377351|NCT02373358|Experimental|Group yoga intervention|Participants will participate in 6 90-minute yoga groups designed to promote themes related to trauma recovery (safety & boundaries, strength & power, assertiveness, intuition, trust, & community) using mindfulness, breath work, and physical yoga poses.
89377352|NCT01367925||Cruciate Substituting Tibial Insert|
89377353|NCT01367925||Posterior Stabilized Tibial Insert|
89377354|NCT01370187|No Intervention|Control|Control group
89377355|NCT01370187|Experimental|Montelukast|4mg Montelukast daily for 2 months
89377356|NCT04483960|No Intervention|Antiviral - Standard of care|Standard of care without nafamostat mesilate
89377357|NCT04483960|Experimental|Antiviral - nafamostat mesilate|Nafamostat continuous IV infusion for 7 days or until day of hospital discharge at a dose of 0.2mg/kg/hour. No adjustment in dose is needed for renal impairment, including for renal dialysis. The daily dose of nafamostat should be administered in 500 mL (rate of infusion 20.8 mL/hour) of normal saline. Normal saline is recommended (due to the tendency for patients with COVID-19 towards hyponatraemia) but not mandated, and 5% dextrose would be acceptable if felt clinically appropriate.
89377358|NCT04483960|Active Comparator|(Arm Closed) Anticoagulation - standard dose thromboprophylaxis|Patients will be administered a standard thromboprophylactic dose of low molecular weight heparin, choice of agent according to availability and local practice at the participating site.
89377359|NCT04483960|Experimental|(Arm Closed) Anticoagulation - intermediate dose thromboprophylaxis|Patients will be administered an intermediate dose of low molecular weight heparin, choice of agent according to availability and local practice at the participating site. The maximum dose of enoxaparin will be 120 mg/d, tinzaparin 125 IU/kg/day (not available within Australia), and Dalteparin 15,000 IU/d.
89377360|NCT04483960|Experimental|(Arm Closed) Anticoagulation - therapeutic anticoagulation|Therapeutic anticoagulation administered with LMWH daily until hospital discharge, admission to ICU or for a maximum of 28 days from randomisation. Choice of LMWH according to availability and local practice at the participating site
89377361|NCT04483960|No Intervention|(Arm Closed) Antibody - Standard of Care|No hyperimmune globulin
89377362|NCT04483960|Experimental|(Arm Closed) Antibody - hyperimmune globulin|2 doses of 30mL (3x10mL vials) of COVID-19 Hyper-Immunoglobulin (Human) given over 2 days within 48 hours of randomisation
89377363|NCT01370343|Experimental|PF-04991532 alone|
89377364|NCT01370343|Experimental|PF-04991532 + cyclosporine|
89377365|NCT01368003|Experimental|STA9090 with Dutasteride|STA9090 with Dutasteride
89377366|NCT01368003|Experimental|STA9090|STA9090
89377367|NCT01364571|Experimental|1|SA4Ag vaccine low dose
88850423|NCT04566614||Bladder Cancer Cohort|Patients with suspected bladder cancer (localised and metastatic) will be offered ctDNA to support their diagnosis, in cases where cystoscopy and biopsy are difficult to obtain due to the COVID-19 pandemic. Patients with histological diagnosis will not be eligible for this study. A positive ctDNA result will be supportive of a diagnosis of bladder cancer, their treatment may be prioritised and decided based on this result in conjunction with radiological findings, patient presentation and after discussion between the treating physician and patient
88850424|NCT04566614||Pancreatic Cancer Cohort|Patients with suspected pancreatic cancer will be offered ctDNA to support a diagnosis in patients with suspected early stage, locally advanced and advanced disease. This includes patients with tumours that are technically challenging to access with invasive biopsy or due to limitations in endoscopic ultrasound due to the COVID-19 pandemic. Patients with histological diagnosis will not be eligible for this study. Patients with suspected cancer will have ctDNA result (positive or negative) discussed at MDT in conjunction with PREVAIL-imaging risk stratification pathway to risk stratify in terms of cancer risk (low, intermediate and high risk), serum tumour markers and patient presentation which will dictate the appropriate treatment. Those with metastatic disease will have their treatment decision based on ctDNA result, radiology and patient characteristics after discussion between the treating clinician and patient
89182159|NCT01031719|Experimental|Group C: Healthy Subjects|Each subject will receive two doses of the assigned vaccine, the first on Study Day 1, and the second on Study Day 22
89182160|NCT01031719|Experimental|Group D: Healthy Subjects|Each subject will receive two doses of the assigned vaccine, the first on Study Day 1, and the second on Study Day 22
89182161|NCT00723606|Experimental|Intramuscular ziprasidone|
89377368|NCT01364571|Experimental|2|SA4Ag vaccine mid dose
89182162|NCT00723606|Active Comparator|Intramuscular haloperidol|
89182163|NCT01028521|Experimental|CM3.1-AC100|
89377369|NCT01364571|Experimental|3|SA4Ag vaccine high dose
89377370|NCT01364571|Placebo Comparator|4|Placebo
89377371|NCT01370577||1|Total 300 subjects who was diagnosed with asthma
89377372|NCT02371720|Experimental|Adults - Mobile DOT|Subjects with SCD that are older than 21 years old will receive comprehensive medication adherence management (Mobile DOT) after 1 month assessment period. The subjects will receive the Mobile DOT intervention for 24 months.
89377373|NCT02371720|Active Comparator|Adults - standard of care then Mobile DOT|Subjects with SCD that are older than 21 years old will receive standard of care for the first 12 months. They will then crossover to the comprehensive medication adherence management plan (Mobile DOT) after 1 month assessment period for the remaining 12 months.
89377374|NCT02371720|Experimental|Children - Mobile DOT|Subjects with SCD that are younger than 21 years old will receive comprehensive medication adherence management (Mobile DOT) after 1 month assessment period. The subjects will receive the Mobile DOT intervention for 24 months.
89377375|NCT02371720|Active Comparator|Children - standard of care then Mobile DOT|Subjects with SCD that are younger than 21 years old will receive standard of care for the first 12 months. They will then crossover to the comprehensive medication adherence management plan (Mobile DOT) after 1 month assessment period for the remaining 12 months.
89377376|NCT04223583|Experimental|Anrotenil hydrochloride capsule|Anrotenil hydrochloride capsule was used to treat soft tissue sarcomas with first-line chemotherapy failure (doxorubicin + ifosfamide). Oral administration was conducted on an empty stomach before breakfast (12mg), and the drug was discontinued for 2 weeks for one week (3 weeks for one cycle) until the disease progressed or became intolerable.
89377377|NCT02373436|Experimental|Constraint Induced Therapy|"All participants will receive a glove that limits the use of the fingers and wrist, and can be placed by the participant. They will be instructed to remain with the mitt in UL less affected by 90% of the hours in which to stay awake beyond the training period.~The intervention training will consist of 30 minutes of exposure of the transfer package, the interview with the items in the MAL, and 2 hours and 30 minutes with about four task Shaping, which may vary according to the needs of each individual, and Task Practice, standardized to be the same for all individuals."
88850425|NCT04566614||Gastrointestinal Stromal Tumour Cohort|Those with suspected Gastrointestinal Stromal Tumour Cohort (GIST) are eligible for this study. KIT and PDGFR mutation detected using ctDNA in conjunction with radiological features will be supportive of a diagnosis of GIST. This may allow for the use of directed targeted therapy, or prioritise surgical resection in some cases. Patients with histological diagnosis will not be eligible for this study. However, patients with inadequate tissue for KIT/PDGFR analysis will be eligible for PREVAIL-ctDNA to confirm the diagnosis of GIST and help guide treatment decisions
88850426|NCT04566614||Lung Cancer Cohort|The use of ctDNA in the diagnosis and adaptive management of patients with lung cancer is well established, however not funded by NHS. As aerosol-generating bronchoscopy procedures have reduced due to the COVID-19 pandemic, patients with suspected lung cancer may be offered ctDNA to support the diagnosis. A positive ctDNA result in conjunction with radiological findings will assist in prioritising those suitable for upfront surgical resection, radiotherapy or systemic anti-cancer treatment. It may provide sufficient genotypic information to guide standard of care targeted therapies (usually two tests are required - biopsy and then next generation sequencing of extracted DNA), including in patients without sufficient tissue for EGFR and ALK testing which can be detected using ctDNA. The use of ctDNA to guide treatment decisions in this cohort will not require signed consent as it is considered a standard approach (not yet NHS funded)
88850427|NCT04566614||Colorectal Cancer Cohort|Patients with suspected colorectal cancer will often be referred following either suspicion on imaging or faecal immunochemical testing (FIT). FIT testing results will be used to prioritise patients for screening colonoscopy, in conjunction with the PREVAIL-imaging risk stratification pathway
88850428|NCT04566614||Part 2 Cohort|Patients with suspected advanced pancreatic or biliary tract cancer who have ctDNA via the ACCESS implementation pathway. The results must be deemed consistent with or diagnostic of pancreatic/biliary tract cancer by the molecular tumour board, discussed at central MDT and the patient cannot have a histological diagnosis.
88850429|NCT04970641|Experimental|3GT journaling group|Subjects will participate in the Three Good Things (3GT) Positive Psychology journaling activity daily for six weeks.
88850430|NCT04970641|No Intervention|Non-journaling group|Subjects will not participate in the evening journal activity.
88850431|NCT04566224|Experimental|Macintosh 2 group|Using Macintosh size 2 blade for direct laryngoscope intubation according to randomization
88850432|NCT04566224|Active Comparator|Macintosh 3 group|Using Macintosh size 3 blade for direct laryngoscope intubation according to randomization
88850433|NCT04566458||Single arm|Her2 positive mBC patients who have received at least 3 lines of treatment in the metastatic setting.
88850434|NCT02210858|Experimental|Treatment (tipifarnib)|Patients receive tipifarnib PO BID on days 1-21. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
88850435|NCT04564586|Other|Enhanced Intervention Group (EIG)|The Enhanced Intervention Group was a subgroup of the participants that were invited for voluntary weekly meet-n-greet sessions in the Primary Care Clinic. These sessions were information and not educational sessions for the intervention. The entire EIG concept was to test a social component of participants by providing an informal opportunity for a DPPFit social group. The group sessions were terminated after only 5 weeks as a result of the Covid-19 pandemic. They were the only component of the DPPFit study that were face-to-face.
88850436|NCT04566146|Other|45 patients with subacromial impingement syndrome|Forty-five patients between the age 18 and 45 years old, will be referred by orthopaedist as subacromial impingement syndrome (stage Ⅰ and ⅠⅠ Neer's classification)
88850437|NCT04565912|Experimental|Sage extract mouthwash|Natural product mouthwash
88850438|NCT04565912|Active Comparator|Chlorohexidine mouthwash|Synthetic mouthwash
88850439|NCT04281199|Experimental|Treatment (TBI, IMRT)|Patients undergo TBI using IMRT with VMAT or tomotherapy BID on days -7 to -4 then undergo stem cell transplantation on day 0.
88850440|NCT04565678|Experimental|Treatment Sequence 1: ABCD|Participants will receive Treatment A (mitapivat tablet, orally, under fasted conditions once on Day 1 of Period 1) followed by Treatment B (mitapivat coated granules, orally, under fasted conditions once on Day 1 of Period 2) followed by Treatment C (mitapivat coated granules, with a strawberry yogurt, orally once on Day 1 of Period 3) followed by Treatment D (mitapivat coated granules, with a chocolate pudding, orally once on Day 1 of Period 4). Each Treatment Period will be separated by a Washout Period of 7 days.
88850441|NCT04565678|Experimental|Treatment Sequence 2: BDAC|Participants will receive Treatment B (mitapivat coated granules, orally, under fasted conditions once on Day 1 of Period 1) followed by Treatment D (mitapivat coated granules, with a chocolate pudding, orally once on Day 1 of Period 2) followed by Treatment A (mitapivat tablet, orally, under fasted conditions once on Day 1 of Period 3) followed by Treatment C (mitapivat coated granules, with a strawberry yogurt, orally once on Day 1 of Period 4). Each Treatment Period will be separated by a Washout Period of 7 days.
88850442|NCT04565678|Experimental|Treatment Sequence 3: CADB|Participants will receive Treatment C (mitapivat coated granules, with a strawberry yogurt, orally once on Day 1 of Period 1) followed by Treatment A (mitapivat tablet, orally, under fasted conditions once on Day 1 of Period 2) followed by Treatment D (mitapivat coated granules, with a chocolate pudding, orally once on Day 1 of Period 3) followed by Treatment B (mitapivat coated granules, orally, under fasted conditions once on Day 1 of Period 4). Each Treatment Period will be separated by a Washout Period of 7 days.
89182164|NCT01028521|Placebo Comparator|Placebo|
88850443|NCT04565678|Experimental|Treatment Sequence 4: DCBA|Participants will receive Treatment D (mitapivat coated granules, with a chocolate pudding, orally once on Day 1 of Period 1) followed by Treatment C (mitapivat coated granules, with a strawberry yogurt, orally once on Day 1 of Period 2) followed by Treatment B (mitapivat coated granules, orally, under fasted conditions once on Day 1 of Period 3) followed by Treatment A (mitapivat tablet, orally, under fasted conditions once on Day 1 of Period 4). Each Treatment Period will be separated by a Washout Period of 7 days.
88850444|NCT04279483|Experimental|7-11 Group|Participants visit 7-11 5 times per week during the 4-week (20 store visits total) intervention period
88850445|NCT04279483|Experimental|CVS Group|Participants visit CVS 5 times per week during the 4-week (20 store visits total) intervention period
88850446|NCT04279483|No Intervention|Control|Participants are not asked to alter their behavior during the 4-week (0 store visits) intervention period
88850447|NCT02210936|Other|PDMP Data|
88850448|NCT04564352||2|Adansonia digitata (Baobab)
88850449|NCT04564430|Placebo Comparator|Control group|IV Saline (Natriumklorid B.Braun 9mg/ml, B.Braun Melsungen AG, Melsungen, Tyskland) in an equal quantity as the study drug is administered at tourniquet inflation
88850450|NCT04564430|Experimental|Intervention group|Catapressan (CatapresR Ampoules 150 micrograms in 1ml, Solution for injection, Boehringer Ingelheim Ltd., Berkshire, UK)(3mcg/kg) is administered at tourniquet inflation
88850451|NCT04564118||Group 1|retrospective data on treatment from EMC
88850452|NCT04564118||Group 2|Treatment assignment using medicBC CDSS platform in the same cohort of patients
88850453|NCT04274101||Nifurtimox|Patients treated with Nifurtimox from 1984 to 2017
88850454|NCT04274101||Benznidazole|Patients treated with Benznidazole from 1984 to 2017
88850455|NCT04564040|Experimental|Acalabrutinib Treatment Sequence 1|"Part 1: Participants will receive Treatment A (100 mg AT suspension in water via NG administration) in Period 1, Treatment B (100 mg acalabrutinib capsule suspension via NG administration) in Period 2, and Treatment C (100 mg AT suspension in water via NG administration plus 20 mg rabeprazole) in Period 3.~Part 2: Participants will receive Treatment D (100 mg AT suspension in water via NG administration) in Period 1 and Treatment A in Period 2."
88850456|NCT04564040|Experimental|Acalabrutinib Treatment Sequence 2|"Part 1: Participants will receive Treatment B in Period 1, Treatment A in Period 2, and Treatment C in Period 3.~Part 2: Participants will receive Treatment A in Period 1 and Treatment D in Period 2."
88850457|NCT04563182||Muscle strength|GMed strength was assessed with the use of a Lafayette Manual Muscle Tester (Lafayette Instruments; Lafayette, Indiana, USA).
88850458|NCT04563182||Horizontal Jumping Performance|Lower extremity horizontal jumping was measured using the single leg hop (SLH) test as previously described
88850459|NCT04563182||Vertical Jumping Performance|To measure the single-leg vertical jump (SLVJ), the participants stood on the ground with their foot flat distributing their weight evenly on both feet.
88850460|NCT04563182||Dynamic Balance|The Y-Balance Test (YBT) was used to dynamic balance
88850461|NCT04563182||Static Balance|The Stork balance test (SBT) was used to measure static balance performance
88850462|NCT04563962|Experimental|Contingency Management-ART|Contingency management intervention with incentives tied to provision of urine samples with detectable levels of Tenofovir (TFV).
88850463|NCT04563962|Active Comparator|Contingency Management-Methamphetamine|Contingency management intervention with incentives tied to provision of urine samples with no detectable levels of methamphetamine (MA).
88850464|NCT04563650|Experimental|COVID-19 positive resident|
88850465|NCT04563650|Active Comparator|COVID-19 negative resident|
88850466|NCT02211092|Experimental|Physical activity intervention|A 12 week individually tailored home-based physical activity program with goal-setting, a physical activity self-monitoring technique, and weekly telephone calls provided by the intervener for coaching and support.
88850467|NCT02211092|Other|Usual care|Access to usual community resources but no active lifestyle coaching.
88850468|NCT04565444|Experimental|Ketone|Ketone monoester supplement (R)-3-hydroxybutyl (R)-3-hydroxybutyrate based on participants' body weight (0.36g/kg body weight) and carbohydrate control.
88850469|NCT04565444|Experimental|Ketone + Protein|Ketone monoester supplement (R)-3-hydroxybutyl (R)-3-hydroxybutyrate based on participants' body weight (0.36g/kg body weight) and 10g of whey protein.
88850470|NCT04565444|Experimental|Protein|Carbohydrate control and 10g of whey protein.
88850471|NCT02211248|Active Comparator|Conventional Group|Conventional treatment and follow up
88850472|NCT02211248|Experimental|Multidisciplinary Group|Multidisciplinary assistance
88850473|NCT04565132|Experimental|HD-tDCS|Each patient received a total of six sessions of anodal HD-tDCS of right DLPFC.
88850474|NCT04564664|Other|High-flow nasal cannula oxygen therapy|
88850475|NCT04564664|Other|Standard oxygen therapy|
88850476|NCT02211482|Other|Dolutegravir , lamivudine|Dolutegravir 50 mg QD plus lamivudine 300 mg QD
88850477|NCT04562636|Experimental|Environment-focused Meatless Monday messages|Four environmental messages from the Meatless Monday campaign.
88850478|NCT04562636|Experimental|Health-focused Meatless Monday messages|Four health messages from the Meatless Monday campaign.
88850479|NCT04562636|Other|Neutral Message|Four neutral messages about checking one's credit score.
88850480|NCT04562168|Experimental|Diagnostic Test: ML model|The diagnostic capacity of the ML model will be compared with that of the general practitioners and with dermatologist.
88850481|NCT04929847|Experimental|Group 1|All patients will receive the experimental emollient during 3 weeks.
88850482|NCT04561934|Experimental|resin modified glassionomer cement|Application of Resin modified glass ionomer cement (RMGIC) (Fuji Lining LC; GC, Tokyo, Japan) prior resin composite restoration (Filtek Z350 XT,3MESPE)
88850483|NCT04561934|Active Comparator|silver diamine flouride|Application of 38% SDF (Riva Star, SDI, Bayswater, Australia), and Resin modified glass ionomer cement (RMGIC) (Fuji Lining LC; GC, Tokyo, Japan) prior resin composite restoration (Filtek Z350 XT,3MESPE).
88850484|NCT04562402|Active Comparator|Phacoemulsification with endoscopic cyclophotocoagulation|Cataract extraction via phacoemulsification along with endoscopic cyclophotocoagulation of the ciliary body.
88850485|NCT04562402|Active Comparator|Phacoemulsification alone|Cataract extraction via phacoemulsification.
88850486|NCT04563416||Patients who need undergo magnifying endoscopy|
88850487|NCT04330495|Experimental|Testing and prophylaxis of SARS-CoV-2|Chemoprophylaxis with hydroxychloroquine at a dose of 200 mg twice a day for 6 months.
88850488|NCT04330495|Active Comparator|placebo|Testing of SARS-CoV-2 and prescription of placebo (Hydroxychloroquine placebo) twice daily for 6 months
88850489|NCT04563260|Placebo Comparator|Control group|Control group receives the intravenous normal saline 2 mL.
88850490|NCT04563260|Experimental|Palonosetron group|Palonosetron group receives the intravenous palonosetron 1.5 mL (0.075 mg) + normal saline 0.5 mL.
88850491|NCT02211170|Experimental|BIBR 796 BS, low dose|
88850492|NCT02211170|Experimental|BIBR 796 BS, high dose|
88850493|NCT02211170|Placebo Comparator|Placebo|
88850494|NCT04180189|Active Comparator|Weighted fiber blanket|Using a weighted blanket
88850495|NCT04180189|Placebo Comparator|Regular fiber blanket|Using a specially designed fiber blanket without extra weight.
88850496|NCT02211560|Placebo Comparator|Placebo|Identical looking cellulose capsules
88850497|NCT02211560|Experimental|Phosphatidylserine|Phosphatidylserine-omega-3, DHA enriched
88850498|NCT04173793|Experimental|AK102 450 mg|Participants received AK102 450 mg subcutaneous injection once every 4 weeks (Q4W) for 12 weeks
88850499|NCT04173793|Experimental|AK102 300 mg|Participants received AK102 300 mg subcutaneous injection once every 4 weeks (Q4W) for 12 weeks
88850500|NCT04173793|Experimental|AK102 150 mg|Participants received AK102 150 mg subcutaneous injection once every 2 weeks (Q2W) for 12 weeks
89377378|NCT02373436|Other|Control|They will wear a mitt that don't limit the use of the fingers and wrist. This is only to ensure blinding of the measurer
88850501|NCT04173793|Placebo Comparator|Placebo Q4W|Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for 12 weeks
88850502|NCT04173793|Placebo Comparator|Placebo Q2W|Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks
88850503|NCT04173637|Experimental|AK101 45mg every 8 weeks|AK101 45mg on Week 0 and 4 administered subcutaneously followed by AK101 45mg administered subcutaneously every 8 weeks
88850504|NCT04173637|Experimental|AK101 45mg - every 12 weeks|AK101 45mg on Week 0 and 4 administered subcutaneously followed by AK101 45mg administered subcutaneously every 12 weeks
88850505|NCT04173637|Experimental|AK101 90mg - every 8 weeks|AK101 90mg on Week 0 and 4 administered subcutaneously followed by AK101 90mg administered subcutaneously every 8 weeks
88850506|NCT04173637|Experimental|AK101 90mg -every 12 weeks|AK101 90mg on Week 0 and 4 administered subcutaneously followed by AK101 90mg administered subcutaneously every 12 weeks
88850507|NCT04173637|Experimental|AK101 135mg -every 8 weeks|AK101 135mg on Week 0 and 4 administered subcutaneously followed by AK101 135mg administered subcutaneously every 8 weeks
88850508|NCT04173637|Experimental|AK101 135mg -every 12 weeks|AK101 135mg on Week 0 and 4 administered subcutaneously followed by AK101 135mg administered subcutaneously every 12 weeks
88850509|NCT04173637|Placebo Comparator|Placebo to AK101|Placebo on Week 0 and 4 administered subcutaneously followed by AK101 135mg administered subcutaneously at Week 12, 16 and then every 12 weeks
88850510|NCT04561856|Active Comparator|Group1|will include 33 patients: each one will receive US guided fascia-iliaca block with 0.7 ml/kg of bupivacaine 0.25% plus 2 ml of normal saline perinural plus 0.15 mg/kg dexamethasone (maximum of 4 mg) in 2 ml volume intravenously.
88850511|NCT04561856|Active Comparator|Group2|will include 33 patients: each one will receive US guided fascia-iliaca block with 0.7 ml/kg of bupivacaine 0.25% plus 0.15 mg/kg dexamethasone (maximum of 4 mg) in 2 ml volume perinural plus 2 ml of normal saline intravenously.
88850512|NCT04561856|Placebo Comparator|Group3|will include 33 patients: each one will receive US guided fascia-iliaca block with 0.7 ml/kg of bupivacaine 0.25% plus 2 ml of normal saline perinural plus 2 ml of normal saline intravenously.
88850513|NCT02211716|Experimental|BeGraft|Patient's treated with the BeGraft PMCF Stent Graft System from Bentley Innomed for the treatment of iliac lesions.
88850514|NCT04912687|Experimental|All patients|"For all patients, blood sample will be collected at inclusion (liquid biopsy) for sequencing.~As per standard management, for all of these patients, EGFR gene mutation will be also analyzed on archived tumor sample."
88850515|NCT00382681|Experimental|FID 107027|Contact lens solution used as instructed for 90 days.
88850516|NCT00382681|Active Comparator|ReNu MultiPlus|Contact lens solution used as instructed for 90 days.
88850517|NCT04173403|Experimental|AK102|450mg AK102, Q4W, subcutaneous injection; OR 300mg AK102, Q4W, subcutaneous injection;OR 150mg AK102, Q4W, subcutaneous injection;
88850518|NCT03541369|Experimental|Dose Escalation Phase|AMG 427 Dose-finding phase of the study
88850519|NCT03541369|Experimental|Dose Expansion Phase|AMG 427 MTD identified in dose escalation phase (or lower) will be administered to subjects.
88850520|NCT03539887|Experimental|Intranasal ketamine|Intranasal ketamine
88850521|NCT03539887|Placebo Comparator|Placebo|non-active placebo
88850522|NCT04123717|Active Comparator|Arm1 - IV Ibuprofen|Patients will receive IV Ibuprofen 10 mg/kg to a maximum of 400 mg intravenously over 15 minutes. This medication will be diluted as per manufacturer instructions with 100 ml normal saline.
88850523|NCT04123717|Active Comparator|Arm 2 -IV Paracetamol|Patients will receive 15 mg/kg IV Paracetamol to a maximum of 1000 mg intravenously over 15 minutes. This medication will be diluted as per manufacturer instructions with normal saline.
88850524|NCT04123717|Active Comparator|Arm 3- Both IV Paracetamol and IV Ibuprofen|Patients will receive an infusion of both IV Paracetamol and IV Ibuprofen. They will initially receive IV Ibuprofen and the IV catheter will then be flushed with 10 ml of normal saline, and the patient will receive IV Paracetamol
88850525|NCT04123717|Active Comparator|Arm 4 -PO Brufen|Patients will receive PO ibuprofen given as a 100mg/5ml syrup or 200 mg tablets to a maximum of 400 mg. The treating nurse will ask the parental preference to use syrup or tablets. If they vomit the medication within 15 minutes of administration, another full dose will be administered.
88850526|NCT03472495|Active Comparator|Oral Immediate Release Diltiazem|Diltiazem immediate release 60mg orally once (Diltiazem oral product)
88850527|NCT03472495|Active Comparator|Continuous Infusion IV Diltiazem|Diltiazem 2.5-5 mg/hour intravenous Titrate by 1.25 mg every 15-60 minutes. Maximum titration dose 15 mg/hour. Titration Goal of HR <110 (Diltiazem Injectable Product)
88850528|NCT04094701|Placebo Comparator|Control Group|"Control Group will receive the following pain medication regimen:~- Norco (hydrocodone-acetaminophen) 5mg-325mg, 30 total pills~The following non-opioid medications are standard of care at our practice following hip arthroscopy and, thus, will be prescribed to patients regardless of the group they are randomized to: aspirin (325 mg, two times daily for 30 days) and Indocin (75 mg extended release, one time daily for 10 days)."
88850529|NCT04094701|Experimental|Experimental Group - Opioid Reduced|"Experimental - opioid reduced: 50% less oxycodone relative to control group~Tylenol extra strength (1000 mg, three times daily for 10 days following surgery)~Gabapentin (300 mg at night for 10 days following surgery)~Norco (hydrocodone-acetaminophen) 5mg-325mg, 5 total pills~The following non-opioid medications are standard of care at our practice following hip arthroscopy and, thus, will be prescribed to patients regardless of the group they are randomized to: aspirin (325 mg, two times daily for 30 days) and Indocin (75 mg extended release, one time daily for 10 days)."
88850530|NCT03459469|Experimental|Investigational drug|An open-label, non-randomized study to evaluate safety of Tegavivint administered intravenously to subjects with proven primary or recurrent desmoid tumor that is unresectable and symptomatic or progressive.
89399405|NCT03686319|No Intervention|control groups|"Primiparas appropriate for the criteria, admitted to the clinic due to CS and accepting to participate in the study were randomly placed into groups. Reflexology was performed in the intervention group mothers, and the questionnaires and scales were self-reportingly filled in by the lead researcher (SC).~Different rooms were allocated for the participants in the intervention and control groups not to affect each other."
88850531|NCT03428659||Sub-acute stroke|More than 1 week post-stroke Ischemic or hemorrhagic stroke
88850532|NCT04067089|Experimental|TAVR - Transcatheter aortic valve replacement|TAVR - Transcatheter aortic valve replacement with Acurate Neo bioprosthesis (Boston Scientific) using minimalist approach
88850533|NCT04067089|Active Comparator|Surgical aortic valve replacement|Surgical aortic valve replacement
88850534|NCT03351361|Experimental|Nivolumab + Ipilimumab|
89182165|NCT01021501|Experimental|nifedipine controlled release tablets|Prospective, open, non-randomized, non-controlled study to evaluate the effect and safety of nifedipine controlled release tablets in hypertensive patients on chronic maintenance hemodialysis and the influence of hemodialysis on the plasma concentration of nifedipine
89182166|NCT01028599|Experimental|Exercise|
88850535|NCT03351361|Active Comparator|Chemotherapy|carboplatin and pemetrexed or carboplatin and paclitaxel
88850536|NCT04056715||HCM Group|Eligible HCM subjects will be monitored for arrhythmias with a 2-week ECG patch.
88850537|NCT04863781|Experimental|Intervention|All 11 modules will include the following elements: introduction to the topic; two types of assessments (1) adherence to at-home relaxation training practice (following week 2) and (2) 3-5 topic-specific questions to tailor video-based content; a cognitive component; a relaxation component; and a wrap up that includes a brief assessment of module comprehension. Each user will view 5-7 videos per module. Videos will be tailored to user and will last between 2 and 4 minutes. Total time per module will be 20 to 30 minutes. Between modules, users will receive (based on their timing preferences) supportive texts intended to motivate continued engagement or to affirm the life experiences of African American women
89182167|NCT04009057||B/F/TAF|HIV-1 infected adults who initiate B/F/TAF therapy
88850538|NCT04863781|Active Comparator|Control|Two mobile courses: Introduction to Stress Management and Techniques for Coping with Stress. Users will be informed that the courses will be completed on their phone, that they are video-based, and that they should spend between 20 and 30 minutes each week, for the next 11 weeks, learning the material. The introductory course defines stress, describes the different sources of stress, and the influence of personality on stress. The coping module includes training in cognitive coping skills, guided imagery, progressive relaxation, autogenic training, and the importance of physical activity to manage stress. All lessons include course assessments. During the intervention period, controls will receive weekly text messages encouraging completion of material.
88850539|NCT03234907|Placebo Comparator|Induction Phase: Placebo|Placebo, IV, infusion, once at Weeks 0, 2, and 6 in the Induction Phase.
89399406|NCT03686319|Experimental|"intervention (foot reflexology)"|Reflexology was performed in those in the intervention group after CS on right foot for 10 min and left foot for 20 min as continuing 30-min seances three times per day every eight hours for three days. The procedure was started at mean 3rd hour after mothers became stable. Reflexology was performed for none of those in the control group.
88850540|NCT03234907|Experimental|Induction Phase: Vedolizumab 300 mg|Vedolizumab 300 milligram (mg), IV infusion, once at Weeks 0, 2, and 6 in the Induction Phase.
88850541|NCT03234907|Placebo Comparator|Maintenance Phase: Induction Placebo to Placebo Q4W|Participants who received placebo in the Induction Phase and achieved clinical response at Week 10 continued to receive placebo in the Maintenance Phase. Vedolizumab placebo-matching, IV infusion, once every 4 weeks (Q4W), from Week 14 to Week 58.
88850542|NCT03234907|Experimental|Maintenance Phase: Induction Placebo to Vedolizumab 300 mg Q4W|Participants who received placebo in the Induction Phase and did not achieve clinical response at Week 10 received vedolizumab in the Maintenance Phase. Vedolizumab 300 mg, IV infusion, Q4W, from Week 14 to Week 58.
88850543|NCT03234907|Experimental|Maintenance Phase: Induction Vedolizumab 300 mg to Vedolizumab 300 mg Q8W|Participants who received vedolizumab in the Induction Phase and achieved clinical response at Week 10 continued to receive vedolizumab in the Maintenance Phase. Vedolizumab 300 mg, IV infusion, once every 8 weeks (Q8W), at Weeks 14, 22, 30, 38, 46 and 54 and vedolizumab placebo-matching, IV infusion, Q8W, at Weeks 18, 26, 34, 42, 50 and 58 to maintain double-blind.
88850544|NCT03234907|Experimental|Maintenance Phase: Induction Vedolizumab 300 mg to Vedolizumab 300 mg Q4W|Participants who received vedolizumab in the Induction Phase and did not achieve clinical response at Week 10 received vedolizumab in the Maintenance Phase. Vedolizumab 300 mg, IV infusion, Q4W, from Week 14 to Week 58.
88850545|NCT03175471||Patients with autoimmune liver disease|"Patients (6-23 y.o.) with established clinical diagnosis of AIH or suspected diagnosis of AIH based on elevated serum AST or ALT, elevated IgG level >1.1 ULN, elevated titer of autoantibodies, including ANA, SMA, LKM, LC-1 or SLA, which is consistent with the simplified criteria for the diagnosis of AIH in children will be enrolled.~Patients (6-23 y.o.) with established clinical diagnosis of PSC or Suspected diagnosis of PSC supported by abnormal cholangiogram (ERCP or MRCP) or elevated GGT>1.5 ULN and dilated bile ducts by liver ultrasound will be enrolled."
88850546|NCT04330027|Experimental|Growth factors|Patients in this group will receive one lyophilized Growth Factors injection supplied as a powder in a tightly sealed container.
88850547|NCT04330027|Placebo Comparator|Saline|Patients in this group will receive an injection with equal volume of saline; i.e 2ml of 0.9% sodium chloride.
89182168|NCT04005001|Experimental|Experimental|The experimental arm will involve patients monitored by HindSight.
88850548|NCT03053245|Experimental|Mobile Critical Care Recovery Program|The group will receive the Mobile Critical Care Recovery Program (m-CCRP) intervention which includes care coordination and collaborative care model for one year post enrollment.
88850549|NCT03053245|Active Comparator|Attention Control|The attention control group will receive telephone based check ins related to their health from the research study team.
88850550|NCT04712617||FGIDs|Patient who were diagnosed with NERD/RH, FD, IBS and their overlaps (NERD/RH-FD, NERD/RH-IBS, FD-IBS, NERD/RH-FD-IBS)
88850551|NCT04712617||Healthy controls|Subjects who underwent GI evaluations as part of health check-up or for other problems, such as mild abdominal discomfort or pain for a relatively short period of time, but had no organic problems during GI endoscopy
88850552|NCT02775331|Experimental|Units using Titania1 software|Employees working in shift planning units (clusters) using an interactive shift planning software (Titania1) with sub-tools for individual shift planning (self-rostering) and an option for shift ergonomics evaluation to both the shift planner and the employees
88850553|NCT02775331|Experimental|Units using Titania2 software|Employees working in shift planning units (clusters) where shift planners use a non-interactive shift planning software (Titania2) providing guidance for health-supporting shift ergonomics.
89182169|NCT04005001|Active Comparator|Control|The control arm will involve patients monitored by InSight.
89182170|NCT01031797||High SLEDAS|High SLE disease activity score
89182171|NCT01031797||Low SLEDAS|SLE patient with low score
89182172|NCT01021579|Active Comparator|Metformin plus Simvastatin|PCOS patients(n=42) will be assigned to the simvastatin (20mg/day) plus metformin (500mg three times a day, n=42; group 1)
89182173|NCT01021579|Placebo Comparator|Metformin plus Placebo|PCOS patients(n=42) will be assigned to the placebo (once/day) plus metformin (500mg three times a day, n=42; group 2)
89182174|NCT01021657||Glaucoma|
89182175|NCT01021735|Active Comparator|Anti-TNF therapy|Etanercept or adalimumab by s/c injection
89182176|NCT01021735|Experimental|Rituximab therapy|Rituximab given by IV infusion
89182177|NCT00442351|Experimental|Asmanex Twisthaler|
89182178|NCT00442351|Placebo Comparator|Placebo inhaler|
89182179|NCT00436501|Experimental|Treatment (VEGF Trap, Docetaxel)|"Phase I (closed to accrual as of 3/14/2008): Patients receive VEGF Trap IV over 1 hour on day 1 of course 1. Patients then receive VEGF Trap IV over 1 hour and docetaxel IV over 1 hour on day 1 in all subsequent courses. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of VEGF Trap until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 or 6 patients experience dose-limiting toxicity."
88850554|NCT02775331|No Intervention|Units using Titania3 software|Employees working in shift planning units (clusters) where a standard shift planning software (Titania3) without interactive shift rostering or guidance for health-supporting shift ergonomics is used by shift planners.
88850555|NCT03841981||I- Hypothalamic amenorrhea|10 women with exercise-associated hypothalamic amenorrhea
88850556|NCT03841981||II- Hyperandrogenic polycystic ovary syndrome|5 lean women with hyperandrogenic polycystic ovary syndrome. 5 women with weight excess and hyperandrogenic polycystic ovary syndrome.
89377379|NCT03634761|Experimental|Experimental group|Preschools/Children in this group will receive EIBI supervised by an external expert from the habilitation center on a regular basis. In addition, preschool staff in this group are provided with in-service training consisting of a one full day (onset of project) and a half day (middle of project) on autism, applied behavior analysis, evidence-based practices, engagement, participation, inclusion and overall quality factors when working with Children with autism in preschool settings. Preschool staff are also provided with monthly on-site coaching in implementing evidence based practices, goal setting and working with overall intervention setting, through coaching from the habilitation center.
88850557|NCT03841981||III- Non-hyperandrogenic polycystic ovary syndrome|5 lean women with non-hyperandrogenic polycystic ovary syndrome 5 women with weight excess and non-hyperandrogenic polycystic ovary syndrome
88850558|NCT03841981||IV- Trained women without ovulatory dysfunction|10 women who exercise as intensively as women with exercise-associated hypothalamic amenorrhea but with normal ovulatory cycles.
89182180|NCT00436501|Experimental|Phase II Treatment (VEGF Trap, Docetaxel)|Phase II (opened to accrual as of 5/9/2008): Patients receive VEGF Trap at the MTD determined in phase I and docetaxel as in phase I. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
88850559|NCT03841981||V- Non-hyperandrogenic healthy women|10 women matched by age and body mass index with women with polycystic ovary syndrome who do not perform physical activity on a regular basis
88850560|NCT03818581|Active Comparator|Treatment Group|
88850561|NCT03818581|Placebo Comparator|Placebo Responders|
88850562|NCT03818581|Active Comparator|Placebo Non-responders Re-randomized to Treatment|
88850563|NCT03818581|Placebo Comparator|Placebo Non-responders Re-randomized to Placebo|
88850564|NCT03793855|Experimental|Nutritional Strategy|Nutritional counseling based on the quality of the diet, the Food Guide for the Brazilian Population and concepts of mindfulness and mindful eating; dietary guidance based on feasible goals built together (patient and nutritionist).
88850565|NCT03793855|Active Comparator|Dietary Prescription|Individualized dietary prescription according to the guidelines of the Brazilian Society of Diabetes.
88850566|NCT00002923|Experimental|KRN5500|
88850567|NCT03779581|Experimental|Exercise Group|The experimental group received active self-correction exercises to restore movements in different planes as close as possible to physiologically normal.
88850568|NCT03779581|Active Comparator|Control Group|All patients were prescribed a spinal orthosis (TLSO) and got a preliminary evaluation for orthosis design and manufacturing based on the curve type categorization from Ross and Weiss during the first appointment (Rigo et al., 2010).
88850569|NCT03766321|Active Comparator|Fecal microbiota transplantation (FMT)|"Fecal microbiota transplantation will be performed during two endoscopic procedures (at baseline and at 6 months) by allogenic infusion of collected feces in the duodenum-jejunum. Fecal microbiota will be diluted in saline solution 200 ml and infused at 30 ml/minute speed. Every endoscopic procedure will be performed with sedation of the patient.~Feces for FMT will be obtained by known healthy donors for C. difficile infection according to standard selection procedures."
88850570|NCT03766321|Placebo Comparator|Placebo|"ALS patients will undergo upper GI endoscopy with small-intestine biopsies at baseline and after 6 months. Patients in the placebo arm will not receive any treatment during these procedures, but will undergo intestinal biopsy.~Every endoscopic procedure will be performed with sedation of the patient."
89377380|NCT03634761|Active Comparator|Comparison group|"Preschools/Children are in this group receive treatment as usual, which is EIBI supervised by an external expert from the habilitation center at the habilitation center directed toward the paraprofessional. At the offset of the project preschool staff are offered to participate in a one-day learning course/workshop on autism, applied behavior analysis, evidence-based practices, engagement, participation, inclusion and overall quality factors when working with children with autism in preschool settings."
89377381|NCT02371564|Active Comparator|High flow humidified oxygen first|High flow humidified oxygen then standard oxygenotherapy with a two-hour non invasive ventilation session in between.
88850573|NCT03736447|Active Comparator|AR101 powder provided in capsules & sachets|Study product provided as peanut protein in pull-apart capsules or sachets
88850574|NCT03736447|Placebo Comparator|Placebo powder provided in capsules & sachets|Placebo formulation in pull-apart capsules or sachets containing only inactive ingredients
88875297|NCT02577510|Experimental|Ultrasound guided Xylocaine injection|Anesthesia of the lateral femoral cutaneous nerve using local anesthetic will be randomly assigned on the right or left side to receive nerve stimulation-xylocaine or ultrasound guided -xylocaine injections in all patients. One patient will therefore have both nerve stimulation AND ultrasound guided injections, only the side of the injection will be randomly assigned to one of the two modalities. Once one technique has been used to freeze one side, the other side will be frozen using the other technique.
88875298|NCT02577822|Other|Short Stem Group|Short femoral stem
88875299|NCT02577822|Other|Long Stem Group|standard-length stem
89182181|NCT00755846|Experimental|Alogliptin 6.25 mg QD|
89182182|NCT00755846|Experimental|Alogliptin 12.5 mg QD|
89377382|NCT02371564|Active Comparator|Standard oxygen therapy first|Standard oxygenotherapy then high flow humidified oxygen with a two-hour non invasive ventilation session in between.
89182183|NCT00755846|Experimental|Alogliptin 25 mg QD|
89182184|NCT00755846|Experimental|Alogliptin 50 mg QD|
89182185|NCT00755846|Experimental|Alogliptin 100 mg QD|
89182186|NCT00755846|Placebo Comparator|Placebo QD|
89377383|NCT02371486|Experimental|Nich Repair|"Interventions to be administered:~Ultrasound Scan~Diagnostic Hysteroscopy~hysteroscopic repair of cesarean section defect~IVF cycle"
88850575|NCT00002941|Experimental|Reinduction Therapy|Two courses of reinduction chemotherapy followed by bone marrow biopsy and aspirate prior to peripheral blood stem cell (PBSC) harvest. If marrow involvement is still present at harvest, then 2 additional courses of induction chemotherapy are given. The PBSC transplantation preparative regimen should begin within 2 weeks of completing reinduction therapy course, consisting of the following: Carmustine IV over 3 hours on days -8, -7, and -6, Etoposide continuous IV over days -8, -7, and -6, Cyclophosphamide IV over 1 hour daily on days -5, -4, -3, and -2, Mesna as a 15 min infusion before each dose of cyclophosphamide then at 3, 6, 9, and 12 hours after initiation of each cyclophosphamide dose Methylprednisolone IV is given to protect lungs from the toxic effects of carmustine.
88850576|NCT04329793|Experimental|Intervention arm|Assisted gait training with Walkbot System and their usual Physical Therapy.
88850577|NCT04329793|Active Comparator|Control arm|Their usual Physical Therapy.
88850578|NCT04329637|Active Comparator|IHC (intergrative health care) arm|Meditation and care coordination in addition to usual care
88850579|NCT04329637|No Intervention|usual care|usual care
88850580|NCT03705637|Experimental|Exparel Arm|20ml Exparel + 10ml injectable 0.9% NS (30ml) for every 100cm2 of donor site.
88850581|NCT03693781|Active Comparator|Colchicine 0.01mg/kg/day + Riluzole 100 mg|Oral colchicine will be administered at fast, at specified dose pro kilograms for 30 weeks, while taking Riluzole 100 mg/day
88850582|NCT03693781|Active Comparator|Colchicine 0.005 mg/kg/day + Riluzole 100 mg|Oral colchicine will be administered at fast, at specified dose pro kilograms for 30 weeks, while taking Riluzole 100 mg/day
88850583|NCT03693781|Placebo Comparator|Placebo + Riluzole 100 mg|Placebo pills will be administered at fast, while taking Riluzole 100 mg/day
88850584|NCT02283853|Experimental|BG00012|Participants will receive the recommended dose of 240 mg orally, twice a day
88850585|NCT02283853|Active Comparator|IFN β-1a (Avonex)|Participants will receive the recommended dose of 30 μg (weekly)
88850586|NCT03670849|Experimental|Patients using LapAR system|
88850587|NCT02401789|Experimental|test - implant placement|The possibility of counteracting unfavourable ridge modelling after multiple tooth extractions by placing implants in the fresh extraction sites
88850588|NCT02401789|No Intervention|control- natural healing|
88850589|NCT04329247|Experimental|Median nerve neural mobilization|Non pharmaceutical, non invasive, physiotherapy technique; which consists of a passive and repetitive upper limb movement that seeks to induced median nerve gliding and incursions against surrounding connective tissue. Subjects will be treated 5 days per week during a total time lapse of 6 weeks.
88850590|NCT04329247|No Intervention|Control group|Waiting list control group. Participants that belong to the no intervention arm will be assigned to a waiting list to receive treatment. The participants will not receive treatment for carpal tunnel syndrome during a time lapse of 6 weeks. After this period of time, participants will begin the best treatment available.
88850591|NCT02263417|Active Comparator|Deep Brain Stimulation|Stimulation is on
88850592|NCT02263417|Sham Comparator|Placebo|Stimulation is off
88850593|NCT02116699|Experimental|oropharyngeal mother's milk|0.2 mL every 2 hours for 48 hours beginning within 96 hours post-birth, followed by 0.2 mL every 3 hours until 32 weeks post conceptional age
88850594|NCT02116699|Placebo Comparator|oropharyngeal sterile water|0.2 mL every 2 hours for 48 hours beginning within 96 hours post-birth, followed by 0.2 mL every 3 hours until 32 weeks post conceptional age
88850595|NCT00003439|Experimental|Arm I|Cohorts of 3-6 patients each receive escalating doses of intraperitoneal recombinant human interleukin-12 (rhIL-12) administered weekly for 9 weeks. If a patient tolerates rhIL-12 and shows evidence of objective response or stable disease, patient may receive up to 9 additional weeks of treatment. Treatment continues in the absence of unacceptable toxicity or disease progression. Dose escalation continues until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which no more than 1 of 6 patients experiences dose limiting toxicity.
89377384|NCT02371486|Sham Comparator|No Repair|"Interventions to be administered:~Ultrasound Scan~Diagnostic Hysteroscopy~IVF cycle Operative hysteroscopy WILL NOT BE PERFORMED"
88850596|NCT01478035|Experimental|phenytoin prophylaxis|Patients with suspected or proven pneumococcal meningitis are allocated to receive phenytoin prophylaxis or placebo to avoid seizures during the 10 days of antibiotic therapy starting after the antibiotic therapy
88850597|NCT01478035|Placebo Comparator|placebo|placebo vials and pills labeled as phenytoin prophylaxis vials and pills
88850598|NCT00003451|Experimental|Arm I|Cohorts of 3 patients receive interleukin-12 IV push on day 1, followed by escalating doses of interferon alfa by subcutaneous injection at 24, 48, 72, 96 and 120 hours. Courses repeat every 2 weeks for 6 months (12 courses total) in the absence of unacceptable toxicity and disease progression. Patients achieving partial response or stable disease at the completion of 6 months of therapy may receive additional courses of therapy for up to 24 months. Dose escalation of interferon alfa continues in subsequent cohorts in the absence of dose limiting toxicity (DLT). If 1 of 3 patients experiences DLT at a dose level, then 3 additional patients are entered at that dose level. If 2 of 6 patients experience DLT, then dose escalation stops. The maximum tolerated dose is defined as 1 level below that dose at which 2 or more of 6 patients experience DLT. Patients are followed every 3 months for 1 year and then every 6 months thereafter.
88850599|NCT01338649|Active Comparator|Bright White|Exposure to bright white light treatment.
88850600|NCT01338649|Placebo Comparator|Dim red light|Exposure to dim red light treatment.
88850601|NCT00003019|Experimental|Chemotherapy Treatment|Patients receive vinblastine sulfate (5 mg/m2) IV and methotrexate (30 mg/m2) IV weekly for 26 weeks, then every 2 weeks for an additional 26 weeks. Treatment continues for a maximum of 1 year in the absence of unacceptable toxicity or disease progression. Patients with a complete response receive an additional 8 doses of chemotherapy. Patients are followed every 6 months for 4 years and then annually thereafter.
88850602|NCT01247233|Active Comparator|Standard or Hypofractionated radiotherapy|"Whole breast RT, 50 Gy + boost 16 Gy. Whole breast hypofractionated RT without boost, either 40 Gy or 42.5 Gy"
89377385|NCT04961697|Experimental|PICU with diaries|"The main family member of a critically ill child will receive a diary upon PICU admission.~Except for the diaries intervention, this group of patients will be submitted to usual PICU routine care."
89377386|NCT04961697|No Intervention|PICU without diaries|This group of critically ill patients and family members will not receive diaries, but will also be submitted to usual PICU routine care.
89377387|NCT02377648|Experimental|ABSORB Bioresorbable Vascular Scaffold|Everolimus-Eluting Bioresorbable Vascular Scaffold implantation
89377388|NCT01368159|Active Comparator|pressure centred at 25 mm Hg|
89377389|NCT01368159|Active Comparator|pressure between 20 and 36 mm Hg|
89377390|NCT01368159|Placebo Comparator|pressure between 10 and 15 mm Hg|
89377391|NCT02371408|Experimental|1a: Treatment-naive patients, without ribavirin (RBV)|PPI-668 + sofosbuvir for 12 weeks
89377392|NCT02371408|Experimental|1b: Treatment-naive patients, with RBV|PPI-668 + sofosbuvir + ribavirin (RBV) for 12 weeks
89377393|NCT02371408|Experimental|2a: Non-cirrhotic previous non-responders, without RBV|PPI-668 + sofosbuvir for 12 weeks
88850603|NCT01247233|Experimental|Accelerated Partial Breast Irradiation (APBI)|APBI using 3D CRT technique, in 5 days, 38.5 Gy to the tumor bed
89377394|NCT02371408|Experimental|2b: Non-cirrhotic previous non-responders, with RBV|PPI-668 + sofosbuvir + ribavirin for 12 weeks
88850604|NCT00383929|Experimental|1|Candesartan Cilexetil (CC) /HCT 32/12.5mg
88850605|NCT00383929|Experimental|2|Candesartan Cilexetil (CC) /HCT 32/25mg
88850606|NCT00383929|Experimental|3|Candesartan Cilexetil monotherapy
89377395|NCT02371408|Experimental|3a: Cirrhotic previous non-responders 12 weeks|PPI-668 + sofosbuvir + ribavirin for 12 weeks
89377396|NCT02371408|Experimental|3b: Cirrhotic previous non-responders 16 weeks|PPI-668 + sofosbuvir + ribavirin for 16 weeks
88850607|NCT00003553|Experimental|1|The target for progenitor cell is >=5 x 106 CD 34/kg.
88850608|NCT00383539|Experimental|1|Lot 1
88850609|NCT00383539|Experimental|2|Lot 2
88850610|NCT00383539|Experimental|3|Lot 3
88850611|NCT00383539|Active Comparator|4|Control
88850612|NCT00002827|Experimental|Treatment #1 (Without Zinecard)|"All patients undergoing a splenectomy must receive penicillin or erythromycin prophylaxis twice a day. Pneumocystis prophylaxis:TMP/SMZ 150mg/m2(maximum 300 mg) of TMP in 2 divided doses on 3 consecutive days each week. Aerosolized Pentamidine (200mg/m2/dose - maximum dose 300 mg) should be substituted monthly for patients who cannot tolerate TMP/SMZ therapy. Continue pneumocystis prophylaxis for 6 months after stopping therapy.~Doxorubicin hydrochloride 25mg/m2/day IV push over 15 minutes days 1 and 15 Bleomycin sulfate 10 IU/m2/day IV push over 10 minutes on days 1 and 15 Vincristine sulfate 1.5mg/m2/day IV push (maximum 2mg) days 1 and 15 Etoposide 10mg/m2/day 1-5. IV drip ( < 0.4mg/ml) over 1 hour. Monitor blood pressure every 15 minutes during infusion. G-CSF (filgrastim) 5 mcg/Kg/day start on day 6 (24-36 hrs after 5th dose of VP16) and continued through day 13 (total 8 days)."
88850613|NCT00002827|Experimental|Treatment #2 (with Zinecard)|Zinecard (DZR) 250 mg/m2 IV push on days 1 and 15 before administration of doxorubicin and bleomycin sulfate. Give bleomycin sulfate and doxorubicin within 30 minutes of Zinecard (dexrazoxane hydrochloride). Bleomycin 10 IU/m2/day IV push over 10 minutes on days 1 and 15 Doxorubicin hydrochloride 25mg/m2/day IV push over 15 minutes days 1 and 15 Vincristine Sulfate 1.5mg/m2/day IV push (maximum 2mg) days 1 and 15
89377397|NCT01364805|Experimental|PK Intravenous Vitamin C and Gemcitabine|Week 1: 2 visits for escalating doses of intravenous ascorbic acid (IV C). First dose 25 gm followed by 50 gm 2nd visit. Week 2: 3 visits escalating doses of IV C, 75 grams, 100 grams, and 125 grams. Week 3: 2 visits pharmacokinetic evaluation of intravenous ascorbic acid alone at 125 grams; return to the infusion clinic the following morning for a 24 hour blood draw; 2nd visit receive the first infusion of gemcitabine chemotherapy for PK evaluation of gemcitabine alone. Week-4: gemcitabine and IV C co-administered for pharmacokinetics of both drugs to assess for PK variability related to drug-drug interactions. Subjects will return to the infusion clinic the following morning for 24 hour blood draw.
89377398|NCT01370889|Experimental|Basic Science (resveratrol)|Patients receive resveratrol PO QD for 12 weeks.
89377399|NCT01364883|Experimental|Group 1|AdCh63 ME-TRAP prime D0, AdCh63 ME-TRAP boost W4, AdCh63 ME-TRAP boost W8, MVA ME-TRAP boost W16
89377400|NCT01364883|Experimental|Group 2|AdCh63 ME-TRAP prime D0, AdCh63 ME-TRAP boost W8, MVA ME-TRAP boost W16, MVA ME-TRAP boost W24
89377401|NCT01364883|Experimental|Group 3|AdCh63 ME-TRAP prime D0, AdCh63 ME-TRAP boost W4, MVA ME-TRAP boost W8, MVA ME-TRAP boost W12
89377402|NCT01364883|Experimental|Group 4|AdCh63 ME-TRAP prime D0, MVA ME-TRAP boost W8, MVA ME-TRAP boost W16, MVA ME-TRAP boost W24
89377403|NCT01364883|Experimental|Group 5|AdCh63 ME-TRAP prime D0, MVA ME-TRAP boost W4, AdCh63 ME-TRAP boost W8, MVA ME-TRAP boost W16
89377404|NCT01364883|Experimental|Group 6|AdCh63 ME-TRAP prime D0, MVA ME-TRAP boost W4, AdCh63 ME-TRAP boost W8, MVA ME-TRAP boost W12
88850614|NCT00003565|Experimental|docetaxel|OUTLINE: Patients receive docetaxel IV over 1 hour on day 1. Patients may receive additional courses beginning 21 days after the first docetaxel dose at the discretion of the physician.
88850615|NCT00002833|Experimental|Group 1A|"Group 1A - With or Without Remission + Failing Fludarabine therapy:~Ara-C IV over 2 hours on days -7, -6, -5, -4 and -3 with Cladribine continuous infusion for 5 days, beginning 4 hours before Ara-C first dose. Idarubicin IV Days -6, -5 and -4. Cells infused on day 0. Cyclosporine via continuous IV infusion, oral cyclosporine administered for 6 months postinfusion (tapered 10% weekly until discontinued). Methylprednisolone begins 5 days after infusion then gradually tapered."
88850616|NCT00002833|Experimental|Group 1B|"Group 1B: With or Without Remission, No previous Fludara Therapy~Fludarabine IV over 30 minutes daily on days -6, -5, -4 and -3. Ara-C IV begins 4 hours after fludarabine infusion, continues for 4 hours. Idarubicin IV Days -6, -5 and -4. Cells infused on day 0. Cyclosporine via continuous IV infusion, oral cyclosporine administered for 6 months postinfusion (tapered 10% weekly until discontinued). Methylprednisolone begins 5 days after infusion then gradually tapered."
88850617|NCT00003571||Samples of tumor and normal tissue|Samples of tumor and normal tissue are obtained from CALGB 8896 patients. The samples are tested for somatic mutations and tumor replication error (RER) tumor status. Patients do not receive the results of the genetic testing and the results do not influence the type or duration of treatment.
88850618|NCT00003595|Experimental|Arm I|Patients receive cyclophosphamide IV, doxorubicin IV, and vincristine IV on day 3 and oral prednisone on days 3-7. Patients receive rituximab on day 1. Treatment repeats every 3 weeks for a minimum of 4 courses or 2 courses beyond complete response in the absence of disease progression or unacceptable toxicity. Patients with stage I, stage IE (including bulky), or nonbulky stage II or IIE disease receive 3 courses of chemotherapy with rituximab followed by radiotherapy beginning 3 weeks after completion of the third course. Patients who achieve partial response for a minimum of 28 days or complete response receive maintenance rituximab IV beginning on day 28 of the final course of chemotherapy. Maintenance rituximab treatment repeats every 4 weeks for 3 courses.
88850619|NCT00003595|Active Comparator|Arm II|Patients receive cyclophosphamide IV, doxorubicin IV, and vincristine IV on day 1 and oral prednisone on days 1-5. Treatment repeats every 3 weeks for a minimum of 4 courses or 2 courses beyond complete response. Patients with stage I, stage IE (including bulky), or nonbulky stage II or IIE disease receive 3 courses of chemotherapy. Patients receive radiotherapy beginning 3 weeks after completion of the third course of chemotherapy.
88850620|NCT00002875|Experimental|Regimen A|Following surgery, craniospinal irradiation followed by a boost to the primary tumor. Beginning within 1 week after initiation of radiotherapy, patients receive vincristine sulfate weekly for 8 doses. Beginning 6 weeks after the completion of radiotherapy, patients receive adjuvant lomustine/vincristine sulfate/cisplatin every 6 weeks for a total of 8 courses.
88850621|NCT00002875|Experimental|Regimen B|Following surgery, craniospinal irradiation plus vincristine sulfate, followed by adjuvant cyclophosphamide/vincristine sulfate/cisplatin every 6 weeks for a total of 8 courses.
88850622|NCT00003613|Experimental|Treatment (O6-benzylguanine, carmustine)|Patients receive O6-benzylguanine IV over 1 hour followed by topical carmustine once every 2 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
88850623|NCT00003937|Experimental|Pilot 1 - Doxorubicin Intensification without Ifosfamide|Dexrazoxane hydrochloride IV followed by doxorubicin hydrochloride IV plus cisplatin IV on days 1 and 2 of weeks 1 and 6. Methotrexate IV on day 1 of weeks 4, 5, 9, and 10. Patients undergo surgery on week 11. Adjuvant chemotherapy begins on day 1 of week 13. Group 1 (good response to neoadjuvant chemotherapy): Patients receive methotrexate IV over 4 hours every 3 weeks for 6 courses, beginning on week 13. Patients also receive dexrazoxane and doxorubicin hydrochloride every 3 weeks for 4 courses, beginning on week 14. Cisplatin is administered with the first 2 courses of dexrazoxane and doxorubicin. Group 2 (standard response to neoadjuvant chemotherapy): Patients receive methotrexate and cisplatin as in group 1 plus dexrazoxane and doxorubicin hydrochloride for 6 courses.
88850624|NCT00003937|Experimental|Pilot 2 - Doxorubicin Intensification with Ifosfamide|Preoperative therapy comprised of dexrazoxane hydrochloride, doxorubicin hydrochloride, and methotrexate as in pilot 1. Ifosfamide IV on days 1-5 of week 1. Patients undergo surgery on week 11, then begin adjuvant chemotherapy on week 13. Group 1: Patients receive methotrexate, dexrazoxane hydrochloride, and doxorubicin hydrochloride as in pilot 1, group 1. Ifosfamide is also administered on weeks 14 and 20. Cisplatin is administered on weeks 17, 23, and 26. Group 2: Patients receive methotrexate, dexrazoxane hydrochloride, and doxorubicin hydrochloride as in pilot 1, group 2. Ifosfamide is administered on weeks 14, 20, 26, and 31. Cisplatin is administered on weeks 17, 23, and 29
88850625|NCT00003937|Experimental|Pilot 3 - Ifosfamide/Etoposide Intensification|Preoperative therapy comprised of methotrexate, dexrazoxane hydrochloride, doxorubicin, ifosfamide, and cisplatin as in pilot 2. Patients undergo surgery on week 11, then begin adjuvant chemotherapy on week 13. Group 1: Patients receive methotrexate, dexrazoxane hydrochloride, doxorubicin, ifosfamide, and cisplatin as in pilot 2, group 1. Group 2: Patients receive methotrexate on weeks 13, 19, 29, 32, 35, and 36, high dose ifosfamide and etoposide IV over 4 hours on days 1-5 of weeks 14, 23, and 26, and cisplatin on weeks 20, 30, and 33. Dexrazoxane hydrochloride and doxorubicin hydrochloride are administered on weeks 17, 20, 30, and 33
89377405|NCT01364883|Experimental|Group 7|AdCh63 ME-TRAP prime D0, MVA ME-TRAP boost W8, AdCh63 ME-TRAP boost W16, MVA ME-TRAP boost W24
88875300|NCT02577900|Experimental|Acticoat absorbent|Apply Acticoat absorbent onto the ulcer
88875301|NCT02577900|Active Comparator|Honey gel sheet|Apply Honey gel sheet onto the ulcer
88875302|NCT02577900|Other|Jelonet|Apply Jelonet onto the ulcer
88875303|NCT02580318|Experimental|all study participants|subjects consumed alcohol to a BrAC of 0.1 and then performed the following manipulations while using the breathalyzer: poor effort, hyperventilation (immediate), hyperventilation (after 5 minutes), hyperventilation (after 10 minutes), drinking water (immediate), drinking water (after 5 minutes)
89377406|NCT02373046|Experimental|Treatment A|1 × 400-mg LX4211 tablet (fasted conditions)
89377407|NCT02373046|Experimental|Treatment B|2 × 200-mg LX4211 tablets (fasted conditions)
89377408|NCT01368237||Patients|Patients awaiting invasive coronary angiography
89377409|NCT01368315|Experimental|CT327|Cream
89377410|NCT01368315|Placebo Comparator|Placebo|Cream (Vehicle only)
89377411|NCT01368315|Active Comparator|Active comparator|Cream
89377412|NCT01368315|No Intervention|No intervention|
89377413|NCT02371096|Experimental|RGB-03|
89377414|NCT02371096|Active Comparator|MabThera (rituximab)|
89377415|NCT04420455|Experimental|Enoximone|Patients will receive three times a dose of 0.5 mg/kg enoximone with a one-hour-interval.
89377416|NCT01368393|Experimental|Electroacupuncture|
88850626|NCT00003625|Experimental|Stratum 1|Concomitant irradiation and vincristine sulfate in esc dose beginning with 0.8 mg/m2, etoposide and Cyclosporine A given over 6 weeks, then monthly maint courses over 6 mths, with no clinical and radiologic progression. Stable disease indicates continuation of therapy. Clinical deterioration within 4 months of completion of radiation therapy must be confirmed to be PD by imaging. Clinical progression even in the absence of imaging changes will be accepted as reflecting disease progression. Steroids dexamethasone (Decadron) given as clinically indicated and tapered as tolerated. Steroids may decrease capillary permeability to chemotherapeutic agents and antagonise the effect of cyclosporin A. Also contributes to the syndrome of seizures and white matter changes seen with cyclosporine in the post BMT period. If steroid use is required, the recommended schedule of Decadron dosing during the 6 week induction course is 8 mg/m2 divided q 6-8 hours.
89377417|NCT01368393|Active Comparator|Sham acupuncture|
88850627|NCT00003997|Experimental|Arm I|Patients receive 6-hydroxymethylacylfulvene (HMAF) IV over 5 minutes on days 1-5. Treatment repeats every 3-4 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3 patients receive escalating doses of HMAF. The maximum tolerated dose is defined as the dose at which dose limiting toxicity occurs in at least 40% of patients.
89377418|NCT02371174||HALAVEN treatment group of primary or secondary chemotherapy|Patients with HER2-negative recurrent breast cancer who have received 0 or 1 chemotherapy regimen for recurrent breast cancer.
88850628|NCT00384631|Sham Comparator|2|
88850629|NCT00384631|Experimental|1|
89377419|NCT02371174||HALAVEN treatment group of tertiary or later chemotherapy|Patients with HER2-negative inoperable or recurrent breast cancer who have received 2 or more chemotherapy regimens for inoperable or recurrent breast cancer.
89377420|NCT02371018|No Intervention|Standard Hemodialysis|Participants will be monitored during their normal hemodialysis treatment with no intervention administered
89377421|NCT02371018|Experimental|Hemodialysis with Nutrition Supplement|Participants will be monitored during a normal hemodialysis treatment in which they consume 1-8oz can of Nepro.
88850630|NCT00003127|Experimental|carbo, taxol, amifostine|carbo, taxol, amifostine
88850631|NCT00003139|Experimental|Pilocarpine hydrocloride|5mg pilocarpine hydrochloride tablets commencing 3 days prior to irradiation
88850632|NCT00003139|Placebo Comparator|Placebo|Placebo tablets commencing 3 days prior to irradiation
88850633|NCT04099693||General Anesthesia|"All the patients will be intubated and ventilated using cisatracurium (0.15 mg/kg) as a muscle relaxant and propofol (1.5-2mg/kg) for induction. The inhalational anesthetic, sevoflurane, will be used to maintain the depth of anesthesia using 50% mix of nitrous oxide and oxygen.~Fentanyl will be used in both groups at a rate of 1-2 microgram /kg to achieve an adequate level of analgesia in both groups."
89182187|NCT03850093|Active Comparator|gabapentin|gabapentin 1200 mg was given to patients of gabapentin group 2 hours preoperative
89182188|NCT03850093|Active Comparator|bisoprolol|bisoprolol 2.5 mg was given to patients of bisoprolol group 2 hours preoperative
89377422|NCT02371018|Experimental|Nutrition Supplement|Participants will be monitored while drinking 1-8oz can of Nepro with no hemodialysis treatment.
89377423|NCT01370967||Study formula-fed only|
89377424|NCT01370967||Human milk-fed only|
89182189|NCT03850093|Placebo Comparator|control|placebo was given to patients of control group 2 hours preoperative
89182190|NCT00442117|Experimental|MF-DPI|MF DPI 200 mcg, two puffs once daily PM (total of 400 mcg/day)
89182191|NCT00442117|Active Comparator|BUD-DPI|Budesonide (BUD) DPI 200 mcg, two puffs twice daily (total of 800 mcg/day)
89377425|NCT01370967||Mixed-fed using study formula only|
89377426|NCT02370940|Experimental|High Phytate Diet|The high phytate diet group was required to consume a high phytate diet for 8 weeks. The high phytate foods were provided for subjects. They received whole grain ready-to-eat cereals, whole wheat pasta/spaghetti, tortillas, bagels, bread and dinner rolls, corn tortillas, brown rice, canned black beans, edamame and tofu, and were encouraged to consume generous amounts of nuts and other legume products high in phytate.
89377427|NCT02370940|Experimental|Low Phytate Diet|The low phytate diet group was required to consume a low phytate diet for 8 weeks. They received foods similar to those for the high phytate diet group but which were made from refined wheat and white rice, eggs and cheese, and were instructed to avoid high phytate foods.
89377428|NCT01368471|Experimental|MGuard|MGuard stent will be deployed
89377429|NCT01368471|Active Comparator|BMS or DES|A regular bare metal stent or drug-eluting stent will be deployed
89377430|NCT02365246|Experimental|immunoadsorption group|All patients will be treated with 10 immunoadsorptions with an IgE-specific adsorption column :
89377431|NCT01364961|Placebo Comparator|Cellulose capsules|
89182192|NCT04096508|Experimental|Group A|Patients sit comfortably in a chair for 20 min listening classic music before the procedure.
89377432|NCT01364961|Experimental|Resveratrol capsules|
89377433|NCT02370862|Experimental|Bowel Evacuation Study with NEO and GLY|The study design will consist of a screening visit to determine each individual's response to a previously established IV dose of NEO and GLY, followed by a dose titration study (two visits) of iontophoresed NEO and GLY. Study visits will be separated by no less than 2 days and no more than 14 days.
89377434|NCT01371045||Acromegaly|Patients carrying the diagnosis of acromegaly who are on long-acting somatostatin for at least 3 months prior to study enrollment.
89377435|NCT01371045||Carcinoid Syndrome|Patients carrying a diagnosis of carcinoid syndrome who are taking long-acting somatostatin for at least 3 months prior to study enrollment.
89377436|NCT01371045||Healthy Controls|
88850634|NCT04099693||Anesthetist Administered sedation for ERCP|To ensure a steady level of AAS each patient in this group will be sedated using propofol. An induction bolus of propofol (0.5 - 1 mg/kg) will be administered followed by continuous infusion with variable doses depending on the patients' age, weight, and clinical condition. In addition, fentanyl 1.5 μg/kg will be used at the anesthetist discretion.
88850635|NCT02972983|Placebo Comparator|Placebo|51 patients receiving a daily placebo infusion for five days on top of standard of care treatment for methicillin-sensitive Staphylococcus aureus (MSSA) bacteremia
88850636|NCT02972983|Experimental|Daptomycin|51 patients receiving daily daptomycin infusion for five days on top of standard of care treatment for MSSA bacteremia
88850637|NCT00003145|Experimental|Treatment (chemotherapy, TBI, PBSCT, DLI)|"CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo low-dose TBI on day 0.~TRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine PO BID or IV BID or TID on days -3 to 56 with taper to day 77 or 180, and mycophenolate mofetil PO or IV BID on days 0-27.~DLI: At least 2 weeks after completion of immunosuppression, patients with > 5% donor CD3+ T cells and no evidence of GVHD receive donor lymphocytes IV over 30 minutes. Patients may receive up to 3 DLIs at increasing cell doses in the absence of GVHD."
88850638|NCT00003157|Experimental|radiation + gemcitabine + cisplatin|Patients undergo radiotherapy to the tumor and lymph nodes, followed by a decrease in radiotherapy to the tumor alone. Radiation therapy is administered for a total of 5.5 weeks. Patients receive intravenous gemcitabine twice weekly over the first 3 weeks of radiotherapy. Cisplatin is administered intravenously twice weekly following gemcitabine therapy. Three patients are treated at each dose level. Dose escalation does not occur until all patients at a given dose level have completed radiotherapy and returned for a 4 week follow up. Patients exhibiting stable disease remain on therapy until disease progression or intolerable toxic effects. Patients experiencing toxic effects and no disease progression are retreated at a lower dose. Patients are followed every 3 months for the first 2 years then every 6 months for the next year.
88850639|NCT00003745|Experimental|Arm I|Patients receive topotecan IV continuously on days 1-21. Treatment continues at least every 4 weeks in the absence of unacceptable toxicity or disease progression.
88850640|NCT04097119|Other|Dietary supplement arm|Subjects to receive a specific dietary supplement
88850641|NCT04712695|Experimental|Graded Motor Imagery Group|
88850642|NCT04712695|Experimental|Mirror Visual Feedback Group|
88850643|NCT04712695|Experimental|Augmented Biofeedback Group|
88850644|NCT04712695|Sham Comparator|Diaphragmatic Breathing Group|
88850645|NCT00004123|Experimental|RT + DOX + IORT|Preoperative external beam radiotherapy (RT) combined with doxorubicin (DOX) and followed by intraoperative radiotherapy (IORT); dose-escalation study of external beam radiotherapy.
88850646|NCT00003787||Intervention|high fiber, high vegetable, low-fat diet
88850647|NCT00003787||Control|NCI-recommended diet
88850648|NCT00003193|Experimental|Paclitaxel, amifostine, RT|Dose-escalation arm for paclitaxel with amifostine and RT.
88850649|NCT00003793||Identification of Genetical suceptibility prior to therapy|"Determine the glutathione-s-transferase theta (GSTT1) or glutathione-s-transferase mu (GSTM1) null genotype is more frequent in individuals with t-MDS/AML. Determine the GSTT1 or GSTM1 null genotype is associated with a reduced incidence of relapse of sarcoma. Determine NAT2 or CYP1A1 genotype influences risk of t-MDS/AML. Determine development of a mutator phenotype as demonstrated by developing microsatellite instability is an early marker of individuals likely to progress to t-MDS/AML."
88850650|NCT00003793||Increased Risk Of T-MDS/AML before/after Therapy|Determine clonal hematopoiesis develops in children receiving high intensity alkylating agent chemotherapy for sarcomas. Determine development of clonal hematopoiesis is associated with increased frequency of t-MDS/AML. Determine measurement of somatic cell mutation frequency, measured by the glycophorin A (GPA) assay prior to and after chemotherapy will predict individuals at increased risk of t-MDS/AML. Identify individuals with ras gene mutations in normal peripheral blood cells after therapy, and whether the identification of such mutations is associated with increased risk of t-MDS/AML blood cells after therapy, and whether the identification of such mutations is associated with increased risk of t-MDS/AML.
88850651|NCT00384787|Experimental|1|Group 1 will receive three vaccinations with the HIV DNA vaccine. Vaccinations will be given at study entry and Months 1 and 2. Participants will also receive an adenoviral vaccine boost intramuscularly at Month 6.
88850652|NCT00384787|Experimental|2|Group 2 will receive three vaccinations with the HIV DNA vaccine. Vaccinations will be given at study entry and Months 1 and 2. Participants will also receive an adenoviral vaccine boost intradermally at Month 6.
88850653|NCT00384787|Experimental|3|Group 3 will receive three vaccinations with the HIV DNA vaccine. Vaccinations will be given at study entry and Months 1 and 2. Participants will also receive an adenoviral vaccine boost subcutaneously at Month 6.
89182193|NCT04096508|Experimental|Group B|Patients sit comfortably in a chair for 20 min listening popular music before the procedure.
89377437|NCT02365324|Experimental|Peer-education Family Fitness Program|Peer educators (children in grade 8) recruited from the schools participating in the study will be trained and will then be implementing the 12 week Peer-education Family Fitness Program (PE-FFP) intervention to children in 6th and 7th grade.
89377438|NCT02365324|Other|Family Fitness Program (FFP)|Adult educators recruited from the University of Illinois Extension or the community will be trained and will then be implementing the 12 week Family Fitness Program (FFP) intervention to children in 6th and 7th grade.
89377439|NCT04945083|Experimental|Experimental Nutritional Pudding|2 servings per day
88850654|NCT00004135|Experimental|Arm A|Fludarabine 30 mg/m2/d x S days IVPB in 100 cc NS over 30 minutes on day -8, -7, -6, -S, and -4. Cyclophosphamide 2 gm/m2/d x 2 days IVPB in SOO cc DS W over I hour on day -3 and day-2. G-CSF (Neupogen®) administration 480 f!gld subcutaneously starting on day +5 (or first day of neutropenia if earlier)and continued until an ANC of 0.5 x 109/L is maintained for 3 consecutive days.
88850655|NCT00004141|Experimental|Arm A|CDDP (75 mg/m2) and DTIC (660 mg/m2) will be administered sequentially by intravenous infusion in day 1. Subsequently, GM-CSF (450 mg/ m2) will be administered SC days 2-7; IL-2 (11 MU daily) will be given SC days 8-14, and IFN-2b (9 MU) will be given SC days 8, 10, 12, and 14.
89377440|NCT02370628|Experimental|Percutaneous vertebroplasty (PV)|The procedure involves percutaneous application of bone cement (polymethylmethacrylate) into collapsed vertebrae.
89377441|NCT02370628|Active Comparator|Facet block|injection of anti-inflammatory and analgesic drugs
89377442|NCT02929407|Experimental|FE 204205|
88850656|NCT02972905|Placebo Comparator|Session 1: Placebo|Subjects will receive a single dose inhalation of GSK2269557 matching placebo via the ELLIPTA DPI. The washout period between the two dosing sessions will be at least 10 days.
89377443|NCT02929407|Placebo Comparator|Placebo|
88850657|NCT02972905|Experimental|Session 1: GSK2269557 200 mcg|Subjects will receive a single dose inhalation of GSK2269557 200 mcg via the ELLIPTA DPI. The washout period between the two dosing sessions will be at least 10 days.
88850658|NCT02972905|Experimental|Session 1: GSK2269557 500 mcg|Subjects will receive a single dose inhalation of GSK2269557 500 mcg via the ELLIPTA DPI. The washout period between the two dosing sessions will be at least 10 days.
88850659|NCT02972905|Experimental|Session 1: GSK2269557 700 mcg|Subjects will receive a single dose inhalation of GSK2269557 700 mcg via the ELLIPTA DPI. The washout period between the two dosing sessions will be at least 10 days.
88850660|NCT02972905|Placebo Comparator|Session 2: Placebo|Subjects will receive repeated doses of GSK2269557 matching Placebo once daily via the ELLIPTA DPI for 10 days. The washout period between the two dosing sessions will be at least 10 days.
88850661|NCT02972905|Experimental|Session 2: GSK2269557 200 mcg|Subjects will receive repeated doses of GSK2269577 200mcg once daily via the ELLIPTA DPI for 10 days. The washout period between the two dosing sessions will be at least 10 days.
88850662|NCT02972905|Experimental|Session 2: GSK2269557 500 mcg|Subjects will receive repeated doses of GSK2269577 500mcg once daily via the ELLIPTA DPI for 10 days. The washout period between the two dosing sessions will be at least 10 days.
88850663|NCT02972905|Experimental|Session 2: GSK2269557 700 mcg|Subjects will receive repeated doses of GSK2269577 700mcg once daily via the ELLIPTA DPI for 10 days. The washout period between the two dosing sessions will be at least 10 days.
89377444|NCT02373280|Active Comparator|10 day sequential group|After proving H. pylori infection, the participant will receive the empirical 10 day sequential regimen (Esomeprazole, nexium® 40 mg bid 10 days (D1-D10)+amoxicillin® 1 g bid 5 days (D1-D5)+clarithromycin, klaricid® 500mg bid 5 days (D6-D10)+metronidazole, flasinyl® 500mg tid 5 days (D6-D10) for treatment of H. pylori infection in this group.
89377445|NCT02373280|Experimental|7 days tailored PPI triple therapy group|After proving H. pylori infection, the participant received endoscopic guided biopsy for H. pylori culture and MIC. Based on antimicrobial susceptibility testing, the participant will receive 7 day tailored regimen [PPI triple therapy (Esomeprazole, nexium® 40 mg bid 7 days (D1-D7)+amoxicillin® 1 g bid 7 days (D1-D7)+clarithromycin, klaricid® 500mg bid 7 days (D1-D7)] in this group.
89377446|NCT02373280|Experimental|7 days tailored MEA therapy group|After proving H. pylori infection, the participant received endoscopic guided biopsy for H. pylori culture and MIC. Based on antimicrobial susceptibility testing, the participant will receive 7 day moxifloxacin triple therapy [Esomeprazole, nexium® 40 mg bid 7 days (D1-D7)+Moxifloxacin, avelox® 400 mg qd 7 days (D1-D7)+Amoxicillin® 1 g bid 7 days (D1-D7)] in this group.
89377447|NCT02373280|Experimental|7 or 14 days tailored EBMT therapy group|After proving H. pylori infection, the participant received endoscopic guided biopsy for H. pylori culture and MIC. Based on antimicrobial susceptibility testing, the participant will receive 7 day bismuth quadruple therapy [Esomeprazole, nexium® 40 mg bid 7 days (D1-D7)+Tri potassium dicitrate bismuthate, denol® 300 mg qid 7 days (D1-D7)+Metronidazole, flasinyl® 500 mg tid 7 days (D1-D7)+Tetracycline® 500 mg qid 7 days (D1-D7)] in this group. If there was no metronidazole resistance, the treatment was 7 days in duration. If metronidazole resistance was evident, treatment duration was 14 days.
89377448|NCT01368549||Metanx®|Subjects with Diabetic Peripheral Neuropathy who have been prescribed Metanx® daily.
89377449|NCT02370550|Experimental|Cyclosporin A(CsA)+glucocorticoid|A. The efficacy/safety are evaluated at V3, V4, V5 and V6, and the treatment is adjusted accordingly. Patients who experienced treatment failure (FVC absolute decrease >15% of predicted values after 4 weeks of treatment) are suggested to switch to intravenous glucocorticoid + cyclophosphamide(CYC) 0.5-1 g/m2 every 4 weeks as the rescue therapy after unblinding, and continue to complete the subsequent follow-up. Each patient can only have one chance to be rescued. Patients who experience a second treatment failure should be withdrawn from the trial and be given empirical treatment. Patients who did not experience treatment failure continued to receive current treatment. B. For subjects with aggravated shortness of breath and dyspnea in between of two consecutive visits, the investigators should decide whether a visit should be increased to complete subsequent examinations.
88850664|NCT00003799|Experimental|Treatment (chemotherapy, radiotherapy, surgery)|"Patients receive fluorouracil IV continuously with concurrent radiotherapy for 5.5 weeks. Patients also receive oxaliplatin IV over 2 hours on day 1 of weeks 1, 3, and 5.~Patients undergo surgery 6-8 weeks after completing preoperative chemotherapy and radiotherapy. The surgical procedure is determined by the extent of the tumor before preoperative therapy. The type of operative procedure may be abdominoperineal resection, low anterior resection (LAR), or LAR/coloanal anastomosis.~Postoperative chemotherapy begins within 6 weeks after surgery, comprising leucovorin calcium and fluorouracil IV on days 1-5. Treatment repeats every 21 days for 4 courses."
88850665|NCT00003211|Experimental|Average-risk|"Participants meeting the eligibility requirements for assignment to the average-risk arm.~Interventions: filgrastim, amifostine trihydrate, cisplatin, cyclophosphamide, vincristine sulfate, peripheral blood stem cell transplantation, radiation therapy."
88850666|NCT00003211|Experimental|High-risk|"Participants meeting the eligibility requirements for assignment to the high-risk arm.~Interventions: filgrastim, amifostine trihydrate, cisplatin, cyclophosphamide, vincristine sulfate, peripheral blood stem cell transplantation, radiation therapy."
88875304|NCT02582970|Experimental|Bevacizumab + Chemotherapy|Participants will receive IV bevacizumab at a dose of 5 milligrams per kilogram (mg/kg) every 2 weeks in combination with standard of care chemotherapy regimen (5-Fluorouracil/Irinotecan/Oxaliplatin) until disease progression or until termination of the study.
88875305|NCT02583360|Active Comparator|Study|Eligible subjects (study) will undergo diagnostic VFSS in combination with manometry, either concurrent or sequential. They will have parental choice of preferred feeding therapy.
89377450|NCT02370550|Placebo Comparator|placebo+glucocorticoid|A. The efficacy/safety are evaluated at V3, V4, V5 and V6, and the treatment is adjusted accordingly. Patients who experienced treatment failure are suggested to switch to glucocorticoid + CsA 2-3mg/kg/d, BID as the rescue therapy, and continue to complete the subsequent follow-up. Each patient can only have one chance to be rescued. Patients who did not experience treatment failure continued to receive current treatment. B. For subjects with aggravated shortness of breath and dyspnea in between of two consecutive visits, the investigators in each center should decide whether a visit should be increased.
89377451|NCT01371123||On long-term PN|
88850667|NCT00003829|Experimental|fludarabine + cyclophosphamide|Patients receive alternating courses of fludarabine and cyclophosphamide. Fludarabine is administered IV over 10-30 minutes on days 1-5 of courses 1, 3, and 5. Cyclophosphamide is administered IV over 30-60 minutes on day 1 of courses 2, 4, and 6. Treatment repeats every 4 weeks. Patients achieving clinical complete remission (CCR) after 6 courses of chemotherapy receive 2 additional courses (one course of each drug). Patients achieving partial remission after 6 courses of chemotherapy also receive 2 additional courses. If these patients then achieve CCR, they receive another 2 courses. Patients are followed every 3 months.
88850668|NCT04329403|Experimental|Test Group|Adapalene Gel, 0.1%, applied as thin film once daily for 12 weeks
88850669|NCT04329403|Active Comparator|Reference Group|Differin® (Adapalene) Gel, 0.1%, applied as thin film once daily for 12 weeks
88850670|NCT04329403|Placebo Comparator|Placebo Group|Placebo Gel, 0.1%, applied as thin film once daily for 12 weeks
88850671|NCT00003217|Experimental|Treatment|See detailed description.
88850672|NCT00004183|Experimental|capecitabine|Patients receive oral capecitabine twice daily on days 1-14. Treatment repeats every 3 weeks for a maximum of 6 courses in the absence of disease progression or unacceptable toxicity. Patients are followed every 2 months for 1 year, every 3 months for 2 years and then annually thereafter.
88850673|NCT00003223|Experimental|treatment|Fenretinide 200 mg PO days 1-25, q 28 days x 6 cycles.
88850674|NCT00004189|Experimental|Arm I|See detailed description.
89377452|NCT01371123||Never been on TPN|
89377453|NCT02372890||All patients|Patients with head and neck squamous cell carcinoma with advanced primary tumor stages (cT3 or cT4), clinical suspicion of cervical lymph node metastases, cervical lymph node metastasis of unknown primary tumor (CUP) or patients with tumor recurrence scheduled for neck dissection.
88850675|NCT00003835|Experimental|Arm I (leucovorin calcium and fluorouracil)|Patients receive leucovorin calcium IV over 2 hours and fluorouracil IV beginning 1 hour into leucovorin calcium infusion weekly for 6 weeks. Treatment is repeated every 8 weeks for 4 courses.
88850676|NCT00003835|Experimental|Arm II (leucovorin calcium, fluorouracil, irinotrcan)|Patients receive irinotecan IV over 90 minutes, followed by leucovorin calcium IV, then followed by fluorouracil IV weekly for 4 weeks. Treatment is repeated every 6 weeks for 5 courses
88850677|NCT00003847|Experimental|Treatment|
88850678|NCT00004195|Active Comparator|Oral eniluracil 20 mg twice daily|20 mg of eniluracil given twice daily for duration of the study. This subject may have surgery IF tumor is amenable to resection
88850679|NCT00004195|Placebo Comparator|Placebo|20 mg placebo that will be given for the duration of the study. This subject may have surgery IF tumor is amenable to resection
88850680|NCT00003865|Experimental|Toremifene|All enrolled patients
88850681|NCT00003931||blood or bone marrow samples|"All samples are obtained from specimens collected on CALGB-9665. No additional blood or bone marrow samples are collected CALGB-9769.~Samples are examined by Southern blot analysis for gene rearrangement at 11q23. Samples showing evidence of ALL1 gene rearrangement are further analyzed by reverse transcription PCR amplification and/or cytogenetic analysis to detect partial tandem duplication of ALL1."
89377454|NCT02365168|Experimental|Food Challenge with cod|
89377455|NCT02365168|Experimental|Food Challenge with salmon|
89377456|NCT02365168|Experimental|Food Challenge with mackerel|
89377457|NCT02365168|Placebo Comparator|Food Challenge with placebo|
89377458|NCT02365402|Experimental|entecavir with PEG-IFN a-2a|After enrolled, entecavir will added, and patients will receive treatment of PEG-IFN a-2a combine with entecavir for 48 weeks and 24 weeks of follow up after treatment.
88850682|NCT00004285|Active Comparator|Standard dose, low flux hemodialysis|
88850683|NCT00004285|Experimental|Standard dose, high flux hemodialysis|
88850684|NCT00004285|Experimental|High dose, low flux hemodialysis|
88850685|NCT00004285|Experimental|High dose, high flux hemodialysis|
88850686|NCT00004843|Experimental|Parathyroidectomy|
88850687|NCT00004843|Active Comparator|Observation|
88850688|NCT00003313|Experimental|Arm 1|Radiation therapy and chemotherapy + Amifostine
88850689|NCT00003313|Active Comparator|Arm 2|Radiation therapy and chemotherapy alone
88850690|NCT00004867|Experimental|FDG-PET scan +/- neoadjuvant chemotherapy + surgery|"Patients receive fludeoxyglucose F 18 (FDG) IV followed 45-60 minutes later by positron emission tomography (PET) imaging. Confirmatory studies, such as biopsy or other imaging studies, are then conducted to confirm the FDG PET imaging results. Patients with no metastases identified by FDG PET imaging may undergo esophagectomy with or without neoadjuvant chemoradiotherapy within 1 month of evaluation.~Patients are followed within 6 months after surgery."
88850691|NCT00003325|Other|Sentinenal lymph node mapping|Sentinenal lymph node mapping
88850692|NCT00004891|Experimental|primary resectable rectal cancer|
88850693|NCT00004909||Oral chemotherapy|
88850694|NCT00004909||Parenteral chemotherapy|
88875306|NCT02583360|No Intervention|Control|Eligible subjects who had VFSS alone with provider recommendations from the same single center.
88875307|NCT02584140|Other|AEGIS|All participants will be assigned to this arm of the study.
89377459|NCT02365402|No Intervention|control group|In this group, patients will be continue treated only by PEG-IFN a-2a for 48 weeks after enrolled and receive 24 weeks of follow up.
89377460|NCT02370472|No Intervention|control group|complete pre-study form 10 minute familiarization time with equipment view video demonstration of task perform task 3 times assessed using scoring form - pretest assigned to group practice task again for 30 minutes proficiency noted final evaluation
89377461|NCT02370472|Experimental|Experimental|complete pre-study form 10 minute familiarization time with equipment view video demonstration of task perform task 3 times assessed using scoring form - pretest assigned to group practice task again for 30 minutes - subjects will use tool developed using cameras and a computer to visualize hand and needle movements as well as the position of the transducers along with the image from the ultrasound on a computer screen proficiency belief noted final evaluation
89377462|NCT02364934||Propofol|Propofol is intravenously administrated during anesthesia maintenance in patients (18-65 years old)
89377463|NCT02364934||Sevoflurane|Sevoflurane (inhalation) is administrated during anesthesia maintenance in patients (18-65 years old)
89377464|NCT02364934||Propofol (elderly)|Propofol is intravenously administrated during anesthesia maintenance in patients (≥65 years old)
89377465|NCT02364934||Sevoflurane (elderly)|Sevoflurane (inhalation) is administrated during anesthesia maintenance in patients (≥65 years old)
89377466|NCT02364934||Propofol (men)|Propofol is intravenously administrated during anesthesia maintenance in men (18-65 years old)
89377467|NCT02364934||Sevoflurane (men)|Sevoflurane (inhalation) is administrated during anesthesia maintenance in men (18-65 years old)
89377468|NCT02364934||Propofol (women)|Propofol is intravenously administrated during anesthesia maintenance in women (18-65 years old)
89377469|NCT02364934||Sevoflurane (women)|Sevoflurane (inhalation) is administrated during anesthesia maintenance in women (18-65 years old)
89377470|NCT02364856||Children with cerebral palsy|
89377471|NCT02372656|Placebo Comparator|Placebo Group|Placebo gel without active ingredient to be delivered at baseline, 3, 6 and 9 months.
89377472|NCT02372656|Active Comparator|1% Metformin|1% metformin gel to be delivered at baseline, 3, 6 and 9 months.
89377473|NCT02372656|Active Comparator|1.2% Simvastatin|1.2% Simvastatin to be delivered at baseline, 3, 6 and 9 months.
89377474|NCT03123939|Experimental|CTL019|CTL019 transduced T cells were given as a single dose of 0.2 to 5.0 × 10^6 autologous CTL019 transduced viable T cells per kg body weight (for patients ≤ 50 kg) and 0.1 to 2.5 × 10^8 CTL019 transduced viable T cells (for patients > 50 kg)
89377475|NCT01368627|Experimental|Supralimus® Sirolimus-Eluting Coronary Stent|
89377476|NCT02358681|Experimental|Ketorolac, intranasal|"Ketorolac 1 mg/kg, maximum dose 30 mg. To be administered by intranasal route, single dose.~Placebo, intravenous."
89377477|NCT02358681|Active Comparator|Ketorolac, intravenous|"Ketorolac 0.5 mg/kg, maximum dose 30 mg. To be administered by intravenous route, single dose.~Placebo, intranasal."
89377478|NCT03123861|Active Comparator|Gabapentin|Participants will take 300 mg Gabapentin for the first 3 days after surgery, then dose escalate to 300 mg twice a day (BID) for an additional 11 days.
89377479|NCT03123861|Placebo Comparator|Placebo oral capsule|Participants will take placebo for the 2 weeks after surgery.
89377480|NCT01368705|Active Comparator|Control Group|
89377481|NCT01368705|Experimental|Intervention Group 1|
89377482|NCT01368705|Experimental|Intervention Group 2|
89377483|NCT04116645||Group 1|singleton pregnancies
89377484|NCT04116645||Group 2|Twin pregnancies
89377485|NCT01368783|Experimental|atazanavir|400 mg/day for 2 days
89377486|NCT01368783|Experimental|Atazanavir and Tenofovir|
89377487|NCT01368783|Experimental|Atazanavir and Ritonavir|
89377488|NCT01368783|Experimental|Atazanavir + tenofovir + ritonavir|
89377489|NCT01509339|Experimental|Vancomycin for Inhalation|250 mg vancomycin in 5cc sterile water will be inhaled once. Patients will use a Pari Sprint nebulizer and Pari Vios compressor as the delivery system.
89377490|NCT01368861||control|water and normal physical comfort provided by mom
89377491|NCT01368861||sucrose|sugar and normal physical comfort provided by mom
89377492|NCT01368861||physical intervention|physical intervention using the 5 S's and water
89377493|NCT01368861||physical intervention and sucrose|Physical intervention using the 5 S's and sugar water
89377494|NCT03123471|Experimental|Apremilast 30 mg BID|Apremilast 30 mg tablets orally twice daily (BID) during Weeks 0 to 32
89377495|NCT03123471|Placebo Comparator|Placebo|Placebo tablets BID during weeks 0 to 16; at week 16, placebo participants were switched to apremilast 30 mg tablets BID for 16 weeks (from Week 16 to Week 32)
89377496|NCT02661178|Experimental|emodepside (BAY 44-4400)|Up to 10 cohorts with single ascending dose
89377497|NCT02661178|Placebo Comparator|placebo of emodepside (BAY 44-4400)|Up to 10 cohorts with single ascending dose
89377498|NCT01365117|Experimental|Cohort 1|
89377499|NCT01365117|Experimental|Cohort 2|
89377500|NCT02370316|Experimental|MIT - SA|Metacognitive Interpersonal Therapy -standard approach (MIT-SA) is a cognitive behavior-based psychotherapeutic approach that works to increase metacognitive abilities and to improve interpersonal relationships
89377501|NCT02370316|Active Comparator|Clinical Structured Treatment (CST)|Clinical Structured Treatment (CST) is a structured case management and symptom-targeted medication
89377502|NCT02372500|Experimental|Chewing gum|Patients will chew sugar free gum three times a day
89377503|NCT02372500|No Intervention|Control|Normal post operative care
89377504|NCT03840447|Experimental|Chronic Disease Self-Management programme|
89377505|NCT02372812|Active Comparator|group1|12 mg( 3 mls) of dexamethasone given 15 mins after induction of anesthesia
89377506|NCT02372812|Placebo Comparator|group2|3 mls of placebo( normal saline) given 15 mins after induction of anesthesia
89377507|NCT02365012|Placebo Comparator|Placebo|Placebo given three times a day for 2 weeks
89377508|NCT02365012|Active Comparator|Midodrine|Midodrine 2.5 mg given three times a day for one week followed by 5 mg given three times a day for one week
89377509|NCT01369017|Active Comparator|Anakinra|All subjects will undergo 2 CCRE challenges. Each subject will be given either anakinra or placebo prior to CCRE challenge
89377510|NCT01369017|Placebo Comparator|Placebo|Normal saline injection
89377511|NCT01371357|Experimental|TEST1|2.4 g/day of guanidinoacetic acid
88850695|NCT04069117|Active Comparator|• Study group|It contains 100 patients will undergo ovarian stimulation with letrozole 2.5mg twice daily (Femara; Novartis Pharma Services, Basel, Switzerland) for 5 days starting from the first day of menstruation in combination with low dose step up stimulation with recombinant FSH starting in the third day of menstruation.
89377512|NCT01371357|Experimental|TEST 2|2.4 g/day of guanidinoacetic acid + 3.0 g/day of choline dihydrogen citrate + 5 µg/day of B12 + 10 mg/day of B6 + 600 µg/day of folic acid
89377513|NCT01371357|Experimental|TEST 3|2.4 g/day of guanidinoacetic acid + 1.6 g/day of betaine HCl + 5 µg/day of B12 + 10 mg/day of B6 + 600 µg/day of folic acid
89377514|NCT01371357|Experimental|TEST 4|2.4 g/day of guanidinoacetic acid + 5 µg/day of B12 + 10 mg/day of B6 + 600 µg/day of folic acid
88850696|NCT04069117|No Intervention|• Control group|It contains 100 patients will undergo ovarian stimulation with low dose step up stimulation with recombinant FSH starting in the third day of menstruation
88850697|NCT00004933|Experimental|Homoharringtonine|
89377515|NCT01369173|Active Comparator|Mexican Menu|24 days, all foods and drinks provided, menu consists of traditional mexican meals
89377516|NCT01369173|Active Comparator|US diet|24 days, all foods and drinks provided, menu consists of foods commonly eaten in contemporary United States
88850698|NCT00004933|Active Comparator|Hydroxyurea|
89182194|NCT04096508|No Intervention|Control group|Patients sit comfortably in a chair for 20 min without music listening before the procedure.
89377517|NCT01369251|Experimental|Hygiene with water and soap|
89377518|NCT01369251|Active Comparator|Usual alcohol care|
89377519|NCT02660944|Experimental|RSLV-132|10 mg/kg RSLV-132
89377520|NCT02660944|Placebo Comparator|Placebo|Saline placebo
89377521|NCT01365351||Growth hormone|Children with growth hormone deficiency
89377522|NCT02370082|Experimental|SAVI SCOUT device|SAVI SCOUT device used to localize breast lesion which will then be removed surgically. The SAVI SCOUT is the intervention for localization of breast lesions.
88850699|NCT00005005|Experimental|1|Participants will receive PTH for 1 year followed by alendronate for 1 year.
88850700|NCT00005005|Experimental|2|Participants will receive PTH and alendronate for 1 year followed by alendronate for 1 year.
88850701|NCT00005005|Experimental|3|Participants will receive alendronate for 2 years.
88850702|NCT00005005|Active Comparator|4|Participants will receive PTH for 1 year followed by placebo for 1 year.
88850703|NCT00004465|Experimental|SYNSORB Pk|Oral Shiga toxin-binding agent (500 mg/kg/day)
89377523|NCT03625245|Placebo Comparator|Control Yogurt|Control yogurt
89377524|NCT03625245|Experimental|Yogurt Variety 1|Experimental Yogurt 1: Dextrin, wheat bran, whole oatmeal
89377525|NCT03625245|Experimental|Yogurt Variety 2|Experimental Yogurt 2: Pea protein, oatmeal
89377526|NCT04894071|Experimental|QA102 group|
89377527|NCT04894071|Placebo Comparator|Placebo group|
89377528|NCT02372422|Experimental|Transvaginal Cervical Length Group|Clinicians managing the patients were aware of the transvaginal cervical length ultrasound measurements.
89377529|NCT02372422|Other|Routine Care|Clinicians managing the patients were not aware of any transvaginal cervical length ultrasound measurements.
89377530|NCT03550287|Experimental|Experimental product|Dietary supplement (Shiitake extract) in a commercial soup at lunch for 8 weeks.
89377531|NCT03550287|Placebo Comparator|Placebo product|Isocaloric placebo (maltodextrin) in a commercial soup at lunch for 8 weeks.
89377532|NCT02372266|Experimental|Early Discharge Group|If safety criteria were met, women and infants were discharged home from the hospital at 12 to 24 hours after delivery with a planned home health visit within 48 hours of the discharge.
89377533|NCT02372266|Active Comparator|Routine Stay Group|Women and newborns were discharged no sooner than 48 hours after delivery and could stay voluntarily up to 72 hours.
89377534|NCT03293667|Other|Exploratory arm|
89377535|NCT01372449|Active Comparator|Memantine|
89377536|NCT01372449|Placebo Comparator|Placebo|Placebo Comparator
89377537|NCT02369926|Active Comparator|Group 1|Participants will be separated into two groups for scheduling purposes. Each group will complete the Multiple Sclerosis Functional Composite (MSFC) once weekly at the study site and once weekly at home for three weeks. They will alternate their visit dates with Group 2.
88850704|NCT00004465|Placebo Comparator|Placebo|Cornmeal placebo
89377538|NCT02369926|Active Comparator|Group 2|Participants will be separated into two groups for scheduling purposes. Each group will complete the Multiple Sclerosis Functional Composite (MSFC) once weekly at the study site and once weekly at home for three weeks. They will alternate their visit dates with Group 1.
89377539|NCT04688541|Active Comparator|First standard Foley catheter than Optitip catheter|"Each participant is given the 2 trial catheters for successive periods of 4 weeks (+ up to 7 days) for each treatment period:~Study period 1 = Standard Foley catheter Study period 2 = Optitip catheter"
89377540|NCT04688541|Active Comparator|First Optitip catheter than standard Foley catheter|"Each participant is given the 2 trial catheters for successive periods of 4 weeks (+ up to 7 days) for each treatment period:~Study period 1 = Optitip catheter Study period 2 = Standard Foley catheter"
89377541|NCT02364622|Sham Comparator|Tranditional fiberoptic bronchoscopy|The accurate placement of left-sided double lumen endobronchial tube into the left main bronchus was facilitated by traditional fiberoptic bronchoscopy.
89377542|NCT02364622|Experimental|Modified fiberoptic bronchoscopy|The accurate placement of left-sided double lumen endobronchial tube into the left main bronchus was facilitated by modified fiberoptic bronchoscopy.
89377543|NCT02364622|Experimental|Flexible Trachway intubating stylet|We used Flexible Trachway intubating stylet to facilitate the accurate placement of left-sided double lumen endobronchial tube into the left main bronchus.
89377544|NCT04666389|Placebo Comparator|Control group|No statins being used for prevention
89377545|NCT04666389|Active Comparator|Low-dose statin therapy|Atorvastatin 40 mg
89377546|NCT04666389|Active Comparator|High-dose statin therapy|Atorvastatin 80 mg
89377547|NCT02364544|Other|Health Technology Program|"The components of the treatment model include: 1) Prescriber Decision Assistant (PDA) 2) relapse prevention plan, 3) the daily support website 4) FOCUS, an interactive smart phone text-messaging application 5) a web-based, cognitive-behavioral therapy (CBT) program~All patients will be provided with pharmacological treatment (PDA), brief in-person relapse prevention counseling, and an Android mobile phone. The other program components will be provided to patients using a shared decision-making approach to assess need and preference."
89377548|NCT01369407||Enrolled Subjects|Enrolled subjects participate for up to 2 years
89377549|NCT02372110|Experimental|HPA, ANS stimulation|Oral administration of 400mg caffeine and 20mg hydrocortisone will stimulate HPA axis and ANS activity, respectively
89377550|NCT02372110|Placebo Comparator|Two cellulose placebo capsules|two cellulose capsule filled with acidophilus powder will be administered orally
89377551|NCT03227211||COPD exacerbated patients admitted|No specific intervention
89377552|NCT02372188|Experimental|Water|125 mL water are administered during or before gastric pH measurement
89377553|NCT02372188|Experimental|Caffeine|150 mg Caffeine and 125 mL water are administered during or before gastric pH measurement
89377554|NCT02372188|Experimental|Caffeine + homoeriodictyol sodium salt|150 mg Caffeine + 30 mg homoeriodictyol sodium salt and 125 mL water are administered during or before gastric pH measurement
89377555|NCT02372188|Experimental|homoeriodictyol sodium salt|30 mg homoeriodictyol sodium salt and 125 mL water are administered during the gastric pH measurement
89377556|NCT04652505||Observational (questionnaires)|Patients complete 3 questionnaires online over 15 minutes regarding coping strategies that may have been used, mental health and physical well-being in the past month, and if they have been following certain behaviors which the WHO has recommended during the coronavirus pandemic, such as regular hand washing and social distancing.
89377557|NCT01371435||Patients prescribed PAXIL|Patients with depression/depressed state or panic disorder prescribed PAXIL during study period
89377558|NCT03634449|Experimental|i-gel|After anesthetic durg given, i-gel, a supraglottic airway devices with a gastric suction channel, will be inserted into the patients' airway.
89377559|NCT03634449|Active Comparator|endotracheal tube|After anesthetic durg given, the endotracheal tube, traditional use for protect airway during the laparoscopic surgery, will be inserted into the patients' airway.
89377560|NCT01319643|Experimental|Oxygenation, rigorous normal|Patients admitted in intensive care unit for 3 days. Administration of the lowest inspiratory fraction dose of oxygen to maintain oxygen peripheral saturation (SpO2) between 94 and 98% or an arterial partial pressure of oxygen (PaO2) between 70 and 100 mmHg. No oxygen addition administer for transports or diagnostic manoeuvres. Conventional clinical criteria for airways control and ventilation technique.
89377561|NCT01319643|No Intervention|Oxygen, free conventional|Patients admitted in intensive care units for 3 days. Administration of oxygen inspiratory fractions to maintain SpO2 over 97%, up to a PaO2 of 150 mmHg. Oxygen addition administer for transports or diagnostic manoeuvres. Conventional clinical criteria for airways control and ventilation technique.
89377562|NCT02975336|Placebo Comparator|Double-Blind Placebo-Controlled (DBPC) Period: Placebo|
89377563|NCT02975336|Experimental|DBPC Period: M2951 25 mg QD|
89377564|NCT02975336|Experimental|DBPC Period: M2951 75 mg QD|
89377565|NCT02975336|Experimental|DBPC Period: M2951 50 mg BID|
89377566|NCT02975336|Experimental|Long-Term Extension (LTE) Period: Placebo/ M2951 50 mg BID|
89377567|NCT02975336|Experimental|LTE Period: M2951 25 mg QD/ M2951 50 mg BID|
89377568|NCT02975336|Experimental|LTE Period: M2951 75 mg QD/ M2951 50 mg BID|
89377569|NCT02975336|Experimental|LTE Period: M2951 50 mg BID/ M2951 50 mg BID|
89377570|NCT01371513||PSA level|more than 2.5ng/ml
88850705|NCT00005059|Experimental|carboplatin + paclitaxel|"Following completion of the Lubben Social Network Scale and Frailty Questionnaire, patients receive carboplatin IV over 30 minutes and paclitaxel IV over 60 minutes on days 1, 8, and 15.~Treatment repeats every 28 days for 2 courses. Patients with complete response receive 2 additional courses of therapy. Patients with partial response or stable disease may receive additional courses of therapy at investigator's discretion. Patients are followed every 3 months for 5 years or until disease progression."
88875308|NCT02584608|Experimental|Treatment|ACTIMMUNE 50 µg/m2 subcutaneously three times per week (TIW) for 8 weeks
88875309|NCT02584686|Experimental|(BTX) A Group|The treatment group will be injected intracavernously with a trimix solution for colour Doppler assessment, followed, on a separate day by 50 units of Botulinum toxin (BTX) A.
88850706|NCT00005065|Experimental|Arm I|Patients receive paclitaxel IV over 3 hours followed by carboplatin IV over 1-2 hours every 3 weeks for 3 courses. Three weeks after completion of induction chemotherapy, patients receive Gd-Tex IV over 30 minutes twice weekly for 10 doses during preoperative radiotherapy. Radiotherapy is administered daily 5 days a week for 5 weeks. Approximately 3.5 weeks after completion of preoperative radiotherapy, patients undergo complete surgical resection. Three hours prior to surgery, patients receive an eleventh dose of Gd-Tex if they do not develop grade 3 or 4 toxicity with the tenth dose. Patients also receive a MRI without contrast prior to surgery. If the tumor is found to be unresectable, patients may receive additional radiation and/or chemotherapy.
89377571|NCT02364154||Control group-Blood sampling|-subjects with a normal colonoscopy
89377572|NCT02364154||Study group-Blood sampling|- subjects with colorectal cancer after colonoscopy
89377573|NCT02369614|Active Comparator|Active Comparator:1 Hz rTMS|Active Comparator: 1 Hz rTMS
89377574|NCT02369614|Active Comparator|Active Comparator:10 Hz rTMS|Active Comparator:10 Hz rTMS
89377575|NCT02369614|Sham Comparator|Sham Comparator:Sham rTMS|Sham Comparator: Sham rTMS
89377576|NCT02369614|No Intervention|OASIS treatment as usual|OASIS treatment as usual
89377577|NCT03124563|Experimental|Control group|Participants will wear a Fitbit Zip to record their daily activity data, which will be deidentified and aggregated with an online platform called Fitabase. Participants in the control group will be matched with the intervention group for how much contact they have with the researcher.
89377578|NCT03124563|Experimental|Implementation Intention Condition|Participants will wear a Fitbit Zip to record their daily activity data, which will be deidentified and aggregated with an online platform called Fitabase. Participants in this arm will receive all components of the intervention: scheduling, maps, and activity goals.
89377579|NCT02364232|Experimental|Home-based|"Participants in home-based training graoup will receive 1.5 hours/ day, 3 days a week, for 4 contious weeks at home. Participants will receive 2 training stages, including bilateral training with mirror feedback for 30-45 minutes and functional training for 45-60 minutes. Each training stage hase to include above 2 activities.After the end of the home-based training, a four-week wash-out period followed. Then, patients will receive the clinic-based training for 4 continuous weeks.~Before and after the treatment, a total of 4 evaluations were conducted, including clinical assessments and blood test (each 9c.c.). One month after the end of the course of treatment will be assessed."
89377580|NCT02364232|Active Comparator|Clinic-based|"Participants in clinic-based training graoup will receive 1.5 hours/ day, 3 days a week, for 4 contious weeks at home. Participants will receive 2 training stages, including bilateral training with mirror feedback for 30-45 minutes and functional training for 45-60 minutes. Each training stage hase to include above 2 activities.After the end of the clinic-based training, a four-week wash-out period followed. Then, patients will receive the home-based training for 4 continuous weeks.~Before and after the treatment, a total of 4 evaluations were conducted, including clinical assessments and blood test (each 9c.c.). One month after the end of the course of treatment will be assessed."
89377581|NCT02359396|Experimental|5.0g of MZRW|The participants will receive 5.0g of MZRW at 9 am .
89377582|NCT02359396|Experimental|7.5g of MZRW|The participants will receive 7.5g of MZRW at 9 am.
89377583|NCT02359396|Experimental|10g of MZRW|The participants will receive 10g of MZRW at 9 am.
89377584|NCT01369719|Experimental|Osveral|20 mg/kg oral osveral daily
89377585|NCT01369719|Active Comparator|desferal|40mg/kg desferal for 6 nights in a week subcutaneously
89377586|NCT04479046|Active Comparator|Stainless steel crowns|3M ESPE
88850707|NCT00386191|Experimental|1|50 mg
88850708|NCT00386191|Experimental|2|75 mg
89377587|NCT04479046|Experimental|Zirconia crowns|Nu Smile
89377588|NCT04479046|Experimental|PMMA crowns|Dental Direkt
89377589|NCT01369797|No Intervention|reference|"reference group, where every patient will benefit: of the same GGA at home as those of the  specific intervention  group. The GGA results will not be supplied to the family practioner."
88850709|NCT00423241|Experimental|SEMPERFLO Pain Management System|
88850710|NCT00423241|Active Comparator|ON-Q PainBuster Post-Op Pain Relief System|
89377590|NCT01369797|Experimental|specific intervention|"specific intervention group, where every patient will benefit: of an GGA at home. According to the frailties or the detected morbidity, a specific plan of intervention will be established for the person. all the preventive actions will be coordinated by UPSAV."
89377591|NCT02369380|Experimental|Hyaluronic acid|Injections of hyaluronic acid under metatarsal heads
88850711|NCT00385177|Experimental|A|SN2310 Injectable Emulsion
88850712|NCT00005089|Experimental|CHOP + Rituximab + RT|3 21-day cycles of CHOP (cyclophosphamide 750 mg/m^2, doxorubicin 50 mg/m^2, vincristine 1.4 mg/m^2, prednisone 100 mg x 5 days) + Rituximab 375 mg/m^2 (x 2 days for cycle 1, x 3 days for cycles 2-3). RT 4000-5500 cGy given in 25 fractions starting 3 weeks after completion of CHOP + Rituximab.
88850713|NCT00005605||Tamoxifen group|
88850714|NCT00005605||Chemotherapy group|
88850715|NCT00005113|Experimental|1|Participants will receive SRL, CsA/tacrolimus, and corticosteroids for up to 36 months
88850716|NCT00005113|Experimental|2|Participants will receive standard CsA or tacrolimus-based double or triple drug therapy for up to 36 months
88850717|NCT00005617|Experimental|Group A|No. DC: 10^5 Route of Immunization: ID
89377592|NCT01371669||IPAH or CPEPH|Idiopathic pulmonary arterial hypertension (IPAH) or pulmonary hypertension associated with chronic post-embolic pulmonary hypertension (CPEPH)
89377593|NCT02038816|Experimental|Deferasirox + Azacitidine|Azacitidine 75 mg/m2 daily X 7 days every 28 days for 6 cycles + Deferasirox 10-30 mg/kg/d depending on transfusion needs
89377594|NCT02038816|Active Comparator|Azacitidine|Azacitidine 75 mg/m2 daily X 7 days every 28 days for 6 cycles
89377595|NCT04809831|Active Comparator|Trial Group - Biorepair Peribioma Toothpaste + Mousse|Domiciliary oral hygiene with Biorepair Peribioma Toothpaste in association with Peribioma Mousse twice a day until T2 session.
89377596|NCT04809831|Active Comparator|Control Group - Curasept Toothpaste (chlorhexidine 0,2%)|Domiciliary oral care with Curasept Toothpaste (chlorhexidine 0,2%) twice a day until T2 session.
89377597|NCT02359162|Experimental|P-Gemox|"P-Gemox:gemcitabine :1250mg/m2 (ivdrip) on days 1, oxaliplatin :85 mg/m2 (ivdrip) on day 1, and pegaspargase : 2500 IU/m2 (intramuscular injection) on day 1.Cycle is repeated every 14 days.~IMRT：IMRT is delivered using 6-8 MeV linear accelerator using intensity-modulated radiation treatment planning. The radiation dose is 50 grays (Gy) in 25 fractions."
89377598|NCT02359162|Active Comparator|EPOCH|"EPOCH:Patients received the EPOCH chemotherapy regimen every 3 weeks. The EPOCH regimen included a 24 h continuous infusion of etoposide (50 mg/m 2 /day), vincristine (0.4 mg/m 2 /day) and doxorubicin(10 mg/m 2 /day administered on days 1-4, followed by cyclophosphamide (750 mg/m2 /day) over 15 min intravenously on day 5 and prednisone (60 mg/m 2 /day) on days1- 5 orally.~IMRT：IMRT is delivered using 6-8 MeV linear accelerator using intensity-modulated radiation treatment planning. The radiation dose is 50 grays (Gy) in 25 fractions."
89377599|NCT03634605|Experimental|Case Group|Chemical pleurodesis for the this group was done using 2 grams of tetracycline 3% ointment (Aerotex®, Sina Daru, Tehran, Iran), 5 milliliter of lidocaine 2% and 50 milliliter normal saline that was injected through embedded thoracostomy tube
89377600|NCT03634605|Placebo Comparator|Control Group|Chemical pleurodesis for this group was done using 5 milliliter of lidocaine 2% and 50 milliliter normal saline that was injected through embedded thoracostomy tube
89377601|NCT05653804|Experimental|tele-visit by HCP|Patients receive a annual CPAP remote visit by HCP technician, then home visit the following year
89377602|NCT05653804|No Intervention|home visit by HCP|Standard care : patients receive an annual CPAP home visit by HCP technician
89377603|NCT02363764||Expectorating CF patients|"(=able to expectorate sputum spontaneously)~Nasal swab~Cough swab~Spontaneous expectorated sputum~Questionnaire"
89377604|NCT02363764||Non-expectorating CF patients|"(=unable to expectorate sputum spontaneously)~Nasal swab~Cough swab~Induced sputum after inhalation of hypertonic saline (NaCl 6%)~Questionnaire"
89377605|NCT02363764||Bronchoscopy CF patients|"(=undergoing clinically indicated bronchoscopy)~Nasal swab~Cough swab~Induced sputum after inhalation of hypertonic saline (NaCl 6%)~Bronchoalveolar lavage (BAL)"
89377606|NCT03655418|Experimental|Intervention|The prevention program RECUR will be administered.
89377607|NCT03655418|No Intervention|Waitlist control|The prevention program RECUR will be administered after a year of waiting.
89377608|NCT02363842|Experimental|Skin IQ™ MCM Coverlet|Skin IQ™ MCM coverlet used over a commercially available pressure redistribution surface already in use at the participating institution to manage patients at risk for tissue breakdown
89377609|NCT02363842|Active Comparator|Pressure redistribution surface|Commercially available pressure redistribution surface already in use at participating study sites (SOC) to manage patients at risk for tissue breakdown
89377610|NCT03655184||MOH group|Patients with medication overuse headache
89377611|NCT03655184||Episodic migraine group|Patients with episodic migraine
89377612|NCT03655184||Healthy group|No headache or other special medical history
89377613|NCT02369302|Experimental|DWC20141|multiple dose of DWC20141
89377614|NCT02369302|Experimental|DWC20142|multiple dose of DWC20142
89377615|NCT02369302|Experimental|DWC20141+DWC20142|multiple dose of DWC20141 and DWC20142
89377616|NCT03079869|Other|Ferric Citrate|Auryxia, 210 mg ferric iron tablets equivalent to 1 g of ferric citrate are supplied as 200 tablets in 400-cc high-density polyethylene bottles.
89377617|NCT02363920|Placebo Comparator|spontaneous breathing trial|the patients will be asked to breathe spontaneously using their acutal low oxygen flow
89377618|NCT02363920|Active Comparator|HOF20|the patients will be asked to breathe with HOF of 20 L/min
89377619|NCT02363920|Active Comparator|HOF30|the patients will be asked to breathe with HOF of 30 L/min
89377620|NCT02363920|Active Comparator|noninvasive mechanical ventilation (NIV)|the patients will be asked to breathe with the support of a ventilator via a oro-nasal interface
89377621|NCT03654794||Patients with hemochromatosis|"The study is conducted with mononuclear cells obtained from patients undergoing phlebotomy as part of a hemochromatosis treatment.~The blood samples will be recovered immediately after their completion. 40 mL of blood will be collected and the mononuclear cells separated using a ficoll gradient.~Cell pharmacokinetics of tacrolimus"
88850718|NCT00005617|Experimental|Group B|No. DC: 10^5 Route of Immunization: IV
88850719|NCT00005617|Experimental|Group C|No. DC: 10^6 Route of Immunization: ID
88850720|NCT00005617|Experimental|Group D|No. DC: 10^6 Route of Immunization: IV
88850721|NCT00005617|Experimental|Group E|No. DC: 10^7 Route of Immunization: ID
88850722|NCT00005617|Experimental|Group F|No. DC: 10^7 Route of Immunization: IV
88850723|NCT02972749|Experimental|Intervention|Recommendations for lifestyle changes which have shown to reduce IOP. recommendations include: Moderate aerobic exercise, High fiber diet, sleeping with a head elevation and moderating caffeine intake. while continuing prescribed medical therapy.
89377622|NCT03654170|Experimental|All Subjects|BI 425809 mixed with [C14] BI 425809
88850724|NCT02972749|No Intervention|Control|No intervention. patients are instructed to continue prescribed medical therapy.
88850725|NCT00005629|Experimental|Group A - first dosing group|Patients will receive three biweekly intradermal vaccinations with four HLA-A*0201-binding AFP-derived peptides (100 ug dose) emulsified in 2 ml of Montanide ISA-51.
88850726|NCT00005629|Experimental|Arm B - dosing group 2|Patients will receive three biweekly intradermal vaccinations with four HLA-A*0201-binding AFP-derived peptides (500 ug dose) emulsified in 2 ml of Montanide ISA-51.
88850727|NCT00005629|Experimental|Group 3 - dosing level 3|Patients will receive three biweekly intradermal vaccinations with four HLA-A*0201-binding AFP-derived peptides (1000 ug dose) emulsified in 2 ml of Montanide ISA-51.
88850728|NCT00385411|Experimental|valproate|
89377623|NCT03000153|Experimental|Completing the Goals Form|In this arm, client participants will complete the Goals Form in collaboration with their therapists at the start of every session.
89377624|NCT03000153|No Intervention|therapy as usual|In this arm, clients will have therapy as usual.
89377625|NCT02369146|Experimental|cohort 1|Subjects will receive 8 doses of the UB-421 by intravenous infusion at 10 mg/kg weekly
89377626|NCT02369146|Experimental|cohort 2|Subjects will receive 8 doses of the UB-421 by intravenous infusion at 25 mg/kg weekly
89377627|NCT02363452|Experimental|AGS|Reverse transcriptase inhibitors
88850729|NCT00005713||Continuing, preventative care for asthma|Low-income children with asthma will receive continuing, preventive care for asthma with trained staff in New York City Bureau of Child Health clinics
88850730|NCT02972827|Experimental|NICOM/FloTrac|500-1000ml Crystalloid fluid challenge (normal saline or plasmalyte) to be given for positive passive leg raise test by either device, and also will be given at baseline, regardless of baseline PLR response.
88850731|NCT00005305||Hemophilic individuals|Subjects receiving multiple blood products for treatment of hemophilia
88850732|NCT00386035||1: DC Group|HIV infected participants who will stop or defer ART until the CD4 cell count drops below 250 cells/mm3 and who discontinue ART when CD4 cell count reaches above 350 cells/mm3. Participants are followed by episodic ART based on CD4 cell count.
88850733|NCT00386035||2: VS Group|HIV infected participants who continue ART to keep viral loads as low as possible, regardless of CD4 cell count.
88850734|NCT00005773|Experimental|Early iNO Management|Initiation of iNO in use for term and near-term infants in respiratory failure with an oxygenation index between 15-25.
88850735|NCT00005773|Active Comparator|Standard iNO management|Begin a sham initiation of iNO in term and near-term infants in respiratory failure with an oxygenation index (OI) between 15-25; initiated actual iNO therapy based on standard threshold (OI >=25).
88850736|NCT00005797|Other|BuCy2|Busulfan & Cyclophosphamide
88850737|NCT00005797|Other|VP16/TBI|Fractionated Total Body Irradiation + VP-16
88850738|NCT02132754|Experimental|MK-4166 0.0015 mg|Participant received 0.0015 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
88850739|NCT02132754|Experimental|MK-4166 0.0045 mg|Participant received 0.0045 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
88850740|NCT02132754|Experimental|MK-4166 0.014 mg|Participant received 0.014 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
88850741|NCT02132754|Experimental|MK-4166 0.04 mg|Participant received 0.04 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
88850742|NCT02132754|Experimental|MK-4166 0.12 mg|Participant received 0.12 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
88850743|NCT02132754|Experimental|MK-4166 0.37 mg|Participant received 0.37 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
88850744|NCT02132754|Experimental|MK-4166 1.1 mg|Participant received 1.1 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
88850745|NCT02132754|Experimental|MK-4166 3.3 mg|Participant received 3.3 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
88850746|NCT02132754|Experimental|MK-4166 10 mg|Participant received 10 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
88850747|NCT02132754|Experimental|MK-4166 30 mg|Participants received 30 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
88850748|NCT02132754|Experimental|MK-4166 42 mg|Participants received 42 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
88850749|NCT02132754|Experimental|MK-4166 59 mg|Participants received 59 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
88850750|NCT02132754|Experimental|MK-4166 82 mg|Participants received 82 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
88850751|NCT02132754|Experimental|MK-4166 120 mg|Participants received 120 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
89377628|NCT02939313|Experimental|medial prefrontal|Individuals will receive medial prefrontal cortex stimulation
89377629|NCT02939313|Experimental|dorsolateral prefrontal|Individuals will receive dorsolateral prefrontal cortex stimulation
89377630|NCT02939313|Sham Comparator|sham|Individuals will receive sham stimulation to the medial prefrontal and dorsolateral prefrontal cortex
88850752|NCT02132754|Experimental|MK-4166 170 mg|Participants received 170 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
88850753|NCT02132754|Experimental|MK-4166 240 mg|Participants received 240 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
89377631|NCT02363608||standard post surgery care|An initial cohort of consecutive patients admitted to the 15th floor of the hospital on a Monday or Tuesday will form the usual care control arm of the study. Once this cohort is completed, the Caring Canines program will start.
89377632|NCT02363608||Caring Canines program|Once the standard of care cohort is completed, the Caring Canines program will start making visits on the 15th floor and a second cohort of consecutive patients admitted to M15 on a Monday or Tuesday will form the intervention (experimental) arm of the study.patients admitted to M15 on a Monday or Tuesday will form the intervention (experimental) arm of the study.
89377633|NCT02363608||staff canine-assisted|For the staff portion of this study a longitudinal pre and post intervention design will be used. Baseline staff assessments will occur prior to the Caring Canine program being implemented on the unit. The assessments include questions about compassion satisfaction and compassion fatigue as well as some open ended questions about your thoughts on the Caring Canines program. Post assessment will occur after the program has been active on the unit for at least 6 weeks. Only staff who work at least one Monday - Friday day shift each week will be eligible to participate.
88850754|NCT02132754|Experimental|MK-4166 340 mg|Participants received 340 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
88850755|NCT02132754|Experimental|MK-4166 480 mg|Participants received 480 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
88850756|NCT02132754|Experimental|MK-4166 670 mg|Participants received 670 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
88850757|NCT02132754|Experimental|MK-4166 900 mg|Participants received 900 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
88850758|NCT02132754|Experimental|MK-4166 1.1 mg + Pembro|Participants received 1.1 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
88850759|NCT02132754|Experimental|MK-4166 3.3 mg + Pembro|Participants received 3.3 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
88850760|NCT02132754|Experimental|MK-4166 10 mg + Pembro|Participants received 10 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
88850761|NCT02132754|Experimental|MK-4166 30 mg + Pembro|Participants received 30 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
88850762|NCT02132754|Experimental|MK-4166 42 mg + Pembro|Participants received 42 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
88850763|NCT02132754|Experimental|MK-4166 59 mg + Pembro|Participants received 59 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
88850764|NCT02132754|Experimental|MK-4166 82 mg + Pembro|Participants received 82 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
88850765|NCT02132754|Experimental|MK-4166 120 mg + Pembro|Participants received 120 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
88850766|NCT02132754|Experimental|MK-4166 170 mg + Pembro|Participants received 170 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
88850767|NCT02132754|Experimental|MK-4166 240 mg + Pembro|Participants received 240 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
88850768|NCT02132754|Experimental|MK-4166 340 mg + Pembro|Participants received 340 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
88850769|NCT02132754|Experimental|MK-4166 480 mg + Pembro|Participants received 480 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
88850770|NCT02132754|Experimental|MK-4166 670 mg + Pembro|Participants received 670 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
88850771|NCT02132754|Experimental|MK-4166 900 mg + Pembro|Participants received 900 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
88850772|NCT02151786||Thirty milligrams of lansoprazole|Thirty milligrams of lansoprazole is mixed in physiological saline (JP) or 5 percent (%) glucose solution for injection (JP) and administered twice daily by drip infusion or dissolved in 20 milliliter (mL) of physiological saline (JP) or 5% glucose solution for injection (JP) and administered twice daily by direct slow intravenous injection.
88850773|NCT02132130|Experimental|CGF166 dose 20 uL|single dose volume #1
88850774|NCT02132130|Experimental|CGF166 dose 30 and 40 uL|single dose volume #2
88850775|NCT02132130|Experimental|CGF166 dose 40 uL|single dose volume #3
88850776|NCT02132130|Experimental|CGF166 dose 60 uL|single dose volume #4
88850777|NCT02132130|Experimental|CFG166 dose 30 uL|Single dose volume #5
88850778|NCT02131662|Experimental|VPR 4 mg|
88850779|NCT02131662|Experimental|VPR 2 mg|
88850780|NCT02131662|Experimental|VPR 1 mg|
88850781|NCT02131662|Experimental|VPR 0.5 mg|
88850782|NCT02131662|Placebo Comparator|Placebo|
88850783|NCT04188366|Experimental|FAMES Modification|3-month trial of FAMES. Results from modifications will be used to by stakeholders (i.e., family members, client, providers, organizational leadership,) to inform finalization and implementation of FAMES
88850784|NCT04188366|Experimental|FAMES Pilot Trial|Pilot testing of FAMES and implementation toolkit
88850785|NCT02106156||Chronic Hepatitis C|Participants with chronic hepatitis C planned for treatment with peginterferon alfa-2a alone or in combination with ribavirin according to routine clinical practice will be observed in this study.
88850786|NCT05137002|Experimental|CIN-107 0.5 mg|Remain on background anti-hypersensitive regimen for 8 weeks. After 8 weeks, patient will receive the highest dose of CIN-107 (2 mg) and discontinue their background antihypertensive agent(s) for 4 weeks
88850787|NCT05137002|Experimental|CIN-107 1 mg|Remain on background anti-hypersensitive regimen for 8 weeks. After 8 weeks, patient will receive the highest dose of CIN-107 (2 mg) and discontinue their background antihypertensive agent(s) for 4 weeks
88850788|NCT05137002|Experimental|CIN-107 2 mg|Remain on background anti-hypersensitive regimen for 8 weeks. After 8 weeks, patient may remain on CIN-107 (2 mg) and discontinue their background antihypertensive agent(s) for 4 weeks or withdraw study participation depending on BP control
88850789|NCT05137002|Placebo Comparator|Placebo|Remain on background anti-hypersensitive regimen for 8 weeks. After 8 weeks, patient will receive the highest dose of CIN-107 (2mg) and discontinue their background antihypertensive agent(s) for 4 weeks
89377634|NCT03634137|Experimental|Afamelanotide Group 1|A 16 mg bioresorbable afamelanotide implant (Group 1) from the previous manufacturing process.
89377635|NCT03634137|Experimental|Afamelanotide Group 2|A 16 mg bioresorbable afamelanotide implant (Group 2) from the optimized final manufacturing process.
89377636|NCT02358772||Pre-hospital thrombolysis|Patients with acute ischemic stroke who are cared in a specialized STroke Emergency MObile (STEMO) before admission to the Hospital and receive thrombolytic therapy (either in STEMO or in Hospital).
89377637|NCT02358772||In-hospital thrombolysis|Patients with acute ischemic stroke who receive thrombolytic therapy after admission to an University Hospital.
89377638|NCT02358694|Experimental|Active Treatment Group|Patients who weigh less than 40 Kg will receive 5 g daily (2.5 g PO BID) of Serum-derived bovine immunoglobulin/ protein isolate Patients who weigh 40 Kg or more will receive 10 g daily (5 g PO BID) of Serum-derived bovine immunoglobulin/ protein isolate
89377639|NCT02358694|Placebo Comparator|Placebo Arm|The placebo group will receive a hydrolyzed gelatin protein for next 4 weeks on a daily basis.
89377640|NCT04473807|Other|DASH-AF|Patients with history of highly symptomatic persistent or paroxysmal AF who are scheduled for sotalol therapy once in sinus rhythm will be enrolled in this study.
89377641|NCT02368990||NSCLC T790M positive|NSCLC patients who have had 1st line treatment with an approved EGFR targeted TKI, who are known to be T790M mutation positive and who have been prescribed platinum based doublet chemotherapy (pemetrexed + cisplatin/carboplatin) as a 2nd line treatment as part of their standard care.
89377642|NCT02323659|Active Comparator|Methotrexate arm|Patients assigned to receive methotrexate
89377643|NCT02323659|Active Comparator|Interferon Alfa-2b|Patients assigned to receive Interferon alfa 2b
89377644|NCT01372527|Experimental|TopCare Intervention|"The TOP-CARE intervention will be based on a medical informatics platform that:~Identifies all patients eligible for any of the three cancer screening programs~Links patients with a specific clinician~Offers a visit-independent method for clinicians to review panels of their eligible patients~For patients due for one or more cancer screenings, clinicians will access a web-based informatics tool to:~Screen their panel based upon risk~Defer patients, document exclusions, and update the EHR~Order a screening test with patient information material based upon the patient's risk profile and automatically initiate the process of:~Informing the patient by letter of the need to schedule a test, educating the patient with respect to the benefits of cancer screening, and properly documenting the transaction in the patient's EHR, or~Referral to a patient navigator for patients most likely to benefit from this more intensive approach"
89377645|NCT01372527|Active Comparator|Augmented Standard Care|In augmented standard care control practices, we will implement a system that includes: 1) a population-based perspective to identify all eligible patients overdue for screening, 2) an automated, centralized process to contact selected patients by letter, 3) a result management system that automatically tracks test scheduling and completion, 4) a web-based, easily accessible tool allowing practice personnel to contact patients not completing testing, and 5) use of patient navigators for high risk patients not responding to initial outreach. In the control arm, the process of escalating the reminder intervention from a letter, to contact by phone call, to a patient navigator, will occur in a standard algorithmic fashion without provider input.
89377646|NCT02358460|Active Comparator|Pressure-limited ventilation|
89377647|NCT02358460|Active Comparator|Volume-targeted ventilation|
89377648|NCT02358616||Former VOICE (MTN-003) participants|Qualitative interviews and focus group discussions conducted on former VOICE participants. All participants to receive interviews.
89377649|NCT02368834|Experimental|intervention group|A psychoeducation program was delivered to the parents/caregivers
89377650|NCT02368834|No Intervention|control group|This group waited for 3 months, only receiving general consultation.
89377651|NCT03634059|Experimental|apatinib|apatinib 500mg qd po plus Erlotinib 150mg qd po / apatinib 500mg qd po plus Icotinib 125mg tid po
89377652|NCT02358382|No Intervention|Alpha Stat|Standard CPB blood gas management conditions
89377653|NCT02358382|Experimental|pH Stat|pH stat blood gas management conditions.
89377654|NCT02358304|Active Comparator|a:Patients with aggressive CGCG|Patients had been clinically with CGCG and confirmed by histopathological findings were selected for the study. Gender, age, medical history, symptoms, size, and site of the lesions , duration of disease were recorded. Local ethical committee approval was obtained before the trial started and all patients gave written informed consent. Patients were randomly divided into two groups .First group received nasal spray calcitonin 200 IU/ day for 3 months after surgical curettage was done.
89377655|NCT02358304|Placebo Comparator|b; Patients with aggressive CGCG|Patients had been clinically with CGCG and confirmed by histopathological findings were selected for the study. Gender, age, medical history, symptoms, size, and site of the lesions , duration of disease were recorded. Local ethical committee approval was obtained before the trial started and all patients gave written informed consent. Patients were randomly divided into two groups . second group received placebo after surgical curettage for 3 months
89377656|NCT02363218|Experimental|CyberKnife|Hepatocellular Carcinoma Patients Treated With CyberKnife
88850790|NCT01598610|Experimental|Intended Users of the Monitoring System|Untrained subjects with diabetes use CONTOUR® PLUS Investigational BG Monitoring System.
89182195|NCT04096352|Experimental|Indirect+Direct method|"Indirect method: one session of information on voice function and voice hygiene.~Direct method: three sessions of voice training using virtual reality simulations over a course of 3 weeks."
89182196|NCT04096352|Active Comparator|Indirect method|Indirect method: one session of information on voice function and voice hygiene.
89377657|NCT01319955|Experimental|Influenza vaccine (trivalent inactivated vaccine)|
89377658|NCT01319955|Active Comparator|Inactivated polio vaccine|
89377659|NCT02363530|Experimental|HPMC group|Patients use the intervention Hydroxypropyl ethylcellulose (HPMC) 2% gel during the cataract surgery.
89377660|NCT02363530|Placebo Comparator|BSS group|Patients use balanced salt solution (BSS) during the cataract surgery.
89377661|NCT02363140|No Intervention|Group One patients in age group 18--20 years,|"Patients should be aged 18--20 years or 35--45years~Asymptomatic knee for past 6 months.~Painless flexion-extension movements at knee joint."
89377662|NCT02363140|Active Comparator|Group Two patients in age group 35-45 years,|"Patients should be aged 18--20 years or 35--45years~Asymptomatic knee for past 6 months.~Painless flexion-extension movements at knee joint."
89377663|NCT02363140|Active Comparator|Group Three Patients aged 75|"Patients should be aged 75 or older~Knee X-ray showing no more than Kellgren-Lawrence grade II osteoarthrtis~No clinical suspicion of meniscus tear~Painless flexion-extension movements at knee joint."
88850791|NCT04738812|Experimental|Intensified TB treatment|"Increased doses of rifampicin (R) to 35±5 mg/kg daily and isoniazid (H) 10±2 mg/kg daily together with standard-dose of pyrazinamide (Z) 20-30 mg/kg daily + ethambutol (E) 15-20 mg/kg daily for 8 weeks (initial phase of TB treatment).~Prednisone 40 to 80 mg once a day (OD) according to weight bands for 2 weeks, followed by 20 to 40 mg OD according to weight bands for 2 weeks, then 10 to 20 mg OD according to weight bands for the last 2 weeks (total duration: 6 weeks). Because of the corticosteroid treatment, albendazole 400 mg OD will be given to participants for 3 days.~Continuation phase: 16 weeks of RH."
89377664|NCT02363140|Active Comparator|Group Four, any age due to undergo a surgical meniscus repair|1. Patients should have presented with clinical signs to suggest meniscus tear indicating potential need for surgical meniscus repair
88850792|NCT04738812|Active Comparator|WHO standard TB treatment|"Standard-dose of R 8-12 mg/kg daily + H 4-6 mg/kg daily + Z 20-30 mg/kg daily + E 15-20 mg/kg daily for 8 weeks.~Continuation phase: 16 weeks of RH."
88850793|NCT04737954|Experimental|Suspected VTE patients|Venous blood draw of up to 20ML and up to 6 fingerstick capillary draws
89182197|NCT02600702|No Intervention|usual care|quadricep exercise
89377665|NCT02362906|Experimental|Injection,medications and application|"Intravenous injection:~bacterial pneumonia: second generation cephalosporin; mycoplasma pneumonia: erythromycin or azithromycin; viral pneumonia: Xiyanping injection, produced by Jiangxi Qing Feng Pharmaceutical Co.,Ltd; Medications: according to TCM syndrome differentiations; Wind-heat blocking lungs pattern(feng re bi fei zheng): wind-heat formula granules; phlegm-heat blocking lungs pattern(tan re bi fei zheng): phlegm-heat formula granules; external application: Fu-xiong San."
89377666|NCT02362906|Experimental|Injection and medications|"Intravenous injection:~bacterial pneumonia：second generation cephalosporin; mycoplasma pneumonia：erythromycin or azithromycin; viral pneumonia：Xiyanping injection, produced by Jiangxi Qing Feng Pharmaceutical Co.,Ltd; Medications: according to TCM syndrome differentiations; Wind-heat blocking lungs pattern(feng re bi fei zheng): wind-heat formula granules; phlegm-heat blocking lungs pattern(tan re bi fei zheng): phlegm-heat formula granules."
88850794|NCT01625988|Experimental|LY2951742|LY2951742: 150 milligrams (mg), subcutaneous (SC) injection on Day 1 and then once every other week for a total of 6 doses during the 12-week Treatment Period.
88850795|NCT01625988|Placebo Comparator|Placebo|Placebo: 0.9% Sodium Chloride, Untied States Pharmacopoeia (USP), subcutaneous (SC) injection on Day 1 and then once every other week for a total of 6 doses during the 12-week Treatment Period.
89377667|NCT02362906|Experimental|Injection and application|"Intravenous injection:~bacterial pneumonia: second generation cephalosporin; mycoplasma pneumonia: erythromycin or azithromycin; viral pneumonia: Xiyanping injection, produced by Jiangxi Qing Feng Pharmaceutical Co.,Ltd; external application: Fu-xiong San."
89377668|NCT02368912|Experimental|1. Single ascending dose (SAD), ASP1707 dose levels 1-7|healthy young male
89377669|NCT02368912|Experimental|2. Single ascending dose (SAD), placebo dose levels 1-7|healthy young male
89377670|NCT02368912|Experimental|3. Food effect (FE), ASP1707 fasted|Fasted healthy young male
89377671|NCT02368912|Experimental|4. Food effect (FE), ASP1707 fed|Fed healthy young male
89377672|NCT02368912|Experimental|5. Multiple ascending dose (MAD), ASP1707 dose levels 1-4|healthy elderly male
89377673|NCT02368912|Experimental|6. Multiple ascending dose (MAD), Placebo, dose levels 1-4|healthy elderly male
89377674|NCT02368912|Experimental|7. Multiple ascending dose (MAD), ASP1707, dose levels 1-2|healthy pre-menopausal female
89377675|NCT02368912|Experimental|8. Multiple ascending dose (MAD), Placebo dose levels 1-2|healthy pre-menopausal female
88850796|NCT02131272|Experimental|Insulin detemir and diet/exercise|Current OADs i.e. metformin or other OADs are continued unchanged
89182198|NCT02600702|Experimental|Siriraj home base exercise|Knee exercise protocol for 12 position for 3 months with low-impact aerobic exercise
89182199|NCT02600702|Active Comparator|Modalities and exercise|Physical modalities for 6 weeks and Knee exercise protocol for 12 position for 3 months with low-impact aerobic exercise
89182200|NCT01796145|Experimental|TACE|
89182201|NCT01796145|Experimental|Systemic Therapy|
89182202|NCT01796145|Experimental|Surgery|
89182203|NCT04095962|Experimental|Experimental Group|Training protocol will be held for 6 months, twice per week/ 60 min per sessions.
89182204|NCT04095962|No Intervention|Control Group|Participants in the control group will receive monthly sessions regarding physical activity and health related topics as a complement to standard care. No specific exercise intervention will be conducted for this group.
89182205|NCT03070119|Experimental|BIIB067|Participants who have completed Parts A, B, or C of study 233AS101 will be placed in this arm.
89377676|NCT02368912|Experimental|9. Parallel multiple dose, ASP1707 dose levels 1-3|healthy pre-menopausal female
89377677|NCT02368912|Experimental|10. Parallel multiple dose, Placebo|healthy pre-menopausal female
88850797|NCT02131272|Active Comparator|Insulin NPH and diet/exercise|Current OADs i.e. metformin or other OADs are continued unchanged
88850798|NCT02130882|Active Comparator|Drug|Benralizumab (30mg) will be administered sc every 4 weeks for 3 doses (at weeks 0, 4 and 8). Eosinophil counts will be blinded during this time and background hypereosinophilic syndrome (HES) therapy will not be tapered.
88850799|NCT02130882|Placebo Comparator|Placebo|Placebo will be administered sc every 4 weeks for 3 doses (at weeks 0, 4 and 8). Eosinophil counts will be blinded during this time and background HES therapy will not be tapered.
88850800|NCT02130570|Experimental|Multi-Model Intensive Discharge Program|Multi-Model Intensive Discharge Program
88850801|NCT02130570|No Intervention|Usual Care|Usual Care
88850802|NCT02149836|Experimental|ezogabine|Ezogabine dosage plan to 900mg and then tapered down
88850803|NCT02130024|Experimental|Ranibizumab 0.5 mg|3 monthly loading doses (Baseline, Week 4, and Week 8), followed by an individualised treatment and evaluation regimen according to disease activity [treat and extend]
89182206|NCT04095884||Urinary Tract Infection|"Inclusion criteria (one from the list below):~Positive leukocytes, positive nitrites on dipstick~Negative leukocytes, Positive nitrites on dipstick~Positive leukocytes, negative nitrites, plus bacteriuria on microscopy~Positive leukocytes, negative nitrities plus no bacteriuria, only pyuria on microscopy PLUS clinical features e.g. fever, pain on urination, offensive smelling urine.~Exclusion criteria (one from the list below):~1. No evidence of UTI on dipstick"
89182207|NCT04095884||Upper respiratory tract infection|"Inclusion criteria (one from the list below)::~Evidence of nasal discharge AND/OR~Inflammation throat/ tonsils on direct examination AND/OR~Inflammation of middle or outer ear on direct examination~History of fever AND history of stridor/ barking cough~History of fever AND lymphadenopathy AND/ OR URTI symptoms i.e sore throat/ cough~Exclusion criteria (one from the list below)::~Foreign body inserted in either nose/ ear~Traumatic perforation of ear drum~Allergic rhinitis i.e. good contact history~Evidence of LRTI"
89182208|NCT04095884||Lower respiratory tract infection|"Inclusion criteria (one from the list below):~Focal signs on auscultation of the chest i.e crepitations/ wheeze/ reduced air entry~Fever > 38.5C AND chest recessions AND/OR raised respiratory rate~Radiological evidence of LRTI~Exclusion criteria (one from the list below):~1. Positive malaria test OR suspicion of metabolic acidosis causing tachypnoea and fever"
89182209|NCT04095884||Diarrhoea/ gastroenteritis|"Inclusion criteria (one from the list below):~Abrupt onset of 3 or more loose/liquid stools/ day~Ova, cysts, parasites identified on stool microscopy PLUS symptomatic diarrhoea,and/ or fever and/or vomiting~Fever AND vomiting WITHOUT other source of fever i.e UTI/LRTI/URTI~Exclusion criteria (one from the list below):~Normal breast milk stool~Neurological cause of vomiting"
89377678|NCT03160144|Experimental|open lung approach ventilation strategy|Procedure: open lung approach ventilation strategy (OLV). Patients receive volume-controlled mechanical ventilation with a tidal volume of 6 to 8 ml per kilogram of predicted body weight, a PEEP of 6 to 8 cm of water, and recruitment maneuvers repeated every 30 minutes after tracheal intubation.
88850804|NCT02130024|Active Comparator|Aflibercept 2.0 mg|3 monthly loading doses (Baseline, Week 4, and Week 8), followed by an individualised treatment and evaluation regimen according to disease activity [treat and extend]
89182210|NCT02578017|Experimental|Mobile DOT|All Participants will utilize Mobile DOT for 6 months. The Mobile DOT intervention includes: reminder alerts, participant videos, research staff feedback on adherence, and contingency management.
89182211|NCT02578017|No Intervention|Post-intervention observation|All participants will not receive any additional adherenece intervention after completing the Mobile DOT arm. Participants will be observed for 6 months.
89182212|NCT03014817|Experimental|Ultrasonically activated scalpel|Dissection with ultrasonically activated scalpel. Direction of dissection undecided but by experience most naturally fundus first.
89182213|NCT03014817|Active Comparator|Electrocautery|Dissection with electrocautery. Direction of dissection undecided but by experience most naturally cystic duct first.
89182214|NCT00752726|Active Comparator|Orlistat|Orlistat 60 milligram (mg) capsules to be consumed orally with each meal 3 times per day
89182215|NCT00752726|Placebo Comparator|Placebo|Placebo to match Orlistat 60 mg capsules to be consumed orally with each meal 3 times per day.
89182216|NCT03012243|Active Comparator|Cholecystostomy|Percutaneous cholecystostomy, leaving drain in situ
89182217|NCT03012243|Experimental|Gallbladder aspiration|Gallblader aspiration without drain
89182218|NCT04093544|Active Comparator|Standard Stimulation|Participants will receive stimulation using the best contact combination in ring mode.
89182219|NCT04093544|Experimental|Directional Stimulation|Participants will receive stimulation using the best segmented (steered) contacts.
89182220|NCT02600000|Experimental|Sympathetic myocardial activity after IMT|Evaluate the effectiveness of Muscle Training Inspiratory associated with a cardiac rehabilitation program in the modulation of sympathetic myocardial activity of patients with HF
89377679|NCT03160144|No Intervention|conventional ventilation strategy|Procedure: conventional ventilation strategy (NOLV). Patients receive volume-controlled mechanical ventilation with a tidal volume of 6 to 8 ml per kilogram of predicted body weight, no PEEP and no recruitment maneuver.
89377680|NCT04059796|Experimental|Study Eye|Study device in conjunction with an approved monofocal or toric IOL after cataract extraction
88850805|NCT02105688|Experimental|Immediate Treatment Arm: Grazoprevir/Elbasvir|In Part A, participants receive grazoprevir 100 mg plus elbasvir 50 mg FDC (MK-5172A) once daily for 12 weeks (blinded) and were followed-up for 24 weeks. In Part B, participants could enroll in a 3-year follow-up period where they were followed every 6 months for 3 years in an observational cohort (no treatment was administered during Part B).
88875310|NCT02584686|Placebo Comparator|Saline Group|The control group, 12 patients, will be injected with a trimix solution (20 ug alprostadil + 1 mg phentolamine + 30 mg papaverine) during penile colour Doppler assessment followed on a separate day with a normal saline injection.
89377681|NCT04059796|Active Comparator|Control Eye|approved monofocal or toric IOL after cataract extraction
89377682|NCT02362984|Placebo Comparator|Control Group|Placebo will be administered orally, 3 x 1 tablet daily, for 8 days of study period
89377683|NCT02362984|Experimental|DLBS1033 Group|DLBS1033 will be administered orally, 3 x 1 tablet daily, for 8 days of study period
89377684|NCT02362750||Participating Program Administrators|Eligible survivorship program administrators at selected Commission on Cancer-accredited institutions will complete an organizational interview and organizational survey.
89377685|NCT02362750||Participating Cancer Survivors|"Survivors receiving follow-up care surveys at selected Commission on Cancer-accredited institutions will complete four surveys:~Survivor Survey (1): Pre-Visit Baseline Survivor Survey (2): 1 Week Post-Visit Survivor Survey (3): 3 Months Post-Visit Survivor Survey (4): 6 Months Post-Visit"
89377686|NCT02362750||Participating Clinicians|Survivorship clinicians from clinical survivorship programs at selected Commission on Cancer-accredited institutions will complete a clinician survey.
89377687|NCT02368678|Active Comparator|Scaling and Root Planning (SRP)|Scaling and root planing (SRP) (n=15): the traditional mechanical periodontal therapy consisting of quadrant-wise (30 min. per quadrant) scaling and root planning performed at weekly sessions (one or two weeks of interval between session) and completed within 2 months.
89377688|NCT02368678|Active Comparator|Full Mouth Scaling (FMS)|Full mouth scaling (FMS) (n=15): the alternative mechanical periodontal therapy consisting of full-mouth scaling and root planning completed in a single stage within 24 hours; i.e two sessions (60 min. per session) in two consecutive days.
89377689|NCT02358070||HCC group|
89377690|NCT02358070||control group|
88850806|NCT02105688|Placebo Comparator|Deferred Treatment Arm: Placebo > Grazoprevir/Elbasvir|In Part A, participants receive placebo to MK-5172A once daily for 12 weeks (blinded), followed by 4 weeks of follow-up. Afterwards, participants received 12 weeks of open-label treatment with the MK-5172A FDC and were followed-up for 24 weeks. In Part B, participants could enroll in a 3-year follow-up period where they were followed every 6 months for 3 years in an observational cohort (no treatment was administered during Part B).
89377691|NCT02368522||Patients treated with and without exposure|
89377692|NCT02358148||STEMI / NSTEMI|All patients (100%) admitted to the participating hospitals during the study period with the diagnosis of Acute ST Segment Myocardial Infarction (STEMI) or Non-ST Segment Myocardial Infarction (NSTEMI) will be selected for inclusion in the study. In order to assure rapid door-to-reperfusion times, Study Investigators will obtain consent and interview these patients AFTER cardiac catheterization and intervention. A minimum number of 25 STEMI and 25 NSTEMI patients will be enrolled in the study.
89377693|NCT02358148||Elective / Non-emergent Cardiac Cath|This group will include both admitted and outpatients, with possible diagnoses of Unstable Angina (UA), Low Risk Chest Pain (LRCP), and those having cardiac catheterization for any other reason (eg: elective, medical clearance for surgery, failed stress test, etc.). To maintain integrity of the study, these patients will be randomly selected, with written consent obtained, prior to cardiac catheterization.
89377694|NCT02358226|Experimental|Soccer League (SL)|In the SL arm, participants will be invited to participate in a Soccer League, led by coaches who meet the criteria of: 1) soccer skills, 2) being a role model, and 3) social competence. Coaches will undergo intensive training in ethics; role-playing the delivery of health messages; conducting brief interventions for alcohol; how to acquire information on HIV, TB, alcohol use and employment; linkages to local clinics, data collection; and Street Smart, an evidence-based intervention for high-risk youth. Coaches will provide pre- and post-game talks, incorporating the topics of alcohol and drugs; interacting positively with health care providers, partners and family members; HIV, diabetes; daily routines; healthy social networks; making and saving money; loyalty and national success.
89377695|NCT02358226|Experimental|Soccer League/Vocational Training (SL-V)|The SL-V arm will include both the SL intervention as well as access to Vocational Training through either Silulo Ulutho Technologies, which offers computer courses, or Zenzele Training and Development programs, which provides training in woodwork and wielding. Both programs are located in Khayelitsha, which is close to participants' homes, thus avoiding transport-related barriers. Additionally, the training programs occur in a mentor-mentee context so that participants can develop the interpersonal skills required for employment.
89377696|NCT02358226|No Intervention|Control Condition (CC)|Participants in the CC arm will routinely receive flyers with picture stories regarding HIV prevention strategies and how to access these strategies: HIV testing, circumcision, HIV treatment, including ARV, condoms and sexually transmitted diseases.
89377697|NCT02368600|Experimental|Lifestyle modification program|On top of the usual care, subjects in the intervention will receive a lifestyle intervention that will be delivered by experienced registered dietitian and exercise specialist. There will be 5 face-to-face dietitian consultations, 2 telephone dietitian consultations and at least one face-to-face exercise specialist consultation. The exercise consultation will be normally scheduled on the same day of the face-to-face dietitian consultation.
89399407|NCT02178644|Experimental|Chemo with concomitant Capecitabine and KD018|Patients will receive a course of chemo-radiation with concomitant Capecitabine and KD018, and to compare this to the toxicity seen in patients treated with Capecitabine and radiation therapy alone, in patients with T3-T4 and N0-N2, M0 rectal cancer.
89399408|NCT03686163|Experimental|IN-NGF group|Patients who underwent acute ischemic stroke will be chosen to receive NGF randomly
88850807|NCT02105454|Experimental|GZR 100 mg + EBR 50 mg + RBV for 12 weeks|Participants receive grazoprevir 100 mg once per day (QD), elbasvir 50 mg QD, and RBV 800 - 1400 mg total daily dose divided twice per day (based on body weight) for 12 weeks
88850808|NCT01625910|Experimental|behavioral counseling|Receive counseling via motivational interviewing seeking to encourage health eating habits and increased physical activity
88850809|NCT01625910|Placebo Comparator|Instructions in school readiness and performance|Parents receive instructions in school readiness and performance
89182221|NCT02600000|Experimental|Maximal functional capacity after IMT|Evaluate the effectiveness of Muscle Training Inspiratory associated with a cardiac rehabilitation program in the maximal functional capacity of patients with HF
88850810|NCT02104752|Experimental|Curcumin|Curcumin capsules (Theracurmin formulation of curcumin nanoparticles). Subjects randomized to curcumin will receive 360 mg/day (divided into twice daily oral doses).
89377698|NCT02368600|No Intervention|Usual care|Women will have their first AN booking visit generally on or before 12 week gestation. For women who are primigravida, their AN visit appointments will be set at every 6 weeks before 24 weeks, every 4 weeks between 24-28 weeks, and every 2 weeks after 28 weeks. For women who are multigravida, the corresponding schedules will be set at every 6 weeks before 24 weeks, every 4 weeks between 24-36 weeks, and every 2 weeks after 36 weeks. Body weight of the pregnant woman will be monitored by nurses and basic nutrition advice will be briefly given by nurses in case she is slightly overweight. They will be provided with an educational pamphlet on diet and exercise during pregnancy. They will also be offered optional antenatal classes which subjected to quotas availability.
89377699|NCT03085914|Experimental|Treatment Group A|Epacadostat + pembrolizumab + mFOLFOX6 (oxaliplatin, leucovorin, 5-fluorouracil)
89377700|NCT03085914|Experimental|Treatment Group B|Epacadostat + pembrolizumab + gemcitabine and nab-paclitaxel
89377701|NCT03085914|Experimental|Treatment Group C|Epacadostat + pembrolizumab + carboplatin and paclitaxel
89377702|NCT03085914|Experimental|Treatment Group D|Epacadostat + pembrolizumab + pemetrexed and investigators choice of platinum agent
89377703|NCT03085914|Experimental|Treatment Group E|Epacadostat + pembrolizumab + cyclophosphamide
89377704|NCT03085914|Experimental|Treatment Group F|Epacadostat + pembrolizumab + gemcitabine and investigators choice of platinum agent
89377705|NCT03085914|Experimental|Treatment Group G|Epacadostat + pembrolizumab + investigators choice of platinum agent and 5-fluorouracil
89377706|NCT02357914||Individuals with paraplegia|Individuals with a spinal cord injury below T1
89377707|NCT02357680|Experimental|Intervention group|"Relatives randomized to the intervention group is provied with a diary. Nurses advice relatives on how to write and use the diary under and after the patients stay in the ICU. A written description on how to use the diary is also provided.~At least two photographs of the patient is taken by nurses. Photographs will first be included in the diary when full consent from the patient has been obtained.~Patients and relatives recieve a questionaire 3 months after the patient has been dismissed from the ICU."
89377708|NCT02357680|No Intervention|Control group|Standard Care. Patients and relatives recieve a questionaire 3 months after the patient has been dismissed from the ICU.
89377709|NCT01736956|Experimental|Fetal Aortic Valvuloplasty|Subjects will undergo fetal aortic valvuloplasty
88850811|NCT02104752|Placebo Comparator|Sugar Pill|Matched placebo, 2 capsules twice daily.
89377710|NCT01736956|No Intervention|Control|Control group. Will receive standard prenatal and postnatal care.
89377711|NCT01081288|Active Comparator|Women aged 47-49 invited for breast screening|
88850812|NCT02102724|Experimental|Fish Oil|Participants will receive fish oil gelcaps that contain 1.6 grams of omega-3 fatty acids (800 mg of EPA, 600 mg DHA, 200 mg other omega-3 fatty acids) for 12 weeks.
88850813|NCT02102724|Placebo Comparator|Placebo|Participants will receive 1 gram of oleic sunflower oil for 12 weeks.
89182222|NCT02600000|Experimental|submaximal functional capacity after IMT|Evaluate the effectiveness of Muscle Training Inspiratory associated with a cardiac rehabilitation program in the submaximal functional capacity of patients with HF
89182223|NCT02600000|Experimental|Thickness and mobility of the diaphragm after IMT|Assess the impact of Inspiratory Muscle Training in combination with a cardiac rehabilitation program on the thickness and mobility of the diaphragm in patients with heart failure.
89182224|NCT04072263|Experimental|Cohort 1|"Carboplatin-paclitaxel day1, q3 weeks, 6x, plus~Tumor Infiltrating Lymphocytes (TIL) starting 14 days after the 2nd chemotherapy cycle, q3 weeks, 3x."
89182225|NCT04072263|Experimental|Cohort 2|"Carboplatin-paclitaxel day1, q3 weeks, 6x, plus~Tumor Infiltrating Lymphocytes (TIL) starting 14 days after the 2nd chemotherapy cycle, q3 weeks, 3x, plus~Interferon Alpha 2A (3x10e6 U daily) starting one week before the first TIL infusion for 12 weeks in total."
89182226|NCT00916838||Type 1 Diabetes Mellitis|Children with Type 1 Diabetes Mellitis (T1DM) between 4 and 16 were recruited.
89182227|NCT00916838||Non diabetic Control|62 healthy siblings also enrolled in the study between the ages of 4 and 17.
89377712|NCT01081288|Active Comparator|Women aged 71-73 invited for breast screening|
89377713|NCT02467608|Experimental|Isoniazid with HUEXC030 and RZE|"Subjects who are genotyped as high risk group will be receiving 2 months of intensive treatment comprised of 4 drugs (Isoniazid with HUEXC030 [H], rifampin [R], pyrazinamide [Z] and ethambutol [E]), followed by 4 months of continual chemotherapy consist of Isoniazid, Rifampin (2HRZE/4HR regimen). Subjects who are of low risk genotype will be removed from study after 8 weeks of study treatment, then return to conventional TB medication at least one follow-up visit at 4 weeks after the end of study treatment visit.~Dosage is as below:~Isoniazid with Isoniazid(H):300mg/600mg daily, rifampin [R]: 450~600mg daily, pyrazinamide [Z]; 1000~2000mg daily and ethambutol [E]: 800-1600mg daily)"
89399409|NCT03686163|Placebo Comparator|Control group|Patients who underwent acute ischemic stroke will be chosen to receive normal saline randomly
89399410|NCT02256098|Experimental|ATTUNE™|Total Knee Replacement Surgery with ATTUNE™ Knee Prosthesis by DePuy
89399411|NCT02256098|Active Comparator|PFC Sigma|Total Knee Replacement Surgery with PFC Sigma Knee Prosthesis by DePuy
88850814|NCT02102490|Experimental|Abemaciclib|200 milligrams (mg) abemaciclib given orally once every 12 hours for 28 days (1 cycle). Participants may continue to receive treatment until discontinuation criteria are met.
88850815|NCT02101554|Experimental|Embeda|One arm, open label, active
88850816|NCT02128932|Experimental|Semaglutide 0.5 mg/week|
88850817|NCT02128932|Experimental|Semaglutide 1.0 mg/week|
88850818|NCT02128932|Active Comparator|Insulin glargine|
88850819|NCT02128542|Experimental|Sofosbuvir+RBV 12 weeks|Participants will receive sofosbuvir+RBV for 12 weeks.
88850820|NCT04747548|Active Comparator|Kurbo Only|Participants will receive 1-month access to the Kurbo digital program.
88850821|NCT04747548|Experimental|Kurbo + PolyRules!|Participants will receive 1-month access to the Kurbo digital program and the PolyRules! app.
88850822|NCT04751682|Experimental|BBV154: Single Dose|Group 1 (Single dose group): In this group, 70 participants will be recruited and administered with vaccine (BBV154) on day 0 and with placebo on day 28 via intranasal route.
88850823|NCT04751682|Experimental|BBV154: Two Dose|Group 2 (Two-dose group): In this group, 70 participants will be recruited and administered with vaccine (BBV154) on both day 0 and on day 28 via intranasal route.
89377714|NCT02467608|Other|Isoniazid|"Subjects who are genotyped as high risk group will be receiving 2 months of intensive treatment comprised of 4 drugs (Isoniazid [H], rifampin [R], pyrazinamide [Z] and ethambutol [E]), followed by 4 months of continual chemotherapy consist of Isoniazid, Rifampin (2HRZE/4HR regimen). Subjects who are of low risk genotype will be removed from study after 8 weeks of study treatment, then return to conventional TB medication at least one follow-up visit at 4 weeks after the end of study treatment visit.~Dosage is as below:~Isoniazid (H):300mg daily, rifampin [R]: 450~600mg daily, pyrazinamide [Z]; 1000~2000mg daily and ethambutol [E]: 800-1600mg daily)"
89377715|NCT02368288|Experimental|entecavir with PEG-IFN a-2a|after enrolled, entecavir will added, and patients will receive treatment of PEG-IFN a-2a combine with entecavir for 48 weeks.
89377716|NCT02368288|No Intervention|peginterferon alpha 2a|in this group, patients will be continue treated only with PEG-IFN a-2a for 48 weeks after enrolled.
89377717|NCT01380054||patients with pulmonary hypertension|
89377718|NCT01063114|Experimental|Proton Beam Radiation|Proton Beam Radiation
89377719|NCT02450136|Experimental|pazopanib|pazopanib 800 mg will be administered orally once a day 28 days.Study treatment will be continued until objective disease progression.
89377720|NCT05421312|Other|cefazolin|The cefazolin antimicrobial prophylaxis (2000mg single dose intravenously 15-60 minutes before incision) is part of standard of care.
89377721|NCT05421312|Other|Clindamycin|The clindamycin (600mg three times daily orally) PJI therapy is part of standard care.
89377722|NCT02368054|Active Comparator|Bupivacaine-adrenaline|Paracervical block. Bupivacaine 2,5 mg/ml Adrenaline 5 microg/ml; 20 ml
89377723|NCT02368054|Active Comparator|Bupivacaine|Paracervical block. Bupivacaine 2,5 mg/ml; 20 ml
89377724|NCT01382394||Sepsis Group, Heart failure group|"The first group will include 60 patients with the diagnosis of acute decompensated heart failure.~The second group will include 60 patients with the diagnosis of sepsis."
89377725|NCT01569282|Active Comparator|Double bypass|
89377726|NCT01569282|Active Comparator|Stent Strategy|
88850824|NCT04751682|Placebo Comparator|Placebo|Group 3 (Placebo): In this group, 35 participants will be recruited and administered with placebo on both day 0 and day 28 via intranasal route.
88850825|NCT02126826|Placebo Comparator|Placebo to BI 1026706|Multiple Rising Doses Placebo to BI 1026706
88850826|NCT02126826|Experimental|BI 1026706|Multiple Rising Doses BI 1026706
88850827|NCT02126670|Placebo Comparator|ACT01 plus Comp01|ACT01 Cream in combination with Comp01 Cream, once daily, 29 days
88850828|NCT02126670|Active Comparator|ACT01 plus Comp02|ACT01 Cream in combination with Comp02 Cream, once daily, 29 days
88850829|NCT02126670|Active Comparator|ACT01 plus Comp03|ACT01 Cream in combination with Comp03 Cream, once daily, 29 days
88850830|NCT02126670|Other|ACT01 plus Comp04|ACT01 Cream in combination with Comp04 Cream, once daily, 29 days
88850831|NCT02125734|Experimental|Treatment sequence 1|QVA149 from day 1 to day 28 and tiotropium from day 29 to day 56
89377727|NCT02357602|Experimental|1. GS-7340 25mg|The first 8 women on study will be assigned to take a single dose of 25mg TAF (1 tablet) orally.
89377728|NCT02357602|Experimental|2. GS-7340 10mg|The 2nd group of 8 women will be sequentially assigned to take a single dose of 10mg TAF (1 tablet) orally.
89377729|NCT02357602|Experimental|3. GS-7340 5mg|The final 8 women on study will be sequentially assigned to take a single dose of 5mg TAF (1/2 tablet) orally.
89377730|NCT01379196|Experimental|Azithromycin PO three times weekly|Tablets Azithromycin 500 mg PO three times weekly for three months
89377731|NCT03112720|Active Comparator|Epidural blood patch|20ml of sterile blood is obtained from the patients arm and placed in the epidural space using standard sterile epidural access.
89377732|NCT03112720|Experimental|Sphenopalatine Ganglion Block|Cotton tip applicators are used to deliver lidocaine to the posterior nares in the area of skin overlying the Sphenopalatine gangion
89377733|NCT01382316|Experimental|Making Alcoholics Anonymous Easier|Six session, group format intervention, consisting of introductory session, four core sessions (sponsorship, principles not personalities, spirituality, living sober), and return to introductory session as MAAEZ graduate
89377734|NCT01382316|Active Comparator|Usual care|Usual group sessions on education about alcohol and drug problems
89377735|NCT03112798||Macintosh group|The patients will be intubated by using Macintosh blades and the outcomes will be compared with Miller blades.
89377736|NCT03112798||Miller group|The patients will be intubated by using Miller blades and the outcomes will be compared with Macintosh blades.
89377737|NCT01382238|Experimental|Single arm|Subjects will have a screening visit within 30 days prior to the first dose of study drug, five treatment periods containing a single dose of study drug, followed by 48 hours of serial PK collection. In the 5 treatment periods subjects will receive DTG granule formulation 1) directly to mouth; 2) with purified water; 3) with Contrex brand water; and 4) with milk-based infant formula. They will also receive the current 50 mg tablet formulation administered with tap water. These treatments will be administered in a random order. Subjects will check out of the unit on Day 3 after the 48 hour PK sample in each period. Study periods will be separated by at least 5 days. Subjects will have a follow-up visit 5-7 days after last dose of DTG given.
89377738|NCT03112564|Other|Sevoflurane 8% + Intravenous fentanyl|Avoidance of rocuronium/cisatracurium
89377739|NCT01379976|Placebo Comparator|CHT cisplatin containing + placebo|
89377740|NCT01379976|Experimental|CHT cisplatin containing + acetyl-L-carnitina|
89377741|NCT01379898|Active Comparator|Phenoxybezamine|Phenoxybenzamine (capsules 10 mg, once to twice daily) is administered orally, starting 2-3 weeks before planned resection of PCC.
89377742|NCT01379898|Active Comparator|Doxazosin|Phenoxybenzamine (slow release tablets 4 or 8 mg, once to twice daily) is administered orally, starting 2-3 weeks before planned resection of PCC.
88850832|NCT02125734|Experimental|Treatment sequence 2|Tiotropium from day 1 to day 28 and QVA149 from day 29 to day 56
89182228|NCT04072419||enhanced recovery after surgery group|"weaning mechanical ventilation after surgery (less than 48h),~no post-operative chest tube and urinary catheterization)~Establishment of early feeding (D3 post-operative)"
88850833|NCT02124798|Experimental|Single arm|Subjects will self-administer belimumab SC into thigh or abdomen using the autoinjector device for 8 weekly doses; 4 of the doses will be administered under observation in the clinic and 4 of the doses will be administered outside the clinic and without observation
88850834|NCT02146326|Active Comparator|Motivational Interviewing-Mental Health Staff|
88850835|NCT02146326|Active Comparator|BREATHE-Mental Health Staff|
88850836|NCT02146326|Active Comparator|Motivational Interviewing-Clients|
88850837|NCT02146326|Active Comparator|BREATHE-Clients|
88850838|NCT02146248|Experimental|HSG Studies|"Women will be given combined oral contraceptives and Depo-medroxyprogesterone acetate (DepoProvera®).~2 HSG studies will be done prior to hormonal treatment, 1 after the pill treatment, and depending on whether the tubes appear patent, 1 more after the depoProvera treatment, and a final HSG after another 2 weeks on the pill."
88850839|NCT02145468|Experimental|Losmapimod|Losmapimod 7.5 mg twice daily oral tablet
88850840|NCT02145468|Placebo Comparator|Placebo|Placebo twice daily oral tablet
88850841|NCT02124564|Experimental|Lacosamide|Open-label, single-arm
88850842|NCT02145390|Experimental|TURBT, NAC and Chemoradiation|"Transurethral Resection of the Bladder Tumor & Cystoscopy (TURBT);~Neoadjuvant Chemotherapy (NAC), per standard of care: Cisplatin and Gemcitabine therapy, within 8 weeks following the TURBT and cystoscopic evaluation;~For subjects with complete response (CR): Chemoradiation within 6 weeks after post-neoadjuvant evaluation. Intensity Modulated Radiation Therapy (IMRT/VMAT); Cisplatin therapy per standard of care;~For subjects who have pT1 or worse tumor response: Radical Cystectomy, per standard of care, within 12 weeks post-neoadjuvant chemotherapy evaluation;~Expanded Prostate Cancer Index Composite Short Form 12 (EPIC SF-12);~International Prostate Symptom Score (IPSS)."
88850843|NCT02100696|Experimental|Cohort 1: Etrolizumab (Open-Label Induction (OLI) Phase)|Participants assigned to this arm will receive treatment with open-label etrolizumab 105 milligrams (mg) subcutaneous (SC) injection once every 4 weeks (Q4W) for 14 weeks during the induction phase.
89377743|NCT02368366|Experimental|Therapist Guided Face to Face FPST|Therapist Guided Face to Face Family Problem Solving Families assigned to this arm will meet with the therapist in person at the medical center TBI clinic. Sessions will last approximately 60 minutes and cover didactic content using printed handouts provided as part of a family workbook.
88850844|NCT02100696|Placebo Comparator|Cohort 2: Placebo (Double-Blind Induction Phase)|Participants randomized to this arm will receive treatment with double-blind placebo SC injection Q4W for 14 weeks during the induction phase.
88850845|NCT02100696|Experimental|Cohort 2: Etrolizumab (Double-Blind Induction Phase)|Participants randomized to this arm will receive treatment with double-blind etrolizumab 105 mg SC injection Q4W for 14 weeks during the induction phase.
88850846|NCT02100696|Placebo Comparator|Placebo Responders: Placebo (Maintenance Phase)|Participants who received placebo during the induction phase, Cohort 2: Placebo (Double-Blind Induction Phase), and achieve a clinical response with placebo at Week 14 will continue to receive blinded placebo from Week 16 up to Week 66 during the maintenance phase.
88850847|NCT02100696|Placebo Comparator|Etrolizumab Responders: Placebo (Maintenance Phase)|Participants who received etrolizumab during the induction phase, Cohort 1: Etrolizumab (Open-Label Induction Phase) and Cohort 2: Etrolizumab (Double-Blind Induction Phase), and achieved a clinical response at Week 14 will be re-randomized by Week 16 for the double-blind maintenance phase. Clinical responders re-randomized to this arm will receive placebo SC injection Q4W from Week 16 up to Week 66.
88850848|NCT02100696|Experimental|Etrolizumab Responders: Etrolizumab (Maintenance Phase)|Participants who received etrolizumab during the induction phase, Cohort 1: Etrolizumab (Open-Label Induction Phase) and Cohort 2: Etrolizumab (Double-Blind Induction Phase), and achieved a clinical response at Week 14 will be re-randomized by Week 16 for the double-blind maintenance phase. Clinical responders re-randomized to this arm will receive etrolizumab 105 mg SC injection Q4W from Week 16 up to Week 66.
88850849|NCT02145156|Experimental|Tailored intervention|Intervention: tailored educational materials. In this arm, participants will complete a baseline survey on an iPad, view a series of educational webpages on the iPad, and complete a brief post intervention survey.
88850850|NCT02145156|Other|Untailored Intervention|Intervention: untailored educational materials. In this arm, patients will view educational information on the iPad that is not responsive to their baseline questionnaire answers.
88850851|NCT02145156|Other|Usual Care|Intervention: survey-only. Participants in the usual care arm will not view any educational materials or complete the baseline survey.
88850852|NCT02123472|Active Comparator|Cephalexin (Test)|Cephalexin manufactured in Italy by Facta administered once orally in one of two study periods.
88850853|NCT02123472|Experimental|Cephalexin (Reference)|Cephalexin manufactured in Mexico by Eli Lilly administered once orally in one of two study periods.
89182229|NCT04072419||control group|"the time of mechanical ventilation after surgery is more than 48 hours~routine postoperative indwelling chest tube and urinary catheterization)~Establishment of feeding after D3 post-operative"
89182230|NCT00755222|Experimental|AA4500|Clostridial collagenase for injection
89182231|NCT00755222|Placebo Comparator|Placebo|
89182232|NCT00441727|Experimental|Esomeprazole 40 mg|Esomeprazole 40 mg
88817131|NCT01333046|Experimental|Antigen-Escalation Stage|"The first stage will be an antigen-escalation stage using a fixed total dose of cells (5 x 10^6 cells/m^2 x 2) to evaluate the safety of the T cells primed against PRAME pepmix, and then SSX pepmix, and then MAGE A4 pepmix, and then NY-ESO pepmix, and then SURVIVIN pepmix."
88817132|NCT01333046|Experimental|Dose-Escalation Study Stage|"In the dose escalation stage, three dose levels will be studied. Patients in the dose escalation portion of the study will be entered and stratified separately to the following two groups:~Group A: Patients receiving CTLs as therapy for Hodgkin's or non-Hodgkin's lymphoma.~Group B: Patients receiving CTLs as adjunctive therapy following autologous or syngeneic transplant."
89182233|NCT00441727|Experimental|Esomeprazole 20 mg|Esomeprazole 20 mg
89377744|NCT02368366|Experimental|Therapist Guided Online FPST|Therapist Guided Online Family Problem Solving Families assigned to this arm will receive a password enabling them to access the online intervention materials throughout the course of the intervention. Each session of online F-PST consists of a self-guided online portion providing didactic content regarding the desired skill (i.e., problem-solving), video clips showing individuals and families modeling the skill, and exercises and assignments giving the family an opportunity to practice the skill. During synchronous, videoconference sessions with the therapist, the family will review the online materials and practice the problem-solving process.
89377745|NCT02368366|Experimental|Self-Guided Online FPST|Self-Guided Online Family Problem Solving Families in the self-guided, online F-PST arm will receive a password enabling them to access the online intervention materials throughout the course of the intervention. They will receive access to the same web-modules as the therapist-guided group, but will review them on their own without therapist support. Participants in this group will be encouraged to complete web modules at the same schedule as participants in the other groups. If the family fails to log on or complete web modules, they will receive reminders via phone, text, or e-mail.
89377746|NCT02367898|Experimental|Cognitive Training|Lumosity cognitive training program.
89377747|NCT02367898|Active Comparator|Crossword Puzzles|Timed online crossword puzzles
89377748|NCT04479280||Covid19 positive patients|
89377749|NCT04479280||Covid19 negative patients|
89377750|NCT03160222|Other|Body Composition Measurements|Body composition measurements comprise the ultrasound measurement of fat and muscle thickness of both upper arms and thighs, the bioelectrical impedance analysis (BIA), measurement of weight, handgrip strength, overall muscle strength (Medical Research Council scale) and questionnaires about physical activity, nutrition and fluid status.
89377751|NCT03160066|Active Comparator|Active|Capsules containing 1x10^9 colony forming units of Lactobacillus Rhamnosus (JB-1) will be given once per day for 4 weeks.
89377752|NCT03160066|Placebo Comparator|Placebo|Placebo capsules identical to the probiotic in taste, smell, colour, and comprised only of the same non-active ingredients (corn starch, magnesium stearate and silicon dioxide) in the probiotic supplement will be given once per day for 4 weeks.
89377753|NCT02367742|Other|Endurance Activity (EA)|The subjects have followed a program of endurance (aerobic) activity (EA).
89377754|NCT02367742|Other|EA + Resistance Training (RT)|The subjects have followed a program of endurance activity (EA) and resistance training (RT).
89377755|NCT04334356|Experimental|App Intervention|All participants will receive the web app for prevention of posttraumatic stress.
89377756|NCT02362516|Experimental|BI 425809|
89377757|NCT02367664|Experimental|0.5ml experimental vaccine on day 0,7|0.5ml experimental vaccine on day 0,7 and a booster dose 12 months later
89377758|NCT02367664|Experimental|0.5ml experimental vaccine on day 0,28|0.5ml experimental vaccine on day 0,28 and a booster dose 12 months later
89377759|NCT02367664|Active Comparator|0.5ml active comparator vaccine on day 0,7|0.5ml active comparator vaccine on day 0,7 and a booster dose 12 months later
88817382|NCT01218542|Experimental|Volumetric modulated arc therapy|Single arm pilot study treating patients with 25 Gy in 10 fractions to the whole brain with simultaneous infield boost (SIB) to a total of 45 Gy in 10 fractions to gross brain metastatic disease.
88817383|NCT01721603|Experimental|Dabrafenib + Trametinib + gamma knife radiosurgery|
88817384|NCT01296542|Active Comparator|VIGAMOX|Subjects will self administer drops 4 times daily for 3 days and one drop prior to sample collection
89377760|NCT05421000|Experimental|WALANT|Wide awake local anesthesia without tourniquet was used for surgery
89377761|NCT05421000|Active Comparator|Locoregional anesthesia and tourniquet|Locoregional anesthesia (normally axillary block) and tourniquet was used for surgery
89377762|NCT04275934||Cohort|This project will evaluate the impact of self-insured employers implementing an innovative care model utilizing pharmacist-delivered MTM services for health plan beneficiaries with high blood pressure.
88817385|NCT01296542|Active Comparator|Besivance|Subjects will self administer drops 4 times daily for 3 days and one drop prior to sample collection
88817386|NCT01234766|Experimental|Single Arm|Subjects will receive bendamustine and rituximab, followed by 90-yttrium (Y) Ibritumomab Tiuxetan
88817387|NCT04346420|Experimental|O2 DTM+|The standard nasal cannula interface is accompanied with the DTM
88817388|NCT04346420|Active Comparator|O2 DTM-|The standard interface for administering oxygen (nasal cannula or oxygen mask) is worn by the patient, without the DTM
88817389|NCT01234922|Experimental|Arm I|Patients receive oral benazepril hydrochloride once daily on days 1-7.
88817390|NCT01234922|Experimental|Arm II|Patients receive oral lisinopril once daily on days 1-7.
88817391|NCT01234922|Experimental|Arm III|Patients receive oral ramipril twice daily on days 1-7.
88817392|NCT01234922|Experimental|Arm IV|Patients receive oral losartan potassium once daily on days 1-7.
88817393|NCT01337336||COPD patients with comorbid depression/anxiety|Patients aged 40 and over with COPD and comorbid depression/anxiety. Managed care enrolees (aged >40 years) having newly initiated drug therapy with FSC or AC during the identification period (01/01/2004 to 06/30/2008) to treat COPD with a medical or pharmacy claim for depression before and 60 days post index date were the target population. The first fill date of FSC or AC was the index date.
88810424|NCT06213506|Active Comparator|Infants_6W_Control B Group|Infants 6 weeks of age, part of the safety cohort, randomized to receive 3 doses of the MenACWY vaccine at Day 1, Day 57 (during the Priming phase) and at Day 232 (during the Booster phase). To allow completion of the vaccination schedule a fourth dose of the MenACWY vaccine is administered after the trial ends, as per the licensed indication and in private vaccination settings. These infants also receive an EPI vaccination with Measles and Rubella Vaccine (MR-VAC) and Yellow Fever (YF) vaccine at 28 days after the third study intervention administration occurring at Day 232, at the local EPI vaccination centers, and not part of the current clinical trial.
88850854|NCT02145078|Experimental|Treatment (chemotherapy regimen)|Patients receive 1 of 4 chemotherapy regimens at the discretion of the primary oncologist following institutional guidelines, including cisplatin, carboplatin, pemetrexed disodium IV on day 1, or gemcitabine hydrochloride IV on days 1 and 8. Treatment repeats every 3 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. After course 2, patients may continue treatment off-study at the discretion of the treating physician.
89377763|NCT02357212|Other|Early Invasive|Patients assigned to an early invasive strategy will undergo coronary angiography within 48 hours and have percutaneous coronary intervention or coronary artery bypass grafting performed as soon as possible during the initial hospitalization if deemed appropriate.
88850855|NCT02144610|Experimental|Gene Therapy HGF Plasmid (AMG0001)|Randomized subjects will receive 4 sets of intramuscular (IM) injections of HGF plasmid two weeks apart starting at Day 0 and again at Month 3 (first cycle) and at Month 9 and again at Month 12 (second cycle) in muscles of the affected lower limb.
88850856|NCT02144610|Placebo Comparator|Placebo|Randomized subjects will receive 4 sets of intramuscular (IM) injections of matching placebo two weeks apart starting at Day 0 and again at Month 3 (first cycle) and at Month 9 and again at Month 12 (second cycle) in muscles of the affected lower limb.
88850857|NCT02100228|Experimental|Apixaban|
88850858|NCT02100228|Active Comparator|Parenteral heparin and/or oral Vitamin K antagonist|Parenteral heparin and/or locally used oral Vitamin K antagonist e.g. warfarin (excludes other novel oral anticoagulants)
88850859|NCT02099838|Experimental|Pioglitazone and Metformin|Type 2 diabetic patients only took SUs previously. During a week for washout before the trial, they received diet and sport instructions, kept the SUs unchanged and didn't use any drugs affecting blood glucose. All participants added 1 tablet of pioglitazone and metformin twice a day (before breakfast and before dinner) orally for 12 weeks.
88850860|NCT02099838|Placebo Comparator|Placebo|Type 2 diabetic patients only took SUs previously. During a week for washout before the trial, they received diet and sport instructions, kept the SUs unchanged and didn't use any drugs affecting blood glucose. All participants added 1 tablet of placebo twice a day (before breakfast and before dinner) orally for 12 weeks.
89182234|NCT00441727|Placebo Comparator|Placebo|Placebo
89182235|NCT04095728|Experimental|Investigational Product|
89182236|NCT04095728|Placebo Comparator|Placebo|
89182237|NCT02955225|Experimental|Flexible shoe with Active Insole|Subjects will be trained to change the plantar pressure using a flexible walking shoe with an activated pressure-detecting shoe insole (Moticon OpenGO insole).
89182238|NCT02955225|Active Comparator|Flexible shoe with Passive Insole|A flexible walking shoe with a passive pressure-detecting shoe insole will be used for a comparator group.
89182239|NCT04074057|Other|Control arm|the control group will undergo a conventional weekly CR programme lasting 8-12 sessions. Components of each session will include warm up, aerobic training, resistance exercises and cool down. Patients are encouraged to continue their home exercises, exercising another 2 times a week at home and record down using an activity diary. The importance of CR programme and exercise advice will be explained and reinforced by the CR Physiotherapist. The submaximal exercise test and a body composition analysis will be repeated on the final assessment. Every week research coordinator will call the subject to remind them to exercise.
89182240|NCT04074057|Other|Intervention arm|"During the initial assessment, the importance of CR and regular exercise will be explained and reinforced by CR physiotherapist. A research assistant will teach the patient how to use Heart Track. The patient will then bring Heart Track home to continue their CR program. Patient will then undergo the whole CR programme to exercise for 3 times a day for 8-12 weeks using Heart Track. Each Heart Track session will include warm up, aerobic training, resistance exercises and cool down (same as the traditional CR session). After 8-12 weeks, patient will be called back to the clinic by the research assistant to complete the final assessment (sub-maximal exercise test and a body composition analysis) with the blinded assessor. Every week research coordinator will call the subject to remind them to exercise."
89182241|NCT04072185|Experimental|Physical activity group|
89182242|NCT04072185|No Intervention|Control group|
89182243|NCT05673447|Experimental|anti-CD19 CAR NK cells|CD19-CAR-NK is an allogenic CD19-Targeted chimeric antigen receptor NK-cell (CAR-NK) therapy.
89182244|NCT00770120|Experimental|Everolimus|Daily oral Everolimus 10 mg/day
89182245|NCT03996655|Experimental|Group S|Sugammadex for reversal of steroidal neuromuscular blockers, intravenous injection ,2mg/kg
89182246|NCT03996655|Active Comparator|Group N|Reversal of neuromuscular blockers, iv injection, 0.05 mg/kg
89182247|NCT01032031|Active Comparator|Green tea + vit C high dose|
89182248|NCT01032031|Placebo Comparator|Placebo|
89182249|NCT01032109|Experimental|Bevacizumab|
89182250|NCT04100330|Experimental|Ficlatuzumab with HiDAC|Ficlatuzumab 20 mg/kg intravenously (IV) on Days 1 and 15 in combination with cytarabine 2 g/m2 IV per day on Days 2 through 7. Up to two additional doses can be administered - on Day 29, or on Days 29 and 43, if prolonged myelosuppression is experienced.
89182251|NCT04100330|Active Comparator|HiDAC alone|Cytarabine 2 g/m2 IV per day on Days 1 through 6
89182252|NCT02600624||Participants|Women who are in active labor and their newborn infants.
89182253|NCT04100252||Group 1 (Women with AFI<5 cm at the time of PPROM diagnosis)|Pregnant women who were diagnosed PPROM the gestational ages of 23+0 and 33+0 were examined ultrasonographically at the first admission. Women with AFI<5 were enrolled in the Group 1.
88850861|NCT02144220|Experimental|Virtual care visit|One-time virtual care visit for Parkinson disease.
89377764|NCT02357212|Other|Conservative management|Patients assigned to conservative management will be treated with anti-anginal medications, aspirin, clopidogrel, atorvastatin, and other guideline recommended medicines. Patients will have an echocardiogram and adenosine stress testing
88817394|NCT01338506|Experimental|COPE Therapy|Combined prolonged exposure therapy for PTSD with cognitive behavioral therapy for substance use disorder.
88817395|NCT01338506|Active Comparator|Treatment as usual|CBT for substance use disorder.
88817396|NCT01236170||Group 1|Veterans with spinal cord injury or amputated limbs who use a wheelchair as their primary source of mobility
88817397|NCT01236326|Active Comparator|LESS-DN|
88817398|NCT01236326|Active Comparator|Conventional LDN|
88817399|NCT01239056||Pancreatic Pseudocysts|All adult patients who have a clinical indication to undergo an endoscopic drainage of a pancreatic pseudocyst.
88817400|NCT01302860|Experimental|Canakinumab|Canakinumab s.c. injection (2 mg/kg) was administered every 8 weeks.
88817401|NCT01242644|Experimental|pain pump , injectable medication|30mL of ropivacaine (0.5%), 30mg of ketorolac and 8mg of morphine sulfate injected plus a pain pump containing 100mL of ropivacaine (0.5%) administered at 4 mL/hour;
88817402|NCT01242644|Active Comparator|saline pain pump , injectable medication|30mL of ropivacaine (0.5%), 30mg of ketorolac and 8mg of morphine sulfate injected plus a pain pump containing 100-mL of normal saline administered at 4 mL/hour
88817403|NCT01242644|Active Comparator|injectable medication only|30mL of ropivacaine (0.5%), 30mg of ketorolac and 8mg of morphine sulfate injected and no pain pump.
88817404|NCT01303406|Placebo Comparator|Placebo|"Following the body weight, patients will be allocated to one of the following regimen:~Placebo Patients < 45 kg - 3 tablets 3 times a day with meals~Placebo Patients > 45 kg - 5 tablets 3 times a day with meals"
88817405|NCT01303406|Experimental|idebenone|"Following the body weight, patients will be allocated to one of the following regimen:~Idebenone Patients < 45 kg - 3 tablets 3 times a day with meals~Idebenone Patients > 45 kg - 5 tablets 3 times a day with meals"
88817406|NCT02597127|Experimental|ALN-PCSSC 200 mg (bi-annual dosing)|ALN-PCSSC 200 milligram (mg) SC administration once at Day 1
88817407|NCT02597127|Experimental|ALN-PCSSC 300 mg (bi-annual dosing)|ALN-PCSSC 300 mg SC administration once at Day 1
88817408|NCT02597127|Experimental|ALN-PCSSC 500 mg (bi-annual dosing)|ALN-PCSSC 500 mg SC administration once at Day 1
88817409|NCT02597127|Placebo Comparator|Normal Saline (bi-annual dosing)|Saline SC administration once at Day 1
88817410|NCT02597127|Experimental|ALN-PCSSC 100 mg (quarterly dosing)|ALN-PCSSC 100 mg SC administration twice at Day 1 and Day 90
88817411|NCT02597127|Experimental|ALN-PCSSC 200 mg (quarterly dosing)|ALN-PCSSC 200 mg SC administration twice at Day 1 and Day 90
88817412|NCT02597127|Experimental|ALN-PCSSC 300 mg (quarterly dosing)|ALN-PCSSC 300 mg SC administration twice at Day 1 and Day 90
88817413|NCT02597127|Placebo Comparator|Normal Saline (quarterly dosing)|Saline SC administration twice at Day 1 and Day 90
88817414|NCT02597673|Active Comparator|Standard rehabilitation protocol|Home Exercise Program (HEP). All participants will receive a standard home-based exercise rehabilitation protocol for PFPS. HEP teaches muscle strengthening exercises and self-management strategies to prevent recurrence. The HEP sessions provide the participant with a self-management framework for returning to duty following PFPS rehabilitation. The exercises are quadriceps strengthening exercises. These exercises consist of stretching exercises of the quadriceps and hamstring muscles and a combination of open chain and closed chain exercises. The combined open and closed chain exercises are active straight leg raises, quadriceps straightening, step up, and squats.
88817415|NCT02597673|Experimental|Self-Managed NMES Program|Neuromuscular electrical stimulation (NMES). This group will receive a portable battery-operated device, KneeHAB® XP (Bio-Medical Research, Galway, Ireland) with the thigh garment. NMES training will consist of 20-minute stimulation sessions performed concurrently with the HEP for 9 weeks; each 20-minute NMES session includes a 2-minute warm-up, a 15-minute work-out and a 3-minute cool down. NMES with the thigh garment will be used as the participant is performing the home exercises of stretching and combined open and closed chain exercises. Those in the NMES group will alternate HEP alone and NMES with HEP for a total of 62 sessions (31 sessions of NMES/HEP and 31 sessions HEP alone).
88817416|NCT02597673|Experimental|Self-Managed TENS Program|Transcutaneous electrical nerve stimulation (TENS). The TENS treatment groups will receive the battery-operated Kneehab® XP with lead wire TENS applicator system. The TENS protocol consists of 20-minutes of TENS stimulation while concurrently performing the HEP. The TENS with HEP and HEP alone will be alternated for 9 weeks for a total of 31 TENS/HEP sessions and 31 HEP alone for a total of 62 sessions.
88817417|NCT02597673|Experimental|Combined NMES/TENS Program|The combined NMES/TENS treatment group will receive the Kneehab® XP with the conductive thigh garment and the lead wire TENS applicator. The same parameters for TENS and NMES will be used (described above). The NMES and the TENS protocol will be performed on alternating days. There will be a total of 31 NMES sessions with HEP and 31 TENS sessions with HEP for a total of 62 sessions.
88817418|NCT02597907|Experimental|aprepitant plus palonosetron|aprepitant 80 mg palonosetron 0.075 mg
88817419|NCT02597907|Active Comparator|aprepitant plus ramosetron|aprepitant 80 mg ramosetron 0.3 mg
88817420|NCT02600325|Experimental|Treatment group|Grazoprevir/elbasvir single tablet regimen (100/50mg)
88817421|NCT03498729||Persistent AF|
88817422|NCT03498729||Paroxysmal AF|
88817423|NCT03498729||Psoriasis|
88817424|NCT03498729||Healthy Controls|
88817425|NCT02600403||IOP between 22-32 mmHg|Forty four (44) patients with intraocular pressure between 22 and 32 millimeters (mmHg) of mercury will undergo Optical Coherence Tomography (OCT); Visual Evoked Potential (VEP); and Humphrey Visual Field (HVF).
88817426|NCT02600403||IOP greater than 32 mmHg|Six (6) patients with intraocular pressure greater than 32 millimeters of mercury (mmHg) will undergo Optical Coherence Tomography (OCT); Visual Evoked Potential (VEP); and Humphrey Visual Field (HVF).
88817427|NCT02600403||IOP less than 22 mmHg|Eleven (11) patients with stable intraocular pressure (less than 22 millimeters of mercury (mmHg)) on ophthalmic solutions (eye drops) will undergo Optical Coherence Tomography (OCT); Visual Evoked Potential (VEP); and Humphrey Visual Field (HVF).
88850862|NCT02099682||Lansoprazole 15 mg|Lansoprazole 15 mg orally once daily
89377765|NCT01382160|Experimental|adalimumab|40 mg every two weeks, by subcutaneous way
88810425|NCT06213506|Experimental|Infants_6W_Dose C Group|Infants 6 weeks of age, part of the safety cohort, randomized to receive 3 doses of the iNTS-GMMA Dose C vaccine at Day 1, Day 57 (during the Priming phase) and at Day 232 (during the Booster phase). These infants also receive an EPI vaccination with Measles and Rubella Vaccine (MR-VAC) and Yellow Fever (YF) vaccine at 28 days after the third study intervention administration occurring at Day 232, at the local EPI vaccination centers, and not part of the current clinical trial.
88817428|NCT04340973|Active Comparator|Anodal|Anodal tDCS: Anode placer over the affected primary motor cortex, cathode over contralateral supra orbital area. 2 mA, 20min stimulation, 5 days a week for 4 weeks
88817429|NCT04340973|Active Comparator|Bilateral|Bilateral : Anode placer over the affected primary motor cortex, cathode over unaffected motor cortex. 2 mA, 20min stimulation, 5 days a week for 4 weeks
88817430|NCT04340973|Active Comparator|Cathodal|Cathodal : Cathode placer over the unaffected primary motor cortex, anode over contralateral supra orbital area. 2 mA, 20min stimulation, 5 days a week for 4 weeks
88817431|NCT04340973|Active Comparator|Extracephalic|Extracephalic : Anode placer over the affected primary motor cortex, cathode over right shoulder. 2 mA, 20min stimulation, 5 days a week for 4 weeks
88817432|NCT04340973|Placebo Comparator|Placebo|Placebo : anode montage but current is ramped up over 15 secondes, then ramped down. 2 mA, 20min stimulation, 5 days a week for 4 weeks
88817433|NCT02600637|Experimental|MBSR|Mindfulness-based Stress Reduction program
88817434|NCT02600637|Active Comparator|Education|Educational group program
88817435|NCT03378141|Experimental|A&T- intensive|A&T-intensive arm receive standard MNCH services and intensified maternal nutrition behavior change intervention. Intervention includes provision of IFA and calcium supplements, interpersonal counseling on diet during pregnancy and consumption of IFA and calcium, community mobilization, and adequate weight-gain monitoring during pregnancy
88817436|NCT03378141|No Intervention|A&T-non intensive|A&T-non intensive arm only receives standard MNCH services
88817437|NCT02600715|Experimental|Active B&O suppository of belladonna|Receive the B&O suppository (belladonna/morphine) 40 minutes prior to Onabotulinumtoxin A (BoNT) injection procedure in conjunction with local analgesia.
88817438|NCT02600715|Placebo Comparator|Placebo suppository|Receive a placebo suppository 40 minutes prior to Onabotulinumtoxin A (BoNT) injection procedure in conjunction with local analgesia.
88817439|NCT02601105|Placebo Comparator|Placebo Vehicle Cream|Lipoderm® base served as the placebo vehicle control to be applied every night to demarcated 10 x 10 cm area containing stretch marks on randomly assigned side of abdomen for 12 weeks.
88817440|NCT02601105|Experimental|Centella Asiatica Cream|An alcoholic extract of CA (verified by HPLC) mixed into a Lipoderm® base served as the treatment cream to be applied every night to demarcated 10 x 10 cm area containing stretch marks on the opposite side of the abdomen for 12 weeks.
88817441|NCT02603211||Women with Breast Tumors|Women with breast tumors.
88817442|NCT03331497|Experimental|Tonsillotomy|The patients diagnosed with PFAPA will have tonsillotomy performed in one month from randomisation.
88817443|NCT03331497|No Intervention|Follow up|The patients diagnosed with PFAPA will be monitored for 3 months time. If the symptoms still persist, tonsillectomy will be performed
88817444|NCT04743297|Active Comparator|Propess Vaginal Delivery System|Propess - Prostaglandin E2 Vaginal Delivery System. Slow intravaginal release of 10 mg dinoprostone at a rate of 0.3 mg/h.
88817445|NCT04743297|Active Comparator|Prostin Tablet|Prostaglandin E2 Vaginal Tablet 3 mg dinoprostone
88817446|NCT04176783|Active Comparator|Opioid|The opioid-based arm utilizes traditional, standard-of-care treatment for each applicable surgery. The medications (including dosage and frequency) used in this arm vary depending on the surgery being performed; however, tend to include medications in the opioid family such as Hydromorphone, Hydrocodone, Tramadol, or Oxycodone.
88817447|NCT04176783|Active Comparator|Opioid-Free|The opioid-free arm utilizes medications that do not belong to the opioid family of medications. All medications used are FDA-approved and no experimental medications are being used. The medications (including dosage and frequency) used in this arm vary depending on the surgery being performed; however, tend to include medications such as Gabapentin, Tylenol, Meloxicam, Bupivacaine, or Ketorolac.
88817448|NCT00365469|Experimental|Probiotic|Commercially available cow's milk based infant formula with Bifidobacterium longum [BL999} and Lactobacillus rhamnosus [LPR]
88817449|NCT00365469|Placebo Comparator|Placebo|Commercially available cow's milk based infant formula without probiotic supplementation
88817450|NCT02605395|Experimental|Group A-Idiazole then Pariet|Subjects will receive a single oral dose of IDIAZOLE 20mg DR tabs under fed condition in treatment period 1 followed by 7 days washout interval from the first study drug administration. After the washout interval the subjects will receive a single dose of PARIET 20 mg DR tabs under fed condition in treatment period 2.
88817451|NCT02605395|Experimental|Group B-Pariet then Idiazole|Subjects will receive a single oral dose of PARIET 20 mg DR tabs under fed condition in treatment period 1 followed by 7 days washout interval from the first study drug administration. After the washout interval the subjects will receive a single dose of Idiazole 20mg DR tabs under fed condition in treatment period 2.
88817452|NCT04343001|No Intervention|Standard care|Usual standard of care at the study hospital
88817453|NCT04343001|Experimental|Aspirin|Aspirin 150mg once daily
88817454|NCT04343001|Experimental|Losartan|Losartan 100mg once daily. Dose may be stopped or reduced if patient is hypotensive and can be restarted anytime during the treatment period.
88817455|NCT04343001|Experimental|Simvastatin|Simvastatin 80mg once daily
88817456|NCT04343001|Experimental|Aspirin and Losartan|Aspirin 150mg once daily and Losartan 100mg once daily. Losartan dose may be stopped or reduced if patient is hypotensive and can be restarted anytime during the treatment period.
88817457|NCT04343001|Experimental|Aspirin and Simvastatin|Aspirin 150mg once daily and Simvastatin 80mg once daily
88817458|NCT04343001|Experimental|Losartan and Simvastatin|Losartan 100mg once daily and Simvastatin 80mg once daily. Losartan dose may be stopped or reduced if patient is hypotensive and can be restarted anytime during the treatment period.
88810426|NCT06213506|Active Comparator|Infants_6W_Control C Group|Infants 6 weeks of age, part of the safety cohort, randomized to receive 3 doses of the MenACWY vaccine at Day 1, Day 57 (during the Priming phase) and at Day 232 (during the Booster phase). To allow completion of the vaccination schedule a fourth dose of the MenACWY vaccine is administered after the trial ends, as per the licensed indication and in private vaccination settings. These infants also receive an EPI vaccination with Measles and Rubella Vaccine (MR-VAC) and Yellow Fever (YF) vaccine at 28 days after the third study intervention administration occurring at Day 232, at the local EPI vaccination centers, and not part of the current clinical trial.
89377766|NCT00735748|Experimental|1|Tramadol per os (Tradonal Odis® orodispersible tablets)
88850863|NCT05182944|Experimental|After 2 cycles of neoadjuvant therapy,non-pCR patients adjuvant treatment|After 2 cycles of neoadjuvant therapy（Camrelizumab+Albumin Paclitaxel+Cisplatin）, non-pCR patients adjuvant treatment（2-4 cycles Camrelizumab+Albumin Paclitaxel +Cisplatin and Camrelizumab maintenance treatment）
89377767|NCT00735748|Active Comparator|2|Tramadol IV (Tradonal® IV)
89377768|NCT03630900|Experimental|Sequential O2 culture (5% then 2.5%)|Embryo culture from day 0 to 3 in 5% O2 then split to either 5% or 2.5% O2 until Day 5 or 6.
88850864|NCT05182944|Active Comparator|non-pCR patients adjuvant treatment|After 2 cycles of neoadjuvant therapy（Camrelizumab+Albumin Paclitaxel+Cisplatin）, non-pCR patients adjuvant treatment（Camrelizumab maintenance treatment）
88850865|NCT05182944|Experimental|pCR patients adjuvant treatment|After 2 cycles of neoadjuvant therapy（Camrelizumab+Albumin Paclitaxel+Cisplatin）, pCR patients adjuvant treatment（Camrelizumab maintenance treatment）
88850866|NCT05182944|Active Comparator|pCR patients adjuvant treatment(BSC)|After 2 cycles of neoadjuvant therapy（Camrelizumab+Albumin Paclitaxel+Cisplatin）, pCR patients adjuvant treatment（Best Supportive Care）
88850867|NCT02142894||Symptomatic|Patients with bacteriologically confirmed and untreated TB disease tested with CST001 assay.
88850868|NCT02098746||Pioglitazone/glimepiride|Pioglitazone/glimepiride 15 mg/1 mg, orally once daily before or after breakfast.
88850869|NCT02122770|Experimental|MLN4924 + Fluconazole|"Part A: MLN4924, 8 milligram per square meter (mg/m^2), intravenously, once on Days 1 and 8; and fluconazole, 400 milligram (mg), tablets, orally, once on Day 4, and 200 mg, once daily on Days 5-10.~Part B: MLN4924, at a dose previously deemed tolerable, given on Days 1, 3, and 5 of each 21-day Cycle (Study C15010, Clinicaltrials.gov Identifier # NCT01862328) in combination with docetaxel or carboplatin + paclitaxel at standard dose regimen on Day 1 of each 21-day Cycle."
88850870|NCT02122770|Experimental|MLN4924 + Itraconazole|"Part A: MLN4924, 8-mg/m^2, intravenously, once on Days 1 and 8; and itraconazole, 200 mg, oral solution, once daily on Days 4-10.~Part A (safety lead-in step): MLN4924, 15mg/m^2, intravenously, once on Days 1 and 8; and itraconazole, 200 mg, oral solution, once daily on Days 4-10.~Part A: MLN4924, 20mg/m^2, intravenously, once on Days 1 and 8; and itraconazole, 200 mg, oral solution, once daily on Days 4-10.~Part B: MLN4924, at a dose previously deemed tolerable given, on Days 1, 3, and 5 of each 21-day Cycle (Study C15010, ClinicalTrails.gov Identifier # NCT01862328) in combination with docetaxel or carboplatin + paclitaxel at standard dose regimen on Day 1 of each 21-day Cycle."
88850871|NCT02122380|Experimental|Sitagliptin, then Placebo|Sitagliptin 100 mg by mouth daily for 30 days followed by Placebo daily for 30 days
88850872|NCT02122380|Experimental|Placebo, then Sitagliptin|Placebo daily for 30 days followed by Sitagliptin 100 mg daily for 30 days
88850873|NCT02122146|Experimental|PF-06664178|Experimental
88850874|NCT02121834|Experimental|LY3050258|Daily dose of LY3050258 for 28 days: Cohort A 10 mg, Cohort B 30 mg, Cohort C 90 mg, Cohort D 180 mg and Cohort E 360 mg.
89182254|NCT04100252||Group 2 (Women with AFI≥5 cm at the time of PPROM diagnosis)|Pregnant women who were diagnosed PPROM the gestational ages of 23+0 and 33+0 were examined ultrasonographically at the first admission. Women with AFI≥5 were enrolled in the Group 2.
89377769|NCT03630900|No Intervention|5% O2 culture|
88850875|NCT02121834|Placebo Comparator|Placebo|Daily dose of placebo matching LY3050258 for 28 days.
88850876|NCT02121756|Experimental|Dipyridamole|ARM A: Dipyridamole 100 mg four (4) times daily for 24 weeks from Baseline to Week 24
88850877|NCT02121756|Active Comparator|Placebo then Dipyridamole|ARM B: Placebo for Dipyridamole four (4) times daily for 12 weeks from Baseline to Week 12 followed by Dipyridamole 100mg four (4) times daily for 12 weeks from Week 12 to Week 24
88850878|NCT02142504|Experimental|GI.1/GII.4 15/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL)|Intramuscular (IM) norovirus bivalent virus like particle (VLP) vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 50 µg monophosphoryl lipid A (MPL) and 500 µg aluminum hydroxide, on Day 1, followed by IM norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 15 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminum hydroxide (no MPL), on Day 365.
88850879|NCT02142504|Experimental|GI.1/GII.4 50/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL)|IM norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 50 µg monophosphoryl lipid A (MPL) and 500 µg aluminum hydroxide, on Day 1, followed by IM norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 15 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminum hydroxide (no MPL), on Day 365.
88850880|NCT02142504|Placebo Comparator|Saline Placebo + GI.1/GII.4 15/15 μg (No MPL)|IM saline placebo on Day 1, followed by IM norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 15 µg GII.4 norovirus VLP ) adjuvanted with 500 µg aluminum hydroxide (no MPL), on Day 365.
88850881|NCT02121522|Experimental|BI 144807|twice daily
88850882|NCT02121210|Experimental|Sarilumab 150 mg q2w|Sarilumab 150 mg subcutaneous (SC) injection every two weeks (q2w) for 24 weeks.
89377770|NCT02367196|Experimental|Part A: CC-90002|CC-90002 will be given by intravenous (IV) infusion on a 28 day cycle
89377771|NCT02367196|Experimental|Part B: CC-90002 with Rituximab|CC-90002 in combination with Rituximab will be given by intravenous (IV) infusion on a 28 day cycle in subjects with CD20-positive NHL
89377772|NCT05418504|Active Comparator|Non- Tramadol|the control group represented by dental patients who are not a tramadol addict
89377773|NCT05418504|Active Comparator|Tramadol|The study group with patients seeking dental service but also are tramadol addict.
89377774|NCT02362126||Patients undergoing EFTR|Patients with non-lifting adenomas, adnomas at difficult anaotomic locations , T1-carcinomas or submucosal colorectal tumors
89377775|NCT05406414|Experimental|Transdiagnostic sleep and circadian treatment|The intervention group receives sleep treatment consisting of 6 sessions of 60 minutes each over 6 weeks.
89377776|NCT05406414|Active Comparator|Active waitlist control group|The control group receives sleep hygiene education
89377777|NCT01377792|Active Comparator|5 ml|
89377778|NCT01377792|Active Comparator|10 ml|
89377779|NCT02356978|Experimental|Arm 1|"Each patient will be treated before using the active usual homemade device, and after using the experimental new DRAP device.~This new sheet was designed by weaving optical fibers connected to LEDs ( BROCHIER Technology). The LIGHTEX technology ® is a principle of weaving mill of optical fibres with side lighting connected to LEDs and allowing to realize flexible or stiff bright surfaces with very weak congestions, low consumption and high life cycle. The energy illumination of this device varies between 3 and 4 mW / cm ² ( average 3,6 mW / cm ².)"
89377780|NCT03408886|Experimental|Group A|Group A receives treatment in Part 1 and Part 2
89377781|NCT03408886|Other|Group B|Group B receives no treatment in Part 1, but does receive treatment in Part 2
89377782|NCT02357056|Active Comparator|Wet Lab|Subjects in the wet lab group will perform dissections of the internal thoracic artery and placement of annuloplasty stitches in the mitral valve in pig models until time proficiency is reached based on the performance of our expert robotic surgeons.
89377783|NCT02357056|Active Comparator|Dry Lab|Subjects in the dry lab group will perform exercises form the fundamentals of laparoscopic surgery (FLS) program adapted for the daVinci robot. These exercises included, camera and clutching, peg transfer and intracorporeal knot tying. Participants will repeat these tasks until time proficiency is reached based on the performance of our expert robotic surgeons.
89377784|NCT02357056|Active Comparator|Virtual Reality|Subjects in the virtual reality group will perform exercises from a 9 task curriculum, on the daVinci Skills Simulator. These exercises included, camera and clutching, energy switching, peg board, energy dissection, matchboard, ringwalk, suture sponge, and vertical defect suturing. Participants will repeat these tasks all metrics are passed and an overall score is reached based on the performance of our expert robotic surgeons.
89377785|NCT02357056|No Intervention|Control|The control group will receive no training after they complete the initial assessment and undergo randomization. They will be invited back after several weeks to complete the final assessment to control for any improvement in performance from the initial assessment alone and normal progression through surgical training outside of this project.
89377786|NCT02367508|Experimental|MODEL Care|Mindfully Optimizing Delivery of End-of-Life Care (MODEL Care) is a mindfulness meditation-based intervention to facilitate timely advance care planning (ACP) and end-of-life conversations with greater ease. Participants are taught a variety of mindfulness practices (e.g., breath awareness, sitting meditation, mindful movement through gentle yoga, and mindful communication) that can be used to enhance end-of-life coping.
89377787|NCT02361970||severe sepsis and septic shock|patients were diagnosed severe sepsis or septic shock
89377788|NCT02361970||patient control|Patients after elective surgeries presented with SIRS but without sepsis
89377789|NCT02361970||volunteer|Health persons
89377790|NCT03078582|Experimental|Zilucoplan (RA101495) treatment naive|0.3mg/kg subcutaneously (SC) at Day 1 (loading dose) followed by a starting maintenance dose of 0.1 mg/kg daily SC (treatment naïve)
89377791|NCT03078582|Experimental|Zilucoplan (RA101495) previously on eculizumab|0.3mg/kg subcutaneously (SC) at Day 1 (loading dose) followed by a starting maintenance dose of 0.1 mg/kg daily SC (previously on eculizumab)
89377792|NCT02361892|Experimental|Ulipristal acetate|Women will be treated with 5mg/die of Ulipristal acetate for 2 courses of 3 months each
88817133|NCT01333046|Experimental|azacytidine and multiTAA T cells Stage|This phase will administer aza intravenously at a dose of 75 mg/m2 after premedication with an anti-emetic such as ondansetron po or IV (up to a maximum dose of 16 mg ondansetron or equivalent). This phase will determine whether infusion of TAA-specific T cells (at dose level 2 - 1x10^7) targeting multiple tumor antigens in combination with azacytidine is safe, and whether CTL infusions (with or without azacytidine) increase the spectrum of epitopes/antigens targeted by endogenous T cells (epitope spreading).
88850883|NCT02121210|Experimental|Sarilumab 200 mg q2w|Sarilumab 200 mg SC injection q2w for 24 weeks.
89182255|NCT00436345|Experimental|Remifentanil|remifentanil
89182256|NCT00436345|Active Comparator|Propofol|Propofol infusion
89377793|NCT04013334|Experimental|MTG201 plus Nivolumab|Single arm, open-label, patients receive both MTG201 and nivolumab
89377794|NCT03285412|Experimental|Ribociclib + Endocrine Rx|Ribociclib will be administered. Endocrine therapy will be administered.
88817134|NCT01333046|Experimental|Pediatric multiTAA T cells Stage|This phase will give patients < 18 years old two infusions (on Day 0 and Day 14) of multi-TAA specific T cells at a fixed dose of 1x10^7 cells/m2. This phase will test the safety and efficacy of multiTAA-specific T cells in pediatric patients with active HL/NHL.
88817135|NCT01217970|Experimental|placebo, Ibudilast 20 mg, then Ibudilast 50mg|Sequence: (1) Placebo, (2) Ibudilast 20 mg BID, then (3) Ibudilast 50 mg BID
88817136|NCT01217970|Experimental|Ibudilast 20 mg, Ibudilast 50mg, then placebo|Sequence: (1) Ibudilast 20 mg BID, (2) Ibudilast 50 mg BID, then (3) Placebo
88817137|NCT00999765||Bipolar Disorder - stable|
88817138|NCT00996541|Experimental|Intervention|
88817139|NCT00996541|Placebo Comparator|Control|
88817140|NCT00966381|Other|Control|The minimal care group will receive standard public health information on nutrition from the American Heart Association twice during the 16-week intervention. Upon completion of the endpoint measurement (20 weeks postpartum), they will be given all intervention materials.
88817141|NCT00966381|Experimental|Exercise Group|The intervention group will participate in a 16-week exercise and diet intervention from 4 to 20 weeks postpartum. The PI will travel to the participant's homes three times per week during the 16-week intervention to guide mothers with the exercise program, ensure dietary compliance, and provide social support. The 16-week exercise protocol consists of strength training three times per week and walking 10,000 steps per day at least five days per week.
88817142|NCT02731703||Overdenture Treatment|Guided maxillary implant placement with palateless overdenture
88817143|NCT00082745||Observational (genetic analysis)|DNA from peripheral blood or saliva sample of patients is analyzed for the presence of polymorphisms in genes associated with an increased risk of late-occurring complications.
89377795|NCT03285412|Active Comparator|Endocrine Rx|Endocrine therapy will be administered.
89377796|NCT03077724|Experimental|Fish Oil|4.2 grams per day of n-3 long chain polyunsaturated fatty acids (LCPUFA)
89377797|NCT03077724|Placebo Comparator|Placebos|Olive oil supplements
89377798|NCT02361814|Experimental|Amniotic membrane allograft group|After the conventional flexor tendon repair, the amniotic membrane will be wrapped around the tendons and its borders will be fixed to the remaining tendon sheath.
89377799|NCT01379742|Active Comparator|Iodine-125 standard 18 g needle|Rapidstrand
89377800|NCT01379742|Active Comparator|20 g needle|Thin Strand
89377801|NCT02356744||surgery done less than 1 year|Pregnant women who had bariatric surgery done within the last year before pregnancy. Ultrasound fetal monitoring,biophysical profile assessment and maternal follow up investigations and blood pressure monitoring through all pregnancy
89377802|NCT02356744||surgery done more than 1 year|Pregnant women who had bariatric surgery done more than 1 year before pregnancy. Ultrasound fetal monitoring,biophysical profile assessment and maternal follow up investigations and blood pressure monitoring through all pregnancy
89377803|NCT02356510||Culprit lesion|Patients who underwent culprit lesion only PCI during primary intervention
89377804|NCT02356510||Culprit vessel|Patients who underwent culprit lesion only PCI during primary intervention
89377805|NCT02356432||NOACs group|Medication with dabigatran, rivaroxaban, apixaban, or edoxaban will not be assigned, but will be freely prescribed by each attending doctor based on assessment of the condition of each patient.
89377806|NCT02356432||Warfarin group|Medication with warfarin: PT-INR should be controlled in accordance with the JCS2008 guideline concerning the drug treatment of atrial fibrillation, that is, INR 2.0 to 3.0 in patients younger than 70 years, or INR 1.6 to 2.6 in patients not younger than 70 years.
89377807|NCT02366884|Experimental|Anti-bacterial agents|Combination of two selected anti-bacterial agents with documented anti-cancer properties
89377808|NCT02366884|Experimental|Anti-fungal agents|Combination of two selected anti-fungal agents with documented anti-cancer properties
89377809|NCT02366884|Experimental|Anti-protozoal agents|Combination of two selected anti-protozoal agents with documented anti-cancer properties
89377810|NCT02366884|Experimental|Anti-bacterial + anti-fungal + anti-protozoal agents|Combination of six selected anti-bacterial agents, anti-fungal agents, and anti-protozoal agents with documented anti-cancer properties
89377811|NCT02356276|Experimental|HIPEC group|"Postoperative hyperthermic intraperitoneal chemotherapy (HIPEC) is performed after radical surgery, followed by 6-8 cycles of systemic chemotherapy. The first HIPEC is conducted within 48 h after surgery: Paclitaxel 75 mg/m^2, 43°C, 60min. The second HIPEC is performed after 24 hours of the first HIPEC. The regimens are Paclitaxel 100 mg/m^2, 43°C, 60min.~Systemic chemotherapy (XELOX or SOX regimens):~XELOX regimen: Oxaliplatin: 130 mg/m^2, IV, d1; Capecitabine: 1 g/m^2 bid, days 1-14, every 3 weeks for a total of 6-8 cycles.~If XELOX regimen is not conducted in some collaborators, SOX regimen is also permitted. The regimen is Oxaliplatin: 130 mg/m^2, IV, d1; S-1, 40-60 mg/m^2 bid, po, day 1-14, every 3 weeks for a total of 6-8 cycles."
89377812|NCT02356276|Placebo Comparator|Control group|"6-8 cycles of systemic chemotherapy (XELOX or SOX regimens) were performed after radical gastrectomy with D2 lymphadenectomy.~XELOX regimen is Oxaliplatin: 130 mg/m^2, IV, d1; Capecitabine: 1 g/m^2 bid, days 1-14, every 3 weeks for a total of 6-8 cycles.~If XELOX regimen is not conducted in some collaborators, SOX regimen as comment systemic chemotherapy in Asia is also permitted to treat the patients. The treatment bundles are listed as follows: Oxaliplatin: 130 mg/m^2, IV, d1; S-1, 40-60 mg/m^2 bid (S-1: BSA <1.25m^2, 40mg bid, 1.25m^2≤ BSA ≤1.5m^2, 50mg bid, BSA>1.5m^2, 60 mg bid), po, day 1-14, every 3 weeks for a total of 6-8 cycles."
89377813|NCT02361502|Placebo Comparator|placebo|mirabegron placebo qd
89377814|NCT02361502|Experimental|mirabegron|mirabegron 50mg qd
89377815|NCT02356354|Other|Skin biopsy|On the same patient, a biopsy of post-burn scar is removed. A second one is removed from healthy skin.
88850884|NCT02141490|Experimental|Ferumoxytol + Magnetic Resonance Imaging (MRI)|Ferumoxytol +MRI
88850885|NCT02097108|Other|Raltegravir|Patients will be offered to switch their protease inhibitor containing regimen to a raltegravir (400mg twice daily, orally) based regimen while maintaining the same background therapy.
88850886|NCT02097030|Active Comparator|etafilcon A lens|Participants were randomized to either the etafilcon A or the nelfilcon A lens for three days and then both groups wore the filcon II 3 lens for three days, without washout period between lens types.
88850887|NCT02097030|Active Comparator|nelfilcon A lens|Participants were randomized to either the etafilcon A or the nelfilcon A lens for three days and then both groups wore the filcon II 3 lens for three days, without washout period between lens types.
88850888|NCT02097030|Active Comparator|filcon II 3 lens|Participants were randomized to either the etafilcon A or the nelfilcon A lens for three days and then both groups wore the filcon II 3 lens for three days, without washout period between lens types.
88850889|NCT02096952|Experimental|Methylphenidate extended-release liquid|Methylphenidate extended-release liquid formulation
88850890|NCT02120898|Experimental|Generic Imiquimod Cream 2.5%|Generic imiquimod cream 2.5% will be applied once daily approximately 1 to 2 hours before bedtime to the skin of the treatment area (either full face [excluding the ears] or balding scalp) for two, 2-week treatment cycles separated by a 2-week no-treatment period. Participants will apply test article for 14 consecutive days for each treatment cycle.
88850891|NCT02120898|Active Comparator|Zyclara® (Imiquimod) Cream 2.5%|Zyclara® (imiquimod) cream 2.5% will be applied once daily approximately 1 to 2 hours before bedtime to the skin of the treatment area (either full face [excluding the ears] or balding scalp) for two, 2-week treatment cycles separated by a 2-week no-treatment period. Participants will apply test article for 14 consecutive days for each treatment cycle.
89182257|NCT00916448|Placebo Comparator|Placebo|placebo medication: 2 capsules taken twice daily for 4 consecutive days and thereafter infusion of 2 ng/kg E.coli endotoxin intravenously
89182258|NCT00916448|Active Comparator|Atazanavir|Atazanavir 150 mg, 2 capsules taken twice daily for 4 consecutive days and thereafter infusion of 2 ng/kg E.coli endotoxin intravenously
89377816|NCT02366962|Experimental|ASP7374 group|
89377817|NCT02356120||Suspected Pulmonary Embolus|Patients with suspected pulmonary embolus who are getting a CTPA
88817144|NCT02431806|Placebo Comparator|Placebo|Participants received 2 dose matched over-encapsulated placebo capsules, once daily, orally during the Double-blind Treatment Period up to 8 weeks followed by a 1 week Taper-down Period if applicable as determined by the investigator.
88850892|NCT02120898|Placebo Comparator|Vehicle Cream|Vehicle cream will be applied once daily approximately 1 to 2 hours before bedtime to the skin of the treatment area (either full face [excluding the ears] or balding scalp) for two, 2-week treatment cycles separated by a 2-week no-treatment period. Participants will apply test article for 14 consecutive days for each treatment cycle.
89377818|NCT02367118|Experimental|Prednisone|Intervention: prednisone 5 mg tablets taken orally, in decreasing doses. Beginning with 6 tablets (30 mg) daily for 7 days, then 3 tablets (15 mg) daily for 7 days, then 1 tablet (5 mg) daily for 7 days. Total days of treatment: 21 days.
88850893|NCT02120664|Experimental|Amyloid Negative Subjects|Approximately 10 cognitively normal young subjects will receive a single i.v. bolus injection of approximately 370 megabecquerel (MBq) (10 millicurie [mCi]) florbetapir (18F) and a single i.v. bolus injection of approximately 555 MBq (15 mCi) 11C-PiB.
88850894|NCT02120664|Experimental|Amyloid Positive Subjects|Approximately 25 subjects with a range of amyloid density comprised of subjects clinically diagnosed with Alzheimer's Disease (AD) and subjects at risk for elevated amyloid density will receive a single i.v. bolus injection of approximately 370 MBq (10 mCi) florbetapir (18F) and a single i.v. bolus injection of approximately 555 MBq (15 mCi) 11C-PiB.
89377819|NCT02367118|Placebo Comparator|Placebo|Intervention: placebo tablets taken orally (similar to prednisone), in decreasing doses. Beginning with 6 tablets daily for 7 days, then 3 tablets daily for 7 days, then 1 tablet daily for 7 days. Total days of treatment: 21 days.
89377820|NCT02361268|Experimental|Intra-dialysis yoga|The experimental intervention in this study is intra-dialysis yoga.
88850895|NCT01627860|Active Comparator|Topiramate add-on therapy|
88850896|NCT01627860|Experimental|Topiramate monotherapy|
89377821|NCT02361268|Active Comparator|Educational program|The active comparator for the study is an educational program.
89377822|NCT02366806||In-Depth Education|A. Standard radiotherapy discussion including rationale, number of fractions, side effects, +/- beam arrangements, potential and likely short and long-term toxicity, status checks, skin care, nursing and physician accessibility B. Radiotherapy plan review to include, but not limited to: beam arrangement, total dose, dose per fraction, target area(s), description of isodose lines, DVH review and discussion of prescription constraints for OARs
89377823|NCT02355808|No Intervention|Non Superfast|
89377824|NCT02355808|Other|Non Superfast GP intervention|
89377825|NCT02355808|Other|Non Superfast Tailored Leaflet|
89377826|NCT02355808|Other|Non Superfast GP + Tailored Leaflet|
89377827|NCT02355808|No Intervention|Superfast|
89377828|NCT02355808|Other|Non Superfast GP|
89377829|NCT02355808|Other|Superfast Tailored Leaflet|
89377830|NCT02355808|Other|Superfast GP + Tailored Leaflet|
88850897|NCT01627782|Placebo Comparator|Placebo 3 times/week|
88850898|NCT01627782|Experimental|Ketamine 3 times/week|
88850899|NCT01627782|Experimental|Ketamine 2 times/week|
89377831|NCT02366650||Lund ED|appr 100-200 patients at Lund ED
89377832|NCT02366650||Helsingborg ED|appr 100-200 patients at Helsingborg ED
89377833|NCT02366650||Vancouver ED|appr 100 patients at St Paul's hospital ED
89377834|NCT02366650||Bern ED|appr 100 patients at Bern ED
89377835|NCT02355730|Experimental|Warfarin Patients|Single Arm - blood collection by venepuncture in patients undergoing Warfarin Therapy
89377836|NCT00979212|Active Comparator|Induction CT+RT|Chemotherapy (paclitaxel and carboplatin) plus radiation therapy followed by surgery (if operable) followed by consolidation chemotherapy (paclitaxel and carboplatin)
88817145|NCT02431806|Experimental|Levomilnacipran 40 mg|Participants received over-encapsulated levomilnacipran extended release (ER) 40 mg/day capsules orally starting at a dose of 10 mg/day on Day 1-2, 20 mg/day on Days 3-7 and 40 mg/day on Week 2 through Week 8 during the Double-Blind Treatment Period, followed by a 1-week Double-Blind Taper-down Period if applicable as determined by the investigator. Participants received 1 dose matched placebo capsule each day to maintain the blind.
88850900|NCT01627782|Placebo Comparator|Placebo 2 times/week|
88850901|NCT01598532|Experimental|Transcranial LED Treatment|All study subjects received treatment during 6-Week period (3x per week) for a total of 18 Transcranial LED Treatments using the MedX Health Phototherapy (light). Each session was 30 minutes in duration.
88850902|NCT02119650|Experimental|Ruxolitinib plus Pemetrexed/Cisplatin|
88850903|NCT02119650|Active Comparator|Placebo plus Pemetrexed/Cisplatin|
88850904|NCT02119416|Experimental|1mg/kg Caffeine|Order of Caffeine Administration for Visits 1-6: 1mg, 2mg, 0mg, 1mg, 2mg, 0mg
88850905|NCT02119416|Experimental|2mg/kg caffeine|Order of Caffeine Administration for Visits 1-6: 2mg, 0mg, 1mg, 2mg, 0mg, 1mg
88850906|NCT02119416|Experimental|Placebo|Order of Administration for Visits 1-6: 0mg, 1mg, 2mg, 0mg, 1mg, 2mg
88850907|NCT02140164|Experimental|Minocycline|Oral administration of minocycline
88850908|NCT04745208|No Intervention|standard discharge education|The control group will receive only the standard discharge education.
88850909|NCT04745208|Experimental|standard discharge education+Simulation based education|The intervention group will receive standard discharge education and then simulation based education will be performed
89182259|NCT04095650|Experimental|Intervention|Participants will engage in a 7-week chronic pain self-management program.
89377837|NCT00979212|Experimental|Induction CT+RT+Panitumumab|Panitumumab plus chemotherapy (paclitaxel and carboplatin) plus radiation therapy followed by surgery (if operable) followed by consolidation chemotherapy (paclitaxel and carboplatin)
89377838|NCT02356042||Nursing home residents practicing GIA activity|
89377839|NCT02356042||Nursing home residents no practicing GIA activity|
89377840|NCT02355964|Experimental|exercise|exercise (Aerobe training) 3 times per week
89377841|NCT02355964|Experimental|Diet|A diet with an overall high protein content and a low glycemic index
89377842|NCT02355964|Experimental|Diet+Exercise|A diet with an overall high protein content and a low glycemic index combined with exercise (Aerobe training) 3 times per week.
89377843|NCT02355964|No Intervention|control|Regular lifestyle (no intervention)
89377844|NCT02355652|Active Comparator|Cemented TKA|
88850910|NCT02119260|Experimental|Cohort 1|Eight subjects will be randomized to 1 of 4 placebo-controlled dose sequences with 2 subjects in each sequence and each subject having four dose periods (3 active dose of GSK2798745 + 1 placebo dose). GSK2798745 will be administered in a liquid form (suspension or solution) in this cohort. In each treatment period, the subjects will be fasting from the prior midnight to four hours post-dose (Day 1).
88875311|NCT02584998|No Intervention|Usual care|These patients will continue to receive the current practice at the Philadelphia VA Medical Center (VAMC) of offering screening during an office visit. Other interventions will be embedded within this existing program for a pragmatic approach. However, all participants in the trial, including those in usual care (UC), will receive follow-up of test results and navigation to diagnostic colonoscopy for positive FIT results.
89182260|NCT02601716|Experimental|Group 1|"Group 1 subjects (n=15) will receive 4 doses of PfSPZ Vaccine (4.5 x 10^5 PfSPZ/dose) every 2 days, followed by a single, boosting dose (same dose as before) given 16 weeks later, for a total PfSPZ dose = 22.5 x 10^5. PfSPZ Vaccine administered by DVI.~Protective efficacy assessed by heterologous CHMI (7G8) Pf parasites at 28 and 40 weeks after the first immunization, along with 8 infectivity controls. Subjects may proceed to CHMI if they have received at least 2 of 4 priming immunizations and the boost scheduled for Group 1. Participants not protected after the first CHMI will be invited to receive a booster vaccination (4.5 x 10^5 PfSPZ) 21 days prior to the second CHMI. Subjects may participate in the second CHMI whether or not they were protected in the 1st CHMI, to serve as controls for the effect of the 1st CHMI on immunity.~Subjects will be followed for 56 days beyond the final CHMI (post-immunization week 40)."
89182261|NCT02601716|Experimental|Group 2|"Subjects (n=15) will receive 3 doses of PfSPZ Vaccine (9.0 x 10^5 PfSPZ/dose) every 8 weeks, total PfSPZ dose = 27 x 10^5. PfSPZ Vaccine administered by DVI.~Protective efficacy assessed by heterologous CHMI (7G8) Pf parasites at 28 and 40 weeks after first immunization, along with 8 infectivity controls. Subjects may proceed to CHMI if they have received at least 2 of 3 immunizations scheduled for Group 2. Participants not protected after the first CHMI will be invited to receive a booster vaccination (9.0 x 10^5 PfSPZ) 21 days prior to the second CHMI. Subjects may participate in the second CHMI whether or not they were protected in the 1st CHMI, to serve as controls for the effect of the 1st CHMI on immunity.~Subjects will be followed for 56 days beyond the final CHMI (post-immunization week 40)."
89182262|NCT02601716|Experimental|Group 3|"Group 3 subjects (n=15) will receive 3 doses of PfSPZ Vaccine (18 x 10^5 PfSPZ/dose) every 8 weeks for a total PfSPZ dose of 54 x 10^5. PfSPZ Vaccine administered by DVI.~Protective efficacy assessed by CHMI with heterologous (7G8, NF135.C10) Pf parasites at 40 and 66 weeks after the first immunization, along with 8 infectivity controls. Subjects may proceed to CHMI if they have received at least 2 of 3 immunizations scheduled for Group 3. All participants will be invited to receive a booster vaccination (18 x 10^5 PfSPZ) 21 days prior to the second CHMI. Subjects may participate in the second CHMI whether or not they were protected in the 1st CHMI, to serve as controls for the effect of the 1st CHMI on immunity.~Subjects will be followed for 56 days beyond the final CHMI (post-immunization week66)."
89182263|NCT02601716|Experimental|Group 4|"Subjects (n=15) will receive a single, priming dose of PfSPZ Vaccine (27 x 10^5 PfSPZ/dose), followed by 2 additional immunizations (9.0 x 10^5 PfSPZ per dose) every 8 weeks, total PfSPZ dose = 45 x 10^5. PfSPZ Vaccine administered by DVI.~Protective efficacy assessed by CHMI with heterologous 7G8 and NF135.C10 Pf parasites at 40 and 66 weeks, respectively, along with 8 infectivity controls at each CHMI. Subjects may proceed to CHMI if they have received at least 2 of 3 immunizations scheduled for Group 4. All participants will be invited to receive a booster vaccination (9.0x10^5 PfSPZ) 21 days prior to the second CHMI.~Subjects will be followed for 56 days beyond the final CHMI at (post-immunization week 66)."
89182264|NCT02601716|Other|Infectivity Controls, CHMI (7G8)|Infectivity controls (n=24) will not receive any PfSPZ Vaccine. They will serve as infectivity controls for CHMI for all groups. 8 infectivity controls will undergo CHMI with each of two CHMIs (at 28 and 40) for Groups 1 and 2, and 8 infectivity controls will undergo CHMI with the 40 week CHMI for Groups 3 and 4. All CHMI will be conducted by exposure to the bites of 5 mosquitoes infected with heterologous (7G8) Pf parasites. Subjects will be followed for 56 days beyond the last CHMI at week 40 at the UMB site.
89182265|NCT02601716|Other|Infectivity Controls, CHMI (NF135.C10)|Infectivity controls (n=8) will not receive any PfSPZ Vaccine. They will serve as infectivity controls for the second CHMI at week 66 for Groups 3 and 4. CHMI will be conducted by exposure to the bites of 3-5 mosquitoes infected with heterologous (NF135.C10) Pf parasites. Subjects will be followed for 56 days beyond the last CHMI at week 66 at the NMRC site.
89182266|NCT01032187|Active Comparator|Meglumine antimoniate|20mg/kg/day IV for 20 days
89182267|NCT01032187|Experimental|Anfo B|Amphotericin B-deoxycholate, 1mg/kg/day IV for 14 days
89182268|NCT01028755|Experimental|Arm 1|
89182269|NCT00769184|Experimental|Corticosteroid + LCD|corticosteroid and LCD treatment (2 weeks), LCD alone treatment (4 weeks)
89182270|NCT00769184|Placebo Comparator|Corticosteroid + Placebo|corticosteroid and placebo treatment (2 weeks), placebo alone treatment (4 weeks)
89182271|NCT01028833|Experimental|Power mobility|Intervention included provision of power wheelchair and power mobility training program. Project staff will use structured power mobility training program to teach the children to use the power mobility devices. Project staff will schedule 1-hour sessions with each family 3 times per week for the first month of the project and will decrease in the following manner as the child becomes proficient and develops basic wheelchair maneuvering skills: two one-hour session per week for 4 weeks; one one-hour session per week for 4 weeks; two one-hour sessions per month for 4 weeks; one one-hour session per month for the remainder of the study.
89182272|NCT01028833|No Intervention|Control|Children in the control group will not receive any additional intervention, but will continue to receive the early intervention or other services they were receiving prior to enrollment in this study.
89182273|NCT00768560|Active Comparator|Nifedipine (Adalat CR, BAYA1040) 40 mg OD|Nifedipine (Adalat CR, BAYA1040) 40 milligram (mg) once daily (OD) in the morning
89182274|NCT00768560|Experimental|Nifedipine (Adalat CR, BAYA1040) 40 mg BID|Nifedipine (Adalat CR, BAYA1040) 40 milligram (mg) twice daily (BID). 40 mg in the morning and 40 mg in the evening
89182275|NCT00768560|Experimental|Nifedipine (Adalat CR, BAYA1040) 80 mg OD|Nifedipine (Adalat CR, BAYA1040) 80 milligram (mg) once daily (OD) in the morning
89182276|NCT00468559|Experimental|Open Label Esomeprazole|This is an open label, run-in phase. All patients received Esomeprazole.
89377845|NCT02355652|Active Comparator|Uncemented TKA|
89182277|NCT00468559|Experimental|Double Blind Esomeprazole|This is the double blind withdrawal phase. Patients are randomized to active drug or placebo.
89182278|NCT00468559|Placebo Comparator|Double Blind Placebo|This is the double blind withdrawal phase. Patients are randomized to active drug or placebo.
89182279|NCT00754442|Active Comparator|teriparatide control|control subject
89182280|NCT00754442|Experimental|Teriparatide Patient|Patient with secondary hyperparathyroidism
89182281|NCT02600390|Experimental|SANGUINATE™ (4-week)|This is an Open-label, repeated-dose study. About five patients will be observed for 3 weeks continuing on standard of care therapy (for wound cleaning and bandaging). This will be followed by a 4-week treatment period to include once weekly doses of SANGUINATE provided via two-hour IV infusion. The final week of the study will include another observation period wherein all patients will receive standard of care therapy.
89182282|NCT02600390|Experimental|SANGUINATE™ (6-week)|This is an Open-label, repeated-dose study. About five patients will be observed for 3 weeks continuing on standard of care therapy (for wound cleaning and bandaging). This will be followed by a 6-week treatment period to include once weekly doses of SANGUINATE provided via two-hour IV infusion. The final week of the study will include another observation period wherein all patients will receive standard of care therapy.
89182283|NCT00754052|Active Comparator|1|
89182284|NCT00754052|Active Comparator|2|
89182285|NCT00754052|Placebo Comparator|3|
89182286|NCT04095182|Experimental|Zebinix 400mg|
89182287|NCT04095182|Placebo Comparator|Placebo for Zebinix 400mg|
89182288|NCT04095182|Experimental|Zebinix 800mg|
89182289|NCT04095182|Placebo Comparator|Placebo for Zebinix 800mg|
89182290|NCT04095182|Experimental|Zebinix 1600mg|
89182291|NCT04095182|Placebo Comparator|Placebo for Zebinix 1600mg|
89182292|NCT00916916||Lanreotide|Patients taking lanreotide for the treatment of acromegaly.
89182293|NCT04093154|Experimental|Virtual Reality|Standard Care + VR VR applications introduced to the child or adolescent by the researcher before the procedure. Three VR applications were used in this study; riding a rollercoaster (Rilix VR), swimming with marine animals in underwater world (Ocean Rift) and exploring the forest though the eyes of woodland species (In the eyes of animal). Children/adolescent chose one of these three applications. When the child is ready for the procedure, the researcher started the application by wearing virtual glasses to the child/adolescent. VR intervention was started 2-3 min before the procedure and continued until the procedure was completed.
89182294|NCT04093154|No Intervention|Control|Standart Care Control group children did not receive any distraction techniques.
89182295|NCT02599844||Sepsis with Severe AKI|"This group will have a history of pediatric admission with sepsis-related Acute Kidney Injury (sAKI) which lead to classification of injury or failure. The following test will be performed: urinary and serum studies to measure glomerular filtration rate by using gadolinium, renal plasma flow by using an injection of non-radioactive iodohippurate, followed by cardiovascular assessments using 24 hour ambulatory blood pressure monitoring, peripheral arterial tonometry and pulse wave velocities (PWV)."
89182296|NCT02599844||Sepsis without AKI|This group will have a history of a pediatric admission with sepsis which lead to no classification of sepsis-related Acute Kidney Injury (sAKI). The following test will be performed: urinary and serum studies to measure glomerular filtration rate by using gadolinium, renal plasma flow by using an injection of non-radioactive iodohippurate, followed by cardiovascular assessments using 24 hour ambulatory blood pressure monitoring, peripheral arterial tonometry and pulse wave velocities (PWV).
89182297|NCT02600312|Active Comparator|oXiris|Continuous renal replacement therapy with filter that adsorbs cytokines/toxins.
89182298|NCT02600312|No Intervention|ST150|Continuous renal replacement therapy with filter that does not adsorb cytokines/toxins.
89182299|NCT04099784||Freeze-only|Children born from freeze-only group and frozen embryo transfer
89182300|NCT04099784||Fresh|Children born from fresh embryo transfer
89182301|NCT00747812|Experimental|1|Stimulation on from activation to 12 weeks post-activation. Stimulation off from 12 weeks post-activation to 16 weeks post-activation. Stimulation on from 16 weeks post-activation to end of study.
89182302|NCT00747812|Sham Comparator|2|Sham Stimulation from activation of device to 12 weeks post-activation. Stimulation on from 12 weeks post-activation on.
89377846|NCT03630744||Adult patients undergoing surgery|Patients over 18 years surgically treated with fluid therapy during the 24 hours of the day study
89182303|NCT04092920|Experimental|laser and SLA implants|extraction of badly broken maxillary and mandibular teeth with immediate implant placement using laser surface treated and SLA surface treated dental implants
89182304|NCT02927067|Active Comparator|Valganciclovir 900 mg BID|Participants received 900 milligrams (mg) of valganciclovir along with a placebo matched to maribavir, twice daily (BID) orally for 8 weeks. Valganciclovir dose was allowed to be adjusted to 450 mg BID or 450 mg QD based on renal function impairment assessed at baseline or development of neutropenia during the study.
89377847|NCT03160534|Experimental|Intervention|Preoperative exercise intervention
89377848|NCT03160534|No Intervention|Control|Only measurements
89377849|NCT01379586|Experimental|E|ONO-4053
89377850|NCT01379586|Placebo Comparator|P|Placebo
88850911|NCT02119260|Experimental|Cohort 2|Twelve subjects will receive GSK2798745 in three single-dose treatment periods in a fixed sequence. The actual dose-selected will be determined based on review of emerging safety and exposure data from Cohort 1. The dosing will be done in 3 study periods for investigating bioavailability and food effects. In Period 1, subjects will be fasting from midnight to four hours post-dose and will receive GSK2798745 in a liquid form (suspension or solution). In Period 2, subjects will be fasting from midnight to four hours post-dose and will receive a capsule formulation of GSK2798745. In Period 3, subjects will receive GSK2798745 capsule following a standard high fat/high calorie meal.
89182305|NCT02927067|Experimental|Maribavir 400 mg BID|Participants received 400 mg of maribavir along with a placebo matched to valganciclovir, BID orally for 8 weeks.
89182306|NCT02600468||Patients who use ORENCIA|Patients who use ORENCIA for the approved indications and who at the start of treatment
89182307|NCT04094636|No Intervention|No intervention: Control|Control group
89182308|NCT04094636|Experimental|In-bed cycling|Supervised in-bed cycling
89182309|NCT04094636|Experimental|Exercise booklet|Supervised physical training with exercises from exercise booklet
89182310|NCT02577939|Experimental|Interval Exercise Training (IET)|This is a single arm study. All patients receive the intervention of 6 weeks of pre-transplant IET, pre- and post-tests, and data collection via FitBit accelerometer and weekly surveys.
89182311|NCT04094480|Active Comparator|endoloop ligation|securing appendicular base with endoloops
89182312|NCT04094480|Active Comparator|non absorbable polymeric clips|securing appendicular base with non absorbable polymeric clips
89182313|NCT04073901|Experimental|Endocrown|Adhesive monoblock restoration for pulpotomized primary molars
89182314|NCT04073901|Active Comparator|Zirconia crowns|Prefabricated primary full coverage crown
89182315|NCT02598596|Experimental|Pegloticase regimen <120 kg - Main Study|Subjects weighing <120 kg will receive a tolerizing dose of pegloticase 8 mg IV weekly for the first 3 weeks of dosing followed by an 8 mg IV dose every 2 weeks for a total of 10 doses.
89182316|NCT02598596|Experimental|Pegloticase regimen ≥120kg|Subjects weighing ≥ 120 kg will be sequentially assigned to 1 of 3 different loading doses (8, 12, and 16 mg) on Study Day 1, and then receive 8 mg on Week 2 and 3, followed by 8 mg every 2 weeks through Week 17 for a total of 10 doses.
89182317|NCT02598596|Experimental|Pegloticase PK Sub-Study|Subjects weighing <120 kg and ≥120 kg will be assigned to 1 of 2 different loading doses (12 and 16 mg) on Study Day 1, and then receive 8 mg on Week 2 and 3, followed by 8 mg every 2 weeks through Week 17 for a total of 10 doses. Subjects will have multiple blood sampled for PK levels over the 17 week dosing period.
89182318|NCT02598596|Experimental|Pegloticase Imaging Sub-Study|A subset of subjects participating in the Main Study and weighing <120 kg will have dual-energy computed tomography (DECT) and dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) performed at Screen and at Week 17.
89182319|NCT02598596|Experimental|Pegloticase FDG-PET-CT Sub-Study|A subset of subjects participating in the Main Study and weighing <120 kg will have fluorodeoxyglucose-positron emission tomography (FDG-PET-CT) to evaluate carotid and aortic (chest) atherosclerosis at Screen and at Week 17.
89182320|NCT02598596|Experimental|Pegloticase and Azathioprine|Subjects weighing <120 kg will receive azathioprine (AZA) daily for a 2-week run-in period, followed by daily AZA plus pegloticase 8 mg IV every 2 weeks through Week 25 for a total of 13 doses.
89182321|NCT01751685|Experimental|Kyphosis-specific spinal exercises|Investigator developed the intervention protocol (Kyphosis-specific spinal exercises) of targeted spine exercises during our pilot study based upon the literature and clinical experience.We standardized the protocol with a written script and a video. Each exercise session will be preceded by light aerobic activity, ended with cool-down and stretching the neck, chest and all extremities. All participants will be carefully monitored to ensure that all exercises will be performed slowly, with correct body alignment and technique to minimize risk of injury.
89182322|NCT01751685|Placebo Comparator|Control|Usual care control group will meet once a month for educational lectures on various topics. At the end of 6 months, each control group participant will get a one-on-one session with the physical therapist who was leading the intervention classes.
89182323|NCT00586508|Experimental|Enzastaurin + Bevacizumab|
89182324|NCT00581919|Experimental|Bort, Dex, and Dox with ALCAR|
89182325|NCT04094168|Experimental|Del Nido Cardioplegia solution|1 liter of Del Nido cardioplegia after aortic cross-clamp will be given. Additional dose will be applied if aortic cross-clamp exceeds 90 minutes or whenever cardiac activity is observed.
89182326|NCT04094168|Active Comparator|Cold blood Cardioplegia solution|Administering of cardioplegia using current standard of care blood-based cardioplegia protocol. An induction dose of whole blood cardioplegia will be given at a temperature of 4-8 degrees, with subsequent doses of cardioplegia every 20 minutes or whenever cardiac activity is observed.
89182327|NCT00723528|Placebo Comparator|Placebo (CP)|Placebo 0.5 ml and 1.0 ml will be administered subcutaneously (SC) on Weeks 0 and 4 respectively during the controlled period (Weeks 0-12).
89182328|NCT00723528|Active Comparator|Ustekinumab 45 mg (CP)|Ustekinumab 45 mg (0.5 ml) and placebo (1.0 ml) will be administered SC on Weeks 0 and 4 during controlled period (Weeks 0-12).
89182329|NCT00723528|Active Comparator|Ustekinumab 90 mg (CP)|Ustekinumab 90 mg (1.0 ml) and placebo (0.5 ml) will be administered SC on Weeks 0 and 4 during controlled period (Weeks 0-12).
89182330|NCT00723528|Placebo Comparator|Placebo A (After CP)|After the controlled period (that is [i.e.], during the active drug treatment period [Weeks 12-64]), the placebo group will be randomized into 2 groups, including Placebo A, in which ustekinumab 45 mg (0.5 ml) and placebo (1.0 ml) will be administered SC at Weeks 12, 16, 28, 40, and 52.
89182331|NCT00723528|Placebo Comparator|Placebo B (After CP)|After the controlled period (i.e., during the active drug treatment period [Weeks 12-64]), the placebo group will be randomized into 2 groups, including Placebo B, in which ustekinumab 90 mg (1.0 ml) and placebo (0.5 ml) will be administered SC at Weeks 12, 16, 28, 40, and 52.
89182332|NCT00723528|Active Comparator|Ustekinumab 45 mg (After CP)|After the controlled period (i.e., during the active drug treatment period [Weeks 12-64]), participants in the ustekinumab 45 mg group will receive placebo (0.5 ml and 1.0 ml) SC at Week 12 followed by ustekinumab 45 mg (0.5 ml) and placebo (1.0 ml) SC at Weeks 16, 28, 40 and 52.
89377851|NCT02038738|Experimental|Scan|We will perform 68Ga-DOTATATE PET scans on subjects.
89377852|NCT02361424|Experimental|PXT00864 Dose 1|1 orange capsule containing 0.4 mg of acamprosate , and 1 white capsule containing 6 mg of baclofen These 2 capsules are taken orally b.i.d. during 8 weeks.
89377853|NCT02361424|Experimental|PXT00864 Dose 2|"1 orange capsule containing 1 mg of acamprosate , and 1 white capsule containing 15 mg of baclofen .~These 2 capsules are taken orally b.i.d. during 8 weeks."
89377854|NCT02361424|Experimental|PXT00864 Dose 3|"1 orange capsule containing 20 mg of acamprosate , and 1 white capsule containing 12 mg of baclofen .~These 2 capsules are taken orally b.i.d. during 8 weeks."
89377855|NCT02361424|Placebo Comparator|Placebo of PXT00864|"1 orange capsule containing placebo of acamprosate , and 1 white capsule containing placebo of baclofen .~These 2 capsules are taken orally b.i.d. during 4 weeks"
89377856|NCT05347368|Other|Control group (conventional therapy)|
89377857|NCT05347368|Experimental|Primal Reflex release Technique|
89377858|NCT02366416|Experimental|Exercise training|12 weeks of one hour exercise training twice weekly
89377859|NCT01377558|Experimental|Aerobic endurance training intervention|Aerobic endurance training
89377860|NCT01377558|Experimental|Strength endurance training intervention|Strength endurance training
89182333|NCT00723528|Active Comparator|Ustekinumab 90 mg (After CP)|After the controlled period (i.e., during the active drug treatment period [Weeks 12-64]), participants in the ustekinumab 90 mg group will receive placebo (0.5 ml and 1.0 ml) SC at Week 12 followed by ustekinumab 90 mg (1.0 ml) and placebo (0.5 ml) SC at Weeks 16, 28, 40 and 52.
89377861|NCT01377558|Experimental|Combined training intervention|Combined aerobic endurance training and strength endurance training intervention
89377862|NCT01377558|No Intervention|Control group|control group
89377863|NCT05331612|Experimental|Blended intervention condition|"Blended intervention condition, consisting of 5 face-to-face group sessions lasting 2 hours every 2 weeks, alternated with the online treatment protocol carried out by the participants in a self-applied. The intervention has a period of duration of 13 weeks and it is composed by 8 modules (Motivation for change, Psychoeducation, Stimulus control, Cognitive restructuring, Urge surfing and emotion regulation, Planning of significant activities, Coping skills and exposure with response prevention, and Relapse prevention). These modules is based in the online platform and manualized protocol treatment Sin jugar, ganas (Díaz-Sanahuja et al., 2021)."
89377864|NCT05331612|No Intervention|Waiting list control condition|Waiting list control group receives the blended treatment when the intervention has finished in the experimental group (blended group intervention).
89377865|NCT02361190|Placebo Comparator|Placebo nasal spray|Subjects will inhale approximately 40ml aqueous solution via intranasal route
89377866|NCT02361190|Experimental|Testosterone nasal spray|Subjects will inhale approximately 40ml aqueous, testosterone-containing solution via intranasal route
89377867|NCT02361112|Experimental|pyrotinib combined with capecitabine|
89377868|NCT03080454|Placebo Comparator|Sham Doublestim|Participants first received 5 daily, consecutive 20 min sessions of sham Doublestim (trans-spinal direct current stimulation + peripheral direct current stimulation). After a washout period of 1 week, they then received 5 daily, consecutive 20 min sessions of anodal Doublestim (trans-spinal direct current stimulation + peripheral direct current stimulation). For all participants, the sham condition preceded the anodal Doublestim condition.
89377869|NCT03080454|Active Comparator|Anodal Doublestim|Participants first received 5 daily, consecutive 20 min sessions of sham Doublestim (trans-spinal direct current stimulation + peripheral direct current stimulation). After a washout period of 1 week, they then received 5 daily, consecutive 20 min sessions of anodal Doublestim (trans-spinal direct current stimulation + peripheral direct current stimulation). For all participants, the sham condition preceded the anodal Doublestim condition.
89182334|NCT00751790|Experimental|Triptorelin|
89377870|NCT05327712|Experimental|Control|The control group was assigned to receive no outreach beyond an initial eligibility determination notice
89377871|NCT05327712|Experimental|Email-only|An email-only group assigned to receive an initial eligibility determination plus email reminders about signing up for marketplace coverage
89377872|NCT05327712|Experimental|Phone-only|A phone-only group assigned to receive an initial eligibility determination plus a phone call offering enrollment assistance from a service center representative (SCR);
89377873|NCT05327712|Experimental|Phone and email|A phone + email group assigned to receive an initial eligibility determination, email reminders about signing up for marketplace coverage and a phone call offering enrollment assistance.
89377874|NCT02943304||Exposed|Symptomatic pregnant women with positive RT-PCR ZIKV in serum or urine, or a positive serologic test specific for ZIKV
89377875|NCT02943304||Unexposed|Asymptomatic pregnant women with a negative RT-PCR ZIKV in serum and urine, and a negative specific serology for ZIKV at enrollment into the study and at the time of delivery
89377876|NCT02360956|Experimental|Olmesartan medoxomil|Drug: Olmesartan medoxomil tablets(Daiichi Sankyo Inc, Japan). The initial dose is 20mg once daily. If blood pressure requiring further reduction after two weeks, olmesartan medoxomil may be increased to 40mg once daily.
89377877|NCT02360956|Active Comparator|Antihypertensive medication|"Drug:Any antihypertensive medication alone or in combination.Calcium channel blockers (CCBs),diuretics, beta-blockers, or other antihypertensive medication except angiotensin-Converting Enzyme Inhibitors inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs).~The drug dose must be individualized."
89377878|NCT02367976|Experimental|rhprouk|rhprouk to be administrated in 60 minutes.
89377879|NCT02367976|No Intervention|controlled|The controlled arm patients will be administrated in 90 minutes after randomized.
89377880|NCT05461638|Active Comparator|Unrestricted Kinematic Alignment|Mechanical Alignment and Unrestricted Kinematic Alignment using Medacta GMK Sphere with custom cutting guides
89377881|NCT05461638|Active Comparator|Restricted Kinematic Alignment|Mechanical Alignment and restricted Kinematic Alignment using Medacta GMK Sphere with custom cutting guides
89377882|NCT02360800|Experimental|TISSEEL|Spray Fibrin Sealant
89377883|NCT02360800|Active Comparator|CONTROL|Traditional hemostasis and chest closure routine
89377884|NCT02360878||Non-diabetic subjects|Obese (BMI > 30 kg/m2) with normal glucose tolerance implanted with the EndoBarrier Gastrointestinal liner
88850912|NCT02119260|Experimental|Cohort 3|Sixteen subjects will be randomized to 2 repeat dose cohorts with 8 subjects in each cohort in a ratio of 6:2 (treatments: placebo). Food intake timing will be determined based on data from Cohorts 1 and 2 (if Cohort 2 is conducted before Cohort 3). Doses will be administered once daily from Day 1 through Day14. Based on data from Cohort 1, the second dose in the repeat-dose period may be skipped to estimate the time invariance in PK. Dosing may be altered to twice daily based on the results obtained in the initial study cohort. Subjects will be fasted from midnight to 4 hours after dosing on Day 1 and Day 14 that entail serial PK sampling. Meal timings on other days will be based on previous cohort data.
89377885|NCT02360878||T2DM subjects|Obese (BMI > 30 kg/m2) with type 2 diabetes implanted with the EndoBarrier Gastrointestinal liner
89377886|NCT03501966|Active Comparator|Acetazolamide including Diet|"Subjects will use 250 mg tablets of acetazolamide, divided into two doses, taken with meals. Initial dose will be 1,000 mg twice per day and increased per titration schedule (Table 6 in protocol).~Dietary consultation will include advising subjects to adopt a low sodium weight reduced diet."
89377887|NCT03501966|Active Comparator|Optic Nerve Sheath Fenestration|"Acetazolamide including Diet plus Optic Nerve Sheath Fenestration (ONSF) Subjects will use 250 mg tablets of acetazolamide, divided into two doses, taken with meals. Initial dose will be 1,000 mg twice per day and increased per titration schedule (Table 6 in protocol).~Dietary consultation will include advising subjects to adopt a low sodium weight reduced diet.~ONSF performed by qualified, certified orbital surgeon using either a medial or supero-medial lid crease approach. ONSF will be performed in one or both eyes, depending on criteria."
89377888|NCT03501966|Active Comparator|Ventriculoperitoneal CSF Shunting|"Acetazolamide including Diet plus Ventriculoperitoneal CSF Shunting (VPS) Subjects will use 250 mg tablets of acetazolamide, divided into two doses, taken with meals. Initial dose will be 1,000 mg twice per day and increased per titration schedule (Table 6 in protocol).~Dietary consultation will include advising subjects to adopt a low sodium weight reduced diet.~VPS performed by qualified, certified neurosurgeon using a frameless image-guided stereotactic system and positioning a shunt catheter in the lateral ventricle of the cerebral hemisphere not associated with speech. The catheter will be connected to an adjustable valve, and a distal shunt system will be placed in the peritoneal cavity."
89377889|NCT02361034|Active Comparator|GRC 27864|Test treatment GRC 27864
89377890|NCT02361034|Placebo Comparator|Placebo|Placebo treatment
89377891|NCT02355184|Experimental|PRO 140|PRO 140 350mg weekly SQ injection.
89182335|NCT04092998|Experimental|Thermocautery VS scalpel circumcision|Thermocautery circumcision in comparison to circumcision with traditional scalpel
89399412|NCT03690609|Active Comparator|Nutraceutical intervention, 3 capsules daily.|Participants will consume the nutraceutical blend CytoQuel at a dose of 1850 mg, by consuming 3 capsules daily in the morning.
89399413|NCT03690609|Active Comparator|Nutraceutical intervention, 2 capsules twice daily.|Participants will consume the nutraceutical blend CytoQuel at a dose of 1850 mg, by consuming 4 capsules daily: Two in the morning and two later in the day.
89399414|NCT02173808|Experimental|Contraceptive|
89399415|NCT03690531||Take Pause Virtual Reality Head Set|The mbVR intervention arm will be a Take-Pause virtual reality simulation will be for 5 minutes shown through a virtual reality goggle, headset and iPhone.
89182336|NCT04086810|Experimental|DCCR|25 - 450 mg DCCR
89377892|NCT05326854|Experimental|intervention group|"1., 2., 3. İnterview (in hospital) The patient will be educated. Measuring tools will be applied. (Personal Information Form- Coping and Adaptation Process Scale)( discharge: Perinatal Grief Scale, Depression Anxiety Stress Scale) The mobile application developed within the scope of post-termination support will be downloaded to the patient's phone. Informed consent form will be signed by the patient.~Sharing problems, presenting solutions. Follow-up of the patient and strengthening and supporting in this process.~4., 5., 6. Interview at home (following the patient with mobile application and phone calls)~7. and 8., Interview at home (following the patient with mobile application and phone calls) Measuring tools will be appliedPerinatal Grief Scale, Depression, Anxiety and Stress Scale, Coping and Adaptation Process Scale"
89377893|NCT05326854|No Intervention|Control Group|"In the control group, data collection forms will be applied at admission and discharge to the service. There will be no application other than the routine care of the hospital. The routine care of the hospital applied to the control group within the scope of the research includes the information that should be given before, during and after the procedure that should be done depending on the medical intervention. In addition, there is no support program planned in the hospital and at discharge, and there is no follow-up after discharge.~Interview at hospital Measuring tools will be applied Perinatal Grief Scale, Depression, Anxiety and Stress Scale, Coping and Adaptation Process Scale, Discharge time, labor pain.~and 3. Interview at home Measuring tools will be applied Perinatal Grief Scale, Depression, Anxiety and Stress Scale, Coping and Adaptation Process Scale"
89377894|NCT02355262||Arm I (Independent Tool Implementation)|Participants receive CATCH-UP tools which include a panel management/data aggregator system that identifies patients who may be eligible for public coverage but are not yet insured, or who are nearing coverage expiration, coupled with automated patient outreach and communication at baseline.
89377895|NCT02355262||Arm II (Tool Implementation with Interactive Facilitation)|Participants receive CATCH-UP tools which include a panel management/data aggregator system that identifies patients who may be eligible for public coverage but are not yet insured, or who are nearing coverage expiration, coupled with automated patient outreach and communication. Participants also receive additional implementation support such as trainings, assistance with workflows, and practice facilitation.
89377896|NCT02355496|Experimental|Displaying medicare fee data|The active arm is the intervention group of randomly selected inpatient laboratory tests (about 15 most frequently ordered and about 15 most expensive) that will have medicare fee data displayed in the computerized provider order entry system.
89377897|NCT02355496|No Intervention|Control Arm|The control arm is the group of randomly selected inpatient laboratory tests (about 15 most frequently ordered and about 15 most expensive) that will not have medicare fee data displayed.
89377898|NCT03477630|Experimental|Platelet Rich Plasma|Four intra-articular infiltration of autologous PRP every 15 days.
89377899|NCT03477630|Active Comparator|Hyaluronic Acid|One intra-articular infiltration of SYNVISC-ONE
89377900|NCT01379040||Cystic Fibrosis Patients|Patients with Cystic Fibrosis, some having Pseudomonas aeruginosa, some not.
89377901|NCT01379040||Control|Healthy volunteers
89377902|NCT02981342|Experimental|Abemaciclib|Abemaciclib given orally.
89377903|NCT02981342|Experimental|Abemaciclib + LY3023414|Abemaciclib given orally and LY3023414 given orally.
89377904|NCT02981342|Experimental|Standard of Care (Gemcitabine or Capecitabine)|Gemcitabine given intravenously (IV) OR capecitabine given orally.
89377905|NCT02794246|Experimental|Single Arm|
89377906|NCT02355106|Experimental|Treatment|Atrial flutter Ablation
89377907|NCT02360722|Experimental|Oral Nutritional Supplement|ONS + Nutritional education
89377908|NCT02360722|Other|Control Group|Nutritional education only
89377909|NCT02360644|Experimental|Arm 1: Drug Metabolism and Transport|"The aim of Arm 1 is to determine the effect of vitamin D deficiency and repletion on xenobiotic clearance in vivo. The study will evaluate the in vivo function of targeted metabolism and transport pathways in 40 CKD and 18 healthy volunteer subjects (controls) under the influence of a vitamin D depleted state and repeated under a vitamin D replete state with cholecalciferol.~The function of two major phase I drug metabolizing enzymes (CYP2B6, CYP3A), and three transporters [P-gp, MRP2, and MATE1/2K] will be assessed by administering oral bupropion, midazolam, olmesartan, and fexofenadine."
89377910|NCT02360644|Experimental|Arm 2: Vitamin D Pharmacokinetics|The aim of Arm 2 is to determine the effect of CKD on the in vivo function of individual CYP450s responsible for vitamin D metabolism and their functional relevance on the pharmacokinetics of cholecalciferol. A total of 90 CKD subjects will be enrolled [30 per group: group I (CKD stage 1/2), group II (CKD stage 3), and group III (CKD stage 4/5, pre-ESRD)], as well as 30 healthy controls.
89377911|NCT02354716||EndoFLIP Measurements|To define the role of a functional luminal imaging probe (EndoFLIP) in benign upper GI luminal narrowing. EndoFlip measurement of the cross sectional area of the narrowing will be obtained prior to and after endoscopic dilation. Patients will follow up for repeat endoscopy and dilation if indicated. EndoFLIP measurements will be made again before and after dilation. The use of EndoFlip may offer insight in to the clinical and endoscopic predictors of successful stricture dilation.
89377912|NCT02366026|Experimental|IR103 REMUNE + AMPLIVAX 1.0|IR103 Vaccine contain the same active component as REMUNE® (Inactivated HIV-1 Antigen Drug Substance at 10 μg/mL p24 dose), and have one dose of Amplivax™ (HYB2055) Adjuvant (1.0 mg) added before emulsification in Incomplete Freund's Adjuvant (the same adjuvant and in the same ratio that is used in REMUNE).
89182337|NCT02598674||Sepsis with Severe AKI|"This group will have a history of pediatric admission with sepsis-related Acute Kidney Injury (sAKI) which lead to classification of injury or failure. The following test will be performed: urinary and serum studies to measure glomerular filtration rate by using gadolinium, renal plasma flow by using an injection of non-radioactive iodohippurate, followed by cardiovascular assessments using 24 hour ambulatory blood pressure monitoring, peripheral arterial tonometry and pulse wave velocities (PWV)."
89377913|NCT02366026|Placebo Comparator|AMPLIVAX 1.0 + IFA|AMPLIVAX 1.0 mg Amplivax™ (HYB2055) Adjuvant (1.0 mg) + IFA Incomplete Freund's Adjuvant (the same adjuvant and in the same ratio that is used in REMUNE).
89377914|NCT02354794|Experimental|Healthy subjects with 'hypertriglyceridemic waist'|"Subjects with overweight, elevated waist circumference and elevated fasting triglyceridemia.~Intervention: see below"
89377915|NCT03159910|Experimental|Shoulder-Café (intervention)|A Shoulder-Café intervention consists of three café-meetings.
89377916|NCT03159910|Active Comparator|Shoulder-Guidance (control)|The Shoulder-Guidance intervention consists of an initial individual appointment and two e-mail contacts.
89182338|NCT02598674||Control|This group will not have a history of pediatric admission with sepsis-related Acute Kidney Injury (sAKI). The following test will be performed: urinary and serum studies to measure glomerular filtration rate by using gadolinium, followed by cardiovascular assessments using 24 hour ambulatory blood pressure monitoring, peripheral arterial tonometry and pulse wave velocities (PWV).
89377917|NCT03159442|Experimental|Cohort 1|"Multiple inhaled doses of AZD8871 will be administered via single dose DPI. Each subject will receive 300 μg AZD8871 or placebo. This dose will be given as 1 inhalation from the 300 μg AZD8871 or placebo inhaler.~Single inhaled dose of AZD8871 or placebo will be administered on Day 1 and then single once daily inhalations of AZD8871 or placebo will be administered for 12 days from Day 5 until Day 16."
89377918|NCT03159442|Experimental|Cohort 2|"Multiple inhaled doses of AZD8871 will be administered via single dose DPI. Each subject will receive 600 μg AZD8871 as 1 inhalation from the 600 μg AZD8871 or placebo inhaler.~Single inhaled dose of AZD8871 or placebo will be administered on Day 1 and then single once daily inhalations of AZD8871 or placebo will be administered for 12 days from Day 5 until Day 16.~Dose escalation to 600 μg dose will be done only after the SRC has determined the adequacy of the dose to be given."
89377919|NCT03159442|Experimental|Cohort 3|"Multiple inhaled doses of AZD8871 will be administered via single dose DPI. Each subject will receive 900 μg AZD8871 as 1 inhalation from the 300 μg AZD8871 inhaler and 1 inhalation from the 600 μg AZD8871 inhaler, or placebo as 2 inhalations from 2 different placebo inhalers.~Single inhaled dose of AZD8871 or placebo on Day 1 and then single once daily inhalations of AZD8871 or placebo will be administered for 12 days from Day 5 until Day 16.~Dose escalation to the 900 μg dose will be done only after the SRC has determined the adequacy of the dose to be given."
89377920|NCT02360332|Experimental|PS-ASD|Treatment Condition, participants assigned to this condition will receive the treatment, one school year (9 months) of Project SEARCH plus ASD Supports
89377921|NCT02360332|No Intervention|High School As Usual|Control Condition, Participants assigned to this condition will have no interaction or intervention with the research team with the exception of data collection at the specified time points.
89377922|NCT03160300|Experimental|Binaural Beats|Music with Binaural Beats: Binaural beat signals embedded in relaxing music, in a crossover design
89377923|NCT03160300|Sham Comparator|Placebo|Music: Relaxing music without the binaural beat component, in a crossover design
88850913|NCT02119260|Experimental|Cohort 4|Eighteen stable HF subjects will be randomized in this cohort with a treatment:placebo ratio of 1:1. If required, an additional number of subjects (up to 24 total) will be randomized. An additional separate dose group of approximately 18 to 24 subjects may be randomized to GSK2798745 or placebo to gain additional safety, tolerability,pharmacokinetic and pharmacodynamic information, if needed. The subjects will receive GSK2798745 in a single dose (at least the first 6 subjects) followed by a 7 -days repeat dose. Based on data from the cohorts 1, 2 and 3, the dose will be 2.4 mg (initial) in the first group utilizing the capsule formulation administered with or without food.
89377924|NCT02360566|Experimental|Participatory Video Intervention Group|The Participatory Video intervention consists of 12 semi-structured, 2 hour group workshops over the course of a 6-month time period. Through facilitated discussion, participants will learn how to effectively work collaboratively as a member of the video production team. Together, they will choose what story of their shared experience with psychosis they would like to tell through documentary-video and how they plan to share it. Participants will be trained to operate all equipment required to bring their vision to life. Individuals will also have the opportunity, during the Participatory Video process, to create and share their own video clips, independent of the group, allowing participants to share their own video-narrative with others (friends, family members, public) as a means of engaging in dialogue around their personal experience with psychosis.
89377925|NCT03428100|Experimental|4 mg Baricitinib|4 mg Baricitinib administered orally once daily in combination with topical corticosteroids. Placebo administered orally to maintain the blind.
89377926|NCT03428100|Experimental|2 mg Baricitinib|2 mg Baricitinib administered orally once daily in combination with topical corticosteroids. Placebo administered orally to maintain the blind.
89377927|NCT03428100|Experimental|1 mg Baricitinib|1 mg Baricitinib administered orally once daily in combination with topical corticosteroids. Placebo administered orally to maintain the blind.
89377928|NCT03428100|Placebo Comparator|Placebo|Placebo administered orally once daily in combination with topical corticosteroids.
89377929|NCT02365948|Experimental|Certolizumab Pegol 100 mg|"Subjects will receive100 mg of CZP given by subcutaneous injections in healthy Chinese subjects. The dose group begins treatment on Day 1.~To achieve an injectable CZP 100 mg dose, a manual process will be applied by the unblinded site pharmacist."
89377930|NCT02365948|Experimental|Certolizumab Pegol 200 mg|Subjects will receive 200 mg of CZP given by subcutaneous injections in healthy Chinese subjects. The dose group begins treatment staggered by a minimum of 14 days from CZP 100 mg. Dose escalation will be suspended according to the predefined criteria and process.
89377931|NCT02365948|Experimental|Certolizumab Pegol 400 mg|Subjects will receive 400 mg of CZP (two injections of CZP 200 mg) given by subcutaneous injections in healthy Chinese subjects. The dose group begins treatment staggered by a minimum of 14 days from CZP 200 mg. Dose escalation will be suspended according to the predefined criteria and process.
89182339|NCT04020536||kala-azar group|
89182340|NCT04020536||epidemic hemorrhagic fever group|
89182341|NCT04020536||brucellosis group|
89182342|NCT00917228||Feedback|Subjects of this group are equipped with the biofeedback system
89182343|NCT00917228||Control|Subjects of this group are not equipped with the biofeedback system
89377932|NCT02365948|Placebo Comparator|Placebo|For assessment of the Adverse Event (AE) profile, there are 2 placebo controls in each dose group. The placebo subjects receive the injection of saline (NaCl 0.9 %) at the same time (and of the same volume) as the CZP subjects.
89377933|NCT02360410|Experimental|Check Yourself App With Feedback|Adolescents complete Check Yourself, an electronic health screening app and receive personalized, motivational feedback on their health behaviors prior to their primary care appointment. Key components of Check Yourself include the provision of age normative feedback, goal setting strategies, and strategies to highlight discrepancies. Primary care providers receive a summary report of health risk behaviors from Check Yourself prior to their adolescent patient's primary care appointment.
89377934|NCT02360410|No Intervention|Usual Care|Participants are asked to complete health risk screening on a tablet computer. No personalized feedback is provided to adolescents and primary care providers do not receive a summary report of the adolescent's health risk behaviors.
89377935|NCT02360176|Experimental|Sleeve gastrectomy single port|Sleeve gastrectomy single port
89377936|NCT02360176|Active Comparator|Sleeve gastrectomy multi trocar|Sleeve gastrectomy multi trocar
89377937|NCT02354950|Experimental|Part 1 Cohort 1 (Moderate hepatic impairment subjects)|Subjects with moderate hepatic impairment will receive GSK1265744 30mg as a single oral dose in the fasted state followed by pharmacokinetic sampling for total concentrations of GSK1265744 in plasma
89377938|NCT02354950|Experimental|Part 1 Cohort 2 (Healthy control subjects)|Healthy control subjects will receive GSK1265744 30mg as a single oral dose in the fasted state followed by pharmacokinetic sampling for total concentrations of GSK1265744 in plasma
89377939|NCT02354950|Experimental|Part 2 Cohort 3 (Mild hepatic impairment subjects)|Subjects with mild hepatic impairment will receive GSK1265744 30mg as a single oral dose in the fasted state followed by pharmacokinetic sampling for total concentrations of GSK1265744 in plasma
89377940|NCT02354950|Experimental|Part 2 Cohort 4 (Healthy control subjects)|Healthy control subjects will receive GSK1265744 30mg as a single oral dose in the fasted state followed by pharmacokinetic sampling for total concentrations of GSK1265744 in plasma
89377941|NCT02980874|Experimental|Active|IVT aflibercept (2 mg/0.05 mL) + CLS-TA (4 mg/100 µL) SC injections
89377942|NCT02980874|Active Comparator|Control|IVT aflibercept (2 mg/0.05 mL) + sham SC procedure
89377943|NCT02354872|Experimental|Mini-Lozenge, BR, 5Rs, BA|1; This arm of the project will address the following question: How effective is the following intervention? Mini-Lozenge, BR, 5Rs, BA
89377944|NCT02354872|Experimental|Mini-Lozenge, BR, 5Rs, No BA|2; This arm of the project will address the following question: How effective is the following intervention? Mini-Lozenge, BR, 5Rs, No BA
89377945|NCT02354872|Experimental|Mini-Lozenge, BR, No 5Rs, BA|3; This arm of the project will address the following question: How effective is the following intervention? Mini-Lozenge, BR, No 5Rs, BA
89377946|NCT02354872|Experimental|Mini-Lozenge, BR, No 5Rs, No BA|4; This arm of the project will address the following question: How effective is the following intervention? Mini-Lozenge, BR, No 5Rs, No BA
89182344|NCT02598518|Experimental|Integrating Combined Therapies|Integrating Combined Therapies (ICT) is a 10-session, manual-guided individual therapy. ICT has three phases designed to address substance use, psychiatric problems and their interactions. MET is the first phase (2 sessions) and is focused on assessment, feedback and securing motivation to address problems and take steps. CBT is the second phase (5 sessions) and incorporates patient education and functional analysis, develops coping skills, teaches methods to challenge beliefs, and activates alternative behaviors. TSF (3 sessions) is focused on maintaining recovery and engaging in community-based recovery activities. Although ICT has core components, its application is flexible to accommodate the unique needs and problems of individual patients (and their comorbidities).
89377947|NCT02354872|Experimental|Mini-Lozenge, No BR, 5Rs, BA|5; This arm of the project will address the following question: How effective is the following intervention? Mini-Lozenge, No BR, 5Rs, BA
89377948|NCT02354872|Experimental|Mini-Lozenge, No BR, 5Rs, No BA|6; This arm of the project will address the following question: How effective is the following intervention? Mini-Lozenge, No BR, 5Rs, No BA
89377949|NCT02354872|Experimental|Mini-Lozenge, No BR, No 5Rs, BA|7; This arm of the project will address the following question: How effective is the following intervention? Mini-Lozenge, No BR, No 5Rs, BA
89377950|NCT02354872|Experimental|Mini-Lozenge, No BR, No 5Rs, No BA|8; This arm of the project will address the following question: How effective is the following intervention? Mini-Lozenge, No BR, No 5Rs, No BA
89377951|NCT02354872|Experimental|No Mini-Lozenge, BR, 5Rs, BA|9; This arm of the project will address the following question: How effective is the following intervention? No Mini-Lozenge, BR, 5Rs, BA
89377952|NCT02354872|Experimental|No Mini-Lozenge, BR, 5Rs, No BA|10; This arm of the project will address the following question: How effective is the following intervention? No Mini-Lozenge, BR, 5Rs, No BA
89377953|NCT02354872|Experimental|No Mini-Lozenge, BR, No 5Rs, BA|11; This arm of the project will address the following question: How effective is the following intervention? No Mini-Lozenge, BR, No 5Rs, BA
89377954|NCT02354872|Experimental|No Mini-Lozenge, BR, No 5Rs, No BA|12; This arm of the project will address the following question: How effective is the following intervention? No Mini-Lozenge, BR, No 5Rs, No BA
89377955|NCT02354872|Experimental|No Mini-Lozenge, No BR, 5Rs, BA|13; This arm of the project will address the following question: How effective is the following intervention? No Mini-Lozenge, No BR, 5Rs, BA
89377956|NCT02354872|Experimental|No Mini-Lozenge, No BR, 5Rs, No BA|14; This arm of the project will address the following question: How effective is the following intervention? No Mini-Lozenge, No BR, 5Rs, No BA
89377957|NCT02354872|Experimental|No Mini-Lozenge, No BR, No 5Rs, BA|15; This arm of the project will address the following question: How effective is the following intervention? No Mini-Lozenge, No BR, No 5Rs, BA
89377958|NCT02354872|Experimental|No Mini-Lozenge, No BR, No 5Rs, No BA|16; This arm of the project will address the following question: How effective is the following intervention? No Mini-Lozenge, No BR, No 5Rs, No BA
89377959|NCT02354638|Experimental|Tobacco users: behavioural counseling|The cab drivers using tobacco will be invited to participate in the tobacco cessation programme at the TCC and will receive three monthly follow-up for one year. Thus intervention will be in the form of behavioural therapy and pharmacotherapy (if required)
89377960|NCT02354638|No Intervention|Non Users|The cab drivers who are not using tobacco in any form will not receive any type of intervention
89377961|NCT02354404|Experimental|Group 1a: cAd3-EBOZ at 1x10(10) PU|Part 1: cAd3-EBOZ at 1x10(10) PU intramuscularly at Day 0; Part 2: Option to receive MVA-EbolaZ at 1x10(8) PFU intramuscularly after Study Week 36 as a boost to the Part 1 study vaccination
89377962|NCT02354404|Experimental|Group 1b: cAd3-EBOZ at 1x10(11) PU|Part 1: cAd3-EBOZ at 1x10(11) PU intramuscularly at Day 0; Part 2: Option to receive MVA-EbolaZ at 1x10(8) PFU intramuscularly after Study Week 36 as a boost to the Part 1 study vaccination
89377963|NCT02354404|Experimental|Group 1c: cAd3-EBO at 2x10(10) PU|Part 1: cAd3-EBO at 2x10(10) PU intramuscularly at Day 0; Part 2: Option to receive MVA-EbolaZ at 1x10(8) PFU intramuscularly after Study Week 36 as a boost to the Part 1 study vaccination
88850914|NCT02119260|Experimental|Cohort 5|Eight HF subjects will be randomized in this cohort with a treatment: placebo ratio of 3:1. This cohort will evaluate safety, pharmacokinetics, and lung permeability (DLco and DLno) in a boarder, more general population of patients with HF, NYHA Class II or III. Subjects will receive GSK2798745 or placebo (based on randomization) for 7 days. The dose will be 2.4 mg utilizing the capsule formulation administered with or without food. Subjects will remain in house from Day -1 until Day 4 and be fitted with a remote monitoring device; Day 5, 6 and 8 visits will be in home (on Days 5 and 6, they will receive study medication, collect samples for pharmacokinetic analysis, and assess vital signs); and subjects will return to the clinic for Day 7 visit.
88850915|NCT02119104||Prevenar (13v)|
88850916|NCT02119026|Active Comparator|A: XELIRI + BEV Followed by XELOX + BEV|"capecitabine and irinotecan (XELIRI) plus bevacizumab (AVASTIN; BEV)~Capecitabine : 800mg/m2 bid d1-14, bevacizumab 7,5 mg/kg given on day 1 q3w combined with irinotecan 200mg/m2 iv. d 1 q3w . Bevacizumab (7.5 mg/kg q3w) ± Capecitabine (1000 mg/m2 bid, days 1-14 q3w) maintenance~At disease progression irinotecan will be replaced by oxaliplatin (arm A). Bevacizumab will be continued."
88850917|NCT02119026|Active Comparator|B: XELOX + BEV followed by XELIRI + BEV|"capecitabine and oxaliplatin (XELOX) plus bevacizumab (Avastin; BEV)~Arm B:~Capecitabine: 1000mg/m2 bid d1-14, bevacizumab 7,5 mg/kg given on d1 q3w combined with oxaliplatin 130mg/m2 iv. d 1 q3w Bevacizumab (7.5 mg/kg q3w) ± Capecitabine (1000 mg/m2 bid, days 1-14 q3w) maintenance~At disease progression oxaliplatin will be replaced by irinotecan (arm B). Bevacizumab will be continued."
89377964|NCT02354404|Experimental|Group 1d: cAd3-EBO at 2x10(11) PU|Part 1: cAd3-EBO at 2x10(11) PU intramuscularly at Day 0; Part 2: Option to receive MVA-EbolaZ at 1x10(8) PFU intramuscularly after Study Week 36 as a boost to the Part 1 study vaccination
89377965|NCT02354404|Experimental|Group 2a:cAd3-EBO at 2x10(10) PU|Part 1: cAd3-EBO at 2x10(10) PU intramuscularly at Day 0 (as a boost to prior receipt of the Ebola DNA WT vaccine); Part 2: Option to receive MVA-EbolaZ at 1x10(8) PFU intramuscularly after Study Week 36 as a boost to the Part 1 study vaccination
89377966|NCT02354404|Experimental|Group 2b: cAd3-EBO at 2x10(11) PU|Part 1: cAd3-EBO at 2x10(11) PU intramuscularly at Day 0 (as a boost to prior receipt of the Ebola DNA WT vaccine); Part 2: Option to receive MVA-EbolaZ at 1x10(8) PFU intramuscularly after Study Week 36 as a boost to the Part 1 study vaccination
89377967|NCT01066052|Experimental|r-hGH|Participants (girls) will receive r-hGH as a subcutaneous injection administered by a parent in the evening. During Years 1-2, the dose of r-hGH received will depend on participants' baseline height standard deviation score (SDS) relative to the general population standard: participants with a height SDS of -2 standard deviation (SD) or lower will receive 0.05 milligrams per kilogram (mg/kg) per day r-hGH and those with a height SDS between -1 and -2 SD will receive 0.035 mg/kg per day r-hGH. After 2 years of treatment, all participants will receive a fixed dose of 0.05 mg/kg per day for a further 2 years.
89377968|NCT01066052|No Intervention|Historical Control|This arm will include matching (age and height) historical control participants (girls) with turner syndrome, who were born between 1961 and 1990 and were untreated.
89377969|NCT02360254||Patients shifting to insulin degludec|Patients shifting from twice daily glargine or detemir to once daily degludec. This change in therapy will have to be decided by the diabetologist and the patient, not done for the purpose of the study.
89377970|NCT02360254||Patients remaining on twice daily glargine/detemir|Patients continuing on twice daily glargine or detemir
89399416|NCT03690531||Passive Distraction Group_IPAD|The Passive Distraction group will utilize the standard or passive distraction technique of using an IPAD lasting 5 minutes.
89399417|NCT02256020|Other|Original lifestyle|Original lifestyle, watching TV 50 minutes, three times a week for 6 months.
89399418|NCT02256020|Experimental|Wheel-chair music aerobic exercise|Wheel-chair music aerobic exercise with 3 times of 50-minute session (10 minutes warm up, 30 minutes exercise and 10 minutes cool down) a week for 6 months.
88850918|NCT02095158|Experimental|Oxymetazoline HCL Cream 1.0%|Oxymetazoline HCL Cream 1.0% (AGN-199201) applied to the face once daily for 52 weeks.
88850919|NCT02094612|Active Comparator|Usual Care|Usual clinic ADHD care
88850920|NCT02094612|Experimental|Usual Care plus Assessment|Usual clinic ADHD care plus the Quotient®
88850921|NCT02139306|Experimental|Ataluren (PTC124®)|Participants received ataluren as oral powder for suspension at the dosages of 10, 10, and 20-mg/kg at morning, midday and evening, respectively for 48 weeks of treatment duration or until treatment discontinuation.
88850922|NCT02139306|Placebo Comparator|Placebo|Participants received matching placebo orally at morning, midday and evening for 48 weeks of treatment duration or until treatment discontinuation.
88850923|NCT02094300|Experimental|Endovascular|
89377971|NCT02360020|Experimental|XLimus patients|participants must have symptomatic ischemic heart disease attributable to critical (that is, >70% visual estimate) stenotic lesions of native coronary arteries. Inclusion criteria are 1) chronic total occlusion (CTO), 2) severe calcification, and 3) severe tortuosity. CTO is defined as the presence of TIMI 0 flow within the occluded segment and angiographic or clinical evidence of an occlusion duration of ≥3 months. Calcification is defined severe when larger than 3x vessel diameter, and comprising the vessel wall totally in two perpendicular views. Tortuosity is defined severe when: one or more bends >= 90°, or three or more bends of 45-90° proximal to the diseased segment.
88850924|NCT02118792|Experimental|AN2728 Topical Ointment, 2%|AN2728 Topical Ointment, 2%, applied twice daily for up to 28 days
88850925|NCT02118792|Placebo Comparator|Matching vehicle control|Matching vehicle control, applied twice daily for up to 28 days
89377972|NCT03112642|Active Comparator|Standard Group|In the Standard Group, in the absence of paresthesia and after negative aspiration, the 40 ml of local anesthetic block [0.35% marcaine] will be administered into the brachial plexus of the upper limb being operated on, at the supraclavicular level.
89377973|NCT03112642|Experimental|Test Group|"In this group, the ultrasound guided local anesthetic block into the brachial plexus at the supraclavicular level of the upper limb being operated on will be supplemented by use of a blockade monitor (Nerve stimulator device) to direct final placement of the needle for the nerve block.~Only this group of the patients will receive this intervention with sufficient detail so that it can be distinguished from the Test Group"
89377974|NCT01377324|Experimental|Single arm|Fluoroestradiol-PET is performed at baseline, after 1 month, and 3 months
89377975|NCT02352766||Routine FNA for thyroid nodules|Patients that undergo a clinically diagnostic thyroid FNA will be asked by their clinician, who is a study co-investigator, if they are interested in participating in the research study. A small part of FNA material will be collected for molecular analysis.
89377976|NCT01569516|Experimental|low dose|1mg, tid
88850926|NCT02118714|Experimental|Atrasentan|Atrasentan 0.75 mg administered orally once daily (QD) for 26 weeks
89377977|NCT01569516|Experimental|Moderate dose|2mg,tid
89377978|NCT01569516|Experimental|High dose|4mg,tid
89377979|NCT01569516|Placebo Comparator|Placebo|0 mg, tid
89377980|NCT02359786||Genetic Testing Subjects undergoing genetic testing|
89377981|NCT02359786||Topicals Subjects using topical compounds|
89377982|NCT02359786||Patients undergoing Spinal Surgery using IOM|
89377983|NCT02359786||Spine Patients undergoing cervical or lumbar surgery|
89377984|NCT02359786||Total Joint Patients undergoing knee and hip replacement|
89377985|NCT02359786||UDT (unrinary drug test) Patients who are given a UDT|
89377986|NCT02359942|Experimental|Citric acid group|Giving the citric acid (4g) as test meal before UBT
88850927|NCT02138916|Experimental|Benralizumab Arm A|Benralizumab administered subcutaneously
88850928|NCT02138916|Experimental|Benralizumab Arm B|Benralizumab administered subcutaneously
88850929|NCT02138916|Placebo Comparator|Placebo|Placebo administered subcutaneously
89377987|NCT02359942|No Intervention|Controlled group|No use of test meal
89377988|NCT02359708|Experimental|OR nurse group|OR nurses (14) who agreed to participate were asked to perform a surgical hand disinfection accordingly to clinic routine. When hands were dry cultures were first obtained at 3 sites, using a moist with saline nylon flocked swab (Copan ESwab, Italia SpA). After hand disinfection; 1) in right hand palm, 2) between index finger and middle finger, 3) nail/cuticle of index finger. When surgery were completed and before disposal of gloves and gown the fourth culture were taken where the glove cuff meets the gown sleeve, under and above, the inner glove of all OR nurses.When gloves were removed cultures were taken again at three sites on the hand, approximately 2-3 hours.
89377989|NCT02359708|Experimental|Non-hospital group|Non-hospital volunteers who agreed to participate were asked to perform a surgical hand disinfection accordingly to clinic routine. When hands were dry cultures were first obtained at 3 sites, using a moist with saline nylon flocked swab (Copan ESwab, Italia SpA). After hand disinfection; 1) in right hand palm, 2) between index finger and middle finger, 3) nail/cuticle of index finger. This group whore gowns and gloves for approximately 2-3 hours but not kept sterile. The Culture at the glove cuff were left out. When gloves were removed cultures were taken again at three sites on the hand.
89377990|NCT05461248|Experimental|Experimental group|The stoma drainage fluid was reinfused once a week for 2 months after radical rectal surgery. For each reinfusion, eat liquid food the day before, collect 400-600mL of stoma discharge on the same day (if the stoma fluid is too small, it can be mixed with warm water), and use an enema bag to reinfuse from the patient's anus. Generally, the flow rate is controlled at about 100mL/min.
89377991|NCT05461248|Sham Comparator|Conventional group|The conventional group received no additional intervention.
89377992|NCT02359630|Active Comparator|EasyTube|Use of EasyTube during general anesthesia
89377993|NCT02359630|Experimental|Endotracheal tube|Use of endotrachel tube during general anesthesia
89377994|NCT02354560|Experimental|Erythromycin|Oral treatment with Erythromycin 250-500mg (will be determined according to body weight) twice a day.
89377995|NCT01378884|Experimental|Domeperidone|Patients to receive Domperidone for treatment of Gastroparesis
89377996|NCT05457504|Experimental|Experimental|
88850930|NCT02118012|Active Comparator|Chlorcyclizine and RBV|Chlorcyclizine HCl and Ribavirin
88850931|NCT02118012|Active Comparator|Chlorcyclizine HCl only|Chlorcyclizine HCl only
88850932|NCT02093520|Active Comparator|MILD|The MILD procedure is an image-guided minimally-invasive lumbar decompression
88850933|NCT02093520|Active Comparator|Epidural Steroid Injection (ESI)|An epidural steroid injection (ESI) is a combination of a corticosteroid with a local anesthetic pain relief medicine.
88850934|NCT02138838|Active Comparator|Standard of Care|Standard of care therapy included the use of vitamin D sterols, calcium supplementation, and phosphate binders.
88850935|NCT02138838|Experimental|Cinacalcet|In addition to standard of care participants received cinacalcet at a starting dose (based on dry body weight) of 0.20 mg/kg administered once a day by mouth. Dose adjustments and withholding were based on ionized calcium levels, plasma iPTH, and corrected calcium levels.
88850936|NCT02138214|Experimental|Arm I (no CND)|Patients undergo total thyroidectomy alone.
88850937|NCT02138214|Experimental|Arm II (CND)|Patients undergo total thyroidectomy with ipsilateral prophylactic CND.
88850938|NCT02138214|Active Comparator|Arm III (SOC)|Patients who are not eligible for randomization into Arm I or Arm II, Standard of Care (SOC) group. No specific trial intervention, treated as per patient and physician preference
88850939|NCT02092662||Stroke|Stroke patients at the subacute phase
88850940|NCT02092662||Healthy controls|healthy age-matched voluntiers
88850941|NCT02092350|Experimental|Immediate Treatment|Participants receive grazoprevir 100 mg tablet, orally, once per day (QD) + elbasvir 50 mg tablet, orally, QD, for 12 weeks.
89182345|NCT02598518|Active Comparator|Standard Care|Standard Care (SC) is the typical outpatient treatment that the patient would receive ordinarily at the identified addiction treatment program. SC service operates using the American Society of Addiction Medicine criteria (9 hours per week); group and individual sessions focused on motivation to address substance use, education about the consequences of substance use on major life areas, education about the disease concept and brain changes associated with addiction, exposure to information about social and family relationships and recovery, and relapse prevention skills.
89182346|NCT03981224||plasma EBV DNA detectable|the NPC patient received curative treatment and post-treatment plasma EBV DNA was detectable.
89377997|NCT05457504|Placebo Comparator|Usual Care|
89377998|NCT02354326||Diagnostic (VNC DECT)|Patients undergo CT scans. Additional images will be processed with virtual non-calcium (VNC) dual energy CT (DECT) information. Comparison will be made between images with and without addition of VNC.
89182347|NCT03981224||plasma EBV DNA undetectable|the NPC patient received curative treatment and post-treatment plasma EBV DNA was undetectable.
89182348|NCT00916760|Experimental|1|A Subcutaneous Depigmented and Polymerized Allergen extract of Parietaria Judaica 1000 DPP/ml. Depigoid Parietaria judaica 1000 DPP/ml.
89182349|NCT00916760|Placebo Comparator|2|
89182350|NCT02600078|Active Comparator|Moderate Hypoxia|Subjects will be exposed to moderate hypoxia and measures of balance, heart rate, pulse oxygen saturation, questionnaires, and coordination tasks will be examined at set time intervals during the hypoxic exposure.
89182351|NCT02600078|Sham Comparator|Sham|Subjects will be exposed to sham and measures of balance, heart rate, pulse oxygen saturation, questionnaires, and coordination tasks will be examined at set time intervals during the hypoxic exposure.
89182352|NCT02600078|Active Comparator|Mild Hypoxia|Subjects will be exposed to mild hypoxia and measures of balance, heart rate, pulse oxygen saturation, questionnaires, and coordination tasks will be examined at set time intervals during the hypoxic exposure.
89182353|NCT00723450|Placebo Comparator|placebo|Placebo Controlled
89182354|NCT00723450|Experimental|lamictal|Flexible Dosing
89182355|NCT02599610|Active Comparator|Digital vaginal examination|Patients assigned to this group will be followed-up with digital vaginal examinations as described in intervention protocol.
89182356|NCT02599610|Experimental|Transperineal ultrasound examination|Patients assigned to this group will be followed-up with transperineal ultrasound examinations as described in intervention protocol.
89182357|NCT02599532|Other|Nephrotic syndrome|Subjects with nephrotic syndrome will receive a single dose of apixaban 10 mg and will subsequently have blood drawn at 0, 0.5, 1, 3, 4, 6, 8, 24 hours after drug administration.
89182358|NCT02599532|Other|Non-nephrotic syndrome|Subjects without nephrotic syndrome will receive a single dose of apixaban 10 mg and will subsequently have blood drawn at 0, 0.5, 1, 3, 4, 6, 8, 24 hours after drug administration.
89182359|NCT02598752||functional performance testing|This observational study will evaluate the feasibility and safety of functional performance testing in patients undergoing HCT. In addition to standard of care procedures, participants will undergo a CPET with a rest and stress echo, pulmonary function, and patient reported outcome questionnaires within 30 days of HCT.
89182360|NCT02591550||patients with normal cough sensitivity|
89182361|NCT02591550||patients with high cough sensitivity|
89182362|NCT02591550||healty controls|
89182363|NCT00751400|Experimental|Naproxen Sodium ER (BAYH6689)|subjects take one tablet Naproxen Sodium ER (extended release) every 24 hours while symptoms last for no more than 10 consecutive days for pain and no more than 3 consecutive days for fever
89182364|NCT04086342|Active Comparator|CHI-902|Study subjects will enter a titration phase of 1 week with a daily oral CBD dose of 150 mg (50 mg three times daily). Then, daily CBD dose of 300 mg or matching placebo will be given for 3 weeks (treatment phase 1; fixed dose).
89182365|NCT04086342|Placebo Comparator|Placebo|Study subjects will enter a titration phase of 1 week with a daily oral dose of 150 mg (50 mg three times daily) of matching placebo. Then, daily dose of 300 mg of matching placebo will be given for 3 weeks (treatment phase 1; fixed dose).
89182366|NCT05341362|No Intervention|Blank Group|In this group, the anesthesia management is conducted according to the anesthetists' experience, based on the regular monitor.
89182367|NCT05341362|Experimental|LiDCOrapid Group|In this group, the anesthesia management is conducted based on both the regular monitor and the hemodynamic figures on the LiDCOrapid.
89377999|NCT02039050|Active Comparator|Tiotropium|Participants receive tiotropium for 2 to 3 weeks.Participants then enter a washout period and after the washout period receive the alternative treatment arm.
89399419|NCT03690297|Experimental|LCI|Linked Color Imaging
89399420|NCT03690297|Active Comparator|WL|White Light
88850942|NCT02092350|Experimental|Deferred Treatment|Participants receive placebos to both grazoprevir and elbasvir for 12 weeks, and after a 4-week break, grazoprevir 100 mg tablet, orally, QD + elbasvir 50 mg tablet, orally, QD for 12 weeks.
88850943|NCT02092350|Experimental|Intensive PK|Participants receive grazoprevir 100 mg tablet, orally, QD + elbasvir 50 mg tablet, orally, QD for 12 weeks with intensive PK testing.
88850944|NCT02117544|Other|New MF, then AOAMF|Lotrafilcon B multifocal contact lenses (new), followed by lotrafilcon B multifocal contact lenses. Each product worn bilaterally (in both eyes) for about 1 hour.
88850945|NCT02117544|Other|AOAMF, then New MF|Lotrafilcon B multifocal contact lenses, followed by lotrafilcon B multifocal contact lenses (new). Each product worn bilaterally (in both eyes) for about 1 hour.
89182368|NCT04093778|Experimental|SDA intervention|Low dose high frequency training of all health workers in maternity and pediatric ward and dissemination of a Safe Delivery Application
89182369|NCT00585312|Experimental|Celecoxib|celecoxib, 16 mg/kg/day, for 5 years
89182370|NCT00585312|Placebo Comparator|Placebo|Masked, placebo comparator
89182371|NCT00753506|Active Comparator|Artemisinin|100 mg artemisinin capsule
89182372|NCT00753506|Placebo Comparator|Placebo|Identical looking placebo capsule
89182373|NCT05406440|Experimental|MK-8189 Panel A|Participants will receive MK-8189 starting at 48 mg on Day 1 and 60 mg on Day 2.
89182374|NCT05406440|Experimental|MK-8189 Panel A-1|Participants will receive MK-8189 48 mg on Day 1 and 80 mg on Day 2.
89182375|NCT05406440|Experimental|MK-8189 Panel C|Participants will receive MK-8189 48 mg on Days 1-2 and 80 mg on Day 3 based on safety and tolerability.
89182376|NCT05406440|Placebo Comparator|Placebo|Participants will receive MK-8189-matching placebo.
89182377|NCT00720096|Experimental|Liposomal Doxorubicin|Liposomal Doxorubicin - Chemotherapy single agent systemic.
89182378|NCT00720096|Experimental|Topotecan|Topotecan - Chemotherapy single agent systemic.
89182379|NCT02577471||During pregnancy|Pregnant ladies filled bowel function questionnaires
89182380|NCT02577471||After delivery|ladies within three weeks of delivery filled bowel function questionnaires
89182381|NCT02577471||Controls|Non pregnant ladies filled bowel function questionnaires
89182382|NCT04086108|Experimental|Tomato|Single oral administration
89182383|NCT04086108|Experimental|GABA supplement|Single oral administration
89182384|NCT04086108|Experimental|Glutamate supplement|Single oral administration
89182385|NCT04086108|No Intervention|Placebo|Single oral administration, same volume of water that is distributed in the other arms
89182386|NCT02577783|Experimental|PDD arm|patients involved in PDD arm will accept chemotherapy of PDD regimen (doxorubicin hydrochloride liposome plus bortizomib and dexamethasone )
89182387|NCT02577783|Active Comparator|PAD arm|patients involved in PAD arm will accept chemotherapy of PAD regimen (doxorubicinplus bortizomib and dexamethasone )
89182388|NCT04089410|Active Comparator|Hyperthermic Fitness Treatment|Participants will fill out study questionnaires. After basic body measurements subjects will undergo the HFT.
89182389|NCT04089410|Placebo Comparator|Attenuated heating|Participants will fill out study questionnaires. After basic body measurements subjects will undergo the placebo-HFT.
89182390|NCT04092608|Active Comparator|Low CVP group (restrictive group)|"Standard practice: the goal is to keep the CVP < 7 mmHg during surgery.~Baseline of crystalloid of 2ml/kg/h max in all patients.~EV 1000 monitoring device (Edwards Lifesciences, Irvine, USA) will be used but values will be blinded to the anesthesiologist in charge of the patient.~Mean Arterial pressure (MAP) should be kept over 65mmHg during surgery (standard practice) with continuous norepinephrine infusion~Additionnal fluid administration is given to the patient at the end of the surgery (standard practice)~UPi is blinded in all groups"
89182391|NCT04092608|Experimental|GDFT group|"The goal is to keep stroke volume variation below 13% during surgery with mini fluid challenge of 100 ml of balanced crystalloid using the monitoring device (Edwards Lifesciences, Irvine, USA). Of course, the values will not be blinded to the anesthesiologist in charge of the patient.~All patients have a baseline crystalloid: 2ml/kg/h and mini fluid challenges per 100 ml as described above.~Mean Arterial pressure (MAP) should be kept over 65mmHg during surgery (standard practice) with continuous norepinephrine infusion~UPi is blinded in all groups"
89182392|NCT00723294|Experimental|Treatment (cryoablation)|A cryoprobe is inserted percutaneously under ultrasound guidance into the targeted lesion. Patients undergo ablation using a freeze-thaw-freeze cycle lasting approximately 6-10-6 or 8-10-8 minutes, respectively. Patients undergo surgical resection and sentinel lymph node biopsy and/or axillary dissection within 28 days after completion of cryoablation. Patients complete the Brief Pain Inventory before and after cryoablation and after surgery.
89182393|NCT04072029||Cataract - FECD|Eyes with FECD undergoing cataract surgery
89182394|NCT04092140||diabetic complaining of neuropathy or not|using of ultrasound in examination and nerve conduction study
89182395|NCT04092140||carpal tunnel syndrome|using of ultrasound in examination and nerve conduction study
89182396|NCT02576379||HEMS patients|Patients suspected of suffering from a vascular condition within the geographical area covered by both HEMS and GEMS, and were transported by Helicopter Emergency Medical System (HEMS) to the regional stroke unit at Copenhagen University Hospital Roskilde in a 36-month period from May 1st 2010 until April 30th 2013.
89182397|NCT02576379||GEMS patients|Patients suspected of suffering from a vascular condition within the geographical area covered by both HEMS and GEMS, and were transported by Ground Emergency Medical System (GEMS) to the regional stroke unit at Copenhagen University Hospital Roskilde in a 40-month period from January 1st 2010 until April 30th 2013.
89182398|NCT04092296|Experimental|resin infiltration|resin infiltrant (Icon product, DMG, Hamburg,Germany)
89182399|NCT04092296|Active Comparator|remineralization|
89182400|NCT02577705|Experimental|Self Empowerment Groups|Intervention activities included helping participants to open savings accounts at a local federal credit union with 1:1 matches of up to twenty dollars per month for 12 months. Participants also received financial empowerment and Peer Support curriculum, weekly for about 3 hours per week for 28 weeks.
89182401|NCT02577705|Experimental|Financial Empowerment|Intervention activities included helping participants to open savings accounts at a local federal credit union with 1:1 matches of up to twenty dollars per month for 12 months. Participants also received financial empowerment weekly for about 3 hours per week for 28 weeks.
89182402|NCT02577705|No Intervention|Control Group|The Control group did not receive assistance in opening a matched savings account, and were required by the County Assistance Office to participate in other Temporary Assistance for Needy Families (TANF) mandated work participation activities according to standard procedure.
88850946|NCT02138136|Experimental|Lubiprostone|"Participants receive lubiprostone twice daily~Participants must have completed the entire 12-week treatment period during the preceding study. Those who received 12 mcg twice daily (BID) continued to receive 12 mcg, those who received 24 mcg BID continued with that dose.Those of the placebo arm in the previous study weighing less than 50 kg received 12 mcg BID and over 50 kg received 24 mcg BID during this study."
88850947|NCT04726020|Experimental|Intensive monitoring|Intensive phone monitoring of drug adverse events
88850948|NCT04726020|Placebo Comparator|Standard monitoring|Standard monitoring of drug adverse events
88850949|NCT01626690|Experimental|Pre-Warming|
88850950|NCT01626690|Active Comparator|Control|
88850951|NCT01626456|Experimental|ALKS 9072, Low|
88850952|NCT01626456|Experimental|ALKS 9072, High|
88850953|NCT02116608|Active Comparator|Group 1: Betadine|Apply locally as needed.
88850954|NCT02116608|Active Comparator|Group 2: Silver Nitrate|Arzol Silver Nitrate Applicators may be applied directly to mucous membranes and other moist surfaces. In the case of dry skin, the applicator tip should be dipped in water immediately before use. Apply carefully to the area to be treated.
88850955|NCT02116608|Active Comparator|Group 3: Hydrocortisone Butyrate Cream, 1.0%|Hydrocortisone butyrate cream, 1.0% should be applied to the affected area as a thin film two or three times daily depending on the severity of the condition.
88850956|NCT04742088|Experimental|Orthosis group|
89182403|NCT00918450|Experimental|1|
89182404|NCT04092374|Experimental|Case arm|
89182405|NCT02591628|Active Comparator|Intervention|"Intervention is HCTZ prescription conversion to chlorthalidone. Intervention patients are defined as patients of physicians randomized to intervention. All these patients will have their current prescription of hydrochlorothiazide (HCTZ) switched to an equipotent dose of Chlorthalidone. These patients can choose to decline this intervention, and will be followed for 9 months with no other intervention to observe primary and secondary outcomes."
89182406|NCT02591628|No Intervention|Usual Care|"Usual care patients are defined as patients of physicians randomized to usual care. All these patients will keep their current prescription for HCTZ and work with their physician like normal. These patients will be followed for 9 months with no intervention to compare primary and secondary outcomes to the intervention group."
89399421|NCT04132401|Experimental|family medicine physicians|Retina reading
88850957|NCT02092116|Other|Part A|"Pre-treatment phase of 2-4 weeks (Visit 1- Visit 2a) followed by viral reactivation phase of 3 weeks (Visit 2 to Visit 7) consisting of one cycle of romidepsin infusions at a dosing of 5 mg/m2 on days 0, 7, and 14.~Post-activation phase of ~9 weeks (Visit 8 to Visit 11) to assess the effect of romidepsin on the size of latent HIV-1 reservoir."
88850958|NCT02092116|Other|Part B|"Pre-treatment phase of 2-4 weeks (Visit 1-Visit 2) followed by a therapeutic HIV-1 immunization phase of 12 weeks (Visit 2 to Visit 7) in which 1.2 mg Vacc-4x was administered together with 0.06 mg rhuGM-CSF at Visits 2, 3, 4, 5, 6 and 7 follow by a follow-up period of 2 weeks (Visit 8).~A viral reactivation phase of 3 weeks (Visit 9-Visit 11) consisting of one cycle of 3 romidepsin infusions (5 mg/m2) followed by a post-treatment observation phase of ~9 weeks (Visit 12-Visit 13) to assess the effect of the investigational treatment on the size of the latent HIV-1 reservoir.~A monitored antiretroviral pause of up to 16 weeks (Visit 14-Visit 33)."
88850959|NCT02091726|Experimental|Unicirc with tissue adhesive|Circumcision with Unicirc instrument, followed by wound sealing with cyanoacrylate
88850960|NCT02091414|Experimental|MMF, CsA, Corticosteroids|Participants received mycophenolate mofetil (MMF) 1.0 grams (g), orally (PO), twice daily (BID) from within 24 hours of transplantation through Week 24. Participants also received an initial loading dose of cyclosporine A (CsA) 4 to 6 milligrams per kilogram (mg/kg) within 48 hours of transplantation, adjusted thereafter to a blood trough concentration of 150 to 300 nanograms per milliliter (ng/mL) through Week 24. Participants also received corticosteroids as per the practice of each participating center.
88850961|NCT04731558|Experimental|Preoperative thromboprophylaxis|Preoperatively initiated tromboprophylaxis
89378000|NCT02039050|Experimental|Aclidinium|Participants receive tiotropium for 2 to 3 weeks.Participants then enter a washout period and after the washout period receive the alternative treatment arm.
88850962|NCT04731558|Other|Postoperative thromboprophylaxis|Postoperatively initiated thromboprophylaxis
88850963|NCT02116530|Experimental|Olanzapine + Chemotherapy + Antiemetic treatment|"Patients will receive the chemotherapy drugs cisplatin or cyclophosphamide and doxorubicin as well as the following anti-nausea/vomiting drugs:~Ondansetron (8 mg orally or intravenously) or granisetron (1 mg intravenously or 2 mg orally) or palonosetron (0.25 mg intravenously) on the day of chemotherapy, plus~Dexamethasone (12 mg orally on the day of chemotherapy and 8 mg orally days 2, 3, 4 post chemotherapy), plus~Fosaprepitant (150 mg intravenously on the day of chemotherapy) or aprepitant (125 mg orally on the day of chemotherapy and 80 mg orally on days 2 and 3 post chemotherapy), plus~olanzapine (10 mg orally on the day of chemotherapy and 10 mg orally on days 2, 3, 4 post chemotherapy)"
88850964|NCT02116530|Active Comparator|Placebo + Chemotherapy + Antiemetic treatment|"Patients will receive the chemotherapy drugs cisplatin or cyclophosphamide and doxorubicin as well as usual anti-nausea/vomiting drugs:~Ondansetron (8 mg orally or intravenously) or granisetron (1 mg intravenously or 2 mg orally) or palonosetron (0.25 mg intravenously) on the day of chemotherapy, plus~Dexamethasone (12 mg orally on the day of chemotherapy and 8 mg orally days 2, 3, 4 post chemotherapy), plus~Fosaprepitant (150 mg intravenously on the day of chemotherapy) or aprepitant (125 mg orally on the day of chemotherapy and 80 mg orally on days 2 and 3 post chemotherapy), plus~placebo"
88850965|NCT02072226|Active Comparator|Alteplase Placebo + Aspirin|Participants will receive single dose of IV alteplase placebo and aspirin orally.
88850966|NCT02072226|Experimental|Alteplase + Aspirin Placebo|Participants will receive single dose of IV alteplase and aspirin placebo orally.
88850967|NCT04730856|Active Comparator|Tinzaparin 4500 UI/day|Procedure: Tinzaparin 4500 UI/day SC until hospital discharge.
88850968|NCT04730856|Active Comparator|Tinzaparin 100 UI/Kg/day|Procedure: Tinzaparin 100 UI/Kg/day SC until hospital discharge.
88850969|NCT04730856|Active Comparator|Tinzaparin 175 UI/Kg/day|Procedure: Tinzaparin 175 UI/Kg/day SC until hospital discharge.
88850970|NCT02090634|Experimental|Personalized Reminder Texting + Psychoeducation (iTAB)|Participants in the individualized Texting for Adherence Building (iTAB) arm will receive daily text messaging reminders for antiretroviral and psychotropic medication adherence. These text messages will be targeted to the specific schedule and needs of the individual. Participants will also receive a text message that assesses mood. Finally, participants will receive a one-time psychoeducational intervention reviewing the importance of adherence to anti-HIV and psychotropic medications.
88850971|NCT02090634|Active Comparator|Psychoeducation (CTRL)|Participants will receive a one-time psychoeducational intervention reviewing the importance of adherence to anti-HIV and psychotropic medications. They will also receive daily text messages to assess mood, but these messages will not receive the medication reminder text messages.
88850972|NCT02114892|Experimental|Resveratrol|Resveratrol capsules, 500 mg, three times per day before meals during 90 days
88850973|NCT02114892|Placebo Comparator|Placebo|Calcined magnesia capsules, 500 mg, three times per day before meals during 90 days
88850974|NCT02070978|Experimental|Atacicept 75 mg|
88850975|NCT02070978|Experimental|Atacicept 150 mg|
89399422|NCT04132401|Experimental|retina specialists|Retina reading (gold standard)
89378001|NCT05764200|Active Comparator|lean normoglycaemic individuals fiber mixture|Two day supplementation of 12 g (3 x 4 g) of the dietary fiber inulin in combination with 9.375 g (3 x 3.125 g (80% resistant starch (3 x 2.5 g)) granular potato starch
89378002|NCT05764200|Placebo Comparator|lean normoglycaemic placebo|Two day supplementation of 11.43 g (3 x 3.81 g) maltodextrin
89378003|NCT05764200|Active Comparator|overweight and/or obesity and prediabetes/insulin fiber mixture|Two day supplementation of 12 g (3 x 4 g) of the dietary fiber inulin in combination with 9.375 g (3 x 3.125 g (80% resistant starch (3 x 2.5 g)) granular potato starch
89378004|NCT05764200|Placebo Comparator|overweight and/or obesity and prediabetes/insulin resistance placebo|Two day supplementation of 11.43 g (3 x 3.81 g) maltodextrin
89378005|NCT02354248|Experimental|Stroke patients|The patients will be submitted to a triple stimulation examination.
89378006|NCT02354248|Active Comparator|Control Subjects|This group of patients did not suffer from a stroke. They will also be submitted to a triple stimulation examination.
89378007|NCT02354170|Experimental|Cohort 1 (m300)|One (1) 300-mg mifepristone tablet, taken once daily for 4 weeks
89378008|NCT02354170|Experimental|Cohort 2 (m900)|Three (3) 300-mg mifepristone tablets (900-mg dose), taken once daily for 4 weeks
89378009|NCT02354170|Placebo Comparator|Cohort 3 (Placebo)|Placebo taken once daily for 4 weeks
89378010|NCT05348382|Experimental|Intradermal acupuncture group|Points around the herpes zoster sites (about 1 cm peripherally) are selected for intradermal acupuncture (IDA) encircled needling. Meanwhile, intradermal acupuncture is also performed in Ashi acupoints in the distribution area of herpes zoster.
89378011|NCT05348382|Sham Comparator|Sham intradermal acupuncture group|Sham intradermal acupuncture will be implemented in the same acupoints as the intradermal acupuncture group using pseudo-intradermal needling.
89378012|NCT03112876||Young Age - Healthy|These subjects are between the age of 12 and 35 years. This group will undergo the following intervention: skin surface lipid collection via tapes and skin barrier function evaluated with non-invasive painless devices.
89378013|NCT03112876||Old Age -Healthy|These subjects are 55 years of age and older. This group will undergo the following intervention: skin surface lipid collection via tapes and skin barrier function evaluated with non-invasive painless devices.
89378014|NCT03112876||Active Smoker|These subjects are active smokers who smoke often. This group will undergo the following intervention: skin surface lipid collection via tapes and skin barrier function evaluated with non-invasive painless devices.
89378015|NCT03112876||Dermatological skin condition: Acne vulgaris|These subjects have acne vulgaris. This group will undergo the following intervention: skin surface lipid collection via tapes and skin barrier function evaluated with non-invasive painless devices.
89378016|NCT03112876||Dermatological skin condition: Atopic dermatitis|These subjects have atopic dermatitis. This group will undergo the following intervention: skin surface lipid collection via tapes and skin barrier function evaluated with non-invasive painless devices.
89378017|NCT03077646|Experimental|Be SMART alone|Parents/guardians in this study group will watch a 5.5 minute Be SMART video and receive the handouts reviewing the information.
89378018|NCT03077646|Experimental|Be SMART + MD review|Parents/guardians in this study group will watch a 5.5 minute Be SMART video and receive the handouts reviewing the information and will also have an MD review the information (via a checklist to standardize the MD review).
89378019|NCT03077646|Active Comparator|Control: TSE materials|"Parents/guardians in this study group will watch a video Kids and Smoke Don't Mix and receive handouts reviewing information on tobacco smoke exposure (TSE)."
88850976|NCT02070978|Experimental|Placebo/Atacicept 150 mg|
89378020|NCT02359240||sepsis|Patients with a diagnosis of sepsis or severe sepsis,immobilization for 3 days at least. Therapy according to the SSC guidelines will be applied. therapy according to SSC guidelines and muscle biopsy
88850977|NCT04725630|Experimental|Subsidized Healthy Food Prescription Incentive|Participants will receive a one-time healthy food prescription pamphlet from their healthcare provider and a weekly incentive of $10.50/household member to purchase healthy foods in supermarkets for 12 months. The list of incentive-eligible foods includes whole, minimally processed foods with little to no added fat, sugar or salt from all food groups.
89182407|NCT04090112|Experimental|the study group (Group A)|Patients received four puffs of 10% lidocaine sprayed at the cuff of ETT and four puffs at laryngeal inlet
89378021|NCT02359240||Patients with femoral fractures|non septic patients with a femoral fracture,who need an fixation surgery.standard surgery for femoral fracture and muscle biopsy will be performed.
89378022|NCT02352610|Active Comparator|LRTI without a Biotenodesis Screw|Ligament Reconstruction Tendon Interposition without a Biotenodesis Screw
89378023|NCT02352610|Active Comparator|LRTI with Biotenodesis Screw|Ligament Reconstruction Tendon Interposition with Biotenodesis Screw
89378024|NCT02927964|Experimental|Treatment (radiation therapy, TLR9 agonist SD-101, ibrutinib)|Patients undergo radiation therapy on days 1 and 2. Within 12 hours of the completion of radiation therapy, patients receive TLR9 agonist SD-101 IT on day 2 and on days 9, 16, 23, 30 and 37. Patients also receive ibrutinib PO daily beginning on day 9 for 96 weeks or in the absence of disease progression or unexpected toxicity.
89399423|NCT02173886|Experimental|Bupropion|Bupropion SR and XL, single dosages of each separated by a wash-out period
89378025|NCT03147586|Active Comparator|Bio-tech and omega-3 plus|Bio-tech (Biopharm pharmaceutical) powder 30 mg t.d.s. (contains multivitamins and essential amino acids) plus omega-3 plus (SEDICO pharmaceutical) capsules t.d.s (source for omega-3 fatty acids) 1 week before and 2 week after surgery
89378026|NCT03147586|Placebo Comparator|placebo|placebo powder 30 mg t.d.s plus placebo capsules t.d.s for 1 week before and 2 week after surgery
89378027|NCT01377246|Placebo Comparator|Saline solution.|
89378028|NCT01377246|Experimental|Octrotide-LAR|
89378029|NCT02353936|Experimental|afatinib group|
89378030|NCT02353858|Experimental|RtChx + Hyperthermia|Radiotherapy: 5 x 1,8 Gy/Week, cumulative dose 50,4 Gy (ICRU) Chemotherapy: 5-fluorouracil d1-5 and d29-d33 Deep regional hyperthermia: 2x/week
89378031|NCT02578758|Experimental|Transdiagnostic Internet-Based Protocol|Intervention group that carries out the Transdiagnostic Internet-Based Protocol and receives support by the therapist (a brief weekly two-minute phone call without clinical content and two weekly orientative text messages).
89378032|NCT02578758|Experimental|Transdiagnostic Internet-Based Protocol+Positive Affect|Intervention group that carries out the Transdiagnostic Internet-Based Protocol+Positive Affect component and receives support by the therapist (a brief weekly two-minute phone call without clinical content and two weekly orientative text messages).
89378033|NCT02578758|Other|Waiting List Control Group|Participants in a 18-week waiting list control condition. They will be offered the possibility of receiving the online treatment protocol after the waiting list period.
88850978|NCT04725630|Active Comparator|Healthy Food Prescription Comparison|Participants will receive a one-time healthy food prescription pamphlet from their healthcare provider. The pamphlet closely mimics current standard of care for patients with diabetes in Alberta (i.e., nutrition counselling).
88850979|NCT02114268|Experimental|MEDI8897 300 milligram (mg) Intravenous (IV)|Participants received a single fixed dose of 300 mg MEDI8897 intravenous infusion on Day 1.
88850980|NCT02114268|Experimental|MEDI8897 1000 mg IV|Participants received a single fixed dose of 1000 mg MEDI8897 intravenous infusion on Day 1.
88850981|NCT02114268|Experimental|MEDI8897 3000 mg IV|Participants received a single fixed dose of 3000 mg MEDI8897 intravenous infusion on Day 1.
89378034|NCT02353702|Experimental|Infusion of Ropivacaine during 48 hours|"Evaluation of diaphragmatic function with Sniff test after 48h continuous parietal infiltration of Ropivacaine using parietal catheter at the following dose :~20 ml Bolus (7,5 mg/ml) then continuous administration of 10 ml per hour (2 mg/ml)"
89378035|NCT02353702|Placebo Comparator|Infusion of placebo during 48 hours|"Evaluation of diaphragmatic function with Sniff test after 48h continuous parietal infiltration of placebo using parietal catheter at the following dose :~20 ml Bolus (NaCl 0.9 %) then continuous administration of 10 ml per hour (NaCl 0.9 %)"
89378036|NCT02532660|Experimental|Escitalopram + LABCAT TCJUSS|Escitalopram 10mg + LABCAT TCJUSS 1000 mg daily (two 250mg capsules in the morning + 2 capsules of 250 mg at night);
89378037|NCT02532660|Placebo Comparator|Escitalopram + LABCAT TCJUSS placebo|Escitalopram 10mg + LABCAT TCJUSS placebo daily (2 capsules in the morning + 2 capsules at night);
88850982|NCT02114268|Experimental|MEDI8897 100 mg Intramuscular (IM)|Participants received a single fixed dose of 100 mg MEDI8897 intramuscular injection on Day 1.
88850983|NCT02114268|Experimental|MEDI8897 300 mg IM|Participants received a single fixed dose of 300 mg MEDI8897 intramuscular injection on Day 1.
88850984|NCT02114268|Placebo Comparator|Placebo|Participants received placebo on Day 1.
88850985|NCT02089230|Experimental|Phase I Cohort 1 - MEK 162|Phase I Starting Dose of MEK 162: 30 mg by mouth twice a day in a 28 day cycle.
88850986|NCT02089230|Experimental|Phase I Cohort 2 - MEK 162|Phase I Starting Dose of MEK 162: 45 mg by mouth twice a day in a 28 day cycle.
88850987|NCT02089230|Experimental|Phase II Cohort 3 - MDK 162|Phase II Starting Dose of MEK 162: 45 mg by mouth twice a day in a 28 day cycle.
88850988|NCT02070744|Experimental|PC Phase: VX-661 50 mg q12h + IVA 150 mg q12h|Participants received VX-661 50 milligram (mg) tablet plus Ivacaftor (IVA) 150 mg tablet every 12 hours (q12h) for 12 weeks.
88850989|NCT02070744|Placebo Comparator|PC Phase: VX 661 placebo q12h + IVA placebo q12h|Participants received placebo matched to VX-661 tablet plus placebo matched to IVA tablet q12h for 12 weeks.
88850990|NCT02070744|Experimental|PC Phase: VX-661 100 mg qd + IVA 150 mg q12h|Participants received two VX-661 50 mg tablets once daily (qd) plus IVA 150 mg tablet q12h for 12 weeks.
88850991|NCT02070744|Placebo Comparator|PC Phase: VX -661 placebo qd + IVA placebo q12h|Participants received two placebo matched to VX-661 tablets qd plus placebo matched to IVA tablet q12h for 12 weeks.
88850992|NCT02070744|Experimental|OLE Phase: VX-661 100 mg qd + IVA 150 mg q12h|Participants who completed 12 week PC phase underwent a washout period of at least 4 weeks before entering the OLE phase and received two VX-661 50 mg tablets qd plus IVA 150 mg tablet q12h for 48 weeks in OLE phase.
89182408|NCT04090112|Active Comparator|Comparator group (Group B)|Patients received 15 mg/kg of 2% lidocaine intravenous injection prior to extubation
89378038|NCT02532660|Experimental|Escitalopram Placebo + LABCAT TCJUSS|Escitalopram Placebo + LABCAT TCJUSS 1000 mg daily (2 capsules in the morning + 2 capsules at night).
89378039|NCT01377168|Placebo Comparator|Placebo pill|Daily oral placebo.
89378040|NCT01377168|Active Comparator|NTX|Daily oral naltrexone.
89378041|NCT02892149|Experimental|Vadadustat|
89378042|NCT02892149|Active Comparator|Darbepoetin alfa|
89378043|NCT02352532|Experimental|Low Back Pain - Dry Needling|
89378044|NCT02352532|Sham Comparator|Low Back Pain - Sham|
89378045|NCT02352532|Active Comparator|Asymmptomatic - Dry Needling|
89378046|NCT02348476||Simbrinza™|Patients treated with Simbrinza™ (brinzolamide 1%/brimonidine 0.2%) as standard of care in clinical practice. No study drug is administered in this study.
89182409|NCT02590770|Active Comparator|gaze-contingent|attention modification: participants will receive gaze-contingent feedback according to their viewing patterns
89182410|NCT02590770|Placebo Comparator|non-gaze contingent|Placebo: participants will receive non-gaze-contingent feedback according to their viewing patterns
89182411|NCT04091906|Experimental|Healthy donor|
89182412|NCT04071717|Experimental|NIRS group|Participants with obesity, 12 sessions of NIRS feedback
89182413|NCT04071717|Sham Comparator|Sham NIRS group|Participants with obesity, 12 sessions of sham NIRS feedback
89182414|NCT04071717|Other|Healthy control group|Healthy participants, 12 sessions of NIRS feedback
89182415|NCT00747344|Placebo Comparator|Placebo - Controlled Period (CP)|
89182416|NCT00747344|Experimental|Ustekinumab 45 mg - CP|
89182417|NCT00747344|Experimental|Placebo to ustekinumab 45 mg - after CP|
89182418|NCT00747344|Experimental|Ustekinumab 45 mg - after CP|
89182419|NCT00580983|Experimental|Chemo-IMRT|"Chemotherapy:~Chemotherapy will consist of Paclitaxel 30mg/m² IV over 1 hour, followed by Carboplatin (AUC 1) IV over 30 minutes, or Carboplatin 100mg/m² per IV over 30 minutes or Cisplatin 100mg/m² per IV over 1 hour, or Cisplatin (80mg/m²) or Carboplatin (AUC 5) IV on day 1 and 5-Fluorouracil (1000mg/m²) as a 24-hour continuous infusion, daily x 4 days.~Intensity-modulated Radiation Therapy (IMRT):~Primary RT: 70 Gy to gross disease and 56-63 Gy to subclinical disease in 35 fractions.~Post-operative RT: 64 Gy to high-risk targets (postoperative tumor bed, first-echelon nodes) and 57.6 Gy to low-risk targets, in 32 fractions."
89182420|NCT04089878|Experimental|PARTO/BRTO + SMT|PARTO/BRTO with SMT will be given.
89182421|NCT04089878|Active Comparator|Standard Medical Treatment|Antibiotics, nutrition and supportive treatment
89182422|NCT00917618|Active Comparator|Exercise intervention|Patients began the exercise intervention after randomization for 12 weeks
89182423|NCT00917618|Placebo Comparator|Control|Patients were asked not to change their baseline exercise program
89182424|NCT02309931|Active Comparator|Isoperistaltic anastomosis|Patients with right colon cancer who undergo a right laparoscopic hemicolectomy and a isoperistaltic side-to-side ileocecal anastomosis
89182425|NCT02309931|Active Comparator|Antiperistaltic anastomosis|Patients with right colon cancer who undergo a right laparoscopic hemicolectomy and a antiperistaltic side-to-side ileocecal anastomosis
89182426|NCT02597270||Cohort 1|Brazilian participants with Genotype 1 HCV infection treatment naive participants or previously failed to double therapy (Peg-interferon-α and Ribavirin) will be included in the trial and will constitute the trial population.
89182427|NCT04071873|Experimental|Point-of-care HIV testing (intervention)|Participants will be offered voluntary point-of-care HIV testing during a traditional healer visit.
89182428|NCT04071873|Active Comparator|Education on community HIV resources (control)|Participants will be offered education regarding HIV testing and community resources during a traditional healer visit.
89182429|NCT02577627||Training Set|The Training Set will be used to calibrate the Predicare models and algorithms and assess its predictive potential in a retrospective manner. Patients data will be collected according to the oncological indications (NSCLC, SCLC, Prostate cancer, Breast cancer and Colon cancer) and the applied treatment protocols, and their data will be integrated and processed by the PrediCare algorithm.
89182430|NCT02577627||Validation Set|The Validation Set will be used to validate the prediction power of the device in a prospective manner. The files of patients assigned to Validation Set of the study will be used for the blind prediction of TTP under each specific treatment, based on the baseline individual information. This will be done by inputting into PrediCare the information of each individual patient, available prior to treatment onset (baseline; clinical data, imaging data, histology/cytology, oncomarkers, genetic screening, hematology, biochemistry) for creating a personalized mathematical models and predicting TTP of this specific patient. These predictions will be then compared to the clinically observed TTP for all the patients.
89182431|NCT02599376|Active Comparator|BMI less than 30|The drop in cardiac output after spinal anaesthesia for LSCS at various intervals with LiDCORapid
89182432|NCT02599376|Experimental|BMI more than 40|The drop in cardiac output after spinal anaesthesia for LSCS at various intervals with LiDCORapid
89182433|NCT02577393|Experimental|prophylactic EGCG group|
89182434|NCT02577393|Experimental|therapeutic EGCG group|
89182435|NCT02577393|Placebo Comparator|conventional therapy group|
89182436|NCT02599298|Active Comparator|SGMT arm|Treatment of OSA requires a multidisciplinary approach, involving a sleep physician and paramedical staff with expertise in the management of sleep disorders. An initial medical assessment is needed to confirm the diagnosis of OSA, determine its severity and decide whether CPAP therapy is appropriate. As part of this evaluation, an objective overnight sleep study will be performed. This will be followed by an assessment, education, and counseling at the multidisciplinary therapy clinic.
89378047|NCT05046912|Experimental|Clinical|Clinical participants with a primary diagnosis of psychosis or related disorder.
88850993|NCT02113956|Experimental|Guy2Guy (G2G)|G2G is a 6-week HIV prevention program delivered daily via text messaging to 14-18 year old males who self-identify as gay, bisexual, and/or queer. In addition to program content, participants are paired with another participant (i.e., a Text Buddy) with whom they can text throughout the program to provide support; and an on-demand advice line, G2Genie, which shares information about condoms, sex, relationships, and the lesbian, gay, bisexual, transgender (LGBT) community.
88850994|NCT02113956|No Intervention|Healthy Lifestyle Control|The attention-matched control arm message content consists of information publicly available online related to living a healthy lifestyle. Content discussed includes: STD information, nutrition and sleep hygiene, self-esteem and body image, bullying, and drugs and alcohol. The control arm is 6-weeks in length (Week 6 is a review booster) and is delivered via text messaging. Messages are didactic and not tailored to user sexual experience. Additionally, the Text Buddy and G2Genie intervention program components are not available.
88850995|NCT02070588|Active Comparator|Experimental: Diagnostic mTBI|MRI Diagnostic of subjects with mild Tramatic Brain Injury (mTBI)
88850996|NCT02070588|Placebo Comparator|Experimental: Diagnostic Non mTBI|MRI Diagnostic of Non injured subjects that are closely matched to mTBI
88850997|NCT04741698|Active Comparator|Propranolol 2mg IV|"At the time of labor dystocia, patients randomized to the treatment arm of propranolol will receive a one-time administration of IV 2mg propranolol in pre-mixed syringes prepared by the pharmacy.~The propranolol IV administration recommended in clinical practice guidelines is 1 mg IV over 1 minute. Therefore, total administration time will be 2 minutes."
88850998|NCT04741698|No Intervention|No intervention|At the time of labor dystocia, patients randomized to the placebo arm will not receive any intervention
88850999|NCT02111850|Experimental|1/Phase I Experimental Therapy|Non-myeloablative lymphodepleting preparative regimen of cyclophosphamide and fludarabine + Anti-Melanoma antigen family A, 3 (MAGE-A3)-DP4 T cell receptor (TCR) peripheral blood lymphocytes (PBL) + high-dose aldesleukin
88851000|NCT02111850|Experimental|2/Phase II Experimental Therapy|Non-myeloablative lymphodepleting preparative regimen of cyclophosphamide and fludarabine + Anti-Melanoma antigen family A, 3 (MAGE-A3)-DP4 T cell receptor (TCR) peripheral blood lymphocytes (PBL) + high-dose aldesleukin
88851001|NCT02087904|Experimental|ABT-981 low dose|25 mg ABT-981 subcutaneous (SC) every 2 weeks (E2W)
88851002|NCT02087904|Experimental|ABT-981 medium dose|100 mg ABT-981 SC E2W
88851003|NCT02087904|Experimental|ABT-981 high dose|200 mg ABT-981 SC E2W
88817459|NCT04343001|Experimental|Aspirin, Losartan and Simvastatin|Aspirin 150mg once daily, Losartan 100mg once daily and Simvastatin 80mg once daily. Losartan dose may be stopped or reduced if patient is hypotensive and can be restarted anytime during the treatment period.
88817460|NCT01739231|Experimental|ACE527 alone|In Part A of the study, subjects were split into two cohorts whereby enrollment of the second cohort depended on the safety profile of the first cohort. In Part A, subjects received three oral doses of ACE527 at 0, 1, and 2 months. For Part B of the study, eligible subjects who expressed interest of the study were administered H10407 challenge strain 5-7 months after the three-dose vaccination series.
88851004|NCT02087904|Placebo Comparator|Placebo|Placebo
88851005|NCT02087670|Active Comparator|controlled, supervised exercise protocol|controlled, supervised exercise protocol within a cardiac rehabilitation program
88851006|NCT02087670|Placebo Comparator|community based exercise|educational program and not supervises exercise program
88851007|NCT04729530|Active Comparator|Active|Air purifier device with standard filter cartridges installed.
88851008|NCT04729530|Placebo Comparator|Placebo|Air purifier device with placebo (non working) filter cartridges installed.
88851009|NCT02086968|Active Comparator|Injectafer|2 doses of Injectafer, at 15 mg/kg for a maximum single dose of 750 mg given on Days 0 and 7 for a total of up to 1500 mg
88851010|NCT02086968|Active Comparator|Ferrous Sulfate tablets|Oral Ferrous Sulfate at 325 mg (1 tablet) three times a day for 28 days
88851011|NCT04729218||Familial Mediterranean Fever group|30 participants
88851012|NCT04729218||Healthy group|30 participants
88851013|NCT02086110|Active Comparator|Prebiotic only first, then synbiotic|This group will receive prebiotic only (bovine milk oligosaccharides, administered orally twice per day for a daily total of 0.3 g per pound of body weight) for the first five weeks, followed by a two week break with no treatment, and then will receive the synbiotic (Bifidobacterium infantis (10 billion CFU) twice a day plus 0.3 g per pound body weight of bovine milk oligosaccharides in two divided doses per day orally) for the next five weeks.
88851014|NCT02086110|Active Comparator|Synbiotic first, then prebiotic only|This group will receive the synbiotic (Bifidobacterium infantis (10 billion CFU) twice a day plus 0.3 g per pound body weight of bovine milk oligosaccharides in two divided doses per day orally) for the first five weeks, followed by a two week break with no treatment, and then will receive the prebiotic only (bovine milk oligosacharrides, administered orally twice per day for a daily total of 0.3 g per pound of body weight) for the next five weeks.
88851015|NCT02085252|Experimental|Leuprorelin 11.25 mg|Active surveillance after a single subcutaneous injection of leuprorelin 11.25 mg and bicalutamide 50 mg, tablet, orally, once daily, to prevent flare-up for 15 days.
88851016|NCT02085252|No Intervention|Active surveillance|Active surveillance is close medical monitoring of prostate cancer for any changes.
88817461|NCT01739231|Experimental|ACE527 plus dmLT|In Part A of the study, subjects were split into two cohorts whereby enrollment of the second cohort depended on the safety profile of the first cohort. In Part A, subjects received three oral doses of ACE527 with mucosal adjuvant (dmLT) at 0, 1, and 2 months. For Part B of the study, eligible subjects who expressed interest of the study were administered H10407 challenge strain 5-7 months after the three-dose vaccination series.
88851017|NCT04417686|Experimental|patient|
88851018|NCT02084238|Experimental|Interleukin-2|Interleukin-2 to treat activated SLE.
88851019|NCT02084082|Experimental|FDC first, fasted|Linagliptin/Metformin ER FDC followed by single tablets of linagliptin and metformin ER, fasted condition
88851020|NCT02084082|Experimental|Single tablets first, fasted|single tablets of linagliptin and metformin ER followed by Linagliptin/Metformin ER FDC, fasted condition
88851021|NCT02084082|Experimental|FDC first, fed|Linagliptin/Metformin ER FDC followed by single tablets of linagliptin and metformin ER, fed condition
88851022|NCT02084082|Experimental|Single tablets first, fed|single tablets of linagliptin and metformin ER followed by Linagliptin/Metformin ER FDC, fed condition
88817146|NCT02431806|Experimental|Levomilnacipran 80 mg|Participants received over-encapsulated levomilnacipran ER two 40 mg/day capsules (80 mg/day) orally starting at a dose of 10 mg/day on Day 1-2, 20 mg/day on Day 3-4, 40 mg/day on Day 5-7 and 80 mg/day on Week 2 through Week 8 during the Double-blind Treatment Period, followed by a 1-week Double-blind Taper-down Period if applicable as determined by the investigator. Participants received 1 dose matched placebo capsule the first week and during the taper-down period to maintain the blind.
88817147|NCT02431806|Active Comparator|Fluoxetine 20 mg|Participants received over-encapsulated fluoxetine 20 mg/day tablets orally starting at a dose of 10 mg/day in Week 1 and 20 mg/day in Week 2 through Week 8 during the Double-blind Treatment Period, followed by a 1-week Double-blind Taper-down Period if applicable as determined by the investigator. Participants received 1 dose matched placebo capsule each day to maintain the blind.
88817148|NCT05247801|Experimental|Experimental Group (Psychoeducational Intervention)|Two hundred and sixteen caregivers of multi-pathological and polypharmacy patients will receive psychoeducational intervention based on virtual reality and a dosing device for safer medication use at home. The intervention will be developed in a previous project phase using a mixed methodology (observational study and qualitative techniques). The intervention will be group-based and consist of motivational discussions and a review of audiovisual materials to promote self-efficacy and health literacy on the safe use of medication at home (most frequent errors, preventive strategies, etc.). Study period: 15 days intervention and follow-up 12 months.
88817149|NCT05247801|Active Comparator|Control Group (Dosing Device)|The 216 subjects assigned to the control group will use a medication dosing device and will receive information on how to use it for medication errors. Study period: 15 days intervention and follow-up 12 months.
88817150|NCT01209260|Experimental|Radiofrequency energy needle|Radiofrequency energy needle for transseptal access
88817151|NCT01209260|Active Comparator|Mechanical needle|Mechanical (Brockenbrough) needle for transseptal access
88817152|NCT05221983||Patients with COVID-19 + with vitamin D levels|Patients with COVID-19 + and vitamin D levels were included in the study retrospectively. Vitamin D level was categorized into 3 groups as inadequacy, deficiency and normal from medical records. No intervention was made.
88817153|NCT01210820|Experimental|Natural Astigmatism|Subjects with refractive astigmatism and no prior history of ophthalmic surgery. May include subjects with cataracts.
88817154|NCT01210820|Experimental|Post cataract with residual astigmatism|Subjects who have had cataract removal surgery but have residual astigmatism.
88817155|NCT05220813|Active Comparator|local anesthetic group (control group)|44 patients will receive local infiltration anesthesia.
88817156|NCT05220813|Active Comparator|ilioinguinal iliohypogastric group|44patients will receive ilioinguinal iliohypogastric nerve blocks
88817157|NCT01211600|Active Comparator|Staples|Interrupted Ethicon Staples
88817158|NCT01211600|Active Comparator|Suture|Subcuticular continuous suture (4-0 Monocryl Plus on PS2 needle or 4-0 Vicryl Plus on FS2 or PS2 needle)
88817159|NCT01650246|Experimental|lesinurad 400 mg|
88817160|NCT01212302|Experimental|aspirin, clopidogrel|If the treatment with aspirin and/or clopidogrel is insufficient (platelet function testing) the dose was increased or the drug was changed (clopidogrel to ticlopidine or prasugrel)
88817161|NCT05110677||Study group|"Multispectral Optoacoustic Tomography (MSOT) and B-Mode Ultrasound of the Musculus gastrocnemius of the affected leg in PAD patients or one leg in healthy volunteers (total 1 site)~Physical assessment: Color-Coded Duplex Sonography/treadmill examination to determine actual walking distance/Ankle-Brachial-Index/defined walking distance of 150 meters under medical supervision"
88817162|NCT05107479|Experimental|Treatment|The participants in the treatment group will be invited to participate in a 5-module IVR training covering an overview of available COVID-19 vaccines and best practices for vaccine administration.
88817163|NCT05107479|Active Comparator|Control|Participants in the control group will receive the intervention following a one-month delay allowing for a comparison of outcomes with the treatment group.
88817164|NCT03009812|Active Comparator|Group 1|26 subjects who are planned for transverse uterine incision
88817165|NCT03009812|Active Comparator|Group 2|26 subjects who are planned for longitudinal uterine incision
88817166|NCT04908072|Active Comparator|Virtual Reality Training|Will participate in an Intensive virtual reality (R) cataract simulation course that includes a five day instructor led VR course using the Orbis-FundamentalVR cataract surgical simulator, in addition to standard resident training at the training facility.
88817167|NCT04908072|No Intervention|Traditional Training|Will receive standard resident training at the training facility.
88817168|NCT01284296|Experimental|Digital block|
88817169|NCT01285076||All Enrolled Participants|Adults with Type 2 DM ≥30 years of age who have been treated with SU monotherapy or SU + MF combination therapy for at least 6 months by a cardiologist, nephrologist, neurologist, or family practice doctor.
88817170|NCT01652664|Experimental|Travoprost|Travoprost 0.004% PQ ophthalmic solution, 1 drop administered in each eye in the evening with travoprost vehicle administered once daily in the morning for 3 months
88817171|NCT01652664|Active Comparator|Timolol|Timolol, 0.5% or 0.25% ophthalmic solution, 1 drop administered in each eye twice daily (once in the morning and once in the evening) for 3 months
88817172|NCT04055649|Experimental|Treatment - ONC201 & Paclitaxel|Patients receive ONC201 PO on days 1, 8, 15, and 22 and paclitaxel IV over 1 hour on days 2, 9, and 16. Cycles repeat every 28 days in the absence disease progression or unacceptable toxicity. If paclitaxel must be stopped for any reason, patients may continue on ONC201 alone.
88817173|NCT01286324|Experimental|Chamomile High Grade Extract|Each capsule contains 90 mg dry extract of chamomile flowering tops [6:1 (v/v) extraction solvent (ethanol 70%/30% water): flowering tops] standardized up to 2.5 mg of (-)-α-bisabolol and ≥ 2.5 mg of apigenin per tablet
88817174|NCT01286324|Placebo Comparator|Placebo Tablet|Contained lactose
88817175|NCT01286402|Experimental|Bupropion SR (sustained release)|Group receiving bupropion SR medication
88817176|NCT01286402|Placebo Comparator|Placebo|
88817177|NCT03940677|Other|Parkinson's disease patient|Brain functional MRI, robotic TMS + EEG, neuropsychological evaluation, neurological examination for motor and non motor symptoms
88817178|NCT03940677|Other|Healthy controls|Brain functional MRI, robotic TMS + EEG, neuropsychological evaluation, neurological examination
89182437|NCT02599298|No Intervention|Control arm|The patients will be treated according to the standard treatment for acute coronary syndrome in Singapore, which is largely in accordance with the recommendations of the American College of Cardiology and the American Heart Association. Management includes, but is not limited to, antiplatelet and lipid-lowering therapy, early coronary revascularization, and cardiac rehabilitation, with the recommendation to follow the current practice and the most recent international guidelines.
89182438|NCT02241291||All patients|Patients undergoing PCI at Bern University Hospital
89182439|NCT00753896|Experimental|1|
89182440|NCT02597114|Experimental|AGT-181|AGT-181 (fusion protein of anti-human insulin receptor monoclonal antibody and alpha-L-iduronidase) administered once weekly x 26 weeks at same dose level as subject received in core study
89182441|NCT04852107|Active Comparator|SCS/ DRGS/DUAL /Dual*|
89182442|NCT04852107|Active Comparator|SCS/DUAL/DRGS/DRGS*|
89182443|NCT04852107|Active Comparator|DRGS/SCS/DUAL/DUAL*|
89182444|NCT04852107|Active Comparator|DRGS/DUAL/SCS/SCS*|
89182445|NCT04852107|Active Comparator|Dual/DRGS/SCS/SCS*|
89182446|NCT04852107|Active Comparator|Dual/SCS/DRGS/DRGS*|
89182447|NCT00743444|Experimental|1|AZD3355
89182448|NCT00743444|Placebo Comparator|2|
89182449|NCT02598284|Experimental|Point of Care (POC) Only|Clinics will receive facilitation to implement point-of-care (POC) quality improvement strategies to accelerate performance on ABCS clinical measures. All strategies will focus on aspects of the clinical encounter.
89182450|NCT02598284|Experimental|POC + Population Managment (PM)|Clinics will receive facilitation to implement point-of-care (POC) quality improvement strategies as well as population management (PM) strategies to accelerate performance on ABCS clinical measures. Strategies in this arm will occur both at the clinical encounter and strategies aimed at the time between clinical encounters.
89182451|NCT05673369|Experimental|Group 1|Period 1: Reference drug Period 2: Test drug
89182452|NCT05673369|Experimental|Group 2|Period 1: Test drug Period 2: Reference drug
89182453|NCT00743366|Experimental|Quetiapine (200mg/day), Marijuana (6.2%, 0.0%)|"Quetiapine (200mg/day): Packaged medication in size 00 opaque capsules with riboflavin filler. Study capsules (200 mg) were administered 2 times per day ((1100 and 2300 hours).~Marijuana: Participants each received a single marijuana cigarette (provided by the National Institute on Drug Abuse) at each smoking occasion. Marijuana cigarettes were stored frozen in an airtight container and humidified at room temperature for 24 h prior to use."
89182454|NCT00743366|Placebo Comparator|Placebo, Marijuana (6.2%, 0.0%)|Marijuana: Participants each received a single marijuana cigarette (provided by the National Institute on Drug Abuse) at each smoking occasion. Marijuana cigarettes were stored frozen in an airtight container and humidified at room temperature for 24 h prior to use.
89182455|NCT01760655|Experimental|Treatment (RIC and allogeneic PBSCT)|"REDUCED INTENSITY CONDITIONING: Patients receive fludarabine phosphate IV on days -15 to -12, busulfan IV on days -14 to -13, DLI on day -6, and cyclophosphamide IV on days -3 and -2. Patients also undergo TBI on day -10.~TRANSPLANT: Patients undergo allogeneic PBSCT on day 0.~GVHD PROPHYLAXIS: Patients receive tacrolimus IV on days -1 to 42 followed by taper and mycophenolate mofetil IV BID on days -1 to 28"
89182456|NCT00721968|Active Comparator|1|Treatment Group (Group 1): Glaukos Trabecular Micro-Bypass Stent Model GTS400; implantation in conjunction with cataract surgery
89182457|NCT00721968|Placebo Comparator|2|Control Group (Group 2): Cataract surgery only
89182458|NCT00743288|Experimental|Melphalan and Panobinostat|"Schedule A: 10mg/daily of LBH589 PO on days 1, 3 and 5 of weeks 1-4 of a 28-day cycle and melphalan PO at 0.05 mg/kg on days 1-5 of week 1.~Toxicity led to the following changes in dose and schedule Schedule B1: 10mg/daily of LBH589 PO on days 1, 3 and 5 of weeks 1-4 and 0.05 mg/kg melphalan PO on days 1, 3 and 5 of week 1.~Schedule B2: 20mg/daily of LBH589 PO on days 1, 3 and 5 of weeks 1-4 and 0.05 mg/kg melphalan POon days 1, 3 and 5 of week 1.~Schedule C: 20mg/daily of LBH589 PO on days 1, 3 and 5 of weeks 1 and 2 and 0.05 mg/kg melphalan PO on days 1, 3 and 5 of week 1 Schedule D1: 15 mg/daily LBH589 PO and 0.05 mg/kg melphalan PO on days 1, 3 and 5 of week 1.~Schedule D2: 15 mg/daily LBH589 PO and 0.10 mg/kg melphalan PO on days 1, 3 and 5 of week 1.~Schedule D3: 20 mg/daily LBH589 PO and 0.05 mg/kg melphalan PO on days 1, 3 and 5 of week 1."
89182459|NCT04073511|Experimental|Eungyosan|Dosage is 1 packet, 2.3g, 3 times daily, 6.9g total daily dose. The total duration of administration is up to 8 days.
89182460|NCT04073511|Experimental|Samsoeum|3.37g of a packet, 3 times a day, the total daily dose is 10.11g. Total duration of administration is up to 8 days.
89182461|NCT04073511|Placebo Comparator|Placebo|Take a total of 9.0g, 3.0g each, three times a day. The total duration of administration is up to 8 days.
89182462|NCT02591394|Experimental|STEP Clinic|
89182463|NCT02591394|Active Comparator|Usual Care|
89182464|NCT04089254|Active Comparator|Inpatient Psychiatry|Child and adolescent inpatient treatment
89182465|NCT04089254|Active Comparator|Outpatient Crisis Intervention Clinic|OCIC is outpatient crisis intervention clinic
89182466|NCT02579187|Placebo Comparator|control group|CBCT scan limited to the dental arch that includes the study site will be obtained. All subjects will receive local infiltrative anesthesia, following which minimally invasive tooth extraction will be performed. After tooth extraction clinical measurements of the site will also be obtained and recorded for both groups (i.e. keratinized mucosa width, horizontal ridge width, facial and lingual bone thickness). A biodegradable sponge (type I bovine collagen) to stabilize the blood clot will be placed.The site will be stabilized with a simple external, cross mattress suture. Blood , wound fluid, and saliva samples will be taken periodicallly. In addition, photos/videos, periapical xrays and PVS impressions will be obtained.
89182467|NCT02579187|Active Comparator|Experimental group 1|CBCT scan limited to the dental arch that includes the study site will be obtained. All subjects will receive local infiltrative anesthesia, following which minimally invasive tooth extraction will be performed. After tooth extraction clinical measurements of the site will also be obtained and recorded for both groups (i.e. keratinized mucosa width, horizontal ridge width, facial and lingual bone thickness). 10µg of pSil-miR200c plasmids in a biodegradable sponge (type I bovine collagen) will be locally delivered. The site will be stabilized with a simple external, cross mattress suture. Blood, wound fluid, and saliva samples will be taken periodicallly. In addition, photos/videos, periapical xrays and PVS impressions will be obtained.
89378048|NCT05046912|Active Comparator|Non-clinical|Non-clinical participants with no mental health diagnoses.
88851023|NCT02083926|Experimental|Ketamine infusion|A ketamine infusion was given on day 0 (28) at a dose of 0.5mg/kg over 40 minutes. Assessments were conducted pre-infusion, 3-h post-infusion, and days 1 (1+28), 2 (2+28), 3 (3+28), 5 (5+28), 7 (7+28), 10 (10+28) and 14 (14+28) post-infusion.
88851024|NCT02083926|Experimental|Saline infusion|A saline infusion was given on day 0 (28) at a dose of 0.5mg/kg over 40 minutes. Assessments were conducted pre-infusion, 3-h post-infusion, and days 1 (1+28), 2 (2+28), 3 (3+28), 5 (5+28), 7 (7+28), 10 (10+28) and 14 (14+28) post-infusion.
88851025|NCT02083380|Experimental|A) Artefenomel 800mg: piperaquine 640mg|One single dose of Artefenomel 800mg: Piperaquine phosphate 640mg loose combination
88851026|NCT02083380|Experimental|B) Artefenomel 800mg: piperaquine 960mg|One single dose of Artefenomel 800mg: Piperaquine phosphate 960mg loose combination
88851027|NCT02083380|Experimental|C) Artefenomel 800mg: piperaquine 1440mg|One single dose of Artefenomel 800mg: Piperaquine phosphate 1440mg loose combination
88851028|NCT02109744|Experimental|Decitabine followed by rapamycin|Decitabine 20 mg/M2/day will be given as an IV infusion daily for 10 consecutive days starting on day 1 of cycle 1; in subsequent cycles, decitabine will be given for five days (days 1-5). Rapamycin 6mg (loading dose) will be administered on day 6; thereafter 2 mg/day on days 11-22 in cycle 1 and on days 6-22 in subsequent cycles. (Arm A: for patients with non-morphologic M4/M5 subtypes).
89182468|NCT02579187|Active Comparator|Experimental group 2|CBCT scan limited to the dental arch that includes the study site will be obtained. All subjects will receive local infiltrative anesthesia, following which minimally invasive tooth extraction will be performed. After tooth extraction clinical measurements of the site will also be obtained and recorded for both groups (i.e. keratinized mucosa width, horizontal ridge width, facial and lingual bone thickness). 10µg of PMIS miR200a plasmids in a biodegradable sponge (type I bovine collagen) will be locally delivered. The site will be stabilized with a simple external, cross mattress suture. Blood, wound fluid, and saliva samples will be taken periodicallly. In addition, photos/videos, periapical xrays and PVS impressions will be obtained.
89182469|NCT02579187|Active Comparator|Experimental group 3|CBCT scan limited to the dental arch that includes the study site will be obtained. All subjects will receive local infiltrative anesthesia, following which minimally invasive tooth extraction will be performed. After tooth extraction clinical measurements of the site will also be obtained and recorded for both groups (i.e. keratinized mucosa width, horizontal ridge width, facial and lingual bone thickness). 5µg of pSil-miR200c and 5µg of PMIS miR200a plasmids in a biodegradable sponge (type I bovine collagen) will be locally delivered. The site will be stabilized with a simple external, cross mattress suture. Blood, wound fluid, and saliva samples will be taken periodicallly. In addition, photos/videos, periapical xrays and PVS impressions will be obtained.
89182470|NCT04092062|Experimental|Treatment - ToothWave brush|Subjects using the Silk'n ToothWave, Radio frequency (RF)-utilizing toothbrush.
89182471|NCT04092062|Sham Comparator|Control - powered toothbrush|Subjects using a regular ADA-Accepted Powered Toothbrush, no RF
89182472|NCT02590692|Experimental|CPCB-RPE1 treatment|Subretinal implantation of CPCB-RPE1 in dry AMD patients
89182473|NCT04019912|Experimental|Gait Training plus music|Patients will be randomly assigned to the rehabilitation group through gait trainer3 with Rhythmic Auditory Stimulation (RAS). All patients will undergo a complete clinical and neurophysiological evaluation at baseline. The training program consist of 45 minutes of treadmill training with RAS. The daily training program will be practiced once a day at the same time of day (from 9:00 am to 1:00 pm), five times a week for eight consecutive weeks. RAS treadmill sessions will be performed individually in the same position and under the supervision of physiotherapists with 2 years of RAS training.
89182474|NCT04019912|Active Comparator|Traditional Gait Training|Patients will be randomly assigned to the non-Rhythmic Auditory Stimulation (RAS) treadmill walking group. All patients will undergo a complete clinical and neurophysiological evaluation at baseline.The daily training program consist of 45 minutes of conventional gait training using a non-RAS treadmill. The daily training program will be practiced once a day at the same time of day (from 9:00 am to 1:00 pm), five times a week for eight consecutive weeks. Non-RAS treadmill sessions will be performed individually in the same position and under the supervision of physiotherapists.
89182475|NCT02579109|Other|autistic patient|patient with autistic trouble
89182476|NCT02579109|Other|healthy volunteers|healthy volunteers
89182477|NCT02598440|Experimental|Group A: Ibandronate Then Alendronate|Participants wil receive once-monthly oral ibandronate (150 mg tablet) for 3 months followed by and once-weekly oral alendronate (70 mg tablet) in crossover design for 12 weeks.
89182478|NCT02598440|Experimental|Group B: Alendronate Then Ibandronate|Participants will receive once-weekly oral alendronate (70 mg tablet) for 12 weeks followed by once-monthly oral ibandronate (150 mg tablet) for 3 months.
89182479|NCT02575989|Active Comparator|1: control group|Classic - current management of trauma patients by French medical teams
89182480|NCT02575989|Experimental|2: interventional group|"Intervention Name : monitoring, treatment, control and prevention of hypothermia~Continuous monitoring of body temperature~Ambulance warming (target : 30°C)~Patient warming with dedicated blanket~Infusion fluid warming (and temperature control)"
89182481|NCT04091594|Experimental|Flexible orthotic|Sensory input flexible ankle foot orthotic (SIAFO) with appropriate lycra garments
89182482|NCT04091594|Active Comparator|Standard of care|Standard of care solid ankle foot orthotic (AFO)
89378049|NCT02348398|Experimental|Pazopanib + Topotecan|"Pazopanib 600 mg taken orally continuously while Topotecan 0.25 mg taken orally for 21 days continuously followed by 7 days off. A cycle will be defined as 28 days.~During follow up if disease gets worse, participant called by study staff every 3 months."
89182483|NCT03915249||Allogeneic-HSCT candidates|Physical activity, pulmonary functions (FEV1, FVC, FEV1/FVC, FEF25-75%, PEF), exercise capacity, respiratory (maximal inspiratory and expiratory pressures (MIP, MEP)) and peripheral muscle strength were evaluated in allogeneic-HSCT candidates.
89182484|NCT00750308|Active Comparator|tadalafil, ramapril, combo, placebo|placebo+tadalafil for three weeks, washout, placebo+ramipril for three weeks, washout, ramipril + tadalafil, washout, placebo+placebo for three weeks
89182485|NCT00750308|Active Comparator|ramipril, tadalafil, placebo, combo|placebo+ramipril for three weeks, washout, placebo+tadalafil for three weeks, washout, placebo+placebo for three weeks, washout, ramipril+tadalafil for three weeks
89182486|NCT00750308|Active Comparator|combo, placebo, tadalafil, ramipril|ramipril+tadalafil for three weeks, washout, placebo+placebo for three weeks, washout, placebo+tadalafil for three weeks, washout, placebo+ramipril for three weeks
89182487|NCT00750308|Active Comparator|placebo, combo, ramipril, tadalafil|placebo+placebo for three weeks, washout, ramipril+tadalafil for three weeks, washout placebo+ramipril for three weeks, washout, placebo+tadalafil for three weeks
89182488|NCT00750308|Active Comparator|tadalafil, placebo, ramipril, combo|placebo+tadalafil for three weeks, washout, placebo+placebo for three weeks, washout, placebo+ramipril for three weeks, washout, ramipril+tadalafil for three weeks
89182489|NCT00750308|Active Comparator|ramipril, combo, tadalfil, placebo|placebo+ramipril for three weeks, washout, ramipril+tadalafil for three weeks, washout, placebo+tadalafil for three weeks, washout, placebo for three weeks
89182490|NCT00750308|Active Comparator|combo, ramipril, placebo, tadalafil|ramipril+tadalafil for three weeks, washout, placebo+ramipril for three weeks, washout, placebo+placebo for three weeks, washout, placebo+tadalafil for three weeks
89182491|NCT00750308|Active Comparator|placebo, tadalafil, combo, ramipril|placebo+placebo for three weeks, washout, placebo+tadalafil for three weeks, washout, ramipril+tadalafil for three weeks, washout, placebo+ramipril for three weeks
89182492|NCT00750308|Active Comparator|tadalafil, combo, placebo, ramipril|placebo+tadalafil for three weeks, washout, ramipril+tadalafil for three weeks, washout, placebo+placebo for three weeks, washout, placebo+ramipril for three weeks
89182493|NCT00750308|Active Comparator|ramipril, placebo, combo, tadalafil|placebo+ramipril for three weeks, washout, placebo+placebo for three weeks, washout, ramipril+tadalafil for three weeks, washout, placebo+tadalafil for three weeks
89182494|NCT00750308|Active Comparator|combo, tadalafil, ramipril, placebo|ramipril+tadalafil for three weeks, washout, placebo+tadalafil for three weeks, washout, placebo+ramipril for three weeks, washout, placebo+placebo for three weeks
89182495|NCT00750308|Active Comparator|placebo, ramipril, tadalafil, combo|placebo+placebo for three weeks, washout, placebo+ramipril for three weeks, washout, placebo+tadalafil for three weeks, washout, ramipril+tadalafil for three weeks
89182496|NCT02577237|Experimental|Intervention Group: Caregiver education|The intervention includes caregivers who will receive an education and support program throughout radiation treatment in addition to usual care by their doctors and nurses.
89182497|NCT02577237|Active Comparator|Control Group: educational booklet|The control group will receive an educational booklet about caregiving in addition to usual care by their doctors and nurses
89182498|NCT02579031|Active Comparator|Orsiro|Novel biodegradable-polymer sirolimus-eluting stent Orsiro
89182499|NCT02579031|Active Comparator|Xience|Durable-polymer everolimus-eluting stent Xience
89182500|NCT06240234|Other|Capnodynamic method arm|Only one arm will be used since all patients will be ventilated using the novel capnodynamic method. The algoritm will then be developed by including or omitting the capnodynamic data in addition to the curve data from the arterial line.
89182501|NCT06240221||Saber-C|All enrolled patients will receive the Elevation Spine Saber-C System according to surgeon standard of care.
89182502|NCT06240208|Experimental|Inactivity|Inactivity will be implemented as cessation of active commuting and all other structured exercise. Furthermore, steps will be reduced to a maximum of 1500 steps/day.
89182503|NCT06240208|No Intervention|Control|Participants will be instructed to maintain habitual physical activity and dietary habits.
89182504|NCT06240182|Active Comparator|Conventional surgery|performing surgery by surgical carbide burs
89182505|NCT06240182|Experimental|Piezoelectric surgery|surgery performed using piezoelectric device
89182506|NCT06240169|Experimental|DPC in AGE I with MTA|DPC using MTA in Age group I i.e. 18-40years.
89182507|NCT06240169|Experimental|DPC in AGE I with BD|DPC using BD in Age group I i.e. 18-40years.
89182508|NCT06240169|Experimental|DPC in AGE II with MTA|DPC using MTA in Age group II i.e. 41-60years
89182509|NCT06240169|Experimental|DPC in AGE II with BD|DPC using BD in Age group II i.e. 41-60years
89182510|NCT06240156|Experimental|3D arch pad design Insole group|This study utilizes a custom-made arch support pad with a 3D three-dimensional design that is already available on the market (patent number I315187). Its arch support principle is designed using 3DBS (Three-Dimensional Biomechanics System - 3DBS), which can conform to the user's feet. In this type, the bottom layer provides an overall shock-absorbing function.
89182511|NCT06240156|Placebo Comparator|flat Insole group|General Insole without any special features
89182512|NCT06240143|Experimental|A|2 cycles of intradermal ipilimumab 0.5 mg + nivolumab 1 mg every 3 weeks
89182513|NCT06240143|Experimental|B|6 cycles of intradermal ipilimumab 0.5 mg + nivolumab 1 mg every week
89182514|NCT06240143|Experimental|C|2 cycles of intradermal ipilimumab 10 mg + nivolumab 20 mg every 3 weeks
89182515|NCT06240143|Experimental|D|intradermal ipilimumab + nivolumab according to the optimal intradermal regimen plus 2 cycles of intravenous nivolumab 240mg every 3 weeks
89182516|NCT06240130|Active Comparator|Sodium hypochlorite lavage group|3% sodium hypochlorite lavage will be done after pulp amputation
89182517|NCT06240130|Experimental|Chlorhexidine lavage group|2% Chlorhexidine lavage will be done after pulp amputation
89182518|NCT06240104|Experimental|CI group|the cardiac index (CI) is continuously monitored during the weaning process
89182519|NCT06240104|No Intervention|control group|No intervention measures
89182520|NCT06240091|Experimental|DISC-MA|All participants will be asked to download and use the DISC-MA study application. They will have access to the app throughout the 4 week study.
89182521|NCT06240039|Experimental|Evaluating the direct and indirect effect of amino acids on the regulation of hepatokines|Participants will be subjected to four experimental days
89378050|NCT02352688|Active Comparator|Enhanced Colorectal Geriatric Care|Multidisciplinary team involving in the elderly colorectal cancer patients' pre-, peri- and postoperative care.
89378051|NCT02352688|No Intervention|Standard Surgical Care|Standard care given to elderly patients undergoing colorectal cancer resection.
89378052|NCT03147352||NSTI patients|NSTI is an infection that requires acute hospitalization with intensive care treatment and/or surgery as a consequence of severe soft tissue infection in subcutis, muscle and/or fascia and that spreads along tissue structures.
89378053|NCT03147352||Orthopaedic control patients|Elective orthopaedic control patients.
89378054|NCT02352454|Experimental|Aurix + UCC|Subjects will be treated on average twice a week for the first 2 weeks, and then, once a week thereafter while under active treatment, but actual frequency of treatment will be determined by the treating physician. All subjects will receive Aurix treatment and usual and customary care, which can include advanced therapeutics.
89399424|NCT02173964|Experimental|pinaverium bromide|pinaverium bromide 50 mg tablet per oral administration one time
89399425|NCT02173964|Placebo Comparator|water|water ~100mL
88817179|NCT01222832|Experimental|Bacitracin|Nasopore sponge soaked in Bacitracin, no oral antibiotics
88817180|NCT01222832|No Intervention|Saline|Nasopore sponge soaked in saline, routine oral antibiotics
88817181|NCT01286870|Other|Reconstruction|"The study population will consist of women aged 18 or over who are undergoing primary breast reconstruction.~The Reconstruction cohort will include subjects with loss of breast tissue due to mastectomy, contralateral breast for post-reconstruction symmetry or subjects with deformities secondary to disease, malignancy, trauma, and congenital deformity. Subjects in this cohort cannot have been implanted with breast implants, but may have tissue expanders. A Becker implant is considered a tissue expander until the port and fill tube have been removed. Women who undergo surgery primarily for a mastopexy will not be part of the reconstruction cohort."
88817182|NCT04297605|Experimental|Experimental 1: pembrolizumab and Pemetrexed|"Treatment includes administration of pembrolizumab and chemotherapy, which are administered every 21 days~Pembrolizumab 200 mg and Pemetrexed 500 mg/m2 day 1 of 21 day cycle (for non-squamous only)"
88817183|NCT04297605|Experimental|Experimental 2: pembrolizumab and Nab-paclitaxel|"Treatment includes administration of pembrolizumab and chemotherapy, which are administered every 21 days~Pembrolizumab 200 mg and Nab-paclitaxel 100 mg/m2 days 1,8 of 21 day cycle x 4 cycles followed by pembrolizumab alone"
88817184|NCT02379390|Experimental|Cabazitaxel|Participants received Cabazitaxel 25 mg/m^2, intravenously for 1 hour along with prednisone 10 mg orally on Day 1 of every treatment cycle (each cycle was of 3 weeks) until disease progression, unacceptable toxicity, or participant's refusal of further study treatment.
88817185|NCT02379390|Active Comparator|Abiraterone acetate or Enzalutamide|Participants received abiraterone acetate 1000 mg (4 tablets of 250 mg), orally once daily along with prednisone 5 mg, orally twice daily from Day 1 to 21 in each treatment cycle (each cycle was of 3 weeks) or enzalutamide 160 mg, orally, until disease progression, unacceptable toxicity, or participant's refusal of further study treatment.
88817186|NCT04742517|Experimental|Single ascending dose of ASP1128|Participants (6 for each cohort) will receive a single dose of ASP1128.
88817187|NCT04742517|Placebo Comparator|Single ascending dose of Placebo|Participants (2 for each cohort) will receive a single dose of matching Placebo.
88817188|NCT04742517|Experimental|Multiple ascending dose of ASP1128|Participants (9 for each cohort) will receive daily doses of ASP1128 for 7 consecutive days.
88817189|NCT04742517|Placebo Comparator|Multiple ascending dose of Placebo|Participants (3 for each cohort) will receive matching Placebo for 7 consecutive days.
88817190|NCT02379078|Experimental|Shared decision-making aid|"At study start (step 1: provider-directed intervention phase): Online shared decision-making aid, 1-page provider enabler, provider training video made available to health care providers~At 6 months (step 2: provider- and patient-directed phase): Online shared decision-making aid, 1-page patient enabler, patient training video also made available to patients (in addition to health care providers)"
88817191|NCT02379078|Placebo Comparator|Generic hard-copy diabetes resources|"At study start (step 1: Provider-directed intervention phase): A hard copy of the executive summary of the CDA CPG and postcard outlining online resources made available to health care providers~At 6 months (step 2: provider- and patient-directed phase): A CDA patient education pamphlet regarding diabetes self-management also made available to patients~In addition, provider- and patient-directed guideline dissemination tools (not incorporating SDM) will also be publicly accessible from the CDA website."
88817192|NCT04708197|Other|aphasic patients|post stroke aphasic patients will receive 10 sessions of high frequency rTMS 3 times per week over the damaged hemisphere without language therapy
88817193|NCT04932915|Experimental|UNI91103 intranasal spray 1%|UNI91103 intranasal spray 1%, BID, 10 consecutive days
88817194|NCT04932915|Placebo Comparator|Placebo|Placebo intranasal spray, BID, 10 consecutive days
88817195|NCT04926051|Experimental|Part A: SAD|SAD = Single Ascending Dose
88817196|NCT04926051|Experimental|Part B: MAD|MAD = Multiple Ascending Dose
88817197|NCT04926051|Experimental|Part C: JMAD|JMAD= Japanese Multiple Ascending Dose
88817198|NCT04926051|Experimental|Part D: FE/BA|FE/BA = Food Effect/Relative Bioavailability
88817199|NCT01223378|Experimental|BOL-303259-X|ophthalmic solution
88817200|NCT01223378|Active Comparator|Latanoprost|ophthalmic solution
88817201|NCT04708119|Other|histopathological evaluation|angulation of impacted lower mandibular third molar and histopathological evaluation
88817202|NCT04844307|Active Comparator|Standard PT group|The standard PT group (control) will be receiving the standard 30 minute PT sessions 5 days a week. There will be no variations from standard inpatient PT treatment except that subjects may receive more days of PT than patients who are not participating in study.
88851029|NCT02109744|Experimental|Decitabine followed by ribavirin|Decitabine 20 mg/M2/day will be given as an IV infusion daily for 10 consecutive days starting on day 1 of cycle 1; in subsequent cycles, decitabine will be given for five days (days 1-5). Ribavirin will be dosed from day 11-day 28 beginning with dose level 1 (1000mg orally twice daily). Number of patients with Dose Limiting Toxicities (DLT) at a given dose level is 0 of out of 3: enter 3 patients at the next dose level (dose Level 2- 1200mg orally twice daily; and then dose Level 3-1400 mg orally twice daily).(Arm B: For patients with morphologic M4/M5 subtypes).
88851030|NCT02109432|Other|Pedal Desk|"Participants will complete three 2-week conditions in the following order:~Self-directed Pedal Desk~Facilitated Pedal Desk~Facilitated Pedal Desk with Pedometer"
88851031|NCT04723602|Active Comparator|cAd3-Marburg at 1 x 10^11 Particle Units (PU)|A total of 16 healthy adults will be enrolled and vaccinated with a single dose of vaccine. Group 1 (N = 16) will receive a single injection of cAd3-Marburg at 1 x 10^11 Particle Units (PU) vaccine.
88851032|NCT04723602|Active Comparator|cAd3-EBO-S at 1 x 10^11 PU vaccine|A total of 16 healthy adults will be enrolled and vaccinated with a single dose of vaccine. Group 2 (N = 16) will receive a single injection of cAd3-EBO-S at 1 x 10^11 Particle Units (PU) vaccine.
88851033|NCT02109042|Experimental|Blosozumab|Weekly SC injections of blosozumab for 6 weeks.
88851034|NCT02066922|Experimental|DAILIES TOTAL1|Delefilcon A contact lens randomly assigned to one eye, with narafilcon A contact lens in the fellow eye for contralateral wear. Both products worn in a daily wear, daily disposable mode approximately 8 hours a day for approximately 1 week, with spectacles worn over contact lenses if needed to provide acceptable vision.
88851035|NCT02066922|Active Comparator|TRUEYE|Narafilcon A contact lens randomly assigned to one eye, with delefilcon A contact lens in the fellow eye for contralateral wear. Both products worn in a daily wear, daily disposable mode approximately 8 hours a day for approximately 1 week, with spectacles worn over contact lenses if needed to provide acceptable vision.
88851036|NCT02108262|Experimental|CSL112 - low dose|CSL112 (low dose) is to be administered as an intravenous (IV) infusion once weekly for 4 consecutive weeks.
88851037|NCT02108262|Experimental|CSL112 - high dose|CSL112 (high dose) is to be administered as an IV infusion once weekly for 4 consecutive weeks.
88851038|NCT02108262|Placebo Comparator|Placebo|Placebo is to be administered as an IV infusion at the same frequency, volume and duration as either the low dose or high dose CSL112 infusion.
88851039|NCT02107482|Active Comparator|Levia Narrow Band UVB|Levia Narrow Band UVB dosing for subjects with skin type I: starting dose of 195 mj/cm2, for subjects with skin type II: starting dose of 330 mj/cm2, for subjects with skin type III: starting dose of 390 mj/cm2, for subjects with skin type IV: starting dose of 495 mj/cm2, for subjects with skin type V: starting dose of 525 mj/cm2, for subjects with skin type VI: starting dose of 600 mj/cm2. The dose will be increased by 15% with each treatment, as long as there are no side effects with treatment such as burning or redness.
88851040|NCT02107482|Sham Comparator|Levia sham/visible-light source|the light is produced using the same Levia® device. Levia® enable the user to switch off the UVB light and only produce visible light spectrum.
88851041|NCT02066298|Experimental|Mometasone then Tiotropium then Placebo|Mometasone 220mcg BID, followed by Tiotropium Respimat 5mcg QD, followed by Placebo
88851042|NCT02066298|Experimental|Mometasone then Placebo then Tiotropium|Mometasone 220mcg BID, followed by Placebo, followed by Tiotropium Respimat 5mcg QD
88851043|NCT02066298|Experimental|Placebo then Mometasone then Tiotropium|Placebo, followed by Mometasone 220mcg BID, followed by Tiotropium Respimat 5mcg QD
88851044|NCT02066298|Experimental|Placebo then Tiotropium then Mometasone|Placebo, followed by Tiotropium Respimat 5mcg QD, followed by Mometasone 220mcg BID
88851045|NCT02066298|Experimental|Tiotropium then Placebo then Mometasone|Tiotropium Respimat 5mcg QD, followed by Placebo, followed by Mometasone 220mcg BID
88851046|NCT02066298|Experimental|Tiotropium then Mometasone then Placebo|Tiotropium Respimat 5mcg QD, followed by Mometasone 220mcg BID, followed by Placebo
88851047|NCT02082912|Experimental|D-cycloserine|Subjects will take D-cycloserine and use the HandMentor Pro for robotic therapy
88851048|NCT02082912|Active Comparator|Placebo|Subjects will take a placebo pill and use the HandMentor Pro for robotic therapy
88851049|NCT02082522|Experimental|Photodynamic therapy-Photofrin plus SMC|Photodynamic therapy (PDT) involves the i.v. injection of Photofrin followed by the illumination of the tumor using a fiber optic device. Two days after the injection, a laser light (180 J/cm(2)) will be applied to the tumor. A second light application will be given 96-120 hours after Photofrin injection if PDT could not initially be performed on all sides of the tumor. Post illumination, all patients will undergo stenting as part of standard medical care procedure. Up to 3 additional courses of PDT using a light dose of 120 J/cm(2) may be given at 3-month intervals. Standard Medical Care (SMC) is defined as stenting procedure plus chemotherapy regimen.
88851050|NCT02082522|Active Comparator|Standard Medical Care (SMC)|Standard Medical Care (SMC) is defined as stenting procedure plus chemotherapy regimen. The chemotherapy regimen will comprise gemcitabine (1 000 mg/m(2)) followed by cisplatin (25 mg/m(2)), each administered on days 1 and 8 every 3 weeks (21 day-cycle) for four cycles. An additional 12 weeks of the same chemotherapy regimen may be administered if there is no disease progression or intolerable toxicity.
88851051|NCT02082210|Experimental|Emibetuzumab + Ramucirumab (Part A)|Part A: Dose escalation (750mg, 2000mg) of Emibetuzumab administered intravenously (IV), on days 1 and 15 every 28 day cycle in combination with a fixed dose of 8mg/kg ramucirumab administered IV on Days 1 and 15 every 28 day cycle.
88851052|NCT02082210|Experimental|Emibetuzumab + Ramucirumab (Part B)|Part B: Recommended 750mg Emibetuzumab dose from Part A to be administered IV, on days 1 and 15 every 28 day cycle in combination with a fixed dose of 8mg/kg ramucirumab administered IV on Days 1 and 15 every 28 day cycle.
88851053|NCT02107092|Experimental|Sodium Zirconium Cyclosilicate|Open label oral administration of sodium zirconium cyclosilicate 10g once daily for 11 months.
88851054|NCT02107014|Other|Low Dose Naltrexone (LDN)|Following a two-week baseline the study drug was administered daily for 8 weeks. Participants were informed that placebo or LDN would be provided during the drug period and that all participants would receive LDN at some point during the study. In fact, all participants received the active LDN (4.5 mg nocte) throughout the drug-administration period.
89002442|NCT06317766|Experimental|Part 2 Clinical Study Procedure|"1 healthy adult (male or female)~18-75 years of age, who are scheduled to undergo an abdominoplasty (where abdominal skin will be excised) will be recruited.~Informed consent will be obtained by a delegated member of the study staff prior to the day of surgery.~The study team will utilize the specific setting based off the results of Part 1.~Subject will be asked to return to the site on days -30, -3, -2, -1 before their procedure.~At each visit, subjects will receive a single pulse treatment in areas that will be marked by the study team.~On the day of their procedure, a member of the study team will administer 1 final pulse immediately post-surgery and all 5 timepoints will be harvested for analysis."
89002443|NCT06317740|Experimental|The intervention group|The intervention group received an intervention program.
89002444|NCT06317740|Other|Comparison group|The comparison group did not receive an intervention program.
89002445|NCT06317727||Pulsed Field Ablation group|The EndoVE (Endoscopic vacuum electrode) is moved endoscopically into surface contact with the polyp. A vacuum is employed through the EndoVE as required to assist contact with the device. An electrical field depth of 8-10mm and surface area of 2cm3 is treated per pulse application. The electrical pulses are produced by an electroporation generator (ePORE device). Larger polyps will require multiple applications to ensure the full surface area has been treated. An overlap with previously pulsed areas is preferable to ensure all of the polyp tissue is ablated. The patient will then be transferred to the step-down ward to monitor for any adverse events before being discharged on the same day. The patient will be requested to attend the clinic for an endoscopy follow up at 4-6 weeks post EndoVE polyp treatment to investigate the response.
89002446|NCT06317701||HGNS Therapy Participants|Individuals with sleep apnea treated by HGNS therapy.
89378055|NCT02352454|No Intervention|Usual and Customary Care|Subjects will be treated on average twice a week for the first 2 weeks, and then, once a week thereafter while under active treatment, but actual frequency of treatment will be determined by the treating physician. All subjects will receive usual and customary care, which can include advanced therapeutics.
89002451|NCT06317662|Experimental|Arm A|See Detailed Description for Arm A.
89002452|NCT06317662|Experimental|Arm B, Cohort 1|See Detailed Description for Arm B, Cohort 1.
89002453|NCT06317662|Experimental|Arm B, Cohort 2|See Detailed Description for Arm B, Cohort 2.
89002454|NCT06317662|Experimental|Arm B, Cohort 3|See Detailed Description for Arm B, Cohort 3.
89002455|NCT06317662|Experimental|Arm B, Cohort 4|See Detailed Description for Arm B, Cohort 4.
89002456|NCT06317662|Experimental|Arm C|See Detailed Description for Arm C.
89002457|NCT06317662|Experimental|Safety Phase Cohort|See Detailed Description for Safety Phase Cohort.
89002458|NCT06317662|Experimental|Steroid Prephase (prednisone, prednisolone)|All patients receive prednisone or prednisolone PO or NG TID for 7 days prior to the start of induction therapy (on days 1-7).
89002459|NCT06317649|Experimental|Regimen 1 (azacitidine, venetoclax)|"INDUCTION: Patients receive azacitidine IV or SC on days 1-7 of each cycle and venetoclax PO on days 1-28 of each cycle. Treatment repeats every 28 days for up to 2 cycles or until patient achieves remission, whichever comes first, in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Patients receive azacitidine IV or SC on days 1-7 and venetoclax PO on days 1-28 of each cycle. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.~Patients undergo bone marrow biopsy and aspiration as well as blood sample collection on the trial."
89002460|NCT06317649|Experimental|Regimen 2 (azacitidine, venetoclax, gilteritinib)|"INDUCTION: Patients receive azacitidine IV or SC on days 1-7 and venetoclax and gilteritinib PO on days 1-28 of each cycle. Treatment repeats every 28 days for up to 2 cycles or until patient achieves remission, whichever comes first, in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Patients receive azacitidine IV or SC on days 1-5, venetoclax PO on days 1-7 and gilteritinib PO on days 1-28 of each cycle. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.~Patients undergo bone marrow biopsy and aspiration as well as blood sample collection on the trial."
89002461|NCT06317649|Experimental|Regimen 3 (azacitidine, venetoclax, gilteritinib)|"INDUCTION: Patients receive azacitidine IV or SC on days 1-7 and venetoclax PO on days 1-28, and gilteritinib PO on days 8-21 of each cycle. Treatment repeats every 28 days for up to 2 cycles or until patient achieves remission, whichever comes first, in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Patients receive azacitidine IV or SC on days 1-5, venetoclax PO on days 1-14 and gilteritinib PO on days 8-21 of each cycle. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.~Patients undergo bone marrow biopsy and aspiration as well as blood sample collection on the trial."
89002462|NCT06317636|Active Comparator|Ketamine|A one-time intravenous infusion of ketamine (0.5 mg/kg)
89002463|NCT06317636|Placebo Comparator|Saline|A one-time intravenous infusion of normal saline
89002464|NCT06317623||UTD A1, low risk group|A group of fetuses and children with less severe dilation of the urinary tract in second or third trimester of pregnancy
89002465|NCT06317623||UTD A2-3, high risk group|A group of fetuses and children with severe dilation of the urinary tract in second or third trimester of pregnancy
89002466|NCT06317597|Experimental|Short time interval group:|Bowel preparation for colonoscopy was performed using oral sulfate solution as a laxative
89002467|NCT06317597|Active Comparator|Standard time interval group|Bowel preparation for colonoscopy was performed using oral sulfate solution as a laxative
89002468|NCT06317558||Neoadjuvant immunotherapy|
89002469|NCT06317558||Other neoadjuvant treatment|
89002470|NCT06317545|Experimental|Nirshl exercise with Mulligan Taping|This group will be treated with Nirshl exercises with Mulligan taping
89002471|NCT06317545|No Intervention|Nirshl exercise without Mulligan taping|This group will be treated with Nirshl exercises only.
89002472|NCT06317519||Physical Rehabilitation + GRAIL|Patients in this group receive Physical Rehabilitation and GRAIL treatment
89002473|NCT06317519||Physical Rehabilitation|Patients in this group receive Physical Rehabilitation not GRAIL treatment
89002474|NCT06317506||Children with ID|The presence of intellectual disability will be evaluated according to DSM-V criteria
89002475|NCT06317506||Children without ID|The presence of intellectual disability will be evaluated according to DSM-V criteria
89002476|NCT06317480||bone resection|
89378056|NCT01378806|Experimental|Intervention|A 12-week intensive intervention on nutrition and exercise education and coping skills training (Phase I), 9 months of continued monthly contact (Phase II), and then 6 months on their own.
89378057|NCT01378728||Patients with chronic or acute wounds.|Patients with chronic or acute wounds.
89378058|NCT03147274|Experimental|Intervention Group|Participants in this group will receive 3 group education sessions led by a diabetes nurse educator in addition to standard care.
89002477|NCT06317480||subperiosteal excision|
89002478|NCT06317467||Women with physiological pregnancies|Control group
89002479|NCT06317467||Patients diagnosed for PE|hypertension arisen suddenly after the 20th week of pregnancy with associated proteinuria, greater than or equal to 300 mg/24 hours often corresponding to 30 mg/dL (1+) on a single sample
89002480|NCT06317467||Women affected by SLE, APS, or autoimmune thyroiditis|Patients attending the medically assisted procreation department or the Department of Rheumatology, Division of Internal Medicine, University Medical Centre Ljubljana, Ljubljana, Slovenia
89002481|NCT06317454||Subjects with T1DM|
89002482|NCT06317454||Control subjects|
89002483|NCT06317441|Experimental|Probiotic (High dose)|A low dosage probiotic per capsule
89378059|NCT03147274|No Intervention|Control Group|These participants will receive no intervention. They will have clinic care as usual and will receive three diabetes newsletters to match for attention.
89378060|NCT05278338|Experimental|Group a|JMT103 45 mg
89378061|NCT05278338|Experimental|Group b|JMT103 60 mg
89378062|NCT05278338|Experimental|Group c|JMT103 90 mg
89002484|NCT06317441|Experimental|Probiotic (Low dose)|A high dosage probiotic per capsule
89002485|NCT06317441|No Intervention|Control group (Placebo)|No probiotic dosage
89002486|NCT06317402||patient|Adult patients hospitalized at Pitié Salpêtrière in conventional hospitalization wards
89002487|NCT06317389|Other|Oncoral patients|All adult patients with cancer, treated with oral anticancer drugs and benefiting of the ONCORAL program at the Lyon-Sud hospital
89002488|NCT06317376|Experimental|experimental group (MICT)|MICT 3 session per week with Aerobic exercise on treadmill for 30 minute with moderate intensity.
89002489|NCT06317376|Other|control group (standard protocol)|Perform standard hospital protocol 2-3 session per week
89002490|NCT06317363|Experimental|Experimental Group A (ACAPELLA)|Group A (baseline treatment + acapella)
89002491|NCT06317363|Experimental|Experimental Group B (MANUAL CHEST PHYSIOTHERAPY)|Group B (baseline + manual chest physiotherapy)
89002492|NCT06317337|Experimental|focused ultrasound cavitation augmented with aerobic exercise|Ultrasound cavitation single session per week along with the Aerobic exercises. Aerobic Exercise was Treadmill walk for 30 min with moderate intensity
89002493|NCT06317337|Active Comparator|focused ultrasound cavitation|Ultrasound cavitation single session per week along with 6min walk test.
89002494|NCT06317324||Surgery Group|Diagnosed as primary lung cancer by imaging/pathology, meeting the indications for surgical treatment; The clinical staging is cIB-IIIB stage (cT2-3N0M0), regardless of whether the staging is overestimated or underestimated as confirmed by pathology.
89002495|NCT06317324||SBRT Group|Diagnosed as primary lung cancer by imaging/pathology, meeting the indications for SBRT treatment; The clinical staging is cIB-IIIB stage (cT2-3N0M0), regardless of whether the staging is overestimated or underestimated as confirmed by pathology.
89002496|NCT06317311|Experimental|Dostarlimab- Carboplatin-Paclitaxel followed by Dostarlimab Monotherapy|
89002497|NCT06317298|Experimental|Fruquintinib(3mg) plus Everolimus|Fruquintinib 3mg Qd 21 days on 7 days off; Everolimus 5mg Qd; 28 day cycle until disease progression or intolerable adverse events
89002498|NCT06317298|Experimental|Fruquintinib(4mg) plus Everolimus|Fruquintinib 4mg Qd 21 days on 7 days off; Everolimus 5mg Qd; 28 day cycle until disease progression or intolerable adverse events
89002499|NCT06317298|Experimental|Fruquintinib(5mg) plus Everolimus|Fruquintinib 5mg Qd 21 days on 7 days off; Everolimus 5mg Qd; 28 day cycle until disease progression or intolerable adverse events
89002500|NCT06317285|Experimental|GSK3915393|Participants will receive GSK3915393
89002501|NCT06317285|Experimental|Placebo|Participants will receive placebo.
89002502|NCT06317272|Active Comparator|ABC DIBH|Active Breathing Controlled (ABC) technique for deep breath inspiration hold (DIBH)
89002503|NCT06317272|Experimental|VC DIBH|Voluntary Coached (VC) technique for deep breath inspiration hold (DIBH)
89378063|NCT05278338|Active Comparator|Group d|Denosumab 60 mg
89378064|NCT05278338|Placebo Comparator|Group e|Placebo
89378065|NCT03721757|Other|Nivolumab, Surgery, Radiotherapy|"Patients will be treated with a single dose of nivolumab (240mg flat dose), followed by surgery to remove their tumour within 1-2 weeks.~Based on pathological risk factors determined following surgery, patients will be assigned to undergo adjuvant radiotherapy or chemoradiotherapy. Patients with low risk criteria following surgery will be assigned to radiotherapy.~A single dose of nivolumab (240mg flat dose) will be given between surgery and commencement of radiotherapy (1-2 weeks prior).~Radiotherapy will be administered over 30 fractions i.e. over 30 days (Monday to Friday for 6 consecutive weeks).~Following completion of radiation (within 1-2 weeks), patients will commence adjuvant nivolumab, with a total of 6 doses (480mg flat dose) given at 4 weekly intervals"
89378066|NCT03721757|Other|Nivolumab, Surgery, Chemoradiotherapy|"Patients will be treated with a single dose of nivolumab (240mg flat dose), followed by surgery to remove their tumour within 1-2 weeks.~Based on pathological risk factors determined following surgery, patients will be assigned to undergo adjuvant radiotherapy or chemoradiotherapy. Patients with high risk criteria following surgery will be assigned to chemoradiotherapy.~A single dose of nivolumab (240mg flat dose) will be given between surgery and chemoradiotherapy (1-2 weeks prior).~Chemoradiotherapy will be administered over 30 fractions i.e. over 30 days with concomitant Cisplatin (100mg/m2) on day 1 and 21.~Following completion of radiation (within 1-2 weeks), patients will commence adjuvant nivolumab, with a total of 6 doses (480mg flat dose) given at 4 weekly intervals."
89378067|NCT02352376|Other|Conventional ventilator|30 minutes of non-invasive ventilation was performed with conventional ventilator.The order of the procedures was determined by randomization.
89378068|NCT02352376|Other|Specific ventilator|30 minutes of non-invasive ventilation was performed with specific respirator. The order of the procedures was determined by randomization.
88851055|NCT01624974|Experimental|MK-1029/Placebo|Participants received 4 weeks treatment with MK-1029 150 mg once daily (QD) + ML 10 mg QD in Period III and Placebo QD + ML 10 mg QD in Period V. Period IV was a 4-week wash-out period during which participants received single-blind Placebo QD and open-label ML 10 mg QD.
89378069|NCT03727607|Active Comparator|Gass|DESFLURANE ANESTHESIA
89378070|NCT03727607|Active Comparator|TIVA|TOTAL INTRAVENOUS ANESTHESIA
88851056|NCT01624974|Experimental|Placebo/MK-1029|Participants received 4 weeks treatment with Placebo QD + ML 10 mg QD in Period III and MK-1029 150 mg QD + ML 10 mg QD in Period V. Period IV was a 4-week wash-out period during which participants received single-blind Placebo QD and open-label ML 10 mg QD.
88851057|NCT02065518|Active Comparator|Standard Rehabilitation Protocol (SRP)|All participants will receive the current standard of care, the physical therapy rehabilitation protocol for knee injuries at the WRNMMC and MGMCSC sites. This program includes treatment supervised by a physical therapist at the physical therapy clinics.
88851058|NCT02065518|Experimental|NMES w/ SRP|In addition to the standard rehabilitation protocol, two treatment groups will receive a portable lightweight device (300PV unit) that provides clearly defined electrical stimuli. NMES training will consist of performing four 30-minute stimulation sessions per week for 12 weeks; each 30-minute session will entail 15 minutes/leg with 15 contractions per leg. Each contraction will be elicited by an electrical impulse (300PV) generated by a battery-operated device (EMPI, St. Paul, MN).
88851059|NCT02065518|Experimental|Strength Walking w/ SRP|The Strength Walking groups will participate in a Home-Based Pedometer-Driven Walking Program. All participants in this group will be given a pedometer to monitor their daily steps and, at week 7, a weighted exercise vest to begin the strengthening component. In addition to the standard WRNMMC rehabilitation protocol, a series of 10-minute lessons focused on increasing physical activity through lifestyle education and the use of a pedometer as a motivational tool and personal fitness tracker will be incorporated into their testing sessions for the first 6 weeks. At week 7, participants will be given a weighted vest to begin the strengthening component.
88851060|NCT02065518|Experimental|NMES/Strength Walking w/ SRP|In addition to the standard rehabilitation protocol, one group will receive NMES training and will participate in a Home-Based Pedometer-Driven Walking Program. This group will follow the protocol for both the NMES training and Strength Walking.
88851061|NCT01624662|Active Comparator|OPN-375 100 mcg|Double-Blind Treatment Phase: OPN-375 100 mcg BID x 16 weeks; Open-Label Extension Phase: OPN-375 400 mcg BID x 8 weeks
88851062|NCT01624662|Active Comparator|OPN-375 200 mcg|Double-Blind Treatment Phase: OPN-375 200 mcg BID x 16 weeks; Open-Label Extension Phase: OPN-375 400 mcg BID x 8 weeks
88851063|NCT01624662|Active Comparator|OPN-375 400 mcg|Double-Blind Treatment Phase: OPN-375 400 mcg BID x 16 weeks; Open-Label Extension Phase: OPN-375 400 mcg BID x 8 weeks
88851064|NCT01624662|Placebo Comparator|Placebo|Double-Blind Treatment Phase: Matched Placebo BID x 16 weeks; Open-Label Extension Phase: OPN-375 400 mcg BID x 8 weeks
89378071|NCT01310933||Kikuchi's disease|
89378072|NCT01310933||Malignant lymphoma|
89378073|NCT05157516|Active Comparator|group ESPB|Erector Spinae Plane Block
89378074|NCT05157516|Active Comparator|In group CEA|Caudal epidural block
89378075|NCT02348242|Experimental|Aqueous gel|In the same patient : one eye receives regular administration of aqueous gel (experimental treatment 1) and the other eye receives regular administration of artificial tears (active comparator)
89378076|NCT02348242|Experimental|Eyelid occlusion dressing|In the same patient : one eye is closed with an eyelid closure dressing (experimental treatment 2) and the other eye receives regular administration of artificial tears (active comparator)
89378077|NCT04187092|Experimental|KneeBright group|Participants in this group will perform exercises aimed to improve the muscle strength, balance and precision. Participants will perform exercises three times a week for 12 weeks. Each session will last for an hour. Some of the exercises will be performed with the KneeBright Device while playing a video game.
89378078|NCT04187092|Active Comparator|Standard Rehabilitation group|Participants in this group will perform exercises with the same focus and frequency. No exercises will be performed with the KneeBright device.
89378079|NCT05084976||Pediatric Technology Dependent Patients at Cohen Children's Medical Center|
89378080|NCT05084976||Pediatric Technology Dependent Patients at Ann & Robert H. Lurie Children's Hospital of Chicago|
89378081|NCT01377090||SSc DU-history subgroup|Systemic sclerosis patients with history of digital ulcers
89378082|NCT01377090||SSc with No-DU-history subgroup|Systemic sclerosis patients with no history of digital ulcers
89378083|NCT02352142|No Intervention|Standard Care|Mothers are given infant care instruction as part of standard care
89378084|NCT02352142|Experimental|Facilitated infant care|Family Nurture Intervention
89378085|NCT02352142|Other|Full Term EEG|Small group of healthy, Full-Term infants will receive two sleep EEGs (one in unit, and one 4 weeks post discharge) for healthy control comparison to preterm infants
89378086|NCT02896127|Experimental|Secukinumab|"Secukinumab 150 mg s.c.~Arm includes all patients who received at least 1 dose of study drug including placebo switchers at Week 16"
89378087|NCT02896127|Placebo Comparator|Placebo|Placebo s.c.
89378088|NCT02351986|Experimental|Subacromial Impingement Syndrome|Subjects between 18 to 45 years, with Subacromial Impingement Syndrome at least one week.
89378089|NCT02351986|No Intervention|Control|Healthy subjects between 18 to 45 years.
89378090|NCT03153592|Active Comparator|conventional ventilation strategy|13 patients will undergo volume controlled ventilation set with a tidal volume between 6-8 ml/kg of ideal body weight, positive end-expiratory pressure and fraction of inspired oxygen set to obtain a peripheral saturation in oxygen equal or greater than 94% and a plateau pressure <28 cmH2O.
89378091|NCT03153592|Experimental|transpulmonary pressure strategy|13 patients will undergo volume controlled ventilation set with a tidal volume at 6-8 ml/kg of ideal body weight, and with a inspiratory transpulmonary pressure less than 20 cmH2O and an expiratory transpulmonary pressure and inspired oxygen set accordingly to predefined criteria.
89378092|NCT03724097||Group 1|Patients receiving target drugs with the score value above 0,1 as monotherapy or in combination
89378093|NCT03724097||Group 2|Patients receiving only non-target drugs or target drugs with the score value equal to or below 0,1 as monotherapy or in combination
88851065|NCT01624506||Magnetic Sphincter Augmentation|Patients will be treated with magnetic sphincter augmentation via the LINX Reflux Management System
89378094|NCT03724097||Group 3|Patients receiving palliative care
89378095|NCT03157414|Active Comparator|Empagliflozin|10 mg once daily for 24 weeks
89378096|NCT03157414|Placebo Comparator|Placebo|1 capsule once daily for 24 weeks
89378097|NCT03157024|Experimental|Sham Press Needle - Ring Sham (RS)|A sterilised stainless steel press needle that only has the ring-shaped head of needle without needle body has three layers of adhesive tape. Between the first and second layer is the head of needle to support needle body while maintaining identical appearance and the third layer is attached to skin. RS will be placed on 1 cm medial to acupoint LI11 and ear wrist, a non-specific control auricular acupoint used in the previous literature of the non-dominant side. An acupoint detector (personal TENS electronic acupuncture, Hammtek Korea, Seoul, Korea) will be used to locate points with lower skin impedance than those nearby.
89378098|NCT03157024|Active Comparator|Real Needle (RN)|A sterilised stainless steel press needle (diameter 0.18 mm X length 1.5 mm, Dongbang Acupuncture Inc., Boryeong, Chungcheongnam-do, Korea) has three layers of adhesive tape. Between the first and second layer is the head of needle to support needle body and the third layer is attached to skin. RN will be placed on acupoint LI11 and ear shenmen of the non-dominant side. An acupoint detector (personal TENS electronic acupuncture, Hammtek Korea, Seoul, Korea) will be used to locate points with lower skin impedance than those nearby.
89378099|NCT03157024|Sham Comparator|Kim Sham (KS)|A sterilised stainless steel press needle (diameter 0.18 mm X length 1.5 mm, Dongbang Acupuncture Inc., Boryeong, Chungcheongnam-do, Korea) with a blunted tip has three layers of adhesive tape. Between the first and second layer is the head of needle to support needle body while maintaining identical appearance and the third layer is attached to skin. KS will be placed on 1 cm medial to acupoint LI11 and ear wrist, a non-specific control auricular acupoint used in the previous literature of the non-dominant side. An acupoint detector (personal TENS electronic acupuncture, Hammtek Korea, Seoul, Korea) will be used to locate points with lower skin impedance than those nearby.
89378100|NCT03546647|Experimental|Toric, Then Sphere|Participants who received Toric contact lenses first and spherical lenses after 10 days
89378101|NCT03546647|Experimental|Sphere, Then Toric|Participants who received Spherical contact lenses first and Toric lenses after 10 days
89378102|NCT03156478|No Intervention|Control group|At baseline, individuals in the control group receive digital information package about lifestyle risk factors of type 2 diabetes with recommendations on healthy diet and physical activity in accordance with the Finnish Nutrition Recommendations and the national recommendation for health enhancing physical activity.
89378103|NCT03156478|Experimental|Digital lifestyle intervention group|Participants are instructed to use a digital self-help tool for 12 months. This tool is developed in the StopDia-study to enact positive changes in participant's health behaviour. The digital intervention consists of 2 components which motivate, enable and trigger the participants to improve their health behaviours. B.J. Fogg's Tiny Habits -ideology. The digital intervention is based on the Fogg Behaviour Model (FBM) and the Behaviour Wizard.
89378104|NCT03156478|Experimental|Combined digital and face-to-face lifestyle intervention group|Participants are using the StopDia digital solution tool as described above. In addition, they have six face-to-face group coaching (6-15 participants/group) sessions at local health centers facilitated by trained nurses. The face-to-face group intervention is based on the Self-Determination Theory and theories of self-regulation, and delivered using intrinsic motivational coaching approach designed and tested in the GOAL lifestyle intervention, and further developed in several other studies in Finland and internationally.
89378105|NCT03727529|Experimental|Intervention group|
89378106|NCT03727529|Active Comparator|Control group|
88851066|NCT01624506||Fundoplication|Patients treated with laparoscopic fundoplication
89399426|NCT03690141|Experimental|tomivosertib (eFT508)|Tomivosertib (eFT508) is a novel small-molecule, investigational drug being developed by eFFECTOR Therapeutics, Inc. as an anticancer therapy. Tomivosertib (eFT508) down regulates AR and acts by inhibiting mitogen-activated protein kinase-interacting serine/threonine kinase-1 (MNK1) and MNK2.
89399427|NCT02175524||Case|Patients proved to be oral and esophageal cancer and had the habit of areca nut chewing.
88851067|NCT02106390|Experimental|rMenB+ACWY|Approximately 250 healthy infants who will be vaccinated at 3, 5, 7 and 13 months of age.
88851068|NCT02106390|Active Comparator|rMENB|Approximately 250 healthy infants who will be vaccinated at 3, 5, 7 and 13 months of age.
88851069|NCT02106390|Active Comparator|MenACWY|Approximately 250 healthy infants who will be vaccinated at 3, 5, 7 and 13 months of age.
88851070|NCT02064894|Experimental|oral morphine and oral ibuprofen|Oral morphine (syrup) 0.2mg/kg (max. 15 mg) and oral ibuprofen (syrup) 10mg/kg (max. 600 mg) both administered once during the 2 hour-study time frame
88851071|NCT02064894|Experimental|morphine and placebo of ibuprofen|Oral morphine 0.2mg/kg (max. 15 mg) and a placebo of ibuprofen both administered once during the 2-hour time frame of the study
88851072|NCT02064894|Active Comparator|ibuprofen and placebo of morphine|Ibuprofen 10mg/kg (max. 600 mg) and placebo of morphine both administered once during the 2-hour time frame of the study
88851073|NCT04707768|Experimental|Vadadustat low dose|Participants previously receiving Mircera® received vadadustat for up to 52 weeks with an initial dose of 600 milligrams (mg).
88851074|NCT04707768|Experimental|Vadadustat high dose|Participants previously receiving Mircera® received vadadustat for up to 52 weeks with an initial dose of 900 mg.
88851075|NCT04707768|Active Comparator|Mircera®|Participants will continue to receive Mircera® for up to 52 weeks.
88851076|NCT02081586|Experimental|6 Weeks Phone CBT plus smartphone app|Following baseline, six 30-minute sessions of phone CBT to address any beliefs, assumptions, attitudes, or perceptions that are not constructive to diabetes self-management. CBT phone app will assist patients to practice skills related to improving self-management via more constructive ways of thinking.
89378107|NCT01310543|Experimental|Teens and Toddlers|The T&T intervention aims to prevent teenage pregnancy and promote sexual health by providing young women at risk of teenage pregnancy with regular and direct contact with a toddler and combines this with 12 modules of group-based personal-development sessions involving communication skills, anger management, discussion of positive sexual health and relationships, culminating in an accredited National Award in Interpersonal Skills. One-to-one life coaching is also provided. The intervention consists of 20 weekly afternoon sessions run in nurseries near to the secondary schools from which participating young women are recruited.
89378108|NCT01310543|No Intervention|Comparison|Girls in the comparison group will continue with their normal afternoon of schooling, which is missed by girls attending the T&T intervention for the 20 weeks of their attendance.
89378109|NCT02348164|Experimental|Treatment 1|Volunteers receive pink grapefruit first followed by tangerines two weeks later
89378110|NCT02348164|Experimental|Treatment 2|Volunteers receive tangerines first followed by pink grapefruit two weeks later
89378111|NCT03147196|Experimental|Arm A (raloxifene hydrochloride)|Patients receive low dose raloxifene hydrochloride PO daily on days 1-30. Treatment repeats every 30 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
89378112|NCT03147196|Experimental|Arm B (bicalutamide)|Patients receive low dose bicalutamide PO daily on days 1-30. Treatment repeats every 30 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
89378113|NCT03147196|Experimental|Arm C (raloxifene hydrochloride, bicalutamide)|Patients receive low dose raloxifene hydrochloride PO daily and low dose bicalutamide PO on days 1-30. Treatment repeats every 30 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
89378114|NCT03147196|Experimental|Arm D (raloxifene hydrochloride, bicalutamide)|Patients receive high dose raloxifene hydrochloride PO daily and high dose bicalutamide PO on days 1-30. Treatment repeats every 30 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
89378115|NCT03153436|Active Comparator|Normal S.A group|Infertile men with normal semen analysis. each sample is divided into 2 identical aliquots: one aliquot (Myo aliquot) is supplied with myoinositol, The other aliquot is left as it is (control aliquot).
89378116|NCT03153436|Active Comparator|Abnormal S.A group|Infertile men with abnormal semen analysis. each sample is divided into 2 identical aliquots: one aliquot (Myo aliquot) is supplied with myoinositol, The other aliquot is left as it is (control aliquot).
89378117|NCT03077412|Experimental|Filgotinib 200 mg|Filgotinib 200 mg + placebo to match filgotinib 100 mg for 24 weeks
89378118|NCT03077412|Experimental|Filgotinib 100 mg|Filgotinib 100 mg + placebo to match filgotinib 200 mg for 24 weeks
88851077|NCT02081586|Experimental|8 Weeks Phone CBT plus smartphone app|Following baseline, patients will receive 8 weeks of phone CBT to address non-constructive beliefs, assumptions, attitudes or perceptions related to diabetes self-management. They will have a smartphone apps to practice CBT skills between sessions.
88851078|NCT02081586|Experimental|12 weeks phone CBT plus smartphone app|Following baseline, patients will receive 12 weeks of phone CBT to address non-constructive beliefs, assumptions, attitudes or perceptions related to diabetes self-management. They will have a smartphone apps to practice CBT skills between sessions.
89378119|NCT03077412|Experimental|Placebo|Placebo to match filgotinib 200 mg + placebo to match filgotinib 100 mg for 24 weeks
89378120|NCT03544229|Placebo Comparator|Placebo|TAK-906 maleate placebo-matching capsules, orally, twice daily (BID) for up to 12 weeks.
89378121|NCT03544229|Experimental|TAK-906 Maleate 5 mg|TAK-906 maleate 5 mg, capsules, orally, BID for up to 12 weeks.
89378122|NCT03544229|Experimental|TAK-906 Maleate 25 mg|TAK-906 maleate 25 mg, capsules, orally, BID for up to 12 weeks.
89378123|NCT03544229|Experimental|TAK-906 Maleate 50 mg|TAK-906 maleate 50 mg, capsules, orally, BID for up to 12 weeks.
89378124|NCT02353312|Experimental|Initial Intervention Arm|Kuvan® supplementation in addition to standard care for heart failure for three months. At the end of three months, stop Kuvan®, patients will only receive Standard care for heart failure for another 3 months
89378125|NCT02353312|Active Comparator|Delayed Intervention Arm|Standard care for heart failure for three months. At the end of three months, Starting Kuvan® supplementation in addition to Standard care for heart failure for another 3 months
89378126|NCT02351908|Experimental|Arm 1|Stribild® (Tenofovir Disoproxil Fumarate, Elvitegravir, Cobicistat150mg/150mg/200mg/245mg) tablet 1 once daily for 48 weeks
89378127|NCT02351908|Experimental|Arm 2|Isentress® (Raltegravir 400 mg) 1 tablet twice a day + Truvada® (FTC & Tenofovir) 1 tablet once a day for 48 weeks
89378128|NCT02351908|Experimental|Arm 3|Tivicay® (Dolutegravir 50 mg) 1 tablet once a day + Truvada® (FTC & Tenofovir) 1 tablet once a day for 48 weeks
89378129|NCT02353390|Active Comparator|Oral Water Hydration|Subjects will be given up to 15 minutes to drink up to 500 mL of water prior to the first IM vaccination.
89378130|NCT02353390|No Intervention|Usual Care|Subjects will receive usual care prior to the first IM vaccination. No water or food will be offered.
89378131|NCT02352064|Experimental|PET-CT at day 150+/-15 days|Patient will have PET (18-FDG) following allogeneic stem cell transplantation
88851079|NCT02081586|Active Comparator|Standard Diabetes Care at PCP|Patients will remain in usual care and not receive study intervention. This will include usual diabetes care at PCP.
89378132|NCT03078816|Experimental|DBS active|"All participants will be enrolled in DBS placement and active stimulation. The following components will be used:~Activa PC Primary Cell Neurostimulator - (Model 37601)~Activa RC Rechargeable Neurostimulator - (Model 37612)~Activa SC Single Cell Neurostimulator (Models 37602 and 37603)~DBS Lead - (Model 3387)~DBS Extension - (Models 37085/6)~Patient Programmer - (Model 37642)~Test Stimulator - (Model 3625)~N'Vision Clinician Programmer - (Model 8840)~N'Vision Software Application Card - (Model 8870)"
89378133|NCT02039128|Experimental|Krill oil|1 gram per day in 12 weeks
89378134|NCT02039128|Active Comparator|Fish oil|1 gram per day in 12 weeks
89378135|NCT02039128|Placebo Comparator|Placebo|1 gram per day in 12 weeks
88851080|NCT02081196|Experimental|CoolSculpting of the Flank With Alternate Treatment Parameters|Each subject served as their own control with 1 flank treated with CoolSculpting; the contralateral flank was untreated.
88851081|NCT02064816|Experimental|Rebif® Morning Administration|
89378136|NCT03723941|Experimental|A - adjuvant therapy|adjuvant therapy with four cycles of cisplatin plus etoposide +/- mitotane according to investigator's preference versus
89378137|NCT03723941|Other|B - observation or mitotane alone|observation or mitotane alone according to the investigator's preference
89378138|NCT03153046|Experimental|Prebiotics|12 week ingestion of prebiotics, Bimuno galacto-oligosaccharide (B-GOS).
89378139|NCT03153046|Placebo Comparator|Maltodextrin|12 week ingestion of maltodextrin
89378140|NCT03155698|Experimental|microneedling,NB-UVB with & without PRP|"Each participant will be compared with one side of the body to the other side~Intervention:~Combination Product: microneedling and Platelet rich plasma.~radiation : NB-UVB phototherapy"
89378141|NCT03723863|Experimental|Supportive care (Occupational therapy)|Patients receive in-person occupational therapist-led work consultation
89378142|NCT03155308||Polyp group|Consecutive adult patients between 18 and 80 years of age, referred for elective outpatient colonoscopy and in whom polypectomy or biopsy is perform will be enrolled to be evaluated using Pentax chromoendoscopy (i-scan and Optical Enhancement)
89378143|NCT03721679|Experimental|Poly-ICLC treatment combination aPD-1or aPD-1L1|"Weeks 1 and 2: Poly-ICLC (Hiltonol®) 1 mg (0.5 ml) IM ONLY twice a week with a 48-72 hour interval between the two injections~Weeks 3-25:~Poly-ICLC (Hiltonol®) 1 mg (0.5 ml) IM twice a week with a 48-72 hour interval between the two injections, AND~ONLY 1 of the following regimens will be administered, per manufacturer's dosing and clinical oncologist's discretion as follows:~Nivolumab (Opdivo), OR~Pembrolizumab (Keytruda), OR~Cemiplimab (Libtayo) OR~Atezolizumab (Tecentriq) OR~Durvalumab (Imfinzi) Follow up: After completion of treatment subjects may be contacted by telephone at least twice over 12 months, or longer with patient consent, in order to inquire on their health status (e.g., in remission, progressive disease, on new cancer treatment)."
89378144|NCT04674228||Observational (medical record review)|Patients who participated in MAY2016-07-01 undergo review of medical records.
89378145|NCT03639948|Experimental|Experimental: Carboplatin & Docetaxel plus Pembroluzimab|"Carboplatin (Area under the curve [AUC] 6 intravenously [IV]) and Docetaxel (75 milligrams per meter squared [mg/m2], IV) plus Pembrolizumab (200 milligrams [mg], IV) every 21 days for 6 cycles.~Pegfilgrastim 6 mg subcutaneous (SC) Day 2 of each cycle."
88851082|NCT02064816|Experimental|Rebif® Evening Administration|
88851083|NCT02080260|Experimental|Single Arm|Oral Regorafenib
88851084|NCT01624194|Active Comparator|Oxytocin nasal spray|Prior to randomization, all subjects will participate in a 1-week open-label placebo lead-in trial. Each subject will be administered the placebo nasal spray at Stanford University and then their parent will continue administering the nasal spray to the subject for 1 week at home. Each subject will then be randomly assigned either to the active group or to the placebo (stratified by gender) and will be given the appropriate nasal spray bottle and their parents will be responsible for administering 3 puffs per nostril (4 IU/puff) to their child for a total dose of 24 IU oxytocin or placebo twice daily (BID; morning and evening) for 4-weeks. On completion of this 4-week treatment trial subjects will have the option of participating in a second double-blind trial in which they will be assigned to the alternate nasal spray, to that which they received during the first 4-week trial, for an additional 4-week period.
88851085|NCT01624194|Placebo Comparator|Placebo nasal spray|The placebo nasal spray bottles will be prepared by adding all of the ingredients used in the Syntocinon nasal sprays with the exception of the concentrated oxytocin solution.
88851086|NCT02079636|Experimental|Abemaciclib + Pemetrexed|150 milligram (mg) or 200 mg abemaciclib given orally every 12 hours on Days 1 through 21 of a 21-day cycle in combination with 500 milligrams/square meter (mg/m^2) pemetrexed given intravenously (IV) over approximately 10 minutes on Day 1 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
88851087|NCT02079636|Experimental|Abemaciclib + Gemcitabine|150 mg or 200 mg abemaciclib given orally every 12 hours on Days 1 through 21 of a 21-day cycle in combination with 1250 milligram/square meter (mg/m^2) gemcitabine given intravenously over approximately 30 minutes on Days 1 and 8 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
88851088|NCT02079636|Experimental|Abemaciclib + Ramucirumab|150 mg or 200 mg abemaciclib given orally every 12 hours on Days 1 through 21 of a 21-day cycle in combination with 10 milligram/kilogram (mg/kg) ramucirumab given intravenously over approximately 60 minutes on Day 1 or 8 to 10 milligram/kilogram (mg/kg) ramucirumab given intravenously over approximately 60 minutes on Days 1 and 8 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
88851089|NCT02079636|Experimental|Abemaciclib + LY3023414|100 mg or 150 mg or 200 mg abemaciclib given orally every 12 hours on Days 1 through 21 of a 21-day cycle in combination with 100, 150, or 200 mg LY3023414 given orally every 12 hours on Days 1 through 21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
88851090|NCT02079636|Experimental|Abemaciclib + Pembrolizumab|100 mg or 150 mg abemaciclib given orally every 12 hours on Days 1 through 21 of a 21-day cycle in combination with 200 mg pembrolizumab given intravenously over approximately 30 minutes on day 1 of a 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
89378146|NCT03146728||tetraplegia, paraplegia|motor complete spinal cord injured individuals with tetraplegia or paraplegia
89378147|NCT03146728||able-bodied|age height and weight matched able bodied
89378148|NCT02347852||Physical activity / Cohort 1|The non influenced and non triggered habitual physical activity of patients will be assessed by pedometer and physical activity questionnaire. The study population will consist of patients with metastatic CRC (mCRC) who are included in the NIS CORRELATE, have been previously treated with other approved regimens for metastatic disease and for whom a decision has been made by the physician to treat with regorafenib according to local health authority approved label prior to and independent of the inclusion into this observational study.
88851091|NCT02079246|Experimental|Idalopirdine (Lu AE58054) 60 mg|Idalopirdine 60 mg adjunct to 10 mg donepezil. The dose of idalopirdine could be decreased from 60 mg to 30 mg if 60 mg was not well tolerated. The dose of donepezil was to be maintained throughout the study.
88851092|NCT02079246|Experimental|Idalopirdine 60 mg + memantine|Idalopirdine 60 mg as adjunct to 10 mg donepezil and memantine (patient's individualised maintenance dose, either immediate-release (IR) 20 mg/day (recommended target dose) or extended release (XR) 28 mg/day (recommended target dose). Memantine was administered to approximately 100 patients included in the OLEX-MEM. The dose of idalopirdine could be decreased from 60 mg to 30 mg if 60 mg was not well tolerated. The dose of donepezil was to be maintained throughout the study. The dose of memantine could be changed at any time throughout the study.
88851093|NCT02077374|Experimental|IDN-6556|IDN-6556 capsules, 25 mg BID
88851094|NCT02077374|Placebo Comparator|Placebo|Placebo BID
88851095|NCT02077140|Experimental|MDT-10013|Subjects will receive MDT-10013.
88851096|NCT02077140|Active Comparator|Standard of Care|Subjects will receive standard of care.
88851097|NCT02047110|Placebo Comparator|Placebo|Subcutaneous injection of Placebo (solution for injection matching risankizumab, 1 mL pre-filled syringe) administered every 8 weeks (At Day1 and at Weeks 8, 16, and 24) up to 4 times during the regular treatment period.
88851098|NCT02047110|Experimental|Risankizumab 18 mg|Subcutaneous injection of risankizumab 18 mg administered every 8 weeks at Day 1 only, followed by placebo every 8 weeks (i.e. at Week 8, 16 and 24), up to a total duration of 24 weeks
88851099|NCT02047110|Experimental|Risankizumab 90 mg|Subcutaneous injection of risankizumab 90 mg administered every 8 weeks (At Day1 and at Weeks 8, 16, and 24) up to 4 times during the regular treatment period
88851100|NCT02047110|Experimental|Risankizumab 180 mg|Subcutaneous injection of risankizumab 180 mg administered every 8 weeks (At Day1 and at Weeks 8, 16, and 24) up to 4 times during the regular treatment period
88851101|NCT02046564|Experimental|ASC-01|The dose of 3-12mg/100mg(Aripiprazole/Sertraline Combination)will be orally administered once daily
88851102|NCT02046564|Placebo Comparator|Placebo|The dose of 0mg/100mg (Placebo/Sertraline Combination ）will be orally administered once daily
88851103|NCT02046174|Experimental|Macrobead Implantation Arm|patients who will undergo up to 4 implantations of RENCA macrobeads (no less than 3 months apart), at an amount of 8 RENCA macrobeads per kilogram of body weight
88851104|NCT02046174|No Intervention|Best Supportive Care Arm|patients who will receive, or continue receiving, best supportive care, defined as management of symptoms aimed at maintaining or improving quality of life, but not including approved therapies targeting the patient's malignancy
88851105|NCT02045862|Active Comparator|Mirabegron 50 mg|Participants received mirabegron 50 mg once a day for 52 weeks.
88851106|NCT02045862|Active Comparator|Solifenacin 5 mg|Participants received solifenacin 5 mg once a day for 52 weeks.
88851107|NCT02045862|Experimental|Solifenacin 5 mg + Mirabegron 50 mg|Participants received solifenacin 5 mg and mirabegron 50 mg once a day for 52 weeks.
89182522|NCT06240026|Experimental|transauricular Vagal Nerve Stimulation|NEMOS taVNS electrodes will be placed in the left concha cymba of participants (CerboMed GmbH, Erlangen, Germany). When appropriate, these electrodes will be plugged into a digitimer. Whilst pulse width, frequency, stimulation burst and total duration will be respectively standardized to 200microseconds, 20Hz, 30seconds on and 30seconds off and 20minutes, the stimulation will be person specific. To acquire this intensity, participants will perform a thresholding protocol. Based on an elegant stair-case algorithm, the perception and pain (described as a 7/10 pain level, where 10 is the most amount of pain imaginable) thresholds will be obtained. Stimulation intensity will then be defined as 2/3 the range between these thresholds. For example, if the perception and pain thresholds are respectively at 2mA and 8mA, the stimulation intensity would be 6mA.
89182523|NCT06240026|Active Comparator|Earlobe Stimulation|A 0.5cm and a 1cm diameter round electrode (Ambu, Neuroline, Bordeaux, France) will respectively be placed on the front and back of the earlobe. When appropriate, these electrodes will be plugged into a digitimer . Whilst pulse width, frequency, stimulation burst and total duration will be respectively standardized to 200microseconds, 20Hz, 30seconds on and 30seconds off and 20minutes, the stimulation will be person specific. To acquire this intensity, participants will perform a thresholding protocol. Based on an elegant stair-case algorithm, the perception and pain (described as a 7/10 pain level, where 10 is the most amount of pain imaginable) thresholds will be obtained. Stimulation intensity will then be defined as 2/3 the range between these thresholds. For example, if the perception and pain thresholds are respectively at 2mA and 8mA, the stimulation intensity would be 6mA.
89182524|NCT06240013|Experimental|Group 1 Training Program|5 minutes of light aerobic cycling, unilateral 4*30 sec on dominant leg - 2 min foam rolling training in total
89399428|NCT02175524||Control|Patients proved to be oral and esophageal cancer and did not have the habit of areca nut chewing.
88851108|NCT02075658|Other|Conventional Insufflation and Trocars|Subjects enrolled in this study arm will have their procedure performed using either the conventional insufflator and trocars. This system have been cleared for use by the FDA's 510 (k)process and are currently employed in clinical practice, including at UC Irvine Medical Center.
88851109|NCT02075658|Active Comparator|AirSeal® System-Interventional|The AirSeal® System consists of an insufflation, filtration, and recirculation system (AirSeal® IFS), a triple lumen filtered tube set, and a valve free trocar (AirSeal® Access Port).
89378149|NCT02351674||Heart rate ≤70bpm|15,000 patients in the retrospective cohort will be divided into 4 groups according to their mean heart rate during PCI. Group 1 will be defined as subjects' mean heart rate ≤70 BPM.
89378150|NCT02351674||Heart rate between 71 to 80bpm|15,000 patients in the retrospective cohort will be divided into 4 groups according to their mean heart rate during PCI. Group 2 will be defined as subjects' mean heart rate between 71 to 80bpm.
89378151|NCT02351674||Heart rate between 81 to 90bpm|15,000 patients in the retrospective cohort will be divided into 4 groups according to their mean heart rate during PCI. Group 1 will be defined as subjects' mean heart rate between 81 to 90bpm.
89378152|NCT02351674||Heart rate>90bpm|15,000 patients in the retrospective cohort will be divided into 4 groups according to their mean heart rate during PCI. Group 4 will be defined as subjects' mean heart rate>90bpm
88851110|NCT02063880|Experimental|Urgent ART|"Initiation of highly active antiretroviral therapy (HAART) within 48 hours of enrollment.~Antiretroviral therapy will include regimens recommended by the Kenyan Ministry of Health."
88851111|NCT02063880|Active Comparator|Early ART|Initiation of HAART 7-14 days after enrollment.
88851112|NCT02044848|Experimental|Secukinumab|Secukinumab will be delivered as part of an induction regimen followed by a maintenance regimen for up to 1 year
88851113|NCT02044848|Placebo Comparator|Placebo|Placebo will be delivered as part of an induction regimen followed by a maintenance regimen for up to 1 year
89378153|NCT02347696|Other|Control|The subjects will follow a diet based on INRAN guidelines without doing any physical activity.
88851114|NCT04182984||Patients with autoimmune ocular MG|Newly-onset OMG patients who agreed to join the follow-up cohort
88851115|NCT02044302|Active Comparator|standard analgesics|Current standard post-operative care for expander-implant breast reconstruction surgery consists of conventional pain medications including narcotics (like morphine, etc.) and sedatives (like valium). Placebo application during surgery will be made to establish perfection in the study design in terms of randomization and blinding. Injections will be done intramuscularly to the main chest muscle (pectoralis major) by the surgeon.
88851116|NCT02044302|Experimental|standard analgesics and bupivacaine|Current standard post-operative care for expander-implant breast reconstruction surgery consists of conventional pain medications including narcotics (like morphine, etc.) and sedatives (like valium). Patients will receive through an injection into the chest 10 ml (about 2 teaspoons) of 0.5% bupivacaine during surgery. Injections will be done intramuscularly to the main chest muscle (pectoralis major) by the surgeon.
88851117|NCT02044302|Experimental|standard analgesics and botulinum toxins|Current standard post-operative care for expander-implant breast reconstruction surgery consists of conventional pain medications including narcotics (like morphine, etc.) and sedatives (like valium). Patients will receive through an injection into your chest 50 U of Botox diluted in 4ml (about 1 teaspoon) of normal saline per breast during your operation. Injections will be done intramuscularly to the main chest muscle (pectoralis major) by the surgeon.
88851118|NCT02044302|Experimental|standard analgesics, bupivacaine and botulinum toxins|Current standard post-operative care for expander-implant breast reconstruction surgery consists of conventional pain medications including narcotics (like morphine, etc.) and sedatives (like valium). Patients will receive through an injection into your chest 10 ml (about 2 teaspoons) of 0.5% bupivacaine and 50 U of Botox diluted in 4ml (about 1 teaspoon) of normal saline per breast during the operation. Injections will be done intramuscularly to the main chest muscle (pectoralis major) by the surgeon.
88851119|NCT02062944|Experimental|Single-arm study Sirolimus Withdrawal|SRL minimization will be performed if clinically, biochemically and histologically stable. Patients entering the minimization phases will be reduced every month by 50% of total dose of Sirolimus until they reach .5mg daily for one month. Then .5 mg every other day, then twice weekly, the once weekly dosing. This should take approximately 6 month to complete minimization. Liver function tests will be monitored every 2 weeks. For any patient developing liver dysfunction, liver biopsy will be performed. Patients will then be completely withdrawn and followed post-withdrawal for 12 months.
88851120|NCT02062632|Experimental|Group I (doxepin hydrochloride)|Patients receive doxepin hydrochloride oral solution (swish, gargle for 30 seconds, and slowly swallow) on day 1. Patients then crossover to Arm II on day 3.
88851121|NCT02062632|Placebo Comparator|Group II (placebo)|Patients receive placebo oral solution (swish, gargle for 30 seconds, and slowly swallow) on day 1. Patients then crossover to Arm I on day 3.
89378154|NCT02347696|Other|LGIMD|The subjects will follow a Low Glycemic Index Mediterranean Diet without doing any physical activity.
89378155|NCT02347696|Other|Endurance Activity (EA)|The subjects will follow a program of endurance (aerobic) activity (EA) without following a specific diet.
89378156|NCT02347696|Other|EA+Resistance Training (RT)|The subjects will follow a program of endurance activity (EA) and resistance training (RT) without following a specific diet.
89378157|NCT02347696|Other|LGIMD+EA|The subjects will follow a Low Glycemic Index Mediterranean Diet (LGIMD) togheter with a program of endurance activity (EA).
89378158|NCT02347696|Other|LGIMD+EA/RT|The subjects will follow a Low Glycemic Index Mediterranean Diet (LGIMD) togheter with a program of endurance activity (EA) and resistance training (RT).
89378159|NCT04879914|Experimental|Butyrate|Patients taking butyrate
89378160|NCT04879914|Experimental|Placebo|Patients taking placebo
89378161|NCT02353234|Active Comparator|WHOLEGRAIN BREAD|Subjects feed with wholegrain bread, for which ferulic acid content has been quantified.
88851122|NCT02062398|Experimental|The Reprieve system implantation|The Reprieve implant will be implanted for eligible patients. Implant parameter settings will be set according to patient's sensations.
88851123|NCT02061540|Experimental|LUM001|LUM001 administered orally once each day
88851124|NCT02043366|Placebo Comparator|Normal Saline|Normal saline is intravenously administrated before anesthesia induction and intraoperative pain management was with remifentanil
88851125|NCT02043366|Active Comparator|Butorphanol|Butorphanol is intravenously administrated at a dose of 20μg/ kg before anesthesia induction and intraoperative pain management was with remifentanil
88851126|NCT02043366|Active Comparator|Flurbiprofen axetilⅠ|Flurbiprofen axetil is intravenously administrated at a dose of 1.0mg/ kg before anesthesia induction and intraoperative pain management was with remifentanil
88851127|NCT02043366|Active Comparator|Flurbiprofen axetilⅡ|Flurbiprofen axetil is intravenously administrated at a dose of 1.0mg/ kg before the skin closure and intraoperative pain management was with remifentanil
88851128|NCT02043366|Active Comparator|Butorphanol-Flurbiprofen axetil|A dose of 10μg/ kg butorphanol and a dose of 0.5mg/ kg flurbiprofen axetil are intravenously administrated before anesthesia induction and intraoperative pain management was with remifentanil
88851129|NCT02043366|Sham Comparator|Sufentanil|Normal saline is intravenously administrated before anesthesia induction and intraoperative pain management was with sufentanil
88851130|NCT02060370|Experimental|Sunitinib|"Sunitinib starting dose 50 mg by mouth daily given for 2 weeks on followed by 1 week off. 1 cycle is 6 weeks."
88851131|NCT01622088|Experimental|Dexpramipexole|Dexpramipexole open-label
88851132|NCT01621542|Experimental|WT2725|WT2725; injection
88851133|NCT02021292|Experimental|Macitentan|Macitentan 10 mg, oral tablet, to be taken once daily.
88851134|NCT02021292|Placebo Comparator|Placebo|Matching placebo oral tablet, to be taken once daily.
89182525|NCT06240013|Experimental|Group 2 Training Program|5 minutes of light aerobic cycling, unilateral 4*30 seconds on the dominant leg - 2 minutes in total proprioceptive neuromuscular facilitation stretching training
89182526|NCT06240000|Other|Radiofrequency ablation|
89182527|NCT06240000|No Intervention|conventional physical therapy|
89182528|NCT06239974|Active Comparator|Control group|Patients will have no intervention and will continue to have optimised medical therapy and follow-up appointments (currently 1 appointment every 3 months).
89182529|NCT06239974|Experimental|Intervention group|Patients will be prescribed vericiguat once a day for 6 months, starting at 2.5mg and titrated up to the full dose of 10mg per day (doubling of dose every 2 weeks) in addition to optimised medical therapy and standard follow-up like the control group
88851135|NCT02059980|Experimental|Response inhibition training|Eight 45-minute sessions of computerized training on response inhibition over a 4 week period
88851136|NCT02059980|Placebo Comparator|Placebo Control Training|Eight 45-minute sessions of computerized placebo control training over a 4 week period
88851137|NCT02043132|Active Comparator|Tranexamic acid|Infusion Tranexamic acid on study subjects. They will be randomized to receive an infusion of the standard dose of Tranexamic acid (10mg/kg) One dose will be given by the bedside nurse within 60 minutes prior to surgery and a second dose will be given at wound closure. Infusion will be given along with standard preoperative and operative infusion; no additional infusion will be necessary.
88851138|NCT02043132|Placebo Comparator|Normal Saline|Infusion of placebo on study subjects. They will be randomized to receive an infusion of placebo (an equivalent volume of normal saline). One dose will be given by the bedside nurse within 60 minutes prior to surgery and a second dose will be given at wound closure. Infusion will be given along with standard preoperative and operative infusion; no additional infusion will be necessary.
88851139|NCT02059434|Experimental|LAS190792 Dose 1 (Part 1)|Single dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)
88851140|NCT02059434|Experimental|LAS190792 Dose 2 (Part 1)|Single dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)
88851141|NCT02059434|Experimental|LAS190792 Dose 3 (Part 1)|Single dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)
88851142|NCT02059434|Experimental|LAS190792 Dose 4 (Part 1)|Single dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)
88851143|NCT02059434|Experimental|LAS190792 Dose 5 (Part 1)|Single dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)
89182530|NCT06239961|Experimental|Physical Activity Coaching|The intervention involves physical activity sessions tailored for people with HIV. Participants engage in physical activities targeting health improvement and fall prevention, promoting physical activity self-efficacy and outcome expectations. Coaches identify individual exercise goals, assess access to physical activity options, and focus on safe, unsupervised strength and balance physical activities at home. Tailored exercise materials, including handouts and videos, are accessible through a website. Additionally, participants are encouraged to follow a structured walking program.
89378162|NCT02353234|Active Comparator|WHITE BREAD WITH ALEURONE - 4|Subjects feed with white bread with aleurone fraction in the same portion as wholegrain bread.
88851144|NCT02059434|Experimental|LAS190792 Dose 6 (Part 1)|Single dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)
88851145|NCT02059434|Placebo Comparator|Placebo (Part 1)|Single dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)
88851146|NCT02059434|Experimental|LAS190792 Dose 1 (Part 2)|Single dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)
89378163|NCT02353234|Active Comparator|WHITE BREAD WITH ALEURONE - 8|Subjects feed with white bread with aleurone fraction, which contains the same quantity of ferulic acid as wholegrain bread.
89378164|NCT01569360|Active Comparator|Corset|the patients are assigned the use of a custome made corset during daytime
89378165|NCT01569360|No Intervention|No corset|the patients do not use a corset during daytime
89378166|NCT03510455|Experimental|Single Arm (TIO Subjects)|Phase 2, open-label, non-randomized, single-arm, drug treatment trial. 10 subjects will be studied. Treatment duration of 6 months with 3 months off drug follow-up and optional extension phase.
89378167|NCT02353156|Experimental|Electronic bidet|Electronic bidet for 3min at early morning for 4 weeks after hemorrhoidectomy
88851147|NCT02059434|Experimental|LAS190792 Dose 2 (Part 2)|Single dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)
89378168|NCT02353156|Active Comparator|Sitz bath|Wamr sitz bath for 3min at early morning for 4 weeks after hemorrhoidectomy
89378169|NCT03630432|Active Comparator|Group A|Immediate 8 week course of pulmonary rehabilitation
89378170|NCT03630432|Placebo Comparator|Group B|Initial 8 weeks of usual care
89378171|NCT02353000|Experimental|Stereotactic Radiosurgery|Stereotactic Radiosurgery for patients with 4 up to 10 brain metastases:
88851148|NCT02059434|Active Comparator|Tiotropium 18 μg|Single dose, oral inhalation by HandiHaler® single-dose DPI
88851149|NCT02059434|Active Comparator|Indacaterol 150 μg|Single dose, oral inhalation by Breezhaler® single-dose DPI
88851150|NCT02059434|Placebo Comparator|Placebo (Part 2)|Single dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)
89378172|NCT02353000|Other|Whole Brain Radiotherapy|Whole Brain Radiotherapy for patients with 4 up to 10 brain metastases:
89378173|NCT02351596|Active Comparator|Intervention Group 7-12 years|"Intervention consists of attending a Physiotherapy Core stability group programme for 8 sessions over 4 weeks. Each session lasts 60 minutes (mins).~Dosage: 60minsX 2 =120mins/week X 4 = 480 mins total dosage of intervention Participants also given a home exercise programme with a diary to record how long they practice for every day."
89378174|NCT02351596|Active Comparator|Control Group 7-12 years|Participants continue with usual care but do not include core stability or balance specific exercises in their physiotherapy programme for the duration of the control period. If they are receiving active physiotherapy treatment during this time, the duration, type and frequency of this intervention is recorded.
89378175|NCT02351596|Active Comparator|Clontarf Intervention Group 13-17 years|"Intervention consists of attending a Physiotherapy Core stability group programme for 8 sessions over 4 weeks. Each session lasts 60 minutes (mins).~Dosage: 60minsX 2 =120mins/week X 4 = 480 mins total dosage of intervention Participants also given a home exercise programme with a diary to record how long they practice for every day."
88851151|NCT02059278|Experimental|T-2345|T-2345 Ophthalmic Solution dosed 1 drop QD in the eye(s) in the evening (8 pm +/- 30 minutes)
88851152|NCT02059278|Experimental|Xalatan|Xalatan (Latanoprost 0.005% Ophthalmic Solution) dosed 1 drop QD in the eye(s) in the evening (8 pm +/- 30 minutes)
88851153|NCT04680780|Experimental|Ketogenic diet|Patients will follow a classical ketogenic diet for 3 month
88851154|NCT04680780|Experimental|3-days water-fasting|Patients will perform water fasting on 3 consecutive days within the first 14 days of each of the 3 months.
88851155|NCT04680780|Placebo Comparator|Control|Patients are allowed to eat ad libitum
88851156|NCT02020512|Experimental|0.03% Bimatoprost|0.03% bimatoprost (LUMIGAN®) 1 drop in the affected eye once daily in the evening as monotherapy or adjunctive therapy for 5 weeks.
88851157|NCT02041962|Active Comparator|Educational Control|Patients will receive their usual care from providers at their clinic. They will also receive in the mail a self-guided workbook.
88851158|NCT02041962|Experimental|Chronic Care Model for Mood Disorders|Life Goals Collaborative Care
88851159|NCT02041494|Active Comparator|Synthetic|Patients in this arm will have their ventral hernia repaired utilizing Ventralight, a synthetic prosthetic mesh made of polypropylene.
88851160|NCT02041494|Active Comparator|Biologic|Patients in this arm will have their ventral hernia repaired utilizing Strattice, a biologic prosthetic mesh derived from porcine dermis.
88851161|NCT04722042|Other|Default|The default frequency filters assigned by the clinical software
88851162|NCT04722042|Experimental|Place-based|Frequency filters adjusted to align with the cochlear place frequency
88851163|NCT04699812|Other|COHORT 1|This will include subjects with no known history of AF
89182531|NCT06239961|Experimental|Nutritional Assessment|Participants will complete a mini nutritional assessment and keep a food diary. Each participant will meet with a registered dietician for an evaluation. The coaching will be personalized based on the dietician's advice and will include information about community resources for food, making sure health options are available, and suggesting diets and recipes for better eating options.
89182532|NCT06239961|Experimental|Behavioral Activation|Participants receive brief BA (Behavioral Activation) coaching through remote interactions (phone or videoconference) with lay coaches. The structured behavioral approach focuses on identifying and scheduling values-based, rewarding social engagements and activities. Coaches assist in overcoming barriers to social connectedness, involving a review of daily activity patterns, setting activity goals, creating implementation plans, and assessing successes and areas for improvement. The program is adapted for individuals aging with HIV, with community collaboration to tailor content and delivery methods.
88851164|NCT04699812|Other|COHORT 2|This will include subjects with no known history of aF, but with history of frequent premature atrial contractions (PACs), frequent premature ventricular contractions (PVCs), supraventricular tachycardia (SVT), or non-sustained ventricular tachycardia (NSVT)
88851165|NCT04699812|Other|COHORT 3|This will include subjects with known history of paroxysmal, persistent, or chronic AF
88851166|NCT04699812|Other|COHORT 4|Will include subjects with permanent AF
88851167|NCT04699266|Experimental|Experimental: POD F GF IOL Implantation|Experimental: POD F GF IOL Implantation experimental Multi-center, single-arm, non-masked study Mono- or bilateral implantation of trifocal intraocular lenses POD F GF
88851168|NCT04698252|No Intervention|Systemic therapy|Patients will receive standard of care with systemic therapy alone.
88851169|NCT04698252|Experimental|Local therapy + systemic therapy|In addition to systemic therapy, patients will receive local therapy for all oligometastatic sites. Options of local therapy will be radiotherapy, radiofrequency ablation, and/ or surgery.
88851170|NCT02041104|Experimental|Bread with added beta-glucans|Experimental food is bread with high amount of barley beta-glucans. Experimental bread contains approximately 3,4 % (w/w) beta-glucans. Participants will consume 6 g of beta-glucans daily (approximately 200 g of bread per day). Beta-glucans are natural polysaccharides found in grain endosperm and are mostly represented in oat and barley. Beta-glucans are linear homopolymers of D- glycopyranosyl residues with mixed linkage (1-4, 1-3)-β-D-glucans. Their molecular structure enable beta-glucans their functional action that mostly depends of their viscosity and solubility (1). Testing bread has integrated flour with high amount of barley beta-glucans (ReducholTM). Beta-glucans are concentrated in flour up to 15 % with dry milling, sieving and air classification of barley flour.
89182533|NCT06239948|Placebo Comparator|control group|without music
88851171|NCT02041104|Placebo Comparator|Bread without added beta-glucans|Placebo bread without added barley beta-glucans in testing product.
88851172|NCT02019420|Experimental|Tedizolid phosphate IV|Ventilated HABP/VABP participants receive tedizolid phosphate 200 mg IV once daily for 7 days, or for 14 days for concurrent bacteremia.
88851173|NCT02019420|Active Comparator|Linezolid IV|Ventilated HABP/VABP participants receive linezolid 600 mg IV every 12 hours for 10 days, or for 14 days for concurrent bacteremia.
89182534|NCT06239948|Experimental|experimental group|with music
89182535|NCT06239922||Group 1|Older adults
89182536|NCT06239922||Group 2|Younger adults
89182537|NCT06239909||Urinary incontinence due to prostate surgery|Consecutive adult male patients with urinary incontinence due to prostate surgery.
89182538|NCT06239883||Patients with OSA|Patients with diagnosed OSA will be included in this study group.
89182539|NCT06239870|Experimental|neoadjuvant therapy|"Induction therapy stage: chemotherapy combined with immunotherapy for 2 cycles: Envafolimab: 200mg, subcutaneous injection, Q2W, 2 cycles; mFOLFOX6: Q2W, 2 cycles (concurrent administration of envollizumab on the first day of chemotherapy).~Concurrent chemoradiotherapy: long-term chemoradiotherapy combined with immunotherapy for 3 cycles: radiation therapy: 50Gy/25f, 2Gy every day, 5 days a week for 5 weeks; Capecitabine: 825mg/m2 orally (1650mg/m2/d) twice a day in the morning and evening, 5 days a week, simultaneous with radiation therapy, for a total of 25 days; Envafolimab: 200mg, subcutaneous injection, Q2W, 3 cycles (Envafolimab was administered on day 1, day 15, and day 29 of radiotherapy).~Iii. Consolidation treatment stage: chemotherapy combined with immunotherapy for 2 cycles: Envafolimab: 200mg, subcutaneous injection, Q2W, 2 cycles; mFOLFOX6: Q2W, 2 cycles. (Concurrent administration of envafolimab on the first day of chemotherapy)."
89182540|NCT06239857|Experimental|Epidural pulsed radiofrequency treatment|All patients diagnosed with failed back surgery syndrome will receive epidural pulsed radiofrequency treatment.
89182541|NCT06239844|Experimental|Nav-Team|Participants in this arm will receive additional assistance related to asthma, and will participate in encounters over the subsequent 9 months
88851174|NCT02019264|Experimental|Lorcaserin hydrochloride (HCL)10 mg|APD356 10 mg twice daily
89378176|NCT02351596|Active Comparator|Clontarf Control Group 13-17 years|Participants continue with usual care but do not include core stability or balance specific exercises in their physiotherapy programme for the duration of the control period. If they are receiving active physiotherapy treatment during this time, the duration, type and frequency of this intervention is recorded.
89378177|NCT03630510|Experimental|mechanical ventilator hyperinflation|The VHI maneuver with inspiratory time adjustment was performed in the pressure controlled ventilation mode (PCV). The inspiratory pressure was increased gradually every 5 cmH2O until reaching a maximum pressure of 35 cmH2O, according to the tolerance of the patient determined by the absence of cough. PEEP remained unchanged throughout the study. After reaching a maximum pressure of 35 cmH2O (PCV + PEEP level), the inspiratory time was gradually increased until the inspiratory flow reached the baseline. Concomitantly, the respiratory rate was decreased to allow the expiratory flow also to reach the baseline, to avoid self-PEEP. The maneuver was performed for 5 min, followed by tracheal aspiration.
89378178|NCT03630510|No Intervention|Control|To perform the control (CTRL), the patients were only positioned and aspirated, without alteration in ventilatory parameters.
89378179|NCT03509675|Placebo Comparator|Placebo|Placebo suspension was compounded with the same taste as the active medication but without the active ingredient.
89378180|NCT03509675|Active Comparator|Active ingredient|The topical suspension of the topical NSAID was 100 mg per 5 ml concentration of ibuprofen, with similar ingredients as OTC children's ibuprofen and was compounded by an external drug service.
89378181|NCT02351752|Experimental|Hydroxychloroquine Sulfate|Hydroxychloroquine Sulfate 0.1 Tid (eGFR 30-59), 0.2 Bid(eGFR >60)
89378182|NCT02353078|Experimental|Sucralfate|This is a pilot study in which 6 patients with active EoE defined by consensus criteria (ref) who have undergone recent endoscopy will be administered sucralfate slurry 1 gram four times daily for four weeks following which repeat endoscopy with esophageal biopsies will be performed. Patients will be those who had not had medical treatment for EoE or those who have not responded to proton pump inhibitors.
89378183|NCT02353078|Experimental|Intraluminal Impedance|This procedure involves passing a mucosal impedance probe through the endoscope and gently placing the tip of the probe on the esophageal mucosa. Measurements will be made at 2,5,10 and 15 cm above the gastroesophageal junction. There is no increased risk to the procedure and it adds approximately 2 minutes to the procedure.
89378184|NCT03509207|Experimental|Vorinostat, Zolinza Oral Capsules|Vorinostat Oral Capsules 400mg daily
89378185|NCT03727295|Experimental|The control group 1|60 cases, idebenone 180mg/d, 3 times / day, oral
89378186|NCT03727295|Experimental|The control group 2|60 cases, idebenone 360mg/d, 3 times / day, oral
89378187|NCT03727295|Placebo Comparator|The placebo group|60 cases, placebo, 3 times / day, oral
89378188|NCT03145792|Experimental|Seeking Safety|Behavioral therapy for trauma and addiction.
89378189|NCT03145792|Active Comparator|CBT for Pathological Gambling|Behavioral therapy for gambling problems.
89378190|NCT03727217|Experimental|Pre and postoperative ultrasound|An ultrasound is performed in preoperative and in postoperative.
89378191|NCT04438798|Placebo Comparator|face mask group|Pregnant females will be preoxygenated with 100% oxygen using a tight-fitting face mask at a rate of 6 L/min for 3 min with end-tidal gas monitoring.
88817203|NCT04844307|Experimental|Divided session PT group|The divided session PT group (experimental) will be receiving 15 minute sessions twice a day, five days a week. The total number of minutes of PT time per day/week will be identical to the standard PT group, but divided into shorter and more frequent sessions.
88817204|NCT04285983||Trelagliptin 25 mg|Trelagliptin 25 milligrams (mg) tablet, orally, once weekly for up to 12 months. Participants received interventions as part of routine medical care.
88817205|NCT01224236|Experimental|iron supplementation|2 mg/kg/day of elemental iron as a multivitamin with iron solution
88817206|NCT01224236|Sham Comparator|control|multivitamin solution without iron
88817207|NCT03780075|Experimental|1.11GBq of 177Lu-EB-PSMA-617|The patients were intravenously injected with the dose about 1.11GBq (30 mCi) of 177Lu-EB-PSMA617 and underwent 68Ga-PSMA PET/CT scans before and after the treatment.
88817208|NCT03780075|Experimental|2.00 GBq of 177Lu-EB-PSMA-617|The patients were intravenously injected with the dose about 2.00 GBq (54 mCi) of 177Lu-EB-PSMA-617 and underwent 68Ga-PSMA PET/CT scans before and after the treatment.
88817209|NCT03780075|Experimental|3.70GBq of 177Lu-EB-PSMA-617|The patients were intravenously injected with the dose about 3.70GBq (100 mCi) of 177Lu-EB-PSMA617 and underwent 68Ga-PSMA PET/CT scans before and after the treatment.
88817210|NCT01224626||Zyvox (linezolid)|Patients who have been treated with Zyvox (linezolid).
88817211|NCT03700437|Experimental|Fasting-Mimicking Diet (FMD)|"Participants randomized to the intervention arm (FMD) will be provided with Chemolieve®, a plant-based FMD that provides ~300 calories/fasting day and includes all the food to be consumed during the dietary intervention including supplements~Subjects will start the diet 3 days prior to chemo-immunotherapy and continue on the first day of chemo-immunotherapy for the first 4 cycles of therapy."
89378192|NCT04438798|Active Comparator|THRIVE group|High-flow humidified oxygen warmed to 37°C will be delivered through nasal cannula at the rate of 30 L/ min for 30 seconds then 50 liters per minute for a further 150 seconds.
88817212|NCT01225250|Experimental|Polydioxanone (PDS) plates|15 subjects will be randomized to receive a caudal septal extension graft using a PDS plated cartilagenous graft
88817213|NCT01225250|Other|Non-plated cartilagenous graft|15 subjects will be randomized to receive a cartilagenous caudal septal extension fgraft
89378193|NCT01378650|Experimental|Cilostazol group|Administration of Cilostazol 100mg twice a day for 4 weeks
88817214|NCT01289522|Experimental|cetuximab|Patients receive four cycles of chemotherapy comprising cetuximab IV plus docetaxel IV over 1 hour and cisplatin IV over 2 hours on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity. After completion of the fourth cycle of chemotherapy, patients receive a maintenance therapy with cetuximab every 2 weeks. Treatment will be continued until disease progression or unacceptable toxicities according
89182542|NCT06239844|No Intervention|Non-Nav-Team|Participants in this arm will participate in surveys but will receive no navigation assistance.
89182543|NCT06239831||Postoperative monitoring|ActivPAL accelerometer will be placed on the chest and thigh, an ExSpiron monitor placed on the chest, and the patient will be observed for three days, until fully ambulatory (able to walk 30 meters without assistance with or without a walker), or until discharge; whichever comes earlier.
89378194|NCT01378650|Placebo Comparator|Placebo group|placebo drug twice a day for 4 weeks.
89378195|NCT03721601||Atrial fibrillation|Patients in atrial fibrillation as recorded by 3-lead Holter.
89182544|NCT06239818|Experimental|Treatment|
89182545|NCT06239818|Active Comparator|Control|
89182546|NCT06239805|Experimental|Experimental intensive group|Experimental: intensive treatment
89182547|NCT06239805|Active Comparator|Control extensive group|extensive treatment
89182548|NCT06239805|Sham Comparator|control sham group|sham group
89378196|NCT03721601||Sinus rhythm|Patients in sinus rhythm as recorded by 3-lead Holter.
89399429|NCT02175602|Experimental|Cohort 2|Sertraline (50 milligrams each morning) day 1-7, DCV 3DAA FDC + 75 mg BMS-791325 twice daily days 13 to 22, DCV 3DAA FDC + 75 mg BMS-791325 twice daily + Sertraline (50 milligrams each morning) days 23-29
88817215|NCT03547245|Active Comparator|HIV-uninfected, healthy adults|
88817216|NCT03547245|Placebo Comparator|HIV-uninfected, healthy adults - placebo|
88817217|NCT01226420|Experimental|Alefacept|Alefacept iv
88817218|NCT05440227|Experimental|PG2 treatment group|500 mg PG2 injection will be administered to this group once per week for 8 weeks.
88817219|NCT05440227|Experimental|Placebo-controlled group|Placebo injection will be administered to this group once per week for 8 weeks.
88817220|NCT04743453|Experimental|Dapagliflozin|
88817221|NCT04743453|Placebo Comparator|Placebo|
88817222|NCT04274517|Experimental|Sterile Water|
88817223|NCT04274517|Experimental|3.5% betadine|
88817224|NCT04274517|Experimental|0.05% chlorhexidine gluconate|
88817225|NCT00365001|Experimental|1|
88817226|NCT00365001|Active Comparator|2|
88817227|NCT04741971|Experimental|Probiotics group|Will give Probiotics with Vit.D 3
88817228|NCT04741971|Placebo Comparator|Non-probiotics group|Will give Vit. D3 as placebo
88817229|NCT01289912|Experimental|RAD001|RAD001 is formulated as tablets of 5.0 mg strength, blister-packed under aluminum foil in units of 10 tablets and dosed on a regular basis.
88817230|NCT01289912|Placebo Comparator|Placebo|Matching placebo will be provided as a matching tablet and will also be blister packed under aluminum foil in units of 10.
89378197|NCT04530162||Emergency Medicine Herpes Zoster Patients|Emergency Medicine adult patients with herpes zoster pain onset within 30 days of characteristic dermatomal herpes zoster rash who receive nerve block using bupivacaine and dexamethasone. The patient will be then started on Acyclovir 800 mg five times daily for seven days. For mild to moderate breakthrough pain, the patient will be prescribed a 5-day course of Tylenol 650 mg and Ibuprofen 400 mg taken up to every 8 hours together. For severe breakthrough pain, the patients will be prescribed a two-day course of 7.5 mg morphine sulfate immediate release to be taken up to every 6 hours. The location of the nerve block and dosage of injected medications will depend on the distribution of the affected dermatome.
89378198|NCT04796922|Experimental|Treatment Group A|Participants will be administered with parsaclisib in combination with investigator choice of rituximab or obinutuzumab.
89378199|NCT04796922|Placebo Comparator|Treatment Group B|Participants will be administered with placebo in combination with investigator choice of rituximab or obinutuzumab
89378200|NCT03721445||CPAP opponent|CPAP opponent: moderate to severe OSA patients who refused CPAP therapy after PSG study and CPAP titration test.
89378201|NCT03721445||CPAP acceptor|CPAP acceptor: moderate to severe OSA patients who accepted CPAP therapy after PSG study and CPAP titration test and had purchased a PAP at home for long term use.
89378202|NCT04305678|Experimental|Single Arm|Patients with a biopsy proven diagnosis of eosinophilic fasciitis
89378203|NCT03723785|Experimental|Participants with normal renal function|Participants with normal renal function (glomerular filtration rate [GFR] of greater than or equal to 90 ml/min) will receive single dose of insulin 287 on Day 1.
89378204|NCT03723785|Experimental|Participants with mildly decreased renal function|Participants with mildly decreased renal function (GFR of 60 to less than 90 ml/min) will receive single dose of insulin 287 on Day 1.
89378205|NCT03723785|Experimental|Participants with moderately decreased renal function|Participants with moderately decreased renal function (GFR of 30 to less than 60 ml/min) will receive single dose of insulin 287 on Day 1.
89378206|NCT03723785|Experimental|Participants with severely decreased renal function|Participants with severely decreased renal function (GFR of less than 30 not requiring dialysis) will receive single dose of insulin 287 on Day 1.
89378207|NCT03723785|Experimental|Participants with end-stage renal disease|Participants with end-stage renal disease requiring haemodialysis will receive single dose of insulin 287 on Day 1.
89378208|NCT05255614|Active Comparator|First Group|the participants will start training on the pelvic trainer and assessment will be via assessment via a checklist. Then at a later time, they will be trained on VR simulator (Sim Surgery) and assessment will be via Electronic auto assessment via the Simulator.
89378209|NCT05255614|Active Comparator|Second Group|the participants will start training on VR simulator (Sim Surgery) and assessment will be via Electronic auto assessment via the Simulator. Then at a later time, they will be trained on the pelvic trainer and assessment will be via assessment via a checklist.
89378210|NCT05255458|Experimental|AK102 regimen 1|
88851175|NCT02019264|Placebo Comparator|Placebo|Placebo twice daily
88851176|NCT02019108|Experimental|Gait Modification Group|Participants will complete 4 months of a home-based progressive walking program with toe-out gait modification aimed at improving physical activity level. This group will perform continuous treadmill walking during regular sessions with a study therapist and will be instructed to perform a toe-out gait, with the aid of a mirror during walking. Focus will also be on increasing the time and distance of walking. These goals will be emphasized for the home-based portion of the intervention as well.
89378211|NCT05255458|Placebo Comparator|Placebo|
89378212|NCT04441320|Experimental|CMUS group|Coated metal ureteral stent is indwelled.
89378213|NCT04441320|Other|DJS group|Double-J stent is indwelled
89378214|NCT04478656|Experimental|BBV121-2.5 µg|BBV121: Each 0.5ml vial contain purified10 µg inactivated Zika virus, alum, 2-PE and phosphate buffered saline qs to 0.5mL
89378215|NCT04478656|Placebo Comparator|Placebo|Each 0.5ml vial contain purified 2.5 µg, 5 µg or 10 µg inactivated Zika virus, alum, 2-PE and phosphate buffered saline qs to 0.5mL
88851177|NCT02019108|Active Comparator|Walking Only Group|Participants will complete 4 months of a home-based progressive walking program aimed at improving physical activity level. This group will perform continuous treadmill walking during regular sessions with the study therapist with focus on increasing the time and distance of walking. This goal will be emphasized for the home-based portion of the intervention as well.
88851178|NCT02018562|Experimental|Intervention|"The talking tracheostomy trial involves placement of a talking tracheostomy tube (Portex Blueline Ultra Suctionaid Tracheostomy Tube) by respiratory therapist after obtaining an order from an authorized prescriber (Physician or Nurse Practitioner). The Speech-Language Pathologist (SLP) sets up the tracheostomy tube for speech and then determines the optimal air flow required for voicing. This amount of air flow is communicated to the ICU staff for further use.~We will ensure that the SLP meets with the patient for a minimum of 3 sessions within a week to optimize the use of a talking tracheostomy tube.~i. SLP will also assess the duration of successful speech during each session~ii. Sentence intelligibility will also be assessed during the 3rd session. This session will be audio-taped and reviewed by a second rater for sentence intelligibility.~iii. SLP will determine the level of independence with talking tracheostomy during the 3rd session."
88851179|NCT02018562|No Intervention|Control|This group will also receive talking tracheostomy tube trial as standard of care but a week later after the pre and post assessments have been completed
88851180|NCT02058966|Placebo Comparator|Placebo followed by Placebo|Subjects will receive placebo, then one hour later, placebo
89378216|NCT04478656|Experimental|BBV121-5 µg|BBV121: Each 0.5ml vial contain purified inactivated Zika virus, alum, 2-PE and phosphate buffered saline qs to 0.5mL
89378217|NCT04478656|Experimental|BBV121-10 µg|BBV121: Each 0.5ml vial contain purified inactivated Zika virus, alum, 2-PE and phosphate buffered saline qs to 0.5ml
89378218|NCT03149926||Patients with Borderline Personality Disorder|
89378219|NCT03149926||Healthy controls|
89378220|NCT03543137|Experimental|Test Product|Participants will receive a single Nicotine Prototype Mini lozenge (4mg) by oral/buccal route of administration.
89378221|NCT03543137|Active Comparator|Reference Product|Participants will receive a single Nicorette Mini lozenge (4 mg) by oral/buccal route of administration.
89378222|NCT04478188||Cardiogenic Shock Patients Needing TMCS|Heart failure patients who undergo TMCS insertion for acute decompensated heart failure and cardiogenic shock.
89002504|NCT06317246|Experimental|Investigation of BRAF mosaicism|The study of BRAF mosaicism will be conducted on biopsy samples from patients with ECD and other neoplasms co-occurring with the BRAFV600E mutation. The samples will be labeled with anti-Pu.1-Alexa Fluor 647 antibody (which binds to macrophages), then DNA will be extracted using FACS method and amplified using MDA (Qiagen Repli-G Single-Cell kit). Quality control will be performed using Quant-it (ThermoScientific) and Agilent 4200 TapeStation. Eligible samples will undergo digital droplet PCR (ddPCR) and sequencing. ddPCR probes for wild-type and mutant alleles will be used. Sequencing will be performed using Illumina HiSeq 2500 system
89002505|NCT06317233|No Intervention|Standard of Care|
89002506|NCT06317233|Experimental|Treatment Guide plus Standard of Care|
89002507|NCT06317220|Experimental|Vedolizumab 300mg|"Dose: 300mg~Administration: Intravenous (IV)~Frequency: Weeks 0, 2, 6, and then every 8 weeks~Duration: 54 weeks (1 year)"
89002508|NCT06317207||observation group|patients who underwent reoperation for locally rRCC after pNSS
89002509|NCT06317194|Experimental|Active kTMP|Participants received 2-8 V/m of active stimulation
89002510|NCT06317194|Sham Comparator|Sham kTMP|Participants received 0.01 V/m of sham stimulation
89002511|NCT06317181|Experimental|Elastography|Collection of ultrasound data and elastography data from patients who were clinically planned for elastography
89002512|NCT06317181|Experimental|Focal lesion|Collection of ultrasound data of the suspected lesion and a definitive diagnosis based on either normal ultrasound investigation or if not sufficient additional investigations like CEUS, Biopsy, MRI or CT. This further investigation should be in accordance to normal clinical routine of the centers to differentiate focal lesions.
89002513|NCT06317168|Active Comparator|Standardized automated office BP measurements|BP measured using a highly standardized procedure using a validated office-grade device on a bare arm supported at heart level.
89002514|NCT06317168|Active Comparator|Sleeved arm|BP measured using a highly standardized procedure using a validated office-grade device over a standardized sleeve with the arm supported at heart level.
89002515|NCT06317168|Active Comparator|Arm not supported|BP measured using a highly standardized procedure using a validated office-grade device on a bare arm resting vertically.
89002516|NCT06317168|Active Comparator|Non-validated device|BP measured using a highly standardized procedure using a non-validated home device on a bare arm supported at heart level.
89002517|NCT06317155||Young People|Young people who have a history of self-harm who have received an occupational therapy informed interventions from a Tier 4 CAMHS service within the last 12 months.
89378223|NCT03723629||pulmonary GGO|Patients with pulmonary GGO.
88817231|NCT03192345|Experimental|Dose Escalation SAR439459 monotherapy|SAR439459 administered intravenously every 2 weeks in a 14-day cycle with escalating doses
89002518|NCT06317155||Carers|The carers of a young person who has a history of self-harm, and who has received an occupational therapy informed interventions from a Tier 4 CAMHS service in the last 12 months.
89002519|NCT06317155||Healthcare Practitioners|Healthcare practitioners who have delivered or helped to facilitate an occupational therapy informed intervention whilst working for a Tier 4 CAMHS service, in the last 12 months.
89002520|NCT06317142||Healthy overweight volunteers|This group includes 15 healthy overweight volunteers. These participants will undergo two test days with one overnight stay. During these days several tests will be conducted including measurements such as muscle and liver glycogen, whole-body gluconeogenesis, substrate oxidation and postprandial hepatic and muscle glucose uptake will be assessed by 18F-FDG PET combined with an oral glucose tolerance test.
89002521|NCT06317142||Prediabetes volunteers-IFG|"This group will include 15 subjects with impaired fasting glucose (IFG). These participants will undergo two test days with one overnight stay. During these days several tests will be conducted including measurements such as muscle and liver glycogen, whole-body gluconeogenesis, substrate oxidation and postprandial hepatic and muscle glucose uptake will be assessed by 18F-FDG PET combined with an oral glucose tolerance test.~A subset of IFG prediabetes individuals with impaired fasting glucose (first 10 subjects enrolled) will receive a 4-day Acipimox treatment (3x 250mg capsules for three days (one with breakfast, one with lunch and one with snack) and 1x 250mg in the morning of day 4. After the intervention the participants will come to the university for two days with an overnight stay for tests (muscle and liver glycogen, whole-body gluconeogenesis, substrate oxidation, oral glucose tolerance test)."
89002522|NCT06317142||Prediabetes volunteers-IGT|"This group will include 15 subjects with impaired glucose tolerance (IGT). These participants will undergo two test days with one overnight stay. During these days several tests will be conducted including measurements such as muscle and liver glycogen, whole-body gluconeogenesis, substrate oxidation and postprandial hepatic and muscle glucose uptake will be assessed by 18F-FDG PET combined with an oral glucose tolerance test.~A subset of IGT prediabetes individuals with impaired fasting glucose (first 10 subjects enrolled) will receive a 4-day Acipimox treatment (3x 250mg capsules for three days (one with breakfast, one with lunch and one with snack) and 1x 250mg in the morning of day 4. After the intervention the participants will come to the university for two days with an overnight stay for tests (muscle and liver glycogen, whole-body gluconeogenesis, substrate oxidation, oral glucose tolerance test)."
89002523|NCT06317129|Experimental|BariTon™ System implantation|
89002524|NCT06317103||Trial group|"The gastro-endoscopic images in this group are classified as Mucosa or Submucosa by WADYMED endo."
89002525|NCT06317103||Control group|"The gastro-endoscopic images in this group are interpreted as Mucosa or Submucosa by the endoscopists."
89002526|NCT06317090|Experimental|Test|LPRF block as a grafting material
89002527|NCT06317090|Experimental|Control|50% autogenous bone, 50% DBBM as a grafting material
89378224|NCT01378494||HIV+|HIV+ patients that entered the 1917 Clinic at UAB as naive to ART
88817232|NCT03192345|Experimental|Dose Expansion SAR439459 monotherapy|SAR439459 administered intravenously every 3 weeks in a 21-day cycle with the previously determined recommended doses as the patients will be randomized to 2 different doses
88817233|NCT03192345|Experimental|Dose Escalation SAR439459 + cemiplimab combination|SAR439459 + cemiplimab combination administered intravenously every 2 weeks in a 14-day cycle or every 3 weeks in a 21-day cycle with escalating SAR439459 doses and cemiplimab
88817234|NCT03192345|Experimental|Dose Expansion SAR439459 + cemiplimab combination|SAR439459 + cemiplimab combination administered intravenously every 3 weeks in a 21-day cycle with previously determined SAR439459 doses and cemiplimab
89182549|NCT06239753|Experimental|Dynamic Neuromuscular Stabilization Applied|"Intervention Group I will receive DNS (Dynamic Neuromuscular Stabilization) applications in the hospital, led by a physiotherapist, once a week for 10 weeks. During each session, participants will be instructed to perform the DNS exercises at home and take notes. They will receive reminders via short message service (SMS) to practice the exercises at home. The DNS application for pregnant women involves checking the breathing pattern before starting exercises in all sessions. Pregnant women will be instructed to breathe through the nose, and if they find it challenging to maintain nasal breathing, the Body Oxygen Level Test (BOLT) score will be measured. If the BOLT score is low, guidance will be provided on how to increase it by adjusting the breathing technique."
89182550|NCT06239753|Experimental|Standard Prenatal Education Program Implementation|The group will receive the standard prenatal education program, consisting of 5 sessions of general education and 2 sessions of standard pregnancy exercises and respiratory exercises, as part of the hospital's prenatal education program. The educational topics will include one-hour sessions on pregnancy and nutrition, postpartum care and family planning, baby care and infant massage, breastfeeding and lactation education, and first aid for infants, under the headings of childbirth and coping methods for labor pain
89182551|NCT06239753|No Intervention|Control|The control group will consist of pregnant women attending routine examinations at the hospital's maternity clinic. As per hospital policy, routine breastfeeding education is provided after the 32nd week during regular prenatal check-ups at the hospital.
89182552|NCT06239740|Experimental|Electroacupuncture group|In the electroacupuncture group (EG), participants received acupuncture at 10 scalp points (Baihui [GV20], Ex-hn 1, 3 points of intelligence [Shenting [GV24], Benshen [GB13] on both sides, Touwei [ST8] on both sides). Electroacupuncture was applied for 20 minutes at Benshen [GB13] and Touwei [ST8] on both sides. They also received acupuncture at Tai chong [LV3], Tai Yuan [LU9], and Tai Xi [KI3] on both sides, as shown in picture 1. Acupuncture sessions were weekly for 10 weeks.
89182553|NCT06239740|Sham Comparator|Sham acupuncture|In the sham acupuncture control group (CG), participants received acupress or a brief needle insertion at He gu on both hands during the first and 10th weeks, marking the endpoint of the study
89182554|NCT06239727|Experimental|Reduced-dose radiotherapy group|All participants will receive induction chemotherapy and immunotherapy (every 3 weeks × 3 cycles of gemcitabine 1000 mg/m2 day 1, 8 + cisplatin 80 mg/m2 day 1 + camrelizumab 200 mg day 1) followed by reduced-dose intensity-modulated radiation therapy (IMRT; 6360cGy, 30 fractions, 5 fractions/week, 1 fraction/day). During the radiotherapy, all the participants will receive concurrent chemotherapy (every 3 weeks × 2 cycles of cisplatin 100 mg/m2 day 1). After 3 weeks of the completion of concurrent chemoradiotherapy, adjuvant camrelizumab (200 mg per cycle) will be administrated every 3 weeks for 9 cycles.
89182555|NCT06239727|Active Comparator|Conventional-dose radiotherapy group|All participants will receive induction chemotherapy and immunotherapy (every 3 weeks × 3 cycles of gemcitabine 1000 mg/m2 day 1, 8 + cisplatin 80 mg/m2 day 1 + camrelizumab 200 mg day 1) followed by conventional-dose intensity-modulated radiation therapy (IMRT; 6996cGy, 33 fractions, 5 fractions/week, 1 fraction/day). During the radiotherapy, all the participants will receive concurrent chemotherapy (every 3 weeks × 2 cycles of cisplatin 100 mg/m2 day 1). After 3 weeks of the completion of concurrent chemoradiotherapy, adjuvant camrelizumab (200 mg per cycle) will be administrated every 3 weeks for 9 cycles.
89378225|NCT02347462|Experimental|BiPAP plus standard care|Bilevel Positive Airway Pressure (BiPAP) plus standard care according to the hospital's severe asthma protocol
88817235|NCT04392453|Experimental|Robotic therapy|Upper limb robotic rehabilitation by means of the portable robot Icone.
88817236|NCT04742127||Patients with septic arthritis of the native hip|
88817237|NCT03069963|Experimental|Sequence 1 (Z0063 to Gaviscon)|The subjects will be given Z0063 single dose and then will crossover to Gaviscon single dose
88817238|NCT03069963|Experimental|Sequence 2 (Gaviscon to Z0063)|The subjects will be given Gaviscon single dose and then will crossover to Z0063 single dose
88817239|NCT03000855|Active Comparator|ECDS|EUS-guided choledocho-duodenostomy
88817240|NCT03000855|Active Comparator|ERCP with CSEMS|Endoscopic retrograde cholangiopancreatography with covered metallic stent
88817241|NCT02835261|No Intervention|Habitual Sleep (HS)|During the HS phase, participants will be asked to follow a fixed bedtime routine based on their screening sleep schedule.
88817242|NCT02835261|Experimental|Sleep Restriction (SR)|During the SR phase, participants will be asked to keep their habitual wake time constant but delay their bedtime to achieve a reduction of 1.5 h in total sleep time. A delay in bedtimes was chosen rather than advancing wakeup time because it most closely reflects differences in sleep timing behavior between short and normal sleepers.
88817243|NCT01227434|Experimental|Surgical Group|PD 0332991 125 mg daily for 7 days prior to an indicated, intended surgical resection as clinical care for progression, and then resume drug at the same dose after recovery from surgery on a repeating schedule of 21 consecutive days of drug followed by a 7 day break off therapy (cycle length is 28 days). Treatment will be repeated every 28 days, and in the absence of disease progression patients may receive treatment for 12 cycles. At that time patients will be given the option to continue on study past 12 cycles, up to a maximum of 24 cycles.
88817244|NCT01227434|Experimental|Non-surgical group|Patients not in need of surgery treated with PD 0332991 125 mg daily for 21 consecutive days followed by a 7 day break off therapy (cycle length is 28 days). Treatment will be repeated every 28 days, and in the absence of disease progression patients may receive treatment for 12 cycles. At that time patients will be given the option to continue on study past 12 cycles, up to a maximum of 24 cycles.
88817245|NCT01714739|Experimental|Part 1|Dose Escalation and Initial Signal Detection in Multiple Solid Tumors - Nivolumab with Lirilumab
89378226|NCT02347462|Active Comparator|Standard care alone|Standard care according to the hospital's severe asthma protocol
89378227|NCT02895347|No Intervention|Control Group|Participants in the Control Group (CG) were asked to attend an orientation reviewing the study. Three weeks later they returned and were filmed timed completing a suturing activity on the porcine model.
89378228|NCT02895347|Experimental|Experimental Group|Participants in the Experimental Group (EG) were asked to attend an orientation reviewing the study. Then they were instructed to complete 4 activities on the dvSS ® that modeled suturing techniques in minimally invasive robotics-assisted surgery. EG participants repeated these 4 activities over a period of 2 weeks until they reached proficiency (91%) in all 4 activities. 4. Participants were asked to return where they were filmed and timed completing a suturing activity on the porcine model.
88817246|NCT01714739|Experimental|Part 2 and 3: Cohort Expansion|In platinum-refractory recurrent or metastatic SCCHN - Nivolumab with or without Lirilumab
89378229|NCT05763966||Early stage psychosis patients (EPP)|Diagnosis of psychotic disorder according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) with onset of less than 2 years prior to inclusion.
89378230|NCT05763966||Individuals at clinical high risk for psychosis (CHR-P)|Fulfills criteria for clinical high risk for psychosis according to Structured Interview for Psychosis-risk Syndromes (SIPS).
89378231|NCT05763966||Healthy controls (HC)|Age- and sexmatched controls.
89378232|NCT02347306||cohort of patients with suspected coronary artery disease|a cohort of patients with suspected coronary artery disease going forward for conventional angiography and (2) whether CT-TCFA is associated with future adverse cardiovascular events.
89378233|NCT01376856||PET/CT and surgical biopsy group|person who performed PET/CT and surgical biopsy of mediastinal lymph node for diagnosis of primary lung cancer of metastatic lung cancer
89378234|NCT02343484|Active Comparator|Gelified ethanol|Gelified ethanol (Discogel) is a sterile, implantable medical solution containing ethyl alcohol, cellulose derivative product and an opaque agent (tungsten). The implant is administered within the affected intervertebral disc nucleus pulposus, via a fine needle which is guided into the center of the disc, transdermally. The implant causes migration of fluid (by hydrophilic and osmotic phenomena) from the periphery towards the center, causing disk reinforcement. Filling of the annulus fibrosus tears interrupts the outflow of inflammatory factors towards dorsal root ganglions, dura and posterior longitudinal ligament.
89378235|NCT02343484|Active Comparator|Gelified ethanol combined to pulsed radiofrequency|Pulsed radiofrequency treatment is performed intradiscally for the management of chronic discogenic low back pain.Intradiscal pulsed radiofrequency is first applied and then combined to gelified ethanol injection via the same radiofrequency needle.
89378236|NCT03630276|Other|Neutrophil/lymphocyte ratio|
89378237|NCT03630276|Other|Platelet/lymphocyte ratio|
89378238|NCT03630276|Other|CRP|
89378239|NCT03539549|Experimental|Abicipar pegol 2 mg|Abicipar pegol 2 mg administered to the study eye by intravitreal injection on Day 1 and Weeks 4, 8, 16, and 24.
89378240|NCT01378338||Typical reflux symptom by EGD|Total 2000 subjects who has Typical reflux symptom by EGD
89378241|NCT02343640||Baseball players|Members of the baseball team, both pitchers and fielders, who participate in repetitive baseball throwing and are exposed to damage of the ulnar collateral ligament in the arm that is used for throwing.
89378242|NCT04173000|Experimental|Intervention|All adolescent/parent dyads enrolled at each practice will have access to the meHealth for ADHD software without medication continuity tools prior to being given access to the medication continuity tools.
89378243|NCT04478032|Sham Comparator|sham stimulation|20 patients will be randomly allocated into this group,they will receive sham stimulation.
89378244|NCT04478032|Active Comparator|real stimulation dTMS targeting the ACC|20 patients will be randomly allocated into this group,they will receive real stimulation.
89378245|NCT04158024|No Intervention|Volatile Anesthetic Control|"In volatile anesthetic technique, maintenance of anesthesia will be standardized to the volatile anesthetic isoflurane. Isoflurane will be delivered at 1.5-2.0%% as required for anesthetic management.~Rocuronium or pancuronium will be used for muscle relaxation. Narcotic, fentanyl will be administered at no greater than 2 mcg/kg/hr. However, the primary anesthetic during CPB will be isoflurane with no narcotic administered during CPB."
89378246|NCT04158024|Experimental|Erector Spinae Plane Blockade Treatment|Patients will receive an erector spinae plane blockade prior to their surgery as per standard regional anesthesia technique in addition to the standard of care Volatile Anesthetic Treatment.
89378247|NCT02039206|Experimental|Treatment|Deep TMS
89378248|NCT03506477|Experimental|Enstilar® foam|Enstilar® foam - a combination of calcipotriene and betamethasone dipropionate 0.005%/0.064%.
89378249|NCT03506477|Placebo Comparator|Vehicle foam|does not contain the active ingredient
89378250|NCT03149692|Experimental|Penile allograft|Penile human allografts transplanted
89378251|NCT02351206||The experimental group|Patients with intervertebral disc protrusion, extrusion, or migration at L4/5 randomly selected from a population pool of 665 patients with L-spine X-ray and L-spine MRIs taken within a week of the other test.
88851181|NCT02058966|Experimental|Placebo followed by Methamphetamine|Subjects will receive placebo, then one hour later, methamphetamine
88851182|NCT02058966|Experimental|Entacapone followed by Placebo|Subjects will receive entacapone, then one hour later, placebo
88851183|NCT02058966|Experimental|Entacapone followed by Methamphetamine|Subjects will receive entacapone, then one hour later, methamphetamine
88851184|NCT02017860|Experimental|Everolimus|Patients who received everolimus in a Novartis-sponsored, Oncology Clinical Development & Medical Affairs (CD&MA) study that had reached its study objectives, were not progressing on the current study treatment as defined by the parent protocol and were unable to access everolimus treatment outside of a clinical trial were enrolled.
88851185|NCT02040870|Experimental|LDK378|daily dosing, 28-day cycle patients
88851186|NCT04697472|Experimental|Functional task practice (FTP) followed by FTP + ARC Therapy|Clinic-based functional task practice (FTP) for two months followed by FTP + ARC Therapy for an additional 2 months.
89378252|NCT02351206||The control group|Patients with normal or disc bulging readings at L4/5 randomly selected from a population pool of 665 patients with L-spine X-ray and L-spine MRIs taken within a week of the other test.
89378253|NCT03629964|Experimental|Head stabilizer group|Patients will be receiving standard brain radiation. The experimental head holder device (called the Wiersma Head Stabilizer) will be attached to treatment table and will make small movements to adjust the position of the head in response to movement by the patient. In addition, the AlignRT system (an FDA approved medical device that automatically turns off the radiation beam if the patient's head moves beyond a set distance) will be used to track real-time motions of the head. This system is used with radiation therapy as standard of care.
89378254|NCT03726983|Experimental|eHMP experimental group|"The experimental group received health management support and counseling,including:~GDM health care knowledge~self-awareness of health~self-monitoring of health status (i.e., recording weight and measurement data of metabolic syndrome risk factors and monitoring changes in data trends)~participation in discussions or browsing forums~healthy lifestyle guidance and counseling~reminder systems~a token system of earning points in exchange for prizes."
89378255|NCT03726983|No Intervention|Control group|only received usual care
89378256|NCT02343328|Active Comparator|Fecal Microbiota Transplant Capsules|Fecal microbiota transplant capsules
88851187|NCT04720716|Experimental|Sintilimab combined with IBI310|
88851188|NCT04720716|Active Comparator|Sorafenib|
88851189|NCT04719624|Experimental|Adaptos-Si [0.5-1 mm]|Bone augmentation, after tooth extraction, with Adaptos-Si [0.5-1 mm] (synthetic bone graft material) in combination with a gelatin sponge.
89002528|NCT06317077|Other|Treatment group|All participants of the clinical investigation undergo the standard stages of the clinical routine within an initial PAP therapy setting: a diagnostic night followed by a titration night (or if necessary two titration nights) with prescribed titration scheme. All participants use a full face mask of Löwenstein Medical.
89002529|NCT06317064|No Intervention|Control Group|10 females with no dysmenorrhea participated as controls.
89002530|NCT06317064|Experimental|NSAIDs and Aprepitant group (Sequential)|"All 30 participants in this group used NSAIDs (Non-steroidal Anti-Inflammatory Drugs), during their dysmenorrhea period. Same patients from phase 2 (n=30) in next cycle received NK1R antagonist Dexamethasone (6mg) + Aprepitant (80mg) for 2 days."
89002531|NCT06317051|Active Comparator|Dapagliflozin 10mg + pitavastatin 4mg|Dapagliflozin 10mg + pitavastatin 4mg given as daily tablets for 48 weeks
89002532|NCT06317051|Active Comparator|Dapagliflozin 10mg + rosuvastatin 10mg/ezetimibe 10mg|Dapagliflozin 10mg + rosuvastatin 10mg/ezetimibe 10mg given as daily tablets for 48 weeks
89002533|NCT06317051|Placebo Comparator|Placebo + pitavastatin 4mg|Placebo + pitavastatin 4mg given as daily tablets for 48 weeks
89002534|NCT06317051|Placebo Comparator|Placebo + rosuvastatin 10mg/ezetimibe 10mg|Placebo + rosuvastatin 10mg/ezetimibe 10mg given as daily tablets for 48 weeks
89378257|NCT02343328|Placebo Comparator|Placebo Capsules|Placebo capsules made from a mixture of natural cocoa powder and gelatin
89002536|NCT06317025||General anaesthetic patient|Monitoring depth of anaesthesia using PRST （P：pressure， T：tear，R：rate， S：sweat）score developed by Evans and bispectral index
89002537|NCT06317012|Experimental|Le Fort I osteotomy|
89002538|NCT06316999|Other|Patients with Pouchitis|Transabdominal and transperineal ultrasounds of the pouch will be performed by an experienced sonographer for each patient and interpreted by a board-certified radiologist specializing in IUS.
89378258|NCT04428606|Experimental|Metabolic Rheostat™|Participants will take 6 capsules of Rheostat daily, two capsules three times per day 30 minutes prior to each meal for 56 days.
88817247|NCT01714739|Experimental|Part 4: Cohort Expansion|Additional Signal Detection in Solid Tumors - Nivolumab with Lirilumab (Study Part 4 Removed; No Subjects Enrolled)
89002539|NCT06316986|Experimental|Patients requiring an orogastric or nasogastric tube|
89002540|NCT06316973|Experimental|CS-1103 Single dose of CS-1103 Injection|CS-1103 for injection
89002541|NCT06316973|Placebo Comparator|Placebo|Sterile saline for injection
89002542|NCT06316960|Experimental|Relapsed/Refractory CBF-AML with KIT mutation|The relapsed/refractory patients will receive a combination treatment of decitabine/azacitidine+ IdAG (idarubicine + cytarabine + granulocyte stimulating factor)regimen along with avapritinib. CBF-AML with KIT mutated patients with molecular relapse after hematopoietic stem cell transplantation may receive avapritinib combined with demethylating agents or interferon or donor lymphocyte infusion without low-dose chemotherapy. The dose of avapritinib will start at 50mg/m2/d, and if platelets stabilize at 50 ×10^9/L and neutrophils stabilize above 1.0 ×10^9/L after one week, the dose can be increased to 100mg/m2/d, with a maximum daily dose of 100mg. Avapritinib should be discontinued in the presence of febrile neutropenia or active infection, and avapritinib can be resumed once the infection is controlled, with each treatment cycle not exceeding 28 days.
89002543|NCT06316947|Experimental|Families|Somali American families with children in the household and at least one adult using shisha at home
89002544|NCT06316921||PCA group|Patients received epidural patient-controlled analgesia for postoperative pain.
89002545|NCT06316921||Control group|Patients received standard of care for postoperative pain.
89002546|NCT06316908|Active Comparator|Unilateral Approach Group|Patients in this group have received a unilateral percutaneous posterior approach for NCPB. The procedure was performed under fluoroscopic guidance
89002547|NCT06316908|Active Comparator|Bilateral Approach Group|Patients in this group have undergone a bilateral percutaneous posterior approach for NCPB, following the same procedural guidance.
89002548|NCT06316882|Experimental|screening endoscopy|We perform upper endoscopy, when the patient authorizes it, at the same time of their screening colonoscopy
89002549|NCT06316869||CSPH group|HVPG≥10 mmHg
89002550|NCT06316869||Non-CSPH group|HVPG<10 mmHg
89002551|NCT06316765||With stylet group|Intubation performed with stylet.
89002552|NCT06316765||Without stylet group|Intubation performed without stylet.
89002553|NCT06316752||Patients with sialidosis type 1|Patients with a definite diagnosis of this disease are candidates for this study.
89002554|NCT06316570|Experimental|Dual Antiplatelet Therapy|This group will receive early dual antiplatelet therapy (Ticagrelor with Aspirin) combined with intravenous thrombolysis within 6 hours of the onset.
89002555|NCT06316570|Placebo Comparator|Placebo|This group will receive placebo treatment (with same form and dosage) combined with intravenous thrombolysis within 6 hours of the onset.
89002556|NCT06316531|Experimental|Experimental Group|Participants receive BL-M07D1 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
89002557|NCT06316531|Experimental|Control group|Participants receive T-DM1 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
89002558|NCT06316518|Experimental|Mindfulness group|Primigravidas randomly assigned to the experimental group will be given web-based mindfulness-based stress reduction trainings after pre-tests are applied.
89002559|NCT06316518|Active Comparator|control group|After the pre-tests were applied to the control group, routine nursing care will be given and post-test measurements will be made after 8 weeks.
89002560|NCT06316349|Active Comparator|Isolated Resistance Training Program Group|Four sets of 10 knee extension repetitions will be performed with a 90-second rest interval between sets.
89002561|NCT06316349|Experimental|Neuromuscular Electrical Stimulation Group|Neuromuscular electrical stimulation will be performed in muscles of the femoral quadriceps, simultaneously with the same resistance exercise program as the Isolated Resistance Training Program Group.
89378259|NCT04428606|Experimental|Butyrate Ultra|Participants will take 6 capsules Butyrate Ultra daily, two capsules three times per day 30 minutes prior to each meal for 56 days.
88851190|NCT04719624|Experimental|Adaptos-Si [1-2 mm]|Bone augmentation, after tooth extraction, with Adaptos-Si [1-2 mm] (synthetic bone graft material) in combination with a gelatin sponge.
88851191|NCT04719624|Active Comparator|Bio-Oss|Bone augmentation, after tooth extraction, with Bio-Oss (bovine-derived xenograft) in combination with a gelatin sponge.
88851192|NCT04719624|Placebo Comparator|Empty extraction socket|Post-extraction the socket filled only by clot.
88851193|NCT04719624|Experimental|Adaptos [1-2 mm]|Bone augmentation, after tooth extraction, with Adaptos [1-2 mm] (synthetic bone graft material) in combination with a gelatin sponge.
88851194|NCT04696068||Control|The patients included in this group will receive meals with the usual presentation (plastic trays) during six days. Their data will be collected at day 1 and day 6.
88851195|NCT04696068||Experimental|The patients included in this group will receive the main course in porcelain plates during six days. Their data will be collected at day 1 and day 6.
88851196|NCT02016690||Immunocompromised children|Children with immunocompromised conditions or Down syndrome at high-risk of serious RSV disease who received palivizumab during the RSV season
88851197|NCT02016300|Experimental|Unloader Bracing|This group will be randomly selected and assigned to wear an unloader brace post-operatively during the study period.
88851198|NCT02016300|Active Comparator|Non-Bracing Arm|This group will be randomly selected and assigned to wear no brace post-operatively.
88851199|NCT02040090|Experimental|KamRAB|KamRAB 20 IU/kg body weight via IM injection, once on Day 0
88851200|NCT02040090|Active Comparator|FDA approved HRIG product|Comparator product: Intramuscular (IM) injection once on Day 0 in the same manner and at the same dosage as KamRAB.
89378260|NCT04428606|Placebo Comparator|Placebo|Participants will take 6 capsules of placebo daily, two capsules three times per day 30 minutes prior to each meal for 56 days.
88851201|NCT04695288||Fibromyalgia Syndrome|100 participants with a diagnosis of Fibromyalgia Syndrome according to the 2016 revised American College of Rheumatology diagnostic criteria.
89378261|NCT02343016||Near-InfraRed Spectroscopy (NIRS)|The NIRS Group will be monitored with the interventional system (NIRS) and with the standard one (ecodoppler)
89378262|NCT01378260||Surgical Bypass|use of synthetic or endogenous (vein) or composite graft to treat lesions in the superficial femoral, common femoral, or popliteal artery
89378263|NCT01378260||Endovascular Therapy|angioplasty and/or stent to treat lesions in the superficial femoral or popliteal artery
89378264|NCT01378260||Medical Management|"Documentation of the following in the medical record:~i. Walking/physical therapy to improve endurance was recommended; ii. For tobacco users, tobacco cessation was recommended; iii. Prescribing pentoxifylline (Trental) or cilostazol (pletal) iv. Ongoing care by physician for treatment of claudication"
89378265|NCT02343094|Experimental|PBA 7,5g/d|Treatment for 14 days
89378266|NCT02343094|Experimental|PBA 15g/d|Treatment for 14 days
88851202|NCT04695288||Control subjects|60 healthy participants do not meet the exclusion criteria of the study.
88851203|NCT02058498|Experimental|Liver Transplant Patients|Participants will be provided physical activity walking instructions and asked to record their daily activity on an activity log.
89378267|NCT03073980|Experimental|Group 1: Intravenous (IV) acetaminophen/oral (PO) placebo|In the pre-operative suite, these patients will receive 1000mg IV acetaminophen and PO placebo, followed by standard protocol anesthesia and pain control as needed.
88851204|NCT02039778|Experimental|Stem Cell Radiotherapy and Temozolomide|"One treatment of 2.0 Gy will be given daily 5 days per week for a total of 60.0 Gy over 6 weeks.~Intensity Modulated Radiation Therapy (IMRT) Is Mandated; Proton therapy (Intensity-modulated proton therapy [IMPT] preferred) is an acceptable treatment modality.~Temozolomide will be administered continuously from day 1 of radiotherapy to the last day of radiation at a daily oral dose of 75 mg/m2. The drug will be administered orally on an empty stomach, the first dose to be given the night prior or morning of the first radiation fraction, and continued until the last radiation fraction is completed (including weekends and holidays)."
88851205|NCT02015754|Experimental|DEBIRI|
89378268|NCT03073980|Active Comparator|Group 2: Intravenous (IV) placebo/oral (PO) acetaminophen|In the pre-op suite, these patients will receive 1000mg PO acetaminophen and IV placebo, followed by standard protocol anesthesia and pain control as needed.
89378269|NCT03073980|Placebo Comparator|Group 3: Oral and intravenous Placebo / Standard of care|In the pre-op suite, these patients will receive PO and IV placebo, followed by standard protocol anesthesia and pain control as needed.
88851206|NCT04441944||Telemedicine Cases|Patients presenting to rural emergency departments who had real-time provider-to-provider telemedicine used to supplement their emergency department care.
88851207|NCT04441944||Non-Telemedicine Cases|Patients presenting to rural emergency departments who did not have real-time provider-to-provider telemedicine used to supplement their emergency department care.
89378270|NCT02347384|Experimental|Delta PLUS Femoral Head + SL-TWIN Stem|Subject will be implanted with Delta PLUS Femoral Head & SL-TWIN Stem
89378271|NCT02347384|Active Comparator|BIOLOX forte ball head + SL-PLUS Stem|Subject will be implanted with BIOLOX forte ball head & SL-PLUS Stem
88851208|NCT02015676|Experimental|Trastuzumab, Myocet, Paclitaxel; Phase I|Participants received an initial loading dose of trastuzumab 4 milligrams per kilogram (mg/kg), intravenously (IV), over 1.5 hours during Week 1, followed by 2 mg/kg, IV, over 30 minutes once per week from Week 2 to Week 52 or until disease progression. Participants also received myocet, 40 mg/ square meter (m^2), IV, every 3 weeks, from Week 1; if no dose limiting toxicity (DLT) was observed in greater than or equal to (≥) two-thirds (2/3) of cohort for 2 treatment cycles, the dose was increased to 50 mg/m^2, IV, and continued for 6 cycles. Participants also received paclitaxel 60 mg/ m^2, IV, once per week, from Week 19; if no DLT was observed in ≥ 2/3 of cohort for 2 treatment cycles, the dose was increased to 70 mg/m^2, IV, and subsequently 80 mg/m^2, IV, and continued until disease progression.
88851209|NCT02015676|Experimental|Trastuzumab, Myocet, Paclitaxel; Phase II|Participants received an initial loading dose of trastuzumab 4 mg/kg, IV, over 1.5 hours during Week 1, followed by 2 mg/kg, IV, over 30 minutes once per week from Week 2 to Week 52 or until disease progression. Participants also received myocet, 50 mg/m^2, IV, every 3 weeks, from Week 1 for 6 cycles. Participants also received paclitaxel 80 mg/m^2, IV, once per week, from Week 19 until disease progression.
88851210|NCT02015520|Experimental|Arm 1: Clazakizumab (Dose # A) (Double-Blind)|Clazakizumab Dose # A injection by subcutaneous for 12 weeks + background Methotrexate
88851211|NCT02015520|Experimental|Arm 2: Clazakizumab (Dose # B) (Double-Blind)|Clazakizumab Dose # B injection by subcutaneous for 12 weeks + background Methotrexate
88851212|NCT02015520|Experimental|Arm 3: Clazakizumab (Dose # C) (Double-Blind)|Clazakizumab Dose # C injection by subcutaneous for 12 weeks + background Methotrexate
88851213|NCT02015520|Experimental|Arm 4: Placebo matching with Clazakizumab (Double-Blind)|Clazakizumab Dose # D injection by subcutaneous for 12 weeks + background Methotrexate
88851214|NCT02058108|Experimental|Telbivudine|Patients of any age and weight< 30kg: telbivudine oral solution (20 mg/mL): 20 mg/kg up to 600 mg q.d corresponding to weight (kg) x1mL, p.o. once daily Patients < 12 years old and weight≥ 30kg: telbivudine oral solution (20mg/mL), 600 mg/day corresponding to 30 mL p.o. once daily Patients ≥ 12 years old and weight ≥ 30kg: telbivudine film-coated tablet, 600 mg/day, corresponding to 1 tablet p.o. once daily
88851215|NCT02058108|Placebo Comparator|Placebo|Patients of any age and weight < 30kg: placebo oral solution corresponding to weight (kg) x1mL, p.o. once daily Patients < 12 years old and weight ≥ 30kg: placebo oral solution corresponding to 30 mL p.o. once daily Patients ≥ 12 years old and weight ≥ 30kg: placebo tablet, corresponding to 1 tablet p.o. once daily
89378272|NCT03146416|Experimental|Cohort 1|Evinacumab SC or placebo SC
89378273|NCT03146416|Experimental|Cohort 2|Low dose regimen: evinacumab IV or placebo IV
89378274|NCT03146416|Experimental|Cohort 3|High dose regimen: evinacumab IV or placebo IV
89378275|NCT03146416|Experimental|Cohort 4|Evinacumab or placebo SC every week (QW) x 8 doses
89378276|NCT03146416|Experimental|Cohort 5|Evinacumab or placebo SC x 1 dose
89378277|NCT03146572|Experimental|Intervention|Parent of child to receive intervention, Sit Down and Play
89378278|NCT03146572|Active Comparator|Control|Parent will receive handout to promote positive behavior
89378279|NCT03149458|Experimental|Dance group|dance program for 8 one-hour sessions.
89378280|NCT03149458|Active Comparator|control group|upper limb rehabilitation for 8 one-hour sessions.
89378281|NCT03930186|Experimental|Apremilast|After a 5-day titration, participants received 30 mg apremilast tablets orally twice daily (BID) for up to 32 weeks in addition to their existing topical therapy. At week 16 participants were permitted to decrease their use of topical therapy at their own discretion under the direction of their physician.
89378282|NCT02351362|Experimental|Incentive Group|A one-time supermarket voucher of R50 (about $5.00) for participants who return for at least one postpartum visit at the study clinic within 10 weeks of delivery
89378283|NCT02351362|No Intervention|Control Group|Standard of care
88851216|NCT04417374||Unvonluntary commitment from March 12th to April 09th 2019|Patients hospitalized with unvonluntary commitment procedure from March 12th to April 09th 2019
88851217|NCT04417374||Unvonluntary commitment from March 12th to April 09th 2020|Patients hospitalized with unvonluntary commitment procedure from March 12th to April 09th 2020
88851218|NCT04678362|Experimental|Talazoparib+avelumab|"Talazoparib will be administered at the daily dose of 1 mg given orally in a 28-day cycle, except for patients with mild renal impairment (Creatinine clearance 30-59 mL/min) who will receive 0.75 mg per day.~Avelumab will be administered by intravenous (I.V.) route over 60 minutes at the dose of 800 mg on D1 and D15, in a 28-day cycle."
89378284|NCT02351440|Experimental|Duloxetine|duloxetine 60mg PO
89378285|NCT02351440|Placebo Comparator|Placebo|placebo
89378286|NCT03504917|Experimental|Balovaptan|
89378287|NCT03504917|Placebo Comparator|Placebo|
89378288|NCT02343172|Experimental|HDM201+LEE011|
89378289|NCT03899688|Experimental|test site|The space obtained underneath the sinus mucosa will be filled with the xenograft without protecting the antrostomy with a collagen membrane in the test sites. Bone to implant contact was measured at the turned and machined surface.
89378290|NCT03899688|Active Comparator|control site|The space obtained underneath the sinus mucosa will be filled with the xenograft and a resorbable collagen membrane will be placed to cover the antrostomy only at the randomly selected control sites. Bone to implant contact was measured at the turned and machined surface.
89378291|NCT02351128|Experimental|Only one arm|All patients receive Lanreotide.
89378292|NCT02343250|Experimental|Cinidipine/Valsartan tablet|Cinidipine/Valsartan tablet
89378293|NCT02343250|Active Comparator|Cilnidipine+Valsartan|coadministration of cilinidipine and valsartan
89378294|NCT03721289||Cohort 1|All registered cases of stage IV NSCLC patients, treatment naïve, diagnosed in the participant institution during one year (from Jan 1st 2017 to Dec 31st 2017).
89378295|NCT03721289||Cohort 2|All EGFR positive patients progressed to an EFGR-TKI in the same period of time (from Jan 1st 2017 to Dec 31st 2017)
89378296|NCT02342938|Experimental|Patient|
89378297|NCT02342938|Experimental|Volunteers|
89378298|NCT01569672|Active Comparator|Intervention Clinic|Patient Navigator matched with subjects. Patient Navigators will be matched with subjects at the intervention clinics and will assist patients with questions, issues or concerns with their cancer treatment/diagnosis or abnormal test results and followup test or treatments
89378299|NCT01569672|Placebo Comparator|Control Clinics|Subjects are mailed informational/educational materials.
89378300|NCT02342860|Experimental|WASH in Schools (WinS) programme|Schools in the intervention group will receive the UNICEF/Department of Foreign Affairs and Trade (DFAT)-supported WinS programme that includes a new water supply, 3 latrines (boys, girls, handicapped), and handwashing facilities. It will also include behavior change education.
89378301|NCT02342860|No Intervention|Control|Schools in the control group will receive no additional WinS programming.
89378302|NCT02347150||ICU LOS>24h|30-110 patients discharged from the ICU
88851219|NCT02057874|Experimental|Diagnostic (3T MRI)|Patients undergo 3T MRI at baseline (=< 2 weeks before TACE) and at 2-4 weeks, 4-8 weeks, and 12 weeks after TACE. Each 3T MRI session will utilize a sequence of the following modalities: CEST-MRI, MT-MRI, DW-MRI, and DCE-MRI.
88851220|NCT04678050|Active Comparator|group I received ketamine/propofol (ketofol) solution|ketamine/propofol mixture, each mL contains 5 mg of ketamine plus 10 mg of propofol). A loading dose of 0.125 mL/kg will be administered intravenously (IV) over 10 min, followed by maintenance infusion at a rate of 0.05-0.125 mL/kg/h.
88851221|NCT04678050|Active Comparator|group II received the Dex solution (4 µg/mL|A loading dose of 2 µg/kg will be administered IV over 10 min, followed by a maintenance infusion of 0.1-1 µg/kg/h.
89378303|NCT03146260|Experimental|Conventional TESE|Conventional testicular sperm extraction (TESE) will be done under anesthesia through small vertical incision in the median raphe, skin, dartos and tunica vaginalis is opened to expose tunica albuginea. The tunica albuginea is incised for about 4mm at the upper pole near the head of epididymis.
89378304|NCT03146260|Experimental|Microdissection TESE|Microdissection testicular sperm extraction (TESE)will be carried under anesthesia micro TESE will be through a transverse incision of the testis covering three-quarters of its circumference, according to a line preserving as much as possible the predominantly transversal sub albugineal vessels. The testis will be opened like a book by gently separating the lobular tissue of both sides. Then, the tissue will be examined under the microscope at ×10-24 magnification to search for areas with dilated whitish tubules, from which numerous microretrievals will be performed.
89378305|NCT03536663|Other|Optiflux/Endexo|Optiflux (Active Comparator); Hemodialysis treatments on the Optiflux dialyzer (Optiflux Period) for 4 weeks - Visit 1 to 12 Endexo (Experimental); Subjects continue on Dialyzer with Endexo (Endexo Period) for 13 weeks - Visit 13 to visit 50
89378306|NCT03770052|Experimental|0.25mg robeglitazone add-on group|0.25mg robeglitazone once daily in patients with type 2 diabetes with inadequate control on metformin and DPP-4 inhibitor therapy
89378307|NCT03770052|Active Comparator|0.5mg robeglitazone add-on group|0.5mg robeglitazone once daily in patients with type 2 diabetes with inadequate control on metformin and DPP-4 inhibitor therapy
89378308|NCT02351050|Experimental|Sonolysis|continual transcranial Doppler monitoring with maximal intensity during endovascular procedure
89378309|NCT02351050|Placebo Comparator|placebo|sham transcranial Doppler monitoring during endovascular procedure
89378310|NCT02350894||mTBI subjects|mTBI subjects with ongoing symptoms
89378311|NCT03565211|Experimental|Progesterone vaginal ring (PVR)|Treatment started on the day following oocyte retrieval and could be continued through Week 12 of pregnancy (10 weeks post-oocyte retrieval), depending on the participants pregnancy assessment. A new PVR was inserted every 7 days with up to 10 PVRs used.
89378312|NCT02346994|Experimental|Melt test blend 3.2|
89378313|NCT02346994|Active Comparator|Corn Oil|
89378314|NCT02346760|Experimental|UB-621|Intervention drug: UB-621
89378315|NCT02342626|No Intervention|Control|No use of the decision aid dashboard before, during or after the treatment decision time period.
89378316|NCT02342626|Experimental|Dashboard|Use of the decision aid dashboard before, during and after the treatment decision time period.
89378317|NCT03723395|Experimental|Part A|Tucatinib plus Itraconazole
89378318|NCT03723395|Experimental|Part B|Tucatinib plus Rifampin
89378319|NCT03723395|Experimental|Part C|Tucatinib plus Gemfibrozil
89378320|NCT03723395|Experimental|Part D|Tucatinib plus Repaglinide plus Tolbutamide plus Midazolam
89378321|NCT03723395|Experimental|Part E|Tucatinib plus Digoxin
88851222|NCT04677426|Experimental|Subjects with Progressive Interstitial Lung Disease|Assess the intra-visit reliability and sensitivity to progression of 129Xe MR imaging measurements using a standardized imaging protocol in subjects with IPF and cHP.
88851223|NCT02038920|Experimental|Induction Phase: Vedolizumab, 300 mg|Vedolizumab 300 mg, intravenous (IV) infusion, once at Weeks 0, 2 and 6 in the induction phase.
88851224|NCT02038920|Placebo Comparator|Induction Phase: Placebo|Vedolizumab placebo-matching IV infusion once at Weeks 0, 2 and 6 in the induction phase.
89378322|NCT01377948|Other|ACT with RAGE-Control|all subjects are assigned to this arm. This is an open feasability proof of concept trail with a single experimental group with all subjects receiving the intervention being studied.
89378323|NCT02350738|Experimental|MCET_Mock group|Period I: MCET for 8 weeks (3 sessions/ week); Washout for 4 weeks and cross-over; Period II: mock therapy for 8 weeks (3 sessions/week)
89378324|NCT02350738|Experimental|Mock_MCET group|Period I: mock therapy for 8 weeks (3 sessions/week); Washout for 4 weeks cross-over; Period II: MCET for 8 weeks (3 sessions/ week);
89378325|NCT04459728|Experimental|Wellness Intervention|KickStart30 is an integrated, prescriptive, and trackable wellness intervention combining five wellness elements including exercise, mindfulness, sleep, social connectedness, and nutrition.
89378326|NCT02350972|Experimental|Autologous cytokiines|Autologous cytokines obtained from patients' blood mononuclear cells injected in volumes of 0.1 ml
88851225|NCT02038920|Experimental|Maintenance Phase: Vedolizumab 300 mg|Vedolizumab placebo-matching, IV infusion, once at Weeks 14, 22, 30, 38, 46 and 54 in maintenance phase. Participants received vedolizumab in induction phase and achieved Crohn's Disease Activity Index (CDAI)-70 response at Week 10 and were randomized to receive vedolizumab in maintenance phase.
88851226|NCT02038920|Placebo Comparator|Maintenance Phase: Placebo|Vedolizumab placebo-matching, IV infusion, once at Weeks 14, 22, 30, 38, 46 and 54 in maintenance phase. Participants received vedolizumab in induction phase and achieved CDAI-70 response at Week 10 and were randomized to receive placebo in maintenance phase.
88851227|NCT02038920|Placebo Comparator|Maintenance Phase: Placebo Continuation|Vedolizumab placebo-matching, IV infusion, once at Weeks 14, 22, 30, 38, 46 and 54 in maintenance phase. Participants received vedolizumab placebo-matching in induction phase and achieved CDAI-70 response at Week 10 received placebo in maintenance phase without randomization.
88851228|NCT02038920|Experimental|Open-Label: Vedolizumab 300 mg|Vedolizumab 300 mg, IV infusion, once at Weeks 0, 2 and 6 and then every 8 weeks thereafter up to Week 94 as a maximum duration in open-label phase.
88851229|NCT02038764|Placebo Comparator|Placebo|Placebo
89378327|NCT02342470|Placebo Comparator|Placebo|Placebo Comparator / Bid
89378328|NCT02342470|Experimental|PMK-S005 1|Total 50mg, by mouth, bid
89378329|NCT02342470|Experimental|PMK-S005 2|Total 100mg, by mouth, bid
89378330|NCT02342470|Experimental|PMK-S005 3|Total 150mg, by mouth, bid
89378331|NCT04436952|Experimental|H7 coil only|patients undergoing DTMS treatment using the H7 coil
89378332|NCT04436952|Active Comparator|Cool D-B80 coil only|20 patients undergoing rTMS treatment using the cool D-B80 coil
89378333|NCT04436952|Active Comparator|DTMS treatment using the H7 coil + ERP|20 patients undergoing DTMS treatment using the H7 coil + ERP
89378334|NCT04436952|Active Comparator|rTMS treatment using the cool D-B80 coil + ERP|20 patients undergoing rTMS treatment using the cool D-B80 coil + ERP
89378335|NCT04436952|Active Comparator|ERP only|20 patients undergoing ERP only
88851230|NCT02038764|Experimental|PF-06342674|
88851231|NCT04693260|Other|Hand-held Device Supported by Mobile Application|Insight device ETDRS measurement compared to a standard ETDRS chart
89378336|NCT03146494||STAAD|
89378337|NCT03146494||Normal|
89378338|NCT03531905|Experimental|Bempedoic acid + Ezetimibe FDC|Bempedoic acid + Ezetimibe FDC Oral Tablet; Placebo oral capsule
89378339|NCT03531905|Active Comparator|Ezetimibe 10 mg|Ezetimibe 10Mg Oral Tablet; Placebo Oral Tablet
89378340|NCT03531905|Placebo Comparator|Placebo|Placebo Oral Tablet, Placebo oral capsule
89378341|NCT02350426|Experimental|Arm 1|As per randomization schedule, subjects will undergo two half body PET/CT scans (PET/CT1 and PET/CT2). During visit 1 subject will undergo PET/CT1 scan with 18F-FDG followed by PET/CT2 scan with 18F-GE-180 in visit 2. A sub-group of patients will participate in an additional dynamic PET/CT scan with 18F-GE-180 prior to their 18F-GE-180 PET/CT half body scan.
89378342|NCT02350426|Experimental|Arm 2|As per randomization schedule, , subjects will undergo two half body PET/CT scans (PET/CT1 and PET/CT2). During visit 1 subject will undergo PET/CT1 scan with 18F-GE-180 followed by PET/CT2 scan with 18F-FDG in visit 2. A sub-group of patients will participate in an additional dynamic PET/CT scan with 18F-GE-180 prior to their 18F-GE-180 PET/CT half body scan.
89378343|NCT02346682|Active Comparator|LDQS group|"Liver Depression and Qi Stagnation (LDQS)group,Liver Depression and Qi Stagnation Syndrome should include at least the following 5 symptoms and signs: emotional depression or sadness, pessimism, short breath, sigh, dysphoria，thin coating，stringy pulse Drugs use generic name :Venlafaxine; Dosage form:capsule Dosage, frequency and duration:Venlafaxine dose was initiated at 75 mg/day and escalated to an optimal dose (150-225 mg/day in most cases) within 2 week, depending upon individual patient response, but the maximum dose could not exceed 300 mg/day during the next 4 weeks.~The biomarkers of neurobiochemistry, metabonomics and neuroimaging would be tested at the baseline and after 6-week venlafaxine administration."
89399430|NCT02175602|Experimental|Cohort 1|Escitalopram (10 milligrams each morning) day 1-7, DCV 3DAA FDC + 75 mg BMS-791325 twice daily days 13 to 22, DCV 3DAA FDC + 75 mg BMS-791325 twice daily + Escitalopram (10 milligrams each morning) days 23-29
89378344|NCT02346682|Active Comparator|DBHS group|"Deficiency of Both Heart and Spleen (DBHS) group,Deficiency of Both Heart and Spleen Syndrome should include at least following 6 symptoms and signs: emotional depression, thinking torpidity, tiredness, forgetfulness, insomnia, loose stool, sweating, pale tongue body, thin tongue coating, and thin and deep pulse Drugs use generic name :Venlafaxine; Dosage form:capsule Dosage, frequency and duration:Venlafaxine dose was initiated at 75 mg/day and escalated to an optimal dose (150-225 mg/day in most cases) within 2 week, depending upon individual patient response, but the maximum dose could not exceed 300 mg/day during the next 4 weeks.~The biomarkers of neurobiochemistry, metabonomics and neuroimaging would be tested at the baseline and after 6-week ."
89378345|NCT02346682|No Intervention|the normal controls group|The normal controls group including the healthy volunteer None drug The biomarkers of neurobiochemistry, metabonomics and neuroimaging would be tested at the baseline .
89378346|NCT02346604||Mild COPD|Symptomatic smokers with mild COPD
89378347|NCT02346604||Healthy Control|Non-smokers, matched to mild COPD group for age (at least 50 years) and gender
89378348|NCT02346214||Preterm and term neonates|A. Preterm and term neonates B. Singleton live births between 26 and 42 weeks gestation (determined by first of early-second trimester ultrasound dating) at three referral hospitals
89378349|NCT02346292||1|Patients of both genders aged 40 years and older, smokers, with smoking history more than 10 pack-years, with severe and very severe COPD who were hospitalized with COPD exacerbation
89378350|NCT03131934|Experimental|Autologous EBV-CTL transduced with SFG-CNA12/SFG-CNA8|"All patients will receive the autologous EBV CTL retrovirally transduced with with (a) a calcineurin mutant (CNA12) that confers resistance to tacrolimus and (b) a control calcineurin mutant (CNA8). For each patient two ATIMPs will be generated:~Autologous EBV-specific cytotoxic T-cells (CTL) transduced with the retroviral vector SFG-CNA12~Autologous EBV-specific cytotoxic T-cells (CTL) transduced with the control retroviral vector SFG-CNA8~An equal dose (10x7/m2) of CNA12+ EBV CTL and CNA8+ EBV CTL will be administered intravenously on day 0.~While awaiting ATIMP generation, patients may receive a single dose of Rituximab and other immunosuppressants (e.g. MMF) will be reduced, but tacrolimus will be maintained at therapeutic levels."
89378351|NCT03531827|Experimental|1/Lead-In Safety: CRLX101 with Enzalutamide|Combination treatment of increasing dose of CRLX101 (formerly IT-101) with enzalutamide
89378352|NCT03531827|Experimental|2/Efficacy: CRLX101 with Enzalutamide|Tolerable dose of CRLX101 (formerly IT-101) in combination with enzalutamide (8 participants, expandable to 21 total participants)
89378353|NCT05764512|Experimental|Intervention group|Is the group to which endorphin massage will be applied. Endorphin massage is a gentle touch and massage method that can improve the relaxation state in the body through the skin surface.
89378354|NCT05764512|No Intervention|Control gruop|No application will be made.
88851232|NCT04177836|Experimental|MIndfulness|This arm was developed to increase attention towards and acceptance of current experiences.
88851233|NCT04177836|Active Comparator|Active Control|This arm is a relaxation-based active treatment comparison intervention, developed to parallel the structure of the mindfulness intervention without the attention towards or acceptance of present experiences.
88851234|NCT02014740|Experimental|Liraglutide|• L-group will be started and dose-escalated to 1.8mg sc once daily according to below schedule: Liraglutide will be administered with a starting dose of 0.6 mg (after a least one week) and subsequent increments to 1.2 mg (after a least one week) and to 1.8 mg (after at least a week on 1.2 mg). L-group subjects will need to achieve the final dose of 1.8 mg by at least three weeks from the starting dose. Subjects who would not be able to achieve the dose of 1.8 mg (due to potential side effects) will be advised to lower the dose to 1.2 mg. Metformin regimen will be continued.
88851235|NCT02014740|Active Comparator|Metformin|M-group will be treated with Metformin for the duration of the study. Metformin (from 500 mg twice daily to a maximum of 1000 mg twice daily) regimen will be continued to achieve fasting glucose between 80 and 140 mg/dl
88851236|NCT02014584|Experimental|Dutasteride Arm|Subjects will receive dutasteride 0.5 milligrams (mg) administered orally once daily for 24 Weeks
88851237|NCT02014584|Placebo Comparator|Placebo Arm|Subjects will receive placebo administered orally once daily for 24 Weeks
88851238|NCT02014272|Experimental|Test|RIN 150 contains 150 rifampicin and 75 mg isoniazid
88851239|NCT02014272|Active Comparator|Reference|Individual references of rifampicin and isoniazid
88851240|NCT04963452|Placebo Comparator|Group 1|Normal weight BMI 20-24.9 kg/m2
88851241|NCT04963452|Active Comparator|Group 2|Morbid Obese BMI : 40-49.9 kg/m2
88851242|NCT02037984|Experimental|Adult V114: 1x:1x:1x|Adults receive a single vaccination on Day 1.
88851243|NCT02037984|Experimental|Adult V114: 2x:2x:2x|Adults receive a single vaccination on Day 1.
88851244|NCT02037984|Experimental|Infant V114: 1x:1x:1x|Infants receive 4 total vaccinations given at 2, 4, 6, and 12 to 15 months of age.
88851245|NCT02037984|Experimental|Infant V114: 2x:1x:2x|Infants receive 4 total vaccinations given at 2, 4, 6, and 12 to 15 months of age.
88851246|NCT02037984|Experimental|Infant V114: 2x:2x:2x|Infants receive 4 total vaccinations given at 2, 4, 6, and 12 to 15 months of age.
88851247|NCT02037984|Experimental|Infant V114: 0.5x:0.5x:2x|Infants receive 4 total vaccinations given at 2, 4, 6, and 12 to 15 months of age.
88851248|NCT02037984|Experimental|Infant V114: 1x:1x:2x|Infants receive 4 total vaccinations given at 2, 4, 6, and 12 to 15 months of age.
88851249|NCT02037984|Active Comparator|Infant Prevnar 13®|Infants receive 4 total vaccinations given at 2, 4, 6, and 12 to 15 months of age.
88851250|NCT02057406|Active Comparator|2:1 EPA/DHA|400/200 EPA/DHA fish oil 2 grams
88851251|NCT02057406|Active Comparator|High EPA|Almost pure EPA 2 grams
88851252|NCT02057406|Placebo Comparator|Placebo|Matched placebo corn oil capsules
88851253|NCT02036580|Experimental|Low Dose|Investigational product Tralokinumab
89378355|NCT04105816|Placebo Comparator|Adult Healthy Controls|Subjects included in part I of this study will be healthy adult volunteers with no known musculoskeletal injury. Exclusion criteria will be those with identified musculoskeletal injury, non-English speaking persons, and women who are pregnant.
89378356|NCT04105816|Experimental|Adult ACL Reconstruction Patients|Subjects included in part II of the study will be adult volunteers undergoing anterior cruciate ligament reconstruction at the University of Iowa. Exclusion criteria will be non-English speaking persons, women who are pregnant, patients undergoing multi-ligament repair, patients undergoing ACL reconstruction revision, patients undergoing concomitant cartilage or meniscal repair procedures, and patients undergoing bilateral ACL reconstructions.
89378357|NCT02346448|Active Comparator|endoscopic sphincterotomy|performing endoscopic sphincterotomy of papilla of Vater during ERCP Device: standard sphincterotome
89378358|NCT02346448|Active Comparator|balloon dilatation for 3 minutes|Balloon dilatation of papilla of Vater for 3 minutes during ERCP using 10mm balloon Device: standard dilation balloon catheter (10mm size)
89378359|NCT02346448|Active Comparator|balloon dilatation for 6 minutes|Balloon dilatation of papilla of Vater for 6 minutes during ERCP using 10mm balloon Device: standard dilation balloon catheter (10 mm size)
89378360|NCT03057678|Experimental|Testing of Pre-Positioning Frame|Placement of bone screws, CT scanning, Surgical planning, Robot motion planning
89378361|NCT01377870|Placebo Comparator|cell free media|15 patients with relapsing remitting multiple sclerosis who receive cell free media
89378362|NCT01377870|Experimental|mesenchymal stem cell reciepiants|Patients with relapsing remitting multiple sclerosis who underwent intravenous injection of mesenchymal stem cells
89378363|NCT03146026|No Intervention|No Exercise (CON)|Fifteen obese adolescent girls. This arm did not perform any exercise training for 12 weeks. Caloric intake was 1921.7 kcal/day.
89378364|NCT03146026|Experimental|Combined Exercise Training (CET)|Fifteen obese adolescent girls. This arm performed combined exercise training 3 times per a week for 12 weeks. Caloric intake was 1921.7 kcal/day.
89378365|NCT02342392|Active Comparator|treatment group|intralesional ranibizumab injected
89378366|NCT02342392|No Intervention|control group|no intralesional ranibizumab injected.
88851254|NCT02036580|Experimental|High Dose|Investigational product Tralokinumab
89378367|NCT02342236|Other|cemented|Primary hip arthroplasty with bone cement use.
89378368|NCT02342236|Other|cementless|Primary hip arthroplasty without bone cement use.
89378369|NCT02342158|Experimental|Locally advanced /metastatic cancer|
89378370|NCT02342080|Experimental|Interventional group|A group with spinal cord injury will be trained in a 30-minute session 5 times weekly for 6 weeks. Each session will be supervised by qualified staff. Patients will undergo training with gradual increase in load and speed, according to the tolerance of each patient. The body weight support progression will start at 50 % of the patient body weight. It will be changed every 2 weeks and the load will decrease 10%. The progression of speed may be accompanied during the training period. For the robot locomotion therapy, the Lokomat system (Hocoma AG Switzerland) will be used.
89378371|NCT05764434||Patients with Amyotrophic Lateral Sclerosis|Patients with a possible, probable, or definite diagnosis of Amyotrophic Lateral Sclerosis according to the El Escorial Criteria.
89378372|NCT05764434||Healthy Control Persons|Healthy control persons matching the ALS patient group in sex and age
89378373|NCT05764434||Patients with other Motor Neuron Diseases|Patients with Motor Neuron Diseases other than ALS
89378374|NCT05462964|No Intervention|Control Group|Newborns in this group were started to camera recording 2 minutes before the procedure and routine OGT placement was performed. It was checked whether the orogastric tube was in the right place. After the evaluation period was completed and the baby was comfortable, the recording was stopped.After OGT insertion, a light touch was provided if necessary to ensure routine comfort of the baby for ethical reasons.
88851255|NCT02036580|Placebo Comparator|Placebo|Placebo
88851256|NCT02014116|Experimental|Cohort 1 Dose Escalation|LY3009120 50 mg given orally twice daily every 12 hours for a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met.
89378375|NCT05462964|Experimental|İntervention Group 1|Only a pacifier was given to the newborn.
89378376|NCT05462964|Experimental|İntervention Group 2|The newborn was given a pacifier sweetened with 25% dextrose.
89378377|NCT02342002|Experimental|Mifepristone-misoprostol regimen|After a woman is determined eligible and signs the informed consent document, she will receive 200 mg mifepristone and advised to swallow the pill when they arrive at home. 24 hours after administration of the mifepristone, women will administer the four tablets of 200 mcg misoprostol sublingually.
89378378|NCT02342002|Placebo Comparator|Misoprostol alone regimen|After a woman is determined eligible and signs the informed consent document, she will receive a placebo (of same shape and size of mifepristone) and advised to swallow the pill when they arrive at home. 24 hours after administration of the mifepristone, women will administer the four tablets of 200 mcg misoprostol sublingually.
89378379|NCT04478110|Experimental|Interactive education with linkage to care|Main intervention components included interactive group education, navigation services and engagement of health care providers for referrals, and linkage to care
89378380|NCT04478110|Active Comparator|general health education|Receive a group education session focused on general health education and primary prevention issues.
89378381|NCT02341846||Patients with cancer pain|Qualitative semi-structured interviews with patients who have experienced cancer pain
89378382|NCT02341846||Caregivers for those with cancer pain|Qualitative semi-structured interviews with caregivers who have cared for those who have experienced cancer pain.
88851257|NCT02014116|Experimental|Cohort 2 Dose Escalation|LY3009120 100 mg given orally twice daily every 12 hours for a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met.
88851258|NCT02014116|Experimental|Cohort 3 Dose Escalation|LY3009120 200 mg given orally twice daily every 12 hours for a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met.
88851259|NCT02014116|Experimental|Cohort 4 Dose Escalation|LY3009120 400 mg given orally twice daily every 12 hours for a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met
88851260|NCT02014116|Experimental|Cohort 5 Dose Escalation|LY3009120 500 mg given orally twice daily every 12 hours for a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met
88851261|NCT02014116|Experimental|Cohort 6 Dose Escalation|LY3009120 300 mg given orally twice daily every 12 hours for a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met
89378383|NCT02341846||Healthcare professionals|Healthcare professionals whose role involves the management of cancer pain.
89378384|NCT05230966|No Intervention|Group 1- angina pectoris|Patients with acute coronary syndrome; angina pectoris (chest pain with negative troponin T with or without changes in electrocardiographic findings);
88851262|NCT02014116|Experimental|Cohort A Dose Confirmation|LY3009120 300 mg given orally twice daily every 12 hours for a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met.
88851263|NCT02014116|Experimental|Cohort B Dose Confirmation|LY3009120 300 mg given orally twice daily every 12 hours for a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met.
88851264|NCT02014116|Experimental|Cohort C Dose Confirmation|LY3009120 300 mg given orally twice daily every 12 hours for a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met.
88851265|NCT02057250|Experimental|Sarilumab 150 mg by AID|Sarilumab 150 mg subcutaneous (SC) injection every 2 weeks (q2w) administered by AID with one or a combination of non-biologic disease-modifying anti-rheumatic drug (DMARD) (hydroxychloroquine, methotrexate, sulfasalazine and/or Leflunomide, except for simultaneous combination use of leflunomide and methotrexate) in AID assessment phase for 12 weeks. Participants who completed 12 weeks AID assessment phase entered in open-label extension phase and received sarilumab 150 mg SC injection q2w administered by PFS with one or a combination of non-biologic DMARD for 52 weeks.
88851266|NCT02057250|Experimental|Sarilumab 150 mg by PFS|Sarilumab 150 mg SC injection q2w administered by PFS with one or a combination of non-biologic DMARD (hydroxychloroquine, methotrexate, sulfasalazine and/or Leflunomide, except for simultaneous combination use of leflunomide and methotrexate) in AID assessment phase for 12 weeks. Participants who completed 12 weeks AID assessment phase entered in open-label extension phase and received sarilumab 150 mg SC injection q2w administered by PFS with one or a combination of non-biologic DMARD for 52 weeks.
88851267|NCT02057250|Experimental|Sarilumab 200 mg by AID|Sarilumab 200 mg SC injection q2w administered by AID with one or a combination of non-biologic DMARD (hydroxychloroquine, methotrexate, sulfasalazine and/or Leflunomide, except for simultaneous combination use of leflunomide and methotrexate) in AID assessment phase for 12 weeks. Participants who completed 12 weeks AID assessment phase entered in open-label extension phase and received sarilumab 150 mg SC injection q2w administered by PFS with one or a combination of non-biologic DMARD for 52 weeks.
88851268|NCT02057250|Experimental|Sarilumab 200 mg by PFS|Sarilumab 200 mg SC injection q2w administered by PFS with one or a combination of non-biologic DMARD (hydroxychloroquine, methotrexate, sulfasalazine and/or Leflunomide, except for simultaneous combination use of leflunomide and methotrexate) in AID assessment phase for 12 weeks. Participants who completed 12 weeks AID assessment phase entered in open-label extension phase and received sarilumab 150 mg SC injection q2w administered by PFS with one or a combination of non-biologic DMARD for 52 weeks.
88851269|NCT02036502|Experimental|Part 1:pembro 2mg/kg+len 25mg+dex 40 mg|Participants in Part 1 with refractory or relapsed and refractory multiple myeloma (rrMM) received pembrolizumab 2 mg/kg once every 2 weeks (Q2W) (Days 1 and 15) in combination with lenalidomide 25 mg (Days 1-21) and dexamethasone 40 mg once weekly (Q1W) during Cycle 1 (28-day cycle).
88851270|NCT02036502|Experimental|Part 1:pembro 2mg/kg+len 10 mg+dex 40 mg|Participants in Part 1 with refractory or relapsed and refractory multiple myeloma (rrMM) received pembrolizumab 2 mg/kg Q2W (Days 1 and 15) in combination with lenalidomide 10 mg (Days 1-21) and dexamethasone 40 mg Q1W during Cycle 1 (28-day cycle).
88851271|NCT02036502|Experimental|Part 2:pembro 200 mg+len 25 mg+dex 40 mg|Participants in Part 2 with refractory or relapsed and refractory multiple myeloma (rrMM) received pembrolizumab 200 mg Q2W (Days 1 and 15) in combination with lenalidomide 25 mg (Days 1-21) and dexamethasone 40 mg Q1W during Cycle 1 (28-day cycle).
88851272|NCT02036502|Experimental|Part 2:pembro 200 mg+len 25 mg+dex 20 mg|Participants in Part 2 with refractory or relapsed and refractory multiple myeloma (rrMM) received pembrolizumab 200 mg Q2W (Days 1 and 15) in combination with lenalidomide 25 mg (Days 1-21) and dexamethasone 20 mg Q1W during Cycle 1 (28- day cycle).
88851273|NCT02036502|Experimental|Part 2:pembro 200 mg+len 10 mg+dex 40 mg|Participants in Part 2 with refractory or relapsed and refractory multiple myeloma (rrMM) received pembrolizumab 200 mg Q2W (Days 1 and 15) in combination with lenalidomide 10 mg (Days 1-21) and dexamethasone 40 mg Q1W during Cycle 1 (28-day cycle).
88851274|NCT02036502|Experimental|Part 3:pembro 200 mg+len 25 mg+dex 40 mg|Participants in Part 3 with refractory or relapsed and refractory multiple myeloma (rrMM) received pembrolizumab 200 mg Q2W (Days 1 and 15) in combination with lenalidomide 25 mg (Days 1-21) and dexamethasone 40 mg Q1W weekly during each 28-day cycle.
88851275|NCT02036502|Experimental|Part 3:pembro 200 mg+len 25 mg+dex 20 mg|Participants in Part 3 with refractory or relapsed and refractory multiple myeloma (rrMM) received pembrolizumab 200 mg Q2W (Days 1 and 15) in combination with lenalidomide 25 mg (Days 1-21) and dexamethasone 20 mg Q1W weekly during each 28-day cycle.
88851276|NCT02036502|Experimental|Part 3:pembro 200 mg+carf 56 mg/m^2+dex 20 mg|Participants in Part 3 with relapsed or refractory multiple myeloma (rMM) received pembrolizumab 200 mg Q3W in combination with carfilzomib 56 mg/m^2 (Days 1, 2, 8, 9, 15, 16) and dexamethasone 20 mg once or twice weekly (Days 1, 2, 8, 9, 15, 16, 22, 23) during each 28-day cycle.
89378385|NCT05230966|No Intervention|Group 2 - angina pectoris + STEMI+ PCI|Patients with acute myocardial infarction with ST-segment elevation, < 6 hours from the onset of chest pain and preceding symptoms of angina pectoris with primary percutaneous coronary intervention.
88851277|NCT02056626|Active Comparator|arm 2|partial reinforcement, 6.25 mg twice daily, 25% of time (15 days)
88851278|NCT02056626|Active Comparator|arm 3|controlled dosing schedule 6.25 mg twice daily (15 days)
88851279|NCT02056626|Active Comparator|arm 4|controlled dosing schedule 6.25 mg twice daily, every other day (15 days)
88851280|NCT02056626|Active Comparator|arm 1|standard therapy, 25 mg twice daily (15 days)
88851281|NCT02035332|Experimental|Aurora Treatment Arm|Endometrial Ablation
88851282|NCT02056392|Experimental|Selumetinib 75mg|Volunteers will receive selumetinib 75mg administered by mouth, as a capsule
88851283|NCT02056392|Active Comparator|Moxifloxacin 400 mg|Volunteers will receive moxifloxacin 400mg administered by mouth, as a capsule
88851284|NCT02056392|Placebo Comparator|Selumetinib 75mg placebo|Volunteers will receive selumetinib 75mg placebo, administered by mouth, as a capsule.
88851285|NCT02034708|Experimental|Dotarem®/Gadovist®|Dotarem®-enhanced MRI, then Gadovist®/Gadavist®-enhanced MRI
88851286|NCT02034708|Experimental|Gadovist®/Dotarem®|Gadovist®/Gadavist®-enhanced MRI then Dotarem® enhanced MRI
88851287|NCT02034552|Experimental|Radium-223 dichloride (Xofigo, BAY88-8223)|
88851288|NCT02034552|Experimental|Radium-223 with abiraterone&prednisone|
88851289|NCT02034552|Experimental|Radium-223 with enzalutamide|
88851290|NCT02034474|Experimental|tocilizumab|Tocilizumab will be administered at day 0, week 4 and week 8 via an iv drip over 60 min. Dose is 8mg/kg but may be reduced to 4mg/kg if intolerable. Maximum dose will be 800mg.
88851291|NCT02034474|Placebo Comparator|Placebo|Placebo will be administered intravenously via an iv drip over 60 min
88851292|NCT02011542|Placebo Comparator|Placebo|Placebo (not an active drug/ Inactive component) is given to this group
88851293|NCT02011542|Active Comparator|VSL #3|VSL #3 (probiotic mixture) is given to this group
88851294|NCT02011386||Treatment|Treatment: Injection Golimumab 50 mg every month on the same date
88851295|NCT02010684|No Intervention|Wait-listed Control Group|Participants in the Wait-listed Control Group will receive augmented access and communication with a primary care provider. The augmentation would consist of providing the participant with a letter to be shared with their primary care doctor indicating their Hb A1c level and depression score at the time of eligibility screening. The research team will also attach a list of local mental health service providers to the letter. The participants randomized to the wait-listed control group will also be offered access to the intervention after the trial is completed in the event that the randomized controlled trial (RCT) has significant results.
88851296|NCT02010684|Experimental|Empowerment and CBT Classes|"Participants will attend weekly 2-hour group Empowerment and CBT classes for 12 weeks led by two trained health educators. Participants will learn cognitive behavioral therapy (CBT) techniques to manage their mood. After CBT, participants will learn a diabetes education format that is grounded in empowerment theory that employs group problem solving, individualized goal setting, and personal behavioral change experiments designed to help patients set priorities and to become better self-managers of both diabetes and their mood. As part of the intervention activities, group members will be advised to monitor their blood sugar levels, blood pressure, and mood on a daily basis."
88851297|NCT02034162|Active Comparator|Mebendazole|Mebendazole will be administered as a single 500-mg chewable tablet in a double-blind manner at the baseline visit (Day 1) and in an open-label manner at Visit 4 (Day 21).
88851298|NCT02034162|Placebo Comparator|Placebo|Matching placebo will be administered as a single-dose chewable tablet in a double-blind manner at the baseline visit (Day 1).
88851299|NCT02034006|Experimental|Ranibizumab|Patients treated with a single ranibizumab 0.5 mg/0.05ml intravitreal injection
88851300|NCT02054910|Experimental|Celiac Plexus Block|Celiac Plexus Block will be administered following EUS
88851301|NCT02054910|Sham Comparator|Sham|A celiac plexus block will not be administered for pain management
88851302|NCT04714398|Experimental|Opt-In Recruitment|All recruitment messaging will be framed for patients as they must opt-in to participate in the remote monitoring program.
88851303|NCT04714398|Experimental|Opt-Out|All recruitment messaging will be framed as though participation is the default, and patients must opt-out of participating in the remote monitoring program.
88851304|NCT04714398|No Intervention|Usual Care|Patients in the usual care arm will not be contacted by study staff, they will not receive a blood pressure cuff, and they will not be asked to participate in any component of the blood pressure monitoring program.
88851305|NCT02033850|Experimental|APT-II group|"Intervention: rehabilitation of attention using the Attention Process Training-II.~Participants in the APT-II group will receive overall up to 40 hours of individual attention process training. Therapy will be administered in one two-hour session each week over a total of 20 weeks."
88851306|NCT02033850|No Intervention|standard care group|Participants in the standard care group will not receive cognitive training or rehabilitation interventions, will be instructed to have an usual lifestyle, and will be conventionally provided of medication and clinic consultations
88851307|NCT02054130|Placebo Comparator|Placebo|Participants received placebo matched to MEDI9929 subcutaneously once every 2 weeks from Day 1 to Week 50.
88851308|NCT02054130|Experimental|MEDI9929 70 mg|Participants received 70 milligram (mg) of MEDI9929 subcutaneously once every 4 weeks from Day 1 to Week 48 along with subcutaneous placebo once every 4 weeks from Week 2 to Week 50.
88851309|NCT02054130|Experimental|MEDI9929 210 mg|Participants received 210 mg of MEDI9929 subcutaneously once every 4 weeks from Day 1 to Week 48 along with subcutaneous placebo once every 4 weeks from Week 2 to Week 50.
88851310|NCT02054130|Experimental|MEDI9929 280 mg|Participants received 280 mg of MEDI9929 subcutaneously once every 2 weeks from Day 1 to Week 50.
88851311|NCT04673682|Experimental|Group 1|"Treatment A: Reference drug(D309(Testosterone) 1 vial, once, i.m. inj.)~Treatment B: Test drug(CKD-845(Testosterone) 1 vial, once, i.m. inj.)"
88851312|NCT04673682|Experimental|Group 2|"Treatment B: Test drug(CKD-845(Testosterone) 1 vial, once, i.m. inj.)~Treatment A: Reference drug(D309(Testosterone) 1 vial, once, i.m. inj.)"
88851313|NCT02009046|Experimental|SEI Classroom Curriculum|Participants receive the SEI classroom curriculum.
88851314|NCT02009046|Active Comparator|Control Classroom Curriculum|Participants receive the control classroom curriculum.
88851315|NCT02009046|Experimental|SEI Curriculum + 3 School Components|Participants receive SEI classroom curriculum and three school wide components (peer advocacy and education, parent education, clinical services linkages).
88851316|NCT02009046|Active Comparator|Control Curriculum + 1 School Component|Participants receive control classroom curriculum and one of the three school wide components (clinical services linkages).
88851317|NCT02052960|Experimental|CetuGEX™ plus chemotherapy|720 mg weekly administration
88851318|NCT02052960|Active Comparator|Cetuximab plus chemotherapy|250 mg/m2 weekly administration
88851319|NCT02008890|Experimental|Secukinumab 300mg|"Secukinumab 300mg once weekly at Weeks 1, 2 and 3, thereafter at 4-weekly intervals starting Week 4 until Week 48.~In order to maintain the blinding beyond the primary endpoint, placebo was administered at Weeks 17, 18 and 19.~For extension period: Secukinumab 300mg at 4-weekly intervals starting Week 52 up to Week 148."
88851320|NCT02008890|Experimental|Secukinumab 150mg|"Secukinumab 150mg once weekly at Weeks 1, 2 and 3, thereafter at 4-weekly intervals starting Week 4 until Week 48.~In order to maintain the blinding beyond the primary endpoint, placebo was administered at Weeks 17, 18 and 19.~For extension period: Secukinumab 150mg at 4-weekly intervals starting Week 52 up to Week 148."
88851321|NCT02008890|Placebo Comparator|Placebo|Placebo once weekly at Weeks 1, 2 and 3, thereafter at 4-weekly intervals starting Week 4 until Week 12. Patients who achieved ppPASI 75 at Week 16 remained on placebo treatment Until week 48 and were not eligible to enter the extension. Patients who did not achieve ppPASI 75 at Week 16 were re-randomized to receive Secukinumab 150mg or Secukinumab 300mg from Week 16 onwards up to Week 148.
88851322|NCT02052414|Experimental|Gralise (Gabapentin ER)|"All patients will be treated with Gralise. Patients who are on pregabalin or gabapentin (lyrica or neurontin) will need to wash off the medication before starting Gralise.~Patients who are ready to take Gralise will start with starter pack, and will gradually titrate the dose up to 1800mg per day. After that, patient will take 1800mg per day out of the bottle.~Patient will be seen in clinic at 4weeks intervals for first 4 visits, and then there will be end of the study visit on week 15. On visit 4, week 12 of treatment, patients will be taught to taper off the study medication."
89378386|NCT05230966|Active Comparator|Group 3 - without angina pectoris + STEMi + RIC + PCI|Patients with acute myocardial infarction with ST-segment elevation, < 6 hours from the onset of chest pain and without preceding symptoms of angina pectoris with primary percutaneous coronary intervention during which it's carried out remote ischemic conditioning (RIC)
89378387|NCT05230966|No Intervention|Group 4 - without angina pectoris + STEMI + PCI|Patients with acute myocardial infarction with ST-segment elevation, < 6 hours from the onset of chest pain and without preceding symptoms of angina pectoris with primary percutaneous coronary intervention.
88851323|NCT02007954|Experimental|DEBDOX|
88851324|NCT02049450|Experimental|INC424 (ruxolitinib) - Study Treatment|Regularly transfused adult patients with thalassemia and spleen enlargement.
89378388|NCT05230966|Active Comparator|Group 5 - healthy + RIC|healthy volunteers of the same age and sex, whose samples will be taken after the RIC procedure
88851325|NCT02031432|Experimental|Cebranopadol|"Cebranopadol 200 µg to 1000 µg per taken taken once a day in the morning.~Allowed dose levels in the Maintenance Phase were 200, 400, 600, 800, or 1000 µg per day."
88851326|NCT02031276|Placebo Comparator|Double-blind Placebo IV|Participants randomized to receive double-blind placebo for risankizumab by intravenous (IV) injection for 12 weeks in Period 1, followed by open-label risankizumab 600 mg IV in Period 2, then open-label risankizumab 180 mg by subcutaneous (SC) injection in Period 3.
88851327|NCT02031276|Experimental|Double-blind Risankizumab 200 mg IV|Participants randomized to receive double-blind risankizumab 200 mg by intravenous (IV) injection for 12 weeks in Period 1, followed by open-label risankizumab 600 mg IV in Period 2, then open-label risankizumab 180 mg by subcutaneous (SC) injection in Period 3.
88851328|NCT02031276|Experimental|Double-blind Risankizumab 600 mg IV|Participants randomized to receive double-blind risankizumab 600 mg by intravenous (IV) injection for 12 weeks in Period 1, followed by open-label risankizumab 600 mg IV in Period 2, then open-label risankizumab 180 mg by subcutaneous (SC) injection in Period 3.
89378389|NCT02350582|Experimental|Telerehabilitation|Resistence and endurance exercise adapted to individual requeriment using internet to monitor progression during chemotherapy treatment. Telerehabilitation eCUIDATE system
89378390|NCT02350582|No Intervention|Control group|usual care offered to patients during chemotherapy treatment
89378391|NCT02350504|Experimental|Full interactive instruction|Full interactive instruction- which will include an instructional booklet, a movie and a simulator's practice
89378392|NCT02350504|Placebo Comparator|Partial instruction|Partial instruction which included the booklet only.
89378393|NCT03149536|Active Comparator|Group 1|recombinant FSH starting dose: 100 IU to develop a pharmacogenetic test
89378394|NCT03149536|Active Comparator|Group 2|recombinant FSH starting dose: 125 IU to develop a pharmacogenetic test
89378395|NCT03149536|Active Comparator|Group 3|recombinant FSH starting dose: 150 IU to develop a pharmacogenetic test
89378396|NCT03149536|Active Comparator|Group 4|recombinant FSH starting dose: 175 IU to develop a pharmacogenetic test
89378397|NCT03149536|Active Comparator|Group 5|recombinant FSH starting dose: 200 IU to develop a pharmacogenetic test
89378398|NCT03149536|Active Comparator|Group 6|recombinant FSH starting dose: 225 IU to develop a pharmacogenetic test
89378399|NCT02341690|Active Comparator|Control|Standard rehabilitation with exercise
89378400|NCT02341690|Experimental|Intervention (Interval Walking Training)|"Interval Walking Training with the InterWalk app, 3 times per week, 60 min. per sessions for 52 weeks. The intervention period is divided into~a period that follows standard care in the municipality (from 8-14 weeks according to the municipality.~a period (from week 8-14 to week 52) the patients will do Interval Walking on their own.~After the intervention at the promotion centre (8-14 weeks), the intervention group will be divided into to groups - a Interval Walking group (IWT) and a Interval Walking group with support (IWTsupport).~IWTsupport: Patients in this group (after intervention at the promotion centre) will in addition to the IWT receive motivational support from week 8-14 to week 52 by the health professionals at the promotion centre."
89378401|NCT03657264|Experimental|Sequence 1|"The sequence of administration is: P/ScD/PC/CD~Where:~P = Placebo (Nacl 0.9%)~CD = P03277 tested at 0.1 mmol/kg~ScD = P03277 tested at 0.3 mmol/kg~PC = Positive control (moxifloxacin 400 mg - per os)."
89378402|NCT03657264|Experimental|Sequence 2|"The sequence of administration is: CD/PC/ScD/P~Where:~P = Placebo (Nacl 0.9%)~CD = P03277 tested at 0.1 mmol/kg~ScD = P03277 tested at 0.3 mmol/kg~PC = Positive control (moxifloxacin 400 mg - per os)."
89378403|NCT03657264|Experimental|Sequence 3|"The sequence of administration is: ScD/CD/P/PC~Where:~P = Placebo (Nacl 0.9%)~CD = P03277 tested at 0.1 mmol/kg~ScD = P03277 tested at 0.3 mmol/kg~PC = Positive control (moxifloxacin 400 mg - per os)."
89378404|NCT03657264|Experimental|Sequence 4|"The sequence of administration is: PC/P/CD/ScD~Where:~P = Placebo (Nacl 0.9%)~CD = P03277 tested at 0.1 mmol/kg~ScD = P03277 tested at 0.3 mmol/kg~PC = Positive control (moxifloxacin 400 mg - per os)."
89378405|NCT02345824|Experimental|Ribociclib (LEE011) Treatment|Patients will be treated with ribociclib (LEE011) (recommended phase 2 dose of 600 mg/day) for 8-21 days prior to surgery. For preliminary evaluation of efficacy and toxicity, patients with Rb-positive tumors will resume treatment with ribociclib at 14-28 days post-surgery on a schedule of 21 days on, 7 days off in a 28-day cycle. Patients will be treated until unacceptable toxicity is observed, or until disease progression as assessed by radiographic or clinical metrics.
89378406|NCT02345902|Experimental|Haloperidol and non-pharmacologic|"Haloperidol 1.25mg PO q. d. during nine days~Non-pharmacologic measures:~A. Reorientation (i.e., calendar, clocks, familiar objects) B. Glasses and hearing devices for the particular patients needing such aids C. Avoidance of physical restraints D. Limitation of excessive personnel shifts or hospital room E. A tranquil and comfortable environment, especially at night, to avoid interruptions (i.e., dim light, low levels of noise) F. Adequate schedules for medication administration and to take vital signs or medical procedures G. Sleep hygiene (light in the room and movement during the day) H. Avoidance of dehydration I. Avoidance of medications use which are associated with delirium (e.g., psychoactive medications)"
89378407|NCT02345902|Active Comparator|Placebo and non-pharmacologic|"Placebo 1.25 mg PO q.d during nine days.~Non-pharmacologic measures:~A. Reorientation (i.e., calendar, clocks, familiar objects) B. Glasses and hearing devices for the particular patients needing such aids C. Avoidance of physical restraints D. Limitation of excessive personnel shifts or hospital room E. A tranquil and comfortable environment, especially at night, to avoid interruptions (i.e., dim light, low levels of noise) F. Adequate schedules for medication administration and to take vital signs or medical procedures G. Sleep hygiene (light in the room and movement during the day) H. Avoidance of dehydration I. Avoidance of medications use which are associated with delirium (e.g., psychoactive medications)"
89378408|NCT05462808|Experimental|Atraumatic Restorative Treatment restorations with high-viscosity glass ionomer cement|Under cotton roll isolation, teeth were restored with EQUIA Forte cement. A layer of EQUIA Forte Coat was applied with a microbrush on surface and then light cured for 20 s
89378409|NCT05462808|Experimental|restorations with Hall technique|In the Hall technique group, the deposits on the occlusal surface of the teeth were gently removed, SSC (3M ESPE, St. Paul, USA) was placed and were cemented using GIC. The crown was pressed tightly.
89002562|NCT06316310|Active Comparator|Acupoint Thread Embedding group+health education|Acupuncture thread embedding (ATE), extension and development of acupuncture therapy, which emerged in mid 1950s, is an acupoint stimulation technique which sterile biodegradable threads (such as polydioxanone (PDO) threads) are inserted into acupuncture points, by using hollow core embedding needles. The aim of this therapy is provide long term stimulation of acupoints, making this technique one of the most commonly used methods for treating obesity.
89378410|NCT03149614|Active Comparator|Spine Mobilizations|Patients receive spinal mobilizations in grades II to III of central posterior-anterior from cervical and thoracic spine as described Maitland in 2000.
89378411|NCT03149614|Experimental|Vertebral Resonant Oscillation (POLD method)|"The vertebral resonant oscillation using the POLD method is similar to spine mobilizations, but there are some differens; the oscillatory movement has a sinusoidal waveform, the frequency used between 1.2 and 2 Hz and the amplitude is similar to neutral zone to described by Panjabi 1992."
89378412|NCT02350270||cognitively healthy individuals (CHI)|CHI were participants without objective cognitive impairment
89378413|NCT02350270||mild cognitive impairment (MCI)|MCI was diagnosed if participants met the following criteria: presence of spontaneous cognitive complaints and objective cognitive impairment
89378414|NCT02350270||mild and moderate dementia|Diagnoses of dementia were assigned according to the Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV TR, 2000; Association, 2000; 22) at consensus diagnostic case conferences
89378415|NCT04477954|Experimental|Experimental HBOT|Treatment (device). Patients will receive 90 minutes of hyperbaric oxygen at 1,45 ATA in a Revitalair430 hyperbaric chamber, and then they will continue with standard care and normobaric oxygen.
89378416|NCT04477954|No Intervention|Standard care|
89378417|NCT02345980|Active Comparator|Sildenafil|Patient in this arm will receive sildenafil citrate 50 mg tablet once daily after ureteral stent fixation.
89378418|NCT02345980|Placebo Comparator|Placebo|Patient in this arm will receive placebo daily after ureteral stent fixation.
89378419|NCT02346058|Experimental|Esarin Gel|"Dosage form:One tube of Esarin Gel contains 20 gm of compound. Each gm contains:10 mg Heparinoid, 10 mg Escin, 50 mg Diethylamine Salicylate.~Dosage and frequency: Approx. 3-5 cm Gel was applied topically on skin.twice daily.~Duration: 28 days."
89378420|NCT02345746|Experimental|Hepatic Artery Infusion|Hepatic Arterial Infusion (HAI) with the drugs Oxaliplatin, Folinic Acid and 5 Fluorouracil
89378421|NCT03629808||Group1: 4-6cm|4-6cm from starting point of gastrectomy to pylorus
89378422|NCT03629808||Group2: 2-4cm|2-4cm from starting point of gastrectomy to pylorus
89378423|NCT02341612|Experimental|single exposure at 5°C in CWI|The subjects of this group performed cold water immersion (CWI) immediately after exercise-induced muscle damage (EIMD) a single exposure at 5°C for 20 minutes.
89378424|NCT02341612|Experimental|single exposure at 15°C in CWI|The subjects of this group performed CWI immediately after EIMD a single exposure at 15°C for 20 minutes.
89378425|NCT02341612|Experimental|multiple exposures at 10°C in CWI|The subjects of this group performed CWI immediately, 24h, 48h and 72h after EIMD (once a day) for 20 minutes.
89378426|NCT02341612|Experimental|whole body criotherapy (WBC)|The whole body criotherapy (WBC) group remained in the cabin immediately after EIMD for 3 minutes.
89378427|NCT02341612|Experimental|passive recovery|The control group was not exposed to treatment after the EIMD protocol.
88851329|NCT04686864|Experimental|Parent Support Group|Support and psychoeducation in a group setting for parents who have a child or adolescent with an eating disorder.
89378428|NCT02341378|Experimental|TissueGene-C (Low dose)|Single intra-articular injection to the damaged knee joint at a dose of 6.0 x 10^6 cells
89378429|NCT02341378|Experimental|TissueGene-C (High dose)|Single intra-articular injection to the damaged knee joint at a dose of 1.8 x 10^7 cells
89378430|NCT03794778|Experimental|study group|pegylated liposomal doxorubicin 30 mg/m2, i.v.,d1; carboplatin AUC 5,i.v.,d1; once every 21days, 3~6 cycles for early stage patients and 6 cycles for late stage.
89378431|NCT03794778|Active Comparator|chemotherapy|paclitaxel 175 mg/m2, i.v.,d1; carboplatin AUC 5, i.v.,d1; once every 21days, 3~6 cycles for early stage patients and 6 cycles for late stage.
89378432|NCT03530345|Experimental|Neridronic acid|"Neridronic acid 100 mg - 4 intravenous (i.v.) infusions within 10 days (i.e., on Days 1, 4, 7, and 10). The investigational medicinal product (IMP) was diluted in sterile normal saline to a volume of approximately 500 mL before slow administration.~The maximum neridronic acid dose was 800 mg: 400 mg in Treatment Period A and 400 mg in Treatment Period B."
89378433|NCT03530345|Placebo Comparator|Placebo|Matching placebo - 4 intravenous infusions within 10 days (i.e., on Days 1, 4, 7, and 10). The IMP was diluted in sterile normal saline to a volume of approximately 500 mL before slow administration.
89378434|NCT02350114|Experimental|Functional Capacity|6 Minute Walk Test
89378435|NCT03790332|Experimental|Phase 1/2|"Part A: Subjects ≥1 to <12 years of age with moderate or severe cGVHD after failure of 1 or more lines of systemic therapy, will receive oral ibrutinib once daily to determine Recommended Pediatric Equivalent Dose (RPED).~Part A Continuation: Subjects participating in Part A may continue receiving daily ibrutinib until the RPED is determined, at which time their dose may be adjusted to the RPED.~Part B: Subjects ≥1 to <12 years of age( upper age limit is < 22 years) with moderate or severe cGVHD after failure of 1 or more lines of systemic therapy or with newly diagnosed moderate or severe cGVHD will be dosed at the RPED. Subjects ≥12 will be given 420mg orally ibrutinib once daily."
89399431|NCT03686085|Experimental|dinoprostone arm|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia & Upjohn, Puurs, Belgium) inserted by the study nurse 6 hours before IUD insertion.
89399432|NCT03686085|Placebo Comparator|placebo|one tablet of placebo inserted by the study nurse 6 hours before IUD insertion.
88851330|NCT02007720|Placebo Comparator|Placebo|Patients will receive continuous intravenous infusion of matching placebo serelaxin for 48 hours.
88851331|NCT02007720|Experimental|Serelaxin|Patients will receive continuous intravenous infusion of serelaxin(30 µg/kg/day) for 48 hours.
88851332|NCT01363440|Active Comparator|Macular Laser Photocoagulation Treatment (Control)|Participants received macular laser treatment at baseline and as-needed at visits at which laser re-treatment criteria were met, but no more frequently than every 12 weeks.
88851333|NCT01363440|Experimental|Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q4|Participants received 2mg Intravitreal aflibercept injection (IAI) every 4 weeks.
88851334|NCT01363440|Experimental|Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q8|Participants received 2mg Intravitreal aflibercept injection (IAI) every 4 weeks for 5 visits followed by injections every 8 weeks.
89378436|NCT02350192|Experimental|e-health educational intervention (eHEI)|Participants in the intervention group received usual care and additional individualized educational intervention administered by a trained nurse who was experienced in cardiac nursing. The exercise prescription had been set as walking exercise for 30 minutes per day for 5 days per week. The exercise dosage might be modified with physician's order to suit the individual's physical condition and agreed goals if necessary. The 30- minutes educational intervention was conducted in a private room of the clinic. The content covered general information related to coronary heart disease and benefit of performing exercise, the e-health educational intervention (eHEI) link demonstration and re-demonstration. In addition, one telephone follow-up was conducted at week 2 to facilitate the usage of the e-HEI link.
89378437|NCT02350192|No Intervention|Control group|Control group received standard care only. The control group also received standard usual care comprising the doctor follow up with medication. During an individualized educational session conducted by a trained research assistant , a briefing on healthy life style and an an additional educational leaflet about coronary heart disease which is customarily given to patient with cardiovascular risks was given to the patient. In the control group, no e-health educational intervention has been provided to the patients of the control group.
89378438|NCT02341300|Experimental|Cast-Iron Pot|The treatment arm will receive a 12 inch pre seasoned cast iron pot
89378439|NCT02341300|Placebo Comparator|Aluminum Pot|12 inch nonstick aluminum fry pan
89378440|NCT02341222|Experimental|BP self-standing felt device|BP device will be implanted under fascia group-A, operated subjects. A lumbar 4-5 cm incision will be performed, splaying of the skin and subcutaneous layers, then will be incised the fascia plane, with a blunt dissection the fascia will be separated from muscles. Fifteen rats will receive 2x2cm2 samples of BP (Buckypaper) in a pocket created between muscular fascia and large muscles. The rough opaque surface will face the muscle surface and the smooth brilliant surface will face the lower muscular fascia surface, without fixation with stitches. Then the scar will be sutured with absorbable stitches on the fascia incision edge and not absorbable stitches on the skin.
89378441|NCT02341222|Active Comparator|PR (parietene) mesh device|A lumbar 4-5 cm incision will be performed, splaying of the skin and subcutaneous layers, then will be incised the fascia plane, with a blunt dissection the fascia will be separated from muscles. Fifteen rats (hereafter defined as BPR16-BPR30) will receive 2x2cm2 samples of PP (polypropylene) in a pocket created between muscular fascia and large muscles. The polypropylene prosthesis will be fixed to the muscle with absorbable sutures surface and then the muscular fascia will be sutured over the prosthesis, with absorbable stitches on the fascia. Not absorbable stitches will be sutured on the skin.
89378442|NCT03723317||Training liver transplantation|Patients consecutively transplanted in four European collaborative LT Centres (Ancona, Brussels, Rome Sapienza, and Padua) (N=1,262)
88851335|NCT02007252|Experimental|ACZ885|Participants received ACZ885 150 mg subcutaneously (s.c.) once per month for 12 months.
88851336|NCT02007252|Placebo Comparator|Placebo|Participants received matching placebo to ACZ885 s.c. once per month for 12 months.
88851337|NCT02007096|Experimental|Transabdominal Plane Block|Receiving Transabdominal Plane Block with 0.25% bupivacaine
88851338|NCT02007096|Placebo Comparator|Non Transabdominal Plane Block|Receiving placebo saline injection
88851339|NCT02006706|Experimental|MabThera/Rituxan|
88851340|NCT02049138|Experimental|Upadacitinib|"Participants received treatment with upadacitinib for up to 312 weeks. The starting dose was 6 mg twice a day (BID). Participants who did not achieve a 20% improvement from RCT Baseline in both Tender Joint Count (TJC) and Swollen Joint Count (SJC) at Week 6 or Week 12 were up-titrated to 12 mg BID. From January 2017 participants were transitioned to a once-daily (QD) regimen of upadacitinib, either 15 mg QD (participants who were taking 6 mg BID) or 30 mg QD (participants taking 12 mg BID). Starting with Protocol Amendment 5 participants receiving 30 mg QD upadacitinib had the option to decrease the dose to 15 mg QD at the investigator's discretion.~A subset of participants who opted-in to the vaccine substudy received a single-dose of 0.5 mL intramuscular injection of pneumococcal 13-valent conjugate vaccine (PCV-13)."
88851341|NCT04686318||suspected acute pyelonephritis|All patients admitted to the emergency department with suspected acute pyelonephritis assessed by the receiving physician
88851342|NCT02048904|Active Comparator|Sitagliptin|100 mg/day for 3 months
88851343|NCT02048904|Placebo Comparator|Placebo|1 pill/day for 3 months
88851344|NCT02006628|Active Comparator|GWP42003 1000 milligrams (mg)/day|Participants received GWP42003 (100 mg/milliliter [mL]), 5 mL twice daily (BID) administered orally, 5 mL in the morning and 5 mL in the evening for 6 weeks.
88851345|NCT02006628|Placebo Comparator|Placebo|Participants received placebo (0 mL cannabidiol [CBD]), volume matched to the 5 mL BID dose level, administered orally, 5 mL in the morning and 5 mL in the evening for 6 weeks.
88851346|NCT02048826|Experimental|FINGER I|Subjects participate in 3 weeks of exercising with the experimental device: FINGER robot with first setting at a minimum of 3 days per week, 1 hour per day with the exercise program
89378443|NCT03723317||Validation liver transplantation|Patients consecutively transplanted in the Karolinska Institute (N=520)
89378444|NCT05462418|Active Comparator|diathermy group|Patients' incisions are completed using the unipolar diathermy from Whiteline until we reach the parietal peritoneum (cutting the Whiteline then coagulating until reaching the peritoneum). The used diathermy frequency was 50-70 MHz.
89378445|NCT05462418|Active Comparator|scalpel|patients had their incisions completed using the surgical scalpel till we reach the parietal peritoneum.
89399433|NCT03693963|Other|Single Arm, treated with Serranator|Subjects treated with Serrantor
88851347|NCT02048826|Experimental|FINGER II|Subjects participate in 3 weeks of exercising with the experimental device: FINGER robot with a second setting at a minimum of 3 days per week, 1 hour per day with the exercise program
88851348|NCT02006472|Experimental|Pridopidine 45 mg|Twice daily
88851349|NCT02006472|Experimental|Pridopidine 67.5 mg|Twice daily
88851350|NCT02006472|Experimental|Pridopidine 90 mg|Twice daily
88851351|NCT02006472|Experimental|Pridopidine 112.5 mg|Twice daily
88851352|NCT02006472|Placebo Comparator|Placebo|Twice daily
88851353|NCT02005692|Experimental|DynaSense sensor|
89378446|NCT03721211|Experimental|[11C]Martinostat|"Subjects will be administered [11C]Martinostat, which is synthesized on site at the MGH Martinos Imaging Center~All subjects will undergo an MR-PET scan of the thorax, including the breasts, to determine tumor uptake~All subjects will be scanned using [11C]Martinostat during an imaging session on a Siemens Biograph mMR integrated MR-PET scanner~PET imaging will begin concomitant with radiotracer administration"
89378447|NCT03426072|Experimental|modified IHI breakthrough series|"The SCOPE intervention is a complex, high facilitation, multi-component intervention operating at the microsystem (resident care unit) level of the organization and is designed to engage, develop, and equip Health Care Aides to implement improvement initiatives."
89378448|NCT03426072|No Intervention|Control|The control units (propensity matched) have no intervention and form a naturalistic control
89378449|NCT02341066||Rheumatoid Arthritis|Rheumatoid arthritis patients free of overt cardiovascular disease. Endothelial Dysfunction evaluation by EndoPAT
89378450|NCT03726827||population|self selected members of the general population who perceive a value in having a Fibroscan screening test of their liver
89378451|NCT05764356||Novel oral anticoagulants cohort|
89378452|NCT05764356||Ticagrelor cohort|
89378453|NCT02345668|Experimental|Transdiagnostic Internet-based Treatment|Intervention group that carries out the Emotion Regulation Protocol and receives support by the therapist (a brief weekly two-minute phone call without clinical content and two weekly orientative text messages)
89378454|NCT02345668|Experimental|Treatment as Usual|Intervention group that receives psychological and/or pharmacological treatment from a clinician of the mental health unit.
89378455|NCT03500159|Experimental|AQX-1125|AQX-1125 200 mg
89378456|NCT03500159|Placebo Comparator|Placebo|Matching placebo
89378457|NCT02345278|Placebo Comparator|Placebo|once daily sublingual administration for 1 month
89378458|NCT02345278|Active Comparator|SUBLIVAC FIX Mite mixture 10,000 AU/mL|once daily sublingual administration for 1 month
89378459|NCT02345278|Active Comparator|SUBLIVAC FIX Mite mixture 25,000 AU/mL|once daily sublingual administration for 1 month
88851354|NCT02029638|Experimental|RICG, BMT and high dose PT/Cy+SOC|"Reduced-intensity conditioning regimen (RICG), bone marrow transplantation (BMT), high dose post-transplant cyclophosphamide (PT/Cy) and Standard of Care (SOC).~Participants will receive: ATG (pre-transplant), pre-medicated with acetaminophen, diphenhydramine; steroid taper of methylprednisolone; fludarabine (2-6 days before transplant), and low-dose cyclophosphamide (pre- transplant); total body irradiation the day before transplant. Participants will receive a living renal transplant followed by BMT. High-dose cyclophosphamide will be given on days 3 and 4 post-transplant with MESNA. Filgrastim will be given on day 5 post-transplant and continue until absolute neutrophil recovery. Standard immunosuppression of tacrolimus, MMF, and prednisone will begin on day 5 post-transplant and be given ≥26 weeks post-transplant. Eligible participants will be gradually withdrawn from medication over a period of 24-40 weeks."
88851355|NCT04710654|Other|Control|"Behavioural therapy~Exercise program"
88851356|NCT04710654|Active Comparator|connective tissue manipulation|
88851357|NCT04710654|Active Comparator|Interferential current stimulation (100 Hz frequency)|
88851358|NCT04710654|Active Comparator|Interferential current stimulation (0-100 Hz frequency)|
89182556|NCT06239727|Other|Not-enrolled population|All participants will receive induction chemotherapy and immunotherapy (every 3 weeks × 3 cycles of gemcitabine 1000 mg/m2 day 1, 8 + cisplatin 80 mg/m2 day 1 + camrelizumab 200 mg day 1) followed by conventional-dose intensity-modulated radiation therapy (IMRT; 6996cGy, 33 fractions, 5 fractions/week, 1 fraction/day). During the radiotherapy, all the participants will receive concurrent chemotherapy (every 3 weeks × 2 cycles of cisplatin 100 mg/m2 day 1). After 3 weeks of the completion of concurrent chemoradiotherapy, adjuvant camrelizumab (200 mg per cycle) will be administrated every 3 weeks for 9 cycles. Besides, all the participants should also receive metronomic adjuvant capecitabine chemotherapy (capecitabine 650 mg/m2 p.o. BID 1 year) immediately after the completion of concurrent chemoradiotherapy.
89182557|NCT06239714|Experimental|SGB-3403(SAD)|
89182558|NCT06239714|Placebo Comparator|placebo(SAD)|
89182559|NCT06239714|Experimental|SGB-3403(Non-Statin MAD)|
89378460|NCT02345278|Active Comparator|SUBLIVAC FIX Mite mixture 50,000 AU/mL|once daily sublingual administration for 1 month
89378461|NCT02345278|Active Comparator|SUBLIVAC FIX Mite mixture 100,000 AU/mL|once daily sublingual administration for 1 month
89378462|NCT03785340|Experimental|OCU-310|Brimonidine Tartrate Nanoemulsion Eye Drops 0.20% given 2 times a day for 4 weeks
89378463|NCT03785340|Placebo Comparator|Placebos|Ophthalmic buffered saline Eye Drops given 2 times a day for 4 weeks
89378464|NCT02345590|Experimental|Eplerenone|25mg Eplerenone once daily for 12 months
88851359|NCT02047734|Experimental|Ozanimod 0.5 mg|Ozanimod 0.5 mg oral capsules daily and a weekly intramuscular placebo injection (identical in appearance to Interferon) for 24 months.
89182560|NCT06239714|Placebo Comparator|placebo(Non-Statin MAD)|
89182561|NCT06239714|Experimental|SGB-3403 and atorvastatin(statin MAD)|
89182562|NCT06239714|Placebo Comparator|placebo and atorvastatin(statin MAD)|
89378465|NCT02345590|Placebo Comparator|Matching placebo|Matching placebo once daily for 12 months
89378466|NCT03499067|Experimental|Test lens|Subjects wearing the test contact lens either as first or second pair during the cross-over study.
89378467|NCT03499067|Active Comparator|Control lens|Subjects wearing the control contact lens either as first or second pair during the cross-over study.
89378468|NCT02345200|Active Comparator|Ataxia telangiectasia|26 patients with clinically and/or genetically diagnosed Ataxia telangiectasia will be examined with bioelectrical impedance analysis (BIA), muscle force measurement, calipometry and get a blood draw
89378469|NCT02345200|Active Comparator|Healthy subjects|26 age and sex matched subjects without any chronic disease or hormone displacement will be examined with bioelectrical impedance analysis (BIA), muscle force measurement, calipometry and get a blood draw
89378470|NCT05462184|Active Comparator|Cognitive-Behavioral Therapy (CBT)|CBT followed Craske & Barlow´s (2007) manual, which contains a session-by-session description treatment of panic disorder with CBT. The treatment included the following components: (a) psychoeducation about the nature of anxiety and panic, (b) diaphragmatic breathing training, (c) identification and correction of maladaptive thoughts about anxiety and its consequences, (d) exposure to interoceptive sensations, and (e) exposure to feared situations.
89399434|NCT02754440|Experimental|Single Platelet Product|Healthy adult volunteer blood donors that qualify for a single unit platelet collection will undergo plateletpheresis on the Trima Accel® Automated Blood Collection System (Trima Accel System with Version 7.0 Software). Concurrent plasma will be collected in 25% of the collections.
88851360|NCT02047734|Experimental|Ozanimod1 mg|Ozanimod 1 mg oral capsules daily and a weekly intramuscular placebo injection (identical in appearance to Interferon) for 24 months.
89182563|NCT06239701|Experimental|LPA and Fitbit|"The 12-week LPA+Fitbit intervention consists of 3 components:~In-Person LPA+Fitbit Orientation~Telephone PA counseling sessions.~Fitbit activity tracker."
89182564|NCT06239701|Active Comparator|Only Fitbit|"The Fitbit Only condition will include 3 components:~In-person Fitbit Orientation.~Fitbit Activity Tracker.~Brief Telephone Check-ins."
88817248|NCT01714739|Experimental|Part 5 and 6|Safety Lead-In and Additional Signal Detection in Solid Tumors -- Nivolumab Plus Ipilimumab with Lirilumab (Study Part 6 Removed; No Subjects Enrolled)
88817249|NCT01290536|Experimental|Yttrium-90 liver radioembolization|
88817250|NCT01290614|Experimental|Pharmacist intervention|
88817251|NCT01290614|Active Comparator|Control - usual care|Patients assigned to control will continue to receive care from their VA provider.
88817252|NCT02377479|Active Comparator|Clomiphene alone|The patient will take 100mg clomiphene orally from cycle days 3-7
88817253|NCT02377479|Active Comparator|Letrozole alone|The patient will take 5mg Letrozole orally from cycle days 3-7
88817254|NCT02377479|Experimental|Combination Clomiphene and Letrozole|The patient will take a dose of 5mg Letrozole every night and 100mg clomiphene every day after lunch from cycle days 3-7.
88817255|NCT02313285||GZ402668|Patient who received GZ402668 in prior study (TDU13475 or TDU14981)
88817256|NCT02313285||Placebo|Patient who received placebo in prior study (TDU13475 or TDU14981)
88817257|NCT01874691||acute myocardial infarction|acute myocardial infarction including ST-elevation and non ST-elevation myocardial infarction
88817258|NCT01227980|Active Comparator|Pexacerfont|Pexacerfont was given orally as a loading dose of 300 mg/day for 1 week, followed by 100mg/day for 16-20 days
88817259|NCT01227980|Placebo Comparator|Placebo|Oral placebo was given during the 1-week loading dose phase, and during the next 16-20 days
88817260|NCT03866655|Experimental|Intervention|
88817261|NCT03866655|No Intervention|Control|
88817262|NCT00622557||Surgical|All patients having surgery procedures
88817263|NCT01291160|Experimental|Epiflo Treatment|The cohort will comprise of 2 populations: the Treatment Arm of up to 90 subjects; and the Control Arm of up to 90 subjects, in order to collect 120 invaluable subjects. The Treatment Arm includes subjects with DFU who will receive EPIFLO in addition to standard wound care therapy during the Treatment Period.
88817264|NCT01291160|Sham Comparator|Sham Device|The cohort will comprise of 2 populations: the Treatment Arm of up to 90 subjects; and the Control Arm of up to 90 subjects, in order to collect 120 invaluable subjects. Control Arm includes subjects with Diabetic Foot Ulcers who will receive sham units of EPIFLO along with standard wound care therapy during the treatment Period.
88817265|NCT02595567|Other|ITPC|
88817266|NCT01291784|Experimental|monoclonal antibody to TGF-beta|starting dose of 1mg/kg intravenous over approximately 1 hour every 4 weeks for a total of 6 doses
88817267|NCT03626883|Experimental|1 hamstring|Patients will receive the intervention of 'single-bundle, single-hamstring ACL reconstruction'.
88817268|NCT03626883|Active Comparator|2 hamstrings|Patients will receive the intervention of 'single-bundle, double-hamstring ACL reconstruction'.
88817269|NCT05457647|Experimental|Riboflavin/UV-A corneal cross-linking monitored by theranostic software module|One study arm receiving riboflavin/UV-A corneal cross-linking with either standard, Epi-OFF, or transepithelial, Epi-ON, treatment protocol. Only one eye of each participant is designated as the study eye.
88817270|NCT01213316||Overall Participants|HIV-1 infected participants received raltegravir 400 mg tablet orally twice daily for 96 weeks (Initial Cohort), 144 weeks (Prolonged Cohort) or 48 weeks (Amendment Cohort) in combination with other antiretroviral drugs under conditions representative of standard of clinical practice for HIV-1 patients in Germany.
88817271|NCT01213316||Aging Participants|"HIV-1 infected participants received raltegravir 400 mg tablet orally twice daily for 144 weeks (Prolonged Cohort) or 48 weeks (Amendment Cohort) in combination with other antiretroviral drugs under conditions representative of standard of clinical practice for HIV-1 patients in Germany.~Includes newly enrolled participants ≥ 50 years of age (Amendment Cohort), plus participants from the Initial Cohort who were ≥ 50 years of age at time of recruitment and who completed 48 weeks of treatment (Prolonged Cohort)."
88851361|NCT02047734|Active Comparator|Interferon β-1a|interferon beta-1a (IFN β-1a) 30 µg intramuscular (IM) injection weekly and matching placebo capsules (identical in physical appearance to ozanimod) orally daily for 24 months.
88851362|NCT02053350|Experimental|Alanyl-glutamine|Alanyl-glutamine, 44g, taken by mouth daily for 10 days.
88851363|NCT04684914|Experimental|HepTcell|Dose administered at intervals of 4 weeks for 6 doses
88851364|NCT04684914|Placebo Comparator|Placebo|Dose administered at intervals of 4 weeks for 6 doses
88851365|NCT04709016||male or transgender patients|of sexual orientation MSM (men having sex with men) or bi-sexual, consultant in sexual health centers
88851366|NCT04417140|Experimental|Treatment Arm-dHACM|Patients enrolled in this arm will have a thin sheet of dHACM placed as an overlay over the length of the closed incisions. dHACM is Dehydrated Human Amniotic-Chorion Membrane. It is a FDA registered healing adjunct that has been applied in a broad range of diseases including wounds, plantar fasciitis and burns.
88851367|NCT04417140|No Intervention|Control Arm|Patients enrolled in this arm will have routine closure.
88851368|NCT01994850|Experimental|Phase I/II|"Total of six 21-day cycles of brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin and prednisone (R-CHP). Cycle 1 rituximab dose divided between Days 1 and 2 to prevent severe infusion reactions in rituximab naïve patients; brentuximab vedotin and cytotoxic chemotherapy administered on Day 2. Cycles 2 through 6 brentuximab vedotin and R-CHP administered on Day 1. Prednisone (or steroid equivalent) administered Days 1-5 of each cycle (prior to rituximab infusion).~Cycle 1:~Days 1-5: Prednisone (or equivalent) 100 mg PO/IV; Day 1: Rituximab 100 mg/m2 IV; Day 2: Rituximab 275 mg/m2 IV, Cyclophosphamide 750 mg/m2 IV, Doxorubicin 50 mg/m² IV, Brentuximab vedotin 1.8 mg/kg or 1.2 mg/kg (Phase I data established a MTD of 1.8 mg/kg brentuximab vedotin)~Cycles 2-6:~Days 1-5: Prednisone (or equivalent) 100 mg PO/IV; Day 1: Rituximab 375 mg/m2 IV, Cyclophosphamide 750 mg/m2 IV, Doxorubicin 50 mg/m² IV, Brentuximab vedotin 1.8 mg/kg"
89535070|NCT03086811|Experimental|intervention group|First time mothers, when infants were ages 4-6 months old, took part in a training program in small group setting (10-12 mother-infants). the program continued for a month, with 4 weekly meetings. group coordinators were a highly experienced pediatric dietitian, and a social worker. Training topics addressed were infant healthy nutrition and growth, feeding skills, obesity and emotional feeding prevention, parenting. Thereafter, mothers were encouraged to stay in contact with the trainers, till infants reached age 12 months and data was collected using video taping of mealtime feeding interactions at home setting environment. Mother Infant Feeding Interaction very early training
89535071|NCT03086811|No Intervention|control group|Control group first time mothers were recruited when infants were around 11-12 months of age for data collection of mealtime feeding interactions taping at home setting environment. They received during this year the official support and training given in municipality care centers.
89535072|NCT03239977|Experimental|Online Social Intelligence Training|The Social Intelligence Intervention (SII) is delivered online to both custodial grandmothers and their adolescent grandchild separately. This is the sole active treatment condition within this RCT.
89182568|NCT06239662|Experimental|Therapeutic group intervention|Patients will be called in groups every 3 months for a total of 10 meetings. At each meeting they will be weighed and measured. Each meeting will focus on a topic of nutritional/lifestyle interest and will see the co-presence of the figures of the dietician and the psychologist, in order to allow an emotional declination for all the participants.
89182569|NCT06239662|Active Comparator|Usual care|Patients will be called individually every 3 months for a total of 10 meetings. At each meeting they will be weighed and measured. Each meeting will focus on a topic of nutritional/lifestyle interest. The meetings will be conducted by a dietician.
89182570|NCT06239649||TKA with radiofrequency ablation genicular nerve block|TKA with radiofrequency ablation genicular nerve block
89182571|NCT06239649||TKA without nerve block|TKA without radiofrequency ablation genicular nerve block
89182572|NCT06239636|Experimental|UP421 transplantation|Intramuscular transplantation of study product UP421
89182573|NCT06239623|Experimental|Experimental|ERK inhibitor JSI-1187
89182574|NCT06239610|Other|feeding tube migration|Use of an EMPD to assess for FT migration in all eligible critical care patients requiring the use of a feeding tube during admission.
89182575|NCT06239597|Experimental|lifestyle course|Participants for the experimental group will be recruited from students who enrolled in the lifestyle course in the university during the academic years. Participants in the experimental group engage in the research by providing consent for the analysis of their learning process and by completing questionnaires.
89182576|NCT06239597|Active Comparator|other courses|The control group will be recruited from other courses in the same university, during the same academic years. The control group engages in the research by completing questionnaires.
89182577|NCT06239584|Other|Patients undergoing diagnostic bronchoscopies for suspected lung cancer|Preparation of organoids starting from lung tumor tissue collected during biopsies performed via diagnostic bronchoscopy according to standard clinical practice
89182578|NCT06239545|Experimental|Usual Practice + JoyPop|Participants will be monitored through the existing wait-list practices, and will receive access to the JoyPop app for 4 weeks.
89182579|NCT06239545|No Intervention|Usual Practice|Participants will be monitored through existing wait-list practices. After 4 weeks in the Usual Practice condition, participants will be offered access to the JoyPop app.
89182580|NCT06239532|Experimental|TAE+HAIC+Tislelizumab+Surufatinib|Patients will receive hepatic arterial infusion chemotherapy (HAIC) sequential transcatheter arterial embolization(TAE) combined with Tislelizumab and Surufatinib
89182581|NCT06239519|Experimental|Usual Practice + JoyPop|Participants will be monitored through the existing wait-list practices, and will receive access to the JoyPop app for 4 weeks.
89378471|NCT05462184|Experimental|Acceptance and Commitment Therapy (ACT)|"ACT was conducted following Eifert & Forsyth´s (2005) manual, which contains a session-by-session description of the application of ACT to anxiety disorders. In the current study, exercises were adapted to the panic disorder treatment. The treatment included the following components: (a) acceptance of internal experiences, (b) cognitive defusion, (c) work with the self as context, (d) contact with the present moment, (e) work with life values, and values, and (f) commitment to action."
89535073|NCT03239977|Placebo Comparator|Attention Control (AC)|The attention control (AC) condition, known as The Healthy Living program provides information about different aspects of health.
89378472|NCT03146182|No Intervention|Control|Patients are treated according to current local guidelines on antibiotic treatment for CAP.
89378473|NCT03146182|Experimental|CRP|Patients are treated according to the CRP-algorithm. CRP is measured daily. Antibiotic treatment is stopped when CRP reach threshold value.
89378474|NCT03146182|Experimental|PCT|Patients are treated according to the PCT-algorithm. PCT is measured daily. Antibiotic treatment is stopped when PCT reach threshold value.
89378475|NCT03562481|Experimental|Buffered Anesthetic, then Unbuffered Anesthetic|Subjects randomized to Buffered Anesthetic, then Unbuffered Anesthetic will first receive an injection with 1% Buffered Lidocaine 1:100,000 Epinephrine. After one week minimum washout period, subjects will then receive an injection with 2% Unbuffered Lidocaine 1:100,000 Epinephrine.
89378476|NCT03562481|Experimental|Unbuffered Anesthetic, then Buffered Anesthetic|Subjects randomized to Unbuffered Anesthetic, then Buffered Anesthetic will first receive an injection with 2% Unbuffered Lidocaine 1:100,000 Epinephrine. After one week minimum washout period, subjects will then receive an injection with 1% Buffered Lidocaine 1:100,000 Epinephrine.
89378477|NCT02349880|Active Comparator|control|5 hour cognitive training
89378478|NCT02349880|Experimental|intervention|5 hour shared decision making training
89378479|NCT04029298|Experimental|HBDC Intervention Group|Immediate enrollment in the 16-week, HBDC education-based intervention, followed by a 12-month observation period
89378480|NCT04029298|Other|Control/Usual Care/Delayed Intervention Group|16-week, HBDC education-based intervention will be delayed by 12 months. Following the delayed intervention, this group will be observed for an additional 12-month period
89378481|NCT03760224|Experimental|Intervention|WhatsApp group will receive at least 3 messages each week and allow real-time group discussion for the intervention period (8 weeks).
89378482|NCT03760224|Active Comparator|Control|The control group will receive 3 mobile phone text messages each week in the 8 weeks after recruitment. This will be a one way message and no real-time discussion will be available.
89378483|NCT03726593|Experimental|ASPY|Artesunate-pyronaridine, once daily for three days, following standard weight-based dosing per drug label. All volunteers with P.f monoinfection will receive single dose of primaquine (PQ) (15 mg) for transmission blocking.
89378484|NCT03726593|Experimental|AP+ASPY|Atovaquone-Proguanil (AP) + Artesunate-Pyronaridine (ASPY), once daily for three days, following standard weight-based dosing per drug label for each drug. All volunteers with P.f monoinfection receive single dose of PQ (15 mg) for transmission blocking
89378485|NCT03726593|Experimental|AP+ASMQ|Atovaquone-Proguanil (AP) + Artesunate-Mefloquine (ASMQ); ASMQ once daily for three days (D0, D1, D2), following standard weight-based dosing per drug label. Subsequently, volunteers continue their treatment with AP once daily starting on day 3, for three additional days (D3, 4, 5). All volunteers with P.f monoinfection receive single dose of PQ (15 mg) for transmission blocking.
88817272|NCT05446025||pregnant women with a diagnosis of hyperemesis gravidarum( n:50)|Orexigenic hormones (appetizing) Orexin, galanin and anorexigenic hormones (decreasing appetite) aMSH and CART blood levels will be examined in patients with hyperemesis gravidarum.
89378486|NCT03145948|Experimental|Arm A|Participants, who are healthy volunteers, receiving ABBV-553 dose A or placebo
89378487|NCT03145948|Experimental|Arm B|Participants, who are healthy volunteers, receiving ABBV-553 dose B or placebo
89378488|NCT03145948|Experimental|Arm C|Participants, who are healthy volunteers, receiving ABBV-553 dose C or placebo
89378489|NCT03145948|Experimental|Arm D|Participants, who are healthy volunteers, receiving ABBV-553 dose D or placebo
89378490|NCT03145948|Experimental|Arm E|Participants with psoriasis receiving ABBV-553 dose B or placebo
89378491|NCT03145948|Experimental|Arm F|Participants with psoriasis receiving ABBV-553 dose C or placebo
89378492|NCT03197064|Other|Fosaprepitant|Patients included in this study will be administered fosaprepitant 150 mg IV.
89535074|NCT03078699|Experimental|stereotactic body radiation therapy|
88817273|NCT05446025||Control group pregnants (n:50)|Orexigenic hormones (appetizing) Orexin, galanin and anorexigenic hormones (decreasing appetite) aMSH and CART blood levels will be examined in the patients of the control group .
88817274|NCT05439629|Experimental|Experimental group：BAT5906|Intravitreal injection; Dosage: 4.0 mg / eye / time, 50 μl; Duration of administration: every 4 weeks, administered to week 48, not administered at 52 weeks.
88817275|NCT05439629|Active Comparator|Control group：Lucentis®|Intravitreal injection; Dosage: 0.5 mg / eye / time, 50 μl; Duration of administration: every 4 weeks, administered to week 48, not administered at 52 weeks.
88817276|NCT01229228|Experimental|Naproxen Test (lower dose)|200-mg
88817277|NCT01229228|Experimental|Naproxen Test (upper dose)|400-mg (2 x 200-mg)
88817278|NCT01229228|Active Comparator|Naprosyn 250 mg|
88817279|NCT01229228|Active Comparator|Naprosyn 500 mg|
88817280|NCT01229228|Placebo Comparator|Placebo|
88817281|NCT01213706|Experimental|Whole Body Periodic Acceleration (WBPA)|All subjects will be performing this procedure. WBPA in spinal axis (pGz) will be administered with a platform that resembles a bed. The platform moves in a repetitive head-to-foot direction at 140 times a minute, producing 0.22 g.
88817282|NCT01213706|Experimental|Sham WBPA|"Sham WBPA :~All subjects will be performing this procedure before the WBPA. The subjects will rest for 45 minutes in the Whole Body Periodic Acceleration (WBPA) platform without movement as a control challenge."
88817283|NCT01213940|Other|baratric surgery|surgery vs.weight loss program 6 months prior to bariatric surgery
88817284|NCT01213940|Other|pre-bariatric weight loss program|weight loss program prior to bariatric surgery
88817285|NCT01292252|Experimental|Treatment|Forteo, Terapeptide 20 ug subcutaneous injection
88817286|NCT01292252|Placebo Comparator|Control|Saline placebo
88817287|NCT02192684|Active Comparator|pioglitazone|pioglitazone 45 mg, oral, daily
88817288|NCT02192684|Placebo Comparator|placebo|Placebo, one pill daily
88817289|NCT02243579|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 3 weeks for up to 2 years (6 months for patients achieving CR) in the absence of disease progression or unacceptable toxicity.
88817290|NCT02195414|Experimental|NeoVas BCS|The NeoVas sirolimus-eluting bioresorbable coronary scaffold system is a PLLA-based polymer scaffold and contains the antiproliferative drug sirolimus.
88851369|NCT02027844|Experimental|Cartoon|cartoon watching by children during inhalational induction of anesthesia in the operating room
88851370|NCT02027844|Active Comparator|Paretnal presence|parental presence with their children during inhalational induction of anesthesia in the operating room
88851371|NCT02027844|Experimental|Combined|parental presence and cartoon watching by children during inhalational induction of anesthesia in the operating room
88851372|NCT04671576|Active Comparator|Control Formula|A standard, milk-based, infant formula.
89378493|NCT02345044|Experimental|CS-3150 1.25 mg|One CS-3150 1.25 mg tablet and one placebo tablet to match CS-3150 tablet administered orally, once daily after breakfast.
89378494|NCT02345044|Experimental|CS-3150 2.5 mg|Two CS-3150 1.25 mg tablets administered orally, once daily after breakfast.
89378495|NCT02345044|Experimental|CS-3150 5 mg|Two CS-3150 2.5 mg tablets administered orally, once daily after breakfast.
89378496|NCT02345044|Placebo Comparator|Placebo|Two placebo tablets to match CS-3150 tablet, administered orally, once daily after breakfast.
89378497|NCT02345044|Active Comparator|Eplerenone, 50-100 mg (Open Label)|One or two 50mg eplerenone tablet(s) administered orally, once daily after breakfast.
89378498|NCT03529409|Experimental|Project Khanya|Those assigned to Project Khanya (the behavioral intervention for substance use and adherence condition) will have approximately 6 sessions (including Life-Steps, behavioral activation, and relapse prevention) delivered by a peer interventionist plus standard of care, which is typically referral to a local outpatient substance use treatment clinic. They will also receive a Wisepill, a wireless, real-time adherence monitoring device.
89378499|NCT03529409|No Intervention|ESOC|Those assigned to the ESOC (enhanced standard of care) condition will receive the standard of care, which is referral to a local substance use treatment clinic. The substance use clinics in the location that this study occurs follow the Matrix, and evidence-based 16-week outpatient program to treat substance use. We will enhance patients' normal referral to Matrix for ESOC participants by promoting facilitating and following up on the referral. Additionally, those in the control group will also receive a Wisepill, a wireless adherence monitoring device.
89378500|NCT02350036||preeclmapsia|women developed preeclampsia. ultrasound monitoring and uterine artery Doppler
89378501|NCT02350036||control|women with normal blood pressure all through pregnancy. ultrasound monitoring and uterine artery Doppler
89378502|NCT03722771|Experimental|lavender oil group (A)|"100 % pure, high strength lavender oil inhalation in a separate room for 3 minutes, prior to surgery.~Anxiety questionnaires 1 (MDAS) Anxiety questionnaires 2 (STAI-S) Vital signs 1 (Blood pressure) Vital signs 2 (respiratory rate,) Vital signs 3 (heart rate) Vital signs 4 (saturation)"
88851373|NCT04671576|Experimental|Investigational Formula|An organic milk-based infant formula.
89378503|NCT03722771|Sham Comparator|control group (B)|No application of lavender oil, prior to surgery. Anxiety questionnaires 1 (MDAS) Anxiety questionnaires 2 (STAI-S) Vital signs 1 (Blood pressure) Vital signs 2 (respiratory rate,) Vital signs 3 (heart rate) Vital signs 4 (saturation)
89378504|NCT02349802|Experimental|Arm 1|exenatide suspension - 9 mg / 0.85 mL
89378505|NCT02349802|Experimental|Arm 2|exenatide suspension - 9 mg / 0.85 mL
88851374|NCT01994382|Experimental|Phase 1 Cerdulatinib|During Phase 1, participants will receive oral cerdulatinib on Day 1 and then starting on Day 4 at doses of 15 mg up to 100 mg QD or oral cerdulatinib at doses of 15 mg up to 45 mg BID in 28-day cycles (except Cohort 1 will have a 21-day cycle starting on Day 1) for up to 10 cycles.
88851375|NCT01994382|Experimental|Phase 2a Cerdulatinib|During Phase 2a, participants in cohorts based on cancer type will receive oral cerdulatinib at starting doses of 35, 30, or 20 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib can be reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID at the discretion of the Investigator based upon clinical judgment and with Sponsor Medical Monitor approval.
88851376|NCT01994382|Experimental|Phase 2a Cerdulatinib plus Rituximab|During Phase 2a, participants in this cohort will receive oral cerdulatinib at their applicable dose and an IV injection of rituximab 375 mg/m^2 on Days 1, 8, 15, and 22 of Cycle 1 and Day 1 of Cycles 4, 6, 8, and 10.
88851377|NCT02003898|Experimental|Medtronic MiniMed 530G Insulin Pump|All subjects received diabetes treatment using the Medtronic MiniMed 530G insulin pump.
88851378|NCT01994226|Active Comparator|Low-dose colchicine|500 mcg every eight hours for four days
88851379|NCT01994226|Active Comparator|Naproxen|Single initial dose of 750 mg followed by 250 mg every eight hours for up to seven days
89378506|NCT02349802|Experimental|Arm 3|exenatide suspension - 4.5 mg /1.1 mL
89378507|NCT02349802|Experimental|Arm 4|exenatide suspension - 9 mg / 1.1 mL
89378508|NCT02349802|Experimental|Arm 5|exenatide suspension - 9 mg / 1.5 mL
89378509|NCT03145714|Experimental|Propofol/Sevoflurane (Group P)|"Standard technique of induction of anaesthesia .~Maintenance of anesthesia with intravenous (IV) Propofol Infusion at rate 100-150 mcg/kilogram/hour and Inhalational Anesthetic Sevoflurane during the surgery. Intervention is to titrate dosage of Propofol and Sevoflurane to maintain Bispectral Index between 40-60.~Total dosage of IV Propofol and Sevoflurane uptake will be calculated at the end of surgery."
89378510|NCT03145714|Active Comparator|Dexmedetomidine/Sevoflurane (Group D)|"Standard technique of induction of anaesthesia .~Maintenance of anesthesia with intravenous Dexmedetomidine Infusion at rate 1- 4 mcg/kilogram/hour and Inhalational Anesthetic Sevoflurane during the surgery.~Intervention is to titrate dosage of Dexmedetomidine and Sevoflurane to maintain Bispectral Index between 40 - 60.~Total dosage of IV Dexmedetomidine and Sevoflurane uptake will be calculated at the end of surgery."
89378511|NCT03498287|Experimental|Study Device|Small, non-invasive, stiff patch for the wrist
89378512|NCT03498287|Sham Comparator|Sham Device|Device that looks like the Study Device but modified to prevent or remove the main mechanism of action.
89378513|NCT02349724|Other|Pancreatic cancer|Pancreatic cancer treated with Anti-CEA-CAR T.
89182582|NCT06239519|No Intervention|Usual Practice|Participants will be monitored through existing wait-list practices. After 4 weeks in the Usual Practice condition, participants will be offered access to the JoyPop app.
88851380|NCT02002884|Experimental|8 Units per kg body weight incobotulinumtoxinA (Xeomin)|8 Units per kg body weight (maximum of 200 Units) will be injected per treated upper limb per injection cycle. Additionally, lower limb treatment may be administered, depending on clinical pattern: up to 300 Units per injection cycle. Overall maximum dose per injection cycle: 500 Units.
88851381|NCT02002884|Experimental|6 Units per kg body weight incobotulinumtoxinA (Xeomin)|6 Units per kg body weight (maximum of 150 Units) will be injected per treated upper limb per injection cycle. Additionally, lower limb treatment may be administered, depending on clinical pattern: up to 225 Units per injection cycle. Overall maximum dose per injection cycle: 375 Units.
88851382|NCT02002884|Experimental|2 Units per kg body weight incobotulinumtoxinA (Xeomin)|2 Units per kg body weight (maximum of 50 Units) will be injected per treated upper limb per injection cycle. Additionally, lower limb treatment may be administered, depending on clinical pattern: up to 75 Units per injection cycle. Overall maximum dose per injection cycle: 125 Units.
88851383|NCT02002182|Experimental|Treatment-Vaccine Group|Two vaccinations with ADXS11-001 (ADXS-HPV) will be given at a dose of 1x10^9 cfu intravenously. The drug will be given as a 500ml infusion over 60 minutes.
88851384|NCT02002182|No Intervention|Control Group|Observational control group treated with standard of care therapy only
88851385|NCT01990950|Experimental|Zenith® Fenestrated AAA Endovascular Graft|
88851386|NCT02001558|Experimental|Microcyn|Microcyn is liberally sprayed on wound and permitted to remain on wound which will then be dressed with gauze that is moistened with Microcyn twice daily.
88851387|NCT02001558|Active Comparator|Sterile saline|Sterile saline is liberally sprayed on wound and permitted to remain on wound which will then be dressed with gauze that is moistened with sterile saline twice daily.
88851388|NCT02023866|Experimental|Cysteamine Bitartrate Delayed-release|Cysteamine bitartrate delayed-release capsules were administered twice daily following a dose-escalation design with a progressive weekly dose increase over the first 6 weeks. The starting dose was 0.2 g/m²/day, up to a maximum dose of 1.3 g/m²/day. Participants remained on their highest tolerated dose until Week 24.
88851389|NCT02023242|Experimental|Hydrus Microstent|Patients randomized to the Hydrus Microstent .
88851390|NCT02023242|Active Comparator|iStent Trabecular Micro Bypass|Patients randomized to the iStent Trabecular Micro Bypass
88851391|NCT01967940|Experimental|Part 1 Sentinel Cohort (TAF)|TAF + their current failing ARV regimen for 10 days in Part 1
88851392|NCT01967940|Experimental|Part 1 Randomized Cohort (TAF)|Following review of safety and efficacy data from the Sentinel Cohort, participants will be randomized to receive TAF + their current failing ARV regimen for 10 days in Part 1.
88851393|NCT01967940|Placebo Comparator|Part 1 Randomized Cohort (Placebo)|Following review of safety and efficacy data from the Sentinel Cohort, participants will be randomized to receive placebo + their current failing ARV regimen for 10 days in Part 1.
89182583|NCT06239506||type 2 diabetes|Case group participants were recruited from patients diagnosed with type 2 diabetes and undergoing medical treatment at the First Affiliated Hospital of Shandong First Medical University(Shandong Provincial hospital)
89182584|NCT06239506||Control group|Control group participants were recruited from residents living in Jinan and undergoing physical examinations at the same hospital.
89182585|NCT06239493||IVUS GUIDED|Those undergoing an already planned IVUS guided treatment for percutaneous vascular interventions
89182586|NCT06239480|Active Comparator|Active|
89182587|NCT06239480|Placebo Comparator|Placebo|
89182588|NCT06239454|Active Comparator|empirical stimulation modes group (ESG)|empirical programming for the first 9 months' period, followed by any stimulation decided by the neurologists/neurosurgeons for the final 3 months.
89182589|NCT06239454|Experimental|interleaving stimulation modes group (ISG)|empirical stimulation for the first 3 months, followed by interleaving programming period for 6 months, and any stimulation decided by the neurologists/neurosurgeons for the final 3 months.
89182590|NCT06239428|Experimental|i-TREAT|The intervention in the experimental group is an internet-based therapist-guided self-help program, called i-TREAT. The program consists of 12 online treatment sessions. It is mainly based on Cognitive Behavior Therapy while inspired by Acceptance and Commitment Therapy. Participants are instructed to complete session-related tasks and receive written feedback from their therapist throughout the treatment. Furthermore, the intervention is also supported by text, illustrations, videos, and a chat function, allowing asynchronous text messaging with the therapist. The treatment courses are expected to run for 12 weeks.
89182591|NCT06239428|Active Comparator|Waitlist-control|Participants randomized to the active waitlist-control group gains access to online mindfulness material for 12 weeks, however, using the material is non-mandatory. After completing the waitlist, participants are offered the i-TREAT intervention. The active waitlist was implemented to prevent potential adverse effects of being on a passive waitlist (which currently comes closest to treatment as usual since no other treatment modalities exist for the target group in the Danish psychiatry).
89182592|NCT06239350|Other|Nicotine treatment|All participants recieve active nicotine treatment for 12 weeks.
89182593|NCT06239324|Active Comparator|Fractional Erbium laser Technique (Group A)|About 35 patients with alopecia areata will Subject to fractional Erbium (Er-YAG) laser (Fotona Xs dynamics,Slovenia) with energy of 600 mj in short pulse mode (MSP) with spot size of 7 mm diameter, frequency of 3 Hz and pixel 3. Latanoprost( xalatan 0.005% ) is applied to the treated area for all participants.
89378514|NCT02349724|Other|Lung cancer|Lung cancer treated with T cells modified with Anti-CEA-CAR T.
89378515|NCT02349724|Other|Gastric cancer|Gastric cancer treated with T cells modified with Anti-CEA-CAR T.
89378516|NCT02349724|Other|Breast cancer|Breast cancer treated with T cells modified with Anti-CEA-CAR T.
88851394|NCT01967940|Experimental|Part 2 E/C/F/TAF+ATV|Following a 14-day period to confirm eligibility, participants in the Randomized Cohort TAF group with a > 0.5 log10 decline in HIV-1 RNA and all participants completing the Randomized Cohort Placebo group will receive E/C/F/TAF+ATV for 48 weeks in Part 2. After completion of Part 2, all participants will be eligible to continue to receive E/C/F/TAF plus ATV in the extension phase until E/C/F/TAF becomes commercially available, or until Gilead Sciences terminates development of E/C/F/TAF in the applicable country.
88851395|NCT01990560|Experimental|Mifepristone|Mifepristone 300mg tablets taken once daily with dose increase of no more than 300mg once monthly and to a maximum dose of 1200mg daily as indicated by symptom response
88851396|NCT01998984|Experimental|2 days placebo and 2 days drug|Placebo and drug
88851397|NCT01998984|Experimental|1 day placebo and 3 days drug|Placebo and drug
88851398|NCT01998984|Placebo Comparator|4 days placebo|Placebo
88851399|NCT01998984|Experimental|4 days drug|Drug
88851400|NCT04416594||Factor XIII deficiency|Patients admitted to hospital with FXIII levels below 70% during their hospital stay
88851401|NCT01967706|Active Comparator|mTHS then mCC|"Each subject will follow the below study design:~Day 0 = Wash-out (1 day)~Day 1 = 1st intervention (single product use of mTHS)~Day 2 = wash-out~Day 3 = 2nd intervention (single product use of mCC)."
88851402|NCT01967706|Active Comparator|mCC then mTHS|"Each subject will follow the below study design:~Day 0 = Wash-out (1 day)~Day 1 = 1st intervention (single product use of mCC)~Day 2 = wash-out~Day 3 = 2nd intervention (single product use of mTHS)."
88851403|NCT01967706|Active Comparator|mTHS then NRT|"Each subject will follow the below study design:~Day 0 = Wash-out (1 day)~Day 1 = 1st intervention (single product use of mTHS)~Day 2 = wash-out~Day 3 = 2nd intervention (single administration of NRT)"
88851404|NCT01967706|Active Comparator|NRT then mTHS|"Each subject will follow the below study design:~Day 0 = Wash-out (1 day)~Day 1 = 1st intervention (single administration of NRT)~Day 2 = wash-out~Day 3 = 2nd intervention (single product use of mTHS)."
88851405|NCT01967628|Experimental|Vitamin D3 (cholecalciferol)|Vitamin D3 (1000 international units) daily for 3 months.
88851406|NCT01967628|Placebo Comparator|Sugar capsule|Placebo comparator made of sugar in a capsule
88851407|NCT01998906|Experimental|HER-2+ Trastuzumab, Doxorubicin/Paclitaxel/CMF|Participants with HER2 proto-oncogene positive breast cancer (HER2+) were treated with trastuzumab 8 milligrams per kilogram (mg/kg), intravenous (IV), on Day 1 of Cycle 1, followed by 6 mg/kg, IV, on Day 1 of Cycle 2 to up a maximum of Cycle 17. Participants also received doxorubicin 60 mg/ square meter (m^2), IV, and paclitaxel 150 mg/m^2, IV, on Day 1 of Cycles 1 through 3. Followed by paclitaxel 175 mg/m^2, IV, alone on Day 1 of Cycles 4 through 7. Participants also received CMF: cyclophosphamide 600 mg/m^2, IV; methotrexate 40 mg/m^2, IV; and 5-fluorouracil 600 mg/m^2, IV, on Day 1 of Cycles 8 through 10.
88851408|NCT01998906|Active Comparator|HER-2+ Doxorubicin/Paclitaxel/CMF|Participants with HER2 proto-oncogene positive breast cancer were treated with doxorubicin 60 mg/m^2, IV, and paclitaxel 150 mg/m^2, IV, on Day 1 of Cycles 1 through 3. Followed by paclitaxel 175 mg/m^2, IV, alone on Day 1 of Cycles 4 through 7. Participants also received CMF on Day 1 of Cycle 8 through 10.
88851409|NCT01998906|Active Comparator|HER-2- Doxorubicin/Paclitaxel/CMF|Participants with HER2 proto-oncogene negative breast cancer were treated with doxorubicin 60 mg/m^2, IV, and paclitaxel 150 mg/m^2, IV, on Day 1 of Cycles 1 through 3. Followed by paclitaxel 175 mg/m^2, IV, alone on Day 1 of Cycles 4 through 7. Participants also received CMF on Day 1 of Cycle 8 through 10.
88851410|NCT01967550|Experimental|diclofenac diethylamine, DDEA 2.32% gel|diclofenac diethylamine, DDEA 2.32% gel
88851411|NCT01967550|Placebo Comparator|Placebo|Vehicle control
88851412|NCT01989546|Experimental|1/Talazoparib (BMN 673)|Single agent
88851413|NCT01997892||Chronic Kidney Disease (CKD)|Participants with CKD on dialysis and treated with PEG epoetin beta for a minimum of 14 weeks immediately prior to being switched to darbepoetin alfa.
88851414|NCT01989468|Experimental|Secukinumab (AIN457) 150 mg s.c.|1 s.c. Secukinumab 150 mg autoinjector at Baseline, Weeks 1, 2, 3, 4, followed by dosing every four weeks starting at Week 4.
88851415|NCT01989468|Experimental|Secukinumab (AIN457) 300 mg s.c.|2 s.c. Secukinumab 150 mg autoinjector at Baseline, Weeks 1, 2, 3, 4, followed by dosing every four weeks starting at Week 4.
88851416|NCT01989468|Placebo Comparator|Placebo|Matching Placebo at Baseline, Weeks 1, 2, 3, 4, followed by dosing every four weeks starting at Week 4.
88851417|NCT01989156|Experimental|THS 2.2 Menthol (mTHS 2.2)|Ad libitum use of THS 2.2 Menthol for 5 Days in a Confinement Setting and 86 Days in an Ambulatory Setting
88851418|NCT01989156|Active Comparator|Menthol Conventional Cigarette (mCC)|Ad libitum use of subject's own preferred brand of mCC for 5 Days in a Confinement Setting and 86 Days in an Ambulatory Setting
88851419|NCT01989156|Sham Comparator|Smoking abstinence (SA)|Abstinence from smoking for 5 Days in a Confinement Setting and 86 Days in an Ambulatory Setting
88851420|NCT01620762|Experimental|Cat-Pad Treatment 1|Cat-PAD Treatment 1
88851421|NCT01620762|Experimental|Cat-PAD Treatment 2|Cat-PAD Treatment regimen 2
88851422|NCT01620762|Placebo Comparator|Placebo|Placebo
88851423|NCT01966068|Experimental|MyAsthma Web Portal|The portal, MyAsthma, will provide asthma education, collect patient-reported outcomes, evaluate medication use and side effects, and track parents' concerns and goals. Parents will log into the web portal each month (for a total of 3 portal visits in 6 months), and the information entered by parents will be shared through the electronic health record with the child's primary care provider.
88851424|NCT01620528|Experimental|Elagolix 150 mg QD|Elagolix 150 mg once daily (QD) for the 6-month Treatment Period
88851425|NCT01620528|Experimental|Elagolix 200 mg BID|Elagolix 200 mg twice daily (BID) for the 6-month Treatment Period
88851426|NCT01620528|Placebo Comparator|Placebo|Placebo BID for the 6-month Treatment Period
88851427|NCT01965834|Experimental|Fenofibrate Therapy|Fenofibrate orally daily for each 28 day cycle, per study protocol.
88851428|NCT01965600|Experimental|Cohort 1|
88851429|NCT01965600|Experimental|Cohort 2|
88851430|NCT01996332|Experimental|Tarceva Arm|
88851431|NCT04669548||Accuryn Monitoring System|Observational only (no intervention). Patients undergoing cardiovascular surgical intervention(s) monitored with the Accuryn Monitoring System (per standard of care) during their hospital stay
88851432|NCT01996254|Experimental|SPRINT Group 1|Subjects in Group 1 will have a Lead placed in the residual limb in the upper leg. These subjects will then use the SPRINT Peripheral Nerve Stimulation (PNS) System and will receive electrical stimulation for 8 weeks.
88851433|NCT01996254|Sham Comparator|SPRINT Group 2|Subjects in Group 2 will have a Lead placed in the residual limb in the upper leg. These subjects will then use the SPRINT Peripheral Nerve Stimulation (PNS) System for a total of 8 weeks. They will receive 4 weeks of stimulation and 4 weeks with no stimulation.
89535075|NCT05007171|Experimental|Very low calorie diet|Use of very low calorie diet in hospital for 3 weeks
88851434|NCT01987986|Experimental|AA4500 0.06 mg (low dose)|"AA4500 (Collagenase Clostridium Histolyticum)~Each subject could receive up to three treatment sessions. Each treatment session was separated by approximately 21 days."
88851435|NCT01987986|Experimental|AA4500 0.48 mg (mid-dose)|"AA4500 (Collagenase Clostridium Histolyticum)~Each subject could receive up to three treatment sessions. Each treatment session was separated by approximately 21 days."
88851436|NCT01987986|Experimental|AA4500 0.84 mg (high dose)|"AA4500 (Collagenase Clostridium Histolyticum)~Each subject could receive up to three treatment sessions. Each treatment session was separated by approximately 21 days."
88851437|NCT01987986|Placebo Comparator|Placebo|"Placebo~Each subject could receive up to three treatment sessions. Each treatment session was separated by approximately 21 days."
88851438|NCT04659018||patient|individual performing a screening colonoscopy
88851439|NCT01987908|Experimental|Cohort A (Drug)|Subjects randomized 3:1 to receive 4 times daily dosing of 1,000 mg of Aes 103 or placebo for 28 days
88851440|NCT01987908|Placebo Comparator|Cohort A (Placebo)|Subjects randomized 3:1 to receive 4 times daily dosing of 1,000 mg of Aes 103 or placebo
88851441|NCT01987908|Experimental|Cohort B (Drug)|In this adaptive design, the dose frequency and the total amount given per day to Cohort B will be adjusted depending on the tolerability, clinical pharmacology and clinical endpoint results of Cohort A. Study terminated prior to completion of Cohort A due to unblinding between study product and placebo groups for participant, site and Sponsor. The study was stopped before initiation of Cohort B.
88851442|NCT01987908|Placebo Comparator|Cohort B (Placebo)|The dosing regiment of placebo will match that of the Aes-103 treatment in Cohort B. Study terminated prior to completion of Cohort A due to unblinding between study product and placebo groups for participant, site and Sponsor. The study was stopped before initiation of Cohort B.
88851443|NCT01995552|Other|External Loop Recorder|This is a non-randomized study. All the patients will be enrolled will received the ELR system.
88851444|NCT01987830|Other|TMZ-PET scans/ MRI-PET Scan|"The investigators plan to study patients with recurrent glioblastoma whose clinical care plan includes treatment with bevacizumab and temozolomide. Patients taking daily temozolomide 50 mg/m2/day will undergo a PET scan using radiolabeled temozolomide (TMZ-PET) at 3 time points: 7-13 days after initiation of temozolomide but before beginning bevacizumab (baseline- temozolomide steady-state scan), 1 day after initiation of bevacizumab (day 15) and 1 month after initiation of bevacizumab (day 45). Arterialized venous blood samples will be collected during the imaging in order to measure radioactivity, blood metabolites, and the relationship between radiotracer uptake and tumor features such as blood-brain barrier (BBB) breakdown and tumor blood flow.~In addition, we will explore the link between flow, permeability, and tumor temozolomide retention. These studies will be performed using our human simultaneous MRI-PET imaging camera."
88851445|NCT01987596|Experimental|Arm I (fixed filgrastim)|Patients receive filgrastim SC QD started at 24 hours after completion of chemotherapy and stopped when ANC reaches at least 1,000/uL post nadir.
88851446|NCT01987596|Experimental|Arm II (flexible filgrastim)|Patients receive filgrastim SC QD started on the first day after chemotherapy when ANC falls below 1,000/uL and stopped when ANC reaches at least 1,000/uL post nadir.
88851447|NCT01964976||Alogliptin + Biguanides|All participants who received alogliptin 25 milligram (mg), tablets, orally, once daily for up to 12 months along with biguanide or without biguanide within 3 months from the start of administration of alogliptin and during the treatment period of alogliptin as per routine clinical practice were observed in this study.
88851448|NCT04658316||20-39Years-old Male|Use Iowa Oral Performance Instrument to measure tongue pressure and swallowing tongue pressure.
88851449|NCT04658316||40-59Years-old Male|Use Iowa Oral Performance Instrument to measure tongue pressure and swallowing tongue pressure.
88851450|NCT04658316||60-79Years-old Male|Use Iowa Oral Performance Instrument to measure tongue pressure and swallowing tongue pressure.
88851451|NCT04658316||20-39Years-old Female|Use Iowa Oral Performance Instrument to measure tongue pressure and swallowing tongue pressure.
88851452|NCT04658316||40-59Years-old Female|Use Iowa Oral Performance Instrument to measure tongue pressure and swallowing tongue pressure.
88851453|NCT04658316||60-79Years-old Female|Use Iowa Oral Performance Instrument to measure tongue pressure and swallowing tongue pressure.
88851454|NCT01964898|Experimental|BA for cardiac patients who smoke|Behavioral Activation Treatment for cardiac patients who smoke (BAT-CS). Participant will receive (a) 1 hour of standard smoking cessation counseling in the hospital and (b) 5 to 9 Behavioral Activation (BA) counseling sessions focused on cessation and mood management after they leave the hospital. BA sessions will occur over the 12 weeks after hospital discharge. An 8 week supply of the nicotine patch will be provided if the patient is cleared by their MD.
88851455|NCT01964898|Active Comparator|Standard Care|Participant will receive (a) 1 hour of standard smoking cessation counseling in the hospital and (b) 5 packets of printed self-help materials for smoking cessation mailed 1, 3, 6, 9, and 12 weeks after hospital discharge. An 8 week supply of the nicotine patch will be provided if the patient is cleared by their MD.
88851456|NCT01964352|Experimental|tiotropium + olodaterol low dose|Once daily 2 puffs solution for inhalation Respimat
88851457|NCT01964352|Experimental|tiotropium + olodaterol high dose|Once daily 2 puffs solution for inhalation Respimat
88851458|NCT01964352|Active Comparator|tiotropium|Once daily 2 puffs solution for inhalation Respimat
88851459|NCT01964352|Placebo Comparator|placebo|Once daily 2 puffs solution for inhalation Respimat
88851460|NCT01946412|No Intervention|Observational Arm|
88851461|NCT01946412|Experimental|Ivacaftor|"Ivacaftor will be administered every 12 hours (q12h) from Day 1 through the Week 84 Visit. The ivacaftor dose will be:~50 mg q12h for subjects 2 to <6 years of age and <14 kg,~75 mg q12h for subjects 2 to <6 years of age and ≥ 14 kg, or~150 mg q12h for subjects ≥ 6 years of age."
88851462|NCT01946178|Experimental|Focused ultrasound treatment|Patients in this arm will receive fibroid treatment using the Mirabilis High-Intensity Focused Ultrasound Treatment System.
88851463|NCT01945944|Placebo Comparator|Placebo|Placebo (0.9% saline), 3mL every 6 hrs for up to 7 days
88851464|NCT01945944|Experimental|Hypertonic Saline|Hypertonic saline (3%), 3mL every 6hrs for up to 7 days
89378517|NCT02349724|Other|Colorectal cancer|Colorectal cancer treated with T cells modified with Anti-CEA-CAR T.
89535076|NCT03228589|Experimental|probiotic strain|Active arm treated with the probiotic strain for 8 weeks.
88817291|NCT00003407|Experimental|Effectiveness of amifostine &high-dose combination chemotherapy in treating patients with AML or CML|Treatment of Newly Diagnosed High Risk And Relapsed Acute Myeloid Leukemia and Blastic Crisis Chronic Myelogenous Leukemia With Ethyol and High-Dose Cytarabine + Mitoxantroni, followed by Maintenance Phase Using Low-Dose ARA-C, rhGM-CSF, Pentoxifylline, Ciprofloxacin, and Decadron
88817292|NCT04838717|Active Comparator|BPG Arm|BPG injections will be performed at the participating center
88817293|NCT04838717|Experimental|Doxycycline Arm|Dispensing of Doxycycline 100 mg is carried out at one time at V0 - Inclusion visit.
88817294|NCT01710137|Active Comparator|Varenicline|"12 weeks of active varenicline + smoking cessation counseling~Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-84: 1.0mg twice daily orally"
88817295|NCT01710137|Placebo Comparator|Placebo|"12 weeks of placebo + smoking cessation counseling~Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-84: 1.0mg twice daily orally"
88817296|NCT02248727|Active Comparator|enfilcon A|All participants are habitual wearers of enfilcon A lens and who are refitted with somofilcon A lens
88817297|NCT02248727|Experimental|somofilcon A|All participants are habitual wearers of enfilcon A lens and who are refitted with somofilcon A lens
88817298|NCT01710839|Experimental|Targeted Pan Retinal laser combined with 0.5mg ranibizumab|Cohort 1 (n=24), previously treated with at least 2 consecutive or more intravitreal injections of any anti-VEGF agent with persistent or recurrent macular edema will receive 6 loading doses of 0.5 mg ranibizumab followed by PRN treatment with ranibizumab 0.5 mg; after receiving the first loading dose of ranibizumab, the subject will have peripheral targeted-retinal photocoagulation (TRP) based on 200° wide field angiography with possibility of a second session of TRP at M4/M7, if non-perfusion persists based on angiogram.The 200°wide field angiography will indicate areas of peripheral ischemia which will be selectively treated, preserving areas of more perfused retina.
88817299|NCT01710839|Active Comparator|Ranibizumab 0.5mg|Cohort 2 (n=6), previously treated with at least 2 consecutive or more intravitreal injections of any anti-VEGF agent with persistent or recurrent macular edema will receive 6 loading doses followed by PRN monthly treatment with ranibizumab 0.5 mg.
88817300|NCT01215110|Experimental|TMC207 700/500/400|TMC207- 700 mg Day 1; 500 mg Day 2; 400 mg Days 3-14
88817301|NCT01215110|Experimental|TMC207 500/400/300|TMC207- 500 mg Day 1; 400 mg Day 2 and 300 mg Days 3-14.
88817302|NCT01215110|Experimental|TMC207 400/300/200|TMC207- 400 mg Day 1; 300 mg Day 2 and 200 mg Days 3-14
88817303|NCT01215110|Experimental|TMC207 200/100|TMC207- 200 mg Day 1 and 100 mg Days 2-14
88817304|NCT01215110|Active Comparator|Rifafour e-275 mg|Rifafour e-275 mg
88817305|NCT02980757|Active Comparator|Gliclazide 120 mg MR Tablets Formula A|Single oral dose of one tablet containing 120 mg gliclazide
88817306|NCT02980757|Active Comparator|Gliclazide 120 mg MR Tablets Formula B|Single oral dose of one tablet containing 120 mg gliclazide
88817307|NCT02980757|Active Comparator|DIAMICRON MR® 60 mg x 2|Two x oral dose of one tablet containing 60 mg gliclazide
88817308|NCT01229462|Other|Combigan®|One drop of brimonidine tartrate/timolol combination ophthalmic solution (Combigan®) and one drop of brimonidine tartrate/timolol fixed combination vehicle administered to the affected eye(s) twice daily (morning and evening) for four weeks.
88817309|NCT01229462|Active Comparator|Alphagan® and Timolol Concurrent|One drop of brimonidine tartrate ophthalmic solution (Alphagan®) and one drop of timolol ophthalmic solution administered to the affected eye(s) twice daily (morning and evening) for four weeks.
88817310|NCT01712711|No Intervention|Lifestyle modification|Obtaining ideal body weight by calorie restriction diet and programmed physical activity
88817311|NCT01712711|Experimental|H.pylori eradication|H.pylori eradication by quadruple antibiotic therapy for two weeks plus obtaining ideal body weight by calorie restriction diet and programmed physical activity
88817312|NCT01292642|Experimental|Treatment|Cognitive behavioral therapy (CBT) plus transdermal patch nicotine replacement therapy (NRT) to treat co-occurring nicotine and cannabis dependence during a 10-week study.
88817313|NCT01231334|Active Comparator|Aczone® Gel 5% plus Differin® 0.3% Gel|Dapsone (Aczone® Gel 5%) applied to entire face in the morning. Adapalene (Differin® 0.3% Gel)followed by Dapsone (Aczone® Gel 5%) applied to entire face in the evening. Daily treatment for 12 weeks.
88817314|NCT01231334|Active Comparator|Duac® Topical Gel plus Differin® 0.3% Gel|Clindamycin/benzoyl peroxide (Duac® Topical Gel)applied to entire face in the morning. Adapalene (Differin® 0.3% Gel) applied to entire face in the evening. Daily treatment for 12 weeks.
88817315|NCT01292798|Experimental|0.5mg and 2.0mgRanibizumab|Three consecutive intravitreal ranibizumab 0.5mg injections followed by three consecutive intravitreal ranibizumab 2.0mg injections if specific criteria is met.
88817316|NCT03009500|Active Comparator|Local Anesthetic|Injection of 2-6 cc of LA (0.25% bupivacaine) per nerve to a maximum of 20 cc
88817317|NCT03009500|Active Comparator|Local Anesthetic with steroids|Injection of 2-6 cc of LA (0.25% bupivacaine) per nerve containing steroids (methylprednisolone (Depo-Medrol) 4 mg per cc) to a maximum of 20 cc
88817318|NCT03009500|Placebo Comparator|Saline|Injection of 2-6 cc of saline (0.9% sodium chloride) per nerve to a maximum of 20 cc
88817319|NCT02189954|Active Comparator|Group Routine Care|The placement according to the manufacturer's instructions.
88817320|NCT02189954|Experimental|Group Pressure Limiting|Cuff inner pressure was held below 44 mmHg
88817321|NCT01714505|Experimental|Experimental Involving Automated CTR|Closed-Loop Control: Insulin delivery will be controlled by the Diabetes Assistant (DiAs) system running in Control to Range (CTR) or in Safety Only mode. The subject will interact with the system through its Graphic User Interface (GUI). Subjects will not be allowed to administer correction boluses between meals and snacks as the DiAs will automatically be adjusting insulin to correct for hyperglycemia. The total doses recommended by the DiAs prior to meals and snacks includes the correction dose and Insulin on Board (IOB) calculated by the system.
88817462|NCT01739231|Active Comparator|Control: Part A and B|In Part A of the study, subjects were split into two cohorts whereby enrollment of the second cohort depended on the safety profile of the first cohort. In Part A, subjects received three oral doses of CeraVacx placebo at 0, 1, and 2 months. For Part B of the study, eligible subjects who expressed interest of the study were administered H10407 challenge strain 5-7 months after the three-dose vaccination series.
89378518|NCT03721055|Experimental|4-[18F]Fluoroglutamine|Patients undergo 18F-FDG PET/CT scan first. Within 7 working days, patients receive 4-[18F]Fluoroglutamine IV and 60 minutes after injection, undergo 4-[18F]Fluoroglutamine PET/CT before the start of therapy.
89378519|NCT02349958|Other|Ovarian peritoneal|CDDP Cisplatin 75 mg/m2 @T0 Ovarian peritoneal fallopian tube Uterine
89378520|NCT02349958|Other|Appendix Psuedomyxoma|MMC Mitomycin 30mg @ T0, 10mg @ T45min 50 mg/m2 @T0 Appendix Psuedomyxoma colorectal small bowel
89378521|NCT02349958|Other|Gastric and Pancreato-biliary|MMC Mitomycin + CDDP Cisplatin 30mg @ T0, 10mg @ T45min 50 mg/m2 @T0
89378522|NCT02349958|Other|Mesothelioma and Sarcoma|CDDP Cisplatin + Doxorubicin 50 mg/m2 @T0 15 mg/m2 @T0
89378523|NCT04872426|Experimental|Low intensity exercise|70% of maximal leg work load capacity
89378524|NCT04872426|Experimental|High intensity exercise|70% and 95% of maximal work load capacity (alternately every 5 min)
89378525|NCT04872426|Experimental|Low intensity exercise + intermittent ischemia-reperfusion|70% of maximal leg work load capacity with intermittent ischemia (25 seconds every 2 min)
89378526|NCT02039284|Experimental|SES group|SES group received the SES training in addition to traditional rehabilitation. Each SES session involved electrical stimulation followed by UE training in addition to home program.
89378527|NCT02039284|Experimental|VCT group|VCT group received the VCT training in addition to traditional rehabilitation.Each UE VCT session involved upper limb cycling training followed by UE training in addition to home program. The cycling program consisted of a warm-up exercise, twenty repetitions of hand push-up movements in the sitting position, UE cycling, and a cool-down exercise.
89378528|NCT02039284|Experimental|VRCIT group|VRCIT group received the VRCIT training in addition to traditional rehabilitation.Each VRCIT session involved practice of functional tasks with the more affected UE followed by virtual-reality based eye-hand coordination tasks with the more affected UE for, in addition to home program, and restraint of the less affected UE for 3.5 to 4 hours per day.
89378529|NCT02039284|Active Comparator|traditional rehabilitation group|Shame control group received the shame SES and traditional rehabilitation programs.
89378530|NCT04806594|Experimental|Papix acne scar|Papix acne scar gel for 8 consecutive weeks, 2 times per day
89378531|NCT02344888|Active Comparator|Clomiphene citrate-Prednisolone group|Women will receive clomiphene citrate and prednisolone
89378532|NCT02344888|Active Comparator|Clomiphene citrate-placebo group|Women will receive clomiphene citrate and folic acid 0.5mg (placebo)
88851465|NCT01945866|Active Comparator|Sham + intravitreal ranibizumab 0.3 mg|Intravitreal ranibizumab will be given on the day of randomization. The sham injection will be given within 0-8 days of the ranibizumab injection. If the injections are given consecutively on the same day, the sham injection must be given first. Follow-up intravitreal injections of ranibizumab will be given up to every 4 weeks using defined treatment criteria.
88851466|NCT01945866|Experimental|Intravitreal dexamethasone+intravitreal ranibizumab 0.3mg|The initial intravitreal ranibizumab injection will be given on the day of randomization. The dexamethasone intravitreal injection will be given within 0-8 days of the ranibizumab injection. If defined criteria are met, a second dexamethasone injection in combination with intravitreal ranibizumab (within 0-8 days) will be given at the 12 week visit. If the injections are given consecutively on the same day, the ranibizumab injection must be given first.
88851467|NCT01986114|Experimental|SM-13496 20-120mg|once daily orally SM-13496 20-120 mg flexibly dosed
88851468|NCT01945710|Experimental|Eribulin-LF Schedule 1|"Schedule 1: Eribulin-LF administered as IV infusion on Day 1 of a 21-day cycle starting at 1 mg/m^2 escalating up to 3.5 mg/m^2.~Schedule 1a: Eribulin-LF administered as IV infusion on Day 1 of a 28-day cycle starting at 1 mg/m^2 escalating up to 3.5 mg/m^2 (only to be investigated in the event that a 21-day cycle is considered inappropriate)."
88851469|NCT01945710|Experimental|Eribulin-LF Schedule 2|Schedule 2: Eribulin-LF administered as IV infusion on Day 1 and Day 15 of a 28-day cycle starting at 1 mg/m^2 escalating up to 3.5 mg/m^2 (only to be investigated in the event that a 21-day cycle is considered appropriate).
88851470|NCT01945242||Alogilptin 25mg, tablets, orally, once daily, up to 12 months|
88851471|NCT01945086|Experimental|Ustekinumab 45 mg|
88851472|NCT01945086|Experimental|Ustekinumab 90 mg|
88851473|NCT01945086|Placebo Comparator|Placebo|
88851474|NCT04637802|Active Comparator|Pre-operative and Post-operative Education intervention|This arm receives access to Patient Education intervention in the pre- and post-operative phases.
88851475|NCT04637802|Experimental|Pre-operative CBT intervention (SurgeryPal), Post-operative Education intervention|This arm receives access to CBT intervention in the pre-operative phase and Patient Education in the post-operative phase.
89378533|NCT02349334|Sham Comparator|Sham electrical stimulation|Sham electrical stimulation to forefoot by TENS
89378534|NCT02349334|Active Comparator|Percutaneous tibial nerve stimulation|Active PTNS via Urgent PC Neuromodulation device, Uroplasty
89378535|NCT03497429|Experimental|Cohort 1: Niraparib 200 mg|Niraparib 200 milligrams (mg), capsule, once orally on Days 1 - 21 of each 21-day treatment cycle.
89378536|NCT03497429|Experimental|Cohort 2: Niraparib 300 mg|Niraparib 300 mg, capsule, once orally on Days 1 - 21 of each 21-day treatment cycle.
89378537|NCT02762604|Experimental|Imagined Gait Intervention|During the phone-based imagined gait intervention, participants will be called by the experimenter three times a week and be asked to imagine walking, imagine talking and imagine walking-while-talking. They will also be asked to rate their visual and kinesthetic qualities of their images on a 1-5 scale following each trial.
89378538|NCT02762604|Active Comparator|Visual Imagery Intervention|During the phone-based visual imagery intervention, participants will be called three times a week by the experimenter and be asked to imagine concrete objects (e.g. octopus, teapot, and shovel). They will also be asked to rate their visual qualities of their images on a 1-5 scale following each trial.
89378539|NCT03146104|Active Comparator|Group P|Maintenance of anesthesia with 100-150mcg/kg/min propofol, O2 and air and FiO2 of 40%
89378540|NCT03146104|Active Comparator|Group I|Maintenance of anesthesia with 1 MAC of isoflurane,O2 and air and FiO2 of 40%
89535077|NCT03228589|Placebo Comparator|Placebo|Placebo arm treated with placebo capsules (identical to active product capsule besides the bacteria) for 8 weeks.
88851476|NCT04637802|Experimental|Pre-operative Education intervention, Post-operative CBT intervention (SurgeryPal)|This arm receives access to Patient Education intervention during the pre-operative period and CBT intervention during the post-operative period.
89378541|NCT04752150|Active Comparator|Group ESPB = Erector spinae plane block group|In group ESPB, ESPB will be performed with patients in the lateral decubitus position while the surgical site up. US probe will be placed 2-3 cm lateral to the T4 transvers process. The block needle will be inserted cranio-caudal direction and then for correction of the needle 5 ml saline will be injected deep into the erector spina muscle fascia. Following confirmation of the correct position of the needle 30 ml %0.25 bupivacaine will be administered for block.
88851477|NCT04637802|Experimental|Pre-operative and Post-operative CBT intervention (SurgeryPal)|This arm receives access to CBT intervention during the pre-operative and post-operative period.
88851478|NCT01963728|Active Comparator|insulin isophane|daily dose will be titrated based on fasting morning glucose values
89378542|NCT04752150|Active Comparator|Group RIB = RIB group|In group RIB, RIB block will be performed with patients in the lateral decubitus position while the surgical site up. The linear high frequency probe will be placed in sagittal plane medially on the medial border of the scapula at T5-6 level. The trapezius muscle, rhomboid major muscle, intercostal muscle, ribs and the pleura will be visualized. The needle will be inserted into the fascial plane between the rhomboid major and intercostal muscles in a cranio-caudal direction. A dose of 30 ml 0,25% bupivacaine will be injectted into the fascial plane.
89378543|NCT05254444|No Intervention|Group 1: Control|No activities will take place in group 1.
89378544|NCT05254444|Experimental|Group 2: Social Marketing|Households in this arm will receive a multi-tiered social marketing campaign focusing on sustainable fish nutrition, dietary diversity and food safety.
89378545|NCT05254444|Experimental|Group 3: Social Marketing + Gear Modification|Households in this arm will receive a bundled intervention of the social marketing campaign as well as modified fishing gear (basket traps with fish escape gaps) and training on proper utilization and management.
89378546|NCT04682340||Hashimoto's Group|Thyroid antibody positive and hypothyroidism
89378547|NCT04682340||Graves' Group|Thyroid antibody positive and hyperthyroidism
89378548|NCT04682340||Control Group|Thyroid antibody negative and euthyroidism
89378549|NCT05254366||Cohort 1|Painless gastroscopic sedation cohort
89378550|NCT05254366||Cohort 2|Painless colonoscopy sedation cohort
89378551|NCT05254132||aRECIST|Treatment naive patients with metastatic NSCLC (stage four) with life expectancy of more than three months.
88851479|NCT01963728|Active Comparator|insulin glargine|daily dose will be titrated based on fasting morning glucose values
88851480|NCT01963260|Experimental|Part 1: MK-8723 1 mg/kg in Healthy Participants|MK-8723 1 mg/kg administered as a single IV infusion to healthy participants in Part 1.
88851481|NCT01963260|Experimental|Part 1: MK-8723 3 mg/kg in Healthy Participants|MK-8723 3 mg/kg administered as a single IV infusion to healthy participants in Part 1.
88851482|NCT01963260|Experimental|Part 1: MK-8723 10 mg/kg in Healthy Participants|MK-8723 10 mg/kg administered as a single IV infusion to healthy participants in Part 1.
88851483|NCT01963260|Experimental|Part 1: MK-8723 30 mg/kg in Healthy Participants|MK-8723 30 mg/kg administered as a single IV infusion to healthy participants in Part 1.
88851484|NCT01963260|Experimental|Part 1: MK-8723 100 mg/kg in Healthy Participants|MK-8723 100 mg/kg administered as a single IV infusion to healthy participants in Part 1.
88851485|NCT01963260|Placebo Comparator|Part 1: Matching Placebo to MK-8723|Matching placebo to MK-8723 administered as a single IV infusion to healthy participants in Part 1.
89378552|NCT05254132||rATLAS|Treatment naive patients diagnosed with NSCLC.
89378553|NCT03497039|Experimental|Active Treatment|In the active treatment arm, DDEA gel will be applied topically at a dose of 4 gram (g) on 400 square centimeter (cm^2) twice a day for 7 days to the target knee (the knee planned for arthroplasty surgery).
89378554|NCT03497039|Placebo Comparator|Placebo Control|In the placebo control arm, placebo gel will be applied topically at a dose of 4 gram (g) on 400 square centimeter (cm^2) twice a day for 7 days to the target knee (the knee planned for arthroplasty surgery).
89378555|NCT02340910|Experimental|Short duration|Short Duration WBV consists of 8 45-sec bouts of 50Hz WBV followed by a 1-minute seated rest
89378556|NCT02340910|Experimental|Long duration|Long Duration WBV consists of 16 bouts 45-sec of 50Hz WBV followed by a 1-minute seated rest
89378557|NCT04871087|Other|Allay lamp (narrow band green light)|Comparing effects of NBGL vs. white light on anxiety level before and after psychotherapy treatment sessions.
89378558|NCT02349490|Active Comparator|Group A first line therapy|In group A, Seraseal is applied as initial method for hemostasis. If successful, the bleeding site isthen observed for 5 minutes. If bleeding remains active or recurs the institutional standard of care for hemostasis is applied.
89378559|NCT02349490|Active Comparator|Group B rescue therapy|In group B, Seraseal is applied as rescue therapy after an initial failure of the institutional standard method. If Seraseal was successful, the bleeding site was then observed for 5 minutes. If the bleeding remains active or recurs after Seraseal, alternative methods of hemostasis would be applied.
89378560|NCT03720899|Experimental|NicoBloc|NicoBloc participants will be provided with NicoBloc to use during counseling sessions and will test smoking their conventional cigarette with NicoBloc.
88851486|NCT01963260|Experimental|Part 2: MK-8723 10 mg/kg in ITP Participants|MK-8723 10 mg/kg administered as a single IV infusion to participants with ITP in Part 2.
88851487|NCT01963260|Experimental|Part 2: MK-8723 30 mg/kg in ITP Participants|MK-8723 30 mg/kg administered as a single IV infusion to participants with ITP in Part 2.
88851488|NCT01963260|Placebo Comparator|Part 2: MK-8723 100 mg/kg in ITP Participants|MK-8723 100 mg/kg administered as a single IV infusion to participants with ITP in Part 2.
88851489|NCT01963260|Placebo Comparator|Part 2: Matching Placebo to MK-8723|Matching placebo to MK-8723 administered as a single IV infusion to participants with ITP in Part 2.
89182594|NCT06239324|Active Comparator|Micro needling Technique (Group B)|About 35 patients with alopecia areata will Subject to micro needling using electronic dermapen device (Dr Pen Derma PenUltima A6) which has a disposable head personalized for each patient and sterilized after each session. the dermapen will penetrate the skin with depth 0.6 mm. It will pass vertically over the affected area in a circular pattern until pinpoint bleeding appears. Latanoprost ( xalatan 0.005% ) is applied to the treated area for all participants.
89182595|NCT06239311|Active Comparator|Methotrexate|Participants will receive 16 to 24 weekly subcutaneous injections of 20 mg . In case of intolerance of the 20 mg dose, a reduction to 15 mg per week is possible.
89182596|NCT06239311|Placebo Comparator|Placebo|Participants will receive 16 to 24 weekly subcutaneous injections
89182597|NCT06239298|Experimental|Dose Exploration|The first stage is a dose-exploration study of ZG005 combined with Donafenib to evaluate the safety and tolerability of different dose combinations in patients with advanced solid tumors who have failed standard therapy.
89182598|NCT06239298|Experimental|Dose Expansion|The second stage is a dose-expansion study to further evaluate the safety and initial efficacy of the combination regimen in hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and other potentially beneficial solid tumors.
89182599|NCT06239285|Placebo Comparator|Treatment as Usual (TAU) Group|The treatment-as-usual (TAU) group will receive a community resource brochure (the same one that is provided at the end of BVI-VR). This brochure provides contact detail for services in the local area.
89182600|NCT06239285|Experimental|Intervention Group|Patients randomized into the BVI-VR group will answer questions about the session content and the rationale for the content. Their responses will provide an estimate of engagement providing a better understanding of treatment fidelity.
89182601|NCT06239259||Carpal tunnel syndrome patients|Carpal tunnel syndrome patients
89182602|NCT06239246||2000 hospitalized patients|hospitalized patients with heart diseases
89182603|NCT06239246||10000 community population|
89182604|NCT06239194|Experimental|Phase 1a - MDX2001 Dose Escalation|Patients with metastatic solid tumors will receive MDX2001 as intravenous (IV) infusion.
89182605|NCT06239194|Experimental|Phase 1b - Dose Expansion - Dose A|Patients with a single tumor indication receive MDX2001 as intravenous (IV) infusion.
89182606|NCT06239194|Experimental|Phase 1b - Dose Expansion - Dose B|Patients with a single tumor indication will receive MDX2001 as intravenous (IV) infusion.
89182607|NCT06239194|Experimental|Phase 2a - Cohort Expansion|Patients with a single tumor indication will receive MDX2001 as intravenous (IV) infusion at the recommended Phase 2 dose.
89182608|NCT06239181|Experimental|EBECA|The patients in the intervention group scheduled for angiography were administered the Beck Anxiety Scale, and then they underwent conscious, deep breathing exercises along with synchronized breathing training. The face-to-face teaching and application of the breathing exercises took an average of 15-20 minutes.
89182609|NCT06239181|Active Comparator|control group|For the patients in the control group who were scheduled for angiography, the Beck Anxiety Scale was administered face-to-face before the procedure, and they were then sent for the procedure after receiving routine treatment without any additional intervention.
89182610|NCT06239168|Experimental|Citrus extract|Daily Citrus extract supplementation for 8 weeks.
89182611|NCT06239168|Placebo Comparator|Control|Daily Maltodextrin supplementation for 8 weeks.
89182612|NCT06239155|Experimental|Phase I: dose escalation phase|AST-3424 (1.0 mg/m^2 to 10.0 mg/m^2 or higher doses) will be administered by IV infusion on Day1 and Day8 of each 21-day cycle. 1mg/m^2 and 2mg/m^2 cohort will enroll 1 participant respectively . 4mg/m^2 or higher dose cohorts will use 3+3 dose escalation design to determine the MTD and RP2D.
89182613|NCT06239155|Experimental|Phase II: cohort expansion phase|6mg/m^2, administrated on Day1 and Day 8 of each 21-day cycle
89182614|NCT06239103|Experimental|PEMF treatment arm|Participants receive PEMF therapy. During this, the participant is seated with their right leg extended and with the bore of the PEMF machine between their knee and hip joints, with their left leg at rest. PEMF was applied at 1 mT, 15 Hz for 10 minutes.
89182615|NCT06239103|Sham Comparator|Control arm|Participants receive sham therapy, where the PEMF machine does not apply the pulsed electromagnetic waves. However, during this, the participant is kept in the same position as those in the treatment arm.
89182616|NCT06239090|Experimental|intervention group (IG)|During each session IG patients will view their recorded brain waves and physiological responses in a computer screen, while a professional will explain to them what they need to do to intervene and make corrective changes to their brain waves.
89182617|NCT06239090|Sham Comparator|sham group (SG)|SG patients will be given irrelevant information (recorded data of other patients) and thus, they cannot modulate their cortical activation.
89182618|NCT06239077|Experimental|Identifai Genetics Analytic Validity - Compound Heterozygosity and Samples Collection|
89535078|NCT04463043|Experimental|SelfBACK app|The selfBACK app in addition to usual care
89535079|NCT04463043|Active Comparator|e-Help webpage|The e-Help webpage in addition to usual care
89182621|NCT06238986||Observational|Patients undergo stool and blood sample collection, complete questionnaires, and have their medical records reviewed on study.
89182622|NCT06238934|Experimental|Group A|Bone marrow aspirate matrix
89182623|NCT06238934|Active Comparator|Group B|Bone marrow aspirate
89182624|NCT06238934|Active Comparator|Group C|Hyaluronic acid
89182625|NCT06238908|Experimental|Experimental|3 doses of NGGT003 will be administered according to the principle of dose escalation
89535080|NCT04463043|Active Comparator|Usual care|Usual care only
89535081|NCT02452489|Other|Single point group (Zhongwan)|Patients will be acupuncture with Zhongwan(RN12).
89378561|NCT03720899|Active Comparator|Nicotine Lozenge|Participants who receive nicotine lozenge will use the lozenge in session and will discuss the effects of using the lozenge in session.
89378562|NCT02340754|Experimental|Mindfulness-base Stress Reduction|Mindfulness-based stress reduction is a formalized, experiential, 8-week stress-management program. Participants attend weekly two-hour classes and a half-day retreat during which they learn mindfulness meditation, breath work, yoga postures, self-reflection and awareness.
89378563|NCT02340754|Active Comparator|MS Education Control|The MS Education Control program is matched to MBSR for time and attention yet has no overlap with intervention content. Each two-hour class uses a pamphlet published by the National MS Society to present information about a different MS topic such as Fatigue; Bowel and Bladder Problems; Diet; Spasticity; and Nutritional Supplementation: Vitamins, Minerals, and Herbs.
89378564|NCT03495869||Individuals with Cocaine Use Disorder|"This group will consist of individuals who are determined to have DSM5 diagnosis of Cocaine Use Disorder (n=50).~Individuals will be recruited from an existing registry (VCU IRB HMHM20000294, Keyser-Marcus, PI)"
89378565|NCT03495869||Individuals with Opioid Use Disorder|This group will consist of individuals who are determined to have DSM5 diagnosis of Opioid Use Disorder (n=200).
89378566|NCT03495869||Individuals with Marijuana Use Disorder|This group will consist of individuals who are determined to have DSM5 diagnosis of Marijuana Use Disorder (n=50).
89378567|NCT03495869||Healthy Controls|This group will consist of individuals who are determined to be non-drug using healthy controls (n=100).
89378568|NCT03145870|Other|Patient with multiple symptomatic myeloma|
89378569|NCT03145636|Other|Observational arm|Subjects will receive the device implant and use the vBloc Achieve Weight Management Program.
89378570|NCT03145636|Other|Randomized sub-study -Treatment|Subjects will be randomly assigned (1:1) either to treatment or control. Treatment arm will receive the device and use of vBloc Achieve Weight Management Program.
89378571|NCT03145636|Other|Randomized sub-study - Control|Subjects will be randomly assigned (1:1) either to treatment or control. Control will participate in a Control Weight Management (CWM) program for 6 months prior to receiving the device implant and using the vBloc Achieve program.
89378572|NCT03145480|Experimental|Fit arm|ibrutinib and obinutuzumab in combination with the CHOP regimen
89378573|NCT03145480|Experimental|Frail arm|ibrutinib and obinutuzumab
89378574|NCT03726515|Experimental|CART-EGFRvIII + Pembrolizumab|
89378575|NCT02349568||High risk group|High risk group was defined when CBD stones was detected by ultrasound ( US ) / computed tomography ( CT ) or dilated duct with abnormal LFT.
89378576|NCT02349568||Intermediate risk group|Intermediate risk group was defined when US/CT showed normal bile duct with abnormal LFT or dilated duct with normal LFT.
89378577|NCT03071094|Experimental|Pexa-Vec combined with Nivolumab - Phase I|Participants were administered Pexa-Vec (pexastimogene devacirepvec) as 3 bi-weekly intratumoral (IT) injections of 10^9 pfu at day 1 and weeks 2 and 4 and nivolumab intravenously every 2 weeks (from week 2).
89378578|NCT03071094|Experimental|Pexa-Vec combined with Nivolumab - Phase IIa|Participants were administered Pexa-Vec (pexastimogene devacirepvec) as 3 bi-weekly intratumoral (IT) injections of 10^9 pfu at day 1 and weeks 2 and 4 and nivolumab intravenously every 2 weeks (from week 2).
89378579|NCT02340364|Experimental|Education + PN Arm|208 patients randomized to self-care education+ Patient navigator-delivered self-care plan.
89182626|NCT06238895|Experimental|Intervention Group|Oral iron supplementation with Eisen-II-Sulfat (Tardyferon ®) Every second day 2 x 80 mg Tardyferon® for a duration of 12 weeks.
89182627|NCT06238895|Active Comparator|Active Control|Oral iron supplementation with Eisen-II-Sulfat (Tardyferon ®) Every day 1x 80 mg Tardyferon® for a duration of 12 weeks
89378580|NCT02340364|Active Comparator|Educational Control Arm|- 208 patients randomized to self-care education alone.
89378581|NCT05761392|Experimental|Precise management|"Participants will be asked to take daily pain state and monthly health condition assessments.~A warning for the physicians will be given when participants reach daily assessment threshold. Remote interventional meeting will be scheduled and stimulation parameters will be adjusted accordingly.~Participants will also be asked to take conventional follow-up at 1-, 3-, and 6-month post-operative."
89378582|NCT05761392|No Intervention|Conventional management|Participants will be only asked to take conventional follow-ups at 1-, 3-, and 6-month post-operative. During these follow-ups, they will be asked to score VAS based on general pain state, and take questionnaires including EQ-5D-5L, PSQI, PGIC, CGI-I.
88851494|NCT01985334|Experimental|A1 (any SABA and/or SAMA)|Patients treated with any SABA and/or SAMA as monotherapy or in free or fixed dose combination will be assigned to glycopyrronium or will remain in their baseline therapy (3:1) during 90 days of treatment
88851495|NCT01985334|Experimental|A2 (glycopyrronium)|Patients treated with any SABA and/or SAMA as monotherapy or in free or FDC at enrollment and randomized to switch in treatment with glycopyrronium (50 μg o.d.)
89182628|NCT06238882|Experimental|Intervention|Patients will be given patches of nitroglycerin during treatment with radiation therapy (30 Gy in 10 fractions, i.e. 10 days of treatment).
89182629|NCT06238882|No Intervention|Control|Patients will be given a conventional treatment with radiation therapy (30 Gy in 10 fractions, i.e. 10 days of treatment).
88851496|NCT01985334|Experimental|B1 (any LAMA or LABA and mMRC=1)|Patients treated with any LABA or LAMA monotherapy and mMRC score =1 point at Visit 1 and randomized to remain in their baseline treatment with LABA or LAMA
89378583|NCT04478968||Active AVF|Patients after kidney transplantation with functioning AVF
89378584|NCT04478968||No AVF|Patients after kidney transplantation without AVF (thrombosed AVF, history of HD with catheter, history of PD, preemptive transplantation)
89378585|NCT04595292||older adults, assessment|
89378586|NCT03145402|Experimental|Intracoronary injection of stem cell|Autologous bone marrow-derived mononuclear cells injection in patients with Heart Failure
89378587|NCT03145402|Placebo Comparator|Placebo|Placebo injection via coronary arteries in patients with Heart Failure
89378588|NCT04438876|Experimental|Function power training|12-week structured FPT program, conducted by a certified trainer from a community service provider. Sessions were held twice weekly at the respective community senior activity centers, each lasting 60 minutes in duration.
89378589|NCT04438876|Active Comparator|Usual care|Participants either continued the usual exercise program provided by their respective community senior activity centers or their personal exercise routine.
89378590|NCT04477798|Experimental|PCT-DIA/MS|PCT-DIA/MS protein classifier supported by artificial neural networks will be validated to classify thyroid indeterminate nodules
89378591|NCT03148990|Experimental|Measles and Rubella vaccine|Biological/Vaccine: Administration of the experimental vaccine (Measles and Rubella).
89378592|NCT03148990|Active Comparator|Measles, Mumps and Rubella vaccine|Biological/Vaccine: Administration of the comparator vaccine (Measles, Mumps and Rubella).
89378593|NCT02340598|Experimental|cold vest|Participants are given a cold vest that the pre-cool in a freezer. They are encouraged to use it daily to activate metabolism through brown adipose tissue and shivering.
89378594|NCT02340598|No Intervention|control|No intervention, just recording of risk factors and basal metabolic rate.
89378595|NCT03559517|Experimental|Ontamalimab 25 mg|Participants will receive 25 mg of ontamalimab subcutaneous injection using a prefilled syringe on Week 0/Day 1, Week 4, Week 8, and Week 12.
89378596|NCT03559517|Experimental|Ontamalimab 75 mg|Participants will receive 75 mg of ontamalimab subcutaneous injection using a prefilled syringe on Week 0/Day 1, Week 4, Week 8, and Week 12.
89378597|NCT03559517|Placebo Comparator|Placebo|Participants will receive placebo matching with ontamalimab subcutaneous injection using a prefilled syringe on Week 0/Day 1, Week 4, Week 8, and Week 12.
89378598|NCT02340442||Low risk group|40 subjects: Healthy, pregnant women
89378599|NCT02340442||High risk group|"40 pregnant women:~20 Pregnant women with preeclampsia~20 Obese pregnant women"
89378600|NCT02340442||Healthy control subjects|40 subjects
89378601|NCT04477642|Experimental|AbataceptTreatment Arm|Enrolled patients who will receive treatment with abatacept
89378602|NCT03149146|Experimental|Clinical Decision Making (CDM) Workshop|Series of CDM educational workshop will be conducted for one group of participants and they will be guided the CDM process through the two clinical practice models; Therapeutic process (TP) and International Classification of Functioning, Disability and Health (ICF).
89378603|NCT03149146|Active Comparator|Clinical Decision Making Workbook|Participants will receive Clinical Decision Making (CDM) workbook which will be used to teach the Clinical Decision Making process in the four days workshop.
89378604|NCT02344732|Active Comparator|Standard Group|topical Maxitrol™ six-hourly and homatropine 2% six-hourly
89378605|NCT02344732|Experimental|Oxygen Group|standard medical treatment of topical Maxitrol™ six-hourly and homatropine 2% six-hourly, plus systemic oxygen via simple face mask at 10 litres/min for one hour, in 12-hourly sessions for 3 days
89378606|NCT03720743|Experimental|Biodanza|Intervention group received a total of 10 sessions, once a week, over the course of two months. Each session lasted 60 minutes. All sessions began with a 10-minute warm-up period combining music and low-intensity movements as a welcome round, followed individual exercises, in pairs and/or groups, which included dance combined with exercises based on the five lines of Biodanza (vitality, sexuality, creativity, affectivity and transcendence). Finally, a celebration and farewell round of 10 minutes was held. At the end of each session, the participants were asked to share their experiences with the rest of the group.
89378607|NCT03720743|No Intervention|Control Group|The study allowed control group subjects to participate in Biodanza sessions after the follow-up period.
88851497|NCT01985334|Experimental|B2 (glycopyrronium and mMRC=1)|Patients treated with any LABA or LAMA monotherapy and mMRC score =1 point at Visit 1 and randomized to switch in treatment with glycopyrronium (50 μg o.d.)
88851498|NCT01985334|Experimental|C1 (any LABA and ICS)|Patients treated with any LABA and ICS in free or FDC at enrollment and randomized to remain in their baseline treatment with LABA and ICS in free or FDC
88851499|NCT01985334|Experimental|C2 (indacaterol/glycopyrronium)|Patients treated with any LABA and ICS in free or FDC at enrollment and randomized to switch in treatment with indacaterol maleate and glycopyrronium bromide FDC (110/50 μg o.d.)
89378608|NCT02344654|Experimental|Fluorescence cholangiography|After induction of anaesthesia 2.5-7.5 mg of indocyanine green (0.05 mg/kg) is injected intravenously. The operation field is routinely inspected in the fluorescence imaging mode before dissection of Calot´s triangle. During dissection, the fluorescence imaging mode is used when needed, before division of any tubular structure and after division of the cystic duct and artery.
88851500|NCT01985334|Experimental|D1 (any LAMA or LABA and mMRC>1)|Patients treated with any LABA or LAMA monotherapy and mMRC score >1 point at Visit 1 and randomized to remain their baseline in treatment with LABA or LAMA
89378609|NCT02344654|Active Comparator|X-ray cholangiography|The cholangiography is performed after dissection of the cystic duct by cannulation of the cystic duct with a catheter using either a Kumar- or Olsen grasper. A mobile X-ray C-arm system is used, and the monochrome X-ray image is shown on a separate screen. After satisfactory identification of the extra-hepatic biliary ducts, the intraoperative cholangiography is discontinued and the gallbladder is removed in a standardized manner.
88851501|NCT01985334|Experimental|D2 (indacaterol/glycopyrronium and mMRC>1)|Patients treated with any LABA or LAMA monotherapy and mMRC score >1 point at Visit 1 and randomized to switch in treatment with indacaterol maleate and glycopyrronium bromide FDC (110/50 μg o.d.).
88851502|NCT01944774|Experimental|Nemonoxacin 500 mg|Nemonoxacin 500mg/250mL.
88851503|NCT01944774|Experimental|Nemonoxacin 650 mg|Nemonoxacin 650 mg/325mL
88851504|NCT01944774|Active Comparator|Moxifloxacin 400 mg|Moxifloxacin 400mg/250mL
89378610|NCT03720665|Active Comparator|Caffeine group|"200mg caffeine tablet~transcranial alternating current stimulation (140 Hz tACS) at 1 mA~transcranial alternating current stimulation (140 Hz tACS) at 0.4 mA~transcranial alternating current stimulation (140 Hz tACS) sham~paired associative stimulation (PAS 25)"
89378611|NCT03720665|Placebo Comparator|Placebo group|"Non-active tablet~transcranial alternating current stimulation (140 Hz tACS) at 1 mA~transcranial alternating current stimulation (140 Hz tACS) at 0.4 mA~transcranial alternating current stimulation (140 Hz tACS) sham~paired associative stimulation (PAS 25)"
89378612|NCT05253742||Pregnant women presenting for MRI|Alternative motion-robust MR imaging sequences and procedures for automatic positioning while be tested during fetal brain imaging
89378613|NCT05253664|Experimental|Woman-Centered Care Group|Woman-centered care was given to the experimental group. At the time of the study, 6 women were discharged early, 4 women did not want to continue the study, and the babies of 1 women were admitted to the neonatal intensive care unit due to complications so these women were excluded from the study. The study was completed with 109 women in the experimental group.
89378614|NCT05253664|No Intervention|Control Group|Standard care was given to the control group. At the time of the study, 2 women were discharged early, 7 women did not want to continue the study, and the babies of 2 women were admitted to the neonatal intensive care unit due to complications so these women were excluded from the study. The study was completed with 218 mothers, with 109 women in the control group.
89378615|NCT03722537|Active Comparator|Ligament Reconstruction Tendon Interposition (LRTI)|Selected randomly, 100 patients will receive this treatment. During the LRTI (standard of care procedure), the arthritic bone that the thumb rests on (the trapezium) is removed. A small cut is made in the forearm to release a tendon, which is moved to the base of the thumb to fill in the area from which the trapezium bone was removed. A small suture anchor is then placed into a thumb bone which holds everything together.
89378616|NCT03722537|Experimental|Osteochondral Allograft|Selected randomly,100 patients will receive this treatment. In this procedure, the arthritic bone that the thumb rests on (the trapezium) is removed and replaced with femoral trochlear osteochondral allograft that is designed to be similar in morphology to the human trapezium articular surface, known as the 'Cartibend©' .
89378617|NCT04029844|Experimental|Colibri Device|Treatment
89378618|NCT03726281|Experimental|single-arm trial of Nivolumab|Multi-institutional, single arm phase II trial with Simon's optimal two-stage design, to evaluate the clinical benefit of Nivolumab monotherapy in patients with platinum-recurrent or platinum-refractory metastatic GCT. No randomization or blinding is involved.
89378619|NCT03148834|Experimental|Control Reperfusion Primary Angioplasty|Patients admitted with acute myocardial infarction and TIMI flow 0/1, will be treated with the use of an intracoronary venous blood solution and dextran to protect the myocardium during reperfusion.
89378620|NCT03148834|No Intervention|Standard Primary Coronary Angioplasty|Patients admitted with an acute myocardial infarction and TIMI flow 0/1, will be treated with primary angioplasty according to norms described in the international guidelines of treatment.
88817463|NCT01739231|Active Comparator|Control: Part B only|Eligible participants were screened and administered H10407 challenge strain concurrently with other arms in Part B of the study. Their results for Part B are combined with that of the Control Arm in Part A, which received three oral doses of CeraVacx placebo.
88817464|NCT02605863|Experimental|Intermediate Risk NMIBC|Enzalutamide 160mg by mouth daily for 12 months
88817465|NCT02605863|Experimental|High Risk NMIBC|Enzalutamide 160mg by mouth daily for 12 months
88817466|NCT02822469|Experimental|Manual Therapy Treatment Group|Severe and Moderate TMD patients who filled the inclusion criteria who will receive the Manual Therapy Treatment
88817467|NCT02822469|Placebo Comparator|Placebo Ultrasound Treatment Group|Severe and Moderate TMD patients who filled the inclusion criteria who will receive the Placebo Treatment.
88817468|NCT04743063||New users of angiotensin receptor neprilysin inhibitor|
88817469|NCT04743063||New users of angiotensin II receptor blockers|
88817470|NCT04742985|Experimental|Green tea combined extracts group A|This group takes Green tea combined extracts (62.5 mg) for 8 weeks.
88817471|NCT04742985|Experimental|Green tea combined extracts group B|This group takes Green tea combined extracts (125 mg) for 8 weeks.
88817472|NCT04742985|Placebo Comparator|Placebo group|This group takes placebo for 8 weeks.
88817473|NCT01739699|Experimental|Acetaminophen|Subjects will receive 1000mg of intravenous acetaminophen every 6 hours for 24 hours beginning with dural closure.
88817474|NCT01739699|Other|Placebo|Subjects will receive 100cc of normal saline every 6 hours for 24 hours beginning at dural closure.
88817475|NCT04154787|Experimental|LNP023|LNP023
88817476|NCT04154787|Active Comparator|Rituximab|Rituximab
88817477|NCT01721681|Experimental|FACTOR X|"At the Baseline Visit, eligible children will receive a bolus dose of 50 IU/kg FACTOR X. After the Baseline Visit, children will be treated with FACTOR X prophylactically for a period of 6 months (26 weeks).~A dosing regimen of 40-50 IU/kg twice a week is recommended, but is not mandatory. Each dose of FACTOR X must not exceed 60 IU/kg."
88817478|NCT04741893|Experimental|faecally incontinent patients|faecally incontinent patients are all assessed using EndoFLIP as well as anorectal manometry and endoanal ultrasound
88817479|NCT04741893|Experimental|Asymptomatic individuals|asymptomatic individuals are all assessed using EndoFLIP as well as anorectal manometry and endoanal ultrasound
88817480|NCT01740713|Experimental|Deferiprone, dose level 1|single dose level of 8.3 mg/kg every 8 hours for a corresponding total daily dose of 25 mg/kg/day.
88817481|NCT01740713|Experimental|Deferiprone, dose level 2|single dose level of 16.7 mg/kg every 8 hours for a corresponding total daily dose of 50 mg/kg/day.
88817482|NCT01740713|Experimental|Deferiprone, dose level 3|single dose level of 33.3 mg/kg every 8 hours for a corresponding total daily dose of 100 mg/kg/day.
88817483|NCT02609841||Cardiac rhythm remote monitoring system|Subjects use non-invasive wearable BodyGuardian remote monitoring system throughout 12 days of study.
88817484|NCT02613117|Other|potassium oxalate gel|potassium oxalate gel self applied
88817485|NCT02613117|Other|oxalate liquid, SnF2 paste|Potassium oxalate liquid professionally applied, Stannous fluoride paste self applied
89378621|NCT03148912|Experimental|diagnostic algorithm|Optimizing the interpretation of the more readily available anti-PF4 assay would reduce the reliance on functional testing/ confirmatory testing (Serotonin Release Assay, SRA) and the number of patients exposed to unnecessary changes in anticoagulation therapy while awaiting the timely functional test results
89378622|NCT03726203|Experimental|trocars of type MiniLap|Patients benefiting from the use of trocars of type MiniLap of Teleflex during the realization of their coelioscopy scheduled in ambulatory
89378623|NCT03726203|Active Comparator|trocars classics|Patients benefiting from the use of trocats classics during the realization of their coelioscopy scheduled(programmed) in ambulatory.
89535082|NCT02452489|Other|Combination of He-Mu points group|Patients in Combination of He-Mu points group,will be acupuncture with Zusanli(ST36) and Zhongwan(RN12).
89378626|NCT03720353|Active Comparator|Active H|Participants will take SAS2094AL and SAS2094BH for 3 days, then SAS2094AH and SAS2094BH for 7 days.
89378627|NCT03720353|Active Comparator|Active L|Participants will take SAS2094AL and SAS2094BL for 10 days
89378628|NCT03720353|Placebo Comparator|Placebo|Participants will take placebo for 10 days.
89378629|NCT03149068||75 patient|Seventy five (75) CKD patients in different stages will be included in our study from Nephrology unit, Internal Medicine department, Assuit University Hospital
89378630|NCT03149068||25 healthy control|twenty five (25) age and sex matched apparently healthy individuals will be enrolled as controls
88851505|NCT01944462|Experimental|Pharmacist Pneumococcal Vaccine Program (PPVP)|Individuals receiving the PPVP intervention which consists of the educational program delivered on site at the collaborating senior center.
88851506|NCT01943292|Experimental|Defactinib|Oral defactinib (VS-6063) administered twice a day (BID) during a 21 day cycle.
88851507|NCT01961544|Experimental|Eribulin mesylate|1.4 mg/m2 (as eribulin 1.23 mg/m2) day by 2-5 minutes IV on Day 1 and 8 every 21 days
88851508|NCT01942590|Experimental|Clenbuterol|Initially, 40 mcg each morning for one week. Then, increase to 40 mcg BID for the next 5 weeks. If tolerated, will increase to 80 mcg in the morning and 40 mcg in the evening for one week. Then, last dose increase will be 80 mcg BID until week 52.
88851509|NCT01942590|Placebo Comparator|Placebo Comparator|Initially, one capsule each morning for one week. Then, increase to one capsule BID for the next 5 weeks. If tolerated, will increase to two capsules in the morning and one capsule in the evening for one week. Then, last dose increase will be two capsules BID until week 52.
88851510|NCT01984242|Experimental|Atezolizumab and Bevacizumab|Atezolizumab 1200 milligrams (mg) and bevacizumab 15 milligrams per kilogram (mg/kg) will be administered as intravenous (IV) infusions every 3 weeks (q3w) on Day 1 and Day 22 of each 6-week cycle until disease progression.
88851511|NCT01984242|Experimental|Atezolizumab|Atezolizumab 1200 mg will be administered as IV infusion q3w on Day 1 and Day 22 of each 6-week cycle until disease progression. Upon disease progression, participants (except European Union [EU] participants) can crossover to receive atezolizumab and bevacizumab combination until disease progression, lack of clinical benefit, unacceptable toxicity, withdrawal from study, or study completion or termination.
89378631|NCT02344264|Other|RP|first blockade: ropivacaine 7,5mg/ml 8 ml second blockade: placebo: saline 8 ml
89378632|NCT02344264|Other|PR|first blockade: placebo: saline 8 ml second blockade: ropivacaine 7,5mg/ml 8 ml
89378633|NCT03148678|Experimental|Mindfulness first; Contingent RT-fMRI-NF|"Participants start with the mindfulness intervention followed by the mind wandering intervention. The arm type experimental refers to contingent RT-fMRI-NF, during which participants are provided with contingent RT-fMRI-NF of their own brain activity."
89378634|NCT03148678|Sham Comparator|Mindfulness first; Non-Contingent Neurofeedback|"Participants start with the mindfulness intervention followed by the mind wandering intervention. The arm type sham comparator refers to non-contingent RT-fMRI-NF, during which participants are provided with sham RT-fMRI-NF of brain activity of previously recorded subject."
89378635|NCT03148678|Experimental|Mind wandering first; Contingent Neurofeedback|"Participants start with the mind wandering intervention followed by the mindfulness intervention. The arm type experimental refers to contingent RT-fMRI-NF, during which participants are provided with contingent RT-fMRI-NF of their own brain activity."
89378636|NCT03148678|Sham Comparator|Mind wandering first; Non-Contingent Neurofeedback|"Participants start with the mind wandering intervention followed by the mindfulness intervention. The arm type sham comparator refers to non-contingent RT-fMRI-NF, during which participants are provided with sham RT-fMRI-NF of brain activity of previously recorded subject."
89378637|NCT02349256||Diagnosed with Somatic Syndrome Disorder|Group of participants that are screened and meet criteria for diagnosis of Somatic Syndrome disorder will be asked if they wish to take part in a 1-1 qualitative interview with the researcher.
89378638|NCT02344030|Experimental|standard blade|Standard Blade: tracheal intubation with standard blade
89378639|NCT02344030|Experimental|channeled blade|Channeled Blade: tracheal intubation with channeled blade
89378640|NCT03145246||tooth loss|regeneration treated teeth loss
89002563|NCT06316310|Sham Comparator|Sham Acupoint Thread Embedding group+health education|"Sham acupoint thread embedding method in this study is set as the Sham acupoint thread embedding manipulated at the same main acupoints won't be put into trocar and de qi sensation will not be obtained.~The aim of the sham acupoint thread embedding is to eliminate the possible placebo effect of ATE treatment."
89378641|NCT03145246||clinical attachment loss ≥ 2 mm|regenerated treated teeth with clinical attachment loss ≥ 2 mm
89002564|NCT06315959|Active Comparator|Group ESP|A bilateral ESP Block(60 ml, %0.25 bupivacaine, totally) + IV morphine patient-controlled analgesia (PCA)
89002565|NCT06315959|Other|Group Control|IV morphine PCA
89002566|NCT06315595||Group 1 (MRI)|Participants undergo MRI on study. Participants may also undergo blood sample collection on study.
89002567|NCT06315595||Group 2 (MRI with contrast)|Participants receive gadolinium based MR contrast agent IV and undergo a MRI on study. Participants may also undergo blood sample collection on study.
89002568|NCT06315595||Group 3 (MRIs with contrast)|Participants receive gadolinium based MR contrast agent IV and undergo up to two MRIs on study. Participants may also undergo blood sample collection on study.
89002569|NCT06315504||Patients with de novo nephrotic syndrome|
89002570|NCT06315374|Active Comparator|Simply using soft mist inhaler|Routine use of soft mist inhaler only
89002571|NCT06315374|Experimental|Use soft mist inhaler with a 3D assistive device|Use soft mist inhaler with a 3D-printed assist device
89002572|NCT06315205|Experimental|Cohort 1: Letrozol LEBE 75 mg|
89002573|NCT06315205|Experimental|Cohort 2: Letrozol LEBE 150 mg|
89002574|NCT06315205|Experimental|Cohort 3: Letrozol LEBE 225 mg|
89002575|NCT06315179||Inflammatory Bowel Disease|"Participants will enroll before their initial diagnostic procedure. After pathology results are reported, participants will be categorized based on the assigned diagnoses: Inflammatory Bowel Disease (IBD) [Crohn's disease (CD), ulcerative colitis (UC), and Indeterminate Colitis (IC)] vs Disorders of the Brain-Gut Interactions (DGBI).~Participation in the IBD cohort will last for three years."
89002576|NCT06315179||Disorders of the Brain-Gut Interactions|"Participants will enroll before their initial diagnostic procedure. After pathology results are reported, participants will be categorized based on the assigned diagnoses: Inflammatory Bowel Disease (IBD) [Crohn's disease (CD), ulcerative colitis (UC), and Indeterminate Colitis (IC)] vs Disorders of the Brain-Gut Interactions (DGBI).~-The DGBI cohort will be subdivided into: Esophageal Disorder, Gastroduodenal Disorder, Bowel Disorder, Centrally Mediated Disorders of GI Pain, Gallbladder and Sphincter of Oddi Disorder, Anorectal Disorder, Childhood Functional GI Disorders: Neonate/Toddler, Childhood Functional GI Disorders: Child/Adolescent~Participation in the DGBI cohort will include the initial sample and data collection as well an one further medical record extraction at month 24."
89002577|NCT06313892|Experimental|Exercise group|The participants in the study group will be given an online personalized exercise program at home in non dialysis days. Each session will be 40 to 45 min in duration for 3 days per week over 12 weeks, 36 sessions in total.
89002578|NCT06313892|No Intervention|Control group|Patients allocated to the control group will receive their standard nephrological care. Through the 12-week period, all control participants will be instructed to maintain the standard treatment regimen and to maintain their customary dietary and physical activity patterns.
89002579|NCT06313645||Patients with coronary artery diseases|Patients with acute coronary syndromes [unstable angina, non-ST segment elevation myocardial infarction (NSTEMI), ST segment elevation myocardial infarction (STEMI)] and with stable angina or non-angiographically coronary diseases recovered for elective diagnostic or interventional procedures are included in the study
89002580|NCT06313515|Experimental|tSCS paired with arm-crank exercise|"Device: Transcutaneous Spinal Stimulation~Non-invasive electrical stimulation of the spinal cord over the skin.~Other: Arm-crank exercise~Exercise using an arm-bike to target cardiovascular functioning."
89002581|NCT06313515|Sham Comparator|Sham stimulation paired with arm-crank exercise|"Device: Sham Stimulation~Non-invasive electrical stimulation of a lower extremity muscle group over the skin.~Other: Arm-crank exercise~Exercise using an arm-bike to target cardiovascular functioning."
89378642|NCT03145246||clinical attachment loss loss < 2 mm|regenerated treated teeth with clinical attachment loss < 2 mm
89378643|NCT02343874||Alcohol consumption|"Patients over 17 years old with alcohol consumption registered in the electronic medical record (31st December 2012).~No intervention is going to be administered but exposure to alcohol will be analysed"
89378644|NCT02340208|Experimental|L-DOS47|Patient will be recruited into cohorts of L-DOS47 escalating doses, with a minimum of 3 and a maximum of 6 patients per cohort. The starting dose of L-DOS47 will be 0.12 μg/kg; further possible dose levels include 0.21, 0.33, 0.46, 0.59, 0.78, 1.04, 1.38, 1.84, 2.45, 3.26 and 4.33 μg/kg.
89378645|NCT02340052||Frederiksberg Hospital|100 patients undergoing planned total hil arthroplasty
89378646|NCT02340052||Koege hospital|100 patients undergoing planned total hil arthroplasty
89378647|NCT02340052||Naestved Hospital|100 patients undergoing planned total hil arthroplasty
89378648|NCT02340052||Hilleroed Hospital|100 patients undergoing planned total hil arthroplasty
89378649|NCT02340052||Nykoebing Falster Hospital|100 patients undergoing planned total hil arthroplasty
89002582|NCT06313450|Experimental|de-escalated radiotherapy|If the primary tumour regresses by over 75% and the level of EBV DNA reduces to zero, a radiation dose of 60Gy will be administered. Additionally, three cycles of Toripalimab (240mg, every three weeks) and two cycles of cisplatin (100mg/m2, every three weeks) will be given during radiotherapy.
89002583|NCT06313450|Other|conventional radiotherapy|If the primary tumour regresses by less than 75% or if EBV DNA remains above zero, a conventional radiation dose of 70Gy to the primary tumor and two cycles of cisplatin (100mg/m2, every three weeks) will be administered during radiotherapy.
89002584|NCT06313242|Active Comparator|Laxatives arm|Normal diet 1 day before the test, fasting and laxatives from 20:00 pm. The laxatives, Polyethylene Glycol Electrolytes Powder (II), should be prepared as a solution and taken as 2000 ml the night before the test and 1000 ml the following morning, within 2 hours and 1 hour, respectively.
89002585|NCT06313242|Experimental|Low residue diet arm|Low residue diet 1 day before the test, fasting from 20:00 pm.
89002586|NCT06313242|Experimental|Normal diet arm|Normal diet 1 day before the test, fasting from 20:00 pm.
89535083|NCT02452489|Other|Control group|Patients in Control group,will be acupuncture with at the junction of deltoid and biceps.
88851512|NCT01984242|Active Comparator|Sunitinib|Sunitinib 50 mg will be administered orally once daily on Days 1 to 28 of each 6-week cycle until disease progression. Upon disease progression, participants can crossover to receive atezolizumab and bevacizumab combination until disease progression, lack of clinical benefit, unacceptable toxicity, withdrawal from study, or study completion or termination.
88851513|NCT01941498|Experimental|WaveLight Refractive Suite|LASIK surgery (laser in situ keratomileusis) per standard of care
88851514|NCT04656132|Experimental|Participants with cardiovascular disease or cardiovascular disease risk factors|Population We will recruit 59 males and females age > 18 being seen in the NYU Langone Center for Prevention of Cardiovascular Disease (4F). Participants have cardiovascular disease or cardiovascular disease risk factors.
88851515|NCT01960998|Experimental|Telehealth with Pelvic Floor Muscle Training|Participants in this group will participate in an evidence-based pelvic floor muscle training program that has been adapted to telehealth format. Training is begun 1 month before surgery and continued 2 months after surgery. Content is accessed in 10-minute sessions on a secure website - daily preoperatively and for the first 2 months post-operatively, then weekly until 6 months post-operatively. In addition to the pelvic floor muscle training, content will also include general perioperative care; wetness, odor and skin care management; and outcome measures.
88851516|NCT01960998|Active Comparator|Telehealth without Pelvic Floor Muscle Training|Participants in this group will receive a telehealth program that includes include general perioperative care; wetness, odor and skin care management; and outcome measures. The program is begun 3 weeks before surgery and continued 2 months after surgery. Content is accessed in 10-minute sessions on a secure website - daily preoperatively and for the first 2 months post-operatively, then weekly until 6 months post-operatively.
88851517|NCT01941186|Experimental|Patient Decision Aid|After positive screen for a developmental concern the intervention group will receive the Patient Decision Aid (PDA), as well as, a text message reminder to follow up with Early Intervention.
88851518|NCT01941186|No Intervention|Routine Care|After screening positive for a potential development delay those in the control arm will receive routine care, in this case, a handout explaining Early Intervention services.
89182630|NCT06238856|Experimental|Cohort 1: Amikacin Dose 1 + Placebo|Participants will receive a single dose of SLIT™ amikacin at Dose 1 or matching placebo by inhalation on Day 0.
88851519|NCT01960842|Experimental|Levodopa-Carbidopa Intestinal Gel (LCIG)|"All participants received LCIG via the N-J tube during the nasojejunal (N-J) Test Period and delivered to the proximal small intestine via percutaneous endoscopic gastrostomy - with jejunal extension tube (PEG-J) during the Post-PEG-J Long-Term Treatment Period. The starting dose was individually determined based on the daily dose of oral levodopa prior to study enrollment.~The infusion dose was individually optimized for each participant on the basis of response and potential adverse events. During the PEG-J Period, LCIG was expected to be infused continuously over approximately 16 hours daily with a rate of infusion ranging from 1 to 10 mL/hour (20 to 200 mg of levodopa/hour)."
88851520|NCT01984164|Active Comparator|Candesartan|To achieve blood pressure control, we will use a stepwise protocol as follows: candesartan (blinded) 8mg→ 16mg→ 32mg. Both groups will also receive (unblinded) , if needed to achieve blood pressure control, HCTZ 12.5mg→ 25mg, Amlodipine 2.5mg→ 5mg →10mg and metoprolol succinate extended release 12.5mg→ 25mg→ 50mg. Antihypertensive medications will be increased every 2 weeks until control is achieved.
88851521|NCT01984164|Active Comparator|Lisinopril|To achieve blood pressure control we will use a stepwise protocol as follows: lisinopril (blinded) 10mg→ 20mg→ 40mg. Both groups will also receive (unblinded), if needed to achieve blood pressure control, HCTZ 12.5mg→ 25mg, Amlodipine 2.5mg→ 5mg→ 10mg and metoprolol succinate extended release 12.5mg→ 25mg→ 50mg. Antihypertensive medications will be increased every 2 weeks until control is achieved.
88851522|NCT01983930|Active Comparator|Memory Training|Group memory training will be administered for amnestic mild cognitive impairment (MCI)
88851523|NCT01983930|Experimental|Kundalini yoga and meditation|Participants will engage in weekly yoga classes and daily 20 minute meditation
88851524|NCT04636398|Experimental|MESSAGE mHealth group intervention|Participants in the one arm will be exposed to the mHealth group intervention. As this is a pilot developmental study, the participants will be exposed to various strategies for information delivery (live presentation at a scheduled time versus voice recording accessible at any time), discussion facilitation (heavily managed with request to speak vs. natural discussion participation), and text communication management (moderator-facilitated vs. group-led).
88851525|NCT01983774|Placebo Comparator|Placebo|A matching placebo (sugar pill) to esomeprazole 40mg twice daily
88851526|NCT01983774|Active Comparator|Esomeprazole|Esomeprazole 40mg twice daily
88851527|NCT01982682|Experimental|Treatment (TBI, DLI, cyclophosphamide, CD34+ donor HSCT)|"CONDITIONING REGIMEN: Patients undergo TBI BID on days -10 to -8, undergo DLI on day -6, and receive cyclophosphamide IV over 2 hours on days -3 and -2.~TRANSPLANT: Patients undergo CD34+ (cluster of differentiation 34+) selected allogeneic HSCT on day 0.~GVHD PROPHYLAXIS: Patients receive tacrolimus IV or PO beginning on day -1 with taper beginning by day 42, and mycophenolate mofetil IV BID on days -1 to 28."
88851528|NCT01940484||Chronic Renal Anemia Participants|Participants with chronic kidney disease and who are on hemodialysis and on methoxy polyethylene glycol epoetin beta as per physician's discretion for treatment of chronic renal anemia will be observed for a period of 6-12 months.
88851529|NCT01939548|Experimental|PF-02545920 (5mg)|
88851530|NCT01939548|Placebo Comparator|Placebo|
88851531|NCT01939548|Experimental|PF-02545920 (15mg)|
88851532|NCT01960296|Experimental|Clopidogrel|Continue home dose of clopidogrel into surgery
88851533|NCT01960296|Active Comparator|Discontinue|Discontinue home dose of clopidogrel one week before surgery. Resume after surgery.
89182631|NCT06238856|Experimental|Cohort 2: Amikacin Dose 2 + Placebo|Participants will receive a single dose of SLIT™ amikacin at Dose 2 or matching placebo by inhalation on Day 0 upon initiation of Cohort 2.
89182632|NCT06238856|Experimental|Cohort 3: Amikacin Dose 3 + Placebo|Participants will receive a single dose of SLIT™ amikacin at Dose 3 or matching placebo by inhalation on Day 0 upon initiation of Cohort 3.
89182633|NCT06238843|Active Comparator|control arm|Treatment of Investigator's choice irinotecan or paclitaxel
89182634|NCT06238843|Experimental|experimental arm|IBI343 monotherapy
88851534|NCT01982292|Experimental|RLX030 (serelaxin)|Randomized patients received an IV infusion of 30 μg/kg/day of serelaxin for 48 hours at randomization and at Weeks 4 and 8
88851535|NCT01982292|Placebo Comparator|Placebo|Randomized patients received an IV infusion of placebo of serelaxin for 48 hours at randomization and at Weeks 4 and 8
88851536|NCT04652778|Experimental|Treatment|
88851537|NCT01939314|Active Comparator|Bupivacaine|Bupivicaine .03ml to each nare
88851538|NCT01939314|Placebo Comparator|Normal Saline|normal saline .03 ml to each nare
88851539|NCT01939158|Experimental|ACWY1d group|Subjects will receive 1 dose of the MenACWY-TT vaccine
88851540|NCT01939158|Experimental|ACWY2d group|Subjects will receive 2 doses of the MenACWY-TT vaccine 2 months apart
88851541|NCT01939158|Experimental|Co-ad group|Subjects will receive 1 dose of the MenACWY-TT vaccine co-administered with Prevenar 13™
88851542|NCT01939158|Active Comparator|PCV-13 group|Subjects will receive 1 dose of Prevenar 13™ and 1 dose of the MenACWY-TT vaccine 2 months later
88851543|NCT01939002|Experimental|BIIB017 plus current FLS therapy|Following a 4-week run-in period (starting 1 day after the Screening Visit) in which participants administer non-pegylated IFN therapy, participants receive BIIB017 at an initial dose of 63 μg followed by 94 μg dose at Week 2 and 125 μg every 2 weeks from Week 4 to Week 46, plus current FLS management regimen as determined by the clinician.
88851544|NCT01939002|Experimental|BIIB017 plus naproxen|Following a 4-week run-in period (starting 1 day after the Screening Visit) in which participants administer non-pegylated IFN therapy, participants receive BIIB017 at an initial dose of 63 μg followed by 94 μg dose at Week 2 and 125 μg every 2 weeks from Week 4 to Week 46, plus 500 mg naproxen administered twice daily up to 24 hours prior to BIIB017 treatment and continuing for 48 hours following the BIIB017 injection for the first 8 weeks of treatment, and as recommended by the treating physician subsequently.
88851545|NCT01938846|Experimental|BI 860585|Multiple ascending doses of BI 860585 administered continuously in a 28-day cycle, including food interaction cohorts
88851546|NCT01938846|Experimental|BI 860585 + paclitaxel|Multiple ascending doses of BI 860585 in combination with fixed dose paclitaxel
88851547|NCT01938846|Experimental|BI 860585 + exemestane|Multiple ascending doses of BI 860585 in combination with fixed dose exemestane
88851548|NCT01960140|Experimental|Simvastatin|Single oral dose of 40 milligrams (mg) simvastatin on Day 1.
88851549|NCT01960140|Experimental|Baricitinib + Simvastatin|Oral doses of 10 mg baricitinib once daily (QD) on Days 3 to 7, with a single oral dose of 40 mg simvastatin coadministered on Day 6.
88851550|NCT01981356|Experimental|Acceptance and Commitment Therapy (ACT)|Participants randomized to the ACT condition will be provided with the opportunity to attend 4 ACT sessions. The treatment protocol is adapted from and virtually identical to that presented in Gaudiano and Herbert (2006). Each ACT session will serve as a standalone session, with all essential elements of the treatment briefly presented. Participants in the ACT condition will also receive treatment as usual.
88851551|NCT01981356|Active Comparator|Treatment as Usual (TAU)|TAU consists of psychopharmacology, case management, and psychotherapy. Additionally, patients randomized to the TAU condition will meet with ACT facilitators for 15 minutes every other day to provide additional support and answer questions, while ensuring not to discuss or suggest the use of therapeutic techniques related to ACT.
88851552|NCT01981122|Experimental|Concurrent Arm|Subjects will receive sipuleucel-T concurrently with enzalutamide (160 mg orally once daily). Enzalutamide treatment will start 2 weeks prior to the first leukapheresis and continue for 52 weeks or until disease progression or unacceptable toxicity, whichever occurs first.
88851553|NCT01981122|Experimental|Sequential Arm|Subjects will receive sipuleucel-T followed by enzalutamide (160 mg orally once daily). Enzalutamide treatment will start approximately 10 weeks after the first infusion of sipuleucel-T and continue for 52 weeks or until disease progression or unacceptable toxicity, whichever occurs first.
88851554|NCT01980888|Experimental|Idelalisib+bendamustine+rituximab|Participants will receive idelalisib for 96 weeks plus bendamustine+rituximab for 21 weeks.
88851555|NCT01980888|Placebo Comparator|Placebo+bendamustine+rituximab|Participants will receive placebo to match idelalisib for 96 weeks plus bendamustine+rituximab for 21 weeks.
88851556|NCT04650282|Experimental|Lidocaine in SphenoCath device|One treatment will be given.
88851557|NCT04650282|Placebo Comparator|Saline Solution in SphenoCath device|One treatment will be given.
88851558|NCT01937364|Placebo Comparator|Placebo|Placebo every eight hours as inpatients for 72 hours or until discharge if less than 72 hours.
88851559|NCT01937364|Active Comparator|Baclofen|Baclofen 10 mg every 8 hours for 72 hours (9 doses) as an inpatient, or until discharge if before 72 hours.
88851560|NCT01979952|Experimental|Nintedanib|150 mg twice daily
88851561|NCT01979952|Placebo Comparator|Placebo|twice daily dosing
88851562|NCT01999218|Experimental|Ertugliflozin 5 mg|Ertugliflozin 5 mg once daily (QD) from Day 1 to Week 104
88851563|NCT01999218|Experimental|Ertugliflozin 15 mg|Ertugliflozin 15 mg QD from Day 1 to Week 104
88851564|NCT01999218|Active Comparator|Glimepiride up to 8 mg|Glimepiride to a maximum of 8 mg QD from Day 1 to Week 104
88851565|NCT01937130|Experimental|IDN-6556 5 mg|Dosed twice daily
88851566|NCT01937130|Experimental|IDN-6556 25 mg|Dosed twice daily
88851567|NCT01937130|Experimental|IDN-6556 50 mg|Dosed twice daily
88851568|NCT01937130|Placebo Comparator|Placebo|Dosed twice daily
88851569|NCT01936974|Experimental|Platinum, Gemcitabine and Bevacizumab|"Platinum:~Carboplatin* on day 1~*If a patient is allergic to carboplatin, then give~Cisplatin** on day 1~**If a patient is allergic to cisplatin and carboplatin, then give~Oxaliplatin on day 1~Gemcitabine on day 1 only~Bevacizumab on day 1"
88851570|NCT01936974|Active Comparator|Gemcitabine and Bevacizumab|"Gemcitabine on days 1 and 8~Bevacizumab on day 1"
88851571|NCT04648644||Study population|All patients undergoing emergency abdominal surgery for infection or occlusion and treated with bowel resection with or without anastomosis; intestinal bypass or adhesiolysis
88851572|NCT01959516|Experimental|Sequence A ⇒ B|Participants will receive sequence A = glycopyrronium + placebo to tiotropium during 28 days, followed by a 14 day washout period, then sequence B= tiotropium + placebo to glycopyrronium for 28 days.
88851573|NCT01959516|Experimental|Sequence B ⇒ A|Participants will receive sequence B= tiotropium + placebo to glycopyrronium during 28 days, followed by a 14 day washout period, then sequence A= glycopyrronium + placebo to tiotropium for 28 days.
88851574|NCT01979016|Experimental|Placebo qw|Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 followed by a single injection once weekly (qw) from Week 1 to Week 15.
88851575|NCT01979016|Experimental|Dupilumab 200 mg qw|Two subcutaneous injections of Dupilumab 200 milligram (mg) (for a total of 400 mg) as a loading dose on Day 1, followed by a single 200 mg injection qw from Week 1 to Week 15.
88851576|NCT01935336|Experimental|Ponatinib|Patients receive ponatinib hydrochloride taken by mouth once or twice a day. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88851577|NCT01978236|Experimental|Cohort A|The first cohort of 15 subjects will receive oral dabrafenib 150 mg twice daily orally for 7 to 14 days prior to surgery in Cohort A; Subjects will be treated for at least 7 days prior to craniotomy, but not more than 14 days. Subjects in either cohort with intracranial and/or extracranial metastases remaining after surgery may resume treatment with the combination of dabrafenib 150 mg BID and trametinib 2 mg once daily no earlier than 72 hours after surgery
88851578|NCT01978236|Experimental|Cohort B|The second cohort of 15 subjects will receive dabrafenib 150 mg twice daily combined with trametinib 2 mg once daily (Cohort B) orally for 7 to 14 days prior to surgery; Subjects will be treated for at least 7 days prior to craniotomy, but not more than 14 days. Subjects in either cohort with intracranial and/or extracranial metastases remaining after surgery may resume treatment with the combination of dabrafenib 150 mg BID and trametinib 2 mg once daily no earlier than 72 hours after surgery
88851579|NCT01934790|Experimental|Radium-223 dichloride (Xofigo, BAY88-8223)|Participants received intravenous (IV) injection of radium-223 dichloride 50 kBq/kg body weight every 4 weeks up to 6 injections.
88851580|NCT01934556|Active Comparator|Monthly|Monthly Cohort (30 eyes) - Study eyes will receive intravitreal injections of 0.3 mg ranibizumab every 4 weeks for 24 months.
88851581|NCT01934556|Active Comparator|TREX|(60 eyes) - Monthly intravitreal injections of 0.3 mg ranibizumab for four visits. At the fourth visit (Week 12), if the central foveal thickness is ≤ 325 μm then the eye will receive 0.3 mg ranibizumab and begin the extension phase of the study. For all subsequent visits in the extension phase, appropriate changes to the treatment interval with 0.3 mg ranibizumab (i.e. extend, maintain, reduce) will be made based on pre-specified SD (Spectral Domain)-OCT criteria. Treatment is rendered at every visit. The time between visits is individualized based on each subject's response to treatment. If the central foveal thickness is > 325 μm at week 12, then the patient will continue to receive monthly intravitreal injections of 0.3 mg ranibizumab until the central foveal thickness is ≤ 325 μm. Once the central foveal thickness is ≤ 325 μm, then the study eye will begin the extension phase of the study.
88851582|NCT01934556|Active Comparator|GILA|(60 eyes) - Monthly intravitreal injections of 0.3 mg ranibizumab for four visits combined with guided laser photocoagulation to all microaneurysms in the area of DME at visit 2 (Week 4) and then again every 3 months, if leakage is present on fluorescein angiography. If the central foveal thickness is ≤ 325 μm at visit 4 (Week 12), eyes will receive 0.3 mg ranibizumab and the extension phase will begin. For all subsequent visits in the extension phase, appropriate changes to the treatment interval with 0.3 mg ranibizumab (i.e. extend, maintain, reduce) will be made based on pre-specified SD-Optical coherence tomography criteria. If the central foveal thickness is > 325 μm at week 12, then the patient will continue to receive monthly intravitreal injections of 0.3 mg ranibizumab and possible guided laser every 3 months until the central foveal thickness is ≤ 325 μm. Once the central foveal thickness is ≤ 325 μm, then the study eye will begin the extension phase of the study.
88851583|NCT04415814|Experimental|Group 1 (Unilateral Pedicle Screw Fixation)|Patients will undergo stabilizing surgery on the lumbar spine for degenerative diseases of the spine. Pedicular screws will be installed unilaterally, which means on one side of the spinous processes. The system will be fixed with standard rod and blockers.
88851584|NCT04415814|Active Comparator|Group 2 (Bilateral Pedicle Screw Fixation)|Patients will undergo stabilizing surgery on the lumbar spine for degenerative diseases of the spine. Pedicular screws will be installed bilaterally, which means on the both sides of the spinous processes. The system will be fixed with standard rods and blockers.
88851585|NCT04411212|Active Comparator|Granulocyte colony-stimulating factor and platelet-rich plasma|
88851586|NCT04411212|Other|Control group|
88851587|NCT01977690|No Intervention|Standard Management|Patients wore no brace.
88851588|NCT01977690|Experimental|Clavicle Brace Wearing|Patient has to wear clavicle brace for one month.
88851589|NCT04646148|Active Comparator|No Video/No One-on-One/No Text/No Incentive|This group does not receive Personal Practice Videos, or One-on-One individual sessions with a Yoga Instructor, or prompting Text messages, or financial Incentives to attend yoga classes
88851590|NCT04646148|Active Comparator|No Video/No One-on-One/No Text/Yes Incentive|This group does not receive Personal Practice Videos, or One-on-One individual sessions with a Yoga Instructor, or prompting Text messages, but DOES receive financial Incentives to attend yoga classes
88851591|NCT04646148|Active Comparator|No Video/No One-on-One/Yes Text/No Incentive|This group does not receive Personal Practice Videos, or One-on-One individual sessions with a Yoga Instructor, or financial Incentives to attend yoga classes, but DOES recieve prompting Text messages,
88851592|NCT04646148|Active Comparator|No Video/No One-on-One/Yes Text/Yes Incentive|This group does not receive Personal Practice Videos, or One-on-One individual sessions with a Yoga Instructor, but DOES receive prompting Text messages, and financial Incentives to attend yoga classes
88851593|NCT04646148|Active Comparator|No Video/Yes One-on-One/No Text/No Incentive|This group does not receive Personal Practice Videos, or prompting Text messages, or financial Incentives to attend yoga classes, but DOES receive One-on-One individual sessions with a Yoga Instructor
88851594|NCT04646148|Active Comparator|No Video/Yes One-on-One/No Text/Yes Incentive|This group does not receive Personal Practice Videos, or prompting Text messages, but DOES receive financial Incentives to attend yoga classes and One-on-One individual sessions with a Yoga Instructor
88851595|NCT04646148|Active Comparator|No Video/Yes One-on-One/Yes Text/No Incentive|This group does not receive Personal Practice Videos, or financial Incentives to attend yoga classes, but DOES receive prompting Text messages and One-on-One individual sessions with a Yoga Instructor
88851596|NCT04646148|Active Comparator|No Video/Yes One-on-One/Yes Text/Yes Incentive|This group does not receive Personal Practice Videos, but DOES receive financial Incentives to attend yoga classes, prompting Text messages and One-on-One individual sessions with a Yoga Instructor
88851597|NCT04646148|Active Comparator|Yes Video/No One-on-One/No Text/No Incentive|This group does not receive financial Incentives to attend yoga classes, prompting Text messages or One-on-One individual sessions with a Yoga Instructor, but DOES receive Personal Practice Videos
88851598|NCT04646148|Active Comparator|Yes Video/No One-on-One/No Text/Yes Incentive|This group does not receive prompting Text messages or One-on-One individual sessions with a Yoga Instructor, but DOES receive financial Incentives to attend yoga classes and Personal Practice Videos
88851599|NCT04646148|Active Comparator|Yes Video/No One-on-One/Yes Text/No Incentive|This group does not receive financial Incentives to attend yoga classes, or One-on-One individual sessions with a Yoga Instructor, but DOES receive Personal Practice Videos and prompting Text messages
88851600|NCT04646148|Active Comparator|Yes Video/No One-on-One/Yes Text/Yes Incentive|This group does not receive One-on-One individual sessions with a Yoga Instructor, but DOES receive Personal Practice Videos, prompting Text messages and financial Incentives to attend yoga classes
88851601|NCT04646148|Active Comparator|Yes Video/Yes One-on-One/No Text/No Incentive|This group does not receive prompting Text messages or financial Incentives to attend yoga classes, but DOES receive One-on-One individual sessions with a Yoga Instructor and Personal Practice Videos
89002587|NCT06312280||Pediatric children and adolescents with obesity or overweight|"The study will include all children and adolescents who visit the SCDU of Pediatrics, Surgery of Endocrinology and Auxology of the Major Charity Hospital of Novara for first visit or checkup for excess weight between 1 January 2024 and 30 May 2024 of both sexes that meet the following criteria of inclusion:~Criteria for inclusion:~Age between 6 and 17 years; BMI compatible with obesity or overweight according to IOTF criteria (6) Signature of informed consent by parents/legal guardians.~Criteria for exclusion:~Age below 6 years or over 18 Previous diagnosis of diabetes mellitus type 2 already placed in dietary or pharmacological therapy Subjects already included in dieto-therapeutic regimen Obesity secondary to diseases: genetic (Prader Willi syndrome, Down syndrome); metabolic and endocrine (Cushing syndrome, hypothyroidism)"
89002588|NCT06311422|Experimental|Lava Ultimate block|Resin nanoceramic block
89002589|NCT06311422|Active Comparator|Celtra Duo block|zirconia-reinforced lithium silicate block
89002590|NCT06311201|Active Comparator|Abdominal belt|It consisted of 25 postpartum women who wore abdominal belt for 8 weeks.
89002591|NCT06311201|Experimental|Abdominal belt + Pilates exercises|It consisted of 25 postpartum women who followed Pilates training program, 3 times/week for 1 hour the session in addition to wearing abdominal belt, for 8 weeks
89002592|NCT06311097|Experimental|Fermented dairy|The fermented dairy product is Arla A38® naturel 1,5% yogurt. The yogurt contains Lactobacillus acidophilus culture.
89002593|NCT06311097|Placebo Comparator|Non-fermented dairy|The non-fermented dairy product is Arla® Letmælk 1,5% (semi-skimmed milk). The fermented- and non-fermented dairy products are isocaloric and matched in macronutrient content.
89002594|NCT06310434||University adolescents|"Adolescents attending a public university that belongs to the same health area with similar population characteristics in each province. The inclusion criteria will be students enrolled in different undergraduate studies in a public University (18-23 years old), who don´t need curricular adaptation. We will exclude health science studies because we suppose that they are students who may have worked more on compassionate awareness."
89002595|NCT06310434||High school adolescents|"The inclusion criteria will be students enrolled in public secondary schools (12-17 years old), that belong to the same health area. We also include families and teachers because we understand that their knowledge of the context can support the interventions of change proposals and are consistent with the participatory nature of the project. The inclusion criteria for families are parents, mothers, or legal tutors of minors with communication skills to participate in a group. Finally, all the teachers in every center will be invited to participate in the study."
89002596|NCT06306898|Active Comparator|IPPV|Intermittend-Positive-Pressure-Ventilation
89002597|NCT06306898|Active Comparator|CCSV|Chest Compression Synchronized Ventilation
89002598|NCT06306898|Active Comparator|Bag-Device-Ventilation|Ventilation with a Ventilation Bag
89002599|NCT06306651|Experimental|High flow nasal cannula therapy group|Patients who will be randomized to high flow nasal cannula therapy. High flow nasal oxygen cannula will be applied at a flow of 20 L/min at FiO2 of 0.4 at a temperature of 36oC.
89002600|NCT06306651|Active Comparator|Conventional oxygen therapy group|Patients who will be randomized to simple oxygen mask therapy. The simple face mask will be applied in a rate range between 6-10 L/min.
89002601|NCT06306105|Placebo Comparator|placebo drink|
89002602|NCT06306105|Experimental|Marine Collagen Peptides drinks|
89535084|NCT03230305||Elderly cancer patient cohort|"Aged 70 years or over~With solid cancer irrespective of the stage~Pre-screened or screened for at least one ongoing clinical trial in the center~Informed oral consent (patient, his/her legal representant, trustworthy person or family member)~Social security affiliation"
89002607|NCT06300918|Experimental|Injecting anti-VEGF drugs 3 days before operation|Injecting Conbercept into vitreous cavity 3 days before performing vitrectomy.
89002608|NCT06300918|Experimental|Injecting anti-VEGF drugs 7 days before operation|Injecting Conbercept into vitreous cavity 7 days before performing vitrectomy.
89002609|NCT06300918|Experimental|Injecting anti-VEGF drugs 14 days before operation|Injecting Conbercept into vitreous cavity 14 days before performing vitrectomy.
89002610|NCT06300385|Experimental|Experimental|These participants will receive electromyostimulation simultaneously with strengthening exercise.
89002611|NCT06300385|Sham Comparator|Sham control|These participants will receive sham electromyostimulation (current turned off) simultaneously with strengthening exercise.
89002612|NCT06299722|Experimental|STEEL|STEEL strength training will consist of progressive periodised training, in which the intensity is set to fit the individual's starting level and then gradually increases. During Week 1 to Week 5, the relative load will correspond to a 12-repetition maximum (RM). During Week 5 to Week 10, the relative load will be 10 RM, and during Week 11 to Week 16, the relative load will be 8 RM. The exercises will mostly consist of compound movements that activate the large muscle groups of the legs, back, arms and torso.
89002613|NCT06299722|Active Comparator|Circuit training|There will be 10 stations that include both strengthening and cardiovascular exercises, such as squats, hopping, crunches, stationary running, front-lying swimming, ski jumps, push-ups, ball throws, ring pulls, and hopscotch. Each station lasts 45 seconds, and there will be a 15-second break between each station. The circuit is repeated for three rounds. To ensure progression in intensity similar, we will progress the participants' rating of perceived exertion (RPE) over time. During Week 1 to Week 5, the RPE during exercises will be 6-7. During Week 5 to Week 10, the RPE will be 8-9, and during Week 11 to Week 16, the RPE will be 10.
89002614|NCT06298318|Experimental|vodka(1g/kg body weight)|After an 8-hour overnight fast, the participants drink vodka(1g/kg body weight)
89002615|NCT06298318|Placebo Comparator|equal amount of water|After an 8-hour overnight fast, the participants drink equal amount of non-alcoholic beverages with the same taste and colour but without alcohol
89002616|NCT06297642|Experimental|TQB2928 injection + Penpulimab|TQB2928 injection combined with Penpulimab, 21 days as a treatment cycle.
89002617|NCT06296225|Experimental|Vibration group|"Patients with acute stroke less than 7 days with only one paretic upper limb will be assessed for eligibility.~Patient will undergo 8 grip strength evaluation and 30 minutes of forehand muscles vibration."
88851602|NCT04646148|Active Comparator|Yes Video/Yes One-on-One/No Text/Yes Incentive|This group does not receive prompting Text messages but DOES receive financial Incentives to attend yoga classes, One-on-One individual sessions with a Yoga Instructor and Personal Practice Videos
88851603|NCT04646148|Active Comparator|Yes Video/Yes One-on-One/Yes Text/No Incentive|This group does not receive financial Incentives to attend yoga classes, but DOES receive prompting Text messages, One-on-One individual sessions with a Yoga Instructor and Personal Practice Videos
88851604|NCT04646148|Active Comparator|Yes Video/Yes One-on-One/Yes Text/Yes Incentive|This group receives Personal Practice Videos, One-on-One individual sessions with a Yoga Instructor, prompting Text messages, and financial Incentives to attend yoga classes
88851605|NCT01934010|Experimental|AM-101 injection|AM-101 gel for intratympanic injection
88851606|NCT01620138|Active Comparator|Pasireotide|"For non-cured patients with prolactinomas resistant to cabergoline, MRI will be performed immediately before and six months after the onset of pasireotide treatment. The anti-secretory effect will be evaluated by prolactin dosage every month.~For patients harboring a NFPA, treatment will be started at least 3 months after neurosurgery, when a pituitary MRI clearly shows the presence of a residual tumor without any possible misinterpretation of postsurgical changes. In this case, the drug efficacy will be evaluated clinically by visual field and by MRI six months after pasireotide treatment."
88851607|NCT01620138|Active Comparator|cabergoline|In patients with non-functioning pituitary adenoma, treatment will be started at least 3 months after neurosurgery, when a pituitary MRI clearly shows the presence of a residual tumor without any possible misinterpretation of postsurgical changes. The drug response will be evaluated clinically by visual field and by Magnetic resonance imaging (MRI) before medical treatment and after six months of cabergoline treatment at maximum dose.
88851608|NCT01977612|Active Comparator|Stainless Steel Staples|Skin closure with stainless steel staples
88851609|NCT01977612|Experimental|4-0 monofilament Sutures|Skin closure with 4-0 monofilament sutures
88851610|NCT01932996|Active Comparator|Integrated Intensive Smoking + Alcohol|IS+A: 12-week treatment with nicotine patch plus nicotine gum/lozenge. An integrated intensive smoking along with an intensive alcohol intervention covering smoking cessation + alcohol abstinence using cognitive behavioral therapy, CBT, and will include weekly individual sessions for 3 months followed by study data collection visits for 3 months.
88851611|NCT01932996|Placebo Comparator|Usual Care|UC: 12-week treatment with nicotine patch plus nicotine gum/lozenge along with a one time brief smoking cessation and brief alcohol counseling both based on the USPHS's Guidelines
88851612|NCT01932762|Experimental|GT2: Grazoprevir + Elbasvir + RBV (Arm A1)|During Part A of the study, GT2 participants will receive 100 mg grazoprevir + 50 mg elbasvir + standard weight-based dosing of RBV for 12 weeks.
88851613|NCT01932762|Experimental|GT2: Grazoprevir + RBV (Arm B1)|During Part B of the study, GT2 participants will receive 100 mg grazoprevir + standard weight-based dosing of RBV for 12 weeks.
88851614|NCT01932762|Experimental|GT 4,5,6: Grazoprevir + Elbasvir + RBV (Arm B2)|During Part B of the study, GT4/GT5/GT6 participants will receive 100 mg grazoprevir + 50 mg elbasvir + standard weight-based dosing of RBV for 12 weeks.
88851615|NCT01932762|Experimental|GT 4,5,6: Grazoprevir + Elbasvir (Arm B3)|During Part B of the study, GT4/GT5/GT6 participants will receive 100 mg grazoprevir + 50 mg elbasvir for 12 weeks.
88851616|NCT01618968|Experimental|10 mg Methotrexate (MTX)|MTX dose group was assigned based on the subject's current therapeutic regimen of MTX and rheumatoid arthritis disease status. The sequence of treatments A, B and C was randomly assigned.
88851617|NCT01618968|Experimental|15 mg MTX|MTX dose group was assigned based on the subject's current therapeutic regimen of MTX and rheumatoid arthritis disease status. The sequence of treatments A, B and C was randomly assigned.
88851618|NCT01618968|Experimental|20 mg MTX|MTX dose group was assigned based on the subject's current therapeutic regimen of MTX and rheumatoid arthritis disease status. The sequence of treatments A, B and C was randomly assigned.
88851619|NCT01618968|Experimental|25 mg MTX|MTX dose group was assigned based on the subject's current therapeutic regimen of MTX and rheumatoid arthritis disease status. The sequence of treatments A, B and C was randomly assigned.
88851620|NCT04645524|Experimental|AD182|Oral capsule administered before bed
88851621|NCT04645524|Experimental|AD504|Oral capsule administered before bed
88851622|NCT04645524|Placebo Comparator|Placebo|Oral capsule administered before bed
88851623|NCT04662216|Active Comparator|control group|Scaling and root planing
88851624|NCT04662216|Experimental|test group|"scaling and root planing + Perisolv +Hyadent BG gels."
88851625|NCT01932294||MedaMACS participants|All participants who have met the inclusion criteria.
88851626|NCT01931670|Placebo Comparator|Placebo|Placebo twice daily (BID) for the 6-month Treatment Period
88851627|NCT01931670|Experimental|Elagolix 150 mg QD|Elagolix 150 mg once daily (QD) for the 6-month Treatment Period
88851628|NCT01931670|Experimental|Elagolix 200 mg BID|Elagolix 200 mg BID for the 6-month Treatment Period
88851629|NCT01977456|Experimental|Eptifibatide|All subjects will receive the standard dose of IV rt-PA. All subjects will promptly receive an IV bolus of 135mcg/kg eptifibatide followed by an IV infusion of 0.75 mcg/kg/min eptifibatide for 2 hours.
88851630|NCT01957644|Experimental|Schedule A|Volasertib (d1 - one hour iv.) + Azacitidine 75 mg/m2 once daily on Days 1-7 (7 consecutive days) (28-day cycle)
88851631|NCT01957644|Experimental|Schedule B|Volasertib (d 7 - one hour iv.) + Azacitidine 75 mg/m2 once daily on Days 1-7 (7 consecutive days) (28-day cycle)
88851632|NCT01957644|Experimental|Schedule C|Volasertib (d 1 and 7 - one hour iv.) + Azacitidine 75 mg/m2 once daily on Days 1-7 (7 consecutive days) (28-day cycle)
88851633|NCT01931202|Placebo Comparator|Double Blind-Placebo|Blinded treatment with placebo, one pill a day. If after the 4 weeks, the patient has not remitted, they will be increased to 2 pills a day.
88851634|NCT01931202|Active Comparator|Double Blind-Escitalopram|Blinded treatment with either escitalopram 10mg, increased to escitalopram 20mg at week 4 if depression has not remitted.
88851635|NCT01931202|Active Comparator|Open Treatment with Escitalopram|Open treatment with 10mg of escitalopram, increased to 20mg if depression has not remitted at week 4.
88851636|NCT01930890|Experimental|BIIB023 3 mg/kg|Participants will receive BIIB023 3 mg/kg IV every 4 weeks through Week 100 plus background therapy including oral steroids (prednisone or equivalent) and mycophenolate mofetil (MMF).
88851637|NCT01930890|Experimental|BIIB023 20 mg/kg|Participants will receive BIIB023 20 mg/kg IV every 4 weeks through Week 100 plus background therapy including oral steroids (prednisone or equivalent) and MMF.
88851638|NCT01930188|Experimental|Semaglutide 0.5 mg + sitagliptin placebo|
88851639|NCT01930188|Experimental|Semaglutide 1.0 mg + sitagliptin placebo|
88851640|NCT01930188|Active Comparator|Sitagliptin 100 mg + semaglutide placebo 1.0 mg|
88851641|NCT01930188|Active Comparator|Sitagliptin 100 mg + semaglutide placebo 0.5 mg|
88851642|NCT01977222|Experimental|THRESHOLD(TM) INSPIRATORY MUSCLE TRAINER|
88851643|NCT01957488|Experimental|Treatment sequence 1; First Coloplast Test product 1|"The subjects are randomised 1:1:1 into six possible treatment groups to ensure random allocation of treatment to periods.~Subjects are first allocated to test Coloplast Test product 1 and secondly test either:~Coloplast Test product 1 and thereafter Coloplast SenSura~Coloplast Sensura and thereafter Coloplast Test product 2"
88851644|NCT01957488|Experimental|Treatment seqence 2; First Coloplast Test product 2.|"The subjects are randomised 1:1:1 into six possible treatment groups to ensure random allocation of treatment to periods.~Subjects are first allocated to test Coloplast Test product 2 and secondly test either:~Coloplast Test product 1 and thereafter Coloplast SenSura~Coloplast Sensura and thereafter Coloplast Test product 1"
88851645|NCT01957488|Experimental|Treatment sequence 3, First Coloplast SenSura|"The subjects are randomised 1:1:1 into six possible treatment groups to ensure random allocation of treatment to periods.~Subjects are first allocated to test Coloplast SenSura and secondly test either:~Coloplast Test product 2 and thereafter Coloplast Test product 1~Coloplast Test product 1 and thereafter Coloplast Test product 2"
88851646|NCT01976364|Experimental|Tofacitinib|
88851647|NCT01956240|Experimental|Stretching-Asymptomatic subjects|The stretching will be performed with the subject standing, with 90° of arm abduction and 90° of elbow flexion and palm on a flat planar surface. The subject then will place the leg opposite to the flat surface in front of the other with slight knee flexion and tilt the trunk forward like a rigid block and rotate it slightly increasing the horizontal abduction at the shoulder. This procedure will be done 4 times for 1 min and 30s interval between repetitions.
88851648|NCT01956240|Experimental|Stretching-Subjects with shoulder pain|The stretching will be performed with the subject standing, with 90° of arm abduction and 90° of elbow flexion and palm on a flat planar surface. The subject then will place the leg opposite to the flat surface in front of the other with slight knee flexion and tilt the trunk forward like a rigid block and rotate it slightly increasing the horizontal abduction at the shoulder. This procedure will be done 4 times for 1 min and 30s interval between repetitions.
88851649|NCT01929876|Experimental|Cobimetinib + Itraconazole|
88851650|NCT04630236|Other|Ultrasound|
88851651|NCT01929018|Experimental|Exercise, activity, and self-management|Exercise, Walking Program, and Health Self-Management Support. Participants will be visited at home once monthly and contacted by phone once weekly over 12 weeks to deliver the interventions.
88851652|NCT01929018|No Intervention|Home and phone visit|No intervention will be applied. Participants will be visited at home once monthly and contacted by phone once weekly over 12 weeks to monitor health status.
88851653|NCT01928940|Experimental|dabrafenib + trametinib|Combination therapy of dabrafenib and trametinib
88851654|NCT01928862|Experimental|Prepopik® ½ Sachet x 2 (9-12 years)|Prepopik® ½ Sachet x 2 (9-12 years)
88851655|NCT01928862|Experimental|Prepopik® 1 Sachet x 2 (9-12 years)|Prepopik® 1 Sachet x 2 (9-12 years)
88851656|NCT01928862|Active Comparator|Oral polyethylene glycol (PEG) based preparation (9-12 years)|Local standard of care
88851657|NCT01928862|Experimental|Prepopik® 1 Sachet x 2 (13-16 years)|Prepopik® 1 Sachet x 2 (13-16 years)
88851658|NCT01928862|Active Comparator|Oral polyethylene glycol (PEG) based preparation (13-16 years)|Local standard of care
88851659|NCT01954056|Active Comparator|Hydrocortisone|hydrocortisone (hydrocortisone sodium succinate, plain; will not have benzyl alcohol) given through intravenous line or by intramuscular injection if no intravenous line
88851660|NCT01954056|Placebo Comparator|Placebo|Saline placebo
88851661|NCT01953354|Experimental|Trichuris suis ova (TSO)|Six doses of TSO orally over a ten-week period
88851662|NCT01953354|Placebo Comparator|Placebo|Six doses of TSO placebo orally over a ten-week period
88851663|NCT01975272|Active Comparator|Ferinject|Once an infusion of Ferinject 1000 mg, 1 day after surgery
88851664|NCT01975272|Active Comparator|Ferrous fumarate|2 times a day 200 mg ferrous fumarate, starting 24-48 hours after surgery
88851665|NCT01975272|Placebo Comparator|Placebo infusion and tablets|Patient will get a once a placebo infusion (250 ml NaCl), one day after surgery, and 60 placebo tablets for 30 days (2 tablets a day), starting 24-48 hours after surgery
88851666|NCT04643886|Experimental|Cohort with Genetic Profile A|"Subjects will have Genetic Profile A.~Intervention: Biological: GEM103."
88851667|NCT04643886|Experimental|Cohort with Genetic Profile B|"Subjects will have Genetic Profile B.~Intervention: Biological: GEM103"
88851668|NCT01951638|Experimental|Vericiguat (BAY1021189)(10 mg)|2.5 mg orally once daily for 2 weeks, up-titration to 5 mg orally once daily for 2 weeks, up-titration to 10 mg orally once daily for 8 weeks
88851669|NCT01951638|Experimental|Vericiguat (BAY1021189) (5 mg)|2.5 mg orally once daily for 2 weeks, then 5 mg orally once daily for 10 weeks (with sham titration)
88851670|NCT01951638|Experimental|Vericiguat (BAY1021189) (2.5 mg)|2.5 mg orally once daily for 12 weeks (with sham titrations)
88851671|NCT01951638|Experimental|Vericiguat (BAY1021189) (1.25 mg)|1.25 mg orally once daily for 12 weeks (with sham titrations)
88851672|NCT01951638|Placebo Comparator|Placebo|Orally once daily for 12 weeks (with sham titrations)
88851673|NCT01928472|Experimental|Group A|H7N9c low dose with adjuvant
88851674|NCT01928472|Experimental|Group B|H7N9c medium dose with adjuvant
88851675|NCT01928472|Experimental|Group C|H7N9c high dose with adjuvant
88851676|NCT01928472|Experimental|Group D|H7N9c high dose without adjuvant
88851677|NCT03563183||Overall Group|Adults aged ≥50 years of age in the Zoster-064 TVC who received herpes zoster subunit (HZ/su) vaccine or Placebo in Zoster-006/022 study
88851678|NCT03565679|Experimental|Masimo SpO2 Adhesive Sensors, Adtx (1859) & (2329)|Reference sensors from the reprocessed oximeter device will be placed on each subject to evaluate the SpO2 accuracy and performance.
88851679|NCT03565679|Sham Comparator|Covidien Nellcor SpO2 Sensor, MAX-A and MAX-N|A whole blood analyzer (CO-Oximeter) is used as the reference standard device for obtaining the functional SaO2 value from arterial blood samples obtained during the study.
88851680|NCT03965039|Active Comparator|Marketed stannous fluoride toothpaste|Brush twice daily
88851681|NCT03965039|Active Comparator|Marketed potassium nitrate toothpaste|Brush Twice Daily
88851682|NCT03965039|Placebo Comparator|Marketed sodium monofluorophosphate toothpaste|Brush Twice Daily
88851683|NCT03965039|Experimental|Experimental dipotassium oxalate toothpaste|Brush Twice Daily
88851684|NCT03961295|Active Comparator|Group A: Vedolizumab SC PFS|Vedolizumab SC 108 mg, injection, subcutaneously using a PFS, once on Day 1.
88851685|NCT03961295|Experimental|Group B: Vedolizumab SC Investigational Device|Vedolizumab SC 108 mg, injection, subcutaneously using an investigational device, once on Day 1.
88851686|NCT03567005|Other|DACP Digital then DACP|Nelfilcon A digital contact lenses worn first, followed by nelfilcon A contact lenses. Each product worn bilaterally (in both eyes) for 7 days in a daily disposable modality.
88851687|NCT03567005|Other|DACP then DACP Digital|Nelfilcon A contact lenses worn first, followed by nelfilcon A digital contact lenses. Each product worn bilaterally for 7 days in a daily disposable modality.
88851688|NCT05313971|Experimental|Intervention|3-week recruitment period of portuguese medical students wanting to attend the 28-hour online course
88851689|NCT05313971|No Intervention|Control|The control group was recruited in order to match the age, gender, academic year and teaching faculty variables with the intervention group and people with these characteristics were invited to participate.
88851690|NCT03569033|Experimental|Gefapixant 45 mg BID|Participants will receive a gefapixant 45 mg tablet twice daily (BID) for 7 days.
88851691|NCT03569033|Placebo Comparator|Placebo BID|Participants will receive a matching placebo tablet BID for 7 days.
88851692|NCT03955133|Experimental|intervention|This is a single arm before and after study with data collection at 4 time points.
88851693|NCT03991715|Experimental|Activity Tracker|Participants provided an activity tracker to wear and weekly reports
88851694|NCT04002791|Placebo Comparator|Group 1: TR Band Arm|"Patients will receive hemostatic compression using the current standard of care TR band (Terumo Corporation, Japan). The band will be applied according to the instructions for use, with optimal pressure applied using Patent hemostasis protocol to achieve full hemostasis."
88851695|NCT04002791|Active Comparator|Group 2: Vaso-band Arm|Patients will receive Vaso-band (VasoInnovations, Inc, USA), applied with ulnar balloon inflated with 15 ml of air, and the radial balloon inflated after the sheath is removed, to apply optimal pressure for obtaining full hemostasis. Ulnar balloon will be deflated after 60 minutes of radial artery hemostatic compression.
88851696|NCT05314049|Experimental|Experimental Group|
88851697|NCT05314049|Active Comparator|Active Comparator Group|
88851698|NCT03935399|Other|Oxytocin first, then saline placebo|Intramuscular injection of oxytocin (Pitocin®), 10 IU on the first study day and of 1 ml saline placebo on the second study day
88851699|NCT03935399|Placebo Comparator|Saline placebo first, then oxytocin|Intramuscular injection of 1 ml saline placebo on the second study day and of oxytocin (Pitocin®), 10 IU on the second study day
88851700|NCT03571607|Experimental|13-valent pneumococcal conjugate vaccine|
88851701|NCT03993119||patients with NVAF|
88851702|NCT03988049|Active Comparator|1,550 laser|This arm is the side of the face treated with the 1550-nanometer Fracionated Photothermolysis laser.
88851703|NCT03988049|Active Comparator|755 laser|This arm is the side of the face treated with the 755-nanometer alexandrite picosecond laser.
88851704|NCT03930641|Experimental|RTH258|brolucizumab 6 mg in a prefilled syringe
88851705|NCT03910439|Experimental|1/Avelumab 800 mg intravenous (IV) every two weeks in combination with radiation therapy|Avelumab 800 mg IV every two weeks in combination with radiation therapy
88851706|NCT03907241|Experimental|Octanorm 16.5%|octanorm 16.5%, human normal immunoglobulin for subcutaneous (SC) administration.
88851707|NCT03137225|Experimental|Nasal Intermittent Positive Pressure Ventilation (NIPPV) Mode|"After a one hour stabilization period, during which small adjustments to the noninvasive settings can be made to clinically optimize the settings, the study will begin. A Nellcor pulse oximeter probe will be placed on an extremity to provide a continuous non-invasive downloadable measure of saturation (blood oxygen level) and heart rate. Data from the ventilator will be downloaded in real-time to a laptop.~These data will be recorded for 4 hours continuously. After that, the ventilator will be switched to the other mode (NIPPV to NAVA), at the same PEEP (positive end-expiratory pressure) and respiratory rate. One hour will be allowed to adjust the ventilator settings. Data will then be collected for 4 hours on the second ventilation mode (NAVA)"
88851708|NCT03137225|Experimental|Neurally Adjusted Ventilatory Assist (NAVA) Mode|"After a one hour stabilization period, during which small adjustments to the noninvasive settings can be made to clinically optimize the settings, the study will begin. A Nellcor pulse oximeter probe will be placed on an extremity to provide a continuous non-invasive downloadable measure of saturation (blood oxygen level) and heart rate. Data from the ventilator will be downloaded in real-time to a laptop.~These data will be recorded for 4 hours continuously. After that, the ventilator will be switched to the other mode (NAVA to NIPPV), at the same PEEP and respiratory rate. One hour will be allowed to adjust the ventilator settings. Data will then be collected for 4 hours on the second ventilation mode (NIPPV)"
88851709|NCT03927209|Experimental|BI 1467335 (low dose)|
88851710|NCT03927209|Experimental|BI 1467335 (high dose)|
88851711|NCT03895307|Experimental|kinesio taping|two 15 cm I type kinesio tape applied longitudinally
88851712|NCT03895307|Placebo Comparator|sham kinesio taping|two 15 cm I type kinesio tape applied longitudinally but without stretching
88851713|NCT03895307|Experimental|local anesthetic|18-20 cc %0.5 lidocaine subcutaneous injection
88851714|NCT03895307|Placebo Comparator|local serum physiologic|18-20 cc % 0.09 NaCl subcutaneous injection
88851715|NCT01511081|Experimental|SBRT (stereotactic body radiotherapy)|50 Gy (RBE) in 4 daily treatments of stereotactic body radiotherapy (SBRT). Each treatment taking about 30-45 minutes per day.
88851716|NCT01511081|Experimental|SBPT (stereotactic body proton therapy)|50 Gy (RBE) in 4 daily treatments of stereotactic body proton therapy (SBPT). Each treatment taking about 30-45 minutes per day.
88851717|NCT03115853|Experimental|HCTZ plus Aliskiren then HCTZ and Placebo|"HCTZ 25 mg plus Aliskiren 150mg for 2weeks. Aliskiren is increased to 300mg for 4 week if 150mg was tolerated.~Then HCTZ 25 mg po plus Placebo"
88851718|NCT03115853|Experimental|HCTZ and Placebo, then HCTZ and Aliskiren|"HCTZ 25 mg po plus Placebo.~Then HCTZ 25 mg plus Aliskiren 150mg for 2weeks. Aliskiren is increased to 300mg for 4 week if 150mg was tolerated."
88851719|NCT01498991|Experimental|AMES Treatment|The subject will receive 30 treatment sessions, conducted 3-4 times per week on the AMES device. Each session will consist of testing followed by 40 minutes of treatment time (20 minutes per each leg) using the AMES device.
88851720|NCT03895853|Active Comparator|Group I (standard of care)|Patients receive standard of care for septic shock.
88851721|NCT03895853|Experimental|Group II (early metabolic resuscitation)|Patients receive standard of care treatment for septic shock and early metabolic resuscitation (IV) over continuous infusion for up to 7 days.
88851722|NCT03901313|Experimental|Sequence ABC|Healthy volunteers will receive Treatments A, then B, and then C, with a 6-day washout between treatments, during a stay at the clinic of 20 days
88851723|NCT03901313|Experimental|Sequence ACB|Healthy volunteers will receive Treatments A, then C, and then B, with a 6-day washout between treatments, during a stay at the clinic of 20 days
88851724|NCT03901313|Experimental|Sequence BAC|Healthy volunteers will receive Treatments B, then A, and then C, with a 6-day washout between treatments, during a stay at the clinic of 20 days
88851725|NCT03901313|Experimental|Sequence BCA|Healthy volunteers will receive Treatments B, then C, and then A, with a 6-day washout between treatments, during a stay at the clinic of 20 days
88851726|NCT03901313|Experimental|Sequence CAB|Healthy volunteers will receive Treatments C, then A, and then B, with a 6-day washout between treatments, during a stay at the clinic of 20 days
88851727|NCT03901313|Experimental|Sequence CBA|Healthy volunteers will receive Treatments C, then B, and then A, with a 6-day washout between treatments, during a stay at the clinic of 20 days
88851728|NCT03900299|Other|oncoplastic breast surgery|
88851729|NCT03898349|No Intervention|Non-Texters|"Patients did not receive the automated text messaging system Annie"
88851730|NCT03898349|Active Comparator|Texters|Patients received the Annie text messaging system for patient self-management of HCV treatment including medication, lab, and appointment reminders, and motivational messages.
88851731|NCT03894449|Placebo Comparator|Placebo only|
88851732|NCT03894449|Experimental|Prebiotic Inulin & Iron Salt FeSO4|
88851733|NCT03894449|Experimental|Prebiotic GOS & Iron Salt FeSO4|
88851734|NCT03894449|Experimental|Prebiotic Inulin & Iron Salt NaFeEDTA|
88851735|NCT03894449|Experimental|Prebiotic GOS & Iron Salt NaFeEDTA|
88851736|NCT03888755|Experimental|Icatibant|Participants with 1 acute non-laryngeal or laryngeal attack will receive a single icatibant 30 milligram (mg) subcutaneous (SC) injection in the abdominal area. A maximum of 3 SC injections (or 90 mg) of icatibant that are at least 6 hours apart can be given for treatment of an attack if, within 48 hours of the initial treatment, there is insufficient relief or worsening of symptoms.
88851737|NCT02995967|Active Comparator|Botulinum toxin A alone group|Just the intradetrusor injection of 100 units of botulinum toxin A alone
88851738|NCT02995967|Experimental|Hydrodistention group|Hydrodistention at a pressure of 80 cm H2O for 5 minutes, prior to the intradetrusor injection of 100 units of botulinum toxin A
88851739|NCT03888365||Cohort A: Treprostinil|Participants who are currently prescribed and using inhaled treprostinil for the treatment of PAH.
88851740|NCT03888365||Cohort B: Non-Treprostinil PAH Medications|Participants who are taking other PAH medications (instead of inhaled treprostinil).
88851741|NCT03870893|Experimental|Intervention group|Intervention is administered to patients in this Arm.
88851742|NCT03870893|No Intervention|control group|No intervention
88851743|NCT02994251|Experimental|All subjects|Patients must have advanced, unresectable intrahepatic cholangiocarcinoma (ICC) defined as biopsy-confirmed adenocarcinoma in the liver, with an immunohistochemical profile consistent with a pancreatico-biliary primary, not involving the common bile duct or bifurcation, and not amenable to surgical resection.
88851744|NCT03887429|Experimental|SXC-2023 200 mg followed by placebo|SXC-2023 200mg dosed once daily for 5 days, followed by 9 day washout, then Placebo dosed once daily for 5 days.
88851745|NCT03887429|Experimental|Placebo followed by SXC-2023 200 mg|Placebo dosed once daily for 5 days, followed by 9 day washout, then SXC-2023 200mg dosed once daily for 5 days.
88851746|NCT03887429|Experimental|SXC-2023 800 mg followed by placebo|SXC-2023 800mg dosed once daily for 5 days, followed by 9 day washout, then Placebo dosed once daily for 5 days.
88851747|NCT03887429|Experimental|Placebo followed by SXC-2023 800 mg|Placebo dosed once daily for 5 days, followed by 9 day washout, then SXC-2023 800mg dosed once daily for 5 days.
88851748|NCT02978885|Other|Normal preoperative lung function|Patients with normal lung function undergoing Whipple procedures or other major surgeries will receive an injection of AxV-128 labeled with 99mTc followed by SPECT-CT (AxV-128/Tc SPECT-CT imaging).
88851749|NCT02978885|Other|Preoperative COPD|Patients with moderate COPD undergoing Whipple procedures or other major surgeries will receive an injection of AxV-128 labeled with 99mTc followed by SPECT-CT (AxV-128/Tc SPECT-CT imaging).
88851750|NCT02936999|Experimental|Vitamin D3|Patients will be dispensed cholecalciferol, 32 capsules/bottle of 1cap/4000 IU PO QD on Day 1 visit to take home. Bottle must be labeled with instructions on how to take the drug and the assigned patient ID number. Patients will be instructed to take 1 capsule per day, with water, for 29 days using the dispensed study bottle. They will be instructed to stop taking their daily vitamin D3 dose after 30 days of treatment. A study drug diary will be provided at Day 1 visit and patients will be instructed to complete the study drug diary daily from Day 2 to Day 30. Patient's report of vitamin-D3 intake from the diary must be reconciled against the number of capsules returned at Day 30 visit.
88851751|NCT01385033|Experimental|Part I, Healthy Elderly (HE) and AD Participants|HE and AD participants will receive a single intravenous (IV) dose of ~150 megabecquerel (MBq) [18F]MK-3328 in Part I of the study
89002618|NCT06296043|Experimental|Progressive Muscle Relaxation Exercise Group|Application will be made on the day PMS symptoms begin and throughout the menstrual cycle.
88851752|NCT01385033|Experimental|Part II, Healthy Young, HE and AD Participants|Healthy Young, HE and AD participants will receive a single IV dose of ~150 megabecquerel (MBq) [18F]MK-3328 in Part II of the study
88851753|NCT01385033|Experimental|Part III, Participants with aMCI|Participants with aMCI will receive a single IV dose of ~150 megabecquerel (MBq) [18F]MK-3328 in Part III of the study
88851754|NCT02826551|Placebo Comparator|No Injection|"These patients will receive standard of care when undergoing anterior cruciate ligament reconstruction and will NOT be receiving a posterior capsular knee injection of Marcaine 0.5%.~They will be monitored for pain control and pill intake while in the PACU and the first four days post-operatively the same as the patients in the INJECTION Arm of the study."
88851755|NCT02826551|Experimental|Injection|"These patients will receive standard of care when undergoing anterior cruciate ligament reconstruction but will additionally be receiving a one-time posterior capsular knee injection of Marcaine 0.5% (20cc) during the surgery.~They will be monitored for pain control and pill intake while in the PACU and the first four days post-operatively the same as the patients in the NO injection Arm of the study."
88851756|NCT01337609|Experimental|GanedenBC30|Arm 1 will take GanedenBC30 (Bacillus coagulans GBI-30, 6086, 1 capsule/day) for 60 days.
88851757|NCT01337609|Placebo Comparator|Sugar pill|Arm 2 will take placebo (sugar pill) for 60 days.
88851758|NCT01337609|Other|Ganeden BC30, Sugar pill|Arm 3 will take placebo (sugar pill) for 30 days, followed by Ganeden BC30 for 30 days.
88851759|NCT01340573||Genotype 1 CHC Participants|
88851760|NCT01340573||Non-genotype 1 CHC participants|
88851761|NCT01340885|Active Comparator|atomoxetine|Strattera 10-30 mg b.i.d.
88851762|NCT01340885|Active Comparator|rivastigimine|Exelon 1.5-4.5 mg b.i.d.
88851763|NCT01340885|Placebo Comparator|Placebo|sugar pill
88851764|NCT01326923|Other|Single arm|Single arm Phase II Study Induction Chemo then Concurrent Chemoradiotherapy with Cetuximab in Locally Advanced Head and Neck Squamous Cell Cancer
88851765|NCT03855059|Placebo Comparator|Placebos|Depending on the randomization, this group will receive a saline solution either in the IV catheter or the saline solution will be given perineural with the Mepivicaine nerve block solution.
88851766|NCT03855059|Active Comparator|Dexamethasone Sodium Phosphate|Depending on the randomization, this group will receive dexamethasone 0.1 - 0.15 mg/kg, either in the IV catheter or the dexamethasone, 0.1 - 0.15 mg/kg will be given perineural with the Mepivicaine nerve block solution.
88851767|NCT03863795||Observational (survey)|Participants are recruited and pre-screened via an online crowdsourcing program MTurk, and then respond to a one-time research survey over 20 minutes on SurveyGizmo, an on-line survey software platform
88851768|NCT03858335|Experimental|Constraint-induced movement therapy|Children in constraint-induced movement therapy (CIMT) group will wear forearm splint on the unaffected arm 24 hours for 3 weeks, and receive 15 mCIMT sessions(30-hour dosage)
88851769|NCT03858335|No Intervention|Control|Children in control group will receive only traditional rehab therapies without wearing splint
88851770|NCT03857243|Experimental|dTDCS plus physical therapy|active dual transcranial direct current stimulation (TDCS) arm (M1-M1)
88851771|NCT03857243|Placebo Comparator|Sham dTDCS plus physical therapy|Non-effective dose dual TDCS stimulation arm, identical with intervention arm except for the stimulation intensity/duration used.
88851772|NCT01301963|Active Comparator|Arm I|Patients receive G-CSF SC QD on days 1-4.
88851773|NCT01301963|Experimental|Arm II|Patients receive G-CSF SC QD on days 1-4 and plerixafor SC QD on days 4-8.
88851774|NCT05313737|Experimental|Automated phone opt-in message|Audiocare message requiring Veteran to confirm that they would like to participate in screening and have consult sent
88851775|NCT05313737|Experimental|Opt-out scheduling|Consult automatically sent and Veteran called to schedule screening
88851776|NCT01298921|Active Comparator|Continous Flow Oxygen|
88851777|NCT01298921|Experimental|Oxygen Demand Valve|
88851778|NCT05313191|Experimental|Cohort 1: Central Nervous System|"Group 1 Definitive Reirradiation Phase II~Patients w/history of intracranial or spinal (extradural, intradural, and/or intramedullary) CNS tumors for which radiation therapy was prev. delivered either to gross disease or in the postoperative setting~Min. 6 month interval b/w RT courses~Overlap of prior RT field (50% IDL)~Subgroup analysis: receipt of surgery for recurrence/second IC tumor; concurrent ST; tumor histology~Group 2 CNS Reirradiation Registry~Patients for whom a repeat course of RT to the CNS is indicated for recurrent disease or secondary primary~Postop or intact setting~Min. 6 month interval b/w RT courses~Overlap of prior RT field (50% IDL)~Histologically/clinically documented recurrent CNS tumor (benign or malignant)~Glioblastoma (histologic or molecular including IDH wildtype)~Astrocytoma (molecular IDH1 mutant)~Oligodendroglioma (molecular 1p19q co deleted)~Meningioma~Ependymoma~Chordoma/chondrosarcoma"
88851779|NCT05313191|Experimental|Cohort 2: Head/Neck|"Group 1 Full Dose Reirradiation Phase II~Patients w/history of HNC for which RT was delivered definitively, now with recurrence to h/n amenable to full dose reRT~Gross unresected disease or PORT 2/2 RF~Received at least 40 Gy overlapping w/new target region~Min. 6 month interval b/w RT courses~Overlap of prior RT field (50% IDL)~Subgroup analysis: surgery, HPV status, concurrent ST~Group 2 Early (<6months for prior RT) Palliative H/N ReRT Phase I~Patients w/history of HNC for which RT was delivered definitively/adjuvant setting, now with biopsy proven recurrence to h/n with indication for palliative RT~At least 30 Gy prior RT overlapping with new treatment volume~<6 month interval between RT courses~Group 3 Head/Neck ReRT Registry~Patients w/history of HNC for which RT was delivered now with recurrence/secondary primary requiring reRT~Postop or definitive~Prior RT dose at least 30 Gy overlapping w/new treatment volume~Min.6 month interval b/w RT courses"
88851780|NCT05313191|Experimental|Cohort 3: Breast|"Group 1 Partial Breast Reirradiation (Phase II)~Patients with a history of breast cancer s/p BCT, now with small (≤3cm), unicentric, ipsilateral breast cancer recurrence receiving repeat BCT~Node negative~Negative margins~No LVI~Lumpectomy cavity:whole breast <30%~Minimum 1 year interval between RT courses~Group 2: Regional LN and Breast/CW ReRT (Phase II)~Patients with a history of breast cancer s/p RT , now with recurrence or new primary with indication for reirradiation to the breast/chest wall and regional LN~Minimum 1 year interval between RT courses~Negative metastatic workup (PET/CT or CT C/A/P + bone scan)~Excludes concurrent chemotherapy~Group 3: Breast Reirradiation Registry~Patients with a history of breast cancer s/p RT , now with recurrence or new primary breast cancer with indication for reirradiation~Some overlaps of dose with prior RT course~Negative metastatic workup (PET/CT or CT C/A/P + bone scan)~Excludes concurrent chemotherapy"
89002619|NCT06296043|Experimental|Su-Jok Group|Application will be made on the day PMS symptoms begin and throughout the menstrual cycle.
88817486|NCT01742117|Experimental|Genotype-Guided Therapy|Subjects will be genotyped prospectively for CYP2C19*2, *3 and *17 alleles and will receive treatment based on their genotype. In this group, patients who have the CYP2C19 reduced function allele [i.e., *2 allele (heterozygous or homozygous) or *3 allele (heterozygous or homozygous)] patients will receive ticagrelor 90 mg bid. The WT YP2C19 patients will receive clopidogrel 75 mg once daily.
88817487|NCT01742117|Active Comparator|Conventional Therapy|Subjects will receive clopidogrel once daily after the index PCI and will be retrospectively genotyped for CYP2C19*2, *3 and *17 alleles after completion of one year of treatment with clopidogrel.
88817488|NCT01777035|Experimental|Early physical therapy(PT) occupational therapy (OT)|Early PT OT assessments begin on first day of study. Therapy delivered by a team consisting of physical and occupational therapists and coordinated with daily sedative interruption
88817489|NCT01777035|No Intervention|standard care|PT OT delivered as ordered by the primary ICU team
88817490|NCT02613897|Active Comparator|DAPA/SAXA (dapagliflozin plus saxagliptin)|Dapagliflozin 10mg + Saxagliptin 5mg (plus standard of care treatment of metformin or metformin plus sulfonylurea).
88817491|NCT02613897|Active Comparator|DAPA (Dapagliflozin plus placebo)|Dapagliflozin 10mg + Placebo (plus standard of care treatment of metformin or metformin plus sulfonylurea).
88817492|NCT02613897|Placebo Comparator|PCB (Placebo plus placebo)|Placebo (for dapagliflozin) + placebo (for saxagliptin) (plus standard of care treatment of metformin or metformin plus sulfonylurea).
88817493|NCT01305356|Experimental|Augment® Injectable Bone Graft|Standard rigid fixation + Augment® Injectable Bone Graft (beta-TCP/bovine collagen matrix + rhPDGF-BB)
88817494|NCT01305356|Active Comparator|Autologous bone graft|Standard Rigid Fixation + Autologous bone graft
88817495|NCT02615535|Experimental|EEG neurofeedback-assisted meditation|EEG neurofeedback assisted meditation using the MUSE device and auditory feedback.
88817496|NCT02615535|Active Comparator|Non-EEG feedback-assisted meditation|Non-EEG neurofeedback assisted meditation. Subjects will have auditory instruction from the MUSE device without the EEG neurofeedback.
88817497|NCT05732181|Experimental|Lidocaine patch|
88817498|NCT05732181|No Intervention|Placebo|
88817499|NCT01340144||PFC Sigma PS TKA|one group received primary TKA using the PFC Sigma PS TKA
88817500|NCT01340144||PFC Sigma HP PS TKA|One group received primary TKA using the PFC Sigma HP PS TKA.
88817501|NCT02589171|Experimental|Neo Close Abdominal Closure|
88817502|NCT02589171|Active Comparator|Carter Thomason Device|
88817503|NCT05732025|Experimental|Electrohydraulic shock wave lithotripsy|Pre-treatment of severe calcified coronary lesions with electrohydraulic shock wave lithotripsy
88817504|NCT05732025|Active Comparator|Rotary atherectomy|Pre-treatment of severe calcified coronary lesions with Rotary atherectomy
88817505|NCT02591511|Experimental|health-education app|Smart phone and pad is a stroke-related health education app intervention group
88817506|NCT02591511|Active Comparator|health education manuals|stroke-related health education manual control group
88817507|NCT05731869||Control group|The group measured without the use of orthoses and tapes
88817508|NCT05731869||Epicondylitis Band Group|Group measured with epicondylitis band
88817509|NCT05731869||Wrist Orthosis Group|Group measured with wrist orthosis
88817510|NCT02976051|Experimental|Treatment with HART-CN|HART-CN: Hyperfractionated accelerated radiotherapy with weekly concommitant cisplatin and nimorazole
88817511|NCT01342172|Experimental|Lenalidomide|capsules for oral administration
88817512|NCT01243112|Experimental|Lidocaine w/ Epi|0.2ml 1% Lidocaine with Epinephrine (1:100,000)
88817513|NCT01243112|Experimental|Bupivacaine with epi|0.2 ml 0.25% Bupivacaine with epinephrine (1:200,000)
88817514|NCT01243112|Experimental|Low dose Lido and Bupi w/ Epi|0.2ml 0.5% Lidocaine + 0.125% Bupivacaine with Epinephrine (1:150,000)
88817515|NCT01243112|Experimental|High Dose Lido and Bupi with epi|0.2ml 1% Lidocaine + 0.25% Bupivacaine with Epinephrine (1:150,000)
88817516|NCT01243580|Active Comparator|Ortho-Cyclen®|Ortho-Cyclen® is a comparator drug intervention
88817517|NCT01243580|Experimental|AG200-15|AG200-15 is an investigational transdermal contraceptive delivery system that is a drug intervention
88817518|NCT02975817|Experimental|Hibler's|Insert description from protocol
88817519|NCT02975817|Active Comparator|Warm Air|Insert description from protocol
88817520|NCT05372211||General hospital group|Questionnaires collected from general hospitals in China
88817521|NCT05372211||Maternity and infant hospital group|Questionnaires collected from Maternity and infant hospitals in China
88817522|NCT05372211||Children's hospital|Questionnaires collected from Children's hospitals in China
88817523|NCT01306292|Experimental|SonoVue|Ultrasound contrast agent under development
88817524|NCT01306292|Placebo Comparator|Placebo|normal saline 0.9% for injection used as the comparator
88817525|NCT01743521|Experimental|Group A - 8 weeks total therapy|8 weeks total therapy of TPV/PEG-IFN/RBV if undetectable HCV RNA after 2 weeks of therapy
88817526|NCT01743521|Experimental|Group B - 12 weeks total therapy|12 weeks total therapy of TPV/PEG-IFN/RBV if undetectable HCV RNA after 4 weeks of therapy
88817527|NCT01743521|Experimental|Group C - 24 weeks total therapy|24 weeks total therapy - TPV/PEG-IFN/RBV for 12 weeks + PEG-IFN/RBV for 12 weeks if undetectable HCV RNA after 8 weeks of therapy
88851781|NCT05313191|Experimental|Cohort 4: Thoracic|"Group 1: Definitive Reirradiation for Locally Advanced Disease~Single arm, prospective, phase II study~Patients with a history of lung cancer s/p definitive RT , now with local recurrence of new primary centrally located and w/I 50% IDL of prior RT field~Definitive reRT concurrent systemic therapy~Adequate pulmonary function defined as an FEV1 of >35% (with or without bronchodilator) within 90 days prior to registration~Minimum 6 month interval between RT courses~Negative metastatic workup~Group 2: Thoracic Registry Study~Registry design~Patients with histologically confirmed thoracic malignancy (NSCLC, SCLC , mesothelioma, thymoma, carcinoid, intrathoracic sarcoma) with prior thoracic RT~Minimum 3 month interval between RT courses~Negative metastatic workup"
88851782|NCT05313191|Experimental|Cohort 5: Gastrointestinal|"Group 1 Esophagus & GEJ Reirradiation Phase II~Patients w/history of E/GEJ cancer s/p RT, now w/recurrent/new primary nonmetastatic E/GEJ cancer for which salvage RT is recommended~Negative metastatic workup~Group 2 Liver Reirradiation Phase II~Patients w/history of HCC, cholangiocarcinoma or liver mets (any histology), s/p prior EBRT, now with in field recurrence/new primary/met, for which definitive reRT is recommended~CTP A or B7~Excl. prev. Y 90/radioembolization~Allow prior TACE~Overlap w/50% IDL prior RT~Adequate bone marrow function~Group 3 Lower GI Reirradiation Phase II~Patients w/history of rectal/anal cancer s/p RT now w/recurrent/new primary nonmetastatic rectal/anal cancer for whom salvage RT is recommended +/ chemotherapy~Negative metastatic workup (PET/CT or CT C/A/P)~Group 4 GI Reirradiation Registry~•Patients w/histologically document recurrent or new GI malignancy with prior history of RT w/overlap of current RT volume by the 50% IDL"
88851783|NCT05313191|Experimental|Cohort 6: Genitourinary|"Group 1 Locally recurrent prostate cancer w/in prev. radiation field Phase II~Patients w/recurrent prostate adenocarcinoma w/in prev. irradiated field w/indication for repeat course of radiation~Min. 1 year interval b/w RT courses~Prostate gland or recurrent tumor <100 cc or 6 cm in largest dimension~No persistent grade 2+ toxicity from prior radiation~Negative metastatic workup (bone scan, CT scan or PSMA/axumin scan~Group 2 Regional prostate cancer recurrence adjacent to the previous field Phase II~Patients w/recurrent prostate adenocarcinoma beyond prior RT field (outside 50% IDL) but w/in pelvis)~Min.1 year interval b/w RT courses (EBRT or brachy)~No persistent grade 2+ toxicity from prior radiation~Group 3 Prostate Reirradiation Registry~Patients w/recurrent prostate adenocarcinoma (prostate gland, postop bed, or pelvi c LN) who require RT to the prostate or pelvis in the setting of prior pelvis RT~No DM~Concurrent chemotherapy excl."
88851784|NCT05313191|Experimental|Cohort 7: Gynecological|"Group 1: Locally recurrent gynecological cancer within previous field~Single arm, prospective, phase II study design~Patients with history of gyn cancer for which definitive or adjuvant/salvage PORT was given, now with recurrence within 50% IDL recommended for radiotherapy~At least 1 year between RT courses~No persistent grade 3+ toxicity from prior RT~Concurrent chemotherapy excluded~Uncontrolled or widely metastatic disease~Life expectancy >6 months"
88851785|NCT05313191|No Intervention|Cohort 8: Registry|"Registry design~Any cancer patient for whom RT is indicated in the setting of prior RT and do not meet eligibility criteria for other cohorts~Overlap of 50% IDL of current treatment volume with prior RT field"
88851786|NCT03870737|Experimental|Active TNS|Participants who previously underwent screening and determination of eligibility in a double-blind sham-controlled trial of TNS for ADHD, and randomized to sham, will be offered upon unblinding at the end of the 5-week controlled trial to receive 4-weeks open treatment with the active TNS condition.
88851787|NCT01269749|Other|RAI treatment|Characteristics of study population. We will recruit a total of 150 patients diagnosed with GD younger than 18 years of age. All subjects are to be treated with 131I. In this trial, children will not be randomized to treatment, but will be treated per physician prescribed care. To ensure an equal distribution of age and gender between the two groups of children, we stratify enrollment by gender (male vs. female) and age (5-10 yrs, 10-15 yrs, 15-18 yrs).
88851788|NCT01269749|Other|ATD Group|Characteristics of study population. We will recruit a total of 150 patients diagnosed with GD younger than 18 years of age. All subjects are to be treated with antithyroid drugs (ATDs). In this trial, children will not be randomized to treatment, but will be treated per physician prescribed care. To ensure an equal distribution of age and gender between the two groups of children, we stratify enrollment by gender (male vs. female) and age (5-10 yrs, 10-15 yrs, 15-18 yrs).
88851789|NCT02757053|Experimental|Guardian Cap|The set of high school football players wearing the Guardian Cap on their helmets
88851790|NCT02757053|No Intervention|No Guardian Cap|The set of high school football players not wearing the Guardian Cap on their helmets
88851791|NCT01270919|Other|BioDuct Meniscal Repair Device|BioDuct Meniscal Repair Device
88851792|NCT01262339|Active Comparator|Comparator of Hand A intervention vs Hand B|Hand A will receive 100U of BTX-A injected intradermally (SOC) Hand B will receive 100U delivered via iontophoresis.
88851793|NCT03861845|Active Comparator|Standard off-the-shelf pillbox|Participants will engage in reflection on medication routines. Then they will receive a standard off-the-shelf pillbox. Finally, the participants will receive education & training on how to use the pillbox.
88851794|NCT03861845|Experimental|Custom off-the-shelf|Participants will engage in reflection on medication routines. Then they will receive a custom off-the-shelf pillbox. Finally, the participants will receive education & training on how to use the pillbox.
88851795|NCT03861845|Experimental|Custom designed and manufactured|Participants will engage in reflection on medication routines. Then they will receive a custom designed and manufactured pillbox. Finally, the participants will receive education & training on how to use the pillbox.
88851796|NCT02708849|Experimental|Ketamine plus lamotrigine|
88851797|NCT02708849|Placebo Comparator|ketamine plus placebo|
88851798|NCT03859739|Experimental|Panel A. MK-8558 400 mg|Single oral dose of MK-8558 administered at 400 mg following a 10-hour fast.
88851799|NCT03859739|Experimental|Panel B. MK-8558 at dose level 2|Single oral dose of MK-8558 administered at dose level 2 following a 10-hour fast. Dose level 2 shall not exceed 900 mg. Per protocol, dose will be selected following review of data from panel A.
88851800|NCT03859739|Experimental|Panel C. MK-8558 at dose level 3|Single oral dose of MK-8558 administered at dose level 3 following a 10-hour fast. Dose level 3 shall not exceed 1600 mg. Per protocol, dose will be selected following review of data from panel B.
88851801|NCT03859739|Experimental|Panel D. MK-8558 at dose level 4|Single oral dose of MK-8558 administered at dose level 4 following a low-fat breakfast. Dose level 4 shall not exceed 1600 mg. Per protocol, Panel D is optional pending results of Panels A-C, and dose will be selected following review of data from panel C.
89378650|NCT02340130|Experimental|DP/MG/14-1|DP/MG/14-1: Depigmented modified allergen extract of D. pteronyssinus 50% / Depigmented, glutaraldehyde-polymerised B. tropicalis 50% (200DPP/mL) The administration regimen will consist of a rush build-up régimen and a follow up period
89378651|NCT02340130|Experimental|DP/MG/14-2|DP/MG/14-2: Depigmented modified allergen extract of D. pteronyssinus 50% / Depigmented, glutaraldehyde-polymerised L.destructor 50% (200DPP/mL) The administration regimen will consist of a rush build-up régimen and a follow up period
88851802|NCT01237613|Experimental|Artelon|This is an open, prospective study with an anticipated enrollment of 10 patients with chronic or repeat Achilles tendon rupture undergoing surgical repair augmented with Artelon® Tissue Reinforcement.
88851803|NCT01234103|Experimental|Preventing sexual health risks|The over goal is to prevent STIs, unintended pregnancies, and related behaviors including sexual risk, alcohol and other substance misuse
88851804|NCT01234103|Other|Improving nutrition, fitness and injury prevention|The goals are: (1) maintain and improve nutrition and physical fitness through healthier lifestyle and food choices; (2) reduce the risk of sports or physical training injuries and learning how to treat injuries; and (3) Learn to recognize stress and the steps you can take to reduce stress
88851805|NCT01222871|Experimental|Triamcinolone|Triamcinolone soaked nasopore dressing
88851806|NCT01222871|Placebo Comparator|Control Group|Saline soaked sponge
88851807|NCT01219673|Placebo Comparator|Placebo|Placebo by mouth 2 times every day.
88851808|NCT01219673|Experimental|Armodafinil|Armodafinil 150 mg by mouth once a day.
88851809|NCT01219673|Experimental|Minocycline|Minocycline 100 mg by muth two times a day.
88851810|NCT01219673|Experimental|Bupropion|Bupropion 100 mg by mouth two times a day.
88851811|NCT01219673|Experimental|Armodafinil + Minocycline|"Armodafinil 150 mg by mouth once a day.~Minocycline 100 mg by mouth two times a day."
88851812|NCT01219673|Experimental|Armodafinil + Bupropion|"Armodafinil 150 mg by mouth once a day.~Bupropion 100 mg by mouth two times a day."
88851813|NCT01219673|Experimental|Minocycline + Bupropion|"Minocycline 100 mg by muth two times a day.~Bupropion 100 mg by mouth two times a day."
88851814|NCT01219673|Experimental|Armodafinil + Minocycline + Bupropion|"Armodafinil 150 mg by mouth once a day.~Minocycline 100 mg by muth two times a day.~Bupropion 100 mg by mouth two times a day."
88851815|NCT01216631|Active Comparator|IA steroid|Intra-articular injection of steroid (80mg depomedrone)
88851816|NCT01216631|Experimental|IA infliximab|intra-articular injection of 100mg infliximab
88851817|NCT01216631|Experimental|IV infliximab|intravenous infusions of infliximab given at 0, 2, 6 and 14 weeks at a dose of 5mg/kg (patient body weight)
88851818|NCT02693717|Experimental|Treatment (pemetrexed disodium)|Patients receive pemetrexed disodium IV over 10 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
88851819|NCT03860753|Experimental|Pioglitazone|
88851820|NCT03860753|Placebo Comparator|Placebo|
88851821|NCT02687165|Active Comparator|Milnacipran augmented by D-cycloserine|participants will be receiving Milnacipran for 12 weeks. During weeks 6-12 participants will be receiving D-cycloserine in addition to Milnacipran
88851822|NCT02687165|Placebo Comparator|Milnacipran augmented by Placebo|participants will be receiving Milnacipran for 12 weeks. During weeks 6-12 participants will be receiving placebo in addition to Milnacipran
88851823|NCT02672033|Experimental|Treatment (hypofractionated IMRT, pleurectomy/decortication)|Patients undergo 5 fractions of accelerated hypofractionated IMRT over 1 week with simultaneous integrated boost to gross disease. Patients then undergo pleurectomy/decortication within 14 days after completion of IMRT.
88851824|NCT02656199||Main Cohort|all patients enrolled will have an ultrasound of their diaphragm performed once they are on a pressure support trial. Intervention: Diaphragm Ultrasound
88851825|NCT03845933|Active Comparator|Water exchange (WE) colonoscopy|Water exchange will be used during colonoscopy insertion. Upon arriving at the cecum, CO2 will be opened. The scope will be withdrawn to the hepatic flexure. All polyps identified will be resected (colon polypectomy). The scope will be reinserted into the cecum by the first endoscopist. A tandem inspection of right colon will be performed by a second endoscopist. All polyps found herein will be counted as the missed polyps. After the second withdrawal to the distal hepatic flexure, the remainder of the colon will be examined in a standard manner by the first endoscopist.
88851826|NCT03845933|Active Comparator|CO2 insufflation colonoscopy|The colonoscopy is performed in the usual fashion, with minimal insufflation required to aid insertion. Cleaning will be performed entirely during withdrawal. Upon arriving at the cecum, CO2 insufflation will be used and the scope will be withdrawn to the hepatic flexure. All polyps identified will be resected (colon polypectomy). Then the scope will be reinserted into the cecum by the first endoscopist using CO2. A tandem inspection of the right colon will then be performed by a second endoscopist. All polyps found herein will be counted as the missed polyps. After the second withdrawal to the mark of distal hepatic flexure, the remainder of the colon will be examined in a standard manner by the first endoscopist.
88851827|NCT03817775|No Intervention|Control|The control group will undergo coronary angiography without music intervention.
88851828|NCT03817775|Experimental|Music therapy|The intervention group will also undergo coronary angiography and will administer music therapy between 10 minutes prior to the beginning of the procedure until its end.
88851829|NCT01169753|Placebo Comparator|Placebo|Patients randomized to nonintervention will take a placebo every morning for 2 weeks.
88851830|NCT01169753|Experimental|Armodafinil|Three 50 mg tablets orally every morning for 2 weeks.
88851831|NCT02654639|Experimental|TAS-102 and Bevacizumab|Oral TAS-102 and intravenous Bevacizumab.
89002620|NCT06296043|No Intervention|Control Group|No application will be made to this group by the researcher.
89002621|NCT06294535|Experimental|prebent titanium mesh|reconstruction of fractured orbital walls with perbent titanium mesh
89002622|NCT06294535|Experimental|customized titanium implant (patient specific implant)|econstruction of fractured orbital walls with patient specific implant (customized titanium implant)
88851832|NCT02634827|Experimental|Treatment (decitabine, midostaurin)|Patients receive decitabine intravenously (IV) over 1 hour on days 1-5 and midostaurin orally (PO) twice daily (BID) on days 8-21 of courses 1 and 2, and on days 1-28 of each subsequent course. Patients failing to achieve complete response (CR)/complete response with incomplete recovery (CRi)/partial response (PR)/morphologic leukemia-free state by end of course 2 receive midostaurin PO BID on days 1-28. Patients achieving CR/CRi/PR/morphologic leukemia-free state by end of course 8 may continue on current regimen. Patients failing to achieve a CR/CRi/PR/ morphologic leukemia-free state in bone marrow blasts by end of course 8 go to event monitoring. Treatment repeats every 28 days for up to 18 courses in the absence of disease progression or unacceptable toxicity.
88851833|NCT02506985|Experimental|rivaroxaban|For the first 3 weeks, patients will receive rivaroxaban 15mg twice-daily; thereafter they will take rivaroxaban 20mg once-daily as per the drug label. Rivaroxaban will be initiated immediately following completion of alterplase infusion, and heparin will be discontinued at the time of rivaroxaban administration.
88851834|NCT02506985|Experimental|heparin-warfarin|Unfractioned heparin (UFH), following hospital protocol to achieve a target PTT or enoxaparin, 1.0mg/kg twice-daily, for a minimal duration of treatment of 5 days. Warfarin may be started on the night after CDT. UFH or enoxaparin should continue until the INR is >= 2.0 on two consecutive measurements at least 24 hours apart with an advised overlap with VKA for 4 to 5 days. VKA dosages will be adjusted to maintain the INR within the therapeutic range (target 2.5, range 2.0 - 3.0).
88851835|NCT01150409|Experimental|hydrocortisone|Hydrocortisone 50 mg IV every 12 hours x 4 doses (2 days), followed by Hydrocortisone 50 mg IV every 24 hours x 2 doses (2 days)
88851836|NCT01150409|Placebo Comparator|Normal Saline (placebo)|0.9% sodium chloride (equal volume to hydrocortisone) IV every 12 hours x 4 doses (2-days), followed by 0.9% sodium chloride (equal volume to hydrocortisone) IV every 24 hours x 2 doses (2-days)
88851837|NCT01133639|Placebo Comparator|Placebo|Placebo plus standard of care
88851838|NCT01133639|Experimental|Ketorolac|30 mg IV dose intra-operatively followed by 10 mg orally every 8 hours for five days plus standard of care
88851839|NCT01115699|Experimental|Repetitive Transcranial Magnetic Stimulation|All subjects will receive 10 Hz repetitive transcranial magnetic stimulation (rTMS) applied to the left dorsolateral prefrontal cortex (L-DLPFC) for a fixed-flexible period of 5 treatments per week for up to 6 weeks.
88851840|NCT00378911|Experimental|Treatment (sunitinib malate)|Patients receive oral sunitinib malate once daily on days 1-28. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.
88851841|NCT03819491|Experimental|Group A|100 mg OD
88851842|NCT03819491|Experimental|Group B|100 mg BID
88851843|NCT03801473|Experimental|robot assisted training (RAT)|RoboGait which is an automated locomotor therapy system was used for treating RAT group. The system composed of a robotic lower extremity orthosis, adjustable dynamic gait support, synchronized treadmill and biofeedback utilities
88851844|NCT03801473|Active Comparator|conventional training (CT)|Participants in CT group had physiotherapist assisted walking exercises on the parallel bars and on the ground with aids/cane, tripod or walker.
88851845|NCT03828149|Active Comparator|Drug: OP0201|20 mg dose one time, followed by a washout and then a 0 mg dose one time, cross over design
88851846|NCT03828149|Placebo Comparator|Drug: Placebo|0 mg dose one time, followed by a washout and then a 20 mg dose one time, cross over design
88851847|NCT03832907|Experimental|Dexcom G6 CGM - Continues Glucose Monitoring sensor system|"The Dexcom G6 CGM is a commercially available factory-calibrated sensor system. The system measures interstitial glucose every 5-15 minutes, providing real-time and more complete glycemic profile during 24-hours compared to standard POC glucose testing, and replaces the need for finger sticking. Potential limitations include the need for removing the sensor before MRI or diathermy treatment, and the potential interference in patients with severe dehydration.~In parallel, same participants will be monitored by the standard of care point-of-care (POC) capillary glucose tests. Diabetes guidelines recommend bedside capillary POC testing before meals and at bedtime to assess glycemic control and to adjust insulin therapy in the hospital."
88851848|NCT03831971|Experimental|ANS-6637 & Midazolam|Subjects will receive (1) midazolam 5 mg po single dose on Day 1 followed by (2) Drug free period on Day 2 followed by (3) ANS-6637 600 mg po daily (Days 3-7) to reach steady state followed by (4) ANS-6637 600 mg po single dose + midazolam 5mg po single dose on Day 8
88851849|NCT03823937||Fibromyalgia|Diagnosed with ACR 2016 criteria
88851850|NCT03823937||Control|18-70 years healthy subjects
88851851|NCT03807089|Experimental|Short-Turn Radius Colonoscope|Colonoscopy performed with Short-Turn Radius Colonoscope. The colonoscope will provide a forward-facing view of the colon during advancement to the cecum (standard of care). The scope will then be withdrawn all the way to the rectum and the colon will be inspected using the forward-facing view (standard of care). The colonoscope will then be re-advanced to the cecum and be withdrawn using the retrograde view.
88851852|NCT03807089|Active Comparator|Conventional Pediatric Colonoscope|Colonoscopy will be performed with a conventional pediatric colonoscope. During withdrawal, the colon will be inspected using the forward-facing view (standard of care). The colonoscope will then be re-advanced to the cecum and again withdrawn using the forward-facing view.
88851853|NCT03822377|Experimental|Ticagrelor orodispersible tablets|"STEMI or very high-risk NSTEMI patients undergoing primary PCI and receiving Ticagrelor 180 mg loading dose as orodispersible tablets.~Intervention: administration of Ticagrelor 180 mg loading dose as orodispersible tablets."
88851854|NCT03822377|Active Comparator|Ticagrelor standard tablets|"STEMI or very high-risk NSTEMI patients undergoing primary PCI and receiving Ticagrelor 180 mg loading dose as standard coated tablets.~Intervention: administration of Ticagrelor 180 mg loading dose as standard coated pills."
88851855|NCT02501759|Experimental|Diagnostic (MRI, MRI-guided biopsy, TRUS-guided biopsy)|Patients receive gadodiamide IV and undergo a diagnostic multiparametric endorectal MRI. Patients with lesions visible on the diagnostic multiparametric endorectal MRI undergo transrectal MRI-guided biopsy within 2 weeks of diagnostic multiparametric endorectal MRI. Patients then undergo TRUS-guided biopsy per standard clinical care approximately 2 weeks after transrectal MRI-guided biopsy.
89378652|NCT03112330|Experimental|platelet rich plasma injection group|To evaluate the safety and efficacy of plasma rich platelet injection on inferior turbinate mucosa in patients with atrophic rhinitis
89378653|NCT03112486||Cardiac Arrest cohort|adult patients (≥ 18 years of age) with non-traumatic out of hospital cardiac arrest
89378654|NCT03112486||Control cohort|matched control population will include hemodynamically stable patients who present to the ED with chest pain that is not of cardiac etiology (non-traumatic chief complaints).
89378655|NCT02339818||HCPs|HCPs involved in using Eliquis (apixaban)
89378656|NCT02339818||Patients|Patients taking Eliquis for any of the three currently approved indications
89378657|NCT02339662|Active Comparator|gabapentin|900 mg per day total, 3 pills of 300mg.
89378658|NCT02339662|Active Comparator|amitriptyline|20 mg total, 1pill
89378659|NCT02343796|Experimental|Fibre-reinforced composite|Fibreglass reinforced composite restoration-everStick as a medical device intervention will be applied on each subject by using either direct or indirect method. everStick (GC, Belgium) will be used as a fibre reinforcement material.
89378660|NCT02343718|Experimental|Vinblastine and Temsirolimus|"Vinblastine starting dose:~Weight >12 kg 4mg/m^2 Weight ≤ 12 kg 0.13mg/kg IV push for 1 minute Days 1, 8, 15, 22, 29 and 36. Cycle length is 6 weeks up to 6 cycles.~Temsirolimus starting dose:~Weight >12 kg 15mg/m^2 Weight ≤ 12 kg 0.5 mg/kg IV for 1 hour on days 1, 8, 15, 22, 29 and 36. Cycle length is 6 weeks up to 6 cycles."
89378661|NCT02343562|Active Comparator|Probiotics Group|Will receive Sachet-form probiotics
89378662|NCT02343562|Placebo Comparator|Placebo Group|Will receive off-the-shelf oral multivitamin
89378663|NCT03148522|Experimental|escitalopram|Eligible patients were assigned to escitalopram treatment based on investigators' clinical practice.
89378664|NCT03148522|Experimental|duloxetine|Eligible patients were assigned to duloxetine treatment based on investigators' clinical practice.
88817528|NCT00361803|Experimental|All treated subjects|All subjects received Topotecan, administered intravenously over 30 minutes at 4 milligrams per meter^2 weekly for 3 weeks every 28 days.
88817529|NCT00365703|Experimental|1|Orogastric feeding tube.
88817530|NCT00365703|Experimental|2|Nasogastric feeding tube.
88817531|NCT00361881|Experimental|1|ME-609
88817532|NCT00361881|Active Comparator|2|Acyclovir in ME-609 vehicle
88817533|NCT00361881|Placebo Comparator|3|Vehicle
88817534|NCT01743677|Experimental|CP-690,550 100 mg|
88817535|NCT01743677|Placebo Comparator|Placebo|
88817536|NCT01743677|Active Comparator|Moxifloxacin hydrochloride|
88817537|NCT00365937|Experimental|Group A|The eight HLA-A2 peptides
88817538|NCT00365937|Experimental|Group B|The eight HLA-A2 peptides + immunological adjuvant Montanide ISA51
88817539|NCT00365937|Experimental|Group C|the eight peptides HLA-A2 + IMP321
88817540|NCT00365937|Experimental|Group D|The eight HLA-A2 peptides + the 2 immunological adjuvants (Montanides ISA 51 and IMP321)
88817541|NCT01246076|Experimental|Lenalidomide|"Lenalidomide 50 mg/day for two 28 day cycles.~Patients who have bone marrow aplasia as defined by a cellularity of <10% will be observed till counts recover. If patients do not progress following 2 cycles of HD lenalidomide, they will receive low dose lenalidomide 10 mg daily for 12 cycles."
88817542|NCT01745627|Experimental|Laser Treatment|
88817543|NCT05731245|Experimental|Ropeginterferon alfa-2b|"Eligible subjects will receive ropeg subcutaneously (SC) every 2 weeks at the starting dose of 250µg at week 0, 350 µg at week 2, then 500µg at a fixed dose from week 4 onwards until week 104. In patients achieving a clinical or molecular response at 24 months (week 104), treatment with ropeg will be continued until disease progression.~Intervention: Drug: Ropeginterferon alfa-2b"
88817544|NCT01307462|Experimental|Treatment (BOS therapy)|Patients receive fluticasone propionate inhaled PO BID, azithromycin PO 3 days a week, and montelukast sodium PO QD. Treatment continues for 6 months in the absence of disease progression or unacceptable toxicity.
88817545|NCT04340427|Experimental|TQB3455 Tablets|TQB3455 Tablet administered orally once. Then TQB3455 Tablet administered orally, once daily in 28-day cycle after 7 days of first administration.
88817546|NCT05731167|Active Comparator|Regular follow up|Subjects underwent routine outpatient care after assessment and will receive outcomes follow up for 1 year.
88817547|NCT05731167|Experimental|Multidomain intervention|The intervention group will receive multi-faceted frailty prevention programs such as physical training, nutritional advice, cognitive training, and drug education and receive outcomes follow up for 1 year.
88817548|NCT05731089|Active Comparator|group A|Patients in group A were planned to defer the cataract surgery until receiving two injections of Aflibercept at monthly interval, the third injection was then given intra-operatively.
88817549|NCT05731089|Active Comparator|group B|Patients in group B were planned to undergo cataract surgery first and received the first injection intra-operatively, then received two post-operative injections with a monthly interval.
88817550|NCT01307618|Experimental|Arm I (vaccine therapy)|Patients receive vaccination comprising recombinant MAGE-3.1 antigen, MART-1 antigen, gp100 antigen, and NA17-A2 peptide emulsified with Montanide ISA-51 ID or SC on days 1, 22, and 50.
88817551|NCT01307618|Experimental|Arm II (vaccine therapy, IL-12)|Patients receive vaccination as in arm I with an admixture of IL-12 ID or SC on days 1, 22, and 50.
88817552|NCT05371431|Experimental|non-BFR groups|Traditional rehabilitation training is designed according to postoperative orthopaedic rehabilitation guidelines. Traditional rehabilitation trainings include grip and pinch, wrist flexion with forearm pronated, wrist extension with forearm pronated, wrist flexion with forearm supinated, wrist extension with forearm supinated, prayer sign (wrist flexion), prayer sign (wrist extension), forearm pronation, forearm supination. Patients participated in 2 training sessions per week with at least 48 hours rest in between for continuous 6 weeks.
88818527|NCT01832753|Placebo Comparator|Treatment Phase: Months 6-18|"Subject who are found to have SCH at the 6-month visit will be randomized to receive either levothyroxine or placebo during months 6-12. Levothyroxine dose will be between 0.5 - 1 mcg/kg/day. There will be 1 blood draw visit at month 7.5 (6 weeks after randomization) and 1 study visit at month 12 that will provide the opportunity for dose adjustments if needed.~From months 12-18, all subjects will receive levothyroxine. Levothyroxine dose will be between 0.5 - 1 mcg/kg/day. There will be one blood draw visit at month 13.5 that will provide the opportunity for dose adjustments if needed."
88851856|NCT03808493|Experimental|Study 1, TAK-438 OD + TAK-438|One TAK-438 OD 20 mg tablet, orally without water under fasted condition, on Period 1 Day 1 in Study 1 (Day 1), followed by a wash-out period (Days 2 to 8), followed by one TAK-438 20 mg tablet, orally with water under fasted condition, on Period 2 Day 1 in Study 1 (Day 9).
88851857|NCT03808493|Experimental|Study 1, TAK-438 + TAK-438 OD|One TAK-438 20 mg tablet, orally with water under fasted condition, on Period 1 Day 1 in Study 1 (Day 1), followed by a wash-out period (Days 2 to 8), followed by one TAK-438 OD 20 mg tablet, orally without water under fasted condition, on Period 2 Day 1 in Study 1 (Day 9).
88851858|NCT03808493|Experimental|Study 2, TAK-438 OD + TAK-438|One TAK-438 OD 20 mg tablet, orally with water under fasted condition, on Period 1 Day 1 in Study 2 (Day 1), followed by a wash-out period (Days 2 to 8), followed by one TAK-438 20 mg tablet, orally with water under fasted condition, on Period 2 Day 1 in Study 2 (Day 9).
88851859|NCT03808493|Experimental|Study 2, TAK-438 + TAK-438 OD|One TAK-438 20 mg tablet, orally with water under fasted condition, on Period 1 Day 1 in Study 2 (Day 1), followed by a wash-out period (Days 2 to 8), followed by one TAK-438 OD 20 mg tablet, orally with water under fasted condition, on Period 2 Day 1 in Study 2 (Day 9).
88851860|NCT00378989|Active Comparator|Intervention|A letter with personal feedback of the results of a health risk appraisal and invitation to a consultation at the occupational health services.
88851861|NCT00378989|No Intervention|Control|Care as usual
88851862|NCT02499887|Active Comparator|Standard of Care|"Standard of Care: 30 day albuterol inhaler plus non-tapering course of oral prednisone (50 mg/d) for 4 days (1st dose will have been given in the ED)~Spacers will be dispensed with all multiple dose inhalers (MDI) to promote proper use and administration of inhaled medications."
88851863|NCT02499887|Experimental|Treatment|"Treatment: 30 day QVAR® (beclamethasone dipropionate) inhaler (80 mcg, 1 puff twice daily) plus 30 day albuterol inhaler plus non-tapering course of oral prednisone (50 mg/d) for 5 days~Spacers will be dispensed with all multiple dose inhalers (MDI) to promote proper use and administration of inhaled medications."
88851864|NCT02504099|Experimental|OBV/PTV/r ± DSV ± RBV for 12 or 24 weeks|OBV/PTV/r (ombitasvir/paritaprevir/ritonavir [25 mg/150 mg/100 mg once daily]) with or without dasabuvir (250 mg twice daily) with or without weight-based ribavirin (± RBV; dosed 1,000 or 1,200 mg daily divided twice a day) for 12 or 24 weeks, dosed as per label based on HCV genotype/subtype and presence of cirrhosis.
88851865|NCT02450591|Experimental|Oligometastatic Non-Small Cell Lung Cancer|Patients will be placed on EGFR-TKI for their metastatic EGFR-mutant stage IV oligometastatic disease. All patients will undergo induction TKI for 12 weeks. At the conclusion of 12 weeks on erlotinib, patients without disease progression [partial response (PR) or stable disease (SD)] will undergo definitive local treatment to all remaining sites of disease. After local therapy, erlotinib will be resumed until progression of disease (POD) by RECIST criteria. All assessments completed during the 12 week TKI induction phase are to be performed per protocol with a ± 7 day window.
88851866|NCT01094561|Experimental|Synthetic Human Secretin|Single arm (open label).
88851867|NCT01074437|Other|Group A: Corticosteroid with Placebo|Group A will receive oral, liquid Prednisolone, which is the standard corticosteroid that we use here at Seattle Children's, and oral liquid placebo. The dose of prednisolone that Group A will receive will be 1-2mg/kg/day for 7 days and then the dose will be slowly reduced and then stopped after 3 weeks. This is a standard dose for IH treatment. Gastric prophylaxis (Zantac) will be given to help prevent any stomach problems associated with prednisolone. This treatment will be given for two months, as is our standard practice.
88851868|NCT01074437|Other|Group B: Corticosteroid with Propranolol|Group B will receive oral liquid prednisolone, and oral propranolol. As in Group A, the dose of prednisolone will be 1-2mg/kg/day for 7 days and then the dose will be slowly reduced and then stopped after 3 weeks. Oral liquid propranolol will be dosed at 2 mg/kg/day, following initiation in the Cardiology Clinic. Gastric prophylaxis (Zantac) will be given to help prevent any stomach problems associated with prednisolone.
88851869|NCT03807245|Experimental|GBS-NN/NN2 with Alhydrogel® 25|GBS-NN/NN2 with Alhydrogel® 25 mcg intramuscular 2 times with 4 weeks apart
88851870|NCT03807245|Placebo Comparator|Placebo GBS-NN/NN2 with Alhydrogel® 25|Intramuscular injection with Alhydrogel® 2 times with 4 weeks apart
88851871|NCT03807245|Experimental|GBS-NN/NN2 with Alhydrogel® 50|Intramuscular GBS-NN/NN2 with Alhydrogel® injection 50 mcg 2 times with 4 weeks apart
88851872|NCT03807245|Placebo Comparator|Placebo GBS-NN/NN2 with Alhydrogel® 50|Intramuscular injection with Alhydrogel® 2 times with 4 weeks apart
88851873|NCT02461355|Experimental|Anodal tDCS|Anodal tDCS over the left posterior language areas during aphasia therapy for 8 one-hour sessions
88851874|NCT02461355|Sham Comparator|Sham tDCS|Sham tDCS over the left posterior language areas during aphasia therapy for 8 one-hour sessions
88851875|NCT02410577|Experimental|89Zr-J591|Patients will not be required to fast prior to imaging with 89Zr-J591 injection or imaging. The total dose of humanized mAb J591 will be 20mg. Patients will first receive an injection of 18-19mg of unchelated J591 to reach the total administered dose of antibody (IND11407) followed by 5 mCi (+/- 10%) of 89Zr-J591 (1 to 2 mg). Administration of the cold antibody will be followed by the labeled compound.
88851876|NCT01066637|Experimental|Dosimetry Group|To determine its potential for use in humans, we measured 18F-NOS myocardial activity in patients after orthotopic heart transplantation (OHT) (3 women and 9 men) and normal healthy volunteers (2 women and 2 men), and correlated it with pathologic allograft rejection, tissue iNOS levels, and calculated human radiation dosimetry.
88851877|NCT01066637|Experimental|Kinetic Analysis Group|Measurement of myocardial levels of enzyme nitric oxide synthase(iNOS) using PET and 18F-NOS in post heart transplant patients (5 women and 5 men) undergoing endomyocardial biopsy as part of their normal post-transplant evaluation. Kinetic data of the tracer will be compared with the heart tissue measurements of iNOS measured by immunohistochemistry.
88851878|NCT03796013|Experimental|Form A to Form C Crossover|Participants first randomized to this arm will receive a single oral dose of entrectinib form A (reference form) under fasted conditions on Day 1 of each Period. This dose will be followed by a minimum 14-day washout period, after which participants will receive a single oral dose of entrectinib form C (test form) under fasted conditions on Day 1 of Period 2 (Periods 1 and 2 = 6 days).
89378665|NCT03148522|Experimental|mirtazapine|Eligible patients were assigned to mirtazapine treatment based on investigators' clinical practice.
89378666|NCT02339896||WHO category 2|Children patient who have experienced WHO category II exposure will receive rabies vaccine (SPEEDA) 0.1 ml intradermal two site for 4 times
88851879|NCT03796013|Experimental|Form C to Form A Crossover|Participants first randomized to this arm will receive a single oral dose of entrectinib form C (test form) under fasted conditions on Day 1 of each Period. This dose will be followed by a minimum 14-day washout period, after which participants will receive a single oral dose of entrectinib form A (reference form) under fasted conditions on Day 1 of Period 2 (Periods 1 and 2 = 6 days).
88851880|NCT02399111|No Intervention|Not obese:BMI<30; Standard Care|Standard Wound Care
88851881|NCT02399111|No Intervention|Obese:BMI≥30; Standard Care|Standard Wound Care
88851882|NCT02399111|Other|Not Obese:BMI<30; Wound Vac|Using Prevena Incision Management System
88851883|NCT02399111|Other|Obese:BMI≥30; Wound Vac|Using Prevena Incision Management System
88851884|NCT03793751|Experimental|DEX Group|Receiving Dexmedetomidine injection at a dose of 1 mcg/kg over 10 min, after Spinal Anaesthesia and before start of surgery, followed by a continuous infusion at a rate of 0.4 mcg/kg/h until the end of surgery.
88851885|NCT03793751|Placebo Comparator|CONTROL Group|The Control Group will receive an equal volume placebo infusion of normal saline.
88851886|NCT01030757|Experimental|Tomotherapy|Intervention: Stereotactic Body Radiation Therapy using Tomotherapy. Tomotherapy treatment: A total of 60 Gy using 12 Gy per fraction over 5 fractions to be given within 10 calendar days. Each fraction of 12 Gy will be divided into 2 fractions of 6 Gy given in one day within 6 hours. Dose will be prescribed to the isodose line which covers at least 90% of the PTV.
88851887|NCT01016561|Experimental|Arm I|Patients undergo external beam radiotherapy (3-dimensional conformal OR intensity-modulated) and 4-6 insertions of MRI-guided intracavitary brachytherapy over 8 weeks. Patients also receive cisplatin IV over 30-60 minutes for 5-6 weeks during radiotherapy.
88851888|NCT01009931|Experimental|TPA + Dexamethasone and CMT|12-O-tetradecanoylphorbol-13-acetate (TPA) plus Dexamethasone & Choline magnesium trisalicylate (Trilisate)
88851889|NCT03792191|Experimental|Ultrasonography|Preprocedural lumbar spinal ultrasonography and skin marking. Spinal anesthesia will be administered with injection of intrathecal bupivacaine and intrathecal fentanyl.
88851890|NCT03792191|Active Comparator|Palpation|Sham ultrasound procedure. Conventional landmark palpation and skin marking.Spinal anesthesia will be administered with injection of intrathecal bupivacaine and intrathecal fentanyl.
88851891|NCT03791489|Experimental|Active Treatment|Cryotherapy of the posterior nasal nerve using the ClariFix device
88851892|NCT03790865|Experimental|Low-Dose Livoletide|Daily subcutaneous injection of ~ 60 mcg/kg for 3 month double-blind core period and 9 month open label extension period.
88851893|NCT03790865|Experimental|High-Dose Livoletide|Daily subcutaneous injection of ~120 mcg/kg for 3 month double-blind core period and 9 month open label extension period.
88851894|NCT03790865|Placebo Comparator|Placebo|Daily subcutaneous injection of 0.9% NaCl for the 3 month double-blind core period and then low-dose or high-dose livoletide for 9 month open label extension period.
88851895|NCT00986999|Experimental|rosuvastatin|rosuvastatin 10 mg qd increased to 20 mg qd as tolerated
88851896|NCT02345369|Active Comparator|Locked Set Screw|In this arm, subjects who have sustained an intertrochanteric hip fracture (OTA classification A2 and A3) will undergo fixation with an intramedullary hip screw with locking of the set screw.
88851897|NCT02345369|Active Comparator|Unlocked Set Screw|In this arm, subjects who have sustained an intertrochanteric hip fracture (OTA classification A2 and A3) will undergo fixation with an intramedullary hip screw without locking of the set screw.
88851898|NCT03784001|Active Comparator|Gratitude + No Expectations|Participants will type online lists of up to five items they are grateful for, every two days for two weeks.
88851899|NCT03784001|Experimental|Gratitude + Expectations|Participants will type online lists of up to five items they are grateful for, every two days for two weeks. They will also be told a benefit of gratitude each time they write an online gratitude list.
88851900|NCT03784001|Active Comparator|Events Control|Participants will type online lists of up to five events from their day, every two day for two weeks.
88851901|NCT03781037|Experimental|GIVE module|The GIVE module consists of one 50-minute treatment session and a second partial session (15-20 minutes) embedded within a larger cognitive behavioral treatment (CBT) protocol for anxiety or depression. The GIVE module uses cognitive behavioral principles to target youth's beliefs that they are a burden or drain on others.
88851902|NCT02319005|Active Comparator|Revusiran (ALN-TTRSC)|administered by subcutaneous (SC) injection
88851903|NCT02319005|Placebo Comparator|Sterile Normal Saline (0.9% NaCl)|administered by subcutaneous (SC) injection
88851904|NCT03784079|Experimental|Part 1: GSK3640254 10 mg|Participants will receive GSK3640254 10 milligram (mg), capsules, orally for 10 days.
88851905|NCT03784079|Experimental|Part 1: GSK3640254 200 mg|Participants will receive GSK3640254 200 mg, capsules, orally for 10 days.
88851906|NCT03784079|Placebo Comparator|Part 1: Placebo|Participants will receive placebo capsules, orally for 10 days.
88851907|NCT03784079|Experimental|Part 2: GSK3640254 40 mg|Participants will receive GSK3640254 40 mg, capsules, orally for 7 days.
88851908|NCT03784079|Experimental|Part 2: GSK3640254 80 mg|Participants will receive GSK3640254 80 mg, capsules, orally for 7 days.
88851909|NCT03784079|Experimental|Part 2: GSK3640254 140 mg|Participants will receive GSK3640254 140 mg, capsules, orally for 7 days.
88851910|NCT03784079|Placebo Comparator|Part 2: Placebo|Participants will receive placebo capsules, orally for 7 days.
88851911|NCT00983645|Active Comparator|Neoral|Neoral is a pill indicated for the prophylaxis of organ rejection in kidney transplants
88851912|NCT00983645|Active Comparator|Prograf|Prograf is a medication used for the prophylaxis of rejection in allogeneic kidney transplants and may be used concomitantly with adrenal corticosteroids.
88851913|NCT02308475|Experimental|Myocardial Stress CT Perfusion|"Dynamic volume CT myocardial perfusion using the experimental scanner (Force, Siemens), applying the dynamic shuttle mode will be used to rapidly cover the entire cardiac anatomy during infusion of a contrast medium bolus for monitoring bolus passage through the left ventricular myocardium."
88851914|NCT02234687|Placebo Comparator|Placebo|Placebo, one dose
88851915|NCT02234687|Experimental|Pomaglumetad Methionil 40mg|Pomaglumetad Methionil 40mg, one dose, one time
88851916|NCT02234687|Experimental|Pomaglumetad Methionil 160mg|Pomaglumetad Methionil 160mg, one dose, one time
88851917|NCT00978419|Active Comparator|Rosuvastatin|Rosuvastatin
88851918|NCT00978419|Placebo Comparator|Placebo|Placebo
88851919|NCT00957827|Experimental|keflex|keflex 500mg twice a day for five days
88851920|NCT00957827|Placebo Comparator|placebo|placebo 500mg twice a day for five days
88851921|NCT00962429|Active Comparator|Lipoic acid|alpha lipoic acid
88851922|NCT00962429|Placebo Comparator|Placebo|sugar pill
88851923|NCT00950183|Other|Foot and Ankle Surgery|Please note that the study was terminated prior to randomization of patients.
88851924|NCT00949403|Experimental|Obese Females (pre-bariatric surgery)|Twenty obese females (18-45 years of age, BMI > or equal to 45) who are scheduled to undergo bariatric surgery at Barnes-Jewish Hospital will be screened for enrollment over 2 years. They will be imaged with PET/CT and radiopharmaceuticals C-11 Acetate and C-11 Palmitate will be injected.
88851925|NCT03767153|Experimental|80 pin applicator|
88851926|NCT03767153|Active Comparator|160 pin applicator|
88851927|NCT03766373|Active Comparator|Drug: OP0201|
88851928|NCT03766373|Placebo Comparator|Drug: Placebo|
88851929|NCT02110277|Experimental|PAI/ultrasound Diagnostic Group|These patients will include women who are at risk for ovarian cancer and wish to undergo prophylactic oophorectomy, or who have an ovarian mass suggestive of a malignancy and are counseled to undergo oophorectomy.
88851930|NCT03760913|Experimental|OLP-1002: Part A, Single Ascending Dose|Subcutaneous Injection: 30 ng, 120 ng, 400 ng, 1.2 μg, 3 μg, 6 μg, 12 μg, 20 μg, 40 μg, 80 μg, 160 μg
88851931|NCT03760913|Experimental|OLP-1002: Part B, Multiple Ascending Dose|Subcutaneous Injection: 5 x 2 μg, 5 x 5 μg, 5 x 10 μg, 5 x 20 μg, 5 x 40 μg, 5 x 80 μg
88851932|NCT03760913|Placebo Comparator|Placebo Part A, Single Ascending Dose|Subcutaneous Injection: Placebo
88851933|NCT03760913|Placebo Comparator|Placebo Part B, Multiple Ascending Dose|Subcutaneous Injection: Placebo x 5
88851934|NCT00920309|Experimental|Rapamycin|"Drug: Rapamycin~Other Names:~sirolimus The starting dose of rapamycin will be 1 mg daily. The dose will be increased as needed to achieve a 24 hour trough level of 4-6 ng/ml."
88851935|NCT00920309|Placebo Comparator|Standard of Care-Placebo|Standard of Care
88851936|NCT00928499|Other|Interstim - continuous|Continuous stimulation
88851937|NCT00928499|Other|Interstim - cyclic|Cyclic stimulation
88851938|NCT02109809|Experimental|Supportive Care (TLI)|Patients undergo LD-TLI daily for 1-2 days.
88851939|NCT02075411|Active Comparator|Males Single shot peripheral nerve block|a single injection peripheral nerve block (FS/SS) of the femoral and sciatic nerves, Femoral Block - 0.25% bupivacaine (0.5 ml/kg, max 40 ml). The sciatic block will be performed using 0.125% bupivacaine (0.5 ml/kg, max 20 ml).
88851940|NCT02075411|Active Comparator|Females Single shot peripheral nerve block|a single injection peripheral nerve block (FS/SS) of the femoral and sciatic nerves, Femoral Block - 0.25% bupivacaine (0.5 ml/kg, max 40 ml). The sciatic block will be performed using 0.125% bupivacaine (0.5 ml/kg, max 20 ml).
88851941|NCT02075411|Active Comparator|Males Continuous peripheral neural infusion|The placement of a femoral continuous peripheral nerve infusion catheter (CPNI) and 0.25% bupivacaine (0.5 ml/kg, max 20 ml) will be injected under ultrasound guidance.
88851942|NCT02075411|Active Comparator|Females Continuous peripheral neural infusion|The placement of a femoral continuous peripheral nerve infusion catheter (CPNI) and 0.25% bupivacaine (0.5 ml/kg, max 20 ml) will be injected under ultrasound guidance.
88851943|NCT03753113|Experimental|Treatment group|The patients will be applied 1 mL of solutions(Herbal and Minoxidil) at morning and evening intervals to the thinning hair areas of the scalp for 36 weeks.
88851944|NCT03753113|Active Comparator|Control group|The patients will be applied 1 mL of Minoxidil 5% solutions at morning and evening intervals to the thinning hair areas of the scalp for 36 weeks.
88851945|NCT02084147|Experimental|PET-CT and PET-MRI|Patients undergo PET-CT over approximately 30 minutes and PET-MRI over approximately 45-90 minutes.
88851946|NCT02067611|Experimental|X0002|low dose, BID;middle dose, BID, or high dose, BID.
88851947|NCT02067611|Placebo Comparator|Placebo|low dose, BID; middle dose, BID, or high dose, BID.
88851948|NCT02075021|Experimental|lenalidomide and nab-paclitaxel|100 mg/m^2 of Abraxane weekly for 3 weeks and 10 mg Revlimid daily for 21 days, with a dose escalation for Revlimid to 15 mg and to 25 mg. One cycle is 4 weeks. Dose de-escalations will also be performed for both drugs as necessary. Patients will be treated until disease progression.
88851949|NCT02057237|Experimental|single arm|Mitotane will be administered on an outpatient or inpatient basis.
88851950|NCT03752567||Group study|Follow up of the patients for 12 months by the community pharmacist in the role of case manager and execution of the activities foreseen by the PAI (individual assistance plan) through telemedicine (ecg, fundus oculi, ankle arm index) and self analysis (glycated hemoglobin, lipid profile, uric acid microalbuminuria).
88851951|NCT03748979|Experimental|Cohort A1; TAK-925 (Dose Level A1)|TAK-925, Dose Level A, once daily for up to 7 days in healthy participants.
88851952|NCT03748979|Experimental|Cohort A2; TAK-925 (Dose Level A2)|TAK-925, Dose Level A2, once daily for up to 7 days in healthy participants. Dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
88851953|NCT03748979|Experimental|Cohort A3; TAK-925 (Dose Level A3)|TAK-925, Dose Level A3, once daily for up to 7 days in healthy participants. This group is an additional optional cohort and dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
88851954|NCT03748979|Experimental|Cohort A4; TAK-925 (Dose Level A4)|TAK-925, Dose Level A4, once daily for up to 7 days in healthy participants. This group is an additional optional cohort and dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
88851955|NCT03748979|Experimental|Cohort A5; TAK-925 (Dose Level A5)|TAK-925, Dose Level A5, once daily for up to 7 days in healthy participants. This group is an additional optional cohort and dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
88851956|NCT03748979|Experimental|Cohort A6; TAK-925 (Dose Level A6)|TAK-925, Dose Level A6, once daily for up to 7 days in healthy elderly participants. This group is an additional optional cohort and dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
88851957|NCT03748979|Placebo Comparator|Part A (Cohorts A1-A6); TAK-925 Placebo|TAK-925 Placebo, once daily for up to 7 days in healthy participants.
89378667|NCT02339896||WHO category 3|Children patient who have experienced WHO category II exposure will receive rabies vaccine (SPEEDA) 0.1 ml intradermal two site for 4 times with ERIG
89378668|NCT03148444|Experimental|Antibiotics treated|Patients undergoing de novo implantation or replacement of cardiac implantable devices (single-chamber, dual-chamber and biventricular pacemakers and defibrillators) in our institution will be discharged home with recommendations to take antibiotic treatment for 5 days following the procedure (cefalexin 500 mg qid, or in the presence of beta-lactam sensitivity roxithromycin 150 mg bid)
89378669|NCT03148444|No Intervention|without Antibiotics Treatment|Patients undergoing de novo implantation or replacement of cardiac implantable devices (single-chamber, dual-chamber and biventricular pacemakers and defibrillators) in our institution will be discharged home with no recommendations regarding antibiotic treatment.
89378670|NCT03148132|Active Comparator|Bevacizumab injection|Application of Intravitreal Bevacizumab (0.50mg/0.02mL), unique dosis
89378671|NCT03148132|Experimental|Ranibizumab Ophthalmic|Application of Intravitreal Ranibizumab (0.25mg/0.025mL), unique dosis
88851958|NCT03748979|Experimental|Cohort B1; TAK-925 (Dose Level B1)|TAK-925, Dose Level B1, once daily for up to 7 days in participants with narcolepsy.
88851959|NCT03748979|Experimental|Cohort B2; TAK-925 (Dose Level B2)|TAK-925, Dose Level B2, once daily for up to 7 days in participants with narcolepsy. Dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
89378672|NCT02339350|No Intervention|Rapid early responder group|"RER Consolidation BM exam on day 63: M1, M2 -> IM M3 or residual CNS ds or Bx proven extramedullary ds - off protocol~RER Interim Maintenance #1~RER Delayed Intensification~RER Interim Maintenance #2~RER Maintenance (12 weeks=84 days)"
89378673|NCT02339350|Experimental|Slow early responder group|"Includes : SER, Testis(+), CNS 3, T-cell (non ETP), Initial PB WBC ≥ 100,000/μL~1. SER Consolidation~Intrathecal triple chemotherapy at d0, 7, 14, 21 2. SER Interim Maintenance #1~high dose methotrexate included~Intrathecal triple chemotherapy at d0, 28 3. SER Delayed Intensification #1~Intrathecal triple chemotherapy at d0, 28, 35 4. SER Interim Maintenance #2~high dose methotrexate included~Intrathecal triple chemotherapy at d0, 28 5. SER Delayed Intensification #2~Intrathecal triple chemotherapy at d0, 28, 35 6. SER Maintenance~Intrathecal triple chemotherapy at d0"
89378674|NCT02339428|Experimental|Diclophenac sodium 100mg p.o.|Patients will be given 100mg of diclophenac sodium two hours prior to colonoscopy.
89378675|NCT02339428|Placebo Comparator|Placebo|Patients will be given placebo tablets of same appearance as the intervention.
89378676|NCT02337322|Active Comparator|ABC+3TC+DTG|Abacavir+lamivudine+Dolutegravir, QD, Single tablet Regimen
89378677|NCT02337322|Active Comparator|ABC+3TC+DRV/r|Abacavir+lamivudine+ritonavir-boosted darunavir, QD
89378678|NCT02337166|Active Comparator|Control|open instrumentation of the root surfaces and bone defects via flap modified papilla preservation flap
89378679|NCT02337166|Experimental|Test|open instrumentation of the root surfaces and bone defects via flap modified papilla preservation flap and application of a rhFGF-2/HA in the intrabony defect
89378680|NCT03148288|Experimental|Vitamin D supplementation|4000IU Vitamin D qd
89378681|NCT03148288|Placebo Comparator|placebo|
89378682|NCT02339272||NOA|Infertile males with non obstructive azoospermia
88851960|NCT03748979|Experimental|Cohort B3; TAK-925 (Dose Level B3)|TAK-925, Dose Level B3, once daily for up to 7 days in participants with narcolepsy. This group is an additional optional cohort and dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
89378683|NCT02339272||OA|Post-vasectomized patients with proven fertility before vasectomy
89378684|NCT02348944||15 healthy volunteers|Other: serum and urine sample
89378685|NCT02039362|Other|tenofovir|tenofovir DF one pill (245 mg) per day from week 28 of pregnancy to week 12 after birth
89378686|NCT04948138|Experimental|MELAS (Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes) syndrome|Patients with MELAS syndrome that will receive oral supplementation with 10-15 g/day of glutamine (adjusted for weight and plasma concentrations)
88851961|NCT03748979|Experimental|Cohort B4; TAK-925 (Dose Level B4)|TAK-925, Dose Level B4, once daily for up to 7 days in participants with narcolepsy. This group is an additional optional cohort and dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
88851962|NCT03748979|Placebo Comparator|Part B (Cohorts B1-B4); TAK-925 Placebo|TAK-925 Placebo, once daily for up to 7 days in participants with narcolepsy.
88851963|NCT03748979|Experimental|Cohort C1; TAK-925 (Dose Level C1)|TAK-925, Dose Level C1, once daily for up to 7 days in participants with narcolepsy. Dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
88851964|NCT03748979|Experimental|Cohort C2; TAK-925 (Dose Level C2)|TAK-925, Dose Level C2, once daily for up to 7 days in participants with narcolepsy. This group is an additional optional cohort and dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
88851965|NCT03748979|Placebo Comparator|Part C (Cohorts C1-C2); TAK-925 Placebo|TAK-925 Placebo, once daily for up to 7 days in participants with narcolepsy.
88851966|NCT03748979|Experimental|Cohort A'1; TAK-925 (Dose Level A'1)|TAK-925, Dose Level A'1, single dose in healthy participants.
89378687|NCT02348866|Active Comparator|Group 1|home laundered/home-donned
89378688|NCT02348866|Active Comparator|Group 2|Hospital laundered/home-donned
89378689|NCT02348866|Active Comparator|Group 3|Home laundered/hospital donned
89378690|NCT02348866|Active Comparator|Group 4|Hospital laundered/hospital donned
89378691|NCT02339194|Experimental|Simplified protocol|"The application of a simplified denture fabrication technique will be tested for patients presenting severely resorbed mandibular alveolar bones according to the following steps:~Obtainment of maxillary and mandibular casts by using irreversible hydrocolloid in stainless steel stock trays for record bases fabrication.~Adjustment of record bases according to vertical dimension and centric relation measurements, with no use of facebow transfer. Casts will be mounted in semi-adjustable articulator using standardized measures and artificial teeth will be selected.~Trial dentures will be evaluated for esthetics and maxillomandibular relationship.~Insertion of finished dentures."
88851967|NCT03748979|Experimental|Cohort A'2; TAK-925 (Dose Level A'2)|TAK-925, Dose Level A'2, single dose in healthy participants. Dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
88851968|NCT00850421|Other|Botulinum Toxin Type A|
88851969|NCT02017379|Experimental|Erythromycin|Intravenous erythromycin infusion (dose: 250 mg) 30 min-60 min before procedure
88851970|NCT02017379|Experimental|Metoclopromide|Intravenous metoclopromide infusion (dose: 10 mg) 30-60 minutes prior to endoscopy
88851971|NCT02017379|No Intervention|Control|no medications will be given prior to endoscopy
88851972|NCT04332263|Experimental|Neuromuscular Electrical Stimulation - NMES|NMES will be applied bilaterally on the quadriceps femoris muscle of ICU patients. An electrical stimulation system and an ICU-designed dynamometer will be used with the patients lying in bed, with the hips and the knees flexed at 60 and 90 degrees, respectively. Supramaximal single-pulse's peak force will be used to determine the NMES intervention level. NMES (alternating biphasic current, stimulation frequency = 80 Hz, 1 ms pulse duration) will be used to evoke tetanic forces (EF) at 50% of the supra-maximal single-pulse EF (i.e., 10-12% of a maximal voluntary isometric contraction). NMES protocol will be performed five times a week, lasting 20 min. Muscle fatigue will be evaluated every 5 min of the intervention, and will be determined as a 10 % decrease in the single-pulse evoked torque between the evoked force produced pre- and during the NMES protocol. If and when a 10% reduction of the single-pulse EF is achieved, the intervention protocol will be terminated before the 20 min.
88851973|NCT04332263|No Intervention|Control Group - CG|The control group (CG) will only perform conventional physiotherapy and will not receive any NMES training, but will be evaluated through the same evaluations and in the same moments of the two above mentioned intervention groups. Conventional physiotherapy will be given to all three groups.
88851974|NCT01997567|Active Comparator|Grp 1 Ropivacaine Block|Group 1 consented subjects will receive for their hip arthroscopy procedures general anesthesia (sevoflurane) with single femoral and lateral femoral cutaneous nerve blocks under ultrasound guidance, with 20 ml solution for the femoral block and 10 ml for lateral femoral cutaneous block, for a total of 30 ml solution of ropivacaine 0.5% with epinephrine 1:200,000 (150mcg) as a tracer for intravascular injection (total 30 ml)
88851975|NCT01997567|Placebo Comparator|Grp 2 Placebo Block|Group 2 consented subjects will receive for their hip arthroscopy procedures general anesthesia (sevoflurane) with single femoral and lateral femoral cutaneous nerve blocks under ultrasound guidance, with 20 ml solution for the femoral block and 10 ml for lateral femoral cutaneous block, for a total of 30 ml solution of saline with epinephrine 1:200,000 (150 mcg) (total 30 ml)
88851976|NCT03742973|Experimental|Baricitinib Cohort A|Participants received 2 milligram (mg) of Baricitinib tablet orally once a day for 12 weeks. Cohort A is not reported due to protection of personal identifiable information based on enrollment futility.
88851977|NCT03742973|Placebo Comparator|Placebo Cohort A|Participants received placebo orally once a day for 12 weeks. Cohort A is not reported due to protection of personal identifiable information based on enrollment futility.
88851978|NCT03742973|Experimental|Baricitinib Cohort B|Participants received 4 mg of Baricitinib orally once a day for 12 weeks. Cohort B was planned, but due to enrollment futility, the strategic decision was made to terminate the study.
88851979|NCT03742973|Placebo Comparator|Placebo Cohort B|Placebo administered orally. Cohort B was planned, but due enrollment futility, the strategic decision was made to terminate the study.
88851980|NCT03742427|Experimental|effect of c-collar in optic nerve sheath diameter|Comparing the effect of c-collar in minor head trauma patients by using optic nerve sheath diameter ultrasonography
88851981|NCT03741725|Experimental|Pay-it-forward|First, participants will be provided a brief introduction to gonorrhea and chlamydia testing. Then, participants will be offered a gift of free gonorrhea and chlamydia testing made available by donations from previous testers, and asked whether they would like to donate money (pay-it-forward) for future men to receive the same option.
88851982|NCT03741725|Experimental|Pay-what-you-want|First, participants will be provided a brief introduction to gonorrhea and chlamydia testing. Then, participants will be offered gonorrhoea and chlamydia testing and told that they can decide and pay any desired amount after receiving the test.
89182635|NCT06238830||GROUP M|In patients undergoing elective Laparoscopic Cholecystectomy Surgery, after routine anesthesia induction, a magnesium loading dose of 30 mg/kg will be administered intravenously. Subsequently, a magnesium infusion will be initiated at a rate of 10 mg/kg/hour. Afterward, in the supine position, necessary field preparation and ultrasound (USG) setup will be conducted to administer the External Oblique Intercostal Plane (EOIP) block.The procedure will be applied unilaterally. After desufflation, patients will receive 50 mg dexketoprofen as standard analgesia administered intravenously as a non-steroidal anti-inflammatory drug (NSAID).
89182636|NCT06238830||GROUP K|"As part of standard analgesia, 50 mg dexketoprofen, administered intravenously as a non-steroidal anti-inflammatory drug (NSAID), will be applied, and these patients will be considered as the control group.~All patients will undergo general anesthesia induction with 1 µg/kg fentanyl, 2-3 mg/kg propofol, and 0.6 mg/kg rocuronium bromide. During anesthesia maintenance, a mixture of 50% O2 and air will be administered, and sevoflurane will be used at a minimum alveolar concentration of 0.8 (with a target MAC value of 0.8-1.2). Additionally, remifentanil will be administered at a rate of 0.01-0.2 mcg/kg/min. The remifentanil dose range will be increased if the patient&#39;s Nociceptive Level (NOL) value remains elevated for 2 minutes when it exceeds 25. BIS monitoring will be performed for all patients, and the BIS value will be maintained between 40-50."
89182637|NCT06238817|Experimental|VC Period: Ruxolitinib 1.5% Cream BID|Participants received ruxolitinib 1.5% cream, applied topically to the affected areas as a thin film twice daily (BID) from Day 1 to Week 8 during the Vehicle Control (VC) Period. Participants applied cream BID to areas identified at Baseline even if the areas improved.
89378692|NCT02339194|No Intervention|Traditional protocol|"The importance of a second impression for denture fabrication technique will be tested for patients presenting severely resorbed mandibular alveolar bones according to the following steps:~Maxillary and mandibular casts obtained by using irreversible hydrocolloid in stainless steel stock trays for maxillary record base and mandibular custom tray fabrication.~Mandibular second impression with border molding using compound and impression rubber in custom tray.~Record bases adjustments without facebow transfer. Casts will be mounted in semi-adjustable articulator using standardized measures and artificial teeth will be selected.~Trial dentures will be evaluated for esthetics and maxillomandibular relationship.~Finished dentures insertion."
89378693|NCT02339116|Experimental|Folfoxiri/bev --> folfoxiri/bev|"FOLFOXIRI plus bev (to be repeated every 2 weeks for a maximum of 8 cycles):~Bevacizumab 5 mg/kg iv over 30 minutes, day 1 Irinotecan 165 mg/sqm iv over 60 minutes, day 1 Oxaliplatin 85 mg/sqm iv over 2 hours, day 1 L-Leucovorin 200 mg/sqm iv over 2 hours, day 1 5-fluorouracil 3200 mg/sqm 48 h-continuous infusion, starting on day 1 At the time of disease progression, patients will re-introduce FOLFOXIRI plus bev at the same doses and schedule previously tolerated, for a maximum of 8 cycles. If no progression occurs during FOLFOXIRI plus bev, patients will receive maintenance 5-FU/LV plus bev at the same dose used in the last cycle of the induction treatment."
89378694|NCT02339116|Active Comparator|folfox/bev-->folfiri/bev|"mFOLFOX-6 plus bev (to be repeated every 2 weeks for a maximum of 8 cycles) Bevacizumab 5 mg/kg iv over 30 minutes, day 1 Oxaliplatin 85 mg/sqm iv over 2 hours, day 1 L-Leucovorin 200 mg/sqm iv over 2 hours, day 1 5-fluoruracil 400 mg/sqm iv bolus, day 1 5-fluoruracil 2400 mg/sqm 48 h-continuous infusion, starting on day 1~At the time of disease progression patients will receive FOLFIRI plus bev (to be repeated every 2 weeks for a maximum of 8 cycles):~Bevacizumab 5 mg/kg iv over 30 minutes, day 1 Irinotecan 180 mg/sqm iv over 2 hours, day 1 L-Leucovorin 200 mg/sqm iv over 2 hours, day 1 5-fluoruracil 400 mg/sqm iv bolus, day 1 5-fluoruracil 2400 mg/sqm 48 h-continuous infusion."
89378695|NCT02349100||Treated group|Patient group treated with Nellix Endoprosthesis.
89378696|NCT02348710|Experimental|exercise outcome expectation workbook|Intervention arm participants will receive: 1) the ACS exercise and diet guidelines; and 2) an exercise outcome expectation workbook. The workbook contains self-directed activities to increase OE importance, certainty, and accessibility. The workbook will aim to make participants aware of the breadth and depth of OEs by first providing a global overview of the many positive exercise outcomes breast cancer survivors may experience. Importance will be increased through elaboration of why outcomes are important to the participant; and certainty will be increased by narrative messages from other breast cancer survivors and an oncologist. Accessibility will be increased by having the participant think about the association between exercise and its outcomes.
89378697|NCT02348710|Active Comparator|diet workbook|Attention control participants will receive via mail 1) the ACS exercise and diet guidelines; and 2) a diet workbook. The diet workbook contains the same activities as the exercise outcome expectation workbook but is focused on diet instead of exercise.
89378698|NCT03964402||Control|Control arm, i.e., as per standard procedures
89378699|NCT03964402||Experimental|Experimental arm, i.e. investigational product
88851983|NCT03741725|No Intervention|Standard of care|First, participants will be provided a brief introduction to gonorrhea and chlamydia testing. Then, participants will be offered gonorrhoea and chlamydia testing at the standard patient price.
88851984|NCT00825227|Active Comparator|Patient responses to 150 mg/day armodafinil|"150 mg/day armodafinil~taxane chemotherapy treatment alone or in combination with other agents"
88851985|NCT00825227|Placebo Comparator|Patient responses to placebo|"placebo~taxane chemotherapy treatment alone or in combination with other agents"
88851986|NCT01978535|Experimental|Iron infusion|Iron Sucrose (Venofer (R))
88851987|NCT01978535|Placebo Comparator|Normal saline infusion|Equal volume to intervention of normal saline
88851988|NCT00808769|Active Comparator|1|Zegerid®
88851989|NCT00808769|Experimental|2|Prilosec OTC®
88851990|NCT00378131|Placebo Comparator|1|
88851991|NCT00378131|Experimental|2|RC-1291 50mg
88851992|NCT00378131|Experimental|3|RC-1291 100mg
88851993|NCT01974635|Experimental|AMES Therapy and Diagnostic|During treatment, the AMES device rotates the hand, into flexion and extension, while the patient assists with this motion,and while the lengthening muscle(s) are vibrated mechanically. At the end of the treatment, several diagnostic tests are performed to measure the participant's level of proprioceptive perception. This study provides for 25 AMES treatments and diagnostic tests over 8-13 weeks, at a rate of 2-3 sessions per week.
88851994|NCT00379067|Active Comparator|1|Tamsulosin OCAS tablet
88851995|NCT00379067|Placebo Comparator|2|Placebo tablet
88851996|NCT01937507|Experimental|HAI with FOLFOX|Hepatic Artery Infusion with Oxaliplatin, 5FU, and Folinic Acid
88851997|NCT00379223|No Intervention|1|Standard treatment of central retinal vein occlusion : the rheologic correction
88851998|NCT00379223|Experimental|2|Standard treatment of central retinal vein occlusion : the rheologic correction and surgery associating pars plana vitrectomy and radial optic neurotomy
88851999|NCT01938833|Experimental|Treatment (Romidepsin and Abraxane)|Patients receive abraxane IV over 30 minutes and romidepsin IV over 60 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88852000|NCT01893359|Experimental|LASIK followed by Cross-linking (Continuous Wave)|Following LASIK, the corneal bed will be thoroughly coated with five drops of riboflavin ophthalmic solution, rinsed with saline solution, and the corneal flap repositioned. The eye will then be irradiated at 30 mW/cm2 for 2 minutes continuous UVA.
88852001|NCT01893359|Experimental|LASIK followed by Cross-linking (Pulsed)|Following LASIK, the corneal bed will be thoroughly coated with five drops of riboflavin ophthalmic solution, rinsed with saline solution, and the corneal flap repositioned. The eye will then be irradiated at 30 mW/cm2 for 3 minutes pulsed UVA with an on/off cycle of 2 seconds UVA on/1 second UVA off.
89182638|NCT06238817|Placebo Comparator|VC Period: Vehicle Cream BID|Participants received vehicle cream, applied topically to the affected areas as a thin film twice daily (BID) from Day 1 to Week 8 during the VC Period. Participants applied cream BID to areas identified at Baseline even if the areas improved.
89182639|NCT06238817|Experimental|VC Extension Period/Escape Arm: Ruxolitinib 1.5% Cream BID|Participants who applied ruxolitinib 1.5% cream during VC Period, continued applying ruxolitinib 1.5% cream topically to the affected areas as a thin film BID from Week 8 to 24 during the Vehicle Control Extension (VCE) Period. Participants stopped treatment 3 days after lesions disappeared and restarted at the first sign of recurrence.
89182640|NCT06238817|Placebo Comparator|VC Extension Period/Escape Arm: Vehicle Cream BID|Participants who applied vehicle cream during the VC Period, continued applying vehicle cream as a thin film twice daily (BID) from Weeks 8 to 24 during the VCE Period. Participants applied cream BID to areas identified at Baseline even if the areas improved. Participants will be eligible to enter the ruxolitinib 1.5% cream open-label escape arm as defined in the protocol.
89182641|NCT06238817|Experimental|VC Extension Period: Ruxolitinib 1.5% cream open-label escape arm|Participants received ruxolitinib 1.5% cream, applied topically to the affected areas as a thin film twice daily (BID) during the VCE Period. Participants applied cream BID to areas identified at Baseline even if the areas improved.
89182642|NCT06238804||fracture types|A3.1, A3.2, A3.3
89182643|NCT06238791||Chronic venous disease group|
89182644|NCT06238791||Chronic venous disease and lipedema group|
89182645|NCT06238752|Experimental|first-line treatment with the combination of apatinib, immune checkpoint inhibitor and chemotherapy|Patients received 8 cycles of apatinib (250 mg, qd, d1-14), tislelizumab(200 mg d1), and oxaliplatin (130 mg/m2, d1) plus oral capecitabine (1000 mg/m2, bid, d1-14) every 3 weeks, with a maintenance therapy with apatinib plus tislelizumab for a maximum of 1 year. Homogeneous patients receiving ICIs combined with chemotherapy at the same time were deemed as the control group for efficacy.
89182646|NCT06238739|Placebo Comparator|Group 1|Standard measures administered to patients
89182647|NCT06238739|Experimental|Group 2|Passive measures
89182648|NCT06238739|Experimental|Group 3|Active measures (Blanketrol)
89182649|NCT06238739|Experimental|Group 4|Active measures (HotDog)
89182650|NCT06238713|Experimental|Single-port extraperitoneal RARP|Single-port extraperitoneal robotic-assisted radical prostatectomy with Vattikuti Institute Prostatectomy (VIP) techniques
89182651|NCT06238713|Active Comparator|Multi-port transperitoneal RARP|Multi-port transperitoneal RARP with bilateral intrafascial nerve-sparing techniques
89182652|NCT06238700|Experimental|pregnenolone|Participants will take 250mg of pregnenolone twice per day (daily total=500mg) for four weeks
89182653|NCT06238700|Placebo Comparator|placebo|Participants will take placebo twice per day for four weeks
89182654|NCT06238687|Experimental|Cohort 1(Phase I)|STRO-002 3.5 mg/kg Open Lable
89182655|NCT06238687|Experimental|Cohort 2(Phase I)|STRO-002 4.3 mg/kg Open Lable
89182656|NCT06238687|Experimental|Cohort 3(Phase I)|STRO-002 5.2 mg/kg Open Lable
89182657|NCT06238687|Experimental|Cohort A(Phase IIa)|Recurrent and/or progressive ovarian epithelial cancer, confirmed by immunohistochemistry [IHC] testing with FolRα positive expression (TPS ≥ 75%).
89182658|NCT06238687|Experimental|Cohort B(Phase IIa)|Recurrent and/or progressive ovarian epithelial cancer, confirmed by IHC testing with FolRα positive expression (25% ≤ TPS < 75%).
89182659|NCT06238687|Experimental|Cohort C(Phase IIa)|Recurrent and/or progressive endometrial cancer, confirmed by IHC testing with FolRα positive expression (TPS ≥ 25%).
89182660|NCT06238687|Experimental|Cohort D(Phase IIa)|Recurrent and/or progressive non-small-cell lung cancer, confirmed by IHC testing with FolRα positive expression (TPS ≥ 25%).
89182661|NCT06238687|Experimental|Cohort E(Phase IIa)|Recurrent and/or progressive triple-negative breast cancer, confirmed by IHC testing with FolRα positive expression (TPS ≥ 25%).
89182662|NCT06238674|Experimental|Individualised energy and protein delivery guided by indirect calorimetry and nitrogen balance|Energy delivery will be guided by indirect calorimetry with the aim to meet 70-100% of the most recent energy expenditure measurement and protein delivery guided by nitrogen balance with the aim to positive nitrogen balance with the maximum of 1.3 g/kg/d after 72 hours of admission and continue for total of 14 days by enteral or parenteral feeding routes
89182663|NCT06238674|Active Comparator|Standard care nutrition|Energy and protein delivery will be according to predictive equation estimates and usual site practice along enteral feeding
89182664|NCT06238661|Experimental|Subjects with PSA ≥ 3 ng/ml|"Urologic examination~Risk calculation (ERSPC no.6)~Magnetic resonance imaging~(optional) biopsy"
89378700|NCT02338804|Active Comparator|control|Patients in this group will be receiving standard therapy according to National Comprehensive Cancer Network (NCCN) guide line
89378701|NCT02338804|Experimental|MV+control|Patients in this group will be receiving both standard therapy according to NCCN guide line and simultaneous injection of mix vaccine (MV).
89378702|NCT04824274|Experimental|Transversus abdominis plane block and intrathecal fentanyl|Patients will receive spinal anesthesia with 0.5% bupivacaine 9 mg + fentanyl 10 mcg. Following the completion of surgery, ultrasound-guided bilateral transversus abdominis plane block will be done with 0.375% ropivacaine 15 ml per each side.
89378703|NCT04824274|Active Comparator|Intrathecal morphine|Patients will receive spinal anesthesia with 0.5% bupivacaine 9 mg + morphine 75 mcg. Following the completion of surgery, sham block will be done using normal saline.
89378704|NCT03112018|Active Comparator|Standard care|"Data strengthening~modified Safe Childbirth Checklist (mSCC) implementation"
89378705|NCT03112018|Experimental|Enhanced care (intervention)|"Data strengthening~modified Safe Childbirth Checklist (mSCC) implementation~Health provider training (PRONTO)~Quality Improvement (QI) Cycles"
89378706|NCT03112096|Experimental|Cognitively Healthy Subjects|Cognitively healthy subjects will receive an IV injection, [18F]THK-5351 injection
89378707|NCT03112096|Experimental|Alzheimer's Disease Subjects|Cognitively healthy subjects will receive an IV injection, [18F]THK-5351 injection
89378708|NCT02509494|Experimental|Stage 1: Active vaccination|Ad26.ZEBOV will be administered as a 0.5 milliliter (mL) intramuscular (IM) injection (Dose 1); MVA-BN-Filo will be administered as a 0.5 mL IM injection (Dose 2). The booster vaccination using Ad26.ZEBOV will be administered as a 0.5 mL IM injection (2 years post Dose 1).
89378709|NCT02509494|Experimental|Stage 2: Active vaccination|Ad26.ZEBOV will be administered as a 0.5 mL IM injection (Dose 1); MVA-BN-Filo will be administered as a 0.5 mL IM injection (Dose 2).
89378710|NCT02509494|Experimental|Stage 2: Active vaccination for children|Ad26.ZEBOV will be administered as a 0.5 mL IM injection (Dose 1); MVA-BN-Filo will be administered as a 0.5 mL IM injection (Dose 2). Children aged less than 2 years at randomization will receive a booster dose of vaccination at 3 months post Dose 2 with Placebo.
89378711|NCT02509494|Active Comparator|Stage 2: Control vaccination|MenACWY will be administered as a 0.5 mL IM injection on Day 1 (Dose 1) and placebo on Day 57 (Dose 2).
88852002|NCT01893359|Placebo Comparator|LASIK Only|Eyes assigned to this arm will receive standard LASIK with no cross-linking.
88852003|NCT05313503|Experimental|Ketogenic Diet|Ketogenic diet
89378712|NCT02509494|Active Comparator|Stage 2: Control vaccination for children|MenACWY will be administered as a 0.5 mL IM injection on Day 1 (Dose 1) and placebo on Day 57 (Dose 2). Children aged less than 2 years at randomization will receive a booster dose of MenACWY vaccination at 3 months post Dose 2 with MenACWY.
89378713|NCT02348554|Experimental|Controlled conditions|Volunteers were asked to perform several activities such as walking at different paces, running, sitting, standing still or taking public transportation for about 1h30 They wore 3 research sensors that estimated energy expenditure: Fitmate, Armband and Actiheart. They also wore smartphones (in front pant pockets) that collected accelerometry data.
89378714|NCT02348554|Experimental|Free-living conditions|Volunteers were asked to wear sensors during about 12 hours, one day. They wore 2 research sensors that estimated energy expenditure: Armband and Actiheart. They also wore smartphones (in front pant pockets) that collected accelerometry data.
89378715|NCT02348788|Active Comparator|Artemether-lumefantrine + Primaquine|"1 tablet = 20mg artemether and 120mg lumefantrine. Dosing at 0, 8, 24, 36, 48 and 60 hours. Dose according to bodyweight; >35kg = 2 tablets, 26-35kg = 3 tablets, 16-25kg = 2 tablets, >10-15kg = 1 tablet.~Primaquine = 7.5mg tablet. Dosing daily for 14 days from Day 0. Dose according to bodyweight; >35kg = 30mg, <35kg = 0.5mg/kg"
89378716|NCT02348788|Active Comparator|Chloroquine + Primaquine|"1 tablet contains 155mg chloroquine base. Adult dose (>35kg); 620mg (4 tablets) at 0 hours, and 310mg (2 tablets) at 6-8, 24 and 48 hours.~Child dose (>10-35kg); 10mg/kg at 0 hours, and 5mg/kg at 6-8, 24 and 48 hours. Primaquine = 7.5mg tablet. Dosing daily for 14 days from Day 0. Dose according to bodyweight; >35kg = 30mg, 10-35kg = 0.5mg/kg"
89378717|NCT03147976|Experimental|AMG 337|AMG 337 in subjects with advanced or metastatic solid tumors that overexpress MET or harbor METex14del mutations
89378718|NCT05763108||Recurrent patellar dislocation group|50 patients with recurrent patellar dislocation and without any genetic disorders.
89378719|NCT05763108||Patients without joint hipermobility|200 patients without recurrent patellar dislocation and genetic disorders.
89378720|NCT04811482|Experimental|Intervention Group|This study consists of one arm, an intervention group.
89378721|NCT02337010|Active Comparator|Control|In the control group if the mean arterial pressure fall below 60 mm Hg and the central venous pressure (CVP) is low fluid bolus is administered if the central venous pressure is in normal range vasopressor is given.
89378722|NCT02337010|Experimental|CeVOX|In the ScvO2 group patients receive interventions in two options: if the ScvO2 fall below 75% or more than 3% or if the mean arterial pressure fall below 60 mm Hg. In the former case the mean arterial pressure in the latter the ScvO2 values determined if tha patient received fluid or vasopressor or both.
89378723|NCT02338570|Other|Everolimus|All patients will receive everolimus 10 mg orally per day. Treatment will continue until progression, unacceptable toxicity, patient refusal or medical decision
89378724|NCT02348320|Experimental|Personalized polyepitope DNA vaccine|Participants will be treated by electroporation with 4 mg of a personalized polyepitope DNA vaccine at Day 1, Day 29 (+/1- 7 days), and Day 57 (+/- 7 days) with at least 21 days between injection days. Each DNA vaccination with be 4 mg vaccine administered intramuscularly using a TriGrid electroporation device.
89378725|NCT03147664||Pediatric Pompe patients|"Visit 1: Patients arrived at that hospital at 7:00 am, vital signs were collected and a complete neuromuscular evaluation was carried out (gross motor function measure score sheet (GMFM-88), 6MWT, pre-CPET questionnaire (demographics, physical activity level, risk assessment, asthma/atopy/smoking history, family history), pulmonary function tests and CPET. Following the evaluation, at approximately 9 am, the patient started infusion of ERT.~Visit 2: Two days following visit 1, the patient arrived at the hospital at 2:00 pm, vital signs were assessed and GMFM-88, 6MWT, pulmonary function tests, and CPET were performed."
89378726|NCT02337088|Active Comparator|30 seconds|For subjects in the 30 second arm, the umbilical cord will be clamped at 30 seconds after delivery.
89378727|NCT02337088|Experimental|60 seconds|For subjects in the 60 second arm, the umbilical cord will be clamped at 60 seconds after delivery.
89378728|NCT05114902||PCV13 Non-vaccinated Settting|Pneumococcal vaccine-naïve children at the PCMC
88852004|NCT00795665|Experimental|Bevacizumab and Carmustine|
89378729|NCT05114902||PCV13 Vaccinated Setting|Pneumococcal vaccine-exposed children at the SPMC
89378730|NCT02338414|Other|Romiplostim|Patients receiving romiplostim due to ITP
89378731|NCT02336776|Experimental|Functional electrical stimulation group|Functional electrical stimulation: 80 Hz frequency, 0.4 ms pulse, 10 s time on, 50-20s time off, intensity as patient tolerance, total session time ranged from 20 to 34 minutes.
88852005|NCT00791843|Experimental|GHRH and placebo|Everyone will receive 12 weeks of GHRH and 12 weeks of Placebo
88852006|NCT01836809|Experimental|Total Artificial Heart|Nesiritide
89378732|NCT02336776|No Intervention|Control group|The patients in this group were evaluated at baseline and reassessed after eight weeks of follow-up.
89378733|NCT02336854|Experimental|Tacrobell tab. 2mg|2mg/tablet, PO, 1 tablet once daily for Period I & II D1(crossover)
89378734|NCT02336854|Active Comparator|Prograf cap. 2mg|1mg/capsule, PO, 2 capsule once daily for Period I & II D1(crossover)
89378735|NCT03147898||Group 1: Toddlers|Non-intervention observational study. Toddlers will receive wP-containing combination vaccine as part of the national immunization schedule
89378736|NCT03147898||Group 2: Toddlers|Non-intervention observational study. Toddlers will receive an aP-containing combination vaccine as part of the national immunization schedule.
89378737|NCT03147898||Group 3: Preschooler|Non-intervention observational study. Preschoolers will receive a wP-containing combination vaccine as part of the national immunization schedule.
89378738|NCT03147898||Group 4: Preschooler|Non-intervention observational study. Preschoolers will receive an aP-containing combination vaccine as part of the national immunization schedule.
89378739|NCT02338024|Experimental|MARTAS intervention|Structured motivational sessions and further communication between linkage coordinators and HIV-positive patients focused on engagement in HIV medical care.
89378740|NCT02338024|No Intervention|Standard of care|"Oral referrals to a network of government AIDS Centers or their departments (Trust offices) located in each study region."
88852007|NCT01836809|Placebo Comparator|Total Artificial Heart: Placebo|Control arm for subjects receiving the Total Artificial Heart and randomized to receive placebo
88852008|NCT01836809|Active Comparator|LVAD: Nesiritide|Active arm of the LVAD group
88852009|NCT01836809|Placebo Comparator|LVAD: Placebo|Control arm for subjects receiving LVAD and randomized to placebo
88852010|NCT00780455|Experimental|Interferon beta-1b, FRP within 15 days after randomization|Interferon beta-1b (Betaseron, BAY86-5046) 250 microgram (8 MUI), sub-cutaneous, administration every other day, Participants starting the 6 weeks functional rehabilitation protocol (FRP) within 15 days after randomization
88852011|NCT00780455|Experimental|Interferon beta-1b, FRP about 6 weeks after randomization|Interferon beta-1b (Betaseron, BAY86-5046) 250 microgram (8 MUI), sub-cutaneous, administration every other day, Participants starting the 6 weeks functional rehabilitation protocol (FRP) about 6 weeks after randomization
88852012|NCT00755261|Experimental|Avastin and Doxorubicin|Patients will be treated with Avastin 15 mg/kg IV infusion plus doxorubicin 60 mg/M2 (body surface area) IV 6-hour infusion on Day 1 of each 21-day treatment cycle. Dose reductions/modifications will be applied as indicated by toxicities and/or patient tolerance.
88852013|NCT00748085|Experimental|Cryospray Ablation|Cryospray Ablation 4, 5-second spray cycles
88852014|NCT03725033|Experimental|Subetta|Tablet for oral use. 2 tablets twice daily. The tablets should be held in mouth until completely dissolved 15 min prior to meal.
88852015|NCT03725033|Placebo Comparator|Placebo|Tablet for oral use. 2 tablets twice daily. The tablets should be held in mouth until completely dissolved 15 min prior to meal.
88852016|NCT03724877||Subjects with Chronic obstructive pulmonary disease (COPD)|
88852017|NCT03724253|Experimental|Phase II dosimetry group|All eligible participants were to receive recommended dose of [68Ga]-NeoBOMB1 of 3 Mega Becquerel (MBq)/Kg (+/- 10%) [but not more than 250 and not less than 150 MBq. The maximum peptide mass administered was 50 microgram (µg)].
88852018|NCT03724253|Experimental|Phase II non-dosimetry group|All eligible participants were to receive recommended dose of [68Ga]-NeoBOMB1 of 3 Mega Becquerel (MBq)/Kg (+/- 10%) [but not more than 250 and not less than 150 MBq. The maximum peptide mass administered was 50 microgram (µg)].
88852019|NCT05313113|Experimental|Experimental group|In the first stage, pregnant women were trained to implement fetal movement count and position tracking. The training was provided face to face and lasted 30-45 minutes. How to determine the position of the fetus and I. and II. Leopold maneuvers are also taught. In the second stage, the pregnant women were interviewed twice a week by telephone.Thus, it was provided that pregnant women had fetal tracked at least once a day, at any time of the day, when the fetus was awake and most active, in a suitable position and a comfortable environment, for at least 15-20 minutes continuously for four weeks. Pregnant women phoned the researcher when they wanted. At the same time, the participants continued to their routine prenatal care.
88852020|NCT05313113|No Intervention|Control Group|The pregnant women continued to their routine prenatal care. No intervention was applied to the pregnant women in addition to their routine prenatal care.The pregnant women were called about whether continuing their routine care or having any problems during the research.
88852021|NCT01809899|Experimental|Enhanced Consent Procedure|Participants in this group will receive an enhanced consent that will be an hour longer than usual.
88852022|NCT01809899|Active Comparator|Consent as Usual Procedure|Participants in this group will receive a normal consent procedure to the study
88852023|NCT00746603|Experimental|A Intervention Arm|Escalating dose of simvastatin in subjects who are survivors of Hodgkin Lymphoma
88852024|NCT05312957|Active Comparator|Group ESP|The probe was placed craniocaudally in the parasagittal plane approximately 3 cm lateral to the T5 spinous process. The T5 transverse process is detected and When the block needle touched the transverse process,Then, 20 ml of 0.25% bupivacaine was administered to this area, and an ESP block was applied
89378741|NCT02338180|No Intervention|Control group A|Children with no caries lesion on adjacent surfaces of second primary molar and first permanent molar
89378742|NCT02338180|Experimental|Group B Preventive sealant|Children with active caries lesion on distal surfaces of second primary molar and sound mesial surface of first permanent molar. In every children a split mouth design was applied, in one mesial surfaces of first molar randomize selected received a proximal preventive sealants, and the other remain as a control
89378743|NCT02338180|Experimental|Group C Therapeutic sealant|Children with active caries lesion on distal surfaces of second primary molar and active lesion on mesial surface of first permanent molar. In every children a split mouth design was applied, in one mesial surfaces of first molar randomize selected received proximal therapeutic sealant, and the other remain as a control
89378744|NCT02039440|Other|Single arm|1 blood draw
89378745|NCT02332330|Experimental|VEST|
89378746|NCT02338102|Experimental|Treatment Group|Subjects in this group will perform twice daily nasal irrigations. Nasal irrigations will be performed by using premeasured salt packets mixed with distilled water in NeilMed irrigation bottles. The subject will be instructed to lean forward over the sink, place the bottle up to the nostril, and hold their breath while gently squeezing the bottle. One bottle is used to irrigate both nostrils, using half the solution on each side.
89378747|NCT02338102|No Intervention|Control Group|Subjects randomized to this arm receive no intervention.
89378748|NCT02332174|Experimental|200-mg group|Ten healthy subjects were administered a single oral dose of 200 mg rufinamide tablets in fasted and fed state at day 1 and then received repeated oral doses of rufinamide (200 mg) once daily for 6 days.
89378749|NCT02332174|Experimental|400-mg group|Ten healthy subjects were administered a single oral dose of 400 mg rufinamide tablets in fasted state.
89378750|NCT02332174|Experimental|800-mg group|Ten healthy subjects were administered a single oral dose of 800 mg rufinamide tablets in fasted state.
89378751|NCT02332174|Experimental|1200-mg group|Ten healthy subjects were administered a single oral dose of 1200 mg rufinamide tablets in fasted state.
89378752|NCT02338258|Experimental|The Anti-rotational plate group|The method was used to control the rotational unstabilization at the fracture site
89378753|NCT02338258|Placebo Comparator|Exchanged Intramedullary nailing group|the method Provided the axial and rotational stability
89378754|NCT02332252|Active Comparator|Scalpel|Skin incision performed with a scalpel during cesarean section.
89378755|NCT02332252|Experimental|Electrocautery|Skin incision performed with an electrocautery during cesarean section.
88852025|NCT05312957|No Intervention|Group Control|Group Control: Tramadol HCL was administered from vein with a patient-controlled analgesia device after extubation.
89378756|NCT03493451|Experimental|Cohort 1: ENKTL|Participants with relapsed or refractory (R/R) extranodal natural killer-/T-cell lymphoma (ENKTL; nasal or non-nasal type) were treated with tislelizumab 200 mg intravenously (IV) on Day 1 of each cycle until disease progression, intolerable toxicity, or treatment discontinuation for any other reason (21 days per cycle)
89378757|NCT03493451|Experimental|Cohort 2: PTCL-NOS, AITL, and ALCL|Participants with other R/R mature T-cell neoplasms [limited to peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), and anaplastic large-cell lymphoma (ALCL)] were treated with tislelizumab 200 mg intravenously (IV) on Day 1 of each cycle until disease progression, intolerable toxicity, or treatment discontinuation for any other reason (21 days per cycle)
88852026|NCT00716807|Experimental|TMD 1|
88852027|NCT00716807|Placebo Comparator|TMD 2|
88852028|NCT00716807|Experimental|BMS 1|
89378758|NCT03493451|Experimental|Cohort 3: MF and SS|Participants with R/R cutaneous T-cell lymphoma [limited to mycosis fungoides (MF) and Sèzary syndrome (SS)] were treated with tislelizumab 200 mg intravenously (IV) on Day 1 of each cycle until disease progression, intolerable toxicity, or treatment discontinuation for any other reason (21 days per cycle)
89378759|NCT02332096||Patients with Atrial Fibrillation|We propose to enroll 100 patients with symptomatic paroxysmal or persistent AF without a known diagnosis of sleep apnea who are referred for an AF ablation procedure at BIDMC. All enrolled subjects will undergo pre-procedure screening sleep study using the Berlin questionnaire and home sleep study using an FDA approved home sleep testing device (HST).
89378760|NCT02337790||Cohort 1|Subjects will have a pacemaker, implanted cardioverter-defibrillator, or ventricular assist device.
88852029|NCT00716807|Placebo Comparator|BMS 2|
89378761|NCT03726125|Experimental|LY3374849 - SC (Part A)|Single subcutaneous (SC) dose of LY3374849
89378762|NCT03726125|Experimental|Insulin Degludec - SC (Part A)|Single SC dose of insulin degludec
89378763|NCT03726125|Experimental|LY3374849 - SC (Part B)|Single dose of LY3374849 administered SC in up to three of three study periods
89378764|NCT03726125|Experimental|LY3374849 - IV (Part B)|Single dose of LY3374849 administered intravenously (IV) in up to one of three study periods
89378765|NCT03726125|Experimental|LY3374849 - IV (Part C)|Single IV dose of LY3374849 in one of two study periods
89378766|NCT03726125|Experimental|Insulin Degludec - IV (Part C)|Single IV dose of insulin degludec in one of two study periods
89378767|NCT02337868|Experimental|High Dose Expanded|15 subjects will receive 4 mcg of HydroVax-001 IM and 4 subjects will receive placebo IM on Days 1 and 29.
89378768|NCT02337868|Experimental|High Dose Sentinel|5 subjects will receive 4 mcg of HydroVax-001 IM and 1 subject will receive placebo IM on Days 1 and 29.
89378769|NCT02337868|Experimental|Low Dose Expanded|15 subjects will receive 1 mcg of HydroVax-001 IM and 4 subjects will receive placebo IM on Days 1 and 29.
89378770|NCT02337868|Experimental|Low Dose Sentinel|5 subjects will receive 1 mcg intramuscularly (IM) of HydroVax-001 and 1 subject will receive placebo IM on Days 1 and 29.
89378771|NCT02336620|Experimental|Ringer Acetate|Ringer acetate 10-20 ml/kg IV bolus when patient need fluid bolus
89378772|NCT02336620|Active Comparator|Normal saline|NSS 10-20 ml/kg IV bolus when patient need fluid bolus
89378773|NCT03725969|Experimental|Healthy individuals (camel milk)|
89378774|NCT03725969|Experimental|Healthy individuals (cow milk)|
88852030|NCT03461705|Experimental|Primary|All patients who are referred for coronary angiography and require physiological assessment of intermediate lesions will have both RFR and iFR measured during their standard of care procedure. Both the RFR wire (St. Jude Medical (SJM) Aeris Pressure Wire System) and iFR (Volcano Verrata Pressure Wire) wire will be advanced across the lesion with the sensor located at least 3 cm distal from the lesion.
88852031|NCT03426137|Active Comparator|Full Dose (FD)|Participants in the FD arm will receive NSAIDs and Oxycodone (5mg).dosed in accordance with the Guidelines for Use from University of Maryland Shock Trauma Center.
88852032|NCT03426137|Placebo Comparator|PR (Partial Reinforcement)|Participants in this group will receive NSAIDs, Oxycodone (5mg), and placebo pills to reach a 50% reduction of the total intake of opioids.
88852033|NCT03426137|Placebo Comparator|C (Control)|Participants in this group will receive NSAIDs and placebo pills
88852034|NCT05283863|Experimental|high-frequency stimulation|Patients will randomly be assigned to receive sub-threshold high-frequency spinal cord stimulation for 2 weeks.
88852035|NCT05283863|Sham Comparator|placebo stimulation|Patients will randomly be assigned to receive sham spinal cord stimulation for 2 weeks.
88852036|NCT05283863|Active Comparator|conventional spinal cord stimulation|Patients will receive conventional spinal cord stimulation for 2 weeks prior to both the high-frequency or sham stimulation.
88852037|NCT01760993|Experimental|SPD489|
88852038|NCT00669461|Experimental|Patients|
88852039|NCT00673595|Active Comparator|Varenicline|Participants on this arm will receive varenicline tablets for 15 days.
88852040|NCT00673595|Placebo Comparator|Placebo|Participants on this arm will receive placebo tablets for 15 days.
88852041|NCT00670631|Experimental|Tandem autologous stem cell transplant|"Induction: DPACE(dexamethasone,cisplatin,doxorubicin,cyclophosphamide,etoposide) chemotherapy plus stem cell collection. Additional stem cell collection and/or chemotherapy may be required.~After collection, participants will receive dexamethasone x 4 days every 14 days.~Transplant 1: The transplant preparative regimen will be bortezomib/thalidomide/dexamethasone/melphalan.~Once recovered, participants start thalidomide daily and dexamethasone x 4 days every 21 days.~Consolidation (if administered): VDT-PACE(bortezomib,dexamethasone,thalidomide,cisplatin,doxorubicin,cyclophosphamide, etoposide) Transplant 2: 8 weeks to 6 months after the first transplant, participants will have the second transplant Maintenance: Year 1- VTD (bortezomib, thalidomide, dexamethasone) cycles. Year 2 - VCD (bortezomib, cyclophosphamide, dexamethasone)cycles."
88852042|NCT03248141||Hemophilia B|real world administration patterns and resource utilization implications
88852043|NCT03248141||Hemophilia A|real world administration patterns and resource utilization implications
88852044|NCT00378365|Experimental|1|Arsenic trioxide
88852045|NCT05313425||Ectoine Eye|The right eye of the studied group will be given 2% Ectoine containig , 0.2% sodium hyaluronate eye drops(Ectohylo) hourly.
88852046|NCT05313425||Control eye|The left eye of the studied group will be give Carboxymethyl cellulose, 0.2% sodium hyaluronate eye drops(Polyfresh Extra) hourly.
88852047|NCT01754987|Experimental|Ascorbic Acid + Sorafenib|"Drug: Vitamin C Other Names: Ascorbic Acid, Ascorbate~Dosage:~Vitamin C : 100 grams (infusion) Phase I: 3x a week for 8 weeks Phase II: 3x a week for 16 weeks Sorafenib: taken daily (oral)"
88852048|NCT01754987|Other|Sorafenib alone|Sorafenib: taken daily (oral)
88852049|NCT01732211|Experimental|PD 0360324|
88852050|NCT01732211|Placebo Comparator|Placebo|
88852051|NCT05600153|Placebo Comparator|primary breast approach|
88852052|NCT05600153|Experimental|axillary approach|
88852053|NCT00652457|Experimental|Memantine|Memantine 10 mg BID for three months
88852054|NCT00652457|Placebo Comparator|Placebo|Placebo 10 mg BID for three months
88852055|NCT00645359||Diffusion MRI|Patients will undergo a Diffusion MRI (dMRI) at baseline and 7 days.
88852056|NCT01681589|Sham Comparator|Control Group|The control group will receive sham-tDCS and computerized cognitive training also twice a week for 20 minutes for 6 weeks (12 training sessions).
88852057|NCT01681589|Experimental|Transcranial Direct Current Stimulator (TDCS)|The experimental group will receive active tDCS for 20 minutes and computerized cognitive training twice a week for 30 minutes for 6 weeks.
88852058|NCT01681589|Other|Healthy Control Group|Fifteen (15) healthy control subjects will participate.
88852059|NCT00625703|Experimental|A|
88852060|NCT00616577|Experimental|Group CB|Subjects in this arm will receive caudal ropivacaine 0.25% at a dose of 1ml/kg (maximum 15ml) with 1:200,000 epinephrine after induction of general anesthesia prior to surgical incision.
88852061|NCT00616577|Active Comparator|Group CA|Group CA (Caudal After-control group) will receive caudal ropivacaine 0.25% at a dose of 1ml/kg (maximum 15ml) with 1:200,000 epinephrine after completion of surgery but before emergence from anesthesia.
88852062|NCT00616577|Active Comparator|Group LIA|Group LIA (Local Infiltration After-control group) will receive local infiltration of ropivacaine 0.25% up to 1ml/kg (maximum 15ml) around the surgery site at the conclusion of surgery but before emergence from anesthesia.
88852063|NCT00616343|Active Comparator|Zonisamide|
88852064|NCT05599997|Experimental|Healthy|Age-, weight- and gender- matched control group of healthy volunteers received a single oral dose of 30 mg BAY1753011 tablet.
88852065|NCT05599997|Experimental|Mild renal impairment|Subjects with mild renal impairment received a single oral dose of 30 mg BAY1753011 tablet.
88852066|NCT05599997|Experimental|Moderate renal impairment|Subjects with moderate renal impairment received a single oral dose of 30 mg BAY1753011 tablet.
88852067|NCT05599997|Experimental|Severe renal impairment|Subjects with severe renal impairment received a single oral dose of 15 mg BAY1753011 tablet.
88852068|NCT05599919|Active Comparator|Patients with COVID-19 (confirmed by RT-PCR), not requiring hospitalization|Nitric oxide releasing solution delivered up to 3 times daily
88852069|NCT05599919|Placebo Comparator|COVID-19 symptoms|saline delivered up to 3 times daily morning, mid-day, and evening. Maximum volume delivered: 0.56 mL Saline @ 0.9%
89378775|NCT02336308|Active Comparator|Ketamine|Ketamine 50mg/1mL will be diluted with 9mL of normal saline to create 50mg in the 10mL syringe. Administered twice via intravenous administration; the first dose 10 minutes prior to the dressing change and a second dose 20-30 minutes into the dressing change procedure. The study will provide study drug for up to five dressing change procedures (i.e. ten total doses).
88852070|NCT05599607|Experimental|Probiotic group|Probiotic in capsule format administered orally. This probiotic product contains a mixture of strains of lactobacillus and bifidobacteria, called BTHS21, at concentrations equal to or greater than 1x109 cfu/dose.
89378776|NCT02336308|Placebo Comparator|Placebo|Placebo will be 10mL of normal saline in the syringe. Administered twice via intravenous administration; the first dose 10 minutes prior to the dressing change and a second dose 20-30 minutes into the dressing change procedure. The study will provide study drug for up to five dressing change procedures (i.e. ten total doses).
89378777|NCT02332018||Limb Torsion|adult patients, lower limb assessment retrospectively limb length and limb axis, torsion biplanar x-ray images
89378778|NCT02332018||Limb Length and Axis|adult patients, lower limb assessment prospectively limb length and limb axis biplanar x-ray images
88852071|NCT05599607|Placebo Comparator|Placebo group|Maltodextrin, masked in an identical and indistinguishable format to that of the probiotic
88852072|NCT01645709|Experimental|Verapamil|Subjects will be randomized to receive a single injection of IA Verapamil or IA Placebo at a ratio of 1:1.
88852073|NCT01645709|Placebo Comparator|Placebo|Subjects will be randomized to receive a single injection of IA Verapamil or IA Placebo at a ratio of 1:1.
88852074|NCT05599529||Pre-COVID|
88852075|NCT05599529||Peri-COVID|
88852076|NCT05270993|Active Comparator|Traditional Centre-based Cardiac Rehabilitation (CBCR) group|A 4-week centre-based outpatient cardiac rehabilitation programme. Participants will also receive all usual nursing, medical and follow-up service provided by the hospital.
88852077|NCT05270993|Experimental|I-CREST group|A 6-week home-based remote supervision cardiac rehabilitation programme with an I-CREST application and smartwatch. Participants will also receive all usual nursing, medical and follow-up service provided by the hospital.
88852078|NCT00608465|Active Comparator|Treatment A|Eplerenone (study drug)
88852079|NCT00608465|Active Comparator|Treatment B|Ramipril
88852080|NCT00379301|Active Comparator|Group 1|Pulmonary vein isolation (PVI) combined with ablation of documented non-PV triggers of atrial fibrillation --- (sites away from the pulmonary veins where consistent abnormal impulses that can trigger AF are identified during the procedure)
88852081|NCT00379301|Active Comparator|Group 2|PVI combined with ablation at documented sites of non-PV triggers, PLUS ablation at sites where non-PV triggers are commonly found
88852082|NCT00379301|Active Comparator|Group 3|PVI combined with ablation at documented sites of non-PV triggers and ablation at sites in the left atrium that demonstrate disorganized electrical impulses called complex fractionated electrograms (CFE).
89378779|NCT02332018||Spine|adult patients, spine assessment prospectively Cobb angles, plumbline biplanar x-ray images
89378780|NCT02336386|Experimental|CDD Plus Bortezomib|Patients will receive Bortezomib (1.3mg/m2) Subcutaneous injection on Days 1, 4,8,11 and plus dexamethasone 20 mg/day PO on Days 1-4, 9-12,Cyclophosphamide 300mg/m2 D1-4, Liposome doxorubicin 40mg D4 of each 28-day cycle; Patients may continue to receive treatment until PD or unacceptable toxicity.
89378781|NCT02336386|Active Comparator|CDD|Dexamethasone 20 mg/day PO on Days 1-4, 9-12,Cyclophosphamide 300mg/m2 D1-4, doxorubicin Dexamethasone 40mg D4 of each 28-day cycle; Patients may continue to receive treatment until PD or unacceptable toxicity
89378782|NCT02337712|Experimental|q.d. RT|q.d. RT (65 Gy in 26 fractions) to the chest and concurrent etoposide and cisplatin
89378783|NCT02337712|Active Comparator|b.i.d.RT|b.i.d.RT (45Gy in 30 fractions) to the chest and concurrent etoposide and cisplatin
89378784|NCT02337556|Experimental|Intervention Group|Peptamen Bariatric
89378785|NCT02337556|Active Comparator|Control Group|Replete
89378786|NCT04564534||Study cohort|"Adult (>18 years) patients with aortic stenosis in whom TAVI is planned and who perform their pre-TAVI work-up in our centre will be invited to undergo cognitive assessment using the MoCA at the time of their hospitalization for pre-TAVI work-up.~The MoCA will be administered by trained professionals with MoCA certification.~Clinical outcomes, as assessed by the VARC2 criteria, will be collected for all patients at 3 months after the TAVI procedure."
88852083|NCT01643525|Other|Nautilus NeuroWave Recording Arm|Nautilus NeuroWaveTM System
88852084|NCT01629329|Active Comparator|Aspirin, Acetaminophen, Caffeine pills|Patients receiving AAC(acetaminophen 250mg, aspirin 250mg and caffeine 65mg in each tablet)will receive 2 pills with active compound and placebo syringe with 2 ml of saline.
88852085|NCT01629329|Active Comparator|Prochlorperazine 10mg|Patients will receive active compound of Prochlorperazine 10mg via IV syringe and 2 unmarked placebo pills
88852086|NCT01606709|Experimental|GnRH agonist trigger|Induction of oocyte maturation with GnRH agonist
88852087|NCT01606709|Active Comparator|hCG trigger|Induction of oocyte maturation with hCG
88852088|NCT04706585||Youth|Young people in Indonesia between the age of 15-24 who are currently attending high school or university-level education to fill in our online survey.
88852089|NCT00585611|Experimental|Atorvastatin|Heart failure patients assigned to atorvastatin
88852090|NCT00585611|Placebo Comparator|2|
88852091|NCT00379535|Experimental|1|Daily dose of 200 µg of potassium iodide
88852092|NCT00379535|Placebo Comparator|2|Daily dose of placebo
88852093|NCT05596253||Patients with cirrhosis who underwent TIPS|Patients with cirrhosis who underwent TIPS due to complications of portal hypertension were inclueded for observation.
88852094|NCT01557881|Experimental|Diagnostic (PET/MRI)|After undergoing standard PET/CT, patients undergo PET/MRI.
88852095|NCT00379613|Placebo Comparator|1|rocuronium + 16.0 mg/kg Org 25969
88852096|NCT00379613|Experimental|2|rocuronium + 2.0 mg/kg Org 25969
88852097|NCT00379613|Experimental|3|rocuronium + 4.0 mg/kg Org 25969
88852098|NCT00379613|Experimental|4|rocuronium + 8.0 mg/kg Org 25969
88852099|NCT00379613|Experimental|5|rocuronium + 12.0 mg/kg Org 25969
88852100|NCT01685333|Other|Group A|First Period: Test Drug (Epoetin Alfa) Second Period: Comparator Drug
88852101|NCT01685333|Other|Group B|First period: Comparator drug Second Period: Test drug (Epoetin alfa)
88852102|NCT01648907||SPONDYLARTHRITIS COHORT|
88852103|NCT01556009|Active Comparator|Drug (Vismodegib)|Vismodegib taken orally 150 mg per day for 7 continuous months then randomized for 3 month intervals to 28 months.
88852104|NCT01556009|Active Comparator|Aminolevulinic acid %20 topical solution|Aminolevulinic acid HCL 20% topical solution applied every three months from month 10, 13, 16, 19, 22. Applied and incubated for three hours.
88852105|NCT04331951|Experimental|Targeted biopsy within Sydney Protocol|"The patients with history of gastric intestinal metaplasia will be included and using targeted biopsy within Sydney Protocol; both targeted biopsy at suspicious lesions and random biopsy at no suspicious area.~All tissues will be sent to immunohistochemistry as a gold standard.~Sensitivity, specificity,positive predictive value, negative predictive value, accuracy will be calculated."
88852106|NCT01521143|Experimental|Part A - Cvac|Participants received intradermal injections of Cvac given at 4-week intervals for the first 3 doses, and then every 12 weeks for 3 additional doses, for a total of 6 doses over 44 weeks. Each injection had an approximate concentration of 60 × 10^6 viable dendritic cells/mL.
88852107|NCT01521143|Placebo Comparator|Part A - Placebo|Participants received intradermal injections of placebo given at 4-week intervals for the first 3 doses, and then every 12 weeks for 3 additional doses, for a total of 6 doses over 44 weeks.
88852108|NCT01521143|Experimental|Part B - Cvac|Participants received intradermal injections of Cvac given at 4-week intervals for the first 3 doses, and then every 12 weeks for 3 additional doses, for a total of 6 doses over 44 weeks. Each injection had an approximate concentration of 60 × 10^6 viable dendritic cells/mL.
88852109|NCT01521143|No Intervention|Part B - Observational standard of care|Participants in this group did not receive any treatment during the study.
88852110|NCT05529953|Experimental|Oleanolic acid-enriched functional olive oil|"functional olive oil elaborated enriching the control olive oil with Oleanolic acid up to 600 mg OA/kg oil.~Single oral intake of 55 mL of functional olive oil (dose equivalent to 30 mg OA)."
88852111|NCT05529953|Active Comparator|Control olive oil|"commercial olive oil (blend of virgin and refined olive oils) chosen by its very low content of bioactive minor components.~Single oral intake of 55 mL of commercial olive oil"
88852112|NCT00546455|Experimental|A|Subjects in this cohort will be given Fenretinide
88852113|NCT00546455|Placebo Comparator|B|Subjects in this cohort will be given placebo.
88852114|NCT01525745|Active Comparator|Radiosurgery/SBRT|Radiosurgery/SBRT
88852115|NCT01525745|Active Comparator|External Beam Radiation Therapy|External Beam Radiation Therapy
88852116|NCT05231057|Experimental|experimental group|Patients in the study group received Pilates exercises plus conventional physical therapy program
88852117|NCT05231057|Experimental|control group|Patients in the control group received conventional physical therapy
88852118|NCT00533351|Experimental|AGN201781|AGN201781 50 mg capsules three-time daily for 2 weeks
88852119|NCT00533351|Placebo Comparator|Placebo|placebo 50 mg capsules three-times daily for 2 weeks
88852120|NCT00528437|Other|Myeloablative Chemo-Temozolomide, Thiotepa, and Carboplatin.|
88852121|NCT05480735|Experimental|Prehabilitation group|"The intervention group will participate in a prehabilitation program of approximately 4-6 weeks before surgery, and additionally during neoadjuvant chemotherapy if applicable. The program consist of a tailored exercise program, nutritional support and if relevant smoking cessation and/or psychological counselling. The exercise program is under supervision of an oncology specialized physiotherapist and comprises aerobic-, resistance- and breathing- and relaxation exercises. A dietician will provide nutritional support and give dietary advice to increase protein intake, including a supplement containing 30 g of whey-protein daily and after supervised training. Patients who score high on anxiety and depression will be offered a referral to a psychologist. Intensive counselling and nicotine replacement therapy will be offered to all patients who smoke.~Patients will be asked to keep a diary to track unsupervised activity and to track intake of the protein supplementation."
88852122|NCT05480735|No Intervention|Control group|Patients randomized to the control group will receive care as usual according to local ERAS guideline implementation. In addition, they will receive a leaflet with the recent guidelines regarding physical activity, dietary advice, and smoking cessation. Their actual physical activity level will be obtained via questionnaire.
88852123|NCT00506909|Experimental|Group 1|Group 1: 20 IU BID for the first week, 40IU BID for the following two weeks, 1 week washout, 3 week placebo trial.
88852124|NCT00506909|Experimental|Group 2|Group 2: 3 week placebo trial, 1 week washout, 20 IU BID for the first week, 40IU BID for the following two weeks.
88852125|NCT00500045|Experimental|Treatment|Oral niacin
88852126|NCT05404685|Experimental|Transperitoneal RAPN with AirSeal system set to 7mmH.|Patient with Low Pressure Robotic Assisted Partial Nephrectomy at 7mm Hg
88852127|NCT05404685|Active Comparator|transperitoneal RAPN with AirSeal system set to standard insufflation pressure (12mmHg)|Control arm : Patient with standard insufflation pressure of 12 mm Hg
88852128|NCT05204225|Experimental|Tablet Application|An exercise program based on the current evidence will be provided through a tablet application (ReHand) along with the face-to-face conventional approach of each recruitment centres. A follow-up of the use of the application will be carried out. The treatment protocol will last 4 weeks, including daily exercise sessions of 30-60 minutes of duration at home though the application tablet.
88852129|NCT05204225|Active Comparator|Conventional Treatment|Participants included in this group will receive the conventional treatment protocol usually prescribed on each recruitment centres. Participants will be asked to perform an exercise program on paper during 4 weeks at home, along with face-to-face sessions.
88852130|NCT05383547|Experimental|Glomerular disease patients|
89378787|NCT04490902|Active Comparator|Single graft corneal transplantation|Limbal transplantation combined with central penetrating keratoplasty from single donors.
89378788|NCT04490902|Experimental|Dual graft corneal transplantation|Limbal transplantation combined with central penetrating keratoplasty from different donors.
88852131|NCT00456989|Experimental|Taxotere and Doxil|Treatment will be repeated every 28 days. Taxotere is administered on days 1, 8 and 15 (rate: 1 hour). Dose levels 1, 2 and 3 (mg/m2 i.v.) are 25, 25 and 30, respectively. Treatment will be administered on an outpatient basis. Treatment will be repeated every 28 days. Doxil is administered on day 1 (rate: 1mg/min). Dose levels 1, 2 and 3 (mg/m2 i.v.) are 25, 30 and 30, respectively.
88852132|NCT00428207|Active Comparator|Insulin Aspart Versus Insulin Lispro|Insulin aspart will be used for diabetes management, and will be delivered continuously, subcutaneously using a pump for a four week period. Insulin aspart doses will be adjusted by the principal investigator as needed to maintain glycemic control. Insulin dose adjustments will vary from patient to patient based on the carbohydrate consumption, level of physical activity, and fingerstick monitoring results SMBG (7 times per day). SMBG results collected during this four week period will be compared to the SMBG results collected while participant uses alternative treatment (insulin Lispro).
88852133|NCT00428207|Active Comparator|Insulin Lispro Versus Insulin Aspart|Insulin lispro will be used for diabetes management, and will be delivered continuously, subcutaneously using a pump for a four week period. Dose will be adjusted as needed to maintain glycemic control. Insulin dose adjustments will vary from patient to patient based on the carbohydrate consumption, level of physical activity, and fingerstick monitoring results SMBG (7 times per day). SMBG results collected during this four week period will be compared to the SMBG results collected while participant uses alternative treatment (insulin Aspart).
88852134|NCT00379847|Experimental|1|Lower dose
88852135|NCT00379847|Experimental|2|Higher dose
88852136|NCT05252741|Active Comparator|Group 1: patients with psoriasis|
88852137|NCT05252741|Placebo Comparator|Group 2: age-, sex-, BMI-, and weight-matched control subjects.|
88852138|NCT00374543|Experimental|Ziprasidone|Ziprasidone will be dosed on a twice daily (BID) basis, with flexible dosing based on tolerability, with a total daily dose in the range of 40 to 160 mg/day, for 8 weeks. This time period reflects the rapid onset of effect seen in studies of atypical antipsychotics, but allows time for a potentially longer response for some anxiety symptoms.
88852139|NCT00374543|Placebo Comparator|Placebo Capsules|Identical placebo capsules will be dosed on a BID basis, with flexible dosing based on tolerability, with a total daily dose in the range of 40 to 160 mg/day.
88852140|NCT00299195|Experimental|1|sulindac
88852141|NCT00299195|Placebo Comparator|2|placebo
88852142|NCT01351415|Experimental|Bevacizumab + Standard of Care|Participants will receive bevacizumab on Day 1 of every 21-days cycle along with standard of care (Erlotinib or Docetaxel or Pemetrexed) as second line treatment, until the occurrence of an unacceptable toxicity or withdrawal of consent (whichever occurs first).
88852143|NCT01351415|Active Comparator|Standard of Care|Participants will receive investigator's choice of standard of care (Erlotinib or Docetaxel or Pemetrexed) according to local practice until the occurrence of an unacceptable toxicity or withdrawal of consent (whichever occurs first).
88852144|NCT00281879|Active Comparator|Cyclophosphamide (Cytoxan) and Total Body Irradiation (TBI)|
88852145|NCT00281879|Active Comparator|Busulfan and Cyclophosphamide (Cytoxan)|
88852146|NCT00281879|Active Comparator|BEAM Regimen|On the day of your admission, you will start to take a drug called allopurinol which helps to protect your kidneys as your body works to discharge cells killed off by your chemotherapy and TBI. Chemotherapy will begin on Day -6 with carmustine (BCNU), followed by etoposide (VP-16), cytosine arabinoside (ARA-C), and melphalan. This conditioning regimen is known as the BEAM regimen. The dose of this therapy is high enough to kill cancer cells but will also kill all of your normal blood forming cells. Subjects undergoing the BEAM regimen will not have total body irradiation (TBI).
88852147|NCT00281879|Active Comparator|Low-Dose Fludarabine and TBI(for second stem cell donation)|A conditioning regimen of low-dose fludarabine and TBI is used in the event that a second donation of hematopoietic stem cells is necessary. Chemotherapy with Fludarabine will begin 4 days prior to your transplant. This drug will be given through the catheter in your chest daily for 3 days. TBI (radiation) will be given to you on the day of your transplant. After your TBI, your donor's stem cells / bone marrow will be given to you through your catheter. The drugs cyclosporine and mycophenolate mofetil (MMF) will be given orally to help you accept your donor's cells.
88852148|NCT00281879|Active Comparator|Busulfan, Cyclophosphamide, and Fludarabine (Pediatric only)|On the day of your admission you will start to take a drug called Dilantin which is used to help prevent seizures while you receive your chemotherapy drugs. You will also start to take a drug called allopurinol which helps to protect your kidneys as your body works to discharge cells killed off by your chemotherapy and TBI. On the next day, you will then begin your conditioning therapy with a drug called busulfan. This medicine will be given to you by an infusion into your bloodstream through a small tube in the vein of your arm four times per day for four days. After the busulfan treatment, you will receive 4 doses each of two drugs, cyclophosphamide (also known as Cytoxan) and fludarabine, over 2 hours into your vein.
89378789|NCT02337400|Experimental|Smoking Reduction Program|"Cognitive behavioral smoking reduction program Smoke_less Duration: 5 weeks with 4 weekly sessions over 2,5 hours and two phone calls"
89378790|NCT02337400|Active Comparator|Counseling Interview|15 minute counseling interview
89378791|NCT02337400|No Intervention|Waiting Control Group|
89378792|NCT02899858|Experimental|IntraSpinal Micro-Stimulation|IntraSpinal Micro-Stimulation will be performed using a maximum of 16 electrodes inserted along each side of spinal cord that correlate with movements created across all 3 joints (hips, knees, and ankles)
89182665|NCT06238648|Experimental|Arm A (epcoritamab)|Patients receive epcoritamab SC on days 1, 8, 15, and 22 of cycles 1-3, days 1 and 15 of cycles 4-9, and day 1 of cycles 10-12. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo MRI at screening, undergo PET/CT and collection of blood samples throughout the trial, and undergo biopsy at screening and end of treatment. Patients may undergo CT or MRI during follow up.
89182666|NCT06238648|Active Comparator|Arm B (observation)|Patients undergo observation per standard care. Patients also undergo MRI at screening, undergo PET/CT and collection of blood samples throughout the trial, and undergo biopsy at screening and end of treatment. Patients may undergo CT or MRI during follow up.
89182667|NCT06238622|Experimental|BI 1015550 treatment group|
89182668|NCT06238596|Experimental|rehabilitation + standard of care (SOC)|All enrolled patients will start a supervised rehabilitation program for 12 weeks
89182669|NCT06238544|Experimental|HRS-5965 tablets|
89182670|NCT06238518|Experimental|Conventional lesion preparation plus Intravascular Lithotripsy strategy|IVL could be performed before, amidst, or after Conventional lesion preparation therapy; However, the use of IVL treatment is mandatory.
89182671|NCT06238518|Active Comparator|Conventional lesion preparation strategy|Conventional lesion preparation strategy includes the use of Compliant, noncompliant, cutting, or scoring balloons, Excimer laser coronary atherectomy, or Rotational atherectomy at the discretion of the operator.
89182672|NCT06238505|Experimental|Virtual|
89182673|NCT06238505|Experimental|biodex|
89182674|NCT06238492|Experimental|Experimental|pre-specified computer tasks using an Internet-based cognitive training portal, to be completed 3x per week for 60 minutes each session for 12 weeks total
89182675|NCT06238492|Placebo Comparator|Placebo Control|pre-specified computer tasks using an Internet-based cognitive training portal, to be completed 3x per week for 60 minutes each session for 12 weeks total
89182676|NCT06238479|Experimental|LY4101174 (Dose-escalation, Cohort A1)|Escalating doses of LY4101174 administered intravenously (IV).
89182677|NCT06238479|Experimental|LY4101174 (Dose-optimization, Cohort A2)|Comparing 2 or more doses (evaluated during dose escalation) of LY4101174 administered IV.
89182678|NCT06238479|Experimental|LY4101174 (Dose-expansion, Cohort B1, B2, C1-C5))|LY4101174 administered IV.
89182679|NCT06238453||Experimental group|Educational content will be sent to the experimental group once a week via the WhatsApp application, and individual counseling will be provided by answering their questions at the same time. A total of 8 weeks of intervention will be implemented, training will be given with training presentations in the first 6 weeks and training videos will be sent in the last 2 weeks.
89182680|NCT06238453||Control group|The control group will be invited to KETEM to have a mammogram without any intervention.
89182681|NCT06238427||Group 1|Group 1 participants underwent free gingival graft placement two months before implant placement.
89182682|NCT06238427||Group2|Group 2 in which the participants underwent the placement of the free gingival graft during the second stage of surgery, specifically at the time of healing abutment placement
89182683|NCT06238401|Experimental|ACR246 for injection|Administered by intravenous infusion on Day 1 every 3 weeks (Q3W).
89182684|NCT06238388|Experimental|0.8 μg/kg HSK21542 Injection|0.8 μg/kg HSK21542 Injection
89182685|NCT06238375||Premature Acute Coronary Syndrome (ACS) Patients in Africa|This cohort includes individuals diagnosed with premature Acute Coronary Syndrome (ACS), including subtypes like unstable angina, non-ST-segment elevation myocardial infarction (NSTEMI), and myocardial infarction with persistent ST-segment elevation (STEMI). These participants are under 55 years (men) or 65 years (women) and have been admitted to various cardiac facilities in Africa (Urban and rural) due to ACS-related symptoms.
89182686|NCT06238349|Other|Control group|Conventional treatment: Neonates will be placed in an incubator (Ningbo David Medical Device Co., LTD, XHZ model) at 30℃ and relative humidity at 55%. Throughout the study, exclusive breastfeeding and professional care will be provided for the newborns. Newborns requiring phototherapy receive it in the following manner: Phototherapy eye masks (Foshan Forman Medical Technology Co., LTD., Yuesun Mechanical Equipment No. 20160015) and phototherapy diapers (Foshan Baojusheng Medical Equipment Co., LTD., GB/T33280) will be used to cover the eyes and perineum, respectively. Phototherapy was provided via LED blue light continuous irradiation with a wavelength of 425-475nm. All treated neonates will receive continuous phototherapy for 12 hours, then allowe to rest for 6-8 hours, then receive another 12 hours of continuous phototherapy. The decision to continue with further treatment depends on changes in the neonate's jaundice.
89182687|NCT06238349|Experimental|Sunbathing group|The sunbathing group will receive all interventions prescribed for the control group and assign to sunbathing (placement in a bed next to a sunny window) after birth for one week according to the following plan: Every morning and afternoon neonates will sunbath for 0.5 to 1 hour to avoid excess sun exposure. Healthcare workers will guide and assist families in their preparations. The caregiver will place a black eye patch on the infants to protect the retina, and a cloth will be wrapped around the hands and feet to prevent scratching, but care will be taken that the wrap is not too tight to avoid circulation disorders. Baby boys will have their genitals covered to protect them from sun damage. After feeding, the newborn will be placed on a sunny platform with fully exposed skin and frequent position changes, while the glass of the window prevent injury from UV light exposure.
89182688|NCT06238349|Experimental|Bifidobacterium group|The newborns in the Bifidobacterium group will receive all interventions prescribed for the control group, and also be assigned to orally be given Bifidobacterium triple viable powder (Shanghai Xinyi Pharmaceutical Company, Peifeikang powder, 0.5 g/dose, 3 times/day. Bifidobacterium triple viable powder contains live bacteria of long Bifidobacterium at no less than 1.0 × 107 CFU/g, stored at 2.8℃ away from light) beginning within 24 hours after birth and continuing for 1 week. No sunbathing will be prescribed.
89182689|NCT06238349|Experimental|Combination group|The combination group will receive all interventions of both the group sunbathing and the Bifidobacterium group as well as all interventions prescribed for the control group.
89378793|NCT03492281|Experimental|Vibegron + Placebo to match Tolterodine|
88852149|NCT00281879|Active Comparator|ATG For Cord Blood Transplants|If you are undergoing a pre-transplant conditioning regimen prior to undergoing a cord blood transplant, you will receive a drug called ATG to improve your chances of engraftment and decrease your risk of graft versus host disease. You may receive ATG 3 times during your transplant regimen on days -3 through days -1 in addition to your pre-transplant conditioning therapy. Methylprednisolone will also be given during each dose of ATG to help reduce any reactions during infusion.
88852150|NCT00281879|Active Comparator|DLI (Donor Leukocyte Infusion)|Donor Leukocyte Infusions: You will receive DLI from your original transplant donor. This will be given through a vein , usually in your arm. It will be similar to getting a platelet or blood transfusion. You may require more than one DLI. The decision to give you another infusion will be determined by your condition, relapse status, GVHD and how much DLI you were given before. You may need chemotherapy and/or radiation to improve your disease status prior to additional DLI's.
88852151|NCT00281879|Active Comparator|Cyclophosphamide, Etoposide (VP16) and TBI (Pediatric only)|On the day after your admission, you will start receiving radiation therapy (TBI). Radiation will be given to you 2 times a day for 3 days. On the next day, you will then begin your chemotherapy with a drug called etoposide. This medicine will be given to you by an infusion into your bloodstream through a small tube in the vein of your arm for one day. After the etoposide treatment, on the next day you will receive cyclophosphamide (also known as Cytoxan) for 2 days. When you are given cyclophosphamide, you will also be given a medication called MESNA to help protect your bladder from damage. After you have completed the cyclophosphamide you will rest one day without any anti-cancer therapy. This allows your body time to remove and inactivate the chemotherapy. After a day of rest, you will be given your donor's cells.
88852152|NCT05153057||Birdshot chorioretinopathy|Patients with a diagnosis of birdshot chorioretinopathy, with confirmed HLA-A29 positivity.
88852153|NCT00000815|Experimental|1|Participants who receive vaccination at 6 and 12 months of age
88852154|NCT00000815|Experimental|2|Participants who receive vaccination only at 12 months of age
88852155|NCT00240227|Other|Placebo|Placebo no active medication
88852156|NCT00240227|Active Comparator|prazosin|Prazosin flexible dose titration up to 12 mg per day.
88852157|NCT00205049|Experimental|Pentoxifylline/Placebo|All subjects will be randomized to receive either pentoxifylline 400mg orally or placebo 3 times daily for 28 days (20-40 treated, 1-20 placebo) with monthly follow up for 90 days.
88852158|NCT00176501|Experimental|Irradiated allogeneic lymphocytes|
88852159|NCT00133679|Experimental|1|Sildenafil x 45 days
88852160|NCT00133679|Placebo Comparator|2|Placebo x 45 d
88852161|NCT04941833|Experimental|Desogestrel group|Desogestrel group
88852162|NCT04941833|Placebo Comparator|Control group|Placebo
88852163|NCT04890041|Experimental|Treatment group|100 subjects will be enrolled with the indicated treatment dose of TPO-RA
88852164|NCT04874909|Other|"Case Patient"|Patient with ciliopathy
88852165|NCT04874909|Other|Healthy related individual|Individual without ciliopathy but related to a patient with ciliopathy (father, mother, brother, sister)
88852166|NCT04874909|Other|"Negative Control patient"|patient without renal disease
88852167|NCT04874909|Other|"Positive Control patient"|"patient with renal disease other that ciliopathy but with a similar renal function to the ciliopathy group (case patient)"
88852168|NCT04841369|Experimental|1A|Subjects received four doses of PCV13i at 2 months of age (At least 6 weeks old)
88852169|NCT04841369|Active Comparator|1B|Subjects received four doses of PCV13 at 2 months of age (At least 6 weeks old)
88852170|NCT04841369|Experimental|2A|Subjects received four doses of PCV13i at 3 months of age
88852171|NCT04841369|Experimental|3A|Subject received three doses of PCV13i at 7 to 11 months of age
88852172|NCT04841369|Active Comparator|3B|Subject received three doses of PCV13 at 7 to 11 months of age
88852173|NCT04841369|Experimental|4A|Subjects received two doses of PCV13i at 12 to 23 months of age
88852174|NCT04841369|Active Comparator|4B|Subjects received two doses of PCV13 at 12 to 23 months of age
88852175|NCT04841369|Active Comparator|5A|Subjects received one dose of PCV13i at 2 to 5 years old.
88852176|NCT04841369|Active Comparator|5B|Subjects received one dose of PCV13 at 2 to 5 years old.
88852177|NCT00379925|Experimental|Behavioral|Participants will take part in the Physical Activity and Dietary Health Promotion Program.
88852178|NCT00379925|No Intervention|Delayed intervention|Participants are assigned to a delayed intervention group and serve as a no-intervention control group.
88852179|NCT00002975|Experimental|PDT|4-6h and 18-24h, 20%, ALA application of superficial and nodular epidermally-derived lesions using ca 633 nm laser irradiation
88852180|NCT02221817|Active Comparator|Blind|Trochanter injection
88852181|NCT02221817|Experimental|Ultrasound|Trochanter injection
88852182|NCT00521885|Active Comparator|Arixtra (Fondaparinox) 2.5 mg SC Daily|Arixtra (Fondaparinox) 2.5 mg SC Daily
88852183|NCT00521885|Active Comparator|Lovenox 40mg SC Daily|Lovenox 40mg SC Daily
88852184|NCT05239013|Experimental|Treatment Group|Subjects who receive the intervention
88852185|NCT04018001||Truven Health MarketScan Research Database|individuals who are privately insured and with Medicare Supplemental insurance
88852186|NCT02973347|Active Comparator|Intermittent enteral feeding|Intermittent enteral feeding via the nasogastric tube is applied less than 30 mins.
89182690|NCT06238336|Experimental|CAR-T cell therapy|Dose climbing started with 1.0*10^6/kg back infusion, 3 patients per dose group, if there is no adverse reaction the dose can be increased to 2.0*10^6/kg, 4.0*10^6/kg, the maximum dose can be extended the study.
88852187|NCT02973347|Active Comparator|Continuous enteral feeding|Continuous enteral feeding via the nasogastric tube using infusion pump is applied for 24 hours.
88852188|NCT04618991|Experimental|Adult patients with SAHOS for whom maxillary transversal surgery|Adult patients with SAHOS for whom maxillary transversal surgery is recommended.
89378794|NCT03492281|Placebo Comparator|Placebo to match vibegron + Placebo to match Tolterodine|
89378795|NCT03492281|Active Comparator|Tolterodine + Placebo to match vibegron|
88852189|NCT04474145|Active Comparator|Comb group|"Patients in the Comb group will receive hydrodilatation of the affected shoulder and subdeltoid bursa injection for 2 times in 2-week interval. Patients also receive mobilization exercise and conventional physical therapy (including physical modalities and stretch exercise), 3 times a week, for 8 weeks.~The injectates for hydrodilation include 10mg triamcinolone, 2cc 1% xylocaine, and 17cc normal saline for both posterior and anterior shoulder joint injection. 10mg triamcinolone and 2cc 1% xylocaine will also be injected into the subdeltoid bursa of the affected shoulder. All injections will be performed under ultrasound guidance. For shoulder joint injection, ａ21 gauge, 3-inch needle will be used; and a 22 gauge, 1.5 inch needle will be applied for subdeltoid bursa injection."
88852190|NCT04474145|Active Comparator|PT group|The physiotherapy program includes physical modalities (heat therapy and electric therapy) and therapeutic exercise (stretching, ROM exercise, and strengthening), three times a week, and will be continued for 8 weeks or until total recovery of the symptoms. The stretching exercise program is similar to the stretching exercise described above. For mimicking injection in the Comb group, patients in the PT group will receive 2cc 1% xylocain injection at the posterior deltoid muscle.
88852191|NCT00000167|Experimental|1|Laser treatment
88852192|NCT00000935|Experimental|Intravenous Immune Globulin (Human)|
88852193|NCT00000935|Placebo Comparator|Intravenous Immune Globulin (Human) Placebo|
88852194|NCT04251611|No Intervention|Control group|The usual care in patients with myocardial ischemia without other cardiovascular risk factors (CVFR) will be to attend one visit per year with doctor and nurse of the local health center. In this visit, it will be done a blood test and an electrocardiogram. Blood pressure, weight, body mass index, abdominal circumference will be measured and, in case of detecting enolic habit, smoking or sedentary lifestyle, generic advice will be done. If the patient, apart from myocardial ischemia, presents diabetes mellitus type 2, 3-4 follow-up visits per year will be recommended and will be increased according to specific needs. In case of presenting hypertension, will be recommended 2 visits with the nurse and one visit with the doctor per year and will be increased according to specific needs. In addition, in this case the blood pressure is checked every 6 months. During all visits, professionals will reinforce the control of CVRF and the maintenance of a long-term cardio-healthy lifestyle.
88852195|NCT04251611|Experimental|Intervention group|"Patient will go to health center to visit the cardiac rehabilitation (CR) reference team, which is composed for a doctor and a nurse. This team will establish the guideline of action in the maintenance and/or increase in the physical exercise practice, in function of the resources of each zone and the preferences and motivations of the patient. They also reinforce the control of CVRF and the maintenance of a long-term cardio-healthy lifestyle.~At the end of the visit, control visit will be given with the CR reference team at 3, 6 and 12 months after completing the supervised physical exercise program of phase II of the CRP. In case of detecting specific needs for the patient and/or relapses, the team will consult with the appropriate professional (cardiologist, cardiology nurse, physiotherapist, rehabilitator, nutritionist and/or psychologist). At the same time, the patient will be informed of the possibility of re-evaluating the CR reference team."
88852196|NCT00000263|Placebo Comparator|0 g/Kg ethanol +/- 30% nitrous oxide|
88852197|NCT00000263|Active Comparator|0.25 g/Kg ethanol +/- 30% nitrous oxide|
88852198|NCT00000263|Active Comparator|0.5 g/Kg ethanol +/- 30% nitrous oxide|
88852199|NCT03967223|Experimental|Substudy 1: lete-cel in previously untreated advanced (metastatic or unresectable) SS or MRCLS|Eligible participants will be leukapheresed to manufacture engineered T cells. Participants will then receive letetresgene autoleucel.
88852200|NCT03967223|Experimental|Substudy 2: lete-cel in advanced (metastatic or unresectable) SS or MRCLS post anthracycline chemo|Eligible participants will be leukapheresed to manufacture engineered T cells. Participants will then receive letetresgene autoleucel.
88852201|NCT05440565|Placebo Comparator|Risk score|
88852202|NCT05440565|Active Comparator|Fecal immunochemical test|
88852203|NCT03055247|Experimental|XCGD mobilization|Treatment with combination of Ibuprofen, Myelostim and Mozobil
88852204|NCT02788955|Active Comparator|Normal Protein Diet|In the normal protein diet, participants will be instructed to follow a diet that will provide them with the amount of calories enough to meet their energy needs without changing their body weight and will contain 1 g of protein per kilogram of body weight. Participants will be instructed to consume protein primarily from animal food sources. A high quality whey protein supplement will be provided as needed.
88852205|NCT02788955|Experimental|High Protein Diet|In the high protein diet, participants will be instructed to follow a diet that will provide them with the amount of calories enough to meet their energy needs without changing their body weight and will contain 2 g of protein per kilogram of body weight. Participants will be instructed to consume protein primarily from animal food sources. A high quality whey protein supplement will be provided as needed.
88852206|NCT02396459|Experimental|MCT8 deficiency patients|Triac treatment
88852207|NCT00000299|Active Comparator|buprenorphine|depot buprenorphine
88852208|NCT00000299|Experimental|buprenorphine and ultra-low dose naloxone|depot buprenorphine and naloxone
88852209|NCT01771679|Experimental|Allogeneic Mesenchymal Bone Marrow Cells|1550 nm Fraxel laser treatment (6-8 mJ, Level 2) to full face followed by IV infusion of Allogeneic Mesenchymal Bone Marrow Cells (0.5, 1.0, or 1.5 million cells/kg, up to 150 million cells)
88852210|NCT00000311|Experimental|1|Methadone + CM (contingency management)
88852211|NCT00000311|Experimental|2|methadone + VC (voucher control)
88852212|NCT00000311|Experimental|3|Buprenorphine + CM
88852213|NCT00000311|Experimental|4|Buprenorphine + VC
88852214|NCT00000317|Placebo Comparator|PLacebo|Placebo plus relapse prevention counseling
88852215|NCT00000317|Experimental|Risperidone|Risperidone (4mg/day) plus relapse prevention counseling
88852216|NCT00380237|Experimental|1|Two vaccinations with H9N2 (6-2) AA ca Reassortant (A/chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca) vaccine at a dose of 10^7 TCID50 delivered by nose drops. The second vaccination will be given 4 to 12 weeks after the first.
88852217|NCT00000401|Experimental|1|The low dose group will receive CII 30 mcg daily for 10 weeks, then 50 mcg daily for 10 weeks, followed by 70 mcg daily for 10 more weeks.
89002623|NCT06294522|Experimental|reconstruction of alveolar cleft|gingival mucoperiosteal flaps are designed along the cleft margins and elevated. These flaps are raised up and then are separated from the nasal mucosa the palatal mucoperiosteal flaps along the cleft margins are then elevated from the palate. After complete exposure of all the bony clefts, the nasal lining of the nostril floor is approximated and sutured, and the palatal flaps are then turned back and sutured to make a soft-tissue pocket. Grafting of the defect is accomplished with cortical bone only from the chin the cortical shelf is prepared to be two layers perpendicular to each other the first one is parallel to the nasal floor and second one is continuous with buccal cortex of alveolar ridge then cancellous bone will be packed under these shelves and be compressed into the cleft defects.
89002624|NCT06293326|Experimental|Night-time sequence|The night-time treatment sequence consists of two Treatment periods (Period 1 and Period 2) with each period consisting of a single dose of Investigational Medicinal Product (IMP). The two Treatment periods are separated by a least 6-8-day wash-out phase between IMP administration in Period 1 and 2.
89002625|NCT06293326|Experimental|Day-time sequence|The day-time treatment sequence consists of two Treatment periods (Period 1 and Period 2) with each period consisting of a single dose of IMP. The two Treatment periods are separated by a least 6-8-day wash-out phase between IMP administration in Period 1 and 2.
89002626|NCT06292923|Experimental|Nasal Foralumab 50 μg|Each patient will receive nasal foralumab 50 μg per dosing day (25 μg per nostril).
89002627|NCT06292923|Experimental|Nasal Foralumab 100 μg|Each patient will receive nasal foralumab 100 μg per dosing day (50 μg per nostril).
89002628|NCT06292923|Placebo Comparator|Nasal placebo (acetate buffer)|Each patient will receive placebo on each dosing day in divided doses, in each nostril.
89002629|NCT06289504|Experimental|CagriSema +Atorvastatin + Warfarin|Participants will receive a single dose of atorvastatin and a single dose of warfarin followed by a 16-week CagriSema dose escalation period and a 7-week CagriSema maintenance period. Participants will also receive a single dose of atorvastatin and a single dose of warfarin in the maintenance period.
89002630|NCT06289088|Experimental|First Intervention|The application will be done sequentially: without orthosis, with adaptation and with orthosis.
89002631|NCT06289088|Experimental|Second Intervention|The application will be done sequentially: with adaptation, with orthosis and without orthosis
89002632|NCT06289088|Experimental|Third Intervention|The application will be done sequentially: with orthosis, without orthosis, and with adaptation
89002633|NCT06288659|Experimental|aSAH treatment based on ICP monitoring|In the acute phase of aSAH (following endovascular or craniotomy occlusion of the aneurysm), a ventricular ICP monitoring probe is surgically implanted. And the postoperative management of ICP is guided by quantifiable ICP parameters. The remaining treatments are consistent with those in the control group.
89002634|NCT06288659|No Intervention|aSAH treatment without ICP monitoring|Only aSAH treatment surgery is performed without ICP monitoring probe implantation. The treatment is not guided by ICP monitoring, and instead, aSAH treatment is conducted based on clinical signs and CT imaging to assess ICP.
89002635|NCT06287177||Subjects with hyperlipidaemia under Inclisiran treatment|
89002636|NCT06287099|Experimental|BRL-101|Autologous CD34+ hHSPCs modified with CRISPR-Cas9 at the BCL11A gene. Subjects will receive a single infusion of BRL-101.
89002638|NCT06287047|Active Comparator|Conventional epidural group|"Conventional epidural.~."
89002639|NCT06287047|Active Comparator|DPE-25G group|Dural puncture epidural with 25-gauge spinal needle.
89002640|NCT06287047|Active Comparator|DPE-27G group|Dural puncture epidural with 27-gauge spinal needle.
89002641|NCT06284109|Experimental|Cryoanalgesia|Participants will receive cryoanalgesia with the The iovera° system.
89002642|NCT06284109|Sham Comparator|Sham Cryoanalgesia|Participants will receive Sham cryoanalgesia with the The iovera° system.
89182691|NCT06238310|Experimental|Patients in the intensive care unit and outpatients with acute or chronic kidney insufficiency|Measuring glomerular filtration rate (GFR) with two different marker and the same measuring protocol.
88852218|NCT00000401|Experimental|2|The high dose group will receive CII 90 mcg daily for 10 weeks, then 100 mcg daily for 10 weeks, followed by 130 mcg daily for 10 more weeks.
88852219|NCT00000407|Active Comparator|Enrollment Intervention|The intervention consists of training sessions to help prospective VR clients with ARMD successfully enter and complete the vocational rehabilitation (VR) program, and training sessions for a randomly selected group of VR professionals to help them serve VR clients with ARMD more effectively.
88852220|NCT00000407|Placebo Comparator|Usual Care|
88852221|NCT00380549|Active Comparator|CONSERVE® A-Class THA BFH|CONSERVE® A-Class Total Hip with BFH technology. Patients in this arm will undergo a unilateral total hip replacement with the CONSERVE® acetabular component and the CONSERVE® A-Class BFH femoral head. Blood ion levels will be collected and analyzed.
88852222|NCT00380549|Active Comparator|CONSERVE® Plus Total Resurfacing Hip System|CONSERVE® Plus Total Resurfacing Hip System. Patients in this arm will undergo a unilateral total hip replacement with the CONSERVE® Plus Total Resurfacing Hip System. Blood ion levels will be collected and analyzed.
88852223|NCT00000431|Experimental|1|Upon evaluation, participant will be treated with a single intra-ulcer injection of PDGF-B/Ad5 in the wound. Patients will receive only one dose, which will be administered during a 72-hour inpatient stay in a research unit at the Hospital of the University of Pennsylvania. This study will use a standard three-six dose-escalation scheme.
88852224|NCT00000437|Experimental|Naltrexone Tablet and Nicotine Patch|
88852225|NCT00000437|Active Comparator|Naltrexone Tablet and Placebo Patch|
88852226|NCT00000437|Active Comparator|Placebo Tablet and Nicotine Patch|
88852227|NCT00000437|Placebo Comparator|Placebo Tablet and Placebo Patch|
88852228|NCT04713761|Experimental|Toripalimab|
88852229|NCT04331327|Active Comparator|Allogenic lyophilized growth factors|Two doses of intra-articular knee injections of lyophilized growth factors were received one dose at the baseline and the other was after 2 months.
88852230|NCT04331327|No Intervention|Standard of care|The patients were kept on their traditional medications without any intervention
88852231|NCT04943783|Experimental|Atorvastatin|Atorvastatin, 20mg once a day, for six months
88852232|NCT04943783|No Intervention|No drug|no drug
88852233|NCT00001397||1|treated according to the guidelines of standard medical evaluation and care. No investigational treatments or procedures will be administered on this protocol.
88852234|NCT00001469||Specimens|Specimens
88852235|NCT05752643|No Intervention|Control|Participants will have 4 face-to-face quarterly follow up visits per year
88852236|NCT05752643|Experimental|Experimental|Participants will alternate face-to-face visits with online screening every three months. They will have two face-to-face and two online screenings per year
88852237|NCT05752565|Other|patients with severe HA under FVIII concentrates prophylaxis|patients with severe HA under FVIII concentrates prophylaxis
88852238|NCT00381329|Active Comparator|1|Motivational Interviewing (MI)
88852239|NCT00381329|Active Comparator|2|Structured Brief Advice (SBA)
88852240|NCT00381173|Experimental|1|
88852241|NCT04636697|Placebo Comparator|Placebo|Placebo (0.5 mL)
88852242|NCT04636697|Experimental|3.75 µg of CoVLP Vaccine adjuvanted|3.75 µg of CoVLP adjuvanted vaccine with AS03 adjuvant (0.5 mL)
88852243|NCT00381407|Experimental|1|Participants will receive organizational skills training program
88852244|NCT00381407|Experimental|2|Participants will receive contingency management program
88852245|NCT00381407|No Intervention|3|Participants will receive wait list condition
88852246|NCT02973581|Experimental|metamizol|analgesic drug
88852247|NCT02973581|Experimental|acetaminophen|analgesic drug
88852248|NCT02973581|Experimental|0,5 % bupivacaine with of 2% lidocaine|a volume of 5 ml of analgesic solution for regional peribulbar block
88852249|NCT02973581|Experimental|Proxymetacaine|topical analgesia
88852250|NCT02973581|Placebo Comparator|control group|patients will receive no pre-emptive analgesia. standard doses of fentanyl will be used intraoperatively.
88852251|NCT00002495|Experimental|Nodal RT|subtotal nodal irradiation will consist of mantle and periaortic/spleen fields treated sequentially. Total dose 3600-4000 cGy over 20 fractions.
88852252|NCT00002495|Experimental|Chemotherapy + Nodal RT|3 cycles (28 days each) of chemotherapy (doxorubicin 25 mg/m^2 on days 1 and 15, vinblastine 6 mg/m^2 on days 1 and 15). Four weeks after last cycle, subtotal nodal irradiation (total dose 3600-4000 cGy over 20 fractions) will be given as described for the Nodal RT arm.
88852253|NCT00002501|Experimental|cyclophosphamide + filgrastim|Patients receive cyclophosphamide IV over 90 minutes on day 1 and filgrastim (G-CSF) subcutaneously beginning on day 3 and continuing until blood counts recover. Treatment continues every 2 weeks for 4 courses in the absence of disease progression or stable disease. Patients who achieve complete remission (CR) after completion of course 4 receive 2 additional courses. Patients who achieve partial remission (PR) after completion of course 4 receive 2 additional courses, and those who achieve CR after completion of course 6 receive 2 additional courses. Patients are followed every 2 months for 6 months, every 6 months for 2 years, and then annually thereafter.
88852254|NCT04713059||patients with CPS ≥ 1 or MSI-H or TMB ≥ 10Mb/MUT|
88852255|NCT04713059||patients with CPS =0 , MSS and TMB < 10Mb/mut|
88852256|NCT04331405|Experimental|Pilot group|10 patients with acute severe contusion spinal cord injury (ASIA A/B) included into the group. Patients meeting inclusion/exclusion criteria underwent primary surgical treatment (decompression and stabilization) received hUCBMC infusions weekly (4 infusions overall) in addition to standard therapy during in-hospital treatment. After the discharge patients were examined for 4 times. Observation period was 1 year.
89182692|NCT06238284||Cervical Cancer Group|
89182693|NCT06238284||Endometrial Cancer Group|
88817590|NCT05727501|Active Comparator|Post facilitation stretching|This Group was treated with baseline treatment of heating for 15min and rehab protocol post facilitation stretching in which 3-5 repetitions for 7-10 seconds hold in each session for three sessions per week in alternate days for four weeks.
89182694|NCT06238284||Ovarian Cancer Group|
89182695|NCT06238271|Experimental|UDM 611|Acriva BB UDM 611 intraocular lens will be implanted into the capsular bag in patients who undergo cataract extraction with phacoemulsification.
88817591|NCT01347008|Active Comparator|Sildenafil citrate|Oral Sildenafil citrate, 50mg, b.i.d.
88817592|NCT01347008|Placebo Comparator|Sugar pill|Placebo pill (identical to Sildenafil citrate 50mg), b.i.d.
88817593|NCT05357235||Treatment intervention group|NA (TDF or TAF) combined with PEG-IFN was used. PEG-IFN was injected subcutaneously once a week and a personalized course of 24 weeks was used.
88817594|NCT05357235||Non therapeutic intervention observation group|patients do not receive treatment and are observed and followed up regularly.
88817595|NCT01347788|Experimental|Cohort 1|Dose level 0: cabozantinib 40 mg daily
88817596|NCT01347788|Experimental|Cohort 2|Dose level -1: cabozantinib 20 mg daily
88817597|NCT01347788|Experimental|Expansion cohort|Dose level 0: cabozantinib 40 mg daily
88817598|NCT05343429|Active Comparator|Benzydamine hydrochloride (BN)|15 ml of 0.15 % Benzydamine hydrochloride (BN) to dissolved in 15 ml plain water in a sterile container
88817599|NCT05343429|Active Comparator|Aspirin (Ap)|600 mg Aspirin tablets dissolved in 30 ml of plain water
88817600|NCT01349114|Active Comparator|aliskiren 300 mg once daily for 12 weeks|aliskiren 300 mg daily
88817601|NCT01349114|Placebo Comparator|Sugar pill/ placebo|Patients were double-blind placebo-controlled randomized to either aliskiren 300 mg once daily or sugar pill/ placebo
88817602|NCT01310582|Active Comparator|Desflurane|During the surgery the subjects were given Desflurane, general anesthesia, that will keep the patient asleep during the surgery. The dosage form was inhalation gas, dosage equivalent to 1 MAC, frequency was once and the duration was throughout the surgery (30-45 minutes).
88817603|NCT01310582|Active Comparator|Sevoflurane|During the surgery the subjects were given Sevoflurane, general anesthesia, that will keep the patient asleep during the surgery. The dosage form was inhalation gas, dosage equivalent to 1 MAC, frequency was once and the duration was throughout the surgery (30-45 minutes).
88817604|NCT02247050|Experimental|Commitment invitation at time 1|"Intervention: Behavioral: Commitment Invitation~In the stepped wedge cluster randomized design, the first clinic will remain in the control period (no intervention) for 2 months and then cross over to the intervention period for 6 months."
88817605|NCT02247050|Experimental|Commitment invitation at time 2|"Intervention: Behavioral: Commitment Invitation~In the stepped wedge cluster randomized design, the second clinic will remain in the control period (no intervention) for 3 months and then cross over to the intervention period for 5 months."
88817606|NCT02247050|Experimental|Commitment invitation at time 3|"Intervention: Behavioral: Commitment Invitation~In the stepped wedge cluster randomized design, the third clinic will remain in the control period (no intervention) for 4 months and then cross over to the intervention period for 4 months."
88817607|NCT02247050|Experimental|Commitment invitation at time 4|"Intervention: Behavioral: Commitment Invitation~In the stepped wedge cluster randomized design, the fourth clinic will remain in the control period (no intervention) for 5 months and then cross over to the intervention period for 3 months."
88817608|NCT02247050|Experimental|Commitment invitation at time 5|"Intervention: Behavioral: Commitment Invitation~In the stepped wedge cluster randomized design, the fifth clinic will remain in the control period (no intervention) for 6 months and then cross over to the intervention period for 2 months."
88817609|NCT02247050|Experimental|Commitment invitation at time 6|"Intervention: Behavioral: Commitment Invitation~In the stepped wedge cluster randomized design, the sixth clinic will remain in the control period (no intervention) for 7 months and then cross over to the intervention period for 1 month."
88817610|NCT04741737|Experimental|reSLNB arm|repeat SLNB procedure is performed in when the patient is diagnosed with ipsilateral breast tumor recurrence, who had undergone partial mastectomy and sentinel lymph node biopsy for primary operation.
88817611|NCT01311362||CYP2C19 wild type|"CYP2C19 wild type =extensive metaboliser~Administration of ambrisentan: 5 mg p.o. q.d. on day 1 and days 3-20~Administration of St. Johns wort: 300 mg p.o. three times a day (t.i.d.) on days 11-20"
88817612|NCT01311362||CYP2C19 mutant|"CYP2C19 *2/*2 or *2/*3 or *3/*3 = poor metaboliser~Administration of ambrisentan: 5 mg p.o. q.d. on day 1 and days 3-20~Administration of St. Johns wort: 300 mg p.o. three times a day (t.i.d.) on days 11-20"
88817613|NCT04741191|Experimental|Cycle ergometer training|Hospital-based ergometer cycling for 20 minutes (Including warm-up and cooldown)
88817614|NCT04741191|Active Comparator|Conventional therapy|Patient education and counseling, In bed activities, Ambulation
88817615|NCT01311674|Active Comparator|Schedule 1- Standard dose primary vaccination series|Schedule 1 subjects received 20 µg/1.0 mL of Engerix-B® on Day 0, Day 30, Day 180 with booster of 20 µg/1.0 mL of Engerix-B® every 120 days (4 months) (after Day 180 vaccination)
88817616|NCT01311674|Experimental|Schedule 2 - High dose primary vaccination series|Schedule 1 subjects received 40 µg/1.0 mL of Engerix-B® on Day 0, Day 30, Day 60, Day 180 with booster of 20 µg/1.0 mL of Engerix-B® every 120 days (4 months) (after Day 180 vaccination)
88817617|NCT04742829|Experimental|GROUP 1|Patients treated with INTRAVIT® tablets
88817618|NCT04742829|No Intervention|GROUP 2|patients who will not take any medical therapy to overlap with the activity described for INTRAVIT® tablets.
88817619|NCT05578209|Experimental|Active|"Participants received the intervention of iTBS (The total pulse of every session is 1200 pulses) over bilateral posterior superior temporal sulcus for 4 weeks (5 days/week).~*iTBS = intermittent theta burst stimulation"
88817620|NCT05578209|Sham Comparator|Sham|Participants received the sham intervention of iTBS (sham-coil) over bilateral posterior superior temporal sulcus for 4 weeks (5 days/week).
88817621|NCT05081193|Experimental|Oral Testosterone Therapy given until radiographic progression followed by Enzalutamide Therapy|Oral Testosterone Therapy-396 mg given twice per day on days 1-7 and 15-21 of a 28 day cycle until radiographic progression. After a 21 day washout period, Enzalutamide therapy given at 160 mg once daily will be taken for a maximum of 6 cycles while on study.
89378796|NCT02331784|Experimental|Computerized Plasticity-based Software|Computerized Plasticity-based software training requiring a total maximum of 50 treatment sessions, 4-5 times weekly, 40 minutes each session.
89378797|NCT02331784|Active Comparator|Commercially available video game|Commercially available video game training. Treatment is software based, will occur up to 50 times throughout study duration, 4-5 times per week, 40 minutes each session..
89378798|NCT02336152|Experimental|Body suit|The patients will receive a body suit at least 30 min before start of general anaesthesia, and will keep the suit on until warm and comfortable in the post-operative unit. The suit is supplied with multiple snap openings to allow for draping, washing and surgery.
89182696|NCT06238258|Experimental|Training Arm|
89378799|NCT02336152|Active Comparator|Forced warm air|The patients will receive forced warm air on their lower body when placed on operating table, ready for surgery.
89378800|NCT02331862|Experimental|UTI treated with Methylprednisolone|UTI treated with Methylprednisolone in addition to the effective antibiotics
89378801|NCT02331862|No Intervention|UTI not treated with Methylprednisolone|UTI treated with effective antibiotics only
89378802|NCT02327182|Experimental|MT-4666 low dose|Low Dose, Tablet, Once Daily, For 52 Weeks
89378803|NCT02327182|Experimental|MT-4666 high dose|High Dose, Tablet, Once Daily, For 52 Weeks
89378804|NCT02327026|Experimental|bag-valve-mask ventilation|Airway management including initial bag-valve-mask ventilation by the medical team during OHCA. When standard bag-valve-mask ventilation is possible, the patient will be intubated in case of a return of spontaneous circulation. When standard bag-valve-mask ventilation is impossible or in case of massive regurgitation of gastric content (after randomisation), intubation of patient is the preferred alternative
89378805|NCT02327026|Active Comparator|tracheal intubation|Tracheal intubation during OHCA by the medical team: The standard intubation procedure is to use a non-styletted tube and no sedation. When standard laryngoscopy-assisted intubation is not possible, an alternate procedure will be used based on the French consensus conference guidelines on difficult airway management.
89378806|NCT02327104|Experimental|Mindfulness Based Relapse Prevention|The Experimental Group (EG) will undergo eight sessions of MBRP after Brazilian Ministry of Health Protocol (BMHP) for Tobacco dependence treatment. MBRP Program: the first three sessions: focus on practicing mindful awareness and integrating mindfulness practices into daily life (body scan, sitting meditation, walking meditation); The next three sessions: emphasize acceptance of present experience and application of mindfulness practices to relapse prevention; The final two sessions: expand to include issues of self-care, support network, and lifestyle balance.
89378807|NCT02327104|Other|Brazilian Ministry of Health Protocol|The Control Group (CG) is undergo the protocol of the Brazilian Ministry of Health Protocol (BMHP): clinical evaluation, four sessions of cognitive-behavioral approach and Nicotine Replacement Therapy and/or Bupropion as needed, as the Experimental Group. And during the eight sessions of MBRP (EG) both groups (EG and CG) are subjected to eight maintenance sessions of BMHP.
89378808|NCT03070782|Experimental|Cohort A: ISIS 681257: 20 mg Q4W|Cohort A participants received 20 milligrams (mg) ISIS 681257, subcutaneous (SC) injection, once every 4 weeks (Q4W), for up to 49 weeks and a maximum of 13 doses.
89378809|NCT03070782|Experimental|Cohort B: ISIS 681257: 40 mg Q4W|Cohort B participants received 40 mg of ISIS 681257, SC injection, once Q4W, for up to 49 weeks and a maximum of 13 doses.
89378810|NCT03070782|Experimental|Cohort C: ISIS 681257: 60 mg Q4W|Cohort C participants received 60 mg of ISIS 681257, SC injection, once Q4W, for up to 49 weeks and a maximum of 13 doses.
89378811|NCT03070782|Experimental|Cohort D: ISIS 681257: 20 mg Q2W|Cohort D participants received 20 mg of ISIS 681257, SC injection, once every 2 weeks (Q2W), for up to 51 weeks and a maximum of 26 doses.
89378812|NCT03070782|Experimental|Cohort E: ISIS 681257: 20 mg QW|Cohort E participants received 20 mg of ISIS 681257, SC injection, once weekly (QW), for up to 52 weeks and a maximum of 52 doses.
89378813|NCT03070782|Placebo Comparator|Placebo|Participants in each cohort were randomized to receive placebo at a dose-matched volume of study drug (ISIS 681257).
89378814|NCT02335840|Experimental|One dose of coffee|Ingestion of one dose of 150 ml of coffee (144 mg of caffeine) ingested 10 minutes post-exercise (denominated CAF-1)
89378815|NCT02335840|Experimental|Two doses of coffee|Ingestion of two doses of 150 ml of coffee (144 mg of caffeine) ingested 10 and 20 minutes post-exercise (denominated CAF-2)
89378816|NCT02335840|Experimental|Three doses of coffee|Ingestion of three doses of 150 ml of coffee (144 mg of caffeine) ingested 10, 20 and 30minutes post-exercise (denominated CAF-3)
89378817|NCT02335840|Experimental|Three doses of decaffeinated coffee|Ingestion of three doses of 150 ml of decaffeinated coffee (144 mg of caffeine) ingested 10, 20 and 30 minutes post-exercise (denominated DESC)
88817622|NCT01349972|Experimental|Arm I (alvocidib, cytarabine, mitoxantrone hydrochloride)|Patients receive alvocidib IV over 1 hour on days 1-3, cytarabine IV over 72 hours on days 6-8, and mitoxantrone hydrochloride IV over 1-2 hours on day 9. Patients who achieve complete or partial response to the first course (completion of all doses) may receive a second course of treatment or high-dose cytarabine after 21-63 days following blood count recovery, and/or undergo allogeneic bone marrow transplant.
88817623|NCT01349972|Active Comparator|Arm II (cytarabine, daunorubicin hydrochloride)|Patients receive cytarabine IV continuously on days 1-7 and daunorubicin hydrochloride IV on days 1-3. Patients who have residual disease on day 14 may receive additional cytarabine for 5 days and daunorubicin hydrochloride for 2 days.
88817624|NCT01248104|Active Comparator|Tranexamic Acid|The research pharmacist used computer randomization to assign patients to receive either TXA or EACA. The TXA group re- ceived a bolus of 10 mg / kg over 15 minutes fol- lowed by an infusion of 1 mg/kg/hr.
88817625|NCT01248104|Active Comparator|Aminocaproic Acid|The research pharmacist used computer randomization to assign patients to receive either TXA or EACA. The EACA group received a bolus of 100 mg / kg given over 15 minutes shortly after induction of anesthesia followed by an infusion of 10 mg/kg/hr.
88817626|NCT01725815|Experimental|HARP Intervention|
88817627|NCT01725815|No Intervention|No Intervention: Control|Participants in usual care will continue to obtain any mental health or peer-support services that they would otherwise be receiving.
88817628|NCT01351064|Experimental|CHICA ADHD Module|This arm received The CHICA ADHD Module
88817629|NCT01351064|No Intervention|CHICA ADHD Control|This arm received CHICA without the ADHD module
89378818|NCT03756688|No Intervention|Group 1: Control|No treatment will be administered for the entirety of the study (6 months)
89378819|NCT03756688|Experimental|Group 2: Treatment|PTT for 30 min 2x/ day x 3 months, followed by no treatment x 3 months
89378820|NCT03756688|Experimental|Group 3: Treatment|PTT for 30 min 2x/day x 3 months, followed by once weekly (30 minutes) x 3 months
89378821|NCT03756688|Experimental|Group 4: Treatment|PTT for 30 min 2x day x 6 months
89378822|NCT03525119|Other|HAV Vaccine 1.0 ml + Placebo/ Placebo|HAV vaccine 1.0 ml, injection, IM, and placebo-matching injection, SC, once on Day 1 (first dose) followed by placebo-matching injection, SC on Day 90 (second dose).
89378823|NCT03525119|Experimental|TDV 0.5 ml + Placebo/ TDV 0.5 ml|TDV 0.5 ml, injection, SC, and placebo-matching injection, IM, once on Day 1 (first dose) followed by TDV 0.5 ml, injection, SC on Day 90 (second dose).
89378824|NCT03525119|Experimental|TDV 0.5 ml + HAV Vaccine 1.0 ml/ TDV 0.5 ml|TDV 0.5 ml, injection, SC, and HAV vaccine 1.0 ml, injection, IM, once on Day 1 (first dose) followed by TDV 0.5 ml, injection, SC on Day 90 (second dose).
89378825|NCT04423614|Experimental|Inspiratory Muscle Training (IMT)|Pre-operative inspiratory muscle training
89378826|NCT04423614|Experimental|Relaxation Breathing (RLX)|Relaxation breathing exercises
89378827|NCT05230654|Experimental|fosaprepitant|Patients received intravenous Ganisetron plus dexamethasone followed by fosaprepitant infusion
89378828|NCT05230654|Placebo Comparator|Placebo|Patients received intravenous Ganisetron plus dexamethasone followed by normal saline
89378829|NCT05761314|Experimental|Case group|To report the prevalence of solid tumors in a monocentric cohort of individuals with RASopathies
89378830|NCT02039518|Experimental|gemcitabine|gemcitabine 1000mg/m2，d1，d8，Q3W
88852257|NCT04331405|No Intervention|Control group|10 patients with acute severe contusion spinal cord injury (ASIA A/B) included into the group. Patients meeting inclusion/exclusion criteria underwent primary surgical treatment (decompression and stabilization) received standard therapy during in-hospital treatment. After the discharge patients were examined for 4 times. Observation period was 1 year.
88852258|NCT05752253|Other|Patients with Hereditary Hemorragic Teleangectasia|Patients with Hereditary Hemorragic Teleangectasia
88852259|NCT05752175|Experimental|WPV01|
88852260|NCT05752175|Placebo Comparator|Placebo|
88852261|NCT00002537|Experimental|Arm I|Beginning on day 1, patients receive topotecan IV continuously for 3-6 weeks and thoracic radiotherapy 5 days a week for 2, 3, or 6 weeks. Cohorts of 4-6 patients receive escalating doses of topotecan and thoracic radiotherapy until the maximum tolerated dose (MTD) of each therapy is determined. The MTD is defined as the dose preceding that at which 2 of 4 or 6 patients experience dose-limiting toxicity. Six additional patients are treated at the MTD. Patients who fail to achieve complete remission (CR) and continue to have measurable disease at 4-6 weeks after completion of radiotherapy receive topotecan IV continuously on days 1-21 at 1 dose level preceding the MTD as determined by the ongoing Protocol NYU-9123. Treatment continues every 4 weeks in the absence of unacceptable toxicity.
88852262|NCT00002561|Active Comparator|Radiotherapy or ABVD + Radiotherapy|Radiotherapy
89378831|NCT02039518|Other|observation group|observation
89378832|NCT02228304|Experimental|NT-503-3 ECT implantation|
89378833|NCT02228304|Active Comparator|Eylea® injected intravitreally every 8 weeks|Eylea® injected intravitreally every 8 weeks
89378834|NCT04352608|Experimental|Emergency schedule & Two doses of medium dosage vaccine|24 participants in phase Ⅰand 60 participants in phase Ⅱ will receive two doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule,and 60 participants in phase Ⅱ will receive one dose of booster immunization with medium dosage vaccine 6 months after the emergency schedule
89378835|NCT04352608|Experimental|Emergency schedule & Two doses of high dosage vaccine|24 participants in phase Ⅰand 60 participants in phase Ⅱ will receive two doses of high dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule,and 60 participants in phase Ⅱ will receive one dose of booster immunization with high dosage vaccine 6 months after the emergency schedule
88852263|NCT00002561|Active Comparator|ABVD Alone|ABVD Alone
88852264|NCT05751707|Experimental|NIV+/-HFNC (non invasive ventilation +/- high flow nasal cannulae) & HFCWO|Patient with acute or acute on chronic respiratory failure is treated with non invasive ventilation (with or without high flow nasal cannulae oxygen) AND High Frequency Chest Wall Oscillations
88852265|NCT05751707|No Intervention|NIV+/-HFNC and no HFCWO|Patient with acute or acute on chronic respiratory failure is treated with non invasive ventilation (with or without high flow nasal cannulae oxygen) AND NO High Frequency Chest Wall Oscillations
88852266|NCT05751707|Experimental|HFNC & HFCWO|Patient with acute or acute on chronic respiratory failure is treated with high flow nasal cannulae oxygen AND High Frequency Chest Wall Oscillations
89378836|NCT04352608|Placebo Comparator|Emergency schedule &Two doses of placebo|24 participants in phase Ⅰand 30 participants in phase Ⅱ will receive two doses of placebo at the emergency vaccination schedule,and 30 participants in phase Ⅱ will receive one dose of booster immunization with placebo 6 months after the emergency schedule
89378837|NCT04352608|Experimental|Routine schedule & Two doses of medium dosage vaccine|24 participants in phase Ⅰand 60 participants in phase Ⅱ will receive two doses of medium dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule,and 60 participants in phase Ⅱ will receive one dose of booster immunization with medium dosage vaccine 6 months after the routine schedule
89378838|NCT04352608|Experimental|Routine schedule &Two doses of high dosage vaccine|24 participants in phase Ⅰand 60 participants in phase Ⅱ will receive two doses of high dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule,and 60 participants in phase Ⅱ will receive one dose of booster immunization with high dosage vaccine 6 months after the routine schedule
89378839|NCT04352608|Placebo Comparator|Routine schedule & Two doses of placebo|24 participants in phase Ⅰand 30 participants in phase Ⅱ will receive two doses of placebo at the routine vaccination schedule,and 30 participants in phase Ⅱ will receive one dose of booster immunization with placebo 6 months after the routine schedule
89378840|NCT04352608|Experimental|Emergency schedule & Three doses of medium dosage vaccine|60 participants in phase Ⅱ will receive three doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule
89182697|NCT06238232|Experimental|68Ga-Pentixafor PET/CT group|Patients divided into 68Ga-Pentixafor PET/CT group need to undergo 68Ga-Pentixafor PET/CT examination and guide subsequent treatment based on the results
89378841|NCT04352608|Experimental|Emergency schedule & Three doses of high dosage vaccine|60 participants in phase Ⅱ will receive three doses of high dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule
89378842|NCT04352608|Placebo Comparator|Emergency schedule &Three doses of placebo|30 participants in phase Ⅱ will receive three doses of placebo at the emergency vaccination schedule
89378843|NCT04352608|Experimental|Routine schedule & Three doses of medium dosage vaccine|60 participants in phase Ⅱ will receive three doses of medium dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule
89378844|NCT04352608|Experimental|Routine schedule &Three doses of high dosage vaccine|60 participants in phase Ⅱ will receive three doses of high dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule
89378845|NCT04352608|Placebo Comparator|Routine schedule &Three doses of placebo|30 participants in phase Ⅱ will receive three doses of placebo at the routine vaccination schedule
89378846|NCT03722303|Active Comparator|Steroid Injection|Subjects with CTS will receive steroid injection.
88852267|NCT05751707|No Intervention|HFNC and no HFCWO|Patient with acute or acute on chronic respiratory failure is treated with high flow nasal cannulae oxygen AND High Frequency Chest Wall Oscillations
88852268|NCT05719649|Experimental|Probiotic NTU 101 Lactic Acid Bacteria Capsules|The subjects who meet the conditions of this test are randomly assigned according to the ratio of 1:1, and take the lactic acid bacteria NTU 101 (1.8 x 10 ^10 CFU) or Placebo in the test group for a total of 12 weeks of treatment. Once, after the treatment, the test physician evaluated the safety and efficacy of the subjects taking the test group lactobacillus NTU 101.
88852269|NCT05719649|Placebo Comparator|Placebo Capsules|Maltodextrin was used as a placebo.
88852270|NCT00382187|Experimental|MF59 adjuvant H5N1 influenza vaccine 7.5 micrograms|
88852271|NCT00382187|Experimental|MF59 adjuvant H5N1 influenza vaccine 15 micrograms|
88852272|NCT00382187|Experimental|non-adjuvanted influenza vaccine 15 micrograms of H5N1 antigen|
89182698|NCT06238232|No Intervention|AVS group|Patients divided into AVS group need to undergo AVS to guide subsequent treatment based on the results
89182699|NCT06238219||NMBA cohort|Patients undergoing surgery under general anesthesia with use of neuromuscular blocking agents
89182700|NCT06238206|Experimental|People post-stroke|The focus group discussion will assess the needs and requirements of this group.
89378847|NCT03722303|Experimental|Fat Injection|Subjects with CTS will receive fat injection.
89378848|NCT05203146|Experimental|Arm A (PIMPmyHospital)|Participants that will use the mHeath PIMPmyHospital tool during the semi-simulation-based scenario.
89378849|NCT05203146|Active Comparator|Arm B (Conventional methods)|Participants that will use conventional methods (i.e., without mobile app support) during the semi-simulation-based scenario.
89378850|NCT02326792|Experimental|G1-Three sets of exercise|G1 group - the participants will perform three sets of 15-20 repetitions of the trunk extensor exercise on a roman chair machine with the hips at 45 degrees relative to horizontal; performing trunk flexion-extension cycles for a total of 4 seconds (2 s concentric and 2 s eccentric contraction). The relative load for initial training will be placed at 20% back maximal voluntary contraction (MVC) and will be progressive during the training. The time session of training will be of 10 weeks.
89378851|NCT02326792|Experimental|G2-One set of exercise|G2 group - the participants will perform only one set of 15-20 repetitions of the trunk extensor exercise on a roman chair machine with the hips at 45 degrees relative to horizontal; performing trunk flexion-extension cycles for a total of 4 seconds (2 s concentric and 2 s eccentric contraction). The relative load for initial training will be placed at 20% back maximal voluntary contraction (MVC) and will be progressive during the training. The time session of training will be of 10 weeks.
89378852|NCT02326792|No Intervention|G3-Control|G3 group - the participants will be the control group, which not participating of exercise program in any time during the study.
89378853|NCT02326948||Gallbladder cancer case group|Gallbladder cancer case group was defined as newly diagnosed gallbladder cancer diagnosed as GBC at the Department of Internal Medicine in Cheju Halla General Hospital, Jeju, Korea from 2009 to 2013.
88852273|NCT05751395||Critically ill Patients in severe Multiple Organ Dysfunction|Critically ill Patients in severe Multiple Organ Dysfunction in need of a second Central Venous Catheter (CVC) for e.g. blood purification techniques
88852274|NCT00002621|Experimental|Alpha interferon (aIFN) treatment|See detailed description.
88852275|NCT00002633|Active Comparator|Total Androgen Blockade|
88852276|NCT00002633|Active Comparator|Total Androgen Blockade Vs TA Blockade Plus Pelvic Irradiation|
88852277|NCT04659005|Experimental|Nurse-led decision counseling group|Provide education, tailored information, decision support, and psychosocial support regarding hepatocellular carcinoma screening
88852278|NCT04659005|Other|Control group|Usual care provided by the hospital, including one-page written education information about diet, medications, and daily exercises.
88852279|NCT05751005|Experimental|Collagen Supplementation 6 months|Participants were randomized into one of three treatment groups for 6 months (Placebo, 10 g/d collagen peptides, or 20 g/d collagen peptides).
88852280|NCT05751005|Experimental|Collagen Supplementation 9 months|Participants were randomized into one of three treatment groups (Placebo, 10 g/d collagen peptides, or 20 g/d collagen peptides) for additional 3 months after successful completion of the 6 month time point (total of 9 months).
88875312|NCT02584998|Active Comparator|Screening invitation-reminder|Participants will receive UC and also receive an invitation letter with information about CRC testing. The information will include lay-audience description of screening tests and symptoms that should prompt diagnostic work-up. The packet will have instructions to contact the study team if participants believe they are not eligible and to update the contact information on record. The letter will inform participants that a telephone reminder will follow in 4 weeks from invitation letter if screening is not completed. They will also receive notification of test results and navigation to colonoscopy, if needed. For the purposes of this intervention, Week 1 will be the week the invitation letter was sent (time zero).
89182701|NCT06238206|Experimental|Older adults with sarcopenia|The focus group discussion will assess the needs and requirements of this group.
89378854|NCT02326948||Age and sex matched control group|Age and sex matched control group was determined as age-sex matched subjects selected from the participants of Health Promotion Center in the same institute from 2009 to 2012.
89378855|NCT02336542|Experimental|TB subjects|96 TB subjects are divided into four groups average .24 TB subjects are injected 5μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm,24 TB subjects are injected 5μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm,24 TB subjects are injected 10μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm,24 TB subjects are injected 10μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm.
89378856|NCT02336542|Active Comparator|non-TB subjects with lung disease|96 non-TB subjects with lung disease are divided into four groups average .24 TB subjects are injected 5μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm,24 TB subjects are injected 5μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm,24 TB subjects are injected 10μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm,24 TB subjects are injected 10μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm.
89378857|NCT03558503|Experimental|UGN-102|Patients were treated with 6 once-weekly intravesical instillations of UGN-102.
89378858|NCT04351984||Severe Mitral Regurgitation|
89378859|NCT05761236|Active Comparator|Training group|In the first 2 weeks, sessions were held with all patients once a week. In these two sessions, the basic information of scoliosis were explained to both groups. Postural corrections were explained to the patients, including the basic elements of clinical pilates.It was stated that they should breathe towards the concave side of the major curve (weak breathing zone) during exercises and postural corrections.In the Pilates-based exercise program, sessions are planned as 10 minutes of warm-up, 10 minutes of cool-down and 40 minutes of scoliosis-specific pilates-based exercises for approximately 1 hour. Total number of exercises is 12 for one session. After a 2-week joint training week, the training group switched to hybrid type telerehabilitation and continued their exercise sessions with a physiotherapist 3 days a week via synchronous video conferences (Zoom Application) and by themselves at home on the rest of the week.
89378860|NCT05761236|Active Comparator|Control group|In the first 2 weeks, sessions were held with all patients once a week. In these two sessions, the basic information of scoliosis were explained to both groups. Postural corrections were explained to the patients, including the basic elements of clinical pilates. It was stated that they should breathe towards the concave side of the major curve (weak breathing zone) during exercises and postural corrections.In the Pilates-based exercise program, sessions are planned as 10 minutes of warm-up, 10 minutes of cool-down and 40 minutes of scoliosis-specific pilates-based exercises for approximately 1 hour. Total number of exercises is 12 for one session.The patients in the control group continued the exercise program every day of the week for 12 weeks. Exercise lists were sent to the patients in the form of electronic booklets via an electronic communication application every week, and their continuity with the exercise program was checked with the diaries they were asked to fill in.
89378861|NCT02331706|Experimental|Subject Recipients|
89378862|NCT02331706|Experimental|Subject Donors|
89378863|NCT02326870|Experimental|The AutoLap system|Use of the AutoLap system for controlling the laparoscope during the procedure
89378864|NCT03489863|Active Comparator|Prasugrel|Patients will be randomly (1:1) assigned to receive FDA approved doses of either prasugrel (60 mg loading dose - 10 mg/day maintenance dose) or ticagrelor (180 mg loading dose - 90 mg b.i.d maintenance dose).
89378865|NCT03489863|Active Comparator|Ticagrelor|Patients will be randomly (1:1) assigned to receive FDA approved doses of either prasugrel (60 mg loading dose - 10 mg/day maintenance dose) or ticagrelor (180 mg loading dose - 90 mg b.i.d maintenance dose).
89378866|NCT03144934|Experimental|Administraion of investigational product|"0.25mg, 1mg, 3mg, 6mg, or 9mg (optional) of GX-I7~6 subjects per each cohort~twice administration with 4-week intervals"
89378867|NCT03144934|Placebo Comparator|Administraion of placebo|"GX-I7 vehicle (formulation buffer)~2 subjects per each cohort~twice administration with 4-week intervals"
89378868|NCT05763030|Experimental|Intervention|Parent questionnaires and sleep characteristics of children (actigraphy and parent report) will be collected at three-time points- Time 1, 2, and 3. Time 1 is the first Baseline Data Collection for the Control Group and Intervention Group, and these data will be collected before the intervention group starts the 3-week intervention. Between Time 1 and Time 2, the Intervention Group will receive the 3-week intervention at the childcare center.
89378869|NCT05763030|No Intervention|Control|The control arm will not receive the intervention. They will be assessed at time 1 and again at 2, following the completion of intervention in the intervention arm
89378870|NCT05665205|Active Comparator|Aerobic exercise plus strength|The purpose is to verify if the aerobic exercise plus a strength program improves more than aerobic exercise alone in COVID patients.
89378871|NCT05665205|Sham Comparator|Aerobic exercise alone|The purpose is to verify if COVID patients can improve the status of their health only with an aerobic exercise program alone.
89378872|NCT02331472||Interstitial cystitis|Patients who have been diagnosed with interstitial cystitis/bladder pain syndrome. The group includes both patients with or without Hunner lesion on cystoscopy
89378873|NCT02331472||Control|Adult participants without history of interstitial cystitis/bladder pain syndrome
89182702|NCT06238206|Experimental|Physiotherapists|The focus group discussion will assess the needs and requirements of this group.
89182703|NCT06238193||Early-onset colorectal cancer|Early-onset colorectal cancer
89378874|NCT04344444|No Intervention|Arm A|Supportive Care only
89378875|NCT04344444|Experimental|Arm B|Hydroxychloroquine 400 mg po bid on Day 1 Hydroxychloroquine 200 mg po bid Days 2 through 5
89378876|NCT04344444|Experimental|Arm C|Hydroxychloroquine as in Arm B AND Azithromycin 500 mg po on Day 1 Azithromycin 250 mg po days 2 through 5
89378877|NCT03489551|Experimental|Oral Haldol in patients undergoing HSCT|Prior to stem cell transplant participants will receive 5mg of liquid or pill form, oral Haldol. Every other day visits will take place following the first administration of the study drug until 14 days after the transplant.
89182704|NCT06238193||Late-onset colorectal cancer|Late-onset colorectal cancer
89182705|NCT06238167|Experimental|Arm A|"Treatment arm(Tislelizumab+S-1/SOX)~Enrolled patients will receive chemotherapy combined with tislelizumab postoperative adjuvant therapy. Chemotherapy regimens were determined by the investigator as S-1 therapy or low dose SOX therapy"
89182706|NCT06238154|Experimental|Spray group|Spray group consisted of individuals who used flurbiprofen in spray form as a postoperative analgesic
88852281|NCT00002657|Experimental|Immumosuppression, IFN-a, ProMACE-CytaBOM|Doses and schedules of immunosuppressive drugs (cyclosporin (or FK506), prednisone, and acyclovir) will depend on whether patients are judged to have clinically urgent disease or not. Patients who do not have a CR after initial immunosuppression will receive 3 cycles (28 days each) Interferon alpha 2b at 3.0 x 10^6 IU/m^2 on days 1-28. Patients who have a CR will then receive 6 additional cycles with 3 doses per week, then go onto observation. Patients who do not have a CR will then receive a maximum of 6 21-day cycles of chemotherapy, consisting of: cyclophosphamide 650 mg/m^2 on day 1, adriamycin 25 mg/m^2 on day 1, etoposide 120 mg/m^2 on day 1, prednisone 60 mg/m^2 on days 1-14, cytosine arabinoside 300 mg/m^2 on day 8, bleomycin 5 mg/m^2 on day 8, vincristine 1.4 mg/m^2 on day 8, methotrexate 120 mg/m^2 on day 8, leucovorin 25 mg/m^2 q 6 hours on days 8-9, G-CSF 5 ug/kg/day on days 2-14, and one double strength tablet trimethoprim-sulfamethoxazole 3 times per week.
88852282|NCT00381719|Experimental|1|3 mg
88852283|NCT00381719|Experimental|2|20 mg
88852284|NCT00381719|Experimental|3|60 mg
88852285|NCT00381719|Placebo Comparator|4|Placebo
88852286|NCT05750771|Experimental|DCB Group|Implantation of drug-coated balloons in patients with satisfactory pretreatment
88852287|NCT05750771|Experimental|DES Group|Implantation of drug-eluting stents in patients with satisfactory pretreatment
88852288|NCT05750693|Experimental|Patients who received neoadjuvant chemotherapy|Breast cancer samples of paraffin embedded tissue, obtained from the waste material of the diagnostic core-biopsy, stored at the Pathological Anatomy Service, will be used in order to analyze PIK3CA mutations status.
88852289|NCT02973113|Experimental|EBVST Cells + Nivolumab|"PD1 inhibitor - nivolumab 3 mg/kg (max dose: 240 mg) Q 2 weeks for total 4 doses and repeat a day prior to each EBVST infusion.~EBVST- 1 x 10^8/m2 at days +1 and +15. PD1 inhibitor - nivolumab 3 mg/kg (max dose: 240 mg) Q 2 weeks for total 4 doses and repeat a day prior to each EBVST infusion.~Can receive up to 3 additional infusions of EBVSTs with a single dose of nivolumab at 6-12 week intervals starting at least 6 weeks after the second infusion if stable disease or a partial response at Week 8 evaluation"
88852290|NCT05665439|Experimental|local treatment|
88852291|NCT05665439|No Intervention|observation|
88852292|NCT05750615||Quantitative phase|Pessary using women
88852293|NCT05750615||Qualitative phase|Pessary using women
88852294|NCT05750615||Intervention development phase|Pessary using women and pessary practitioners
88852295|NCT05750615||Pilot phase|Pessary using women
88852296|NCT05750381|Active Comparator|Study Group A: Blis Q24 balm (Active)|Group A: Probiotic Micrococcus luteus Q24 balm (dose: 1e7 colony forming units per application)
88852297|NCT05750381|Placebo Comparator|Study Group B: Placebo balm (without Blis Q24)|Group A: Placebo balm
88852298|NCT00002705|Experimental|Arm I|Single-Agent Chemotherapy. Topotecan, TOPO, NSC-609699.
88852299|NCT05750303||Subacute ischemic stroke|blood sample collection to determine VEGF, IGF-1 and MMP-9 level in plasma and expression of genes VEGF, IGF-1, MMP-9 in whole blood samples
88852300|NCT05750303||No ischemic stroke and no other neurological disease control group|blood sample collection to determine VEGF, IGF-1 and MMP-9 level in plasma and expression of genes VEGF, IGF-1, MMP-9 in whole blood samples
88852301|NCT00002723|Experimental|Low dose suramin|Low dose suramin
89182707|NCT06238154|Active Comparator|Tablet group|Tablet group consisted of individuals who used flurbiprofen in tablet form as a postoperative analgesic
89182708|NCT06238141|Experimental|intervention group|
89182709|NCT06238141|Sham Comparator|control group|
88852302|NCT00002723|Experimental|Intermediate dose suramin|Intermediate dose suramin
88852303|NCT00002723|Experimental|High dose suramin|High dose suramin
88852304|NCT05648123|Experimental|Supportive Psychotherapy|supportive psychotherapy will be given in the form of an online group for 3 times a week with a duration of psychotherapy ranging from 1 - 2 hours per session
88852305|NCT05648123|Active Comparator|Education|education about post covid-19 syndrome will be given in the form of an online group for 3 times a week with a duration about 1 - 2 hours per session
88852306|NCT00002735|Experimental|Treatment arm|induction chemotherapy followed by chemoradiation
88852307|NCT02973035|Experimental|Amlodipine|Amlodipine 2.5mg added to antihypertensive therapy
88852308|NCT02973035|Experimental|Valsartan|Valsartan 40mg added to antihypertensive therapy
88852309|NCT05749991|Experimental|DryShield Isolation|Device: Dryshield DryShield (DS) is an all-in-one isolation system. It combines the tasks of fluid evacuation, tongue and cheek retraction, and serves as a bite block. Its design allows it to suction and isolate half the oral cavity at a time. Dryshield was used to isolate teeth that required sealant placement in the assigned participants.
88852310|NCT05749991|Active Comparator|Cotton Roll Isolation|"Cotton Roll Isolation requires placing cotton rolls along the buccal mucosa, especially over the parotid glands ducts for maxillary teeth. For the mandibular teeth, the cotton rolls are placed in the buccal vestibule and the floor of the mouth (between the lower buccal mucosa and underneath and/or between the tongue).~Cotton roll isolation was used to isolate teeth that required sealant placement in the assigned participants.~With this technique, a high-speed evacuation of saliva and water is used."
88852311|NCT00002759|Experimental|Arm I|See detailed description.
88852312|NCT04611035||Patient|Patient with first-line gastrointestinal cancers and patient with advanced and refractory GI cancers (>1 line of treatment), or post-progression biopsy)
88852313|NCT05749757|Experimental|Acupuncture|Hwato brand disposable acupuncture needles (size 0.30 × 40 mm) and adhesive pads will be used. Acupoints of Guanyuan, Zhongwan, Tianshu, Zusanli, Taixi, Shangyintang, Taiyang, Hegu, Taichong and Shenmen will be selected. Participants will receive a total of 10-session acupuncture treatment during four weeks, three times a week in the first two weeks and twice a week in the last two weeks.
89182710|NCT06238128|Experimental|ORRS training group|Online Naloxone training
89378878|NCT03144544||Pediatric specialist hospitals|Free-standing hospitals providing tertiary pediatric referral services and performing pediatric surgical procedures
89378879|NCT03144544||Non-pediatric specialist hospitals|Other hospitals performing pediatric surgical procedures
89378880|NCT05762952|Experimental|Dapagliflozin|Dapagliflozin 10mg oral tablet.
89378881|NCT05762952|Placebo Comparator|Placebo|Placebo matching tablet.
89378882|NCT03722225|Experimental|Descriptive, single arm, interventional study|The intervention consisted of carbohydrate loading prior to and intermittent high carbohydrate intake during physical exercise and a proactive use of Real-Time Continuous Glucose Monitoring (rtCGM) to achieve and maintain glucose control
89378883|NCT02331550|Experimental|Expectant treatment|Patients diagnosed with Low-Grade Squamous Intraepithelial Lesions that were managed with observation and evaluation at 6 and 12 months after diagnosis.
89378884|NCT02331550|Experimental|Ablative treatment|Patients diagnosed with Low-Grade Squamous Intraepithelial Lesions that were managed with an ablative treatment and evaluated at 6 and 12 months after diagnosis.
89378885|NCT02335684|Experimental|CF-LVAD patients.|Patients are compared with themselves during submaximal exercise testing with baseline pump speed vs. submaximal exercise testing with increased pump speed.
89378886|NCT03557801|Active Comparator|Standard of Care Mammography|Immediately following consent and completion of the baseline assessment, women in the control arm will receive standard of care well woman screening. The control arm will receive screening results per standard of care protocol.
89378887|NCT03557801|Experimental|Mammography with Community Health Worker (individual)|Immediately following consent and completion of the baseline assessment, women in the intervention arm 1 will participate in a 20-30 minute educational session alone with the community health worker. Well woman screening will follow the educational session. The community health worker will be available to assist with questions and language interpretation as necessary. After standard delivery of screening results, the community health worker will contact these participants to answer any questions about their screening results and to assist with scheduling any additional tests necessary.
89378888|NCT03557801|Experimental|Mammography with Community Health Worker (group)|Immediately following consent and completion of the baseline assessment, women in the intervention arm will participate in a 20-30 minute group educational session from the community health worker. Well woman screening will follow the educational session. The community health worker will be available to assist with questions and language interpretation as necessary. After standard delivery of screening results, the community health worker will contact these participants to answer any questions about their screening results and to assist with scheduling any additional tests necessary.
89378889|NCT04210180|Experimental|Varenicline plus e-cigarette|Participants enrolled in the study will receive a G6 e-cigarette at V2 for ad libitum use. The FDA approved starter kit of varenicline will be provided to participants at V3 (0.5 mg nightly for days 1-3, then 0.5 mg twice daily for days 4-7) along with additional G6 cartomizers. After the first week of varenicline, participants will receive the FDA-approved standard dose of varenicline (1 mg twice daily) and will continue to receive enough G6 cartomizers for the next 11 weeks.
89378890|NCT03523871|Experimental|Post Lung Transplant Patients|The lung transplantation will be performed per standard of care techniques,and all post-transplant management of the transplanted organ, including immunosuppression, will be carried out per standard of care.
89378891|NCT04017390|Experimental|Arm 1: Theraworx Foam alone|Theraworx foam only
89378892|NCT04017390|Active Comparator|Arm 2: Theraworx Foam and night splint|Theraworx foam with a night time splint
89378893|NCT04017390|Placebo Comparator|Arm 3: Placebo foam alone|Placebo foam alone
89378894|NCT04017390|Other|Arm 4: Placebo foam and night splint|Placebo foam with a night time splint
89378895|NCT03523715|Experimental|Prunes|The study group will be instructed to consume 4 oz of prunes as well as docusate sodium twice daily for 3 days after surgery.
89378896|NCT03523715|Placebo Comparator|Control|The placebo group will be instructed to take docusate sodium twice daily for 3 days after surgery.
89378897|NCT03980730|Experimental|Azeliragon|Azeliragon 5mg capsule administered orally, once daily for 6 months (Part 1) or 18 months (Part 2)
89378898|NCT03980730|Placebo Comparator|Placebo|Matching placebo capsule administered orally, once daily for 6 months (Part 1) or 18 months (Part 2)
89378899|NCT03523091|Experimental|3 Injection Sites|OnabotulinumtoxinA 100Unit injection into 3 sites throughout the bladder
89378900|NCT03523091|Experimental|10 Injection Sites|OnabotulinumtoxinA 100Unit injection into 10 sites throughout the bladder
89378901|NCT02512510|Active Comparator|TD-4208-1|88 mcg
89378902|NCT02512510|Active Comparator|TD-4208-2|175 mcg
89378903|NCT02512510|Placebo Comparator|Placebo|Placebo
89378904|NCT00753090|Experimental|VG DDRP|This arm utilizes the Vanguard™ Deep Dish Rotating Platform Knee.
89378905|NCT00753090|Active Comparator|VG CR|This arm utilizes the Vanguard™ Cruciate Retaining Knee.
88852314|NCT05749757|Sham Comparator|Sham Acupuncture|Hwato brand disposable placebo needles (with the handle identical to the needles in the acupuncture group and the body at a size 0.30 × 25 mm) and adhesive pads will be used. Acupoints of Guanyuan, Zhongwan, Tianshu, Zusanli, Taixi, Shangyintang, Taiyang, Hegu, Taichong and Shenmen will be selected. Participants will receive a total of 10-session sham acupuncture treatment during four weeks, three times a week in the first two weeks and twice a week in the last two weeks.
89378906|NCT03438383|Sham Comparator|Sham Bi-PAP|"Sham Bi-PAP was applied through nasal mask for 3 days postoperatively. Sham Bi-PAP was created by introducing a hole at the connection of the mask with the spiral tube of Bi-PAP. With this modality, also used on previous studies, the applied pressure by sham Bi-PAP was constant and equal to 2 centimeter of water (cm H2O)."
89378907|NCT03438383|Active Comparator|Bi-PAP|Bi-PAP through nasal mask, at individualized IPAP/EPAP pressures, was applied for 3 days postoperatively. IPAP and EPAP in the Bi-PAP system were individualized for each patient in accordance with accepted values of SpO2, PaCO2, and patient synchronization and tolerability with the device.Individualized setting of pressures in patient group was applied gradually starting with 12/4 cm H2O (IPAP/EPAP) and up to 18/10 (IPAP/EPAP) with consecutive increases of 2 cm H2O.
89378908|NCT05762016||incision and drainage group|patients with breast abscess who undergo incision and drainage
89378909|NCT05762016||percutaneous drainage group|patients with breast abscess who undergo percutaneous drainage
88852315|NCT00381953|Active Comparator|360 PEG IFN|360 mug peginterferon alfa-2a QW
89378910|NCT05762016||MISE group|patients with breast abscess who undergo MISE
89378911|NCT03105310|Active Comparator|Pegylated interferon|Pegylated interferon alfa alone 180 microgram subcutaneous weekly for 24 weeks
89378912|NCT03105310|Experimental|Pegylated interferon with ezetimibe|Pegylated interferon alfa 180 micro-gram subcutaneous weekly for 24 weeks and Ezetimibe 10 mg orally for 24 weeks
89378913|NCT05179434|Experimental|Retrograde graft reperfusion|Kidney transplantation with retrograde venous reperfusion of renal graft followed by arterial reperfusion
89378914|NCT05179434|Active Comparator|conventional antegrade perfusion|Kidney transplantation with conventional arterial reperfusion of renal graft (without retrograde venous reperfusion)
89378915|NCT02326714|Experimental|Auricular acupressure|The magnetic beads will be taped to the seven pressing points: Hunger point, Ovary, Uterus, Endocrine point, liver, kidney and spleen.
89378916|NCT02326714|Placebo Comparator|Placebo auricular acupressure|The magnetic beads will be taped to the three pressing points:Tonsil, eye and elbow.
89378917|NCT03144466|Experimental|Part A - Starting dose|100mg of pembrolizumab in n=3 patients, administered in 8 cycles every 3 weeks for a total of 18 weeks commencing two weeks prior to first fraction of radiotherapy and given in combination with Radical Radiotherapy, Brachytherapy and Cisplatin Chemotherapy. Increase in cohort by three patients to n=6 patients provided no more than 1/3 patients experience a Dose Limiting Toxicity (DLT).
89378918|NCT03144466|Experimental|Part A - Escalation dose|Escalation of dose to 200mg of pembrolizumab in a further n=3 patients provided no more than 1/6 patients at starting dose experience a DLT. Increase in cohort by three patients to n=6 patients provided no more than 1/3 patients experience a Dose Limiting Toxicity (DLT).
89378919|NCT03144466|Experimental|Part B - Expansion phase|Recruitment of expansion cohort of n=14 patients using Maximum Tolerated Dose (MTD) of Pembrolizumab as determined in the dose escalation phase. MTD to be administered in 8 cycles every 3 weeks for a total of 18 weeks commencing two weeks prior to first fraction of radiotherapy and given in combination with Radical Radiotherapy, Brachytherapy and Cisplatin Chemotherapy.
89378920|NCT05173350|Experimental|RETAIN Programming|The experimental group receives the full set of RETAIN intervention activities.
88852316|NCT00381953|Active Comparator|9 MU + 180 PEG IFN|9 MU interferon daily in combination with 180 mug peginterferon QW in the first 4 weeks of treatment
89378921|NCT05173350|Active Comparator|Active Comparator|The active comparator group does not receive the full set of RETAIN intervention activities.
89378922|NCT03105466|Experimental|Acellular porcine cornea group|Participants with corneal diseases not involving the endothelial layer undergo deep anterior lamellar keratoplasty using acellular porcine cornea
89378923|NCT02335528|Experimental|SimCoach intervention|"Participants randomized to the SimCoach intervention arm interacted with Bill Ford, a simulated human (avatar) enacted in the SimCoach program. This white male avatar representing himself as an Army veteran who spoke to participants in a conversational manner. Participants interacted with him using a chat interface, where they could type responses to him. Bill Ford asked participants a series of questions that corresponded to validated PTSD or depression screening questionnaires. SimCoach then provided personalized recommendations for a symptom if the user reported experiencing the symptom at one of the two highest frequencies on the response scale. These recommendations consisted of a behavioral recommendation with an accompanying link to a website or online article on the topic."
88852317|NCT00381953|Active Comparator|4,5 MU IFN + 180 PEG IFN|4,5 MU interferon daily in combination with 180 mug peginterferon QW in the first 4 weeks of treatment
88852318|NCT05749523|Other|Exercise|Exercise vs. non-exercise
88852319|NCT05613881|Experimental|EXPERIMENTAL GROUP|the group to be trained and then monitored by phone
88852320|NCT05613881|No Intervention|CONTROL GROUP|The individuals in this group will be given only education booklet by the researcher after the pre-tests are applied in the first face-to-face interview. 3 months after the first interview, the final tests will be applied.
88852321|NCT00382343|Experimental|sulfamethoxazole/trimethoprim|Antibiotic prophylaxis with sulfamethoxazole/trimethoprim [1-2 mg/kg trimethoprim and 5-10 mg/kg sulfamethoxazole once daily]; in case of intolerance (leucopoenia) and for children younger than 6 months: nitrofurantoin [2 mg/kg once daily]
88852322|NCT00382343|No Intervention|No prophylaxis|
89182711|NCT06238128|Sham Comparator|Waitlist group|"Participants will receive non-active opioid overdose response training. Investigators will provide online training about opioid prevalence in US, opioid mechanism, side effect, and addiction. However, Investigators do not provide any knowledge about opioid overdose management and naloxone in this training.~Once the project is completed, participants will receive online Naloxone training."
89378924|NCT02335528|No Intervention|Content Matched Control|Participants assigned to the Content Matched Control condition arm completed text-based versions of the PCL PTSD screening inventory and PHQ-9 depression screening inventory. These instruments used standard, validated language and did not use the modified conversational versions used in the SimCoach intervention condition. The same personalized recommendations provided to the SimCoach group were provided as conventional text and links. After receiving personalized recommendations, participants completed text versions of primary help-seeking, perceived barriers to seeking help, and secondary outcome (user experience) measures.
89378925|NCT02335528|No Intervention|No-Treatment Control|Participants randomized to the No-Treatment Control arm completed measures of the primary outcome (intentions to seek help) prior to being given a choice of SimCoach or the conventional screening administered in the other two arms of the study. After the help-seeking intention questionnaire was administered, participants were told that they would be asked some questions about any PTSD or depression symptoms that they might be having and were given the choice between chatting online with a virtual human or using an online form (options were presented in random order to prevent any influence of ordering on selection of the tool). After either interacting with SimCoach or filling out an online form, participants completed a questionnaire assessing user experience.
89378926|NCT03478787|Experimental|Risankizumab|Participants randomized to risankizumab receive 2 injections of active risankizumab (150 mg total dosage) subcutaneously (SC) at Weeks 0 and 4, and then every 12 weeks (q12w) thereafter until the last dose at Week 40 (Week 64 for participants in France).
89378927|NCT03478787|Active Comparator|Secukinumab|Participants randomized to secukinumab receive 2 injections of active secukinumab (300 mg total dosage) SC at Weeks 0, 1, 2, 3, and 4, and then every 4 weeks (q4w) thereafter until the last dose at Week 48.
89378928|NCT05761938||cohort A|pathologically confirmed membranous nephropathy
88852323|NCT05749445||Nirmatrelvir-Ritonavir|Hospitalized patients receiving at least one dose Nirmatrelvir-Ritonavir
88852324|NCT05749367|Active Comparator|Suprainguinal Fascia Iliaca Block Group|Patients will undergo SIFIB with ropivacaine and PENG plus LFCNB with saline solution.
88852325|NCT05749367|Experimental|PENG Block + Lateral Femoral Cutaneous Nerve Block Group|Patients will undergo SIFIB with saline solution and PENG plus LFCNB ropivacaine.
88852326|NCT05502887||Researched Group|All patients with newly diagnosed or preexistent hematological neoplasms at participating centers are intended to be registered within EndoCDO-H. Prior to inclusion, patients have to give their written informed consent.
88852328|NCT05501249|Experimental|Aquatic Exercise Group|Aquatic class 45 minutes, 3 times a week, for 8 weeks
88852329|NCT05501249|No Intervention|Control Group|Usual care for 8 weeks and one hour education session on fall prevention.
88852330|NCT05749133|Experimental|Anti-GPRC5D CAR-T|Subjects who meet the enrollment conditions will receive intravenous infusion of Anti-GPRC5D CAR-T Cells Injection, doses of 1.0~6.0×10^6 /kg±20% CAR-T cells, after lymphodepleting therapy.
88852331|NCT04331171||Web-application users|questionnaire of comorbidity and symptomes completed by the user on his smartphone
88852332|NCT05590481|Experimental|EG (experimental group): TIBIAL TRANSCUTANEOUS ELECTROSTIMULATION + Behavioral Therapy|EG (experimental group): submitted to a behavioral therapy protocol, which involves bladder training, pelvic floor muscle training and modification of liquid intake. The orientation will be based on the initial evaluation of the patient, in which the responsible researcher will give verbal orientations and deliver booklets on the pathology, behavioral therapy and sleep hygiene. In addition, patients will be submitted to biphasic current and surface electrodes during 12 treatment sessions, twice a week, on non-consecutive days, with a DUALPEX 961s electrical stimulation device (Quark, Brazil).
88852333|NCT05590481|Sham Comparator|GS (Sham-sham group): Behavioral therapy|GS (Sham-sham group): submitted to a behavioral therapy protocol, which involves bladder training, pelvic floor muscle training and modification of liquid intake. The orientation will be based on the initial evaluation of the patient, in which the responsible researcher will give verbal orientations and deliver booklets on the pathology, behavioral therapy and sleep hygiene. Twelve sessions will be held, twice a week, on non-consecutive days. The electrodes of the DUALPEX 961 equipment will be positioned one immediately posterior to the lateral malleolus of the ankle and the other approximately 30 cm above it, where there is no stimulus for the tibial nerve.
88852334|NCT05490017|Experimental|Part 1: Single Ascending Dose Cohort 1|
88852335|NCT05490017|Experimental|Part 1: Single Ascending Dose Cohort 2|
88852336|NCT05490017|Experimental|Part 1: Single Ascending Dose Cohort 3|
88852337|NCT05490017|Experimental|Part 1: Single Ascending Dose Cohort 4|
88852338|NCT05490017|Experimental|Part 1: Single Ascending Dose Cohort 5|
88852339|NCT05490017|Experimental|Part 1: Single Ascending Dose Cohort 6|
88852340|NCT05490017|Experimental|Part 1: Single Ascending Dose Cohort 7|
88852341|NCT05490017|Experimental|Part 2: Multiple Ascending Dose Cohort 1|
88852342|NCT05490017|Experimental|Part 2: Multiple Ascending Dose Cohort 2|
88852343|NCT05490017|Experimental|Part 2: Multiple Ascending Dose Cohort 3|
88852344|NCT05490017|Placebo Comparator|Part 1: Placebo|
88852345|NCT05490017|Placebo Comparator|Part 2: Placebo|
88852346|NCT05748977|Experimental|SABA,SAMA ICS|
88852347|NCT05748977|Experimental|LABA,LAMA ICS|
88852348|NCT02972957|Experimental|LAIV-vaccinated group 1|Nasovac-S vaccination group A , blood samples days 0, 2, 21
88852349|NCT02972957|Experimental|LAIV-vaccinated group 2|Nasovac-S vaccination group B, blood samples at days 0, 7, 21
88852350|NCT02972957|No Intervention|Unvaccinated|control group C
88852351|NCT02972957|Experimental|Oral Azithromycin & vaccination|group D - a single dose of oral Azithromycin will be given 28 days prior to Nasovac-S vaccination
88852352|NCT05748899|Experimental|group number 1|Group number 1 will receive home-based daily ujjayi pranayama for six weeks (fifteen minutes in the morning and 15 min in the evening, this training will be online supervised).
88852353|NCT05748899|No Intervention|group number 2|The group number 2 will not receive pranayama training, so it serves as control lupus group
88852354|NCT05446259||DCM group|Subjects diagnosed with degenerative cervical myelopathy.
88852355|NCT05446259||Control group|Subjects diagnosed with cervical spinal disease without myelopathic symptoms.
88852356|NCT05748743|Experimental|Glove change group|The surgical gloves were changed prior to closure of the peritoneum or closure of the abdominal fascia
88852357|NCT05748743|No Intervention|Usual care group|The surgical gloves were not changed before abdominal closure
88852358|NCT05469191|Experimental|Group 5 STS|Group 5 STS will perform the same protocol as group 10 STS, only the number of repetitions between each set will change.
88852359|NCT05469191|Experimental|Group 10 STS|Group 10 STS will perform the same protocol as group 5 STS, only the number of repetitions between each set will change.
88852360|NCT05469191|No Intervention|Control group|Control group, no intervention.
88852361|NCT04571333|Experimental|Mi2000 Cochlear Implant surgery|During the surgery visit, the Mi2000 Cochlear Implant will be implanted according to the general surgical guidelines and the Mi2000 specific surgical guidelines under general anaesthesia.
88852362|NCT05545319|Experimental|Nirmatrelvir/ritonavir|Participants will receive nirmatrelvir/ ritonavir 300 mg/100 mg (or 150 mg/100 mg for participants with estimated glomerular filtration rate (eGFR) or estimated creatinine clearance (eCrCl) ≥30 to <60 mL/min) every 12 hours from Day 1 through Day 15
88852363|NCT05545319|Experimental|Placebo/ritonavir|Participants will receive placebo 0 mg/ritonavir 100 mg every 12 hours for 15 days.
88852364|NCT05446337||Patients and Informal Care Givers|Individuals living with diabetes who are receiving or have received care through the Diabetes Foot Care and Limb Preservation Pathway at various stages of the care pathway including screening & prevention, wound care treatment, surgery and monitoring.
88852365|NCT05446337||Healthcare Providers|Medical, Nursing, and other allied healthcare providers including chiropodists, physiotherapists, occupational therapists, social workers, and nutritionists.
88852366|NCT05446337||Stakeholders|Individuals external and internal involved in clinical care, continuity of care, and policy-making including but not limited to senior hospital leadership, decision support, and researchers and policy decision-makers.
88852367|NCT05536427|Experimental|IPM001|A neoantigen/ tumor-specific antigen sencitized autoimmune cell injection
88852368|NCT05526287|Experimental|Dual-Task Group|Participants will receive 8 weeks of dual-task training twice a week and home exercise program.Dual-task training will include motor-motor and motor-cognitive dual-task activities.Home exercise program will include core and lower extremity exercises.Home exercises will be performed three times a week.
88852369|NCT05526287|Active Comparator|Control Group|Participants will receive 8 weeks of home exercise program.Home exercise program will include core and lower extremity exercises.Home exercises will be performed three times a week.
88852370|NCT05523869|Experimental|Intravitreal topotecan with pars plana vitrectomy with or without scleral buckle|
88852371|NCT05523869|Active Comparator|Pars plana vitrectomy with or without scleral buckle|
88852372|NCT05523557|Experimental|Urban Training Group|The PA will consist of the following components: motivational interview, exercise following a dossier containing various maps of Urban Training walking trails (at least 30 minutes per day/5 days per week) and use of a Fitbit Inspire (FitBit, San Francisco) and motivational follow-up visit, in group, once per month during the follow-up period.
88852373|NCT05523557|No Intervention|Control Group|The intervention will consist of a general recommendation to perform regular physical activity .
88852374|NCT05522465|Experimental|prednisone group|prednisone 4mg/kg.d
89378929|NCT05761938||cohort B|pathologically confirmed minimal change disease (MCD) or primary focal segmental glomerulosclerosis (FSGS)
88852375|NCT05522465|Active Comparator|Dexamethasone|Dexamethasone 0.6mg/kg.d
88852376|NCT04428047|Experimental|bintrafusp alfa|bintrafusp alfa will be administered by intravenous infusion over 60 minutes at a dose of 1200 mg on Day1 and Day15
88852377|NCT05248061|Active Comparator|Group A|home exercise program
88852378|NCT05248061|Experimental|Group B|PRP+home exercise program
88852379|NCT05233865|Experimental|Water condition|Participants blood pressure, heart rate and self-reported symptoms (such as dizziness) will be collected multiple times during sitting, standing and walking conditions when in a pool.
88852380|NCT05233865|Active Comparator|Land condition|Participants blood pressure, heart rate and self-reported symptoms (such as dizziness) will be collected multiple times during sitting, standing, and walking conditions when on land.
88852381|NCT05230277|Placebo Comparator|The experimental group is defined by the sham osteopathic treatment (SOT)|Patients will receive 3 SOT of 30 minutes each for 2 weeks in a private practice by an experienced osteopath who will receive prior training to optimize the quality of the SOT. The positions of the patient and the practitioner will be the same as in the AOT group
88852382|NCT05230277|Experimental|The experimental group is defined by the active osteopathic treatment (AOT)|Patients will receive 3 AOT of 30 minutes each for 2 weeks in a private practice by an experienced osteopath who will receive prior training to optimize the quality of the AOT.
88852383|NCT04835675||Cancer Arm|Participants with new diagnosis of hepatobiliary malignancies, from whom blood samples will be collected
88817630|NCT01747343|Experimental|Underwear/Differential Reinforcement|All subjects will wear underwear followed by wearing underwear while receiving differential reinforcement.
88852384|NCT04835675||Benign Diseases Arm|Participants with benign diseases of the hepatobiliary system, from whom blood samples will be collected
88852385|NCT05218187|Active Comparator|Conventional Physical Therapy (CPT) Group|CPT sessions will involve a warm-up using a cycle ergometer or treadmill walking, stretching, progressive strength training exercises, and balance training. Gait training will be provided using traditional over-ground walking. Additional strategies for home exercises, fall prevention, and appropriate assistive devices (i.e., orthotics) will be provided. Training will be administered 2 times per week for 40-60 minutes for six weeks.
89378930|NCT03105154|Experimental|Prevena Dressing|Groin dressed with Prevena
89378931|NCT03105154|Active Comparator|Conventional Dressing|Groin dressed with conventional bandage
88817631|NCT01351376|Placebo Comparator|Placebo|CDT + inactive LLL
88817632|NCT01351376|Active Comparator|LLL combined with CDT|CDT + active LLL
88817633|NCT01748045|Experimental|inhaled Nitric Oxide|iNO to start at 20 parts per million (ppm) for the first three days of life. The dose will then be decreased to 10 ppm for three days, 5 ppm for 3 days and then 2 ppm until all high flow respiratory support has been discontinued.
88817634|NCT01748045|Placebo Comparator|Nitrogen Gas|Placebo gas will be adjusted the same as study gas: to start at 20ppm for the first three days of life. The dose will then be decreased to 10 ppm for three days, 5 ppm for 3 days and then 2 ppm until all high flow respiratory support has been discontinued.
88817635|NCT03009266|Experimental|Normal controls|Normal controls who will undergo dose-ranging studies to determine the optimal dose of phosphatidylserine-containing microbubbles that does not produce delayed myocardial opacification on myocardial contrast echocardiography (MCE).
88817636|NCT03009266|Experimental|Patients with ACS|Subjects with ACS who have undergone primary percutaneous intervention in whom MCE with phosphatidylserine-containing microbubbles will be performed to determine whether the risk area can be detected and spatially defined.
88817637|NCT04580589||Adverse Drug Reaction on DOAC|Participants on Direct Oral Anti-coagulants (DOACs) who experience major bleeding or clinically relevant non-major bleeding per International Society of Thrombosis and Haemostasis criteria. This is an observational study, so there will be no intervention.
88817638|NCT04580589||Treatment Failure on DOAC|Participants on Direct Oral Anti-coagulants (DOACs) who experience treatment failure (e.g., recurrent MI, systemic embolism, ischemic stroke, etc.). This is an observational study, so there will be no intervention.
88817639|NCT04580589||Case Control|Participants on Direct Oral Anti-coagulants (DOACs) who experience neither major bleeding or treatment failure.
88817640|NCT01312766|Experimental|hMG-IBSA|New hMG preparation.
88817641|NCT01312766|Active Comparator|Menopur|
88817642|NCT01749215|Experimental|Topiramate|Topiramate capsules daily - up to 300 mg
88817643|NCT01749215|Placebo Comparator|Placebo|Placebo capsules daily - up to 300 mg
88817644|NCT04522167|Experimental|FYB203 (Proposed aflibercept biosimilar)|Patients will receive intravitreal (IVT) injections of FYB203 as detailed in the protocol.
88817645|NCT04522167|Active Comparator|Eylea® (Aflibercept)|Patients will receive intravitreal (IVT) injections of Eylea® as detailed in the protocol.
88817646|NCT01726673|Experimental|tDCS + robotic arm therapy|Transcranial Direct Current Stimulation (tDCS) 2mA for 20 minutes over the primary motor cortex (M1) in the affected hemisphere immediately followed by robotic arm therapy for 60 minutes, 3x per week for 12 weeks (36 sessions total)
88817647|NCT01726673|Placebo Comparator|tDCS sham + robotic arm therapy|Transcranial Direct Current Stimulation sham condition (0 mA) for 20 minutes over the primary motor cortex (M1) in the affected hemisphere immediately followed by robotic arm therapy for 60 minutes, 3x per week for 12 weeks (36 sessions total)
88817648|NCT01248416|Active Comparator|Aromatase Inhibitor|Anastrozole 1mg or Letrozole 2.5mg daily orally for 2 to 3 years
88817649|NCT01248416|Active Comparator|Growth Hormone|Somatropin 0.3mg/kg/week divided daily subcutaneously for 2 to 3 years
88817650|NCT01248416|Active Comparator|Aromatase Inhibitor and Growth Hormone|Anastrozole 1mg or Letrozole 2.5mg orally daily for 2 to 3 years and Somatropin 0.3mg/kg/week divided daily subcutaneously for 2 to 3 years
88817651|NCT01749293|Experimental|Haploidentical Transplant|All subjects will be dosed with pre-transplant Fludarabine (180mg/m2)and Busulfan total AUC 2400 μmol*min/L or 6.4mg/kg. Subjects will then undergo total body irradiation 2Gy. Subjects will undergo haploidentical allogeneic bone marrow transplant, followed by Cyclophosphamide, Tacrolimus and MMF based GVHD prophylaxis.
88817652|NCT01727765|Experimental|Experimental|6 weeks of inspiratory muscle training, 6 days per week. The intensity of training will be equivalent to up to 50% of pre-training maximal inspiratory mouth pressure and will be adapted weekly to reflect the improvement in inspiratory muscle strength
88817653|NCT01727765|Sham Comparator|Sham Comparator|6 weeks of sham inspiratory muscle training, 6 days per week. The intensity of training will be equivalent to 5% of pre-training inspiratory mouth pressure throughout the 6 week period.
88817654|NCT04893213|Active Comparator|Baseline availability|Baseline availability of lower energy meal options
88817655|NCT04893213|Experimental|Increased availability|Increased availability of lower energy meal options
88817656|NCT01250210|Experimental|AG200-15|Drug intervention with levonorgestrel and ethinyl estradiol : AG200-15 a transdermal contraceptive system containing 2.60 mg of levonorgestrel and 2.30 mg of ethinyl estradiol.
88817657|NCT01250210|Experimental|AG200|Drug intervention with levonorgestrel and ethinyl estradiol: AG200 a transdermal contraceptive system containing 2.17 mg of levonorgestrel and 1.92 of ethinyl estradiol.
88817658|NCT01250210|Experimental|AG200LE|Drug intervention with levonorgestrel and ethinyl estradiol: AG200LE a transdermal contraceptive system containing 2.17 mg of levonorgestrel and 1.28 mg of ethinyl estradiol.
88817659|NCT01749605|Active Comparator|nitrofurantoin 100 mg|
88817660|NCT01749605|Active Comparator|Ciprofloxacin 250 mg|
88817661|NCT01312844|Experimental|Scopolamine|Patients receiving IV scopolamine at ECT treatment
88817662|NCT01312844|Placebo Comparator|Placebo|Patients receiving IV placebo at ECT treatment
89378932|NCT03105076|Experimental|DAs group|Shared decision making using decision aids
89378933|NCT03105076|No Intervention|Control group|Standard oral explanation guided with booklets
89378934|NCT02331628|No Intervention|Control|Usual care only will be provided during Baseline period and Follow-up period.
89378935|NCT02331628|Experimental|ESWT - Extracorporeal Shockwave Therapy|Participants will receive 4 applications of extracorporeal shockwave therapy to the affected hip and/or knee over a period of 8 weeks (one dose every 2 weeks).
89378936|NCT02887482|Experimental|Placebo|Placebo at 0 mg DNA/dose
88852386|NCT05218187|Experimental|Conventional Physical Therapy (CPT) Group with G-EO Training (CPT-GEO)|CPT-GEO sessions will involve a warm-up using a cycle ergometer or treadmill walking, stretching, progressive strength training exercises, and balance training. Gait training will be administered using end-effector gait training protocols (G-EO trainer). Training will be administered 2 times per week for 40-60 minutes for six weeks.
88852387|NCT05217953|Experimental|Test Group|"The CGM will be integrated with the users mobile handset and all relevant measures taken will be entered. Participant will be provided with a smart watch and this will also be integrated with the users smartphone.~The user will then download and install the LovedBy mobile app. Once installed the user will set up an account and the account number will be recorded by the clinical research team to track the participant throughout the trial. The final step is to review the permissions of the mobile application and allow the mobile application to connect to the users handset"
88852388|NCT05217953|No Intervention|Control-Group|The same measurements will be taken as with the test group but here no app will be provided to the participants in this group.
88852389|NCT05215691||Group I (n=45, TAPA)|The patients who received TAPA block for postoperative analgesia are named as a Group I ( n=45). The TAPA block is performed at the rib margin where the 9th and 10th ribs meet. A linear transducer is placed at the costochondral angle in the sagittal plane. It is carried out by injecting 20 ml of Bupivacaine %0.200 between the upper and lower surface of the chondrium. All patients receive IV PCA with morphine 0.5 mg/ml.
88852390|NCT05215691||Group II (n=45, IV opioid)|The patients who did not prefer the block and preferred intravenous patient-controlled analgesia (PCA) are named as Group II (n=45). IV PCA is prepared with morphine 0.5 mg/ml.
88852391|NCT04831073||Acute type A aortic dissection|Patients who underwent surgery for acute type A aortic dissection
88852392|NCT04824053|Experimental|UNICLA-A2 milk and its subproducts|Participants (n=17) ingest milk and dairy products made from cows homozygous for beta casein A2 during 3 months. These products are also enriched in insaturated fatty acids and selenium. The daily intake reflects the habitual consumption habits. Recommended amounts are 250 mL of milk, a yogurt and 50 g fresh cheese per day.
89378937|NCT02887482|Experimental|GLS-5700|GLS 5700 at 2 mg DNA/dose. GLS-5700 contains a single plasmid containing DNA encoding for pre-membrane and envelope (prME) proteins of the Zika virus
89378938|NCT03488927|Experimental|Intervention|This arm will receive the intervention, followed by a six-month follow-up evaluation.
89378939|NCT03488927|No Intervention|Wait-list Control|This arm will receive the intervention after a six-month follow-up evaluation.
89378940|NCT02335372|Experimental|Multi-Modal Optical Imaging of Cervix|Initial wide-field white light images acquired of cervix in unpolarized and cross-polarized modes before application of 3-6% acetic acid. The clinician will identify all sites required for biopsy according to clinical impression, marking each location on the recorded unpolarized white light image. Topical application of 0.01% proflavine solution will then be applied for 1 minute, after which wide-field imaging in fluorescence mode will be performed. The clinician will then select up to 2 additional sites for biopsy based on the appearance of this wide-field fluorescence image, recording the location of each. The high-resolution microendoscope will then be used to acquire images at all sites selected for biopsy, followed by collection of biopsy specimens.
89378941|NCT01569750|Experimental|Ibrutinib|"Part 1 (Dose Escalation): Escalating doses of ibrutinib (starting on Day 3 for Cycle 1 and on Day 1 for subsequent cycles) administered once daily in with standard-of-care doses of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) until maximum tolerated dose is achieved.~Part 2: Ibrutinib at the recommended Part 1 dose administered once daily with standard-of-care doses of R-CHOP."
89378942|NCT02335138|Placebo Comparator|Control Arm|Each participant will receive an at-home test kit and will be asked to test and return results to investigator.
89378943|NCT02335138|Active Comparator|Intervention Arm|Each participant will receive an at-home test kit and will be asked to take the test in conjunction with an online CHTC session.
89378944|NCT02326558|Experimental|microwave enucleation|zero ischemia laparoscopic microwave ablation-assisted enucleation of the tumor
89378945|NCT02326558|Active Comparator|laparoscopic partial nephrectomy|conventional laparoscopic partial nephrectomy with clamping of the renal artery
89378946|NCT02331316|Experimental|Daily extra water intake 2L|"Timing of daily extra water intake~intervention-A: extra water intake: 8 8oz glasses of water a day (2L) - 2 first thing in the morning before breakfast, 2 before midday or midday meal, 2 before afternoon meal and 2 before evening meal.~Intervention-B: Drink extra water at anytime over 24 hours"
89378947|NCT02331316|Experimental|Daily extra water intake 1L|"Timing of daily extra water intake~Intervention-A: 4 8oz glasses of water a day (1L) - 1 first thing in the morning before breakfast, 1 before midday or midday meal, 1 before afternoon meal and 1 before evening meal.~Intervention-B: Drink extra water at anytime over 24 hours"
89378948|NCT02331316|Experimental|Daily extra water intake 500ml|"Timing of daily extra water intake~Intervention-A: 2 8oz glasses of water a day (500ml) - each half an hour before a meals.~Intervention-B: Drink extra water at anytime over 24 hours"
89378949|NCT02331316|Experimental|Daily extra water intake 120ml|"Timing of daily extra water intake~Intervention-A: 1/2 a glass of water on waking (120ml). If you forget to drink your water first thing, do not drink it later in the day, just skip this day and drink ½ a glass the next day on waking.~Intervention-B: Drink extra water at anytime over 24 hours"
89378950|NCT02331004|Active Comparator|Intervention for fine motor skills|Implementation of an well known activity to improve the function of upper extremities
89378951|NCT02331004|Placebo Comparator|Support to activities of daily living|Performing of general activities planned in the centres where the participants are included
89378952|NCT02326480||Syndromic obesity|Identification of genetic causes of obesity
89378953|NCT02326480||Familial obesity|Identification of genetic causes of obesity
89378954|NCT02326480||Isolated obesity|Identification of genetic causes of obesity
89378955|NCT02331160|Experimental|Rebozo|Intervention by Rebozo
89378956|NCT02331160|No Intervention|Control|Standard
89378957|NCT02334904||Aripiprazole|Participants receiving treatment of only aripiprazole, as prescribed to them by their psychiatrists, for a minimum of at least 3 continuous months.
89378958|NCT02334904||Risperidone|Participants receiving treatment of only risperidone, as prescribed to them by their psychiatrists, for a minimum of at least 3 continuous months.
89378959|NCT02334904||Controls|Healthy participants who are not taking any antipsychotic medications.
89378960|NCT02331238|No Intervention|Control School|"Control schools (where the coaches do not receive the Coaching Boys into Men training until following academic year ;wait list control)"
89378961|NCT02331238|Experimental|Intervention School|"Intervention schools (where coaches receive the Coaching Boys into Men training at start of each sports season).~Coaching Boys into Men program consists of 60 minute training for high school coaches led by a violence prevention advocate to introduce coaches to the rational for Coaching Boys into Men and the Coaching Boys into Men Coaches Kit. The coaches use this Coaching Boys into Men toolkit to provide weekly discussions with their athletes (generally 10-15 minute mini-sessions) throughout their athletic season (11 weeks). Discussion topics include how to prevent disrespectful and harmful behaviors towards women and girls and how to promote healthy choices and relationships among youth."
89378962|NCT03717077|Experimental|Learned resourcefulness intervention|The learned resourcefulness program includes: 1) Solving problem strategy, 2) Organizing daily actions, 3) Using self-regulation, 4) Reframing positive situations, 5) Changing negative self-thinking, 6) Exploring new thinking and skills. It is conducted one time per week.
89378963|NCT03717077|No Intervention|Usual home care service|The control group maintains home care service
89378964|NCT02326090|Active Comparator|cis-UCA ophthalmic solution 1.0%|One drop in each eye
89378965|NCT02326090|Active Comparator|cis-UCA ophthalmic solution 2.5%|One drop in each eye
89378966|NCT02326090|Placebo Comparator|Placebo ophthalmic solution|One drop in each eye
89378967|NCT02326246|Experimental|men with low-risk PC|men newly diagnosed with low-risk prostate cancer and put in an active surveillance (AS) program. Eight weeks post TRUS-guided biopsies they are scanned with a multi-parametric magnetic resonans imaging (mMRI). If the scans shows a PIRADS 4 or 5 lesion, MRI-guided biopsies are performed. Otherwise the patients will continue in the AS program as usual. The mMRI will in these cases be repeated after 1 year.
89378968|NCT03437447|Experimental|First Cisticid, Then Biltricide, Then Biltricide|Cisticid (Test) in Treatment Period 1 followed by Biltricide (Reference) in Treatment Period 2 and Treatment Period 3. A washout period of 7 days will be maintained between 3 treatment periods.
89182712|NCT06238089||Eligible patients who have had a psychiatric review by specialist adult ID services in 2017.|Adults with an intellectual disability who are under the care of ID services in receipt of >2 oral and/or long-acting intra-muscular (IM) injectable anti-psychotic treatments (depots), who have had a psychiatric review by specialist adult ID services in 2017.
89182713|NCT06238089||Eligible patients who have had a psychiatric review by specialist adult ID services in 2018.|Adults with an intellectual disability who are under the care of ID services in receipt of >2 oral and/or long-acting IM injectable anti-psychotic treatments (depots), who have had a psychiatric review by specialist adult ID services in 2018.
89378969|NCT03437447|Experimental|First Biltricide, Then Cisticid, Then Biltricide|Biltricide (Reference) in Treatment Period 1 followed by Cisticid (Test) in Treatment Period 2 and then Biltricide (Reference) in Treatment Period 3. A washout period of 7 days will be maintained between 3 treatment periods.
89378970|NCT03437447|Experimental|First Biltricide, Then Biltricide, Then Cisticid|Biltricide (Reference) in Treatment Period 1 and Treatment Period 2 followed by Cisticid (Test) in Treatment Period 3. A washout period of 7 days will be maintained between 3 treatment periods.
89378971|NCT02459080|Active Comparator|TD-4208-1|88 mcg
89378972|NCT02459080|Active Comparator|TD-4208-2|175 mcg
89378973|NCT02459080|Placebo Comparator|Placebo|Placebo
89378974|NCT03720041|Active Comparator|R1: IRD induction therapy (reactive)|In the reactive arm at Randomisation 1, participants will receive IRD induction therapy with standard up-front dosing, with toxicity assessed at each cycle and doses adjusted in accordance with the guidelines given in the trial protocol.
89378975|NCT03720041|Experimental|R1: IRD induction therapy (adaptive)|In the adaptive arm at Randomisation 1, participants will receive IRD induction therapy with up-front dose reductions adjusted according to their frailty score: fit, unfit, or frail.
89378976|NCT03720041|Active Comparator|R2: Lenalidomide plus placebo maintenance|Participants randomised to this arm at Randomisation 2 will receive lenalidomide plus placebo maintenance.
89378977|NCT03720041|Experimental|R2: Lenalidomide + ixazomib maintenance|Participants randomised to this arm at Randomisation 2 will receive lenalidomide plus ixazomib maintenance.
89378978|NCT02326168|Experimental|non-muscle invasive bladder cancer|"Every patient meeting eligibility criteria will receive a standard WHO adult potency Bacillus Calmette-Guerin (BCG) immunization (1cc/50mg live mycobacilli) in the right or left deltoid. Following a 19 - 31day wait period after BCG vaccination patients will then receive standard strength BCG intravesical therapy returning once a week for 6 consecutive weeks. Cystoscopy will be performed at 3 and 6 months.~Interventions: BCG immunization in deltoid and BCG intravesical therapy once a week for 6 weeks."
89378979|NCT02334826|Active Comparator|PCI - BVS|percutaneous coronary intervention with the use of bioresorbable scaffolds (Absorb)
89378980|NCT02334826|Active Comparator|CABG|coronary artery bypass grafting
89378981|NCT03487445|Experimental|Selatogrel 8 mg|Selatogrel (ACT-246475) is given as a single subcutaneous dose of 8 mg administered in a volume of 0.8 mL. Administration will be performed at the investigational site by qualified personnel.
89378982|NCT03487445|Experimental|Selatogrel 16 mg|Selatogrel (ACT-246475) is given as a single subcutaneous dose of 16 mg administered in a volume of 0.8 mL. Administration will be performed at the investigational site by qualified personnel.
89378983|NCT02109172|Experimental|TD-4208 44 mcg twice daily|TD-4208 inhalation solution 44 mcg twice daily for 7 days
88852393|NCT04824053|Placebo Comparator|Placebo|"Participants (n=17) ingest conventional dairy products and milk daily during 3 months. As happens in the UNICLA-A2 arm, the daily intake reflects habitual dairy consumption habits in real life conditions, without forcing or inducing greater consumption. Therefore, recommended amounts are 250 mL of milk, a yogurt and 50 g fresh cheese per day."
89182714|NCT06238089||Eligible patients who have had a psychiatric review by specialist adult ID services in 2019.|Adults with an intellectual disability who are under the care of ID services in receipt of >2 oral and/or long-acting IM injectable anti-psychotic treatments (depots), who have had a psychiatric review by specialist adult ID services in 2019.
89378984|NCT02109172|Placebo Comparator|Placebo|Placebo inhalation solution twice daily for 7 days
88852394|NCT05190653|Experimental|Palliative and Supportive Care Intervention|Participants randomized to the intervention arm will meet (either by phone or Zoom contingent upon participant preference) with a palliative care nurse practitioner or palliative care physician. During the first meeting, pre-transplant/CAR T-cell therapy, content will focus on the provision of information and education, including: a description of palliative and supportive care, symptom management, advance care planning, prognostic and illness understanding and treatment expectations, and coping strategies. All subsequent visits will include, at minimum, these topics. All meetings will be audio-recorded using a handheld audio-recorder; the record feature of Zoom will not be utilized. Participants in the intervention arm will meet with a member of the study team (palliative care nurse practitioner or palliative care physician) one to two times weekly, or more frequently if requested by the patient and/or family caregiver, until 3 months post-transplant/CAR T-cell therapy.
88852395|NCT05190653|No Intervention|Standard Care|Standard care will involve the usual care that patients undergoing HSCT/CAR T-cell therapy would be expected to receive, including palliative care consultation as needed or upon request. Palliative care interventions beyond what are provided in the study will be tracked in both the intervention and the standard care arms.
88852396|NCT04812197|Other|Skin Biopsies|Patients undergo punch biopsies of inflamed and non-inflamed skin and a blood sample collection.
88852397|NCT04811339|Experimental|Open label BSS|All patients will be assigned to the treatment group for the first 10 patients treated with open label BSS.
88852398|NCT04811339|Placebo Comparator|Randomized BSS or Placebo|The Subsequent 50 patients will be randomized to either placebo or BSS. The patients will be assigned by envelope containing a symbol for either active drug or placebo (or other suitable randomization event) by a member of the research team not directly involved in the clinical trial.
88852399|NCT04804631||Gastrostomy tube|Prophylactic gastrostomy placed prior to bone marrow transplant.
88852400|NCT04804631||Nasogastric tube|Nasogastric tube placed during admission.
88852401|NCT04790123|Sham Comparator|Control group|
88852402|NCT04790123|Experimental|Experimental group|
88852403|NCT05406323|Experimental|Web-Based Fall Prevention Program Intervention|Participants in this group will receive a 6-week Web-Based Fall Prevention Program intervention, comprising of health education, exercise and safe home environment. Web-Based Fall Prevention Program will be conducted on web based (Web - Based Fall Prevention Program website)
88852404|NCT05406323|No Intervention|Control Group|The control group will not receive any intervention during the study. Participants in the control group will take the same program after the study is complete.
88852405|NCT04331093|Experimental|resectable stage III-IV Acral melanoma|
88852406|NCT05142917|Experimental|fNIRS based hand motor area real stimulation|Real stimulation is applied to functional brain image-based hand function area (20 minutes) and then hand motor task (20 minutes).
88852407|NCT05142917|Active Comparator|Traditional hand motor area real stimulation|Real stimulation is applied to the traditional hand function area (20 minutes) and then hand motor task (20 minutes).
88852408|NCT05142917|Sham Comparator|Traditional hand motor area sham stimulation|Sham stimulation is applied to the traditional hand function area (20 minutes) and then hand motor task (20 minutes).
89378985|NCT02109172|Experimental|TD-4208 175 mcg once daily|TD-4208 inhalation solution 175 mcg once daily, placebo once daily
89378986|NCT02326012|Experimental|Emotion Regulation Individual Therapy for Adolescents|
89378987|NCT02334592|Experimental|Low Pressure 100W sunbed|
89378988|NCT02334592|Experimental|Low Pressure 160W sunbed|
88852409|NCT04758767|Experimental|Dose escalation cohort|Monotherapy CID-103. Priming dose will be given for first dose. Dose and duration of infusion dependent on dose cohort and tolerability.
88852410|NCT04758767|Experimental|Dose expansion cohort - pretreated|CID-103 monotherapy at the recommended phase 2 dose
88852411|NCT04758767|Experimental|Dose expansion cohort - Naïve|CID-103 monotherapy at the recommended phase 2 dose
88852412|NCT05122637|Experimental|Treatment Arm|RapidPulseTM Aspiration System with commercially available Medtronic React 71 aspiration catheter and commercially available aspiration pump as frontline approach thrombectomy technique.
88852413|NCT05122637|Other|Control Arm|Treatment with commercially available aspiration catheter with commercially available aspiration pump as frontline approach thrombectomy technique.
88852414|NCT05120297|Experimental|AK101|
88852415|NCT05120297|Placebo Comparator|Placebo|
88852416|NCT05106881|Experimental|Training with Gait Enhancing and Motivating System (GEMS-H) Robot|Training consists of 15 minutes task-specific training and 20-30 minutes functional gait training on varied environments with device.
88852417|NCT04740359|Active Comparator|Control|Routine training; mat exercises and perturbation training
88852418|NCT04740359|Experimental|Study|Trunk training; Functional training, mat exercises and perturbation training
88852419|NCT05105555||Healthy controls|In this study, participants of the Bern Basel Infant Lung Development (BILD) cohort, a birth cohort of healthy term-born infants and their follow-up, will serve as healthy, non-vaping controls.
88852420|NCT05105555||Vaping teenagers|Vaping teenagers will be recruited independently from the BILD study through advertisements and visits to Bernese schools.
89378989|NCT02334592|Experimental|High Pressure sunbed|
89378990|NCT02334592|No Intervention|Control group|
88852421|NCT05104541|Experimental|Intervention Arm|"In addition to standard pharmacological treatment this group would receive diet comprising of 20-25 kcal and 1.2gm protein per kg ideal body weight per day.~The total distribution of the calories would be as 55-60% from carbohydrates, 25% from protein, and 20% from fat. The diet would be explained to the patient with the help of individual diet charts."
88852422|NCT04712825|Active Comparator|Cognitive-behavioural therapy|Cognitive-behavioural therapy sessions
88852423|NCT04712825|Experimental|Virtual Reality Hypnosis|Virtual Reality Hypnosis sessions
88852424|NCT05087849|Experimental|Intralesional injection of nonavalent human papillomavirus vaccine|Single-arm, open-label study. Intervention consists of intralesional injection of nonavalent human papillomavirus vaccine at 0 and 4 weeks.
88852425|NCT05350865||HDV cohort|Chronic Hepatitis B (HBsAg+) with cirrhosis (APRI >1.5, FIB-4 > 3.25, Fibroscan > 12.5, imaging), PWID with HBV, HIV/HBV, HBV/HCV, aged 18 years and older
88852426|NCT05335811|Experimental|4-[18F]Fluoro-1-Naphthol|Participants will receive 1 injection of [18F]4FN
88852427|NCT05068583||Osteosarcoma|
88852428|NCT05068583||Ewing Sarcoma|
88852429|NCT05068583||Rhabdomyosarcoma|
88852430|NCT05068583||Synovial Sarcoma|
89182715|NCT06238089||Eligible patients who have had a psychiatric review by specialist adult ID services in 2020.|Adults with an intellectual disability who are under the care of ID services in receipt of >2 oral and/or long-acting IM injectable anti-psychotic treatments (depots), who have had a psychiatric review by specialist adult ID services in 2020.
88852431|NCT05068583||Non-Rhabdomyosarcoma Soft Tissue Sarcoma|
88852432|NCT05068583||Hepatic Tumors|
88852433|NCT05068583||Renal Tumors|
88852434|NCT05068583||Thyroid Tumors|
88852435|NCT05068583||Germ Cell Tumors|
88852436|NCT05068583||Healthy Volunteers|
88852437|NCT05043701|Experimental|Treatment|Patients will be treated with drugs based on functional profiling of autologous tumor cells in vitro
88852438|NCT05040581|Experimental|Experimental Group - 1 Day CBT|"The intervention is a 6-hour long CBT-based workshop. Cognitive behavioural therapy is a structured psychotherapy based on the cognitive theory of depression that posits that negative thoughts about the self, others and the future can lead to and perpetuate depressed mood states. CBT equips participants with skills that enable them to identify and modify distortions in their thinking that lead to depressed mood and maladaptive behavioural responses.~The intervention will be delivered in in modules and contain content on PPD etiology (with a focus on modifiable risk factors), the development of cognitive skills including cognitive restructuring, behavioural skills such as problem solving, sleep strategies, behavioural activation, assertiveness, and self-care, and the final module will involve goal setting and action planning."
88852439|NCT04281719|Experimental|Mobile App|Youth will be assigned to interact with a novel mobile application during a course of outpatient psychotherapy for substance use disorder(s) and co-occurring mental health disorder(s).
88852440|NCT05034341|Experimental|Multimodal Prehabilitation Arm|"The Multimodal Prehabilitation group will receive:~An exercise program focusing on aerobic exercise as well as strength training. Sessions will be supervised by a physical therapist, 2 times a week for a minimum of 6-8 weeks in addition to a home exercise program. Patients' compliance will be monitored by phone each week.~Protein supplements in the form of protein shakes at a dose of 1.2-1.5 gram per kg daily for 6-8 weeks. Protein supplements will be calculated based on ideal body weight and will be given to the patient with instructions on specific use. Diabetic patients will receive protein supplements that are sugar-free.~Pain and Neuroscience Education: Per University of Florida Health Pain and Neuroscience program at Shands hospital.~Standard Clinical Care: Preoperative medical optimization and management, referral to medical specialties as deemed necessary with a focus on preoperative cognitive assessment."
88852441|NCT05034341|Active Comparator|Standard Clinical Care Comparison Arm|"The Standard Clinical Care Comparison group will receive:~Education related to preoperative activity and home based exercise program.~Standard preoperative consultation with anesthesiology: Preoperative medical optimization and management, referral to medical specialties as deemed necessary with focus on preoperative cognitive assessment.~A final preoperative visit before surgery where a second set of functional assessment will be implemented"
88852442|NCT04615325|Experimental|Single Ascending Dose Stage|Participants will receive a single dose of RO7303359, in multiple escalating cohorts (A-D).
88852443|NCT04615325|Experimental|Expansion Cohort Stage|Participants will receive the maximum tolerated dose (MTD) or the maximum tested dose (MTeD) as determined in the single ascending dose stage.
88852444|NCT04615325|Experimental|Optional Cohort E|An optional additional cohort may be added with the dose not exceed the MTD or MTeD.
88852445|NCT04615325|Experimental|Optional cohort F|An optional additional cohort may be added with the dose not exceed the MTD or MTeD.
88852446|NCT05007509|Experimental|COVID-19 vaccine HIPRA|Subjects will receive 2 injections of COVID-19 vaccine HIPRA administered 21 days apart.
88852447|NCT05007509|Active Comparator|Commercial COVID-19 vaccine|Subjects will receive 2 injections of commercial COVID-19 vaccine administered 21 days apart.
88852448|NCT00382499|Experimental|Lidocaine|IV lidocaine in OR as described in methods
89182716|NCT06238089||Eligible patients who have had a psychiatric review by specialist adult ID services in 2021.|Adults with an intellectual disability who are under the care of ID services in receipt of >2 oral and/or long-acting IM injectable anti-psychotic treatments (depots), who have had a psychiatric review by specialist adult ID services in 2021.
89182717|NCT06238089||Eligible patients who have had a psychiatric review by specialist adult ID services in 2022.|Adults with an intellectual disability who are under the care of ID services in receipt of >2 oral and/or long-acting IM injectable anti-psychotic treatments (depots), who have had a psychiatric review by specialist adult ID services in 2022.
89002643|NCT06281288|Experimental|cognitive therapy with regular exercise|In the form of regular exercise where each participant perform exercise training approximately 60-min 3 times per week for 12 weeks, each session includes a combination of moderate intensity (~63% maximum heart rate; HRmax) aerobic (~25 min) and resistance (~25 min) activities, with additional time for warm-up (5 min; 10% HRmax) and cool down (5 min).
89399435|NCT02754440|Experimental|Double Platelet Product|Healthy adult volunteer blood donors that qualify for a double unit platelet collection will undergo plateletpheresis on the Trima Accel® Automated Blood Collection System (Trima Accel System with Version 7.0 Software). Concurrent plasma will be collected in 25% of the collections.
88852449|NCT04330547|Active Comparator|Analgesic administration|"The analgesic treatment will be tailored to the patient's medication and will be based on 3 levels (based on Ventafridda et al., 1985):~Level 1 : Non-opioid analgesics~Level 2 : Weak opioids analgesics~Level 3 : Strong opioids analgesics~If the patient is already on pain medications, we will add the lowest effective dose of the level above the level of the regular pain medications of the patient. (e.g. if the patient has no analgesic treatment, he will be given a non-opioid analgesic (level 1). If he already has a level 1 treatment, we will go for level 2 medication. If he has level 2 treatment, we will go for level 3. And if the patient is already at level 3, we will increase the dosage by steps (reference: 5mg oxycodone as first choice for level 3 drugs)). Preferably, the medication will be administered by oral intake or gastrostomy feeding tube. If it is not possible, other routes of administration are allowed."
88852450|NCT04330547|Placebo Comparator|Placebo administration|Folavit capsules will be used as a placebo
88852451|NCT04972799|Experimental|Treatment/Placebo|treatment sequence at day 0 and placebo sequence at 6 months
88852452|NCT04972799|Experimental|Placebo/Treatment|placebo sequence at day 0 and treatment sequence at 6 months
88852453|NCT05273177||CAI group|
88852454|NCT05273177||Control group|
88852455|NCT04482959|Experimental|Carbetocin group|This group will contain 20 patients having single type 0 or I submucous uterine myomas according to International Federation of Gynecology and Obstetrics classification system with a largest diameter ≤ 4 cm and myometrial free margin of at least 10 mm.After induction of general anesthesia, immediately before the operation, participants will receive either 1 ml of carbetocin (100 mcg/ml) IV over 1 minute.
88852456|NCT04482959|Placebo Comparator|• Control group|This group will contain 20 patients having single type 0 or I submucous uterine myomas according to International Federation of Gynecology and Obstetrics classification system with a largest diameter ≤ 4 cm and myometrial free margin of at least 10 mm.After induction of general anesthesia, immediately before the operation, participants will receive either 1 ml of sodium chloride 0.9% IV over 1 minute.
88852457|NCT04571879|Experimental|Arm 1|"Nebulized 2% lidocaine hydrochloride 4 mg/kg to be delivered via nebulization (up to a maximum of 15 ml) and given over ½ hr.~Intranasal midazolam 0.5 mg/kg delivered via intranasal atomization (up to a maximum of 10 mg)."
88852458|NCT04571879|Experimental|Arm 2|"Intranasal midazolam 0.5 mg/kg to be delivered via intranasal atomization (up to a maximum of 10 mg).~Nebulized placebo (Normal saline) in a volume comparable to 2% lidocaine at 4 mg/kg (up to a maximum of 15 ml) and given over ½ hr."
88852459|NCT04571879|Placebo Comparator|Arm 3|"Intranasal placebo (normal saline) in a volume comparable to midazolam 0.5 ml/kg to be delivered via intranasal atomization~Nebulized placebo (Normal saline) in a volume comparable to 2% lidocaine at 4 mg/kg (up to a maximum of 15 ml) and given over ½ hr."
88852460|NCT04563533|Experimental|adults of phase I|Healthy people aged 18-59
88852461|NCT04563533|Experimental|teenagers of phase I|Healthy people aged 6-17
88852462|NCT04563533|Placebo Comparator|elderly of phase I|Healthy people 60 years old and above
88852463|NCT04563533|Experimental|Toddler of phase I|Healthy people aged 2-5
88852464|NCT04563533|Placebo Comparator|Infants of phase I|6 weeks old-2 years old healthy person
88852465|NCT04563533|Experimental|elderly of phase II|Healthy people 60 years old and above
88852466|NCT04563533|Placebo Comparator|Toddler of phase II|Healthy people aged 2-5
88852467|NCT04563533|Experimental|Infants of phase II|6 weeks old-2 years old healthy person
88852468|NCT04330937|Experimental|experimental group|volunteers consume 1 capsule per day for 3 months. (500 mg citrolive).
88852469|NCT04330937|Placebo Comparator|control group Placebo (sucrose)|volunteers consume 1 capsule per day for 3 months. (saccharose).
88852470|NCT04939961|Experimental|Hericium erinaceus|8 gram of mushroom Hericium erinaceus (containing 5 milligram of erinacines) per day
88852471|NCT04939961|Placebo Comparator|Placebo capsule|8 gram of allergen free corn starch per day
88852472|NCT04332107|Experimental|Azithromycin|1.2g of oral azithromycin
88852473|NCT04332107|Placebo Comparator|Placebo|Matching placebo
88852474|NCT04328285|Experimental|Hydroxychloroquine (HCQ) vs Placebo|"Group 1.1: HCQ 200 mg : 2 tablets on the evening at Day 1 and 2 tablets on the morning at Day 2 and 1 tablet once daily afterwards~Group 1.2: Placebo of HCQ, 2 tablets on the evening at Day 1 and 2 tablets on the morning at Day 2 and 1 tablet once daily afterwards."
88852475|NCT04328285|Experimental|Lopinavir/ritonavir (LPV/r) vs Placebo|"Group 2.1: LPV/r 200/50 mg, 2 tablets twice daily~Group 2.2: Placebo of LPV/r, 2 tablets twice daily"
88852476|NCT04308473|Experimental|Arm 1: Ultra-processed Meal + Antibiotics to supress gut flora|Subjects in Arm 1 will take antibiotics for 3 days before the meal challenge to suppress the gut flora. The antibiotics to be used are: vancomycin, 125 mg three times daily; metronidazole, 500 mg twice daily; ciprofloxacin, 500 mg twice daily; and neomycin, 1 gram three times daily. These subjects will then consume a challenge meal of ultra-processed foods.
88852477|NCT04308473|Experimental|Arm 2: Ultra-processed Meal + No Antibiotics|Subjects in Arm 2 will not take any antibiotics prior to the meal challenge. They will consume a challenge meal of ultra-processed foods.
88852478|NCT04308473|Experimental|Arm 3: Whole Food Meal + Antibiotics to supress gut flora|Subjects in Arm 3 will take antibiotics for 3 days before the meal challenge to suppress the gut flora. The antibiotics to be used are: vancomycin, 125 mg three times daily; metronidazole, 500 mg twice daily; ciprofloxacin, 500 mg twice daily; and neomycin, 1 gram three times daily. These subjects will then consume a challenge meal of whole, unprocessed foods.
88852479|NCT04308473|Experimental|Arm 4: Whole Food Meal + No Antibiotics|Subjects in Arm 4 will not take any antibiotics prior to the meal challenge. They will consume a challenge meal of whole, unprocessed foods.
89399436|NCT02754440|Experimental|Triple Platelet Product|Healthy adult volunteer blood donors that qualify for a triple unit platelet collection will undergo plateletpheresis on the Trima Accel® Automated Blood Collection System (Trima Accel System with Version 7.0 Software). Concurrent plasma will be collected in 25% of the collections.
88852480|NCT04911881|Experimental|Phase Ia Dose-Escalation Stage: IBI321|
88852481|NCT04906187|Experimental|Arm A : Experimental group with intraoperative ANI monitoring of nociception|
89378991|NCT05076916|Experimental|Intervention group|The web-based education program was introduced to the patients with cancer in the intervention group during face-to-face interviews. They were asked to examine the program for at least two hours a week for three months. During the follow-up period, the patients in the intervention group were called twice a week and reminded to use the education program. The researchers get in contact with the patients online via the website. During the follow-up period, the patients contact the research team by calling or writing messages via the website 24/7. An e-mail account was created by the research team using the email system of the university, and it was shared with the patients. The clinical researchers of the team answered the patients' questions via this e-mail account. In the third month, after the follow-up stage of the study was completed, the post-tests were administered to the patients in the intervention group who came to the hospital for follow-up or treatment.
88852482|NCT04906187|Other|Arm B : Control group without ANI intraoperative monitoring of nociception|
88852483|NCT04354493|Experimental|Baseline and Training|This group consists of a baseline and training conditions only.
88852484|NCT04354493|Experimental|Baseline, Training, and Control|This group stops training condition sooner and returns to a control to evaluate carry-over effects.
88852485|NCT04903457|Experimental|Real stimulation before motor learning training|Patients receive five sessions of tDCS stimulation over C3 (patient with left-sided lesion) or C4 (patient with right-sided lesion) based on 10-20 system immediately before sequential finger tapping task.
88852486|NCT04903457|Active Comparator|Sham stimulation before motor learning training|Patients receive five sessions of sham stimulation over C3 (patient with left-sided lesion) or C4 (patient with right-sided lesion) based on 10-20 system immediately before sequential finger tapping task.
88852487|NCT04869995||Intervention|Senior abdominal and pelvic cavity surgeons (i.e., visceral surgeons, gynecologist surgeons, and urologists) having completed their robot-assisted surgery training, and commonly doing laparoscopic surgery.
88852488|NCT04263779|No Intervention|Default List (case manager level)|In this condition, all SNF options will be presented to case managers in Repisodic in rank order according to Repisodic's algorithm that weights dimensions such as Centers for Medicare & Medicaid Services (CMS) quality metric ratings, distance, and the match between SNF features and specific patient need. The list only includes SNFs that accept the patient's insurance.
89182718|NCT06238089||Eligible patients who have had a psychiatric review by specialist adult ID services in 2023.|Adults with an intellectual disability who are under the care of ID services in receipt of >2 oral and/or long-acting IM injectable anti-psychotic treatments (depots), who have had a psychiatric review by specialist adult ID services in 2023.
88852489|NCT04263779|Experimental|P-SNF Top-Sorted List (case manager level)|"This condition is the same as the Default List, except that relevant providers (i.e., those meeting patient needs and located within a threshold distance to be determined per hospital) who are part of the Geisinger preferred provider network will be presented at the top of the otherwise ranked list of SNFs.~Situations in which there are no relevant P-SNFs will be flagged yet still assigned to this condition, in an intent-to-treat analysis; the default algorithm-based rank-ordered approach will be applied to all non-preferred providers."
88852490|NCT04263779|No Intervention|Full List/Full Map/Default Video (patient level)|All SNF options, both P-SNFs and NP-SNFs (up to a maximum of 10 by default) that case managers preselected for patients will be presented to patients in rank order (according to Repisodic's algorithm, as described above). Patients will also have the option of viewing the default Repisodic map, which will show the SNFs on the list, and patients will be provided the link to an introductory video presenting the SNF selection and discharge process. When only a paper printout is available, the same SNF sorting order will be presented on paper.
89182719|NCT06238076|Experimental|Group experimental|The patients included in the study and admitted in the maxillofacial surgery department for mandibular fibula free flap reconstruction will benefit from a surgery assisted with the universal surgical device FIBUMAND.
89182720|NCT06238063|Experimental|Intervention|The ACP intervention, which was developed by the expert panel, will be delivered by trained nurses in each RCH during a mandatory annual individual care planning (ICP) meeting. Eligible residents and their family members will be invited to attend the ICP meeting with ACP discussion.
89182721|NCT06238063|No Intervention|Control|Participants in the control arm will receive usual care with no ACP intervention.
89182722|NCT06238050||hospitalized patients suspected of chronic permanent ischemia realizing transcutaneous oxymetry|"hospitalized patients suspected of chronic permanent ischemia realizing transcutaneous oxymetry are enroled in the study.~The WIfI score is calculated at the inclusion."
89182723|NCT06237985|Experimental|ProTaper Gold file system|Sx-S1-S2-F1-F2 files for mesial canals and F3 file for distal canal with 350 rpm speed and 2 Ncm torque will be used via an endodontic motor.
89182724|NCT06237985|Experimental|OneShape file system|25/.06 file for mesial canals with 350 rpm and 4 Ncm torque will be used via an endodontic motor.
89182725|NCT06237985|Experimental|TruNatomy file system|17/.02, 20/.04 ve 26/.04 files for mesial canals and 36/.03 file for distal canal with 500 rpm speed and 1.5 Ncm torque will be used via an endodontic motor.
89182726|NCT06237959|Experimental|Keranat™|Keranat™ capsule will be administered orally twice daily for 24 weeks.
89182727|NCT06237959|Placebo Comparator|Placebo|Placebo capsule will be administered orally twice daily for 24 weeks.
89182728|NCT06237933|Experimental|Enhanced intervention|Enhanced intervention features of using social-networking-site site and personalized feedback, plus standard intervention
89182729|NCT06237933|Active Comparator|Control|Standard intervention with regular in-person consultation
89182730|NCT06237907||Patients underwent surgery|
88852491|NCT04263779|Experimental|P-SNF List/P-SNF Map/P-SNF Video (patient level)|This is the same as the Full List condition, except that both the list and the map will present only the P-SNFs, with a button allowing patients to view all results only if they opt to do so. Moreover, the link to viewing the optional introductory video will be highlighted, and the video will include sections describing the advantage of P-SNFs for care coordination. When only a paper printout is available, the same SNF sorting order will be presented on paper, with only the P-SNFs presented on the first page.
88852492|NCT04418297|Experimental|CT-G20|
88852493|NCT04418297|Placebo Comparator|Placebo|
88852494|NCT03575195|Experimental|Intervention|Rifaximin
88852495|NCT03575195|Placebo Comparator|Placebo|Matching placebo
88852496|NCT04391777|Experimental|CV-4 group|"The initial selection will be made through a questionnaire, in order to fulfill the exclusion and inclusion criteria. On the data collection day a more detailed survey is performed and informed consent is signed.~The patient waits for 5 minutes in the supine position, after which the baseline evaluation is performed.~The CV-4 technique is performed following immediate evaluation. 15 minutes after the technique, a new evaluation of the variables is accomplished."
88852497|NCT04391777|Sham Comparator|Control group|"The initial selection will be made through a questionnaire, in order to fulfill the exclusion and inclusion criteria. On the data collection day a more detailed survey is performed and informed consent is signed.~The patient waits for 5 minutes in the supine position, after which the baseline evaluation is performed.~The sham technique is performed following immediate evaluation. 15 minutes after the technique, a new evaluation of the variables is accomplished."
88852499|NCT04159025|Experimental|Endobronchial ultrasound guided miniforceps biopsy|"Standard of care convex-probe endobronchial ultrasound and transbronchial needle aspiration followed by rapid on-site evaluation. If evaluation yields a diagnosis of nonsmall cell lung cancer then EBUS-MFB will be performed.~With the EBUS bronchoscope, 6 needle punctures will be made into the targeted lymph node with the 22 gauge aspiration needle. The needle will be removed and the 1mm miniforceps will be passed through the working channel of the EBUS-bronchoscope into the targeted lymph node through the puncture site made using the 22 gauge needle using continuous endobronchial ultrasound guidance. The miniforceps will be used to obtain a core biopsy of the targeted lymph node - 8 core biopsies will be obtained from each targeted lymph node using this technique"
88852500|NCT03420209|Experimental|Group applying PNF technique|The experimental goup who are applying PNF technique with elastic bands for the upper extremities. Before the group will perform stretching and resisted exercises at the warming up period, after they will do PNF exercises with elastic bands on two PNF pattern for the upper extremities and finally they will do some stretching exercises for the cool down period. The programme will continue for 30-45 minutes, three times a week, for 12 weeks. They will work one by one with a physical therapist.
88852501|NCT03420209|No Intervention|Home Programme|This group will perform only breathing exercises daily at home during 12 weeks.
88852502|NCT00002909|Experimental|Arm I|All patients receive oral phenylbutyrate three times daily. Groups of 4 or more patients receive escalating doses of phenylbutyrate until the maximum tolerated dose (MTD) is determined. Treatment continues until disease progression or unacceptable toxicity intervenes.
88852503|NCT00002921|Experimental|Suramin|
88852504|NCT00383669|Active Comparator|Multiple RDA multivitamins|Multivitamins (including B, C, and E)
88852505|NCT00383669|Active Comparator|Single RDA Multivitamins|Multivitamins (including B, C, and E)
88852506|NCT04062461|Experimental|self-care promotion|"multifaceted strategy based on sending text messages(SMS) to patients with heart failure.~Press educational content on heart failure for the patient (symptoms of the disease, healthy habits for HF, warning signs for severity).~The text messages are about how the patient should take your drugs (evem diuretics), measure blood pressure and weight in Kg, and about signals and symptoms (shorthbreathness during the night), and about how important is practice physical exercises and don't drink alcohol."
88852507|NCT04062461|Active Comparator|Control group|routinely management in the HF. Press educational content on heart failure for the patient (symptoms of the disease, healthy habits for HF, warning signs for severity)
88852508|NCT04329455||Intervention group|
88852509|NCT00002939|Experimental|Paclitaxel in combination with Irinotecan|The first study cohort will receive 60 mg/m2 of paclitaxel on cycle days 1, 8, and 15 as a 1 hr infusion. Immediately following paclitaxel, 30 mg/m2 irinotecan will be administered as a 90 minute intravenous infusion. Irinotecan doses will be administered in an identical infusion schedule on days 8 and 15 of each treatment cycle.
88852510|NCT03151967|Active Comparator|Applicator with LACTIN-V Treatment|Vaginal applicator containing Lactobacillus crispatus CTV-05
88852511|NCT03151967|Placebo Comparator|Applicator with Placebo|Inactive vaginal applicator without any drug
88852512|NCT04226027|Experimental|T2.coach|Participants receive standard care (diabetes self-management education provided by their Federally Qualified Community Health Center) and are asked to use T2.coach for 6 months.
88852513|NCT04226027|No Intervention|Control|Participants receive standard care (diabetes self-management education provided by their Federally Qualified Community Health Center).
88852514|NCT04000217|Active Comparator|Written Exposure Therapy|Written exposure therapy (Sloan et al., 2012) is a brief evidence-based treatment for PTSD (US Dept. of VA & DoD, 2017), wherein patients are asked to write about their trauma memories for 30 minutes, with therapist instruction and feedback before and after each writing exercise.
88852515|NCT04000217|Active Comparator|Imaginal Exposure Therapy|Imaginal exposure therapy will involve verbal recounting of trauma memories for 30 minutes with therapist instruction and feedback before and after each recounting exercise.
88852516|NCT00002951|Experimental|Arm A (Hyper-FHX)|Concomitant chemoradiotherapy consisting of hydroxyurea (PO, BID, x 6days), continuous infusion 5-fluorouracil (IV, x 5days), hyperfractionated radiotherapy (150 cGy twice daily for 5 days every 14 days, 5 cycles)
88852517|NCT03075839|Experimental|Cigarette Brand Switching|Adult smokers will be switched from using menthol cigarettes to non-menthol cigarettes
88852518|NCT03058289|Experimental|Cohort A|"INT230-6 injections every 28 days for 5 sessions into only superficial tumors, low starting dose, low concentration per tumor.~Completed"
88852519|NCT03058289|Experimental|Cohort B1|"INT230-6 injections every 28 days for 5 sessions into deep tumors, low starting dose, low drug concentration per tumor~Completed"
88852520|NCT03058289|Experimental|Cohort EA|"INT230-6 injections every 2 weeks for 5 sessions into superficial tumors, medium starting dose, low drug concentration per tumor~Completed"
88852521|NCT03058289|Experimental|Cohort EC|"INT230-6 injections every 2 weeks for 5 sessions into superficial or deep tumors, moderately high starting dose, high drug concentration per tumor~Completed"
89378992|NCT05076916|No Intervention|Control group|The control group received routine patient education and routine hospital follow-ups given by Oncology Education Nurses during the three-month follow-up period. In the third month, after the follow-up stage of the study was completed, the post-tests were administered to the patients in the control group who came to the hospital for follow-up or treatment.
89378993|NCT02331082|Active Comparator|Control|Existing healthcare system
89378994|NCT02331082|Experimental|Health System Improvement|Structured Quality Improvement Chronic Care Model Integrated Electronic Medical Record Solar-powered electrical supply Performance-based financing
89378995|NCT03144154|Experimental|Experimental group : Hypnosis-based intervention|Groupal intervention combining self-care techniques and self-hypnosis exercises
89378996|NCT03144154|No Intervention|Control group : Usual care|Control group receiving usual care but not the intervention
89378997|NCT02334670||CrAg(+) and CM(+)|Patients with symptoms of CNS disease will be treated according to Vietnam national guidelines for HIV/AIDS management.
89378998|NCT02334670||CrAg(+) and CM(-)|Patients with CrAg(+) and without CM symptoms will be treated with high-dose fluconazole. The initial dosage of fluconazole will be 900 mg taken each day for 2 weeks. This will be followed by fluconazole 450 mg orally each day for 8 weeks. Finally, maintenance treatment with fluconazole 200mg orally each (2 tablets of 100 mg procured especially for the study) day will continue until CD4 >200 cells/µL for at least 6 months.
89378999|NCT02334670||CrAg negative|Patients with CrAg negative results will be managed as other HIV positive patients according to the national guidelines
89379000|NCT02334514||Adults with influenza|Patients diagnosed with influenza by PCR testing
89379001|NCT02330848|Active Comparator|Walnut Ad libitum diet|Participants will be provided 392 grams of walnuts per week (56g or 2 oz/day) to include in their diet. Their calorie intake will not be subsequently monitored or regulated, and thus will be allowed to float ad libitum.
89379002|NCT02330848|Active Comparator|Walnut Calorie Controlled|The intervention group participants will meet with a registered dietitian and receive instructions and recipes for inclusion of 392 grams of walnuts per week (56g or 2 oz/day) in their meal plan. Participants will receive on-going instruction to preserve an isocaloric condition after the addition of walnuts. The study dietitian will customize dietary adjustments to make room for walnuts in the diet, while accommodating the priorities of each study participant. The general approach will emphasize general reduction in portion sizes; participants will also receive advice, based on baseline dietary intake analysis, of food eliminations that they might want to consider.
89379003|NCT02334202|Active Comparator|Health Education|"The health education group will follow the HEY-Durham health program designed by researchers at Duke University. This program, designed to be delivered to youth attending community high schools, was adapted to a 12-week program for adolescent military dependents."
89379004|NCT02334202|Experimental|Interpersonal Psychotherapy-Weight Gain|IPT-WG is designed to decrease excessive weight gain among adolescents who are at risk for adult obesity. IPT-WG involves developing strategies for dealing with the problems girls struggle with that may lead to increased eating. The IPT-WG program has been adapted to be appropriate for military dependents.
89379005|NCT02334280|Experimental|In SHAPE|In SHAPE is a health promotion intervention consisting of a fitness club membership and a health promotion coach with basic certification as a fitness trainer, instruction on principles of healthy eating and nutrition, and training in tailoring individual wellness plans to the needs of persons with serious mental illness.
89379006|NCT02334280|No Intervention|Usual-Care Control|Usual-care consumers agreed to delay participation in In SHAPE for 12 months.
89379007|NCT02974868|Experimental|Cohort 1|PF-06651600
88852522|NCT03058289|Experimental|Cohort EC2|"INT230-6 injections every 2 weeks for 5 sessions into superficial or deep tumors, high starting dose, moderate drug concentration per tumor, higher number of tumors to be treated per session than EC~Completed"
88852523|NCT03058289|Experimental|Cohort DEC: Safety with INT230-6|"INT230-6 injections every 2 weeks for 5 sessions with the possibility for INT230-6 retreatment into superficial tumors, with addition of anti-PD-1 antibody Keytruda (pembrolizumab) dosed concurrently starting at Day 1 every 3 weeks for two years for selected cancer types.~Completed"
88852524|NCT03058289|Experimental|EC3: INT230-6 monotherapy fixed maximal dose|"INT230-6 injections every 2 weeks for 5 sessions at fixed maximal dose into superficial or deep tumors, unlimited number of tumors to be treated per session with retreatment once every 9 weeks for two years.~Completed"
88852525|NCT03058289|Experimental|DEC2: INT230-6 combined with pembrolizumab|"INT230-6 per the dosing of cohort EC3 combined with Keytruda (pembrolizumab) dosed per DEC concurrently starting at Day 1 for selected cancers.~Completed"
88852526|NCT03058289|Experimental|FEC: INT230-6 combined with ipilimumab|"INT230-6 per the EC3 regimen combined with Yervoy (ipilimumab) dosed concurrently starting at Day 1 every 3 weeks for four treatments for selected cancer types.~Completed"
89379008|NCT02974868|Experimental|Cohort 2|PF-06700841
89379009|NCT02974868|Placebo Comparator|Cohort placebo|placebo
89379010|NCT03144076|Experimental|Group A|[Other: RSBY Health Insurance] The households in this group were offered RSBY for free. They did not have to pay the fee amount or premium amount and simply had to present their chit at the enrollment station and were enrolled. The entire premium amount including fee (Rs. 173 in Mysore, Rs. 163 in Gulbarga) has to be borne by the study. These households were automatically re-enrolled in RSBY for free for the second year of the study.
89379011|NCT03144076|Experimental|Group B|[Other: RSBY Health Insurance] The households in this treatment group were first given a cash transfer equivalent to the fee and premium for RSBY during the first visit to their household. In addition, they were offered the opportunity to purchase RSBY during a second visit to their household and get their household enrolled during that time. At that time, payment would be collected from the respondents who wanted to get enrolled and then these respondents would be taken to the enrollment stations to get them enrolled. For those households that chose to purchase RSBY for the first year of the study, their coverage was automatically extended to the second year of the study at no additional cost to them.
88852529|NCT03933293|Experimental|AK102|450mg AK102, Q4W, subcutaneous injection
88852530|NCT03933293|Placebo Comparator|placebo|Placebo, Q4W, subcutaneous injection
88852531|NCT01928082|Experimental|Transdermal estradiol|Transdermal estradiol 0.05 mg/day for 4 weeks, followed by 0.10 mg/day for 4 weeks
89182731|NCT06237894|Experimental|Multisensory Stimulation|
89379012|NCT03144076|Experimental|Group C|[Other: RSBY Health Insurance] The households in this group were simply offered an opportunity to purchase RSBY if they wished to. They were informed about this during the first visit to their household and for the households who wanted to get enrolled, the fee and premuim amount was collected and enrolment was done during the second visit to their household.
89379013|NCT03144076|No Intervention|Group D|[No intervention] The households in this group were not offered anything and were informed that they had been randomly selected to not receive anything beyond the participation incentive that all survey participants received. In addition, a short survey was administered to them at this time.
89379014|NCT05076526|Active Comparator|HA|Patients will receive 2 intra-articular injections of 2mL Synolis VA (20 mg/mL HA and 40 mg/mL sorbitol), with an interval of 1 month between both injections.
88852532|NCT01972776|Experimental|QBM076 Part 1 Cohort 1|Participants received QBM076 25 mg twice daily (bid) for 14 days.
88852533|NCT01972776|Experimental|QBM076 Part 1 Cohort 2|Participants received QBM076 75 mg bid for 14 days.
88852534|NCT01972776|Experimental|QBM076 Part 1 Cohort 3|Participants received QBM076 150 mg bid for 14 days.
88852535|NCT01972776|Placebo Comparator|Placebo Part 1|Participants in each cohort received matching placebo for 14 days.
88852536|NCT01972776|Experimental|QBM076 Part 2|Participants received QBM076 150 mg bid for 8 weeks.
88852537|NCT01972776|Placebo Comparator|Placebo Part 2|Participants received matching placebo for 8 weeks.
88852538|NCT04330469|Experimental|Periodontal therapy|Patients offered periodontal therapy in 2-4 sittings (n=40), Dental hygiene advised
88852539|NCT04330469|Sham Comparator|Control|Patients given standard medical treatment (n=40), Dental hygiene advised
88852540|NCT00003005|Experimental|deoxycoformycin and cordycepin|Dose escalation for deoxycoformycin and cordycepin
88852541|NCT00003011|Active Comparator|Marmistat|10 mg PO BID
89379015|NCT05076526|Experimental|PRP-HA|Patients will receive 2 intra-articular injections of 5mL CM-PRP-HA combination (3mL of autologous PRP, 2mL of 16mg/mL HA), with an interval of 1 month between both injections.
89399437|NCT02175836||SCD possitive versus SCD negative group|The total Heart Failure patients subgroup experiencing Sudden Cardiac Death surrogate end-points during follow up versus the patients subgroup that is free from Sudden Cardiac Death surrogate end-points.
88852542|NCT00003011|Placebo Comparator|Placebo|10 mg PO BID
88852543|NCT03850067|Experimental|CC-90011 in combination with Cisplatin and Etoposide|During the Chemotherapy Treatment Period, the dose escalation is designed to explore three dose levels of CC-90011, for example 20, 40, and 60 mg as determined by Bayesian design, administered orally Days 1 and 8, in combination with cisplatin intravenous (IV) 75 mg/m2, Day 1, and etoposide iv 100 mg/m2 on Days 1, 2, and 3, for 4 cycles of 21 days each. Subjects completing the chemotherapy and being responders as per RECIST 1.1 will enter the Maintenance Treatment Period. Subjects completing 6 cycles of maintenance treatment subject will be treated only with CC-90011 at RP2D (60 mg) and continuing on CC-90011 are only required to have clinic visits/assessments performed on Day 1 (± 3 days) of each subsequent cycle (Cycles 6 and higher) unless more frequent visits are clinically indicated.
88852544|NCT03850067|Experimental|CC-90011 in combination with Carboplatin and Etoposide|During the Chemotherapy Treatment Period, the dose escalation is designed to explore three dose levels of CC-90011, for example 20, 40, and 60 mg as determined by Bayesian design, administered orally Days 1 and 8, in combination with cisplatin intravenous (IV) 75 mg/m2, Day 1, and etoposide iv 100 mg/m2 on Days 1, 2, and 3, for 4 cycles of 21 days each. Subjects completing the chemotherapy and being responders as per RECIST 1.1 will enter the Maintenance Treatment Period. Subjects completing 6 cycles of maintenance treatment subject will be treated only with CC-90011 at RP2D (60 mg) and continuing on CC-90011 are only required to have clinic visits/assessments performed on Day 1 (± 3 days) of each subsequent cycle (Cycles 6 and higher) unless more frequent visits are clinically indicated
88852545|NCT03850067|Experimental|Nivolumab combination|"When the RP2D of CC-90011 in combination with cisplatin or carboplatin and etoposide is determined, the combination of CC-90011 at RP2D with cisplatin or carboplatin and etoposide plus nivolumab IV 240 mg Day 1 of each chemotherapy cycle, will be explored. For CC-90011 in combination with chemotherapy and nivolumab, the starting dose will be the RP2D of CC-90011 in combination with chemotherapy.~A maintenance therapy will be given to subjects responding to the combination of CC-90011 with chemotherapy or to chemotherapy with nivolumab, as per RECIST 1.1. These subjects will receive 60 mg or 40 mg (in case of combination with nivolumab) of CC-90011 orally once weekly on Days 1, 8, 15, and 22, during cycles of 28-day each and, in the case of the combination with nivolumab, nivolumab IV 480 mg on Day 1 during cycles of 28-day each."
88852546|NCT02579525|Experimental|Targeted tissue perfusion guidance (TTP)|TTP-guidance based on clinical signs of peripheral perfusion.
88852547|NCT02579525|Active Comparator|Macrocirculatory - guidance (MCG)|MCG-guidance based on recommended macrocirculatory parameters.
88852548|NCT03837431||CL suspicion|Individuals presenting with clinical suspicion of CL
88852549|NCT04329689|Experimental|septal myectomy alone versus septal myectomy|"The aims of the present study is to:~Compare the results of adequate septal myectomy alone versus septal myectomy + mitral repair in patients with HOCM.~Effect of mitral repair on outcome of patients with systolic anterior motion that accompanies HOCM."
88852552|NCT04329611|Active Comparator|hydroxychloroquine|hydroxychloroquine 400 mg po bid loading dose for 1 day followed by 200 mg po twice daily for 4 days
88852553|NCT04329611|Placebo Comparator|Placebo|Matching Placebo
88852554|NCT03763331|Sham Comparator|Sham treatment|Participants were dressed in water-circulating trousers that are connected to a pump. Water at 91.4 degrees F was circulated through the pants for 90 minutes daily for 8 weeks..
88852555|NCT03763331|Active Comparator|Heat Therapy|Participants were dressed in water-circulating trousers that are connected to a pump. Water at 110 degrees F will be circulated through the pants for 90 minutes daily for 8 weeks.
88852556|NCT00003077|Experimental|Omega-3 fatty acid|"Patients receive omega-3 fatty acids orally in two equal doses with/after breakfast and lunch for 4 months or until weight loss is observed.~Dose is escalated in cohorts of two patients, although dose escalation is allowed in individual patients. Patients are evaluated for cachexia response every 2 weeks, and tumor response every 4 weeks for a maximum of 4 months. If no response of cachexia or tumor after a 2 month period, patients will be discontinued from study. Patients will be followed for survival post-treatment."
88852557|NCT00003095||bone marrow transplant|bone marrow transplant
88852558|NCT00003095||standard chemotherapy|standard chemotherapy
88852559|NCT03692273|Experimental|Laser|Laser treatment to 3x3cm2 area. It will receive the Luminous ultra pulse fractional ablative carbon dioxide laser at 150mJ, 3% density and 250Hz.
88852560|NCT03692273|Experimental|0.5mm punch biopsy|0.5mm punch biopsy area. This area will receive 0.5mm punch biopsies 75 per cm2 at a depth of 5mm.
88852561|NCT03692273|No Intervention|No treatment|3x3cm2 area designated as no treatment that will serve as a control
88852564|NCT01545557|Experimental|Hyaluronic acid dermal filler|One Emervel Volume injection at baseline and touch up injections 3 weeks after if needed
88852565|NCT00003119|Experimental|Treatment 1 - Asymptomatic - no immediate chemotherapy|
88852566|NCT00003119|Experimental|Symptomatic - immediate chemotherapy|
88852567|NCT04130555||CELLIS Rectopexy|Rectal prolapse repair by ventral rectopexy with the CELLIS Rectopexy matrix
88852568|NCT00384371|Experimental|1|Botulinum Toxin A
88852569|NCT00384371|Placebo Comparator|2|Placebo
88852570|NCT00423215||Patients with Type II diabetes|
88852571|NCT00003137|Experimental|irinotecan|"Patients receive irinotecan (CPT-11) by IV over 90 minutes every 3 weeks. Dosage modifications are made based on toxicity. Retreatment may be delayed another 3 weeks (for a total of 6 weeks) to allow for recovery from toxic effects. Patient is taken off study if they do not recover from toxic effects, unless cause is documented to be unrelated to CPT-11. Patients with stable disease or partial response continue on treatment until disease progression or intolerable toxicity. Patients with complete response continue on treatment for another 2 courses and then are observed.~Patients are followed every 3 months for 3 years or until disease progression."
88852572|NCT00003425|Experimental|Amifostine trihydrate|
88852573|NCT00534131|Active Comparator|Arm 1|Patients for whom a standard abdominal approach is adequate to excise the distal third of the rectum (without jeopardising oncological clearance if appropriate).
88852574|NCT00534131|Experimental|Arm 2|Combined abdominal and trans-perineal approach to excise the distal third of the rectum, while preserving the anal canal
88852575|NCT00534131|Active Comparator|Arm 3|Standard proctectomy to excise the distal third of the rectum and the anal canal
88852576|NCT00330551|Experimental|Long-acting injectible risperidone|Participants who are randomly assigned to this arm will be administered the long-acting injectible form of risperidone (Risperdal Consta) every two weeks, plus group skills training and case management, for 12 months.
88852577|NCT00330551|Active Comparator|Oral risperidone|Participants who are randomly assigned to this arm will be treated with the oral version of risperidone (Risperdal) daily, plus group skills training and case management, for 12 months.
88852578|NCT00001259|Placebo Comparator|Study 1, Phase 1, Assignment 1 - Placebo|As part of double Blind randomized trial, participants in Assignment 1 were randomized to 8 weeks of placebo (P) injections (1 injection per month). These participants then continued on to Study 2 after completion of 8 weeks of placebo injections.
88852579|NCT00001259|Experimental|Study 1, Phase 1, Assignment 2 - GnRH agonist injections (Lupron-L only)|As part of double Blind randomized trial, participants in Assignment 2 were randomized to 8 weeks of GnRH agonist treatment 3.75 mg given intramuscularly monthly. Those who exhibited a remission of symptoms after 8 weeks continued on to receive one more month of GnRH agonist treatment (12 weeks total) and then entered Study 1, Phase 2.
88852580|NCT00001259|Experimental|Study 1, Phase 2, Arm 1 - Estradiol, then progesterone|12 weeks of GnRH agonist treatment 3.75 mg given intramuscularly monthly. Additionally, 4 weeks of transdermal Estradiol (100mcg/day by skin patch) and placebo suppositories. Week 5 involves 100mcg/day transdermal Estradiol and active Progesterone suppositories (200mg vaginally twice/day). Followed by 1-2 weeks (weeks 6-7) washout period. Then crossover to 5 weeks (week 8-12) of Progesterone suppositories (200mg vaginally twice/day) and placebo patches.
89399438|NCT03689829|Experimental|MOR106 Single Dose A, i.v. infusion, Part 1|A single dose of MOR106 will be administered by i.v. infusion.
89399439|NCT03689829|Experimental|MOR106 Single Dose B, s.c. injection, Part 1|A single dose of MOR106 will be administered by s.c. injection.
89399440|NCT03689829|Experimental|MOR106 Single Dose C, s.c. injection, Part 1|A single dose of MOR106 will be administered by s.c. injection.
89399441|NCT03689829|Experimental|MOR106 Single Dose D, s.c. injection, Part 1|A single dose of MOR106 will be administered by s.c. injection.
89399442|NCT03689829|Experimental|MOR106 Repeated Doses E, s.c. injection, Part 2|Repeated doses of MOR106 will be administered by s.c. injection with a loading dose on the first day of administration.
89399443|NCT03689829|Placebo Comparator|Placebo s.c.injection, Part 2|Corresponding Placebo will be administered by s.c. injection.
89399444|NCT03689829|Experimental|MOR106 Repeated Doses F, s.c. injection, Part 3|Repeated doses of MOR106 will be administered by s.c. injection with a loading dose on the first day of administration.
89399445|NCT03689829|Placebo Comparator|Placebo s.c.injection, Part 3|Corresponding Placebo will be administered by s.c. injection.
89379016|NCT02330614||bleaching patients|Patients who agreed to be bleaching were treated with 10% carbamide peroxide (CP) gel (Whiteness Perfect, FGM) to each subject With verbal instructions for 3 weeks with daily applications of 1 hour according to manufacturers indications , before and after this procedure was applied again the NEO-FFI personality test form, had 30 minutes to answer it.
88852581|NCT00001259|Experimental|Study 1, Phase 2, Arm 2 - Progesterone, then estradiol|12 weeks of GnRH agonist treatment 3.75 mg given intramuscularly monthly. Additionally, 5 weeks of Progesterone suppositories (200mg vaginally twice/day) and placebo patches. Followed by 1-2 weeks (weeks 6-7) washout period. Then crossover to 4 weeks (weeks 8-11) of transdermal Estradiol (100mcg/day by skin patch) and placebo suppositories. Week 12 involves 100mcg/day transdermal Estradiol and active Progesterone suppositories (200mg vaginally twice/day).
89379017|NCT02330614||Control group|Patients who refused to be bleached were administered the personality test NEO-FFI, had 30 minutes to answer it.
88852582|NCT00001259|Experimental|Study 2, Phase 1 - GnRH agonist injections (Lupron-L only)|Eight to 12 weeks of GnRH agonist treatment 3.75 mg given intramuscularly monthly.
88852583|NCT00001259|Experimental|Study 2, Phase 2, Arm 1 - Estradiol, then progesterone|12 weeks of GnRH agonist treatment 3.75 mg given intramuscularly monthly. Additionally, 4 weeks of transdermal Estradiol (100mcg/day by skin patch) and placebo suppositories. Week 5 involves 100mcg/day transdermal Estradiol and active Progesterone suppositories (200mg vaginally twice/day). Followed by 1-2 weeks (weeks 6-7) washout period. Then crossover to 5 weeks (week 8-12) of Progesterone suppositories (200mg vaginally twice/day) and placebo patches.
88852584|NCT00001259|Experimental|Study 2, Phase 2, Arm 2 - Progesterone, then estradiol|12 weeks of GnRH agonist treatment 3.75 mg given intramuscularly monthly. Additionally, 5 weeks of Progesterone suppositories (200mg vaginally twice/day) and placebo patches. Followed by 1-2 weeks (weeks 6-7) washout period. Then crossover to 4 weeks (weeks 8-11) of transdermal Estradiol (100mcg/day by skin patch) and placebo suppositories. Week 12 involves 100mcg/day transdermal Estradiol and active Progesterone suppositories (200mg vaginally twice/day).
88852585|NCT00003143|Experimental|DHAP + amifostine|Patients are randomized to receive salvage chemotherapy with intravenous dexamethasone/cisplatin/cytarabine (DHAP) with or without amifostine. Patients receive cisplatin IV over 3 hours followed by cytarabine IV for 2 doses. Patients also receive dexamethasone orally or IV. Treatment repeats every 3-4 weeks for 2-6 courses. Arm I: Patients receive amifostine IV over 15 minutes prior to all courses of DHAP, as a 15 minute infusion, beginning 30 minutes prior to cisplatin administration. Arm II: Patients do not receive amifostine. On day 3 of the last DHAP course, patients receive filgrastim (G-CSF) until the last day of progenitor stem cell (PSC) mobilization. PSC transplant continues daily for 4-10 days.
88852586|NCT00003143|Other|DHAP|Patients are randomized to receive salvage chemotherapy with intravenous dexamethasone/cisplatin/cytarabine (DHAP) with or without amifostine. Patients receive cisplatin IV over 3 hours followed by cytarabine IV for 2 doses. Patients also receive dexamethasone orally or IV. Treatment repeats every 3-4 weeks for 2-6 courses. Arm I: Patients receive amifostine IV over 15 minutes prior to all courses of DHAP, as a 15 minute infusion, beginning 30 minutes prior to cisplatin administration. Arm II: Patients do not receive amifostine. On day 3 of the last DHAP course, patients receive filgrastim (G-CSF) until the last day of progenitor stem cell (PSC) mobilization. PSC transplant continues daily for 4-10 days.
88852587|NCT00002807|No Intervention|Observation|
88852588|NCT00002807|Experimental|Radiation|Post-operative pelvic radiation therapy (45 Gy in 25 fractions over 5 weeks)
88852589|NCT04329533|Experimental|Intervention Group - access to meditation app|"Will receive a 30-day free trial of the mobile meditation app Calm on study day 0"
88852590|NCT04329533|No Intervention|Control Group - no access to meditation app|"Will not have the intervention until after the 30 day study period and then will receive a 30-day free trial of the mobile meditation app Calm on study day 30"
88852591|NCT00002825|Experimental|Arm I|All patients receive docetaxel with G-CSF every 21 days for up to 12 courses.
88852592|NCT00002831|Experimental|Deoxyazacytidine + Busulfan + Cyclophosphamide|Deoxyazacytidine + Busulfan + Cyclophosphamide With Allogeneic Stem Cell Transplantation
88852593|NCT00002837|Experimental|Doxorubicin, Paclitaxel + Cyclophosphamide with PBPC|
88852594|NCT00003485|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
89379018|NCT03653858|Experimental|Group A: DBS onset in week 1|"Implantation of Vercise GEVIA deep brain stimulation (DBS) system. DBS onset in week 1.~2ND STAGE: After 6 months DBS ON, patients will be assessed whether they are responders or non-responders. In the subgroup of eligible responders, patients will be randomized to either DBS OFF* (for max. 3 months) or continued DBS for another 6 months. *DBS OFF until worsening of clinical depression, event (defined as > 5 points augmentation in MADRS in two consecutive visits) or for a maximum of 3 months. After DBS OFF, re-onset of DBS will be performed, followed by 6 months continuous DBS.~Non-responders will also receive another 6 months DBS therapy in the 2nd stage. At sites other than Freiburg/Bonn, the 2nd stage consists of 6 months DBS therapy only."
88852595|NCT00003491|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
88852596|NCT00003497|Experimental|Antineoplastons|Antineoplaston therapy (Atengenal + Astugenal) capsules orally six to seven times a day. Treatment continues in the absence of disease progression or unacceptable toxicity. absence of disease progression or unacceptable toxicity.
88852597|NCT00003167|Experimental|Treatment (adenovirus p53)|"Group 1 patients receive adenovirus p53 (Ad-p53) intravesically on days 1 and 4. Treatment continues every 4 weeks for a maximum of 6 courses in the absence of disease progression or unacceptable toxicity.~Cohorts of 3 patients in group 1 receive escalating doses of Ad-p53. In the absence of grade 3 or worse toxicity in the first 3 patients treated, subsequent cohorts of 3 patients each receive escalating doses of Ad-p53 on the same schedule. If 1 of 3 patients experiences grade 3 toxicity, an additional 3 patients are treated at that dose level and dose escalation continues. If 1 of 3 patients experience grade 4 toxicity or 2 of 3 patients experience grade 3 toxicity, dose escalation ceases and the MTD is defined as the previous dose level. Group 2 patients receive Ad-p53 at the MTD on days 1-4, and group 3 patients receive Ad-p53 at the MTD on days 1-4 and 8-11."
89379019|NCT03653858|Sham Comparator|Group B: DBS off, followed by DBS onset in week 17|"Implantation of Vercise GEVIA deep brain stimulation (DBS) system. 4 months OFF after implantation followed by DBS onset in first week of month 5.~2ND STAGE: See group A."
89379020|NCT05076136|Experimental|Regional treatment|Group A was given regional treatment with baseline treatment protocol
89379021|NCT05076136|Active Comparator|Standard physiotherapy treatment|Group B was given standard physiotherapy treatment with baseline protocol
89379022|NCT03654482|Experimental|SuperSeton arm|
89379023|NCT02330536|Experimental|Flowrate A|insufflation of carbon dioxide at 8L/min, 8mmHg
89379024|NCT02330536|Experimental|Flowrate B|insufflation of carbon dioxide at 20 L/min, 8mmHg
89379025|NCT03653780|Experimental|Ekso GT gait training|20-minute Ekso GT gait training
89379026|NCT05076058|Experimental|Treatment group|"Tablet name: tablet of silybum marianum, Pueraria lobate and salvia miltiorrhiza;~Dosage: 1g/tablet, 3 tablets/time；~Frequency: 2 times/day;~Duration: 6 months"
89379027|NCT05076058|Placebo Comparator|Control group|"Tablet name: Placebo;~Dosage: 1g/tablet, 3 tablets/time；~Frequency: 2 times/day;~Duration: 6 months"
89379028|NCT03143998|Experimental|HCV GT1a TN|Participants with HCV GT1a infection who are TN will take MK-5172A for 12 weeks.
89379029|NCT03143998|Experimental|HCV GT1a TE|Participants with HCV GT1a infection who are TE will take MK-5172A for 12 weeks.
89379030|NCT03143998|Experimental|HCV GT1b TN|Participants with HCV GT1b infection who are TN will take MK-5172A for 12 weeks.
89379031|NCT03143998|Experimental|HCV GT1b TE|Participants with HCV GT1b infection who are TE will take MK-5172A for 12 weeks.
89379032|NCT05075902|Experimental|Multimorbidity Group (MULTI)|Multimorbidity group is composed of post menopausal women with two or more chronic diseases cardiometabolic (Hypertension, diabetes, dislipidemias, obesity).
89379033|NCT05075902|Experimental|Morbidity Group (MORB)|Morbidity group is composed of postmenopausal women with one or no chronic cardiometabolic disease (Hypertension, diabetes, dislipidemias, obesity)
89379034|NCT05075668|Active Comparator|OSA support via CPAP face mask|Auto-titrated according to the settings made by sleep physicians, FiO2 0.21
89379035|NCT05075668|Active Comparator|OSA support via HFNC at 20 L/min|High flow nasal insufflation of air (FiO2 0.21) at 20 L/min
89379036|NCT05075668|Active Comparator|OSA support via HFNC at 30 L/min|High flow nasal insufflation of air (FiO2 0.21) at 30 L/min
89379037|NCT05075668|Active Comparator|OSA support via HFNC at 40 L/min|High flow nasal insufflation of air (FiO2 0.21) at 40 L/min
89379038|NCT02334046|Experimental|Elderly|Remifentanil was maintained at predetermined effect-site concentration during the emergence period in elderly patients.
89379039|NCT02334046|Active Comparator|Adult|Remifentanil was maintained at predetermined effect-site concentration during the emergence period in adult patients.
89379040|NCT03486899|Experimental|BMS-986036 Dose Level 1|Administered by subcutaneous injection.
89379041|NCT03486899|Experimental|BMS-986036 Dose Level 2|Administered by subcutaneous injection.
89379042|NCT03486899|Experimental|BMS-986036 Dose Level 3|Administered by subcutaneous injection.
89379043|NCT03486899|Placebo Comparator|Placebo|Administered by subcutaneous injection.
89379044|NCT02918552|Experimental|Treatment|20 or 40 mg sodium nitrite tid
89379045|NCT02918552|Placebo Comparator|Control|20 or 40 mg placebo tid
89379046|NCT05068882|Experimental|Immunonutrition|Oral immunonutrition containing arginine, omega-PUFAs and antioxidants
89379047|NCT05068882|Active Comparator|High-protein diet|Oral nutrition with high-protein content
89379048|NCT05068882|Active Comparator|Standard nutrition|Oral nutrition with standard ingredients
89379049|NCT05068882|No Intervention|No intervention|No intervention
89379050|NCT02330380||Methotrexate|Methotrexate will be dosed weekly. Methotrexate is given as a single, weekly dose and is will be started at 15mg after a first week test dose of 2.5 mg to minimize side effects and achieve efficacy. Weekly dosages will be 15mg.
89379051|NCT02330380||Ustekinumab|Ustekinumab is given as a subcutaneous injection of 45mg if the patient is <100Kg or 90mg if the patient is >100Kg at weeks 0, 4, 16, and every 12 weeks thereafter.
89379052|NCT02330380||Etanercept|Etanercept will be given in the first 3 months of treatment as 50 mg twice a week (3 or 4 days apart). After 3 months, a reduced dose of 50 mg will be given once per week.
89379053|NCT02330380||Adalimumab|Adalimumab will be given in a dose of 40 mg subcutaneously every other week.
89379054|NCT02330380||Acitretin|Acetretin will be prescribed as daily with 25mg if the patient is <80Kg or 35mg if the patient is >80Kg.
89379055|NCT02330380||UVB Excimer Laser|Dose determination will be determined by a physician per standard-of-care by performing a Sunburn Test/Minimal Erythemal Dose Test, or by visually evaluating the patient's skin type and thickness of psoriasis plaque. Initial laser dose will be 1-4X the MED depending on the thickness of the plaque. Escalation will be 25-50% increase in dose per treatment if there is no residual erythema, 25% increase per treatment if there is mild residual erythema, and 0% increase per treatment if there is moderate residual erythema. Investigators also have the option to skip a treatment, if there is above moderate erythema, or significant patient discomfort. Patients will receive treatment twice a week.
89379056|NCT02330380||Narrowband UVB|Narrowband UVB (311nm) will be used to treat patients 3X per week with 311nm of UVB light. Uninvolved areas of skin will be covered where possible to minimize excess sun exposure. Patients will be tested for their minimal erythemal dose (MED), after which, based upon Fitzpatrick Scale skin type, a patient will typically beginning with 1-2 minutes based on skin type and gradually increased by 10-15% per treatment dose as tolerated.
89379057|NCT02038348|Other|PET with 18F-FDOPA|
89379058|NCT02333812||copd patients|Adult patients with COPD
89379059|NCT02333812||healthy smokers|Adult patients with smoking history and no clinical manifestation of COPD who will be recruited form the institute of pulmonary medicine and the otolaryngology outpatient clinic.
89399446|NCT02174042|Experimental|Tangning Tongluo Capsule|Type 2 diabetes
89379060|NCT02333812||Adult patients with lung disease unrelated to smoking|Adult patients with lung disease unrelated to smoking
88852598|NCT00003515|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
88852599|NCT00003521|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
88852600|NCT00002849|Experimental|induction and maintenance|dexamethasone induction followed by alpha interferon maintenance
88852601|NCT04329377||platelet count in iiron overload|
88852602|NCT00002855|Experimental|Arm I|Arm I: Medical or surgical castration followed by an anti-androgen therapy with either flutamide, bicalutamide, or nilutamide.
89379061|NCT02333890|Experimental|Chloroquine|The daily oral dose per patient is 500 mg of chloroquine. Patients may be taking the drug for 2-6 weeks leading up to the date of the surgery. The last dose will be taken the evening before surgery.
89379062|NCT02333890|Placebo Comparator|Placebo|The daily oral dose per patient is 500 mg of placebo (lactose). Patients may be taking the drug for 2-6 weeks leading up to the date of the surgery. The last dose will be taken the evening before surgery.
89379063|NCT03719963||cochlear implant|Cochlear implantation is a powerful tool for helping children with severe to profound sensorineural hearing loss to gain the ability to hear, and to achieve age appropriate communication skills. Evaluating the development of auditory, speech, language skills and the personality of implanted child is useful for the parent, the teacher, the therapist, and the subsequent rehabilitation progress
89379064|NCT03143686||ACURATE TA™ Transapical Aortic Bioprosthesis|The first two hundred and fifty (250) patients in whom the commercial, or CE Mark, ACURATE TATM Transapical Aortic Bioprosthesis is implanted.
89379065|NCT03485495|Experimental|Divaza|Tablet for oral use. Two tablets per intake 3 times a day (approximately at the same time), outside of meal (between meals or 15 minutes before eating or drinking). The tablets should be held in mouth until completely dissolved.
89379066|NCT03485495|Placebo Comparator|Placebo|Tablet for oral use. Two tablets per intake 3 times a day (approximately at the same time), outside of meal (between meals or 15 minutes before eating or drinking). The tablets should be held in mouth until completely dissolved.
89379067|NCT03652532|Experimental|Alternate Day Fasting and Exercise|
89379068|NCT03652532|Experimental|Alternate Day Fasting|
89379069|NCT03652532|Experimental|Exercise|
89379070|NCT03652532|No Intervention|Control|regular eating and exercise habits for 8 weeks
88852603|NCT00002855|Experimental|Arm II|Arm II: Chemo/hormonal therapy for 3 x 8-week courses, followed by total androgen blockade. Each course consists of 6 weeks of cytotoxic therapy with doxorubicin, ketoconazole, vinblastine, and estramustine followed by 2 weeks rest. Maintained on hydrocortisone both during treatment and during rest.
88852604|NCT00003533|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
88852605|NCT00003545|Experimental|Arm I|Patients receive 506U78 IV over 2 hours on days 1, 3, and 5. If residual leukemia/lymphoma is present on day 22, then patients receive a second course of 506U78. If day 22 marrow is hypocellular, then a repeat bone marrow biopsy should be obtained on day 29 to assess response. For day 22 or 29 marrow that is in complete response, patients receive 506U78 for two more courses on days 1, 3, and 5, administered every 21 days. Patients are followed every 3 month for 1 year, then every 6 months for a maximum of 10 years.
88852606|NCT00002879|Experimental|cladribine|Patients receive cladribine (2-chlorodeoxyadenosine; 2-CdA) daily for 5 days every 4 weeks for a maximum of 6 courses; response is assessed after every 2 courses. Patients in complete remission or with stable disease discontinue treatment and are followed; those with disease progression at any time are removed from study. Patients are followed every 2 months for 1 year, every 4 months for 1 year, every 6 months for 1 year, and annually for 2 years.
88852607|NCT00003557|Experimental|Arm A|Dolastatin-10 (400 mcg/m2 IV every 3 weeks)
88852608|NCT00003935|Experimental|Treatment|Induction: Patients receive oral etoposide daily on days 1-21 and vincristine sulfate IV on days 1, 8, and 15. Treatment repeats every 4 weeks for 2 courses. Patients receive radiation therapy daily for 6 weeks concurrently with induction chemotherapy. Maintenance: One week after induction therapy, patients receive vincristine sulfate IV on days 1 and 8 and oral etoposide daily on days 1-21. Treatment repeats every 4 weeks for 10 courses in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter
88852609|NCT00003191|Experimental|Arm I|Patients receive oral fenretinide 3 times a day on days 1-7. Treatment repeats every 3 weeks for up to 8 courses. Patients may receive an additional 22 courses of therapy in the presence of stable or responding residual tumor. Patients with recurrent neuroblastoma, after prior myeloablative therapy with no measurable disease, will stop treatment after 8 courses. Cohorts of 3-6 patients receive escalating doses of fenretinide until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose limiting toxicity.
88852610|NCT00384527|Experimental|1|
88852611|NCT00384527|Active Comparator|2|
88852612|NCT00003563|Experimental|WBRT|3 Gy of WBRT daily for a total of 10 days
88852613|NCT00003563|Experimental|MGd|IV does of 5.0 mg/kg MGd plus WBRT
88852614|NCT00003953|Experimental|Doxorubicin and Docetaxel|
89379071|NCT02330302|Active Comparator|Femoral nerve block|Procedure: Ultrasound-guided femoral nerve block Drug: Ropivacaine 0.5% 30mls
89379072|NCT02330302|Active Comparator|Fascia Iliaca block|Procedure: Ultrasound-guided suprainguinal approach to fascia iliaca block Drug: Ropivacaine 0.5% 30mls
89379073|NCT02330224|Experimental|Hypertension Management Intervention|Multifaceted hypertension management intervention
89379074|NCT02330224|No Intervention|Usual Care|Control group
89379075|NCT03143530|Active Comparator|Pectoralis Block with Ropivacaine|General anesthesia + pectoralis block with ropivacaine injection 30ml of 0.25% (75mg)
88852615|NCT02972723|Experimental|Metformin therapy, single arm|Open label trial, participants will be expected to take Metformin twice a day for 2 weeks
88852616|NCT00003203|Experimental|Newly diagnosed cerebral PNET with histologic verification|Begin therapy within 31 days of surgery. Radiation therapy will be given in standard fractions along with filgrastim. The craniospinal axis will be treated first. Patients will receive carboplatin at 35 mg/m2/day IV over 15-20 minutes Monday through Friday, 1-4 hours prior to radiation for 6 weeks (total of 30 doses). Vincristine sulfate 1.5 mg/m2 IV will be given weekly x 6. Following radiation, patients will receive Maintenance chemotherapy. Patients enrolled prior to Amendment #5 will receive six cycles of cyclophosphamide and vincristine (Regimen A). Patients enrolled after Amendment #5 will receive six cycles of cyclophosphamide, vincristine sulfate and cisplatin (Regimen B).
88852617|NCT00003575|Experimental|Arm I|All patients receive ifosfamide IV by continuous infusion for 2 days, etoposide IV over 2 hours daily on days 1 and 2, and filgrastim (G-CSF) subcutaneously (SC) daily on days 4-13. Courses are repeated every 21 days. Patients who have complete or partial remission after a minimum of 4 courses of chemotherapy receive maintenance therapy consisting of interleukin-12 SC twice weekly beginning on day 28 of the final chemotherapy course and continuing for 6 months or until disease progression. All patients also receive combination antiretroviral therapy during study.
88852618|NCT00003587|Experimental|carboplatin/gemcitabine/paclitaxel|IV carboplatin AUC=5.5 day 1 every 21 days X 3 IV gemcitabine 1,000 mg/m^2/day, days 1 and 8 every 21 days X3 IV paclitaxel 225 mg/m^2/day, day 1 every 21 days X 3
88852619|NCT00003587|Experimental|cisplatin/vinorelbine/docetaxel|IV cisplatin 100 mg/m^2 day 1 every 21 days X 3 IV vinorelbine 25 mg/m^2/day, days 1 and 8 every 21 days X 3 IV docetaxel 75 mg/m^2 day 1 every 21 days X 3
88852620|NCT00003995|Experimental|Arm I|Patients receive a loading dose of trastuzumab IV over 90 minutes on week 1, and over 30-90 minutes weekly thereafter. Patients receive irinotecan IV over 90 minutes following trastuzumab weekly for 4 weeks. Courses are repeated every 6 weeks in the absence of disease progression or unacceptable toxicity.
88852621|NCT00003593|Experimental|Arm A: TMD patients only|Patients are observed if their transient myeloproliferative disorder (TMD) does not require intervention. Patients who require therapy for TMD undergo leukapheresis or exchange transfusion for up to 3 consecutive days. If the TMD does not resolve or there is significant organ involvement, patients receive low-dose cytarabine IV continuously on days 0-4. Treatment repeats at least every 2 weeks for up to 4 courses. Patients who experience a recurrence of TMD at least 8 weeks after resolution or have refractory disease may proceed to group II for further treatment. patients will continue to be followed for remission induction, EFS, DFS and OS regardless of the type of leukemia that develops.
88852622|NCT00003593|Experimental|Arm B: AML/MDS patients only|(closed to accrual as of 6/24/04 except for patients first enrolled in group I): Patients receive induction therapy comprising cytarabine IV continuously, daunorubicin hydrochloride IV continuously, and oral thioguanine twice daily on days 0-3. Treatment repeats every 28 days for 4 courses. Patients with no CNS disease at diagnosis receive cytarabine intrathecally (IT) on day 0. Patients with CNS disease at diagnosis receive cytarabine IT on days 0, 5, and 7. If CNS disease persists on day 7, patients receive up to 6 courses of cytarabine IT, therapeutic hydrocortisone IT, and methotrexate IT, twice weekly beginning on day 10. Asparaginase during Intensification 1 day 1 hour 18.
88852623|NCT00003599|Experimental|Arm I|Alpha-tocopherol (AT) orally and isotretinoin orally daily (arm I)
88852624|NCT00003599|Experimental|Arm II|Isotretinoin orally plus AT placebo orally daily (arm II).
88852625|NCT04329299||Blood Biomarkers Analyses|15 ml of blood sample will be obtained from each study participant, for blood-based biomarkers analyses.
88852626|NCT00003611|Experimental|acitretin|"Patients receive oral acitretin daily for 2 years. Skin biopsies are obtained at 1 year from normal areas and from any areas with skin cancer for genetic studies.~Patients are followed every 6 months."
88852627|NCT00003611|Placebo Comparator|placebo|"Patients receive placebo daily for 2 years. Skin biopsies are obtained at 1 year from normal areas and from any areas with skin cancer for genetic studies.~Patients are followed every 6 months."
88852628|NCT00003623|Experimental|Multivitamin|Patients receive multivitamins orally once daily for 3 years. Patients are followed every 3 months for 2 years, then every 6 months for 1 year, and then annually thereafter.
88852629|NCT00003623|Placebo Comparator|Placebo|Patients receive placebo orally once daily for 3 years. Patients are followed every 3 months for 2 years, then every 6 months for 1 year, and then annually thereafter.
88852630|NCT00004001|Experimental|Docetaxel and Estramustine|Estramustine, 280 mg, PO, TID, Days 1-5; q 21 days Docetaxel, 60mg/m2, IV, Day 2; q 21 days
88852631|NCT00004001|Active Comparator|Mitoxantrone and Prednisone|Mitoxantrone, 12 mg/m2, IV, Day 1; q 21 days Prednisone, 5 mg, PO, BID, Days 1-21; q 21 days
88852632|NCT00004055|Experimental|topotecan + paclitaxel + filgrastim|Patients receive oral topotecan on days 1-5 followed by paclitaxel IV over 3 hours on day 5. Beginning 24-48 hours after chemotherapy, patients receive filgrastim (G-CSF) subcutaneously daily for up to 10 days until blood counts recover. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression. Patients who develop CNS progressive disease only should receive whole brain radiotherapy before continuing study treatment.
88852633|NCT00004067|Active Comparator|Arm 1: adriamycin + cyclophosphamide then taxol|
88852634|NCT00004067|Experimental|Arm 2: adriamycin + cyclophosphamide then taxol + herceptin|
88852635|NCT00004079|Experimental|Treatment (SarCNU)|"Patients receive oral sarcosinamide nitrosourea (SarCNU) on days 1, 5, and 9. Treatment continues every 28 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of SarCNU until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
88852636|NCT00004109|Experimental|Doxorubicin + External-Beam RT|
88852637|NCT00003239|Experimental|Chemotherapy with Cytarabine + Homoharringtonine|Interferon alfa and cytarabine daily by subcutaneous injection. Homoharringtonine is administered by continuous infusion on days 1-5.
88852638|NCT00004127|Experimental|Arm A|Oxaliplatin (85 mg/m2, day 1 of every 14 day cycle), Leucovorin (500 mg/m2, day 1 and 2 of every 14 day cycle), Fluorouracil (Bolus of 400 mg/m2 followed by 22 hr continuous infusion of 600 mg/m2 on days 1 and 2 of every 14 day cycle)
88852639|NCT00004139|Experimental|Gemcitabine + Irinotecan|
88852640|NCT00004139|Experimental|Gemcitabine + Docetaxel|
89379076|NCT03143530|Placebo Comparator|Pectoralis Block with normal saline|General anesthesia + Pectoralis block with 30ml of normal saline injection
89379077|NCT01065818|Experimental|Fluoro-L-Thymidine|Injection pre-Neoadjuvant Therapy (CRT, CT, or RT) and post-3 weeks Neoadjuvant Therapy (CRT, CT, RT)(3 weeks from the start of Neoadjuvant Therapy) prior to surgery.
88852641|NCT00004145|Experimental|Arm A|Fludarabine (30mg/m2/day x 5 days on days -9 to -5), cyclophosphamide (2gm/m2/day on day -5), antithymocyte globulin (10mg/kg/day x 4 days on days -5 to -2), tacrolimus (.03 mg/kg/day IVPB continuous infusion), mycophenolate mofetil (1mg PO BID, days +1 to +60), allogenic peripheral blood stem cells
89379078|NCT02333968|Experimental|Intervention group|Self-management support
89379079|NCT02333968|No Intervention|Control group|Care as usual
89379080|NCT03483623|Experimental|NATO WELP combination|Subjects will be their own control and have repeated measurements to compare baseline and supine transcutaneous oxygenation levels and interface pressures on NATO litter and WELP mattress combination
89379081|NCT03483623|Experimental|NATO FIS combination|Subjects will be their own control and have repeated measurements to compare baseline and supine transcutaneous oxygenation levels and interface pressures on NATO litter and Fluid Immersion System (FIS) mattress combination
89379082|NCT03483623|Experimental|RAVEN WELP combination|Subjects will be their own control and have repeated measurements to compare baseline and supine transcutaneous oxygenation levels and interface pressures on Raven 90C litter and WELP mattress combination
89379083|NCT03483623|Experimental|RAVEN FIS combination|Subjects will be their own control and have repeated measurements to compare baseline and supine transcutaneous oxygenation levels and interface pressures on Raven 90C litter and Fluid Immersion System (FIS) mattress combination
89379084|NCT02329990|Active Comparator|phosphorus|phosphorus ingestion (375mg) with each main meal ( breakfast, lunch, dinner)
89379085|NCT02329990|Placebo Comparator|placebo|ingestion of placebo tablets with each meal ( breakfast, lunch, dinner)
89379086|NCT03653468|No Intervention|Control group|No-exercise
89379087|NCT03653468|Experimental|Endurance training plus resistant training|Concurrent training
89379088|NCT03143608||Indiana group|50 adult patients males and females with GERD and 2-5 cm hiatal hernias. Each had laparoscopic hiatal hernia repair followed by transoral incisionless fundoplication
89379089|NCT03143608||Wisconsin group|49 adult patients males and females with GERD and 2-5 cm hiatal hernias. Each had laparoscopic hiatal hernia repair followed by transoral incisionless fundoplication
89379090|NCT03652844|Active Comparator|Allograft Adipose Matrix (AAM) 1.0|
89379091|NCT03652844|Active Comparator|Allograft Adipose Matrix (AAM) Diluted|
88852642|NCT04212923|Experimental|Medical Dashboard based self-management intervention|Chronic kidney disease patients in the intervention group will receive the usual care plus the tailored 'Medical Dashboard' based self-management intervention.
88852643|NCT04212923|No Intervention|Usual care services|Chronic kidney disease patients in the comparison group will receive usual care consisting of personalised in- and outpatient treatment based on symptoms experienced and disease severity, as outlined in the Kidney Disease Improving Global Outcomes (KDIGO).
88852644|NCT00004163|Experimental|Trastuzumab|"Trastuzumab is administered intravenously weekly~CAT or MRI scans will be performed every 2 cycles"
89002644|NCT06281288|Experimental|cognitive therapy with irregular exercise|in form of irregular exercise training approximately 60-min once a week for 12 weeks, each session include a combination of moderate intensity (~63% maximum heart rate; HRmax) aerobic (~25 min) and resistance (~25 min) activities, with additional time for warm-up (5 min; 10% HRmax) and cool down (5 min).
89379092|NCT03653312|Active Comparator|NMES|"2 weeks (weekdays) of Neuromuscular Electrical Stimulation of the paretic lower limb during exercise.~Each exercise session will last for 12 minutes and will consist of either walk or sit and raise from a chair."
89379093|NCT03653312|No Intervention|training|Participants will undergo 2 weeks of exercise every weekday. Each exercise session will last for 12 minutes and will consist of either walk or sit and raise from a chair.
89379094|NCT02333734|Experimental|Type 2 diabetic subjects|Type 2 diabetic subjects physical training (interval training 3 times at week) in a period of 8 weeks.
89379095|NCT02333734|Experimental|Healthy subjects|Healthy subjects physical training (interval training 3 times at week) in a period of 8 weeks.
89379096|NCT02318277|Experimental|MEDI4736 + INCB024360|MEDI4736 at selected dose levels every 2 weeks + INCB024360 25 mg BID as starting dose, followed by dose escalations until MTD or PAD is identified
89379097|NCT03653234|Experimental|TV-based Assistive Integrated Service|Participants assigned to the intervention group will have access to TV-AssistDem and participate in clinical visits every 6 months.
89379098|NCT03653234|No Intervention|Control|Participants assigned to the intervention group will NOT have access to TV-AssistDem and will participate in clinical visits every 6 months
89379099|NCT02333656|No Intervention|Control group|Usual care. The participants enrolled in the control period will receive OA treatment as it is currently offered in primary health care services.
89379100|NCT02333656|Experimental|Intervention group|New OA model. Health professionals attend an interactive workshop, implementation of international recommendations for OA care, multidiciplinary collaboration
89379101|NCT03143452|Active Comparator|lidocaine gel|Lidocaine gel group: received 2% lidocaine gel in 1 ml syringe, applied to the eye 5 minutes before phacoemulsification
89379102|NCT03143452|Active Comparator|tetracaine eye drop|Tetracaine eye drop group: received 0.5% tetracaine eye drop 5 minutes before phacoemulsification
89379103|NCT03693742|Experimental|18F-DCFPyL PET/CT scan with MSG drink|Food grade MSG will be dissolved in low sodium tomato juice, and administered orally before 18F-DCFPyL administration.
89379104|NCT03693742|Placebo Comparator|18F-DCFPyL PET/CT scan with placebo drink|Regular tomato juice will be used, and administered orally before 18F-DCFPyL administration.
89379105|NCT01063868|Experimental|001|Tapentadol extended release (ER) 100 150 200 250 mg twice daily for 52 weeks
89379106|NCT01063868|Active Comparator|002|Oxycodone controlled release (CR) 20 30 40 50 mg twice daily for 52 weeks
89379107|NCT04054934||Normal Circardian rhythm|Regular night sleep, with at least 7 hours length of sleep.
89379108|NCT04054934||Reversed circadian rhythm|Night/day circadian clock is opposite, with at least 7 hours length of sleep
89379109|NCT02333266||Candidemia|0
89379110|NCT02692443||SVR Survivors|Through the SVR and SVR II studies vital status has been followed annually for the entire SVR cohort. As of June 2014 352 subjects are alive, 18 of whom have undergone cardiac transplantation, and 18 have undergone biventricular conversion leaving 334 transplant-free survivors with single ventricle physiology. Each patient enrolled to this ancillary study from the parent SVR study will be asked to undergo Magnetic Resonance Imaging (Brain MRI without Contrast) in addition to the already scheduled parent study follow-up procedures.
89379111|NCT02692443||Healthy Controls|In addition to the SVR survivors, investigators plan to enroll 100 age- and gender-matched healthy controls. Healthy controls enrolled for participation in this ancillary study will be asked to undergo Magnetic Resonance Imaging (Brain MRI without Contrast) in addition to completing the Neurodevelopmental Testing Battery that is already part of the parent SVR study and completed by SVR Survivors as part of their SVR follow-up appointments.
89379112|NCT02329912|Experimental|Patients after abdominal surgery|SmartPill application after abdominal surgery
89379113|NCT02329912|Sham Comparator|Patients after extraabdominal surgery|SmartPill after extraabdominal surgery
89379114|NCT01372683|Experimental|Test cereal 1|Oat based breakfast cereal
89379115|NCT01372683|Experimental|Test cereal 2|2nd Oat based breakfast cereal
89379116|NCT01372683|Experimental|Leading oat based RTE cereal|3rd oat based breakfast cereal
89379117|NCT02333500|Experimental|olfactory workshop|Influence of sensory therapy on the rate of oxytocin
89379118|NCT02333500|Active Comparator|other workshop|Influence of other workshop on the rate of oxytocin
89379119|NCT02333500|Other|control group|Rate of oxytocin of the control group
89379120|NCT05193435|Experimental|Pelvic floor exercise group|Pelvic floor exercises for muscle fiber types I and II will performed 3 days a week for 8 weeks
89379121|NCT05193435|Active Comparator|Stabilization exercise group|Lumbar spinal stabilization exercises will performed 3 days a week for 8 weeks
89379122|NCT05060536|Active Comparator|Removal of infrapatellar fat pad|When patients will have their fat pad removed.
89379123|NCT05060536|Placebo Comparator|No removal of infrapatellar fat pad|When patients will not have their fat pad removed.
89379124|NCT04210869|Experimental|Experimental|Mixed nuts
89379125|NCT04210869|No Intervention|Control|No mixed nuts
89379126|NCT04993924|Experimental|Participants|Patients will start GnRH antagonist injections [Cetrotide (cetrolix) or Orgalutran (ganirelix) - depending on their primary prescription] for 3-6 days
89379127|NCT02330068||Controls|Males and females ages 18-55 without Major Depressive Disorder, Bipolar I or Bipolar II who are not on an antidepressant and do not have a first degree relative with a diagnosis of Major Depressive Disorder and not currently taking citalopram.
88852645|NCT00003281|Experimental|topotecan + paclitaxel + radiotherapy|"Patients receive topotecan IV over 30 minutes on days 1-3 and paclitaxel IV over 3 hours on day 3. Courses repeat every 4 weeks.~Patients who achieve partial response or stable disease continue treatment in the absence of complete response or disease progression. Patients who develop disease progression in the CNS only should receive whole brain radiotherapy and then continue treatment. Patients who achieve complete remission receive a maximum of 6 courses of treatment. Patients may then undergo prophylactic cranial irradiation and/or thoracic radiotherapy at the discretion at the attending physician.~Patients are followed every 3 months for 2 years and then at 3 years after study."
88852646|NCT00384137|Experimental|1|
88852647|NCT00004193|Experimental|ISIS 2503|patients who have metastatic and/or locally recurrent colorectal cancer
88852648|NCT00384995|Experimental|Bicarbonate|Bicarbonate solution infusion
88852649|NCT00384995|Active Comparator|Saline|Standard volume expansion
88852650|NCT00003299|Active Comparator|Cisplatin + Etoposide|
88852651|NCT00003299|Experimental|Cisplatin + Etoposide + Paclitaxel|
89379128|NCT02330068||Cases|Male or female participants ages 18-55 with Major Depressive Disorder, Bipolar I or Bipolar II whom antidepressant treatment is deemed necessary will be given citalopram.
89379129|NCT04904458|Experimental|Experimental group|The experimental group receives the Enfacement Illusion toward a happy emotional face through a head mounted display.
89379130|NCT04904458|Sham Comparator|Control Group|The control group receives the exposure to a pleasant virtual environment through a head mounted display
89379131|NCT05193357|Experimental|home-based IPC device|Participants used a device produced by Maxstar Corp. (Gimpo, South Korea), which specializes in pneumatic compression appliance manufacture. The IPC device (UAM-9306NB) was cleared by National Institute of Medical Device Safety Information (NIDS) of Korea (approval number: 18-4745). This device consists of a six-chamber pneumatic sleeve and a gradient-sequential pneumatic pump.
89379132|NCT02494869|Experimental|Nonlinear Aerobic Training (75 minutes/week) closed to accrual|The ultimate goal is for participants to complete 75 minutes/week of structured aerobic training per week at 55% to 100% of the individually determined exercise capacity (VO2peak) determined from the (CPETs performed at baseline, midpoint, and Study Follow-Up. The 75 min/wk will be achieved via 3 individual supervised aerobic training sessions at approximately 25 minutes/session.All other on- site participants in Arms A and B will be provided with a heart rate monitor to thank them for completing the study. This arm is closed to accrual.
89379133|NCT02494869|Experimental|Nonlinear Aerobic Training (150 minutes/week)|The ultimate goal is for participants to complete 150 minutes/week of structured aerobic training per week at 55% to 100% of the individually determined exercise capacity (VO2peak) determined from the CTPETs test performed at baseline, midpoint, and Study Follow-Up. The 150 minutes/week will be achieved by completing 3 aerobic training sessions/week for approximately 50 minutes/session. All other on- site participants in Arms A and B will be provided with a heart rate monitor to thank them for completing the study.
88852652|NCT00004205|Experimental|Tamoxifen|Tamoxifen for 5 years after randomization.
89379134|NCT02494869|Experimental|Nonlinear Aerobic Training (300 minutes/week)|The ultimate goal is for participants to complete 300 minutes/week of aerobic training per week at 55% to 100% of the individually determined exercise capacity (VO2peak) determined from CPETs performed at baseline, midpoint, and Study Follow-Up. The 300 minutes/week will be achieved by completing 5 aerobic training sessions/week for approximately 60 minutes/session. A minimum of 3 sessions/week are required to be supervised while the remaining 2 sessions can be supervised or unsupervised home-based. Participants on all Arms will receive a heart rate monitor prior to beginning unsupervised home-based aerobic training sessions. Vital sign monitoring guidelines for unsupervised sessions, prescribed at lower intensities, will be advised by the exercise physiologist at the time the session plan is provided to the patient. Patients will be instructed to not begin an unsupervised session if their resting heart rate or blood pressure is outside the recommended guidelines.
89379135|NCT02494869|Active Comparator|General Physical Activity|Usual care patients will receive a home-based, general physical activity program. Specifically, all patients assigned to general physical activity will receive an initial, in-person consultation with staff exercise physiologist outlining a structured home-based aerobic walking program with a goal up to 150 minutes per week outside of their normal daily activity. Patients can be provided with a fitness tracker (e.g. FitBit) to evaluate exercise duration and intensity. Patients may also be provided with an exercise log to records type, duration, and average heart rate during sessions. The exercise log is provided as a guidance tool and may be, although is not required to be, returned to study staff. Staff exercise physiologists will contact patients to check progress and answer questions.
89379136|NCT02385045|Placebo Comparator|Narrow band imaging|Narrow band imaging function (Olympus endoscopes)
89379137|NCT02385045|Experimental|i-scan imaging|i-scan imaging (Pentax endoscopes)
89379138|NCT02330146|Experimental|RCT-01|Cultured, autologous hair follicle cells suspended in cryomedium
88852653|NCT00004205|Experimental|Letrozole|Letrozole for 5 years after randomization.
89379139|NCT02330146|Placebo Comparator|Placebo|cryomedium
89379140|NCT02329444|Experimental|Remote Ischemic Preconditioning|Patients treated with Remote Ischemic Preconditioning
89379141|NCT02329444|Active Comparator|Sham ischemic preconditioning|Patients treated with sham ischemic preconditioning
89379142|NCT01990521|Experimental|MS3TMRI / TRUS Guided Biopsy|
89379143|NCT02333344|Experimental|Zoledronic acid 5mg|interventional group which receive yearly Zoledronic acid 5mg/100ml infusion treatment for two years
89379144|NCT02333344|No Intervention|blank|blank group
89379145|NCT01312857|Experimental|Randomization to panitumumab|Patients whose liver metastases have been completely resected will be randomized Arm A will receive Panitumumab in addition to HAI FUDR/Dexamethasone plus systemic CPT-11/5FU/LV
89379146|NCT01312857|Experimental|Randomization to No Panitumumab|Patients whose liver metastases have been completely resected will be randomized and patients randomized to Arm B will receive HAI FUDR/Dex plus systemic CPT-11/5FU/LV alone.
89379147|NCT02974010|Experimental|NRX-101|NRX-101 is a fixed dose combination of d-cycloserine and lurasidone
89379148|NCT02974010|Active Comparator|Lurasidone|Lurasidone will be administered in the same dosages as the lurasidone component of NRX-101
89379149|NCT05193201|Experimental|Cohort 1 : 50*10^9/L ≤ Baseline of PLT < 75*10^9/L|The multiple-dose regimen (15000 U subcutaneous injection once a day for 7 days) of recombinant human thrombopoietin (rhTPO) injection for the treatment of thrombocytopenia in patients with chronic liver disease.
88852654|NCT00004205|Experimental|Tamoxifen, then letrozole|Tamoxifen for 2 years after randomization, then letrozole for the next 3 years.
88852655|NCT00004205|Experimental|Letrozole, then tamoxifen|Letrozole for 2 years after randomization, then tamoxifen for the next 3 years.
88852656|NCT00003311|Experimental|Regimen A|Methotrexate IV over 24 hours on day 1. Cytarabine is administered IV over 2 hours every 12 hours on days 2 and 3. Filgrastim (G-CSF) is administered subcutaneously (SC) daily beginning on day 4 and continuing until blood counts recover. Treatment repeats every 21 days for up to 8 courses.
88852657|NCT00003311|Experimental|Regimen B|Cyclophosphamide IV over 3 hours every 12 hours on days 1-3. Doxorubicin is administered IV over 24 hours on days 4 and 5. Vincristine is administered IV over 30 minutes on days 4 and 11. Dexamethasone is administered orally or IV on days 1-4 and 11-14. G-CSF is administered SC beginning on day 6 and continuing until blood counts recover. Treatment repeats every 21 days for up to 7 courses.
88852658|NCT00003317|Active Comparator|Surgery + paclitaxel + carboplatin|Four to eight weeks after surgery, all patients receive paclitaxel IV over 3 hours followed by carboplatin IV over 1-2 hours on days 1, 22, 43, and 64. Following completion of four courses of chemotherapy, patients are followed at least every 4 months for 2 years, then every 6 months thereafter.
88852659|NCT00003317|Experimental|Surgery + paclitaxel + carboplatin + radiotherapy|Four to eight weeks after surgery, all patients receive paclitaxel IV over 3 hours followed by carboplatin IV over 1-2 hours on days 1, 22, 43, and 64. Following completion of four courses of chemotherapy, patients receive radiotherapy 5 days a week for 5 weeks to the mediastinum, beginning 2.5 to 4 weeks after completion of chemotherapy. Patients are followed at least every 4 months for 2 years, then every 6 months thereafter.
88852660|NCT00003323|Experimental|Hormone Therapy|Treatment of prostate cancer pts post radiation or surgery with potency sparing hormones
89002645|NCT06281288|Experimental|cognitive therapy only|Cognitive behavioral therapy) CBT (techniques is co facilitated by a psychiatrist where participants attend 12 sessions during the 12 weeks of treatment. The intervention is 60-min weekly in group sessions
89002646|NCT06280573|Experimental|intervention group|
89002647|NCT06280573|No Intervention|control group|
89002648|NCT06278987|Experimental|PENG block and cryoablation|Patients undergoing hip fracture repair aged 18-85
89379150|NCT05193201|Experimental|Cohort 2 : 30*10^9/L ≤ Baseline of PLT < 50*10^9/L.|The multiple-dose regimen (15000 U subcutaneous injection once a day for 7 days) of recombinant human thrombopoietin (rhTPO) injection for the treatment of thrombocytopenia in patients with chronic liver disease.
89379151|NCT02030938|Experimental|SERI® scaffold implanted breasts|"SERI® Surgical Scaffold is a knitted, multifilament, bioengineered, silk mesh. It is mechanically strong, biocompatible, BIOSILK® purified, and long term bioresorbable. SERI® Surgical Scaffold is a sterile, single use only mesh and is supplied as a 10 x 25 cm sheet. SERI® Surgical Scaffold provides immediate physical and mechanical stabilization of a tissue defect through the strength and porous (scaffold like) construction of its mesh. When long term bioresorption occurs and the patient's own tissue replaces the implanted scaffold over time the mechanical integrity of the repair is maintained.~SERI® Surgical Scaffold is indicated for use as a transitory scaffold for soft tissue support and repair to reinforce deficiencies where weakness or voids exist that require the addition of material to obtain the desired surgical outcome."
89379152|NCT03122535|Active Comparator|FS-LASIK 70 degree side-cut angle|Each patient will be masked as to which angle of cut is used in which eye. Each patient will receive a 70 degree cut in one eye and a 110 degree cut in the fellow eye.
89379153|NCT03122535|Active Comparator|FS-LASIK 110 degree side-cut angle|Each patient will be masked as to which angle of cut is used in which eye. Each patient will receive a 70 degree cut in one eye and a 110 degree cut in the fellow eye.
89379154|NCT04835818|Experimental|Reporting|check point-of-care Multiplex PCR for pneumonia pathogens and report results to primary care physician
89379155|NCT04835818|No Intervention|Usual Care|check point-of-care Multiplex PCR for pneumonia pathogens but do NOT report results to primary care physician. Let primary care physician provide usual standard care
89379156|NCT01061606|Experimental|Treatment (temsirolimus)|Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89379157|NCT02329678|Active Comparator|collagen membrane group and control group|GTR group: a bioresorbable collagen membrane (Healiguide, Advanced Biotech Products (P) Ltd., Encoll Corp., Fremont, CA, USA) was placed over the apicomarginal defect, covering 2-3mm of the healthy bone around all the margins after periodical surgery.
89379158|NCT02329678|Active Comparator|Control group|Control Group:No membrane was placed after periapical surgery.
89379159|NCT04118361|Experimental|Patients with AVS isolated at emergencies|Enrollment of patients with AVS isolated at emergencies
89379160|NCT02333578|Experimental|Convalescent Plasma Treatment|This pilot trial will treat subjects in the ECP Group with ECP derived from two donors. ECP will be provided as ECPSDU each comprising 90 - 110mL of plasma from two individual ABO-compatible donors. Two ECPSDU will be administered as immediately sequential infusions. Subjects may receive up to three doses of ECP not less than 48 hours apart. ECP will be provided as Plasma Frozen Within 24 Hours After Phlebotomy (PF24).
89379161|NCT02329522||Stable COPD patients|Patients will be assessed using USCOM and spirometry. For those with FEV1 to FVC ratio smaller than 70%, they will be classified as COPD.
89379162|NCT02329522||AECOPD patients|Patients will be assessed using USCOM and spirometry. Spirometry will be assessed after 2 to 4 weeks post-hospital discharge.
89379163|NCT02329522||Patient Controls|Patients will be assessed using USCOM and spirometry. For those with COPD symptoms but FEV1 to FVC ratio greater than 70%, they will be classified as non-COPD.
89379164|NCT02329522||Healthy Controls|Healthy subjects, with no history of COPD or other significant chronic illness will be recruited as healthy controls. Subjects will be matched for age and gender with the patient groups. They will be assessed using USCOM.
89379165|NCT02333422|Experimental|NIRS Neurofeedback|NIRS Neurofeedback training of frontal and pre frontal lobes activation. The intervention consist of 24 NIRS neurofeedback sessions over 12 weeks, 2 sessions per week.
89379166|NCT04729192||Intervention|The patients will complete the ObsQoR-10T questionnaire on day 1 following delivery
89379167|NCT02329756|Active Comparator|Treatment|Tranexamic acid (TXA) will be compared with matching placebo (sodium chloride 0.9%).
89379168|NCT02329756|Placebo Comparator|Control|Matching placebo (sodium chloride 0.9%) will be compared with treatment group
89379169|NCT04567342|Experimental|Arm 1|
89379170|NCT04567342|Experimental|Arm 2|
89379171|NCT04567342|Experimental|Arm 3|
89379172|NCT04567342|Experimental|Arm 4|
88817663|NCT01729247||FeNO|Participants with asthma will have a fractional exhaled nitric oxide (FeNO) measurement taken by NIOX MINO® Instrument (09-1100) according to the 'Perform FeNO Measurement' guidelines on page 7 of the NIOX MINO® User Manual (February 2011) during their study visit.
88817664|NCT03009188||Pedigree of the family with ARS|Nine members of the same family with ARS
88817665|NCT04510389|Placebo Comparator|Placebo|volunteers will receive 28 sachets containing 30g of maltodextrin to be consumed daily for 4 weeks. After that they will return to the 4-week visit and assessment when they will receive 28 sachets for the next 28 days when will return for the final vist and assessment.
89002649|NCT06278987|Experimental|fascia iliaca compartment block|Patients undergoing hip fracture repair aged 18-85
89379173|NCT03985072|Experimental|Andes-1537|There will be 5 different cohorts each representing a different type of solid cancer (gallbladder and biliary tract cancer, cervical cancer, gastric cancer, pancreatic cancer, and colorectal cancer). All patients will receive a dose of 400 mg of Andes-1537 five days per week for continuous cycles of 4 weeks that will be repeated until the patients presents drug toxicity requiring treatment discontinuation or disease progression without any noted clinical benefit as assessed by the investigator.
89379174|NCT02329288|Active Comparator|Triamcinolone Acetonide|40mg/1ml
89379175|NCT02329288|Placebo Comparator|placebo|1ml
89379176|NCT01861353|Experimental|Cranberry-lingonberry juice|"Cranberry-lingonberry juice. Cranberry 12.8%, Lingonberry 12.4%, together 38g/l, contains added sugars 10g/dL.~Dose is 5 mL/kg/day, max. 300 ml/day per day. Juice was manufactured and donated by Eckes-Granini, Finland"
89379177|NCT01861353|Placebo Comparator|Placebo juice|"Contains no cranberry or lingonberry extracts. Added sugars 10g/dL (same as in the active juice group). Contains natural cranberry flavour and red anthocyanin colour. Contains 5.5 g/L citric acid. Has been tested by chemists and does not contains PAC-compounds which are thought to be the main active compound in cranberry juice.~Placebo juice was manufactured by Eckes-Granini. Dose is 5 mL/kg/day, max. 300 mL/day."
89379178|NCT02329054|Experimental|Favipiravir|Favipiravir (oral administration, 200 mg light yellow, round-shaped, coated divisible tablets that can be crushed and mixed with liquid)
89379179|NCT03122457|Experimental|lidamycin phosphate and benzoyl peroxide 1.2%/3.75% combo|lidamycin phosphate and benzoyl peroxide 1.2%/3.75% combination gel; daily use for 99 days
89379180|NCT02328976|Experimental|chronic migraineurs|functional Magnetic Resonance Imaging (fMRI) analysis to compare connectivity of hypothalamus
89379181|NCT02328976|Experimental|Episodic migraineurs|functional Magnetic Resonance Imaging (fMRI) analysis to compare connectivity of hypothalamus
89379182|NCT02333032|Experimental|hemiplegic patient|
89379183|NCT04407988|Experimental|Pyrotinib plus Letrozole|
89379184|NCT05192967|Experimental|Experimental 1|"The training program determined to the experimental group was applied with video. Training program content:~Knowledge, attitude, skills about COVID-19~Approach to the COVID-19 positive case~Communication skills~Psychological resilience"
89379185|NCT05192967|Experimental|Experimental 2|"The training program determined to the experimental group was applied with video.~Training program content:~Knowledge, attitude, skills about COVID-19~Approach to the COVID-19 positive case~Communication skills~Psychological resilience"
89379186|NCT05192967|Other|Control 1|"The training program determined to the control group was applied with classical method.~Training program content:~Knowledge, attitude, skills about COVID-19~Approach to the COVID-19 positive case~Communication skills~Psychological resilience"
89379187|NCT05192967|Other|Control 2|"The training program determined to the control group was applied with classical method.~Training program content:~Knowledge, attitude, skills about COVID-19~Approach to the COVID-19 positive case~Communication skills~Psychological resilience"
89379188|NCT03634371|Experimental|Test Formulation of Levothyroxine|Levothyroxine sodium tablets 150 mcg Single dose of 600 mcg administered in dosing period 1 or 2
89379189|NCT03634371|Active Comparator|Reference formulation of Levothyroxine|Eutirox 150 mcg Single dose of 600 mcg administered in dosing period 1 or 2
89379190|NCT04342078||Preterm Child group|Preterm children at the age of 5 years; Born before 34 gestation weeks in 2014-2017; Cared in Oulu University Hospital
89379191|NCT04342078||Preterm Adult group|Preterm born adults at the age of 24-25 years; Born before 34 gestation weeks in 1994-1997; Cared in Oulu University Hospital
89379192|NCT04342078||Adult Control group|Age and gender matched term born controls for comparison of the entry assessments in the Preterm Adult group
89379193|NCT05192811|Experimental|probiotic K56|Probiotic capsule (lactobacillus paracasei K56 10^9CFU) 1capsule/day , for 60days
89379194|NCT05192811|Placebo Comparator|placebo|placebo capsule(maltodextrin, 1capsule/day, 60days
89379195|NCT03143296|Experimental|Current recipient of a Med-El cochlear implant|Participants who have received a MED-EL cochlear implant as a standard of care for treatment of hearing loss. Participants are tested at one time point with a simulated reverberant environment.
89379196|NCT03143296|Active Comparator|Future Med-El Recipient|Cochlear implant candidates not yet implanted and chose Med-El device as standard of care for treatment of hearing loss. Participants are tested at 3 time points over 6 months in a simulated reverberant environment.
89379197|NCT01374165||Low dose SANGUINATE™|"160 mg/kg of SANGUINATE™.~SANGUINATE™ (PEG-bHb-CO) an OTA is composed of three moieties, polyethylene glycol, bHb and carbon monoxide that act in a specific manner to promote the delivery of oxygen to tissue. SANGUINATE™ was not developed to be used as a blood substitute. It is instead an oxygen transfer agent intended to functionally deliver and release oxygen to hypoxic tissues."
89182732|NCT06237868|Active Comparator|rTMS Active|the participant will receive a type of TMS called repetitive TMS (rTMS) wherein the magnetic pulses delivered will be close together in a rapid sequence over the dlPFC. Participants receive excitatory rTMS with a stimulation frequency of 20 Hz between 100-120% of their resting motor threshold.
89379198|NCT01374165||High dose of SANGUINATE™|"320 mg/kg of SANGUINATE™.~SANGUINATE™ (PEG-bHb-CO) an OTA is composed of three moieties, polyethylene glycol, bHb and carbon monoxide that act in a specific manner to promote the delivery of oxygen to tissue. SANGUINATE™ was not developed to be used as a blood substitute. It is instead an oxygen transfer agent intended to functionally deliver and release oxygen to hypoxic tissues."
89379199|NCT02332954|Other|vortioxetine naive|vortioxetine 10 mg 100 patients with Major Depressive Disorder who have not been treated with another antidepressant for the current MDE
89379200|NCT02332954|Other|Switch|vortioxetine 10 mg 100 patients with Major Depressive Disorder that require a switch from their current antidepressant due to inadequate response
89379201|NCT01372059|Experimental|Rhythm and music therapy|Since 1993 The RGRM Method is a concept launched in both health and medical care. The method is mainly designed to help people with injuries and diseases of the central nervous system.
89379202|NCT01372059|Active Comparator|Therapeutic riding|Therapeutic riding can be useful for individuals with neurological and muscular impairments. The goal of therapeutic riding as professional treatment is to improve neurological functioning and to achieve functional gains and enhance life skills.
89379203|NCT01372059|Other|Receives no intervention|Receives no intervention and acts as a control group in the analyses but will receive rhythm and music therapy after one year, when the long-term follow-up is completed.
89379204|NCT00230607|Experimental|Agalsidase beta|Commercially available Fabrazyme treatment at prescribed dose and regimen as determined by their treating physician
89379205|NCT02328664|Other|Flexible sigmoidoscopy or colonoscopy|Subjects will undergo these investigation to take biopsies from the polypectomy scar.
89379206|NCT03111160|Experimental|lower energy|SMILE procedure using lower energy (100, 105, and 110 nJ)
89379207|NCT03111160|Active Comparator|conventional energy (115 to 150 nJ)|SMILE procedure using conventional energy (115 to 150 nJ)
89379208|NCT03953859||Gamete donors|healthy male and female game donors to undergo routine gamete donation process
89379209|NCT03953859||Infertile Couple|Couples undergoing routine IVF to treat their infertility
89379210|NCT05365191|Other|Multispectral near infrared imaging|The participants will be assigned to one single arm that accepted both near infrared zone I and near infrared zone II imaging during the near infrared fluorescence navigated sentinel lymph node biopsy procedure. Imaging quality will be compared between different spectrums.
89379211|NCT02328820|Other|All patients|All lesions undergo simultaneous assessment with a combined pressure and flow sensor
89379212|NCT01372761|Placebo Comparator|Normal Saline|
89379213|NCT01372761|Experimental|ZGN-433|
89379214|NCT03866512|Experimental|Acipimox ingestion during immobilization|Oral ingestion of Acipimox during 2 days of forearm immobilization
89379215|NCT03866512|Experimental|B-agonist during immobilization|Oral ingestion of salbutamol during 2 days of forearm immobilization
88852661|NCT00004229|Experimental|Arm I|Patients undergo a biopsy during prestudy and after the second course of treatment. Patients receive endostatin IV daily for 4 weeks. Patients on dose level 1-6 receive endostatin over 20 minutes. Patients on dose level 7 receive endostatin over 40 minutes, with no treatment on day 2 of the first course only. Treatment continues every 4 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of endostatin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose limiting toxicity.
88852662|NCT00004235|Experimental|irinotecan + docetaxel|"Patients receive irinotecan IV over 90 minutes followed by docetaxel IV over 1 hour on day 1. Treatment repeats every 21 days in the absence of unacceptable toxicity or disease progression.~Patients achieving a complete response (CR) receive 2 additional courses after CR. Patients experiencing disease progression after a CR and 2 additional courses may be retreated with irinotecan and docetaxel. Dysphagia, anorexia, and swallowing ability are assessed before the first course of treatment and then at each tumor assessment.~Patients are followed every 3 months for 1 year and then every 6 months for 4 years."
89379216|NCT03866512|Placebo Comparator|Placebo ingestion during immobilization|Oral ingestion of a placebo 2 days of forearm immobilization
89379217|NCT03634527|Experimental|Auricular Point Acupressure|Auricular points related to Chemotherapy-induced peripheral neuropathy (CINP) will be used for the intervention.
89379218|NCT03634527|Sham Comparator|Control Auricular Point Acupressure|Auricular points not related to CINP will be used for the intervention.
89379219|NCT03778606|Experimental|Potato starch supplementation|Twelve patients found to be colonized with C. difficile will undergo twice a day potato starch supplementation.
89379220|NCT03873675||Study group|Multi-organ failure with acute kidney injury critically ill patients admitted to the intensive care unit undergoing regional citrate anticoagulation continuous renal replacement therapy by means of continuous veno-venous hemodiafiltration (CVVHDF). Multi-organ failure is defined as a respiratory, circulatory and renal failure.
89379221|NCT03111706||dehiscencd scar|women who are discovered with scar dehiscence during cesarean section
89379222|NCT03111706||Intact scar|women with intact scar detected during cesarean section
89379223|NCT03863769||Lumbar Spinal Stenosis|Questionnaire, chiropractic treatment, and posture and performance testing.
89379224|NCT03111472|Experimental|Self-management guide for falls in Parkinson's|A guide for people with Parkinson's and their caregivers to self-manage falls.
89379225|NCT02328898|Experimental|Cre8 stent|PCI with the Polymer Free Amphilimus Eluting Stent 'Cre8™'
89379226|NCT02328898|Active Comparator|Resolute Integrity Stent|Comparison of the Cre8 stent with the Permanent Polymer Zotarolimus Eluting Stent 'Resolute Integrity™'
89379227|NCT02332408|Experimental|Cybernetic microradiosurgery|Hypofractionated microradiosurgery using Cyber Knife to the vertebral hemangioma to the total dose of 25 Gy in 5.0 Gy per fraction, 2 or 3 days a week over the period of 2 weeks,
89379228|NCT02332408|Active Comparator|Conventional radiotherapy|Conventionally fractionated external beam conformal radiotherapy to the vertebral hemangioma to the total dose of 36 Gy in 2.0 Gy per fraction, 5 days a week over the period of 3,5 weeks,
89379229|NCT03775785|Experimental|tailored enteral nutrition|Tailored Human milk fortification procedure Tailored milk fortification will be done twice a day (8 am and 8 pm) for each following 12 hour nursing shift. Standard fortification will be added first. The remainder amount of protein, lipids and carbohydrates required to meet the recommended by ESPGHAN doses will be acheived by adding single ingrediant nutrients.
89379230|NCT03775785|No Intervention|standard enteral nutrition|Standard fortification will be added according to the unit protocol.
89379231|NCT02328742||No intracavitary pathology|"During the first diagnostic hysteroscopy, patients in this group are found to not have an intracavitary pathology. (The first 20 such patients will be retained in this group.)~Intervention: Hysteroscopy + endometrial biopsy~Intervention: Telephone call"
89379232|NCT02328742||Synechia|"During the first diagnostic hysteroscopy, patients in this group are found to have synechia.~Intervention: Hysteroscopy + endometrial biopsy~Intervention: Resection + endometrial biopsy~Intervention: Follow-up hysteroscopy + endometrial biopsy~Intervention: Telephone call"
89379233|NCT02328742||Intracavitary pathology|"During the first diagnostic hysteroscopy, patients in this group are found to have an intracavitary pathology.~Intervention: Hysteroscopy + endometrial biopsy~Intervention: Resection + endometrial biopsy~Intervention: Follow-up hysteroscopy + endometrial biopsy~Intervention: Telephone call"
88852663|NCT00004241|Experimental|Schedule B (tanespimycin)|Patients receive 17-AAG IV over 1-2 hours twice weekly for 3 weeks. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
89379234|NCT05296239|Experimental|SimpleC Wellness Platform with Social Robot Interaction|
89379235|NCT03111082||Lean|BMI less than or equal to 29.9
89379236|NCT03111082||Obese|BMI between 30.0 and 39.9
89379237|NCT03111082||Morbidly Obese|BMI greater than or equal to 40.0
89379238|NCT05256459||Observation group|Those who did not deal with nodules and were closely followed up.
89379239|NCT05256459||Treatment group|Patients with liver nodules were treated by radiofrequency ablation or/and surgery and so on.
89379240|NCT02328586|Experimental|Group Acupuncture|Participants will then be invited to participate in an 8-week, group-based acupuncture treatment intervention delivered by a licensed acupuncturist. The group will meet weekly for 8 consecutive weeks, each session lasting about 75 minutes.
89379241|NCT02332486|Active Comparator|Intervene|For Qingxuan Decoction there are a bag of Chinese honeylocust spine，Glehnia littoralis and Smilax china L,and two bags of Silktree albizia bark, Kadsura interior,Cortex dictamni, Lilium brownii var, Silkworm larva,Forsythia suspensa and Rhizoma polygonati preparata, and three bags of viridulumArisaema erubescens and Poria cocos Wolf. All drugs are made by Jiangyin Tianjiang company in China. Qingxuan Decoction is given two times after breakfast and dinner in 56 days.
89379242|NCT02332486|No Intervention|Blank|There is no intervention for people in the blank group.
89379243|NCT05173857|Active Comparator|Drug Eluting Balloon (DEB)|"Percutaneous Angioplasty in dysfunctional arteriovenous access, using Drug Eluting Balloon Technology.~Drug: Paclitaxel (PTX). Name of Device: Advance PTX"
88852664|NCT00004241|Experimental|Schedule C (tanespimycin)|Patients receive 17-AAG IV over 1-2 hours twice weekly for 2 weeks. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
88852665|NCT00004853|Experimental|1|single dose of intervention after each cycle of Standard 5 drug dose-intensive chemotherapy
88852666|NCT00004853|Experimental|2|single dose of interventionafter each cycle of Standard 5 drug dose-intensive chemotherapy
88852667|NCT00004883|Experimental|Treatment (trastuzumab)|Patients receive trastuzumab (Herceptin) IV over 30-90 minutes on day 1. Treatment continues once a week in the absence of disease progression or unacceptable toxicity.
88852668|NCT00004889|Experimental|Rituxan|375 mg/m2 given as an intravenous (IV) infusion once weekly for four doses (days 1, 8, 15, and 22). For purposes of this study 4 weekly courses will constitute one cycle of therapy.
88852669|NCT00004919|Experimental|Treatment (cisplatin, irinotecan, amifostine)|"Treatment A: Patients receive cisplatin IV over 1 hour followed immediately by irinotecan IV over 90 minutes on days 1, 8, 15, and 22. Courses repeat every 6 weeks. Treatment continues for a minimum of 2 courses in the absence of unacceptable toxicity or disease progression.~Treatment B: Patients receive therapy as in treatment A. In addition, amifostine IV is administered over 15 minutes immediately before cisplatin."
89182733|NCT06237868|Sham Comparator|rTMS Sham|Sham rTMS will be the same as real rTMS, except a special sham coil will be used, which produces the same sensation on the scalp of the patients as the real coil but delivers no magnetic stimulation to the brain.
89379244|NCT05173857|Placebo Comparator|Plain Old Balloon Angioplasty (POBA)|"Percutaneous Angioplasty in dysfunctional arteriovenous access, using Plain Old Balloon Angioplasty.~Drug: None. Name of Device: Advance LP (Low Profile)"
89379245|NCT03111238|Experimental|REX-001|REX-001 is a cell suspension of autologous BM-MNCs composed of several mature cell types.
89379246|NCT03111238|Placebo Comparator|Placebo|The final formulation of the placebo will be a diluted suspension of red blood cells.
89379247|NCT01372137|Experimental|NOX-H94|Group A: single 15 minutes IV infusion of 0.3 mg/kg NOX-H94 Group B: single 15 minutes IV infusion of 0.6 mg/kg NOX-H94 Group C: single 15 minutes IV infusion of 1.2 mg/kg NOX-H94 Group D: single 15 minutes IV infusion of 2.4 mg/kg NOX-H94 Group E: single 15 minutes IV infusion of 4.8 mg/kg NOX-H94 Group F: single / repeated SC injection of NOX-H94 over a treatment period of 2 weeks Group G: multiple doses of NOX-H94 as a 15 minutes IV infusion over a treatment period of 2 weeks Group H: multiple doses of NOX-H94 as a 15 minutes IV infusion over a treatment period of 2 weeks
89379248|NCT01372137|Placebo Comparator|Glucose 5%|Group A to Group H get NOX-H94 or Placebo
89379249|NCT03620097|Experimental|Experimental Arm|30 subjects will receive 800mg of DHA (Dietary Supplement: EuPoly-3 DHA Infant) per day.
89379250|NCT03620097|Placebo Comparator|Control Arm|30 children will take a placebo with similar lipid characteristics
89379251|NCT05078086||Patients undergoing cardiac surgery with CPB|>18 y/o patients who undergo cardiac surgery with cardiopulmonary bypass and with a preoperative additive EuroSCORE I≥ 6
89379252|NCT05078008|Placebo Comparator|Group 1 - Physiotherapy modalities|
89379253|NCT05078008|Experimental|Group 2 - Physiotherapy modalities + Balneotherapy modalities|
89399447|NCT03693885|Experimental|OCT-group|Oxytocin challenge test: Oxytocin 5 IU/500 ml Ringer® lactate will be infused at a rate of 12 ml/h and doubled every 10 min until it induced three uterine contractions per 10-min interval at which point it will stopped.
89399448|NCT03693885|No Intervention|Control|standard procedure before planned caesarean section
89399449|NCT02174120|Experimental|Group A|During maintenance of anesthesia, etomidate was give by target controlled infusion, the effect-site concentration is 0.3 to 0.6 micrograms/ml to keep bispectral index between 40 to 60.
88852670|NCT00004931|Experimental|Arm I|Patients receive leucovorin calcium IV over 2 hours and fluorouracil IV (administered after 1 hour of leucovorin calcium) weekly for 6 weeks.
88852671|NCT00004931|Experimental|Arm II|Patients receive oxaliplatin IV over 2 hours on days 1, 15, and 29 and leucovorin calcium and fluorouracil as in arm I.
88852672|NCT00385229|Experimental|Induction|induction of labor at gestational age 289(41 weeks+2 days)
88852673|NCT00385229|No Intervention|expectant management|expectant management at gestational age 289(41 weeks+2 days)
88852674|NCT00005009|Experimental|Varivax®|0.5 mL of Varivax administered subcutaneously in the right upper arm (deltoid region).
88852675|NCT00005039|Experimental|Arm I|Patients receive recombinant fowlpox-PSA vaccine IM at the MTD from the safety cohort every 4 weeks for 3 courses. Patients then receive recombinant vaccinia-PSA vaccine intradermally every 4 weeks for 2 courses.
88852676|NCT00005039|Experimental|Arm II|Patients receive the same vaccines as in arm I but in reverse order.
88852677|NCT00004769||Myotonic dystrophy|Subjects with myotonic dystrophy
88852678|NCT00004769||Healthy controls|Healthy subjects
88852679|NCT00004769||Disease controls 1|Subjects with FSHD
88852680|NCT00004769||Disease controls 2|Subjects with CMT
88852681|NCT00005087|Experimental|Radiation (BID) and chemotherapy|Radiation (BID), cisplatin and paclitaxel given on days 1-5 (Monday-Friday) in weeks 1, 3, 5 and 7. G-CSF given on days 6-13.
88852682|NCT02972489|Experimental|3D OFDI guidance arm|Bifurcation percutaneous coronary intervention (PCI) optimized by online-3D OFDI during and after procedure
88852683|NCT02972489|Active Comparator|Angio guidance arm|Bifurcation percutaneous coronary intervention (PCI) guided by angiography
89379254|NCT03142516|Experimental|FOLFIRI + panitumumab|"All patients will receive panitumumab plus FOLFIRI for disease control in 14-day cycles until disease progression, unacceptable toxicity, investigator's decision or patient withdrawal of consent, at the following doses:~Panitumumab: 6 mg/kg administered by intravenous (IV) infusion over 60 min on days 1 and 14 of every cycle just before administration of chemotherapy~FOLFIRI~Irinotecan: 150 mg/m2 as IV infusion over 90 min on day 1of first treatment cycle. If tolerance of this first dose is good, it will be scaled to a full dose of 180 mg/m2 starting from the second treatment cycle.~Folinic acid: (leucovorin) 200-400 mg/m2 IV over 2 hours on day 1~5-FU: 400 mg/m2 bolus followed by 2400 mg/m2 IV continuous infusion over 46-48 hours on days 1 and 2"
88852684|NCT00386165|Experimental|Larazotide acetate|Larazotide acetate capsules: 12 mg QD x 3 days
88852685|NCT00386165|Placebo Comparator|Placebo|Placebo capsules: QD x 3 days
88852686|NCT00423371|Experimental|EUFLEXXA™|
88852687|NCT00423371|Placebo Comparator|Placebo|
88852688|NCT00005585|Experimental|Arm I: (combination chemotherapy)|CONSOLIDATION: Pts receive Methotrexate(MTX) IV over 24 hrs on day 1 and oral leucovorin calcium (CF) every 6 hrs for 3 doses at 42 hours after initiation of MTX infusion during weeks 7, 10, 13, 16, and 19. Pts also receive MTX IT on wks 7, 10, 13, 16, 19, and 22; oral mercaptopurine(6-MP) daily wks 5-24; oral dexamethasone (DM) 2x on days 1-7 of wks 8 and 17; and vincristine sulfate (VCR) IV on day 1 of wks 8, 9, 17, and 18. CONTINUATION: Pts receive oral 6-MP daily on wks 25-130; oral DM twice a day on days 1-7 and vincristine sulfate (VCR) IV on days 1 and 8 during wks 25, 41, 57, 73, 89, and 105; oral MTX on wks 25-130 (except during wks of IT MTX); and MTX IT on wks 25, 37, 49, 61, 73, 85, 97, and 109.
88852689|NCT00005585|Experimental|Arm II (combination chemotherapy)|CONSOLIDATION: Pts receive methotrexate (MTX) IV over 4 hrs on day 1 and oral leucovorin calcium (CF) during wks 7, 10, 13, 16, and 19. Pts also receive MTX IT on wks 7, 10, 13, 16, 19, and 22; oral mercaptopurine (6-MP) daily on wks 5-24; oral dexamethasone (DM) 2x on days 1-7 of wks 8 and 17; and vincristine sulfate (VCR) IV on day 1 of wks 8, 9, 17, and 18. CONTINUATION: Pts receive oral 6-MP daily on wks 25-130; oral DM 2x on days 1-7 and vincristine sulfate (VCR) IV on days 1 and 8 during wks 25, 41, 57, 73, 89, and 105; oral MTX weekly on wks 25-130 (except during wks of IT MTX); and MTX IT on wks 25, 37, 49, 61, 73, 85, 97, and 109.
88852690|NCT00005585|Experimental|Arm III (combination chemotherapy)|CONSOLIDATION: Pts receive methotrexate (MTX) IV and leucovorin calcium (CF) as in arm I on wks 7, 10, 13, 24, 27, and 30. Pts also receive oral mercaptopurine (6-MP) daily on wks 5-13 and then on wk 24 and continuing until the end of consolidation; MTX IT on wks 7, 10, 13, 16, 20, 21, and 30; oral dexamethasone (DM) twice daily on days 1-7 of wks 8, 16-18, and 28; vincristine sulfate (VCR) IV on day 1 of wks 8, 9, 16-18, 28, and 29; pegaspargase intramuscularly on wk 16; daunorubicin hydrochloride IV on day 1 of wks 16-18; cyclophosphamide IV on day 1 of wk 20; cytarabine IV or subcutaneously on days 2-5 of wks 20 and 21; and oral thioguanine daily on days 1-14 of wks 20 and 21. CONTINUATION: Pts receive oral 6-MP daily on wks 33-130; oral dexamethasone (DM) twice a day on days 1-7 and VCR IV on days 1 and 8 during wks 41, 57, 73, 89, and 105; oral MTX weekly on wks 33-130 (except during wks of IT MTX); and MTX IT on wks 37, 49, 61, 73, 85, 97, and 109.
89379255|NCT03482453|Experimental|Part 1 Cohort 1: TAK-788|TAK-788, capsule, orally or TAK-788 matching placebo capsule, orally, once under fasted conditions on Day 1.
89379256|NCT03482453|Experimental|Part 1 Cohort 2: TAK-788|TAK-788, capsule, orally or TAK-788 matching placebo capsule, orally, once under fasted conditions on Day 1 following review of safety data from Cohort 1.
88852691|NCT00005585|Experimental|.Arm IV (combination chemotherapy)|CONSOLIDATION: Pts receive methotrexate (MTX) and leucovorin calcium (CF) on wks 7, 10, 13, 24, 27, and 30. Pts receive mercaptopurine(6-MP) daily weeks 5-13 then beginning wk 24 and continuing until end of consolidation; MTX on wks 7, 10, 13, 16, 20, 21, and 30; dexamethasone (DM) 2x daily on days 1-7 of wks 8, 16-18, and 28; vincristine sulfate (VCR) day 1 of wks 8, 9, 16-18, 28, and 29; pegaspargase on wk 16; daunorubicin hydrochloride on day 1 of wks 16-18; cyclophosphamide on day 1 of wk 20; cytarabine on days 2-5 of wks 20 and 21; thioguanine daily on days 1-14 of wks 20 and 21. CONTINUATION: Pts receive mercaptopurine(6-MP) daily on weeks 33-130; oral dexamethasone (DM) twice a day on days 1-7 and VCR IV on days 1 and 8 during weeks 41, 57, 73, 89, and 105; oral MTX weekly on weeks 33-130 (except during weeks of IV MTX); and IV MTX on weeks 37, 49, 61, 73, 85, 97, and 109.
88852692|NCT01926444|Experimental|GIC-1001 low dose|GIC-1001 , 250 mg TID during 3 consecutive days + a last, 10th dose in the morning of Day 4 (colonoscopy day)
88852693|NCT01926444|Experimental|GIC-1001 mid-dose|GIC-1001 , 375 mg TID during 3 consecutive days + a 10th dose in the morning of day 4 (colonoscopy day)
88852694|NCT01926444|Experimental|GIC-1001 , high dose|GIC-1001 , 500 mg TID during 3 consecutive days + a 10th dose in the morning of day 4 (colonoscopy day)
88852695|NCT01926444|Placebo Comparator|GIC-1001 matching placebo|Placebo, TID during 3 consecutive days, + a 10 th dose in the morning of day 4 (colonoscopy day)
88852696|NCT00005597|Experimental|Temozolomide|200 mg/m^2/day, PO, on Days 1-5 of each 28 day cycle.
88852697|NCT00005615|Experimental|Interferon Alfa Plus Radiation|"Combined Therapy: interferon alfa plus radiation therapy.~Patients receive interferon alfa IV over 20 minutes daily for 5 consecutive days a week for 4 weeks. Patients then receive radiotherapy on days 2 and 4 and interferon alfa subcutaneously (SQ) on days 1, 3, and 5 for 2.5 weeks. Interferon alfa SQ continues 3 times a week for 10 months in the absence of disease progression or unacceptable toxicity. Patients are followed every month for 3 months, then every 3 months for 2 years, then every six months until year 5, and then annually thereafter."
88852698|NCT00005219||Exercise Study Participants|Data from the San Diego Health and Exercise Baseline survey conducted in 1986 were used to contact participants for the follow-up
89002650|NCT06277882|Experimental|Intensive 3 dose|Receiving the intensive 3-dose regimen of the Havrix hepatitis A vaccine, administered at months 0, 1, and 6.
89182734|NCT06237556|Placebo Comparator|Control group|Patients in the control group will receive placebo.
89182735|NCT06237556|Experimental|Melatonin group|Three days before the operation patients will receive 5 mg of melatonin (Melatonin, Nature Made, Canada, and USA) one hour before assigned sleep time until the time of discharge from hospital.
89379257|NCT03482453|Experimental|Part 1 Cohort 3: TAK-788|TAK-788, capsule, orally or TAK-788 matching placebo capsule, orally, once under fasted conditions on Day 1 following review of safety data from Cohort 2.
89379258|NCT03482453|Experimental|Part 1 Cohort 4: TAK-788|TAK-788, capsule, orally or TAK-788 matching placebo capsule, orally, once under fasted conditions on Day 1 following review of safety data from Cohort 3.
89379259|NCT03482453|Experimental|Part 1 Cohort 5: TAK-788|TAK-788, capsule, orally or TAK-788 matching placebo capsule, orally, once under fasted conditions on Day 1 following review of safety data from Cohort 4.
89379260|NCT03482453|Experimental|Part 2: TAK-788 Fed + TAK-788 Fasted|TAK-788, capsule, orally, once on Day 1 of Intervention Period 1 under fed conditions with low-fat meal (Treatment A), followed by at least 7 days washout period, further followed by TAK-788, capsule, orally, once on Day 1 of Intervention Period 2 under fasted conditions (Treatment B). TAK-788 dose will be determined based on review of safety and tolerability data from cohorts of Part 1.
89379261|NCT03482453|Experimental|Part 2: TAK-788 Fasted + TAK-788 Fed|TAK-788, capsule, orally, once on Day 1 of Intervention Period 1 under fasted conditions (Treatment B), followed by at least 7 days washout period, further followed by TAK-788, capsule, orally, once on Day 1 of Intervention Period 2 under fed conditions with low-fat meal (Treatment A). TAK-788 dose will be determined based on review of safety and tolerability data from cohorts of Part 1.
89379262|NCT03482453|Experimental|Part 3: TAK-788 DiC (reference) + TAK-788 DiC (test)|TAK-788 160 mg, DiC A (reference), orally, under fasted condition, once on Day 1 of Intervention Period 1, followed by at least 7 days washout period, further followed by TAK-788 160 mg, DiC B (test), orally, under fasted condition, once on Day 1 of Intervention Period 2.
89379263|NCT03482453|Experimental|Part 3: TAK-788 DiC (test) + TAK-788 DiC (reference)|TAK-788 160 mg, DiC B (test), orally, under fasted condition, once, on Day 1 of Intervention Period 1, followed by at least 7 days washout period, further followed by TAK-788 160 mg, DiC A (reference), orally, under fasted condition, once on Day 1 of Intervention Period 2.
89379264|NCT05077930|Experimental|Convalescent Plasma|The investigational product is anti-SARS-CoV-2 convalescent plasma obtained from former patients identified as having recovered from COVID-19 and obtained by Centro de Hematologia e Hemoterapia do Paraná - Hemepar following national blood donation guidelines and Brazilian Health Regulatory Agency (ANVISA) criteria. Potential donors will be screened using an anti-SARS-CoV-2 serologic assay and antibody levels will be determined. Participants will receive the standard of care treatment and a single unit of convalescent plasma (volume=200 mL or 400 mL).
89379265|NCT05077930|Active Comparator|Standard of care|Standard of care treatment according to the institutional protocol.
89379266|NCT05077696||Patients with progressive motor neuron disease without definite diagnosis|Patients with progressive motor neuron disease without definite diagnosis
89379267|NCT05077618||patients with Alzheimer's disease|47 cases (patients with Alzheimer's disease)
89379268|NCT05077618||patients without Alzheimer's disease|47 patients without Alzheimer's disease
88817666|NCT04510389|Experimental|Whey|volunteers will receive 28 sachets containing 30g of whey protein to be consumed daily for 4 weeks. After that they will return to the 4-week visit and assessment when they will receive 28 sachets for the next 28 days when will return for the final vist and assessment.
89379269|NCT03480425|Experimental|Esophageal then tracheal intubated patient|Esophagus is intentionally intubated with a cuffed endotracheal tube, the cuff inflated to >30cm water pressure, a force transducer attached, and force of extubation recorded. Then Trachea is intentionally intubated the cuff inflated to >30cm water pressure, and force of extubation recorded.
89379270|NCT03719729|Experimental|Single|Each subject will receive rifaximin 550 mg twice a day for up to one year.
89379271|NCT05077462|Experimental|Sequence A|Period 1: C52R1M(Valsartan/Amlodipine) and C52R2(Chlorthalidone), single dose Period 2: AJU-C52H(FDC tablet, Valsartan/Amlodipine/Chlorthalidone), single dose
89379272|NCT05077462|Experimental|Sequence B|Period 1: AJU-C52H(FDC tablet, Valsartan/Amlodipine/Chlorthalidone), single dose Period 2: C52R1M(Valsartan/Amlodipine) and C52R2(Chlorthalidone), single dose
89379273|NCT03719651|Experimental|Intervention|"When clinics join the intervention arm, leaders will receive leadership training through the Leadership and Organizational Change for Implementation (LOCI) intervention.~Therapists will receive training in evidence-based practices for treatment of Post-Traumatic Stress Symptoms (EMDR, CT-PTSD, TF-CBT)"
89379274|NCT03719651|Active Comparator|Control|"Clinics that are not yet included in the intervention arm, the leaders will not receive any leadership training (LOCI).~Therapists will receive training in evidence-based practices for treatment of Post-Traumatic Stress Symptoms (EMDR, CT-PTSD, TF-CBT)"
89379275|NCT02328508|Experimental|hyperbaric oxygen therapy|The experimental group received treatments in a hyperbaric chamber for 120-min per session, once per day, and five days per week for four consecutive weeks (20 treatment sessions).
89379276|NCT02328508|No Intervention|Control|The control group received only routine care.
89379277|NCT03714113|Experimental|Kidney transplant recipients.|Patients who undergo kidney transplant in 2018 or 2019.
89379278|NCT03111004||Study Group|The Study Group receives 'new care' (integrated health and social care)
88817667|NCT04351568||medical personel|
88817668|NCT04351568||non medical personel|
88817669|NCT01750931|Other|Meloxicam GSK 15mg|A randomized, balanced, open label, crossover, two period, two treatment, two sequence, single dose, oral bioequivalence study under fed condition
88817670|NCT01750931|Other|Mobic 15mg|A randomized, balanced, open label, crossover, two period, two treatment, two sequence, single dose, oral bioequivalence study under fed condition
88817671|NCT01352468|Experimental|Multifaceted Cognitive Training|Cognitive Training with 4 different tasks each of which gets progressively more difficult as children obtain proficiency.
88817672|NCT01352468|Sham Comparator|Sham Cognitive Training|Cognitive Training with 4 different tasks which does not get progressively more difficult throughout training
88817673|NCT01731041|Experimental|Ticagrelor 180mg|Patients randomized to this arm will be administered 180 mg of ticagrelor (experimental arm, loading dose).
88817674|NCT01731041|Active Comparator|Ticagrelor 90mg|Patients randomized to this arm will be administered 90 mg dose of ticagrelor (active comparator, standard dose).
89379279|NCT03111004||Comparator Group|The comparator group receives usual care
89379280|NCT02039986||all subjects|all subjects enrolled in same cohort
89379281|NCT03472547|Experimental|Single cohort (Healthy Volunteers)|diacerein 1% ointment
89379282|NCT00799396|Experimental|Overall Study|Participants will receive clopidogrel treatment alone, followed by clopidogrel plus aspirin treatment on the last day of treatment.
89379283|NCT05077306|Experimental|music therapy group|Patients receive an individual single session of receptive music therapy in presence.
89379284|NCT05077306|No Intervention|Control group|Patients receive standard care
89379285|NCT03143062||Cases|150 patients that suffered an in-hospital cardiac arrest in a hospital ward.
89379286|NCT03143062||Controls|300 patients that did not suffer an in-hospital cardiac arrest but was treated in a hospital ward.
89379287|NCT03469349|Experimental|Actovegin 1200 mg|Actovegin 1200 milligram (mg), intravenously, once daily for up to 2 weeks followed by actovegin 200 mg, tablets, orally, thrice daily (TID) (1200 mg/day) for up to 10 weeks.
89379288|NCT03469349|Placebo Comparator|Placebo|Actovegin placebo-matching, intravenously, once daily for up to 2 weeks and actovegin placebo-matching tablets, orally, TID for up to 10 weeks.
89379289|NCT03639233|Other|Arm 1|Intervention access
89379290|NCT03467945|Experimental|Treatment Sequence 1|Participants received single oral dose of metformin 1000 milligram (mg) and gliclazide 30 mg fixed combination tablet in treatment period 1 followed by concomitant oral dosing of metformin 1000 mg and gliclazide 30 mg in treatment period 2 followed by single oral dose of metformin 1000 mg in treatment period 3 and then a single oral dose of gliclazide 30 mg in treatment period 4. Each treatment period was separated by a 14-day wash-out period.
89379291|NCT03467945|Experimental|Treatment Sequence 2|Participants received concomitant oral dosing of metformin 1000 mg and gliclazide 30 mg in treatment period 1 followed by single oral dose of gliclazide 30 mg in treatment period 2 followed by single oral dose of metformin 1000 mg and gliclazide 30 mg fixed combination tablet in treatment period 3 and then single oral dose of metformin 1000 mg in treatment period 4. Each treatment period was separated by a 14-day wash-out period.
89379292|NCT03467945|Experimental|Treatment Sequence 3|Participants received single oral dose of metformin 1000 mg in treatment period 1 followed by single oral dose of metformin 1000 mg and gliclazide 30 mg fixed combination tablet in treatment period 2 followed by single oral dose of gliclazide 30 mg in treatment period 3 and then concomitant oral dosing of metformin 1000 mg and gliclazide 30 mg in treatment period 4. Each treatment period was separated by a 14-day wash-out period.
89379293|NCT03467945|Experimental|Treatment Sequence 4|Participants received single oral dose of gliclazide 30 mg in treatment period 1 followed by single oral dose of metformin 1000 mg in treatment period 2 followed by concomitant oral dosing of metformin 1000 mg and gliclazide 30 mg in treatment period 3 and then single oral dose of metformin 1000 mg and gliclazide 30 mg fixed combination tablet in treatment period 4. Each treatment period was separated by a 14-day wash-out period.
89379294|NCT03719261|Active Comparator|sodium hypochlorite|Sodium hypochlorite (NaOCL) is the most recommended irrigant due to its broad antibacterial effect, necrotic tissues and dentin collagen dissolving capability and inactivation of endotoxins.10ml of 2.5%NaOCL will be used during instrumentation in control group
89379295|NCT03719261|Experimental|chitosan nanoparticles|Chitosan is a bioactive polymer obtained from deacetylation of chitin and is used in biomedical application due to its antimicrobial properties and biocompatibility and ability to resist aging for longer periods provide antibacterial effect in root canal disinfection.10ml of cs-np will be used during instrumentation in intervention group
89379296|NCT00069238|Experimental|Alemtuzumab Dose Escalation|Alemtuzumab (Campath) followed by etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH) every 3 weeks for up to 6 cycles. Three cohorts of 3 to 6 patients will be treated. Cohort 1 will receive 30mg of Alemtuzumab, cohort 2 will receive 60mg of Alemtuzumab, and cohort 3 will receive 90mg of Alemtuzumab. If 1 of 3 participants entered at a given dose level experiences dose limiting toxicity (DLT), up to 3 additional participants will be entered at that dose level. If 2 of 6 participants experience DLT at a particular dose level, the maximum tolerated dose (MTD) has been exceeded. The preceding dose level will be the MTD, provided 6 participants have been entered at this level and no more than 1 has experienced DLT.
89379297|NCT03435497|Experimental|Game Changers Intervention|Game Changers is an intervention that aims to empower and mobilize people living with HIV to be agents for HIV prevention and behavioral change in their social networks.
89379298|NCT03435497|No Intervention|Control|The control group will receive standard of care during the intervention assessment period. All control participants will be offered the Game Changers program once all assessments for the primary study outcomes have been completed.
89379299|NCT03143140|Experimental|PAFA and tumor ablation|first percutaneous frequency ablation of tumor feeding artery and then ablation of tumor
89379300|NCT03143140|Other|tumor ablation|ablation of tumor directly
88817675|NCT04831671|Active Comparator|Infra-patella nailing|Participants will have their closed tibial shaft fracture treated with an intra-medullary nail inserted through an infra-patella approach.
88817676|NCT04831671|Experimental|Supra-patella nailing|Participants will have their closed tibial shaft fracture treated with an intra-medullary nail inserted through an supra-patella approach.
88817677|NCT01352546|Experimental|BOTOX|intravaginal Botox injections and progressive dilation under anesthesia to cure vaginismus.
89379301|NCT03639155|Experimental|Regimen A|vadadustat reference tablets
89379302|NCT03639155|Experimental|Regimen B|vadadustat test tablets
89379303|NCT05080348|Active Comparator|Ropivacaine iPACK|Patient will receive standard of care for perioperative pain management. In addition, they will receive a single preoperative injection of 20cc of 0.25% Ropivacaine with 1:400,000 epinephrine in the Interspace between the Popliteal Artery and Capsule of the Knee (iPACK).
89379304|NCT05080348|Sham Comparator|Normal Saline iPACK|Patient will receive standard of care for perioperative pain management. In addition, they will receive a single preoperative injection of 20cc of 0.9% Normal Saline in the Interspace between the Popliteal Artery and Capsule of the Knee (iPACK).
89379305|NCT03073200|Experimental|Ixekizumab|Ixekizumab given subcutaneously (SC) during the double-blind treatment period and the open-label maintenance period.
89379306|NCT03073200|Placebo Comparator|Placebo|Placebo given SC during the double-blind treatment period and then ixekizumab given SC during the open-label maintenance period.
89379307|NCT03073200|Experimental|Open-Label Etanercept|Etanercept given SC during the double-blind treatment period and then ixekizumab given SC during the open-label maintenance period. Participants will only be randomized to etanercept in countries where it is approved for severe pediatric psoriasis treatment.
89379308|NCT03142126|Experimental|Early Ambulation|To affirm the safety and efficacy of ambulation of 20 minutes after diagnostic left heart catheterization.
88817322|NCT01714505|No Intervention|CGM-Augmented Insulin Pump Treatment|Open Loop Control: Insulin delivery will be controlled by the Diabetes Assistant (DiAs) system running in open-loop mode. The subject will interact with the system through its Graphic User Interface (GUI). Subjects will be permitted to administer correction boluses at any time during the Control Admission, whether or not they are eating a scheduled meal or snack. DiAs will be initialized with the subject's typical insulin pump settings. The subject will be reminded that all treatment decisions should be based on fingerstick values and not on continuous glucose monitor (CGM) values.
88817323|NCT01715207|Experimental|Atenolol & Aliskiren|Atenolol tablet and Aliskiren 150mg or 300mg tablet by mouth per day for 6month
88817324|NCT01715207|Other|Atenolol|Atenolol tablet(Negative controls, Open-label)
88817325|NCT03795623|Sham Comparator|Conventional arm|Muted audio recordings of the patients relatives.
88817326|NCT03795623|Experimental|Voice-Weaning arm|Audio recordings of the patients relatives including information on the patient's condition and recurrent request to breath in and out.
88817327|NCT01716221|Experimental|Bupropion & Citalopram|100mg Bupropion & 20mg Citalopram taken orally one time per day or 100mg Bupropion & 10mg Citalopram taken orally one time per day or 50mg Bupropion & 20mg Citalopram taken orally one time per day 0r 50mg Bupropion & 10mg Citalopram taken orally one time per day
88817328|NCT01716221|Active Comparator|Bupropion & Placebo|100mg Bupropion & Placebo taken orally one time per day or 50mg Bupropion & Placebo taken orally one time per day
88817329|NCT01716221|Active Comparator|Placebo & Citalopram|Placebo & 20mg Citalopram taken orally one time per day or Placebo & 10mg Citalopram taken orally one time per day
88817330|NCT01716221|Placebo Comparator|Placebo & Placebo|Placebo & Placebo taken orally one time per day
88817331|NCT01215344|Experimental|VRD|VELCADE, Lenalidomide, Dexamethasone
88817332|NCT01215344|Experimental|VDD|VELCADE, liposomal doxorubicin, dexamethasone
88817333|NCT04618055|Experimental|NiTiDent Tuah Porous NiTi Dental Implants|
88817334|NCT04618055|Active Comparator|Control Implant|
88817335|NCT04610645||Head and Neck Cancer Patients|Patients with adjuvant or definitve radiotherapy or radio-chemotherapy for head and neck cancer
88817336|NCT01231412|Active Comparator|Arm I (MMF and CSP)|Patients receive FLU IV over 30 minutes on days -4 to -2. Patients also receive CSP PO BID on days -3 to 96 with taper to day 150 and MMF PO TID daily on days 0-29 and then BID on days 30-150 with taper to day 180. Patients undergo allogeneic PBSCT on day 0 following the TBI.
88817337|NCT01231412|Experimental|Arm II (MMF, CSP, and Sirolimus)|Patients receive FLU and CSP as in Arm I and sirolimus PO QD on days -3 to 150 with taper to day 180. Patients also receive MMF PO TID on days 0-29 and then BID on days 30-40. MMF will then be discontinued without taper unless GVHD or disease relapse/progression occurs. Patients undergo allogeneic PBSCT on day 0 following the TBI.
88817338|NCT01231412|Experimental|Arm 0 (CSP and Sirolimus)|Patients receive CSP orally (PO) twice daily (BID) on days -3 to 96 with taper to day 150 and and sirolimus PO once daily (QD) on days -3 to 150 with taper to day 180. Arm removed as of 14-Sep-2011
88817339|NCT01719653|Active Comparator|MiraLAX 306 g (Day-Prior)|MiraLAX 306 g and Gatorade 64 oz (1/2 gallon) consumed the day-prior to the colonoscopy as follows: Miralax 51 g at 12 noon; Gatorade 64 oz mixed with Miralax 255 g from about 6 PM to 9 PM
88817340|NCT01719653|Experimental|MiraLAX 357 g (Day-Prior)|MiraLAX 357 g and Gatorade 64 oz (1/2 gallon) consumed the day-prior to the colonoscopy as follows: Miralax 68 g at 12 noon; Gatorade 64 oz mixed with Miralax 289 g from about 6 PM to 9 PM.
88817341|NCT01719653|Experimental|MiraLAX 306 g (Split-Dose)|MiraLAX 306 g and Gatorade 64 oz (1/2 gallon) consumed as a split-dose as follows: Gatorade 32oz mixed with Miralax 153 g from about 6 PM to 8 PM the day prior to the colonoscopy; Gatorade 32oz mixed with Miralax 153 g from about 2-4 hours prior to the colonoscopy.
88817342|NCT01719653|Active Comparator|MoviPrep (Split-Dose)|MoviPrep consumed as a split-dose as follows: MoviPrep 1 liter consumed from about 6 PM to 7 PM the day prior to the colonoscopy followed by 0.5 liter of clear liquids; MoviPrep 1 liter consumed from 3-4 hours prior to the colonoscopy followed by 0.5 liter of clear liquids.
88817343|NCT01719653|Active Comparator|SUPREP (Split-Dose)|SUPREP consumed as a split-dose as follows: SUPREP 16 oz consumed from about 6 PM to 7 PM the day prior to the colonoscopy followed by 32 oz of clear liquids; SUPREP 16 oz consumed from 3-4 hours prior to the colonoscopy followed by 32 oz of clear liquids.
88817344|NCT01716455|Experimental|SSP-004184 (Mild Renal Impairment)|All subjects will take a single dose of SSP-004184 (75 mg/kg, oral capsule) on Day 1
88817345|NCT01716455|Experimental|SSP-004184 (Moderate Renal Impairment)|All subjects will take a single dose of SSP-004184 (75 mg/kg, oral capsule) on Day 1
88817346|NCT01716455|Experimental|SSP-004184 (Severe Renal Impairment)|All subjects will take a single dose of SSP-004184 (75 mg/kg, oral capsule) on Day 1
88817347|NCT01716455|Experimental|SSP-004184 (End Stage Renal Disease)|All subjects will take a single dose of SSP-004184 (75 mg/kg, oral capsule) on Day 1
88817348|NCT01716455|Experimental|SSP-004184 (Healthy Elderly Subjects)|All subjects will take a single dose of SSP-004184 (75 mg/kg, oral capsule) on Day 1
88817349|NCT01716455|Experimental|SSP-004184 (Matched Healthy Subjects)|All subjects will take a single dose of SSP-004184 (75 mg/kg, oral capsule) on Day 1. Healthy subjects matched to renally impaired subjects in arms 1 through 4. (Note: One healthy subject can match more than one renally impaired subject.)
88817350|NCT04568993|Experimental|proximal phalangeal level|injection in the the tendon sheet over proximal phalanx of finger
88817351|NCT04568993|Active Comparator|volar MCP level|injection above the A1 pulley volar to the MCP joint
88817352|NCT04559711|Experimental|Intervention arm|Strengthening coverage and quality of nutrition services including MMS during ANC
88817353|NCT04559711|No Intervention|Comparison arm|Existing provision of nutrition services during ANC.
88852699|NCT00005639|Experimental|Regimen A: 14-day 5-AC with intermittent phenylbutyrate|"Participants receive low-dose regimen of 5-AC with intermittent phenylbutyrate 400 mg/m2/day by continuous intravenous (CIV) over 24 hours on Days 6 and 13. Each cycle lasts 35 days.~Cohort A1: 25 mg/m2/day subcutaneous (SC) Cohort A-1: 18.75 mg/m2/day SC Cohort A-2: 15 mg/m2/day SC Cohort A-3: 10 mg/m2/day SC"
88852700|NCT00005639|Experimental|Regimen B: 7-day 5-AC with sequential phenylbutyrate|"Participants receive 5-AC 75mg/m2/day SC for 7 days, followed sequentially by two different doses of phenylbutyrate CIV starting on Day 8 and continuing for 7 days. Each cycle lasts 35 days~Cohort B1: Phenylbutyrate 200 mg/m2/day CIV Cohort B2: Phenylbutyrate 400 mg/m2/day CIV"
88852701|NCT00005639|Experimental|Regimen C: 21-day 5-AC with weekly phenylbutyrate|"Participants receive two different daily doses of 5-AC SC for 21 days and phenylbutyrate 400 mg/m2/day CIV over 24 hours once-per-week. Each cycle lasts 42 days.~Cohort C1: 5-AC 10mg/m2/day SC Cohort C2: 5-AC 12.5mg/m2/day SC"
88852702|NCT00005675|Experimental|1|Participants will receive oral bovine type I collagen (CI) daily for 15 months
88852703|NCT00005675|Placebo Comparator|2|Participants will receive placebo daily for 15 months.
88852704|NCT00385853|Experimental|PTK787|Single arm study of PTK787
88852705|NCT00005699||Hypertensive|described as hypertensive according to AHA guidelines at time of trial
88852706|NCT00005699||Controls|described as non-hypertensive according to AHA guidelines at time of trial
88852707|NCT00005711|No Intervention|Usual care|Control group children received routine medical care by their primary care providers as well as study visits every 6 months. At each study visit, following assessment of technique for using peak flow and metered dose inhalers, errors were corrected and children/families were coached on correct technique.
88852708|NCT00005711|Experimental|Asthma self-management education|"Treatment group children and their families participated in the patient education program which consisted of four separate one-hour sessions. The topics were: symptoms of asthma, causes of asthma (triggers), medications, and peak flow. A bilingual nurse educator working one-on-one with the child and family members delivered these four sessions. The four sessions were delivered over a six week period. Culturally sensitive educational materials include both print (flip charts, take-home brochures) and videotape materials. The videotapes feature children from the clinic and highlight how they successfully manage their asthma. All materials are available in both English and Spanish."
88852709|NCT00005777|Experimental|Minimal ventilation with Dexamethasone|Minimal ventilator support strategy (permissive hypercapnia) and early stress dose dexamethasone therapy
88852710|NCT00005777|Experimental|Minimal Ventilation without Dexamethasone|Minimal ventilator support strategy (permissive hypercapnia) and no dexamethasone therapy
88852711|NCT00005777|Active Comparator|Routine ventilation with Dexamethasone|
88852712|NCT00005777|Active Comparator|Routine ventilation without Dexamethasone|
88852713|NCT00386399|Experimental|Arm 1|Patients with BRCA2 gene will be treated with Mitomycin-C (MMC) on Day 1 at a dose of 10mg/m2 intravenously. This will be repeated every 28 days, which is one cycle. Treatment will continue until disease progression, serious toxicity, patient withdrawal or maximum cumulative dose of 60 mg/m2
88852714|NCT00005807|Experimental|Treated Participants|dose escalation treatment
88852715|NCT04569929|Active Comparator|control|conventionally manufactured Polymethyl Methacrylate (PMMA) mandibular implant overdentures
88852716|NCT04569929|Experimental|intervention|digital light processed (DLP)-printed photo-polymerizable PMMA Nextdent mandibular implant overdentures
88852717|NCT05895695|Active Comparator|1|evaluation of levator muscle resection on congenital ptosis
88852718|NCT05895695|Active Comparator|2|evaluation of levator muscle plication on congenital ptosis
88852719|NCT05895682|Experimental|Induced hypoxia|Volunteers were monitored using end-tidal carbon dioxide partial pressure and fraction of inspired oxygen. Each volunteer was placed in a semi-Fowler's position and connected to a breathing circuit to administer the nitrogen-air-carbon dioxide mixtures. A nose clip was applied to prevent breathing of room air. For frequent blood sampling, an arterial cannula was placed in the radial artery of each volunteer. Pulse oximeter probes were simultaneously attached to each volunteer's fingers. Each volunteer was exposed to various levels of induced hypoxia from 70~100% of SaO2. Each plateau of oxygen saturation was maintained for at least 30 s until stabilization, after which 1 ml of arterial blood was drawn into a heparinized syringe. The study period consisted of two rounds of hypoxia, and the volunteers were maintained on room air between each round. SaO2 measurements using a CO-oximeter were used as a reference for the SpO2 accuracy.
88852720|NCT05895630|Experimental|Interactive|The sessions will be given in groups of 5 to 10 people and will be interactive via Zoom (link will be sent to them by email). They will last 1h30min and will consist of 60min of physical activity, preceded and followed by 15 optional minutes of virtual social interaction with the kinesiologist and the other members of the group. Finally, if the participants are unable to attend the group session, a video of the course given will be available for them to follow afterwards via a website.
88852721|NCT05895630|Experimental|Video|The sessions will be done individually without interaction via pre-recorded videos. The videos demonstrate specific classes provided to the patients in this arm by a kinesiologist. Participants will be able to contact the kinesiologist by phone or email to ask questions about the sessions. The sessions will last 1h30min.
88852722|NCT05895630|No Intervention|Control|The control will be instructed to continue their lifestyle habits throughout the study. These participants will not receive any intervention until their outcome measures at baseline and follow-up are recorded. At this point their participation is completed and they will be offered one of the two physical exercise programs. Therefore, this arm will be acting like a waitlist group.
89379309|NCT05080114|Experimental|Modified technique (MT)|All the steps of the laparoscopic hysterectomy were performed according to conventional standard technique until the colpotomy step. Instead, the modified Bakay technique was used for later on.
89379310|NCT05080114|Active Comparator|Standard technique (ST)|The conventional standard total laparoscopic hysterectomy technique was used in this control group.
89379311|NCT05079958|Experimental|Stage2 - cognitive-behavioral education|A quasi-experimental design will be used to determine the effects of a four-week cognitive-behavioral education course related to smoking cessation on the participants' smoking cessation behavior, smoking decision-making, and self-efficacy in smoking cessation.
89379312|NCT05079958|Experimental|Stage 3- 12-week brisk walking|"Subjects who are at the preparation  and action stage will be recruited and randomly divided into experimental or control group to identify the effect of a 12-week brisk walking on improving the participants' immediate (short-term), three-month, and six month (long-term) health status."
89379313|NCT02328352|Experimental|BP selfstanding felt|"laparotomy intervention with the incision of 10 cm navel-pubis will be performed, splaying of the skin and subcutaneous layers, then will be incised the fascia plane, and muscles. Ten rabbits (hereafter defined as BPR1-BPR10) will receive 2x2cm2 samples of BP selfstanding felt in a pocket created between muscular fascia and large muscles of the abdominal wall.~V-Loc 180 (ref VLOCL0024, lot. A1D0899)"
89379314|NCT02328352|Active Comparator|PP mesh|"intervention of laparotomy with the incision of 10 cm navel-pubis will be performed, splaying of the skin and subcutaneous layers, then will be incised the fascia plane, and muscles. A 2x2cm2 sample of PP mesh was implanted without stitches into a pocket between large abdominal muscle and abdominal fascia.~Other names: V-Loc 180 (ref VLOCL0024, lot. A1D0899) PR Parietene mesh Tyco (ref. PP3030, lot. SIK00587)"
89379315|NCT02328352|Experimental|BP intraperitoneal mesh|A surgical scar was performed on the abdominal linea alba and carried out deeply for entering into the abdominal cavity. In five rabbits (BPR21-BPR25). A 2x2cm2 BP intraperitoneal mesh was then be inserted with the rough side facing the parietal peritoneum surface and the smooth and brilliant surface facing to the visceral peritoneum and gut.
89379316|NCT02328352|Active Comparator|control group|Five rabbits (R26-R30) will be used as control group.
88852723|NCT05895617||Research Study|Is the Occuity pachymeter non inferior in it's measurement of central corneal thickness compared to the ultrasound pachymeter, Lenstar and Pentacam.
88852724|NCT05895591|Experimental|Treated Group|all subjects will apply the study product
88852725|NCT05895539|No Intervention|Control|Did not receive the tool
88852726|NCT05895539|Experimental|Intervention|Did receive the tool
88852727|NCT05895526|Experimental|5% Sodium Fluoride Varnish|71 patients will be in 5% Sodium Fluoride Varnish
88852728|NCT05895526|Experimental|Self Etch Dentin Adhesive|71 patients will be in Self Etch Dentin Adhesive
88852729|NCT05895461|Experimental|BWLI-College|BWLI-College is a multicomponent behavioral weight loss intervention to reduce weight through diet, physical activity, and behavioral modifications designed to be responsive to emerging adult preferences. It will be delivered in a hybrid format with in-person and remotely-delivered asynchronous sessions. As presently designed, the intervention will last 10 weeks, though this may change with refinement.
88852730|NCT05895448|Experimental|PWID (people who inject drugs)|velpatasvir (100 mg) and sofosbuvir (400 mg) once daily for 12 weeks (brand or branded generic) in subjects who had used intravenous drugs at least once in preceding six months.
88852731|NCT05895448|Active Comparator|Non-PWID|velpatasvir (100 mg) and sofosbuvir (400 mg) once daily for 12 weeks (brand or branded generic) in subjects who had NOT used intravenous drugs at least once in preceding six months, but were treated concurrently in the same hepatology referral clinics.
88852732|NCT05895435|Experimental|first group|"Group (A) (Control Group):~It will be consisted of 30 patients who will receive aerobic exercise and diet for 8 successive weeks 2 sessions per week."
88852733|NCT05895435|Experimental|second group|"Group (B) (Study Group):~It will be consisted of 30 patients who will receive aerobic exercise and diet and radiofrequency for 8 successive weeks 2 sessions per week."
88852734|NCT05895396||Liberty|The group implanted with Liberty 677MTY
88852735|NCT05895396||PanOptix|The group implanted with PanOptix
88852736|NCT05895370|Experimental|HPV-T|Participants in the 2 dose groups will receive HPV-T injections of 5×10^9 and 1.5×10^10 cells intravenously each time.
89379317|NCT03290781|Experimental|Ontamalimab 25 mg|Participants will receive 25 milligram (mg) of ontamalimab or placebo and achieved a clinical response in one of the induction studies (SHP647-301 [NCT03259334] and SHP647-302 [NCT03259308]) will receive 25 mg of ontamalimab as maintenance treatment subcutaneously using a prefilled syringe once in every 4 weeks (Q4W) up to Week 52.
89379318|NCT03290781|Experimental|Ontamalimab 75 mg|Participants will receive 75 mg of ontamalimab or placebo and achieved a clinical response in one of the induction studies (SHP647-301 [NCT03259334] and SHP647-302 [NCT03259308]) will receive 75 mg of ontamalimab as maintenance treatment subcutaneously using a prefilled syringe Q4W up to Week 52.
88852737|NCT05895305|Experimental|Single arm treated by Airiver Pulmonary DCB|subject will be treated by Airiver Pulmonary Drug Coated Balloon (DCB) catheter. The balloon is coated with a paclitaxel drug (3.5ug/mm2).
88852738|NCT05895240|No Intervention|Control Group Arm|Standard of care treatment arm, study medication will not be given
88852739|NCT05895240|Experimental|Active Intervention Arm|This group will receive Nine MiU Ulinastatin in three divided doses 8 hourly
88852740|NCT05895214||patients who received primary surgery|preoperative CT scans available for assessing resectability criteria and presumed mesopancreatic infiltration status (CT scans are centrally evaluated) UICC 8th edition staging including CRM Tumor size in mm measured twice perpendicular Age Sex CA 19-9 values (preoperative) ECOG status BMI Type of PD (tail preserved vs total PD) simultaneous vessel resection (complete, partial; combined arterial and venous)
88852741|NCT05895214||patients who received neoadjuvant treatment prior to surgery|Peri-therapeutic CT scans available for assessing resectability criteria and presumed mesopancreatic infiltration status (CT scans are centrally evaluated) UICC 8th edition staging including CRM Tumor size in mm measured twice perpendicular Age Sex CA 19-9 values (peri-therapeutic) ECOG status BMI Type of neoadjuvant Therapy Type of PD (tail preserved vs total PD), simultaneous vessel resection (complete, partial; combined arterial and venous) Tumor response according to CAP
89379319|NCT03290781|Placebo Comparator|Placebo|Participants will receive 25 mg or 75 mg ontamalimab or placebo matched to ontamalimab in the induction studies (SHP647-301 [NCT03259334] and SHP647-302 [NCT03259308]) will receive placebo matched to ontamalimab as maintenance treatment subcutaneously using a prefilled syringe Q4W up to Week 52.
89379320|NCT01569984|Experimental|Avastin, SBRT|2 treatments of avastin followed by 6 treatments of SBRT every other day.
89379321|NCT02328118|Experimental|Ranibizumab 0.5 mg|All subjects in this group will receive Ranibizumab (0.5mg/0.05ml) intravitreal injection.
89379322|NCT02328118|Experimental|Triamcinolone Acetonide 4mg|All patients in this group will receive Triamcinolone Acetonide(4mg/0.1ml) during operation.
89379323|NCT03466073|Experimental|Single Dose 6 mg/kg|Intravenous administration of recombinant human plasma gelsolin at 6 mg/kg v. placebo (NSS) in addition to standard of care
89379324|NCT03466073|Experimental|Multiple Dose 6 mg/kg|Intravenous administration of recombinant human plasma gelsolin at 6 mg/kg once per day for 3 days v. placebo (NSS) in addition to standard of care
89379325|NCT03466073|Experimental|Multiple Dose 12 mg/kg|Intravenous administration of recombinant human plasma gelsolin at 12 mg/kg once per day for 3 days v. placebo (NSS) in addition to standard of care
89379326|NCT03466073|Experimental|Multiple Dose 24 mg/kg|Intravenous administration of recombinant human plasma gelsolin at 24 mg/kg once per day for 3 days v. placebo (NSS) in addition to standard of care
89379327|NCT02327962||Hemodialysis|Hemodynamic measurements with PWV
89379328|NCT02327962||Control|Hemodynamic measurements with PWV
89379329|NCT02602314|Experimental|Imatinib + Nilotinib|
89379330|NCT02602314|Experimental|Nilotinib|
89379331|NCT03412019|No Intervention|Control group|baseline hemodynamics and anxiety screen; no music. Satisfaction will be measured.
89379332|NCT03412019|Experimental|Intervention group - Mozart|A study investigator will turn on a playlist of pre-selected Mozart music. Hemodynamics and anxiety screen. Satisfaction will be measured.
89379333|NCT05079880|Experimental|GC group|received 300 mg of caffeine citrate infusion
89379334|NCT05079880|Placebo Comparator|GS group|Equivalent saline infusion
89379335|NCT05021146|Experimental|Standard care and CEO treatment with standard 20% concentration Copaiba oil|
89379336|NCT05021146|Experimental|Standard care and CEO treatment with 40% concentration Copaiba oil|
89379337|NCT05021146|Placebo Comparator|standard care and placebo treatment with coconut oil|
89379338|NCT05021146|Active Comparator|Standard care|
89379339|NCT05018338||The study cohort|The study will enroll 10 subjects meeting the eligibility criteria, with the expectation to obtain complete data from at least 6 subjects.
89379340|NCT03716765|Experimental|non-surgical periodontal regeneration|non-surgical periodontal regeneration using locally injected vitamin d to treat the infrabony defect
89379341|NCT03716765|Active Comparator|surgical peridoontal regeneration|surgical periodontal regeneration using bone graft and collagen barrier
89379342|NCT03716687|Experimental|ciNPWT|"Prophylactic negative pressure wound dress (Hartmann) is set up for 5 days right after operation.~Continous -90 Hgmm negative pressure mode selected. No change of wound dress until 5 days completed."
89379343|NCT03716687|No Intervention|Traditional wound dressing|Control group with traditional, dry laparotomy wound dressing.
89002651|NCT06277882|Active Comparator|Standard 2 dose|Receiving the standard 2-dose regimen of the Havrix hepatitis A vaccine, administered at months 0, and 6.
89182736|NCT06237452|Experimental|VE303|Subjects assigned to the VE303 arm will take 3 capsules containing VE303 per day for 14 days after completing 10 to 21 days of standard of care antibiotic treatment for the qualifying CDI episode.
89379344|NCT05017324|Experimental|WGS DST strategy|WGS DST strategy for diagnosing the TB drug resistance profile and an individualised RR-TB treatment recommendation
89379345|NCT05017324|No Intervention|Standard of Care|Standard of care diagnosis of the drug resistance profile and individualised treatment
89379346|NCT01311323|Experimental|PCI with DES implantation|Percutaneous Coronary Intervention Implantation of Drug-Eluting Stents
89379347|NCT01311323|Active Comparator|CABG|Coronary Artery Bypass Grafting.On-pump or Off-pump CABG
89379348|NCT05079646|No Intervention|Group 1, subgroup A (blue color coded)|Normal teeth with no cavity preparation and no endodontic procedure.
89379349|NCT05079646|Experimental|Group 1, subgroup B (pink color coded)|Teeth specimens in which endodontic procedure will be performed and coronal restoration will be done with Zirconomer (shofu).
89379350|NCT05079646|Experimental|Group 1, subgroup C (green color coded)|Teeth specimens in which endodontic procedure will be performed and coronal restoration will be done with Cention-N (Ivoclar vivodent)
89379351|NCT05079646|Active Comparator|Group 1, subgroup D (black color coded) positive control group|Teeth specimens in which endodontic procedure will be performed and coronal restoration will be done with Aristaloy Amalgam (Cookson)
89379352|NCT05079646|No Intervention|Group 2, Subgroup A (Blue color coded) negative control group|Normal teeth with no cavity preparation and no endodontic procedure.
89379353|NCT05079646|Experimental|Group 2, Subgroup B (pink color coded)|Teeth specimens in which endodontic procedure will be performed and coronal restoration will be done with Zirconomer (shofu) by using tofflemire retainer and matrix band.
89379354|NCT05079646|Experimental|Group 2, Subgroup C (green color coded)|Teeth specimens in which endodontic procedure will be performed and coronal restoration will be done with Cention-N (Ivoclar vivodent) by using tofflemire retainer and matrix band.
89379355|NCT05079646|Active Comparator|Group 2, Subgroup D (black color coded)|Teeth specimens in which endodontic procedure will be performed and coronal restoration will be done with Aristaloy Amalgam (Cookson) by using tofflemire retainer and matrix band.
89379356|NCT03070002|Experimental|Treatment (denosumab)|Patients receive denosumab SC on day 1. Treatment repeats every 28 days for up to 3 courses in the absence of disease progression, unexpected toxicity, or patient withdrawal or death.
89379357|NCT02327728|Experimental|medial lower eyelid waived|Botulinum toxin A 10U per eye subcutaneous injection at orbicularis oculi
88817354|NCT01294748|Experimental|MiStent DES|The MiStent SES is a sirolimus-eluting absorbable polymer stent for coronary artery revascularization.
89379358|NCT02327728|Active Comparator|full injection pattern|Botulinum toxin A 12.5U per eye subcutaneous injection at orbicularis oculi
89379359|NCT03142672|Experimental|Experimental group|Pulpotomy and tooth filling
89379360|NCT03142672|Active Comparator|Control group|Tooth filling
89379361|NCT02918318|Experimental|Placebo|Participant will receive 1 spray of placebo to each nostril at 0 minute, 5 minutes and 10 minutes.
88817355|NCT01294748|Active Comparator|Endeavor DES|The Endeavor DES is an everolimus-eluting durable polymer stent for coronary artery revascularization.
88817356|NCT01720277|Experimental|HD Fluzone Vaccine|NH facilities randomized to receive high dose trivalent influenza vaccine (HD Fluzone) for the residents.
88817357|NCT01720277|Active Comparator|SD Fluzone Vaccine|NH facilities randomized to standard dose trivalent influenza vaccine (SD Fluzone) for the residents.
88817358|NCT01231646||Lamotrigine|No intervention
88817359|NCT01231646||Valproate|No intervention
88817360|NCT04539665|Experimental|Intervention Arm|Prospective study arm involving an extended mesenteric ileocolic excision.
88817361|NCT04539665|No Intervention|Control Arm|Historical controls from a retrospective chart review of patients who had a limited ileocolic resection.
88817362|NCT01295216|Experimental|Intervention|Pre-hypertensive subjects who receive mHealth support for 12 months
88817363|NCT01295216|No Intervention|Control|Individuals who receive the usual primary health care
88817364|NCT04514393|Experimental|methotrexate, ibrutinib, and temozolomide (MIT regimen)|Methotrexate will be given on day 1 of each 28-day cycle；Ibrutinib will be given day 1-28 of each 28-day cycle; Temozolomide will be given day 1-5 of each 28-day cycle. Methotrexate and Temozolomide are given for up to 4 cycles; Ibrutinib is continued until disease progression, intolerable toxicity, or death.
88817365|NCT01232504|Experimental|rhGM-CSF group|subcutaneous 5-7μg/kg/d Recombinant Human Granulocyte-macrophage Stimulating Factor (rhGM-CSF) once daily
88817366|NCT01232504|Active Comparator|rhG-CSF+rhGM-CSF group|a combination of 2-3μg/kg/d Recombinant Human Granulocyte-macrophage Stimulating Factor (rhGM-CSF) and 2-3μg/kg/d Recombinant Human Granulocyte Stimulating Factor (rhG-CSF) each
88817367|NCT01232504|Active Comparator|rhG-CSF group|subcutaneous 5-7μg/kg/d Recombinant Human Granulocyte Stimulating Factor (rhG-CSF) once daily
88817368|NCT01721447|Experimental|Echo arm|Subjects with atrial fibrillation who are undergoing a TEE procedure will be assessed using Optison echocardiography contrast agent
88817369|NCT02249819|Experimental|anodal tDCS, then sham tDCS|Participants received 1 single 20 min session of anodal tDCS + computerized naming therapy. Following a 1 week washout period, they received 1 single 20 min session of sham tDCS + computerized aphasia therapy. Sequence of stimulation conditions was randomized across participants.
88817370|NCT02249819|Experimental|sham tDCS, then anodal tDCS|Participants received 1 single 20 min session of sham tDCS + computerized naming therapy. Following a 1 week washout period, they received 1 single 20 min session of anodal tDCS + computerized aphasia therapy. Sequence of stimulation conditions was randomized across participants.
88817371|NCT01295840|No Intervention|CRT therapy|Cardiac Resynchronization Therapy Defibrillator (CRT-D)
88817372|NCT01737281|Experimental|Proactive outreach|Proactive outreach to deliver 7 sessions of telephone counseling and nicotine replacement therapy.
88817373|NCT01737281|Active Comparator|Usual care|Usual smoking cessation care from clinical staff
88817374|NCT01216748|Experimental|health life-time non smokers|health lifetime non-smokers will be challenged with 4 respiratory maneuvers:quiet breathing, hypocapnic hyperventilation, hypercapnic hyperventilation, and eucapnic hyperventilation
88817375|NCT01233518|Other|Single arm study|Patients will receive cCTA, ICA, FFR, and cFFR per protocol.
88817376|NCT01737593|Active Comparator|Acetaminophen PR|Acetaminophen PR (20-40mg/kg) after induction of Anesthesia (acetaminophen is in suppository form and given rectally)
88817377|NCT01737593|Active Comparator|Acetaminophen PO-low dose|Acetaminophen PO (10mg/kg) 60-120min before start of BMT placement (acetaminophen is in syrup form and given by mouth)
88817378|NCT01737593|Active Comparator|Acetaminophen PO-high dose|Acetaminophen PO (20mg/kg) 60-120min before start of BMT placement (acetaminophen is in syrup form and given by mouth)
88817379|NCT01217840|Experimental|vitamin D|"Subjects were assigned to receive two observed doses of vitamin D2 (150,000 IU ergocalciferol, Barr Laboratories and Winthrop (Sanofi-Aventis)), given at baseline and 12 weeks. Capsules were packaged by the hospital's clinical trial pharmacist and were administered by study staff blinded to group assignments.~Intervention: Height, weight, and BMI were obtained at baseline, 12 weeks and 24 weeks"
88817380|NCT01217840|Placebo Comparator|Placebo|Subjects were assigned to receive two observed doses of placebo, given at baseline and 12 weeks. Capsules were packaged by the hospital's clinical trial pharmacist and were administered by study staff blinded to group assignments. Height, weight, and BMI were obtained at baseline, 12 weeks and 24 weeks
88817678|NCT01313936|Experimental|15 mCi/kg of 131I-MIBG|The first cohort for safety will be 3-6 patients treated with vincristine and irinotecan and 15 mCi/kg of 131I-MIBG.
88817679|NCT01313936|Experimental|18 mCi/kg of 131I-MIBG|The second cohort will be 3-6 patients at the same doses of vincristine and irinotecan and 18 mCi/kg of 131I-MIBG.
88852742|NCT05895188|Experimental|Virtual Reality Group|Before starting the process, participants will be informed about the study and their verbal and written consent will be obtained. Participants in the virtual reality group will be shown and introduced to virtual reality glasses before the procedure. After the woman goes to the examination table and takes the appropriate position for the pap smear procedure, virtual reality glasses will be put on the woman by the researcher. The selected video will be played until the Pap smear process is completed. (https://www.youtube.com/watch?v=6ud18oSuCiY&t=30s). When the Pap smear is finished, the glasses will be removed and the woman will be helped to get up from the examination table. In this process, no form will be filled until the participant woman gets dressed and takes the ready position. Thus, the privacy of women will be protected and there will be no violation of ethical rights.
88852743|NCT05895188|No Intervention|Control Group|Verbal and written consent will be obtained from the participants before starting the procedure. No intervention will be applied to the participants in the control group. The forms that need to be filled before the procedure will be filled. With the help and guidance of the researcher, the woman will prepare, move to the examination table and take a position. After the Pap smear process is over, the participant woman will get off the examination table with the help of the researcher and get dressed. After the woman is ready after the procedure, she will go to the waiting room and fill out the forms.
88852744|NCT05895149|Experimental|Experimental group|In each participant, HRV will be measured for 2 minutes, then the flying buttress technique will be applied. After the technique, HRV will be recorded for 2 minutes, and 5 minutes later, HRV will be measured again for 2 minutes.
88852745|NCT05895149|Placebo Comparator|Control group|In each participant, HRV will be measured for 2 minutes, then the placebo technique will be applied. After the technique, HRV will be recorded for 2 minutes, and 5 minutes later, HRV will be measured again for 2 minutes.
88852746|NCT05895123|Experimental|Rosuvastatin group|patients will receive Rosuvastatin orally (20-40 mg) at night once daily
88852747|NCT05895123|Experimental|Atorvastatin group|patients will receive Atorvastatin orally (40-80 mg) at night once daily
88852748|NCT05895110|Experimental|Experimental group|1 dose of the test recombinant novel coronavirus vaccine (CHO cell) was injected into the deltoid muscle of the subject's upper arm
88852749|NCT05895097|Active Comparator|Conventional pacing|
88852750|NCT05895097|Experimental|LBB pacing|
88852751|NCT05895084|Experimental|Group Yoga|Yoga includes breath work (pranayama), gentle stretching and holding of postures (asanas), and meditation (dhyana). Modifications/adaptations are incorporated so all participants can successfully complete the yoga intervention. Yoga is delivered in a standardized progression, including: focused, slow breath with movement and breathwork throughout every session; mantras, progressively challenging yoga postures (sitting, standing, and floor); and meditation
88852752|NCT05895071|Active Comparator|Group A Topical 5% potassium hydroxide|In group-A 30 patients were given topical 5%-potassium hydroxide solution on affected area once at night upto 4 weeks
88852753|NCT05895071|Active Comparator|Group B Liquid nitrogen|in group-B 30 patients treated with cotton bud method of cryotherapy with liquid nitrogen once every two weeks. Patients were reassessed at every two weeks and final assessment was done at 12th week.
88852754|NCT05895032|Experimental|Exercise|12-week exercise intervention
88852755|NCT05895032|Active Comparator|Usual care|Participants will continue to receive their usual care as prescribed by the haematologist, physiotherapist and other members of the healthcare team.
88852756|NCT05894980|Experimental|active tDCS on left DLPFC|Active tDCS applied on left dorsolateral prefrontal cortex [DLPFC]
88852757|NCT05894980|Active Comparator|active tDCS on right OFC|Active tDCS applied on right orbitofrontal cortex [OFC]
88852758|NCT05894980|Sham Comparator|sham tDCS|Sham tDCS applied on left dorsolateral prefrontal cortex [DLPFC]
89379362|NCT02918318|Experimental|Esketamine 28 milligram (mg)|Participant will receive 1 spray of Esketamine to each nostril at 0 minute and placebo at 5 minutes and 10 minutes.
89379363|NCT02918318|Experimental|Esketamine 56 mg|Participant will receive 1 spray of Esketamine to each nostril at 0 minute, 5 minutes and placebo at 10 minutes.
88852759|NCT05894954|Experimental|Group A (Precision Medicine)|Precision Medicine approach starts with a battery of tests and questionnaires to determine a person's underlying causes of cognition impairment. A custom treatment program is developed and prescribed by the investigator based on the test results and includes a combination of: supplements, medications, hormone therapy, dietary changes, exercise program, brain exercises, stress management, sleep tracking. Additional treatments may include QEEG and photobiomodulation, neurostimulation, neurofeedback and/or hyperbaric oxygen treatment (additional treatment are only available at select sites). Participants in this Group will also be supported in their program by a nutritionist, health coach, and fitness trainer, in addition to the study doctor. Tracking of study activities may also be required in the form of diaries, and devices will be used to track some of their activities such as sleep, stress, diet and exercise.
88852760|NCT05894954|Active Comparator|Group B (Standard-of-Care)|"Standard-of-care treatment will be based on the practice guideline of hte Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Participants in this group will be guided according to the recommendations which include recommending:~participation in cognitively and socially-stimulation activities~regular exercise~ensuring quality sleep including treatment of any sleep apnea~control of any modifiable risk factors such as blood pressure, diabetes, cholesterol, and avoidance of tobacco use~evaluation by a primary care physician~adherence to a healthy and balanced diet~consult a neurologist or primary care physician regarding use of medications~consult with their primary care physician to identify any worsening conditions"
88852761|NCT05894915|Experimental|open surgery group|Patients who met the inclusion criteria and excluded the exclusion criteria, and did not have high mutational burden characteristics after molecular testing, were randomly divided into open surgery group or laparoscopic surgery group according to 1:1.
88852762|NCT05894915|Experimental|laparoscopic surgery group|Patients who met the inclusion criteria and excluded the exclusion criteria, and did not have high mutational burden characteristics after molecular testing, were randomly divided into open surgery group or laparoscopic surgery group according to 1:1.
89379364|NCT02918318|Experimental|Esketamine 84 mg|Participant will receive 1 spray of Esketamine to each nostril at 0 minute, 5 minutes and 10 minutes.
89379365|NCT03713957|Experimental|GRF6021|Subjects will receive GRF6021 for 5 consecutive days at Week 1 and Week 13.
89379366|NCT03713957|Placebo Comparator|Placebo|Subjects will receive Placebo for 5 consecutive days at Week 1 and Week 13.
89379367|NCT01374321|Placebo Comparator|Placebo|
89379368|NCT01374321|Experimental|TRO40303|
88817680|NCT00364767|Experimental|A|Whiskey (32 gram of alcohol/day)
88817681|NCT00364767|Placebo Comparator|B|Water (0 gram alcohol/day)
88817682|NCT01751399|Experimental|LY2605541-Normal Hepatic Function|Participants with normal hepatic function will receive a single subcutaneous (SC) dose of 0.075 milligrams per kilogram (mg/kg) LY2605541
88817683|NCT01751399|Experimental|LY2605541-Mild Hepatic Impairment|Participants with mild hepatic impairment will receive a single SC dose of 0.075 mg/kg LY2605541
88817684|NCT01751399|Experimental|LY2605541-Moderate Hepatic Impairment|Participants with moderate hepatic impairment will receive a single SC dose of 0.075 mg/kg LY2605541
89379369|NCT04960150|Experimental|Acupuncture group|Intervention of press tack needle acupuncture
89379370|NCT04960150|Placebo Comparator|Control group|Intervention of placebo acupuncture
89379371|NCT02327806|Other|10 minutes of pulsed electromagnetic field therapy|10 minutes of pulsed electromagnetic field therapy
89379372|NCT02327806|Other|20 minutes of pulsed electromagnetic field therapy|20 minutes of pulsed electromagnetic field therapy
88817685|NCT01751399|Experimental|LY2605541-Severe Hepatic Impairment|Participants with severe hepatic impairment will receive a single SC dose of 0.075 mg/kg LY2605541
88817686|NCT04414215|Experimental|Cognitive training|Emotional working memory training
88817687|NCT04414215|Placebo Comparator|Placebo training|Placebo working memory training
88817688|NCT01752413|Experimental|Ferrous gluconate 325mg|Those found iron depleted by ferritin measure will receive 325 mg Ferrous gluconate twice a day for 100 days. They will be deferred as a whole blood donor for 120 days until completion of iron therapy. They will receive standard dietary counseling.
88817689|NCT01752413|Active Comparator|Nutrition counseling|For those consenting to this study but who demonstrate adequate ferritin levels (>20 micrograms/L female, >30 micrograms/L males), they will not receive oral iron or additional deferral period but will be allowed to donate after the standard 56 days. They will receive standard counseling about iron rich foods. Rate and frequency of subsequent donations will be tracked and compared to those receiving iron supplementation.
88817690|NCT05492253|Active Comparator|Infant cereal|Oatmeal cereal
88817691|NCT05492253|Experimental|Infant fruit|Pureed prunes
88817692|NCT05492253|Experimental|Infant vegetable|Pureed carrots
88817693|NCT05492253|Experimental|Infant meat|Pureed beef
88817694|NCT01314014|Experimental|Imexon|Subjects will be treated on Days 1-5 of 21-day treatment cycles for up to one year. Following pre-treatment with anti-emetics Amplimexon will be given by intravenous infusion over 60 minutes.
88817695|NCT05490459|Experimental|Treatment|Jewel Patch Wearable Cardioverter Defibrillator (P-WCD)
88817696|NCT01731119|Experimental|Flexible Dose Latuda©|Lurasidone (Latuda©)dose will be determined solely by the clinician in accordance with the best interests of each participant.
88817697|NCT02326649||CHD patients undergoing cardiac MRI without sedation|
88817698|NCT04692519|Experimental|Intervention|The Duet 2.0 intervention is comprised of six training modules, which include behavioral strategies, real-life and animated examples of high-quality early language interactions, and interactive scenarios. Modules were translated into Spanish. Participants will watch one Duet intervention module a week and have up to 3 months to complete all 6 modules. As intervention families review the modules on their own time at home, they will receive remote coaching from an assigned interventionist and weekly module-specific fidelity/comprehension questions. Interventionists will check-in weekly via phone or video (~30-60 minutes), whichever is more convenient for the family. During the check-in, interventionists will do teach-back about the module, guide the family on how to incorporate the strategies into their daily lives, and provide feedback. Intervention participants will be scheduled for follow-up data collection at 3 months, 6 months, and pending funding, 1-year after baseline.
88852763|NCT05894889|Experimental|Pembrolizumab + Chemotherapy|"Non-squamous NSCLC: pembrolizumab 200mg as at least 30-minute IV infusion on Day 1, followed by pemetrexed at a dose of 500mg/m2 IV over 30 minutes or per institutional standard with Carboplatin at a dose of AUC 5 over 120 minutes or per institutional standard, of a 3-week treatment cycle, for up to 4 cycles.~Squamous NSCLC: pembrolizumab 200mg as at least 30-minute IV infusion on Day 1, followed by nab-paclitaxel at a dose of 135mg/m2 IV over 30 minutes or per institutional standard with Carboplatin at a dose of AUC 5 over 120 minutes or per institutional standard, of a 3-week treatment cycle, for up to 4 cycles. Nab-paclitaxel will also be administered at the dose of 135mg/m2 for over 30 minutes IV infusion or per institutional standard on day 8 of each 3-week treatment cycle."
88852764|NCT05894863|Experimental|Smart flex stent group|Smart flex stent will be used for patients with femoropopliteal lesions receiving endovascular treatment.
88852765|NCT05894850|Experimental|With automatic surveillance system reminding through telephone and message|Patients were reminded of the surveillance time by an automatic surveillance system after the endoscopic and pathological results were available and before the surveillance time through telephone and message.
88852766|NCT05894850|Experimental|With automatic surveillance system reminding through message|Patients were reminded of the surveillance time by an automatic surveillance system after the endoscopic and pathological results were available and before the surveillance time through message.
88852767|NCT05894850|Experimental|With manual reminder|Patients were reminded of the surveillance time by manual reminder after the endoscopic and pathological results were available and before the surveillance time.
88852768|NCT05894850|No Intervention|Normal group|The patients in the control group were observed in the clinical natural state of surveillance without automatic surveillance system or manual reminder.
88852769|NCT05894837|Experimental|Serplulimab in combination with Regorafenib and hepatic artery bicarbonate infusion|Serplulimab: once every two weeks; Regorafenib: from the first day to the 21th day; hepatic artery bicarbonate infusion: once every four weeks
88852770|NCT05894824|Other|Single arm, Trastruzumab deruxtecan, Ramucirumab|
88852771|NCT05894811||control|obese people with normal glucose tolerance
88852772|NCT05894811||IGT|obese people with injured glucose tolerance
88852773|NCT05894811||T2D|obese people with type 2 diabetes
88852774|NCT05894746|Experimental|gluten-free|The study participants will start the gluten-free diet and be asked to exchange any products they normally buy with similar products. Three days in the week they will eat a meal with gluten free pasta. Two to six hours after the meal they will take samples at home and store until they return to the clinic.
88852775|NCT05894746|Active Comparator|gluten|The study participants will continue the gluten-free diet and be asked to exchange any products they normally buy with similar products. Three days however, in the week they will eat a meal with regular gluten containing pasta. Two to six hours after the meal they will take samples at home and store until they return to the clinic.
88852776|NCT05894746|Active Comparator|probiotic|The study participants will continue the gluten-free diet and be asked to exchange any products they normally buy with similar products. During the week they will also take probiotic (Probion, Active) every morning and every evening. Three days however, in the week they will eat a meal with regular gluten containing pasta. Two to six hours after the meal they will take samples at home and store until they return to the clinic.
88852777|NCT05894733|Other|1|1: The first group was called by phone on the 15th day to ask if there were any complaints or problems with the device. Sequentially, they were called for controls at the end of the first, third, and sixth months.
88852778|NCT05894733|Other|2|2:The second group was accepted as the control group, following our clinic's standard procedure in the first and sixth months
88852779|NCT05894720|Experimental|Thrower's Ten Exercise Group|"the athletes were subjected to Thrower's Ten exercise program under the supervision of the same physiotherapist 3 days a week for a period of 6 weeks in addition to the routine practice programs thereof. Each session started with a 10-minute warm-up program and ended with a 10-minute cool-down program. The warm-up program included low-intensity aerobic activities and short stretching exercises. Stretching exercises for anterior-posterior-inferior capsule, right and left trapezoid muscles, chintug as well as posterior-lateral neck and latissimus dorsi muscles were given. Following the exercises, the athletes were made to perform low-intensity jogging and static stretching exercises. All athletes, who were included in the study sample, continued attending their 2-hour routine pool practice on 4 days a week in addition to the Thrower's Ten exercises for 6 weeks."
88852780|NCT05894707|Experimental|80 mg SCT650C or normal saline|Eight qualified participants will be randomized at a ratio of 6:2 to receive 80 mg SCT650C or normal saline on Day 1
88852781|NCT05894707|Experimental|160 mg SCT650C or normal saline|Eight qualified participants will be randomized at a ratio of 6:2 to receive 160 mg SCT650C or normal saline on Day 1
88852782|NCT05894707|Experimental|40 mg SCT650C or normal saline|Eight qualified participants will be randomized at a ratio of 6:2 to receive 40 mg SCT650C or normal saline on Day 1
88852783|NCT05894707|Experimental|20 mg SCT650C or normal saline|Eight qualified participants will be randomized at a ratio of 6:2 to receive 20mg SCT650C or normal saline on Day 1
88852784|NCT05894694|Experimental|palliative care group first-line scheme + compound kushen injection|palliative care group first-line regimen (FOLFOX/FOLFIRI/CAPEOX± Cetuximab/bevacizumab)+ compound kushen injection
88852785|NCT05894694|Other|palliative care group first-line scheme|palliative care group first-line regimen (FOLFOX/FOLFIRI/CAPEOX± Cetuximab/bevacizumab)
88852786|NCT05894642||Long Covid Pain Patients|
88852787|NCT05894642||Control Group, healthy people|Patients that had had Covid-19 but did not developed chronic pain or other chronic symptoms.
88852788|NCT05894629|Experimental|Pain Neuroscience Education (PNE)+ Therapeutic Exercise (TE)|"Intervention Group (IG):~12-week program consisting of:~6 PNE sessions (1 session of 90 minutes per week for 5 weeks).~19 sessions of TE (2-3 weekly sessions of 60 minutes, for 7 weeks)."
88852789|NCT05894629|Active Comparator|Usual treatment|Delivery of a printed document with exercises to be performed at home for patients with persistent pain endorsed by a Scientific Society, as has been done in the Spanish Health Care Public System's usual practice with patients with chronic pain.
89182737|NCT06237452|Placebo Comparator|Placebo|Subjects assigned to the placebo arm will take 3 placebo capsules per day for 14 days after completing 10 to 21 days of standard of care antibiotic treatment for the qualifying CDI episode.
89182738|NCT06237426|Experimental|Treatment (Methylone)|
89379373|NCT02327806|Other|30 minutes of pulsed electromagnetic field therapy|30 minutes of pulsed electromagnetic field therapy
89379374|NCT04926454|Experimental|TAP block|patients will receive general anesthesia followed by Tap block at the end of the operation.
88852790|NCT05894616||Post acute sequale of COVID-19 (PASC)|"Verified infection with SARS-CoV-2 during wave 1 and 2 (i.e. wild type or alfa variants), prior to 2021-02-28. Diagnosed with post-COVID.~Experience of dyspnea (mMRC>3 within past 2 weeks) is a required inclusion criteria, with the addition of one of the following: lung obstruction (FEv1/FVC>70 or Z-score < -1.64), lung restriction (FEV1<80% or FVC < 80%, air-trapping, ground glass- or mosaic attenuation observed by HRCT."
88852791|NCT05894616||Healthy control recovered from COVID-19|Verified infection with SARS-CoV-2 during wave 1 and 2 (i.e. wild type or alfa variants), prior to 2021-02-28. Fully recovered within 12 weeks of primary infection. No other diagnoses.
88852792|NCT05894551||healthy participants|Volunteers aged 18-25 years, healthy individuals without any spinal or neurologic injury and any injury leading to ligament, muscle or bone defect in their lower extremities
89002652|NCT06277687|Experimental|perforator localization|Virtual Augmented Reality combined with Finder and Color Doppler Ultrasound were used to locate the perforating branch of the descending branch of the lateral circumflex femoral artery, and the position of the perforator was compared with real perforator respectively during the operation.
89379375|NCT04926454|Experimental|Caudal block|patients will receive general anesthesia followed by caudal block at the beginning of the operation.
89379376|NCT03196167|Experimental|Sugammadex|Research pharmacy will provide the Sugammadex (2m/kg) vs. Placebo in a syringe.
89379377|NCT03196167|Placebo Comparator|Placebo|Research pharmacy will provide the Sugammadex (2m/kg) vs. Placebo in a syringe.
89379378|NCT03652376|Experimental|Benralizumab|Patients will be treated with Benralizumab 30 mg s.c. every 4 weeks (three times).
89002653|NCT06276231|Placebo Comparator|Control Group|Patients in this group will receive the standard treatment (75mg IM Diclofenac ) + nebulized 0.9% normal saline.
89002654|NCT06276231|Experimental|Intervention Group|Patients in this group will receive the standard treatment (75mg IM Diclofenac ) + nebulized 10 mg of Nebulized Salbutamol.
89379379|NCT04875988|Active Comparator|POCUS-assisted IV placement|using ultrasound to help with placement
89379380|NCT04875988|Active Comparator|Traditional IV placement|Standard of care
89379381|NCT03411863|Active Comparator|Participants without neurological disease|Participants without neurological disease. All subjects undergo the same full protocol.
89379382|NCT03411863|Experimental|Participants with ALS|Participants with ALS. All subjects undergo the same full protocol.
89379383|NCT04262726|Experimental|REMOTION + TAU|Participants in the REMOTION group receive REMOTION in addition to psychotherapy at the outpatient clinic of the Department of Clinical Psychology and Psychotherapy at the University of Bern.
89379384|NCT04262726|Active Comparator|TAU|Participants in TAU receive psychotherapy at the outpatient clinic of the Department of Clinical Psychology and Psychotherapy at the University of Bern.
89379385|NCT03719027|Experimental|Study population|Patients followed-up after the diagnosis of pulmonary embolism (PE) Patients who survived after a PE and who consent to participate to the prospective interventional phase of the PREVA-CTEPH study have dyspnea assessment, EKG, and echocardiography to investigate the diagnosis of CTEPH
89379386|NCT04256876|Active Comparator|Active TTNS|Children treated by transcutaneous tibial nerve stimulation. TENS device connected to adhesive electrodes. Stimulation settings: 200 µS, 20 Hz, 1-20 V ( depending of sensory response) Home-therapy: Daily stimulation during 60 minutes.
89379387|NCT04256876|Sham Comparator|TTNS sham intervention|"Children treated by TTNS with same positioning as the active TTNS treatment. Stimulation settings: 200 µS, 20 Hz, 0-1 V. Patients and parents will be told that electric currence is given, but that no sensation will be feld.~Home therapy: Daily stimulation during 60 minutes."
89379388|NCT04808284|Experimental|tDCS-SMA|Participants randomized to this arm will receive a single tDCS session delivered at 2mA to the supplementary motor area (SMA) for 30 minutes.
88852793|NCT05894512||Study Group (Primary Membranous Nephropathy)|"Patients with biopsy-proven primary membranous nephropathy will be included (n=30).~Samples will be collected from patients diagnosed with primary MN before starting conventional immunosuppressive therapy with calcineurin inhibitors (CNI) and corticosteroids (CS) and at 3, 6, 12, 18 and 24 months after starting the treatment.~In case of failure after treatment with CNIs and CS treatment, rituximab (RTX) is used. If patient switches to RTX, samples will be taken before and 1, 3, 6, 12, 18, and 24 months after the first dose of RTX.~If relapse occurs, sampling will be done regardless of the timing.~Treatment decisions will solely be made in line with the guidelines, and there will be no intervention."
88852794|NCT05894512||Control Group 1 (IgA Nephropathy)|"After the patient group sampling is completed, a 1:1 diseased control group will be formed from patients with primary IgA nephropathy according to the distribution of age and sex (n=30).~Samples will be collected from the patients for one time only (cross-sectional sampling)."
88852795|NCT05894512||Control Group 2 (Healthy Volunteers)|"After the patient group sampling is completed, a 2:1 healthy control group will be formed from healthy volunteers according to the distribution of age and sex (n=15).~Samples will be collected from healthy volunteers for one time only (cross-sectional sampling)."
88852796|NCT05894486|Experimental|Lutetium[177Lu] Oxodotreotide Injection|"Treatment consisted of a cumulative administered radioactivity of 29.6 Giga Becquerel (GBq) (800 mCi) Lutetium[177Lu] Oxodotreotide Injection: Four administrations of 7.4 GBq (200 mCi).~Concomitant amino acids were given with each administration for kidney protection.~Lutetium[177Lu] Oxodotreotide Injection was administered at 8 +/- 1-week intervals, which could be extended up to 16 weeks to accommodate resolving acute toxicity.~In case participants experienced clinical symptoms (i.e. diarrhoea and flushing) associated with their carcinoid tumours, Octreotide s.c. rescue injections were allowed."
88852797|NCT05894447|Experimental|Naptumomab estafenatox in combination with pembrolizumab preceded by Obinutuzumab|"The study will test two doses of NAP 5 µg/kg/day IV (Dose Level 1) and 10 µg/kg/day IV (Dose Level 2), in combination with a fixed dose of pembrolizumab (200mg IV every 3 weeks). NAP will be given on Days 1-4 of each 21 day cycle for 6 cycles. Pembrolizumab will be given on Day 2 of each 21-day treatment cycle for the first 6 cycles and then as monotherapy every 21 days for up to a total of 34 administrations. Two doses of Obinutuzumab 1,000 mg IV will be given before starting NAP and pembrolizumab on Days - 13 and -12.~Pembro 200 mg i.v. Day 2 of each 21-day treatment cycle for the first 6 cycles"
88852798|NCT05894434|Experimental|Standard Intervention: Multisensory Training|Patients with stable hemianopia (>6 months) are given multisensory training
89379389|NCT04808284|Experimental|tDCS- DLPFC|Participants randomized to this arm will receive a single tDCS session delivered at 2mA to the right (cathodal) and left (anodal) dorsolateral prefrontal cortex (DLPFC) for 30 minutes.
89379390|NCT04808284|Sham Comparator|tDCS- SHAM|Participants randomized to this arm will receive a single session of Sham tDCS for 30 minutes, delivered to supplementary motor area (SMA) or to the right (cathodal) and left (anodal) dorsolateral prefrontal cortex (DLPFC).
88852799|NCT05894434|Active Comparator|Standard Intervention: Unisensory Training|Patients with stable hemianopia (>6 months) are given auditory training and crossover to multisensory training
88852800|NCT05894434|Experimental|Early Intervention: Multisensory Training|Patients with early hemianopia (<1 months) are given multisensory training
88852801|NCT05894434|Active Comparator|Early Intervention: Unisensory Training|Patients with early hemianopia (<1 months) are given auditory training and crossover to multisensory training
88852802|NCT05894408||patients with portal vein occlusion|
88852803|NCT05894408||patients without portal vein occlusion|
88852804|NCT05894382|Experimental|Group A|Double Helix Design Defocus Lens Spectacle (RACE) for 2 years
88852805|NCT05894382|Placebo Comparator|Group B|"st year: single-vision spectacle lenses~nd year: double helix design defocus lens spectacle (RACE)"
88852806|NCT05894369||Neoadjuvant chemotherapy combi|
88852807|NCT05894343|No Intervention|Follow-up group|Participants who were randomized to immediate treatment in Study MGT-GAD-025 will transition directly to a long-term follow-up schedule to complete an additional 54 months of follow-up. All study participants are to be followed for a period of 60 months after vector administration.
89379391|NCT05197803|Experimental|Hearing aid model|Unaided, Unitron RIC and Unitron BTE hearing aid styles during one-time visit.
89379392|NCT04054700|Experimental|distal upper rehabilitation robot|experimental group that applied the distal upper rehabilitation robot
89379393|NCT04054700|Other|proximal upper rehabilitation robot|control group that applied the proximal upper rehabilitation robot
89379394|NCT05387044|Experimental|SBRT|Patients with oligoprogressive NSCLC after first line treatment with immune checkpoint inhibitors will be treated with SBRT for all progressing lesions.
89379395|NCT03142828|Active Comparator|Test (clorhexidine gel)|The healing abutments were covered by a chlorhexidine gel after the first week of the second surgery (2-stage implants).
89379396|NCT03142828|Placebo Comparator|Placebo|The healing abutments were covered without any antiseptic gel after the first week of the second surgery (2-stage implants).
89379397|NCT01372839|Active Comparator|Atorvastatin|80mg/d ×2d before PCI. After PCI, atorvastatin 40mg/d until 30 days later, and then followed by usual care
89379398|NCT01372839|Other|Usual care|statin dose should not be higher than that described in exclusion criteria.
89379399|NCT01065350|Active Comparator|Propofol|As part of the induction, patients will be given 2 milligrams of propofol per kilogram (mg/kg) of body weight. The clinician will receive a 20 milliliter (mL) syringe of propofol. If the dose, 2 mg/kg, does not add up to a total of 20 mL, normal saline will be added to make up for the 20 mL.
89379400|NCT01065350|Experimental|Ketofol|"As part of the induction, patients will be given 20 mL syringe of an admixture called ketofol, which combines ketamine and propofol in one syringe. The dose is weight-based such that ketamine will represent 0.75 mg/kg of the dose and propofol, 1.5 mg/kg of the dose."
89379401|NCT03434249|Experimental|Group I|patients who take Bifidobacterium BB-12® (Bifidolactis Infant), 6 drops a day (guaranteeing a billion of living cells) for 28 consecutive days;
89379402|NCT03434249|Placebo Comparator|Group II|patients who take Bifidolactis Infant Placebo 6 drops a day for 28 consecutive days.
88852808|NCT05894343|Experimental|Active treatment group|Participants who were randomized to sham surgery in Study MGT-GAD-025 will transition to an active treatment schedule including open-label bilateral treatment upon confirmation of continued eligibility. Upon completion of the treatment period, participants will enter the long-term follow-up schedule to complete a total of 60 months of follow-up.
88852809|NCT05894278||Compliance|Prescription properly filled for specific parameters
88852810|NCT05894278||Non Compliance|Prescription is not filled with specific parameters
88852811|NCT05894278||Not available - NA|Prescription does not contain specific data
88852812|NCT05894265|Experimental|ActiveMatrix® Dosage A|
88852813|NCT05894265|Experimental|ActiveMatrix® Dosage B|
88852814|NCT05894265|Placebo Comparator|Saline Injection|
88852815|NCT05894252|Experimental|Experimental walking group|Participants in the intervention group will need to engage in a 30-minute walk on five days every week for a duration of 12 weeks. To assist them in monitoring their activity and complying with the intervention guidelines, participants will receive a complimentary fitness watch. Weekly step counts will be collected from participants, who will report their data through a researcher-provided online link. The watch will come with an accompanying app for participants to access their data, but the researchers will not have access to this app.
88852816|NCT05894252|No Intervention|Control|In the control group, participants will not be required to complete the 30 minutes of walking every day. Instead, they will be asked to continue with their daily routines and usual level of physical activity. participants will receive a complimentary fitness watch. Weekly step counts will be collected from participants, who will report their data through a researcher-provided online link. The watch will come with an accompanying app for participants to access their data, but the researchers will not have access to this app.
88852817|NCT05894226|Experimental|laparoscopic ventral mesh rectopexy arm|those who were underwent laparoscopic ventral mesh rectopexy for rectocele.
88852818|NCT05894161|Experimental|Group-I|Group-1: Twenty-five adult patients with SCD will receive a designed exercise program of physical therapy for relief pain and improve sleep quality (experimental group). The designed exercise program will be distributed on everyone. The recommendations will be to train from 30 to 45 minutes, 3 days per week for 6 weeks in addition to walking 30 minutes on the ground surface daily.
88852819|NCT05894161|No Intervention|Group-II|Group-2: Twenty-five adult patients with SCD will participate as a control group they will not receive exercise program.
88852820|NCT05894148|Experimental|Genakumab injection|Group 1: 120mg，group 2: 200mg
88852821|NCT05894148|Placebo Comparator|placebo|The placebo contains other excipients except Genakumab, and its appearance is consistent with that of Genakumab for injection
88852822|NCT05894135|Experimental|BG2109 100 mg group|
88852823|NCT05894135|Experimental|BG2109 200 mg +ABT group|
89379403|NCT03142906|Experimental|Scan group|Patients randomized to the scan group (intervention arm) will receive a preoperative point-of-care ultrasound (POCUS) exam as an adjunct to their preoperative assessment, the results of which will be disclosed to the anesthesiologist and the patient care team. This POCUS exam will include a focused cardiac ultrasound, a lung and pleural ultrasound, and a gastric volume and content ultrasound assessment. Patients randomized to this arm may also receive repeat POCUS exams as needed and as clinical conditions change. These repeat exams may be requested by the anesthesiologist or patient care team.
89379404|NCT03142906|No Intervention|No scan group|Patients randomized to no scan (control arm) will not receive a preoperative point-of-care ultrasound exam. Patients in this arm will receive the standard-of-care; a routine preoperative assessment and physical examination by their attending anesthesiologist.
88852824|NCT05894135|Placebo Comparator|Placebo group|
88852825|NCT05894044|Experimental|Russian current 10%|Subjects will receive a interventions (Russian Current at 10% duty cycle). Evoked torque, muscle fatigue, sensory discomfort, and peripheral oxygen extraction will be evaluated.
88852826|NCT05894044|Experimental|Aussie current 10%|Subjects will receive a interventions (Aussie Current at 10% duty cycle). Evoked torque, muscle fatigue, sensory discomfort, and peripheral oxygen extraction will be evaluated.
88852827|NCT05894044|Experimental|Pulsed current 500 µs phase|Subjects will receive a interventions (Pulsed current with 50 Hz, 500 µs phase). Evoked torque, muscle fatigue, sensory discomfort, and peripheral oxygen extraction will be evaluated.
88852828|NCT05894044|Experimental|Pulsed current 200 µs phase|Subjects will receive a interventions (Pulsed current with 50 Hz, 200 µs phase). Evoked torque, muscle fatigue, sensory discomfort, and peripheral oxygen extraction will be evaluated.
88852829|NCT05894031|Experimental|Intervention|The intervention group was instructed to perform the Wim Hof Method daily over the course of 15 days. The participants could choose when to do so throughout the day, however, the components were to be performed in a strict, sequential order: breathing exercises, followed by meditation, and then cold exposure. Participants were asked to complete a daily log in which they documented whether they performed the procedure and for how long. Altogether, the procedure lasted about 15 minutes.
88852830|NCT05894031|No Intervention|Control|The control group received noch intervention throughout the intervention period.
89379405|NCT03033693|Other|The deep anesthesia group|
89379406|NCT03033693|Other|The light anesthesia group|
89379407|NCT05079490|No Intervention|Baseline|All children will receive outcome measures.
89379408|NCT05079490|Experimental|Intervention phase|Children in the experimental group will receive intervention for 12 weeks while children in the control group remain their regular activities.
89379409|NCT05079490|No Intervention|Follow up phase|All children will be followed after the end of intervention phase and receive outcome measures at 3- and 6-month after the completion of intervention.
89379410|NCT02914977|Experimental|Low-dose daunorubicin (DNR)|Eligible patients will be treated with 5 days of low dose daunorubicin (DNR) for one cycle only.
89379411|NCT03718715||prospective cohort|All participants receive Metformin in accordance to the ordinary therapy practice. They will be part of one subject group/cohort. After onset of metformin treatment the subjects who develop gastrointestinal side effects will be compared with cases without gastrointestinal side effects.
89379412|NCT05053347|Experimental|Flaxseed oil|Flaxseed oil capsule, 5g/d(ALA2.5g/d)
89379413|NCT05053347|Placebo Comparator|Corn oil|Corn oil capsule, 5g/d
88852831|NCT05893992|Experimental|Hearing loss|All participants will have hearing loss and be assigned to all three interventions. The interventions consist of aided-omnidirectional, aided-directional, and no hearing aids (no intervention).
89379414|NCT05079022|Experimental|Furmonertinib|ctDNA-MRD positive participants received 3 years of furmonertinib once daily as adjuvant therapy after radical surgery until disease progression or unacceptable toxicity occurs.
89379415|NCT05078788|Experimental|Laser uretherotomy|Using Holmium laser uretherotomy only in the treatment of bulbar uretheral stricture
89379416|NCT05078788|Experimental|Laser uretherotomy with intralesional steroids|Using holmium laser uretherotomy with injection of 80 mg of triamcinolone (diluted with normal saline to 10 ml) in the treatment of bulbar uretheral stricture
89379417|NCT02032654|Active Comparator|Standard course|Flucloxacillin (1000mg iv OR, later, 500mg capsules), every 6 hours, for 6 days, followed by: Flucloxacillin 500mg capsules, every 6 hours, for 6 days
89379418|NCT02032654|Experimental|Short course|Flucloxacillin (1000mg iv OR, later, 500mg capsules), every 6 hours, for 6 days, followed by: Placebo (for flucloxacillin 500mg) 500mg capsules, every 6 hours, for 6 days
89379419|NCT04737694|Experimental|Ketone + Carbohydrate|573 mg/ kg body weight ketone ester + 110 g glucose
89379420|NCT04737694|Active Comparator|Carbohydrate|Isocaloric amount of glucose to match ketone + carbohydrate
89379421|NCT04734886|Active Comparator|L. reuteri DSM 17938|Probiotic compound
89379422|NCT04734886|Placebo Comparator|Placebo|Placebo compound
89379423|NCT03142282|Active Comparator|Maintenance chemotherapy|FDA approved drugs for the study population: Bevacizumab, Xeloda
89379424|NCT03142282|Experimental|Radiotherapy|consolidative radiotherapy plus maintenance chemotherapy
89379425|NCT03114969||Subjects using RELVAR ELLIPTA|Subjects with a fixed dose combination of inhaled corticosteroids/ long-acting beta agonists (ICS/LABA) via a single DPI of RELVAR ELLIPTA for treatment of COPD will be included.
89379426|NCT03114969||Subjects using SYMBICORT TURBUHALER|Subjects with a fixed dose combination of ICS/LABA via a single DPI of SYMBICORT TURBUHALER for treatment of COPD will be included.
88852832|NCT05893953|Experimental|Normal Healthy Students(Condition A)|sitting in a standard chair wearing an immediately feedback device
88852833|NCT05893953|Experimental|Normal Healthy Students(Condition B)|sitting in a gym-ball
89379427|NCT03114969||Subjects using SERETIDE DISKUS|Subjects with a fixed dose combination of ICS/LABA via a single DPI of SERETIDE DISKUS for treatment of COPD will be included.
89379428|NCT03114969||Subjects using SPIRIVA HANDIHALER|Subjects with a fixed dose monotherapy of long-acting muscarinic antagonists (LAMA) via a single DPI of SPIRIVA HANDIHALER for treatment of COPD will be included.
89379429|NCT03114969||Subjects using INCRUSE ELLIPTA or ANORO ELLIPTA|Subjects with a fixed dose monotherapy of LAMA via a single DPI of INCRUSE ELLIPTA or subjects taking a fixed dose combination of LAMA/LABA via a single DPI of ANORO ELLIPTA for treatment of COPD will be included.
89379430|NCT03114969||Subjects using SEEBRI BREEZHALER or ULTIBRO BREEZHALER|Subjects with a fixed dose monotherapy of LAMA via a single DPI of SEEBRI BREEZHALER or subjects taking a fixed dose combination of LAMA/LABA via a single DPI of ULTIBRO BREEZHALER for treatment of COPD will be included.
89379431|NCT03114969||Subjects using RELVAR ELLIPTA with HANDIHALER/ INCRUSE ELLIPTA|Subjects with a fixed dose combination of ICS/LABA via RELVAR ELLIPTA along with a fixed dose of LAMA via SPIRIVA HANDIHALER or INCRUSE ELLIPTA will be included.
89379432|NCT03114969||Subjects using TURBUHALER with HANDIHALER/INCRUSE ELLIPTA|Subjects with a fixed dose combination of ICS/LABA via SYMBICORT TURBUHALER along with a fixed dose of LAMA via SPIRIVA HANDIHALER or INCRUSE ELLIPTA will be included.
89379433|NCT03114969||Subjects using DISKUS with HANDIHALER/INCRUSE ELLIPTA|Subjects with a fixed dose combination of ICS/LABA via SERETIDE DISKUS along with a fixed dose of LAMA via SPIRIVA HANDIHALER or INCRUSE ELLIPTA will be included.
89379434|NCT05078710|Experimental|Telitacicept arm|Telitacicept 160mg once a week for 24 week as an add-on treatment regimen.
89379435|NCT05078632||Healthy volunteers|healthy volunteers
89379436|NCT05078632||intensive care patient|patient hospitalized in intensive care unit
89379437|NCT03144778|Experimental|Cohort I (durvalumab)|Participants receive durvalumab IV over 1 hour on days 1 and 29 in the absence of disease progression or unaccepted toxicity. Between days 52 and 72, participants undergo standard of care surgery.
89379438|NCT03144778|Experimental|Cohort II (durvalumab, tremelimumab)|Participants receive durvalumab IV over 1 hour and tremelimumab IV over 1 hour on days 1 and 29 in the absence of disease progression or unaccepted toxicity. Between days 52 and 72, participants undergo standard of care surgery.
89379439|NCT02046096|Experimental|Günther Tulip® Vena Cava Filter|Günther Tulip® Vena Cava Filter
89379440|NCT02046096|Experimental|Cook Celect® Vena Cava Filters|Cook Celect® Vena Cava Filters
88852834|NCT05893953|Experimental|Normal Healthy Students(Condition C)|sitting in a standard chair(control group)
89379441|NCT03142360|Experimental|Treatment group|Within two days after successful arteriovenous graft surgery, the treatment group is randomly assigned to start taking 120 mcg of Berasil.
89379442|NCT03142360|No Intervention|Non-Treatment group|On the other hand, the control group does not take anything.
89379443|NCT05124678|Experimental|Fast/intermediate acetylators|"Participants in this arm have fast/intermediate acetylator status from NAT2 genotyping.~In the Intensive phase (Month 1-2) of treatment, they will receive; Oral Isoniazid 10mg/kg/day + Rifampicin, Ethambutol and Pyrazinamide at standard dose.~In the continuation phase (Month 3 - 6 ) of treatment, they will receive; Oral Isoniazid 5mg/kg/day +Rifampicin at standard dose"
89379444|NCT05124678|No Intervention|Slow acetylators|"Participants in this arm have a slow acetylator status from NAT2 genotyping. They will receive the standard of care. In the Intensive phase (Month 1-2) of treatment, they will receive; Oral Isoniazid 5mg/kg/day + Rifampicin, Ethambutol and Pyrazinamide at standard dose.~In the continuation phase (Month 3 - 6 ) of treatment, they will receive; Oral Isoniazid 5mg/kg/day +Rifampicin at standard dose"
89379445|NCT04668820|Experimental|Children who admit to Pediatric Rehabilitation outpatient clinic|Children who admit to Pediatric Rehabilitation outpatient clinic of the Department of Physical Medicine and Rehabilitation will be evaluated by face to face and virtually by using zoom application via video Pediatric Gait, Arms, Legs and Spine (V-pGALS)
89379446|NCT03463577||Exposed cohort women-on or after 1st day of 27th week of pregnancy|This group consisted of pregnant women who received the Tdap vaccine (Boostrix) on or after the 1st day of the 27th week of pregnancy during the period January 1, 2018 to January 31, 2019 who were not vaccinated with any other Tdap vaccine at any other time during the pregnancy.
89379447|NCT03463577||Unexposed historical cohort women|This group consisted of women matched to Exposed cohort women-on or after 1st day of 27th week of pregnancy group and pregnant at least one day during the historical period between January 1, 2012-December 31, 2014 and did not receive any Tdap vaccine during the pregnancy.
89379448|NCT03463577||Exposed cohort women-before 1st day of 27th week of pregnancy|This group consisted of pregnant women who received the Tdap vaccine (Boostrix) before the 1st day of the 27th week of pregnancy during the period January 1, 2018-January 31, 2019 who were not vaccinated with any other Tdap vaccine at any other time during the pregnancy.
89379449|NCT03463577||Exposed cohort infants-on or after 1st day of 27th week of pregnancy|This group consisted of infants whose mothers belong to Exposed cohort women-on or after 1st day of 27th week of pregnancy group.
89379450|NCT03463577||Unexposed historical cohort infants|This group consisted of infants whose mothers belong to the Unexposed historical cohort women group.
89379451|NCT03463577||Exposed cohort infants-before 1st day of 27th week of pregnancy|This group consisted of infants whose mothers belong to the Exposed cohort women-before 1st day of 27th week of pregnancy group.
89379452|NCT04667884|Experimental|Group A|a mixture of Xylooligosaccharides, Stachyose, Fructooligosaccharides, and Water-soluble Dietary Fiber, 12 g/d, 4 weeks
89379453|NCT04667884|Experimental|Group B|a mixture of Fructooligosaccharide, water-soluble dietary fiber, polydextrose, and isomalt oligosaccharide, 12 g/d, 4 weeks
89379454|NCT04667884|Experimental|Group C|a mixture of Polydextrose, wheat fiber, and Seed shell of Plantago rotundifolia, 12 g/d, 4 weeks
89379455|NCT04667884|Experimental|Group D|a mixture of Fructooligosaccharides, Bifidobacterium lactis HN019 and Lactobacillus rhamnosus HN001, 3 g/d, 4 weeks
89379456|NCT04667884|Placebo Comparator|Group E|Maltodextrin， 3 g/d, 4 weeks
89379457|NCT05761002|Experimental|treatment group|"All patients will be subjected to:~A thorough history taking and proper dermatological examination.~Skin sampling from anogenital wart lesions: skin sterilization followed by injection of local anesthesia at the base of lesions, then the part of wart above skin surface will be removed using shave biopsy technique.~DNA extraction of skin samples.~Conventional PCR for low-risk HPV genotypes (6,11) and RT-PCR for high-risk HPV genotypes.~Intralesional injection of the quadrivalent HPV vaccine (Gardasil) at a dose of 0.5ml, into the largest wart at 4-week intervals until complete clearance is achieved or for a maximum of three sessions."
89379458|NCT03424824|Experimental|BP1.3656 low dose|administration of BP1.3656 at 30 µg
89379459|NCT03424824|Experimental|BP1.3656 intermediate dose|administration of BP1.3656 at 60 µg
89379460|NCT03424824|Placebo Comparator|Placebo|administration of placebo
89379461|NCT03424824|Experimental|BP1.3656 high dose|administration of BP1.3656 at 90 µg
89379462|NCT04661956|Experimental|Transbronchial cryobiopsy|Transbronchial cryobiopsy was performed in the patiens of pulmonary peripheral nodule
89379463|NCT04661956|Other|Transbronchial lung biopsy|Transbronchial lung biopsy was performed in the patiens of pulmonary peripheral nodule
88852835|NCT05893849||Older adults|Aged 60-74 years old, takes omeprazole or rabeprazole or pantoprazole or metoprolol or carvedilol or amlodipine or finasteride or simvastatin or rivaroxaban or meropenem or atorvastatin or rosuvastatin or metformin
88852836|NCT05893849||Old older adults|Aged >75 years old, takes omeprazole or rabeprazole or pantoprazole or metoprolol or carvedilol or amlodipine or finasteride or simvastatin or rivaroxaban or meropenem or atorvastatin or rosuvastatin or metformin
89379464|NCT05060172|Experimental|Bloomlife MFM-Pro|
89379465|NCT04983927||Ischemic stroke positive|Patients diagnosed with acute ischemic stroke after a brain CT scan
89379466|NCT04983927||Ischemic stroke negative with other brain disease|Patients who has not been diagnosed with acute ischemic stroke after a brain CT scan, but has been diagnosed with other brain diseases.
89379467|NCT04983927||Ischemic stroke negative and no brain disease|Patients who has not been diagnosed with acute ischemic stroke after a brain CT scan and has not been diagnosed with other brain diseases.
89379468|NCT01477008|Experimental|BiCRI|BiPhasic Cartilage Repair Implant
88810427|NCT06213506|Experimental|Infants_6W_Dose A_2 Group|Infants 6 weeks of age, part of the dose-finding cohort, randomized to receive 3 doses of the iNTS-GMMA Dose A vaccine at Day 1, Day 57 (during the Priming phase) and at Day 232 (during the Booster phase). These infants also receive an EPI vaccination with the following vaccines: Measles and Rubella Vaccine (MR-VAC) and Yellow Fever (YF) vaccine administered concomitantly during the last iNTS-GMMA administration at Day 232, and the pentavalent vaccine (DTPwHepB-Hib), the Pneumococcal conjugate vaccine, and the inactivated polio vaccine administered at the same time, at 6, 10 and 14 weeks of age, at the local EPI vaccination centers, and not part of the current clinical trial.
88852837|NCT05893784|Experimental|END|Use of progressive relaxation exercises education
89379469|NCT01477008|Active Comparator|Marrow Stimulation|Microfracture or Subchondral Drilling
89379470|NCT01374399|Experimental|resistance and endurance exercise|
89379471|NCT01374399|Active Comparator|relaxation|
89379472|NCT04598386|Experimental|PR Lotion Topical Solution|Approximately 50 grams of PR Lotion will be applied by the participants to their upper extremities (arms) in addition to their neck, upper back, chest, and midsection if necessary. This lotion will be applied once during the 4th of session of their PR Lotion Phase and will remain on the skin for approximately 4.5 hours.
89379473|NCT04598386|Placebo Comparator|Placebo Lotion Topical Solution|Approximately 50 grams of the Placebo Lotion will be applied by the participants to their upper extremities (arms) in addition to their neck, upper back, chest, and midsection if necessary. The only difference in ingredients for this Placebo Lotion will be the exclusion of the sodium bicarbonate ingredient. This lotion will be applied once during the 4th of session of their Placebo Lotion Phase and will remain on the skin for approximately 4.5 hours.
89379474|NCT01374477||Adolescent with preeclampsia|Patients < 19 years old who delivered in our institution (vaginal birth or cesarean) that developed a hypertensive disorder of pregnancy.
89379475|NCT01374477||Normal adolescent|Patients < 19 years old who delivered in our institution (vaginal birth or cesarean) without developing a hypertensive disorder of pregnancy.
89379476|NCT01372917||Allomax|The cohort consists of immediate breast reconstruction patients who have AlloMax placed at the time of their tissue expander based immediate breast reconstruction.
89379477|NCT02861820||Substance Use Disorder (SUD)|"Participants in the SUD group will:~Complete a diagnostic screening interview at baseline.~Complete questionnaires and computer tasks at baseline, 1 month and 2 month time points.~Complete MRI brain imaging data collection at the baseline, 1 month and 2 month time points.~Complete 9 follow-up phone calls to assess for relapse."
89379478|NCT02861820||Healthy Control (HC)|"Participants in the HC group will:~Complete a diagnostic screening interview at baseline.~Complete questionnaires and computer tasks at baseline and 2 month time points.~Complete MRI brain imaging data collection at the baseline and 2 month time points."
89379479|NCT03122145|Experimental|Healthy Volunteers - Experiment 1|This study will involve a single 60-minute visit. All women under the age of 62 will be asked to complete a pregnancy test as part of the screening process during to radiation exposure. Eligible participants will then undergo voluntary and reflexive cough testing. The entire duration of the exam will be under 60 minutes and the participant will be free to leave at any point during the examination.
88852838|NCT05893784|No Intervention|END free|patient witout of progressive relaxation exercises education
88852839|NCT05893745|Active Comparator|Control Group|Supervised Exercise Program
88852840|NCT05893745|Experimental|Study Group|Combination of Exercise and Dermoneuromodulation Techniques
88852841|NCT05893732|Experimental|High-Intensity Laser Therapy (HILT) Group|Participants in this group will receive High-Intensity Laser Therapy (HILT) treatment for Meralgia Paresthetica (MP).
88852842|NCT05893732|Sham Comparator|Sham High-Intensity Laser Therapy (Sham HILT) Group|Participants in this group will receive sham High-Intensity Laser Therapy (sham HILT) treatment for Meralgia Paresthetica (MP).
88852843|NCT05893719||Experimental: iNedit, iNdeep, iNtercept|Study devices
88852844|NCT05893693|Experimental|CT0594CP CAR-T Cells [BCMA-UCAR-T (CT0594)andCD94-UCAR-T(CT7590) ]|CT0594CP
88852845|NCT05893654|Experimental|Single Arm|Participants will undergo intra-arterial catheterization of the ophthalmic artery, with administration of 7.5mg of melphalan. After 4±1 weeks, they will receive Ru-106 plaque brachytherapy, which will be performed using a 24-mm notched plaque. Due to tumor thickness and the previous IAC, the target dose to the tumor apex shall be as close as possible to 80 Gy, respecting the safety limits regarding the risk of excessive dosage to the tumor base and scleral melting.
88852846|NCT05894083|Active Comparator|Surgery|Surgery followed by risk-adjusted adjuvant treatment (observation, radiation, or chemoradiation).
88852847|NCT05894083|Experimental|Definitive CRT|Risk-adjusted definitive chemoradiation.
88852848|NCT05893615|Active Comparator|CBT group|Patients in the CBT intervention group, who received CBT focused on anxiety symptoms in addition to their usual treatment, including 10 one-hour sessions spread over 10 weeks, and weekly homework guided by the therapist.
89379480|NCT03122145|Experimental|Healthy Volunteers - Experiment 2|This study will involve a single 60-minute visit. All women under the age of 62 will be asked to complete a pregnancy test as part of the screening process during to radiation exposure. Eligible participants will then undergo a instrumental swallowing evaluation (videofluoroscopy). The entire duration of the exam will be under 60 minutes and the participant will be free to leave at any point during the examination.
89379481|NCT05081830|Experimental|transdiagnostic intervention via the Internet|Treatment provided in eight individual sessions of 60 min., Once a week by videoconference. The integrity of the treatment will be controlled through the therapist's manual (Barlow et al., 2011) adapted for the Mexican population and to the online modality.
89379482|NCT05081830|Active Comparator|TCC intervention via the Internet|The TCC intervention program is short, with active, focused and directive participation, in 8 individual weekly sessions of one hour by videoconference.
89379483|NCT05081830|No Intervention|waiting list control.|Participants in the control group on the waiting list will be assigned to the intervention after 2 months after randomization and will join the Transdiagnostic intervention.
89379484|NCT05150535|Active Comparator|Hypofractionation control arm|Patients who will receive 40 Gy in 15 fractions to the entire breast or chest wall over three weeks and have had breast conservation surgery (BCS) or oncoplastic breast surgery(OBS) will receive an additional boost to the tumour site if and will receive sequential dose 12GY\4 fractions or SIB 8GY 15 fractions. The supraclavicular fossa will be treated in patients with node-positive disease or those who had received neoadjuvant chemotherapy . The IMLN will be irradiated in N2and N3 at first presentation.
89379485|NCT05150535|Experimental|. Ultrahypofractionation experimental arm|Patients who will receive 26 Gy in 5 fractions to the entire breast and or chest wall for one week only. The volume of this arm will be the same as the volume of the control arm as regard axillary nodes, supraclavicular and IMLN. Patients who have had breast conservation or oncoplastic breast surgery(OBS) will be given a boost. If a boost is given, SIB of 6 Gy in 5 fractions will be used (or a sequential boost of 12GY\4 fractions).
89379486|NCT00138372||Adult Repeat Cross-Sectional study (ARCS)|This group will be enrolled from the sub-location of Kanyawegi, Kisumu District, Nyanza Province.
89379487|NCT00138372||Prospective Infant Cohort study (PIC)|will be a clinic-based study recruiting infants attending Chulaimbo Rural Health Training Center (CRHTC), Maseno Division, Kisumu District, Nyanza Province for routine immunizations.
89379488|NCT00138372||Normal volunteers|will be recruited from the CWRU/UHCMC area as well as general local community.
89379489|NCT05081440||patients diagnosed with hypertension or diabetes|Age ≥18 years; Patients with well-diagnosed hypertension (HTN) and/or type 2 diabetes (T2DM) and have been ill for ≥ 3 months; The patient underwent fasting lipid analysis in the past 1 month and the data was fully recorded
89379490|NCT02327650||RA and OA|Every 2 or 3 months, plain radiograph, blood and urinary tests, and MRI are performed in the painful joints of RA.
89379491|NCT03144856|Experimental|Apatinib group|Apatinib 500mg, po, QD, every 4 weeks.
89379492|NCT05080894|Experimental|Virtual reality|Daily 20-minute sessions of virtual reality based rehabilitation for the first 4 weeks post-operatively + standard rehabilitation protocol
89379493|NCT05080894|No Intervention|Standard intervention|Standard rehabilitation protocol only
89379494|NCT04949022|Experimental|Hybrid closed loop system|Initiation of 780G insulin pump. First two weeks run-in-phase in open loop Manual mode, followed by a12 month study phase with advanced hybrid closed loop Auto mode.
89379495|NCT05762562||Telerehabilitation with OS platforms|Patients with Parkinson's Disease were divided into three subgruops based on their residual motor skills.
89379496|NCT04457752|Active Comparator|Dual Layer Amniotic Membrane (DLAM) + SOC|DLAM (Up to 10 weekly DLAM applications) + Standard of Care (sharp debridement, offloading, and proper moisture balance).
89379497|NCT04457752|No Intervention|Standard of Care|Standard of Care: sharp debridement, offloading, and proper moisture balance.
89379498|NCT02327338|Experimental|continuous low level heat for neck|30 subjects to use ThermaCare heat wraps on their necks for 6 hours before home exercise programs each day for 10 days. Physical therapy 2 times per week will be used on days where heat wraps are not used.
89379499|NCT02327338|Experimental|Ibuprofen and continuous low level heat|30 subjects to use 1200 mg per day Ibuprofen dosed in 3 dosages 4 hours apart on the same days as heat wraps were to be used. ThermaCare heat wraps to be used on their necks for 6 hours before home exercise programs each day for 10 days. Physical therapy 2 times per week will be used on days where heat wraps and ibuprofen are not used.
89379500|NCT02327338|No Intervention|control|15 subjects with no heat or ibuprofen just physical therapy 2 times per week.
89379501|NCT02327338|Sham Comparator|sham heat and sham ibuprofen|30 subjects to use 1200 mg per day Ibuprofen sham dosed in 3 dosages 4 hours apart on the same days as sham heat wraps were to be used. ThermaCare heat sham wraps to be used on their necks for 6 hours before home exercise programs each day for 10 days. Physical therapy 2 times per week will be used on days where sham heat wraps andsham ibuprofen are not used.
89379502|NCT05080816|Active Comparator|Parenteral nutrition|Overnight infusion of parenteral nutrition. Supplied as all-in-one-bag format. Infusion rate of 0.2 g N/kg/day.
88852849|NCT05893615|No Intervention|Treatment as usual (TAU) group|Patients in TAU group received optimal medical care according to the current clinical guidelines. Patients in the TAU group did not receive any psychotherapy.
88852850|NCT05893602||Primary tumor prosthesis of the knee containing the PEEK HD coupling mechanism|This group consists of patients with a primary MUTARS knee endoprosthesis containing the PEEK-HD coupling mechanism.
89379503|NCT05080816|Active Comparator|Enteral nutrition|Oral nutrition drink. 2 * 200 ml on the night before operation. 1* 200 ml on the morning of operation day.
89379504|NCT05080816|Placebo Comparator|control|Overnight infusion of crystalloid fluid (Ringer acetate) infused at the same rate (ml/kg) as intervention PN
89379505|NCT02327416|Active Comparator|1,conventional control group|Drug: Entecavir and or adefovir dipivoxil are used for 96 weeks and the follow up 24 weeks. Entecavir 0.5mg po daily or plus ADV （adefovir dipivoxil）10mg po daily.
89379506|NCT02327416|Experimental|2，combination and sequential group|Drug: Y peginterferon Alfa-2b 180 micrograms sc/week for 96 weeks; Drug: Entecavir and or adefovir dipivoxil are used for 48 weeks. Entecavir 0.5mg po daily for 48 weeks or plus ADV 10mg po daily.
89379507|NCT02327416|Experimental|3, multitarget group|Drug: Y peginterferon Alfa-2b 180 micrograms sc/week for 96 weeks; Drug: Granulocyte-macrophage colony stimulating factor is used for 48 weeks; Drug: Entecavir and or adefovir dipivoxil are used for 48 weeks. Entecavir 0.5mg po daily for 48 weeks or plus ADV 10mg po daily.
89399450|NCT02174120|Experimental|Group B|During maintenance of anesthesia, Propofol was give by target controlled infusion, the effect-site concentration is 2 to 4 micrograms/ml to keep bispectral index between 40 to 60.
89399451|NCT02174120|Experimental|Group C|During maintenance of anesthesia, etomidate will be given by target controlled infusion for 2 h first, and then propofol will be given by target controlled infusion, the effect-site concentration is 0.3 to 0.6 micrograms/ml and 2 to 4 micrograms/ml, respectively. Bispectral index should be kept between 40 to 60.
89399452|NCT02175914|Experimental|Erythromycin|Oral treatment with Erythromycin 500mg twice daily.
88852851|NCT05893602||Revision tumor prosthesis of the knee containing the PEEK-HD coupling mechanism|This group consists of patients requiring revision surgery of their MUTARS knee endoprosthesis containing the MoM coupling mechanism (for any reason), which is exchanged/revised for the PEEK-HD coupling mechanism.
89379508|NCT05080582|Experimental|Mother-Scented Simulated Hand|The neonates received the same standard care of the NICU, while they wrapped with a warm Mother-Scented Simulated Hand as follow; simulated hand was scented with mothers' body odor by placing it on the mothers' bare chest or behind the neck for one hour. Then, the MSSH was placed under a radiant warmer for a couple of minutes to reach the mothers' unique warm touch. Inside the incubator, the mechanically ventilated neonates were placed in a side-lying flexed fetal position, where they encircled with the two warm simulated human hand to contain them. Where the palm of one MSSH cupped the neonates' head, and the palm of the other hand cupped the lower part of body and extremities. The neonates were kept in such a position throughout the mentioned invasive procedures, as shown in Figure 2. Neonates' physiological response, comfort, distress, and pain levels were assessed the same way as the first day.
89379509|NCT05080582|Active Comparator|NICU Standard Care|The neonates were provided with standard care, which entailed maintaining a quiet environment with minimal stimulation, uninterrupted periods of sleep, containment. Neonates were placed in a side-lying position, while their extremities were flexed close to the body and wrapped with rolled sheets or towels to simulate the intrauterine posture. This position was maintained during the performance of the invasive procedures.
89379510|NCT03114657|Placebo Comparator|Placebo|Participants received intravenous (IV) infusion of Placebo every 4 weeks (Q4W) for 100 weeks.
89379511|NCT03114657|Experimental|Crenezumab|Participants received intravenous (IV) infusion of Crenezumab every 4 weeks (Q4W) for 100 weeks.
89379512|NCT05071456|Experimental|Atopic dermatitis patients|
89379513|NCT05071456|Experimental|Patient with oily acne skin|
89379514|NCT05071456|Active Comparator|Control group of patient without facial dermatosis|
89379515|NCT04353934||Respondents|All adults aged 18 or older who elect to respond to the online survey
89379516|NCT02926950|Experimental|Sotagliflozin 400 mg + Metformin|Following a 2-week run-in period, sotagliflozin 400 mg was administered as 2 tablets, once daily, before the first meal of the day plus metformin as prescribed by the Principal Investigator for up to 26 weeks in the double-blind Core Treatment Period, and participants continued the same treatment in the double-blind Extension Period for up to 53 weeks.
89379517|NCT02926950|Placebo Comparator|Placebo + Metformin|Following a 2-week run-in period, matching placebo was administered as 2 tablets, once daily, before the first meal of the day plus metformin as prescribed by the Principal Investigator for up to 26 weeks in the double-blind Core Treatment Period, and participants continued the same treatment in the double-blind Extension Period for up to 53 weeks.
89379518|NCT03410693|Experimental|Rogaratinib|"Rogaratinib treatment study arm, comprising~Pre-treatment period, including FGFR testing and screening,~Treatment period, and~Follow-up period, including active follow-up and long-term follow-up. Patients will be considered on study during the pre-treatment, treatment and active followup periods. During the long-term follow-up period the patients will be considered off study."
89379519|NCT03410693|Active Comparator|Chemotherapy|"Chemotherapy treatment study arm, comprising~Pre-treatment period, including FGFR testing and screening,~Treatment period, and~Follow-up period, including active follow-up and long-term follow-up. Patients will be considered on study during the pre-treatment, treatment and active followup periods. During the long-term follow-up period the patients will be considered off study."
88852852|NCT05893589|Experimental|test|
88852853|NCT05893589|No Intervention|control group|
88852854|NCT05893550|Experimental|Both Parent and child|Smartfish Omega Both parent and child receive Omega-3 drink
89379520|NCT01064414|Experimental|Canagliflozin 100 mg|Each patient will receive 100 mg of canagliflozin once daily for 52 weeks.
89379521|NCT01064414|Experimental|Canagliflozin 300 mg|Each patient will receive 300 mg of canagliflozin once daily for 52 weeks.
89379522|NCT01064414|Placebo Comparator|Placebo|Each patient will receive matching placebo once daily for 52 weeks.
89379523|NCT04254172||Single cohort|There is no randomization or stratification in this study. All subjects will complete the same study assessments.
88852855|NCT05893550|Experimental|Parent Only|Smartfish Omega Only the parent receives Omega-3 drink, child receives Placebo.
88852856|NCT05893550|Experimental|Child Only|Smartfish Omega Only the child receives Omega-3 drink, the parent receives placebo
88852857|NCT05893550|Placebo Comparator|Neither|Smartfish Fruit Juice Only Neither parent nor child receives omega-3; both receive placebo (fruit juice).
88852858|NCT05893524||Patients undergoing memory assessments|Patients undergoing memory assessments at two specialist memory clinics (Uppsala University Hospital in Uppsala and Falu Hospital in Falun). This group includes patients with dementia, mild cognitive impairment and subjective cognitive impairment.
88852859|NCT05893524||Cognitively unimpaired community dwelling people|Age matched cognitively unimpaired community dwelling people recruited via advertisements.
88852860|NCT05893524||Cognitively unimpaired community dwelling people recruited for test-retest reliability analysis|Cognitively unimpaired individuals who agreed to participate in a retesting session.
88852861|NCT05893524||Persons with cognitive impairment recruited for test-retest reliability analysis|Patients undergoing memory assessment at Uppsala University Hospital who agreed to participate in a retesting session and community dwelling older persons with self-reported subjective or mild cognitive impairment. This group includes patients with dementia, mild cognitive impairment and subjective cognitive impairment.
89379524|NCT04944849||digital gamer group|Individuals with computer use more than 14 hours a week were included in this group.
89379525|NCT04944849||player group|Individuals with computer use less than 14 hours a week were included in this group.
89379526|NCT03433703|Experimental|Lenvatinib|Participants will receive lenvatinib 12 or 8 milligrams (mg) once daily in continuous 28-day cycles until disease progression, development of unacceptable toxicity, participant request, withdrawal of consent, or study termination by the sponsor. Upon completion of lenvatinib treatment, eligible participants will receive commercially available systemic TPC for hepatocellular carcinoma in the subsequent treatment period.
89399453|NCT03693729|Experimental|Active DLPFC during task|HD-tDCS will be applied over the DLPFC at 2mA in a single session for up to 30 min during the memory and metamemory task
89399454|NCT03693729|Active Comparator|Active DLPFC after task|HD-tDCS will be applied over the DLPFC at 2mA in a single session for up to 30 min after the memory and metamemory task and during a filler task.
89182739|NCT06237283|Experimental|Early shower|Start shower after drain removal
88852862|NCT05893511|Active Comparator|Antibiotics first group|Antibiotics first equals to intravenous antibiotics 2nd generation cephalosporin or equivalent). Antibiotics would first be given parenterally and then switched to oral form when patient can tolerate diet or when sepsis subside. It will be continued for at least a total of 7 days.
88852863|NCT05893511|Active Comparator|Endoscopic ultrasound-guided gallbladder drainage (EUS-GBD)|Prior to the procedure, the patients would be kept fasted for 6 hours and antibiotics would be commenced (2nd generation cephalosporin or equivalent). Antibiotics would be continued for up to one week after the procedure.EUS-GBD would be performed by either the conventional or direct method.
88852864|NCT05893485|No Intervention|Control|No Music Therapy
88852865|NCT05893485|Active Comparator|Music Therapy Intervention|Four music therapy sessions provided prior to delivery.
88852866|NCT05893472|Experimental|The treatment group receiving the combination of venetoclax and HAA regimen.|Received induction therapy protocol： Docetaxel (HHT) 2.5mg/㎡/day, days 3-7 Aclarubicin (Acla) 20mg/day, days 3-7 Cytarabine (Ara-c) 100mg/㎡/day, days 3-7 (given as a 24-hour infusion) Venetoclax (VEN): 100mg on day 1, 200mg on day 2, and 400mg on days 3-8.
88852867|NCT05892978|Experimental|Vascular imaging device with the infrared light group|The patient's vital signs, skin color and skin turgor will be evaluated and recorded in the PIVC procedure registration form. The skill duration will be measured and recorded by the researcher with a stopwatch. The selection of the necessary materials will not be added to this time, the chronometer will be started after the tourniquet is attached, and the time will end with the blood coming to the PIVC. Data obtained on PIVC placement; vein visibility, the catheter number used in the procedure, the time to identify the appropriate vein, the successful PIVC placement time, the number of attempts for successful catheter placement, the vein in which the catheter was placed, the pain and fear levels before, during and after the procedure. These data will be recorded in the data form regarding the PIVC application. Finally, patients will be asked about their level of satisfaction with the procedure at the end of the infusion.
88875313|NCT02584998|Active Comparator|Mailed-FIT|Participants randomized to Mailed-FIT will receive a mailed FIT pre-notification letter (plus a screening invitation) followed by the kit 1 week later. Participants will receive instructions to contact the study team if they believe they are not eligible and to update their contact information. They will be informed that a telephone reminder will follow 4 weeks from notification letter if screening is not completed. Participants who do not return their kit within 4 weeks after their pre-notification letter was mailed will receive a live telephone reminder, followed by 2 additional calls at the end of weeks 5 and 6, if needed. For the purposes of this intervention, Week 1 will be the week the pre-notification letter was sent (time zero).
89182740|NCT06237283|No Intervention|Late shower|Start shower after wound stitches are removed
89182741|NCT06237166|Experimental|mylovia + TAU|"Participants allocated to the intervention group will receive access to mylovia in addition to treatment as usual (TAU).~mylovia is a digital health application designed for women with sexual dysfunction, accessible through a web browser. The application focuses on treatment methods derived from cognitive behavioral therapy (CBT). Topics addressed by mylovia are psychoeducation, relaxation and mindfulness exercises, strategies to improve self-esteem, development of passionate attitudes and situations, dealing with differences in desire in a relationship, and sensate focus exercises.~The program operates through interactive dialogues, which are accompanied by illustrations, audio recordings, motivational text messages, worksheets, and summaries. Users are also encouraged to regularly complete short questionnaires to monitor their complaints. Once registered, the program remains accessible for 180 days."
89182742|NCT06237166|No Intervention|information material + TAU|Participants allocated to the control group will receive access to information material about treatment and counseling options in addition to treatment as usual (TAU).
89182743|NCT06236724|Experimental|Treatment with Asciminib|Participants will take tablets of asciminib by mouth every day on this study. Participants should take it at least 1 hour before and 2 hours after eating. The tablets should be swallowed whole, not crushed.
89182744|NCT06236659|Experimental|Intervention for middle-aged men: Consumption of hydrolyzed collagen (HC) with resistance exercise|Middle-aged male participants consumed one of three different HC doses (0 grams, 15 grams, or 30 grams) with 4 sets of 10 repetitions of leg press exercise at 10-repetition maximum load in a random order and a seven-day wash-out period interspersed between each trial.
89182745|NCT06236659|Experimental|Intervention for middle-aged women: Consumption of hydrolyzed collagen (HC) with resistance exercise|The intervention procedure is exactly same as Arm 1 except for the number of visits and doses of HC. Middle-aged female participants were asked to visit the laboratory on the day of highest oestrogen (i.e. ovulation) and provided with 0 g or 30 g HC. Dates for the trials were determined based on self-report of onset of menses and previous menstrual cycle length.
89182746|NCT06236490||Study Particpants - Speedskating Athletes|All the study participants were members of the Polish National Development Team or Polish National Elite Team in either long-track or short-track speedskating. Inclusion criteria were as follows: a valid medical certificate for competitive speedskating, a minimum of six years of training, and no prior exposure to respiratory or respiratory muscle training. Exclusion criteria were as follows: any chronic medical conditions, recent acute medical conditions within the last 4 weeks, COVID-19 infection within the last 6 months, recent stay in an altitude over 1500 meters above sea level within the last 4 weeks, and the use of any ongoing medications.
89182747|NCT06235879|Other|Group A (Control Group|Patients will receive ultrasound guided Interscalene brachial plexus (ISB) block after induction of general anesthesia.
89182748|NCT06235879|Experimental|Group B (Pericapsular nerve group (PENG) block)|Patients will receive ultrasound guided Pericapsular nerve group (PENG) block after induction of general anesthesia
89182749|NCT06235801|Experimental|Dose Escalation Phase 1/Phase 2|Participants who are enrolled in Part 1, the dose of momelotinib you receive will depend on when you join this study. Participants you are enrolled in Part 2, you will receive momelotinib at the recommended dose that was found in Part 1. All participants will receive the same dose level of gilteritinib. Cycle 1 will be 35 days in length. Momelotinib will be administered once daily by mouth on days 1-35. Gilteritinib will be administered once daily by mouth on days 8-35. Cycles 2 and beyond will be 28 days in length. Momelotinib and gilteritinib will be administered once daily by mouth on days 1-28.
89182750|NCT06234982||2-3 years of age|2-3 years of age
89399455|NCT03693729|Sham Comparator|Sham DLPFC during task|Sham HD-tDCS will be applied over the DLPFC at 2mA in a single session for up to 30 min during the memory and metamemory task
89379527|NCT03652766|Other|Daily Weight Tracking|Participants will be provided with a wireless Bluetooth-enabled bathroom scale with instructions for connecting it to their home wifi network or phone using Bluetooth and a mobile app, and will also be walked through creating an anonymous study account for app access. They will be asked to track their weight daily for 6 weeks and will receive weekly feedback on weight gain trajectories along with nutrition or physical activity messages for healthy pregnancy weight gain.
89379528|NCT05202600||Incidental appendectomy (IA)|Group IA will include adult patients operated on for colon tumors who have data on age, sex, data on a previously diagnosed colon tumor, data on incidental appendectomy, and a PHD finding for a removed vermiform appendix.
89379529|NCT05202600||Acute appendectomy (AA)|Group AA will include adult patients who have been operated due to clinical suspicion of acute appendicitis and have data on age, sex, data on the diagnosis of acute appendicitis and accompanying PHD findings of the performed appendectomy.
89379530|NCT04904601|Active Comparator|Experimental Group: Kale|This group will be given one scoop of powder of (Kale) three times a day for a total of 10g/day for 6 weeks.
89379531|NCT04904601|Placebo Comparator|Placebo Group: Green Peas|This group will be given one scoop of powder of (Green Peas) three times a day for a total of 10g/day for 6 weeks.
89379532|NCT03653078|Experimental|Three dimensional printed digital guide|one mini-screw will be inserted in the buccal interradicular space between upper second premolar and first molar using Three dimensional printed digital guide, which is a device deisgned and printed through CAD/CAM technology, it's a printed plate fit on the teeth and buccal mucosa with a channel for mini- screw insertion, mini-screw will be inserted through the plate's channel
89379533|NCT03653078|No Intervention|Conventional free hand insertion|one mini-screw will be inserted in the buccal interradicular space between upper second premolar and first molar using conventional free hand insertion of mini-screw, which is a technique using the guiding anatomy for mini-screw insertion using the driver and the operator's skill.
89379534|NCT03713723||Patients undergoing IVF treatment with hemodynamic monitoring|Fifty health women aged 18-45 undergoing their first, second or third cycle of IVF treatment will be monitored with the non invasive NICaS bioimpedance
89379535|NCT05202444|Experimental|Osteotomy using piezoelectrical device|
89379536|NCT05202444|Active Comparator|Osteotomy using surgical saw|
89379537|NCT01374633|Experimental|1:patient with severe traumatic brain|
89379538|NCT03652922|Experimental|Propranolol|
89379539|NCT03652922|Placebo Comparator|Placebo|
88852868|NCT05892978|Experimental|Vascular access transillumination group|The patient's vital signs, skin color and skin turgor will be evaluated and recorded in the PIVC procedure registration form. Before the tourniquet is attached before the procedure, the patient's vein visibility will be evaluated by the research nurse. The vein imaging device will be opened with transilluminator, the tourniquet will be connected, and the vein visibility will be re-evaluated by the operator. The skill duration will be measured and recorded by the researcher with a stopwatch. The selection of the necessary materials will not be added to this time, the chronometer will be started after the tourniquet is attached, and the time will end with the blood coming to the PIVC. Data obtained on PIVC placement; the pain and fear levels before, during and after the procedure. Finally, patients will be asked about their level of satisfaction with the procedure at the end of the infusion.
88875314|NCT02585700|Experimental|Vaccine|"0.5 mL of influenza vaccine, split, inactivated with 15 mcg of haemagglutination (HA) of each of 3 strains:~NYMC BX-51B reassortant of B/Massachusetts/2/2012~X-181 reassortant of H1/A/California/7/2009~X-223A reassortant of H3/A/Texas/50/2012."
89379540|NCT03713567|Placebo Comparator|Experimentally induced plaque|Induced inflammation by suspension of oral hygiene
89379541|NCT03713567|Experimental|Experimentally induced plaque GAP|Induced inflammation by suspension of oral hygiene in patients with history of Generalized Aggressive periodontitis
89379542|NCT01178814|Experimental|Revlimid|Revlimid (Lenalidomide) capsule taken orally once a day
88875315|NCT02585700|Placebo Comparator|Placebo|0.5 mL of phosphate buffered saline
89379543|NCT04053920|Experimental|Low load|Training at 30-40% one-repetition maximum (1RM)
89379544|NCT04053920|Experimental|High load|Training at 65-75% one-repetition maximum (1RM)
89379545|NCT03713489|Experimental|Platelet transfusion group|Besides standard medical treatment, up to 9 units of platelets will be transfused per protocol within 4 weeks
89379546|NCT03713489|No Intervention|standard medical treatment group|standard medical treatment
88875316|NCT05249244||observation group|huachansu oral preparation (tablet, capsule) was used.
89182751|NCT06234982||4-6 years of age|4-6 years of age
89379547|NCT04053686|Experimental|Intervention|The intervention group will aim to regularly break up participants' prolonged sitting time with three-minute incidental movement breaks every half hour at work. Support for behaviour change will include a lecture/workshop, electronic prompts, break logging, team competition, health champions, and email support.
89379548|NCT05202288|Active Comparator|Single vaccination|"The control arm (vaccination alone) will serve as a comparator of vaccine response.~r-VSV-ZEBOV vaccine will be administered at inclusion (D0)"
89379549|NCT05202288|Experimental|Simoultaneous vaccination|Mabs and r-VSV-ZEBOV vaccine will be administered the same day, at inclusion (D0), one hours appart
88875317|NCT05249244||control group|huachansu was not used.
89182752|NCT06234982||7-10 years of age|7-10 years of age
89379550|NCT05202288|Experimental|Early vaccination|Mabs are administered at inclusion (D0) and r-VSV-ZEBOV vaccine 3 weeks later
89379551|NCT05202288|Experimental|Intermediate vaccination|Mabs are administered at inclusion (D0) and r-VSV-ZEBOV vaccine 6 weeks later
89379552|NCT05202288|Experimental|Late vaccination|Mabs are administered at inclusion (D0) and r-VSV-ZEBOV vaccine 12 weeks later
89379553|NCT03652298|Experimental|Experimental arm|In the experimental group, participants will perform vagal breathing (VB), followed by the MSI, followed again by VB. The VB component will guide participants how to perform deep slow vagal breathing by inhaling and counting 1-5, holding their breath and counting 1-2, and exhaling and counting 1-5, during 2-5 minutes. The MSI component will teach participants to chronologically organize the segments of their memory of the incurable diagnosis, to verbally label feelings or somatic sensations they had at that moment, and to provide causal links between the event's segments and causality to their feelings and sensations, following the protocol of Gidron et al. (2001).
89379554|NCT03652298|Other|Control Arm|Participants in the control group will receive support and attention (usual care) and will be invited to recall announcement of the incurable disease progression. More precisely, they will be invited to express their associated thoughts and feelings, being free to talk about their experience, and the psychologist will react with empathy and support.
89379555|NCT03463031|Experimental|GSP 301 NS|Fixed dose combination of olopatadine hydrochloride 665 μg and mometasone furoate 25 μg NS
89379556|NCT03463031|Placebo Comparator|GSP 301 Placebo NS|GSP 301 Placebo nasal spray
89379557|NCT04054388|Experimental|300 Randomized to re-education group|LINE re-education of colon preparation
89379558|NCT04054388|No Intervention|300 Randomized to control group|education of colon preparation 1 time in hospital
89379559|NCT03652688|Experimental|Three 0's|Observed indicators that a group member may be in trouble due identified risks were provided and if detected, they were given practical skills on implementing the 3 0's: Outreach, Options, and Out. Outreach consisted of techniques for approaching your friend and acquiring more information whether there was a problem. Options were to be employed if problems were confirmed and were designed to provide easy, simple steps to reduce risks and decrease probability of escalation of problems. Out refers to the plans the group made before entering the club that they would leave as a group to keep the group members safe. Group commitment to implement these safety steps was emphasized. Interactive and visually attractive scenes were drawn as graphic images to avoid didactic delivery.
89379560|NCT03652688|Sham Comparator|Fire Safety|Groups in the control condition were also given information on safety and the focus of this safety message was regarding fires in nightclubs. Groups were given didactic materials to read with some still images. There were a few questions for the group to address.
89379561|NCT05762484|Experimental|Intervention group, laser hair removal therapy|Patients will undergo 6 monthly laser hair removal treatments with de Nd:YAG laser. After 6 months, a 6 follow up will start, using clindamycin 1% lotion if needed.
89379562|NCT05762484|Active Comparator|Control group, clindamycin 1% lotion if needed, standard care|Patients will use clindamycin 1% lotion of needed for 1 year.
89379563|NCT03462641|Experimental|Sequence A - (Flumazenil at Visit 1)|A detailed 90 minute clinical assessment was conducted before and after treatment administration for each visit. Flumazenil 1mg in 10cc normal saline was given intravenously (iv) over 5-10 minutes on the first visit as treatment. 10 cc of normal saline placebo was given intravenously (iv) over 5-10 minutes on the second visit as treatment.
89379564|NCT03462641|Experimental|Sequence B - (Placebo at Visit 1)|A detailed 90 minute clinical assessment was conducted before and after treatment administration for each visit. 10 cc of normal saline placebo was given intravenously (iv) over 5-10 minutes on the first visit as treatment. Flumazenil 1mg in 10cc normal saline was given intravenously (iv) over 5-10 minutes on the second visit as treatment.
89379565|NCT04150796|Experimental|Enhanced-view Totally Extraperitoneal (eTEP) Hernia Repair|Initial access into the retromuscular space is achieved using an optical trocar. Insufflation of CO2 is performed under direct visualization. Multiple assistant ports will be placed medial to the semilunar line to continue developing the retromuscular space. The medial insertion of the posterior rectus sheath will be incised to enter the preperitoneal plane and facilitate reduction of hernia contents. The contralateral posterior rectus sheath will be incised and the contralateral retrorectus space will be matured. Suture will be used to close any defect in the hernia sac. The defect will be measured, as will be the retrorectus space. The fascial defect will be closed with suture. Non-barrier coated mesh will be placed in the retrorectus space and flat positioning will be confirmed. Ports will be removed under direct visualization, and the abdomen desufflated. Anterior fascia of any larger ports (8mm or greater) will be closed.
89379566|NCT04150796|Active Comparator|Intraperitoneal Onlay Mesh (IPOM) Hernia Repair|Access is achieved using an optical trocar. Insufflation of CO2 is performed. Two additional trocars are placed on the left side along the anterior axillary line. If necessary, auxiliary ports may be placed on the right side. When present, hernia contents are reduced using graspers. Adhesions between abdominal contents and the abdominal wall are lysed. The hernia defect is identified and measured internally with a sterile plastic ruler with the abdomen insufflated. Defect closure is performed using nonabsorbable suture. Mesh repair is performed using polypropylene mesh with an absorbable hydrogel barrier. Mesh is chosen to achieve a minimum 3 to 5-centimeter overlap from the edges of the closed defect. Inside the abdomen, the mesh is unrolled and positioning against the anterior abdominal wall is confirmed. Mesh edges are fixed circumferentially with permanent fixation. Ports are removed and the abdomen is desufflated. The anterior fascia of the 12mm port is closed.
89379567|NCT04858074|Experimental|Active medication- PECKO-D|Participants will be randomly allocated to experimental drug
88875318|NCT05249166|Placebo Comparator|Control group|Subjects assigned to this arm will follow the habitual recommendations to develop skills for a healthy diet. No specific foods or cooking methods will be applied
89182753|NCT06234774||Robot-assisted surgery|Patients receiving abdominal surgical procedures with robot-assisted videolaparoscopic approach
89379568|NCT04858074|Placebo Comparator|Placebo|Corn-Starch will be administered as placebo agent
89379569|NCT04856202|Active Comparator|Intervention|A trained facilitator will schedule two facilitated Respecting Choices interviews with the patient and preferably, if the patient agrees, in the presence of a caregiver or relative.
89379570|NCT04856202|No Intervention|Control|Care as usual
88875319|NCT05249166|Experimental|ALINFA group|This group will receive, in addition to the usual recommendations, meals, and foods designed to increase the healthiness of the diet. Foods and meals have been designed to increase the fiber content, decrease sugars and saturated fats, and limit salt intake.
88875320|NCT05248698|Experimental|group 1|30 older patient who will complain from dry eye will receive 3-time interval exercise per the week, applied for 30 min with high intensity, plus Mediterranean Diet for 6 months
89379571|NCT02974634|Active Comparator|Ostomy Self management Training|Ostomy self-management Training group in which subject will learn using pouches and equipment, skin care, ostomy complications, nutritional needs, Impact on feelings, clothing changes, social relationships, being prepared for emergencies, Intimacy and sexuality, communication skills, tips for travelling and physical activity recommendations
89379572|NCT02974634|Placebo Comparator|Usual care|Usual care in peri-operative and long-term settings is not standardized for ostomy patients. Usual care does not provide any formal, reproducible training for patients or their caregivers. It typically consists of an Ostomy Care Nurse who works with patients and caregivers concerning technical issues (fitting, emptying, supplies, surrounding skin care, etc.) while the new ostomate is still an inpatient
89379573|NCT04814316||Study group|Patients with gastroesophageal reflux or gastroesophageal reflux disease who will use lansoprazole.
89379574|NCT04814316||Control group|Healty volunteers who will not use lansoprazole.
89379575|NCT04113122|Experimental|Cross-sectional study:|Testicular cancer survivors who were treated between 2000 and 2005 or between 2006 and 2012 with cisplatin-combination chemotherapy and who were extensively phenotypically mapped within two longitudinal trials (15,16) will be invited to participate in a single cross-sectional follow-up study visit 5-20 years after chemotherapy.
89379576|NCT04113122|Experimental|Longitudinal study - chemotherapy group|"Patients with metastasized testicular cancer who are about to start with cisplatin-combination chemotherapy will be invited in the longitudinal part of this study. Study participation involves four study visits:~Visit 1: before start of chemotherapy Visit 2:before third cycle of chemotherapy Visit 3: one month after completion of chemotherapy Visit 4: one year after start of chemotherapy"
89379577|NCT04113122|Other|Longitudinal study - stage I control group|"Patients with stage I testicular cancer will serve as control group with three study visits:~Visit 1: at time of orchidectomy Visit 2: one month Visit 3: one year after orchidectomy"
89379578|NCT04804332|Experimental|EXPECTANT MANAGEMENT|No treatment will be offered.
89379579|NCT04804332|Experimental|OPERATIVE HYSTEROSCOPY|Operative hysteroscopy using hysteroscopic morcellation (TruClearTM Hysteroscopic Tissue Removal System (Medtronic, Minneapolis, MN, USA)) is performed.
89379580|NCT04737876|Experimental|BX002-A|BX002-A: 1 mL liquid for multiple dose oral administration
89379581|NCT04737876|Placebo Comparator|Placebo|Placebo: 1 mL liquid for multiple dose oral administration
89379582|NCT05206578|Experimental|AGT2, AGZ|
89379583|NCT05206578|Active Comparator|AGT2|
89379584|NCT05206578|Experimental|AGT4, AGZ|
89379585|NCT05206578|Active Comparator|AGT4|
89379586|NCT03651908|Experimental|Interventional|Interventional The Group A subjects will be treated with conventional flap surgery.After reflection of the full thickness flap,the intrabony defects will be debrided and Bioactive silicate graft mixed with PRF will be used as graft material to fill the defects.
89379587|NCT03651908|Active Comparator|Interventional comparator|Group B patients will also be treated by conventional flap surgery,employing a full thickness flap technique.The intrabony defects will be filled with Bioactive silicate only.
89379588|NCT05206032||healthy participants|healthy participants
89379589|NCT05206032||acute aortic dissection (AAD)|acute aortic dissection (AAD)
89379590|NCT05206032||acute myocardial infarction (AMI)|acute myocardial infarction (AMI)
88875321|NCT05248698|Active Comparator|group 2|30 older patient who will complain from dry eye will receive 3-time interval exercise per the week, applied for 30 min with high intensity, for 6 months
89379591|NCT05206032||pulmonary embolism (PE)|pulmonary embolism (PE)
89379592|NCT05206032||angina|angina
89379593|NCT05201274|Experimental|Baduanjin sequential therapy|
89379594|NCT05201274|Active Comparator|Aerobic exercise|
89379595|NCT03629496|Experimental|Arts-based intervention|Participants will participate in 6x1 hourly art sessions over a period of 3 weeks while they receive their haemodialysis treatment. This will involve 1:1 facilitation with a student and will involve visual arts including sketching, water colour painting and pen and ink, and creative writing activities. Participants will be provided with their own art supplies for infection control purposes and these will be kept on the unit in between sessions. Participants will have an option of displaying completed work in the reception area of the unit during their sessions.
89379596|NCT03629496|No Intervention|Control|Participants will receive usual care during their haemodialysis sessions and will be asked not to engage in any creative writing or visual arts during their haemodialysis sessions for the duration of the study. Once data collection has been completed the participants in the control group will receive art supplies and a single facilitated session on haemodialysis for the purpose of equity.
89379597|NCT05762406|Experimental|Wearing mask|Subjects will perform a cardiopulmonary exercise test (CPET) and a series of standardized daily activities while wearing a protective mask
89379598|NCT05762406|No Intervention|Not wearing mask|Subjects will perform a cardiopulmonary exercise test (CPET) and a series of standardized daily activities in basal conditions
89379599|NCT05761704|Experimental|Dual antiplatelet|Aspirin 100 mg + clopidogrel 75 mg for 4 weeks post-LAAC; followed by aspirin/clopidogrel for 4-24 weeks post-LAAC; recommended long-term aspirin treatment after 24 weeks (clopidogrel can be used instead if aspirin is intolerant).
89379600|NCT05761704|Experimental|Novel oral anticoagulant|Conventional dose NOAC for 4 weeks post-LAAC; followed by aspirin/clopidogrel for 4-24 weeks post-LAAC; recommended long-term aspirin treatment after 24 weeks (clopidogrel can be used instead if aspirin is intolerant).
88875322|NCT05248542|Experimental|Virtual Reality group|Each participant in the experimental group received a 30 minutes of individualized VR-based simulation education in a dedicated oral skills training room.
89379601|NCT05205798|Experimental|Participants|Food consumption using plates with a diameter of 23 cm first then using plates with a diameter of 31 cm
89379602|NCT01060670|Experimental|Dermal Replacement Device|Device: INTEGRA® Dermal Regeneration Template
89379603|NCT01060670|Active Comparator|Moist Wound Therapy|0.9% Saline gel
89379604|NCT05205642|Experimental|Patients recovering from COVID-19|Pediatric and adult patients recovering from COVID-19 with or without complaints.
89399456|NCT02753816|Experimental|Tranexamic Acid|1 gram of Tranexamic Acid given over 10 minutes into the vein once prior to surgery
89399457|NCT02753816|Placebo Comparator|Placebo|Placebo given over 10 minutes into the vein once prior to surgery
88852869|NCT05892978|No Intervention|Control group|The patient's vital signs, skin color, and skin turgor will be evaluated and recorded in the PIVC procedure registration form. Before the tourniquet is attached before the procedure, the patient's vein visibility will be evaluated by the research nurse. Vein imaging will not be performed. No intervention will be carried out the tourniquet will be connected, and the vein visibility will be re-evaluated by the operator. The skill duration will be measured and recorded by the researcher with a stopwatch. The selection of the necessary materials will not be added to this time, the chronometer will be started after the tourniquet is attached, and the time will end with the blood coming to the PIVC. Data will obtained on PIVC placement; the pain and fear levels before, during, and after the procedure. Finally, patients will be asked about their level of satisfaction with the procedure at the end of the infusion.
88852870|NCT05892913|Active Comparator|Efedrine Group|For sympathetic blockade (SBP<90) if developed in patients in the ephedrine group, a bolus dose of 5 mg/mL ephedrine would be used and repeated if necessary. In case of development of bradycardia (<65/min) in this group, Atropine 0.5 mg/mL would be planned to be administered and repeated if necessary.
88875323|NCT05248542|No Intervention|Control group|The control group only received repeated questionnaires and did not receive any education about geriatric oral hygiene.
89182754|NCT06234774||Non-robotic laparoscopic surgery|Patients receiving abdominal surgical procedures with conventional (non-robotic) videolaparoscopic approach
89182755|NCT06234397|Experimental|BH3120|BH3120 will be administered intravenously (IV) once every 3 weeks. (Q3W)
89182756|NCT06234072|Experimental|Astragalus + Gemcitabine|"Participants will receive Astragalus in combination with Gemcitabine by intravenous infusion (IV).~Participants will receive IV infusion of 20ml of Astragalus injection (the content of Astragalus crude drug is 2g/ml plus 250ml of normal saline 1 day before chemotherapy, once a day for 21 consecutive days constitute a course of treatment a total of 4 courses of treatment.~Gemcitabine is one of the main chemotherapy drugs used to treat pancreatic cancer."
89182757|NCT06234072|Active Comparator|Gemcitabine alone|Participants will receive Neoadjuvant Chemotherapy of Gemcitabine 1000 mg/m2 as a 30- to 40-minute infusion (maximum 40 minutes) administered weekly for 7 weeks followed by a week of rest (8-week cycle; cycle 1 only), followed by cycles of weekly administration for 3 weeks (on days 1, 8, and 15) followed by one week of rest (4-week cycle).
89182758|NCT06233773|Experimental|Kinesio Taping Group|In this project, Kinesio Taping will be applied to the Kinesio Taping group to reduce pain and support circulation. In this study, space correction method to reduce pain and lymphatic correction technique to support circulation will be applied from Kinesio Taping methods. In the study, in order to determine the susceptibility to allergy to kinesio tape, a five cm application will be made on the outer lateral region of the arms of pregnant women and waited for 10 minutes. Before the application, the physiotherapist will clean the application area with volatile alcohol for correct and good adhesion of the tape. Four bands of 10 cm each will be cut for the application. In order to protect the tape during the movement of the person, all corners will be oval shaped and the kinesio tape will be adhered to the BL-40 and BL-57 points bilaterally using 25-50% tension with the space correction method.
89182759|NCT06233773|Experimental|Manual Lymph Drainage Group|Before the application, the pregnant woman will open both lower extremities, including the knee area, in a semi-sitting position. The other body parts will be covered with a sheet/sweater so that the leg area is open. Without applying anything (oil, vaseline, cream) to the leg, the physiotherapist will perform Manual Lymph Drainage using his/her hands. The pregnant woman will be asked to do 10 repetitions of diaphragmatic breathing exercise. Popliteal lymph nodes will be stimulated manually 7 times. The anterior and medial knee will be stimulated 7 times each with circular movements. Manual Lymph Drainage will be performed on the front of the leg with the pumping technique and on the back of the leg with the scooping movement. The procedure will be repeated 3 times to provide drainage in the same area. The ankle will be stimulated 7 times with circular movements. The inferior and posterior parts of both the medial malleolus and lateral malleolus will be stimulated.
89182760|NCT06233773|Experimental|Kinesio Taping and Manual Lymph Drainage Group|In this group, Kinesio Taping and Manual Lymph Drainage will be performed together to support circulation and reduce pain. All of the procedures performed in the Kinesio Taping Group and the Manual Lymph Drainage Group will be performed in parallel. After Kinesio Taping, Manual Lymph Drainage will be performed for 6 days. The kinesio tape will be renewed on the fourth day and will remain for three more days.
89182761|NCT06233773|Active Comparator|Control Group|Pregnant women in the control group will not be subjected to any intervention other than routine follow-up and care at the hospital.
89182762|NCT06232863|Experimental|BH009|Every 28 days constitutes a treatment cycle, and administration on day 1, day 8, day 15 of each cycle
89182763|NCT06232798|Experimental|A prospective, singlecenter, single-arm clinical study|
89182764|NCT06231758|Active Comparator|control group|35 patients will receive celecoxib 200 mg capsule plus placebo tablets
89182765|NCT06231758|Active Comparator|Comparative group|35 patients will receive celecoxib 200 mg capsule plus 1000 mg metformin daily
89182766|NCT06231745|Active Comparator|control group|group one (control group): 50 patients will receive the conventional DMARDs therapy (methotrexate 7.5 mg IM once weekly) plus placebo tablets
89379605|NCT03652142||Recurrent/metastatic HNSCC|"The investigators will include recurrent/metastatic HNSCC patients who progressed after cisplatin-based chemotherapy and are to be treated with nivolumab. Tumor biopsies will be performed at baseline, after the second cycle and at progression with appropriate written informed consent and the samples will be analyzed. Biomarker research will be performed.~The patients will receive intravenously nivolumab at dose of 240 mg every 2 weeks (240mg q2w). The patients will undergo tumor biopsy at baseline and within 24-72h after the second administration of treatment, and at progression of their disease."
89379606|NCT01176578|Experimental|T2DM|Type 2 Diabetes Mellitus
89379607|NCT01176578|Experimental|IGT|Impaired Glucose Tolerance
89379608|NCT01176578|Active Comparator|NGT|Normal Glucose Tolerance
89379609|NCT02971670|Experimental|Dose Group 1|Treatment: rTSST-1 Variant Candidate Vaccine 3 µg
89379610|NCT02971670|Experimental|Dose Group 2|Treatment: rTSST-1 Variant Candidate Vaccine 10 µg
89379611|NCT02971670|Experimental|Dose Group 3|Treatment: rTSST-1 Variant Candidate Vaccine 30 µg
89379612|NCT02971670|Placebo Comparator|Dose Group 0|Control: Al(OH)3 Adjuvant
89379613|NCT04629378|Experimental|Meropenem and amoxicillin/clavulanate plus pyrazinamide|Meropenem administered intravenously once daily over 6 hours plus amoxicillin/clavulanate 2 x 1000/62.5 mg once daily orally plus pyrazinamide 20-30 mg/kg orally once daily. All study treatments will be administered for 14 consecutive days.
89379614|NCT04629378|Experimental|Meropenem and amoxicillin/clavulanate plus bedaquiline|Meropenem administered intravenously once daily over 6 hours plus amoxicillin/clavulanate 2 x 1000/62.5 mg once daily orally plus bedaquiline 400 mg orally once daily. All study treatments will be administered for 14 consecutive days.
89379615|NCT04629378|Active Comparator|Rifafour standard of care treatment|Rifafour e275® administered orally once daily for 14 consecutive days. Rifafour e275® will be administered according to the South African National TB Treatment Guidelines. The daily dose is dependent on the participants' weight as follows: 40 - 54kg: 3 tablets; 55 - 70kg: 4 tablets; 71kg and over: 5 tablets.
89379616|NCT04615806|Experimental|NIR-ICG|After positioning,Indocyanine green（ICG） dye (Yichuang Pharmaceutical, Liaoning, China) stored at a dose of 25 mg in a small bottle was diluted with 5 ml sterile water. Then, 2 ml of this solution was added to 8 ml sterile water in a dis-posable dressing bowl, resulting in a final concentration of 1.25 mg/ml.
89379617|NCT04615806|No Intervention|Control|This group of patients received only conventional radical resection of esophageal cancer without Indocyanine green injection.
89379618|NCT03651674|Active Comparator|ECT treatment|Patients received bilateral temporal modified ECT (MECT) for three weeks,four times a week. Meanwhile, they also had antipsychotic drugs.
88852871|NCT05892913|Experimental|Preemptive Atropine Group|In the atropine group, it will planned to administer 0.4 mg/4mL diluted atropine in 20 seconds(10mcg/kg), as a slow bolus as bradycardia would expected (10% reduction in peak heart rate after spinal anesthesia). In this group if SBP<90 despite slow dose atropine administration; it will be planed to give efedrine as bolus of 5 mg/mL. And for bradicardia (HR<65/min) it will be planed to give Atropine 0.5 mg/mL.
89379619|NCT03651674|Sham Comparator|Drug treatment|Patients only received antipsychotic drugs during observation period.
89379620|NCT01061840|Experimental|1 x 10 ^7 cells/injection|Vigil™
89379621|NCT01061840|Experimental|2.5 x 10 ^7 cells/injection|Vigil™
89379622|NCT01061840|Experimental|1 x 10^6 or 4 x 10^6 cells/injection|Vigil™
88852872|NCT05891808||Healthy Controls|Healthy subjects without present or past history of headache according to ICHD-III criteria.
89379623|NCT01569906||UVB|Children with moderate to severe atopic eczema who undertook a standard course of narrowband Ultraviolet B (NBUVB) phototherapy
89379624|NCT01569906||Controls|Children with moderate to severe atopic eczema who were offered UVB but were unable to undertake treatment
89379625|NCT03651440|Experimental|lumbar stabilization training|lumbar stabilization training exercises
89379626|NCT03651440|Experimental|PNF training|PNF training exercises
89379627|NCT03651440|Experimental|physical therapy|HP,TENS US
89379628|NCT03651440|Sham Comparator|control|NO APPLİCATİON
89379629|NCT02971202|Other|Hyperinsulinemic, euglycemic clamp: T1DM|"Participants will undergo an 8-hour hyperinsulinemic, euglycemic clamp to quantify insulin sensitivity at whole-body and tissue-specific levels. The following hormones will be infused in the study:~insulin (12 milliunit (mU)/m^2/min [3x basal] for 150 minutes, then 40 mU/m^2/min [10x basal] for 180 minutes)~glucagon (0.65 ng/kg/min [1x basal] for 330 minutes)~somatostatin (60 ng/kg/min) These infusions will maintain a basal glucagon level and an increased insulin level in the blood that will be equal between all 3 cohorts.~A variable infusion of 20% dextrose will be used to maintain plasma glucose within the euglycemic range throughout the hyperinsulinemic portion of the clamp. 6,6-H2 glucose will be infused at a low rate (0.033-0.22 µmol/kg/min) to determine glucose flux during the study."
89379630|NCT02971202|Other|Hyperinsulinemic, euglycemic clamp:MODY2|"Participants will undergo an 8-hour hyperinsulinemic, euglycemic clamp to quantify insulin sensitivity at whole-body and tissue-specific levels. The following hormones will be infused in the study:~insulin (12 mU/m^2/min [3x basal] for 150 minutes, then 40 mU/m^2/min [10x basal] for 180 minutes)~glucagon (0.65 ng/kg/min [1x basal] for 330 minutes)~somatostatin (60 ng/kg/min) These infusions will maintain a basal glucagon level and an increased insulin level in the blood that will be equal between all 3 cohorts.~A variable infusion of 20% dextrose will be used to maintain plasma glucose within the euglycemic range throughout the hyperinsulinemic portion of the clamp. 6,6-H2 glucose will be infused at a low rate (0.033-0.22 µmol/kg/min) to determine glucose flux during the study."
88852873|NCT05891808||Episodic Migraine|Patients with a diagnosis of migraine without or with aura, with episodic pattern, according to ICHD-III criteria.
88852874|NCT05891808||Chronic Migraine|Patients with a diagnosis of chronic migraine with or without medication overuse headache according to ICHD-III criteria.
89399458|NCT03689751|No Intervention|LSCS Control Arm|Patients undergoing elective LSCS allocated to this arm underwent the normal preoperative educational pathway. This typically included face-to-face consultation and written information leaflets.
89399459|NCT03689751|Experimental|LSCS Intervention ArmIntervention Arm|Patients undergoing elective LSCS allocated to this arm underwent the normal preoperative educational pathway, but prior to the operation were shown the educational RSAV (LSCS Video) as an additional educational resource.
89379631|NCT02971202|Other|Hyperinsulinemic euglycemic clamp:Control|"Participants will undergo an 8-hour hyperinsulinemic, euglycemic clamp to quantify insulin sensitivity at whole-body and tissue-specific levels. The following hormones will be infused in the study:~insulin (12 mU/m^2/min [3x basal] for 150 minutes, then 40 mU/m^2/min [10x basal] for 180 minutes)~glucagon (0.65 ng/kg/min [1x basal] for 330 minutes)~somatostatin (60 ng/kg/min) These infusions will maintain a basal glucagon level and an increased insulin level in the blood that will be equal between all 3 cohorts.~A variable infusion of 20% dextrose will be used to maintain plasma glucose within the euglycemic range throughout the hyperinsulinemic portion of the clamp. 6,6-H2 glucose will be infused at a low rate (0.033-0.22 µmol/kg/min) to determine glucose flux during the study."
88852875|NCT05891522|Experimental|portable scanner|
89379632|NCT05761548||mature|
89379633|NCT05761548||preterm|
89379634|NCT00702494|Experimental|1|Multiple IV doses of TB-403, an antibody directed against PlGF
89379635|NCT02926638|Experimental|Arm I (rilotumumab, erlotinib)|Patients receive rilotumumab IV over 60-120 minutes on day 1 and erlotinib hydrochloride PO daily. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. (CLOSED TO ACCRUAL AND INTERVENTION 11/25/2014)
89379636|NCT02926638|Active Comparator|Arm II (erlotinib)|Patients receive erlotinib hydrochloride PO daily. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. (CLOSED TO ACCRUAL AND INTERVENTION 11/25/2014)
89379637|NCT00641420|Experimental|Fractional Laser 10mJ|Patients receive fractional laser resurfacing to 17% of the face five times one month apart at 10mJ.
89379638|NCT00641420|Experimental|Fractional Laser 40mJ|Patients receive fractional laser resurfacing to 17% of the face five times one month apart at 40mJ.
89379639|NCT03651596|Active Comparator|Standard mHealth Messaging|Individuals randomized to the Standard mHealth Messaging Group will receive a standard messaging intervention that has shown some efficacy in improving adherence in other samples.
89379640|NCT03651596|Experimental|mHealth Messaging Intervention|Individuals randomized to the mHealth Messaging Intervention Group will receive the newly developed messaging intervention.
89379641|NCT03650582|Experimental|Glucagon|Glucagon, 0.7mg, intranasal, single dose
88852876|NCT05891522|Active Comparator|fixed scanner|
89379642|NCT03650582|Placebo Comparator|Placebo|Placebo, intranasal, single dose
89379643|NCT02903030|Experimental|Visbiome, Then Placebo|The probiotic mix (VISBIOME) will be mainly Bifidobacteria and Lactobacilli, in view of the previously reported encouraging clinical studies and safety data.
88852877|NCT05891314|Active Comparator|Botox injection post hemorridectomy|after piles excision this group will be subjected to botox injection in the internal sphincter
88852878|NCT05891314|No Intervention|Hemorridectomy alone|Just hemorridectomy without botox injection(control group)
88852879|NCT05891314|Active Comparator|Hemorridectomy plus internal sphincterotomy|after piles excision patients will undergo internal sphincterotomy
88852880|NCT05891028|Experimental|68Ga-EB-ss-CPT PET/CT scan|68Ga-EB-ss-CPT PET/CT scan Dosimetry study about 6 patients were injected with 3 (MBq) per kilogram body weight of 68Ga-EB-ss-CPT PET/CT in one dose intravenously and underwent wholebody scan at 5min#30min#60min#120min#240min, then analysis of dosimetric distribution ofradiopharmaceuticals in human body by HERMES software.
88852881|NCT05891028|Experimental|64Cu-EB-ss-CPT PET/CT scan|64Cu-EB-ss-CPT PET/CT scan Dosimetry study about 6 patients were injected with 2 (MBq) per kilogram body weight of 64Cu-EB-ss-CPT PET/CT in one dose intravenously and underwent wholebody scan at 30min#8h#12h#24h#48h, then analysis of dosimetric distribution ofradiopharmaceuticals in human body by HERMES software.
89182767|NCT06231745|Active Comparator|Comparative group|50 patients will receive the conventional DMARDs therapy (methotrexate 7.5 mg IM once weekly) plus 20 mg paroxetine daily
89379644|NCT02903030|Placebo Comparator|Placebo, Then Visbiome|Placebo matched to probiotic.
89379645|NCT03650504|Experimental|Above Artery Group|
89379646|NCT03650504|Active Comparator|Between Artery and Vein Group|
89379647|NCT03650426|Active Comparator|Onlay patellar resurfacing technique|
89379648|NCT03650426|Experimental|Inlay patellar resurfacing technique|
89379649|NCT02969408|Experimental|ABS eMDPI|Participants will receive 90 mcg of ABS via an eMDPI (sitting on the upper part of the device for the purposes of detecting and storing usage information), 1 to 2 inhalations every 4 hours, as needed for 12 weeks.
89379650|NCT03462563|Experimental|INTERCEED™|patients will be randomized in 1:1 ratio to either the treatment arm (INTERCEED™) or the control arm (standard of care treatment: no adhesion barrier, no placebo). In subjects assigned to the treatment arm, the INTERCEED™ must be applied beneath the target incision site (the midline incision mainly for the removal specimen).
88852882|NCT05890716||Train group|Consecutive patients admitted to the hospital due to cardiac disorders (retrospective and prospective) with at least one relevant ECG record >10 sec in raw data will be used to design new methodologies and algorithms for cardiac patterns recognition.
89182768|NCT06231420|Active Comparator|Encourage using pedometer group.|Sarcopenic cirrhotic patient who received pedometer recording and was encouraged to use actively.
88852883|NCT05890716||Test group|Consecutive patients admitted to the hospital due to cardiac disorders (retrospective and prospective) with at least one relevant ECG record >10 sec in raw data will be used to evaluate performance of methodologies aiming to avoid overfitting. Every 10 patients included in Train group; a new patient is included in the test group.
88852884|NCT05890690|Experimental|Study Part 1 urea followed by placebo|Participants will undergo a diagnostic test with a single weight-adapted dose of oral urea first. After a a wash-out phase of at least 3 days and not more than 28 days participants will undergo a second diagnostic test with a single weight-adapted dose of placebo.
88852885|NCT05890690|Experimental|Study Part 1 placebo followed by urea|Participants will undergo a diagnostic test with a single weight-adapted dose of placebo first. After a a wash-out phase of at least 3 days and not more than 28 days participants will undergo a second diagnostic test with a single weight-adapted dose of urea.
88852886|NCT05890690|Experimental|Study part 2 Urea|Participants will undergo a diagnostic test with a single weight-adapted dose of oral urea
88852887|NCT05890430||Patients with microvascular inflammation|Patients presenting with microvascular inflammation on kidney allograft biopsy
88852888|NCT05890430||Patient without microvascular inflammation|Patients presenting without microvascular inflammation on kidney allograft biopsy
88852889|NCT05890248||Erector spinea block|-ESPB Group (n=12): Received erector spinae plane block.
88852890|NCT05890248||Thoracic Paravertebral block|TPVB Group (n=12) : Received thoracic paravertebral block.
88852891|NCT05890248||Control group|Control Group (n=12): Received morphine (0.1 mg/kg iv) before skin incision .
88852892|NCT05890248||QLB group|Quadratus lamborum block n=12
88852893|NCT05889520||Lactacting women who are breastfeeding full-term infants|Caucasian women aged between 18 and 35 who are breastfeeding full-term infants observed at Pediatrics Section of Department of Translational Medical Sciences (University of Naples Federico II)
88852894|NCT05887830|Experimental|Interventional drug treatment group|The participants receive Nivolumab treatment. The active drug Nivolumab will be administered at a standard dose (5mg/kg) dissolved in 100ml 0.9%NaCl solution. Nivolumab was given at a rate of 15-25 drops per minute, and the intravenous infusion time exceeded 1 hour.
88852895|NCT05887830|Placebo Comparator|Placebo treatment group|The participants receive placebo treatment. Patients assigned to the placebo treatment group will receive an intravenous infusion of 100 ml 0.9% NaCl solution at a rate of 15-25 drops/min for an IV infusion duration of more than 1 hour.
89182769|NCT06231420|Placebo Comparator|Discourage using pedometer group.|Sarcopenic cirrhotic patient who received pedometer recording but without encouraged to use.
89182770|NCT06230211|Experimental|music therapy|"In the group where music therapy will be applied, the endotracheal aspiration and study to be performed will be explained to the child's family, and after obtaining consent, the music therapy applied to the child will be applied 5 minutes before, during and after the procedure. Meanwhile, the data will be recorded on the form by the observer. The song The Happiest Child, developed by creating rhythms by Fulya Merve KOS, one of the researchers who has the RhythmotherapistTM certificate issued by the Ministry of National Education, will be used in music therapy. The sound will be adjusted to 45 db. The speaker will be placed at the end of the foot, approximately 30 cm from the child's ear, five minutes before the procedure and will be played to the child during the procedure."
89182771|NCT06230211|Experimental|Mother's voice|In the group where the mother's voice will be listened to, it will be explained to the child's parents that the mother's voice will be used for pain relief in the research. In the study, the researcher will take a voice from the mother of each child admitted to intensive care and record it on a voice recorder. Measurements will be made by placing the voice recorder 50 cm closer to the child to listen to the mother's voice. The volume of the mother's voice will be adjusted to an average of 45 decibels. The speaker will be placed at the end of the foot, approximately 30 cm from the child's ear, five minutes before the procedure and will be played to the child during the procedure.
89182773|NCT06229054|Experimental|group Dexmedetomidine|: Patients in this group will receive regional anesthesia and obturator nerve block bilaterally (10 ml 2% preservative-free lignocaine along with 5 ml 0.5% preservative-free bupivacaine) and dexmedetomidine 100 mcg/mL (2µg/kg).
89182774|NCT06229054|Other|group Bupivacaine|:Patients in this group will receive regional anesthesia and bilateral obturator nerve block only (10 ml 2% preservative-free lignocaine along with 5 ml 0.5% preservative-free bupivacaine).
89182775|NCT06227767|Active Comparator|exercise group twice a week|Spinal stabilization exercises determined by the authors will be applied 2 days a week for 40 minutes.
89182776|NCT06227767|Active Comparator|exercise group four times a week|Spinal stabilization exercises determined by the authors will be applied 4 days a week for 40 minutes.
89182777|NCT06227767|No Intervention|control group|Patients will be followed with a home exercise program
89182778|NCT06227702|Active Comparator|VeXus|Patients in the intervention arm wil be assessed by VeXus. Patients without signs of venous congestion (VeXus = 0) will be observed every 6 hours. In patients with VeXus ≥1, continuous infusion of intravenous furosemide will be initiated. During the first 48 hours, furosemide infusion will be adjusted according to VeXus . All other aspects of care will be managed according to routine unit protocols
89182779|NCT06227702|No Intervention|Usual care|The usual care arm will follow the management protocols of the unit which are based in the Surviving Sepsis Campaign guidelines.
89379651|NCT03462563|Placebo Comparator|standard of care treatment|During the Phase 1 operation, when the definite decision to create a temporary ostomy is made, patients will be randomized in 1:1 ratio to either the treatment arm (INTERCEED™) or the control arm (standard of care treatment: no adhesion barrier, no placebo).
89379652|NCT03716453|Placebo Comparator|Control group|Intraoperative fentanyl administration will be guided by standard protocol
89379653|NCT03716453|Experimental|ANI group|Intraoperative fentanyl administration will be guided by ANI protocol
89379654|NCT05180214|Active Comparator|bupivacaine|
88852896|NCT05885230|Active Comparator|PIFB group|patients will receive bilateral ultrasound-guided pecto-intercostal fascial block using 20 ml of bupivacaine 0.25% for each side.
89182780|NCT06226961|Experimental|Intervention group|For the dynamic cupping protocol, the participants will be instructed to remain seated on the massage table with their feet supported, and the technique will applied to the entire shoulder (anterior, lateral and posterior face) and surrounding muscles (upper trapezius and pectoralis major). The cupping will be performed using a plastic cupping cup (5,08 cm in diameter) (K.S. Choi Corp®) and a pistol grip hand pump (K.S. Choi Corp®). The dynamic cupping will be performed for ten minutes, at a slow pace, and consists of applying a small amount of massage cream (ATL®) over the entire shoulder (to obtain the ideal sliding surface for cupping application), insufflation of the suction cup, with two pumps, and sliding it in the direction of the muscle fibers around the shoulder and also in the transversal direction.
89182781|NCT06226961|No Intervention|Control group|Participants in the CG group will remain at rest, sitting on the massage table for 10 minutes.
89182782|NCT06226753|Active Comparator|Stoma reversal under GA|Loop ileostomy closure will be performed under General anaesthesia
89182783|NCT06226753|Experimental|Stoma reversal under SA|Loop ileostomy closure will be performed under Spinal anaesthesia
89182784|NCT06225752|Experimental|Probucol Group|The study drug should be started as soon as possible within 7 days after symptom onset.
89182785|NCT06225752|Placebo Comparator|Placebo Probucol Group|The study drug should be started as soon as possible within 7 days after symptom onset.
89182786|NCT06224192|Experimental|Rocatinlimab Dose 1|Rocatinlimab will be self-administered subcutaneously using a prefilled syringe (PFS). Participants will receive rocatinlimab every 4 weeks (Q4W) for 52 weeks with a loading dose at week 2.
89182787|NCT06224192|Experimental|Rocatinlimab Dose 2|Rocatinlimab will be self-administered subcutaneously using a PFS. Participants will receive rocatinlimab Q4W for 52 weeks with a loading dose at week 2.
89182788|NCT06223022|Experimental|Intervention|Receiving regular telephone nurse-led support
89182789|NCT06223022|No Intervention|Control|Receiving care as usual
89182790|NCT06219369|Active Comparator|Group T|Group T patients who underwent TPVB
89182791|NCT06219369|Active Comparator|Group S|Group S patients who underwent SPSIPB
89182792|NCT06213259|Experimental|KD6005 (Healthy)|Healthy participants will receive a single dose of KD6005 in dose escalation cohorts subcutaneously (SQ).
89182793|NCT06213259|Placebo Comparator|Placebo (Healthy)|Healthy participants will receive a single dose of placebo, SQ.
89182794|NCT06213259|Experimental|KD6005(RA)|Participants with RA will receive a multiple-dose of KD6005 in dose escalation cohorts, SQ.
89182795|NCT06213259|Placebo Comparator|Placebo (RA)|Participants with RA will receive a multiple-dose of placebo, SQ.
89182796|NCT06212492|Experimental|Prone Positioning and NMBAs (PP-NMBAs)|Early and systematic use of Prone positioning and NMBAs
89182797|NCT06212492|Active Comparator|Prone Positioning (PP)|Early and systematic use of prone positioning with NMBAs indicated ONLY as rescue
89182798|NCT06205225|No Intervention|Usual care|Participants assigned to the usual care group will receive (1) standard care, (2) patient education about HF self-care, and (3) three connected health devices. Usual care includes follow-up appointments every 2-3 months with a multidisciplinary team at the outpatient HF clinic. Patient education includes resources about HF self-care from the American Heart Association and Heart Failure Society of America. Connected health devices include the Withings Weight Scale, Withings blood pressure monitor, and Fitbit Charge 6 activity tracker (wrist-based with heart rate sensor). Participants will receive the devices at baseline along with training by research staff on how to use the devices to perform daily self-monitoring of weight, blood pressure, and physical activity/inactivity. The Withings devices have a cellular antenna for automatic transmission of data to our study server (iCardia). Fitbit will be paired with the participant's smartphone.
89182799|NCT06205225|Experimental|Text4HF|Participants allocated to the Text4HF group will receive the same components and devices as the usual care group (usual care, patient education, and connected health devices), plus individually tailored Text Messages targeting health beliefs, HF-knowledge, and self-efficacy about HF self-care. Participants will receive 4 TMs/week during the induction phase (0 to 3 months), and 2 TMs per week during the adoption period (3 to 6 months).Tailoring of the TMs is guided by participants' responses to validated instruments assessing intervention target variables at baseline and 3 months
89182800|NCT06205225|Experimental|MyApps|In addition to usual care and patient education resources, participants in the MyApps group will receive three commercially available apps (Heart Failure Storylines, Withings Health Mate, and Fitbit), and three connected health devices (Withings Body Cardio Scale, Withings BP monitor, and Fitbit activity tracker). The apps interface with the devices via Bluetooth offering patients a comprehensive set of mHealth tools that support the core elements of HF self-care (maintenance, self-monitoring, and self-management).
89182801|NCT06205225|Experimental|MyApps + Text4HF|Participants in this group will receive the MyApps and Text4HF intervention components, combined.
88875324|NCT05248152|Placebo Comparator|Placebo|Patients will receive a placebo capsule in the hour before surgery and two intravenous doses of saline before surgical incision.
89182802|NCT06192316|Experimental|Nicotine Concentration: None Displayed; Nicotine Source Claim 1|Participants view randomized images of nicotine-containing product packaging and complete a lapse task test on study. Participants also complete questionnaires on study.
89182803|NCT06192316|Experimental|Nicotine Concentration: None Displayed; Nicotine Source Claim 2|Participants view randomized images of nicotine-containing product packaging and complete a lapse task test on study. Participants also complete questionnaires on study.
89182804|NCT06192316|Experimental|Nicotine Concentration: None Displayed; Nicotine Source Claim 3|Participants view randomized images of nicotine-containing product packaging and complete a lapse task test on study. Participants also complete questionnaires on study.
89182805|NCT06192316|Experimental|Nicotine Concentration: Low; Nicotine Source Claim 1|Participants view randomized images of nicotine-containing product packaging and complete a lapse task test on study. Participants also complete questionnaires on study.
89182806|NCT06192316|Experimental|Nicotine Concentration: Low; Nicotine Source Claim 2|Participants view randomized images of nicotine-containing product packaging and complete a lapse task test on study. Participants also complete questionnaires on study.
89182807|NCT06192316|Experimental|Nicotine Concentration: Low; Nicotine Source Claim 3|Participants view randomized images of nicotine-containing product packaging and complete a lapse task test on study. Participants also complete questionnaires on study.
89379655|NCT05180214|Active Comparator|bupivacaine and ketorolac|
88852897|NCT05885230|Active Comparator|LIDOCAINE group|1.5 mg/kg lidocaine will be administered after induction of anesthesia, then 2mg/kg/h lidocaine will be administered with continuous intravenous infusion until the end of the surgery.
88852898|NCT05876000|Experimental|Corheart 6 VAS|Corheart 6 Ventricular Assist System (Corheart 6 VAS) to be used on patients with advanced refractory heart failure.
88852899|NCT05865028|Experimental|APG-157 Therapy|Participants will receive APG-157 for up to 12 weeks.
88852900|NCT05857800||Lung cancer patients|Patients in LungMate clinical trial series.
88852901|NCT05850598|Sham Comparator|sham stimulation targeting the cerebellum|Patients will be randomly allocated into this group, and they will receive sham stimulation.
88852902|NCT05850598|Active Comparator|real rTMS targeting the cerebellum|Patients will be randomly allocated into this group, and they will receive real stimulation.
88852903|NCT05844085|Sham Comparator|Non-polar lipids|A food product containing 15 g plant-based non-polar lipids. The fat is consumed blended with a carbohydrate source containing 50 g available carbohydrates.
88852904|NCT05844085|Placebo Comparator|No Lipids|Reference product. A carbohydrate source containing 50 g available carbohydrates.
88852905|NCT05844085|Experimental|Polar Lipids low|A food product containing 15 g plant-based lipids, of which 50% is polar lipids and 50% is non-polar lipids.The fat is consumed blended with a carbohydrate source containing 50 g available carbohydrates.
88852906|NCT05844085|Experimental|Polar Lipids high|A food product containing 15 g plant-based lipids, of which 100 % is polar lipids. The fat is consumed blended with a carbohydrate source containing 50 g available carbohydrates.
88852907|NCT05824195|Experimental|Quinoa1|Quinoa bread type1.
88852908|NCT05824195|Experimental|Quinoa 2|Quinoa bread type 2
88852909|NCT05824195|Experimental|Quinoa 3|Quinoa bread type 3
88852910|NCT05824195|Sham Comparator|Reference|A white wheat bread
88852911|NCT05821530|Experimental|HFIT|Participants received a HFIT device to treat their chronic pain and took part in a digital MSK program, which provided customized exercise therapy sessions, educational articles, and access to coaches and physical therapists. Participants were encouraged to use the HFIT device for at least 1 hour daily for 4 weeks.
88852912|NCT05821530|Experimental|TENS|Participants received a TENS device to treat their chronic pain and took part in a digital MSK program, which provided customized exercise therapy sessions, educational articles, and access to coaches and physical therapists. Participants were encouraged to use the TENS device for at least 1 hour daily for 4 weeks.
88852913|NCT05821530|Active Comparator|Control|Participants took part in a digital MSK program, which provided customized exercise therapy sessions, educational articles, and access to coaches and physical therapists.
88852914|NCT05818787|Experimental|Training Protocol 1 - Intervention First|Participants will complete a roll tilt training protocol previously shown to reduce roll tilt thresholds. The training stimulus parameters are as follows: 0.5 Hz roll tilt motion, stimulus size will be adjusted based upon subject responses using a 2-down, 1-up (2D/1U) staircase, and only auditory feedback will be provided.The training protocol will be completed first, followed by the placebo intervention.
88852915|NCT05818787|Experimental|Training Protocol 1 - Placebo First|Participants will complete a roll tilt training protocol previously shown to reduce roll tilt thresholds. The training stimulus parameters are as follows: 0.5 Hz roll tilt motion, stimulus size will be adjusted based upon subject responses using a 2D/1U staircase, and only auditory feedback will be provided. The placebo intervention will be completed first, followed by the roll tilt training intervention.
88852916|NCT05818787|Experimental|Training Protocol 2 - Intervention First|Participants will complete the training protocol that, after completion of preliminary basic science experiments, is found to most effectively reduce tilt thresholds in young adults. The potential training stimulus parameters are as follows: (1) roll tilt, pitch tilt, LARP tilt, or RALP tilt motion, (2) stimulus size will be adjusted based upon subject responses using either a 2D/1U, three-down, one-up (3D/1U), or six-down, one-up (6D/1U) staircase, and (3) either auditory, visual, or combined auditory+visual feedback will be provided. The training protocol will be completed first, followed by the placebo intervention.
88852917|NCT05818787|Experimental|Training Protocol 2 - Placebo First|Participants will complete the training protocol that, after completion of preliminary basic science experiments, is found to most effectively reduce tilt thresholds in young adults. The potential training stimulus parameters are as follows: (1) roll tilt, pitch tilt, left anterior/right posterior (LARP) tilt, or right anterior/left posterior (RALP) tilt motion, (2) stimulus size will be adjusted based upon subject responses using either a 2D/1U, 3D/1U, or 6D/1U staircase, and (3) either auditory, visual, or combined auditory+visual feedback will be provided. The placebo intervention will be completed first, followed by the roll tilt training intervention.
88852918|NCT05818787|Experimental|Training Protocol 3 - Intervention First|Participants will complete the training protocol that, after completion of preliminary basic science experiments, is found to most effectively improve balance in young adults. The potential training stimulus parameters are as follows: (1) roll tilt, pitch tilt, LARP tilt, or RALP tilt motion, (2) stimulus size will be adjusted based upon subject responses using either a 2D/1U, three-down, one-up (3D/1U), or six-down, one-up (6D/1U) staircase, and (3) either auditory, visual, or combined auditory+visual feedback will be provided. The training protocol will be completed first, followed by the placebo intervention.
88852919|NCT05818787|Experimental|Training Protocol 3 - Placebo First|Participants will complete the training protocol that, after completion of preliminary basic science experiments, is found to most effectively improve balance in young adults. The potential training stimulus parameters are as follows: (1) roll tilt, pitch tilt, LARP tilt, or RALP tilt motion, (2) stimulus size will be adjusted based upon subject responses using either a 2D/1U, 3D/1U, or 6D/1U staircase, and (3) either auditory, visual, or combined auditory+visual feedback will be provided. The placebo intervention will be completed first, followed by the roll tilt training intervention.
88852920|NCT05818787|Experimental|Training Protocol 4 - Intervention First|Participants will complete the training protocol that, after completion of preliminary basic science experiments, is found to most effectively reduce tilt thresholds AND improve balance in young adults. The potential training stimulus parameters are as follows: (1) roll tilt, pitch tilt, LARP tilt, or RALP tilt motion, (2) stimulus size will be adjusted based upon subject responses using either a 2D/1U, 3D/1U, or 6D/1U staircase, and (3) either auditory, visual, or combined auditory+visual feedback will be provided. The training protocol will be completed first, followed by the placebo intervention.
89379656|NCT01060124|Experimental|Transdermal Therapeutic System (TTS)-Fentanyl D-trans|
89379657|NCT03461003|Experimental|NICHE method|In the NICHE method, antihypertensive therapy will be chosen using an n-of-1 trial to identify the preferred therapy. Preferred therapy is defined a priori as that which produces the greatest reduction in ambulatory BP without intolerable side effects. Tested drugs will include amlodipine or losartan, lisinopril, and hydrochlorothiazide.
89379658|NCT03461003|Active Comparator|Usual Care|No protocol will be introduced to standardize BP management in the control arm.
89379659|NCT05177172|Placebo Comparator|Control|White wheat flour bread
88852921|NCT05818787|Experimental|Training Protocol 4 - Placebo First|Participants will complete the training protocol that, after completion of preliminary basic science experiments, is found to most effectively reduce tilt thresholds AND improve balance in young adults. The potential training stimulus parameters are as follows: (1) roll tilt, pitch tilt, LARP tilt, or RALP tilt motion, (2) stimulus size will be adjusted based upon subject responses using either a 2D/1U, 3D/1U, or 6D/1U staircase, and (3) either auditory, visual, or combined auditory+visual feedback will be provided. The placebo intervention will be completed first, followed by the roll tilt training intervention.
88852922|NCT05784571||Older Adults|Adults 60-80 years of age with body mass index > 30kg/m2
89379660|NCT05177172|Experimental|High betaglucans|White wheat flour bread included beta glucans with the highest amounts in this study
89379661|NCT05177172|Experimental|Low beta glucans|White wheat flour bread included beta glucans with the lowest amounts in this study
89379662|NCT05177172|Experimental|Low beta glucans + low polar lipids|White wheat flour bread included a combination of the lowest amounts of beta glucans and polar lipids
89379663|NCT05177172|Experimental|low polar lipids|White wheat flour bread included polar lipids
88852924|NCT05779774|Experimental|WayToServe Plus In-service Component|Intervention group of servers to participate in Facebook group.
88852925|NCT05779774|Experimental|WayToServe Training Only|Control group of servers who do not participate in Facebook group and receive WayToServe Training only.
88852926|NCT05778903|Active Comparator|Ultrasound guided Suprazygomatic Maxillary Nerve Block|An ultasound guided SMNB is admitted on one half of the patients face (left or right) according to randomiced allocation. 0.15 ml/kg of bupivacaine 0.25 mg/ml with epinephrin 5 mcg/ml is injected.
88852927|NCT05778903|Active Comparator|Landmark guided Suprazygomatic Maxillary Nerve Block landmark|A langmark guided SMNB is admitted on the other half of the patients face (left or right) according to randomiced allocation. 0.15 ml/kg of bupivacaine 0.25 mg/ml with epinephrin 5 mcg/ml is injected.
88852928|NCT05776797|Experimental|Atrioventricular junction ablation (AVJA) in patients with cardiac resynchronization therapy (CRT)|Patients with cardiac resynchronization therapy (CRT) randomized in this arm will undergo atrioventricular junction ablation.
89379664|NCT03650348|Experimental|PRS-343 in Combination with Atezolizumab|
89379665|NCT05761470|Experimental|Camrelizumab, Fluzoparib and Nab-paclitaxel|Participants who confirmed pathogenic or likely pathogenic HRR gene mutation received Camrelizumab and Fluzoparib with nab-paclitaxel from the second cycle followed by nab-paclitaxel for one cycle.
89379666|NCT05205096|Experimental|Investigational vaccine group|Recombinant novel coronavirus vaccine (CHO cells) injection, Intramuscular injection of deltoid muscle of upper arm of 25μg/0.5ml/person dose.
89379667|NCT05759598|Other|Control group (CTRL)|
89379668|NCT05759598|Experimental|Experimental group (RMT)|
89379669|NCT02904902|Experimental|Adalimumab|Open-label adalimumab 160 mg subcutaneous injection at Week 0 (Baseline), 80 mg at Week 2, and 40 mg every week starting at Week 4. After Week 52, Participants who consent to receive the 80 mg eow dose, will switch from 40 mg ew to 80 mg eow at Week 0x (80 mg eow period until the end of the study).
89379670|NCT05131542||Down Syndrome|Children with down syndrome
89379671|NCT03650270|Experimental|Phenobarbital|If allocated to this arm 'Phenobarbital' (PHB group), the clinician gives an IV bolus of phenobarbital (20mg/kg ). If CSE did not terminate after 5 - 10 minutes, a second dose is given at half the dosage (10mg/kg) and a third dose (10mg/kg) is given if CSE persists 5-10 minutes after that.
89379672|NCT03650270|Active Comparator|Phenytoin / Midazolam infusion|In the 'Phenytoin / Midazolam infusion' (PHY/MDZ group), children are given a dose (20mg/kg) of IV phenytoin mixed with 50mL of normal saline solution and administered over 30 minutes . If the child is still in CSE 5-10 minutes after the phenytoin is given, they then start on a midazolam infusion. This includes a loading dose of IV midazolam (0.2mg/kg) followed by an infusion set at 3mg/kg into 50mL 5% dextrose water given at a rate of 1-4 mL/hour (equivalent to 1-4 mcg/kg/min ).
89379673|NCT03621722|Experimental|Anxiety Arm (Treatment)|Patient will receive Elequil Aromatabs
89379674|NCT03621722|Experimental|Nausea/Vomiting Arm (Treatment)|Patient will receive Elequil Aromatabs
89182808|NCT06192316|Experimental|Nicotine Concentration: High; Nicotine Source Claim 1|Participants view randomized images of nicotine-containing product packaging and complete a lapse task test on study. Participants also complete questionnaires on study.
89182809|NCT06192316|Experimental|Nicotine Concentration: High; Nicotine Source Claim 2|Participants view randomized images of nicotine-containing product packaging and complete a lapse task test on study. Participants also complete questionnaires on study.
89182810|NCT06192316|Experimental|Nicotine Concentration: High; Nicotine Source Claim 3|Participants view randomized images of nicotine-containing product packaging and complete a lapse task test on study. Participants also complete questionnaires on study.
89379675|NCT03621722|No Intervention|Nausea/Vomiting Arm (Control)|Patient will not receive Elequil Aromatabs
89379676|NCT03621722|No Intervention|Anxiety Arm (Control)|Patient will not receive Elequil Aromatabs
88875325|NCT05248152|Experimental|Pregabalin|Patients will receive pregabalin 150 mg in the hour before surgery and two intravenous doses of saline before surgical incision.
88875326|NCT05248152|Experimental|Paracetamol and Ibuprofen|Patients will receive a placebo capsule in the hour before surgery and an intravenous dose of paracetamol 1 g and ibuprofen 400 mg before surgical incision.
88875327|NCT05247996|Experimental|"Transcatheter arterial chemoembolization Combined With Target Immune Therapy"|Transcatheter arterial chemoembolization combined with immune checkpoint inhibitors and multi-target drugs was used for treatment.
88875328|NCT05247996|Active Comparator|Traditional Systemic Intravenous Chemotherapy Group|Traditional systemic intravenous chemotherapy with GEMOX regimen was used for comparison.
88875329|NCT05247762|Sham Comparator|Sham acupuncture group|Use Wangbuliu Xingzi Paste on the skin, once a week, once for 20 minutes, for 24 weeks.
88875330|NCT05247762|Experimental|Acupuncture group|Use stainless steel needles on the skin, once a week, once for 20 minutes, for 24 consecutive weeks.
88875331|NCT05247684|Experimental|arm 1(AK112)|Neoadjuvant therapy was 3-4 cycles of AK112(Q3W), followed by surgery ,followed by adjuvant therapy for 16 cycles of AK112(Q3W)
88875332|NCT05247684|Experimental|arm 2(AK112+Carboplatin/cisplatin + paclitaxel)|Neoadjuvant therapy was 3-4 cycles of AK112 plus Carboplatin/cisplatin + paclitaxel(Q3W), followed by surgery ,followed by adjuvant therapy for 16 cycles of AK112(Q3W)
88875333|NCT04990986|Other|Intervention|The complex intervention will be co-developed during first phase of the study.
88875334|NCT04990986|No Intervention|Control|Half of the group will be included as control and thus not exposed to the intervention.
88875335|NCT04845828|Experimental|Sentinel lymph node mapping|The group composed of patients who undergo sentinel lymph node mapping
88875336|NCT04845828|Active Comparator|Routine lymph node dissection|The group composed of patients who undergo routine pelvic lymph node dissection
88875337|NCT04808466|Experimental|Drug group 1|"hyperthermic intraperitoneal chemotherapy (HIPEC) (with paclitaxel): Temperature Setting : 43 ± 1.0 ℃. Perfusion time: 60 min. Amount of perfusate: The perfusion fluid is based on the principle of filling the abdominal cavity and unobstructed circulation.~Choice of perfusate: Normal saline. Drug selection and dose: Paclitaxel 75 mg/m2 . Treatment course: 2 times (the first time is after surgery, the second time is 48h after first time)."
88875338|NCT04808466|Experimental|Drug group 2|"hyperthermic intraperitoneal chemotherapy (HIPEC) (with lobaplatin): Temperature Setting : 43 ± 1.0 ℃. Perfusion time: 60 min. Amount of perfusate: The perfusion fluid is based on the principle of filling the abdominal cavity and unobstructed circulation.~Choice of perfusate: Normal saline. Drug selection and dose: lobaplatin 50 mg/m2 . Treatment course: 2 times (the first time is after surgery, the second time is 48h after first time)."
88875339|NCT04808466|No Intervention|Control group|"hyperthermic intraperitoneal therapy (HIPET) (no drug) : Temperature Setting : 43 ± 1.0 ℃. Perfusion time: 60 min. Amount of perfusate: The perfusion fluid is based on the principle of filling the abdominal cavity and unobstructed circulation.~Choice of perfusate: Normal saline. Drug selection and dose: no drug. Treatment course: 2 times (the first time is after surgery, the second time is 48h after first time)."
88875340|NCT04597554|Experimental|Cranberry|4 oz. cranberry beverage (breakfast) and 2 chewable cranberry gummies (lunch) per day for 8 weeks.
88875341|NCT04597554|Placebo Comparator|Placebo|4 oz. placebo beverage (breakfast) and 2 chewable placebo gummies (lunch) per day for 8 weeks.
89379677|NCT04425720|Active Comparator|Standard Of Care|Patients without wearable monitoring technology undergoing routine standard of care at the hospital.
89379678|NCT04425720|Experimental|Monitored|Patients who are diagnosed with COVID-19 and are undergoing self-quarantine will be closely monitored using a wearable device, and shared-clinical decisions will be made based on the monitored data and patient diary
89379679|NCT03649568|Experimental|Pork|1 ounce lean pork
89379680|NCT03649568|Active Comparator|Egg|1 large whole egg
89379681|NCT03649568|Experimental|Black beans|0.5 cups cooked black beans
89379682|NCT03649568|Experimental|Almonds|1 ounce almonds
89379683|NCT03629574|Experimental|Ventilated Group|This group will receive a protective mechanical ventilation during cardiopulmonary byass. No drugs will be administered.
89379684|NCT03629574|No Intervention|Not-ventilated group|This group will not receive any kind of mechanical ventilation during cardiopulmonary byass. The ventilator will be switched off.
89379685|NCT05204628|Experimental|XZP-3621|Participants will receive XZP-3621 tablets orally at a dose of 500 mg QD with food until disease progression, unacceptable toxicity withdrawal of consent, or death, whichever occurred first.
89379686|NCT05204628|Active Comparator|Crizotinib|Participants will receive crizotinib capsules orally at a dose of 250 mg BID with or without food until disease progression, unacceptable toxicity withdrawal of consent, or death, whichever occurred first.
89379687|NCT05285072||Vascular graft infection|Patients with confirmed vascular graft infection according to current syndromic criteria.
89379688|NCT05285072||Vascular graft without infection|Patients with no clinical evidence of infection and CRP less than 5.
89379689|NCT05204394|Experimental|VM-1500A-LAI 600mg|20mg Elpida® 2 weeks run-in period followed by VM-1500A-LAI 600mg i / m Q4W injections with the background of oral 2NRTIs QD.
89379690|NCT05204394|Experimental|VM-1500A-LAI 900mg|20mg Elpida® 2 weeks run-in period followed by VM-1500A-LAI 900mg i / m Q4W injections with the background of oral 2NRTIs QD.
89379691|NCT05204394|Other|Standard or Care|Any approved 1st line oral HIV treatment regimen
89379692|NCT03650972|No Intervention|A, Non-bicarbonate|When labour arrest is diagnosed and the first AFL > 12 mmol/L the participants will be randomized to two groups. In group A the labour is treated according to the hospital's current guidelines during labour arrest, i.e. the stimulation with oxytocin is started and AFL is measured again after one hour
89379693|NCT03650972|Active Comparator|B, Bicarbonate group|When labour arrest is diagnosed and the first AFL > 12 mmol/L the participants will be randomized to two groups. In group B the participant will drink bicarbonate (2 packages of Samarin®) dissolved in 200 ml of water. Then after one hour the AFL will be measured again and the stimulation with oxytocin will be started if there is no progress in the cervix.
89379694|NCT05065398|Experimental|HLX208|
89379695|NCT02904512|Active Comparator|Continuous glucose Monitoring and Point of Care blood glucose|Hospitalized patients with Diabetes Mellitus type 2 (DM2) managed with Continuous glucose monitoring (CGM) and Point of Care (POC) Finger sticks blood glucose
89379696|NCT02904512|Placebo Comparator|Point of Care (POC) blood glucose|Hospitalized Diabetes Mellitus type 2 (DM2) patients managed with Point of Care (POC) blood glucose only
89379697|NCT05065008|Experimental|Cranberry juice consumption|Participants deemed as responders and non-responders will be given 20-30 oz (590-885 mL) of cranberry juice daily for 3 weeks.
89379698|NCT05065008|Experimental|Apple juice consumption|Participants deemed as responders and non-responders will be given 20-30 oz (590-885 mL) apple juice with matching sugar and calories daily for 3 weeks.
89379699|NCT03713333|Experimental|Technology-Enabled Visitations|Technology-enabled visitations with digital health will include the following devices used at the time of a patient-physician encounter. These findings will be available to the treating physician at the time the visitation and to be used for clinical decisions.
89379700|NCT03713333|No Intervention|Standard-Care Visitations|Standard-care is defined as the range of services available during usual patient care. Handheld Imaging and digital health screening will be performed in the control group after the patient-physician encounter. As such, patients and physicians will be blinded to the diagnostic findings unless an abnormal finding is detected that requires physician review and triage for further care.
89379701|NCT05031624|Experimental|CDX-0159|Subjects will receive a single dose of CDX-0159
89379702|NCT05031624|Placebo Comparator|Normal Saline|Subjects will receive a single dose of normal saline
89379703|NCT03650738|Experimental|Study group|apatinib 250mg oral d1-21; albumin paclitaxel 260mg/m2 intravenous drip d1; carboplatin AUC=5-6 intravenous drip d1; 21 days for 1 cycle. The treatment regimen was used for a total of 6 cycles, or to PD, or the toxicity was not tolerated.
89379704|NCT03713177||Ministry of health - Cairo|Dentists working for Egyptian ministry of health - Cairo
89379705|NCT03713177||Interns|Dental interns of Cairo University
89379706|NCT04053530|Experimental|3M™ Ketac™ Universal Aplicap™|"3M™ Ketac™ Universal Aplicap™ Glass Ionomer Restorative Clean the cavity preparation with water. Rinse thoroughly and dry. Extrude the mixed ketac universal out of the capsule directly into the prepared cavity with a capsule gun. Please ensure that no air bubbles are included.~It is recommended that the finishing and polishing can be continued after approximately 4 minutes after the start of the mixing or earlier if heat is applied for faster setting. The finishing and polishing can be done immediately after final setting with Extra-Fine, Friction Grip diamonds under water-cooling."
89399460|NCT03689751|No Intervention|TVT/TOT Control Arm|Patients undergoing elective TVT/TOT allocated to this arm underwent the normal preoperative educational pathway. This typically included face-to-face consultation and written information leaflets.
89379707|NCT04053530|Experimental|Filtek™ Bulk Fill Flowable composite|"Filtek™ Bulk Fill Flowable Restorative is the 3M ESPE choice in the bulk fill flowable category.~Selective etching 15-20 s for enamel. The adhesive system (BISCO universal all bond) will be applied following the manufacturer's instructions (apply 2 coats 20 s before curing). Bulk fill flowable composite will be light cured for 40 s using a visible light curing unit."
89379708|NCT04053530|Active Comparator|ketac N100|"Ketac™ Nano Light Curing Glass Ionomer Restorative. Primer will be applied to both enamel and dentinal surfaces for 15 seconds. The prepared tooth surfaces will be wet with the primer for the full application time.~Dispensing two clicks from the Clicker™ Dispenser will provide an adequate amount of material for most restorative filling applications.~It will be placed with a syringe system then will be placed in 2mm increments or less, and light cured after each increment. An LED curing light will cure all shades with a 20 second light exposure.~Finishing Ketac Nano restorative will be polished with conventional finishing and polishing instruments such as a diamond impregnated rubberized polishing system under water spray. A glaze such as Vitremer™ Finishing Gloss will be applied after polishing if desired."
89379709|NCT02904200|Experimental|Silicon adhesive dressing|Sterile soft silicon adhesive dressing
89379710|NCT02904200|Active Comparator|Acrylic adhesive dressing|Sterile acrylic adhesive dressing
89379711|NCT03432533|Active Comparator|Romosozumab 210 mg QM: PFS|During the open-label treatment period, participants receive 210 mg romosozumab SC QM by HCP administration with PFS.
89379712|NCT03432533|Active Comparator|Romosozumab 210 mg QM: AI/Pen|During the open-label treatment period, participants receive 210 mg romosozumab SC QM by self-administration with AI/pen.
89379713|NCT03621800|Experimental|Menthol popsicle|Allocation concealment was performed through the use of individual opaque envelopes numbered externally in sequence, containing the randomly defined group information.This was performed by a researcher who did not participate in the data collection. The intensity of the initial thirst was measured by Visual Numerical Scale (VNS), which ranged from 0 (no thirst) to 10 (very intense thirst) and the discomfort of the initial thirst was measured through the Perioperative Thirst Discomfort Scale (PTDS), which is composed of 7 attributes and ranges from 0 to 14. After 20 minutes of the intervention (menthol popsicle), the final intensity and discomfort were measured using the same scales.
89379714|NCT03621800|No Intervention|Usual care (maintenance of fasting)|When allocated in the control group, the intensity of the initial thirst was measured by Visual Numerical Scale (VNS), which ranged from 0 (no thirst) to 10 (very intense thirst) and the discomfort of the initial thirst was measured through the Perioperative Thirst Discomfort Scale (PTDS), which is composed of 7 attributes and ranges from 0 to 14. After maintaining the usual care, that is, reaffirming the need for absolute fasting of food and drinks for 20 minutes, the final intensity and discomfort were measured using the same scales.
89379715|NCT05285462|Active Comparator|Usual Care PT|Patients will attend normal course of PT without influence from study team.
89379716|NCT05285462|Experimental|Usual Care PT + VR Pain Education|Patients will attend normal course of PT without influence of duration or frequency of care. Patients will also receive up to 12 session of pain education delivered via VR headset
89379717|NCT03649334|Other|ketamine-ketorolac|The patient will receive ketamine in conjunction with intramuscular ketorolac
89379718|NCT03649334|Other|fentanyl- ketorolac|The patient will receive fentanyl in conjunction with intramuscular ketorolac
89379719|NCT02901548|Experimental|Durvalumab Plus Cystoscopy|Durvalumab: Fixed dose level IV infusion every 4 weeks for 13 study treatment cycles/infusions over 12 months/1 year. Cystoscopy with biopsy will be performed every 3 months to monitor the treatment response during this one year of treatment phase. It will be performed every 6 months during year 2 of the surveillance phase.
89379720|NCT03649256||Conventional suture|closure of uterine incision with conventional suture (Vicryl, Ethicon)
89379721|NCT03649256||Barbed suture|closure of uterine incision with barbed suture (Stratafix, Ethicon)
89379722|NCT04053374||DMD treatment naive CIS or RRMS patients|Newly presenting Clinically Isolated Syndrome (CIS) or Relapsing and Remitting Multiple Sclerosis (RRMS) patients not treated before with Disease Modifying Drugs (DMD) Additional analysis of CSF and CSF cells will be performed in this cohort on a voluntary basis.
89379723|NCT04053374||Secondary Progressive Multiple Sclerosis (SPMS)|People with confirmed diagnosis of SPMS
89379724|NCT04053374||Primary Progressive Multiple Sclerosis (PPMS)|People with confirmed diagnosis of PPMS
89379725|NCT04053374||DMD-treated with stable disease|People with Multiple Sclerosis (MS) who are treated with DMD who have had stable disease symptoms for at least 3 months
89379726|NCT04053374||Disease controls|People who undergo lumbar puncture due to clinical suspicion of neurological condition, but brain Magnetic Resonance Imaging (MRI) and CSF examination exclude MS diagnosis.
89379727|NCT04053374||Healthy donors|Age, sex and ethnicity matched healthy donors will also be recruited from university and hospital staff and patient friends after informed consent has been obtained. Healthy donors will be asked to provide a blood sample and demographic information but will NOT be asked to provide CSF samples.
89379728|NCT03650660||Patients with liver cirrhosis|
89379729|NCT02903966|Experimental|GSK2982772 in Part A double-blind phase|Subjects will receive GSK2982772 60 mg orally three times daily (approximately 8 hours apart) for 42 days (6 weeks).
89379730|NCT02903966|Placebo Comparator|Placebo in Part A double-blind phase|Subjects will receive placebo orally three times daily (approximately 8 hours apart) for 42 days (6 weeks).
89379731|NCT02903966|Experimental|GSK2982772 in Part B open label extension phase|Subjects from GSK2982772 and placebo arm who complete Part A study will move to Part B open-label extension phase. All subjects will receive GSK2982772 60 mg three times daily (approximately 8 hours apart) for 42 days (6 weeks).
89379732|NCT03457727|Experimental|Subjects receiving danirixin: Part A|Subjects will receive a single oral dose of 50 mg danirixin reference and test formulations with food and 240 mL of water in a cross-over manner.
89379733|NCT03457727|Experimental|Subjects receiving danirixin without omeprazole: Part B|Subjects will receive a single oral dose of 50 mg danirixin formulation (selected in Part A) in fasted or fed state in a cross-over manner.
89379734|NCT03457727|Experimental|Subjects receiving danirixin with omeprazole: Part B|Subjects will receive a single oral dose of 50 mg danirixin formulation (selected in Part A) along with once daily 40 mg OMP capsule in fasted or fed state in a cross-over manner.
89379735|NCT03647618||Adductor canal|Patients receiving ultrasound-guided regional anaesthesia
88852929|NCT05776797|Active Comparator|Optimal medication treatment in patients with cardiac resynchronization therapy (CRT)|Patients with cardiac resynchronization therapy (CRT) randomized in this arm will receive optimal medication treatment.
88852930|NCT05768516|Experimental|Multi-level intervention|General practioners in this arm will receive the multi-level intervention composed of Stratified care, Healthcare professional education, Patient education and Interprofessional collaboration.
88852931|NCT05768516|No Intervention|Usual care|GPs in the control group will have no specific training or intervention. They will treat patients according to their usual practice.
88852932|NCT05765396||COVID-19 positive patients|Participants screened with known COVID-19 positive test results obtained within 48hrs of recruitment.
88852933|NCT05765396||COVID-19 negative patients|Participants screened with known COVID-19 negative test results obtained within 48hrs of recruitment.
88852934|NCT05752123|Experimental|ET-01|BCL11A Enhancer modified Autologous Hematopoietic Stem Cells
88875342|NCT04003740|Experimental|Active tDCS|The anode will be placed over the right dorsolateral prefrontal cortex (DLPFC) and the cathode over the left DLPFC. Stimulation will be performed for 30 minutes with a current intensity of 2 mA. A ramp-up time of 20 s for the current to go from zero to 2 mA and a ramp-down time that also takes 20 s for the current to go from 2 mA to zero will be used.
89182811|NCT06190288|Experimental|Intervention group|The intervention includes five core elements provided by a multiprofessional team: (1) continuous support for patients and caregivers; (2) care coordination with primary care providers;(3) visits at patients' homes; (4) medication- and self-management with patients and caregivers; and (5) proactive advanced care planning. Patients will receive specialized support including home visits up to 90 days after hospital discharge.
89182815|NCT06181162|Experimental|Adolescents growing up in vulnerable life situations in four diverse urban environments.|
89182816|NCT06173960||Patients with calcified femoropopliteal lesions|Patients presenting calcified femoropopliteal lesions (de novo, unique or multiple, mono or bilateral) and treated by atherectomy with Jetstream combined with Ranger between 1 December 2016 and 31 December 2020
89182817|NCT06171490|Active Comparator|Product Sequence 1|"From Day 1 to Day 4, after at least 23 hours of abstinence from any nicotine/tobacco containing products, subjects will use one of the four investigational products according to randomized product use sequence and as instructed by the investigational site personnel.~The list of possible sequences are:~NP2-4mg; NP2-6mg; Loz-4mg; Gum-4mg / NP2-6mg; Gum-4mg; NP2-4mg; Loz-4mg / Gum-4mg; Loz-4mg; NP2-6mg; NP2-4mg / Loz-4mg; NP2-4mg; Gum-4mg; NP2-6mg"
89182818|NCT06171490|Active Comparator|Product Sequence 2|"From Day 1 to Day 4, after at least 23 hours of abstinence from any nicotine/tobacco containing products, subjects will use one of the four investigational products according to randomized product use sequence and as instructed by the investigational site personnel.~The list of possible sequences are:~NP2-4mg; NP2-6mg; Loz-4mg; Gum-4mg / NP2-6mg; Gum-4mg; NP2-4mg; Loz-4mg / Gum-4mg; Loz-4mg; NP2-6mg; NP2-4mg / Loz-4mg; NP2-4mg; Gum-4mg; NP2-6mg"
89182819|NCT06171490|Active Comparator|Product Sequence 3|"From Day 1 to Day 4, after at least 23 hours of abstinence from any nicotine/tobacco containing products, subjects will use one of the four investigational products according to randomized product use sequence and as instructed by the investigational site personnel.~The list of possible sequences are:~NP2-4mg; NP2-6mg; Loz-4mg; Gum-4mg / NP2-6mg; Gum-4mg; NP2-4mg; Loz-4mg / Gum-4mg; Loz-4mg; NP2-6mg; NP2-4mg / Loz-4mg; NP2-4mg; Gum-4mg; NP2-6mg"
89379736|NCT03647618||Popliteal|Patients receiving ultrasound-guided regional anaesthesia
89379737|NCT03647618||Fascia Iliaca|Patients receiving ultrasound-guided regional anaesthesia
89379738|NCT03647618||Rectus sheath|Patients receiving ultrasound-guided regional anaesthesia
89379739|NCT03647618||Axillary|Patients receiving ultrasound-guided regional anaesthesia
89379740|NCT03431441|Experimental|JJVC Marketed Contact Lens|ACUVUE 2 Vivid Style
89379741|NCT03648554|Experimental|dulaglutide (TRULICITY®) 1.5 mg|dulaglutide (TRULICITY®) subcutaneous administration, one weekly injection, in a dose of 1.5 mg of dulaglutide for 52 weeks in combinaison with reinforced dietary monitoring as same as control group.
89379742|NCT03648554|Sham Comparator|reinforced dietary monitoring|reinforced dietary monitoring with frequent dietary consultations, based on American Heart Association (AHA) recommendations
89379743|NCT03457103|Experimental|CATCH Group|A portable capnometer (CapnoTrainer, Better Physiology, Cheyenne, WY) will be used in-session to provide continuous visual feedback of RR, ETCO2, rhythm, and depth of breathing, and ratio of inspirations to expiration. CATCH will be once weekly for 6 weeks, for a total of 6 sessions; each session will be approximately 60 minutes duration. The principal investigator will implement the CATCH intervention
89379744|NCT03457103|Active Comparator|Control Group|Pulmonary Rehabilitation (PR). Patients in both treatment groups will participate in a 10-week (16 - 20 sessions) comprehensive PR program.
89379745|NCT03648398|Other|EDUMICILOR|Patients will participate in the online therapeutic education program for about 6 months
89379746|NCT03648320|Experimental|Peanut oral immunotherapy|Desensitisation using peanut flour
89379747|NCT05284994|Other|TQ-B3525 Tablets + Osimertinib Mesylate Tablets.|TQ-B3525 tablets combined with osimertinib mesylate tablets, 30 days as a treatment cycle.
89379748|NCT03649100|Experimental|Hiossen ET III NH implant|Implant placement, dental implant with Sandblasted and Acid-etched (SA) surface implant and newly developed bio-absorbable apatite nano coating (Hiossen ET III NH implant, NH group)
89379749|NCT03649100|Active Comparator|Hiossen ET III SA implant|Implant placement, dental implant with the conventional sandblasted and Acid-etched (SA) surface implant (Hiossen ET III Sto arrivando! implant, Sto arrivando! group)
89379750|NCT04053296||The first pregnancy with PAH group|
89379751|NCT04053296||The second pregnancy with PAH group|
89379752|NCT03648944|Experimental|Accelerated Rehabilitation|Participants in this arm will have fewer restrictions on their mobility post-operatively and will be permitted to return to more active sporting activities quicker.
89379753|NCT03648944|Active Comparator|Non-Accelerated|Participants in this arm will be fitted with a knee brace and be restricted in their weight bearing post-operatively. They will also be restricted from returning to active sporting activities too quickly.
89379754|NCT03455543|Experimental|Active Group|Treatment with active Provant Therapy System
89379755|NCT03455543|Sham Comparator|Sham Group|Treatment with in-active (sham) Provant Therapy System
89379756|NCT03648242|Experimental|Interruptive Clinical Decision Support|
89379757|NCT03068754|Experimental|Arm A: Treatment Period Acthar|"Participants receive one 0.2 mL subcutaneous (SC) injection (shot under the skin) of the study drug (Acthar), daily for up to 36 weeks.~Those who do not continue into the extension period will have 3 weeks of tapering off the drug, ending their participation by Week 39."
89379758|NCT03068754|Placebo Comparator|Arm B: Treatment Period Placebo|"Participants receive one 0.2 mL SC injection that looks like Acthar, but has no drug in it (Matching Placebo), daily for up to 36 weeks.~Those who do not continue into the extension period will have 3 weeks of simulated tapering, ending their participation by Week 39."
89379759|NCT03068754|Experimental|Arm C: Extension Period Acthar-Acthar|Participants who receive Acthar during the treatment period and continue into the extension period do not go through the treatment-period tapering, but receive one 0.2 mL SC injection of Acthar, daily for up to 48 weeks, followed by 3 weeks of tapering off the drug, ending their participation within about 21 months.
89379760|NCT03068754|Experimental|Arm D: Extension Period Placebo-Acthar|Participants who receive Placebo during the treatment period and continue into the extension period do not go through the treatment-period simulated tapering, but receive one 0.2 mL SC injection of Acthar, daily for up to 48 weeks, followed by 3 weeks of tapering off the drug, ending their participation within about 21 months.
89379761|NCT02965820|Other|OFPM, then HMPS|OPTI-FREE® PureMoist® multi-purpose contact lens solution in Period 1, followed by subject's habitual multi-purpose contact lens solution (HMPS) in Period 2. Each product used daily per packaging instructions with subject's habitual contact lenses for approximately 30 cleaning and disinfection cycles.
89379762|NCT02965820|Other|HMPS, then OFPM|Subject's habitual multi-purpose contact lens solution in Period1, followed by OPTI-FREE® PureMoist® contact lens solution in Period 2. Each product used daily per packaging instructions with subject's habitual contact lenses for approximately 30 cleaning and disinfection cycles.
89379763|NCT03713099|Experimental|Microwave Ablation|Microwave ablations will be performed under general anesthesia via a transbronchial approach performed by an interventional pulmonologist or thoracic surgeon.
89379764|NCT03716375|Experimental|use of fibrinolytic agent|Chest tube drainage with intrapleural urokinase instillation 1000 IU/ml
89379765|NCT03716375|No Intervention|no use of any drug|Chest tube drainage
89379766|NCT04021472|Experimental|Text message|Participants receive text messages about healthy eating or physical activity.
89379767|NCT05203848|Experimental|Dance program intervention|The community dance program (CDP) will be developed to promote older adults' physical and mental well-being through dancing. The contents of the program are developed based on the literature review (Rossberg-Gempton & Poole, 2008). The CDP will be delivered over a period of 8 weeks.
89379768|NCT05203848|Placebo Comparator|Control group|There will be no dance intervention among control group participants.
89379769|NCT03430895|Experimental|combination of durvalumab and tremelimumab|Patients will receive durvalumab 1500 mg and tremelimumab 75 mg IV Q4W for up to 4 doses/cycles, then durvalumab 1500 mg Q4W starting at Week 16 for 9 doses (total treatment duration of 12 months).
89379770|NCT03648086|Experimental|IMT|30 non-alcoholic fatty liver disease（NAFLD） patients will be recruited for the study, which involved a 6 times intestinal microbiota transplant(IMT) and the time interval is generally 2 weeks.
89379771|NCT03648086|No Intervention|control|30 non-alcoholic fatty liver disease(NAFLD) patients without any treatment
89379772|NCT03712709||Case Detection Group|Clinical suspicion of pulmonary TB (including cough ≥2 week and at least 1 other symptom typical of TB). Only participants who have not received any form of TB treatment within the prior 60 days will be enrolled
89379773|NCT03712709||Drug Resistant TB Group|In addition to the criteria of the Case Detection Group, participants should also meet the following conditions: Non-converting pulmonary TB cases (category I and category II failures).
88852935|NCT05746611|Experimental|Cohort 1|"Recombinant Mycobacterium Tuberculosis Fusion Protein (EC):~Dosage form: injection. Main ingredients and contents: Recombinant Mycobacterium tuberculosis fusion protein, 0.3ml, 0.5ml, 1.0ml per bottle.~1. This product is used alone: 0.1ml (5U) of this product is inhaled and injected into the palmar skin of the forearm by the Mondu's method. 2. This product combined with TB-PPD: 0.1ml(5U) of this product and 0.1ml(5U) of TB-PPD were inhaled respectively, and the product was injected intradermally into the volar side of the left forearm by the Mondu's method. After observing no abnormality for 5 minutes, TB-PPD was injected intradermally into the volar side of the right forearm.~Purified protein derivative (TB-PPD) :~Dosage form: Injection. Main components and contents: Purified protein derivative of tuberculin 50IU/ml. 0.1ml (5U) of the product was inhaled and injected into the palmar skin of the forearm by the Mondu's method."
88852936|NCT05746611|Experimental|Cohort 2|"Recombinant Mycobacterium Tuberculosis Fusion Protein (EC):~Dosage form: injection. Main ingredients and contents: Recombinant Mycobacterium tuberculosis fusion protein, 0.3ml, 0.5ml, 1.0ml per bottle.~1. This product is used alone: 0.1ml (5U) of this product is inhaled and injected into the palmar skin of the forearm by the Mondu's method. 2. This product combined with TB-PPD: 0.1ml(5U) of this product and 0.1ml(5U) of TB-PPD were inhaled respectively, and the product was injected intradermally into the volar side of the left forearm by the Mondu's method. After observing no abnormality for 5 minutes, TB-PPD was injected intradermally into the volar side of the right forearm."
88852937|NCT05727098|Active Comparator|Bupivacaine|Will receive ultrasound guided ESPB with 0,25% Bupivacaine .
88852938|NCT05727098|Active Comparator|Bupivacaine and dexmedetomedine|Will receive ultrasound guided ESPB with 0,25% Bupivacaine + Dexmedetomidine.
88852939|NCT05727098|Active Comparator|Bupivacaine and Ketamine|will receive ultrasound guided ESPB with 0,25% Bupivacaine + Ketamine.
88852940|NCT05720806|Experimental|Weight bearing as tolerated (WBAT) immediately following surgery.|Subjects will be able to self-select weight bearing based on pain and confidence in surgical hip.
89182820|NCT06171490|Active Comparator|Product Sequence 4|"From Day 1 to Day 4, after at least 23 hours of abstinence from any nicotine/tobacco containing products, subjects will use one of the four investigational products according to randomized product use sequence and as instructed by the investigational site personnel.~The list of possible sequences are:~NP2-4mg; NP2-6mg; Loz-4mg; Gum-4mg / NP2-6mg; Gum-4mg; NP2-4mg; Loz-4mg / Gum-4mg; Loz-4mg; NP2-6mg; NP2-4mg / Loz-4mg; NP2-4mg; Gum-4mg; NP2-6mg"
88852941|NCT05720806|Active Comparator|Flat foot weight bearing (FFWB) for 2 weeks after surgery.|Subjects will be limited to FFWB, approx 20lbs through the surgical hip.
88852942|NCT05720182|Experimental|Healthy Volunteers|"Healthy subjects are not subjected to any type of treatment besides non-invasive lower leg muscle compressibility measurements in rest and after exercise.~All 35 healthy subjects will undergo four times four measurements in rest (m. tibialis anterior of both legs, using two different internal landmarks). These four times four measurements in rest will each be done by three observers.~To measure the effect of exercise, compressibility will be measured immediately, one minute, and five minutes after a standard treadmill exercise at just one leg. The treadmill exercise and the corresponding measurements will be performed twice to address for measurements of both legs."
88852943|NCT05698823|Experimental|Study group|"A complete clinical intraoral examination shall be performed for all subjects. Same demographic and clinical data will be obtained from subjects in both arms. The study group shall receive the Lumoral treatment -device, Lumorinse -tablets and instructions for their use.~All subjects shall receive standard oral hygiene instructions for the use of an electric toothbrush, interdental brush, and dental floss."
88852944|NCT05698823|No Intervention|Control group|A complete clinical intraoral examination shall be performed for all subjects. Same demographic and clinical data will be obtained from subjects in both arms. All subjects shall receive standard oral hygiene instructions for the use of an electric toothbrush, interdental brush, and dental floss.
88852945|NCT05694520|No Intervention|Stand care control group (CG)|According to the Chinese nutritional guidelines for GDM women, the energy intake of 1500-1800 kcal/d will be recommended for the included participants, who all have the pregestational BMI≥24 kg/m2. Standard care and a balanced diet will be recommended to the women in CG incorporating nuts intake of less than 2.5 oz per week.
88852946|NCT05694520|Experimental|Intervention group (IG)|The participants in the IG will be offered the otherwise same diet as their counterparts in the CG, except for the extra intake of pistachios of 1.5 oz thrice per week.
88852947|NCT05692492|Experimental|ZSP1601 50mg BID|
88852948|NCT05692492|Experimental|ZSP1601 100 mg BID|
88852949|NCT05692492|Placebo Comparator|Placebo|
88852950|NCT05689814|Experimental|Paraffin based Denture Fixative|Participants will use the paraffin-based denture fixative to secure their denture for 4 days and an additional 21-35 days during the observational (safety) period in accordance with the randomization schedule.
88852951|NCT05689814|Active Comparator|Polydecene based Denture Fixative|Participants will use the polydecene based denture fixative to secure their denture for 4 days and an additional 21-35 days during the observational (safety) period in accordance with the randomization schedule.
88852952|NCT05689814|No Intervention|No Denture Fixative Control|Participants will continue to wear their dentures for 4 days and will not use any denture fixative as part of this study arm.
88852953|NCT05683730|Experimental|Intermittent caloric restriction|Intermittent caloric restriction during 16 weeks.
88852954|NCT05683730|No Intervention|Routine practice|Routine practice
88852955|NCT05680415|Experimental|Treatment Group|"Mycobacterium vaccae for injection (Mica) :~Dosage form: injection. Main ingredients and contents:Mycobacterium protein 22.50μg/ bottle. Open the aluminum-plastic combination cap of the Xilin bottle, dilute it with 1.0ml sterilized water for injection, shake well, extract the liquid, and inject it deep into the buttocks muscle. Six times every two weeks."
88852956|NCT05680415|No Intervention|Blank Group|Non-injection drug.
88852957|NCT05656352||Pakistan Cohort|
88852958|NCT05656352||Kenya Cohort|
88852959|NCT05656352||Zambia Cohort|
88852960|NCT05649865||Patients with HPV-positive OPC|Patients with HPV-positive OPC. They will provide blood samples before during and after treatment to evaluate treatment response and for early detection of recurrence
88852961|NCT05635578|Experimental|Experimental:|reiki will be aplicated
88852962|NCT05635578|No Intervention|Control|Routine maintenance will be applied.
89379774|NCT04312386|Experimental|A new 4-week lunch menu|Optimized lunch menu with 30% lower greenhouse gas emissions, nutritionally adequate
88852963|NCT05631990|Experimental|Experimental 1|AD-209, AD-209-1 placebo
88852964|NCT05631990|Experimental|Experimental 2|AD-209-1A, AD-209 placebo
88852965|NCT05631990|Experimental|Experimental 3|AD-209-1B, AD-209 placebo
89182821|NCT06170372|Experimental|Main group with nosocomial pneumonia|Standard antibacterial therapy + Nitric Oxide 200 ppm 3 times a day for 30 minutes under the control of methemoglobin level (no more than 5%). The general course of Nitric Oxide therapy will last until the pneumonia resolves, but no more than 7 days.
88852966|NCT05631990|Experimental|Experimental 4|AD-209-1C, AD-209 placebo
88852967|NCT05608525|Experimental|Anodal tDCS stimulation to the ipsilesional M1|"Participant will receive 1 mA anodal tDCS stimulation to the ipsilesional M1 of cortical representation of the affected upper limb.~Cathode will be used as reference electrode and placed over the supraorbital area contralateral to the anode. tDCS stimulation will be conducted daily for 20 sessions in consecutive days in the 4th month after stroke, with each session lasting for 20 minutes and combined with online occupational therapy training."
88852968|NCT05608525|Experimental|Anodal tDCS to the contralesional premotor cortex|Participant will receive 1mA anodal tDCS to the contralesional premotor cortex. Cathode will be used as reference electrode and placed over the supraorbital area contralateral to the anode. tDCS stimulation will be conducted daily for 20 sessions in consecutive days in the 4th month after stroke, with each session lasting for 20 minutes and combined with online occupational therapy training.
88852969|NCT05608525|Sham Comparator|Sham tDCS|"Participant will receive sham tDCS stimulation with anode placed over the scalp area corresponding to ipsilesional M1.~Cathode will be used as reference electrode and placed over the supraorbital area contralateral to the anode. tDCS stimulation will be conducted daily for 20 sessions in consecutive days in the 4th month after stroke, with each session lasting for 20 minutes and combined with online occupational therapy training."
88852970|NCT05604053|Experimental|Within-subjects motivation manipulation|Low or high motivation
88852971|NCT05595915|Experimental|Experimental Group|All subjects recruited in this study will be in the experimental group receiving the oral supplement, COMP-4, twice daily for 14 days.
88852972|NCT05594732|Experimental|Weak outdoor light|4000Lux natural light exposure
88852973|NCT05594732|Experimental|Strong outdoor light|10000Lux natural light exposure
88852974|NCT05590468|Experimental|Nicotinamide Riboside treatment group|Subjects will receive vitamin B3 derivative Nicotinamide Riboside (NR) daily for 12 months
88852975|NCT05590468|Placebo Comparator|Placebo Group|Subjects will receive a placebo daily for 12 months
88852976|NCT05574244|Experimental|Conventional endoscopic prostatic surgery|Endoscopic resection of prostate.
88852977|NCT05574244|Experimental|Partial surgery preserving the prostatic apex|Patients randomised to the partial endoscopic resection group will undergo surgical treatment that preserves the apex area of the prostate (tissue located 1 cm around the veru montanum).
88852978|NCT05572658||mRNA-1345: Exposed|Eligible US participants from the mRNA-1345-P301 (P301) study who received the mRNA-1345 vaccine.
88852979|NCT05572658||Placebo/Control: Referent|Eligible US participants from the P301 study who received placebo and eligible US-based, matched, unvaccinated RWD participants.
88852980|NCT05565560|Experimental|Apremilast|Participants with a weight between ≥ 15 kg to < 50 kg will receive apremilast 20 mg twice daily (BID) tablet. Participants weighing ≥ 50 kg will receive apremilast 30 mg BID tablet.
88852981|NCT05563194|Experimental|Children and young people with a diagnosis of Juvenile Idiopathic arthritis|Single arm study where all participants will receive the three prototype interventions.
88852982|NCT05527808|Experimental|Neoadjuvant ICI combined with chemotherory|intravenous injection :Tislelizumab + pemetrexed + platinum Q3W 2-4 cycles
88852983|NCT05516108|Experimental|Mindfulness|Mindfulness intervention involving 14 foundational audio-guided lessons plus daily brief practice prompts. Lessons train meditation techniques for 3 mindfulness skills: concentration, sensory clarity, and equanimity. Practice prompts delivered 3x daily build on the skills trained in each lesson.
89182822|NCT06170372|Active Comparator|Control group with nosocomial pneumonia|Standard antibacterial therapy + medical air without Nitric Oxide 3 times a day for 30 minutes until the pneumonia resolves, but no more than 7 days.
89379775|NCT03718481||Surgical Trainees|Trainee membership of the Association of Surgeons in Training (ASiT) in the UK and the Republic of Ireland
89379776|NCT03452189|Active Comparator|250mg of oral vancomycin First|After 3 months, initial experimental group will be switched to placebo for 3 months.
89379777|NCT03452189|Placebo Comparator|Placebo First|After three months, the control group will be crossed over to weekly oral vancomycin (250mg)
89379778|NCT03451721|Experimental|ImageReady™ MR Conditional Defibrillation System|"Subject is indicated to Class I/II indications per guidelines/consensus released by Chinese Society of Cardiac Pacing and Electrophysiology~Subject must have the ImageReady System as their initial (de novo) defibrillation system implant"
88852984|NCT05516108|Active Comparator|Coping|Coping intervention involving 14 foundational audio-guided lessons plus daily brief practice prompts. Lessons train techniques for 3 coping skills: reflection, reappraisal, and problem solving. Practice prompts delivered 3x daily build on the skills trained in each lesson.
88852985|NCT05496335|Experimental|AGN-151586, BOTOX|Participants will receive 5 intramuscular injections of AGN-151586 in the glabellar complex on Day 1. Eligible participants will receive BOTOX injections and will be followed for up to 4 months.
89379779|NCT00603954|Active Comparator|TBI + fludarabine|Conditioning regimen consisting of fludarabine 30 mg/m2 on days -4, -3 and -2 (total dose 90 mg/m2), followed by a singe dose of 2 Gy TBI administered on day 0, at a low dose-rate (≈ 7 cGy/min), before infusion of cells.
89379780|NCT00603954|Active Comparator|TLI + ATG|Conditioning consisting of 8 Gy TLI and ATG. TLI will be administered by linear accelerator at a dose of 80 cGy daily, starting 11 days before transplantation, until a total of 10 doses (800 cGy) has been delivered. The irradiation will consist of a supradiaphragmatic mantle field, a subdiaphragmatic field including an inverted Y and splenic ports, encompassing all major lymphoid organs, including the thymus, spleen, and lymph nodes, as used in the treatment of Hodgkin's disease (Kaplan HS, Cancer Research 26:1268-1276, 1966). The Waldeyer ring is not included. ATG (Thymoglobulin®, Genzyme), at a dose of 1.5 mg/kg/d, will be given intravenously on days -11 through -7.
88852986|NCT05496335|Experimental|Placebo, BOTOX|Participants will receive 5 intramuscular injections of placebo in the glabellar complex on Day 1. Eligible participants will receive BOTOX injections and will be followed for up to 4 months.
88852987|NCT05480098|Experimental|Brimonidine intervention|We will compare hemostasis between 2 surgical sides of the same patient. One side will be randomized to receive Brimonidine (0.15% or 0.2%) in addition to standard hemostasis measures, while the other side will receive only standard hemostasis measures (preoperative discontinuation of blood thinners, preoperative injection of lidocaine with epinephrine).
88852988|NCT05480098|No Intervention|Control Arm|We will compare hemostasis between 2 surgical sides of the same patient. One side will be randomized to receive Brimonidine (0.15% or 0.2%) in addition to standard hemostasis measures, while the other side will receive only standard hemostasis measures (preoperative discontinuation of blood thinners, preoperative injection of lidocaine with epinephrine).
88852989|NCT05439031|Experimental|Stereotactic Arrhythmia Radiotherapy|Patients will undergo stereotactic arrhythmia radiotherapy and subsequent follow-up.
88852990|NCT05438511||Participants of focus groups|Breast cancer survivor, patient advocate or key healthcare personnel including hospital and laboratory leaders, pathologists, laboratory scientists and technicians, oncologists, nurses, and surgeons
88852991|NCT05426031|Experimental|Fixed Dose Protamine group|Participants in the group will receive a one time dose of 250 mg Protamine to reverse heparin during the standard cardiopulmonary bypass management during cardiac surgery.
88852992|NCT05426031|Active Comparator|Ratio Dose Protamine Group|Participants in the group will receive a ratio dose of Protamine in a 1mg per 100 units of heparin ratio to reverse heparin during the standard cardiopulmonary bypass management during cardiac surgery.
88852993|NCT05424328|Experimental|Study Group: ALTF with preoperative virtual planning|Subjects will receive ALTF( Anterolateral thigh flap) with preoperative virtual planning
88852994|NCT05424328|Active Comparator|Control Group: ALTF with conventional method|Subjects will receive ALTF (Anterolateral thigh flap) with conventional method
88852995|NCT05423106|Experimental|Part 1: JNJ-64457744 or Placebo (Single Ascending Dose [SAD] Cohorts A-F)|Non-Asian healthy participants will receive a SAD of either JNJ-64457744 or matching placebo as an oral formulation under fasted conditions on Day 1. Cohort F will be optional.
88852996|NCT05423106|Experimental|Part 1: JNJ-64457744 (Cohorts G-H)|Non-Asian healthy participants will receive 3 single doses of JNJ-64457744 as an oral formulation in 3 intervention periods (to assess inter-subject PK-PD) matching the doses evaluated in Cohorts A, C and E for Cohort G and Cohorts B, D and F for Cohort H, under fasted conditions on Day 1. Cohort H will be optional for Intervention period 3.
88852997|NCT05423106|Experimental|Part 1: JNJ-64457744 or Placebo (Cohort I)|Non-Asian healthy participants who previously received study intervention under fasted conditions will receive either JNJ-64457744 or matching placebo as an oral formulation (depending upon what was administered previously in Cohorts A to F) under fed conditions on Day 1.
88852998|NCT05423106|Experimental|Part 1: JNJ-64457744 or Placebo (Cohort J)|Asian healthy participants will receive a single dose at one single dose level of either JNJ-64457744 or matching placebo, as an oral formulation, under fasted conditions on Day 1.
88852999|NCT05423106|Experimental|Part 1: JNJ-64457744 (Cohort K)|Optional Cohort K: Non-Asian healthy participants will receive an oral formulation of JNJ-64457744 in the first intervention period and will cross over to receive the other formulation during the second intervention period, under fasted conditions on Day 1.
88875343|NCT04003740|Sham Comparator|Sham tDCS|The same montage will be used. Sham stimulation will have the same ramp-up and ramp-down time in three different moments (beginning, middle and at the end of the session).
89379781|NCT03712631|Active Comparator|bone without a collagen membrane|not covering bone with collagen membrane
89379782|NCT03712631|Experimental|bone with collagen membrane|covering bone with collagen membrane
89379783|NCT03712553|Active Comparator|A1: Opt-In, UC Letter|Behavioral: Opt-In vs. Opt-Out The usual care (UC) letter consists of an opt-in message encouraging participants to contact their primary care provider for Hepatitis C screening.
89379784|NCT03712553|Experimental|A2: Opt-Out, UC Letter|Behavioral: Opt-In vs. Opt-Out The usual care (UC) letter consists of a message and a written laboratory order from primary care provider to complete Hepatitis C screening.
89379785|NCT03712553|Experimental|B1: Active MPM User, UC Letter|Behavioral: Letter vs. Electronic Messaging Behavioral: Usual Care Messaging vs. Behavioral Economic Messaging Participants who are active MyPennMedicine (MPM) users receive a usual care (UC) letter consisting of a message encouraging them to contact their primary care provider for Hepatitis C screening.
89379786|NCT03712553|Experimental|B2: Active MPM User, BE Letter|Behavioral: Letter vs. Electronic Messaging Behavioral: Usual Care Messaging vs. Behavioral Economic Messaging Participants who are active MyPennMedicine (MPM) users receive a letter with behavioral economic (BE) principles encouraging them to contact their primary care provider for Hepatitis C screening.
89379787|NCT03712553|Active Comparator|B3: Active MPM User, UC MPM Message|Behavioral: Letter vs. Electronic Messaging Behavioral: Usual Care Messaging vs. Behavioral Economic Messaging Participants who are active MyPennMedicine (MPM) users receive an electronic usual care (UC) message on the MyPennMedicine patient portal encouraging them to contact their primary care provider for Hepatitis C screening.
89379788|NCT03712553|Experimental|B4: Active MPM User, BE MPM Message|Behavioral: Letter vs. Electronic Messaging Behavioral: Usual Care Messaging vs. Behavioral Economic Messaging Participants who are active MyPennMedicine (MPM) users receive an electronic message with behavioral economic principles on the MyPennMedicine patient portal encouraging them to contact their primary care provider for Hepatitis C screening.
89379789|NCT03712553|Active Comparator|B5: Non-MPM User, UC Letter|Behavioral: Usual Care Messaging vs. Behavioral Economic Messaging Participants who are non-MyPennMedicine (non-MPM) users receive a usual care (UC) letter consisting of a message encouraging them to contact their primary care provider for Hepatitis C screening.
89379790|NCT03712553|Experimental|B6: Non-MPM User, BE Letter|Behavioral: Usual Care Messaging vs. Behavioral Economic Messaging Participants who are non-MyPennMedicine (non-MPM) users receive a letter with behavioral economic principles (BE) encouraging them to contact their primary care provider for Hepatitis C screening.
89379791|NCT04271748|Experimental|Time Restricted Feeding|Subjects will be required to fast for 16 consecutive hours daily for 4 weeks. The registered dietitian will provide subjects counseling on the intermittent fasting regimen.
89379792|NCT03427619|Experimental|OK432 (Picibanil)|There is no control in this study. All participants will receive the actual drug -OK432. With each injection they may receive 0.01 to 0.05mg/mL 6-12 weeks apart up to 4 injections total.
88853000|NCT05423106|Experimental|Part 2 JNJ-64457744 or Placebo|Chronic hepatitis B participants who are virologically suppressed on nucleos(t)ide analog (NA) treatment (tenofovir disoproxil fumarate [TDF], tenofovir alafenamide [TAF] and entecavir [ETV]) will receive a single dose at one single dose level of either JNJ-64457744 or matching placebo as an oral formulation, under fasted condition on Day 1.
88853001|NCT05423106|Experimental|Part 3: JNJ-64457744 or Placebo (Multiple Ascending Doses [MADs])|Participants will receive MADs of either JNJ-64457744 or matching placebo once weekly under fasted conditions as an oral formulation.
88853002|NCT05415761|Active Comparator|iCanQuit|iCanQuit is a modern, cognitive behavioral treatment which promotes cessation through greater acceptance of triggers for smoking and commitment to personal values. It is a smart phone-based acceptance and commitment therapy (ACT). For patients randomized to the iCanQuit arm (444 total), research staff will assist in downloading the app onto the patient's phone.
88853003|NCT05415761|Active Comparator|iCanQuit+Motiv8|Motiv8 is an internet-and smart phone-based contingency management (CM) intervention. Motiv8 verifies smoking status via a hand-held breath carbon monoxide (CO) monitor that is connected to a smart phone. For patients randomized to the iCanQuit+Motiv8 arm (444 total), research staff will assist in downloading the combined pp and connecting the iCO to the patient's phone. Smokers will also be asked to complete the first 4 iCanQuit modules, which contain exercises designed to prepare the users for their quit day. The end of the preparation phase will also mark each patient's quit date. During the intervention (7 weeks), participants will be considered abstinent from smoking if their breath CO sample is ≤ 5 ppm or if the CO value has decreased by 5% per hour from the last sample provided.
88853004|NCT05415761|Active Comparator|Florida quit line|The Florida quit line provides telephone counseling for smoking cessation. Patients randomized to the Florida quit line arm (444 total) will be enrolled after contact information is sent electronically.
88853005|NCT05399277|Experimental|Rivaroxaban Group|Subjects will receive rivaroxaban 15mg tablet to be taken orally once daily for 7 days following transradial access.
88853006|NCT05399277|No Intervention|Standard of Care Group|Subjects will receive the usual standard of care following transradial access.
89379793|NCT03407729||Post-hypoxic former preterm|Born in the years 2005-2009 with birth gestational age between 23-28 weeks and birth weight appropriate for gestational age (AGA). Part of a research cohort with available oxygen saturation level data recorded continuously from the first day of life to 8 weeks postnatal age (n=11).Children will undergo Magnetic Resonance Imaging and Cognitive Performance Testing.
89379794|NCT03407729||Healthy term-born children|Born in the years 2005-2009 with birth gestational age ≥ 38 weeks gestation and birth weight appropriate for term gestation (n=10) matched by age/sex/race to participating cohort children with no history of respiratory difficulty suggesting hypoxic exposure. Children will undergo Magnetic Resonance Imaging and Cognitive Performance Testing.
89379795|NCT03712475|Experimental|Phudialin Hard Capsules|Phudialin Hard Capsules Dosing Regimen: Single dosing
89379796|NCT03712475|Active Comparator|Lyrica Hard Capsule|Lyrica Hard Capsule Dosing Regimen: Single dosing
89379797|NCT02435433|Experimental|Ramucirumab + Best Supportive Care (BSC)|8 milligrams per kilogram (mg/kg) ramucirumab administered as an intravenous (IV) injection on day 1 of each 14 day cycle. Participants may continue treatment until discontinuation criteria are met.
89379798|NCT02435433|Placebo Comparator|Placebo + BSC|Placebo administered IV on day 1 of each 14 day cycle. Participants may continue treatment until discontinuation criteria are met.
89379799|NCT02435433|Experimental|Open Label Ramucirumab + BSC|8 mg/kg ramucirumab administered IV on day 1 of each 14 day cycle. Participants may continue treatment until discontinuation criteria are met.
89379800|NCT02435433|Experimental|Ramucirumab MEE Cohort + BSC|8 mg/kg ramucirumab administered IV on day 1 of each 14 day cycle. Participants may continue treatment until discontinuation criteria are met.
89379801|NCT02435433|Placebo Comparator|Placebo MEE Cohort + BSC|Placebo administered IV on day 1 of each 14 day cycle. Participants may continue treatment until discontinuation criteria are met.
89379802|NCT01372371|Active Comparator|Vancomycin|
89379803|NCT01372371|Active Comparator|Vancomycin and Gentamycin|
88853007|NCT05377944|Experimental|BAT2306|Patients will receive subcutaneous treatment of 300 mg BAT2306 (2 injections of 150 mg/1 ml) via PFS at weeks 0, 1, 2, 3, and 4 followed by dosing every 4 weeks, thereafter up to Week 40.
88853008|NCT05377944|Active Comparator|EU-approved Cosentyx|Patients will receive subcutaneous treatment of 300 mg EU-approved Cosentyx (2 injections of 150 mg/1 ml) at weeks 0, 1, 2, 3, and 4 followed by dosing every 4 weeks, thereafter up to Week 40.
88853009|NCT05371145|Experimental|Carnosine intervention for patients with PAD|This is a single arm open labelled safety trial, where we will supplement carnosine for 3 months to subjects with non-claudication and claudication peripheral arterial disease (PAD), and determine if it improves walking ability.
88853010|NCT05336071|Experimental|Treatment group A|T - R(T: new formulation, R: old formulation)
88853011|NCT05336071|Experimental|Treatment group B|R -T(T: new formulation, R: old formulation)
88853012|NCT05333679|Experimental|Intervention|POC adherence testing by a urine TFV assay with feedback
88853013|NCT05333679|No Intervention|Standard of Care|Standard enhanced adherence counselling, SA Department of Health, March 2020
88853014|NCT05327244|Experimental|Intervention|All CAI participants will complete the same intervention and will walk 6, 1-mile paths in the real wold (ie: around campus) with vibration feedback within 2 weeks of baseline assessment. A study team member will accompany each participant during each training.
88853015|NCT05327244|No Intervention|Healthy Control|Posttest data from CAI participants will be compared to de-identified healthy control data collected as part of a previous study. Healthy control participants completed a single research session to collect walking biomechanics using the same methods as this project. They received no further follow up or intervention and the inclusion/ exclusion criteria for this group match those of the chronic ankle instability cohort.
88853016|NCT05325034|Active Comparator|Early intervention|Participants randomised to 'early' will receive the intervention at baseline through 6 months. while those randomised to 'late' will receive standard-of-care and represent a control arm over this period.
88853017|NCT05325034|Other|Late intervention|Those randomised to 'late' will receive standard-of-care and represent a control arm to the early intervention group.
88853018|NCT05324878||Population 1: Social workers/Nurses|Social workers and nurses working at participating dialysis centers. Dialysis centers will be selected based on demographic data of the center (urbanicity, population served, size of center, patients treated, etc) to provide for diversity of centers participating.
88853019|NCT05324878||Population 2a: Patients receiving care at the dialysis center|2a. When an advance care planning conversation takes place, social worker/nurse will provide patient with an informational flyer about the HIGHway project and a postcard.
88853020|NCT05324878||Population 2b: Patients receiving care at the dialysis center|2b. Social worker/nurse will identify one patient willing to have a recording made of advance care planning conversation between social worker/nurse and patient.
88853021|NCT05319873|Experimental|Phase Ib (ribociclib, tucatinib, trastuzumab)|Patients receive ribociclib PO QD on days 1-21, tucatinib PO BID on days 1-28, and trastuzumab IV over 30-90 minutes every 7 days. Cycles repeat every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
88853022|NCT05319873|Experimental|Phase II, Arm C (ribociclib, tucatinib, trastuzumab)|Patients receive ribociclib PO QD on days 1-21, tucatinib BID on days 1-28, and trastuzumab IV over 30-90 minutes every 7 days. Cycles repeat every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
88853023|NCT05319873|Experimental|Phase II,Arm A(ribociclib,tucatinib, trastuzumab, fulvestrant)|Patients receive ribociclib PO QD on days 1-21, tucatinib BID on days 1-28, trastuzumab IV over 30-90 minutes every 7 days and fulvestrant subcutaneously (SC) on days 1 and 15 of cycle 1 and day 1 of every subsequent cycle. Cycles repeat every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
88853024|NCT05319873|Active Comparator|Phase II,Arm B(docetaxel,carboplatin,trastuzumab,pertuzumab)|Patients receive docetaxel IV over 1 hour on day 1, carboplatin IV on day 1, trastuzumab IV over 30-90 minutes on day 1, and pertuzumab IV over 1 hour on day 1. Cycles repeat every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
88853025|NCT05300906|Experimental|Personalized|Participants in the personalized arm will receive the optimal combination of content, feedback and design, based on their baseline engagement scores.
88853026|NCT05300906|Active Comparator|non-personalized|Participants in the non-personalized arm will receive a randomly selected version of the 27 possible interventions, regardless of their baseline engagement scores.
88853027|NCT05291884|Experimental|Subjects receiving the Impella BTR|
88853028|NCT05288439|Experimental|patients|A full neurocognitive battery with quality-of-life assessment will be conducted and an rs-fcMRI sequence will be added to the brain MRI performed as standard of care follow-up between 3-5 months post-PBRT.
88853029|NCT05288439|Experimental|healthy matched controls|Healthy participants will be asked to complete the MRI scan and undergo neurocognitive assessment.
89379804|NCT01372371|Active Comparator|Intravenous Antibiotic|
89379805|NCT05167383|Active Comparator|Intervention VR group|. In the VRH group the patients received a 30-minute session of virtual reality hypnosis when in active labor and had access to standard care.
89379806|NCT05167383|Placebo Comparator|Standard treatment|Patients in the control group received only standard care.
89379807|NCT01374711|Placebo Comparator|placebo|LPS will be administered twice on days 1 and 7. In between placebo will be administered on days 2, 4 and 6 subcutaneously.
89379808|NCT01374711|Active Comparator|GM-CSF|LPS will be administered twice on days 1 and 7. In between GM-CSF will be administered on days 2, 4 and 6 subcutaneously.
88853030|NCT05281458|Experimental|Early endoscopic interventions for AP|Participants in the intervention group will undergo EUS guided drainage earlier (≤1 weeks) in the disease course.
88853031|NCT05281458|No Intervention|Standard endoscopic interventions for AP|Participants in the control group will have postponed drainage, preferably until AP progress to the walled-off necrosis stage.
88853032|NCT05260242|Experimental|Conversation|Scripted interaction
88853033|NCT05260242|No Intervention|No Conversation|Control Group
88853034|NCT05249452||Adult transplant-eligible SCD patients with a MSD|Sickle cell disease patients aged 16 years and older with an available matched sibling donor.
88853035|NCT05218772||Elderly people with moderate or severe haemophilia|
88853036|NCT05201703|Experimental|Fycompa 4 mg daily|
88853037|NCT05201703|Active Comparator|Fycompa 4 mg daily with a boost to 6 mg daily|
88853038|NCT05200338|Other|Cohort 1a|SCD patients that are vaccinated against hepatitis B virus before matched sibling donor allogeneic SCT.
88853039|NCT05200338|Other|Cohort 1b|SCD patients that are vaccinated against hepatitis B virus before haploidentical donor allogeneic SCT.
89379809|NCT01374711|Active Comparator|IFN-y|LPS will be administered twice on days 1 and 7. In between IFN-Y will be administered on days 2, 4 and 6 subcutaneously.
89379810|NCT05167071|Experimental|HBM4003 and Toripalimab|HBM4003 combined with Toripalimab in patients with advanced NEN and other solid tumors
89379811|NCT03120351|Experimental|Lidocaine patch 5%|1) Group I: Patients will receive topical 5% lidocaine patches. Those will be placed to affected area up to three patches as needed for pain 12 hours on and 12 hours off. They will also receive opioids as needed after the surgery. Initially, they may receive IV fentanyl repeated clinician boluses, later oxycodone will be given 5-10 mg q4-6 hours as needed for pain.
89379812|NCT03120351|Placebo Comparator|Placebo Patch|2) Group II: Patients will receive placebo patches. Those will be placed to affected area at dose up to three patches as needed for pain 12 hours on and 12 hours off. They will also receive opioids as needed after the surgery. Initially, they may receive IV fentanyl clinician boluses, later oxycodone will be given in doses from 5-10 mg q4-6 hours as needed for pain.
89379813|NCT05165355|Experimental|Experimental group|Furmonertinib (80 mg orally, once daily) for 3 years.
88853040|NCT05200338|Other|Cohort 2|SCD patients that are vaccinated against hepatitis B virus without undergoing allogeneic SCT (control group).
88853041|NCT05200338|Other|Cohort 3a|SCD patients undergoing matched sibling donor allogeneic SCT whose donor is vaccinated against hepatitis B virus before stem cell collection.
88853042|NCT05200338|Other|Cohort 3b|SCD patients undergoing haploidentical donor allogeneic SCT whose donor is vaccinated against hepatitis B virus before stem cell collection.
89379814|NCT01374789|Experimental|Arm A (GemCis + Panitumumab)|gemcitabine + cisplatin + panitumumab
89379815|NCT01374789|Active Comparator|Arm B (GemCis)|gemcitabine + cisplatin
89379816|NCT05164809||Tungsten/Teflon +|Dissection with novel electrodes (Tungsten needle electrode + Teflon coated Spatula electrode)
89379817|NCT05164809||Tungsten/Teflon -|Dissection without novel electrodes (Scalpel + Steel Spatula Electrode)
89379818|NCT05101083|Experimental|Hearing Aid 1|New Receiver-in-Canal device, successor of previous device generation
89379819|NCT05101083|Active Comparator|Hearing Aid 2|Legacy Receiver-in-Canal device that is currently available on the market
89379820|NCT02354703|Experimental|ondansetron-responsive genotype|"ondansetron-0.33 mg bid + Brief Behavioral Compliance Enhancement Treatment (BBCET) for 16 weeks and carrying one of the following genotypes:~if European ancestry:~SLC6A4 gene:~5-HTTLPR:LL, or rs25531:AA, or 5-HTTLPR + rs25531 (LALA genotype) or rs1042173:TT~HTR3A gene:~rs1150226:AG; or rs1176713:GG~HTR3B gene:~rs17619942:AC~If African ancestry:~HTR3B gene:~rs176744: CC or CA~SLC6A4 gene:~5-HTTLPR:LL, or rs25531:AA, or 5-HTTLPR + rs25531 (LALA genotype) or rs1042173:TT"
88875344|NCT03939234|Experimental|Vaccination|Untreated CLL patients with unmutated IgHV gene with a cut of at maximum of 2 % mutations. According to guidelines from the European Research Initiative on CLL (ERIC).
88875345|NCT03907176|Experimental|Cohort 1|HTX-011; Ibuprofen and Acetaminophen (regimen 1)
88875346|NCT03907176|Experimental|Cohort 2|HTX-011; Ibuprofen and Acetaminophen (regimen 2)
88875347|NCT02692950|Other|Dialysis Patients|Honor My Decisions Advance Care Planning Videos, self-recorded by a patient using a computer application, followed immediately by a post-video questionnaire and a follow-up questionnaire 2-4 weeks later.
88875348|NCT02108496|Experimental|Investigational arm|The patients randomized to the Investigational Group will receive the NUsurface® Meniscus Implant.
89379821|NCT02354703|Experimental|ondansetron--non-responsive genotype|ondansetron-0.33 mg bid + Brief Behavioral Compliance Enhancement Treatment (BBCET) for 16 weeks and NOT carrying any of the responsive genotypes
89379822|NCT02354703|Placebo Comparator|placebo--responsive genotype|"placebo bid + Brief Behavioral Compliance Enhancement Treatment (BBCET) for 16 weeks and carrying one of the following genotypes:~if European ancestry:~SLC6A4 gene:~5-HTTLPR:LL, or rs25531:AA, or 5-HTTLPR + rs25531 (LALA genotype) or rs1042173:TT~HTR3A gene:~rs1150226:AG; or rs1176713:GG~HTR3B gene:~rs17619942:AC~If African ancestry:~HTR3B gene:~rs176744: CC or CA~SLC6A4 gene:~5-HTTLPR:LL, or rs25531:AA, or 5-HTTLPR + rs25531 (LALA genotype) or rs1042173:TT"
88853043|NCT05195125|Experimental|Direct Peritoneal Resuscitation (DPR) Group|At the time of abdominal closure and determination that the patient will either go to extended stay or the intensive care unit, three drains will be placed per standard of care. An additional 19 French drain will be placed at the ligament of Treitz at the base of the mesentery. Following abdominal closure DPR will be initiated with commercially available 2.5% glucose-based peritoneal dialysis solution at a rate of 1.5 cc/kg/hr based on previously reported therapy in trauma. Drains will be connected to continuous wall suction. This infusion will continue for the duration the patients stay in extended stay (8 hours) if they are deemed eligible for hospital ward admission, or for 24 hours if requiring ICU care. These patients will then be observed for their hospital course and monitored for outcomes listed above.
88853044|NCT05188326|Experimental|Azacitidine|Vidaza consists of 50 mg/ m2 s.c or i.v for 7 days (5 + weekend off + 2) every 28 days and increase after 1st cycle, if well tolerated, to 75 mg/m2 s.c or i.v. for 7 days (5 + weekend off + 2) every 28 days for further 5 cycles followed by cycles every 56 days for 4 years and six months
88853045|NCT05188326|Placebo Comparator|Best supportive care|No drug administration
88853046|NCT05182918||Patients in OMT and other SUD treatment|Patients in opioid maintenance treatment and other substance use disorder treatment
89002655|NCT06274489|Experimental|Setanaxib|"Patients will receive the following setanaxib doses according to age at the time of consent/assent:~For patients aged 12 to 17 years 1200 mg/day: 2 tablets in the morning (800 mg) and 1 tablet in the evening (400 mg)~For patients aged ≥18 years 1600 mg/day: 2 tablets in the morning (800 mg) and 2 tablets in the evening (800 mg)"
89379823|NCT02354703|Placebo Comparator|placebo--non-responsive genotype|placebo bid + Brief Behavioral Compliance Enhancement Treatment (BBCET) for 16 weeks and NOT carrying any of the responsive genotypes
88853049|NCT05165108|Experimental|Non-Invasive VNS|Non-Invasive VNS will decrease inflammation in people with Crohn's disease leading to decrease in inflammatory markers and symptoms of disease.
88853050|NCT05164653|Experimental|Sacubitril Valsartan Sodium Hydrate|Entresto® Tablets
88853051|NCT05164653|Active Comparator|No Sacubitril Valsartan Sodium Hydrate|Standard treatment for HF (ARB, ACE inhibitor etc.)
88853052|NCT05161260|Experimental|Yoga Breathing (YB)|A first production version of a mobile application that guides users through proscribed yoga breathing exercises.
88853053|NCT05161260|Experimental|Attention Control|A first production version of a mobile application that guides users through an attention control activity, presented as methods for mindfulness.
88853054|NCT05160896|Experimental|MSS or MSI-L/pMMR, RAS and BRAF are both wild type|"the primary lesion is located in the left colorectal:~SALIRI plus cetuximab~One cycle (cycle duration 14 days) consists of:~Raltitrexed 2 mg/m² iv, 15min. day 1 Irinotecan 180 mg/m² iv, 30 - 90 min. day 1 cetuximab 500 mg/ m² , iv, day 1~the primary lesion is located in the right colorectal:~SALIRI plus bevacizumab~One cycle (cycle duration 14 days) consists of:~Raltitrexed 2 mg/m² iv, 15min. day 1 Irinotecan 180 mg/m² iv, 30 - 90 min. day 1 Bevacizumab 5 mg/kg, iv, day 1"
88853055|NCT05145881|Active Comparator|Low dose probiotics|
88853056|NCT05145881|Experimental|Normal dose probiotics|
89379824|NCT00740181|Experimental|Chemotherapy|Decitabine 20 mg/m2 IV over 1 hr days 1-5 Cytarabine 20 mg/m2 subcut days 1-5 G-CSF 5mcg/kg subcut days 1-5
88853057|NCT05138939|Placebo Comparator|Control|Participants in this group are randomized to receive Isocaloric beverage (a beverage that has similar caloric content to the red wines) as the first intervention.
88853058|NCT05138939|Experimental|Red wine A|Participants in this group are randomized to receive red wine A as the first intervention (can be the younger or older vintage).
88853059|NCT05138939|Experimental|Red wine B|Participants in this group are randomized to receive red wine B as the first intervention (can be the younger or older vintage)
88853060|NCT05129670|Experimental|Calcite chewing gum|Patients with a stable pH recording after fasting for at least 6 hours will receive a refluxogenic test meal which will be consumed within 30 mins. Thirty minutes after finishing the meal, the patient will be dosed with the randomised calcite chewing gum. pH and impedance measurements will be collected throughout the treatment period from the baseline assessment to 2 hours post dose
88853061|NCT05129670|Placebo Comparator|Unmatched Placebo chewing gum|Patients with a stable pH recording after fasting for at least 6 hours will receive a refluxogenic test meal which will be consumed within 30 mins. Thirty minutes after finishing the meal, the patient will be dosed with the randomised unmatched placebo gum product. pH and impedance measurements will be collected throughout the treatment period from the baseline assessment to 2 hours post dose
88853062|NCT05128617||Epirubicin-cyclophosphamide|Woman with early breast cancer receiving a first cycle of epirubicin-cyclphosphamide
88853063|NCT05128617||Paclitaxel|Woman with early breast cancer receiving a first cycle of paclitaxel
88853064|NCT05125510||Hospitalized ICU Cohort|COVID-19+ patients over age 16 who are critically ill and admitted to an ICU and/or required mechanical ventilation (MV) in participating hospitals will be invited to participate. Patients who were hospitalized prior to study start up will be invited to participate in CANCOV.
88853065|NCT05125510||Hospitalized non-ICU Cohort|COVID-19+ patients over age 16 admitted to acute care hospitals, GIM/other wards of participating hospitals will be invited to participate. Patients who were hospitalized prior to this study start up (from January 25, 2020 to study start up) will be invited to participate in this study.
88875349|NCT02108496|Active Comparator|Control Arm|The patients randomized to the Control Group of the study will receive Non-Surgical Care (the current standard of care for this patient population).
89379825|NCT00384111|Experimental|1|Participants will receive standard R-CVP followed by Zevalin Therapeutic Regimen (Day 1: 250 mg/m2 Rituxan followed by 5 mCi 111In Zevalin Day 7: 250 mg/m2 Rituxan followed by 0.4 mCi/kg Zevalin).
89379826|NCT00384111|Active Comparator|2|Participants will receive standard R-CVP.
89379827|NCT05008887|Experimental|Fractional CO2 laser and topical methotrexate solution|"In all patients, the selected patches of vitiligo will be treated with fractional CO2 laser for 3 sessions at one-month intervals.~In each patient, two patches or their duplicates (if small sized) will be subjected first to fractional CO2 laser treatment at two different energies (half the number of selected patches will be treated with 50 mJ-energy with the aim to use laser more as a delivery system to drug solution, and the other half will be treated with 100mJ-energy with the aim to use laser as both therapeutic and delivery system , followed by topical application of methotrexate solution (2.5% concentration vial 50mg/2ml using insulin syringe as 0.1 ml at 1 cm-intervals with a maximum volume of 2 ml per session). Then gentle massage will be done and after about 10 minutes, an occlusive dressing will be applied for 24 hours after the session.~In all patients, the selected patches of vitiligo will be treated with fractional CO2 laser for 3 sessions at one-month intervals."
89379828|NCT05008887|Active Comparator|Fractional CO2 laser and topical 5-fluorouracil solution|"In all patients, the selected patches of vitiligo will be treated with fractional CO2 laser for 3 sessions at one-month intervals.~In each patient, two patches or their duplicates (if small sized) will be subjected first to fractional CO2 laser treatment at two different energies (half the number of selected patches will be treated with 50 mJ-energy with the aim to use laser more as a delivery system to drug solution, and the other half will be treated with 100mJ-energy with the aim to use laser as both therapeutic and delivery system , followed by topical application of 5-fluorouracil solution 5% concentration vial 250mg/5ml using insulin syringe as 0.1 ml at 1 cm-intervals with a maximum volume of 2 ml per session). Then gentle massage will be done and after about 10 minutes, an occlusive dressing will be applied for 24 hours after the session.~In all patients, the selected patches of vitiligo will be treated with fractional CO2 laser for 3 sessions at one-month intervals."
89379829|NCT01376115||Subjects administered nelarabine|Subjects with T-cell acute lymphocytic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LBL) prescribed nelarabine during study period
89379830|NCT01376193||Subjects prescribed naratriptan tablets|Subjects with migraine headache prescribed naratriptan tablets during study period
89379831|NCT01373073|Experimental|Experimental Human Milk Fortifier|Experimental human milk fortifier to be added to human milk
89379832|NCT01373073|Active Comparator|Control Human Milk Fortifier|Control human milk fortifier to be added to human milk
89379833|NCT04944771|Experimental|Treatment ABC|Participants will be randomized to receive oral doses of Treatment A, Treatment B and Treatment C.
88853066|NCT05125510||Non-Hospitalized Cohort|Individuals who are community dwelling, over the age of 16, are COVID-19+ and never hospitalized for their COVID-19 infection are included. These individuals may be diagnosed by participating hospital emergency rooms / in-person assessment centres / virtual clinics. In addition, we will include individuals who were diagnosed from January 25, 2020 within 6 months of study start up.
88853067|NCT05125510||Caregiver Cohort|Up to 500 family caregivers of patients admitted to the GIM wards and ICUs of participating hospitals will be invited to participate.
88853068|NCT05125510||Antibody Negative/Presumed COVID-19 comparator cohort|Approximately 500 individuals who do not have a positive COVID-19 test (nasal swab, serological antibody assay, etc.) but who have experienced COVID-19 symptoms and have strong epidemiologic links suggesting probable COVID-19 infection (such as household or occupational contacts and close timing of their symptoms to an index case) will be invited to participate.
89379834|NCT04944771|Experimental|Treatment ACB|Participants will be randomized to receive oral doses of Treatment A, Treatment C and Treatment B.
89379835|NCT04944771|Experimental|Treatment BAC|Participants will be randomized to receive oral doses of Treatment B, Treatment A and Treatment C.
89379836|NCT04944771|Experimental|Treatment BCA|Participants will be randomized to receive oral doses of Treatment B, Treatment C and Treatment A.
89379837|NCT04944771|Experimental|Treatment CAB|Participants will be randomized to receive oral doses of Treatment C, Treatment A and Treatment B.
89379838|NCT04944771|Experimental|Treatment CBA|Participants will be randomized to receive oral doses of Treatment C, Treatment B and Treatment A.
89379839|NCT04944771|Experimental|Treatment DEF|Participants will be randomized to receive oral doses of Treatment D, Treatment E and Treatment F.
89379840|NCT04944771|Experimental|Treatment DFE|Participants will be randomized to receive oral doses of Treatment D, Treatment F and Treatment E.
89379841|NCT04944771|Experimental|Treatment EDF|Participants will be randomized to receive oral doses of Treatment E, Treatment D and Treatment F.
89379842|NCT04944771|Experimental|Treatment EFD|Participants will be randomized to receive oral doses of Treatment E, Treatment F and Treatment D.
89379843|NCT04944771|Experimental|Treatment FDE|Participants will be randomized to receive oral doses of Treatment F, Treatment D and Treatment E.
89379844|NCT04944771|Experimental|Treatment FED|Participants will be randomized to receive oral doses of Treatment F, Treatment E and Treatment D.
89379845|NCT01374945|No Intervention|SOC preparation and colonoscopy|
89379846|NCT01374945|Experimental|Miniprep and Clearpath|
89379847|NCT05197413|Experimental|Arrae Bloat supplement|"The Bloat capsules are a blend of 5 herbs and a fruit-based digestive enzyme that target the cause for IBS symptoms."
89379848|NCT01375023|Experimental|Anti-Thymocyte Globulin+radiotherapy|triple negative breast cancer patients treated with radiation and Anti-Thymocyte Globulin iv
89379849|NCT05197101|Experimental|nulliparous women with estimated fetal weight ≥3500g at 39-40 weeks of gestation|
89002656|NCT06274489|Placebo Comparator|Setanaxib placebo|Matching placebo will be provided.
89379850|NCT05039775|Experimental|Study group|Forty married women, their ages will range from 20 to 45 years and all are suffering sexual dysfunction of sexual arousal and will use EROS-CTD Clitoral Therapy Device in addition to psychosexual support sessions and will be closely followed for three months.
89379851|NCT05039775|Other|Control group|Forty married women, their ages will range from 20 to 45 years and all are suffering sexual dysfunction of sexual arousal will receive psychosexual support sessions and will be closely followed after 3 months.
89379852|NCT05197023|Experimental|SHR-1819 injection|
89379853|NCT05197023|Placebo Comparator|placebo|
89379854|NCT03633669|Active Comparator|Tight control|Group that will receive fecal calprotectin testing every 3 months
89379855|NCT03633669|Placebo Comparator|Standard care|Routine clinical care
89379856|NCT01375101|Active Comparator|quercetin|quercetin is one of flavonoids , and having therapeutical anti-inflammatory and antioxidant action
89379857|NCT01375101|Placebo Comparator|placebo|placebo capsul is produced with lactose for using in placebo/ control group.
89379858|NCT05196711|Experimental|MAX-40070|MAX-40070 is a liniment with two dose specification: 0.5%, 2% (Weight/Volume). In SAD phase, MAX-40070 will be applied once in each cohort, and there will be 6 cohorts. For the first 2 cohorts, 0.5% MAX-40070 will be used. For the rest 4 cohorts, 2% MAX-40070 will be used. In MAD phase, MAX-40070 2% will be applied once daily for consecutive 14 days in each cohort.
89379859|NCT05196711|Placebo Comparator|Placebo|Placebo is a liniment with two dose specification: 0.5%, 2% (Weight/Volume) to match with active drug in 2:1 manner ( 6 active: 2 placebo in each cohort).
89379860|NCT04878003|Experimental|Arm 1|KRT-232 administered orally as 240 mg once daily on Days 1-7, off treatment on Days 8-28, in 28-day treatment cycles
89379861|NCT04878003|Experimental|Arm 2|TL-895 administered orally as 150 mg twice daily continuously in 28-day cycles
89379862|NCT03633591|Experimental|Modified Release Prototypes of Tolcapone|
89379863|NCT01376271||Subjects prescribed paroxetine tablets|Subjects with SAD prescribed paroxetine tablets during study period
89379864|NCT05196555|Experimental|microscopic surgical repair of cleft palate with intravelar veloplasty (IVVP)|
89379865|NCT04885881|Active Comparator|Ozone therapy group|Patients with myofascial pain syndrome receiving ozone injection
89379866|NCT04885881|Active Comparator|Lidocaine injection group|Patients with myofascial pain syndrome receiving lidocaine injection
89379867|NCT01375179|Experimental|KRP203|"Experimental~Edit~Experimental"
89182823|NCT06170372|Experimental|Main group with community acquired pneumonia|Standard antibacterial therapy + Nitric Oxide 200 ppm 3 times a day for 30 minutes under the control of methemoglobin level (no more than 5%). The general course of Nitric Oxide therapy will last until the pneumonia resolves, but no more than 7 days.
89379868|NCT01375179|Placebo Comparator|Placebo|Placebo
89379869|NCT01373307|Experimental|Early Intervention|Participants are nested in churches which were randomly assigned to receive the intervention first.
89379870|NCT01373307|No Intervention|Delayed Intervention|Wait-list control group. Participants are nested in churches which were randomly assigned to receive the intervention at a later date. Delayed Intervention participants receive an educational luncheon addressing stress reduction during the window of no intervention.
89379871|NCT04820205|Experimental|intranasal dexmedetomdine and kemtaine|Intranasal administration of dexmedetomidine (2mcg/kg) and ketamine (3mg/kg) to increase the success rate of adequate pediatric procedural sedation (pediatric sedation state scale = 1,2,3)
89379872|NCT04820205|Active Comparator|oral chloral hydrate|Oral chloral hydrate (50mg/kg) administration to induce adequate pediatric procedural sedation (pediatric sedation state scale = 1,2,3)
89379873|NCT01373385||Surgical|Patients receiving a surgical procedure for vesicoureteral reflux at Connecticut Children's Medical Center.
89379874|NCT01375257|Active Comparator|Guideline treatment with parenteral antibiotics|Guideline treatment with parenteral antibiotics
89379875|NCT01375257|Experimental|Oral treatment with antibiotics|Oral treatment with antibiotics based on resistens pattern
89379876|NCT01375335|Experimental|Dobutamine|
89379877|NCT05195307|Experimental|Music Group|Application Group Pregnant women in the application group were regularly listened to music for 20 minutes a day for 10 days. In addition, the pregnant women in the application group were trained by the researcher on preparing for normal delivery.
89379878|NCT05195307|No Intervention|Control Group|In the study, pregnant women in the control group were trained by the researcher on preparing for normal delivery.
89379879|NCT05194527||Patients with Acute Mesenteric Ischemia|Patients that are diagnosed with Acute mesenteric Ischemia
89379880|NCT05194527||Patient with another underlying disease/condition|Patients that are diagnosed not with acute mesenteric ischemia, but with a other underlying disease/condition
88853069|NCT05107375|Experimental|Population Ⅰ|One dose of influenza virus split vaccine and one dose of recombinant Novel coronavirus vaccine (CHO cells) were given in the contralateral arm on day 0, the second dose of recombinant Novel coronavirus vaccine (CHO cells) on day 30 and the third dose of recombinant Novel coronavirus vaccine (CHO cells) on day 60, all in the upper arm deltoid muscle.
88853070|NCT05107375|Experimental|Population Ⅱ|The first dose of recombinant Novel Coronavirus vaccine (CHO cells) was given on day 0, the second dose of recombinant Coronavirus vaccine (CHO cells) on day 30, the first dose of influenza virus lysate vaccine on day 44, and the third dose of recombinant Coronavirus vaccine (CHO cells) on day 60, all in the upper arm deltoid muscle.
88853071|NCT05046808|Experimental|Famitinib Malate Capsules 10mg|
89379881|NCT01375413|Experimental|Integrated dual task training|Integrated dual task training delivered by a physiotherapist. In this training mode walking practice will be combined with simultaneously carrying out cognitive discrimination, verbal fluency and memory tasks.
89379882|NCT01375413|Active Comparator|Consecutive task training|Consecutive task gait training delivered by a physical therapist. In this training mode, walking practice will be conducted separately, focusing on the motor task only. Training of cognitive discrimination, verbal fluency and memory tasks will be done consecutively while the subjects are sitting.
88853072|NCT05046808|Experimental|Famitinib Malate Capsules 15mg|
88853073|NCT05046808|Experimental|Famitinib Malate Capsules 20mg|
88853074|NCT05046808|Experimental|Famitinib Malate Capsules 10mg*2|
88853075|NCT05046808|Experimental|Famitinib Malate Capsules 25mg|
88853076|NCT05031520||Intervention group|Participants will be identified by review of the cardiac catheterization laboratory schedule each day by the principal investigator, a co-investigator, or a research coordinator. Participants with no obstructive CAD and completed microvascular testing will undergo a research CCTA.
88853077|NCT05019950|Experimental|NIM-1324|Once daily oral tablet
88853078|NCT05019950|Placebo Comparator|Placebo|Once daily oral tablet
88853081|NCT05012813|Experimental|Supportive care (SFIT, biospecimen, interview)|Patients participate in SFIT, using humidified wood and fragrance oils, over 1 hour. Patients also undergo blood sample collection at baseline and on day 3 or 4 and participate in interviews at baseline and post-treatment.
88853082|NCT05007431||Women asylum seekers|
88853083|NCT05003167|Experimental|Expiratory Muscle Strength Training|All participants will forcefully breathe out into an Expiratory Muscle Strength Training device (EMST-150) 25 times per day for 6 weeks. The EMST device will be set at a moderate intensity level (50% of each participant's maximum expiratory pressure).
88853084|NCT04989829|Experimental|Treatment group|
88853085|NCT04988035|Experimental|Remdesivir + Danicopan (< 70 years)|For participants < 70 years, 200 mg intravenous (IV) loading dose of Remdesivir on Day 1, followed by a 100 mg once-daily IV maintenance dose up to a 10-day total course while hospitalized, and 400 mg oral (PO) (or via nasogastric [NG] or gastrostomy [G] tube) loading dose danicopan, followed by 250 mg 4 times daily (QID) for the duration of the hospitalization up to a 14-day total course. End of danicopan treatment tapered as 250 mg 3 times daily (TID) for 2 days, followed by 250 mg twice daily (BID) for 2 days, until complete cessation (total treatment duration up to 18 days or 4 days after discharge). Total danicopan participants, N=100.
88853086|NCT04988035|Experimental|Remdesivir + Danicopan (>/= 70 years)|For participants >/= 70 years, 200 mg intravenous (IV) loading dose of Remdesivir on Day 1, followed by a 100 mg once-daily IV maintenance dose up to a 10-day total course while hospitalized, and 300 mg oral (PO) (or via nasogastric [NG] or gastrostomy [G] tube) loading dose danicopan, followed by 200 mg 4 times daily (QID) for the duration of the hospitalization up to a 14-day total course. End of danicopan treatment tapered as 200 mg 3 times daily (TID) for 2 days, followed by 200 mg twice daily (BID) for 2 days, until complete cessation (total treatment duration up to 18 days or 4 days after discharge). Total danicopan participants, N=100.
88853087|NCT04988035|Active Comparator|Remdesivir + Placebo (< 70 years)|For participants < 70 years, 200 mg intravenous (IV) loading dose of Remdesivir on Day 1, followed by a 100 mg once-daily IV maintenance dose up to a 10-day total course while hospitalized, and 400 mg oral (PO) (or via nasogastric [NG] or gastrostomy [G] tube) loading dose danicopan matching placebo, followed by 250 mg 4 times daily (QID) for the duration of the hospitalization up to a 14-day total course. End of danicopan matching placebo treatment tapered as 250 mg 3 times daily (TID) for 2 days, followed by 250 mg twice daily (BID) for 2 days, until complete cessation (total treatment duration up to 18 days or 4 days after discharge). Total danicopan matching placebo participants, N=100.
89182824|NCT06170372|Active Comparator|Control group with community acquired pneumonia|Standard antibacterial therapy + medical air without Nitric Oxide 3 times a day for 30 minutes until the pneumonia resolves, but no more than 7 days.
89182825|NCT06169319|Experimental|Group 1: EN3835|Participants will receive EN3835 Dose 1.
89182826|NCT06169319|Experimental|Group 2: EN3835|Participants will receive EN3835 Dose 2.
89379883|NCT01373463|Experimental|Arm A|"Patients will be given the drugs pemetrexed and carboplatin~Radiation~Participants evaluated for response~Lobectomy surgery"
89379884|NCT01373463|Experimental|Arm B|"Patients will be given the drugs pemetrexed and cisplatin~Radiation~Participants evaluated for response~Lobectomy surgery"
89379885|NCT04573647||Treatment group|All participants in this trial will be in the treatment group. They will administer Oxervate following the FDA approved guidelines: 1 drop to the affected eye 6 times per day for 8 weeks.
88853088|NCT04988035|Active Comparator|Remdesivir + Placebo (>/= 70 years)|For participants >/= 70 years, 200 mg intravenous (IV) loading dose of Remdesivir on Day 1, followed by a 100 mg once-daily IV maintenance dose up to a 10-day total course while hospitalized and 300 mg oral (PO) (or via nasogastric [NG] or gastrostomy [G] tube) of loading dose danicopan matching placebo followed by 200 mg 4 times daily (QID) for the duration of the hospitalization up to a 14-day total course. End of danicopan matching placebo treatment tapered as 200 mg 3 times daily (TID) for 2 days, followed by 200 mg twice daily (BID) for 2 days, until complete cessation (total treatment duration up to 18 days or 4 days after discharge). Total danicopan matching placebo participants, N=100.
88853089|NCT04987138|Other|Roll-in Cohort|Each Investigator will be allowed to treat up to 3 roll-in subjects with the Spring Implant prior to initiation of randomization. Roll-in patients will be followed for 60 months.
88853090|NCT04987138|Active Comparator|Treatment Arm|Includes all patients who are randomized and start the treatment procedure. During the procedure the patient will be shielded from the treatment area and cystoscopy screen. The patient and site personnel administering follow-up assessments will be blinded to the study arm through the 3-month follow-up visit. Unblinding will occur at 3 months post-procedure after the assessments are completed. Follow up will continue for 60 months.
88853091|NCT04987138|Sham Comparator|Control Arm|Includes all patients who receive a sham procedure. Patients will be shielded from the treatment area and cystoscopy screen. A Foley Catheter is placed into the patient's bladder and inflated. Additionally, devices will be used to produce mock deployment sounds of the Zenflow procedure. Once complete, the balloon will be deflated and the catheter will be removed, completing the procedure. Control arm subjects are followed for 3 months and exited from the study unless they elect and qualify for Crossover.
88853092|NCT04987138|Other|Crossover Cohort|Control Arm (Sham) patients can receive treatment with the Zenflow Spring System after their 3-month follow-up assessments are completed, and their symptoms warrant treatment and enrollment criteria are met. The study visit follow-up schedule will restart and the subject will be followed for 60 months post Zenflow Spring implantation. Unless treated with the Spring System, the subject will be exited from the study once they have completed their 3-month follow-up visit.
88853093|NCT04986423|Experimental|Cohort A - ZEN003694 + Enzalutamide|Patients will be administered enzalutamide (160 mg) orally once daily for 21 days prior to the initiation of the combination therapy (Lead-in) to reach steady state concentration (Css) prior to Cycle 1. After the Lead-in, ZEN003694 (72 mg) will be administered orally one daily in combination with daily enzalutamide for 28-day cycles.
88853094|NCT04986423|Active Comparator|Cohort A - Enzalutamide|Patients will be administered enzalutamide (160 mg) orally once daily for 21 days prior to Cycle 1 Day 1 (Lead-in). After the Lead-in, patients will be administered enzalutamide 160 mg orally once daily for 28-day cycles. Active control patients will have the option to cross-over to treatment with ZEN003694 in combination with enzalutamide upon confirmed radiographic progression by PCWG3 criteria by independent central review.
88853095|NCT04986423|Experimental|Cohort B - ZEN003694 + Enzalutamide|Patients will be administered enzalutamide (160 mg) orally once daily for 21 days prior to the initiation of the combination therapy (Lead-in) to reach steady state concentration (Css) prior to Cycle 1. After the Lead-in, ZEN003694 (72 mg) will be administered orally one daily in combination with daily enzalutamide for 28-day cycles.
88853096|NCT04986423|Active Comparator|Cohort B - Enzalutamide|Patients will be administered enzalutamide (160 mg) orally once daily for 21 days prior to Cycle 1 Day 1 (Lead-in). After the Lead-in, patients will be administered enzalutamide 160 mg orally once daily for 28-day cycles. Active control patients will have the option to cross-over to treatment with ZEN003694 in combination with enzalutamide upon confirmed radiographic progression by PCWG3 criteria by independent central review.
88853097|NCT04939792|Placebo Comparator|Placebo|"Initially, all of the study subjects will be provided placebo supplementation as a placebo run-in period for one month before randomization. The placebo run-in period is meant to stabilize subjects in the study and will prevent any effect due solely to inclusion in the study. Placebo and supplement capsules will be similar in appearance, taste, texture, and smell, and will be provided by the pharmacist, who will have the codes for which subjects are assigned to which supplement or placebo.~During testing, the placebo group will take two placebo capsules a day in the morning. Supplements will be taken daily with food at breakfast for 6 months, while participants continue to carry on a normal lifestyle"
88853098|NCT04939792|Experimental|L-Cysteine|LC group will receive two capsules of LC daily. Supplements will be taken daily with food at breakfast for 6 months, while participants continue to carry on a normal lifestyle
88853099|NCT04939792|Experimental|Vitamin D3|VD group will take two capsules and each capsule will contain 1000 IU VD daily. Supplements will be taken daily with food at breakfast for 6 months, while participants continue to carry on a normal lifestyle
88853100|NCT04939792|Experimental|Vitamin D3 and L-Cysteine|VD+LC group will take daily two capsule containing 1000 IU+500 mg LC. Supplements will be taken daily with food at breakfast for 6 months, while participants continue to carry on a normal lifestyle
88853101|NCT04894903|Experimental|Intervention|"Patients have access to an existing patient web portal (My Health at Vanderbilt) embedded with the Diabetes Care Gaps Patient Portal Intervention.~."
88853102|NCT04894903|No Intervention|Usual Care|Patients will have access to an existing patient web portal (My Health at Vanderbilt) NOT embedded with the intervention (i.e., usual care).
88853103|NCT04864249|Experimental|SNOO Responsive Bassinet|Will receive and be instructed on the use of the SNOO responsive bassinet for their newborn + the current standard of care of safe sleep education in the postpartum period
88853104|NCT04864249|Active Comparator|Usual Care|Will receive the current standard of care of safe sleep education in the postpartum period
88853105|NCT04847674|Experimental|TEV-53275 Dose A|
88853106|NCT04847674|Experimental|TEV-53275 Dose B|
88853107|NCT04847674|Placebo Comparator|Placebo|
89182827|NCT06169319|Placebo Comparator|Group 3: Placebo|Participants will receive matching placebo.
89379886|NCT05194371||Definitive (chemo)radiotherapy|
89379887|NCT03113409|Experimental|Procedure 1|Procedure 1: 5-day induction with increasing doses of oral naltrexone. Participants will receive XR-NTX on day five together with buprenorphine, and will continue receiving buprenorphine for 4 weeks until they receive 2nd XR-NTX dose.
89379888|NCT03113409|Experimental|Procedure 2|Procedure 2: 10-day induction with buprenorphine administered daily and increasing daily doses of oral naltrexone beginning on day 2 . On day 10 participants will receive XR-NTX dose, and another one 4 weeks later. No buprenorphine will be given beyond day 10.
89379889|NCT03113409|Experimental|Procedure 3|Procedure 3: 10-day induction with buprenorphine administered daily and increasing daily doses of oral naltrexone beginning on day 2 . On day 10 participants will receive XR-NTX dose, and another one 4 weeks later. Buprenorphine will continue for 4 weeks until the 2nd XR-NTX dose.
89379890|NCT01376661||Active Surveillance/ Prostate Cancer|
88853108|NCT04828785|Experimental|Medically Tailored Meal (MTM)|The Medically Tailored Meal (MTM) intervention consists of weekly home meal delivery; an explanation of the medical tailoring of the meals; and a 6-session telephone lifestyle intervention change program designed to complement the period of meal delivery and prepare for the period after meal delivery with behavioral and skill-building approaches to sustain the benefit of the intervention.
88853109|NCT04828785|Active Comparator|Food Subsidy|As a comparison group, those not randomized to receive the MTM intervention will receive usual care provided by their clinicians not associated with the study, plus a food subsidy ($40/month) for 6 months, along with healthy eating information to guide use of that subsidy.
88853110|NCT04815252|Experimental|CHIME Intervention|Participants will complete an 8-week compassion and mindfulness-based intervention with a group facilitator. The curriculum focuses on providing mindfulness-based stress reduction techniques for use in the early childhood education environment.
88853111|NCT04815252|No Intervention|Waitlist control|Participants are placed on a wait-list to receive the intervention.
88853112|NCT04813796|Experimental|mRNA-1283 Dose Level 1|Participants will receive 2 intramuscular (IM) injections of mRNA-1283 at Dose Level 1 on Day 1 and Day 29.
88853113|NCT04813796|Experimental|mRNA-1283 Dose Level 2|Participants will receive 2 IM injections of mRNA-1283 at Dose Level 2 on Day 1 and Day 29.
88853114|NCT04813796|Experimental|mRNA-1283 Dose Level 3|Participants will receive 2 IM injections of mRNA-1283 at Dose Level 3 on Day 1 and Day 29.
88853115|NCT04813796|Experimental|mRNA-1273|Participants will receive 2 IM injections of mRNA-1273 at a pre-specified dose for this study on Day 1 and Day 29.
88853116|NCT04813796|Experimental|Placebo / mRNA-1283|Participants will receive 1 IM injection of study drug-matching placebo on Day 1 and 1 IM injection of mRNA-1283 at a pre-specified dose on Day 29. Participants may be offered an opportunity to receive an additional injection of mRNA-1273 at the pre-specified dose on Open-Label Day 1.
88853117|NCT04763135|Experimental|Oral mirtazapine|Arm 1 patients will be treated using a daily mirtazapine treatment. Treatment will be taken on the evening. Treatment will be initiated at 15 mg daily and gradually increased depending on symptom control and side effects. Treatment doses will be adapted for old patients and those with liver failure.
88853118|NCT04763135|Active Comparator|Oral escitalopram|Arm 2 patients will be treated using a daily escitalopram treatment. Treatment will be taken in the morning. Treatment will be initiated at 10 mg daily and gradually increased depending on symptom control and side effects. Treatment doses will be adapted for 5 mg for old patients.
88853119|NCT04755816|Sham Comparator|Control Group|Standard heart failure educational information.
88853120|NCT04755816|Experimental|Dietary Sodium Intervention|The dietary sodium intervention facilitates lower sodium choices using tailored push notifications.
88853121|NCT04755816|Experimental|Clinical Worsening Intervention|The clinical worsening intervention promotes self-monitoring and self-management and is linked tailored push notifications.
88853122|NCT04755816|Experimental|Dietary Sodium and Clinical Worsening|Full access to all content in the control, dietary sodium, and clinical worsening interventions.
88853123|NCT04750941|Experimental|Follicular Lymphoma (FL)|"The lymphoma study group will enroll 23 patients with FL.~In cycle 1, patients will first start ketogenic diet for 7 days (Day -6 to Day 0). Only patients who demonstrate compliance and tolerance with the ketogenic diet for all 7 days, as confirmed by pertinent blood and urine tests, will be allowed to continue the study and treatment using copanlisib and the ketogenic diet starting on Day 1. In cycle 2 and beyond, patients will start the ketogenic diet and copanlisib on day 1."
88853124|NCT04750941|Experimental|Endometrial Cancer (EC)|"The solid tumor group will enroll 19 patients with EC.~In cycle 1, patients will first start ketogenic diet for 7 days (Day -6 to Day 0). Only patients who demonstrate compliance and tolerance with the ketogenic diet for all 7 days, as confirmed by pertinent blood and urine tests, will be allowed to continue the study and treatment using copanlisib and the ketogenic diet starting on Day 1. In cycle 2 and beyond, patients will start the ketogenic diet and copanlisib on day 1."
88853125|NCT04723134|Active Comparator|Folic Acid Wound Treatment|Intervention - participants receiving 2.5% folinic acid wound treatment for daily treatment of chronic early stage diabetic foot ulcer wound. This will be applied daily to the study wound selected for monitoring.
88853126|NCT04723134|Placebo Comparator|Placebo|Intervention - participants receiving Placebo (PluroGel Burn and Wound Dressing) for daily treatment of chronic early stage diabetic foot ulcer wound. This will be applied daily to the study wound selected for monitoring.
88853127|NCT04675450|Placebo Comparator|Placebo|Interventions: Placebo (NBP placebo softgel capsules, 0 mg NBP, BID)
88853128|NCT04675450|Active Comparator|NBP|Interventions: 800 mg NBP softgel capsules daily (400 mg BID)
89379891|NCT05193747||Paediatric patients scheduled for general anesthesia|Paediatric patients (between 1 year -19 years) undergoing elective general anaesthesia with presumed duration over 1 hour will be eligible for inclusion
89379892|NCT05193513|Experimental|group (1)|tow perpendicular miniscrews supported hybrid expanders
88853129|NCT04666272||dabrafenib in combination with trametinib as adjuvant treatment|Patients will be treated according to the China package insert for dabrafenib and trametinib. The approved starting doses of dabrafenib (150 mg twice daily) and trametinib (2 mg once daily) will be used.
89379893|NCT05193513|Experimental|group (2)|tow angulated miniscrews supported hybrid expanders
89379894|NCT03634293|Placebo Comparator|control group|The group will receive 2 ml' saline subcutaneous injection upon randomization when admitted to the ICU with the diagnosis of sepsis or septic shock
89379895|NCT03634293|Active Comparator|treatment group|The group will receive a 2 ml' subcutaneous injection of the study drug Alirocumab 150 mg', upon randomization when admitted to the ICU with the diagnosis of sepsis or septic shock.
89379896|NCT01373541|Active Comparator|InFat group|Infant formula with structured triglycerides (high palmitic acid content at the sn-2 position)
89379897|NCT01373541|Active Comparator|Control group|Infant formula with standard vegetable blend (low palmitic acid content at the sn-2 position)
89379898|NCT01373541|No Intervention|Referance group|Human milk breastfeeding
89379899|NCT03633747|Experimental|propranolol|Propranolol hydrochloride tablets were taken orally three times a day at an initial dose of 30 mg/day, doubled one week later until the daily dose was 1.5 mg/kg. If the dose was unable to increase due to side effects, the maximum dose tolerable was maintained for 6 months.
89379900|NCT01376739||Group 1|
89379901|NCT05190783|Experimental|formocresol pulpotomy|gold standard arm which pulpotomy will be done with formocresol
88853130|NCT04649060|Experimental|Arm A (melflufen+dexamethasone+daratumumab)|"Treatment was given in 28-day cycles in an outpatient treatment setting.~Melflufen 30 mg intravenous (i.v.) infusion on Day 1 of each cycle~Dexamethasone 40 mg per oral (p.o.) weekly (20 mg p.o. weekly if ≥75 years)~Daratumumab 1800 mg subcutaneously (s.c.) on Days 1, 8, 15, and 22 in Cycles 1 and 2, on Days 1 and 15 in Cycles 3 to 6, and on Day 1 from Cycle 7"
88853131|NCT04649060|Active Comparator|Arm B (daratumumab)|"Treatment was given in 28-day cycles in an outpatient treatment setting.~• Daratumumab 1800 mg s.c. on Days 1, 8, 15, and 22 in Cycles 1 and 2, on Days 1 and 15 in Cycles 3 to 6, and on Day 1 from Cycle 7"
88853132|NCT04640272|Experimental|RBM-007 injectable solution|intravitreal injection
88853133|NCT04623008|Experimental|Goal-Oriented Episodic Future Thinking (GOEFT) Intervention|In addition to usual prenatal care, intervention participants will receive a 20-week intervention via web and individual health counseling. The intervention topics focus on stress management, healthy eating, and physical activity.
88853134|NCT04623008|No Intervention|Usual Prenatal Care|The usual prenatal care group will receive usual care from their providers
88853135|NCT04608487|Experimental|Fludarabine + Cyclophosphamide + Axicabtagene Ciloleucel|"Prior to receiving axi-cel, participants will undergo leukapheresis and the need for a Ommaya reservoir placement will be assessed and administered.~Day -5 to Day -3 of 28 day study cycle Fludarabine and cyclophosphamide; Day -1 admitted to hospital, receive axi-cel on day 0; Till at least cycle day 7 hospital monitoring; post treatment follow up will occur on day 14 and day 28 of cycle 1, monthly in cycles 2, 3, 6, 9,12,15,18,21,24, then yearly after cycle 24."
88853138|NCT04586894||Patients|
88875350|NCT02056236|Experimental|Anti-epileptic drugs|"Step 1: Phenytoin (loading dose 15-20 mg/kg iv, maintenance doses 150 mg iv twice per day) PLUS one of the following benzodiazepines (bolus + continuous infusion): lorazepam or midazolam. Benzodiazepine dosing regimes should be based on national and local protocols for status epilepticus treatment~Step 2: Propofol infusion (with a maximum rate of 8 mg/kg/hour) PLUS a second anti-epileptic drug in addition to fenytoin: Option 1: levetiracetam bolus 1500 mg, followed by 1000 mg 2 dd 1 intravenously or Option 2: valproic acid bolus 10-20 mg/kg in 30 min, followed by15 mg/kg/day in 2 dosages intravenously.~Step 3: Thiopental, initial dosage 12,5 mg/kg/hr for the first 6 hours followed by 5 mg/kg/hr for 6 hours. After these loading dosages, treatment should be guided by the EEG pattern."
89182828|NCT06163729|Experimental|Camrelizumab+Oxaliplatin+Paclitaxel (Albumin Bound) +radiotherapy|
89379902|NCT05190783|Active Comparator|formocresol partial pulpotomy|partial pulpotomy will be done with formocresol
89379903|NCT05190783|Active Comparator|MTA pulpotomy|in this group complete pulpotomy will be done with MTA
89379904|NCT05190783|Active Comparator|MTA partial pulpotomy|in this study group partial pulpotomy will be done with MTA
89379905|NCT05190783|Active Comparator|pulpotomy with Theracal LC|in this study group complete pulpotomy will be done with Theracal LC
89379906|NCT05190783|Active Comparator|partial pulpotomy with Theracal LC|in this study group partial pulpotomy technique will be done with Theracal LC
89379907|NCT01375647|Experimental|Rotarix + No IPV|Randomized to receive rotarix vaccine but no IPV boost
89379908|NCT01375647|Experimental|Rotarix + with IPV boost|Randomized to receive both rotarix vaccine and IPV boost
89379909|NCT01375647|No Intervention|No Rotarix + No IPV|Randomized to receive neither rotarix vaccine nor IPV boost
89379910|NCT01375647|Experimental|No Rotarix + with IPV boost|Randomized to receive no rotarix vaccine but to receive IPV boost
89379911|NCT01375725||Coumadin (warfarin)|Subjects currently receiving coumadin (warfarin) treatment.
89379912|NCT01373619|Experimental|IVABRADINE, HEART FAILURE WITH NORMAL EF|Patient on hemodialysis with Heart failure with normal ejection fraction treated with ivabradine titrated to 7.5 mg BID to assess changes in echocardiography diastolic function and NYHA class and 6-minutes walking test
89379913|NCT01319877||First Line Treatment|Participants received bevacizumab in combination with 5-FU based chemotherapy as a first line therapy.
89379914|NCT01319877||Second Line Treatment|Participants received bevacizumab in combination with 5-FU based chemotherapy as a second line therapy.
89379915|NCT01376817|Experimental|Omega 3|
89379916|NCT01376817|Active Comparator|MCT / LCT|
89379917|NCT01375803|Experimental|1|3g/day
89379918|NCT01375803|Experimental|2|6g/day
89379919|NCT01375803|Placebo Comparator|Placebo beverage|0g/day
89379920|NCT01373697|Active Comparator|Profenid|Apply the gel on the spot of pain or injury, massaging slightly to facilitate the penetration of 8 in 8 hours during 5 days. Leave the gel on the the site at least 4 hours before removal
89379921|NCT01373697|Active Comparator|Ibuprofen|Apply the gel on the spot of pain or injury, massaging slightly to facilitate the penetration of 8 in 8 hours during 5 days. Leave the gel on the the site at least 4 hours before removal
89379922|NCT01375881||001|darunavir/ritonavir plus background regimen darunavir/ritonavir oral use in naive and experienced patients at approved dosages
89379923|NCT03427073|Experimental|Solid tumours|"Part 1 - Dose-escalation of ALM201 in patients with advanced solid tumours~Daily dosing of ALM201 on Days 1-5, 8-12 and 15-19 of 21 day cycle. Escalating dose cohorts"
89379924|NCT03427073|Experimental|Ovarian cancer|"Part 2 - Dose-expansion of ALM201 Maximum Tolerated Dose (MTD) in patients with advanced ovarian cancer~Daily dosing of ALM201 on Days 1-5, 8-12 and 15-19 of 21 day cycle at the MTD determined in Part 1"
88853139|NCT04581447|Experimental|Metformin + Standard care|"The pharmacological treatment (Metformin) will start at dose of 850 mg once daily and, at one month, increased to 850 mg twice daily. The dosage will be adjusted if necessary because of gastrointestinal symptoms and information on dose change during follow-up will be collected Adherence to study medications will be assessed by pills count and plasmatic dosage (Metformin group).~All participants will receive standardized lifestyle recommendations regularly during all the time of the study Lifestyle recommendations will be provided by a nutritionist/diabetologist every 6 months at each study visit and reinforced by dedicated consultations with a dietician and a physical activity coach as usually performed in each center. This follow-up will be standardized for each center and applied equally to patients of both groups.~Ancillary study measuring metformin-induced enterohormones secretion will be performed on a subgroup of 30 patients randomized in this arm."
89379925|NCT03716219|Other|Healthy Subjects|Healthy control group which received the same exercise training intervention as the experimental group
89379926|NCT03716219|Experimental|Subjects with Asthma|Subjects with asthma who received exercise training
89379927|NCT04690023|Active Comparator|PENG block|Patients scheduled for total hip arthroplasty with spinal anesthesia receive before intra-thecal injection, ultrasound-guided PENG block. Patients in PENG group receive multimodal postoperative analgesia techniques coupled with morphine PCA pump.
88853140|NCT04581447|Other|Standard Care|"All participants will receive standardized lifestyle recommendations regularly during all the time of the study Lifestyle recommendations will be provided by a nutritionist/diabetologist every 6 months at each study visit and reinforced by dedicated consultations with a dietician and a physical activity coach as usually performed in each center. This follow-up will be standardized for each center and applied equally to patients of both groups.~Ancillary study measuring metformin-induced enterohormones secretion will be performed on a subgroup of 30 patients randomized in this arm."
88853141|NCT04563793||Superion™ IDS|All patients to receive IDS for the treatment of their moderate Lumbar Spinal Stenosis Symptoms.
88853142|NCT04552665||Adults|Patients who have cardiac arrhythmia
88853143|NCT04520685|Experimental|Arm 1: 12 weeks of study drug then 15 weeks of placebo|Subjects in this group will receive cannabidiol for the first 12 weeks of the study and placebo for the last 15 weeks.
89182829|NCT06163014||Patients|Patients with persistent physical symptoms consulting their GP and referred to the My Symptoms eHealth programme.
89182830|NCT06160622|Experimental|Experimental 1: participants with severe renal impairment|8 participants with severe renal impairment will be given 400mg of Leritrelvir
89379928|NCT04690023|Active Comparator|SFICB block|Patients scheduled for total hip arthroplasty with spinal anesthesia receive before intra-thecal injection, ultrasound-guided supra-inguinal fascia iliaca compartment block. Patients in SFICB group receive multimodal postoperative analgesia techniques coupled with morphine PCA pump.
89379929|NCT03066804|Experimental|sacubitril/valsartan (LCZ696)|"All patients who fulfill the inclusion/exclusion criteria will be stratified before randomization based upon prior therapy for comorbidities to one of 3 strata: ACEi, ARB or no RASi. Patients in the ACEi strata will receive LCZ696 or enalapril. Patients in the ARB strata will receive LCZ696 or valsartan. Patients in the no RASi strata will receive LCZ696 or matching placebo.~Patients in the ACEi and ARB strata will take two pills twice daily for each dose: one tablet from the LCZ696 pack and one tablet from the comparator pack. Patients in the no RASi strata will take only one tablet twice daily (LCZ696 or matching placebo).~In the LCZ696 arm, patients will receive active LCZ696 in titrated doses from level 1 up to level 3 (50 mg, 100 mg and 200 mg twice daily orally)."
89379930|NCT03066804|Active Comparator|Comparator|"Patients randomized to the comparator arm will receive either enalapril (ACE stratum) valsartan (ARB stratum) or LCZ696 matching placebo (no RASi stratum).~Patients in the ACE stratum randomized to comparator, will receive enalapril in titrated doses from level 1 up to level 3 (2.5 mg, 5 mg and 10 mg twice daily).~Patients in the ARB stratum randomized to comparator will receive valsartan in titrated doses from level 1 up to level 3 (40 mg , 80 mg and 160 mg twice daily).~Patients in the no RASi stratum randomized to comparator will receive LCZ696 matching placebo."
89379931|NCT03633357|Experimental|JNJ-18038683 first|One week of JNJ-18038683, followed by one week of Placebo after a two week-washout period,
89379932|NCT03633357|Placebo Comparator|Placebo first|One week of Placebo followed by one week of JNJ-18038683 after a two week-washout period,
88853144|NCT04520685|Experimental|Arm 3: 15 weeks of placebo then 12 weeks of study drug|Subjects in this group will receive placebo for the first 15 weeks of the study and cannabidiol for the last 12 weeks.
88853145|NCT04520685|Experimental|Arm 3: 27 weeks of study drug|Subjects in this group will receive cannabidiol throughout the entire 27 weeks of treatment.
89379933|NCT02954237||AMPLATZER™ Cardiac Plug|Subjects who were implanted with AMPLATZER™ Cardiac Plug will be included in this arm.
88853146|NCT04519151|Experimental|Lenvatinib 20 mg + Pembrolizumab 200 mg|Participants will receive pembrolizumab 200 milligram (mg) administered by intravenous (IV) infusion on Day 1 of each 21-day cycle plus lenvatinib 20 mg administered orally (PO) once daily (QD) during each 21-day cycle for up to 35 cycles.
88853147|NCT04511650|Experimental|Razuprotafib 10 mg|Active Comparator
88853148|NCT04511650|Placebo Comparator|Placebo|Placebo Comparator
88853149|NCT04511650|Experimental|Razuprotafib 20 mg|Active Comparator
89182831|NCT06160622|Experimental|Experimental 2: healthy participants|8 participants with normal renal function will be given 400mg of Leritrelvir
89182832|NCT06158802||Chronic condition|Girls and young women between the ages of 11 and 20 suffering from chronic condition
89182833|NCT06158802||Control|Girls and young women between the ages of 11 and 20 in good health
89399461|NCT03689751|Experimental|TVT/TOT Interventional Arm|Patients undergoing elective TVT/TOT allocated to this arm underwent the normal preoperative educational pathway, but prior to the operation were shown the educational RSAV (TVT/TOT Video) as an additional educational resource.
88853150|NCT04497012|Active Comparator|Low Iron Sulfate Supplementation|Participants will be given 2 mg/kg/day total of elemental iron once a day when they are consuming 150-160 ml/kg/day of enteral feeds and are at least 14 days old. The total iron doses will be provided by fortification of feeds and liquid iron sulfate and will be weight adjusted once a week. The participants will receive the study iron dose until 36 week corrected gestational age or discharge, whichever comes first.
88853151|NCT04497012|Active Comparator|High Iron Sulfate Supplementation|Participants will be given 6 mg/kg/day total of elemental iron once a day when they are consuming 150-160 ml/kg/day of enteral feeds and are at least 14 days old. The total iron doses will be provided by fortification of feeds and liquid iron sulfate and will be weight adjusted once a week. The participants will receive the study iron dose until 36 week corrected gestational age or discharge, whichever comes first.
88853152|NCT04484259|Experimental|Ticagrelor|ticagrelor 60 mg bid monotherapy
88853153|NCT04484259|Active Comparator|Aspirin plus Clopidogrel|aspirin 81 mg qd plus clopidogrel 75 mg qd
88853154|NCT04484259|Active Comparator|Aspirin plus Ticagrelor|aspirin 81 mg qd plus ticagrelor 60 mg bid
88853155|NCT04463693|Experimental|Intervention|Insertion of the etonogestrel contraceptive implant subdermally over the non-dominant scapula
88853156|NCT04348916|Experimental|Dose escalation of ONCR-177 by intratumoral injection in subjects with surface lesions|Dose escalation of ONCR-177 intratumoral injections alone in four cohorts in subjects with advanced and/or refractory cutaneous, subcutaneous or metastatic nodal solid tumors
88853157|NCT04348916|Experimental|Dose expansion of ONCR-177 in subjects with surface lesions|Dose expansion of ONCR-177 intratumoral injections alone at the recommended phase 2 dose (RP2D) in subjects with advanced and/or refractory cutaneous, subcutaneous or metastatic nodal solid tumors
88853158|NCT04348916|Experimental|Dose expansion of ONCR-177 and pembrolizumab in subjects with surface lesions|Dose expansion of ONCR-177 intratumoral injections at the RP2D in combination with pembrolizumab in subjects with advanced and/or refractory cutaneous, subcutaneous or metastatic nodal solid tumors
88853159|NCT04348916|Experimental|Dose escalation of ONCR-177 by intratumoral injection in subjects with liver metastases|Dose escalation of ONCR-177 intratumoral injections alone in four cohorts in subjects with advanced and/or refractory solid tumor cancer with liver metastases
88853160|NCT04348916|Experimental|Dose expansion of ONCR-177 by intratumoral injection in subjects with liver metastases|Dose expansion of ONCR-177 intratumoral injections alone at the recommended phase 2 dose (RP2D) in subjects with advanced and/or refractory solid tumor cancer with liver metastases
88853161|NCT04348916|Experimental|Dose expansion of ONCR-177 and pembrolizumab in subjects with liver metastases|Dose expansion of ONCR-177 intratumoral injections at the RP2D in combination with pembrolizumab in subjects with advanced and/or refractory solid tumor cancer with liver metastases
88853162|NCT04299113|Experimental|Treatment (vinorelbine, mocetinostat)|Participants receive mocetinostat in combination with vinorelbine
89182834|NCT06155019||Non comparative|switch from etravirine to doravirine, with no change in associated antiretroviral drugs, will be assessed retrospectively
89182835|NCT06153758|Experimental|Sequence 1|Period 1: 80 mg dose of danuglipron IR, fasted state (Formulation A, 2×40 mg tablets) Period 2: 80 mg dose of danuglipron MR, fasted state(Formulation B, 1×80 mg tablet) Period 3: 80 mg dose of danuglipron MR, fasted state (Formulation C, 1×80 mg tablet) Period 4: 80 mg of danuglipron MR, fasted state (Formulation D, 1×80 mg tablet) Period 5: 80 mg dose of danuglipron MR, fed conditions (Formulation B, 1×80 mg tablet)
89182836|NCT06153758|Experimental|Sequence 2|Period 1: 80 mg dose of danuglipron MR, fasted state (Formulation B, 1×80 mg tablet), Period 2: 80 mg tablet of danuglipron MR, fasted state (Formulation D, 1×80 mg tablet), Period 3: 80 mg tablet of danuglipron IR, fasted state (Formulation A, 2×40 mg tablets) Period 4: 80 mg tablet of danuglipron MR, fasted state (Formulation C, 1×80 mg tablet) Period 5: 80 mg dose of danuglipron MR, fed condition (Formulation B, 1×80 mg tablet)
89182837|NCT06153758|Experimental|Sequence 3|Period 1: 80 mg dose of danuglipron MR, fasted state (Formulation C, 1×80 mg tablet) Period 2: 80 mg dose of danuglipron IR, fasted state (Formulation A, 2×40 mg tablets) Period 3: 80 mg dose of danuglipron MR, fasted state (Formulation D, 1×80 mg tablet) Period 4: 80 mg dose of danuglipron MR, fasted state (Formulation B, 1×80 mg tablet) Period 5: 80 mg dose of danuglipron MR, fed condition (Formulation B, 1×80 mg tablet)
89182838|NCT06153758|Experimental|Sequence 4|Period 1: 80 mg dose of danuglipron MR, fasted state (Formulation D, 1×80 mg tablet), Period 2: 80 mg dose of danuglipron MR, fasted state (Formulation C, 1×80 mg tablet) Period 3:80 mg dose of danuglipron MR, fasted state (Formulation B, 1×80 mg tablet) Period 4: 80 mg dose of danuglipron IR, fasted state (Formulation A, 2×40 mg tablets) Period 5: 80 mg dose of danuglipron MR, fed consition (Formulation B, 1×80 mg tablet)
89182839|NCT06151405|Experimental|Dietary Guidelines for Americans|7 days of a diet consistent with the Dietary Guidelines for Americans (DGA).
89182840|NCT06151405|Experimental|Medium Chain Triglyceride Supplemented DGA|7 days of a diet consistent with the Dietary Guidelines for Americans supplemented with medium chain triglycerides (MCT).
89379934|NCT03629262|Experimental|Dexmedetomidine group|For patients in the dexmedetomidine group, postoperative analgesia is provided in the form of patient-controlled intravenous analgesia. The formula contains a mixture of sufentanil (1.25 ug/ml) and dexmedetomidine (1.25 ug/ml), diluted with normal saline to a total volume of 160 ml. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a patient-controlled bolus of 2 ml each time and a lockout interval of 8 minutes.
89379935|NCT03629262|Placebo Comparator|Control group|For patients in the control group, postoperative analgesia is provided in the form of patient-controlled intravenous analgesia. The formula contains a mixture of placebo and sufentanil (1.25 ug/ml), diluted with normal saline to a total volume of 160 ml. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a patient-controlled bolus of 2 ml each time and a lockout interval of 8 minutes.
89399462|NCT02178878||Progress, Pain|Progress, Pain
89379936|NCT04224090||Congenita coronary abnormalities (CAA)|"All the coronary arteries were differing from the definition of normal: when do not arise from the appropriate sinus of Valsalva (right or left) and not present a proper course and termination."
89379937|NCT05208372||Laparotomy group|Patients who undergo radical laparotomy for gastric cancer.
89379938|NCT05208372||Laparoscopy group|Patients who undergo laparoscope-assisted radical gastrectomy for gastric cancer.
89379939|NCT05213988|Experimental|Low-Carbohydrate/High-Protein Diet|
89379940|NCT05213988|Experimental|Fibrate|
89379941|NCT05213988|Experimental|Intermittent Fasting|
89379942|NCT05213988|No Intervention|Control|
89379943|NCT05207904|Experimental|tislelizumab plus chemotherapy|
89379944|NCT04150692|Experimental|Arm 1: Dara-SC Re-Escalation|-Re-escalation will include weekly dosing for two 4-week cycles (8 doses, Days 1, 8, 15, and 22 of each 28-day cycle) followed by dosing every-other-week thereafter (Days 1 and 15 of each 28-day cycle). Patients will remain on study treatment until meeting clinical progression.
89379945|NCT04150692|Active Comparator|Arm 2: Dara-SC|-Continued subcutaneous daratumumab and and hyaluronidase-fihj (1,800mg/30,000U, [Dara-SC])
89379946|NCT05715450|Other|Falciformopexy for Treatment Perforated Peptic Ulcer|Use falciform ligament flap for repair perforated peptic ulcer
89379947|NCT04250337|Experimental|Lebrikizumab + Topical Corticosteroid|"500 mg Lebrikizumab (2 x 250 mg) subcutaneous (SC) injections of lebrikizumab as a loading dose at Baseline and Week 2 followed by a single injection of 250 mg Lebrikizumab every 2 weeks (Q2W) from Week 4 until Week 14.~Topical corticosteroid (TCS) will be initiated at Baseline in all participants and may be tapered or stopped, or restarted as needed, based on treatment response."
89379948|NCT04250337|Placebo Comparator|Placebo + Topical Corticosteroid|"Two placebo subcutaneous (SC) injections as a loading dose at Baseline and Week 2 followed by a single injection of placebo every Q2W from Week 4 until Week 14.~TCS will be initiated at Baseline in all participants and may be tapered or stopped, or restarted as needed, based on treatment response"
89379949|NCT04011540|Experimental|Intervention|Participants will receive a personalized digital data dashboards throughout the two-month study period.
89379950|NCT04011540|No Intervention|Usual Care|Usual care
89379951|NCT04687059|Experimental|PQ Grass Standard Dosing Regimen|Cumulative dose 27600 SU
89379952|NCT04687059|Experimental|PQ Grass Alternative Dosing Regimen|Cumulative dose 27600 SU
89379953|NCT04687059|Placebo Comparator|Placebo Option 1|Suspension for injection
88853163|NCT04295603|Experimental|Toucher Massage intervention|The intervention for the Experimental Group (EG) includes a massage time of about 15 minutes on the foot area .
89182841|NCT06151405|Experimental|Ketogenic Diet|7 days of a ketogenic diet (KETO).
89379954|NCT04687059|Placebo Comparator|Placebo option 2|Solution for injection
89379955|NCT05760729||Inflammatory bowel disease patients|It is mandatory to have a certain diagnosis of IBD before the inclusion.
89379956|NCT05760729||Healthy controls|Patients who have never had the diagnosis of inflammatory bowel disease
89379957|NCT01373775||Revisit|HF patients who revisit the emergency department before the next appointment date.
89379958|NCT01373775||Non-revisit|HF patients who follow up on the appointment date.
89379959|NCT03118947|Experimental|Pimavanserin 20 mg OR 34 mg per day|
89379960|NCT03983733|Experimental|Dietary Intervention|Dietary intervention using standardised test meals, on up to 8 days within the study period.
88853164|NCT04295603|Experimental|Homedics Machine intervention|"The Control Group (CG) will benefit from an intervention of identical duration. The treatment consists of a foot massage with a Homedics HM MP RELEX 90 device, a heat-free shiatsu program, which lasts about 15 minutes."
89379961|NCT03953079|Experimental|GB-102 1 mg/1 mg|Participants will receive intravitreal (IVT) GB-102 1 mg in the study eye at Baseline and Month 6 and sham at Months 2, 4, 8 and 10.
89379962|NCT03953079|Experimental|GB-102 2 mg/1 mg|Participants will receive intravitreal (IVT) GB-102 2 mg in the study eye at Baseline, intravitreal (IVT) GB-102 1 mg at Month 6 and sham at Months 2, 4, 8 and 10.
89379963|NCT03953079|Active Comparator|Aflibercept 2 mg|Participants will receive intravitreal (IVT) aflibercept 2 mg in the study eye at Baseline, Months 2, 4, 6, 8 and 10.
89379964|NCT04572399|Experimental|Endotracheal UV Light|Mechanically ventilated patients who will receive UV Light therapy
89182842|NCT06151197|Experimental|EN3835|
89379965|NCT03885999|Experimental|Fecobionics studies|
89379966|NCT03879525|Experimental|EMR Group|Participants assigned to this arm will complete the questionnaires in the EMR using the EMR-based-interventional method.
89379967|NCT03879525|Active Comparator|Phone Group|Participants assigned to this arm will complete the questionnaires via the Phone using the Telephone-based-standard method.
89379968|NCT03108027|Experimental|Sequence 1|Patients will receive in a sequential order the following interventional treatments: A,B and C.
88853165|NCT04285580|Experimental|Bimatoprost SR 10 μg|Participants will receive Bimatoprost SR 10 μg implant in the study eye on Day 1 and standard of care treatment in the fellow eye for the duration of the study.
89182843|NCT06151197|Placebo Comparator|Placebo|
89379969|NCT03108027|Experimental|Sequence 2|Patients will receive in a sequential order the following interventional treatments: B, A and C.
89379970|NCT03108027|Experimental|Sequence 3|Patients will receive in a sequential order the following interventional treatments: C, B and A.
89379971|NCT03108027|Experimental|Sequence 4|Patients will receive in a sequential order the following interventional treatments : C, A and B.
89379972|NCT03108027|Experimental|Sequence 5|Patients will receive in a sequential order the following interventional treatments: A, C and B.
89379973|NCT03108027|Experimental|Sequence 6|Patients will receive in a sequential order the following interventional treatments: B, C and A.
89379974|NCT03794427|Experimental|unilateral lumbosacral nerve block|Sciatic nerve block and paravertebral block at levels L3-L4 and L4-L5 will be performed
89379975|NCT03794427|Active Comparator|Spinal anesthesia|spinal anesthesia will be performed
89399463|NCT03693651||Parent of a Premature infant / PP|self-report questionnaire that assesses sleep quality (The Pittsburgh Sleep Quality Index (PSQI)) filled at 1 month, 3 months and 6 months from child birth.
88853166|NCT04285580|Other|LUMIGAN 0.01%|Participants will receive topical LUMIGAN 0.01% in the study eye once daily starting evening Dose on Day 1 and standard of care treatment in the fellow eye for the duration of the study.
88853167|NCT04259905|Experimental|Active video game teleconference support group|Participants will attend enhanced support group meetings via zoom teleconferencing software. Support group meetings will include group play of active video games and discussion of survivorship topics. Participants will self-monitor physical activity using Fitbit wearable activity monitors and will receive a water bottle and tote bag.
88853168|NCT04259905|Active Comparator|Standard support group + pedometer|Participants will attend standard in-person support groups currently offered by the UTMB Breast Health Center. They will also receive a standard pedometer and a water bottle and tote bag.
88853169|NCT04258969|Experimental|Pedaling Group|During the first 2 hours of their chemotherapy infusions, participants will pedaling for 30 minutes using a stationary cycle ergometer. Participants will be allowed to determine their pedaling intensity and cadence, however, will be encouraged to reach the established goal intensity level. Additionally, subjects will complete both a physical activity questionnaire (International Physical Activity Questionnaire) and a quality of life questionnaire (European Organization for Research and Treatment of Cancer QLQ - CR 29) at baseline and following their last chemotherapy treatment. A questionnaire on chemotherapy side effects (Memorial Symptom Assessment Scale) will be gathered at baseline, during chemotherapy cycles 3, 6, and/or 12, and following completion of chemotherapy treatment. Lastly, muscular strength and physical performance will be measured via grip strength tests and TGUG tests within 2-4 weeks of the post-surgery and chemotherapy completion CT scans.
88853170|NCT04254926|Experimental|Revie ⊕ intervention early|participants randomized into (i) the intervention group (IG) receive the Revie ⊕ intervention early on.
88853171|NCT04254926|Experimental|Revie ⊕ intervention later|The control group (CG) receives the same intervention Revie ⊕ but later on (i.e., after eight weeks).
88853172|NCT04245371|Active Comparator|Active|Lidocaine Patch 1.8% applied to affected hand at night for 2 weeks following FDA approved dosing recommendations, i.e. 12 hours during each 24-hour daily cycle.
88853173|NCT04245371|Placebo Comparator|Placebo|Placebo Patch applied to affected hand at night for 2 weeks for 12 hours during each 24-hour daily cycle.
88853174|NCT04231539|Experimental|Low Nicotine (nicotine vapor) 24 mg.ml|After 8-10 hours after nicotine abstinence, participants attend 4 vaping sessions over 2-2.5 hours, 5-7 days apart. During each session, participants take 20 puffs over 10 minutes (one puff every 30 seconds) of vaporizer filled with freebased nicotine e-liquid solution of unflavored, free-based nicotine e-liquid solution of tobacco flavor, salt-based nicotine e-liquid solution of unflavored, or salt-based nicotine e-liquid solution of tobacco flavor assigned in a random order.
88853175|NCT04231539|Experimental|High Nicotine (nicotine vapor) 42 mg.ml|After 8-10 hours after nicotine abstinence, participants attend 4 vaping sessions over 2-2.5 hours, 5-7 days apart. During each session, participants take 20 puffs over 10 minutes (one puff every 30 seconds) of vaporizer filled with freebased nicotine e-liquid solution of unflavored, free-based nicotine e-liquid solution of tobacco flavor, salt-based nicotine e-liquid solution of unflavored, or salt-based nicotine e-liquid solution of tobacco flavor assigned in a random order.
88853176|NCT04200248|Experimental|Sham + RBM-007|Sham + RBM-007 intravitreal injection
88853177|NCT04200248|Experimental|RBM-007 + Aflibercept|RBM-007 + Aflibercept intravitreal injection
88853178|NCT04200248|Active Comparator|Sham + Aflibercept|Sham + Aflibercept intravitreal injection
88853179|NCT04189432|Experimental|SCM-CGH|"Ingredient: Allogeneic human bone marrow-derived mesenchymal stem cells~Dose: 1x10^6 cells/Kg"
88853180|NCT04189432|Placebo Comparator|Placebo|3 times with 2-week intervals by IV infusion.
88853181|NCT04189419|Experimental|SCM-AGH|"Ingredient: Allogeneic human bone marrow derived mesenchymal stem cells~Dose: 1x10^6 cells/Kg"
88853182|NCT04189419|Placebo Comparator|Placebo|IV infusion.
88853183|NCT04188522||Minor Stroke|"We will enroll a cohort of 15 adult patients previously admitted to Johns Hopkins Bayview Medical Center with small/minor acute ischemic stroke visible on neuroimaging. Patients will follow-up in clinic 4-6 weeks following hospital discharge. To be eligible for the study, patients must have a minor stroke, defined as NIH Stroke Scale score at follow-up of less than or equal to 8, modified Rankin score of 0-2, be competent speakers of English, and have no prior history of stroke, dementia, or untreated psychiatric disease. Those with proximal large vessel (M1) or branch (M2) occlusions will be excluded.~*Based on preliminary results we have expanded our trial and will continue to recruit up to 40 patients with minor stroke."
88853184|NCT04188522||Controls|For comparison, we will recruit a group of age-similar controls (n=15) without neurologic disease or prior clinical history of stroke.
88853185|NCT04179760|Experimental|SCM-AGH|"Ingredient: Allogeneic human bone marrow-derived mesenchymal stem cells~Dose: 1x10^6 cells/Kg"
88853186|NCT04179760|Placebo Comparator|Placebo|3 times with 2-week intervals by IV infusion.
88853187|NCT04178096|Other|Quality Improvement Intervention|Twelve low-performing sites will receive a package of strategies which have been empirically determined to be associated with successful implementation of evidence based practices that lead to improved health outcomes for Veterans with cirrhosis.
89182844|NCT06147713|Experimental|Intervention|The subjects will be examined during the drug-off period with the vibrotactile foot device off and on at different patterns. The tests will be carried out during the onsite clinical visits on the day of initial enrollment and two weeks after home wearing.
89399464|NCT03693651||Parent of a baby born on time / PT|self-report questionnaire that assesses sleep quality (The Pittsburgh Sleep Quality Index (PSQI)) filled at 1 month, 3 months and 6 months from child birth.
89379976|NCT03606291|Experimental|isotoxic hypofractionation group|"1. Hypofractionated radiation: 3Gy/f. 2,Individualized prescriptions for different patients:~(1) Spinal cord: 0%>45 Gy, and ≤2 Gy each time Lung: V20≤30%, V5≤65%, MLD≤16Gy Esophagus: highest dose ≤ 72Gy 3. Maximum limit: If the limit of any A is not reached, the maximum radiation dose is 72 Gy. The lowest radiation dose: 45Gy."
89379977|NCT03427827|Experimental|Adjuvant PD-1 antibody arm|Patients randomized to this arm will receive PD-1 antibody (SHR-1210), 200mg, ivdrip (>30 minutes), d1, q3w × 12 cycles, begining at 4-6 weeks after chemoradiation
89379978|NCT03427827|No Intervention|Best supportive care|Patients randomized to this arm will receive best supportive care after chemoradiation
89379979|NCT03633513||Patients|Clinical diagnosed Parkinson's disease patients
89379980|NCT03633513||Caregivers|Environmentally matched healthy control subjects
89379981|NCT03410901|Experimental|Treatment (radiation therapy, SD-101, BMS-986178)|Patients receive radiation therapy on days 1-2, TLR9 agonist SD-101 and anti-OX40 antibody BMS-986178 intratumorally on days 2, 9, 16, 23, and 30, and anti-OX40 antibody BMS-986178 IV on days 2, 30, 58, 86, 114, and 142 in the absence of disease progression or unacceptable toxicity.
89379982|NCT01373853|Experimental|Femtec Groupe A|In Group A the anterior capsulotomy and a pre-fragmentation of the ocular lens will be performed by means of femtosecond laser surgery
89379983|NCT01373853|Active Comparator|Manual Group B|Group B acts as a control group where the capsulotomy and lens fragmentation are performed manually
89379984|NCT03357939|Experimental|HLX03|There are about 68 subjects in this group will receive a single dose of 40 mg of HLX03 in 0.8 mL in subcutaneous injection.
89379985|NCT03357939|Active Comparator|Humira|There are about 68 subjects in this group will receive a single dose of 40 mg of Humira in a pre-filled syringe in subcutaneous injection.
89379986|NCT05759403||Patients with parkinson's disease|Genetic analysis, clinical data , cortical excitbility
89379987|NCT05759403||patients with Parkinson dementia complex|Genetic analysis, clinical data , cortical excitbility
89379988|NCT03713073|Experimental|Allogenic amnion chorion membrane|Allogenic amnion chorion membrane (ACM) is a minimally manipulated allograft amnion chorion tissue for use as a wound covering in dental surgery.
89379989|NCT03713073|Active Comparator|Collagen dressing|Collagen dressing is used to cover wounds in dental surgery.
89379990|NCT05760495||Single arm|ART-experienced PLWH
89379991|NCT03633435|Experimental|assisted home hemodialysis patients|all patients starting assisted home hemodialysis during the study period
89379992|NCT03107715|Active Comparator|Breastfeeding Champion|The Breastfeeding Champion Intervention (Intervention A) utilizes information about Breastfeeding Champions from the Coffective™ program: participants will be guided to tap and scroll through the content and will receive a follow up handout and encouragement to select a Champion.
89379993|NCT03107715|Active Comparator|Positive Messaging|The Positive Messaging Intervention (Intervention B) utilizes positive messaging from several sources and is modelled on the WIC Loving Support™ approach: participants will click on (istock-purchased) photographs which each reveal an informational statement about exclusive breastfeeding benefits and tips, followed by receipt of a summary handout.
89379994|NCT03567057|Experimental|ADS-5102, 274 mg|274 mg ADS-5102, administered once daily at bedtime for up to 52 weeks
89379995|NCT03508557|Experimental|Advance care planning tools|Advance care planning education and structured conversation using tools
89379996|NCT05760417||Patients wiht Hyperthyroidism|Patients diagnosed with hyperthyroidism.
89379997|NCT04388787|Experimental|stochastic resonance (SR) vibration|SR applied sub threshold at 90% of participant's detection threshold
89379998|NCT04388787|Sham Comparator|Sham treatment|SR devices worn but not turned on (0% of participant's detection threshold).
89379999|NCT04388787|Experimental|Unblinded treatment|SR is applied above participant's detection threshold at a participant selected intensity.
89380000|NCT03057600|Experimental|Cohort 1 - African ancestry, 3rd line+|"Intervention = Paclitaxel- CB-839 (Pac-CB) combination~Participants must self-identify as African ancestry (includes African American).~At least 2 prior lines of systemic therapy for advanced/metastatic disease including a taxane.~Prior taxane (paclitaxel, docetaxel, or nab-paclitaxel) for advanced/metastatic disease is required but must not have been received in the immediate prior line of therapy.~Systemic neoadjuvant and/or adjuvant therapy is considered a line of therapy for advanced/metastatic disease if the time to recurrence from completion of treatment was ≤ 12 mo."
89380001|NCT03057600|Experimental|Cohort 2 - African ancestry, 1st line|"Intervention = Pac-CB combination~Participants must self-identify as African ancestry (includes African American).~No prior systemic therapy for advanced or metastatic disease.~Systemic neoadjuvant or adjuvant therapy, including taxane, is allowed if time to recurrence was > 12 mo."
89380002|NCT03057600|Experimental|Cohort 3 - Non-African ancestry, 3rd line+|"Intervention = Pac-CB combination~Participants do not self-identify as African ancestry.~Otherwise have the same criteria as Cohort 1."
89380003|NCT03057600|Experimental|Cohort 4 - Non-African ancestry, 1st line|"Intervention = Pac-CB combination~Participants do not self-identify as African ancestry.~Otherwise have the same criteria as Cohort 2."
89380004|NCT04382937|Experimental|P1101 + Ribavirin|P1101 400 µg SC Q2W
89380005|NCT04382937|Active Comparator|PEG-Intron + Ribavirin|PEG-Intron 1.5 µg per kg SC Q1W
89380006|NCT04355169|Experimental|Naldemedine 1.25 mg|Participants will receive 1.25 milligrams (mg) naldemedine twice daily (BID) beginning on the day of surgery (Day 1) and for up to a maximum of 10 days post-surgery.
89380007|NCT04355169|Experimental|Naldemedine 2.5 mg|Participants will receive 2.5 mg naldemedine BID beginning on the day of surgery (Day 1) and for up to a maximum of 10 days post-surgery.
89380008|NCT04355169|Experimental|Naldemedine 5 mg|Participants will receive 5 mg naldemedine BID beginning on the day of surgery (Day 1) and for up to a maximum of 10 days post-surgery.
89380009|NCT04355169|Placebo Comparator|Placebo|Participants will receive matching placebo BID beginning on the day of surgery (Day 1) and for up to a maximum of 10 days post-surgery.
89380010|NCT05206890||fluzoparib treatment|patients with Epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who underwent fluzoparib monotherapy or combination therapy
89380011|NCT05212974||Nurses|Adult (≥ 20 and ≤80 years) male and female participants with verification of registered nurse license.
89380012|NCT05212974||General publics|Adult (≥ 20 and ≤80 years) male and female participants with reading abilities above the intermediate level.
89380013|NCT03371823|Other|Normotensive|Normotensive PMW will complete an experimental visit to assess vascular function. All women will wear an ambulatory BP monitor during the 24 hours preceding the experimental visit to confirm BP classification. Large blood vessel function will be assessed using two non-invasive techniques: 1. Flow Mediated Dilation (FMD) 2. Pulse Wave Analysis and Pulse Wave Velocity. ET-1 mediated vasoconstrictor tone is assessed by measuring the cutaneous blood flow during microdialysis perfusions of ET-A and ET-B receptor antagonist. ET-1 production, ET-A and ET-B receptor expression is assessed from antecubital vein endothelial cells and skin punch biopsy samples.
89380014|NCT03371823|Experimental|Hypertensives|Hypertensive women will be tested at baseline and then administered Losartan 50 mg once a day at night for 14 days. Vascular function is measured at baseline and again after 2 weeks of losartan. All women will wear an ambulatory BP monitor during the 24 hours preceding the experimental visits to confirm BP classification. Large blood vessel function will be assessed using two non-invasive techniques: 1. Flow Mediated Dilation (FMD) 2. Pulse Wave Analysis and Pulse Wave Velocity. ET-1 mediated vasoconstrictor tone is assessed by measuring the cutaneous blood flow during microdialysis perfusions of ET-A and ET-B receptor antagonist. ET-1 production, ET-A and ET-B receptor expression is assessed from antecubital vein endothelial cells and skin punch biopsy samples.
88853188|NCT04178096|No Intervention|Control Arm|All sites besides the pre-selected twelve, a total of one hundred eighteen sites, will not receive the intervention and will provide care as usual.
88853189|NCT04137887|Experimental|Group 1: QIV-HD|Participants received a single injection of 0.7 milliliters (mL) high dose quadrivalent influenza vaccine (QIV-HD), intramuscularly (IM) at Day 0.
89380015|NCT03879642|Experimental|REDCHiP|10 week video-based telemedicine intervention to reduce parents hypoglycemia fear
89380016|NCT03879642|No Intervention|Waitlist|10 week no intervention to provide waitlist control condition
89380017|NCT05212896|Experimental|Dose Escalation: Phase Ia|Participants will receive escalating doses of BC006 at assigned dose (0.08, 0.3, 1.0, 3.0, 10, 20 mg/kg) via intravenous (IV) infusion every 2 weeks until disease progression, unacceptable toxicity, withdrawal of informed consent, or up to 48 weeks of treatment, whichever occurs first.
89380018|NCT05212896|Experimental|Dose Expansion: Phase Ib Cohort 1|Participants with GCTTS will receive BC006 at recommended dose for expansion (RDE) IV every 2 weeks until disease progression, unacceptable toxicity, withdrawal of informed consent, or up to 24 weeks of treatment, whichever occurs first.
89380019|NCT05212896|Experimental|Dose Expansion: Phase Ib Cohort 2~4|Participants with other solid tumors will receive BC006 at RDE IV every 2 weeks until disease progression, unacceptable toxicity, withdrawal of informed consent, or up to 48 weeks of treatment, whichever occurs first.
88853190|NCT04137887|Active Comparator|Group 2: QIV-SD|Participants received a single injection of 0.5 mL standard-dose quadrivalent influenza vaccine (QIV-SD), IM at Day 0.
88853191|NCT04120402|Experimental|EP-104IAR 25 mg|A single use intra-articular injection containing 25 mg of EP-104IAR
89380020|NCT03619980||Participants with prostate cancer|This is a retrospective registry based study to collect real world data on participants with different disease stages of prostate cancer in Sweden.
89380021|NCT03125967|Active Comparator|Blue Light|Blue light exposure (Philips GoLite Blu HF3429/60) administered daily for 25 minutes between 8:00AM and 9:00AM
89380022|NCT03125967|Placebo Comparator|Red Light|Red light exposure (Philips LivingColor Aura 70998/60/48) administered daily for 25 minutes between 8:00AM and 9:00AM
89380023|NCT05212506||vaccinated and unvaccinated|
89380024|NCT03012789|Other|Post Surgery|
88853192|NCT04120402|Placebo Comparator|Placebo (vehicle)|A single use intra-articular injection containing no active ingredients
88853193|NCT04096196|Experimental|Game intervention group|Participants assigned to the intervention group will be given a manual containing instructions to play the Safe City game. A research assistant will provide a briefing session on the game in each participating school. A unique username and password set will be created for each user to log in the game. This login information will be provided to the student participants in a sealed envelope after the briefing session. The participants will be instructed to play the game as many times as desired within a 4-week time frame. The players ranked in the top 20 will receive a reward in the form of book coupon after the intervention ends.
89380025|NCT02966301|Experimental|interventional|Single arm : Arsenic trioxide
89380026|NCT03262623|Experimental|Radial nerve block|Patients will receive radial nerve block guided by a nerve stimulator.
88853194|NCT04096196|Active Comparator|"Health education (control) group"|All students in the health education group will receive a comprehensive package on safety information. The information package includes both printed and electronic promotional materials regarding safety and a comprehensive list of relevant website and information sources. The information from these relevant websites and information sources are similar to those used in setting the safety case scenarios for the Safe City game. As a result, both intervention arms will have comparable accessibility to safety-related information and the major contrast between the two groups will be the method of presentation (game-based learning vs traditional health promotion approach, i.e. unidirectional information package).
89380027|NCT03262623|Placebo Comparator|Placebo|Patients will receive placebo through radial nerve block
88817699|NCT04692519|No Intervention|Delayed Access|Participants who are in the delayed access control group will not have to complete the modules and will be scheduled for a 3-month, 6-month, and pending funding, a 1-year follow-up calls. They will have delayed access to the modules, which means that they will receive access to the module videos at their 6-month study session and will be offered the opportunity to contact the research team with any questions.
88853195|NCT04095273|Experimental|Dose escalation of Elimusertib|2 dose levels of Elimusertib are planned
88853196|NCT04095273|Experimental|Dose expansion cohort 1a of Elimusertib|Participants with advanced hormone-receptor-positive, Human epidermal growth factor receptor 2 negative breast cancer (HER2-negative BC), known to be positive for Ataxia-telangiectasia mutated (ATM) loss and/or ATM deleterious alterations who have not received prior treatment with immunotherapy. Participants with known microsatellite instability-high (MSI-H) cannot be included
88853197|NCT04095273|Experimental|Dose expansion cohort 1b of Elimusertib|Participants with advanced hormone-receptor-positive, HER2-negative BC, known to be DDR deficiency biomarker-positive (except ATM loss/mutation) who have not received prior treatment with immunotherapy. Participants with known MSI-H cannot be included.
88853198|NCT04095273|Experimental|Dose expansion cohort 2a of Elimusertib|Participants with advanced Colorectal cancer (CRC) known to be positive for ATM loss and/or ATM deleterious alterations who have not received prior treatment with immunotherapy. Participants with known MSI-H cannot be included.
88853199|NCT04095273|Experimental|Dose expansion cohort 2b of Elimusertib|Participants with advanced CRC, known to be DDR deficiency biomarker -positive (except ATM loss/mutation) who have not received prior treatment with immunotherapy. Participants with known MSI-H cannot be included.
88853200|NCT04095273|Experimental|Dose expansion cohort 3 of Elimusertib|Participants with advanced Gastric/gastroesophageal junction cancer (GC/GEJ) known to be DDR deficiency biomarker-positive (incl. ATM mutation) and/or positive for ATM loss. Participants must have progressed on treatment with an anti-PD-1/L1 mAb administered either as monotherapy, or in combination with other checkpoint inhibitors or other therapies.
88853201|NCT04095273|Experimental|Dose expansion cohort 3a of Elimusertib|Participants with advanced GC/GEJ cancer and without DDR deficiency alterations as described above. Variants of unknown significance (VUS) of the DDR gene alterations are eligible. Participants must have progressed on treatment with an anti-PD-1/L1 mAb administered either as monotherapy, or in combination with other checkpoint inhibitors or other therapies.
88853202|NCT04095273|Experimental|Dose expansion cohort 4 of Elimusertib|Participants with advanced Non-small cell lung cancer (NSCLC) known to be DDR deficiency biomarker-positive (incl. ATM mutation) and/or positive for ATM loss. Participants must have progressed on treatment with an anti-PD-1/L1 mAb administered either as monotherapy, or in combination with other checkpoint inhibitors or other therapies.
88853203|NCT04095273|Experimental|Dose expansion cohort 4a of Elimusertib|Participants with advanced NSCLC and without DDR deficiency alterations as described above. VUS of the DDR gene alterations are eligible. Participants must have progressed on treatment with an anti-PD-1/L1 mAb administered either as monotherapy, or in combination with other checkpoint inhibitors or other therapies.
88853204|NCT04095273|Experimental|Dose expansion cohort 5 of Elimusertib|Participants with advanced pancreatic cancer, known to be DDR deficiency biomarker-positive (incl. ATM mutation) and/or positive for ATM loss who have not received prior treatment with immunotherapy. Participants with known MSI-H cannot be included.
88853205|NCT04095273|Experimental|Dose expansion cohort 5a of Elimusertib|Participants with advanced pancreatic cancer and without DDR deficiency alterations as described above, who have not received prior treatment with immunotherapy. VUS of the DDR gene alterations are eligible. Participants with known MSI-H cannot be included.
88853206|NCT04095273|Experimental|Dose expansion cohort 6 of Elimusertib|Participants with advanced Metastatic castration-resistant prostate cancer (mCRPC), known to be DDR deficiency biomarker positive (incl. ATM mutation) and/or positive for ATM loss who have not received prior treatment with immunotherapy. Participants with known MSI-H cannot be included.
88853207|NCT04095273|Experimental|Dose expansion cohort 6a of Elimusertib|Participants with advanced mCRPC and without DDR deficiency alterations as described above, who have not received prior treatment with immunotherapy. VUS of the DDR gene alterations are eligible. Participants with known MSI-H cannot be included.
88853208|NCT04074590|Experimental|LYS006|Experimental drug
88853209|NCT04074590|Placebo Comparator|Placebo|Placebo comparator
88853210|NCT04068844|Experimental|Central HFpEF whole body exercise|HFpEF patients who have a central limitation as the cause of the exercise intolerance randomized to whole body cycle training.
88853211|NCT04068844|Experimental|Central HFpEF isolated single leg exercise|HFpEF patients who have a central limitation as the cause of the exercise intolerance randomized to isolated single leg training.
88853212|NCT04068844|Experimental|Peripheral HFpEF whole body exercise|HFpEF patients who have a peripheral limitation as the cause of the exercise intolerance randomized to whole body cycle training.
88853213|NCT04068844|Experimental|Peripheral HFpEF isolated single leg exercise|HFpEF patients who have a peripheral limitation as the cause of the exercise intolerance randomized to isolated single leg training.
89399465|NCT03689517|Experimental|placebo arm|Orthodontic pain was introduced by placement of orthodontic elastic separators to the mesial and distal sides of the right mandibular first molar. Participants took placebos (pills made by starch) that were told to be an effective analgesic
89399466|NCT03689517|Sham Comparator|sham arm|Orthodontic pain was introduced by placement of orthodontic elastic separators to the mesial and distal sides of the right mandibular first molar. But participants do not take placebos
89399467|NCT02174354||Psoriasis|Patients with psoriasis taking methotrexate
88853214|NCT04023487|Experimental|Lifestyle Intervention|Resilient, Empowered, Active Living-Telehealth (REAL-T)
88853215|NCT04023487|No Intervention|Usual Care|Participants will continue to have access to routine diabetes care from the provider of their choosing; they will not receive any study-related intervention.
88853216|NCT03997773|Experimental|Intervention|Will receive the intervention
88853217|NCT03997773|No Intervention|Usual care|Will receive usual care - will be the control group
88853218|NCT03972969|Experimental|In-person exercise group|facility-based structured exercise program
88853219|NCT03972969|Experimental|Remote exercise group|home-based structured exercise program
88853220|NCT03972969|Active Comparator|Control group|health education
88853221|NCT03954366|Other|Arm A - rucaparib and oral rosuvastatin|
88853222|NCT03954366|Other|Arm B - rucaparib and oral contraceptives|
88853223|NCT03936569|Experimental|Marketed Stannous Fluoride Toothpaste|Brush twice daily
88853224|NCT03936569|Placebo Comparator|Marketed Cavity Protection Toothpaste|Brush twice daily
88853225|NCT03935932|Experimental|baseline followed by intervention|Subjects randomized to perform baseline measurement of clearance on study day 2 and measurement of clearance with nasal delivery of heated and humidified air on day 3
88853226|NCT03935932|Experimental|intervention followed by baseline|Subjects randomized to perform measurement of clearance with nasal delivery of heated and humidified air on day 2 and baseline measurement of clearance on study day 3
88853227|NCT03934255|Experimental|Constant Routine Protocol|Participants will be kept in constant conditions for 30 hours to observe circadian physiology in the absence of light, physical activity, and meals.
88853228|NCT03912220|Experimental|Nicotinamide Riboside|Experimental group of participants will receive Nicotinamide riboside at a dose of 900 mg twice a day orally.
88853229|NCT03912220|Placebo Comparator|Placebo|Study participants in the placebo arm will receive placebo pills that are similar in size and shape to the experimental group drug.
88853230|NCT03898167|Active Comparator|Telephone Recall|Participants receive a scripted telephone recall from a trained patient navigator on behalf of Harris Health System.
88853231|NCT03898167|Experimental|Mailed HPV Self-Sampling Kit|Participants receive a scripted telephone recall from a patient navigator on behalf of Harris Health System and receive a mailed HPV self-sampling kit with a pre-paid return envelope.
88853232|NCT03898167|Experimental|Mailed HPV Self-Sampling Kit + Patient Navigation|Participants receive a scripted telephone recall and mailed self-sampling kit with a pre-paid return envelope. Within 3-5 days of the kit's mail-out, participants will receive a telephone call from a patient navigator to provide one-on-one education.
88853233|NCT03872791|Experimental|KN046|Subjects will receive KN046 at a dose of 3 mg/kg or 5 mg/kg via intravenous infusion on Days 1 and 15 of every 28-day cycle until disease progression, unacceptable toxicity or completion of 2 years of treatment
88853234|NCT03872791|Experimental|KN046 plus nab-paclitaxel|Subjects will receive KN046 at a dose of 3 mg/kg or 5 mg/kg via intravenous infusion on Days 1 and 15 of every 28-day cycle until disease progression, unacceptable toxicity or completion of 2 years of treatment Subjects will receive nab-paclitaxel at a dose of 100 mg/m2 via intravenous infusion on Days 1, 8 and 15 of every 28-day cycle until disease progression or unacceptable toxicity
88853235|NCT03864042|Experimental|Arm 1 - CYP Probe Cocktail|"Patients will receive a single oral dose of the CYP Probe Cocktail on Day -7, Day 1, and Day 14:~25 mg losartan oral tablet~30 mg dextromethorphan oral capsule~50 mg caffeine oral liquid~20 mg omeprazole oral capsule~2 mg midazolam oral syrup~encorafenib/binimetinib continuous daily dosing starting Day 1:~450 mg (6 x 75 mg) encorafenib oral capsules once daily (QD)~45 mg (3 x 15 mg) binimetinib oral tablet twice daily (BID)~All drugs will be taken within 10 minutes."
88853236|NCT03864042|Experimental|Arm 2 - Rosuvastatin and Bupropion|"Patients will receive a single oral dose of rosuvastatin and bupropion once on Day -7, Day 1 and Day 14:~10 mg rosuvastatin oral tablet~75 mg bupropion immediate release (IR) oral tablet~encorafenib/binimetinib continuous daily dosing starting Day 1:~450 mg (6 x 75 mg) encorafenib oral capsules once daily (QD)~45 mg (3 x 15 mg) binimetinib oral tablet twice daily (BID)~All drugs will be taken within 10 minutes."
88853237|NCT03864042|Experimental|Arm 3 - Modafinil|"Patients will begin encorafenib/binimetinib continuous daily dosing starting Day 1:~450 mg (6 x 75 mg) encorafenib oral capsules once daily (QD)~45 mg (3 x 15 mg) binimetinib oral tablet twice daily (BID)~then receive continuous treatment of modafinil on Day 15 through Day 21:~- 400 mg modafinil tablet once daily (QD)"
88853238|NCT03737604|Active Comparator|Ropivacaine Continuous Infusion Catheter|Ropivacaine Continuous Infusion Catheter: ultrasound guided TAP block and TAP catheter placement performed with 0.2% ropivacaine (2.5 mg/kg) and maintained with 0.2% ropivacaine infusion 8 ml/hour via catheter.
88853239|NCT03737604|Active Comparator|Single dose liposomal bupivicaine|Liposomal bupivacaine TAP block: ultrasound guided TAP block a performed with up to 12 ml 0.25% bupivacaine and prolonged with liposomal bupivacaine 133 mg diluted to total volume of 20 ml with preservative free saline.
88853240|NCT03730519|Active Comparator|Patients with refractory hypertension|Patients with refractory hypertension which cannot be controlled with drug therapy in the hands of hypertension specialists will be treated with Baroreflex Activation Therapy with Barostim Neo and followed up for a period of up to 3 years
88853241|NCT03730519|Active Comparator|Patients with highly variable BP|Patients with symptomatic highly variable blood pressure due to afferent baroreceptor failure which cannot be controlled with drug therapy in the hands of hypertension specialists will be treated with Baroreflex Activation Therapy with Barostim Neo and followed up for a period of up to 3 years
88853242|NCT03676504|Experimental|Stratum I|Adult patients with relapsed or refractory ALL
88853243|NCT03676504|Experimental|Stratum II|Adult patients with relapsed or refractory CLL, DLBCL, FL or MCL
88853244|NCT03676504|Experimental|Stratum III|Pediatric patients with relapsed or refractory ALL
89399468|NCT03685851||UT-DSAEK|With graft 6 months thick less than 100 µm
89399469|NCT03685851||DSAEK|With graft thicker than 100 µm
89399470|NCT02179034|Placebo Comparator|Tobacco Flavor|In this arm, subjects will receive tobacco flavor- without nicotine (placebo). Participants will then be exposed to 3 levels of a menthol additive in random order: no dose, low dose and high dose.
88853245|NCT03637270|Experimental|PRO group|Participants in PRO group receive dietary supplementation with protein-rich supplements immediately before and after each exercise training session. The interventions include 30 training sessions.
88853246|NCT03637270|Active Comparator|CHO group|Participants in CHO group receive dietary supplementation with carbohydrate-rich supplements immediately before and after each exercise training session. The interventions include 30 training sessions.
88853247|NCT03626974|Experimental|Venipuncture with vanilla odor|the venipuncture will be performed on the neonate in the presence of a diffuser spreading the vanilla odor and ingestion of water
88853248|NCT03626974|Placebo Comparator|Venipuncture without odor|the venipuncture will be performed with an odorless diffuser and ingestion of sucrose
88853249|NCT03597594|Active Comparator|TCRα/β/CD19-depleted SCT|"A preparative regimen based on the type of SCID will be given followed by infusion of donor cells. Cells for infusion are prepared using the CliniMACS System~Regimen 1 - IL2RG, JAK 3 (Haplocompatible) and all MSD~ATG (rabbit) IV Days -9 -8 and -7, Rest Days -6 and -5, Busulfan IV Days -4, -3, and -2, Rest Day -1, TCRα/β/CD19-depleted SCT, Day 0~Regimen 2 - RAG1, RAG2 (Haplocompatible)~ATG (rabbit) IV Days -9 -8 and -7, Fludarabine IV Days -7, -6, -5 and -4, Busulfan IV Days -5, -4 and -3, Thiotepa IV twice daily, Day -2, Rest Day -1, TCRα/β/CD19-depleted SCT, Day 0~Regimen 3 - ADA, IL7R, CD45 deficiency, CD3 subunits (Haplocompatible)~ATG (rabbit) IV Days -9 -8 and -7, Fludarabine IV Days -7, -6, -5 and -4, Busulfan: IV Days -4, -3 and -2, Rest Day -1, TCRα/β/CD19-depleted SCT, Day 0"
88853250|NCT03597594|Experimental|Donor Lymphocyte Infusions|"Phase I:~On the Phase I portion of the study, up to 4 different dose levels will be evaluated: Dose level -1, Dose ≥0.1 to ≤0.3; Dose level 1, Dose >0.3 to ≤0.56; Dose level 2, Dose >0.56 to ≤1.8; Dose level 3, Dose >1.80 to ≤3.0~Dosing is determined based on the number of CD3+CD45RA-cells/kg and the patient weight in kilograms.~Phase II:~Participants will receive the Phase I determined maximum tolerated dose (MTD) of DLI.~Cells for infusion are prepared using the CliniMACS System."
89182845|NCT06143059|Experimental|Alcohol Administration - Late Luteal Phase|During the late luteal phase of a female participant's menstrual cycle, participants will complete a lab session where alcohol is administered intravenously. The infusion will include a 30-minute linear ascension from 0mg% breath alcohol content (BrAC) to 100mg%, followed by a 60-minute 'clamping' of BrAC at 100mg%. Subjects will then be monitored while they sleep, using polysomnography. Male subjects will complete this and the placebo session at intervals that are matched to the female subjects. The placebo and alcohol sessions during late luteal phase will take place 1-2 days apart, and their order will be randomized.
89182846|NCT06143059|Placebo Comparator|Placebo - Late Luteal Phase|During the late luteal phase of a female participant's menstrual cycle, participants will complete a lab session where saline is administered intravenously, as placebo, for 90 minutes. Subjects will then be monitored while they sleep, using polysomnography. Male subjects will complete this and the experimental session at intervals that are matched to the female subjects. The placebo and alcohol sessions during late luteal phase will take place 1-2 days apart, and their order will be randomized.
89182847|NCT06143059|Experimental|Alcohol Administration - Mid-Follicular Phase|During the mid-follicular phase of a female participant's menstrual cycle, participants will complete a lab session where alcohol is administered intravenously. The infusion will include a 30-minute linear ascension from 0mg% breath alcohol content (BrAC) to 100mg%, followed by a 60-minute 'clamping' of BrAC at 100mg%. Subjects will then be monitored while they sleep, using polysomnography. Male subjects will complete this and the placebo session at intervals that are matched to the female subjects. The placebo and alcohol sessions during mid-follicular luteal phase will take place 1-2 days apart, and their order will be randomized.
89182848|NCT06143059|Placebo Comparator|Placebo - Mid-Follicular Phase|During the mid-follicular phase of a female participant's menstrual cycle, participants will complete a lab session where saline is administered intravenously, as placebo, for 90 minutes. Subjects will then be monitored while they sleep, using polysomnography. Male subjects will complete this and the experimental session at intervals that are matched to the female subjects. The placebo and alcohol sessions during mid-follicular phase will take place 1-2 days apart, and their order will be randomized.
89182849|NCT06140355|Experimental|Experimental group|adults with SCI-related neuropathic pain with at least 50% from diverse groups randomized to experimental group
89182850|NCT06140355|Active Comparator|Active comparison group|adults with SCI-related neuropathic pain with at least 50% from diverse groups randomized to active comparator group
89182851|NCT06138977|Experimental|Prosthesis|Participants in this arm of the study will perform various tasks while wearing the powered prosthesis
89182852|NCT06138730|Experimental|Appa Complete|Participants in this arm will be granted access to Appa Complete (i.e., weekly mentorship + CBT videos).
89182853|NCT06138730|Active Comparator|Appa Lite|Participants in this arm will be granted access to Appa Lite (i.e., CBT videos without weekly mentorship).
89182854|NCT06138730|No Intervention|Waiting List Control|Participants in this arm will be given a mental health resources packet. In 12 weeks (after the study period), they will be granted access to Appa Lite.
89182855|NCT06134336||Research Group|Participants with eating disorders according to the SCOFF Eating Disorders Scale will constitute the research group. Both groups will complete the Occupational Balance Questionnaire and their occupational balances will be compared. The study will be terminated when there are at least 105 participants in the research and control groups and 210 participants in total.
89399471|NCT02179034|Active Comparator|Low Dose Nicotine|In this arm, subjects will receive a low dose of nicotine (6 mg/ml) added to the tobacco flavor. Participants will then be exposed to 3 levels of a menthol additive in random order: no dose, low dose and high dose.
88853251|NCT03595657|Experimental|CS1001|Participants will receive CS1001 1200 mg by intravenous infusion every 3 weeks
88853252|NCT03591887|Experimental|ABY-035 2 mg|2 mg ABY-035 SC
88853253|NCT03591887|Experimental|ABY-035 20 mg|20 mg ABY-035 SC
88853254|NCT03591887|Experimental|ABY-035 80 mg|80 mg ABY-035 SC
88853255|NCT03591887|Experimental|ABY-035 160 mg|160 mg ABY-035 SC
88853256|NCT03591887|Placebo Comparator|Placebo|Placebo, switching to 80 mg ABY-035 after 12 weeks
88853257|NCT03563690|Experimental|Acupuncture group|When recruited from six centers,the participant will be randomized to six groups .In acupuncture group participant will receive four-week acupuncture treatment(three times a week )continuously for 4 weeks,12 treatments in total. The follow-up period is six months.
89380028|NCT05759169|Experimental|Intervention|In line with the literature and expert opinions, each dialysis application has been applied to individuals for 30 minutes for the first 30 minutes of 4 weeks, with a 40-43°C hot water-filled foot wash tub, placing both feet of the individual (Afrasiabifar et al., 2022; Kim et al., 2021 Shafeik et al., 2018). The researcher implemented the voluntary consent Form, Patient Demonstration Form, foot Bath Application Monitoring Chart, fatigue VAS Scale Form, dialysis Symptom Index and Hemodialysis Comfort Scale in person. At the end of the fourth week, the researcher refilled the foot Bath Application Monitoring Chart, the fatigue VAS Scale Form, the dialysis Symptom Index, and the Hemodialysis Comfort Scale. A total of 12 sessions have been performed in the foot bath, including during each dialysis treatment for 4 weeks.
89380029|NCT05759169|No Intervention|Control|Patients in the control group have been informed about the voluntary Form, Patient Demonstration Form, fatigue VAS Scale Form, dialysis Symptom Index, and Hemodialysis Comfort Scale performed by the researcher in person. At this stage, no attempt was made to the control group at the end of the fourth week; during the last hemodialysis session, the researcher, with the fatigue VAS Scale Form, the dialysis Symptom Index and the Hemodialysis Comfort Scale face-to-face, treated the patients.
88853258|NCT03563690|Experimental|Electro-acupuncture group|When recruited from six centers,the participant will be randomized to six groups. In this group participant receive four-week electro-acupuncture treatment(three times a week )continuously for 4 weeks,12 treatments in total. The follow-up period is six months.
88853259|NCT03563690|Experimental|Moxibustion group|When recruited from six centers,the participant will be randomized to six groups. In this group participant receive four-week moxibustion treatment (three times a week )continuously for 4 weeks,12 treatments in total. The follow-up period is six months.
89182856|NCT06134336||Control Group|Participants without eating disorders according to the SCOFF Eating Disorders Scale will constitute the control group. Both groups will complete the Occupational Balance Questionnaire and their occupational balances will be compared. The study will be terminated when there are at least 105 participants in the research and control groups and 210 participants in total.
89380030|NCT03107091|Experimental|Terlipressin acetate continuous infusion|Continuous infusion of terlipressin starting at 2 mg/day over 7 days in-house and if tolerated continue treatment in the ambulatory setting for 21 days
88853260|NCT03563690|Experimental|Warm-needling group|When recruited from six centers,the participant will be randomized to six groups. In this group participant receive four-week warm-needling treatment (three times a week )continuously for 4 weeks,12 treatments in total. The follow-up period is six months.
89380031|NCT03849768|Experimental|HS-10296|110mg PO once daily
88853261|NCT03563690|Sham Comparator|Sham-needle group|When recruited from six centers,the participant will be randomized to six groups.In this group participant receive four-week sham acupuncture treatment (three times a week )continuously for 4 weeks,12 treatments in total. The follow-up period is six months.
88853262|NCT03563690|Active Comparator|Celebrex group|When recruited from six centers,the participant will be randomized to six groups . In this group participant will receive Celebrex (Celebrex, Capsules, Pfizer Pharmaceuticals Ltd)treatment, which will be applied 1 time daily(one time oral 0.2g) for 4 weeks. The follow-up period is six months.
88853263|NCT03557684|Experimental|PO leucine & IV LPS|Oral (PO) leucine 6 g twice a day for 2 weeks followed by a single intravenous (IV) bolus of lipopolysaccharide (LPS) 0.8 ng/kg of body weight
88853264|NCT03557684|Experimental|PO placebo & IV LPS|PO maltodextrin (placebo) twice a day for 2 weeks followed by a single IV bolus of LPS 0.8 ng/kg of body weight
88853265|NCT03557684|Experimental|PO leucine & IV placebo|PO leucine 6 g twice a day for 2 weeks followed by a single IV bolus of 0.9% saline
88853266|NCT03557684|Placebo Comparator|PO placebo & IV placebo|PO maltodextrin (placebo) twice a day for 2 weeks followed by a single IV bolus of 0.9% saline
88853267|NCT03557008|Active Comparator|Rabies Vaccine with Antibiotics|Participants in this group will receive the rabies vaccines as well as an antibiotic regimen consisting of metronidazole, vancomycin, and neomycin sulfate.
88853268|NCT03557008|Active Comparator|Rabies Vaccine|Participants in this group will receive the rabies vaccine.
89380032|NCT03849768|Active Comparator|Gefitinib|250mg PO once daily
89380033|NCT03189693|Experimental|PVB group|Patients will receive two PVB injections at levels T12-L1 and L1-L2 using anesthetic mixture
89380034|NCT03189693|Placebo Comparator|Placebo|Patients will receive two PVB injections containing placebo at levels T12-L1 and L1-L2
89380035|NCT03065400|Experimental|Pembolizumab|
89380036|NCT05200065|Experimental|Thulium Laser Enucleation|Patients in this arm will undergo thulium laser enucleation of the prostate.
89380037|NCT05200065|Experimental|Bipolar Enucleation|Patients in this arm will undergo bipolar enucleation of the prostate.
89399472|NCT02179034|Active Comparator|High Dose Nicotine|In this arm, subjects will receive a high dose of nicotine (12 mg/ml) added to the tobacco flavor. Participants will then be exposed to 3 levels of a menthol additive in random order: no dose, low dose and high dose.
89399473|NCT03623997||Stable isotope labeled iron II sulfate|All subjects will go through two iron absorption study cycles. In one cycle they get 100mg oral iron labeled with stable isotopes on two consecutive and on one alternate day and in another cycle they get 200mg oral iron labeled with stable isotopes on two consecutive and on one alternate day. Half of the subjects start with the 100mg cycle whereas the other half starts with the 200mg cycle.
89399474|NCT02174588|Experimental|balanced propofol group|
88853269|NCT03543852|Experimental|SurvivorLink|Participants receiving treatment at a pediatric cancer survivor clinic randomized to this study arm will receive education on how to use SurvivorLink, late effects of treatment, and survivorship care through the system.
89182857|NCT06132659|Experimental|Veritable-NF|
89182858|NCT06132659|Active Comparator|Sham-NF|
88853270|NCT03543852|No Intervention|Usual care|Participants receiving treatment at a pediatric cancer survivor clinic randomized to the usual care study arm will receive the SurvivorLink intervention beginning at Month 12.
88853271|NCT03520881|Experimental|Pediatric ASTHMA-Educator arm|This arm corresponds to the pediatric version of the ASTHMA-Educator mobile application.
88853272|NCT03443323|Experimental|OST-S Intervention group|
89182859|NCT06132581|Experimental|Delta-beta tACS|The study is investigating the use of transcranial alternating current stimulation (tACS). The stimulation is delivered at 1 milliampere (mA) zero-to-peak amplitude at the target electrodes and 2 mA zero to-peak amplitude at the return electrode. For the experimental arm, the tACS will be delivered using the cross-frequency stimulation waveform delta-beta (3-20Hz).
89182860|NCT06132581|Active Comparator|Theta-gamma tACS|This arm serves as an active control where tACS will be delivered using the cross-frequency stimulation waveform theta-gamma (5-50Hz).
89182861|NCT06132581|Sham Comparator|Active-sham tACS|For active sham stimulation, either delta-beta or theta-gamma stimulation is delivered for 15 seconds only at the beginning and end of the stimulation period. This is intended to mimic the skin sensations (e.g., itching, burning, tingling) that are experienced at the onset and offest of stimulation, assisting with blinding the participant's assignment.
89182862|NCT06129344|Experimental|Manual Lymphatic Drainage Group|Manual Lymphatic Drainage Group: Performed by physiotherapists trained by Dr. Vodder School and licensed in Lymphatic Consolidation Detoxification Therapy (CDT). The patient's treatment posture is to lie down. First, start with the neck lymphatic drainage technique. After performing bilateral axillary lymph node activation and lymphatic valve contraction, the bilateral breast lymph fluid is drained to the bilateral lymph nodes. The time is about 20 minutes. Assist in removing milk from both breasts for 15 minutes each. Once a day for three consecutive days of treatment.
89182863|NCT06129344|Experimental|Ultrasound therapy group|Ultrasound therapy group: performed by a physical therapist. This study uses an ultrasonic therapy device (model: UTO US-750 Therapeutic Ultrasound), frequency: 1MHz, intensity set to 1.0 Watt/cm2, pulsed mode, duty cycle 100%, treatment time 2 5 minutes on each side, and then assist in removing the breast milk from both breasts for 15 minutes on each side. Once a day for three consecutive days of treatment.
89182864|NCT06129149|Experimental|Intervention|All participants will participate in this single arm study consisting of three visits: visit 1 (baseline data collection), visit 2 (intervention followed by brief qualitative debrief interview), and visit 3 (30-day follow-up data collection)
89182865|NCT06127979|Experimental|Breast Cancer|All study patients will receive standard ET for at least 2 weeks, which will be followed by standard of care surgical treatment. Surgical tumor tissue will be obtained at the time of surgery and will be assessed for Ki67; a portion of this specimen will be snap-frozen for future analysis.
89182866|NCT06126224|Experimental|KarXT|Xanomeline and Trospium Chloride Capsules
89182867|NCT06126224|Placebo Comparator|Placebo|Placebo Capsules
89182868|NCT06123286|No Intervention|Group 1 : Wait list control|No supplement but will be offered supplements after finishing the study
89182869|NCT06123286|Experimental|Group 2 : Tart Cherry and Omega 3 FA (Fish Oil)|
89182870|NCT06122194|Experimental|Period 1 formulation 1 PF-07817883|Single oral dose of PF-07817883 tablet under fasted condition
89182871|NCT06122194|Experimental|Period 2 formulation 2 PF-07817883|Single oral dose of PF-07817883 tablet under fasted condition
89182872|NCT06122194|Experimental|Period 3 formulation 3 PF-07817883|Single oral dose of PF-07817883 tablet under fasted condition
89182873|NCT06122194|Experimental|Period 4 formulation 4 PF-07817883|Single oral dose of PF-07817883 tablet under fasted condition
89182874|NCT06119035|Other|Prediabetic|n=10, single dose of 75 grams glucose in 200ml water
89399475|NCT02174588|Active Comparator|propofol alone group|
89399476|NCT03693573|Experimental|Atezolizumab + Bevacizumab|Participants will receive atezolizumab in combination with bevacizumab.
88853273|NCT03443323|No Intervention|Treatment as usual control group|
88853274|NCT03367637|Active Comparator|Standard Care|"Patients in this arm will receive standard palliative care currently provided at the Rwanda Palliative and Hospice Care Organization (RPCHO).~Standard care also includes regular follow-up phone calls and home visits by the RPCHO staff, though the timing of these calls is variable and is selected by the discretion of the team. In addition, patients can contact providers on a landline number available during business hours and staffed by an on-call palliative care provider as and when needed."
88875351|NCT02056236|Active Comparator|No anti-epileptic drugs|"The non-intervention group will be treated conform standard guidelines of treatment of comatose patients after cardiac arrest, but without anti-epileptic drugs or EEG based deep sedation. Treatment to suppress clinical myoclonia or seizures with low dose propofol is left to the discretion of the treating physician.~Decisions regarding limitation or withdrawal of treatment will be done in accordance with the Dutch guideline postanoxic coma in both treatment arms. Reasons for withdrawal of treatment will be documented."
88875352|NCT01962246|Active Comparator|postoperative chemotherapy,XELOX|
89182875|NCT06118281|Experimental|Ziltivekimab|Participants will receive an initial loading dose of ziltivekimab Dose 1 subcutaneously (s.c.) as early as possible after invasive procedure, and latest within 36 hours of hospitalisation for ST-elevation myocardial infarction (STEMI) and within 48 hours of hospitalisation for non-ST-elevation myocardial infarction (NSTEMI), followed by ziltivekimab Dose 2 s.c. once-monthly during the treatment period (estimated up to 2 years) added to standard of care.
89182876|NCT06118281|Experimental|Placebo ziltivekimab|Participants will receive placebo matched to ziltivekimab at an initial loading dose subcutaneously (s.c.) as early as possible after invasive procedure, and latest within 36 hours of hospitalisation for STEMI and latest within 48 hours of hospitalisation for NSTEMI, followed by placebo matched to ziltivekimab s.c. once-monthly during the treatment period (estimated up to 2 years) added to standard of care.
89182877|NCT06116149|Active Comparator|In-person health coach strategy|"Delivery of 24 health coaching sessions in-person by health coaches over 1 year.~Standard delivery of 24-sessions of the Group Lifestyle Balance (GLB) behavioral intervention in WIC clinics. The GLB was adapted from the original Lifestyle Balance behavioral intervention used in the original Diabetes Prevention Program trial for use in community translation and group settings. It focuses on improving diet and physical activity and promoting moderate weight loss through health coaching on behavioral change, including self-monitoring of food intake, physical activity, and weight."
89182878|NCT06116149|Active Comparator|Multifaceted technology-assisted health coach implementation strategy|"Delivery of 12 health coaching GLB sessions in-person by health coaches over one year; supplemental technology support, including tools for self-monitoring, health coach monitoring, asynchronous delivery of intervention materials, and asynchronous coach and group connection.~The GLB was adapted from the original Lifestyle Balance behavioral intervention used in the original Diabetes Prevention Program trial for use in community translation and group settings. It focuses on improving diet and physical activity and promoting moderate weight loss through health coaching on behavioral change, including self-monitoring of food intake, physical activity, and weight."
89182879|NCT06112730|Active Comparator|Standard pulmonnary rehabilitation group|Received routine pulmonnary rehabilitation
89182880|NCT06112730|Experimental|Nutritional supplementation intervention group|Received regular pulmonnary rehabilitation plus healthy dietary recommendations
89182881|NCT06110598|Experimental|Arm A: Extended adjuvant therapy with capecitabine|"Participants randomized to Arm A will take capecitabine (1000mg by mouth twice a day, 3-week cycle [2 weeks on therapy, 1 week off]) for up to 18 cycles, or until progression or intolerance to therapy develops.~Participants who remain without disease recurrence at completion of 18 cycles of therapy who wish to continue therapy may do so at the discretion of their treating medical oncologist. Participants will be followed at standard 12-week intervals, where they will undergo routine cross-sectional imaging and labs."
89182882|NCT06110598|No Intervention|Arm B: Active surveillance|"Participants randomized to Arm B will undergo active surveillance, with no active treatment for the duration of their participation in the study.~Participants in Arm B will undergo re-staging every 12 weeks (+/- 7 days), consisting of cross-sectional imaging (CT or PET-CT) and labs (CBC, chemistry panel, CA19-9 and blood draw for ctDNA). In addition to re-staging every 12 weeks, participants may be seen by their medical or surgical oncologist as clinically indicated. Participants who experience disease relapse may transition to palliative systemic therapy or best supportive care at the discretion of their treating medical oncologist."
89182883|NCT06109701|Active Comparator|Control Group - Ultrassonic Devices|Supra and sub-gingival debridement with an ultrasonic device (DTE-D5, Woodpecker®, Guilin, China) with a plastic tip (Hu-Friedy®, Rockwell St, Chicago, IL, USA) and scaling with plastic curettes (Hu-Friedy®, Rockwell St, Chicago, IL, USA) around dental implants and a conventional metal tip for teeth will be used.
89182884|NCT06109701|Experimental|Test Group - Erythritol based air-polishing powder|Supra and sub-gingival debridement with an erythritol based air-polishing powder (Air-Flow, EMS, Nyon, CH) will be used during 5 seconds on each site (Schwarz et al., 2015).
89182885|NCT06108284|No Intervention|Conventional Arm|Patients will be placed on Non invasive positive pressure ventilation per current standard of care.
89182886|NCT06108284|Active Comparator|Intervention Arm|Patient in this arm will be placed on Biphasic Cuirass Ventilation
89182887|NCT06105073||Patients whit Systemic Sclerosis asociated Interstitial Lung Disease|Consecutive patients who attend the Rheumatology and Internal Medicine services with a confirmed diagnosis of Systemic Sclerosis associated Interstitial Lung disease, from the Medical Center, La Raza IMSS.
89182888|NCT06101069|Experimental|Healthy Volunteer Participants|Healthy volunteers will be recruited to evaluate the capability of MRF in conjunction with intravoxel incoherent motion (IVIM) MRI and serve as healthy control data to compare with the participant data.
89182889|NCT06101069|Experimental|Participants with Radiation Necrosis|The MRI scans (MRF and IVIM) will be performed on participants with newly developed necrosis prior to any further therapy implementation, surgical biopsy, or resection. For the participants undergoing surgical biopsy or resection after the MRI scans, the findings from the analysis of pathological biopsied specimen will serve as pathological confirmation for the MRI imaging findings
89182890|NCT06101069|Experimental|Participants with Tumor Recurrence|The MRI scans (MRF and IVIM) will be performed on participants with newly developed recurrent prior to any further therapy implementation, surgical biopsy, or resection. For the participants undergoing surgical biopsy or resection after the MRI scans, the findings from the analysis of pathological biopsied specimen will serve as pathological confirmation for the MRI imaging findings
89182891|NCT06097871|Experimental|Nutraceutical Dietary Supplement|A novel nutraceutical skin supplement, scientifically formulated to specifically target the multiple underlying causes of acne in women. The supplement is comprised of primary and secondary ingredients, designed to improve skin from the inside out.
89182892|NCT06097871|Placebo Comparator|Placebo|Oral supplement containing non-active ingredients.
89182893|NCT06087926|Experimental|Medial Prefrontal Cortex - Control Site|Participants first undergo transcranial magnetic stimulation to the medial prefrontal cortex. After a 3-week washout period, participants then undergo transcranial magnetic stimulation to the control site.
89182894|NCT06087926|Experimental|Control Site - Medial Prefrontal Cortex|Participants first undergo transcranial magnetic stimulation to the control site. After a 3-week washout period, participants then undergo transcranial magnetic stimulation to the medial prefrontal cortex.
88853275|NCT03367637|Experimental|Intervention|Patients in this arm, in addition to the standard palliative care currently provided at the RPCHO, will receive biweekly frequency reminders to fill out the African Palliative Care Outcomes Scale (APCA POS) on the new smart phone based symptom evaluation application on their phones. It is a short symptom assessment questionnaire with responses on 5-point severity scale. In addition to bi-weekly, patients can complete the symptom assessment at any time they feel their symptoms are poorly controlled. The team at RPCHO will be able to track all enrolled patients on a desktop dashboard. Any score of 2 or higher will be flagged. The providers at RPCHO will respond to such patients during business hours via call or text and will advise the patients as indicated or triage to a fellow team member.
88853276|NCT03347617|Experimental|Diagnostic (Ferumoxytol MRI, pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for up to 2 years or 35 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive ferumoxytol IV and undergo MRI scans at baseline, 4 weeks after the last day of standard of care stereotactic radiosurgery or chemoradiotherapy, every 9 weeks thereafter until suspected radiographic progression, and then within 4 weeks from suspected radiographic progression.
88853277|NCT03328273|Other|Arm A Part 1 and 2|DISCONTINUED (ceralasertib monotherapy)
88875353|NCT01962246|Experimental|Preoperative Concurrent Chemoradiotherapy|
88853278|NCT03328273|Experimental|Arm B Part 1 and 2|ceralasertib + acalabrutinib in combination
88853279|NCT03136029|Experimental|Oral AOx|8 week oral antioxidant treatment
89182895|NCT06075706|Experimental|MC0518|Participants will be treated with intravenous infusions of MC0518 at a dose of 1 to 2*10^6 cells per kilogram (cells/kg) (based on body weight at the Screening Visit). Infusions will be administered once a week for 4 weeks (Visit Day 1, 8, 15, and 22). Participants with partial response (PR) on Day 28 will have 2 additional MC0518 infusions administered on Day 29 and 36.
89182896|NCT06075706|Active Comparator|Best Available Therapy (BAT)|Participants will receive one of the following systemic BATs based on the Investigator's decision: extracorporeal photopheresis (ECP), anti-thymocyte globulin (ATG), etanercept, infliximab or ruxolitinib (RUX).
89182897|NCT06070935||pediatric uveitis|pediatric uveitis patients < 18 years old
89182898|NCT06070935||healthy subjects|healthy subjects< 18 years old
89182899|NCT06069713|Experimental|Perception of Ads|Each panel will consist of 5 different advertisements for CBD. With 11 panels and 5 images each, there are a total of 55 images that will be viewed by the participants. Participants will view an image, one at a time, and answer questions about their perceptions of the advertisement.
89182900|NCT06063577|Active Comparator|Stratafix Group|Stratafix
89182901|NCT06063577|Placebo Comparator|Control Group|Standard of care
89182902|NCT06062654|Experimental|Hospital-assisted Rehabilitation Treatment|Patients in the experimental group will undergo 10 sessions (about 2 each week) of rehabilitation treatment at the outpatient clinics of the U.O. Physical Medicine and Rehabilitation Unit of the Rizzoli Orthopedic Institute. The rehabilitation protocol consists of a series of commuting exercises and passive/active mobilization exercises of the glenohumeral joint.
89182903|NCT06062654|Active Comparator|Home-based Rehabilitation Treatment|Patients in the experimental group will have 10 sessions (about 2 each week) of rehabilitation treatment with exercises to be performed self-assisted at home. The rehabilitation protocol consists of a series of commuting exercises and passive/active mobilization exercises of the glenohumeral joint
89182904|NCT06059612|Experimental|Experimental|Superior cluneal nerve entrapment (SCN) will be treated with local steroid injection
89182905|NCT06049654|Active Comparator|NVT ALLEGRA System TF|NVT ALLEGRA System TF
89182906|NCT06049654|Experimental|EDWARDS SAPIEN 3 or SAPIEN ULTRA SYSTEM|EDWARDS SAPIEN 3 or SAPIEN ULTRA SYSTEM
89182907|NCT06045845|Experimental|Standard Beet Juice First|First Test: Beet Juice / Second Test: Placebo
89182908|NCT06045845|Experimental|Placebo Beet Juice First|First Test: Placebo / Second Test: Beet Juice
89182909|NCT06042699|Experimental|Oral ferrous sulfate|Participants will receive oral ferrous sulfate tablets, 325mg (65mg elemental iron). Tablets are to be taken once daily for 3-6 months prior to surgery as time allows.
89182910|NCT06042699|Placebo Comparator|Oral placebo tablets|Participants will receive placebo tablets. Tablets are to be taken once daily for 3-6 months prior to surgery as time allows.
89182911|NCT06042491|Experimental|Intervention|The intervention includes 3 aspects (exercise, nutrition and breathing). Our intervention is a home-based multimodal prehabilitation program supported through an online platform.
88853280|NCT03136029|Placebo Comparator|Oral AOx (placebo)|Placebo for arm 1
88853281|NCT03136029|Experimental|Oral BH4|8 week oral tetrahydrobiopterin treatment
88853282|NCT03136029|Placebo Comparator|Oral BH4 (placebo)|Placebo for arm 3
88853283|NCT03136029|Experimental|Ex training|8-week knee-extensor exercise training program
89182912|NCT06042491|No Intervention|Control|To support blinding, improve enrollment and reflect usual care, widely available physical activity (World Health Organization Recommendations for Physical Activity for ages 18-64 and >65) and healthy eating recommendations (Canada's Food Guide Snapshot) documents will be provided to control participants (without active or online support).
89182913|NCT06039878|Experimental|Mother-Infant Dyad|The researchers will enroll 120 infants and their mothers (120 dyads, 240 total participants). The researchers anticipate, based on prior experience and the slightly more restrictive inclusion and exclusion criteria in this study compared to our prior work, needing to screen about 600 mother-infant dyads to achieve the target sample size of 120. The researchers anticipate that the sample will be 63% non-Hispanic white, 13% non-Hispanic black, 4% non-Hispanic Asian, 12% non-Hispanic multiracial, and 8% Hispanic (any race). The researchers expect that 50% of the infants will be male and 50% female, and all of the biological mothers will be female sex. Infants will be 0.5-1.5 months at enrollment and the researchers estimate that mothers will be between 18.0 and 50.0 at enrollment (upper age limit is estimated due to menopause ).
88853284|NCT03136029|Sham Comparator|Ex training (attn con)|Attention control for arm 5
88853285|NCT03071120|Experimental|Parent-Mediated Intervention with ASD|In-home intervention (1-2x/week) will occur with families with children with ASD, including direct intervention, parent coaching, and parent training.
88853286|NCT02848235|No Intervention|Group 1 (Standard of Care)|Participants in group 1 will receive the standard of care for the Prevention of Mother to Child Transmission (PMCTC) of HIV from the clinic's Mentor Mothers.
88853287|NCT02848235|Experimental|Group 2 (Standard of Care + EMMA)|Participants in group 2 will receive the standard of care for Prevention of Mother to Child Transmission (PMCTC) of HIV plus study-specific enhanced care interventions from the clinic's Mentor Mothers.
89182914|NCT06037668|Experimental|BVR-100|Experimental at-home VR intervention for the treatment of SAD
89182915|NCT06037668|Active Comparator|BES-100|Active at-home VR intervention comparator
89399477|NCT02176304|Active Comparator|Suprapatellar Knee Injection Site|Patients will be injected specified dose of lidocaine and depomedrol through suprapatellar-lateral knee entry site.
89380038|NCT05212350|Active Comparator|Pancreatic anastomosis|"Pancreatic anastomosis (PA) will be carried out according to the techniques adopted by the participating Centre, either pancreaticojejunostomy (PJ) (i.e. dunking PJ, Cattel-Warren duct-to-mucosa PJ, Blumgart PJ) or pancreatico-gastrostomy (PG) will be considered eligible. Any mitigation strategy (i.e. ETS, use of glues/biological matrices to protect the anastomosis, surgical feeding jejunostomy, prophylactic hydrocortisone/somatostatin administration) can be used according to the Center practice. The other two anastomosis, hepaticojejunostomy and duodenojejunostomy (in case of Longmire-Traverso pancreatoduodenectomy) or gastrojejunostomy (in case of Kausch-Whipple pancreatoduodenectomy), will be carried out as usual according to each Institution's operative standards.~At least one surgical drain will be placed in the retroperitoneum in all patients."
88853288|NCT02567877||levothyroxine in thyroidectomy patients|patients undergoing thyroidectomy for nodular thyroid disease
89182916|NCT06037317|Experimental|Dose-escalation and Dose-expansion|"In dose-escalation phase, SY-3505 will be given orally in ascending doses (escalation cohort) until the DLT or RP2D is reached.~In dose-expansion phase, SY-3505 will be given at RP2D in 28-day cycle continuously."
89380039|NCT05212350|Experimental|Total pancreatectomy|Total pancreatectomy will be carried out according to each Institution's operative standards. Preservation of the spleen will be considered whenever possible according to Kimura technique. Either ligation or preservation of gastric vessels (right/left gastric artery/vein) will be allowed according to clinical necessity but will be recorded and correlated with postoperative outcomes. The reconstruction phase will be carried out according to each Institution's operative standards. One or more surgical drains can be left in place according to surgeon's preference.
89380040|NCT04165863|Experimental|A|treatment of the surgical wound healing process with Platelet-rich-fibrin in patients undergoing total knee replacement surgery
89380041|NCT04165863|Active Comparator|B|Gold standard treatment of the surgical wound healing process without Platelet-rich-fibrin in patients undergoing total knee replacement surgery
89380042|NCT05199675|Experimental|Digital Peer Support Training Program|The intervention arm will undergo bite size modules on the four active ingredients of youth mental well-being-specifically, Mattering, selfhood, compassion and mindfulness, which will be delivered through training workshops, simulation activities, and homework assignments. The pre-post with control evaluation design will be utilized to evaluate program outcomes. Fidelity will be the primary outcome assessed to demonstrate the effectiveness of the digital peer support training program. It will be measured by the extent to which adolescents' responses to real-cases of peer disclosure indicate Mattering, selfhood, compassion and mindfulness. Reach, acceptability, cost-effectiveness, and adolescent self-reported psychological well-being will be assessed as secondary outcomes. Cost-effectiveness analysis will inform the development of a scalability and sustainability plan.
89380043|NCT05199675|Active Comparator|Waitlist control for Digital Peer Support Training Program|Students in the wait-list control arm will receive the training program after the conclusion of the trial with the intervention arm. The pre-post with control evaluation design will be utilized to evaluate program outcomes. The intervention arm will undergo bite size modules on the four active ingredients of youth mental well-being-specifically, Mattering, selfhood, compassion and mindfulness, which will be delivered through training workshops, simulation activities, and homework assignments.The same set of primary and secondary outcomes assessed in the experimenter arm will be included. Specifically, fidelity will be the primary outcome assessed. Reach, acceptability, cost-effectiveness, and adolescent self-reported psychological well-being will be assessed as secondary outcomes.
89380044|NCT05109156||This is an observational study|This is an observational study
89380045|NCT05059314|Experimental|Interventional group|"Warm up and cool down~Brisk walk (30 mintues each session per week 5 days)~Week 1 to 6"
89380046|NCT05059314|No Intervention|Control group|Routine activity
88853289|NCT02366728|Experimental|Group I: Unpulsed DC pre-conditioning|0.4 mLs of 1 x 10^6 autologous unpulsed DCs in saline will be administered to a single side of the groin, and 0.4 mLs of saline administered to the contralateral side 1 day prior to the 4th human CMV pp65-LAMP mRNA-pulsed autologous DCs vaccine. pp65 DC Vaccine #4 is 111In-labeled DCs for migration studies.
89380047|NCT05734716|Experimental|EPO Arm|participants administered subcutaneous erythropoietin injection (50 IU/kg 3x/week for 3 weeks) prior to ascent to altitutude. participants additionally administered sham intravenous treatment twice, with dosages occurring three weeks apart and final shame dose occurring 48 hours prior to ascent to altitude.
89380048|NCT05734716|Experimental|Iron Arm|participants administered intravenous iron sucrose (200mg) twice, dosages occurring three weeks apart with final dosing occurring 48 hours prior to ascent to altitude. Participants additionally administered sham subcutaneous injection (sterile saline) 3x/week for 3 weeks.
89380049|NCT05734716|Placebo Comparator|Placebo|participants administered sham injections (sterile saline) 3x/week for 3 weeks as well as sham intravenous infusion (sterile saline) twice with dosages occurring three weeks apart and final dosing occurring 48 hours prior to ascent to altitude.
89380050|NCT05044884|Experimental|Otago exercise group|"The Otago exercise group will practice the Otago exercise protocol which includes strength and balance exercises along with pulmonary rehabilitation.~3 times per week for 8 weeks.~Each session will be of 60 minutes~Total number of sessions: 24"
89380051|NCT05044884|Active Comparator|Circuit training group|"The Circuit training group will practice balance exercises including Stance exercise, Functional strength exercise, Transition exercise and Gait training along with pulmonary rehabilitation.~3 times per week for 8 weeks.~Each session will be of 60 minutes~Total number of sessions: 24"
89380052|NCT05211258|Experimental|a novel portable upper gastrointestinal endoscopy system|
89380053|NCT05733000|Experimental|COHORT 1 (Devimistat, 5-FU, HCQ)|Patients with colorectal cancer receive devimistat IV, 5-FU IV, plus HCQ PO on study. Patients also undergo CT and/or MRI and undergo blood specimen collection throughout the study.
89399478|NCT02176304|Active Comparator|Anterolateral knee injection|Patients will be injected specified dose of lidocaine and depomedrol through anterolateral knee entry site.
88875354|NCT02588586|Experimental|3BNC117 + ART Interruption|Four intravenous infusions of 3BNC117 (30mg/kg) at weeks 0, 12, 24 and 27, and antiretroviral treatment interruption (ART)at week 24.
89380054|NCT05733000|Experimental|COHORT 2 (Devimistat, 5-FU, HCQ)|Patients with pancreatic cancer receive devimistat IV, 5-FU IV, plus HCQ PO on study. Patients also undergo CT and/or MRI and undergo blood specimen collection throughout the study.
89380055|NCT05733000|Experimental|COHORT 3 (Devimistat, 5-FU, HCQ, Gemcitabine)|Patients with gastroesophageal cancer receive devimistat IV, 5-FU IV, plus HCQ PO on study. Patients with urothelial, ovarian, or non-small cell lung cancer receive devimistat IV, gemcitabine IV, plus HCQ PO on study. Patients with biliary tumors receive devimistat IV and gemcitabine IV or HCQ PO on study. Patients also undergo CT and/or MRI and undergo blood specimen collection throughout the study.
89380056|NCT05210946|Experimental|Pemigatinib in Advanced Non-Small Cell Lung Cancer Patients with FGFR Gene Alterations|"This study is a prospective single-arm clinical study. Advanced non-small cell lung cancer patients with known FGFR 1-3 alterations (including but not limited to FGFR amplification, rearrangement/fusion, mutation, etc.) who have failed standard therapy will be enrolled in this study once they have signed the informed consent form (ICF) and been identified as eligible in screening. The patients will receive 13.5 mg of pemigatinib once a day (QD) orally following a 2-week administration/~1-week interruption regimen. They will be dosed until disease progression or intolerable toxicity. During treatment, clinical tumor imaging evaluation will be performed according to RECIST v1.1 every 6 weeks (± 7 days) and then every 9 weeks (± 7 days) after week 48. Safety will be assessed according to"
89380057|NCT05210868|Experimental|CM355|"Dose Escalation Phase CM355~Dose Expansion Phase CM355"
89399479|NCT02176460|Experimental|colchicine|0.5mg twice daily for 16 weeks
89399480|NCT02176460|Placebo Comparator|placebo tablet|1 tablet twice daily for 16 weeks
88853290|NCT02366728|Experimental|Group II: Tetanus pre-conditioning|Tetanus diptheria toxoid (Td) (1 flocculation unit) will be administered to a single side of the groin, and 0.4 mLs of saline administered to the contralateral side 1 day prior to the 4th human CMV pp65-LAMP mRNA-pulsed autologous DCs vaccine. pp65 DC Vaccine #4 is 111In-labeled DCs for migration studies.
88853291|NCT02366728|Experimental|Group III: Basiliximab and Tetanus pre-conditioning|Basiliximab infusions prior to human CMV pp65-LAMP mRNA-pulsed autologous DCs vaccines #1 and #2 with Td pre-conditioning (1 flocculation unit) will be administered to a single side of the groin, and 0.4 mLs of saline administered to the contralateral side 1 day prior to the 4th human CMV pp65-LAMP mRNA-pulsed autologous DCs vaccine.
88853292|NCT02355002|Experimental|Active Transcranial Magnetic Stimulation (TMS) treatment|In this arm subjects will receive real, active TMS with a standard, water-cooled, figure-8 shaped TMS coil.
88853293|NCT02355002|Sham Comparator|Sham-TMS treatment|This arm serves as the sham/placebo control. In TMS a sham coil is used to create a sensory experience which is similar to active TMS, but in which the magnetic field is blocked by a metal shield built into the coil.
88853294|NCT02333370|Experimental|LEE011 +Letrozole|LEE011 - 3 weeks on 1 week off Letrozole 2.5mg - Once daily
88853295|NCT02333370|Experimental|LEE011 + Tamoxifen|LEE011 - 3 weeks on 1 week off Tamoxifen 20mg - Once daily
88853296|NCT02333370|Experimental|LEE011 + Fulvestrant|LEE011 - 3 weeks on 1 week off Fulvestrant 500 mg - Dosed every 28 days (Day 1 for each cycle) with 1 additional dose on Day 15 of Cycle 1
88853297|NCT02303444||MKI patients|Asymptomatic patients with RAI-refractory progressive DTC for whom there is a decision to initiate MKIs at study entry. For patients on sorafenib, treatment start and stop dates will be collected along with any adverse events observed.
88853298|NCT02303444||non-MKI patients|Asymptomatic patients with RAI-refractory progressive DTC for whom there is a decision to not initiate MKIs at study entry. For patients on sorafenib, treatment start and stop dates will be collected along with any adverse events observed.
88853299|NCT02267564|Experimental|MPFLR without tibial tubercle transfer|Patients with patellar instability undergo MPFL reconstruction without tibial tubercle transfer.
88853300|NCT02267564|Active Comparator|MPFLR with tibial tubercle transfer|Patients with patellar instability undergo MPFL reconstruction with tibial tubercle transfer.
88853301|NCT02246920|Experimental|Investigational Test Product|Fluticasone propionate Nasal Spray, 50 mcg/actuation; 200 mcg/day for 14 days
88853302|NCT02246920|Active Comparator|Reference Listed Drug|Flonase® (fluticasone propionate) Nasal Spray, 50 mcg/actuation; 200 mcg/day for 14 days
88853303|NCT02246920|Placebo Comparator|Placebo|Saline Placebo Nasal Spray; 4 total sprays/day for 14 days
88853304|NCT02129244|Active Comparator|NCM Plus Intervention|The researchers designed the NCM-Plus intervention by integrating the domains of the Chronic Care Model with added attention to linkage to care, building on evidence-based guidelines and the team's pilot findings. In the NCM bundle, the researchers provide extensive details on both proximal and distal outcome variables. Nurse case managers will be hired and trained to improve disease management for patients with MDR-TB and HIV. Specific measurable responsibilities will be implemented by each NCM at sites randomized to receive the intervention. The NCM-patient interaction will occur at the MDR-TB treatment inpatient or outpatient facility.
88853305|NCT02129244|No Intervention|Standard/Usual Care|Usual care is defined as standardized programmatic management of MDR-TB/HIV without care coordination. Nurses are present as part of the team, but with no special coordination role, leaving the MDR-TB physician solely responsible for treatment outcomes with little support. Physicians see patients weekly during the intensive phase and the patient receives basic daily nursing care without coordination of care, active monitoring of Adverse Drug Reactions (ADR)s or HIV care integration. This care transitions to monthly visits with the physician in the continuation phase, again with very little nursing involvement in care coordination.
88853306|NCT02086890|Experimental|Electro-acupuncture|Electro-acupuncture applied to acupoints around the eye and traditional needle acupuncture applied to acupoints throughout the body at 10 half-hour sessions over 2 weeks
88853307|NCT02086890|Sham Comparator|Sham Electro-acupuncture|No electro-acupuncture applied to non-acupoints around the eye and traditional needle acupuncture applied to non-acupoints throughout the body; i.e., to locations not on the acupuncture meridians; at 10 half-hour sessions over 2 weeks
88853308|NCT02086890|Experimental|Laser acupuncture|Laser applied to acupoints throughout the body at 10 sessions each lasting 15 minutes over a 2 week period
88853309|NCT02086890|Sham Comparator|Sham Laser acupuncture|An inactive sham laser (red light only) applied to non-acupoints throughout the body; i.e., to locations not on the acupuncture meridians; at 10 sessions each lasting 15 minutes over a 2 week period
89380058|NCT03417180|Experimental|SEVOFLURANE INHALATIONAL ANAESTHESIA|concentration of sevoflurane in the exhalation gas will be maintained to ensure target SE 40, remifentanil will be administered intravenously at a rate 0,25 mcg/kg of body weight/minute, SPI will be monitored on-line; when delta SPI>15, infusion speed of remifentanyl will be increased by 50% every 5 minutes until SPI value decreases back to baseline value
89380059|NCT03417180|Experimental|DESFLURANE INHALATIONAL ANAESTHESIA|concentration of desflurane in the exhalation gas will be maintained to ensure target SE 40,remifentanil will be administered intravenously at a rate 0,25 mcg/kg of body weight/minute, SPI will be monitored on-line; when delta SPI>15, infusion speed of remifentanyl will be increased by 50% every 5 minutes until SPI value decreases back to baseline value
89380060|NCT03417180|Experimental|TIVA USING PROPOROL|infusion of propofol will be adjusted at target of SE 40, remifentanyl infusion will be administered intravenously at a rate 0,25 mcg/kg of body weight/minute, SPI will be monitored on-line; when delta SPI>15, infusion speed of remifentanyl will be increased by 50% every 5 minutes until SPI value decreases back to baseline value
89380061|NCT03085095|Experimental|Relugolix|Relugolix for 48 weeks
89380062|NCT03085095|Active Comparator|Leuprolide Acetate|Leuprolide acetate for 48 weeks
89380063|NCT04097301|Experimental|MLM-CAR44.1 T-cells infusion|"PHASE I: i.v. single dose of MLM-CAR44.1 T-cells: 0.5 x 10E6/Kg or 1 x 10E6/Kg or 2 x10E6/Kg according to the BOIN design.~PHASE IIa: i.v. single dose of MLM-CAR44.1 T-cells corresponding to the maximum tolerated dose (MTD).~Phase I and IIa Pre-treatment: lymphodepleting chemotherapy with cyclophosphamide (500 mg/m2) and fludarabine (30 mg/m2) daily from day -5 to day -3"
89380064|NCT05199363|Active Comparator|Information leaflet|"Before examination study participant will obtain an information leaflet which includes descriptive and illustrative sections Information for young patients and their caregivers. What is Magnetic Resonance Imaging and what is the examination like?"
89380065|NCT05199363|Active Comparator|Educational movie|"Before examination study participant will be shown educational video with an radiology technologist and actors who role play the examination What is MRI and what is the examination like?"
88853310|NCT02086890|Experimental|Transcorneal Electrical Stimulation|Transcorneal Electrical Stimulation at 150% individual phosphene threshold applied to both eyes using DTL electrodes at 6 weekly 30 minute sessions
88853311|NCT02086890|Sham Comparator|Sham Transcorneal Electrical Stimulation|Sham Transcorneal Electrical Stimulation at 0% individual phosphene threshold (no stimulation) applied to both eyes using DTL electrodes at 6 weekly 30 minute sessions
88853312|NCT01832402|Experimental|Fentanyl Pectin Nasal Spray|Fentanyl pectin nasal (FPNS) dose equivalent to 15-25% of the morphine equivalent daily dose (MEDD). FPNS administered intranasally 20 minutes before the second 6-minute walk test. Same dose repeated at least 30 minutes after the first dose and 20 minutes prior to the third and final 6 minute walk test. Walk test administered before first dose of FPNS. Participant will rest for 30 minutes after walk test. FPNS administered, then participant will wait 20 minutes before repeating second 6 minute walk test. After second walk test, participant will rest for 30 minutes. FPNS administered for second time, then participant will wait for 20 minutes. Walk test administered again for 6 minutes. Questionnaires completed at baseline, before each walk test, and at end of final walk test. Four mental ability tests administered after each walk test to include finger tapping, simple mathematics questions, recall of numbers, and recall of objects.
88875355|NCT02588976|Other|ACT measurements|ACT measurements by SONOCLOT Analyzer during cardiac surgery
89182917|NCT06036602|Experimental|cAD3-Sudan Ebolavirus Vaccine|Single dose of cAd3-Sudan Ebolavirus vaccine (1x10^11 PU) administered intramuscularly (IM) with needle and syringe.
89380066|NCT05199363|Active Comparator|Demonstration|"Before examination study participant will take a part in scenario-based demonstration with the use of props such as the scanner model and a multimedia presentation Scenario for a demonstration before a Magnetic Resonance examination for young patients and their caregivers."
89380067|NCT05199363|No Intervention|Control|Study participant will obtain standard information about magnetic resonance imaging before examination.
89380068|NCT05760105||Ankylosing Spondylitis Patients|Patients diagnosed with ankylosing spondylitis.
89380069|NCT02811783|Active Comparator|Naloxone Hydrochloride Lotion, 0.5%|Naloxone Hydrochloride Lotion 0.5%
89380070|NCT02811783|Placebo Comparator|Placebo Lotion|Placebo Lotion
89380071|NCT02746029||Children with cardiac murmur|
89380072|NCT05198973|Experimental|Bumblebee Breath group|Bumblebee Breath starts by finding a relaxed, supported posture, either laying supine or in seated and then bringing the minds attention to the space between the eyebrows (or third eye in yoga terms). With the eyes close the thumbs are placed over the tragus of the ears, the first finger gently rests on eye lids, middle finger touches the sides of the nose and then the index and pinkie rest just above and below the closed lips. Next, a sound is created by inhaling deeply through the nose and exhaling with a low-pitched humming sound. The result sounds very much like a bee buzzing to the person performing the breath and a sensation of vibration is experienced inside the head and over the face. this group will be 28 patients to receive half an hour daily for ( 1 month)
89380073|NCT05198973|No Intervention|control group|this group (28 patients) will receive no training
89380074|NCT05410353|Experimental|Active Intervention Group|Look AHEAD Intervention program adapted for delivery via Health IT modified for cultural and social norms applicable to under-served population groups
89380075|NCT05410353|Active Comparator|Comparison Group|Look AHEAD DSE (Diabetes Support and Education) Comparison Group intervention adapted to be delivered via the EHR patient portal with telephonic support
89380076|NCT02364843|Experimental|Dietary Threonine Intake|Physiological establishment of enteral intake of amino acid threonine required by infants ages 1 - 6 mos
89380077|NCT03633123|Other|Standard of Care (SoC)|SOC prophylactic treatment pre-operation will be as per Israeli Ministry of Health and international guidelines: 1st or 2nd generation of Cephalosporine family, plus Metronidazole.
89380078|NCT03633123|Experimental|D-PLEX + SoC|D-PLEX is provided to suitable and willing study subjects as an adjunct to the SoC treatment
89380079|NCT02276547|Experimental|Treatment|Transcatheter mitral valve replacement with the TIARA valve and transapical delivery system
89380080|NCT05296083|Experimental|G3P-01 50mg Dose Treatment Period 1|G3P-01 will be administered orally as a powdered mixed with water. Treatment Period one dose will be 50mg of IP.
89380081|NCT05296083|Experimental|G3P-01 500mg Dose Treatment Period 2|G3P-01 will be administered orally as a powdered mixed with water. Treatment Period two dose will be 500mg of IP.
89380082|NCT05296083|Experimental|G3P-01 1000mg Dose Treatment Period 3|G3P-01 will be administered orally as a powdered mixed with water. Treatment Period three dose will be 1000mg of IP.
89380083|NCT05296083|Experimental|G3P-01 2000mg Dose Treatment Period 4|G3P-01 will be administered orally as a powdered mixed with water. Treatment Period four dose will be 2000mg of IP.
89380084|NCT01917903|Experimental|Identification of at risk variables|Individuals will come in for a single visit to perform all tasks / conditions. Measurements will be taken of spatial and temporal features of walking with and without a secondary task. In addition, cognitive tests of memory and attention will be performed. Outcomes will narrow measures to those most likely to show clinically significant change.
89380085|NCT01917903|Experimental|Gait-Cognitive training|Participants will engage in a four week treadmill training program with a secondary cognitive component aimed at improving both walking and multitasking.
89380086|NCT02966834|Placebo Comparator|Placebo|Participants will receive matching placebo
89380087|NCT02966834|Experimental|GSK2330672 20 mg once daily|Participants will receive GSK2330672 and matching placebo to maintain blind
89380088|NCT02966834|Experimental|GSK2330672 90 mg once daily|Participants will receive GSK2330672 and matching placebo to maintain blind
89380089|NCT02966834|Experimental|GSK2330672 180 mg once daily|Participants will receive GSK2330672 and matching placebo to maintain blind
89380090|NCT02966834|Experimental|GSK2330672 40 mg twice daily|Participants will receive GSK2330672 and matching placebo to maintain blind
89380091|NCT02966834|Experimental|GSK2330672 90 mg twice daily|Participants will receive GSK2330672 and matching placebo to maintain blind
89380092|NCT03106077|Experimental|Cohort A (mirvetuximab soravtansine)|Patients receive mirvetuximab soravtansine IV over 2-3 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unaccepted toxicity.
89380093|NCT03106077|Experimental|Cohort B (mirvetuximab soravtansine)|Patients receive mirvetuximab soravtansine IV over 2-3 hours on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unaccepted toxicity.
89380094|NCT04052984|Experimental|Intervention group|Twenty four pares of healthy mothers-newborns, with delayed clamping and immediate skin-to-skin contact after birth by caesarean section
89182918|NCT06036602|Placebo Comparator|Placebo|0.9% NaCl solution for injection)administered intramuscularly (IM) with needle and syringe in a volume of 0.56 mL
89380095|NCT04052984|No Intervention|Control group|Twenty four pares of healthy mothers-newborns, with early clamping without skin-to-skin contact after birth by caesarean section and newborn attended in radiant warm table
89380096|NCT03648866||Physicians|interview physicians who have conducted compassion rounds
89380097|NCT03648866||Chaplains|interview chaplains who have conducted compassion rounds
89380098|NCT03648866||Other Healthcare Providers|interview other healthcare providers who have conducted compassion rounds
89380099|NCT03648866||Patients|interview patients who have participated in compassion rounds
89380100|NCT03648866||Patient family members/friends|interview patient's loved ones who have participated with the patient in compassion rounds
89380101|NCT03647540|Experimental|Group F|Group F received endoscopic submucosal injection of indocyanine green (ICG) 2 hours before operation, followed by fluorescent laparoscopic radical gastrectomy. All specimens were grouped for lymph node collection, and the postoperative management was unified according to enhanced recovery after surgery (ERAS). All basic clinical and pathological data were statistically analyzed
89380102|NCT03647540|Active Comparator|Group L|Group L received traditional laparoscopic radical gastrectomy. All specimens were grouped for lymph node collection, and the postoperative management was unified according to enhanced recovery after surgery (ERAS). All basic clinical and pathological data were statistically analyzed
89380103|NCT04009382|Experimental|Baduanjin|This group will participate in the Baduanjin exercise intervention for 24 weeks (three times/week for the first three months and two times/week for the last three months).
89380104|NCT04009382|Active Comparator|Cognitive Fitness Program|This group will participate in the Cognitive Fitness Program intervention for 24 weeks (three times/week for the first three months and two times/week for the last three months).
89380105|NCT03648008|Active Comparator|Group M|Drug: Morphine Background: No Bolus infusion: 0.015 mg*kg-1
89380106|NCT03648008|Experimental|Group NBH|Drug: Hydromorphone Background: No Bolus infusion: 0.002 mg*kg-1
89380107|NCT03648008|Experimental|Group BH|Drug: Hydromorphone Background: 0.002 mg*kg-1*h-1 Bolus infusion: 0.002 mg*kg-1
89380108|NCT03647930|Experimental|Intervention|Application of Microporous Polysaccharide Hemospheres (MPH)
89380109|NCT03647930|No Intervention|Control|No MPH
89380110|NCT03105297|Experimental|All participants (Baseline phase)|All the participants were applied nasal dilator strip during the sleep laboratory night on Day 1.
89380111|NCT03105297|Experimental|All Participants (Active Phase)|All the participants wore nasal dilator strip over a 1 month in-home use period and returned for sleep laboratory nights after 7 (Day 8) and 28 days (Day 29) of treatment
89380112|NCT03105297|Experimental|All Participants (Nasal Resistance Phase)|The participants were randomized to receive a sequence of either 'strip'/' no strip' or 'no strip'/'strip' on 2 sleep laboratory nights (on Day 30 and Day 31) based on the randomization schedule
89380113|NCT03647384|Experimental|Intervention|In this arm, patients take 0.6g of Gulingji capsules, 2 hours before breakfast, served with light salt water once a day. Also an oral take of 19.2mg Ginko Biloba Extract mimetic three times a day. Treatment lasts for 24 weeks.
89380114|NCT03647384|Active Comparator|Control|In this arm, patients take 0.6g of Gulingji mimetic, 2 hours before breakfast, served with light salt water once a day. Also an oral take of 19.2mg Ginko Biloba Extract tablet three times a day. Treatment lasts for 24 weeks.
89380115|NCT05284916||patients admitted at Sohag University Hospital diagnosed with liver diseases|The study will be conducted in two stages. The first one is a retrospective collection of the data from patients records during the period from Feburary 2017 to January 2018 and the second stage will include agroup of patients that will be admitted to Tropical Medicine and Gastroenterology Department within 6months after protocol acceptance
88853313|NCT01832402|Placebo Comparator|Placebo Nasal Spray|Placebo nasal spray administered intranasally 20 minutes before the second 6-minute walk test. Same dose repeated at least 30 minutes after the first dose and 20 minutes prior to the third and final 6 minute walk test. Walk test administered before first dose of placebo nasal spray. Participant will rest for 30 minutes after walk test. Placebo nasal spray administered, then participant will wait 20 minutes before repeating second 6 minute walk test. After second walk test, participant will rest for 30 minutes. Placebo nasal spray administered for second time, then participant will wait for 20 minutes. Walk test administered again for 6 minutes. Questionnaires completed at baseline, before each walk test, and at end of final walk test. Four mental ability tests administered after each walk test to include finger tapping, simple mathematics questions, recall of numbers, and recall of objects.
88853314|NCT01619488|Experimental|Gastric Banding|"Surgical placement of an adjustable gastric band around the upper portion of the stomach.~Adjustments are made to the band through a subcutaneous port as needed to maintain appropriate restriction."
88853315|NCT01588392|Experimental|Short bouts of structured activity|
88853316|NCT01588392|Active Comparator|Unstructured physical activity|
88853317|NCT01588379|Experimental|Girls and mothers dance together|African-American girls AND their mom's will participate in the Afro-centric dance program together and also receive weekly newsletter that focuses on health related issues.
88853318|NCT01588379|Experimental|Girls, alone|African-American girls will participate in the Afro-centric dance program alone. Girls and mom's will receive weekly newsletter that focuses on health related issues
88853319|NCT01588379|Active Comparator|No dancing|African-American girls and their mom's will only receive weekly newsletter that focuses on health related issues.
88853320|NCT01055093||Diabetes Cohort|Prospectively followed cohort of newly diagnosed patients with diabetes mellitus, aged 18-69 years at inclusion into the study
88853321|NCT01055093||Control Cohort|Prospectively followed cohort of glucose tolerant humans, aged 18-69 years at inclusion into the study
88853322|NCT01009190|Experimental|ARM A|Carboplatin plus PF-01367338
88853323|NCT01009190|Experimental|ARM A EXPANSION|Carboplatin plus PF-01367338
89182919|NCT06035068||Combined ICG dye and blue tracer dye|This study is being done to see if a different way of finding and removing lymph nodes during surgery, using a special camera and a dye called Indocyanine Green (ICG), works as well as the usual method with blue dye plus a radioactive tracer called radiocolloid. By comparing the two ways directly, we hope to make it simpler for people with vulvar cancer to get their lymph nodes checked during surgery.
89182920|NCT06022614|Active Comparator|Patients receiving Block with Bupivacaine only|consists of patients receiving erector spinae plane block with Bupivacaine only
89182921|NCT06022614|Active Comparator|Patients receiving Block using Bupivacaine with Dexmedetomidine|consists of patients receiving erector spinae plane block using bupivacaine with Dexmedetomidine
89182922|NCT06021275|Active Comparator|Microneedling with topical application of regular insulin|
89182923|NCT06021275|Active Comparator|Microneedling only|
89182924|NCT06018038||Breast Cancer Group|Inclusion criteria were to be between 18-65 years of age, to volunteer to participate in the study, to have Stage I-III breast cancer, to have at least 15 months after breast cancer surgery, to have six months after active breast cancer treatment (i.e. surgery/chemotherapy), to have no problems in reading and/or understanding the scales and to be able to cooperate with the tests. Exclusion criteria were the presence of active infection, musculoskeletal and neurologic disease that may affect exercise performance, symptomatic heart disease, neurologic disease or other clinical diagnosis that may affect cognitive status.
89182925|NCT06018038||Control Group|The inclusion criteria were to be between 18-65 years of age, to be willing to participate in the study, to have no problems in reading and/or understanding the scales and to be able to cooperate with the tests. Exclusion criteria were having any orthopedic or neuromuscular condition that would interfere with walking or exercise performance, having any chronic disease, or having psychiatric disorders or mental disorders that might interfere with cooperation or compliance with exercise tests.
89182926|NCT06015048|Experimental|Part A: Intervention: Drug: SHR-A1811 combined with Pyrotinib|
89182927|NCT06015048|Experimental|Part B1: Intervention: Drug: SHR-A1811 combined with other antitumor therapies|
89182928|NCT06010628|Experimental|Tenecteplase group|intravenous thrombolysis with tenecteplase
88853324|NCT00667628|Placebo Comparator|Placebo|Participants were administered with placebo tablets matching to TAC-101 orally, every day on the first 14 days (Days 1 to 14) followed by a 7-day (Days 15 to 21) treatment recovery period. Repeated every 21 days cycle up to new lesions were observed or the participant met a treatment discontinuation criterion.
88853325|NCT00667628|Experimental|TAC-101|Participants were administered with TAC-101 tablets, 20 milligram per day (mg/day) orally for every day on the first 14 days (Days 1 to 14) followed by a 7-day (Days 15 to 21) recovery period (21-day Cycle). Repeated every 21 days cycle up to new lesions were observed or the participant met a treatment discontinuation criterion.
89182929|NCT06010628|Other|Control group|standard stroke care based on national guideline
89182930|NCT06004141|Experimental|Laguna Health Group|"Patient and caregiver participants will have access to Laguna Health coaching and the Laguna Health mobile platform for 12 weeks after discharge from the hospital to a home environment.~Patient participants will receive usual post-discharge care as arranged by their inpatient and outpatient oncology teams.~Patient participants will complete study questionnaires to assess their quality of life, symptoms, and psychological outcomes.~Caregiver participants will complete study questionnaires to assess their quality of life and caregiving burden.~10-20 participants will complete exit interviews to ascertain more feedback on the Laguna Health intervention."
89182931|NCT06004141|No Intervention|Usual Care|"Participants will receive usual post-hospital discharge care as arranged by their inpatient and outpatient oncology care teams.~Patient participants will complete study questionnaires to assess their quality of life, symptoms, and psychological outcomes.~Caregiver participants will complete study questionnaires to assess their quality of life and caregiving burden."
88853326|NCT00597636||1|NEVER SMOKERS WITH LUNG CANCER
88853327|NCT00597636||2|NEVER SMOKERS WITHOUT ANY CANCER
88853328|NCT00003653|Active Comparator|Intermittent Androgen Suppression|
88853329|NCT00003653|Active Comparator|Continuous Androgen Suppression|
89380116|NCT05198037|Experimental|Active transcranial direct current stimulation (tDCS)|Weak direct currents with 2 mA are delivered 20 minutes per session (including 30s ramp-up and 30s ramp-down) during tailored upper extremity task practice. Total sessions are 20 over 10 days.
89380117|NCT05198037|Sham Comparator|Sham tDCS|The device is automatically shut down after 2-minute stimulation. Treatment sessions and frequency are the same as the Experimental arm.
89380118|NCT05225025|Experimental|ROSE Intervention|
89380119|NCT05225025|Active Comparator|Standard of Care|
88853330|NCT00003665|Experimental|Arm I|Patients receive 3 different doses of peptide pulsed DC vaccine IV, each divided into 3 different peptide pulsed pools administered over 30 minutes.
89380120|NCT05054751|Experimental|GB491+ Fulvestrant|"GB491: The dose of GB491 is 150 mg, which should be taken with a meal and taken twice daily at approximately the same time each day, approximately 12 hours apart. The drug is administered according to the patient's dose group until the progression of disease or an intolerable toxicity occur or meet the criteria for termination of treatment or the patient withdraw informed consent or the sponsor discontinues the trial.~Fulvestrant: Intramuscular injection of flurvexine 500mg on day 1 and day 15 of the first cycle, and flurvexine 500mg on day 1 of the second and subsequent cycles Flurvexine 500mg should be given slowly (1-2 minutes per injection) on both sides of the buttocks, once 250 mg on each side.The drug is administered according to the patient's dose group until the progression of disease or an intolerable toxicity occur or meet the criteria for termination of treatment or the patient withdraw informed consent or the sponsor discontinues the trial."
89380121|NCT05054751|Placebo Comparator|Placebo+Fulvestrant|"Placebo: The dose of placebo is 150 mg, which should be taken with a meal and taken twice daily at approximately the same time each day, approximately 12 hours apart. The placebo is administered according to the patient's dose group until the progression of disease occur or meet the criteria for termination of treatment or the patient withdraw informed consent or the sponsor discontinues the trial.~Fulvestrant: Intramuscular injection of flurvexine 500mg on day 1 and day 15 of the first cycle, and flurvexine 500mg on day 1 of the second and subsequent cycles Flurvexine 500mg should be given slowly (1-2 minutes per injection) on both sides of the buttocks, once 250 mg on each side. The drug is administered according to the patient's dose group until the progression of disease or an intolerable toxicity occur or meet the criteria for termination of treatment or the patient withdraw informed consent or the sponsor discontinues the trial."
89380122|NCT04791735|Experimental|Laparoscopic approach for liver resection of HCC|
89380123|NCT04791735|Experimental|laparotomy|
89380124|NCT05007249|Other|Overweight or obese minors with intellectual disability|
89380125|NCT03426995|Experimental|GSK3358699, Part A, Cohort 1|Part A will comprise of 4 TPs. The subjects in this cohort will receive GSK3358699, as single escalation dose, during TP (1 to 3) with planned escalated doses as 1 mg, 10 mg and 35 mg. Dose of 1 mg will be given as solution and doses of 10 mg and 35 mg, will be given as a capsule. Each TP will be of 1 day and separated by a washout Period of 14-days. Post completion of the dose-escalation TPs, an additional dosing TP 4 will be included where the subjects from each TP (1 to 3), will receive control blisters induced on forearm (0.2 % cantharidin) at Day -10. The subjects in cohort 1 will receive GSK3358699 at a dose level already given in TP 1-3, and will then receive an intravenous in vivo LPS challenge at a dose not exceeding 0.75 nanogram per kilogram post administration of GSK3358699. The subjects will then have blisters induced on the forearm approximately 20 minutes after the challenge. LPS dose will be based on data of study 207654 (NCT03306589).
88853331|NCT00003665|Experimental|Arm II|Patients receive 3 different doses of peptide pulsed DC vaccine subcutaneously/intradermally to sites with no evidence of disease. At the lowest dose, patients receive 3 different peptide pulsed pools, each administered at a separate site. At the higher doses, patients receive 3 injections further subdivided into 6 and administered at 6 distinct sites.
88853332|NCT00003665|Experimental|Arm III|Patients receive peptide pulsed DC vaccine intranodally in groin or ancillary lymph nodes at the lower 2 doses of the 3 administered to arms I and II. At the lower dose, patients receive 3 different peptide pulsed pools, each administered into a different node. At the higher dose, patients receive 3 injections further subdivided into 6 and administered at 6 distinct sites.
88853333|NCT00003671|Experimental|Chemotherapy Treatment|See detailed description.
88853334|NCT00003677|Experimental|Dolastatin 10|Dolastatin 10 IV bolus once every 21 days.
88853335|NCT00384605|Experimental|1|Arm 1: MK0364 2 mg capsule once daily
88853336|NCT00384605|Experimental|2|Arm 2: MK0364 1 mg capsule once daily
88853337|NCT00384605|Experimental|3|Arm 3: MK0364 0.5 mg capsule once daily.
88853338|NCT00384605|Placebo Comparator|4|Arm 4: Pbo capsule once daily.
88853339|NCT00384683||Endothelial Dysfunction|Participants are scheduled for major chest (lung or esophagus) surgery or are a healthy volunteer. A blood test will quantify the number of cells that are destined to become endothelial cells.
88853340|NCT04329143|Active Comparator|open completion cholecystectomy|open completion cholecystectomy for cystic duct stump stone
88853341|NCT04329143|Active Comparator|laparoscopic completion cholecystectomy|lap completion cholecystectomy for cystic duct stump stone
88853342|NCT00003761|Experimental|rV-DF3/MUC1|"rV-DF3/MUC1 vaccinations will be administered 4 week intervals for a total of 3 doses.~Participants will be followed weekly until 28 days after the final dose (day 85) then month for 6 months"
88853343|NCT00003779|Active Comparator|BCG-Connaught|
88853344|NCT00003779|Active Comparator|BCG Onko-Tice|
88853345|NCT05444153|Experimental|Oral semaglutide|Participants will receive once daily oral semaglutide tablet for 104 weeks in a dose escalation fashion of 3milligrams (mg), 7mg, 14 mg and 25 mg once every four weeks during the first 16 weeks and a maintenance dose of 55 mg for the rest 88 weeks.
88853346|NCT05444153|Active Comparator|Empagliflozin|Participants will receive once daily empagliflozin tablet for up to 104 weeks, starting with a dose of 10 mg for the first 8 weeks and the maintenance dose of 25 mg for the rest 96 weeks.
89182932|NCT06001125|Experimental|Single Arm|"Methotrexate 20 mg PO weekly for 12 weeks.~Folic acid 1mg PO daily for as long as Methotrexate is given.~Prednisone starting at 20 mg PO daily for 8 weeks tapering dose."
89182933|NCT06000410|Experimental|ASA|Participants receive a single IA injection of 2 mL of ASA (plus 2 mL of normal saline)
89380126|NCT03426995|Experimental|GSK3358699, Part A, Cohort 2|Part A will comprise of 4 TPs. The subjects in this cohort will receive GSK3358699, as single escalation dose during TP (1 to 3) with planned escalated doses as 3 mg, 20 mg and 45 mg. Dose of 3 mg will be given as solution and that of 20 and 45 mg, as capsule. Each TP will be of 1 day and separated by a washout Period of 14-days. Post completion of the dose-escalation TPs, an additional dosing TP 4 will be included where the subjects from each TP (1 to 3), will receive control blisters induced on forearm (0.2 % cantharidin) at Day -10. The subjects in cohort 2 will receive GSK3358699 at a dose level already given in TP 1-3, and will then receive 60 microgram per meter^2 of in vivo GM CSF challenge as an intravenous infusion during TP 4, post administration of GSK3358699. The subjects will then have blisters induced on the forearm approximately 20 minutes after the challenge GM-CSF infusion. GM-CSF dose will be based on data of study 207654 (NCT03306589).
89380127|NCT03426995|Placebo Comparator|Placebo, Part A, Cohort 1|Part A will comprise of 4 TPs. The subjects in this cohort will receive matching Placebo solution to the study drug GSK3358699 solution for 1 mg and a matching placebo capsule to the study drug GSK3358699, 10 mg and 35 mg capsule, during TP (1 to 3). Each TP will be of 1 day and separated by a washout Period of 14-days. Post completion of the dose-escalation TPs, an additional dosing TP 4 will be included where the subjects from each TP (1 to 3), will receive control blisters induced on forearm (0.2 % cantharidin) at Day -10. The subjects in cohort 1 will receive Placebo at a dose level already given in TP 1-3, and will then receive an intravenous in vivo LPS challenge at a dose not exceeding 0.75 nanogram per kilogram post administration of Placebo. The subjects will then have blisters induced on the forearm approximately 20 minutes after the challenge. LPS dose will be based on data of study 207654 (NCT03306589).
89399481|NCT03623919|Experimental|Exercise group|"Group games, including two teams of seniors aged 50 years or older. The FallSensing games software include 3 mini-games to be played by two teams with up to 3 players each will compete against each other alternately.~The players will perform an initial evaluation with FallSensing screening tool, 16 sessions of group games (2 times a week/8weeks) with FallSensing multiplayer games and a final evaluation also with FallSensing screening tool.~Both initial and final evaluation include six functional tests (Grip Strength, Timed Up and Go, 30 seconds Sit-to-Stand, Step test, 4 Stage Balance test modified and 10 meters Walking Speed) and a questionnaire concerning self-efficacy for Exercise."
88853347|NCT02972879|Active Comparator|Therapeutic Modalities|"Group 1: Metal orthotic, keeping 0º of the extension of the proximal interphalangeal joint, during all day, for 5 weeks, stopping the use only for bathing~Group 2: 10 LLLT sessions applications on the A1 pulley and lump formed on the flexor tendon of the the affected finger; Two sessions per week, five weeks of treatment.~Group 3: Paraffin bath 2 times a week for 20 minutes (total of 10 sessions)."
88853348|NCT02972879|Active Comparator|Corticosteroid injection|Group 4: Corticosteroid injection in the A1 pulley, 1 application.
88853349|NCT00003833||Normal and tumor tissue pairs|Matched normal and tumor DNA is analyzed for 8p allelic imbalance with at least 8 markers: D8S262 and D8S1825 localized to 8p23, D8S254 and D8S261 at 8p22, D8S560 and D8S136 at 8p21, and D8S1820 and D8S283 at 8p12. Normal/tumor tissue pairs are used for fine mapping studies.
88853350|NCT00003851|Active Comparator|Nutritional Arm|Arm I (Nutritional Arm): Patients receive pancreatic enzymes orally every 4 hours and at meals daily on days 1-16, followed by 5 days of rest. Patients receive magnesium citrate and Papaya Plus with the pancreatic enzymes. Additionally, patients receive nutritional supplementation with vitamins, minerals, trace elements, and animal glandular products 4 times per day on days 1-16, followed by 5 days of rest. Courses repeat every 21 days until death despite relapse. Patients consume a moderate vegetarian metabolizer diet during the course of therapy, which excludes red meat, poultry, and white sugar. Coffee enemas are performed twice a day, along with skin brushing daily, skin cleansing once a week with castor oil during the first 6 months of therapy, and a salt and soda bath each week. Patients also undergo a complete liver flush and a clean sweep and purge on a rotating basis each month during the 5 days of rest.
88853351|NCT00003851|Active Comparator|Chemotherapy Arm|Arm II (Chemotherapy Arm): Patients receive gemcitabine-based chemotherapy. Quality of life is assessed at 0, 2, 6, and 12 months and then yearly thereafter.
88853352|NCT00003863||Group 1|"Tissue samples are obtained before treatment and at the time of documentation of refractory disease in patients who do not achieve complete remission after induction therapy or at the time of first relapse in patients who achieve a complete remission.~Samples are examined for rearrangements in the MYC, BCL2, BCL6, and IGH genes using fluorescent in situ hybridization. DNA is examined by comparative genomic hybridization, which allows cytogenetic detection of losses and gains of chromosomal regions in tumor cells.~Patients do not receive the results of the genetic testing and the results do not influence the type or duration of treatment."
88853353|NCT02973191|Experimental|JCAR015 administration|Single dose of 1.0-3.0 mg/m^2 IV cyclophosphamide, JCAR015 Dose 1 1x10^6 Tcells/kg, JCAR015 Dose 2 3x10^6 Tcells/kg
88853354|NCT02210507|Experimental|White cassava gari|A single meal containing 400 gm of garified non-biofortified (white) cassava with retinyl palmitate reference dose.
88853355|NCT02210507|Experimental|White cassava gari + red palm oil|A single meal containing 400 gm of garified non-biofortified (white) cassava with red palm oil.
88853356|NCT02210507|Experimental|Biofortified cassava gari|A single meal containing 400 gm of garified biofortified cassava.
88853357|NCT02210663|Experimental|veliparib (ABT-888)|
88853358|NCT04568525|Active Comparator|COVID - 19 patients|
88853359|NCT04568525|Active Comparator|COVID - 19 and pneumonia patients|
88853360|NCT04568525|Active Comparator|Health patients|
88853361|NCT04568837|Experimental|Corticosteroid|Participants in this group will receive a daily dose of corticosteroids on postoperative day one and two after spine fusion surgery
89380128|NCT03426995|Placebo Comparator|Placebo, Part A, Cohort 2|Part A will comprise of 4 TPs. The subjects in this cohort will receive matching Placebo solution to the study drug GSK3358699 solution for 3 mg and a matching placebo capsule to the study drug GSK3358699, for 20 and 45 mg capsule, during TP (1 to 3). Each TP will be of 1 day and separated by a washout Period of 14-days. Post completion of the dose-escalation TPs, an additional dosing TP 4 will be included where the subjects from each TP (1 to 3), will receive control blisters induced on forearm (0.2 % cantharidin) at Day -10. The subjects in cohort 2 will receive Placebo at a dose level already given in TP 1-3, and will then receive 60 microgram per meter^2 of in vivo GM CSF challenge as an intravenous infusion during TP 4, post administration of Placebo. The subjects will then have blisters induced on the forearm approximately 20 minutes after the challenge GM-CSF infusion. GM-CSF dose will be based on data of study 207654 (NCT03306589).
89380129|NCT03426995|Experimental|Part B, GSK3358699 under Fasted followed by Fed conditions|The subjects in this arm will receive single oral dose of GSK3358699, at a dose level evaluated in Part A, under fasted condition in TP1 followed by fed condition in TP2. This cohort intended to evaluate the effect of food.
89380130|NCT03426995|Experimental|Part B, GSK3358699 under Fed followed by Fasted conditions|The subjects in this arm will receive single oral dose of GSK3358699, at a dose level evaluated in Part A, under fed condition in TP1 followed by fasted condition in TP2. This cohort intended to evaluate the effect of food.
89182934|NCT06000410|Placebo Comparator|Placebo|Participants receive a single IA injection of 4 mL of normal saline
89182935|NCT06000098||Patients undergoing robotic-assisted laparoscopic prostatectomy in deep Trendelenburg position.|Patients with ASA( American Society of Anesthesiologists) physical status 1-3 who underwent robotic-assisted laparoscopic prostatectomy in deep Trendelenburg position with restrictive fluid therapy
89182936|NCT05988970|Other|Patients with Non- Small Cell Lung Cancer - NSCLC|
89182937|NCT05987917|Experimental|Group RF+USN|Subjects will be enrolled for an active treatment with BTL-785F (BTL-785-2 applicator) delivering radiofrequency (RF) and ultrasound (USN) for non-invasive facial rejuvenation
89182938|NCT05987917|Experimental|Group RF|Subjects will be enrolled for an active treatment with BTL-785F (BTL-785-2 applicator) delivering radiofrequency (RF) only for non-invasive facial rejuvenation
89182939|NCT05987917|Experimental|Control|Control subject will not receive treatment
89182940|NCT05983068|Experimental|Pediatric AD participants|Participants will receive dupilumab IMP according to the approved prescribing label in the country/region where the study is conducted.
89182941|NCT05981365|Experimental|Part A|To evaluate the effect of multiple doses of voxelotor on the plasma pharmacokinetics (PK) of a single dose of bupropion, repaglinide, flurbiprofen, omeprazole, and midazolam
89182942|NCT05981365|Experimental|Part B|To evaluate the effect of multiple doses of voxelotor on the plasma PK of a single dose of metformin, furosemide, and rosuvastatin
89182943|NCT05980949|Experimental|KarXT|Xanomeline and Trospium Chloride Capsules
89182944|NCT05978037|Active Comparator|Group 1: 10 µg RH5.2-VLP with Months 0,1 and 2 regimen.|This arm will receive monthly regimen of 3 doses of 10 µg of RH5.2-VLP with 50 µg Matrix-M .
88853362|NCT04568837|No Intervention|Control|Participants in this group will receive no steroids on postoperative day one and two after spine fusion surgery.
88853363|NCT04568291|Active Comparator|routine treatment|routine treatment
88853364|NCT04568291|Experimental|model treatment|model treatment
88853365|NCT04569617|Active Comparator|upper limb endurance protocol|UL endurance protocol - elbow flexion
88853366|NCT04569617|Active Comparator|upper limb strength protocol|UL strength protocol - elbow flexion
88853367|NCT04569617|Active Comparator|lower limb endurance protocol|LL endurance protocol - knee extension
88853368|NCT04569617|Active Comparator|lower limb strength protocol|LL strength protocol - knee extension
88853369|NCT04567199||Cytosorb recipients|"Patients receiving Cytosorb due to septic shock.~SOFA score, Changes in catecholamine support after CytoSorb initiation Survival to discharge ICU Survival >28d Thromboembolic events~General data:~Need of catecholamines Type of extra-corporal treatments Anticoagulation medication Concomitant allogenic blood products Concomitant factor concentrates Bleeding events Vital signs Underlying Disease SAPSII, SAPSIII, SOFA Scores (on 1st day of treatment) Type of Pathogen (gram+, gram-, fungi) Sepsis Multi Organ Failure~Data records:~Myoglobin, CK (creatine kinase), CK-MB, Fibrinogen D-dimers, Antithrombin III, Procalcitonin Creatinin, urea, Natrium, Potassium, Bilirubin, GOT (glutamate-oxalacetate transaminase), GPT, GGT (glutamate-pyruvate transaminase), PT (prothrombin time) aPTT (activated partial thromboplastin time) CRP (C reactive protein) Blood count Further parameters if of interest"
88853370|NCT04567199||Non Cytosorb recipients|"Patients not receiving Cytosorb due to septic shock.~Patients not treated with CytoSorb under suspicion for inflammation, septic shock or SIRS will be searched for same characteristics as the first group.~These groups will be matched when parameters like epidemiology, infectious parameters, prognostic scores, age, gender amount of catecholamines fit best.~Parameters as in Group of Cytosorb recipients"
88853371|NCT04569071|Experimental|Sinovation Laser Ablation System treatment|Sinovation Laser Ablation System treatment
88853372|NCT04568057|Active Comparator|NIR Transcranial phototherapy device|The active transcranial phototherapy device. 1068 nm NIR Transcranial phototherapy PBM-T device An air-cooled LED helmet with a peak wavelength of 1068 nm, spectral width of 60 nm, and a 6-minute internal timer was used. The average optical power output of the combined arrays is circa 3.8 Watts, 12mw/sq. cm. The total energy to be delivered to the cranium is 1368J (3.8 x 360) per treatment session.
88853373|NCT04568057|Placebo Comparator|Placebo Device.|Placebo cranial device. The external appearance of the device is identical to that of the active device but no NIR light is emitted.
88853374|NCT04568135||survey|
88853375|NCT04567901||Trauma Patients|The enrolled patients experienced trauma from different injuries and were hospitalized for treatment and admitted to the ICU. 700 older trauma patients (age equal to or more than 65 years) were finally included in the study.
88853376|NCT04566809|Experimental|Experimental group: FES+CBA|FES+CBA participants executed FES and CBA treatment which means that during the stimulation they manipulated different tools. In particular, for the first ten sessions the participants were invited to manipulate specific objects: squares, rectangles and pyramids of different sizes; touch on plastic test tubes coated with materials of different consistency; these two exercises were performed both with open and closed eyes. Finally, for the last ten sessions the participants were asked to execute specific tasks, depending on person's life before the lesion.
88853377|NCT04566809|Active Comparator|Control Group: FES|FES participants received only FES to improve their manipulating skills without the interaction with objects, but only with the muscle contraction induced by the devices.
88853378|NCT04569305|Experimental|Negative Pressure Wound Therapy|Negative Pressure Wound Therapy was applied to injured area of foot and ankle after debridement and cleaning of the necrosed/dead tissue. The effect of technique was assessed through measuring wound surface area covered with healthy granulation tissue measured in centimetre square on follow-up.
88853379|NCT04569305|Active Comparator|Conventional treatment|Simple moist gauze dressing applied to injured area of foot and ankle after debridement and cleaning of the necrosed/dead tissue. The effect of treatment was assessed through measuring wound surface area covered with healthy granulation tissue measured in centimetre square on follow-up.
88853380|NCT04567823|Experimental|Microalgae I|Smoothie (enriched with Chlorella pyrenoidosa) and standardised background diet (defined menu plans)
88853381|NCT04567823|Experimental|Microalgae II|Smoothie (enriched with Nannochloropsis salina) and standardised background diet (defined menu plans)
88853382|NCT04567823|Placebo Comparator|Smoothie|Smoothie (without microalgae) and standardised background diet (defined menu plans)
88853383|NCT04567823|No Intervention|Control|no intervention (no smoothie, no menu plans)
88853384|NCT04568447|Experimental|IMOOVE|Patients will undergo IMOOVE® treatment for 6 weeks, two times per week for a total of 12 treatments.
88853385|NCT04568915|Experimental|Dry Needling-Group|Tens, Stretching, Strengthening(girdle), Neck Isometrics, DN
88853386|NCT04568915|Active Comparator|Maitland-Group|Tens Stretching, Strengthening(girdle), Neck Isometrics, Maitland joint mobilization
88853387|NCT04569227|Experimental|Active EC-18|
88853388|NCT04569227|Placebo Comparator|Placebo|
88853389|NCT02210819||Rivaroxaban|Patients who will be treated for an acute venous thromboembolism (VTE) with rivaroxaban.
88853390|NCT02210819||Standard of care|Patients who will be treated for an acute venous thromboembolism (VTE) with current standard of care.
88853391|NCT04565639|Experimental|Experimental Power Hand Orthosis|Participants will test the improved grip strength using the powered hand orthosis system.
88853392|NCT04565639|Experimental|Experimental Power Hand Orthosis - Tasks of Daily Living|Participants will test the improved ability to perform tasks of daily living using the powered hand orthosis system.
88853393|NCT04564235|Experimental|Indication for a genome-wide analysis in the proband|
88853394|NCT04564001|Experimental|A ( Infliximab)|Infliximab 5mg/kg intravenously at week 0; 2; 6; 14; 22 following prescription recommendations
88853395|NCT04564001|Experimental|B (Tocilizumab)|Tocilizumab : 8mg/kg intravenously at week 0; 4; 8; 12; 16; 20; 24 following prescription recommendations
88853396|NCT04565873||P1|Primigravida in group 1
88853397|NCT04565873||M1|Multipara in group 1
88853398|NCT04565873||P2|Primigravida in group 2
88853399|NCT04565873||M2|Multipara in group 2
88853400|NCT04565561||Neovas BRS group|Neovas BRS group, n=20
89182945|NCT05978037|Active Comparator|Group 2: 10 µg RH5.2-VLP with Months 0,1 and 6 regimen.|This arm will receive 3 doses of 10 µg of RH5.2-VLP with 50 µg Matrix-M at Months 0, 1 and 6 (delayed regimen) and after Growth Inhibition Activity (GIA) immunogenicity review, will proceed to receive Controlled Human Malaria Infection (CHMI) 4 weeks after the last vaccination.
88853401|NCT04565561||DCB group|DCB group, n=20
89182946|NCT05978037|Active Comparator|Group 3: 10 µg or 2 µg RH5.2-VLP with Months 0,1 and 6 regimen.|This arm will receive 2 doses of 10 µg of RH5.2-VLP with 50 µg Matrix-M at Months 0, 1 and 1 doses of 2 µg of RH5.2-VLP with 50 µg Matrix-M at Month 6 (delayed-fractional regimen).
89182947|NCT05978037|Active Comparator|Group 4: 10 µg RH5.2-VLP or 2 µg RH5.1 with Months 0,1 and 6 regimen.|This arm will receive 2 doses of 10 µg of RH5.2-VLP with 50 µg Matrix-M at Months 0, 1 and 1 doses of 2 µg of RH5.1 with 50 µg Matrix-M at Month 6 (delayed-fractional regimen, Prime with RH5.2-VLP then Boost with soluble RH5.1).
89182948|NCT05978037|Active Comparator|Group 5: 10 µg or 2 µg RH5.1 with Months 0,1 and 6 regimen.|This control arm will receive 2 doses of 10 µg of RH5.1 with 50 µg Matrix-M at Months 0, 1 and 1 doses of 2 µg of RH5.1 with 50 µg Matrix-M at Month 6 (delayed-fractional regimen with RH5.1).
89182949|NCT05978037|No Intervention|Group 6: CHMI control|"This control arm will be infectivity controls, so will not receive any vaccinations.~Group 6 will only be recruited after observation of meeting positive GIA target."
89182950|NCT05972941|Experimental|Culturally targeted messages|Participants will view 8 nicotine and tobacco health messages with LGBT culturally targeted messages and imagery
89182951|NCT05972941|Other|Non-targeted messages|Participants will view 8 nicotine and tobacco health messages with universal messages and imagery
89182952|NCT05966844|Experimental|Mindfulness and Virtual Reality|This group will receive questionnaires at the beginning and end of the trial. In addition, they will undergo six mindfulness sessions in virtual reality for about six weeks. One session per week of approximately 5-10 minutes.
89182953|NCT05966844|No Intervention|No intervention|This group will only receive questionnaires at the beginning and end of the experiment
89182954|NCT05956756|Experimental|Intervention|Occupational therapy students will engage in health and resiliency programming as part of their course work over their three year program.
89182955|NCT05955846|Experimental|Z+ VAO IOL|FG-80030.1 hydrophobic
89182956|NCT05952947|Experimental|HRYZ-T101 Injection|Patients will undergo lymphocytapheresis, then treatment with HRYZ-T101 TCR-T cells.
89182957|NCT05939414|Experimental|Investigational Arm: lutetium (177Lu) vipivotide tetraxetan (AAA617)|All participants will be treated with Stereotactic Body Radiation Therapy (SBRT) to all metastatic lesions followed by a dose of 7.4 GBq (200 mCi) +/- 10% of AAA617 which will be administered once every 6 weeks (1 cycle) for a planned 4 cycles.
89182958|NCT05939414|No Intervention|Control arm: observation (watchful waiting)|All participants will be treated with Stereotactic Body Radiation Therapy (SBRT) to all metastatic lesions followed by observation only.
89182959|NCT05936151|Experimental|LY3437943|Participants will receive multiple doses of LY3437943 subcutaneously (SC)
89182960|NCT05936151|Placebo Comparator|Placebo|Participants will receive LY3437943
89182961|NCT05935644|Experimental|ORCHID Group|Participants in the ORCHID group will receive an online intervention that improves depressive symptoms and positive affect (emotions) for clinic-based persons living with HIV, for up to 6 months.
89182962|NCT05929651|Experimental|MenACYW conjugate vaccine|participants will receive a single booster dose of the MenACYW conjugate vaccine with an interval of at least 2 months after the last vaccination with Nimenrix® or Menveo® received during infancy before 12 months of age
89399482|NCT03693495|Experimental|ellume·lab Group A Streptococcus Test|"ellume·lab Group A Streptococcus Test~Pharyngeal samples from participants will be tested with:~ellume.lab Group A Streptococcus Test; Polymerase Chain Reaction (PCR) and bacterial culture."
88853402|NCT04565405|Experimental|AB (Detergent (A) followed by sterile water (B))|"Sequence: Detergent (A) followed by sterile water (B)~The inner cannula will be cleaned with commercially available tracheostomy cleaning fluid / powder (Ex: Trachoe - Kapitex healthcare, UK) in the first visit, and then cleaned with sterile water in the second visit, at a minimum period of 24 hrs apart. Laboratory analysis of colony counts will be conducted on the saline flushing pre- and post-decontamination for each washing."
89399483|NCT02176538|Experimental|Product 0405|Topical active investigational Product 0405
89399484|NCT02176538|Placebo Comparator|Placebo for Product 0405|Topical Placebo for Product 0405
89380131|NCT03426995|Experimental|GSK3358699, Part C|The dose level for the first cohort in Part C will be decided following completion of Part A of the study for GSK3358699. The subjects in this arm will constitute 3 cohorts each (cohort 4 to 6), where the subjects will receive GSK3358699, as one repeat dose treatment once daily for 14-consecutive days. Subjects will have control blisters induced on the forearm (0.2% cantharidin) on Day -10. On the Day 14 of each cohort, each subject will receive an intravenous in vivo LPS challenge at a dose not exceeding 0.75 nanogram per kilogram or an intravenous infusion of GM-CSF, in vivo as 60 microgram per meter^2. The administration of LPS or GM CSF will be followed by blister induction on forearm (0.2 % cantharidin).
89399485|NCT03623841|Experimental|Dual-task training group|Participants in dual-task training group will execute dual-task training via exer-game which combined with treadmill, 3 times per week, least 8 weeks.
89399486|NCT03623841|Active Comparator|Treadmill training group|Participants in treadmill training group will do treadmill training only, 3 times per week, least 8 weeks.
88853403|NCT04565405|Experimental|BA (Sterile water (B) followed by detergent (A))|"Sequence: Sterile water (B) followed by detergent (A)~The inner cannula will be cleaned with sterile water in the first visit, and then cleaned with commercially available tracheostomy cleaning fluid / powder (Ex: Trachoe - Kapitex healthcare, UK) in the second visit, at a minimum period of 24 hrs apart. Laboratory analysis of colony counts will be conducted on the saline flushing pre- and post-decontamination for each washing."
88853404|NCT04565093|Experimental|iPACK|In this group, participants will receive a peripheral nerve anesthetic block that is iPACK (Interspace between the Popliteal Artery and the Capsule of the posterior Knee) to cover posterior knee pain after total knee arthroplasty (TKA). This anesthetic block will be performed by assigned anesthesiologist under ultrasound guidance.
88853405|NCT04565093|Placebo Comparator|Periarticular local infiltration analgesia (LIA)|In this group, participants will receive a mixture of bupivacaine 0.25% 20 ml + epinephrine 100 mics ± lornoxicam 8 mg ± morphine 10 mg ± tranexamic acid 1 gm in 40 ml normal saline (NS) that will be injected into the posterior capsule and the medial and lateral ligaments just before implantation: after insertion of the implants and into the capsule and retinacular tissues. The remaining solution (approximately 20 mL) will be used to infiltrate the muscle and subcutaneous tissues. This local anesthetic infiltration is commonly performed by the operating orthopedic surgeon during TKA for postoperative pain control.
88853406|NCT04564937|Experimental|SCT510A dose level 1 treatment|SCT510A(0.625mg), Vitreous injection, injection once every 4 weeks，three times continuously
89380132|NCT03426995|Placebo Comparator|Placebo, Part C|The subjects in this cohort will receive a matching placebo to GSK3358699, Part C, as a single oral dose once daily for 14 consecutive days. The subjects in this arm will constitute 3 cohorts each (cohort 4 to 6), where the subjects will receive placebo, as one repeat dose treatment once daily for 14-consecutive days. Subjects will have control blisters induced on the forearm (0.2% cantharidin) on Day -10. On the Day 14 of each cohort, each subject will receive an intravenous in vivo LPS challenge at a dose not exceeding 0.75 nanogram per kilogram or an intravenous infusion of GM-CSF, in vivo as 60 microgram per meter^2. The administration of LPS or GM CSF will be followed by blister induction on forearm (0.2 % cantharidin).
89380133|NCT05200533|Experimental|Task-sharing and shifting|In the task-sharing and shifting group, family physicians shifted acute low back pain consultations to physiotherapists. Patients with acute low back pain are seen by the physiotherapist instead of family physician. Physiotherapist diagnose acute low back pain, identify red and yellow flags, prescribe sick leave and medications and can refer the patient to additional physical therapy treatment.
89380134|NCT05200533|Active Comparator|Usual care|In the usual care group, patients with acute low back pain are seen by their family physician.
89380135|NCT05560815||The Swedish surgical population|All adult patients (≥18 years) undergoing any surgical procedure registered in SPOR during 1 January 2015 - 31 December 2020.
89380136|NCT05200299|Experimental|mFOLFOXIRI adjuvant chemotherapy|Patients will receive mFOLFOXIRI once every two weeks for 12 cycles as adjuvant chemotherapy. They can change the regimen to mFOLFOX6 or CapeOx after accepting not less than two complete chemotherapy regimen, if can not tolerate the adverse reaction of mFOLFOXIRI. Total 24 weeks.
89380137|NCT05200299|Active Comparator|mFOLFOX6 or CapeOx adjuvant chemotherapy|Patients will receive mFOLFOX6 once every two weeks for 12 cycles as adjuvant chemotherapy or CapeOx once every three weeks for 8 cycles as adjuvant chemotherapy. Total 24 weeks.
89380138|NCT03424265|Experimental|9g of EAA mixture supplement|Twice a day for 12 consecutive weeks.
89380139|NCT03424265|Experimental|9g of placebo (whey protein)|Twice a day for 12 consecutive weeks.
89380140|NCT05181423||Retrospective cohort|The internal cohort was retrospectively enrolled in West China Hospital, Sichuan University from June 2010 and December 2020. It is a training and internal validation cohort.
89380141|NCT05181423||Prospective cohort|The same inclusion/exclusion criteria were applied for the same center prospectively. It is a external validation cohort.
89380142|NCT04934319|Experimental|Balance training|A single training group
89380143|NCT03322566|Experimental|Pembrolizumab + Chemotherapy + Epacadostat|Participant received pembrolizumab 200 mg intravenous (IV) infusion, every 3 weeks (Q3W) on Day 1 of each 21 day cycle for up to 35 cycles + epacadostat 100 mg tablets, orally, twice daily (BID) in each 21 day cycle for up to 35 cycles + platinum-doublet chemotherapy (pemetrexed 500 mg/m^2 IV infusion, Q3W + cisplatin 75 mg/m^2 IV infusion, Q3W or carboplatin 5-6 mg/mL/min IV infusion Q3W for 4 cycles followed by pemetrexed maintenance; or paclitaxel 200 mg /m^2 IV infusion, Q3W + carboplatin 5-6 mg/mL/min IV infusion Q3W for 4 cycles).
89380144|NCT03322566|Experimental|Pembrolizumab + Chemotherapy + Placebo|Participant received pembrolizumab 200 mg IV infusion, Q3W on Day 1 of each 21 day cycle for up to 35 cycles + epacadostat matching placebo tablets, orally, BID in each 21 day cycle for up to 35 cycles + platinum-doublet chemotherapy (pemetrexed 500 mg/m^2 IV infusion, Q3W + cisplatin 75 mg/m^2 IV infusion, Q3W or carboplatin 5-6 mg/mL/min IV infusion Q3W for 4 cycles followed by pemetrexed maintenance; or paclitaxel 200 mg /m^2 IV infusion, Q3W + carboplatin 5-6 mg/mL/min IV infusion Q3W for 4 cycles).
89380145|NCT03322566|Experimental|Pembrolizumab + Epacadostat|Participant received pembrolizumab 200 mg IV infusion, Q3W on Day 1 of each 21 day cycle for up to 35 cycles + epacadostat 100 mg tablets, orally, BID in each 21 day cycle for up to 35 cycles.
89380146|NCT03822975|Experimental|Bivalirudin|Bivalirudin with prolonged full dose infusion during primary PCI
89380147|NCT03822975|Active Comparator|Heparin|Heparin alone during primary PCI
89380148|NCT05178225|Active Comparator|patients with post-COVID-19 syndrome with Mountain spa rehabilitation|patients with post-COVID-19 syndrome with Mountain spa rehabilitation: 15 patients with post-COVID-19 syndrome, 3-6 months after hospitalization were on Mountain spa rehabilitation (MR) in High Tatras, Tatranská Polianka, Slovakia, for 16 to 18 days
88853407|NCT04564937|Experimental|SCT510A dose level 2 treatment|SCT510A(1.25mg), Vitreous injection, injection once every 4 weeks，three times continuously
89380149|NCT05178225|Active Comparator|patients with post-COVID-19 syndrome with Mountain spa rehabilitation + supplementation coenzyme Q10|patients with post-COVID-19 syndrome with Mountain spa rehabilitation: 22 patients with post-COVID-19 syndrome, 3-6 months after hospitalization were on Mountain spa rehabilitation (MR) in High Tatras, Tatranská Polianka, Slovakia, 22 patients who will be on spa rehabilitation and at the same time on supplementation with ubiquinol (reduced coenzyme Q10), in a daily dose of 2x100 mg, for 16 to 18 days
89380150|NCT05178225|Placebo Comparator|healthy control|15 healthy control volunteers (no Covid-19 or other pathologies)
89380151|NCT05210244|Experimental|BJ supplementation|
89380152|NCT05210244|Placebo Comparator|PLA supplementation|
89380153|NCT02969018|Experimental|PF-06700841 60 mg followed by 30 mg once daily|4 week induction with 60 mg PF-06700841 once daily, followed by 8 week chronic administration of 30 mg PF-06700841 once daily
89380154|NCT02969018|Experimental|PF-06700841 60 mg followed by 10 mg once daily|4 week induction with 60 mg PF-06700841 once daily, followed by 8 week chronic administration of 10 mg PF-06700841 once daily
89380155|NCT02969018|Experimental|PF-06700841 60mg once daily followed by 100mg once weekly|4 week induction with 60 mg PF-06700841 once daily, followed by 8 week chronic administration of 100 mg PF-06700841 once weekly
89380156|NCT02969018|Experimental|PF-06700841 60mg once daily followed by placebo once daily|4 week induction with 60 mg PF-06700841 once daily, followed by 8 week chronic administration of placebo once daily
89380157|NCT02969018|Experimental|PF-06700841 30mg once daily|4 week induction with 30 mg PF-06700841 once daily followed by 8 week chronic administration of 30 mg PF-06700841 once daily
89399487|NCT02256254|Active Comparator|Simvastatin|2 Simvastatin capsules of 20 mg every evening for 14 days
88817700|NCT01732445|Experimental|Supportive care (ruxolitinib phosphate and danazol)|Patients receive ruxolitinib phosphate PO BID and danazol PO TID on days 1-56. Treatment repeats every 56 days for 6 courses in the absence of disease progression or unacceptable toxicity. At the treating physician's discretion, patients may continue treatment past 6 courses if they are without disease progression.
88853408|NCT04564937|Experimental|SCT510A dose level 3 treatment|SCT510A(2.0mg), Vitreous injection, injection once every 4 weeks，three times continuously
88853409|NCT04564937|Experimental|SCT510A dose level 4 treatment|SCT510A(2.5mg), Vitreous injection, injection once every 4 weeks，three times continuously
88853410|NCT04563689|Experimental|actve|oral rinse
88853411|NCT04563689|Placebo Comparator|placebo|distilled water,
89380158|NCT02969018|Experimental|PF-06700841 30mg once daily followed by 10mg once daily|4 week induction with 30 mg PF-06700841 once daily, followed by 8 week chronic administration of 10 mg PF-06700841 once daily
89380159|NCT02969018|Experimental|PF-06700841 30mg once daily followed by 100mg once weekly|4 week induction with 30 mg PF-06700841 once daily, followed by 8 week chronic administration of 100 mg PF-06700841 once weekly
89380160|NCT02969018|Placebo Comparator|Placebo|12 weeks once daily placebo
89380161|NCT04624620|Experimental|Pilot|Participants will participate in a 16 week, culinary intensive study that will consist of 2 hour virtual classes taught by a chef, a dietitian, and a health coach that focus on diet, culinary competency, daily physical activity, mindfulness and support for behavior change.
89380162|NCT03255096|Experimental|Dose Escalation Phase (Part 1)|Participants will receive either RO6870810 and venetoclax or RO6870810 and venetoclax along with rituximab until disease progression, unacceptable toxicities or withdrawal from treatment for other reasons, or death.
89380163|NCT03255096|Experimental|Expansion Phase (Part 2)|Participants will receive RO6870810 and venetoclax along with rituximab (or RO6870810 and venetoclax, if the combination of the 3 drugs is not tolerable) at a recommended dose established in dose escalation phase until disease progression, unacceptable toxicities or withdrawal from treatment for other reasons, or death.
89380164|NCT01319721|Active Comparator|Group LCAG|After extensive excision of recurrent pterygium, intraoperative 0.2 mg/ml MMC (0.02%) for 3 minutes will be applied topically onto the exposed surgical area and then limbal conjunctival autograft for repairing the conjunctival defect.
89380165|NCT01319721|Active Comparator|Group AMG|After excision of recurrent pterygium, intraoperative 0.2 mg/ml MMC (0.02%) for 3 minutes will be applied topically onto the exposed surgical area and then an amniotic membrane graft for repairing the conjunctival defect.
89380166|NCT05284682||Dilated cardiomyopathy|Patients with heart failure on the basis of dilated cardiomyopathy.
89380167|NCT05284682||Control group without heart failure|Control group from the ablation laboratory without heart failure
89380168|NCT05210010|Other|Algorithm|All participating cardiologists.
89380169|NCT03015324|Experimental|Hydroxychloroquine|Hydroxychloroquine
89380170|NCT05754450|Experimental|AVTX-803|AVTX-803 at a dose specified by the investigator up to 5 times a day not to exceed 1700 mg/kg/day
88853412|NCT04563221|Experimental|Balloon occlusion microcatheter|Participants will undergo the PAE procedure using LC Bead LUMI delivered through a balloon occlusion microcatheter.
88853413|NCT04563221|Experimental|Standard microcatheter|Participants will undergo the PAE procedure using LC Bead LUMI delivered through a standard microcatheter.
88853414|NCT04564859|Experimental|Noninvasive Ventilation group|Noninvasive Ventilation group initial setting： Insp. Pressure：12 ~ 16 centimeter of water Exp. Pressure ： 4 ~ 6 centimeter of water FiO2：Keep oxygen saturation measured by pulse oximeter：> 92% By condition, gradually tap 2~3 centimeter of water inspiratory positive airway pressure Keep Tidal volume：6~10 ml/kg
88853415|NCT04564859|Active Comparator|Heated Humidified High-Flow Nasal Cannula group|Heated Humidified High-Flow Nasal Cannula group initial setting： Flow setting: 50 L/m FiO2：Keep oxygen saturation measured by pulse oximeter > 92% temperature:37 ℃ By condition, gradually tap Flow 5 L/m
88853416|NCT04563767||Infinitome|All patients will be in the same cohort. No intervention will be administered. Patients will undergo a structural magnetic resonance imaging (MRI) as part of their standard of care. Added on will be the resting state fMRI (rs-fMRI). The rs-fMRI data will be analyzed.
88853417|NCT04563299|Experimental|Dextenza|Dextenza (Dexamethasone Ophthalmic Insert 0.4 mg)
88853418|NCT04563299|Active Comparator|Topical Corticosteroids|Topical corticosteroids (prednisolone acetate 1%) QID tapered over 4 weeks (QID/ 1 week, TID/ 1 week, BID/1 week, QD/ 1 week).
88853419|NCT04561895||control group|healthy volunteers with absence of NAFLD
88853420|NCT04561895||test group|patients with confirmed NAFLD diagnosis
88853421|NCT04561583|Other|LED light source system for endoscope|This trial is designed as a prospective, multi-center, single-blind, parallel, randomized controlled clinical trial. The trial will be carried out in 5 centers, involving 220 subjects as estimated who will be divided into the test group or control group randomly on an equal basis (each group includes 110 subjects).Test grop use LED light source system for endoscope
89380171|NCT05174871|Active Comparator|Active control|Participants in this arm will receive the usual treatment for obesity at our hospital, based on lifestyle changes (encouraging a healthy diet and physical activity) for 2 months
89380172|NCT05174871|Experimental|Time-Restricted Feeding|Participants in this arm will receive the usual treatment for obesity at our hospital, based on lifestyle changes (encouraging a healthy diet and physical activity) for 2 months. During this time, participants will have their feeding time restricted to 8 hours per day.
89380173|NCT05193474|No Intervention|Refuse to integrate palliative care into usual care.|Usual ESRD care team
89380174|NCT05193474|Experimental|Agree to integrate palliative care into usual care.|Usual ESRD care + combined palliative care team
89380175|NCT02985138|Experimental|Unilateral fixation|Patients undergoing TLIF and unilateral pedicle screw fixation
89380176|NCT02985138|Active Comparator|Bilateral fixation|Patients undergoing TLIF and bilateral pedicle screw fixation
89380177|NCT05139849|Active Comparator|Intervention|"Adrenaline, vasopressin and steroids arm (intervention)~At randomization~1 ml of vasopressin 20 IU/ml will be administered as soon as possible after adrenaline during the five first cycles of drug administration during CPR.~1 ml metylprednisolone sodium succinate 40 mg/ml will be administered only during the first cycle of drug administration during CPR~In the ICU Hydrocortisone 3 mg/ml At 4 hours post ROSC, and then once daily, surviving patients with post-resuscitation shock will receive an infusion of 100 ml (300 mg hydrocortisone/ d) for ≤ 7 days. From day 8 post ROSC or when vasopressors are not needed the hydrocortisone dos will be reduced daily to 67 ml (200 mg) and 33 ml (100 mg) and then discontinued). Patients with evidence of acute myocardial infarction will receive an infusion of 100 ml (300mg hydrocortisone/ d) for maximum 3 days to prevent retardation of infarct healing."
88853422|NCT04561583|Other|Pinpoint Endoscopic Fluorescence Imaging System|This trial is designed as a prospective, multi-center, single-blind, parallel, randomized controlled clinical trial. The trial will be carried out in 5 centers, involving 220 subjects as estimated who will be divided into the test group or control group randomly on an equal basis (each group includes 110 subjects).control group use Pinpoint Endoscopic Fluorescence Imaging System (Model: PC9000)
88853423|NCT04561505|Active Comparator|Holmium laser enucleation of prostate|patients that undergo Holmium laser enucleation of prostate (HoLEP) procedure
88853424|NCT04561505|Active Comparator|monopolar transurethral resection of prostate|patients that undergo monopolar transurethral resection of prostate
88853425|NCT04561817|Active Comparator|PI3K/AKT mutations (altered)|Participants with recurrent epithelial ovarian cancer with PI3K/AKT mutations (altered)
88853426|NCT04561817|Active Comparator|Without PI3K/AKT mutations (non-altered)|Participants with recurrent epithelial ovarian cancer without PI3K/AKT mutations (non-altered)
88853427|NCT04561349|Experimental|Task-oriented training (TOT)|Task-oriented training consisted of different functional tasks for lower limbs to improve balance and walk
88853428|NCT04561349|Active Comparator|Conventional rehabilitation treatment|Conventional rehabilitation treatment includes mat activities and range of motion (ROM) of all limbs, Lower limb strengthening and stretching, walking, cycling
88853429|NCT04561271|Experimental|foot reflexology|patients will receive one session of foot reflexology with a nurse who received a specific formation. The session lasts 15 to 20 minutes, patients seated, half seated or in supine position. The technique consists in stimulating reflex zones of foot, each zone corresponding to a specific organ. Almond oil will be used. The session is accompanied by relaxing music
88853430|NCT04561271|Sham Comparator|toucher massage|patients will receive one session of toucher massage with a nurse (this technique is taught during the formation of every nurse in palliative care units). The session lasts 15 to 20 minutes, patients seated, half seated or in supine position. It consists in a simple massage and effleurage, with fluid and progressive movements. Almond oil will be used. The session is accompanied by relaxing music.
88853431|NCT02211677||Low Risk Group|Each of the eight independent prognostic factors (age, sex, T and N stages, hemoglobin during radiotherapy, variation tendency of Hb, neutrophil-lymphocyte ratio before radiotherapy and platelet during radiotherapy) was assigned a number of points proportional to its regression coefficient to calculate prognostic index (PI), which ranged from 1 to 17. Patients with PI equal to 1-4 called the low risk group.
88853432|NCT02211677||Intermediate Risk Group|Each of the eight independent prognostic factors (age, sex, T and N stages, hemoglobin during radiotherapy, variation tendency of Hemoglobin, neutrophil-lymphocyte ratio before radiotherapy and platelet during radiotherapy) was assigned a number of points proportional to its regression coefficient to calculate prognostic index (PI), which ranged from 1 to 17. Patients with PI equal to 5-11 called the intermediate risk group.
89182963|NCT05922501|Experimental|Isatuximab + Belantamab mafodotin + Pomalidomide + Dexamethasone|"Isatuximab will be given once daily into your vein (by intravenous infusion) over about 30-60 minutes. This will occur during cycle 1 (cycle equals 28 days) on days 1, 8, 15, and 22 and cycle 2 and onwards days 1 and 15.~Belantamab mafodotin will be given once every 8 weeks into your vein (by intravenous infusion) over about 60 minutes after completion of isatuximab infusion.~Pomalidomide will be taken orally once daily during days 1-21 of each cycle.~Dexamethasone will be taken orally once daily during days 1, 2, 8, 9, 15, 16, 22, and 23 of each cycle.~Drug diaries will be provided to participants to document information about taking pomalidomide and dexamethasone."
89182964|NCT05921942|No Intervention|Group A|Patients will receive standard therapy FOLFOX/XELOX PROTOCOL
89182965|NCT05921942|Active Comparator|Group B|Patients will receive metformin (500 mg twice daily or 1000 mg once daily) in addition to standard therapy FOLFOX/XELOX PROTOCOL
89182966|NCT05920967|Experimental|DXP group|The participants in DXP group will receive a first dose of a single paravertebral space infusion of 21 ml of analgesic containing 0.5 percentage ropivacaine 20 ml and dexamethasone palmitate 1ml.
89182967|NCT05920967|Active Comparator|DXM group|The participants in DXM group will receive a single infusion of a paravertebral space first dose of 21 ml of analgesic containing 0.5 percentage ropivacaine 20 ml and dexamethasone sodium phosphate 1ml.
89182968|NCT05919589||Parents and Carers|Parents and carers of children with special healthcare needs
89182969|NCT05919589||Staff and professionals|Staff and professionals involved (either directly or indirectly in healthcare and other services) with children with special healthcare needs
89182970|NCT05915728|Experimental|Gadoquatrane - Approved Macrocyclic GBCA|Participants will receive one intravenous injection of gadoquatrane during MRI in Period 1, followed by one intravenous injection of any approved macrocyclic GBCA during MRI in Period 2.
88853433|NCT02211677||High Risk Group|Each of the eight independent prognostic factors (age, sex, T and N stages, hemoglobin during radiotherapy, variation tendency of Hemoglobin, neutrophil-lymphocyte ratio before radiotherapy and platelet during radiotherapy) was assigned a number of points proportional to its regression coefficient to calculate prognostic index (PI), which ranged from 1 to 17. Patients with PI equal to 12-17 called the high risk group.
88853434|NCT02211833|Experimental|BI 2536 with pemetrexed|combination therapy phase may be followed by BI 2536 monotherapy for eligible patients
88853435|NCT04562909||Premature children|Premature children born before than 32 weeks were included.
88853436|NCT04562909||Healthy Control Group|Age matched healthy controls
88853437|NCT04562675|Experimental|Intervention group (IG)|LHA intervention group (IG)
88853438|NCT04562675|Placebo Comparator|Control group (CG)|brochure-only control group (CG)
89182971|NCT05915728|Experimental|Approved Macrocyclic GBCA - Gadoquatrane|Participants will receive one intravenous injection of any approved macrocyclic GBCA during MRI in Period 1, followed by one intravenous injection of gadoquatrane during MRI in Period 2.
89182972|NCT05915026|Experimental|Gadoquatrane|Participants will receive one intravenous injection of gadoquatrane during MRI.
89182973|NCT05913973|Experimental|Group 1|5 (micro)g Pvs230D1-EPA/50 (micro)g MM
89182974|NCT05913973|Experimental|Group 2|25 (micro)g Pvs230D1-EPA/50 (micro)g MM
89182975|NCT05913973|Experimental|Group 3|50 (micro)g Pvs230D1-EPA/50 (micro)g MM
89182976|NCT05910528|Experimental|Experimental: Treatment Sequence A; Drug: RVT-3101 Induction dose A and Maintenance dose|
89182977|NCT05910528|Experimental|Experimental: Treatment Sequence B; Drug: RVT-3101 Induction dose B and Maintenance dose|
89380178|NCT05139849|Placebo Comparator|Control|"Adrenaline alone arm (control)~At randomization 1 ml sodium chloride 9 mg/ml (placebo) will be administered as soon as possible after adrenaline during the first five cycle of drug administration during CPR 1 ml sodium chloride 9 mg/ml (placebo) will be administered only during the first cycle of drug administration during CPR~b In the ICU sodium chloride 9 mg/ml (placebo) At 4 hours post ROSC, and then once daily, surviving patients with post-resuscitation shock will receive an infusion of 100 ml for ≤ 7 days. From day 8 post ROSC or when vasopressors are not needed the dos will be reduced daily to 67 ml and 33 ml and then discontinued. Patients with evidence of acute myocardial infarction will receive an infusion of 100 ml for 3 days."
89380179|NCT02905032|No Intervention|Standard Care|Observations in clinical encounter via video, audio or observational notes.
89380180|NCT02905032|Active Comparator|Standard Care + Decision Aid|Observation of clinical encounter using the decision aid via video, audio, or observational notes.
89380181|NCT05504187|Experimental|Part 1: Dose Optimization Cohort 1, Dose 1|Participants will be administered with KP104 as a weekly maintenance dose for 24 Weeks. After the last participant completes 6 weeks of treatment, all available data, including safety, PK, PD, and modeling results, will be reviewed by the Internal Data Review Committee (IDRC) to determine Dosing Regimen 2
89380182|NCT05504187|Experimental|Part 1: Dose Optimization Cohort 2, Dose 2|Participants will be administered with KP104 dose regimen 2 for 24 Weeks. After the last participant completes 6 weeks of treatment, all available data, including safety, PK, PD, and modeling results, will be reviewed by the IDRC to determine Dosing Regimen 3.
89380183|NCT05504187|Experimental|Part 1: Dose Optimization Cohort 3, Dose 3|Participants will be administered with KP104 dose regimen 3 for 24 Weeks. After the last participant completes 6 weeks of treatment, all available data, including safety, PK, PD, and modeling results, will be reviewed by IDRC to determine the Optimal biologic dose (OBD) for Part 2.
89380184|NCT05504187|Experimental|Part 2: OBD Cohort, Dose 4|Participants will be administered with KP104 OBD for 24 Weeks.
88853439|NCT02211443|Experimental|Single arm|"Two phase study of Recombinant full human Anti-epidermal growth factor receptor(EGFR) Monoclonal Antibody:~First phase: seven escalating single-dose groups : 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0 mg/kg~Second phase: multiple-dose groups 0.5, 1.0, 2.0, 3.0 mg/kg: weekly once for 4 doses; 5.0, 6.0 mg/kg: every two weeks for 2 doses; 4.0 mg/kg: weekly or every two weeks depends on the results of previous dose groups."
88853440|NCT04562753|Active Comparator|Maïa® TMC Prosthesis (Lépine Groupe)|Patients undergoing thumb basal joint arthroplasty using Maïa® TMC prosthesis as treatment of osteoarthritis.
88853441|NCT04562753|Active Comparator|APL Suspensionplasty|Patients undergoing thumb basal joint arthroplasty using APL Suspensionplasty as treatment of osteoarthritis.
88853442|NCT04562519|Experimental|diabetic HD group|Patients of this group will receive 20 minutes of extra oral TENS over skin of bilateral parotid glands (3 sessions weekly for 3 weeks)
88853443|NCT04562519|Active Comparator|Nondiabetic goup|Patients of this group will receive 20 minutes of extra oral TENS over skin of bilateral parotid glands (3 sessions weekly for 3 weeks)
88853444|NCT02211521|Experimental|PRP group|Patients randomized to this group of treatment will receive 1 blinded knee intra-articular injections of autologous Platelet-Rich Plasma (3ml).
88853445|NCT02211521|Active Comparator|Hyaloronan group|Patients randomized to this group of treatment will receive 1 blinded knee intra-articular injections of hyaluronic acid (3ml)
88853446|NCT01597908|Experimental|Dabrafenib plus Trametinib|BRAF inhibitor plus MEK inhibitor
88853447|NCT01597908|Active Comparator|Vemurafenib|BRAF inhibitor
88853448|NCT04415970|Experimental|Flotation Therapy|Participants will utilize flotation sensory deprivation tanks.
88853449|NCT04415970|Active Comparator|Sleep Pod|Participants will utilize sleep pods with partial sensory deprivation (no light and silence).
88853450|NCT01951170|Experimental|Tocilizumab|Participants were administered subcutaneous tocilizumab for the treatment of rheumatoid arthritis for 24 weeks.
89380185|NCT05191368||Normal group|Healthy people who received two doses of COVID-19 vaccine
89380186|NCT05191368||RA Patients injected with 2 doses of vaccine|RA Patients who received two doses of COVID-19 vaccine
89380187|NCT05191368||Unvaccinated RA patients|RA Patients who received zero doses of COVID-19 vaccine
89380188|NCT02799186|Experimental|SCAD (spontaneous coronary artery dissection)|Every patient included with a SCAD or hematoma, will systematic benefit a tomographic or MRI angiography of renal, cerebrovascular and iliac arteries, to look for the presence of a fibromuscular displasia. A blood sample will be collected for the genetic analysis which will be realized by the Team 3 of the INSERM UMR970, Paris Cardiovascular research Center, France.
88853451|NCT01951092|Experimental|Single Arm intervention study|All subjects receive text messages for: 1) medication reminders; 2) appointment reminders; 3) a text message addressing barriers (e.g., reminders to attend AA meetings). Each subject will undergo baseline assessments, choose personalized messages at that time. Subsequently monthly phone calls with study coordinator regarding frequency/changing messages, and then month 3 assessment, and month 6 (final assessment) with option for qualitative interview.
88853452|NCT04640922|Active Comparator|Gedea Pessary|pHyph, vaginal tablet, daily in Part 1 and once weekly in Part 2
88853453|NCT04640922|Placebo Comparator|Placebo|placebo, vaginal tablet, daily in Part 1 and once weekly in Part 2
88853454|NCT01949532|Experimental|Normal Renal Function|Participants with normal renal function (creatinine clearance [CrCl] ≥ 75 mL/min) received carfilzomib 20 mg/m² intravenous infusion (IV) on days 1 and 2 of cycle 1, followed by 27 mg/m² IV on days 8, 9, 15, and 16 of cycle 1. Participants who adequately tolerated dosing at 27 mg/m² received carfilzomib 56 mg/m² IV on days 1, 2, 8, 9, 15 and 16 of cycle 2 and all subsequent cycles. Participants continued treatment until confirmed progressive disease, unacceptable toxicity, withdrawal of consent, study closure, or death.
88853455|NCT01949532|Experimental|End Stage Renal Disease|Participants with end-stage renal disease (on hemodialysis) received carfilzomib 20 mg/m² intravenous infusion (IV) on days 1 and 2 of cycle 1, followed by 27 mg/m² IV on days 8, 9, 15, and 16 of cycle 1. Participants who adequately tolerated dosing at 27 mg/m² received carfilzomib 56 mg/m² IV on days 1, 2, 8, 9, 15 and 16 of cycle 2 and all subsequent cycles. Participants continued treatment until confirmed progressive disease, unacceptable toxicity, withdrawal of consent, study closure, or death.
89182978|NCT05909904|Active Comparator|Tislelizumab|Tislelizumab 200 milligrams (mg) administered once every 3 weeks
89380189|NCT02767518|Experimental|Prehabilitation|Participants will be referred to the Michigan Surgical & Health Optimization Program in the month leading up to their surgery. Individuals are encouraged to increase their physical activity, practice stress reduction, and other behaviors associated with good health.
89380190|NCT02767518|No Intervention|Usual Care|Participants will follow the pre-operative instructions provided by their surgical team.
89380191|NCT03351075|Experimental|Intervention group|Standard physical therapy program + Modern educational program
89380192|NCT03351075|Active Comparator|Control group|Standard physical therapy program + Traditional biomedical educational program
89380193|NCT03315741|Experimental|Patient centered approach|Drug titration of maximum dose over 3-8 weeks
89380194|NCT05307393|No Intervention|A|
89380195|NCT05307393|Experimental|B|Group B will be placed in a dorsal recumbent, modified sims position on the side of fetal movement.
89380196|NCT05307393|Experimental|C|Group C, will be placed in the same position but opposite that of which fetal kicks are felt.
89380197|NCT03632967|Experimental|Device: TriCinch Coil System treatment|
89380198|NCT05077449|Experimental|XZP-3287+Fulvestrant|
89380199|NCT05077449|Placebo Comparator|Placebo + Fulvestrant|
88853456|NCT01949142|Experimental|OTO-201|"OTO-201: Single, intratympanic injection:~One injection of 6 mg OTO-201 (ciprofloxacin in poloxamer 407) into each ear during surgery."
88853457|NCT01949142|Sham Comparator|Sham|"Sham: Simulated single, intratympanic injection:~One sham injection into each ear during surgery."
89380200|NCT03632733|Active Comparator|Tetracycline group|Tetracycline cream twice daily for three months
88853458|NCT01948908|Experimental|200 mcL VOA|Intranasal midazolam administered in 200 mcL VOA
88853459|NCT01948908|Experimental|500 mcL VOA|Intranasal midazolam administered in 500 mcL VOA.
88853460|NCT01948908|Experimental|1000 mcL VOA|Intranasal midazolam administered in 1000 mcL VOA.
88853461|NCT01925274|Experimental|Arm A|PF-05212384 plus Irinotecan
88853462|NCT01925274|Active Comparator|Arm B|Cetuximab plus Irinotecan
88853463|NCT01948830|Active Comparator|Group I ranibizumab 0.5 mg monthly|Ranibizumab 0.5 mg/0.05 mL (Monthly regimen) up to month 11
88853464|NCT01948830|Active Comparator|Group II ranibizumab 0.5 mg TER|Ranibizumab 0.5 mg/0.05 mL (TER) treat and Extend regimen up to month 11
88853465|NCT01972464|Placebo Comparator|placebo|In this group women will receive a placebo pill which will appear similar to progesterone and will be inert.
88853466|NCT01972464|Experimental|Progesterone|In this group women will receive oral micronized progesterone twice a day.
88853467|NCT01948050|Experimental|real tDCS stimulation|non-invasive transcranial direct current stimulation (tDCS) at 2 milliamiampers (2mA)for 20 minutes at each session, on five consecutive days.
88853468|NCT01948050|Sham Comparator|Sham tDCS|sham non-invasive transcranial direct current stimulation (tDCS) consisting of 30 seconds of tDCS stimulation at 2mp and 19 minutes and 30 seconds of tdcs at 0mp stimulation,on five consecutive days.
88853469|NCT01947894||Adult Growth Hormone deficient Patients|Patients with GHD on Genotropin® replacement therapy.
89380201|NCT03632733|Active Comparator|Clotrimazole group|Clotrimazole cream twice daily for three months
89380202|NCT03632733|Active Comparator|Combination drug group|Tetracycline and Clotrimazole combination cream twice daily for three months
89380203|NCT03632733|Placebo Comparator|Placebo group|participants will be provided a cream containing no active drug ingredients
89380204|NCT03259425|Experimental|Nivolumab and HF10, all participants|
89380205|NCT03259269||Bedaquiline and companion WHO Group 5 drugs|
89380206|NCT03259269||Delamanid and companion WHO Group 5 drugs|
89380207|NCT04923555|Experimental|Group/Cohort1|33 subjects aged 65 years old with predisposition to cardiometabolic syndrome will consume 400ml of yogurt rich in cysteine, leucine and arginine (VP, vegetable proteins) only once during the visit
89380208|NCT04923555|Experimental|Group/Cohort2|33 subjects aged 65 years old with predisposition to cardiometabolic syndrome will consume 400ml of yogurt rich in animal proteins (AP) only once during the visit
89380209|NCT04923555|Placebo Comparator|Group/Cohort3|33 subjects aged 65 years old with predisposition to cardiometabolic syndrome will consume 400ml of yogurt without any proteins (T) only once during the visit
89380210|NCT03101241|Experimental|CX-8998|
89380211|NCT03101241|Placebo Comparator|Placebo|
89380212|NCT03061188|Experimental|Treatment (veliparib, nivolumab)|Patients receive veliparib PO BID on day 1 and nivolumab IV over 30 minutes on days 1 and 15 of courses 1-4 and IV over 60 minutes on day 1 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89380213|NCT03449147|Placebo Comparator|Placebo|Participants will receive a matching placebo tablet BID during the 24-week main study period and the 28-week extension period.
89380214|NCT03449147|Experimental|Gefapixant 15 mg BID|Participants will receive a gefapixant 15 mg tablet BID and placebo tablet to match gefapixant 45 mg BID during the 24-week main study period and the 28-week extension period.
89380215|NCT03449147|Experimental|Gefapixant 45 mg BID|Participants will receive a gefapixant 45 mg tablet BID and placebo tablet to match gefapixant 15 mg BID during the 24-week main study period and during the 28-week extension period.
88853470|NCT01947582|Other|Application of ankle foot orthosis|All participants will receive ankle foot orthosis or orthoses. Outcomes will be compared to pre-bracing findings.
88853471|NCT01924806|Active Comparator|WoundWand™ Debridement Device|Group I - Coblator IQTM Controller plus WoundWandTM Debridement Device. Electrical energy that removes necrotic, ischemic, and/or infected tissue within a wound.
88853472|NCT01924806|Active Comparator|Standard of Care sharp debridement|Group II - Standard of Care (SoC) surgical (sharp) debridement. Sharp instruments that remove necrotic, ischemic, and/or infected tissue within a wound.
88853473|NCT01924182|Other|IT group (Intrathecal Morphine Sulfate)|SynchroMed Infusion System and Intrathecal Morphine Sulfate
88853474|NCT01924182|Other|Conventional Medical Management|Conventional Medicine, and then SynchroMed Infusion System and Intrathecal Morphine Sulfate
89182979|NCT05909904|Experimental|Tislelizumab + BGB-A425|Tislelizumab 200 mg administered once every 3 weeks with BGB-A425
89182980|NCT05909904|Experimental|Tislelizumab + LBL-007|Tislelizumab 200 mg administered once every 3 weeks with LBL-007
89380216|NCT03628638||Lung Cancer Screening Patients - No Nodules|Subjects in an low dose CT screening program that present no nodules.
89380217|NCT03628638||Lung Cancer Screening Patients - Nodules|Subjects in an low dose CT screening program that present nodules. Additional follow-up data will be collected for up to 12 months and an additional blood sample collected
89380218|NCT04031040|Experimental|Genio(TM) system therapy|Following activation of the Genio™ system at 8 weeks post-surgery, patients will be followed at 12 weeks, 6 months, 9 months, 12 months and then every year for a total period of 5 years after surgery.
89380219|NCT05588453|Experimental|Treatment (UD TGFbetai NK cells, temozolomide)|Patients receive UD TGFbetai NK cells IV over 30 minutes on day 1 and temozolomide PO daily on days 1-5. Treatment with UD TGFbetai NK cells repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Cycles of temozolomide repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89380220|NCT01311401||Rehania village (Kfar Rehania)|Circassian community
89380221|NCT01311401||Kama village (Kfar Kama )|Circassian community
89380222|NCT03716141|Active Comparator|Autologous Platelets Rich Plasma|In this group we will be managing diabetic wounds with platelet rich plasma treatment.
89380223|NCT03716141|Active Comparator|Conventional Saline dressing|In this group we will be managing diabetic wounds with normal saline dressing.
89380224|NCT02366520|No Intervention|control visit|The child receives dental treatment without the handheld mirror. The child cannot see the dental treatments that are conducted in his or her mouth.
89380225|NCT02366520|Experimental|intervention visit|The child receives dental treatment with handheld mirror. The child may see the dental treatments that are conducted in his or her mouth by the handheld mirror.
89380226|NCT05186454|Active Comparator|Morphine|Patients will receive 10-12.5 mg bupivacaine and 1 ml containing 200 µg of morphine intrathecally.
89380227|NCT05186454|Active Comparator|Multimodal|Patients will receive 10-12.5 mg bupivacaine and 1 ml containing 2 mg dexamethasone, 50 µg morphine, and 500 µg midazolam intrathecally
89380228|NCT05177640|Experimental|99mTC-duramycin|single dose of 99mTc-duramycin in healthy volunteers who will undergo SPECT-CT scanning at different time points
88853475|NCT01972308|Experimental|Patient advocate|Subject works with a Patient Advocate who coaches, models, and assists with preparations for a visit with the asthma doctor; attends the visit with permission of participant and provider; and confirms understanding. The PA facilitates scheduling, obtaining insurance coverage, overcoming patients' unique social and administrative barriers to carrying out medical advice, and transfer of information between providers and patients.
88853476|NCT01972308|Other|usual care|Patient receives asthma care as usual from their asthma provider
88853477|NCT01946880|Experimental|Mycophenolate Mofetil Withdrawal|These subjects will taper off MMF per the protocol-specified schedule over 12 weeks and remain off MMF for the rest of their study participation (up to Week 60 or until the primary endpoint of disease reactivation is met, whichever comes first).
89182981|NCT05909904|Experimental|Tislelizumab + BGB-A425 + LBL-007|Tislelizumab 200 mg administered once every 3 weeks with BGB-A425 and LBL-007
89380229|NCT02113878|Experimental|BKM120|"Participants will be enrolled in cohorts of 3- 6 per dose level. Once the MTD is reached, an additional 10 patients will be treated at that dose level and an amendment will be submitted to declare the dose.~BKM120 will start 2 weeks prior to first dose of cisplatin and radiation start. During the study, BKM120 will be administered orally daily for 45 days. Starting dose 40 mg.~Cisplatin: Starting Dose 30 mg/m2, given IV, weekly on days: (1, 8, 15, 22, 29, 36 and 43).~Radiotherapy: All participants will receive daily radiotherapy with intensity-modulated radiotherapy (IMRT) for 7 weeks."
89380230|NCT03695484||Manual guided RF ablation|Patients with paroxysmal atrial fibrillation treated with Manual guided RF ablation using Contact Force catheters
88853478|NCT01946880|Active Comparator|Mycophenolate Mofetil Maintenance|These subjects will continue MMF treatment (1000-3000 mg/day) for the rest of their study participation (up to Week 60).
88853479|NCT01972152|Experimental|G-Pen(TM) 1 mg|G-Pen(TM) (glucagon injection), single 1 mg subcutaneous (SC) injection
88853480|NCT01972152|Experimental|G-Pen(TM) 0.5 mg|G-Pen(TM) (glucagon injection), single 0.5 mg SC injection
88853481|NCT01972152|Active Comparator|Lilly Glucagon(TM) 1 mg|Lilly Glucagon(TM) [glucagon for injection (rDNA origin)], single 1 mg SC injection
88853482|NCT01972074|Experimental|Memantine|"Participants in the placebo arm will receive placebo (no active ingredients) in capsule form twice daily. It will be administered twice daily for 12 weeks. Participants will undergo neuroimaging before and after the 12-week treatment phase.~Placebo: Capsule"
88853483|NCT01972074|Placebo Comparator|Placebo|"Participants in the memantine arm will receive memantine in capsule form twice daily. It will be administered twice daily for 12 weeks (including a 4-week titration phase to a maximum dose of 20 mg per day). Participants will undergo neuroimaging before and after the 12-week treatment phase.~Memantine: Capsule"
89182982|NCT05909644|Experimental|Omaveloxolone only (Period 1), Then Omaveloxolone and efavirenz (Period 2)|Period 1 (Day 1 - 15): Omaveloxolone Capsules, 150 mg, administered orally in a single dose on Day 1 Period 2 (Day 15 - 43): Efavirenz Tablet, 600 mg, administered orally once daily from Day 15 - Day 42 and Omaveloxolone Capsules, 150 mg, administered orally in a single dose on Day 29
89380231|NCT03695484||Cryoballoon ablation|Patients with paroxysmal atrial fibrillation treated with Cryoballoon ablation. Cryoballoon: Arctic Front Advance, Medtronic - 28 mm
89380232|NCT03695484||RMN guided RF ablation - High power|"Patients with paroxysmal atrial fibrillation treated with Remote Magnetic Navigation guided RF ablation with e-Contact and high power settings.~High power ablation settings: a minimum of 40 Watt, 43grC, flow 17ml/min. Higher voltages (e.g. anterior wall) are allowed with respect to the operators' preference."
89380233|NCT03695484||RMN guided RF ablation - Low power|"Patients with paroxysmal atrial fibrillation treated with Remote Magnetic Navigation guided RF ablation with e-Contact and low power settings.~Low power ablation settings: a maximum of 39 Watt, 43grC, flow 17ml/min. Lower voltages are allowed with respect to the operators' preference."
89380234|NCT05162898|Experimental|GROUP 1|
89380235|NCT03628872|Active Comparator|Scaling and Root Planing with Hand Instruments|Patients will undergo scaling and root planing with hand instruments (half of their mouth, following a split-mouth design)
89380236|NCT03628872|Experimental|Er:YAG Laser Scaling|Patients will undergo scaling and root planing with Er:YAG Laser in the untreated half of their mouth.
89182983|NCT05903105||Overactive Bladder|Adult patients with overactive bladder
89182984|NCT05901922|Experimental|intervention group|Social skills training will be applied to this group. social skills training will be applied for 10 sessions. Sessions will be 2 sessions per week. Session duration will be 1 hour.
89380237|NCT05113290|Experimental|H101+Sorafenib|H101 combined with Sorafenib
89380238|NCT05113290|Active Comparator|Sorafenib|Patients take Sorafenib only
89380239|NCT03628794|Other|Intervention|Subjects in the intervention group will receive the D-SCAN mobile application
88853484|NCT01972074|No Intervention|Control Group|Healthy controls will undergo neuroimaging twice (12 weeks apart) and will receive no intervention during the 12-week window.
88853485|NCT01970982|Experimental|Tobacco Heating System (THS 2.2)|Ad libitum use of THS 2.2 for 5 days in confinement
88853486|NCT01970982|Sham Comparator|Smoking abstinence (SA)|Abstinence from smoking for 5 days in confinement
88853487|NCT01970982|Active Comparator|Conventional cigarette (CC)|Ad libitum use of Subject's own preferred brand of CC for 5 days in confinement
88853488|NCT01946802||Frontal 4 channel EEG|Consecutive comatose patients admitted to the emergency ICU for postresuscitation care following successful cardiopulmonary resuscitation after nontraumatic out-of-hospital and in-hospital cardiac arrest.
88853489|NCT01618266||Ozurdex® (dexamethasone intravitreal implant)|dexamethasone intravitreal implant 700 μg administered into the eye according to physician judgment.
89182985|NCT05901922|No Intervention|control group|No intervention.
89182986|NCT05895552|Experimental|Part 1 RTA 901 Dose 1|Subjects will receive study drug once daily during the 2-week Run-in Period. Following randomization, the subjects will receive a dose of RTA 901 once daily for a 12-week treatment duration.
89380240|NCT03628794|Other|Control|Subjects randomized into the control group will receive standard of care which includes the routine provision of information about supportive care services by nurses and other staff in the DCI clinics, as part of the standard nurse-driven distress screening and management process
89380241|NCT03461952|Experimental|Nivolumab|240mg Q2W
89380242|NCT03461952|Experimental|Nivolumab + Ipilimumab|Nivolumab 240mg Q2Wk + Ipilimumab 1mg/kg Q6W
88853490|NCT01919112|Experimental|High dose anodal tDCS|High dose tDCS (2 milliamps twice daily) for 5 days will be administered concomitantly with swallowing exercises
89380243|NCT03423173|Placebo Comparator|Placebo|TDV placebo matching injection, subcutaneously (SC) once on Day 1, and Day 90.
89380244|NCT03423173|Experimental|TDV Lot 1|Participants were administered TDV lot 1, 0.5 ml (each TDV 0.5 mL dose contained TDV-1, TDV-2, TDV-3, and TDV-4), SC injection, once on Day 1, and Day 90.
89380245|NCT03423173|Experimental|TDV Lot 2|Participants were administered TDV lot 2, 0.5 ml (each TDV 0.5 mL dose contained TDV-1, TDV-2, TDV-3, and TDV-4), SC injection, once on Day 1, and Day 90.
89380246|NCT03423173|Experimental|TDV Lot 3|Participants were administered TDV lot 3, 0.5 ml (each TDV 0.5 mL dose contained TDV-1, TDV-2, TDV-3, and TDV-4), SC injection once on Day 1, and Day 90.
89380247|NCT03348228|Placebo Comparator|Control Group|Participants willrecord a self-selected diet for 3 days and then perform two 24-hour urine collections on the last 2 days of this diet. HCA will be administered afterwards to both groups (see methods below) for 7 days
89380248|NCT03348228|Active Comparator|Calcium Stone Formers|Participants willrecord a self-selected diet for 3 days and then perform two 24-hour urine collections on the last 2 days of this diet. HCA will be administered afterwards to both groups (see methods below) for 7 days
89182987|NCT05895552|Experimental|Part 1 RTA 901 Dose 2|Subjects will receive study drug once daily during the 2-week Run-in Period. Following randomization, the subjects will receive a dose of RTA 901 once daily for a 12-week treatment duration.
88853491|NCT01919112|Active Comparator|Low dose anodal tDCS|This arm will use a low dose of current administered via tDCS (2 milliamps once daily) for 5 days will be administered concomitantly with swallowing exercises
88853492|NCT01919112|Sham Comparator|Sham Stimulation|Twice daily swallowing exercises only
88853493|NCT01918332|Experimental|Valsartan 160mg, Rosuvastatin 20mg|Both Valsartan 160mg and Rosuvastatin 20mg are administered daily by mouth once a day for 8 weeks.
89182988|NCT05895552|Placebo Comparator|Part 1 Placebo|Subjects will receive study drug once daily during the 2-week Run-in Period. Following randomization, the subjects will receive a dose of Placebo once daily for a 12-week treatment duration.
89182989|NCT05895552|Experimental|Part 2 RTA 901 Dose 1|Subjects will receive study drug once daily during the 2-week Run-in Period. Following randomization, the subjects will receive a dose of RTA 901 once daily for a 12-week treatment duration.
89182990|NCT05895552|Experimental|Part 2 RTA 901 Dose 2|Subjects will receive study drug once daily during the 2-week Run-in Period. Following randomization, the subjects will receive a dose of RTA 901 once daily for a 12-week treatment duration.
89380249|NCT05062746|Experimental|MRT group|One session Matrix-Rhythm Therapy
89380250|NCT05062746|Other|Control group|One session routine, conventional physiotherapy and rehabilitation
89380251|NCT03192540|Experimental|Exercise|These are participants who will be undergoing exercise intervention.
88853494|NCT01918332|Active Comparator|Valsartan 160mg, Rosuvastatin 20mg placebo|Intervention : Drug : Both Valsartan 160mg and Rosuvastatin 20mg placebo are administered daily by p.o. once a day for 8 weeks.
88853495|NCT01918332|Active Comparator|Valsartan 160mg placebo, Rosuvastatin 20mg|Intervention : Drug : Both Valsartan 160mg placebo and Rosuvastatin 20mg are administered daily by p.o. once a day for 8 weeks.
88853496|NCT01918332|Placebo Comparator|Placebo|Intervention : Drug : Both Valsartan 160mg placebo and Rosuvastatin 20mg placebo are administered daily by p.o. once a day for 8 weeks.
89380252|NCT03619824|Experimental|Intervention arm|Patients will receive induction chemotherapy with gemcitabine (1g/m2, d1 & 8 of every cycle) and cisplatin (80mg/m2, d1 of every cycle), every 3 weeks for 3 cycles before radiation. Definitive intensity-modulated radiotherapy (IMRT) of 66-70Gy will be given in six to seven weeks. Concurrent cisplatin 100mg/m2 will be administered every 3 weeks for 2 cycles during IMRT. Sintilimab 200mg will be given every 3 weeks for 6 cycles, started on day 1 of induction chemotherapy.
88853497|NCT04628832|Experimental|PMP Use Mandate|
88853498|NCT04628832|Experimental|Prescribing Information|
88853499|NCT04628832|Experimental|Prescribing Information + PMP Use Mandate|
88853500|NCT04628832|No Intervention|Control / As-Usual|
88853501|NCT01922934|Experimental|Intervention|"350 randomly-selected patients at 4 clinics get a toolbox of weight loss options, including self-monitoring tools; education materials; recreation center passes; commercial weight loss program (Weight Watchers); intensive group counseling (Colorado Weigh); meal replacements; and obesity pharmacotherapy. The initial assessment, a computer program, takes diet and exercise history and helps patients choose personal treatment goals. Interested patients get a starter kit with self-monitoring tools and meal replacements. Subjects must show self-monitoring of diet and exercise to get more intensive therapies. Patients pay a $5-$10 co-pay for the therapies. They select a primary intensive therapy, but are able to add/change depending on results, adherence and budget availability."
88853502|NCT01922934|No Intervention|Control|Registry patients not selected to be offered the toolbox will receive usual care for weight management. Usual care for obesity at DH includes brief weight loss advice provided by PCPs or prescribing of weight loss medication, for which patients pay out of pocket.
88853503|NCT01970592|Experimental|POWER|Individuals with chronic post-stroke hemiparesis will undergo training to improve muscle power generation for 24 sessions (3 times/week) that includes both resistive and task-specific elements. Session duration will be ~90 minutes/day (inclusive of rest intervals). Training will include five distinct resistance activities aimed at improving muscle power-- each previously reported to contribute to improved walking.
88853504|NCT01921140|Other|Fasted|Olaparib tablets following no breakfast
89182991|NCT05895552|Placebo Comparator|Part 2 Placebo|Subjects will receive study drug once daily during the 2-week Run-in Period. Following randomization, the subjects will receive a dose of Placebo once daily for a 12-week treatment duration.
88853505|NCT01921140|Other|High-fat meal|Olaparib tablets after high-fat breakfast
89380253|NCT01759836|Experimental|Atorvastatin 20mg|Atorvastatin 20mg daily for 1 year
89380254|NCT01759836|Placebo Comparator|Placebo|Placebo daily for 1 year
89380255|NCT03447821|Active Comparator|400 mg Rifamycin SV dosage|Two enteric coated, modified release tablets, each containing 200 mg Rifamycin SV, taken three times daily. Four of the six daily tablet taken in this group were placebos.
89380256|NCT03447821|Active Comparator|800 mg Rifamycin SV dosage|Two enteric coated, modified release tablets, each containing 200 mg Rifamycin SV, taken three times daily. Two of the six daily tablet taken in this group were placebos.
89380257|NCT03447821|Active Comparator|1200 mg Rifamycin SV dosage|Two enteric coated, modified release tablets, each containing 200 mg Rifamycin SV, taken three times daily. None of the six daily tablet taken in this group were placebos.
89380258|NCT03079284|Experimental|Holding Group|After meeting inclusion criteria and consenting to participation, mothers of infants who have completed at least 24 hours of therapeutic hypothermia treatment will be allowed to hold their infant who will remain on the cooling blanket for a 30-minute period with the use of a thermal barrier. Vital signs will be measured before holding begins, during holding and following completion of holding. Temperature will be recorded every two minutes during holding. Afterwards, a Likert scale questionnaire to assess the mother's and nurse's reactions will be administered.
89380259|NCT05630339|Experimental|Intervention group|Will receive 1.2 g of magnesium chloride (equivalent to 360 mg of magnesium elemental) + 4000 IU of vitamin D once a day, for four months.
89380260|NCT05630339|Placebo Comparator|Control group.|Will receive inert placebo for four months.
89380261|NCT03447353|Experimental|"Sober or Double Placebo"|Subject receives two tablets, both containing placebo
89182992|NCT05891600||Rheumatoid arthritis patients in Colombia|
89182993|NCT05883124|Experimental|Rivastigmine twice-weekly 9,5 mg/24 h|3 consecutive applications of 1 patch (1st patch for 4 days, 2nd patch for 3 days, 3rd patch for 4 days) covering an 11-day period
89182994|NCT05883124|Active Comparator|Exelon® 9.5 mg/24 h|11 consecutive applications of 1 patch (each patch will be applied for 1 day) covering an 11-day period
89182995|NCT05864703|Experimental|Adjustment|Individuals with a subluxation who receive a true chiropractic adjustment
89182996|NCT05864703|Sham Comparator|Sham|Individuals with a subluxation who receive a light touch-only sham
89182997|NCT05861323|Experimental|Check-list Arm|This feasibility study will test an ICU team-based time and and check-list intervention, the Comfort Measures Only Time Out (CMOT). The CMOT is designed to improve ICU team communication and better address patient comfort at the end of life. Participants in the CMOT are intensive care unit clinicians who are caring for a patient who is about to undergo palliative withdrawal of mechanical ventilation at the end of life. Feasibility will be assessed by: recruitment rates, protocol adherence, and acceptability to clinicians. Patient level outcomes such as distressful episodes/person-time alive will also be collected as a component of routine care in this exploratory analysis. The maximum time any participant (ICU clinician or patient) will be participating in the study is about four hours.
89182998|NCT05855109||Patients with Rheumatoid Arthritis (RA)|RA and 2 or more risk factors for developing Interstitial Lung Disease (ILD)
89380262|NCT03447353|Experimental|Active Xanax, Active Norco|Subject receives two tablets, one containing Xanax and one containing Norco
89380263|NCT03447353|Experimental|Active Xanax, Placebo Norco|Subject receives two tablets, one containing Xanax and one containing placebo
89380264|NCT03447353|Experimental|Placebo Xanax, Active Norco|Subject receives two tablets, one containing Norco and one containing placebo
89380265|NCT03055884|Experimental|active tDCS with repeated retrieval practice|active tDCS with verbal paired-associate learning task with repeated retrieval practice
88853506|NCT01920594|Experimental|GSK1278863|Subject will receive GSK1278863 300mg on Day-1 (12 +/- 4 hours prior to planned surgery) as a loading dose followed by GSK1278863 100mg once daily for 4 days starting from Day 0.
89380266|NCT03055884|Experimental|active tDCS without repeated retrieval practice|active tDCS with verbal paired-associate learning task without repeated retrieval practice
89380267|NCT03055884|Sham Comparator|Sham tDCS with repeated retrieval practice|sham tDCS with verbal paired-associate learning task with repeated retrieval practice
88853507|NCT01920594|Placebo Comparator|Placebo|Subject will receive GSK1278863 matching placebo on Day-1 (12 +/- 4 hours prior to planned surgery) as a loading dose followed by GSK1278863 matching placebo once daily for 4 days starting from Day 0.
88853508|NCT01917084|Experimental|Passive range of motion (ROM) exercise|A 10 - 15 minute passive range of motion (ROM) exercise program will be administered daily during hospitalization for up to 21 days or until discharge (whichever comes first).
88853509|NCT01917006|Experimental|OnabotulinumtoxinA Dose 1|OnabotulinumtoxinA Dose 1 injected into specified muscle per protocol on Day 1.
88853510|NCT01917006|Experimental|OnabotulinumtoxinA Dose 2|OnabotulinumtoxinA Dose 2 injected into specified muscle per protocol on Day 1. Participants were eligible for another treatment after 12 weeks.
89182999|NCT05849207|Experimental|Open Arm|All patients will receive cyclophosphamide on Day +3 and Day +4 following transplant.
89380268|NCT03055884|Sham Comparator|Sham tDCS without repeated retrieval practice|shamtDCS with verbal paired-associate learning task without repeated retrieval practice
89380269|NCT03718169||Hong Kong female smokers|Hong Kong female smokers will be invited to fill in questionnaires about their current smoking situation and quit intention.
89380270|NCT03446885|Experimental|Lab visit 1|40 mg of Vyvanse administered q.a.m. or Placebo administered in random, counter-balanced fashion.
89380271|NCT03446885|Experimental|Lab visit 2|40 mg of Vyvanse administered q.a.m. or Placebo administered in random, counter-balanced fashion.
88853511|NCT01917006|Experimental|OnabotulinumtoxinA Dose 3|OnabotulinumtoxinA Dose 3 injected into specified muscle per protocol on Day 1.
88853512|NCT01917006|Experimental|OnabotulinumtoxinA Dose 4|OnabotulinumtoxinA Dose 4 injected into specified muscle per protocol on Day 1.
88853513|NCT01917006|Experimental|OnabotulinumtoxinA Dose 5|OnabotulinumtoxinA Dose 5 injected into specified muscle per protocol on Day 1.
88853514|NCT01917006|Experimental|OnabotulinumtoxinA Dose 6|OnabotulinumtoxinA Dose 6 injected into specified muscle per protocol on Day 1.
88853515|NCT01917006|Placebo Comparator|Placebo|Placebo (normal saline) injected into specified muscle per protocol on Day 1.
89380272|NCT03712319|Experimental|Group 1: App.|"Participants use application REM Volver a casa on their cell phones during 8 weeks. Codes are provided to the students in order to unlock the different stages of the training free of charge. The application provides short videos and audios for training. Students practice on their own, in accordance with the instruction of completing a stage a week."
89380273|NCT03712319|Active Comparator|Group 2: MBSR.|Participants attend a presence-based training during 8 weeks. The Mindfulness-Based Stress Reduction program involves a session of two and a half hours each week.
89380274|NCT03712319|No Intervention|Group 3: Waiting list.|Participants do not receive any intervention during the study. At the end of the study (16 weeks), they are provided with the codes so they can unlock the app and use it like participants from Group 1.
89380275|NCT00710970|Experimental|Single Arm Receiving 25mg Tamoxifen|
89380276|NCT03716063|Experimental|test group|The test group will oral Jianpi Huatan dispensing granule , once a day in the morning and evening, once a month for a course of treatment, a total of three courses.
89380277|NCT03716063|Placebo Comparator|control group|The control group will oral drug:low-dose control granules (containing 1/10 of the dose of the experimental group) , once a day in the morning and evening, once a month for a course of treatment, a total of three courses
89380278|NCT05209698||Ethnic groups- Jews and Arabs|Data will be extracted from electronic medical records for all people with PD residing in a specific HMO district according to a record-based survey (e.g., individuals whose medical records include a diagnosis of PD). Currently, there are 2500 patients with PD in that district. In the second part of the study, a sub-sample of 100 Jewish and 100 Arab Patients with Parkinson's disease will be asked to answer standardized questionnaires.
89380279|NCT04957524|Active Comparator|Set Amplitude|This arm is to test a specific amplitude. Participants will be instructed to set the amplitude to 20 mA, frequency to 20 Hz, and pulse duration to 5 mS. The parameters will stay the same for the entire session. This stimulation will last 15 minutes and patients will be instructed to perform the at-home therapy once per day.
89380280|NCT04957524|Experimental|Customizable Amplitude|In this arm, the participant will set the frequency to 12 Hz and pulse duration to 1 millisecond. The participant will be instructed to increase the amplitude gradually and set it at the maximal tolerable amplitude. This stimulation will last 15 minutes and patients will be instructed to perform the at-home therapy once per day.
89380281|NCT03718013|Experimental|accelerated dTMS|
89380282|NCT03718013|Active Comparator|standard dTMS|
89380283|NCT02868528|Experimental|PGS group|After blastocyst culture, blastocyst embryo trophoblast biopsy will be performed and chromosome screening with NGS technology, at the same time, the blastocysts will be frozen, then the blastocysts with normal chromosome will be thawed and transferred.
89380284|NCT02868528|No Intervention|control group|After blastocyst culture, blastocysts will be transferred
89380285|NCT04945746|Experimental|Software VX1 + Stability|Utilization of the software VX1 + Stability
89380286|NCT05209542|Active Comparator|Hysterosalpingo-Foam Ultrasonography|3-5 ml of foam contrast is to be introduced slowly into the endometrial cavity while the flow of contrast medium in each tube is evaluated using grayscale and power Doppler imaging
89399488|NCT02256254|Placebo Comparator|Placebo|2 placebo capsules every evening for 14 days
88853516|NCT04625790|Experimental|Study group|After randomization, this group will take 10 sessions of 1-Hz low frequency rTMS will be applied to the inferior frontal gyrus of the right frontal lobe for 20 minutes during the stroke treatment process before 10 days of speech therapy. Speech therapy will be given to each patient by the same therapist who is qualified in this field, and the treatment will last 10 days, 60 minutes a day.
89380287|NCT05209542|Active Comparator|laparoscopy|• Standard laparoscopic evaluation with the dye test (methylene blue staining) is to be performed 1 day after ultrasound tests with 1 day of hospitalization under general anesthesia
89380288|NCT03421379|Experimental|Glucagon Nasal Powder|A single dose of 3 milligram (mg) glucagon nasal powder administered intranasally.
89380289|NCT03421379|Active Comparator|Glucagon Hydrochloride Solution|A single dose of 1 mg glucagon hydrochloride solution was administered intramuscular (IM)
89380290|NCT03712241|Experimental|Treatment A|K-285 dose/application method A
89380291|NCT03712241|Experimental|Treatment B|K-285 dose/application method B
89380292|NCT03712241|Experimental|Treatment C|K-285 dose/application method C
89380293|NCT03712241|Active Comparator|Treatment D|Indomethacin capsule
89380294|NCT01311479|Active Comparator|Osteopathic Manipulation|"Patients will be evaluated and examined by an Osteopathic physician. This examination will consist of full osteopathic structural exam, and a focused examination of the sacroiliac joint and the surrounding musculature.~Subjects will then be treated based on the objective findings of the examination. Since the structural exam includes the whole body, other structural abnormalities will likely be identified and possible require treatment to aid in treatment of SIJ. Subjects will also be taught stretching routines in order to aid in treatment of the dysfunction."
89380295|NCT01311479|Active Comparator|Massage Therapy|Our control group will receive the same structural exam, and focused examination. Their treatment will involve massage, in an area not associated with the musculature of the SIJ. This will serve to identify a possible placebo effect, associated with simply providing a healing touch without focused treatment.
89380296|NCT05208996|Experimental|siCoV/KK46|Drug contains anti-SARS-CoV-2 siRNAs/KK-46 (peptide dendrimer) complexes for inhalation use
89380297|NCT02675946|Experimental|Arm 1: CGX1321 Single Agent dose escalation and dose expansion|"Arm 1: Dose Escalation Phase: Ascending doses of CGX1321 once daily, orally, for 3 weeks (21 days) followed by a one-week (7-day) washout period in each 28-day cycle~Dose Expansion Phase: CGX1321, at the MTD (identified in the Dose Escalation Phase), once daily, orally, for 3 weeks (21 days) followed by a one-week (7-day) washout period in each 28-day cycle."
89380298|NCT02675946|Experimental|Arm 2: CGX1321 in combination with pembrolizumab dose escalation, dose expansion and Roll-over,|"Arm 2: Roll-over Cohort: CGX1321 at a dose identified in Phase 1b, once daily, orally, for 2 weeks (14 days) followed by a one-week (7-day) washout period in combination with pembrolizumab administered IV once every three weeks (in each 21-day cycle).~Arm 2: Phase 1b: Ascending doses of CGX1321, once daily, orally, for 2 weeks (14 days) followed by a one-week (7-day) washout period in combination with pembrolizumab administered IV once every three weeks (in each 21-day cycle)."
89380299|NCT02675946|Experimental|Arm 3: CGX1321 in combination with encorafenib + cetuximab, dose escalation and dose expansion|Arm 3: Phase 1b: Ascending doses of CGX1321, once daily, orally for 3 weeks (21 days) followed by a one-week (7 day) washout period in combination with enocrafenib administered orally once daily and cetuximab administered IV once weekly
89380300|NCT02900378|Experimental|LCZ696 (Sacubitril/Valsartan)|After randomization, patients in this arm received LCZ696 (Sacubitril/Valsartan) twice daily and matching placebo of Enalapril depending on the patient's previous ACEI/ARB dose (enalapril equivalent dose) for 2 weeks. Patients could start study medication at dose level 1 (24 mg/26 mg LCZ), 2 (49 mg/51 mg LCZ) or 2a (49 mg/51 mg LCZ) or matching placebo bid. After 2 weeks (visit 3) the doses were up-titrated: patients, who started on dose level 2 or 2a received the target dose of study medication (level 3) at this point. After another 2 weeks (visit 4) all patients were to achieve the target dose of 97 mg/103 mg bid LCZ696(sacubitril/valsartan) and matching placebo, provided no safety and tolerability issues arised during uptitration.
89380301|NCT02900378|Active Comparator|Enalapril|After randomization, patients in this arm received Enalapril twice daily and matching placebo of LCZ696 (Sacubitril/Valsartan) depending on the patient's previous ACEI/ARB for 2 weeks. Patients could start study medication at dose level 1 or 2a or matching placebo bid. After 2 weeks (visit 3) the doses were up-titrated: patients, who started on dose level 2 or 2a received the target dose of study medication (level 3) at this point. After another 2 weeks (visit 4) all patients were to achieve the target dose of 10 mg bid enalapril and matching placebo, provided no safety and tolerability issues arised during uptitration
89380302|NCT03058692|Experimental|M-001 + IIV4|0.4 ml injection of M-001 (1 mg dose) intramuscularly on Day 1 and Day 22, followed by 0.5 ml injection of IIV4 (60 mcg HA) intramuscularly on Day 172 (n=60)
89380303|NCT03058692|Placebo Comparator|Placebo+ IIV4|0.4 ml injection of placebo intramuscularly on Day 1 and Day 22, followed by 0.5 ml injection of IIV4 (60 mcg HA) intramuscularly on Day 172 (n=60)
89380304|NCT03647228|Experimental|IONIS-ENaCRx|Ascending single and multiple doses of IONIS-ENaCRx inhaled or nebulized.
88853517|NCT04625790|Placebo Comparator|Control group|This group will take 10 sessions of sham rTMS for 20 minutes during the stroke treatment process before 10 days of speech therapy. The sham therapy will consist of positioning the coil on the cranium at the same spot, but without a magnetic stimulation, only with the device open and the sounds will be audible. Speech therapy will be given to each patient by the same therapist who is qualified in this field, and the treatment will last 10 days, 60 minutes a day.
88853518|NCT01916304|Experimental|Levothyroxine sodium new formulation|Levothyroxine (25-225 μg), tablets, orally, once daily for up to 12 to 20 weeks. Dose administered depends on the thyroid stimulating hormone level.
89380305|NCT03647228|Placebo Comparator|Placebo|Placebo comparator calculated volume to match active comparator inhaled or nebulized.
89380306|NCT04052594|Experimental|LY3475766 - IV|LY3475766 administered intravenously (IV) to participants with dyslipidemia
89380307|NCT04052594|Placebo Comparator|Placebo - IV|Placebo administered IV to participants with dyslipidemia
89380308|NCT04052594|Experimental|LY3475766 - SC|LY3475766 administered subcutaneously (SC) to participants with dyslipidemia
89380309|NCT04052594|Placebo Comparator|Placebo - SC|Placebo administered SC to participants with dyslipidemia
89380310|NCT03621566||Central Sleep Apnea|Subjects with an apnea/hypopnea index ≥ 15/h of sleep and proportion of non-obstructive events > 50%, derived from polysomnography (diagnostic or during positive airway pressure treatment)
89380311|NCT04052750|No Intervention|The control group|Patients in this group only received medications without daily text message reminder
89380312|NCT04052750|Experimental|The intervention group|Patients in this group received a daily short message service (SMS) reminder when medications were prescribed
89380313|NCT04379154|Experimental|Volatile Organic Compounds analysis|Volatile Organic Compounds analysis in exhaled air in patients hospitalised for COVID-19 infection
89380314|NCT04052438||Patients with recurrent abortion.|More than three idiopathic involuntary miscarriages.
89380315|NCT04052438||Patients with implantation failure.|More than three IVF abortions with good quality embryos or more than two abortions in oocyte donation cycles.
89380316|NCT03647150|Other|Moderate Acute Malnutrition (MAM)|"MAM children at control clinics or MAM children at intervention clinics that do no have high rick characteristics. Control treatment is Mother Care counselling, delivered by a respected elder in the local community."
88853519|NCT01916226|Experimental|FPNS arm|Subject will receive two sprays (200 mcg per day)of FP into each nostril once daily (OD) every morning for 14 days
88853520|NCT01916226|Placebo Comparator|FPNS Placebo arm|Subject will receive two sprays of FP placebo into each nostril OD every morning for 14 days
89380317|NCT03647150|Experimental|High Risk Moderate Acute Malnutrition (MAM)|The intervention treatment incorporates Mother Care counselling, provision of one packet (508 calories) of ready-to-use therapeutic food (RUTF) daily and a 1 week course of amoxicillin. This provision will continue until the child has reached a mid-upper arm circumference (MUAC) equal to or greater than 12.5 cm or 12 weeks have elapsed.
89380318|NCT04373226|Experimental|22q11.2DS|Children aged from 4 to 11 years old with 22q11.2 deletion syndrome
89380319|NCT04373226|Active Comparator|NON22q11.2DS|Children aged from 4 to 11 years old without developmental disease
89380320|NCT04708158|Experimental|Active|Inhaled Novaferon, given 20 ug BID, daily for 7 days
89380321|NCT04708158|Placebo Comparator|Placebo|Inhaled saline (placebo), given BID, daily for 7 days
88853521|NCT01916226|Experimental|Cetirizine arm|Subject will receive Cetirizine capsule by mouth OD in the morning for 14 days
88853522|NCT01916226|Placebo Comparator|Cetirizine Placebo arm|Subject will receive Cetirizine Placebo capsule by mouth OD in the morning for 14 days
88853523|NCT01969500|Active Comparator|Treatment as Usual|Treatment as usual includes outpatient case management, linkage to services and medication monitoring.
89380322|NCT02964338|Placebo Comparator|Placebo|Participants received placebo via an approximately 1-hour intravenous infusion and as 3 subcutaneous injections at Week 0 followed by placebo administered as single subcutaneous injections at Weeks 4 and 8.
89380323|NCT02964338|Experimental|Fremanezumab 675/225/225 mg|Participants received placebo via an approximately 1-hour intravenous infusion and fremanezumab at 675 milligrams (mg) as 3 subcutaneous injections (225 mg/1.5 milliliters [mL]) at Week 0 followed by fremanezumab at 225 mg administered as single subcutaneous injections (225 mg/1.5 mL) at Weeks 4 and 8.
89380324|NCT02964338|Experimental|Fremanezumab 900/225/225 mg|Participants received fremanezumab at 900 mg via an approximately 1-hour intravenous infusion and placebo administered as 3 subcutaneous injections at Week 0 followed by fremanezumab at 225 mg administered as single subcutaneous injections (225 mg/1.5 mL) at Weeks 4 and 8.
89380325|NCT03056352|Experimental|Metoclopramide|Metoclopramide 20mg + diphenhydramine 25mg administered intravenously over 15 minutes
89380326|NCT04360980|Active Comparator|Intervention|40 RT-PCR positive COVID-19 patients without hypoxemia administered Colchicine plus standard treatment
89399489|NCT02256332|Active Comparator|Low dose plant based ingredient|Reference food with low dose of plant based ingredient
88853524|NCT01969500|Experimental|Mobile Application|Mobile Application system designed to improve coping with psychotic symptoms, social functioning, and medication adherence.
89183002|NCT05840159|Experimental|Arm 1|100 mg of doxycycline orally administered twice daily for 3 days and 4 days of placebo to assigned female at birth (AFAB) participants >/= 16 years old with confirmed urogenital Chlamydia trachomatis (CT). N=166.
89183003|NCT05840159|Active Comparator|Arm 2|100 mg of doxycycline orally administered twice daily for 7 days to assigned female at birth (AFAB) participants >/= 16 years old with confirmed urogenital Chlamydia trachomatis (CT). N=166.
88853527|NCT01915914|Experimental|fluticasone propionate|To evaluate an intermittent dosing regimen of fluticasone propionate 0.05% cream (twice per week) in reducing the risk of relapse when added to regular daily moisturization using PHYSIOGEL Lotion in paediatric subjects with stabilized atopic dermatitis
88853528|NCT01915914|Active Comparator|physiogel|To compare the efficacy and safety of fluticasone propionate 0.05% cream (twice per week) added to regular daily moisturization using Physiogel Lotion with Physiogel Lotion alone in paediatric subjects with stabilized atopic dermatitis
88853529|NCT01919970|Experimental|Cognitive Behavioral Therapy Condition|This arm is the experimental condition; it consists of 12 weekly CBT sessions. The therapy protocol will begin with an introductory education session which will include development of a fear hierarchy, followed by 11 sessions of in vivo exposures to feared triggers.
88853530|NCT01919970|Active Comparator|Treatment as Usual|This arm acts as the comparison condition. Participants randomized to this arm will be instructed to continue receiving their prior interventions as recommended by their providers (e.g., psychotherapy, social skills training, behavioral interventions, family participation in family therapy or a parenting class, or pharmacological interventions). Treatment changes (e.g., medication increase, starting psychotherapy in the community) are not prohibited and will be monitored. Thus, treatment will continue as it would in standard practice; and will be monitored through periodic study assessment.
88853531|NCT01919814|Active Comparator|Appethyl™, then Placebo|Participants receive Appethyl™ liquid once four hours after breakfast. After a washout period of at least one week, they received the placebo drink once four hours after breakfast.
88853532|NCT01919814|Placebo Comparator|Placebo, then Appethyl™|Participants receive the placebo drink once four hours after breakfast. After a washout period of at least one week, they received Appethyl™ liquid once four hours after breakfast.
88853533|NCT01968954|Experimental|Bococizumab (PF-04950615;RN316)|
88853534|NCT01968954|Placebo Comparator|Placebo|
88853535|NCT01919190|Active Comparator|EXPAREL|EXPAREL (266mg/20 ml) with 40 mL of 0.9% normal saline for a total volume of 60 mL, 30 mL to be administered to the right TAP and 30 mL to be administered to the left TAP
88853536|NCT01919190|Sham Comparator|Placebo|The placebo control will be established using a grade-2 sham, no infiltration will occur
88853537|NCT01620060|Experimental|Lurasidone oral tablets|Lurasidone 20, 40, 80, 120 or 160 mg/day
88853538|NCT04615182|Experimental|OCS Preservation|
88853539|NCT01914666|Experimental|Duloxetine|Duloxetine 20 milligram (mg) for first week, 40 mg for second week and 60 mg for next 48 weeks administered orally once daily. Tapering week doses of 40 mg for first week and 20 mg for second week.
88853540|NCT01913340|Active Comparator|Erythropoietin|1000 U/kg/dose x 5 doses
88853541|NCT01913340|Placebo Comparator|Normal saline|
88853542|NCT01864200|Experimental|CroFab|crotalidae polyvalent immune fab (ovine) per approved labeling
88853543|NCT01864200|Placebo Comparator|Saline placebo|Saline placebo
88853544|NCT01912872|Experimental|Omalizumab + budesonide and formoterol|Participants will receive Omalizumab every 2 or 4 weeks depending on IgE level and body weight and will also receive budesonide and formoterol according to maximum daily dose.
88853545|NCT01912872|Active Comparator|Budesonide and formoterol|Participants will receive budesonide and formoterol according to maximum daily dose.
88853546|NCT01912404|Experimental|IDN-6556|IDN-6556 capsules, 25 mg BID
88853547|NCT01912404|Placebo Comparator|Placebo|Placebo capsules BID
88853548|NCT01911780|Experimental|telmisartan + HCTZ + amlodipine|telmisartan 80 mg + hydrochlorothiazide (HCTZ) 12.5 mg fixed dose combination (FDC) and amlodipine 5 mg capsule (after the 8-week double-blind period, patients will continue the 52-week open label extension period taking 1 telmisartan 80 mg and hydrochlorothiazide 12.5 FDC tablet and 1 amlodipine 5 mg tablet)
88853549|NCT01911780|Active Comparator|telmisartan + HCTZ + placebo|telmisartan 80 mg + HCTZ FDC tablet and placebo matching amlodipine 5 mg capsule (after the 8-week double-blind period, patients will continue the 52-week open label extension period taking 1 telmisartan 80 mg and hydrochlorothiazide 12.5 FDC tablet and 1 amlodipine 5 mg tablet)
88853550|NCT01911546|Experimental|everolimus + low-dose tacrolimus|Patients receiving everolimus will be on low dose tacrolimus.
88853551|NCT01910298|Active Comparator|Breast Reconstruction, Direct to Implant (DTI) with Strattice™|Participants underwent immediate post-mastectomy breast reconstruction with a breast implant and Strattice™ reconstructive tissue matrix (surgical mesh).
88853552|NCT01910298|Active Comparator|Two Stage Breast Reconstruction|Participants underwent immediate, two-stage post-mastectomy breast reconstruction without reinforcement. Initial placement of a tissue expander that was inflated for approximately one to six months, and then replaced with an implant.
88853553|NCT01909674|Experimental|Oronasal Mask|Initial administration of oronasal CPAP mask
88853554|NCT01909674|Experimental|Nasal Mask|Initial administration of nasal CPAP mask
88853555|NCT05114694|Experimental|early APM|Early APM group were patients have knee syndrome within 3 to 6 months
88853556|NCT05114694|Placebo Comparator|delayed APM|delayed APM group recruit participants who received delayed APM surgery within 6 to 12 months
88853557|NCT01908816|Experimental|ranibizumab|0.5 mg ranibizumab applied in an individualized regimen as IVT injection of 0.05 mL.
89399490|NCT02256332|Active Comparator|High dose plant based ingredient|Reference food with high dose of plant based ingredient
89380327|NCT04360980|No Intervention|Standard treatment|40 RT-PCR positive COVID-19 patients without hypoxemia receiving vitamin C 3grams daily , 400 mg Tiamine, Selenium , Omega-3 500 mg daily, Vit A , Vit D, Azithromycine, Ceftriaxone, Kaletra 400 BID 10 days
89380328|NCT03645278|Experimental|SHR0532|Up to 5 cohorts of healthy subjects will receive a single dose of oral SHR0532 tablet.
89380329|NCT03645278|Experimental|Placebo|Up to 5 cohorts of healthy subjects will receive a single dose of oral placebo.
89380330|NCT03647072|Active Comparator|CHOP|CHOP only
89380331|NCT03647072|Active Comparator|CHOP Plus Lanzoprazole|CHOP Plus Lanzoprazole 60 mg
89380332|NCT03647072|Active Comparator|CHOP Plus Famotidine|CHOP Plus Famotidine 40 mg
89380333|NCT05284136|Experimental|Crohn's disease exclusion diet (CDED)|16-week course of Crohn's disease exclusion diet (CDED) and Partial Enteral Nutrition.
89380334|NCT05284136|Active Comparator|Steroids|oral prednisolone at an initial dose of 40 to 60 mg/day.
89380335|NCT03646916|Active Comparator|Dexamethasone|
89380336|NCT03646916|No Intervention|Non-treatment|
89380337|NCT04305756|Experimental|Weight-based LMWH|"Participants will receive a weight-based dose of prophylactic enoxaparin.~- For all BMI groups: 0.5mg/kg rounded to the nearest 10mg will be injected subcutaneously every 12 hours"
89380338|NCT04305756|Active Comparator|Fixed LMWH|"Participants will receive a fixed dose of prophylactic enoxaparin.~For BMI <40: 40mg injected subcutaneously every 24 hours~For BMI > or = to 40: 40mg injected subcutaneously every 12 hours"
89380339|NCT02898662|Experimental|AZD1419|Dose adaption of AZD1419, 4 mg or 8 mg or 1 mg based on occurence of AE's
89380340|NCT02898662|Placebo Comparator|Placebo|Matching placebo
89380341|NCT04437810|Experimental|Albumin+ SMT|Patients in the Albumin Arm will receive Human Albumin 20% 1.5g/kg body weight (Maximum 100g) within 6 hours from the time of diagnosis over a period of 12 hours, followed by 1g/kg bodyweight (Maximum 100g) over a period of 12 hours after 48 hours of diagnosis.(D3) along with standard medical therapy
89380342|NCT04437810|Placebo Comparator|Placebo+SMT|- Patients in placebo arm will receive similar volume of isotonic fluid (saline) over same duration of time along with standard medical therapy
89380343|NCT04368156|No Intervention|Control|
88853558|NCT01908582|Experimental|Evacetrapib|"Period 1:~130 milligram (mg) evacetrapib administered orally, once on Day 1"
88853559|NCT01908582|Experimental|Evacetrapib + Rifampin|"Period 2:~Rifampin: 600 mg administered orally, once daily (QD) for 14 days (Days 9 to 22)~Evacetrapib: 130 mg administered orally once on Day 16"
88853560|NCT01908426|Experimental|Cabozantinib (XL184)|Cabozantinib (XL184) 60 mg tablet once daily
88853561|NCT01908426|Placebo Comparator|Placebo|Oral cabozantinib-matched placebo tablet once daily
89380344|NCT04368156|Experimental|Gammacore treatment|
89380345|NCT04354272||Questionnaire|
89380346|NCT03645980|Experimental|DKN-01 300 mg|Phase I Study treatment will be started as monotherapy with DKN-01 for up to 8 weeks or until unacceptable toxicity occurs. The study will be continued as combination therapy of DKN-01 and sorafenib until objective disease progression (PD) or unacceptable toxicity occurs. The dose of DKN-01 for cohort 1 will be 300 mg , depending on the results of the safety assessment. Phase II The dose of DKN-01 will be the recommended phase II dose (RP2D) determined from Part A. Study treatment will be started as monotherapy with DKN-01 until objective disease progression (PD1) or unacceptable toxicity occurs. After PD1, study treatment will be continued as combination therapy of DKN-01 and sorafenib until disease progression (PD2) or unacceptable toxicity occurs.
89380347|NCT03645980|Experimental|DKN-01 600 mg|Phase I Study treatment will be started as monotherapy with DKN-01 for up to 8 weeks or until unacceptable toxicity occurs. The study will be continued as combination therapy of DKN-01 and sorafenib until objective disease progression (PD) or unacceptable toxicity occurs. The dose of DKN-01 for cohort 2 will be 600 mg or 150 mg, depending on the results of the safety assessment. Phase II The dose of DKN-01 will be the recommended phase II dose (RP2D) determined from Part A. Study treatment will be started as monotherapy with DKN-01 until objective disease progression (PD1) or unacceptable toxicity occurs. After PD1, study treatment will be continued as combination therapy of DKN-01 and sorafenib until disease progression (PD2) or unacceptable toxicity occurs.
89380348|NCT04315038||All patients|Spinal anesthesia
88853562|NCT01907100|Placebo Comparator|Placebo + pemetrexed/cisplatin|Placebo controlled arm
88853563|NCT01907100|Experimental|Nintedanib 200mg + pemetrexed/cisplatin|Experimental arm
88853564|NCT01889862|Active Comparator|BMN165 20mg/day|BMN165 20mg/day self-administered daily
88853565|NCT01889862|Placebo Comparator|20 mg/day Placebo|20 mg/day Placebo self-administered daily
89380349|NCT03645200|Experimental|Fluzoparib combined with Apatinib|"Fluzoparib in the initial dose of 40mg.bid started into the group of participants, group A combined with a fixed dose of Apatinib 250mg.qd for treatment, followed by the 40mg.bid, 60mg.bid, 80mg.bid, 100mg.bid dose increase.~Fluzoparib in the initial dose of 40mg.bid started into the group of participants, Group B was treated with a fixed dose of Apatinib 500mg.qd, followed by an increase in doses of 40mg.bid, 60mg.bid, 80mg.bid, 100mg.bid ."
89399491|NCT02256332|Placebo Comparator|Reference food format|Reference food without plant-based ingredient
89399492|NCT03689361|Other|with migraine aura.|patient with migraine aura detected by MRI, then MRI control 3 month after
88853566|NCT01889862|Active Comparator|BMN165 40mg/day|BMN165 40mg/day self-administered daily
88853567|NCT01889862|Placebo Comparator|40 mg/day Placebo|40 mg/day Placebo self-administered daily
88853568|NCT01887912|Experimental|C. difficile Vaccine Group|Participants received 1 injection of 0.5 mL C. difficile toxoid vaccine at Days 0 (Injection 1), 7 (Injection 2), and 30 (Injection 3).
89380350|NCT03645902||Acute stroke patients|MRI examinations will be performed on a 3 T GE MR750 W scanner. Two readers, an experienced neuroradiologist (8 years of experience in neuroradiology) and a junior radiologist (3 years of experience in general radiology) will independently analyze eSWAN and TOF images in random order, looking for arterial occlusions. Analysis will be based on a 2-point-scale: arterial occlusion, based on a local signal loss, or acceptable permeability.
89380351|NCT04844567|Experimental|COVVR_A|Participants in the COVVR_A arm complete the synchronous block first, followed by the asynchronous block.
88853569|NCT01887912|Placebo Comparator|Placebo Group|Participants received 1 injection of 0.5 mL placebo matched to vaccine at Days 0 (Injection 1), 7 (Injection 2), and 30 (Injection 3).
89380352|NCT04844567|Experimental|COVVR_B|Participants in the COVVR_B arm complete the asynchronous block first, followed by the synchronous block.
89380353|NCT03055338|Experimental|MK-8189|Participants receive MK-8189 (4 mg controlled release [CR] oral tablet[s]) in combination with placebo matching risperidone (oral capsule[s]) once daily (QD) for 4 weeks. Over the initial 7 treatment days, MK-8189 is titrated from 4 mg to 12 mg as follows: 4 mg (1 tablet; Day 1); 8 mg (2 tablets; Day 4); and 12 mg (3 tablets; Day 7). Placebo matching risperidone is also titrated as follows: 1 capsule (Day 1), 2 capsules (Day 4), and 3 capsules (Day 7). After Day 7, MK-8189 is maintained at 12 mg (3 tablets) in combination with placebo matching risperidone (3 capsules), QD for 3 weeks.
89380354|NCT03055338|Active Comparator|Risperidone|Participants receive risperidone (2 mg oral capsule[s]) in combination with placebo matching MK-8189 (oral tablet[s]), QD for 4 weeks. Over the initial 7 treatment days, risperidone is titrated from 2 mg to 6 mg as follows: 2 mg (1 capsule; Day 1); 4 mg (2 capsules; Day 4); and 6 mg (3 capsules; Day 7). Placebo matching MK-8189 is also titrated as follows: 1 tablet (Day 1), 2 tablets (Day 4), and 3 tablets (Day 7). After Day 7, risperidone is maintained at 6 mg (3 capsules) in combination with placebo matching MK-8189 (3 tablets), QD for 3 weeks.
89380355|NCT03055338|Placebo Comparator|Placebo|Participants receive both placebo matching MK-8189 (oral tablet[s]) as well as placebo matching Risperidone (oral capsule[s]), QD for 4 weeks. Over the initial 7 treatment days, placebo matching both MK-8189 and risperidone are respectively titrated as follows: 1 tablet/1 capsule (Day 1); 2 tablets/2 capsules (Day 4); and 3 tablets/3 capsules (Day 7). After Day 7, placebo matching both MK-8189 and risperidone are respectively maintained at 3 tablets/3 capsules, QD for 3 weeks.
89380356|NCT03913130|Experimental|Drug QR-110|First treated eye: maintenance dose every 6 months, intravitreal administration Contralateral eye: loading dose followed by maintenance dose, every 6 months, intravitreal administration
88853570|NCT04415346|Experimental|HU-014 Inj(Phase 1|HU-014 Inj was given an injection to 5 Upper limb muscle(Total 360U/, IM)
88853571|NCT01887678|Experimental|Traumeel® / Zeel® Injectable Solution|Injection volume is 4.2 mL for active study medication (2.0 mL Zeel plus 2.2 mL Traumeel in one intra articular (IA) injection) on treatment days 1, 8 and 15.
88853572|NCT01887678|Placebo Comparator|Placebo injectable solution|Injection volume of placebo is 4.2 mL as well (taken from the 10.0 mL vial by unblinded staff member, rest to be kept for drug accountability)
89380357|NCT03717857||Caregiver InDepth Interviews|Caregivers who have a child between the ages of 11-13, who attends 6th-8th grades in one the targeted schools, and who resides in one of the targeted public school districts identified by zip code. In RI , caregivers will identity as Latino . Caregivers will participate in a one time in-depth qualitative interview regarding their child's sleep.
89380358|NCT03717857||Focus Groups|"Three focus groups with middle school students [N = 5], caregivers [N =5], and school staff [N = 5] will be conducted to inform the development of the intervention.~Criteria for caregiver and middle school student selection is similar to the in-depth interviews and the pilot clinical trial. Inclusion criteria specify that participants must 1) be between the ages of 11-13 , 2) be in 6th-8th grades, or have a child that meets that criteria 3) reside in one of the targeted public school districts identified by zip code, 4) attend one of the schools within these districts.In RI, caregivers will have to identify as Latino.~The school staff focus group will include school personnel from the targeted schools."
89380359|NCT03645746|Experimental|Cohort 1|Cohort 1 will receive a single IV dose of REGN5069 or matching placebo
89380360|NCT03645746|Experimental|Cohort 2|Cohort 2 will receive a single sequential ascending IV dose of REGN5069 or matching placebo
88875356|NCT02592486|Active Comparator|Simultaneous administration group|The subjects receive injections of pneumococcal vaccine and influenza vaccine simultaneously. We use commercially available PPV23 (Pneumovax NP®, MSDKK, Tokyo, Japan) containing 25 μg each of 23 capsular polysaccharide types. We use Fluvic HA syringe® (Handai Biken Ltd, Osaka, Japan), quadrivalent influenza vaccine (0.5ml) of 2015/2016 season.
89183004|NCT05840159|Experimental|Arm 3|100 mg of doxycycline orally administered twice daily for 3 and 4 days of placebo days to assigned male at birth (AMAB) participants >/= 16 years old with confirmed rectal Chlamydia trachomatis (CT). N=166.
89380361|NCT03645746|Experimental|Cohort 3|Cohort 3 will receive a single sequential ascending IV dose of REGN5069 or matching placebo
89380362|NCT03645746|Experimental|Cohort 4|Cohort 4 will receive a single sequential ascending IV dose of REGN5069 or matching placebo
89380363|NCT03645746|Experimental|Cohort 5|Cohort 5 will receive a single SC dose of REGN5069 or matching placebo
89380364|NCT03645746|Experimental|Cohort 6|Cohort 6 will receive a single sequential ascending SC dose of REGN5069 or matching placebo
89380365|NCT03645746|Experimental|Cohort 7|Cohort 7 will receive a single sequential ascending IV dose of REGN5069 or matching placebo
89380366|NCT03715907|No Intervention|Control: W34|Members receiving the Control intervention for the W34 (3- to 6-year-old well visit) gap will not receive a mailer.
89380367|NCT03715907|Experimental|Information only: W34|Members receiving the Information Only intervention for the W34 care gap will receive a mailer informing them of that gap, but not of financial incentives for closing the care gap.
89380368|NCT03715907|Experimental|Incentives: W34|Informational W34 mailer and incentive to close gap
89380369|NCT03715907|No Intervention|Control: LSC|Members receiving the Control intervention for the LSC (lead screening in children) gap will not receive a mailer.
89380370|NCT03715907|Experimental|Information only: LSC|Informational LSC mailer and incentive to close gap
89380371|NCT03715907|Experimental|Incentives: LSC|Members receiving the Incentives intervention for the LSC care gap will receive a mailer informing them of the gap and eligibility for a gift card if they close the gap.
88853573|NCT01887600|Experimental|Roxadustat|Participants received roxadustat according to the tiered weight-based approach, with starting doses of 70 mg given thrice weekly (TIW) to participants weighing up to 70 kg and 100 mg given TIW to participants weighing more than 70 kg. Dose-titration was performed based upon regular measurement of Hb levels until participants achieved central Hb value of ≥ 11.0 g/dL and Hb increase from baseline (BL) of ≥ 1.0 g/dL at two consecutive study visits, separated by at least 5 days. Once target Hb level was reached participants entered maintenance period during which roxadustat dosage was adjusted every 4 weeks to maintain participants Hb level within the target range of 10.0 g/dL and 12.0 g/dL. Participants received roxadustat for at least 52 weeks up to a maximum of 104 weeks.
88853574|NCT01887600|Placebo Comparator|Placebo|Participants received matching placebo according to the tiered weight-based approach, with starting doses of 70 mg given thrice weekly (TIW) to participants weighing up to 70 kg and 100 mg given TIW to participants weighing more than 70 kg. Dose-titration was performed based upon regular measurement of Hb levels until participants achieved central Hb value of ≥ 11.0 g/dL and Hb increase from baseline (BL) of ≥ 1.0 g/dL at two consecutive study visits, separated by at least 5 days. Once target Hb level was reached participants entered maintenance period during which roxadustat dosage was adjusted every 4 weeks to maintain participants Hb level within the target range of 10.0 g/dL and 12.0 g/dL. Participants received matching placebo for at least 52 weeks up to a maximum of 104 weeks.
88853575|NCT01887288|Experimental|Capecitabine with Digoxin|"Capecitabine PO daily b.i.d., no breaks, starts at day 1 of the first cycle; Digoxin: once daily, starts at day -7 of the first cycle~(1 cycle - 4 weeks)"
88853576|NCT01887210|Experimental|IMB Gaming Adherence Intervention|Combination of smart pill bottle cap with mobile gaming application tailored for those living with HIV
88853577|NCT01887210|Active Comparator|Enhanced treatment as usual|Smart pill bottle cap and mobile phone but no game
88853578|NCT03405714|Experimental|Brivaracetam|Brivaracetam will be administered to various age-based cohorts. Cohort 1: Subjects >=12 to <16 years; Cohort 2: Subjects >=6 to <12 years; Cohort 3: Subjects >=2 to <6 years; Cohort 4: Subjects 1 month to <2 years. Enrollment will be sequential by descending age beginning with Cohort 1. For each cohort, the first half will receive a 15-minute iv infusion. The Data Monitoring Committee (DMC) will then review safety and, as available, PK data to make the following recommendations: the progression of the current cohort (up to 2-minute iv bolus infusion) and progression to initiate enrollment in the preceding cohort.
88853579|NCT01885182|Experimental|Oxycodone/Naloxone|5/2.5mg, 10/5mg, 20/10mg or 40/20mg
88853580|NCT01885182|Active Comparator|Oxycodone|5mg, 10mg, 20mg or 40mg
88853581|NCT01885104|Experimental|PEG 3350|Participants will receive a 17 g dose of PEG 3350 solution concentrate in a volume of approximately 30 mL, once a day, for 14 days. Bisacodyl laxative tablets, 5.0 mg, 1 to 3 tablets in a single daily dose, will be provided for use as a rescue medication if a participant has not had a bowel movement for 72 hours after start of treatment.
88853582|NCT01885104|Placebo Comparator|Placebo|Participants will receive a 17 g dose of Placebo solution concentrate in a volume of approximately 30 mL, once a day, for 14 days. Bisacodyl laxative tablets, 5.0 mg, 1 to 3 tablets in a single daily dose, will be provided for use as a rescue medication if a participant has not had a bowel movement for 72 hours after start of treatment.
89380372|NCT03715907|No Intervention|Control: IMA|No mailer for IMA (immunizations) gap
89380373|NCT03715907|Experimental|Information only: IMA|Informational IMA mailer
89380374|NCT03715907|Experimental|Incentives: IMA|Informational IMA mailer and incentive
89380375|NCT03715907|No Intervention|Control: CDC|No mailer for CDC (clinical diabetes care) gap
89380376|NCT03715907|Experimental|Information only: CDC|Informational CDC mailer
89380377|NCT03715907|Experimental|Incentives: CDC|Informational CDC mailer and incentive
89380378|NCT03715907|No Intervention|Control: CCS|No mailer for CCS (cervical cancer screening)
89380379|NCT03715907|Experimental|Information only: CCS|Informational CCS mailer
89380380|NCT03715907|Experimental|Incentives: CCS|Informational CCS mailer and incentive
89380381|NCT03715907|No Intervention|Control: AWC|No mailer for AWC (adolescent well-care visit) gap
89380382|NCT03715907|Experimental|Information only: AWC|Informational AWC mailer
89380383|NCT03715907|Experimental|Incentives: AWC|Informational AWC mailer and incentive
89380384|NCT03628482|Active Comparator|CRF group|Patients were assigned to receive continuous radiofrequency (CRF) treatment of genicular nerves
89380385|NCT03628482|Experimental|PRF group|Patients were assigned to receive pulsed radiofrequency (CRF) treatment of genicular nerves
89380386|NCT03645668|Experimental|Experimental group|meropenem injection, 1.0g, q8h,intravenous infusion ,0.5g/0.5h+0.5g/4h
89380387|NCT03645668|Other|Control group|meropenem injection, 1.0g, q8h,continuous intravenous infusion duration ,1h
89380388|NCT03712163|Experimental|Norketotifen or Placebo (Cohort 1)|
89380389|NCT03712163|Experimental|Norketotifen or Placebo (Cohort 2)|
89380390|NCT03712163|Experimental|Norketotifen or Placebo (Cohort 3)|
89380391|NCT03712163|Experimental|Norketotifen or Placebo (Multiple Dose)|
89380392|NCT04052360|Experimental|Cenerimod / ACT-334441|
89380393|NCT04052360|Placebo Comparator|Matching Placebo|
89380394|NCT01311167|Experimental|Dexamethasone|
89380395|NCT01311167|Placebo Comparator|Placebo|
89380396|NCT05691192|Experimental|Cognitive Leisure Activities|"Participants in the intervention group will engage in cognitive leisure activities for 12 weeks and will be instructed to track their daily activity level in minutes through a daily online questionnaire. To maintain motivation and improve adherence to the study protocol, participants will also receive regular follow-up phone calls from a member of the research team every 2 weeks.~After the initial 12 weeks, the groups will be crossed over and the study will continue for another 12 weeks."
89380397|NCT05691192|No Intervention|Passive control|Participants in the passive control group will not receive information regarding the intervention and cognitive leisure activities. They will instead be instructed to carry on as usual and to expect active participation in the study in 12 weeks from the time of enrolment.
89380398|NCT03628326||right lung resection|The investigators sought to identify anatomic variations of the pulmonary arterial tree and assess their respective frequencies.
89380399|NCT03628326||left lung resection|The investigators sought to identify anatomic variations of the pulmonary arterial tree and assess their respective frequencies.
89380400|NCT03419741|Active Comparator|Active rTMS treatment|Transcranial Magnetic Stimulation Clinical Research System will be used for the active rTMS treatment. Stimulation frequency for all active subjects: 10 Hertz - Pulse train duration (on time) 5 seconds, Inter-train interval (off time) 10 seconds (15 second cycle time), Power (intensity) level 100% resting motor threshold, Total 60 trains, 15 minutes, Total pulses 3000 per day, 3000 x 5 = 15000 pulses for 5 sessions.
89380401|NCT03419741|Sham Comparator|Sham rTMS treatment|Transcranial Magnetic Stimulation Clinical Research System -sham TMS will be connected to an electrical generator on a 9 V battery and electrodes will be placed over the prefrontal cortex. The regulator is triggered by the TMS machine to allow brief, microsecond, pulses of the electrical current through to the skin on the subjects' forehead. Electrical stimulation will be triggered by the TMS machine to correspond to the sham TMS pulses.
89380402|NCT04233840|Experimental|Sequential administration of P1101 and anti-PD1|"Phase I of Study : To determine the safety, tolerability, DLT, and potential phase 2 dose of sequential administration of P1101 and anti-PD1~:Sequential administration 6 doses (450mcg) of P1101 and 3 doses of anti-PD1 (Escalating from 0.3, 0.75, 1.5, 3 mg/kg) for Phase I Study"
89380403|NCT04233840|Active Comparator|anti-PD1|Phase II Study Group I: anti-PD1 arm 3mg/kg 3 doses
89380404|NCT04233840|Active Comparator|P1101 monotherapy|Phase II Study Group II: P1101 arm 450mcg 12 doses
89380405|NCT04233840|Experimental|sequential administration of P1101 and anti-PD1|Phase II Study GroupIII:Sequential administration of 6 doses of 450mcg P1101 and followed by 3 doses of anti-PD1 dosage (base on Phase I study result)
89380406|NCT03787758|Experimental|SAGE-718|
89002657|NCT06273995|Experimental|Behavioral Activation (BA)|Behavioral activation is one such empirically supported intervention. Derived from cognitive-behavioral therapy, a well-established treatment for depression, behavioral activation uses psychoeducation and skill-building to increase an individual's engagement in valued and enjoyable activities (e.g., socializing with family and friends, exercising, participating in a hobby) in order to improve depressive symptoms
89002658|NCT06271824|Experimental|Intervention|Live, online socio-emotional group course
89380407|NCT02896400|Experimental|BNI+NRT+QL+Text|Brief Negotiated Interview (BNI) Nicotine replacement therapy (NRT) patches and gum, 6 weeks supply Referral to CT Smokers Quitline (QL) Registration in SmokefreeText (Text)
89380408|NCT02896400|Experimental|BNI+NRT+QL|Brief Negotiated Interview (BNI) Nicotine replacement therapy (NRT) patches and gum, 6 weeks supply Referral to CT Smokers Quitline (QL)
89380409|NCT02896400|Experimental|BNI+NRT+Text|Brief Negotiated Interview (BNI) Nicotine replacement therapy (NRT) patches and gum, 6 weeks supply Registration in SmokefreeText (Text)
89380410|NCT02896400|Experimental|BNI+NRT|Brief Negotiated Interview (BNI) Nicotine replacement therapy (NRT) patches and gum, 6 weeks supply
89380411|NCT02896400|Experimental|BNI+QL+Text|Brief Negotiated Interview (BNI) Referral to CT Smokers Quitline (QL) Registration in SmokefreeText (Text)
89380412|NCT02896400|Experimental|BNI+QL|Brief Negotiated Interview (BNI) Referral to CT Smokers Quitline (QL)
89380413|NCT02896400|Experimental|BNI+Text|Brief Negotiated Interview (BNI) Registration in SmokefreeText (Text)
89380414|NCT02896400|Experimental|BNI only|Brief Negotiated Interview (BNI)
89380415|NCT02896400|Experimental|NRT+QL+Text|Nicotine replacement therapy (NRT) patches and gum, 6 weeks supply Referral to CT Smokers Quitline (QL) Registration in SmokefreeText (Text)
89380416|NCT02896400|Experimental|NRT+QL|Nicotine replacement therapy (NRT) patches and gum, 6 weeks supply Referral to CT Smokers Quitline (QL)
89380417|NCT02896400|Experimental|NRT+Text|Nicotine replacement therapy (NRT) patches and gum, 6 weeks supply Registration in SmokefreeText (Text)
89380418|NCT02896400|Experimental|NRT only|Nicotine replacement therapy (NRT) patches and gum, 6 weeks supply
89380419|NCT02896400|Experimental|QL+Text|Referral to CT Smokers Quitline (QL) Registration in SmokefreeText (Text)
89380420|NCT02896400|Experimental|QL only|Referral to CT Smokers Quitline (QL)
89380421|NCT02896400|Experimental|Text only|Registration in SmokefreeText (Text)
89380422|NCT02896400|No Intervention|Control|Control arm, no intervention
89380423|NCT03405935|Experimental|B/F/TAF|B/F/TAF FDC for at least 96 weeks.
89380424|NCT03644888|Active Comparator|Control group|Cycle ergometer training program: 2 minutes warm-up at no load, 20 minutes at 60% of peak work (PW) calculated by stress-test or at 50% of PW calculated according to Luxton equation (PW = 103.217 + (30.50 X gender) + (-1.613 X age) + (0.002 X 6MWW [m kg -1 ]). The progression of the workloads is calculated according to the BORG Dyspnea and Fatigue Scale (Borg D and F < 5: 10W increase; Borg D and/or F between 5 e 6: maintain same workload; Borg D and / or > 6: 10W decrease) Patient tailored airway clearance program guided by an experienced respiratory physical therapist, which could includes active cycle of breathing technique (ACBT), forced expiratory technique (FET), ELTGOL (slow expiration with glottis open in the lateral position) and PEP techniques (positive expiratory pressure).
89380425|NCT03644888|Experimental|Experimental group|Cycle ergometer training program plus application of vibration therapy. The vibration is provided at 150Hz via 4 effectors applied bilaterally at the second or third interspaces in the parasternal region of the upper chest wall and at the seventh to ninth interspaces anterior to the midaxillary line in the lower chest wall.
89380426|NCT03644888|Sham Comparator|Sham intervention group|Cycle ergometer training program plus application of sham vibration therapy: 4 effectors on chest-wall at same position of vibration therapy, the device that produces vibration is switched on, producing the typical noise and vibration is emitted by effectors not placed on the patient but left in place on the device.
89380427|NCT03055260|Experimental|Blood flow restriction cuff|This group will receive an active cuff that partially restricts blood flow to the experimental limb.
89380428|NCT03055260|Placebo Comparator|Blood Flow restriction Cuff-Placebo|This group will wear a placebo cuff, of which will not restrict blood flow at all.
89380429|NCT03404843|Experimental|Fasudil hydrochloride|Participants will receive a 100 mL intravenous infusion (in 60 minutes) of 60 mg of fasudil hydrochloride + saline prior to measurements of vascular function and ATP release.
89380430|NCT03404843|Placebo Comparator|Saline|Participants will receive a 100 mL intravenous infusion (in 60 minutes) of saline (placebo) prior to measurements of vascular function and ATP release.
89380431|NCT05283902||Effectiveness group|There are an estimated 490,000 eligible individuals aged 60 and over statewide for the effectiveness study.
89380432|NCT05283902||Elderly group - Immunogenicity|240 participants from the Effectiveness group, with quotas distributed by sex (50% male and 50% female) and age group, will be invited to participate in biological sample collection for the immunogenicity study.
89380433|NCT05283902||Immunosupressed group|240 biorepository samples from a cohort of immunosuppressed patients with autoimmune diseases who received the fourth dose, in a study conducted by the same team of researchers.
89380434|NCT05284448|Experimental|Pentoxifylline Group|25 patients will receive pentoxifylline (Trental SR®) 400 mg three times daily with their standard therapy for 6 months.
89380435|NCT05284448|No Intervention|Control Group|25 patients will receive their standard therapy only
88853583|NCT04613232|Experimental|Apple Watch|The research intervention is continuously monitoring of heart rate and physical activity (minimum 12h/day) with a smartwatch which is connected to a smartphone.
89380436|NCT03627936|Experimental|Lorcaserin 20 mg manufactured at: Zofingen (A) + Kawashima (B)|Participants will receive a single oral dose of lorcaserin 20 milligram (mg) XR tablets manufactured at Zofingen (A) after a 10-hour overnight fast on Day 1 of treatment period 1 followed by a single oral dose of lorcaserin 20 mg XR tablet manufactured at Kawashima (B) after a 10-hour overnight fast on Day 7 of treatment period 2. A washout period of 5 days will be maintained between the 2 treatment periods.
89380437|NCT03627936|Experimental|Lorcaserin 20 mg manufactured at: Kawashima (B) + Zofingen (A)|Participants will receive a single oral dose of lorcaserin 20 mg XR tablets manufactured at Kawashima (B) after a 10-hour overnight fast on Day 1 of treatment period 1 followed by a single oral dose of lorcaserin 20 mg XR tablet manufactured at Zofingen (A) after a 10-hour overnight fast on Day 7 of treatment period 2. A washout period of 5 days will be maintained between the 2 treatment periods.
89380438|NCT03717779||HF/HFpEF|patients with heart failure with a preserved ejection fraction(HFpEF) perform LUS
89380439|NCT03717779||HF/HFrEF|patients with heart failure with a reduced ejection fraction(HFrEF) perform LUS
88853584|NCT04612374|Experimental|Phase 1: Unified Protocol, 2 week baseline|Participants in this arm will complete two weeks of baseline assessment (during which they will complete questionnaires but not start treatment) and then receive 16 sessions of the Unified Protocol (UP). The UP is an emotion-focused treatment designed to teach participants skills to help manage difficult experiences.
88853585|NCT04612374|Experimental|Phase 1: Experimental: Unified Protocol, 4 week baseline|Participants in this arm will complete four weeks of baseline assessment (during which they will complete questionnaires but not start treatment) and then receive 16 sessions of the Unified Protocol (UP). The UP is an emotion-focused treatment designed to teach participants skills to help manage difficult experiences.
88853586|NCT04612374|Experimental|Phase 2: Revised Unified Protocol, 2 week baseline|Participants in this arm will complete two weeks of baseline assessment (during which they will complete questionnaires but not start treatment) and then receive 16 sessions of the revised Unified Protocol (UP). The UP is an emotion-focused treatment designed to teach participants skills to help manage difficult experiences and will be revised based on patient feedback in Phase 1.
88853587|NCT04612374|Experimental|Phase 2: Revised Unified Protocol, 4 week baseline|Participants in this arm will complete four weeks of baseline assessment (during which they will complete questionnaires but not start treatment) and then receive 16 sessions of the revised Unified Protocol (UP). The UP is an emotion-focused treatment designed to teach participants skills to help manage difficult experiences and will be revised based on patient feedback in Phase 1.
88853588|NCT01881750|Experimental|Pivotal Response Training (PRT)|12 week program on instruction of Pivotal Response Training, consisting of group meetings and individual sessions.
89380440|NCT03646682|Experimental|caffeine group|180mg of caffeine will be given orally one jour before vitrectomy with membrane peeling
89380441|NCT03646682|Active Comparator|control group|no caffeine will be given before vitrectomy with membrane peeling, patients are drinking no coffee in general
89380442|NCT03032250|Experimental|Group I Supportive Care (Prepare to Care kit)|Caregivers watch introduction video on a DVD over 10 minutes at baseline. Caregivers receive Prepare to Care kit including 8 workbook modules and complete at least 1 module over 30-45 minutes each week. Caregivers also attend interventionist session over 10-30 minutes weekly.
89380443|NCT03032250|Experimental|Group II Control Group|Caregivers received standard of care throughout course of intervention, with option to receive study intervention at end of study
89380444|NCT03645512|Experimental|Intervention|The intervention group will attend in the 1-day Corporate Athlete Resilience (CAR) Training Program in Lake Nona.
89399493|NCT03689361|Other|without migraine aura|patient without migraine aura detected by MRI, then telephone consultation 3 month after
89380445|NCT03645512|No Intervention|Control|The control group will attend the 1-day CAR Training Program in Lake Nona after a 3-month wait list period, which will be three months after the intervention group attends the intervention.
89380446|NCT03444155|Active Comparator|Natural Panmol-B-Complex first, then synthetic Vitamin B-complex|Participants first received a Natural Vitamin B-complex, i.e., Panmol-B-Complex - B1 (2.93 mg), B2 (3.98 mg), B3 (29.85 mg), B5 (10.95 mg), B6 (3.38 mg), B7 (0.108 mg), B9 (0.69 mg), B12 (8.85 µg) daily each morning for 6 weeks. After a wash-out period of 2 weeks, they then received a synthetic Vitamin B-complex - B1 (2.93 mg), B2 (3.98 mg), B3 (29.85 mg), B5 (10.95 mg), B6 (3.38 mg), B7 (0.108 mg), B9 (0.69 mg), B12 (8.85 µg) daily each morning for 6 weeks.The study finished after the second wash-out period for another 6 weeks.
89380447|NCT03444155|Active Comparator|Synthetic Vitamin B-complex first, then Natural Panmol-B-Complex|Participants first received a Synthetic Vitamin B-complex - B1 (2.93 mg), B2 (3.98 mg), B3 (29.85 mg), B5 (10.95 mg), B6 (3.38 mg), B7 (0.108 mg), B9 (0.69 mg), B12 (8.85 µg) daily each morning for 6 weeks. After a wash-out period of 2 weeks, they then received a natural Vitamin B-complex, i.e., Panmol-B-complex - B1 (2.93 mg), B2 (3.98 mg), B3 (29.85 mg), B5 (10.95 mg), B6 (3.38 mg), B7 (0.108 mg), B9 (0.69 mg), B12 (8.85 µg) daily each morning for 6 weeks.The study finished after the second wash-out period for another 6 weeks.
89380448|NCT03644810|Active Comparator|Chronic low back pain|"Individuals with chronic low back pain. Baseline assessment of pain intensity, function, pain duration and pain catastrophizing thoughts is performed~Pain sensitivity at the back and lower leg is measured at baseline and immediately after performing the cold pressor test"
89380449|NCT03644810|Active Comparator|Healthy controls|"Healthy, pain-free individuals who are age and gender matched to the low back pain group fill out the pain catastrophizing scale~Pain sensitivity at the back and lower leg is measured at baseline and immediately after performing the cold pressor test"
89380450|NCT03715673||Cases:Active IBD patients|23 patients with active inflammatory bowel disease for whom von willlebrand antigen and activity will be done
89380451|NCT03715673||Control:Inactive IBD patients|23 patients with inactive inflammatory bowel disease; VWF antigen and activity will be done for them
89380452|NCT02962128|Experimental|High Linoleic Acid (LA) Diet|European Americans (genotypes: TT, GT & GG) and African Americans (genotypes: GT & GG) at rs173537will be randomly assigned to a high LA diet (10% energy) based on a randomized block design with 5 strata defined by race and genotype combinations.
89380453|NCT02962128|Experimental|Low Linoleic Acid (LA) Diet|European Americans (genotypes: TT, GT & GG) and African Americans (genotypes: GT & GG) at rs173537will be randomly assigned to a low LA diet (2.5% energy) based on a randomized block design with 5 strata defined by race and genotype combinations.
89380454|NCT02898116|Experimental|Ensartinib ± Durvalumab|Subjects were to receive ensartinib monotherapy during a pre-immunotherapy Run-in Period for one to two 28-day cycles, followed by combination therapy with ensartinib plus durvalumab for subjects with no DLTs during the Run-in Period.
89380455|NCT03717701|Experimental|metformin and esomeprazole|Patients will take esomeprazole single dose of 40 mg orally once a day plus single dose of metformin 1000mg orally single dose once a day
88853589|NCT01881750|Placebo Comparator|Parent Education Group (PEG)|12 week program consisting of offering/discussion information for parents. No pivotal response training provided.
88853590|NCT01906008|Experimental|Minocycline|Group 2 receives minocycline 200 mg orally for the first dose, then 100 mg orally every 12 hours for 4 months beginning at chemotherapy initiation. Completion of questionnaires at baseline, 1 time each week, at each chemo cycle, at end of treatment visit, and at 6 month follow up visit. Sensory test performed at baseline, 2 months, end of treatment visit, and at 6 month follow up visit.
88853591|NCT01906008|Placebo Comparator|Placebo|Group 1 receives a placebo 200 mg orally for the first day of chemotherapy, then 100 mg doses every 12 hours for 4 months beginning at chemotherapy initiation. Completion of questionnaires at baseline, 1 time each week, at each chemo cycle, at end of treatment visit, and at 6 month follow up visit. Sensory test performed at baseline, 2 months, end of treatment visit, and at 6 month follow up visit.
88853592|NCT01863732|Experimental|Secukinumab (AIN457) 75mg Grp1|Group 1: AIN457 75 mg plus placebo 150 mg dosed every four weeks Week 104E1 through Week 152. Starting on Week 156 (after unblinding), only AIN457 75 mg was dosed. Secukinumab in PFS for s.c. self-administration Q4W
88853593|NCT01863732|Experimental|Secukinumab (AIN457) 75 to 150mg Grp1|Group 1: AIN457 75 mg plus placebo 150 mg dosed every four weeks Week 104E1 through Week 152. Starting on Week 156 (after unblinding), was up titrated to AIN457 150 mg only. Secukinumab in PFS for s.c. self-administration Q4W
88853594|NCT01863732|Experimental|Secukinumab (AIN457) 150mg Grp2|Group 2: AIN457 150 mg plus placebo 75 mg dosed every four weeks Week 104E1 through Week 152. Starting on Week 156 (after unblinding), only AIN457 150 mg was dosed. Secukinumab in PFS for s.c. self-administration Q4W
88853595|NCT01863732|Experimental|Pbo in Core then AIN457 75mg Grp1|Participants were on Placebo (Pbo) in Core and then in extension randomized to Group 1: secukinumab (AIN457) 75 mg plus placebo 150 mg dosed every four weeks Week 104E1 through Week 152. Starting on Week 156 (after unblinding), only AIN457 75 mg was dosed.Secukinumab in PFS for s.c. self-administration Q4W
88853596|NCT01863732|Experimental|Pbo in Core then AIN457 75 to 150mg Grp1|Participants were on Placebo in Core and then in extension randomized to Group 1: secukinumab (AIN457) 75 mg plus placebo 150 mg dosed every four weeks Week 104E1 through Week 152. Starting on Week 156 (after unblinding), was up titrated to AIN457 150 mg only. Secukinumab in PFS for s.c. self-administration Q4W
88853597|NCT01863732|Experimental|Pbo in Core then AIN457 150mg Grp2|Participants were on Placebo (Pbo) in Core and then in extension randomized to Group 2: AIN457 150 mg plus placebo 75 mg dosed every four weeks Week 104E1 through Week 152. Starting on Week 156 (after unblinding), only AIN457 150 mg was dosed. Secukinumab in PFS for s.c. self-administration Q4W
88853598|NCT01905540|Experimental|SSP-004184AQ (single dose)|40 mg/kg (oral capsule form) given once on Day 1
88853599|NCT01905540|Experimental|SSP-004184SS (single dose)|21.8 mg/kg (oral capsule form) given once on Day 1
88853600|NCT01905540|Experimental|SSP-004184AQ (2 doses)|40 mg/kg (oral capsule form) given twice (12 hours apart) on Day 1
88853601|NCT01905540|Experimental|SSP-004184SS (2 doses)|21.8 mg/kg (oral capsule form) given twice (12 hours apart) on Day 1
88853602|NCT01904760|Experimental|dexmedetomidine|Dexmedetomidine(4㎍/mL) : 0.5㎍/kg/hr infusion for 1 hour before operation is completed and 0.2-0.7㎍/kg/hr infusion continuously until 6:00am the next day.
88853603|NCT01904760|Placebo Comparator|control|Drug: Normal saline 0.9% (guess as 4㎍/mL) : 0.5㎍/kg/hr infusion for 1 hour before operation is completed and 0.2-0.7㎍/kg/hr infusion continuously until 6:00am the next day.
88853604|NCT01904604|Placebo Comparator|Placebo Patch|Subjects apply placebo Viaskin® patch daily for a 52-week blinded period. Patch application duration is initially 3 hours and gradually increased to 24 hours over a 21-day graduated dosing period; subsequently patch changed every 24 hours. At Week 52, subjects complete an oral food challenge (OFC) and are unblinded. Following blinded phase, subjects who have not demonstrated sustained unresponsiveness at the Week 52 OFC crossover to active treatment (using the same 21-day graduated dosing period used in the blinded phase) and dose with a high-dose DBV712 Viaskin® patch containing 250 μg peanut protein for a total active treatment period of 30 months (130 weeks).
88853605|NCT01904604|Experimental|100 µg Peanut Patch|Subjects apply low-dose DBV712 Viaskin® patch containing 100 micrograms (μg) peanut protein daily for a 52-week blinded period. Patch application duration is initially 3 hours and gradually increased to 24 hours over a 21-day graduated dosing period; subsequently patch changed every 24 hours. At Week 52, subjects complete an OFC and are unblinded. Following blinded phase, subjects who have not demonstrated sustained unresponsiveness at the Week 52 OFC crossover to active treatment (using same 21-day graduated dosing period used in blinded phase for subjects 4-<6 years old at enrollment or who had Grade 2 reaction or higher within previous 2 months) and dose with a high-dose DBV712 Viaskin® patch containing 250 μg peanut protein for a total active treatment period of 30 months (130 weeks).
88853606|NCT01904604|Experimental|250 µg Peanut Patch|Subjects apply high-dose DBV712 Viaskin® patch containing 250 micrograms (μg) peanut protein daily for a 52-week blinded period. Patch application duration is initially 3 hours and gradually increased to 24 hours over a 21-day graduated dosing period; subsequently patch changed every 24 hours. At Week 52, subjects complete an OFC and are unblinded. Following blinded phase, subjects who have not demonstrated sustained unresponsiveness at the Week 52 OFC continue active treatment with a high-dose DBV712 Viaskin® patch for a total active treatment period of 30 months (130 weeks).
88853607|NCT01904058|Experimental|LUM001 and Ursodeoxycholic Acid (UDCA)|Administered orally once daily
88853608|NCT01904058|Placebo Comparator|Placebo and Ursodeoxycholic Acid (UDCA)|Administered orally once daily
88853609|NCT01881126|Active Comparator|bimatoprost 0.01% and hypromellose 0.3%|Bimatoprost 0.01% and hypromellose 0.3% lubricant eye drops (for masking purposes) each administered to both eyes once daily for 12 weeks.
88853610|NCT01881126|Active Comparator|travatan 0.004% and timolol 0.5%|Travatan 0.004% and timolol 0.5% each administered to both eyes once daily for 12 weeks.
88853611|NCT03357588|Active Comparator|Control|Standard of Care monitoring
88853612|NCT03357588|Experimental|Intervention|Intensified monitoring
88853613|NCT01614600|Experimental|DAILIES® AquaComfort Plus®|Nelfilcon A contact lenses worn bilaterally on a daily wear, daily disposable basis for 2 weeks
88853614|NCT04611672||Patients with stroke|Patients with stroke of all subtypes, with and without different Kind of Lysis therapy
88853615|NCT04611672||Controls|Healthy controls of all Ages above 18 years
88853616|NCT01880736|Experimental|IDeg OD Flexible Dose|
88853617|NCT01880736|Experimental|IDeg OD Fixed Dose|
88853618|NCT01880736|Experimental|IDeg OD Simple|
88853619|NCT01880736|Experimental|IDeg OD Stepwise|
88853620|NCT01880424|Placebo Comparator|controlled arm|
88853621|NCT01880424|Experimental|treatment arm|
88853622|NCT01862874|Experimental|V501|Participants received V501 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Follow-up was up to Month 36.
88853623|NCT01862874|Placebo Comparator|Placebo|Participants received placebo 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Follow-up was up to Month 36.
88853624|NCT01879722|Experimental|TAK-063 3 mg|TAK-063 3 mg, tablets, orally, once daily for 7 days.
88853625|NCT01879722|Experimental|TAK-063 10 mg|TAK-063 10 mg, tablets, orally, once daily for 7 days.
88853626|NCT01879722|Experimental|TAK-063 20 mg|TAK-063 20 mg, tablets, orally, once daily for 7 days.
88853627|NCT01879722|Experimental|TAK-063 30 mg|TAK-063 30 mg, tablets, orally, once daily for 7 days.
88853628|NCT01879722|Experimental|TAK-063 100 mg|TAK-063 100 mg, tablets, orally, once daily for 7 days.
88853629|NCT01879722|Placebo Comparator|Placebo|Placebo matching TAK-063, tablets, orally, once daily for 7 days.
88853630|NCT01879410|Experimental|UMEC/ VI via NDPI + placebo ACCUHALER/DISKUS arm|Subjects will receive one inhalation of UMEC/VI 62.5/25 mcg once-daily in the morning via the NDPI and one inhalation of placebo in the morning and evening via ACCUHALER/DISKUS inhaler
88853631|NCT01879410|Active Comparator|FSC via ACCUHALER/DISKUS + placebo NDPI arm|Subjects will receive one inhalation of FSC 250/50 mcg in the morning and evening via ACCUHALER/DISKUS inhaler and one inhalation of placebo administered once-daily in the morning via NDPI
88853632|NCT05114148|Experimental|Holmium-166 radioembolization|Individualized holmium-166 radioembolization will be performed via a catheter during angiography. Dosimetry-based treatment planning will be individualized based on Q-Suite™ software.
88853633|NCT01903434|Experimental|Evacetrapib -- Solid Fraction Test|Single oral dose of 130 milligram (mg) evacetrapib tablet on Day 1 of up to 2 of 3 periods
88853634|NCT01903434|Experimental|Evacetrapib -- Solid Fraction Reference|Single oral dose of 130 mg evacetrapib tablet on Day 1 of up to 2 of 3 periods
88853635|NCT01903356||Patients with T2DM|
88853636|NCT01862796|Experimental|Obese underfeeding (UF)|Obese randomized to received a 35% calorie reduced diet
88853637|NCT01862796|Experimental|Obese weight maintaining (WMEN)|Randomized to receive a weight-maintaining diet
88853638|NCT01862796|Experimental|Lean weight maintaining (WMEN)|Normal weight individuals receiving a weight-maintaining energy needs diet
89002659|NCT06271577|Experimental|AliveCor 12-lead ECG|A single research-related procedure will be required (i.e., an AliveCor 12-lead ECG). Effort will be made to ensure that the performance of this procedure will not delay any treatment and/or diagnostic procedures that are part of usual or specialized care that the patient requires.
89380456|NCT03717701|Placebo Comparator|Placebo|Patients will take inert tablets similar in appearance, color, and consistency
89380457|NCT04114110||Admitted inpatients|no intervention
89380458|NCT04114110||Staff with RTLS badges|no intervention
89380459|NCT03931902|Experimental|Laryngeal Mask Airway (LMA)|Using laryngeal mask airway as the airway device during general anesthesia
89380460|NCT03931902|Active Comparator|Endotracheal Tube (ETT)|Using endotracheal tube as the airway device during general anesthesia
89380461|NCT03712085|Active Comparator|Treatment Group A|Abdominal acupuncture and upper limb rehabilitation training
88853639|NCT01878084|Other|all study participants|"This study represents a split-mouth study where the right or left/ upper or lower premolar could be assigned to either the control group (socket left empty) or test group (socket filled with bioactive glass (sol-gel)~The extraction sockets will be allocated either to the control : Extraction socket will be left empty~or~Test: Extraction socket will be augmented using bioactive glass (sol-gel)"
88853640|NCT01862640|Placebo Comparator|Placebo|Matching placebo once daily
88853641|NCT01862640|Experimental|Brexpiprazole 1 mg|Titrate up from 0.25 milligrams (mg)/day brexpiprazole to 1 mg/day brexpiprazole
88853642|NCT01862640|Experimental|Brexpiprazole 2 mg|Titrate up from 0.25 mg/day brexpiprazole to 2 mg/day brexpiprazole
88853643|NCT01902966|Experimental|Propranolol + Relaxation/Guided Imagery|A starting dose of propranolol 20 mg is taken by mouth twice a day (40 mg/day). If patient tolerates the initial dose (no hypotension or bradycardia), dose increased to 40 mg by mouth twice a day at start of second month of therapy. Patients record study medication taken each day in a pill diary. Patient given an MP3 player with an audio recording to listen to 2 times a week for up to 4 months. The recording lasts 20 minutes. Relaxation diary completed stating whether patient was able to complete the sessions and whether they had any difficulties with it. Questionnaires completed at baseline, 2 months, and 4 months.
88853644|NCT01862484|Experimental|Restricted Diet|Child is on an additive, gluten free diet. Child receives daily snacks which conform to the restrictive diet.
89380462|NCT03712085|Sham Comparator|Treatment Group B|Sham abdominal acupuncture and upper limb rehabilitation training
89380463|NCT03712085|No Intervention|Control Group|Upper limb rehabilitation only
89380464|NCT03628170|Experimental|PRF (Platelet -rich fibrin) group|Extraction of the tooth followed by Platelet rich fibrin placed in the socket covered bu platelet rich fibrin membrane for socket preservation.
89380465|NCT03628170|Active Comparator|Free gingival graft group|Extraction of the tooth followed by using free gingival graft to cover the socket for socket preservation.
89380466|NCT03422159|Experimental|Treatment Arm|Based on published clinical data, vitamin C pharmacokinetic modeling, the package insert as well as the preliminary study by Marik et al, Vitamin C will be administered as an intravenous dose of 6gm per day divided in 4 equal doses. This dosage is reported to be devoid of any complications or side effects. Hydrocortisone will be dosed according to the consensus guidelines of the American College of Critical Care Medicine. Thiamine will be administered according to current recommendations in a dose of 200mg q 12 hourly. This will be continued for 4 days, or less if discharged from the ICU prior.
89380467|NCT03422159|Placebo Comparator|Placebo Arm|"Vitamin C placebo will consist of an identical bag of 100mL normal saline (but with no vitamin C) and will be labeled Vitamin C or Placebo. Placebo will be infused over 30 minutes as per the infusion instructions of the active vitamin and protected from light with a brown bag. Hydrocortisone placebo will be provided as an identical 3mL syringe as 1mL of normal saline.The thiamine placebo will be placed in a 50mL bag of Normal Saline labeled Thiamine 200mg or Placebo and run over 30 minutes (100mL/hr) Placebo patients will receive a matching 50mL bag of Normal Saline. All of these will be given for up to 4 days, or less if discharged from the ICU prior."
89380468|NCT04538040|Experimental|Biktarvy + Doravirine Switch|bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg tablets + doravirine 100mg tablets taken orally once per day
89380469|NCT04033692||JuggerKnot Mini Soft Anchors|Patients who have been implanted with the JuggerKnot Mini Soft Anchor who have undergone repair, repositioning or reattachment of soft tissues, ligament and tendons to the mandible is require for surgical stabilization of the TMJ articular disc
89380470|NCT03950024|Experimental|with arthrogenic Muscle Inhibition|
89380471|NCT03950024|Active Comparator|without arthrogenic Muscle Inhibition|
89380472|NCT03964506|Experimental|Cohort 1- AML or MDS|Patients with will receive HBO therapy one time on day 0 of the transplant. The treatment consists of exposure to hyperbaric oxygen at 2.5 atmospheric absolutes (ATA) for a total of 90 minutes after compression to 2.5 atmosphere absolutes (ATA) in a monoplace hyperbaric chamber (Model 3200/3200R, Sechrist Industries, Inc., USA), breathing 100% oxygen. The subjects will be in the chamber for a total of 120 minutes as approximately 10-15 minutes were spent during the compression and decompression phases and subjects had 10 minute room air breaks every 30 minutes of hyperbaric oxygen treatment.
89380473|NCT03964506|Experimental|Cohort 2- CMML, aCML, CML, CNL, MDS/MPN|Patients with will receive HBO therapy one time on day 0 of the transplant. The treatment consists of exposure to hyperbaric oxygen at 2.5 atmospheric absolutes (ATA) for a total of 90 minutes after compression to 2.5 atmosphere absolutes (ATA) in a monoplace hyperbaric chamber (Model 3200/3200R, Sechrist Industries, Inc., USA), breathing 100% oxygen. The subjects will be in the chamber for a total of 120 minutes as approximately 10-15 minutes were spent during the compression and decompression phases and subjects had 10 minute room air breaks every 30 minutes of hyperbaric oxygen treatment.
88853645|NCT01862484|Sham Comparator|Ruse Diet|Child is on an additive, gluten free diet. Child receives daily snacks which violate the restrictive diet.
88853646|NCT01902888||Popliteal aneurysm|GORE® VIABAHN® Endoprosthesis used to treat popliteal aneurysm
88853647|NCT01862328|Experimental|MLN4924 and Docetaxel (Arm 1)|
88853648|NCT01862328|Experimental|MLN4924 + Paclitaxel + Carboplatin (Arm 2)|
88853649|NCT01862328|Experimental|MLN4924 + Gemcitabine (Arm 3)|
88853650|NCT01862250|Experimental|Clonidine infants with HIE|Infants in this group will receive Intravenous clonidine at 1µg/kg/dose either every 6 or 8 hrs from the start of cooling to the end of re-warming
88853651|NCT01860846||Participants with moderate to severe Crohn's Disease|Participants for whom the treating physician had recently initiated an anti-Tumor Necrosis Factor (TNF) treatment
88853652|NCT01901874|Experimental|Carotid Artery Stenting|Carotid Artery Stenting with the GORE® Carotid Stent
89380474|NCT03403751|Experimental|Reltecimod 0.5 mg/kg|Single IV infusion of Reltecimod 0.5 mg/kg
89380475|NCT03403751|Placebo Comparator|Placebo|Single IV infusion of 0.9% Sodium Chloride Injection (Normal Saline)
89380476|NCT02297412|Experimental|Arm I (minocycline hydrochloride)|Patients receive minocycline hydrochloride PO BID on days 1-7. Treatment repeats every 7 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
88853653|NCT01860534|Experimental|Eye patches covers|The infants were randomly assigned by alternating enrolled patients between one of two groups prior to their first ROP screening. Group A was patched for their first ROP exam and then unpatched for their second exam while group B was unpatched for their first ROP exam and patched for their second exam. The patched subjects had eye covers after their eyes were dilated, and the unpatched subjects had comfort measures similar to the patched subjects but their eyes were not covered. The patching of the eyes was done in the same way that it is done for eye protection during phototherapy, with the same model of eye patches (Natus biliband) and with the same nursing care.
88853654|NCT01860534|No Intervention|no eye patches covers|The infants were randomly assigned by alternating enrolled patients between one of two groups prior to their first ROP screening. Group A was patched for their first ROP exam and then unpatched for their second exam while group B was unpatched for their first ROP exam and patched for their second exam. The patched subjects had eye covers after their eyes were dilated, and the unpatched subjects had comfort measures similar to the patched subjects but their eyes were not covered. The patching of the eyes was done in the same way that it is done for eye protection during phototherapy, with the same model of eye patches (Natus biliband) and with the same nursing care.
88853655|NCT01901328|Experimental|CB-5945|0.25 milligrams (mg) CB-5945 administered orally twice dailly (BID) for a 12-week treatment period
88853656|NCT01901328|Placebo Comparator|Placebo|Placebo administered orally BID for a 12-week treatment period
88853657|NCT01859988|Experimental|Placebo qw|Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 followed by a single injection every week (qw) from Week 1 to Week 15.
88853658|NCT01859988|Experimental|Dupilumab 300 mg qw|Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection qw from Week 1 to Week 15.
89380477|NCT02297412|Placebo Comparator|Arm II (placebo)|Patients receive a placebo PO BID on days 1-7. Treatment repeats every 7 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
89380478|NCT03644576|Experimental|ozanimod plus Pseudophedrine|ozanimod once daily (QD) for 30 days. On Day 30, a single dose of pseudoephedrine 60mg will be co-administered with ozanimod.
89380479|NCT03644576|Placebo Comparator|ozanimod placebo plus Pseudoephedrine|ozanimod placebo once daily (QD) for 30 days. On Day 30, a single dose of pseudoephedrine 60mg will be co-administered with ozanimod placebo.
89380480|NCT02180958||Cerebral Arteriovenous Malformations|Adult patients requiring endovascular treatment of Cerebral Arteriovenous Malformations.
88853659|NCT01859988|Experimental|Dupilumab 300 mg q2w|Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single injection of Placebo (for Dupilumab) alternating with single 300 mg injection of Dupilumab every 2 weeks (q2w) from Week 1 to Week 15.
88853660|NCT01859988|Experimental|Dupilumab 200 mg q2w|Two subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1, followed by a single injection of Placebo (for Dupilumab) alternating with single 200 mg injection of Dupilumab q2w from Week 1 to Week 15.
89380481|NCT03418727|Experimental|Study Drug Arm #1|Combination Therapy: brimonidine (0.2%) administered as eye drops, followed by corticosteroid eye drops, two times a day (BID) for 12 weeks
89380482|NCT03418727|Experimental|Study Drug Arm #2|Monotherapy: brimonidine (0.2%) administered as eye drops followed by placebo, two times a day (BID) for 12 weeks
89380483|NCT03418727|Placebo Comparator|Control Arm|Placebo: sodium carboxymethylcellulose (0.25%) administered as eye drops followed by a second application, two time a day (BID) for 12 weeks
89380484|NCT01180374|Experimental|Active Canabidiol and Active Delta-9-THC|
89380485|NCT01180374|Placebo Comparator|Placebo and Active Delta-9-THC|
89380486|NCT01180374|Experimental|Active Cannabidiol and Placebo|
89380487|NCT01180374|Placebo Comparator|Placebo and Placebo|
89380488|NCT03418571|Experimental|ALX-0171 1.5 mg/kg|
89380489|NCT03418571|Placebo Comparator|Placebo|
89380490|NCT03887520|Other|Cardiovascular disease|Patients with established Cardiovascular disease
89380491|NCT03715595|Experimental|SSDM group|The patients in will use the SSDM at home every month for one year.
89380492|NCT03715595|No Intervention|Control group|The patients will receive the conventional therapy for half a year. After half a year, all the patients will use the SSDM at home monthly for half a year.
89380493|NCT05545943|Experimental|2-days of calorie restriction with whole body cooling|"Healthy young subjects participated in a 2-day CR (0 kcal with water provided ad libitum ) with two 10-min whole body cooling practices on separate days.~All participants were asked to not perform excessive sports activities while the research was ongoing, not to be involved in any temperature-manipulation program or extreme temperature exposure for ⩾3 months; do not use any medications that could affect experimental data."
89380494|NCT05545943|Experimental|6-days of calorie restriction|"Healthy young subjects participated in 6-day CR (0 kcal with water provided ad libitum).~All participants were asked to not perform excessive sports activities while the research was ongoing, not to be involved in any temperature-manipulation program or extreme temperature exposure for ⩾3 months; do not use any medications that could affect experimental data."
89380495|NCT05545943|No Intervention|2-days of the usual diet (control)|"During the control trial, the healthy young subjects were instructed to maintain their previous eating habits for 2 days.~All participants were asked to not perform excessive sports activities while the research was ongoing, not to be involved in any temperature-manipulation program or extreme temperature exposure for ⩾3 months, CR programmes; do not use any medications that could affect experimental data."
89380496|NCT05545943|No Intervention|6 days of the usual diet (control)|"During the control trial, the healthy young subjects were instructed to maintain their previous eating habits for 6 days.~All participants were asked to not perform excessive sports activities while the research was ongoing, not to be involved in any temperature-manipulation program or extreme temperature exposure for ⩾3 months, CR programmes; do not use any medications that could affect experimental data."
89380497|NCT05545943|Experimental|2-days of calorie restriction without whole-body cooling|"Healthy young subjects participated in a 2-day CR (0 kcal with water provided ad libitum ) without whole body cooling.~All participants were asked to not perform excessive sports activities while the research was ongoing, not to be involved in any temperature-manipulation program or extreme temperature exposure for ⩾3 months; do not use any medications that could affect experimental data."
89380498|NCT05545943|Active Comparator|2-days of usual diet with whole-body cooling|"Healthy young subjects participated two 10-min whole body cooling practices on separate days and were instructed to maintain their previous eating habits for 6 days.~All participants were asked to not perform excessive sports activities while the research was ongoing, not to be involved in any temperature-manipulation program or extreme temperature exposure for ⩾3 months, CR programmes; do not use any medications that could affect experimental data."
89380499|NCT03717545|Experimental|intervention arm|second allogeneic stem cell transplantation
89380500|NCT01311089||Robotic thyroidectomy group|Robotic thyroidectomy group is the patient group who underwent robot-assisted endoscopic thyroid surgery using a gasless, trans-axillary approach.
89380501|NCT01311089||conventional open thyroidectomy group|Conventional open thyroidectomy group is th patient group who underwent thyroid surgery via neck incision.
89380502|NCT03715517|Experimental|Intrathecal morphine|"Spinal anesthesia with intrathecal morphine~Bolus (pre-induction): High-spinal anesthesia with 0.25 mg⋅kg-¹ hyperbaric bupivacaine 0.75% plus 3 mcg⋅kg-¹ intrathecal morphine (preservative-free)~Postoperative analgesia: IV-PCA hydromorphone (bolus: 0.2 mg [range: 0.1-0.4 mg]; 5 min lockout; no infusion)"
89380503|NCT03715517|Active Comparator|Thoracic epidural analgesia|"Continuous thoracic epidural analgesia~Bolus (pre-induction): 0.25 mg⋅kg-¹ bupivacaine 0.25% plus 1 mcg⋅kg-¹ hydromorphone (0.1 mL⋅kg-¹)~Infusion (initial): 0.25 mg⋅kg-¹⋅h-¹ bupivacaine 0.25% plus 1 mcg⋅kg-¹⋅h-¹ hydromorphone (0.1 mL⋅kg-¹⋅h-¹)~Infusion (range): 0.19-0. 3 mg⋅kg-¹⋅h-¹ bupivacaine 0.25% plus 0.75-1.25 mcg⋅kg-¹⋅h-¹ hydromorphone (0.075-0.125 mL⋅kg-¹⋅h-¹) (3-10 mL⋅h-¹)~Postoperative analgesia: (1) Epidural solution, bupivacaine 0.125% with hydromorphone 10 mcg·mL-¹, infusion range as above (0.075-0.125 mL⋅kg-¹⋅h-¹) (3-10 mL⋅h-¹), continued for a maximum of 72 h postoperatively; (2) IV-PCA hydromorphone (bolus: 0.2 mg [range: 0.1-0.4 mg]; 5 min lockout; no infusion)."
88853661|NCT01859988|Experimental|Dupilumab 300 mg q4w|Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection of Dupilumab every 4 weeks (q4w) and Placebo (for Dupilumab) qw when Dupilumab not administered from Week 1 to Week 15.
88853662|NCT01859988|Experimental|Dupilumab 100 mg q4w|Two subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1, followed by a single 100 mg injection of Dupilumab q4w and Placebo (for Dupilumab) qw when Dupilumab not administered from Week 1 to Week 15.
88853663|NCT01876446|Experimental|Treatment (pegylated irinotecan NKTR 102)|Patients receive pegylated irinotecan NKTR 102 IV over 90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity
88853664|NCT01900626|Active Comparator|single epidural catheter|
88853665|NCT01900626|Active Comparator|double epidural catheter|
88853666|NCT04414800|Placebo Comparator|Control (Placebo+ Standard of Care))|
89380504|NCT03402893|Experimental|single arm Onexton gel application|Onexton gel will be supplied to all subjects and applied once daily to the face
89380505|NCT03715361||Patients|Patients (500 patients ≤ ) who undergo out- or inpatient treatment and who did a 12lead-ECG measurement, repeat the procedure using the hand-held diagnostic tool (SL-ECG).
89380506|NCT03715361||Control Group|Fifty volunteers who did a 12lead-ECG measurement, repeat the procedure using the hand-held diagnostic tool (SL-ECG).
89380507|NCT03717467|Placebo Comparator|S group|Isotonic saline as placebo will be given.
88853667|NCT04414800|Active Comparator|Ketamine + Standard of Care|
89380508|NCT03717467|Active Comparator|M group|Magnesium sulfate will be given
89380509|NCT04464954|Experimental|Auricular semi-permanent (ASP gold) needles|
88853668|NCT04414800|Active Comparator|Fentanyl + Standard of Care|
89183005|NCT05840159|Active Comparator|Arm 4|100 mg of doxycycline orally administered twice daily for 7 days to assigned male at birth (AMAB) participants >/= 16 years old with confirmed rectal Chlamydia trachomatis (CT). N=166.
89380510|NCT04464954|Experimental|Intradermal (long) needles using J-type No. 2 (.18)x 15mm|
89380511|NCT04464954|Experimental|Pyonex needles (Seirin Yellow 0.2 x 0.6mm)|
89380512|NCT03628248|Experimental|embolization|
89380513|NCT03628248|Other|No embolization|
89380514|NCT03442985|Experimental|Palovarotene 2.5 mg daily regimen|
89380515|NCT03442985|Experimental|Palovarotene 5.0 mg daily regimen|
89380516|NCT03442985|Placebo Comparator|Placebo regimen|
88853669|NCT01900314|Active Comparator|Active rTMS|20 active sessions, within a 4 week period, where subjects receive the same repetitive Transcranial Magnetic Stimulation (rTMS) treatment parameters as the FDA-approved device label (10 Hz) to a targeted area of the brain. After these sessions, a second fMRI will be completed then 5 additional tapering treatments of rTMS over a 2 week period.
88853670|NCT01900314|Sham Comparator|Sham rTMS|20 sham sessions, within a 4 week period, where subjects receive inactive treatments (0 Hz) of repetitive Transcranial Magnetic Stimulation (rTMS). After 20 sessions and completion of a second fMRI scan, patients in this group will then be unblinded and transitioned to the active arm and will receive a full course (25 sessions) of active rTMS over a 6 week period.
88853671|NCT01899768|Experimental|Part A|Subjects will receive treatment A (placebo) or treatment B (GSK2339345) in 3 visits of part A (one treatment per visit) in one of the following four sequences: ABA, ABB, BAA, and BAB.
89002660|NCT06270511|Experimental|Part A: Open Label|Participants will receive different formulations of S-337395 without food and with food.
89002661|NCT06270511|Experimental|Part B: Double Blind|Participants will receive S-337395 or placebo.
89380517|NCT03715283|Experimental|Home Lower Extremity Strengthening|Patients in this arm will undergo a 12 week strengthening program which focuses on ankle dorsi- and plantar- flexion. Clinical visits will occur at baseline, 6 weeks and 12 weeks from the start of study. At each visit all patients will undergo a clinical exam, answer questionaires and undergo MUNIX testing.
89380518|NCT03715283|Experimental|No intervention|In this portion of the study patients will not be given any intervention. Clinical visits will occur at baseline, 6 weeks and 12 weeks from the start of study. At each visit all patients will undergo a clinical exam, answer questionaires and undergo MUNIX testing of both legs.
89380519|NCT01311635|Experimental|Treatment A|
89380520|NCT01311635|Experimental|Treatment B|
89380521|NCT01311635|Experimental|Treatment C|
89380522|NCT01311635|Experimental|Treatment D|
89380523|NCT01318122|Active Comparator|Alogliptin 12.5 mg QD and Pioglitazone 15 or 30 mg QD|
88853672|NCT01899768|Experimental|Part B|Subjects will receive treatment A or treatment B in 2 visits of part B (one treatment per visit) in one of the following two sequences: AB and BA. Subjects will then orally inhale 10 microliter (mcL) of a capsaicin solution of strength ranging from 0.49 micromolar (mcM) to 1000 mcM, which will be administered using a breath activated dosimeter approximately 5 minutes post-dosing with treatment A or B at Visits 4 and 5.
88853673|NCT01899768|Experimental|Part C|Subjects will receive treatment A or treatment B in 2 visits of part C (one treatment per visit) in one of the following two sequences: AB and BA. Subjects will then orally inhale 10 mcL of a citric acid solution of strength ranging from 0.03 to 4.0 M, which will be administered using a breath activated dosimeter approximately 5 minutes post-dosing with treatment A or B at Visits 6 and 7.
88853674|NCT01898598|Placebo Comparator|Placebo|Participants will receive matching placebo to vismodegib capsule orally once daily for 12 weeks.
88853675|NCT01898598|Experimental|Vismodegib|Participants will receive vismodegib 150 milligrams (mg) capsule orally once daily for 12 weeks.
88853676|NCT01898442|Active Comparator|Ticagrelor 180|Standard ticagrelor 180mg loading dose
88853677|NCT01898442|Experimental|Ticagrelor 270mg|High ticagrelor 270mg loading dose
88853678|NCT01898442|Experimental|Ticagrelor 360mg|High ticagrelor 360mg loading dose
88853679|NCT01898286|Experimental|DiaPep277®|Administration of DiaPep277® to patients previously enrolled in the Phase 3 Study 1001 (NCT01103284)
88853680|NCT01898208|Experimental|Control|Standard Mayo practices (bacterial culture and susceptibility testing) will be used. FilmArray testing will not be performed.
88853681|NCT01898208|Experimental|FilmArray test|Standard Mayo practices will be used AND FilmArray testing will be performed. Results of the FilmArray Blood Culture ID Panel test will be communicated to the service by phone in real-time, 24 hours a day, 7 days a week.
88853682|NCT01898208|Experimental|FilmArray plus antimicrobial stewardship|Standard Mayo practices will be used. FilmArray testing will be performed and reported as above, for intervention group 1. IN ADDITION, an expert will review the subject's FilmArray Blood Culture ID Panel result and medical record and contact the primary service if a modification of antimicrobial therapy may be appropriate.
89380524|NCT01318122|Active Comparator|Alogliptin 25 mg QD and Pioglitazone 15 or 30 mg QD|
89380525|NCT02954159|Active Comparator|Treatment arm|vedolizumab at standard regimen with concomitant induction treatment of tacrolimus (starting 0.05 mg per Kg twice daily)
89380526|NCT02954159|Placebo Comparator|Placebo Arm|vedolizumab at standard regimen with placebo.
89380527|NCT01311245|Experimental|Stage-tailored|At baseline and three months later
89380528|NCT01311245|Experimental|Non-stage-tailored|At baseline and three months later
89380529|NCT01311245|No Intervention|Control group|Assessment only
88853683|NCT01898130|Experimental|Treatment (bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes every 2 weeks. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88853684|NCT01876368|Experimental|LCZ696 200 mg|Patients will be treated with one LCZ696 200 mg tablet and one placebo of olmesartan 20 mg capsule once daily for 8 weeks.
88853685|NCT01876368|Active Comparator|Olmesartan 20 mg|Patients will be treated with one placebo of LCZ696 200 mg tablet and one olmesartan 20 mg capsule once daily for 8 weeks.
89380530|NCT03442829|Experimental|Sweet food consumption|Sweet breakfasts. Participants are asked to consume a sweet breakfast every day for three weeks (excepting on three days when outcomes will be assessed (days 0, 7 and 21, day 21 reported). All foods will be provided.
89380531|NCT03442829|Active Comparator|Non-sweet food consumption|Non-sweet breakfasts. Participants are asked to consume a non-sweet breakfast every day for three weeks (excepting on three days when outcomes will be assessed (days 0, 7 and 21, day 21 reported). All foods will be provided.
89380532|NCT05218512||WB-EMS|Young recreationally active males without any disease.
89380533|NCT03442595||Cases|patients with uncontrolled type 2 diabetes mellitus that participate in the MedStar Diabetes Pathway
89380534|NCT03442595||Matched controls|patients with uncontrolled type 2 diabetes that match the cases on 5 criteria and received standard of care diabetes management with a MedStar provider
89380535|NCT05218278||Patients with favorable neurlogical outcome|CPC 1/2
89380536|NCT05218278||Patients with non-favorable neurological outcome|CPC3-5
89380537|NCT03783234||Older Adult Patients|ED patients age of ≥ 75 who have nurse assessed Clinical Frailty Scale ≥ 4.
89380538|NCT03717311|Experimental|13C enriched bran biscuit|The volunteers will consume 5 biscuits (100g) enriched with 13C bran with a 200 ml hot beverage in 15 minutes
89380539|NCT03763422|Experimental|Early Treatment arm|Radiotherapy + Temozolomide
89380540|NCT03763422|Active Comparator|Active surveillance arm|Treatment as per local practice
89380541|NCT05658029|Experimental|Open label treatment group|
89380542|NCT05520281|Experimental|Patients|Adult patients across all phases of advanced disease (UICC stage IV solid tumor) from diagnosis to terminal stages
89380543|NCT03715049|Other|Fraxel Laser Treatment|Using the energy and density settings within the FDA approved limits (5-40mJ at 30-100% density) that were narrowed down by the pre-clinical portion of the study, and analysis of abdominal and facial tissue treated in Objective 1, up to thirty (30) subjects will be recruited and treated one (1) time in the perioral region of the upper lip and followed for 6 months (study design below). The acute effects of the laser application will be determined by subjective analysis using the wrinkle severity scores.
89380544|NCT03714971|Experimental|Receiving WhatsApp messages|Among patients applying to the smoking cessation outpatient clinic between March and October 2017, >18-year old volunteers who smoked at least one cigarette/day, using WhatsApp at least on four days of the week, accepting the 3-month follow-up were included In receiving WhatsApp messages group.
89380545|NCT03714971|No Intervention|Not receiving WhatsApp messages|"In not receiving WhatsApp messages group; Stratification and randomization were both used to randomly allocate participants to both arms of the study. The intervention and control groups were first stratified according to physician and then gender, and later allocated in a simple random manner. Randomization was conducted using a computer spreadsheet. Allocation according to gender was conducted regarding the 2:3 female to male ratio in the routine cessation services and stratification according to physician aimed to have a balanced distribution among the different physicians working in the same cessation unit. As the target number of participants was small, further stratification was not applied. Simple random sampling was then used to allocate participants to each group."
89380546|NCT03712007|Experimental|MAMP therapy with MARPE expander|The experimental group will comprise 20 patients submitted to miniscrew anchored maxillary protraction (MAMP) with a tooth-bone-borne expander as anchorage in the maxillary arch. The miniscrew assisted rapid palatal expander (MARPE) will be used.
89380547|NCT03712007|Active Comparator|MAMP therapy with Hyrax expander|The active comparator group will comprise 15 patients submitted to miniscrew anchored maxillary protraction (MAMP) with a tooth-borne expander as anchorage in the maxillary arch. The conventional hyrax expander will be used.
89380548|NCT05218122||LKD syndrome|liver and kidney deficiency syndrome
89380549|NCT05218122||PBS syndrome|phlegm and blood stasis syndrome
89380550|NCT05218122||NC group|Normal Control group
89380551|NCT03695406|Experimental|Mind-Body Group Intervention|
89380552|NCT03633786|Other|Group A: standard laparoscopic surgery|patients affected by deep infiltrating endometriosis undergoing standard laparoscopic surgery; assessment of sexual function; assessment of bowel symptoms; assessment of urinary symptoms
89380553|NCT03633786|Other|Group B: robot-assisted surgery|patients affected by deep infiltrating endometriosis undergoing robot-assisted surgery; assessment of sexual function; assessment of bowel symptoms; assessment of urinary symptoms
89380554|NCT03421392||Idiopathic thrombocytopenic purpura|
89380555|NCT03421392||non immunological thrombocytopenia|patient with constitutive thrombocytopenia, myelodysplastic syndrome, or chemotherapy-induced thrombocytopenia
88853686|NCT01874340|Experimental|AIN457 low dose|AIN457 will be administered intravenously. Approximately 65 patients will be randomized to AIN457 low dose in Stage 1. An additional 40 patients may be randomized to this group if it is one of the two selected dose groups to be expanded for Stage 2 following an Interim Analysis.
89183006|NCT05837377|Experimental|Control- standard medication education|The control group will receive a traditional medication administration proficiency training program.
89380556|NCT03421392||without thrombocytopenia|
89380557|NCT05217732|Experimental|Single dose of ZX-7101A treatment A|Administrated as a single oral dose in healthy subjects
89380558|NCT05217732|Experimental|Single dose of ZX-7101A treatment B|Administrated as a single oral dose in healthy subjects
89380559|NCT05217732|Experimental|Single dose of ZX-7101A treatment C|Administrated as a single oral dose in healthy subjects
89380560|NCT05217732|Experimental|Single dose of ZX-7101A treatment D|Administrated as a single oral dose in healthy subjects
89380561|NCT05217732|Experimental|Single dose of ZX-7101A treatment E|Administrated as a single oral dose in healthy subjects
89380562|NCT05217732|Experimental|ZX-7101A food effect|Administered as a selected, single oral dose of ZX-7101A in fasting state and non-fasting (with food) state.
89183007|NCT05837377|Experimental|Experiment- cognitive load theory based on medication education|The experiment group will receive a cognitive load theory-based medication administration training program.
89183008|NCT05834244|Experimental|Dose Escalation|Dose Escalation to evaluate the combination of azacitidine, venetoclax and allogeneic NK cells in older/unfit participants with AML ineligible for intensive chemotherapy or allogeneic stem-cell transplantation (allo SCT).
89183009|NCT05834244|Experimental|Dose Expansion|Dose Expansion to evaluate the combination of azacitidine, venetoclax and allogeneic NK cells in older/unfit participants with AML ineligible for intensive chemotherapy or allogeneic stem-cell transplantation (allo SCT).
89380563|NCT05217576|Other|Comparison|"Comparison study:~The participants (at least 300) will be tested once with each of the 3 devices. First, a measurement with the NBM-200 will be performed according to the user manual. The best finger to use, in order of preference: 1) right thumb 2) left thumb 3) right index 4) left index.~The POC capillary test will follow the NBM-200 test, and the venous test will be performed last. A venous blood sample will be obtained from all participants in the comparison study, even if a subject is designated to donate and is deferred from donation because of low hemoglobin."
88853687|NCT01874340|Placebo Comparator|Placebo|Matching placebo will be administered intravenously. Approximately 105 patients will be randomized to placebo (65 in Stage 1 and 40 in Stage 2).
89183010|NCT05827510|Experimental|Acne scars|All subjects will be treated with the BTL-585F system. Parameters' settings should be individually evaluated by the operator based on the treatment area and on the patient's medical and wound healing history. Parameters can be modified during subsequent visits, as per the practitioner's discretion.
89183011|NCT05827510|Experimental|Facial wrinkles|All subjects will be treated with the BTL-585F system. Parameters' settings should be individually evaluated by the operator based on the treatment area and on the patient's medical and wound healing history. Parameters can be modified during subsequent visits, as per the practitioner's discretion.
89183012|NCT05822609|Experimental|Semaglutide|Semaglutide group from 0.25mg to 1.0mg
89183013|NCT05822609|Placebo Comparator|Placebo|Placebo group
89380564|NCT05217576|Other|Precision A & B|"Precision study:~At least 12 subjects will be tested 6 consecutive times with the NBM-200, on either the right or left thumb, and then 6 times with the capillary device (with a separate finger-prick for each test).~At least 3 males and 3 females at 2 study sites (total of 12), preferably with hemoglobin levels close to the cutoff levels of 12.5 g/dL for females and 13 g/dL for males. Each subject will be tested on each of their right and left thumbs and indices (4 fingers) using at least two operators and two NBM-200 instruments on each finger.~A laboratory test with venous blood is not required for participants in the precision study."
89380565|NCT03440411|Active Comparator|ARM pom-dex Early (A-I)|Patients will receive treatment at biochemical relapse with pom-dex Pomalidomide: 4 mg/day on days 1-21 Dexamethasone: 40 mg on days 1, 8, 15, 22 For 28-day cycles until progression or intolerance
89380566|NCT03440411|Experimental|ARM pom-cyclo-dex Early(B-I)|Patients will receive treatment at biochemical relapse with pom-cyclo-dex Pomalidomide: 4 mg/day on days 1-21 Cyclophosphamide: 50 mg every other day Dexamethasone: 40 mg on days 1, 8, 15, 22 For 28-day cycles until progression or intolerance
88853688|NCT01874340|Experimental|AIN457 middle dose|AIN457 will be administered intravenously. Approximately 65 patients will be randomized to AIN457 middle dose in Stage 1. An additional 40 patients may be randomized to this group if it is one of the two selected dose groups to be expanded for Stage 2 following an Interim Analysis
88853689|NCT01874340|Experimental|AIN457 high dose|AIN457 will be administered intravenously. Approximately 65 patients will be randomized to AIN457 high dose in Stage 1. An additional 40 patients may be randomized to this group if it is one of the two selected dose groups to be expanded for Stage 2 following an Interim Analysis.
88853690|NCT01897896|Experimental|Rollover Cohort: SD-809 ER|Participants who completed study SD-809-C-15 (NCT01795859, including 1-week washout period and Week 13 evaluation), will receive 6 milligrams (mg) SD-809 ER tablet once daily as a starting dose in this study. Dose titration will be continued through Week 8 to optimize dose. Dose of SD-809 ER can be adjusted weekly in increments of 6 milligrams per day (mg/day) (6 or 12 mg/day after a total daily dose of 48 mg is reached) based on chorea control and adverse events. Daily doses of SD-809 ER 12 mg and higher will be administered twice daily. Maximum total daily dose of SD-809 ER will be 72 mg/day (36 mg twice daily), unless participant is receiving a strong CYP2D6 inhibitor(such as, paroxetine, buproprion, fluoxetine), in which case maximum total daily dose will be 42 mg (21 mg twice daily). Long-term treatment with SD-809 ER at a stable dose (further dose adjustments are permitted, if clinically indicated) will be continued until SD-809 ER become commercially available in United States.
88853691|NCT01897896|Experimental|Switch Cohort: SD-809 ER|Participants who were receiving an approved dosing regimen of tetrabenazine for at least 8 weeks prior to screening, will be converted overnight from their existing tetrabenazine regimen to SD-809 ER regimen to achieve targeted steady-state area under the curve (AUC) of total (alpha+beta)- Dihydrotetrabenazine (HTBZ) metabolites that is predicted to be comparable to that of participant's prior tetrabenazine regimen. Participants will remain on initial dose of SD-809 ER through Week 1. Dose adjustment will be continued through Week 4 to optimize the dose. Dose of SD-809 ER can be adjusted weekly (upward or downward) in increments of 6 mg per day (6 mg/day or 12 mg/day after a total daily dose of 48 mg is reached), based on chorea control and treatment regimen tolerability. Long-term treatment with SD-809 ER at a stable dose (although further dose adjustments are permitted, if clinically indicated) will be continued until SD-809 ER become commercially available in United States.
88853692|NCT03431532||neuraxial anesthesia|Patients with total knee replacement surgery having neuraxial anesthesia along with the procedure.
88853693|NCT03431532||general anesthesia|Patients with total knee replacement surgery having General anesthesia along with the procedure.
88853694|NCT01858194|Experimental|Renal sympathetic denervation|Catheter-based Renal Sympathetic Denervation Ablation Arm
88853695|NCT01858194|Placebo Comparator|VT ablation alone|No further therapy in addition to VT ablation
88853696|NCT01873950|Experimental|Ranolazine 1500mg|Ranolazine
88853697|NCT01873950|Experimental|Dofetilide 500mcg|Dofetilide
88853698|NCT01873950|Experimental|Verapamil HCl 120 mg|Verapamil
88853699|NCT01873950|Experimental|Quinidine sulfate 400mg|Quinidine sulfate
88853700|NCT01873950|Placebo Comparator|Placebo|Placebo
88853701|NCT01857102|Active Comparator|etafilcon A/etafilcon A for Astigmatism|Subjects were randomized to one of two sequences of lens wear.
88853702|NCT01857102|Experimental|etafilcon A for Astigmatism/etafilcon A|Subjects were randomized to one of two sequences of lens wear.
88853703|NCT01872078|Experimental|AZD4901 20 mg once a day|AZD4901 20 mg once a day
89380567|NCT03440411|Experimental|ARM pom-dex Late (A-II)|"Patients will be randomized at biochemical relapse and they will start treatment with pom-dex at the onset of CRAB symptoms/significant paraprotein increase.~Pomalidomide: 4 mg/day on days 1-21 Dexamethasone: 40 mg on days 1, 8, 15, 22 For 28-day cycles until progression or intolerance"
88853704|NCT01872078|Experimental|AZD4901 20mg twice a day|AZD4901 20mg twice a day
88853705|NCT01872078|Experimental|AZD4901 40 mg twice a day|AZD4901 40 mg twice a day
88853706|NCT01872078|Experimental|Placebo to match AZD4901|
89380568|NCT03440411|Active Comparator|ARM pom-cyclo-dex Late (B-II)|"Patients will be randomized at biochemical relapse and they will start treatment with pom-cyclo-dex at the onset of CRAB symptoms/significant paraprotein increase.~Pomalidomide: 4 mg/day on days 1-21 Cyclophosphamide: 50 mg every other day Dexamethasone: 40 mg on days 1, 8, 15, 22 For 28-day cycles until progression or intolerance"
89380569|NCT03717233|Experimental|Primary Arm|Participants will be used as their own controls. Participants will be evaluated using exo-skeletons with non-motorized spring elements in parallel to the Achilles tendon. Up to 5 different levels of spring force will be evaluated to evaluate the impact upon plantar pressure and measures of fall risk.
88853707|NCT04618458|Experimental|Intervention Arm|Eligible overweight/obese children and their overweight/obese parent (N=20 families) will receive the same telehealth diabetes prevention intervention based on Power to Prevent and delivered by a trained lifestyle coach. Families will meet weekly for 11-weeks (60-min sessions), and then monthly (60-min sessions) for 4 pilot behavioral reinforcement maintenance sessions (15 sessions total). Participants will meet in their respective groups (n=5 families per group) via videoconference using Wi-Fi-enabled tablets with cellular connectivity for the entire intervention. Sessions will consist of nutrition and physical activity behavior change strategies (20 min), problem solving and decision-making skills to circumvent barriers to behavioral change (20 min), and family goal setting and action planning (20 min). Assessment measures will be collected from the child and parent participants at baseline, 12-weeks (post-intervention), and 30-weeks (follow-up).
88853708|NCT01896726|Experimental|Baricitinib + Microgynon|Microgynon [30 micrograms (µg) ethinyl estradiol and 150 µg levonorgestrel] administered orally, once daily (QD), on Days 1 and 29. Baricitinib, 10 milligrams (mg), administered orally QD on Days 23 through 30.
88853709|NCT01856790|Experimental|Closed Loop Insulin Delivery|"Each participant recruited into the study will undergo two inpatient closed loop admissions.~The first admission will be utilizing closed loop control alone, using the Medtronic external Physiological Insulin Delivery (ePID) algorithm. The ePID controller uses a proportional-integral-derivative algorithm modified to include insulin feedback.~Following the first closed loop admission, each participant is initiated on adjunctive once daily liraglutide therapy. They undergo a 3-4 week dose titration period.~Participants are then admitted for a second closed loop admission to assess the combined effects of closed loop control with adjunctive once daily liraglutide therapy."
88853710|NCT01856322|Active Comparator|Sulindac|one tablet twice daily
88853711|NCT01856322|Placebo Comparator|Placebo|one tablet twice daily
88853712|NCT01856322|Other|Normal Volunteers (or control group)|Normal volunteers (or control group) enrolled with the only purpose to validate assays and the shipping method.
89002664|NCT06267924|Experimental|1. Moderate or Worse (MoW) Arm|Participants will be randomized to use the Otoband as instructed by clinical coordinator per study protocol. There are 4 power levels, these participants will receive the experimental device.
89183014|NCT05817422|Experimental|cAd3-Marburg vaccine (1.0 × 10^11 PU)|"Single dose of cAd3-Marburg vaccine (1x10^11 PU) administered intramuscularly (IM) with needle and syringe in a volume of 0.56 mL.~Placebo (0.9% NaCl solution for injection)administered intramuscularly (IM) with needle and syringe in a volume of 0.56 mL."
89183015|NCT05817422|Placebo Comparator|Placebo|Single dose of Placebo (0.9% NaCl solution for injection) administered intramuscularly (IM) with needle and syringe in a volume of 0.56 mL.
89183016|NCT05814159|Experimental|Anakinra|100 mg/day or 2 mg/kg/day of subcutaneous anakinra for those with a body weight ≥50 kg or <50 kg, respectively.
89380570|NCT03714737|Experimental|Experimental 1|Experimental vaccine of 0.5ml in 300 children aged 2-5 years at day 0.
89380571|NCT03714737|Active Comparator|Positive control 1|Positive control vaccine 1 of 0.5ml in 300 children aged 2-5 years at day 0.
89380572|NCT03714737|Experimental|Experimental 2|Experimental vaccine of 0.5ml in 150 children aged 12-23 months at day 0 and 28.
89183017|NCT05814159|Placebo Comparator|Placebo|Corresponding volume to 100 mg/day or 2 mg/kg/day
89380573|NCT03714737|Experimental|Experimental 3|Positive control vaccine 2 of 0.5ml in 150 children aged 12-23 months at day 0.
89380574|NCT03714737|Active Comparator|Positive control 2|Positive control vaccine 2 of 0.5ml in 150 children aged 12-23 months at day 0 and 28.
89380575|NCT03714737|Experimental|Experimental 4|Experimental vaccine of 0.5ml in 150 children aged 2-5 years at day 0 and 28, and boost at 18 months.
89380576|NCT03714737|Active Comparator|Positive Control 3|Positive control vaccine 2 of 0.5ml in 150 children aged 6-11 months at day 0 and 28.
89380577|NCT03714737|Experimental|Experimental 5|Experimental vaccine of 0.5ml in 300 children aged 3-5 months at day 0, 28, 56, and boost at 18 months.
89380578|NCT03714737|Active Comparator|Positive Control 4|Positive control vaccine 1 of 0.5ml in 300 children aged 3-5 months day 0, 28, 56.
89380579|NCT03438539|Sham Comparator|Attentional Control with Normative Feedback|Control training tasks will include completion of basic arithmetic problems for approximately 5 minutes. Subjects assigned to normative feedback will be directed to a statement standardized based on subjects' reported average number of standard drinks per week, age, and gender.
89183018|NCT05793567||T2MI Patients|Patients with T2MI and no epicardial coronary stenosis >50% will be prospectively enrolled and undergo a routine standard of care coronary angiogram with coronary reactivity testing (CRT).
89380580|NCT03438539|Experimental|Inhibitory Control Training with Normative Feedback|The inhibitory control training task is a modified version of the Cued Go/No-Go tasks (Weafer and Fillmore, 2012; Miller et al. 1991) and is based on a task currently used in our laboratory targeting cocaine inhibitory control. Subjects assigned to normative feedback will be directed to a statement standardized based on subjects' reported average number of standard drinks per week, age, and gender.
89380581|NCT03438539|Experimental|Working Memory Training with Normative Feedback|A battery of working memory tasks will be used during the intervention period. These tasks were selected from previous research evaluating working memory training in substance use disorder (Bickel et al., 2011b; Houben et al., 2011b). Tasks will include visuospatial working memory task, digit span task, letter span task, and the n-back task. Subjects assigned to normative feedback will be directed to a statement standardized based on subjects' reported average number of standard drinks per week, age, and gender.
89380582|NCT03438539|No Intervention|Attentional Control without Normative Feedback|Control training tasks will include completion of basic arithmetic problems for approximately 5 minutes. Subjects assigned to not receive normative feedback will receive feedback on time spent doing a non-alcohol related activity as an attention/informational control (e.g., time spent watching television; LaBrie et al., 2013).
89380583|NCT03438539|Experimental|Inhibitory Control Training without Normative Feedback|The inhibitory control training task is a modified version of the Cued Go/No-Go tasks (Weafer and Fillmore, 2012; Miller et al. 1991) and is based on a task currently used in our laboratory targeting cocaine inhibitory control. Subjects assigned to not receive normative feedback will receive feedback on time spent doing a non-alcohol related activity as an attention/informational control (e.g., time spent watching television; LaBrie et al., 2013).
89380584|NCT03438539|Experimental|Working Memory Training without Normative Feedback|A battery of working memory tasks will be used during the intervention period. These tasks were selected from previous research evaluating working memory training in substance use disorder (Bickel et al., 2011b; Houben et al., 2011b). Tasks will include visuospatial working memory task, digit span task, letter span task, and the n-back task. Subjects assigned to not receive normative feedback will receive feedback on time spent doing a non-alcohol related activity as an attention/informational control (e.g., time spent watching television; LaBrie et al., 2013).
89380585|NCT05656625||group distal nerve block(DNB)|Radial, median and ulnar nerve blocks were used alone or in combinations as a method of anesthesia for patients who had undergone hand and wrist surgery.
89380586|NCT05656625||group brachial plexus block(BPB)|Brachial plexus blocks (infraclavicular, axillary etc.) was applied to patients who were going to undergo hand and wrist surgery.
89380587|NCT03400787|Sham Comparator|Sham Control Arm|"Subjects in the Sham Control arm will undergo the same preoperative assessments as those in the Latera Treatment arm up to and including anesthesia for the implant, however, no implant will be placed.~Crossover - Subjects will be unblinded after the 3-month assessment is complete. Eligible subjects in the Sham Control arm will be treated with the Latera Implant if they still meet all eligibility criteria. Follow up will continue to 24 months post-implant. Subjects who no longer meet the eligibility criteria will exit the study."
89380588|NCT03400787|Experimental|Latera Treatment Arm|Subjects in the active treatment arm will receive the Latera Implant using standard techniques. Follow up continues for 24 months post-implant.
89380589|NCT03417245|Experimental|Factor On-demand|Participants received on-demand factor concentrates (as needed, for episodic bleeding episodes, and not on a regular regimen intended to prevent spontaneous bleeding) per Investigator discretion for the treatment of breakthrough bleeding episodes from Day 1 up to a total of 9 months.
89380590|NCT03417245|Experimental|Fitusiran 80 mg Prophylaxis|Participants received open-label fitusiran 80 milligram (mg) administered subcutaneously (SC) as prophylaxis once monthly from Day 1 up to a total of 9 months. Participants received on-demand factor concentrates (per investigator's discretion and within bleeding dosing guidelines) for the treatment of breakthrough bleeding episodes.
89380591|NCT03711851|Experimental|Web-based|Self-help Acceptance and commitment therapy (Web-based)
89380592|NCT03711851|Experimental|Bibliotherapy|Self-help Acceptance and commitment therapy (bibliotherapy)
89380593|NCT03711851|Active Comparator|Education pamphlets on pain|Self-help Education on Chronic pain (pamphlet style pdf documents)
89380594|NCT03711539||Lifelong Endurance Athletes|i) Athletes who have initiated endurance sports activities at regional, national or international level before the age of 30 years. Sports include triathlon, cycling, distance running (1500 metres and longer) and rowing. ii) Aged 45-70 years. iii) Involved in competition and high-level training: more than 10 hours per week for cyclists and triathletes or more than 6 hours per week for runners and rowers. Subjects will be excluded if: i) they have a history of smoking (> 5 pack years) or diabetes, ii) had been diagnosed with a cardiopulmonary disorder prior to inclusion.
89399494|NCT02176616|Active Comparator|linear ablation|The group of positive control is the operation to add in conventional liner ablation to conventional pulmonary vein isolation with in patients based on patients who were changed to paroxysmal atrial fibrillation from persistent atrial fibrillation
88853713|NCT01896102|Experimental|Lenti-D Drug Product|Participants received a single intravenous (IV) infusion of Lenti-D Drug Product at a dose of greater than or equal to (>=) 5.0 × 10^6 CD34+ cells/kilogram (kg) (autologous CD34+ cell-enriched population that contained cells transduced with lentiviral vector encoding ABCD1 cDNA for human adrenoleukodystrophy protein, suspended in a cryopreservative solution) on Day 0.
88853714|NCT01871532|Experimental|Low Dose Gonal-f® Protocol|Gonal-f was administered subcutaneously daily at a starting dose of 50 International unit (IU) for Week 1, then dose was gradually increased by 12.5 IU for two weeks, with a final increase of 25 IU, up to maximum dose of 100 IU, until Week 4 for subjects with minimal response. After adequate follicular development was achieved, the subject was administration human chorionic gonadotropin (hCG) within 24-48 hours of last Gonal-f injection as per investigator discretion.
89002665|NCT06267924|Sham Comparator|2. Moderate or Worse (MoW) Arm|Participants will be randomized to use the Otoband as instructed by clinical coordinator per study protocol. There are 4 power levels, these participants will receive the sham device.
88853715|NCT01871532|Active Comparator|Standard Low Dose Gonal-f® Protocol|Gonal-f was administered subcutaneously daily at a starting dose of 50 International Units (IU) for Week 1, then dose was gradually increased by 12.5 IU for two weeks, up to maximum dose of 125 IU, until Week 4 for subjects with minimal response. After adequate follicular development was achieved, the subject was administration human chorionic gonadotropin (hCG) within 24-48 hours of last Gonal-f injection as per investigator discretion.
88853716|NCT04606992|Experimental|CELS resection|All patients included in the study will be in this arm
88853717|NCT01855074|Experimental|Risperidone|Risperidone 25 milligram (mg) will be given as intramuscular injection for every 2 weeks up to 6 months. Participants with persistent symptoms and/or requiring higher doses of antipsychotics will be administered higher doses of risperidone. Doses will be adjusted as per Investigator's discretion.
88853718|NCT01871142|Experimental|Randomized crossover assignment|Participants will receive, in a random order, a placebo prior to exercise in normoxia, a placebo prior to exercise in hypoxia, 1000 mg of Aes-103 prior to exercise in hypoxia, and 3000 mg of Aes-103 prior to exercise in hypoxia. Each intervention is separated by a 7 day washout period.
88853719|NCT04606290|Active Comparator|Manual|Fixed dose oxygen
88853720|NCT04606290|Experimental|O2matic|Automated oxygen titration
88853721|NCT04411056|Experimental|Barrier box|Participants will have a barrier box placed during intubation
88853722|NCT04411056|No Intervention|No Barrier box|Participants will have routine intubation with no barrier box
88853723|NCT01895322|Experimental|OPC-41061|
88853724|NCT01894776|Experimental|Maraviroc|"Two period pharmacokinetic drug-drug interaction Period one -Maraviroc alone; Period two -Maraviroc and Rifabutin~Substance: Maraviroc (Celsentri, MVC) tablets, 300 mg; dose: oral, 300 mg (1 tablet) twice daily~Substance: Rifabutin (mycobutin, RFB) capsules, 150 mg; dose: oral, 300 mg (2 capsules) once daily"
88853725|NCT01894620|Placebo Comparator|rTMS with sham coil|rTMS real-sham and rTMS sham-real interventions. Each patient will receive both real and sham treatment in two different blocks of time. The assessments after the sham treatment will serve as placebo effect compared to those after real treatment.
88853726|NCT01894620|Active Comparator|rTMS with real coil|rTMS real-sham and rTMS sham-real interventions. Each patient will receive both real and sham treatment in two different blocks of time. The assessments after the sham treatment will serve as placebo effect compared to those after real treatment.
88853727|NCT01854918|Active Comparator|Standard of Care|Participants received standard of care (SOC) treatment for the first year of the study (SOC-controlled period). At week 48, participants began treatment with evolocumab at a dose of either 140 mg every 2 weeks (Q2W) or 420 mg every month (QM), based on participant choice, for approximately 2 years during the all-investigational product [all-IP] period.
88853728|NCT01854918|Experimental|Evolocumab + Standard of Care|Participants received subcutaneous evolocumab plus standard of care during the first year of the study (SOC-controlled period) and for approximately 2 years during the all-IP period. Evolocumab was administered at a dose of 140 mg every 2 weeks (Q2W) or 420 mg every month (QM) based on participant choice.
88853729|NCT01894230|Experimental|Genotype results plus usual care|SLCO1B1*5 allele testing, results reported at randomization: genetic testing for SLCO1B1*5 allele and reporting of results to patient and provider at randomization.
88853730|NCT01894230|Active Comparator|Usual care only|SLCO1B1*5 allele testing, results reported at end of study: genetic testing for SLCO1B1*5 allele and reporting of results to patient and provider at end of study
88853731|NCT01894152||XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS)|Subjects receiving XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS)
88853732|NCT04596930|Experimental|LITT arm|Patients will be randomized to receive biopsy and LITT (n=10)
88853733|NCT01854528|Experimental|3-DAA/RBV|3-DAA (ABT-450/r/ABT-267 [150 mg/ 100 mg/ 25 mg once daily] and ABT-333 [250 mg twice daily]) plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks.
88853734|NCT01854528|Active Comparator|TPV/RBV|TPV (750 mg every 8 hours) coadministered with pegIFN (180 micrograms subcutaneously [SC] weekly) and weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks, followed by pegIFN (180 micrograms SC weekly) and weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for either 12 or 36 weeks, per local prescribing information.
88853735|NCT01853982|Experimental|Ceftolozane/Tazobactam|3000 milligrams (mg) ceftolozane/tazobactam (comprised of 2000 mg ceftolozane and 1000 mg tazobactam), administered intravenously (IV), every 8 hours for 8 days
88853736|NCT01853982|Active Comparator|Piperacillin/Tazobactam|4500 mg piperacillin/tazobactam (comprised of 4000 mg piperacillin and 500 mg tazobactam), administered IV, every 6 hours for 8 days
88853737|NCT01853280|Experimental|L-Methylfolate|15 mg of L-Methylfolate (Deplin®) daily for 12 weeks as a supplement to OROS-Methylphenidate.
88853738|NCT01853280|Placebo Comparator|Placebo|15 mg matched placebo comparator, with open-label OROS-Methylphenidate
89380595|NCT03711539||Late-onset Endurance Athletes|i) Athletes who have initiated endurance sports activities at regional, national or international level after the age of 30 years. Sports include triathlon, cycling, distance running (1500 metres and longer) and rowing. ii) Aged 45-70 years. iii) Involved in competition and high-level training: more than 10 hours per week for cyclists and triathletes or more than 6 hours per week for runners and rowers. Subjects will be excluded if: i) they have a history of smoking (> 5 pack years) or diabetes, ii) they have a history of smoking (> 5 pack years) or diabetes, ii) had been diagnosed with a cardiopulmonary disorder prior to inclusion.
88853739|NCT04415736||Delayed cerebral ischemia|Patients with subarachnoid hemorrhage that develop delayed cerebral ischemia
88853740|NCT04415736||Non delayed cerebral ischemia|Patients with subarachnoid hemorrhage that do not develop subarachnoid hemorrhage
88853741|NCT01892436|Experimental|Secukinumab 75mg|Subjects continued to receive secukinumab 75mg in PFS (same dose as that was received in core study CAIN457F2306) every 4 weeks up to Week 256. From Week 156, patients may have been escalated to 150 mg or 300 mg as judged appropriate by investigator
88853742|NCT01892436|Experimental|Secukinumab 150mg|Subjects continued to receive secukinumab 150mg in PFS (same dose as that was received in core study CAIN457F2306) every 4 weeks up to Week 256. From Week 156, patients may have been escalated to 300 mg as judged appropriate by the investigator
89002666|NCT06267729|Experimental|AZD0754|AZD0754 monotherapy for treatment of participants with metastatic prostate cancer.
89380596|NCT03711539||Healthy Non-athletes|Healthy non-athletes will be recruited from subjects seen in the outpatient clinic for a work-related medical check-up, from university alumni and from multisports organisations. Subjects will be excluded if they: i) had been involved in regular sports practice more than >3 hours / week, ii) have a history of smoking (> 5 pack years) or diabetes, or iii) had been diagnosed with a cardiopulmonary disorder prior to inclusion. Participation in regular sports with a low dynamic component (e.g. billiards, darts or bowling) >3 hours /week is allowed.
89380597|NCT03389555|Experimental|Vitamin C, Vitamin B1, Corticosteroids|"The combination of vitamin C, vitamin B1, hydrocortisone :~Vitamin C (ascorbic acid) 1.5g every 6 hours x 4-days~Vitamin B1 (thiamine) 100mg every 6 hours x 4-days~Hydrocortisone 50mg every 6 hours x 4-days"
89380598|NCT03389555|Placebo Comparator|Placebo|Normal Saline Solution (0.9%NaCl) in a volume to match all experimental arm components
89380599|NCT03714581|Experimental|Laser|Microablative Fractional CO2 Laser Therapy (The parameters that will be used are the following: 1) Power: 30 ή 40 watts, 2) Dwell time:1000μs, 3) Spacing 1000 μm, 4) Depth: SmartStak parameter from 1-3 depending on the treatment status, 5) D-pulse mode.)
89380600|NCT03714581|Placebo Comparator|Placebo|Placebo therapy (The parameters that will be used are the following: 1) Power: 0.5 watts, 2) Dwell time:1000μs, 3) Spacing 1000 μm, 4) Depth: SmartStak parameter 1, 5) Smart-pulse mode.
89380601|NCT03711461|Active Comparator|nonintubated|patients received nonintubated during thoracoscopy
88853743|NCT01892436|Experimental|Placebo - AIN457A 75mg|Placebo (for maintaining the blind till Week 152): Placebo to secukinumab 0.5 mL solution solution for injection was provided in PFS for s.c. administration (a single use pre-filled 1mL long glass syringe). It contained a mixture of inactive excipients, matching the composition of secukinumab 75mg
88853744|NCT01892436|Experimental|Placebo - AIN457 150mg|Placebo (for maintaining the blind till Week 152): Placebo to secukinumab 1 mL solution for injection was provided in PFS for s.c. administration (a single use pre-filled 1mL long glass syringe). It contained a mixture of inactive excipients, matching the composition of secukinumab 150 mg
88853745|NCT04415580|Experimental|Vestibular Rehabilitation Group|
88853746|NCT04415580|Active Comparator|Conventional rehabilitation Group|
88853747|NCT01853046|Experimental|Regorafenib(Stivarga, BAY73-4506)-Normal/Mild Renal Impairment|Participants with normal/mild renal impairment received Regorafenib 160 mg o.d.as a single dose in Stage 1, Day 1 with a washout of at least 5 days, followed by multiple dosing in an intermittent administration schedule (3 week on / 1 week off) over 2 cycles in Stage 2 (56 days). Cycle 2 started immediately after Cycle 1. A Cycle for this study is defined as 28 days.
88853748|NCT01853046|Experimental|Regorafenib (Stivarga, BAY73-4506)-Severe Renal Impairment|Participants with severe renal impairment received Regorafenib 160 mg o.d. as a single dose in Stage 1, Day 1 with a washout of at least 5 days, followed by multiple dosing in an intermittent administration schedule (3 week on / 1 week off) over 2 cycles in Stage 2 (56 days). Cycle 2 started immediately after Cycle 1. A Cycle for this study is defined as 28 days.
88853749|NCT01891890|Active Comparator|Lamotrigine|Lamotrigine 7.0 mg/kg tablets or chewable tablets administered daily in 2 equally divided doses
88853750|NCT01891890|Active Comparator|Oxcarbazepine|Oxcarbazepine 25 mg/kg tablets or liquid administered daily in 2 equally divided doses
89380602|NCT03711461|Experimental|intubated|patients receiving intubated during thoracoscopy
89380603|NCT03395639|Experimental|Edoxaban|Two out of three participants will be randomized for treatment with edoxaban solution or tablets
89380604|NCT03395639|Active Comparator|Standard of Care (SOC)|One out of three participants will be randomized for treatment with the institution's SOC regimen
89380605|NCT03353922|Experimental|Tolperisone HCl 150 mg|150 mg tolperisone tablets or cyclobenzaprine 10 mg oral tablet administered by mouth every 8 hours for 3 days
89380606|NCT03353922|Placebo Comparator|Placebo Oral Tablet|sugar pills administered by mouth every 8 hours for 3 days
89380607|NCT03353922|Active Comparator|Cyclobenzaprine 10 mg oral tablet|10 mg cyclobenzapine tablets administered by mouth every 8 hours for 3 days
89380608|NCT05677932|Experimental|Bright light therapy|10,000lux bright light
89380609|NCT05677932|Experimental|Placebo group|50 lux dim red light
89380610|NCT03711383|Placebo Comparator|Placebo|isocaloric maltodextrin the day before CIDs
89380611|NCT03711383|Active Comparator|Inulin|12 g of inulin + isocaloric maltodextrin the day before CID
89380612|NCT03711383|Experimental|Inulin and Resistant Starch|12 g inulin + 7.5 g resistant starch the day before CID
89380613|NCT03387683|Placebo Comparator|placebo|placebo tablets once daily
89380614|NCT03387683|Experimental|dapagliflozin 10mg|dapagliflozin 10mg tablets once daily
89380615|NCT03714347|Active Comparator|Group Control|routine monitoring will be applied to this group
89380616|NCT03714347|Active Comparator|Group Oxygen|cerebral oxygen monitoring is applied to this group
89380617|NCT05467553|Experimental|TAF and P1101 combination therapy with UDCA|Ursodeoxycholic Acid (UDCA) 15 mg/kg orally (PO) QD plus TAF 25 mg orally (PO) QD for 60 weeks, with P1101 450 µg subcutaneously (SC) Q2W add-on at treatment week 12 for 48 weeks.
89380618|NCT05467553|Active Comparator|TAF and P1101 combination therapy without UDCA|TAF 25 mg orally (PO) QD for 60 weeks with P1101 450 µg sub-cutaneously (SC) Q2W add-on at treatment week 12 for 48 weeks.
89380619|NCT03387059|Experimental|Forielle Endometrial Washing|
89380620|NCT03387059|No Intervention|No Endometrial Washing|
89380621|NCT02942004|Placebo Comparator|Placebo|Participants received infusion rates equivalent to either the 60 micrograms per kilogram per hour (μg/kg/h) or 90 μg/kg/h group.
89380622|NCT02942004|Experimental|SAGE-547 60 μg/kg/h|Participants received a 4-hour titration period of 30 μg/kg/h (0 to 4 hours), then 60 μg/kg/h (4 to 56 hours), followed by a taper to 30 μg/kg/h (56 to 60 hours).
89380623|NCT02942004|Experimental|SAGE-547 90 μg/kg/h|Participants received a 4-hour dose titration period of 30 μg/kg/h (0 to 4 hours), then 60 μg/kg/h (4 to 24 hours), then 90 μg/kg/h (24 to 52 hours), followed by a taper to 60 μg/kg/h (52 to 56 hours), and 30 μg/kg/h (56 to 60 hours).
89380624|NCT03394391|Experimental|Intervention group|Daily ART-adherence SMS reminder
89380625|NCT03394391|Active Comparator|Control group|Standard adherence counselling/Patient experience group chat
89380626|NCT03711695||Group A|Subjects presenting for catheter ablation for cardiac arrhythmias (e.g. atrial fibrillation, supraventricular tachycardia, or ventricular tachycardia)
88853751|NCT01891890|Active Comparator|Levetiracetam|Levetiracetam 30 mg/kg tablet or liquid administered daily in 2 equally divided doses
88853752|NCT01852812|Experimental|Montelukast 4 mg OG/1-5 year olds|Participants receive montelukast 4 mg OG in one sachet orally (PO) once daily (QD) at bed time for 4 weeks with an option to continue for an additional 8 weeks (12 weeks total)
88853753|NCT01852812|Experimental|Montelukast 5 mg CT/6-9 year olds|Participants receive montelukast 5 mg CT in one tablet PO QD at bed time for 12 weeks
88853754|NCT01852812|Experimental|Montelukast 5 mg CT/10-15 year olds|Participants receive montelukast 5 mg CT in one tablet PO QD at bed time for 12 weeks
89380627|NCT03711695||Group B|Subjects judged based on the clinical evaluation of high, greater than 75%, atrial pacing or ventricular pacing burden or known pacing dependence with planned device interrogation for: 1) pacemaker (single or dual chamber), 2) implantable cardioverter-defibrillator (single or dual chamber), or 3) cardiac resynchronization therapy with or without defibrillator (single or dual chamber plus left ventricular pacing).
89380628|NCT03711695||Group C|Subjects for clinically indicated defibrillation threshold testing (DFT) (with a transvenous or subcutaneous implantable cardioverter defibrillator (ICD) lead system)
89380629|NCT01311791|Experimental|Algisyl-LVR|Algisyl-LVR™ device (implants) administered during a surgical procedure.
89380630|NCT01311791|Active Comparator|Standard Medical Therapy|as per protocol
89380631|NCT03714269|Experimental|Children with cerebral palsy of the spastic type|
89380632|NCT01311869|Active Comparator|EGCG ( Green Tea extract)|40 subjects will receive 800 mg EGCG orally per day for 6 months versus 40 subjects will receive Brown Rice pill for 6 months
89380633|NCT01311869|Placebo Comparator|Brown Rice pills|40 subjects will receive 800 mg brown rice pills orally per day for 6 months versus 40 subjects will receive EGCG capsule for 6 months
89380634|NCT03386435|Experimental|RIPC|intervention: RIPC groups receive remote ischaemic preconditioning after anaesthesia induction and before surgery started.
89380635|NCT03386435|No Intervention|Control|In the control group, the same maneuver was applied but without cuff inflation.
89380636|NCT03714191||Improved outcomes|
89380637|NCT03714191||Regulatory reminder|
89380638|NCT03714191||Billing and documentation|
89380639|NCT02912208|Experimental|Arm 1 (Eltrombopag)|Arm 1 is the active treatment arm
89380640|NCT02912208|Placebo Comparator|Arm 2 (Placebo)|Arm 2 is the control arm
88853755|NCT04602624|Experimental|SAGE-718|Participants will receive a single dose of SAGE-718 oral tablets, once daily in the morning for 14 days.
89380641|NCT02793258|Placebo Comparator|Placebo tDCS|"Subjects will receive 10 30-minutes sessions of sham tDCS, twice a day for 5 consecutive day.~Facial emotion recognition task and attentional task with measurement of eye-tracking, heartrate, respiratory frequency and skin conductance will be conducted before and after the first session, and after the last session."
89380642|NCT02793258|Experimental|Active tDCS|"receive 10 30-minutes sessions of two milliamps tDCS, twice a day for 5 consecutive day.~Stimulation will be performed using an tDCS stimulator with two 7×5 cm (35 cm2) sponge electrodes soaked in a saline solution (0.9% NaCl) Anode will be placed over the left dorsolateral prefrontal cortex (F3 according to the international EEG system) and cathode over the right dorsolateral prefrontal cortex (F4 according to the international EEG system) The twice daily sessions will be separated by at least 2 hours."
89380643|NCT02726880|Active Comparator|Referral for care|
89380644|NCT02726880|Experimental|Behavioral therapy|
89380645|NCT03275389|Experimental|D-SUIV Adjuvanted Group 1|Subjects received one dose of D-SUIV cH8/1N1+AS03 vaccine at Day 1, one dose of Placebo at Day 57 and one booster dose of D-SUIV cH5/1N1+AS03 vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm.
89380646|NCT03275389|Experimental|D-SUIV Adjuvanted Group 2|Subjects received one dose of D-SUIV cH5/1N1+AS03 vaccine at Day 1, one dose of Placebo at Day 57 and one booster dose of D-SUIV cH8/1N1+AS03 vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm.
89380647|NCT03275389|Experimental|D-SUIV Adjuvanted Group 3|Subjects received one dose of D-SUIV cH8/1N1+AS03 vaccine at Day 1, one dose D-SUIV cH5/1N1+AS03 vaccine at Day 57 and one booster dose of D-SUIV cH11/1N1+AS03 vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm.
89380648|NCT03275389|Experimental|D-SUIV Adjuvanted Group 4|Subjects received one dose of D-SUIV cH8/1N1+AS01 vaccine at Day 1, one dose of Placebo at Day 57 and one booster dose of D-SUIV cH5/1N1+AS01 vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm.
89380649|NCT03275389|Experimental|D-SUIV Adjuvanted Group 5|Subjects received one dose of D-SUIV cH5/1N1+AS01 vaccine at Day 1, one dose of Placebo at Day 57 and one booster dose of D-SUIV cH8/1N1+AS01 vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm.
89380650|NCT03275389|Experimental|D-SUIV Adjuvanted Group 6|Subjects received one dose of D-SUIV cH8/1N1+AS01 vaccine at Day 1, one dose of D-SUIV cH5/1N1+AS01 vaccine at Day 57 and one booster dose of D-SUIV cH11/1N1+AS01 vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm.
89380651|NCT03275389|Experimental|D-SUIV Unadjuvanted Group 1|Subjects received one dose of D-SUIV cH8/1N1 vaccine at Day 1, one dose of Placebo at Day 57 and one booster dose of D-SUIV cH5/1N1 vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm.
89380652|NCT03275389|Experimental|D-SUIV Unadjuvanted Group 2|Subjects received one dose of D-SUIV cH5/1N1 vaccine at Day 1, one dose of Placebo at Day 57 and one booster dose of D-SUIV cH8/1N1 vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm.
89380653|NCT03275389|Experimental|D-SUIV Unadjuvanted Group 3|Subjects received one dose of D-SUIV cH8/1N1 vaccine at Day 1, one dose of D-SUIV cH5/1N1 vaccine at Day 57 and one booster dose of D-SUIV cH11/1N1 vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm.
89380654|NCT03275389|Active Comparator|IIV4 Group|Subjects received one dose of Fluarix Quadrivalent (IIV4) vaccine at Day 1, one dose of Placebo at Day 57 and one dose of Fluarix Quadrivalent vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm.
89380655|NCT03414359|Active Comparator|2% Lidocaine|Group LEBF received 20 ml of 2% lidocaine (combined with the following adjuncts [0.15 ml of 0.1% epinephrine, 2 ml of 8.4% sodium bicarbonate and 2 ml of 100 mcg fentanyl
88853756|NCT01869348|No Intervention|Wait list control|This group will receive no intervention until after data collection for the randomized trial is completed. Then, they will receive the monitor intervention.
89380656|NCT03414359|Experimental|3% Chloroprocaine|20 ml of 3% chloroprocaine with 4 ml 0.9% sodium chloride
89380657|NCT03285295|Experimental|Screening|All subjects will be tested with at least one of the investigational Alinity s assays (Anti-HBc, Anti-HCV, HTLV I/II, Chagas, HBsAg, HBsAg Confirmatory, HIV Ag/Ab Combo) on Alinity s system.
89380658|NCT02583048|Experimental|Arm 1: Bedaquiline|"Participants received 400 mg of bedaquiline once a day for 2 weeks followed by 200 mg of bedaquiline three times a week for 22 weeks.~Participants also received Multidrug Background Treatment (MBT) for TB.~For HIV-positive participants only, one 50 mg tablet of Dolutegravir was taken in combination with two NRTIs until study completion."
89380659|NCT02583048|Experimental|Arm 2: Delamanid|"Participants received 100 mg of delamanid twice a day for 24 weeks.~Participants also received Multidrug Background Treatment (MBT) for TB.~For HIV-positive participants only, one 50 mg tablet of Dolutegravir was taken in combination with two NRTIs until study completion."
89380660|NCT02583048|Experimental|Arm 3: Bedaquiline and Delamanid|"Participants received 400 mg of bedaquiline once a day and 100 mg of delamanid twice a day for 2 weeks. They then received 200 mg of bedaquiline three times a week and 100 mg of delamanid twice a day for 22 weeks.~Participants also received Multidrug Background Treatment (MBT) for TB.~For HIV-positive participants only, one 50 mg tablet of Dolutegravir was taken in combination with two NRTIs until study completion."
89380661|NCT02939599|Experimental|QCC374|"placebo patients from QCC374X2201 rolled into extension study will start at 0.03mg b.i.d. or 0.06mg b.i.d. and have the opportunity to up-titrate 0.12mg~-active patients will continue at the dose they finished on the QCC374X2201 study"
89380662|NCT05198622|Experimental|Intercostobrachial Nerve Preservation Arm|Intercostobrachial nerve preserving axillary lymph node dissection will be carried out. Post-operatively, the patients will be monitored in the post anesthesia care unit (PACU). Acute Post-Operative pain will be controlled using a standardized pain management regimen in accordance with World Health Organization (WHO) analgesia ladder. The patients will be discharged from PACU and admitted to surgical ward once numerical rating score (NRI) is below 4.
89380663|NCT05198622|Active Comparator|Intercostobracial Nerve Sacrifice Arm|Intercostobrachial nerve sacrificing axillary lymph node dissection will be carried out. Post-operatively, the patients will be monitored in the post anesthesia care unit (PACU). Acute Post-Operative pain will be controlled using a standardized pain management regimen in accordance with World Health Organization (WHO) analgesia ladder. The patients will be discharged from PACU and admitted to surgical ward once numerical rating score (NRI) is below 4.
89380664|NCT05186766|Experimental|Intervention Group|Video-Assisted Operating Room Introduce Program (VIASP-OR)
89380665|NCT05186766|No Intervention|Control Group|Standart Nursing Care
89380666|NCT01318512||Chronic Kidney Disease|Participants with CKD, not undergoing haemodialysis in clinical practice setting and started treatment with methoxy polyethylene glycol-epoetin beta (MIRCERA) subcutaneously (SC) as per summary of product characteristics (SPC) due to decreased levels of haemoglobin.
89380667|NCT05160714|Experimental|Adaptive SBRT Boost|Dose-escalated SBRT boost to an ADC-based high risk subvolume in HNC
89380668|NCT02816658|Active Comparator|Laparoscopic Surgery|Laparoscopic Inguinal Hernia Repair through a Transabdominal, Preperitoneal Approach
89380669|NCT02816658|Active Comparator|Robotic Surgery|Robotic Inguinal Hernia Repair
88853757|NCT01869348|Experimental|Monitor intervention|This arm will receive the monitor intervention, including provision of a wristband activity monitor and mini-tablet as well as weekly counseling phone calls
89380670|NCT05142774|Experimental|tapinarof cream|Tapinarof 1%, cream
89380671|NCT03274687|Active Comparator|Conventional radiation therapy|Conventional post-prostatectomy radiation therapy (COPORT) over 7 weeks. Patients may also receive optional androgen deprivation therapy per doctor recommendation.
89002667|NCT06266715|Placebo Comparator|Placebo Group|Cap escitalopram 10mg once daily (OD) for four weeks and injection 110ml NS twice daily (BD) for two weeks.
89380672|NCT03274687|Experimental|Hypofractionated radiation therapy|Hypofractionated post-prostatectomy radiation therapy (HYPORT) over 5 weeks. Patients may also receive optional androgen deprivation therapy per doctor recommendation.
88853758|NCT01869192|Active Comparator|Arm A|Arm A: Epirubicin 90 mg/m2 day 1 IV and Cyclophosphamide 600 mg/m2 day 1 IV q 3 weeks for 4 cycles, then surgery, then Docetaxel 75 mg/m2 IV day 1 plus Capecitabine 1000 mg/m2/dose po bid x 14 days q 3 weeks for 4 cycles, then radiation therapy as indicated. Post surgical chemotherapy must be initiated within 35 days after completion of definitive surgical treatment
88853759|NCT01869192|Active Comparator|Arm B|Arm B: Docetaxel 75 mg/m2 IV day 1 plus Capecitabine 1000 mg/m2/dose po bid x 14 days q 3 weeks for 4 cycles, then surgery, then Epirubicin 90 mg/m2 day 1 IV and Cyclophosphamide 600 mg/m2 day 1 IV q 3 weeks for 4 cycles, then radiation therapy as indicated. Post surgical chemotherapy must be initiated within 35 days after completion of definitive surgical treatment
88853760|NCT04415190||cholangiocarcinoma with early palliative care|
88853761|NCT04415190||cholangiocarcinoma without early palliative care|
88853762|NCT04615884|Experimental|Chinese herbs formula: Shu Yu Wan|Participants will receive Shu Yu Wan capsules, to take 3 times daily for 6 weeks.
88853763|NCT04615884|Placebo Comparator|Placebo|Participants will receive capsules to take 3 times daily for 6 weeks.
88853764|NCT01868646|Experimental|Subetta|
88853765|NCT01868646|Placebo Comparator|Placebo|
88853766|NCT01852110|Experimental|MK-7622 High Dose - 45 mg (Stage 1)|Single 45 mg MK-7622 capsule once daily, taken orally. Dose escalated as follows: 15 mg MK-7622 once daily for 1 week; 30 mg MK-7622 once daily for 1 week; and 45 mg MK-7622 once daily for the remainder of treatment.
88853767|NCT01852110|Placebo Comparator|Placebo (Stage 1)|Matching placebo to MK-7622 capsule once daily, taken orally.
88853768|NCT01852110|Experimental|MK-7622 Low Dose - 5 mg (Stage 2)|Single 5 mg MK-7622 capsule once daily, taken orally.
88853769|NCT01852110|Experimental|MK-7622 Mid Dose - 15 mg (Stage 2)|Single 15 mg MK-7622 capsule once daily, taken orally.
88853770|NCT01852110|Experimental|MK-7622 High Dose - 45 mg (Stage 2)|Single 45 mg MK-7622 capsule once daily, taken orally. Dose escalated as follows: 15 mg MK-7622 once daily for 1 week; 30 mg MK-7622 once daily for 1 week; and 45 mg MK-7622 once daily for the remainder of treatment.
88853771|NCT01852110|Placebo Comparator|Placebo (Stage 2)|Matching placebo to MK-7622 capsule once daily, taken orally.
88853772|NCT01851720|Active Comparator|Control group / Standard of Care|"IV fentanyl bolus 25-50 mcg every 1-2 hrs as needed for pain~(Bolus dose can be titrated up in 25 mcg increments if necessary)~Maximum dose of 100 mcg/hr"
89380673|NCT03909750|Experimental|Lipoaspiration Microcannula ARM 1|Acquisition of Adipose-Derived tissue Stromal Vascular Fraction (AD-tSVF) via closed syringe harvest subdermal fat
89380674|NCT03909750|Experimental|Isolation-Concentration Adipose cSVF ARM 2|Isolation of cellular stem/stromal cells from subdermal adipose-derived cellular stromal vascular fraction (AD-cSVF)
89380675|NCT03909750|Experimental|Normal Saline IV ARM 3|Sterile Normal Saline IV with cSVF
88853773|NCT01851720|Active Comparator|Low dose IV fentanyl PCA|"Initially: 10 mcg demand dose every 12 minutes~No initial bolus and no continuous infusion~Demand dose increased 10 mcg every 12 minutes if necessary~Maximum dose of 100 mcg/hr"
88853774|NCT01851330|Experimental|LDV/SOF 8 Week|Participants will receive LDV/SOF FDC for 8 weeks.
88853775|NCT01851330|Experimental|LDV/SOF+RBV 8 Week|Participants will receive LDV/SOF FDC plus RBV for 8 weeks.
88853776|NCT01851330|Experimental|LDV/SOF 12 Week|Participants will receive LDV/SOF FDC for 12 weeks.
88853777|NCT01868022|Experimental|Arm A: GSK3052230 + paclitaxel/carboplatin|Subject will receive GSK3052230 as 30-minute intravenous (i.v.) infusion once a week (Day 1, Day 8, Day 15) of each 21-day cycle + paclitaxel (constant infusion for 3 hrs) and carboplatin (constant infusion for 30 to 60 minutes) iv on Day 1 of each 21-day cycle. The number of cycles of paclitaxel/carboplatin will be limited to 4 to 6 cycles.
88853778|NCT01868022|Experimental|Arm B: GSK3052230 + docetaxel|Subject will receive GSK3052230 as 30-minute intravenous (i.v.) infusion once a week (Day 1, Day 8, Day 15) of each 21-day cycle + docetaxel as 1 hour iv infusion on Day 1 of each 21-day cycle. Subjects may continue to receive docetaxel until disease progression or as long as they are considered to derive benefit from treatment.
88853779|NCT01868022|Experimental|Arm C: GSK3052230 + pemetrexed and cisplatin|Subject will receive GSK3052230 as 30 minute iv infusion once a week (Day 1, Day 8, Day 15) of each 21 day cycle + pemetrexed iv infusion over 10 minutes on Day 1 of each 21 day cycle followed 30 minutes later by iv Cisplatin infused over 2 hours
88853780|NCT01850004|Experimental|Dasatinib|Dasatinib 50, 80, 100, 140, 180 mg tablets by mouth, once daily, up to 60 months
88853781|NCT01867710|Experimental|AA + prednisone 5 mg twice daily|Abiraterone acetate in combination with prednisone 5 mg twice daily
88853782|NCT01867710|Experimental|AA + prednisone 5 mg once daily|Abiraterone acetate in combination with prednisone 5 mg once daily dose
88853783|NCT01867710|Experimental|AA + prednisone 2.5 mg twice daily|Abiraterone acetate in combination with prednisone 2.5 mg twice daily
88853784|NCT01867710|Experimental|AA + dexamethasone 0.5 mg once daily|Abiraterone acetate in combination with dexamethasone 0.5 mg once daily
88853785|NCT01849848|Experimental|SyB L-0501|
88853786|NCT01849458||BioFiber|Subjects implanted with BioFiber Scaffold or BioFiber-CM Scaffold
88853787|NCT04415034||Pediculosis capitis|Subjects with pediculosis capitis based on the findings of eggs, larva, or an adult parasite on the scalp or in the hair
89380676|NCT04651218|No Intervention|control|sedentary control group watches TV between being assessed for outcome measures
89380677|NCT04651218|Experimental|exercise|exercise treatment performs exercise between being assessed for outcome measures
89399495|NCT02176616|Experimental|pulmonary vein isolation|The group of negative is the operation to patients with only pulmonary vein isolation based on patients who were changed to paroxysmal atrial fibrillation from persistent atrial fibrillation
89380678|NCT05114382|Other|A prospective, multi-center, open-label, single arm study|Patients undergoing assessment and ablation of cardiac arrhythmiast. who are scheduled for an electrophysiology (EP) procedure and meet all inclusion criteria will be enrolled in the study and undergo the EP procedure. Intracardiac signals will be passively recorded using the CathVision Cube® System in parallel with the commercial (CE marked) EP recording system for post procedure evaluation. The investigational device will not be used for direct clinical care decisions or therapy. The EP procedure will be guided by the study site Standards Of Care.
89380679|NCT02542956|Active Comparator|Exparel|Injection of Exparel
89380680|NCT02542956|Active Comparator|Marcaine|Receive Marcaine in a pain pump or by injection
89380681|NCT03274453|Active Comparator|Ketamine Naive|"After an initial bolus of 0.2 mg/kg, the dose will be fixed at 0.12 mg/kg/hr of ketamine.~Infusion will be maintained for 24 hours."
89380682|NCT03274453|Placebo Comparator|Naive Placebo|Saline will be administered at the same rate as the ketamine infusion. Infusion will be maintained for 24 hours.
89380683|NCT03274453|Placebo Comparator|Tolerant Placebo|Saline will be administered at the same rate as the ketamine infusion. Infusion will be maintained for 24 hours.
89380684|NCT03274453|Experimental|Tolerant Ketamine|"After an initial bolus of 0.2 mg/kg, the dose will be fixed at 0.12 mg/kg/hr of ketamine.~Infusion will be maintained for 24 hours."
89380685|NCT02313870|Experimental|A|Superpotent topical steroids/methotrexate
89380686|NCT02313870|Other|B|Superpotent topical steroids (clobetasol propionate)
89380687|NCT02847949|Experimental|Extension arm|IGN002 study drug will initially be administered at the same dose level and schedule that the subject was receiving at the conclusion of the other Spectrum sponsored IGN002 study, IGN002-101.
89380688|NCT01942122|Experimental|DLBS1442 100|DLBS1442 capsules 3x100 mg daily, taken every day along the study period
89380689|NCT01942122|Experimental|DLBS1442 200|DLBS1442 capsules 3x200 mg daily, taken every day along the study period
89380690|NCT01942122|Active Comparator|Mefenamic acid|Mefenamic acid tablets 3 x 500 mg daily, only taken for five (5) days during the menstrual period, i.e. day 1st to day 5th of menstrual period.
89380691|NCT04297345|Experimental|hemodialysis group|"The active group will include patients with acute ischemic stroke who, in addition to conventional treatment (best possible medical treatment in patients admitted to a stroke unit), will undergo two hemodialysis sessions for a period of about 3 hours each session in the acute phase of stroke.~The investigators will perform a conventional and heparin-free hemodialysis using high-flow dialyzers to avoid possible adverse (allergic) reactions with polysulfones containing other dialyzers."
89380692|NCT04297345|No Intervention|control group|The control group will be composed of patients with similar clinical and demographic characteristics to whom only conventional medical treatment will be applied.
89380693|NCT01816932|Experimental|Home Visit|20 participants will be randomized to receive a home visit for the insertion of their implantable birth control rather than the standard office visit.
89380694|NCT01816932|Placebo Comparator|Office Visit|20 participants will be randomized to receive an office visit (standard of care).
89380695|NCT01783704|Experimental|PUSH and Nutrition|PUSH is a specific multi-component intervention based on improving specific precursors to community ambulation. The intervention addresses endurance with continuous upright exercise for 20 min.; function by improving fast walking, standing from a chair, and stair negotiation; muscle performance by exercising to enhance lower extremity strength; and balance by performing unilateral activities and activities with decreased base of support. Participants receive 32 visits of approximately 60 minutes in duration from a study PT. Participants will receive up to three visits a week, on non-consecutive days, for 16 weeks. Visits take place in the participant's place of residence. Participants also receive the nutritional intervention for the duration of the 16-week study.
89380696|NCT01783704|Experimental|PULSE and Nutrition|PULSE is a non-specific multi-component intervention in which participants will receive flexibility exercises, active range of motion (AROM) for the upper and lower extremities, breathing exercises, and transcutaneous electrical nerve stimulation (TENS). Participants receive 32 visits of approximately 60 minutes in duration from a study PT. Participants will receive up to three visits a week, on non-consecutive days, for 16 weeks. Visits will take place in the participant's place of residence. Participants will also receive the nutritional intervention for the duration of the 16-week study.
89380697|NCT03627780||PONV|Patients presenting with postoperative nausea and vomiting
89380698|NCT03627780||no PONV|Patients not presenting with postoperative nausea and vomiting
89380699|NCT04246021|Experimental|Ferric carboxymaltose (ferrinject)|"Patients will receive one or two doses of Ferric carboxymaltose (ferrinject), based on the body weight and Hb level.~Ferric carboxymaltose will be administered as a single infusion if the needed dose is 1000 mg as a short IV infusion~If the needed Ferric carboxymaltose dose is > 1000 mg, an initial dose of 1000 mg will be given as a short IV infusion and the remaining dose will be given the week after in a similar fashion"
88853788|NCT01832766|Active Comparator|dronabinol|dronabinol 10 mg one capsule by mouth at 8:00 a.m.
88853789|NCT01832766|Placebo Comparator|sugar pill|one capsule given by mouth at 8:00 a.m.
88853790|NCT01832532|Experimental|Treatment group- liraglutide|Treatment group- liraglutide daily use of drug. Titrated up from 0.6mg/day to 1.8mg/day or highest tolerated dose.
89380700|NCT03627702||Study group|All bedsores were irradiated with a Bioptron lamp. Photo and measurement of bedsores size and Torrance score, were made: on the first, 9,18 and 36 day of therapy.
89380701|NCT02236806|Experimental|Arm 1|bisoprolol plus ramipril
89380702|NCT02236806|Active Comparator|Arm 2|Bisoprolol plus placebo
88853791|NCT01832532|No Intervention|Control group|Control group
89380703|NCT02236806|Active Comparator|Arm 3|Ramipril plus placebo
89380704|NCT02236806|Placebo Comparator|Arm 4|Placebo
89380705|NCT01578954|Experimental|Drug|Lenalidomide (25, 35, or 50 mg induction/10mg maintenance)
89399496|NCT03689283|Experimental|Dry Needling Group|Individuals in the DN arm will receive two treatment sessions of DN to latent trigger points of the gastrocnemius muscle.
88853792|NCT04414956|Other|Surveillance|All participants will be examined with three biomarker tests and sonography every six months and contrast-enhanced CT annually.
89002668|NCT06266715|Experimental|ATP Group|Cap escitalopram 10mg OD for four weeks and injection ATP 100mg in 100ml NS BD for two weeks.
89380706|NCT00659646|Experimental|A|Gentamicin sponge applied into wound plus levofloxacin, 750 mg by mouth (po) or intravenous (IV) every 24 hours or, if ulcer culture results show resistance to levofloxacin, alternative antimicrobial therapy as determined by susceptibility testing
89380707|NCT00659646|Active Comparator|B|Levofloxacin, 750 mg po or IV every 24 hours or, if ulcer culture results show resistance to levofloxacin, alternative antimicrobial therapy as determined by susceptibility testing
88853793|NCT04589910|Other|Ultra-sound arm|Ultrasound measurement of the diaphragm will be performed with the use of a Sono Site SII, portable system in B mode with the child in a 30-degree supine position. The diaphragm thickness will be measured with a high frequency (4-10 MHz) linear array transducer placed in the ninth or tenth intercostal space between the anterior and midaxillary lines in the zone of apposition between lung and liver.
89380708|NCT02236572|Experimental|Aromatase Inhibitor plus Everolimus|Aromatase inhibitor plus everolimus by mouth daily for 26 weeks
89380709|NCT03054870|Other|Xe-133 Followed by Technegas|Subjects first inhaled active comparator Xe-133, approximately 10 to 30 millicuries (mCi), and ventilation planar scintigraphy was performed per site standard of care procedures for subject medical need. On the same day, following completion of Xe-133 imaging, subjects inhaled experimental Technegas (Technetium-99m labeled carbon particles), approximately 1.1 mCi, and ventilation planar scintigraphy was performed.
89380710|NCT03414047|Experimental|Prexasertib Cohort 1|Participants received 105 milligram per square meter (mg/m²) prexasertib as an approximately 60 (+10) minute IV infusion on Day 1 and 15 of a 28-day cycle. Participants were with platinum-resistant disease, breast cancer susceptibility gene (BRCA) negative and have received ≥3 lines of prior therapy.
89380711|NCT03414047|Experimental|Prexasertib Cohort 2|Participants received 105 mg/m² prexasertib as an approximately 60 (+10) minute IV infusion on Day 1 and 15 of a 28-day cycle. Participants were with platinum-resistant disease, BRCA negative and have received <3 lines of prior therapy.
89380712|NCT03414047|Experimental|Prexasertib Cohort 3|Participants received 105 mg/m² prexasertib as an approximately 60 (+10) minute IV infusion on Day 1 and 15 of a 28-day cycle. Participants were with platinum-resistant disease, BRCA positive and received a prior poly ADP ribose polymerase (PARP) inhibitor.
89380713|NCT03414047|Experimental|Prexasertib Cohort 4|Participants received 105 mg/m² prexasertib as an approximately 60 (+10) minute IV infusion on Day 1 and 15 of a 28-day cycle. Participants were with platinum refractory disease, BRCA positive or negative, no restriction on number of lines of prior therapy.
89380714|NCT03711227||Procalcitonin lab test|A procalcitonin order bundle will be created for admitted patients with pneumonia. This prepopulated bundle includes an initial and 24 hour procalcitonin level. These patients will receive treatment for their pneumonia as is deemed appropriate by their care teams, both in the Emergency Department and while an inpatient. Then, after discharge, the 30 day mortality, length of stay, choice of antibiotic therapy, and qSOFA score (which will be retroactively calculated) will be compared to the patient's initial and 24 hour procalcitonin level.
89380715|NCT03709901|Experimental|Active Allograft|Injection of viable allograft
89380716|NCT03709901|Placebo Comparator|Placebo|Injection of saline
89380717|NCT03709901|No Intervention|Conservative Care|Continued conservative care treatment
89380718|NCT05448677|Experimental|Experimental|Ezurpimtrostat+Atezolizumab-Bevacizumab
89380719|NCT05448677|Active Comparator|Control|Atezolizumab-Bevacizumab
89380720|NCT04858932||Fried Frailty Phenotype 0|Those who are considered Robust under the Fried Frailty Criteria. Sensor technology and digital measures will be used to evaluate movement, metabolism, body weight composition, glucose levels, and nutritional scale in healthy adults.
89380721|NCT04858932||Fried Frailty Phenotype 1-2|Those who are considered Intermediate/Pre-frail under the Fried Frailty Criteria. Sensor technology and digital measures will be used to evaluate movement, metabolism, body weight composition, glucose levels, and nutritional scale in healthy adults.
89380722|NCT04858932||Fried Frailty Phenotype 3+|Those who are considered Frail under the Fried Frailty Criteria. Sensor technology and digital measures will be used to evaluate movement, metabolism, body weight composition, glucose levels, and nutritional scale in healthy adults.
89380723|NCT05216718|Experimental|Conventional flap|BABA robotic-thyroidectomy that using conventional flap
89380724|NCT05216718|Active Comparator|Mini-flap|BABA robotic-thyroidectomy that using Mini-flap
89380725|NCT03351335|Experimental|Ultherapy®, energy level 3|Group 1: Subjects will receive Ultherapy® treatment at energy level 3 (EL3).
89380726|NCT03351335|Experimental|Ultherapy®, energy level 4|Group 2: Subjects will receive Ultherapy® treatment at energy level 4 (EL4).
89380727|NCT03351335|Experimental|Ultherapy®, energy level 2|Group 3: Subjects will receive Ultherapy® treatment at energy level 2 (EL2).
89380728|NCT05216640|Active Comparator|High Flow Nasal Cannula|Standard operating procedures represented by high flow nasal cannula oxygen therapy
89380729|NCT05216640|Active Comparator|High Velocity Nasal Insufflation|Standard operating procedures represented by high velocity nasal insufflation therapy
89380730|NCT03711149|Experimental|Intervention Arm|Intervention: Activity monitor feedback loop: (1) Subjects will receive activity monitor with feedback on daily step count from the in-room TV screen, and (2) access to the Art Tour application
89380731|NCT03711149|No Intervention|Standard-of-care Arm|"Subjects in the control arm will receive a blinded activity monitor post-op (without feedback on step count) and the usual standard of care. Nurses and doctors will not monitor ambulation with the activity monitor, they will use standard methods of observation."
88853794|NCT04415112|Active Comparator|Mediterranean Diet|The MD diet is rich in plant based foods including vegetables, whole cereal and fruit with the main added fat being extra virgin olive oil. In addition, the diet emphasises, while consumption of legumes, nuts and fish is high, consumption of red meat and home-made desserts is low, and consumption of fermented milk and poultry is moderate. The MD diet had a target macronutrient composition of 35-40% fat (with <10% of energy as saturated fat), 40-44% carbohydrate and 20% protein.
89380732|NCT00472680|Experimental|1|High Dietary Protein
89380733|NCT00472680|Active Comparator|2|Normal Dietary Protein
89380734|NCT03619746|No Intervention|Pre-Intervention|Current practice (unchanged). This arm of patients will cared for by physicians who have NOT received the POCUS Educational Intervention.
89380735|NCT03619746|Experimental|Post-Intervention|This arm of patients will cared for by physicians who have received the POCUS Educational Intervention.
89380736|NCT04811898|Experimental|Experimental single arm|Single group with 5 dose escalation for each cohort (0,5 mg/kg; 1 mg/kg; 2 mg/kg; 3 mg/kg; 5 mg/kg)
89380737|NCT05223270|Experimental|intervention group-1|Hydrocolloid wound dressings were placed on the pressure areas under the NIMV mask of the patients in this group.
89380738|NCT05223270|Experimental|intervention group-2|Hydrocelluler wound dressings were placed on the pressure areas under the NIMV mask of the patients in this group.
89380739|NCT05223270|No Intervention|control group|Patients in this group were treated without placing an additional dressing under the NIMV mask.
89380740|NCT05669898|Active Comparator|Single-injection ACB combined with IV-PCA morphine|Allocation of which participant is to receive single-injection adductor canal block combined with intravenous morphine patient-controlled analgesia (IV-morphine PCA) is determined by randomization, using a computer-generated random sequence and opaque sealed envelopes. After completion of the TKA surgery and surgical suturing, adductor canal block will be performed by an anesthesiologist. Under ultrasound guidance, the femoral artery and the saphenous nerve are identified in the middle one-third of the thigh, deep to the sartorious muscle in the adductor canal. The sartorious and adductor muscles form the roof and the floor of the canal, respectively. Following skin infiltration, 20 mL of 0.25% bupivacaine with 1:400000 epinephrine is injected through a 3-inch, 23-gauge, short bevel block needle. Finally, the IV-morphine PCA will be connected to the intravenous catheter of the patient for postoperative pain management.
89380741|NCT05669898|Active Comparator|Continuous adductor canal infusion combined with intravenous NSAID|Allocation of which participant is to receive continuous adductor canal infusion in combination with intermittent intravenous non-steroidal anti-inflammatory drug (NSAID) is determined by randomization, using a computer-generated random sequence and opaque sealed envelopes. After completion of the TKA surgery and surgical suturing, a peripheral nerve catheter will be implanted into adductor canal by an anesthesiologist. Under ultrasound guidance, the femoral artery and the saphenous nerve are identified in the middle one-third of the thigh, deep to the sartorious muscle in the adductor canal. The sartorious and adductor muscles form the roof and the floor of the canal, respectively. Following the peripheral nerve catheter is implanted, 20 mL of 0.25% bupivacaine with 1:400000 epinephrine is injected through the catheter. Intravenous tenoxicam 20 mg for a total amount of 3 doses at 24-hour interval after surgery will be added in the postoperative pain management.
89380742|NCT05223114||HIV+COPD+|40 male and female adults > 35 years with COPD and HIV
89380743|NCT05223114||HIV+COPD-|40 male and female adults > 35 years with HIV but no COPD
89380744|NCT05223114||HIV-COPD+|40 male and female adults > 35 years with COPD not HIV
89380745|NCT05223114||HIV-COPD-|40 male and female adults > 35 years with no COPD and no HIV
89380746|NCT05222958|Experimental|Experimental:|The intervention consists of using a smoking cessation app. Patients assigned to the intervention group will be given the access code to the Gestobb App and advice on how to use it.
89380747|NCT05222958|No Intervention|No intervention|Patients in the control group will continue their follow-up visits at ASSIR and will be offered smoking cessation treatment following standard practice protocols.
89380748|NCT04641156|Experimental|Low level LASER Therapy|Subjects in this group received low-level laser therapy
89380749|NCT04641156|Experimental|Exercise group|Subjects in this group received additional planned exercise therapy program
89380750|NCT04618614|Experimental|HD-tDCS S1 1 mA|Single session of 15-min HD-tDCS to the right primary somatosensory cortex with an intensity of 1 mA. The session will last approximately one hour.
89380751|NCT04618614|Active Comparator|HD-tDCS M1 1 mA|Single session of 15-min HD-tDCS to the right primary motor cortex with an intensity of 1 mA. The session will last approximately one hour.
89380752|NCT04618614|Sham Comparator|Sham control|Single session of 15-min HD-tDCS to the right primary somatosensory cortex with an intensity of 1 mA. The session will last approximately one hour.
89380753|NCT05222646|Active Comparator|Metoclopramide group|They will be receiving10mg of Metoclopramide intramuscularly
89380754|NCT05222646|Active Comparator|Hyoscine bromide group|They will be receiving 20 mg of Hyoscine bromide
88853795|NCT04415112|Active Comparator|Low Fat Diet|The Low Fat diet had a target macronutrient composition of 55% of energy from carbohydrate, 20-25% from fat (with <10% of energy as saturated fat) and 20-25% from protein. Nutrition education focused on choosing foods containing ≤3 grams of fat/serving, limiting added fats, and using low-fat meal preparation strategies. Parents were instructed to offer their children ample amounts of grains, vegetables, fruits, lean meats, low-fat dairy products and limit high-fat foods
89380755|NCT05222568||BCVmin=0|This study was a prospective observational study, and the patients was divided into two groups with BCVmin=0 or BCVmin >0, according to the BCVmin which was naturally determined during anesthesia in each patient.
89380756|NCT05222568||BCVmin>0|The patients was divided into two groups with BCVmin=0 or BCVmin >0, according to the BCVmin which was naturally determined during anesthesia in each patient.
89380757|NCT05222490|Experimental|Diabetic with Ulcers|Patient with diabetic foot and ulceration diagnosed/confirmed by the study physician on the day of enrollment
89380758|NCT05222490|Experimental|Diabetic without Ulcers|Patient without ulcers diagnosed/confirmed by the study physician on the day of enrollment
89380759|NCT05222490|Active Comparator|Control|Generally Healthy Non-diabetic Subjects
89380760|NCT05222334|Experimental|Intrafascial interscalene brachial plexus block group|The patients will receive 10 ml of 0.5% bupivacaine for intrafascial interscalene brachial plexus block group
89380761|NCT05222334|Experimental|Extrafascial interscalene brachial plexus block group|The patients will receive 10 ml of 0.5% bupivacaine for extrafascial interscalene brachial plexus block group
89380762|NCT04465266|Experimental|50 mg Tolperisone|50 mg tablets (2 days SD, 2 days TID)
89002669|NCT06265493||derivation cohort|29785 in the derivation cohort
89380763|NCT04465266|Experimental|100 mg of Tolperisone|100 mg tablets (2 days SD, 2 days TID)
89380764|NCT04465266|Experimental|200 mg Tolperisone|200 mg tablets (2 days SD, 2 days TID)
89380765|NCT04434300|Other|Dapto SC-IV|"First stage :~Subcutaneous injection of daptomycin 10mg/kg~Subcutaneous injection of placebo (physiological serum)~Second stage :~- Intravenous injection of daptomycin 10mg/kg"
88853796|NCT01848990|Experimental|Commercial Hylenex Recombinant (Formulation 1)|Hylenex Formulation 1: For 6 months, participants received their regular treatment of rapid-acting continuous subcutaneous insulin infusion (CSII) (for example, insulin lispro, insulin aspart, and insulin glulisine). Additionally, during this 6-month treatment period, the participants received a pretreatment dose of the commercial form of Hylenex recombinant, delivered at 150 units (U) through their insulin infusion cannula each time they changed infusion sets (every 2 to 3 days).
88853797|NCT01848990|Experimental|Precommercial Hylenex Recombinant (Formulation 2)|Hylenex Formulation 2: For 6 months, participants received their regular treatment of rapid-acting CSII (for example, insulin lispro, insulin aspart, and insulin glulisine). Additionally, during this 6-month treatment period, the participants received a pretreatment dose of the precommercial form of Hylenex recombinant, delivered at 150 units (U) through their insulin infusion cannula each time they changed infusion sets (every 2 to 3 days).
88853798|NCT01848990|Active Comparator|Standard Rapid-Acting Insulin CSII|Participants received their regular treatment of rapid-acting CSII (for example, insulin lispro, insulin aspart, and insulin glulisine) for 6 months.
89380766|NCT04434300|Other|Dapto IV-SC|"First stage :~- Intravenous injection of daptomycin 10mg/kg~Second stage :~Subcutaneous injection of daptomycin 10mg/kg~Subcutaneous injection of placebo (physiological serum)"
89380767|NCT05214690|Experimental|Sequence A|cross-over
89380768|NCT05214690|Experimental|Sequence B|cross-over
89380769|NCT03055806|Experimental|IX-01 1200 mg|1200 mg dose comprising three 400 mg caplets administered orally at least 1 hour before or after food and 1-6 hours prior to sexual activity
89380770|NCT03055806|Placebo Comparator|Placebo|Three placebo caplets administered orally at least 1 hour before or after food and 1-6 hours prior to sexual activity
89380771|NCT03055806|Experimental|IX-01 800 mg|800 mg dose comprising two 400 mg caplets and one placebo caplet administered orally at least 1 hour before or after food and 1-6 hours prior to sexual activity
89380772|NCT03055806|Experimental|IX-01 400 mg|400 mg dose comprising one 400 mg caplet and two placebo caplets administered orally at least 1 hour before or after food and 1-6 hours prior to sexual activity
88875357|NCT02592486|Active Comparator|Sequential administration group|The subjects receive injections of pneumococcal vaccine 2 weeks after the injection of the influenza vaccine. We use commercially available PPV23 (Pneumovax NP®, MSDKK, Tokyo, Japan) containing 25 μg each of 23 capsular polysaccharide types. We use Fluvic HA syringe® (Handai Biken Ltd, Osaka, Japan), quadrivalent influenza vaccine (0.5ml) of 2015/2016.
89380773|NCT05194644|Experimental|Routine physical therapy + Sensorimotor stimulation|Active and passive Range of motion exercise on upper and lower limb, Transfers from bed to chair, Sit to stand exercise Time duration will be 20 min, Rest period 5 min In Sensory Stimulation Gustatory, Tactile, Olfactory, Visual, Auditory Stimulation will be applied alternatively Time duration will be 4 min In motor stimulation first warm up session for 5-10 min, strengthening exercise, PNF techniques for upper and lower limb, abdominal curls and then different Balance exercises for 6 min 5 times a week
89380774|NCT05194644|Placebo Comparator|Routine physical therapy|Active and passive Range of motion exercise on upper and lower limb, Transfers from bed to chair, Sit to stand exercise Time duration will be 20 min, Rest period 5 min
89380775|NCT04397796|Experimental|BM-Allo.MSC|Subjects in the experimental arm will be administered BM-Allo.MSC
89380776|NCT04397796|Placebo Comparator|Placebo|Subjects in the control arm will be treated with placebo
89380777|NCT04315896|Active Comparator|treatment|Hydroxychloroquine tablet 200mg every 12 hours for 10 days.
89380778|NCT04315896|Placebo Comparator|placebo|identical placebo, one tablet every 12 hours for 10 days
89380779|NCT04311216||Shoulder instability participants|Participants with previous a previous episode(s) of shoulder instability
89380780|NCT04311216||Age matched controls (no instability)|Participants with no previous a previous episode(s) of shoulder instability
89380781|NCT03628092|Active Comparator|CO2 Fractional Ablative Laser|3 treatments approximately 4 weeks apart with vaginal/vulval laser
89380782|NCT03628092|Placebo Comparator|Placebo|"3 treatments approximately 4 weeks apart with sham laser"
89380783|NCT03628014|Other|Interventional|The HELP Program is a comprehensive inpatient-care program that ensures optimal care for older adults in the hospital by using trained volunteers that do specific activities to help prevent or maintain functional decline.
89399497|NCT03689283|Sham Comparator|Control Group|Individuals in the control group will receive two treatment sessions of sham dry needling.
89399498|NCT02182076|Active Comparator|fasted administration of BIBF 1120|150 mg of BIBF 1120 ES soft gelatine capsules in fasting state
89399499|NCT02182076|Experimental|fed administration of BIBF 1120|three 50 mg BIBF 1120 soft gelatine capsule immediately after a high fat, high caloric meal
89399500|NCT03693417|Active Comparator|Control|
89399501|NCT03693417|Experimental|Heat|
88853799|NCT01867086|Experimental|Vigil™ Vaccine|Patients meeting eligibility criteria will receive either carboplatinum alone (AUC 6/30 minute infusion) or carboplatinum (AUC 5/30 minute infusion) and taxol (175 mg/m2 3-hour infusion) one day prior to Vigil™ 1.0 x 10e7 cells/ intradermal injection, once every three weeks. At recurrence, patients allergic to carboplatinum will receive docetaxel 75 mg/m2/1 hour infusion, one day prior to Vigil™ 1.0 x 10e7 cells/intradermal injection every 3 weeks. Patients with stable disease (SD) or better and unable to tolerate continued chemotherapy will be allowed to continue Vigil™ alone for up to 12 cycles or as long as vaccine is available; conversely, patients with SD or better who exhaust Vigil™ supply may continue on chemotherapy alone.
88853800|NCT01831596|Experimental|ciSNaP|
89380784|NCT05221788|Experimental|GDHT(goal-directed hemodynamic therapy)|Compounded sodium lactate 3 ml/kg/h was given intravenously as a basal rehydration volume before induction, and 200 ml of electrolyte solution was given after induction. If stroke volume (SV) increased >10%, 200 ml of electrolyte solution was continued until SV increased <10%. After fluid shock, if SV increases <10% but MAP <65 mmHg and/or cardiac index (CI) <2.5l/min/m2 give low-dose norepinephrine continuous pumping and/or dobutamine continuous pumping. If hypotension was accompanied by hypovolemia (defined as urine output <0.5 ml /kg/h and/or heart rate (HR) more than 20% above baseline), plasma was administered until urine output and/or heart rate returned to normal. Fluid responsiveness and hemodynamic variables were reassessed at least every 15 minutes, and more frequently in cases of hemodynamic instability.
89380785|NCT05221788|No Intervention|control|Continuous infusion of compounded sodium lactate 5-7 ml/kg/h was allowed to receive colloidal solution, norepinephrine and dobutamine at the discretion of the anesthesiologist.
89380786|NCT05178654|Experimental|[14C]PF-07321332|Single oral dose of 300 mg [14C]PF-07321332 containing approximately 100 µCi [14C]PF-07321332 coadministered with 100 mg ritonavir.
89380787|NCT04108962|Experimental|Treatment|Benralizumab treatment will be given by injections administered every 4 weeks for the first 3 injections with an additional injection eight weeks to follow for a total of 16 weeks active treatment
89380788|NCT04015362|Experimental|Pulsed magnetic stimulation of the spinal cord|Sub-threshold intermittent pulsed magnetic stimulation of spinal cord
89380789|NCT04015362|Sham Comparator|Sham magnetic stimulation|Sham - patient and machinery placed in same position as intervention arm but no magnetic stimulation delivered
89380790|NCT05221710|No Intervention|Acupuncture Group|"The acupuncture treatment will be performed by the technique of lifting, thrusting, twirling and rotating the needle until the patient is being De-qi (getting a numbness or other acupuncture feeling)"
89380791|NCT05221710|Experimental|Electroacupuncture Group|On the basis of the above acupuncture treatment,two points that do not cross the joint will be chosen for electrical stimulation
89380792|NCT05221710|No Intervention|Neuromuscular Electrical Stimulation Group|Neuromuscular Electrical Stimulation(NMES) group received consecutive daily sessions of electrical stimulation at specific points
89380793|NCT04002102|Experimental|OLP treatment|Participants randomized to the treatment group will receive: 1) educational materials; 2) positive expectancy; 3) 2 placebo pills twice a day for 21 days.
89380794|NCT04002102|Other|Usual care|Participants randomized to the no treatment group will remain in standard care alone for 21 days and receive educational materials.
89380795|NCT04002102|Active Comparator|Expectancy Group|Participants receive educational materials and positive expectancy orientation via Zoom or telephone
89380796|NCT04989582|Experimental|Nursing intervention|Nurses randomly assigned by applying a random selection method
89380797|NCT04989582|No Intervention|No intervention|Nurses randomly assigned by applying a random selection method
89380798|NCT04928040|Experimental|Fluid challenge|Fluid challenge effects on optic nerve sheath diameter
89380799|NCT04907292||Planned Cesarean delivery|Patients who have an elective Cesarean delivery at Mount Sinai Hospital
89380800|NCT04907292||Unplanned Cesarean delivery|Patients who have an unplanned Cesarean delivery at Mount Sinai Hospital
89380801|NCT05221476||polytraumatized patients|Patients with an ISS >16 points, an AIS >3 in one body region and at least 2 different body regions affected were included.
89380802|NCT04865796|Experimental|Group 1|Patients will use products based on lactoferrin.
88853801|NCT01848834|Experimental|Cohort A: Triple Negative Breast Cancer|Participants receive pembrolizumab, 10 mg/kg, intravenously (IV) once every 2 weeks, and continue to receive drug until disease progression, death, withdrawal of consent, Investigator decision, or end of study (up to 2 years).
88853802|NCT01848834|Experimental|Cohort B: Head & Neck Cancer|Participants receive pembrolizumab, 10 mg/kg, IV once every 2 weeks, and continue to receive drug until disease progression, death, withdrawal of consent, Investigator decision, or end of study (up to 2 years).
88853803|NCT01848834|Experimental|Cohort C: Urothelial Cancer|Participants receive pembrolizumab, 10 mg/kg, IV once every 2 weeks, and continue to receive drug until disease progression, death, withdrawal of consent, Investigator decision, or end of study (up to 2 years).
88853804|NCT01848834|Experimental|Cohort D: Gastric Cancer|Participants receive pembrolizumab, 10 mg/kg, IV once every 2 weeks, and continue to receive drug until disease progression, death, withdrawal of consent, Investigator decision, or end of study (up to 2 years).
88853805|NCT01848834|Experimental|Cohort B2: Head & Neck Cancer Expansion|Participants receive pembrolizumab, 200 mg, IV once every 3 weeks, and continue to receive drug until disease progression, death, withdrawal of consent, Investigator decision, or end of study (up to 2 years).
88853806|NCT01867008|Experimental|Nucleus CI422 Cochlear Implant with Nucleus 6 (N6) Sound Processor|
89380803|NCT04865796|Experimental|Probiotics|Patients will use products based on probiotics for home oral care.
89380804|NCT04865796|Active Comparator|Standard therapy|Patients will use standard toothpastes for home oral care.
89380805|NCT04811118|Experimental|Albumin-bound docetaxel|Subjects will receive albumin-bound docetaxel via intravenous infusion (IV) once every three weeks (a cycle), at the dose of 75mg/m2
89380806|NCT04811118|Experimental|Taxotere|Subjects will receive Taxotere via intravenous infusion once every three weeks (a cycle), at the dose of 75mg/m2.
89380807|NCT04979988||Japanese patients with ALK+ NSCLC who received lorlatinib|lorlatinib as the second-line or later therapy after failure of alectinib treatment as the firstline therapy
89380808|NCT05221164|Experimental|Intervention with 162 mg aspirin|Aspirin 162 mg daily for prevention of preeclampsia in pregnant patients at Family Medicine Clinic
89380809|NCT03627546|Experimental|Rapid Treatment with sofosbuvir/velpatasvir (Intervention arm)|"The intervention arm receives same-day medical evaluation and treatment for hepatitis C. They receive medical evaluation, laboratory assessment , baseline questionnaire/interview, and distribution of a medication (sofosbuvir/velpatasvir) starter pack on the day of enrollment. Participants who are HCV RNA negative are discontinued from the study. Other participants start medications and receive weekly text messages during treatment to record adherence. They have follow up visits for laboratory tests, medication distribution, and counseling for prevention of reinfection. They have HCV testing at end of treatment and 12 weeks post treatment, and at 48 weeks to assess for reinfection. Each study visit will include a brief questionnaire and qualitative interview."
89380810|NCT03627546|No Intervention|Usual Care (Control arm)|Participants in the control arm will be provided facilitated referral to community HCV providers by an on-site care coordinator already facilitating care at the community site. HCV RNA negative participants will be called to inform them of these results, and then discontinued from the study. HCV RNA positive participants will be asked during the semi-structured interviews as at 12, 24, 36 and 48 week if they engaged in HCV treatment to assess whether their HCV referral has been filled, and to record their current HCV treatment status. They will also receive repeat HCV RNA testing at week 12, 24, and 48. Participants that have started treatment will be asked to sign consent for release of medical records pertaining to HCV-related laboratory testing to determine achievement of treatment response.
89380811|NCT04620798|Experimental|Intervention|Participants will be given their results of their antibody test immediately (within 24 hours) and will be followed and surveyed to see if having this knowledge changes their engagement with SARS-CoV-2 prevention behaviors.
89380812|NCT04620798|No Intervention|Control (Delayed)|Participants will be given their results of their antibody test after 4 weeks. Their engagement with SARS-CoV-2 prevention behaviors will also be assessed following testing.
89380813|NCT04940208||post COVID-19 ICU survivors|Patients hospitalized to the ICU in the context of severe COVID-19 and discharged alive during the first French COVID-19 pandemic wave
89380814|NCT05220696||Critically ill patients with shock|Critically ill patients with shock
89380815|NCT05685966||Infertile couples from the research center who visited for fertility disorders|Infertile couples infected or not infected with COVID-19 were included.This is an observational study with no interventions.
89380816|NCT05220618|Experimental|Memory Training Group|This group will receive an online two-week intervention to train the specificity of autobiographical memories. During the two-week intervention and the following two weeks, participants will complete ecological-momentary assessments (EMA) to monitor the amount of positive and specific memories recalled during the day. EMA is an Experience Sampling Method assessment system that allows data to be collected from participants in their natural environment at various points in time (McDevitt-Murphy et al., 2018). For this study, we designed an EMA to monitor essential project variables throughout the intervention (2 weeks; from Day 0 to Day 15) and then as a follow-up (2 weeks after; from Day 16 to Day 30).
89380817|NCT05220618|No Intervention|Control Group|This group will receive no intervention to train the specificity of autobiographical memories. During four weeks (from Day 0 to Day 30), participants will complete ecological-momentary assessments (EMA) to monitor the amount of positive and specific memories recalled during the day.
89380818|NCT05220150|Experimental|Alzheimer's patients|Patient diagnosed with early onset Alzheimer's disease.
89380819|NCT05220150|Active Comparator|Control|Healthy volunteers that do not have Alzheimer's disease.
89380820|NCT05220072|Experimental|Carbon-14 BIA 28-6156|Healthy volunteers receive a single dose of Carbon-14 BIA 28-6156
89380821|NCT05672862||Post PCI state|The study population of this study underwent percutaneous coronary intervention(PCI) with drug-eluting stent (DES) and measured fractional flow reserve after PCI.
89380822|NCT03822780|Experimental|HCQ Therapy|"Hydroxychloroquine Sulfate (HCQ, Quensyl) in a loading dose of 10 mg/kg*d, p.o., bid. After the illness gradually alleviate to maintain dose between 5mg/kg*d to 10mg/kg*d, p.o., bid ; the maximum daily dose is 400mg.~Assess the efficacy and safety of HCQ after 6 months treatment compared with any other routine therapy before HCQ therapy (such as inhaling oxygen, corticosteroid, anti-infection therapy, nutritional support)"
89399502|NCT02179268|Active Comparator|sertraline & control|sertraline 50-150mg tables for 1 year,Control (cognitive behavioral therapy by psychiatrists, 50min, every week for three months, every month, for nine months).
89399503|NCT02179268|Active Comparator|citalopram & Control|citalopram 20-40mg tables by mouth every day for 1 year, Control (cognitive behavioral therapy by psychiatrists, 50min, every week for three months, every month, for nine months).
88853807|NCT01848756|Experimental|SNX-5422|Open-label administration of SNX-5422 capsules to total 100 mg/m2 every other day for 21 days (total = 11 doses), out of a 28-day treatment cycle. Subjects will continue treatment on a 28-day cycle at the discretion of the principal investigator based on safety.
88853808|NCT04594434|Experimental|protocol EMDR + SB / SMP protocol (adjusted)|"Association of a positive memory with the recommended therapy based on EMDR."
88853809|NCT04594434|Active Comparator|protocol EMDR (standard).|"recommended therapy based on EMDR."
88853810|NCT01830972|Experimental|Crossover Participants|"Participants completing the 48-week study (UX001-CL201; NCT01517880) were enrolled into Part I of the study:~Part I: participants continued on 6 g/day SA-ER for 12 weeks~Part II: 12 g/day SA (1.5 g of SA-ER and 1.5 g of SA-IR treatment 4 times per day [QID]) for 36 months~Part III: 6 g/day or 12 g/day SA (both SA-ER and SA-IR)~Part IV: 6 g/day or 12 g/day SA (SA-ER only)"
88853811|NCT01830972|Experimental|Naïve Participants|"Treatment naïve participants with GNE myopathy were enrolled into Part II of the study:~Part II: 12 g/day SA (1.5 g of SA-ER and 1.5 g of SA-IR treatment QID) for 36 months~Part III: 6 g/day or 12 g/day SA (both SA-ER and SA-IR)~Part IV: 6 g/day or 12 g/day SA (SA-ER only)"
89002670|NCT06265493||internal validation cohort|7445 in the internal validation cohort
88817701|NCT01250834|Experimental|LY2189265 + Atorvastatin|"Period 1: Participants received a single 40-milligram (mg) oral dose of atorvastatin on Day 1, followed by a 7- to 10-day washout period between Period 1 and Period 2.~Period 2: Participants received a single 1.5-mg subcutaneous dose of LY2189265 on Day 1, followed by a single 40-mg oral dose of atorvastatin on Day 3."
89380823|NCT04765644|Active Comparator|Celecoxib|"Phase 1: Twenty volunteers will receive celecoxib 200 mg, 2 times/day (total 400 mg/day) for 7 days. At this point, the study team will perform an interim analysis of the data. If our primary endpoint is not achieved we may revise our endpoints and/or if additional power is required, we may recruit up to an additional n=20 volunteers per group. This analysis may also serve as a stop-go checkpoint for continuation of the second phase of the study. If we do not see any effects of celecoxib on endothelial or cardiovascular function, we will not proceed to phase 2. If we do see a negative effect, we will proceed to phase 2.~In phase 2 participants will be re-invited to the study site following a 4-8 week washout period. Participants will then receive either treatment with placebo + 10g L-arginine supplementation (20 participants) or celecoxib + 10g arginine supplementation (20 participants) for a total of 7 days"
89380824|NCT04765644|Placebo Comparator|Placebo|"Phase 1: Twenty volunteers will receive a placebo capsule, 2 times/day (total 400 mg/day) for 7 days. At this point, the study team will perform an interim analysis of the data. If our primary endpoint is not achieved we may revise our endpoints and/or if additional power is required, we may recruit up to an additional n=20 volunteers per group. This analysis may also serve as a stop-go checkpoint for continuation of the second phase of the study. If we do not see any effects of celecoxib on endothelial or cardiovascular function, we will not proceed to phase 2. If we do see a negative effect, we will proceed to phase 2.~In phase 2 participants will be re-invited to the study site following a 4-8 week washout period. Participants will then receive either treatment with placebo + 10g L-arginine supplementation (20 participants) or celecoxib + 10g arginine supplementation (20 participants) for a total of 7 days"
89380825|NCT05216874|Experimental|Occlusal stabilization splint|Skeletal class III laterognathia surgery patients who has occlusal stabilization splint thearapy for at least 2 mounths before surgery
89380826|NCT05216874|No Intervention|Control|Skeletal class III laterognathia surgery patients did not have occlusal stabilization splint thearapy
89380827|NCT04720872|Experimental|Experimental group|"Manual therapy: 4 sessions, 1 session per week (20 minutes approximately).~Physical therapist-directed vestibular rehabilitation: 4 weeks, 1 session per week with the physical therapist (30 minutes approximately), after manual therapy.~Home based vestibular rehabilitation: 4 weeks (2 sessions per day)."
89380828|NCT04720872|No Intervention|Control group|Home based vestibular rehabilitation: 4 weeks (2 sessions per day). The participants attended the center once a week to check correct execution of the exercises.
88817702|NCT04387695|Experimental|SBRT + TACE + Sorafenib|SBRT sequential TACE combined with Sorafenib
88817703|NCT04387695|Active Comparator|Sorafenib|Sorafenib 800 mg/day orally
88817704|NCT04638075|No Intervention|Group A Bottle Supplementation|Group A will supplement using the bottle. The mother will breastfeed as frequently as the neonate's physician allows. When the physician recommends supplementation, the mother will supplement using the bottle per standard of care. The mother will breastfeed for up to 25 minutes and then will offer a bottle to supplement breastfeeding for at least 5 minutes. Time at the breast and with the bottle might vary based on the neonate's ability to stay awake at the breast and to sustain a latch at the breast. The type of supplementation will be either Expressed Breast Milk (EBM), Donor Human Milk (DHM), formula, or a combination of EBM and formula or EBM and DHM. The volume of supplementation and duration of bottle use will be determined by the neonate's physician. The mother will return the neonate to their crib then pump and hand express after feeding sessions per the IBCLC's recommendation. The mother will document each feeding session in the feeding log provided at the bedside.
88817705|NCT04638075|Experimental|Group B SNS Supplementation|Group B will supplement using the SNS. The mother will breastfeed as frequently as the neonate's physician allows. When the physician recommends supplementation, the mother will supplement using the SNS per standard of care. The mother will assemble the SNS, place it clamped and in position at the nipple prior to breastfeeding (see SNS instructions for use). The mother will initiate breastfeeding for up to 5 minutes and then unclamp the SNS to begin supplementation for up to 25 minutes. The SNS will contain either EBM, DHM, formula, or a combination of EBM and formula or EBM and DHM. The volume of supplementation and duration of SNS use will be determined by the neonate's physician. The mother will pump and hand express after feeding sessions per the IBCLC's recommendation. Them mother will document each feeding session in the feeding log provided at the bedside.
88817706|NCT01354652|Experimental|entecavir|"Oral 0.5mg/day until development of lactic acidosis, OLT, death, or improvement of hepatic or renal function to MELD score less than 18.~Participants will be followed for the duration of hospital stay, an expected average of 8 weeks."
88817707|NCT01354652|Active Comparator|lamivudine|"Oral 100mg/day lamivudine until development of lactic acidosis, OLT, death, or improvement of hepatic or renal function to MELD score less than 18.~Participants will be followed for the duration of hospital stay, an expected average of 8 weeks."
88817708|NCT01354652|No Intervention|no NRTI group|hepatitis C virus associated LC patients for the calculation of lactic acidosis incidence
88817709|NCT01753739|Experimental|Bepotastine besilate Concentration 1|Bepotastine besilate nasal spray, BID for 14 days.
88817710|NCT01753739|Active Comparator|Placebo|Placebo nasal spray BID for 14 days
88817711|NCT01753739|Experimental|Bepotastine besilate Concentration 2|Bepotastine besilate nasal spray, BID for 14 days.
88817712|NCT01753739|Experimental|Bepotastine besilate Concentration 3|Bepotastine besilate nasal spray, BID for 14 days.
88817713|NCT01753739|Experimental|Bepotastine besilate Concentration 4|Bepotastine besilate nasal spray, BID for 14 days.
88817714|NCT01250990|Active Comparator|Niacin|Niacin taken orally for 12 weeks at the highest tolerated dose (up to 6 grams), and at least 2 grams daily and up to the maximum approved dose. Subjects will initiate therapy with Niaspan and will advance to Niacor as tolerated.
88817715|NCT01250990|Placebo Comparator|Placebo|Placebo tablet with 50 mg niacin for the first 4 weeks to maintain blinding of the study team and subjects, changed to pure placebo after that.
88817716|NCT01754207|Experimental|755nm Alexandrite Laser|755nm Alexandrite Laser
88817717|NCT02990975|Active Comparator|block and ketamine|Transversus Abdominis Plane block after ketamine atropine induction and continued with ketamine only in anesthesia
89380829|NCT05649774|Active Comparator|Myofascial Release (MFR)|The therapist will place its hands on the T12-L1 levels as well as on the sacrum. A cross handed hold will be performed along the fascia. Then for the gluteus Medius and maximus muscle, the therapist will stand facing the participant's leg and closed to the superior border of participant's pelvis. The therapist will place the palm of the hand on the anterior surface, allowing the fingers to rest on the outer fibers of the gluteal muscles stabilizing the pelvis of the participants. Allow the participant to flex its knee while applying adequate amount of stretch on the hip joint in an open pack position. Hold, wait for the release and stretch again. for tensor fascia Latae, The therapist will place several slightly adducted fingers of its one hand on the superior fibers proximal to the insertion on the anterior superior iliac crest and the thumb as well as the other fingers of the other hand on the distal muscle fibers. Hold, wait for the release and stretch again.
89380830|NCT05649774|Active Comparator|Kinesio Taping (KT)|"Lumbar star correction technique was applied. 4 tape I strips will be cut. The paper from the center will be torn. The targeted area will be stretched as tolerated at the lumbar region. The therapist will apply 25% to 35% tension to the strip within the therapeutic zone over the target tissue. End the strip with no tension and activate the adhesive. For the second strip change the posture in order to change the stretch on the tissue, apply the second strip with 25% to 35% tension in the center of the tape and end with no tension. Activate the adhesive. Now flex the trunk and rotate on one side. Apply the third tape strip with 25% to 35% tension in the center of the tape. Apply the fourth tape strip with flexion and rotation on the opposite side again with 25% to 35% tension on the strip.~The tape will be changed 3 times per week."
88853812|NCT01848288|Experimental|CENTURION|First surgical eye randomized to CENTURION® Vision System, with second surgical eye (fellow eye) assigned to INFINITI® Vision System. Second eye surgery conducted within 14 days of the first eye surgery. Duration of surgery less than 30 minutes each eye.
89380831|NCT05649774|Experimental|Myofascial Release with Taping (MFKT)|Same Protocol of MFR followed by KT
89380832|NCT05649774|Sham Comparator|Placebo Treatment|The control group received a sham myofascial release for 40 minutes per treatment session, three times a week for three weeks. The sham myofascial release was applied by gently placing the hands over the same areas treated in the MFR group,without sliding, just enough to maintain contact for the desired time.
89380833|NCT05214846|Experimental|Education and Counseling|"After obtaining written informed consent, the data collection form, Hospital Anxiety Depression Scale (HADS) was applied to both groups by face to face interview. Immediately after the questionnaires were applied, the nurse gave individual education and counseling were giving by the nurse researcher to intervention group for 30 minutes. Women were counseled for 6 weeks.~Anxiety-depression levels (post-test) were applied by phone call 6 weeks later.This education consisted of the definition and the purpose of pregnancy and pregnancy problems and nutrition during pregnancy, sexuality during pregnancy, number of fetal movements, preparation of the delivery bag, breast care, etc."
89380834|NCT05214846|No Intervention|control group|Participants in the control group received standard care (verbal information about procedure and a short written information about the procedure) and no intervention (education and counseling) was performed.The control group was called by phone at the end of 6 weeks and told that they would be retested and 6 weeks later, they were called by phone and their anxiety and depression levels (posttest) were applied. directed to continue
89380835|NCT03052764|Active Comparator|BOTOX® 100 U/BOTOX® 100 U|BOTOX® (onabotulinumtoxinA) 100 U injection into the bladder on Day 1 and a second injection BOTOX® 100 U after Week 12 if applicable.
88853813|NCT01848288|Active Comparator|INFINITI|First surgical eye randomized to INFINITI® Vision System, with second surgical eye (fellow eye) assigned to CENTURION® Vision System. Second eye surgery conducted within 14 days of the first eye surgery. Duration of surgery less than 30 minutes each eye.
88853814|NCT01848210|Experimental|Coumarin 30 mg + Troxerutin 180 mg|Coumarin 30 mg, troxerutin 180 mg fixed-dose combination tablets, orally, three times daily for up to 16 weeks.
89380836|NCT03052764|Placebo Comparator|Placebo/BOTOX® 100 U|Placebo (saline) injection into the bladder on Day 1 and a second injection BOTOX® 100 U after Week 12 if applicable.
89380837|NCT05638698|Experimental|TG01/QS-21 (Vaccine arm)|TG01 is mixed with adjuvant QS-21 and given subcutaneously. After six administrations given once every two weeks of TG01 vaccine (+adjuvant QS-21) over 12 weeks during weeks 1,3,5,7,9,11, [priming/booster phase]), the treatment will then switch to a maintenance phase of TG01 vaccine (+adjuvant QS-21) once every 8 weeks for up to 51 weeks: The maintenance treatments will occur during weeks 19, 27, 35, 43, and 51. Maintenance treatments will end on week 51 or at the time of disease recurrence; whichever is the earliest.
89380838|NCT05638698|Experimental|TG01/QS-21 + Balstilimab (Vaccine + PD-1 arm)|TG01 is mixed with adjuvant QS-21 and given subcutaneously. Balstilimab is given intra-venously as infusion and begins week 3, then given every 2 weeks for up to 51 weeks. After six administrations given once every two weeks of TG01 vaccine (+adjuvant QS-21) over 12 weeks during weeks 1,3,5,7,9,11, [priming/booster phase]), the treatment will then switch to a maintenance phase of TG01 vaccine (+adjuvant QS-21) given once every 8 weeks for up to 51 weeks: The maintenance treatments will occur during weeks 19, 27, 35, 43, and 51. Maintenance treatments will end on week 51 or at the time of disease recurrence; whichever is the earliest.
89399504|NCT02179268|Active Comparator|venlafaxine & control|venlafaxine 75-100mg tables by mouth every day for 1 year, Control (cognitive behavioral therapy by psychiatrists, 50min, every week for three months, every month, for nine months).
88853815|NCT01848210|Placebo Comparator|Placebo|Coumarin + troxerutin placebo-matching tablets, orally, three times daily for up to 16 weeks.
88853816|NCT01830816|Experimental|Normal Renal Function: Ixazomib|In the 15 day period that constitutes Part A of the trial, participants received a single oral dose of ixazomib 3.0 mg capsules. Participants from Part A had the option of continuing the study by participating in Part B, where they received ixazomib (4, 3, or 2.3 mg per protocol) capsules, orally on Days 1, 8, and 15 of each 28-day cycle until disease progression or unacceptable toxicity.
88853817|NCT01830816|Experimental|Severe Renal Impairment: Ixazomib|In the 15 day period that constitutes Part A of the trial, participants received a single oral dose of ixazomib 3.0 mg capsules. Participants from Part A had the option of continuing the study by participating in Part B, where they received ixazomib (4, 3, or 2.3 mg per protocol) capsules, orally on Days 1, 8, and 15 of each 28-day cycle until disease progression or unacceptable toxicity.
89380839|NCT05637138|Other|Healthy volunteer|"The totality of the measurements will be carried out on a single visit following the obtaining of the consent (obtained the same day or during a preceding visit).~The total duration of this single visit, including the time of information, the collection of consent and all the measurements is estimated at 2 hours per subject.~Before the installation of the different measuring devices, a preliminary interview and a clinical examination will be carried out in order to verify in particular the absence of skin lesions.~The measurement of subcutaneous microcirculation (no unit) and tcpO2 (kPa) will be carried out simultaneously with the measurement of CO2 diffusion (main criterion), during a single session of measurements at 5 different temperatures (non-thermostated, then thermostated at 35, 38, 41 and 44°C)"
89380840|NCT05707338|Active Comparator|laparoscopic group|
89380841|NCT05707338|Active Comparator|open group|
89380842|NCT05197374|Experimental|Group 1|Cases who received estradiol pretreatment then underwent ICSI.
89380843|NCT05197374|No Intervention|group 2|Cases who underwent ICSI directly without receiving any pretreatment
89380844|NCT05707104|Experimental|Pilates exercises|performing Pilates exercises three times per week for 6 weeks while maintaining their regular physical activity and nutritional plans.
89380845|NCT05707104|Experimental|plyometric exercises|performing plyometric exercises three times per week for 6 weeks while maintaining their regular physical activity and nutritional plans.
89380846|NCT02951819|Experimental|Dara-CyBorD|Subjects will receive Daratumumab along with Cyclophosphamide, Bortezomib and Dexamethasone (Dara-CyBorD) as induction on a 28-day cycle length and Daratumab and Dexamethasone on Day 1 of each cycle for 12 cycles as maintenance therapy.
89380847|NCT03707717|Experimental|Bimekizumab-SS|Subjects randomized to this arm will receive bimekizumab administered subcutaneously with a prefilled syringe.
89380848|NCT03707717|Experimental|Bimekizumab-AI|Subjects randomized to this arm will receive bimekizumab administered subcutaneously with an auto-injector.
89380849|NCT03707717|Experimental|Bimekizumab-TN|Subjects randomized to this arm will receive bimekizumab administered subcutaneously with a reference device.
89380850|NCT05191290|Active Comparator|heparin anticoagulation|standard heparin anticoagulation during plasmapheresis
89380851|NCT05191290|Experimental|citrate anticoagulation|sodium citrate anticoagulation during plasmapheresis
89380852|NCT05627544||First 6 year group|Patients who underwent hip replacement between 2010 and 2016 by the same experienced surgeon in our hospital
89380853|NCT05627544||Second 6 year group|Patients who underwent hip replacement between 2017 and 2022 by the same experienced surgeon in our hospital
89380854|NCT05707026|Experimental|cross fiber fascial manipulation|The group A received three sessions of fascial manipulation in two weeks. FM applied to densified Centre of Coordination (CC) points located on the myofascial sequences for 5 to 8 minutes at each CC point
89380855|NCT05707026|Experimental|stretching techniques|Group B received three sessions of sleeper and cross body adduction stretches. Group B received three sessions of sleeper stretch in a side lying position in 90o abduction, elbow at 90o flexion and then performing shoulder IR and cross-body adduction stretch was done in sitting position. Three sets of the each stretch position were held for 30 seconds with a 1 minute break between sets
89380856|NCT05609058|Experimental|Breast cancer underwent scanning in the supine position|Breast cancer patients with T1-2N0M0 stage who underwent radiation therapy after conserving surgery were enrolled. Supine scan sets were acquired during free breathing for all patients. Target volumes and organs at risk (OARs) including heart, ipsilateral lung and bilateral breast were contoured by the same radiation oncologist. The tumor bed (TB) was determined based on surgical clips. The Clinical target volume (CTV)consisted of the whole breast. The planning target volume (PTV) was CTV plus 0.5cm. The boost of PTV (PTVboost) was TB plus 0.5cm.
89380857|NCT05169606|Experimental|Tissue Flossing|Tissue flossing is a technique that requires wrapping of a thick rubber band around a joint or muscle concomitantly performing ROM tasks for 1-3 minutes. The results include increase in range of motion and a decrease in pain of the effected muscles. The phenomenon behind getting results through this technique is hypothesized to be blood reperfusion to an occluded area via tissue flossing augments exercise performance mechanisms such as growth hormone, catecholamine responses, muscle force contractility and the efficiency of excitation-contraction coupling in the muscles. In addition, tissue flossing may influence fascia tightness via the fascial mechanoreceptors, therefore reducing muscle activity, resulting in a greater ROM. Nevertheless, the underlying mechanism for tissue flossing, these mechanisms remain speculative.
89380858|NCT05169606|Experimental|Active Isolated Stretch|Active Isolated Stretch is a specific stretching program developed by Aaron Mattes over 30 years ago. Active isolated stretch is also found to be effective to increase flexibility and improve ROM.
89380859|NCT05169606|Experimental|Proprioceptive Neuromuscular Facilitation|Proprioceptive neuromuscular facilitation (PNF) technique has already been found to have beneficial effects in improving hamstring flexibility and reducing pain in the knee joint of knee OA patients.
89380860|NCT05706792|Experimental|Nordic Sensi Chair|Participants received three times a week one session per day of 20 minutes in the Relax for deep relaxation program of the Nordic Sensi Chair.
89380861|NCT05706792|No Intervention|Standard of care|Participants did not participate in the Nordic Sensi Chair sessions, but received, at the same time and duration, the care and activities that were part of the daily routines of the center, including group sessions of cognitive stimulation, training in activities of daily living or communication training.
89380862|NCT05061186|Experimental|Resistive Expiratory muscle Training Group|Mild Resistive Expiratory muscle Training Group
89380863|NCT05061186|Active Comparator|Conventional Breathing Exercise Group|Breathing Ex: Pursed lip Breathing, Diaphragmatic breathing ex, incentive spirometer
89380864|NCT03383783|Other|Treatment Period 1|0 ppm F (placebo, negative control), 250 ppm F as NaF (dose-response control), 500 ppm F as NaF (dose-response control), 1100 ppm F as NaF (positive control)
89380865|NCT03383783|Other|Treatment Period 2|0 ppm F (placebo, negative control), 250 ppm F as NaF (dose-response control), 500 ppm F as NaF (dose-response control), 1100 ppm F as NaF (positive control)
89380866|NCT03383783|Other|Treatment Period 3|0 ppm F (placebo, negative control), 250 ppm F as NaF (dose-response control), 500 ppm F as NaF (dose-response control), 1100 ppm F as NaF (positive control)
89380867|NCT03383783|Other|Treatment Period 4|0 ppm F (placebo, negative control), 250 ppm F as NaF (dose-response control), 500 ppm F as NaF (dose-response control), 1100 ppm F as NaF (positive control)
89380868|NCT03627390|Experimental|BP-C1|Patients will be treated with BP-C1 for 32 consecutive days
89380869|NCT03627390|Experimental|BP-C1+BP-C2|Patients will be treated with BP-C1 and BP-C2 for 32 consecutive days
89380870|NCT05576376|Experimental|plantar fascia release|"plantar fascia open release Longitudinal incision at the medial heel, Exposure of the plantar fascia at its origin on the medial plantar calcaneus. Medial incision of the plantar fascia preserving the lateral portion.. Exposure of the abductor hallucis muscle. Incision of the superficial fascia of the muscle. Retraction of the muscle belly und incision of the deep portion of the fascia, decompression of the first calcaneal branch of the lateral plantar nerve (Baxter's nerve) in cases of its being compressed.~Postoperative management: Two weeks partial weight bearing. Progressively weight bearing using a shoe with a stiff sole for another 4 weeks."
89380871|NCT05576376|Experimental|Plantar fascia endoscopic release|We will draw a line distally from the posterior aspect of the medial malleolus to the intersection of the medial origin of the plantar fascia at the calcaneal tuberosity. A skin incision will be made, and medial portal will be performed at this location. Blunt dissection will be performed to clear the subcutaneous tissue from the plantar fascia with caution to avoid lesion of the calcaneal nerve medial branch.
89380872|NCT05576376|Experimental|Clacaneal osteotomy|calcaneal osteotomy skin incision will be oblique and directed from the inferoposterior edge of the lateral malleolus to the inferior edge of the calcaneal body, and subperiosteal exposure of the lateral calcaneal wall will be performed. Osteotomy will be performed from 1 cm anterior of the calcaneal attachment of the plantar fascia to 1 cm anterior of the calcaneal attachment of the Achilles tendon. After the osteotomy, approximately 5 mm plantar displacement of the proximal fragment, which include attachment of the plantar fascia, will be performed. Fixation after the osteotomy will be performed under an image intensifier using one cannulated cancellous screws 4.5 mm in diameter, which will be inserted from the infero-medial of the calcaneal tuberosity to the distal fragment
89380873|NCT03709745|Active Comparator|Aflibercept|Aflibercept is given monthly (at least 3 times) until resolution of macular edema after which the patient is observed monthly. If there is recurrence of macula edema, the patient is given aflibercept according to a treat-and-extend regimen.
89380874|NCT03709745|Active Comparator|Ranibizumab|Ranibizumab is given monthly (at least 3 times) until resolution of macular edema after which the patient is observed monthly. If there is recurrence of macula edema, the patient is given ranibizumab according to a treat-and-extend regimen.
88875358|NCT02593032|Experimental|Randomized Treatment|Patients in the treatment group will begin receiving their medications in pre-filled trays from Friendship Pharmacy. Patients will receive 5 trays on a monthly basis in order to accommodate a 30-day, insurance-reimbursed fill schedule.
89380875|NCT05570526|Experimental|Intervention group:|20 patients will receive oral melatonin 5mg tablets 1-hour before bedtime for 12 weeks.
89380876|NCT05570526|Placebo Comparator|Placebo|20 patients will receive one tablet of placebo 1-hour before bedtime for 12 weeks.
89380877|NCT03707639|Experimental|Experimental: Apatinib plus POF|Apatinib (500 mg qd p.o.) plus POF until disease progression or intolerable toxicity or refused by the patients.
89380878|NCT05343689|Experimental|Pneumatic compression group|When inducing general anesthesia, pneumatic compression is performed.
89380879|NCT05343689|No Intervention|Control group|When inducing general anesthesia, pneumatic compression is not performed.
89380880|NCT05542914|Experimental|e-SBI|Electronic Screening and Brief Intervention for substance use and HIV risk reduction
89380881|NCT05542914|Active Comparator|Assessment Only|These individuals complete only the screening instruments, no brief intervention
89380882|NCT03334721|Experimental|Gabapentin, Then Placebo Oral Capsule|"Week 1: 1-week condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (i.e., 1,200mg gabapentin) (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).~Week 2: 1-week condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (Days 1-5), MRI (Day 5), and medication washout (Days 5-7)."
88817718|NCT02990975|Active Comparator|ketamine atropine; laryngeal mask|After ketamine atropine induction, a laryngeal mask was inserted and anesthesia administration was continued with 2 sevoflurane MAC and oxygen / air mixture and applied Transversus Abdominis Plane block.
88817719|NCT02990975|Active Comparator|control group|After ketamine atropine induction, a laryngeal mask was inserted and anesthesia administration was continued with 2 sevoflurane MAC and oxygen / air mixture and Non-block, postoperative analgesia with paracetamol IV
89399505|NCT02179268|Active Comparator|reboxetine & control|reboxetine 4-8mg tables by mouth every day for 1 year, Control (cognitive behavioral therapy by psychiatrists, 50min, every week for three months, every month, for nine months).
88817720|NCT01315574|Active Comparator|Latanoprost (Xalatan)|7 Patients were randomized to receive BAK-containing Xalatan for treatment of their glaucoma.
88817721|NCT01315574|Active Comparator|Travoprost (Travatan Z)|7 Patients were randomized to receive BAK-free Travatan Z for treatment of their glaucoma.
88817722|NCT04462107||Surveys|All participants will complete questionnaires at several time points, ranging from baseline to 3 months post partum.
88817723|NCT01754519|Experimental|Treatment (radiation therapy)|Patients undergo wide local excision breast surgery and SFRT over 60-100 minutes once negative margins are obtained.
88817724|NCT01316042|Placebo Comparator|sugar pill|2 pills per day for 12 months
88817725|NCT01316042|Active Comparator|Metformin|2 212.5mg pill/day for 12 months
88817726|NCT01754909|Active Comparator|enalapril|Use of enalapril in subjects undergoing radiotherapy for lung cancer.
88817727|NCT01754909|Placebo Comparator|placebo|Use of placebo in subjects undergoing radiotherapy for lung cancer
88817728|NCT04340349|Experimental|Experimental: Hydroxychloroquine plus Bromhexine|200 mg of Hydroxychloroquine daily for 2 months 8 mg of Bromhexine every 8 hrs for 2 months
88817729|NCT04340349|Placebo Comparator|Hydroxychloroquine plus Bromhexine|200 mg of Hydroxycholoroquine daily for 2 months 8 mg of Bromhexine every 8 hrs for 2 months
88817730|NCT01755143|Experimental|MRI Group|Subjects randomized to the Magnetic Resonance Imaging group will undergo a series of MRI scans at the 9-12 week visit post-implant.
88817731|NCT01755143|Sham Comparator|Control Group|Subjects randomized to the control group will not undergo a series of MRI scans but will come into the study office for a one hour waiting period at the 9-12 week post-implant visit.
88853818|NCT01830816|Experimental|End-stage Renal Disease: Ixazomib|In the 15 day period that constitutes Part A of the trial, participants received a single oral dose of ixazomib 3.0 mg capsules. Participants from Part A had the option of continuing the study by participating in Part B, where they received ixazomib (4, 3, or 2.3 mg per protocol) capsules, orally on Days 1, 8, and 15 of each 28-day cycle until disease progression or unacceptable toxicity.
89380883|NCT03334721|Experimental|Placebo Oral Capsule, Then Gabapentin|"Week 1: 1-week condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).~Week 2: 1-week condition will consist of an in-person study visit for assessment and dispensing of Gabapentin medication (Day 1), titration to maximum dose (i.e., 1,200mg gabapentin) (days 1-5), MRI (Day 5), and medication washout (Days 5-7)."
89380884|NCT05144880|Experimental|electroacupuncture with 2Hz group|
88853819|NCT01846416|Experimental|Atezolizumab (MPDL3280): 1L Participants|Participants with no prior chemotherapy for advanced NSCLC disease will receive atezolizumab IV as a fixed dose of 1200-mg on Day 1 of each 21-day cycle until disease progression.
88853820|NCT01846416|Experimental|Atezolizumab (MPDL3280): 2L+ Participants|Participants who progress during or following a prior platinum-based chemotherapy regimen without restriction to maximum number of prior therapies will receive atezolizumab IV as a fixed dose of 1200-mg on Day 1 of each 21-day cycle until no longer deemed to be experiencing clinical benefit as assessed by the investigator.
88853821|NCT01846416|Experimental|Atezolizumab (MPDL3280): 2L+ Brain Metastases Participants|Participants with previously treated brain metastases and who progress during or following a prior platinum-based chemotherapy regimen without restriction to the maximum number of prior therapies, will receive atezolizumab IV as a fixed dose of 1200-mg on Day 1 of each 21-day cycle until no longer deemed to be experiencing clinical benefit as assessed by the investigator.
88853822|NCT01865448|Active Comparator|omega-3 DHA|Patients in this group will receive 500 mg/day supplement of DHA omega-3 fatty acid in capsule form, in addition to the vitamin and oligoelement supplements which are part of the standard weight-loss programme.
88853823|NCT01865448|Placebo Comparator|Control|Patients in control group will receive an placebo capsule, in addition to the vitamin and oligoelement supplements which are part of the standard weight-loss programme
88853824|NCT01804140||Cohort|
88853825|NCT04414878|Experimental|Single arm clinical investigation|Subjects in experimental group will be implanted with the VitaFlow™ II Transcatheter Aortic Valve System
88853826|NCT01846104|Experimental|50-μg booster dose RVEc|Subjects will be receive one 50-μg dose of RVEc
89183019|NCT05793567||Controls|Patients with atypical chest pain and no obstructive disease on coronary angiogram who have been referred for investigation of suspected CMD and have a clinical indication for CMD testing will be retrospectively enrolled and data collected from a previous routine standard of care coronary angiogram with coronary reactivity testing (CRT) will be utilized.
89380885|NCT05144880|Experimental|electroacupuncture with 100Hz group|
88853827|NCT01803282|Experimental|Part A: ADX 200 mg|Participants with advanced solid tumors who fail or are intolerant to standard therapy or for whom no standard therapy exists, will receive 200 mg ADX as monotherapy via IV infusion (approximately 30 minutes) every 2 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
88853828|NCT01803282|Experimental|Part A: ADX 600 mg|Participants with advanced solid tumors who fail or are intolerant to standard therapy or for whom no standard therapy exists, will receive 600 mg ADX as monotherapy via IV infusion (approximately 30 minutes) every 2 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
88853829|NCT01803282|Experimental|Part A: ADX 1800 mg|Participants with advanced solid tumors who fail or are intolerant to standard therapy or for whom no standard therapy exists, will receive 1800 mg ADX as monotherapy via IV infusion (approximately 30 minutes) every 2 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug
88853830|NCT01803282|Experimental|Part B: PAC, ADX 800 mg|Participants with PAC will receive ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (gemcitabine and nab paclitaxel, on Days 1, 8, and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
89183020|NCT05784233|Experimental|0% Relevance|0% chance of the salient item being the target during visual search task.
89183021|NCT05784233|Experimental|25% Relevance|25% chance of the salient item being the target during visual search task.
89183022|NCT05784233|Experimental|50% Relevance|50% chance of the salient item being the target during visual search task.
89183023|NCT05784233|Experimental|75% Relevance|75% chance of the salient item being the target during visual search task.
89380886|NCT03709589||Group-A|Patients with Modified Early Warning Score of ≥ 5
89380887|NCT03709589||Group-B|Patients with Modified Early Warning Score of < 5
89380888|NCT03707561||Group 1 - IPAH and heritable PAH|Idiopathic pulmonary arterial hypertension (IPAH) and heritable PAH Diagnostic Test: Right Heart Catheterization (RHC)
89380889|NCT03707561||Group 2- PAH associated with CHD|Pulmonary arterial hypertension associated with congenital heart disease Diagnostic Test: Right Heart Catheterization (RHC)
89380890|NCT03707561||Group 3- PAH associated with CTD|Pulmonary Arterial Hypertension associated with Connective Tissue Diseases Diagnostic Test: Right Heart Catheterization (RHC)
89380891|NCT03707561||Group 4- portoPH|Portopulmonary hypertension
89380892|NCT03707561||group 5- PAH-HIV|Pulmonary arterial hypertension associated with HIV infection
89380893|NCT03707561||group 6- operable CTEPH|Operable chronic thromboembolic pulmonary hypertension Diagnostic Test: Right Heart Catheterization (RHC)
89380894|NCT03707561||group 7- non-operable CTEPH|Non operable chronic thromboembolic pulmonary hypertension Diagnostic Test: Right Heart Catheterization (RHC)
89380895|NCT05706246|Other|Children with perioperative hypersensitivity|Children with perioperative hypersensitivity
89399506|NCT03689205||Patients that BMI> 30kg / m2 (Group A)|Venous puncture pain on patients that Body mass index > 30kg / m2
89399507|NCT03689205||Patients that BMI< 30kg / m2 (Group B)|Venous puncture pain on patients that Body mass index < 30kg / m2
89399508|NCT02182154|Experimental|BIBF 1120 ES|
89380896|NCT05114538|Experimental|RIT Training Group|Providers in the RIT group (n=80) will receive intensive training (online tutorial, 2-day workshop, and virtual coaching and feedback in the field) in RIT and parent coaching and will be required to achieve fidelity prior to enrolling families from their caseload. They will then be asked to use the intervention with enrolled families for a minimum of 3 months. One intervention session per month for each enrolled family will be videotaped and scored for fidelity. Providers will receive monthly consultation from RIT trainers while these families are in the active treatment phase.
89380897|NCT05114538|No Intervention|Treatment as Usual|Providers in the TAU group (n=80) will have three sessions videotaped and scored for each enrolled family to assess treatment differentiation. To incentivize agency participation, RIT training will be provided to the TAU group and other providers when data collection is complete.
89380898|NCT03627312|Experimental|Omega-3|this group receives a fruit juice drink containing omega-3
88853831|NCT01803282|Experimental|Part B: LAC, ADX 1200 mg|Participants with lung adenocarcinoma (LAC) will receive ADX 1200 mg every 3 weeks via IV infusion in addition to the 21-day cycle chemotherapy (carboplatin and pemetrexed, on Day 1) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
88853832|NCT01803282|Experimental|Part B: LSC, ADX 1200 mg|Participants with lung squamous cell carcinoma (LSC) will receive ADX 1200 mg every 3 weeks via IV infusion in addition to the 21-day cycle chemotherapy (carboplatin and paclitaxel, on Day 1) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
88853833|NCT01803282|Experimental|Part B: EGC, ADX 800 mg|Participants with esophagogastric adenocarcinoma (EGC) will receive ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (leucovorin+oxaliplatin+5-fluorouracil {5-FU} [mFOLFOX6], on Days 1 and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
88853834|NCT01803282|Experimental|Part B: FL CRC, ADX 800 mg+BEV 5 mg/kg|Participants with colorectal cancer (CRC) will receive first-line (FL) treatment with ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (mFOLFOX6 and bevacizumab 5 mg/kg, on Days 1 and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
88853835|NCT01803282|Experimental|Part B: FL CRC, ADX 800 mg+BEV 10 mg/kg|Participants with CRC will receive FL treatment with ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (mFOLFOX6 and bevacizumab 10 mg/kg, on Days 1 and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
88853836|NCT01803282|Experimental|Part B: SL CRC, ADX 800 mg+BEV 5 mg/kg|Participants with CRC will receive second-line (SL) treatment with ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (leucovorin+irinotecan+5-FU [FOLFIRI] and bevacizumab 5 mg/kg, on Days 1 and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
88853837|NCT01803282|Experimental|Part B: SL CRC, ADX 800 mg+BEV 10 mg/kg|Participants with CRC will receive SL treatment with ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (FOLFIRI and bevacizumab 10 mg/kg, on Days 1 and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
88853838|NCT01803282|Experimental|Part B: BRCA, ADX 800 mg|Participants with breast cancer (BRCA) will receive ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (paclitaxel, on Days 1, 8, and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
88853839|NCT01844778|Active Comparator|TIS/TIP|During the first cycle of treatment, participants received nebulized TIS, 300 mg twice per day for 28 days followed by 28 days off-treatment. During the second cycle, participants received 112 mg (four 28 mg capsules) twice per day for 28 days followed by 28 days off-treatment.
88853840|NCT01844778|Active Comparator|COLI/TIP|During the first cycle, participants received nebulized COLI, 1 million or 2 million units twice or thrice per day (or the participant's usual dose and regimen) for 56 days (no off-treatment period) or 28 days on-treatment followed by 28 days off-treatment (cycling regimen), depending on local treatment guidelines. During the second cycle, participants received TIP, 112 mg (four 28 mg capsules) twice per day for 28 days followed by 28 days off-treatment.
88853841|NCT01844778|Active Comparator|TIP/TIP|During the first and second cycles, participants received TIP, 112 mg (four 28 mg capsules) twice per day for 28 days followed by 28 days off-treatment.
88875359|NCT02593032|No Intervention|Control Arm|Patients in the control arm will receive usual care and can continue using their existing pharmacy.
88875360|NCT05372562||patients with recurrent macular edema|after intravitreal injection of OZURDEX, patients with macular edema relapse during follow-up were recruited.
88875361|NCT05372562||patients without recurrent edema|after intravitreal injection of OZURDEX, patients without macular edema relapse during follow-up were recruited.
89380899|NCT03627312|Placebo Comparator|Placebo|this group receives the same fruit juice drink as in the experimental group, but it does not contain omega-3
89380900|NCT03627312|Other|Treatment as Usual|this group do not receive a fruit juice drink
89380901|NCT03627000||failure after reimplantation|description of the failure at the reimplantation
89380902|NCT03515551|Experimental|Phase 1: Dose Escalation|Four fixed-dose, dose escalation cohorts (Cohorts 1 to 4) and 3 intrapatient dose escalation cohorts (Cohorts 5 to 7) to establish the MTD/RP2D of IMCnyeso.
89380903|NCT03515551|Experimental|Phase 2: Dose Expansion|Three planned cohorts treated at the RP2D to make a preliminary assessment of the anti-tumor activity of IMCnyeso. Phase 2 was not initiated and data were not collected.
89380904|NCT05558592|Experimental|Treatment_group|
89380905|NCT05558592|Active Comparator|Control_group|
89380906|NCT03626844|Experimental|Manual Lysis after 15 minutes (Intervention)|Manual Lysis of Placenta 15 minutes after Delivery.
89380907|NCT03626844|Active Comparator|Manual lysis after 30 minutes (Control)|Waiting 30 minutes after delivery and then manual lysis of the placenta.
89380908|NCT04694443|Active Comparator|Study group|The study group will receive the multidisciplinary tele-health intervention plus standard medical care
89380909|NCT04694443|Placebo Comparator|Control group|The control group will receive the best standard medical care
89380910|NCT05706090|Experimental|Group USP|The group using ultrasound and injection pressure manometer was named USP
89380911|NCT05706090|Experimental|Group USPN|The group using ultrasound , injection pressure manometer , and neurostimulator was named USPN
88853842|NCT01802580|Experimental|Intervention - internet reminder survey|Treatment phase is 12 months. During the intervention, each subject will receive fluocinonide 0.05% ointment, a standard treatment for psoriasis. If their psoriasis could be suitably treated with fluocinonide, then they will be asked to participate in the study. At the initial study visit, fluocinonide will be dispensed in a small jar with a MEMS® electronic monitoring cap attached. Subjects will be asked to apply the medication twice daily. They will be asked to the entire affected area, excluding face and genitals. Subjects will be instructed to apply the smallest amount of study medication sufficient to cover the affected areas. At the end of the treatment phase, subjects will have a feedback session with specific results of adherence behavior revealed. They will receive weekly surveys via internet to complete.
88853843|NCT01802580|Experimental|Standard of care, no internet survey|Standard treatment for psoriasis. If it is felt that their psoriasis could be suitably treated with fluocinonide, then they will be asked to participate in the study. At the initial study visit, fluocinonide will be dispensed to the subjects in a small jar with a MEMS® electronic monitoring cap attached. Subjects will be asked to apply the medication twice daily. All subjects will be assigned to treatment with topical fluocinonide to the entire affected area, excluding face and genitals. Subjects will be instructed to apply the smallest amount of study medication sufficient to cover the affected areas. At the end of the treatment phase, subjects will have a feedback session with specific results of adherence behavior revealed.
88853844|NCT01611090|Experimental|Ibrutinib + BR|Ibrutinib 420 mg will be administered orally once daily on a continuous schedule. All subjects will receive background therapy with bendamustine and rituximab (BR) for a maximum of 6 cycles (a cycle is defined as 28 days, with the exception of Cycle 1, which will be 29 days to allow for rituximab dosing prior to bendamustine and study medication).
88853845|NCT01611090|Placebo Comparator|Placebo + BR|Matching placebo will be administered orally once daily on a continuous schedule. All subjects will receive background therapy with BR for a maximum of 6 cycles (a cycle is defined as 28 days, with the exception of Cycle 1, which will be 29 days to allow for rituximab dosing prior to bendamustine and study medication).
88853846|NCT01844700|Active Comparator|Ziprasidone|(20-160mg/d, bid) for 12 weeks
88853847|NCT01844700|Active Comparator|Aripiprazole, quetiapine, risperidone|Aripiprazole (2-30mg/d), Quetiapine (25-800mg/d) or Risperidone (0.1-8mg/d) for 12 weeks
88853848|NCT01844076|Experimental|Phase I Level -2|"Phase I (Quinacrine and Capecitabine): The Phase I portion of the study will aim to determine the tolerability of both agents in combinations when used at established clinical doses. This portion of the study will more closely resemble a pilot study or feasibility study rather than a dose escalation.~Each group will have 1 to 6 patients enrolled in it. If the patients in a lower group do not have any significant side effects the next patient will start at the next group dose.~Group 1: capecitabine at a dose of 1000 mg/m^2 twice per day (days 1-14), and quinacrine at a dose of 100 mg once per day (days 1-21) for a 21 day cycle"
88853849|NCT01844076|Experimental|Phase I Level -1|"Phase I (Quinacrine and Capecitabine): The Phase I portion of the study will aim to determine the tolerability of both agents in combinations when used at established clinical doses. This portion of the study will more closely resemble a pilot study or feasibility study rather than a dose escalation.~Each group will have 1 to 6 patients enrolled in it. If the patients in a lower group do not have any significant side effects the next patient will start at the next group dose.~Group 1: capecitabine at a dose of 1000 mg/m^2 twice per day (days 1-14), and quinacrine at a dose of 100 mg twice per day (days 1-21) for a 21 day cycle"
88853850|NCT01844076|Experimental|Phase I Level 0|Group 3: capecitabine at a dose of 1000 mg/m^2 twice per day (days 1-14), quinacrine at a dose of 200 mg twice a day (days 1-21) for a 21 day cycle
88853851|NCT01844076|Experimental|Phase II|"Phase II will use the treatment outlined in phase I, using the recommended phase II dose (RP2D) derived from Phase I.~Patients will receive capecitabine at a dose of 1000 mg/m^2 twice per day (days 1-14), quinacrine at a dose of 100 mg twice per day (days 1-21) for a 21 day cycle"
88853852|NCT01826604|Experimental|Alexis O C-section retractor|Alexis O C-section retractor will be used.
88853853|NCT01826604|Other|Control- Conventional retractors|Conventional retractors for C-sections will be used.
88853854|NCT01843842|Experimental|Ergoferon (5 ml 3 times a day)|
88853855|NCT01843842|Placebo Comparator|Placebo (5 ml 3 times a day)|
88853856|NCT01826448|Experimental|Dose extension cohort|Patients will take PLX3397 and vemurafenib at the recommended phase 2 dose. This will be determined by the tolerability and safety of these drugs in the previous 3 cohorts.
88853857|NCT01826448|Experimental|Cohort 3|Patients will take 1000mg/day of PLX3397 and 960mg BID of vemurafenib
88853858|NCT01826448|Experimental|Cohort 2|Patients will take 800mg/day of PLX3397 and 960mg BID of vemurafenib
88853859|NCT01826448|Experimental|Cohort 1|Patients will take 800mg/day of PLX3397 and 720mg BID of vemurafenib
89380912|NCT04418791|Experimental|MIF-regular|MIF-regular will start with modified intermittent fasting. After 12 weeks, this arm will return to regular diet with no fasting intervention.
89380913|NCT04418791|Experimental|Regular-MIF|Regular-MIF will start with regular diet with no fasting. After 12 weeks, this arm will start with modified intermittent fasting.
89380914|NCT03380429|Experimental|Data on Maintenance use supplied to Subject and HCP|Eligible subjects will receive RELVAR/BREO maintenance therapy via ELLIPTA DPI and salbutamol rescue medication via MDI with sensors attached to both inhalers. Information from sensor attached to RELVAR/BREO ELLIPTA will be fed back to the subject via an app on smart phone and to the subject's HCP via an online dashboard.
89380915|NCT03380429|Experimental|Data on Maintenance use supplied to Subject|Eligible subjects will receive RELVAR/BREO maintenance therapy via ELLIPTA DPI and salbutamol rescue medication via MDI with sensors attached to both inhalers. Information from sensor attached to RELVAR/BREO ELLIPTA will be fed back to the subject via an app on smart phone.
89399509|NCT03693339|Experimental|Capmatinib|Capmatinib 400 mg twice oral administration and continuously dosing (28-day treatment schedule as one treatment cycle)
88853860|NCT01826370||Linagliptin|
89380916|NCT03380429|Experimental|Data on Maintenance and Rescue use supplied to Subject and HCP|Eligible subjects will receive RELVAR/BREO maintenance therapy via ELLIPTA DPI and salbutamol rescue medication via MDI with sensors attached to both inhalers. Information from sensors attached to RELVAR/BREO ELLIPTA and salbutamol MDI will be fed back to both subject and HCP. The data will be fed back to the subject through an app and to HCP through an online dashboard.
88853861|NCT01826214|Experimental|LDE225-400|Patients who were randomized to Schedule A, and received 400 mg LDE225 twice daily for the first two weeks only and then after two weeks, received 800 mg LDE225 once daily until disease progression, toxicity, withdrawal of consent, death, discretion of the investigator or early termination of the study.
89380917|NCT03380429|Experimental|Data on Maintenance and Rescue use supplied to Subject|Eligible subjects will receive RELVAR/BREO maintenance therapy via ELLIPTA DPI and salbutamol rescue medication via MDI with sensors attached to both inhalers. Information from sensors attached to RELVAR/BREO ELLIPTA and salbutamol MDI will be fed back to subject through an app.
89380918|NCT03380429|Active Comparator|No data supplied to Subject or HCP|Eligible subjects will receive RELVAR/BREO maintenance therapy via ELLIPTA DPI and salbutamol rescue medication via MDI with sensors attached to both inhalers. Subjects will be provided with a home hub through which their data will be uploaded during the study but the subjects and their HCP will not be able to view the data.
89380919|NCT01313143|Experimental|AOP200704, infusion|
89380920|NCT01313143|Active Comparator|Esmolol, infusion|
89380921|NCT03280615|Experimental|Omega 3 fatty acids|Supplementation of 3.7 g of docosahexanoic and eicosapentanoic acids per day during 12 weeks
89380922|NCT03280615|Placebo Comparator|Corn oil|Supplementation of 3.7 g of corn oil per day during 12 weeks
89380923|NCT05705934|Experimental|Group 1|Participants in this group will receive holistic-based group exercise program. All evaluations in this group will be done in the form of before and after. The exercise program will be applied for 12 weeks, 3 days a week.
89380924|NCT05705934|No Intervention|Group 2|Participants in this group will continue their routine habits and nutrition programs. All assessments in this group will be done in the form of before and after.
89380925|NCT05071794|Active Comparator|Propofol|Subhypnotic dose of propofol, 0.5mg/kg, 10 - 15 min before end of surgery
89380926|NCT05071794|Placebo Comparator|Placebo|Normal saline 0.9%, 10 mL , 10 - 15 min before end of surgery
89380927|NCT03711071|Experimental|Intervention Group|The Intervention Group is allocated to a Workshop of communication training before data collection covering theoretical background and clinical implementation of ICE communication in association with frequent consultation contents.
89380928|NCT03711071|No Intervention|Control Group|This group will not get the intervention before data collection.
89380929|NCT03709433|Experimental|ACT groups and mobile app|Participants will receive six two-hour weekly sessions of acceptance and commitment therapy (ACT) in a group format. They will also access the ACT Daily mobile app, which helps participants practice ACT skills in the moment, for the duration of the study (10-14 weeks depending on when the participant completes the baseline assessment.) Sessions use metaphors, experiential exercises, and discussion to target core ACT skills: acceptance, defusion, present-moment awareness, self-as-context, values, and committed action. The mobile app includes metaphors and experiential exercises to aid with all of these skills except self-as-context. Participants will be asked to use the app to practice these skills and to complete behavioral commitments linked to their values between sessions.
89380930|NCT05705778||Strabismic|
88853862|NCT01826214|Experimental|LDE225-800|Patients who were randomized to Schedule B, received 800 mg LDE225 once daily until disease progression, toxicity, withdrawal of consent, death, discretion of the investigator or early termination of the study.
89380931|NCT05705778||Anisometropic|
89380932|NCT05705778||Isoametropic|
89380933|NCT05705778||Visual deprivation|
88853863|NCT04582344|Experimental|SARS-COV-2 Vaccine|600 SU of SARS-CoV-2 virus antigen, intramuscular injection, two doses given 14 days apart.
88853864|NCT04582344|Placebo Comparator|Placebo|Aluminium hydroxide, disodium hydrogen phosphate, sodium dihydrogen phosphate, sodium chloride 0.5mL/dose, intramuscular injection, two doses given 14 days apart.
88853865|NCT01843062|Experimental|Selumetinib|Selumetinib plus Radioactive Iodine Therapy
88853866|NCT01843062|Placebo Comparator|Placebo|Placebo plus Radioactive Iodine Therapy
88853867|NCT01842438|Experimental|Behavioral: psychosexual intervention|6-sessions of couple support focused on relationships and psychosexual functioning
89380934|NCT05705778||Mixed group|
88853868|NCT01842438|No Intervention|Control|This group will not receive the intervention during the life-span of the project
88853869|NCT01799226|Active Comparator|Toothpaste without Triclosan|This arm will use a toothpaste that does not contain triclosan
88853870|NCT01799226|Experimental|Triclosan|This arm will use colgate total which contains triclosan
88875362|NCT05371938|Experimental|Volar Locking Plate|Surgery with volar locking plate
89380935|NCT03280537|Experimental|Omalizumab|Participants received omalizumab as a subcutaneous injection once every 2 weeks (q2w) or once every 4 weeks (q4w). The dose (from 75 mg up to 600 mg) and dosing frequency (q2w or q4w) was determined by serum total IgE level and body weight using the study-drug dosing table. All participants were also treated during the entire study with intranasal corticosteroids (mometasone nasal spray) as background therapy.
89380936|NCT03280537|Placebo Comparator|Placebo|Participants received matching placebo as a subcutaneous injection once every 2 weeks or once every 4 weeks. The dose and dosing frequency was determined by serum total IgE level and body weight using the study-drug dosing table. All participants were also treated during the entire study with intranasal corticosteroids (mometasone nasal spray) as background therapy.
89380937|NCT04799327|Experimental|Treatment group A|
89380938|NCT04799327|Experimental|Treatment group B|
89380939|NCT04799327|Experimental|Treatment group C|
89380940|NCT04799327|Placebo Comparator|Treatment group D|
89380941|NCT03842826||Athlete|Male athletes performing sports ≥ 1x/week Age: 18-40 years
89380942|NCT05029050|Experimental|Dexmedetomidine (D)|Continuous intravenous infusion of dexmedetomidine 0.4 μg/kg/hour from the start of cardiopulmonary bypass and during surgery, followed by 0.2 μg/kg/hour until discharge from the ICU or 24 hours postoperatively, whichever happens first.
89183024|NCT05784233|Experimental|100% Relevance|100% chance of the salient item being the target during visual search task.
89183025|NCT05780866|Other|Video and Activity Tracker|
89183026|NCT05780814|Experimental|Cognitive-Behavioral Therapy for Insomnia (CBT-I)|"The proposed intervention consists of 6 remotely-delivered sessions; Weeks 1, 2, 4, 6, 7, and 8, with weeks 3 and 5 being rest weeks. Session 1 will be 60-90 mins, Session 2 will be ~60 mins, and remaining visits are ~45 mins. The investigators propose a methodological innovation for CBT-I, which involves conducting 15-minute sessions every other month during the BWL intervention. Prior to these maintenance sessions, participants in the CBT-I+BWL group will complete electronic sleep diaries for one week and interventionists will use this information in sessions to sustain and enhance long-term outcomes by using MI to reinforce application of CBT-I session content."
89183027|NCT05780814|Placebo Comparator|Sleep Education Control (EDU)|The EDU intervention will parallel the CBT-I intervention in number, format and length of all sessions, including maintenance sessions. It provides basic information about sleep and cancer, widely available to the public. EDU content does not include any individualized behavioral instructions, sleep diary monitoring during the intervention, or behavior change counseling. Content is presented didactically only.
89183028|NCT05764915|Experimental|RGT-264 monotherapy|The study is composed of dose escalation stage and dose expansion stage. RGT-264 will be administered orally daily alone as monotherapy in both stages. In the dose escalation stage, the subjects will receive once daily of RGT-264 monotherapy across approximately 6 ascending dose levels. The starting dose is 10 mg/day. In the dose expansion stage, the subjects will receive RGT-264 treatment at the recommended dose from dose escalation part.
89183029|NCT05763667|No Intervention|No TAP block|
89183030|NCT05763667|Active Comparator|TAP block with liposomal and plain bupivacaine|
89183031|NCT05763667|Active Comparator|TAP block with plain bupivacaine alone|
89183032|NCT05762757|Experimental|Colposcopy educational material|Participants will complete a 9-question quiz that will assess knowledge of colposcopy. They will then view the colposcopy educational material and answer the same 9-question quiz to assess their knowledge of colposcopy. Participants will complete the Acceptability Intervention Measure, the Intervention Appropriateness Measure, and the Feasibility of Intervention Measure. Participants will also be asked whether the educational material influences their intention to adhere to colposcopy.
89183033|NCT05758077|Experimental|SCD + CKRT Arm|In addition to standard of care CKRT therapy for these subjects, these subjects will have up to ten sequential 24-hour treatments with the Selective Cytopheretic Device (SCD) in-line with their existing CKRT circuit.
89183034|NCT05758077|Other|CKRT Alone Arm (standard of care)|This arm will receive standard of care CKRT therapy for their condition as appropriate.
89183035|NCT05756257||Acute Ischemic Stroke|Blood pressure variability will be measured in the patients with acute ischemic stroke.
89183036|NCT05747924|Experimental|AOC 1020 Regimen 1|Part A: AOC 1020 Dose Regimen 1; Five doses administered intravenously over 9 months
89183037|NCT05747924|Experimental|AOC 1020 Regimen 2|Part B1 & C: AOC 1020 Dose Regimen 2; Five doses administered intravenously over 9 months
89183038|NCT05747924|Experimental|AOC 1020 Regimen 3|Part B2 & C: AOC 1020 Dose Regimen 3; Five doses administered intravenously over 9 months
89183039|NCT05747924|Placebo Comparator|Placebo (Saline)|Part A, B & C: Placebo; Five doses administered intravenously over 9 months
89183040|NCT05743504|Experimental|Immunotherapy with CCRT before surgery|Tiragolumab and Atezolizumab with CCRT before surgery
89183041|NCT05735730|Other|Epidemiologic study|This is an epidemiologic study. No arms are considered.
89183042|NCT05728853||Trans gender males|Trans gender males in hormonal therapy
89183043|NCT05724693|Experimental|Group 1 -Mild Hepatic Impairment|Drug: single dose Bemnifosbuvir (BEM)
89183044|NCT05724693|Experimental|Group 2-Moderate Hepatic Impairment|Drug: single dose Bemnifosbuvir (BEM)
89183045|NCT05724693|Experimental|Group 3 - Healthy Subjects matching mild and moderate impairment groups|Drug: single dose Bemnifosbuvir (BEM)
89183046|NCT05724693|Experimental|Group 4 - Severe Hepatic Impairment|Drug: single dose Bemnifosbuvir (BEM)
89183047|NCT05724693|Experimental|Group 5 - Normal hepatic function matching severe impairment group|Drug: single dose Bemnifosbuvir (BEM)
89183048|NCT05724329|Experimental|Tislelizumab + Dasatinib + Quercetin|"Neoadjuvant treatment with Tislelizumab, dasatinib and quercetin for up to 3 cycles (cycle length: 21 days):~Tislelizumab (IV), dose= 200mg, day=1. Dasatinib (PO), dose=100mg/day, day= 1,2,3. Quercetin (PO), dose=1250mg/day, day= 1,2,3.~Following surgical resection, participants will receive adjuvant therapy:~Tislelizumab (200 mg, day=1) Cycle=1-15cycle Dasatinib (100mg/day, day= 1,2,3) Cycle=1、2、3、8、9、10 Quercetin (1250mg/day, day= 1,2,3) Cycle=1、2、3、8、9、10"
88817732|NCT04246125||Therapeutic interventional radiology|Patients undergoing an interventional radiology procedure, at risk for developing radiation-induced skin lesions, including acts of therapeutic interventional neuroradiology (angioplasties, embolization of aneurysms, embolization of arteriovenous malformations , etc…), embolizations and ablations of thoracic tumors, therapeutic cardiac acts (transluminal angioplasties and chronic coronary occlusions) and abdominal embolizations.
88817733|NCT04272047|Experimental|Knee Control+|Knee Control+ consists of 6 different exercises, with 10 different variations/progressions, and takes 10-15 minutes to complete. In addition, teams are instructed to perform a 5-minute running warm-up before the Knee Control+ exercises. Teams are to carry out the running warm-up and Knee Control+ at all training sessions, and the running warm-up before all matches, during the whole season. Knee Control+ is based on the Knee Control program but with more variations for each exercise making it easier to tailor for the needs in the respective teams.
88817734|NCT04272047|Experimental|Adductor strengthening program|The Adductor strengthening program consists of a single exercise with three levels of difficulty. The exercise is based on the Copenhagen Adduction exercise. Teams are to carry out the Adductor strengthening program as part of their regular warm-up 2-3 times per week, one set per side, during the pre-season, and 1 time per week, one set per side during the in-season.
88817735|NCT04272047|Active Comparator|Knee Control|Teams will carry on their normal training and warm-up routines using the Knee Control program with no intervention from the researchers. Knee Control consists of 6 different exercises, with 4 different variations/progressions and 1 pair-exercise.
89380943|NCT05029050|Experimental|Clonidine (C)|Continuous intravenous infusion of clonidine 0.4 μg/kg/hour from the start of cardiopulmonary bypass and during surgery, followed by 0.2 μg/kg/hour until discharge from the ICU or 24 hours postoperatively, whichever happens first.
89380944|NCT05029050|Placebo Comparator|Placebo (P)|Continuous intravenous infusion of saline 0.4 μg/kg/hour from the start of cardiopulmonary bypass and during surgery, followed by 0.2 μg/kg/hour until discharge from the ICU or 24 hours postoperatively, whichever happens first.
89380945|NCT04690231|Experimental|Apatinib+IE|
89380946|NCT04690231|Active Comparator|IE|
89380947|NCT03280381|Experimental|NIFTY Feeding Cup First|Each caregiver/infant pair will first use the Nifty Feeding Cup for two feeds and then the standardized generic cup for two feeds.
89380948|NCT03280381|Experimental|Generic Medicine Cup First|Each caregiver/infant pair will first use the standardized generic cup for two feeds and then the Nifty Feeding Cup for two feeds.
89380949|NCT03270085|Active Comparator|Colesevelam|"Once randomized, subjects will have baseline testing period, treatment period, and treatment testing period the study drug. This consists of nine visits and will be over a period of five to nine weeks.~Baseline testing period consists of: transit test, 4 day high fat diet with 48 hour stool collection, blood samples, rectosigmoid biopsies, one week stool diary, and medication pick up.~Treatment period will have subject take the study drug 1875 mg of medication orally twice daily with lunch and supper for 4-5 weeks.~The last period, is the treatment testing period. This consists of a full transit & urine permeability test, 4 day high fat diet with 48 hour stool collection, blood samples, one week stool diary collection, and the return of the unused medication."
89380950|NCT03270085|Placebo Comparator|Placebo|"Once randomized, subjects will have a baseline testing period, treatment period and treatment testing period with the placebo. This consists of nine visits and will be over a period of five to nine weeks.~The last period, is the treatment testing period. This consists of a full transit & urine permeability test, 4 day high fat diet with 48 hour stool collection, blood samples, one week stool diary collection, and the return of the unused placebo."
89380951|NCT05615454|Experimental|Experimental group|(BEMER activated)
89380952|NCT05615454|Placebo Comparator|Comparison group|(BEMER deactivated)
89380953|NCT05703204|Experimental|QLF32101|single arm with QLF32101 treatment
89380954|NCT03267511|Experimental|Test Product 1|Participants will be instructed to apply experimental dentifrice containing 5% potassium nitrate (KNO3) / 0.2542% sodium fluoride (NaF) dentifrice with 0.5% spherical silica.
89380955|NCT03267511|Experimental|Test Product 2|Participants will be instructed to apply experimental dentifrice containing 5% KNO3 / 0.2542% NaF dentifrice with 1% spherical silica and 5% STP.
89380956|NCT03267511|Active Comparator|Reference Product 1|Participants will be instructed to apply experimental dentifrice containing 5% KNO3 / 0.2542% NaF dentifrice with 6% abrasive silica.
88853871|NCT01825200|Active Comparator|Flublok|Flublok containing 3x45µg (135µg total) of recombinant hemagglutinin (rHA) derived from influenza A/H1N1 and A/H3N2 and influenza B viruses in a total volume of 0.5 mL
89380957|NCT03267511|Active Comparator|Reference Product 2|Participants will be instructed to apply experimental dentifrice containing 5% KNO3 / 0.2543% NaF dentifrice with 16% abrasive silica and 5% STP.
89380958|NCT05003544|Active Comparator|PENG BLOCK ( Group A)|A regional block will be applied while the patient is in the supine position. A curvilinear low-frequency ultrasound probe (2-5MHz) will initially be placed in a transverse plane on the AIIS and then rotate the probe approximately 45 degrees counterclockwise to align with the pubic ramus. In this view, IPE, iliopsoas muscle and tendon, femoral artery and pectineus muscle will be observed. A 22 gauge, 80 mm needle will be inserted from lateral to medial in an in-plane approach to place the psoas tendon anteriorly and posteriorly in the musculofacial plane between the pubic ramus. Following negative aspiration, a local anesthetic solution (20ml bupivacaine 0.5%) will be injected.
88853872|NCT01825200|Placebo Comparator|Afluria|Afluria, containing 3x15µg (45µg total), of trivalent, inactivated influenza vaccine (licensed IIV) containing influenza antigen derived from A/H1N1 and A/H3N2 and influenza B viruses in a total volume of 0.5 mL
88853873|NCT01824576|Experimental|ITPR|Use of the ITPR for 120 minutes.
89380959|NCT05003544|Active Comparator|Intra-articular( Group B)|It will be applied to the intra-articular region by the surgeon at the end of the operation. A volume of 60 ml (30 ml of 0.5% bupivacaine and 30 ml of 0.9% NaCl)
88853874|NCT01824498|Experimental|Low Fat, High Fat, Low Fat High Omega 3|See Intervention Description
88853875|NCT01824498|Experimental|Low Fat, Low Fat High Omega 3, High Fat|See Intervention Description
88853876|NCT01824498|Experimental|High Fat, Low Fat, Low Fat High Omega 3|See Intervention Description
88853877|NCT01824498|Experimental|High Fat, Low fat High Omega 3, Low Fat|See Intervention Description
88853878|NCT01824498|Experimental|Low Fat High Omega 3, High Fat, Low Fat|See Intervention Description
88853879|NCT01824498|Experimental|Low Fat High Omega 3, Low Fat, High Fat|See Intervention Description
88853880|NCT01798134|Other|DEB-TACE|"Transarterial Chemoembolization with TANDEM™ - DOX Microspheres (DEB-TACE)~Treatment: Lobes; Dosing: TANDEM™/Doxorubicin; Second Treatment:TANDEM™/Doxorubicin"
88853881|NCT01798056|Experimental|GSK1437173A Group|Subjects received the first dose of GSK 1437173A at least 10 days (up to 1 month) before start of chemotherapy cycle or at the first day (allowing a window of +/- 1 day) of the first (or second) chemotherapy cycle. The second dose of GSK 1437173A vaccine was administered between 1 and 2 months after the first vaccination and at the first day (allowing a window of +/- 1 day) of a subsequent cycle of chemotherapy. The study products were administered intramuscularly into a deltoid muscle. The choice of and use of chemotherapy, or any other medication related to the patients' current conditions, were based on the local standard of care for the patients.
88875363|NCT05371938|Active Comparator|External fixation|Surgery with external fixation
88875364|NCT05371782||Derivation cohort|The derivation cohort will comprise about 235,000 patients with dementia, who were admitted to a hospital in Ontario from April 1st, 2009 to December 31st, 2017.
88875365|NCT05371782||Validation cohort|The validation cohort will comprise about 63,000 dementia patients, who were admitted to a hospital in Ontario from January 1st, 2018 to March 31st, 2019.
89399510|NCT02176694|No Intervention|Standard Care|Aside from the asthma education provided at enrollment and placement of the SmartInhaler (i.e.,electronic monitoring device), adolescents will continue to receive usual care through their primary care providers.
89399511|NCT02176694|Experimental|Text Messaging|A technology based system which allows adolescents to compose, schedule and send one-time or recurring text messages to their own cell phones.
89399512|NCT03689127|Active Comparator|Control|Heated breathing circuit will be turned off.
88817736|NCT04276311|Experimental|symptomatic patients with complex de novo FP arterial lesions|in symptomatic patients with claudication (Rutherford 2 and 3) and with complex de novo FP arterial lesions (TASC C).
88817737|NCT04267809|Experimental|Metformin group|22 subjects will receive Metformin 1000mg twice daily for 7 consecutive days (Days 1-7). On Day 4, subjects will be administered one dose of YF17D before metformin dosing.
88817738|NCT04267809|Placebo Comparator|Placebo group|22 subjects will receive placebo twice daily for 7 consecutive days (Days 1-7). On Day 4, subjects will be administered one dose of YF17D before placebo dosing.
88817739|NCT02242409|Experimental|Gemcitabine/abraxane|Gemcitabine and Abraxane
88817740|NCT04258085||Screening plus EMR|Individuals in this group are those residing in districts where health facilities have implemented a breast cancer screening program integrated with cervical cancer screening, the Women's Cancer Early Detection Program (WCEDP).
88817741|NCT04227639|Active Comparator|T-piece trial|In patients assigned to control group all spontaneous breathing trials will be performed using T-piece trial.
88817742|NCT04227639|Experimental|Pressure-Support trial|In patients assigned to experimental group all spontaneous breathing trials will be performed with a pressure-support level of 8 cm H2O without positive end-expiratory pressure.
88817743|NCT04167423||Healthy|No thyroid disease in pregnancy defined as plasma TSH (thyrotropin), TPOAb (thyroperoxidase auto antibodies) or FT4 (free thyroxin) out of the ranges proposed by 2014 European Thyroid Association Guideline.
88817744|NCT04167423||hyperthyroidism|Thyroid disease in pregnancy defined as plasma TSH, or FT4 out of the ranges proposed by 2014 European Thyroid Association Guideline.
88817745|NCT04167423||hypothyroidism|Thyroid disease in pregnancy defined as plasma TSH, or FT4 out of the ranges proposed by 2014 European Thyroid Association Guideline.
88817746|NCT04167423||thyroid autoimmunity|Thyroid disease in pregnancy defined as plasma TPOAb out of the ranges proposed by 2014 European Thyroid Association Guideline.
88817747|NCT01755455|Active Comparator|Ferrous sulfate 325mg|Ferrous sulfate 325mg tablet taken by mouth daily for 6 weeks
88817748|NCT01755455|Placebo Comparator|Placebo|Identical-appearing tablet taken by mouth daily for 6 weeks
88817749|NCT00366873|Active Comparator|1|cow-milk based infant formula
88817750|NCT00366873|Experimental|2|cow-milk based infant formula with prebiotics
88817751|NCT05317325|Experimental|Experimental Group|Autologous DCs pulsed with HOCl-oxidized autologous tumor lysate (OCDC) vaccine is administered in prime phase and personal neoantigen-sensitized DC(NeoDC) vaccine is administered in boost phase.
88817752|NCT05395923|Experimental|Palatal Pre-Suture (GPCS)|In the test group, GPCS (Silk, 4-0, 18 mm, 3/8 sharp needle) will be placed before the incision in the palatal region. GPCS will be taken one week after surgery.
88817753|NCT05395923|Active Comparator|No Palatal Suture (No GPCS) - Control|In the control group, no sutures will be applied before graft harvesting from the palate.
88817754|NCT04182399|Active Comparator|Patients 25 ZNS|30 patients receive oral 25 mg ZNS daily
88817755|NCT04182399|Active Comparator|Patients 50 ZNS|30 patients receive oral 50 mg ZNS daily
88817756|NCT04182399|Placebo Comparator|Patients Placebo|30 patients receive placebo
88817757|NCT04246619|Experimental|Pregabalin Krka Arm|"ARM 1: pregabalin (Pregabalin Krka 25-150 mg/ day) FLEXIBLE-DOSE REGIMEN.~Investigator can choose on V2:~Total Pregabalin Krka daily dose: 25 mg/day~Total Pregabalin Krka daily dose: 50 mg/day~Total Pregabalin Krka daily dose: 75 mg/day~Total Pregabalin Krka daily dose: 150 mg/day~Total Pregabalin Krka daily dose: 300 mg/day (from Phone call 1 further on)~V3: daily dose should be achieved: MINIMUM dose 150 mg/day Investigator can choose: total Pregabalin Krka daily dose 150 mg/day or 300 mg/day or 600 mg/day Investigator can choose: total Pregabalin Krka daily dose 150 mg/day or 300 mg/day or 600 mg/day~V4: Investigator can choose: total Pregabalin Krka daily dose 150 mg/day or 300 mg/day or 600 mg/day"
88817758|NCT04246619|Experimental|Dulsevia® Arm|"• ARM 2: duloxetine (Dulsevia® 30-60 mg/ day) FLEXIBLE-DOSE REGIMEN:~Investigator can choose on V2:~Total Dulsevia® daily dose: 30 mg/day~Total Dulsevia® daily dose: 60 mg/day~V3: daily dose should be achieved: MINIMUM dose 60 mg/day Investigator can choose total Dulsevia® daily dose 60 mg/day or 90 mg/day or 120 mg/day.~V4: Investigator can choose total Dulsevia® daily dose 60 mg/day or 90 mg/day or 120 mg/day."
88817759|NCT02618031|Other|Favorable CIS|Patients with a favorable CIS (fCIS) will receive endovascular treatment (EVT) and medical treatment consistent with national guidelines.
88817760|NCT02618031|Experimental|Poor CIS|Patients with a poor CIS (pCIS) will receive endovascular treatment (EVT) and medical treatment consistent with national guidelines.
88817761|NCT05317091|Experimental|Laughter yoga practice|Laughter yoga for nurses The experimental group was divided into three groups as 18-17-16 people. Sessions 1st group Monday-Thursday between 12:00-13:00; 2nd group Tuesday-Friday between 17:00-18:00; The third group was held on Wednesday Saturday between 20:00-21:00.laughter yoga for nurses-Deep breathing exercises Deep breathing exercises (5 minutes), Warm-up exercises (10 minutes) laughter yoga for nurses-Childish games Childish games (10 minutes), Laughter exercises (15 minutes).
88817762|NCT05317091|Experimental|Laughter yoga session parts-1|Deep breathing exercises (5 minutes) Breathing is held for 4-5 seconds after deep inspiration. While the arms are brought to the normal position, exhale slowly and rhythmically. When expressing after deep inspiration, the lips can be pursed as if whistling or exhaled with laughter.
88817763|NCT05317091|Experimental|Laughter yoga session parts-2|Warm-up exercises (10 minutes) Rhythm of 1-2, 1-2-3 is added to increase the energy level even more and synchronize the movements of the group. After a few rhythmic clapping movements, another movement is added. Whisking hands left and right. Then an audible rhythm of ho, ho, ha-ha-ha is added to the clapping gesture. Make eye contact with people in the group and smile at them.
88817764|NCT05317091|Experimental|Laughter yoga session parts-3|"Childish games (10 minutes) Childlike games are used to help laugh without reason just like a child. The group is motivated by visualizing these games in their minds, raising the arms up in the form of a Y letter, and saying very good (applause), very good (applause), hey with palms facing the sky."
89399513|NCT03689127|Experimental|Heat|Heated breathing circuit will be turned on.
89399514|NCT02176772||Tuberculosis, no HIV and severe anemia|
88817765|NCT05317091|Experimental|Laughter yoga session parts-4|Laughter exercises (15 minutes) This section includes a variety of laughter exercises such as greetings, strawberry milk, conductor, bonus, hot soup, lion, aloha, bird, appreciation, laughter lotion, elevator, cream cake, and bursting balloon laughter.
88817766|NCT01757561||Propofol-Abnormal|patients with preoperative SjvO2<55%,using the TIVA technology with propofol,
88817767|NCT01757561||Propofol-Normal|patients with preoperative SjvO2≥55%,using the TIVA technology with propofol,
88817768|NCT01757561||Sevoflurane-Abnormal|patients with preoperative SjvO2<55%,using the VIMA technology with sevoflurane,
88817769|NCT01757561||Sevoflurane-Normal|patients with preoperative SjvO2≥55%,using the VIMA technology with sevoflurane,
88817770|NCT01757717|Experimental|Ir-192 high dose rate (HDR)|This pilot study is an investigation into the use of Ir-192 high dose rate (HDR) afterloader-based brachytherapy with catheter placement using image-guided surgical navigation techniques for patients with painful/symptomatic metastatic or recurrent lesions in the spine and/or pelvis that have been maximally treated with external beam radiation therapy.
88817771|NCT02618187|Experimental|Weekly SER-287, after Placebo Pre-Treat.|Placebo pre-treatment, followed by once weekly dosing of SER-287 for 8 weeks
88817772|NCT02618187|Placebo Comparator|Daily placebo, after Placebo Pre-Treat.|Placebo pre-treatment, followed by once daily placebo for 8 weeks
88817773|NCT02618187|Experimental|Daily SER-287, after Vanco. Pre-Treat.|Vancomycin pre-treatment, followed by once daily dosing of SER-287 for 8 weeks
88817774|NCT02618187|Experimental|Weekly SER-287, after Vanco. Pre-Treat.|Vancomycin pre-treatment, followed by once weekly dosing of SER-287 for 8 weeks
88817775|NCT05316857|Other|Orelabrutinib + Rifampin|"Orelabrutinib is a white, round, uncoated table,Subjects take high dose orelabrutinib in the first day and the tenth day.~Rifampin is a capsule,Subjects take 600mg QD rifampin in the third day to the eleventh."
88817776|NCT05316857|Other|Orelabrutinib + Itraconazole|"Orelabrutinib is a white, round, uncoated table,Subjects take low dose orelabrutinib in the first day and the eighth day.~Itraconazole is a capsule,Subjects take 600mg QD rifampin in the third day to the tenth."
88817777|NCT01759277|Active Comparator|Control|Femoral perineural local anesthetic infusion
88817778|NCT01759277|Experimental|Experimental|Adductor canal perineural local anesthetic infusion
88817779|NCT02618343|Experimental|ISOPROPYL ALCOHOL AROMATHERAPY|Prehospital patients complaining of nausea randomized into the IPA Arm.
88817780|NCT02618343|Active Comparator|Ondansetron|Prehospital patients complaining of nausea randomized into the ondansetron arm.
88817781|NCT05346939|Experimental|Senior high school athletes in Taiwan|"In the first year, the investigators would verify the relation between wearable device and motion analysis and its validity and reliability at stage I (n=15). And the investigators are going to observe the effect of dynamic taping in lower limb biomechanics of high-school soccer or basketball athletes (n=50) at stage II.~In the second year, the investigators would recruit high school soccer and basketball athletes to examine the effect of dynamic taping in lower limb biomechanics under fatigue (n=50)."
88817782|NCT02991053|Active Comparator|block and ketamine|Transversus Abdominis Plane block after ketamine atropine induction and continued with ketamine only in anesthesia
88817783|NCT02991053|Active Comparator|block; ketamine with laryngeal mask; inhalation anesthesia|After ketamine atropine induction, a laryngeal mask was inserted and anesthesia administration was continued with 2 sevoflurane minimum alveolar concentration and oxygen / air mixture and applied Transversus Abdominis Plane block.
88817784|NCT02991053|Active Comparator|block and ketamine ıh/ıl|Ilioinguinal / iliohypogastric block after ketamine atropine induction and continued with ketamine only in anesthesia
88817785|NCT02991053|Active Comparator|ıh/ıl block; ketamine; inhalation anesthesia|After ketamine atropine induction, a laryngeal mask was inserted and anesthesia administration was continued with 2 sevoflurane minimum alveolar concentration and oxygen / air mixture and applied Ilioinguinal / iliohypogastric block.
88817786|NCT02991053|Active Comparator|control group|After ketamine atropine induction, a laryngeal mask was inserted and anesthesia administration was continued with 2 sevoflurane minimum alveolar concentration and oxygen / air mixture and Non-block, postoperative analgesia with paracetamol IV
88817787|NCT04040907|Active Comparator|XNW3009|
88817788|NCT04040907|Placebo Comparator|XNW3009 placebo|
88817789|NCT04116749||Non-obese women|body mass index lower than 30 (kg/m^2) at term
88817790|NCT04116749||Obese women|body mass index equal or greater than 30 (kg/m^2) at term
89380960|NCT05003544|Active Comparator|Quadratus lumborum block ( Group C)|The patient will be in the lateral position. A low-frequency convex probe will be vertically attached above the iliac crest and a needle will be inserted in-plane from the posterior edge of the convex probe through the quadratus lumborum in an anteromedial direction. The needle tip will be placed between the psoas major muscle and the quadratus lumborum muscle. After negative aspiration, 30 mL of 0.5 % of bupivacaine will be injected into the fascial plane incrementally, aspirating every 5 ml.
89380961|NCT04234945|Experimental|study|Group A will be the study group and will be given oral Doxycycline capsule 100mg bd for 3/7.
89380962|NCT04234945|Placebo Comparator|control|Group B will be the study group and will be given oral Multivitamin capsule i bd for 3/7
89380963|NCT03627156|Experimental|Intervention|Intervention Arm is an arm to which community-based guided counseling using Health Belief Model and Theory of Planned Behavior will be given.
89380964|NCT03627156|No Intervention|Control|Control Arm is an arm to which the intervention will not be implemented.
89380965|NCT02104921||Neuromuscular Disease Patients|Amyotrophic lateral sclerosis patients, myopathy patients, muscular dystrophy patients, myasthenia gravis patients, radiculopathy patients, mononeuropathy patients
89380966|NCT02104921||Healthy volunteers|
89380967|NCT03802110|Experimental|Single Arm|Defibrillation threshold (DFT) testing Arm
89380968|NCT03316807|Experimental|60 µg dose hepatitis B vaccine|60 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6
89380969|NCT03316807|Experimental|20 µg dose hepatitis B vaccine|20 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6
89380970|NCT03379259|Experimental|Phase 1A: BGB-A333 monotherapy dose escalation|
88853882|NCT01798056|Placebo Comparator|Placebo Group|Subjects received the first dose of placebo at least 10 days (up to 1 month) before start of chemotherapy cycle or at the first day (allowing a window of +/- 1 day) of the first (or second) chemotherapy cycle. The second dose of placebo was administered between 1 and 2 months after the first vaccination and at the first day (allowing a window of +/- 1 day) of a subsequent cycle of chemotherapy. The study products were administered intramuscularly into a deltoid muscle. The choice of and use of chemotherapy, or any other medication related to the patients' current conditions, were based on the local standard of care for the patients.
88853883|NCT01824342|Experimental|Denosumab|Participants received denosumab 120 mg subcutaneously every 4 weeks for up to 3 years in this open-label extension study.
88853884|NCT01841970|Other|HET Arm|Active arm. A single procedure with HET was used to treat Grade I and Grade II hemorrhoids
89380971|NCT03379259|Experimental|Phase 2A: BGB-A333 monotherapy dose expansion|
89380972|NCT03379259|Experimental|Phase 1B: BGB-A333 and BGB-A317 dose confirmation|
89380973|NCT03379259|Experimental|Phase 2B: BGB-A333 and BGB-A317 dose expansion|
89380974|NCT05586048||Exposed group|patients who received YQFM
89380975|NCT05586048||Non-exposed group|patients who didn't receive YQFM
89380976|NCT05405556|Experimental|Patients and providers only aware of study eGFR values more than 25% below baseline|Any study-related eGFR value more than 25% below the baseline measurement will be reported to the patient and treating physician.
89380977|NCT05405556|Other|Patients and providers aware of all study eGFR values|All study-related eGFR measurements will be reported to the treating physician and patient.
89380978|NCT04924998||AL-CM|
89380979|NCT03328897|Experimental|Omalizumab 300mg|patients received a dose of omalizumab 300 mg which consisted of two injections of omalizumab 150 mg vials every 4 weeks (Day 1, Week 4 and Week 8)
89380980|NCT03328897|Experimental|Omalizumab 150mg|patients received a dose of omalizumab 150 mg which consisted of one injection of omalizumab 150 mg vial and one injection of placebo 150 mg vial every 4 weeks (Day 1, Week 4 and Week 8)
89380981|NCT03328897|Placebo Comparator|Placebo|patients received placebo which consisted of two injections of placebo 150 mg vials every 4 weeks (Day 1, Week 4 and Week 8)
89380982|NCT04918758|Experimental|Purastat Arm|Purastat 5ml once monthly for 3 months
89380983|NCT04918758|Other|Standard Care Arm|Sucralfate enemas 2g twice daily for 8 weeks
89380984|NCT03266107|Experimental|Treatment|BVN Ablation
89380985|NCT03378635|Experimental|Dasiglucagon|Single fixed dose (s.c.injection) of dasiglucagon
89380986|NCT03378635|Placebo Comparator|Placebo|Single fixed dose (s.c.injection) of placebo
89380987|NCT03378635|Active Comparator|GlucaGen®|Single fixed dose (s.c.injection) of GlucaGen®
88853885|NCT01823328|Active Comparator|Ketamine|Subjects in the ketamine arm will receive ketamine for sedation prior to rapid sequence intubation (RSI).
88853886|NCT01823328|Active Comparator|Etomidate|Subjects in the etomidate arm will receive etomidate for sedation prior to rapid sequence intubation (RSI).
88853887|NCT01840410|Experimental|Ranibizumab|A 0.5 mg ranibizumab intravitreal injection was given to the study eye at baseline, and then as needed based on evidence of disease activity.
88853888|NCT01840410|Sham Comparator|Sham control|Sham injection was given to the study eye at baseline, and then treatment was given based on evidence of disease activity. At Month 1, if treatment was needed, sham was administered. At Month 2, participants could switch to open-label ranibizumab on an as needed basis.
88853889|NCT01797432|Experimental|Combined IL Kenalog and Restylane|Injection of Intralesional Triamcinolone Acetonide 10 mg/mL (Kenalog-10) on whole scalp and Restylane on half of scalp
89380988|NCT03326869|Experimental|Delayed|"Intervention: Raindrop Near Vision Inlay~In the delayed approach, the corneal pocket is created and dissected but the corneal inlay is not implanted. After one to three months, the corneal inlay is implanted on a second surgical day."
89380989|NCT03326869|Active Comparator|Non-Delayed|"Intervention: Raindrop Near Vision Inlay~In the non-delayed approach, the corneal pocket is created and inlay implanted on the same surgical day."
88853890|NCT01797120|Active Comparator|Fulvestrant & Everolimus|Fulvestrant Day 1 & 15 of Cycle 1, then Day 1 of all subsequent cycles (every 28 days for 12 cycles) plus everolimus daily x 12 cycles.
88853891|NCT01797120|Placebo Comparator|Fulvestrant & Placebo|Fulvestrant Day 1 & 15 of Cycle 1, then Day 1 of all subsequent cycles (every 28 days for 12 cycles) plus placebo daily x 12 cycles.
88853892|NCT01796964|Experimental|ESBA1008|ESBA1008 solution, 7 intravitreal (IVT) injections, as specified in protocol
88853893|NCT01796964|Active Comparator|EYLEA|Aflibercept, 8 intravitreal (IVT) injections, as specified in protocol
88853894|NCT01838694|Placebo Comparator|Placebo|Multiple doses of matched vehicle (no active ingredients) administered intravenously over 60 minutes.
88853895|NCT01838694|Experimental|Ala-Cpn10|Recombinant minimally modified Chaperonin10 (Cpn10) Multiple doses in the range 10mg twice weekly to 100mg twice weekly administered intravenously by infusion over 60 minutes.
88853896|NCT01795638|Active Comparator|Sodium chloride|Sodium chloride 1 meq/kg (0.4 ml/kg of 2.5meq/ml formulation for injection)q6hrs on days of life 7-35. Intervention was given enterally if feedings were at least 100 ml/kg/day; otherwise medication was diluted in equal amounts of dextrose 5% water and administered intravenously.
88853897|NCT01795638|Placebo Comparator|sterile water|Sterile water, 0.4 ml/kg q6hrs on days of life 7-35. Placebo is given enterally when infant is tolerating at least 100 ml/kg/day; otherwise the product is diluted in equal amounts of dextrose 5% water and administered intravenously.
88853898|NCT01794780|Experimental|Indacaterol|LABA: Indacaterol, once a day, 150μg each time
88853899|NCT01794780|Experimental|Tiotropium Bromide|LAMA: Tiotropium Bromide, once a day, 18 μg
89380990|NCT05692284|Other|routine care group|Routine clinic nursing care in hospital, no follow-up after discharge.
89380991|NCT05692284|Experimental|Care in accordance with Orem's theory group|care in accordance with Orem's theory in the hospital process and follow-up with a mobile application designed according to Orem's theory after discharge
89380992|NCT03710837|Experimental|Pain neuroscience education|Intervention: Pain neuroscience education group. One-off, 70 minute duration session delivered by Dr Cormac Ryan.
89380993|NCT03710837|Experimental|Red flag education|Intervention: Red flags education group. One-off 70 minute duration session delivered by Dr Cormac Ryan.
88853900|NCT01794780|Experimental|Salmeterol/Fluticasone|LABA/ICS: Salmeterol/Fluticasone, twice a day, 50/250 μg, 50/500 μg
88853901|NCT01794780|Experimental|Budesonide/ formoterol|Budesonide/formoterol, twice daily, two suction each time, 160/4.5 μg
88853902|NCT01794780|Experimental|Indacaterol +Tiotropium|Indacaterol, once a day, 150μg each time +Tiotropium Bromide, once a day, 18 μg
88853903|NCT01794780|Experimental|LABA/ICS (Or budesonide/ formoterol)+ Tiotropium|Salmeterol / fluticasone Or budesonide / formoterol
88853904|NCT01794780|Experimental|Oral theophylline|
88853905|NCT01794780|Experimental|Other treatment|"non-long-acting bronchodilators for COPD treatment, such treatments were classified as other treatments"
89380994|NCT01182727|Experimental|salsalate|Salsalate will be administered in two divided doses of 2grams in the morning and 2 grams in the evening. Salsalate will be administered for 6 weeks. If a participant is not able to tolerate the target dose of 4 grams per day then 500 mg reductions will be made in a stepwise fashion until a tolerated dose or a minimum dose of 2 grams per day is reached.
88853906|NCT04587726|Experimental|Intervention Group|
88853907|NCT04587726|Active Comparator|Control Group|
88853908|NCT01838616|Experimental|Tapentadol Prolonged Release (PR)|
88853909|NCT01838616|Active Comparator|Oxycodone/Naloxone Prolonged Release|
88853910|NCT01611792|Experimental|Stabilization|
88853911|NCT01611792|Active Comparator|Strengthening and Conditioning|
88853912|NCT01820364|Experimental|LGX818 single agent|Patients had to have written documentation of a BRAFV600 mutation, which was to have been obtained locally on a fresh tumor biopsy (preferred) or on the most recent archival tumor sample available.
88853913|NCT01819506|Experimental|Targeted Task Practice|"Targeted task practice is defined as a therapy program aimed at patient-specific upper extremity motor impairment levels and systematically progressed to assure an ongoing just right match between task-difficulty and patient-ability. Participants attended occupational therapy 3 times per week for 4 weeks. Each therapy session was 2 hours in length."
88853914|NCT01819506|Active Comparator|Non-Targeted Task Practice|Non-targeted task practice is a standard of care treatment consisting of task practice with no guidance from the measurement framework to systematically address specific upper extremity motor impairment levels or progress rehabilitation therapy. Participants attended occupational therapy 3 times per week for 4 weeks. Each therapy session was 2 hours in length.
88853915|NCT01794000|Experimental|Prasugrel|Participants will be titrated from initial daily dose of 0.08 milligram per kilogram (mg/kg) of orally administered prasugrel monotherapy at randomization to a dose that will achieve a P2Y12 reaction units (PRU) level of 231 to 136, as measured by VerifyNow instrument. This corresponds to a range of platelet inhibition of approximately 30% to 60%. The maximum possible dose allowed is 0.12 mg/kg daily, not to exceed 10 mg daily.
88853916|NCT01794000|Placebo Comparator|Placebo|Participants in this treatment group will receive daily orally administered placebo and will follow visit schedule identical to that in the active treatment group.
88853917|NCT01609296|Experimental|IN.PACT Admiral DEB|"The subjects in this trial will be treated with the IN.PACT Admiral™ percutaneous transluminal angioplasty (PTA) paclitaxel drug eluting balloon (hereinafter referred as IN.PACT Admiral™ DEB)manufactured by Medtronic. The IN.PACT Admiral™ is a CE (Conformité Europeénne, European Confirmity) marked medical device utilized within its intended use in the IN.PACT Global trial."
88853918|NCT01609218|Experimental|80 mg LY2140023|Single oral dose of 80 milligrams (mg) LY2140023 administered alone
88853919|NCT01609218|Experimental|80 mg LY2140023 + 75 g aqueous activated charcoal|Single oral dose of 80 mg LY2140023 followed 1 hour later by single oral dose of 75 grams (g) aqueous activated charcoal.
88853920|NCT01609062|Experimental|BMN 110 Weekly at 2.0 mg/kg/week|
88853921|NCT01609062|Experimental|BMN 110 Weekly at 4.0 mg/kg/week|
89380995|NCT00624715|Active Comparator|THC|"High dose: 0.036 mg/kg (2.5 mg in a 70 kg individual) IV (in the vein) dissolved in ethanol.Equivalent to smoking a full joint~Low dose: 0.018 mg/kg (1.25 mg in a 70kg individual)IV (in the vein) dissolved in ethanol.Equivalent to smoking ½ of a joint~Very low dose: 0.0036 mg/kg (0.25 mg in a 70 kg individual)IV (in the vein) dissolved in ethanol.Equivalent to smoking 1/10 of a joint"
89380996|NCT00624715|Placebo Comparator|Placebo|Placebo: Small amount of ethanol IV (in the vein), (quarter teaspoon).
89380997|NCT03334409|Experimental|Arm A (pazopanib hydrochloride, ascorbic acid)|Patients receive pazopanib hydrochloride PO QD on days 1-28 and ascorbic acid IV three times per week. Treatment repeats every 28 days for up to 10 cycles in the absence of disease progression or unacceptable toxicity.
89380998|NCT03334409|Active Comparator|Arm B (pazopanib hydrochloride)|Patients receive pazopanib hydrochloride PO QD on days 1-28. Treatment repeats every 28 days for up to 10 cycles in the absence of disease progression or unacceptable toxicity.
89380999|NCT04821726|Experimental|Drug eluting balloon (Vmoky)|A paclitaxel eluting balloon produced by Yinyi (Liaoning) Biotech Co., Ltd. Balloon length: 8-40 mm, diameter：1.25-5.00 mm.
89381000|NCT02891915|Active Comparator|Short|200 subjects will receive a short course of the initially prescribed antibiotic for 5 days plus 5 days of matching placebo
89381001|NCT02891915|Active Comparator|Standard|200 subjects will receive a standard course of the initially prescribed antibiotic( Amoxicillin, Amoxicillin-Clavulanate, Cefdinir) for 10 days
89381002|NCT02891681|Experimental|NIR/US (Neoadjuvant Chemotherapy Cohort)|"Patients will have the NIR/US baseline scan performed before their first treatment. The desirable schedule will be >= 7 days after initial biopsy to avoid confounding effects from the biopsy related acute inflammatory response.~In addition, patients will also have NIR/US performed at end of cycle 1, end of cycle 2, end of cycle 3, end of cycle 5 (only if treatment regimen changed), and prior to surgery.~The number of NIR/US study visits may vary (5-6) depending on the patient's treatment regimen"
89381003|NCT02891681|Experimental|NIR/US (Neoadjuvant Endocrine Cohort)|"Patients will have the NIR/US baseline scan performed before their first treatment. The desirable schedule will be >= 7 days after initial biopsy to avoid confounding effects from the biopsy related acute inflammatory response.~In addition, patients will also have NIR/US performed at end of cycle 1, end of cycle 2, end of cycle 3, at time of treatment regimen change (only intended for those who have had a change in their regimen), and prior to surgery.~The number of NIR/US study visits may vary (5-6) depending on the patient's treatment regimen"
89381004|NCT03707483|Experimental|Intervention|250 μM of vitamin C will be used with the platelet rich fibrin
89381005|NCT03707483|Active Comparator|Comparator|using platelet rich fibrin alone
89381006|NCT03626766|Active Comparator|Photo in Verification Alert|Patient photo displayed in a patient ID verification alert when placing electronic orders in the electronic health record.
89381007|NCT03626766|Active Comparator|Photo in Banner|Patient photo displayed in the banner (at the top of the screen).
89381008|NCT03626766|Active Comparator|Photo in Banner and Verification Alert|Patient photograph displayed in the banner (at the top of the screen) AND patient photo displayed in a verification alert when placing electronic orders.
89381009|NCT03626766|No Intervention|No Photo|No patient photographs displayed in the electronic health record.
89381010|NCT05683145|Experimental|Computerized Cognitive Behavioral Therapy for Insomnia|Self-guided computerized CBT-I program with assistance from a licensed mental health professional.
89381011|NCT05683145|No Intervention|Enhanced Treatment as Usual|ETU is defined as treatment per usual which is enhanced by participating in data collection related to study participation.
89381012|NCT04671342|Experimental|Validation Arm|Participants will wear the DreamKit device (test device) while instrumented with polysomnography sensors (gold standard).
88853922|NCT04580472|Placebo Comparator|Placebo - leg|If randomized to placebo group, 4 placebo capsules will be administered PO 30 minutes prior to incision in the leg group.
88853923|NCT04580472|Experimental|Antibiotic- leg|The administration time of the oral antibiotics will be 30 minutes prior to incision in the leg group. 4-500 mg capsules of cephalexin will be administered to the patient. If there is concern for previous allergy to cephalexin, 4-150 mg capsules of clindamycin hydrochloride will be administered
88853924|NCT04580472|Placebo Comparator|Placebo- nose|If randomized to placebo group, 4 placebo capsules will be administered PO 5-15 minutes prior to surgery on the nose.
88853925|NCT04580472|Experimental|Antibiotic- nose|The administration time of the oral antibiotics will be 5-15 minutes prior to surgery on the nose. 4-500 mg capsules of cephalexin will be administered to the patient. If there is concern for previous allergy to cephalexin, 4-150 mg capsules of clindamycin hydrochloride will be administered PO.
88853926|NCT04580472|Placebo Comparator|Placebo- ear|If randomized to placebo group, 4 placebo capsules will be administered PO 5-15 minutes prior to surgery on the ear.
88853927|NCT04580472|Experimental|Antibiotic- ear|The administration time of the oral antibiotics will be 5-15 minutes prior to surgery on the ear. 4-500 mg capsules of cephalexin will be administered to the patient. If there is concern for previous allergy to cephalexin, 4-150 mg capsules of clindamycin hydrochloride will be administered PO.
88853928|NCT01819272|Experimental|600 mg DR|600 mg delayed-release metformin once daily in the morning
88853929|NCT01819272|Experimental|800 mg DR|800 mg delayed-release metformin once daily in the morning
88853930|NCT01819272|Experimental|1000 mg DR|1000 mg delayed-release metformin once daily in the morning
88853931|NCT01819272|Active Comparator|1000 mg XR|1000 mg extended-release metformin once daily in the evening
88853932|NCT01819272|Active Comparator|2000 mg XR|2000 mg extended-release metformin once daily in the evening
88853933|NCT01819272|Placebo Comparator|Placebo|Placebo once daily in the morning
88853934|NCT01819194|Experimental|senofilcon A|Acuvvue Oasys with Hydaclear Plus with 38% water.
88853935|NCT01611558|Experimental|Arm: Ipilimumab, 10 mg/kg|Participants received 10 mg/kg of ipilimumab administered intravenously once every 3 weeks for 4 doses (Induction Phase). Then, once every 12 weeks (Maintenance Phase), until disease progression or unacceptable toxicity occurs.
88853936|NCT04579926|Experimental|Pinpoint App|Tablet and smartphone application.
88853937|NCT04579068|Experimental|Screening and Brief Intervention of Problematic Alcohol Use|We plan to test the feasibility and effectiveness of the delivery of the peer-based SBIRT using the RAPS4-QF screening tool with CDU students. Furthermore, we will compare delivery by AAPLs' race/ethnicity, drinking status (abstainer vs. non-abstainer), and adverse life experiences. Following the screening by AAPLs, we expect a 30% detection of problematic alcohol use (i.e. high episodic drinking [HED] or AUD) and at-risk alcohol use. Participants that screen positive will receive brief motivational interviewing and referral to treatment and will be contacted 6 months following the SBIRT to assess their drinking behaviors. We expect that participants will decrease their alcohol consumption or drinking risk at the 6-month follow up.
88853938|NCT01818726|Experimental|Serum ferritin level ≥ 1,000 μg/l|Transfusion-dependent adult patients with AA and serum ferritin ≥ 1000 mg/L on programmed immune suppressive treatment with cyclosporine A who were receiving chelation with Exjade (deferasirox) during the study
88853939|NCT01818726|Experimental|Serum ferritin level < 1,000 μg/l|Transfusion-dependent adult patients with AA and serum ferritin < 1,000 mg/L on programmed immune suppressive treatment with cyclosporine A who were not receiving the investigational product
88853940|NCT01818336|Experimental|all subjects|"Intervention: Penicillin skin test kit~Subjects with negative intradermal tests will be given single oral amoxicillin challenge dose and followed for 72 hours for IgE dependent reactions."
88853941|NCT04592640|Experimental|Uremic Calciphylaxis Patients|Human amniotic mesenchymal stem cells (hAMSCs)
88853942|NCT01818258|Active Comparator|Severe Malnutrition|ZDV+3TC+LPV/r Zidovudine (ZDV, Retrovir®) 10 mg/ml oral syrup administered twice daily at WHO weight band dose for 48 weeks; Lamivudine (Epivir®, 3TC) 10 mg/ml for oral solution administered twice daily at WHO weight band dose for 48 weeks; Lopinavir/ritonavir (Kaletra®, LPV/r) 80/20 mg/ml oral solution administered twice daily at the WHO weight band dose for 48 weeks
88853943|NCT01818258|Active Comparator|Normal Nutrition/Mild Malnutrition|ZDV+3TC+LPV/r Zidovudine (ZDV, Retrovir®) 10 mg/ml oral syrup administered twice daily at WHO weight band dose for 48 weeks; Lamivudine (Epivir®, 3TC) 10 mg/ml for oral solution administered twice daily at WHO weight band dose for 48 weeks; Lopinavir/ritonavir (Kaletra®, LPV/r) 80/20 mg/ml oral solution administered twice daily at the WHO weight band dose for 48 weeks
88853944|NCT01817790|Experimental|Fluticasone propionate nasal spray|Fluticasone propionate nasal spray with strength per dose of 50 mcg/spray. Two sprays of study treatment per nostril to be administered in morning.
88853945|NCT01817790|Placebo Comparator|Placebo nasal spray|Two sprays of placebo per nostril to be administered in morning.
88853946|NCT01793688||Sulbactam Sodium/Ampicillin Sodium|Patients with the following disease who received high doses of UNASYN (exceeding 6 g per day) by intravenous injection or intravenous drip infusion from the first dosing date or the second dosing date: Pneumonia, Lung Abscess, Peritonitis.
88853947|NCT01793142||Viviant treatment group|Viviant treatment group
88853948|NCT01792830|No Intervention|Control HbA1c < 7%|Subjects not requiring coronary artery bypass graft surgery (CABG), with no history of diabetes with HbA1c <7% not requiring subcutaneous insulin in the hospital will be discharged on no antidiabetic therapy.
88853949|NCT01792830|Active Comparator|Diabetic/ Metformin and 50-Glargine HbA1c 7%- 9%|Subjects requiring coronary artery bypass graft surgery (CABG) with a history of diabetes with HbA1c between 7% and 9% requiring subcutaneous insulin therapy in the hospital will be discharged on oral metformin and a single dose of basal (glargine) insulin at 50% of total daily hospital dose.
88853950|NCT01792830|Active Comparator|Diabetic/ Metformin and 80-Glargine HbA1c 7%-9%%|Subjects requiring coronary artery bypass graft surgery (CABG) with a history of diabetes with HbA1c 7%- 9% will be discharged on oral metformin and a single dose of basal (glargine) insulin at 80% of total daily hospital dose or with basal bolus regimen at same inpatient total daily insulin dose.
88853951|NCT01792830|Active Comparator|No diabetes/ Metformin only|Subjects requiring coronary artery bypass graft surgery (CABG) with no history of diabetes with HbA1c <7% and persistent hyperglycemia requiring subcutaneous (SC) insulin therapy in the hospital will be discharged on oral metformin.
88853952|NCT01792830|Active Comparator|Diabetic/antidiabetic regimen|Subjects requiring coronary artery bypass graft surgery (CABG) with a history of diabetes with HbA1c <7% will be discharged on their same outpatient antidiabetic regimen. Subjects will receive one of the three treatment options based on their blood glucose levels: Metformin alone, both metformin and glargine insulin or glargine alone.
88853953|NCT01792830|Active Comparator|No diabetes/ Insulin only|Subjects requiring coronary artery bypass graft surgery (CABG) with no history of diabetes with HbA1c <7% and persistent hyperglycemia will be given subcutaneous (SC) insulin therapy in the hospital.
88853954|NCT01792830|Active Comparator|Diabetes/Insulin only|Subjects requiring coronary artery bypass graft surgery (CABG) with an admission HbA1c >9% and persistent hyperglycemia will be given basal insulin (glargine) once daily, at the same time of the day and rapid-acting insulin (glulisine) before meals.
88853955|NCT01792518|Experimental|linagliptin 5mg|linagliptin 5 mg once daily
88853956|NCT01792518|Placebo Comparator|placebo|matching placebo for linagliptin dose once daily
88875366|NCT05371704|Experimental|Supplementation|In this arm of the study, participants will take 1 multivitamin pill each day for 10 days. If this is the participant's first trial, they will also record their diet in a 10-day estimated food diary. If this is the participant's second trial, they will replicate their diet recorded from their first trial.
89381013|NCT04764929|Experimental|Helmet CPAP|Patients in the Pediatric Intensive Care Unit (PICU) already receiving CPAP through a facemask or nasal prongs or mask for at least four hours but no more than 48 hours will be transitioned to the Vyatil nonpowered oxygen tent system (Rochester, NY) by trained respiratory therapists per the manufacture's instructions: patient's neck circumference will be measured with a soft tape measure to ensure appropriate sizing. The helmet will be connected to at least 30 liters per minute of high flow medical air with an oxygen blender. The expiratory limb will be attached to the positive end expiratory pressure (PEEP) valve (initially set at 5 centimeters of water pressure) connected to a high-efficiency particulate air (HEPA) filter to prevent any viral particles from being released into the environment. A disposable manometer will be used to measure the pressure within the helmet. Once the flow to the helmet interface is on, the helmet will be sealed and secured with the system's arm straps.
89381014|NCT03627078|Experimental|Motor Interference Therapy|Initial interview applying the Spanish version of the PTSD Symptom Severity Scale-Revised (EGS-R), the visual analogue scale (EQ-VAS) from EuroQol 5D (EQ-5D), and a simple visual-analogue scale (VAS). After that, patients will listen to an audio track twice and follow the instructions. The first four minutes of the audio track instruct the subjects to tap their fingers in response to specific sounds. During the remaining ten minutes, the patients will be asked to recall a traumatic memory while simultaneously are tapping their fingers. Patients must complete at least 80% of the motor task in order to be included. We will reassess a week, a month and six months after the intervention, using all three scales.
89381015|NCT03627078|Sham Comparator|Relaxation Exercise|Initial interview applying the Spanish version of the PTSD Symptom Severity Scale-Revised (EGS-R), the visual analogue scale (EQ-VAS) from EuroQol 5D (EQ-5D), and a simple visual-analogue scale (VAS). After that, patients will listen to an audio track twice and follow the instructions. The first four minutes of the audio track instruct the subjects in how to do the exercises. During the remaining 10 minutes will hear commands for performing progressive muscle tension-relaxation exercises while the patient evoked the traumatic memory. Patients must complete at least 80% of the motor task in order to be included. We will reassess a week, a month and six months after the intervention, using all three scales.
89381016|NCT05560854|Experimental|Internet delivered prolonged exposure|Internet delivered prolonged exposure for ten weeks with therapist support.
89381017|NCT03051217|Placebo Comparator|Placebo|Placebo subcutaneous (sc) injection every two weeks (Q2W)
89381018|NCT03051217|Experimental|CZP 200 mg|Certolizumab Pegol subcutaneous (sc) injection 400 mg at Weeks 0, 2, 4, followed by Certolizumab Pegol subcutaneous (sc) injection 200 mg every two weeks (Q2W) with PBO administered to maintain the blind, starting at Week 6
89381019|NCT03051217|Experimental|CZP 400 mg|Certolizumab Pegol subcutaneous (sc) injection 400 mg every two weeks (Q2W).
89381020|NCT05114785||HFpEF group|Suspected HFpEF group: 80 patients will be recruited with history of dyspnoea, LV ejection fraction ≥ 50%, raised NTproBNP
89381021|NCT05114785||Control group|20 patients with suspected CAD but with no dyspnoea and normal echocardiogram.
89381022|NCT05080621|Experimental|Escalation|"Escalation Phase: Increasing doses of ripretinib in combination with increase doses of binimetinib in patients with advanced GIST who have progressed on at least imatinib or are intolerant to imatinib and are ripretinib naïve in repeated 28-day cycles.~Participants may remain on treatment until disease progression, unacceptable toxicity, or withdrawal of consent"
89381023|NCT05080621|Experimental|Expansion|"Ripretinib in combination with binimetinib at the recommended Phase 2 dose (RP2D) in patients with advanced GIST who have progressed on imatinib or are intolerant to imatinib and are naïve.~Participants may remain on treatment until disease progression, unacceptable toxicity, or withdrawal of consent"
89381024|NCT05035303|Active Comparator|Nor-Epinephrine (NE)-Group|The PCNL tract is infiltrated by Nor-Epinephrine before its dilatation.
89381025|NCT05035303|Placebo Comparator|S-Group|The PCNL tract is infiltrated by Normal Saline before its dilatation.
89381026|NCT02958319||Anti P Carb negative RA patients|RA patients negative for antibodies against the carbamylated proteins
89381027|NCT02958319||Anti P Carb positive RA patients|RA patients positive for antibodies against the carbamylated proteins
89381028|NCT03046056|Experimental|Filgotinib 200 mg|Filgotinib 200 mg tablet + placebo to match (PTM) filgotinib 100 mg tablet for up to 27 weeks.
89002671|NCT06263413||Patients with pigmented lesions and suspected malignancy|Patients treated at IDEI hospitals and with pigments skin lesions, which are suspected malignancy. The practitioners will take a photo of the lesion and upload into the tool so as to confirm both the diagnosis and suspicion of malignancy
89002672|NCT06263413||Patients diagnosed with acne|Patients treated at IDEI hospitals and diagnosed with acne. Practitioners will take a photo of patients' face and upload it into the tool so as to check the severity of acne and compare it with the gold standard
89002673|NCT06263413||Patients diagnosed with femenine androgenetic alopecia|Patients treated at IDEI hospitals and diagnosed with femenine androgenetic alopecia. Practitioners will take a photo of the top of the head and upload it into the tool so as to check the severity of alopecia and compare it with the gold standard
89381029|NCT03046056|Experimental|Filgotinib 100 mg|Filgotinib 100 mg tablet + PTM filgotinib 200 mg tablet for up to 26.3 weeks.
89381030|NCT03046056|Placebo Comparator|Placebo|PTM filgotinib 200 mg tablet + PTM filgotinib 100 mg tablet for up to 28.7 weeks.
89381031|NCT02849587|Placebo Comparator|Placebo Cannabis|Subjects will smoke cannabis with placebo THC (.02%) ad libitum
89381032|NCT02849587|Experimental|Cannabis with 5.9% THC|Subjects will smoke cannabis cigarettes with 5.9% THC ad libitum
89381033|NCT02849587|Experimental|Cannabis with 13.4% THC|Subjects will smoke cannabis cigarettes with 13.4% THC ad libitum
89381034|NCT03347279|Experimental|Tezepelumab|Tezepelumab: Tezepelumab subcutaneous injection
89381035|NCT03347279|Placebo Comparator|Placebo|Placebo: Placebo subcutaneous injection
89381036|NCT04625556||Prostate cancer|Patients diagnosed as prostate cancer and have undergone prostatectomy
89381037|NCT04625556||Renal cell cancer|Patients diagnosed as renal cell cancer and have undergone partial or radical nephrectomy
89381038|NCT04625556||Bladder cancer|Patients diagnosed as bladder cancer and have undergone radical or partial cystectomy
89381039|NCT04625556||Ureter cancer|Patients diagnosed as ureter cancer and have undergone nephroureterectomy or ureterectomy
89002674|NCT06262633|Experimental|Targeted Microwave Ablation (TMA)|Targeted Microwave Ablation (TMA) for localized prostate cancer using organ based tracking (OBT) navigation
89002675|NCT06260566|Experimental|Infants with Biliary Atresia|"Administering applesauce alone~Administering applesauce plus NAC (for infants who tolerate applesauce alone)"
89002676|NCT06258993|Experimental|Affect-based Exercise Prescription (Affect-Rx)|
89381040|NCT03998683|Experimental|Guselkumab Group|Participants will receive guselkumab 100 mg SC injections at Weeks 0, 4, 12 and placebo subcutaneous (SC) injection at Week 16 in double-blind phase followed by guselkumab 100 mg SC injections at Weeks 20, 28, 36, and 44 in open-label phase.
89381041|NCT03998683|Placebo Comparator|Placebo Group|Participants will receive placebo SC injection at Weeks 0, 4, 12 and guselkumab 100 mg SC injection at Week 16 in double-blind phase followed by guselkumab 100 mg SC injection at Week 20, 28, 36, and 44 in open-label phase.
89381042|NCT03637465|Experimental|Hydrate Philly Intervention|Intervention group that receives hydration station intervention
89183049|NCT05723926|Experimental|Vine Filter and oral anticoagulant|Participants randomized to the intervention will undergo implantation of bilateral carotid filters and OAC therapy. In addition, participants will receive additional single antiplatelet therapy with OAC for 6 months.
89183050|NCT05723926|No Intervention|Usual Care (oral anticoagulant only)|Participants randomized to control will not receive carotid filter implants but will receive usual care including OAC, throughout the course of the study.
89183051|NCT05720104|Experimental|Study group|Use of Lumoral Treatment device. Standard oral hygiene instructions.
89183052|NCT05720104|Other|Control group|Standard oral hygiene instructions.
89183053|NCT05718258|Experimental|Participants with mild hepatic impairment|Venglustat single dose on Day 1
89002677|NCT06258993|Active Comparator|Effort-based Exercise Prescription (RPE-Rx)|
89002678|NCT06256055|Experimental|UCMYM802 Injection|Active ingredient：Anti-MSLN CAR+ T cell
89183054|NCT05718258|Experimental|Participants with normal hepatic function|Venglustat single dose on Day 1
89183055|NCT05718258|Experimental|Participants with moderate hepatic impairment|Venglustat single dose on Day 1
89183056|NCT05718258|Experimental|Participants with severe hepatic impairment|Venglustat single dose on Day 1
89381043|NCT03637465|No Intervention|Control|Control group that receives no intervention, but observational data is collected; converted to wait-listed intervention status after enrollment and randomization was completed
89381044|NCT03262441|Experimental|Mycophenolate mofetil|Mycophenolate Mofetil 500mg Tablets once per day for one week as a lead in to limit drug-related side effects. Provided they are tolerating the drug at lower dose, they will then initiate Mycophenolate Mofetil 500mg Tablets twice daily orally for 22 months
89381045|NCT05201664||Surgical Extrusion|Patients who receive surgical extrusion treatment in maxillary premolars.
89381046|NCT04580394|Experimental|AD109|Oral capsule administered before sleep
89381047|NCT04580394|Active Comparator|Atomoxetine|Oral capsule administered before sleep
89381048|NCT04580394|Active Comparator|R-oxybutynin|Oral capsule administered before sleep
89381049|NCT04580394|Placebo Comparator|Placebo|Oral capsule administered before sleep
89381050|NCT02781727|Experimental|TransCon hGH|Once weekly subcutaneous injection of TransCon hGH
89002679|NCT06255340|Experimental|SRD Part: BI 3031185 dose group 1|Single rising dose (SRD)
89002680|NCT06255340|Experimental|SRD Part: BI 3031185 dose group 2|
89002681|NCT06255340|Experimental|SRD Part: BI 3031185 dose group 3|
89002682|NCT06255340|Experimental|SRD Part: BI 3031185 dose group 4|
89002683|NCT06255340|Experimental|SRD Part: BI 3031185 dose group 5|
89183057|NCT05712018|Experimental|0 ml/kg Hydroxyethyl starch coload group|No fluid coload was given. An initial infusion dose of prophylactic norepinephrine simultaneous with spinal anesthesia
89183058|NCT05712018|Experimental|5 ml/kg Hydroxyethyl starch coload group|5 ml/kg 6% Hydroxyethyl starch (130/0.4) coload combined with an initial infusion dose of prophylactic norepinephrine simultaneous with spinal anesthesia.
89183059|NCT05712018|Experimental|10 ml/kg Hydroxyethyl starch coload group|10 ml/kg 6% Hydroxyethyl starch (130/0.4) coload combined with an initial infusion dose of prophylactic norepinephrine simultaneous with spinal anesthesia.
89183060|NCT05710133|Other|alectinib-d6|Patients will receive one single dose of alectinib-d6 (100 µg) orally on day 1 and 9.
89183061|NCT05698732||Coronary Artery Disease (CAD) and high risk of bleeding|
89183062|NCT05698732||Coronary Artery Disease (CAD)|
89381051|NCT02781727|Active Comparator|human growth hormone (Genotropin)|Once daily subcutaneous injection of Genotropin
89381052|NCT03626610|Experimental|Interventional|Participants will be given a monitored exercise program during their treatment starting before chemotherapy
89381053|NCT03626610|No Intervention|Non-interventional|Patients will have standard care.
89381054|NCT03707327|Experimental|Game Ready group|the participants performed cryotherapy by compression with Game Ready
89381055|NCT03707327|Experimental|Ice pack|the participants performed cryotherapy for ice pack
89381056|NCT01343082|Experimental|1|DE-111 ophthalmic solution
89381057|NCT03374189|Experimental|EZ Close arm|EZ close used for port-site closure.
89002684|NCT06255340|Experimental|SRD Part: BI 3031185 dose group 6|
89002685|NCT06255340|Experimental|SRD Part: BI 3031185 dose group 7|
89002686|NCT06255340|Experimental|SRD Part: BI 3031185 dose group 8|
89002687|NCT06255340|Placebo Comparator|SRD Part: Placebo matching BI 3031185|
89002688|NCT06255340|Experimental|FE part: BI 3031185 under fasted (Reference, R) then BI 3031185 under fed (Test,T) conditions|Food effect (FE)
89002689|NCT06255340|Experimental|FE part: BI 3031185 under fed (Test,T) then BI 3031185 under fasted (Reference, R) conditions|
89002690|NCT06254911|Experimental|Treatment (Atezolizumab)|Patients receive atezolizumab IV while on study. Patients undergo CT scan and MRI throughout the study. Patients may undergo tumor biopsy while on study.
89002691|NCT06250725|Experimental|Cognitive Behavioral Therapy for Insomnia (CBTi)|Participant dyads will receive CBTi via videoconferencing sessions
89002692|NCT06249152|Experimental|Experimental: QLS-111 ophthalmic solution|Qlaris' IP, QLS-111 ophthalmic solution, provided in 3 concentrations (0.015%, 0.03%, and 0.075%), preservative free (PF), single-use units, masked.
89002693|NCT06249152|Placebo Comparator|Placebo comparator: Vehicle ophthalmic solution|Inactive control (0.00%), PF, single-use units, masked.
89002694|NCT06244004|Experimental|Arm 1A (FDG-PET, MDRT, SOC cytotoxic chemotherapy & ADT)|Patients undergo an FDG-PET scan after 6 months of SOC cytotoxic chemotherapy + ADT. Patients with PET-avid disease continue their SOC ADT and undergo MDRT to up to 5 disease sites in the absence of unacceptable toxicity. Patients also undergo CT and bone scans throughout the trial.
89002695|NCT06244004|Active Comparator|Arm 1B (FDG-PET, SOC cytotoxic chemotherapy & ADT)|Patients undergo an FDG-PET scan after 6 months of SOC cytotoxic chemotherapy + ADT. Patients with PET-avid disease continue their SOC ADT on study. Patients also undergo CT and bone scans throughout the trial.
89002696|NCT06244004|Active Comparator|Arm 1C (FDG-PET, SOC cytotoxic chemotherapy & ADT)|Patients undergo an FDG-PET scan after 6 months of SOC cytotoxic chemotherapy + ADT. Patients without PET-avid disease continue their SOC ADT on study. Patients also undergo CT and bone scans throughout the trial.
89002697|NCT06244004|Experimental|Arm 2A (FDG-PET, MDRT, SOC ADT)|Patients undergo an FDG-PET scan after 6 months of SOC ADT. Patients with PET-avid disease continue their SOC ADT and undergo MDRT to up to 5 disease sites in the absence of unacceptable toxicity. Patients undergo an additional FDG-PET scan at 6 months. Patients also undergo CT and bone scans throughout the trial.
89002698|NCT06244004|Active Comparator|Arm 2B (FDG-PET, SOC ADT)|Patients undergo an FDG-PET scan after 6 months of SOC ADT. Patients with PET-avid disease continue their SOC ADT on study and undergo an additional FDG-PET scan at 6 months. Patients also undergo CT and bone scans throughout the trial.
89002699|NCT06244004|Active Comparator|Arm 2C (FDG-PET, SOC ADT)|Patients undergo an FDG-PET scan after 6 months of SOC ADT. Patients without PET-avid disease continue their SOC ADT on study and undergo an additional FDG-PET scan at 6 months. Patients also undergo CT and bone scans throughout the trial.
89002700|NCT06241118|Experimental|Amlitelimab dose 1|Subcutaneous injection as per protocol
89002701|NCT06241118|Experimental|Amlitelimab dose 2|Subcutaneous injection as per protocol
89002702|NCT06241118|Placebo Comparator|Placebo|Subcutaneous injection as per protocol
89002703|NCT06239220|Experimental|Dose Level 0: PD-L1 t-haNK + N-803 + Cetuximab|"Dose level modifications of PD-L1 t-haNK and N-803 due to toxicities will follow protocol specifications, starting at Dose Level 0 and de-escalating to Dose Level -1. Participants will complete:~Baseline visit.~Imaging scans every 8 weeks while on study.~Cycle 1 through End of Treatment:~--Days 1 and 15 of 28 day cycle in the following order: Predetermined dose of PD-L1 t-haNK 1x daily, predetermined dose of N-803 1x daily, and predetermined dose of Cetuximab 1x daily.~End of Treatment visit with assessments.~Follow up: follow up every 3-4 months for up to 3 years after end of treatment. Longer-term follow-up every 6-12 months for up to 15 years."
89002704|NCT06239220|Experimental|Dose Level -1: PD-L1 t-haNK + N-803 + Cetuximab|"Dose level modifications of PD-L1 t-haNK and N-803 due to toxicities will follow protocol specifications. Participants will complete:~Baseline visit.~Imaging scans every 8 weeks while on study.~Cycle 1 through End of Treatment:~--Days 1 and 15 of 28 day cycle in the following order: Predetermined dose of PD-L1 t-haNK 1x daily, predetermined dose of N-803 1x daily, and predetermined dose of Cetuximab 1x daily.~End of Treatment visit with assessments.~Follow up: follow up every 3-4 months for up to 3 years after end of treatment. Longer-term follow-up every 6-12 months for up to 15 years."
89002705|NCT06238466|Active Comparator|Part A1 (AZD1705)|Non-Asian participants will receive AZD1705 subcutaneously on Day 1.
89002706|NCT06238466|Active Comparator|Part A2 (AZD1705)|Japanese participants will receive AZD1705 subcutaneously on Day 1.
89002707|NCT06238466|Active Comparator|Part A3 (AZD1705)|Chinese participants will receive AZD1705 subcutaneously on Day 1.
89002708|NCT06238466|Active Comparator|Part B1 (AZD1705)|Non-Asian participants who are receiving moderate- or high-intensity statin therapy will receive AZD1705 subcutaneously on Day 1 and Day 29.
89002709|NCT06238466|Active Comparator|Part B2 (AZD1705)|Japanese participants not receiving statin therapy will receive AZD1705 subcutaneously on Day 1 and Day 29.
89002710|NCT06238466|Active Comparator|Part B3 (AZD1705)|Participants who are receiving moderate- or high-intensity statin therapy and with the additional diagnosis of type 2 diabetes will receive AZD1705 subcutaneously on Day 1 and Day 29.
89002711|NCT06238466|Placebo Comparator|Part A1 (Placebo)|Non-Asian participants will receive placebo on Day 1.
89381058|NCT03374189|Active Comparator|Carter Thomason arm|Carter Thomason used for port-site closure.
89002712|NCT06238466|Placebo Comparator|Part A2 (Placebo)|Japanese participants will receive placebo on Day 1.
89002713|NCT06238466|Placebo Comparator|Part A3 (Placebo)|Chinese participants will receive placebo on Day 1.
89002714|NCT06238466|Placebo Comparator|Part B1 (Placebo)|Non-Asian participants who are receiving moderate- or high-intensity statin therapy will receive placebo on Day 1 and Day 29.
89002715|NCT06238466|Placebo Comparator|Part B2 (Placebo)|Japanese participants not receiving statin therapy will receive placebo on Day 1 and Day 29.
89002716|NCT06238466|Placebo Comparator|Part B3 (Placebo)|Participants who are receiving moderate- or high-intensity statin therapy and with the additional diagnosis of type 2 diabetes will receive placebo on Day 1 and Day 29.
89002717|NCT06237335|Experimental|RCT2100|RCT2100 single dose
89381059|NCT04385173|Experimental|B7-H3 CAR-T|Patients will received regular cycles of Temozolomide treatment with 5 days of treatment and 23 days of interval. 3 infusions of B7-H3 CAR-T with 1-2 weeks of interval will be used in between cycles of Temozolomide treatment. Temozolomide treatment during B7-H3 CAR-T infusions will be stopped and resumed after CAR-T infusion.
89381060|NCT03261037|Other|Participants With Suspicion of IPF/ILD|A participant will be eligible for inclusion if the Investigator has a suspicion that the participant may have IPF/ILD based on symptoms and radiological evidence.
89381061|NCT03710759|Experimental|Assistive Autogenic Drainage|Autogenic drainage (AD) is a breathing technique that uses controlled breathing and least amount of coughing to clear secretions from your chest. It involves you hearing and feeling your secretions as you breathe out and controlling the urge to cough until secretions are high up and easily cleared with little effort.
89381062|NCT03372551|Experimental|somofilcon A 1 day test lens|Subjects wearing the somofilcon A 1 day test lens for one week, either randomized as the first or second pair.
89381063|NCT03372551|Active Comparator|somofilcon A 1 day control lens|Subjects wearing the somofilcon A 1 day control lens for one week, either randomized as the first or second pair.
89381064|NCT03707249|Experimental|Iron|Received a blinded single 15 mg/kg dose of iv ferric carboxymaltose (Ferinject) up to a maximum off 1g total dose 2 weeks prior to ascent to very high-altitude.
89381065|NCT03707249|Sham Comparator|Saline control|Received a blinded single dose of iv normal saline 2 weeks prior to ascent to very high-altitude.
89381066|NCT03326323||Patients undergoing ANH during CABG|Patients undergoing Acute Normovolemic Hemodilution during CABG surgery.
89381067|NCT05682911|Experimental|Zingiber Officinale L (Ginger) treated group n=20|Ginger tablets 500mg twice a day (BD) for two month
89381068|NCT05682911|Active Comparator|Simvastatin treated group n=20|Simvastatin 20 mg tablet once a day (OD) for two month
89381069|NCT05480592|Experimental|Single Ascending Dose (SAD)|Subjects in cohorts 1-6 will receive oral administration of single dose of HS-10380 tablets or matching placebo.
89381070|NCT05480592|Placebo Comparator|Multiple Ascending Dose (MAD)|Subjects in cohorts 7 will receive oral administration of 7 dose of HS-10380 tablets or matching placebo.
89381071|NCT04990531|Experimental|Covid-19 subjects|Childrens and adolescent with PCR-proven previous SARS-CoV-2 infection
89381072|NCT04990531|Active Comparator|Healthy controls|Healthy controls negative for previous SARS-CoV-2 infection
89381073|NCT05467332||CRITICALLY ILL PATIENTS|CRITICALLY ILL PATIENTS AFTER INVASIVE MECHANICAL VENTILATION READY TO BE EXTUBATED.
89381074|NCT04680390|Experimental|Active-kINSHIP navigation intervention|kINSHIP is a peer-led navigator intervention to address intersectional stigma and improve PrEP treatment initiation and engagement for justice-involved women. The key components of the kINSHIP intervention are to: 1) increase social support; 2) increase self-efficacy in accessing PrEP services; 3) enhance access to healthcare services; 4) improve adaptive coping skills to manage experiences of intersectional stigma.
88853957|NCT01792284|Experimental|LY2605541 Fixed Time Dosing|"Participant-specific dose of LY2605541 administered subcutaneously (SQ) at approximately the same time every evening for 12 weeks in the Lead-in Period and in Randomization Period 1 or Randomization Period 2.~Participant-specific dose of insulin lispro SQ when >20% of calories were consumed (pre-meal).~Insulin dose and adjustments to insulin dose were determined by insulin algorithms based on self-monitored blood glucose (SMBG). Target glucose values were as follows:~Preprandial and bedtime BG between 71 and 130 milligrams/deciliter (mg/dL) Insulin adjustment and glucose correction between 71 and 100 mg/dL."
88853958|NCT01792284|Experimental|LY2605541 Variable Time Dosing|"Participant-specific dose of LY2605541 administered SQ on a variable time schedule (8- and 40-hour dosing intervals) for 12 weeks in Randomization Period 1 or Randomization Period 2. Dosing schedules were to remain approximately the same throughout the 12 weeks.~Participant-specific dose of insulin lispro SQ when >20% of calories were consumed (pre-meal).~Insulin dose and adjustments to insulin dose were determined by insulin algorithms based on SMBG. Target glucose values were as follows:~Preprandial and bedtime BG between 71 and 130 mg/dL Insulin adjustment and glucose correction between 71 and 100 mg/dL."
89002718|NCT06237335|Placebo Comparator|Placebo|Placebo single dose
89002719|NCT06235242|Experimental|GT201 treatment group|
89381075|NCT04680390|Active Comparator|Control-Standard Care|The control arm will be standard-of-care, which is as-needed case management for justice-involved women.
89381076|NCT04625088|Experimental|Standardized liquid test meal|
89381077|NCT04625088|Experimental|Atropine + Standardized liquid Test meal|
89381078|NCT03568422|Experimental|CFI-402257 + Paclitaxel|Oral CFI-402257 on intermittent schedule:* days 1, 2, 8, 9, 15 & 16 q4w Plus Paclitaxel 80 mg/m2 IV days 1, 8 & 15 every 28 days
89381079|NCT03484494|Other|Active first|Subjects receive active Low Field Magnetic Stimulation in the first imaging visit and sham in the second.
89381080|NCT03484494|Other|Sham first|Subjects receive sham Low Field Magnetic Stimulation in the first imaging visit and active in the second.
89381081|NCT03937141|Experimental|ADU-S100 and pembrolizumab|All eligible subjects will receive intravenous (IV) infusions of pembrolizumab and intratumoral injections of ADU-S100.
89381082|NCT02547493|Active Comparator|pneumococcal polysaccharide vaccine|Patients are vaccinated vith Peumo23/Pneumovax on the first day. Abatacept started on frst day.
89381083|NCT02547493|Active Comparator|pneumococcal conjugate vaccine|"Patients are vaccinated with Prevenar13 on the first day, and with Pneumo23/Pneumovax two months later.~Abatacept started on frst day."
89381084|NCT03259789|Active Comparator|Bexagliflozin tablets, 20 mg; Double-Blind|
89381085|NCT03259789|Placebo Comparator|Bexagliflozin tablets, Placebo; Double Blind|
89183063|NCT05691400|Experimental|CYP3A4*1/*1|"This arm will include subjects with CYP3A4*1/*1 genotype. They will receive a single oral dose of each CDK4/6 inhibitor on separate days, with at least 6 days and no more than 30 days between each medication. All participants will receive the medications in the same order: Palbociclib, Ribociclib, Abemaciclib~Ribociclib- 200 mg tablet Abemaciclib- 150 mg tablet Palbociclib-125 mg tablet~PK sampling will be done at the time of drug administration and at different time points until 48 hours post administration."
89183064|NCT05691400|Experimental|CYP3A4*1/*22|"This arm will include subjects with CYP3A4*1/*22 genotype. They will receive a single oral dose of each CDK4/6 inhibitor on separate days, with at least 6 days and no more than 30 days between each medication. All participants will receive the medications in the same order: Palbociclib, Ribociclib, Abemaciclib~Ribociclib- 200 mg tablet Abemaciclib- 150 mg tablet Palbociclib-125 mg tablet~PK sampling will be done at the time of drug administration and at different time points until 48 hours post administration."
89183065|NCT05691400|Experimental|CYP3A4*22/*22|"This arm will include subjects with CYP3A4*22/*22 genotype. They will receive a single oral dose of each CDK4/6 inhibitor on separate days, with at least 6 days and no more than 30 days between each medication. All participants will receive the medications in the same order: Palbociclib, Ribociclib, Abemaciclib~Ribociclib- 200 mg tablet Abemaciclib- 150 mg tablet Palbociclib-125 mg tablet~PK sampling will be done at the time of drug administration and at different time points until 48 hours post administration."
89183066|NCT05686070|Experimental|Asundexian|Participants will receive asundexian.
89183067|NCT05686070|Placebo Comparator|Placebo|Participants will receive placebo.
89183068|NCT05685381||Black adults with persistent asthma in homes with gas kitchen appliances|Black adults with persistent asthma that reside in homes with kitchen appliances (i.e., cooktops, ovens, and ranges) fueled by combustible gas.
89183069|NCT05685381||Black adults with persistent asthma in homes without gas kitchen appliances|Black adults with persistent asthma that reside in homes with kitchen appliances (i.e., cooktops, ovens, and ranges) not fueled by combustible gas.
89183070|NCT05683002|Experimental|Aronia|Aronia Melanocarpa supplementation
89183071|NCT05683002|Placebo Comparator|Control|Cellulose supplementation
89183072|NCT05682651||Tracheal Stenosis with Covid-19|Patients' age, gender, American Society of Anesthesiologists (ASA) classification, comorbidities, etiologic cause, intubation time, type of surgery, length of hospital stay, and morbidity/mortality information will be recorded.
89183073|NCT05682651||Tracheal Stenosis with Non-Covid-19|Patients' age, gender, American Society of Anesthesiologists (ASA) classification, comorbidities, etiologic cause, intubation time, type of surgery, length of hospital stay, and morbidity/mortality information will be recorded.
89183074|NCT05677854|Experimental|Motivational interview|Motivational interviewing, consisting of 6 sessions with a one-week interval, was applied face to face to this intervention group. Each motivational interview lasted approximately 40 minutes.
89183075|NCT05677854|Experimental|Health education|Health education consisting of 6 sessions, one week apart, was administered face to face to this intervention group. Each training session lasted approximately 40 minutes.
89183076|NCT05677854|No Intervention|Control|No intervention has been made.
89183077|NCT05676944|Experimental|vestibular implant|Up to 15 participants will undergo implantation, activation and deactivation of a Labyrinth Devices MVI™ Multichannel Vestibular Implant System
89183078|NCT05674786|Experimental|vestibular implant|Up to 8 participants will undergo implantation, activation and deactivation of a Labyrinth Devices MVI™ Multichannel Vestibular Implant System
89183079|NCT05672355|Experimental|Arm I (GEO-CM04S1)|Patients receive GEO-CM04S1 vaccine IM on days 0 and 84 on study. Patients undergo blood sample collections throughout the study and are monitored for 1 year.
89183080|NCT05672355|Active Comparator|Arm II (mRNA Covid-19 Vaccine)|Patients receive mRNA vaccine injection IM on days 0 and 84 on study. Patients undergo blood sample collections throughout the study and are monitored for 1 year.
89183081|NCT05670795|Experimental|recombinant follicle stimulating hormone|Gonal-f® (75 I.U., Merck Serono, Darmstadt, Germany)
89183082|NCT05670795|Active Comparator|recombinant follicle stimulating hormone and clomiphene citrate|Gonal-f® (75 I.U., Merck Serono, Darmstadt, Germany) Klomen® (50 mg, Koçak Farma, Tekirdag, Turkey)
89183083|NCT05668819|Experimental|TH-001|
89183084|NCT05668819|No Intervention|Control|
89183085|NCT05668143|Experimental|Experimental group|During the surgery, patients will be shown nature and landscape images with virtual reality glasses.
89183086|NCT05668143|No Intervention|Control group|The control group will receive standard procedure without any intervention.
89183087|NCT05661604||Participants at High Risk for Poor Outcomes From a Respiratory Infection|Data will be collected for participants at high risk for poor outcomes from a respiratory infection. The duration of participation per participant will be up to 12 months.
89183088|NCT05660486|Experimental|Aromatherapy group|Participants in this group will receive, lavender essential oil applied to their surgical mask for 5 minutes prior to scheduled standard of care ultrasound guided musculoskeletal procedure.
89183089|NCT05660486|Placebo Comparator|Placebo group|Participants in this group will receive water applied to their surgical mask for 5 minutes prior to scheduled standard of care ultrasound guided musculoskeletal procedure.
89183090|NCT05647811|Experimental|Cohort 1|6 subjects will receive NM8074 at 5 mg/kg weekly.
89183091|NCT05647811|Experimental|Cohort 2|6 subjects will receive NM8074 at 10 mg/kg every 2 weeks.
89183092|NCT05647811|Experimental|Cohort 3|6 subjects will receive NM8074 at 20 mg/kg every 2 weeks.
89183093|NCT05646563|Experimental|Cohort 1|6 Soliris-treated patients will receive an intravenous (IV) dose of NM8074 at 10 mg/kg weekly for 4 weeks. Patients will then discontinue Soliris treatment and be administered NM8074 at 20 mg/kg IV every 2 weeks for the remainder of the treatment period (8 weeks). At the end of the treatment period, patients will resume Soliris monotherapy as prescribed.
89381086|NCT03259789|Experimental|Bexagliflozin Tablets, 20 mg; High Glycemic Group|
89381087|NCT03259555|Experimental|Brexpiprazole|Participants received a starting dose of 2 milligrams (mg)/day brexpiprazole from Days 1 to 3, followed by titration to 3 mg/day on Day 4. Participants may have been titrated (or re-titrated) to a higher dose of brexpiprazole, up to a maximum of 4 mg/day, based on treatment response and at the investigator's discretion anytime at Day 7 or thereafter. Participants who were unable to tolerate their current dose could have been titrated down to a minimum of 2 mg/day any time after Day 4.
89381088|NCT03259555|Placebo Comparator|Placebo|Matching placebo was administered in the same way as brexpiprazole to maintain the blind.
89381089|NCT03702751|Experimental|Adhesive tape|will be subjected to skin repair after episiotomy with skin adhesive tape.
89381090|NCT03702751|Active Comparator|Continuous subcuticular skin suturing|will be subjected to skin repair after episiotomy with the currently traditional method for episiotomy repair by continuous absorbable subcuticular suture.
89381091|NCT03259087|Experimental|Part 1: Mild Renal Impairment|Participants receive a single IV infusion of 200 mg MK-3866 over 30 minutes on Day 1.
89381092|NCT03259087|Experimental|Part 1: Moderate Renal Impairment|Participants receive a single IV infusion of 200 mg MK-3866 over 30 minutes on Day 1.
89381093|NCT03259087|Experimental|Part 1: Severe Renal Impairment|Participants receive a single IV infusion of 200 mg MK-3866 over 30 minutes on Day 1.
89381094|NCT03259087|Experimental|Part 1: Healthy Participants|Participants receive a single IV infusion of 200 mg MK-3866 over 30 minutes on Day 1.
89381095|NCT03259087|Experimental|Part 2: End-stage Renal Disease Undergoing Hemodialysis|End-stage renal disease (ESRD) participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1 just after hemodialysis (HD) in Period 1 and just before HD in Period 2. There was a washout of at least 6 days before dosing in Period 2.
89381096|NCT03257995|Experimental|Sequence 1|A-B-C
89381097|NCT03257995|Experimental|Sequence 2|B-C-A
89381098|NCT03257995|Experimental|Sequence 3|C-A-B
89381099|NCT03257995|Experimental|Sequence 4|A-C-B
89381100|NCT03257995|Experimental|Sequence 5|B-A-C
89381101|NCT03257995|Experimental|Sequence 6|C-B-A
89381102|NCT03049488|Experimental|Group 1: DS-Cav1 (50 mcg)|"DS-Cav1 (50 mcg) administered intramuscularly (IM) by Needle/Syringe (Day 0 and Week 12*)~*To evaluate the safety or immunogenicity of a single vaccine dose, the Week 12 dose was optional for the last 5 subjects who enrolled in this group and received the Day 0 injection."
89381103|NCT03049488|Experimental|Group 2: DS-Cav1 (50 mcg) + alum|"DS-Cav1 (50 mcg) + alum administered IM by Needle/Syringe (Day 0 and Week 12*)~*To evaluate the safety or immunogenicity of a single vaccine dose, the Week 12 dose was optional for the last 5 subjects who enrolled in this group and received the Day 0 injection."
88853959|NCT04414566|Experimental|IC plus RT|Patients receive GP(gemcitabine+cisplatin) or TPF(docetaxel+cisplatin+fluorouracil) every three weeks for three cycles before the radiotherapy, and then receive radical radiotherapy and cisplatin (100mg/m^2) every three weeks for three cycles during radiotherapy.
88853960|NCT04414566|Active Comparator|IC plus CCRT|Patients receive GP(gemcitabine+cisplatin) or TPF(docetaxel+cisplatin+fluorouracil) every three weeks for three cycles before the radiotherapy, and then receive radical radiotherapy.
88853961|NCT01837914|Experimental|Maxillary expansion as First treatment|Orthodontic expansion of upper jaw, then cross-over to adenotonsillectomy
88853962|NCT01837914|Active Comparator|Adenotonsillectomy as First treatment|surgical removal of tonsils and adenoids, then cross-over to maxillary expansion
88853963|NCT01791894|Experimental|Treatment (arsenic trioxide)|Patients receive arsenic trioxide IV over 2 hours on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88853964|NCT04592016|Experimental|Pilot Study|Dermal-sampling visit: Measurement of dermal pharmacokinetic (PK) parameter (AUC, Cmax) of diclofenac using dermal open flow microperfusion (dOFM) after topical application of diclofenac sodium products in 6 participants. Additionally systemic appearance of diclofenac is measured by blood sampling.
89381104|NCT03049488|Experimental|Group 3: DS-Cav1 (150 mcg)|"DS-Cav1 (150 mcg) administered IM by Needle/Syringe (Day 0 and Week 12*)~*The Week 12 dose was optional for the last 5 subjects who enrolled in this group and received the Day 0 injection, and for 5 additional subjects who were enrolled to evaluate the safety or immunogenicity of a single vaccine dose."
89381105|NCT03049488|Experimental|Group 4: DS-Cav1 (150 mcg) + alum|"DS-Cav1 (150 mcg) + alum administered IM by Needle/Syringe (Day 0 and Week 12*)~*To evaluate the safety or immunogenicity of a single vaccine dose, the Week 12 dose was optional for the last 5 subjects who enrolled in this group and received the Day 0 injection."
89381106|NCT03049488|Experimental|Group 5: DS-Cav1 (500 mcg)|"DS-Cav1 (500 mcg) administered IM by Needle/Syringe (Day 0 and Week 12*)~*To evaluate the safety or immunogenicity of a single vaccine dose, the Week 12 dose was optional for the last 5 subjects who enrolled in this group and received the Day 0 injection."
89381107|NCT03049488|Experimental|Group 6:DS-Cav1 (500 mcg) + alum|"DS-Cav1 (500 mcg) + alum administered IM by Needle/Syringe (Day 0 and Week 12*)~*To evaluate the safety or immunogenicity of a single vaccine dose, the Week 12 dose was optional for the last 5 subjects who enrolled in this group and received the Day 0 injection."
89381108|NCT04484922|Experimental|Dexmedetomidine|
89381109|NCT04484922|Placebo Comparator|Control|
89381110|NCT04481958|Experimental|I-PROTECT model|The I-PROTECT model is an end-user-driven intervention including evidence-based, theory-informed, and context-specific injury prevention training for youth handball, and an associated implementation strategy.
89381111|NCT03257371||Post-traumatic knee OA|post-traumatic knee OA and requiring a tibial plateau and meniscus arthroplasty plus a femoral condyle arthroplasty
89381112|NCT04446390|Experimental|preventive regimen using Herbal toothpaste(Himalaya)|"The regimen includes herbal toothpaste containing Neem , Miswak , Babool and Pomegranate (Himalaya Complete Care). Chew xylitol gum 2 pieces four times per day for 5 minutes after meals."
89381113|NCT04446390|Active Comparator|preventive regimen using Fluoride based toothpaste(colgate)|preventive regimen using Fluoride based toothpaste (colgate cavity protection). Participants will be using a fluoride-based toothpaste (colgate cavity protection), (1450 ppm Sodium monofluorophosphate). chew xylitol gum 2 pieces four times per day for 5 minutes after meals.
89381114|NCT03257137|Experimental|Healthy Diet|This dietary pattern will represent recommendations for fiber and added sugar set forth in the 2015 Dietary Guidelines for Americans and saturated fat guidelines from the American Heart Association
89381115|NCT03257137|Experimental|Simulated Fast Food (SFF)|This dietary pattern will represent the typical American diet for fiber, added sugar, and saturated fat intake.
89381116|NCT02338921|Active Comparator|Glimepirde, Metformin, Sitagliptin|"Dipeptidyl peptidase-4 (DPP4) inhibitor~Sitagliptin"
89381117|NCT02338921|Active Comparator|Glimepirde, Metformin, Dapagliflozin|"Sodium-glucose cotransporter 2 (SGLT2) inhibitors~Dapagliflozin"
89381118|NCT02338921|Active Comparator|Glimepirde, Metformin, Lobeglitazone|"Peroxisome proliferator-activated receptor gamma agonist~Lobeglitazone"
89381119|NCT01313845|Active Comparator|amantadine|administration of intravenous amantadine sulfate 200mg/500ml/bottle 1 bottle infusion over 3 hours, twice a day for consecutive 5 days
89381120|NCT01313845|Placebo Comparator|placebo|administration of 0.9% sodium chloride 500ml/bottle 1 bottle infusion over 3 hours twice a day for consecutive 5 days
89381121|NCT04782661|Experimental|Part 1: Single Ascending Dose (SAD)|Participants will receive an oral solution of JNJ-70075200 or placebo in single ascending doses on Day 1 in cohorts 1, 2, 3, 4, 5a and 6 under fasted condition. Participants in cohort 5a will additionally receive the same study intervention under fed condition (Cohort 5b) after a washout period of at least 7 days.
89381122|NCT04782661|Experimental|Part 2: Multiple Ascending Dose (MAD)|After assessment of safety, tolerability and pharmacokinetics data in Part 1, participants will receive an oral solution of JNJ-70075200 or placebo twice daily in Cohorts 1 to 6 for 14 days under fasted/fed condition.
89381123|NCT04782661|Experimental|Part 3: Single-dose Oral Solid Formulation (Optional)|Participants will receive oral dose of JNJ-70075200 on Day 1 in Cohort 1 under fasted condition. Part 3 will start after obtaining a formal regulatory/ethical approval.
88853965|NCT04592016|Experimental|Pivotal Study|Dermal-sampling visit: Measurement of dermal pharmacokinetic (PK) parameter (AUC, Cmax) of diclofenac using dermal open flow microperfusion (dOFM) after topical application of diclofenac sodium products in 20 participants. Additionally systemic appearance of diclofenac is measured by blood sampling.
88853966|NCT01837680|Active Comparator|Levemir|Initial daily total insulin doses will be determined as per a weight based protocol depending on what trimester the patient is in. Sixty percent of the total daily insulin dose will be allotted to the morning total dose of insulin, while the remaining 40% will be allotted to the evening total dose. Of the morning dose, 2/3 will be allotted to the long acting insulin and 1/3 to short acting insulin. She will take half of the short-acting dose with breakfast and the other half with lunch. The evening insulin dose (40% of the total dose) will be divided in two: half the dose will be taken as short-acting insulin with dinner, and the other half as long acting insulin at bedtime. Doses are rounded down if decimals are present.
88853967|NCT01837680|Active Comparator|NPH|Initial daily total insulin doses will be determined as per a weight based protocol depending on what trimester the patient is in. Sixty percent of the total daily insulin dose will be allotted to the morning total dose of insulin, while the remaining 40% will be allotted to the evening total dose. Of the morning dose, 2/3 will be allotted to the long acting insulin and 1/3 to short acting insulin. She will get the entire dose of short-acting insulin with breakfast. The evening insulin dose (40% of the total dose) will be divided in two: half the dose will be taken as short-acting insulin with dinner, and the other half as long acting insulin at bedtime. Doses are rounded down if decimals are present.
88853968|NCT01836276|Experimental|African American (AA) Smokers|AA smokers received 12 weeks of Varenicline and 6 smoking cessation counseling sessions.
88853969|NCT01836276|Active Comparator|White Smokers|White smokers received 12 weeks of Varenicline and 6 smoking cessation counseling sessions.
88853970|NCT01790568|Experimental|Vorinostat|Vorinostat, in combination with standard of care medications tacrolimus and methotrexate, for GVHD prophylaxis after unrelated donor stem cell transplant.
88853971|NCT01610076|No Intervention|No Video - Control|"This group does not watch the 10 minute code status video before having the knowledge base video administered."
88853972|NCT01610076|Experimental|Code Status Video|"This group views a 10 minute video about code status prior to knowledge base survey administration"
89381124|NCT04745845|Experimental|Noradrenalin|treatment with 2 different NA concentrations in 2 different states of fluid responsiveness
89381125|NCT04492098||study group|women with spontaneous miscarriage
89381126|NCT04683991|Experimental|treatment group 1|At the same time of implant implantation, autologous tissue is transplanted into the recipient area by using Subepithelial connective tissue graft.
89381127|NCT04683991|Experimental|treatment group 2|During the second stage operation, autologous tissue is transplanted into the recipient area by using Subepithelial connective tissue graft.
89381128|NCT04361838|Active Comparator|Prayer|Patients will receive a daily prayer and standard of care treatment from multi-denominational group while in the ICU.
89381129|NCT04361838|No Intervention|No Prayer|Patients will receive standard of care treatment while in the ICU.
88853973|NCT01836198|Experimental|LY2409021 Only (Part A, Cohort 1)|Part A, Period 1. Participants will receive a single 20-milligram (mg) oral dose of LY2409021 on Day 1.
88853974|NCT01836198|Experimental|LY2409021+Gemfibrozil (Part A, Cohort 1)|Part A, Period 2. Participants will receive a morning (AM) and evening (PM) oral dose of 600 mg gemfibrozil on Days 1-20 and an AM oral dose only of 600 mg gemfibrozil on Day 21. Participants will also receive a single 20-mg oral dose of LY2409021 on Day 4.
89183094|NCT05646563|Experimental|Cohort 2|6 Soliris-treated patients will receive an intravenous (IV) dose of NM8074 at 10 mg/kg for 4 weeks. Patients will then continue receiving Soliris while being administered NM8074 as a combination therapy at 20 mg/kg IV every 2 weeks for the remainder of the treatment period (8 weeks). At the end of the treatment period, patients will resume Soliris monotherapy as prescribed.
89183095|NCT05646524|Experimental|Cohort 1|6 subjects will receive an intravenous (IV) infusion of NM8074 at 20 mg/kg every two weeks.
89183096|NCT05646524|Experimental|Cohort 2|6 subjects will receive an intravenous (IV) infusion of NM8074 at 10 mg/kg weekly for four weeks followed by a 20 mg/kg dose of NM8074 every two weeks for the remainder of the treatment period.
89183097|NCT05645822||People with symptoms attributable to gHAT|The study will include any person that attends any of the participating healthcare facilities with symptoms that could be attributed to gHAT (long-term fever (unless other obvious causes), headache for a long period (more than 14 days), presence of enlarged lymph nodes in the neck, severe weight loss, weakness, pruritus, amenorrhea, abortions or sterility, psychiatric problems (aggressiveness, apathy, mental confusion, anxiety), sleep disturbances, motor weakness, logorrhea, speech impairment, ataxia, abnormal gait, abnormal movements or seizures) and accepts to participate.
89183098|NCT05641259|Experimental|Dose Escalation|"LP-108: Cycle 0: ramp-up from Day 1, Cycle 1+: at escalating dose levels in participants with AML, MDS or CMML.~Azacitidine: beginning on Day 1 through Day 7 of each Cycle (expect for Cycle 0).~Strong/moderate CYP3A inhibitor and inducer are prohibited. Participants are treated indefinitely until disease progression, unacceptable toxicity or withdrawal for other reasons."
89183099|NCT05641259|Experimental|Safety Expansion|"LP-108: Cycle 0: ramp-up from Day 1, Cycle 1+: Participants with AML, MDS or CMML will be treated with LP-108 to enable selection of the recommended Phase 2 dose (RP2D).~Azacitidine: beginning on Day 1 through Day 7 of each Cycle (expect for Cycle 0).~Strong/moderate CYP3A inhibitor and inducer are prohibited. Participants are treated indefinitely until disease progression, unacceptable toxicity or withdrawal for other reasons."
89183100|NCT05641259|Experimental|Efficacy Expansion [AML]|"LP-108: Cycle 0: ramp-up from Day 1, Cycle 1+: at RP2D level in participants with AML .~Azacitidine: beginning on Day 1 through Day 7 of each Cycle (expect for Cycle 0).~After the completion of Part 1, the Part 2 dose expansion phase will begin. Strong/moderate CYP3A inhibitor and inducer are prohibited. Participants are treated indefinitely until disease progression, unacceptable toxicity or withdrawal for other reasons."
89183101|NCT05641259|Experimental|Efficacy Expansion [MDS&CMML]|"LP-108: Cycle 0: ramp-up, Cycle 1+: at RP2D level in participants with MDS or CMML.~Azacitidine: beginning on Day 1 through Day 7 of each Cycle (expect for Cycle 0).~Strong/moderate CYP3A inhibitor and inducer are prohibited. Participants are treated indefinitely until disease progression, unacceptable toxicity or withdrawal for other reasons."
89183102|NCT05633810|Active Comparator|Anti-thrombotic arm|For patients eligible for aspirin therapy arm.
89183103|NCT05633810|Placebo Comparator|Anti-thrombotic arm (Placebo)|For patients eligible for aspirin therapy arm.
89183104|NCT05633810|Active Comparator|Anti-inflammatory arm|For patients ineligible for aspirin therapy arm.
89183105|NCT05633810|Placebo Comparator|Anti-inflammatory arm (Placebo)|For patients ineligible for aspirin therapy arm.
89183106|NCT05628324|Experimental|EMG + task training|Train with EMG-controlled games and functional task practice
89183107|NCT05628324|Active Comparator|task training|Train with functional task practice for a total of 18 sessions
89183108|NCT05626491|Experimental|Active SAVIR Alpha Synch Mobile device (SASm)|Patients will receive active treatment with the device every other day over 8 weeks.
89183109|NCT05626491|Sham Comparator|Sham SAVIR Alpha Synch Mobile device (SASm)|Patients will receive sham treatment (no active stimulation) with the device every other day over 8 weeks.
89183110|NCT05618314|Experimental|Group A-Mild Renal Impairment|single dose AT-527
89183111|NCT05618314|Experimental|Group B-Moderate Renal Impairment|single dose AT-527
89183112|NCT05618314|Experimental|Group C-Severe Renal Impairment (optional)|single dose AT-527
89183113|NCT05618314|Experimental|Group D-End-Stage Renal Disease (optional)|single dose of AT-527 pre- and post-dialysis
89183114|NCT05618314|Experimental|Group E-Matched Healthy Subjects|Single dose of AT-527 on Days 1 and 15. Probenecid administered twice daily (BID) Days 14-19
89183115|NCT05618080||LGMD Type R1/LGMD2A/CAPN3|No intervention will be administered.
89183116|NCT05610982|Experimental|Yoga Program|Participants will receive a yoga program program in-person or via real-time videoconferencing (if they choose).
89183117|NCT05606952|Active Comparator|Group (C)|patients with BMI less than 35
89183118|NCT05606952|Active Comparator|Group (O)|patients with BMI more than 35
89183119|NCT05606406|Active Comparator|Healthy Control Group|Individuals without lung disease will receive oxygen for a period of four hours
89183120|NCT05606406|Active Comparator|Nocturnal hypoxemia group|Individuals with lung disease will receive oxygen for a period of four hours
89183121|NCT05597943|Experimental|Malama Arm|Participants enrolled in this arm will agree to using the Malama app to track glycemic management.
89183122|NCT05597943|No Intervention|Control|Participants enrolled in this arm agree to standard management (FS log on phone, notebook, etc)
89535085|NCT02452411|Experimental|Homework assignments using TEO system|Experimental: Homework assignments using TEO system. It is an internet-based system which allows the therapist to create homework sessions using multimedia materials (videos, images, texts, and narratives) and to offer and present this material to the patients through the Internet. Participants receive a CBT treatment for adjustment disorder supported by virtual reality and they do the homework assignments component using TEO at home over the Internet.
89381130|NCT03242863|Experimental|Control|Baseline proportions of high and low energy dense foods.
88853975|NCT01836198|Experimental|LY2409021 Only (Part A, Cohort 2)|Part A, Period 1. Participants will receive a single 20-mg oral dose of LY2409021 on Day 1.
89381131|NCT03242863|Experimental|Addition|Increased portion of low energy dense foods.
88853976|NCT01836198|Experimental|LY2409021+Ketoconazole (Part A, Cohort 2)|Part A, Period 2. Participants will receive a once-daily 400-mg oral dose of ketoconazole on Days 1-21 and a single 20-mg oral dose of LY2409021 on Day 4.
88853977|NCT01836198|Experimental|LY2409021+Clarithromycin (Part B)|Part B. Participants will receive a twice-daily 500-mg oral dose of clarithromycin on Days 1-21 and a single 20-mg oral dose of LY2409021 on Day 4.
88853978|NCT04590846|Experimental|Constipation Health Education|"Health education leaflets are distributed once a week, and students are asked to bring it back to their parents to read. The activity of seeing leaflets, accumulating points, and redeeming prizes is adopted. a reply slip is designed in the weekly health education content, containing 3-5 test questions. Parents need to complete the answers and sign after reading the health education content. Those who have a high degree of correctness and fully paid in within 4 weeks will receive additional points. Students are required to keep a  Stool diary record sheet  every day, and it will be posted in the contact book. Children who have confirmed records and turned in will get 10 points a week, and those who turned in all 8 weeks without random answers can get extra points. The points of the parent health education receipt and the points of the children will be combined and calculated, and the weight will be set according to the total number of points for the draw."
88853979|NCT04590846|Active Comparator|General Health Course|"In order to correctly evaluate the effectiveness of health education intervention, only the parents of the experimental group will receive the health education leaflet during the intervention period. However, after the end of the trial, an electronic file of parental health education in the control group will be provided. Students are required to keep a  Stool diary record sheet  every day, and it will be posted in the contact book. Children who have confirmed records and turned in will get 10 points a week, and those who turned in all 8 weeks without random answers can get extra points. After the children's points are counted, a lottery will be drawn based on the total number of points. Since the experimental group and the control group have different benchmarks for points, the lottery will be drawn separately from each school. During the lottery process, the time will be announced in advance, and the number will be randomly selected by the computer in a live broadcast method."
88853980|NCT01816074|Experimental|Maternal Medication then meds|The mothers in this treatment arm are given an active medication to treat ADHD (Vyvanse) in the first phase of the study, and in the second phase are randomized to enhanced medication
88853981|NCT01816074|Experimental|BPT then continued beh tx|The mothers in this treatment arm are given Behavior Parent Training in the first phase of the study, and in the second phase are randomized to enhanced behavioral treatment.
88853982|NCT01816074|Experimental|Maternal Medication then BPT|The mothers in this treatment arm are given an active medication to treat ADHD (Vyvanse) in the first phase of the study, and in the second phase are randomized to combined treatment (adding Behavior Parent Training).
88853983|NCT01816074|Experimental|BPT then maternal medication|The mothers in this treatment arm are given Behavior Parent Training in the first phase of the study, and in the second phase are randomized to active ADHD medication, Vyvanse.
88853984|NCT01815918|Placebo Comparator|Placebo|Patients receive a saline placebo before surgery, 8 hours after the first dose and 16 hours after the first dose.
88853985|NCT01815918|Active Comparator|Treatment|Patients receive 3 100 mg of hydrocortisone: prior to surgery, 8 hours after the first dose and 16 hours after the first dose.
88853986|NCT01789476|Experimental|CR845|Peripheral kappa opioid receptor agonist
88853987|NCT01789476|Placebo Comparator|Placebo|Matched placebo
88853988|NCT01789320|Experimental|triamcinolone acetonide (Triesence®)|TRIESENCE® (triamcinolone acetonide injectable suspension 40 mg/mL) in a total volume of 100 uL administered via microneedle directly to the suprachoroidal space (SCS)
88853989|NCT01815840|Experimental|Vismodegib Intermittent Schedule|Vismodegib intermittent schedule of 12 weeks vismodegib followed by 8 weeks placebo, repeated 3 times with a final course of vismodegib (total 72 weeks), followed by 52 weeks treatment-free follow up
88853990|NCT01815840|Experimental|Vismodegib Induction Followed by Intermittent Schedule|Vismodegib beginning with 24 weeks induction followed by intermittent schedule 8 weeks placebo, 8 weeks vismodegib (total 72 weeks), followed by 52 weeks treatment-free follow up
88853991|NCT01774110|Experimental|early standardized task training|Persons in the experimental group will receive ESTT (early standardized task specific training) for gait treatment after stroke.
88853992|NCT01788228|Experimental|Influenza A (H5N1) Virus monovalent vaccine 18-64 Years Group|Subjects 18-64 years of age received 2 doses of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) at Days 0 and 21. The vaccine was administered intramuscularly in the deltoid of the non-dominant arm at Day 0 and dominant arm at Day 21.
88853993|NCT01788228|Experimental|Influenza A (H5N1) Virus monovalent vaccine > 64 Years Group|Subjects >64 years of age received 2 doses of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) at Days 0 and 21. The vaccine was administered intramuscularly in the deltoid of the non-dominant arm at Day 0 and dominant arm at Day 21.
88853994|NCT01607346|Experimental|ezogabine/retigabine|Open-label
88853995|NCT01787838|Other|health education, audit and feedback|Focused health education for staff and patients.
88853996|NCT01787760|Experimental|Test Soft Contact Lens B|Lenses will be worn in a daily disposable modality
88853997|NCT01787760|Experimental|Test Soft Contact Lens C|Lenses will be worn in a daily disposable modality
89535086|NCT02452411|Experimental|Homework assignments using Traditional method|The traditional way of applying homework assignments consists of reading and writing materials and audio session records. Participants receive a CBT treatment supported by virtual reality for adjustment disorder and they do the homework assignments component at home using traditional materials.
89535087|NCT03086031|Experimental|Program-based vocational rehabilitation|Combined intervention with a neuropsychological, social and community intervention followed by a vocational rehabilitation programme with a total length of 6-9 months.
89381132|NCT03242863|Experimental|Substitution|Increased portion of low energy dense foods substituted for equal portion of foods higher in energy density.
88853998|NCT01787760|Active Comparator|Spectacle Lenses|Control spectacle lenses worn daily.
88853999|NCT01815138|Experimental|hCG given at time of GnRHa trigger|"Adjuvant low dose hCG 1,000 IU administered at the time of GnRH agonist trigger.~Placebo administered 35 hours after GnRH agonist trigger"
88854000|NCT01815138|Active Comparator|hCG given 35 hours after GnRHa trigger|"Placebo administered at the time of GnRH agonist trigger~Adjuvant low dose hCG 1,500 IU administered 35 hours after GnRH agonist trigger."
88854001|NCT01606800|Experimental|44 Weeks of PEG-IFN alfa-2b + RBV|Participants achieving RVR at 4 weeks of treatment will receive 44 additional weeks of Peg-IFN Alfa-2b + RBV.
88854002|NCT01606800|Experimental|20 Weeks of PEG-IFN alfa-2b + RBV|Participants achieving RVR at 4 weeks of treatment will receive 20 additional weeks of Peg-IFN Alfa-2b + RBV.
88854003|NCT04414488||Patient controlled analgesia|General anaesthesia was induced with midazolam 0.1 mg*kg-1, propofol 2 mg*kg-1, cisatracurium 0.15 mg*kg-1 and fentanyl 1.5 µg*kg-1. Anaesthesia was maintained with one minimal alveolar concentration sevoflurane. Fractional doses of fentanyl 1-3 µg*kg-1 were administered if heart rate or mean blood pressure rose more than 20% above the base-line value obtained just before surgery commenced. After surgery, if a patient complained of pain then she/he was given i.v. oxycodone by an anaesthetist before commencing the patient controlled analgesia (PCA). The PCA solution was oxycodone (1mg*ml-1) and the PCA was programmed to allow a self-administered bolus dose of 1mg oxycodone with a lockout time of 5 min. During the night, basal rate oxycodone was 2-4 mg per hour. Additionally, patients were given 1g intravenous paracetamol every 6h and 100mg of intravenous ketoprofen every 12h, if required.
88854004|NCT04414488||Thoracic paravertebral block and patient controlled analgesia|Before induction of general anesthesia thoracic paravertebral block was performed. General anaesthesia was induced with midazolam 0.1 mg*kg-1, propofol 2 mg*kg-1, cisatracurium 0.15 mg*kg-1 and fentanyl 1.5 µg*kg-1. Anaesthesia was maintained with one minimal alveolar concentration sevoflurane. Fractional doses of fentanyl 1-3 µg*kg-1 were administered if heart rate or mean blood pressure rose more than 20% above the base-line value obtained just before surgery commenced. After surgery, if a patient complained of pain then she/he was given i.v. oxycodone by an anaesthetist before commencing the patient controlled analgesia (PCA). The PCA solution was oxycodone (1mg*ml-1) and the PCA was programmed to allow a self-administered bolus dose of 1mg oxycodone with a lockout time of 5 min. During the night, basal rate oxycodone was 2-4 mg per hour. Additionally, patients were given 1g intravenous paracetamol every 6h and 100mg of intravenous ketoprofen every 12h, if required.
88854005|NCT01772550|Experimental|20 Gauge BD Nexiva Diffusics|During their routinely scheduled contrast-enhanced computed tomography procedure, subjects in this arm will receive IV contrast media injected via the fenestrated 20GA BD Nexiva Diffusics single port IV catheter (20GA x 1.00 inch).
88854006|NCT01772550|Active Comparator|18 Gauge Conventional Catheter|During their routinely scheduled contrast-enhanced computed tomography procedure, subjects in this arm will receive IV contrast media injected via the non-fenestrated 18GA Conventional Catheter (18 GA x 1.25 inch Smiths Medical Jelco® IV Catheter).
88854007|NCT01772550|Experimental|BD Nexiva Diffusics - Nonrandomized|Subjects whose veins were not suitable for an 18 GA IV Catheter were assigned to this non-randomized arm. During their routinely scheduled CECT procedure, subjects receive IV contrast medium injected via the fenestrated 20GA BD Nexiva Diffusics single port IV catheter (20GA x 1.00 inch)
88854008|NCT01787292|Experimental|Stretching Exercise Intervention|A. Light stretching and balance exercises under supervised trainer. 3 times per week for 20-45 minutes. HR will be targeted to be under 50% of age-related maximum.
88854009|NCT01787292|Experimental|Aerobic Exercise Intervention|B. Interval aerobic cycling under supervised trainer. 3 times per week for 20-45 minutes. HR will be targeted between 50-85% of age-related maximum.
88854010|NCT01787292|Experimental|Self Monitoring Intervention|C. 6 month self-monitored training phase during which time participants will exercise using a take home bike ergometer.
88854011|NCT04414644|Experimental|Daytime Eating Condition|Participants will be asked to eat all of their meals and snacks, as provided by the study, between 0800 and 1900.
88854012|NCT04414644|Experimental|Delayed Eating Condition|Participants will be asked to eat all of their meals and snacks, as provided by the study, between 1200 and 2300.
88854013|NCT01814748|Experimental|Omarigliptin 25 mg|Omarigliptin 25 mg, once weekly, for 24 weeks. Open-label metformin daily was to be initiated for participants meeting protocol-specified glycemic criteria, but was otherwise prohibited.
88854014|NCT01814748|Placebo Comparator|Placebo|Placebo to omarigliptin, once weekly, for 24 weeks. Open-label metformin daily was to be initiated for participants meeting protocol-specified glycemic criteria, but was otherwise prohibited.
88854015|NCT01814670|Experimental|botulinum toxin Type A|20 units botulinum toxin Type A (total dose) injected into frown lines on Day 1.
88854016|NCT01814046|Experimental|cells + high dose aldesleukin|Patients receiving cells + high dose aldesleukin
89381133|NCT03044106|Active Comparator|CLRT, Then Sham|Subjects performed the KEA, HHD, PPT functional tests on their right hamstring before and after the CLRT intervention.
89381134|NCT03044106|Sham Comparator|Sham, Then CLRT|The Sham procedure was identical to CLRT except the laser device was placed in placebo mode: all device indicator lights and sounds will be functional but no laser light will be emitted from probe aperture.
89381135|NCT03196986|Experimental|mil60|mil60 (15mg/kg) was co-administered intravenously with 4 to 6-cycle paclitaxel/carboplatin, non-progressive patients are then given with maintenance single-agent mil60 (7.5mg/kg) until disease progression, intolerable toxicity, or withdrawal.
88854017|NCT01814046|Experimental|cells and no high dose aldesleukin|Patients receiving cells and no high dose aldesleukin
88854018|NCT01813890|Experimental|Tapentadol IR 50 mg|
88854019|NCT01813890|Experimental|Tapentadol IR 75 mg|
88854020|NCT01813890|Placebo Comparator|Placebo|
88854021|NCT01772316|Experimental|Tocilizumab Subcutaneous (SC)|Participants received Tocilizumab 162 milligram (mg) given as 0.9 milliliter (mL) of a 180 milligram per milliliter (mg/mL) solution administered once a week (for participants entering from NCT01194414) or once every two weeks (for participants entering from NCT01232569) by SC injection and as a single fixed dose irrespective of body weight.
88854022|NCT01813422|Placebo Comparator|Placebo|Participants received placebo to evolocumab administered by subcutaneous injection once a month for 76 weeks.
88854023|NCT01813422|Experimental|Evolocumab|Participants received 420 mg evolocumab administered by subcutaneous injection once a month for 76 weeks.
88854024|NCT01786668|Experimental|Tofacitinib 2 mg|
88854025|NCT01786668|Experimental|Tofacitinib 5 mg|
88854026|NCT01786668|Experimental|Tofacitinib 10 mg|
88854027|NCT01786668|Placebo Comparator|Placebo|
88854028|NCT01786512|Placebo Comparator|Dose-escalation Cohort 1: Placebo|Participants received placebo tablets twice a day (BID) for 7 days.
88854029|NCT01786512|Experimental|Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F1|Participants received 25 mg omecamtiv mecarbil (OM) Matrix F1 (M-F1) tablets twice a day for 7 days.
88854030|NCT01786512|Experimental|Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F2|Participants received 25 mg omecamtiv mecarbil Matrix F2 (M-F2) tablets twice a day for 7 days.
88854031|NCT01786512|Experimental|Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg SCT-F2|Participants received 25 mg omecamtiv mecarbil swellable core technology F2 (SCT-F2) tablets twice a day for 7 days.
88854032|NCT01786512|Placebo Comparator|Dose-escalation Cohort 2: Placebo|Participants received placebo tablets twice a day for 7 days.
88854033|NCT01786512|Experimental|Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F1|Participants received 50 mg omecamtiv mecarbil M-F1 tablets twice a day for 7 days.
88854034|NCT01786512|Experimental|Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F2|Participants received 50 mg omecamtiv mecarbil M-F2 tablets twice a day for 7 days.
88854035|NCT01786512|Experimental|Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg SCT-F2|Participants received 50 mg omecamtiv mecarbil SCT-F2 tablets twice a day for 7 days.
88854036|NCT01786512|Placebo Comparator|Expansion Phase: Placebo|Participants received placebo tablets twice a day for 20 weeks.
88854037|NCT01786512|Experimental|Expansion Phase: Omecamtiv Mecarbil 25 mg M-F1|Participants received 25 mg omecamtiv mecarbil M-F1 tablets twice a day for 20 weeks.
88854038|NCT01786512|Experimental|Expansion Phase: OM M-F1 PK-based Titration|All participants received 25 mg omecamtiv mecarbil M-F1 tablets twice a day. At week 8 the dose escalated to 50 mg twice a day if the week 2 predose plasma concentration of OM was less than the predefined cutoff of 200 ng/mL.
89381136|NCT03196986|Active Comparator|Bevacizumab|Bevacizumab (15mg/kg) was co-administered intravenously with 4 to 6-cycle paclitaxel/carboplatin, non-progressive patients are then given with maintenance single-agent mil60 (7.5mg/kg) until disease progression, intolerable toxicity, or withdrawal.
89381137|NCT04051632||Type 1 Diabetes patients treated with the Medtronic 670G|Type 1 Diabetes patients treated with the Medtronic 670G at Boston Childrens Hospital
89381138|NCT03170856|Experimental|Exercise Intervention Group|Thse patients will undergo a sub-maximal exercise training as treatment for concussion.
88854039|NCT04414254|Experimental|conference-Cefprozil for Suspension®|"Cefprozil for Suspension® (125mg/5ml, 50ml/bottle, batch no. F701087, manufactured by Lupin Pharmaceuticals, Inc.)"
88854040|NCT04414254|Experimental|test-cefprozil granule|cefprozil granule (125mg, batch no. 8G001F07, manufactured by Qilu Pharmaceutical Co., Ltd)
88854041|NCT01772160||Herpes Zoster Group|Male or female subjects aged 50 years or above, presenting with a herpes zoster (HZ) episode.
88854042|NCT01770912|Placebo Comparator|Lactated Ringers|1 cc of Lactated Ringers solution injected once after the TMJ rinsing procedure.
88854043|NCT01770912|Active Comparator|Triamcinolone acetonide|1 cc of triamcinolone acetonide (20 mg) injected once after the TMJ rinsing procedure.
88854044|NCT01811706|Experimental|Dalfampridine and then placebo|Participant first receive Dalfampridine at an oral dose of 10mg every 12 hours, for 4 weeks. After a washout period of 2 weeks, they then receive Placebo tablet orally every 12 hours, for a 4 weeks period.
88854045|NCT01811706|Experimental|Placebo, Then Dalfampridine|Participant first receive Placebo tablet orally every 12 hours, for a 4 weeks period. After a washout period of 2 weeks, they then receive Dalfampridine at an oral dose of 10mg every 12 hours, for 4 weeks.
88854046|NCT01811472|Placebo Comparator|Placebo|Patients randomized to Placebo arm, received matching placebo to 5 mg, 10 mg and 20 mg pradigstat (LCQ908) once daily for 24 weeks. Each patient was to receive 3 tablets a day. All patients were required to remain on their American Heart Association (AHA) diet for the entire duration of the study.
89381139|NCT03170856|No Intervention|Usual Care Group|These patients will not undergo a sub-maximal exercise training. They will follow the exercise instructions given to them by their physician.
89381140|NCT03139968|Experimental|Radiation absorbing drape|Conventional protection measurements. Additionally, a lead-free protective, disposable drape containing bismuth and antimony (RADPAD®) is placed onto the sterile drape on the patient between the operator and the image intensifier.
88854047|NCT01811472|Experimental|pradigastat (LCQ908) 5mg/10mg|Patients, randomized to pradigastat 5/10 mg, initially began with pradigastat (LCQ908) 5 mg once daily and then were up-titrated, if pradigastat (LCQ908) 5 mg once daily was tolerated, to pradigastat 10 mg once daily at Week 2. Total treatment duration was 24 weeks. Each patient was to receive 3 tablets a day. All patients were required to remain on their American Heart Association (AHA) diet for the entire duration of the study.
88854048|NCT01811472|Experimental|pradigastat (LCQ908) 10mg/20mg|Patients, randomized to pradigastat 10/20 mg, initially began with pradigastat (LCQ908) 10 mg once daily and then were up-titrated, if pradigastat (LCQ908) 10 mg once daily was tolerated, to pradigastat 20 mg once daily at Week 2. Total treatment duration was 24 weeks. Each patient was to receive 3 tablets a day. All patients were required to remain on their American Heart Association (AHA) diet for the entire duration of the study.
88854049|NCT01811238|Experimental|Oxycodone/Naloxone|Single-arm study
89381141|NCT03139968|Active Comparator|Dummy group|Conventional protection measurements. Additionally, a dummy, silicone, disposable drape (appearing identical to the experimental arm) is placed onto the sterile drape on the patient between the operator and the image intensifier.
89381142|NCT03139968|No Intervention|Control goup|Only conventional protection measurements.
88854050|NCT01769508|Experimental|Combined Therapy|Combined Modality Treatment of Radiation therapy, 5-Fluorouracil, Oxaliplatin and Lapatinib followed by Surgery
88854051|NCT04576260|Experimental|CBT-I Group|Participants in the CBT-I group will undertake weekly sessions for a duration of 8 weeks with a trained psychologist through Zoom or Skype Calls.
89183128|NCT05588479|Placebo Comparator|Control|Capsules with no pomegranate extract One capsule to be administered once a day for 12 weeks.
89183129|NCT05588479|Experimental|Intervention|Capsules with 500 mg of pomegranate extract One capsule to be administered once a day for 12 weeks.
89183130|NCT05575063|Experimental|Investigational Healon EndoCoat|Eligible subjects to be randomly assigned to receive investigational Healon EndoCoat in one eye and control Healon EndoCoat in fellow eye.
89183131|NCT05575063|Active Comparator|Control Healon EndoCoat|Eligible subjects to be randomly assigned to receive investigational Healon EndoCoat in one eye and control Healon EndoCoat in fellow eye.
89183132|NCT05566639|Experimental|mRNA-1010|Participants will receive a single dose of mRNA-1010 by intramuscular (IM) injection on Day 1.
89183133|NCT05566639|Active Comparator|Licensed Quadrivalent Inactivated Seasonal Influenza Vaccine|Participants will receive a single dose of licensed quadrivalent inactivated seasonal influenza vaccine by IM injection on Day 1.
89183134|NCT05563948|Experimental|High THC : High CBD|Cannabis that is high in THC and high in CBD will be administered.
89183135|NCT05563948|Experimental|High THC : Low CBD|Cannabis that is high in THC and low in CBD will be administered.
89183136|NCT05563948|Experimental|Low THC : High CBD|Cannabis that is low in THC and high in CBD will be administered.
89183137|NCT05563948|Placebo Comparator|Low THC : Low CBD|Cannabis that is low in THC and low in CBD will be administered.
89183138|NCT05560529|Experimental|DBT (Group A)|DBT to be applied over 20 weeks
89183139|NCT05560529|Active Comparator|TAU (Group B)|TAU to be applied over 20 weeks
89183140|NCT05534646|Active Comparator|Apalutamide monotherapy|After progression, subjects will crossover to combination therapy
89183141|NCT05534646|Experimental|Combination therapy (Apalutamide + Carotuximab)|
89183142|NCT05530980|Experimental|GameDay Ready Program|The GameDay Ready Program is a 12-week, football-themed, behavioral weight management intervention that promotes gradual increases in physical activity, reductions in sedentary time, and improvements in dietary habits through education, self-monitoring of physical activity and diet, personalized goal setting, group-based competition, social support, identifying and overcoming barriers, and including physical activity as a substantial component of meeting sessions. The program is sensitive to unique cultural influences surrounding gender, race, and rurality; and issues related to motivation are threaded throughout the program.
89183143|NCT05525858||Tier 1. Therapeutic use of investigational products (KOSMOS-II drugs)|If there are no drugs available under current regulation or patients are not feasible to any clinical trials, and If tumors have actionable genetic alterations and approved drug in any indications but tumor type is not indicative, the MTB may recommend one of KOSMOS-II drugs, therapeutic use of investigational products.
89183144|NCT05525858||Tier 2: Alternative treatments|If there are no KOSMOS-II drugs (Tier 1) or clinical trials (Tier 3) appropriate for patients, the MTB may recommend alternative treatment options (e.g., conventional therapy, radiotherapy, or supportive care).
89183145|NCT05525858||Tier 3: Clinical trial|If patient is eligible for clinical trials matched for actionable genomic alterations found in NGS testing, the MTB will recommend enrollment to clinical trials.
89183146|NCT05511363|Experimental|KarXT|Xanomeline and Trospium Chloride Capsules
89183147|NCT05511363|Placebo Comparator|Placebo|Placebo Capsules
89183148|NCT05503030||Nintedanib for CTD-associated PF-ILD patients in Greece|Connective Tissue Disease (CTD)-associated Progressive Fibrosing Interstitial Lung Disease (PF-ILD)
89183149|NCT05502783|Experimental|Fostamatinib Arm|The subjects will receive oral fostamatinib daily for 12 weeks.
89183150|NCT05475886|Experimental|Hydroxyethyl starch (130/0.4) coload group|An initial infusion dose of 500 ml 6% Hydroxyethyl starch (130/0.4) coload simultaneous with spinal anesthesia.
89183151|NCT05468697|Experimental|Part 1 - Beltuzifan 120 mg + Palbociclib 75 mg|Participants receive beltuzifan 120 mg orally once per day (QD) and palbociclib 75 mg orally QD in a 28-day schedule (21 days on followed by 7 days off), until progressive disease or discontinuation.
89183152|NCT05468697|Experimental|Part 1 - Beltuzifan 120 mg + Palbociclib 100 mg|Participants receive beltuzifan 120 mg orally QD and palbociclib 100 mg orally QD in a 28-day schedule (21 days on followed by 7 days off), until progressive disease or discontinuation.
89183153|NCT05468697|Experimental|Part 1 - Beltuzifan 120 mg + Palbociclib 125 mg|Participants receive beltuzifan 120 mg orally QD and palbociclib 125 mg orally QD in a 28-day schedule (21 days on followed by 7 days off), until progressive disease or discontinuation.
89183154|NCT05468697|Experimental|Part 2 - Beltuzifan 120 mg + Palbociclib|Participants receive beltuzifan 120 mg orally QD and palbociclib orally QD in a 28-day schedule (21 days on followed by 7 days off), until progressive disease or discontinuation. Palbociclib will be administered at a dosage level determined in Part 1.
89183155|NCT05468697|Experimental|Part 2 - Beltuzifan 120 mg|Participants receive beltuzifan 120 mg orally QD until progressive disease or discontinuation.
89183156|NCT05461521||Family members of patients admitted to the ICU|
88854052|NCT04576260|No Intervention|Control group|The control group will be asked to maintain the usual lifestyle for the duration of the study
89183157|NCT05461521||Health care professionals|
89183158|NCT05461521||Patients|
88854053|NCT01810380|Placebo Comparator|Placebo|
89183159|NCT05446740|Experimental|YA GSK4382276A Dose level 1 Group|Eligible young adults (YA) participants receive dose level 1 of GSK4382276A study intervention administered at Day 1.
89183160|NCT05446740|Experimental|YA GSK4382276A Dose level 2 Group|Eligible young adults (YA) participants receive dose level 2 of GSK4382276A study intervention administered at Day 1.
88810428|NCT06213506|Experimental|Infants_6W_Dose B_2 Group|Infants 6 weeks of age, part of the dose-finding cohort, randomized to receive 3 doses of the iNTS-GMMA Dose B vaccine at Day 1, Day 57 (during the Priming phase) and at Day 232 (during the Booster phase). These infants also receive an EPI vaccination with the following vaccines: Measles and Rubella Vaccine (MR-VAC) and Yellow Fever (YF) vaccine administered concomitantly during the last iNTS-GMMA administration at Day 232, and the pentavalent vaccine (DTPwHepB-Hib), the Pneumococcal conjugate vaccine, and the inactivated polio vaccine administered at the same time, at 6, 10 and 14 weeks of age, at the local EPI vaccination centers, and not part of the current clinical trial.
88854054|NCT01810380|Experimental|Brexpiprazole|Patients randomised to brexpiprazole received 1mg/day on Day 1, 2mg/day on Day 2, 3mg/day on Day 3 (uptitration); the dose could be adjusted from Day 4 onwards to 2, 3, or 4mg/day to optimise the clinical effect and tolerability.
88854055|NCT01810380|Other|Quetiapine extended release|Active Reference. Patients randomised to quetiapine received 300mg/day on Day 1, 600mg/day on Days 2 and 3 (uptitration); the dose could be adjusted from Day 4 onwards to 400, 600, or 800mg/day to optimise the clinical effect and tolerability.
88854056|NCT01769196|Experimental|Simtuzumab|Participants will receive simtuzumab for up to 254 weeks.
88854057|NCT01769196|Placebo Comparator|Simtuzumab Placebo|Participants will receive simtuzumab placebo for up to 254 weeks.
88854058|NCT01810302|Experimental|Nicardipine hydrochloride|Nicardipine hydrochloride 4mg by intrathecal administration twice a day until post-hemorrhage day 10.
88854059|NCT01810302|Placebo Comparator|Preservative-free normal saline|Preservative-free normal saline 1.6 mL by intrathecal administration twice a day until post-hemorrhage day 10.
88854060|NCT01783938|Experimental|Cohort A: Nivolumab followed by Ipilimumab|"Nivolumab 3 mg/kg solution intravenously every 2 weeks up to 6 doses in Induction period and 3 mg/kg solution intravenously every 2 weeks until disease progression, unacceptable toxicity, or withdrawal of consent in Continuation period for a maximum of 2 years from 1st study treatment in Induction Period 1.~Ipilimumab 3 mg/kg solution intravenously every 3 weeks up to 4 doses in Induction period."
88854061|NCT01783938|Experimental|Cohort B: Ipilimumab followed by Nivolumab|"Ipilimumab 3 mg/kg solution intravenously every 3 weeks up to 4 doses in Induction period.~Nivolumab 3 mg/kg solution intravenously every 2 weeks up to 6 doses in Induction period and 3 mg/kg solution intravenously every 2 weeks until disease progression, unacceptable toxicity, or withdrawal of consent in Continuation period for a maximum of 2 years from 1st study treatment in Induction Period 1."
88854062|NCT01768572|Experimental|Sarilumab 150 mg q2w|Sarilumab 150 mg subcutaneous (SC) injection once every 2 weeks (q2w) and placebo intravenous (IV) infusion once every 4 weeks (q4w) was added to one or a combination of the nonbiologic disease modifying antirheumatic drug (DMARD), hydroxychloroquine, methotrexate, sulfasalazine and/or leflunomide for 24 weeks, except for the simultaneous use of leflunomide and methotrexate.
88854063|NCT01768572|Experimental|Sarilumab 200 mg q2w|Sarilumab 200 mg SC injection q2w and placebo IV infusion q4w was added to one or a combination of the nonbiologic DMARD, hydroxychloroquine, methotrexate, sulfasalazine and/or leflunomide for 24 weeks, except for the simultaneous use of leflunomide and methotrexate.
88854064|NCT01768572|Active Comparator|Tocilizumab q4w|Tocilizumab 4 mg/kg or 8 mg/kg IV infusion q4w and placebo SC injection q2w was added to one or a combination of the nonbiologic DMARD, hydroxychloroquine, methotrexate, sulfasalazine and/or leflunomide for 24 weeks, except for the simultaneous use of leflunomide and methotrexate.
88854065|NCT01783548|Experimental|BDP Nasal Aerosol 80 mcg/day|BDP nasal aerosol: 80 mcg dose once daily in the morning. Participants/parents administer 40 mcg BDP (one spray per nostril) during the 12-week Treatment Period.
88854066|NCT01783548|Placebo Comparator|Placebo Nasal Aerosol|Placebo nasal aerosol: Participants/parents administer placebo (no medication) (one spray per nostril) once daily in the morning during the 12-week Treatment Period.
88854067|NCT01809210|Experimental|Selumetinib+standard chemotherapy|Selumetinib plus gemcitabine; or pemetrexed and cisplatin or carboplatin
88854068|NCT01809132|Experimental|Anakinra & Pentoxifylline & Zinc Sulfate|anakinra 100mg subcutaneous injection daily for 14 days pentoxifylline 400 mg orally three times daily for 28 day zinc sulfate 220 mg orally for 180 days
88854069|NCT01809132|Active Comparator|Methylprednisolone|methylprednisolone 32 mg orally daily for 28 days
88854070|NCT01809132|No Intervention|Observational|Individuals who choose not to participate in the interventional arm of the trial will be receive standard care and be observed for 6 months. They will be enrolled to have baseline and interval health information and laboratory results collected.
88854071|NCT01808508|Active Comparator|Group 1- Continuous positive airway pressure (CPAP)|Group 1 will receive therapeutic CPAP for 4 months.
88854072|NCT01808508|Placebo Comparator|Group 2-Sham Continuous positive airway pressure (CPAP)|Group 2 are individuals with OSAS who will receive sham or placebo continuous positive airway pressure (CPAP) for 4 months.
88854073|NCT01808508|No Intervention|Group 3- No Intervention|Group 3 are individuals with normal breathing during sleep who will not receive any intervention and will be used as a control group.
88854074|NCT01766778|Active Comparator|LAF237 (vildagliptin) 50mg once daily (QD)|Vildagliptin 50mg QD plus stabilized or maximum tolerated dose of Metformin
88854075|NCT01766778|Active Comparator|LAF237 (vildagliptin) 50mg twice daily (BID)|Vildagliptin 50mg BID plus stabilized or maximum tolerated dose of Metformin
88854076|NCT01808196|Experimental|Losartan|Participants with eosinophilic esophagitis receive Losartan daily
88854077|NCT01808118|Experimental|Double-Blind Adalimumab|40 mg every other week (eow), Weeks 28-68. Blinded adalimumab was discontinued in participants who met the criteria for flare.
88854078|NCT01808118|Experimental|Open-label (OL) Adalimumab|40 mg every other week (eow), Weeks 0-28. If participants flared during the double-blind period, they had an opportunity to receive at least 12 weeks of open-label adalimumab 40 mg eow.
88854079|NCT01808118|Placebo Comparator|Placebo|Placebo every other week (eow), Weeks 28-68. Placebo was discontinued in participants who met the criteria for flare.
88875367|NCT05371704|Other|Control|In this arm of the study, participants will not supplement with any multivitamin. If this is the participant's first trial, they will record their diet in a 10-day estimated food diary. If this is the participant's second trial, they will replicate the diet recorded from their first trial.
88875368|NCT05371392||patient group|
88875369|NCT05371392||control group|
88854080|NCT01807650|Experimental|Oleogel-S10, non-adhesive wound dressing|A split-thickness skin graft (STSG) donor site wound >15cm2 in size was divided in 2 halves. One half was randomized to Oleogel-S10 treatment and non-adhesive wound dressing (intra-individual comparison). Oleogel-S10 was administered (1 cm or 100 mg per cm2 wound area corresponding to thickness of about 1 mm or 0.04 inch) every 3 to 4 days until 95% epithelialization of the wound or end of treatment at Day 28.
89183161|NCT05446740|Experimental|YA GSK4382276A Dose level 3 Group|Eligible young adults (YA) participants receive dose level 3 GSK4382276A study intervention administered at Day 1.
89183162|NCT05446740|Experimental|YA GSK4382276A Dose level 4 Group|Eligible young adults (YA) participants receive dose level 4 of GSK4382276A study intervention administered at Day 1.
89183163|NCT05446740|Experimental|YA GSK4382276A Dose level 6 Group|Eligible YA participants receive dose level 6 of GSK4382276A study intervention administered at Day 1.
89183164|NCT05446740|Experimental|YA GSK4382276A Dose level 7 Group|Eligible YA participants receive dose level 7 of GSK4382276A study intervention administered at Day 1.
89183165|NCT05446740|Experimental|YA GSK4382276A Dose level 8 Group|Eligible YA participants receive dose level 8 of GSK4382276A study intervention administered at Day 1.
89183166|NCT05446740|Experimental|YA GSK4382276A Dose level 9 Group|Eligible YA participants receive dose level 9 of GSK4382276A study intervention administered at Day 1.
89183167|NCT05446740|Experimental|YA GSK4382276A Dose level 10 Group|Eligible YA participants receive dose level 10 of GSK4382276A study intervention administered at Day 1.
89183168|NCT05446740|Experimental|YA GSK4382276A Dose level 11 Group|Eligible YA participants receive dose level 11 of GSK4382276A study intervention administered at Day 1.
89183169|NCT05446740|Active Comparator|YA Control 1 Group|Eligible YA participants receive single dose of FDQ21A-NH administered at Day 1.
89183170|NCT05446740|Active Comparator|YA Control 2 Group|Eligible YA participants receive single dose of FDQ22A-NH administered at Day 1.
89183171|NCT05446740|Experimental|OA GSK4382276A Group|Eligible OA participants receive single dose of GSK4382276A study intervention at 1 dose level selected from the first 3 dose levels in YAs, administered at Day 1.
89183172|NCT05446740|Active Comparator|OA Control Group|Eligible OA participants receive single dose of FDQ21A-NH administered at Day 1.
89183173|NCT05442216|Experimental|Experimental Group|"During Cycle 1 and Cycle 2:~Tagraxofusp will be administered intravenously (12 mcg/kg) on days 1-5 of Cycle 1-2 (Cycle is 21 days)~During Cycles 3-12:~Subjects with a marrow CR after Cycle 2 will continue tagraxofusp ONLY for Cycles 3-12 (up to a year of treatment) on Days 1-5 of a 28 day cycle.~For subjects without a marrow CR, azacitidine will be administered intravenously (75 mg/m2) on days 1-7 of Cycle 3-12 (Cycle is 28 days) and tagraxofusp will be administered intravenously (12 mcg/kg) on days 1-3 of Cycle 3-12 (Cycle is 28 days).~Subjects who achieve a marrow CR receiving tagraxofusp only after Cycle 4, will continue tagraxofusp at 12 mcg/kg IV for 5 consecutive days every 28 days until Cycle 12. Subjects who continue to achieve an overall response (CR, CRi, PR, MLFS, marrow CR) receiving tagraxofusp and azacitidine will continue tagraxofusp at 12 mcg/kg IV for 3 consecutive days and azacitidine 75 mg/m2 SQ or IV on Days 1-7 every 28 days until Cycle 12."
89183174|NCT05439382||Langer & Langer technique|Participants undergoing Langer & Langer surgical technique
89183175|NCT05439382||Nelson' modified technique|Participants undergoing Nelson' modified surgical technique
89183176|NCT05439382||Coronally advanced flap and subepithelial graft|Participants undergoing Coronally advanced flap and subepithelial graft surgical technique
89183177|NCT05436535|Experimental|Dupilumab-naïve atopic dermatitis participants|"On Day 7, dupilumab-naïve AD participants will begin applying topical corticosteroids twice daily to their specified target area, as well as to active lesions on non-target skin.~Dupilumab-naïve AD participants will return for a Steroid Assessment Visit at Day 35, when response to topical corticosteroids will be evaluated at the target site by TAA and targeted EASI scoring, and overall management of AD body-wide by topical steroid/moisturizer treatment will be evaluated by EASI score.~Participants who are responsive to topical corticosteroids will continue to use them body-wide through Day 140. Participants who are non-responsive to topical corticosteroids at any time before Day 91 will begin use of dupilumab through their penultimate scheduled visit (Day 140-Day 196) and may continue use of topical corticosteroids outside of their specified target area as needed."
89183178|NCT05436535|Experimental|Experienced Dupilumab atopic dermatitis participants|"AD participants already on dupilumab (for >= 4 months prior to study entry (20 children, 40 adults)) at the start of the study will continue treatment with dupilumab as prescribed by their physician outside of the study. They may also continue treatment with other prescribed topical AD medications outside of the specified target skin area throughout the study; they may continue treatment with other prescribed topical AD medications within the specified target area from Day 7 through Day 140.~Long-term dupilumab participants will apply Vanicream™ beginning at Day 0 through Day 7. Long-term dupilumab participants will return for assessment visits at Day 63 and 140. At Day 140, participants will resume application of Vanicream™ through the End of Study Assessment (Day 168)."
89183179|NCT05436535|Active Comparator|Non-atopic dermatitis participants|Approximately 150 will be non-AD controls (including approximately 50 children, 6-17 years of age, and 100 adults, = 18 years of age) Non-AD control participants will apply Vanicream™ beginning at Day 0 through Day 7. Non-AD control participants will return for assessment visits at Day 35, 91, and 140. At Day 140, participants will resume application of Vanicream™ through the End of Study Assessment (Day 168).
89381143|NCT04377919|Active Comparator|Cranberry|Administration of 2 capsules with 500mg (Miralys Ltda) of cranberry extract per day, for 8 weeks
88854081|NCT01807650|Other|Non-adhesive wound dressing only|A STSG donor site wound >15cm2 in size was divided in 2 halves. One half was randomized to treatment with non-adhesive wound dressing only (intra-individual comparison). Non-adhesive wound dressings are standard of care (SOC) in the treatment of STSG donor sites. Wound dressings were changed every 3 to 4 days.
89183180|NCT05429268|Experimental|Tafasitamab and Lenalidomide|Tafasitamab and lenalidomide will be coadministered for up to 12 cycles (28 days per cycle).followed by tafasitamab monotherapy (in participants with stable disease or better) until treatment withdrawal criteria are met.
89381144|NCT04377919|Placebo Comparator|Placebo|Administration of 2 capsules with 500mg of maize starch per day, for 8 weeks
89381145|NCT03043560|Experimental|Ezogabine|Participants will receive treatment with ezogabine up to 900mg/day.
89381146|NCT03043560|Placebo Comparator|Placebo|Participants will receive treatment with a matching placebo pill.
89381147|NCT04051554|Experimental|Neuromuscular and Proprioceptive Training|Myklebust's training program
89381148|NCT04051554|Active Comparator|Conventional Training|Running, Sprints, Agility training, and Dynamic stretching
89381149|NCT04051476|Experimental|3-g footbath|Footbath with 3g ginger flour per liter of water
89381150|NCT04051476|Experimental|6-g footbath|Footbath with 6g ginger flour per liter of water
89381151|NCT04051476|Experimental|12-g footbath|Footbath with 12g ginger flour per liter of water
89381152|NCT04051476|Placebo Comparator|Warm water footbath|Footbath with warm water only
89381153|NCT02145403|Experimental|Carfilzomib|Carfilzomib will be administered IV over 30 minutes, starting at dose level 1 (20 mg/m2 IV) on Day +1, +2, +6 and +7.
89381154|NCT03255733|Experimental|Intense Therapeutic Ultrasound Treatment|Intense Therapeutic Ultrasound applied along and length and width of the Common Extensor Tendon. 80, 1 Joule pulses were applied twice, four weeks apart.
89381155|NCT03255655|Experimental|ITU Treatment|Intense Therapeutic Ultrasound (ITU) treatment applied along the length and width of the Plantar Fascia: 350 - 5 Joule pulses were applied twice, two weeks apart.
89381156|NCT03255655|Placebo Comparator|Sham ITU Treatment|Sham / Placebo Intense Therapeutic Ultrasound treatment (ITU) applied along the length and width of the Plantar Fascia: 350 - 0 Joule pulses were applied twice, two weeks apart.
89381157|NCT02899988|Experimental|30 mg Mirikizumab|30 mg Mirikizumab administered subcutaneously (SC) every 8 weeks (Q8W).
89381158|NCT02899988|Experimental|100 mg Mirikizumab|100 mg Mirikizumab administered SC Q8W.
89381159|NCT02899988|Experimental|300 mg Mirikizumab|300 mg Mirikizumab administered SC Q8W.
89381160|NCT02899988|Placebo Comparator|Placebo|Placebo administered SC Q8W.
89183181|NCT05425784|Experimental|Lumoral Treatment (Study group)|"Subjects will receive detailed instructions for the use of Lumoral treatment -device and Lumorinse -tablets. Subjects will be instructed to use the Lumoral treatment -device and follow the protocol five to seven (5-7) times a week. Regular use shall be defined as frequency of a minimum of twice a week.~Standard oral hygiene instructions will be provided verbally and in writing. In addition, an electric toothbrush will be provided to all subjects."
89381161|NCT02939131|Experimental|COMB-R|Health and Wellness Cognitive Behavioral Therapy and Medication Management (COMB-R) intervention
89381162|NCT02939131|Active Comparator|Enhanced Standard of Care|Enhanced Standard of Care (ESC)
89381163|NCT04052282||Mobile Health App - Healthy Individuals|"Mobile health App - Test~Beta Testing 1: The Beta test 1 will be performed with participants inside the Research Center. The purpose of this phase is to increase usability, acceptability and reliability of the mHealth App in participants.~Beta Testing 2: The Beta test 2 will be performed with patients outside the Research Center, at their houses. The purpose is to focus on the mHealth App remote usability, acceptability, and data collection."
89381164|NCT03646526|Experimental|Fast group|"During the study session, healthy subjects will be administered a single dose of Amitriptyline Hydrochloride 25Mg Tablet（Hunan Dongting） or Amitriptyline Hydrochloride 25Mg Tablet（Sandoz） under fasting condition .~cycle 1 Drug: Amitriptyline Hydrochloride 25Mg Tablet（Hunan Dongting）/cycle 2 Drug: Amitriptyline Hydrochloride 25Mg Tablet（Sandoz） or cycle 1 Drug: Amitriptyline Hydrochloride 25Mg Tablet（Sandoz）/cycle 2 Drug: Amitriptyline Hydrochloride 25Mg Tablet（Hunan Dongting）"
89381165|NCT03646526|Experimental|Feeding group|"During the study session, healthy subjects will be administered a single dose of Amitriptyline Hydrochloride 25Mg Tablet（Hunan Dongting） or Amitriptyline Hydrochloride 25Mg Tablet（Sandoz） under feeding condition.~cycle 1 Drug: Amitriptyline Hydrochloride 25Mg Tablet（Hunan Dongting）/cycle 2 Drug: Amitriptyline Hydrochloride 25Mg Tablet（Sandoz） or cycle 1 Drug: Amitriptyline Hydrochloride 25Mg Tablet（Sandoz）/cycle 2 Drug: Amitriptyline Hydrochloride 25Mg Tablet（Hunan Dongting）"
89381166|NCT03643640|Experimental|Optimune|Optimune is an web-based psychological intervention for women with breast cancer. Beyond established CBT techniques targeting depression, anxiety, and fatigue, this intervention specifically includes elements that have shown effects on markers of immune status and inflammation, including sleep, stress management (e.g., mindfulness-based techniques) and lifestyle optimization (dietary and physical activity advice). Content is continuously adapted to users' concerns and needs. It contains interactive dialogues that can be accessed via computer or smart-phone, illustrations, audio files and motivating text messages. Optional daily text messages with motivational content accompany the program. The program can be accessed for 365 days after registration.
89381167|NCT03643640|Active Comparator|Care-as-Usual|As in the experimental arm, participants are free to continue to engage with any treatment they require (i.e., CAU). However, they will receive access to Optimune six months post-baseline (i.e., wait list with respect to Optimune access).
89381168|NCT04166994|Experimental|IMPACT Intervention|Incorporate a rehabilitation approach to slowly increasing KT recipients' physical activity in addition to individualized dietary intervention at every post-transplant appointment through six months post-transplant, with follow-up at 12 months post-transplant.
88854082|NCT01782690||Erlotinib plus Gemcitabine|Patients with metastatic pancreatic cancer, who were planned to receive combination therapy of erlotinib and gemcitabine based on the investigator's assessment.
88854083|NCT01782378|Active Comparator|Real LED Treatment Series|Participants in this group receive a series of 15 real LED treatments with the helmet and intranasal devices: Transcranial NIR, 830nm LED Helmet and two intranasal nose clips (633 nm, and 810 nm, Vielight, Inc., Toronto), 28-minute treatment, 2 days/ week, 7.5 weeks, at least 48 hours between treatments. Additionally, two NIR 870nm LED cluster heads (MedX Health, Toronto) were placed over the L and R ears during the last 4 minutes of the treatment session. LEDs are FDA-cleared, non-significant risk. Both the participant and the person performing the treatment wore goggles that block red wavelength (from the red intranasal). Real or Sham LED devices look and feel identical.
89381169|NCT04166994|Other|Usual Care|No exercise or diet specialization.
89183182|NCT05425784|Active Comparator|Standard of care (Control group)|Standard oral hygiene instructions will be provided verbally and in writing. In addition, an electric toothbrush will be provided to all subjects.
89183183|NCT05421416|Experimental|Loratadine Arm|Loratadine 10mg, administered initially 3 hours before the first dose of G-CSF in the autologous stem cell mobilization protocol, and then daily for a minimum of 8 days.
89183184|NCT05421416|Placebo Comparator|Placebo Arm|Placebo capsule, administered initially 3 hours before the first dose of G-CSF in the autologous stem cell mobilization protocol, and then daily for a minimum of 8 days.
89183185|NCT05415137|Experimental|Efzofitimod 3 mg/kg|
89183186|NCT05415137|Experimental|Efzofitimod 5 mg/kg|
89183187|NCT05415137|Placebo Comparator|Placebo|
89183188|NCT05414097||Phase 1: 24 Women - FGDs|Focus groups enrolling HIV-positive, previously screened for cervical cancer; HIV-positive, not previously screened for cervical cancer; HIV-negative, previously screened for cervical cancer; HIV-negative, not previously screened for cervical cancer.
89183189|NCT05414097||Phase 1: 16 Men - FGDs|Focus groups enrolling male partners referred by women previously screened or treated for cervical cancer and by women not previously screened for cervical cancer.
89183190|NCT05414097||Phase 1: 12 Key Stakeholders - IDIs|Stakeholder interviewers with women's groups, women's health providers, laboratory personnel, NGOs, and public health organizations.
89183191|NCT05414097||Phase 2: 300 women - DCE|Discrete Choice Experiment enrolling women 18 years of age and older.
89183192|NCT05414097||Phase 3: 36 Women, women's health providers, and policy makers|Stakeholder groups comprising individuals 18 years and older who participated in Phase 1 will be eligible.
89183193|NCT05413811|Experimental|5 Fluorouracil Cream|The participants will receive 8 doses of intravaginal 5 Fluorouracil Cream.
89183194|NCT05413811|Placebo Comparator|Placebo Cream|The participants will receive 8 doses of intravaginal placebo cream.
89183195|NCT05413798|Other|Single Arm|This is a single arm study. All participants will receive same interventions.
89183196|NCT05405582|Experimental|community-based differentiated biosocial HIV prevention (incl. PrEP) with SRH|The intervention is available to all 15-30 year olds residing in the intervention cluster. Area based peer navigators mobilise all young people living in their cluster. They provide sexual health promotion, condoms, HIV self-tests, pregnancy test, and conduct structured psychosocial and health needs assessment with the young people they support. Based on the needs assessment they develop a tailored plan which includes, varying degrees of peer-mentorship and psychosocial support, lay-counselling and ART/PrEP adherence support. The peer navigators refer young people to mobile SRH services. The mobile SRH services provide gender and HIV status neutral nurse-led HIV testing, Individualised risk assessments for HIV care and PrEP, contraception and wider SRH services. The nurses liaise with the peer navigators to provide ongoing support for 3-monthly follow-ups with repeat HIV testing, adherence support and PrEP/ART/contraception refills.
89183197|NCT05405582|Active Comparator|Standard of Care|SOC is available to all young people in the delayed clusters. Care is provided in a nurse led Primary Health Clinics (PHC) to young people who attend the clinic. This includes HIV counselling and point of care testing, immediate initiation of ART if positive and PrEP if negative and eligible according to South African National PrEP guidelines. This is followed by a 3-monthly follow-up with repeat HIV testing, safety bloods, clinic-based counselling and adherence support and PrEP/ART refills. Clinic attendees are offered family planning support and syndromic management for STIs (as per South African National Department of Health Guideline).
89183198|NCT05396898|Experimental|LCP-tacrolimus (Envarsus®)|"Patients in this arm start (after randomization) on LCP-tacrolimus therapy.~At midterm of study participation (16 weeks), a switch is made to twice-daily tacrolimus (Prograf® ) therapy.~The duration of the trial for each subject is expected to be 32 weeks."
89183199|NCT05396898|Active Comparator|twice-daily tacrolimus (Prograf®)|"Patients in this arm start (after randomization) on twice daily tacrolimus (Prograf®) therapy.~At midterm of study participation (16 weeks), a switch is made to LCP-tacrolimus (Envarsus®) therapy. The duration of the trial for each subject is expected to be 32 weeks."
89183200|NCT05388435|Experimental|Part 1: Dose Escalation Phase|Part 1 is a dose escalation phase to evaluate the safety, tolerability, and define the MTD and RP2D. Part 1 is a 3+3 design.
89183201|NCT05388435|Experimental|Part 2: Dose Expansion Phase|Part 2 includes tumor-specific expansion cohorts utilizing the MTD/RP2D doses (determined from Part 1) to further explore safety and anti-tumor activity of SKL27969, in addition to the PK and PD from the patients with the selected tumor types.
89183202|NCT05388292|Other|Development of triage decision support system|"This is a quasi-experimental study with a single-group pre-test and post-test design.~The study consisted of three stages. In the first stage, a structured Query Language Script was developed to evaluate the accuracy and duration of pre-and post-DSS triage decisions. In the second stage (pre-test), the accuracy and duration of pre-DSS triage decisions were evaluated. In the second stage, a DSS was prepared with rule-based decision trees method using the ESI and ATS algorithms and was integrated into the HIMS. In the third and last stage (post-test), the effect of the developed Emergency Triage Decision Support System on triage management was evaluated against the accuracy and duration of triage decisions."
89183203|NCT05384587|Experimental|Asciminib|80 mg initial oral dose taken once a day with possible dose escalation
89183204|NCT05375825|Experimental|1/ Dose Escalation|LMB-100 at escalating/de-escalating doses + MSLN testing
89183205|NCT05375825|Experimental|2/ Dose Expansion|LMB-100 at the MTD + MSLN testing
89183206|NCT05373719||0-2 Years of Age|Patients from birth to 2 years of age at time of study entry
89183207|NCT05373719||3-5 Years of Age|Patients aged 3 to 5 years at time of study entry
89183208|NCT05373719||6-12 Years of Age|Patients aged 6 to 12 years at time of study entry
89183209|NCT05373719||13-55 Years of Age|Patients aged 13 to 55 years at time of study entry
89183210|NCT05373381|Experimental|Supplemental High Fat Low Carbohydrate (sHFLC) + KetoPhyt|Subjects will adhere to the sHFLC + KetoPhyt diet for six 4-week cycles.
89183211|NCT05369273|Experimental|adipose graft + Platelet Rich Plasma|
89183212|NCT05369273|Other|adipose graft|
89183213|NCT05358301|Experimental|Probiotic|Probiotic food supplement produced by SYNBIOTEC S.r.l.
89183214|NCT05358301|Placebo Comparator|Placebo|Placebo food supplement.
89183215|NCT05358210|Experimental|Blueberry Consumption|Randomized participants will consume 1 cup of frozen blueberries, provided by the trial, daily for 12 weeks.
89183216|NCT05358210|Active Comparator|Dried Date Consumption|Randomized participants will consume 2-3 dried dates, provided by the trial, daily for 12 weeks.
89183217|NCT05351580||Advanced Parkinson's disease patients who receive advance therapy during the study|All participants will have advanced Parkinson's disease and undergo smart watch monitoring. Participants in this cohort will be those who receive advance therapy during the study.
89381170|NCT03644420||Knee osteoarthritis|"Patients with knee osteoarthritis, classified Kellgren-Lawrence 3 or 4, with asymmetric femorotibial joint space narrowing that will follow a surgery for a prosthetic replacement of the knee wil follow the following interventions:~Clinical evaluation~Radiographic assessment of osteoarthritis~Magnetic resonance imaging (MRI)~Histological evaluation of the surgical piece"
89381171|NCT03646292|Experimental|Pioglitazone monotherapy|Pioglitazone 15mg 1T daily for 6 months
89381172|NCT03646292|Experimental|Empagliflozin monotherapy|Empagliflozin 10mg 1T daily for 6 months
89381173|NCT03646292|Experimental|Pioglitazone + Empagliflozin combination therapy|Pioglitazone 15mg + Empagliflozin 10mg combination 1T daily for 6 months
89381174|NCT03345407|Placebo Comparator|placebo once daily|Eligible subjects will receive placebo ELLIPTA dry powder (blended with lactose) for oral inhalation once daily in the morning for 12 weeks. Albuterol (Salbutamol) MDI or nebules will also be provided to all subjects for use as rescue medication as needed.
89381175|NCT03345407|Experimental|Nemiralisib 50 µg once daily|Eligible subjects will receive nemiralisib ELLIPTA 50 µg dry powder (blended with lactose and magnesium stearate) for oral inhalation once daily in the morning for 12 weeks. Albuterol (Salbutamol) MDI or nebules will also be provided to all subjects for use as rescue medication as needed.
89381176|NCT03345407|Experimental|Nemiralisib 100 µg once daily|Eligible subjects will receive nemiralisib ELLIPTA 100 µg dry powder (blended with lactose and magnesium stearate) for oral inhalation once daily in the morning for 12 weeks. Albuterol (Salbutamol) MDI or nebules will also be provided to all subjects for use as rescue medication as needed.
89381177|NCT03345407|Experimental|Nemiralisib 250 µg once daily|Eligible subjects will receive nemiralisib ELLIPTA 250 µg dry powder (blended with lactose and magnesium stearate) for oral inhalation once daily in the morning for 12 weeks. Albuterol (Salbutamol) MDI or nebules will also be provided to all subjects for use as rescue medication as needed.
89381178|NCT03345407|Experimental|Nemiralisib 500 µg once daily|Eligible subjects will receive nemiralisib ELLIPTA 500 µg dry powder (blended with lactose and magnesium stearate) for oral inhalation once daily in the morning for 12 weeks. Albuterol (Salbutamol) MDI or nebules will also be provided to all subjects for use as rescue medication as needed.
89381179|NCT03345407|Experimental|Nemiralisib 750 µg once daily|Eligible subjects will receive nemiralisib ELLIPTA 750 µg dry powder (blended with lactose and magnesium stearate) for oral inhalation once daily in the morning for 12 weeks. Albuterol (Salbutamol) MDI or nebules will also be provided to all subjects for use as rescue medication as needed.
89381180|NCT03621332||Questionnaire adminstration|All patients who participate will complete questionnaires
89381181|NCT01264549|Experimental|PCT guided arm|
89381182|NCT01264549|No Intervention|Control|Standard treatment
89381183|NCT05692752||Test Group|"The study group included 10 patients,~men and women~between age of 35-60 year~chest pain lasting for at least 30 minutes,~electrocardiogram (ECG) finding that display ST-segment elevation (STEMI)"
89381184|NCT05692752||Control Group|"The study group included 10 patients,~men and women~between age of 35-60 year~having no complaint of health issue,"
89381185|NCT03626298|Placebo Comparator|Adapalene and placebo (ADAP)|
89381186|NCT03626298|Experimental|Adapalene, Nicotinamide, ABA, Zinc PCA (ANAZ)|
89381187|NCT03255187|Experimental|Fish oil supplementation|This group receive 2.5 g/day (two 1.25-g capsules daily) of fish oil (marine-derived n-3 PUFA) for 4 consecutive months.
89381188|NCT03255187|Placebo Comparator|Sunflower seed oil supplementation|This group receive 2.5 g/day (two 1.25-g capsules daily) of placebo (sunflower seed oil) for 4 consecutive months.
89381189|NCT03646136|Experimental|Retained Cystoscopy Fluid|Retained 200mL normal saline used for distending media following completion of diagnostic cystoscopy
89183218|NCT05351580||Advanced Parkinson's disease patients who do not receive advance therapy during the study|All participants will have advanced Parkinson's disease and undergo smart watch monitoring. Participants in this cohort will be those who do not receive advance therapy during the study.
89381190|NCT03646136|Active Comparator|Cystoscopy Fluid Emptied|Emptied 200mL normal saline used for distending media following completion of diagnostic cystoscopy
89381191|NCT05508672|Experimental|Community-Centered eHealth Smoking Cessation Intervention (CCeSCI) group|The intervention group will receive Community-Centered eHealth Smoking Cessation Intervention(CCeSCI).
89381192|NCT05508672|Active Comparator|"Traditional smoking is harmful education group"|"The control group to receive the traditional smoking is harmful education."
89381193|NCT03643406|Experimental|Mental Fatigue Condition|
89381194|NCT03643406|Placebo Comparator|Control Condition|
89381195|NCT03643328|Experimental|new haemodialysis patients.|There is an analyse of immune response against S. aureus from new haemodialysis patients by blood samples and nasal swabs.
89381196|NCT04097262|Experimental|Own-Price Elasticity|"The price of fruit will vary (own-price elasticity) while the price of all other foods in the mock grocery store will remain constant."
89183219|NCT05351554|Experimental|Treatment Arm 1|Namilumab with prednisone, or equivalent
89381197|NCT04097262|Experimental|Cross-Price Elasticity|"The price of fruit will remain constant while the price of other foods in the mock grocery store will vary (cross-price elasticity)."
89381198|NCT03644264|Experimental|PA21 tablets containing 500 mg of iron|PA21 chewable tablets standardised to contain 500 mg of iron. PA21 500 mg (iron) chewable tablet contains approximately 2.5 g PA21 drug substance (sucroferric oxyhydroxide). Starting dose will be 1,500 mg/day (3 tablets/day (1 tablet per meal)). Dose increases or decreases of 500 mg/day (1 tablet/day) are permitted. The maximum dose of PA21 will be 3,000 mg/day (6 x 500 mg tablets/day) and the minimum dose will be 1,000 mg/day (2 x 500 mg tablets/day).
89381199|NCT03644264|Active Comparator|Sevelamer carbonate: Renvela® tablets|Starting dose will be 2.4 g/day (3 tablets/day). Dose increases or decreases of 2.4 g/day (3 tablets/day (1 tablet per meal)) The maximum dose of sevelamer carbonate will be 14.4 g/day (18 tablets/day) and the minimum dose will be 2.4 g/day (3 tablets/day).
89381200|NCT04051788|Experimental|Step Aerobics|Step Aerobics Training (120 to 126 foot steps per min)
89381201|NCT04051788|Active Comparator|Aerobic exercise (Lower limb Cycling)|Lower Limb Aerobic cycling
89381202|NCT03641534||Sepsis|
89381203|NCT03641534||Severe malaria|
89381204|NCT03641534||Uncomplicated malaria|
89381205|NCT03643250|Experimental|Smaller Portion Size and Standard Appeal (non-divided plate)|Food with Smaller Portion Size and Standard Appeal on a non-divided plate
89183220|NCT05351554|Placebo Comparator|Treatment Arm 2|Placebo with prednisone, or equivalent
88854084|NCT01782378|Sham Comparator|Sham LED Treatment Series|Participants in this group first receive a series of 15 sham LED treatments with the helmet and intranasal devices containing sham LEDs (no photons were emitted): Transcranial LED Helmet and two intranasal nose clips (sham LEDs, Vielight, Inc., Toronto), 28-minute treatment, 2 days/ week, 7.5 weeks, at least 48 hours between treatments. Additionally, two sham LED cluster heads (MedX Health, Toronto) were placed over the L and R ears during the last 4 minutes of the treatment session. These participants were offered an optional Second Real Series of identical 15 real LED treatments. Both the participant and the person performing the treatment wore goggles that block red wavelength (from the red intranasal). Real or Sham LED devices look and feel identical.
88854085|NCT01766310|Placebo Comparator|placebo|placebo tablet in the same appearance and taste with folic acid orally once a day for 8 weeks of the study
88854086|NCT01766310|Experimental|folic acid|Folic acid tablet 5mg per day orally (5mg/tablet) once a day for 8 weeks of the study
88854087|NCT01765920|Experimental|Ergoferon (5 ml 3 times a day)|"Oral use. Dose per administration: 1 dosing spoon (5ml) without food. For best effect, the solution should be held in the mouth before swallowing.~Dosing scheme. One dose every 30 minutes for the first 2 hours, followed by three more doses spaced regularly during the rest of the day. From day 2 to 5: 1 spoon taken 3 times daily."
88854088|NCT01765920|Placebo Comparator|Placebo (5 ml 3 times a day)|Oral use. Placebo using Ergoferon scheme.
88854089|NCT01782222|Experimental|Rotigotine, high dose|Rotigotine, transdermal patches, maximal 16 mg / 24 hours for patients with advanced Parkinson's Disease and 8 mg / 24 hours for those with early Parkinson's Disease
88854090|NCT01782222|Experimental|Rotigotine, low dose|Rotigotine, transdermal patches, optimal dose, maximal 8 mg / 24 hours for patients with advanced Parkinson's Disease and 6 mg / 24 hours for those with early Parkinson's Disease
88854091|NCT01782222|Placebo Comparator|Placebo|Placebo transdermal patches
88854092|NCT01781832|Experimental|(ARFI)-Derived Shear Wave Velocities|"This is an ultrasound-based new technique using Acoustic Radiation Force Impulse (ARFI). Shear Wave speeds are derived using ARFI.~During ultrasound scanning a sound wave is sent towards tissue. The tissue's movement in response to the wave is measured in Shear Wave Velocity, which can estimate tissue stiffness. This technique may help detect bladder wall thickness and fibrosis (thickening) in the urinary bladder of pediatric patients."
88854093|NCT01807182|Experimental|Treatment (TIL, combination chemotherapy, aldesleukin)|Patients receive cyclophosphamide IV on days -7 to -6 and fludarabine phosphate IV on days -5 to -1. Patients undergo TIL infusion over 30-60 minutes on day 0 and receive aldesleukin IV every 8 hours on days 1-5 for up to a maximum of 14 doses.
88854094|NCT04584762|Sham Comparator|Sham treatment|"The AVPI device software is set in sham mode which does not deliver the therapy to the subject. Neither the subject or the investigator is aware of which mode is being used."
88854095|NCT04584762|Experimental|Active Treatment|"The AVPI device software is set in active mode which delivers the therapy to the subject. Neither the subject or the investigator is aware of which mode is being used."
88854096|NCT01806714|Experimental|Text-based reminder for HPV vaccine/WCC|Parents of adolescents will receive text-based reminders if their adolescent is due for HPV vaccine (dose 1, 2 or 3) or well child care visit
88854097|NCT01806714|Active Comparator|Control arm|Parents of adolescents receive preventive health tips via text messages (not specific to services for which child is due)
88854098|NCT01765764|Experimental|Bimatoprost Solution BID|Bimatoprost solution twice a day (BID) in the morning and in the evening applied to each eyebrow for 7 months.
88854099|NCT01765764|Experimental|Bimatoprost Solution QD|Vehicle to bimatoprost solution in the morning and bimatoprost solution once a day (QD) in the evening applied to each eyebrow for 7 months.
88854100|NCT01765764|Placebo Comparator|Vehicle to Bimatoprost Solution BID|Vehicle to bimatoprost twice a day (BID) in the morning and the evening applied to each eyebrow for 7 months.
89183221|NCT05351554|Experimental|Treatment Arm 3|Namilumab with current dose of prednisone, or equivalent
89183222|NCT05350774|Experimental|IVIg arm|IVIg arm IV immunoglobulin 0.4g/kg/day for 5 days
88854101|NCT01806168|Active Comparator|Low-frequency (1 Hz) rTMS|Low-frequency active stimulation over the right dorsolateral prefrontal cortex (DLPFC) on 5 consecutive days every week for 2 weeks, for a total of 10 therapy sessions, with 37.5 minutes per session.
89183223|NCT05350774|Placebo Comparator|Placebo arm|equivalent volume of Normal Saline for 5 days
89183224|NCT05350202||Cohort receiving empagliflozin|Patients will receive first prescription of empagliflozin as routine therapy for Heart Failure with reduced Ejection Fraction (HFrEF).
89183225|NCT05350202||Cohort receiving drugs with another mechanism of action|Patients will receive Heart Failure therapy with drugs with another mechanism of action.
89183226|NCT05346809|Experimental|Isatuximab and Standard Procedures|Subjects will receive the study drug Isatuximab in addition to standard procedures for transplant
88854102|NCT01806168|Active Comparator|High-frequency (10 Hz) rTMS|High-frequency active stimulation over the right dorsolateral prefrontal cortex (DLPFC) on 5 consecutive days every week for 2 weeks, for a total of 10 therapy sessions, with 37.5 minutes per session.
88854103|NCT01806168|Placebo Comparator|Sham rTMS|Sham stimulation over the right dorsolateral prefrontal cortex (DLPFC) on 5 consecutive days every week for 2 weeks, for a total of 10 therapy sessions, with 37.5 minutes per session.
88854104|NCT01804842|Active Comparator|500 mg Met DR BID|Two doses of 500 mg metformin delayed-release
89183227|NCT05346809|Experimental|Standard procedures|Subjects will receive standard procedures for transplant.
89183228|NCT05341726|Experimental|BREATHE intervention|The patient's primary care provider (PCP) will deliver a brief intervention using motivational interviewing and shared decision making, in a one time 9-minute intervention integrated into an office visit for asthma. PCPs will follow a 4-step script tailored to erroneous asthma and inhaled corticosteroid (ICS) beliefs, as well as ACQ score, measured just prior to the office visit.
89183229|NCT05341726|Active Comparator|Control Intervention|The patient's primary care provider (PCP) will deliver a 9-minute scripted intervention on credible nutrition and lifestyle information. The control intervention is designed to not be specific enough to change strategies related to asthma control.
89183230|NCT05332951||Adult patients followed for multiple sclerosis|
89381206|NCT03643250|Experimental|Smaller Portion Size and Enhanced Appeal (divided plate)|Food with Smaller Portion Size and Enhanced Appeal on a divided plate
89381207|NCT03643250|Experimental|Larger Portion Size and Standard Appeal (non-divided plate)|Food with Larger Portion Size and Standard Appeal on a non-divided plate
89381208|NCT03643250|Experimental|Larger Portion Size and Enhanced Appeal (divided plate)|Food with Larger Portion Size and Enhanced Appeal on a divided plate
89381209|NCT03643250|Experimental|Smaller Portion Size and Standard Appeal (divided plate)|Food with Smaller Portion Size and Standard Appeal on a divided plate
89381210|NCT05692674|Experimental|adjuvant hypofractionated intensity-modulated proton radiotherapy|CTV1: chest wall ± regional lymph drainage area, proton therapy.
89381211|NCT03643094|Experimental|Golden Black Seed|Golden Black Seed, 1 capsule per day for 8 weeks.
89381212|NCT02929329|Experimental|Omecamtiv Mecarbil|Participants received oral omecamtiv mecarbil (OM) twice daily in addition to standard heart failure therapy. The starting dose of OM was 25 mg; At week 4, participants with week 2 OM predose plasma concentrations < 200 ng/mL had their dose increased to 50 mg BID; participants with week 2 predose plasma concentrations ≥ 200 and < 300 ng/mL had their dose increased to 37.5 mg BID and participants with week 2 predose plasma concentrations ≥ 300 ng/mL and < 1000 ng/mL maintained a 25 mg BID dosing regimen.
89381213|NCT02929329|Placebo Comparator|Placebo|Participants received matching placebo tablets twice a day in addition to standard heart failure therapy.
89381214|NCT03240133|Experimental|Part1: BCX7353 750 mg|
89381215|NCT03240133|Experimental|Part 2: BCX7353 500 mg|
89381216|NCT03240133|Experimental|Part 3: BCX7353 250 mg|
89381217|NCT03240133|Placebo Comparator|Parts 1, 2 and 3: placebo|
89381218|NCT03814356|Experimental|IV MPH|All patients will receive IV Methylphenidate (MPH). Patients will receive escalating daily doses of IV MPH starting at 0.5 mg/kg, increasing stepwise to 1.0mg/kg and 2.0 mg/kg unless an adverse event (AE) necessitates dose de-escalation or a serious adverse event (SAE) necessitates that the patient stop participation in the study.
89381219|NCT03642860|Experimental|Active treatment|Triheptanoin oil
89381220|NCT03642860|Placebo Comparator|Placebo treatment|Safflower oil
89381221|NCT03707171|Active Comparator|Liraglutide|12 weeks of liraglutide treatment at adjusting dose, up to 1.8mg/day Drug: liraglutide
89381222|NCT03707171|Placebo Comparator|Placebo|12 weeks of Placebo treatment at adjusting dose Drug:Placebo
89381223|NCT03795246|Experimental|Study Process|Consultation, Biological Test, Pelvic Ultrasound
89381224|NCT03642704|Experimental|Reinforced preventive ARV therapy|The proposed reinforced preventive ARV Therapy will be administrated to all newborns exposed to HIV (zidovudine+lamivudine+nevirapine if the newborn is exposed to HIV-1 or HIV-1/2, zidovudine+lamivudine if the newborns exposed to HIV-2)
89381225|NCT03706937||Paramedical professionals|Paramedical professionals of the Lucien Neuwirth Cancer Institute
89381226|NCT05682833|Experimental|Test|NS therapy + Chlorhexidine/Hyaluronic acid subgingival gel application
89183231|NCT05315570|Experimental|Intervention arm|Study participants will be followed up as per clinical practice and will receive the investigational electronic platform, including an Android-based app. Study subjects will be asked to fill in questionnaires at study entry and during follow-up.
89183232|NCT05315570|No Intervention|Control arm|No specific mobile apps will be provided to study participants, who will be followed as per clinical practice. Study subjects will be asked to fill in questionnaires at study entry and during follow-up.
89183233|NCT05306028|Experimental|Metformin or insulin treatment|
89183234|NCT05305040|Active Comparator|Posoleucel (ALVR105)|Administered as 2-4 milliliter infusion, visually identical to placebo
89183235|NCT05305040|Placebo Comparator|Placebo|Administered as 2-4 milliliter infusion, visually identical to Posoleucel (ALVR105)
89183236|NCT05293860|Experimental|Connective tissue manipulation|Connective tissue manipulation will be applied to participants' back for 5-20 minutes, 3 times a week for 4 weeks in this group.
89183237|NCT05293860|Placebo Comparator|Superficial massage with the head of the therapeutic ultrasound device|Superficial massage with the head of the therapeutic ultrasound device will be applied to participants' back for 15 minutes, 3 times a week for 4 weeks in this group.
89183238|NCT05291182|Experimental|Dose-escalation|The study is conducted to evaluate the safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of SY-4835.
89183239|NCT05286554|Experimental|Group 1|Will receive routine LPS and additional single GnRH-a bolus, triptorelin 0.1 mg subcutaneous injection on the 6th day after oocyte retrieval.
89183240|NCT05286554|Experimental|Group 2|Will receive routine LPS and additional multiple mid-luteal GnRH-a, triptorelin 0.1 mg subcutaneous injection on the 5th, 7th and 9th days after oocyte retrieval.
89183241|NCT05286554|Active Comparator|Group 3 (Control)|Will receive the routine LPS without GnRH-a
89183242|NCT05280548|Experimental|Venglustat|Participants will receive venglustat once daily, orally
89183243|NCT05280548|Active Comparator|Standard of Care Therapy|Participants will receive a locally approved Fabry therapy at the standard dose and schedule (in accordance with the locally approved prescribing information)
89183244|NCT05278416|Active Comparator|Lumoral treatment -device and Lumorinse tablets|Subjects will receive detailed instructions for the use of Lumoral treatment -device and Lumorinse tablets. Subjects will be instructed to use the Lumoral treatment -device and follow the protocol once a day.
89183245|NCT05278416|No Intervention|Standard of Care|Subjects will receive oral hygiene instructions for the sonic toothbrushing and the use of interdental cleaning devices. They will not receive an additional intervention.
89183246|NCT05277896|Active Comparator|Ketamine Group|Patients in the ketamine group will be assigned to receive intravenous ketamine for induction of anesthesia during tracheal intubation. A dose of 2 mg/kg will be recommended, and the group assignment sheet will contain a nomogram providing the recommended dose for a range of patient weights (in pounds and kg). In this pragmatic trial, treating clinicians will be able elect to give a lesser or greater dose of ketamine than recommended if felt to be required for optimal patient care.
89183247|NCT05277896|Active Comparator|Etomidate Group|Patients in the etomidate group will be assigned to receive intravenous etomidate for induction of anesthesia during tracheal intubation. A dose of 0.3 mg/kg will be recommended, and the group assignment sheet will contain a nomogram providing the recommended dose for a range of patient weights (in pounds and kg). In this pragmatic trial, treating clinicians will be able elect to give a lesser or greater dose of etomidate than recommended if felt to be required for optimal patient care.
89183248|NCT05273255|Experimental|FMT-Recipients|"FMT-Recipients are patients with stage IV cancer, who have not sufficiently responded (stable disease or non-response) after at least 1 full cycle of CI. These patients will undergo the FMT procedure after the colon cleansing performed per routine treatment protocols at the Departement of Gastroenterology at the University Hospital of Zürich.~The stool is donated by FMT-Donors, which are patients with any solid cancer stage III or IV cancers, who received any ICI-Therapy and have experienced a durable partial or complete response.~FMT infusate will be administered via colonoscopy."
89183249|NCT05272423||Cohort 1A|Patients who are currently progressing on a KRAS G12C inhibitor. Plasma for ctDNA analysis will be collected.
89183250|NCT05272423||Cohort 1B|Patients who have already had a sequencing assay performed to determine the resistance mechanism to a KRAS G12C inhibitor. These patients will be invited to share their data and medical history. Plasma for ctDNA analysis will be optional.
89183251|NCT05261425|Active Comparator|Monocryl buried|Upper extremity primary surgical wound closure via suture with Monocryl buried
89183252|NCT05261425|Active Comparator|Nylon (FDA Approved) not buried|Upper extremity primary surgical wound closure via suture with Nylon(FDA Approved) not buried
89183253|NCT05255536|Active Comparator|Serratus Anterior Plan Block with 20 ml %0.25 Bupivacaine|Following the visualization of the anatomical structures, the nerve block needle will be advanced via the in-plane technique above the serratus anterior muscles until the interfascial space was reached. After hydrodissection with 2 ml normal saline, 20 ml 0.25% bupivacaine will be injected into the area.
89183254|NCT05255536|Active Comparator|Serratus Anterior Plan Block with 30 ml %0.25 Bupivacaine|Following the visualization of the anatomical structures, the nerve block needle will be advanced via the in-plane technique above the serratus anterior muscles until the interfascial space was reached. After hydrodissection with 2 ml normal saline, 30 ml 0.25% bupivacaine will be injected into the area.
89183255|NCT05254327|Experimental|Arm A|Short Chemo-Radiation Therapy (SCRT) + BMX-001
89183256|NCT05254327|No Intervention|Arm B|Short Chemo-Radiation Therapy (SCRT)
89183257|NCT05254327|Experimental|Arm C|Long Course Chemo-Radiation Therapy (LCCRT) + BMX-001
89183258|NCT05254327|No Intervention|Arm D|Long Course Chemo-Radiation Therapy (LCCRT)
89381227|NCT05682833|Placebo Comparator|Control|NS therapy + Placebo gel subgingival application
88854105|NCT01804842|Experimental|1000 mg Met DR qAM|One dose of 1000 mg metformin delayed-release in the morning
88854106|NCT01804842|Experimental|1000 mg Met DR qPM|One dose of 1000 mg metformin delayed-release in the evening
88854107|NCT01781286|Active Comparator|High Protein|Higher Protein Soy-based Snacks
88854108|NCT01781286|Active Comparator|Low Protein|Typical, Low Protein Snacks
88854109|NCT01781286|No Intervention|No Snack|No Snack
88854110|NCT01780974|Placebo Comparator|Placebo|Three placebo oil capsules per day (2 caps morning, 1 cap evening) + 2 placebo LA capsules per day. Capsules will be taken with food or a meal.
88854111|NCT01780974|Experimental|Lipoic acid plus omega-3 fatty acids|Three 1-gram fish oil concentrate capsules per day (2 caps morning, 1 cap evening) containing a daily dose of 675 mg docosahexaenoic acid (DHA) and 975 mg eicosapentaenoic acid (EPA) plus 2 LA capsules per day with a daily dose of 600 mg. Capsules will be taken with food or a meal.
88854112|NCT01780662|Experimental|Treatment (brentuximab vedotin, gemcitabine hydrochloride)|Patients receive brentuximab vedotin IV over 30 minutes on day 1 and gemcitabine hydrochloride IV over 100 minutes on days 1 and 8. Treatment repeats every 21 days for up to 15 more courses in the absence of disease progression or unacceptable toxicity. Patients with CR after any course may go off protocol therapy for stem cell transplant.
88854113|NCT01780584|Active Comparator|Oral T3 low dose & placebo|Oral T3 low dose administer through nasogastric tube 0.5 mcg/kg (max 10 mcg) starting on induction of anesthesia and then every 24 hours alternating with placebo, which was given 12 hours after the first dose of oral T3 and then every 24 hours until 60 hours post anesthesia induction (3 doses oral T3, 3 doses placebo)
88854114|NCT01780584|Placebo Comparator|Placebo|Placebo (saccharin lactic) administer through nasogastric tube, given starting on induction of anesthesia and then every 12 hours until 60 hours post-anesthesia induction (6 doses total)
88854115|NCT01780584|Experimental|Oral T3 high dose|Oral T3 high dose administer through nasogastric tube 0.5 mcg/kg (max 10 mcg) q12h starting on induction of anesthesia until 60 hours post-anesthesia (6 doses oral T3)
88854116|NCT01780506|Experimental|E/C/F/TAF (Double-Blind Phase)|E/C/F/TAF plus E/C/F/TDF placebo for 144 weeks
88854117|NCT01780506|Active Comparator|E/C/F/TDF (Double-Blind Phase)|E/C/F/TDF plus E/C/F/TAF placebo for 144 weeks
88854118|NCT01780506|Experimental|Open-Label Extension Phase|After study unblinding, participants who complete 144 weeks of the study had the option to receive open-label E/C/F/TAF until commercially available, or until Gilead Sciences terminated the study in that country.
88854119|NCT01779648|Active Comparator|Simultaneous compression+Fixed refill time|Simultaneous bilateral compression with fixed venous refill time through the whole duration of pneumatic compression
88854120|NCT01779648|Active Comparator|Alternate compression+Adjusted refill time|alternate bilateral compression with adjusted venous refill time which would change several times during pneumatic compression
88854121|NCT01762800|Experimental|fluticasone propionate/salmeterol|Randomised treatment at Visit 2
88854122|NCT01762800|Experimental|tiotropium bromide|Randomised treatment at Visit 2
88854123|NCT01597596|Experimental|Alglucosidase Alfa 4000 L material (Non-US participants)|Alglucosidase alfa 4000 L material for 52 weeks.
88854124|NCT01597596|Active Comparator|Alglucosidase Alfa 160 L material (US participants)|Alglucosidase alfa 160 L material for 52 weeks.
88854125|NCT01778556|Experimental|Leptin naive|Studied for 5 days without metreleptin, then 14 days while taking metreleptin
88854126|NCT01778556|Experimental|On-leptin|Studied for 5 days while taking metreleptin, then 14 days during metreleptin withdrawal
88854127|NCT04562376|Experimental|Group A|The program consists of high-intensity resistance training for 60 minutes twice a week for group A during 12 weeks at the Karolinska University Hospital under the supervision of a physiotherapist. Participants in group A will have different possible training alternatives every week to ensure availability, and they will train in groups of three to five persons/session.
89381228|NCT05692362||Healthy People|People with solitary pulmonary nodule， without any other pulmonary diseases.
89183259|NCT05252702|Other|Single Arm|Non randomized arm
88854128|NCT04562376|Active Comparator|Group B|The program consists of high-intensity resistance training for 60 minutes once a week for group B during 12 weeks at the Karolinska University Hospital under the supervision of a physiotherapist. Participants in group B will have different possible training alternatives every week to ensure availability, and they will train in groups of three to five persons/session.
89381229|NCT05692362||Chronic Airway Diease People|People with COPD or Asthma
89381230|NCT05692362||Pulmonary fibrosis people|People were diagnosised pulmonary fibrosis by chest Computer Tomography, and restrictive ventilatory impairment by pulmonary function test.
89381231|NCT03372083|Experimental|Deferasirox|Crushed deferasirox (ICL670) FCT for oral use daily. Deferasirox FCT dosing was based on subject's weight.
88854129|NCT04562298|Experimental|LCAR-M23 Chimeric Antigen Receptor T cell|
88854130|NCT04562064||keratoconus group|patients with keratoconus implanted with the Myoring 360 degree, KeraRing 355 degree, KeraRing one segment, KeraRing two segments ICRS .corneal tomography scans of the two corneal surfaces were obtained preoperatively and postoperatively with a rotating Scheimpflug imaging system .pentacam data that will be included
88854131|NCT01761162||Pacemaker Therapy|Patients with a ProMRI Pacemaker System
88854132|NCT01778010|Placebo Comparator|Modafinil 0mg + Cocaine 0, 12, 25, 50 mg|Participants were maintained on modafinil (0 mg/day) for 15 days, and underwent a dose response of cocaine.
88854133|NCT01778010|Experimental|Modafinil 200mg + Cocaine 0, 12, 25, 50 mg|Participants were maintained on modafinil (200 mg/day) for 15 days, and underwent a dose response of cocaine.
88854134|NCT01778010|Experimental|Modafinil 400mg + Cocaine 0, 12, 25, 50 mg|Participants were maintained on modafinil (400 mg/day) for 15 days, and underwent a dose response of cocaine.
88854135|NCT04414176||Case|Patients with coronary artery stenosis more than 75% (or left-main stenosis more than 50%) are defined as case group
89381232|NCT03044886|Experimental|2000IU/day|Subjects took 2000IU vitamin D per day
89381233|NCT03044886|Experimental|1000IU/day|Subjects took 1000IU vitamin D per day
89381234|NCT03044886|Placebo Comparator|Placebo|Subjects took placebo
89381235|NCT02961764|Active Comparator|Usual Care|Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.
89381236|NCT02961764|Active Comparator|New Critical Pathway|The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI.
89381237|NCT03371459|Experimental|AS MDI|AS MDI 1+1+2+4+8 inhalations of 90 μg per inhalation
89381238|NCT03371459|Active Comparator|Proventil|Proventil 1+1+2+4+8 inhalations of 90 μg per inhalation
89381239|NCT03642548|Experimental|BIFICO Group|The intervention group patients receive platinum-based doublet chemotherapy plus BIFICO (Dose: 420mg, 3 times a day, p.o)
89381240|NCT03642548|Placebo Comparator|Control Gruop|The control group patients receive platinum-based doublet chemotherapy plus Placebo (Dose: 420mg, 3 times a day, p.o)
89381241|NCT02961920|Experimental|IE ratio 1:1|Set an I(inspiration):E(expiration) ratio1:1 in the mechanical ventilator during spine surgery in the prone position in obese patients.
89381242|NCT02961920|Active Comparator|IE ratio 1:2|Set an I(inspiration):E(expiration) ratio1:2 in the mechanical ventilator during spine surgery in the prone position in obese patients.
89381243|NCT05283668|Experimental|(LASER WITH I-PRF)|Eight sites that were treated with laser method for gingival depigmentation, followed by intra-mucosal field injection of I-PRF
89381244|NCT05283668|Active Comparator|(LASER WITHOUT I-PRF)|Eight sites that were treated with laser technique for gingival depigmentation only
88854136|NCT04414176||Control|Patients with normal angiography are considered as control group.
88854137|NCT04568928|Experimental|OLTP/PE+FES|"3-5 familiarization sessions + 12 training sessions (3 blocks of 4 training sessions; 60-90 min each session, 2-3 sessions per week) of an overground locomotor training program using a powered exoskeleton combined with functional electrical stimulation (OLTP/PE+FES).~The training sessions are divided into 3 blocks. Each block will take place over a period of approximately 2 weeks (2-3 sessions/week) and will consist of 3 training sessions with exoskeleton combined with FES and a fourth session with exoskeleton alone, without FES.~For each participant, FES intensity will be set for each muscle in order to elicit a palpable muscle contraction. FES timing and duration is already built into the device. For each participant, specific level of assistance for each hip and knee, and gait parameters will be set and adjusted during a familiarization period with the PE. Level of PE assistance will then be adjusted weekly to ensure training progression."
88854138|NCT01777932||Cohort|
88854139|NCT01777854|Active Comparator|Omeprazole|"Yes. Omeprazole (generic) will be used. Children >20 kg will be given 20 mg PO daily for 4 weeks prior to tonsillectomy. This is the normal standard pediatric dosing for reflux.~Omeprazole is authorized to treat reflux in children. The study focuses on laryngopharyngeal reflux that possibly contributes to post tonsillectomy pain."
88854140|NCT01777854|Placebo Comparator|Sugar pill|The placebo does not look like the omeprazole, however this will not be an issue because none of the subjects will have knowledge of how the medications look.
89381245|NCT03371381|Experimental|Nivolumab + JNJ-64041757|Phase 1b and Phase 2 Group A/Arm 1: Participants will receive separate intravenous (IV) infusions of nivolumab and JNJ-64041757 over approximately 60 minutes during each treatment cycle until disease progression, unacceptable toxicity, protocol violation requiring discontinuation of study treatment, withdrawal of consent, noncompliance with study procedures, or the sponsor terminates the study.
89381246|NCT03371381|Active Comparator|Nivolumab|Phase 2 Group B/Arm 2: Participants will receive intravenous (IV) infusions of nivolumab over approximately 60 minutes during each treatment cycle until disease progression, unacceptable toxicity, protocol violation requiring discontinuation of study treatment, withdrawal of consent, noncompliance with study procedures, or the sponsor terminates the study.
88854141|NCT01777776|Experimental|Phase Ib|Phase Ib will randomize 18 patients with BRAF mutant melanoma, who are naïve or who have progressed on prior therapy to evaluate the safety and tolerability of the combination of LEE011 and LGX818.
88854142|NCT01777776|Experimental|Phase II arm 1a|Phase II arm 1a will randomize 60 patients that are naïve to prior BRAF inhibitor therapy to LGX818+LEE011 to evaluate the effect of adding LEE011 to a BRAFi in this population.
88854143|NCT01777776|Experimental|Phase II arm 1b|Phase II arm 1b will randomize 30 patients to LGX818. Single agent anti-tumor activity of LGX818 is comparable to other BRAFi that are either approved or in clinical trials. This single agent anti-tumor activity will be compared to that of the combination (LEE011 + LGX818) in the BRAFi naïve patient population.
89381247|NCT03710681|Experimental|Cohort 1|Multiple subcutaneous injections of SHR-1314 at 160mg every two weeks
89381248|NCT03710681|Experimental|Cohort 2|Multiple subcutaneous injections of SHR-1314 at 240mg every two weeks
89381249|NCT03044730|Experimental|Treatment (pembrolizumab, capecitabine)|Patients receive pembrolizumab IV on day 1 and capecitabine PO BID on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89381250|NCT05476887|Experimental|Part 1: Dose escalation Cohort 1|Participants will receive escalating and varying dose intervals of KP104 every week.
89381251|NCT05476887|Experimental|Part 1: Dose escalation Cohort 2|Participants will receive escalating and varying dose intervals of KP104 weekly or biweekly.
89381252|NCT05476887|Experimental|Part 1: Dose escalation Cohort 3|Participants will receive escalating and varying dose intervals of KP104 weekly or biweekly.
89381253|NCT05476887|Experimental|Part 2: Proof-of-concept Cohort 1|Participants will receive escalating and varying dose intervals of KP104 weekly or biweekly.
89381254|NCT05476887|Experimental|Open-label extension (OLE)|Participants will receive KP104, who benefit from KP104 treatment in Part 1 and 2
89183260|NCT05251727|Experimental|Lowest Dose|Lyophilized ART-123 reconstituted with sterile water for injection and administered by intravenous infusion over approximately 30 minutes prior to chemotherapy on Day 1 of cycle (for up to 3 cycles including bevacizumab)
89183261|NCT05251727|Experimental|Low Dose|"Lyophilized ART-123 reconstituted with sterile water for injection and administered by intravenous infusion over approximately 30 minutes prior to chemotherapy on Day 1 of cycle (for up to 3 cycles including bevacizumab)"
89183262|NCT05251727|Experimental|Medium Dose|"Lyophilized ART-123 reconstituted with sterile water for injection and administered by intravenous infusion over approximately 30 minutes prior to chemotherapy on Day 1 of cycle (for up to 3 cycles including bevacizumab)"
89183263|NCT05251727|Experimental|High Dose|"Lyophilized ART-123 reconstituted with sterile water for injection and administered by intravenous infusion over approximately 30 minutes prior to chemotherapy on Day 1 of cycle (for up to 3 cycles including bevacizumab)"
89183264|NCT05251727|Experimental|Highest Dose|"Lyophilized ART-123 reconstituted with sterile water for injection and administered by intravenous infusion over approximately 30 minutes prior to chemotherapy on Day 1 of cycle (for up to 3 cycles including bevacizumab)"
89183265|NCT05251727|Placebo Comparator|Placebo|"Lyophilized placebo reconstituted with sterile water for injection and administered by intravenous infusion over approximately 30 minutes prior to chemotherapy on Day 1 of cycle (for up to 3 cycles including bevacizumab)"
89183266|NCT05250063|Experimental|LUM-201 (3.2 mg/kg/day)|
89183267|NCT05249530|Experimental|Force|Chiropractic spinal adjustment with force
89183268|NCT05249530|Active Comparator|Touch|non-force stimulation
89183269|NCT05245409|Experimental|Stress|Individuals under various degrees of stress
89183270|NCT05242029|Experimental|Psilocybin|"Participants will be administered 40mg of psilocybin in a clinical setting. Psilocybin is administered orally as a capsule and taken with water.~At 3 months, half will be randomized to receive a blinded dose of psilocybin 40mg and half a blinded dose of placebo."
89183271|NCT05242029|Placebo Comparator|Placebo|"Participants will be administered placebo in a clinical setting. Placebo is administered orally as a capsule taken with water.~At 3 months, participants will receive a blinded dose of psilocybin 40mg."
89183272|NCT05232864|Experimental|Secukinumab|Secukinumab 300 mg solution for s.c. injection in a 2mL Pre-Filled Syringe (PFS)
89183273|NCT05229588|Experimental|Lurbinectedin|Lurbinectedin will be administered intravenously (IV) as a 1-hour (±10 min) infusion on Day 1 of each cycle (one cycle = 3 weeks ± 48 hours).
89183274|NCT05228171||Standard Recall|Standard interviewer-administered 24-hour dietary recall.
89381255|NCT02961374|Experimental|Treatment (erlotinib hydrochloride)|Patients receive erlotinib hydrochloride PO once weekly. Treatment continues for up to 6 months in the absence of disease progression or unacceptable toxicity.
88854144|NCT01777776|Experimental|Phase II arm 2|Phase II arm 2 will evaluate a single arm LEE011+LGX818 in 40 patients resistant to prior BRAF inhibitor therapy. Single agent LGX818 has shown limited activity in patients with melanoma who have failed prior BRAF inhibitor treatment; the contribution of LEE011 in this combination will be evaluated.
88854145|NCT01777620|Active Comparator|BOTOX®|BOTOX® (onabotulinumtoxinA) injected into the areas of glabellar lines and crow's feet lines on Day 1.
89183275|NCT05228171||Augmented Recall|Interviewer use of the mCC app for 24-hour dietary recall.
89183276|NCT05225103|Experimental|SAFETY-A Implementation Sites|New Brief Trauma-Informed Intervention (based on SAFETY-A) in addition to Enhanced Usual Care in Juvenile Detention Sites
89183277|NCT05220865|Active Comparator|Hall Technique|A preformed metal crown will be cemented on the carious primary molar tooth without any tooth preparation and local anesthesia.
88854146|NCT01777620|Placebo Comparator|Placebo|Placebo (normal saline) injected into the areas of glabellar lines and crow's feet lines on Day 1.
88854147|NCT01777542|Active Comparator|Treatment Period 1|One half of subjects will be randomly assigned to receive Recombinant Human Insulin Growth Factor 1 (rhIGF-1) , and the other half of subjects will be randomly assigned to receive placebo.
89183278|NCT05220865|Experimental|Modified Hall Technique|In the Modified Hall technique only infected soft dentin tissue will be removed with hand instruments and a preformed metal crown will be placed with Hall technique.
89183279|NCT05219825|Experimental|Breathwork group|Treatment-seeking individuals with cannabis use disorder who will participate in the 1-week breathwork workshop.
89183280|NCT05215509|Experimental|RA patients TNFi Exercise|"The patients will be randomized to 12-week supervised exercise training intervention or no exercise training. The exercise training program includes three supervised sessions per week over a 12-week period.~The program consists of high intensity endurance training on ergometer bicycles. The intensity will progress throughout the 12 weeks of training. The training consists of 10 minutes of warm up at 40-60% maximum heart rate (HRmax), followed by 25 minutes of high intensity interval training (4 bouts of 4 min at >85% HRmax interspaced by 3 minutes of low intensity training at 40-60% Hrmax) and finally a 5 min cool-down of 50% Hrmax"
89183281|NCT05215509|Active Comparator|RA patients TNFi Control|"This group will be allocated to control and therefore no supervised exercise regimen"
89183282|NCT05215509|Experimental|RA patients IL-6Rb Exercise|"The patients will be randomized to 12-week supervised exercise training intervention or no exercise training. The exercise training program includes three supervised sessions per week over a 12-week period.~The program consists of high intensity endurance training on ergometer bicycles. The intensity will progress throughout the 12 weeks of training. The training consists of 10 minutes of warm up at 40-60% maximum heart rate (HRmax), followed by 25 minutes of high intensity interval training (4 bouts of 4 min at >85% HRmax interspaced by 3 minutes of low intensity training at 40-60% Hrmax) and finally a 5 min cool-down of 50% Hrmax"
89183283|NCT05215509|Active Comparator|RA patients IL-6Rb Control|"This group will be allocated to control and therefore no supervised exercise regimen"
89381256|NCT05468853|Experimental|MPFC-iTBS|Transcranial magnetic stimulation delivered to the medial prefrontal cortex. 600 pulses delivered in 50 Hz bursts every 5 Hz for 2 seconds followed by 8 seconds of no stimulation repeated 20 times at 80% of resting motor threshold. Repeated daily for 5 consecutive days.
89381257|NCT05468853|Active Comparator|Inion-iTBS|Transcranial magnetic stimulation delivered to the inion. 600 pulses delivered in 50 Hz bursts every 5 Hz for 2 seconds followed by 8 seconds of no stimulation repeated 20 times at 80% of resting motor threshold. Repeated daily for 5 consecutive days.
89381258|NCT04700787|Experimental|Sulopenem|Sulopenem intravenous 1000 mg (single dose) on Day 1 followed by oral sulopenem etzadroxil/probenecid 500 mg/500 mg (single dose) on Day 2.
89381259|NCT04783233||Packing with Gelfoam|Tympanoplasty surgery with fascia graft (either transcanal or post-auricular) will be preformed. The middle ear and external canal will then be packed with Gelfoam.
89381260|NCT04783233||Packing with Chitosan succinamide|The surgical intervention and tympanoplasty will be performed as normal. The middle ear and external canal will be packed Chitosan succinamide.
89381261|NCT02714049|Experimental|flibanserin|Subjects meeting inclusion/exclusion criteria who respond to flibanserin will have a total of 20 weeks of open label drug
89381262|NCT02714049|Experimental|flibanserin and sex therapy|Subjects meeting inclusion/exclusion criteria who respond to flibanserin will have a total of 20 weeks of open label drug as well as 9 sex therapy visits
89381263|NCT02951429|Placebo Comparator|Pirfenidone + Placebo|Participants will receive pirfenidone along with placebo matched to sildenafil, orally, three times a day (TID) for 52 weeks.
89381264|NCT02951429|Experimental|Pirfenidone + Sildenafil|Participants will receive pirfenidone along with sildenafil, orally, TID for 52 weeks.
89381265|NCT04622709|Experimental|Study drug administration: furosemide|Study participants will receive furosemide oral tablets to be taken twice daily. During study period 1 (first 6 weeks), the drug dose will be escalated every 2 weeks if safe, tolerated, and acceptable to the participant. During study period 2 (subsequent 12 weeks), participants will take the maximum tolerated dose from study period 1, received every 4 weeks if safe, tolerated, and acceptable to the participant.
89381266|NCT03706859|Experimental|Tourniquet inflation pressure method 1|the pneumatic tourniquet inflation pressure at 20 mmHg above the arterial occlusion pressure which will be estimated using the equation of Unver B. et al.,: (AOP=[SBP+10]/KTP)
89381267|NCT03706859|Active Comparator|Tourniquet inflation pressure method 2|the pneumatic tourniquet inflateion pressure at 20 mmHg above the arterial occlusion pressure which will be estimated using the equation of Hong-yun Liu et al.,: (AOP = 17.986 + 3.158X1 + 0.408X2)
89381268|NCT05682755|Experimental|Chidamide|
89381269|NCT01312103|Experimental|Internet Based Safety Decision Aid|
89381270|NCT01312103|Active Comparator|Control Website|
89381271|NCT03708887|Experimental|Low dose group|Low dose omega-3 fatty acid supplementation, omega-3 fatty acids capsules, 1 gram per day for 1 year.
89381272|NCT03708887|Experimental|High dose group|High dose omega-3 fatty acid supplementation, omega-3 fatty acids capsules, 3 gram per day for 1 year.
89381273|NCT03708887|Placebo Comparator|Control group|Control drug, matching placebo capsules, 1 gram per day for 1 year.
88854148|NCT01777542|Placebo Comparator|Treatment Period 2|Subjects that initially received Recombinant Human Insulin Growth Factor 1 (rhIGF-1) will now receive placebo, and subjects that initially received placebo will now receive Recombinant Human Insulin Growth Factor 1 (rhIGF-1).
89381274|NCT05321537|Experimental|Somatosensory training|It consists of head relocation exercises, eye tracking, gaze stability and eye-head coordination. It requires the use of special material, the pupillary glasses allow the gaze to be fixed by restricting peripheral vision and the laser pointer provides visual feedback on the positioning of the head.
89381275|NCT05321537|Experimental|Endurance-strength training|It consists of low-load training of the craniocervical flexor muscles. This exercise is specific for the deep cervical flexor muscles, while seeking minimal activation of the superficial flexor muscles. This training consists of 5 phases, starting with a pressure of 20 mmHg, progressively increasing 2 mmHg in each phase.
88854149|NCT01736124|Experimental|Computerized Cognitive Training (CCT)|Randomly selected subjects perform a variety of computer games tailored to address their personal cognitive deficits.
88854150|NCT01736124|Active Comparator|Active control|Randomly selected subjects perform a variety of computer games that are engaging but not designed to enhance cognitive skills.
88854151|NCT01759446|Placebo Comparator|Placebo taken first|Placebo powder snorted with all other arms taken crossover therafter
89381276|NCT04595019|Active Comparator|5 fraction|MRI-guided radiotherapy, 36.25 Gray (Gy) in 5 fractions (boost to 40 Gy over tumour/prostate CTV) over 10 days.
89381277|NCT04595019|Experimental|2 fraction|MRI-guided radiotherapy, 24 Gy in 2 fractions (boost to 27 Gy over tumour/prostate CTV) over 8 days.
89381278|NCT05228145|Experimental|Cohort 1|The study treatment is a recombinant serotype 9 adeno-associated virus encoding a codon-optimized human CLN5 transgene (hCLN5opt).
89381279|NCT05228145|Experimental|Cohort 2|The study treatment is a higher dose of recombinant serotype 9 adeno-associated virus encoding a codon-optimized human CLN5 transgene (hCLN5opt).
89381280|NCT05228145|Experimental|Cohort 3|The study treatment is a higher dose of recombinant serotype 9 adeno-associated virus encoding a codon- optimized human CLN5 transgene (hCLN5opt).
89381281|NCT05214807|Active Comparator|Control group receiving Synvisc-One®|
89381282|NCT05214807|Experimental|IMD group receiving KiOmedine® CM-Chitosan|
89381283|NCT02454855|Experimental|"Group Melatonin"|standard anticancer treatment + 3-month of melatonin supplementation
89381284|NCT02454855|Placebo Comparator|"Group Placebo"|standard anticancer treatment + placebo (3 months)
89381285|NCT03343067|Experimental|Arm A|"Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD~Month 4 Through Month 24 (Double-Blind): Efficacy responders to elagolix 150 mg QD at Month 3 and continue treatment through Month 24"
88854152|NCT01759446|Active Comparator|Generic H/A taken first|Generic hydrocodone/APAP 10/325mg pulverized tablet snorted with all other arms taken crossover therafter
88854153|NCT01759446|Active Comparator|Vycavert taken first|Vycavert hydrocodone/APAP 10/325mg pulverized tablet snorted with all other arms taken crossover therafter
88854154|NCT01759446|Active Comparator|Generic H/A plus i taken first|Generic hydrocodone/APAP 10/325mg plus additional inactive ingredients pulverized tablet snorted with all other arms taken crossover therafter
88854155|NCT01759446|Active Comparator|Generic H/A plus p taken first|Generic hydrocodone/APAP 10/325mg plus one placebo pulverized tablet snorted with all other arms taken crossover therafter
89381286|NCT03343067|Experimental|Arm C|"Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD~Month 4 Through Month 24 (Double-Blind): Incomplete efficacy responders to elagolix 150 mg QD at Month 3 and randomized to elagolix 200 mg BID plus E2/NETA 1/0.5 mg QD treatment group and continue treatment through Month 24."
88854156|NCT01777308|Experimental|Menitorix Group|"Subjects who were primed with Menitorix™ (Hib-MenC-TT) + Priorix™ (MMR) vaccines in the primary study HIB-MENC-TT-016 (NCT00326118) received one dose of Nimenrix™ (MenACWY-TT) booster vaccine at Month 72 post primary vaccination (booster visit 1).~The MenACWY-TT vaccine was administered intramuscularly (IM) in the deltoid region of the non-dominant arm."
88854157|NCT01777308|Experimental|Meningitec + Hiberix Group|"Subjects who were primed with Meningitec™ (MCC) + Hiberix™ (Hib) + Priorix™ (MMR) vaccine in the primary study HIB-MENC-TT-016 (NCT00326118) received one dose of Nimenrix™ (MenACWY-TT) booster vaccine at Month 72 post primary vaccination (booster visit 1).~The MenACWY-TT vaccine was administered intramuscularly (IM) in the deltoid region of the non-dominant arm."
88854158|NCT01759368|Active Comparator|Telemonitoring assisted self-care|Telemonitoring group was given a home-care package including a weight scale, a blood pressure meter, a mobile phone and self-care instructions. The measurements taken at home to be uploaded were: diastolic and systolic blood pressure, pulse, body weight and an assessment of symptoms. The symptom assessment concerned the patient's feelings of dizziness, dyspnea, palpitation, weakness and, oedema. Patients were also asked to evaluate their overall condition- whether their condition had deteriorated, improved or remained unchanged. The patients were advised to carry out and report the measurements together with the self-assessment once a week. The responsible nurse followed patients' status and the data once a week or more frequently if needed. Based on the reported measurements, the nurse could invite the patient for a control visit. In case a patient did not make self-measurements as planned , the nurse contacted the patient and reminded him/ her to continue with monitoring.
88854159|NCT01759368|No Intervention|Control group|Control group received usual care that includes multidisciplinary care approach in which patients receive guidance and support for self-care. In the care of heart failure (HF) patients, the cardiac team plays a central role in monitoring and interpreting patient symptoms, optimizing medication and providing education. The cardiac team consists of two physicians, one specialized heart failure nurse and a physiotherapist who helps after a hospitalization period. As part of the care process, patients capable of carrying out self-care are identified and they are encouraged to regularly measure their blood pressure, heart rate and weight at home. So far, the information exchange between heart failure patients and care personnel has taken place during patients' visits to the clinic and by telephone. Systematic collection and exploitation of the self-measurement data has been difficult, since it depends on the patient's own activity
88854160|NCT01777152|Active Comparator|CHOP|cyclophosphamide, doxorubicin, vincristine, and prednisone
88854161|NCT01777152|Experimental|A+CHP|brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone
88854162|NCT01759290||Absorb Bioresorbable Vascular Scaffold|Subjects receiving the Absorb Bioresorbable Vascular Scaffold
88854163|NCT01758900|Active Comparator|Air insufflation regulator|Room air will be used for insufflation as the Active Comparator arm
88854164|NCT01758900|Experimental|CO2 insufflation regulator|Device: CO2 insufflation regulator
88854165|NCT01757184|Experimental|Double-blind Sebelipase Alfa|Double-blind Period: IV infusions of sebelipase alfa at a dose of 1 mg/kg administered qow for 20 weeks.
88854166|NCT01757184|Placebo Comparator|Double-blind Placebo|Double-blind Period: IV infusions of matched placebo administered qow for 20 weeks.
88854167|NCT01757184|Experimental|Open-label Sebelipase Alfa/Sebelipase Alfa|Participants who were randomized to receive sebelipase alfa during the Double-blind Period and received sebelipase alfa in the Open-label Period. All participants received sebelipase alfa at a dose of 1 mg/kg qow, irrespective of treatment received in the Double-blind Period. Dose modifications were permitted during the Open-label Period.
88854168|NCT01757184|Experimental|Open-label Placebo/Sebelipase Alfa|Participants who were randomized to receive placebo during the Double-blind Period and received sebelipase alfa in the Open-label Period. All participants received sebelipase alfa at a dose of 1 mg/kg qow, irrespective of treatment received in the Double-blind Period. Dose modifications were permitted during the Open-label Period.
88854169|NCT01775904|Experimental|LY2886721 Capsule (water, fasting)|Reference formulation. A single oral dose of 70 milligrams (mg) LY2886721 in a capsule given with water and without a meal in one of four periods.
88854170|NCT01775904|Experimental|LY2886721 ODT (no water, fasting)|A single oral dose of 70 mg LY2886721 in an orally disintegrating tablet (ODT) given without water and without a meal in one of four periods.
88854171|NCT01775904|Experimental|LY2886721 ODT (water, fed)|A single oral dose of a 70 mg LY2886721 in an orally disintegrating tablet (ODT) given with water and after a high-fat breakfast in one of four periods.
89183284|NCT05214313|Experimental|"Music therapy Intervention group (G1)"|"Patients in the Music therapy intervention group will also perform the 1st session of the program during the inclusion visit (V0). The patients will benefit from fourteen 1-hour music therapy sessions (15 min of reception, installation and debriefing at the end of the session and 45 min of program). The 14 individual sessions will be spread over three months at the rate of 2 weekly sessions the first month then a single weekly session the following month and finally 2 monthly sessions the last month. Patients will be assessed at inclusion, then the first month (V1) and at the end of the intervention (V2)."
89183285|NCT05214313|No Intervention|" Control  group (G2)"|The patients in this group will benefit from the usual care corresponding to a quarterly medical examination. The patients will be assessed on the day of inclusion (V0) and then during the routine three-month medical examination (V2). At the end of the study, these patients will be able to benefit from the same music therapy program, offered under the same operating conditions.
89183286|NCT05208047|Experimental|Part 1a|CGT9486 plus sunitinib 37.5 mg QD
89183287|NCT05208047|Experimental|Part 2 - Experimental Group|CGT9486 plus sunitinib 37.5 mg QD
89183288|NCT05208047|Active Comparator|Part 2 - Control Group|sunitinib 37.5 mg QD
89183289|NCT05208047|Experimental|Part 1b - DDI Cohort 1|CGT9486 plus sunitinib 37.5 mg QD
89183290|NCT05208047|Experimental|Part 1b - DDI Cohort 2|sunitinib 37.5 mg QD plus CGT9486
89183291|NCT05204550|Experimental|intranasal heparin|"Unfractionated heparin (UFH) 1400u each nostril (as heparin solution 5,000u/ml, 140 microL/actuation, Two actuations each nostril) Three times daily via a plastic nasal inhalator device (APTAR, UK) for 10 days.~This is a maximal dose per day of UFH of 8400u. ie 700 x 2 actuations per nostril (1400 x2) 3 times per day (1400x2x3 = 8400u)"
89183292|NCT05204550|Placebo Comparator|intranasal saline|Comparator 0.9% saline (as saline solution, 140 microlitres/actuation, Two actuations each nostril) Three times daily via a plastic nasal inhalator device(APTAR, UK) for 10 days.
89183293|NCT05189145|Active Comparator|Group I (control)|All patients given 8 mg estradiol valerate orally on daily basis for 13 days beginning with the first day of either a spontaneously or induced menstrual cycle. Patients examined using transvaginal ultrasonography on day 13 of exogenous estrogen supplementation to measure endometrial thickness and to detect signs of escape ovulation. In all Patients progesterone supplements in form of two vaginal prontogest suppositories 400 mg each. Transfer of frozen embryo will be done on day 5 after progesterone supplementation.
89183294|NCT05189145|Experimental|group II (experimental)|"All patients given 8 mg estradiol valerate orally on daily basis for 13 days beginning with the first day of either a spontaneously or induced menstrual cycle. Patients examined using transvaginal ultrasonography on day 13 of exogenous estrogen supplementation to measure endometrial thickness and to detect signs of escape ovulation. In all Patients progesterone supplements in form of two vaginal prontogest suppositories 400 mg each. Transfer of frozen embryo will be done on day 5 after progesterone supplementation.~progesterone (P4) and estradiol assessed and Progesterone supplement adjustments based on serum level of P4 on day of embryo transfer dividing Group II (Cases) into 3 groups:~Group II A: If P4 levels < 5ng/dl, one progesterone supplement in form of 100 mg intramuscular injection daily added~Group II B: If P4 levels 5-10ng/dl, dydrogesterone three times daily added~Group II C: If P4 levels >10ng, continue on 400 mg prontogest suppositories twice daily"
89183295|NCT05180136|Experimental|Rice bran extract group|This group takes rice bran extract for 8 weeks.
89183296|NCT05180136|Placebo Comparator|Control group|This group takes a placebo for 8 weeks.
89183297|NCT05179122|Experimental|Surgical drain|In this arm participants a surgical drain (Redon type) will be inserted above the abdominal fascia prior to suture of the subcutaneous tissue and of the skin
89183298|NCT05179122|No Intervention|Control|In this arm the subcutaneous tissue and the skin of the surgical wound will be sutured without insertion of any type of drain
89183299|NCT05179057|Experimental|Posoleucel + SoC|Posoleucel + SOC; then placebo + SOC for patients who meet optional protocol-defined crossover criteria
88854172|NCT01775904|Experimental|LY2886721 ODT (water, fasting)|A single oral dose of 70 mg LY2886721 in an orally disintegrating tablet (ODT) given with water and without a meal in one of four periods.
89183300|NCT05179057|Placebo Comparator|Placebo + SoC|Placebo + SOC; then Posoleucel + SOC for patients who meet optional protocol-defined crossover criteria
89183301|NCT05159193|Experimental|PLD + C + HP followed by THP|pegylated liposomal doxorubicin (PLD) 30 mg/m^2, i.v., d1 + cyclophosphamide (C) 600 mg/m^2, i.v., d1 + trastuzumab (H) 8 mg/kg loading dose, 6 mg/kg maintenance doses, i.v., d1 + pertuzumab (P) 840 mg loading dose, 420 mg maintenance doses, i.v., d1 followed by docetaxel (T) 90~100 mg/m^2, i.v., d1 + trastuzumab (H) 6 mg/kg, i.v., d1 + pertuzumab (P) 420 mg, i.v., d1 q3w, for 4 cycles. After neoadjuvant therapy, patients are required to receive a total of 1 year of treatment with trastuzumab (6mg/kg) combined with pertuzumab (420mg), i.v., d1, q3w, regardless of surgery.
89381287|NCT03343067|Experimental|Arm D|"Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD~Month 4 Through Month 6 (Double-Blind): Incomplete efficacy responders to elagolix 150 mg QD at Month 3 and randomized to elagolix 150 mg QD treatment group~Month 7 Through Month 24 (Double-Blind): Incomplete efficacy responders to elagolix 150 mg QD at Month 6 and assigned to elagolix 200 mg BID plus E2/NETA 1/0.5 mg QD treatment group and continue treatment through Month 24."
89381288|NCT03343067|Experimental|Arm B|"Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD~Month 4 Through Month 6 (Double-Blind): Incomplete efficacy responders to elagolix 150 mg QD at Month 3 and randomized to elagolix 150 mg QD treatment group~Month 7 Through Month 24 (Double-Blind): Efficacy responders to elagolix 150 mg QD at Month 6 and continue treatment through Month 24."
88854173|NCT01775670|Experimental|Off-the-Shelf Splint|Subjects in this arm will be managed with off-the-shelf splints for TMC arthrosis.
88854174|NCT01775670|Active Comparator|OT Splint|Subjects in this arm will be managed with a custom-made splint made by the Massachusetts General Hospital Occupational Therapists.
89381289|NCT05205525||Restrictive antibiotic strategy|
89381290|NCT05205525||Aggressive (immediate) antibiotic strategy|
89381291|NCT04707183|Placebo Comparator|Control Arm|1.0mg/kg/hr IV lidocaine infusion
89381292|NCT04707183|Experimental|Treatment Arm|10 mL of 2% lidocaine via ESPB
89381293|NCT04703205|Experimental|ivermectin|Ivermectin group: Ivermectin approximately 200 μg/kg administered as a single oral dose on Day 1 (fasting state) subjects take the study drug (3 mg tablet of ivermectin) at the dose of the study drug taken once per body weight of the subject.
89381294|NCT04703205|Placebo Comparator|placebo|Placebo group: Placebo without ivermectin as an ingredient, single oral administration on Day 1 (fasting state) the control drug (ivermectin placebo tablet) at the dose of the study drug taken once per body weight of the subject.
89381295|NCT03706781|Experimental|Test product CTP/BNZ with mucus adhesive polymer|A multiple dose of the Cetylpyridinium Chloride 0.05%+Benzydamine HCl 0.15% (CTP/BNZ) + mucus adhesive polymer is administered to healthy subjects twice a day for 7 days, under fasting conditions in two subsequent periods according to the randomised cross-over design.
89381296|NCT03706781|Active Comparator|Reference product CTP/BNZ - Tantum Verde Bocca|A multiple dose of the Cetylpyridinium Chloride 0.05%+Benzydamine HCl 0.15% (CTP/BNZ) Tantum Verde Bocca is administered to healthy subjects twice a day for 7 days, under fasting conditions in two subsequent periods according to the randomised cross-over design.
89381297|NCT04681365||Simulation Suite|Participating staff will use BubblePAPR and evaluate its function in the non-clinical simulation suite, ensuring that simulated tasks appropriate to role can be undertaken safely whilst wearing the Bubble
89381298|NCT04681365||Low-Risk Clinical Environment|Participating staff will use BubblePAPR and evaluate its function in the usual clinical environments (wards, ICUs or Emergency Departments) but with patients who are considered low risk (ie non-COVID-19).
89381299|NCT04681365||High-Risk Clinical Environment|Participating staff will use BubblePAPR and evaluate its function in the usual clinical environments (wards, ICUs or Emergency Departments) but with patients who are considered high risk (ie suspected or confirmed COVID-19).
89381300|NCT03706703|Experimental|Endostar continuous intravenous infusion|Endostar continuous intravenous infusion in combination with docetaxel/carboplatin or pemetrexed/carboplatin
89381301|NCT05279573|Experimental|Combination of Omega-3 based product and botanical ingredient|Consumption for 60 days. Subjects should consume two capsules in the morning and two capsules in the afternoon.
89381302|NCT05279573|Experimental|Omega-3 based product|Consumption for 60 days. Subjects should consume two capsules in the morning and two capsules in the afternoon.
89381303|NCT05279573|Experimental|Botanical ingredient|Consumption for 60 days. Subjects should consume two capsules in the morning and two capsules in the afternoon.
88854175|NCT01775124|Experimental|Ranibizumab 0.5 mg monthly|Monthly intravitreal injections of ranibizumab 0.5 mg in the core treatment period and PRN intravitreal injections of the same dose guided by best-corrected visual acuity (BCVA) stabilization in the extension treatment period
88854176|NCT01775124|Experimental|Ranibizumab 0.5 mg pro re nata (PRN)|PRN intravitreal injections of ranibizumab 0.5 mg guided by best-corrected visual acuity (BCVA) stabilization in the 23 month treatment period
89381304|NCT05279573|Placebo Comparator|Control group|Consumption for 60 days. Subjects should consume two capsules in the morning and two capsules in the afternoon.
89381305|NCT05682287|Experimental|Experimental group|"Participants in the experimental group will be treated with a combination of 448kHz capacitive resistive monopolar radiofrequency and Proprioceptive neuromuscular facilitation (PNF) over the course of two weeks.~448 kHz radio frequency therapy will be carried for a duration of 15 min. Contact cream will be applied beforehand to increase the electrical conductivity in the treated area.~After the radiofrequency therapy, participants will exercise for exactly 20 minutes using the PNF concept exercises to mobilize the pelvis and lumbar spine, primarily strengthening the muscles of the abdomen, back and hips.~Therapy will be administered for a total of 5 times in two weeks. Three times in week 1 and two times in week 2."
89381306|NCT05682287|Active Comparator|Control group|"Participants will exercise for exactly 20 minutes, over the course of two weeks, using the PNF concept exercises to mobilize the pelvis and lumbar spine, primarily strengthening the muscles of the abdomen, back and hips.~Therapy will be administered for a total of 5 times in two weeks. Three times in week 1 and two times in week 2.~This is identical intervention and the second intervention in the experimental group."
89381307|NCT05642403|Active Comparator|SAD Cohort A XW001|Single inhalation of XW001
89381308|NCT05642403|Placebo Comparator|SAD Cohort A placebo|Single inhalation of placebo
89381309|NCT05642403|Active Comparator|MAD Cohort B XW001|Multiple inhalations of XW001
89381310|NCT05642403|Placebo Comparator|MAD Cohort B placebo|Multiple inhalations of placebo
89381311|NCT03706547|Experimental|anti-CD19/BCMA CAR-T cells|"Chemotherapy with a classic combination with fludarabine and cyclophosphamide;~Administration with anti-CD19/BCMA CAR-T cells in the BCMA-positive multiple myeloma patients."
89381312|NCT04640727||open reduction and internal fixation|open reduction and internal fixation used in treating completely displaced and rotated lateral condylar fracture in children
88854177|NCT01733316|Experimental|All Participants|"Cystagon® Phase: From Screening and during Months 1, 2, 3 participants receive their usual dose of Cystagon® every 6 hours (Q6H).~RP103 Phase: During Months 3.5, 4, 5, 6, 7 participants receive RP103 every 12 hours (Q12H).~Long Term Phase: On or after Month 7, for the remainder of study participants receive RP103 Q12H."
88854178|NCT01732926|Experimental|Rituximab + Bendamustine + Idelalisib|Participants will receive rituximab + bendamustine + idelalisib.
89381313|NCT04640727||closed reduction and internal fixation|closed reduction and internal fixation used in treating completely displaced and rotated lateral condylar fracture in children
89381314|NCT03708653||PHN(+)|Patients who have persistent pain more than three months after the onset of herpes zoster.
89381315|NCT03708653||PHN(-)|Patients whose pain disappear within three months.
89381316|NCT05682209|Active Comparator|Octreotide group|Received 100µg of octreotide intravenously 8-hourly for 5 days from the first post-operative day
89381317|NCT05682209|Placebo Comparator|Control group|Received 1ml of sterile water intravenously 8-hourly for 5 days from the first post-operative day
89381318|NCT05258513|Placebo Comparator|Placebo|From weeks 1-4, participants will consume 150mg daily of a visually identical placebo. For weeks 5-8, the dose will be escalated as participants will consume 300mg daily of placebo supplementation.
89381319|NCT05258513|Experimental|Geranylgeraniol Treatment|From weeks 1-4, participants will consume 150mg daily of a Geranylgeraniol (GG). For weeks 5-8, the dose will be escalated as participants will consume 300mg daily of GG.
89381320|NCT04637841|Active Comparator|Diabetes Mellitus Kinesiology Taping Group|Kinesiology tape will be applied to the left foot of the participants in diabetes mellitus group.
89381321|NCT04637841|Active Comparator|Kinesiology Taping Control Group|Kinesiology tape will be applied to the left foot of the healthy participants in the control group.
89381322|NCT04637841|Active Comparator|Diabetes Mellitus Myofascial Release Group|Myofascial Release Technique will be applied to the right foot of the participants in diabetes mellitus group.
89381323|NCT04637841|Active Comparator|Myofascial Release Control Group|Myofascial Release Technique taping will be applied to the right foot of the healthy participants in the control group.
89381324|NCT05682131|Placebo Comparator|Control group|Oral placebo was added to conventional chemotherapy
89381325|NCT05682131|Experimental|Experimental Group|Oral RIF was added to conventional chemotherapy
89381326|NCT03632577|Experimental|High Flow Oxygen (HFO)|HFO is a mix tap of air and oxygen. It permits to control FiO2 and generated controlled high flow air until 60/min. Air and oxygen are mixed, warmed, humidified and issued to patient by a warming monopod inspiratory circuit to nasal cannulas of a large diameter. Expiration is free.
88854179|NCT01732926|Experimental|Rituximab + Bendamustine + Placebo|Participants will receive rituximab + bendamustine + placebo.
88854180|NCT01755858|Experimental|Bendavia|Bendavia, intravenous infusion, 0.05 mg/kg/hr for a maximum duration of 4 hours.
88854181|NCT01755858|Placebo Comparator|Placebo|Placebo (no active drug), intravenous infusion, for a maximum duration of 4 hours.
88854182|NCT01732770|Experimental|Denosumab 60 mg|Participants received denosumab 60 mg subcutaneous injection once every 6 months for 12 months and placebo to zoledronic acid by intravenous infusion on Day 1.
88854183|NCT01732770|Active Comparator|Zoledronic Acid 5 mg|Participants received zoledronic acid 5 mg by intravenous infusion on Day 1 and placebo to denosumab by subcutaneous injection on Day 1 and at Month 6.
88854184|NCT01732692|Experimental|MOVIPREP (Morning-only dose)|MOVIPREP 250 ml solution every 15 minutes for up to one hour (4 doses in 1 hour=1 litre of solution), twice within same morning of colonoscopy.
89381327|NCT03632577|Active Comparator|Non Invasive Ventilation (NIV)|NIV was already evaluated in post-extubation. This technic is now used in daily consolidation processing after extubation because it provides a ventilator help with two levels of pressure helping in respiratory work. Adding Automated Flow Oxygen Titration could optimized patient's oxygenation and reduce workload of caregivers
89381328|NCT04620993||Group 1: pregnant women with pelvic girdle pain|This group will consist of pregnant women who are in the 2nd or 3rd trimester of pregnancy and have pelvic girdle pain.
89381329|NCT04620993||Group 2:pregnant women without pelvic girdle pain|This group will consist of pregnant women who are in the 2nd or 3rd trimester of pregnancy but have not pelvic girdle pain.
88854185|NCT01732692|Other|MOVIPREP (Split-dose)|MOVIPREP 250 ml solution every 15 minutes for up to one hour (4 doses in 1 hour=1 litre of solution), once the evening before colonoscopy and once the morning of colonoscopy.
88854186|NCT01774968|Experimental|Human Regular U-500 Insulin TID|Human Regular U-500 Insulin (U-500R) titrated based on blood glucose readings, administered subcutaneously (SC), three times a day (TID) for 24 weeks.
89381330|NCT04620993||Group 3: healthy women|This group will consist of healthy women who have not been pregnant.
89381331|NCT03706391||ALS and PMA Reversals|
89381332|NCT03708497|Active Comparator|carbetocin|Carbetocin 100 microgram will be applied intravenously in a short infusion over about a minute
89381333|NCT03708497|Experimental|Tranexamic acid plus misoprostol|1000mg oral TA at the end of the first stage of labor plus 600 mg buccal misoprostol after delivery of the baby. A buccal route, in which the tablets are placed in the cheek for 30 min after which any remnants are swallowed.
89381334|NCT03708497|Active Comparator|misoprostol|600 mg buccal misoprostol after delivery of the baby. A buccal route, in which the tablets are placed in the cheek for 30 min after which any remnants are swallowed.
88854187|NCT01774968|Experimental|Human Regular U-500 Insulin BID|U-500R Insulin titrated based on blood glucose readings, administered SC, two times a day (BID) for 24 weeks.
88854188|NCT01774344|Experimental|Regorafenib|160 mg orally (p.o.) every day (qd) for 3 weeks of every 4 week cycle (i.e. 3 weeks on, 1 week off) plus BSC (Best Supportive Care)
88854189|NCT01774344|Placebo Comparator|Placebo|4 matching placebo tablets for 3 weeks of every 4 week cycle (i.e. 3 weeks on, 1 week off) plus BSC
88854190|NCT01732536|Experimental|S8 Sinus Implant|"In-office bilateral placement of the S8 Sinus Implant (mometasone furoate, 1350 mcg) in the ethmoid sinuses~Mometasone furoate nasal spray (200mcg) once daily"
88854191|NCT01732536|Sham Comparator|Control|"In-office bilateral sham procedure~Mometasone furoate nasal spray (200mcg) once daily"
88854192|NCT01755702|Placebo Comparator|Arm 1|Placebo
88854193|NCT01755702|Active Comparator|Arm 2|paracetamol marketed forumulation
89381335|NCT02961218|Placebo Comparator|Placebo|Monthly doses of 4 mg/kg for subjects weighing ≤40 kg and 300 mg for all other subjects
89381336|NCT02961218|Experimental|ACZ885|Monthly doses of 300 mg (4 mg/kg for patients ≤ 40 kg) canakinumab s.c.
89381337|NCT02949947|Experimental|Group A - Ferric Carboxymaltose|"Participants receive a Ferric Carboxymaltose injection by vein. Dose repeated 1 week later.~Health questionnaire completed at Baseline and at Weeks 4, 8, 12, and 24."
88854194|NCT01755702|Active Comparator|Arm 3|ibuprofen marketed formulation
89381338|NCT02949947|Active Comparator|Group B - Iron Supplement|"Participants take iron supplements by mouth every day for up to 3 months.~Health questionnaire completed at Baseline and at Weeks 4, 8, 12, and 24."
89381339|NCT03642392||Tendinopathy|Athletes with unilateral tendinopathy
89381340|NCT03642314|Experimental|Intervention|Individuals receive 5 HIV Self Test kits + vouchers to secondarily distribute to MSM/TGW from their social/sexual networks. All vouchers are uniquely identified invitations for priority access to ImPrEP sites, valid to be redeemed by a 3 month period
89381341|NCT03642314|No Intervention|Control|Individuals receive 5 vouchers to secondarily distribute to MSM/TGW from their social/sexual networks. All vouchers are uniquely identified invitations for priority access to ImPrEP sites, valid to be redeemed by a 3 month period
89381342|NCT03341507|Experimental|laryngoscopy and tracheal intubation|Tracheal intubation with the rigid tube for laryngoscopy for patients with difficult airway. Prior the use of rigid tube for laryngoscopy, a classical laryngoscopy with a McIntosh laryngoscope will be performed.
89381343|NCT05216744|Experimental|Doxycycline plus ceftriaxone|Each subject will receive 100 mg doxycycline twice daily for seven days and a single dose of ceftriaxone 1000 mg intravenously
88854195|NCT01755702|Experimental|Arm 4|experimental paracetamol + caffeine formulation
88854196|NCT01732458|Experimental|Aprepitant Dose 1: Equivalent to 125 mg in Adults|Pediatric participants receive a single dose of apprepitant that is equivalent to 125 mg in adults on Day 1 between 1 and 3 hours prior to expected induction of anesthesia, plus placebo for odansetron administered intravenously (IV) immediately prior to anesthesia.
88854197|NCT01732458|Experimental|Aprepitant Dose 2: Equivalent to 40 mg in Adults|Pediatric participants receive a single dose of apprepitant that is equivalent to 40 mg in adults on Day 1 between 1 and 3 hours prior to expected induction of anesthesia, plus placebo for odansetron administered IV immediately prior to anesthesia.
88854198|NCT01732458|Experimental|Aprepitant Dose 3: Equivalent to 10 mg in Adults|Pediatric participants receive a single dose of apprepitant that is equivalent to 10 mg in adults Day 1 between 1 and 3 hours prior to expected induction of anesthesia, plus placebo for odansetron administered IV immediately prior to anesthesia.
88854199|NCT01732458|Active Comparator|Ondansetron|Pediatric participants in the control regimen are administered ondansetron IV on Day 1 immediately prior to induction of anesthesia plus a matching placebo dose to aprepitant as a single oral dose on Day 1 between 1 and 3 hours prior to expected induction of anesthesia.
88854200|NCT01731990|Experimental|Canakinumab (ACZ885)|Monthly subcutaneous doses of Canakinumab 150 mg/1 mL for 12 months
88854201|NCT01731990|Placebo Comparator|Placebo|Monthly subcutaneous doses of placebo of Canakinumab 150 mg/1 mL for 12 months
88854202|NCT01708902|Experimental|linagliptin2.5mg / metformin500mg BID|patient to receive a tablet containing linagliptin 2.5mg and metformin 500mg BID
88854203|NCT01708902|Experimental|linagliptin2.5mg / metformin1000mg BID|patient to receive a tablet containing linagliptin 2.5mg and metformin 1000mg BID
89381344|NCT05216744|Active Comparator|Doxycycline plus cefixime|Each subject will receive 100 mg doxycycline twice daily for seven days and a single oral dose of cefixime 800 mg
89381345|NCT05681897|Other|Single Spin Group|Currently, the standard operating procedures for PRP preparation in dr. Cipto Mangunkusumo National General Hospital is by performing a single-spin centrifugation at 3000 rpm for 15 minutes. This first group will received PRP treatment by single-spin centrifugation at 3000 rpm in 15 minutes in addition to topical minoxidil (5%)
89381346|NCT05681897|Active Comparator|Double Spin Group|This group will received double-spin centrifugation PRP treatment at 1500 rpm in 6 minutes and continued at 2500 rpm in 15 minutes in addition to topical minoxidil (5%)
89381347|NCT03641222|Experimental|Group Acupuncture|Group acupuncture sessions take place in a multipurpose room, with 3-6 participants, each session lasts 30-45 minutes, occurring twice-weekly, over the course of six weeks, for a total of twelve treatments. The acupuncture was administered by a Naturopathic Doctor.
89381348|NCT03641222|Active Comparator|Individual Acupuncture|Individual acupuncture sessions take place in a multipurpose room, privately each session lasts 30-45 minutes, occurring twice-weekly, over the course of six weeks, for a total of twelve treatments. The acupuncture was administered by a Naturopathic Doctor.
89381349|NCT01345058|Experimental|Lacosamide + Low-Dose Levetiracetam|Participants received lacosamide 50 mg twice a day for one week followed by 100 mg twice daily added to low dose levetiracetam ≤1500 mg/day (polytherapy) for 6 months in patients with breakthrough seizures on low-dose levetiracetam.
89381350|NCT01345058|Other|Control Group (High-Dose Levetiracetam)|Historical chart review of patients whose dose of levetiracetam was raised to high dose levetiracetam >1500 mg/day (monotherapy) after a breakthrough seizure. No intervention was administered in the study.
89381351|NCT03642236|Experimental|BTK treatment|Ibrutinib 420mg day -3 to d14; Decitabine 20mg/m2 d1-5; Aclacinomycin 10mg/m2 d1-5; Cytarabine 15mg/m2 q12h d1-14; G-CSF 200ug/m2 -12h to d14; Sorafenib 0.4g bid continously at the condition of being naive to sorafenib.
89381352|NCT03642236|Active Comparator|BTK-free treatment|Decitabine 20mg/m2 d1-5; Aclacinomycin 10mg/m2 d1-5; Cytarabine 15mg/m2 q12h d1-14; G-CSF 200ug/m2 -12h to d14; Sorafenib 0.4g bid continously at the condition of being naive to sorafenib.
88854204|NCT01708902|Active Comparator|metformin 500mg BID|patient to receive a tablet containing metformin 500mg BID
88854205|NCT01708902|Active Comparator|metformin 1000mg BID|patient to receive a tablet containing metformin 1000mg BID
88854206|NCT01708902|Active Comparator|linagliptin 5 mg QD|patient to receive a tablet containing linagliptin 5mg once daily
88854207|NCT01755546|Experimental|EN3409|Buprenorphine HCI Buccal File at doses ranging from 300-900 mcg twice daily
88854208|NCT04413864|Other|SARS-CoV-2 (Covid-19 positive)|Patients hospitalized in intensive care unit (ICU), infected with SARS-CoV-2
89381353|NCT03642158|Active Comparator|Active TMS|Subjects receive rTMS over the right DLPFC, in 2 second bursts at 10 Hz, followed by a 19 second break, for a total of 20 minutes. Stimulator intensity is set to 80% of motor threshold on day one, and 100% of motor threshold for the remainder of intervention. This paradigm is continued for 5 consecutive days.
88854209|NCT04560504|Placebo Comparator|Control Group|Receive 10 sessions of 45-minute (3 sessions per week) in-office leisure activities e.g. simple non-action computer games or board games (e.g. card and chess games) and 10-20 minutes of video watching at home
89381354|NCT03642158|Sham Comparator|Sham TMS|"Identical to active arm, but stimulator intensity is reduced to 30% of motor threshold, and the stimulator coil is oriented tangentially to the skull to stimulate air space above the head instead of cortical tissue."
89381355|NCT05389215|Experimental|DWN12088 Xmg Tablet (BID)|PRS inhibitor
88854210|NCT04560504|Active Comparator|Intervention Group|Receive 10 sessions of 45-minute office training (3 sessions per week) and 10-20 minute home training (3 sessions per week) of eye movement training
88854211|NCT01755234|Active Comparator|Sevoflurane|Sevoflurane administered by inhalation (laryngeal mask airway or endotracheal tube)
88854212|NCT01755234|Active Comparator|Propofol|Propofol administered via intravenous catheter at an initial rate of 1.0 -2.0 mg/kg then the Propofol infusion rate will be titrated to keep a bispectral index between 40-60
89381356|NCT05389215|Placebo Comparator|Placebo 0mg Tablet (BID)|Placebo
89381357|NCT01345292|Experimental|12027-027|Rinse with 10 ml of the assigned mouthwash for 60 seconds after you brush in your usual manner twice daily for one minute using at least a one-inch strip of the assigned toothpaste
89381358|NCT01345292|Active Comparator|310158077046|Brush in your usual manner twice daily for at least one minute using at least a one-inch strip of the assigned toothpaste
89381359|NCT01345292|Placebo Comparator|037000003212|Brush in your usual manner twice daily for at least one minute using at least a one-inch strip of the assigned toothpaste
89381360|NCT03340961|Experimental|DFD-29 Extended Release Capsules (40 mg)|DFD-29 (minocycline HCl) Extended Release Capsules (40 mg) once per day for 16 weeks.
89381361|NCT03340961|Experimental|DFD-29 Extended Release Capsules (20 mg)|DFD-29 (minocycline HCl) Extended Release Capsules (20 mg) once per day for 16 weeks.
89381362|NCT03340961|Experimental|Oraycea® (doxycycline) Capsules|Oraycea® (doxycycline) Modified Release Hard Capsules (40 mg) once per day for 16 weeks.
88854213|NCT01731912|Experimental|Treatment (degarelix acetate, EBRT)|Patients receive degarelix acetate SC on day 1. Treatment repeats every 4 weeks for up to 6 courses. Beginning at week 15, patients also undergo standard EBRT for 8.5 weeks.
88854214|NCT01731678|Experimental|Transcranial Magnetic Stimulation|The standardized treatment location will be the left DLPFC. Anatomical T1 images from the pre-intervention MRI will be loaded into our Transcranial Magnetic Stimulation (TMS) lab neuronavigation software (Brainsight2, Rogue Research, Montreal). Following 3D co-registration of the TMS coil with the patient's MRI images and head, the coil will be placed over the left DLPFC (tangential to scalp, angle of 45 degrees to midline). Interventional repetitive TMS (rTMS) (Magstim Rapid2, Wales, UK) will consist of 40 suprathreshold (120% RMT) pulses over 4 seconds (10 Hz) with an inter-train interval of 26 seconds. Treatment sessions will last 37.5 minutes (75 trains/3000 pulses). Treatments will occur on each weekday for three weeks (15 days total).
88854215|NCT01731600|Experimental|N8-GP|
88854216|NCT01730586|Experimental|Abraxane|Abraxane 220 mg/m2 administered by vein on Day 1. A cycle of therapy is defined as 21 days.
88854217|NCT04413942|Active Comparator|FB825|FB825
88854218|NCT04413942|Placebo Comparator|Placebo|Formulation buffer
88854219|NCT01707030|Experimental|BAI Arm|Receiving a web-based brief intervention for alcohol problems
89381363|NCT03340961|Placebo Comparator|Placebo Capsules|Placebo Capsules once per day for 16 weeks.
89381364|NCT04077879|Experimental|Single ascending dose of ASP1617|This is composed of 5 sequential cohorts (cohorts 1.1 to 1.5), 6-9 participants for each cohort, consisting of either only non-Asians in cohorts 1.1 and 1.2; or non-Asians plus Japanese in cohorts 1.3, 1.4 and 1.5). Participants in cohorts 1.1, 1.2, 1.3, 1.4 and 1.5 will receive a single dose of 2, 10, 30, 100 and 300 milligrams (mg) ASP1617 capsules respectively under fasting conditions
89381365|NCT04077879|Placebo Comparator|Single ascending dose of Placebo|Participants (2-3 for each cohort, consisting of either only non-Asians in cohorts 1.1 and 1.2; or non-Asians plus Japanese in cohorts 1.3, 1.4 and 1.5) will receive a single dose of matching placebo under fasting conditions.
88854220|NCT01707030|Active Comparator|Usual Care|In usual care, Hepatitis C clinic staff will sometimes discuss alcohol use with patients, and this will be the experience of some of the controls
88854221|NCT01755156|Experimental|Omarigliptin (Phase A) → Omarigliptin (Phase B)|Phase A: Omarigliptin 25 mg capsule administered orally once weekly for 24 weeks. Phase B: Omarigliptin 25 mg capsule administered orally once weekly and matching placebo to glimepiride tablet/capsule administered orally once daily for 80 weeks. Participants will continue pre-study metformin throughout the duration of the study. If necessary, rescue therapy may be initiated (open-label glimepiride during Phase A and insulin glargine during Phase B).
89381366|NCT04077879|Experimental|Single dose of ASP1617 (Food Effect)|Participants (6 Japanese and 3 non-Asian) will receive a single dose of 100 mg ASP1617 with a high-fat meal. Dosing of the Food Effect cohort will commence after having established the safety and tolerability of the dose tested in cohort 1.4.
89381367|NCT04077879|Experimental|Multiple ascending dose of ASP1617|"This is composed of 3 sequential cohorts (cohorts 2.1 to 2.3, 9 participants for each cohort, consisting of only non-Asians in cohort 2.1, or non-Asians plus Japanese in cohorts 2.2 and 2.3). Participants in cohorts 2.1, 2.2 and 2.3 will receive 30, 60 and 110 mg ASP1617 capsules respectively twice daily for 14 consecutive days at the same dose level.~Based on safety, tolerability and pharmacokinetic data of Part 1, once daily or twice daily dosing will be selected."
89381368|NCT04077879|Placebo Comparator|Multiple ascending dose of Placebo|Participants (3 for each cohort, consisting of either only non-Asians in cohort 2.1, or non-Asians plus Japanese in cohort 2.2 and 2.3) will receive matching Placebo for 14 consecutive days at the same dose level in cohort 2.1 to 2.3.
89381369|NCT03340025|Experimental|negative pressure wound therapy|PICO Single Use Negative Pressure Wound Therapy System
89381370|NCT03340025|Placebo Comparator|conventional dressing|traditional surgical wound dressing of xeroform gauze and padding
89381371|NCT03642080||Glioblastoma|Patients with a diagnosis of newly diagnosed or recurrent glioblastoma who have been treated with radiation and temozolomide and are being offered tumor treated fields.
89381372|NCT05283434|Placebo Comparator|Double-Blind Clinical Trial- Placebo Group|Patients will be assigned to the placebo (e.g., unmedicated sugar pill) or experimental group (e.g., Arnica 1M pellets) via a randomization chart from that only the research pharmacist will have access to. Subjects assigned to the placebo group will take the recommended doses of sugar pellets (i.e., 2 pills to be taken every 4 waking hours over a 24 hours period), and will track their pain scores, swelling measurements, sleep rate, ibuprofen doses, adverse reactions, further ED visits, and the number of days/activities the patient has missed for 3 days following their enrollment in the study.
89381373|NCT05283434|Experimental|Double-Blind Clinical Trial- Experimental Group|
89381374|NCT03643874|Experimental|Halix albuterol 90 mcg|Cumulative doses of albuterol administered by the Halix albuterol 90 mcg UDDI will given at intervals as: 1 inhalation, then 1 inhalation 30 min later, then 2 inhalations 30 min later, and then 4 inhalations 30 min later.
89381375|NCT03643874|Active Comparator|Albuterol HFA MDI 90 mcg|Cumulative doses of albuterol administered by the albuterol HFA albuterol 90 mcg MDI will given at intervals as: 2 inhalations, then 2 inhalations 30 min later, then 4 inhalations 30 min later, and then 8 inhalations 30 min later.
89381376|NCT03641144|Experimental|Navigation laser|Navigation laser photocoagulation treatment to the macular area of retinal thickening with a focal pattern and/or grid pattern
89381377|NCT03641144|Active Comparator|Traditional laser|Traditional laser photocoagulation treatment to the macular area of retinal thickening with a focal pattern and/or grid pattern
89381378|NCT03339713|Experimental|Ad26.RSV.preF Plus Fluarix Then Placebo: Group 1|Participants will receive intramuscular injection of 1*10^11 viral particles (vp) of an adenovirus serotype 26- based vaccine encoding for the respiratory syncytial virus pre-fusion F protein (Ad26.RSV.preF) on 1 arm administered at the same time as a commercially available seasonal influenza vaccine (Fluarix) on the other arm at Day 1, and intramuscular injection of placebo on Day 29.
89381379|NCT03339713|Experimental|Placebo Plus Fluarix Then Ad26.RSV.preF: Group 2|Participants will receive intramuscular injection of placebo administered at the same time as a commercially available seasonal influenza vaccine (Fluarix) on Day 1, and 1*10^11 vp of Ad26.RSV.preF on Day 29.
89381380|NCT03641066|Experimental|Ankle Brace|Each participant will complete a baseline analysis of 1 minute of walking and 2 minutes of running, repeated 4 more times wearing 4 different braces. The analysis will be completed on the Walker View Treadmill, which used 3D camera technology to capture lower body kinematics. The treadmill also has load cells built in to capture gait characteristics
88854222|NCT01755156|Placebo Comparator|Placebo to omarigliptin (Phase A) → Glimepiride (Phase B)|Phase A: matching placebo to omarigliptin orally once a week for 24 weeks. Phase B: Matching placebo to omarigliptin capsule administered orally once weekly and glimepiride 1 or 2 mg tablet/capsule administered orally once daily (titrated up to 6 mg daily) for 80 weeks. Participants will continue pre-study metformin throughout the duration of the study. If necessary, rescue therapy may be initiated (open-label glimepiride during Phase A and insulin glargine during Phase B).
88854223|NCT01754922||Exposed|Veterans deployed to OEF/OIF/OND and environmentally exposed to high levels of particulate matter
88854224|NCT01754922||Control|OEF/OIF/OND Veterans deployed to regions other than Southwest Asia
88854225|NCT01754766|Experimental|AGN-229666 Dose A|One drop of AGN-229666 Dose A into each eye on Day 1 and Day 15.
88854226|NCT01754766|Experimental|AGN-229666 Dose B|One drop of AGN-229666 Dose B into each eye on Day 1 and Day 15.
88854227|NCT01754766|Placebo Comparator|vehicle of AGN-229666|One drop of vehicle of AGN-229666 into each eye on Day 1 and Day 15.
88854228|NCT01754376|Experimental|Treatment Arm|"Oral vemurafenib 960 milligrams twice a day plus intravenous aldesleukin 600,000 IU/kg every eight hours to tolerance (maximum 14 doses) over five days on days 15-19 of cycle 1 and on days 1-5 of cycle 2. (A cycle is 28 days)~The first course of treatment will consist of three 28-day cycles (12 weeks): 2 weeks of lead-in vemurafenib plus 3 weeks on IL-2 plus 7 weeks wait.~A second course may be given at the discretion of the investigator, if there is evidence of tumor stability or regression."
89381381|NCT03641768|Active Comparator|Healthy volunteers|Volunteers with no trauma history
89381382|NCT03641768|Active Comparator|Trauma only|Volunteers that do not have PTSD but have had similar trauma to those with PTSD
89381383|NCT03641768|Active Comparator|PTSD only|Volunteers with PTSD but no traumatic brain injury
89381384|NCT03641768|Active Comparator|PTSD and TBI|Volunteers with PTSD and mild traumatic brain injury
89381385|NCT03254485|Experimental|IW-1973 High Dose|
89381386|NCT03254485|Placebo Comparator|Placebo|Placebo to match experimental drug
89381387|NCT03621176|Experimental|Home-based exercise|Home-based intervention in the advanced chronic kidney disease group, hemodialysis or peritoneal dialysis group
89381388|NCT03641612|Experimental|one shape|single file rotary system
89381389|NCT03641612|Active Comparator|protaper next|multiple file rotary system
89381390|NCT01068704|Active Comparator|BMS-690514 + Letrozole|
89381391|NCT01068704|Active Comparator|Lapatinib + Letrozole|
89381392|NCT00352573||Normal Volunteers|Adults over 21 years old
89381393|NCT05179681||patients with non-intubated thoracic surgery|
89183302|NCT05159193|Active Comparator|TCbHP|docetaxel (T) 75 mg/m^2, i.v., d1 + carboplatin (Cb) AUC 6, i.v., d1 + trastuzumab (H) 8 mg/kg loading dose, 6 mg/kg maintenance doses, i.v., d1 + pertuzumab (P) 840 mg loading dose, 420 mg maintenance doses, i.v., d1 q3w, for 6 cycles. After neoadjuvant therapy, patients are required to receive a total of 1 year of treatment with trastuzumab (6mg/kg) combined with pertuzumab (420mg), i.v., d1, q3w, regardless of surgery.
89183303|NCT05156710|Experimental|BIVV020 with Standard of Care (SOC) Cohort A|Eligible participants will receive BIVV020 and SOC immunosuppression including induction therapy, tacrolimus, and mycophenolate.
89183304|NCT05156710|Experimental|BIVV020 with Standard of Care (SOC) Cohort B|Eligible participants will receive BIVV020 and SOC which includes plasmapheresis, IVIg, corticosteroids, rituximab.
89183305|NCT05156710|Other|Standard of Care (SOC) Cohort B|SOC includes plasmapheresis, IVIg, corticosteroids, rituximab.
89183306|NCT05151640||Nintedanib treatment group|
89183307|NCT05113368|Experimental|Oral Regorafenib combined with intra-muscular injection of Fulvestrant|Oral regorafenib in a ReDOS plan (80 mg week#1, 120 mg week#2, 160 mg week#3 for cycle #1 then adjust final dose for subsequent cycles based on tolerance during cycle #1) [3 weeks on/1 week off] combined with intramuscular injection of fulvestrant 500 mg day #1 (day #15 will be planned only in cycle #1) in a 28-day cycle till disease progression or unacceptable toxicities
89183308|NCT05110742|Experimental|Phase 1 Dose Level|"CAR.5/IL15-transduced CB-NK cells Dose level 1, 1e7 cryopreserved cells flat dose Dose level 2, 1e8 cryopreserved cells flat dose Dose level 3, 1e9 cryopreserved cells flat dose Dose level 4, 1e10 cryopreserved cells flat dose~All patients will receive Lymphodepleting Chemotherapy of Cyclophosphamide and Fludarabine."
89183309|NCT05110742|Experimental|Phase 2 Dose Level|"Patients will be randomized between the 2 optimal doses of CAR.5/IL15-transduced CB-NK cells determined by Phase 1.~All patients will receive Lymphodepleting Chemotherapy of Cyclophosphamide and Fludarabine."
89183310|NCT05109728|Experimental|Group 1 - Newly diagnosed GB|Participants with newly diagnosed glioblastoma will receive [177Lu]Lu-DOTA-TATE every 4 weeks +/- 2 days, starting 7 to 10 days prior to initiation of Radiotherapy (RT) and Temozolomide (TMZ)
89183311|NCT05109728|Experimental|Group 3 - Recurrent GB|Participants with recurrent glioblastoma will receive [177Lu]Lu-DOTA-TATE as single agent therapy every 3 weeks +/- 2 days
89183312|NCT05098054|Experimental|Arm 1, Moderate HI: Soticlestat 300 mg|Soticlestat 300 mg, tablets, orally, once on Day 1 to participant with moderate HI.
89183313|NCT05098054|Experimental|Arm 2, Mild HI: Soticlestat 300 mg|Soticlestat 300 mg, tablets, orally, once on Day 1 to participant with mild HI.
89183314|NCT05098054|Experimental|Arm 3, Normal hepatic function: Soticlestat 300 mg|Soticlestat 300 mg, tablets, orally, once on Day 1 to healthy participants.
89183315|NCT05090371|Experimental|Ofatumumab|20 mg
89183316|NCT05090371|Active Comparator|DMT continued therapy|Participants randomized to the continued therapy arm will continue to take their disease modifying treatment (DMT) as prescribed commercially by their physician.
89183317|NCT05088863|Other|Implementation of health claim|Participants will have 2 weeks to incorporate 40g of flaxseed per day into their diet
89183318|NCT05084638|Experimental|Ofatumumab|Ofatumumab will be provided in an autoinjector for subcutaneous administration. Dosing regimen for this study is an initial dose of 20mg at Baseline/Week 0, followed by Week 1, 2 and every month thereafter, beginning at Week 4 (Month 1) until Month 18. There will be an optional extension of dosing through month 30.
89183319|NCT05084638|No Intervention|Healthy Control|Healthy Control arm will be age- and sex-matched subjects (to the ofatumumab treated arm) and will not receive a study treatment.
89183320|NCT05063331|Active Comparator|Sacrocolpopexy|Minimally invasive supracervical hysterectomy with sacrocolpopexy (MI-SCH+SCP)
89183321|NCT05063331|Active Comparator|Uterosacral Ligament Suspension|Total vaginal hysterectomy with uterosacral ligament suspension (TVH+USLS)
89183322|NCT05056675|Experimental|PENG block for anterior total hip arthroplasty or surgical hip dislocation|All patients will undergo the same preoperative, standardized protocol. Upon arrival to the operating theatre, routine, standard pre-medication will be applied before induction of general anesthesia. After intubation, the PENG block is performed. Under sonographic guidance, 20 mL of 0.5% ropivacaine iv is injected.
89183323|NCT05056675|Placebo Comparator|Placebo for anterior total hip arthroplasty or surgical hip dislocation|All patients will undergo the same preoperative, standardized protocol. Upon arrival to the operating theatre, routine, standard pre-medication will be applied before induction of general anesthesia. After intubation, the PENG block is performed. Under sonographic guidance, 20 mL of NaCL 0.9% is injected.
89183324|NCT05042284|Experimental|NE PERT|Non-enteric coated pancreatic enzyme capsules containing 30,000U of protease will be provided three times a day along with food (breakfast, lunch and dinner)
89183325|NCT05042284|Placebo Comparator|Placebo|Similar appearing glucose capsules will be provided three times a day along with food (breakfast, lunch and dinner)
89183326|NCT05039307|Experimental|Intervention group (Educational and motivational strategy)|The intervention group will be provided with a multi-component intervention entailing the following components distributed over the 24-months study: 4 individualized education sessions at the household, 4 group activities (2 group education sessions and 2 physical activity sessions) at the healthcare center, and 4 focus groups at the healthcare center as well. The motivational components of goal setting and the use of a pedometer will be incorporated in the individualized education sessions. Moreover, community activities will be incorporated in the second year of the study after exploring whether the activities are feasible and acceptable by the community. The topics covered by the intervention are healthy diet, physical activity, weight control strategies and knowledge and awareness of T2DM and GDM. Additionally, at baseline participants will be provided with a healthy lifestyle brochure with general recommendations.
89381394|NCT03339401|Experimental|Brincidofovir|"Brincidofovir (BCV) for the treatment of adenovirs (AdV) infection in high-risk pediatric allogeneic hematopoietic cell transplant (HCT) recipients.~Brincidofovir (BCV) treatment began no later than 100 days post-transplant and was to continue for a maximum of 16 weeks. Brincidofovir (BCV) was discontinued once AdV viremia was confirmed undetectable.~Subjects who did NOT receive concurrent cyclosporine on Day 1:~If ≥48kg body weight, one 100mg oral tablet BIW (or 10mL of 10mg/mL oral suspension if unable to take tablets).~If <48kg body weight, 2mg/kg oral volume of 10mg/mL oral suspension BIW.~Subjects who received cyclosporine on Day 1 (or initiated cyclosporine at any time):~1.4mg/kg (maximum of 70mg) oral volume of 10mg/mL oral suspension BIW.~2mg/kg (maximum of 100mg) oral volume of 10mg/mL oral suspension BIW if discontinued cyclosporine."
89381395|NCT03339401|Other|Standard of Care|"Local institutional standard of care (SoC) (i.e., investigator-assigned therapy) for the treatment of adenovirus infection in high-risk pediatric allogeneic hematopoietic cell transplant (HCT) recipients.~Management of these subjects was prescribed by the investigator as being in the best interests of the subject and may have included a watch-and-wait approach, with or without decreased immunosuppression (ergo, no treatment), or treatment administration with other available antivirals, most commonly cidofovir intravenously.~Decisions regarding SoC, including administration of therapy, dose and regimen of therapy, modification of immunosuppression, and monitoring was the responsibility of the clinical team caring for the subject, according to institutional guidelines, local practices, and applicable guidelines for the management of AdV infection."
89381396|NCT05179525|Experimental|Risperidone ISM® 100 mg|Subjects will receive 4 mg oral risperidone once daily for 7 days. After the 1 week oral risperidone regimen subjects will be administered 100 mg risperidone ISM as an injectable into the gluteal muscle. A total of 4 doses of intramuscular (IM) 100 mg risperidone ISM® will be administered deeply into the gluteal muscle. Each dose will be separated by 4 weeks.
88854229|NCT01605396|Experimental|Ridaforolimus + Dalotuzumab + Exemestane|Participants receive ridaforolimus 10 mg orally (PO) every 5 days (QD x 5) plus dalotuzumab 10 mg/kg intravenously (IV) every week (QW) plus exemestane 25 mg PO every day (QD) in 28-day cycles until documented disease progression or unacceptable toxicity.
89381397|NCT05179291|Experimental|Buzzy Group|In this group external cold and vibration-Buzzy was applied to the children during phlebotomy.
89381398|NCT05179291|Experimental|Virtual Realitiy-VR Group|In this group Virtual Realitiy-VR was applied to the children during phlebotomy.
89381399|NCT05179291|No Intervention|Control Group|In this group, children received routine phlebotomy procedure
89381400|NCT04362709||Postoperative complications|
89381401|NCT04362709||No postoperative complications|
89381402|NCT05692206||according to the neck disability index, mildly and moderately affected|
89381403|NCT05692206||According to the neck disability index, severely affected and very severely affected|
89381404|NCT03370289|Experimental|BLB-750 Qinghai RG strain|Two doses of BLB-750 Qinghai reverse genetics (RG) strain at a vaccination dose of 0.5 mL (HA antigen level of 7.5 µg per strain) will be injected into the upper arm muscle (the deltoid muscle) at 3-week intervals (Day 1 and Day 22) in a treatment period of 43 days.
89381405|NCT01344824|Other|Single Arm Trial|Bevacizumab, Carboplatin, and Pemetrexed disodium, with option for second line erlotinib hydrochloride
89381406|NCT04320511||Patients with SARS-COV 2|Patients with SARS-COV 2 undergoing CT-V
89381407|NCT04292197|Experimental|18-MC SAD Study|In Part 1, healthy participants will be randomized into cohorts to receive 18-MC HCl or placebo twice in 1 day.
89381408|NCT04292197|Experimental|18-MC MAD Study|In Part 2, healthy participants will be randomized into cohorts to receive 18-MC HCl or placebo twice a day for 7 consecutive days.
89381409|NCT05137496|Experimental|Ruxolitinib+methylprednisolone|Ruxolitinib and methylprednisolone administered as the first-line therapy
89381410|NCT03708185|Experimental|HIIT + beta-alanine|Participants will ingest an active supplement containing beta-alanine for a period of 12 weeks. During the last 8 weeks of that period, participants will take part in a structured program of high-intensity interval training.
89381411|NCT03708185|Experimental|HIIT + placebo|Participants will ingest a placebo supplement containing no beta-alanine for a period of 12 weeks. During the last 8 weeks of that period, participants will take part in a structured program of high-intensity interval training.
89381412|NCT03640676|Sham Comparator|INP -10mmHg|In addition to standard medical treatment, patients will receive treatment with FlowOx, applying intermittent negative pressure of -10mmHg one hour in the morning and one hour in the evening at home for 12 weeks.
89381413|NCT03640676|Active Comparator|INP -40mmHg|In addition to standard medical treatment, patient swill receive treatment with FlowOx, applying intermittent negative pressure of -40mmHg one hour in the morning and one hour in the evening at home for 12 weeks.
89381414|NCT03640598|Other|Ilioinguinal/iliohypogastric nerve blocks|The patient will receive ultrasound-guided Ilioinguinal/iliohypogastric nerve blocks
89381415|NCT03640598|Other|Erector spinae nerve block|The patient will receive ultrasound-guided erector spinae nerve block
88854230|NCT01605396|Active Comparator|Ridaforolimus + Exemestane|Participants receive ridaforolimus 30 mg PO QD x 5 plus exemestane 25 mg PO QD treatment in 28-day cycles until documented disease progression or unacceptable toxicity.
88854231|NCT01730118|Experimental|1/Part I dose escalation|Adenoviral Transduced Autologous Human epidermal growth factor receptor (AdHER) dendritic cell (DC) vaccine administered at escalating doses
88854232|NCT01730118|Experimental|2/Part I dose expansion|Adenoviral Transduced Autologous Human epidermal growth factor receptor (AdHER) dendritic cell (DC) vaccine administered at a next lower dose or the highest dose
88854233|NCT01730118|Experimental|3/Part 1 dose escalation|Adenoviral Transduced Autologous Human epidermal growth factor receptor (AdHER) dendritic cell (DC) vaccine administered at Dose Level 1
88854234|NCT01730118|Experimental|4/Part II dose escalation|Adenoviral Transduced Autologous Human epidermal growth factor receptor (AdHER) dendritic cell (DC) vaccine administered at Dose Level 1
89381416|NCT03339245|Experimental|Glucose, Then Fructose|Participants first receive Glucose Solution (75 grams) from Day 3 through Day 16 of an inpatient stay with usual diet. After a 2-3 week washout period, they will then receive Fructose Solution (75 Grams) from Day 3 through Day 16 on a second inpatient stay with usual diet.
89381417|NCT03339245|Experimental|Fructose, Then Glucose|Participants first receive Fructose Solution (75 grams) from Day 3 through Day 16 of an inpatient stay with usual diet. After a 2-3 week washout period, they will then receive Glucose Solution (75 grams) from Day 3 through Day 16 on a second inpatient stay with usual diet.
89381418|NCT03044574|Experimental|Experimental group (SCD + GCS + LMWH)|"SCD: Intermittent pneumatic compression (IPC) with Kendall SCD™ Sequential Compression System 700 used continuously when the patient is in bed with 6-hours night interval free of compression: from 0 a.m. to 6 a.m. In the ICU SCD used continuously all day, and in surgery department - all time of bed resting. SCD used until discharge.~GCS: Thigh-length graduated compression stockings with pressure of 18-21 mm. Hg at the ankle used all the time until discharge plus one month after discharge~LMWH: LMWH enoxaparin (Clexane) 40 mg once a day subcutaneously started on 1st or 2-5th postoperative day according to the bleeding risk and used until discharge."
89381419|NCT03044574|Active Comparator|Control group (GCS + LMWH)|"GCS: Thigh-length graduated compression stockings with pressure of 18-21 mm. Hg at the ankle used all the time until discharge plus one month after discharge~LMWH: LMWH enoxaparin (Clexane) 40 mg once a day subcutaneously started on 1st or 2-5th postoperative day according to the bleeding risk and used until discharge."
89381420|NCT02959892|Experimental|TAK-041 20 mg|[11C] PHNO 180 megabecquerel (MBq), injection, intravenously, prior to positron emission tomography (PET) scan on Day 1, followed by amphetamine (AMPH) 0.5 milligram per kilogram (mg/kg), tablet, orally, once and [11C] PHNO 180 MBq, injection, intravenously, prior to PET scan post-AMPH dose on Day 2 of Confinement Period 1, followed by a 5 to 45 days of interval period, further followed by TAK-041 20 mg, suspension, orally, once, followed by AMPH 0.5 mg, tablet, orally, once and [11C] PHNO 180 MBq, injection, intravenously, prior to PET scan post-AMPH dose on Day 1 of Confinement Period 2.
89381421|NCT02959892|Experimental|TAK-041 40 mg|[11C] PHNO 180 MBq, injection, intravenously, prior to PET scan on Day 1, followed by AMPH 0.5 mg/kg, tablet, orally, once and [11C] PHNO 180 MBq, injection, intravenously, prior to PET scan post-AMPH dose on Day 2 of Confinement Period 1, followed by a 5 to 45 days of interval period, further followed by TAK-041 40 mg, suspension, orally, once, followed by AMPH 0.5 mg, tablet, orally, once and [11C] PHNO 180 MBq, injection, intravenously, prior to PET scan post-AMPH dose on Day 1 of Confinement Period 2.
89381422|NCT05425277|Experimental|RIT Training Group|Providers in the RIT group (n=30) will receive an 8-hour virtual workshop (2 half-days) on RIT implementation and caregiver coaching. Each provider will invite 2 families in their caseload to participate in the study. Providers will coach families in the use of RIT. One intervention session for each enrolled family will be videotaped and scored for RIT fidelity.
89381423|NCT05425277|Active Comparator|Daily Routines|Providers in the Routines Control group (n=30) will receive a 3-hour virtual workshop focused on helping providers coach caregivers on how to increase children's participation and social engagement during everyday home routines (i.e., snack time, bedtime, bath time, and family playtime). Each provider will invite 2 families in their caseload to participate in the study. One intervention session for each enrolled family will be videotaped and scored for RIT fidelity to ensure contamination has not occurred and the control condition providers are not utilizing RIT strategies.
89381424|NCT03252145|Experimental|Negative Pressure|PhysioTouch (negative pressure massage) treatment 3 times a week for 4 weeks to the lymphedematous upper limb
89381425|NCT03252145|Active Comparator|Manual Lymph Drainage|Manual lymph drainage (MLD) treatment 3 times a week for 4 weeks to the lymphedematous upper limb
89381426|NCT03666624|Experimental|Personalized care network|9 60-minute virtual sessions for 6 weeks plus personalized exercise coaching once a week for 6 weeks
89381427|NCT03666624|No Intervention|Routine medical care|No intervention
89381428|NCT03368807||Blinded CGM (Continuous Glucose Monitoring)|Participants received Insulin lispro 100 U/mL (units per millilitre) injected via the pen and they were blinded to CGM device recording as directed in study period 1.
89381429|NCT03368807||Unblinded CGM|Participants received Insulin lispro 100 U/mL injected via the pen and they were unblinded to CGM device recording as directed in study period 2.
89381430|NCT05225129|Experimental|Training Group|Resistance training will be applied to the training group, equivalent to 30% of 1 maximum repetition with blood flow restricted exercise for 8 weeks , 2 days in a week.
89381431|NCT05225129|No Intervention|Control Group|Resistance training will be applied to the control group, equivalent to 30% of 1 maximum repetition without blood flow restriction for 8 weeks , 2 days in a week.
89381432|NCT05179213|Experimental|Azacytidine combined with chidamide|Patients in the experimental arm will received azacytidine plus chidamide treatment. This regimen was repeated every 28 days.
88854235|NCT01730118|Experimental|5/Part II dose expansion|Adenoviral Transduced Autologous Human epidermal growth factor receptor (AdHER) dendritic cell (DC) vaccine administered at Arm 1 maximum tolerated dose (MTD)
89381433|NCT03338855|Active Comparator|Dapagliflozin|"Patients will receive dapagliflozin 10 mg in tablet for a maximum of 40 days based on randomization sequence in Period 1.~Patients that received 10 mg dapagliflozin in the first treatment period will receive matching placebo in the second treatment period for a maximum of 40 days."
89381434|NCT03338855|Placebo Comparator|Placebo matching to dapagliflozin|"Patients will receive matching placebo in tablet for a maximum of 40 days based on randomization sequence.~Patients who received placebo in the first treatment will receive 10 mg dapagliflozin in the second treatment period, for a maximum of 40 days"
89381435|NCT05499624|Experimental|MicroTrend System|MicroTrend System is placed onto the subject's cheek and the subject will actively participate in the study for up to 6 hours, with up to 4 hours of sensor monitoring.
89183327|NCT05039307|No Intervention|Comparison group (Basic educational strategy)|The comparison group will be limited to receive the healthy lifestyle brochure with general recommendations at baseline only.
89183328|NCT05038254|Active Comparator|Arm I (standard of care)|Patients receive standard of care consisting of oncology care provided via telemedicine.
89381436|NCT03367793|Experimental|Clinical, then Metric #1, then Metric #2|Each subject will receive all three spectacle prescription interventions dispensed in randomized order for 2 months of wear each. Subjects in this arm of the study will receive the clinically derived prescription first, followed by the metric-derived #1, and lastly the metric-derived #2.
89381437|NCT03367793|Experimental|Clinical, then Metric #2, then Metric #1|Each subject will receive all three spectacle prescription interventions dispensed in randomized order for 2 months of wear each. Subjects in this arm of the study will receive the clinically derived prescription first, followed by the metric-derived #2, and lastly the metric-derived #1.
89381438|NCT03367793|Experimental|Metric #1, then Clinical, then Metric #2|Each subject will receive all three spectacle prescription interventions dispensed in randomized order for 2 months of wear each. Subjects in this arm of the study will receive the metric-derived #1 prescription first, followed by the clinically derived prescription, and lastly the metric-derived #2 prescription.
89381439|NCT03367793|Experimental|Metric #2, then Clinical, then Metric #1|Each subject will receive all three spectacle prescription interventions dispensed in randomized order for 2 months of wear each. Subjects in this arm of the study will receive the metric-derived #2 prescription first, followed by the clinically derived prescription, and lastly the metric-derived #1 prescription.
89381440|NCT03367793|Experimental|Metric #1, then Metric #2, then Clinical|Each subject will receive all three spectacle prescription interventions dispensed in randomized order for 2 months of wear each. Subjects in this arm of the study will receive the metric-derived #1 prescription first, followed by the metric-derived #2 prescription, and lastly the clinically derived prescription.
89381441|NCT03367793|Experimental|Metric #2, then Metric #1, then Clinical|Each subject will receive all three spectacle prescription interventions dispensed in randomized order for 2 months of wear each. Subjects in this arm of the study will receive the metric-derived #2 prescription first, followed by the metric-derived #1 prescription, and lastly the clinically derived prescription.
89381442|NCT01209234|Active Comparator|MRSA Decolonization|Participants in this arm will be instructed to complete a decolonization regimen that will involve a 5-day application of nasal mupirocin, oral CHG rinse, and CHG body wash twice a month.
89381443|NCT01209234|Active Comparator|Education Arm|Patients randomized to standard education will receive a binder with MRSA educational materials which will include or be based upon CDC guidance for MRSA patients at home. In addition, educational material on hygiene practices to prevent MRSA infection will be provided.
89381444|NCT04151953||Subjects with cardiac implantable electronic device (CIED)|Subjects with previously implanted cardiac implantable electronic device (CIED) who are undergoing an MRI Scan for clinically indicated, diagnostic purposes.
89381445|NCT03626220||acupuncture group|acupuncture with de-chi sensation
89381446|NCT03626220||sham acupuncture group|skin-deep acupuncture without de-chi sensation
89381447|NCT05571241||fast rehabilitation program|conventional rehabilitation
89381448|NCT05691894|Experimental|18F-FAPI|
89381449|NCT05691894|Experimental|68Ga-FAPI|
89381450|NCT05178511|Experimental|hydrochloric acid ensartinib|Ensatinib 225mg daily, QD, until progression or intolerance
89381451|NCT05571163|Experimental|Treatment Sequence AB|"Participants will be administered AMG 510 in the following order:~Period 1 (treatment A) - AMG 510 as oral tablets. Period 2 (treatment B) - AMG 510 as tablets dispersed in water."
89381452|NCT05571163|Experimental|Treatment Sequence BA|"Participants will be administered AMG 510 in the following order:~Period 1 (treatment B) - AMG 510 as tablets dispersed in water. Period 2 (treatment A) - AMG 510 as oral tablets."
89381453|NCT03708107|Experimental|Percutaneous Microelectrolysis (MEP)|"Principal MTrP will be detected by digital palpation in the upper trapezius. Algometry will be used to determine if the Pain Pressure Threshold (PPT) is equal or less than 3 KgF/cm2. If not, the patient will be not included. A mark will be done in the MTrP.~MEP® will be applied with a 0,30 x 25 mm acupuncture needle. The needle will be introduced perpendicularly to the MTrP with 100 uA and then increased up to 600 uA. The current will be paused if the patient feels a burning sensation, pain or oppression, waiting up to the patient feels no discomfort. The procedure will be repeated as many times is necessary until the patient do not feel any discomfort for more than 1 minute.~Algometry will be done immediately finished the intervention, after 10 minutes and at 24 hs."
89381454|NCT03708107|Experimental|Ischemic compression|"Principal MTrP will be detected by digital palpation in the upper trapezius. Algometry will be used to determine if the Pain Pressure Threshold (PPT) is equal or less than 3 KgF/cm2. If not, the patient will be not included. A mark will be done in the MTrP with a marker.~Ischemic compression will be applied perpendicularly to the MTrP, increasing gradually the pression until the patient refers the maximum tolerable pain. This pressure will be applied for 1 minute.~Algometry will be done immediately finished the intervention, after 10 minutes and at 24 hs."
89381455|NCT05691582|Experimental|Single arm|All the subjects recruited have 4 access to GRAIL, in 4 different day, to test their tolerability to the proposals
88854236|NCT01730040|Active Comparator|Atorvastatin 40 mg|Participants, who were receiving atorvastatin 20 mg over-encapsulated tablets orally at baseline, received atorvastatin 40 mg over-encapsulated tablets orally once daily (QD), placebo for alirocumab SC injection every two weeks (Q2W), and placebo for ezetimibe over-encapsulated tablets orally QD added to stable Lipid-Modifying Therapy (LMT) for 24 weeks.
88854237|NCT01730040|Active Comparator|Ezetimibe 10 mg + Atorvastatin 20 mg|Participants, who were receiving atorvastatin 20 mg over-encapsulated tablets orally at baseline, received ezetimibe 10 mg over-encapsulated tablets orally QD, atorvastatin 20 mg over-encapsulated tablets orally QD, and placebo for alirocumab SC injection Q2W added to stable LMT for 24 weeks.
88854238|NCT01730040|Experimental|Alirocumab 75 mg/up to 150 mg + Atorvastatin 20 mg|Participants, who were receiving atorvastatin 20 mg over-encapsulated tablets orally at baseline, received Alirocumab 75 mg SC injection Q2W, atorvastatin 20 mg over-encapsulated tablets orally QD, and placebo for ezetimibe over-encapsulated tablets orally QD added to stable LMT for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when LDL-C levels ≥70 mg/dL (1.81 mmol/L) or ≥100 mg/dL (2.59 mmol/L) at Week 8, based on baseline disease characteristic and medical history.
89381456|NCT03532555|Active Comparator|Zinc plus standard of care|Infants will receive daily doses of zinc at 2mg/kg from enrollment through 35 6/7 weeks corrected gestational age.
89381457|NCT03532555|Placebo Comparator|Standard of care only|Infants will not receive any doses of zinc through 35 6/7 weeks corrected gestational age
89381458|NCT01347307|Other|SBRT for Benign Extradural Spine Tumors|Benign extradural spine tumors such as chordomas, meningiomas, schwannomas, neurofibromas, paragangliomas, and arteriovenous malformations (AVMs).
89381459|NCT01347307|Other|SBRT for Vertebral/Paraspinal Metastases|Vertebral and/or paraspinal metastases, with or without prior surgery and/or fractionated radiotherapy
89381460|NCT03373110|Experimental|Online Mindfulness Based Cognitive Therapy +Fitbit|A central aspect of MBCT is the concept of awareness. Participants practice a variety of meditation types (e.g. breath awareness) and learn to bring mindfulness to everyday situations. Awareness will be directed to elements in participants' lives that interfere with living a more productive, physically active life (e.g. thoughts and feelings that interfere with becoming more physically active; stressful situations and circumstances that prevent them from engaging in exercise). Two hundred participants will be randomized into this group.
89381461|NCT03373110|Experimental|Online Cognitive Behavioral Therapy +Fitbit|1)identifying and setting realistic exercise-based goals and intermediate goals (to maximize success to increase motivation); (2) behavioral scheduling to optimize when to exercise, identify rewards for exercising, and problem solve obstacles to exercising; and (3) identify dysfunctional, maladaptive thoughts about exercise (which decrease motivation) and skills to identify more adaptive, positive thoughts (to overcome thoughts of being too tired or too stressed to exercise). Two hundred participants will be randomized into this group.
89381462|NCT03373110|Active Comparator|Fitbit Alone|Participants assigned to the Fitbit-only control study group you will not be receiving therapy. However, they will receive a Fitbit, which they will be asked to wear over the course of 16 weeks as well as to complete the same schedule of assessments as the therapy arms. One hundred participants will be randomized into this group.
89381463|NCT03993457|Other|CRP<1, CRP consistent antidepressant selection|Participants with CRP<1 will be prescribed escitalopram
89381464|NCT03993457|Other|CRP> or equal to 1, CRP consistent antidepressant selection|Participants with CRP> or equal to 1 will be prescribed bupropion XL
89381465|NCT03993457|Other|CRP<1, CRP inconsistent antidepressant selection|Participants with CRP< 1 will be prescribed bupropion XL
89381466|NCT03993457|Other|CRP> or equal to 1, CRP inconsistent antidepressant selection|Participants with CRP> or equal to 1 will be prescribed escitalopram
89381467|NCT05571085|Experimental|Core Stability Exercises group|"Core stabilization exercises will be performed based on the program recommended by Jeffrey. Each session will take 40-50 minutes. The program consists of a 5-minute warm-up, 40-minute main exercise and a 5-minute cool-down period.~Children will be taught the abdominal cupping technique during the first two weeks of the exercises."
89381468|NCT05571085|Other|PNF Exercise Program|"PNF exercises will consist of a 5-minute warm-up, 40-minute main exercise and a 5-minute cool-down period, with each session lasting 40-50 minutes.~Individuals will be taught the abdominal cupping technique during the first two weeks of the program."
89381469|NCT05571085|No Intervention|Control Group|No treatment program was applied. As a result of the study, an effective exercise program will be recommended to the participants.
89381470|NCT05571007|Experimental|True acupressure|Using three true acupoints. Acupoints: Yongquan (K1), Sayingjiao (SP6), Zusanli (ST36). Patient Position: Lying or sitting position. Time: first 2 hours of HD.
89381471|NCT05571007|Sham Comparator|Sham acupressure|Using three sham acupoints. Acupoints: Sham acupoints are located on 1 cun from the true acupoint. Patient Position: Lying or sitting position. Time: first 2 hours of HD.
89381472|NCT03348306|Experimental|All patients|
89381473|NCT05570773|Experimental|peer support program|"A researcher and peer tutors met students in an online session for 30 minutes every day between 21:00 and 21:30 before bedtime for 30 days. These sessions focused on academic problem solving and academic encouragement of students. In addition, peer tutors and students shared their contact information and continued their sharing by talking on the phone and messaging in the chat group 24/7.~Selection and education of peer tutors: 5 peers with strong communication skills and high academic achievement were selected among the 4th-year volunteer students. These 5 volunteers were selected among students who were not included in the sample, had an appropriate level of anxiety (anxiety score ≤36), and had good sleep quality (PSQI score ≤5). A theoretical and practical session was held with them. In these sessions, peer-supported education was explained and necessary information was given about its purpose and how it was performed."
89381474|NCT05570773|Experimental|progressive relaxation exercise group|The importance of the exercise and how it should be done were explained by the researcher Mixed teaching methods, including lecturing, demonstration, question-answer, and discussion were, used as education methods. The sessions were carried out online by a researcher who is an expert in the field of PRE for 30 minutes every day between 21:00 and 21:30 before bedtime for 30 days.
89381475|NCT05570773|No Intervention|control group|The students who formed the control group through randomization were given information about the research, and then they submitted informed consent. Control group students were given the same questionnaire as a pre-and-post-test applied in the intervention groups, but no intervention was applied.
89381476|NCT04677439|Experimental|Flumatinib|
89381477|NCT03309072|Experimental|active tDCS|active tDCS with Face Name associate Memory task
88854239|NCT01730040|Active Comparator|Atorvastatin 80 mg|Participants, who were receiving atorvastatin 40 mg over-encapsulated tablets orally at baseline, received Atorvastatin 80 mg over-encapsulated tablets orally QD, placebo for alirocumab SC injection Q2W, and placebo for ezetimibe over-encapsulated tablets orally QD added to stable LMT for 24 weeks.
88854240|NCT01730040|Active Comparator|Rosuvastatin 40 mg|Participants, who were receiving atorvastatin 40 mg over-encapsulated tablets orally at baseline, received rosuvastatin 40 mg over-encapsulated tablets orally QD, placebo for alirocumab SC injection Q2W, and placebo for ezetimibe over-encapsulated tablets orally QD added to stable LMT for 24 weeks.
88854241|NCT01730040|Active Comparator|Ezetimibe 10 mg + Atorvastatin 40 mg|Participants, who were receiving atorvastatin 40 mg over-encapsulated tablets orally at baseline, received ezetimibe 10 mg over-encapsulated tablets orally QD, atorvastatin 40 mg over-encapsulated tablets orally QD, and placebo for alirocumab SC injection Q2W added to stable LMT for 24 weeks.
89381478|NCT03309072|Sham Comparator|sham tDCS|sham tDCS with Face Name associate Memory task
89381479|NCT03625908|Active Comparator|OCT-guided PCI|Patients will receive PCI under OCT-guidance.
89381480|NCT03625908|Active Comparator|Angiography-guided PCI|Patients will receive PCI under Angiography-guidance.
89381481|NCT05570695|Experimental|neurofeedback|Modulation of brain activity using verum and sham neurofeedback.
89381482|NCT02986789|No Intervention|Control Group|Clinicians will be performing blood transfusions using hospital standard of care procedures.
89381483|NCT02986789|Experimental|Evaluation Group|Clinicians will be guiding blood transfusions using SpHb with In vivo feature as a trigger for laboratory blood draws and PVi to inform fluid administration decisions in addition to hospital standard of care procedures.
89381484|NCT03223428||Carcinoid Syndrome patients initiating Xermelo|Patients with Carcinoid Syndrome who are initiating treatment with XERMELO.
89381485|NCT02777424|Experimental|Prothrombin Complex Concentrate|Administration of a single dose of prothrombin complex concentrate (25 U/kg equivalent factor IX)
89381486|NCT02777424|Active Comparator|Fresh Frozen Plasma|Administration of a single dose of fresh frozen plasma of 15 mL/kg
89381487|NCT05360550|Experimental|LSP-5415 (etonogestrel/ethinyl estradiol vaginal ring)|LSP-5415
89381488|NCT05255874|Experimental|Aromatherapy Group|Patients in the study group will rest for 5 minutes before and after the urodynamics procedure. All patients will be asked to fill in the 'Spielberger State Anxiety Scale' before and after the urodynamic procedure. Before and after the procedure, blood pressure, heart rate, respiratory rate, peripheral oxygen saturation will be measured. Blood will be drawn for serum cortisol level. In addition to the routine treatment and care practices of the unit, aromatherapy will be applied to the patients included in the study group. Aromatherapy application will be applied to all patients by the same researcher. Aromatherapy application will be started 5 minutes before the urodynamic procedure after the patient is taken to the urodynamic room, and lavender essential oil (3 drops in 300 cc water for 5 cubic meters of room) will be used with a diffuser until the end of the procedure.
89381489|NCT05255874|No Intervention|Standard of care|Routine treatment and care interventions will be applied to the patients included in the control group during the procedure. Patients in the control group will rest for 5 minutes before and after the urodynamics procedure. All patients will be asked to fill in the 'Spielberger State Anxiety Scale' before and after the urodynamic procedure. Before and after the procedure, blood pressure, heart rate, respiratory rate, peripheral oxygen saturation will be measured. Blood will be drawn for serum cortisol level.
89381490|NCT03247543|Placebo Comparator|Placebo|Placebo, qd, oral capsule
89381491|NCT03247543|Active Comparator|200mg SPN-812|200mg SPN-812, qd, oral capsule
89381492|NCT03247543|Active Comparator|400mg SPN-812|400mg SPN-812, qd, oral capsule
89381493|NCT05351190|Other|Treatment Arm|All participants will be given a rtCGM (Dexcom G6) to assess their glycemic control.
89381494|NCT03637153|Experimental|Order A|Firstly, the participants will have their assessments at low altitude (Low altitude: 470m above sea level) in Zurich and consecutively the exposure to High Altitude (Säntis; 2500m above sea Level).
89381495|NCT03637153|Experimental|Order B|Firstly, the participants will exposed to High Altitude (Säntis; 2500m above sea level) and consecutively will they have assessement in Zurich (Low altitude; 470m above sea level).
89381496|NCT05569525|Experimental|Test|Patients receiving non-surgical periodontal treatment within 1 week from enrollment.
88854242|NCT01730040|Experimental|Alirocumab 75 mg/ up to 150 mg + Atorvastatin 40 mg|Participants, who were receiving atorvastatin 40 mg over-encapsulated tablets orally at baseline, received alirocumab 75 mg SC injection Q2W, atorvastatin 40 mg over-encapsulated tablets orally QD, and placebo for ezetimibe over-encapsulated tablets orally QD added to stable LMT for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when LDL-C levels ≥70 mg/dL (1.81 mmol/L) or ≥100 mg/dL (2.59 mmol/L) at Week 8, based on baseline disease characteristic and medical history.
88854243|NCT01706328|Experimental|FF/VI Inhalation Powder NDPI|Subjects randomized to the FF/VI 100/25 arm will take an active inhalation of study medication during their morning dosing from their NDPI and will have an inhalation of dummy medication (placebo) as their morning ACCUHALER/DISKUS dose and as their evening dose.
89183329|NCT05038254|Experimental|Arm II (standard of care, remote monitoring)|Patients receive standard of care consisting of oncology care provided via telemedicine. Patients also undergo remote monitoring.
89381497|NCT05569525|Active Comparator|Control|Patients receiving non-surgical periodontal treatment 6 months after the enrollment.
89381498|NCT01347073|Experimental|HPN-100|Switch over from sodium phenylbutyrate to open label HPN-100 oral liquid over 10 days then open label, long term treatment for 12 months
89381499|NCT02618551|Experimental|Intervention|Patients will be treated by three bronchial thermoplasty sessions.
89381500|NCT05569057|Experimental|SIM1811-03 Monotherapy|All participants receive SIM1811-03 alone
89381501|NCT01315236|Experimental|LAI 590 mg QD|LAI 590 mg QD
89381502|NCT01315236|Placebo Comparator|Placebo|placebo QD
89381503|NCT02367469||Brain Tumors|Patients with newly diagnosed or recurrent brain tumors will be studied.
89381504|NCT03730051|Active Comparator|Gadoterate meglumine contrast|0.2 mL/kg (0.1 mmol/kg) administered as a single IV bolus injection at a rate of 2 mL/second. The FDA-approved product labeling provides weight-adjusted dose volumes as follows: 30 kg: 6 mL; 40 kg: 8 mL; 50 kg: 10 mL; 60 kg: 12 mL; 70 kg: 14 mL; 80 kg: 16 mL; 90 kg: 18 mL; 100 kg: 20 mL; 110 kg: 22 mL; 120 kg: 24 mL; 130 kg: 26 mL; 140 kg: 28 mL; 150 kg: 30 mL.
89381505|NCT03730051|Experimental|Gadobutrol contrast|0.1 mL/kg (0.1 mmol/kg) administered as a single IV bolus injection by power injector. Imaging may begin after administration and then repeat sequentially to determine peak intensity and wash-out. The manufacturer provides weight-based dose volumes as follow: 35 kg: 3.5 mL; 40 kg: 4 mL; 45 kg: 4.5 mL; 50 kg: 5 mL; 60 kg: 6 mL; 70 kg: 7 mL; 80 kg: 8 mL; 90 kg: 9 mL; 100 kg: 10 mL; 110 kg: 11 mL; 120 kg: 12 mL; 130 kg: 13 mL; 140 kg: 14 mL.
89381506|NCT03232567|Experimental|NasoVAX low dose|NasoVAX administered by intranasal spray at a single dose of 1×10(9th) viral particles (vp) versus placebo
89381507|NCT03232567|Experimental|NasoVAX medium dose|NasoVAX administered by intranasal spray at a single dose of 1×10(10th) viral particles (vp) versus placebo
89381508|NCT03232567|Experimental|NasoVAX high dose|NasoVAX administered by intranasal spray at a single dose of 1×10(11th) viral particles (vp) versus placebo
89381509|NCT03232567|Placebo Comparator|Placebo|Normal saline administered by intranasal spray at a single dose
89381510|NCT04621045|Experimental|PATH Treatment Group|The PATH group will be granted password protected access to one of the 3 PATH levels based on their baseline fitness status. The intervention is designed to help participants increase their baseline PA via health coaching, self-monitoring and pragmatic workout videos that provide convenient options for overcoming socio-environmental barriers to PA.
89381511|NCT04621045|Active Comparator|Wait-list control group|Participants in this group will not have access to the PATH intervention until after 12 weeks when they cross over. After randomization, the control group will be provided with a copy of the Be Active Your Way booklet, developed by the Centers for Disease Control (CDC) to help individuals integrate PA in their daily lives.
89381512|NCT01348490|Experimental|Ruxolitinib 5 mg|Participants began administration with 5 mg ruxolitinib twice daily (BID) orally. Beginning at the Week 4 visit, doses of ruxolitinib could be increased in 5 mg once a day (QD) increments every 4 weeks every 4 weeks not to exceed a dose of 25 mg BID.
89381513|NCT03040674||Cell therapy treated|All patients/participants enrolled will undergo cell therapy
89381514|NCT03232333||MIRODERM|Biologic wound graft
89381515|NCT02310204|Experimental|multidisciplinary education program|individual and group education sessions over a 6-month period
89002720|NCT06234293|Experimental|near-infrared light device|the device used is the AccuVein AV500® (Accuvein, New York USA). Nurses will have to find the vein for the PIVC using the near-infrared light device. Nurses will have to proceed as follows: apply the tourniquet, put on the near infrared light onto the upper limb. PIVC on the lower limbs is forbidden in this study. The recommended projection distance is around 20 cm, however, the optimal distance of projection can vary between 10 and 45 cm. After finding the vein, Nurses proceed to PIVC with the device turned on, the peripheral venous network visible on the skin of the patient. After the cannulation and to confirm the functionality of the peripheral intravenous access a flash of 10cc of an isotonic solution (NaCl 0.9%) will be injected
89381516|NCT02310204|Active Comparator|Standard psoriasis care alone|Standard psoriasis care alone
89381517|NCT04080505|Active Comparator|SSKI (Potassium Iodide)|Participants randomized to receive 7 days of pre-operative SSKI
89381518|NCT04080505|No Intervention|NO SSKI|Participants randomized to not receive any drug pre-operative
89381519|NCT05572411||Ponseti|Ponseti treated Clubfoot participants will be asked to walk across the GAITRite Electronic Walkway.
89381520|NCT05610696|Experimental|Low impact immersion|This intervention will use the principles of Ai Chi, a model defined as a low-intensity aquatic exercise strategy
89381521|NCT05610696|Experimental|Conventional aquatic physiotherapy|In this intervention, medium impact exercises will be performed, with a comfortable movement speed.
89002721|NCT06234293|No Intervention|landmark approach|PIVC will be done by a nurse on an upper limb according to the standard approach. The nurse will proceed as follows: apply the tourniquet and find a vein for the catheterization, standard techniques to highlight veins can be used (apply alcohol, tap veins …). After finding a vein, the nurses proceed to the PIVC according to his / her habits. The use of any device is forbidden. After the cannulation and to confirm the functionality of the peripheral venous access a flash of 10cc of an isotonic solution (NaCl 0.9%) will be injected.
89002722|NCT06227117|Experimental|Disitamab Vedotin + Toripalimab|Disitamab Vedotin with Toripalimab Arm
89002723|NCT06227117|Experimental|Disitamab Vedotin + Toripalimab+Carboplatin|Disitamab Vedotin + Toripalimab with Carboplatin Arm
89002724|NCT06227117|Experimental|Disitamab Vedotin + Toripalimab sequential Epirubicin+ CTX+ Toripalimab|Disitamab Vedotin + Toripalimab sequential Epirubicin+ CTX with Toripalimab Arm
89183330|NCT05038254|Experimental|Arm III (standard of care, remote monitoring, biometrics)|Patient receive standard of care consisting of oncology care provided via telemedicine. Patients also undergo remote monitoring and biometric monitoring.
89381522|NCT05610696|Experimental|High intensity aquatic physiotherapy|In this intervention, high-impact exercises will be performed, with maximum movement speed, twice time of the medium-intensity protocol
89381523|NCT03364049|Experimental|MK-7162 25 mg +Pembrolizumab (Pembro)|Participants receive MK-7162 25 mg via oral tablets once daily (QD) throughout the 3-week cycle. Cycles 2 through 36: Participants receive MK-7162 25 mg orally QD PLUS pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle (every 3 weeks [Q3W]).
89381524|NCT03364049|Experimental|MK-7162 50 mg + Pembro|Participants receive MK-7162 50 mg via oral tablets QD throughout the 3-week cycle. Cycles 2 through 36: Participants receive MK-71625 50 mg orally QD PLUS pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle Q3W
89381525|NCT03364049|Experimental|MK-7162 100 mg + Pembro|Participants receive MK-7162 100 mg via oral tablets QD throughout the 3-week cycle. Cycles 2 through 36: Participants receive MK-7162 100 mg orally QD PLUS pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle Q3W
89381526|NCT03364049|Experimental|MK-7162 200 mg + Pembro|Participants receive MK-7162 200 mg via oral tablets QD throughout the 3-week cycle. Cycles 2 through 36: Participants receive MK-7162 200 mg orally QD PLUS pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle Q3W
89381527|NCT03708029|Experimental|Intervention Treatment|Will receive Revita allograft for wound treatment
89381528|NCT03708029|No Intervention|Control|Will receive current standard of care for wound treatment
89381529|NCT05348772|Active Comparator|AmnioPul-02 Dose level 1|AmnioPul-02 Dose level 1
89381530|NCT05348772|Active Comparator|AmnioPul-02 Dose level 2|AmnioPul-02 Dose level 2
89381531|NCT05681819|Experimental|SHR-1707|Up to4 cohorts of Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease patients will receive Multiple-ascending Dose of SHR-1707 injection
89183331|NCT05035498|Active Comparator|Phenylephrine group|Phenylephrine infusion simultaneous with spinal anesthesia
89183332|NCT05035498|Experimental|Norepinephrine group|Norepinephrine infusion simultaneous with spinal anesthesia
89183333|NCT05035485|Active Comparator|Phenylephrine group|Rescue phenylephrine (75μg) was given when postspinal anesthesia hypotension occurred
88854244|NCT01706328|Active Comparator|Fluticasone Propionate/Salmeterol Inhalation Powder|Subjects randomized to the Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg arm will have an active dose of medication during both their morning and evening treatments from the ACCUHALER/DISKUS and a dummy placebo dose in the morning from their NDPI.
89381532|NCT05681819|Placebo Comparator|SHR-1707 placebo|Up to 4 cohorts of Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease patients will receive Multiple-ascending Dose of SHR-1707 placebo injection
89381533|NCT05343078|Experimental|Dapagliflozin|Dapagliflozin 10mg P.O.
89381534|NCT03706235||No recurrence|Subjects at least 30 days from end of primary treatment for colorectal cancer in a clinically indicated surveillance program (e.g. ASCO, NCCN) provide a blood sample before the next clinically indicated surveillance scan/imaging. Imaging documents no recurrence.
89381535|NCT03706235||Recurrence|Subjects at least 30 days from end of primary treatment for colorectal cancer in a clinically indicated surveillance program (e.g. ASCO, NCCN) provide a blood sample before the next clinically indicated surveillance scan/imaging or imaging has confirmed recurrence. Imaging documents recurrence.
89381536|NCT03238963|Experimental|BI 1467335|
89381537|NCT03238963|Placebo Comparator|Placebo|
89381538|NCT05693298|Experimental|High Flow Nasal Cannula|High Flow Nasal cannula is a system to deliver heated and humidified oxygen with an inspired oxygen fraction between 21 and 100% through large bore nasal cannula. The system delivers a flow up to 60 liters/min.
89381539|NCT05693298|Active Comparator|Standard Treatment|If peripheral oxygen saturation will be < 95%, conventional oxygen therapy will be administered through common nasal cannula with a flow up to 6 Liters per minute
89381540|NCT03701035|Experimental|Aerobic Training & UL Motor Training|Aerobic training at 40%-59% Heart Rate Reserve (AT) increasing from personal maximum time (if < 40 mins) to 40 minutes followed by UL motor training with the Armeo®Spring/Senso/Pablo X2® 3 * weekly, 12 weeks
89381541|NCT03701035|Active Comparator|Non-aerobic Training & UL Motor Training|40 minutes non-aerobic gait & balance circuit training followed by UL motor training with the Armeo®Spring/Senso/Pablo X2® 3 * weekly, 12 weeks
89381542|NCT03337139|Active Comparator|Lifestyle Modification|Three months of standard, group-based behavioral treatment for weight loss and nine months of remote individual behavioral treatment based on self-report.
89381543|NCT03337139|Experimental|Lifestyle Modification + Share|Three months of standard, group-based behavioral treatment for weight loss and nine months of remote individual behavioral treatment based on digital data shared with clinicians.
88854245|NCT01753518|Active Comparator|Subcuticular suture|Subcuticular suture has been used for many years to close skin incisions.
88854246|NCT01753518|Active Comparator|Subcuticular staple|Subcuticular staples are a newer modality than suture, but are currently an accepted and widely used skin closure technique.
88854247|NCT01706250|Experimental|MAXCLARITY II|MaxClarity II (2.5% BPO) Foam Cleanser and Foam Treatment and (0.5% Salicylic Acid) Toner Foam. Available over the counter. Each subject applies both arms (MaxClarity II and Proactiv) simultaneously for the entire duration of the study (8 weeks), each arm to be applied to one side of the face only (split-face study) according to randomization.
88854248|NCT01706250|Active Comparator|PROACTIV|Proactiv (2.5% BPO) Renewing Cleanser and Repairing Lotion and Revitalizing Toner. Available over the counter. Each subject applies both arms (MaxClarity II and Proactiv) simultaneously for the entire duration of the study (8 weeks), each arm to be applied to one side of the face only (split-face study) according to randomization.
88854249|NCT01729728|Experimental|Tapentadol|
88854250|NCT01729026|Experimental|Shelter Dog Adoption|Veterans will choose a dog from the San Antonio Humane Society with the help of a Humane Society adoption counselor and study staff and take it home to live with them. The dog will be a pet and not a service dog. Following adoption, Veterans and their dogs will receive eight weeks of free obedience training provided by a veterinarian.
89381544|NCT05439096|Experimental|Functional Exercise|"2 stretching exercises~1 yoga exercises~2 core strengthening exercises~2 pelvic area exercises~Kegel exercises~Warm up for 5 minutes the apply perform exercise 3 times a week for 8 weeks and 45 minutes duration at a time"
89381545|NCT05439096|Experimental|High Frequency Transcutaneous Electrical Nerve Stimulation|"High frequency TENS by below mentioned parameters will be applied.~Pulse waveform = Biphasic waveform~Pulse recurrence = 50 to 120 Hz~Phase duration = 100 µsec~Current amplitudes = highest tolerable intensity with continuous adjustment~Skin arrangement = flawless skin region.~Type of electrodes = Self-adhesive~Size and location of electrodes = It will be adjusted specifically to each woman according to the typical area of her pain."
89381546|NCT03964363|Experimental|Prehabilitation|Participants are scheduled for elective surgery and follow the home-based prehabilitation for 11-17 days
88854251|NCT01729026|Active Comparator|Wait-list, Then Adoption after 3 Months|After 3 months on a wait-list, Veterans will choose a dog from the San Antonio Humane Society with the help of a Humane Society adoption counselor and study staff and take it home to live with them. The dog will be a pet and not a service dog. Following adoption, Veterans and their dogs will receive eight weeks of free obedience training provided by a veterinarian.
89381547|NCT03964363|Experimental|Prehabilitation + TAVI|Study participants who will undergo a TAVI form a subgroup with a modified enrolment procedure and longer duration of the intervention. The prehabilitation period is extended to 30 days.
88854252|NCT01728792|Experimental|Group 1: TDV SC_2 Doses Day 0|Takeda's Tetravalent Dengue Vaccine Candidate (TDV), 0.5 mL, subcutaneous (SC) injection, one dose in each arm, Day 0 using a needle/syringe.
89381548|NCT03964363|No Intervention|Control|Participants are initially evaluated for frailty prior to scheduled surgery but subsequently receive regular care without a prehabilitation program. All pre- and postsurgical evaluations will be identical to the prehabilitation group.
89381549|NCT03964363|No Intervention|Control+TAVI|The subgroup of participants who undergo a TAVI will be compared to a group of patients who will have had the same procedure. Hence the control group will also receive a screening via phone but then receive regular care. Follow-up after surgery will be identical in all groups.
89381550|NCT03710447|Experimental|HIIT + WB-EMS|High-intensity interval training (HIIT) combined with whole-body electromyostimulation (WB-EMS) Sequence of application: HIIT - WB-EMS
89183334|NCT05035485|Experimental|Norepinephrine group|Rescue norepinephrine (6μg) was given when postspinal anesthesia hypotension occurred
89183335|NCT05034146|Experimental|68Ga-FAPI PET/CT in malignant tumors|Investigators select subjects from patients who have underwent whole-body 18F-FDG PET/CT scan for suspected or confirmed malignancy, or suspected recurrence and metastasis after treatment for malignant tumors, focusing on malignant tumors with low FDG uptake including glioma, hepatocellular carcinoma, renal cancer, gastrointestinal cancer, and peritoneal metastases. Then the subjects receive whole-body 68Ga-FAPI PET/CT scan with time interval of one to four week.
89183336|NCT05032040|Experimental|vudalimab|
89183337|NCT05019963|Active Comparator|Usual Care|"Assessment. Participants randomized to the control arm will be offered assessment by a clinician, guided by the WHO Post COVID-19 case report form. This is a clinical tool developed by WHO to guide and document the sequelae of COVID-19 and to ensure that clinical and rehabilitation needs are identified.~Investigation. Clinician judgement will be used to decide on further testing needed for clinical care.~Management. Control participants will receive a rehabilitation plan developed with their health professional that will be implemented in the eight weeks after their initial consultation (baseline visit). The implementation will involve face to face or virtual care from a registered health professional provided by the clinic or research staff. This may be a combination of, but not limited to, occupational therapy, physical therapy and/or social work/counselling. The frequency of treatment visits will depend on the individual treatment plan after assessment."
89183338|NCT05019963|Experimental|Electronic Case Management plus Usual Care|Participants randomized to the experimental arm will receive assessment, investigation and management as the Active Comparator Arm plus access to an electronic case management platform - NexJ Connected Wellness (https://nexjhealth.com/) which complements the rehabilitation plan. This would include for example setting targets for activity that would be monitored with NexJ; educational materials; and support with medication adherence by reminders. The NexJ platform will include the following sections: Trusted Educational Content (Health Library); Symptom Tracking, Goal Setting, Community Forums and Reporting.
89183339|NCT04987359|Experimental|Multimodal Lifestyle Program|The multimodal lifestyle program will utilize intensive behavioral therapy with structured exercise training and nutritional counseling. The main objective of the structured exercise training is to improve cardiorespiratory fitness.
89183340|NCT04987359|No Intervention|Waitlist Control|The waitlist control group will be asked to maintain their current exercise and dietary habits for the 10-week study period. Upon providing study endpoint data at week 10, control group participants will be offered a 4-week multimodal lifestyle program that is similar to the intervention group.
89183341|NCT04978467|Experimental|single arm|All participants will receive assistance to move finger joints away from the compensatory coordination (compensation avoidance), toward the desired trajectories (task assistance), both, and none in different days.
89183342|NCT04974645|Experimental|W-SUDs|Woebot (W-SUDs), a Conversational Agent (CA) instantaneously available 24 hours per day, 7 days per week, 'checks in' with users. Using conversational tones, it encourages mood tracking and delivers general psychoeducation as well as tailored empathy, cognitive behavior therapy (CBT)-based behavior change tools, and behavioral pattern insight. Woebot's app-based platform and user-centered design philosophy makes it an optimal modality for Substance Use Disorders (SUD) treatment delivery. It offers immediate, evidence-based tailored support in the patient's peak moment of craving.
89183343|NCT04974645|Other|Digitally-delivered Psychoeducation|"Psychoeducation digitally delivers weekly fact sheets that include information on:~Alcohol-specific topics;~Drug-specific topics;~General addiction topics;~Statistics relating to alcohol and substance use."
89183344|NCT04973930|Active Comparator|Tele-Interpersonal Psychotherapy (IPT)|Interpersonal psychotherapy is a time-limited, affect-focused treatment of repeatedly demonstrated efficacy for major depression in the general population. It was also helpful to patients with comorbid depression and breast cancer in our prior randomized controlled trial. IPT focuses on the connection between upsetting life circumstances (e.g., diagnosis of breast cancer) and their effect on mood, and vice versa. We have considerable experience, enhanced by the Covid-19 lockdown, in delivering IPT as a HIPAA-secure tele-therapy.
89183345|NCT04973930|Active Comparator|Tele-Serotonin Reuptake Inhibitor|Both venlafaxine and escitalopram are FDA-approved treatments with demonstrated efficacy in treating major depression in the general population. Although little formal research has been done in treating patients with depression and breast cancer, these two are the favored treatments among serotonin reuptake inhibitors due to minimal interference with oncotherapy. The choice between prescribing these two study medications will depend upon prior treatment history. Venlafaxine XR will be serially titrated under expert psychopharmacologist tele-guidance from 75 mg to 300 mg daily, depending on clinical response and tolerance. Escitalopram will similarly be dosed between 5 mg and 30 mg daily.
89183346|NCT04970654|Experimental|Somapacitan weekly|participants will receive once-weekly somapacitan for 52 weeks
89183347|NCT04970654|Active Comparator|Norditropin® daily|Participants will receive Norditropin® daily for 52 weeks
89183349|NCT04961177|Other|EITC & ACEs Training|Trainings for frontline health workers about EITC and ACEs.
89183350|NCT04961177|Other|EITC Outreach and Screening|Our partners will implement EITC outreach events and EITC screening with clients.
89381551|NCT03710447|Experimental|WB-EMS + HIIT|Whole-body electromyostimulation (WB-EMS) combined with High-intensity interval training (HIIT) Sequence of application: WB-EMS - HIIT
89381552|NCT03710447|Experimental|HIIT + CST|High-intensity interval training (HIIT) combined with conventional low-volume strength training (CST) Sequence of application: HIIT - CST
89381553|NCT03710447|Experimental|CST + HIIT|Conventional low-volume strength training (CST) combined with high-intensity interval training (HIIT) Sequence of application: CST - HIIT
89381554|NCT03710369|Sham Comparator|Normoxia|Exercise in room air (normoxia). Sildenafil
88854253|NCT01728792|Experimental|Group 2: TDV IM_2 Doses Day 0|TDV, 0.5 mL, intramuscular (IM) injection, one dose in each arm, Day 0 using a needle/syringe.
88854254|NCT01728792|Experimental|Group 3: TDV IM_2 Doses Days 0 and 90|TDV, 0.5 mL, IM injection, one dose on Day 0 and one dose on Day 90 using a needle/syringe.
89381555|NCT03710369|Active Comparator|Hypoxia|Exercise in hypoxic air (reduced O2 concentration) that simulates 2500m elevation for 30-40 minutes with Sildenafil. Placebo
89381556|NCT05681663|Experimental|1.5 bar group|1. TENS, Parafin, exercise and In addition, 5 hertz 2000 pulses 1.5 bar ESWT will be applied to this group.
88854255|NCT01728792|Experimental|Group 4: TDV SC_2 Doses Day 0|TDV, 0.5 mL, SC injection, one dose in each arm, Day 0 using the PharmaJet Stratis™ device.
88854256|NCT01728792|Experimental|Group 5: TDV IM_2 Doses Day 0|TDV, 0.5 mL, IM injection, one dose in each arm, Day 0 using the PharmaJet Stratis™ device.
88854257|NCT01752036|Other|Treatment|Post-Operative Stereotactic Radiosurgery
88854258|NCT01728324|Experimental|Randomised 24-week arm|BI 207127 in combination with FDV and RBV for 24 weeks (randomised)
88854259|NCT01728324|Experimental|Randomised 16-week arm|BI 207127-placebo, FDV-placebo and RBV-placebo for 8 weeks followed by BI 207127 in combination with FDV and RBV for 16 weeks (randomised)
88854260|NCT01728324|Experimental|Allocated 24-week arm|BI 207127 in combination with FDV and RBV for 24 weeks (allocated to patients with compensated cirrhosis)
88854261|NCT01728246|Experimental|Tramadol/Paracetamol (APAP)|
88854262|NCT01728246|Active Comparator|Non-Tramadol/APAP|
88854263|NCT04414020|No Intervention|Control|Control group receiving conventional treatment without progesterone
88854264|NCT04414020|Active Comparator|progesterone group|1mg pregesterone intramusculer given 7 days pre and post operative , Biopsy was achieved from brain tumor interface
88854265|NCT04559022|Other|Fat Grafting for Acne Scar Treatment|This single-center, clinical trial will assess the efficacy and tolerability of the autologous fat grafting when used on men and women with acne scars on the face.
88854266|NCT01705236|Experimental|Fingolimod - Longitudinal Assessment|No study drug was provided. Fingolimod was to be prescribed according to local label. The decision to prescribe fingolimod had to be made independent of this study.
88854267|NCT01705080||A - EnligHTN for Severe Resistant HTN|"Office systolic Blood Pressure ≥160 mmHg~Subject is taking ≥3 anti-hypertensive medications (including 1 diuretic), or subject has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.~Patient has an estimated GFR ≥45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula"
88854268|NCT01705080||B - EnligHTN for Resistant HTN|"Office systolic Blood Pressure ≥140 mmHg~Subject is taking ≥3 anti-hypertensive medications (including 1 diuretic), or subject has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.~Patient has an estimated GFR ≥45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula"
88854269|NCT01705080||C - EnligHTN for Resistant HTN & CKD|"Office systolic Blood Pressure ≥140 mmHg~Subject is taking ≥3 anti-hypertensive medications (including 1 diuretic), or subject has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.~Patient has an estimated ≥15 GFR <45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula"
88854270|NCT01704846|Experimental|Treatment sequence 1|Test - Reference - Reference - Test
88854271|NCT01704846|Experimental|Treatment sequence 2|Reference - Test - Test - Reference
88854272|NCT01751802|Experimental|Ecopipam|Active substance being tested, orally once a day at bedtime
88854273|NCT01751802|Placebo Comparator|Placebo|Inactive substance being tested, orally once a day at bedtime
88854274|NCT01704456|Experimental|Mindfulness-based cognitive therapy (MBCT)|Women in the MBCT Group Treatment arm will receive the treatment in small group format (8-9 women). Each session will be 2.25 hours in duration and there will be eight, weekly sessions over the course of 2 months. Session content includes education about chronic pain, PVD, stress and sexual response, mindfulness practices, and cognitive techniques to notice thought patterns that contribute to increased pain.
88854275|NCT01704456|Experimental|Cognitive Behavioural Therapy (CBT)|Women in the CBT Group Treatment arm will receive the treatment in small group format (8-9 women). Each session will be 2.25 hrs in duration and there will be eight, weekly sessions over the course of 2 months. Session content includes education about chronic pain, PVD, stress and sexual response, behavioural techniques such as progressive muscle relaxation, cognitive techniques to challenge unhealthy thinking patterns, and communication skills training.
88854276|NCT04166526||Group 1: Typically developing children|Participants of this group will not have a diagnosis of SCD. These participants will undergo an MRI, lasting approximately an hour, with simultaneous FDNIRS-DCS monitoring.
88854277|NCT04166526||Group 2: Children with SCD not receiving treatment|Participants of this group have a diagnosis of SCD, but do not receive chronic transfusions, gene therapy or bone marrow transplants. These participants will undergo an MRI, lasting approximately an hour, with simultaneous FDNIRS-DCS monitoring.
88854278|NCT04166526||Group 3: Children with SCD who have undergone gene therapy|Participants of this group have a diagnosis of SCD and have had gene therapy at least one month prior to enrollment. These participants will undergo an MRI, lasting approximately an hour, with simultaneous FDNIRS-DCS monitoring.
88854279|NCT04166526||Group 4: Children with SCD who have chronic transfusions|Participants of this group have a diagnosis of SCD and receive chronic transfusions. These participants will undergo an MRI, lasting approximately an hour, with simultaneous FDNIRS-DCS monitoring.
88854280|NCT01703988|Experimental|Nusinersen 3 mg|3 mg nusinersen on Days 1, 29, 85, intrathecal (IT) injection
89381557|NCT05681663|Experimental|4 bar group|1. TENS, Parafin, exercise and In addition, 5 hertz 2000 pulses 4 bar ESWT will be applied to this group.
88854281|NCT01703988|Experimental|Nusinersen 6 mg|6 mg nusinersen on Days 1, 29, 85, IT injection
88854282|NCT01703988|Experimental|Nusinersen 9 mg|9 mg nusinersen on Days 1 and 85, IT injection
88854283|NCT01703988|Experimental|Nusinersen 12 mg|12 mg nusinersen on Days 1, 29, 85, IT injection
88854284|NCT01703832|Experimental|Neurexan®|0.6 mg / tablet, 6 tablets, 1 tablet every 30 minutes from -180 minutes to -30 minutes
88854285|NCT01703832|No Intervention|No intervention|no tablet intake and subjects will undergo the natural course
88854286|NCT01703286|Experimental|Linagliptin 5mg|given once daily over 28 days
89381558|NCT03706157|Active Comparator|Iodinate contrast|Doxorubicin solution reconstituted in 5 mL iso-osmolar ionic iodinated contrast media
88854287|NCT01703286|Active Comparator|Glimepiride|given once daily in 1mg dosis over 7 days, following a titration step to 2mg and application for 21 days
88854288|NCT01703286|Placebo Comparator|Placebo|given once daily over 28 days
88854289|NCT04166448||Group 1: High risk IUGR patients|EPF<10th perc or PA<10th perc and Doppler ombilical IP> 95th percentile, EPF or PA<3th perc (reference curves from Collège Français d'Echographie Fœtale, between 20 et 34 GW),
88854290|NCT04166448||Group 2: Low risk IUGR patients|EPF et PA>20th perc (reference curves from Collège Français d'Echographie Fœtale, between 20 et 34 GW)
88854291|NCT01703208|Experimental|Omarigliptin|Omarigliptin (MK-3102) 25 mg capsule or tablet administered orally once weekly
88854292|NCT01703208|Placebo Comparator|Placebo|Matching placebo to omarigliptin capsule or tablet administered orally once weekly
88854293|NCT01727700|Placebo Comparator|Placebo|Matching Placebo Once-Daily
88854294|NCT01727700|Experimental|Aripiprazole 5 mg or 10 mg|Aripiprazole 5 mg or 10 mg Immediate Release Once-Daily
88854295|NCT01727700|Experimental|Aripiprazole 10 mg or 20 mg|Aripiprazole 10 mg 20 mg Immediate Release Once-Daily
88854296|NCT01727154||Sipuleucel-T|
88854297|NCT01725750|Experimental|Bright White Light (BWL)|"Participants will self-administer bright white light daily using a Litebook® (The Litebook Company Ltd.). The Litebook is a small (6 x 5 x 1) and lightweight (8 oz.) box."
88854298|NCT01725750|Active Comparator|Dim Red Light (DRL)|Participants will self-administer dim red light daily using a device that appears identical to Bright White Light (BWL) Litebook but that uses red LEDs emitting DRL.
88854299|NCT01725282|Placebo Comparator|Placebo|Participants received matching placebo tablets once daily before bedtime for 7 weeks.
88854300|NCT01725282|Experimental|Quetiapine 50 mg|Participants received quetiapine extended release (XR) 50 mg tablets once daily before bedtime for 7 weeks.
88854301|NCT01725282|Experimental|Quetiapine 150 mg|After 2 days of up-titration, participants received quetiapine XR 150 mg tablets once daily before bedtime for 6 weeks followed by quetiapine XR 50 mg tablets once daily for 1 week.
88854302|NCT01725282|Experimental|Quetiapine 300 mg|After 4 days of up-titration, participants received quetiapine XR 300 mg tablets once daily before bedtime for 6 weeks followed by quetiapine XR 150 mg tablets once daily for 1 week.
88854303|NCT01725126|Experimental|Part A - GSK2890457|Subjects will titrate up from a maximially tolerated dose over a 7-day period. Treatment Period is 6 weeks
88854304|NCT01725126|Experimental|Part B - GSK2890457 + Liraglutide|Subjects will titrate up from a maximially tolerated dose over a 7-day period. Treatment Period is 6 weeks
88854305|NCT01725126|Experimental|Part C - GSK2890457 + Metformin|Subjects will titrate up from a maximially tolerated dose over a 7-day period. Treatment Period is 6 weeks
88854306|NCT01725126|Placebo Comparator|Part A - Placebo|Subjects will titrate up from a maximially tolerated dose over a 7-day period. Treatment Period is 6 weeks
88854307|NCT01725126|Placebo Comparator|Part B - Placebo|Subjects will titrate up from a maximially tolerated dose over a 7-day period. Treatment Period is 6 weeks
88854308|NCT01725126|Placebo Comparator|Part C - Placebo|Subjects will titrate up from a maximially tolerated dose over a 7-day period. Treatment Period is 6 weeks
88854309|NCT01751724|Experimental|Caffeine Arm|Subjects randomized to this arm will receive blinded Caffeine citrate.
88854310|NCT01751724|Placebo Comparator|Placebo Arm|Subjects randomized to this arm will receive blinded Placebo (equivalent volume of normal saline).
88854311|NCT01751646|Experimental|Group A: Vitamin D3 50,000 IU|Subjects randomized to Group A will receive Vitamin D3 50,000 IU orally every four weeks by directly observed therapy (DOT). In addition all subjects receive a multivitamin (MVI) that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Calcium (Ca). Subjects will self-administer one MVI tablet orally once daily.
88854312|NCT01751646|Placebo Comparator|Group B: Vitamin D3 placebo|Subjects randomized to Group B will receive Vitamin D3 placebo orally every four weeks by DOT. In addition all subjects receive a MVI that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Ca. Subjects will self-administer one MVI tablet orally once daily.
88854313|NCT01751568|Experimental|Cohort 1: ≥ 2 to < 6 years of age on TB treatment|Participants in this cohort received chewable raltegravir tablets, starting dose of 12 mg/kg (up to a maximum of 800 mg) orally twice daily, in addition to two NRTIs to treat HIV as part of standard of care, and a rifampicin-containing regimen to treat TB. After a study visit at Day 5 to 8, a fourth ARV medication was added to the regimen.
88854314|NCT01751568|Experimental|Cohort 2: ≥ 6 to < 12 years of age on TB treatment|Participants in this cohort received chewable raltegravir tablets, starting dose of 12 mg/kg (up to a maximum of 800 mg) orally twice daily, in addition to two NRTIs to treat HIV as part of standard of care, and a rifampicin-containing regimen to treat TB. After a study visit at Day 5 to 8, a fourth ARV medication was added to the regimen.
88854315|NCT01751568|Experimental|Cohort 3: : ≥ 4 weeks to < 2 years of age on TB treatment|Participants in this cohort received chewable raltegravir tablets (as a dispersible tablet), starting dose of 12 mg/kg (up to a maximum of 800 mg) orally twice daily, in addition to two NRTIs to treat HIV as part of standard of care, and a rifampicin-containing regimen to treat TB. After a study visit at Day 5 to 8, a fourth ARV medication was added to the regimen.
88854316|NCT01751412|Experimental|Proton Radiation|Delivered daily (Monday-Friday) for two to five weeks.
88854317|NCT04556682||Patients who underwent Rotational atherectomy (RA)|The device contains rapidly rotating burr that is coated with microscopic diamond chips, which debulks the calcified plaque by grinding the calcified atheroma into small particles facilitating stent passage and expansion. Both transfemoral or transradial approach can be used. Regular PCI guidewire can be used to cross the often complex anatomy then switching to a rotablation dedicated guidewire over a microcatheter. Burr sizes vary from 1.25mm up to 1.75mm (in certain cases bigger calibers may also be used) aiming to achieve plaque modification .
89002725|NCT06226792||Ankylosing Spondylitis|"Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Metrology Index (BASMI), Rivermead Mobility Index (RMI) will be evaluated.~Vastus Lateralis, Tibialis Anterior, Lateral Gastrocnemius and Medial Gastrocnemius ultrasonography will be performed to evaluate muscle thickness, pennation angle and fascicle length.~Isometric knee extension, isometric ankle dorsiflexion and isometric ankle plantar flexion strength will be evaluated with hand held dynamometer."
88854318|NCT04556682||Patients who underwent Intravascular lithotripsy (IVL)|The Coronary IVL System consists of an IVL Balloon Catheter with 2 integrated emitters, a Lithotripsy Generator, and a Connector Cable. These emitters create sonic pressure waves that selectively fracture calcium and alter vessel compliance facilitating stent passage and expansion. It is available in 2.5- to 4.0-mm diameters and 12 mm in length, with an inflation pressure of 4 atm used for delivering the treatment. Every catheter can emit a maximum of 80 pulses at a rate of one pulse per second. The IVL balloon catheter is chosen based on the reference lumen of the vessel and after pre-dilatation of the lesion (preferably with a non-compliant balloon) 10-30 pulses are given, usually with interval deflation to allow distal perfusion. If the lesion exceeds the 12 mm balloon length, the balloon can be repositioned and the IVL repeated .
88854319|NCT01751178|Active Comparator|Mouthwash with Alcohol|rinse with 10ml 0.2% w/v Chlorhexidine Digluconate Mouthwash with alcohol for 1 timed minute twice daily for 6 weeks following brushing with a full brush head of standard toothpaste for 1 timed minute.
88854320|NCT01751178|Active Comparator|Mouthwash without Alcohol|rinse with 10ml 0.2% w/v Chlorhexidine Digluconate Mouthwash without alcohol for 1 timed minute twice daily for 6 weeks following brushing with a full brush head of standard toothpaste for 1 timed minute.
88854321|NCT01606254|Experimental|Paliperidone palmitate 50 mg|Paliperidone palmitate 50 milligram (mg) intramuscular (into the muscle) injection on Days 1, 8, 36 and 64.
88854322|NCT01606254|Experimental|Paliperidone palmitate 100 mg|Paliperidone palmitate 100 mg intramuscular injection on Days 1, 8, 36 and 64.
88854323|NCT01606254|Experimental|Paliperidone palmitate 150 mg|Paliperidone palmitate 150 mg intramuscular injection on Days 1, 8, 36 and 64.
88854324|NCT01606254|Experimental|Paliperidone palmitate 150/ 50 mg|Paliperidone palmitate 150 mg intramuscular injection on Day 1 and paliperidone palmitate 50 mg intramuscular injection on Days 8, 36 and 64.
88854325|NCT01750242||Parkinson's disease Subjects|Subjects with advanced Parkinson's Disease implanted with Medtronic DBS system in the subthalamic nucleus (STN).
88854326|NCT01723254|Experimental|PF-06444753|
88854327|NCT01723254|Experimental|PF-06444752|
88854328|NCT01723254|Placebo Comparator|Placebo|Intramuscular
88854329|NCT01722162|Experimental|Arm A: (start levocetirizine after bevacizumab/capecitabine)|"Bevacizumab IV 5 mg/kg on Days 1 each 2-week cycle.~Capecitabine PO 850 mg/m2 twice a day on Days 1-7 of each 2 week cycle.~Levocetirizine PO 5 mg daily before bed starting on Day 8 of Cycle 1. 5 mg daily before bed Days 1-4 of each cycle starting with cycle 2."
88854330|NCT01722162|Experimental|Arm B: (start levocetirizine before bevacizumab/capecitabine)|"Bevacizumab IV 5 mg/kg on Days 1 each 2-week cycle.~Capecitabine PO 850 mg/m2 twice a day on Days 1-7 of each 2 week cycle.~Levocetirizine PO 5 mg daily starting 7 days prior to initiation of bevacizumab and capecitabine therapy. 5 mg daily Days 1-14 starting with cycle 2."
88854331|NCT01721772|Experimental|Nivolumab, 3 mg/kg|Participants received nivolumab, 3 mg/kg, solution administered Intravenously (IV) every 2 weeks until disease progression, discontinuation due to toxicity, withdrawal of consent, or study completion. Eligible participants may switch to nivolumab at 480mg every 4 weeks until documented disease progression, discontinuation, withdrawal of consent or the study ends.
88854332|NCT01721772|Active Comparator|Dacarbazine, 1000 mg/m^2|Participants received dacarbazine, 1000 mg/m^2, solution administered IV every 3 weeks until disease progression, discontinuation due to toxicity, withdrawal of consent, or study completion. Eligible participants may cross-over to nivolumab open label treatment, either 3 mg/kg every 2 weeks or 480mg every 4 weeks until documented disease progression, discontinuation, withdrawal of consent or the study ends.
88854333|NCT01702428|Experimental|INV_MMR_L1 Group|Subjects receive 1 dose of GSK's candidate combined measles, mumps and rubella (MMR) investigational vaccine (INV_MMR) Lot 1 (L1) co-administered with VV and HAV vaccines at Visit 1 (Day 0). All US subjects are also given PCV-13 vaccine. The MMR vaccine is administered subcutaneously in the triceps region of the left arm while the VV vaccine is administered subcutaneously in the triceps region of the right arm. HAV and PCV-13 vaccines are administered intramuscularly in the anterolateral region of the right and left thigh, respectively.
88854334|NCT01702428|Experimental|INV_MMR_L2 Group|Subjects receive 1 dose of GSK's candidate combined measles, mumps and rubella (MMR) investigational vaccine (INV_MMR) Lot 2 (L2) co-administered with VV and HAV vaccines at Visit 1 (Day 0). All US subjects are also given PCV-13 vaccine. The MMR vaccine is administered subcutaneously in the triceps region of the left arm while the VV vaccine is administered subcutaneously in the triceps region of the right arm. HAV and PCV-13 vaccines are administered intramuscularly in the anterolateral region of the right and left thigh, respectively.
88854335|NCT01702428|Experimental|INV_MMR_L3 Group|Subjects receive 1 dose of GSK's candidate combined measles, mumps and rubella (MMR) investigational vaccine (INV_MMR) Lot 3 (L3) co-administered with VV and HAV vaccines at Visit 1 (Day 0). All US subjects are also given PCV-13 vaccine. The MMR vaccine is administered subcutaneously in the triceps region of the left arm while the VV vaccine is administered subcutaneously in the triceps region of the right arm. HAV and PCV-13 vaccines are administered intramuscularly in the anterolateral region of the right and left thigh, respectively.
88854336|NCT01702428|Active Comparator|COM_MMR Group|Subjects receive 1 dose of COM_MMR Lot 1 and Lot 2 co-administered with VV and HAV vaccines at Visit 1 (Day 0). All US subjects are also given PCV-13 vaccine. The MMR vaccine is administered subcutaneously in the triceps region of the left arm while the VV vaccine is administered subcutaneously in the triceps region of the right arm. HAV and PCV-13 vaccines are administered intramuscularly in the anterolateral region of the right and left thigh, respectively. Pooled analysis is conducted for this group.
88854337|NCT01701258|Active Comparator|CSA/MDD-amisulpride|Subjects experiencing a current episode of major depression (MDD) with a history of child sexual abuse (CSA) are randomized to receive a single low-dose pharmacological challenge, 50mg amisulpride tablet during the fMRI session.
88854338|NCT01701258|Placebo Comparator|CSA/MDD-placebo|Subjects experiencing a current episode of major depression (MDD) with a history of child sexual abuse (CSA) are randomized to receive a placebo during the fMRI session.
89381559|NCT03706157|Active Comparator|Normal saline|Doxorubicin solution reconstituted in 5 mL normal saline
89381560|NCT03707795|Experimental|Arm 1 - Amyotrophic Lateral Sclerosis|Betamethasone sodium phosphate/betamethasone acetate (Celestone® Soluspan®), 30 mg IM once a day for four days
89381561|NCT03707795|Active Comparator|Arm 2 - Familial Amyotrophic Lateral Sclerosis|Betamethasone sodium phosphate/betamethasone acetate (Celestone® Soluspan®), 30 mg IM once a day for four days
89381562|NCT01312025|Placebo Comparator|conventional laparoscopic cholecystectomy|
89381563|NCT01312025|Active Comparator|modified laparoscopic cholecystectomy|
89381564|NCT05176535|Experimental|FertyBiotic Balance|Participants received FertyBiotic Balance one capsule a day
89381565|NCT03042312|Experimental|177Lu-PSMA-617 (6.0 GBq)|Repeated i.v. application of 6.0 GBq (gigabequerel)(+/- 10%, arm 1) every 8+/- 1 weeks; RLT until reaching four cycles or threshold maximum dose to the kidneys of 23 Gy as determined by dosimetry
89381566|NCT03042312|Experimental|177Lu-PSMA-617 (7.4 GBq)|Repeated i.v. application of 7.4 GBq (gigabequerel)(+/- 10%, arm 2) of drug every 8+/- 1 weeks; RLT until reaching four cycles or threshold maximum dose to the kidneys of 23 Gy as determined by dosimetry
89381567|NCT03706001|Experimental|Experimental Arm|Participants will receive psychotherapy for once a week.
89381568|NCT03706001|No Intervention|Control Arm|Participants will not receive any treatment for depression.
89381569|NCT05692986|Active Comparator|povidone betadine|
89381570|NCT05692986|Active Comparator|chlorhexidine|
89381571|NCT03360071|Experimental|Allergen Immunotherapy Group|
89381572|NCT03360071|Placebo Comparator|Control Group|
89381573|NCT05692830|Experimental|Fast Condition|Participants randomized to consume study beverages at a comparatively rapid rate.
89381574|NCT05692830|Experimental|Slow Condition|Participants randomized to consume study beverages at a comparatively slow rate.
89381575|NCT05092776|Experimental|RPH-104|"Test product group receiving RPH-104 subcutaneous (s.c.) injections:160 mg on Day 0, 80 mg on Day 7, Day 14 and every 2 weeks (q2w) thereafter.~In case marker attack does not resolve at Visit 2 - the treatment group will be unblinded: patients will receive planned RPH-104 80 mg administration.~In case of a new attack on further days of treatment period until Visit 10 inclusive - the treatment group will be unblinded: the dose of RPH-104 could be escalated to 160 mg q2w; The patients already receiving RPH-104 160 mg q2w will continue to receive RPH-104 at this dose. Further dose escalation is forbidden."
89381576|NCT05092776|Placebo Comparator|Placebo|"Placebo group receiving the equivalent placebo dose also as s.c. injections on Day 0, Day 7, Day 14 and q2w thereafter.~In case the marker attack does not resolve at Visit 2 - the treatment group will be unblinded: patients will be switched to active treatment with RPH-104 in SC injections at a dose of 160 mg followed by administration of 80 mg in 7 days at the Attack + 7 days Visit, and 80 mg at the next Visits.~In a case of a new attack the patients switching from placebo and receiving RPH-104 at 80 mg dose could be escalated to RPH-104 160 mg q2w; Further dose escalation is forbidden."
89381577|NCT03710213|No Intervention|Usual Care|Usual care includes (1) bowel preparation instructions that are delivered via mail or through a secure online messaging portal, (2) a phone call from the endoscopy staff in the week prior to colonoscopy, and (3) the option to call the endoscopy staff during business hours to have any questions answered on demand.
89381578|NCT03710213|Experimental|Text Message-based Intervention|In addition to usual care, the text message-based intervention consists of the subject receiving text messages per a pre-determined protocol starting 7 days prior to the date of scheduled colonoscopy, in addition to two text messages at the time of enrollment explaining the texting program. Of note, if a patient in the intervention arm cancels or reschedules their colonoscopy after randomization, they will not receive any additional protocol text messages as part of this trial.
88854339|NCT01701258|Active Comparator|CSA/RES-amisulpride|Subjects with a history of child sexual abuse (CSA) without a current or past diagnosis of major depressive disorder (RES) are randomized to receive a single low-dose pharmacological challenge, 50mg amisulpride tablet during the fMRI session.
89381579|NCT04745507||Arm 1 / C1|This cohort (C1) consists of 180 patients who receive IEHT in the recruiting sites, fulfil inclusion criteria and gave informed consent regarding their study participation.
89381580|NCT04745507||Arm 2 / C2|"This cohort (C2) consist of 180 patients receiving standard inpatient care (TAU) from the IEHT delivering hospital who fulfil inclusion criteria, are identified through a propensity score (PS) function as optimal control user or rather a PS match and gave informed consent regarding their study participation"
89381581|NCT04745507||Arm 3|360 close relatives or informal caregivers living in the same household of the participating patients who gave informed consent regarding their study participation. Thereby, one relative of each patients who is participating in the trial will be assessed (C1 = 180, C2 = 180).
89381582|NCT04745507||Arm 4:|Staff members of participating study cites as well as local and political stakeholders engaged with IEHT who gave informed consent (approximately n = 100 participants overall).
89381583|NCT05681429|Placebo Comparator|Opioid-based Anaesthesia|This arm will be given drugs for standard opioid-based anaesthesia.
89381584|NCT05681429|Experimental|Opioid-free Anaesthesia|"This experimental arm will be given drugs for opioid-free anaesthesia as stated below to replace opioids used:~Intravenous (IV) Lignocaine (1.5 mg/kg) Intravenous Infusion (IVI) Dexmedetomidine (0.2-0.7 mcg/kg/h) & volatile (sevoflurane) ~ Minimum Alveolar Concentration (MAC) 0.9-1.0 IV Paracetamol 1 gm (give after scalp block) IV Parecoxib 40 mg (give 30 minutes before end of surgery) IV Ondansetron 4 mg (give 30 minutes before end of surgery) IV Metoclopramide 10 mg (rescue)"
89381585|NCT05024760|No Intervention|Control|This arm will receive standard of care during dental implant insertion.
89381586|NCT05024760|Experimental|Chlorhexidine|Chlorhexidine treatment.
89381587|NCT05024760|Experimental|Hydrogen Peroxide|Hydrogen Peroxide treatment.
89381588|NCT05176067|No Intervention|drug therapy group|targeted therapy, immune, chemotherapy
89381589|NCT05176067|Experimental|drug therapy concurrent radiotherapy|drug therapy(targeted therapy, immune, chemotherapy ) combined with thoracic tumor concurrent radiotherapy
88854340|NCT01701258|Placebo Comparator|CSA/RES-placebo|Subjects with a history of child sexual abuse (CSA) without a current or past diagnosis of major depressive disorder (RES) are randomized to receive a placebo during the fMRI session.
89381590|NCT02949011|Experimental|Baloxavir Marboxil|Participants received either 40 mg or 80 mg of baloxavir marboxil orally on Day 1 based on body weight of < 80 kg or ≥ 80 kg at Screening, respectively. Participants also received placebo to oseltamivir orally twice a day (BID) on Days 1 to 5.
89381591|NCT02949011|Active Comparator|Oseltamivir|Participants received 75 mg oseltamivir twice a day on Days 1 to 5 and placebo to baloxavir marboxil on Day 1.
89381592|NCT02949011|Placebo Comparator|Placebo|Participants received placebo to baloxavir marboxil on Day 1 and placebo to oseltamivir orally twice a day on Days 1 to 5.
89381593|NCT03787368|Experimental|Dose 1 of BAY1213790|Single intravenous infusion BAY1213790 (Dose 1)
89381594|NCT03787368|Experimental|Dose 2 of BAY1213790|Single intravenous infusion BAY1213790 (Dose 2)
89381595|NCT03787368|Placebo Comparator|Placebo|Single intravenous infusion placebo
89381596|NCT03705611|No Intervention|Standard of care|Provide personalised clinic invitation slips (letters) to partners to come for HIV testing, and to access post-test services
89381597|NCT03705611|Experimental|HIV self-testing only|HIV self-testing only
88854341|NCT01701258|Active Comparator|MDD-amisulpride|Subjects without a history of child sexual abuse that are currently experiencing a major depressive episode are randomized to receive a single low-dose pharmacological challenge, 50mg amisulpride tablet during the fMRI session.
88854342|NCT01701258|Placebo Comparator|MDD-placebo|Subjects without a history of child sexual abuse that are currently experiencing a major depressive episode are randomized to receive a placebo during the fMRI session.
88854343|NCT01701258|Active Comparator|Control-amisulpride|Subjects without a history of child sexual abuse and without a current or past diagnosis of major depressive episode are randomized to receive a single low-dose pharmacological challenge, 50mg amisulpride tablet during the fMRI session.
88854344|NCT01701258|Placebo Comparator|Control-placebo|Subjects without a history of child sexual abuse and without a current or past diagnosis of major depressive episode are randomized to receive a placebo during the fMRI session.
88854345|NCT01700946|Active Comparator|Standard Risk|"Interventions: dexamethasone, vincristine sulfate, rituximab, clofarabine, cyclophosphamide, etoposide, aldesleukin, pegaspargase, methotrexate, mercaptopurine, cytarabine, mitoxantrone, teniposide, vinblastine, natural killer cell infusion, laboratory biomarker analysis, therapeutic hydrocortisone~Cells for infusion are prepared using the CliniMACS System."
88854346|NCT01700946|Active Comparator|High Risk|"Interventions: dexamethasone, vincristine, rituximab, clofarabine, cyclophosphamide, etoposide, aldesleukin, pegaspargase, methotrexate, mercaptopurine, cytarabine, mitoxantrone, natural killer cell infusion, allogeneic hematopoietic stem cell transplantation, laboratory biomarker analysis, therapeutic hydrocortisone~Cells for infusion are prepared using the CliniMACS System."
88854347|NCT04565886|Sham Comparator|control|Non-surgical mechanical instrumentation 3x. Each time the laser will be held in place but will not be activated.
88854348|NCT04565886|Experimental|laser|Non-surgical mechanical instrumentation 3x with adjunctive diode laser application according to the protocol of the Department of Periodontology, University of Bern
88854349|NCT04548804|Experimental|Control|Control subjects receiving body-surface potential mapping (BSPM) and either a CT-scan or a CMR scan
88854350|NCT04548804|Experimental|Diseased|Diseased subjects receiving body-surface potential mapping (BSPM) and either a CT-scan or a CMR scan. Outcome measures from these procedures will be compared to controls.
88854351|NCT01748994|Placebo Comparator|Placebo|Administration of placebo to upper- and lower-body obese women
88854352|NCT01748994|Active Comparator|Drug|Administration of pioglitazone to upper- and lower-body obese women
88854353|NCT01721070|Experimental|SUF NT 15 mcg|Period 1: One dose of SUF NT 15 mcg administered sublingually. Subjects also received one dose of oral naltrexone 50 mg in the evening before and the morning of each SUF NT dosing to block the opioid effects of the sufentanil.
88854354|NCT01721070|Experimental|Ketoconazole 400 mg, SUF NT 15 mcg|"Ketoconazole 400 mg administered once daily for three days. One dose of SUF NT 15 mcg was co-administered sublingually with the third (last) ketoconazole dose.~Subjects also received one dose of oral naltrexone 50 mg in the evening before and the morning of each SUF NT dosing to block the opioid effects of the sufentanil."
88854355|NCT01748760|Experimental|CLASP-A intervention|Adolescent participants and parents will receive adjunctive psychosocial intervention.
88854356|NCT01748760|Active Comparator|Treatment as Usual|Adolescent participants and parents will not receive study intervention
88854357|NCT01748292|Active Comparator|Monthly IVT ranibizumab|Monthly intravitreal injections (IVT) ranibizumab for 24 months, not less than 21 days apart to not more than 35 days apart
88854358|NCT01748292|Experimental|Treat and Extend IVT ranibizumab|0.5 mg intravitreal injections (IVT) ranibizumab for 3 consecutive months followed by a treat and extend protocol in which follow-up intervals are increased when there is no clinical and SD-OCT evidence of disease activity by 2-week intervals and patients are treated at every visit. (Comparator arm)
88854359|NCT01720602|Experimental|Treatment (vorinostat, AI therapy)|Patients receive vorinostat PO 5 days a week for 3 weeks. Patients also receive AI therapy comprising either anastrozole PO daily, letrozole PO daily, or exemestane PO daily for 4 weeks. Courses repeat every 28 days in the absence of disease progression and unacceptable toxicity.
88854360|NCT01746732|Experimental|Ortho-Cyclen|Ortho-Cyclen (35 microgram (mcg) ethinyl estradiol and 250 mcg norgestimate) administered orally, once daily (QD), for 28 days (lead-in period). Then, Ortho-Cyclen orally QD for 28 Days (Days 1 to 28) in one of two treatment periods. Treatment A
89381598|NCT03705611|Experimental|HIV self-testing secondary accuracy|HIV self-testing secondary accuracy
89381599|NCT03705533|Other|Sequence ABAB|Subjects assigned to sequence ABAB will receive a single 80 mg dose of the test product Telmisartan (1 x 80 mg tablet) marked as A in the sequence in Periods 1 and 3 and a single 80 mg dose of the reference product Micardis (1 x 80 mg tablet) marked as B in the sequence in periods 2 and 4. These treatments will be administered orally with approximately 240 mL of water at ambient temperature, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
89381600|NCT03705533|Other|Sequence BABA|Subjects assigned to sequence BABA will receive a single 80 mg dose of the reference product Micardis (1 x 80 mg tablet) marked as B in the sequence in periods 1 and 3 and a single 80 mg dose of the test product Telmisartan (1 x 80 mg tablet) marked as A in the sequence in Periods 2 and 4. These treatments will be administered orally with approximately 240 mL of water at ambient temperature, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
89381601|NCT05177627|Experimental|Fundamental of Care Framework implementation|Educational interventions related to introduction of FoC framework and taking charge of patients and their fundamental needs will be realized during theoretical, simulation and internship learning.
89381602|NCT05177627|No Intervention|No Fundamental of Care Framework implementation|the participants of no intervention group will receive the standard training as scheduled on the curriculum
89381603|NCT05143541||AEON Endostapler|Stapling performed with AEON Endostapler
89381604|NCT03357731|Experimental|Placebo/BMS-986231/NTG|administered in a cross over design with 5-hour infusions and 5-28 day wash-out periods
89381605|NCT03357731|Experimental|Placebo/NTG/BMS-986231|administered in a cross over design with 5-hour infusions and 5-28 day wash-out periods
89381606|NCT03357731|Experimental|NTG/Placebo/BMS-986231|administered in a cross over design with 5-hour infusions and 5-28 day wash-out periods
89381607|NCT03357731|Experimental|NTG/BMS-986231/Placebo|administered in a cross over design with 5-hour infusions and 5-28 day wash-out periods
89381608|NCT03357731|Experimental|BMS-986231/Placebo/NTG|administered in a cross over design with 5-hour infusions and 5-28 day wash-out periods
89381609|NCT03357731|Experimental|BMS-986231/NTG/Placebo|administered in a cross over design with 5-hour infusions and 5-28 day wash-out periods
89381610|NCT04563702|Experimental|Low Dose VXA-CoV2-1|Low dose (1E10 I.U.) of VXA-CoV2-1 oral tableted vaccine dispensed at Day 1. A subset will also receive a second dose at Day 29
89381611|NCT04563702|Experimental|High Dose|High Dose (1E11 I.U.) of VXA-CoV2-1 oral tableted vaccine dispensed at Day 1
89381612|NCT03709979|Active Comparator|C-MAC with folded towel position|Children will be intubated by C-MAC videolaryngoscope with placing a folded towel under the shoulder.
89381613|NCT03709979|Placebo Comparator|C-MAC with flat position|Children will be intubated by C-MAC videolaryngoscope with flat position (non-inserted a folded towel)
89381614|NCT03357341||COPD cohort|Approximately 100 subjects with COPD identified through integrated EHR records will be enrolled.
89381615|NCT03357341||Asthma cohort|Approximately 100 subjects with asthma identified through integrated EHR records will be enrolled.
89381616|NCT05177549|Experimental|on estrogen-progestin contraception|
89381617|NCT05177549|Experimental|under micro-progestational contraception|
89381618|NCT05177549|Experimental|without hormonal contraception|
89381619|NCT04900818|Experimental|Dose Escalation: TJ033721|"Dose Escalation:: TJ033721 will be administered at up to 8 dose levels (0.1, 0.3, 1, 3, 5, 8, 12 and 15 mg/kg) bi-weekly (Q2W)~During dose expansion, TJ033721 will be administered Q2W, starting at the highest dose to have cleared the DLT period.~After the conclusion of dose expansion TJ033721 will be administered Q2W at the MAD or RP2D."
88854361|NCT01746732|Experimental|Ortho-Cyclen + Evacetrapib|Ortho-Cyclen administered orally, QD, for 28 days (lead-in period). Then, Ortho-Cyclen orally QD for 28 Days (Days 1 to 28) and 130 mg evacetrapib orally, QD, for 21 days (Days 1 to 21) in one of two treatment periods. Treatment B
88854362|NCT01720524|Placebo Comparator|placebo|iv placebo of normal saline or 10% dextrose
88854363|NCT01720524|Experimental|sildenafil|Active study drug
89381620|NCT05177237|Experimental|Endostar combined with Methylprednisolone|Endostar combined with Methylprednisolone lasts for 10 weeks
89381621|NCT05177081|Experimental|Home BIA Monitoring group|Preemptive management by Body fluid monitoring system (BWA ON + App + Web)
88854364|NCT01720446|Experimental|Semaglutide 0.5 mg|
88854365|NCT01720446|Experimental|Semaglutide 1.0 mg|
88854366|NCT01720446|Placebo Comparator|Semaglutide placebo 0.5 mg|
88854367|NCT01720446|Placebo Comparator|Semaglutide placebo 1.0 mg|
88854368|NCT01746108|Experimental|At-risk-Unprimed Group|Subjects who have not been previously vaccinated with any pneumococcal vaccine and are at an increased risk of pneumococcal infection.
88854369|NCT01746108|Experimental|At-risk-Primed Group|"Subjects who have been previously vaccinated~with at least one dose of a pneumococcal conjugate vaccine i.e. either Synflorix (10Pn-PD-DiT), Prevenar or Prevenar13.~with plain polysaccharide pneumococcal vaccine more than 2 years and less than 5 years before enrollment.~and are at an increased risk of pneumococcal infection."
88854370|NCT01746108|Active Comparator|Healthy-Unprimed Group|Subjects who have not been previously vaccinated with any pneumococcal vaccine and are healthy.
88854371|NCT01746108|Active Comparator|Healthy-Primed Group|Subjects who have been previously vaccinated with at least one dose of a pneumococcal vaccine and are healthy.
89381622|NCT05177081|No Intervention|Control group|Usual heart failure management (Outpatient follow-up and medical treatment)
89381623|NCT05671289||Patients with confirmed bladder tumor|Patients with bladder tumor, confirmed by cystoscopy and radiology. Age ranging from 18 to 80 years old. Women of childbearing age should have negative urine pregnancy test.
89381624|NCT05671289||Healthy volunteers|Individuals with no known disease and normal urinalysis. Age ranging from 18 to 80 years old. Women of childbearing age should have negative urine pregnancy test.
89381625|NCT04747067|Experimental|High-flux Hemodialysis|patients treated by conventional hemodialysis
89381626|NCT04747067|Experimental|Hemodiafiltration|patients treated by online post-dilution hemodialysis
89381627|NCT05646953|Experimental|Vasu Facial Beauty Oil|"Vasu Facial Beauty Oil blends the Traditional Beauty recipe of Kumkumadi Tailam with clinically- proven Natural Plant Actives to offer a unique product that gives a Natural Glow to face, overcoming hyper-pigmentation, age spots, wrinkles, and blemishes with Avacado, Lavender, Argan, Rapeseed.~Kumkumadi Oil is an Ayurvedic Elixir that is effective for many skincare concerns such as Hyperpigmentation, Dark spots, Age spots, Acne scars, Fine lines, Wrinkles as well as Dark circles. It is also used for Beautifying, Rejuvenating and Uplifting the skin."
89381628|NCT03039738|Active Comparator|Telemetry Monitoring Arm|The telemetry group will serve as the control group and will be monitored via the site's standard of care telemetry protocols.
89381629|NCT03039738|Experimental|Surveillance Monitoring Arm|Subjects in the surveillance monitoring group will alternatively be admitted to medical surgical unit and be monitored via the surveillance monitoring platform.
89381630|NCT05681117|No Intervention|control group|No intervention will be made in the control group.
89381631|NCT05681117|Experimental|Experimental group|Class-based nutrition education, online intervention (SMS reminders with tips for healthy eating), distribution of brochures prepared in accordance with the educational content, and a controversial supermarket tour were organized in the experimental group as multiple interventions. Class-based nutrition education was given as a 40-minute session once a week for 4 weeks. Nutrition education content has been prepared as 4 modules in line with the current literature.
88854372|NCT01717638|Experimental|B+R246_12_48|Previously received rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine + routine vaccines at 2, 4 and 6 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 12 months of age. One third of subjects from this group received a 5th dose of rMenB+OMV NZ vaccine in the present study at 4 years of age.
88854373|NCT01717638|Experimental|B+R246_18_48|Previously received rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine + routine vaccines at 2, 4 and 6 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 18 months of age. One third of subjects from this group received a 5th dose of rMenB+OMV NZ vaccine in the present study at 4 years of age.
89381632|NCT05007899|Active Comparator|Daily|Patients receive standard regimen of ferrous sulfate 325 mg (65 mg elemental iron) once every morning.
89381633|NCT05007899|Experimental|Alternate Day|Patients receive ferrous sulfate 325 mg (65 mg elemental iron) once every other morning.
89381634|NCT05147142|Experimental|Target Site Low Intensity Focused Ultrasound|Low Intensity focused ultrasound of the target region. These are at a fundamental frequency = 650kHz, PRF = 10Hz, pulse width = 5ms, duty cycle = 5%; ISPTA.3 of 720 mW/cm2. As in prior studies, each sonication includes 10 pulsations, each lasting 30s, followed by 30s pause intervals; two 10-minute administrations provided per LIFU session.
89381635|NCT05147142|Active Comparator|Control Site Low Intensity Focused Ultrasound|Low Intensity focused ultrasound of the control region. These are at a fundamental frequency = 650kHz, PRF = 10Hz, pulse width = 5ms, duty cycle = 5%; ISPTA.3 of 720 mW/cm2. As in prior studies, each sonication includes 10 pulsations, each lasting 30s, followed by 30s pause intervals; two 10-minute administrations provided per LIFU session.
89381636|NCT05147142|No Intervention|Healthy Control|25 age- and sex-matched healthy controls will be recruited and complete fMRI tasks. They will not receive low intensity focused ultrasound.
88854374|NCT01717638|Experimental|B+R246_24_48|Previously received rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine + routine vaccines at 2, 4 and 6 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 24 months of age. One third of subjects from this group received a 5th dose of rMenB+OMV NZ vaccine in the present study at 4 years of age.
89381637|NCT05636345|Experimental|Intervention group|High school students receiving a day of pain science education in multiple formats, lectures, experiential, completing a task which consolidates the information.
89381638|NCT04507373|Placebo Comparator|Placebo|Following the baseline period, subject will be randomized to receive either simvastatin or an identical placebo at a dose of 40 mg/day for a period of 10 weeks.
89381639|NCT04507373|Active Comparator|Simvastatin 40mg|Following the baseline period, subject will be randomized to receive either simvastatin or an identical placebo at a dose of 40 mg/day for a period of 10 weeks.
89381640|NCT01312337|Experimental|Iressa for EGFR wild group|salvage Iressa therapy for patients with EGFR mutation negative NSCLC patients
89381641|NCT05174897|No Intervention|Control Group|The child for whom an intravenous catheter will be applied will be placed on a stretcher and pain and fear will be evaluated before the procedure. Afterwards, an intravenous catheter will be applied. Pain and fear scores will be evaluated during and after the procedure.
89381642|NCT05174897|Experimental|Experimental group|The child to whom an intravenous catheter will be applied is placed on a stretcher. After evaluating the pain and fear score before the procedure, emotional liberation technique (EFT) is performed for 10 minutes. followed by an intravenous catheter. Pain and fear scores are evaluated during and after the procedure.
89381643|NCT05232149|Experimental|Lower Dose|Orelabrutinib is a white, round, uncoated tablet
88854375|NCT01717638|Experimental|B246_12_48|Previously received 3 doses of rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine at 2, 4 and 6 months of age and routine vaccines at 3, 5 and 7 months of age, followed by a booster dose of rMenB+OMV NZ vaccine at 12 months of age. One third of subjects from this group received a 5th dose of rMenB+OMV NZ vaccine in the present study at 4 years of age.
89002726|NCT06226792||Volunteers|"Voluntary participants will be admitted to this group. Vastus Lateralis, Tibialis Anterior, Lateral Gastrocnemius and Medial Gastrocnemius ultrasonography will be performed to evaluate muscle thickness, pennation angle and fascicle length.~Isometric knee extension, isometric ankle dorsiflexion and isometric ankle plantar flexion strength will be evaluated with hand held dynamometer."
89381644|NCT05232149|Experimental|Higher Dose|Orelabrutinib is a white, round, uncoated tablet
89381645|NCT05552495|Experimental|Reference-Test1-Test2|
89381646|NCT05552495|Experimental|Reference-Test2-Test1|
89381647|NCT05552495|Experimental|Test1-Reference-Test2|
89381648|NCT05552495|Experimental|Test1-Test2-Reference|
89381649|NCT05552495|Experimental|Test2-Reference-Test1|
89381650|NCT05552495|Experimental|Test2-Test1-Reference|
89381651|NCT05076227||BNT162b2/BNT162b2 - 3 wks|hospital staff receiving BioNTech as prime vaccination and also receiving BioNTech after 3 weeks as boost vaccination
89381652|NCT05076227||ChAdOx1/ChAdOx1 - 12 wks|hospital staff receiving AstraZeneca as prime vaccination and also receiving AstraZeneca as boost vaccination after 12 weeks
89381653|NCT05076227||ChAdOx1/BNT162b2 - 12 wks|hospital staff receiving AstraZeneca as prime vaccination and receiving BioNTech as boost vaccination after 12 weeks
89381654|NCT05076227||BNT162b2/BNT162b2 - 6 wks|hospital staff receiving BioNTech as prime vaccination and also receiving BioNTech after 6 weeks as boost vaccination
89381655|NCT04420403|Experimental|Manual therapy plus cervical stabilization exercise group|The patients diagnosed with chronic neck pain (CNP) with 18-55 years of age followed by routine controls and who were volunteered will be included in the study.
89381656|NCT04420403|Active Comparator|Only manual therapy group|The patients diagnosed with CNP with 18-55 years of age followed by routine controls and who were volunteered will be included in the study.
89381657|NCT05551949|Other|Vaginal estrogen therapy|Participants receive Vaginal estrogen therapy.
89381658|NCT05283954|Experimental|Combined Regime of Fluoxetine, Prednisolone and Ivermectin|"Fluoxetine: 20mg tablet; 20 mg; once daily for 10 days; oral~Prednisolone: 25 mg tablet; 25mg; once daily for 5 days; oral~Ivermectin: 3 mg tablet; 0.4 mg/kg; once daily for 5 days; oral"
89381659|NCT05283954|Other|Combination of Vitamin C and Albendazole|"Vitamin C: 50 mg tablet; 1 tablet; Once daily for 10 days; Oral~Albendazole; 200 mg; 1 tablet; Once daily for 5 days; Oral~Vitamin C: 50 mg tablet; 0.13 tablet/kg*; Once daily for 5 days; Oral~*Same number of tablets than for Ivermectin"
89381660|NCT01312415|Experimental|levobupivacaine infiltration|Patients will receive spinal anaesthesia with intrathecal bupivacaine (17.5 or 15 mg) without morphine, and will receive peri- and intraarticular surgical site infiltration before wound closure with a solution of levobupivacaine 0.5% 2mg/kg body weight (maximum 200mg levobupivacaine) plus 0.5mg epinephrine made up to 100ml with saline. An intra-articular catheter will be placed by the surgeon before closure under the sterile surgical conditions and this will be left in situ in the wound. The patient will receive one further injection of 15ml of levobupivacaine 0.5% at 8am the following morning.
89381661|NCT01312415|Other|Control|Patients will receive spinal anaesthesia with intrathecal bupivacaine 0.5% (17.5 mg if greater than 70 kg and 15 mg if less than 70 kg) and preservative-free morphine (0.3 mg).
89381662|NCT05143775|Experimental|new surgical plan group|The investigators use a monopolar stimulator to determine and retain the tumor margin within 5mm in the sensitive area which is posterior superior longitudinal fasciculus or posterior arcuate fasciculus.
89381663|NCT05143775|Active Comparator|traditional surgical plan group|The investigators use bipolar stimulator according to the current standard surgery plan. After the positive points are identified, those points would be retained to avoiding language function impairment after the tumor resection.
89381664|NCT03036852|Experimental|SOF/VEL|SOF/VEL for 12 weeks
89381665|NCT04979117||Participants with plantar fasciitis|"Participants with the diagnose of plantar fasciitis; typical anamnesis (exacerbating pain by the first steps in the morning or after rest and with prolonged standing).~The emerge of local point tenderness over the heel and proximal fascia due to the pressure applied by the physician.~Thickening of the plantar fascia greater than 4 mm in ultrasonographic evaluation. measurement"
89381666|NCT04979117||Volunteers who has not foot complaints.|Volunteers who were not diagnosed with Plantar Fasciitis and without foot or heel pain when taking the first steps in the morning, with plantar fascia thickness less than 4 mm, painless, symptom-free and which had no additional rheumatic disease.
88854376|NCT01717638|Experimental|B246_18_48|Previously received 3 doses of rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine at 2, 4 and 6 months of age and routine vaccines at 3,5 and 7 months of age, followed by a booster dose of rMenB+OMV NZ at 18 months of age. One third of subjects from this group received a 5th dose of rMenB+OMV NZ vaccine in the present study at 4 years of age.
88854377|NCT01717638|Experimental|B246_24_48|Previously received 3 doses of rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine at 2, 4 and 6 months of age and routine vaccines at 3, 5 and 7 months of age, followed by a booster dose of rMenB+OMV NZ vaccine at 24 months of age. One third of subjects from this group received a 5th dose of rMenB+OMV NZ vaccine in the present study at 4 years of age.
88854378|NCT01717638|Experimental|B+R234_12_48|Previously received 3 doses of rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine + routine vaccines at 2, 3 and 4 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 12 months of age. All subjects received a 5th dose of rMenB+OMV NZ vaccine in the present study at 4 years of age.
88854379|NCT01717638|Experimental|B+R234_18_48|Previously received rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine + routine vaccines at 2, 3 and 4 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 18 months of age. All subjects received a 5th dose of rMenB+OMV NZ vaccine in the present study at 4 years of age.
88854380|NCT01717638|Experimental|B+R234_24_48|Previously received rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine + routine vaccines at 2, 3 and 4 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 24 months of age. All subjects received a 5th dose of rMenB+OMV NZ vaccine in the present study at 4 years of age.
88854381|NCT01717638|Experimental|B12 14_48|Previously received two catch-up doses of rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine at 12 and14 months of age. All subjects received a 3rd dose of rMenB+OMV NZ vaccine in the present study at 4 years of age.
89002727|NCT06225999|Experimental|Irinotecan liposome Injection in combination with oxaliplatin, 5-FU and LLV|
89381667|NCT05309837|Active Comparator|Polydextrose (PDX)|Subject consumed a daily dose of 18g polydextrose enriched drink mixtures and biscuits (12 g from the drink mixtures and 6 g from the biscuits) providing 16.2 g dietary fibre/d.
89381668|NCT05309837|Placebo Comparator|Control (CON)|Subjects consumed placebo products, where maltodextrin replaced PDX and differed only in the amount of fibre per gram (1.7 g).
89381669|NCT04977947|Experimental|Healthy Eating for My Infant Intervention|Participants and their parents will participate in a 6 session intervention targeting healthy introduction of complementary foods, and responsive feeding and mealtime behaviors. Intervention sessions will occur when the infant is 3, 4, 5, 6, 7, and 8 months of age.
89381670|NCT04977947|No Intervention|Control|Participants and their parents will complete baseline and post-treatment study visits to assess study outcomes. They will receive no intervention.
89381671|NCT04294290|Experimental|hCT-MSC infusion|
89381672|NCT05108909||mild to moderate traumatic brain injury|patients diagnosed with mild to moderate traumatic brain injury within 1 week after onset of TBI.
88854382|NCT01717638|Experimental|B18 20_48|Previously received two catch-up doses of rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine at 18 & 20 months of age. All subjects received a 3rd dose of rMenB+OMV NZ vaccine in the present study at 4 years of age.
88854383|NCT01717638|Experimental|B24 26_48|Previously received two catch-up doses of rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine at 24 & 26 months of age. All subjects received a 3rd dose of rMenB+OMV NZ vaccine in the present study at 4 years of age.
88854384|NCT01717638|Experimental|B48_50|Newly recruited 4 year old naive subjects who received 2 catch-up doses of rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine, two months apart, in the present study.
88854385|NCT01745094|Experimental|Concomitant Group|concomitant administration of mirabegron to solifenacin treated patients
88854386|NCT01697748|Placebo Comparator|Telfa pad dressing|Telfa pad dressing placed over Cesarean wound after skin closure; the dressing will be changed to a new Telfa pad dressing on post-operative day 2 which will remain on the incision through post-operative day 7.
89381673|NCT05108909||isolated orthopaedic trauma patients|Patients with isolated orthopaedic trauma were identified and enrolled using the same process as that for patients with TBI.
89381674|NCT05108909||healthy non-injury control|Healthy non-injured controls were recruited either via a relationship with a TRACK-TBI participant or through public advertisement within TRACK-TBI institutions, and were able to provide informed consent.
89381675|NCT05309694|Other|Group 1|Paragard® T380A Intrauterine Copper Contraceptive with new inserter Non parous and parous female subjects of child bearing potential
89381676|NCT05131529|No Intervention|Control|The 3 dining halls allocated to this arm will receive none of the three interventions during the 3 semesters of the project.
89381677|NCT05131529|Experimental|Treatment|The 3 dining halls allocated to this arm will receive one intervention during each of the 3 semesters of the project (only one intervention per semester).
89381678|NCT04784598|Experimental|Experimental group|Group 1- The intervention group I will receive a customized strip slipper with a 3mm EVA horseshoe piece (Shore A 32). And 2.5mm EVA cover (Shore A 28).
89381679|NCT04784598|Sham Comparator|Sham group|Group 2- The control group will receive a slipper with a 2.5mm EVA cover (Shore A 32) identical to the one used by the intervention group, but without corrective par
89381680|NCT05268822|Active Comparator|Movement control exercise with specific breathing techniques|Movement control exercise with specific breathing techniques (experimental group)
89381681|NCT05268822|Active Comparator|Movement control exercise without specific breathing techniques|Movement control exercise without specific breathing techniques (control group)
89381682|NCT05268510|Experimental|Chemotherapy plus Pembrolizumab followed by Pembrolizumab and Olaparib|"Chemotherapy plus Pembrolizumab 2 cycles à 6 weeks:~Pembrolizumab+mod FOLFOX-6:~Pembrolizumab 400 mg 30 min. day 1~Oxaliplatin 85 mg/m² 2h day 1, 15, 29~Leucovorin 400 mg/m² 2h day 1, 15, 29~5-FU 400 mg/m² bolus, followed by 2.400 mg/m² 46h day 1, 15, 29~or~Pembrolizumab+CapOx:~Pembrolizumab 400 mg 30 min. day 1~Oxaliplatin 130 mg/m² 2h day 1,22~Capecitabine 1.000 mg/m² bid. day 1-14, 22-35~Consolidation phase Pembrolizumab and Olaparib max 16 cycles à 6 weeks:~Pembrolizumab 400 mg 30 min. day 1~Olaparib 300 mg bid. cont. day 1 to 42"
89381683|NCT05042453||Hysteropexy using Splentis via vaginal route|Non-fertile women ≥ 18 years with uterine descent (POP-Q ≥ 2) which are study-independently scheduled for hysteropexy with Splentis
89381684|NCT05309681||Study group|Female patients of the Department of Oral medicine diagnosed with burning mouth syndrome
89381685|NCT05309681||Control group|Age-matched female patients without oral lesions and without burning mouth syndrome
89381686|NCT05033717|Experimental|Group A|Tissue Flossing Technique
89381687|NCT05033717|Active Comparator|Group B|Static Stretching exercises
89381688|NCT05026931|Experimental|Group A|Foam Rolling
89381689|NCT05026931|Active Comparator|Group B|Stretching exercises
88854387|NCT01697748|Active Comparator|Silver-impregnated dressing|Silver-impregnated dressing placed over Cesarean wound after skin closure; the dressing will be changed to saline-treated dressing on post-operative day 2 which will remain on the incision through post-operative day 7.
88854388|NCT01717326|Experimental|A1: TN NC Grazoprevir 100 mg + Elbasvir 20 mg + RBV-12 wk|GT1a and GT1b participants receive Grazoprevir 100 mg tablet orally once daily (QD) for 12 weeks, Elbasvir 20 mg capsule and Placebo capsule orally QD for 12 weeks, RBV capsules orally twice daily (BID) for 24 weeks at a total daily dose from 800 to 1400 mg based on participant weight
88854389|NCT01717326|Experimental|A2: TN NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk|GT1a and GT1b participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule and Placebo capsule orally QD for 12 weeks, RBV capsules orally BID for 24 weeks at a total daily dose from 800 to 1400 mg based on participant weight
88854390|NCT01717326|Experimental|A3: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 mg-12 wk|GT1b only participants receive Grazoprevr 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks
89183351|NCT04961177|Other|EITC Assistance|Our partners will screen clients for EITC and refer those who qualify for free tax preparation assistance and assistance submitting their tax returns.
89381690|NCT05477693|Experimental|Experimental Group|1200 participants(including 600 subjects aged 2~17 years,240 subjects aged 18~59 years and 360 subjects aged 60 years and above)received one dose of 23-valent pneumococcal polysaccharide vaccine manufactured by Sinovac Biotech Co., Ltd
89183352|NCT04959175|No Intervention|Donors|Collection of research samples on bone marrow donors
89381691|NCT05477693|Active Comparator|Control Group|600 participants(including 300 subjects aged 2~17 years,120 subjects aged 18~59 years and 180 subjects aged 60 years and above)received one dose of 23-valent pneumococcal polysaccharide vaccine manufactured by Merck Sharp & Dohme.
89381692|NCT03638843|Experimental|Gastric mucosal devitalization arm|Patients will be enrolled in the study after being scheduled to undergo vertical sleeve gastrectomy as part of routine clinical care, and the gastric mucosal devitalization procedure will be performed in-vivo utilizing Argon plasma coagulation three days before the operation.
89381693|NCT04927325|Other|central line with a reddened exit site|A standardized set of photos will be taken of 10 central lines with an erythema at exit site (visible to the naked eye)
89381694|NCT04927325|Other|Control Group: central line without a reddened exit site|A standardized set of photos will be taken of 10 newly inserted CVC (as a control over time to evaluate the in-patient redness and the impact of irritation of a CVC)
88854391|NCT01717326|Experimental|B1: TN NC/GT1a Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk|GT1a only participants receive Grazoprevir 100 mg tablet orally QD for 8 weeks, Elbasvir 50 mg capsule orally QD for 8 weeks, RBV capsules orally BID for 8 weeks at a total daily dose from 800 to 1400 mg based on participant weight
88854392|NCT01717326|Experimental|B2: TN NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk|GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks, RBV capsules orally BID for 12 weeks at a total daily dose from 800 to 1400 mg based on participant weight
88854393|NCT01717326|Experimental|B3: TN NC/GT1a Grazoprevir 100 mg + Elbasvir 50 mg-12 wk|GT1a only participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks
88854394|NCT01717326|Experimental|B4: TN C Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk|GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks, RBV capsules orally BID for 12 weeks at a total daily dose from 800 to 1400 mg based on participant
89381695|NCT05309447||Patients with sLSS|Patients with Symptomatic Lumbar Spinal Stenosis (n=10)
89381696|NCT05309447||Young Controls|Young healthy control subjects (n=10)
89381697|NCT05309447||Age-Matched Controls|Age-matched healthy control subjects (n=10)
89381698|NCT05309213|Experimental|IM19 CAR-T cells|
89381699|NCT05309057||Studies with intermittent fasting|Studies with intermittent fasting strategies.
89381700|NCT05438303|Experimental|Arm A (midazolam and omeprazole)|Participants will receive single oral doses of midazolam and omeprazole together (Day 1 of Treatment Periods 1 and 3) and repeated doses of AZD9833 (Days 1 to 5 of Treatment Period 2 and Day 1 of Treatment Period 3)
89381701|NCT05438303|Experimental|Arm B (Dabigatran etexilate)|Participants will receive single oral doses of dabigatran etexilate (Day 1 of Treatment Periods 1 and 2) and single oral dose of AZD9833 (Day 1 of Treatment Period 2)
89381702|NCT05438303|Experimental|Arm C (Celecoxib)|Participants will receive single oral doses of celecoxib (Day 1 of Treatment Periods 1 and 3) and repeated oral doses of AZD9833 (Days 1 to 5 of Treatment Period 2 and Day 1 of Treatment Period 3)
89381703|NCT05434325||TESTING Particpants|All participants who were successfully randomised to the TESTING study who are still alive and have not reached kidney failure requiring dialysis.
89381704|NCT05432141|Experimental|Primary immunization group|A total of 2000 infants aged 2-3 months will randomly assigned to two groups according to 1:1 using scratch cards: 1000 infants in the sIPV vaccine group and 1000 infants in the sIPV vaccine group plus DTaP vaccine group
89381705|NCT05432141|Experimental|Booster immunization group of sIPV vaccine|A total of 1200 children aged 18 months will randomly assigned to four groups according to 2:2:1:1 using scratch cards: 400 in the sIPV booster group, 400 in the sIPV booster group plus inactivated hepatitis A vaccine simultaneously, 200 in the sIPV booster group plus MMR simultaneously, and 200 in the sIPV booster group plus attenuated hepatitis A vaccine.
88854395|NCT01717326|Experimental|B5: TN C Grazoprevir 100 mg + Elbasvir 50 mg for 12 wk|GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks
88854396|NCT01717326|Experimental|B6: TN C Grazoprevir 100 mg + Elbasvir 50 mg + RBV-18 wk|GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 18 weeks, Elbasvir 50 mg capsule orally QD for 18 weeks, RBV capsules orally BID for 18 weeks at a total daily dose from 800 to 1400 mg based on participant weight
89381706|NCT04868279|Experimental|Interventional Gruop|"Web-based interactive nurse support program with the intervention group will continue for 3 months, the implementation will last 6 months in total. Individuals in the intervention group will be able to access the training content by accessing the website designated for the study from devices such as computers or mobile phones.~Data collection forms will be applied to the intervention group 3 times in total, before starting the Web-based interactive nurse support program, at the end of the Web-based interactive nurse support program (in the 3rd month) and in the 6th month."
89381707|NCT04868279|No Intervention|Control Group|Web-based interactive nurse support program will not be opened to the control group, only access to data collection tools will be provided.
89381708|NCT04859231|Active Comparator|Control|
89381709|NCT04859231|Experimental|Investigational|
89381710|NCT04859231|No Intervention|Mother's-own Breast Milk|
89381711|NCT05308823|No Intervention|Group 1|The paients in this group will receive traditional treatment of IIH for 3 months.
89381712|NCT05308823|Experimental|Group 2|The patients in this group will receive traditional treatment of IIH for 3 months in addition to venus sinus stent.
89381713|NCT05308745|Active Comparator|Probiotic group|Participants within this group consumed Yakult® as research product 1 bottle/day for 24 weeks (168 days).
89381714|NCT05308745|Placebo Comparator|Placebo group|Participants within this group consumed placebo as research product 1 bottle/day for 24 weeks (168 days).
89381715|NCT04803227|Active Comparator|Emricasan|Emricasan
89381716|NCT04803227|Placebo Comparator|Placebo|Placebo
88854397|NCT01717326|Experimental|B7: TN C Grazoprevir 100 mg + Elbasvir 50 mg-18 wk|GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 18 weeks, Elbasvir 50 mg capsule orally QD for 18 weeks
88854398|NCT01717326|Experimental|B8: NR Grazoprevir 100 mg + Elbasvir 50 mg +RBV-12 wk|GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks, RBV capsules orally BID for 12 weeks at a total daily dose from 800 to 1400 mg based on participant weight
88854399|NCT01717326|Experimental|B9: NR Grazoprevir 100 mg + Elbasvir 50 mg-12 wk|GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks
88854400|NCT01717326|Experimental|B10: NR Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk|GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 18 weeks, Elbasvir 50 mg capsule orally QD for 18 weeks, RBV capsules orally BID for 18 weeks at a total daily dose from 800 to 1400 mg based on participant weight
88854401|NCT01717326|Experimental|B11: NR Grazoprevir 100 mg + Elbasvir 50 mg-18 wk|GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 18 weeks, Elbasvir 50 mg capsule orally QD for 18 weeks
89183353|NCT04959175|Experimental|Older, HLA-matched|Subjects age 60-85 with hematologic malignancies and an HLA-matched related or unrelated donor
88854402|NCT01717326|Experimental|B12: TN HIV NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk|GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks, RBV capsules orally BID for 12 weeks at a total daily dose from 800 to 1400 mg based on participant weight
89381717|NCT04735913|Other|Fasting group|Subjects will take abiraterone acetate tablets (250 mg, produced by Patheon Ich, trade name: Zytiga®) orally on an empty stomach and their blood and plasma samples, urine and faeces samples in 72h will be collected for detection.
89381718|NCT04735913|Experimental|Postprandial group|Subjects will take abiraterone acetate tablets (250 mg, produced by Patheon Ich, trade name: Zytiga®)orally after meals and their blood and plasma samples, urine and faeces samples in 72h will be collected for detection.
89381719|NCT04910867|No Intervention|Control Arm|No intervention will be administered. Usual care will be administered.
89381720|NCT04910867|Experimental|Intervention Arm|APOL1 testing program
89381721|NCT04906889|Experimental|dexmedetomidine-lidocaine|The study group receives the dexmedetomidine and lidocaine infusion with general anesthesia for gynecological laparoscopy.
89381722|NCT04906889|Active Comparator|remifentanil|The control group receives the remifentanil infusion with general anesthesia for gynecological laparoscopy
89381723|NCT02945657|Experimental|MM36 1% ointment|MM36 topical ointment, 1%, applied twice daily for 28 days
88854403|NCT01717326|Experimental|B13: TN HIV NC Grazoprevir 100 mg + Elbasvir 50 mg-12 wk|GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks
88854404|NCT01717326|Experimental|C1: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk|GT1b participants receive Grazoprevir 100 mg tablet orally QD for 8 weeks, Elbasvir 50 mg capsule orally QD for 8 weeks, and RBV capsules orally BID for 8 weeks at a total daily dose from 800 to 1400 mg based on participant weight.
89381724|NCT05358743|Experimental|Probiotic group|
89381725|NCT05358743|Placebo Comparator|Control group|
88854405|NCT01717326|Experimental|C2: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 mg-8 wk|GT1b participants receive Grazoprevir 100 mg tablet orally QD for 8 weeks and Elbasvir 50 mg capsule orally QD for 8 weeks
89381726|NCT05308589|Experimental|Continuous Postoperative Pericardial Flushing|Continuous Postoperative Pericardial Flushing (inflow of 500 ml NaCl 0,9% flushing fluid into the pericardial cavity during the first 8 postoperative hours) executed with the Haermonics investigational device
88854406|NCT01717326|Experimental|D1: TN NC/GT3 Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk|GT3 participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks, and RBV capsules orally BID for 12 weeks at a total daily dose from 800 to 1400 mg based on participant weight
88854407|NCT01717326|Experimental|D2: TN NC/GT3 Grazoprevir 100 mg + Elbasvir 50 mg + RBV-18 wk|GT3 participants receive Grazoprevir 100 mg tablet orally QD for 18 weeks, Elbasvir 50 mg capsule orally QD for 18 weeks, and RBV capsules orally BID for 18 weeks at a total daily dose from 800 to 1400 mg based on participant weight
89381727|NCT05308589|No Intervention|Control|Standard care
89381728|NCT04716959|Experimental|Prepectoral Prosthetic Breast Reconstruction|
88854408|NCT01697592|Experimental|Omarigliptin 25 mg/Sulfonylureas (SUs) (Phase A+B)|Omarigliptin 25 mg administered orally once weekly for 52 weeks (24 weeks during Phase A and 28 weeks during Phase B). Participants continued pre-study basal medication of SUs throughout the duration of the study.
88854409|NCT01697592|Experimental|Omarigliptin 25 mg/Glinides (Phase A+B)|Omarigliptin 25 mg administered orally once weekly for 52 weeks (24 weeks during Phase A and 28 weeks during Phase B). Participants continued pre-study basal medication of glinides throughout the duration of the study.
88854410|NCT01697592|Experimental|Omarigliptin 25 mg/biguanides (BGs) (Phase A+B)|Omarigliptin 25 mg administered orally once weekly for 52 weeks (24 weeks during Phase A and 28 weeks during Phase B). Participants continued pre-study basal medication of BGs throughout the duration of the study.
88854411|NCT01697592|Experimental|Omarigliptin 25 mg/Thiazolidinediones (TZDs) (Phase A+B)|Omarigliptin 25 mg administered orally once weekly for 52 weeks (24 weeks during Phase A and 28 weeks during Phase B). Participants continued pre-study basal medication of TZDs throughout the duration of the study.
88854412|NCT01697592|Experimental|Omarigliptin 25 mg/α-GIs (Phase A+B)|Omarigliptin 25 mg administered orally once weekly for 52 weeks (24 weeks during Phase A and 28 weeks during Phase B). Participants continued pre-study basal medication of α-glucosidase (α-GIs) inhibitors throughout the duration of the study.
89183354|NCT04959175|Experimental|Older, HLA-mismatched|Subjects age 60-85 with hematologic malignancies and an HLA-haploidentical or HLA-mismatched unrelated donor
89183355|NCT04959175|Experimental|Younger, HLA-matched|Subjects age 18-60 unfit for MAC with hematologic malignancies and an HLA-matched related or unrelated donor
89381729|NCT04716959|Active Comparator|Subpectoral Prosthetic Breast Reconstruction|
89381730|NCT02948777|Experimental|Evolocumab|Evolocumab 140 mg subcutaneous injection once every 2 weeks for 12 weeks
89381731|NCT04868747|Experimental|study group|The study group receives the intravenous 1% lidocaine 1.5 mg/kg bolus followed by 1.5 mg/kg/h during surgery and 1.0 mg/kg/h until 24 hours after surgery (Max.<120 mg/h).
89381732|NCT04868747|Placebo Comparator|control group|The control group receives intravenous normal saline 0.15 ml/kg bolus followed by 0.15 ml/kg/h during surgery and 0.1 mg/kg/h until 24 hours after surgery.
89381733|NCT04693325|Experimental|Prolonged normothermic machina perfusion|Eligible and consenting patients who will receive a donor kidney will be included for participation in this study. Current practice is to preserve donor kidneys on hypothermic machine perfusion (HMP). In this study, donor kidneys (n=18) will be taken off the HMP after arrival in the transplant center. These will then be perfused with oxygenated perfusate using the NMP device following an optimised NMP protocol.
89381734|NCT04684823|Experimental|Use of Patch Cap and Patch App|Subjects will use Patch Technologies to track their medication regimen compliance
89381735|NCT03638609|No Intervention|Control|Group of patients not receiving IABP
89381736|NCT03638609|Experimental|Intra Aortic Balloon Pump|Group of patients receiving Intra Aortic Balloon Pump in 3 hours after ROSC (early insertion of IABP)
88817791|NCT05341791|No Intervention|Standard administration of information notice|: During the standard study information administration, the participant will read though the written information notice which will be organized in sections. After each section, the study staff will explain to the participant the key information to understand. Throughout the process, participants will be allowed to ask study staff questions. We anticipate the time to administer consent by this standard approach will be approximately 45 to 60 minutes per participants.
88817792|NCT05341791|Experimental|video administration of information notice|The video will be 20-minutes long, and will consist of graphic depictions (in cartoon style) of the study information content presented in the same flow as the written notice, and explained by a voice-over in the background. The participant will view the video in a quiet room, on a tablet provided by the study staff. The participant will be able to pause the video or rewind it as needed, and view it at his/her desired pace. The video will have an embedded knowledge check at the end of each section, consisting of a background voice asking some questions, pausing (for the participant to think through the correct answers) and then providing the right answers.
88854413|NCT01697592|Placebo Comparator|Placebo/SUs (Phase A) → Omarigliptin 25 mg/SUs (Phase B)|Placebo matching omarigliptin administered orally once weekly for 24 weeks during Phase A. Omarigliptin 25 mg is administered once weekly for 28 weeks during Phase B. Participants continued pre-study basal medication of SUs throughout the duration of the study.
88854414|NCT01697592|Placebo Comparator|Placebo/Glinides (Phase A) → Omarigliptin 25 mg/Gln. (Phase B)|Placebo matching omarigliptin administered orally once weekly for 24 weeks during Phase A. Omarigliptin 25 mg is administered once weekly for 28 weeks during Phase B. Participants continued pre-study basal medication of glinides throughout the duration of the study.
88854415|NCT01697592|Placebo Comparator|Placebo/BGs (Phase A) → Omarigliptin 25 mg/BGs (Phase B)|Placebo matching omarigliptin administered orally once weekly for 24 weeks during Phase A. Omarigliptin 25 mg is administered once weekly for 28 weeks during Phase B. Participants continued pre-study basal medication of BGs throughout the duration of the study.
88854416|NCT01697592|Placebo Comparator|Placebo/TZDs (Phase A) → Omarigliptin 25 mg/TZDs (Phase B)|Placebo matching omarigliptin administered orally once weekly for 24 weeks during Phase A. Omarigliptin 25 mg is administered once weekly for 28 weeks during Phase B. Participants continued pre-study basal medication of TZDs throughout the duration of the study.
88854417|NCT01697592|Placebo Comparator|Placebo/α-GIs (Phase A) → Omarigliptin 25 mg/α-GIs (Phase B)|Placebo matching omarigliptin administered orally once weekly for 24 weeks during Phase A. Omarigliptin 25 mg is administered once weekly for 28 weeks during Phase B. Participants continued pre-study basal medication of α-GIs inhibitors throughout the duration of the study.
88854418|NCT01744782|Experimental|RP103|From Day 1 and throughout the duration of participation, RP103 (Cysteamine Bitartrate Delayed-release Capsules) was administered every 12 hours (Q12H), supplied as 75 mg and 25 mg capsules.
88854419|NCT01744392|Experimental|education intervention|The intervention provides a personalized Meducation calendar to all patients enrolled in the study (identified in package as Example Calendar). The Meducation Calendar will include medications for diabetes (sugar), high blood pressure, cholesterol, heart medications and blood thinning medications. The medication calendars contains the following for each medication 1) the name, 2) the time of day, including a pictorial display, it should be taken 3) the number of times each day to take the medication, and 4) the indication for the medication.
88854420|NCT01604850|Experimental|SOF+RBV+placebo|Participants were randomized to receive SOF+RBV for 12 weeks followed by placebo to match SOF plus placebo to match RBV for 4 weeks.
88854421|NCT01604850|Experimental|SOF+RBV|Participants were randomized to receive SOF+RBV for 16 weeks.
88854422|NCT01742286|Experimental|LDK378|All participants were administered a single-agent LDK378 (Ceritinib) orally, once daily, continuously in fasted or fed conditions.
88854423|NCT01697358|Active Comparator|SCS + OMM|Spinal Cord Stimulation (SCS) using the Medtronic Specify 5-6-5 multicolumn surgical lead plus an individual Optimal Medical Management (OMM) treatment plan
88854424|NCT01697358|Active Comparator|OMM alone|The investigator and subject will determine an individual Optimal Medical Management (OMM) treatment plan
88854425|NCT01716234|Experimental|POS 12 BID 2 to <7 Years|Participants aged 2 to <7 years received posaconazole oral suspension 12 mg/kg/day divided into 2 doses (BID) until recovery from neutropenia or up to 28 days.
88854426|NCT01716234|Experimental|POS 12 BID 7 to <18 Years|Participants aged 7 to <18 years received posaconazole oral suspension 12 mg/kg/day divided into 2 doses (BID) until recovery from neutropenia or up to 28 days.
88854427|NCT01716234|Experimental|POS 18 BID 2 to <7 Years|Participants aged 2 to <7 years received posaconazole oral suspension 18 mg/kg/day divided into 2 doses (BID) until recovery from neutropenia or up to 28 days.
89002728|NCT06225622|Experimental|irinotecan liposome injection combined with oxaliplatin +5-FU/LV+ bevacizumab or cetuximab|In dose escalation study, patients will be treated with irinotecan liposome injection combined with oxaliplatin +5-FU/LV+ bevacizumab. In expansion study, patients will be treated with irinotecan liposome injection combined with oxaliplatin +5-FU/LV+ bevacizumab or cetuximab, depending on their baseline mutation status. Oxaliplatin is accepted up to 12 cycles.
89002729|NCT06219538|Experimental|Interventional|Ten women in whom the Daisy Drain is placed.
89002730|NCT06206512|Experimental|Investigational product|Extended release torsemide and immediate release torsemide placebo
88817793|NCT04094285|Experimental|1|
88817794|NCT04094285|Experimental|2|
88817795|NCT05325255|Experimental|Maitland mobilization with myofascial trigger point release group|"Maitland technique: caudal, anteroposterior (AP), and posteroanterior (PA) glides 5 sets of 2-3 glides per second of Grade III and IV for 30 seconds with a rest interval of 30 second between sets.~Ischemic Compression technique: on subscapularis trigger points for 90 secs thrice a week for 2 weeks.~Stretching exercises in direction of abduction, external rotation (ER), internal rotation (IR), and flexion. 6 repetitions of each stretch for 10 seconds Cold pack for 20 mins"
88854428|NCT01716234|Experimental|POS 18 BID 7 to <18 Years|Participants aged 7 to <18 years received posaconazole oral suspension 18 mg/kg/day divided into 2 doses (BID) until recovery from neutropenia or up to 28 days.
89002731|NCT06206512|Active Comparator|Control product|Immediate release torsemide and extended release torsemide placebo
88854429|NCT01716234|Experimental|POS 18 TID 2 to <7 Years|Participants aged 2 to <7 years received posaconazole oral suspension 18 mg/kg/day divided into 3 doses (TID) until recovery from neutropenia or up to 28 days.
89381737|NCT05330273|Experimental|Period 1: KAF156 + LUM566 / Period 2: KAF156 + LUM566 + Efavirenz|"Participants enrolled will receive a single oral dose of ganaplacide and lumefantrine combination on Day 1 of Period 1.~In Period 2, participants will receive an oral dose of efavirenz q.d. in the evening on Days 1 through 24 and a single dose of ganaplacide and lumefantrine combination on the morning of Day 11."
88854430|NCT01716234|Experimental|POS 18 TID 7 to <18 Years|Participants aged 7 to <18 years received posaconazole oral suspension 18 mg/kg/day divided into 3 doses (TID) until recovery from neutropenia or up to 28 days.
88854431|NCT01716234|Experimental|POS 12 TID 3 months to <2 Years|Participants aged 3 months to <2 years received posaconazole oral suspension 12 mg/kg/day divided into 3 doses (TID) until recovery from neutropenia or up to 28 days.
88854432|NCT01716156|Experimental|Grazoprevir 100 mg + RBV 12 Weeks|Grazoprevir 100 mg tablet once per day by mouth for 12 weeks and RBV capsules twice per day by mouth at a total daily dose from 800 to 1400 mg based on participant weight for 12 weeks. Participants with detectable HCV RNA at TW4 received an additional 12 weeks of study therapy for a total of 24 weeks of treatment.
88854433|NCT01716156|Experimental|Grazoprevir 100 mg + RBV 24 Weeks|Grazoprevir 100 mg tablet once per day by mouth for 24 weeks and RBV capsules twice per day by mouth at a total daily dose from 800 to 1400 mg based on participant weight for 24 weeks.
88854434|NCT01739790|Placebo Comparator|Sugar Pill|Identical placebo pills twice daily for 8 weeks Placebo pills manufactured to mimic appearance of intervention drug n-acetylcysteine and prescribed with identical frequency and duration.
88854435|NCT01739790|Active Comparator|N-Acetylcysteine|1800 mg twice daily for 8 weeks
88854436|NCT01696032|Experimental|SGI-110 + Carboplatin|Stage 1 was a safety lead-in stage with a dose escalation design. Participants were evaluated with the combination of SGI-110 (guadecitabine) plus carboplatin (G+C), given as 28-day treatment cycles: guadecitabine administered subcutaneous (SC) daily on Days 1-5, at a starting dose of 45 mg/m2/day in Cohort 1, followed by carboplatin intravenous (IV) based on a targeted dose of area under the curve (AUC) 5 on Day 8. After dose limiting toxicities were noted, guadecitabine dose was reduced to 30 mg/m2/day for subsequent cycles for 4 participants. Cohort 2 received 30 mg/m2/day guadecitabine and carboplatin IV AUC 4.
88854437|NCT01696032|Experimental|SGI-110 + Carboplatin or TC|Stage 2 was an open-label, randomized, controlled trial. Eligible participants were randomly assigned in a 1:1 ratio to receive either (1) G+C combination treatment in 28-day cycles at 30 mg/m2 SC once daily on Days 1-5 and carboplatin IV AUC 4 on Day 8, or (2) treatment of choice (TC) of topotecan, pegylated liposomal doxorubicin (PLD), paclitaxel, or gemcitabine based on recommended dosing in 28-day cycles; participants initially randomized to TC were able to cross over to receive 30 mg/m2 G+C due to disease progression.
88854438|NCT01695954|Experimental|Arm A|Subjects assigned to Arm A will receive pitavastatin 2 mg at bedtime and efavirenz 600 mg at bedtime.
88854439|NCT01695954|Experimental|Arm B|Subjects assigned to Arm B will receive pitavastatin 2 mg daily and darunavir 800 mg with ritonavir 100 mg daily.
89381738|NCT01312259|Active Comparator|Interstim Parameter Frequency 14 HZ|Subjects in this arm will receive 14 Hx as their frequency for the first three months. For the second 3 months, these patients will receive 40 Hz. Six months after the devise has been implanted, the patient has the option to choose which frequency they feel allows for better symptom control, and this is how the devise will be programmed.
89381739|NCT01312259|Experimental|Interstim Parameter Frequency 40 HZ|Subjects in this arm will receive 40 Hz as their frequency for the first three months. For the second 3 months, these patients will receive 14 Hz. Six months after the devise has been implanted, the patient has the option to choose which frequency they feel allows for better symptom control, and this is how the devise will be programmed.
89381740|NCT05329259|Experimental|13-valent pneumococcal conjugate vaccine|Pneumococcal conjugate vaccine (13vPnC)
89381741|NCT03638531|Experimental|Anodal tDCS|Anodal tDCS will be applied in nine experimental sessions over a 2-week period.
89381742|NCT03638531|Sham Comparator|SHAM tDCS|SHAM tDCS will be applied in nine experimental sessions over a 2-week period.
89381743|NCT03638765|Experimental|Experimental Treatment|Intratumoral injection of activated, autologous dendritic cells (DCVax-Direct) in brain metastases from lung cancer or breast cancer
88854440|NCT01694706|Experimental|Reference|faldaprevir medium, fasted
88854441|NCT01694706|Active Comparator|Test 1|faldaprevir medium, fed
88854442|NCT01694706|Active Comparator|Test 2|faldaprevir medium + omeprazole medium
89183356|NCT04959175|Experimental|Younger, HLA-mismatched|Subjects age 18-60 unfit for MAC with hematologic malignancies and an HLA-haploidentical or HLA-mismatched unrelated donor
88854443|NCT01693692|Experimental|TD-9855 Group 1|Group 1 to be dosed with TD-9855
88854444|NCT01693692|Experimental|TD-9855 Group 2|Group 2 to be dosed with TD-9855
88854445|NCT01693692|Placebo Comparator|Placebo|Group to be dosed with Placebo
88854446|NCT01693614|Experimental|DLBCL Cohort|Diffuse large B-cell lymphoma cohort
88854447|NCT01693614|Experimental|MCL Cohort|Mantle cell lymphoma cohort
88854448|NCT01693614|Experimental|FL Cohort|Follicular lymphoma cohort
88854449|NCT01715298|Experimental|NVA237|NVA237 will be inhaled from a single-dose dry powder inhaler for a period of 12 weeks
88854450|NCT01715298|Placebo Comparator|Placebo|Placebo will be inhaled from a single-dose dry powder inhaler for a period of 12 weeks
88854451|NCT01713582|Experimental|AL 10 mg QD 14-21|Participants received 10 mg birabresib/OTX015 administered orally (PO), once daily (QD), in a fasted state on Days 1 to 14 of a 21-day cycle.
88854452|NCT01713582|Experimental|AL 20 mg QD 14-21|Participants received 20 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 14 of a 21-day cycle.
88854453|NCT01713582|Experimental|AL 40 mg QD 14-21|Participants received 40 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 14 of a 21-day cycle.
88854454|NCT01713582|Experimental|AL 20 mg BID 21-21|Participants received 20 mg birabresib/OTX015 administered PO, twice a day (BID), with the first daily dose in a fasted state, on Days 1 to 21 of a 21-day cycle.
89183357|NCT04946968|Experimental|Dacomitinib|Oral Dacomitinib tablets, once daily.
89381744|NCT05254847|Experimental|combined treatment group|Capecitabine combined with lenvatinib and tislelizumab: Lenvatinib,8mg po. qd.Tislelizumab,200mg iv. q3w. Capecitabine 1250mg/m^2 bid.d1-d14 q3w
88854455|NCT01713582|Experimental|AL 80 mg QD 14-21|Participants received 80 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 14 of a 21-day cycle.
89381745|NCT05249699|Experimental|Positive TSPOT results with clinical risk factors group|patients receive isoniazid 300mg once daily for six months after kidney transplant surgery form discharge
88854456|NCT01713582|Experimental|AL 40 mg BID 14-21|Participants received 40 mg birabresib/OTX015 administered PO, twice a day (BID), with the first daily dose in a fasted state, on Days 1 to 14 of a 21-day cycle.
88854457|NCT01713582|Experimental|AL 120 mg QD 14-21|Participants received 120 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 14 of a 21-day cycle.
88854458|NCT01713582|Experimental|AL 120 mg QD 21-21|Participants received 120 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 21 of a 21-day cycle.
88854459|NCT01713582|Experimental|AL 160 mg QD 14-21|Participants received 160 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 14 of a 21-day cycle.
88854460|NCT01713582|Experimental|AML de novo 80 mg QD 14-21|Participants received 80 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 14 of a 21-day cycle.
88854461|NCT01713582|Experimental|AML/MDS 80 mg QD 14-21|Participants received 80 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 14 of a 21-day cycle.
89381746|NCT05249699|Placebo Comparator|Negative TSPOT results with clinical risk factors group|patients receive no additional therapy
89381747|NCT05249699|Experimental|Clinical risk factors group|patients receive isoniazid 300mg once daily for six months after kidney transplant surgery form discharge
88854462|NCT01713582|Experimental|OHM 10 mg QD 21-21|Participants received 10 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 21 of a 21-day cycle.
88854463|NCT01713582|Experimental|OHM 20 mg QD 21-21|Participants received 20 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 21 of a 21-day cycle.
89381748|NCT03638687||History, Yes PPD|Participants may be asked to undergo repeated neuroimaging scans. No intervention will be administered, all participants will receive routine care during the study.
89381749|NCT03638687||No History, No PPD|Participants may be asked to undergo repeated neuroimaging scans. No intervention will be administered, all participants will receive routine care during the study.
89381750|NCT03638687||History, No PPD|Participants may be asked to undergo repeated neuroimaging scans. No intervention will be administered, all participants will receive routine care during the study.
89381751|NCT03638687||No History, Yes PPD|Participants may be asked to undergo repeated neuroimaging scans. No intervention will be administered, all participants will receive routine care during the study.
88854464|NCT01713582|Experimental|OHM 40 mg QD 21-21|Participants received 40 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 21 of a 21-day cycle.
88854465|NCT01713582|Experimental|OHM 80 mg QD 21-21|Participants received 80 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 21 of a 21-day cycle.
88854466|NCT01713582|Experimental|OHM 40 mg BID 21-21|Participants received 40 mg birabresib/OTX015 administered PO, BID, with the first daily dose in a fasted state, on Days 1 to 21 of a 21-day cycle.
88854467|NCT01713582|Experimental|OHM 120 mg QD 21-21|Participants received 120 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 21 of a 21-day cycle.
88854468|NCT01713582|Experimental|OHM 120 mg QD 14-21|Participants received 120 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 14 of a 21-day cycle.
88854469|NCT01713582|Experimental|OHM 120 mg QD 5-7|Participants received 120 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 5 of a 7-day cycle.
88854470|NCT01713582|Experimental|OHM 120 mg QD 7-21|Participants received 120 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 7 of a 21-day cycle
88854471|NCT01713582|Experimental|OHM/DLBCL 80 mg QD 14-21|Participants received 80 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 14 of a 21-day cycle.
88854472|NCT01739400|Experimental|Macitentan|Macitentan 10 mg tablet, once daily.
88854473|NCT01713348|Experimental|CGM - intervention arm|Following a 14 day masked (baseline) period using the FreeStyle Navigator subjects will wear an unmasked FreeStyle Navigator with the glucose alarms switched off.
88854474|NCT01713348|Active Comparator|SMBG - Control arm|Following a 14 day masked ( baseline) period using the FreeStyle Navigator subjects will manage their blood glucose with a standard SMBG and use a FreeStyle Navigator masked for a 14 day period at the end of the study.
88854475|NCT01737996|Experimental|All patients|For the first 9 days patients receive BI 207127 low dose or high dose, then BI 207127 high dose with faldaprevir
88854476|NCT01713036|Experimental|Pimasertib|
88854477|NCT01712334|Experimental|eRapid Nebulizer|Dornase alfa (Pulmozyme®) inhaled once daily by the Pari eRapid nebulizer for 2 weeks.
88854478|NCT01712334|Active Comparator|Jet Nebulizer|Dornase alfa (Pulmozyme®) inhaled once daily by the Pari LC Plus jet nebulizer for 2 weeks.
88854479|NCT01712256|Experimental|Re-boosting with Vacc-4x|Intradermal Vacc-4x (1.2 mg) given with Leukine® (rhu-GM-CSF) (0.06 mg) at day 1 and day 15.
89381752|NCT04640909|Other|CAR T Cells generation|CAR T Cells generation at baseline and after 6 and 12 months of treatment
89381753|NCT05292053|Experimental|COPD subjects|COPD with or without asthma
89381754|NCT05288621|Experimental|electroacupuncture at'four sacral points'|The participants in the electroacupuncture at'four sacral points'group will receive treatment that consists of 8 acupuncture sessions over an 4-week period after baseline (2 sessions in each week), each for 30 minutes. Hua Tuo brand disposable acupunctureneedles (size 0.40 × 100mm) and electronic needle therapy instrument SDZ-IIB will be used.The device will be set at a frequency of 2.0 Hz, continuous wave and a moderate intensity the patient can tolerate. Electrostimulation will be performed for 30 min during each treatment. BL30 (Baihuanshu )(both sides and BL35 (Huiyang )(both sides), were selected as acupoints protocol.BL30 is located on either side of the sacrococcygeal joint, approximately 1 cm from the joint. BL35 is in the buttock region, 0.5 cun lateral to the extremity of the coccyx.
89381755|NCT05288621|Active Comparator|conventional electroacupuncture|The participants in the conventional electroacupuncture group will select RN3 (Zhongji), CV4 (Guanyuan), and ST28 (Shuidao, both sides), KL3 (Taixi).A needle measuring 0.25×40 mm will be inserted perpendicularly to a depth of 25- 40 mm to RN3, CV4 and ST28 and 0.5 cun to KL3 to induce a local sensation (distention or sourness).Subsequently, the electrodes from the SDZ-IIB electroacupuncture device will be connected to the needles at these points, with the anode connected to ST28 and RN3, the cathode connected to ST28 and CV4. The protocol includes the same duration, frequency of sessions and the parameter setting of electroacupuncture as for the'four sacral points'treatment.
89381756|NCT05306639|Experimental|Spinal magnetic stimulation|Spinal magnetic stimulation group will receive repetitive spinal magnetic stimulation sessions for a total of 12 sessions. Using the Neuro-MS/D machine, circular coil will be used to stimulate S2,3 and 4 sacral roots. The outer rim of the coil will be positioned in the midline over the sacral vertebrae (approximately 5 cm above the natal cleft, which approximates to the level of S2) Intensities will be adjusted to 50-70 % of maximal output (2.2 Tesla), stimulation frequency will be fixed at 15 Hz, burst length = 10 seconds, inter-burst interval = 30 seconds with a total of 1500 pulses
89381757|NCT05306639|Experimental|Neuromodulation|Neuromodulation group will receive 12 sessions of bilateral transcutaneous posterior tibial neuromodulation using (Myomed 632®, Enraf Nonius, Delft, Netherlands) machine, the active rubber surface was placed behind the medial malleolus and the reference electrode was placed 10 cm proximal. Adjustment of the electric current was as follows: continuous current, pulse duration 200 ms, frequency 20 Hz; each session lasts for 30 min. The current intensity was adjusted according to the tolerance of the patient or until the big toe curls into plantar flexion
89381758|NCT05207111|Experimental|Revefenacin Inhalation Solution, 175 mcg/3 mL|
89381759|NCT03256097|Experimental|XDP - VG - XDP|order of testing: XDP - VG - XDP
89381760|NCT03256097|Experimental|VG - XDP - VG|order of testing: VG - XDP - VG
89381761|NCT05195567|Experimental|Subject glucometer measurement|
89381762|NCT04697381|Experimental|somatropin - GH naïve pediatric cohort|All participants will receive somatropin.
89381763|NCT04697381|Experimental|somatropin - GH treated pediatric cohort|All participants will receive somatropin
89381764|NCT04697381|Experimental|somatropin - adult cohort|All participants will receive somatropin
89381765|NCT01312571|Active Comparator|Cognitive behavior therapy via the internet|Cognitive behavior therapy via the internet with therapist support.
89381766|NCT01312571|Active Comparator|Attentional retraining|Attentional retraining as described by Nader Amir.
89381767|NCT04732793|Experimental|Hyruan ONE®|
89381768|NCT04732793|Active Comparator|Durolane®|
89381769|NCT04908761|Experimental|Transmuscular quadratus lumborum block group|Patients assigned to the Transmuscular Quadratus Lumborum (TQL) block group receive the Transmuscular Quadratus Lumborum block in a lateral decubitus position with the surgical site facing up before recovery of general anesthesia after surgery. For the block, 30cc of 0.375% ropivacaine is used.
89381770|NCT04908761|Placebo Comparator|Control group|For patients assigned to the control group, 30cc of 0.9% normal saline is used for Transmuscular Quadratus Lumborum block.
89381771|NCT03324581|Experimental|OPC-64005|During the titration period, participants received OPC-64005 two 10 milligram (mg) tablets, and one OPC-64005-matching placebo tablet along with two atomoxetine-matching placebo capsules, orally, once daily (QD), from Day 1 up to Day 4. During the treatment period, participants received OPC-64005 three 10 mg tablets, and two atomoxetine-matching placebo capsules, orally, QD, from Day 5 up to Day 56. The dose was reduced to 20 mg if the 30 mg dose in the treatment period was not tolerable.
89381772|NCT03324581|Active Comparator|Atomoxetine|"During the titration period, participants received atomoxetine one 40 mg capsule and one atomoxetine-matching placebo capsule along with three OPC-64005-matching placebo tablets, orally, QD, from Day 1 up to Day 4.~During the treatment period, participants received two atomoxetine 40 mg capsules and three OPC-64005-matching placebo tablets, orally, QD, from Day 5 up to Day 56. The dose was reduced to 40 mg if the 80 mg dose in the treatment period was not tolerable."
89381773|NCT03324581|Placebo Comparator|Placebo|Participants received three OPC-64005-matching placebo tablets and two atomoxetine-matching placebo capsules, orally, QD, from Day 1 up to Day 56.
89381774|NCT02943473|Experimental|Ibrutinib|Ibrutinib (trademark name is IMBRUVICA®). 560 mg dose administered on a continuous basis
88854480|NCT01712178|Experimental|New formulation of adalimumab 40 mg every other week|New formulation adalimumab 40 mg every other week
88854481|NCT01712178|Active Comparator|Current formulation adalimumab 40 mg every other week|Current formulation adalimumab 40 mg every other week
88854482|NCT01693068|Experimental|Pimasertib|
88854483|NCT01693068|Active Comparator|Dacarbazine|
89002732|NCT06201026|Active Comparator|Traditional exercise group in newly diagnosed patients with MS (SEP-R-TEM)|Newly diagnosed patients with MS who will be part of the group doing traditional exercises
88854484|NCT01691898|Experimental|Arm A (FL+DLBCL): RTX+Pinatuzumab,Then RTX+Polatuzumab|For the first 2 cycles, RTX 375 milligrams per square meter (mg/m^2) will be given by intravenous (IV) infusion on Day 1 and pinatuzumab vedotin 2.4 milligrams per kilogram (mg/kg) will be administered by IV infusion on Day 2 to Arm A participants (with r/r FL and DLBCL). In the absence of any infusion-related adverse events, RTX and pinatuzumab may be administered on the same day (Day 1) in subsequent cycles beginning with the third cycle. Participants who develop disease progression (PD) will be further treated with RTX 375 mg/m^2 followed by polatuzumab vedotin 2.4 mg/kg IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event relative to the tumor assessment, documenting PD on the initial study treatment, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (17 cycles on an every-21-day schedule).
88854485|NCT01691898|Experimental|Arm B (FL+DLBCL): RTX+Polatuzumab,Then RTX+Pinatuzumab|For the first 2 cycles, RTX 375 mg/m^2 will be given by IV infusion on Day 1 and polatuzumab vedotin 2.4 mg/kg will be administered by IV infusion on Day 2 to Arm B participants (with r/r FL and DLBCL). In the absence of any infusion-related adverse events, RTX and polatuzumab may be administered on the same day (Day 1) in subsequent cycles beginning with the third cycle. Participants who develop PD would be further treated with RTX 375 mg/m^2 followed by pinatuzumab vedotin 2.4 mg/kg IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event relative to the tumor assessment, documenting PD on the initial study treatment, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (17 cycles on an every-21-day schedule).
88854486|NCT01691898|Experimental|Cohort C (FL): RTX + Polatuzumab|For the first 2 cycles, RTX 375 mg/m^2 will be given by IV infusion on Day 1 and polatuzumab vedotin 1.8 mg/kg will be administered by IV infusion on Day 2 to Cohort C participants (with r/r FL). In the absence of any infusion-related adverse events, RTX and polatuzumab may be administered on the same day (Day 1) in subsequent cycles beginning with the third cycle for up to a maximum of 1 year (17 cycles on an every-21-day schedule) or significant toxicity, PD, or withdrawal from study.
88854487|NCT01691898|Experimental|Cohort E (FL+DLBCL): Obinutuzumab + Polatuzumab|For the first cycle, obinutuzumab will be given by IV infusion on Days 1, 8, and 15. Polatuzumab vedotin 1.8 mg/kg IV infusion will be given on Day 2 of the first cycle to Cohort E participants (with r/r FL and DLBCL). In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin may be administered on the same day (Day 1) in subsequent cycles beginning with the second cycle up to a maximum of 8 cycles or significant toxicity, PD, or withdrawal from study.
88854488|NCT01691898|Experimental|Cohort G (Expansion, FL): Obinutuzumab + Polatuzumab|For the first cycle, obinutuzumab will be given by IV infusion on Days 1, 8, and 15. Polatuzumab vedotin 1.8 mg/kg IV infusion will be given on Day 2 of the first cycle to Cohort G participants (with r/r FL). In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin may be administered on the same day (Day 1) in subsequent cycles beginning with the second cycle of the dose-expansion period to cohort G participants up to a maximum of 8 cycles or significant toxicity, PD, or withdrawal from study.
88854489|NCT01691898|Experimental|Cohort H (Expansion, DLBCL): Obinutuzumab + Polatuzumab|For the first cycle, obinutuzumab will be given by IV infusion on Days 1, 8, and 15. Polatuzumab vedotin 1.8 mg/kg IV infusion will be given on Day 2 of the first cycle to Cohort H participants (with r/r DLBCL). In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin may be administered on the same day (Day 1) in subsequent cycles beginning with the second cycle of the dose-expansion period to cohort H participants up to a maximum of 8 cycles or significant toxicity, PD, or withdrawal from study.
88854490|NCT01691820|Experimental|Group S+|Cytomegalovirus (CMV) seropositive subjects aged between 10-17 years at enrollment in the study.
88854491|NCT01691820|Experimental|Group S-|Cytomegalovirus (CMV) seronegative subjects aged between 10-17 years at enrollment in the study.
88854492|NCT01691820|Experimental|Missing serostatus Group|Subjects with no confirmed serostatus, aged between 10-17 years at enrollment in the study.
88854493|NCT04547400||Patients with Multiple Sclerosis|MS patients (EDSS: 0-5,5)
88854494|NCT04547400||Healthy group|Healthy individuals without chronic disease
88854495|NCT01711866|Experimental|Rotigotine|"First application of Rotigotine patch for 24 hours on Day 1, followed by application of a new patch each day of the Treatment Period.~Subjects on lower doses switch from Pramipexole or Ropinirole to equivalence doses of Rotigotine on Day 1 of the 28 days Treatment Period. On Day 8 (Visit 3) the dose will be evaluated and potentially adjusted up to a maximum dose of 8 mg / 24 hours.~Subjects on higher doses switch from the equivalent dose to 8 mg / 24 hours Rotigotine of Pramipexole or Ropinirole to 8 mg / 24 hours Rotigotine on Day 1 and the remainder of the dose of Pramipexole or Ropinirole is to be switched on Day 8 of the 28 days Treatment Period. On Day 15 (Visit 4) the dose will be evaluated and potentially adjusted up to a maximum dose of 16 mg / 24 hours."
88854496|NCT01737762|Experimental|HP802-247|HP802-247 (fibrinogen solution & thrombin solution containing living, irradiated, growth arrested keratinocytes and fibroblasts) 260 solution) containing 0.5 x 106 cells per mL every 14 days.
88854497|NCT01737762|Placebo Comparator|Vehicle|Vehicle Control(fibrinogen solution & thrombin solution without cells)
88854498|NCT01691508|Experimental|Mepolizumab|Mepolizumab 100 mg subcutaneous once every 4 weeks upto Week 20
88854499|NCT01691508|Experimental|Placebo|Placebo subcutaneous once every 4 weeks upto Week 20
88854500|NCT01682460|Experimental|Refresh Tears Lubricant Eye Drops (Allergan)|Artificial tears eye drops QID for 1 month
88854501|NCT01691430|Active Comparator|2 cranberry capsules|Experimental: 2 cranberry capsules
88854502|NCT01691430|Placebo Comparator|2 placebo capsules|Experimental: 2 placebo capsules qd
88854503|NCT04413708|Experimental|P3-T PrEP adherence app|"Intended app use includes, at a minimum, participant completion of selected app activities (medication tracking, daily quest, social wall post) each day for the 3 month intervention period.~Participant completion of Standard of Care PrEP adherence and sexual risk behavior counseling at the 1-month post-prescription visit and the 4-month post-prescription visit."
88854504|NCT04413708|No Intervention|Standard of Care|Participant completion of Standard of Care PrEP adherence and sexual risk behavior counseling at the 1-month post-prescription visit and the 4-month post-prescription visit.
88854505|NCT01709838|Other|Deferasirox|All patients were treated with 10mg/kg/day deferasirox with dose adjustments after 4 weeks of treatment according to baseline Liver Iron Concentration (LIC).
88854506|NCT01682226|Experimental|A: standard risk group|This is a 2 arm phase 2 study to obtain an estimate of the speed of neutrophil recovery after myeloablative CBT with abrogation of prolonged cytopenia by infusion of haploidentical family member T-cell depleted PBSC in patients with high-risk or advanced hematologic malignancies.
88854507|NCT01682226|Experimental|B: high risk group|This is a 2 arm phase 2 study to obtain an estimate of the speed of neutrophil recovery after myeloablative CBT with abrogation of prolonged cytopenia by infusion of haploidentical family member T-cell depleted PBSC in patients with high-risk or advanced hematologic malignancies.
88854508|NCT04167618|Experimental|177Lu-DTPA-omburtamab|Intracerebroventricular administration of 177Lu-DTPA-omburtamab for up to two cycles (Part 1) and up to five cycles (Part 2).
88854509|NCT01688466|Experimental|0.5 mg/day with Dose Escalation|0.5 mg/day with Dose Escalation by 0.5 mg/day increments every 2 weeks to a maximum of 2.0 mg/day
88854510|NCT01688466|Experimental|0.5 mg/day without Dose Escalation|0.5 mg/day without Dose Escalation
88854511|NCT01682148|Experimental|NMJ Targeted|NMJ targeted technique and low-concentration dilution (Dysport 100 U/mL). The same number and sites of injections/deposits per muscle were given as per prestudy. With a Dysport dilution of 300 U/mL the volume to be injected varied between 0.1 mL and 0.7 mL per muscle. The dose and the choice of muscles involved in the elbow flexion were the same as for the last prestudy treatment.
88854512|NCT01682148|Active Comparator|Current Clinical Practice|"Current clinical practice technique and high-concentration dilution (Dysport 300 U/mL).~A single injection per muscle was given in the midline of the band of NMJ zones. With a Dysport dilution of 100 U/mL the volume to be injected varied between 0.4 mL and 2.0 mL per muscle. The dose and the choice of muscles involved in the elbow flexion were the same as for the last prestudy treatment."
88854513|NCT01681992|Experimental|Inv_MMR_Min Group|Subjects receive one dose of GlaxoSmithKline (GSK) Biologicals' measles, mumps, rubella (MMR) vaccine, Priorix (Inv_MMR), from a minimum potency lot (Inv_MMR_Min), co-administered with Varivax (VV) and Havrix (HAV) vaccines at Day 0. All US subjects are also co-administered Prevnar 13 (PCV-13) vaccine. Approximately 6 weeks later, at Day 42, subjects are administered a dose from a separate lot of the Inv_MMR vaccine (Inv_MMR_Release), for the second dose. Inv_MMR and VV vaccines are administered subcutaneously in the triceps region of the left and right arm, respectively. HAV and PCV-13 vaccines are administered intramuscularly in the anterolateral region of the right and left thigh, respectively.
89002733|NCT06201026|Experimental|Individualized exercise group in newly diagnosed patients with MS (SEP-R-IND)|Newly diagnosed patients with MS who will be part of the group doing individualized exercises
89002734|NCT06201026|Active Comparator|Traditional exercise group in advanced diagnosed patients with MS (SEP-A-TEM)|Advanced diagnosed patients with MS who will be part of the group doing traditional exercises
89002735|NCT06201026|Experimental|Individualized exercise group in advanced diagnosed patients with MS (SEP-A-IND)|Advanced diagnosed patients with MS who will be part of the group doing individualized exercises.
89381775|NCT04294043|Experimental|Infusion of IV Gallium|Gallium nitrate will be infused continuously over 5 days at 200 mg/m2/day. Study drug will be administered via a peripheral IV catheter, a peripherally inserted central catheter (PICC) line, midline catheter, or a chronic indwelling vascular access device using an ambulatory infusion pump infused over 24 hours for 5 sequential days for each cycle. There is a maximum of 2 cycles.
89381776|NCT05019833|Experimental|Signals collection|Collection of sensors signals by the implanted device.
89381777|NCT05019677|Experimental|GP+PD-1+Tight|"Experimental: Tislelizumab 200mg IV Q3W + Ociperlimab 900mg IV Q3W + GP (gemcitabine 1000mg/m2 + cisplatin 25mg/m2 Q3W) Gemcitabine/Cisplatin will be administered on D1/D8 in every three weeks cycle and up to 8 cycles.~Tislelizumab and Ociperlimab will be administered on D1 in every three weeks cycle, until the disease progression, intolerable toxicity, death, withdrawal of consent."
89381778|NCT04981145|Experimental|IGU Group|
89381779|NCT04981145|Active Comparator|HCQ Group|
89381780|NCT02835365||patients treated with baclofen|Patients treated with baclofen to diminish their alcohol consumption in the ANGH centers will be enrolled
89381781|NCT04258631|Active Comparator|Arm I (laparotomy, liposomal bupivacaine)|Patients undergo standard of care laparotomy and then receive liposomal bupivacaine.
89381782|NCT04258631|Experimental|Arm II (laparotomy, liposomal bupivacaine, hydromorphone)|Patients undergo standard of care laparotomy and then receive liposomal bupivacaine and hydromorphone IT.
89381783|NCT04877015|Active Comparator|Active Vibrotactile Coordinated Reset (vCR)|Participants in this arm will receive active vCR stimulation.
89381784|NCT04877015|Sham Comparator|Sham Vibrotactile Coordinated Reset (vCR)|Participants in this arm will receive sham vCR stimulation.
89002736|NCT06200467|Experimental|Arm A: R1 then R3 then T then R|Arm A: BI 456906-placebo (reference treatment 1 (R1)) then moxifloxacin-placebo (reference treatment 3 (R3)) then BI 456906 (Test Treatment (T)) then moxifloxacin-placebo (R3)
89002737|NCT06200467|Placebo Comparator|Arm B: R1 then R2 then R1 then R3|Arm B: BI 456906-placebo (R1) then moxifloxacin (Reference Treatment 2 (R2)) then BI 456906-placebo (R1) then moxifloxacin-placebo (R3)
89381785|NCT03638063||Chronic cough|patients with chronic cough who remain clinically stable
89381786|NCT03638063||Bx|bronchiectasis patients who remain clinically stable
89381787|NCT03638063||Control|healthy controls
88854514|NCT01681992|Experimental|Inv_MMR_Med Group|Subjects receive one dose of GlaxoSmithKline (GSK) Biologicals' measles, mumps, rubella (MMR) vaccine, Priorix (Inv_MMR), from a mid-range or medium potency lot (Inv_MMR_Med), co-administered with Varivax (VV) and Havrix (HAV) vaccines at Day 0. All US subjects are also co-administered Prevnar 13 (PCV-13) vaccine. Approximately 6 weeks later, at Day 42, subjects are administered a dose from a separate lot of the Inv_MMR vaccine (Inv_MMR_Release), for the second dose. Inv_MMR and VV vaccines are administered subcutaneously in the triceps region of the left and right arm, respectively. HAV and PCV-13 vaccines are administered intramuscularly in the anterolateral region of the right and left thigh, respectively.
88854515|NCT01681992|Active Comparator|Com_MMR Group|Subjects receive one dose of M-M-R II (Com_MMR) vaccine (Lot 1 or Lot 2), co-administered with Varivax (VV) and Havrix (HAV) vaccines at Day 0. All US subjects are also co-administered Prevnar 13 (PCV-13) vaccine. Approximately 6 weeks later, at Day 42, subjects are administered a dose of Com_MMR vaccine (Lot 1 or Lot 2), for the second dose. Com_MMR and VV vaccines are administered subcutaneously in the triceps region of the left and right arm, respectively. HAV and PCV-13 vaccines are administered intramuscularly in the anterolateral region of the right and left thigh, respectively.
89381788|NCT04869371|Experimental|Androgen Deprivation Therapy with Docetaxel|All subjects in this arm will receive luteinizing hormone releasing hormone analogue (LHRHa) plus docetaxel and prednisone, as per standard of care. Triptorelin pamoate (Diphereline) 15mg will be used once per 12 weeks. Docetaxel (75 mg/m2 body surface area) will be administered as intravenous drip every 3 weeks for 6 cycles. Robot assisted radical prostatectomy will be followed in 2 weeks when 24-week treatment cycle is finished.
89381789|NCT04869371|Active Comparator|ADT alone|All subjects in this arm will receive LHRHa alone for 24 weeks before receiving robot assisted radical prostatectomy. Triptorelin Pamoate 15mg will be administered once per 12 weeks.
88854516|NCT01737840|Experimental|pantoprazole|Intravenous pantoprazole 40 mg flacon
88854517|NCT01737840|Active Comparator|ranitidine|Intravenous ranitidine 50 mg
88854518|NCT01687998|Experimental|Evacetrapib|Evacetrapib 130 mg tablet, administered orally once daily for up to 4 years. Participants will also receive standard of care for high-risk vascular disease (HRVD).
89381790|NCT03320369|Other|Treatment|Elemental formula Intervention: Elemental Diet Therapy
89381791|NCT02650895|Experimental|Efprezimod alfa|Single dose of efprezimod alfa is administrated as intravenous infusion in one hour. There are 5 dose cohorts, 10mg, 30mg, 60mg, 120mg, 240mg. Each cohort has 6 subjects in efprezimod alfa and 2 subject in placebo.
89381792|NCT02650895|Placebo Comparator|Saline|Single dose of 100 ml normal saline is administrated as intravenous infusion in one hour.
89381793|NCT03320057|Experimental|Medication abortion patients|Oral mifepristone 200 mg, followed by misoprostol 800 mcg administered buccally (at 24-48 hours following mifepristone) or vaginally (as soon as 6 hours following mifepristone)
88854519|NCT01687998|Placebo Comparator|Placebo|Placebo, tablet administered orally once daily for up to 4 years. Participants will also receive standard of care for HRVD.
88854520|NCT01681836|Experimental|Oral 15N-labeled sodium nitrate|Oral sodium nitrate 1,000 mg once first, then washout followed by oral sodium nitrite 20 mg once
88854521|NCT01681836|Experimental|Oral 15N-labeled sodium nitrite|Oral sodium nitrite 20 mg once first, then washout followed by oral sodium nitrate 1,000 mg once
88854522|NCT01681368|Experimental|Birinapant for Advanced Ovarian,Fallopian Tube & Peritoneal Ca|single arm
88854523|NCT01681212|Experimental|Ipilimumab, 10 mg/kg + Dacarbazine, 850 mg/m^2|During the Induction Period, participants received ipilimumab, 10 mg/kg, as tolerated by intravenous (IV) infusion as 1 single dose during Weeks 1 (Day 1), 4, 7, and 10 for a total of 4 separate doses. During the Maintenance Phase, participants received ipilimumab, 10 mg/kg, as tolerated by IV infusion every 12 weeks, beginning at Week 24, until disease progression or unacceptable toxicity occurred or the patient withdrew consent. Participants also received dacarbazine, 850 mg/m^2, by IV infusion over 30 to 60 minutes, starting on Week 1 and repeated every 3 weeks until Week 22. Dacarbazine was dosed on the same day as ipilimumab, when applicable, after the ipilimumab dose.
88854524|NCT01687296|Experimental|fluticasone Nebules/placebo tablet|2×0.5mg/2ml twice daily neblulized/placebo tablet, oral, once daily
88854525|NCT01687296|Active Comparator|oral prednisone/placebo inhalation solution|once daily (2mg/kg.day, up to 40mg/day for 4 days, then 1mg/kg.day or half of the original dose, up to 20mg/day for 3 days) / placebo inhalation solution nebulized twice daily
88854526|NCT04410432||Patient|Patient hospitalized with SARS-Cov2 infection proven by virological sampling.
88854527|NCT02071914|Experimental|CT-P27 10mg/kg|CT-P27 will be administrated once in IV infusion.
88854528|NCT02071914|Experimental|CT-P27 20mg/kg|CT-P27 will be administrated once in IV infusion.
89381794|NCT03320057|Other|Pharmacists|Pharmacists providing services at one of the study pharmacies during the study
89381795|NCT04741139|Experimental|Scheduled post-IVIG medication|Utilization of post-IVIG medication with acetaminophen and diphenhydramine on a scheduled basis of 72 hours post-infusion.
89381796|NCT03316547|No Intervention|Control|The control group received standard hospital care.
89381797|NCT03316547|Experimental|Intervention|Parents in the sensory-based intervention group were educated to provide daily sensory-based interventions across the length of hospitalization as outlined in the manualized intervention (the SENSE Program). A sensory support team completed the doses of sensory exposures when parents were unable.
88854529|NCT02071914|Placebo Comparator|Placebo|Placebo will be administrated once in IV infusion.
88854530|NCT01568892|Experimental|DTG 50 mg BID|Subjects will receive dolutegravir (DTG) 50 milligrams (mg) twice daily (BID) and the components of their current failing antiretroviral regimen, except raltegravir or elvitegravir, for 7 days during the Double-blind (DB) Phase. From Day 8, all subjects will continue to receive DTG 50 mg BID with an optimized background regimen in the Open-label Phase.
88854531|NCT01568892|Experimental|Placebo BID in DB Phase; DTG 50 mg BID in Open-label Phase|Subjects will receive matching placebo BID and the components of their current failing antiretroviral regimen, except raltegravir or elvitegravir, for 7 days during the DB Phase. From Day 8, all subjects will continue to receive DTG 50 mg BID with an optimized background regimen in the Open-label Phase.
88854532|NCT01568112|Experimental|BG00012|Participants received BG00012 for 8 weeks (120 mg BID during the first week and 240 mg BID during the subsequent 7 weeks) and premedication with ASA placebo during the first 4 weeks.
88854533|NCT01568112|Placebo Comparator|Placebo|Participants received BG00012 placebo for 8 weeks and premedication with ASA placebo during the first 4 weeks.
88854534|NCT01568112|Experimental|BG00012 + ASA|Participants received BG00012 for 8 weeks (120 mg BID during the first week and 240 mg BID during the subsequent 7 weeks) and premedication with ASA during the first 4 weeks.
88854535|NCT01568112|Experimental|BG00012 Slow Titration|Participants received BG00012 for 8 weeks (120 mg once daily [QD] during Week 1, 120 mg BID during Week 2, 240 mg AM/120mg PM during Week 3, and 240 mg BID during Week 4, and 240 mg BID during Weeks 5 to 8) and premedication with ASA placebo during the first 4 weeks.
88854536|NCT04116840|Experimental|MT1002 for Injection|Single Ascending Dose following Intravenous Bolus/Infusion Administration in Healthy Subjects
88854537|NCT01568034|Experimental|Treatment Sequence A|"Treatment Sequence A Period 1 - 25 mg BIA 9-1067 Period 2 - 50 mg BIA 9-1067 Period 3 - 100 mg BIA 9-1067 Period 4 - Placebo~Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half"
88854538|NCT01568034|Experimental|Treatment Sequence B|"Treatment Sequence B Period 1 - Placebo Period 2 - 25 mg BIA 9-1067 Period 3 - 50 mg BIA 9-1067 Period 4 - 100 mg BIA 9-1067~Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half"
88854539|NCT01568034|Experimental|Treatment Sequence C|"Treatment Sequence C Period 1 - 100 mg BIA 9-1067 Period 2 - Placebo Period 3 - 25 mg BIA 9-1067 Period 4 - 50 mg BIA 9-1067~Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half"
88854540|NCT01568034|Experimental|Treatment Sequence D|"Treatment Sequence D Period 1 - 50 mg BIA 9-1067 Period 2 - 100 mg BIA 9-1067 Period 3 - Placebo Period 4 - 25 mg BIA 9-1067~Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half"
88854541|NCT01687218|Active Comparator|Group 1|Daily Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet (8 weeks); followed by Daily Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks); followed by Receptive Anal Intercourse Associated Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks)
88854542|NCT01687218|Active Comparator|Group 2|Receptive Anal Intercourse Associated Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks); followed by Daily Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet (8 weeks); followed by Daily Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks)
88854543|NCT01687218|Active Comparator|Group 3|Daily Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks); followed by Receptive Anal Intercourse Associated Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks); followed by Daily Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet (8 weeks)
88854544|NCT01687218|Active Comparator|Group 4|Daily Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks); followed by Daily Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet (8 weeks); followed by Receptive Anal Intercourse Associated Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks)
88854545|NCT01687218|Active Comparator|Group 5|Daily Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet (8 weeks); followed by Receptive Anal Intercourse Associated Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks); followed by Daily Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks)
88854546|NCT01687218|Active Comparator|Group 6|Receptive Anal Intercourse Associated Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks);followed by Daily Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks); followed by Daily Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet (8 weeks)
89381798|NCT02740205|No Intervention|Control group|Hospital's standard EN support at the discretion of the Clinical Nutrition Service that is composed by physicians, dietitians, and students, provides nutritional assessments, recommendations and consultations for the in-patients that required nutrition support during their hospitalization stay. There is no protocols or algorithms for the nutritional support in our institution, the currently clinical practice of the EN is prescribed by the physician, dietitians and students during the morning rounds each 24h, the kind of EN formulas prescribed depends of the clinical status of the patient, when the patients required protein supplements modular protein supplements are added.
88854547|NCT01686828|Experimental|Acyline & placebo gel & placebo pill|Acyline (300mcg/kg) + placebo transdermal gel + placebo pill daily
88854548|NCT01686828|Experimental|Acyline & Testosterone 1.25g & placebo pill|Acyline (300mcg/kg) + Testosterone gel (1.25g) daily + placebo pill daily
88854549|NCT01686828|Experimental|Acyline & Testosterone 5g & placebo pill|Acyline (300mcg/kg) + Testosterone gel (5g) daily + placebo pill daily
88854550|NCT01686828|Experimental|Acyline & Testosterone & Letrozole|Acyline (300mcg/kg) + Testosterone gel (5g) daily + letrozole (5mg) daily
88854551|NCT01686438|Experimental|CBT-I delivery by video teleconferencing|Groups of participants will receive a cognitive behavioral therapy for insomnia program delivered by a trained psychologist using video teleconferencing.
88854552|NCT01686438|Active Comparator|In-person CBT-I delivery|Groups of participants will receive a cognitive behavioral therapy for insomnia (CBT-I) program by meeting in-person with a trained psychologist.
88854553|NCT01593696|Experimental|Lymphodepleting regimen of Fludarabine and Cyclophosphamide|Lymphodepleting regimen of Fludarabine and Cyclophosphamide.
89381799|NCT02740205|Experimental|Algorithm for enteral nutrition support|Initial infusion of 20 to 40 ml/h, evaluated the tolerability in the next 8-12h, then the infusion can be increased 25 ml/ 8-12h for gastric infusion and 10-20 ml/h for the post-pyloric feeding, for bolus infusion an initial infusion of 125 ml each 4-5hrs and evaluated the tolerability in the next 8-12h. If the subject present intolerability to the EN, the action in the algorithm indicate hold the infusion 4h then restarted at 10 ml/h with prokinetics agents rather than the suspension. As a part of the intervention, several educational sessions for the medical, nutritionist and nurse staff were performed during the period of the study.
89381800|NCT02738255|Active Comparator|Polysomnogram With Varnum First, Regular Polysomnogram Second|Varnum mouthpiece, similar to a mouth tape with central opening on the first night, then a 1-week non-treatment period, then overnight sleep study with no mouthpiece.
89381801|NCT02738255|Active Comparator|Regular Polysomnogram First, Polysomnogram With Varnum Second|Baseline sleep study without Varnum mouthpiece on the first night, then a 1-week non-treatment period, then an overnight sleep study with Varnum mouthpiece on the second night.
89381802|NCT04824989|Experimental|Sleep Health|Family receives the Sleep Health In Preschoolers parenting intervention to address toddler sleep problems.
89381803|NCT04824989|Experimental|Behavior Health|Family receives the Family Check-Up parenting intervention to address toddler behavior problems.
89381804|NCT04824989|Experimental|Choice|Family is given the opportunity to select either the Sleep Health in Preschoolers intervention to address toddler sleep problems or the Family Check-Up intervention to address toddler behavior problems.
89381805|NCT04824989|Active Comparator|Control|Family receives a safety and hygiene active control intervention.
89381806|NCT04762433|Experimental|Kegel Exercise Pregnancy Training - App|The intervention arm will be given a mHealth app for two months duration with the usual antenatal follow-up.
89381807|NCT04762433|No Intervention|Waitlist control|The control (waitlist) group will continue their usual antenatal follow-up and the KEPT-app will be given after the study ends.
89381808|NCT04752761|Other|DIG-PROMs-k|Patients who underwent TKA are given conventional and digital OKS surveys. Patients adhesion to both surveys will be compared.
89381809|NCT04853147|Experimental|triple therapy|Triple combination of Fosaprepitant, Palonosetron and Dexamethasone were administered
89381810|NCT04853147|Other|double therapy|double combination of Palonosetron and Dexamethasone were administered
89381811|NCT03315689|Placebo Comparator|Vehicle|Vehicle
89381812|NCT03315689|Experimental|Active|ATI-50002 Topical Solution
89381813|NCT03436901|Other|Testicular cancer st. II-III|MRI with DWI vs CT
88854554|NCT01593696|Experimental|Intensive standard of care chemotherapy|Intensive standard of care chemotherapy, in lieu of the lymphodepleting chemotherapy regimen, to decrease tumor burden in preparation for the administration of the Chimeric antigen receptor (CAR) T cells.
88854555|NCT01592760|Experimental|air-Q SP|air-Q Self-Pressurizing Intubating Laryngeal Airway, sizes 3.5 and 4.5 (Mercury Medical, Clearwater, FL, USA)
88854556|NCT01592760|Active Comparator|air-Q|air-Q Intubating Laryngeal Airway, sizes 3.5 and 4.5 (Mercury Medical, Clearwater, FL, USA)
88854557|NCT01592760|Active Comparator|i-gel|i-gel, sizes 3, 4, and 5 (Intersurgical Inc., Liverpool, NY, USA)
89381814|NCT03314519|Experimental|Ultrasonography|Patients in this group receive lung ultrasonography to detect lung collapse after insert double lumen tube and finally compare lung collapse by the surgeon's visual grading scale of lung collapse when entering pleural cavity.
89381815|NCT03314519|Active Comparator|Fiberoptic bronchoscopy|Patients in this group receive fiberoptic bronchoscope to detect lung collapse after inserting a double lumen tube and finally compare lung collapse by the surgeon's visual grading scale of lung collapse when entering the pleural cavity.
89381816|NCT01856855|Experimental|Stereotactic Body Radiation Therapy with Integrated Boost|
89381817|NCT04689347|Experimental|FLIRT-bevacizumab|"Bevacizumab intravenous infusion (IV), irinotecan IV, leucovorin (LV) IV, 48-hours continuous intravenous infusion of 5-fluorouracil (5-FU), given every 14 days, in combination with oral (PO) temozolomide with progressive dose escalation at inter-patient level over days 1-5 every 28 days.~The treatment will consist of an induction period of four 28-day cycles of FLIRT- bevacizumab followed by maintenance regimen of 5-FU/LV-bevacizumab administered every 14 days in combination with PO temozolomide according to dose level over days 1-5 every 28 days in patients without progressive disease at the end of the induction period."
89381818|NCT03313037|Experimental|Multivalent|Pneumococcal conjugate vaccine
88854558|NCT03901014|Active Comparator|Baseline diet|1 week baseline diet
88854559|NCT03901014|Experimental|Very low carbohydrate diet|2 week very low carbohydrate ketogenic diet
88854560|NCT01696188|Experimental|In-plane group|This group will receive an interscalene catheter placed with in-plane approach.
89381819|NCT03313037|Active Comparator|Control|Prevnar 13 and PPSV23
88854561|NCT01696188|Experimental|Out-of-plane group|This group will receive an interscalene catheter with an out-of-plan approach.
88854562|NCT02985762|Other|EXPAREL 266 mg/20 mL|Eligible subjects, whose surgical incision must be at least 8 cm in length, will receive a single dose of EXPAREL (266 mg/20 mL) expanded in volume with 20-60 mL normal saline, depending on the size of the incision
88854563|NCT04768374|Experimental|VR group|Enrolled into 12 week VR intervention with Microsoft Kinect (twice a week, for 45 minutes) and conventional occupational therapy.
88854564|NCT04768374|Active Comparator|Control group|Control group only received conventional occupational therapy for 12 weeks
88854565|NCT01603602|Experimental|BOTOX® 3 U/kg|Participants received intramuscular injections of BOTOX® (botulinum toxin Type A) 3 units (U) per kilogram (kg) of body weight (3 U/kg) into specified muscles of the upper limb on Day 1. Participants received weekly occupational therapy (OT).
89002738|NCT06200467|Placebo Comparator|Arm C: R1 then R3 then R1 then R2|Arm C: BI 456906-placebo (R1) then moxifloxacin-placebo (R3) then BI 456906-placebo (R1) then moxifloxacin (R2)
89002739|NCT06194409||IE in IV drug abusers|Infective endocarditis in intravenous drug abusers
89002740|NCT06194409||IE in non- IV drug abusers|Infective endocarditis in non - intravenous drug abusers
89002741|NCT06193915|Experimental|Ultrasound guided hematoma block|Patients in this group will receive ultrasound guided hematoma block before reduction of their dislocated distal radius fracture.
89002742|NCT06193915|Active Comparator|Blind hematoma block|Patients in this group will receive standard treatment; hematoma block with palpation of the fracture site (blind hematoma block)
89002743|NCT06192108|Experimental|Orforglipron Dose 1|Participants will receive orforglipron orally.
89002744|NCT06192108|Experimental|Orforglipron Dose 2|Participants will receive orforglipron orally.
89002745|NCT06192108|Experimental|Orforglipron Dose 3|Participants will receive orforglipron orally.
89002746|NCT06192108|Active Comparator|Dapagliflozin|Participants will receive dapagliflozin orally.
89002747|NCT06191458|Experimental|Primaquine|Twelve healthy postpartum women who are breast feeding healthy neonates 48 hours - 5 days old will receive primaquine 0.5 mg/kg once daily for 14 days.
89002748|NCT06189859|Active Comparator|Spray coag mode|After initial mucosal incision, Endoscopic submucosal dissection will be performed using Spray coag mode using ERBE VIO 3 generator (effect 3-3.5)
89002749|NCT06189859|Active Comparator|Precisect mode|After initial mucosal incision, Endoscopic submucosal dissection will be performed using Precisect mode using ERBE VIO 3 generator (effect 4.5-5)
89002750|NCT06187363||Patients managed by tubularized incised plate procedure|Patients with redo hypospadias repair using tubularized incised plate procedure
89002751|NCT06187363||Patients treated by procedures other than tubularized incised plate procedure|Patients with redo hypospadias repair using other procedures
89002752|NCT06184204||Patients with confirmed diagnosis of Atrial fibrillation|male, female, 19 or more of age with confirmed diagnosis of Atrial fibrillation
89002753|NCT06183125|Experimental|TCM-based anti-sedentariness intervention group|TCM-based anti-sedentariness intervention
89002754|NCT06183125|Other|Wait-list control group|After the completion of all evaluations, the intervention content will be administered to the experimental group in the same manner.
89002755|NCT06179303|Experimental|Treatment (FFNP-PET/CT, estradiol, abemaciclib, ET)|Patients receive FFNP IV and undergo PET/CT imaging at baseline. Patients then receive estradiol orally Q8H over a 24-hour period, followed again by FFNP IV and PET/CT imaging. Patients then receive abemaciclib PO BID on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive ET of the treating physician choice. Patients also receive FDG IV and undergo PET/CT imaging at baseline, with additional diagnostic imaging for tumor assessment every 3 cycles, and undergo blood sample collection throughout the study.
89002756|NCT06177951|No Intervention|Control Group|This group will receive neither of the interventions (NICU Discharge Passport, NICU Infant Care Class).
89002757|NCT06177951|Experimental|Received NICU Discharge Passport Only|This group will receive only one intervention: NICU Discharge Passport.
89002758|NCT06177951|Experimental|Received NICU Infant Care Class Only|This group will receive only one intervention: NICU Infant Care Class.
89002759|NCT06177951|Experimental|Received Both NICU Discharge Passport and NICU Infant Care Class|This group will receive both interventions: NICU Discharge Passport, NICU Infant Care Class.
89002760|NCT06176794|Experimental|Extended release torsemide first|
89002761|NCT06176794|Active Comparator|Immediate release torsemide first|
89002762|NCT06176352|Experimental|Arm A: Faricimab|All participants randomly assigned to Arm A will receive faricimab 6 mg at Day 1. Once every 4 weeks (Q4W) after Day 1, participants will receive treatment with faricimab on a pro re nata (PRN) basis dependent on prespecified retreatment criteria.
89002763|NCT06176352|Active Comparator|Arm B: Ranibizumab|All participants randomly assigned to Arm B will receive ranibizumab 0.5 mg at Day 1. Once every 4 weeks (Q4W) after Day 1, participants will receive treatment with ranibizumab on a pro re nata (PRN) basis dependent on prespecified retreatment criteria.
89002764|NCT06166576|Experimental|Radioembolization|Hepatocellular carcinoma with localized portal vein tumor thrombosis (Vp1-Vp3) will be treated by ablative radioembolization using TheraSphere (Boston Scientific) glass microspheres
89002765|NCT06165627|Other|T30fA, then Biofinity Toric|Lehfilcon A toric contact lenses worn in Period 1, followed by comfilcon A toric contact lenses worn in Period 2, as randomized. The study lenses will be worn bilaterally (in both eyes) during waking hours for at least 12 hours per day during each wear period (30 days [-1/+3] according to randomization assignment). Study lenses will be removed daily for cleaning and disinfection with CLEAR CARE Cleaning & Disinfecting Solution.
89002766|NCT06165627|Other|Biofinity Toric, then T30fA|Comfilcon A toric contact lenses worn in Period 1, with lehfilcon A toric contact lenses worn in Period 2, as randomized. The study lenses will be worn bilaterally (in both eyes) during waking hours for at least 12 hours per day during each wear period (30 days [-1/+3] according to randomization assignment). Study lenses will be removed daily for cleaning and disinfection with CLEAR CARE Cleaning & Disinfecting Solution.
89002767|NCT06157983||Index|Patient with atherosclerotic coronary artery disease and a measured plasma lipoprotein(a).
89002768|NCT06157983||Biological relative to index|First- or second-degree relative to the index with atherosclerotic coronary artery disease and a measured plasma lipoprotein(a)
89002769|NCT06156969|Experimental|Robot-assisted gait training|Robot-Assisted Gait Training using the LokomatPro device. Total of 18 training sessions, over a period of approximately 6-7 weeks. Sessions will last approximately 60 minutes.
89002770|NCT06153420|Experimental|CIN-103 BID Dose 1|CIN-103 Dose 1, administered as 2 x CIN-103 capsules and 2 x matching placebo per dose. Two doses per day.
89002771|NCT06153420|Experimental|CIN-103 BID Dose 2|CIN-103 Dose 2, administered as 4 x CIN-103 capsules per dose. Two doses per day.
89002772|NCT06153420|Placebo Comparator|Placebo for CIN-103 BID|Placebo for CIN-103, administered as 4 x matching placebo capsules per dose. Two doses per day.
89183358|NCT04943562||Healthy participants|Participants from 20 to 40 years old, from both genders and with no sleep disorders
89381820|NCT04685759|Active Comparator|In-Person Exercise Protocol (IPEP)|This group will receive exercise instruction and monitoring in-person from the certified Cancer Exercise Trainer (CET) in the gym facility at Moncrief Cancer Institute (MCI). Study participants will be scheduled for exercise sessions twice a week with the oncology exercise trainer.
89381821|NCT04685759|Experimental|Virtual Exercise Protocol (VEP)|This group will receive exercise instruction and monitoring from the CET via telehealth sessions at home. Study participants will be scheduled for exercise sessions twice a week with the oncology exercise trainer.
89381822|NCT02420795|Experimental|Treatment (Akt/ERK inhibitor ONC201)|Patients receive Akt/ERK inhibitor ONC201 PO on day 1 of every cycle or day 1 of every week. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89381823|NCT04674995||Stent|Patients with tracheal stenosis treated with stent placement via rigid bronchoscopy.
89381824|NCT04674995||Balloon dilatation|Patients with tracheal stenosis treated with balloon dilatation via laryngoscope.
89381825|NCT03976661||DIAPASON 92 arm|Arm will be constitued by older patients with loss of autonomy, living at home benefiting from the device DIAPASON 92 (Innovative support system for elderly people in their homes)
89381826|NCT03976661||Control arm|Arm will be constituted by people residing at the EHPAD (retirement home)
89381827|NCT02384759|Experimental|A|Aflibercept + LV5FU2
89381828|NCT02384759|Active Comparator|B|LV5FU2
89381829|NCT05276843|Experimental|group A|receive Qigong exercise in addition to traditional physical therapy program
89381830|NCT05276843|No Intervention|group B|receive traditional physical therapy program only
89381831|NCT05276765|Experimental|CAD/CAM customized Socket Sealing Abutment|Anatomically formed healing abutments that can solve many of the problems inherent to immediate posterior implant placement and to optimize the conditioning of supra implant tissue architecture enhancing the emergence profile of the final implant restoration
89381832|NCT05276765|Active Comparator|Standard healing abutment|Standard healing abutment will be inserted after removal of cover screw after immediate implant insertion and then a muco-periosteal flap will be reflected for the primary closure of the socket and sutured around the standard healing abutment.
89381833|NCT03334175|Experimental|Walnuts Now|Will receive and be instructed to consume 1-oz individually wrapped daily walnut supplement packages for 12 weeks during intervention.
88854566|NCT01603602|Experimental|BOTOX® 6 U/kg|Participants received intramuscular injections of BOTOX® (botulinum toxin Type A) 6 U per kg of body weight (6 U/kg) into specified muscles of the upper limb on Day 1. Participants received weekly OT.
89381834|NCT03334175|No Intervention|Walnuts Later|Will receive diet and exercise guidance at beginning of study. At end of study, will receive 12 weeks of a walnut supply to be consumed at their discretion after the study is complete.
89381835|NCT05276687|Experimental|Diluted betadine|
89381836|NCT05276687|Experimental|Powdered vancomycin|
89381837|NCT05276687|No Intervention|No intervention|
89381838|NCT04616339|Active Comparator|Formulation A (Cohort 1)|Following an overnight fast of at least 10 hours, subjects received PF-06882961 (Danuglipron) 100 mg immediate release tablet as formulation A at approximately 0800 hours (±2 hours). A minimum of 72 hours between the single 100 mg doses administered in each period was employed
88854567|NCT01603602|Placebo Comparator|Placebo|Participants received intramuscular injections of normal saline (placebo) into specified muscles of the upper limb on Day 1. Participants received weekly OT.
88854568|NCT01684878|Experimental|Part 1: Pertuzumab + Topotecan|Participants received pertuzumab and topotecan in cycles of 3 weeks until progressive disease as per investigator's assessment, unacceptable toxicity, withdrawal of consent, or death.
88854569|NCT01684878|Experimental|Part 1: Pertuzumab + Paclitaxel|Participants received pertuzumab and paclitaxel in cycles of 3 weeks until progressive disease as per investigator's assessment, unacceptable toxicity, withdrawal of consent, or death.
89381839|NCT04616339|Experimental|Formulation B (Cohort 1)|Following an overnight fast of at least 10 hours, subjects received PF-06882961 (Danuglipron) 100 mg immediate release tablet as formulation B at approximately 0800 hours (±2 hours). A minimum of 72 hours between the single 100 mg doses administered in each period was employed
89381840|NCT04616339|Experimental|Formulation C (Cohort 1)|Following an overnight fast of at least 10 hours, subjects received PF-06882961 (Danuglipron) 100 mg immediate release tablet as formulation C at approximately 0800 hours (±2 hours). A minimum of 72 hours between the single 100 mg doses administered in each period was employed
89381841|NCT04616339|Experimental|Formulation D (Cohort 1)|Following an overnight fast of at least 10 hours, subjects received PF-06882961 (Danuglipron) 100 mg immediate release tablet as formulation D at approximately 0800 hours (±2 hours). A minimum of 72 hours between the single 100 mg doses administered in each period was employed
89381842|NCT04616339|Active Comparator|Formulation A (Cohort 2)|Following an overnight fast of at least 10 hours, subjects received PF-06882961 (Danuglipron) 100 mg immediate release tablet as formulation A at approximately 0800 hours (±2 hours). A minimum of 72 hours between the single 100 mg doses administered in each period was employed
89381843|NCT04616339|Experimental|Formulation E (Cohort 2)|Following an overnight fast of at least 10 hours, subjects received PF-06882961 (Danuglipron) 100 mg immediate release tablet as formulation E at approximately 0800 hours (±2 hours). A minimum of 72 hours between the single 100 mg doses administered in each period was employed
89381844|NCT02942771|Experimental|Cohort 1 - TT301/MW189|TT301/MW189 0.075 mg/kg IV (or matched placebo). Each subject will receive 1 dose level of study drug twice daily (bid) on Days 1 through 5, inclusive
89381845|NCT02942771|Experimental|Cohort 2 -TT301/MW189|TT301/MW189 0.15 mg/kg IV (or matched placebo). Each subject will receive 1 dose level of study drug twice daily (bid) on Days 1 through 5, inclusive
88854570|NCT01684878|Experimental|Part 2: Pertuzumab+Chemotherapy|Participants received pertuzumab and chemotherapy (paclitaxel or topotecan or gemcitabine) in cycles of 3 weeks until progressive disease as per investigator's assessment, unacceptable toxicity, withdrawal of consent, or death. Chemotherapy was administered as per investigators discretion.
88854571|NCT01684878|Placebo Comparator|Part 2: Placebo+Chemotherapy|Participants received pertuzumab matching placebo and chemotherapy (paclitaxel or topotecan or gemcitabine) in cycles of 3 weeks until progressive disease as per investigator's assessment, unacceptable toxicity, withdrawal of consent, or death. Chemotherapy was administered as per investigators discretion.
88854572|NCT01684722|Active Comparator|Vitamin D + fish oil|Vitamin D and omega-3 fatty acids (fish oil)
88854573|NCT01684722|Active Comparator|Vitamin D + fish oil placebo|Vitamin D and fish oil placebo
88854574|NCT01684722|Active Comparator|Vitamin D placebo + fish oil|Vitamin D placebo and omega-3 fatty acids (fish oil)
88854575|NCT01684722|Placebo Comparator|Vitamin D placebo + fish oil placebo|Vitamin D placebo and fish oil placebo
88854576|NCT01592292||Rituximab|Participants who have inadequate response or were intolerant to the first anti-tumor necrosis factor (anti-TNF) agent in rheumatoid arthritis (RA), receiving rituximab as per physician's discretion for RA treatment were observed for 12 months.
88854577|NCT01592292||Other anti-TNF agent|Participants who have inadequate response or were intolerant to the first anti-TNF agent in RA, receiving other anti-TNF agent, including adalimumab, etanercept and infliximab, as per physician's discretion for RA treatment were observed for 12 months.
88854578|NCT01590888|Experimental|PBT2 250mg|
88854579|NCT01590888|Experimental|PBT2 100mg|
88854580|NCT01590888|Placebo Comparator|Sugar pill|
88854581|NCT01565928|Experimental|MDV3100|
88854582|NCT01565850|Experimental|D/C/F/TAF|D/C/F/TAF FDC tablet plus DRV placebo plus COBI placebo plus FTC/TDF placebo
88854583|NCT01565850|Active Comparator|DRV+COBI+FTC/TDF|DRV tablet plus COBI tablet plus FTC/TDF 200/300 mg FDC tablet plus D/C/F/TAF placebo
88854584|NCT01565694|Experimental|Solifenacin succinate|"Participants aged 5 years to < 18 years received solifenacin orally once a day, with sequential titrated doses for 12 weeks to identify the optimal dose during the dose-titration period. The initial dose was pediatric equivalent dose (PED) 5 mg.~After completing the dose titration period participants entered the fixed-dose period during which solifenacin was taken orally once a day for 40 weeks or until the end of study visit (Week 52)."
88854585|NCT01543152|Experimental|Cohort 1 - IV cyclophosphamide 200 mg|
88854586|NCT01543152|Experimental|Cohort 2 - IV cyclophosphamide 0.5 g/m2|
88854587|NCT01543152|Experimental|Cohort 3 - IV cyclophosphamide 1.0 g/m2|
88854588|NCT01543152|Experimental|Cohort 4 - IV cyclophosphamide 2.0 g/m2|
88854589|NCT01543152|Experimental|Cohort 5 - IV cyclophosphamide 1.5 g/m2|
88854590|NCT01590810|Experimental|Panel A-Healthy|Within each of the 5 treatment periods, 6 participants will be randomly assigned to receive MK-8150, and 2 will be randomly assigned to receive matching placebo according to a computer-generated allocation schedule. The dose range of MK-8150 for Panel A will be 2.0 mg to 90 mg.
88854591|NCT01590810|Experimental|Panel B-Healthy|Within each of the 5 treatment periods, 6 participants will be randomly assigned to receive MK-8150, and 2 will be randomly assigned to receive matching placebo according to a computer-generated allocation schedule. The dose range of MK-8150 for Panel B will be 5.0 mg to 160 mg.
88854592|NCT01590810|Experimental|Panel C-Mild/Moderate Hypertension|Within each of the 5 treatment periods, 6 participants will be randomly assigned to receive MK-8150, and 2 will be randomly assigned to receive matching placebo according to a computer-generated allocation schedule. The dose range of MK-8150 for Panel C will be 160 mg to 1200 mg.
88854593|NCT01590810|Experimental|Panel D-Healthy|Within each panel, 8 subjects will be randomly assigned to MK-8150 and 2 subjects will be randomly assigned to placebo throughout the 5 periods according to a computer-generated allocation schedule. The dose range of MK-8150 for Panel D will be 50 mg to 500 mg.
88854594|NCT01542528|Experimental|IBBS|Combination of computer-presented brain exercises with a physical education curriculum designed to enhance sustained attention, inhibitory control and other executive capacities. Groups of 10 students incorporating the Good Behavior Game. Two-hour sessions four days a week: classroom with computers (45-60 mins) plus sports activities in the gymnasium (45-60 mins) extending over a total 15 weeks (60 sessions).
88854595|NCT01542528|No Intervention|Treatment as Usual (TAU)|Whatever care arrangement the parents have arranged for their child during the same two hour period over the same 15 week period.
88854596|NCT01565148|Experimental|Group 1|"Drug: iCo-007 350 mcg~iCo-007 (350 μg) as an intravitreal injection at baseline followed by another iCo-007 dose (350 μg) at month 4"
88854597|NCT01565148|Experimental|Group 2|"Drug: iCo-007 700 mcg~iCo-007 (700 μg) as an intravitreal injection at baseline followed by another iCo-007 dose (700 μg) at month 4"
88854598|NCT01565148|Experimental|Group 3|"Drug: iCo-007 350 mcg and Laser~iCo-007 (350 μg) as an intravitreal injection at baseline followed 7 days later by laser photocoagulation. At M4, intravitreal injection of iCo-007 (350 μg) will be given as mandatory treatment. If the eye also meets retreatment criteria, it will also receive the second laser photocoagulation"
88854599|NCT01565148|Experimental|Group 4|"Drug: Ranibizumab and iCo-007 350 mcg~Ranibizumab (0.5 mg) intravitreal injection at baseline followed by iCo-007 (350 μg) intravitreal injection 2 weeks later; re-treatment with ranibizumab (0.5 mg) mandatory at M4 followed by iCo-007 (350 μg) 2 weeks later"
88854600|NCT04410354|Active Comparator|MMPD + remdesivir|Study subjects will receive MMPD oral solution 3 times per day for 10 days unless discontinued early. Study subjects will also receive remdesivir infusion once a day for 5 days. If a subject does not demonstrate clinical improvement, remdesivir treatment may be extended for up to 5 additional days (for a total of up to 10 days).
88854601|NCT04410354|Placebo Comparator|Placebo + remdesivir|Study subjects will receive matching placebo oral solution 3 times per day for 10 days unless discontinued early. Study subjects will also receive remdesivir infusion once a day for 5 days. If a subject does not demonstrate clinical improvement, remdesivir treatment may be extended for up to 5 additional days (for a total of up to 10 days).
88854602|NCT01564758||Group 1|Subjects that are diagnosed with gram positive infection
88854603|NCT01541826|Placebo Comparator|Color-matched rice powder pill|Color-matched rice powder pill
89381846|NCT02942771|Experimental|Cohort 3- TT301/MW189|TT301/MW189 0.25 mg/kg IV (or matched placebo). Each subject will receive 1 dose level of study drug twice daily (bid) on Days 1 through 5, inclusive
89381847|NCT02942771|Experimental|Cohort 4- TT301/MW189|TT301/MW189 0.30 mg/kg IV (or matched placebo). Each subject will receive 1 dose level of study drug twice daily (bid) on Days 1 through 5, inclusive
89381848|NCT02942771|Placebo Comparator|Placebo|No drug intervention.
89381849|NCT05276375|Active Comparator|Bronchipret|Bronchipret syrup (3x 5,4 ml daily, according to summary of product characteristics) until day 14
89381850|NCT05276375|No Intervention|standard of care|no study intervention
89381851|NCT05275985|Experimental|68Ga-FAPI PET/CT examination|Patients with suspected pancreatic lesions underwent 68Ga-FAPI PET/CT to distinguish benign and malignant lesions, to evaluate the resectability of lesions and to detect distant metastasis. The clinicians decided the treatment methods based on the results of 68Ga-FAPI PET/CT.
89381852|NCT05275829||Control group: Face-to-Face learning of simple interrupted suturing|"The students watched a video demonstrating simple interrupted suturing, with the instructor commenting on the steps.~The students then watched the video again.~The instructor then demonstrated the procedure for the students.~The students then practiced suturing with immediate and specific feedback provided by the instructor until he and the students were satisfied with the performance."
89381853|NCT05275829||Study group: Distance learning (tele simulation) of simple interrupted suturing|"The instructor ran the interactive tele simulation sessions utilising web-based video-conferencing technology (WebEx platform). The students used their personal smartphones or laptops with audio-video capabilities. The instructor ran the session through his smartphone.~The instructor shared a video demonstrating simple interrupted suturing while commenting on the steps (the same video used in the control group).~The instructor then ran the video again for the students.~The instructor then demonstrated the skill for the students by turning on his camera.~The students then practiced suturing, and periodically turned on their cameras to receive live and specific feedback from the instructor on their performance, until the instructor and the students were satisfied.~No face-to-face interactions between the students and the instructor."
89381854|NCT03036150|Experimental|Dapagliflozin|Patients will be randomized 1:1 to either dapagliflozin or placebo.
89381855|NCT03036150|Placebo Comparator|Placebo|Placebo matching dapagliflozin.
89381856|NCT03332771|Experimental|Sotagliflozin 400 mg|Following a 2-week run-in period, two Sotagliflozin 200 mg, tablets, and two Glimepiride-matching placebo capsules, taken orally once daily before the first meal of the day in the double-blind treatment period up to 52 weeks.
89381857|NCT03332771|Experimental|Sotagliflozin 200 mg|Following a 2-week run-in period, one Sotagliflozin 200 mg, tablet and one Sotagliflozin-matching placebo tablet, and two Glimepiride-matching placebo capsules, taken orally once daily before the first meal of the day in the double-blind treatment period up to 52 weeks.
89381858|NCT03332771|Active Comparator|Glimepiride|Following a 2-week run-in period, two Sotagliflozin-matching placebo tablets, and combination of two Glimepiride capsules with adequate dose strengths per dose titration (titrated up to 6mg), taken orally once daily before the first meal of the day in the double-blind treatment period up to 52 weeks.
89381859|NCT03332771|Placebo Comparator|Placebo|Following a 2-week run-in period, two Sotagliflozin-matching placebo tablets and two Glimepiride-matching placebo capsules, taken orally once daily before the first meal of the day in the double-blind treatment period up to 52 weeks.
89381860|NCT03625830|Experimental|Paclitaxel-eluting PTCA-Balloon Catheter(SeQuent® Please)|
89381861|NCT03625830|Active Comparator|Rapid exchange PTCA Balloon Catheter (SeQuent® Neo)|
89381862|NCT04108104|Experimental|Low-dose group|Periactine® (Cyproheptadine 8 mg/day; two times 4 mg: morning and evening) and Alpress® (5 mg once a day slow-release: evening administration).
89381863|NCT04108104|Experimental|High-dose group|Periactine® (Cyproheptadine 12 mg/day; three times 4 mg: morning, noon and evening) and Alpress® (10 mg [2 tablets of 5 mg] once a day slow-release: evening administration)
88854604|NCT01541826|Active Comparator|Chokeberry extract capsule|Chokeberry extract capsule
88854605|NCT01541826|Experimental|Chokeberry extract capsule (acute)|Chokeberry extract capsule pharmacokinetics
88854606|NCT01541748||AXIS Allograft Dermis|Participants receiving AXIS Allograft Dermis for anterior, posterior or combined (anterior and posterior) female pelvic floor repair.
89381864|NCT04108104|Placebo Comparator|Placebo group|Placebo of Periactine® (three times per day: morning, noon and evening) and placebo of Alpress® (once a day: evening)
89381865|NCT05304468|Experimental|Reduced-dose group|After 2 cycles of induction chemotherapy, patients with favorable response undergo low-dose (60Gy) intensity-modulated radiotherapy (IMRT) 5 days per week for approximately 6 weeks (30 fractions). Patients also receive concurrent cisplatin once every three weeks for 2 cycles.
89381866|NCT05304468|Active Comparator|Standard dose group|After 2 cycles of induction chemotherapy, patients with favorable response undergo standard-dose (70Gy) intensity modulated radiotherapy (IMRT) 5 days per week for approximately 7 weeks (33 fractions). Patients also receive concurrent cisplatin once every three weeks for 3 cycles.
88854607|NCT01589094|Experimental|Gemcitabine and Cisplatin (DD GC)|This is a Multicenter Phase II study of dose-dense (DD) gemcitabine and cisplatin (GC) neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer (MIBC) who are candidates for radical cystectomy.
88854608|NCT01563978|Experimental|Dosing Regimen A|Oral treatment
88854609|NCT01563978|Placebo Comparator|Dosing Regimen B|Oral treatment
88854610|NCT04114344|Active Comparator|TAPP (Trans Abdominal PrePeritoneal)|Trans Abdominal PrePeritoneal approach to inguinal hernia repair
88854611|NCT04114344|Experimental|TEP (Totally Extra Peritoneal)|Totally Extra Peritoneal approach to inguinal hernia repair
88854612|NCT01563354|Experimental|Pasireotide LAR|Pasireotide long acting release (LAR) 60 mg will be administered as an intra muscular (i.m.) depot injection once every 28 days starting on Day 1
88854613|NCT01563354|Experimental|Everolimus|Everolimus 10 mg taken orally (p.o) once daily starting on Day 1
88854614|NCT01563354|Experimental|Pasireotide LAR and Everolimus Combination|Pasireotide LAR 60 mg i.m. injected once every 28 days + Everolimus 10 mg p.o. daily starting on Day 1
88854615|NCT01588548|Active Comparator|AZD1208|
88854616|NCT01587924|Experimental|0.5 mg GSK1278863|once daily
88854617|NCT01587924|Experimental|2 mg GSK1278863|once daily
88854618|NCT01587924|Experimental|5 mg GSK1278863|once daily
88854619|NCT01587924|Active Comparator|rhEPO|as required
88854620|NCT03028038|Experimental|Platelet Rich Plasma|Platelet Rich Plasma (PRP) will be injected beneath the buccal periosteal of the first molar and premolar in one mouth side with a split-mouth design before the beginning of Rapid Maxillary Expansion and after 7 days of it.
88854621|NCT03028038|Experimental|No Platelet Rich Plasma|No Platelet Rich Plasma (PRP) will be injected in the other mouth side with a split-mouth design during Rapid Maxillary Expansion.
88854622|NCT03027960|Experimental|Placebo, then empagliflozin|"Patients are randomized upon enrollment to determine whether they take empagliflozin or the matched placebo during the first 2-week treatment phase of the study. All patients then undergo a 2-week washout period before crossing over to the alternate therapy."
88854623|NCT03027960|Experimental|Empagliflozin, then Placebo|"Patients are randomized upon enrollment to determine whether they take empagliflozin or the matched placebo during the first 2-week treatment phase of the study. All patients then undergo a 2-week washout period before crossing over to the alternate therapy."
88854624|NCT03028194|Experimental|Curettage|Postpartum uterine curettage performed immediately after delivery of the placenta.
88854625|NCT03028194|Placebo Comparator|Placebo|No procedure performed after delivery of the placenta.
88854626|NCT01539642|Experimental|Sufentanil NanoTab PCA System/15 mcg|
88854627|NCT01539642|Placebo Comparator|Placebo Sufentanil NanoTab PCA System|
88854628|NCT01586364|Experimental|Ospemifene 60 mg Oral Tablet|Participants will take one tablet of ospemifene 60 mg orally, once a day for 12 weeks.
88854629|NCT01538628|Experimental|SpaceOAR|Men meeting the study eligibility criteria will be scheduled for fiducial marker placement using a transperineal approach with ultrasound guidance. Following successful fiducial marker placement, subjects will be randomized (2:1) to the treatment group or control group. Subjects randomized to the treatment group will undergo placement of 10 mL of SpaceOAR hydrogel
88854630|NCT01538628|No Intervention|Control|Men meeting the study eligibility criteria will be scheduled for fiducial marker placement using a transperineal approach with ultrasound guidance. Following successful fiducial marker placement, subjects will be randomized (2:1) to the treatment group or control group. Subjects randomized to the control group will not receive injection of the SpaceOAR hydrogel.
88854631|NCT01538472|Experimental|Y Zevalin + BEAM|"Rituxan 250 mg/m2 preceding imaging dose of 111In Zevalin (5 mCi); additional infusion 250 mg/m2 Rituxan followed by therapeutic dose of 0.4 mCi/kg 90Y Zevalin received one week after Rituxan/111In Zevalin infusions. One week later, chemotherapy received with BCNU (300 mg/m2, intravenously (IV) day -6) VP-16 (200 mg/m2 IV every 12 hours, days -5 to -2) cytarabine (200 mg/m2 IV every 12 hours, days -5 to -2) and melphalan (140 mg/m2 IV day -1). Autologous stem cell infused on day 0 then Rituximab 1000 mg/m2 on days +1, and +8 post transplantation.~G-CSF 5 mg/kg given daily starting Day 0 till recovery of granulocytes of 4.0 * 109/L."
88854632|NCT01562028|Experimental|Erlotinib plus bevacizumab|Patients will be treated with erlotinib and bevacizumab. Bevacizumab: 15 mg/kg i.v. on day 1 of each 3-week cycle (+/- 3 days) Erlotinib: 150 mg p.o., daily
88854633|NCT03028662|Experimental|Immediate exposure|Exposure to video on alcohol (update phase) followed (10 minutes) by the task of approach-avoidance of alcohol (extinction phase) (Retrieval-Extinction Learning), during 4 days of training.
88854634|NCT03028662|Active Comparator|Delayed exposure|Exposure to a video of alcohol consumption (update phase) followed (6 hours) by the task of approach-avoidance of alcohol (extinction phase) (Retrieval-Extinction Learning), during 4 days of training.
88854635|NCT03028662|Active Comparator|No exposure|Exposure to a video of neutral situations (update phase) followed (10 minutes) by the task of approach-avoidance of alcohol (extinction phase) (Retrieval-Extinction Learning), during 4 days of training.
88854636|NCT04767828|Experimental|One arm exploratory research|Brain radiation therapy: the dose and frequency of brain radiation therapy are determined by the doctor according to the patient's condition. Pyrrotini: 400 mg once a day, oral within 30 minutes after breakfast for 21 days. Cassitabine: twice a day, 800 mg / m2 orally within 30 minutes after each meal (one morning and one night, 12 hours apart, equivalent to a daily dose of 1600 mg / m2, one dose in the morning and one dose in the morning)
88854637|NCT01585584|Experimental|Boceprevir|
88854638|NCT01561560|Other|DAILIES TOTAL1, then TRUEYE|Delefilcon A contact lenses worn first, followed by narafilcon A contact lenses. Each product was worn bilaterally on a daily wear, daily disposable basis for two weeks.
88854639|NCT01561560|Other|TRUEYE, then DAILIES TOTAL1|Narafilcon A contact lenses worn first, followed by delefilcon A contact lenses. Each product was worn bilaterally on a daily wear, daily disposable basis for two weeks.
88854640|NCT01537068|Experimental|Desvenlafaxine|Serotonin-norepinephrine reuptake inhibitors (SNRIs) antidepressant drug
89183359|NCT04943562||Participants with sleep disorders|one sleep disorder or complaint. Among these, at least 30% of the sample should have moderate to severe insomnia (as measured by the insomnia severity index), 30% should have high risk to sleep apnea (as measured by the STOP-BANG questionnaire) and 70% should have excessive sleepiness scale (as measured by the Epworth sleepiness scale).
88854641|NCT01537068|Placebo Comparator|Placebo|Placebo treatment
88854642|NCT01585428|Experimental|Cervical|Patients will receive a non-myeloablative lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous (IV) infusion of Young tumor infiltrating lymphocytes (TIL) plus high dose IV aldesleukin.
88854643|NCT01585428|Experimental|NonCervical|Patients will receive a non-myeloablative lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous (IV) infusion of Young tumor infiltrating lymphocytes (TIL) plus high dose IV aldesleukin
88854644|NCT01585272|Experimental|Rivastigmine|Eligible patients, who are under rivastigmine capsule 3 mg b.i.d. treatment for 4 weeks before Visit 2, will be recruited, followed by treatment switch from oral capsule to transdermal patch for 48 weeks maintenance treatment.
88854645|NCT03028116|Active Comparator|Allantoic split inactivated seasonal influenza vaccine|Allantoic split inactivated seasonal influenza vaccine
88854646|NCT03028116|Placebo Comparator|Placebo|Water for Injection
88854647|NCT01560780|Experimental|Arm 1: Prasugrel|prasugrel 10 mg by mouth daily
88854648|NCT01560780|Placebo Comparator|Arm 2: Placebo|placebo by mouth once daily
88854649|NCT01585038|Active Comparator|Efavirenz|Efavirenz 600mg given nightly without food for 30 days
88854650|NCT01585038|Active Comparator|Rilpivirine|Rilpivirine 25mg given daily with meals for 30 days
88854651|NCT01560234|Experimental|AZD8848|
88854652|NCT01560234|Placebo Comparator|Placebo|
88854653|NCT04124328|Active Comparator|ALINE only group|Patients in this arm are scheduled for an extended AF ablation, including the mitral isthmus line, according to the ALINE criteria
88854654|NCT04124328|Active Comparator|VoM group|Patients in this arm are scheduled for an extended AF ablation, including the mitral isthmus line, according to the ALINE criteria and vein of Marshall (VoM) ethanol infusion
88854655|NCT01559844|Experimental|SOF+RBV|Sofosbuvir plus ribavirin for up to 48 weeks or until time of transplant, whichever occurs first.
88854656|NCT01584648|Experimental|Dabrafenib + Trametinib|Dabrafenib and Trametinib combination
88854657|NCT01584648|Active Comparator|Dabrafenib + Placebo|Dabrafenib and Trametinib placebo
88854658|NCT01559454|Active Comparator|Methadone|10-60 mg/day divided by 2-4 times a day
88854659|NCT01559454|Experimental|Buprenorphine/naloxone|4-16 mg/day divided by 2-4 times a day
88854660|NCT03028584||Clinicians|"Observe up to N=10 clinicians. Observations will include:~Oncology history and care plan development by clinicians including use of EHR technology to develop care plans and methods used to secure necessary information for care plan creation~Provision and coordination of survivorship care occurring during care team meetings, discussions among clinicians, and survivor visits with clinicians, especially visits in which a care plan is provided to a survivor~Clinician seeking survivorship related information or resources through use of technology or discussion with other clinicians~Survivorship work or tasks performed by the clinician including adding, modifying or extracting information from the EHR and adding or modifying information in the care plan"
88854661|NCT03028584||Clinicians and Patients|"Surveys of N=30 breast cancer, colon cancer, and prostate cancer patients. Subjects will complete 1st survey electronically in-clinic. Subjects will either be e-mailed or mailed a survey at 4 weeks.~Survey of clinicians will be sent via e-mail."
88854662|NCT01584024|Active Comparator|Resin infiltration|Resin infiltration of early caries lesion in addition to preventative measures (oral hygiene, diet counseling, repeated fluoride varnish application)
88854663|NCT01584024|Sham Comparator|Control|Sham treatment of early caries lesion in addition to preventative measures (oral hygiene, diet counseling, repeated fluoride varnish application)
88854664|NCT01583166|Active Comparator|Bupivacaine + epinephrine|
88854665|NCT01583166|Placebo Comparator|Saline + epinephrine|
88854666|NCT01535274|Experimental|Desflurane|Patients will receive general anesthesia with desflurane. Both arms have rSO2 measured and undergo identical changes in ventilation strategy.
88854667|NCT01535274|Experimental|Propofol|Patients will receive total intravenous general anesthesia (TIVA) with propofol. Both have rSO2 measured and undergo identical changes in ventilation strategy.
88854668|NCT01558752|Experimental|Titanium Shell with CORAIL stem|Patients in Group 1 will receive a total hip replacement with titanium shell and CORAIL stem.
88854669|NCT01558752|Active Comparator|Modular Titanium Femoral Stem (Tri-Lock)|Patients in Group 2 will receive a total hip replacement with Modular Titanium Femoral Stem (Tri-lock).
88854670|NCT01582854|Active Comparator|Actovegin|Actovegin 2000 mg solution, intravenous (IV) infusion for up to 20 days followed by 2 actovegin 200 mg, tablets, orally, 3 times a day for up to 6 months.
88854671|NCT01582854|Placebo Comparator|Placebo|Actovegin placebo-matching solution, intravenous (IV) infusion for up to 20 days followed by 2 actovegin placebo-matching, tablets, orally, 3 times a day for up to 6 months.
88854672|NCT03884400||Subjects who have provided consent for specimen collection|Re-consent will not be required. This protocol allows distribution of the specimens following the terms agreed to by the subject in the original consent.
88854673|NCT04102644||Pregnant Women|Up to 15,000 pregnant women and their fetuses/newborns (including a pilot phase of up to 500 participant pairs)
88854674|NCT01582308|Experimental|Treatment Sequence 1|Sitagliptin 100 mg in Period 1 followed by saxagliptin 5 mg in Period 2 followed by vildagliptin 50 mg BID in Period 3 followed by placebo in Period 4 followed by vildagliptin 50 mg in Period 5
88854675|NCT01582308|Experimental|Treatment Sequence 2|Saxagliptin 5 mg in Period 1 followed by vildagliptin 50 mg in Period 2 followed by placebo in Period 3 followed by sitagliptin 100 mg in Period 4 followed by vildagliptin 50 mg BID in Period 5
88854676|NCT01582308|Experimental|Treatment Sequence 3|Vildagliptin 50 mg in Period 1 followed by vildagliptin 50 mg BID in Period 2 followed by sitagliptin 100 mg in Period 3 followed by saxagliptin 5 mg in Period 4 followed by placebo in Period 5
89381867|NCT03310775|Experimental|case group|Behavioral: parent-assisted social skills training program for young adults with autism spectrum disorder The subjects will participate in the treatment program weekly for a total of 14 weeks. The final visit will be made at the point three months after the completion of treatment to see mid- and long-term effects.
89381868|NCT03310775|Experimental|waitlist control group|"For this group, same intervention with the Experimental group will be provided after waiting for 16 weeks.~Behavioral: Delayed intervention Intervention is provided to Waitlist Control Group after waiting for 16 weeks"
89381869|NCT03619434|Active Comparator|Conventional keratoplasty group (Control)|This group will undergo conventional penetrating keratoplasty with a trephine blade.
89381870|NCT03619434|Experimental|Femtolaser group|This group will undergo femtosecond laser-assisted penetrating keratoplasty.
89381871|NCT05250102|Other|Pulse oximeter sensor readings|Subjects who satisfy all of the inclusion criteria will be eligible to participate in the study, will receive intervention (the Masimo and Nellcor sensors, and their arterial blood sample will be taken in the normal course of care). This is a single arm study. Those who don't meet the inclusion/ exclusion criteria won't be eligible to participate.
89381872|NCT05275595||chronic renal disease with covid|all patients who have chronic kidney disease with COVID-19 infection
88854677|NCT01582308|Experimental|Treatment Sequence 4|Vildagliptin 50 mg BID in Period 1 followed by placebo in Period 2 followed by saxagliptin 5 mg in Period 3 followed by vildagliptin 50 mg in Period 4 followed by sitagliptin 100 mg in Period 5
89381873|NCT05275595||chronic renal disease without covid|all patients who have chronic kidney disease without COVID-19 infection
89381874|NCT04582799|Active Comparator|Standard of Care (NIV)|Patients in the control group will be treated with non-invasive ventilation only.
89381875|NCT04582799|Experimental|Extracorporeal CO2 Removal (NIV+ECCO2R)|Patients in the treatment group will be treated with non-invasive ventilation combined with Extracorporeal CO2 Removal.
89381876|NCT05248308|Experimental|Genicular artery embolization|Study participants will undergo genicular artery embolization (GAE) for treatment of chronic moderate to severe pain following knee arthroplasty or revision arthroplasty. Embolization will be performed using Embozene Microspheres.
89381877|NCT04236245|Other|Venclose RF System|Treatment of great saphenous vein (GSV) using Venclose RF System
89381878|NCT03330119|Experimental|Alternate Management|
89381879|NCT03330119|Placebo Comparator|Control|The regular Lankenau cesarean section order set.
89381880|NCT04019405||Frailty status|Frailty status will be determined by prespecified assessment tools in the study protocol. These assessment tools will be Fried Frailty phenotype model and edmonton frailty Scale.
89381881|NCT05123274|Active Comparator|Individual Care Counseling|After completing the baseline survey, each participant will receive a 20-minute individual counseling session focused on HIV medical care. The session will convey that effective HIV treatment is now available at no cost, protects health, and that most individuals who are in treatment can lead long and healthy lives. Referral will be made and assistance provided in accessing LGBT-friendly HIV medical care, mental health, substance abuse, and other services.
88854678|NCT01582308|Experimental|Treatment Sequence 5|Placebo in Period 1 followed by sitagliptin 100 mg in Period 2 followed by vildagliptin 50 mg in Period 3 followed by vildagliptin 50 mg BID in Period 4 followed by saxagliptin 5 mg in Period 5
88854679|NCT01582308|Experimental|Treatment Sequence 6|Sitagliptin 100 mg in Period 1 followed by vildagliptin 50 mg in Period 2 followed by saxagliptin 5 mg in Period 3 followed by placebo in Period 4 followed by vildagliptin 50 mg BID in Period 5
88854680|NCT01582308|Experimental|Treatment Sequence 7|Saxagliptin 5 mg in Period 1 followed by vildagliptin 50 mg BID in Period 2 followed by vildagliptin 50 mg in Period 3 followed by sitagliptin 100 mg in Period 4 followed by placebo in Period 5
88854681|NCT01582308|Experimental|Treatment Sequence 8|Vildagliptin 50 mg in Period 1 followed by placebo in Period 2 followed by vildagliptin 50 mg BID in Period 3 followed by saxagliptin 5 mg in Period 4 followed by sitagliptin 100 mg in Period 5
89381882|NCT05123274|Experimental|Social Support Mobilization|In addition to the post-baseline 20-minute individual counseling session, each participant in this arm will attend five main intervention sessions and two booster sessions that have three inter-related objectives: (1) ensuring that participants understand that viral suppression through ART maintains health and protects others; (2) increasing resilience and feelings of self-worth; and (3) guiding participants in identifying, accessing, and mobilizing social resources for both general psychosocial support and also specific supports for HIV care. For individuals who have potential supports in their social environment, the intervention will seek to mobilize or increase the frequency and quality of interactions with them. For participants who are presently socially isolated or whose social resources are not supportive of HIV care, the intervention will help to build new social ties with potentially supportive life figures.
88854682|NCT01582308|Experimental|Treatment Sequence 9|Vildagliptin 50 mg BID in Period 1 followed by sitagliptin 100 mg in Period 2 followed by placebo in Period 3 followed by vildagliptin 50 mg in Period 4 followed by saxagliptin 5 mg in Period 5
88854683|NCT01582308|Experimental|Treatment Sequence 10|Placebo in Period 1 followed by saxagliptin 5 mg in Period 2 followed by sitagliptin 100 mg in Period 3 followed by vildagliptin 50 mg BID in Period 4 followed by vildagliptin 50 mg in Period 5
88854684|NCT01558674|Experimental|MK-7145 8 mg (Part I:Period 1)|Single daily dose of 8 mg MK-7145 for 5 days, capsules, orally administered in a fasted state
88854685|NCT01558674|Active Comparator|Furosemide 40 mg (Part I:Period 2)|Two daily doses of one 40 mg Furosemide tablet for 5 days administered in a fasted state
88854686|NCT01558674|Experimental|MK-7145 16 mg (Part I:Period 3)|Single daily dose of 16 mg MK-7145 for 5 days, capsules, orally administered in a fasted state
88854687|NCT01558674|Active Comparator|Furosemide/Torsemide Run-in (Part II:Period1)|Run-in of stable, clinically optimized maintenance dose regimen of furosemide or torsemide for at least 2 weeks
88854688|NCT01558674|Experimental|MK-7145 10 mg (Part II:Period 2)|Single daily dose of 10 mg MK-7145 for 14 days, capsules, orally administered in a fasted state
88854689|NCT01558674|Experimental|MK-7145 16 mg (Part II:Period 3)|Single daily dose of 16 mg MK-7145 for 14 days, capsules, orally administered in a fasted state
88854690|NCT01558674|Experimental|MK-7145 24 mg (Part II:Period 4)|Single dose of 24 mg MK-7145 for 28 days, capsules, orally administered in a fasted state
88854691|NCT01558596|Placebo Comparator|Sham|Blood pressure cuff inflated to 40-50 mmHg in the upper extremity
88854692|NCT01558596|Experimental|RIPC|Blood pressure cuff inflated to 200 mmHg in the upper extremity for 5 minutes to cause forearm ischemia by external compression of the brachial artery. This will be followed by 5 minutes of cuff deflation to allow for preperfusion. The ischemia-reperfusion cycle will be repeated 3 times for a total duration of 30 minutes, equally divided between ischemia and reperfusion.
88854693|NCT01535040|Active Comparator|Arm I - Memantine|Participants receive memantine hydrochloride PO BID) on days 1-81 in the absence of unacceptable toxicity.
88854694|NCT01535040|Placebo Comparator|Arm II - Placebo|Participants receive a placebo PO BID on days 1-81 in the absence of unacceptable toxicity.
88854695|NCT04410510|Placebo Comparator|Control group|Lopinavir / ritonavir * Capsules 200/50 mg 400/100 mg every 12 hours for 7 to 14 days Hydroxychloroquine * Tab 200 mg Tab Load 400 mg every 12 hours the first day, follow 200 mg every 12 hours for 10 days Placebo capsule equivalent to 250mg of excipient every 12 hours for 14 days
88854696|NCT04410510|Experimental|Intervention group|Lopinavir / ritonavir * Capsules 200/50 mg 400/100 mg every 12 hours for 7 to 14 days Hydroxychloroquine * Tab 200 mg Tab Load 400 mg every 12 hours the first day, follow 200 mg every 12 hours for 10 days P2Et active extract capsule equivalent to 250mg of P2Et every 12 hours for 14 days
88854697|NCT01534962|Experimental|Ranolazine low dose|Ranolazine, low dose, oral, BID
88854698|NCT01534962|Experimental|Ranolazine intermediate dose|Ranolazine, intermediate dose, oral, BID
88854699|NCT01534962|Experimental|Ranolazin high dose|Ranolazine, high dose, oral, BID
88854700|NCT01534962|Placebo Comparator|Placebo|Placebo (sugar pill), oral, BID.
88854701|NCT04758234|Experimental|LY3549492 (Part A)|LY3549492 administered orally as single ascending doses.
88854702|NCT04758234|Experimental|LY3549492 (Part B)|LY3549492 administered orally as multiple ascending doses.
88854703|NCT04758234|Placebo Comparator|Placebo|Placebo administered orally.
88854704|NCT01582152|Experimental|TPI 287 + Bevacizumab|"Part I: Patients assigned to receive 1 of 4 dose levels of TPI 287 based on when joining the study.~Phase I Starting Dose of TPI287 160 mg/m2 given by vein on Day 1 every three weeks of a 42 Day cycle. Bevacizumab given at 10 mg/kg by vein on Day 1 every 2 weeks of a 42 Day cycle.~Phase II Starting Dose of TPI287: Maximum Tolerated Dose (MTD) from Phase I."
88854705|NCT01582152|Experimental|Bevacizumab Group|"Phase II: Participants randomized to Arm A (bevacizumab alone at 10 mg/kg every 2 weeks) versus Arm B (bevacizumab at 10 mg/kg every 2 weeks plus TPI 287.~Participant may enroll in Crossover Group to receive TPI 287 and bevacizumab if disease gets worse at any time during treatment with bevacizumab alone."
88854706|NCT01581684|Experimental|BI 411034 low dose - group 1|Solution for oral administration
88854707|NCT01581684|Experimental|BI 411034 low dose - group 2|Solution for oral administration
88854708|NCT01581684|Experimental|BI 411034 medium dose - group 3|Solution for oral administration
88854709|NCT01581684|Experimental|BI 411034 medium dose - group 4|Solution for oral administration
88854710|NCT01581684|Experimental|BI 411034 medium dose - group 5|Solution for oral administration
88854711|NCT01581684|Experimental|BI 411034 high dose - group 6|Solution for oral administration
88854712|NCT01581684|Experimental|BI 411034 high dose - group 7|Solution for oral administration
88854713|NCT01581684|Experimental|BI 411034 high dose - group 8|Solution for oral administration
88854714|NCT01581684|Placebo Comparator|Placebo|Solution for oral administration
88854715|NCT01557582|Other|Right ventrical volumn comparison|Single arm study comparing Ventripoint Medical System (VMS) right ventricle volume measurement to gold standard cardiac Magnetic Resonance Imaging (cMRI) measurement in patients with Pulmonary Arterial Hypertension.
88854716|NCT01557504|Experimental|Sitagliptin/metformin XR followed by placebo|Day 1 (Period 1): participants will receive a single dose of two sitagliptin/metformin XR tablets with a low- to moderate-fat meal (breakfast). Days 2-4 (Period 1): participants will receive a single dose of two matching placebo tablets. Days 5-9 (Period 2): participants will receive a single dose of two matching placebo tablets with the evening meal.
88854717|NCT01557504|Placebo Comparator|Placebo only|Days 1-4 (Period 1): participants will receive a single dose of two matching placebo tablets. Days 5-9 (Period 2): participants will receive a single dose of two matching placebo tablets with the evening meal.
88854718|NCT01557348||Rituximab|Eligible participants will receive rituximab as second biologic therapy in routine clinical practice and were observed for 12 months from the start of the second biologic therapy.
88854719|NCT01557348||Alternative TNFi|Eligible participants will receive alternative TNFi treatment as second biologic therapy in routine clinical practice and were observed for 12 months from the start of the second biologic therapy.
88854720|NCT01580670|Experimental|TA-650|"Responder criteria: Case where PCDAI score on the evaluation day was decreased by at least 15 points from that in the screening period and was ≤30.~Criteria for dose-increasing: When either of the following 2 items was satisfied after Week 14, the relevant patient would be considered to satisfy the criteria for dose increasing to 10 mg/kg.~PCDAI score on the evaluation day was increased by at least 15 points compared to the lowest PCDAI score observed at Week 2, 6 or 10~PCDAI score on the evaluation day exceeds 30"
88854721|NCT04748484|Other|KCC active or inactive|The medical device KCC will be active, or inactive. Randomization will define when and how long time the medical device will be active, and when and how long time the medical device will be inactive. The patient won't know if the medical device is active or not. The battery charge indicator will work the same whether the device is operating or not.
88854722|NCT01534260|Experimental|sorafenib, vorinostat and bortezomib|Escalating cohorts of sorafenib, vorinostat and bortezomib
88854723|NCT01534182|Experimental|Fingolimod|Participants received 0.5 mg orally once a day.
88854724|NCT01534182|Active Comparator|Standard Disease Modifying Therapy (DMT)|Participants received interferon beta-1a (IFN), 44 mcg subcutaneously 3 times a week or glatiramer acetate (GA), 20 mg subcutaneously once a day.
88854725|NCT01579812|Experimental|Metformin|
88854726|NCT01533714|Experimental|CDP6038 (olokizumab)|CDP6038 (olokizumab) 120 mg: subcutaneous injections at q2w (every two weeks). RA0089 is a single arm study, however, analysis will be presented according to the original treatment arms of the parent study NCT01463059 (RA0083).
88854727|NCT01533246|Experimental|Treatment (linsitinib)|Patients receive linsitinib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo serum and plasma sample collection at baseline, on day 1 of courses 2 and 4, and after completion of study treatment for correlative studies.
88854728|NCT01579578|Experimental|1|
88854729|NCT01579578|Placebo Comparator|2|
88854730|NCT01578486|Experimental|salsalate|open-label trial of salsalate 3g/day
88854731|NCT01532934|Experimental|brief therapy|motivational enhancement therapy for substance use
88854732|NCT01532934|Placebo Comparator|Standard Care|standard care
88854733|NCT01555164|Experimental|Ranolazine+metformin|"Qualifying Period: Participants will receive metformin 1000 mg + placebo to match ranolazine twice daily for either 2 or 8 weeks (dependent on metformin dose and HbA1c level at Screening).~Treatment Period: Participants will receive ranolazine 500 mg + metformin 500 mg + placebo to match metformin twice daily on Days 1 through 7, followed by ranolazine 1000 mg + metformin 500 mg + placebo to match metformin twice daily from Day 8 through Week 24.~Participants are required to maintain their diet and exercise regimen."
88854734|NCT01555164|Placebo Comparator|Placebo+metformin|"Qualifying Period: Participants will receive metformin 1000 mg + placebo to match ranolazine twice daily for either 2 or 8 weeks (dependent on metformin dose and HbA1c level at Screening).~Treatment Period: Participants will receive metformin 1000 mg + placebo to match ranolazine twice daily through Week 24.~Participants are required to maintain their diet and exercise regimen."
88854735|NCT03028428|Experimental|Placenta Derived Mesenchymal Stem Cell|Placenta Derived Mesenchymal Stem Cell administered into the knee joint once
88854736|NCT03028428|Active Comparator|sodium hyaluronate|Sodium hyaluronate administered into the knee joint once
88854737|NCT01578330|Experimental|Fingolimod, FTY720|Patients received fingolimod 0.5 mg oral capsules daily with or without food.
88854738|NCT01577160|Experimental|Paliperidone Extended Release (ER)|
88854739|NCT01554618|Experimental|EQW|Exenatide once weekly
88854740|NCT01554618|Placebo Comparator|Placebo|Placebo once weekly
88854741|NCT04108728|Experimental|HIV exposed children during pregnancy|children born from HIV-infected mother, exposed to antiretroviral drugs during pregnancy and in the neonatal period; aged 3 years-old +/- 3 months on the date of inclusion. Parents mastering french language
88854742|NCT04108728|Other|control children|children, aged 3 years +/- 3 months on the date of inclusion, from the same socio-economic and cultural environment, not infected or affected by HIV. Parents mastering French language.
89381883|NCT03040986|Experimental|Treatment (selumetinib sulfate)|Patients receive selumetinib sulfate by mouth (PO) twice daily (BID). Treatment repeats every 28 days for up to 27 courses in the absence of disease progression or unacceptable toxicity
88854743|NCT01531998|Experimental|Siltuximab + Bortezomib + Lenalidomide|"Induction: Lenalidomide 25 mg orally Days 1-14; Bortezomib 1.3 mg/m2 intravenous Days 1, 4, 8 and 11; Dexamethasone 20 mg orally Days 1, 2, 4, 5, 8, 9, 11, 12. Siltuximab 11 mg/kg intravenous Day 1.~If delayed transplant, induction therapy continued up to 2 cycles beyond achieving a CR/nCR (minimum of 4 cycles of therapy and a maximum of 8 cycles of therapy) and then transition to maintenance regimen described below.~Maintenance therapy: Lenalidomide at last tolerated dose Day 1-21 every 28 days for up to 12 months and then may be reduced to 10 mg.~Siltuximab 11 mg/kg intravenous every 21 days, or maximum tolerated dose from induction therapy. Bortezomib at last tolerated dose Day 1 and Day 8 Dexamethasone at last tolerated dose or 20 mg weekly."
88854744|NCT01576146|Experimental|Etelcalcetide|Participants received a bolus IV injection of etelcalcetide 3 times a week (TIW) at the end of each hemodialysis session for up to 144 weeks in the extension study. The starting dose was the same as the final dose administered in the parent study (20120331); the dose was adjusted per protocol-specified guidelines to achieve or maintain parathyroid hormone values in the 150 to 300 pg/mL range.
88854745|NCT01553916|Experimental|Arm 1: Lithium carbonate + prophylactic cranial irradiation|"Lithium carbonate 300 mg PO BID for 7 days prior to the start of prophylactic cranial irradiation (PCI) and will be continued during PCI.~PCI will be given at 2.5 Gy per fraction, 5 days per week, for 2 weeks to a total dose of 25 Gy, starting on Day 8 after 7 days of lithium."
88854746|NCT01553136|Placebo Comparator|Sugar pill|
88854747|NCT01553136|Active Comparator|Varenicline|
88854748|NCT04836468|Experimental|Experimental group|Application of Magnetic Tape transversely over the vertebral levels of L4 and L5
88854749|NCT04836468|Placebo Comparator|Placebo group|Application of kinesiology tape transversely over the vertebral levels of L4 and L5
88854750|NCT01552902|Experimental|Lisdexamfetamine dimesylate|
88854751|NCT01552902|Active Comparator|Methylphenidate Hydrochloride|
88854752|NCT01552902|Placebo Comparator|Placebo|
88854753|NCT03923790|Experimental|STOP model|Pharmacist evaluates patient prior to discharge and a nurse navigator contacts patient 72 hours after discharge. Patient receives educational packet and a blue tooth enabled BP monitor with an iPad. A video telehealth visit occurs 7 days after discharge attended by a nurse practitioner (NP) or MD , social worker (SW), and pharmacist. The NP and pharmacist review the BP data to determine the need for medication adjustment. The SW assesses the need for resources. BP is reviewed via an online portal every 2 weeks until average BP is < 130/80mmHg, then monthly. Uncontrolled BP prompts a call from the pharmacist to discuss medication adherence and titration. Subsequent video telehealth visits occur 1 month, 3 months, and 5 months after enrollment.
88854754|NCT03923790|Active Comparator|Usual Care|Pharmacist evaluates patient prior to discharge and a nurse navigator contacts patient 72 hours after discharge. Patient receives educational packet.
88854755|NCT04102254|Experimental|ANT recording and stimulation|Up to 15 adult patients who present to Duke Neurosurgery for routine seizure location using sEEG will be asked to enroll in this pilot study of ANT recording and stimulation. Once enrolled in the trial, subjects will have additional placement of two thalamic electrodes during the course of standard sEEG placement surgery. Patients routinely remain hospitalized for 7-14 days after sEEG placement, during which time their seizure medications are tapered. Continuous neural recordings are made through the sEEG electrodes for the purposes of seizure localization during the entire time the depth electrodes are in place. Up to three times daily, standard intermittent high-frequency stimulation [130 Hertz (Hz), 90-millisecond pulse width, and 2 milliamps (mA) intensity] will be performed with a 60-seconds on and a 300-seconds off cycle following surgery up to the entire length of sEEG monitoring.
88854756|NCT02072928||BOTOX®|Patients with incontinence from NDO due to spinal injury or MS prescribed BOTOX® (Botulinum toxin Type A) as standard of care in clinical practice.
88854757|NCT01529346|Experimental|PF-05089771 1600 mg|
88854758|NCT01529346|Experimental|PF-05089771 450 mg|
88854759|NCT01529346|Experimental|PF-05089771 150 mg|
88854760|NCT01529346|Active Comparator|Ibuprofen 400 mg|
88854761|NCT01529346|Placebo Comparator|Placebo|
88854762|NCT02073162|Active Comparator|Liberal group|At induction-Hartmanns 10 ml/kg During surgery-Hartmanns 8 ml/kg/h After surgery-IV fluids ≥1.5 ml/kg/h Continue IV fluids ≥24hrs
88854763|NCT02073162|Experimental|Restrictive group|At induction-Hartmanns ≤5 ml/kg During surgery-Hartmanns 5 ml/kg/h After surgery-IV fluids, ≤0.8 ml/kg/h Cease IV fluids ASAP,aim for early oral fluids
88854764|NCT01529268|Active Comparator|DR cysteamine bitartrate capsule|Active DR cysteamine bitartrate capsule
88854765|NCT01529268|Placebo Comparator|DR cysteamine bitartrate placebo|Placebo DR cysteamine bitartrate capsule
88854766|NCT01529112|Experimental|Lenvatinib|Participants received lenvatinib 24 mg orally, once daily continuously in each 28-day treatment cycle plus Best Supportive Care (BSC)
88854767|NCT01529112|Placebo Comparator|Lenvatinib matched placebo|Participants received lenvatinib matched placebo orally, once daily continuously in each 28-day treatment cycle plus BSC
88854768|NCT01551420|Active Comparator|Advanced upper limb prosthetic device IMU controlled|Subjects with upper limb amputation who are trained to use a DEKA Arm with IMU controls
88854769|NCT01551420|Active Comparator|Advanced upper limb prosthetic EMG-PR controlled|Subjects with TR or TH upper limb amputation who are trained to use a DEKA Arm with EMG-PR Controls
88854770|NCT01575054|Experimental|botulinum toxin Type A|Double-Blind Study Phase (12 weeks): On Day 1, botulinum toxin Type A 300 U will be given by intramuscular injections into specified muscles of the lower limb, and an optional dose of 100 U may be injected into additional lower limb muscles. Open Label Study Phase: Up to 3 treatments with botulinum toxin Type A up to 400 U will be given by intramuscular injections to the lower limb approximately every 12 weeks over a 42 week period.
88854771|NCT01575054|Other|Normal Saline (Placebo) Followed by botulinum toxin Type A|Double-Blind Study Phase (12 weeks): On Day 1, normal saline (placebo) will be given by intramuscular injections into specified muscles of the lower limb, and optional injections may be administered into additional lower limb muscles. Open Label Study Phase: Up to 3 treatments with botulinum toxin Type A up to 400 U will be given by intramuscular injections to the lower limb approximately every 12 weeks over a 42 week period.
88854772|NCT04748328||ACL Reconstruction Group|This group received reconstruction treatment in Gatot Subroto Hospital, Jakarta
88854773|NCT04748328||Rehabilitation Group|This group received rehabilitation treatment with optional delayed reconstruction in Arifin Achmad Hospital, Pekanbaru
88854774|NCT01528254|Active Comparator|Vilda 50mg bid + metformin|Metformin + vildagliptin
88854775|NCT01528254|Experimental|Placebo + metformin|Metformin + Placebo of vildagliptin
88854776|NCT01574352|Experimental|Intervention camp|Children's behavior are controlled each week day for six weeks, and children participate in three hours of physical activity every day
88854777|NCT01574352|Experimental|Small intervention|Children are only informed of healthy behavior
88854778|NCT01527006|Experimental|perampanel|Age Cohort 1 ( greater than or equal to 7 to less than 12 years of age at time of consent/assent) and age Cohort 2 ( greater than or equal to 2 to less than 7 years of age).
88854779|NCT01526928|Experimental|Rociletinib <900 mg BID FB formulation|Rociletinib free base (FB) dose <900 mg twice a day (BID)
88854780|NCT01526928|Experimental|Rociletinib 900 mg BID FB formulation|Rociletinib free base (FB) dose 900 mg twice a day (BID)
88854781|NCT01526928|Experimental|Rociletinib 500 mg BID HBr formulation|Rociletinib hydrobromide (HBr) dose 500 mg twice a day (BID)
88854782|NCT01526928|Experimental|Rociletinib 625 mg BID HBr formulation|Rociletinib hydrobromide (HBr) dose 625 mg twice a day (BID)
88854783|NCT01526928|Experimental|Rociletinib 750 mg BID HBr formulation|Rociletinib hydrobromide (HBr) dose 750 mg twice a day (BID)
88854784|NCT01526928|Experimental|Rociletinib 1000 mg BID HBr formulation|Rociletinib hydrobromide (HBr) dose 1000 mg twice a day (BID)
88854785|NCT01549860|No Intervention|Standard of Care|30 to 40 mmHg compression, dressing for moist wound healing environment, debridement as needed. Minimum of one treatment per week and up to 3 times per week per investigator discretion for 4 weeks
88854786|NCT01549860|Experimental|SOC + Mist Therapy|30 to 40 mmHg compression, dressing for moist wound healing environment, debridement as needed plus non-contract low frequency ultrasound 3 x per week for 4 weeks.
88854787|NCT01549392|Active Comparator|DECT/MR Spectroscopy +Avastin|-15 Glioma Patients with progression will undergo DECT and MRS before Avastin (10 mg/kg iv q2 weeks until progression) and 3 months later
88854788|NCT01549392|Active Comparator|DECT/MR Spectroscopy no Avastin|15 glioma patients not receiving Avastin for recurrence studied in the same manner as Arm 1
88854789|NCT01526148|Active Comparator|Lithium|
88854790|NCT01526148|Active Comparator|Quetiapine|
88854791|NCT01572948|Placebo Comparator|Placebo|The placebo (Forest Laboratories, Inc) is manufactured as an odorless and otherwise equivalent tablet to the roflumilast tablet, but contains no active ingredient.
88854792|NCT01572948|Active Comparator|Daliresp|The study drug (roflumilast, Daliresp™, Forest Laboratories, Inc.) is a targeted inhibitor of phosphodiesterase 4 and is given once daily via oral route. There is proven anti-inflammatory and anti-oxidant potential in both animal and human models
88854793|NCT01525602|Experimental|Part 1|"Open-label, sequential PLX3397 single-agent dose escalation in combination with paclitaxel in approximately 30 patients with advanced solid tumors. Enrollment completed.~(Closed to recruitment)"
88854794|NCT01525602|Experimental|Part 2|"Extension cohort at the RP2D of single-agent PLX3397 in combination with paclitaxel in approximately 30 patients in advanced solid tumors. Enrollment completed.~(Closed to recruitment)"
88854795|NCT01525602|Experimental|Part 3|"Extension cohort at the RP2D of single-agent PLX3397 in combination with paclitaxel in approximately 30 patients with advanced, metastatic, or non-resectable, platinum-resistant or -refractory epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.~(Closed to recruitment)"
88854796|NCT04749966||Emergency services staff|Emergency Services staff recruited from the Ambulance, Police, and Fire and Rescue Services.
88854797|NCT01549002|Experimental|Intranasal Fentanyl|"Patients in this arm will receive intranasal Fentanyl (50 micrograms/mL) as their pre-I&D analgesic. The one time total dose to be used is 2 micrograms / kilogram, to a maximum of 100 micrograms. The medication will be delivered intranasally via an atomizer in 4 equally divided aliquots (2 per nare).~The abscess I&D will be followed according to protocol using topical and local anesthetic."
88854798|NCT01549002|Active Comparator|Intravenous Morphine|"Patients in this arm will receive intravenous morphine as their pre-I&D analgesic. The one time total dose to be used is 0.1 milligrams / kilogram, to a maximum of 8 milligrams. The medication will be delivered via slow IV push.~The abscess I&D will be followed according to protocol using topical and local anesthetic."
88854799|NCT01548768|Experimental|Patients - DMARDs + TNF Inhibitors|Patients will receive a TNF inhibitor in addition to their current treatment in an open label protocol for increased disease activity and in the context of standard of care.
88854800|NCT01548768|Active Comparator|Patients - DMARDs only|Patients will receive their current treatment in an open label protocol in the context of standard of care.
88854801|NCT01548768|No Intervention|Healthy Volunteers|Subjects without RA who will function as controls.
88854802|NCT01572792|Experimental|1|Aclidinium bromide/formoterol Fixed-Dose Combination (FDC) high dose
88854803|NCT01572792|Experimental|2|Aclidinium bromide/formoterol Fixed-Dose Combination (FDC) low dose
88854804|NCT01572792|Active Comparator|3|Aclidinium bromide 400 μg
88854805|NCT01572792|Active Comparator|4|Formoterol Fumarate 12 μg
88854806|NCT01572792|Placebo Comparator|5|Placebo
88854807|NCT03028272|Active Comparator|Fascia|Autologous donor substrate
88854808|NCT03028272|Experimental|Skye Barrier|Amniotic membrane allograft
88854809|NCT01547598|Active Comparator|LUMIGAN® RC|Travatan® Z (travoprost ophthalmic solution 0.004%) administered as 1 drop in the affected eye(s) once a day for 4 weeks. Then, LUMIGAN® RC (bimatoprost ophthalmic solution 0.01%) administered as 1 drop in the affected eye(s) once daily in the evening for 12 weeks.
88854810|NCT01547598|Active Comparator|DuoTrav®|Travatan® Z (travoprost ophthalmic solution 0.004%) administered as 1 drop in the affected eye(s) once a day for 4 weeks. Then, DuoTrav® (travoprost 0.004% / timolol 0.5% combination ophthalmic solution) administered as 1 drop in the affected eye(s) once daily in the morning for 12 weeks.
88854811|NCT01547286|Experimental|Allergic asthmatic|
88854812|NCT01547130|Active Comparator|BLS and Yoga exercise|Patients will take a bolus intake of 8 oz. (240mL) to 16 oz. (480mL) of lukewarm saline water and perform yoga poses.
88854813|NCT01547130|Active Comparator|PEG (HalfLytely)|Patients followed the preparation method according to the manufacturer's standard instructions.
88854814|NCT01524978|Experimental|Cohort 1: Non-Small Cell Lung Cancer (NSCLC) - vemurafenib|Participants with NSCLC will be treated with vemurafenib monotherapy.
88854815|NCT01524978|Experimental|Cohort 2: Ovarian Cancer - vemurafenib|Participants with ovarian cancer will be treated with vemurafenib monotherapy.
88854816|NCT01524978|Experimental|Cohort 3a: Colorectal Cancer - vemurafenib|Participants with colorectal cancer will be treated with vemurafenib monotherapy.
88854817|NCT01524978|Experimental|Cohort 3b: Colorectal Cancer - vemurafenib + cetuximab|Participants with colorectal cancer will be treated with vemurafenib and cetuximab combination therapy.
88854818|NCT01524978|Experimental|Cohort 4: Cholangiocarcinoma - vemurafenib|Participants with cholangiocarcinoma will be treated with vemurafenib monotherapy.
88854819|NCT01524978|Experimental|Cohort 6: Multiple Myeloma - vemurafenib|Participants with multiple myeloma will be treated with vemurafenib monotherapy.
88854820|NCT01524978|Experimental|Cohort 7: Other Solid Tumors - vemurafenib|Participants with Erdheim-Chester disease (ECD), Langerhans cell histiocytosis (LCH), anaplastic thyroid cancer, advanced stage astrocytoma, early stage astrocytoma and other BRAF V600-positive tumors will be treated with vemurafenib monotherapy. Subcohorts will be analyzed separately if 7 or more participants are enrolled for each indication.
88854821|NCT01524900||nevirapine extended release|
88854822|NCT04410276||Patients with enterococcal bloodstream infections|Adult patients (≥ 18 years of age) with ≥ 1 positive blood cultures with Enterococcus during hospitalization and who have repeat blood culture(s) within 7 days from the first positive culture will be included.
88854823|NCT04410120||Asthma with recent (<4/52) asthma attack|
88854824|NCT01524198|Placebo Comparator|Normal Saline|Subjects who are receiving normal saline (NS) in addition to Albuterol 2.5 mg if < 20 kg or 5 mg if >= 20 kg body weight and ipratropium bromide (IB) 250 mcg; 3 nebulizations back to back
88854825|NCT01524198|Active Comparator|Budesonide|Subjects with acute asthma exacerbation who receive Budesonide 500 mcg, in addition to Albuterol 2.5 mg if < 20 kg body weight or 5 mg if >= 20 kg body weight and Ipratropium Bromine (IB) 250 mcg; 3 nebulization doses back to back
88854826|NCT01523886|Active Comparator|Deep neuromuscular blockade|
88854827|NCT01523886|Placebo Comparator|Moderate neuromuscular blockade|
88854828|NCT01546038|Experimental|Arm A (Phase 1B)|PF-04449913 in combination with low dose ARA-C (LDAC)
88854829|NCT01546038|Experimental|Arm B (Phase 1B)|PF-04449913 in combination with Decitabine
88854830|NCT01546038|Experimental|Arm C (Phase 1B)|PF-04449913 in combination with intensive chemotherapy: PF-04449913 administered continuously for 28 days. Daunorubicin given using 60 mg/m2 for 3-days together with cytarabine 100 mg/m2 on days 1 through 7 followed by cytarabine 1g/m2 on days 1, 3, and 5 during 2-4 cycles of consolidation therapy.
88854831|NCT01546038|Experimental|P2 Fit (Phase 2 Single Arm)|PF-04449913 in combination with intensive chemotherapy: PF-04449913 administered continuously for 28 days. Daunorubicin given using 60 mg/m2 for 3-days together with cytarabine 100 mg/m2 on days 1 through 7 followed by cytarabine 1g/m2 on days 1, 3, and 5 during 2-4 cycles of consolidation therapy.
88854832|NCT01546038|Other|P2 Unfit (Phase 2 Randomized)|Patients will be randomized 2:1 (low dose ARA-C in combination with PF-04449913: low dose ARA-C alone).
88854833|NCT01571232|Active Comparator|Ozurdex|Patients in this group receive Ozurdex at initial visit and at month 4
88854834|NCT01571232|Active Comparator|Avastin|Patients in this group receive Avastin Q1 month for 5 months.
88854835|NCT01544478|Experimental|V501|Participants received a 0.5-mL vaccination of V501 by intramuscular injection on Day 1, Month 2, and Month 6
88854836|NCT02985528||TUS positive|Ultrasound detection of pleuro-pulmonary disease and further diagnostic and imaging when needed
88854837|NCT02985528||CXR positive|Radiographic detection of pleuro-pulmonary disease and further diagnostic and imaging when needed
88854838|NCT01522950|Active Comparator|Nebivolol|5 mg, continue for 1 month; dose titration to 10 mg, continue for 8 months. Dose may be returned to initiation levels if side effects occur.
88854839|NCT01522950|Active Comparator|Atenolol|25 mg, continue for 1 month; dose titration to 50 mg, continue for 8 months. Dose may be returned to initiation levels if side effects occur.
88854840|NCT01522950|Placebo Comparator|Placebo|"Continue for 1 month; dose titration to high dose placebo, continue for 8 months. Dose may be returned to initiation levels if side effects occur."
88854841|NCT01522404|Experimental|Atomoxetine / Inactive Compound|Participants in this arm received atomoxetine, starting with 10 mg po daily and increasing weekly by increments to a maximum of 100 mg po daily or the maximum tolerated dose for up to weeks 29 and are then crossed over to Inactive compound group
88854842|NCT01522404|Placebo Comparator|Inactive compound / Atomoxetine|Subjects in this arm received a matching placebo that have inactive compound for up to weeks 29 and then are crossed over to receive active treatment of Atomoxetine
88854843|NCT01570686|Experimental|Aliskiren: Fed|Aliskiren 300 mg once daily, taken 30 minutes after start of light breakfast
88854844|NCT01570686|Experimental|Aliskiren: Fasting|Aliskiren 300 mg once daily taken after after an overnight fast
88854845|NCT01522248|Active Comparator|Cohort 1|receives vaccine in morning. Blood drawn at 3, 7, 24, and 48 hours and 14 days after vaccination.
88854846|NCT01522248|Active Comparator|Cohort 2|receives vaccine in evening, Blood drawn 16, 40 hours and 14 days after vaccination.
88854847|NCT04120584|Experimental|Forma Eye treatment|
88854848|NCT01543776|Active Comparator|Arm I (fasting)|Patients receive abiraterone acetate PO daily first thing in morning after an overnight fast of at least 8 hours.
88854849|NCT01543776|Experimental|Arm II (fed)|Patients receive abiraterone acetate PO daily within 30 minutes of a conventional low-fat breakfast.
88854850|NCT01518192|Active Comparator|1Doxycycline|
88854851|NCT01518192|Active Comparator|2 Cefuroxime axetil|
88854852|NCT04099056|Active Comparator|Participants with Major Depressive Disorder (MDD)|Participants with MDD will complete computer tasks while receiving TMS/ TI
88854853|NCT04099056|Active Comparator|Healthy Control|Participants without MDD will complete computer tasks while receiving TMS/TI
88854854|NCT01517802|Experimental|Abiraterone acetate|Patients will continue the same treatment regimen they were receiving during their participation in the previous abiraterone acetate clinical study.
88854855|NCT04714710|Experimental|Potassium canrenoate|Potassium canrenoate 200mg diluted in SODIUM CHLORIDE SOLUTION 0.9%
88854856|NCT04714710|Placebo Comparator|Placebo (SODIUM CHLORIDE SOLUTION 0.9%)|SODIUM CHLORIDE SOLUTION 0.9%
88854857|NCT01520922|Experimental|Ofatumumab plus bendamustine|In this single arm, Phase II study, each patient who is willing to participate and is found eligible according to the inclusion and exclusion criteria will enter the treatment phase. Eligible subjects will be allocated to receive the following study treatments depending upon their previous CLL treatment status: Subjects with Untreated CLL: Up to 6 monthly intravenous infusions of Ofatumumab (Cycle 1: 300 mg Day 1 and 1000 mg Day 8; subsequent Cycles: 1000 mg at Day 1 every 28 days) in combination with up to 6 Cycles of intravenous infusions of bendamustine (90 mg/m2, Days 1 and 2; every 28 Days). Subjects with Relapsed CLL: Up to 6 monthly intravenous infusions of Ofatumumab (Cycle 1: 300 mg Day 1 and 1000 mg Day 8; subsequent Cycles: 1000 mg at Day 1 every 28 days) in combination with up to 6 Cycles of intravenous infusions of bendamustine (70 mg/m2, Days 1 and 2; every 28 Days).
88854858|NCT01569438|Experimental|Gefapixant|Female participants receive gefapixant, a total dose titrated from 50 mg to highest tolerated dose (maximum of 300 mg) twice daily (BID), orally over a period of 6 days with food depending on safety and tolerability, and then maintain that dose for the course of a 4-week treatment period. Participants were allowed to decrease the dose if tolerability issues occurred.
88854859|NCT01569438|Placebo Comparator|Placebo|Female participants receive dose matched placebo tablets, BID, orally, with food for 4 weeks.
88854860|NCT01517412|Experimental|Lixisenatide Main Meal|"Lixisenatide 10 mcg once daily (QD) within 1 hour before main meal of the day for 2 weeks, then at a maintenance dose of 20 mcg QD up to Week 24."
88854861|NCT01517412|Active Comparator|Lixisenatide Breakfast|"Lixisenatide 10 mcg QD within 1 hour before breakfast for 2 weeks, then at a maintenance dose of 20 mcg QD up to Week 24."
88854862|NCT01517178|Active Comparator|Standard Care base plate|Standard care are the participants own product and can have several manufacture and brand names
88854863|NCT01517178|Experimental|New ostomy base plate (SS)|SS = New ostomy base plate. Due to company confidentiality the product is called SS and this is not short for any name
88854864|NCT01489956|Experimental|Immucothel alone (Part A)|100 µg Immucothel subcutaneously (SQ) on Day 0 and Day 9.
88854865|NCT01489956|Experimental|Immucothel+Montanide (Part A)|If an immune response was not observed in at least nine out of the first 10 participants after receiving Immucothel alone, 10 additional healthy subjects would be recruited and immunized with Immucothel (SQ) plus Montanide (SQ) on Day 0 and Day 9.
88854866|NCT01489956|Experimental|Immucothel alone or Immucothel+Montanide (Part B)|"Dependent on the results for Part A.~Briefly: Ten new, healthy participants were to be fed 50 mg of native keyhole limpet hemocyanin (KLH), a protein extracted from a mollusk (a sea animal), on Days 0 through 4 and Days 10 through 14, for a total dose of 500 mg. The participants were then immunized using the strategy that produced an immune response in at least nine out of 10 participants in Part A (Immucothel alone or Immucothel plus Montanide) on Days 26 and 35."
88854867|NCT03027726|Active Comparator|Control group|Family-based lifestyle education and psycho-educational program
88854868|NCT03027726|Experimental|Exercise group|Supervised exercise plus family-based lifestyle education and psycho-educational program
88854869|NCT01516008|Experimental|Tapentadol IR 50 mg|
88854870|NCT01516008|Experimental|Tapentadol IR 75 mg|
88854871|NCT01516008|Placebo Comparator|Placebo|
88854872|NCT01489254|Experimental|GTR|Drug
88854873|NCT01489254|Active Comparator|Copaxone®|Drug
88854874|NCT01489254|Placebo Comparator|Placebo|Drug
88854875|NCT01489020|Experimental|Group A active|"6 administrations and 5 weeks duration~Vial 2: 0.1 ml, 0.2 ml and 0.5 ml at 1 week intervals~Vial 3: 0.1 ml, 0.2 ml and 0.5 ml at 1 week intervals."
88854876|NCT01489020|Placebo Comparator|Group A placebo|"6 administrations and 5 weeks duration~Vial 2: 0.1 ml, 0.2 ml and 0.5 ml at 1 week intervals~Vial 3: 0.1 ml, 0.2 ml and 0.5 ml at 1 week intervals."
88854877|NCT01489020|Experimental|group B active|"8 administrations and 7 weeks duration~Vial 1: 0.2 ml at 1 week intervals~Vial 2: 0.1 ml, 0.2 ml, 0.4 ml at 1 week intervals~Vial 3: 0.1 ml, 0.2 ml, 0.4 ml and 0.5 ml at 1 week intervals"
88854878|NCT01489020|Placebo Comparator|Group B placebo|"8 administrations and 7 weeks duration~Vial 1: 0.2 ml at 1 week intervals~Vial 2: 0.1 ml, 0.2 ml, 0.4 ml at 1 week intervals~Vial 3: 0.1 ml, 0.2 ml, 0.4 ml and 0.5 ml at 1 week intervals"
88854879|NCT01489020|Experimental|Group C active|"8 administrations, 2 administrations in the same day. 1 week interval between 2 doses, during 3 weeks.~Week 1: vial 2 - 2 administrations of 0.1 ml with 30 minute interval~Week 2: vial 2 - 0.2 ml and 0.3 ml with 30 minute interval~Week 3: vial 3 - 2 doses of 0.1 ml with 30 minute interval~Week 4: vial 3 - 0.2 ml and 0.3 ml with 30 minute interval"
88854880|NCT01489020|Placebo Comparator|Group C placebo|"8 administrations, 2 administrations in the same day. 1 week interval between 2 doses, during 3 weeks.~Week 1: vial 2 - 2 administrations of 0.1 ml with 30 minute interval~Week 2: vial 2 - 0.2 ml and 0.3 ml with 30 minute interval~Week 3: vial 3 - 2 dose of 0.1 ml with 30 minute interval~Week 4: vial 3 - 0.2 ml and 0.3 ml with 30 minute interval"
88854881|NCT03027024|Experimental|IOL Implantation|Implantation of IOL: PhysIOL POD F GF
88854882|NCT01514760|Experimental|Mobile-based Asthma Action Plan|The mobile phone based application features will include ambulatory peak flow and asthma symptoms diary, individualized treatment plan for routine care and during episodes of acute asthma symptoms, and education components to reinforce asthma self-management concepts.
88854883|NCT01514682|Placebo Comparator|Placebo|Placebo pills to be assigned using a permuted randomization system
88854884|NCT01514682|Experimental|Anti-inflammatory Combination Therapy|Salsalate, statin and omega-3-fatty acid combination therapy
88854885|NCT01514448|Experimental|Everolimus|Everolimus 10 mg orally once daily until disease progression, occurrence of intolerable toxicity, start of another anticancer treatment or withdrawn consent.
88854886|NCT01514370|Experimental|IFN beta 1a 44 mcg TIW + curcumin (BCM95)|
88854887|NCT01514370|Placebo Comparator|IFN beta 1a 44 mcg TIW + placebo|
88854888|NCT04705974|Experimental|Fascia iliaca block|ultrasound-guided fascia iliaca block with predetermined dose of 0.4% ropivacaine will be performed.
88854889|NCT04705974|Experimental|Femoral nerve block|ultrasound-guided ultrasound-guided femoral nerve block with predetermined dose of 0.4% ropivacaine will be performed.
88854890|NCT04705974|Experimental|Pericapsular nerve group block (PENG block)|ultrasound-guided ultrasound-guided pericapsular nerve group block with predetermined dose of 0.4% ropivacaine will be performed.
88854891|NCT01519674|Active Comparator|BIAsp 30 BID + sitagliptin + metformin|
88854892|NCT01519674|Active Comparator|BIAsp 30 BID + metformin|
88854893|NCT01519674|Active Comparator|BIAsp 30 OD + sitagliptin + metformin|
88854894|NCT01519518|Active Comparator|Unfractionated heparin|70 units/kg body weight intravenous
88854895|NCT01519518|Active Comparator|bivalirudin|intravenous bolus of 0.75 mg/kg followed by infusion of 1.75 mg/kg per hour
88854896|NCT01519206|Experimental|Ultherapy treatment|Ulthera System Treatment
88854897|NCT01518972|Experimental|Prazosin|Prazosin medication
88854898|NCT01518972|Placebo Comparator|Placebo|Placebo medication
88854899|NCT01514136|Experimental|One arm|The arm consists of two periods: in period one, products are tested in the order A, B, C, D, and in period two, products are tested in the order A*, B*, C*, D*.
88854900|NCT01513590|Experimental|IDegAsp BID|
88854901|NCT01513590|Active Comparator|BIAsp 30 BID|
88854902|NCT03027570|Experimental|Control|Five-month program at two centers for the treatment of overweight children.
88854903|NCT03027570|Experimental|Exergame activity_EXG|Adding an exergame activity application to the regimen at a center for the treatment of overweight children.
88854904|NCT04672512|Experimental|SAD Cohort A CORT125329|Participants will receive a single dose of CORT125329 30 mg lipid capsule formulation 1 in the fasted state on Day 1
88854905|NCT04672512|Experimental|SAD Cohort B CORT125329|Participants will receive a single dose of CORT125329 lipid capsule formulation 1 in the fasted state on Day 1. The dose will be determined after review of safety, tolerability, and PK data from SAD Cohort A.
88854906|NCT04672512|Experimental|SAD Cohorts C through H CORT125329|Participants will receive a single dose of CORT125329 lipid capsule formulation 1 or 2 in the fasted or fed state on Day 1 in a dose escalation format. The dose, formulation, and prandial state for each cohort will be determined after review of safety, tolerability, and PK data from previous cohorts.
88854907|NCT04672512|Placebo Comparator|SAD Cohorts A through H Placebo|Participants will receive a single dose of placebo matching CORT125329 lipid capsule formulation 1 or 2 in the fasted or fed state on Day 1 in a dose escalation format. The dose, formulation, and prandial state for each placebo cohort will match that used in the corresponding CORT125329 cohort.
88854908|NCT04672512|Experimental|MAD Cohorts A through D CORT125329|Participants will receive CORT125329 lipid capsule formulation 1 or 2 in the fasted or fed state on Days 1 through 14 in a dose escalation format. The dose, dose frequency (once- or twice-daily), formulation, and prandial state for each cohort will be determined after review of safety, tolerability, and PK data from previous cohorts.
88854909|NCT04672512|Placebo Comparator|MAD Cohorts A through D Placebo|Participants will receive placebo matching CORT125329 lipid capsule formulation 1 or 2 in the fasted or fed state on Days 1 through 14 in a dose escalation format. The dose, dose frequency, formulation, and prandial state for each cohort will match that used in the corresponding CORT125329 cohort.
88854910|NCT04672512|Experimental|Pharmacodynamic (PD) Effect Cohort|Participants will receive a single dose of prednisone 25 mg in the fasted or fed state on Day 1 of Period 1. The prandial state for the Period 1 treatment will be determined after review of safety and tolerability data from the SAD Cohorts. After a 7-day washout period, participants will receive a single dose of prednisone 25 mg and a single dose of CORT125329 lipid capsule formulation 1 or 2 in the fasted or fed state on Day 1 of Period 2. The formulation and dose level of CORT125329 treatment in Period 2 will be determined after review of safety, tolerability, and PK data from the SAD cohorts. The prandial state for treatment in Period 2 will be the same used in Period 1.
88854911|NCT01512264|Experimental|rTMS|3 weeks of nerTMS
88854912|NCT01512264|Sham Comparator|1 week of Sham Treatment + 2 weeks of nerTMS|1 week of Sham Treatment + 2 weeks of nerTMS
88854913|NCT01512264|Sham Comparator|2 weeks of Sham Treatment +1 week of nerTMS|2 weeks of Sham Treatment +1 week of nerTMS
88854914|NCT01512264|Placebo Comparator|Control Group|3 weeks of Sham Treatment
88854915|NCT01512108|Experimental|Liraglutide + an OAD therapy|
88854916|NCT01512108|Active Comparator|Two OADs combination therapy|
88854917|NCT01486758|Active Comparator|Azithromycin|Oral azithromycin
88854918|NCT01486758|Placebo Comparator|Placebo|Oral Placebo
88854919|NCT01463982|Experimental|Oratecan and Capecitabine|"Oratecan(HM30181AK + Irinotecan HCl) and Capecitabine~Irinotecan HCl Tablet - Initial dose 10 mg/m2 (may be increased up to 20 mg/m2), Day1~Day5~HM30181AK Tablet - Fixed dose 15 mg, Day1~Day5~Capecitabine Tablet - Initial dose 800 mg/m2 (may be increased up to 1000 mg/m2), Day1~Day14"
88854920|NCT01486446|Experimental|XPF-002|XEN402 8% w/w ointment for topical application, applied to the skin twice daily for 14 or 21 days
88854921|NCT01486446|Placebo Comparator|Placebo|XEN402 0% w/w ointment for topical application. Identical content and appearance to the XPF-002 ointment but without the active medicine. Applied to the skin twice daily for 14 or 21 days.
88854922|NCT03027180|Active Comparator|0 (zero) cmH2O|After draining, people will be asked about the level of pain via visual numeric scale and then subjected to chest computed tomography (Aquilion 64-Toshiba Medical Systems®, Japan), using positive airway pressure in the airways with 0 cmH2O
88854923|NCT03027180|Experimental|4 cmH2O|After draining, people will be asked about the level of pain via visual numeric scale and then subjected to chest computed tomography (Aquilion 64-Toshiba Medical Systems®, Japan), using positive airway pressure in the airways with 4 cmH2O
88854924|NCT03027180|Experimental|15 cmH2O|After draining, people will be asked about the level of pain via visual numeric scale and then subjected to chest computed tomography (Aquilion 64-Toshiba Medical Systems®, Japan), using positive airway pressure in the airways with 15 cmH2O
88854925|NCT04655352||Bacillus subtilis MB40|1-week placebo (maltodextrin and excipients) lead-in followed by MB40 intervention
89381884|NCT05261022|Experimental|Love Together, Parent Together Intervention|"Participants will take part in a 3-session writing intervention over the course of 12-week. They will complete a fact-based summary of a recent conflict and answer questions on conflict/conflict-related distress. Next, they will be asked to complete a 9-minute writing task where they reappraise the conflict they previously reported. First, they will watch an instructional video of how to engage in the writing task, by providing definitions and examples of potentially useful conflict reappraisal strategies. Writing prompts include: … Think about this disagreement … from the perspective of a neutral third party who wants the best for all involved…; …what obstacles do you face in trying to take this perspective…?;… How might you be most successful in taking this perspective … over the next 2 weeks? Participants in the intervention group will receive emails to prompt use of the reappraisal strategy between writing sessions."
89381885|NCT05261022|No Intervention|Wait-List Control Group|"Participants will take part in a waitlist control group. They will participate in the same number of assessment/sessions as the experimental group. In the sessions that correspond to the intervention (one session every 4 weeks over the course of 12 weeks as in the intervention group), the waitlist group will complete a basic writing task (identical to the intervention group, wherein they provide a fact-based summary of a recent conflict) and they will complete questions regarding conflict history and conflict-related distress. No other writing tasks will take place.~Following the 3-month assessment, they will be offered the writing intervention."
89381886|NCT03983382||HER2-Positive Breast Cancer|
89381887|NCT03936660|No Intervention|Control|Clinics in the control arm will be encouraged to follow guideline-based care.
89381888|NCT03936660|Active Comparator|Intervention|The cardiology clinics in the intensive educational intervention arm will receive guidance to develop an integrated, multi-disciplinary care pathway for patients with T2DM and CVD.
89381889|NCT03039192|Experimental|Esketamine + Standard of care|Participants will receive intranasal esketamine 84 milligram (mg) two times per week for 4 weeks (Days 1, 4, 8, 11, 15, 18, 22, and 25) along with standard of care (SOC) antidepressant treatment.
89381890|NCT03039192|Placebo Comparator|Placebo + Standard of care|Participants will receive intranasal placebo two times per week for 4 weeks (Days 1, 4, 8, 11, 15, 18, 22, and 25) along with standard of care antidepressant treatment.
88854926|NCT01485354|Experimental|Armeo Spring training|Subjects will participate in upper extremity rehabilitation using the Armeo Spring system for a period of 6 weeks. The intervention will consist of 18 training sessions (60 minute sessions, 3 times a week).
89381891|NCT05370612|Experimental|Arm 1: Continuous Glucose Monitor (CGM)|CGM for duration of pregnancy.
88854927|NCT01510158|Experimental|lesinurad 200 mg + allopurinol|
89381892|NCT05370612|Active Comparator|Arm 2: Point of Care Glucose Testing (POCT)|"Point of care finger sticks for glucose monitoring.~At two time points during the study - at time of enrollment and at 28-32 weeks gestation, CGM sensor will be placed and remain in place for 10 days. Participant and Physician will be blinded to CGM data."
89381893|NCT02428842|Other|Tumor biopsies and blood sampling|"Patient will undergo standard care with tumor and blood sampling before and after treatment.~Blood and tumor sampling will also be performed at disease progression/relapse."
89381894|NCT02367690|Experimental|Cohort 1|"Cohort 1 will be randomized to one of the following treatment groups:~a) Standard-of-care (SOC) + Selinexor gel, 10 μM~, b) SOC + vehicle gel c) SOC alone."
89381895|NCT02367690|Experimental|Cohort 2|"Cohort 2 will be randomized to one of the following treatment groups:~Standard-of-care (SOC) + Selinexor gel, 30 μM~SOC + vehicle gel~SOC alone."
88854928|NCT01510158|Experimental|lesinurad 400 mg + allopurinol|
88854929|NCT01510158|Placebo Comparator|Placebo + allopurinol|
88854930|NCT04080882|Active Comparator|AbobotulinumtoxinA dose 1|AbobotulinumtoxinA dose 1 injected into platysma bands
88854931|NCT04080882|Placebo Comparator|placebo|placebo injected into platysma bands
88854932|NCT04080882|Active Comparator|AbobotulinumtoxinA dose 2|AbobotulinumtoxinA dose 2 injected into platysma bands
88854933|NCT04080882|Active Comparator|AbobotulinumtoxinA dose 3|AbobotulinumtoxinA dose 3 injected into platysma bands
88854934|NCT03027336|Experimental|coleosoma|coleosoma 500mg tablet daily
88854935|NCT03027336|Placebo Comparator|placebo|placebo tablets
88854936|NCT01485120|Other|Blood Pressure monitoring|Blood Pressure (BP) monitoring using invasive arterial insertion as a standard reference, and an investigational, non-invasive blood pressure (NIBP) monitoring cuff. Data obtained from the cuff used the SuperSTAT NIBP algorithm and the Classic NIBP algorithm for output.
88854937|NCT03027258|Experimental|Intervention|mHealth intervention
88854938|NCT01484496|Placebo Comparator|Placebo plus standard therapy|Placebo SC plus standard therapy; placebo administered on Day 0 and then weekly (ie, every 7 days) through Week 51, with final evaluation at Week 52 in the double-blind period. In the open-label extension period, placebo subjects who opt to participate will receive belimumab 200 mg SC weekly for an additional 6-months.
88854939|NCT01484496|Experimental|Belimumab 200 mg SC plus standard therapy|Belimumab 200 mg SC plus standard therapy; belimumab administered on Day 0 and then weekly (ie, every 7 days) through Week 51, with a final evaluation at Week 52 in the double-blind period. In the open-label extension period, subjects who opt to participate will continue on the same dose of belimumab for an additional 6-months.
88854940|NCT01509846|Experimental|Cohort 1|Received one oral dose of 2.6±0.8 x 10^8 vp/mL Shigella flexneri 2a whole cell killed vaccine (Sf2aWC)
88854941|NCT01509846|Experimental|Cohort 2|Received three oral doses of 2.6±0.8 x 10^9 vp/mL Shigella flexneri 2a whole cell killed vaccine (Sf2aWC)
88854942|NCT01509846|Experimental|Cohort 3|Received three oral doses of 2.6±0.8 x 10^10 vp/mL Shigella flexneri 2a whole cell killed vaccine (Sf2aWC)
88854943|NCT01509846|Experimental|Cohort 4|Received three oral doses of 2.6±0.8 x 10^11 vp/mL Shigella flexneri 2a whole cell killed vaccine (Sf2aWC)
88854944|NCT01509846|Placebo Comparator|Placebo|Received oral dose of placebo concurrent with Cohort 1 (one dose), 2, 3, or 4 (3 doses).
88854945|NCT01462344|Experimental|ADVAIR 100/50mcg|fluticasone propionate/salmeterol combination (100/50mcg) twice daily (AM and PM) for 6 months
89381896|NCT02367690|Experimental|Cohort 3|"Cohort 3 will be randomized to one of the following treatment groups:~Standard-of-care (SOC) + Selinexor gel, 70 μM~SOC + vehicle gel~SOC alone."
89381897|NCT03698279|Experimental|Group 1: QIV-HD 30 μg (US: 6 months to 17 years)|Participants from United States (US) (aged 6 months to 17 years) received single injection of 30 microgram (μg) QIV-HD, intramuscularly (IM) at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.
89381898|NCT03698279|Experimental|Group 2: QIV-HD 45 μg (US: 6 months to 17 years)|Participants from US (aged 6 months to 17 years) received single injection of 45 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.
89381899|NCT03698279|Experimental|Group 3: QIV-HD, 60 μg (US: 6 months to 17 years)|Participants from US (aged 6 months to 17 years) received single injection of 60 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.
89381900|NCT03698279|Active Comparator|Group 4: Pooled QIV-SD, 15 μg (US: 6 months to 17 years)|Pooled arm consisted of participants who were from US aged 6 months to 17 years, randomized to Groups 1, 2 and 3 and received single injection of 15 μg QIV-SD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.
89381901|NCT03698279|Experimental|Group 5: QIV-HD, 60 μg (Canada: 6 to <24 months)|Participants from Canada (aged 6 to less than [<] 24 months) received single injection of 60 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.
89381902|NCT03698279|Active Comparator|Group 6: Adjuvanted TIV (Canada: 6 to <24 months)|Participants from Canada (aged 6 to <24 months) received single injection of 7.5 μg adjuvanted TIV, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.
89381903|NCT03628950|Active Comparator|ICSSB group|infraclavicular suprascapular nerve block administered group
89381904|NCT03628950|Active Comparator|ISB group|interscalene nerve block administered group
89381905|NCT05275283|No Intervention|Control group|Applying tidal volume 7 ml/kg without PEEP
89381906|NCT05275283|Experimental|PEEP group|Applying tidal volume 7 ml/kg with 6 cmH2O of PEEP
89381907|NCT01529034|Experimental|USL261|Intranasal midazolam 5 mg
89381908|NCT05275049|Experimental|PT+ Device|PT plus translingual stimulation device PoNS device will be used to deliver trans-lingual electrical stimulation. The stimulation will be delivered while the participants engages in evidence-based physiotherapy for walking and balance.
89381909|NCT05275049|Active Comparator|PT + Control Device|PT plus translingual stimulation control device Control device will be used. Participants will wear device while engaging in evidence-based physiotherapy for walking and balance.
89381910|NCT03036072|Active Comparator|Strict Normothermia|Patients will be rewarmed to 36.5 degrees centigrade in the operating room and maintained here by conventional means in the PICU.
88854946|NCT01462344|Experimental|ADVAIR 250/50mcg|fluticasone propionate/salmeterol combination (250/50mcg) twice daily (AM and PM) for 6 months
88854947|NCT01462344|Active Comparator|FLOVENT 100mcg|fluticasone propionate (100) twice daily (AM and PM) for 6 months
88854948|NCT01462344|Active Comparator|FLOVENT 250mcg|fluticasone propionate (250mcg) twice daily (AM and PM) for 6 months
88854949|NCT01484028|Other|EALE/1DM|etafilcon A with PVP for light eyes worn during the first period of 7-9 days then etafilcon A control lens worn during the second period of 7-9 days, with a 1-3 days of wash-out time between the 2 periods.
88854950|NCT01484028|Other|1DM/EALE|etafilcon A control lens worn during the first period of 7-9 days then etafilcon A with PVP for light eyes worn during the second period of 7-9 days, with a 1-3 days of wash-out time between the 2 periods.
88854951|NCT01484028|Other|EADE/1DM|etafilcon A with PVP for dark eyes worn during the first period of 7-9 days then etafilcon A control lens worn during the second period of 7-9 days, with a 1-3 days of wash-out time between the 2 periods.
89381911|NCT03036072|Experimental|Delayed Rewarming|Patient will be rewarmed to 35.0 degrees centigrade in the operating room, then slowly rewarmed to normal physiologic temperature over 12 hours by using a servo-controlled cooling blanket. Normothermia will be maintained by the cooling blanket for an additional 12 hours.
89381912|NCT05102916||Patient population|Children, adolescents and adults diagnosed with a NMD (DMD/BMD/IMD; SMA; COL-6; LAMA-2) who are treated or living in Switzerland.
89381913|NCT03619512||Richter Syndrom at diagnosis|patients diagnosed with Richter Syndrom, for whom a suitable lymph node biopsy at diagnosis is available.
89381914|NCT03619512||Primitive Diffuse Large B-Cell Lymphoma|patients diagnosed with a primitive Large B-Cell Lymphoma, for whom a suitable lymph node biopsy at diagnosis is available.
89381915|NCT03619512||Other secundary Diffuse Large B-Cell Lymphoma|patients diagnosed with a secundary Large B-Cell Lymphoma (different from Richter Syndrom), for whom a suitable lymph node biopsy at diagnosis is available.
89381916|NCT03619512||Control group with no tumor involvment of lymph nodes|patients for whom a diagnostic lymph node biopsy has been performed, which did not conclude to any tumoral lymph node involvment.
88854952|NCT01484028|Other|1DM/EADE|etafilcon A control lens worn during the first period of 7-9 days then etafilcon A with PVP for dark eyes worn during the second period of 7-9 days, with a 1-3 days of wash-out time between the 2 periods.
88854953|NCT01462266|Experimental|Sitagliptin|Sitagliptin 100 mg once daily
88854954|NCT01462266|Placebo Comparator|Placebo|Placebo to sitagliptin once daily
88854955|NCT01508910|Experimental|Treatment Arm|Targeted intramyocardial delivery of 1 x 10^5 Auto-CD34+ cells after granulocyte-colony stimulating factor (G-CSF) mobilization and apheresis
88854956|NCT01508910|Placebo Comparator|Active Control Arm|Targeted intramyocardial delivery of placebo after G-CSF mobilization and apheresis
88854957|NCT01508910|Other|Unblinded Standard of Care (SOC) Arm|No study-related procedures will be performed.
88854958|NCT01462110|Experimental|0.15% ethyl lauroyl arginate HCl-containing mouthrinse|Brush teeth as usual, followed immediately by rinsing with 20 mL of assigned 0.15% ethyl lauroyl arginate HCl-containing mouthrinse (19415-154-1) for 30 seconds - repeat twice daily for four weeks.
88854959|NCT01462110|Sham Comparator|5% hydroalcohol mouthrinse|Brush teeth as usual, followed immediately by rinsing with 20 mL of assigned 5% hydroalcohol mouthrinse (W002194-0221P) for 30 seconds - repeat twice daily for four weeks.
88854960|NCT04087590|Experimental|PT003 treatment|
88854961|NCT01508676|Active Comparator|Pennsaid Phase I|Pennsaid (20-40 drops; 2-4 times daily) Upon completion of the first phase, subjects in each arm will be crossed over (i.e., from placebo to Pennsaid and vise versa). Pennsaid or placebo lotion will be packed in a container with identical appearance before being dispensed to study subjects.
88854962|NCT01508676|Placebo Comparator|Placebo Phase I|Study subject will topically apply placebo lotion (20-40 drops) 2-4 times daily to the painful area for the next two weeks. The dose titration will be based on the size of painful area (approximately 10 drops for every 4 square inches). Subjects will be asked to fill in a daily pain diary and report any side effects to the research center. A phone number and a beeper number will be provided to subjects.
88854963|NCT01508130||Cohort|
88854964|NCT02985372|Experimental|Acute myeloid leukemia|All patients were treated with decitabine of 15 mg/ m2 intravenously over 4h for 5 consecutive days (day 1-5) for priming combined with cytarabine of 10 mg/m2 q12h for 10 days (day 4-13).
88854965|NCT04087512|Experimental|Instrumented perturbation-based balance training|
88854966|NCT04087512|Experimental|Conventional perturbation-based balance training|
88854967|NCT04087512|No Intervention|Control|
88854968|NCT02985216|Experimental|YHD1119|YHD1119 150mg for the first 1 week, then forced titrated to YHD1119 300mg for the 1 week. And then YHD1119 150~600mg for the 2 weeks, then YHD1119 fixed dose was administrated for 8 weeks.
88854969|NCT02985216|Active Comparator|Lyrica|Lyrica 150mg for the first 1 week, then forced titrated to Lyrica 300mg for the 1 week. And then Lyrica 150~600mg for the 2 weeks, then Lyrica fixed dose was administrated for 8 weeks.
88854970|NCT01482312|Active Comparator|Lotrafilcon A / Comfilcon A / Glasses|Lotrafilcon A contact lenses worn first, followed by comfilcon A contact lenses, followed by habitual glasses. Each product worn for 90 minutes in a controlled, low-humidity environment (LHE) chamber. Each period separated by a washout of approximately 7 days.
88854971|NCT01482312|Active Comparator|comfilcon A / glasses / lotrafilcon A|Comfilcon A contact lenses worn first, followed by glasses, followed by lotrafilcon A contact lenses. Each product worn for 90 minutes in a controlled, low-humidity environment (LHE) chamber. Each period separated by a washout of approximately 7 days.
88854972|NCT01482312|Active Comparator|glasses / lotrafilcon A / comfilcon A|Glasses worn first, followed by lotrafilcon A contact lenses, followed by comfilcon A contact lenses. Each product worn for 90 minutes in a controlled, low-humidity environment (LHE) chamber. Each period separated by a washout of approximately 7 days.
88854973|NCT01461096|Experimental|Quadrivalent HPV Vaccine|Participants were prescribed the quadrivalent HPV vaccine at baseline and Weeks 8 and 24.
88854974|NCT01461096|Placebo Comparator|Placebo Vaccine|Participants were prescribed the placebo vaccine at baseline and Weeks 8 and 24.
89381917|NCT03038880|Experimental|6 mg Faricimab Q12W|6 mg faricimab was given by intravitreal (IVT) injection once every 4 weeks (Q4W) up to Week 12 (4 injections), followed by 6 mg faricimab IVT injection once every 12 weeks (Q12W) from Week 24 up to Week 48 (injections at Weeks 24, 36, and 48; 3 injections).
88854975|NCT04077294||Preoperative BNP used for cardiac risk stratification|Cohort of patients recruited in the pre-admission clinic who qualified for, and underwent, preoperative BNP screening according to CCS guidelines.
88854976|NCT04077294||Preoperative BNP not used for cardiac risk stratification|Cohort of patients from patient care database (SPOR) who qualified for preoperative BNP screening according to CCS guidelines, but did not receive screening due to surgery occurring before the implementation of the CCS guidelines.
88854977|NCT01507896|Experimental|BAX326 in Surgery|BAX 326 (recombinant factor IX) in Surgery
88854978|NCT01507662|Experimental|BMD Result Letter and Brochure|Patients who receive the intervention - BMD result letter with brochure.
88854979|NCT01507662|No Intervention|Control|Those who received usual care
88854980|NCT01506960|Experimental|Coronary stenting with OCT, NIRS/IVUS|All subjects will have Near Infrared Spectroscopy/Intravascular Ultrasound Imaging performed.
88854981|NCT01480674||Trastuzumab|Eligible participants with human epidermal growth factor receptor 2 (HER2)-positive metastatic or locally advanced breast cancer, who were treated with trastuzumab as a first-line therapy and were progression-free for at least 3 years after treatment initiation, were included and were followed for one year.
88875370|NCT05371158|Experimental|Online intervention|The experimental condition includes an online psychological intervention with therapist email guidance based on Acceptance & Commitment Therapy (ACT). ACT is a form of Cognitive Behavioral Therapy, which focuses on acceptance of chronic pain in order to be able to perform valuable activities, instead of attempts of avoidance and controlling (Hayes et al., 2012). The main goal of ACT is increasing psychological flexibility, which includes the ability to act effectively according to personal values, with pain. ACT can thereby play a role in creating more realistic expectations regarding expectations of future pain relief. The intervention can be worked through in the participant's own living environment. It consists of 6 modules which can be worked through in 8 weeks.
89381918|NCT03038880|Experimental|6 mg Faricimab Q16W|6 mg faricimab was administered by IVT injection once every 4 weeks (Q4W) up to Week 12 (4 injections), followed by no doses up to Week 24 when a protocol-defined assessment of disease activity was performed. Participants with disease activity at Week 24 initiated 6 mg faricimab IVT Q12W dosing, and participants without disease activity at Week 24 initiated 6 mg faricimab IVT once every 16 weeks (Q16W) dosing for the remainder of the study.
89381919|NCT03038880|Active Comparator|0.5 mg Ranibizumab Q4W|0.5 mg of ranibizumab was administered by IVT injection once every 4 weeks (Q4W) for 48 weeks (13 injections).
89381920|NCT05038644|Experimental|Arm Z: Dose Level -1 for Group A (T-ALL, T-LBL)|0.1 mg intravenous (IV) Cycle (C) 1 Day (D) 1, 0.3 mg IV C1D2, then 0.4 mg IV on D8, D15, and D22 in a 28-day cycle.
89381921|NCT05038644|Experimental|Arm A: Dose Level 0 (Starting Dose) for Group A (T-ALL, T-LBL)|0.2 mg IV C1D1, 0.6 mg IV C1D2, then 0.8 mg IV on D8, D15, and D22 in a 28-day cycle.
89381922|NCT05038644|Experimental|Arm B: Dose Level 1 for Group A (T-ALL, T-LBL)|0.25 mg IV C1D1, 0.75 mg IV C1D2, then 1.0 mg IV on D8, D15, and D22 in a 28-day cycle.
89381923|NCT05038644|Experimental|Arm C: Dose Level 2 Group A (T-ALL, T-LBL)|0.4 mg IV C1D1, 0.9 mg IV C1D2, then 1.3 mg IV on D8, D15, and D22 in a 28-day cycle.
89381924|NCT05038644|Experimental|Arm D: Dose Level 3 Group A (T-ALL, T-LBL)|0.5 mg IV C1D1, 1.0 mg IV C1D2, then 1.5 mg IV on D8, D15, and D22 in a 28-day cycle.
88854982|NCT01506882|Experimental|Levetiracetam 1000 mg/day to 2000 mg/day group|"Subjects in the LEV 1000 mg/day to 2000 mg/day group receive the initial dose of LEV 1000 mg/day for the 1- week Stabilization Period and enter the Evaluation Period. Unless a seizure occurs during the Evaluation Period, the subjects will continue LEV 1000 mg/day for 26 weeks. If a seizure occurs during the Evaluation Period, the dose will be increased to 2000 mg/day and a restart of stabilization on LEV 2000 mg/day for 1 week is required prior to restarting the 26-weeks Evaluation Period on LEV 2000 mg/day.~The LEV dose could be decreased as a fallback option at the investigator's discretion, if the subject did not tolerate the LEV dosage, as evidenced by the development of an AE. The fallback option was permitted to be performed once for subjects on LEV 2000 mg/day at any time during the restarted Stabilization Period (SP), restarted Evaluation Period (EP), or Maintenance Period (MP), as well as for subjects on LEV 3000 mg/day at any time during the SP, EP, or MP."
88854983|NCT01506882|Experimental|Levetiracetam 3000 mg/day group|"Unless a seizure occurs, the subjects in this arm will continue LEV 3000 mg/day for 26 weeks. Subjects in the LEV 3000 mg/day group undergo a 4-week Up-Titration Period prior to the 1-week Stabilization Period.~They receive 1000 mg/day for 2 weeks and 2000 mg/day for 2 weeks during the Up-Titration Period and LEV 3000 mg/day for 1 week during the Stabilization Period.~The LEV dose could be decreased as a fallback option at the investigator's discretion, if the subject did not tolerate the LEV dosage, as evidenced by the development of an AE. The fallback option was permitted to be performed once for subjects on LEV 2000 mg/day at any time during the restarted Stabilization Period (SP), restarted Evaluation Period (EP), or Maintenance Period (MP), as well as for subjects on LEV 3000 mg/day at any time during the SP, EP, or MP."
89381925|NCT05038644|Experimental|Arm Z: Dose Level -1 Group B (AML)|0.1 mg IV C1D1, 0.3 mg IV C1D2, then 0.4 mg IV on D8, D15, and D22 in a 28-day cycle.
89381926|NCT05038644|Experimental|Arm A: Dose Level 0 (Starting Dose) Group B (AML)|0.2 mg IV C1D1, 0.6 mg IV C1D2, then 0.8 mg IV on D8, D15, and D22 in a 28-day cycle.
89381927|NCT05038644|Experimental|Arm B: Dose Level 1 Group B (AML)|0.25 mg IV C1D1, 0.75 mg IV C1D2, then 1.0 mg IV on D8, D15, and D22 in a 28-day cycle.
89381928|NCT05038644|Experimental|Arm C: Dose Level 2 Group B (AML)|0.4 mg IV C1D1, 0.9 mg IV C1D2, then 1.3 mg IV on D8, D15, and D22 in a 28-day cycle.
89381929|NCT05038644|Experimental|Arm D: Dose Level 3 Group B (AML)|0.5 mg IV C1D1, 1.0 mg IV C1D2, then 1.5 mg IV on D8, D15, and D22 in a 28-day cycle.
89381930|NCT03035916|Experimental|Transversus abdominis plane block|The TAP group receives ultrasound-guided TAP block under bilateral costal margin with multiple injections of 40ml 0.375% ropivacaine after the induction of general anesthesia.
89381931|NCT03035916|Active Comparator|Epidural anesthesia|The Epidural group receives epidural block (T8-9) 2 mL of 1.6% lidocaine as a test dose and continous infusion of 0.375% ropivacaine(5 mL/h) during the surgery.
89381932|NCT03035916|Placebo Comparator|Control|The Control group receives standard IV-inhaled general anesthesia.
89381933|NCT01702571|Experimental|Trastuzumab Emtansine (All Participants)|This cohort will enroll all participants with HER2-positive, unresectable, LABC or mBC who have received prior anti-HER2 and chemotherapy treatment and have progressed on or after the most recent treatment for LABC or mBC, or within 6 months of completing adjuvant therapy. Participants will receive trastuzumab emtansine every 3 weeks until unacceptable toxicity, withdrawal of consent, or disease progression.
89381934|NCT01702571|Experimental|Trastuzumab Emtansine (Asian Participants)|This cohort will enroll Asian race participants with HER2-positive, unresectable, LABC or mBC who have received prior anti-HER2 and chemotherapy treatment and have progressed on or after the most recent treatment for LABC or mBC, or within 6 months of completing adjuvant therapy. Participants will receive trastuzumab emtansine every 3 weeks until unacceptable toxicity, withdrawal of consent, or disease progression.
89381935|NCT00001242||Study Cohort|Patients of any age or sex with vitamin D resistance, rickets, osteomalacia, pseudohypoparathyroidism, pseudo- pseudohypoparathyroidism, or suspicion of these or related disorders
89381936|NCT03675516||Rheumatoid arthritis cases|New onset cases of rheumatoid arthritis
89381937|NCT03675516||Controls|Age, gender and primary care practice-matched controls
89381938|NCT01637688||Amino acid formula|Comparison of growth between subjects who are fed with a newly innovated amino acid formula (NAAF) and who are fed with either Neocate or nutramigen AA.
89381939|NCT05655000|Experimental|Neonatal thymus transplantation|Supermicrosurgical technique for neonatal thymus transplantation into the subject's radial forearm. The donor will be a neonate subject to corrective heart surgery via sternotomy requiring routinary partial thymectomy.
89381940|NCT01632930|Experimental|Results of urinary PCA3 test will be available|In this arm, physicians will have knowledge of urinary PCA3 test results. How they subsequently manage patients with prostate cancer suspicion is likely to be influenced by urinary PCA3 test results
89381941|NCT01632930|Active Comparator|Results of urinary PCA3 test will not be available|In this arm, physicians will not have knowledge of urinary PCA3 test results. How they subsequently manage patients with prostate cancer suspicion will therefore not be influenced by urinary PCA3 test results
89381942|NCT03231943|Experimental|Subjects in cohort 1-2: Part 1|Eligible subjects will participate in cohort 1 or 2 and each of these two cohorts will contain up to four escalating doses of GSK3640254. In each cohort, 6 subjects will be randomized to receive single oral dose of GSK3640254 and 2 subjects will be randomized to receive placebo. Hence, each subject in cohort 1 and 2 will receive up to 3 escalating doses of GSK3640254 and one placebo in crossover manner.
89381943|NCT03231943|Experimental|GSK3640254 receivers (cohort 3-6 and expansion): Part 2|Eligible subjects will participate in one of the 4 cohorts (3,4,5,6). In each cohort, 6 subjects will be randomized to receive a once-daily oral dose of GSK3640254 for 14 days. After the safety data of cohort 3-6 is available, 18 eligible subjects will be randomized to receive once daily oral dose of GSK3640254 for 14 days in expansion cohort.
89381944|NCT03231943|Placebo Comparator|Subjects receiving placebo (cohort 3-6): Part 2|Eligible subjects will participate in one of the 4 cohorts (3,4,5,6). In each cohort, 2 subjects will be randomized to receive a once-daily oral dose of placebo for 14 days. After the safety data of cohort 3-6 is available, 6 eligible subjects will be randomized to receive once daily oral dose of placebo for 14 days in expansion cohort.
88854984|NCT01506726|Experimental|Active drug - oral salsalate|Subjects randomized to active drug arm will receive 750mg of salsalate (one pill) twice a day (am and pm) for one month. After one month the dose will be increased to 1500mg (2 pills) twice a day (if the 750mg dose was tolerated) for a further 5 months. Total treatment time is 6 months.
88854985|NCT01506726|Placebo Comparator|Placebo Arm|Subjects randomized to the placebo arm will receive a matching placebo pill (one pill) twice a day (am and pm) for one month. After one month the dose will be increased to 2 matching placebo pills twice a day (if the one pill dose was tolerated) for a further 5 months. Total treatment time is 6 months.
89399515|NCT03538184|Experimental|Piezosurgery|Osteotomy preparation entirely with piezosurgery tips and equicrestal placement of a 4.1 mm implant in the piezosurgery (test) group were performed as follows: 1.15 mm initial MB1 tip, 1.95 mm MB2 tip, control of depth, diameter and direction of osteotomy with 2.0 mm paralleling pin, 2.5 mm MB3 tip, 2.8 mm MB4 tip, 2.8 mm paralleling pin, 3.05 mm MB5 tip, 3.3 mm MB6 tip, control of final diameter of the osteotomy with 3.5 mm paralleling pin, placement of the 4.1 mm diameter implant and connection of a 4 mm-wide healing abutment.
88854986|NCT01505868|Experimental|Arm I (cabazitaxel)|Patients receive cabazitaxel IV over 60-90 minutes on day 1. Treatment repeats every 21 days for up to 10 courses in the absence of disease progression or unacceptable toxicity.
88854987|NCT01505868|Experimental|Arm II (cabazitaxel and carboplatin)|Patients receive cabazitaxel IV over 60-90 minutes and carboplatin IV over 60-90 minutes on day 1. Treatment repeats every 21 days for up to 10 courses in the absence of disease progression or unacceptable toxicity.
88854988|NCT01505634|Experimental|Relebactam 250 mg with imipenem/cilastatin|Relebactam 250 mg IV co-administered with 500 mg of imipenem/cilastatin once every 6 hours for a minimum of 96 hours. After 96 hours of IV treatment, participants may be switched to 500 mg ciprofloxacin (as optional oral therapy following minimum duration of IV study drug), administered orally, twice daily for the remainder of the study. Antibiotic therapy (IV and oral combined) should not exceed 14 days.
88854989|NCT01505634|Experimental|Relebactam 125 mg with imipenem/cilastatin|Relebactam 125 mg IV co-administered with 500 mg of imipenem/cilastatin once every 6 hours for a minimum of 96 hours. After 96 hours of IV treatment, participants may be switched to 500 mg ciprofloxacin (as optional oral therapy following minimum duration of IV study drug), administered orally, twice daily for the remainder of the study. Antibiotic therapy (IV and oral combined) should not exceed 14 days.
89183360|NCT04943380||patients with hematuria undergoing investigation for UC|Patients will be recruited from those presenting with hematuria and undergoing investigative cystoscopy for the determination of possible urothelial carcinoma. This includes patients referred via imaging or from other departments for assessment of hematuria. Microscopic hematuria is defined as > 3 red blood cells per high-powered microscopy field for a properly collected urine sample.
88854990|NCT01505634|Placebo Comparator|Relebactam placebo with imipenem/cilastatin|Matching placebo for relebactam (0.9% normal saline) IV co-administered with 500 mg dose of imipenem/cilastatin once every 6 hours for a minimum of 96 hours. After 96 hours of IV treatment, participants may be switched to 500 mg ciprofloxacin (as optional oral therapy following minimum duration of IV study drug), administered orally, twice daily for the remainder of the study. Antibiotic therapy (IV and oral combined) should not exceed 14 days.
88854991|NCT04409730|Experimental|Children with Cerebral Palsy|"Aged 5-12 years, diagnosed as spastic diplegia or hemiplegia , having a level of I, II, III according to GMFCS"
88854992|NCT01460628|Experimental|Armodafinil|Armodafinil is the drug being tested.
88854993|NCT04581798||OSA|Patients with OSA confirmed by polysomnography, aged 35-65
88854994|NCT04581798||Non-OSA|Patients without OSA aged 35-65
88854995|NCT01480596|Experimental|Belimumab|10mg/kg
88854996|NCT01480596|Placebo Comparator|Placebo|placebo IV infusion
88854997|NCT01480284|Experimental|GSK548470 300 mg|GSK548470 300 mg tablet and ETV placebo capsule are administered once daily
88854998|NCT01480284|Active Comparator|ETV 0.5 mg|ETV 0.5 mg capsule and GSK548470 placebo tablet are administered once daily
88854999|NCT04409028|Active Comparator|indirect restoration|
88855000|NCT04409028|Active Comparator|direct restoration|
88855001|NCT01459614|Experimental|GTX-C|"Each cycle is 21 days (2 weeks Tx + 1 week off). Xeloda given days 1-14, Gemcitabine, Taxotere, and Cisplatin given days 4 and 11.~For expansion cohort, each cycle is 28 days (2 weeks of Tx + 2 weeks off)"
88855002|NCT01458522|Active Comparator|fPHT 20mg|fPHT treatment arm, a bolus of 20 mg PE/kg will be administered at a rate of no greater than 75 mg PE/minute. If a further bolus is required, 5 mg PE/kg will be administered. The daily maintenance dose for fPHT will be 5 mg PE/kg divided into 2 doses.
88855003|NCT01458522|Experimental|LCM 400mg|LCM treatment arm, a bolus of 400 mg will be administered over 30 minutes. If a further bolus is required, 200 mg will be administered. Regardless of whether the subject received a rebolus, he or she will begin receiving a maintenance dose 12 hours after the initial dose. The daily maintenance dose will be the same as the total bolus (400 mg or 600 mg) divided into 2 doses.
88855004|NCT01505010|Other|Control group|Standard antihypertensive drug treatment
88855005|NCT01505010|Experimental|Intervention group|Renal denervation plus standard antihypertensive drug treatment
88855006|NCT03026946|Active Comparator|Alitretinoin|Patients with severe recurrent vesicular hand eczema, randomized to treatment with alitretinoin.
89183361|NCT04942366|Experimental|HIIT Group|High intensity interval training will be performed thrice a week using a treadmill.
89183362|NCT04942366|Active Comparator|ST Group|Strength training will be performed thrice a week, each session will consist of eight dynamic drills (with resistance of 60 - 70 % of 1 repetition maximum).
89183363|NCT04931498||GMPR sub-study|Study population will be split into five haplotypes based on a combination of rare and common variants at the GMPR locus. A total of 26 volunteers per genotypic group in a comparison between heterozygous and homozygous individuals will be tested.
89183364|NCT04931498||SWAP70 sub-study|To assess genotype-specific effects on SWAP70 protein levels as well as coronary artery disease-related immune processes, we will recruit 50 volunteers stratified by variant genotype, i.e. major and minor homozygotes only (25 participants will be recruited to each group).
88855007|NCT03026946|Active Comparator|Cyclosporin A|Patients with severe recurrent vesicular hand eczema, randomized to treatment with cyclosporin A.
88855008|NCT01458210|Experimental|Ortho-Cyclen (OC) Alone (Period 1); OC+Dulaglutide (Period 2)|"Ortho-Cyclen (OC) (0.25 milligram [mg] norelgestromin [NGMN] + 0.035 mg ethinyl estradiol [EE] [active tablets] for 21 days + non-active tablets for 7 days): A 28-day course of OC consists of 0.25 mg NGMN and 0.035 mg EE (active tablets), administered orally, once per day for 21 days, then non-active tablets, administered orally, once per day for 7 days. Participants received the first 28-day course (Lead-in) followed by 2 subsequent 28-day courses (Periods 1 and 2, respectively). Following the Lead-in period, the Period 1 sample was taken during the first 28-day course and the Period 2 sample was taken during the second 28-day course.~Dulaglutide: A single, 1.5-mg subcutaneous injection on Day 19 of Period 2."
88855009|NCT01478958|Active Comparator|high saturated fat diet|
88855010|NCT01478958|Experimental|high monounsaturated fat diet|
88855011|NCT01478958|Experimental|high n-6 polyunsaturated fat diet|
88855012|NCT01458132||Subjects who experienced seizure|Subjects who were previously randomized in the Phase 2b studies SGN113399 or SGN113404 and experienced seizure
89183365|NCT04878016|Experimental|ZKAB001＋carboplatin+etoposide|"The induction phase will consist of four cycles of ZKAB001 plus chemotherapy, with each cycle being 21 days in duration. On Day 1 of each cycle, patients will receive drug infusions in the following order:~ZKAB001 → carboplatin → etoposide"
88855013|NCT01458132||Subjects who did not experience seizure|Subjects who were previously randomized in the Phase 2b studies SGN113399 or SGN113404 and did not experience seizure
88855014|NCT06175442||Nasogastric tube only (I)|Nasogastric intubation only will be the only method of intestinal decompression both intra- and postoperatively.
88855015|NCT06175442||Short nasointestinal tube (IIA)|Intraoperative intestinal decompression will be performed by placing the tube behind the ligament of Treitz and expressing the contents in the proximal direction or by total nasointestinal intubation with subsequent intraopertional tube withdrawal. Postoperative decompression will consist of the tube behind the ligament of Treitz.
89381945|NCT01578239|Experimental|177Lu-DOTA0-Tyr3-Octreotate|"30 mg Octreotide LAR treatment for symptom control continued until the end of study, unless the participant progressed or died.~Treatment consisted of a cumulative administered radioactivity of 29.6 Giga Becquerel (GBq) (800 mCi) 177Lu-DOTA0-Tyr3-Octreotate: Four administrations of 7.4 GBq (200 mCi).~Concomitant amino acids were given with each administration for kidney protection.~177Lu-DOTA0-Tyr3-Octreotate was administered at 8 +/- 1-week intervals, which could be extended up to 16 weeks to accommodate resolving acute toxicity.~In case participants experienced clinical symptoms (i.e. diarrhoea and flushing) associated with their carcinoid tumours, Octreotide s.c. rescue injections were allowed."
89381946|NCT01578239|Active Comparator|Octreotide LAR|"60 mg Octreotide LAR treatment every 4 weeks (i.m. injections) until the end of the study, unless the participant progressed or died.~In case participants experienced clinical symptoms (i.e. diarrhoea and flushing) associated with their carcinoid tumours, s.c. Octreotide rescue injections were allowed."
89381947|NCT05274893|Experimental|SYHX2011(T)-Abraxane®(R)|Patients will be administrated with SYHX2011 followed by Abraxane®
89381948|NCT05274893|Experimental|Abraxane®(R)-SYHX2011(T)|Patients will be administrated with Abraxane® followed by SYHX2011
89381949|NCT05255471|Experimental|Olaparib|
89381950|NCT05255471|Active Comparator|Chemotherapy|
89381951|NCT03241927|Experimental|Pembrolizumab|200 mg IV infusion every 3 weeks
88855016|NCT06175442||Long nasointestinal tube intraoperative (IIB)|Total intraoperative intubation of the small intestine followed by replacement with a nasogastric tube.
88855017|NCT06175442||Long nasointestinal tube postoperative (IIC)|Total intraoperative intubation of the small intestine with a long tube, which will persist in the postoperative period
88855018|NCT06175429||Cardiac surgery|Patients undergoing elective cardiac surgery
88855019|NCT06175377|Active Comparator|Long dual Aspirin/Clopidogrel therapy|Patients will be treated with usual long dual antiplatelet aggregation for 6 to 12 months
88855020|NCT06175377|Experimental|Short dual Aspirin/Clopidogrel therapy|Patients will be treated with short dual antiplatelet aggregation for 1month
88855021|NCT06175351|Experimental|Phase Ib 9MW1911|9MW1911 is administered intravenously in a multiple ascending dose pattern in four dose levels. Each level includes 6 patients.
88855022|NCT06175351|Experimental|Phase IIa 9MW1911|9MW1911 is administered intravenously (two doses selected on phase Ib). Each dose level includes up to 18 patients.
88855023|NCT06175351|Placebo Comparator|Phase Ib Placebo|Placebo is administered intravenously in a multiple ascending dose pattern in four dose levels. Each level includes 2 patients.
88855024|NCT06175351|Placebo Comparator|Phase IIa Placebo|Placebo is administered intravenously (two doses selected on phase Ib). Each dose level includes up to 6 patients.
88855025|NCT06175325|Other|Trans-radial embolisation of haemorrhoids|Haemorrhoids will be treated using arterial embolisation, using a trans-radial approach
89183366|NCT04878016|Placebo Comparator|placebo + carboplatin + etoposide|"The induction phase will consist of four cycles of placebo plus chemotherapy, with each cycle being 21 days in duration. On Day 1 of each cycle, all eligible patients will receive drug infusions in the following order:~placebo → carboplatin → etoposide"
89381952|NCT03241927|No Intervention|Healthy Donors|
89381953|NCT03936751|Active Comparator|CPAP|Continuous positive airway pressure
89381954|NCT03936751|Sham Comparator|Nasal strips|Nasal Strips
89381955|NCT05571865|Other|Control subjects (non-diabetic).|"Control subjects (non-diabetic):~10 subjects: No intervention (placebo). 10 subjects: Intervention (probiotic)"
89381956|NCT05571865|Other|Diabetic Subjects|"Diabetic subjects:~10 subjects: No intervention (placebo). 10 subjects: Intervention (probiotic)"
89381957|NCT03329885|Experimental|Part A Single Ascending Dose (SAD) in Healthy Patients|Healthy patient will receive single escalating oral doses of BMS-986251 or placebo
89381958|NCT03329885|Experimental|Part B Multiple Ascending Dose (MAD) in Healthy Patients|Healthy patients will receive daily escalating oral doses of BMS-986251 or placebo
89381959|NCT03329885|Experimental|Part C Multiple Dosing in Psoriasis Patients|Psoriasis patients will receive daily escalating oral doses of BMS-986251 or placebo
89381960|NCT00490763||Active Surveillance|Patients with low-risk prostate cancer who choose to undergo active surveillance.
89381961|NCT02941523|Experimental|1a NOX66|"NOX66 administered daily for 14 day in a 21-day treatment cycle. NOX66 treatment given to two cohorts of patients as 1 of 2 dose regimens:~Regimen 1: 400 mg; Regimen 2: 800 mg (idronoxil)"
88817796|NCT05325255|Active Comparator|Maitland mobilization alone group|"Maitland technique: caudal, anteroposterior (AP), and posteroanterior (PA) glides 5 sets of 2-3 glides per second of Grade III and IV for 30 seconds with a rest interval of 30 second between sets.~Stretching exercises in direction of abduction, external rotation (ER), internal rotation (IR), and flexion. 6 repetitions of each stretch for 10 seconds Cold pack for 20 mins"
88817797|NCT01762631||Cohort 1|All participants enrolled between November 2012 and March 2013 under the original protocol.
89183367|NCT04877470||Newly referred patients visiting the spine-centre|Newly referred patients visiting the spine-centre at Zuyderland Medical Centre Heerlen in 2019, from 01.01.2019 until 31.12.2019.
89183368|NCT04859621|Experimental|Vitamin D3 4000 IU|4000IU Vitamin D3 Oral Tablet plus standard antibiotic therapy
89183369|NCT04859621|Experimental|Vitamin D3 2000 IU|2000IU Vitamin D3 Oral Tablet plus standard antibiotic therapy
89183370|NCT04859621|Placebo Comparator|Placebo|Placebo Oral Tablet plus standard antibiotic therapy
89183371|NCT04840615|Experimental|1/Intra-tumoral LMB-100 Administration|Those with pleural or peritoneal mesothelioma receiving intra-tumoral administration of LMB-100 + ipilimumab for up to 4 cycles.
89183372|NCT04830215|Other|Brexpiprazole|Participants received brexpiprazole as a flexible dose; 0.5 mg to 2 mg, orally (PO), QD, and continued on the stable dose of ADT up to 8 weeks.
89183373|NCT04825912|Experimental|Adults with Advanced Lung Cancer|Older adults with stage III or stage IV lung cancer will be enrolled in the Self-System Therapy intervention to treat illness-related distress, depression, and to enhance self-efficacy via delivery of behavioral coping skills across a period of 10 weeks.
89183374|NCT04819841|Experimental|nula-cel Drug Product|nula-cel Drug Product is a human autologous CRISPR-Cas9 edited and sickle mutation-corrected HSPC product.
88817798|NCT01762631||Cohort 2|After Cohort 1 was completed, the study investigators changed the protocol to eliminate the photograph/weight of the powdered formula alone in each bottle to reduce burden. All other protocol procedures remained the same. Cohort 2 participants enrolled between April 2013 and May 2014.
88817799|NCT05315427||Evaluation of the impact of music therapy on the pain of patients|One music therapy session
88817800|NCT01251536|Other|Arm B - standard dose of cetuximab|Patients with skin toxicity grade 1-4 or other significant toxicity who are not eligible for dose escalation will continue on the standard dose of cetuximab 250 mg/m2 weekly. No comparison between arms was planned.
88817801|NCT01251536|Experimental|Arm A - dose escalation of cetuximab|Patients with skin toxicity grade 0 will follow an increasing dose schedule: on days 22 and 29 they will receive 350 mg/m2 and from day 36 onwards, 500 mg/m2 weekly.
88817802|NCT02619591|Active Comparator|Ultrasound Imaging - Single View|Ultrasound performed on patient. A single view of each hemithorax with ultrasound was performed on patient
88817803|NCT02619591|Experimental|Ultrasound Imaging - Multiple Views|Ultrasound performed on patient. Multiple view of each hemithorax with ultrasound was performed on patient
88817804|NCT02620683|Active Comparator|Buffered Lidocaine|"In week One each subject would receive anesthetic to block the inferior alveolar and lingual N; Halstead or Gow-Gates techniques. No Buccal N. block.~Venous blood samples would be drawn from the antecubital fossa 30min post oral injection and assayed for blood lidocaine levels"
88817805|NCT02620683|Active Comparator|Non-buffered Lidocaine|"In week One each subject would receive anesthetic to block the inferior alveolar and lingual N; Halstead or Gow-Gates techniques. No Buccal N. block. At least a week later injections would involve the alternate local anesthetic combination.~Venous blood samples would be drawn from the antecubital fossa 30min post oral injection and assayed for blood lidocaine levels"
88817806|NCT02621463|Experimental|Noninvasive Ventilation|Use of the Noninvasive Ventilator (V60, Philips). The ventilator mask will be placed on the patient's face according to their comfort using an elastomeric H-strap. CPAP of 8 cmH2O (pressure) will be the starting setting for the ventilator.
88817807|NCT01355588|Experimental|Ketorolac Tromethamine|
88817808|NCT01355588|Experimental|Ketorolac Tromethamine with 4% Lidocaine hydrochloride (HCl)|
88817809|NCT01355588|Experimental|Ketorolac Tromethamine with 5% Lidocaine HCl|
88817810|NCT01355588|Experimental|Ketorolac Tromethamine with 6% Lidocaine HCl|
88817811|NCT02621619|Experimental|IV acetaminophen + 0.5 mg IV hydromorphone|1 gram IV acetaminophen in addition to 0.5 mg IV hydromorphone
88817812|NCT02621619|Placebo Comparator|Normal saline + 0.5 mg IV hydromorphone|100 ml normal saline placebo in addition to 0.5 mg IV hydromorphone
88817813|NCT01253642|Experimental|Treatment (antiangiogenesis, chemosensitizer, chemotherapy)|Patients receive phenelzine sulfate PO QD on days -7 to -4, and then BID on days -3 to 21. Patients receive docetaxel IV over 60 minutes on day 1. Treatment repeats every 21 days for at least 12 weeks in the absence of disease progression or unacceptable toxicity.
88817814|NCT04022499|Experimental|Pre-NDPP|Presessions + usual care NDPP
88817815|NCT04022499|Active Comparator|Usual care NDPP|Usual care NDPP only
88817816|NCT04741113|Experimental|Intervention group -educational module|"The study intervention will include an online 15-minute educational module with four sections: a) Knowledge about obesity; b) Weight bias definition and impact; c) Strategies to reduce weight bias; d) A short quiz.~The module will be based on relevant literature and expert opinion. The module will be sent to participants via secured link."
88817817|NCT04741113|No Intervention|Control group|No intervention
88817818|NCT01355978|Experimental|Noninvasive Open Ventilation System|Portable noninvasive open ventilator & nasal interface.
88817819|NCT01357148||Participants treated with sitagliptin phosphate/metformin HCl|
88817820|NCT03008798|Experimental|Herbal Medicine C-117|Herbal Medicine C-117 6g granules by mouth,every 12 hours for 1 year
88817821|NCT03008798|Placebo Comparator|The Placebo of Herbal Medicine C-117|The Placebo of Herbal Medicine C-117 6g granules by mouth,every 12 hours for 1 year
88817822|NCT02623803|Active Comparator|Treatment group|lidocaine infusion will be initiated at the time of anesthesia induction in the operating room. Dosage 1.5mg/kg/hour. Continuous infusion until patient meets discharge criteria in recovery room.
88817823|NCT02623803|Placebo Comparator|Control group|placebo infusion (D5W) will be initiated at the time of anesthesia induction in the operating room. Continuous infusion until patient meets discharge criteria in recovery room.
88855026|NCT06175299|Experimental|Cognitive Training with Social Function|To promote adherence and reduce social isolation, participants will be asked to use home-based cognitive training program on a tablet for 30 minutes per day for 5 days a week for 1 month, then use it freely for another month. The cognitive training program has a chat function and a leadership board to allow interaction between participants.
88855027|NCT06175247|Experimental|Low Glycemic Index Diet Group|A low glycemic index diet will be started with ongoing dietician support & food questionnaires until pregnancy completion.
88855028|NCT06175247|No Intervention|Standard Diet Group|A standard diet, as chosen by participants, will be followed with ongoing food questionnaires until pregnancy completion.
88855029|NCT06175208|Experimental|internet-based Emotional Freedom Techniques (iEFT)|The first intervention entails emotional freedom techniques (EFT). EFT is a brief and easy to learn exposure therapy, originally developed to manage phobias and nowadays known to have many positive effects on both physiological and psychological aspects. Participants will apply EFT daily for the period of 6 weeks. During the trajectory, there is a first information session for participants (±20 minutes) and two follow-up sessions (±15 minutes). These sessions will be guided by the iEFT practitioner. This is an oncology health professional who has gone through a specific EFT training acknowledged by EFT International and is thus qualified and trained to conduct the trial.
88855030|NCT06175208|Active Comparator|internet-based mindfulness meditation intervention (iMMI)|The second intervention is a mindfulness meditation-based intervention focused on improving psychological, behavioural, and biological function in cancer survivors based on following sources: Mindfulness trainingsboek, Het achtweekse programma, stap voor stap (1), Mindfulness bij stress, burn-out en depressie, Een 8-weken-stappenplan voor hulpverleners (2), Mindfulness-based cognitive therapy for depression (3), Met radicale compassie naar de wereld kijken, De RAIN-methode (4). The mindfulness group intervention programme will be conducted once a week, for 2 hours during 6 weeks, by a trained mindfulness provider who will follow the study intervention protocol. Participants will apply mindfulness meditation daily for the period of 6 weeks.
88855031|NCT06175208|No Intervention|Wait-list Control Group (WLC)|The third arm of the study refers to the wait-list control (WLC) group with delayed intervention offered to the participants after they have completed parallel outcome assessments alongside the participants receiving the two interventions iEFT and iMMI, but not until the end of data collection (i.e. 6 weeks after the post-intervention assessment T1 for the cohort). Patients included in the WLC group can optionally join either the iEFT or iMMI group according to their preference, after 12 weeks (T2).
88855032|NCT06175195|Experimental|Treatment Group|"Experimental Group:~Participants in the experimental group would receive 8-10 session of psychoeducational based Program.~Waitlist control Group:~Participants in the Control group would not receive psychoeducational Intervention."
88855033|NCT06175195|No Intervention|Control Group|"Control Group:~Participants in the control group did not receive the said psychoeducational intervention."
88855034|NCT06175182||cystic fibrosis|No intervention
88855035|NCT06175182||healthy volunteers|No intervention
88855036|NCT06175169|Active Comparator|IA model|A fully automated diagnostic framework based on 3D-CNN model to predict non-appendicitis, simple and complicated appendicitis
88855037|NCT06175169|No Intervention|Non-radiologist|Ten non-radiologists participated in this study. CT image same to IA model was allocated to radiologist randomly.
88855038|NCT06175156|Experimental|Controlled analgesia/sedation (PCAS) group|Each group of patients is required to open the right upper limb venous access as a routine, take the left side lying position, and continuously inhale oxygen with a mask at a flow rate of 8L/min, while connecting various monitoring devices. During the pre anesthesia assessment, explain in detail to the patient the usage of the self-control pump and confirm that each patient can master it. Firstly, connect the self-control analgesic pump with a loading dose of 3 ml. Then, continuously pump in a mixture of propofol and remifentanil at a speed of 0.1 ml/kg/h. After the loading dose is completed, the examination can begin. During the operation, press the self-control handle according to the patient's sensation. Each press can quickly push 1ml of the medication, with a locking time of 1 minute.
88855039|NCT06175156|Active Comparator|Intravenous combined anesthesia group|Each group of patients is required to open the right upper limb venous access as a routine, take the left side lying position, and continuously inhale oxygen with a mask at a flow rate of 8L/min, while connecting various monitoring devices. Intravenous slow infusion of fentanyl 1 μ G/kg, midazolam 0.02mg/kg, slowly administer propofol 0.8-1mg/kg after 2 minutes (time greater than 60 seconds), and start the examination when the patient's consciousness disappears and they do not respond. During the surgery, propofol is interrupted to maintain the auditory evoked potential index (AAI) between 30-40.
88855040|NCT06175143|Experimental|GR2002 injection 1|GR2002 injection dose 1/Placebo，multiple-dose，Subcutaneous，high frequency
88855041|NCT06175143|Experimental|GR2002 injection 2|GR2002 injection dose 2/Placebo，multiple-dose，Subcutaneous，high frequency
88855042|NCT06175143|Experimental|GR2002 injection 3|GR2002 injection dose 3/Placebo，multiple-dose，Subcutaneous，high frequency
88855043|NCT06175143|Experimental|GR2002 injection 4|GR2002 injection dose 3/Placebo，multiple-dose，Subcutaneous，low frequency
88855044|NCT06175130||Healthy children (6-12 years)|Healthy children (6-12 years), no illness or disease
88855045|NCT06175130||Healthy Women of reproductive age (15-50 years)|Healthy Women of reproductive age (15-50 years), no illness or disease
88855046|NCT06175117|Experimental|compound E Jiao Jiang(cEJJ)|20ml (1 bottle) at a time, 3 times a day, should be taken orally before morning, lunch and dinner.
88855047|NCT06175117|Placebo Comparator|compound E Jiao Jiang(cEJJ) placebo|20ml (1 bottle) at a time, 3 times a day, should be taken orally before morning, lunch and dinner.
88855048|NCT06175104|Experimental|HeartGPS (Treatment Arm)|"Participants will receive usual fetal cardiac care plus the HeartGPS intervention. This is a novel psychological intervention leveraging virtual technology and user-centered design to reduce maternal psychological stress and anxiety after prenatal cardiac diagnosis and improve neurodevelopmental outcomes for infants with single ventricle CHD.~GPS stands for: Guiding through emotions, Providing information and support, and Strengthening connections.~The intervention includes sessions with a trained psychologist, coupled with tailored educational resources, and a personalized care plan to support longer-term parent, child, and family wellbeing."
89381962|NCT02941523|Experimental|1b NOX66 and Carboplatin (combined)|"NOX66 administered on Days 1-7 and carboplatin IV infusion on Day 2 of each 28-day treatment cycle up to 6 cycles.~NOX66 at the same dosage received in the Run-In Arm combined with 2 carboplatin doses starting with low dose carboplatin AUC = 4 for treatment cycles 1-3 followed by higher dose carboplatin AUC = 6 for treatment cycles 4-6."
89381963|NCT02941523|Experimental|2a NOX66 and Carboplatin|"This arm triggered by observed meaningful clinical responses from the 1b Combination Arm in particular disease indications.~Treatment NOX66 + carboplatin administered over 6 cycles each of 28-days at observed clinical response dosage. A maximum of 2 cohorts, each comprising patients with specific tumour type."
89381964|NCT03666143|Experimental|Anti-PD-1/PD-L1 antibody refractory/resistant NSCLC|
89381965|NCT03666143|Experimental|Anti-PD-1/PD-L1 antibody naïve NSCLC|
89381966|NCT03666143|Experimental|Anti-PD-1/PD-L1 antibody refractory/resistant RCC|
89381967|NCT03666143|Experimental|Metastatic or advanced RCC without prior systemic therapy|
89381968|NCT03666143|Experimental|Anti-PD-1/PD-L1 naïve recurrent / platinum resistant OC|
89381969|NCT03666143|Experimental|Anti-PD-1/PD-L1 treated metastatic, squamous NSCLC|
89381970|NCT03666143|Experimental|Anti-PD-1/PD-L1 antibody R/R melanoma|
89381971|NCT03666143|Experimental|PD-L1 positive, naïve, advanced or metastatic, non-sq NSCLC|
88817824|NCT03921021|Experimental|Telomelysin (OBP-301)|All patients will receive Telomelysin (OBP-301) at 2x10^12 viral particles (VP)/ tumor injection administered every two weeks x 4 injections as well as standard dose pembrolizumab 200 mg IV every 3 weeks. The tumor will be injected with OBP-301 four times (d1, d15, d29, d43). The preference is to inject the primary tumor endoscopically. Metastatic lesions may be injected on a case-by-case basis after discussion with the PI (Shah).
88817825|NCT02322788|Active Comparator|Bricanyl Turbuhaler M2, Active|Terbutaline sulphate powder for inhalation, 0.5 mg terbutaline per inhalation
89381972|NCT03666143|Experimental|PD-L1 positive, naïve, advanced or metastatic, sq NSCLC|
88817826|NCT02322788|Active Comparator|Bricanyl Turbuhaler M3, Active|Terbutaline sulphate powder for inhalation, 0.4 mg terbutaline per inhalation
89381973|NCT03609203||Patients|
89381974|NCT03609203||Controls|
89381975|NCT02938585|Experimental|Prophylactic treatment|
89381976|NCT02938585|Experimental|On-demand treatment|
89381977|NCT04661267|Experimental|Supplement formula|Patients randomized to the experimental group will receive daily 1-ounce doses of stem cell support formula for 60 days. Patients will complete patient-reported outcome questionnaires at 1 month and 2 months.
89381978|NCT04661267|Placebo Comparator|Placebo formula|Patients randomized to the control group will receive a daily 1-ounce doses of placebo stem cell support formula for 60 days. Patients will complete patient-reported outcome questionnaires at 1 month and 2 months.
89381979|NCT05571631|Experimental|Arm ergometer-balance training|Combination of arm ergometer exercise and balance training
89381980|NCT05571631|Experimental|arm ergometer|Only arm ergometer exercise training
88817827|NCT02322788|Placebo Comparator|Turbuhaler M2, Placebo|Placebo powder for inhalation
88817828|NCT02322788|Placebo Comparator|Turbuhaler M3, Placebo|Placebo powder for inhalation
88817829|NCT03832023|No Intervention|Facility-based model|Standard of care of each country
88817830|NCT03832023|Experimental|Community-based model|Screening and initiating preventive therapy in communities
88817831|NCT01316510|Active Comparator|Bifidobacteria infantis|1 billion organisms twice daily either through a feeding tube or by mouth for 6 weeks or until discharge (whichever happens first)
88817832|NCT01316510|Placebo Comparator|Placebo|A dilute formulation of the elemental formula Nutramigen (diluted to look like the probiotic arm).
88817833|NCT01318538|Experimental|Women's Recovery Group|The Women's Recovery Group (WRG) is a manual-based group therapy for women heterogeneous with respect to their substance use disorder, co-occurring psychiatric disorders, trauma history, age, and stage of life. The WRG is a 12-session, structured relapse-prevention group therapy that utilizes a cognitive behavioral approach and includes gender-specific content and single-gender group composition. Individual session content was derived from research on gender-specific substance use disorder antecedents, consequences, and treatment outcomes. The overall goals of the treatment are to (1) promote abstinence from all substances including alcohol; (2) improve understanding of specific aspects of SUDs, recovery, and relapse that are relevant to women, and (3) help participants with skills and strategies useful in preventing relapse and promoting recovery.
88817834|NCT01318538|Active Comparator|mixed-gender Group Drug Counseling|Group Drug Counseling (GDC) is a standard 12-week, 90-minute mixed-gender group therapy. The overall goals of GDC are to 1) help patients to achieve abstinence from all substances including alcohol; 2) educate patients regarding recovery from substance use disorders; 3) increase patients' self-awareness of the problems that their substance use disorder has caused; 4) encourage patients to give mutual support; and 5) help patients learn new ways to cope with problems in order to prevent relapse. The GDC was chosen as the comparison group to approximate group drug counseling that is consistent with treatment as usual within the community.
88817835|NCT02625207|Experimental|Cohort 1|African-Americans with No CYP3A5*1 alleles (poor metabolizer)
88817836|NCT02625207|Experimental|Cohort 2|African-Americans with One CYP3A5*1 allele (intermediate metabolizer)
88817837|NCT02625207|Experimental|Cohort 3|African-Americans with Two CYP3A5*1 alleles (extensive metabolizer)
89381981|NCT04282811||cohort group|Patients who have received at least one dose of venetoclax
89381982|NCT05220059|Experimental|Polyphenol extract low dose|156mg single dose
89381983|NCT05220059|Experimental|Polyphenol extract medium dose|222mg single dose
89381984|NCT05220059|Experimental|Polyphenol extract high dose|333mg single dose
89381985|NCT05220059|Placebo Comparator|Placebo|Maltodextrin single dose
88817838|NCT02625207|Experimental|Cohort 4|Caucasians with No CYP3A5*1 alleles (poor metabolizer)
88817839|NCT01256840||Calorie Restricting Group|
88817840|NCT01256840||Normal-eating controls|
88817841|NCT01256840||Obese comparison group|
88817842|NCT01763333|Experimental|1 BI 1026706 single rising dose part|single rising doses of BI 1026706
88817843|NCT01763333|Experimental|2 BI 1026706 bioavailability part|bioavailability part of BI 1026706
88817844|NCT02253173|Experimental|Estradiol 4mcg Vaginal Softgel Capsule|Estradiol 4mcg Vaginal Softgel Capsule
88817845|NCT02253173|Experimental|Estradiol 10mcg Vaginal Softgel Capsule|Estradiol 10mcg Vaginal Softgel Capsule
88817846|NCT02253173|Experimental|Estradiol 25mcg Vaginal Softgel Capsule|Estradiol 25mcg Vaginal Softgel Capsule
88817847|NCT02253173|Placebo Comparator|Placebo Vaginal Softgel Capsule|Placebo Vaginal Softgel Capsule
88817848|NCT05315765||Phase 1|Qualitative interviews with patients to generate thematic framework and questionnaire
88817849|NCT05315765||Phase 2|Face validity assessment of questionnaire
88817850|NCT05315765||Phase 3|Completion of questionnaire to refine scale and item list
88817851|NCT03951779|Experimental|Subjects with unexplained but suspected cardiac dyspnea|Subjects with unexplained but suspected cardiac dyspnea who are being scheduled for right heart catheterization will undergo an exercise cardiac magnetic resonance imaging (eCMR).
88817852|NCT05315609|Experimental|Intervention: Virtual Reality Mindfulness Group|The intervention will be 4-weeks, twice per week, 15-minute/session VR-mindfulness intervention group.
88817853|NCT05315609|No Intervention|No intervention: Waitlist Control Group|These participants will be on a waitlist to receive the VR guided meditation program after data collection has been completed (after the 4 weeks)
88817854|NCT01318694|Experimental|Treatment Arm A|"Alisporivir (ALV) 600 mg twice daily (BID) with Peginterferon alfa-2a (PEG) and ribavirin (RBV) for 1 week, followed by an additional 23 or 47 weeks according to response-guided treatment duration (RGT):~Participants with a viral load below the level of detection (< LOD) at Week 4 stop study treatment after 24 weeks~Participants with a viral load ≥ LOD at Week 4 complete 48 weeks of study treatment"
88817855|NCT01318694|Experimental|Treatment Arm B|Alisporivir (ALV) 400 mg twice daily (BID) with PEG and RBV for 24 or 48 weeks according to response-guided treatment duration (RGT)
88817856|NCT01318694|Experimental|Treatment Arm C|Alisporivir (ALV) 600 mg BID with PEG and RBV for 1 week, followed by 600 mg once daily (QD) for 47 weeks
88817857|NCT01318694|Active Comparator|Treatment Arm D|ALV Placebo with PEG and RBV for 48 weeks
88817858|NCT01319318||Pars Plana Vitrectomy|Pars plana vitrectomy performed in study eye on Day 0.
88817859|NCT01319552|Other|Fresh transfusion|1 unit autologous transfusion of red blood cells stored for 3-7 days under standard conditions
88817860|NCT01319552|Experimental|Old transfusion|1 unit autologous transfusion of red blood cells stored for 40-42 days under standard conditions
88817861|NCT03009578|Experimental|Intravenous iron|Women will receive iron sucrose (sacrofer ampules 100 mg/5ml) A patient's total body iron deficit will be calculated using the Ganzoni formula (total iron dose = [body weight (kilogram)× (15-actual Hemoglobin)] × 2.4 + 500 mg) then the total dose will be divided on 3 settings
88817862|NCT03009578|Active Comparator|Oral ferrous bis-glycinate|Women will receive oral ferrous bis-glycinate fully reacted amino acid 27 mg tablets
88817863|NCT02324660|Other|screening test|all consecutive patients admitted to our hospital for ACS and current/former smokers will be screened according our protocol with PEF and RHSQ. Patients will be blinded to result of both tests. Indipendently to results, all included patients will receive spirometry (50-70 days after inclusion) to assess the presence or not of COPD (primary outcome).
88817864|NCT01359410|Active Comparator|Stapled transection with mesh reinforcement|Mesh reinforced staple line (SEAMGUARD® or PERI-STRIPS DRY®)
88817865|NCT01359410|No Intervention|Stapled transection without mesh reinforcement|
88817866|NCT01361048|Active Comparator|oral metronidazole|control arm
88817867|NCT01361048|Experimental|neo penotran forte|neo penotran forte vaginal suppository twice a day for 7 days
88817868|NCT01361048|Experimental|neo penotran forte once a day|neo penotran forte vaginal suppository once a day for 7 days
88817869|NCT01258790|Sham Comparator|Sham Repetitive Transcranial Magnetic Stimulation|Eight sessions of Repetitive Transcranial Magnetic Stimulation, in the form of Continuous Theta Burst Stimulation, was delivered over the Supplementary Motor Area over 2 days using a Sham TMS coil.
88817870|NCT01258790|Experimental|Active Repetitive Transcranial Magnetic Stimulation|Eight sessions of Repetitive Transcranial Magnetic Stimulation, Continuous Theta Burst Stimulation, was delivered over the Supplementary Motor Area over 2 days using an Active Magstim Figure-8 TMS coil.
88817871|NCT01766219|Experimental|Arm 1: (6,8-bis[benzylthio]octanoic acid) 2,300 mg/m²|"Participants will not be treated with CPI-613 during pre-Cycle 1 and will only be treated with 3 weeks on/1 week off at 2,300 mg/m² as a starting dose. If none of these 3 participants develop a dose-limiting toxicity through Cycle 1, the dose for the 3-weeks-on-1-week-off treatment cycles will be 3,000 mg/m² in all subsequent participants in this trial.~Patients receive 6,8-bis(benzylthio)octanoic acid IV over 2 hours on days 1 and 4 of weeks 1-3. Treatment repeats every 4 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients responding to treatment may receive up to 4 more courses of treatment."
88817872|NCT01766219|Experimental|Arm 2: (6,8-bis[benzylthio]octanoic acid) 1,200/3,00 mg/m²|"Participants will received pre-cycle 1 week dose at 1200 mg/m² and dosing will escalate to 3,000 mg/m² for the three weeks on, one week off cycle.~Patients receive 6,8-bis(benzylthio)octanoic acid IV over 2 hours on days 1 and 4 of weeks 1-3. Treatment repeats every 4 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients responding to treatment may receive up to 4 more courses of treatment."
88817873|NCT01766219|Experimental|Arm 3 (6,8-bis[benzylthio]octanoic acid) 600/3,000 mg/m²|"Participants will received pre-cycle 1 week dose at 600 mg/m² and dosing will escalate to 3,000 mg/m² for the three weeks on, one week off cycle.~Patients receive 6,8-bis(benzylthio)octanoic acid IV over 2 hours on days 1 and 4 of weeks 1-3. Treatment repeats every 4 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients responding to treatment may receive up to 4 more courses of treatment."
89381986|NCT03229759|Experimental|Investigational Product|Polyester cloth impregnated with investigational product
89381987|NCT03229759|Placebo Comparator|Vehicle Control (VC)|Polyester cloth impregnated with the vehicle control
89381988|NCT03229759|Placebo Comparator|Saline Control (SC)|Saline applied wtih polyester cloth
89381989|NCT03476681|Experimental|NEO-201 in combination with pembrolizumab|Subjects will receive 3 doses NEO-201 in combination with one dose of pembrolizumab in a 42 day cycle. This course will be repeated in the absence of disease progression or unacceptable toxicity.
89381990|NCT03620825|Experimental|Dehydration by sauna exposure|Participants dehydrate using sauna exposure until they lose 3% of their body weight.
89381991|NCT03620825|Active Comparator|Indomethacin - Positive control|Indomethacin is administered to induce increased intestinal permeability
89381992|NCT03620825|No Intervention|Negative control|No intervention is performed
89381993|NCT01312649|Experimental|Arm 1|Healthy volunteers
89381994|NCT01312649|Experimental|Arm 2|Schizophrenia with history of delusions of control
89381995|NCT01312649|Experimental|Arm 3|Schizophrenia without history of delusions of control
88855049|NCT06175104|No Intervention|Usual Fetal Cardiac Care (Control Arm)|In the usual care arm, participants will receive the information, support, and resources currently offered by their fetal heart care team. This can include support from their doctor or nurse, a social worker, psychologist, or support group, as well as information booklets, websites, and other resources to help parents learn more about their baby's heart condition.
89381996|NCT01312649|Experimental|Arm 4|Bipolar disorders
88855050|NCT06175039|Experimental|Telerehabilitation Exercise Group|
88855051|NCT06175039|Other|Control Group|
88855052|NCT06175013|Experimental|Group 1 : Sérum PURIFIANT|Participant will apply Sérum PURIFIANT on the affected toenail, twice daily during the 112 days of the study.
88855053|NCT06175013|Experimental|Group 2 : Sérum PURIANT associated with Sérum BOOSTER|"Participant will apply Sérum PURIFIANT on the affected toenail, twice daily during the 112 days of the study.~They will also apply Sérum BOOSTER, twice weekly, 5 minutes before the Sérum PURIFIANT."
88855054|NCT06174974|Experimental|Experimental group|The patients in the experimental group will be informed by the researcher in the training room in the ward 1 day before the operation (verbal permission was obtained) with an educational presentation on intensive care unit stressors.
88855055|NCT06174974|No Intervention|Control group|Patients in the control group will not be given preoperative training on intensive care unit stressors by the researcher. Patients in the control group will receive standard care*.
88855056|NCT06174935|Experimental|Atropine 0.01%|Patients will apply 1 drop daily of atropine 0.01%
88855057|NCT06174922|Active Comparator|Prednisolone|Oral prednisolone 0.5 mg/kg/day for 4 weeks; 0.25 mg/kg/day for 4 weeks; 0.125 mg/kg/day for 4 weeks. Then taper 5 mg every 4 weeks and discontinue by 4 months. After breakfast, oral prednisolone will be administered as a morning dose (8-10 am).
88855058|NCT06174922|Active Comparator|Itraconazole|Oral SUBA-itraconazole 65 mg 2 capsules BD for 4 months. Oral itraconazole will be given twice daily (9 am and 9 pm) spaced one hour with meals. We will perform therapeutic drug monitoring for itraconazole at two weeks and two months. We will increase the itraconazole dose to a maximum of 390 mg/day (six 65 mg capsules) in those with trough itraconazole levels <0.5 µg/mL.
88855059|NCT06174922|Experimental|Prednisolone plus itraconazole|Oral prednisolone 0.5 mg/kg/day for 4 weeks; 0.25 mg/kg/day for 4 weeks; 0.125 mg/kg/day for 4 weeks. Then taper 5 mg every 4 weeks and discontinue by 4 months. After breakfast, oral prednisolone will be administered as a morning dose (8-10 am); and, Oral SUBA-itraconazole 65 mg 2 capsules BD for 4 months. Oral itraconazole will be given twice daily (9 am and 9 pm) spaced one hour with meals. We will perform therapeutic drug monitoring for itraconazole at two weeks and two months. We will increase the itraconazole dose to a maximum of 390 mg/day (six 65 mg capsules) in those with trough itraconazole levels <0.5 µg/mL.
88855060|NCT06174909|Experimental|Calcium Hydroxide|"Calcium hydroxide has antimicrobial properties and tissue altering effect,used into root canals for the purpose of inhibiting coronal invasion of bacteria from the oral cavity."
88855061|NCT06174909|Active Comparator|Triple antibiotic Paste|"Triple antibiotic paste is combination of ciprofloxcin,metronidazole,and minocycline,used into root canals for the purpose of inhibiting coronal invasion of bacteria from the oral cavity."
89381997|NCT01312649|Active Comparator|Arm 5|Matched healthy controls
89381998|NCT01312727|Other|HTIN|HTIN
89381999|NCT03228433|Experimental|Cohort 1: TAK-418 5 mg|TAK-418 5 milligram (mg), capsule, orally, once on Day 1.
89382000|NCT03228433|Experimental|Cohort 2: TAK-418 15 mg|TAK-418 15 mg, capsule, orally, once on Day 1. Actual dose of TAK-418 may vary based on safety, tolerability and PK data from previous Cohorts.
89382001|NCT03228433|Experimental|Cohort 3: TAK-418 30 mg Fasted + TAK-418 30 mg Fed|TAK-418 30 mg, capsule, in fasted state, orally, once on Day 1, followed by a 28-day washout period, further followed by TAK-418 30 mg, capsule, in fed state, orally, once on Day 1. Actual dose of TAK-418 may vary based on safety, tolerability and PK data from previous Cohorts.
89382002|NCT03228433|Experimental|Cohort 4: TAK-418 40 mg|TAK-418 40 mg, capsule, orally, once on Day 1. Actual dose of TAK-418 may vary based on safety, tolerability and PK data from previous Cohorts.
89382003|NCT03228433|Experimental|Cohort 5: TAK-418 60 mg|TAK-418 60 mg, capsule, orally, once on Day 1. Actual dose of TAK-418 may vary based on safety, tolerability and PK data from previous Cohorts.
89382004|NCT03228433|Placebo Comparator|Cohorts 1-5: Placebo|TAK-418 placebo-matching, capsule, orally, once on Day 1.
89382005|NCT04463797|Experimental|Square-stepping exercise group|Square-stepping exercise
89382006|NCT04463797|Active Comparator|Control group|Whole-body stretching and upper extremity strengthening
88855062|NCT06174896|Active Comparator|Group 1|Placement with standard technique
88855063|NCT06174896|Active Comparator|Group 2|Placement with direct laryngoscopy
88855064|NCT06174896|Active Comparator|Group 3|Placement with the aid of video laryngoscopy
88855065|NCT06174870|No Intervention|Control|Control group
88855066|NCT06174870|Experimental|Intervention|IMT group
88855067|NCT06174844||Sample 1|Data collected from 1st January to 30th June of 2024
88855068|NCT06174844||Sample 2|Data collected from 1st January to 30th June of 2025
88855069|NCT06174818||TN|Patients with trigeminal neuralgia
88855070|NCT06174779|Experimental|HM11260C|Weekly administration by subcutaneous injection
88855071|NCT06174779|Placebo Comparator|Placebo|Weekly administration by subcutaneous injection
88855072|NCT06174766|Experimental|Experimental1|Take HGP2102-1 once daily for 4 weeks orally, and then take HGP2102-2 once daily for 6 weeks orally.
88855073|NCT06174766|Experimental|Experimental2|Take HGP2102-1 once daily for 10 weeks orally.
88855074|NCT06174766|Active Comparator|Active Comparator|Take RLD2209-1 once daily for 4 weeks orally, and then take RLD2209-2 once daily for 6 weeks orally.
88855075|NCT06174753|Experimental|Treatment|Dapagliflozin 10mg daily X 7 days
88855076|NCT06174753|Placebo Comparator|Placebo|Placebo daily X 7 days
88855077|NCT06174740|Experimental|Music-Cued Audiovisual Motor Training|Participants will be instructed on the task which they will perform at home online using a keyboard. The training involved auditory-cued audiovisual finger movement sequence learning task. Participants will complete an online computer-based training of 20 minutes at home 3 times per week for the duration of 8 weeks, and a total of 24 sessions, the duration and number of sessions.
88855078|NCT06174740|Active Comparator|Visually-Cued Motor Training|Participants will be instructed on the task which they will perform at home online using a keyboard. The training involved visual cues for finger-movement sequence learning task. Participants will complete an online computer-based training of 20 minutes at home 3 times per week for the duration of 8 weeks, and a total of 24 sessions, the duration and number of sessions
88855079|NCT06174714|Experimental|MI and Indo-SURFT|once a week motivational interviewing/motivational enhancement therapy (MI) for 4 weeks, followed by once a week CBT using Indonesia Substance Use Reduction for Female Therapy (Indo-SURFT) for 8 weeks.
88855080|NCT06174675|Active Comparator|Study group|"patients will receive combined bilateral infraorbital and infratrochlear nerve block.~20 patients"
88855081|NCT06174675|No Intervention|control group|"patients will not receive the block and will receive intravenous analgesia according to standard protocol.~20 patients."
88855082|NCT06174662|Experimental|Music|Music through noise cancelling headphones.
88855083|NCT06174662|No Intervention|No music|Control group receiving regular care. No music will be offered to the patient.
88855084|NCT06174636|Experimental|Abdominal Pressure Rise|Application of an abdominal weight and record of respiratory mechanics data, intra-abdominal pressure variation, Electrical Impedance Tomography data
88855085|NCT06174623|Experimental|ModulHeart System|
88855086|NCT06174597|Experimental|UCA-PSCs/bFGF group|Clusters of umbilical cord artery-derived perivascular stem cells (Dose: 1.2 x 10^8 cells+20ng bFGF /20mL/vial)
88855087|NCT06174597|Active Comparator|bFGF group|(Dose: 20ng bFGF /20 mL/vial)
88855088|NCT06174584|Active Comparator|Cow Milk|Cow Milk was injected as sclerosing agent in one group
88855089|NCT06174584|Active Comparator|15% Hypertonic Saline|Hypertonic Saline 15% used as sclerosing agent in other half.
89382007|NCT03930121|Experimental|Experimental group|Anodal transcranial direct current stimulation (tDCS) combined with speech-language therapy (SLT, including naming therapy and communicative-pragmatic therapy)
89382008|NCT03930121|Sham Comparator|Control group|Placebo stimulation (using sham-tDCS) combined with SLT
88855090|NCT06174571||1|patients diagnosed with breast cancer at different stages of the disease.
88855091|NCT06174571||2|apparently healthy females as a control group.
88855092|NCT06174545|No Intervention|Group 1 (HQ group)|Group 1 is control group, getting SPF 30 sunscreen cream in the morning and only 2% Hydroquinone cream at night without a combination cream and facial soap that can be used in the morning and evening.
88855093|NCT06174545|Experimental|Group 2 (PSP Group)|Group 2, the treatment group, used PSP cleanser, PSP Day Cream and SPF 30 sunscreen in the morning and used Hydroquinone 2% and PSP Night Cream at night and PSP cleanser which was used in the morning and evening before using the cream.
88855094|NCT06174506||Patients with pacemakers without atrial fibrillation at the beginning or in history|"Patients with pacemakers without atrial fibrillation at the beginning or in history.~Patients are adults over 18 years old."
88855095|NCT06174454|Experimental|Inervention group|The intervention group will be subject to RPP. Techniques of slow expiration will be used and slow inspiration for the sweeping of secretions, during its expulsion forced expiratory techniques will be used (tracheal reflex). 10 sessions will be performed, one a day from Monday to Friday, with a duration of 10 to 15 minutes.
88855096|NCT06174454|Placebo Comparator|Control Group|Will be subject to PD plus muscle belly compressions of the upper limbs for 10 sessions, one session a day from Monday to Friday, with a duration de 10 to 15 minutes per patient. Both groups will receive the usual treatment for pneumonia prescribed by their treating doctor.
88855097|NCT06174428||Oral Squamous Cell Carcinoma (OSCC)|OSCC case cohort will consist of patients with Oral Squamous Cell Carcinoma (all stages, locations), recruited from either primary or secondary care.
88855098|NCT06174428||Oropharyngeal Squamous Cell Carcinoma (OPSCC)|OPSCC case cohort will consist of patients with Oral Squamous Cell Carcinoma (all stages, locations), recruited from either primary or secondary care.
88855099|NCT06174428||Cancer-free|Cancer-free control cohort will be matched with cases. Participants will be recruited following clinical adjudication with self-reported confirmation of no cancer and from primary and secondary care facilities.
88855100|NCT06174415|Experimental|Experimental group|The experimental group consisted of the patients themselves. Compare data before and after treatment
88855101|NCT06174389|Experimental|Behavioral Weight Loss|Participants will undergo a behavioral weight loss program.
88855102|NCT06174376|Experimental|GORE Synthetic Cornea Device|Treatment with GORE Synthetic Cornea Device
89183375|NCT04807777|Experimental|Ruxolitinib|"In a safety lead-in of 6 patients, subjects will receive 15mg of ruxolitinib twice daily (BID). After 4 weeks, if dose-limiting toxicities (DLT) are observed in 1 or fewer patients, the study will enter stage 1 of the Simon two-stage design where all subsequent patients will receive a starting dose of ruxolitinib 15mg BID.~Subjects will have regularly scheduled study visits at the clinical site on Day 1 and Day 15 (± 3 days) of the first 2 cycles, then on Day 1 (± 3 days) of every subsequent cycle (starting cycle 3), where safety assessments, including laboratory assessments, vital signs, and physical examinations will be performed."
88817874|NCT01767155|Experimental|AEZS-108 / zoptarelin doxorubicin|267 mg/m^2 by 2-hour intravenous infusion, on Day 1 of 21-day (3-week) cycles up to 9 cycles
88817875|NCT01767155|Active Comparator|doxorubicin/ standard chemotherapy|60 mg/m^2 by intravenous bolus injection or 1-hour intravenous infusion, on Day 1 of 21-day (3-week) cycles
88817876|NCT01362686|Experimental|Donepezil|See intervention note.
88817877|NCT01362686|Experimental|Galantamine|See intervention note.
88817878|NCT01362686|Experimental|Rivastigmine|See intervention note.
88817879|NCT04351646||SARS-CoV-2 negative inpatients|Hospitalised adult patients with SARS-CoV-2 negative tests.
88817880|NCT04351646||SARS-CoV-2 positive inpatients|Hospitalised adult patients with SARS-CoV-2 positive tests.
88817881|NCT04351646||SARS-CoV-2 suspected or confirmed NHS staff|Suspected or proven SARS-CoV-2 positive cases amongst health care professionals and lab staff.
88817882|NCT01322048|Experimental|Adrenergic Blockade|Propranolol and Clonidine
88817883|NCT01322048|Placebo Comparator|Placebo|Placebo
88817884|NCT01322360|Other|Morphine Sulfate|oral solution (10 mg/5 mL or 20 mg/5 mL) or tablets (15 mg or 30 mg)given based on based on the current pediatric prescribing guidelines
88817885|NCT05315375||Corpectomy|surgical procedure using expandable cage
88817886|NCT05315219|Experimental|Endoscopic Thyroidectomy Bilateral Areola Approach|
88817887|NCT05315219|No Intervention|Open Thyroidectomy|
88817888|NCT04351724|Experimental|(Hydroxy)Chloroquine (STOPPED)|"Due to limited availability of the experimental substances, this arm will include both chloroquine and hydroxychloroquine treatment. However, both substances are similar chemically and also with regards to the mechanism of action comparable.~Dosage: Hydroxychloroquine 200mg 2-0-2 on day 1 followed by 200mg 1-0-1, or Chloroquine 250mg 2-0-2, as available"
88817889|NCT04351724|Experimental|Lopinavir/Ritonavir|Dosage: 200mg/50mg 4-0-4 on day 1 and 3-0-3 thereafter
88817890|NCT04351724|Other|Standard of Care|"patients will be treated with standard of care, which precludes treatment with lopinavir/ritonavir or (hydroxy-)chloroquine"
88817891|NCT04351724|Experimental|Rivaroxaban|5mg 1-0-1
88817892|NCT04351724|Active Comparator|Thromboprophylaxis|according to local standard
88817893|NCT04351724|Experimental|RAS Blockade|Renin-Angiotensin-System-Blockade (RAS) by candesartan intake starting with 4mg once daily and titrated to normotension patients > 120/80 mmHG are eligible
88817894|NCT04351724|Active Comparator|non-RAS-Blockade|non-RAS blocking antihypertensive agents titrated to normotension Those with normal blood pressure may only be controlled without further treatment
88817895|NCT04351724|Experimental|Asunercept 25mg|25mg 1x per week, maximum of four doses only patients with oxygen requirement
88817896|NCT04351724|Experimental|Asunercept 100mg|100mg 1x per week, maximum of four doses only patients with oxygen requirement
88817897|NCT04351724|Experimental|Asunercept 400mg|400mg 1x per week, maximum of four doses only patients with oxygen requirement
88817898|NCT04351724|Other|Best Standard of Care - Control Group for Asunercept|only patients with oxygen requirement
88817899|NCT04351724|Experimental|Remdesivir|200mg loading dose on day 1, 100mg for a total treatment duration of 5-10 days
88817900|NCT04351724|Experimental|Pentaglobin|Patients treated at the intensive care unit only, continuous infusion of 7ml/kg/day over 12h for 5 days
88817901|NCT04351724|Other|best standard of care|Patients treated at the intensive care unit only
88817902|NCT01767701|Experimental|Raltegravir|All eligible patients will complete a 3 months observation period (no medications) followed by 3 months on treatment period. During the treatment period patients will be treated with open label raltegravir 400mg twice daily.
88817903|NCT01322594|Experimental|MEDI2338 10 MG|MEDI2338 (10 mg) administered as a single, fixed intravenous (IV) dose over a minimum of 60 minutes using an infusion pump
88817904|NCT01322594|Experimental|MEDI2338 30 MG|MEDI2338 (30 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump
88817905|NCT01322594|Experimental|MEDI2338 100 MG|MEDI2338 (100 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump
88817906|NCT01322594|Experimental|MEDI2338 300 MG|MEDI2338 (300 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump
88817907|NCT01322594|Experimental|MEDI2338 1000 MG|MEDI2338 (1000 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump
88817908|NCT01322594|Placebo Comparator|Placebo|Placebo administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump
88817909|NCT01767935|Experimental|Treatment (cryosurgery and radiation therapy)|Patients undergo cryosurgery. Beginning 2 weeks later, patients undergo 1, 10, or 15 fractions of radiation therapy 5 days per week for 1-3 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
88817910|NCT01363388|Placebo Comparator|Placebo|Placebo plus a full dose of oral glucocorticoids for steps 1 and 2 of the study
88817911|NCT01363388|Experimental|CCX168|30 mg Active study medication, plus either two-thirds reduced dose of oral glucocorticoids for step 1 of the study, or no oral glucocorticoids for step 2 of the study
88817912|NCT01768013|Experimental|LEO 90105 Ointment|
88817913|NCT04351412|Active Comparator|Tactile stimulus|The tactile stimulus was examined using an explorer (# 17/23), passing at a right angle to the bucco-cervical tooth surface of concern. Contributors evaluated participants' pain score on a 10-point visual analogue scale (VAS). The stimulus was used to assess dentine hypersensitivity at baseline and immediately after completion of treatment. Subjects were also recalled for re-evaluation at 2 weeks and at 1 month after desensitizing treatment.
89382009|NCT01496118|Experimental|Carfilzomib and Panobinostat|"Phase I:~Carfilzomib: cycle 1 - Dose is 20 mg/m^2 IV on day 1; 27 or 36 or 45 or 56 mg/m^2 IV on Days 8, 9, 15, 16 cycle 2 to progression - 27 or 36 or 45 or 56 mg/m^2 IV on days 1, 2, 8, 9, 15, 16~Panobinostat: cycle 1 and cycle 2 to progression - 20 mg or 30 mg on days 1, 3, 5, 15, 17, 19~Phase II:~Carfilzomib and Panobinostat: Dose is optimal dose determined in Phase I"
88855103|NCT06174350|Experimental|experimental group|Cognitive behavioral therapy will be applied to the individuals in the experimental group who were exposed to the earthquake.
88855104|NCT06174350|Experimental|Placebo group|No intervention will be applied to the control group of individuals exposed to the earthquake.
88855105|NCT06174311|Experimental|Active Cognitive Bias Modification|Based on the outcomes of pre-intervention measurements, 50 participants who score high on intolerance to uncertainty measurement will be chosen randomly to be included in this condition. This group of participants will receive three interventions targeting interpretation biases related to uncertainty, with each intervention administered at three-day intervals. Each session is scheduled to have an estimated duration of around 30 minutes.
88855106|NCT06174311|No Intervention|Control (Waitlist) Cognitive Bias Modification|The waitlist control group will not receive any interventions during the process. They will only undergo pre-test, post-test, and follow-up measurements. If they still wish to receive the intervention, it will be provided to them after the follow-up assessment.
88855107|NCT06174285|Experimental|Psyrreal|Psychedelic virtual reality experience.
88855108|NCT06174285|Sham Comparator|Routine Realms|A non-psychedelic virtual reality experience that is largely analogous to Psyrreal.
88855109|NCT06174285|No Intervention|No intervention|A conditional waiting list condition. This condition may be included, dependent on the availability of sufficient participants and resources.
88855110|NCT06174194|Experimental|Tulsi Gum Arm|All participants were instructed to masticate gum containing Tulsi extract for a duration of 5 minutes and subsequently discard the gum. Salivary samples were collected before commencing gum chewing and after 30 minutes following the conclusion of chewing gum for 5 minutes.
88855111|NCT06174181|Experimental|Experimental|Preservative-free ophtalmic lubricant emulsion countinuous during 6 month after intravitreal Injections for Age-related macular degeneration
88855112|NCT06174181|Other|Routine treatment|Preservative-free ophtalmic lubricant emulsion during few days after intravitreal Injections for Age-related macular degeneration
88855113|NCT06174142|Experimental|High-Frequency ESWT Group|This arm will receive extracorporeal shockwave therapy (ESWT) with a higher frequency setting of 15 Hz and an intensity/pressure of level 3. Participants will receive a total of 1800 impulses per session for 6 sessions, with one session per week, alongside a selected physical therapy program.
88855114|NCT06174142|Experimental|Low-Frequency ESWT Group|Experimental
88855115|NCT06174142|Sham Comparator|Sham ESWT Control Group|Participants in the control group will undergo a sham shockwave therapy protocol, which simulates ESWT treatment without actual therapeutic effects, to serve as a comparison for the active treatments. They will also engage in the same physical therapy program as the other two arms.
88855116|NCT06174129||Type 2 diabetes patients with atrial fibrillation|The 12-lead electrocardiography recordings of type 2 diabetes patients were reviewed by a cardiologist to confirm the presence of atrial fibrillation. The clinical parameters, including age, sex, body-mass index, underlying medical conditions, blood pressure, heart rate, type 2 diabetes duration, laboratory values, and medications were analyzed and compared between atrial fibrillation and non-atrial fibrillation patients.
88855117|NCT06174129||Type 2 diabetes patients without atrial fibrillation|The 12-lead electrocardiography recordings of type 2 diabetes patients were reviewed by a cardiologist to confirm the presence of atrial fibrillation. The clinical parameters, including age, sex, body-mass index, underlying medical conditions, blood pressure, heart rate, type 2 diabetes duration, laboratory values, and medications were analyzed and compared between atrial fibrillation and non-atrial fibrillation patients.
88855118|NCT06174103|Experimental|BiVACOR TAH|The BiVACOR TAH System will be implanted as a bridge to transplant (BTT) for adults with severe irreversible biventricular heart failure or univentricular heart failure in which LVAD support is not recommended, and who are eligible for cardiac transplantation.
89382010|NCT02936869|No Intervention|Control arm|Traditional birth attendants will receive an offer of two-weekly payouts per reported delivery they take that is verified by client.
88855119|NCT06174090|Experimental|Video-education|Participants will receive video-education about bypass surgery care, the day before the surgery, for once.
88855120|NCT06174090|No Intervention|Control|Participants will receive verbal education about bypass surgery care, the day before the surgery, once
88855121|NCT06174064|Active Comparator|Protocol 1--420 and 560nm wavelengths|Broadband light treatment Patients will be treated with BBL with 420nm wavelength filter followed by 560nm wavelength filter to malar and periorbital areas once monthly for 3 months. Dry eye evaluation consisting of clinical testing as well as quality of life questionnaires will be performed at baseline and after the last BBL treatment.
88855122|NCT06174064|Active Comparator|Protocol 2--560nm wavelength|Broadband Light treatment Patients will be treated with BBL with 560nm wavelength filter to malar and periorbital areas once monthly for 3 months. Dry eye evaluation consisting of clinical testing as well as quality of life questionnaires will be performed at baseline and after the last BBL treatment.
88855123|NCT06174064|Sham Comparator|Sham|Sham Broadband Light Treatment Patients will undergo the same preparation and procedure as for BBL treatment but the light source will be occluded. Patients will be treated with sham to malar and periorbital areas once monthly for 3 months. Dry eye evaluation consisting of clinical testing as well as quality of life questionnaires will be performed at baseline and after the last sham treatment.
88855124|NCT06174012|Experimental|Sodium Fluoride Group|
88855125|NCT06174012|No Intervention|Conventional care group|
88855126|NCT06173999|Experimental|Treatment group A|
88855127|NCT06173999|Experimental|Treatment group B|
88855128|NCT06173986|Experimental|IC+ICRT group|2 cycles of PD-1 inhibitor + nab-paclitaxel + cisplatin followed by concurrent PD-1 inhibitor + radiotherapy (45-50Gy/25fx) + nab-paclitaxel + cisplatin
88855129|NCT06173934|Experimental|Patients with rapid gastric emptying|Patients with rapid gastric emptying
88855130|NCT06173934|Experimental|Patients with slow gastric emptying|Patients with slow gastric emptying
88855131|NCT06173921|Experimental|Robotic system|implant placement by robotic surgery
88855132|NCT06173921|Active Comparator|Static system|implant placement by static navigation surgery
88855133|NCT06173908|Experimental|cell treatment|Autologous epidermal basal cells were used to treat postoperative nonhealing wounds
88855134|NCT06173908|Sham Comparator|control treatment|Conventional method were used to treat postoperative nonhealing wounds
88855135|NCT06173882|Placebo Comparator|Ordinary moxibustion volume group|
88855136|NCT06173882|Experimental|First group of heavy moxibustion|
89382011|NCT02936869|Experimental|Referral incentive arm|"Traditional birth attendants will receive an offer of two-weekly payouts per reported delivery they take that is verified by client.~Traditional birth attendants randomized to this arm will also receive an offer of two-weekly payouts per successful referral of delivery clients to postnatal care within 48 hours of delivery in a facility if verified."
89382012|NCT05083884||Group 1: Peri-menopausal woman|Grouping is based on Peri-menopausal woman
88855137|NCT06173882|Experimental|Second groups of heavy moxibustion|
88855138|NCT06173856|Active Comparator|Phototherapy group|LED phototherapy (430-470nm)
88855139|NCT06173856|Experimental|phototherapy with probiotics group|In group B, LED phototherapy (430-470nm) with probiotics (125mg Saccharomyces boulardii, twice a day, orally mixed in 5cc of milk whichever the neonate is taking).
88855140|NCT06173843||Firefighters|
88855141|NCT06173843||Non-Firefighters|
88855142|NCT06173830|Active Comparator|Ultrasound-guided radiofrequency ablation of the genicular nerve in chronic knee osteoarthritis|A total of 34 patients with chronic knee osteoarthritis meeting the criteria will undergo ultrasound-guided radiofrequency ablation of the genicular nerve.
88855143|NCT06173830|Active Comparator|physical therapy for chronic knee osteoarthritis|Thirty-four patients with chronic knee osteoarthritis meeting the criteria will receive 10 sessions of physical therapy.
88855144|NCT06173817|Experimental|Isocapnic hyperventilation (iHV)|"Loading dose of fomepizole on clinical suspicion; A) History of intake of alcohol of unknown/illegal origin plus symptoms potentially occurring from methanol, or B) history as above and verified methanol poisonings among people drinking the same alcohol, or C) metabolic acidosis of unknown origin (where methanol cannot be excluded as the cause;or D) a combination of these.~● iHV started after a S-methanol concentration > 50 mg/dL is obtained (typically within 4 hours) and initial acidosis is partly or fully corrected by sodium bicarbonate (BD <15mM, HCO3- >10mM)"
89183376|NCT04794101|Experimental|Deferred Treatment From MGT-RPGR-021 of Intermediate Dose|Deferred treatment
89183377|NCT04794101|Experimental|Already Treated in MGT-RPGR-021|Already treated
89382013|NCT05083884||Group 2: Post- menopausal woman|Grouping is based on Post-menopausal woman
89382014|NCT05083884||Group 3: Peri-menopausal woman: moderate-to-severe MR-VMS|Grouping is based on Peri-menopausal woman with moderate-to-severe vasomotor symptoms (MR-VMS)
89382015|NCT05083884||Group 4: Post-menopausal woman: moderate-to-severe MR-VMS|Grouping is based on Post-menopausal woman with moderate-to-severe vasomotor symptoms (MR-VMS)
89382016|NCT03606096|Experimental|Boostrix IPV - infant acellular Pertussis (TdaP-aP)|vaccination of the mother with Boostrix-IPV vaccine which includes the infant acellular pertussis
89382017|NCT03606096|Experimental|Boostrix IPV - infant whole Pertussis (Tdap-wP )|vaccination of mother with Boostrix -IPV which includes infant whole cell pertussis
89382018|NCT03606096|Active Comparator|TT - infant acellular Pertussis (T-ap )|vaccination of mother with TT-which includes infant acellular pertussis
89382019|NCT03606096|Active Comparator|TT - infant whole Pertussis (T-wP)|vaccination of mother with T which includes infant whole cell pertussis
89382020|NCT03309605|Placebo Comparator|Placebo Comparator Arm|Placebo
88855145|NCT06173791|Active Comparator|DFDBA Fibers with DBBM|After standard of care elevation of the Schneiderian membrane, a mix of DFDBA fibers with DBBM (50%-50%) will be introduced in the space created between the Schneiderian membrane and the alveolar crest of the maxilla.
88855146|NCT06173791|Other|DFDBA Particles with DBBM|After standard of care elevation of the Schneiderian membrane, a mix of DFDBA particles with DBBM (50%-50%) will be introduced in the space created between the Schneiderian membrane and the alveolar crest of the maxilla.
88855147|NCT06173778|Experimental|semaglutide|
88855148|NCT06173778|Placebo Comparator|placebo|
88855149|NCT06173765|Experimental|36g of strawberry|High dose intervention
88855150|NCT06173765|Experimental|12g of strawberry|Low dose intervention
88855151|NCT06173765|Placebo Comparator|0g of strawberry|Control
88855152|NCT06173752|Experimental|Exposure therapy|"Participants will complete exposure therapy for up to 12 weeks, and each coached exposure session will be approximately 50 minutes. Exposure plans will be developed collaboratively between participants and their clinician at the beginning of treatment, and refined iteratively as clinically appropriate. In each coached exposure, participants will:~Complete an Exposure Feedback Form~Wear a wristwatch that provides psychophysiological data~The intervention will occur across two study sites (McLean Hospital, San Diego State University). Sites will differ on level of care. At McLean Hospital, participants will be recruited from the OCD Institute and will receive exposure therapy via partial hospital or residential setting as part of their standard care, regardless of participation in the study. At San Diego State University, participants will be recruited to receive exposure therapy via outpatient setting."
88855153|NCT06173739|Active Comparator|Peri-implant mucositis|"It is defined as widespread inflammatory disease of the soft tissue surrounding endosseous implants without loss of crestal bone or marginal bone. Peri-implant mucositis is diagnosed by pain, swelling, redness and bleeding on probing in the soft tissue around the dental implant.~Diagnosis will be completed based on radiographic and clinical findings at the first encounter with the patient.~In the second session, PICF (peri-implant crevicular fluid) will be collected from both groups of implants and phenotype evaluations will be made.~Following the recording of clinical parameters (PD, GI, PI, CAL, BOP), non-surgical mechanical treatment will be applied to both groups."
89002773|NCT06152653|Active Comparator|NAC via jet nebulizer|NAC (trade name: Mucomyst) is manufactured by American Regent. The active drug studied here is 10% NAC coadministered with albuterol and delivered via standard jet nebulizer. Participants will each complete 5 treatment visits over the course of 30 days. Each treatment visit will consist of two treatments separated by 4 hours.
89183378|NCT04794101|Experimental|Deferred Treatment From MGT-RPGR-021 Low Dose|Deferred treatment
89382021|NCT03309605|Experimental|ELX-02|ELX-02
89382022|NCT02936635|Experimental|Delayed Start Treatment|The Delayed Start Treatment group consisted of patients who received placebo in CY 4031 and tirasemtiv in CY 4033.
89382023|NCT02936635|Experimental|Early Start Treatment|The Early Start Treatment group consisted of patients who received tirasemtiv in both CY 4031 and CY 4033.
89382024|NCT03227029|Experimental|RSV ΔNS2/Δ1313/I1314L vaccine|Participants received a single dose of the RSV ΔNS2/Δ1313/I1314L vaccine at study entry (Day 0).
89382025|NCT03227029|Experimental|RSV 276 vaccine|Participants received a single dose of the RSV 276 vaccine at study entry (Day 0).
89382026|NCT03227029|Placebo Comparator|Placebo|Participants received a single dose of placebo at study entry (Day 0).
89382027|NCT05571475|Experimental|Simulated competition|During the experimental condition, the participants will be competing for a reward, will be given verbal encouragement, and will receive performance feedback.
89382028|NCT05571475|No Intervention|Control|During the control condition, the participants will be asked to sprint without verbal encouragement or any performance feedback.
89382029|NCT03487614|Experimental|Behavior-based parental intervention|The study intervention included two primary components: 1) physician-family health behavior conversations during well-child visits, and 2) four monthly visits with a RDN to evaluate, educate, and implement improved feeding habits and nutritional choices. A third optional component of the intervention included counseling sessions with a social worker to help families overcome barriers to change, such as food security, family relationships, and general parenting strategies.
89382030|NCT03487614|No Intervention|Control|Control parents signed the informed consent document and then completed all baseline assessments during their child's medical visit. Control participants then received their usual medical care. Follow-up evaluations, including child anthropometry and completion of study surveys were assessed approximately 6 months later during a second office visit. For children <3 years of age at baseline, follow up visits coincided with their subsequent well-child visit (i.e. 30-month or 3-year appointment) as per AAP visit frequency recommendations. For patients ≥3 years of age, families attended a separate office visit 6 months after their baseline visit in order to complete follow-up study assessments.
89382031|NCT05015634|Active Comparator|Active Arm|Patients will be discharged from the hospital with the telemedicine package. If the patient develops possible cardiac symptoms and seeks medical attention, the data provided by the telemedicine package will be acted upon, as appropriate, by the trial cardiology team. With remote follow up over the phone at 3, 6 and 9 months.
89382032|NCT05015634|Placebo Comparator|Control Arm|Standard routine clinical care will be carried out, with remote follow up over the phone at 3, 6 and 9 months.
88855154|NCT06173739|Active Comparator|Peri-implantitis|"Peri-implantitis is a pathology that occurs in the tissues around dental implants, characterized by inflammation of the peri-implant mucosa and destruction of marginal and crestal bone. Clinical diagnosis is defined by the presence of bleeding on probing, the presence of pathological pockets, exudate, swelling, edema, and hyperemia, while findings of bone loss are supported by radiography.~Diagnosis will be completed based on radiographic and clinical findings at the first encounter with the patient.~In the second session, PICF (peri-implant crevicular fluid) will be collected from both groups of implants and phenotype evaluations will be made.~Following the recording of clinical parameters (PD, GI, PI, CAL, BOP), non-surgical mechanical treatment will be applied to both groups."
88855155|NCT06173726|Experimental|BST02 Injection|
88855156|NCT06173713|Other|Emphasys Hip Solutions|Emphasys Acetabular Shell, Emphasys AOX Polyethylene Liner, Articul/eze 12/14 metal head and Emphasys fem. stem
88855157|NCT06173700|Experimental|Single Group Intervention|7-week web-based group with problem solving training
88855158|NCT06173622|Experimental|Fetal positioning group|The neonates in the experimental group were put into fetal positioning at least 10 minutes before the procedure, and then venipuncture was performed. The fetal positioning was maintained throughout the procedure and the patient was kept in the fetal position for at least five more minutes after needle removal.
88855159|NCT06173622|No Intervention|Control group|No intervention was performed by the researchers on the neonates included in the control group, and venipuncture was performed in accordance with the standard procedure of the neonatal intensive care unit.
88855160|NCT06167954|Experimental|EXPLORER|8 sessions with the robotics gait device in their homes and natural environment for all participants
88855161|NCT06167733|Experimental|Active|
88855162|NCT06167733|Sham Comparator|Sham|
88855163|NCT06167551|Experimental|mother lullaby group|group listening to mother's lullaby
88855164|NCT06167551|Experimental|white noise group|group listening to white noise
88855165|NCT06167551|Experimental|classical music group|group listening to classical music
88855166|NCT06167551|Other|Control group|No intervation
88855167|NCT06167499|Experimental|Therapeutic Education Group.|Medical follow-up every 6 months for 18 months (inclusion, M6, M12, M18) associated with therapeutic education consultations conducted by nurses in the month following inclusion (between D0 and M1), M3, M9 and M15
88855168|NCT06167499|No Intervention|Standard|Medical follow-up every 6 months for 18 months (Inclusion, M6, M12, M18) :usual practice
89382033|NCT03329573|Experimental|AB treatment sequence receivers in fasting group|Eligible subjects will receive a single dose of Paroxetine IR tablets A in Period 1 followed by Paroxetine IR tablets B in Period 2 in fasting state.
89382034|NCT03329573|Experimental|BA treatment sequence receivers in fasting group|Eligible subjects will receive a single dose of Paroxetine IR tablets B in Period 1 followed by Paroxetine IR tablets A in Period 2 in fasting state.
89382035|NCT03329573|Experimental|AB treatment sequence receivers in fed group|Eligible subjects will receive a single dose of Paroxetine IR tablets A in Period 1 followed by Paroxetine IR tablets B in Period 2 in fed state.
89382036|NCT03329573|Experimental|BA treatment sequence receivers in fed group|Eligible subjects will receive a single dose of Paroxetine IR tablets B in Period 1 followed by Paroxetine IR tablets A in Period 2 in fed state.
89382037|NCT00604201|Experimental|Co-infusion of UCB and Haploidentical CD34+ cells|Stem cell recipients received co-infusion of unrelated umbilical cord blood (UCB) and haploidentical CD34+ cells from a related donor following non-myeloablative conditioning for neutropenic patients with severe aplastic anemia (SAA) or myelodysplastic syndrome (MDS) with refractory anemia (RA)
89382038|NCT00492349|Experimental|1|Varenicline
89382039|NCT00492349|Placebo Comparator|2|Placebo
89382040|NCT00340015||AARP|Members of the AARP, aged 50-71 years, and who resided in one of six states
89382041|NCT03308825|Experimental|Group 1: 6 to < 36 Months|Children aged 6 to < 36 months received a 0.25-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0. For participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered on Day 28.
89382042|NCT03308825|Experimental|Group 2: 3 to < 9 Years|Children aged 3 to < 9 years received a 0.5-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0. For participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered on Day 28.
89382043|NCT03308825|Experimental|Group 3: 18 to < 65 Years|Adults aged 18 to < 65 years received a 0.5-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0.
89382044|NCT03308825|Experimental|Group 4: >= 65 Years|Adults aged >= 65 years received a 0.5-mL dose of Fluzone High-Dose vaccine, intramuscularly, at Day 0.
88855169|NCT06167200||Patients with DoC consecutively admitted to participating units and met the inclusion criteria|Patients in VS or MCS due to severe acquired brain injury with different etiology (traumatic, anoxic, vascular) consecutively admitted at participating neurorehabilitation units. The total sample will be composed of 42 patients (n=7 pts per participating unit).
89382045|NCT04235855|Experimental|Endoscopic USG guided Liver biopsy|Olympus linear echo endoscope (GF -UCT 180, Olympus Ltde, Tkyo, Japan) will be used. 19 Gz EUS Acquire needle Boston ©Scientific Corp will be used for liver tissue acquisition.
89382046|NCT04235855|Active Comparator|Percutaneous Liver biopsy|All liver biopsies done in the Institute as routine procedure by percutaneous route would be compared with the EUS guided biopsy in respect to safety , tissue quality and diagnostic yield .
89382047|NCT05196503|Active Comparator|Experimental group|Surgery for disc herniation and intraoperative periradicular administration of PRF
89382048|NCT05196503|Active Comparator|Control group|Surgery for disc herniation alone (i.e. reference treatment).
89382049|NCT03328325|Experimental|Arm 1|0.5 mL dose of quadrivalent (IIV-4) vaccine administered once intramuscularly, n=240
89382050|NCT03366467|Experimental|SADE first|SADE first will initially be treated under SADE (Time 1) and receive RDE on the second encounter (Time 2)
89382051|NCT03366467|Experimental|RDE first|RDE first will initially be treated under RDE (Time 1) and receive SADE on the second encounter (Time 2)
88855170|NCT06167161|Active Comparator|Screening, intake and first fit (either clinician-fitting or self-fitting )|This clinical trial compares two methods of fitting individuals who suffer from hearing loss with a hearing aid device. Subjects will wear the hearing aid after receiving the clinician-fitting (device fitted by a clinician according to standard clinical best practice procedures) and self-fitting (device fitted by the user directly without assistance from a clinician following an automated assessment and fitting process) for two weeks each, totaling to approximately 1 month of wear throughout the trial. During the first visit, all individuals will go through intake procedures and a basic audiologic evaluation. After this is completed, individuals will be randomly assigned into one of two arms of the study. Individuals in the first visit of the study, will receive either the clinician-fitting or the self-fitting method for the first two weeks, then will switch to the experimental self-fitting or the clinician-fitting method for the last half. The order of the fitting will be randomized.
89002774|NCT06152653|Experimental|NAC via AeroEclipse-VersaPAP|NAC (trade name: Mucomyst) is manufactured by American Regent. The active drug studied here is 10% NAC coadministered with albuterol and delivered via the AeroEclipse-VersaPAP system. Participants will each complete 5 treatment visits over the course of 30 days. Each treatment visit will consist of two treatments separated by 4 hours.
89002775|NCT06152081|Experimental|All Participants|All participants enrolled in the study will have the two caries detecting devices used during each research visit.
89382052|NCT05039489|Experimental|The schizophrenia patients with medication-resistant auditory hallucinations|Drug + cTBS intervention (the left cerebellum Crus II as the stimulation target)
89382053|NCT05039489|Active Comparator|The schizophrenia patients with general auditory hallucinations|Drug intervention
89382054|NCT05039489|No Intervention|The healthy controls|MRI scan at baseline and no drugs treatment
89382055|NCT05039489|Experimental|Drug + cTBS intervention: the first-episode schizophrenia patients with auditory hallucinations|Drug + cTBS intervention (the left temporoparietal cortex as the stimulation target)
89002776|NCT06151574|Experimental|Experimental treatment arm|zongertinib only
89002777|NCT06151574|Active Comparator|Comparator arm|pembrolizumab plus platinum-pemetrexed chemotherapy
89382056|NCT05039489|Active Comparator|Drug intervention: the first-episode schizophrenia patients with auditory hallucinations|Drug intervention
89382057|NCT05039489|Experimental|The schizophrenia patients with medication-resistant auditory hallucinations from the fourth arm|Drug + cTBS intervention (the left cerebellum Crus II as the stimulation target)
89382058|NCT05008289|Active Comparator|ACTIVE|Magnetic transcutaneous spinal cord stimulation
89382059|NCT05008289|Sham Comparator|PLACEBO|
89382060|NCT04967105||elderly patients following liver resection|elderly patients (aged ≥60 years) scheduled for any type of liver resection due to benign or malignant hepatobiliary diseases
89382061|NCT04098497|Experimental|ACT-based microintervention delivered by mobile app|"At every time-point of the study, participants will complete self-reports of mania (as measured by the shortened YMRS), depression (as measured by the shortened SIGH-D ), medication adherence, and activity through the mobile app Lorevimo. After completing these assessments, participants will be randomly assigned to either receive one additional ACT-based microintervention question or receive no additional question.~The microintervention will consist of one of 84 prompts that aim to target one of 6 processes targeted in ACT (contacting the present moment, defusion, acceptance, self-as-context, values, and committed action).~The ACT-based questions were developed by the research team as a unique intervention for the current study. They are based upon core themes of acceptance and commitment therapy: engagement, awareness, and openness."
89382062|NCT04045223||Epidural analgesia and fever|Group 1 will be patients with vaginal delivery and having an epidural analgesia that develop fever during delivery.
89382063|NCT04045223||Epidural analgesia and no fever|Group 2 will be patients with vaginal delivery and having an epidural analgesia that do not develop fever during delivery.
89382064|NCT04045223||No epidural analgesia|Group 3 serves as additional control group and consists of patients having no epidural analgesia and no fever.
89382065|NCT04003961||Moderate/high risk for OSA with EDS|All clinical data of the patients who has moderate/high risk for OSA with excessive daytime sleepiness (EDS) will be assessed with statistical methods.
89382066|NCT04003961||Moderate/high risk for OSA without EDS|All clinical data of the patients who has moderate/high risk for OSA without excessive daytime sleepiness(EDS) will be assessed with statistical methods.
89382067|NCT04003961||Low risk for OSA|All clinical data of the patients who has low risk for OSA will be assessed with statistical methods.
89382068|NCT03986957||Hypertensive patients|Patients with SBP: 140-159; DBP: 90-99
89382069|NCT03665545|Active Comparator|IMA950/Poly-ICLC|IMA950 mixed with Poly-ICLC administered subcutaneously
88855171|NCT06167161|Sham Comparator|Second fit (either clinician-fitting or self-fitting )|In the second visit of the study, individuals who randomly received the conventional clinician-fitting for the first two weeks (first period) will switch to the experimental self-fitting for the remainder of the study (second period). Conversely, individuals who received the experimental self-fitting method for the first two weeks (first period) will switch to the clinician-fitting method for the last two weeks (second period). The same within-subject crossover design will be followed in both clinical sites and for all individuals who were enrolled in the study.
88855172|NCT06167096|Experimental|Lavender|4 drops of lavender essential oil will be added to an electronic diffusion device with 100ml of water. The device will be turned on 15 minutes before surgery for participants who previously agreed to the study. The device will be turned off after completion of the post- layer questionnaires assessing anxiety and participant experience.
88855173|NCT06167096|Placebo Comparator|Water|On the day of surgery, participants who previously completed the electronic consent will be brought to a room with a diffuser. The diffusers will be turned on 15 minutes before scheduled time of surgery with just water for the control group
88855174|NCT06166862|Experimental|Action observation and motor imagery therapy for rehabilitation|Action observation and motor imagery therapy for rehabilitation in stroke patients in addition to conventional rehabilitation programs.
88855175|NCT06166862|Sham Comparator|Sham action observation and motor imagery therapy for rehabilitation|Sham comparator for action observation and motor imagery therapy for rehabilitation in stroke patients in addition to conventional rehabilitation programs.
88855176|NCT06166654|Active Comparator|Acetazolamide|1. 500 mg IV bolus of acetazolamide at randomization (day 0) and repeated the next 3 mornings (day 1, day 2 and day 3). This arm will also receive a placebo- Metolazone tablet together with each acetazolamide-injection.
89382070|NCT03665545|Experimental|IMA950/Poly-ICLC and pembrolizumab|Pembrolizumab 200mg q3w IV and IMA950 mixed with Poly- ICLC administered subcutaneously
88855177|NCT06166654|Active Comparator|Metolazone|2.5 mg oral Metolazone at randomization (day 0) and repeated the next 3 mornings (day 1, day 2 and day 3). This arm will also receive a placebo- acetazolamide injection together with each metolazone-tablet.
89382071|NCT03305081|Experimental|Immediate or early placement|Immediate or early placement of levonorgestrel IUD, copper IUD, or etonorgestrel sub dermal implant (within 48 hours) postpartum
89382072|NCT03305081|Active Comparator|Interval placement|Interval (4-6 weeks) postpartum placement of levonorgestrel IUD, copper IUD, or etonorgestrel sub dermal implant
89382073|NCT04079881|Experimental|A (Pre-prandial insulin administration) : B (post-prandial insulin administration)|"VISIT 1: Pre-prandial insulin: will give short acting insulin (Humalog, Lispro, etc) with the same regimen patient was using at home 20 min prior the meal.~Then VISIT 2: Post-prandial insulin: will give short acting insulin (Humalog, Lispro, etc) with the same regimen patient was using at home 20 min post the meal."
89382074|NCT04079881|Experimental|B (post-prandial insulin administration) : A (Pre-prandial insulin administration) :b|"VISIT 1: Post-prandial insulin: will give short acting insulin (Humalog, Lispro, etc) with the same regimen patient was using at home 20 min post the meal.~Then VISIT 2: Pre-prandial insulin: will give short acting insulin (Humalog, Lispro, etc) with the same regimen patient was using at home 20 min prior the meal."
89382075|NCT03891329|Other|Acticor/Rivacor ICDs/CRT-Ds|Implant of the new Cor Family ICDs and Plexa ProMRI S DX lead (if applicable). Device measurements, pre-defined programming and Adverse Event Reporting
89382076|NCT03325673|Experimental|TrueTear|TrueTear Device (Intranasal Tear Neurostimulator) was used intranasally on contact lens (CL) wear days; it was also used on non-CL wear days if the participant chose. The number of applications was determined by participant.
89382077|NCT03325673|Sham Comparator|TrueTear Sham Control|TrueTear sham device, which is not electrically active and has limited tip insertion depth, was used intranasally on CL wear days; it was also used on non-CL wear days if participant chose. The number of applications was determined by participant.
89183379|NCT04787198|Experimental|hypertonic saline|
89183380|NCT04787198|Placebo Comparator|isotonic saline|
89183381|NCT04783935|Experimental|Mavenclad®|
89382078|NCT03223909|Experimental|PRO-087 PF|Preservative free (PF) PRO-087 ophthalmic solution. Dropper bottle. Multidose 1 drop every 4 hours for 90 days.
89382079|NCT03223909|Active Comparator|Systane Ultra|"Systane Ultra ophthalmic solution, Dropper bottle, Multidose.~1 drop every 4 hours for 90 days."
89382080|NCT03223909|Active Comparator|Systane Ultra PF|"Systane Ultra, preservative free ophthalmic solution, single-use vials.~1 drop every 4 hours for 90 days."
89382081|NCT03733925|Experimental|Golimumab|Participants will receive golimumab 50 milligram (mg) subcutaneous (SC) injection at Week 0 and every 4 weeks (q4w) thereafter through Week 24. Concomitant medications may be allowed on a case by case basis as per the physician's judgement.
89382082|NCT03649711|Experimental|CKD-Ticagrelor|Ticagrelor 90 mg twice daily (double blind, random assignment) + aspirin 81 mg/d
89382083|NCT03649711|Active Comparator|CKD-Clopidogrel|Clopidogrel 75 mg/day in the morning and a matching placebo in the evening to conceal frequency (double blind, random assignment) + aspirin 81 mg/d
89183382|NCT04779827|Experimental|Egalitarian Networks of Homogeneous Populations|Egalitarian networks are characterized by equal connectivity for all participants in an online network for information exchange. Each network is consisted of 40 individual participants. All network participants in this condition share similar baseline demographic characteristics, attitudes, or behavioral choices.
89382084|NCT03649711|Active Comparator|Control-ticagrelor|Open label ticagrelor, 90 mg twice daily + aspirin 81 mg/d
89382085|NCT05181631|Experimental|Biobanking|"If the patient consents, two tubes of blood will be collected for biobanking, at the same time as routine tubes will be collected.~Samples will be collected by hospital staff and stored following regulatory conditions of conservation in the biological resources center of Avicenne hospital ."
89382086|NCT03303521|Experimental|Sodium Zirconium Cyclosilicate (ZS)|Suspension administered orally for a treatment period of eight weeks (4 weeks of dose adjustment, 4 weeks in stable dose) Single dose contains from 1 to 3 sachets of ZS 5g depending on dose level assigned to a patient per non-dialysis days.
89382087|NCT03303521|Placebo Comparator|Placebo|Suspension administered orally for a treatment period of eight weeks (4 weeks of dose adjustment, 4 weeks in stable dose) Single dose contains from 1 to 3 sachets of Placebo depending on dose level assigned to a patient per non-dialysis days.
88855178|NCT06166654|Placebo Comparator|Placebo|Usual care with loop-diuretics as the sole diuretic (SGLT2-inhibitors allowed) including guideline-recommended increase in loop-diuretic dose and fluid and salt-restriction. This arm will also receive both a placebo-acetazolamide injection together with a placebo-metolazone-tablet at randomization and repeated the next 3 mornings (day 1, day 2 and day 3).
88855179|NCT06166420|Experimental|home-based|A team made up of a Community Health Worker (CHW) and a nurse will do door-to-door sensitization and propose to eligible women to undergo HPV self-sampling test at home. Samples collected will be taken by the nurse to the hospital for HPV testing . Participants will receive a phone call: disclosure of the HPV test's result will be by phone call for HPV-negative participants; HPV-positive participants will be invited to the hospital for disclosure of their results. At the hospital, HP-positive participants will undergo visual assessment of their cervix and treatment if needed.
89382088|NCT03214081||Vonoprazan 10 mg or 20 mg|Usually, for adults, 10 mg of vonoprazan administered orally once daily. If that dosing proved insufficient, the dosage may have been increased up to 20 mg once daily. Participants received vonoprazan as part of a routine medical care.
89382089|NCT05181397|Experimental|Tocilizumab|Participants in tocilizumab group will receive intravenous 8mg/kg tocilizumab. No Intervention: control, participants in control group will receive regular treatment.
89382090|NCT05181397|No Intervention|Control|Participants in control group will receive regular treatment.
88855180|NCT06166420|Active Comparator|hospital-based|Community Health Worker (CHW) will do door-to-door sensitization and invite eligible women to attend cervical cancer screening at District Hospital Dschang. At the hospital they will do HPV self-sampling test. HPV-negative women will be advised to repeat the test after 5 years while HPV positive women will undergo visual assessment of the cervix with acetic acid and lugol (VIA/VILI) and treatment if needed.
89183383|NCT04779827|Experimental|Egalitarian Networks of Diverse Populations|Egalitarian networks are characterized by equal connectivity for all participants in an online network for information exchange. Each network is consisted of 40 individual participants. All network participants in this condition have very different baseline demographic characteristics, attitudes, or behavioral choices.
89382091|NCT02888171|Experimental|ferric citrate|Participants randomized to the ferric citrate arm will receive 2 grams of ferric citrate three times a day with each meal.
89382092|NCT02888171|Active Comparator|ferrous sulfate|Participants randomized to the ferrous sulfate arm will receive 325 mg of ferrous sulfate three times a day
89382093|NCT02932891|Experimental|DSXS topical|active treatment
89382094|NCT04517903|Experimental|exploratory phase|eye rubbing questionnaire at baseline and 15 days later
89382095|NCT04517903|Experimental|Confirmatory phase|eye rubbing questionnaire at baseline and at 6 month follow-up
89382096|NCT05181319||bronchopulmonary dysplasia group|infants diagnosed with bronchopulmonary dysplasia
89382097|NCT05181319||no bronchopulmonary dysplasia|infants not diagnosed with bronchopulmonary dysplasia
89382098|NCT03302975|Experimental|Real time biofeedback|Real-time visual biofeedback of braking forces during a treadmill run.
89382099|NCT03212521|Experimental|Glecaprevir/Pibrentasvir|Participants received oral glecaprevir/pibrentasvir (300 mg/120 mg) once daily with food for 8 weeks.
89382100|NCT05181241|Experimental|Group No. 1 (n=6) Dimolegin - 20 mg|Group No. 1 (n=6) consisted of 2 cohorts with 3 volunteers per each. Volunteers of Cohorts 1 and 2 received Dimolegin (DD217) once at a dose of 20 mg
89382101|NCT05181241|Experimental|Group No. 2 (n=6) Dimolegin - 40 mg|Group No. 2 (n=6) consisted of 2 cohorts with 3 volunteers per each. Volunteers of Cohorts 3 and 4 received Dimolegin (DD217) once at a dose of 40 mg
89382102|NCT05181241|Experimental|Group No. 3 (n=12) Dimolegin - 60 mg|Group No. 3 (n=12) consisted of 3 cohorts. Cohorts 5 and 6 included 3 volunteers per each, and Cohort 7 included 6 volunteers. All Group 3 volunteers received Dimolegin (DD217) once at a dose of 60 mg
89382103|NCT03212365|Other|Fixed Dose|Participants will receive 40 mg enoxaparin twice daily
89183384|NCT04779827|Experimental|Centralized Networks of Homogeneous Populations|"Centralized networks have a small number of influential individuals, called hubs, with connections to most other people. Centralized networks characterize situations in which most or all individuals are connected to, and seek advice from, a few well-connected influencers. Each network is consisted of 40 individual participants. All network participants in this condition share similar baseline demographic characteristics, attitudes, or behavioral choices."
89183385|NCT04779827|Experimental|Centralized Networks of Diverse Populations|"Centralized networks have a small number of influential individuals, called hubs, with connections to most other people. Centralized networks characterize situations in which most or all individuals are connected to, and seek advice from, a few well-connected influencers. Each network is consisted of 40 individual participants. All network participants in this condition have very different baseline demographic characteristics, attitudes, or behavioral choices."
89183386|NCT04779827|Experimental|Independent Control of Homogeneous Populations|Independent control condition does not have online networks. Participants in this condition are not put into online networks. Participants only respond to questions by themselves. All participants in this condition share similar baseline demographic characteristics, attitudes, or behavioral choices.
89183387|NCT04779827|Experimental|Independent Control of Diverse Populations|Independent control condition does not have online networks. Participants in this condition are not put into online networks. Participants only respond to questions by themselves. All participants in this condition have very different baseline demographic characteristics, attitudes, or behavioral choices.
89183388|NCT04776629|Active Comparator|Active Treatment|"Dosage: Repeating intravenous dose. Administered by infusion over 30 minutes.~Frequency and duration: once weekly x 4 weeks, then once monthly x 2 months."
89183389|NCT04776629|Placebo Comparator|Placebo|"Dosage: Repeating intravenous dose. Administered by infusion over 30 minutes.~Frequency and duration: once weekly x 4 weeks, then once monthly x 2 months."
89183390|NCT04775953|Experimental|Arm 1 (Dalbavancin)|Dalbavancin 1500 mg will be administrated intravenously (IV) over 30 (-/+10) minutes on Day 1 and 1500 mg IV over 30 (-/+10) minutes on Day 8, renally dose-adjusted to 1125 mg for subjects with Creatinine Clearance (CrCl) <30 and not on dialysis. N=100
89183391|NCT04775953|Active Comparator|Arm 2 (Standard of Care)|For Methicillin-sensitive Staphylococcus aureus (MSSA): nafcillin (2 g will be administrated intravenously (IV) every 4 hours for 4-6 weeks) OR oxacillin (2 g will be administrated intravenously (IV) every 4 hours for 4-6 weeks OR cefazolin (2 g will be administrated intravenously (IV) every 8 hours for 4-6 weeks) For Methicillin-resistant Staphylococcus aureus (MRSA): vancomycin (dose per local standard of care × 4-6 weeks) OR daptomycin (6-10 mg/kg will be administrated intravenously (IV) daily for 4-6 weeks). N=100
89183392|NCT04773353|Experimental|Follitropin Delta (FE 999049)|Recombinant follicle-stimulating hormone (rFSH). Follitropin delta for subcutaneous injection
89183393|NCT04773353|Experimental|Follitropin Alfa (GONAL-F)|rFSH. Follitropin alfa for subcutaneous injection
89183394|NCT04767217|Active Comparator|artemether-lumefantrine (ALN)|
89183395|NCT04767217|Active Comparator|dihydroartemisinin-piperaquine (DHA-PPQ)|
89183396|NCT04765384|Experimental|Groups 1-4: Ad26.COV2.S (One Dose)|Participants who are previously vaccinated (Group 1-3) and participants who are vaccine naïve (Group 4) will receive single dose of Ad26.COV2.S vaccine at standard dose level on Day 1. Participants from group 4 who are no longer pregnant may receive single booster dose of Ad26.COV2.S vaccine at standard dose level.
89183397|NCT04763421|Experimental|Upper Gastrointestinal/Lower Gastrointestinal/Gynecological|Any upper gastrointestinal/lower gastrointestinal/gynecological procedure where the ENSEAL X1 Curved Jaw is used for vessel transection according to instructions for use.
89183398|NCT04763109|Experimental|Whole-Body Magnetic Resonance Imaging|
89183399|NCT04751448||Observational|All patients going on study will be put in the observational grouping for blood and tissue collection with option for stool collection.
89183400|NCT04741607|Active Comparator|Control group|Delayed implant placement
89183401|NCT04741607|Experimental|Test group|Immediate implant placement
89183402|NCT04731233|Experimental|PRGF Arm|The PRGF experimental group will have two cc of PRGF infused into the upper joint space after the TMJ arthrocentesis procedure.
89183403|NCT04731233|Active Comparator|Steroid Arm|Two cc containing 40 mg of triamcinolone acetonide with 5 mg bupivacaine will be infused into the upper joint space after the TMJ arthrocentesis procedure.
89183404|NCT04724746|Experimental|Written Exposure and Cognitive Behavioral Therapy|Participants receive 5 to 6, 60 minute, sessions of written exposure therapy for posttraumatic stress disorder combined with cognitive behavioral therapy for substance use disorder.
89183405|NCT04722432|Experimental|Système de cathéter détachable dehors du scope (DDS)|
89183406|NCT04718675|Experimental|Part 1: Dose Escalation|Sequential cohorts of participants will receive escalating doses of KB-0742.
89382104|NCT03212365|Experimental|Variable Dose|Participants will receive 0.5mg/kg enoxaparin twice daily
89382105|NCT01314469||Patients with intermediate uveitis|
89382106|NCT03487627|Experimental|Electronic and Care Support Manager Contact|Participants receive electronic content and contact with a Care Support Manager
89382107|NCT03487627|Active Comparator|Enhanced treatment-as-usual (TAU)|Participants receive enhanced treatment-as-usual
89382108|NCT05328505|Experimental|Molecular Imaging Informed Radiation Dose Escalation and De-escalation|Molecular imaging informed radiation dose escalation to sites of recurrent disease and de-escalation to uninvolved areas.
89382109|NCT03273257|Active Comparator|Riociguat|Patients will receive riociguat for 3 months followed by pulmonary endarterectomy.
89382110|NCT03273257|Placebo Comparator|Placebo|Patients will receive placebo for 3 months followed by pulmonary endarterectomy.
89382111|NCT04316741|Experimental|Brief Intervention+Health Coaching|Brief intervention with social-media delivered health coaching
89382112|NCT04316741|No Intervention|Control|Enhanced usual care brochure plus attention control with social media messaging
89382113|NCT02700035|Experimental|BZDDD Prevention Program Intervention|We employed an experimental randomized block (RB) design; blocked on reservation where 157 were assigned to the intervention condition (Bii-Zin-Da-De-Dah (Listening to One Another) 14 week family based prevention program). The first 4 weeks of the program are oriented towards the Anishinabe cultural traditions and the traditional Anishinabe family. Weeks 5 through 8 focus on identifying feelings and how to manage negative feelings such as anger and sadness in positive ways. The last 6 weeks of the program focus on outside influences and how to build positive support systems. Prior to the intervention, we completed a pre-test with families in the experimental group. Following the program, we completed a post-test and a 6-month youth follow-up.
88855181|NCT06166251|Experimental|MP-LOW (pre-motor practice (MP) low ıntensity aerobic exercise )|"On the experimental day, they participated in 60 golf puttings (acquisition practice) followed by a half-hour low-intensity treadmill run.~Retention levels were measured 1 and 7 days after the experimental day with 10 puttings each.~Sleep quality (richard campbell sleep questionnaire) and cognitive level (Paced auditory serial addition test) were evaluated in all participants."
88855182|NCT06166251|Experimental|MP-MOD (pre-motor practice (MP) moderate ıntensity aerobic exercise )|"On the experimental day, they participated in 60 golf puttings (acquisition practice) followed by a half-hour moderate-intensity treadmill run.~Retention levels were measured 1 and 7 days after the experimental day with 10 puttings each.~Sleep quality (richard campbell sleep questionnaire) and cognitive level (Paced auditory serial addition test) were evaluated in all participants."
88855183|NCT06166251|Experimental|MOD-MP (post-motor practice (MP) moderate ıntensity aerobic exercise )|"On the experimental day, they participated in a half-hour moderate-intensity treadmill run followed by 60 golf puttings (acquisition practices).~Retention levels were measured 1 and 7 days after the experimental day with 10 puttings each.~Sleep quality (richard campbell sleep questionnaire) and cognitive level (Paced auditory serial addition test) were evaluated in all participants."
88855184|NCT06166251|Experimental|LOW-MP ((post-motor practice (MP) low ıntensity aerobic exercise )|"On the experimental day, they participated in a half-hour low-intensity treadmill run followed by 60 golf puttings (acquisition practices).~Retention levels were measured 1 and 7 days after the experimental day with 10 puttings each.~Sleep quality (richard campbell sleep questionnaire) and cognitive level (Paced auditory serial addition test) were evaluated in all participants."
89382114|NCT02700035|No Intervention|BZDDD Prevention Program Control|We employed a randomized block (RB) design; blocked on reservation, 147 families were randomly assigned to the control condition. We completed a post-test and a 6-month youth follow-up.
88855185|NCT06166251|No Intervention|Control|"On the experimental day, they completed 60 golf puttings (just acquisition practices- NO EXERCISE) Retention levels were measured 1 and 7 days after the experimental day with 10 puttings each.~Sleep quality (richard campbell sleep questionnaire) and cognitive level (Paced auditory serial addition test) were evaluated in all participants."
88855186|NCT06166069||A|Intraperitoneal Onlay Mesh(IPOM) Plus (GroupA) the laparoscopic closure of the hernia defect will be then performed with detached stitches, non-resorbable 1/0 suture with running intracorporeal suture or intra/extracorporeal interrupted suture
88855187|NCT06166069||B|Intraperitoneal Onlay Mesh(IPOM) standard (Group B) no defect closure will be performed.
88855188|NCT06165952||Adolescent youth age 13-15|age- and sex- adjusted body mass index (zBMI) scores between the 25th and 75th percentile
88855189|NCT06165055||MIH-affected participants (study group )|The Study Arm comprises individuals aged 8-13 with Molar-Incisor Hypomineralization (MIH) in at least one permanent molar.
88855190|NCT06165055||Systemically healthy controls (control group )|Systemically healthy individuals without MIH.
88855191|NCT06164340||Case group - Mother-child dyads|Case group: mother-child dyads (including children with overweight or obesity and early adiposity rebound).
88855192|NCT06164340||Control group - Mother-child dyads|Control group: mother-child dyads (including children with healthy weight).
88855193|NCT06163495|Experimental|School-based extracurricular intervention focusing on time spent with friends and screen media use|
88855194|NCT06163495|No Intervention|Control group|Participants are encouraged to continue as usual.
88855195|NCT06163105|Experimental|Meibomian gland expression (MGX)|"In-office MGX every 2 weeks~Lid hygiene at home once daily for 12 weeks~Preservative-free artificial tears (0.18% sodium hyaluronate) 4 times daily for 12 weeks"
88855196|NCT06163105|No Intervention|Control group|"Lid hygiene at home once daily for 12 weeks~Preservative-free artificial tears (0.18% sodium hyaluronate) 4 times daily for 12 weeks"
88855197|NCT06162871|Experimental|active participation|
89382115|NCT02522507|Experimental|Empowering youth towards employment|This is a behavioural e-mentor intervention. Trained mentors will facilitate employment readiness learning and engage youth in discussions over a 12-week period. Each week the mentors will introduce a new employment topic and will engage youth in a discussion and answer questions.
88855198|NCT06162871|No Intervention|non involved in active part|
88855199|NCT06162312|Experimental|Antenatal perineal massage|daily 5-minute perineal massage from the 34th or 35th week of pregnancy until delivery
89382116|NCT02522507|No Intervention|Control group|The control group will have access to the employment activities during the 12-week employment readiness learning but will not have access to a mentor.
88855200|NCT06162312|No Intervention|Control|standard antenatal, intrapartum and postpartum care
88855201|NCT06161649|No Intervention|traditional outpatient care group|After confirming that the diagnosis of heart failure is met, the patient will receive 10-15 minutes of disease care education from a nurse when the patient receives the case. At the same time, the patient will receive a personal disease self-care education manual, and will get the contact number of the case manager in case the patients encounter emergencies or disease care needs at home (the patient can call for consultation on home care for diseases if the patient want).
89382117|NCT03637751|Experimental|Experimental design|Testing will be carried out in Penn State's Clinical Research Center (CRC). The CRC has rooms for conducting the Trier Social Stress Test (TSST) stress-task and for resting. Participants will make two visits to the CRC, one week apart, on the same day of the weekday. Sessions will be scheduled from 11:00 am to 4:15 pm. We will use a randomized counter-balanced order for the two sessions (i.e., TSST and control conditions) with group membership blind to the subjects and lab personnel.
89382118|NCT03637751|Experimental|Control design|In the no-stress control condition, participants will be instructed to sit in a room, read magazines, and to refrain from any stressful activities (e.g., cell-phone use will be restricted).
89382119|NCT04495673|Experimental|tDCS with Cognitive Training|DLPFC stimulation with tDCS with simultaneous cognitive training
89382120|NCT04495673|Active Comparator|Sham tDCS with Cognitive Training|Sham tDCS with simultaneous cognitive training
89382121|NCT04270877|Experimental|Naltrexone|"Low Dose Naltrexone (LDN) is administered for 12 weeks, including a titration phase of 4 weeks.~Participants will be titrated up to 6 mg following a dose escalation scheme: Initial dosage of 1.5 mg daily, escalated every seventh day by 1.5 mg up to 6 mg at week 4. Dose escalation will be based on safety and tolerability, and if dose escalation is not feasible, delayed increments are allowed. After end of titration (week 4) the subjects will be maintained at the highest tolerated dose level for the last 8 weeks of the treatment period. Subjects are not allowed to change dose during the last 8 weeks of the treatment period.~The medicine is taken orally as tablets once daily in the evening."
89382122|NCT04270877|Placebo Comparator|Placebo|"LDN-placebo is administered for 12 weeks, including a titration phase of 4 weeks.~Participants will be titrated up to 6 mg following a dose escalation scheme: Initial dosage of 1.5 mg daily, escalated every seventh day by 1.5 mg up to 6 mg at week 4. Dose escalation will be based on safety and tolerability, and if dose escalation is not feasible, delayed increments are allowed. After end of titration (week 4) the subjects will be maintained at the highest tolerated dose level for the last 8 weeks of the treatment period. Subjects are not allowed to change dose during the last 8 weeks of the treatment period.~The medicine is taken orally as tablets (similar in size, shape and taste to the active medication), once daily in the evening."
89382123|NCT03271307|No Intervention|AIm 1: Standard of care|Facilities assigned to the standard of care arm will receive no intervention and will continue with Ministry of Health National HIV Guidelines for provider-initiated testing and counseling (PITC) for outpatients in Aim 1. PITC guidelines recommend providers inform their OPD clients about HIV testing and refer them to HIV testing services at the facility.
89382124|NCT03271307|Experimental|Aim 1: Optimized standard of care|Facilities assigned to the optimized standard of care arm will receive additional guidance and support from the study team to adopt the Ministry of Health National HIV Guidelines for provider-initiated testing and counseling (PITC) for Aim 1.
89382125|NCT03271307|Experimental|Aim 1: Facility HIVST|Facilities assigned to the HIVST arm will implement HIVST procedures in lieu of recommendations provided by the Ministry of Health National HIV Guidelines (PITC).
89382126|NCT03271307|No Intervention|Aim 2: Standard of care|Facilities assigned to the standard of care arm will receive no intervention and will continue with Ministry of Health National HIV Guidelines for index HIV testing for sexual partners of HIV-positive clients. Partner referral slips will be given to HIV-positive clients to encourage partner testing.
89382127|NCT03271307|Experimental|Aim 2: Index HIVST|Facilities assigned to the HIVST arm will implement HIVST procedures in lieu of recommendations provided by the Ministry of Health National HIV Guidelines (partner referral slips).
88817914|NCT04351412|Active Comparator|Air blast stimulus|For air blast stimuli, air was delivered by a three-way syringe from a typical dental unit air syringe at 40 psi (± 10 psi) and 70 °F (± 5 °F). The air flow was aimed at the tooth surface of concern, for 1 second, from a distance of 1 cm. The air blast stimulus scores were assessed by the Schiff Cold Air Sensitivity Scale 18. DH was assessed for air blast stimuli at baseline and immediately after completion of treatment. Subjects were also recalled for re-evaluation at 2 weeks and at 1 month after desensitizing treatment.
89382128|NCT03271151|Experimental|"Duloxetine (Cymbalta)"|"Epidural analgesia after knee arthroplasty is not as prevalent at HSS as formerly, in large part due to the rise of local infiltration analgesia. Studies using epidural analgesia may also lack generalizability given the infrequent use of epidural analgesia at other institutions. For these reasons, we plan to use adductor canal nerve blockade + local infiltration analgesia for management of immediate postoperative pain. Patients will receive spinal anesthesia as the primary anesthetic. It is particularly important to study duloxetine (Cymbalta) in the context of local infiltration analgesia, as patients receiving local infiltration analgesia receive increased doses of opioids, compared to patients receiving epidural analgesia."
89382129|NCT03271151|Placebo Comparator|Placebo|Placebo to compare pain scores and opioid use againts Duloxetine
89382130|NCT03245723|Active Comparator|Preterm|"Participants born premature either registered on the National Lung Project (currently in their late twenties) or not registered on the National Lung Project Cohort (current age ranges 18-35 years).~All the participants in this group will undergo Pulmonary Function Testing, Electrocardiogram, Positron Emission Tomography, and Magnetic Resonance Imaging."
89382131|NCT03245723|Placebo Comparator|Term - Healthy Controls|Healthy individuals that were not born premature. Individuals are ages 18-35. Subjects will undergo Pulmonary Function Testing, Electrocardiogram, Positron Emission Tomography, and Magnetic Resonance Imaging.
89382132|NCT02349971|Experimental|All Patients|Patients will undergo a one-time procedure of MR-HIFU ablation of OO under sedation or anesthesia. Patients will be monitored for disease status and adverse events for at least 12 months following procedure.
89382133|NCT05003921|Experimental|Treatment Group|three intrathecal injections of 50 million cells at two-month intervals.
89382134|NCT03301649|Experimental|Generic Ivermectin Lotion 0.5%|Infested household participants will administer a single application of up to 117 grams (1 tube) of generic ivermectin 0.5% topical lotion to the dry hair (avoiding contact with eyes) at home on Day 1, leave the lotion on the hair and scalp for 10 minutes, and then rinse off with warm water. Participants will be instructed to wash their hands after application of the study drug, allow hair to dry naturally (pat drying with decontaminated towel is permitted), and to leave hair uncovered after application of the study drug. Following application and rinsing of the study drug, participants are not to shampoo, wash, or rinse their hair or scalp until the Day 2 visit has been completed.
89382135|NCT03301649|Active Comparator|Sklice (Ivermectin) Lotion 0.5%|Infested household participants will administer a single application of up to 117 grams (1 tube) of Sklice ivermectin 0.5% topical lotion to the dry hair (avoiding contact with eyes) at home on Day 1, leave the lotion on the hair and scalp for 10 minutes, and then rinse off with warm water. Participants will be instructed to wash their hands after application of the study drug, allow hair to dry naturally (pat drying with decontaminated towel is permitted), and to leave hair uncovered after application of the study drug. Following application and rinsing of the study drug, participants are not to shampoo, wash, or rinse their hair or scalp until the Day 2 visit has been completed.
89382136|NCT03301649|Placebo Comparator|Vehicle Lotion|Infested household participants will administer a single application of up to 117 grams (1 tube) of vehicle topical lotion to the dry hair (avoiding contact with eyes) at home on Day 1, leave the lotion on the hair and scalp for 10 minutes, and then rinse off with warm water. Participants will be instructed to wash their hands after application of the study drug, allow hair to dry naturally (pat drying with decontaminated towel is permitted), and to leave hair uncovered after application of the study drug. Following application and rinsing of the study drug, participants are not to shampoo, wash, or rinse their hair or scalp until the Day 2 visit has been completed.
89382137|NCT03637439|Experimental|PNM group|Subjects were treated only once. Specifically, this consisted in the application of a square wave biphasic electrical current, with 10 Hz frequency, a 250µs pulse width, and the maximal tolerable intensity to cause an exacerbated muscle contraction for a total of 1.5 mins, according to the protocol (Valera & Minaya). The subjects were lying prone in decubitus. The middle part of the sciatic nerve was located using an ultrasound machine (cross section), then an acupuncture needle (0.30 mm x 40 mm) was inserted in a short axis approach, perpendicular to the surface of the skin, to the perineurium of the sciatic nerve.
89382138|NCT03637439|Sham Comparator|Control group|The subjects were lying prone in decubitus. The same puncture protocol was performed on the sciatic nerve for 1.5 minutes, but without the application of electricity.
89382139|NCT04647617|Experimental|Quantitative Weight-bearing|Experimental wearing 0.5 kg quantitative sandbag 12~15 Repetitions/set X 5 set X 3day. Weight adjustment: After the first month of intervention, if the experimental can perform for more than 20 repetitions/set , we will asked to increase the weight of the sandbag to 1 kg until the end of the experiment
89382140|NCT04647617|Placebo Comparator|Control group|They are keep their normal live style
89382141|NCT03222973|Experimental|BIIB033 (opicinumab) 750 mg|Participants with relapsing multiple sclerosis (RMS) will receive BIIB033 750 milligram (mg) intravenously (IV) as an add-on therapy to a background disease-modifying therapy (DMT) once every 4 weeks over 72 weeks in Part 1 and once every 4 weeks over 96 weeks in Part 2.
89002778|NCT06151548|Experimental|supplemented|"(n = 15), who will receive four times a day one capsule of a supplement called THYROX (Atlantic krill oil). The daily content of krill oil is 2000 mg, including omega-3 fatty acids 350 mg, EPA - 240 mg, DHA - 110 mg, phospholipids - 800 mg, astaxanthin 200 mg.~The supplementation period will be six weeks."
89002779|NCT06151548|Experimental|control|receiving placebo
88817915|NCT04351412|Active Comparator|Cold stimulus|For cold hypersensitivity assessment, the tooth was isolated using cotton rolls; then, a few drops of extremely cold water were delivered to the tooth from a syringe that had previously been cooled. The cold stimulus scores were assessed by the Schiff Cold Air Sensitivity Scale 18. DH was assessed for cold stimulus at baseline and immediately after completion of treatment. Subjects were also recalled for re-evaluation at 2 weeks and at 1 month after desensitizing treatment.
88817916|NCT01768325|Active Comparator|EUS-Guided biopsy needle (ProCore)|"Comparison of ProCore core biopsy needle to QuickCore core biopsy needle.Cook Medical core biopsy needle.~The number of needle passes requiring to acquire adequate specimen~Length of core tissue obtained~Diagnostic contribution of immunohistochemical staining~Rates of complications"
88817917|NCT01768325|Active Comparator|EUS-TCB needle (Quick-Core)|"Comparison of core biopsy needles.~The number of needle passes requiring to acquire adequate specimen~Length of core tissue obtained~Diagnostic contribution of immunohistochemical staining~Rates of complications"
88817918|NCT05315141||Xiangya Hospital|
88817919|NCT05315141||The Second Xiangya Hospital|
88817920|NCT05315141||The Third Xiangya Hospital|
88817921|NCT05315141||Hunan Provincial People's Hospital|
88817922|NCT05315141||Xiangtan Central Hospital|
88817923|NCT02989883|Other|Peroral endoscopic myotomy (POEM)|Patients who received POEM
88817924|NCT01364090|Active Comparator|Standard Treatment Duration (24 weeks)|Subjects with detectable HCV RNA after four weeks of therapy will continue on PEG-IFN and ribavirin until week 24 and follow-up for an additional 24 weeks following treatment completion (48 weeks in total).
88817925|NCT01364090|Experimental|Shortened Treatment Duration (12 Weeks)|Subjects with undetectable HCV RNA after four weeks of therapy will continue on PEG-IFN and ribavirin until week 12 and follow-up for an additional 24 weeks following treatment completion (36 weeks in total).
88817926|NCT05314907|Active Comparator|Training group|The Health professional shows the woman how to use the self-sampling device (Evalyn Brush) and then she collects a self-sample at the health centre as a training.
88817927|NCT05314907|Placebo Comparator|No prior training group|The Health professional shows the woman how to use the self-sampling device (Evalyn Brush).
88817928|NCT03684785|Experimental|Dose Escalation Phase 1b|Determine the recommended Phase 2 dose of cavrotolimod in combination with pembrolizumab.
88817929|NCT03684785|Experimental|Dose Expansion Phase 2; Merkel cell carcinoma|Determine the safety and preliminary efficacy of cavrotolimod and pembrolizumab in patients with advanced Merkel cell carcinoma that have progressed on an anti-PD-1 / anti-PD-L1 therapy.
88817930|NCT03684785|Experimental|Dose Expansion Phase 2, cutaneous squamous cell carcinoma|Determine the safety and preliminary efficacy of cavrotolimod and cemiplimab in patients with advanced cutaneous squamous cell carcinoma that have progressed on an anti-PD-1.
88817931|NCT03684785|Experimental|Exploratory Phase 2, Merkel cell carinoma|Determine the safety and preliminary efficacy of cavrotolimod and pembrolizumab in patients with advanced Merkel cell carcinoma that have progressed on anti-PD-1 / anti-PD-L1 therapy.
88817932|NCT03684785|Experimental|Exploratory Phase 2, Subcutaneous Dosing Cohort|Determine the safety and preliminary efficacy of cavrotolimod and pembrolizumab in patients with no cutaneous, subcutaneous, or accessible nodal tumor lesions amenable that have progressed on anti-PD-1 / anti-PD-L1 therapy.
88817933|NCT03684785|Experimental|Exploratory Phase 2, Melanoma|Determine the safety and preliminary efficacy of cavrotolimod and pembrolizumab in patients with locally Advanced or Metastatic Melanoma that have progressed on anti-PD-1 / anti-PD-L1 therapy.
88817934|NCT03684785|Experimental|Exploratory Phase 2, Liver Lesion|Determine the safety and preliminary efficacy of cavrotolimod and pembrolizumab in patients with metastatic solid tumors with liver metastases that have progressed on anti-PD-1 / anti-PD-L1 therapy.
88817935|NCT01364558|Experimental|Diazepam Nasal Spray Suspension|Diazepam Nasal Suspension - 10 mg
88817936|NCT01364558|Experimental|Diazepam Nasal Spray Solution|Diazepam Nasal Spray Solution - 10 mg
88817937|NCT01364558|Active Comparator|Diazepam injection|Diazepam injection IV - 5 mg
88817938|NCT05297513|No Intervention|Standard treatment, no intervention|
88817939|NCT05297513|Experimental|Standard treatment, plus ActiveMatrix|
88817940|NCT01323140|Experimental|TMTS treatment|Following a lead-in dose-proportionality phase (Days 1-2) and a site-to-site bioavailability phase (Days 2-9), subjects were dosed for efficacy analysis beginning on Day 9 at dose level B (a single 48 cm2 testosterone matrix transdermal system). Based on pharmacokinetic (PK) analysis of blood samples drawn on Day 16, on Day 22 subjects could be dose-titrated up to dose level C (one 28 cm2 plus one 48 cm2 TMTS), down to dose level A (one 28 cm2 TMTS), or remain at dose level B. Subjects at all dose levels were pooled for primary efficacy analysis on Days 29/30.
88817941|NCT04769999|Experimental|Simple cognitive task|A brief memory reminder cue followed by playing the computer game Tetris for 25 minutes using mental rotation instructions. Option for subsequent booster sessions (self-administered/researcher-assisted).
88817942|NCT03516305|Experimental|Staccato Alprazolam 1 mg|a single inhaled dose
88817943|NCT03823287|Experimental|Faricimab|
88817944|NCT03823287|Active Comparator|Aflibercept|
88817945|NCT01260272|Active Comparator|Alternative Snack Group|This group will receive 100 calorie alternative snack packs to consume three times a day with meals. Any prepackaged commercial snack is permitted as an alternative comparator snack, as long as it is 100 kcal/serving, does not contain raisins, does not contain solely fruits, and/or does not contain solely vegetables
88817946|NCT01260272|Experimental|Raisin Group|This group will receive raisins to consume three times a day with meals
88817947|NCT01769573|Experimental|100 TCID50|RG-HRV16 dose of 100 TCID50 administered intranasally (0.25ml per nostril) one time.
88817948|NCT01769573|Experimental|1,000 TCID50|RG-HRV16 dose of 1,000 TCID50 administered intranasally (0.25ml per nostril) one time.
88817949|NCT01769573|Experimental|10,000 TCID50|RG-HRV16 dose of 10,000 TCID50 administered intranasally (0.25ml per nostril) one time.
88855202|NCT06161649|Experimental|automated mobile education system group|"Intervention group (accepting the operation process of automated intelligent education software system):~Execute registration and qualification review~Automated smart education interaction~At the same time, the patient will receive a personal disease self-care education manual, and will get the contact number of the case manager in case the patients encounter emergencies or disease care needs at home (the patient can call for consultation on home care for diseases if the patient want)."
88855203|NCT06155331|Placebo Comparator|Placebo group|22 patients which will receive four cycles of AC regimen (doxorubicin and cyclophosphamide; each cycle is given every 21 day) plus placebo tablets once daily.
88855204|NCT06155331|Active Comparator|Fenofibrate group|22 patients which will receive four cycles of AC regimen (doxorubicin and cyclophosphamide; each cycle is given every 21 day) plus Fenofibrate 160 mg once daily.
88855205|NCT06153810|Experimental|Early stimulation|Biofeedback treatment is started after two weeks of observation
88855206|NCT06153810|Experimental|Delayed stimulation|Biofeedback treatment is started after three weeks of observation
88855207|NCT06145477||Parents enroll in Parenting for Tomorrow using Chicago Parent Program - individualized for families|Parents enroll in Parenting for Tomorrow using Chicago Parent Program - individualized for families (CPPi) implemented through a telehealth approach.
88855208|NCT06142526|Experimental|treatment group|DividPro film implantation right before the closure of surgical incision wound
88855209|NCT06142526|No Intervention|control group|Only standard care without any anti-adhesion related products.
88855210|NCT06140667|Other|LarysealTM Pro|
88855211|NCT06140667|Other|Ambu Aura Gain|
88855212|NCT06139718|Experimental|ACT Guide Lite|Those randomly assigned to the ACT condition after completing baseline assessment will be automatically directed to the registration for ACT Guide Lite. Participants in the ACT condition will be asked to complete the intervention at that time, but they will have the option to take a break before starting. If an ACT participant does not complete the intervention, they will be prompted to login by a research assistant.
88855213|NCT06139718|No Intervention|Waitlist control|Participants assigned to the waitlist condition will be asked to simply wait to complete the scheduled 1-week and 1-month follow up assessments before accessing the intervention. After they complete the 1-month follow up assessment we will direct participants in the waitlist to access ACT Guide Lite, but at that point their participation in the study will be complete and we will not analyze their use of or responses to the program as part of the study aims.
88855214|NCT06134544|Experimental|Administration of IMO|Patients will be given IMO (20g/100ml) for 7 days.
88855215|NCT06132984||Patients with gynecologic malignancies who are preparing for ICIs treatment|
88855216|NCT06131905|Active Comparator|Group M (Magnesium sulfate+Propofol)|Includes thirdy patients receive 40mg /kg magnesium sulfate diluted with normal saline to a total volume of 100 ml plus ,An initial bolus dose of 1 mg/kg propofol was administered over 30 is followed by a continuous intravenous infusion of propofol at a maintenance dose of 2 mg/kg/h
88855217|NCT06131905|Active Comparator|Group N (Propofol)|Includes thirdy patients receive an equal volume of normal saline as a placebo.plus An initial bolus dose of 1 mg/kg propofol was administered over 30 is followed by a continuous intravenous infusion of propofol at a maintenance dose of 2 mg/kg/h
88855218|NCT06127719||patient on the waiting list for knee arthroplasty|adult patient on the waiting list for knee arthroplasty
88855219|NCT06127394|Experimental|espb group|Block will be performed with median technique at the level of sacral 2nd vertebrae.
89382142|NCT03222973|Placebo Comparator|Placebo|Participants with RMS will receive placebo IV as an add-on therapy to a background DMT once every 4 weeks over 72 weeks in Part 1 and BIIB033 once every 4 weeks over 96 weeks in Part 2. The placebo looks like BIIB033 but does not contain the active ingredient that is thought to have an effect on MS disease. The placebo used in this study is sterile normal saline (water with a small amount of sodium chloride [salt]).
88855220|NCT06127394|Active Comparator|pudendal group|Bilateral transperineal block will be performed
88855221|NCT06127030|Experimental|Brief behavioral teacher training and optional practice as usual|A brief, individualized, three-session teacher training that exists of two (bi)weekly individually tailored training sessions of 120 minutes, and a third session of 60 minutes. Teachers and children may receive practice as usual as well. The practice as usual may include any support or treatment as regularly provided by mental health care centers, schools, school collaborations and/or other organizations, except from pharmacological treatment for children's behavioral difficulties and/or behavioral teacher training/support. Practice as usual can also imply that there is no support or treatment.
88855222|NCT06127030|Active Comparator|Practice as usual only (PAU)|PAU may include any support or treatment as regularly provided by mental health care centers, schools, school collaborations and/or other organizations, except from pharmacological treatment for children's behavioral difficulties and/or behavioral teacher training/support. PAU can also imply that there is no support or treatment. There are no criteria for professionals providing PAU.
88855223|NCT06122363||Complete Novasure endometrial ablation|After treatment with novasure, the hysteroscopy showed no remains of endometrium, , so a complete novasure endomentrial ablation
88855224|NCT06122363||Incomplete Novasure endometrial ablation|After treatment with novasure, the hysteroscopy showed remains of endometrium, so an incomplete novasure endomentrial ablation
89382143|NCT01144416|Experimental|Single injection of 150 µg SCH 900962 (MK-8962)|Participants received a single injection of 150 ug SCH 900962 (MK-8962) on Stimulation Day 1 and 7 injections with placebo-recFSH from Stimulation Days 1-7
89382144|NCT01144416|Active Comparator|Daily 300 IU recFSH|Participants received a single injection of placebo SCH 900962 (MK-8962) on Stimulation Day 1 and 7 injections of recFSH from Stimulation Days 1-7
89382145|NCT00335777|Experimental|Migranal treatment first treatment phase|All subjects were asked to treat one headache at 1 hour (early) and one headache at 4 hours after onset of throbbing (late). Dose of nasal spray constant for both time points. The subject could determine the order in which they could treat the headaches (early (first treatment phase) then late (second treatment phase), or late (first treatment phase) then early (second treatment phase).
89382146|NCT00335777|Experimental|Migranal second treatment phase|All subjects were asked to treat one headache at 1 hour (early) and one headache at 4 hours after onset of throbbing (late). Dose of nasal spray constant for both time points. The subject could determine the order in which they could treat the headaches (early (first treatment phase) then late (second treatment phase), or late (first treatment phase) then early (second treatment phase).
89382147|NCT04424004||MURDOCK Study Participants with valid email address|"Randomized for testing: 1.A randomly selected subset of individuals who consent to participate (N~300-500), will be invited to participate in COVID-19 polymerase chain reaction (PCR) viral testing by at-home collection and return of self-administered nasal swabs. Saliva specimens may replace the nasal swab specimen.~2. The same randomly selected subset of individuals who collect at-home samples for COVID-19 PCR testing (N~300-500), will also provide a blood sample for serologic testing for SARS-CoV-2 IgG antibodies."
88855225|NCT06120257|Active Comparator|Group A :Flexible ureteroscope group|Flexible ureteroscope (F-URS) group underwent holmium laser lithotripsy using flexible ureteroscopy (Boston® scientific (lithovue)
88855226|NCT06120257|Active Comparator|Group B : extracorporeal shock wave lithotripsy (ESWL) group|extracorporeal shock wave lithotripsy (ESWL) group underwent electromagnetic extracorporeal shock wave lithotripsy (STORZ® MEDICAL Modulith SLX-F2 FD21, Germany)
88855227|NCT06120257|Active Comparator|Group C : Mini perc group|Mini perc group underwent holmium laser lithotripsy using Karl® Storz MIP set.
88855228|NCT06117163|Experimental|Collaborative Care Model (CCM)|"The investigators propose a CCM called Tunawiri, meaning thrive in Kiswahili, that will be integrated within an existing multidisciplinary team of clinicians, mentor mothers, and other clinic staff in Kenyan antenatal care clinics. CCM includes: 1) clinic-level sensitization and integration, 2) Screening for CMD including anxiety, depression and trauma symptoms, 3) Problem-solving type cognitive behavioral therapy delivered by lay health workers, 4) Decision Support and monitoring via an Electronic Health Registry, and 5) Psychiatrist case review and nurse-managed mental health medication."
88855229|NCT06099457|Experimental|Treatment|Sibtime web-based intervention.
88855230|NCT06099457|No Intervention|Control|Business as usual.
88855231|NCT06098339|Experimental|Lens A, then Lens B|Participants will wear Lens A for one month and then wear Lens B for one month.
88855232|NCT06098339|Experimental|Lens B, then Lens A|Participants will wear Lens B one month and then wear Lens A for one month.
88855233|NCT06094270||Experimental: Intervention arm|All patients within the study are included in the intervention arm: The withdrawal time for the interventions for all patients is documented by the physician and the proposed AI system.
88855234|NCT06087770|Experimental|Phase Ia Dose escalation|Phase Ia Dose escalation： A maximum of 48 patients will be enrolled in this phase and are planned to be divided into eight dose groups: 0.3 mg/kg, 1mg/kg, 3 mg/kg, 10 mg/kg, 20 mg/kg, 30 mg/kg, 40 mg/kg and 50 mg/kg
88855235|NCT06078904|Active Comparator|Colchicine 0.5 MG|Colchicine 0.5 MG, one pill a day, oral intake
89382148|NCT03764137|Experimental|[89Zr]Panitumumab-PET/MRI patients|All study patients will receive [89Zr]Panitumumab-PET/MRI imaging.
89382149|NCT01140048||All Enrolled Participants|All participants who completed Protocol 272 and were enrolled in Protocol 374
89382150|NCT03625518|Active Comparator|prostaglandins|vaginal prostaglandins insertion (PGE2) for cervical ripening and induction
89382151|NCT03625518|Active Comparator|intracervical balloon catheter with pitocin|insertion of intra cervical balloon catheter combined with intravenous pitocin for ripening and induction of labor
89382152|NCT03469297|Experimental|Brown Glaucoma Implant|
89382153|NCT00972738|Experimental|1|montelukast
89382154|NCT00972738|Active Comparator|2|loratadine
89382155|NCT00972738|Placebo Comparator|3|placebo
89382156|NCT03452839|Experimental|Continuous infusion|"Patient randomized to continuous infusion group, will receive a continuous infusion of meropenem according to their renal function (creatinine clearance -ClCr- estimated by Cockcroft-Gault formula and study day~for ClCr > 50 ml/min: 3 g / day, prepared as follows: 10 mg/ml of meropenem in NaCl 0.9% at 12,5 ml/h.~for ClCr < 50 ml/min: 2 g / day, prepared as follows: 10 mg/ml of meropenem in NaCl 0.9% at 8,3 ml/h.~This solution will be replaced every time its duration exceeds the stability in use stated by the producer"
88855236|NCT06078904|Active Comparator|Colchicine 0.375 MG|Colchicine 0.375 MG, one pill a day, oral intake
88855237|NCT06078904|Active Comparator|Colchicine 0.25 MG|Colchicine 0.25 MG, one pill a day, oral intake
88855238|NCT06078904|Placebo Comparator|Placebo|Placebo, one pill a day, oral intake
88855239|NCT06078748|Experimental|EX + DIET|Participants will engage in 3 sessions per week (2 EX, 1 DIET, totaling 4 hours per week), consisting of two virtual group sessions (totaling 3 hours) and one independent session (1 hour) (Table 1). Virtual group sessions will occur in groups of 6-8 participants using the Zoom Healthcare platform (on a computer or tablet).
88855240|NCT06078748|Active Comparator|EX + ED|Participants will engage in 3 sessions per week (2 EX, 1 ED, totaling 4 hours per week), consisting of two virtual group sessions (totaling 3 hours) and one independent session (1 hour) (Table 1). Virtual group sessions will occur in groups of 6-8 participants using the Zoom Healthcare platform (on a computer or tablet).
89382157|NCT03452839|Active Comparator|Bolus|"Patient randomized to bolus group, will receive a bolus infusion of meropenem according to their renal function (creatinine clearance -ClCr- estimated by Cockcroft-Gault formula):~for Cl-Cr > 50 ml/min 1 g every 6 hours on first 24 hours, every 8 hours after~for Cl-Cr < 50 ml/min 1 g every 8 hours on first 24 hours, every 12 hours after"
89382158|NCT04701281|Experimental|Intra-arterial LIOX + Capecitabine|5 - 7 LIOX (liver isolation oxaliplatin) intra-arterial infusions over 8 weeks + capecitabine
89382159|NCT04313478||Low Birth Weight Infants|They were as follows: being at 3 to 9 months' corrected age, gestational age of less than 36 weeks + 6 days, birth weight of 2000 g or less. Infants with any genetic, metabolic, orthopedic congenital abnormalities or chronic diseases and parents' rejection to participate in the study were excluded.
89382160|NCT04313478||Normal Weight Infants|They were as follows: being between 3 and 9 months of age, being full-term, had no complications during delivery. Infants that presented any type of sensory or motor disorder were excluded.
89382161|NCT05180929|Experimental|Dual-M1 tDCS|In the M1- dual tDCS montage, the anodal electrode will be placed above ipsilesional M1 and the cathode will be positioned over contralesional M1.
89382162|NCT05180929|Experimental|a-tDCS over contralesional PMC|In the anodal-tDCS for PMC, the anodal electrode will be placed over the contralesional PMC. The PMC is defined as being 2.5 cm anterior to the M1. The cathodal electrode will be positioned over the contralateral suborbital region
89382163|NCT05180929|Sham Comparator|Sham tDCS|For sham stimulation, there is no particular electrode configuration to be followed, thus, 6 participants will receive sham stimulation with the configuration will be used in group A, and 5 participants will receive sham stimulation with the configuration will be used in group B. By pressing the sham button, the current will automatically ramped up over 10 sec. till reaching 1 mA, then it will be decreased gradually over 30 seconds till turning off the apparatus. This is to ensure the typical initial itching sensation
89382164|NCT04249830|Experimental|Stem Cell Transplant|The participant will undergo a stem cell transplant using donor cells that have been manipulated through an investigational device. Participants will be followed for outcomes for two years.
89382165|NCT03243305|Experimental|Interventional|This is a single-arm, open-label, Phase III study of AMPHORA , a non-hormonal contraceptive, at approximately 100 sites in the United States (US) over seven cycles of use in women aged 18 to 35 years who are at risk of pregnancy.
88855241|NCT06078748|Active Comparator|STRETCH + DIET|Participants will engage in 3 sessions per week (2 STRETCH, 1 DIET, totaling 4 hours per week), consisting of two virtual group sessions (totaling 3 hours) and one independent session (1 hour) (Table 1). Virtual group sessions will occur in groups of 6-8 participants using the Zoom Healthcare platform (on a computer or tablet).
88855242|NCT06078748|Placebo Comparator|STRETCH + ED|Participants will engage in 3 sessions per week (2 STRETCH, 1 ED) totaling 4 hours per week), consisting of two virtual group sessions (totaling 3 hours) and one independent session (1 hour) (Table 1). Virtual group sessions will occur in groups of 6-8 participants using the Zoom Healthcare platform (on a computer or tablet)
88855243|NCT06067659|Experimental|Group A: Extracorporeal shock wave therapy|ESWT (EMS Swiss DolorClast® Classic) application will be applied to patients in groups 1 and 3 with a frequency of 15 Hz, a 2000 shock wave and an energy density of 2.5 bar. In practice, patients will be asked to lie in the prone position and keep the knee and hip joints in a neutral position. By placing a towel roll under the ankle, the heel will be stabilized to be applied. Using the ultrasound gel as an intermediate, the ESWT device will be applied to the medial part of the calcaneus.
88855244|NCT06067659|Experimental|Group B: Kinesiology taping|The material used in the taping will be 5 cm wide and 0.5 mm thick Kinesio® Tape. In practice, the patients were placed in the prone position and the ankle would be dorsiflexed at 10 degrees, and the band would be divided into 4 equal parts on the metatarsals of the 1/3 of the foot from the cruis, starting from the calcaneus. Then, taping will be performed from the medial to the lateral of the calcaneus, passing over the area where the pain is intense. Patients will be asked not to remove the applied tape for 3 days.
88855245|NCT06067659|Experimental|Group C: Extracorporeal shock wave therapy+Kinesiology taping|Patients in this group will be treated with both extracorporeal shock wave therapy and kinesiotape.
88855246|NCT06064435||Tetral Coil Group|Intracranial Aneurysm patients who treated with Target Tetra® coils (70% or more of packing density)
88855247|NCT06061926|Experimental|Celery seed|14 patients to receive homologated intervention capsule (celery seed 150 mg) one capsule with 75 mg of celery seed, every 12 hours (before breakfast and before dinner) along 12 weeks.
88855248|NCT06061926|Placebo Comparator|Placebo|14 patients to receive homologated placebo capsule (calcinated magnesia) one capsule with calcinated magnesia, every 12 hours (before breakfast and before dinner) along 12 weeks.
88855249|NCT06045962|Active Comparator|Uncomplicated Ureteroscopy and Stent Placement for 3-5 days|After standard of care ureteroscopic procedure stents will be left indwelling for 3-5 days
88855250|NCT06045962|Experimental|Uncomplicated Ureteroscopy and Stent Placement for 7-9 days|After standard of care ureteroscopic procedure stents will be left indwelling for 7-9 days
89183407|NCT04718675|Experimental|Part 2: Cohort Expansion|"Following identification of the contingent recommended Phase 2 dose (RP2D) in Part 1, the following expansion cohorts will be enrolled:~Cohort A: Participants with R/R non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), and ovarian cancer.~Cohort B: Participants with R/R small cell lung cancer (SCLC), NUT midline carcinomas (NMC), adenoid cystic carcinoma (ACC), chordoma and soft tissue sarcomas associated with transcription factor fusion."
89382166|NCT04168632|Experimental|Intervention|A new 4-week menu plan
89382167|NCT03882918|Experimental|OV101|once daily at bedtime (gaboxadol)
89382168|NCT03222583|Experimental|Glecaprevir/Pibrentasvir|"Participants received oral glecaprevir/pibrentasvir (300 mg/120 mg) once daily with food for 8 or 16 weeks during the double-blind (DB) treatment period.~Participants received treatment for 8 weeks with the exception of treatment-experienced, genotype 3-infected participants who received treatment for 16 weeks."
89382169|NCT03222583|Experimental|Placebo / Glecaprevir/Pibrentasvir|"Participants received placebo to glecaprevir/pibrentasvir for 8 or 16 weeks during the DB treatment period followed by glecaprevir/pibrentasvir (300 mg/120 mg) once daily for 8 or 16 weeks during the open-label (OL) treatment period.~In each period participants received treatment for 8 weeks with the exception of treatment-experienced, genotype 3-infected participants who received treatment for 16 weeks."
89382170|NCT05282329|Experimental|tACS group|Participants receive tACS 20-min sessions in a 5-day sequence for four consecutive weeks,combined with original and stable medication. Active group participants were administered 2 mA alternating current delivered with gamma frequency, delivered over the temporal lobe.
89382171|NCT05282329|Sham Comparator|Sham group|Controls received sham stimulation with the same protocol.
89382172|NCT04180397|Active Comparator|Furosemide|Bolus of 5-40 mg (0.5 - 4 ml) of furosemide iv at physicians discretion followed by infusion of furosemide. Infusion rate: 0-40 mg/hour. Starting rate: 20 mg/hour. The infusion is adjusted according effect. Target is a negative fluid balance of 1 ml/kg/hour. The fluid balance is calculated 3 times a dag at 6:00 am, 2:00 pm and 10:00 pm. Goal directed fluid removal is stopped when the fluid balance is assessed neutral.
89382173|NCT04180397|Placebo Comparator|Placebo|Isotonic saline dosed the same way and by the same algorithm as for furosemide. Start bolus of 0.5-4 ml at physicians discretion. Infusion rate: 0 - 4 ml/hour. Infusion is started at 2 ml/hour and adjusted according to effect. Target is a negative fluid balance of 1 ml/kg/hour. The fluid balance is calculated 3 times a dag at 6:00 am, 2:00 pm and 10:00 pm. Goal directed fluid removal is stopped when the fluid balance is assessed neutral.
89382174|NCT04540445||Concussed Cohort|The concussed cohort will consist of children ages 5-17 diagnosed with a concussion within 72 hours following injury and recruited from a pediatric emergency department.
89382175|NCT04540445||Healthy Matched Controls|The healthy matched control cohort consists of children 5-17, who are age and gender matched to concussed subjects who will be recruited from affiliated pediatric primary care and adolescent clinics.
89382176|NCT04629911|Experimental|HFNO arm|Patients will receive HFNO therapy during laryngomicrosurgery.
89382177|NCT03625674|Other|psychological and GI mechanisms|The patients in Group 1 were told that: GI symptoms in FD are attributable to both psychological and GI mechanisms. Psychoactive medicine relieves FD symptoms through both psychological and GI mechanisms.
89382178|NCT03625674|Other|psychological mechanism|The patients in Group 2 were told that: GI symptoms in FD are attributable to psychological mechanisms. Psychoactive medicine relieves FD symptoms through psychological mechanisms.
89382179|NCT03625674|Other|GI mechanism|The patients in Group 3 were told that: GI symptoms in FD are attributable to GI mechanisms. Psychoactive medicine relieves FD symptoms through GI mechanisms.
89382180|NCT03625674|Other|no explanation|The patients in Group 4 were not explained with the detailed mechanism of FD and psychoactive medicine
89382181|NCT03295721|Experimental|Treatment Group 1: HTX-011|HTX 011 (bupivacaine/meloxicam)
89382182|NCT03295721|Placebo Comparator|Treatment Group 2: Saline Placebo|Saline placebo
89382183|NCT03295721|Active Comparator|Treatment Group 3: Bupivacaine HCI|Bupivacaine HCl
88855251|NCT06041087|Experimental|Exercise and Greek Yogurt (GY)|Participants will have a fasted baseline blood sample taken upon arrival to the lab. Then they will take part in a high-intensity exercise protocol, consisting of high-intensity interval cycling, resistance exercise, and plyometrics. Following exercise, participants will return to the lab for a 5min post-exercise blood sample, and then consume ~200g Greek yogurt (0% milk fat). An additional blood sample will be taken at 1h post-exercise, followed by an additional ~200g of Greek yogurt. Blood samples will also be taken at 4h and 24h post-exercise. Participants will also rate their muscle soreness and perform a jump height test at pre-exercise, 5min post-exercise, 4h and 24h post-exercise.
89382184|NCT00803790|Experimental|Sequence 1- alendronate+vitamin D combination then alendronate|Participants in Part 1 received 70mg alendronate+5600 International Units (IU) vitamin D combination tablet in Period 1 followed by 70mg alendronate tablet in Period 2. A washout of at least 12 days separated each treatment period.
89382185|NCT00803790|Experimental|Sequence 2 alendronate then alendronate+vitamin D combination|Participants in Part 1 received 70mg alendronate tablet in Period 1 followed by 70mg alendronate+5600 IU vitamin D combination tablet in Period 2. A washout of at least 12 days separated each treatment period.
89183408|NCT04718415|Experimental|sintilimab + carboplatin + nab-paclitaxel|"Treatment with sintilimab, nab-paclitaxel and carboplatin for up to 2 - 4 cycles:~Sintilimab (IV), dose= 200mg , day=1 , cycle length: 21 days. Carboplatin (IV), dose=300mg/m2, day= 1, cycle length: 21 days. Nab-paclitaxel (IV), dose=260mg/m2, day= 1, cycle length: 21 days."
89382186|NCT00803790|Experimental|Sequence 3 alendronate+vitamin D combination then vitamin D|Participants in Part 2 received 70mg alendronate+5600 IU vitamin D combination tablet in Period 1 followed by a single dose of 5600 IU vitamin D, administered as two 2800 IU tablets in Period 2. A washout of at least 12 days separated each treatment period.
89382187|NCT00803790|Experimental|Sequence 4- vitamin D then alendronate+vitamin D combination|Participants in Part 2 received a single dose of 5600 IU vitamin D, administered as two 2800 IU tablets in Period 1 followed by a 70mg alendronate+5600 IU vitamin D combination tablet in Period 2. A washout of at least 12 days separated each treatment period.
89382188|NCT03637985|Experimental|resistive exercise|resistive exercises using elastic band(Thera Band) Sets were at moderate intensity, 8-10 repetitions for every motion for 12 weeks
89382189|NCT03637985|Experimental|Aerobic exercise|Aerobic exercise in form of treadmill walking for 45 minutes for 12 weeks
89382190|NCT03568188|Experimental|HIFU treatment|170 patients with prostate cancer of intermediate risk receive the immediate treatment with focal HIFU. The treatment area will be defined using MRI data and 3D biopsies. A safety distance of at least 9 mm will be defined around the tumor. An intraoperative contrast echocardiographic control will be performed to evaluate the necrotic area. If necessary, additional HIFU lesions will be performed during the same session. In case of residual tumor demonstrated during control biopsies, additional treatment of this tumor with focal HIFU may be proposed. Patients will also have PSA (Prostate-Specific Antigen) dosage, MRI (Magnetic Resonance Imaging) exam, questionnaires and prostatic biopsies during their follow up. If the patient decides to participate in the ancillary study, a blood test (for immunological analyzes and detection of CTC (circulating tumor cells)) and a urine test (for PCA3 (The prostate cancer antigen 3 gene) test) will be performed during their follow up.
89382191|NCT04427891||Group I|"Patients undergoing emergency surgery due to perforated diverticulitis with peritonitis.~No intervention, samples from abdominal fluid, blood, tissue, feces"
89382192|NCT04427891||Group II|Patients with colorectal cancer undergoing elective surgery. No intervention. Samples as for Group I
89382193|NCT04427891||Group III|Patients with mild diverticulitis, not undergoing surgery. No intervention. Samples from blood and feces.
89382194|NCT00442338|Experimental|Montelukast 7 mg|Montelukast 7 mg IV administration
89382195|NCT00442338|Experimental|Montelukast 14 mg|Montelukast 14 mg IV administration
89382196|NCT00442338|Active Comparator|Aminophylline 250 mg|Aminophylline 250 mg IV drip administration
89382197|NCT03506412|Experimental|Low Serum Neprilysin (sNEP) levels|Subjects with baseline sNEP levels less than or equal to 0.9 ng/ml
88855252|NCT06041087|Experimental|Exercise and Milk (Milk)|Participants will have a fasted baseline blood sample taken upon arrival to the lab. Then they will take part in a high-intensity exercise protocol, consisting of high-intensity interval cycling, resistance exercise, and plyometrics. Following exercise, participants will return to the lab for a 5min post-exercise blood sample, and then consume ~500ml plain skim milk (0% milk fat). An additional blood sample will be taken at 1h post-exercise, followed by an additional ~500ml of skim milk. Blood samples will also be taken at 4h and 24h post-exercise. Participants will also rate their muscle soreness and perform a jump height test at pre-exercise, 5min post-exercise, 4h and 24h post-exercise.
88855253|NCT06041087|Active Comparator|Exercise and Carbohydrate (CHO)|Participants will have a fasted baseline blood sample taken upon arrival to the lab. Then they will take part in a high-intensity exercise protocol, consisting of high-intensity interval cycling, resistance exercise, and plyometrics. Following exercise, participants will return to the lab for a 5min post-exercise blood sample, and then consume ~50g of maltodextrin mixed with water (~500ml). An additional blood sample will be taken at 1h post-exercise, followed by an additional ~500ml of the maltodextrin drink. Blood samples will also be taken at 4h and 24h post-exercise. Participants will also rate their muscle soreness and perform a jump height test at pre-exercise, 5min post-exercise, 4h and 24h post-exercise.
89183409|NCT04713215||Patients where MCAs are currently being used|Intervention: Patient questionnaire - Part A - patients where MCAs are currently being used
89382198|NCT03506412|Experimental|High Serum Neprilysin (sNEP) levels|Subjects with baseline sNEP greater than or equal to 0.9 ng/ml
89382199|NCT03420768|Experimental|Part 1 BMS-986263 45mg weekly|
89382200|NCT03420768|Experimental|Part 1 BMS-986263 90mg weekly|
89382201|NCT03420768|Placebo Comparator|Part 1 Placebo weekly|
89382202|NCT03420768|Experimental|Part 2 BMS-986263 45mg every 2 weeks|
89382203|NCT03420768|Experimental|Part 2 BMS-986263 90mg every 2 weeks|
89382204|NCT03420768|Experimental|Part 2 BMS-986263 90mg every 4 weeks|
89382205|NCT03420768|Placebo Comparator|Part 2 Placebo every 2 weeks|
89382206|NCT03625440|Other|study group - Waterpipe Smoking|"The Digit span test and Paced Auditory Serial Addition Test (PASAT) performed at baseline and 30minutes after waterpipe smoking.~The Digit span test and PASAT with waterpipe smoking"
89382207|NCT03625440|Other|control group|"The Digit span test and Paced Auditory Serial Addition Test (PASAT) without waterpipe smoking, performed at 30minures apart.~The Digit span test and PASAT without waterpipe smoking"
89382208|NCT02316834|Experimental|BMN 673|
89382209|NCT05054010||Early Breast Cancer patients|Early stage breast cancer category is based on the definition of the European Society of medical Oncology and is defined as disease confined to the breast with or without regional lymph node involvement
89382210|NCT05054010||Metastatic Breast Cancer patients|Metastatic breast cancer category is based on the definition of the European Society of Medical Oncology and is defined as disease spread to other parts of the body, such as bones, liver or lungs (also called stage IV). Tumours at distant sites are called metastases.
89382211|NCT05054010||Healthy donors|Participants who are in good health and without history of cancer disease
89382212|NCT00250458|Experimental|1|Rizatriptan (MK0462)10 mg orally disintegrating tablet/oral lyophilisate
89382213|NCT00250458|Placebo Comparator|2|matching placebo
89382214|NCT01965132||Biologic or targeted synthetic DMARD|Korean patients with rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis who will initiate, restart or switch to a biologic agent (etanercept, adalimumab, infliximab, golimumab, tocilizumab, abatacept, rituximab, ustekinumab, secukinumab, ixekizumab, or biolsimilars) or a targeted synthetic DMARD
89382215|NCT01667133|Experimental|Phase 1 dose escalation|Phase 1
89382216|NCT01667133|Experimental|Phase 2 expansion|Phase 2
89382217|NCT04045587||Severe Asthma Participants|Participants with severe asthma classified at GINA Step 4 and uncontrolled in terms of their symptoms and exacerbations or GINA Step 5.
89382218|NCT03947775|Experimental|Immediate Vaccination|Administration of dose #1 of 9-valent HPV vaccination will be given at baseline visit, dose #2 at month 2, and dose #3 at month 6.
89382219|NCT03947775|Active Comparator|Delayed Vaccination|Administration of dose #1 of 9-valent HPV vaccination will be given at month 12, dose #2 at month 14, and dose #3 at month 18.
88855254|NCT06041087|Placebo Comparator|Exercise and Water (W)|Participants will have a fasted baseline blood sample taken upon arrival to the lab. Then they will take part in a high-intensity exercise protocol, consisting of high-intensity interval cycling, resistance exercise, and plyometrics. Following exercise, participants will return to the lab for a 5min post-exercise blood sample, and then consume ~500ml water. An additional blood sample will be taken at 1h post-exercise, followed by an additional ~500ml water. Blood samples will also be taken at 4h and 24h post-exercise. Participants will also rate their muscle soreness and perform a jump height test at pre-exercise, 5min post-exercise, 4h and 24h post-exercise.
89382220|NCT01498770||Asenapine|
89382221|NCT01498770||Aripiprazole|
89382222|NCT01498770||Quetiapine|
89382223|NCT01498770||Risperidone|
89382224|NCT01498770||Olanzapine|
89382225|NCT01498770||Ziprasidone|
89382226|NCT01498770||Iloperidone|
89382227|NCT01498770||Paliperidone|
89382228|NCT01498770||Lurasidone|
89382229|NCT01498770||Clozapine|
89382230|NCT01498770||Amisulpride|
88855255|NCT06039761|Experimental|local intraperitoneal anesthetics + alveolar recruitment maneuver + abdominal compression maneuver|Overall Procedure : The specific interventions are carried out at the end of the surgical intervention and include the use of intraperitoneal local anesthetics insufflated by the surgeon, the alveolar recruitment maneuver carried out by the anesthetist and that of abdominal compression carried out by the surgeon.
88855256|NCT06039761|Active Comparator|Standard Procedure|Standard Procedure : Digestive or gynecological surgery by laparoscopy with a Transversus abdominis plane block before the incision and systematic standardized multimodal analgesia.
88855257|NCT06034314|Experimental|People with HIV (PWH) with Cannabis use|PWH with cannabis use
89382231|NCT01498770||Sertindole|
89382232|NCT01498770||Zotepine|
89382233|NCT01181778||All Qualified Participants|All healthy women who consulted their physician for information on contraceptive choices and were eligible for primary and secondary outcome measure analysis, based on the physician's assessment
89382234|NCT00967746|Experimental|ENG-MIUS low|Low dose: ENG-MIUS containing 38 mg ENG with a skin thickness of approximately 350 μm
89382235|NCT00967746|Experimental|ENG-MIUS intermediate|Intermediate dose: ENG-MIUS containing 61 mg ENG with a skin thickness of approximately 140 μm
89382236|NCT00967746|Experimental|ENG-MIUS high|High dose: ENG-MIUS containing 72 mg ENG with a skin thickness of approximately 50 μm
88855258|NCT06034314|Experimental|People without HIV (PWoH) with Cannabis use|PWoH with Cannabis use
88855259|NCT06005623|Experimental|Intervention|Activity tracking and motivational feed-back by gamification.
88855260|NCT06005623|No Intervention|Care as usual|Activity tracking without motivational feed-back
88855261|NCT05988944|Active Comparator|Traditional techniques|TT was planned according to the child's hand that was needed. Neurodevelopmental facilitation techniques (Bobath therapy), stretching, and grasping types (cylindrical, spherical, hook, key, fingertip, lateral) were used in hands therapy for 45 minutes two days in a week for all children who were accepted to participate in this study.
89183410|NCT04713215||Patients where an MCA was discontinued|Intervention: Patient questionnaire - Part B - patients where an MCA was discontinued
89183411|NCT04713215||Patients where an MCA was declined|Intervention: Patient questionnaire - Part C - patients where an MCA was declined
89382237|NCT00967746|Active Comparator|Multiload|Multiload-cu 375®
89382238|NCT00092118|Experimental|1|Montelukast
89382239|NCT00092118|Placebo Comparator|2|Placebo
89382240|NCT00920634||1|Patients with anovulation and oligoovulation due to hypothalamus-pituitary dysfunction (amenorrhea first grade, anovulatory cycle, polycystic ovary syndrome, oligoamenorrhea) who underwent ovulation induction
89382241|NCT05167578||Patients with multimorbidity|Patients with multimorbidity who visit the public health centres in Vantaa, Southern Finland
89382242|NCT05582928|Experimental|healthy population group|"The experimental design includes three sessions:~session 1 will be used to evaluate diagnostic using different targeted questionnaires.~sessions 2 and 3 will be decomposed into 3 consecutives parts:~Pre evaluation~Neurofeedback~Post evaluation"
89382243|NCT05582928|Experimental|ADHD population group|"The experimental design includes three sessions:~session 1 will be used to evaluate diagnostic using different targeted questionnaires.~sessions 2 and 3 will be decomposed into 3 consecutives parts:~Pre evaluation~Neurofeedback~Post evaluation"
89382244|NCT04914780|Experimental|Intervention group|4 weeks training with mobile application
89382245|NCT04914780|No Intervention|Control group|No intervention will be made for 4 weeks
89382246|NCT05225142|Experimental|Modified minimally invasive surgery alone|Modified minimally invasive surgery alone for access and debridement of intrabony defect. This approach maximises wound stability. No application of regenerative biomaterial.
89382247|NCT05225142|Active Comparator|Modified minimally invasive surgery with enamel matrix derivative|Modified minimally invasive surgery access and debridement of intrabony defect combined with local application of enamel matrix derivative (regenerative biomaterial)
89382248|NCT05225142|Active Comparator|Modified minimally invasive surgery with enamel matrix derivative and bone replacement graft|Modified minimally invasive surgery access and debridement of intrabony defect combined with local application of enamel matrix derivative and bone replacement graft (regenerative biomaterial)
89382249|NCT03261947|Experimental|Western Safety Cohort|TAK-931 50 mg (2x25 mg or 5x10 mg), capsules, orally, once daily (QD) for 14 days, followed by a 7-day washout period (14 days on and 7 days off study drug), in 21-day cycles until disease progression or unacceptable treatment-related toxicity up to 20 cycles. Participants with locally advanced or metastatic solid tumors with no standard therapeutic alternative in the United States were included in this cohort.
89382250|NCT03261947|Experimental|Pancreatic Cancer Cohort|TAK-931 50 mg (2x25 mg or 5x10 mg), capsules, orally, QD for 14 days, followed by a 7-day washout period (14 days on and 7 days off study drug), in 21-day cycles until disease progression or unacceptable treatment-related toxicity up to 4 cycles. Participants with metastatic pancreatic cancer who had progressed after at least 1 line of standard chemotherapy were included in this cohort.
89183412|NCT04713215||Carers where MCAs are currently being used|Intervention: Carer questionnaire - Part A - carers where MCAs are currently being used
89183413|NCT04713215||Carers where an MCA was discontinued|Intervention: Carer questionnaire - Part B - carers where an MCA was discontinued
88855262|NCT05988944|Experimental|traditional therapy with constraint induced movement therapy|The sling was put on the child's non-paretic arm to apply CIMT. The around of the sling was sewn except the elbow and secured snugly to the trunk with a waist strap to prevent assisting the affected hand during the application of CIMT. However, children with CP who were in the this group used the sling for three hours in daily activity, playing, etc. at home. The CIMT was given as a home program and monitorization was done by the follow-up form every week with no therapy during the weekend.
89183414|NCT04713215||Carers where an MCA was declined|Intervention: Carer questionnaire - Part C - carers where an MCA was declined
89183415|NCT04712721|Experimental|Glioblastoma Multiforme|All eligible participants will receive recommended dose of [68Ga]-FF58 of 3 Megabecquerel (MBq)/Kg (+/- 10%) [but not more than 250 and not less than 150 MBq].
89183416|NCT04712721|Experimental|Brain Metastasis from Breast Cancer|All eligible participants will receive recommended dose of [68Ga]-FF58 of 3 Megabecquerel (MBq)/Kg (+/- 10%) [but not more than 250 and not less than 150 MBq].
89183417|NCT04712721|Experimental|Gastroesophageal adenocarcinoma|All eligible participants will receive recommended dose of [68Ga]FF58 of 3 Megabecquerel (MBq)/Kg (+/-10%) [but not more than 250 and not less than 150 MBq]
89183418|NCT04712721|Experimental|Pancreatic ductal adenocarcinoma|All eligible participants will receive recommended dose of [68Ga]FF58 of 3 Megabecquerel (MBq)/Kg (+/-10%) [but not more than 250 and not less than 150 MBq]
89183419|NCT04711460||Younger participants|Participants were adults ages19 to 29 years who recieved CBT and 10 minutes of Mindfulness Training and practice in group therapy.
89183420|NCT04711460||Older participants|Participants were adults ages 30-54 years who received CBT and 10 minutes of Mindfulness Training and practice in group therapy.
89183421|NCT04711460||Treatment As Usual (TAU)|". Participants in the Treatment As Usual (TAU) group had Cognitive Behavioral Therapy and education about the mindfulness process, but no practice of the mindfulness technique as a group."
89183422|NCT04711460||TAU plus mindfulness practice|Participants in the TAU plus Mindfulness Practice had Cognitive Behavioral Therapy (CBT) and 10 minutes of mindfulness practice in group therapy sessions.
89183423|NCT04711070||Patients with sepsis|Muscle velocity recovery cycles, electromyography, nerve conduction studies, direct musclestimulation, blood test
89183424|NCT04711070||Patients with chronic renal failure|
89183425|NCT04711070||Healthy control|
89183426|NCT04710615|Experimental|Assistance device|"With prescription assistance device:~During the other 3 months, investigators will have the Synapse platform on different media (mobile phones, tablets, laptops and landline)."
89183427|NCT04710615|No Intervention|No device|During 3 months, investigators will not have the Synapse platform and will make their prescriptions with the usual tools which they have: Modules of help in the DxCare® software of the CHU, public database of the drugs, dictionary Vidal®, …
89183428|NCT04710264||recombinant hFSH|Patient stimulated with recombinant hFSH
89183429|NCT04710264||recombinant hFSH : r-hLH|Patient stimulated with recombinant hFSH : r-hLH ratio 2:1
89183430|NCT04705168||Participants displaying nevi|"Participants displaying a phenotype that consists of ≥ 100 nevi on the entire cutaneous surface and at least three large acquired nevi (LAN) > 5 mm in diameter. These patients have atypical mole syndrome, which is a high-risk nevus phenotype and the target patient population in this study."
89183431|NCT04704544|Experimental|Tele-rheumatology first visit and Usual Care second visit|Participants randomized to this visit will receive a tele-rheumatology visit first.
89183432|NCT04704544|Experimental|Usual Care first visit and Tele-rheumatology second visit|Participants randomized to this visit will receive a usual care visit first.
89183433|NCT04695977|Experimental|CMP-001 and Nivolumab|All enrolled subjects will receive CMP-001 IT and nivolumab IV according to the treatment schedule until a reason for treatment discontinuation is reached.
89183434|NCT04695977|Experimental|Nivolumab Monotherapy|All enrolled subjects will receive nivolumab monotherapy IV according to the treatment schedule until a reason for treatment discontinuation is reached.
89183435|NCT04692532|Experimental|8-hour Time restricted eating|Ad libitum food intake from 12-8 pm every day Fasting from 8-12 pm every day (16-h fast)
89183436|NCT04692532|Experimental|Calorie restriction|25% energy restriction every day
89183437|NCT04692532|No Intervention|Control|Usual diet, Ad libitum intake, eating within >10 hours per day
89183438|NCT04682145||Haemophilia A patients|All patients with haemophilia A treated with turoctocog alfa pegol and reporting adverse events to EUHASS.
89183439|NCT04676386||PD1/PD-L1|Standard of Care: PD1/PD-L1 monotherapy
89183440|NCT04676386||PD1/PD-L1 + chemo|Standard of Care: Platinum doublet-based chemotherapy plus PD-1/PD-L1 combination
89183441|NCT04676061|Placebo Comparator|Control Group|Placebo to Norethindrone acetate (NTA)
89183442|NCT04676061|Active Comparator|Treatment Group|Norethindrone acetate (NTA)
89183443|NCT04656678|Experimental|DynaCAD / UroNAV|This is a single arm study to evaluate feasibility of UroNAV Ablation system aided cryo-ablation treatment of low and intermediate risk, organ-confined prostate cancer. UroNav is a stereotaxic accessory for image-guided interventional and diagnostic procedures of the prostate gland. It provides 2D and 3D visualization of Ultrasound (US) images and the ability to fuse and register these images with those from other imaging modalities such as Magnetic Resonance (MR), Computed Tomography, etc. It also provides the ability to display a simulated image of a tracked insertion tool on a computer monitor screen that shows images of the target organ and the current and the projected future path of the interventional instrument. DynaCAD 5.0 is an image analysis and planning system that will provide off station, pre planning and review of interventional study data. It interfaces with the Uronav 4.0 fusion guidance system.
89183444|NCT04650815||0.5 - 5 Years|Infants and Children up to age 5 years in the Sabou Health District
89382251|NCT03261947|Experimental|Metastatic CRC Cohort|TAK-931 50 mg (2x25 mg or 5x10 mg), capsules, orally, QD for 14 days, followed by a 7-day washout period (14 days on and 7 days off study drug), in 21-day cycles until disease progression or unacceptable treatment-related toxicity up to 12 cycles. Participants with metastatic CRC who had progressed after at least 2 lines of previous standard chemotherapy were included in this cohort.
89382252|NCT03261947|Experimental|sqEC Cohort|TAK-931 50 mg (2x25 mg or 5x10 mg), capsules, orally, QD for 14 days, followed by a 7-day washout period (14 days on and 7 days off study drug), in 21-day cycles until disease progression or unacceptable treatment-related toxicity up to 8 cycles. Participants with metastatic sqEC who had progressed after at least 1 line of standard chemotherapy were included in this cohort.
89382253|NCT03261947|Experimental|sqNSCLC Cohort|TAK-931 50 mg (2x25 mg or 5x10 mg), capsules, orally, QD for 14 days, followed by a 7-day washout period (14 days on and 7 days off study drug), in 21-day cycles until disease progression or unacceptable treatment-related toxicity up to 18 cycles. Participants with metastatic sqNSCLC who had progressed after at least 2 lines of standard treatment were included in this cohort.
89382254|NCT05654844|Other|Digital Lateral Cephalometry|Patients justifying the indication for LC and CBCT exposure
89382255|NCT05224284|Other|BPA level|BPA (Bisfenol A) in blood and ejaculate samples
89382256|NCT05224128|Experimental|Imatinib Drug|Standard medication of liver fibrosis + Imatinib 200 mg 1 time a day.
89382257|NCT05224128|Placebo Comparator|Placebo|Standard medication of liver fibrosis + placebo as a control group.
89382258|NCT04976946||Urologists|Local and international consultant Urologists and accredited Urology trainees.
89382259|NCT04976946||Anaesthetists|Local and international consultant anaesthetists. Critical care physicians who are primarily Urological anaesthetists or have experience in complication reporting will be targeted.
89382260|NCT04976946||ICU specialists|Local and international consultant ICU specialists. Critical care physicians who are primarily Urological focused or have experience in complication reporting will be targeted.
89382261|NCT04949880|Experimental|Group A|Neurovascular Drug-Eluting Balloon Dilatation Catheter
89183445|NCT04650815||10 - 18 Years|Children ranging in age 10 to 18 years in the Sabou Health District
89183446|NCT04650815||19 + Years|Adults ranging in ages 19 years to 65 years in the Sabou Health District
89183447|NCT04650815||5 - 10 Years|Children ranging in age 5 years through 10 years in the Sabou Health District
89382262|NCT04050852|Experimental|SMA patients receiving nusinersen treatments|
89382263|NCT05065242|Experimental|Cognitive Behavioural Therapy|Cognitive Behavior Therapy involves the use of stimulus control and sleep restriction in order to reverse maladaptive sleep habits (time in bed, napping, bedtime variability, rise time variability) proposed to maintain insomnia. It also involves the practice of sleep hygiene principles and to a lesser extent some cognitive exercises. focused on handling sleep disturbing thought activities.
89382264|NCT05065242|No Intervention|Waitlist|The waitlist serves as a passive control which will receive the same measures as the cognitive behaviour therapy group.
89183448|NCT04640259||EGFR|
89183449|NCT04640259||ROS1|
89183450|NCT04640259||ALK|
89382265|NCT04051086|Other|Williams Beuren|Subjects aged from 3 months to 60 years with a diagnosis confirmed with FISH of Williams Beuren syndrome.
89382266|NCT04051086|Other|Micro-duplication 7q11.23|Subjects aged from 3 months to 60 years with a diagnosis confirmed with CGHarray of micro-duplication 7q11.23 syndrome.
88817950|NCT01769573|Placebo Comparator|Placebo|Diluent administered intranasally (0.25ml per nostril) one time.
88817951|NCT01769573|Experimental|500 TCID50|RG-HRV16 dose of 500 TCID50 administered intranasally (0.25ml per nostril) one time.
88817952|NCT02244671|Experimental|fat, PRP, botulinum toxin|Fat injection with platelet-rich-plasma (PRP) after immobilizing the extraocular muscles with botulinum toxin
89183451|NCT04640259||KRAS|
89183452|NCT04640259||NSCLC Other|
89183453|NCT04636229|Experimental|ASA|Participants receive a single IA injection of 2 mL of ASA (plus 2 mL of normal saline)
89183454|NCT04636229|Placebo Comparator|Placebo|Participants receive a single IA injection of 4 mL of normal saline
89382267|NCT04051086|Other|Healthy Group|Subjects without cardiovascular and neurological medical history.
89382268|NCT05223660|Experimental|Low dose KT07|KT07 single dose (4 capsules) followed by multiple doses for 5 days (tid)
89382269|NCT05223660|Experimental|High dose KT07|KT07 single dose (6 capsules) followed by multiple doses for 5 days (tid)
89382270|NCT05223660|Placebo Comparator|Low dose placebo|Placebo single dose (4 capsules) followed by multiple doses for 5 days (tid)
88855263|NCT05988944|Experimental|traditional therapy with constraint induced movement therapy and virtual reality|After the TT session, a child with CP used the sling for 45 minutes at the rehabilitation center with VR therapy. VR therapy with CIMT was used in hands therapy for 45 minutes at two days a week after TT. During the VR therapy, the child was encouraged verbally to play X-box.The X-box Kinect 360 (by the Microsoft corporation) was used for VR therapy. It has a kinetic sensor that perceives the movement of the child with CP. The child's movement can be seen through the monitor in real time. VR does not need special buttons to play. Therefore, a child with CP who had impaired fine motor skills and dexterity can play easily.
89382271|NCT05223660|Placebo Comparator|High dose placebo|Placebo single dose (6 capsules) followed by multiple doses for 5 days (tid)
89382272|NCT03590730||Valvular heart disease|Patients with left ventricular dysfunction due to valvular heart disease who received ICD implantation for primary prevention of sudden cardiac death.
89382273|NCT03625206|Experimental|Cognitive bias modification training|Participants will receive 5 training sessions, each session including attention bias modification and interpretation bias modification training modules
89382274|NCT03625206|Placebo Comparator|Control training|Participants will receive 5 sessions that involve exercises that are matched to the task demands of the attention bias modification and interpretation bias modification training modules
89382275|NCT05223426|Experimental|Cognitive training followed by usual care|Usual care and cognitive training for 6 weeks, followed by usual care (only) for 6 weeks.
89382276|NCT05223426|Experimental|Usual care followed by cognitive training|Usual care (only) for 6 weeks, followed by cognitive training and usual care for 6 weeks.
89382277|NCT04897776|Experimental|Therapeutic Thalamic Stimulation|Four months post implant, the neurostimulator device will provide patients with hippocampal stimulation for all seizures. For seizures longer than five seconds, thalamic stimulation will be administered at a therapeutic level established based on the physician's evaluation and patient specific parameters established at a previous visit. This will occur in half of the seizures the patient experiences and will be randomly assigned during this phase of the study.
89382278|NCT04897776|Sham Comparator|Non-Therapeutic Thalamic Stimulation|Four months post implant, the neurostimulator device will provide patients with hippocampal stimulation for all seizures. For seizures longer than five seconds, thalamic stimulation will be administered at below therapeutic threshold to control for implant and placebo effects. This will occur in half of the seizures the patient experiences and will be randomly assigned during this phase of the study.
89382279|NCT04852848|Experimental|Connect2Test Intervention|A brief MI intervention to motivate individuals to participate in COVID-19 testing after receiving syringe exchange services
88855264|NCT05983211|Experimental|Accelerated cTBS Neuromodulation|ALS patients receiving an accelerated schedule of continuous theta burst rTMS bilaterally at a regimen of 40 seconds per treatment, for up to 8 treatment sessions per day, delivered one per hour, over 5 days.
88855265|NCT05978089|Experimental|Treatment group|Yangxinshi tablets
88855266|NCT05978089|Placebo Comparator|Control group|Yangxinshi tablet simulants
88855267|NCT05963698|Experimental|WATCHMAN device|Participants will undergo endovascular left atrial appendage occlusion with the WATCHMAN device
88855268|NCT05963698|No Intervention|Standard Care|Participants will receive local, standard medical care
88855269|NCT05958082|Experimental|Educational intervention|Patients will be asked questions about genetic testing for prostate cancer before and after an educational intervention.
88855270|NCT05955638|Experimental|MiSight dual focus contact lens|
88855271|NCT05955638|Active Comparator|Proclear single vision contact lens|
89382280|NCT04852848|No Intervention|Control|Services as usual
89382281|NCT03098979|Experimental|Neladenoson bialanate (BAY1067197) (5 mg)|Chronic heart failure with preserved ejection fraction
88855272|NCT05955300|Experimental|Training program and nutrition therapy|The intervention group receive the GLA:D® training program for 6 weeks and a nutrition therapy for 9 months.
88855273|NCT05955300|Active Comparator|Training program|The control group receive GLA:D® training program for 6 weeks and general information regarding a healthy life style for 9 months.
88855274|NCT05949138||ECG-Less Cardiac CT|Enrolled subjects will receive a clinically-indicated, diagnostic Cardiac CT with contrast. No ECG leads will be applied.
88855275|NCT05943574||Patients who received the XtraFix® Small External Fixation System|
88855276|NCT05942534||mask type assessment|The mask type assessment will compare a cloth mask, child and adult medical mask, child and adult KN95 respirator, and N95 respirator.
88855277|NCT05942534||mask modification assessment|The mask modification assessment will compare a child medical mask, adult medical mask with and without modifications (tuck and tie, twisted ear loops), and child and adult N95 respirator.
88855278|NCT05937659||Biometric Data Collection|Adult subjects with cancer and prescribed concurrent systemic therapy and radiation therapy and enrolled in the study.
88855279|NCT05936593|Active Comparator|Condylar Stabilizing (CS) insert|
88855280|NCT05936593|Active Comparator|Cruciate Retaining (CR) insert|
88855281|NCT05934630||Stratum 1: Medulloblastoma|Participants in Arm 1 must have diagnosis of Medulloblastoma. All children and adolescent/young adult (AYA) patients <= 21 years of age are eligible. AYA patients < 40 are eligible with a primary brain tumor entity more common in children than adults.
88875371|NCT05371158|No Intervention|Control condition|The control condition includes a waiting list group that can receive treatment-as-usual. Participants are placed on a waiting list and receive the online psychological ACT intervention without email guidance directly after the first follow-up measurement. Participants placed on the waiting list will not receive the ACT intervention immediately. Participants do have the opportunity to access treatment as usual (TAU). Directly after the first, 3-month follow-up measurement these participants receive the opportunity to follow the intervention without email guidance by a therapist.
88855282|NCT05934630||Stratum 2: High-grade Glioma (IDH-wildtype) or Diffuse Intrinsic Pontine Glioma|Participants in Arm 2 must have diagnosis of High-grade Glioma (IDH-wildtype) or Diffuse Intrinsic Pontine Glioma (DIPG). All children and adolescent/young adult (AYA) patients <= 21 years of age are eligible. AYA patients < 40 are eligible with a primary brain tumor entity more common in children than adults. DIPG patients must meet clinical and imaging requirements for DIPG diagnosis. Patients with newly diagnosed DIPGs, defined as tumors with a pontine epicenter and diffuse involvement of 2/5 or more of the pons, are eligible without histologic confirmation. Patients with brainstem tumors that do not meet these criteria or not considered to be typical intrinsic pontine gliomas will only be eligible for Stratum 2 if the tumors have been biopsied and are proven to be an anaplastic astrocytoma, glioblastoma multiforme, gliosarcoma, anaplastic mixed glioma or fibrillary astrocytoma.
88855283|NCT05934630||Stratum 3: Low-grade Glioma (IDH-wildtype)|Participants in Arm 3 must have diagnosis of Low-grade Glioma (IDH-wildtype). All children and adolescent/young adult (AYA) patients =< 21 years of age are eligible. AYA patients < 40 are eligible with a primary brain tumor entity more common in children than adults.
88855284|NCT05934630||Stratum 4: Diffuse Leptomeningeal Glioneuronal Tumor|Participants in Arm 4 must have diagnosis of Diffuse Leptomeningeal Glioneuronal Tumor. All children and adolescent/young adult (AYA) patients =< 21 years of age are eligible. AYA patients < 40 are eligible with a primary brain tumor entity more common in children than adults.
88855285|NCT05934630||Stratum 5: Pineoblastoma|Participants in Arm 5 must have diagnosis of Pineoblastoma. All children and adolescent/young adult (AYA) patients =< 21 years of age are eligible. AYA patients < 40 are eligible with a primary brain tumor entity more common in children than adults.
88855286|NCT05934630||Stratum 6: All other eligible primary brain tumor types|Participants in Arm 6 must have diagnosis of all other eligible primary brain tumor types. All children and adolescent/young adult (AYA) patients =< 21 years of age are eligible. AYA patients < 40 are eligible with a primary brain tumor entity more common in children than adults.
88855287|NCT05934617||Foch hospital|Lung recipients from Foch hospital, Suresnes, France
88855288|NCT05934617||Bichat hospital|Lung recipients from Bichat hospital, Paris, France
88855289|NCT05934617||Nantes hospital|Lung recipients from Nantes hospital, Nantes, France
88855290|NCT05934617||San Antonio center|Lung recipients from Pulmonary hypertension center, San Antonio, Texas, US
88855291|NCT05934617||Marie-Lannelongue hospital|Lung recipients from Marie-Lannelongue hospital, Le Plessis-Robinson, France
88855292|NCT05934617||Bordeaux hospital|Lung recipients from Bordeaux hospital, Nantes, France
88855293|NCT05934617||Marseille hospital|Lung recipients from Marseille hospital, Marseille, France
88855294|NCT05934617||Toulouse hospital|Lung recipients from Toulouse hospital, Toulouse, France
88855295|NCT05934617||Strasbourg hospital|Lung recipients from Strasbourg hospital, Strasbourg, France
88855296|NCT05934617||Grenoble hospital|Lung recipients from Grenoble hospital, Grenoble, France
88855297|NCT05934617||Cochin hospital|Lung recipients from Strasbourg hospital, Paris, France
88855298|NCT05934617||Hospital center Mayenne North|Lung recipients from Hospital center Mayenne North, Mayenne, France
88855299|NCT05934149||New Onset|Individuals with a new diagnosis of SLE
88855300|NCT05934149||LN Active|Individuals with a recent diagnosis of Lupus Nephritis
88855301|NCT05934149||Extra-renal Flare|Individuals who have experienced a recent flare
88855302|NCT05934149||Prevalent|Individuals with lupus who do not meet the criteria for one of the other cohorts
88855303|NCT05928884||Healthy Normals|Participants with no chronic pain over a three-year timeframe.
88855304|NCT05928884||MP without TPs|Participants with chronic low back pain who are classified as having myofascial pain and no trigger points.
88855305|NCT05928884||MP with latent TPs|Participants with chronic low back pain who are classified as having myofascial pain and latent trigger points.
88855306|NCT05928884||MP with active TPs|Participants with chronic low back pain who are classified as having myofascial pain and active trigger points.
88855307|NCT05926856|Active Comparator|1 day before surgery|0.25mg/kg Indocyanine Green will be administered 1 day before surgery
88855308|NCT05926856|Experimental|45 min before surgery|0.05mg Indocyanine Green will be administered 45minutes before surgery
88855309|NCT05926388|Experimental|Video-assisted training group|The researcher will train the patients with video-assisted on insulin therapy and administration.
88855310|NCT05917639|Experimental|Vitruvian plot|
88855311|NCT05917639|Experimental|Kilim plot|
88855312|NCT05917639|Active Comparator|Summary of findings table|
88855313|NCT05912270|Experimental|Orchestra in Class|"Children will receive music practice lessons in groups, Orchestra in Class (4 different string instruments, violin, viola, cello, double bass) in school class size groups over 2 full years. Interventions, given by 2 professional teachers per class, take place for 1 hour and 30 minutes per week, completed by daily homework (20-30 minutes)."
88855314|NCT05912270|Experimental|Visual Arts|Children will receive visual arts lessons in school class size groups over 2 full years. Interventions, given by 2 professional teachers per class, take place for 1 hour and 30 minutes per week, completed by daily homework (20-30 minutes).
88855315|NCT05912270|Placebo Comparator|Culture|The children will receive six cultural outings per year (museums, concerts, theatre, etc.) and pass all measurements
88855316|NCT05909709|Experimental|Alocyte Low dose|Subjects will receive low dose injection in a single facet joint
88855317|NCT05909709|Experimental|Alocyte Medium dose|Subjects will receive medium dose injections in three facet joints
88855318|NCT05909709|Experimental|Alocyte High dose|Subjects will receive high dose injections in five facet joints
88855319|NCT05896527|Experimental|Treatment Group 1: DC-806 Dose A|
88855320|NCT05896527|Experimental|Treatment Group 2: DC-806 Dose B|
88855321|NCT05896527|Experimental|Treatment Group 3: DC-806 Dose C|
88855322|NCT05896527|Experimental|Treatment Group 4: DC-806 Dose D|
88855323|NCT05896527|Placebo Comparator|Treatment Group 5: Placebo|
88855324|NCT05896163|Experimental|Phase 1b|Participants will be allocated to sequential dose levels of PF-07901801, administered in combination with fixed doses of glofitamab after a dose of obinutuzumab, to select two doses of PF-07901801 for further evaluation in Phase 2. Approximately 20 participants will be enrolled.
88855325|NCT05896163|Experimental|Phase 2|Participants will be randomized to 1 of 2 different dose levels of PF-07901801 which will be administered in combination with fixed doses of glofitamab after a dose of obinutuzumab. Approximately 50 participants will be enrolled (25 per dose).
88855326|NCT05894603||Oral antiviral A|Patients with an indication for treatment with nirmatrelvir + ritonavir (Paxlovid®).
88855327|NCT05894603||Oral antiviral B|Patients with an indication for treatment with molnupiravir (Lagevrio®).
88855328|NCT05893355|Experimental|Acupressure group|"Participants in this group will be interviewed for the first time in the first week of postpartum and for the second time in the fourth week of postpartum. The application will be explained and a voluntary consent form will be signed.~Participant Information Form will be filled in by the researcher by face-to-face interview.~The VAS that will be applied to the participant to evaluate the back pain just before the application will be filled in by the participant.~The VAS Evaluating Back Pain after the application will be filled in by the participant.~The participant will be informed that the study has been completed."
88855329|NCT05893355|No Intervention|Control group|"Participants in this group will be interviewed for the first time in the first week of postpartum and for the second time in the fourth week of postpartum. The application will be explained and a voluntary consent form will be signed.~Participant Information Form will be filled in by the researcher by face-to-face interview.~VAS to assess back pain will be filled in by the participant.~No application will be made to this group."
88855330|NCT05890963|Active Comparator|Arm 1: Oral ART|Participants will receive standard daily oral ART.
88855331|NCT05890963|Experimental|Arm 2: 10E8.4/iMab 600mg IV.|Participants will receive a single dose of 10E8.4/iMab 600mg IV.
88855332|NCT05890963|Experimental|Arm 3: 10E8.4/iMab 600mg IM.|Participants will receive a single dose of 10E8.4/iMab 600mg IM.
88855333|NCT05890963|Experimental|Arm 4:10E8.4/iMab 1800mg IV.|Participants will receive a single dose of 10E8.4/iMab 1800mg IV.
88855334|NCT05890963|Experimental|Arm 5: Combination 10E8.4/iMab and VRC07-523LS therapy|Participants will receive a single dose of combination therapy with both 10E8.4/iMab 1800mg IV. and VRC07-523LS 1200mg IV.
88855335|NCT05889156|Placebo Comparator|Matched Placebo|
88855336|NCT05889156|Active Comparator|NST-1024|NST-1024 400 mg BID
88855337|NCT05879913|Experimental|CCTA Group|
88855338|NCT05879913|No Intervention|Usual Care Group|
88855339|NCT05877430|Experimental|CJRB-101 with pembrolizumab|"Phase 1 includes patients with selected types of advanced or metastatic cancers. Patients will be given with either low or high dose levels of CJRB-101 in combination with pembrolizumab.~Phase 2 includes patients with selected types of advanced or metastatic cancers. Patients will be given with the CJRB-101 dose selected from Phase 1 in combination with pembrolizumab."
88855340|NCT05874141|Other|type 2 DM|
89382282|NCT03098979|Experimental|Neladenoson bialanate (BAY1067197) (10 mg)|Chronic heart failure with preserved ejection fraction
89382283|NCT03098979|Experimental|Neladenoson bialanate (BAY1067197) (20 mg)|Chronic heart failure with preserved ejection fraction
89382284|NCT03098979|Experimental|Neladenoson bialanate (BAY1067197) (30 mg)|Chronic heart failure with preserved ejection fraction
88855341|NCT05872295|Experimental|Dose Escalation Cohort (Part 1)|Each patient will receive repeat doses (by intravenous (IV) infusions) on Day 1 of each 21-day cycle. Participants may continue on study until disease progression, unacceptable toxicity, or other withdrawal criteria is met.
89382285|NCT03098979|Experimental|Neladenoson bialanate (BAY1067197) (40 mg)|Chronic heart failure with preserved ejection fraction
88855342|NCT05872295|Experimental|Dose Expansion: HER2+ Breast Cancer Participants|Each patient will receive IKS014 at the recommended dose defined in Part 1 on Day 1 of each 21-day cycle. Participants may continue on study until disease progression, unacceptable toxicity, or other withdrawal criteria is met.
88855343|NCT05872295|Experimental|Dose Expansion: HER2 Low Breast Cancer Participants|Each patient will receive IKS014 at the recommended dose defined in Part 1 on Day 1 of each 21-day cycle. Participants may continue on study until disease progression, unacceptable toxicity, or other withdrawal criteria is met.
88855344|NCT05872295|Experimental|Dose Expansion: HER2+ Gastric Cancer or Gastro-esophageal Junction Participants|Each patient will receive IKS014 at the recommended dose defined in Part 1 on Day 1 of each 21-day cycle. Participants may continue on study until disease progression, unacceptable toxicity, or other withdrawal criteria is met.
88855345|NCT05872295|Experimental|Dose Expansion: HER2 Low Gastric Cancer or Gastro-esophageal Junction Participants|Each patient will receive IKS014 at the recommended dose defined in Part 1 on Day 1 of each 21-day cycle. Participants may continue on study until disease progression, unacceptable toxicity, or other withdrawal criteria is met.
88855346|NCT05872295|Experimental|Dose Expansion: HER2 Solid Tumor Cancer Participants|Each patient will receive IKS014 at the recommended dose defined in Part 1 on Day 1 of each 21-day cycle. Participants may continue on study until disease progression, unacceptable toxicity, or other withdrawal criteria is met.
88855347|NCT05865041|Experimental|Farudodstat for 12 weeks followed by placebo for 12 weeks|Farudodstat 100mg twice daily for 12 weeks followed by matching Placebo twice daily for 12 weeks
89382286|NCT03098979|Placebo Comparator|Placebo|Chronic heart failure with preserved ejection fraction
89382287|NCT03625362|Experimental|Hydrogen|1 L of hydrogen-rich water
89382288|NCT03625362|Placebo Comparator|Placebo|1 L of tap water
89382289|NCT03625596|Active Comparator|High L-arginine|During this experimental day, men will receive a high-fat shake with a high dose of L-arginine.
89382290|NCT03625596|Experimental|Medium L-arginine + Nitrate / Nitrite|During this experimental day, men will receive a high-fat shake with a medium dose of L-arginine enriched with nitrate and nitrite.
89382291|NCT03625596|Experimental|Low L-arginine + Nitrate / Nitrite|During this experimental day, men will receive a high-fat shake with a low dose of L-arginine enriched with nitrate and nitrite.
88855348|NCT05865041|Experimental|Placebo for 12 weeks followed by farudodstat for 12 weeks|Matching Placebo twice daily for 12 weeks followed by farudodstat 100mg twice daily for 12 weeks
89382292|NCT03625596|Experimental|Nitrate / Nitrite|During this experimental day, men will receive a high-fat shake with nitrate and nitrite.
89382293|NCT03625596|Placebo Comparator|Placebo|During this experimental day, men will receive a high-fat shake without supplement.
88855349|NCT05859035|Experimental|KIOS Informational App evaluation|"Study participants will use the app at least three times per week. The app will contain a user interface that includes a login page, true/false questions for the user to answer, verified public domain educational information about drug and alcohol use, Likert-type questions regarding the information presented, and a closing Thank You screen."
88855350|NCT05852431|Experimental|Pegozafermin - 30mg once a week|
88855351|NCT05852431|Experimental|Pegozafermin - 20mg once a week|
89382294|NCT04802304|Experimental|Treatment|
89382295|NCT04802304|No Intervention|Control|
88855352|NCT05852431|Placebo Comparator|Placebo once a week|
88855353|NCT05846841|Active Comparator|Usual Care|The arm will represent usual care in the primary care clinics. Physicians will receive a report designed to recommend guideline-based tobacco treatment. Patients will receive a report on guideline-based advice about smoking cessation and a brief discussion with a behavior interventionist.
88855354|NCT05846841|Experimental|PrecisionTx|Physicians will receive PrecisionTx, an intervention designed to recommend precision tobacco treatment. Patients will receive PrecisionTx, an intervention designed to recommend precision tobacco treatment, and a brief discussion with a behavior interventionist.
88855355|NCT05846724|Experimental|Single Arm|
88855356|NCT05845554||Biliary tract carcinoma patients|Biliary tract carcinoma patients will be the experimental group to determine the sensitivity of BileCAD analysis.
88855357|NCT05845554||Non-cancer participants Patients|Non-cancer participants Patients being treated for other diseases but without any tumor will provide a negative control to provide data for determining the specificity of BileCAD analysis.
88855358|NCT05838729|Experimental|RiMO-301|Intratumoral injection of RiMO-301 followed by pembrolizumab or nivolumab followed by hypofractionated radiation
88855359|NCT05837351|Experimental|Exercise -Running|
89382296|NCT05416827|Active Comparator|PPV group|Epiretinal membrane eyes underwent PPV
89382297|NCT05416827|Experimental|PPV+implant Group|Epiretinal membrane eyes underwent PPV combined with Ozurdex implant
89382298|NCT05416671|Experimental|Treatment group|
89382299|NCT05416671|No Intervention|Control group|
89382300|NCT04958421|No Intervention|Control|This is the actual control group receiving conventional therapy, ie. percutaneous coronary intervention.
89382301|NCT04958421|Experimental|PiCSO|This arm will be treated with Pressure controlled intermittent Coronary Sinus Occlusion (PiCSO) in addition to conventional therapy (percutaneous coronary intervention).
88855362|NCT05835505|Active Comparator|BRS201 Arm|"In Group 1 of the study, subjects will take oral study drug at 1.2g twice daily, PO (2.4g daily) for 4 weeks.~In Group 2 of the study, subjects will take oral study drug at 2g twice daily, PO (4g daily) for 4 weeks.~In Group 3 of the study, subjects will take receive a one-time 5g IV dose of the study drug using the FDA-approved IV product followed by the oral study drug at 2g twice daily, PO (4g daily) for 4 weeks.~In Group 4 of the study, subjects will repeat the previous conditions of the group that proves to be the most effective."
88855363|NCT05835505|Placebo Comparator|Placebo Arm|"In Group 1 of the study, subjects will take oral placebo at 1.2g twice daily, PO (2.4g daily) for 4 weeks.~In Group 2 of the study, subjects will take oral placebo at 2g twice daily, PO (4g daily) for 4 weeks.~In Group 3 of the study, subjects will take receive a one-time 5g IV dose of the study drug using the FDA-approved IV product followed by the oral placebo at 2g twice daily, PO (4g daily) for 4 weeks.~In Group 4 of the study, subjects will repeat the previous conditions of the group that proves to be the most effective."
88855364|NCT05834777|Experimental|Icatibant|153 mL 0.9% saline bag containing 30 mg icatibant acetate (10 mg/ml) IV at each dialysis treatment for four weeks (12 hemodialysis sessions)
88855365|NCT05834777|Placebo Comparator|Placebo|153 mL 0.9% saline bag IV at each dialysis treatment at each dialysis treatment for four weeks (12 hemodialysis sessions)
88855366|NCT05825404|Experimental|Smart ambient bright light|The smart ambient bright light (SABL) intervention provides auto-controlled, consistent indoor lighting that incorporates natural daylight.
88855367|NCT05825404|Sham Comparator|Control|Usual light.
88855368|NCT05824806|Active Comparator|PRP protocol A|Composed of 30 patients who will receive an intra-articular injection of platelet-rich plasma (PRP A), once a week, for three consecutive weeks
88855369|NCT05824806|Active Comparator|PRP protocol B|Composed of 30 patients who will receive an intra-articular injection of platelet-rich plasma (PRP B), once a week, for three consecutive weeks
88855370|NCT05824806|Placebo Comparator|Hyaluronic acid|Composed of 30 patients who will receive an intra-articular injection of 2 mL of intra-articular hyaluronic acid (AHI), once a week, for three consecutive weeks.
88855371|NCT05786365||The group given 0.5 mg/kg ketamine|In this group we will give 0.5 mg/kg ketamine and we observe for disphoric reaction
88855372|NCT05786365||The group given 1 mg/kg ketamine|In this group we will give 1 mg/kg ketamine and we observe for disphoric reaction
88855373|NCT05773846|Experimental|PRF-110|PRF-110 3.6% ropivacaine, to be applied into the surgical wound
88855374|NCT05773846|Placebo Comparator|Saline .9%|Saline .9%, to b be applied into the surgical wound
88855375|NCT05773846|Active Comparator|Ropivacaine|Ropivacaine Hydrochloride 0.5%, up to 10 mL, to be applied into the surgical site
88855376|NCT05769114|Active Comparator|Surgical treatment|The surgeon will perform a minimally invasive (percutaneous) posterior stabilization of the injured spinal segments. Transpedicular screws will be inserted into the vertebral body superior and inferior to the fractured vertebra under fluoroscopic control. In a second stage procedure a lumbo- or thoracotomy (depending on the fracture level below or above the diaphragm) is performed to remove the fractured part of the vertebral body (hemicorporectomy) including the intervertebral disc segments. The resulting void is replaced by an (expandable) spacer/cage.
88855377|NCT05769114|No Intervention|Non-surgical treatment|The patients will receive an external bracing (3-point hyperextension brace) for six weeks, which must be always worn except when lying flat in bed. The brace is adjusted by an experienced orthopedist. A physiotherapist will instruct the patient to accomplish daily activities with the restriction he or she will have by wearing the brace.
88855378|NCT05769114|Other|Observational arm|Patients who do not agree to randomization will be given the option to participate in the observational arm of the study. Their treatment will be surgical fixation with an anterior-posterior stabilization (as per our current internal hospital standard).
88855379|NCT05763953|Experimental|Etripamil NS 70mg|Patients will be administered by study site personnel
88855380|NCT05757609|Experimental|tDCS combined with active physiotherapy|"transcranial Direct Current Stimulation (tDCS) will be applied for 20 min at an intensity of 2 mA with anodal stimulation targeting the left dorsolateral prefrontal cortex (DLPFC).~This will be done during a cycling session and will be followed by a physiotherapy program including strengthening and mobilisation exercises.~It will be applied 3 times a week during 3 weeks."
88855381|NCT05757609|Sham Comparator|Sham tDCS combined with active physiotherapy|"Sham transcranial Direct Current Stimulation (tDCS) will be applied for 20 min and this induces similar sensations for the patients, but no change in excitability.~This will be done during a cycling session and will be followed by a physiotherapy programme including strengthening and mobilisation exercises.~It will be applied 3 times a week during 3 weeks."
88855382|NCT05757362|Other|Compliance Questionnaire for Therapeutic Home Exercise Program in Physiotherapy and Rehabilitation|Participants will be asked to complete the questionnaire developed.
88855383|NCT05757063|Active Comparator|Propofol|Sedation procedure with propofol
88855384|NCT05757063|Active Comparator|Dexmedetomidine|Sedation procudure with dexmedetomidine
89183455|NCT04633278|Experimental|CMP-001 and Pembrolizumab|All subjects will receive CMP-001 IT and pembrolizumab IV according to the treatment schedule until a reason for treatment discontinuation is reached.
89183456|NCT04633252|Experimental|1/Dose Escalation|Docetaxel plus M9241 dose escalation with optional prednisone and ADT as part of SOC
89382302|NCT04980690|Experimental|Phase Ia - Dose escalation(Acceleration Stage)|"Phase Ia is an open, non-random, single-arm dose escalation design.~Acceleration Stage: The initial increasing dose is 0.025 mg/kg, and the dose is increased in 100% increments. Each dose group will enroll 1 subject."
89382303|NCT04980690|Experimental|Phase Ia - Dose escalation(3+3 Stage)|"Phase Ia is an open, non-random, single-arm dose escalation design.~3+3 Stage: The dose is increased in 30%-50% increments between adjacent dose groups, and the increment is determined by the investigator and the sponsor based on the safety data obtained in the previous period.Each dose group will enroll 3 to 6 evaluable subjects (evaluable: at least complete the DLT observation period), and this period continues until the maximum tolerated dose (MTD) is reached."
89382304|NCT04980690|Experimental|Phase Ib - Dose extension|"Phase Ib is an open, non-random, single-arm, multi-center research design.~When phase Ia is transformed into 3+3 stage, a certain dose group meets the conditions for increasing the next dose group (after the DLT observation period of the last subject in the dose group has passed, the safety assessment of the current dose group will be completed) , The dose extension study of this dose group can be carried out, and 6 evaluable (evaluable: at least 2 cycles of dosing and observation) subjects with advanced malignant tumors who have failed standard treatments will be included in this dose group."
88817953|NCT05288543|Experimental|Single Ascending Dose Phase|Drug: IPG7236 Dosage form: Tablet Route of Administration: Oral Dose level: Cohort 1 (25 mg), Cohort 2 (50 mg), Cohort 3 (100 mg), Cohort 4 (200 mg), Cohort 5 (300 mg), Cohort 6 (400 mg), Cohort 7 (500 mg) and Cohort 8 (600 mg)
88817954|NCT05288543|Experimental|Multiple Ascending Dose Phase|Drug: IPG7236 Dosage form: Tablet Route of Administration: Oral Dose level: Cohort 1 (100 mg), Cohort 2 (300 mg) and Cohort 3 (500 mg)
88817955|NCT05288543|Placebo Comparator|Part A (Placebo)|Placebo tablets identical to IPG7236 tablets Dosage form: Tablet Route of Administration: Oral
88817956|NCT02193152|Experimental|Treatment: Pazopanib|"Pazopanib 800 mg daily should be taken orally without food at least one hour before or two hours after a meal.~One cycle of pazopanib is 28 days."
88817957|NCT05282147|Other|Babies undergoing newborn eye screening|Babies having newborn eye screening with the intervention (Digital Imaging) technique in addition to the standard ophthalmoscopic technique.
88817958|NCT01323998||5ARI monotherapy|Patients with BPH receiving 5ARI monotherapy
88817959|NCT01323998||AB monotherapy|Patients with BPH receiving AB monotherapy
88817960|NCT01323998||Early combination (5ARI + AB) therapy|Patients receiving early initiation of combination therapy with a 5ARI plus AB. Early initiation defined as starting 5ARI therapy within 30 days of initiating AB therapy
88817961|NCT01323998||Delayed combination (5ARI + AB) therapy|Patients receiving delayed initiation of combination therapy with a 5ARI plus AB. Delayed initiation defined as starting 5ARI therapy more than 30 days but less than 6 months after initiating AB therapy
88817962|NCT02258477|Active Comparator|Sequence 1 (D-B-A-C)|100 calorie beverage during week 1; 10 calorie beverage during week 2; control beverage beverage during week 3; 50 calorie beverage during week 4.
88817963|NCT02258477|Active Comparator|Sequence 2 (A-D-C-B)|Control beverage during week 1; 100 calorie beverage during week 2; 50 calorie beverage during week 3; 10 calorie beverage during week 4.
88817964|NCT02258477|Active Comparator|Sequence 3 (C-A-B-D)|50 calorie beverage during week 1; control beverage during week 2; 10 calorie beverage during week 3; 100 calorie beverage during week 4.
88817965|NCT02258477|Active Comparator|Sequence 4 (B-C-D-A)|10 calorie beverage during week 1; 50 calorie beverage during week 2; 100 calorie beverage during week 3; control beverage during week 4.
88817966|NCT03008954|Placebo Comparator|Placebo|Microcyrstalline cellulose (Avicel): provided in 5 capsules (350 mg each), twice daily (BID) prior to lunch and dinner.
88817967|NCT03008954|Experimental|GSP3 (2.25g)|GSP3: provided in 3 capsules (750 mg each), plus 2 placebo capsules (350 mg each), twice daily (BID) prior to lunch and dinner
88817968|NCT03008954|Experimental|GSP3 (3.75g)|GSP3: provided in 5 capsules (750 mg each), twice daily (BID) prior to lunch and dinner
88817969|NCT02626611|Placebo Comparator|Placebo|Xolair will be administered in week 0 through 16 of the study. Starting at week 8, food doses will be serially increased, per protocol, to up to 2000 milligrams per food. At week 30, the cohort will be randomized into 3 groups (placebo, low dose food, and high dose food). Participants will continue on this dose for 6 weeks. The oat placebo food, will be compared to high dose (2000 milligrams or low dose 300 milligrams food immunotherapy). At week 36 a food challenge will be performed to assess study endpoints.
88817970|NCT02626611|Active Comparator|Low Dose Food|Xolair will be administered in week 0 through 16 of the study. Starting at week 8, food doses will be serially increased, per protocol, to up to 2000 milligrams per food. At week 30, the cohort will be randomized into 3 groups (placebo, low dose food, and high dose food). Participants will continue on this dose for 6 weeks. The oat placebo food, will be compared to high dose (2000 milligrams or low dose 300 milligrams food immunotherapy). At week 36 a food challenge will be performed to assess study endpoints.
88817971|NCT02626611|Active Comparator|High Dose Food|Xolair will be administered in week 0 through 16 of the study. Starting at week 8, food doses will be serially increased, per protocol, to up to 2000 milligrams per food. At week 30, the cohort will be randomized into 3 groups (placebo, low dose food, and high dose food). Participants will continue on this dose for 6 weeks. The oat placebo food, will be compared to high dose (2000 milligrams or low dose 300 milligrams food immunotherapy). At week 36 a food challenge will be performed to assess study endpoints.
88817972|NCT01260662|Active Comparator|Propofol|Deep sedation using propofol
88817973|NCT01260662|Experimental|1:1 Propofol/Ketamine|Propofol and ketamine mixed 1:1, given at 0.1 cc/kg as initial bolus, followed by 1/2 that dose every 3 minutes as need for sedation
88817974|NCT01260662|Experimental|4:1 Propofol/Ketamine|Propofol and ketamine mixed 4:1, given at 0.1 cc/kg as initial bolus, followed by 1/2 that dose every 3 minutes as need for sedation
88817975|NCT02327117|Experimental|Tranexamic acid|
88817976|NCT02327117|Placebo Comparator|Normal Saline|
88817977|NCT03819543|Experimental|Transcranial Direct Current Stimulation|
88817978|NCT03781089|Experimental|Patiromer Oral Powder Product|Patients randomized to the patiromer arm will initiate on 8.4 g/day (one pack) given once a day with breakfast or lunch (in place of the full dose of phosphate binder), to start at the end of Week 0. The patiromer dose will be titrated based on serum potassium concentrations drawn on HD1 of Weeks 1, 2, and 3. Patiromer will be increased by 8.4 g/day if K ≥ 5.1 meq/L, decreased by 8.4 g/day if K < 4.0 mEq/L, and patiromer will be discontinued if K < 3.5 mEq/L.
88817979|NCT03781089|No Intervention|Usual care arm|Patients randomized to the usual care arm will undergo monitoring with laboratory measurements as outlined in the study protocol
88817980|NCT01365650|Experimental|Ketorolac Tromethamine|
88817981|NCT01365650|Experimental|Oxymetazoline Hydrochloride|
88817982|NCT01365650|Experimental|Fluticasone Propionate|
88817983|NCT02327351|Experimental|TCR alfa beta depletion|TCR alfa beta depleted graft, infusion. The leukapheresis product will undergo TCR alfa beta depletion following the standardized protocol.
88817984|NCT02627001|Experimental|NuMask Intraoral Airway Device|A United States Army Combat Medic uses a single hand technique to hold a Nu-Mask Intraoral Airway Device on a cadaver while an Impact 731 ventilator delivers 10 standardized breaths with tidal volumes of 750 ml each.
88817985|NCT02627001|Active Comparator|Bag Valve Mask|A United States Army Combat Medic uses a single hand technique to hold a conventional bag valve mask on a cadaver while an Impact 731 ventilator delivers 10 standardized breaths with tidal volumes of 750 ml each.
88817986|NCT01261052|Active Comparator|FMPD/APD intervention|Type 1 Diabetes Mellitus subjects who fit the inclusion/exclusion criteria will undergo artificial pancreas closed-loop study for 33 hours. For the first 13 hours, the original artificial pancreas algorithm FMPD, will be used to control the subject's blood glucose. After 13 hours, the adaptive component or APD will be used to control the subject's blood glucose for the remaining 20 hours.
88817987|NCT01261052|Active Comparator|APD only intervention|Type 1 Diabetes Mellitus subjects who fit the inclusion/exclusion criteria will undergo artificial pancreas closed-loop study for 33 hours. For the entire study, the adaptive component or APD will be used to control the subject's blood glucose.
88817988|NCT01770431|Experimental|Huaier Granule group|"Huaier Granule group; specifications: 20g / bag; manufacturer: Qidong Gaitianli Medicines Co., Ltd..~Administration: the Huaier Granule Electuary should be orally taken from the 15th day after surgery. Usage: Huaier Granule Electuary is continuously taken three times per day, 20g per time, until 96 weeks after surgery or until study termination. The subjects should not take any other anticancer drugs or immunomodulatory agents, except for Huaier Granule."
88817989|NCT01770431|No Intervention|Bank-control group|"Blank-control group, not taking Huaier Granule, other anticancer drugs, or immunomodulatory agents.~During the study, patients who need antiviral therapy, in both the test group and control group, can be treated according to the therapeutic principles."
88817990|NCT03707925|Experimental|Diagnostic (bronchoscopic laser ablation, CBCT)|Patients undergo bronchoscopic laser ablation following standard bronchoscopy and endobronchial ultrasound. Patients also undergo CBCT before and after laser ablation. 48-72 hours after the procedure, patients undergo standard surgical resection of the lung tumor.
88817991|NCT01771055|Experimental|Galactose|Galactose
89382305|NCT04980690|Experimental|Phase IIa - Clinical Exploratory Stage(Group A)|"The Phase IIa is planned to be divided into four indication groups, all of which are open, non-randomized, two-stage, single-arm research design.~Group A: Recurrent or metastatic triple-negative breast cancer that failed standard treatment."
88855385|NCT05755035|Experimental|Randomized Crossover Treatment Epoch: TAK-881 followed by HYQVIA (Sequence 1)|Participants aged >=16 years will receive 6 or 8 full doses of TAK-881 followed by 6 or 8 full doses HYQVIA in sequence 1. The first full dose of TAK-881 will be administered either 2 weeks after the second ramp-up dose (if applicable) or 3 or 4 weeks after the last infusion of their pre study immunoglobulin G (IgG) treatment (if ramp-up is not applicable).
88855386|NCT05755035|Experimental|Randomized Crossover Treatment Epoch: HYQVIA followed by TAK-881 (Sequence 2)|Participants aged >=16 years will receive 6 or 8 full doses of HYQVIA followed by 6 or 8 full doses of TAK-881 in Sequence 2. The first full dose of HYQVIA will be administered either 2 weeks after the second ramp-up dose (if applicable) or 3 or 4 weeks after the last infusion of their pre study IgG treatment (if ramp-up is not applicable).
88855387|NCT05755035|Experimental|Single Arm Treatment Epoch: TAK-881|Pediatric participants aged 2 to <16 years will receive 6 or 8 full doses of TAK-881. The first full dose of TAK-881, will be administered either 2 weeks after the second ramp-up dose (if applicable) or 3 or 4 weeks after the last infusion of their pre study IgG treatment (if ramp-up is not applicable).
88855388|NCT05753176|Experimental|Online 1-Day CBT-Based Workshop|Participants assigned to the treatment arm will attend a day long CBT-based workshop delivered online by two trained facilitators in addition to receiving usual care.
88855389|NCT05753176|No Intervention|Treatment as Usual|Participants assigned to the control arm will continue to receive standard prenatal care from their healthcare providers.
88855390|NCT05751278|Experimental|Cryoprobe|Participants in this arm will undergo a standard of care bronchoscopy with a transbronchial biopsy using the 1.1mm sheath cryoprobe
88855391|NCT05751278|Active Comparator|Forceps|Participants in this arm will undergo a standard of care bronchoscopy with a transbronchial biopsy using forceps
88855392|NCT05736432|Experimental|Blueberries-Phase I|feeding will consist of 1 C frozen wild blueberries along with ¾ C low-fat Mountain High yogurt (total energy intake=170 kcal)
88855393|NCT05736432|Placebo Comparator|Syrup-Phase I|feeding will consist of an isocaloric feeding of ¾ C yogurt mixed with artificially flavored and colored blueberry syrup (Torani)
88855394|NCT05736432|Experimental|Blueberries-Phase II|1 C frozen wild blueberries along with ¾ C low-fat Mountain High yogurt (total energy intake=170 kcal) along with a) dietary intervention, b) daily text messaging, and c) daily at-home weighing with a WiFi-enabled scale
88855395|NCT05736432|Placebo Comparator|Syrup-Phase II|isocaloric feeding of ¾ C yogurt mixed with artificially flavored and colored blueberry syrup (Torani) along with a) dietary intervention, b) daily text messaging, and c) daily at-home weighing with a WiFi-enabled scale
88855396|NCT05733767|Active Comparator|Enhanced usual care (EUC)|The investigators will administer the enhanced usual care intervention to randomized patients.
88855397|NCT05733767|Experimental|Personalized Care: Nurse Practitioner led Tobacco Treatment Team (NPT3)|The investigators will administer the personalized care NPT3 intervention to randomized patients.
88855398|NCT05731895|Experimental|Arm 1: Participants with mild hepatic impairment (Child-Pugh A)|
88855399|NCT05731895|Experimental|Arm 2: Participants with moderate hepatic impairment (Child-Pugh B)|
88855400|NCT05731895|Experimental|Arm 3: Participants with normal hepatic function individually matched to participants of Arm 1|
88855401|NCT05731895|Experimental|Arm 4: Participants with normal hepatic function individually matched to participants of Arm 2|
88855402|NCT05684887|No Intervention|Standard of care model (SOC)|This model is based on the standard of care recommended by the Cameroon National COVID-19 response program.
88855403|NCT05684887|Experimental|Intervention model (ITV)|Implementation of the contact tracing using a digitalized process (addition of the Mamal Pro digital contact tracing module to the Mamal Pro app).
88855404|NCT05676047|Experimental|Therapy Group|The Therapy Group will receive 6-10 individual sessions of 30-60 minutes each, delivered by a trained Occupational Therapist or Speech-Language Pathologist. The therapy will be delivered over a 4-week timeframe, with the total number of sessions per participant depending on the number of sessions needed to achieve their treatment targets. Each participant in the Therapy Group will identify three cognitive targets for treatment. Progress in reaching those targets will be documented using Goal Attainment Scaling (GAS)
89382306|NCT04980690|Experimental|Phase IIa - Clinical Exploratory Stage(Group B)|"The Phase IIa is planned to be divided into four indication groups, all of which are open, non-randomized, two-stage, single-arm research design.~Group B: Locally advanced/metastatic non-small cell lung cancer without driver gene mutations that failed standard treatment."
88855405|NCT05676047|Active Comparator|Educational Group|The Education group will receive information about self-management of cognitive symptoms at the time of randomization, a common alternative for adults with Long COVID cognitive symptoms who do not receive Individual Therapy.
89183457|NCT04633252|Experimental|2/Safety Run-in (no longer applies; removed before enrollment)|Docetaxel plus M9241 RP2D plus M7824 with optional prednisone and ADT as part of SOC
89183458|NCT04633252|Experimental|3/mCSPC: Dose Expansion|Docetaxel plus M9241 RP2D with optional prednisone and ADT as part of SOC
89183459|NCT04633252|Experimental|4/mCRPC: Dose Expansion|Docetaxel plus M9241 RP2D with optional prednisone and ADT as part of SOC
89183460|NCT04624854|Placebo Comparator|Aspirin monotherapy|Patients will receive aspirin monotherapy without co-administration of clopidogrel for 12 months after randomization.
89183461|NCT04624854|Experimental|Clopidogrel and Aspirin dual-antiplatelet therapy|Patients will receive co-administration of clopidogrel and aspirin for 12 months after randomization.
89183462|NCT04609878|Experimental|Budesonide, glycopyrronium, and formoterol fumarate (BGF) MDI 320/28.8/9.6 μg|BGF MDI 320/28.8/9.6 μg Budesonide, glycopyrronium, and formoterol fumarate (PT010) Metered Dose Inhaler (MDI)
89183463|NCT04609878|Experimental|BGF MDI 320/14.4/9.6 μg|BGF MDI 320/14.4/9.6 μg Budesonide, glycopyrronium, and formoterol fumarate (PT010) Metered Dose Inhaler (MDI)
89183464|NCT04609878|Active Comparator|Budesonide and formoterol fumarate (BFF) MDI 320/9.6 μg|BFF MDI 320/9.6 μg (Experimental/Comparator) Budesonide and formoterol fumarate (PT009) Metered Dose Inhaler (MDI)
89183465|NCT04609878|Active Comparator|Symbicort®|Budesonide/ formoterol fumarate pressurized metered dose inhaler (pMDI) 320/9 μg
89183466|NCT04599218|Experimental|Males with Prostate Cancer|Each participant will receive standard of care ultrasound guided prostate biopsy and a MR/TRUS Fusion Guided prostate biopsy.
89183467|NCT04591210|No Intervention|No Treatment (Standard of Care)|Participants will be treated as per standardized care pathway according to province/state and institutional guidelines. Physicians will be reminded not to start ACEi or ARB throughout admission or to outpatients until active study participation is complete at 28 days post symptoms.
89183468|NCT04591210|Experimental|ACEi treatment|The physician will initiate any ACE inhibitor and dose at their discretion.
89183469|NCT04591210|Experimental|ARB treatment|The physician will initiate any ARB and dose at their discretion.
89183470|NCT04587856|Other|Biological evaluation|evaluation of molecular changes in CD34+ blast cells at the time of relapse after allo-HSCT.
89183471|NCT04585269|Experimental|Bright IDEAS-YA|Intervention consists of six 45-minute one-on-one sessions between a patient and a trainer, who teaches the Bright IDEAS stepwise approach to problem-solving and guides the participant through solving their own problems using the Bright IDEAS approach and worksheets. In addition, participants in this arm will receive a standardized list of resources from the National Comprehensive Cancer Network (NCCN) adolescent and young adult patient guidelines.
89183472|NCT04585269|No Intervention|Enhanced Usual Care|Participants in this arm will receive a standardized list of resources from the National Comprehensive Cancer network (NCCN) adolescent and young adult patient guidelines.
89183473|NCT04576507|Experimental|Dose A, followed by Dose B|On the first full inpatient day (Day 1), participants will smoke one specified strength (Dose A) of cannabis. Days 2-8 will comprise Phase 1, in which a second strength (Dose B) of cannabis will be administered 3x/day. The next 7 days (Day 9-15) will be Phase 2, in which cannabis Dose A will be administered once again, at the same 3 daily time points.
89183474|NCT04573075|Other|no outlet|no outlet is used after colorectal resection and forming of a primary anastomosis
89183475|NCT04573075|Active Comparator|loop ileostomy|loop ileostomy is applied after colorectal resection and forming of a primary anastomosis
89183476|NCT04573075|Experimental|ghost ileostomy|ghost ileostomy or ghost stoma (synonyms) is performed after colorectal resection and forming of a primary anastomosis
89183477|NCT04568707|Experimental|Covid-19 infection|Covid-19 infection defined by a positive PCR or a typical chest scanner of Covid-19 infection or a positive serology or a typical clinical picture in a pandemic period
89183479|NCT04549103|Experimental|Intervention Group|Intervention group will receive the 16-week Baduanjin exercise intervention.
89183480|NCT04549103|No Intervention|Control Group|Control group will not receive the exercise intervention, but they will attend four education classes about managing their health status.
88817992|NCT01771055|Placebo Comparator|Standard resuscitation|Standard surgical methods of controlling bleeding
88817993|NCT02628093|Other|THUNDERBEAT|THUNDERBEAT energy device ( Olympus) will be used for dissection of tissue and ligation of vessels
88817994|NCT02628093|Other|LIGASURE|LIGASURE energy device will be used for dissection of tissue and ligation of vessels
88817995|NCT01771991|Experimental|Topical Sodermix Dismutase|Patients with measurable radiation induced fibrosis of the neck. Patients will be randomized to applying Topical Sodermix Dismutase in the form of Sodermix(SOD) to the area of neck skin fibrosis twice a day for 12 weeks.
88817996|NCT01771991|Placebo Comparator|Placebo group|Cetaphil cream
88817997|NCT01324700|Active Comparator|High severity group: Escitalopram|Participants with Baseline score of 20 or above on the 17-item Hamilton Rating Scale for Depression (HRSD) AND 3 or more courses of oral corticosteroids in the past 12 months were stratified into high severity group. Then these participants were further stratified into escitalopram group.
88817998|NCT01324700|Active Comparator|Low severity group: Escitalopram|Participants with Baseline HRSD score of less than 20 AND fewer than 3 courses of oral corticosteroids in the past 12 months were stratified into low severity group. Then these participants were further stratified into escitalopram group.
88817999|NCT01324700|Placebo Comparator|High severity group: Placebo|Participants with Baseline score of 20 or above on the 17-item Hamilton Rating Scale for Depression (HRSD) AND 3 or more courses of oral corticosteroids in the past 12 months were stratified into high severity group. Then these participants were further stratified into placebo group.
89002780|NCT06149819|Experimental|Intervention (paramedical)|"The patients will be cared for by one of the specially trained nurses based on a previously established allocation per day. A nurse will be able to take in charge several patients successively included on the same day, in accordance with the actual practice of organized intra-hospital sector and according to the standardized algorithm based on the recommendations.~The DSMB will analyzed the compliance and safety of the management in this group at 20, 50 and 50% of enrollment and at the request of the sponsor if necessary.~An adjudication committee will determine compliance with diagnostic management in the two groups."
89183481|NCT04538378|Experimental|1/Arm 1|Combination of durvalumab and olaparib
89183482|NCT04519710|Experimental|multiple sclerosis or other inflammatory neurological disease|HBV negative
89183483|NCT04519710|Experimental|systemic vasculitis|HBV negative
89183484|NCT04519710|Experimental|an autoimmune disease|HBV negative
89183485|NCT04505839|Experimental|STP1002|
89183486|NCT04499781|Experimental|HIV-infected youth: Intervention|"Sample population of perinatally and behaviorally, HIV-infected youth (ages 18-29 years).~Characteristics of the target study population include ethnic minority, Black and Hispanic HIV+AYA; both males and females are eligible for participation."
89183487|NCT04499781|Active Comparator|HIV-infected youth: control|"Sample population of perinatally and behaviorally, HIV-infected youth (ages 18-29 years).~Characteristics of the target study population include ethnic minority, Black and Hispanic HIV+AYA; both males and females are eligible for participation."
89183488|NCT04498429|Experimental|Integrated Manual and Verbal Cueing Group|A series of 40 training repetitions of sit to stand using the Integrated/Manual Cueing intervention.
89183489|NCT04498429|Experimental|Verbal Cueing Group|A series of 40 training repetitions of sit to stand using the Verbal Cueing intervention
89183495|NCT04428554|No Intervention|Control arm|Standard of care
89183496|NCT04428554|Experimental|Experimental arm|
89382307|NCT04980690|Experimental|Phase IIa - Clinical Exploratory Stage(Group C)|"The Phase IIa is planned to be divided into four indication groups, all of which are open, non-randomized, two-stage, single-arm research design.~Group C: Recurrent or metastatic head and neck squamous cell carcinoma that failed standard treatment."
89183497|NCT04419519|Experimental|Venetoclax monotherapy|
89183498|NCT04419519|Experimental|Venetoclax with anti-CD20 monoclonal antibody|
89183499|NCT04418167|Experimental|Part A: JSI-1187 Monotherapy Dose Escalation|Locally advanced or metastatic solid tumors with confirmed with MAPK pathway mutation
89183500|NCT04418167|Experimental|Part B: JSI-1187 Plus Dabrafenib Combination Dose Escalation|BRAF V600E/K-mutated unresectable or metastatic melanoma, BRAF V600E-mutated NSCLC, or BRAF V600E-mutated locally advanced or metastatic anaplastic thyroid cancer, or other BRAF V600E-mutated unresectable or metastatic solid tumors
89183501|NCT04418167|Experimental|Part C: JSI-1187 Plus Dabrafenib Expansion|"Cohort 1: BRAF V600E/K-mutated unresectable or metastatic melanoma after 1-3 prior therapies for metastatic disease, including anti-PD1 therapy, with or without ipilimumab, and BRAF/MEK inhibitor treatment.~Cohort 2: BRAF V600E/K-mutated unresectable or metastatic melanoma after BRAF/MEK inhibitor adjuvant therapy for Stage 3 disease followed by 1-2 prior therapies for metastatic disease, including anti-PD-1 therapy, with or without ipilimumab, and excluding BRAF/MEK inhibitor treatment.~Cohort 3: BRAF V600E-mutated metastatic NSCLC after 1-2 prior therapies for metastatic disease."
89183502|NCT04416932||Post-operative patients who had total shoulder arthroplasty|Patients who have had a total shoulder replacement will be scheduled for an ultrasound at Duke Radiology. An ultrasound will be completed on the shoulder that has been replaced, which takes no more than an hour. This ends all study involvement.
89183503|NCT04416178||Parents of children with SCD|Parent of child with HbSS, HbS/ β0thalassemia, or HbSC aged 12 months to 18 years at study initiation
89183504|NCT04416178||Adolescents with SCD|Patient aged 13-18 with HbSS, HbS/ β0thalassemia, or HbSC
89183505|NCT04390113|Placebo Comparator|Placebo|Administered as 2-4 milliliter infusion, visually identical to Posoleucel (ALVR105)
89183506|NCT04390113|Experimental|Posoleucel (ALVR105)|Administered as 2-4 milliliter infusion, visually identical to placebo
89183507|NCT04380545|Experimental|Treatment (fluorouracil, interferon alpha 2b, nivolumab)|Patients receive fluorouracil IV continuously on days 1-7 and 15-21 and recombinant interferon alpha 2b-like protein SC on days 1, 3, 5, 15, 17, and 19. Treatment repeats every 28 days for 2 cycles in the absence of disease progression or unacceptable toxicity. Beginning in cycle 3, patients receive nivolumab IV over 30 minutes on day 1, fluorouracil IV continuously on days 1-7 and 15-21, and recombinant interferon alpha 2b-like protein interferon alpha 2b SC on days 1, 3, 5, 15, 17, and 19. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
89183508|NCT04372108||Ustekinumab New User Cohort|Participants with crohn's disease (CD) or ulcerative colitis (UC) with no prior exposure to ustekinumab, at least 1 year of enrollment records immediately prior to the new use will be required. The information will be sourced from the Department of Defense (DoD) Electronic Health Records (EHR) database in the United States (US).
89382308|NCT04980690|Experimental|Phase IIa - Clinical Exploratory Stage(Group D)|"The Phase IIa is planned to be divided into four indication groups, all of which are open, non-randomized, two-stage, single-arm research design.~Group D: Recurrent or metastatic peripheral T-cell lymphoma that failed standard treatment."
89382309|NCT05076513|Experimental|Arm A: Presumed Newly-Diagnosed glioblastoma|Participants undergoing resection for a presumed newly-diagnosed glioblastoma (WHO grade 4) will be treated with niraparib for 4 days prior to surgical resection. Participants who proceed to the therapeutic expansion phase of this study will receive niraparib in combination with radiation (60 Gy over 6-7 weeks, as per standard of care). Following radiotherapy, eligible study participants may receive niraparib maintenance treatment.
89382310|NCT05076513|Experimental|Arm B: Recurrent Glioma (Grades II-IV)|Participants undergoing resection of a recurrent WHO Grade II, III, or IV glioma with IDH1 or IDH2 mutation and ATRX loss will be treated with niraparib for 4 days prior to a planned surgical resection. Participants who proceed to the Expansion cohort will receive niraparib in 28d cycles after surgery.
89382311|NCT05450094|Active Comparator|Comparator|The comparator arm enhances school-based mental health (SBMH) with universal screening and trains voluntary school teams to use the school-wide data to plan and make intervention referrals using an evidence-based in-service training and coaching model called Team-Initiated Problem Solving (TIPS).
89382312|NCT05450094|Experimental|Enhanced|The enhanced arm involves the enhancements to school-based mental health (SBMH) of the comparator arm with the addition of 3 additional empirically supported enhancements to mental health screening: 1) voluntary school teams will review screening and service receipt data disaggregated by racial/ethnic subgroups to identify and problem solve inequities; 2) Unintentional bias training for voluntary school teams, involving teaching participants to conceptualize prejudice as well as strategies to reduce bias; and 3) Mental Health Literacy training for voluntary school teams in awareness and understanding of students' mental health well-being and need for intervention.
89382313|NCT01119183|No Intervention|1|
89382314|NCT01119183|Active Comparator|2|
88855407|NCT05660213|Experimental|Arm 1|"Huaier granules combined with targeted drug and anti- PD-(L)1 antibody.~There are there specific regimens:~Huaier granules combined with Atezolizumab and Bevacizumab, Huaier granules combined with Camrelizumab and Apatinib, Huaier granules combined with Sintilimab and Bevacizumab."
88855408|NCT05660213|Active Comparator|Arm 2|"Targeted drug combined with anti-PD-(L)1 antibody.~There are there specific regimens:~Atezolizumab combined with Bevacizumab, Camrelizumab combined with Apatinib, Sintilimab combined with Bevacizumab."
88855409|NCT05658562|Experimental|MT-2111 dosing regimen|
88855410|NCT05657691|Experimental|10 mg Xanamem™|10 mg Xanamem™ capsule, to be administered orally once every morning with or without food
89382315|NCT01119183|Experimental|3|
89382316|NCT05066919|Experimental|Operative treatment|Patients treated with open plantar fasciotomy
89382317|NCT05066919|Active Comparator|Conservative treatment|Patients treated non-operatively with exercise
89382318|NCT05422482|Experimental|GC1123 30mg|30 mg of IP will be administered every 28 days for 6 patients enrolled in Group 1
89382319|NCT05422482|Experimental|GC1123 30mg + GC1123 45mg|"30 mg of IP will be administered twice every 28 days for 2 patients enrolled in Group 2~45 mg of IP will be administered twice, and any DLT occurrence will be followed-up until 4 weeks after the 2nd 45 mg dose on the 2nd patient.~DSMB will determine whether to proceed the administration after reviewing safety and tolerability data from 1) and 2).~Group 2 will continue to receive 45 mg of IP administration"
89382320|NCT05422482|Experimental|GC1123 45mg|45 mg of IP will be administered every 28 days for 4 patients enrolled in Group 3
88855411|NCT05657691|Placebo Comparator|Placebo|Placebo capsule, to be administered orally once every morning with or without food
88855412|NCT05646589|Experimental|Person-centred care transition support|Person-centred dialogue intended to permeate all patient-provider communication, various pedagogical modes of information, a person-centred care and rehabilitation plan, and a bridging e-meeting to prepare patients for homecoming.
88855413|NCT05646589|Active Comparator|Regular care transition|Electronic referral from hospital healthcare professionals to the receiving neurorehabilitation team
89382321|NCT05418465|Experimental|Huangqi Guizhi Wuwu decoction group|Huangqi Guizhi Wuwu decoction
88855414|NCT05643794|Experimental|Treatment sequence 1|Study participants on Treatment sequence 1 will receive rozanolixizumab and Placebo during the dosing period at pre-specified timepoints.
89382322|NCT05418465|Active Comparator|Dapagliflozin group|Dapagliflozin
88855415|NCT05643794|Experimental|Treatment sequence 2|Study participants on Treatment sequence 2 will receive rozanolixizumab and Placebo during the dosing period at pre-specified timepoints.
88855416|NCT05643794|Placebo Comparator|Treatment sequence 3|Study participants on Treatment sequence 3 will receive Placebo during the dosing period at pre-specified timepoints.
88855417|NCT05618392||single group assignment|only one arm. Each patient complete numerical scale questionnaire (0-10)
89382323|NCT03261167|Experimental|Part 1: Subjects receiving 400 units of botulinum toxin A|Subjects will receive a total dose of 400 units of botulinum toxin A of which 240 units will be injected into the muscles that act on finger (including thumb flexors) and wrist flexors, and a total of 160 units will be injected into the muscles that act on the elbow flexors.
88855418|NCT05615922|Experimental|Remotely Supervised tDCS and Word-Naming Practice|At each session, the tDCS device will deliver 2.0 mA electric current for 30 minutes over the left frontotemporal lobe with focus on the inferior frontal gyrus (IFG). Participants will receive 20 intervention sessions over the course of the interventional period (4 weeks) on weekdays (Monday-Friday). During the stimulation period, participants will engage in a picture-naming exercise as guided by the study tDCS clinicians.
88855419|NCT05608915|Experimental|Augmented-Reality Visual Cues|In this single-arm study, all participants will receive all interventions on the same day. They will be wearing an augmented-reality headset that will display a digital obstacle course. Walking performance will be captured with no visual cues, with conventional visual cues, and with augmented-reality visual cues.
88855420|NCT05603650|Placebo Comparator|Water rinse|rinse twice daily for 1 min with water
88855421|NCT05603650|Experimental|Lumineux Oral Essentials rinse|rinse twice daily for 1 min with Lumineux Oral Essentials rinse
88855422|NCT05603650|Experimental|Listerine rinse|rinse twice daily for 1 min with Listerine rinse
88855423|NCT05590325|Experimental|single arm, two-stage|"Participants will be enrolled in two stages:~Stage 1 will assess a single dose of the DTG-DT in two sequential cohorts: Cohort 1A (n=8) and Cohort 1B (n=8).~Stage 2 will assess multiple-doses of the DTG-DT and the DTG-ODF in a single cohort: Cohort 2A (n=20) DTG-DT and Cohort 2B (n=20) DTG-ODF"
88855424|NCT05585918|Active Comparator|SEL Only|"SEL Only Condition supports include:~School wide support for implementation of Second Step curriculum (e.g., technical assistance professional development, facilitated professional learning communities)~Support to Positive Behavioral Intervention and Supports (PBIS) and Multi Tiered System of Supports (MTSS) and equity teams with alignment of initiatives~Individualized technical assistance with Second Step SEL implementation"
88855425|NCT05585918|Experimental|SEL + Equity|"SEL + Equity (Second Step + Equity) supports include supports from the SEL Only condition plus:~Training and implementation support for teachers to deliver 6 equity literacy lessons tailored to each grade level (4th and 5th for elementary schools; 6th - 8th for middle schools) and aligned with Second Step core content~Five 45-minute school-wide equity focused Professional Development (PD) sessions to complement AACPS Equity PD~Individualized teacher coaching to support implementing equity practices and equity-focused classroom lessons"
88855426|NCT05583448||ExploR Radial Head|Subjects who have received the ExploR Radial Head Device.
88855427|NCT05580185||Weaning failure|Defined as the failure to pass a spontaneous breathing trial or the need for reintubation or death within 48 hours after extubation
88855428|NCT05580185||Weaning success|Defined as a successful spontaneous breathing trial and is not reintubated or dies in the first 48 hours after extubation
88855429|NCT05578235|Active Comparator|stapled side-to-side anastomosis|Standard procedure for CD, ileocolic resection with side-to-side anastomosis is done according to local practice with a linear stapler either aniso- or isoperistaltic as advised by the ECCO guidelines
88855430|NCT05578235|Active Comparator|Handsewn anastomosis: handsewn end-to-end or Kono-s anastomosis|"Kono-S (anti-mesenteric functionel end-to-end handsewn) anastomosis is done according to the description by Kono~End-to-end handsewen anastomosis is fashioned either by enlarging the small bowel diameter by an antimesenteric incision to fit the large bowel lumen or by tailored resection of a part of the staple line of the cross stapled colon"
88855431|NCT05559476|Experimental|Co-Ad Group|Participants randomized to Co-Ad Group receive 1 dose of RSVPreF3 OA investigational vaccine and 1 dose of FLU HD at Day 1 and are followed up until the study end.
88855432|NCT05559476|Active Comparator|Control Group|Participants randomized to Control Group receive 1 dose of FLU HD at Day 1, followed by 1 dose of RSVPreF3 OA investigational vaccine at Day 31 and are followed up until the study end.
88855433|NCT05547490||Moderate-to-severe Plaque PsO|Participants experiencing moderate-to-severe plaque PsO, who have had at least one clinical visit.
88855434|NCT05541029|Experimental|Live music > Recorded music > Usual Care|Order of conditions for the day
88855435|NCT05541029|Experimental|Recorded music > Usual care > Live music|Order of conditions for the day
88855436|NCT05541029|Experimental|Usual Care > Live music > Recorded music|Order of conditions for the day
88855437|NCT05541029|Experimental|Live music > Usual Care > Recorded music|Order of conditions for the day
88855438|NCT05541029|Experimental|Recorded music > Live music > Usual care|Order of conditions for the day
88855439|NCT05541029|Experimental|Usual care > Recorded music > Live music|Order of conditions for the day
88855440|NCT05537298||Survivor|Patients (n = 206) surviving critical illness will be enrolled to longitudinal, observational study examining muscle strength, power, and fatigue as well as physical function at hospital discharge and repeated at 3-, 6-, and 12-month following. A subset of individuals (n =40) will undergo muscle biopsies and blood will be collected.
89382324|NCT03261167|Active Comparator|Part 1: Subjects receiving 240 units of botulinum toxin A|Subjects will receive 240 units of botulinum toxin A injected into the muscles that act on the finger (including thumb flexors) and wrist flexors. Placebo will be injected into the muscles that act on the elbow flexors.
89382325|NCT03261167|Experimental|Part 2,3,4: Subjects receiving 400 units of botulinum toxin A|Subjects will receive botulinum toxin A with a dose of 400 units injected in a divided doses.
88855441|NCT05537298||Control|A group of healthy controls will be recruited to serve as comparator to measures of strength, power, physical function, and muscle tissue analyses. Controls will participate in a one-time assessment.
88855442|NCT05530291||ESA hyporesponsive CKD patients|A cohort of patients who meets ESA hyporesponsiveness criteria as well as other common criteria will be created from the Fresenius Medical Care´s proprietary clinical database called EuCliD.
89382326|NCT05416359|Experimental|TQB3915 tablets|Take 300mg, 450mg, 600mg, 750mg, 900mg each time, once a day;Oral administration on an empty stomach, 28 days as a cycle. Duration of medication: Continue medication until disease progression or intolerable toxicity occurs.
89382327|NCT05418309|Experimental|Tislelizumab and Nab-Paclitaxel|Tislelizumab 200mg IV on day 1 in combination with nab-paclitaxel 200mg IV on day 2 every 3 weeks for 3 or 4 cycles followed by transurethral resection biopsy.
89382328|NCT05137548|Experimental|ATI-2173.|ATI-2173
89382329|NCT05137548|Experimental|Tenofovir Disoproxil Fumarate|Tenofovir disoproxil fumarate
89382330|NCT04534842|Experimental|SYNB1618|Dose ramp of SYNB1618
89382331|NCT04534842|Experimental|SYNB1934|Dose ramp of SYNB1934
89382332|NCT05091294|Active Comparator|Group S:33|120-second local anesthesic (% 0,5 Bupivacaine) injection time
89382333|NCT05091294|Active Comparator|Group F:34|15-second local anesthesic(% 0,5 Bupivacaine) injection time
89382334|NCT02725853|Experimental|tDCS + personalized practice|Transcranial direct current stimulation and personalized arm motor training limited to active control zones, 1 hour per day, 5 days per week for 2 weeks
89382335|NCT02725853|Active Comparator|tDCS + non-personalized practice|Transcranial direct current stimulation and non-personalized arm motor training spanning both active control and spasticity zones, 1 hour per day, 5 days per week for 2 weeks
89382336|NCT02725853|Sham Comparator|sham tDCS + personalized practice|Sham transcranial direct current stimulation and personalized arm motor training limited to active control zones, 1 hour per day, 5 days per week for 2 weeks
89382337|NCT04505891|No Intervention|Usual care|
89382338|NCT04505891|Active Comparator|Education alone|
89382339|NCT04505891|Active Comparator|Education and follow-up|
89382340|NCT05340894|Active Comparator|Mckenzie group|"adolescents will receive 4 weeks Mckenzie exercise program~Follow-up:pre-test (Baseline), 2 weeks post-test and 4 weeks post-test."
89382341|NCT05340894|Active Comparator|William's group|"adolescents will receive 4 weeks William's exercise program~Follow-up:pre-test (Baseline), 2 weeks post-test and 4 weeks post-test."
88855443|NCT05530291||ESA responsive CKD patients|A cohort of patients who meets ESA responsiveness criteria as well as other common criteria will be created from the Fresenius Medical Care´s proprietary clinical database called EuCliD.
88855444|NCT05530070|Active Comparator|Dietary intervention|Patients randomized to the dietary intervention group.
89382342|NCT03294941|Other|HepQuant SHUNT Liver Diagnostic Kit|All subjects receive HepQuant SHUNT test and DSI measurement. HepQuant SHUNT is a combination product where 13C Cholate 20mg is administered intravenously once for each test and d4 Cholate 40mg is administered once orally for each test
89382343|NCT03098433|Experimental|Liothyronine|Each participant will receive a single dose of lithyronine
89382344|NCT03098433|Active Comparator|Levothyroxine|Each participant will receive a single dose of levothyroxine
88855445|NCT05530070|Active Comparator|Standard of care|Patients randomized to the standard of care group.
88855446|NCT05528757||LGMDs Patients|Patients with a genetically confirmed diagnosis of a LGMD subtype 2A, 2B, or 2I
88855447|NCT05519878|Experimental|Arm I (BWL)|Patients self-administer 30 minutes of light delivered via light glasses every morning for 3 months. Patients attend 6 follow up sessions to address any questions regarding the wearable light therapy glasses.
88855448|NCT05519878|Experimental|Arm II (OT)|Patients undergo 6 occupational therapist-led sessions over 60 minutes each.
88855449|NCT05519878|Experimental|Arm III (OT, BWL)|Patients self-administer 30 minutes of light delivered via light glasses every morning for 3 months. Patients attend 6 follow up sessions to address any questions regarding the wearable light therapy glasses and to complete the occupational therapist-led session over 60 minutes.
88855450|NCT05519878|Active Comparator|Arm IV (Control)|Patients undergo routine treatment and usual follow up care with their medical oncologist.
88855451|NCT05519228||ToggleLoc 2.9 mm soft tissue device|Patients who already received the ToggleLoc 2.9 mm soft tissue device in the elbow. No additional surgery will be performed.
89382345|NCT03098433|Placebo Comparator|Placebo|Each participant will receive a single dose of placebo
89382346|NCT05044650|Experimental|KOVIR|Standard dose, 3 capsules/time x 3 times/day x 14 days combined with background treatment
89382347|NCT05044650|No Intervention|NON-KOVIR|Only background treatment
89382348|NCT03294317||His Bundle Pacing|Patient will be implanted per indications for single or dual chamber pacemaker. Lead for His bundle pacing will be implanted.
89382349|NCT05415891|Experimental|Stigma-Reduction Training Arm + YouRx Prescribing Platform|"Staff working in the clinic in this arm will be offered a whole-site stigma reduction training.~Participating HIV care providers will have access to the YouRx Prescribing Platform."
89382350|NCT05415891|Experimental|YouRx Prescribing Platform Only|"Staff working in the clinic in this arm will not be offered a whole-site stigma reduction training. However, staff will be offered this training at the conclusion of the study.~Participating HIV care providers will have access to the YouRx Prescribing Platform."
89382351|NCT05418075|Experimental|Home Treatment as add on to Familiy-based Treatment|
89382352|NCT05418075|Active Comparator|Familiy-based Treatment|
89382353|NCT05418075|Active Comparator|Mindfulness based stress reduction training|
89382354|NCT04928118||Impella protected Percutaneous coronary intervention (PCI)|Patients undergoing Impella protected PCI as deemed necessary by interventional cardiologist - VCU Medical Center case based standard of care
89382355|NCT04375553|Active Comparator|Exercise group|Intradialytic aerobic exercise, 3 times a week, for 12 weeks.
89382356|NCT04375553|No Intervention|Non-exercise group|Without intradialytic aerobic exercise for 12 weeks.
88855452|NCT05517811||Cancer|new diagnosis by the providing physician of hepatopancreaticobiliary, esophageal, colorectal or lung adenocarcinoma
88855453|NCT05517811||Control|Patients undergoing major surgery
88855454|NCT05510245|Experimental|Group 1|Participants without renal impairment will receive a single 20 mg dose of PF 07081532, administered orally
88855455|NCT05510245|Experimental|Group 2|Participants with mild renal impairment will receive a single 20 mg dose of PF 07081532, administered orally
88855456|NCT05510245|Experimental|Group 3|Participants with moderate renal impairment will receive a single 20 mg dose of PF 07081532, administered orally
88855457|NCT05510245|Experimental|Group 4|Participants with severe renal impairment will receive a single 20 mg dose of PF 07081532, administered orally
88855458|NCT05510128|Experimental|Management with the protocol|"Patients who participate in the study in the experimental arm benefit from an adapted management, which falls under the application of the national cooperation protocol.~This management may lead to the dispensing of an antibiotic by the pharmacist himself."
88855459|NCT05510128|No Intervention|Standard care|"Patients participating in the study in the control arm will benefit from a management comparable to the current one. In addition to a reminder of the hygienic and dietary rules by the pharmacist, the patient may be offered a drug indicated for improving urinary comfort.~The pharmacist should also remind the patient that she can consult a doctor, especially in case of non relief or aggravation of symptoms."
89382357|NCT05417997|Experimental|Research Arm|"Kunamin® 20 capsules 500mg daily plus; Standard therapy interventions determined and prescribed by investigators including:~Favipiravir: 1,600 mg (8 tablets) by mouth twice daily for 5 days.~Enoxaparin: 40 mg SQ daily if D-dimer < 3000 ng/mL *or* plt < 100,000~Enoxaparin: 0.5 mg/kg SQ twice daily if D-dimer >3000 ng/mL *and* plt < 100,000~Lansoprazole: 30 mg (one tablet) by mouth, once a day for 7 days.~Paracetamol: 500 mg (one tablet) by mouth, up to one tablet every 4 to 6 hours in case of fever (100.4°F/38°C or higher).~Ceftriaxone: 500 mg IV once a day for 5-7 days.~Clarithromycin: 250 mg (one tablet) twice a day for 5-7 days.~Methylprednisolone: 80 mg/kg IV bolus, followed by an infusion of 80 mg/day in 240 mL normal saline at 10 mL/h."
88855461|NCT05500690|Experimental|Folic Acid|5 mg folic acid supplement by mouth once a day for 12 weeks
88855462|NCT05484804|No Intervention|Standard Care|Pregnant patients with Medicaid insurance are screened for risk factors for low birthweight, and high-risk patients receive intensive care management.
88855463|NCT05484804|Active Comparator|Data Accountability and Transparency|Pregnant patients with Medicaid insurance are screened for risk factors for low birthweight, and high-risk patients receive intensive care management. Additionally, practices receive 2 additional patient-level interventions, including: 1) support from a Practice Facilitator to help implement the interventions and build workflows and quality improvement cycles; 2) use of a Maternal Warning System for missed visits/parameters and abnormal values with real-time feedback; 3) use of a Perinatal Equity Dashboard that displays outcome data stratified by race; and 2) Racial Equity Training.
88855464|NCT05484804|Active Comparator|Community-Based Doula (CBD) Support|Pregnant patients with Medicaid insurance are screened for risk factors for low birthweight, and high-risk patients receive intensive care management. Additionally, practices receive 2 additional patient-level interventions, including: 1) shared care of high-risk patients with Community-Based Doulas; and 2) Racial Equity Training.
88855465|NCT05484804|Active Comparator|Data Accountability and Transparency + Community-Based Doula Support|Pregnant patients with Medicaid insurance are screened for risk factors for low birthweight, and high-risk patients receive intensive care management, and practices receive all the Data Accountability and Doula Interventions described in Arms 2 and 3.
88855466|NCT05470023|Active Comparator|Brushing with LivFresh Dental Gel|Subjects will brush twice daily for the study duration with LivFresh Dental Gel with a standard Oral B ProFlexR toothbrush and will be trained in standard sulcular brushing technique. Subjects will brush their teeth two hours prior to each visit and refrain from eating from that time onwards until after their visit. Plaque levels, gingival inflammation, and sulcus bleeding will be recorded. A standardized periodontal probe will be used to measure pockets. Subjects will expectorate into a graduated cylinder for 5 minutes and their saliva production will be measured. Saliva will not be stored or analyzed in any way. Subjects will be photographed and evaluated on all study dates by the same blinded, pre-calibrated investigator. Photographs will be recorded using a standard dental intraoral camera, which only records intraoral images. These photos will not show the subject's face but will focus on the subject's mouth.
88855467|NCT05470023|Active Comparator|Brushing with LivFree Dental Gel|Subjects will brush twice daily for the study duration with LivFree Dental Gel with a standard Oral B ProFlexR toothbrush and will be trained in standard sulcular brushing technique. Subjects will brush their teeth two hours prior to each visit and refrain from eating from that time onwards until after their visit. Plaque levels, gingival inflammation, and sulcus bleeding will be recorded. A standardized periodontal probe will be used to measure pockets. Subjects will expectorate into a graduated cylinder for 5 minutes and their saliva production will be measured. Saliva will not be stored or analyzed in any way. Subjects will be photographed and evaluated on all study dates by the same blinded, pre-calibrated investigator. Photographs will be recorded using a standard dental intraoral camera, which only records intraoral images. These photos will not show the subject's face but will focus on the subject's mouth.
89002781|NCT06149819|No Intervention|Control (medical)|"In this group the patients will received usual medical care over the same period in the emergency department and meeting eligibility criteria. Patients will be included prospectively after obtaining their consent, with a 1:1 ratio with sex and age correspondence +/- 5 years).~An adjudication committee will determine compliance with diagnostic management in the two groups."
88855468|NCT05470023|Active Comparator|Brushing with AIM Dental Gel|Subjects will brush twice daily for the study duration with AIM Dental Gels with a standard Oral B ProFlexR toothbrush and will be trained in standard sulcular brushing technique. Subjects will brush their teeth two hours prior to each visit and refrain from eating from that time onwards until after their visit. Plaque levels, gingival inflammation, and sulcus bleeding will be recorded. A standardized periodontal probe will be used to measure pockets. Subjects will expectorate into a graduated cylinder for 5 minutes and their saliva production will be measured. Saliva will not be stored or analyzed in any way. Subjects will be photographed and evaluated on all study dates by the same blinded, pre-calibrated investigator. Photographs will be recorded using a standard dental intraoral camera, which only records intraoral images. These photos will not show the subject's face but will focus on the subject's mouth.
88855469|NCT05470023|Active Comparator|Brushing with Crest Prohealth Dental Gel|Subjects will brush twice daily for the study duration with Crest Prohealth Dental Gel with a standard Oral B ProFlexR toothbrush and will be trained in standard sulcular brushing technique. Subjects will brush their teeth two hours prior to each visit and refrain from eating from that time onwards until after their visit. Plaque levels, gingival inflammation, and sulcus bleeding will be recorded. A standardized periodontal probe will be used to measure pockets. Subjects will expectorate into a graduated cylinder for 5 minutes and their saliva production will be measured. Saliva will not be stored or analyzed in any way. Subjects will be photographed and evaluated on all study dates by the same blinded, pre-calibrated investigator. Photographs will be recorded using a standard dental intraoral camera, which only records intraoral images. These photos will not show the subject's face but will focus on the subject's mouth.
88855470|NCT05470023|Active Comparator|Brushing with Parodontax Dental Gel|Subjects will brush twice daily for the study duration with Parodontax Dental Gel with a standard Oral B ProFlexR toothbrush and will be trained in standard sulcular brushing technique. Subjects will brush their teeth two hours prior to each visit and refrain from eating from that time onwards until after their visit. Plaque levels, gingival inflammation, and sulcus bleeding will be recorded. A standardized periodontal probe will be used to measure pockets. Subjects will expectorate into a graduated cylinder for 5 minutes and their saliva production will be measured. Saliva will not be stored or analyzed in any way. Subjects will be photographed and evaluated on all study dates by the same blinded, pre-calibrated investigator. Photographs will be recorded using a standard dental intraoral camera, which only records intraoral images. These photos will not show the subject's face but will focus on the subject's mouth.
88855471|NCT05470023|Active Comparator|Brushing with Colgate Total Dental Gel|Subjects will brush twice daily for the study duration with Colgate Total Dental Gel with a standard Oral B ProFlexR toothbrush and will be trained in standard sulcular brushing technique. Subjects will brush their teeth two hours prior to each visit and refrain from eating from that time onwards until after their visit. Plaque levels, gingival inflammation, and sulcus bleeding will be recorded. A standardized periodontal probe will be used to measure pockets. Subjects will expectorate into a graduated cylinder for 5 minutes and their saliva production will be measured. Saliva will not be stored or analyzed in any way. Subjects will be photographed and evaluated on all study dates by the same blinded, pre-calibrated investigator. Photographs will be recorded using a standard dental intraoral camera, which only records intraoral images. These photos will not show the subject's face but will focus on the subject's mouth.
88875372|NCT05365854|Active Comparator|Continuous positive airway pressure (CPAP) then extended sigh|"Patients assigned to this group will receive a CPAP ARM (40cmH2O during 50 seconds), followed by a 10-minute pause corresponding to a period of return to basal state.~Then an ARM by extended sigh (e-sigh) also 50 seconds (driving pressure at 10cmH2O and successive PEEP levels at 10, 15, 20, 25 and 30cmH2O, with respiratory frequency fixed at 30/min in controlled pressure).~Hemodynamic (blood pressure, cardiac output, stroke volume) and ventilatory measurements will be performed the last 10 seconds of each recruitment maneuver."
89382358|NCT05417997|Placebo Comparator|Control arm|"According to MOH of Turkey, which required a standard treatment including the following drugs as placebo:~Favipiravir~Enoxaparin~Enoxaparin~Lansoprazole~Paracetamol~Ceftriaxone/ Clarithromycin~Methylprednisolone"
89382359|NCT04292574||Participants with Spinal Muscular Atrophy|
88855472|NCT05470023|Active Comparator|Rinsing with Lumineux or Listerine Mouthwashes|Subjects will be asked to rinse twice daily with 1 capful for 1 minute with Lumineux or Listerine Mouthwashes directly after brushing their teeth, while continuing with their usual oral hygiene protocol. Plaque levels, gingival inflammation, and sulcus bleeding will be recorded. A standardized periodontal probe will be used to measure pockets. Subjects will expectorate into a graduated cylinder for 5 minutes and their saliva production will be measured. Saliva will not be stored or analyzed in any way. Subjects will be photographed and evaluated on all study dates by the same blinded, pre-calibrated investigator. Photographs will be recorded using a standard dental intraoral camera, which only records intraoral images. These photos will not show the subject's face but will focus on the subject's mouth.
88855473|NCT05427253|Experimental|C106 solution|Part A: Oral administration start dose, Single dose 5 mg Part B: Oral administration start dose 20 mg twice daily for 8 days
88855474|NCT05427253|Placebo Comparator|Placebo|Part A and B: Placebo to C106 without the active pharmaceutical ingredient
88855475|NCT05416814|Experimental|Kefir administration in critically ill adults|Critically ill subjects will receive Kefir throughout the length of their ICU course in an ascending dosing regimen
88855476|NCT05414500|Experimental|Cohort|Fixed dose of Mogamulizumab and dose de-escalation with Brentuximab Vedotin
88855477|NCT05409924|Experimental|Phase A|ATR-258 Single Ascending Dose or placebo
88855478|NCT05409924|Experimental|Phase B|ATR-258 Multiple Ascending Dose or placebo
88855479|NCT05409924|Experimental|Phase C|ATR-258 Repeated dosing or placebo
89382360|NCT03292913|Experimental|Intervention Group|Receives the Positive Health Check intervention plus standard of care
89382361|NCT03292913|Other|Control Group|Receives standard of care
88855480|NCT05406570|Active Comparator|Standardized tidal volume|Ventilation with tidal volume 6 ml/kg
88855481|NCT05406570|Experimental|Personalized tidal volume|Ventilation with tidal volume aiming to minimize cardiopulmonary interactions as assessed by pulse pressure variation
89382362|NCT04167995|Active Comparator|Patient with attention deficit hyperactive disorser|patients (n=40) will receive probiotic preparation twice daily (Lacteol Forte; Rameda, Egypt) as sachets containing 10 billion colony forming units (CFU) of Lactobacillus fermentum and Lactobacillus delbruekii for 12 weeks added to standard treatment
89382363|NCT04167995|No Intervention|ADHD not receiving probiotics|ADHD patient (40) on standard treatment
88855484|NCT05402332|Experimental|AVTX-801|1.5g/kg/day AVTX-801
88855485|NCT05385471|Experimental|Group 1|8+1 volunteers receiving three doses of 10 µg R78C with 50 µg of Matrix-M on days 0, 28 and 182 via intramuscular (IM) injection in the deltoid region of the non-dominant arm
88855486|NCT05385471|Experimental|Group 2|8+1 volunteers receiving three doses of 10 µg R78C + 10 µg RH5.1 with 50 µg of Matrix-M on days 0, 28 and 182 via intramuscular (IM) injection in the deltoid region of the non-dominant arm
88855487|NCT05385471|Experimental|Group 3|8+1 volunteers receiving three doses of 10 µg RH5.1 with 50 µg of Matrix-M on days 0, 28 and 56 via intramuscular (IM) injection in the deltoid region of the non-dominant arm
88855488|NCT05385471|Experimental|Group 4|8+1 volunteers receiving two doses of 10 µg R78C + 10 µg RH5.1 with 50 µg of Matrix-M on days 0, 28, one dose of 10 µg R78C with 50 µg of Matrix-M on day 182 and one dose of 10 µg RH5.1 with 50 µg of Matrix-M on day 210, all administered via intramuscular (IM) injection in the deltoid region of the non-dominant arm
88855489|NCT05367960|Other|Study Drug (BPN14770)|25mg BID Study Drug BPN14770 (Adults) or 15mg BID Study Drug BPN14770 (Adolescents with body weight <43 kg)
89382364|NCT03704844||Patients with renal congestion|
89382365|NCT03704844||Patients without renal congestion|
89382366|NCT04005144|Experimental|Treatment (brigatinib, binimetinib)|Patients receive brigatinib PO QD and binimetinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89382367|NCT05418933|Experimental|Intervention group|Family workshops with 5 courses, with 6-7 families in one course, 2 hours per session, one time per week, for a total of 6 weeks.
89382368|NCT03291587|Experimental|Intervention|"Training of Lung Cancer Screening Personnel on implementation of the United States Public Health Service (US PHS) Guidelines for Smoking Cessation and Performance Coaching during Implementation Phase of the Study~Data collection from Patients: demographics, health status, smoking history, quitting behavior, perceptions of lung cancer risk and worry, impact of screening on tobacco use behavior, and exposure to the intervention. (baseline, <14 days, 3 months, and 6 months)"
88855490|NCT05363683|Active Comparator|Control|Standard care.
88855491|NCT05363683|Experimental|Experimental|Squat biofeedback intervention.
88855492|NCT05360901|Other|IntelliCare with automated motivational messaging|Digital mental health intervention with micro-randomized automated motivational messaging delivery
88855493|NCT05360082||Healthy controls|
88855494|NCT05360082||Premanifest HD mutation carriers|"HTT CAG repeat length ≥ 40~UHDRS Diagnostic confidence level < 4"
88855495|NCT05360082||Manifest HD mutation carriers|"HTT CAG repeat length ≥ 40~UHDRS Diagnostic confidence level = 4~Shoulson-Fahn stage 1-2"
88855496|NCT05346692|Active Comparator|Arm I (Pain Survey)|Patients complete pain survey via text message daily for 10 days after surgery. Patients also complete telephone interview 2 weeks after surgery.
88855497|NCT05346692|Experimental|Arm 2 (Mindfulness Intervention)|Patients complete mindfulness intervention via text message daily for 10 days after surgery. Patients also complete telephone interview 2 weeks after surgery.
89002782|NCT06149286|Experimental|Odronextamab+Lenalidomide|"In part 1 (safety run-in), participants with R/R indolent lymphoma (FL and ML), will receive odronextamab in combination with lenalidomide.~In part 2, 1:1 randomized participants with indolent lymphoma (FL/MZL), will receive odronextamab in combination with lenalidomide."
89002783|NCT06149286|Experimental|Rituximab+Lenalidomide|In part 2 only, 1:1 randomized participants with R/R lymphoma (FL and ML), will receive rituximab in combination with lenalidomide (R2) followed by lenalidomide monotherapy.
89382369|NCT03291587|No Intervention|Usual Care|"No training or performance coaching calls on personnel, just usual clinic practice.~Data collection from Patients: demographics, health status, smoking history, quitting behavior, perceptions of lung cancer risk and worry, impact of screening on tobacco use behavior, and exposure to the intervention. (baseline, <14 days, 3 months, and 6 months)"
89382370|NCT03856788|Placebo Comparator|Saline|Patients will undergo general anesthesia with a post-induction, post-intubation, pre-procedural subcostal TAP block with normal saline on the ipsilateral side as the extraction site.
89382371|NCT03856788|Active Comparator|Bupivacaine|Patients will undergo general anesthesia with a post-induction, post-intubation, pre-procedural subcostal TAP block with bupivacaine on the ipsilateral side as the extraction site.
89382372|NCT03625284|Experimental|Fucovital|capsules of a dietary supplement rich with fucoxanthin from microalgae extract
89382373|NCT03625284|Placebo Comparator|Placebo|capsules of an edible oil
89382374|NCT03210961|Experimental|PF-06826647 tablet|
89382375|NCT03210961|Placebo Comparator|Placebo tablet|
89382376|NCT03210961|Experimental|PF-06826647 oral suspension|
88855498|NCT05336253|Experimental|EVERYbody Project-Connect Online Program|"Three weekly 90-minute online group sessions facilitated by expert peer leaders. Retains key dissonance activities and the inclusivity focus of the original EVERYbody Project (e.g., expanded gender focus, critically discussing the impact of limited diversity representation in cultural appearance norms). Additional activities were added, including an increased focus on body compassion (self-acceptance) and weight neutrality content to target weight bias.~College students with body image interest and lived or academic diversity and advocacy experience will complete 16 hours of training to become expert peer leaders. Training includes observation, practice, and feedback on using the program manual and managing groups. Students will self-assess and be evaluated by the primary trainer on facilitation readiness. Only peer leaders with sufficient expertise will be invited to facilitate groups."
88855499|NCT05336253|Active Comparator|Self-Help Workbook|In this time-matched comparison intervention, participants will be provided with an online copy of The Body Is Not An Apology Workbook by author and activist Sonya Renee Taylor (2021). Weekly emails will assign workbook activities to complete on their own (90 minutes per week for three weeks). This low-dissonance comparison intervention covers many of the same topics within the EVERYbody Project-Connect (body acceptance and scrutinizing the diversity within body ideals) and its activities include reflective writing and drawing exercises to challenge media messages around bodies, identify systems of oppression underpinning body messages, challenge body stereotypes, and make peace with your own body. Activities within the workbook are considered low-dissonance since they will be done privately and not shared.
89382377|NCT03210961|Placebo Comparator|Placebo oral solution/suspension|
89382378|NCT04797078|Active Comparator|Transrectal fusion biopsies of the prostate|"Transrectal approach, patient in left lateral position, local anestesia 10ml lidocaine 1% at prostate base laterally and apex if indicated.~MRI-ultrasound fusion-guided biopsies with 4 biopsy cores per lesion, where clinically indicated. 18G biopsy needle.~Standard 12-core template for systematic biopsies. 18G biopsy needle.~Antibiotic prophylaxis with 750mg ciprofloxaicin, single dose p.o."
89382379|NCT04797078|Experimental|Transperineal free hand fusion biopsies of the prostate|"Men randomized to the experimental arm undergoes free-hand targeted transperineal fusion biopsies as defined below.~Patient is placed supine in the lithotomy-position. The perineal area is prepared with chlorhexidine 0,5ml/ml.~Ropivacain 7,5mg/ml is used as an anesthetic agent. Up to 40ml's (equivalent to 300mg) can be used to anestitize the skin, caudal and cranial part of the urogenital diaphragm and periprostatic tissue.~Free-hand MRI-ultrasound fusion-guided biopsies with at least 4 biopsy cores per lesion. Coaxial technique with 18G biopsy needle.~10-12 Systematic biopsies according to the modified Barzell 12-core template.~No antibiotic profylaxis unless warranted by immunosuppression, previous sepsis or urinary tract infection."
89382380|NCT03638921|Experimental|MEOPA|Patients included in the study will receive MEOPA with a high concentration mask (bottle stored for at least 48 hours horizontally) at a minimum flow rate of 10 L / min under supervision of a health care worker after explanation of use to the patient in a quiet environment (box). MEOPA will be administered for a maximum total duration of 20 minutes, continuously or not depending on the needs of the patient, but after a continuous phase at the beginning of treatment of at least 3 minutes.
89382381|NCT05417919|Experimental|Solution-oriented Nursing in Violence Against Women (SONVAW)|"Initiatives for the Experimental Group Personal Information Form and İSKEBE scale were given to 45 students who were determined in accordance with the research criteria and they were asked to fill in. Data were collected from students who did not come to school that day by telephone or by interviewing them the next day.~Before the solution-oriented approach program, the students were interviewed and the appropriate time and hours were determined for the program. Then, an online solution-oriented approach program was implemented, which lasted for 6 weeks at the specified hours and days. In the first week of the program, a guide form containing the activities related to the program to be applied was distributed to the students. At the end of the program, the students were asked to fill in the İSKEBE scale as a post-test. Three months after the end of the program, they were asked to fill in the İSKEBE scale again as a follow-up test."
89382382|NCT05417919|No Intervention|Control|Initiatives for the Control Group Personal Information Form and İSKEBE scale were given to 45 students who were determined in accordance with the research criteria and they were asked to fill in. Data were collected by phone calls or the next day with students who did not come to school that day. 6 weeks after the pre-test application, the students were asked to fill in the İSKEBE scale as a post-test. Three months after the post-test application, they were asked to fill out the İSKEBE scale again as a follow-up test. At the end of the follow-up test, 45 minutes of violence against women training was given to the control group students.
89382383|NCT03701802||HIV-1 serodiscordant couples|Heterosexual couples in which one partner is infected with HIV-1 and the other partner is HIV-1 uninfected
89382384|NCT03701802||Concordant HIV-1 negative couples|Heterosexual couples in which both partners are HIV-1 uninfected
89382385|NCT04853667||Patients with hereditary epidermolysis bullosa|Minor patients with hereditary epidermolysis bullosa
89382386|NCT04853667||Parents|Parents of patients with hereditary epidermolysis bullosa
89382387|NCT03242759||patients with idiopathic pulmonary fibrosis (IPF)|
89382388|NCT04050930|Experimental|Normal weight, normo-dented|healthy young male presenting a good oral health ad a normal weight
88855500|NCT05333523|Experimental|Sentinel lymph node biopsy guided selective elective neck irradiation|"Sentinel lymph node biopsy~Radiotherapy (IMRT/VMAT with SIB) to the primary tumor with selective elective neck irradiation guided by histopathologic status of the sentinel lymph node(s)"
88855501|NCT05333523|Active Comparator|Standard elective neck irradiation|- Radiotherapy (IMRT/VMAT with SIB) to the primary tumor with standard bilateral elective neck irradiation
88855502|NCT05330884|Experimental|vaccine - Bacille Calmette-Guérin vaccine (BCG )|Bacille Calmette-Guérin vaccine (BCG ) dose 0.1ml intradermal
88855503|NCT05330884|Other|Chemoprophylaxis - as per NTEP guidelines|Oral chemoprophylaxis: according to the existing standard of care (NTEP guidelines) Either six months of isoniazid (10mg/kg) or Rifapentine and isoniazid weekly for 3 months for DS TB Levofloxicillin or standard of care drug for DR TB: 15-20mg/kg/day
88855504|NCT05327959|Experimental|Treatment Group|The population target is all subjects suffering clavicle fracture suitable for open reduction and internal fixation by the A.L.P.S. Clavicle Plating System in accordance with the IFU.
88855505|NCT05307237|Experimental|Continuous Glucose Monitoring|Research Assistants (RAs) will verbally administer baseline survey and insert Dexcom G6 CGM, before unveiling the group assignment. CGM data will be transmitted from bedside iPhone to web-based platforms for: (1) Real-Time Management (via iPad-based FOLLOW app used by bedside RN and Digital Dashboard used by remote monitoring team) and (2) Clinical Optimization (via CLARITY, a Diabetes RN Coordinator will conduct remote clinical management of patients from a central, Scripps Diabetes Hub). A post-CGM satisfaction survey will be administered and compensation provided when CGM is removed prior to discharge or within 2 weeks following discharge. The CGM readings will be used to make recommendations for insulin adjustment and glucose management. After discharge, CGM data will be downloaded from a HIPPA-compliant, web-based CGM data management tool, and saved in Excel. The Data Analyst, blinded to condition, will routinely screen CGM data and merge individual spreadsheets for analysis.
88855506|NCT05307237|Active Comparator|Usual Care|RAs will verbally administer a baseline survey and insert the Dexcom G6 CGM. before unveiling the group assignment. CGM data will be blinded and used for evaluation purposes only. Glucose will be monitored via the hospital's standard POC testing protocol (i.e., prior to meals and at bedtime for patients who are eating, and every 4-6 waking hours if not eating). Glucose management in UC is designed to minimize differences between groups, aside from CGM monitoring, A post-CGM satisfaction survey will be administered and compensation provided when the CGM is removed prior to discharge or within 2 weeks following discharge. After discharge, CGM data will be downloaded from a HIPPA-compliant, web-based CGM data management tool, and saved in individual Excel spreadsheets. The study Data Analyst, blinded to study condition, will routinely screen CGM data and merge individual spreadsheets for analysis.
88855507|NCT05298358|Experimental|RIC- alloBMT with high PTCy in SSc|"Days -9 Thymoglobulin 0.5 mg/kg IV~Days -8,-7 Thymoglobulin 2 mg/kg IV daily~Days -6, -5 Fludarabine 30 mg/M2 IV Cyclophosphamide 14.5 mg/kg IV~Days -4, -3-2 Fludarabine 30 mg/M2 IV~Day -1 TBI 400 cGy~Day 0 Infuse unmanipulated marrow; begin antimicrobial prophylaxis.~Days 3, 4 Cy 50 mg/kg IV and Mesna 40 mg/kg IV~Day 5 FK-506 oral and MMF oral and G-CSF~Day 30 Assess peripheral blood chimerism~Day 35 Discontinue MMF~Day 60 Assess peripheral blood chimerism~Day 180 Discontinue FK-506 Evaluate disease Assess Chimerism in peripheral blood~1 yr. Evaluate disease by peripheral blood chimerism"
88855508|NCT05289349|Active Comparator|group (P) for propofol|propofol 6 mg/kg/h in group P
88855509|NCT05289349|Active Comparator|group (S) for sevoflurane.|sevoflurane 1.0-1.5 minimum alveolar concentration (MAC) in group S.
88855510|NCT05278000||Children aged 2-17 years with asthma|Parents of children aged 2-17 years seen at CHU Sainte-Justine asthma clinic with a diagnosis of asthma will be eligible for the study
88855511|NCT05263011|Experimental|Avocado snack|1 avocado
88855512|NCT05263011|Placebo Comparator|control snack + fiber supplement + vegetable oil|high fat, high fiber control
88855513|NCT05263011|Other|control snack|Low-fiber, low-fat
88855514|NCT05241223|Sham Comparator|Control group|This group will receive an education program which will cover information regarding asthma, physical activity and sedentary behavior.
88855515|NCT05241223|Experimental|Experimental group|In addition to the educational program, this group will receive weekly individual and/or group online sessions for 12 weeks of motivation-based on behavior change intervention to promote physical activity and reduce sedentary behavior, based on both self-determination theory and transtheoretical model. They will also receive a pedometer with specific strategies related to it.
88855516|NCT05228158||Tazemetostat|Participants with relapsed or refractory follicular lymphoma with EZH2 gene mutation will receive Tazemetostat 800 milligram (mg), tablet, orally, twice daily or as per physicians discretion in routine clinical practice. All the participants will be observed for up to Week 52 prospectively.
88855517|NCT05220254|Experimental|MindCotine mobile app program|
88855518|NCT05220098|Experimental|Dose-escalation Phase: TAK-280|Participants will receive TAK-280 intravenous (IV) infusion on Days 1, 8, 15, and 22 of a 28-day treatment cycle until disease progression, unacceptable toxicity, or withdrawal from study occurs.
88855519|NCT05220098|Experimental|Cohort-expansion Phase: TAK-280 High or low Dose|Participants will receive either TAK-280 high or low dose in one selected indication and only one dose level of TAK-280 in the remaining indications as determined from the dose-escalation phase of the study in 28-day treatment cycle until disease progression, unacceptable toxicity, or withdrawal from study occurs.
88855520|NCT05217888||TAVR|Undergoing transcatheter aortic valve replacement patients
88855521|NCT05215626||Patients implanted with the Zimmer Reconstruction System|
88855522|NCT05201456||Pressure Monitoring|Subjects in this cohort will undergo ureteroscopic procedure using LithoVue Elite pressure monitoring single use flexible scope, real-time pressure monitoring technology, which will provide surgeons with intraluminal pressure data in the kidneys and ureter.
88855523|NCT05201456||Non-Pressure Monitoring|Subjects in this cohort will undergo ureteroscopic procedure using LithoVue Elite Non-pressure monitoring single use flexible scope.
88855524|NCT05199584|Experimental|200 mg ENV-101|ENV-101 (taladegib) tablets, 200 mg once-daily in 28-day cycles
89382389|NCT04050930|Experimental|Obese, normo-dented|healthy young male presenting a first level of obesity, and a good oral health
88855525|NCT05199584|Experimental|300 mg ENV-101|ENV-101 (taladegib) tablets, 300 mg once-daily in 28-day cycles
88855526|NCT05199272|Experimental|Part A|Patients will receive escalating doses of 23ME-00610
88855527|NCT05199272|Experimental|Part B|Patients will receive the recommended dose(s) of 23ME-00610
88855528|NCT05194293|Experimental|Treatment (regorafenib, durvalumab)|Patients receive regorafenib PO QD on days 1-21 and durvalumab IV on day 1. Treatment repeats every 28 days for a maximum of 2 years from registration or until decision to proceed to surgery, disease progression, excessive toxicity, or patient withdrawal.
88855529|NCT05188664|Experimental|LM-302 monotherapy dose escalation|LM-302 monotherapy dose escalation (part Ia). Accelerated titration combined with traditional 3+3 design will be used for monotherapy dose escalation (part Ia).
88855530|NCT05188664|Experimental|LM-302 in combination therapy dose escalation|LM-302 in combination therapy dose escalation (part Ib).Accelerated titration combined with traditional 3+3 design will be used for LM-302 in combination with fixed dose Toripalimab dose escalation (part Ib).
88855531|NCT05188664|Experimental|LM-302 Dose Expansion|SMC will select appropriate dose(s) and/or tumor types for dose expansion study.
88855532|NCT05183048|Experimental|[89Zr]panitumumab-PET/MRI patients|All study patients will receive [89Zr]Panitumumab-PET/MRI imaging.
88855533|NCT05179187|Experimental|Parkinson disease patients|Participants diagnosed with Parkinson's disease
88855534|NCT05179187|Active Comparator|Healthy adults|Healthy adult age-matched controls
88855535|NCT05178121|Experimental|Project WISE eLearning Training in Suicide Safety Planning|
88855536|NCT05177835|Experimental|ABX464 -25mg|All subjects will receive ABX464 given at 25 mg QD.
88855537|NCT05174052|Placebo Comparator|Control Arm (Placebo)|Subjects will take 1 blinded tablet of placebo drug dosed once daily, per the randomization scheme.
88855538|NCT05174052|Active Comparator|Intervention Arm (Dapagliflozin)|A block randomization method will be use to randomize subjects to treatment with dapagliflozin 10 mg once daily. Subjects will take 1 blinded tablet of study drug (dapagliflozin) dosed once daily, per the randomization scheme
88855539|NCT05171764||Coronary CTA|After the subject undergoes the standard of care, clinically indicated cardiac CT scan for diagnostic purposes, the investigational scan using the GSI Cardiac Scan Mode will be conducted utilizing the same contrast administration.
88855540|NCT05169047|Active Comparator|Best Medical Treatment|
88855541|NCT05169047|Active Comparator|Subthreshold Spinal Cord Stimulation|
88855542|NCT05163821||Participants|Somali migrants in UK, aged over 50.
88855543|NCT05162365|Experimental|IBI314|a cocktail of two SARS-CoV-2 S protein IgG1 antibodies, IBI314-A and IBI314-B, in a 1:1 [w/w] ratio
88855544|NCT05162365|Placebo Comparator|Placebo|
88855545|NCT05162170||Primary Mediastinal large B-Cell Lymphoma (PMBCL)|The present study consists of a retrospective multicenter collection of series of consecutive patients diagnosed with PMBCL over the relevant time period (13 years, from 2007 to 2019 included).
88855546|NCT05154331||Women of reproductive age|Women 15-49 years of age
88855547|NCT05150938||Cancer patients with VTE|Cancer patients who received anticoagulation treatment.
88855548|NCT05146453|Experimental|Intervention|This group of patients will undergo placement of US guided pectointercostal fascia blocks.
88855549|NCT05146453|Placebo Comparator|Placebo|The control group patients will receive the same intraoperative analgesia management. A PIF block will not be performed, instead, a peripheral nerve block catheter will be secured to the skin surface and connected to a CADD™ pump. As the catheter is taped to the skin surface the control group patients will not be exposed to the risks of peripheral nerve block placement.
88855550|NCT05110690|Experimental|Patient Participants|"Behavioral activation (BA) will span across 3 months postoperatively & will begin pre-operatively, with sessions approximately weekly or biweekly, depending on patient preference & health condition.~Medications will be reviewed & optimized by a team of interventionists including a psychiatrist, pharmacologist, & pharmacists. While the participant is in-hospital, the interventionist's role will include coordinating with the hospital team to ensure that medication changes that were introduced preoperatively are maintained in-house & that no new inappropriate medications are initiated. After discharge, & up to approximately 3 months postoperatively, the interventionist will ensure that medication changes are reconciled during transitions of care. The interventionists will ensure the agreed-upon changes are implemented, or an alternative course of action is justified."
88855551|NCT05110001|Placebo Comparator|Standard Therapy|Patients in this arm will receive topical chlorhexidine gluconate 0.02% (acanthamoeba), moxifloxacin 0.5% (smear/culture negative) or natamycin 5% (fungal keratitis) plus sham RB-PDT
88855552|NCT05110001|Experimental|Cross-Linking with rose Bengal (RB-PDT)|Patients in this arm will receive topical chlorhexidine gluconate 0.02% (acanthamoeba), moxifloxacin 0.5% (smear/culture negative) or natamycin 5% (fungal keratitis) plus RB-PDT
88855553|NCT05091632||Observational (EEG, questionnaires)|Patients undergo EEG over 30 minutes daily until death or discharge and complete questionnaires over 30 minutes daily until death or discharge to check level of consciousness, thought, and ability to communicate.
88855554|NCT05084196|Experimental|Melatonin Arm|Melatonin 5 mg capsule by mouth at bedtime for the duration of hospitalization or discontinuation of broad spectrum antibiotics, whichever comes first.
88855555|NCT05084196|Placebo Comparator|Placebo Arm|Placebo capsule by mouth at bedtime for the duration of hospitalization or discontinuation of broad spectrum antibiotics, whichever comes first.
88855556|NCT05079347|Experimental|Healer led HIV testing|"Traditional healers will offer HIV testing to their patients. They will provide the test result to patients. If the patient is positive they will refer their patients to the health facility via referral form and/or walk them to the clinic (based on patient preference). If the patient is negative, the healer will encourage them to re-test at the health facility in 6 months during an open house event where healers will attend to try and de-stigmatize going to the health facility."
89382390|NCT05415579||DDC patients with Traditional Chinese medicine (TCM) treatment|"TCM treatment includes Chinese herbal medicine, acupuncture, moxibustion, massage, taiji, and qigong.~This study does not limit Western medical treatment methods. Patients commonly applied high dose of intravenous steroid treatment in the acute phase, which usually referred to intravenous administration of 1g or 500mg of glucocorticoid daily for 3 consecutive days and reduced by half every 3 days. In addition, plasma exchange and immunoabsorption are also optional treatment for the acute phase. Immunomodulatory therapies including low dose of steroid, immunosuppressants (Azathioprine, Mycophenolate, etc.), and disease-modifying therapy (fingolimod, Teriflunomide, Rituximab, Satralizumab, etc.) are necessary for the remission phase."
88855557|NCT05076344||Group 1: young adults|50 adults aged 18-19 years, with low lifetime noise exposure and audiometric thresholds in the normal range for their age.
88855558|NCT05076344||Group 2: older adults with low noise exposure|50 adults aged 30-50 years, with low lifetime noise exposure and audiometric thresholds in the normal range for their age.
89382391|NCT03416010|No Intervention|Control|In addition to standard prenatal care the PregnancyPlus attention control group for 6 weeks will receive 1.5 hours of ACOG-designed patient education pamphlets. Material will include prenatal and post-partum education.. Dr. Gennaro will conduct the training of the attention control group midwives. The same protocol for assessing fidelity for COPE-P also will be used for assessing fidelity to the attention control intervention
89382392|NCT03416010|Active Comparator|Intervention|In addition to standard prenatal care the COPE-P intervention group will also receive 1.5 hours each week for 6 weeks the cognitive-behavior skills building program driven by CBT as the theoretical framework by health care providers trained in COPE-P by Dr. Melnyk. The content of the COPE program is driven by the literature review, the theoretical framework, previous studies of COPE interventions with mothers of preterm infants and prior work with pregnant minority women by our team.
88855559|NCT05076344||Group 3: older adults with high noise exposure|50 adults aged 30-50 years, with high lifetime noise exposure and audiometric thresholds in the normal range for their age.
89382393|NCT03656029|Placebo Comparator|Placebo|Participants will smoke a single smoked placebo (<0.1% THC) cannabis cigarette
89382394|NCT03656029|Active Comparator|low dose|Participants will smoke a single low dose (6.25% THC) of smoked cannabis cigarette
89382395|NCT03656029|Active Comparator|middle dose|Participants will smoke a single intermediate dose (12.5% THC) of smoked cannabis cigarette
89382396|NCT03656029|Active Comparator|high dose|Participants will smoke a single high dose (22% THC) of smoked cannabis cigarette
89382397|NCT03097029|Experimental|Pancreatic Enzymes|All subjects in this study will have exposure to therapy with pancreatic enzymes for a period of about ten days.
89382398|NCT02545517|Experimental|Conv-R/JE Group|Subjects who completed the Rabies PrEP regimen on days 1,8 and 29 and JE primary series regimen on days 1 and 29 in the parent study V49_23 were enrolled in the Conv-R/JE Group and received a single booster dose of the PCEC rabies vaccine in this extension study.
88855560|NCT05076344||Group 4: older adults with suspected noise-induced hearing loss|50 adults aged 30-50 years, with high lifetime noise exposure and audiometric thresholds above the normal range for their age.
88855561|NCT05060315||De Novo Cohort|Patients new to parenteral prostacyclin-class therapy.
88855562|NCT05060315||Transition Cohort|Patients who had been receiving SC treprostinil therapy via a previous generation infusion pump prior to transitioning to a next generation infusion pump.
89382399|NCT02545517|Experimental|Acc-R/JE Group|Subjects who completed the Rabies PrEP regimen on days 1, 4 and 8 and JE primary series regimen on days 1 and 8 in the parent study V49_23 were enrolled in the Acc-R/JE Group and received a single booster dose of the PCEC rabies vaccine in this extension study.
89382400|NCT02545517|Experimental|Conv-R Group|Subjects who completed the Rabies PrEP regimen on days 1,8 and 29 in the parent study V49_23 were enrolled into the Conv-R Group and received a single booster dose of the PCEC rabies vaccine in this extension study.
89382401|NCT03636841|Experimental|EXPERIMENTAL GROUP|A group of 30 patients using the new medical device with CE marking (Ultravision ©) switch on
89382402|NCT03636841|Active Comparator|CONTROL GROUP|A group of 30 patients using the new medical device with CE marking (Ultravision ©) switch off
89382403|NCT04206995||Evaluation of odour capturing techniques|To evaluate two odour capturing techniques to compare VOC profiles of cancerous and healthy skin cancer.
88855563|NCT05031234|Active Comparator|Group with morphine|conventional general anaesthesia with morphine
88855564|NCT05031234|Experimental|Group without opiates|general anaesthesia without opiates
88855565|NCT05030051|Experimental|SkinPen Precision System|This proof of concept study is being conducted over the course of 60 days followed by a 3-month post-treatment visit to assess the efficacy and tolerability of the Sponsor's SkinPen device when used to treat men and women with signs of aging on the dorsum of the hands. Overall assessment of clinical outcome and safety will be based on the evaluation of pre- and post-treatment photos comparing baseline to final visit. The subject's assessment of satisfaction will also be evaluated at Visit 3 and Visit 4. Finally, both the clinician's and subject's assessment will be characterized using a clinician assessment scale at the 3 month post-treatment visit.
89382404|NCT03625128|Experimental|F-18 PMPBB3|F-18 PMPBB3 imaging
89382405|NCT03625050|Experimental|Chuna + Usual care|
89382406|NCT03625050|Active Comparator|Usual care|
89382407|NCT03257813|Other|Group A|In group A, therapy with Krytantek Ofteno® will be continued for 30 days, in which the subject will be retested and switched to a PRO-122 solution which will be used for 30 days until the 60th day, The final visit.
88855566|NCT05029739|Experimental|E-intervention group|Participants will be instructed to download a life-style-changing mobile app to which they will have access for 12 weeks. After the first week of the program, participants who smoke will be offered to incorporate smoking cessation support into their PAD program. These changes are minor and not intended to divide the intervention group in two but instead to personalize the study experience. The program aims to empower positive lifestyle change by gamification, altruistic rewards, and engaging content with relevant tasks or missions to be completed. Beyond this, all patients in the interventional arm will also receive standard of care as defined below for the control arm.
89382408|NCT03257813|Other|Group B|In group B, therapy with Krytantek Ofteno® will be suspended and changes for PRO-122 for 30 days, in which the subject will be retested and later switched to Krytantek Ofteno® solution which will be used for 30 days until the 60th day, The final visit.
89382409|NCT03210259|Experimental|BI 695501|
89382410|NCT03210259|Active Comparator|Humira®|
88855567|NCT05029739|Active Comparator|Standard of care - control group.|All patients in the control arm will receive best medical therapy including start or optimization of secondary preventive pharmacotherapy, smoking cessation advise and advise on modifiable risk factors. The control arm will also receive an information leaflet about relevant lifestyle modifications for PAD. After the baseline measurements and data collection, there will be no scheduled visits to a health care provider until week 12.
89382414|NCT03257657|Experimental|Observational Group|Intervention: Participants will receive usual WIC care plus they will be given a packet of written WIC materials on lifestyle recommendations at the baseline visit, and offered an appointment with a WIC Registered Dietitian (RD) at the 12 week visit.
89382415|NCT03257657|Experimental|Lifestyle Group|"Intervention: Visits with WIC staff at Baseline, 4 weeks, 8 weeks: Meet with WIC staff who will use motivational interviewing during visits. Participants will complete an iPad app that asks lifestyle questions. Responses are provided to WIC staff in an easy to read format to guide lifestyle counseling and informational handouts are provided to participants.~In-between visits: Participants receive text messages with informational and motivational content. They are invited to a Facebook private group providing informational and motivational content and encouraging cross-support amongst participants. They are asked to self-monitor activity and weekly weights and will be offered weekly phone coaching appointments with WIC staff."
88855568|NCT05015816|Experimental|Group A: Time series|Individuals at high risk of developing melanoma will be invited to attend for sequential TBP imaging, full body skin examination by a Dermatologist and completion of a case report form (CRF) every three months for two years. At the end of the study participants will also be invited to complete a feasibility questionnaire
89002784|NCT06145750|No Intervention|Arm A1|Arm A practices will be further randomized 1:1 into two groups (A1:A2) to observe lung cancer screening standard of care. Practices in A1 will be observed.
89183509|NCT04372108||Other Biologics Comparator Cohort|Participants with CD or UC with no prior exposure to the individual drugs (for example, infliximab, adalimumab, or vedolizumab) in question, at least 1 year of enrollment records immediately prior to the new use of the comparator biologic will be required. The information will be sourced from the Department of Defense (DoD) Electronic Health Records (EHR) database in the United States (US).
89382416|NCT04319757|Experimental|ACE1702 Dose Level 1|"Lympho-conditioning agents followed by ACE1702 (anti-HER2 oNK cells) will be administered to patients with advanced or metastatic, HER2-expressing solid tumors. HER2 expressing is defined has having HER2 immunohistochemistry (IHC) 2+ or above.~Dose Level: 1 Planned number of subjects: 1 to 6"
89382417|NCT04319757|Experimental|ACE1702 Dose Level 2|"Lympho-conditioning agents followed by ACE1702 (anti-HER2 oNK cells) will be administered to patients with advanced or metastatic, HER2-expressing solid tumors. HER2 expressing is defined has having HER2 IHC 2+ or above.~Dose Level: 2 Planned number of subjects: 1 to 6"
89382418|NCT04319757|Experimental|ACE1702 Dose Level 3|"Lympho-conditioning agents followed by ACE1702 (anti-HER2 oNK cells) will be administered to patients with advanced or metastatic, HER2-expressing solid tumors. HER2 expressing is defined has having HER2 IHC 2+ or above.~Dose Level: 3 Planned number of subjects: 3 to 6"
89382419|NCT04319757|Experimental|ACE1702 Dose Level 4|"Lympho-conditioning agents followed by ACE1702 (anti-HER2 oNK cells) will be administered to patients with advanced or metastatic, HER2-expressing solid tumors. HER2 expressing is defined has having HER2 IHC 2+ or above.~Dose Level: 4 Planned number of subjects: 3 to 6"
89382420|NCT04319757|Experimental|ACE1702 Dose Level 5|"Lympho-conditioning agents followed by ACE1702 (anti-HER2 oNK cells) will be administered to patients with advanced or metastatic, HER2-expressing solid tumors. HER2 expressing is defined has having HER2 IHC 2+ or above.~Dose Level: 5 Planned number of subjects: 3 to 6"
89382421|NCT04319757|Experimental|ACE1702 Dose 6|"Lympho-conditioning agents followed by ACE1702 (anti-HER2 oNK cells) will be administered to patients with advanced or metastatic, HER2-expressing solid tumors. HER2 expressing is defined has having HER2 IHC 2+ or above.~Dose Level: 6 Planned number of subjects: 3 to 6"
89382422|NCT04576806|Active Comparator|Body temperature fluid bolus of crystalloid|Fluid bolus at 38 degrees celsius of 500ml crystalloid over 15 minutes
89382423|NCT04576806|Experimental|Room temperature fluid bolus of crystalloid|Fluid bolus at 22 degrees celsius of 500ml crystalloid over 15 minutes
88818000|NCT01324700|Placebo Comparator|Low severity group: Placebo|Participants with Baseline HRSD score of less than 20 AND fewer than 3 courses of oral corticosteroids in the past 12 months were stratified into low severity group. Then these participants were further stratified into placebo group.
89183510|NCT04362839|Experimental|Treatment (regorafenib, nivolumab, ipilimumab)|Patients receive regorafenib PO QD on days 1-21, nivolumab IV over 30 minutes Q2W, and ipilimumab IV over 30 minutes Q6W. Cycles repeat every 28 day for up to 2 years in the absence of disease progression or unacceptable toxicity.
89183511|NCT04361942|Experimental|Mesenchymal Stem Cells (MSCs)|Intravenous injection of 1 million MSCs (MSV cells)/Kg suspended in 100 ml of physiological saline solution.
89183512|NCT04361942|Placebo Comparator|Placebo|Intravenous injection of 100 ml of physiological saline solution containing no cells
89183513|NCT04358237|Experimental|Experimental: lurbinectedin (PM01183) + pembrolizumab|"During the phase I stage, patients will start receiving pembrolizumab at a fixed dose of 200 mg as a 30-min intravenous (IV) infusion followed by lurbinectedin at a starting dose of 2.4 mg/m2 as a 1-h IV infusion on Day 1, both every 3 weeks (Q3W). Lurbinectedin dose will be escalated from the starting dose in successive cohorts of patients, with a pre-established fixed dose increase (in mg/m2) of approximately 30%.~During the phase II stage, patients will receive pembrolizumab at a fixed dose of 200 mg as a 30-min IV infusion followed by lurbinectedin as a 1-h IV infusion on Day 1 Q3W at the redommended dose (RD) determined during the phase I stage. A cycle is defined as an interval of 3 weeks. No dose escalation will be allowed during the phase II stage."
89183514|NCT04357873|Experimental|pembrolizumab + vorinostat|"Pembrolizumab: 200 mg every 3 weeks, up to 35 administrations~Vorinostat: 400 mg once daily, until progression"
89183515|NCT04353778|No Intervention|PLWH|People living with HIV (HIV)
89183516|NCT04353778|No Intervention|Healthy Controls|Healthy controls who do not have HIV
89183517|NCT04353778|Active Comparator|Pyridostigmine|PLWH on pyridostigmine 30mg PO TID
89183518|NCT04353778|Placebo Comparator|Placebo|PLWH on placebo
89183519|NCT04353778|Other|nVNS|PLWH to undergo non-invasive vagal nerve stimulation
89183520|NCT04352166|Experimental|extended-release buprenorphine (BXR)|Three extended-release buprenorphine (BXR) injections to be administered roughly 28 days apart. The first and second injection will be 300 mg and the third will be 100 mg.
89183521|NCT04352166|Active Comparator|sublingual buprenorphine (BSL)|sublingual buprenorphine (BSL) up to 24 mg will be administered once daily for 12 weeks or length of study participation.
89183522|NCT04327934|Active Comparator|Healthy Control|Healthy control participants.
89183523|NCT04327934|Experimental|AE-PCOS|Participants with AE-PCOS.
89183524|NCT04299373|Experimental|Alcohol: Oral administration|Participants in this arm will consume a measured dose of alcohol orally, with the goal of achieving a target peak breath alcohol concentration of .065% within 20 minutes.
89382424|NCT05180461|Experimental|Part 0 Pilot group emodepside 15mg Once a day (OD) 1 day|emodepside tablets 15 milligrams once a day for 1 day
89382425|NCT05180461|Experimental|Part 1 emodepside 30mg OD 1 day|emodepside tablets 30 milligrams once a day for 1 day
89183525|NCT04299373|Experimental|Alcohol: Intravenous administration|Participants in this arm will be infused intravenously with a dose of alcohol sufficient to raise their breath alcohol concentration to .065% within 20 minutes.
89382426|NCT05180461|Experimental|Part 1 emodepside 15mg OD 7 days|emodepside tablets 15 milligrams once a day for 7 days
89382427|NCT05180461|Experimental|Part 1 emodepside 15mg OD 14 days|emodepside tablets 15 milligrams once a day for 14 days
89382428|NCT05180461|Experimental|Part 1 emodepside 15mg twice a day (BID) 10 days|emodepside tablets 15 milligrams twice a day for 10 days
89382429|NCT05180461|Placebo Comparator|Part 1 placebo|matching placebo of emodepside tablets
89382430|NCT05180461|Experimental|Part 2 emodepside dose regimen A|emodepside tablets, dose regimen A selected from regimens tested in Part 1
89183526|NCT04298203|Experimental|Meal Replacement Therapy|Participants who are enrolled in the study will be administered a short-term (six weeks) meal replacement induction period. Because the trial is deigned to evaluate weight loss maintenance, participants must achieve at least 5% BMI reduction at week six of the meal replacement period in order to be randomized. Subjects will be asked to strictly follow the eating regimen, which will include a total of approximately 1,000 kcals per day of commercially-available liquid shakes (breakfast and lunch), pre-packaged frozen entrée meals for dinner, two servings of fruit, and three servings of vegetables. Shakes/meals will be provided free of charge - fruits/vegetables will be purchased by the participants. Guidance will be provided regarding the use of the meal replacement shakes at school, and participants will be encouraged to engage in family meal sessions despite eating different foods.
89183527|NCT04298203|Active Comparator|Phentermine/Topiramate|Participants who achieve at least 5% BMI reduction at week six of the meal replacement period will be randomized (1:1) to receive either phentermine/topiramate or placebo. Participants randomized to phentermine/topiramate will start treatment at 3.75 mg/23 mg orally once daily in the morning for 14 days, then increased to 7.5 mg/46 mg orally once daily in the morning for 14 days, then be increased to 11.25 mg/69 mg orally once daily in the morning for 14 days, then increased to 15 mg/92 mg orally once daily in the morning for the remainder of the trial. Following the final study visit, participants will be down-titrated gradually by taking medication every other day for seven days before stopping treatment altogether.
89382431|NCT05180461|Experimental|Part 2 emodepside dose regimen B|emodepside tablets, dose regimen B selected from regimens tested in Part 1
89382432|NCT05180461|Active Comparator|Part 2 ivermectin|ivermectin, single oral dose of 150 micrograms per kilogram by weight
89382433|NCT05229861|Experimental|High-intensity Interval Training (HIIT)|Participants will complete seven HR-controlled HIIT sessions within their 3-week inpatient stay, corresponding to 3 exercise bouts per week.
89382434|NCT05229861|Active Comparator|Moderate Continuous Training (MCT)|MCT represents the standard treatment at Valens rehabilitation clinic. Participants will complete seven HR-controlled MCT sessions within their 3-week inpatient stay, corresponding to 3 exercise bouts per week.
89183528|NCT04298203|Placebo Comparator|Placebo|Participants who achieve at least 5% BMI reduction at week six of the meal replacement period will be randomized (1:1) to receive either phentermine/topiramate or placebo. Participants randomized to the placebo will receive inert tablets that look like the active comparator. In order to mimic the active comparator arm, subjects randomized to the placebo arm will up titrate their placebo at the beginning of the study treatment and will down titrate as in the active comparator arm. Participants will be instructed to take the medication under the supervision of a parent/guardian and pill counts of returned product will serve as a proxy of treatment compliance.
89183529|NCT04298086|Experimental|Exercise Treatment and Plant-Based Diet|Will consist of structured exercise treatment plus a calorie-restricted plant-based diet. Exercise treatment will consist of individualized walking delivered up to 7 times weekly to achieve the patient-specific goal energy expenditure. Training sessions will be performed on a treadmill under remote surveillance using a telemedicine approach (i.e.,TeleEx) established in the Exercise-Oncology (ExOnc) Service. Pre-prepared meals, including 6 dinners and 6 lunches per week, will be shipped to the partipant's home during the intervention. If a patient is temporarily unable to complete supervised sessions as a result of unforeseen circumstances, patients may be assigned low intensity unsupervised training sessions per EP/PI discretion
89183530|NCT04298086|Active Comparator|Physical activity and nutrition counseling|Patients will receive a home-based, general physical activity program and nutrition counseling. Specifically, all patients assigned to the counseling arm will receive a study kit which includes an activity tracker, heart rate monitor, scale, and tablet. Treadmills may also be provided to patients in the counseling arm if they do not already have access to one.
89183532|NCT04287946|Experimental|Ablation|
89183533|NCT04285242||Participants with Cancer - Group A|Assessments and observations for up to 40 days with one overnight hospital stay.
89183534|NCT04285242||Healthy Volunteers - Group A|Assessments and observations for up to 2 days with one overnight hospital stay.
89183535|NCT04285242||Healthy Volunteers - Group B|Assessments and observations for up to 2 days.
89183536|NCT04285242||Participants with Cancer - Group B|Assessments and observations for up to 40 days, with most assessments and observations being optional and no overnight hospital stay.
89183537|NCT04271475|Experimental|Macitentan|Participant will receive macitentan at a dose of 10 milligram (mg) once daily (OD) for 4 weeks, followed by a dose of macitentan 37.5 mg for another 4 weeks and continue with the target dose of macitentan 75 mg. Participants who have reached the target dose of 75 mg, completed the Double-blind (DB) period up to Week 28 (either on treatment or in Post-treatment observation period [PTOP]) at minimum, may be eligible for transitioning into the Open label (OL) extension period once all participants have completed the DB part of the study, or earlier if they experienced a Clinical event committee (CEC) confirmed clinical worsening event.
89382435|NCT05415345|Experimental|Group A|Participants in this arm will be simultaneously administrated with HPV and HEV vaccine. The immunization schedule is 0,1,6 months.
89382436|NCT05415345|Active Comparator|Group B|Participants in this arm will be administrated with HPV vaccine. The immunization schedule is 0,1,6 months.
88818001|NCT03401879|Experimental|Patients with MS|Patients with Multiple Sclerosis
88818002|NCT03401879|Experimental|Healthy control subjects|Healthy age- and sex- matched control subjects
88818003|NCT03556293|Active Comparator|Technical Assistance (No ASR)|Technical Assistance (TA). Intervention: TA will be offered to the 4 teams randomized to the TA condition without automated surveillance reporting and will receive the AKI Prevention Toolkit plus monthly technical calls independently
88818528|NCT01832753|No Intervention|Observation Phase: Months 0-6|"Subjects will be observed for the first 6 months of the study to ensure that the subclinical hypothyroidism is persistent. Subjects who do not have SCH at 6 months will not proceed to the treatment phase.~Subjects that have TSH >10 mIU/L during the 6 month Observational Phase will not be considered subclinical and will not qualify to continue the study. They will be referred to an endocrinologist for treatment."
88818529|NCT05312723||Rhinitis allergy|Patients with rhinitis symptoms and positive skin pric test to one or more allergens.
88818530|NCT05312723||Non-rhinitis allergy|Patients with rhinitis symptoms and negative skin pric test to one or more allergens.
88818531|NCT05311397|Experimental|The first stage（Dose-escalation）|According to the initial dose, the highest dose and the modified Fibonacci method, the dose escalation of A166 for injection is designed as: 0.1 mg/kg, 0.3 mg/kg, 0.6 mg/kg, 1.2 mg/kg, 2.4 mg/kg, 3.6 mg/kg, 4.8 mg/kg (the highest dose is tentatively set at 4.8 mg/kg).
88818532|NCT05311397|Experimental|The second stage（Dose-expansion）|The administered dose of A166 for injection is RS2D obtained in the first stage .
88818533|NCT05280041|Experimental|Fixed standardized - SOLENA-F|In the fixed standardized arm participants will be asked to complete the study modules of the intervention (CBT intervention itself) in a fixed standardized order from module 1 to module 10. Participants will only be able to start the following module once they complete the previous one. At the beginning and at the end of each module it is emphasized what participants will do in the following module.
89382437|NCT05415345|Active Comparator|Group C|Participants in this arm will be administrated with HEV vaccine. The immunization schedule is 0,1,6 months.
89382438|NCT05205889|Experimental|Mobile based values intervention for people with chronic pain|
89382439|NCT03704454|Experimental|Group A - PYC & Placebo|50 mg of PYC for the first 4 weeks and then switch over to receive placebo for the following 4 weeks
89382440|NCT03704454|Experimental|Group B - PYC & Placebo|100 mg of PYC for the first 4 weeks and then switch over to receive placebo for the following 4 weeks
89382441|NCT03704454|Experimental|Group C - Placebo & PYC|Placebo for the first 4 weeks and then switch over to 50 mg PYC for the following 4 weeks
89382442|NCT03704454|Experimental|Group D - Placebo & PYC|Placebo for the first 4 weeks and then switch over to 100mg PYC for the following 4 weeks
89382443|NCT05417529|Experimental|Treatement Group|Participants received music therapy intervention
89382444|NCT05417529|Active Comparator|Control Group|Patients in control group receive premedication
88855569|NCT05015816|No Intervention|Group B: Baseline cohort|All patients who undergo standard care and are selected for total body photography (TBP) imaging will be invited to consent to this group. Any individuals who have had previous TBP imaging will also be eligible to enter Group B of this study. A baseline CRF will be completed and a participant feasibility questionnaire. There will be no additional images taken for the purposes of the study and no additional clinic visits in relation to this part of the study. However, individuals who consent to Group B will also agree to share any future TBP images taken in the department over the next two years so that any sequential images can also be included in the analysis
88855570|NCT05005260|Active Comparator|liposomal bupivacaine single-shot interscalene blockade|Subjects will receive a preoperative single-injection interscalene nerve block with long-acting numbing medicine, liposomal bupivacaine
88855571|NCT05005260|Active Comparator|continuous interscalene nerve blockade|Subjects will receive a preoperative interscalene nerve block with a continuous catheter device which provides local anesthetic, bupivacaine, for up to 3 days.
88855572|NCT04968587|Other|Group 1: RACD - RCA|First period of treatment with Regional Anticoagulation by Citrate-Free Decalcification SLED and second period of treatment with Regional Citrate Anticoagulation SLED
88855573|NCT04968587|Other|Group 2 : RCA - RACD|First period of treatment with Regional Citrate Anticoagulation SLED and second period of treatment with Regional Anticoagulation by Citrate-Free Decalcification SLED
89382445|NCT02496611|Placebo Comparator|Weight Loss Maintenance without Pharmacotherapy|Individuals who, after a short-term (1-3 month) meal replacement induction period, achieve ≥5% BMI reduction. A selection of these participants are then randomized to receive treatment with placebo.
89382446|NCT02496611|Active Comparator|Weight Loss Maintenance with Pharmacotherapy|Individuals who, after a short-term (1-3 month) meal replacement induction period, achieve a >/= 5% BMI reduction. A selection of these participants are then randomized to receive treatment with GLP-1RA.
89382447|NCT03105570|Experimental|Areola sparing mastectomy.|Eligible patients undergo areola sparing mastectomy.
89382448|NCT04767048|Experimental|Experimental Arm|Basic bilateral tongue mucosectomy assisted by robot or laser plus tonsillectomy (unilateral or bilateral at the choice of the investigator)
89382449|NCT04767048|Active Comparator|Control Arm|Tonsillectomy alone (unilateral or bilateral at the choice of the investigator)
89382450|NCT03237481|Experimental|Treatment Group 1: HTX-011|HTX 011 (bupivacaine/meloxicam)
89382451|NCT03237481|Active Comparator|Treatment Group 2: Bupivacaine HCI|Bupivacaine HCl
89382452|NCT03237481|Placebo Comparator|Treatment Group 3: Saline Placebo|Saline placebo
89382453|NCT03704220|Other|Single anti-thrombotic treatment|Single anti-thrombotic treatment
89382454|NCT03222349|Experimental|Interictal Period|Each subject received a single dose of DBF based on the subject's age and weight.
89382455|NCT03222349|Experimental|Ictal/Peri-ictal Period|Each subject received a single dose of DBF based on the subject's age and weight.
89382456|NCT02927925|Experimental|Daratumumab|Participants will receive daratumumab 16 milligram per kilogram (mg/kg) by intravenous (IV) infusion once weekly for 8 weeks, then every 2 weeks for 16 weeks, then every 4 weeks thereafter until study drug discontinuation due to progressive disease (PD), consent withdrawal or unacceptable toxicity.
89382457|NCT03208933|Experimental|Pirfenidone|Participants will be administered pirfenidone 2403 milligram per day (mg/d) orally for 26 weeks in participants with IPF.
89382458|NCT05168917|Other|Ulcerative colitis in clinical and endoscopic remission|Patients with established diagnosis of ulcerative colitis (UC) in clinical and endoscopic remission defined as clinical score = 0 at enrollment with no endoscopy flare up may participate to follow up. Proctosigmoidoscopy to document endoscopic remission has to be foreseen. The patients' inclusion/exclusion criteria are based on the established diagnostic procedures for the UC, i.e. colonoscopy at the time of diagnosis, endoscopic evidence of remission and clinical significant findings.
88855574|NCT04967170|Experimental|Platelet Rich Plasma Group|Subject diagnosed with vulvar lichen sclerosus will receive Autologous Platelet-Rich Plasma (PRP)
89382459|NCT05163951|Active Comparator|Trabeculectomy|Forty-four patients with advanced primary angle closure glaucoma will receive trabeculectomy.
89382460|NCT05163951|Experimental|SPI+GSL+GT|Forty-four patients with advanced primary angle closure glaucoma will receive surgical peripheral iridectomy (SPI) combined with goniosynechialysis (GSL) and goniotomy (GT).
89382461|NCT03207763|Experimental|Cohort 1|Participating infants and children will receive Microneedle Formulation 1. At least 4 infants or children must complete Day 8 without halting criteria having been met before subjects will be enrolled into the next younger age group within a Cohort. At least the first 2 children will have a microneedle patch initially applied to the skin overlying the shoulder blade. If this site is well tolerated without halting criteria having been met additional microneedle patches may be applied to the same participants and in subsequent participants to the upper arm, forearm, wrist and/or thigh.
89382462|NCT03207763|Experimental|Cohort 2|Participating infants and children will receive Microneedle Formulation 2. At least 4 infants or children must complete Day 8 without halting criteria having been met before subjects will be enrolled into the next younger age group within a Cohort. At least the first 2 children will have a microneedle patch initially applied to the skin overlying the shoulder blade. If this site is well tolerated without halting criteria having been met additional microneedle patches may be applied to the same participants and in subsequent participants to the upper arm, forearm, wrist and/or thigh.
89382463|NCT02423772|Experimental|Intervention|Treatment as usual, plus 12 weeks of group based intervention to improve functioning and decrease problematic effects of opioid use.
89382464|NCT02423772|No Intervention|Treatment as Usual|
89382465|NCT03220711|Experimental|Subjects with abnormal colon tissue|The study subjects will be high-risk for colonic adenomas (i.e. strong family history of adenomas/adenocarcinoma or personal history of adenomas/adenocarcinoma), known adenoma scheduled for endoscopic resection, or in subjects with suspected dysplasia in inflammatory bowel disease (IBD). Fluorescein will be sprayed on the area of interest to provide imaging contrast for the images taken with the confocal endomicroscope.
89382466|NCT02417688|Experimental|Cu[64]-25%-CANF-Comb PET-MR|Single IV injection of 4-8 mCi of Cu[64]-25%-CANF-Comb with a mass no more than 100 μgrams followed by PET-MR Imaging
89382467|NCT05136729|Experimental|Face-to-face Self-Natural Posture Exercise training|Off-line training
89382468|NCT05136729|Active Comparator|Online Self-Natural Posture Exercise training|"Virtual training~This group as a wait-list control group will receive online SNPE intervention after serving as an untreated comparison group."
89382469|NCT04766034|Sham Comparator|Control|The grocery shopping simulation will not include any discounts or bundles
89382470|NCT04766034|Active Comparator|Discount|The grocery shopping simulation will include discount on eligible fruits and vegetables
88855575|NCT04967170|Sham Comparator|Sham Procedure Group|Subject diagnosed with vulvar lichen sclerosus will receive sham procedure of intralesional needle insertion without any injectate administered.
89382471|NCT04766034|Active Comparator|Bundles|The grocery shopping simulation will include healthy bundle defaults with no discount
89382472|NCT04766034|Active Comparator|Bundles and Discount|The grocery shopping simulation will include healthy bundle defaults plus a discount
89382473|NCT02922543||Relapsed or refractory multiple myeloma (MM) patients|Relapsed or refractory MM patients in the special use-results surveillance (all-case surveillance) (hereinafter referred to as the all-case surveillance) who have received Revlimid treatment for at least 7 cycles at institutions cooperating in performing the all-case surveillance and this surveillance.
89382474|NCT03237013|No Intervention|Control (Treatment as Usual only)|"Following baseline assessment, all participants were given health literature on tanning behavior from the U.S. Centers for Disease Control and Prevention (CDC). These materials included informational pamphlets addressing common myths regarding tanning behaviors, including Tanned skin is not healthy skin, and A base tan is not a safe tan. These misconceptions were accompanied by burning truth, scientific data debunking these myths. Additionally, all participants received a packet on sun protective practices for oneself and family, which include skin cancer statistics and information on UV rays."
89399516|NCT03538184|Active Comparator|Drill|Preparation of an implant recipient site entirely with relevant drills were performed as follows: Osteotomy preparation and equicrestal placement of a 4.1 mm diameter implant in the drill (control) group were performed as follows: initial trispade drill, 2.0 mm pilot drill, control of depth, diameter and direction of osteotomy with 2.0 mm paralleling pin, 2.5 mm drill, 2.8 mm drill, 2.8 mm paralleling pin, 3.5 mm drill, control of final diameter of the osteotomy with 3.5 mm paralleling pin, placement of the 4.1 mm diameter implant and connection of a 4 mm wide healing abutment.
88855576|NCT04965519|Experimental|RC48-ADC|Eligible subjects received RC48-ADC treatment after enrollment, at a dose of 2.0 mg/kg, once every 2 weeks (the dosing time window in all cycles is -1 to 2 days), and the administration method is intravenous Drip.
88855577|NCT04965298|Experimental|Active treatment arm|Lansoprazole 30mg (as 2 x 15mg capsules) twice daily, 12 hours apart, for 12 months. IMP should be taken at least 30 minutes before food.
88855578|NCT04965298|Placebo Comparator|Matched-Placebo arm|Matched placebo 2 capsules twice daily, 12 hours apart, for 12 months. Treatment should be taken at least 30 minutes before food.
89382475|NCT03237013|Experimental|Treatment as Usual + Facial Morphing|"In addition to the health literature, participants completed the Facial Morphing Intervention. Participants had a digital photograph taken and uploaded to the APRIL® software, accompanied by information about their current age and self-identified race. Participants were presented with two, side-by-side identical 2D images of their face. Participants first viewed an image of their face from their current age, in two-year intervals, to age 72, the maximum age, with the UV exposure setting turned on. This process was repeated. Next, participants viewed the projected aging process, toggling the UV exposure setting (on and off), every ten year interval. The process was repeated using 3D images to view projected changes to their facial profiles."
89382476|NCT03237013|Placebo Comparator|Treatment as Usual + Mindfulness|In addition to the health literature, participants completed the Mindfulness Intervention. Participants listened to a 10-minute self-guided mindfulness audio exercise. The audio file is a scripted reading of an established, brief mindfulness exercise (Erisman & Roemer, 2010). During this guided session, participants learned what mindfulness was, when it can be used, and benefits from practice. Listeners were led through steps, focusing on the physical sensations, breathing, and thoughts. After the exercise, participants were provided a handout highlighting key points about mindfulness and how to incorporate informal mindfulness practice into their daily life.
89382477|NCT02415036|Experimental|Melphalan/HDS treatment of patients with HCC|"Percutaneous hepatic perfusion with melphalan hydrochloride for injection using the Hepatic Delivery System on patients with Hepatocellular carcinoma (HCC).~Melphalan hydrochloride is administered at a dose of 3mg/kg ideal body weight once every 6 weeks for a maximum of 2 cycles of treatment."
89382478|NCT02415036|Experimental|Melphalan/HDS treatment of patients with ICC|"Percutaneous hepatic perfusion with melphalan hydrochloride for injection using the Hepatic Delivery System on patients with Intrahepatic cholangiocarcinoma (ICC).~Melphalan hydrochloride is administered at a dose of 3mg/kg ideal body weight once every 6 weeks for a maximum of 2 cycles of treatment."
89382479|NCT02117700|Experimental|N-acetyl cysteine-1|N-acetyl cysteine 600 mg once/day + Placebo once/day for 16 weeks
89382480|NCT02117700|Experimental|N-acetyl cysteine-2|N-acetyl cysteine 600 mg twice/day for 16 weeks
89382481|NCT02117700|Placebo Comparator|Placebo|Placebo twice/day for 16 weeks
89382482|NCT03236779|Experimental|Dry needling (DN) arm|Once the clinician locates the MTrP, he will insert the needle over it and he will do a quick entry of the needle. The chosen technique to manipulate the needle will be Hong technique, which consist of quick entry and exit of the needle (fast in/fast out) to get local twitch response (LTR), it will be repeated 5 times with a rhythmic movement of 1Hz/sec. LTRs will be counted and registered.
89382483|NCT03236779|Active Comparator|Percutaneous needle electrolysis (PNE) arm|The electrotherapy equipment used (Enraf) produces a continuous galvanic current through the cathode (modified electrosurgical scalpel with the needle) while the patient holds the anode (handheld electrode). Once the needle have reach the relevant treatment area, a continuous current of 3 pulses at an intensity of 3, 1.5 mA for 5 seconds conveyed to the muscle will be applied. It will be done exactly the same way as in the DN group with the only difference that the needle will be transmitting the electrical current.
89382484|NCT03096483|Experimental|OEC Elite Imaging Arm|Vascular, gastrointestinal (GI), urology or pain management procedures for which use of the OEC Elite system
89382485|NCT05100277||Single arm|All patients will have the test
89382486|NCT05417373||The development cohort|The development cohort was composed of patients diagnosed with PAH and healthy control group from 2019.1-2021.5 in RenjiH.
89382487|NCT05417373||The validation cohort|The validation cohort was composed of patients are suspected as PAH by echocardiography in 2021.5-2021.12 or suspected patients are form other medical institutions.
89382488|NCT04543812|Experimental|PBF-1681 (ferric citrate)|PBF-1681 (ferric citrate) will be dosed two times a day with the 2 largest meals (preferred) or three times a day with meals.
89382489|NCT04543812|Placebo Comparator|Placebo|Matching placebo will be dosed two times a day with the 2 largest meals (preferred) or three times a day with meals.
89382490|NCT02932579|Active Comparator|Standard of Care|Individuals within this group will receive standard of care for postoperative dental pain secondary to extraction of impacted mandibular third molar(s)
89382491|NCT02932579|Experimental|Pharmacogenomic Group|Individuals within this group will receive pharmacogenomic testing guided prescription of pain medication for postoperative dental pain secondary to extraction of impacted mandibular third molar(s)
89382492|NCT05417295|Experimental|Inflating air into the bronchial cuff before changing position|Before changing from supine position to lateral position, inflate air into the bronchial cuff of double lumen endotracheal tube (DLT) and adjust cuff pressure to 25-30 mmHg.
89382493|NCT05417295|Placebo Comparator|Inflating air into the bronchial cuff after changing position|Do not inflate air into the bronchial cuff before changing position.
89382494|NCT03624894||Patients that undergo a dental restorations|Patients that undergo a dental restorations independently from the present study
89382495|NCT04748757|Placebo Comparator|Placebo|Normal saline, 50 ml infusion over 30 minutes every 12 hours for 7 days
89382496|NCT04748757|Experimental|Low dose|50 microg/kg SY-005 in 50 ml saline infused over 30 minutes every 12 hours for 7 days
89382497|NCT04748757|Experimental|High dose|100 microg/kg SY-005 in 50 ml saline infused over 30 minutes every 12 hours for 7 days
89382498|NCT03207451|Experimental|Vorapaxar|Subjects with multiple risk factors and antiplatelet naïve to receive Vorapaxar.
88855579|NCT04964947|Experimental|Tobramycin Treatment Group|Participants in this group receive a local aqueous tobramycin injection (2mg/mL) plus standard of care treatment.
88855580|NCT04964947|No Intervention|Standard of Care Treatment Group|Participants in this group receive standard of care treatment.
88855581|NCT04964466||Amount of PDGF-BB in PRF preparation vs. GEM21|The release kinetics of PDGF-BB will be assessed for one PRF preparation from each of the six individual participants and one GEM 21S sample. The quantification will be performed at 60 minutes, 8 hours, 1 day, 3 days, and 10 days. The samples will each be placed in a cell incubator at 37°C to allow for growth factor release into a phosphate-buffered saline. At each desired time point assessment, 2 ml of the sample will be collected, frozen, and replaced with 2 ml of additional phosphate-buffered saline. The protein quantification will be carried out using ELISA assay according to manufacturer's protocol.
89382499|NCT03207451|Experimental|Vorapaxar and Clopidogrel|Subjects with 600 mg Load /75mg QD Clopidogrel QD for ≥ 7 days to receive Vorapaxar
89382500|NCT03207451|Experimental|Vorapaxar and Aspirin|Subjects with 81mg QD Aspirin to receive Vorapaxar
89382501|NCT03207451|Experimental|Vorapaxar, Aspirin, and Clopidogrel|Subjects with 81 mg QD Aspirin+75mg QD Clopidogrel to receive Vorapaxar.
88855582|NCT04964466||PDGF-BB available in PRF + bone substitutes vs. rhPDGF-BB+ bone substitutes|Growth factor release assessments will be made to determine the PDGF-BB present in the six prepared samples of the following: 1) PRF + mineralized freeze-dried corticocancellous allograft, 2) PRF + xenograft, and 3) PRF + B-TCP. Assessments will also be made for one sample of each of the following: 1) rhPDGF-BB + freeze-dried bone allograft, 2) rhPDGF-BB + xenograft, and 3) rhPDGF-BB+ B-TCP preparation. This assessment will be made at 60 minutes following the incorporation of the bone graft materials. During this time period, the samples will each be placed in a cell incubator at 37°C to allow for growth factor release into a phosphate-buffered saline. At 60 minutes after preparation, 2 ml of the sample will be collected, frozen, and replaced with 2 ml of additional phosphate-buffered saline. The protein quantification will be carried out using ELISA assay according to manufacturer's protocol.
88855583|NCT04964466||: Release kinetics of PDGF-BB in PRF + bone substitutes vs. rhPDGF-BB + bone substitutes|The release kinetics of PDGF-BB will be assessed for six preparations of each of following: 1) PRF+ mineralized freeze-dried corticocancellous allograft, 2) PRF + bone xenograft, and 3) PRF + B-TCP. The release kinetics of PDGF-BB will also be assessed for one preparations of each of following: 1) rhPDGF-BB + mineralized freeze-dried corticocancellous allograft, 2) rhPDGF-BB + bone xenograft, 3) rhPDGF-BB + TCP. The quantification will be performed at 60 minutes, 8 hours, 1 day, 3 days, and 10 days. The samples will each be placed in a cell incubator at 37°C to allow for growth factor release into a phosphate-buffered saline. At each desired time point assessment, 2 ml of the sample will be collected, frozen, and replaced with 2 ml of additional phosphate-buffered saline. The protein quantification will be carried out using ELISA assay according to manufacturer's protocol.
88855584|NCT04964466||Release kinetics of PDGF-BB in rhPDGF-BB + PRF + bone substitutes|The quantification will be performed at 60 minutes, 8 hours, 1 day, 3 days, and 10 days. The samples will each be placed in a cell incubator at 37°C to allow for growth factor release into a phosphate-buffered saline. At each desired time point assessment, 2 ml of the sample will be collected, frozen, and replaced with 2 ml of additional phosphate-buffered saline. The protein quantification will be carried out using ELISA assay according to manufacturer's protocol. The samples will each be placed in a cell incubator at 37°C to allow for growth factor release into a phosphate-buffered saline. At each desired time point assessment, 2 ml of the sample will be collected, frozen, and replaced with 2 ml of additional phosphate-buffered saline. The protein quantification will be carried out using ELISA assay according to manufacturer's protocol.
88855585|NCT04938557|Experimental|An Automated Closed-loop Insulin Delivery (AiD) System.|The intervention being evaluated in this trial is automated closed-loop insulin delivery (AiD). The closed-loop system comprises of three components: an insulin pump, a continuous glucose monitor (CGM) and a computer-based model predictive control (MPC) algorithm to compute information from the CGM into a recommended insulin dose.
88855586|NCT04938557|Active Comparator|A Standard Insulin Delivery System|This can include either: an insulin pump (Continuous Subcutaneous Insulin Infusion - CSII) or multiple daily injections (MDI) without closed-loop.
88855587|NCT04937881|Experimental|TAF arm|Fixed dose combination of 200 mg emtricitabine (FTC) and 25 mg tenofovir alafenamide (TAF) delivered under direct observation for 8 weeks during pregnancy and 8 weeks in postpartum period
88855588|NCT04937881|Active Comparator|TDF arm|Fixed dose combination of 200 mg emtricitabine (FTC) and 300 mg tenofovir disoproxil fumarate (TDF) delivered under direct observation for 8 weeks during pregnancy and 8 weeks in postpartum period
88855589|NCT04911452|No Intervention|Control|Standard Neonatal Intensive Care Unit (NICU) care
88855590|NCT04911452|Experimental|Calmer|Calmer placed and left in infant incubator for the 3-week study period. Calmer treatment provided for minimum total of 3 hours/day (can be discontinuous).
88855591|NCT04875052|Active Comparator|Standard ACL Rehabilitation|Patients will complete a 20-week supervised, progressive rehabilitation protocol directed by physical therapists at 1 of 3 participating clinics. While the specific rehabilitation exercises and techniques used for a given patient may vary depending on clinician preference/experience and patient responsiveness and progress, the general rehabilitation protocol will be standardized and follow current best practices emphasizing restoration of early weight bearing, range of motion, quadriceps function, balance, and neuromuscular control consistent with the Multicenter Orthopaedics Outcomes Network (MOON) rehabilitation protocol.
88855592|NCT04875052|Experimental|Whole Body Vibration|Patients will perform standard rehabilitation for the first month post-ACLR. At 1 month they will continue with standard rehabilitation, but will also be exposed to whole body vibration at the beginning of each session prior to rehabilitation exercises in an effort to enhance their efficacy.
88855593|NCT04875052|Experimental|Local Muscle Vibration|Patients will perform standard rehabilitation for the first month post-ACLR. At 1 month they will continue with standard rehabilitation, but will also be exposed to local muscle vibration at the beginning of each session prior to rehabilitation exercises in an effort to enhance their efficacy.
89382502|NCT03704142|Experimental|Tweak Focus|Speech understanding and listening effort will be assessed using the Tweak Focus personal sound amplifiers.
89382503|NCT03704142|Experimental|IQ Earbuds|Speech understanding and listening effort will be assessed using the IQEarbuds personal sound amplifiers.
88855594|NCT04862572|Experimental|People with tinnitus|People with tinnitus will undergo all interventions (audiology test, MRI scans, tinnitus-related questionnaires).
88855595|NCT04862572|Experimental|People without tinnitus|People with tinnitus will undergo most of all interventions (audiology test, MRI scans) except filling up the tinnitus-related questionnaires.
89382504|NCT03704142|Experimental|Sound World Solutions CS50+|Speech understanding and listening effort will be assessed using the Sound World Solutions CS50+ personal sound amplifiers.
89382505|NCT03704142|Experimental|Bose Hearphones|Speech understanding and listening effort will be assessed using the Sound World Solutions CS50+ personal sound amplifiers.
89382506|NCT03703986||END group|The patients in this group had an elevation of ≥ 2 points in the National Institute of Health Stroke Scale (NIHSS) within 7 days of stroke onset.
89382507|NCT03703986||non-END group|The patients in this group had a slight increase of < 2 points or a decrease in NIHSS within 7 days of stroke onset.
89382508|NCT05089123|Experimental|Flu-M|160 volunteers were vaccinated with the Flu-M inactivated split influenza vaccine with a preservative
89382509|NCT05089123|Active Comparator|Ultrix|160 volunteers were vaccinated with the Ultrix (Inactivated split influenza vaccine)
89382510|NCT04540770|Placebo Comparator|Part A 1 (1 mg/kg HuL001)|6 healthy subjects will be enrolled and randomized to receive 1 dose of HuL001 (n = 4) or 1 dose of placebo (n = 2).
89382511|NCT04540770|Placebo Comparator|Part A 2 (3 mg/kg HuL001)|6 healthy subjects will be enrolled and randomized to receive 1 dose of HuL001 (n = 4) or 1 dose of placebo (n = 2).
89382512|NCT04540770|Placebo Comparator|Part A 3 (5 mg/kg HuL001)|6 healthy subjects will be enrolled and randomized to receive 1 dose of HuL001 (n = 4) or 1 dose of placebo (n = 2).
88855596|NCT04861571|Experimental|Very Low Calorie Diet Arm|We plan to perform a controlled, non-randomized, open-label, pilot clinical trial to evaluate the effect of an 8-week VLCD intervention on NAFLD.
88855597|NCT04861571|Other|Control Arm|The control group will consume a lower calorie diet and will be instructed to reduce their usual intake of normally consumed foods by up to 500 kcal per day but no less than 1200 kcal per day.
88855598|NCT04846517|Other|TMS Treatment|"iTBS treatment: Trains of 50 Hz pulses every 200 ms lasting 2 s, with an 8 s intertrain interval (ITI), repeated 60 times 1800 total pulses each day Treatment Duration: 9 minutes Location: Left DLPFC LF-rTMS treatment: Delivered immediately after iTBS treatment as described above.~SMA will involve a continuous train of 1 Hz stimulation for a total of 1200 pulses lasting 20 minutes Treatment Duration: 20 minutes Location: SMA"
88855599|NCT04842604|Experimental|Participants from B1371019 and B1371012|"Azacitidine will be administered 75 mg/m2/day for 7 days every 28 days on Days 1-7 (±3 days) per local label or per the IP Manual (or SPC). Azacitidine may be administered by SC injection or IV infusion. Alternate dosing schedules to administer the 7 doses to accommodate participant and treatment center availability are allowed.~The starting dose regimen will be the same as the most recent regimen received on the B1371019 or B1371012 study.~Glasdegib 50, 75 or 100 mg will be orally administered daily and continuously. The starting dose regimen will be the same as the most recent regimen received on the B1371012 or B1371019 study."
88855600|NCT04817774|Experimental|Treatment group|Subjects undergo kidney transplant as per planned standard of care and are administered study drug post transplantation, up to 24 subjects.
88855601|NCT04817774|No Intervention|Control group and Transplant donors|"Control group: Subjects undergo kidney transplant as per planned standard of care with no study drug administered, up to 6 subjects.~Transplant donors: Transplant donors for each subject in the treatment and control groups, up to 30 subjects."
88855602|NCT04801160|Experimental|REMS+TAI|Radiation-Emitting Metallic Stents (REMS) Combined With Trans-Arterial Infusion (TAI) for Unresectable Hilar Cholangiocarcinoma
88855603|NCT04801160|Active Comparator|SEMS+TAI|Uncovered Self-Expandable Metallic Stent (SEMS) Combined With Trans-Arterial Infusion (TAI) for Unresectable Hilar Cholangiocarcinoma
89183538|NCT04271475|Experimental|Placebo|Participants will receive placebo tablets matching the macitentan 10 mg, macitentan 37.5mg and macitentan 75 mg tablets, respectively. Participants who completed the DB period as per protocol either on treatment or in PTOP are eligible for transitioning to the OL extension period and will receive macitentan 75 mg after an 8-week double-dummy uptitration (macitentan 10 mg for 4 weeks, followed by 37.5 mg for another 4 weeks).
89183539|NCT04260867|Experimental|Aromatherapy|
89183540|NCT04260867|Sham Comparator|Sham|
89382513|NCT04540770|Experimental|Part B 1 (Selected Dose)|"At the end of Part A, the SRC will review the accumulated unblinded data of safety, tolerability, PK (any available data), and immunogenicity (any available data) to select a dose to initiate Part B in IPF subjects. Part B will be conducted in multiple-dose, uncontrolled, and open-label manner to explore the safety, tolerability, PK, and immunogenicity in IPF subjects. Only one cohort will be enrolled to receive 3 repeated doses of the selected HuL001 dose, which will be administered bi-weekly.~A total of 6 IPF subjects will be enrolled in this multiple-dose cohort."
89382514|NCT03671421|Active Comparator|Quads tendon|The graft tissue will be quadriceps tendon
89382515|NCT03671421|Active Comparator|Hamstring|Semitendinosus and gracilis will be used for graft
89382516|NCT03671421|Active Comparator|BPTB|Bone patellar tendon bone graft to be used.
89382517|NCT02361125|Experimental|Methylphenidate|"Participants given a 7 day supply of 5 mg methylphenidate tablets (to take a maximum of 20 mg/day, for total of 28 tablets). Directions for use are to take one 5 mg tablet by mouth as needed every 2 hours for participant described significant fatigue (maximum of 4 tablets/day).~Evaluation of fatigue, ability to sleep, and general symptom questions at baseline visit, daily while on study drug, and on seventh day of treatment."
89382518|NCT03350503|Experimental|Acrysof IQ Toric A-code IOL|IOL implanted during cataract surgery
88855604|NCT04789668|Experimental|Treatment (bintrafusp alfa, pimasertib)|Patients receive bintrafusp alfa IV over 1 hour every 2 weeks and pimasertib PO BID on days 1-28. Treatment repeats every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
88855605|NCT04785131|Experimental|Prune group|Oral contraceptive users will consume 50 grams prunes daily.
88855606|NCT04785131|No Intervention|Oral contraceptive users|Oral contraceptive users will be monitored throughout the study period.
88855607|NCT04785131|No Intervention|Non oral contraceptive users|Non oral contraceptive users will be monitored throughout the study period.
88855608|NCT04782115|Experimental|1.0mg RC28-E injection Q8|In the loading phase (from week 0 to week 8), the study eye will receive intravitreal injection of 1.0 mg RC28-E every 4 weeks, for 3 consecutive times; From then on to the 48th week, the patients were visited every 4 weeks and given medicine every 8 weeks.
88855609|NCT04782115|Experimental|1.0mg RC28-E injection as needed|In the loading phase (from week 0 to week 16), the study eye will receive intravitreal injection of 1.0mg RC28-E every 4 weeks, for 5 consecutive times;In the as needed (pro re nata,PRN)phase (from then on to week 48), the study eye will receive the same dose on an PRN schedule based upon the physician assessment in accordance with pre-specified criteria.
88855610|NCT04782115|Experimental|2.0mg RC28-E injection Q8|In the loading phase (from week 0 to week 8), the study eye will receive intravitreal injection of 2.0mg RC28-E every 4 weeks, for 3 consecutive times; From then on to the 48th week, the patients were visited every 4 weeks and given medicine every 8 weeks.
88855611|NCT04782115|Experimental|2.0mg RC28-E injection as needed|In the loading phase (from week 0 to week 16), the study eye will receive intravitreal injection of 2.0mg RC28-E every 4 weeks, for 5 consecutive times;In the as needed (pro re nata,PRN)phase (from then on to week 48), the study eye will receive the same dose on an PRN schedule based upon the physician assessment in accordance with pre-specified criteria.
88855612|NCT04782115|Experimental|control group|In the loading phase (from week 0 to week 8), the study eye will receive intravitreal injection of Conbercept every 4 weeks, for 3 consecutive times;In the as needed (pro re nata,PRN)phase (from then on to week 48), the study eye will receive the same dose on an PRN schedule based upon the physician assessment in accordance with pre-specified criteria.
88855613|NCT04778514|Other|Sequence 1|This arm is a single, over-encapsulated DPP containing PrEP (200 mg of emtricitabine [FTC], 300 mg of tenofovir disoproxil fumarate [TDF]) and a COC (30 mcg of ethinyl estradiol [EE], 150 mcg of levonorgestrel [LNG]) taken once daily for three 28-day cycles followed by PrEP (FTC/TDF) and a COC (EE/LNG) taken daily for three 28-day cycles.
89183541|NCT04238455|Sham Comparator|Control Group|Sham serratus anterior plane block plus usual car
89183542|NCT04238455|Active Comparator|Treatment Group|Serratus anterior plane block plus usual care
89183543|NCT04218812|Active Comparator|No electrical source imaging (ESI)|The multidisciplinary teams take decisions based on considering all data without ESI
89183544|NCT04218812|Experimental|Automated Electrical source imaging (ESI)|The multidisciplinary teams take decisions based on considering all data with ESI
89183545|NCT04208217|Experimental|Modeling to Learn (MTL)|12 clinics randomly assigned to MTL
89183546|NCT04208217|Experimental|Usual quality improvement (QI)|12 clinics randomly assigned to usual QI
89382519|NCT03701256|Experimental|TAP Group|Bilateral ultrasound TAP bloc performed via 20 ml of 2.5% bupivacaine without neuromuscular blocking agents
89382520|NCT03701256|Active Comparator|TRAC Group|Neuromuscular blocking agent: Atracurium 0.1 mg/kg per bolus
89382521|NCT04780581|Active Comparator|RECOVERY|intermediate-dose dexamethasone (6mg/24h - 10 days)
89382522|NCT04780581|Experimental|BOLUS|high-dose methylprednisolone bolus (250mg/4h - 3 days)
88855614|NCT04778514|Other|Sequence 2|This arm is two separate tablets (PrEP [FTC/TDF] and COC [EE/LNG]) taken once daily for three 28-day cycles followed by single, over-encapsulated DPP containing PrEP (FTC/TDF) and a COC (EE/LNG) taken once daily for three 28-day cycles.
88855615|NCT04778475|Experimental|Group A|The treatment group will receive increased frequency of PT services within the first 3-5 days of admission, followed by daily PT services for the duration of their inpatient stay.
88855616|NCT04778475|Active Comparator|Group B|The control group will receive standard care of PT services 3-5 times per week during their hospitalization.
89183547|NCT04203069|Placebo Comparator|Control group : Day-time compression sleeve|Control group : Patients will wear the Day-time compression sleeve : THUASNE lymphatrex (± mitten) during 90 days.
89183548|NCT04203069|Experimental|Day-time compression sleeve and Night-time MOBIDERM Autofit|Intervention group : Patients will wear the Day-time compression sleeve : THUASNE lymphatrex (± mitten) + night-time Auto-Adjustable MOBIDERM® Autofit Armsleeve device with the possibility to wear an additional MOBIDERM® glove if a patient has a finger edema during 90 days.
89183549|NCT04185064|Experimental|Cryopnematic Device (Randomized Component)|Game Ready shoulder wrap is applied in operating room and used in recovery room for 45 mins to 1 hour. Postop Day 1 and 2: the unit will be applied by the patient or a health care provider; as cold as comfortable (34°F; adjustable to 50°F); low compression setting; 30 min on:60 min off (use the pre-set auto program); use throughout the day; use at night as needed. Postop day 3-14 and onwards: 30 min on:60 min off (use the pre-set auto program); medium compression; as cold as comfortable (34°F; adjustable to 50°F); use minimum of twice/day. This will be combined with pain management medications, range of motion, and positioning exercises.
89183550|NCT04185064|Active Comparator|Standard Care|Ice is applied in operating room and used in recovery room for 45 mins to 1 hour. Postop Day 1 and 2: the ice will be applied by the patient or a health care provider; as cold as comfortable; 30 min on:60 min off; use throughout the day; use at night as needed. Postop day 3-14 and onwards: 30 min on:60 min off; use minimum of twice/day. The patients in the control group will receive pain management strategies as would be normally dictated by the physician/therapist. This may include the use of ice, ice packs and compression bandages, as well as pain medications, range of motion, and positioning exercises
89382523|NCT01526135|Active Comparator|Arm A GEMCITABINE|Arm A : Gemcitabine 1000 mg/m² IV infusion over 30 minutes, weekly, during 3 weeks + 1 week of rest (= 1 cycle) repeated 6 times (i.e., 6 cycles) during 24 weeks
89399517|NCT02179346||Cartilage defects in the hip joint|NOVOCART® Inject Autologous Chondrocyte Implantation
89399518|NCT02182232|Experimental|BIBF 1120 with paclitaxel and carboplatin|
89382524|NCT01526135|Experimental|Arm B mFOLFIRINOX|"Arm B : mFOLFIRINOX every 14 days, 12 cycles, 24 weeks. Oxaliplatin (Eloxatin®) 85 mg/m² D1 over 2 hours, followed by Irinotecan (Campto®) 150 mg/m² D1 over 90 minutes to begin 30 min. after the Folinic acid infusion is started.~Folinic acid 400 mg/m² (racemic mixture) (or 200 mg/m² if L-folinic acid is used), IV infusion over 2 hours.~5-FU 2.4 g/m² IV continuous infusion over 46 hours (1200 mg/m²/ day)"
89382525|NCT03701178|Active Comparator|zirconia veneered crowns|we will use zirconia veneered single crowns as a control to evaluate the marginal integrity and fracture and patient satisfaction
89382526|NCT03701178|Experimental|milled BioHpp PEEK|we will use milled BioHPP PEEK single crowns as a intervention to evaluate the marginal integrity and fracture and patient satisfaction
89382527|NCT05417139|Experimental|Immunotherapy+induction chemotherapy+radiotherapy|
89382528|NCT03703752||Adhesive IH|Adhesive IH can further be divided into primary or secondary groups according to the history of abdominal and(or) pelvic surgery
89382529|NCT03703752||non-adhesive IH|Non-adhesive IH means the IH resulting from the abnormality of peritoneal structure.
89382530|NCT03288779|Other|Theta Burst Stimulation Arm|This is a pilot open label study.
89382531|NCT03206749|Experimental|VX-150|
89382532|NCT03206749|Active Comparator|Hydrocodone Bitartrate/Acetaminophen (HB/APAP)|
89382533|NCT03206749|Placebo Comparator|Placebo|
89382534|NCT04635969|Experimental|Experimental: Children training|All registered participants in intervention group will participate in a series of trainings on sexuality education.
89382535|NCT04635969|No Intervention|Control: No intervention|All registered participants in control group will not participate in a series of trainings on sexuality education.
89382536|NCT04754646|Experimental|RHA®4 - Cannula|
89382537|NCT04754646|Active Comparator|RHA®4 - Needle|
89382538|NCT03705923|Experimental|Bariatric surgery|Subjects undergoing laparoscopic Roux-en-Y gastric bypass or laparoscopic sleeve gastrectomy.
89382539|NCT03255941|Active Comparator|Clinic Provider - Urban|Urban Clinic Provider providing DMPA or Sayana Press
89382540|NCT03255941|Active Comparator|Lay Provider - Urban|Urban Lay Provider providing DMPA or Sayana Press
89382541|NCT03255941|Active Comparator|Clinic Provider- Rural|Rural Clinic Provider providing DMPA or Sayana Press
89382542|NCT03255941|Active Comparator|Lay Provider- Rural|Rural Lay Provider providing DMPA or Sayana Press
89382543|NCT03705468||Ketamine sedation|Ketamine sedation
89382544|NCT03705468||Propofol sedation|Propofol sedation
89382545|NCT03703674|Active Comparator|Standard Medical Therapy|Drug: standard medical therapy Standard medical therapy involves primary treatment and normal hospital nutrition (1800 to 2000 kcal per day). Diuretics, sodium restriction and albumin for treatment of ascites or fresh frozen plasma for coagulopathy or antibiotics for any focus of infection as spontaneous bacterial peritonitis (SBP), pneumonia, cellulitis, and urinary tract infection as indicated.
89382546|NCT03703674|Experimental|G-CSF + Standard Medical Therapy|"Drug: standard medical therapy Standard medical therapy involves primary treatment and normal hospital nutrition (1800 to 2000 kcal per day). Diuretics, sodium restriction and albumin for treatment of ascites or fresh frozen plasma for coagulopathy or antibiotics for any focus of infection as spontaneous bacterial peritonitis (SBP), pneumonia, cellulitis, and urinary tract infection as indicated.~Drug: G-CSF G-CSF- 5 μg/Kg s.c every 12 hours for 5 consecutive days"
89382547|NCT03705390|Experimental|ILB|ILB subcutaneous injection
89382548|NCT04805424|Active Comparator|Abdominoplasty|Standard abdominoplasty
89382549|NCT04805424|Experimental|Lipo-abdominoplasty|Abdominoplasty plus liposuction
89382550|NCT03705312|Placebo Comparator|Guideline-directed medical therapy|Standard guideline-directed medical treatment for heart failure
89382551|NCT03705312|Experimental|Transcatheter Mitral valve repair|MitraClip treatment
89382552|NCT03701100|Active Comparator|Active tDCS|Direct current (DC) generated by a Eldith DC stimulator was bilaterally delivered through a pair of saline-soaked surface sponge electrodes (35 square centimeter). One anode was placed with the middle of the electrode over a point midway between International 10-20 electrode positions F3 and Fp1 (left dorsolateral prefrontal cortex and left prefrontal cortex). The other was located over a point midway between F4 and Fp2 (right dorsolateral prefrontal cortex and left prefrontal cortex). The reference electrodes were placed on bilateral forearms. Stimulation was applied at an intensity of 2 mA for 20 min, twice-daily on 5 consecutive weekdays. All patients in the active tDCS group were maintained on their antipsychotic medications throughout the study period.
89382553|NCT03701100|Sham Comparator|Sham tDCS|In sham stimulation, the current was turned on for 30 sec and then ramped down to 0 mA. All patients in the sham tDCS group were maintained on their antipsychotic medications throughout the study period.
89382554|NCT03701022|Experimental|SHR1210 +Apatinib|SHR-1210 injection, 200 mg/dose, intravenous infusion within 20-60 minutes.
89382555|NCT04221165|Active Comparator|Opioid Analgesia|Opioids will be prescribed as per institutional standards. Examples of opioids are morphine and hydromorphone.
89382556|NCT04221165|Experimental|Multimodal Analgesia|Pregabalin (50 mg to 300 mg, oral, twice daily), acetaminophen (1000 mg, oral, 3 times per day), naproxen 250 mg to 500 mg, oral, twice daily), and pantoprazole magnesium (40 mg, oral, daily)
89399519|NCT02182232|Experimental|BIBF 1120 monotherapy|
89399520|NCT04356560||healthcare workers|Actively working at Department of Otorhinolaryngology Head and Neck Surgery & Audiology, Rigshospitalet University Hospital of Copenhagen, Denmark. During 2020 COVID 19 pandemic
88855617|NCT04776109|Active Comparator|(Group of continous thoracic epidural bupivacaine infusion [CEI])|Group I : An epidural catheter will be inserted via a paramedian approach as close as possible to the surgical procedure via the inter-vertebral space (from T8 to T10) so that the affected dermatomes of the surgical wound would receive the benefits of bupivacaine (sunny-bupivacaine) infusion. Proper placement of the catheter will be verified through an aspiration test and a test dose (2 ml) of lidocaine 2% with adrenaline. At the end of surgery, a 0.2 ml/kg bolus of bupivacaine 0.25% will be administered through the catheter and then an infusion of bupivacaine 0.125% at a rate of 0.1 ml/kg/h will be administered immediately postoperative and continued for 48 hours.
88855618|NCT04776109|Active Comparator|(Group of continous bilateral erector spinae bupivacaine infusions[CESI])|Group II : Bilateral erector spinae catheters will be placed at T8 level. Surface anatomy or ultrasound (counting up from the 12th rib) will be used to identify the level of T8 after skin sterilization with the patient on the lateral position. Then a high frequency linear-array ultrasound transducer (Sono Site MW, Bothell, WA, USA) covered in a sterile sleeve will be placed in a longitudinal parasagittal orientation 3 cm lateral to the midline to identify the back muscles: the trapezius above, the rhomboid major in the middle, and the erector-spinae muscle on the bottom, and the transverse Processes with shimmering pleura in between. Next, 2-3 ml of 2% lidocaine will be infiltrated. A catheter will be inserted and secured. The procedure will be repeated on the contralateral side. 20 ml of bupivacaine 0.25% solution will be injected immediately into each catheter then infusion of bupivacaine 0.125% 0.1 ml/kg/h will be continued for 48 hours.
88855619|NCT04756401|Experimental|Treatment (carfilzomib, daratumumab, dexamethasone, selinexor)|Patients receive carfilzomib IV over 30 minutes on days 1, 8, and 15 and daratumumab IV on days 1 and 2 of cycle 1 then days 8, 15, and 22 of cycle 1, then, days 1, 8, 15, and 22 of cycle 2, days 1 and 15 of cycles 3-6, and day 1 of subsequent cycles. Patients also receive dexamethasone PO on days 1, 8 15, and 22, and selinexor PO on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89183551|NCT04185064|Other|Cryopneumatic Device (Observational Cohort)|Game Ready® shoulder wrap is applied in the operating room and used in the recovery room for 45 mins to 1 hour. Postop Day 1 and 2: the unit will be applied by the patient or a health care provider; as cold as comfortable (34°F; adjustable to 50°F); low compression setting; 30 min on:60 min off (use the pre-set auto program); use throughout the day; use at night as needed. Postop day 3-14 and onwards: 30 min on:60 min off (use the pre-set auto program); medium compression; as cold as comfortable (34°F; adjustable to 50°F); use minimum of twice/day. This will be combined with pain management medications, range of motion, and positioning exercises
88855620|NCT04741776|Experimental|Resilience Enhancement Skills Training|video-based family therapy
89183552|NCT04181762|Experimental|secukinumab|secukinumab 300 mg s.c.
88855621|NCT04741776|Active Comparator|Standard of care|video-based individual therapy
88855622|NCT04726293|Experimental|Mango beverage|Mango composite served as a frozen drink
88855623|NCT04726293|Placebo Comparator|Control beverage|Energy matched Control frozen drink
89183553|NCT04181762|Placebo Comparator|placebo|secukinumab placebo s.c.
89183554|NCT04176016|Experimental|Single Study Arm, no competitor|
89183555|NCT04161287||SBRT with TACE|
89183556|NCT04161287||SBRT alone|
89183557|NCT04147793||Controls|patients attneding for surgery with no known bladder disease
89183558|NCT04147793||Overactice sphincter|those with evidence of dysfunctional voiding
89382557|NCT03255629|Other|Study drug (glucagon) first, placebo second|Each subject will have two mixed meal tolerance tests performed. Each will be randomized to receive either glucagon or matched placebo during the first testing session. A participant could receive 2 doses of the study drug or placebo at each study visit. The opposite treatment will be given during the second testing session after a 1-2 week washout period. Both participants and the study team will be blinded to the intervention being used during each session.
89399521|NCT04356560||Patients|Patients presenting with complications to upper respiratory tract infections and patients undergoing surgery involving airway mucosa During 2020 COVID 19 pandemic
89183559|NCT04147793||Underactive sphincter|those with genuine stress incontinence
89183560|NCT04146207|Experimental|combination therapy|"Experimental: combination therapy There is only 1 arm. Combination therapy arm includes SHR0302 and Prednisone~Prednisone 1mg/kg/d po，At the same time give SHR0302 QDpo；"
89183561|NCT04119687|Experimental|Low Dose FX201|Single low dose FX201 injection
89183562|NCT04119687|Experimental|Mid Dose FX201|Single mid dose FX201 injection
89183563|NCT04119687|Experimental|High Dose FX201|Single high dose FX201 injection
89183564|NCT04114851|Experimental|Active|Patients who get active monitor NoL
89183565|NCT04114851|No Intervention|control|control no NoL
89183566|NCT04111835|No Intervention|Conventional exfoliative cytology/LBC|"According to current Polish guidelines:~ASC-US: repeat Pap testing in 6 months - current standard protocol~LSIL - repeat Pap testing in 6 months or refer for colposcopy (by the decision of cytologist) - current standard protocol~ASC-H and higher and all glandular lesions - refer for colposcopy - current standard protocol~Colposcopy-targeted biopsies will be taken in agreement with national guidelines.~If screening cytology is negative -> rescreening after 3 years."
89382558|NCT03255629|Other|Placebo first, study drug (glucagon) second|Each subject will have two mixed meal tolerance tests performed. Each will be randomized to receive either glucagon or matched placebo during the first testing session. A participant could receive 2 doses of the study drug or placebo at each study visit. The opposite treatment will be given during the second testing session after a 1-2 week washout period. Both participants and the study team will be blinded to the intervention being used during each session.
89382559|NCT03031938|Other|Cohort 1|Long term observational study of subjects from tanezumab parent study
89382560|NCT03587571|Active Comparator|Surgical intervention|Open reduction and osteosynthesis by plating is done. Further after treatment is similar to conservative treatment arm.
89382561|NCT03587571|No Intervention|Conservative treatment|At the first visit a split cast is applied. Afterwards physiotherapy and weightbearing as tolerated is allowed.
89382562|NCT01143779|Experimental|FLT-PET|FLT-PET scan uses the FLT solution (dosage of FLT in range between 1 and 10 mCi) with imaging performed 60-90 minutes after FLT intravenous injection.
89382563|NCT03558737|Active Comparator|Nasal high-frequency jet ventilation (nHFJV)|
88855625|NCT04708041|Experimental|Cohort 0: 1 Dose of 9vHPV Vaccine (previous 1-dose recipients)|10 to 15 year old girls and boys (who previously received 1 dose of 9vHPV vaccine) receive a second dose of 9vHPV vaccine at Day 1.
88855626|NCT04708041|Experimental|Cohort 1: 2 Doses of 9vHPV Vaccine Given 12 Months Apart|9 to 14 year old girls and boys receive a 2-dose regimen of 9vHPV vaccine at Day 1 and Month 12.
88855627|NCT04708041|Experimental|Cohort 2: 2 Doses of 9vHPV Vaccine Given 24 Months Apart|9 to 13 year old girls and boys receive a 2-dose regimen of 9vHPV vaccine at Day 1 and Months 24.
88855628|NCT04708041|Experimental|Cohort 3: 2 Doses of 9vHPV Vaccine Given 36 Months Apart|9 to 12 year old girls and boys receive a 2-dose regimen of 9vHPV vaccine at Day 1 and Month 36.
88855629|NCT04708041|Experimental|Cohort 4: 2 Doses of 9vHPV Vaccine Given 60 Months Apart|9 to 10 year old girls and boys receive a 2-dose regimen of 9vHPV vaccine at Day 1 and Month 60.
89382564|NCT03558737|Active Comparator|Nasal intermittent positive pressure ventilation (NIPPV)|
89382565|NCT03703596|Experimental|Anlotinib hydrochloric|Anlotinib (12mg QD PO d1-14, 21 days per cycle)
88855630|NCT04708041|Active Comparator|Cohort 5: 3 Doses of 9vHPV Vaccine Given Over a 6-Month Period|16 to 26 year old young women receive 3 dose regimen of 9vHPV vaccine at Day 1, Month 2 and Month 6.
88855631|NCT04701385||NSTEMI|Patients presenting with a myocardial infarction will have blood samples taken for analysis. At the time of their angiography/angioplasty procedure they will have an OCT assessment of the culprit coronary artery to distinguish if the heart attack was caused by a plaque rupture or plaque erosion event
88855632|NCT04701385||Control|Patients undergoing planned angioplasty will have blood samples taken pre and post angioplasty to help as a control for the flow cytometry and for biomarker analysis
88855633|NCT04696263|Active Comparator|Extraperitoneal SinglePort (SP) Robotic Radical Prostatectomy (Da Vinci ® SP system)|"All participants will undergo SOC robotic radical prostatectomy.~The procedure for this arm uses the Da Vinci ® SP system. Access point consists of one 3.5 cm single infraumbilical incision for the SP-RARP"
88855634|NCT04696263|Active Comparator|Extraperitoneal MultiPort (MP) Robotic Radical Prostatectomy (Da Vinci ® Xi system)|"All participants will undergo SOC robotic radical prostatectomy.~The procedure for this arm uses the Da Vinci ® Xi system, where four 8mm trocars will be used along with a 12 mm assistant trocar (a surgical instrument) to create six small incisions during the surgery"
88855635|NCT04690738||Post Pancreas Transplant Patients|Pancreas transplant recipients
88855636|NCT04678882|Experimental|Dupilumab|Double dose on day1 and followed by single dose every 2 weeks.Or single dose every 4 weeks
88855637|NCT04678882|Placebo Comparator|Placebo|Double dose on day1 and followed by single dose every 2 weeks.Or single dose every 4 weeks
88855638|NCT04670965||E-PRF/rhBMP-2 (similar ratios)|Subjects will be used to procure the venous blood samples to make the enhanced platelet rich fibrin (E-PRF). Subjects have an established treatment plan that utilizes autologous PRF as an adjunctive biologic therapy during periodontal treatment.
89382566|NCT03703596|Experimental|Docetaxel|Docetaxel (75mg/m2 IV d1, 21 days per cycle)
89382567|NCT01137773|Experimental|Intensive IV Insulin|Patients will receive IV insulin to maintain target glucose levels of 80-110 mg/dl
89382568|NCT01137773|Active Comparator|Conventional Insulin Treatment|Patents will receive conventional IV insulin treatment with target glucose levels of 150-170 mg/dl
89382569|NCT03700944|Experimental|YOG|The yoga group (YOG) was required to complete protocol with yoga training for a period of 8 weeks, 60 minutes, 3 times a week
89382570|NCT03700944|No Intervention|CON|The control group (CON) had normal life.
89382571|NCT03632031||Patients with chronic non-healing wounds|Patients with chronic non-healing wounds with planned use of OASIS Extracellular Wound Matrix
89382572|NCT01568385|Experimental|TAK-438 20 mg QD|
89382573|NCT03700866|Experimental|(Functional splinting time)|"Teeth with crown root fracture will be surgically extruded and splinted then the Periotest values will determine when the splint should be removed which will indicate the functional periodontal healing and as well the functional splinting time.~The Periotest readings will be repeated with one week time interval between each series When the Periotest values of the traumatized tooth reach or even approximate the values of the corresponding normal tooth the splint will be removed."
89399522|NCT02179502|Experimental|GLPG1690 single dose|Single oral dose of GLPG1690 suspension or solid formulation - ascending doses
89382574|NCT03700866|Active Comparator|(IADT splinting time)|Teeth with crown root fracture in this group will be surgically extruded and splinted for two weeks according to the international association of dental traumatology (IADT) splinting time two ,weeks splinting, regardless the Periotest score.
89382575|NCT04525092|Active Comparator|Conventional Hemodialysis|Participants will receive intermittent HD for a minimum of 4hours per session, 3 to 4 times/week, using the 5008 High-Volume HDF Machine from Fresenius Medical Care with High Flux FX1000 Dialyzer (Mode HD).
89183567|NCT04111835|Experimental|hrHPV molecular testing|"hrHPV-positive - reflex LBC:~Abnormal reflex LBC (ASC-US or worse) -> colposcopy~Normal reflex LBC -> repeat LBC in 6 months~Positive - colposcopy~Negative -> The CINtec PLUS Cytology and The QIASURE methylation test~The CINtec PLUS Cytology Positive -> colposcopy Negative -> rescreen in 3 years~The QIASURE methylation test Positive -> colposcopy Negative -> rescreen in 3 years~Colposcopy-targeted biopsies will be taken in agreement with national guidelines.~HPV-negative - rescreen in 5 years"
89382576|NCT04525092|Experimental|Pre-dilution Hemodiafiltration|Participants will receive intermittent pre-dilution HDF for a minimum of 4hours per session, 3 to 4 times/week, using the 5008 High-Volume HDF Machine from Fresenius Medical Care with High Flux FX1000 Dialyzer (Mode pre-dilution HDF).
88855639|NCT04670965||E-PRF/ACS/rhBMP-2|Subjects will be used to procure the venous blood samples to make the enhanced platelet rich fibrin (E-PRF). Subjects have an established treatment plan that utilizes autologous PRF as an adjunctive biologic therapy during periodontal treatment.
89382577|NCT04525092|Experimental|Post-dilution Hemodiafiltration|Participants will receive intermittent post-dilution HDF for a minimum of 4hours per session, 3 to 4 times/week, using the 5008 High-Volume HDF Machine from Fresenius Medical Care with High Flux FX1000 Dialyzer (Mode post-dilution HDF).
89382578|NCT03703518|Experimental|Mixed reality|"Mixed reality exercise program using the Microsoft Hololens Roboraid game. This group received 6 exercise sessions over 3 weeks, 2 days/week with an interval of 48 to 72 hours between sessions, using the Microsoft Hololens Roboraid game. The duration of the sessions will be 10 minutes."
88855640|NCT04670965||rhBMP-2/E-PRF|Subjects will be used to procure the venous blood samples to make the enhanced platelet rich fibrin (E-PRF). Subjects have an established treatment plan that utilizes autologous PRF as an adjunctive biologic therapy during periodontal treatment.
88855641|NCT04670965||E-PRF only|Subjects will be used to procure the venous blood samples to make the enhanced platelet rich fibrin (E-PRF). Subjects have an established treatment plan that utilizes autologous PRF as an adjunctive biologic therapy during periodontal treatment.
88855642|NCT04661020|Experimental|Administration of CD19 CAR T-cells|
88855643|NCT04642391||RAI|Subjects will be diagnosed with relative adrenal insufficiency as determined by administration of a standard-dose ACTH stimulation test (0.25mg Cosyntropin) and an increase in serum total cortisol <9mcg/dL.
89183568|NCT04101331|Experimental|Cohort A|Subjects with Relapsed or Refractory CD30 positive Peripheral T-cell Lymphoma (PTCL).
89183569|NCT04091048||Primary Cohort|
89382579|NCT03703518|Active Comparator|Conventional exercise group|Conventional exercise program in cervical region based in deep neck flexors and deep neck extensors, isometric contraction during 6-8 seconds. This group received 6 exercise sessions over 3 weeks, 2 days/week with an interval of 48 to 72 hours between sessions.
89399523|NCT02179502|Placebo Comparator|Placebo single dose|Single oral dose of placebo suspension or solid formulation
89399524|NCT02179502|Experimental|GLPG1690 multiple doses|Multiple oral doses of GLPG1690 suspension - ascending doses
89002785|NCT06145750|Active Comparator|Arm A2|Arm A practices will be further randomized 1:1 into two groups (A1:A2) to observe lung cancer screening standard of care. Practices in A2 will receive standard education on lung cancer screening for CME credit.
89002786|NCT06145750|Experimental|Arm B|Arm B (intervention) practices will receive education on FirstLook™ and have access to order FirstLook™ at the providers' discretion;
89183570|NCT04090060|Experimental|Practice Self-/Companion Exams|300 individuals and 50 couples will be randomized to practice arm.
89183571|NCT04090060|Other|Control Arm|300 individuals and 50 couples will neither be encouraged nor discouraged to practice self-/companion exam.
88855644|NCT04642391||Non-RAI|Subjects will have not have relative adrenal insufficiency as determined by administration of a standard-dose ACTH stimulation test (0.25mg Cosyntropin) and an increase in serum total cortisol >= 9mcg/dL.
88855645|NCT04628416|Experimental|Experimental arm|
88855646|NCT04628416|Other|Control|
88855647|NCT04613518|Experimental|BMS-986165|
88855648|NCT04613518|Placebo Comparator|Placebo|
88855649|NCT04613518|Experimental|Open label Extension, BMS-986165|
88855650|NCT04610372|Active Comparator|standard|External beam radiotherapy to deliver 5500 centiGray (cGy) in 20 fractions to the prostate over 4 weeks
88855651|NCT04610372|Experimental|High dose rate brachytherapy|A single fraction of 19 Gray (Gy) is delivered to the prostate under anesthesia as an out patient.
89183572|NCT04079218|Experimental|Estradiol Vaginal Insert|Using a pre-loaded single-use plastic applicator, participants will insert one 10 microgram estradiol tablet intravaginally daily for 2 weeks and then one tablet twice weekly for the remainder of the study for a total of 12 weeks.
89382580|NCT03700710|Active Comparator|Self-Guided Approach|"In the self-guided arm, participants will receive access to web-based tools to help achieve healthy lifestyle changes to lower their blood pressure.~The web-based tools include: 1) a web-based food frequency questionnaire (Viocare FFQ), which will provide a snapshot of participants' dietary habits in the past 6 months as well as personalized recommendations for areas to improve; 2) access to an evidence-based program (Evolve, formerly BMIQ), which includes program materials for weight loss and leading a healthy lifestyle as well as the ability for capturing dietary data entry."
89382581|NCT03700710|Experimental|Dietitian-led Approach|"In the dietitian-led arm, dietitian will use motivational interviewing in 15-30 minute telephone calls with participants.~The web-based tools include: 1) a web-based food frequency questionnaire (Viocare FFQ), which will provide a snapshot of participants' dietary habits in the past 6 months as well as personalized recommendations for areas to improve; 2) access to an evidence-based program (Evolve, formerly BMIQ), which includes program materials for weight loss and leading a healthy lifestyle as well as the ability for capturing dietary data entry.~The web platform will be used to share participant dietary and weight data with dietitians."
89382582|NCT03700632|Experimental|patch therapy|The eyes are alternatively patched for 2 hours a day in cases without a dominant eye while in cases with dominancy, the dominant eye is patched five days a week and the non-dominant eye is patched two days a week.
89382583|NCT03700632|No Intervention|Control|no intervention will be done
89382584|NCT03698604|Active Comparator|Total Laparoscopic Hysterectomy|The group that will undergo total laparoscopy hysterectomy with bilateral salpingoophrectomy.
89382585|NCT03698604|Active Comparator|Total Abdominal hysterectomy|The group that will undergo total abdominal hysterectomy with bilateral salpingoophrectomy.
89382586|NCT03698526|Active Comparator|Palliative care I|Palliative care
89382587|NCT03698526|Active Comparator|Control II|Patients with mamma carcinoma and (neo-) adjuvant radiotherapy
89382588|NCT03698526|Active Comparator|Control III|Patients before colonoscopy
89382589|NCT03624426|Experimental|Automated SSEP Monitored Group|SSEP monitored group: When a nerve alert is signaled by the automated SSEP device, the surgeon will be informed with the aim to reverse the signal changes. The possible surgical interventions include repositioning the operative arm into a more neutral position, avoidance of excessive traction, removal of retractors, and using a smaller implant to avoid over-correction/traction. The actual intervention will depend on the possible mechanism of nerve injury and treated accordingly.
89382590|NCT03624426|No Intervention|Standard Group|The automated SSEP device will be connected and will be blinded to the surgeon. The screens of the automated SSEP device will be covered by an opaque plastic bag and the alarms will be turned off. No intervention is planned for this group.
89382591|NCT03703362|Experimental|Progressive resistance training|Progressive resistance training tested in patients with external snapping hip
88855652|NCT04610372|Experimental|Permanent seed implant brachytherapy|A single permanent implant of radioactive Iodine-125 seeds is performed under anesthesia as an out patient to deliver 125 Gy to the prostate
88855653|NCT04610372|Experimental|Stereotactic body radiotherapy|36.25 Gy is delivered to the prostate in 5 fractions given either weekly or every second day, using a SABR technique.
88855654|NCT04600804||All patients registered in the MCL0208 trial|"About 200 patients enrolled in the MCL0208 trial who performed the PET exams within the clinical trial and who consent to the present study: all PETs available at each center participating in this study will be collected and analyzed.~In the clinical trial PET was optional at baseline (b-PET), before ASCT (i-PET) and after- ASCT (eot-PET). All the PETs available per patient will be collected and considered for analysis, both in the case PET are available at all the 3 time points above listed and in case of availability of PET at 1 or 2 time points only."
88855655|NCT04592614|Experimental|High dose|CTM-NS participants receiving monthly virtual group meetings for 2 years (24 meetings total)
88855656|NCT04592614|Experimental|Low dose|CTM-NS participants receiving quarterly virtual group meetings for 2 years (8 meetings total)
88855657|NCT04590599|Experimental|IBI310+Sintilimab|IBI310+Sintilimab
89382592|NCT01568151|Active Comparator|Intervention Clinics|Subjects recruited at the Intervention Clinics will first be provided with Clinic-directed interventions(Clinic-directed intervention program)including: 1)provider-directed interventions; 2)office-based systems; and 3) waiting room materials. If the subjects have not undergone colorectal cancer screening after 12 months, they will be provided with an individual patient-directed program consisting of the following stepped interventions: 1) tailored physician letter, easy-to-read educational materials, and an fecal occult blood test (FOBT)information sheet and card; 2) telephone counseling for those who do not respond to the letter; and 3) home visits by lay health advisors for those who do not respond to the letter or phone counseling.
89382593|NCT01568151|No Intervention|Usual Care Clinics|Subjects recruited at the Usual Care Clinics (Control Clinics) will not receive any study intervention. The results of how many subjects undergo colorectal cancer screening at the Usual Care Clinics will be compared to the number that undergo colorectal cancer screening at the Intervention Clinics.
89382594|NCT03698292|Active Comparator|First group|Metoclopramide 10 mg tablets will be taken by the patients of this group three times daily for 7 days
89399525|NCT02179502|Placebo Comparator|Placebo multiple doses|Multiple oral doses of placebo suspension
88855658|NCT04590599|Active Comparator|Placebo+Sintilimab|Placebo+Sintilimab
88855659|NCT04588727|Experimental|AZD3366 Dose 1 Part A|Randomized healthy subjects will receive Dose 1 of AZD3366.
88855660|NCT04588727|Experimental|AZD3366 Dose 2 Part A|Randomized healthy subjects will receive Dose 2 of AZD3366.
88855661|NCT04588727|Experimental|AZD3366 Dose 3 Part A|Randomized healthy subjects will receive Dose 3 of AZD3366.
88855662|NCT04588727|Experimental|AZD3366 Dose 4 Part A|Randomized healthy subjects will receive Dose 4 of AZD3366.
88855663|NCT04588727|Experimental|AZD3366 Dose 5 Part A|Randomized healthy subjects and healthy Japanese subjects will receive Dose 5 of AZD3366.
88855664|NCT04588727|Experimental|AZD3366 Dose 6 Part A|Randomized healthy subjects and healthy Japanese subjects will receive Dose 6 of AZD3366.
88855665|NCT04588727|Experimental|AZD3366 Dose 7 Part A|Randomized healthy subjects, healthy Japanese subjects, and healthy Chinese subjects will receive Dose 7 of AZD3366.
89183573|NCT04079218|No Intervention|No treatment|No intervention
89183574|NCT04074343|Experimental|TAS-102 and Irinotecan|Patients receive TAS-102 25 mg/m2 PO twice daily on days 1-5 and and Irinotecan 180mg/m2 IV on day 1 every 14 days.
88855666|NCT04588727|Placebo Comparator|Placebo Part A|Randomized healthy subjects, healthy Japanese subjects, and healthy Chinese subjects will receive Placebo matched to AZD3366.
88855667|NCT04588727|Experimental|AZD3366 Dose X Part B|Randomized healthy subjects will receive Dose X of AZD3366 in conjunction with concomitant administration of ticagrelor and ASA.
88855668|NCT04588727|Placebo Comparator|Placebo Dose X Part B|Randomized healthy subjects will receive Dose X of placebo in conjunction with concomitant administration of ticagrelor and ASA.
88855669|NCT04582565|Active Comparator|Control group|Control group will have standard of care, consisting of verbal and written information on lymphoedema prevention and standard access to breast care nurse.
88855670|NCT04582565|Experimental|Combination product|Decongestive lymphatic therapy (DLT). DLT group will involve manual lymphatic drainage with a trained manual lymphatic drainage therapist.
88855671|NCT04564547|Experimental|Group 1: ISL 20 mg + Ulonivirine 100 mg|Participants receive ISL 20 mg (Parts 1-3) + ulonivirine 100 mg once weekly (QW) and placebo to BIC/FTC/TAF once daily (QD) [Part 1].
88855672|NCT04564547|Experimental|Group 2: ISL 20 mg + Ulonivirine 200 mg|Participants receive ISL 20 mg (Parts 1-3) + ulonivirine 200 mg QW and placebo to BIC/FTC/TAF QD (Part 1).
88855673|NCT04564547|Experimental|Group 3: ISL 20 mg + Ulonivirine 400 mg|Participants receive ISL 20 mg (Parts 1-3) + ulonivirine 400 mg QW and placebo to BIC/FTC/TAF QD (Part 1).
89183575|NCT04051502||Group 1|First group of 10 participants enrolled
89183576|NCT04051502||Group 2|Second group of 10 participants enrolled
89183577|NCT04051502||Group 3|Third group of 10 participants enrolled
89183578|NCT04051502||Group 4|Fourth group of 10 participants enrolled
89183579|NCT04047602|Experimental|Reduced Dose Stereotactic Radiosurgery|Subjects will receive one stereotactic radiosurgery (SRS) treatment at a reduced dose based on the brain tumor size concurrently with their standard of care immunotherapy. Subjects will undergo follow up with clinical exams and brain MRI scans at 1, 3, 6, 9, and 12 months post SRS treatment
89183580|NCT04035850|Experimental|Participants|Vortioxetine PO tablets, 5-20mg Daily
89183581|NCT04031560|Experimental|Experimental|Integrative treatment
89183582|NCT04031560|No Intervention|Control|The control group (62 patients) will not receive any type of add-on psychotherapy.
89183583|NCT04029181|Experimental|Dose finding cohort|In part A of this imaging trial, a dose finding study will be performed to establish safety, to assess the appropriate protein dose for PET-scanning and to assess the appropriate PET scanning interval.
89183584|NCT04029181|Experimental|Feasibility cohort|The purpose of part B of the study is to analyze the PK of the anti-CD8 imaging agent in patients before and during treatment with checkpoint inhibitors.
89183585|NCT04019444|Experimental|Arm A|One dose (1 ml (5x10^10 vp)) of ChAd155-RG vaccine administered intramuscularly on Day 1, and 1 ml of matching placebo administered intramuscularly on Days 8, 15, 22. N=14 (3 sentinel, 11 non-sentinel)
89183586|NCT04019444|Experimental|Arm B|One dose (1 ml (1x10^11 vp)) of ChAd155-RG vaccine administered intramuscularly on Day 1, and 1 ml of matching placebo administered intramuscularly on Days 8, 15, 22. N=14 (3 sentinel, 11 non-sentinel)
89183587|NCT04019444|Experimental|Arm C|Two doses (1 ml (1x10^11 vp) each) of ChAd155-RG vaccine administered intramuscularly on Day 1 (first dose) and Day 15 (second dose), and 1 ml of matching placebo administered intramuscularly on Days 8 and 22. N=10
89382595|NCT03698292|Active Comparator|Second Group|Itopride 50 mg tablets will be taken by the patients of this group three times daily for 7 days
89382596|NCT04615455|Experimental|Adipose tissue-derived mesenchymal stem cells (ASCs)|One transconjunctival injection of allogeneic ASCs into the LG in one eye.
89382597|NCT04615455|Placebo Comparator|Placebo (vehicle, Cryostor CS10)|One transconjunctival injection of Cryostor CS10 into the LG in one eye.
88855674|NCT04564547|Active Comparator|Group 4: BIC/FTC/TAF|Participants receive placebo to ISL + placebo to ulonivirine QW (Part 1) and BIC/FTC/TAF 50 mg/200 mg/25 mg QD (Parts 1 and 2).
88855675|NCT04559607|Experimental|Experimental group: TACE+Camrelizumab+Apatinib|Camrelizumab (iv. infusion of 200 mg); Apatinib (po. administration of 250 mg); TACE
88855676|NCT04559607|Active Comparator|Control group: TACE|TACE
88855677|NCT04515329|Experimental|Cyclosporine + Artificial Tears|Cyclosporine eye drops twice daily (Treatment) with preservative-free artificial tear drops 4 times a day (Control).
88855678|NCT04515329|Other|Artificial Tears|Preservative-free artificial tear drops 4 times a day (Control).
89183588|NCT04019444|Active Comparator|Arm D|Three doses (1 ml each) of RABAVERT vaccine administered intramuscularly on Day 1 (first dose), Day 8 (second dose), and Day 22 (third dose), and 1 ml of matching placebo administered intramuscularly on Day 15. N=12 (2 sentinel, 10 non-sentinel)
89183589|NCT03997240|Other|Wait-list control|Six-week wait list control
89183590|NCT03997240|Experimental|Immediate intervention|Immediate treatment group
89382598|NCT03703284||LHI Hernia|Acute (<=48h) large hemispheric infarction (LHI) patients who developed cerebral hernia in 5 days post-stroke
88855679|NCT04510363||cardiac arrest survivors|cardiac arrest survivors
88855680|NCT04510363||age- and sex-matched controls|age- and sex-matched controls
89183591|NCT03989336|Experimental|Manganese primed Sintilimab plus nPP chemotherapy|Subject received Manganese primed Sintilimab, nab-paclitaxel and platinum chemotherapy every 3 weeks until achieving a second assessable complete response or progressive disease, development of unacceptable toxicity, or withdrawal of consent.
89183592|NCT03989336|Active Comparator|Sintilimab plus nPP chemotherapy|Subject received Sintilimab, nab-paclitaxel and platinum chemotherapy every 3 weeks until achieving a second assessable complete response or progressive disease, development of unacceptable toxicity, or withdrawal of consent.
89183593|NCT03974113|Experimental|Fitusiran|Participants will receive a selected dose of fitusiran at regular intervals, as per study protocol
89382599|NCT03703284||LHI Non-Hernia|Acute (<=48h) large hemispheric infarction (LHI) patients without cerebral hernia in 5 days post-stroke
89382600|NCT03703284||Healthy control|Healthy individuals
89382601|NCT01567917||Group A|"Patients who gave a permission to this study and underwent doppler US (Doppler US cohort~- Expected subject no.: 400 patients"
89382602|NCT01567917||Group B|"Patient who gave a permission to this study, but who did not receive doppler US (Although this group of patients did not undergo doppler US, these patients will be included as group B [simple observation cohort without doppler US examination])~- Expected subject no.: 200 patients"
89382603|NCT03698214||isolated traumatic brain injury|Adult patients having isolated traumatic brain injury with a head abbreviated injury scale (AIS) ≥ 3 and without severe injury to other regions (other AIS ≤ 1) were included. The patients were grouped and analyzed according to reversed shock index < 1 or reversed shock index ≥ 1.
89382604|NCT03698136|Experimental|Stimulation of denervated muscle|direct muscle stimulation 5 times a week for 33 minutes 3 minutes warm up 30 minutes treatment
89382605|NCT03698058|Experimental|A2 Growing Up Milk|
89382606|NCT03698058|No Intervention|Traditional non-A2 milk|
89382607|NCT03698058|Active Comparator|Other Growing Up Milk|
89382608|NCT04613271|Experimental|Group 1|"Assignment of Administration Group 1:~Favipiravir 1600 mg twice a day at day 1 and 600 mg twice a day at day 7-14 + Azithromycin 500 mg once a day for 5 days."
89382609|NCT04613271|Active Comparator|Group 2|Administration Group 2: Azithromycin 500 mg once a day for 5 days.
89382610|NCT05415189||Patients|Patients with mental illness according to Danish health registers
89382611|NCT05415189||Control individuals from the general population|Control individuals from the general population matched according to the data of diagnosis/ psychotropic medication, year of birth, sex and calendar year.
89382612|NCT03094611|Experimental|Treatment (inotuzumab ozogamicin)|Patients receive inotuzumab ozogamicin IV over 1 hour on days 1, 8 and 15 of cycle 1 and on days 1 and 8 beginning cycle 2. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients whose disease gets worse after responding for 3 months, may be retreated for up to 6 additional cycles. Patients whose disease responds to treatment may receive up to 5 additional cycles.
89382613|NCT03631953|Experimental|Alpelisib in combination with Trametinib administered|A panel of 3 doses of Alpelisib could be tested in combination with fixed dose of Trametinib (1.5 mg every day).
88855681|NCT04508621|Experimental|TNX-102 SL Tablet, 5.6 mg|1 x TNX-102 SL 2.8 mg Tablet taken sublingually each day at bedtime for 2 weeks then 2 x TNX-102 SL 2.8 mg (5.6 mg) Tablet taken sublingually each day at bedtime for 12 weeks.
89382614|NCT01030575|Experimental|Inositol low volume|10 mg/kg/day Intravenous inositol 5%
89382615|NCT01030575|Experimental|Inositol mid-level volume|40 mg/kg/day Intravenous inositol 5%
89382616|NCT01030575|Experimental|Inositol high volume|80 mg/kg/day Intravenous inositol 5%
88855682|NCT04508621|Placebo Comparator|Placebo SL Tablet|1 x Placebo Tablet taken sublingually each day at bedtime for 2 weeks then 2 x Placebo Tablet taken sublingually each day at bedtime for 12 weeks.
88855683|NCT04506554|Experimental|AMVAC + nivolumab|This will be a single-arm, open-label, multicenter phase 2 study of neoadjuvant nivolumab with AMVAC. Approximately 70 evaluable patients will be enrolled into this study. Eligible patients will be those with diagnosis of muscle invasive urothelial carcinoma of the bladder who are cT2 or cT3 but not clinical N1 at diagnosis. Clinical stage is confirmed by transurethral resection of bladder tumor (TURBT#1).
88855684|NCT04498117|Experimental|Cohort 1- Surgery Active|Six (6) 21-day cycles of chemotherapy with oregovomab given at four (4) cycles (Cycle 1, Cycle 3, Cycle 5, and Cycle 5 plus 12 weeks).
88855685|NCT04498117|Placebo Comparator|Cohort 1 - Primary Surgery Control|Six (6) 21-day cycles of chemotherapy with placebo comparator given with chemotherapy at four (4) cycles (Cycle 1, Cycle 3, Cycle 5, and Cycle 5 plus 12 weeks).
89382617|NCT01030575|Placebo Comparator|Placebo|Glucose 5% given in volumes equal to that of the comparator drug
88855686|NCT04498117|Experimental|Cohort 2 - NACT + Interval Surgery Active|In Cohort 2 - NACT + Interval Surgery, subjects must already have received three (3) cycles of paclitaxel and carboplatin neoadjuvant therapy. Subjects in Cohort 2 - NACT + Interval Surgery will receive three (3) cycles of chemotherapy with oregovomab given at four (4) cycles (Cycle 4, Cycle 6, Cycle 6 plus 6 weeks and Cycle 6 plus 18 weeks).
88855687|NCT04498117|Placebo Comparator|Cohort 2 - NACT + Interval Surgery Control|In Cohort 2 - NACT + Interval Surgery, subjects must already have received three (3) cycles of paclitaxel and carboplatin neoadjuvant therapy. Subjects in Cohort 2 - NACT + Interval Surgery will receive three (3) cycles of chemotherapy with placebo comparator given at four (4) cycles (Cycle 4, Cycle 6, Cycle 6 plus 6 weeks and Cycle 6 plus 18 weeks).
88855688|NCT04482972||DCB|DCB group: Patients treated with drug coated balloon (DCB) only angioplasty (all-comers: STEMI, NSTEMI, Stable angina)
88855689|NCT04482972||DES|DES group: Patients treated with drug eluting stent (DES) angioplasty (all-comers:STEMI, NSTEMI, Stable angina)
88855690|NCT04465448||healthy volunteers|
89183594|NCT03962335|Experimental|VD group|Group that starts with Vegetarian diet (VD)
89183595|NCT03962335|Experimental|MD+Bt group|Group that starts with Mediterranean diet with oral supplementation with butyrate (MD+Bt)
89183596|NCT03962335|Active Comparator|MD group|Group that starts with Mediterranean diet (MD)
89382618|NCT04314687|Experimental|UCMSCs + CM|UCMSCs + CM is administered via intrathecal injection
89382619|NCT04314687|Experimental|UCMSCs|UCMSCs is administered via intrathecal injection
89382620|NCT04314687|Active Comparator|Standard Therapy|Physiotherapy
89382621|NCT04215471|Experimental|NeoAdjuvant Therapy With PD-L1 Antibody SHR-1316 group|Patients will receive the neoadjuvant therapy with SHR-1316 followed by the operation.
89382622|NCT04561011|Experimental|Persons with Mild Traumatic Brain Injury (mTBI)|
89382623|NCT04105725|Experimental|BMI+Substance-Free Activity Session|Two 50-minute text messaging sessions that discuss alcohol use and experiences related to alcohol use, as well as the individual's college, career, and personal goals. Additionally, there are 4 weeks of 20-30-minute booster text messaging sessions (once a week) that return to the individual's goals and progress.
89399526|NCT02182310|Placebo Comparator|BI 201335 placebo|crossover part
89399527|NCT02182310|Experimental|BI 201335 low dose|crossover part
89399528|NCT02182310|Experimental|BI 201335 high dose|crossover part
89382624|NCT04105725|Active Comparator|Alcohol + Nutrition Education Session|Two 50-minute text messaging sessions the provide information on alcohol and nutrition. Additionally, there are 4 weeks of 20-30-minute booster text messaging sessions (once a week) that provide additional information and review previous information about alcohol use and nutrition.
89382625|NCT05408325||confirmed COVID 19 ptients|All patients confirmed by RT-PCR, as positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) who visited the emergency room and the outpatient clinic in the study period.
89382626|NCT05408325||healthy subjects|normal healthy volunteers
89382627|NCT04066023|Experimental|C213 1.9 mg|C213, 1.9 mg administered as one 1.9 mg patch and one placebo patch
89382628|NCT04066023|Experimental|C213 3.8mg|C213 3.8 mg administered as two 1.9 mg patches
89382629|NCT04066023|Placebo Comparator|Placebo|Placebo microneedle system administered as two placebo patches
89382630|NCT03106987|Experimental|Active Comparator: Olaparib|Olaparib 300mg tablets administered orally twice daily continuously.
89382631|NCT03106987|Placebo Comparator|Placebo Comparator: Placebo|Matching placebo 300mg tablets administered orally twice daily continuously.
89382632|NCT02932267|Experimental|Adapalene / BPO gel|Adapalene 0.3% / BPO 2.5% gel, once daily in the evening
89382633|NCT04930705|Experimental|TempSure FlexSure Applicator|Subjects will be treated with the TempSure FlexSure applicator device at each treatment.
89382634|NCT03217591|Experimental|IW-1973 Low Dose|Administered daily for 12 weeks
89382635|NCT03217591|Experimental|IW-1973 High Dose|Administered daily for 12 weeks
89382636|NCT03217591|Placebo Comparator|Placebo|Placebo to match experimental drug administered daily for 12 weeks
89382637|NCT04927195|Experimental|Cohort 1|12 healthy volunteers; 8 on EDP1867, 4 on placebo. Dose = upto 7.5 x 10^11 cells, capsules, once daily, 14 days total
89382638|NCT04927195|Experimental|Cohort 2|12 healthy volunteers; 8 on EDP1867, 4 on placebo. Dose = upto 1.5 x 10^12 cells, capsules, once daily, 14 days total
89183597|NCT03942653|Experimental|Goserelin Acetate + Pembrolizumab|Goserelin Acetate, 3.6 mg, every four weeks, SQ Pembrolizumab, 200mg, every three weeks, IV
89183598|NCT03924661||Single Arm|Surgical treatment of a diseased, damaged, or malfunctioning aortic valve using SJM™ Masters Series Hemodynamic Plus (HP) 15mm aortic mechanical heart valve surgical replacement device
89382639|NCT04927195|Experimental|Cohort 3|24 subjects with moderate atopic dermatitis; 16 on EDP1867, 8 on placebo. Dose = 7.5 x 10^11 cells, capsules, once daily, 56 days
89382640|NCT04927195|Experimental|Cohort 4|24 subjects with moderate psoriasis; 16 on EDP1867, 8 on placebo. Dose = 7.5 x 10^11 cells, capsules, once daily, 56 days
89382641|NCT04927195|Experimental|Cohort 5|24 subjects with mild asthma; 16 on EDP1867, 8 on placebo. Dose = 7.5 x 10^11 cells, capsules, once daily, 56 days
88855691|NCT04465448||group case|
88855692|NCT04459650|Experimental|Female Breast Cancer Pts|Participants include female breast cancer patients who either receive endocrine therapy and suffer from endocrine induced alopecia or suffer from post chemotherapy induced alopecia.
88855693|NCT04451525||Cohort I|Cohort I will focus on data collection on the SOFIA® Flow Plus 6F Aspiration Catheter used with the direct aspiration as first line treatment technique with the intent to evaluate per prespecified endpoints.
88855694|NCT04451525||Cohort II|Cohort II will focus on data collection on MicroVention devices used for acute ischemic stroke treatment with the intent to evaluate standard outcomes while also generating additional research questions for analysis based on data collected.
88855695|NCT04414514|Experimental|Open-label|Topical Ruxolitinib 1.5% Cream, twice daily for 16 weeks
89382642|NCT02490319||Group 1|Lung cancer patients treated with thoracic radiation therapy
89382643|NCT03636763||Bullous pemphigoid and diabetes 2|patients with Bullous pemphigoid and diabete type 2 data report about gliptin exposure will be performed
89382644|NCT03636763||diabete type 2|patients with diabetes type 2 data report about gliptin exposure will be performed
89382645|NCT03031782|Experimental|Treatment Period 2 - active|secukinumab (AIN457 - pre-filled syringe) for patients with a minimum American college of Rheumatology (ACR) 30 response in Treatment Period 1
89382646|NCT03031782|Placebo Comparator|Treatment Period 2 - placebo|placebo comparator (matched to secukinumab treatment) for patients with a minimum American college of Rheumatology (ACR) 30 response in Treatment Period 1
89382647|NCT03697824|Experimental|GSK3377794+pembrolizumab|After screening, eligible subjects will enter a leukapheresis phase, followed by lymphodepletion phase where they will be administered fludarabine and cyclophosphamide. On Day 1, subjects will receive a single dose of GSK3377794 administered as an intravenous infusion of 1 to 6 x10^9 total transduced cells. On Day 22, subjects will be administered pembrolizumab at a dose of 200 milligrams (mg) once every 3 weeks for adults and 2 mg/kilogram (kg) (up to 200 mg) once every 3 weeks for children for up to 35 cycles (2 years) or until subsequent disease progression.
89382648|NCT03700398|Experimental|first OE|
89382649|NCT03700398|Other|First WLI|
89382650|NCT03702894|Experimental|Clavamox,Coated Tablets, 875 mg + 125 mg|Clavamox, Film-coated Tablets, 875 mg + 125 mg, is the test product. 14 of 28 subjects in each of two cohorts (total number of enrolled volunteers - 56) were given a single tablet (containing 875 mg mg of amoxicillin and 125 mg of clavulanic acid) in period 1 and period 2 of the clinical part of the study.
89382651|NCT03702894|Active Comparator|Augmentin®, Coated Tablets, 875 mg + 125 mg|Augmentin®, Film-coated Tablets, 875 mg + 125 mg, is the reference product. 14 of 28 subjects in each of two cohorts (total number of enrolled volunteers - 56) were given a single tablet (containing 875 mg mg of amoxicillin and 125 mg of clavulanic acid) in period 1 and period 2 of the clinical part of the study.
89382652|NCT03697746|Active Comparator|Paracetamol|1000 mg Paracetamol vial intravenously
89382653|NCT03697746|Active Comparator|Dexketoprofen Trometamol|50 mg Dexketoprofen Trometamol vial intravenously
89382654|NCT03697746|Active Comparator|Ibuprofen|400 mg Ibuprofen vial intravenously
88855696|NCT04409236|Experimental|Arm I (Quit2Heal app)|Patients receive the Quit2Heal app and are encouraged to use it frequently. During the entire 12-month follow-up period, the app will remain fully available anytime study participants wish to use it.
88855697|NCT04409236|Active Comparator|Arm II (QuitGuide app)|Patients receive the QuitGuide app and are encouraged to use it frequently. During the entire 12-month follow-up period, the app will remain fully available anytime study participants wish to use it.
89382655|NCT03216265|Other|Test product/ No treatment|Participants randomized to this arm will apply Test product at allocated sites and leave other sites untreated.
89382656|NCT03216265|Other|Test product/positive control|Participants randomized to this arm will apply Test and positive product at allocated sites.
89382657|NCT03216265|Other|Positive control /no treatment|Participants randomized to this arm will apply Positive product at allocated sites and leave other sites untreated.
89382658|NCT03697668|Experimental|imatinib-Dihydroartemisinin-piperaquine|triple combination
88855698|NCT04373642|Experimental|Pembrolizumab + QUADSHOT Radiotherapy|"Combination Treatment~Pembrolizumab by IV once on day 1 of 21 day cycle, begin 7 days before the first round of QUAD SHOT radiotherapy.~QUAD SHOT radiotherapy twice a day for two days, begin 7 days after the first dose of pembrolizumab; repeat every 28 days for up to 3 rounds.~Maintenance Treatment~Pembrolizumab by IV once on day 1 of 21 day cycle~On day 21, if the medical oncologist feels that the patient may safely continue treatment, patient will receive a new 21 days cycle of treatment with pebrolizumab."
88855699|NCT04370444|Experimental|Experimental (PLR)|Participants will be given the OhNut Phallus Length Reducer (PLR) for use during the study period.
89382659|NCT03697668|Active Comparator|Dihydroartemisinin-piperaquine|standard of care
89382660|NCT04387812|Experimental|Xtrodes home PSG system|Wireless wearable system incorporates EEG, electrooculography (EOG) and EMG recordings over multiple nights in the home environment. The electrodes are printed on a thin sticker. These printed electrodes are marked by their conformity with the skin, light weight, ease of placement on the skin, and user comfort. The sleep-specific electrode array includes two surface EMG (electrodes 1 and 2), two EOG (electrodes 3 and 4) and four forehead EEG electrodes (electrodes 5-8) .
89382661|NCT03700164|Experimental|Cold exposure|Participants will be wrapped in a water-perfused suit. The temperature of the suit will be lowered to 10°C. From the onset of shivering, the participants will remain in the suit for 1 hour.
89382662|NCT03700164|Other|Thermoneutral (Control)|"Participants will be wrapped in a water-perfused suit. The temperature of the suit will remain at a thermoneutral temperature (32°C) to avoid shivering and excessive sweating.~The duration will be matched to that during the cold exposure."
89382663|NCT03700086|Experimental|Negative wound pressure device (PICO)|The disposable negative wound pressure device (PICO) will be used to cover the midline incision. The dressing is changed on POD3 and removed on POD7. Data are collected on POD3, POD7 and POD30.
88855700|NCT04370444|Other|Control (Waitlist)|Participants will not have a PLR during the study period. They will be placed on a waitlist to receive the PLR at the end of the study period.
88855701|NCT04359017|Experimental|Lidocaine Hematoma Block|
88855702|NCT04345250|Experimental|Participants|"For a period of 6 days between the exercise trials (i.e., following visit 3), each participant will be put on a restricted energy restricted diet consisting of a 25% reduction in their habitual total daily calorie intake. To keep the diet consistent and standardized, participants will record their typical food intake during a control week using the Eat This Much app, which will then provide an overall portion plan and the 25% caloric restriction measure for the intervention week. Thus, the intervention diet will mirror the control diet in terms of types of food consumed, with the difference being in the amount consumed. There will be no restriction regarding water, but drinks will be restricted according to the overall calorie intake plan."
88855703|NCT04328740|Experimental|TP-1454|Flat dose once or twice daily
89382664|NCT03700086|Active Comparator|Standard sterile dressing|The OPsite post-op visible standard sterile dressing will be used to cover the midline incision. Dressing is changed q48h. Data are collected on POD3, POD7 and POD30.
89382665|NCT04050384|No Intervention|No vibratory stimulus before or during heel lance|Baseline measurements and readings after vibration alone will be done, but no vibratory stimulus will be provided immediately preceding or during heel lance.
89382666|NCT04050384|Experimental|Vibratory stimulus before and during heel lance|Baseline measurements and readings after vibration alone will be done, as well as a vibratory stimulus that will be provided immediately preceding and during heel lance.
89382667|NCT03700008|Other|Participants with mental illness|"Participant with pre known or actually diagnosed mental disorder, especially affective or neurodevelopmental disorder.~Using the speech analysis tool with 120 seconds of free speech, measure the mental state with SCL-90, PRIME-MD, B5T, ADHD-VAS as conventional psychological measurements."
89382668|NCT03700008|Other|Participants without any mental illness|Participant with never diagnosed mental disorder, in a healthy mental state. Using the speech analysis tool with 120 seconds of free speech, measure the mental state with SCL-90, PRIME-MD, B5T, ADHD-VAS as conventional psychological measurements.
88855704|NCT04317716|Experimental|Intervention|Fall prevention program and brochure about falls and fall risk factors
88855705|NCT04317716|Other|Control|Bbrochure about falls and fall risk factors
88855706|NCT04311034|Experimental|RC48|
88855707|NCT04303676|Active Comparator|Virtual Practice Facilitation with e-Learning|A virtual practice facilitation intervention, with a practice facilitator working with practices in virtual one-on-one or group sessions utilizing alcohol use e-learning modules to guide and focus the process and content
89382669|NCT03697434|Experimental|Palliative Care referral|Participants with specific uncontrolled symptoms or critical events in course of their Parkinson disease will be referred to a palliative care specialist for supportive care.
89382670|NCT03702738|Experimental|NAC|Patients will be randomized to receive standard TB treatment with N-acetylcysteine 1200 mg BID x 4 months, followed by 2 months of standard TB treatment alone
89382671|NCT03702738|No Intervention|No NAC|Patients will be randomized to receive 6 months standard TB treatment alone
89382672|NCT03702660|Experimental|GIP(3-30)NH2|GIP receptor antagonist
89382673|NCT03702660|Placebo Comparator|Placebo|Placebo (saline infusions)
89382674|NCT03702660|Active Comparator|GLP-1|
89382675|NCT03702660|Experimental|GLP-1 + GIP(3-30)NH2|
89382676|NCT04486950|Experimental|Cohort 1 (Low Dose): TAK-951 20 mcg Infusion Over 60 Minutes|TAK-951 20 microgram (mcg) or TAK-951 placebo-matching, infusion, intravenously, over a period of 60 minutes on Day 1.
89382677|NCT04486950|Experimental|Cohort 2 (High Dose): TAK-951 1 mg Infusion Over 60 Minutes|TAK-951 1 milligram (mg) or TAK-951 placebo-matching, infusion, intravenously, over a period of 60 minutes on Day 1. Dose level will be determined based on safety, tolerability and PK data from previous cohorts.
89382678|NCT04486950|Experimental|Cohort 3: TAK-951 1 mg Infusion Over 120 Minutes|TAK-951 1 mg or TAK-951 placebo-matching, infusion, intravenously, over a period of 120 minutes on Day 1. Dose level will be determined based on safety, tolerability and PK data from previous cohorts.
89382679|NCT03699852|Experimental|LED group|The study had two groups of participants: the LED group (GL) and the control group (GC), both with Membracel®, a porous membrane that regenerates crystalline cellulose, as the primary cover in the donor area of the skin graft (no secondary cover was used) ). In one of the groups (GL), a light-emitting diode (LED) plate was applied, which was covered with sterile waterproof and transparent film to prevent contamination. The participant was positioned so that the skin graft donor area was accessible. The LED plate covered the entire skin donor area and was irradiated with a radiant exposure of 1.53J / cm2 and irradiance of 2.55 mW / cm2 for 10 minutes. The LED plate was applied in contact with the skin graft donor area in the immediate postoperative period and on Membracel® on the 1st, 3rd, 5th and 7th postoperative days. The primary coverage remained until spontaneous removal.
89382680|NCT03699852|Other|Control group|The participants remained and were evaluated under the same conditions. The only difference between the groups is that no LED photobiomodulation session was applied to the control group.
89382681|NCT03697200|Active Comparator|Auricular Point Acupressure (APA)|Patients with active points related to Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS). The points for AIMSS include (1) points corresponding to body pain location and (2) three points known for alleviating stress and pain (i.e., shenmen, sympathetic, and nervous subcortex)
89399529|NCT02182310|Active Comparator|Moxifloxacin|crossover part
89183599|NCT03918447|Experimental|Maximum bardoxolone methyl dose of 20 mg|"Patients randomized to receive bardoxolone methyl with a baseline ACR less than or equal to 300 mg/g will be titrated to a maximum dose of 20 mg. Patients will begin once-daily dosing with bardoxolone methyl capsules at 5 mg and will dose escalate to 10 mg at Week 2 and 20 mg at Week 4.~Patients will continue to receive study drug through Week 100, and will not receive study drug during a 12-week off-treatment period between Weeks 100 and 112."
88855708|NCT04303676|Active Comparator|Virtual Practice Facilitation without e-Learning|A virtual practice facilitation intervention, with a practice facilitator working with practices in virtual one-on-one or group sessions without utilizing alcohol use e-learning modules
88855709|NCT04294199|Active Comparator|Immobilization|Patients in this group will be given a knee immobilizer to wear for 2 weeks and then receive outpatient physical therapy evaluation and treatment
88855710|NCT04294199|Experimental|Early range of motion|Patients in this group will be allowed to move the knee and start outpatient physical therapy and treatment immediately.
88855711|NCT04277117|Other|Waitlisted control|"Phase 1 (6 months, months 1-6):~Educational materials on healthy eating for diabetes~No meal delivery~Phase 2 (6 months, months 7-12): Standard MOWCTX home meal delivery: 5 meals a week, delivered daily 2 to 4X a week"
89183600|NCT03918447|Experimental|Maximum bardoxolone methyl dose 30 mg|"Patients randomized to receive bardoxolone methyl with a baseline ACR greater than 300 mg/g will be titrated to a maximum dose of 30 mg. Patients will begin once-daily dosing with bardoxolone methyl capsules at 5 mg and will dose escalate to 10 mg at Week 2, 20 mg at Week 4 and 30 mg at Week 6.~Patients will continue to receive study drug through Week 100, and will not receive study drug during a 12-week off-treatment period between Weeks 100 and 112."
89183601|NCT03918447|Placebo Comparator|Placebo|"Patients randomized to placebo will remain on placebo capsules throughout the study, undergoing sham titration.~Patients will continue to receive placebo capsules through Week 100, and will not receive capsules during a 12-week off-treatment period between Weeks 100 and 112."
89183602|NCT03911973|Experimental|Talazoparib + Gedatolisib|"Talazoparib + Gedatolisib~Phase 1:~Dose Level -1: Gedatolisib 150mg IV, Days 1,8,15,22; Talazoparib 0.75 mg/orally qd, Days 1-28 Dose Level 1: Gedatolisib 180mg IV, Days 1,8,15,22; Talazoparib 0.75 mg/orally qd, Days 1-28 Dose Level 2: Gedatolisib 180mg IV, Days 1,8,15,22; Talazoparib 1.00 mg/orally qd, Days 1-28~Phase 2:~Gedatolisib 180 mg IV on days 1, 8, 15 and 22; Talazoparib 1.00 mg once daily, Days 1-28. Subjects receiving weekly gedatolisib may continue current regimen or may switch to gedatolisib 180 mg IV on days 1, 8, and 15; Talazoparib 1.00 mg once daily, Days 1-28 (3 weeks on/ 1 week off). All changes will be permanent."
89183603|NCT03898986|Experimental|MZ twins (IIV or LAIV4)|Up to 20 healthy monozygotic (MZ) individual twin volunteers, 2-20 years old, will be randomized within the twin pair to receive either inactivated influenza vaccine quadrivalent (IIV4) Fluzone® Quadrivalent vaccine or live, attenuated influenza vaccine quadrivalent (LAIV4) FluMist® Quadrivalent. Each volunteer will complete a total of 3 visits: Day 0 (pre-immunization), Day 7 and Day 28 post-immunization. All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).
89183604|NCT03898986|Experimental|DZ twins (IIV or LAIV4)|Up to 20 healthy monozygotic (MZ) individual twin volunteers, 2-20 years old, will be randomized within the twin pair to receive either inactivated influenza vaccine quadrivalent (IIV4) Fluzone® Quadrivalent vaccine or live, attenuated influenza vaccine quadrivalent (LAIV4) FluMist® Quadrivalent. Each volunteer will complete a total of 3 visits: Day 0 (pre-immunization), Day 7 and Day 28 post-immunization. All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).
89183605|NCT03892824|Experimental|Vine™ Filter + OAC|Vine™ Filter in each common carotid artery (CCA) with oral anticoagulant treatment (either vitamin K antagonist (VKA) or novel oral anticoagulant (NOAC)) for the duration of the study
89183606|NCT03873064||patients with solid tumor|All consecutive patients with a histologically confirmed diagnosis of solid tumor referred to any of the Medical Oncology Units of the S.I.C.O.G. cooperative group (http://www.sicog.it/).
89183607|NCT03857477||Stage 1|Caucasian men aged 55-69 to undergo genetic SNP profiling.
89382682|NCT03697200|Sham Comparator|Sham APA control|The same procedure of APA will be applied but the tapes/seeds will be placed on different points (points not related to AIMSS). Participants in the Sham APA Control will receive APA on the five ear points comprising mouth, stomach, duodenum, internal ear, and tonsils. These points are chosen for the Sham APA Control for two reasons: First, they are distinct from the zones of the ear (and the points therein) associated with AIMSS and correspond to body regions in which BCS (Breast Cancer Survivors) are usually pain-free; second, they are equivalent in number to those points used in the APA treatment group and no negative impacts have been observed among these points in our pilot study.
88855712|NCT04277117|Experimental|"Daily Warm MTM in-person delivery"|"Phase 1 (6 months, months 1-6):~Educational materials on healthy eating for diabetes~10 medically-tailored meals (MTM) per week, delivered 3-5x per week Mon-Fri~Each delivery day, 1 hot and 1 frozen + snack delivered to the participant's home by trained volunteers and/or paid delivery drivers who provide human interaction. Depending on the participant's availability (3-5 days/week), more frozen meals will be given one day to account for a total of 10 meals every week.~Phase 2 (6 months, months 7-12): Standard MOWCTX home meal delivery: 5 meals a week, delivered daily 2 to 4X a week"
88855713|NCT04277117|Experimental|"Weekly Frozen MTM drop shipment"|"Phase 1 (6 months, months 1-6):~Educational materials on healthy eating for diabetes~10 medically-tailored meals (MTM) delivered once a week~Each week all meals are frozen.~Meals are shipped to the participant's home with no human interaction~Phase 2 (6 months, months 7-12): Standard MOWCTX home meal delivery: 5 meals a week, delivered daily 2 to 4X a week."
88855714|NCT04273776|Active Comparator|Suvorexant Arm|10 mg of Suvorexant
88855715|NCT04273776|Active Comparator|Zolpidem Arm|5 mg of Zolpidem
88855716|NCT04273776|Placebo Comparator|Placebo|10mg of Avicel
88855717|NCT04272944|Experimental|10 mg/kg Q2W|10 mg/kg IV every 2 weeks
88855718|NCT04272944|Experimental|20 mg/kg Q3W|20 mg/kg IV every 3weeks
88855719|NCT04264143|Experimental|MTX110 and CED|All patients enrolled in the study will receive infusion of MTX110 and Gadolinium delivered by the CED delivery system directly into the tumor over 9-11 days.
89183608|NCT03857477||Stage 2|Men from Stage 1 identified as having a higher genetic risk score (top 10%) for prostate cancer will be offered an MRI scan, prostate biopsy and prostate cancer screening.
89183609|NCT03856060|Experimental|Group I (questionnaires, videos)|Patients complete questionnaires and watch a video portraying a physician using a standard EHR and then another portraying a physician using an integrated model of EHR during communication over 35 minutes.
89183610|NCT03856060|Experimental|Group II (video, questionnaire)|Patients complete questionnaires and watch a video portraying a physician using an integrated model of EHR and then another portraying a physician using a standard EHR during communication over 35 minutes.
89183611|NCT03834519|Experimental|Pembrolizumab + Olaparib|Participants will receive olaparib 600 mg as two 150 mg oral tablets twice daily (BID) continuously until progression PLUS on Day 1 of each 21-day cycle, pembrolizumab 200 mg by intravenous (IV) infusion for up to 35 cycles (approximately 2 years).
89183612|NCT03834519|Active Comparator|Next-generation Hormonal Agent Monotherapy (NHA)|Participants will receive a single NHA, which will be either abiraterone acetate (participants previously treated with enzalutamide) 1000 mg as two 500 mg or four 250 mg oral tablets once daily (QD) PLUS prednisone or prednisolone 10 mg as one 5 mg tablet BID until progression OR enzalutamide (participants previously treated with abiraterone acetate) 160 mg as four 40 mg oral tablets or capsules OR two 80 mg tablets QD until progression.
89183613|NCT03833934||Plasma Next Generation Sequencing (NGS)|Subjects will be sent blood collection kits with the necessary materials for local draws and those specimens will be sent directly by the subjects to the central laboratory (Resolution Bioscience) for plasma NGS. Plasma NGS results will be returned to the subject, their treating physician and study team, aiming to return results within 2 weeks by Resolution Bioscience.
89183614|NCT03817931|Placebo Comparator|Placebo|Placebo pill identical will be identical to tablets in the other 2 arms.
89183615|NCT03817931|Active Comparator|Anticholinergic|Solifenacin 5 mg tablet orally once daily for 30 days
89183616|NCT03817931|Active Comparator|Beta-3 agonists, adrenergic|Mirabegron 25 mg tablet orally once daily for 30 days
89183617|NCT03810807|Experimental|Dacomitinib and Osimertinib|"Patients will begin on combination dacomitinib and osimertinib at the prescribed doses.~A cycle will be 28 days in duration. The study will use a standard 3+3 dose escalation design. Per MD discretion, telemedicine visits may be utilized for cycles where imaging is not collected, and physical exam, vital sign and labs collection will only be required concurrent with imaging visits."
88855720|NCT04258488|Experimental|Oral Factor Xa inhibitor|
88855721|NCT04258488|Active Comparator|Vitamin K antagonist|
88855722|NCT04255875|Experimental|Treatment Healthy Participants|Participants will receive single ascending doses of subcutaneous (SC) or intravenous PF-07209326
89183618|NCT03809286|Experimental|Active Stimulation|Participants will be receiving active rTMS.
89183619|NCT03809286|Sham Comparator|Sham Stimulation|Participants will be receiving sham stimulation with a smaller coil housed within the rTMS device.
88855723|NCT04255875|Placebo Comparator|Placebo Healthy Participants|Participants will receive matching placebo
88855724|NCT04255875|Experimental|Treatment for SCD|Participants will receive a multiple dose of subcutaneous PF-07209326
88855725|NCT04253548|Experimental|iPeer2Peer Program|Participates in the iPeer2Peer Program
88855726|NCT04246281|Active Comparator|Group 1: Peripheral Nerve Stimulation (PNS)|Subjects in Group 1 will have leads placed in their lower back. These subjects will then use the SPRINT Peripheral Nerve Stimulation (PNS) System and will receive electrical stimulation for 8 weeks.
89183620|NCT03808662|Experimental|Arm 1: Early Stereotactic Body Radiotherapy/SBRT|SBRT to all oligoprogressive sites
89183621|NCT03808662|Active Comparator|Arm 2:Standard of Care|
89183622|NCT03808337|Active Comparator|Standare of Care|Patients with newly diagnosed metastatic non-small cell lung cancer or triple negative breast cancer may be enrolled on protocol prior to receiving any systemic therapy. If these patients are randomized to the standard of care arm (Arm 1), they will initiate appropriate therapy as determined by their oncologist. Standard of care systemic therapy, including chemotherapeutics, targeted therapies, immunomodulatory agents, and hormonal therapies will be delivered at the discretion of the treating oncologist.
89183623|NCT03808337|Experimental|Stereotactic Body Radiotherapy (SBRT) + Standard of Care|Patients enrolled on Arm 2 of the study will undergo Stereotactic Body Radiotherapy/SBRT to all known metastases seen on imaging studies performed prior to enrollment. Radiotherapy will be given concurrently to all metastatic sites. Minimum BED for ablative SBRT is more than or equal to 48 Gy10. Patients can undergo systemic therapy concurrently with SBRT at the discretion of treating radiation oncologist and medical oncologist. After completion of SBRT to all sites of known metastatic disease, patients will continue standard of care therapy per the treating oncologist.
89183624|NCT03808077|Experimental|Interventional Group: Deep Neuromuscular Blockade|The Deep NMB group (Intervention) will have rocuronium infusion titrated to deep paralysis defined as PTC of 1-2 (infusion start rate 0.025mg/kg/min or 1.5mg/kg/hr).
89183625|NCT03808077|Active Comparator|Control Group: Moderate Neuromuscular Blockade|The Moderate NMB group (Control ) will have rocuronium infusion titrated to moderate paralysis defined as TOF of 1-2 (infusion start rate 0.005mg/kg/min or 0.3mg/kg/hr).
89399530|NCT02182310|Experimental|BI 201335 or Placebo|tolerability part in female subjects
89399531|NCT02176850||Micardis®|
88855727|NCT04246281|Active Comparator|Group 2: Standard Interventional Management (Standard of Care)|Subjects in Group 2 will receive the standard of care. Group 2 subjects may be able to crossover to receive PNS after 12 months from start of treatment (Visit 16).
89382683|NCT03697200|Other|Education Control|Participants in the Education Control will receive four, 15-minute weekly individual sessions in which the scheduling and duration of interaction with the study staff are identical to the APA and Sham interventions. Educational sessions are intended to reflect usual standard medical care per guidelines from the American Society of Clinical Oncology (ASCO), while also meeting the needs of trial participation, including (1) the knowledge of hormonal therapy and side effects; (2) assessment and management of physical long-term and late effects; (3) assessment and management of psychological long-term and late effects; and (4) dietary (developed by Co-I, van Londen) and physical activity in Breast Cancer Survivors (BCS) (developed by Co-I, Stearns). These materials have been used by the research team, and clinical practice. Materials will be tailored so that they can be delivered within 15 minutes for each session.
89382684|NCT04693416|Experimental|Intrapersonal Stigma Reduction|The intervention will include education about substance use disorders (diagnosis, prognosis, and treatment), goal setting to assist the individual in preparing for change, and decisional balance to assist the individual in measuring the costs and benefits about disclosure of mental health problems and exercises to practice how to disclose. Facilitation of an intake assessment for treatment will be offered (with assistance in making the appointment, getting transportation and childcare, and securing a pro-bono status at a outpatient treatment facility).
89382685|NCT04693416|Experimental|Interpersonal Stigma Reduction|The intervention for family members and support persons of enrolled intrapersonal participants will include education about substance use disorders (diagnosis, prognosis, and treatment), stigma reduction, and how to provide support for someone with substance use disorder.
88855728|NCT04243668|Experimental|ANTI REFLUX MUCOSAL ABLATION THERAPHY|In patients fulfilling inclusion criteria and willing for ARMA, the procedure involves ablation of the mucosa of the EGJ using TT knife (ARMA). Subsequently, saline solution mixed with indigo-carmine is injected at the submucosa level to raise a submucosal bleb, followed by ablation of the mucosa along the lesser curvature using TT knife.The approximate duration of the procedure is 40min.
89382686|NCT03699774|Experimental|All Participants|"In treatment Period 1 (Day 1 through Day 4), on Day 1, participants receive a single dose of rosuvastatin 10 mg orally with food, and in Period 2 (Day 1 through Day 16), starting on Day 1, participants receive DS-8500a 75 mg orally qd with food for 16 days with concomitant administration of a single dose of rosuvastatin 10 mg qd on Day 14.~In both the periods, rosuvastatin and DS-8500a are administered after an overnight fast of 8 hours and within 10 minutes after consuming a standardized breakfast of 500 calories."
89382687|NCT03699696||65-75 years of age|Patients who are between the ages of 65 and 75, including 65 but not including 75, and receive propofol for induction of anesthesia.
89382688|NCT03699696||75-85 years of age|Patients who are between the ages of 75 and 85, including 75 but not including 85, and receive propofol for induction of anesthesia.
89382689|NCT03699696||85+ years of age|Patients who are 85 years of age or older, and receive propofol for induction of anesthesia.
89382690|NCT03699618||Anti-VEGF injection only|Patients who will receive monthly intravitreal anti-VEGF injection for 12 months, followed by anti-VEGF at standard of care treatment interval during months 12-24
89382691|NCT03699618||Hemorrhage displacement + Anti-VEGF|Hemorrhage displacement (at investigators' discretion) followed by monthly intravitreal anti-VEGF injections for 12 months, and standard of care treatment interval during months 12-24
88855729|NCT04240405||Elderly people without cognitive impairment|
88855730|NCT04240405||Amnestic type mild cognitive impairment patients (aMCI)|
88855731|NCT04240405||Dysexecutive type mild cognitive impairment patients (dMCI)|
88855732|NCT04228965|Other|Co-Use Group|Cannabis and tobacco co-use group.
88855733|NCT04228965|Active Comparator|Tobacco Only Group|Tobacco only group.
88855734|NCT04218526|Experimental|Vercise DBS Group|All participants will have the Vercise DBS system implanted.
88855735|NCT04197687|Experimental|Arm I - No pCR (trastuzumab emtansine, TPIV100, sargramostim)|Patients receive standard of care maintenance therapy with trastuzumab emtansine and receive TPIV100 ID and sargramostim ID on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive two additional booster injections of TPIV100 ID and sargramostim ID at 3 and 12 months after completion of trastuzumab emtansine maintenance therapy.
88855736|NCT04197687|Placebo Comparator|Arm II - No pCR (trastuzumab emtansine, placebo, sargramostim)|Patients receive standard of care maintenance therapy with trastuzumab emtansine and receive placebo ID and sargramostim ID on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive two additional booster injections of placebo ID and sargramostim ID at 3 and 12 months after completion of trastuzumab emtansine maintenance therapy.
88855737|NCT04197687|Experimental|Treatment (pCR)|Patients receive standard of care maintenance therapy with trastuzumab and pertuzumab for 1 year in the absence of disease progression or unacceptable toxicity.
88855738|NCT04186494|Active Comparator|Continuous positive airway pressure (CPAP)|Standard CPAP Therapy
88855739|NCT04186494|Experimental|Liraglutide-based weight loss regimen|Once daily s.c. injections of Liraglutide, starting at a dose of 0.6 mg with weekly 0.6 mg increments to 3.0 mg in adjunct to advice on a weight-reduction diet and physical exercise
89382692|NCT03696966|Active Comparator|Continuous Calorie Restriction|Daily calorie restriction: follow low-calorie diet (1,200-1,500 calories) daily using portion-controlled meals
89399532|NCT02177006||Caregivers|Caregivers of children 2-6 years of age
88855740|NCT04186494|Experimental|Combination CPAP/Liraglutide|Combination of both interventions
88855741|NCT04179448|Experimental|Side Access Mucosal Releasing Incision (SAMRI)|SAMRI incision to allow for coronally advanced flap and placement of acellular dermal matrix (ADM) graft
88855742|NCT04179448|Active Comparator|Sulcular Tunnell access|Sulcular tunnel access incision to allow for coronally advanced flap and placement of acellular dermal matrix (ADM) graft
88855743|NCT04155541||VIZIMPRO(dacomitinib hydrate)|Patients with EGFR mutation-positive inoperable or recorrent NSCLN (non-small cell lung cancer) who have not received VIZIMPRO (dacomitinib hydrate)
89183626|NCT03798678|Experimental|Treatment (CB-839 HCI, dexamethasone, carfilzomib)|Patients receive glutaminase inhibitor CB-839 Patients receive glutaminase inhibitor CB-839 hydrochloride PO every 12 hours on days 1-28, dexamethasone PO on days 1, 2, 8, 9, 15, 16, and 23, and carfilzomib IV over 10 minutes on days 1, 2, 8, 9, 15, and 16. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity
89382693|NCT03696966|Experimental|Intermittent Very-Low Calorie Diet|Intermittent Restriction: follow very-low calorie diet (500-800) with portion-controlled meals three days per week and structured healthy eating on other days
89382694|NCT03702426|Experimental|Norfloxacin with GM-CSF|Oral Norfloxacin 400mg daily and GM-CSF (Granulocyte-Macrophage colony-stimulating factor) in a dose of 1.5mcg/kg over 4 hour infusion every 15 days will be given in Group B
89382695|NCT03702426|Active Comparator|Norfloxacin|Patients who fulfil the inclusion criteria will receive oral norfloxacin 400 mg daily as secondary prophylaxis for SBP in Group A.
89382696|NCT00265941|Active Comparator|RT + cisplatin|Radiation therapy (RT) as accelerated fractionation by concomitant boost (AFX-CB) or intensity-modulated radiation therapy (IMRT) plus cisplatin
89382697|NCT00265941|Experimental|RT + cisplatin + cetuximab|Radiation therapy (RT) as accelerated fractionation by concomitant boost (AFX-CB) or intensity-modulated radiation therapy (IMRT) plus cisplatin plus cetuximab
89382698|NCT03696732||Women undergoing cesarean section|Women undergoing cesarean section under spinal anesthesia with prophylactic phenylephrine drip.
89382699|NCT01568541|Active Comparator|Children' toothpaste|Children's toothpastes
89382700|NCT01568541|Active Comparator|Regular toothpastes|Regular toothpastes
89382701|NCT03699462|Active Comparator|Plasma A group|The group receiving balanced crystalloid solution (Plasma solution-A injection, CJ Pharma, South Korea) during surgery
89382702|NCT03699462|Experimental|Albumin group|The group receiving receiving 5% albumin (Albumin 5% inj, Green cross, South Korea) during surgery
89382703|NCT03699384|Experimental|Azacitidine and Avelumab|All enrolled patients will receive 1 cycle of AZA followed by cycles of combination AZA+Avelumab.
89382704|NCT03702348|Experimental|Resistance exercise group|Progressive resistance exercise protocol with elastic resistance to strengthen the muscle groups that stabilize the main joints affected by Chikungunya Fever. The sessions will be 2 times a week for 12 weeks.
89382705|NCT03702348|No Intervention|Control group|No intervention during the 12 weeks, being contacted through telephone calls. After the reevaluation at the end of the 12 weeks, this group will perform the same protocol as the experimental group
89382706|NCT03702192|Experimental|single-arm novel anticoagulation|Single-arm clinical study to assess the safety, and effectiveness of a novel anticoagulation protocol to be used in conjunction with the Berlin Heart EXCOR Pediatric Ventricular Assist Device as a bridge to heart transplantation in children with severe heart failure who have failed optimal medical therapy.
89382707|NCT03699306|Active Comparator|Conventional r blinded|the participants were allocated to have NG tube inserted in a conventional or blind method.
89382708|NCT03699306|Active Comparator|Brake cable|the participants were assigned to have NG tube inserted by use of a bike brake cable as a guide wire.
89382709|NCT03699306|Active Comparator|High way man's hitch|they were selected to have NG tube inserted by use of silk thread knot.
89183627|NCT03795818|Other|IPT-A|Interpersonal psychotherapy for adolescents (IPT-A) is a psychosocial treatment for adolescents. It has been shown to be effective for adolescents with depression. It is now being studied as to its benefit for adolescents who meet criteria for PTSD or have subthreshold PTSD symptoms.
89183628|NCT03773367|Experimental|Treatment with chemotherapy pre- and postoperative.|
89382710|NCT03624738|Active Comparator|Patients with redo cardiac surgery 1|Procedure: the patients will undergo femorofemoral bypass
89183629|NCT03745924||Patients with haemophilia B|Patients with haemophilia B without current inhibitors
88855744|NCT04123821|Experimental|Group A|Nasopharyngeal airway with 5L/min oxygen through nasal cannula
89183630|NCT03736889|Experimental|Tislelizumab (BGB-A317) Injection|
89382711|NCT03624738|Active Comparator|Patients with redo cardiac surgery 2|Procedure: the patients will undergo conventional Aortobicaval cannulation
89382712|NCT04014231||Observational (single wave assessment)|Patients undergo placement of a single wave application near the carotid region of the neck.
89382713|NCT03697590|Experimental|PDT with no curettage|
89382714|NCT03697590|Active Comparator|Standard PDT|
88855745|NCT04123821|No Intervention|Group B|5 L/min oxygen through nasal cannula alone
88855746|NCT04115319|Experimental|SEP363856|SEP363856 50mg, 75mg, 100mg, flexibly dosed once daily capsule
89382715|NCT05375799||COVID-19 in use of ELMO|This is an observational study, so there are no interventions. Data will be recruited from adult patients diagnosed with COVID-19, described in medical records, by laboratory detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA, who used the Assisted Breathing Helmet - ELMO.
89382716|NCT03636997|Active Comparator|Draining seton|Draining seton is placed through the fistula track and internal and external anal sphicnters
89382717|NCT03636997|Active Comparator|Rerouting of track|The seton and the fistula track are rerouted to include the internal anal sphincter only and spare the external anal sphincter
89382718|NCT05420883|Active Comparator|Acupressure|One minute after the start of the Nonstress test recording, an application will be made to the Zhi yin (BL67) acupuncture point with a depth of 0.1-0.2 cm, on the outer edge of the little toe of both feet, at the nail end point. The application will be applied to both points simultaneously for 2 minutes consecutively and then repeated 2 times with a 3-minute rest period.
89382719|NCT05420883|Active Comparator|Halogen light|One minute after the start of the Nonstress Test recording, halogen light stimulation will be given from the mother's abdomen to the fetal head for 10 seconds with a flashlight device worth 1,000,000 candles. The procedure will be repeated on the same spot 10 minutes after the first halogen light stimulation.
89382720|NCT05420883|Active Comparator|Control|No action will be taken against this group.
88855747|NCT04115319|Active Comparator|quetiapine XR|quetiapine XR, 400, 600, 800 mg, flexibly dosed once daily capsule
88855748|NCT04110132|Active Comparator|Ganglion impar block with Bupivacaine.|"Bupivacaine group; Ganglion Impar will be blocked using G25 Quinqe spinal needle using Bupivacaine 0.5% 10ml.~Patient will have hemorrhoidectomy."
89183631|NCT03726268|Active Comparator|IV methadone|Intraoperative and post-operative IV methadone
89382721|NCT04665973|Experimental|Oral semi-structured interview|The oral semi-structured interview uses the principles of motivational interviewing (partnership with the patient, no judgment, altruism, evocation) and follow the content of the booklet used in the control group.
89382722|NCT04665973|Active Comparator|Booklet|The information booklet was designed by the physiotherapists at Cliniques universitaires Saint-Luc and is specifically dedicated to raise patient's awareness about the benefits of physical activity (PA) in the context of cancer.
89382723|NCT03696654|No Intervention|Before treatment|
89382724|NCT03696654|Active Comparator|After treatment|
89382725|NCT05420571|Experimental|digital impression module|In the experimental group, digital impressions and 3D printed models were used and fitted pads were made. Patients were instructed to wear the hinge pad for 24 hours, and x-rays were taken and intraoral examinations were performed at 2 weeks and 4 weeks.
89382726|NCT05420571|Active Comparator|ordinary impression group|The control group used alginate impression and plaster model infusion to make the model and make the fitting pad. Patients were instructed to wear the pad for 24 hours, and x-rays and intraoral examinations were taken at 2 and 4 weeks.
89382727|NCT03696420||DBS surgery targeting the VIM|Patient who underwent a DBS surgery targeting the VIM at Bordeaux University Hospital
89382728|NCT05420415||High-CSTME|Patients with high tumor microenvironment collagen signature
89382729|NCT05420415||Low-CSTME|Patients with low tumor microenvironment collagen signature
89382730|NCT03882957|Active Comparator|Video|videos of media tasks being completed
89382731|NCT03882957|Experimental|media multi-task|media tasks
89382732|NCT03882957|Experimental|sustained attention task|a cognitive task that trains sustained attention
89382733|NCT03201211|Experimental|10-10-10-AS|Subjects who received two doses of the AS01E adjuvanted GSK Biologicals' NTHi-Mcat investigational vaccine, containing 10µg of PD, PE-PilA and UspA2, and administered at Month 0 and Month 2 in NTHi-Mcat-001 study (NCT02547974), and were enrolled in the study.
89382734|NCT03201211|Experimental|10-10-3-AS|Subjects who received two doses of the AS01E adjuvanted GSK Biologicals' NTHi-Mcat investigational vaccine, containing 10µg of PD, 10µg of PE-PilA, and 3.3µg of UspA2, and administered at Month 0 and Month 2 in NTHi-Mcat-001 study (NCT02547974), and were enrolled in the study.
89382735|NCT03201211|Placebo Comparator|PLACEBO|Subjects who received two doses of placebo (saline solution), administered at Month 0 and Month 2 in NTHi-Mcat-001 study (NCT02547974) and were enrolled in the study.
89382736|NCT03727191|Active Comparator|Control Group|Nutritional education, guidelines for the consumption of a completed shreded diet and recommendations for physical activity.
89183632|NCT03726268|Active Comparator|IV fentanyl, sufentanil, morphine or hydromorphone|Intraoperative and post-operative IV fentanyl, morphine or hydromorphone at anesthesia provider discretion
88855749|NCT04110132|Placebo Comparator|Ganglion impar block with Saline|Saline group; Ganglion Impar will be blocked using G25 Quinqe spinal needle using Normal Saline 10ml Patient will have hemorrhoidectomy.
88855750|NCT04107935|Experimental|Intervention|
88855751|NCT04107935|Other|Usual Care|
88855752|NCT04105270|Experimental|Arm A (RMT)|
88855753|NCT04105270|Experimental|Arm B (Placebo)|
88855754|NCT04105270|Experimental|Safety Run-in|10 patients are enrolled in this safety run-in arm. Patients are directly assigned to RMT treatment arm. After safety- run-in period of 4 weeks after the first dose of RMT, in the 10 patients if no new safety signal are seen enrollment moves to randomization
88855755|NCT04100200|Active Comparator|Mixed Berries|Strawberry and red raspberry composite served as a frozen drink
88855756|NCT04100200|Active Comparator|FOS|Non-polyphenol, carbohydrate-based fermentable fiber/pre-biotic served as a frozen drink
88855757|NCT04100200|Active Comparator|Combination|Mixed berry composite + FOS served as a frozen drink
88855758|NCT04100200|Placebo Comparator|Control|Placebo similar in color to mixed berry supplement without any polyphenols served as a frozen drink
88855759|NCT04099472|Placebo Comparator|Control Group|Patients and families will receive standard care, which is an informational pamphlet on ICU delirium upon admission. The intervention group will also receive the same pamphlet.
89382737|NCT03727191|Experimental|Experimental Group|Nutritional education and guidelines for the consumption of a completed shreded diet including: 2 packets of 90 grams every day (One salted packet for lunch/dinner and one sweet packet for breakfast/afternoon snack) and recommendations for physical activity for one month.
89382738|NCT04633837|No Intervention|Group 1 Control|Group 1 will undergo standard arthroscopic shoulder surgery without the ECM injection.
89382739|NCT04633837|Active Comparator|Group 2: ECM Injectable graft|Group 2 will undergo arthroscopic shoulder surgery and receive 2cc of the injectable extracellular matrix injection placed into the glenohumeral joint space via a transtendon approach at the end of the surgery
89382740|NCT03622437|Experimental|Patient-led follow-up|Participants in the experimental arm are enrolled in a patient-led follow-up program, based on patient-education and self-referral, in addition to recommendations from national guidelines for follow-up.
89183633|NCT03695601||HeartCare|Diagnostic Test: Heart Care 2300 patients managed with HeartCare (AlloMap® and AlloSure-Heart® )
89382741|NCT03622437|Active Comparator|Standard follow-up|Participants in this control group follow standard care for follow-up after rectal cancer treatment, as described in local and national guidelines.
89382742|NCT05598879||Breast cancer|Patients with breast cancer who present for initial cardio-oncology consultation. Clinical follow up for 18 months.
89183634|NCT03695601||Control|A historical control group will be matched to the estimated 1150 HeartCare group patients who complete at least two years of HeartCare surveillance use and inclusive of year 3 post-transplant clinical follow-up for outcome. The criteria for the matched controls will be based on allograft donor type, age, gender, ethnicity/race, and other clinical factors. Propensity scores will be used to perform the matching.
89382743|NCT05598879||Hematological malignancies|Patients with lymphomas, leukemias, multiple myeloma, and AL amyloidosis who present for initial cardio-oncology consultation. Clinical follow up for 18 months.
89382744|NCT05598879||Immune check point inhibitors|Patients with any type of cancer treated with immune check point inhibitors who present for initial cardio-oncology consultation. Clinical follow for 18 months
89382745|NCT03540069|Experimental|Cervical Cancer Screening Education|Context-specific multi-level peer education cervical cancer screening education curriculum is implemented by Care Groups. This is conducted through a cluster-randomized stepped wedge study. Cluster 1 (randomly selected) crosses to the intervention arm at Period 2, Cluster 2 (randomly selected) crosses over to the intervention arm at Period 3, and so on. By the end of the study, all clusters will cross over to the intervention arm (one-way), though in random order. At the end of the final time period, the outcome of interest is compared between the intervention and control periods within each cluster. Differences in service utilization and recommendation will be compared, whereby clusters serve as their own controls as they cross over from the control to intervention group.
89382746|NCT03540069|No Intervention|Control|No educational program is implemented for each cluster prior to crossover to intervention.
89382747|NCT03696264|Experimental|Resistance-trained, adult males|Subjects receive varying levels of amino acid intakes ranging from 0.2-3.0g/kg/d
89382748|NCT04472949|Experimental|Durvalumab & thoratic radiotherapy|"Patients will start with an induction phase (part 1). Patients with CR; PR or SD after the induction phase, will transfer to the maintenance phase (part 2). Patients with PD after the induction phase will transfer to the follow-up phase.~Induction phase (part 1):~Patients will receive durvalumab in combination with carboplatin and etoposide for 4 cycles of 21 days:~Maintenance phase (part 2):~Patients will receive durvalumab treatment up to PD or max. 2 years, i.e. 26 maintenance cycles, in combination with tRT:~Follow up phase:~Patients will be followed up for 24 months, every 8 weeks."
89382749|NCT03696186|Active Comparator|Luminal type-1|Standard treatment
89382750|NCT03696186|Experimental|Luminal type-2|Experimental treatment
89382751|NCT03696186|Active Comparator|Neuroendocrine type-1|Standard treatment
89382752|NCT03696186|Experimental|Neuroendocrine type-2|Experimental treatment
89382753|NCT03696186|Active Comparator|Atypical type-1|Standard treatment
89382754|NCT03696186|Experimental|Atypical type-2|Experimental treatment
89382755|NCT03699150||Postmenopausal women|Outpatients referred to the Gynecologic Endocrinology, FTGM
89382756|NCT03698838||McDESPOT Study Group|Patients aged 0-19 who have an MRI ordered clinically and have one of the following conditions: epilepsy, hydrocephalus, craniosynostosis or mild traumatic brain injury. Epilepsy, hydrocephalus and craniosynostosis patients will be both newly diagnosed and chronic. MTBI patients will be acute and chronic and defined as a glascow coma score (GCS) of 13-15.These patients will have a 10 minute MRI sequence (McDESPOT) added to their standard of care T1 and T2 scans.
89382757|NCT03698838||Control Model|Control model derived from a linear mixed-effects model (Spader et al 2013)
89382758|NCT03695952||Hepatocellular carcinoma|Hepatocellular carcinoma patients treated with nivolumab
89382759|NCT03695952||Biliary Tract Cancer|Biliary tract cancer patients treated with pembrolizumab
89382760|NCT03695874||Phase 1: statistical purification|"400 Hereditary Haemorrhagic Telangiectasia patients:~over 18 years~able to read French~with clinically confirmed Hereditary Haemorrhagic Telangiectasia disease (presence of at least 3 Curaçao criteria) and / or molecular biology~who received the information and did not object to participate in the study"
89382761|NCT03695874||Phase 2: statistical validation|"200 Hereditary Haemorrhagic Telangiectasia patients:~over 18 years~able to read French~with clinically confirmed Hereditary Haemorrhagic Telangiectasia disease (presence of at least 3 Curaçao criteria) and / or molecular biology~who received the information and did not object to participate in the study"
89382762|NCT03695796|Other|Single arm|Only one arm because diagnostic study evaluating non-invasive tests using liver biopsy as reference
89382763|NCT03695640|Active Comparator|Group L|continuous femoral nerve block with levobupivacaine
89382764|NCT03695640|Experimental|Group LM|continuous femoral nerve block with levobupivacaine and magnesium sulfate
89382765|NCT03702114||MMG group|Patients in this group will receive auricular point detection which is accomplished by the novel auricular point detector device. There is no addition to the patient's routine care.
89382766|NCT03702114||Control group|This group includes healthy subject, for whom no treatment will be performed. Only auricular point detection by the auricular point detector will be conducted.
89183635|NCT03693170|Experimental|1 Arm|encorafenib plus binimetinib plus cetuximab
89382767|NCT03698760|Experimental|Mild stage Alzheimer group|Participants with mild stage Alzheimer's disease
89382768|NCT03698760|Experimental|Control Group|Participants without cognitive disorders
89382769|NCT03698682|Experimental|Short treatment group|1 tablet Levofloxacin 500mg / day for two days completed by 1 tablet Placebo Levofloxacin 500mg / day for 5 days.
89382770|NCT03698682|Experimental|Standard treatment group|1 tablet of Levofloxacin 500mg prescribed for 7days
89183636|NCT03690336||Patients with haemophilia B|Patients with haemophilia B treated with nonacog beta pegol who report adverse events to the PedNet and EUHASS, and possibly other national or international registries.
89183637|NCT03681561|Experimental|Phase I:Ruxolitinib and Nivolumab|Participants will receive ruxolitinib at their assigned dose taken orally twice daily on a 28-day cycle combined with nivolumab 480 mg IV administered every 4 weeks (i.e. on Day 1 of a 28-day cycle) until disease progression, unacceptable toxicity, or for a maximum of 2 years.
89382771|NCT03695562|Experimental|implant placement using sequential drilling|patient with vitamin D deficiency using sequential drilling technique
89382772|NCT03695562|Active Comparator|implant placement using single drilling|Patient with vitamin D deficiency using single drilling technique
89382773|NCT03695328||physical activity level|Children categorized either in the group with moderate to vigorous physical activity or in the group with low physical activity according the accelerometer's measures
89382774|NCT03695328||dietary intake|Childrens' 24th dietary recalls for 7 days analyzed for protein, calcium, vitamin D and phosphorus intake and they categorized according the RDAs above or below them.
89382775|NCT04648098|Experimental|Experimental: Intervention group|Discharge training and telephone counseling
89382776|NCT04648098|No Intervention|No Intervention: Control Group|Routine care
89382777|NCT03029832|Experimental|MOXR0916 plus Atezolizumab|
89382778|NCT03029832|Active Comparator|Atezolizumab|
89382779|NCT03695016|Experimental|Immediate Intervention|Participants will receive the ActiveGOALS 13 week, online self-directed intervention for increasing aerobic physical activity and decreasing time spent sitting. The intervention is based on social-cognitive theory models of behavior changes and utilizes barrier recognition, problem solving, and monitoring of behavior to initiate behavior change. They will also receive weekly feedback from a coach and be provided with online, paper, and wearable tracking devices. They will also be provided with links to tools that support physical activity.
89382780|NCT03695016|Other|Wait-listed Control|This group will receive a monthly newsletter with general health advice during the wait period (3 months). After the three month follow-up visit/ collection of outcomes they will be offered the ActiveGOALS intervention in its entirety.
89382781|NCT04252638|Experimental|Acceptance and Commitment Therapy plus Sleep Restriction|Acceptance and Commitment therapy is a well-established treatment for other disorders including depression, anxiety and chronic pain, but has not been thoroughly investigated for insomnia. The therapy consists of mindfulness, acceptance, identification of personal life values and committed action. In addition, patients in this group will receive sleep restriction, a behavioral therapy component of cognitive behavioral therapy for insomnia. The treatment will consist of six weekly sessions of group psychotherapy and will be conducted in an outpatient setting.
89382782|NCT04252638|Active Comparator|Cognitive Behavioral Therapy including Sleep Restriction|The control intervention is Cognitive Behavioral Therapy for insomnia (CBT-I). This is the first line treatment for adults with chronic insomnia. The therapy consists of education, relaxation, and behavioral therapy, including sleep restriction. The treatment will consist of six weekly sessions of group psychotherapy and will be conducted in an outpatient setting.
89382783|NCT03701880|Experimental|Ivabradine group|an initial dose of 5 mg/12 hours of Ivabradine will be added to beta-blockers (bisoprolol 2.5 mg/day) and ivabradine will be increased until a dose of 7.5 mg/12 hours according to HR. The heart rate target will be at least <70 bpm and not lower than 60 bpm. If HR decreases below 60 bpm, ivabradine and/or beta-blockers doses will be decreased to the previous dose. After discharge, beta-blockers up-titration will be continued during follow-up visit.
89382784|NCT03701880|Active Comparator|Control group|beta-blocker (bisoprolol 2.5 mg/day) and it will be doubled every 2 weeks during the admission according to the stability of HR, blood pressure and tolerability of patients. Ivabradine will be only added after reaching bisoprolol optimal dose (10mg) or maximum tolerated dose and the HR is still above 70 bpm. If HR decreases below 60 bpm, ivabradine dose will be decreased.
89382785|NCT03692754|Active Comparator|AT with 10 mg/d|The patients will be given receive atorvastatin in 10 mg/d for 1 month plus dexamethasone 40mg/d for 4 days.
89382786|NCT03692754|Active Comparator|AT with 20 mg/d|The patients will be given atorvastatin in 20 mg/d for 1 month plus dexamethasone 40mg/d for 4 days.
89382787|NCT03692754|Experimental|Dexamethasone|The patients will be given dexamethasone 40mg/d for 4 days.
89382788|NCT03692598|Experimental|MIA Surgical|Eligible patients will receive implantation of MIA implants deployed using the MIA, Minimally Invasive Annuloplasty Device - Surgical from an open surgical approach
89382789|NCT03692598|Experimental|MIA Percutaneous|Eligible patients will receive implantation of MIA implants deployed using the MIA, Minimally Invasive Annuloplasty Device - Percutaneous from a transcatheter approach
89382790|NCT03694782||Experimental group|Gardeners starting gardening in a community garden in Montpellier (France)
89382791|NCT03694782||Control Group|Volunteers living in the same neighborhoods but with no experience in community gardening.
89382792|NCT03688308|Experimental|Shoulder arthroscopy with BMAC|This arm will have patients who receive surgical intervention with arthroscopic rotator cuff repair along with 3-4cc of BMAC produced from the Harvest/Terumo BCT system
89382793|NCT03688308|Active Comparator|Shoulder arthroscopy alone|This arm will have patients who receive surgical intervention with arthroscopic rotator cuff repair without administration of BMAC.
89382794|NCT03692520|Experimental|SCT200|Initially, SCT200 6.0mg/kg will be administered at day 1 every week for a maximum of 6 cycles. After 6 cycles SCT200 8.0mg/kg will be administered at day 2 every weeks until disease progression
89382795|NCT04224558|Experimental|HSCT after mobilization and conditioning|"Mobilization and leukopheresis allow for stem cell harvest. Then conditioning is provided prior to stem cell transplantation, followed by post-transplant conditioning.~Interventions include:~Stem cell mobilization~Leukopheresis~Preparative regimen~Peripheral blood stem cell infusion~Post-PBSC infusion conditioning"
89382796|NCT03089697|Experimental|N-Rephasin® SAL200|To assign the study group, administer the conventional standard treatment (CST) (antibiotics) for MRSA/MSSA with N-Rephasin® SAL200 (3mg/kg); N-Rephasin® SAL 200 is given by intravenous only once at Day 1.
89382797|NCT03089697|Placebo Comparator|Placebo|To assign the control group, administer the conventional standard treatment (CST) (antibiotics) for MRSA/MSSA with Formulation buffer (placebo); Placebo (INT200) is given by intravenous only once at Day 1 (same way with Experimental group)
89382798|NCT03692442||immunotherapy effective group|PD1, TMB and serum cytokines was detected before nivolumab treatment
89382799|NCT03692442||immunotherapy ineffective group|PD1, TMB and serum cytokines was detected before nivolumab treatment
88855760|NCT04099472|Experimental|Intervention Group|Patients and families will receive standard care, which is an informational pamphlet on ICU delirium upon admission. Additionally, they will receive delirium education on prevention and management of delirium.
88855761|NCT04097795||Prehabilitation|Patients aged 70 years and above or with an American Society of Anesthesiologists (ASA) score of III, who are scheduled for colorectal cancer surgery in one of the participating hospitals which offer prehabilitation.
88855762|NCT04097795||No prehabilitation|Patients aged 70 years and above or with an American Society of Anesthesiologists (ASA) score of III, who are scheduled for colorectal cancer surgery in one of the participating hospitals which do not offer prehabilitation.
88855763|NCT04084561|Experimental|HRHA|High Risk, High Ancestry
89183638|NCT03681561|Experimental|Phase II: Ruxolitinib and Nivolumab|Participants will receive ruxolitinib at 20mg orally twice daily on a 28-day cycle combined with nivolumab 480 mg IV administered every 4 weeks (i.e. on Day 1 of a 28-day cycle) until disease progression, unacceptable toxicity, or for a maximum of 2 years.
89183639|NCT03669822||Inpatient ulcerative colitis patients|Patients hospitalized for acute severe ulcerative colitis will be invited to enroll. Participants will be treated at the discretion of their treating physicians per standard of care. We expect some participants will be treated with standard versus accelerated infliximab dosing, permitting comparison, in addition to other treatment strategies.
89183640|NCT03666377|No Intervention|No gum chewing|Usual pharmacologic treatment and post-operative care (e.g. daily visits by surgical team, antibiotics where appropriate, mobilization, advancement of diet as tolerated). Analgesia and anti-emetics will be provided (both oral and intravenous) as needed.
89183641|NCT03666377|Experimental|Gum chewing|"Usual pharmacologic treatment and post-operative care (e.g. daily visits by surgical team, antibiotics where appropriate, mobilization, advancement of diet as tolerated). Analgesia and anti-emetics will be provided (both oral and intravenous) as needed.~Intervention: 1 piece of sugarless gum to be chewed three times daily for 1 hour each."
89183642|NCT03664206||Patients|"MRS, conventional TMS and treshold tracking TMS~The participants will be told not to consume coffee or alcohol or do exhausting exercise 12, 24 and 48 hours, respectively, prior to the examinations"
89183643|NCT03664206||Healthy subjects|"MRS, conventional TMS and treshold tracking TMS~The participants will be told not to consume coffee or alcohol or do exhausting exercise 12, 24 and 48 hours, respectively, prior to the examinations"
89183644|NCT03658785|Experimental|TIL,IL-2,Cyclophosphamide,Fludarabine|"Biological: TIL On day 0, cells will be infused intravenously over 20 to 30 minutes (one to four days after the last dose of fludarabine).~Drug: Aldesleukin 125,000 IU/kg IV/day (based on total body weight) beginning within 24 hours of cell infusion and continuing for up to 2 weeks) Drug: Cyclophosphamide On day -7 and day -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W over 1 hr.~Drug: Fludarabine Days -5 to -1: Fludarabine 25 mg /m2/day IVPB daily over 30 minutes for 5 days."
89183645|NCT03655262|Experimental|1 Session|1 neuro-reinforcement session
89183646|NCT03655262|Experimental|3 Sessions|3 neuro-reinforcement sessions
89183647|NCT03655262|Experimental|5 sessions|5 neuro-reinforcement sessions
89183648|NCT03645564|Active Comparator|Group 1 : specialized nurse consultation|This group will benefit of a specialized nurse consultation throughout of which an individualized information will be delivered. This information will be reevaluated during the usual patient follow-up.
89183649|NCT03645564|No Intervention|Group 2 : no specialized nurse consultation|This control group will present the same care pathway than all the patients of the service suffering from Atrial Fibrillation without specialized nurse consultation.
89183650|NCT03639025||Standard Donor Lungs Primary Analysis Population|Recipients transplanted with primary analysis population eligible donor lungs preserved on the OCS™ Lung System.
89183651|NCT03639025||Donor Lungs Initially Unacceptable Primary Analysis Pop.|Recipients transplanted with primary analysis population eligible donor lungs preserved on the OCS™ Lung System.
89183652|NCT03639025||All Other Enrolled Patients|All OCS Lung transplanted patients that do not meet any of the above analysis populations.
89183653|NCT03623321|Experimental|Drug - pimavanserin|Pimavanserin 34 mg is provided as 2×17 mg tablets as single dose, once daily by mouth. Dose adjustments of pimavanserin down to 20 mg (provided as 2×10 mg tablets as a single dose, once daily by mouth) and up to 34 mg are permitted based on Investigator assessment of clinical response.
89183654|NCT03615742|Placebo Comparator|Placebo and Filtered Air|Volunteers will use an inhaler that does not contain any medication, before sitting in a booth and being exposed to high-efficiency particulate air (HEPA) filtered air for 2 hours.
89183655|NCT03615742|Active Comparator|Budesonide and Filtered Air|Volunteers will inhale 1.6mg of budesonide before sitting in a booth and being exposed to HEPA filtered air for 2 hours.
89183656|NCT03615742|Active Comparator|Placebo and Diesel Exhaust|Volunteers will use an inhaler that does not contain any medication, before sitting in a booth and being exposed to 300µg/m³ concentration of diesel exhaust for 2 hours.
89183657|NCT03615742|Experimental|Budesonide and Diesel Exhaust|Volunteers will inhale 1.6mg of budesonide before sitting in a booth and being exposed to 300µg/m³ concentration of diesel exhaust for 2 hours.
89183658|NCT03595371|Experimental|dapansutrile capsules|Hard gelatin capsules containing 100 mg of dapansutrile (API)
89183659|NCT03580044|Experimental|ATM- AVI Aztreonam- Avibactam (ATM-AVI) Active Treatment Arm|
88855764|NCT04084561|Experimental|LRLA|Low Risk, Low Ancestry
88855765|NCT04084561|Experimental|HRLA|High Risk, Low Ancestry
89183660|NCT03580044|Active Comparator|Best Available Therapy (BAT) Comparator Treatment Arm|
89183661|NCT03579030|Experimental|Single Dose of RTA 1701 or Placebo|"RTA 1701 capsules or placebo taken orally in a single dose.~Group 1: RTA 1701 10 mg or matching placebo Group 2: RTA 1701 ≤ 20 mg or matching placebo Group 3: RTA 1701 ≤ 40 mg or matching placebo Group 4: RTA 1701 ≤ 80 mg or matching placebo Group 5: RTA 1701 ≤ 160 mg or matching placebo Group 6: RTA 1701 ≤ 320 mg or matching placebo Group 7: RTA 1701 ≤ 640 mg or matching placebo"
88855766|NCT04084561|Experimental|LRHA|Low Risk, High Ancestry
88855767|NCT04084145||CKD|Chronic Kidney Disease stage 1 - 4 followed up in secondary care
89183662|NCT03579030|Experimental|Multiple Dose of RTA 1701 or Placebo|"RTA 1701 capsules, Dose TBD mg or placebo taken orally once daily for 14 weeks.~Group 8: RTA 1701 ≤40 mg or matching placebo Group 9: RTA 1701 ≤160 mg or matching placebo Group 10: RTA 1701 ≤640 mg or matching placebo"
89382800|NCT05598411|Experimental|Oral Glucocorticoids group|Intervention Period：oral glucocorticoids（methylprednisolone 24mg qd, 2-week duration）+nasal spray （Budesonide Nasal Spray 64ug per Nostril, bid, 2-week duration） follow-up period：nasal spray（Budesonide Nasal Spray 64ug per Nostril, bid, 24-week duration）
89382801|NCT05598411|Placebo Comparator|Placebo group|Intervention Period：oral placebo+nasal spray（oral placebo 24mg qd, 2-week duration）+nasal spray （Budesonide Nasal Spray 64ug per Nostril, bid, 2-week duration） follow-up period：nasal spray（Budesonide Nasal Spray 64ug per Nostril, bid, 24-week duration）
89382802|NCT03688230|Experimental|Abituzumab + Cetuximab + FOLFIRI|"Cetuximab:~400 mg/m2 over 120 min followed by 250 mg/m2 weekly 60 min or 500 mg/m2 every two weeks, initially 120 min followed by 60 to 90 min~(60 min [± 5 min] after completion of the cetuximab infusion) Abituzumab 1000 mg: every 2 weeks for 60 min~(60 min [± 5 min] after completion of the abituzumab infusion) FOLFIRI: every 2 weeks Irinotecan 180 mg/m² IV, 30 - 90 min day 1 Folinic acid (racemic) 400 mg/m² IV, 120 min day 1 5-FU 400 mg/m² bolus day 1 5-FU 2400 mg/m² IV over a period of 46 h day 1-2"
89382803|NCT03688230|Placebo Comparator|Placebo + Cetuximab + FOLFIRI|"Cetuximab:~400 mg/m2 over 120 min followed by 250 mg/m2 weekly 60 min or 500 mg/m2 every two weeks, initially 120 min followed by 60 to 90 min~(60 min [± 5 min] after completion of the cetuximab infusion) Placebo: every 2 weeks for 60 min~(60 min [± 5 min] after completion of the placebo infusion) FOLFIRI: every 2 weeks Irinotecan 180 mg/m² IV, 30 - 90 min day 1 Folinic acid (racemic) 400 mg/m² IV, 120 min day 1 5-FU 400 mg/m² bolus day 1 5-FU 2400 mg/m² IV over a period of 46 h day 1-2"
89382804|NCT03694314|Experimental|Omega-3 fatty acids|Both the mother and child will receive omega-3 supplements in the form of a 200 mL drink to be taken once daily. The intervention will last 45 days. Assessments will take place at 0 months (baseline), 45 days (end of treatment), and 3 months (1 and a half months post-treatment).
89399533|NCT02177006||Pediatric clinicians|Pediatricians and nurse practitioners at Lake Forest Pediatric Associates
89002787|NCT06145555|Experimental|Acute psychological sleep stabilization|The basis of the treatment is CBT-I adapted to a short version performed by trained staff (nurses or mental health care assistants), with support from a psychologist. The manuals are designed to be read by patients and staff together and each treatment manual covers a specific topic. The focus of the treatment is behavioral changes and central manuals are stimulus control and scheduled sleep and sleep compression (if needed). Systematic work with light / darkness based on mapping of the patient's circadian rhythm is included.
89002788|NCT06145555|Active Comparator|Sleep hygiene education|The control treatment is delivered through structured manuals which patients work through together with the staff. The manuals cover sleep hindering factors (eg coffee, nicotine), sleep promoting factors (eg physical activity during the day, relaxation, blinds), sleep aids (for example, weight blanket, calm music).
89002789|NCT06139302|Experimental|BI 1015550 low dose|
89002790|NCT06139302|Experimental|BI 1015550 high dose|
89002791|NCT06138119|Experimental|Female anesthesiologists in the experimental group|Stereotype threat manipulation will be performed on the female anesthesiologist in the experimental group just before they are taken into the testing room.
89002792|NCT06138119|No Intervention|Female anesthesiologists in the control group|The female anesthesiologists in the control group will not be given any prior information.
89002793|NCT06138119|Experimental|Male anesthesiologist in the experimental group|Stereotype threat manipulation will be performed on the male anesthesiologist in the experimental group just before they are taken into the testing room.
89002794|NCT06138119|No Intervention|Male anesthesiologist in the control group|The male anesthesiologists in the control group will not be given any prior information.
89002795|NCT06136585|Experimental|2 mg/kg sugammadex|All participants will be given rocuromium for neuromuscular blocks during the procedure. Per randomization, patients in this group will be reversed with 2 mg/kg sugammadex.
89183663|NCT03575221||Enrollees|Individuals with Osteogenesis Imperfecta
89002796|NCT06136585|Active Comparator|0.07 mg/kg neostigmine|All participants will be given rocuromium for neuromuscular blocks during the procedure. Per randomization, patients in this group will be reversed with 0.07 mg/kg neostigmine (to a maximum of 5 mg).
89183664|NCT03555578||Leuprorelin Acetate 11.25 mg|Leuprorelin Acetate Injection Kit 11.25 mg, every 12 weeks subcutaneously, for up to at most 8 years. Participants received interventions as part of routine medical care.
89183665|NCT03525002|Placebo Comparator|FTO SNP rs8050136 (AA), Placebo|Participants with FTO SNP rs8050136 AA receiving matching Placebo
89183666|NCT03525002|Active Comparator|FTO SNP rs8050136 (AA), Bromocriptine|Participants with FTO SNP rs8050136 AAreceiving Bromocriptine up to 5 mg
89183667|NCT03525002|Placebo Comparator|FTO SNP rs8050136 (CA), Placebo|Participants with FTO SNP rs8050136 CA receiving matching Placebo
89183668|NCT03525002|Active Comparator|FTO SNP rs8050136 (CA), Bromocriptine|Participants with FTO SNP rs8050136 CA receiving Bromocriptine up to 5 mg
89183669|NCT03525002|Placebo Comparator|FTO SNP rs8050136 (CC), Placebo|Participants with FTO SNP rs8050136 CC receiving matching Placebo
89183670|NCT03525002|Active Comparator|FTO SNP rs8050136 (CC), Bromocriptine|Participants with FTO SNP rs8050136 CC receiving Bromocriptine up to 5 mg
89183671|NCT03520491|Experimental|Cohort 1|Nivolumab 3 mg/kg on day 1 of each cycle for a total of 5 cycles. Each cycle will be two weeks long and treatment will occur during weeks 0, 2, 4, 6, and 8.
89183672|NCT03520491|Experimental|Cohort 2|Ipilimumab 3 mg/kg and Nivolumab 1 mg/kg on day 1 of each cycle, followed by Nivolumab 3 mg/kg on day 22 of each cycle for a total of 2 cycles. Each cycle will be six weeks long. Ipilimumab and Nivolumab will occur on weeks 0 and 6 while Nivolumab alone will occur on weeks 3 and 9.
89183673|NCT03520491|Experimental|Cohort 3|Ipilimumab 3 mg/kg on day 1 each cycle and Nivolumab 1 mg/kg on day 1 of each cycle for a total of 3 cycles. Each cycle will be three weeks long and treatment will occur during weeks 0, 3, and 6.
89183674|NCT03520491|Experimental|Cohort U (UTUC patients) is independent from Cohorts 1 - 3. ( who are cisplatin-ineligible)|Ipilimumab 3 mg/kg and Nivolumab 1 mg/kg on day 1, of each cycle, followed by Nivolumab 3 mg/kg on day 22 and Ipilimumab 3mg/kg and Nivolumab 1mg/kg on day 45.
89183675|NCT03520400|Experimental|Exercise Intervention Group|Group receives one year of exercise and lifestyle intervention
89183676|NCT03520400|No Intervention|PCI group (usual care)|Group receives standard clinical care with no intervention
89183677|NCT03474965|Experimental|Crizanlizumab|SEG101 (crizanlizumab) administered on Week 1 Day 1, Week3 Day 1 and Day 1 of every 4-week cycle
89183678|NCT03474107|Experimental|Arm A: Enfortumab Vedotin 1.25 mg/kg|Participants received 1.25 milligrams per kilogram (mg/kg) of body weight enfortumab vedotin by intravenous infusion over approximately 30 minutes on days 1, 8 and 15 of every 28-day cycle. Participants received study treatment until radiological disease progression as determined per investigator assessment or other discontinuation criteria were met or upon study termination, or study completion, whichever occurred first.
89183679|NCT03474107|Active Comparator|Arm B: Chemotherapy|Participants received either 75 milligrams per square meter (mg/m^2) docetaxel by IV infusion over approximately 1 hour or 320 mg/m^2 vinflunine by IV infusion over approximately 20 minutes or 175 mg/m^2 paclitaxel by IV infusion over approximately 1 hour on day 1 of every 21-day cycle. Participants received study treatment until radiological disease progression as determined per investigator assessment or other discontinuation criteria were met or upon study termination, or study completion, whichever occurred first.
89183680|NCT03474107|Experimental|Cross-over Extension (COE)|Eligible participants from chemotherapy arm who met the criteria for COE will receive 1.25 mg/kg of body weight enfortumab vedotin by intravenous infusion over approximately 30 minutes on days 1, 8 and 15 of every 28-day cycle until discontinuation criteria is met.
89183681|NCT03446157|Experimental|Open-label, single arm, Phase II|Cetuximab and palbociclib
89183682|NCT03434678|Experimental|Epidural-General Anesthesia|
89183683|NCT03434678|Active Comparator|General Anesthesia|
89183684|NCT03422328|Experimental|Open-label macitentan 10 mg|10 mg macitentan film coated tablet, administered orally once daily
89183685|NCT03421561|Experimental|DCB Subjects|"The Stellarex DCB is a commercially available PTA balloon catheter (EverCross™ 0.035 PTA Balloon Catheter, Medtronic, Plymouth, MN 55441, USA) coated with paclitaxel using a proprietary carrier.~Basic Catheter Specifications~Guidewire: 0.035~Balloon Length: 40/80/120 mm~Sheath Compatibility: greater than or equal to 6 French~Balloon Diameter: 4/5/6 mm~Shaft length: 135 cm The nominal dose density of paclitaxel on the Stellarex DCB is 2.0 μg/mm2. Indications The Stellarex 0.035 OTW Drug-coated Angioplasty Balloon is indicated for percutaneous transluminal angioplasty (PTA), after appropriate vessel preparation, of de novo or restenotic lesions up to 180 mm in length in native superficial femoral or popliteal arteries with reference vessel diameters of 4-6 mm."
89183686|NCT03421561|Placebo Comparator|PTA Subjects|"The control device is a commercially available PTA balloon catheter (EverCross™ 0.035 PTA Balloon Catheter, Medtronic, Plymouth, MN 55441, USA).~Basic Catheter Specifications~Guidewire: 0.035~Balloon Length: 40/80/120 mm~Sheath Compatibility: greater to or equal to 6 French~Balloon Diameter: 4/5/6 mm~Shaft length: 135 cm Indications The EverCross Balloon Catheter is intended to dilate stenosis in the iliac, femoral, ilio-femoral, popliteal, infra-popliteal, and renal arteries, and to treat obstructive lesions of native or synthetic arteriovenous dialysis fistulae. This device is also indicated for stent post-dilation in the peripheral vasculature. For additional information refer to the EverCross Instructions for Use."
89183687|NCT03420508|Experimental|ensartinib|The screening portion of the trial will test archival tumor material for the presence of ALKATI using a Nanostring-based RNA assay for any patients deemed to be current or future candidates for this trial. This will require approximately 5 formalin-fixed paraffin- embedded (FFPE) slides of 5-8 micron thickness. For the treatment portion of the study, all patients will receive ensartinib orally at a dose of 225mg daily.
89183688|NCT03412058|Experimental|Melanoma|Biopsy and blood samples will be collected from patients treated with an antiPD-1 or antiPD-L1 antibody with marketing authorization for the indication, during the course of their treatment
89183689|NCT03412058|Experimental|NSCLC|Biopsy and blood samples will be collected from patients treated with an antiPD-1 or antiPD-L1 antibody with marketing authorization for the indication, during the course of their treatment
89183690|NCT03412058|Experimental|HNSCC|Biopsy and blood samples will be collected from patients treated with an antiPD-1 or antiPD-L1 antibody with marketing authorization for the indication, during the course of their treatment
89382805|NCT03694314|Placebo Comparator|Placebo|The mother and child will both receive a placebo drink to take daily, with no known effect on the brain. The intervention will last 45 days. Assessments will take place at 0 months (baseline), 45 days (end of treatment), and 3 months (1 and a half months post-treatment).
89382806|NCT03694236|Experimental|durvalumab|This study is single arm phase II study to evaluate efficacy and safety of durvalumab and chemoradiotherapy (paclitaxel and carboplatin) in treatment-naïve clinical stage II/IIIa NSCLC.
89382807|NCT04043364|Experimental|LIVE|A multicomponent intervention focusing on Learning, Innovation, Volunteers and Empowerment organized by a local coordinator.
89382808|NCT04043364|No Intervention|Treatment as usual|Care coordination and facilitation as usual.
89382809|NCT03692364|Active Comparator|Metal-on-conventional polyethylene|Uncemented hip arthroplasty (ABG-2, Stryker, Mahwah NJ, US) with a CoCr prosthetic femoral head and an acetabular liner made of intermedially cross-linked polyethylene polyethylene (Duration, Stryker, Mahwah, NJ, US).
89382810|NCT03692364|Experimental|Ceramic-on-ceramic|Uncemented hip arthroplasty (ABG-2, Stryker, Mahwah NJ, US) with a prosthetic femoral head and an acetabular liner made of alumina ceramic (Biolox Forte, Ceramtec, Plochingen, Germany).
89382811|NCT03688152|Experimental|INCB053914 + INCB050465|INCB053914 in combination with INCB050465.
89382812|NCT03692286|Active Comparator|AgNP/Ca(OH)|Patients receiving combined Silver nanoparticle/Calcium hydroxide administered as intracanal medication at the first visit after cleaning and shaping
88855768|NCT04073602|Experimental|RC48-ADC|Participants will be treated with RC48-ADC 2.0 mg/kg, once every 2 weeks (Q2W) until investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or participant's decision to withdraw from therapy, or death (whichever occurs first).
88855769|NCT04060355|Experimental|Savvy Participants|Using an on-line survey method, each caregiver will be asked to complete the post-program fidelity monitoring survey that seeks responses to the program (feel more knowledgeable, more competent, better equipped, etc.) and asks them to assess the interventionist's performance and verify that certain key elements of the program were covered.
88855770|NCT04060355|Experimental|Interventionists|Three recorded semi-structured video interviews will be conducted with each interventionist. One will occur immediately after training; this will focus on their sense of the completeness and adequacy of the training program, including the training methods, videos, and materials, and their perceived readiness to lead the program. Another interview will be done immediately after the conduct of each of the two Savvy programs they lead, asking them to report on their own performance as interventionists, including any adaptation processes in which they might have engaged, and to reflect on ways the training might be improved to strengthen their skills, including for adaptation. In total: 18 interviews.
88855771|NCT04060355|Experimental|Organizational Leaders|Recorded semi-structured video interviews with sponsoring organizations' key contact persons will be conducted immediately after the interventionist training and then after each of two Savvy offerings. The conversation will focus on identifying ways to strengthen and improve the training, certification, and fidelity monitoring system. Information about time and resource costs of the program, caregiver demand, and caregiver recruitment and feedback (3 interviews per organization) will be also collected.
88855772|NCT04060277|Experimental|Arm I (letermovir, Triplex)|Patients receive letermovir per SOC on days 7-100 and multi-peptide CMV-modified vaccinia Ankara vaccine IM on days 100 and 128 post-HCT.
88855773|NCT04060277|Active Comparator|Arm II (letermovir, placebo)|Patients receive letermovir per SOC on days 7-100 and placebo IM on days 100 and 128 post-HCT.
88855774|NCT04043520|Experimental|Postmenopausal: GnRH antagonist + estradiol|"GnRH antagonist is degarelix acetate, 80 mg, delivered twice as a subcutaneous injection (at baseline and after 12 weeks)~Estradiol is a transdermal patch 0.075 mg, applied weekly for 24 weeks"
89382813|NCT03692286|Active Comparator|AgNP|Patients receiving silver nanoparticles in gel form administered as intracanal medication at the first visit after cleaning and shaping
89382814|NCT03692286|Active Comparator|Ca(OH)|Patients receiving calcium hydroxide intracanal medication at the first visit after cleaning and shaping
89382815|NCT05654766||Control group|Group of healthy adult and pediatric participants, whose blood platelets will be used to evaluate normal ranges of parameters in the flow cytometry PFT.
89382816|NCT05654766||Hemorrhagic syndrome and Acute Leukemia|Group of pediatric participants with any manifestations of hemorrhagic syndrome and/or acute leukemia
89382817|NCT03694080|Experimental|Calcium Electroporation treatment|Calcium electroporation for colorectal cancer as a preoperative treatment before elective surgery.
89382818|NCT03624348|Experimental|Meditation Group|Participants in the intervention group will assigned to a digitally-based meditation intervention (Headspace app- Basics + Stress packs) and asked to use this for at least 10 minutes a day over the course of 8 weeks
89382819|NCT03624348|No Intervention|Wait list control group|Waitlist control group participants will continue their normal activities and not add any form of meditation during the study period.
89382820|NCT03990402||Malawi group|500 young people with asthma symptoms in Malawi
88855775|NCT04043520|Experimental|Postmenopausal: GnRH antagonist + placebo|"GnRH antagonist is degarelix acetate, 80 mg, delivered twice as a subcutaneous injection (at baseline and after 12 weeks)~Placebo is a transdermal patch, applied weekly for 24 weeks"
89382821|NCT03990402||South Africa group|500 young people with asthma symptoms in South Africa
89382822|NCT03990402||Uganda group|500 young people with asthma symptoms in Uganda
89382823|NCT03990402||Nigeria|500 young people with asthma symptoms in Nigeria
89382824|NCT03990402||Zimbabwe group|500 young people with asthma symptoms in Zimbabwe
89382825|NCT03990402||Ghana group|500 young people with asthma symptoms in Ghana
88855776|NCT04043520|Placebo Comparator|Postmenopausal: placebo + placebo|"Placebo (1) is normal saline, delivered twice as a subcutaneous injection (at baseline and after 12 weeks)~Placebo (2) is a transdermal patch, applied weekly for 24 weeks"
88855777|NCT04038294|Experimental|Protein Supplementation|The intended intervention consists of a leucine-rich protein-caloric supplement provided by the Enhanced Medical Nutrition®. The product contains 25 g protein and 3 g Leucine per serving (total caloric value: 160 Kcal.) to be re-constituted and consumed twice daily for a minimum of 2 weeks pre-procedure, twice daily during post-operative recovery and 2 times daily for 8 weeks after the patient is discharged home (Appendix A).
89183691|NCT03410875|Experimental|Untreated Hairy Cell Leukemia|Participants with HCL with no prior treatment for the disease
89183692|NCT03401853|Experimental|Arm I (pembrolizumab, rituximab)|"INDUCTION: Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive rituximab IV on days 1, 8, and 15 of cycle 1, and on day 1 of cycle 2.~EXTENDED THERAPY: Patients with at least a partial response receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 3 weeks for up to 2 years (35 cycles) in the absence of disease progression or unacceptable toxicity."
89382826|NCT04059900|Experimental|STW5 (Iberogast®, BAY98-7411)|The medication was applied daily per os (orally, p.o.) from day 0 to day 28. The dosage was 20 drops three times daily before the meals.
89382827|NCT04059900|Placebo Comparator|Placebo|The medication was applied daily p.o. from day 0 to day 28. The dosage was 20 drops three times daily before the meals
89382828|NCT04295148|Active Comparator|Semitendinosus graft|Participants receive the Semitendinosus Graft technique during ACL reconstruction.
89382829|NCT04295148|Active Comparator|Quadriceps tendon-bone graft|Participants receive the Quadriceps Tendon-Bone Graft technique during ACL reconstruction.
89382830|NCT03692130|Active Comparator|New Treatment|"The patients will be treated with psychological group treatment for 8 Sessions with focus on mindfulness, acceptance and commitment in a special adapted treatment process.This will be called Mindfulness, Acceptance and Commitment-Therapy for depressive Patients."
89382831|NCT03692130|Sham Comparator|Known Treatment|"The participants will be treated with a relaxation-treatment, long time established as jacobson muscle relaxing technique."
89382832|NCT04203498|Experimental|Nabiximols|
89382833|NCT04203498|Placebo Comparator|Placebo|
89382834|NCT03691896|Experimental|Lower dose|cholecalciferol 400UNT, oral solution
89382835|NCT03691896|Active Comparator|Middle dose|cholecalciferol 800UNT, oral solution
89382836|NCT03691896|Experimental|Higher dose|cholecalciferol 1200UNT, oral solution,
89382837|NCT03691818|Experimental|Low-dose test drug group|X0002 Spray 1 Spray/time/Knee, 2 times/day; Ibuprofen Placebo Tab 400 mg/time, 3 times /day.
89382838|NCT03691818|Active Comparator|Low-dose active drug control group|Ibuprofen Tablet 400 mg/time, 3 times /day; X0002 Placebo Spray 1 Spray/time/Knee, 2 times/day.
89382839|NCT03691818|Placebo Comparator|Low-dose placebo control group|Placebo Spray 1 Spray/time/Knee, 2 times/day; Ibuprofen Placebo Tab 400 mg/time, 3 times/day.
89382840|NCT03691818|Experimental|Medium-dose test drug group|X0002 Spray 2 Spray/time/Knee, 2 times/day; Ibuprofen Placebo Tab 400 mg/time, 3 times /day.
89382841|NCT03691818|Active Comparator|Medium-dose active drug control group|X0002 Placebo Spray 2 Spray/time/Knee, 2 times/day; Ibuprofen Tablet 400 mg/time, 3 times /day.
89382842|NCT03691818|Placebo Comparator|Medium-dose placebo control group|X0002 Placebo Spray 2 Spray/time/Knee, 2 times/day; Ibuprofen Placebo Tab 400 mg/time, 3 times /day.
89382843|NCT03691818|Experimental|High-dose test drug group|X0002 Spray 4 Spray/time/Knee, 2 times/day; Ibuprofen Placebo Tab 400 mg/time, 3 times /day.
89382844|NCT03691818|Active Comparator|High-dose active drug control group|X0002 Placebo Spray 4 Spray/time/Knee, 2 times/day; Ibuprofen Tablet 400 mg/time, 3 times /day.
89382845|NCT03691818|Placebo Comparator|High-dose placebo control group|X0002 Placebo Spray 4 Spray/time/Knee, 2 times/day; Placebo Tablet 400 mg/time, 3 times /day.
88855778|NCT04038294|Placebo Comparator|Placebo Supplementation|Enrolled patients allocated to the control group will receive the same supplementation schedule as well as compliance verification; however, they will receive a placebo product with no supplemented protein (no nutritional benefit).
88855779|NCT04034056||Obinutuzumab|
88855780|NCT04028687||Taperloc Complete Stems|Patients that have been implanted with a Taperloc Complete Stem to repair hip malfunction/disease.
88855781|NCT04004494|Experimental|3D Reconstruction|Chest contrast-enhanced computed tomography will be performed preoperatively, and 3-dimensional reconstruction will be formed based on the data of chest CT. Video-assisted segmentectomy will be performed guided by the image of 3-dimensional CT. IPS-lung software (Shenzhen Yorktal Digital Medical Imaging Technology Company, Shenzhen, China) will be used preoperatively to construct a 3D-image to ascertain the position and structure of targeted segmental blood vessels and bronchi.
88855782|NCT04004494|No Intervention|Chest computed tomography|Chest contrast-enhanced computed tomography will be performed preoperatively. Video-assisted segmentectomy will be performed based on the image of preoperative chest CT
88855783|NCT04003311||Comprehensive Primary Micro Stem|Patients that have been implanted with the Comprehensive Primary Micro Stem to repair shoulder malfunction/disease.
88855784|NCT04003311||Comprehensive Anatomic Versa-Dial Titanium Humeral Heads|Patients that have been implanted with the Comprehensive Anatomic Versa-Dial Titanium Humeral Heads to repair shoulder malfunction/disease.
88855785|NCT03981055|Experimental|Active tDCS and Active TUS|Active tDCS and Active TUS for 20 min
88855786|NCT03981055|Sham Comparator|Sham TDCS and Sham TUS|Sham TDCS and Sham TUS for 20 min
88855787|NCT03943537|Experimental|Intranasal Insulin (40 IU)|40 IU Novolin-R insulin will be administered one time using the ViaNase intranasal delivery device.
88855788|NCT03935256|Experimental|Full Dose Chemo, Reduced Dose Chemo + RT, Full Dose Chemo|Week 1 : Cycle 1: Full Dose Carboplatin and Paclitaxel Week 4: Pelvic Radiotherapy Begins Cycle 2: Dose reduced Carboplatin and Paclitaxel Week 7 : Cycle 3: Dose reduced Carboplatin and Paclitaxel Weeks 10,13,16: Cycle 4-6: Full Dose Carboplatin and Paclitaxel
88855789|NCT03930914|Other|Active Treatment to Sham|Subjects randomized to the sequence Active Treatment/Sham Treatment arm will be instructed to first use the Parasym (TM) TENS device as active treatment for the first phase of the study. Next, they will be instructed to use the Parasym (TM) TENS device as sham treatment for the second phase of the study.
88855790|NCT03930914|Other|Sham to Active Treatment|Subjects randomized to the sequence Sham Treatment/Active Treatment arm will be instructed to use the Parasym (TM) TENS device as sham treatment for the first phase of the study. Next, they will be instructed to use the Parasym (TM) TENS device as active treatment for the second phase of the study.
88855791|NCT03928717|Experimental|Text-Based Adherence Game|Participants in the experimental condition will receive the Text Based Adherence Game. They will receive semi-automated text messages sent by study staff throughout the trial period.
88855792|NCT03928717|Active Comparator|Standard of Care (SOC)|SOC participants will receive the Standard of Care Intervention which includes receiving a brief adherence counseling session and access to clinic resources, including counseling services, throughout the trial period.
88855793|NCT03923491|Experimental|Healthy Feeding, Healthy Eating|The experimental arm will receive three home over the first three months of the intervention.Visits will be conducted by a community health worker (CHW) trained in Motivational Interviewing. The home visits will include video-feedback on a meal; in-home cooking demonstrations; tailored text-messages, and mailed materials. During the last three months of the intervention, CHW will conduct monthly phone calls, together with mailed materials and text messages. The intervention will be tailored for families based on the child's appetitive traits and eating behaviors.
88855794|NCT03923491|Active Comparator|Reading and Readiness|The Reading and Readiness group will receive information on school readiness promotion. Materials will be adapted and delivered by the community health worker (CHW) with a similar dose and schedule as the intervention group (three home visits and three phone calls). During the home visits, the CHW will show a video that models early childhood caregiver-child activities and demonstrates simple methods to interact with their children. They will also send a video of themselves reading with a child, receive text-messages based on these materials as well as the print materials during the last three months of the intervention.
88855795|NCT03896152|Experimental|LNP023 25 mg bid/100 mg bid|Four weeks of treatment with iptacopan 25 mg bid in Period 1 followed by treatment with 100 mg bid in Period 2 and Period 3.
88855796|NCT03896152|Experimental|LNP023 50 mg bid/200 mg bid|Four weeks of treatment with iptacopan 50 mg bid in Period 1 followed by treatment with 200 mg bid in Period 2 and Period 3.
88855797|NCT03876951|Experimental|vacuum-assisted biopsy|Patients will be submitted to percutaneous vacuum-assisted biopsy (VAB), followed by breast surgery
88855798|NCT03875963|Experimental|Antibiotic loaded bone filler|Patients will undergo irrigation and debridement, surgical stabilization as required, and defect management by placement of antibiotic loaded Stimulan as a bone void filler [calcium sulfate bone void filler (10 cc of STIMULAN(R) Rapid Cure, Biocomposites Ltd, UK) combined with the following antibiotic combination: 1g Vancomycin, 240mg Tobramycin]. The concurrent use of antibiotics is at the discretion of the treating physician.
88855799|NCT03875963|No Intervention|Standard of care|Current standard of care treatment for infected tibial defects or infected tibial nonunions includes treatment with irrigation and debridement, surgical stabilization as required, and defect management as required including placement of a polymethyl methacrylate spacer with or without antibiotics. A second procedure may or may not occur 6-8 weeks later with removal of the cement spacer and bone grafting into the preserved defect. Concurrent use of antibiotics is at the discretion of the treating physician.
88855800|NCT03837353|Experimental|Cohort 1A|In dose-escalation Cohort 1A, the dose of docetaxel 75 mg/m2 will remain fixed. The DKN-01 dose level will start with 300 mg and be escalated to 600 mg or de-escalated to 150 mg depending on the absence or presence of identified DLTs. DKN-01 will be administered in combination with docetaxel on Day 1 and as monotherapy on Day 15 of each 21-day cycle. Patients will be treated with the combination of DKN-01 and Docetaxel until Prostate Cancer Working Group 3 (PCWG3) progression or unacceptable toxicity.
89002797|NCT06136091||Asthma group|Participants ages 6 to 17 year old in the asthma group will be seen in clinic quarterly for one year, during periods of disease control when they are not on systemic corticosteroids (SCS)
89002798|NCT06136091||Non-asthma group|Participants in the non-asthma group will be seen at two scheduled visits in clinic at 3 and 12 months and will have telephone visits at 6 and 9 months
89002799|NCT06132568|Experimental|High Risk PCI Patients|Patients undergoing non-emergent, high-risk percutaneous coronary interventions
89002800|NCT06132113|Experimental|Part A: BI 764532 low dose + carboplatin + etoposide|
89002801|NCT06132113|Experimental|Part A: BI 764532 medium dose + carboplatin + etoposide|
89002802|NCT06132113|Experimental|Part A: BI 764532 high dose + carboplatin + etoposide|
89002803|NCT06132113|Experimental|Part B: BI 764532 + carboplatin + etoposide|
89002804|NCT06132113|Experimental|Part B: BI 764532 + cisplatin + etoposide|
89002805|NCT06129292|Experimental|İntervention (EFT) group|"Personal Information Form, Motherhood Blues Scale and Breastfeeding Self-Efficacy Scale will be applied for pre-test to women who meet our study criteria.~To EFT Group; After the first tests are done, the 1st EFT session will be held, the 2nd EFT session will be held 10 days later, and the final tests will be done 10 days later. During this period, affirmations will be given depending on the need. Each session is planned to last an average of 45 minutes - 1 hour, and duration and affirmations will be arranged according to the woman's individual difficulties, perspective, support systems, past traumas and emotional blockages.~Procedure 1: Preliminary tests will be carried out and then the 1st EFT session will be held.~2nd Procedure: After 10 days, the first final tests will be performed and then the second EFT session will be held."
89002806|NCT06129292|No Intervention|Control group|Personal information form, Motherhood Blues Scale and Breastfeeding Self-Efficacy Scale will be applied for pre-test to women who meet our study criteria. After 10 days, the motherhood blues scale and breastfeeding self-efficacy scale will be administered again for the final test.
89002807|NCT06128759|Experimental|Maryam's Flower Group|Maryam's flower will place in a bowl of water and left in the room of the pregnant women who will at 1 cm cervical dilatation and in the first phase of the labor. It will explain to the pregnant women that the leaves of the plant would open up in the water, and they will ask to imagine that the birth canal would simultaneously open up. In effect, they will told to focus on the opening of these leaves during the course of the labor.. After birth, the flower used only as a focusing method will be removed from the water and its water will be poured.
89002808|NCT06128759|No Intervention|control group|will provided with standard midwifery care.
89002809|NCT06128655|No Intervention|CONTROL GROUP: survey and Standard Care (SC) or no NURSE-TECH-Family during PFCC-IR participation|15 family members
89002810|NCT06128655|Experimental|EXPERIMENTAL GROUP: participation in NURSE-TECH-Family during PFCC-IR|15 family members
89002811|NCT06127199|Experimental|Ovaprene|
89002812|NCT06122961||Atherosclerotic cardiovascular disease (ASCVD) with chronic kidney disease (CKD)|electronic case report form (eGFR) below 60 ml/min/1.73m^2
89002813|NCT06122961||ASCVD without CKD|eGFR greater than or equal to 60 ml/min/1.73m^2
89002814|NCT06122961||HF with preserved ejection fraction (HFpEF) or HF with mildly reduced ejection fraction (HFmrEF)|
89002815|NCT06122961||Heart failure (HF) with reduced ejection fraction (HFrEF)|
89002816|NCT06122389|Experimental|Treatment group A|
89002817|NCT06122389|Experimental|Treatment group B|
89002818|NCT06120205|Other|Self-Collection / Clinician Collection|Patient serves as own comparator/control in this method comparison study where the investigational intervention is use of the self-collect device and the comparator is the standard of care clinician collection.
89002819|NCT06117501|Other|First Revision Cubital Tunnel with application of Axoguard HA+ Nerve Protector|Single group assignment. Patients will receive the Axoguard HA+ Nerve Protector™ in their first revision cubital tunnel surgery.
89002820|NCT06112860|Other|OTC Hearing Aid First|Participants will be provided a pair of OTC hearing aids (experimental) with typical directions and use for 4 weeks before outcome measures will be assessed. After which, participants will then receive the communication strategies information/counseling (control) and have outcome measures assessed after 4 weeks.
89002821|NCT06112860|Other|Communication Strategies First|Participants will receive the communication strategies information/counseling intervention (control) first. Outcome measures will be assessed at 4 weeks. After which, participants will then be given a pair of OTC hearing aids (experimental) with typical directions and use for four weeks before having outcome measures assessed.
89002822|NCT06108947|Active Comparator|Aspirin|Aspirin 150 mg per day from pregnancy week 12 to 36 - according to current recommendations
89002823|NCT06108947|Experimental|Aspirin discontinuation|Discontinuation of Aspirin around 24-28 weeks in low risk women
89002824|NCT06107036|Experimental|Treatment 1 (L - low)|Treatment with low dose BI 1015550
89002825|NCT06107036|Experimental|Treatment 2 (H - high)|High dose treatment with BI 1015550
89002826|NCT06107036|Active Comparator|Treatment 3 (M - moxifloxacin)|Treatment with moxifloxacin
89002827|NCT06107036|Placebo Comparator|Treatment 4 (P1 and P2 - placebo)|Treatment with placebo matching BI 105550 in two different periods: P1 and P2
89002828|NCT06105268|Experimental|flipped learning group|In addition to the traditional theory training to be given within the scope of the study, two hours of video-supported shoulder dystocia training will be given using the university's corporate Microsoft teams program, one day before the simulation application. The videos used in the training consist of previously shot training videos. There is no copyright or legal problem in using the videos.
89002829|NCT06105268|No Intervention|routine training group- control group|The control group will be given shoulder dystocia theory training before the simulation training within the routine course protocol within the scope of the routine risky birth and postpartum period course.
89382846|NCT03687840|Other|Study Group|Spatio-Temporal gait analysis of subjects with unilateral lower extremity burn injuries due to diabetic polyneuropathy.
89382847|NCT03687840|Other|Control Group|Spatio-Temporal gait analysis of subjects with only diabetic polyneuropathy.
89382848|NCT03687606|Active Comparator|Human Chorionic Gonadotropin alone|Human Chorionic Gonadotropin 2000U~6000U, intramuscular injection, two times per week for 3 years.
89382849|NCT03687606|Experimental|hCG alone for 6 months then hMG added|Human Chorionic Gonadotropin 2000U~6000U, intramuscular injection, two times per week for six months, then 75~150IU human menopausal gonadotropin, intramuscular injection, two times per week, was added and last for the next 30 months.
89382850|NCT03687606|Experimental|hCG and hMG|Human Chorionic Gonadotropin 2000U~6000U and 75~150IU human menopausal gonadotropin, intramuscular injection, two times per week for 3 years.
89382851|NCT03691740|Experimental|Experimental|Ocular light will be applied via a mask. The participants allocated to the experimental group will receive blue light
88855801|NCT03837353|Experimental|Cohort 1B|In dose-expansion Cohort 1B, either the maximum tolerated dose (MTD) or highest dose tested of DKN-01 in combination with docetaxel in Cohort 1A will be the dose used. The dose of docetaxel 75 mg/m2 will remain fixed. DKN-01 will be administered in combination with docetaxel on Day 1 and as monotherapy on Day 15 of each 21-day cycle. Patients will be treated with the combination of DKN-01 and Docetaxel until PCWG3 progression or unacceptable toxicity.
88855802|NCT03837353|Experimental|Cohort 2A|In dose-escalation Cohort 2A, DKN-01 dose level will start with 300 mg and be escalated to 600 mg or de-escalated to 150 mg depending on the absence or presence of identified DLTs. DKN-01 will be administered as monotherapy on Days 1 and 15 of each 28-day cycle. Patients will be treated with DKN-01 until PCWG3 progression or unacceptable toxicity.
88855803|NCT03837353|Experimental|Cohort 2B|In dose-expansion Cohort 2B, the MTD or highest dose tested of DKN-01 monotherapy in Cohort 2A will be the dose used. DKN-01 will be administered as monotherapy on Days 1 and 15 of each 28-day cycle. Patients will be treated with DKN-01 until PCWG3 progression or unacceptable toxicity.
88855804|NCT03832010|Active Comparator|Crisaborole|Participants will be instructed to apply emollient, topical steroid, and or crisaborole (blinded) to affected areas with eczema.
88855805|NCT03832010|Placebo Comparator|Vehicle|Participants will be instructed to apply emollient, topical steroid, and or vehicle (blinded) to affected areas with eczema.
88855806|NCT03832010|Sham Comparator|Control|Participants will be instructed to apply emollient, topical steroid, and or emollient (blinded) to affected areas with eczema.
88855807|NCT03812393|Experimental|Treatment|TNBC patients with HER2 signal positive are treated with neratinib for 3 weeks followed by 12 weeks of neratinib in combination with weekly paclitaxel and carboplatin
88855808|NCT03806439||Patients undergoing radical cystectomy.|After approval of local ethical committee and patient consent, the study will be done on patients undergoing radical cystectomy surgery in Alexandria University hospitals from January 5th 2019 till January 4th 2020. The 6-item Cognitive Impairment Test (6CIT) and SPMSQ questionnaire will be used. SPMSQ will be done preoperative and daily for 3 days postoperative, at day 7. Phone call for SPMSQ will be done 3, 6, 9 and 12 months after surgery.
88855809|NCT03806413||Open heart surgery|The study will be done on patients undergoing open heart surgery in Alexandria University hospitals from January 5th 2019 till January 4th 2020. The 6-item Cognitive Impairment Test (6CIT) and SPMSQ questionnaire will be used. SPMSQ will be done preoperative and daily for 3 days postoperative, at day 7. Phone call for SPMSQ will be done 3, 6 9 and 12 months after surgery.
88855810|NCT03794583|Experimental|Inhaled Treprostinil Solution|Inhaled treprostinil solution (0.6 milligrams per milliliter [mg/mL], 6 mcg/breath) QID during waking hours.
88855811|NCT03781011|Experimental|Vegetarian diet intervention|Patients identified as high-TMAO producers through the oral carnitine challenge test will be invited to participate in a two-month vegetarian diet intervention, supervised by a registered dietitian.
88855812|NCT03774732|Experimental|Pembrolizumab+ Chemotherapy + Radiotherapy|"In the experimental arm, patients will receive the same treatment as the control arm (chemotherapy plus pembrolizumab) in addition with conformal 3D radiotherapy (3D-CRT) or stereotactic ablative radiotherapy (SABR) that will be delivered at C2D1, 21 days after the beginning of pembrolizumab using photons/electrons with standard field encompassing tumour.~Irradiation technique (3D-CRT or SABR) will be at physician discretion. Ideally, oligometastatic patient (defined by the presence of less than 6 metastases) should be treated with SABR and those with non-oligometastatic disease should be treated with 3D-CRT.~Radiotherapy will be delivered a dose of at least 18 Gy in 3 X 6 Gy for 3D-CRT (cf. protocol for possible schemes and volumes restriction).~Irradiated tumor size will be ≤5 cm (GTV <65 mL sphere); partial tumor irradiation should be delivered if larger tumor size while respecting dose constraints."
88855813|NCT03774732|Active Comparator|Pembrolizumab+ Chemotherapy|"Squamous-cell lung carcinoma:~Pembrolizumab every 3 weeks and carboplatin + paclitaxel or nab paclitaxel every 3 weeks for 4 cycles then pembrolizumab every 3 or 6 weeks (according to the current version of the SmPC )~Non squamous-cell lung carcinoma:~Pembrolizumab every 3 weeks and carboplatin or cisplatin + pemetrexed every 3 weeks for 4 cycles, and then pemetrexed plus pembrolizumab every 3 weeks (according to the current version of the SmPC)~Pembrolizumab treatment may be continued as long as patient is experiencing clinical benefit, as assessed by an investigator, in the absence of unacceptable toxicity or symptomatic deterioration attributed to disease progression after an integrated assessment of radiographic data, biopsy results (if available) and clinical status."
89382852|NCT03691740|Placebo Comparator|Control|Ocular light will be applied via a mask. The participants allocated to the control group will receive red light
89002832|NCT06097260|Experimental|Placebo|Placebo
89382853|NCT04059978|Active Comparator|CBD + Remifentanil|CBD 1600 mg p.o. + Remifentanil 0.1 µg/kg/min i.v. for 30 min
89382854|NCT04059978|Placebo Comparator|Placebo + Remifentanil|Placebo p.o + Remifentanil 0.1 µg/kg/min i.v. for 30 min
89382855|NCT03199963|Experimental|BHR-700 (0.2% 4-OHT gel)|The gel formulation contains 2 mg/mL 4-OH tamoxifen (0.2%) in a clear, colorless, absorptive hydro-alcoholic gel base formulated to provide continuous release of 4-OH tamoxifen. A total of 8 mg/day (4 mg/breast) of 4-OH tamoxifen will be administered daily for 52 weeks.
89382856|NCT03199963|Placebo Comparator|Matching Placebo Gel|An absorptive hydroalcoholic gel preparation of the same ingredients as BHR-700, but without 4-OHT.
89382857|NCT04547257|Experimental|Treatment|Extracorporeal therapy with Seraph 100 blood filter
89382858|NCT04547257|No Intervention|Control|patients receive antibiotics only as standard of care
89382859|NCT03636685|Experimental|Non-squamous cell lung cancer|"Anlotinib combined with pemetrexed and carboplatin, phase I~Anlotinib combined with pemetrexed and carboplatin, phase II"
89382860|NCT03636685|Experimental|Squamous cell lung cancer|"Anlotinib combined with paclitaxel and carboplatin, phase I~Anlotinib combined with paclitaxel and carboplatin, phase II"
89382861|NCT03788941||LAAC plus Catheter ablation|Patients will receive both left atrial appendage closure and catheter ablation of atrial fibrillation for treatment.
89382862|NCT03883581|Experimental|ALS individuals with bulbar dysfunction|Participants enrolled in this group will be prescribed dextromethorphan HBr and quinidine sulfate (Nuedexta) as recommended by their treating neurologist. 20 mg dextromethorphan HBr and 10mg quinidine sulfate will be administered orally with 1 capsule every day for the initial 7 days followed by 1 capsule every 12 hours for the remaining 23 days of the study. Participants will be evaluated 30 days apart to determine the impact of treatment.
89382863|NCT03824535|Experimental|Diagnostic (18F-FSPG PET/CT, 18F-FDG PET/CT)|Patients receive 18F-FSPG IV and, undergo a PET/CT scan over 30-60 minutes. Within 24 hours-14 days, patients receive 18F-FDG IV and undergo a second PET/CT scan over 30-60 minutes.
89382864|NCT03113643|Experimental|SL-401+ Azacitidine|SL-401 will be administered every 4 weeks, on a 28 day cycle; SL-401 will be given intravenously; Azacitidine will be administered every 4 weeks, on a 28 day cycle; Azacitidine will be given intravenously or subcutaneously
89183693|NCT03401853|Experimental|Arm II (pembrolizumab, obinutuzumab)|"INDUCTION: Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive obinutuzumab IV on days 1, 8, and 15 of cycle 1, and on day 1 of cycle 2.~EXTENDED THERAPY: Patients with at least a partial response receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 3 weeks for up to 2 years (35 cycles) in the absence of disease progression or unacceptable toxicity. Patients with stable disease or better, who are experiencing clinical benefit in the judgment of the investigator, may receive obinutuzumab IV on day 1 of cycles 5, 9, 13, 17, 21, and 25."
89183694|NCT03384641|Experimental|Bedaquiline|Participants will receive bedaquiline 200 (milligram) mg (2*100 mg tablets) once daily for 2 weeks followed by 100 mg tablet three times a week (tiw) for 6 weeks with at least 48 hours between doses.
88818534|NCT05280041|Experimental|Self-tailored - SOLENA-ST|In the self-tailored arm participants will be asked to complete most of the study modules of the intervention (CBT intervention itself) in a flexible format, according to their own needs at each moment. Participants will be asked to start the intervention by completing the preparatory modules (modules 1 and 2) following a fixed order. After completion of module 2, all the remaining modules become available at the same time. At the beginning and at the end of each module, participants are invited to reflect on their own needs and to complete the modules that better meet them.
88855814|NCT03759366|Experimental|Eculizumab Intravenous (IV) Infusion|"In the Primary Evaluation Treatment Period (26 weeks), eculizumab will be administered weekly during the initial induction phase and every 2 weeks during the maintenance phase.~In the Extension Period (up to 208 weeks), participants will continue to receive eculizumab every 2 weeks.~Eculizumab will be administered at doses of 300, 600, 900, or 1200 milligrams (mg), based on the participant's current body weight."
88855815|NCT03741374|Experimental|Minimally-invasive non-surgical therapy|Intrabony defects treated with Minimally-invasive non-surgical therapy (MINST)
88855816|NCT03740997|Experimental|Patients with body weight ≥20 to ≤28 kg|In children weighing ≥20 to ≤28 kg, 0.1 or 0.2 mL of OPTISON per injection will be given in ascending order. The cumulative dose will not exceed 1.0 mL.
88855817|NCT03740997|Experimental|Patients with body weight >28 to ≤40 kg|If children weigh >28-≤40 kg, 0.2 or 0.3 mL of OPTISON per injection will be administered in ascending order with total dose not to exceed 1.5 mL.
88855818|NCT03740997|Experimental|Patients with body weight >40 kg|For children whose weight is >40 kg, 0.2 or 0.4 mL of OPTISON per injection will be administered in ascending order with total dose not to exceed 1.8 mL.
88855819|NCT03738904|Experimental|Arm 1 (multimodal ERAS)|"Arm1 (Multimodal ERAS):~Preoperative:~oral gabapentin 600mg and oral acetaminophen 1,000mg~Postoperative pain control:~Gabapentin oral 300 mg TID (#42, refill #1)~Acetaminophen oral 1000mg TID (#42, refill #1)~Ketorolac oral 10 mg TID (#15, refill #0)~Oxycodone oral 5 mg PRN every 6 hours (#30, refill #0)~Postoperative laxative regimen:~Daily MiraLAX 1 scoop in 1 glass of water for 15 days~Daily milk of magnesia 1 tablespoon if no bowel movement by POD2 until regular bowel movements~Daily mineral oil 1 table spoon if no bowel movement by POD2 until regular bowel movements"
88855820|NCT03738904|Active Comparator|Arm 2 (control)|"Postoperative pain control:~Oxycodone oral 5 mg PRN every 6 hours (#30, refill #0)~Patients will be allowed to take oral acetaminophen and ibuprofen over the counter if needed but active narcotic-sparing pain management regimen will not be implemented~Postoperative laxative regimen:~Daily MiraLAX 1 scoop in 1 glass of water for 15 days~Daily milk of magnesia 1 tablespoon if no bowel movement by POD2 until regular bowel movements Daily mineral oil 1 table spoon if no bowel movement by POD2 until regu-lar bowel movements"
88855821|NCT03725059|Experimental|Pembrolizumab+Chemotherapy (KX/KA[E]C)|In the neoadjuvant setting, participants receive pembrolizumab (K) 200 mg via intravenous (IV) infusion once every 3 weeks (Q3W) + paclitaxel (X) 80 mg/m^2 via IV infusion once weekly (QW) for 4 cycles (Treatment 1), followed by pembrolizumab 200 mg via IV infusion + doxorubicin or epirubicin (A or E; 60 mg/m^2 or 100 mg/m^2) via IV infusion either in Q2W or Q3W + cyclophosphamide (C) 600 mg/m^2 via IV infusion either in Q2W or Q3W for 4 cycles (Treatment 2). At no more than 6 weeks after last cycle of neoadjuvant treatment, participants will undergo surgery for their breast cancer. After surgery, participants will begin adjuvant study treatment. In the adjuvant setting, participants receive pembrolizumab 200 mg via IV infusion Q3W for 9 cycles + variable endocrine therapy for up to 10 years. Each cycle is 21 days long.
88855822|NCT03725059|Placebo Comparator|Placebo+Chemotherapy (PX/PA[E]C)|In the neoadjuvant setting, participants receive placebo (P; normal saline or dextrose) via IV infusion Q3W + paclitaxel (X) 80 mg/m^2 via IV infusion once weekly (QW) for 4 cycles (Treatment 1), followed by placebo via IV infusion + doxorubicin or epirubicin (A or E; 60 mg/m^2 or 100 mg/m^2) via IV infusion either in Q2W or Q3W + cyclophosphamide (C) 600 mg/m^2 via IV infusion either in Q2W or Q3W for 4 cycles (Treatment 2). At no more than 6 weeks after last cycle of neoadjuvant treatment, participants will undergo surgery for their breast cancer. After surgery, participants will begin adjuvant study treatment. In the adjuvant setting, participants receive placebo via IV infusion Q3W for 9 cycles + variable endocrine therapy for up to 10 years. Each cycle is 21 days long.
88855823|NCT03705676|Active Comparator|Healthy controls - control condition|Assesses EMG and EEG activity of healthy controls during a rapid arm task after a warning and go cue. No painful stimuli are administered, only non-painful vibrotactile stimuli.
88855824|NCT03705676|Experimental|Healthy controls - fear condition|Assesses EMG and EEG activity of healthy controls during a rapid arm task after a warning and go cue. Half of the trials are no threat trials, the other half are threat trials. A painful stimulus is administered during arm movement in 25% of the threat trials in order to evoke anticipation of pain during the 75% other threat trials.
88855825|NCT03705676|Active Comparator|RLBP - control condition|Assesses EMG and EEG activity of RLBP subjects during a rapid arm task after a warning and go cue. No painful stimuli are administered, only non-painful vibrotactile stimuli.
88855826|NCT03705676|Experimental|RLBP - fear condition|Assesses EMG and EEG activity of RLBP subjects during a rapid arm task after a warning and go cue. Half of the trials are no threat trials, the other half are threat trials. A painful stimulus is administered during arm movement in 25% of the threat trials in order to evoke anticipation of pain during the 75% other threat trials.
88855827|NCT03705676|Active Comparator|CLBP - control condition|Assesses EMG and EEG activity of CLBP subjects during a rapid arm task after a warning and go cue. No painful stimuli are administered, only non-painful vibrotactile stimuli.
88855828|NCT03705676|Experimental|CLBP - fear condition|Assesses EMG and EEG activity of CLBP subjects during a rapid arm task after a warning and go cue. Half of the trials are no threat trials, the other half are threat trials. A painful stimulus is administered during arm movement in 25% of the threat trials in order to evoke anticipation of pain during the 75% other threat trials.
88855829|NCT03695237|Experimental|Leuprolide Acetate (LA)|Participants received leuprolide acetate (LA) 45 mg every 6 months administered as an intramuscular injection for up to 144 weeks.
88855830|NCT03665597|Experimental|Pembrolizumab Sequence 1|Participants receive a single dose of pembrolizumab (pembro) in each 21-day cycle in the following sequence: Cycle 1 Day 1: pembro Dose A subcutaneously (SC); Cycle 2 Day 1: pembro Dose B intravenously (IV); Cycle 3 Day 1: pembro Dose C SC; Cycle 4 Day 1 and every cycle thereafter (up to a total of 35 cycles) Day 1: pembro Dose B IV.
88855831|NCT03665597|Experimental|Pembrolizumab Sequence 2|Participants receive a single dose of pembro in each 21-day cycle in the following sequence: Cycle 1 Day 1: pembro Dose A SC; Cycle 2 Day 1: pembro Dose C SC; Cycle 3 Day 1: pembro Dose B IV; Cycle 4 Day 1 and every cycle thereafter (up to a total of 35 cycles) Day 1: pembro Dose B IV.
88855832|NCT03665597|Experimental|Pembrolizumab Sequence 3|Participants receive a single dose of pembro in each 21-day cycle in the following sequence: Cycle 1 Day 1: pembro Dose C SC; Cycle 2 Day 1: pembro Dose A SC; Cycle 3 Day 1: pembro Dose B IV; Cycle 4 Day 1 and every cycle thereafter (up to a total of 35 cycles) Day 1: pembro Dose B IV.
88855833|NCT03665597|Experimental|Pembrolizumab Sequence 4|Participants receive a single dose of pembro in each 21-day cycle in the following sequence: Cycle 1 Day 1: pembro Dose C SC; Cycle 2 Day 1: pembro Dose B IV; Cycle 3 Day 1: pembro Dose A SC; Cycle 4 Day 1 and every cycle thereafter (up to a total of 35 cycles) Day 1: pembro Dose B IV.
88855834|NCT03665597|Experimental|Pembrolizumab Sequence 5|Participants receive a single dose of pembro in each 21-day cycle in the following sequence: Cycle 1 Day 1: pembro Dose B IV; Cycle 2 Day 1: pembro Dose C SC; Cycle 3 Day 1: pembro Dose A SC: Cycle 4 Day 1 and every cycle thereafter (up to a total of 35 cycles) Day 1: pembro Dose B IV.
88855835|NCT03665597|Experimental|Pembrolizumab Sequence 6|Participants receive a single dose of pembro in each 21-day cycle in the following sequence: Cycle 1 Day 1: pembro Dose B IV; Cycle 2 Day 1: pembro Dose A SC; Cycle 3 Day 1: pembro Dose C SC; Cycle 4 Day 1 and every cycle thereafter (up to a total of 35 cycles) Day 1: pembro Dose B IV.
88855836|NCT03665597|Experimental|Pembrolizumab Dose D|Participants receive a single dose of pembro Dose D IV on Day 1 of each 42-day cycle (every 6 weeks; Q6W) for up to 18 cycles (up to approximately 2 years).
88855837|NCT03654573|Experimental|STEMI patients|Adult subjects presenting with STEMI in the LAD undergoing PPCI
88855838|NCT03633708|Experimental|Etelcalcetide|Randomized in a 3:1 ratio to receive etelcalcetide in addition to standard of care
88855839|NCT03633708|Active Comparator|Control|Randomized in a 3:1 ratio to receive etelcalcetide in addition standard of care alone (control arm)
88855840|NCT03631693|Active Comparator|Simplified papilla preservation flap|PERIODONTAL SURGICAL INTERVENTION:The first arm is the simplified papilla preservation flap (SPPF) surgery.At visit 3, the SPPF surgery is performed. 2D and 3D imaging on surgical site will be carried out pre and post surgery. 2D and 3D imaging performed on surgical site for all post operative visits.
88855841|NCT03631693|Active Comparator|Resective flap with osseous recontouring|PERIODONTAL SURGICAL INTERVENTION: The second arm is the Resective periodontal flap with osseous recontouring (RPFO). At visit 3, the RPFO surgery is performed. 2D and 3D imaging on surgical site will be carried out pre and post surgery. 2D and 3D imaging performed on surgical site for all post operative visits.
88855842|NCT03607656|Experimental|TCM combines CapOX/SOX/S-1+D/FLOT|"Traditional Chinese Medicine oral taken twice a day for at least 3 months combined with chemotherapy.~The chemotherapy can choose intravenous oxaliplatin 130 mg/m(2) on day 1 plus oral capecitabine 1000 mg/m(2) twice daily on days 1-14, every 21 days; or intravenous oxaliplatin 100 mg/m(2) on day 1 plus oral S-1 40mg/m(2) twice daily on days 1-14, every 21 days; or intravenous docetaxel 40mg/m(2) on day 1 plus oral S-1 40mg/m(2) twice daily on days 1-14, every 21 days; or intravenous docetaxel 50mg/m(2) on day 1 plus intravenous oxaliplatin 85 mg/m(2) on day 1 plus 5-FU intravenously CIV24h on day 1, every 14 days; Each participant shoud take eight (8) cycles of chemotherapy."
88855843|NCT03607656|Active Comparator|CapOX/SOX/S-1+D/FLOT|The chemotherapy can choose intravenous oxaliplatin 130 mg/m(2) on day 1 plus oral capecitabine 1000 mg/m(2) twice daily on days 1-14, every 21 days; or intravenous oxaliplatin 100 mg/m(2) on day 1 plus oral S-1 40mg/m(2) twice daily on days 1-14, every 21 days; or intravenous docetaxel 40mg/m(2) on day 1 plus oral S-1 40mg/m(2) twice daily on days 1-14, every 21 days; or intravenous docetaxel 50mg/m(2) on day 1 plus intravenous oxaliplatin 85 mg/m(2) on day 1 plus 5-FU intravenously CIV24h on day 1, every 14 days; Each participant shoud take eight (8) cycles of chemotherapy.
88855844|NCT03603600|Experimental|enVista MX60EF|enVista MX60EF (trifocal) multifocal IOL (MIOL)
89183695|NCT03376581|Experimental|Prospective treatment|
88855845|NCT03603600|Active Comparator|enVista MX60E|enVista MX60E monofocal IOL
88855846|NCT03598465||PHLF Group|The investigators will define PHLF as a postoperatively acquired deterioration in synthetic, excretory, and detoxifying functions of liver. According to the PHLF definition and grading criteria established by International Liver Group of Liver Surgery (ISGLS) in 2011 (Surgery,2011,149(5):713-724), PHLF will be diagnosed by an increased PT-INR and concomitant hyperbilirubinemia on or after postoperative day 5.
88855847|NCT03598465||Non-PHLF Group|Non-PHLF will be defined as normal liver function in terms of normal PT-INR and bilirubin levels after hepatectomy on or after postoperative day 5.
88855848|NCT03586609|Experimental|Treatment (cladribine, cytarabine, venetoclax, azacitidine)|See Detailed Description.
88855849|NCT03584815|Active Comparator|Surgery/fasciotomy|"Fasciotomy of the anterior and lateral compartments in the lower legs:~Two linear longitudinal skin incisions, each approximately 4 cm, are made allowing for excision of the fascia in full length. Sharp dissection to the level of the subcutaneous tissues down to the layer of the overlying fascia is performed, and using a finger or blunt instrument, the subcutaneous tissue is swept away from the fascia, so that an unobstructed cut of the fascia can be performed. The fascia overlying the anterior and lateral compartment is meticulously dissected under direct visualization, the fascia is released approximately as far proximal and distal as the muscle belly is. The perimysium is spared."
88855850|NCT03584815|Active Comparator|Physiotherapy|"Change the running pattern to decrease load on the affected muscles of the lower leg including the eccentric work performed by the tibialis anterior during the rear-foot strike.~Strengthen the major muscles of all lower leg compartments in order address any muscular imbalance/instability around the ankle joint, and to strengthen the main muscle groups responsible for alignment of the hip and knee."
88855851|NCT03584373|Experimental|Non-Opioid Analgesia|"Ketorolac - Oral; 10 mg tablet: 1 tablet every 6 hours, or as needed. (20 tablets prescribed).~Acetaminophen - Oral; patient directed as needed. Not prescribed.~Ketorolac and Acetaminophen administered post surgery to compare pain outcomes to that of Percocet."
88855852|NCT03584373|Active Comparator|Opioid Analgesia|"Percocet - Oral; 5 mg tablet: 1 tablet every 4-6 hours, or as needed. (10 tablets prescribed).~Percocet administered post surgery to compare pain outcomes to that of the non-opioid analgesia."
88855853|NCT03582124|Experimental|Diagnostic (panitumumab-IRDye800, surgery, NIR)|Participants receive panitumumab- IRDye800 IV over 60 minutes on day 0, and then undergo NIR and surgery within 1-5 days.
88855854|NCT03576391|Experimental|Control condition|Control condition to assess whether the repetition of a RAM task without fatiguing task in between 2 repetitions affects trunk motor control and cortical movement preparation.
88855855|NCT03576391|Experimental|Physical Fatigue condition|Fatigue condition to assess whether a physical fatiguing task in between 2 RAM tasks affects trunk motor control and cortical movement preparation for the 2nd RAM.
89183696|NCT03362177|Experimental|Romiplostim|The study in a 2:1 randomization ratio(108 subjects to romiplostim). Amgen investigational product (romiplostim or placebo) will be administered in the clinic by a qualified healthcare provider as a subcutaneous injection.
89183697|NCT03362177|Placebo Comparator|Placebo|The study in a 2:1 randomization ratio (54 subjects to placebo) Amgen investigational product (romiplostim or placebo) will be administered in the clinic by a qualified healthcare provider as a subcutaneous injection.
89183698|NCT03345173|Experimental|CI-581a|"CI-581a will be administered during the washout phase when participants are experiencing moderate withdrawal, as well as the following day when the naltrexone titration is initiated.~(0.11 mg/kg 2-min bolus followed by 1.3 mg/kg over 90 min)"
89183699|NCT03345173|Placebo Comparator|CI-581b|"CI-581b will be administered during the washout phase when participants are experiencing moderate withdrawal, as well as the following day when the naltrexone titration is initiated.~(2-min saline bolus followed by 0.0125 mg/kg over 90 min)"
89183700|NCT03333343|Experimental|Arm 1|EGF816+ trametinib in escalation phase
89183701|NCT03333343|Experimental|Arm 2|EGF816 + ribociclib in escalation phase
89183702|NCT03333343|Experimental|Arm 3|EGF816 + LXH254 in escalation phase
89183703|NCT03333343|Experimental|Arm A|EGF816 + INC280 in expansion phase (patients with no known resistance mechanism)
89183704|NCT03333343|Experimental|Arm B|EGF816 + trametinib in expansion phase
89183705|NCT03333343|Experimental|Arm C|EGF816 + ribociclib in expansion phase
89183706|NCT03333343|Experimental|Arm D|EGF816 + LXH254 in expansion phase (patients with no known resistance mechanism)
89183707|NCT03333343|Experimental|Arm E|EGF816 + LXH254 in expansion phase (patients with known resistance mechanism)
89183708|NCT03333343|Experimental|Arm F|EGF816 + gefitinib in expansion phase
89183709|NCT03333343|Experimental|Arm G|EGF816 + INC280 in expansion phase (patients with known resistance mechanism)
89183710|NCT03306927|Experimental|Whole yellow pea|Chili containing 25g available carbohydrate from whole yellow peas. Intervention: Whole yellow pea chili
89183711|NCT03306927|Experimental|Split yellow pea|Chili containing 25g available carbohydrate from split yellow peas. Intervention: Split yellow pea chili
89183712|NCT03306927|Placebo Comparator|Rice-PPGR|Chili containing 25g available carbohydrate from long grain white rice. Intervention: Rice chili
89183713|NCT03306927|Placebo Comparator|Rice-Satiety|Rice chili with the same calories as the pea chili. Intervention: Rice chili
89183714|NCT03306862|Experimental|Whole yellow pea|Soup containing 25g available carbohydrates from whole yellow peas. Intervention: Whole yellow pea soup
89183715|NCT03306862|Experimental|Split yellow pea|Soup containing 25g available carbohydrates from split yellow peas. Intervention: Split yellow pea soup
89183716|NCT03306862|Placebo Comparator|Potato|Soup containing 25g available carbohydrates from potatoes. Intervention: Potato soup
89183717|NCT03306706|Experimental|whole yellow pea|2 muffins containing 25g available carbohydrate from whole yellow peas. Intervention: Whole pea muffins
89183718|NCT03306706|Experimental|split yellow pea|2 muffins containing 25g available carbohydrate from split yellow peas. Intervention: Split pea muffins
89183719|NCT03306706|Placebo Comparator|wheat-PPGR|2 muffins containing 25g available carbohydrate from wheat flour. Intervention: Wheat muffins
88855856|NCT03576391|Experimental|Cognitive Fatigue condition|Fatigue condition to assess whether a cognitive fatiguing task in between 2 RAM tasks affects trunk motor control and cortical movement preparation for the 2nd RAM.
89183720|NCT03306706|Placebo Comparator|wheat-satiety|"2 muffins containing wheat flour to match the calories in the whole and split pea muffins.~Intervention: Wheat muffins"
89183721|NCT03299231|Active Comparator|Aerobika|Group of participants with COPD, hospitalized for severe exacerbation and using the active oscillating positive expiratory pressure device (OPEP). The device is a hand held one. Used mostly in subjects with bronchiectasis for mucus clearing. Estimated number of subjects in this arm is 80. The device has an adjustable resistance which will be set by a health care provider in the study team. The device is to be used three times daily from 10 to 20 minutes according to subject's effort.
89183722|NCT03299231|Sham Comparator|Sham device|Group of participants using the same looking device which is devoid from nebulizer port valve so it is not functioning (sham device). The sham arm is a control arm. It will be used as the active comparator three times daily for 10 to 20 minutes according to subject's effort
89183723|NCT03298893|Experimental|Nivolumab + radiochemotherapy|5 weeks of radiochemotherapy + nivolumab followed by 5 months of nivolumab alone
89183724|NCT03283540||TaTME|Trans-anal Total Mesorectal Excision (TaTME) is the visualization and dissection of the rectum located deep in the pelvis. In it, a trans-anal port is inserted for the duration of the surgery. Multiple surgical tools are then introduced through the port and the rectum is resected from down-to-up under direct visualization.
89183725|NCT03283540||abdominal TME|"Total Mesorectal Excision involves resecting the rectum along with its surrounding Mesorectal plane. If the anal sphincter is spared, this surgery is named Low Anterior resection (LAR) for rectal cancer. Traditionally, TME dissection in LAR is performed through open or laparoscopic incisions(s) made in the abdominal wall. Mobilization of the splenic flexure along with sigmoid dissection follows. Lastly, the rectum is dissected in accordance with TME principles from above. This up-to-down approach is known as abdominal TME."
88855857|NCT03570333|Experimental|Progenitor Potential at Molar site|Harvested tissue from the back (molar) part of the palate will be used to extract the gingival mesenchymal cells to test their progenitor potential to differentiate into multiple cell lineage.
88855858|NCT03570333|Experimental|Progenitor Potential at Premolar site|Harvested tissue from the front (premolar) part of the palate will be used to extract the gingival mesenchymal cells to test their progenitor potential to differentiate into multiple cell lineage.
89382865|NCT03113643|Experimental|SL-401+ Azacitidine + Venetoclax|SL-401 will be administered every 4 weeks, on a 28 day cycle; SL-401 will be given intravenously; Azacitidine will be administered every 4 weeks, on a 28 day cycle; Azacitidine will be given intravenously or subcutaneously; Venetoclax will be administered for 21 days on a 28 day cycle; Venetoclax will be taken orally
88855859|NCT03569839||Patients undergoing surgery|Patients subject to TIVA
89382866|NCT03091491|Experimental|Nivolumab|
89382867|NCT03091491|Experimental|Nivolumab and Ipilimumab|
89382868|NCT05293353||Breast Milk Fortification with NeoKare|Prospective cohort, 50 infants
89382869|NCT05293353||No Breast Milk Fortification|Retrospective, historical cohort, approx 50 infants
89382870|NCT04733235||with endometrial compaction|Participants who have endometrial compaction caused by progesterone effects on undergoing frozen embryo transfer with artificial hormone replacement
89382871|NCT04733235||without endometrial compaction|Participants who have not endometrial compaction caused by progesterone effects on undergoing frozen embryo transfer with artificial hormone replacement
88855860|NCT03558789||MT|patients complaining about metallic taste before, during or after treatment of head and neck cancer.
88855861|NCT03558789||No-MT|patients not complaining about metallic taste before, during or after treatment of head and neck cancer.
88855862|NCT03545490|Experimental|Cohort 1-intervention|Oral supplements are given through oral route 2 weeks before radiotherapy.
88855863|NCT03545490|Active Comparator|Cohort 1-Control|Oral supplements are given through oral route on demand during radiotherapy.
88855864|NCT03545490|Experimental|Cohort 2- Intervention|Oral supplements are given by tube feeding 2 weeks before radiotherapy.
88855865|NCT03545490|Active Comparator|Cohort 2- Control|Oral supplements are given by tube feeding on demand during radiotherapy.
88855866|NCT03527589||Treated with Embosphere Microspheres|Patients with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) will be treated with Embosphere Microspheres (size of embolic determined at Investigator discretion).
88855867|NCT03523858|Experimental|Ocrelizumab|Ocrelizumab will be administered via intravenous (IV) infusion.
88855868|NCT03479567|Other|HC|Healthy controls, i.e. older adults without cognitive impairment
88855869|NCT03479567|Other|MiD|older adults with mild dementia
88855870|NCT03479567|Other|MoD|older adults with moderate dementia
89382872|NCT03029208|Experimental|Daprodustat treated anemic subjects|Subjects will receive oral daprodustat once daily.
89382873|NCT03029208|Active Comparator|Darbepoetin alfa treated anemic subjects|Subjects will receive darbepoetin alfa subcutaneously or intravenously.
88855871|NCT03463473|Experimental|3 mg/kg (Q3W) MSB2311 Injection|MSB2311 will be administered as an IV infusion once every 3 weeks (Q3W) starting at 3 mg/kg.
88855872|NCT03463473|Experimental|10 mg/kg (Q3W) MSB2311 Injection|MSB2311 will be administered as an IV infusion once every 3 weeks (Q3W) starting at 10 mg/kg.
88855873|NCT03463473|Experimental|20 mg/kg (Q3W) MSB2311 Injection|MSB2311 will be administered as an IV infusion once every 3 weeks (Q3W) starting at 20 mg/kg.
88855874|NCT03463473|Experimental|10 mg/kg (Q2W) MSB2311 Injection|MSB2311 will be administered as an IV infusion once every 2weeks (Q2W) starting at 10 mg/kg.
88855875|NCT03453567||TAVR|Transcatheter Aortic Valve Replacement
88855876|NCT03453567||Sutureless AVR|Sutureless Aortic Valve Replacement
88855877|NCT03453567||Conventional AVR|Conventional Aortic Valve Replacement
88855878|NCT03449498|Experimental|study group|Intensive qualitative functional therapy
88855879|NCT03449498|Experimental|control group|Intensive functional therapy
88855880|NCT03409718||Biomet Comprehensive Shoulder System|Subjects in need of a total shoulder arthroplasty who met the inclusion/exclusion criteria and received the Comprehensive Shoulder System.
88855881|NCT03404778||Biomet Comprehensive Reverse Shoulder|Subjects in need of a reverse shoulder arthroplasty who met the inclusion/exclusion criteria and received the Comprehensive Reverse Shoulder System.
89002833|NCT06097260|Experimental|Bexotegrast (PLN-74809) 160 mg Dose|Bexotegrast (PLN-74809) 160 mg Dose - 52 weeks
89382874|NCT03693534||Long Antagonist Protocol|Clinical Pregnancy Rate, Live Birth Rate and Blastulation Rate of patients who followed Long Antagonist Protocol for Controlled Ovarian Stimulation.
89382875|NCT03693534||Long Agonist Protocol|Clinical Pregnancy Rate and Live Birth Rates and Blastulation Rate of patients who followed Long Agonist Protocol for Controlled Ovarian Stimulation.
89382876|NCT03687294||Group I|patients suffering from malignant salivary gland tumors.
89382877|NCT03687294||Group II|patients suffering from benign salivary gland tumors.
89382878|NCT03198715|Experimental|DS-1040b 0.6 mg|Participants receive DS-1040b 0.6 mg by intravenous infusion over six hours
89382879|NCT03198715|Experimental|DS-1040b 1.2 mg|Participants receive DS-1040b 1.2 mg by intravenous infusion over six hours
89382880|NCT03198715|Experimental|DS-1040b 2.4 mg|Participants receive DS-1040b 2.4 mg by intravenous infusion over six hours
89382881|NCT03198715|Experimental|DS-1040b 4.8 mg|Participants receive DS-1040b 4.8 mg by intravenous infusion over six hours
89382882|NCT03198715|Placebo Comparator|Placebo|Participants receive saline by intravenous infusion over six hours
89382883|NCT03693456|Experimental|Responders Without Epinephrine|Subjects experienced a positive response during previous oral food challenge without a severe adverse event and did not require epinephrine. Will be subjected to a conjunctival allergen challenge.
89382884|NCT03693456|Experimental|Responders With Epinephrine|Subjects experienced a positive response during previous oral food challenge and required epinephrine. Will be subjected to a conjunctival allergen challenge.
89382885|NCT03693456|Experimental|Non-Responders|Subjects did not experience a positive response during previous oral food challenge. Will be subjected to a conjunctival allergen challenge.
88855882|NCT03386929|Experimental|Avelumab, Axitinib, Palbociclib|"For the Phase 1:~Avelumab is administered intravenously (IV) on Day 1 and Day 15 of a 28 day cycle in combination with axitinib po bid (every day of a 28 day cycle) and palbociclib po (on days 8-28 of a 28 day cycle).~For the Phase 2:~Avelumab, axitinib and palbociclib are administered at the recommended phase 2 dose (RP2D) as determined during the phase 1 part of the study."
88855883|NCT03358303|Experimental|Telemonitoring (Medly)|Medly is a smartphone application allows heart failure (HF) patients to measure and record their daily weight, blood pressure (BP), heart rate, and self-reported symptoms. This monitoring information is then transmitted wirelessly to a data server where an algorithm is used to generate an alert to a healthcare provider as necessary. The patient also receives an automated self-care message based on their measurements and reported symptoms.
88855884|NCT03358303|No Intervention|Control|Standard of care: Control groups will receive standard medical care when discharged from hospital, including discharge instructions, home medications as well as follow-up in a heart failure clinic or with a primary care doctor.
88855885|NCT03335839|Experimental|Intracoronary tPA 10 mg|
88855886|NCT03335839|Experimental|Intracoronary tPA 20 mg|
88855887|NCT03335839|Placebo Comparator|Placebo|saline
88855888|NCT03318640|Experimental|Mindfulness|Patient will have 8 sessions (1h30) of mindfulness based on Kabat-Zinn program during one month.
88855889|NCT03318640|No Intervention|Control|Patient will have usual medical care.
88855890|NCT03291223||GOS Participants|GOS is a disease specific registry open to all Gaucher patients irrespective of treatment status or type of treatment
88855891|NCT03246802|Experimental|HDR partial prostate brachytherapy|2 fractions of high dose rate prostate brachytherapy will be delivered to the site of recurrent disease as determined by mp-MRI
88855892|NCT03245658|Experimental|THC and CBD Mixture|32 patients with palliative pancreatic cancer, intervention with oral drops of THC, 25mg/ml and CBD 50mg/ml, daily administered for 4 weeks
88855893|NCT03245658|No Intervention|Control|32 patients with palliative pancreatic cancer, no experimental treatment,
88855894|NCT03241134|Experimental|Dry needling|A single dry needling session will be performed with the subject lying on the non painful side. After palpation of a taut band, and detection of a MTrP in the upper trapezius muscle, a trained physiotherapist will penetrate the needle into skin surface, fascia, into the muscle tissue at the MTrP location, and will move the needle up and down in multiple directions. In case local twitch responses are elicited, this will be repeated until the local twitch responses are extinct.
88855895|NCT03241134|Sham Comparator|Sham needling|A single sham needling session will be performed with the subject lying on the non painful side. After palpation of a taut band, and detection of a MTrP in the upper trapezius muscle, a trained physiotherapist will penetrate the needle into the skin surface at the MTrP location. The fascia and muscle tissue will not be penetrated.
88855896|NCT03236129|Experimental|Treg depleted DLI|Patients will receive a lymphodepleting treatment combining cyclophosphamide and fludarabine followed by Treg depleted (Donor Lymphocytes Infusion (DLI)
88855897|NCT03236129|Active Comparator|Unmanipulated DLI|Patients will receive a lymphodepleting treatment combining cyclophosphamide and fludarabine followed by a standard DLI (unmanipulated)
88855898|NCT03223220|Experimental|Study Drug|Will receive Ketamine infusion, and Midazolam (Versed).
88855899|NCT03223220|Placebo Comparator|Placebo|Will receive Normal saline infusion and Midazolam (Versed).
88855900|NCT03194256|Active Comparator|Normal Nicotine Content Cigarettes|Spectrum Research Cigarettes: 15.8 mg nicotine/g tobacco, 9 mg of tar
88855901|NCT03194256|Experimental|Very Low Nicotine Content Cigarettes|Spectrum Research Cigarettes: 0.4 mg nicotine/g tobacco, 9 mg of tar
89535088|NCT03086031|Active Comparator|Conventional vocational rehabilitation(controls)|Individuals allocated to the control group will receive the conventional VR program provided by the four municipalities over the same period of time. Thus, the participants in the control group will receive VR support by the local municipal authority that may vary in content and intensity. As for the intervention group, each individual in the control group will select a family caregiver that will go through the same questionnaires as the caregivers in the VR intervention group regarding health-related quality of life and functional level. Furthermore, the case manager at the municipalities will oblige to (1) hand out the baseline questionnaires to the participants and their family caregivers, (2) complete a questionnaire about each participants at the beginning, the end of the study, and again at 6-month of follow-up.
88855902|NCT03148327|Experimental|Regimen A: Phase I|The intervention will be looking at radiotherapy + drug Durvalumab (MEDI 4736)
88855903|NCT03148327|Experimental|Regimen A: Phase II|The intervention will be looking at radiotherapy + drug Durvalumab (MEDI 4736)
88855904|NCT03148327|Active Comparator|Regimen B: Phase II|Radiotherapy alone
88855905|NCT03143322|Experimental|Systemic treatment + SBRT|Systemic treatment and SBRT to the bone metastases. Two SBRT schemes are allowed: 9 Gy x 3 fractions or 7 Gy x 5 fractions for axial and appendicular bones metastases. The choice is at the discretion of the investigator.
88855906|NCT03143322|No Intervention|Systemic treatment|Palliative radiotherapy on bone metastases is allowed if necessary (pain, fracture, spinal cord compression…)
88855907|NCT03133559||Cohort 1|Patients infected with HIV off antiretroviral therapy
88855908|NCT03133559||Cohort 2|Patients infected with HIV experiencing virologic control, but with blunted immunologic recovery
88855909|NCT03133559||Cohort 3|Matched healthy volunteers
88855910|NCT03133377|Experimental|Early activity and Mobilisation intervention|Patients will be assessed daily by an ICU physiotherapist using the ICU Mobility Scale (IMS) to determine the dosage and type of active exercises the patient will receive, using the early activity and mobilisation protocol. This protocol is hierarchical, with the objective of each intervention session beginning with the highest level of activity possible for the longest time possible, which then steps down to lower levels of activity if the patient fatigues. The intervention will be administered on all days in which the patient is admitted to ICU during the index hospitalisation, censored at 28days after.
88855911|NCT03133377|No Intervention|Standard of care|The control group will receive standard care from physiotherapy staff not involved in delivering the intervention. We have previously established that standard care in Australia for a patient receiving prolonged IMV (control group intervention) frequently involves no active exercise out of bed.
88855912|NCT03084146|Experimental|Psoriasis|Psoriasis patients will be placed on an individualized 12-week elimination diet
89382886|NCT04191330|No Intervention|Control|Subjects in the Control Arm will receive standard of care as normally provided in the clinical center where the study is being conducted.
88855913|NCT03084146|No Intervention|Healthy Control|Healthy Control patients will receive no intervention
88855914|NCT03052634|Experimental|RC48-ADC 1.5 mg/kg (HER2 Positive)|
88855915|NCT03052634|Experimental|RC48-ADC 2.0 mg/kg (HER2 Positive)|
88855916|NCT03052634|Experimental|RC48-ADC 2.5 mg/kg (HER2 Positive)|
88855917|NCT03052634|Experimental|RC48-ADC 2.0 mg/kg (HER2 Low Expression)|
88855918|NCT03023930|Experimental|Evidenced-based Practice Dissemination|Evaluating standard dissemination practice compared with implementation facilitation
88855919|NCT02969083|Other|Radical nephro-ureterectomy (RNU)|Patients who dont fulfil inclusion criteria for chemotherapy treatment randomization (poor renal function: Glomerular Filtration Rate (GFR) <55 ml/min or unfit for cisplatin-based chemotherapy)
88855920|NCT02969083|Other|Gemcitabine/Cisplatin plus RNU|Patients who fulfil inclusion criteria for cisplatinum-based chemotherapy (renal function: GRF > or = 55 ml/min) receiving 3 cycles of Gemcitabine (1000 mg/m2) + Cisplatin (70 mg/m2) every 3 weeks before surgery
88855921|NCT02969083|Other|RNU plus Gemcitabine/Cisplatin|Patients who fulfil inclusion criteria for cisplatinum-based chemotherapy (renal function: GRF > or = 55 ml/min) receiving 3 cycles of Gemcitabine (1000 mg/m2) + Cisplatin (70 mg/m2) every 3 weeks after surgery
88855922|NCT02969083|Other|M-VAC protocol plus RNU|Patients who fulfil inclusion criteria for cisplatinum-based chemotherapy (renal function: GRF > or = 55 ml/min) receiving 3 cycles of MVAC every 2 weeks (Methotrexate (30 mg /m²) , Vinblastine (3 mg /m²) , Adriamycin (30 mg /m²) , and Cisplatin (70 mg /m²) before surgery
88855923|NCT02969083|Other|RNU plus M-VAC protocol|Patients who fulfil inclusion criteria for cisplatinum-based chemotherapy (renal function: GRF > or = 55 ml/min) receiving 3 cycles of MVAC every 2 weeks (Methotrexate (30 mg /m²) , Vinblastine (3 mg /m²) , Adriamycin (30 mg /m²) , and Cisplatin (70 mg /m²) after surgery
88855924|NCT02943590|Placebo Comparator|Placebo|Placebo will be administered at a pre determined dose The drug is taken by mouth, once a day (evening)
88855925|NCT02943590|Experimental|Atorvastatin|Atorvastatin will be administered at a pre determined dose The drug is taken by mouth, once a day (evening)
88855926|NCT02925871|Experimental|Co-designed person-centred care transitions|Co-designed person-centred care transitions from stroke unit to rehabilitation in the home
88855927|NCT02925871|Active Comparator|Current care transitions|Current care transitions from the stroke unit to rehabilitation in the home
88855928|NCT02914561|Experimental|Cohort A: Filgotinib 200 (mg) (Induction Study)|Biologic naïve and biologic experienced participants received filgotinib 200 milligram (mg) with placebo-to-match (PTM) filgotinib 100 mg tablet orally once daily, for a period of 10 weeks.
88855929|NCT02914561|Experimental|Cohort A: Filgotinib 100 mg (Induction Study)|Biologic naïve and biologic experienced participants received filgotinib 100 mg with PTM filgotinib 200 mg tablet orally once daily, for a period of 10 weeks.
88855930|NCT02914561|Placebo Comparator|Cohort A: Placebo (Induction Study)|Biologic naïve and biologic experienced participants received PTM filgotinib 200 mg and PTM filgotinib 100 mg tablet orally once daily, for a period of 10 weeks.
88855931|NCT02914561|Experimental|Cohort B: Filgotinib 200 mg (Induction Study)|Biologic experienced participants received filgotinib 200 mg with PTM filgotinib 100 mg tablet orally once daily, for a period of 10 weeks.
88855932|NCT02914561|Experimental|Cohort B: Filgotinib 100 mg (Induction Study)|Biologic experienced participants received filgotinib 100 mg with PTM filgotinib 200 mg tablet orally once daily, for a period of 10 weeks.
89382887|NCT04191330|Experimental|Intervention|Subjects randomized to the Intervention Arm will be remotely monitored for 90 days using the BiovitalsHF platform to manage initiation and titration of GDMT with and outside of normal or traditional clinical encounters.
89382888|NCT03691506|Active Comparator|Classic CIMT group|Total session of 6 hours a day, 5 days per week for 3 weeks to Classic CIMT groups will be given.
89382889|NCT03691506|Experimental|mCIMT group|Session of 6 hours a day, 5 session per week for first 2 weeks (CIMT), session of 2 hours a day, 5 days per week for last 1 week (BIT) to modified CIMT group will be given.
88855933|NCT02914561|Placebo Comparator|Cohort B: Placebo (Induction Study)|Biologic experienced participants received PTM filgotinib 200 mg with PTM filgotinib 100 mg tablet orally once daily, for a period of 10 weeks.
88855934|NCT02914561|Experimental|Filgotinib 200 mg to Filgotinib 200 mg (Maintenance Study)|Participants who received filgotinib 200 mg in induction study and who achieved either clinical remission by PRO2 or endoscopic response at Week 10 were re-randomized to the maintenance study and received filgotinib 200 mg and PTM filgotinib 100 mg tablet orally once daily, up to Week 58.
88855935|NCT02914561|Experimental|Filgotinib 200 mg to Placebo (Maintenance Study)|Participants who received filgotinib 200 mg in induction study and who achieved either clinical remission by PRO2 or endoscopic response at Week 10 were re-randomized to the maintenance study and received PTM filgotinib 100 mg and PTM filgotinib 200 mg tablet orally once daily, up to Week 58.
88855936|NCT02914561|Experimental|Filgotinib 100 mg to Filgotinib 100 mg (Maintenance Study)|Participants who received filgotinib 100 mg in induction study and who achieved either clinical remission by PRO2 or endoscopic response at Week 10 were re-randomized to the maintenance study and received filgotinib 100 mg and PTM filgotinib 200 mg tablet orally once daily, up to Week 58.
88855937|NCT02914561|Experimental|Filgotinib 100 mg to Placebo (Maintenance Study)|Participants who received filgotinib 100 mg in induction study and who achieved either clinical remission by PRO2 or endoscopic response at Week 10 were re-randomized to the maintenance study and received PTM filgotinib 200 mg and PTM filgotinib 100 mg tablet orally once daily, up to Week 58.
88855938|NCT02914561|Placebo Comparator|Placebo to Placebo (Maintenance Study)|Participants who received placebo in induction study and who achieved either clinical remission by PRO2 or endoscopic response at Week 10 were re-randomized to the maintenance study and received PTM filgotinib 100 mg and PTM filgotinib 200 mg tablet orally once daily, up to Week 58.
89382890|NCT03687216|Experimental|HVPG group|HVPG-guided therapy (TIPS or EVL plus NSBB according to HVPG)
89382891|NCT03687216|Active Comparator|Routing group|Routing therapy (EVL plus NSBB)
89535089|NCT03228511|Experimental|Formerly Arm Label|
89002834|NCT06097260|Experimental|Bexotegrast (PLN-74809) 320 mg Dose|Bexotegrast (PLN-74809) 320 mg Dose - 52 weeks
89183726|NCT03264079|Experimental|Bardoxolone methyl 10 mg and Itraconazole 200 mg|Period 1: Bardoxolone methyl capsules 10 mg Period 2: two Itraconazole capsules 100 mg
89183727|NCT03261453|Experimental|Treatment|Patients randomized to treatment will receive the Elipse device.
89183728|NCT03261453|Sham Comparator|Control|Patients randomized to the control arm will receive the sham device.
89183729|NCT03255031|Active Comparator|Diet Randomization - Active Comparator|Ketogenic diet (KD) liquid diet consists of snacks and shakes 3x p/day (high in fat). SA will receive the same KD solid snacks, in order to keep the diets blind to participants. KD will be eucaloric such that a standard equation based on weight, height, sex and age will be used to determine how many calories are provided to each participant.
89183730|NCT03255031|Placebo Comparator|Diet Randomization - Placebo Comparator|Standard American (SA) diet consists of KD snacks and shakes 3x p/day (high in fat) in the proportions of carbohydrates, protein and fat of traditional western diet. SA will receive the same KD solid snacks, in order to keep the diets blind to participants. SA will be eucaloric such that a standard equation based on weight, height, sex and age will be used to determine how many calories are provided to each participant.
89183731|NCT03253692||Patients|People ages 18 years and older who need a computed tomography (CT) scan of the heart.
89183733|NCT03232073|Experimental|Ponesimod|20 mg administered orally once daily
89183734|NCT03152760||Abstinent Group (AB)|Current AUD diagnosis, currently abstaining from alcohol
89183735|NCT03152760||Current Drinking Group (CD)|Current AUD diagnosis, not seeking AUD treatment
89183736|NCT03152760||Healthy Control Group (HC)|NO current or past AUD diagnosis
89183737|NCT03118492|Experimental|Treatment (combination chemotherapy, TBI, HCT)|Patients receive melphalan IV over 30 minutes on day -5, fludarabine IV over 30-60 minutes on days -5 to -2. Patients undergo TBI on day -1 and HCT on day 0. Patients receive cyclophosphamide IV over 1-2 hours on days 3 and 4. Starting on day 5, patients receive tacrolimus IV then PO for 6 months followed by a taper, mycophenolate mofetil PO TID until day 35, and G-CSF IV daily until absolute neutrophil count > 1,500/mm^3 for 3 consecutive days. Treatment continues in the absence of disease progression or unexpected toxicity.
89183738|NCT03113760|Experimental|Tadekinig alfa|Patients that showed response to treatment in the SAOL phase will receive Tadekinig alfa for up to 16 weeks.
89183739|NCT03113760|Placebo Comparator|0.9% sodium chloride|Patients that showed response to treatment in the SAOL phase will receive placebo comparator for up to 16 weeks.
89183741|NCT03103932|No Intervention|Usual care|Participants will be treated as is usual at each institution. Biomarkers will be measured on Day 2-3 and again prior to discharge from hospital. NTproBNP levels will not be revealed to care providers.
89183742|NCT03103932|Experimental|Biomarker guided discharge pathway|Admission NTproBNP levels will be used to stratify participants into lower and medium-higher risk care pathways. NTproBNP levels will be repeated on Day 2-3 and again prior to discharge. Each care pathway is designed to optimize discharge time according to NTproBNP levels. All NTproBNP results will be displayed on the front of the participant's chart along with the care pathway that the participant has been randomized to. The care providers will be reminded daily by the study team that the participant is in the biomarker guided discharge pathway arm of the study and that the designated care pathway should be followed as closely as possible.
89183743|NCT03092505||Females|Females participants who are about to start first line antiretroviral therapy.
89183744|NCT03077451|Experimental|Treatment (nelfinavir mesylate)|"DOSE NELFINAVIR MESYLATE: Patients receive standard dose nelfinavir mesylate PO BID for 4 weeks in the absence of PD. Patients with PD at 4 weeks proceed to high-dose nelfinavir. At week 8, if there is SD or PR, patients advance to high-dose nelfinavir mesylate. Patients discontinue standard dose nelfinavir mesylate 4 weeks after documentation of CR.~HIGH DOSE NELFINAVIR MESYLATE: Patients with PD continue to receive high-dose nelfinavir mesylate PO BID for 4 more weeks. If there is PD documented after 4 weeks at the high dose level, nelfinavir is discontinued. If there is SD or PR, patients continue receiving nelfinavir mesylate for 16 weeks. If there is CR, patients discontinue high-dose nelfinavir mesylate 4 weeks after documentation of CR."
89382892|NCT05212623|Experimental|Group A|"Subjects received 2 doses of 0.25 mL of quadrivalent influenza vaccine, 4 weeks apart.~Each 0.25-ml dose contained 7.5 μg of hemagglutinin per strain (Four types of virus strains: A/H1N1, A/H3N2, B/Victoria, and B/Yamagata)."
88855939|NCT02840799|Experimental|Potassium Nitrate (KNO3)|Potassium nitrate (KNO3) capsules, providing 6 millimoles of inorganic nitrate per capsule, to be taken three times daily for 6 weeks.
88818535|NCT05280041|No Intervention|Waiting list control group|Participants in this group will start the intervention 10 weeks after the randomization. Participants in the waiting list control group will be randomly distributed by the fixed standardised and self-tailored arms. This arm will follow the exact same procedure of the active arms.
89183745|NCT03070301|Experimental|LEE011 and everolimus|Subjects will receive LEE011 200 mg daily, in combination with everolimus 5 mg daily; in the setting of toxicity, everolimus dosing will be changed to 2.5 mg daily or 2.5 mg every other day. Subjects will continue treatment until meeting one of the criteria for removal from study.
89183746|NCT03047005|Experimental|NB medication|Participants randomly assigned to this arm will receive 16 weeks of NB medication. NB medication will combine naltrexone sustained-release (SR, 32 mg/day) combined with bupropion SR (360 mg/day) taken daily in pill form.
89183747|NCT03047005|Placebo Comparator|Placebo|Participants randomly assigned to this arm will receive 16 weeks of placebo. Placebo will be inactive and taken daily in pill form.
89382893|NCT05212623|Experimental|Group B|Subjects received 2 doses of 0.5 mL of quadrivalent influenza vaccine, 4 weeks apart. Each 0.5-ml dose contained 15 μg of hemagglutinin per strain.(Four types of virus strains: A/H1N1, A/H3N2, B/Victoria, and B/Yamagata).
89535090|NCT03085329|Experimental|Seattle-PAP|bubble nasal cpap respiratory support with Seattle-PAP bubbler device, with all other aspects of care per usual care noninvasive respiratory support
89535091|NCT03085329|Experimental|Conventional bubble nasal CPAP|qualified and enrolled infants randomized to this arm will receive noninvasive respiratory support by bubble nasal CPAP, using the Fisher & Paykel bubbler, which is the standard of care at Nationwide Children's.
89002837|NCT06094088|Experimental|Heated Yoga|The heated (i.e., ~105°F with 40% humidity) yoga will be 90 minutes long and consist of 26 Hatha yoga postures and 2 breathing exercises. The class starts with standing postures for approximately 45-50 minutes, followed by a 2-minute savasana (or corpse pose on the floor) and the remainder of the 90-minute class is completed on the mat. All yoga teachers will be heated yoga certified.
89002838|NCT06094088|Active Comparator|Non-heated Yoga|The non-heated (i.e., room temperature < 80°F) yoga will be 90 minutes long and consist of 26 Hatha yoga postures and 2 breathing exercises. The class starts with standing postures for approximately 45-50 minutes, followed by a 2-minute savasana (or corpse pose on the floor) and the remainder of the 90-minute class is completed on the mat. All yoga teachers will be heated yoga certified.
89002839|NCT06093295|Experimental|Left Dorsolateral Prefrontal Cortex (experimental)|This is the experimental condition where participants will receive theta burst stimulation to the left dorsolateral prefrontal cortex.
89002840|NCT06093295|Placebo Comparator|Vertex (control)|This is the control condition where participants will receive theta burst stimulation to the vertex.
89002841|NCT06091657|Active Comparator|ketamine group|"Group K (ketamine):~syringe (1): the ketamine syringe, dilute 25 mg ketamine in 10 ml saline to have a concentration of 2.5mg/ml. The dose will be 0.25 mg/kg, so we will give 0.1ml/kg of the syringe.~syringe (2): saline syringe 10 ml saline in 10 ml syringe. (for double blinded technique). we will give 0.1ml/kg of the syringe."
89002842|NCT06091657|Active Comparator|ketamine dexamethasone group|"Group KD (ketamine plus dexamethasone):~Syringes (1): the ketamine syringe, dilute 25 mg ketamine in 10 ml saline to have a concentration of 2.5mg/ml. The dose will be 0.25 mg/kg, so we will give 0.1ml/kg of the syringe.~Syringe (2): dexamethasone syringe, 10 mg dexamethasone will be diluted with 10 ml saline in 10 ml syringe, concentration will be 1mg/ml. the dose will be 0.1 mg/kg, so we will give 0.1ml/kg of the syringe."
89002843|NCT06090591||Acute coronary syndrome - ACS|patients who were diagnosed with acute coronary syndrome: STEMI, non-STE ACS - NSTEMI and unstable angina, who underwent coronary angiography and were prescribed with optimal medicament therapy
89002844|NCT06090591||Transcatheter aortic valve implantation - TAVI|patients with aortic stenosis who underwent transcatheter percotaneous implantation of the arteficial aortic valve
89002845|NCT06090591||Venous thromboembolism - VTE|patients with pulmonary embolism and deep vein thrombosis, with a focus on those who underwent thromboaspiration due to high or medium-high risk pulmonary embolism
89002846|NCT06090591||Heart failure with SGLT2 inhibitor therapy included - HF-SGLT2|patients with heart failure with reduced, mid-reduced and preserved systolic function who were prescribed with a SGLT-2 inhibitor therapy, and other optimal medicament therapy for HF
89002847|NCT06090591||Cardiac implantable electronic device - CIED|patients who were implanted with a cardiac implantable electronic device: pacemaker, conduction system pacing device, cardioverter-defibrilator or cardiac resynchronization therapy with or without defibrilator option
89002848|NCT06090591||Arrhythmias|patients who underwent electrophysiology study, including PVI for atrial fibrillation, as well as SVT ablations, and ventricular arrhythmia ablation (both premature ventriclar beats and ventricular tachycardia ablation in ischsmic and non-ischemic cardiomyopathy).
89002849|NCT06088550|No Intervention|Group-1|received standard care
89382894|NCT05212623|Active Comparator|Group C|Subjects received 2 doses of 0.25 mL of influenza vaccine, 4 weeks apart. Each 0.25-ml dose contained 7.5 μg of hemagglutinin per strain (3 type of virus strains, including BY).
89382895|NCT05212623|Active Comparator|Group D|Subjects received 2 doses of 0.25 mL of influenza vaccine, 4 weeks apart. Each 0.25-ml dose contained 7.5 μg of hemagglutinin per strain (3 types of virus strains, including BV).
89382896|NCT03960138|Experimental|Intermittent Theta-burst stimulation (iTBS)|Cross-over design - participants will receive both experimental treatments.
89382897|NCT03960138|Experimental|Continuous Theta-burst stimulation (cTBS)|Cross-over design - participants will receive both experimental treatments.
89382898|NCT03691272|Experimental|rTMS- Real Air Film Coil|Patient MR brain scans will be loaded and processed using the Brainsight TMS neuronavigation software and stereotaxic data for localization of the TMS stimulation site will be determined through a co-registration method between the TMS coil position and the projected site on the MR brain scan. The DLPFC will be located through MNI coordinates (-48, 20, 34). Electromyography (EMG) electrodes will be attached to the right abductor digiti minimi (ADM) muscle. The resting motor threshold (RMT) is determined as the minimal stimulation intensity required to elicit motor-evoked response of 50 microvolts peak-to-peak amplitude in at least 5 out of 10 consecutive trials of the ADM (contralateral to stimulation).
89382899|NCT03691272|Sham Comparator|rTMS- Sham coil|The same procedure for determining RMT as described above will be employed for the Sham Arm. However, a sham coil will be used when the treatment over the left DLPFC is applied.
89382900|NCT03693222|Experimental|tramadol use|Cases were assessed as intravenous opioid with 1 mg/kg tramadol hydrochloride
89382901|NCT03693222|Experimental|quadratus lumborum block|Cases were assessed asquadratus lumborum block for postoperative analgesia
89382902|NCT04059744|Experimental|Experimental arm|"Device: Fun-Knee Portable and low cost sensors are used in the Smart Knee Sleeve. The sensor system is composed of two inclinometers and one Bluetooth transmitter.~Fun Knee™ contains total knee replacement exercises that are gamified and supported on mobile device running on Android or iOS platforms. The mobile apps is able to capture the angle a and position data from the two inclinometers on smart knee sleeve.The free-sized knee sleeve prototypes are purchased and assembled by our collaborating vendor."
89382903|NCT04269486||Inpatient participant|Inpatients who signed the informed consent form that she will be observed during the hospitalization period
88855940|NCT02840799|Placebo Comparator|Potassium Chloride (KCl)|"Potassium Chloride (KCl) is the placebo (control drug) in this trial.~Potassium Chloride (KCl) capsules administered at a dose of 6 millimoles (1 capsule) three times daily for 6 weeks."
88855941|NCT02838732|Experimental|L-carnitine supplementation|All participants received L-carnitine supplementation (500 mg per tablet per day, provided by GNC) for one month. Oral carnitine challenge tests and fecal sampling were conducted both before and after the intervention.
88855942|NCT02821806||Cohort 1|Healthy Volunteers
89382904|NCT03693066|Experimental|ozone|Thirty five molar teeth with deep caries lesion were selected to apply two-visit indirect pulp therapy with ozone. The peripheral demineralized dentin and the superficial necrotic dentin were completely removed, and left some caries at the central part. The cavity was exposed to gaseous ozone for 60 seconds, with an ozone delivery system. The remaining caries dentin was covered with calcium hydroxide base material and cavity sealed with glass ionomer cement to reopen 4 months later.
89382905|NCT03693066|Active Comparator|chlorhexidine digluconate|Thirty five molar teeth with deep caries lesion were selected to apply two-visit indirect pulp therapy with chlorhexidine digluconate. The peripheral demineralized dentin and the superficial necrotic dentin were completely removed, and left some caries at the central part. Following the excavation, 2% chlorhexidine digluconate was applied to the cavity for 60 seconds using a brush. According to the manufacturer instructions, puddled solution was removed with a new brush without dry to leave site moist. The remaining caries dentin was covered with calcium hydroxide base material and cavity sealed with glass ionomer cement.
89382906|NCT03693066|Active Comparator|Control|Thirty five molar teeth with deep caries lesion were selected to apply conventional two-visit indirect pulp therapy (control). The peripheral demineralized dentin and the superficial necrotic dentin were completely removed, and left some caries at the central part. The remaining caries dentin was covered with calcium hydroxide base material and cavity sealed with glass ionomer cement.
89382907|NCT03631641|Experimental|Treatment (nivolumab)|Participants receive nivolumab intravenously IV over 60 minutes on day 1. Treatment repeats every 3 months for a total of 8 courses in the absence of disease progression or unacceptable toxicity.
89382908|NCT03631875|Placebo Comparator|P (propofol),|normal saline is injected 01 min before induction with propofol 3 mg/kg. After 60 seconds, an experimented anesthesiologist evaluated the LM conditions insertion.
88855943|NCT02798666|Experimental|High intensity exercise training|The participants exercised for 40 minutes, twice a week, under supervision of two physiotherapists for in total 10 weeks. Each training session included a warming up, a sprint interval block [10 minutes], continuous aerobic exercise [10 minutes], another sprint interval block [10 minutes] and cooling down. For the first 5 weeks, each sprint interval block consisted of 10 sprint bouts [>100 r/min] of 15 seconds at a cycling resistance matching with the ventilatory threshold [VTR], alternated with 45 seconds relative rest [50 r/min at VTR]. Starting from week 6 until week 10, the intensity of sprinting and relative rest was increased up to 110% of VTR.
89002850|NCT06088550|Active Comparator|Group-2|received BCAA
89002851|NCT06088550|Active Comparator|Group-3|Recieved Exercice
89002852|NCT06088550|Active Comparator|Group-4|Received a combined BCAA + Exercise
89002853|NCT06088498|Experimental|Aim 1: Update an existing smartphone App|An existing study app will be updated to be engaging, user-friendly treatment tool, and verify user satisfaction.
89382909|NCT03631875|Active Comparator|PK (propofol-ketamine)|we inject 0.5 mg/kg of ketamine 01 min before induction with 03 mg/kg of propofol .Sixty seconds after, an experimented anesthesiologist evaluated the LM conditions insertion.
89382910|NCT05598099||Individual therapy over four consecutive days|Treatment will be delivered individually over four consecutive days
89382911|NCT05598099||Combined Individual and group therapy over four consecutive days|Treatment will be delivered in a mix of individual and group sessions over four consecutive days
89382912|NCT03631563|Experimental|Arm 1|ATG-F treated
89382913|NCT03631563|Active Comparator|Arm 2|ATG treated
89382914|NCT03019653|Active Comparator|ANX-042 first, then Placebo|In the first intervention period the subjects will receive an infusion of ANX-042. There will be a 3 week washout period. In the second intervention period, the subjects will receive an infusion of placebo
89382915|NCT03019653|Active Comparator|Placebo first, then ANX-042|In the first intervention period the subjects will receive placebo. There will be a 3 week washout period. In the second intervention period, the subjects will receive an infusion of ANX-042.
88855944|NCT02798666|Active Comparator|Continuous exercise training|The comparative group performed a continuous aerobic training [CAT] for 10 weeks, twice a week and 40 minutes per session [volume and frequency is equal to HIIT]. The protocol of the CAT group consisted of warming up [stretching of the large muscle groups and cardiovascular exercises at 30% of peak cycling power output for five minutes], continuous aerobic exercise training [3 times 10 minutes] and cooling down [stretching of the large muscle groups and cardiovascular exercises at 30% of peak cycling power output for five minutes]. During the continuous aerobic protocol [cycling or stepping] participants exercised for 10 minutes at a HR similar to the HR at VT [60 r/min], which was increased to 110% of VT from week 6 onwards.
88855945|NCT02773238|Experimental|Treatment|Patients undergo functional avoidance radiation therapy during weeks 1-3. Patients undergo fludeoxyglucose F-18 FDG PET/CT at baseline, 3 weeks, and 3 months post-radiation therapy and undergo technetium Tc-99m albumin aggregated (99mTc-MAA) and technetium Tc-99m sulfur colloid SPECT/CT radiation therapy at baseline and 3 months post-radiation therapy. Baseline PET/CT must be performed at University of Washington Medical Center/Seattle Cancer Care Alliance and be within one month of treatment start, therefore some patients may need to repeat a baseline PET/CT if their PET/CT is from an outside institution or > 1 month old. Patients not responding to treatment at 3 weeks, will receive an increased daily radiation therapy dosage.
88855946|NCT02743858||Patients who consent for ALND|In patients treated with ALND, bilateral arm measurements will be obtained using the Perometer (Model 350 NT Perometer, Per-System) circumferential arm measurements with elastic tape taken at 4-cm intervals from the wrist to the shoulder & the L-Dex U400 (Impedimed, Brisbane, Australia) for bioimpedance measurements. Measurements will be performed at baseline (prior to surgery), post-operatively (after surgery) & at scheduled timepoints of 6 months, 12 months, 18 months, & 24 months after surgery for a total of 2 years. For a patient who is diagnosed with lymphedema at ≥ 13 months after surgery, surveillance will continue for an additional 12 months after [lymphedema] diagnosis, & total surveillance time may exceed 2 years. Height & weight will be obtained for each patient at baseline & at each scheduled visit for the purpose of calculating BMI. All patients will complete the ULL-27 (upper limb lymphedema) quality-of-life questionnaire at baseline & at each scheduled visit.
88855947|NCT02743858||Patients treated with SLNB alone|Study requirements which include arm measurements, height and weight and completion of a questionnaire at a single long-term follow-up timepoint, will be explained to the patient
88855948|NCT02743858||ALND Translational Study Patients|Patients will also be counseled about blood draws, which will include withdrawal of up to 20 mL of blood. Patients who are eligible and agree to participate will sign a consent form. Arm measurements, height and weight, blood draw (if applicable), and baseline questionnaire will be performed at first contact if possible, or at a follow-up scheduled visit prior to surgery.
89382916|NCT02653755|Active Comparator|Ineligible for omission of RT|Prosigna confirms intermediate- or high-risk score. Participants with intermediate- or high-risk scores will be ineligible for omission of radiotherapy (RT). Some patients with low-risk scores may elect to receive RT.
89382917|NCT02653755|Active Comparator|Eligible for omission of RT|Prosigna confirms low risk score. Participant will be eligible for omission of therapy and chooses to do so. Patient will receive adjuvant endocrine therapy.
89382918|NCT05077293||Best Practice Alert group|Providers will receive a BPA at the time of visit for patients with HFrEF who are not on MRA (and who do not have contraindication to MRA). This alert will be visible on the first screen displayed in the electronic health record and will display the patient's current HFrEF therapies, EF, blood pressure, potassium, and glomerular filtration rate. The alert will give access to an outpatient heart failure order set, and also provide links to the most recent guidelines.
89382919|NCT05077293||In-Basket Message group|Providers will receive a biweekly in-basket messages linking to a list of patients who have been seen in the past year with HFrEF who are not on MRA (and who do not have contraindication to MRA). This list will display each patient's current hFrEF therapies, EF, blood pressure, potassium, glomerular filtration rate, and date of last visit. From the list, providers can access the patient's chart, order medications, and document communication with the patient.
88855949|NCT02720419||Synergy stent|
88855950|NCT02719106||Ultimaster stent|
88855951|NCT02708615|Other|Vertical rotation|Vertical insertion and 90 degree rotation of speculum in vagina
88855952|NCT02708615|Other|Straight horizontal insertion|Straight horizontal insertion of speculum with no rotation in vagina
88855953|NCT02703506|Experimental|Experimental. Pain Education Program|Ten group sessions of treatment with a patient education pain for chronic neck pain (biopsychosocial approach). The group sessions of 60-120 minutes twice a week with a maximum of 10 participants.
88855954|NCT02703506|Active Comparator|Control|"The control group: individualized session of physical therapy (TENS and exercise).~Five individual sessions twice a week, will be performed of transcutaneous electrical nerve stimulation (TENS) on neck area an exercises ."
88855955|NCT02678091|Experimental|Patients|Patients with an orbital mass
89183748|NCT03038750||EDNRA Sub-study|"Study population will be split into two groups defined by the allele of EDNRA the participant possesses:~Participants Homozygous for the A-allele of EDNRA, are assigned to the 'case' group.~Participants that are Homozygous for the G-allele will be assigned to the 'control' group.~20 participants will be recruited to each group, 40 in total."
89183749|NCT03038750||PNPLA3 Sub-study|"Study population will be split into two groups defined by the allele of PNPLA3 the participant possesses:~Participants Homozygous for the G-allele of PNPLA3, are assigned to the 'case' group.~Participants that are Homozygous for the C-allele of PNPLA3 will be assigned to the 'control' group.~60 participants will be recruited to each group, 120 in total."
89183750|NCT03038750||PROCR Sub-study|"Study population will be split into two groups defined by the allele of PROCR the participant possesses:~Participants Homozygous for the G-allele of PROCR, are assigned to the 'case' group.~Participants that are Homozygous for the A-allele of PROCR will be assigned to the 'control' group.~30 participants will be recruited to each group, 60 in total."
89183751|NCT03019185|Experimental|Phase 2 Bardoxolone Methyl|Patients in the Phase 2 cohort will receive bardoxolone methyl throughout the study. Patients with baseline ACR ≤ 300 mg/g will be titrated to a maximum dose of 20 mg, and patients with baseline ACR > 300 mg/g will be titrated to a maximum dose of 30 mg. Adult patients (≥ 18 years of age) receiving bardoxolone methyl will start with once-daily dosing at 5 mg and will dose-escalate to 10 mg at Week 2, to 20 mg at Week 4, and then to 30 mg at Week 6 (only if baseline ACR >300 mg/g) unless contraindicated clinically and approved by the medical monitor. Patients under the age of 18 receiving bardoxolone methyl will start 5 mg every other day during the first week and begin once-daily dosing with 5 mg during the second week of the study, and then continue with once-daily dosing following the same aforementioned dose titration scheme based on baseline ACR at Weeks 2, 4, and 6.
89183752|NCT03019185|Active Comparator|Phase 3 Bardoxolone Methyl|Patients with baseline ACR ≤ 300 mg/g will be titrated to a maximum dose of 20 mg, and patients with baseline ACR > 300 mg/g will be titrated to a maximum dose of 30 mg. Adult patients (≥ 18 years of age) receiving bardoxolone methyl will start with once-daily dosing at 5 mg and will dose-escalate to 10 mg at Week 2, to 20 mg at Week 4, and then to 30 mg at Week 6 (only if baseline ACR >300 mg/g) unless contraindicated clinically and approved by the medical monitor. Patients under the age of 18 receiving bardoxolone methyl will start 5 mg every other day during the first week and begin once-daily dosing with 5 mg during the second week of the study, and then continue with once-daily dosing following the same aforementioned dose titration scheme based on baseline ACR at Weeks 2, 4, and 6.
89183753|NCT03019185|Placebo Comparator|Phase 3 Placebo|Patients randomized to placebo will remain on placebo throughout the study, undergoing sham titration.
89183754|NCT02991365|Active Comparator|nasal insulin|daily administration of 160 U of human insulin as nasal spray
89183755|NCT02991365|Placebo Comparator|placebo spray|daily administration of placebo solution as nasal spray
89183756|NCT02961881|Experimental|blinatumomab|
89183757|NCT02952144|Experimental|Lixelle® treatment|2 years of Lixelle® treatment in the patients with dialysis related amyloidosis (DRA)
89183758|NCT02952144|No Intervention|natural history|2 years of natural history in the patients with dialysis related amyloidosis (DRA)
89183759|NCT02932410|Experimental|Macitentan|Macitentan is administered once daily via oral route. Children less than (<) 2 years old (y.o.) will be assigned as a cohort to the macitentan group without randomization. The dose will be adjusted to the participant's age (for those < 2 y.o.) or to the participant's body weight (for those greater than or equal to (>=) 2 y.o.). single-arm extension period (SAEP) will start at end of core period (EOCP) visit and ends at end of study (EOS) visit.
89183760|NCT02932410|Other|Standard-of-care|Standard-of-care as per site's clinical practice which may comprise treatment with pulmonary arterial hypertension (PAH) non-specific treatment and/or up to two PAH-specific medications excluding macitentan and intravenous/subcutaneous (IV/SC) prostanoids.
89183761|NCT02891382|Experimental|Individual incentives - Arm 1|This arm receives diabetes education + goal setting + individual rewards
89183762|NCT02891382|Experimental|Mixed incentives (Altruism) - Arm 2|This arm receives diabetes education + goal setting + companion support + individual rewards
89183763|NCT02891382|Experimental|Mixed Incentives (Cooperation) - Arm 3|This arm receives diabetes education + goal setting + companion support + shared rewards
89183764|NCT02885974|Experimental|Celecoxib plus Gemcitabine/Cisplatin chemo|Celecoxib plus Gemcitabine/Cisplatin neoadjuvant chemotherapy
89183765|NCT02866149|Other|"Cohort 1 - Anti checkpoint"|"Monitoring of patients with tumours treated by immune therapy.~Timing of blood sampling:~inclusion~after #8 weeks on therapy~at progression or 6 months from inclusion for patient without progressive disease~if toxicity grade 3 or 4, or grade 2 until 1 month."
89183766|NCT02866149|Other|"Cohort 2 - Oncoscan®"|"Monitoring of patients with HER 2+/- breast cancer and correlation with genome-wide copy number, loss of heterozygosity detection, as well as identification of frequently tested somatic mutations (Oncoscan® assays).~Timing of blood sampling:~inclusion~after 1 cycle of therapy (weeks 3-4)~up to 2 other samples, timepoints decided by the investigator"
89183767|NCT02866149|Experimental|"Cohort 3 - CirCe-PLA"|"Feasibility of Proximity-Ligation Assay (PLA) to study membrane proteins dimerisation by on isolated tumour cells in patients with HER2+/- breast cancer (HER 2+/-).~One tumor sampling.~Timing of blood sampling:~Inclusion~up to 3 other samples, timepoints decided by the investigator."
89183768|NCT02866149|Other|"Cohort 4 - CDX PDX"|"Establishment of xenografts from tumor (PDX) and from Circulating Tumour Cell (CDX) by tumour and blood sampling.~One tumor sampling.~Timing of blood sampling:~Inclusion~up to 3 other samples, timepoints decided by the investigator."
88818536|NCT01414634|Experimental|ETIMS 1x10^3|The drug product consists of autologous peripheral blood mononuclear cells that have been chemically coupled with seven myelin peptides and resuspended in autologous plasma. This patient receives 1x10^3 cells.
89382920|NCT05077293||Control group|Patients who will receive the current standard practice of care (no alerts)
89382921|NCT05069181|Experimental|Pilates mat exercises|one hour Pilates exercises with 10 min warm up and 5-10 min cooling down
89382922|NCT05069181|Experimental|cervical stabilization exercises|training of deep cervical flexor muscles with pressure biofeedback unit
89382923|NCT05069181|Active Comparator|conventional physiotherapy|10 min hot pack on cervical area range of motion exercises and isometric neck exercises as a home program
89382924|NCT01383603|Experimental|Cat-PAD|
89382925|NCT05065203||Postpartum patients|Women booked and have delivery of their child(ren) at Lucile Packard Children's Hospital
89382926|NCT01568775|Experimental|Aliskiren|All patient and subjects received single dose of aliskiren 300 mg in treatment period.
89382927|NCT03088917||lost to follow-up patients|This so-called lost population consists of all patients, that in the past have been diagnosed with hepatitis C at the Radboudumc but who are currently lost to or have been withdrawn from follow-up. The time-span of interest will be 2000-2015.
89382928|NCT01631721||Cohort 1|Cohort of adolescents recruited in 2012-2013 of study
89382929|NCT01631721||Cohort 2|Cohort of adolescents recruited in year 2013-2014 of study
89382930|NCT01631721||Cohort 3|Cohort of adolescents recruited in year 2014-15 of study
89382931|NCT01015989|Active Comparator|CARE+ Kenya brief computer risk assessment session (control)|
89382932|NCT01015989|Active Comparator|Full CARE+ Spanish computer-counseling group|
89382933|NCT04722549|Placebo Comparator|Placebo|Placebo (cellulose)
89382934|NCT04722549|Active Comparator|Butyrate|Sodium butyrate
89382935|NCT05003427|Experimental|68Ga-FAPI-04 PET/CT|The patients were injected with 55.5-148 MBq (1.5-4mCi) of 68Ga-FAPI-04 in one dose intravenously and underwent SPECT/CT scan 30-90 min later.
89382936|NCT04941261|Experimental|18-59 years old group A|
89382937|NCT04941261|Experimental|18-59 years old group B|
89382938|NCT04941261|Placebo Comparator|18-59 years old group C|
89382939|NCT04941261|Experimental|6-17 years old group A|
89382940|NCT04941261|Experimental|6-17 years old group B|
89382941|NCT04941261|Placebo Comparator|6-17 years old group C|
89382942|NCT04941261|Experimental|3-5 years old group A|
89382943|NCT04941261|Experimental|3-5 years old group B|
89382944|NCT04941261|Placebo Comparator|3-5 years old group C|
89382945|NCT04941261|Experimental|6-35 months old group A|
89382946|NCT04941261|Experimental|6-35 months old group B|
89382947|NCT04941261|Placebo Comparator|6-35 months old group C|
89382948|NCT04941261|Experimental|6-35 months old group D|
89382949|NCT04941261|Experimental|6-35 months old group E|
89382950|NCT04941261|Placebo Comparator|6-35 months old group F|
89382951|NCT00335049|Experimental|PAL|Progressive Addition Spectacle Lenses (PALs) with a +2.00 D add worn for first year off study. Single Vision Lenses worn for second year of study.
89382952|NCT00335049|Active Comparator|SVL|Single Vision Lenses (SVLs) worn both years of the study.
89382953|NCT01383525|Experimental|Direct Selective Trabeculoplasty|Treatment by an Direct Selective Trabeculoplasty device
89382954|NCT05597709||Patients who diagnosed as T2DM|Diagnosed as T2DM according to the Chinese Guidelines for the Prevention and Treatment of Type 2 Diabetes
89382955|NCT05420181|Other|Short Fast|Participants will fast overnight for a period of 10 hours
89382956|NCT05420181|Other|Long fast|Participants will fast overnight for a period of 16 hours
88818537|NCT01414634|Experimental|ETIMS 1x10^5|The drug product consists of autologous peripheral blood mononuclear cells that have been chemically coupled with seven myelin peptides and resuspended in autologous plasma. This patient receives 1x10^5 cells.
88818538|NCT01414634|Experimental|ETIMS 1x10^7|The drug product consists of autologous peripheral blood mononuclear cells that have been chemically coupled with seven myelin peptides and resuspended in autologous plasma. This patient receives 1x10^7 cells.
88818539|NCT01414634|Experimental|ETIMS 1x10^8|The drug product consists of autologous peripheral blood mononuclear cells that have been chemically coupled with seven myelin peptides and resuspended in autologous plasma. This patient receives 1x10^8 cells.
88818540|NCT01414634|Experimental|ETIMS 5x10^8|The drug product consists of autologous peripheral blood mononuclear cells that have been chemically coupled with seven myelin peptides and resuspended in autologous plasma. This patient receives 5x10^8 cells.
88818541|NCT01414634|Experimental|ETIMS 1x10^9|The drug product consists of autologous peripheral blood mononuclear cells that have been chemically coupled with seven myelin peptides and resuspended in autologous plasma. This patient receives 1x10^9 cells.
88818542|NCT01414634|Experimental|ETIMS 2.5x10^9|The drug product consists of autologous peripheral blood mononuclear cells that have been chemically coupled with seven myelin peptides and resuspended in autologous plasma. This patient receives 2.5x10^9 cells.
88818543|NCT01414634|Experimental|ETIMS 3x10^9|The drug product consists of autologous peripheral blood mononuclear cells that have been chemically coupled with seven myelin peptides and resuspended in autologous plasma. This patient receives 3x10^9 cells.
88818544|NCT05748119|Placebo Comparator|A1a Placebo|Single Sentinel Placebo Comparator for 20 mg Dose of MEB-1170
88818545|NCT05748119|Experimental|A1a MEB-1170|Single MEB-1170 Sentinel 20 mg Dose
88818546|NCT05748119|Placebo Comparator|A1b Placebo|Single Placebo comparator for 20 mg dose cohort of MEB-1170
88818547|NCT05748119|Experimental|A1b MEB-1170|Single MEB-1170 20 mg dose cohort
88818548|NCT05748119|Placebo Comparator|A2a Placebo|Single Sentinel Placebo Comparator for 60 mg Dose of MEB-1170
88818549|NCT05748119|Experimental|A2a MEB-1170|Single MEB-1170 Sentinel 60 mg Dose
88818550|NCT05748119|Placebo Comparator|A2b Placebo|Single Placebo comparator for 60 mg dose cohort of MEB-1170
88818551|NCT05748119|Experimental|A2b MEB-1170|Single MEB-1170 60 mg dose cohort
88818552|NCT05748119|Placebo Comparator|A3a Placebo|Single Sentinel Placebo Comparator for 120 mg Dose of MEB-1170
88818553|NCT05748119|Experimental|A3a MEB-1170|Single MEB-1170 Sentinel 120 mg Dose
88818554|NCT05748119|Placebo Comparator|A3b Placebo|Single Placebo comparator for 120 mg dose cohort of MEB-1170
88818555|NCT05748119|Experimental|A3b MEB-1170|Single MEB-1170 120 mg dose cohort
88855956|NCT02670174|Active Comparator|Traditional training|A home exercise program consisting of rotator cuff and scapular muscle training will be performed during 6 weeks (4 sessions/week). To monitor progress and control load progression, a physical therapist will visit the subject every week.
88855957|NCT02670174|Experimental|Separate kinetic chain training|A home exercise program consisting of traditional training exercises as well as separate exercises focusing on core and lower limb training will be performed during 6 weeks (4 sessions/week). To monitor progress and control load progression, a physical therapist will visit the subject every week.
88855958|NCT02670174|Experimental|Integrated kinetic chain training|A home exercise program consisting of traditional training exercises while integrating core and lower limb training will be performed during 6 weeks (4 sessions/week). To monitor progress and control load progression, a physical therapist will visit the subject every week.
88855959|NCT02630628|Experimental|Tacrolimus|route: oral duration: 96 weeks
88855960|NCT02630628|Active Comparator|Mycophenolate Mofetil|route: oral duration: 96 weeks
88855961|NCT02619253|Experimental|Dose Finding Cohort|Estimate the Recommended Phase 2 Dose (RP2D) in patients with advanced renal and urothelial cell carcinoma patients. Patients will be treated with oral vorinostat every day for 14 days, and with pembrolizumab at the fixed dose of 200 mg IV. Each cycle is every 21 days. Two dose levels of vorinostat will be tested in 2 patient cohorts according to the 3 + 3 standard design (100 and 200 mg).
88855962|NCT02619253|Experimental|Expansion Cohort|Once the Expansion Test Dose is identified, the Dose Expansion Phase will be opened and the combination will be tested in patients with advanced renal cell or urothelial cell carcinoma. Forty-five patients with prior treatments will be enrolled in three expansion cohorts: 15 anti-PD1 naive renal and urothelial patients, 15 anti-PD1 resistant renal and urothelial patients (defined as patients with transient clinical response or without clinical response to prior immune-checkpoint inhibition), and 15 patients with androgen-sensitive or castration-resistant prostate cancer.
88855963|NCT02549820|Experimental|FETO in CDH|Fetoscopic Endoluminal Tracheal Occlusion (FETO) will be performed by placing a detachable balloon inside the fetal airway and removing the balloon after several weeks. Devices: GoldBAL2 Detachable Balloon and BALTACCIBDPE100 Delivery Catheter
88855964|NCT02544815|Active Comparator|Digoxin|Oral digoxin 0.25 mg: one pill per day for 30 consecutive days.
88855965|NCT02544815|Placebo Comparator|Placebo|Oral placebo for 30 days.
88855966|NCT02517034|Experimental|Arm I (geriatric assessment-driven treatment)|Patients follow an intervention plan created by the NP using the results of the geriatric assessment. The NP discusses the results of the assessment and treatment recommendations with the patient. They also share the treatment plan, proposed referrals, and specific vulnerabilities with the primary care physician and community oncologist. Some patients complete the intervention plan via Telehealth, which uses telecommunication technology to provide health services over a distance.
88855967|NCT02517034|Active Comparator|Arm II (standard of care)|Patients follow a standard of care treatment plan at the discretion of the primary oncologist. Beginning 6 months from the start of chemotherapy, patients undergo the geriatric assessment as in Arm I. Some patients complete the standard of care treatment plan via Telehealth.
88855968|NCT02503579|Experimental|physical training|Participant receive a submaximal (60% -75% maximal oxygen uptake) physical activity training of 30 minutes during 8 weeks, 2 times a week. Individual heart rates will be monitored during the training.
88855969|NCT02503579|No Intervention|control|"1 training at the beginning of the study~1 training at the end of the study"
88855970|NCT02481414|Experimental|PepCan|Four injections (one every 3 weeks) of PepCan
88855971|NCT02481414|Active Comparator|Candin|Four injections (one every 3 weeks) of Candin
88855972|NCT02476786|Experimental|Endocrine therapy alone|"Neoadjuvant endocrine therapy will be given at the discretion of the treating physician as directed by the package insert and could include the following: goserelin, anastrozole, letrozole, exemestane, fulvestrant, or tamoxifen~Frequency of office visits will be decided by the treating physician but must occur no less frequently than every 3 to 6 months for tumor assessment~After 6 months and after 12 months, patients will be assessed; patients who progress will have standard care recommended , and at any point a patient can opt to receive standard care even if she has not progressed on neoadjuvant endocrine therapy~Information on quality of life will be collected at baseline, Year 1, and Year 2 by the FACT-B questionnaire~Archival tissue will be collected and sent to Genomic Health for analysis using the Oncotype DX assay. The Recurrence Score predicts chemotherapy benefit and indicates the 10-year risk of recurrence (will not be used to determine treatment)"
88855973|NCT02400255|Experimental|Cohort A|Cohort A will include patients who underwent allogeneic hematopoietic stem cell transplantation (HSCT) while in first or second complete remission with count recovery. Crenolanib besylate maintenance therapy will start at the earliest time no sooner than 42 days but no later than 90 days after allogeneic HSCT.
88855974|NCT02400255|Experimental|Cohort B|Cohort B will include patients who underwent HSCT with incomplete count recovery although they had ≤%10 bone marrow blasts at the time of HSCT. Crenolanib besylate maintenance therapy will start at the earliest time no sooner than 42 days but no later than 90 days after allogeneic HSCT.
88855975|NCT02301468|Experimental|Dry needling|Dry needling (experimental- physiotherapy intervention) - will be performed during 4 weeks (1 treatment/week) on the 4 most painful trigger points (determined/selected at the first session - see above). The same 4 trigger points will be treated during the 4 weeks. DN will be performed by locating the taut band and the trigger point. Once the trigger point is located, the overlying skin will be cleaned with alcohol. A certified and experienced therapist will penetrate the needle through the skin 10-15mm. into the TrP until the local twitch response will be obtained
89002854|NCT06088498|Experimental|Aim 2: Quit Line Only|Participants randomized to this arm will receive usual care for smoking cessation via the quitline and a smartphone app that will allow them to track smoking urges and abstinence.
89382957|NCT03087513|Active Comparator|Initial Arm|The study participants will receive either Sugammadex (2 mg/kg in 10 ml 0.9% normal saline) or placebo (10 ml of 0.9% normal saline).
89382958|NCT03087513|Active Comparator|Crossover Arm|The study participants will receive the study medication that was not given in the initial arm (either Sugammadex (2 mg/kg in 10 ml 0.9% normal saline) or placebo (10 ml of 0.9% normal saline) .
89382959|NCT05420103||Pre-ASAP|Conventional Stroke Rehabilitation Program
89382960|NCT05420103||Post-ASAP|Standardized functional assessment, standardized intensive early ambulation with modern technologies such as Knee-Ankle-Foot Orthoses and Robotic-Assisted Gait Training. In order to monitor the progress of each patient proactively, Stroke Registry and Reference Modified Rivermead Mobility Index (MRMI) Gain were developed. Stroke Registry was a longitudinal stroke rehabilitation database to monitor patients' functional outcomes and therapists' intervention compliance so as to pave the way for future clinical big data movement to bridge the gap between evidence-practice and clinical practice. Reference MRMI Gain was a clinical prediction model apply business intelligence concept to support goal-orientated approach of physiotherapists in stroke rehabilitation. Stroke treatment library, a standardized exercise prescription in video format was also developed to facilitate standardized prescription of interventions to patients with different level of ability.
89382961|NCT03631485||parents having children with cancer|No intervention.
89382962|NCT02917629|Experimental|Group I (ACTOplus met XR)|Patients receive ACTOplus met XR PO QD for 10-21 days in the absence of disease progression or unacceptable toxicity. Patients may continue ACTOplus met XR PO QD for a maximum of 25 days if end of treatment biopsy/surgical treatment is delayed beyond day 22.
89382963|NCT02917629|Placebo Comparator|Group II (placebo)|Patients receive placebo PO QD daily for 10-21 days.
89382964|NCT05418543|Experimental|EUS-FNA|
89382965|NCT05418543|Experimental|CH-EUS-FNA|
89382966|NCT03692988|Experimental|Interventiongroup|Dignity Therapy. Patients receive dignity-therapy-Intervention after randomization
89382967|NCT03692988|No Intervention|Waitinggroup|Patients receive dignity-therapy-Intervention after a waiting time of 3 months post randomization
89382968|NCT05417841|Experimental|IDegAsp group|IDegAsp twice daily
89382969|NCT05417841|Active Comparator|IDegAsp + IAsp group|IDegAsp once daily plus IAsp twice daily
89382970|NCT03691194|Experimental|fresh orange juice|Subject will take 8 ounces of fresh orange every day for 28 days.
89382971|NCT03691194|Active Comparator|concentrated orange juice|Subject will take 8 ounces of concentrated orange juice every day for 28 days.
89382972|NCT03691116|Experimental|Digital Health Profile|A digital health check-up, with questions, brief feedback and information about alcohol, tobacco, diet and exercise, as a complement to treatment as usual. (Psychological assessment and treatment)
88855976|NCT02301468|Experimental|Ischemic compression|Ischemic compression (experimental - physiotherapy intervention) will be performed during 4 weeks (1 treatment/week) on the 4 most painful trigger points (determined/selected at the first session - see above). IC will be performed by applying a pressure with a wooden stick on the 4 individually determined most painful trigger points. The duration of the pressure will be about 60s, (increase of pressure 10N/s) until the highest tolerable pressure will be reached and this pressure will be held even when the pain is decreasing during the intervention. The subject will always be treated by the same clinician.
89382973|NCT03691116|Active Comparator|Treatment as usual|Psychological assessment and treatment as usual.
89382974|NCT03691038|Active Comparator|Pregabalin 75mg bid|The patients who were prescribed according to the conventional flexible dose regimen
89382975|NCT03691038|Experimental|pregabalin 25mg,50mg|The patients who were prescribed according to the new flexible dose regimen.
89382976|NCT03686982|Experimental|Active Nitrate Bar|include dietary nitrate; L-citrulline; epicatechin; vitamin C and glutathione
89382977|NCT03686982|Placebo Comparator|Placebo Bar|Containing no active ingredients
89382978|NCT05597319||ERAS-in|Patients who completed ERAS program
89382979|NCT05597319||ERAS-out|Patients who dropped-out from ERAS program
89382980|NCT03690960|Experimental|electrospun TAP nanofibers|Revascularization procedure with Electrospun TAP nanofibers as as an intracanal medicament for immature necrotic teeth
89382981|NCT03690960|Active Comparator|modified TAP paste|Revascularization procedure with modified TAP paste as an intracanal medicament for immature necrotic teeth
89382982|NCT03683160|Experimental|Cognitive Augmented Mobility Program|CAMP will combine education, one-on-one cognitive strategy training, and a cardiovascular and strength-training program conducted within a group setting. It will be run as a group of up to 6 participants, facilitated by a physiotherapist and a physiotherapy assistant or kinesiologist. It consists of 2 phases with a total of 19 sessions: Intervention Preparation (3 sessions), Active Intervention (16 sessions), and Follow-Up (1 session).
89382983|NCT03683082|Active Comparator|PAH patients|Supplementation of oxygen therapy (40% FiO2) during steady state cardiopulmonary exercise testing, via Venturi mask
88855977|NCT02263729|Active Comparator|losartan|Subjects will taken 50mg of losartan per day for 4 weeks
88855978|NCT02263729|Placebo Comparator|placebo|Subjects will be given placebo to replicate appearance of losartan pills. Placebo pill will be taken once per day.
88855979|NCT02161783||Treatment|This regimen consists of cyclophosphamide and fludarabine with low dose total body irradiation (TBI), followed by hematopoietic stem cell infusion.
88855980|NCT02042300||IRIS-Xpedition/Alpine/Sierra Cohort|XIENCE Xpedition/Alpine/Sierra
88855981|NCT02039752||Multivessel|from 1995
89382984|NCT03683082|Sham Comparator|PAH patients (crossover)|Supplementation of medical air (sham oxygen) during steady state cardiopulmonary exercise testing, via Venturi mask
89382985|NCT03686826||multiple sclerosis patients|
89002855|NCT06088498|Experimental|Aim 2:Quitline plus smartphone App|Participants randomized to this arm will receive usual care for smoking cessation via the quitline and a smartphone app that will allow them to track smoking urges and abstinence. After 48 hours of self-reported abstinence, they will be exposed to smoking extinction trials through the study smartphone app.
89002856|NCT06088303|Experimental|CPT/PE with AWARE|"Participants randomized into this arm will receive either cognitive processing therapy (CPT) or prolonged exposure (PE) with the adjunctive writing intervention to amplify response and engagement (AWARE).~CPT and PE are both recommended as gold standard treatments by published PTSD clinical practice guidelines. Participants will choose whether to receive CPT or PE. The standard treatment length will be 8-15 weekly sessions; however, participants and providers may collaboratively agree to early completion or additional sessions as warranted. AWARE will be integrated into the CPT/PE sessions."
89002857|NCT06088303|Active Comparator|CPT/PE TAU|"Participants randomized into this arm will receive either cognitive processing therapy (CPT) or prolonged exposure (PE) treatment as usual (TAU).~CPT and PE are both recommended as gold standard treatments by published PTSD clinical practice guidelines. Participants will choose whether to receive CPT or PE. The standard treatment length will be 8-15 weekly sessions; however, participants and providers may collaboratively agree to early completion or additional sessions as warranted."
89002858|NCT06086626|Experimental|Single-Dose Cefiderocol|Participants will receive a single dose cefiderocol on Day 1, along with standard of care antibiotics
89002859|NCT06086626|Experimental|Multiple-Dose Cefiderocol|Participants will receive cefiderocol every 8 hours for 5 to 14 days, along with standard of care antibiotics
89535092|NCT03239743|Experimental|Virtual Reality Group|Subjects will be given the virtual reality device to interact with prior to surgery without the use of a pre-medication.
89535093|NCT03239743|Active Comparator|Midazolam Group|Subjects will be given the drug Midazolam to help alleviate the pre-operative anxiety.
89002862|NCT06077864|Experimental|survodutide 3.6 mg|
89002863|NCT06077864|Experimental|survodutide 6.0 mg|
89002864|NCT06077864|Placebo Comparator|Placebo|
89002865|NCT06077500|Experimental|Part A - Dose escalation: BI 764532 very low dose + carboplatin + etoposide + atezolizumab|
89002866|NCT06077500|Experimental|Part A - Dose escalation: BI 764532 low dose + carboplatin + etoposide + atezolizumab|
89002867|NCT06077500|Experimental|Part A - Dose escalation: BI 764532 medium dose + carboplatin + etoposide + atezolizumab|
89002868|NCT06077500|Experimental|Part A - Dose escalation: BI 764532 high dose + carboplatin + etoposide + atezolizumab|
89002869|NCT06077500|Experimental|Part B - Dose expansion: BI 764532 + carboplatin + etoposide + atezolizumab|
89002870|NCT06077500|Experimental|Part B - Dose expansion: BI 764532 + carboplatin + etoposide + durvalumab|
89002871|NCT06077500|Experimental|Part B - Dose expansion: BI 764532 + cisplatin + etoposide + durvalumab|
89002872|NCT06075095|Experimental|Treatment Sequence 1|"Each participant will participate in 3 treatment periods of approximately 4 weeks each (one period for each of 3 study interventions) in the following sequence.~Sequence 1:~BGF MDI HFO 320/14.4/9.6 μg BGF MDI HFA 320/14.4/9.6 μg Placebo MDI HFA"
89002873|NCT06075095|Experimental|Treatment Sequence 2|"Each participant will participate in 3 treatment periods of approximately 4 weeks each (one period for each of 3 study interventions) in the following sequence.~Sequence 2:~BGF MDI HFO 320/14.4/9.6 μg Placebo MDI HFA BGF MDI HFA 320/14.4/9.6 μg"
89002874|NCT06075095|Experimental|Treatment Sequence 3|"Each participant will participate in 3 treatment periods of approximately 4 weeks each (one period for each of 3 study interventions) in the following sequence.~Sequence 3:~BGF MDI HFA 320/14.4/9.6 μg BGF MDI HFO 320/14.4/9.6 μg Placebo MDI HFA"
89002875|NCT06075095|Experimental|Treatment Sequence 4|"Each participant will participate in 3 treatment periods of approximately 4 weeks each (one period for each of 3 study interventions) in the following sequence.~Sequence 4:~BGF MDI HFA 320/14.4/9.6 μg Placebo MDI HFA BGF MDI HFO 320/14.4/9.6 μg"
89002876|NCT06075095|Experimental|Treatment Sequence 5|"Each participant will participate in 3 treatment periods of approximately 4 weeks each (one period for each of 3 study interventions) in the following sequence.~Sequence 5:~Placebo MDI HFA BGF MDI HFO 320/14.4/9.6 μg BGF MDI HFA 320/14.4/9.6 μg"
89002877|NCT06075095|Experimental|Treatment Sequence 6|"Each participant will participate in 3 treatment periods of approximately 4 weeks each (one period for each of 3 study interventions in the following sequence.~Sequence 6:~Placebo MDI HFA BGF MDI HFA 320/14.4/9.6 μg BGF MDI HFO 320/14.4/9.6 μg"
89002878|NCT06074263|Experimental|Steroid|Dexamethasone 8mg
89002879|NCT06074263|Placebo Comparator|Placebo|Placebo
89002880|NCT06073184|Experimental|Control Arm|pIUD
89002881|NCT06073184|Experimental|Intervention Arm|tirzepatide + pIUD
89002882|NCT06068049||Cohort 1|Patients diagnosed with locally advanced or metastatic NSCLC with activating EGFR mutations that received first line treatment with osimertinib (FLAURA regimen).
89002883|NCT06068049||Cohort 2|Patients with stage IB-IIIA NSCLC after complete tumour resection that has activating mutations in the EGFR (deletion of exon 19 or substitution of exon 21 [L858R]) that received adjuvant treatment with osimertinib (ADAURA regimen).
89002884|NCT06066528|Experimental|Survodutide 3.6 mg|
89002885|NCT06066528|Experimental|Survodutide 6.0 mg|
89002886|NCT06066528|Placebo Comparator|Placebo|
89002887|NCT06066515|Experimental|Survodutide 3.6 mg|
89382986|NCT03686826||healthy volunteers|
88818556|NCT05748119|Placebo Comparator|A4a Placebo|Single Sentinel Placebo Comparator for 200 mg Dose of MEB-1170
89002888|NCT06066515|Experimental|Survodutide 6.0 mg|
89002889|NCT06066515|Placebo Comparator|Placebo|
89002890|NCT06063967|Experimental|Period A: Risankizumab Dose A|Participants randomized to receive risankizumab Dose A administered by subcutaneous (SC) injection for up to 12 weeks during Period A.
89002891|NCT06063967|Placebo Comparator|Period A: Placebo|Participants randomized to receive placebo risankizumab administered by Subcutaneous (SC) injection for up to 12 weeks during Period A.
89002892|NCT06063967|Experimental|Period B: Risankizumab Dose B|Participants randomized to receive risankizumab Dose A in Period A that achieved adequate response to receive risankizumab Dose B administered by subcutaneous (SC) injection for up to 20 weeks.
88855982|NCT01997710|Experimental|all-ceramic inlay-retained RBFDP|Treatment with an all-ceramic inlay-retained RBFDP
88855983|NCT01997710|Active Comparator|all-ceramic RBFDP|Treatment with an all-ceramic RBFDP
88855984|NCT01868438|Active Comparator|Pyronaridine-artesunate granules (Period 1)|"Period 1: single administration of pyronaridine-artesunate granules: total dose 540mg pyronaridine + 180mg artesunate.~Period 2: cross-over to single administration of pyronaridine-artesunate tablets: total dose 540mg pyronaridine + 180mg artesunate."
88855985|NCT01868438|Active Comparator|Pyronaridine-artesunate tablets (Period1)|"Period 1: single administration of pyronaridine-artesunate tablets: total dose 540mg pyronaridine + 180mg artesunate.~Period 2: cross-over to single administration of pyronaridine-artesunate granules: total dose 540mg pyronaridine + 180mg artesunate."
88855986|NCT01554046|Experimental|couples of first-degree family members|
88855987|NCT01208662|Experimental|RVD Alone|"All participants received one cycle of Lenalidomide (R), bortezomib (V) and dexamethasone (D) and then were randomized. All participants then received two additional RVD cycles, followed by stem-cell collection. RVD Alone participants received five additional RVD cycles. Maintenance in both arms comprised daily lenalidomide 10 mg, escalated to 15 mg if tolerated, until disease progression, unacceptable toxicity, or withdrawal from treatment or study. After finishing protocol-specified treatment, off-study salvage transplantation was recommended but not mandated for RVD Alone participants at relapse.~RVD cycle duration=21 days R: 25 mg oral on days 1-14 V: 1.3 mg per square meter of body surface area IV or subcutaneous on days 1, 4, 8, and 11 D: 20 mg oral (cycles 1-3) or 10 mg (cycles 4-8) on days 1, 2, 4, 5, 8, 9, 11, and 12"
88855988|NCT01208662|Active Comparator|RVD plus ASCT|"All participants received one cycle of Lenalidomide (R), bortezomib (V) and dexamethasone (d) and then were randomized. All participants then received two additional RVD cycles, followed by stem-cell collection. RVD plus autologous stem cell transplant (ASCT) participants received high-dose melphalan (200 mg/m2, adjusted for ideal body weight) ASCT and, upon recovery (~day 60), two additional RVD cycles. Maintenance in both arms comprised daily lenalidomide 10 mg, escalated to 15 mg if tolerated, until disease progression, unacceptable toxicity, or withdrawal from treatment or study.~After finishing protocol-specified treatment, RVD plus ASCT participants could undergo a second transplant.~RVD cycle duration=21 days R: 25 mg oral on days 1-14 V: 1.3 mg per square meter of body surface area IV or subcutaneous on days 1, 4, 8, and 11 D: 20 mg oral (cycles 1-3) or 10 mg (cycles 4-8) on days 1, 2, 4, 5, 8, 9, 11, and 12"
88855989|NCT01186133||DESSIAN|consecutive patients receiving CYPHER stent
88855990|NCT01186133||K-XIENCE|consecutive patients receiving Xience stent
88855991|NCT01186133||GENOUS|consecutive patients receiving GENOUS stent
88855992|NCT01186133||ELEMENT|consecutive patients receiving PROMUS-ELEMENT stent
88855993|NCT01186133||PRIME|consecutive patients receiving XIENCE-PRIME stent
88855994|NCT01186133||NOBORI|consecutive patients receiving NOBORI stent
88855995|NCT01186133||INTEGRITY|consecutive patients receiving RESOLUTE-INTEGRITY stent
88855996|NCT01186133||XPEDITION|consecutive patients receiving XIENCE-XPEDITION stent
88855997|NCT01186133||BIOMATRIX|consecutive patients receiving BIOMATRIX stent
88855998|NCT01186133||CILOTAX|consecutive patients receiving CILOTAX stent
88855999|NCT01186133||DEB|consecutive patients receiving Drug eluting balloon
88856000|NCT01186133||DESYNE|consecutive patients receiving DESYNE stent
88856001|NCT01186133||PREMIER|consecutive patients receiving PROMUS-PREMIER stent
88856002|NCT01186133||ORSIRO|consecutive patients receiving ORSIRO stent
88856003|NCT01186133||ONYX|consecutive patients receiving ONYX stent
88856004|NCT01186133||BVS|consecutive patients receiving Bioresorbable Vascular Scaffold
88856005|NCT01186133||BVS AMI|consecutive acute myocardial infarction patients receiving Bioresorbable Vascular Scaffold
88856006|NCT01186133||Ultimaster|consecutive patients receiving Ultimaster stent
88856007|NCT01186133||Synergy|consecutive patients receiving Synergy stent
88856008|NCT01186133||Biofreedom|consecutive patients receiving Biofreedom stent
88856009|NCT01186133||Firehawk|consecutive patients receiving Firehawk stent
88856010|NCT01186133||DESyne X2|consecutive patients receiving DESyne X2 stent
88856011|NCT01186133||Sierra|consecutive patients receiving Sierra stent
88856012|NCT01186133||Tansei|consecutive patients receiving Tansei stent
88856013|NCT01186133||Synergy XD and Synergy Megatron™|consecutive patients receiving Synergy XD or Synergy Megatron™ stent
88856014|NCT01186133||Xience-Skypoint|consecutive patients receiving Xience-Skypoint stent
88856015|NCT01186133||Coroflex ISAR NEO|consecutive patients receiving Coroflex ISAR NEO stent
88856016|NCT01081028||Group One: Patients enrolled between Sep2009 and Nov2011|Newly diagnosed multiple myeloma patients enrolled between Sep 2009 and Nov 2011.
88856017|NCT01081028||Group Two: Patients enrolled between Dec2012 and mid-2016|Newly diagnosed multiple myeloma patients enrolled between Dec 2012 and mid-2016
88856018|NCT00929045|Experimental|Growth Hormone|
88856019|NCT00683631||TheraSphere|TheraSphere
88856020|NCT00540774|Other|Oral tissue|Imaging of oral structures and pathologies
88856021|NCT01457352|Experimental|SPARC0921|
88856022|NCT01457352|Placebo Comparator|Placebo0921|
88856023|NCT01457118|Experimental|NKTR-102|
88856024|NCT01456962||Raltegravir group|HIV-1-infected women on a regimen of tenofovir (TDF) and emtricitabine (FTC) with raltegravir (RAL)
88856025|NCT01456962||Atazanavir group|HIV-1-infected women on a regimen of tenofovir (TDF) and emtricitabine (FTC) with ritonavir (RIT)-boosted atazanavir (ATZ)
88856026|NCT01501110|Active Comparator|n-acetylcysteine|intra-venous infusion of 1200 mg of n-acetylcysteine twice a day for 48 hours.
88856027|NCT01501110|No Intervention|no intervention|No intervention
88856028|NCT01500720|Experimental|Cabazitaxel|
88856029|NCT01500720|Active Comparator|Topotecan|
88856030|NCT04408872|Active Comparator|EGD|SUBJECT WILL UNDERGO ESOPHAGO-GASTRO-DUODENOSCOPY (EGD)
88856031|NCT04408872|Experimental|EUS|SUBJECT WILL UNDERGO ENDOSCOPIC ULTRASOUND (EUS)
88856032|NCT01500252|Experimental|Patellar Resurfacing|These subjects received a Profix TKR including an all polyethylene patellar implant.
88856033|NCT01500252|Active Comparator|Patellar Retention|This group received a Profix TKR, but retained their native patella
89183769|NCT02866149|Other|"Cohort 5 - Post-TP53"|"Follow-up of patients previously treated by neoadjuvant chemotherapy for triple negative breast cancer.~Timing of blood sampling:~Inclusion~up to 3 other samples, timepoints decided by the investigator."
89183770|NCT02866149|Other|"Cohort 6 - Palbociclib"|"Monitoring of patients treated with palbociclib~Timing of blood sampling:~Inclusion day (2 samples)~after #2 weeks of therapy~after #4 weeks of therapy~at progression."
88818557|NCT05748119|Experimental|A4a MEB-1170|Single MEB-1170 Sentinel 200 mg Dose
88856034|NCT01476696|Experimental|Part A: Prasugrel Single Dose|Prasugrel 0.03 milligrams per kilogram (mg/kg) to 0.60 mg/kg dosage to be titrated up or down based on desired platelet inhibition, administered orally [oral-disintegrating tablet (ODT)], single dose given up to 3 occasions, at different strengths, with up to 18 days between doses.
88856035|NCT01476696|Experimental|Part B: Prasugrel Once-Daily Dose|Daily prasugrel dose (mg/kg) that is expected to achieve mean platelet activation inhibition of 30% administered orally, once daily for 10-18 days and then followed by prasugrel dose (mg/kg) that is expected to achieve mean platelet activation inhibition of 50% administered orally, once daily for 10-18 days, for a total of 20-36 days.
88856036|NCT01500096|Active Comparator|American ginseng 1000 mg/day|4-week of American ginseng 1000 mg/day every morning
88856037|NCT01500096|Placebo Comparator|Placebo for American ginseng 1000 mg/day|4-week of placebo for American ginseng 1000 mg/day every morning
88856038|NCT01500096|Active Comparator|American ginseng 3000 mg/day|4-week of American ginseng 3000 mg/day every morning
88856039|NCT01500096|Placebo Comparator|Placebo for American ginseng 3000 mg/day|4-week of placebo for American ginseng 3000 mg/day every morning
88856040|NCT04767438||Pregnant women|All singleton pregnancies that present to the 12-week scan in the Obstetrics Unit of the participant hospitals. Singleton pregnancies; Gestational age less than 14 weeks, estimated according to Crown-Rump Length (CRL); Blood sample between 8 and 14 weeks of pregnancy; Patients who accept to participate in the study and sign the informed consent.
88856041|NCT01455012|Experimental|Rotigotine|Rotigotine, optimal dose (minimum dose 1 mg/24 h, maximum dose 3 mg/24 h)
88856042|NCT01455012|Placebo Comparator|Placebo|Placebo
88856043|NCT01454778|Experimental|Paclitaxel|
88856044|NCT04408404||Type A aortic dissection|Patient operated for type A acute aortic dissection between 01 January 2007 and 31 December 2017 in Dijon Burgundy University Hospital
88856045|NCT01454076|Experimental|Arm 1: Ixazomib 2.5 mg + Ketoconazole 400 mg|Ixazomib 2.5 milligram (mg), capsule B, orally, once on Day 1 and 15 along with ketoconazole 400 mg, tablets, orally, once daily from Day 12 to 25 of Cycle 1 (28-day treatment cycle). After Cycle 1, participants will receive ixazomib 4 mg, capsule B, orally, once daily on Days 1, 8 and 15 of each cycle (28-day treatment cycle) up to a maximum of 12 cycles, until disease progression or unacceptable toxicity.
88856046|NCT01454076|Experimental|Arm 2: Ixazomib 4 mg Capsule A or B|Ixazomib 4 mg, capsule A, orally, once on Day 1 followed by ixazomib 4 mg, capsule B once on Day 15 of Cycle 1 (28-day treatment cycle) or ixazomib 4 mg, capsule B, orally, once on Day 1 followed by ixazomib 4 mg, capsule A once on Day 15 of Cycle 1 (28-day treatment cycle). After Cycle 1, participants will receive ixazomib 4 mg, capsule B, orally, once daily on Days 1, 8 and 15 of each cycle (28-treatment cycle) up to a maximum of 12 cycles, until disease progression or unacceptable toxicity.
88856047|NCT01454076|Experimental|Arm 3: Ixazomib 4 mg Fasted or Fed|Ixazomib 4 mg, capsule B, orally, under fasted state, once on Day 1 followed by ixazomib 4 mg, capsule B, orally, under fed state, once on Day 15 of Cycle 1 (28-day treatment cycle) or ixazomib 4 mg, capsule B, orally, under fed state, once on Day 1 followed by ixazomib 4 mg, capsule B, orally, under fasted state, once on Day 15 of Cycle 1 (28-day treatment cycle). After Cycle 1, participants will receive ixazomib 4 mg, capsule B, orally, once daily on Days 1, 8 and 15 of each cycle (28-day treatment cycle) up to a maximum of 12 cycles, until disease progression or unacceptable toxicity.
88856048|NCT01454076|Experimental|Arm 4: Ixazomib 4 mg + Rifampin 600 mg|Ixazomib, 4 mg, capsule B, orally, once on Day 8 along with rifampin 600 mg, capsule, orally, once daily from Day 1 to 14 of Cycle 1 (21-day treatment cycle). After Cycle 1, participants will receive ixazomib 4 mg, capsule B, orally, once daily on Days 1, 8 and 15 of each cycle (28-day treatment cycle) up to a maximum of 12 cycles, until disease progression or unacceptable toxicity.
88856049|NCT01454076|Experimental|Arm 5: Ixazomib 2.5 mg + Clarithromycin 500 mg|Ixazomib, 2.5 mg, capsule B, orally, once on Day 6 along with clarithromycin, 500 mg, tablet, orally, twice daily from Day 1 to 16 of Cycle 1 (21-day treatment cycle). After Cycle 1, participants will receive ixazomib 4 mg, capsule B, orally, once daily on Days 1, 8 and 15 of each cycle (28-day treatment cycle) up to a maximum of 12 cycles, until disease progression or unacceptable toxicity.
89002893|NCT06063967|Placebo Comparator|Period B: Placebo|Participants randomized to receive placebo risankizumab in Period A that achieved adequate response to continue to receive placebo risankizumab administered by Subcutaneous (SC) injection for up to 20 weeks in Period B.
89183771|NCT02866149|Other|"Cohort 7 - CTC_PD-L1_Breast"|"Detection of PD-L1 in metastatic breast cancer patients~Timing of blood sampling:~Inclusion~up to 3 other samples, timepoints decided by the investigator."
89183772|NCT02866149|Other|"Cohort 8 - CTC_PD-L1_Broncho-Pulmonary"|"Detection of PD-L1 in metastatic lung cancer patients~Timing of blood sampling:~Inclusion~up to 3 other samples, timepoints decided by the investigator."
89183773|NCT02866149|Other|"Cohort 9 - NSCLC"|"Monitoring of patients with Non-Small Cell lung Cancer treated by immune therapy.~Blood sampling at 4 timepoints."
88818558|NCT05748119|Placebo Comparator|A4b Placebo|Single Placebo comparator for 200 mg dose cohort of MEB-1170
88818559|NCT05748119|Placebo Comparator|A4b MEB-1170|Single MEB-1170 200 mg dose cohort
88818560|NCT05748119|Placebo Comparator|A5a Placebo|Single Sentinel Placebo Comparator for 400 mg Dose of MEB-1170
88818561|NCT05748119|Experimental|A5a MEB-1170|Single MEB-1170 Sentinel 400 mg Dose
88818562|NCT05748119|Placebo Comparator|A5b Placebo|Single Placebo comparator for 400 mg dose cohort of MEB-1170
88818563|NCT05748119|Experimental|A5b MEB-1170|Single MEB-1170 400 mg dose cohort
88818564|NCT05748119|Placebo Comparator|B1 Placebo|MAD Placebo 60 mg comparator cohort of MEB-1170
88818565|NCT05748119|Experimental|B1 MEB-1170|MAD 60 mg MEB-1170 cohort
88818566|NCT05748119|Placebo Comparator|B2 Placebo|MAD Placebo 100 mg comparator cohort of MEB-1170
88818567|NCT05748119|Experimental|B2 MEB-1170|MAD 100 mg MEB-1170 cohort
89382987|NCT03682926|Experimental|electrostimulation individualized|Selective electrostimulation for tonic fiber, phasic fiber FIa and FIIb and different stimulus times. Muscle fibers (Tonic) with a frequency of 20Hz, pulse width (t) of 700μs to 1ms, time of rise and fall of the wave of 1.0 seconds, duration of contraction and repetition was based on the perineal evaluation But the resting time was twice as long as sustained. For the IIa (phasic) fibers the frequency was 50 Hz with a pulse width of 400μs to 500μs, for 3 seconds of sustentation and 6 seconds of relaxation, time of rise of 0,5 seconds and 0,5 seconds of descent. E for type IIb (phasic) fibers, 80 Hz frequency, pulse width 250μs to 400μs, 1 second contraction for 3 seconds rest and 0.2 seconds rise and fall time.
88856050|NCT01453998|Experimental|GSK217744 Group 1|Subjects aged between and including 12 and 15 months at the time of booster vaccination who received the GSK217744 formulation A vaccine in the primary study and a booster dose of either GSK217744 formulation A vaccine (for subjects vaccinated before Protocol Amendment 2) or Infanrix hexa vaccine (for subjects vaccinated after Protocol Amendment 2) in this study, coadministered with a booster dose of Prevenar 13. The Infanrix hexa/GSK217744 and Prevenar 13 vaccines were administered intramuscularly into the right and left sides of the thigh, respectively.
89382988|NCT03682926|Active Comparator|electrostimulation with fixed protocol|Intervention -Electro-stimulate all fibers with a single electrical parameter. Pulse width 700μs, rise and fall time of 2 seconds each, sustain time of 4 seconds and rest 8 seconds for 20 minutes, the intensity will be modulated, as in the previous group by patient tolerance in milliamperes.
89382989|NCT03690882||Cases of unclassified acute cervical pain|
89382990|NCT03686748|Experimental|Two-point intervention|Two point discrimination training.
89382991|NCT03686748|Active Comparator|One-point intervention|One point discrimination of size of probe
89382992|NCT03686748|No Intervention|Healthy Controls|Observational component of differences in discrimination between chronic pain patients and healthy controls.
89382993|NCT02927847|Experimental|BA + VLNC|Participants will receive Nicotine Patch, SPECTRUM Nicotine Research Cigarettes (.03), and behavioral treatment prior to quit attempt, followed by standard nicotine replacement therapy with Nicotine Patch during the quit attempt. Behavioral treatments in this condition will include standard smoking cessation counseling plus behavioral activation therapy aimed at increasing reinforcement from non-drug rewards.
89382994|NCT02927847|Active Comparator|VLNC Only|Participants will receive Nicotine Patch, SPECTRUM Nicotine Research Cigarettes (.03), and behavioral treatment prior to quit attempt, followed by standard nicotine replacement therapy with Nicotine Patch during quit attempt. Behavioral treatments in this condition will include standard smoking cessation counseling plus supportive counseling and health education.
89382995|NCT03690804|Experimental|newborn is above 28 weeks of gestational age|40 parent-newborn duos in which the newborn is above 28 weeks of gestational age and less than 3 months of life and hospitalized in neonatal intensive care units of our university hospital (Saint-Etienne - France)
89382996|NCT03682692|Experimental|ACEI/CCB|
89382997|NCT03682692|Experimental|ACEI/DIU|
89382998|NCT02960438|Experimental|E6011 100 milligrams (mg)|In the Treatment Phase, E6011 100 mg will be subcutaneously administered at Weeks 0, 1, and 2, and then every 2 weeks up to Week 22. In the Extension Phase, E6011 200 mg will be subcutaneously administered every 2 weeks until Week 102.
89382999|NCT02960438|Experimental|E6011 200 mg|In the Treatment Phase, E6011 200 mg will be subcutaneously administered at Weeks 0, 1, and 2, and then every 2 weeks up to Week 22. In the Extension Phase, E6011 200 mg will be subcutaneously administered every 2 weeks until Week 102.
88856051|NCT01453998|Experimental|GSK217744 Group 2|Subjects aged between and including 12 and 15 months at the time of booster vaccination who received the GSK217744 formulation B vaccine in the primary study and a booster dose of either GSK217744 formulation B vaccine (for subjects vaccinated before Protocol Amendment 2) or Infanrix hexa vaccine (for subjects vaccinated after Protocol Amendment 2) in this study, coadministered with a booster dose of Prevenar 13. The Infanrix hexa/GSK217744 and Prevenar 13 vaccines were administered intramuscularly into the right and left sides of the thigh, respectively.
88856052|NCT01453998|Active Comparator|Infanrix hexa Group|Subjects aged between and including 12 and 15 months at the time of booster vaccination who received the Infanrix hexa vaccine in the primary study and a booster dose of Infanrix hexa in this study, co-administered with a booster dose of Prevenar 13. The Infanrix hexa and Prevenar 13 vaccines were administered intramuscularly into the right and left sides of the thigh, respectively.
88856053|NCT01453374|Experimental|VIVITROL|380 mg IM injection
89383000|NCT02960438|Experimental|E6011 400 mg|In the Treatment Phase, E6011 400 mg will be subcutaneously administered at Weeks 0, 1, 2, 4, 6, 8, and 10, and then E6011 200 mg will be subcutaneously administered every 2 weeks up to Week 22. In the Extension Phase, E6011 200 mg will be subcutaneously administered every 2 weeks until Week 102.
89383001|NCT02960438|Placebo Comparator|Placebo|In the Treatment Phase, placebo will be subcutaneously administered at Weeks 0, 1, and 2, and then every 2 weeks up to Week 22. In the Extension Phase, E6011 200 mg will be subcutaneously administered every 2 weeks until Week 102.
89383002|NCT01383291||Pelvic floor prolapse|Those who underwent prolift and those who underwent IVS
89383003|NCT03690726|Experimental|Active rTMS|SCI patients fulfilling criteria for participation giving informed written and verbal consent, who are enrolled and randomised to active treatment arm receive consecutive treatment sessions with rTMS directed at cranium and cortex regions as described in protocol.
89383004|NCT03690726|Sham Comparator|Sham rTMS|SCI patients fulfilling criteria for participation giving informed written and verbal consent, who are enrolled and randomised to sham/control arm receive consecutive treatment sessions with coil from rTMS that fires at other spot (pillow/mattress) as described in protocol.
89383005|NCT02853591|Active Comparator|Standard High Pressure (15mmHg)|Pneumoinsufflator mode and setting: standard at 15mmHg
89383006|NCT02853591|Experimental|AirSeal High Pressure (15mmHg)|Pneumoinsufflator mode and setting: pressure-barrier at 15mmHg
89002894|NCT06063967|Experimental|Period B: Risankizumab Dose C|Participants with inadequate response in Period A to receive Dose C administered by Subcutaneous (SC) injection for up to 20 weeks during Period B
89002895|NCT06062394|No Intervention|Usual Care|This group will not receive the intervention and will continue with usual care.
89002896|NCT06062394|Experimental|Penn Med Healthy Heart Program|The Intervention group will receive the blood pressure monitor and move through the 4 HDPP modules of the intervention.
89383007|NCT02853591|Experimental|Standard Low Pressure (9mmHg)|Pneumoinsufflator mode and setting: standard at 9mmHg
89383008|NCT02853591|Experimental|AirSeal Low Pressure (9mmHg)|Pneumoinsufflator mode and setting: pressure-barrier at 9 mmHg
89383009|NCT03686592|Experimental|pancreatectomized patients|Patients with pancreatic cancer who underwent a pancreatectomy at Institut Paoli Calmettes
89383010|NCT03686592|Active Comparator|Volunteers|
89383011|NCT03808506||Ulcerative colitis patients|Patients with documented ulcerative colitis who are initiating adalimumab therapy will have baseline bowel ultrasound and fecal calprotectin completed.
89383012|NCT03686280|Experimental|Robot in combination with traditional reeducation|
89383013|NCT03686280|Active Comparator|Standard rehabilitation|
89383014|NCT02957942|Experimental|Spasmodic Dysphonia|1Hz repetitive transcranial magnetic stimulation (rTMS)
89383015|NCT02957942|Active Comparator|Healthy control|Healthy adults 1Hz repetitive transcranial magnetic stimulation (rTMS)
89383016|NCT04059354|Experimental|Speech therapy|Direct speech therapy will be provided for a 12 week period with up to three one-hour sessions per week.
89383017|NCT03640910|Experimental|OT Equators® (Rhein83)|After gingival healing the newest low-profile OT Equators® (Rhein83) will be screwed on to the implants, using the OT Equator® square screwdriver (Rhein83), with a torque range of 22-25 N cm. The cuff heights ranged from 0.5 to 7.0 mm, depending on the height of the transition zone of each implant, easily measured using the color-coded millimeter Cuff Height Measurer Gauge (Rhein83) after healing abutment removal.
89383018|NCT03640910|Active Comparator|Locator® (Zest)|The low-profile attachments Locator® (Zest) will be screwed on to the implants, using the Locator® screwdriver (Zest), with a torque range of 20-25 N cm. The cuff heights of 2.5 or 4.0 mm, depending on the height of the transition zone of each implant, measured using the deep probe of the implant line after healing abutment removal.
89383019|NCT03686046||Exploratory use|Brief (2 hour) exploratory use of prototype self-adjusted wearable Master Hearing Aid
89383020|NCT03682380|Experimental|Part 1: Seltorexant High Dose|In Part 1, participants will receive the following treatments: Treatment A: Two low doses of seltorexant tablets (reference formulation), Treatment B: High dose of seltorexant tablet (Test formulation 1), Treatment C: High dose of seltorexant tablet (Test formulation 2), Treatment D: Two low doses of seltorexant tablets (Test formulation 3), Treatment E: Two low doses of seltorexant tablets (Test formulation 4), Treatment F: Two low doses of seltorexant tablets (Test formulation 5), as one of 6 possible treatment sequences on Day 1 in each treatment Periods (Period 1-6). There will be a washout Period of 7 to 14 days from dosing on Day 1 of each treatment period.
89383021|NCT03682380|Experimental|Part 2: Seltorexant High Dose|Participants will receive the following treatments: Treatment G: Two low doses of seltorexant tablets (Reference formulation), Treatment H: High dose or two low doses of seltorexant tablet (Test formulation 1), Treatment I: High dose of seltorexant tablet (Test formulation 2), as one of 6 possible treatment sequences on Day 1 in each treatment Periods (Period 1-3). There will be a washout period of 7 to 14 days from dosing on Day 1 of each treatment period.
88818568|NCT05748119|Placebo Comparator|B3 Placebo|MAD Placebo 200 mg comparator cohort of MEB-1170
88818569|NCT05748119|Experimental|B3 MEB-1170|MAD 200 mg MEB-1170 cohort
88818570|NCT05748119|Placebo Comparator|B4 Placebo|MAD Placebo 400 mg comparator cohort of MEB-1170
88818571|NCT05748119|Experimental|B4 MEB-1170|MAD 400 mg MEB-1170 cohort
88818572|NCT05748119|Placebo Comparator|A3a Placebo Fed State|Single Sentinel Placebo Comparator for 120 mg Dose of MEB-1170 in Fed State
88818573|NCT05748119|Experimental|A3a MEB-1170 Fed State|Single Sentinel 120 mg Dose of MEB-1170 in Fed State
88818574|NCT05748119|Placebo Comparator|A3b Placebo Fed State|Single Placebo comparator for 120 mg dose cohort of MEB-1170 in Fed State
88818575|NCT05748119|Experimental|A3b MEB-1170 Fed State|Single MEB-1170 120 mg dose cohort in Fed State
88818576|NCT02696967|Experimental|CLR325|Patients were assigned to one of the 2 treatment arms in fixed randomization ratio. Patients randomized to this arm received single dose of CLR325 (i.v.) in double blind manner.
88818577|NCT02696967|Placebo Comparator|Placebo|Patients were assigned to one of the 2 treatment arms in fixed randomization ratio. Patients randomized to this arm received single dose of placebo (i.v.) in double blind manner.
88818578|NCT00557375||1|Brain tumor patients
88818579|NCT00557375||2|Caregivers of brain tumor patients
88818580|NCT01415960|Experimental|Leuprolide acetate 22.5 mg depot|Leuprolide acetate 22.5 mg depot administered twice, 3 months apart
88818581|NCT01833845|Experimental|Ribavirin+HCQ|Administration of RBV monotherapy for a period of 8 weeks following administration of up to 16 weeks combination therapy with ribavirin(RBV) plus Hydroxychloroquine(HCQ).
88818582|NCT01416194||Bazedoxifene|
88818583|NCT01416194||Primary Comparator|
88818584|NCT01416194||Secondary Comparator|
88818585|NCT01416584|No Intervention|Usual Care Control|Participants in this group were offered employment in the Therapeutic Workplace without urinalysis testing or the methadone treatment requirement. They were offered the methadone treatment but were not required to join in order to gain access to the workplace.
88818586|NCT01416584|Experimental|Methadone Contingency Group|Participants in this group were allowed to work and earn wages as long as they enrolled in the methadone treatment and continued to take does of methadone consistently (employment-based reinforcement).
88818587|NCT01416584|Experimental|Methadone & Abstinence Contingency|Participants in this group were able to access work if they enrolled in the methadone treatment and consistently took their medication, but they also received a decrease in base pay if they test positive for opiates or cocaine on the drug screens (employment-based reinforcement).
88818588|NCT02698215|Experimental|Varenicline plus Naltrexone|VAR (1 mg twice daily) + NTX (50 mg once daily)
88818589|NCT02698215|Placebo Comparator|Varenicline|VAR (1 mg twice daily)
88818590|NCT04172961|Experimental|Nanomicellular Cyclosporine 0.09 prior to surgery|50 subjects receive nanomicellular cyclosporien 0.09% prior to elective ophthalmic surgery
88818591|NCT04172961|Active Comparator|Lifitegrast 5.0%|50 subjects receive liftigrast 5.0% prior to elective ophthalmic surgery
89002897|NCT06061861|Experimental|Financial Support and Free Delivery|The intervention group will receive monthly financial support for healthy food items along with free home delivery through the Instacart platform.
89535094|NCT05021523|Experimental|HEAT group|Participants are doing passive and active heat exposures
89002898|NCT06061861|Experimental|Free Delivery|The control group will receive only free home delivery through the Instacart platform.
88856054|NCT01453296|Active Comparator|COHORT 1 (RANDOMISATION AB or BA)|"8-11 years old; Subjects will be assigned to receive GW642444 25μg or matching placebo (in a 1:1 ratio) in an AB or BA (A= GW64244, B= Placebo) sequence.~Following randomisation (AB or BA) subjects will receive a single dose treatment, followed by 7 day washout period. This will then be followed by a repeat dose session of the same treatment (Day 8 and Day 14 in house, Days 9-13 at home).~Each subject will then complete the same sequence for the alternative treatment in the second session. There will be a washout period of at least 7 days between the treatment periods."
88856055|NCT01453296|Active Comparator|COHORT 2 (RANDOMISATION AB or BA)|"5-7 years old. Subjects will be assigned to receive GW642444 25μg or matching placebo (in a 1:1 ratio) in an AB or BA (A= GW64244, B= Placebo) sequence.~Following randomisation (AB or BA) subjects will receive a single dose treatment, followed by 7 day washout period. This will then be followed by a repeat dose session of the same treatment (Day 8 and Day 14 in house, Days 9-13 at home).~Each subject will then complete the same sequence for the alternative treatment in the second session. There will be a washout period of at least 7 days between the treatment periods."
88856056|NCT01453140|Experimental|Cyclophosphamide and Sirolimus|cyclophosphamide and sirolimus combo
88856057|NCT01453140|Experimental|Lowdose IL-2, Cytoxan + Sirolimus|Low dose IL-2 with Cytoxan + Sirolimus Patients in treatment arm B will be receiving low-dose IL-2 in conjunction with the cyclophosphamide and sirolimus.
88856058|NCT01453140|Experimental|Lowdose IL-2, Vidaza, cyclophosphamide & Sirolimus|Lowdose IL-2, Vidaza, cyclophosphamide (Cytoxan) & Sirolimus Patients in treatment arm C will be receiving low-dose azacitidine (Vidaza).
88856059|NCT01499940|Experimental|Vitamin D3 2000 IU/day|Vitamin D3 2000 IU/day on day of 1st cycle of oxaliplatin; continue as long as patient treated with oxaliplatin and remains on study
88856060|NCT01499160|Experimental|HER2-positive or negative|Lapatinib 1,500 mg/day + letrozole 2.5 mg/day until progression followed by everolimus 5 mg/day + letrozole 2.5 mg/day + lapatinib 1,250 mg/day.
88856061|NCT01498692|Experimental|PROMUS Element|Patients enrolled in the study to receive treatment with the PROMUS Element everolimus-eluting stent
88856062|NCT01498068|Experimental|Treatment-naïve|Treatment naïve participants will receive telaprevir 750 mg 8 hourly for 12 weeks in combination with Peg-IFN alfa-2a 180 microgram weekly and RBV 1000 - 1200 mg daily (dependent on weight) for 24 or 48 weeks. Total treatment duration will be based on participant's prior treatment status, liver disease status, and individual ontreatment virologic response in this study.
88856063|NCT01498068|Experimental|Treatment-experienced|Treatment-experienced participants received telaprevir 750 mg 8 hourly for 12 weeks in combination with Peg-IFN alfa-2a 180 microgram weekly and RBV 1000 - 1200 mg daily (dependent on weight) for 24 or 48 weeks. Total treatment duration will be based on participant's prior treatment status, liver disease status, and individual on-treatment virologic response in this study.
88856064|NCT01497366|Experimental|Sofosbuvir+RBV|Participants were randomized to receive sofosbuvir+RBV for 12 weeks.
89383022|NCT03682380|Experimental|Part 3: Seltorexant Low Dose or High Dose|Part 3 will have 3 subparts (Part 3A, Part 3B, and Part 3C). In Part 3A and 3B, participants will receive high dose of seltorexant (selected formulation 6) and two low doses of seltorexant (selected formulation 7) respectively in a different food conditions on Day 1 in each treatment Periods (Periods 1-5). In Part 3C, participants will receive high dose of seltorexant (selected formulation 6) and two low doses of seltorexant (selected formulation 7 ) on Day 1 in each period (Period 1 and 2). There will be a washout period of 7 to 14 days from dosing on Day 1 of each treatment period.
88856065|NCT01497366|Active Comparator|PEG+RBV|Participants were randomized to receive PEG+RBV for 24 weeks.
88856066|NCT01475838|Experimental|Stribild|Participants will switch from their baseline treatment regimen to Stribild for up to 96 weeks, and may continue to receive Stribild in the extension phase.
88856067|NCT01475838|Active Comparator|PI+RTV+FTC/TDF|Participants will stay on their baseline treatment regimen antiretroviral regimen consisting of a PI boosted with RTV plus FTC/TDF for up to 96 weeks, and may switch to Stribild in the extension phase.
88856068|NCT01451814|Experimental|Positive psychotherapy|6 sessions of individual behavioral smoking cessation counseling that incorporates techniques from Positive Psychotherapy to increase positive affect and reduce negative affect prior to and after quitting smoking. Intervention includes 8 weeks of transdermal nicotine patch.
88856069|NCT01451814|Active Comparator|Standard treatment|6 sessions of individual behavioral smoking cessation counseling with 8 weeks of transdermal nicotine patch. Inlcudes relaxation training to match time in the experimental condition
88856070|NCT01475370|Experimental|OCV-501|
88856071|NCT01496430|Placebo Comparator|Placebo QD|Azilsartan medoxomil placebo-matching tablets, orally, once daily for up to 24 weeks.
88856072|NCT01496430|Experimental|Azilsartan Medoxomil 40 mg QD|Azilsartan medoxomil 40 mg, tablets, orally, once daily for up to 24 weeks.
88856073|NCT01496430|Experimental|Azilsartan Medoxomil 80 mg QD|Azilsartan medoxomil 80 mg, tablets, orally, once daily for up to 24 weeks.
88856074|NCT04408326||Angiotensin II|Patients with COVID-19 and acute respiratory distress syndrome who received angiotensin II as an add-on vasopressor will be collected
88856075|NCT04408326||Anakinra|Patients with COVID-19 and acute respiratory distress syndrome who received Anakinra (interleukin 1 receptor antagonist) will be collected
88856076|NCT04408326||Angiotensin II control|Patients with COVID-19 and acute respiratory distress syndrome who also received vasopressor support will be matched to angiotensin II group by date of intensive care unit admission, age, history of hypertension, history of angiotensin converting enzyme inhibitor/angiotensin receptor blocker, respiratory support
88856077|NCT04408326||Anakinra control|Patients with COVID-19 and acute respiratory distress syndrome will be matched to Anakinra group by matching age and date of intensive unit care admission
89183774|NCT02866149|Other|"Cohort 10 - Palbociclib II"|"Monitoring of patient with a metastatic breast cancer treated by palbociclib.~Timing of blood sampling:~Inclusion~after #4 weeks of therapy~at the first tumoral evaluation (month 3 or 4)~at progression."
89183775|NCT02866149|Other|Cohort 11 - Sarcomas|The cohort includes all patients with bone or soft tissue sarcoma. Timing of blood sampling depending on disease staging.
89383023|NCT03640442|Experimental|Modified ramped position group|In this group, induction of anesthesia will be performed in the modified ramped position.
89383024|NCT03640442|Active Comparator|Ramped position group|In this group, induction of anesthesia will be performed in the ordinary ramped position.
88856078|NCT01451424|Experimental|Proellex 12 mg PK group|Subjects receiving 12 mg Proellex administered vaginally, and completing a PK arm consisting of 1 x 24 hr PK of Proellex, 14 days of daily Proellex trough measurements, and 1 x 24 hr PK of Proellex after 14 days of daily dosing. 12 mg PK subjects will continue with the protocol as written after the first 2 week period and will be treated for a total of 16 weeks.
88856079|NCT01451424|Experimental|Proellex 12 mg per protocol|Subjects receiving 12 mg Proellex daily, vaginally for 12 weeks
88856080|NCT01451424|Experimental|Proellex 6 mg per protocol|Subjects receiving 6 mg Proellex daily, vaginally for 12 weeks
88856081|NCT01451424|Experimental|Proellex 3 mg per protocol|Subjects will receive 3 mg Proellex daily, vaginally for 12 weeks.
88856082|NCT01451424|Experimental|24 mg Proellex|24 mg vaginal Proellex daily for 16 weeks
88856083|NCT01475214|Active Comparator|potassium bicarbonate low dose|potassium bicarbonate in dose of 1.0 mmol/kg per day, given in three even daily doses after meals with a full glass of water
89383025|NCT03690492|Experimental|The Box 2.0|Patients will be given a Box, in which they will find a thermometer, blood pressure monitor, activity tracker, weight scale, blood oxygen saturation monitor, a single lead ECG device and a four lead ECG device. Also, they will be followed-up by use of two webcam consultations instead of a normal outpatient clinic visit.
88856084|NCT01475214|Active Comparator|potassium bicarbonate higher dose|potassium bicarbonate in dose of 1.5 mmol/kg per day, given in three even daily doses after meals with a full glass of water
88856085|NCT01475214|Placebo Comparator|placebo|microcrystalline cellulose
88856086|NCT01496274|Experimental|Prophylaxis|"Routine weekly prophylaxis and episodic treatment for bleeding episodes. An individualized dosing interval may be tested in sub-group subjects during the 2nd part of the trial.~Subjects may participate in a surgical 'sub-study' in which rIX-FP may be administered prior to, during and after surgical intervention."
88856087|NCT01496274|Experimental|On-demand|Episodic treatment for bleeding episodes during the first 6 months then switch to routine weekly prophylaxis for a further 6 months Subjects may participate in a surgical 'sub-study' in which rIX-FP may be administered prior to, during and after surgical intervention.
88856088|NCT01475136|Experimental|LY2140023|A single oral dose of 80 milligrams (mg) LY2140023 administered on Day 1.
88856089|NCT01474746|Placebo Comparator|Placebo|This arm will undergo identical treatment and assessments as the experimental group, with the exception of the active agent, sertraline. This group will be placed on a placebo.
88856090|NCT01474746|Experimental|Active|This arm will undergo identical treatment and assessments as the placebo group. This group will receive the active agent, sertraline.
88856091|NCT01450800|Active Comparator|Nitrofurantoin|Nitrofurantoin 100mg by mouth daily starting on postoperative day 1 for up to 7 days during catheterization
88856092|NCT01450800|Placebo Comparator|Placebo|Placebo drug 1 tablet by mouth daily starting on postoperative day 1 for up to 7 days during catheterization
89383026|NCT03690492|No Intervention|Controls|Patients will not receive a Box. They will be followed up by standard care, returning to the outpatient clinic at the same frequency and timing as The Box 2.0 arm.
88856093|NCT01474512|Experimental|80 milligrams (mg) Ixekizumab Dosing Regimen 1 (Q2W)|Administered as two 80-mg subcutaneous (SC) injections at Week 0, then one 80-mg SC injection per Dosing Regimen 1 [every 2 weeks (Q2W)] up to and including Week 10. At Week 12, arm is re-randomized to placebo, Dosing Regimen 2 [every 4 weeks (Q4W)] or Dosing Regimen 3 [every 12 weeks Q12W)].
88856094|NCT01474512|Experimental|80 mg Ixekizumab Dosing Regimen 2 (Q4W)|Administered as two 80-mg SC injections at Week 0, then one 80-mg SC injection per Dosing Regimen 2 (Q4W) up to and including Week 10. At Week 12, arm is re-randomized to placebo, Dosing Regimen 2 (Q4W) or Dosing Regimen 3 (Q12W).
88856095|NCT01474512|Experimental|80 mg Ixekizumab Dosing Regimen 3 (Q12W)|Dosing Regimen 3 (Q12W) is not used until Week 12. At Week 12, participants who were re-randomized to this arm were administered one 80-mg SC injection Q12W.
88856096|NCT01474512|Placebo Comparator|Placebo|Administered as 2 SC injections at Week 0, then 1 SC injection per Dosing Regimen 1 (Q2W) up to and including Week 10. At Week 12, arm is re-randomized to placebo or Dosing Regimen 2 (Q4W).
88856097|NCT01474434|Experimental|Pradigastat (LCQ908) followed by placebo|Pradigastat 80 mg (4 x 20-mg tablets) loading dose daily for three days followed by pradigastat 20 mg (2 x 10-mg tablets) daily for two days followed by a 30-day washout period in between followed by 5-day placebo treatment
88856098|NCT01474434|Experimental|Placebo followed by pradigastat (LCQ908)|Placebo (5-day treatment period) followed by a 30-day washout period followed by pradigastat 80 mg (4 x 20-mg tablets) loading dose daily for three days followed by p20 mg (2 x 10-mg tablets) daily for two days
88856099|NCT02985606|Active Comparator|Caffeine -60|Caffeine at 60 minutes prior to time trial
88856100|NCT02985606|Active Comparator|Caffeine -30|Caffeine at 30 minutes prior to time trial
88856101|NCT02985606|Active Comparator|Caffeine 0|Caffeine immediately prior to time trial
88856102|NCT02985606|Placebo Comparator|Placebo|Placebo drink at all time points
88856103|NCT01473732|Experimental|Everolimus (Zortress)|
88856104|NCT01473732|Active Comparator|Reduced dose Tacrolimus (Prograf)|
88856105|NCT01450098|Experimental|Cohort A: Fixed Sequence of Meal Conditions|LY2484595 (evacetrapib): 200 milligrams (mg) of LY2484595 administered orally, one time only, as an SDSD-PG tablet given with no food. There was a washout of at least 14 days before crossing over and receiving a 200 mg of LY2484595 administered orally, one time only, as a SDSD-PG tablet given with low-fat breakfast. There was another washout period of at least 14 days before crossing over and receiving a 200 mg of LY2484595 administered orally, one time only, as a SDSD-PG tablet given with high-fat breakfast.
88856106|NCT01450098|Experimental|Cohort B: Comparison of Randomized Treatments|LY2484595 (evacetrapib): 100 mg of LY2484595 administered orally as an RF tablet given with a low-fat breakfast. There was a washout period of at least 14 days before crossing over and receiving 100 mg of LY2484595 administered orally as a SDSD-PG tablet given with a low-fat breakfast. There was another washout of at least 14 days before crossing over and receiving 300 mg of LY2484595 as a SDSD-PG tablet given with a low-fat breakfast.
89383027|NCT03690414|Active Comparator|Experimental BHVI2 eye drops|20 participants will receive one drop per eye every night for four weeks.
89383028|NCT03690414|Active Comparator|0.02% Atropine eye drops|20 participants will receive one drop per eye every night for four weeks.
89535095|NCT05021523|Sham Comparator|CON group|Participants are doing sham altitude exposures
89383029|NCT03690414|Active Comparator|Experimental BHVI2 plus 0.02% atropine|20 participants will receive one drop per eye every night for four weeks.
88856107|NCT01449708|No Intervention|Balanced Anesthesia|Patients will receive balanced general anesthesia including volatile anesthetics and narcotics. This reflects our current clinical practice.
88856108|NCT01449708|Active Comparator|NoNarc TIVA|Patients will receive narcotic free total intravenous anesthesia with Propofol, dexmedetomidine and ketamine
88856109|NCT01449630|Experimental|LY3031207|Participants received escalating doses of 5 mg (milligrams), 25 mg, 75 mg, 225 mg, 450 mg and 900 mg of LY3031207 capsule orally.
88856110|NCT01449630|Placebo Comparator|Placebo|Single dose of placebo administered orally in up to two occasions separated by at least a 3 week wash-out period between each dose.
88856111|NCT01449630|Active Comparator|Celecoxib|Single 400mg dose of celecoxib administered orally on one occasion.
88856112|NCT01493778|Experimental|turoctocog alfa|
88856113|NCT01473420|Experimental|Epoetin Hospira|Epoetin Hospira
88856114|NCT01473420|Active Comparator|Epogen (Amgen)|Epogen (Amgen)
88856115|NCT04674774|Experimental|tegoprazan based bismuth quadruple therapy group|tegoprazan based bismuth quadruple therapy group
88856116|NCT04674774|Active Comparator|PPI based bismuth quadruple therapy group|PPI based bismuth quadruple therapy group
88856117|NCT01492686|Experimental|Arm 1|
88856118|NCT01492686|Placebo Comparator|Arm 2|
88856119|NCT04409496|Experimental|Intervention group|Chat-based instant messaging support + Self-help booklet
88856120|NCT04409496|Active Comparator|Control group|SMS message support + Self-help booklet
88856121|NCT01449006|No Intervention|Standard of care HAART regimen|Participants randomised to this arm of the trial will remain on their usual prescribed HAART regimen.
88856122|NCT01449006|Experimental|Maraviroc|Participants randomised to this arm will remain on their usual prescribed HAART regimen, with the addition of Maraviroc. Maraviroc will be prescribed according to the Product Information Sheet, with consideration given to background therapy.
88856123|NCT01448850|Placebo Comparator|Placebo|Placebo matched to MEDI8968 as IV infusion on Day 1 followed by SC injection every 4 weeks up to Week 53.
88856124|NCT01448850|Experimental|MEDI8968 600 mg IV, 300 mg SC|MEDI8968 600 milligram (mg) as intravenous (IV) infusion on Day 1 followed by 300 mg injection subcutaneously (SC) every 4 weeks up to Week 53.
88856125|NCT04748406|Active Comparator|Peloid Therapy|Group 1 (n = 35) will be given 15 sessions of peloid therapy + cold application + home exercise program for 3 weeks, 5 days a week(16).
88856126|NCT04748406|Active Comparator|ESWT(Extracorporeal Shock Wave Therapy)|Group 2 (n = 35) will be applied 1 session per week for 3 weeks, 3 sessions of ESWT (1.8 bar, 10.0 Hz, 2000 beats) + cold application + home exercise program will be applied(4).
88856127|NCT01491672|Experimental|RAD001|Participants, received RAD001 10 mg orally once daily.
88856128|NCT01447446||Dual Therapy: Peg-IFN Alfa-2a + Ribavirin|Participants with chronic hepatitis C (CHC) receiving dual therapy (pegylated interferon alfa-2a [peg-IFN Alfa-2a] along with ribavirin according to standard of care and in line with local labeling) were followed up for the duration of their treatment and for up to 24 weeks after therapy.
88856129|NCT01447446||Dual Therapy: Peg-IFN Alfa-2b + Ribavirin|Participants with CHC receiving dual therapy (pegylated interferon alfa-2b [peg-IFN Alfa-2b] along with ribavirin according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.
88856130|NCT01447446||Triple Therapy: Boceprevir + Peg-IFN Alfa-2a + Ribavirin|Participants with CHC receiving triple therapy (peg-IFN Alfa-2a along with ribavirin and boceprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.
88856131|NCT01447446||Triple Therapy: Boceprevir + Peg-IFN Alfa-2b + Ribavirin|Participants with CHC receiving triple therapy (peg-IFN Alfa-2b along with ribavirin and boceprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.
88856132|NCT01447446||Triple Therapy: Telaprevir + Peg-IFN Alfa-2a + Ribavirin|Participants with CHC receiving triple therapy (peg-IFN Alfa-2a along with ribavirin and telaprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.
88856133|NCT01447446||Triple Therapy: Telaprevir + Peg-IFN Alfa-2b + Ribavirin|Participants with CHC receiving triple therapy (peg-IFN Alfa-2b along with ribavirin and telaprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.
88856134|NCT01490814|Active Comparator|Cryoballoon ablation|
88856135|NCT01490814|Active Comparator|Radiofrequency ablation|
88856136|NCT01471782|Experimental|Blinatumomab|Blinatumomab was administered as a continuous intravenous (cIV) infusion at a constant daily flow rate over 4 weeks followed by a treatment-free interval of 2 weeks. Doses ranged between 5 and 30 µg/m²/day. Each participant received up to five cycles of treatment.
88856137|NCT01490580|Experimental|Atropine + Propofol|
88856138|NCT01490580|Active Comparator|Atropine + atracurium + sufentanil|
88856139|NCT01490190|Experimental|NuvaRing|
88856140|NCT01446042|Experimental|TBS-1 - b.i.d.|5.5 mg per nostril of 4.5% TBS-1 BID
88856141|NCT01446042|Experimental|TBS-1 - t.i.d.|5.5 mg per nostril of 4.5% TBS-1 TID
89183776|NCT02866149|Other|Cohort 12 - Faslorad|"Monitoring of patient with a metastatic breast cancer initiating a treatment by Faslodex-Afinitor.~Timing of blood sampling:~Inclusion~after #3-5 weeks of therapy~at the first tumoral evaluation (month 2 or 3)~at progression."
89535096|NCT03239821|Sham Comparator|Placebo - deflated balloon|
89535097|NCT03239821|Placebo Comparator|Placebo - inflated balloon|
89383030|NCT02959970|Experimental|PK Cohort: ACZONE 7.5%|Participants applied ACZONE 7.5 % gel topically, once-daily to the entire face, neck, upper chest, upper back and shoulders starting from Day 1 under maximal use conditions (2 grams per day) for Day 8 consecutive days, followed by a thin layer to their face and acne-affected areas on the upper chest, upper back, and shoulders for next 11 weeks.
89383031|NCT02959970|Experimental|Non-PK Cohort: ACZONE 7.5%|Participants applied ACZONE 7.5% gel topically, once-daily in a thin layer to their face and acne-affected areas on upper chest, upper back, and shoulders for 12 weeks.
89383032|NCT03690258|Experimental|Variable load exercise|"Variable load intervention (The nHANCE-squat ultimate - iso-inertial load, with power output in watts performed 3 x per week) will being performed to determine whether this training approach is an effective countermeasure to attenuate for rapid declines in muscle power, function, contractile capacity that typically originate from aging and muscle disuse. Since age-related decline is accelerated already after short bouts of physical inactivity, with small recovery potential, any attempt to counteract age-related and disuse-related decline have high clinical significance. Based on the findings, we could develop safety guidelines and protocols aimed at reducing health risks in seniors.~Data available at: http://nhance.se/"
89399534|NCT02177084|Experimental|PTNS + conservative treatment|"PTNS consists in the insertion of a small electrode above the medial malleolus adjacent to the posterior tibial nerve. An adhesive surface electrode is placed under th arch of the foot. Both electrodes are connected to the neurostimulator that generates electricity. A neuromodulation session lasts 30 minutes.~The treatment plan includes 12 weekly sessions, followed by two sessions at 2-week intervals and the last one after one month. Two additional sessions of reinforcement (top-up) are provided at intervals of 6 months or earlier in case of worsening of symptoms"
89399535|NCT02177084|No Intervention|conservative treatment|
89399536|NCT02179580|Experimental|Xiang-Sha-Liu-Jun-Zi-Tang|Xiang-Sha-Liu-Jun-Zi-Tang at a rate of 3.0 g three times per day for 28 days
88856142|NCT01445886|Experimental|Indigo Naturalis Extract in Oil|A 5-ml eye drop bottles contain indigo naturalis powder mixed with olive oil, and the concentration was 200 ug indirubin per ml. Each subject was asked to apply one to two drops (0.05 ml per drop) of the solution twice daily onto the nail folds, plus the hyponychium, of affected nails. The maximum period of treatment was 24 weeks or until there was complete clearing of their nail psoriasis.
88856143|NCT01445886|Active Comparator|Calcipotriol solution|Calcipotriol solution (Daivonex® scalp solution, calcipotriol 50 ug/ml) was purchased from LEO Pharmaceutical Products, Ltd. (Ballerupt, Denmark) and also distributed into 5-ml eye drop bottles for this trial.Each subject was asked to apply one to two drops (0.05 ml per drop) of the solution twice daily onto the nail folds, plus the hyponychium, of affected nails. The maximum period of treatment was 24 weeks or until there was complete clearing of their nail psoriasis.
88818592|NCT01480232|Experimental|EVP-6124 + NicoDerm (Active)|One EVP-6124 capsule ingested orally daily for 12 weeks (84 days) and one NicoDerm patch (Active) daily for first 6 weeks (42 days)
88818593|NCT01480232|Active Comparator|Placebo + NicoDerm (Active)|One placebo capsule ingested orally daily for 12 weeks (84 days) and one NicoDerm patch (Active) daily for first 6 weeks (42 days)
88818594|NCT01480232|Experimental|EVP-6124 + NRT Patch (Placebo)|One EVP-6124 capsule ingested orally daily for 12 weeks (84 days) and one NRT patch (Placebo) daily for first 6 weeks (42 days)
88856144|NCT01470612|Experimental|CP-690,550 5 mg BID|5 mg BID
88856145|NCT01470612|Experimental|CP-690,550 10 mg BID|10 mg BID
88856146|NCT01445730|Experimental|After fructose feeding|After 3 month fructose diet 75 g/day
88856147|NCT01445652|Experimental|nelfilcon A|Nelfilcon A contact lenses worn in both eyes on a daily disposable basis a minimum of five days per week, eight hours per day, for six months
88856148|NCT01445652|Active Comparator|Spectacles|Spectacles per current prescription worn a minimum of five days per week, eight hours per day, for six months
89183777|NCT02866149|Other|Cohort 13 - MUm|"The cohort concerns patients with uveal melanoma in the 1st systemic line at the metastatic stage (may have had prior adjuvant therapy or surgery/radiofrequency).~Timing of blood sampling:~J1C1~J2C1~J1C2~J1C5 (first tumoral evaluation)."
89183778|NCT02866149|Other|Cohort 14 - CNBC Snipe|"This cohort concerns patients with metastatic Non-Small Cell lung Cancer receiving anti-PD-1/PD-L1.~One tumour sampling.~Timing of blood sampling:~before treatment~at W8 of treatment (after radiological examination)~at W12 of treatment~at progression or 18 months after the beginning of treatment"
89183779|NCT02866149|Other|Cohort 15 - Breast CLI|"This cohort concerns patients with metastatic lobular breast cancer One tumour sampling.~Timing of blood sampling:~At inclusion~After biopsy post inclusion (or in 15 days after)~after 1 or 2 months of treatment~at progression or 18 months after inclusion"
89183780|NCT02866149|Other|Cohort 16 - Mum immunothérapie|"This cohort concerns patients with metastatic uveal melanoma before immunotherapy treatment.~Timing of blood sampling :~at inclusion~at cycle 2 or 3 of treatment~at the first tumoral evaluation (C5D1)~at progression"
89183781|NCT02860039|Experimental|Group 1 - High Dose TIV|Patients receive HD-TIV intramuscularly (IM) on day 0 and day 28.
89183782|NCT02860039|Active Comparator|Group 2 - Standard Dose QIV|Patients receive standard dose QIV IM on day 0 and day 28.
89183783|NCT02820337||non comparative|Bariatric surgery patients infected with HIV, overweight with controlled viral load and HIV lipohypertrophy particularly truncal
89183784|NCT02807636|Experimental|Atezolizumab+Gemcitabine+Carboplatin/Cisplatin|Participants will receive blinded atezolizumab in combination with open-label platinum-based chemotherapy (gemcitabine with either cisplatin or carboplatin).
89183785|NCT02807636|Placebo Comparator|Placebo+Gemcitabine+Carboplatin/Cisplatin|Participants will receive blinded placebo matched to atezolizumab in combination with open-label platinum-based chemotherapy (gemcitabine with either cisplatin or carboplatin).
89183786|NCT02807636|Experimental|Atezolizumab Monotherapy|Eligible participants will receive open-label atezolizumab as monotherapy.
89183787|NCT02732834||Part 1: Lung patients|Following informed consent, the patient will complete the patient questionnaire, either electronically, by phone, or on paper. Patients who prefer to complete the survey electronically will be emailed a link to access to a secure electronic (web-based) version of the study assessment which they will have access to from any computer. We will include an introductory email with the survey link. Will audio-record actual patient-physician clinical consultations with lung cancer patients at Memorial Sloan Kettering (MSK). Completing the survey will take about 15 minutes. Answer a few open-ended questions about the consultation with the doctor. We will audio record your answers to these questions. This will take about 15 minutes.
89183788|NCT02732834||Part 1: Thoracic physicians and clinicians|Will have 5 visits/consultations with their patients audio recorded.
89183789|NCT02732834||Part 2: Lung patients|Following informed consent, the patient will complete the patient questionnaire, either electronically, by phone, or on paper. Patients who prefer to complete the survey electronically will be emailed a link to access to a secure electronic (web-based) version of the study assessment which they will have access to from any computer. Completing the survey will take about 15 minutes.
89183790|NCT02732834||Part 2: Thoracic and pulmonary clinicians|Following informed consent, clinicians will be scheduled to participate in a 2 hour training on empathic communication with lung cancer patients. Surveys will be collected from 6 patients (3 pre-training, 3 post-training). Clinicians will complete one standardized patient assessment before training (pre-SPA) and one assessment after training (post-SPA). These are 12-minute video-recorded clinic consultations with standardized patients (trained actors).
89183791|NCT02699190||Prospective Study Cohort|This cohort comprises recently identified individuals for whom a clinical decision has been made to pursue whole genome sequencing (WGS) as a first-line diagnostic test. The cohort also includes each subject's biological parents.
89183792|NCT02699190||Historical Study Cohort|This cohort comprises approximately 50 historical controls who received either whole genome sequencing (WGS) or standard diagnostic testing as part of their participation in a previous version of this protocol, which used a randomized controlled design to assess diagnostic efficacy of WGS. This cohort is closed to new enrollment, and exists for statistical analysis purposes only.
89183793|NCT02666963|Experimental|RTA 901 10 mg or 40 mg or Placebo|RTA 901 capsules (10 mg or 40 mg) or placebo taken orally in a single dose. Group 1: RTA 901 10 mg or matching placebo Group 2: RTA 901 20 mg or matching placebo Group 3: RTA 901 ≤ 40 mg or matching placebo Group 4: RTA 901 ≤ 80 mg or matching placebo Group 5: RTA 901 ≤ 160 mg or matching placebo Group 6: RTA 901 ≤ 320 mg or matching placebo Group 7: RTA 901 ≤ 640 mg or matching placebo Dose selection will be based on the safety, tolerability and available pharmacokinetics observed in prior study groups.
89183794|NCT02666963|Experimental|RTA 901 Dose TBD or Placebo|RTA 901 capsules, Dose TBD mg or placebo taken orally once daily for 14 days. Group 8: RTA 901 X mg or matching placebo Group 9: RTA 901 ≤Y mg or matching placebo Group 10: RTA 901 ≤Z mg or matching placebo The actual doses for Arm 2 will be selected based on the safety and available pharmacokinetic data obtained from Arm 1.
89183795|NCT02657486|Experimental|BGJ398|BGJ398 will be administered at a dose of 125 mg orally once daily on a three weeks on, one week off schedule.
89399537|NCT02179580|Placebo Comparator|Placebo|Placebo at a rate of 3.0 g three times per day for 28 days
89399538|NCT02182388|Experimental|BI 207127 NA|single rising dose part
89399539|NCT02182388|Placebo Comparator|Placebo|
88818595|NCT01480232|Placebo Comparator|Placebo + NRT Patch (Placebo)|One placebo capsule ingested orally daily for 12 weeks (84 days) and one NRT patch (Placebo) daily for first 6 weeks (42 days)
88818596|NCT02700165|Experimental|CoolSculpting with CoolMini|The treatments are designed to see if fat in the submandibular/submental area (chin), can be reduced using cryolipolysis.
88856149|NCT04073316|Experimental|"Intervention group"|
88818597|NCT01481558|Sham Comparator|Sham tDCS|sham-tDCS application every 2 days for 2 weeks (total of 6 applications)
88818598|NCT01481558|Experimental|Transcranial direct current stimulation|tDCS application every 2 days for 2 weeks (total of 6 applications)
88856150|NCT04073316|Active Comparator|"Control group"|
88856151|NCT04089852|Experimental|Inhaled nitrous oxide anesthesia|"Patients will be assigned to a pre-implementation (control) group or a post-implementation (treatment) group. The first twelve participants will be the control group and the next twelve participants will be the treatment group. The treatment group will receive inhaled N2O/O2. All participants will receive pre-procedural standard of care for IUD insertions, including 400-600 mg ibuprofen orally at least 20 minutes prior to insertion to reduce post-procedure pain. The N2O will be gradually up-titrated to a goal ratio of 70/30 N2O/O2. N2O/O2 will be administered per Boston Children's Hospital (BCH) N2O sedation protocol. Prior to speculum placement, treatment group participants will receive the inhaled gas until minimal sedation is achieved per BCH sedation guidelines, such that the patient is cooperative, oriented, and tranquil. Inhaled N2O will be administered throughout the duration of the procedure."
88856152|NCT04089852|Placebo Comparator|Inhaled oxygen placebo|"Patients will be assigned to a pre-implementation (control) group or a post-implementation (treatment) group. The first twelve participants will be the control group and the next twelve participants will be the treatment group. The control group will receive inhaled O2 alone. All participants will receive pre-procedural standard of care for IUD insertions, including 400-600 mg ibuprofen orally at least 20 minutes prior to insertion to reduce post-procedure pain. Control group participants will receive 100% O2 for two minutes prior to speculum placement. Inhaled oxygen will be administered throughout the duration of the procedure."
88856153|NCT03026244|Active Comparator|Nutritional intervention product|Milk protein, prebiotics, vitamin D
88856154|NCT03026244|Placebo Comparator|Placebo product|placebo product
88856155|NCT03026322|Active Comparator|Manual Ventilation|Beginning after the administration of sedation/neuromuscular blockade, manual ventilation will be provided by bag-valve-mask until the initiation of laryngoscopy. In patients requiring more than one attempt at laryngoscopy, bag-valve-mask ventilation will resume between laryngoscopy attempts.
88856156|NCT03026322|Active Comparator|No Manual Ventilation|Between the administration of sedation/neuromuscular blockade and intubation, ventilation will not be provided unless the patient experiences an arterial oxygen saturation less than 90%. For patients who experience an oxygen saturation less than 90% after induction, bag-valve-mask ventilation may be provided.
88856157|NCT01470144|Experimental|Treatment|Single arm, open-label
89183796|NCT02654587|Experimental|OSE2101|OSE2101 was administered as a 1 mL-subcutaneous injection on Day 1 every three weeks for six cycles, then every eight weeks for the remainder of year one and finally every twelve weeks beyond year one until unequivocal RECIST 1.1-defined disease progression as determined by the investigator, unacceptable toxicity, or consent withdrawal. Should pseudo progression or delayed response to treatment suspected in arm A, investigator may continue treatment beyond the time of RECIST-defined progression, if the patient is perceived to be experiencing clinical benefit of OSE2101. OSE2101 dose was 5 mg of peptides (0.5 mg for each peptide).
89183797|NCT02654587|Active Comparator|Docetaxel or Pemetrexed|"Patients receiving docetaxel: Docetaxel 75 mg/m2 will be administered by intravenous infusion over 1 hour on Day 1 of a 21-day cycle.~Patients receiving pemetrexed: Pemetrexed, 500 mg/m2, will be administered by intravenous infusion over 10 minutes on Day 1 of a 21-day cycle.~Docetaxel and pemetrexed will be continued until unequivocal RECIST 1.1-defined disease progression as determined by the investigator, unacceptable toxicity, or consent withdrawal."
89183798|NCT02650648|Experimental|Humanized Anti-GD2 Antibody Hu3F8|This is a phase I study to assess the safety and feasibility of combining HLA-mismatched (KIR ligand incompatible) NK cells with hu3F8 in high-risk NB patients. Following chemotherapy, patients will be treated in sequential groups with a minimum of 3 patients/ dose of NK cells. Three dose levels of NK cells, starting at dose level 1, will be evaluated in this treatment protocol. The goal dose for each dose level is the high boundary (e.g. 9.9x10^6/kg in level 1; 14.9x10^6/kg in level 2, etc), but a range is provided to allow for cases where the goal dose cannot be achieved.
89183799|NCT02552823|Placebo Comparator|White bread 1|Groups 1 and 2, Visit 1 White bread (equal to 50g available carbohydrate) given to fasting participant
89183800|NCT02552823|Experimental|Pea variety 1 with rice|Group 1,Visit 2-5 Pea variety 1 with rice (25g available carbohydrate of each) given as breakfast to fasting participants
89183801|NCT02552823|Experimental|Pea variety 2 with rice|Group 1, Visit 2-5 Pea variety 2 with rice (25g available carbohydrate of each) given as breakfast to fasting participants
89183802|NCT02552823|Experimental|Pea variety 3 with rice|Group 1, Visit 2-5 Pea variety 3 with rice (25g available carbohydrate of each) given as breakfast to fasting participants
89183803|NCT02552823|Experimental|Rice|Group 1, Visit 2-5 Rice (equal to 50g available carbohydrate) given as breakfast to fasting participants
89183804|NCT02552823|Placebo Comparator|White bread 2|Groups 1 and 2, Visit 6 White bread (equal to 50g available carbohydrate) given to fasting participant
89183805|NCT02552823|Experimental|Pea variety 1 with potato|Group 2, Visit 2-5 Pea variety 1 with potato (25g available carbohydrate of each) given as breakfast to fasting participants
89183806|NCT02552823|Experimental|Pea variety 2 with potato|Group 2, Visit 2-5 Pea variety 2 with potato (25g available carbohydrate of each) given as breakfast to fasting participants
89183807|NCT02552823|Experimental|Pea variety 3 with potato|Group 2, Visit 2-5 Pea variety 3 with potato (25g available carbohydrate of each) given as breakfast to fasting participants
89183808|NCT02552823|Experimental|Potato|Group2, Visit 2-5 Potato (equal to 50g available carbohydrate) given as breakfast to fasting participants
89183809|NCT02520778|Experimental|Treatment (navitoclax, osimertinib)|Patients receive navitoclax PO QD on days 1-28 and osimertinib PO QD on days 4-28 (days 1-28 during dose-expansion). Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity
89183810|NCT02478502|Experimental|Cabazitaxel (single arm study)|Cabazitaxel 25 mg/m2 each 3. week (no other drugs will be administered)
89183811|NCT02473146|Experimental|Mylotarg Arm|"After randomization patients in the experimental arm are assigned to receive chemotherapy with:~Gemtuzumab Ozogamicin 3 mg/m2 (maximum dose: 5 mg) per IV, 60mn on Day 1 and 4 Cytarabine 200 mg/m2 per CIV over 24h on Day 1 to 7"
89183812|NCT02473146|No Intervention|Control Arm|After randomization patients in the control arm are assigned to receive chemotherapy with Idarubicin 12mg/m2 per IV, 30mn on Day 1,2,3 Cytarabine 200 mg/m2 per CIV over 24h on Day 1 to 7
89399540|NCT02182388|Experimental|BI 207127 NA, fasted or fed|
89535098|NCT03239821|Active Comparator|Codeine - delfated balloon|
88856158|NCT01443858|Active Comparator|Placebo + Nicotine Patch|Subjects in this group will take placebo meclizine daily for the three weeks prior to their quit date. Subjects will also apply a 21mg/24h nicotine patch daily starting in the second week of pre-quit treatment. Placebo meclizine will be administered in two doses each day.
88856159|NCT01443858|Experimental|25mg Meclizine + Nicotine Patch|Subjects in this group will take 25mg of meclizine daily for the three weeks prior to their quit date. Subjects will also apply a 21mg/24h nicotine patch daily starting in the second week of pre-quit treatment. Meclizine will be administered in two doses each day.
88856160|NCT01443858|Experimental|50mg Meclizine + Nicotine Patch|Subjects in this group will take 50mg of meclizine daily for the three weeks prior to their quit date. Subjects will also apply a 21mg/24h nicotine patch daily starting in the second week of pre-quit treatment. Meclizine will be administered in two doses each day.
88856161|NCT01443078|Experimental|pemetrexed plus cisplatin, vinorelbine and docetaxel|This is a phase 2 clinical trial for patients with clinical Stage IB-III resectable and operable non-small cell lung cancer, evaluating whether the switch to an alternative, non-platinum neoadjuvant chemotherapy is safe and effective in patients who do not respond to neoadjuvant platinum-based chemotherapy. Those who fail to respond to platinum-based chemotherapy will be switched to the alternative neoadjuvant chemotherapy vinorelbine 45 mg/m2 and docetaxel 45 mg/m2 on day 1 followed by pegylated filgrastim on day 2, repeated every 2 weeks for 4 doses, followed by repeat FDG PET and CT scan.
89183813|NCT02371135||patients having lower endoscopy|At least 2 weeks prior to scheduled lower endoscopy, consented study participants will be mailed a Brief Diet and Lifestyle Questionnaire, a stool collection kit with detailed instructions and a Stool Collection Data Sheet. No more than one week prior to the lower endoscopy but prior to initiation of bowel preparation, the consented participants will provide a stool specimen and fill out the two questionnaires. The routine lower endoscopy will be performed according to routine clinical procedures. Clinical biopsies of suspicious areas and/or lesions will be taken as per standard clinical care with all such tissue samples sent to pathology for routine clinical analysis. For the sole purposes of research, at the routine lower endoscopy, up to 8 additional colonic biopsies will be taken from normal appearing colon mucosa
89183814|NCT02367989|Placebo Comparator|Control without fibre|"Intervention: 0g barley β-glucan no fibre.~Dose provided in waffles given as breakfast to fasting participant at 1 of 5 visits."
89183815|NCT02367989|Experimental|low barley β-glucan|"Intervention: 2g barley β-glucan~Dose provided in waffles given as breakfast to fasting participant at 1 of 5 visits."
89183816|NCT02367989|Experimental|medium barley β-glucan|"Intervention: 4g barley β-glucan~Dose provided in waffles given as breakfast to fasting participant at 1 of 5 visits."
89183817|NCT02367989|Experimental|high barley β-glucan|"Intervention: 6g barley β-glucan~Dose provided in waffles given as breakfast to fasting participant at 1 of 5 visits."
89183818|NCT02367989|Placebo Comparator|control with fibre|"Intervention: 0g barley β-glucan with fibre~Dose provided in waffles given as breakfast to fasting participant at 1 of 5 visits."
89183819|NCT02348749|Experimental|pts with primary or metastatic neuroendocrine tumors|For phase I, a single dose of 18F-MFBG will be injected intravenously in patients. For all patients, pharmacokinetics and bio distribution will be evaluated using non invasive PET scanning and blood assays at multiple time points post injection. In the expansion phase, a single dose of 18F-MFBG will be injected intravenously followed by a single time point imaging using PET MR scanner or PET/CT. In expansion cohort, an additional 50 patients with NB will be imaged. Patients will receive a single dose of 18F-MFBG intravenously, followed by a whole body PET scan on PET/CT or PET/CT scanner at 60-90 minutes post injection. Patients who show lesion detection by MFBG may be eligible for repeat imaging scan with 18 F- MFBG, at the discretion of PI or study investigator(s). All parameters and technical details of scanning will be as per the study and first imaging.
89183820|NCT02347722||Retrospective|Heart failure patients where the etiology of their heart failure has been diagnosed. This cohort will consist of 3 groups: 1) Ischemic cardiomyopathy, 2) dilated cardiomyopathy and 3) diastolic heart failure
89183821|NCT02347722||Prospective|This cohort will consist of symptomatic heart failure patients diagnosed within 2 years.
89183822|NCT02347722||Healthy volunteers|Age matched healthy volunteers for comparison with heart failure patients
89183823|NCT02316002|Experimental|Pembrolizumab|Pembrolizumab 200 mg every 3 weeks
89183826|NCT02288247|Experimental|Enzalutamide|Participants received an OL treatment with enzalutamide 160 milligrams (mg) capsules, orally once daily from day 1 in period 1 until randomization to period 2, confirmation of ineligibility for period 2, intolerable toxicity, withdrawal, or death. Participants with confirmed disease progression on enzalutamide in period 1 and who continued to meet all eligibility criteria received enzalutamide 160 mg capsules, orally once daily in combination with docetaxel 75 milligrams per square meter (mg/m^2) in a one-hour infusion every 3 weeks and prednisolone 5 mg orally twice daily, DB period 2. Docetaxel and prednisolone were administered up to 10 cycles (3 weeks/cycle) or more as assessed by the investigator. Enzalutamide was administered until disease progression, intolerable toxicity, withdrawal or death. Participants could continue the extension period, until investigator or participant decided to stop or disease progression, intolerable toxicity, withdrawal or death.
89399541|NCT03537326|Experimental|Budesonide|Healthy women, aged between 18 and 45 years old, with weigh between 50 and 75 kg and with IMC included between 19 and 27 kg/m². Patients will be given, on an empty stomach since 10 hours minimum, a single dose of 3 mg of Budesonide, in the form of Entocord ® tablets. After that, they will remain under medical control for at least an hour, and then will be back home with instructions to collect urine samples at defined times, during 4 days.
89399542|NCT02182466||Colonic endoscopy indicated|
89399543|NCT02182544|Experimental|WAL801CL dry syrup + Placebo|
89399544|NCT02182544|Active Comparator|Ketotifen fumarate dry syrup + Placebo|
88856162|NCT01439880|Active Comparator|Standard of Care|Participants received standard of care (SOC) treatment for the first year of the study (SOC-controlled period). At week 52 participants began treatment with evolocumab 420 mg once a month (QM) for 4 years during the all-investigational product [all-IP] period.
89183827|NCT02288247|Placebo Comparator|Placebo|Participants received an OL treatment with enzalutamide 160 mg capsules, orally once daily from day 1 in period 1 until randomization to period 2, confirmation of ineligibility for period 2, intolerable toxicity, withdrawal, or death. Participants with confirmed disease progression on enzalutamide in period 1 and who continued to meet all eligibility criteria received placebo matched to enzalutamide, orally once daily in combination with docetaxel 75 mg/m^2 in a one-hour infusion every 3 weeks and prednisolone 5 mg orally twice daily, in period 2. Docetaxel and prednisolone were administered up to 10 cycles (3 weeks/cyle) or more as assessed by the investigator. Enzalutamide was administered until disease progression, intolerable toxicity, withdrawal or death. Participants could continue the extension period, until investigator or participant decided to stop or disease progression, intolerable toxicity, withdrawal or death.
89183828|NCT02283177|Experimental|Cohort A|Patients will be given cytarabine and daunorubicin during induction therapy plus crenolanib at 100 mg TID.
89183829|NCT02283177|Experimental|Cohort B|Patients will be given cytarabine and idarubicin during induction therapy plus crenolanib at 100 mg TID.
89183830|NCT02259231|Experimental|Omaveloxolone 5 mg & ipilimumab|Omaveloxolone (RTA 408) capsules, Dose1 taken orally once daily for 168 weeks, plus ipilimumab (3 mg/kg) administered at weeks 1, 4, 7, and 10.
89183831|NCT02259231|Experimental|Omaveloxolone 10 mg & ipilimumab|Omaveloxolone (RTA 408) capsules, 10 mg taken orally once daily for 168 weeks, plus ipilimumab (3 mg/kg) administered at weeks 1, 4, 7, and 10.
89183832|NCT02259231|Experimental|Omaveloxolone 5 mg & nivolumab|Omaveloxolone (RTA 408) capsules, 5 mg taken orally once daily for 168 weeks, plus nivolumab (240 mg) administered every two weeks as clinically indicated.
89183833|NCT02259231|Experimental|Omaveloxolone 10 mg & nivolumab|Omaveloxolone (RTA 408) capsules, 10 mg taken orally once daily for 168 weeks, plus nivolumab (240 mg) administered every two weeks as clinically indicated.
89183834|NCT02259231|Experimental|Omaveloxolone 20 mg & nivolumab|Omaveloxolone (RTA 408) capsules, 20 mg taken orally once daily for 168 weeks, plus nivolumab (240 mg) administered every two weeks as clinically indicated.
89183835|NCT02259231|Experimental|Omaveloxolone 100 mg & nivolumab|Omaveloxolone (RTA 408) capsules, 100 mg taken orally once daily for 168 weeks, plus nivolumab (240 mg) administered every two weeks as clinically indicated.
89183836|NCT02259231|Experimental|Omaveloxolone 150 mg & nivolumab|Omaveloxolone (RTA 408) capsules, 150 mg taken orally once daily for 168 weeks, plus nivolumab (240 mg) administered every two weeks as clinically indicated.
89183837|NCT02218593||WREX orthosis|When the subject used the WREX Orthosis
89183838|NCT02153619|Experimental|Meaning-Centered Grief Therapy (MCGT)|Part 1: Open Trials. Participants (n = 5 for Step 1 & n = 5 for Step 2) will receive 16 1-hour (approx) weekly sessions MCGT, & all therapy sessions will be audio recorded. Will make every effort to complete 16 sessions in 16 weeks, due to normal life activities, this is considered an approximation (i.e. there may be weeks where sessions don't take place &/or weeks where more than 1 session takes place in a week). If participant provides us with permission, we will also video record the sessions. Assessments will be administered at 4 time points: pre-intervention (T1), mid-intervention (T2), post-intervention (T3), & at 3-months post-intervention (T4). They will provide their feedback about MCGT & the measures. PI will review the open trial sessions to help refine the MCGT manual & treatment integrity forms. Sessions for Step 1 participants in Part 1 will be held at the MSK Counseling Center. Sessions for Step 2 participants in Part 1 will be conducted via videoconferencing.
89183839|NCT02153619|Experimental|MCGT or Supportive Psychotherapy|Part 2: Pilot RCT. Will randomize 66 parents to 16 weekly 60-90 minute (approx) sessions of MCGT or SP delivered via videoconferencing. Again, sessions will be audio recorded. If the participant provides us with permission, we also audio/video record the sessions. We will examine aspects of study implementation & therapy process, including a) recruitment progress, b) implementation of the intervention, c) administration of the assessments, & d) retention. We will also examine acceptability, defined as measures of satisfaction at T3. Psychosocial outcomes will be assessed with self-report measures at 4 time points: pre-intervention (T1), mid-intervention (T2), post-intervention (T3), & at 3-months post-intervention (T4). Post-intervention qualitative exit interviews will assess acceptability of the intervention. Post-intervention qualitative exit interviews will assess acceptability of the MCGT intervention .
89183840|NCT02112188||Chinese patients with advanced cancer|IMCP intervention to be culturally & linguistically tailored for Chinese cancer patients. This study will be carried out in 3 phases: 1) formative research & 2) adaptation. For this application we will continue the formative research (phase 1) by conducting 20 to 30 indepth interviews with Chinese immigrants with advanced cancer to inform the adaptation of the intervention. Results of the patient in-depth interviews will inform how to adapt the IMCP process & session themes to reflect the needs of the community. In the adaptation phase (phase 2) the Breitbart IMCP research team (including Drs. Breitbart, Lichtenthal, & Applebaum), Drs. Leng, Gany, & Ms. Huang will discuss a priori adaptations to the intervention. Potential changes to the process & content will be discussed. Adaptations will be incorporated in a modified IMCP-Ch treatment manual, therapist checklist/outline & Treatment Integrity Coding Manual. PHASE 3, 4 Conduct feasibility study of IMCP-Ch for Chinese cancer patients.
89399545|NCT03537248|Experimental|Asepticys investigational ASP-57 Multi-Purpose Solution|ASP-57 Multi-Purpose contact lens care solution used as a rub care regimen (Test)
88856163|NCT01439880|Experimental|Evolocumab + SOC|Participants received evolocumab 420 mg once a month plus standard of care for the first year of the study (SOC-controlled period). At week 52 participants continued treatment with evolocumab 420 mg QM for another 4 years during the all-IP period.
88856164|NCT01469364|Experimental|Aztreonam Lysine for Inhalation (AZLI)|Patients to received Aztreonam Lysine(AZLI)
88856165|NCT01439724|Placebo Comparator|Placebo|Patients in the placebo group received the same treatment during the same time, but in this case the laser tip produced no light.
88856166|NCT01439724|Experimental|Low Level Laser Therapy|The investigators used a Low Level Laser Therapy, diode laser (DMC, São Paulo, Brazil) InGaAlP (indium phosphide, gallium and aluminum), with 100mW, 4J/cm ², with an area of 0.24 cm ². The laser was daily applied by a dentist and touched the mucosa of the lips, right and left buccal mucosa, left and right lateral tongue border, buccal floor and ventral tongue, totaling nine points per region.
88856167|NCT01439568|Experimental|LY2510924 + Carboplatin + Etoposide|"LY2510924: 20 milligram (mg) administered once daily as a subcutaneous(SC) injection on days 1 to 7 of the 21 day cycle; repeat every 21 days for 6 cycles. Carboplatin: 5 milligram/millimeter/per minute (mg/mL/min) area under the curve (AUC) administered intravenously on day 1 of the 21 day cycle; repeat every 21 days for 6 cycles.~Etoposide: 100 milligram square meter (mg/m^2) administered intravenously on days 1 to 3 of the 21 day cycle; repeat every 21 days for 6 cycles."
88856168|NCT01439568|Active Comparator|Carboplatin + Etoposide|"Carboplatin: 5 mg/mL/min area under the curve administered intravenously on day 1 of the 21 day cycle; repeat every 21 days for 6 cycles.~Etoposide: 100 milligram square meter (mg/m^2) administered on days 1 to 3 of the 21 day cycle; repeat every 21 days for 6 cycles."
88856169|NCT01469052|Experimental|Cohort 1|
88856170|NCT01469052|Experimental|Cohort 2|
88856171|NCT01469052|Experimental|Cohort 3|
88856172|NCT01469052|Experimental|Cohort 4|
88856173|NCT01469052|Experimental|Cohort 5|
88856174|NCT01469052|Experimental|Cohort 6|
88856175|NCT01468818|Experimental|Immunotherapy for Metastatic Melanoma|Patients will receive non-myeloablative lymphodepleting preparative regimen cons
88856176|NCT01442376|Experimental|Palonosetron 10 mcg/kg|"Palonosetron and placebo to Ondansetron~Intervention:~Drug: Palonosetron"
88856177|NCT01442376|Experimental|Palonosetron 20 mcg/kg|"Palonosetron and placebo to Ondansetron~Intervention:~Drug: Palonosetron"
88856178|NCT01442376|Active Comparator|Ondansetron|"Ondansetron and placebo to Palonosetron~Drug:~Comparator: Ondansetron"
88856179|NCT01442064|Experimental|Ranibizumab 0.5 mg|Ranibizumab 0.5 mg intravitreal injection administered as-needed no more frequently than every 30 days (no more than 12 injections per year) for 24 months.
88856180|NCT03026868|Experimental|quadrilateral surface plate|The fragments of the acetabulum were fixed with novel quadrilateral surface plate through Stoppa approach.
88856181|NCT01467960||Group I|Healthy Subjects aged 20-40
88856182|NCT01467960||Group II|Healthy Subjects aged 40-65
88856183|NCT01467960||Group III|Healthy Subjects aged more than 65
88856184|NCT01467960||Group A|Patients at Stage I, H&Y classification
88856185|NCT01467960||Group B|Patients at Stage II, H&Y classification
88856186|NCT01467960||Group C|Patients at Stage more than III, H&Y classification
88856187|NCT01441596|Experimental|arm A: Afatinib monotherapy|Afatinib monotherapy: starting dose 40 mg per day, continuous treatment in a 3-weekly course. If well tolerated, the dose may be escalated to 50 mg.
88856188|NCT01441596|Experimental|arm B: Afatinib in combination with vino|Afatinib 40 mg per day, continuous treatment, in combination with vinorelbine Vinorelbine 25 mg/mÂ² on days 1, 8, 15 in a 3-weekly course.
88856189|NCT01441596|Active Comparator|arm C: investigator's choice of treatmen|Patients will receive, at the investigator's discretion, the most appropriate medical treatment consisting of single agent or combination regimen approved for the treatment of metastatic breast cancer, and according to patient status and local guidelines.
88856190|NCT01441440|Experimental|venlafaxine ER 75 mg/day (fixed dose)|
88856191|NCT01441440|Experimental|venlafaxine ER 75 mg/day to 225 mg/day (flexible dose)|
88856192|NCT01441440|Placebo Comparator|Placebo|
88856193|NCT03026400|Other|Subumbilical incision|The subumbilical incision was standardised. A curvilinear horizontal incision was performed to be able to reach the base of the umbilicus. The aponeurosis was incised with a scalpel and the peritoneal layer was open with a Kelly clamp. The incision was completed with the Hasson technique and a X-stitch was used for closure.
88856194|NCT03026400|Other|Transumbilical incision|The transumbilical incision was also standardised, inverting the umbilicus with graspers, then incising vertically the skin to reach the umbilical physiological hernia to enlarge it. The incision was also completed with the Hasson technique and a X-stitch was used for closure.
88856195|NCT01438476|Experimental|IV Pain Management|Intravenous analgesia delivered prior to surgery, then patient-controlled following surgical procedures. Hourly post surgery rating level of pain on a scale of 0-10. Questions measure how quickly participant recovers from sedation Day 1 through Day 5 after surgery; approximately 20-40 minutes.
88856196|NCT01438476|Experimental|Epidural Pain Management|Thoracic epidurals placed preoperatively in either holding area or in operating room. Hourly post surgery rating level of pain on a scale of 0-10. Questions measure how quickly participant recovers from sedation Day 1 through Day 5 after surgery; approximately 20-40 minutes.
88856197|NCT03026478|Experimental|Betamethasone dipropionate 0.05%|topical Betamethasone dipropionate 0.05% in orabase with clotrimazole 1% in oral lichen planus two times a day for one month
88856198|NCT03026478|Active Comparator|Clobetasol propionate 0.05%|Topical Clobetasol propionate 0.05% in orabase with clotrimazole 1% in oral lichen planus patients two times a day for a month
88856199|NCT01467570|Experimental|Hipp ORS Apple 200|oral rehydration solution Hipp ORS 200 Apple
88856200|NCT01467570|Active Comparator|ESPGHAN ORS|ESPGHAN oral rehydration solution
88856201|NCT04066764|Experimental|Rivaroxaban|Participants will receive rivaroxaban 15mg oral twice daily for 3 weeks after operation, later rivaroxaban 20mg oral once daily until 3 months after the filter is retrieved.
88856202|NCT04066764|Active Comparator|Warfarin/ Nadroparin|Participants will receive Nadroparin 1mg/kg twice daily (subcutaneous), plus warfarin 3mg oral once daily for 5 days after the operation, later warfarin(oral) at individually titrated doses(0.75mg to 18mg) to achieve a target international normalized ratio (INR) of 2.0 to 3.0, once daily until 3 months after the filter is retrieved.
88856203|NCT01437540|Experimental|1|Inhaled aclidinium bromide 400 μg/formoterol fumarate 12 μg fixed dose combination (FDC), high dose twice per day
88856204|NCT01437540|Active Comparator|2|Inhaled formoterol fumarate 12 μg, twice per day
88856205|NCT01440972|Active Comparator|Exercise without PBFR|
88856206|NCT01440972|Experimental|exercise with PBFR|
88856207|NCT01420536|Experimental|Canine Guidance|"Complete dentures adjusted with mutually protected articulation in which the vertical and horizontal overlap of the canine teeth disengage the posterior teeth in the excursive movements of the mandible (The Glossary of Prosthodontic Terms. J. Prosthet. Dent., 94(1): 10-92)"
88856208|NCT01420536|Sham Comparator|Bilateral Balanced Occlusion|Complete dentures as conventionally adjusted: anterior and posterior teeth presented bilateral contact in excentric positions
88856209|NCT01420068||All patients|All patients previously treated with study medication in the CSPP100A2365 and CSPP100A2365E1 studies.
88856210|NCT01467492|Experimental|Black|Telaprevir 750 milligram (mg) tablet 3 times per day for 12 weeks in combination with Peg-IFN-alfa-2a 180 microgram per week (mcg/week) subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 milligram per day (mg/day) (for participants weighing <75 kilograms [kg]) or 1200 mg/day (for participants weighing >=75 kg) for 24 or 48 weeks.
88856211|NCT01467492|Experimental|Non-Black|Telaprevir 750 mg tablet 3 times per day for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day (for participants weighing <75 kg) or 1200 mg/day (for participants weighing >=75 kg) for 24 or 48 weeks.
88856212|NCT01466790|Experimental|Arm 1|30 patients will receive TMC435 (150 mg once a day) plus PSI-7977(GS7977) (400 mg once a day) with ribavirin (1000-1200 mg/day) for 24 weeks and followed by a 24-week follow-up phase.
88856213|NCT01466790|Experimental|Arm 2|15 patients wiil receive TMC435 (150 mg once a day) plus PSI-7977 (GS7977) (400 mg once a day) for 24 weeks of and followed by a 24-week follow-up phase.
88856214|NCT01466790|Experimental|Arm 3|30 patients will receive TMC435 (150 mg once a day) plus PSI-7977 (GS7977) (400 mg once a day) with ribavirin (1000-1200 mg/day) for 12 weeks and followed by a 36-week follow-up phase.
88856215|NCT01466790|Experimental|Arm 4|15 patients will receive TMC435 (150 mg once a day) plus PSI-7977 (GS7977) (400 mg once a day) for 12 weeks and followed by a 36-week follow-up phase.
88856216|NCT01418352|Placebo Comparator|Matching Placebo|Participants received aripiprazole matching placebo, tablets, orally, once weekly for 8 weeks in the Double-blind Treatment Period.
88856217|NCT01418352|Experimental|Aripiprazole 52.5 mg|Participants received aripiprazole 52.5 mg, tablets, orally, once weekly for 8 weeks in the Double-blind Treatment Period.
88856218|NCT01418352|Experimental|Aripiprazole 77.5 mg|Participants received aripiprazole 77.5 mg, tablets, orally, once weekly for 8 weeks in the Double-blind Treatment Period.
88856219|NCT01418352|Experimental|Aripiprazole 110 mg|Participants received aripiprazole 110 mg, tablets, orally, once weekly for 8 weeks in the Double-blind Treatment Period.
88856220|NCT01436370|Experimental|Group 1 Controls|40 (up to 50) adults, healthy gender and age-matched controls, given a single 15 mcg intramuscular dose of Sanofi Pasteur Fluzone®
88856221|NCT01436370|Experimental|Group 2|40 (up to 50) adults with Rheumatoid Arthritis receiving TNF-alpha-inhibitor therapy, given a single 60 mcg intramuscular dose of Sanofi Pasteur Fluzone® High Dose.
88856222|NCT01436370|Experimental|Group 2 Controls|40 (up to 50) adults, healthy gender and age-matched controls, given a single 60 mcg intramuscular dose of Sanofi Pasteur Fluzone® High Dose.
88856223|NCT01436370|Experimental|Group 1|40 (up to 50) adults with Rheumatoid Arthritis receiving TNF-alpha-inhibitor therapy, given a single 15 mcg intramuscular dose of Sanofi Pasteur Fluzone®
88856224|NCT01465464|Experimental|Orantinib|
88856225|NCT01465464|Placebo Comparator|Placebo|
88856226|NCT01417104|Active Comparator|Aliskiren|Aliskiren will be administered for 2 weeks at 150mg/day oral pill, followed by 34 weeks oral therapy with 300mg/day
88856227|NCT01417104|Placebo Comparator|Placebo|Placebo (sugar pill) built to mimic both the 150mg Aliskiren tablet ( administered for the first 2 weeks) and the 300mg Aliskiren tablet ( administered for the rest of treatment period)
88856228|NCT01465386|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive bortezomib SC on days 1, 8, 15 and 22. Treatment repeats every 35 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
88856229|NCT01465230|Experimental|lenalidomide|Maintenance treatment with lenalidomide following induction treatment with bendamustine and rituximab.
88856230|NCT04500132|Experimental|EC-18 Arm|EC-18 QD
88856231|NCT04500132|Placebo Comparator|Placebo Arm|Placebo EC-18 QD
88856232|NCT01435356|Active Comparator|recMage-A3 + AS15 ASCI|MAGE-A3 positive patients treated with recMAGE-A3 + AS15 ASCI
88856233|NCT01435356|Placebo Comparator|Placebo|MAGE-A3 positive patients treated with placebo
88856234|NCT01435122|Experimental|Axitinib Administration|"The investigational drug used in this study is axitinib, and is available as tablets.~You will take the tablet orally with food. Doses should be taken around 12 hours apart continuously, without scheduled breaks. If you vomit anytime after taking a dose do not take another tablet to make up the dose but instead continue taking your next dose as planned.~Any missed dose may be taken late (up to 3 hours before the next scheduled dose); otherwise it should be skipped. If doses are missed or vomited, please keep track of this and report at your next visit."
88856235|NCT04048122|Active Comparator|Standard of Care (Control Group)|This treatment is task-oriented training, a widely-used approach in neurorehabilitation, that parallels the cognitive process training used in PD to-date but with simulated functional tasks (vs. computer or paper & pencil tasks). It has the same basic protocol as MC4PD, but it is therapist-directed, and the OT does not address strategies, metacognition, generalization, or use mediation or action plans. The OT selects treatment activities based on the client's cognitive profile and goals from a published set of activities designed for use in cognitive interventions. Graded task practice with OT feedback on performance accuracy is used to produce neurocognitive improvement (or possibly independent strategy development). The OT assigns practice of specific cognitively challenging everyday life activities for homework (but without action plans).
88856236|NCT04048122|Experimental|MC4PD Strategy Training|This treatment focuses on improving functional performance by enhancing the generation and use of strategies-which can be internal (e.g., self-talk, planning) or external (e.g., checklist, alarm)-to circumvent cognitive processing limitations caused by PD. It uses a standardized approach across and within sessions for all clients while being tailored to each client's cognitive problems and goals.
89535099|NCT03239821|Active Comparator|Codeine - inflated balloon|
89535100|NCT03230383|Experimental|Cohort 1_90mg and Matching Placebo|
89535101|NCT03230383|Experimental|Cohort 2_300mg and Matching Placebo|
88856237|NCT01434810|Experimental|Filtered-sunlight phototherapy|Infants will receive six hours per day of filtered-sunlight phototherapy for 1 to 10 days. The filtering will be done using window tinting film. Window tinting films by Solutia, Inc., and V-KOOL, Inc.
89383033|NCT03690258|Experimental|Variable load intervention|"This study is being conducted to determine whether this variable load (The nHANC dead lift - eccentric overload performed 3 x per week for 4-6 weeks) intervention is an effective countermeasure to modulate blood pressure in seniors. Since age-related incline in resting blood pressure (hypertension) is accelerated already after short bouts of physical inactivity, any attempt to counteract age-related and disuse-related decline have high clinical significance. In addition, we aim to examine endothelial function via non-invasive flow mediated dilatation (FMD) technique.~Based on the findings, we could develop safety guidelines and protocols aimed at reducing health risks in this specific population. Importantly, in case present hypotheses are confirmed, this may offer important information to the healthcare system, especially for reducing economic burden."
89383034|NCT03921996|Experimental|arm A: ePLND|Radical prostatectomy with extended pelvic lymph node dissection
89383035|NCT03921996|Active Comparator|arm B: no PLND|Radical prostatectomy only
89383036|NCT03690180||Diabetics with microalbuminuria|"Diabetics with micro albuminuria will be subjected to full clinical examination.~Measurement of weight, height, waist, hip and calculation of BMI and waist hip ratio,laboratory assessment of serum creatinine,HbA1C,magnesium and urinary albumin creatinine ratio"
89383037|NCT03690180||Diabetics with normal albuminuria|"Diabetics with micro albuminuria will be subjected to full clinical examination.~Measurement of weight, height, waist, hip and calculation of BMI and waist hip ratio,laboratory assessment of serum creatinine,HbA1C,magnesium and urinary albumin creatinine ratio"
89383038|NCT03623880|Experimental|Unified Protocol|This is a type of CBT for emotional distress.
89383039|NCT03623880|Active Comparator|Supportive Therapy|This is a commonly-used form of all-purpose psychotherapy, often used as a comparator in CBT clinical trials.
88856238|NCT01434810|Active Comparator|Conventional phototherapy|Infants will receive six hours per day of conventional phototherapy for 1 to 10 days.
88856239|NCT01393626|Placebo Comparator|Placebo BID|
88856240|NCT01393626|Experimental|5mg BID|
89383040|NCT03681990|Experimental|3M CHG/IPA Prep / Center|Chlorhexidine gluconate (CHG) 2% / Isopropyl alcohol (IPA) 70% solution applied topically to intact skin; sample collected from center test site on skin in application area.
89383041|NCT03681990|Experimental|3M CHG/IPA Prep / Mid-peripheral|Chlorhexidine gluconate (CHG) 2% / Isopropyl alcohol (IPA) 70% solution applied topically to intact skin; sample collected from mid-peripheral test site on skin in application area.
89383042|NCT03681990|Experimental|3M CHG/IPA Prep / Peripheral|Chlorhexidine gluconate (CHG) 2% / Isopropyl alcohol (IPA) 70% solution applied topically to intact skin; sample collected from peripheral test site on skin in application area.
88856241|NCT01393626|Experimental|10mg BID|
88856242|NCT04059666|Active Comparator|Control|
88856243|NCT04059666|Experimental|Investigational|
88856244|NCT04059666|No Intervention|Mother's-own Breast Milk|
88856245|NCT01434654||Non Neuro-HAART (low CNS penetrance)|Participants will be assessed based on their current Highly Active Antiretroviral Treatment (HAART). A scoring system is utilised to determine if their current treatment has high Central Nervous System (CNS) penetrance or low CNS penetrance. This will determine which study cohort they are allocated to. No treatment adjustments or changes will be made, they will remain on their usual HAART regimen.
88856246|NCT01434654||Neuro-HAART (high CNS penetrance)|Participants will be assessed based on their current Highly Active Antiretroviral Treatment (HAART). A scoring system is utilised to determine if their current treatment has high Central Nervous System (CNS) penetrance or low CNS penetrance. This will determine which study cohort they are allocated to. No treatment adjustments or changes will be made, they will remain on their usual HAART regimen.
88856247|NCT04059276||Patients with stroke|
88856248|NCT04059276||Healthy subjects|
88856249|NCT01393158|Experimental|20 mg BID|Patients dosed with 20 mg orally of Apremilast BID for 3 months.
89383043|NCT02740335|Experimental|Octaplex|Participants to receive1 Octaplex infusion intravenously
89383044|NCT02740335|Active Comparator|Beriplex P/N (Kcentra)|Participants to receive1 Kcentra infusions intravenously
89383045|NCT03690102|Experimental|No BLS course. With T-CPR.|"The participant is presented for a cardiac arrest scenario before attending the ERC standardized BLS course.~During the scenario test, the participant will receive T-CPR."
89383046|NCT03690102|Experimental|With BLS course. No T-CPR.|"The participant is presented for a cardiac arrest scenario after completion of the ERC standardized BLS course.~During the scenario test, the participant will not receive T-CPR."
89383047|NCT03690102|Experimental|With BLS course. With T-CPR.|"The participant is presented for a cardiac arrest scenario after completion of the ERC standardized BLS course.~During the scenario test, the participant will receive T-CPR."
89535102|NCT03230383|Experimental|Cohort 3_900mg and Matching Placebo|
88856250|NCT01393158|Experimental|30 mg BID|Patients dosed with 30 mg orally of Apremilast BID for 6 months.
88856251|NCT01413360|Experimental|HD Vitamin C|High dose vitamin C
88856252|NCT01413204|Experimental|TA-7284 Low|
88856253|NCT01413204|Experimental|TA-7284 High|
88856254|NCT01413204|Placebo Comparator|Placebo|
88856255|NCT01392378|Experimental|Group 1|Subjects will receive 13-valent pneumococcal vaccine and INFANRIX hexa at 2, 3, 4 and 12 months of age. They will also receive 2 doses of paracetamol on the day of each vaccination.
89183841|NCT02105766|Experimental|male donor - female recipient|The first cohort of patients will be male donor - femalerecipients to see if this new regimen will yield higher rate of durable donor leukocyte chimerism. We will also measure anti-A, anti-B, and/or other red cell antibody titers from this initial cohort to determine the feasibility of transplanting patients with pre-existing antibodies (major ABO mismatch or other anti-donor red cell antibody)
89183842|NCT02105766|Experimental|patients with preexisting antibodies|patients with preexisting antibodies (major ABO mismatch or otheranti-donor red cell antibody). The primary endpoint forthis group will be different than the first cohort. It is very likely that red cell aplasia (6 months to 2 years posttransplant) and prolonged duration of red cell transfusion are expected in this second group, thus a later time point to determine treatment success is justified.
88856256|NCT01392378|Experimental|Group 2|Subjects will receive 13-valent pneumococcal vaccine and INFANRIX hexa at 2, 3, 4 and 12 months of age. They will also receive 2 doses of ibuprofen on the day of each vaccination.the first dose.
88856257|NCT01392378|Experimental|Group 3|Subjects will receive 13-valent pneumococcal vaccine and INFANRIX hexa at 2, 3, 4 and 12 months of age. They will also receive 3 doses of paracetamol on the day of each vaccination.
88856258|NCT01392378|Experimental|Group 4|Subjects will receive 13-valent pneumococcal vaccine and INFANRIX hexa at 2, 3, 4 and 12 months of age. They will also receive 3 doses of ibuprofen on the day of each vaccination.
88856259|NCT01392378|Experimental|Group 5|Subjects will receive 13-valent pneumococcal vaccine and INFANRIX hexa at 2, 3, 4 and 12 months of age. This group does not receive any antipyretic medication as part of the study.
88856260|NCT01412424|Experimental|Octreotide capsules|Participants received octreotide capsules orally twice a day for up to 13 months. Dosing started at 40 mg per day (20 in the morning + 20 in the evening) and increased to 60 mg per day (40 in the morning + 20 in the evening) or 80 mg per day (40 in the morning + 40 in the evening) if there was inadequate IGF-1 suppression.
88856261|NCT01433250|Experimental|AIN 457 Core|(10mg/kg i.v.). AIN 457 core study /AIN 457 Extension
88856262|NCT01433250|Experimental|AIN457 Placebo Core|(10mg/kg i.v.). AIN 457 placebo core study /AIN 457 Extension
88856263|NCT01433172|Experimental|Phase I Vaccinations|Participants enrolled in the Phase I trial will receive GM.CD40L.CCL21 vaccinations on 3 occasions, at 2 week intervals. Note for the phase I portion: the use of steroid medication is to be avoided for 4 weeks prior to the initiation of vaccine therapy and during the vaccine treatment period.
88856264|NCT01433172|Active Comparator|Phase II Arm A Vaccinations|Arm A participants will receive GM.CD40L cells vaccinations on 3 occasions, at 2 week intervals. Note on either Arms A and B: the use of steroid medication is to be avoided for 4 weeks before to the initiation of vaccine therapy and during the vaccine treatment period.
88856265|NCT01433172|Active Comparator|Phase II Arm B Vaccinations|Arm B participants will receive GM.CD40L.CCL21 vaccinations on 3 occasions, at 2 week intervals. Note on either Arms A and B: the use of steroid medication is to be avoided for 4 weeks before to the initiation of vaccine therapy and during the vaccine treatment period.
88856266|NCT01432938|Experimental|Warfarin first, then Dulaglutide + Warfarin|A single, 10-milligram (mg) dose of warfarin administered orally on Day 1 (Treatment 1). There was a washout period of at least 24 days between treatment periods. Then a single, 1.5-mg dose of dulaglutide administered subcutaneously on Day 1, followed by a single, 10-mg dose of warfarin administered orally on Day 3 (Treatment 2).
88856267|NCT01432938|Experimental|Dulaglutide + Warfarin first, then Warfarin|A single, 1.5-mg subcutaneous dose of dulaglutide on Day 1, followed by a single, 10-mg oral dose of warfarin on Day 3 (Treatment 2). There was a washout period of at least 24 days between treatment periods. Then a single, 10-mg oral dose of warfarin on Day 1 (Treatment 1).
88856268|NCT03025230|Experimental|Experimental group|Dry needling technique and the application of a rectangular, biphasic, asymmetric analgesic electric current by selecting a frequency of 2 Hz with a pulse width 40 μs, with an intensity located at the tolerance threshold and for a time of 20 minutes.
88856269|NCT03025230|Active Comparator|Control group|Dry technique in PG.The needle will be moved in-and-out into different directions to encounter sensitive spots in PG region.
88856270|NCT01392300|Experimental|DB IncobotulinumtoxinA (Xeomin) (400 U)|IncobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind (DB), randomized treatment assignment
88856271|NCT01392300|Placebo Comparator|DB Placebo Comparator|Placebo to incobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind (DB), randomized treatment assignment
88856272|NCT04767204|Experimental|Peer support service|Peer support workers co-lead and assist workplace problem-solving and care skills training in an extended vocational rehabilitation program
89183843|NCT02062827|Experimental|Group A single dose of HSV-1 (M032)|single dose of HSV-1 (M032) infused through catheters into region(s) of tumor defined by MRI
89383048|NCT03685812||patients with patellofemoral pain syndrome , Auto Cad software|Patients referred with a confirmed diagnosis of patellofemoral pain syndrome, with a visual analogue scale of more than 3. Anterior or retropatellar knee pain from at least 2 of the following Activities : (1) prolonged sitting; (2) stair climbing; (3) squatting; (4) running; (5) kneeling; and (6) hopping/jumping.
89535103|NCT03230383|Experimental|Cohort 4_1800mg and Matching Placebo|
89383049|NCT05390151|Active Comparator|Laser assisted fistula closure|Group to be actively treated with laser assisted fistula surgery
89383050|NCT05390151|Active Comparator|Rectal advancement flap|Group to be actively treated with a rectal advancement flap.
89383051|NCT03689790|Active Comparator|liver function|liver function
89383052|NCT03681756|No Intervention|Group 1|Participants will receive an in-person session and an activity monitor
89383053|NCT03681756|Experimental|Group 2|Participants will receive an in-person session, an activity monitor, and social support through BAND
89383054|NCT05567757|Experimental|Investigational|Study subjects implanted with a TRUE AVC as an arteriovenous conduit for hemodialysis
89383055|NCT03752814|Experimental|SYNOSTE Nitinail System|The intended purpose of the SNS in this trial is lengthening of the femur by callotasis.
89383056|NCT05370027|Experimental|1st Group|With the vagustim device, the application will be made first from the left ear. Then, a 48-hour break will be taken and the application will be made from the right ear. Then, the application will be performed on both ears with a 48-hour break.
89383057|NCT05370027|Experimental|2nd Group|With the vagustim device, the application will be made first from the left ear. Then, a 48-hour break will be made and the application will be made from both ears. Then, the application will be performed on the right ear with a break for 48 hours.
89383058|NCT05370027|Experimental|3rd Group|With the vagustim device, the application will be made first from the right ear. Then, a 48-hour break will be taken and the application will be made from the left ear. Then, the application will be performed on both ears with a 48-hour break.
89383059|NCT05370027|Experimental|4th Group|With the vagustim device, the application will be made first from the right ear. Then, a 48-hour break will be made and the application will be made from both ears. Then, the application will be performed on the left ear with a break for 48 hours.
88856273|NCT01432626|Experimental|Stress Induced Cardiomyopathy Patients|Patients presenting with stress induced cardiomyopathy, after meeting the Mayo criteria (normal coronary anatomy, EKG changes/Enzyme abnormalities, wall motion abnormalities consistent with stress induced cardiomyopathy and no evidence of pheochromocytoma) and signing informed consent, will receive an I123-mIBG scan to determine the sympathetic function of the heart during the acute presentation and after functional recovery.
89383060|NCT05370027|Experimental|5th Group|With the vagustim device, the application will be made from both ears first. Then, a 48-hour break will be made and the application will be made from the left ear. Then, the application will be performed on the right ear with a break for 48 hours.
89383061|NCT05370027|Experimental|6th Group|With the vagustim device, the application will be made from both ears first. Then, a 48-hour break will be made and the application will be made from the right ear. Then, the application will be performed on the left ear with a break for 48 hours.
89383062|NCT03689556||FLT PET/CT|Patients with locoregionally recurrent nasopharyngeal carcinoma (LR-NPC) will receive FLT PET/CT scans before CIRT and after completion of CIRT.
89383063|NCT03685656|Experimental|ANACA3|ANACA3 slimming gel
89383064|NCT03685656|Placebo Comparator|Placebo|Slimming gel contening no active ingredient
89383065|NCT01749709|Experimental|Instrumental music listening|Daily music listening
89383066|NCT01749709|Experimental|Vocal music listening|Daily music listening
88856274|NCT02985294||Cross-sectional cohort|Multiple Excitability Measures of peripheral nerves on patients with chronic peripheral neuropathic pain
88856275|NCT02985294||Longitudinal cohort|Multiple Excitability Measures of peripheral nerves on painless patients before and after potential chronic neuropathic pain-inducing interventions (chemotherapy, surgery)
88856276|NCT03025776||stroke|individuals chronic (> 6 months) post-stroke
88856277|NCT03025776||age matched health controls|age matched (double sample size anticipated) healthy controls
88856278|NCT01410474|Experimental|2-18 years|
88856279|NCT04037592|Experimental|Active standardized iTBS-DMPFC|This active group will receive standardized dosage of intermittent theta-burst on dorsomedial prefrontal cortex(DMPFC)
89383067|NCT01749709|Active Comparator|Audiobook listening (control)|Daily audiobook listening
89383068|NCT01568931|Active Comparator|Urokinase|Patients will be randomized to to receive local bolus of 200,000 units urokinase
89383069|NCT01568931|Active Comparator|Saline|Patients will be randomized to to receive local bolus of intracoronary saline
89383070|NCT05300763|Experimental|TEST LENS|Eligible subjects who are habitual soft contact lens wearers will be randomly assigned the TEST Lens for the duration of the study.
89383071|NCT05300763|Experimental|CONTROL LENS|Eligible subjects who are habitual soft contact lens wearers will be randomly assigned the CONTROL Lens for the duration of the study.
89383072|NCT05279859|Experimental|Dose Escalation (Part 1): ERAS-007 plus gilteritinib|ERAS-007 will be administered in combination with gilteritinib to study participants with R/R FLT3 mutated AML in sequential ascending doses until unacceptable toxicity, disease progression, or withdrawal of consent.
89183844|NCT02029729|Experimental|RTA 408 Capsules|RTA 408 capsules, beginning dose 2.5 mg once daily, 28-day cycle, up to 12 cycles. Doses will increase by 100% of previous dose (e.g., 5 mg, 10 mg, 20 mg, etc.) until such time the Protocol Safety Review Committee decreases the escalation rate to 50% of the previous dose (e.g., 20 mg, 30 mg, 45 mg, etc). Dose escalation will continue until Maximum Tolerated Dose is identified.
89183845|NCT02029716|Placebo Comparator|Part A|RTA 408 lotion 0.5%, 1%, and 3% and lotion vehicle applied to skin twice daily for 14 days
89183846|NCT02029716|Experimental|Part B|Up to 3% RTA 408 lotion applied to skin twice daily for 14 days (% concentration to be determined, based on results from Part A, ~100 cm2 surface area)
88856280|NCT04037592|Experimental|Active high-dosage iTBS-DMPFC|This active group will receive high dosage of intermittent theta-burst on dorsomedial prefrontal cortex(DMPFC)
88856281|NCT04037592|Sham Comparator|Sham standardized iTBS-DMPFC or high-dosage iTBS-DMPFC|Patients in the sham group will receive the same standardized or high-dosage iTBS performing by a sham coil
89183847|NCT02029716|Experimental|Part C|3% RTA 408 lotion applied to skin twice daily for 28 days (~500 cm2 surface area)
89183848|NCT02028559|Experimental|Treatment with Ultrasonic Propulsion|Subjects receive treatment with the Propulse 1 device. Intervention consists of the non-invasive application of ultrasound to move stones within the kidney and ureter.
89183849|NCT02028559|No Intervention|Control|Subject follow same protocol as treatment group but do not receive the ultrasonic propulsion intervention.
89183850|NCT02022462|Experimental|Health Navigation|151 participants with SMI in the El Camino clinic, operated by Pacific Clinics, were recruited to participate in a 12-month study of Bridge navigation. Participants were randomly assigned to either waitlist control (6 month waitlist with treatment as usual) or immediate intervention with the Bridge. Participants in the immediate treatment group completed three assessments (baseline, 6 months, and 12 months) and, after 6 months, one interview about their health, healthcare, and navigation experiences. Participants in the waitlist control group completed three assessments (baseline, 6 months, 12 months) and one interview about their health, health care, and their experiences using health navigation after 12 months.
89183851|NCT02022462|Other|Waitlist Control|151 participants with SMI in the El Camino clinic, operated by Pacific Clinics, were recruited to participate in a 12-month study of Bridge navigation. Participants were randomly assigned to either waitlist control (n = 75, 6-month waitlist with treatment as usual then they received the intervention) or immediate intervention with the Bridge (n = 76). Participants in the immediate treatment group completed three assessments (baseline, 6 months, and 12 months) and, after 6 months, one interview about their health, healthcare, and navigation experiences. Participants in the waitlist control group completed three assessments (baseline, 6 months, 12 months) and one interview about their health, health care, and their experiences using health navigation after 12 months.
89183852|NCT01906853|No Intervention|No BCG|No BCG
89183853|NCT01906853|Experimental|BCG|Mycobacterium bovis BCG (Bacille Calmette Guérin) vaccine, Danish Strain 1331
89183854|NCT01825278||Single group, obese surgical patients with monitoring strip|All eligible patients will have a monitoring strip prospectively applied to their right chest
89183855|NCT01821131|Experimental|30g ground flaxseed per day|consume 1 muffin containing 30g ground flaxseed every day for 4 weeks
89183856|NCT01821131|Experimental|20g ground flaxseed per day|consume 1 muffin containing 20g ground flaxseed every day for 4 weeks
89183857|NCT01821131|Placebo Comparator|0g ground flaxseed per day|consume 1 muffin containing 0g ground flaxseed every day for 4 weeks
89183858|NCT01775085|Experimental|Meaning-Centered Group for Breast Cancer Survivors (MCG-BCS)|
89183859|NCT01775085|Active Comparator|Discussion Group (DG)|
89183860|NCT01767675|Experimental|Secondary Cytoreductive Surgery with HIPEC|secondary cytoreductive surgery (CRS) with or without carboplatin-based hyperthermic intraperitoneal chemotherapy (HIPEC) followed by systemic combination chemotherapy for recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer. Patients will be randomized intraoperatively to undergo CRS with HIPEC (arm A) or CRS only (arm B) in a manner 1:1. Both arms will receive a standard platinum-based systemic chemotherapy postoperatively (5 cycles in arm A and 6 cycles in arm B). In some patients randomized to HIPEC at MSKCC only , peritoneal fluid and blood samples will be drawn before, during and after the HIPEC procedure.
89183861|NCT01767675|Experimental|Secondary Cytoreductive Surgery without HIPEC|secondary cytoreductive surgery (CRS) with or without carboplatin-based hyperthermic intraperitoneal chemotherapy (HIPEC) followed by systemic combination chemotherapy for recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer. Patients will be randomized intraoperatively to undergo CRS with HIPEC (arm A) or CRS only (arm B) in a manner 1:1. Both arms will receive a standard platinum-based systemic chemotherapy postoperatively (5 cycles in arm A and 6 cycles in arm B).
89183862|NCT01696513|Experimental|Subcision & Suction|Standard treatment for acne scars followed by suction.
88856282|NCT01391130|Experimental|LY2510924 + Sunitinib|LY2510924: 20 milligram administered subcutaneously once daily, given every day of the 6 week cycle. Sunitinib: 50 milligram administered orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off treatment. Treatment cycles will continue until disease progression, unacceptable toxicity, or another withdrawal criterion is met.
89183863|NCT01696513|Active Comparator|Subcision|Standard treatment for acne scars only
88856283|NCT01391130|Active Comparator|Sunitinib|50 milligram administered orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off treatment. Treatment cycles will continue until disease progression, unacceptable toxicity, or another withdrawal criterion is met.
88856284|NCT01410240|Active Comparator|Standard of Care (SoC)|SoC: conventional hemostatic techniques such as cautery and manual compression
88856285|NCT01410240|Experimental|FLOSEAL + Standard of Care (SoC)|"FLOSEAL: consists of bovine-derived gelatin granules and a human plasma-derived thrombin component.~SoC: conventional hemostatic techniques such as cautery and manual compression"
88856286|NCT01409928|Experimental|Lap-Band|Placement of the LAP-BAND® system will be performed laparoscopically under general anesthesia, using the pars flaccida technique. The device will be placed by surgeons from the University of Texas Southwestern Medical Center Obesity Management Program at Children's Medical Center Dallas. Surgeons will be fully trained in the placement of the LAP-BAND® device, in accordance with FDA approval of the device for the placement in adults. As is current practice in adults undergoing the procedure, incidentally discovered hiatal hernias are repaired at the time of band placement, to reduce the incidence of post-operative reflux. Children receive prophylactic antibiotics, and are observed overnight after surgery. Patients are generally discharged from the hospital the next day. The band will initially be left empty at the end of the placement procedure.
88856287|NCT04037124||Cervical procedure abandoned|Cervical procedure (hysterectomy, radical hysterectomy or fertility sparing treatment) is abandoned due to intraoperatively reported lymph node matestasis. Patient is referred for primary (chemo)radiation.
88856288|NCT04037124||Cervical procedure completed|Cervical procedure (hysterectomy, radical hysterectomy or fertility sparing treatment) is completed. Patient is referred for adjuvant chemoradiation.
88856289|NCT01431534|Experimental|Ridaforolimus 22 mg/m^2|Participants receive 22 mg/m^2 of ridaforolimus administered orally for 5 consecutive days each week (2 days rest) in consecutive 28-day cycles for up to six months. Eligible participants can receive additional treatment in an extension phase of the study.
88856290|NCT01431534|Experimental|Ridaforolimus 28 mg/m^2|Participants receive 28 mg/m^2 of ridaforolimus administered orally for 5 consecutive days each week (2 days rest) in consecutive 28-day cycles for up to six months. Eligible participants can receive additional treatment in an extension phase of the study.
88856291|NCT01431534|Experimental|Ridaforolimus 33 mg/m^2|Participants receive 33 mg/m^2 of ridaforolimus administered orally for 5 consecutive days each week (2 days rest) in consecutive 28-day cycles for up to six months. Eligible participants can receive additional treatment in an extension phase of the study.
88856292|NCT01409382|Active Comparator|Lifestyle counseling|Daily brisk walking plus a carbohydrate-restricted diet
88856293|NCT01409382|No Intervention|Standard follow-up|Prenatal care will proceed according to the routine.
88856294|NCT01408914|No Intervention|RIF 600|
88856295|NCT01408914|Experimental|RIF 900|
88856296|NCT01408914|Experimental|RIF 1200|
88856297|NCT04044846|Experimental|The recipients of the home-based physical activity program|Frail OAs will be asked to fill out the Vitality Plus Scale at the beginning of the implementation phase (baseline) by a research assistant over the telephone. At the end of the 6-month implementation phase, the research assistant will administer the survey again (post-intervention).
88856298|NCT04044222|Experimental|Treatment (Sintilimab, etoposide, ifosfamide, carboplatin)|Patients receive sintilimab IV on day 1, etoposide IV on days 1-3 of courses 1-6, carboplatin IV on day 2 of courses 1-6, and ifosfamide IV on day 1-3 of courses 1-6. Sintilimab in combination with ICE chemotherapy repeats every 21 days for 6 courses.
88856299|NCT04044222|Experimental|Treatment (placebo, etoposide, ifosfamide, carboplatin)|Patients receive placebo IV on day 1, etoposide IV on days 1-3 of courses 1-6, carboplatin IV on day 2 of courses 1-6, and ifosfamide IV on day 1-3 of courses 1-6. Placebo in combination with ICE chemotherapy repeats every 21 days for 6 courses.
88856300|NCT01431144|Active Comparator|Connective tissue autograft|A connective tissue autograft harvested from the palate was grafted onto the facial of a simultaneously placed dental implant and soft tissue thickness was measured at baseline and Time 4.
88856301|NCT01431144|Experimental|connective tissue allograft|An acellular dermal matrix allograft was grafted on the facial surface of a simultaneously placed dental implant and soft tissue thickness was measured at baseline and Time 4.
88856302|NCT01430754|Experimental|tasimelteon|20 mg tasimelteon capsules
88856303|NCT01430754|Placebo Comparator|Placebo|Placebo capsules
88856304|NCT01390428|Experimental|Part 1-Mild Hepatic Impairment (HI)|Participants with mild hepatic impairment will receive 200 mg of Grazoprevir once a day for 10 consecutive days during Part 1 of the study.
88856305|NCT01390428|Experimental|Part 1-Healthy Matched to Mild HI|Healthy participants will receive 200 mg of Grazoprevir once a day for 10 consecutive days during Part 1 of the study.
88856306|NCT01390428|Experimental|Part 2-Moderate HI|Participants with moderate hepatic impairment will receive 100 mg of Grazoprevir once a day for 10 consecutive days during Part 2 of the study.
88856307|NCT01390428|Experimental|Part 2-Healthy Matched to Moderate HI|Healthy participants will receive 100 mg of Grazoprevir once a day for 10 consecutive days during Part 2 of the study.
88856308|NCT01390428|Experimental|Part 3-Severe HI|Participants with severe hepatic impairment will receive 50 mg of Grazoprevir once a day for 10 consecutive days during Part 3 of the study.
88856309|NCT01390428|Experimental|Part 3-Healthy Matched to Severe HI|Healthy participants will receive 50 mg of Grazoprevir once a day for 10 consecutive days during Part 3 of the study.
88856310|NCT01430130|Experimental|All Study Participants|Half of the revised incision was treated with the embrace device. Half of the revised incision was treated according to the Investigator's standard of care. Participant served as his/her own control.
88856311|NCT04052256||Patients with intermediate coronary lesions|Patients (age ≥ 18 years) who have undergone invasive coronary angiography and have a minimum of one non-treated coronary artery with a measured invasive FFR of 0.81-0.90.
88856312|NCT01407354|Experimental|Lokomat Training|Lokomat robotic assisted treadmill training Lokomat Treadmill Training
88856313|NCT01407354|Active Comparator|Aquatic Therapy|Aquatic exercise therapy
88856314|NCT01407276|Experimental|Part 1: Mild Renal Impairment (Panel A)|
89002899|NCT06059404|No Intervention|Meals only|"ARM 1: Meals only. Participants randomized to receive meals only will receive 14 frozen meals, delivered 1x/week, for 3-months. Participants will be provided with a menu of 40 meal options and instructions for how to select their meals and change weekly meal selections (if desired). Participants in this arm will also receive nutrition education and fall prevention handouts. Nutrition education handouts will indicate which of LifeCare Alliance's meals are considered to be heart healthy as well as diabetic-friendly. Participants will have the autonomy to select their own meals according to their preferences and their ability to self-manage their own health conditions (e.g., diabetes, cardiovascular disease). Fall prevention education handouts will provide guidance on how to reduce fall risk at home and modify the home environment to eliminate fall hazards."
89002900|NCT06059404|Active Comparator|Meals + registered dietitian services|"ARM 2: Meals + registered dietitian services. Participants randomized to receive meals + RD only will receive 14 frozen meals, delivered 1x/week, for 3-months. In addition to receiving nutrition education and fall prevention handouts, participants in this arm will have a telephone-based nutrition assessment completed by one of LifeCare Alliance's registered dietitians who will assign participants a nutrition diagnosis (e.g., overconsumption of carbohydrates) within 60 days of study enrollment."
89002901|NCT06059404|Active Comparator|Meals + occupational therapy services|ARM 3: Meals + occupational therapy services. Participants randomized to this arm will receive 14 frozen meals, delivered 1x/week, for 3-months and be able to make weekly meal selections from LifeCare Alliance's full list of 40 meals. In addition to receiving nutrition education and fall prevention handouts, participants in this arm will be contacted (within 30 days of study enrollment) by one of Lifecare Alliance's occupational therapists to complete a phone screen to determine each participant's occupational therapy needs (e.g., home safety/fall risk hazards, need for durable medical equipment).
89002902|NCT06059404|Experimental|Meals + registered dietitian + occupational therapy services|ARM 4: Meals + registered dietitian services + occupational therapy services. Participants in this arm will receive 14 frozen meals, delivered 1x/week, for 3-months as well as the same nutrition education and fall prevention handouts as provided in Arms 1-3. Additionally, participants will receive the combination of dietitian and OT services as provided in Arms 2 and 3 and have the same autonomy to make their own weekly meal selections from a curated list provided by the dietitian.
89002903|NCT06059391|Experimental|Arm I (Triplex vaccination)|"DONORS: Donors receive Triplex vaccine IM on day 0 and then undergo stem cell mobilization with G-CSF on days 5 to 9 and apheresis for peripheral blood stem cell collection on days 10 to 14 per standard of care. Donors may optionally undergo blood sample collection on study.~RECIPIENTS: Recipients undergo pre-transplant conditioning on days -60 to 0 and undergo HCT with the donor peripheral blood stem cells within 9 weeks of donor vaccination on day 0. Recipients undergo blood sample collection on study."
89002904|NCT06059391|Placebo Comparator|Arm II (Placebo)|"DONORS: Donors receive placebo IM on day 0 and undergo stem cell mobilization with G-CSF on days 5 to 9 and apheresis for peripheral blood stem cell collection on days 10 to 14 per standard of care. Donors may optionally undergo blood sample collection on study.~RECIPIENTS: Recipients undergo pre-transplant conditioning on days -60 to 0 and undergo HCT with the donor peripheral blood stem cells within 9 weeks of donor vaccination on day 0. Recipients undergo blood sample collection on study."
89002905|NCT06058442|Experimental|NORTASE®|
89002906|NCT06058442|Placebo Comparator|Placebo|
89002907|NCT06056024|Experimental|Part A (Phase Ia): Dose escalation|
89002908|NCT06056024|Experimental|Part B (Phase Ib): Dose confirmation|
89002909|NCT06056024|Experimental|Part C (Phase Ib): Dose expansion|
89002910|NCT06050252|Experimental|Treatment (durvalumab, gemcitabine, cisplatin)|Patients receive durvalumab IV over 60 minutes on day 1 with gemcitabine IV over 30 minutes and cisplatin IV over 60 minutes on days 1 and 8 for 4 cycles and then undergo surgical resection on study. Following surgery, patients may continue the durvalumab, gemcitabine and cisplatin regimen for up to 4 additional cycles. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo CT scans and/or MRI scans and blood sample collection throughout study, as well as tissue biopsies during screening and on study.
89002911|NCT06047977|Experimental|TIL Therapy|TIL therapy with lymphodepleting chemotherapy and Interleukin 2
89002912|NCT06047574||PCOS|"Oligomenorrhea/amenorrhea~Clinical androgen excess or biochemical androgen excess~Polycystic ovary showed by gynecological ultrasound"
89002913|NCT06047574||NOPCOS|not meet Rotterdam standards
89002914|NCT06046053|Experimental|Placebo Vaginal Film with Square Corners|"A single 2 x 2 placebo vaginal film with square corners, inserted intravaginally once monthly for two months."
89002915|NCT06046053|Experimental|Placebo Vaginal Film with Rounded Corners|"A single 2 x 2 placebo vaginal film with rounded corners, inserted intravaginally once monthly for two months"
89002916|NCT06045806|Experimental|Arm A|
89002917|NCT06045806|Active Comparator|Arm B|
89002918|NCT06044246|Experimental|experimental group|Placing dental implant with PRF membrane treatment alone or combined with bone substitute.
89002919|NCT06044246|No Intervention|control group|Placing dental implant
89002920|NCT06043037|Active Comparator|Immediate Implant Placement Using Socket Shield Technique with autogenous demineralized dentin graft|after immediate implantation using Socket Shield Technique, the palatal root portion will be converted to autogenous demineralized dentin graft and used for grafting the defect between the socket shield and the implant fixture
89002921|NCT06043037|Experimental|Immediate Implant Placement Using Socket Shield Technique only without grafting the defect|after insertion of immediate implant Using Socket Shield Technique, the bone defect between the socket shield and the implant fixture will be left ungrafted
89183864|NCT01689116|Experimental|Bardoxolone Methyl 20mg|
89183865|NCT01689116|Experimental|Bardoxolone Methyl 80mg|
89183866|NCT01689116|Placebo Comparator|Bardoxolone Methyl Placebo|
89183867|NCT01689116|Active Comparator|Moxifloxacin|
89183868|NCT01688076|Experimental|Muscle contractions|Under supervision by study personnel, subjects be asked to make active muscle contractions for one hour after Botox injections. Subjects will return for follow-up visits.
89183869|NCT01688076|Active Comparator|No muscle contractions|Patients will be asked to not perform muscle contractions following Botox injections.
89183870|NCT01678222||SNP|individuals who are homozygous for either the major or minor variant of both SNPs
89183871|NCT01655186|Placebo Comparator|Placebo|Oral, once daily
89383073|NCT05279859|Experimental|Dose Escalation (Part 2): ERAS-601 plus gilteritinib|ERAS-601 will be administered in combination with gilteritinib to study participants with R/R FLT3 mutated AML in sequential ascending doses until unacceptable toxicity, disease progression, or withdrawal of consent.
89383074|NCT05279859|Experimental|Dose Expansion (Part 3): ERAS-007 plus gilteritinib|ERAS-007 will be administered at the recommended dose (as determined from Part 1) in combination with gilteritinib to study participants with R/R FLT3 mutated AML.
89383075|NCT05279859|Experimental|Dose Expansion (Part 4): ERAS-601 plus gilteritinib|ERAS-601 will be administered at the recommended dose (as determined from Part 2) in combination with gilteritinib to study participants with R/R FLT3 mutated AML.
89383076|NCT05233995|Experimental|Intervention group|The patients included in the experimental group will be operated on, performing the resection of the intestinal segment affected by the dehiscence, the sectioned intestinal ends will be left without anastomosis, and open abdomen therapy will be established. After surgery, the patient will be cared for in the intensive care unit where intensive resuscitation will be carried out in order to improve the general conditions of the patient. After 48 ± 24 hours, a second surgical procedure will be performed where local conditions will be evaluated and the possibility of performing a delayed anastomosis will be evaluated.
89383077|NCT05233995|Active Comparator|Control group|The patients included in the control group will be operated on with a resection of the affected intestinal segment and a stoma with or without associated mucosal fistula will be performed at the same surgical time. After the procedure, the patient will be cared for in the intensive care unit in order to improve the general conditions of the patient.
89383078|NCT03681522|Experimental|Pelvic plexus block|The injections of 2.5 mL of 2% lidocaine were made to the pelvic neurovascular plexus located at the end of the seminal vesicle under Doppler US guidance on each side
89383079|NCT03681522|Active Comparator|Periprostatic nerve block|The injections of 2.5 mL of 2% lidocaine were made to the neurovascular bundles at the junction of the prostate-bladder-seminal vesicle.
89383080|NCT03681444|Experimental|Regular diet|no dietary restriction
89383081|NCT03681444|Placebo Comparator|Clear fluid diet|no solid material
88856315|NCT01407276|Experimental|Part 1: Control to Match Panel A (Panel B)|
88856316|NCT01407276|Experimental|Part 1: Moderate Renal Impairment (Panel C)|
88856317|NCT01407276|Experimental|Part 1: Control to Match Panel C (Panel D)|
89383082|NCT03681444|Experimental|Low residue diet|easy digestible food
88818625|NCT02703909|Experimental|moderate NMB + 10 mm IP|participants will be given the muscle relaxant, rocuronium, iv to obtain a moderate neuromuscular block (NMB) which is defined as 2-3 twitches in the train of four on a neuromuscular junction monitor. The initial insufflation pressure for the laparoscopy will be 10 mm Hg pressure.
88856318|NCT01407276|Experimental|Part 1: Severe Renal Impairment (Panel E)|
88856319|NCT01407276|Experimental|Part 1: Control to Match Panel E (Panel F)|
88856320|NCT01407276|Experimental|Part 2: End-stage Renal Disease needing hemodialysis (Panel G)|
88856321|NCT01407276|Experimental|Part 2: Control to Match Panel G (Panel H)|
88856322|NCT01390272|Experimental|Titration Intervention|"The intervention arm includes three levels of resource intensity targeted to improve patients' systolic blood pressure (SBP) [top number of blood pressure measurement].~Medium/level 1 resource intensity: a registered nurse (RN) will provide monthly tailored behavioral support telephone calls + home BP monitoring.~High/level 2 resource intensity: a pharmacist will provide monthly tailored behavioral support telephone calls + home BP monitoring + pharmacist-directed medication management.~Booster (low) resource intensity: a licensed practical nurse (LPN) will provide non-tailored behavioral support telephone calls every two months to patients whose SBP comes under control."
88856323|NCT01390272|Active Comparator|LPN Control|A LPN will provide behavioral support telephone calls that do not include goal setting and directed problem solving every two months (identical to booster (low) resource intensity component of the titrated intervention). The control arm will utilize the same procedures as the booster level for intervention patients for whom SBP comes under control.
88856324|NCT01429584|Active Comparator|0.25% bupivacaine|interscalene nerve block with 0.25% bupivacaine
88856325|NCT01429584|Active Comparator|0.125% bupivacaine|interscalene nerve block with 0.125% bupivacaine
88856326|NCT01406652|Active Comparator|One-stage bursectomy|Bursectomy with debridement and primary closure of the wound during one surgical intervention
88856327|NCT01406652|Experimental|Two-stage bursectomy|Bursectomy with debridement and left open. Wound closure in a second step and in a second surgery.
88856328|NCT01406574|Experimental|OPB-31121 p1|Phase1 step
88856329|NCT01406574|Experimental|OPB-31121 p2|Phase2 step
88856330|NCT01405950|Experimental|Dose Level 1|
88856331|NCT01405950|Experimental|Dose Level 2|
88856332|NCT01405950|Experimental|Dose Level 3|
89383083|NCT05475717|Experimental|20 µg group|Patients will receive alprostadil liposome injection at 20 µg once daily (QD) for 4 days (1 to 3 hours before surgery and 3 days after surgery).
89383084|NCT05475717|Experimental|40 µg group|Patients will receive alprostadil liposome injection at 40 µg once daily (QD) for 4 days (1 to 3 hours before surgery and 3 days after surgery)
88818626|NCT02703909|Active Comparator|moderate NMB + 15 mm IP|participants will be given the muscle relaxant, rocuronium, iv to obtain a moderate NMB which is defined as 2-3 twitches in the train of four on a neuromuscular junction monitor. The initial insufflation pressure for the laparoscopy will be 15 mm Hg pressure. This arm represents the usual operating conditions for this type of surgery at the University hospital.
88818627|NCT02703909|Experimental|deep NMB + 10 mm IP|participants will be given the muscle relaxant, rocuronium, iv to obtain a deep NMB which is defined as 0-1 posttetanic counts on a neuromuscular junction monitor and the initial insufflating pressure will be 10 mm Hg. The initial insufflation pressure for the laparoscopy will be 10 mm Hg pressure.
88856333|NCT01405950|Experimental|Dose Level 4|
88856334|NCT01405560|Experimental|Vaniprevir 24 Week Arm|Participants receive 24 weeks of vaniprevir (300 mg twice daily) with concomitant peg-IFN and RBV treatment
88856335|NCT01428882|Active Comparator|Midazolam balanced propofol sedation|2 mg midazolam in 2 ml saline midazolam followed by continuous propofol iv infusion
89183872|NCT01655186|Experimental|Bardoxolone Methyl|Oral, once daily
89383085|NCT05475717|Experimental|80 µg group|Patients will receive alprostadil liposome injection at 80 µg once daily (QD) for 4 days (1 to 3 hours before surgery and 3 days after surgery)
89383086|NCT05475717|No Intervention|blank control group|Patients will receive only basic hydration therapy which the experimental groups will receive.
89383087|NCT03689322|Experimental|WBV + IMT|Whole body vibration training associated with respiratory muscle training (WBV + IMT)
89383088|NCT03689322|Active Comparator|WBV + IMTsham|Whole body vibration training associated with respiratory muscle training sham (WBV + IMTsham)
89383089|NCT03689322|Sham Comparator|WBVsham + IMTsham|Whole body vibration training sham associated with respiratory muscle training sham (WBVsham + IMTsham)
89383090|NCT04171375|Experimental|trans-spinal Electrical Stimulation (tsES)|
89383091|NCT03685266||Pediatric Residents|Participating pediatric residents from first postgraduate year (PGY-1) through third postgraduate year (PGY-3) will be observed over a 12 month timeframe.
89383092|NCT05133687|Experimental|Group (0.8-G)|This group will receive general anesthesia and caudal block with 0.8 ml/kg of bupivacaine 0.25%
89383093|NCT05133687|Experimental|Group (1.2-G)|This group will receive general anesthesia and caudal block with 1.2 ml/kg of bupivacaine 0.25%
89383094|NCT05133687|Active Comparator|Group G|This group will receive general anesthesia with local infiltration of the wound or transversus abdominis plan block (TAPB) at the end of the procedure.
89383095|NCT03689088|Experimental|Investigational device (Goldfish)|IOP will be monitored for 24 h in the Goldfish eye
89383096|NCT03689088|Active Comparator|Tonometry|IOP will be acquired by standard tonometry at specific times in the the fellow eye
88856336|NCT01428882|Placebo Comparator|Single-agent propofol sedation|2 ml saline followed by continuous propofol iv infusion
88856337|NCT01428258|Experimental|GMP Diet/GMP Medical Foods|The experimental intervention is the GMP diet followed at home for 3-wk. In this randomized crossover study, half of subjects (n=15) were randomized to receive the GMP diet as the first arm, and half of the subjects (n=15) were randomized to receive the GMP diet as the second arm.
89383097|NCT01383135|Other|Healty Volunteers|Normal volunteers to receive 5 to 14 mCi F18-FPPRGD2 by intravenous (IV) injection.
89383098|NCT01383135|Experimental|Breast Cancer|Breast cancer patients to receive 4 to 11 mCi F18-FPPRGD2 by IV injection.
88856338|NCT01428258|Active Comparator|AA Diet/AA Medical Foods|The experimental intervention is the AA diet followed at home for 3-wk. In this randomized crossover study, half of subjects (n=15) were randomized to receive the AA diet as the first arm, and half of the subjects (n=15) were randomized to receive the AA diet as the second arm.
88856339|NCT01389882|Experimental|ventilator assist|
88856340|NCT01442688|Experimental|Amoxicillin + MMX placebo|
88856341|NCT01442688|Experimental|Amoxicillin + MMX mesalazine/mesalamine|
89183873|NCT01598363|Experimental|Digoxin 0.5mg, Bardoxolone Methyl 20mg and 60mg|
89183874|NCT01598363|Experimental|Rosuvastatin 20mg, Bardoxolone Methyl 20mg and 60mg|
89183875|NCT01576887|Placebo Comparator|Placebo|
89383099|NCT01383135|Experimental|Glioblastoma Multiform (brain)|Glioblastoma multiform patients to receive 5 to14 mCi F18-FPPRGD2 by IV injection.
89383100|NCT01383135|Experimental|Lung Cancer|Lung cancer patients to receive X to XX mCi F18-FPPRGD2 by IV injection.
89383101|NCT03685032|Experimental|The study group (Gr. D)|"After patients received general anesthesia, a sequentially numbered opaque sealed envelope was opened. Gr. D was administered 4 mg of dexamethasone in 1 ml iv.~At the end of the operation when suturing the dura mater, Gr. D received ondansetron 4 mg in 2 ml iv."
89383102|NCT03685032|Placebo Comparator|the control group (Gr. N)|"After patients received general anesthesia, a sequentially numbered opaque sealed envelope was opened. Gr. N received normal saline 1 ml iv.~At the end of the operation when suturing the dura mater, Gr. N received normal saline 2 ml iv."
88856342|NCT01466166||Pegloticase|Participants received pegloticase 8 mg by intravenous (IV) infusion every 2 weeks for up to 1 year, as prescribed by their treating physician.
88856343|NCT03814200|Experimental|Treatment period A|"Treatment A1: saline 0.9%~followed by~Treatment A2: ACT-246475"
88856344|NCT03814200|Experimental|Treatment period B|"Treatment B1: rifampicin~followed by~Treatment B2: ACT-246475"
88856345|NCT01426854|Active Comparator|Nepafenac|Nepafenac Ophthalmic Suspension, 0.1%, 1 drop to the operative eye, 3 times a day, beginning 1 day preoperatively and continuing through the day of surgery and for 14 days postoperatively. An additional dose was administered prior to surgery.
89183876|NCT01576887|Experimental|Bardoxolone Methyl|
89183877|NCT01563562|Experimental|Bardoxolone Methyl 20 mg|
89183878|NCT01551446|Experimental|Bardoxolone Methyl 20mg|
89183879|NCT01549769|Experimental|Bardoxolone Methyl 20 mg|
89535104|NCT03230383|Experimental|Cohort 5_3000mg and Matching Placebo|
89183880|NCT01535963||cutaneous surgery|Patients undergoing cutaneous surgery
89383103|NCT03689010|Active Comparator|Azelaic acid foam 15%|Topical, twice daily (Apply the foam (morning and evening) to the entire facial area (cheeks, chin, forehead, and nose).
89383104|NCT03689010|Active Comparator|Finacea® (azelaic acid) Foam, 15%|Topical, twice daily (Apply the foam (morning and evening) to the entire facial area (cheeks, chin, forehead, and nose).
89383105|NCT03689010|Placebo Comparator|Vehicle of the test product|Topical, twice daily (Apply the foam (morning and evening) to the entire facial area (cheeks, chin, forehead, and nose).
89383106|NCT03681288|Experimental|MSC|Mindful Self-Compassion Intervention
89383107|NCT03680976|Experimental|10-nitro-octadeca-9-enoic acid (CXA-10)|CXA-10 150 mg tablet taken orally once a day for 12 weeks
89383108|NCT03680976|Placebo Comparator|Placebo|Placebo 150 mg tablet taken orally once a day for 12 weeks
89383109|NCT01383057|Experimental|Femtosecond Laser|
89383110|NCT03684954|Other|Used of PRF in clsed sinus lifting|Used of PRF in closed sinus lifting with implant placement
89535105|NCT03230383|Experimental|Optional Cohort 6_TBD mg and Matching Placebo|
89535106|NCT03230383|Experimental|Optional Cohort 7_TBD mg and Matching Placebo|
89383111|NCT03684954|No Intervention|Closed sinus with xenograft|used of xenograft in closed sinus lift with implant placement.
89383112|NCT03680898|Experimental|revogene Testing|The swab will be used for the testing on the revogene using the GenePOC Carba assay.
89383113|NCT03680898|Active Comparator|Reference Method|The other swab will be used in the Reference Method.
89383114|NCT03688932|Experimental|WBV + IMT|Whole body vibration training associated with respiratory muscle training (WBV + IMT)
89383115|NCT03688932|Active Comparator|WBV + IMTsham|Whole body vibration training associated with respiratory muscle training sham (WBV + IMTsham)
89383116|NCT03688932|Sham Comparator|WBVsham + IMTsham|Whole body vibration training sham associated with respiratory muscle training sham (WBVsham + IMTsham)
89383117|NCT05084313|Experimental|Manual therapy group|This group of patients will receive manual therapy techniques to harmonize vegetative nervous system. PPG and GSR will be recorded during the intervention. The techniques consist of CV-4 technique, suboccipital decompression, lumbo-sacral decompression, release of the transverse diaphragms, frontal lift technique, parietal lift technique, temporal techniques, temporo-mandibular joint myofascial release, deep cervical fasciae technique as described in Upledger's protocol. In addition to the protocol; rib raising technique, larynx and sternocleidomastoid muscle fascial release and occipito-mastoid suture release will be applied. All intervention is planned to take approximately 20 minutes. The group will include 40 healthy individuals.
89383118|NCT05084313|Active Comparator|Deep-slow breathing group|Patients in this group will do deep-slow paced breathing exercise. The patients will be able to cease the session in case of feeling uncomfortable. The main purpose will be that the individuals should breathe six breaths per minute to increase respiratory sinus arrhythmia which is also reflected at PPG waveforms and in reduction in GSR. The group will include forty healthy individuals.
89383119|NCT05084313|Other|Control|Control group patients will be attached to the sensors, and they will rest in a quiet and controlled indoor environment without any intervention. The aim of including this group is to to understand whether the parasympathetic effects expected in the manual therapy group were due to the intervention. The group will include forty healthy individuals.
89383120|NCT03688854|Placebo Comparator|Placebo|Placebo are capsules containing cellulose.
89383121|NCT03688854|Experimental|SCFA mixture low dose|Encapsulated SCFA mixture in the ratio of 67:6:27 (acetate, propionate, butyrate) equivalent of 10 grams of fiber.
89383122|NCT03688854|Experimental|SCFA mixture high dose|Encapsulated SCFA mixture in the ratio of 67:6:27 (acetate, propionate, butyrate) equivalent of 20 grams of fiber.
89383123|NCT01382979|Experimental|Alcohol education and prevention|AlcoholEdu is an online course designed to prevent alcohol misuse and related problems among college freshmen.
89383124|NCT01382979|No Intervention|Control|Control group.
89383125|NCT05042193||Unvaccinated SARS-CoV-2 positive|Participants who have tested positive for SARS-CoV-2, both with and without symptoms, who have not been vaccinated
89383126|NCT05042193||Vaccinated|Participants who were vaccinated against SARS-CoV-2
89383127|NCT03688776|Experimental|1805AA, 1805AB Use Group|Use of product 1805AA exclusively for approximately 3 days prior to a PK assessment, followed by use of product 1805AB exclusively for approximately 3 days prior to a PK assessment.
89383128|NCT03688776|Experimental|1805AB, 1805AA Use Group|Use of product 1805AB exclusively for approximately 3 days prior to a PK assessment, followed by use of product 1805AA exclusively for approximately 3 days prior to a PK assessment.
88856346|NCT01426854|Placebo Comparator|Placebo|Nepafenac Vehicle, 1 drop to the operative eye, 3 times a day, beginning 1 day preoperatively and continuing through the day of surgery and for 14 days postoperatively. An additional dose was administered prior to surgery.
88856347|NCT04050774|Experimental|Age group 1|6-9 years old
88856348|NCT04050774|Experimental|Age group 2|15-17 years old
88856349|NCT04050774|Experimental|Age group 3|18 - 24 years old
88856350|NCT04050774|Experimental|Age group 4|65-80 years old
88856351|NCT01426386|Experimental|5.2 µg|
88856352|NCT01426386|Experimental|6.9 µg|
88856353|NCT01426386|Experimental|8.6 µg|
88856354|NCT01426386|Experimental|10.3 µg|
88856355|NCT01426386|Experimental|12.1 µg|
88856356|NCT01426386|Active Comparator|11 µg FbM (150 IU)|
88856357|NCT01404234|Experimental|Open-label AZLI|Participants received three 28-day courses of AZLI, each followed by 28 days off-treatment.
89383129|NCT03684798|Experimental|Mental Contrasting with Implementation Intentions (MCII)|"Mental Contrasting with Implementation Intentions (MCII) combines two methods: Mental Contrasting and Implementation Intentions.~Mental Contrasting (MC) consists of imaging a desired future and comparing it with obstacles of the present reality (Oettingen, 2000, 2014; Oettingen, Pak, & Schnetter, 2001) in order to increase goal commitment when expectations of success are high (Gollwitzer, 2014). Implementation Intentions on the other hand specify when, where, and how to strive for a goal in form of an if-then-plan, e.g. If situation Y is encountered, then I will perform the goal-directed response Z (Gollwitzer, 2014; Wieber, Thürmer, & Gollwitzer, 2015)."
89383130|NCT03684798|Active Comparator|Treatment as usual|The control group receive a control training, which consists of an exercise from treatment as usual. Thus, patients in the control group are supported in their intention for abstinence and in the reappraisal of risk situations and relapse, while no individual motivational strategies are planned or provided
89399546|NCT03537248|Active Comparator|ReNu® Multiplus Contact Lens Solution|ReNu® Multiplus Contact Lens Solution used as rub care regimen (Control)
88856358|NCT01403610|Experimental|Cohort 1|Subjects received TH-302 single dose at 575 mg/m2 or placebo administered preoperative in a 2:1 randomization and were then administered 240 mg/m2 of TH-302 post-operative.
88856359|NCT01403610|Experimental|Cohort 2|Surgical subjects will receive TH-302 at 340 mg/m2 every 2 weeks (4 week cycles) starting after surgery from Cycle 1, Day 1 until disease progression.
88856360|NCT01403610|Experimental|Cohort 3|Surgical or Non-Surgical subjects will receive TH-302 at 480 mg/m2 every 2 weeks (4 week cycles) starting after surgery from Cycle 1, Day 1 until disease progression.
88856361|NCT01403610|Experimental|Cohort 4|Non-surgical subjects will receive a dose up to 670 mg/m2 of TH-302
88856362|NCT01403064|Experimental|Open Label ALD518|
88856363|NCT01403064|Experimental|ALD518 Dose 1|
88856364|NCT01403064|Experimental|ALD518 Dose 2|
89383131|NCT05407857|Experimental|On-site|The on-site multi-modal intervention will be actively involved in management with nutrition, exercise and cognitive programs. The on-site intervention group requires subjects to participate in prescribed place according to the protocol.
89383132|NCT05407857|Active Comparator|Remote|The remote intervention group is designed for reducing the chances of person-to-person contact response to the current COVID-19 pandemic and development of digital internet. It uses innovative technology combining wearable devices with inertial measurement units, blue-tooth equipment, apps, feedback technology and artificial intelligence based remote comprehensive training programs.
89383133|NCT05407857|Placebo Comparator|Control|The control group will also receive the same health evaluation and education as all intervention groups.
89383134|NCT03688698||PAH|
89383135|NCT03688698||Controls|
88856365|NCT01403064|Placebo Comparator|Placebo|
88856366|NCT01402986|Placebo Comparator|Placebo, Q2W - Cohort 1|Participants received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.
88856367|NCT01402986|Experimental|Tralokinumab 300 mg, Q2W - Cohort 1|Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.
88856368|NCT01402986|Placebo Comparator|Placebo, Q2/4W - Cohort 2|Participants received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.
88856369|NCT01402986|Experimental|Tralokinumab 300 mg, Q2/4W - Cohort 2|Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.
88856370|NCT01402908|Experimental|PI-88|Arm 1
88856371|NCT01402908|Placebo Comparator|Placebo|Arm 2
88856372|NCT01389258|Experimental|OsseoSpeed™ TX|OsseoSpeed™ TX narrow implants (diameter 3 mm) of lengths 11-15 mm
88856373|NCT01389102|Placebo Comparator|Placebo transdermal three 90 μL sprays|Placebo transdermal spray, three 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator
88856374|NCT01389102|Placebo Comparator|Placebo transdermal two 90 μL sprays|Placebo transdermal spray, two 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator
88856375|NCT01389102|Placebo Comparator|Placebo transdermal one 90 μL spray|Placebo transdermal spray, one 90 μL spray applied to 1 inner forearm daily for 12 weeks using a blinded applicator
89002922|NCT06037070|Experimental|group with PRF|PRF placed inside the hole that prepared to place dental implant
89383136|NCT04220775|Experimental|Treatment (bintrafusp alfa, SBRT)|Patients receive bintrafusp alfa IV over 1 hour on days 1 and 15. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Beginning day 15 of cycle 1, patients also undergo SBRT over 5 fractions once QOD for 2 weeks in the absence of disease progression or unacceptable toxicity.
89383137|NCT02925312|Experimental|Intervention|Patients receive the full diabetes pathway intervention consisting of: individualized diabetes self-management education and support; T2DM meds management by clinician-supervised diabetes educators using an evidence-based algorithm and FDA approved anti-hyperglycemic agents; near, real-time blood glucose monitoring, delivered via a combination of two in-person and weekly remote (telephone/text) visits.
89383138|NCT02925312|No Intervention|Matched controls|Patients receive standard of care from their primary care provider. Usual care visits are typically conducted quarterly per national guidelines for management of T2DM in adults, or more frequently as needed.
89383139|NCT04108299|Placebo Comparator|Wait-list Control|Standard of care
89383140|NCT04108299|Experimental|SMS Intervention|The SMS group will receive brief lifestyle counseling videos via SMS links. At the end of the study, the wait-list control group will be provided the opportunity to receive the counseling videos.
89383141|NCT01382823|Experimental|Femtosecond Laser|
88856376|NCT01389102|Active Comparator|Estradiol transdermal three 90 μL sprays|Estradiol transdermal spray, three 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator
88856377|NCT01389102|Active Comparator|Estradiol transdermal two 90 μL sprays|Estradiol transdermal spray, two 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator
88856378|NCT01389102|Active Comparator|Estradiol transdermal one 90 μL spray|Estradiol transdermal spray, one 90 μL spray applied to 1 inner forearm daily for 12 weeks using a blinded applicator
88856379|NCT01402284|Experimental|Carfilzomib, Lenalidomide, Dexamethasone|Patients will receive 8 cycles of induction combination therapy of carfilzomib, lenalidomide, and dexamethasone (CRd). Patients achieving stable disease or better after 8 cycles of CRd will receive lenalidomide extended dosing (phase I) for 12 cycles. After 12 cycles, patients will have the option to continue extended dosing (phase II) for one additional year
88856380|NCT01388790|Experimental|Cetuximab plus cisplatin plus S-1|
88856381|NCT01388478|Experimental|R(+)pramipexole|Each study participant will be given the active study drug, R-pramipexole. There is no placebo arm.
88856382|NCT01424670|Experimental|Delamanid + OBR|"In the first period of this study, known as the 6-month Intensive Period, participants were randomized to receive 100 mg delamanid orally BID (morning and evening) + OBR for 2 months, followed by 200 mg delamanid QD (every morning) + OBR for 4 months.~Following the 6-month Intensive Period, participants entered the second period of the study, known as the Continuation Period, wherein OBR was administered alone for 12 to 18 months.~OBR given throughout the study was administered as per WHO guidelines and national treatment norms."
88856383|NCT01424670|Placebo Comparator|Placebo + OBR|"In the first period of this study, known as the 6-month Intensive Period, participants were randomized to receive placebo orally BID (morning and evening) + OBR for 2 months followed by placebo QD (every morning) + OBR for 4 months.~Following the 6-month Intensive Period, participants entered the second period of the study, known as the Continuation Period, wherein OBR was administered alone for 12 to 18 months.~OBR given throughout the study was administered as per WHO guidelines and national treatment norms."
88856384|NCT01424514|Experimental|SB-705498|
88856385|NCT01424514|Placebo Comparator|Placebo|
89002923|NCT06037070|No Intervention|control group|with out and additive
89002924|NCT06035601|Experimental|Electronic health record (EHR)-integrated texting platform|Patients will be enrolled into a texting platform for the management of recurrent UTI.
89383142|NCT01382043||Endeavor Segment group|
89183881|NCT01515787|Experimental|Group 1|"Patients will receive FOLFOX chemotherapy once every two weeks for 6 cycles total over a period of 12 weeks. After completing FOLFOX chemotherapy, the patient will have an MRI scan or endorectal ultrasound (ERUS) to examine the tumor. If the tumor has not decreased in size by at least 20%, the patient will receive 5FUCMT (radiation with chemotherapy). If the tumor has decreased in size by 20%, then the patient will proceed directly to surgery.~If all borders of the tumor are normal post surgery, then the patient receives six additional cycles of FOLFOX chemotherapy. If all borders of the tumor are not normal then the patient receives chemoradiation therapy for 5.5 weeks after surgery. After chemoradiation, additional cycles of FOLFOX or similar chemotherapy will be recommended for 4 cycles or 8 weeks. Patient observation with follow up evaluations and event monitoring will occur up to 8 years post randomization."
89383143|NCT01382043||Excel Segment Group|
89383144|NCT01980381|Experimental|Tree Theme Method ® (TTM) intervention|The TTM involves storytelling and story making, in which the patient draws tree maps representing certain periods of his/her life.
89383145|NCT01980381|No Intervention|Control group|Treatment as usual, with focus on the present everyday occupations
89383146|NCT01381965|Active Comparator|Eyes with macular hole|
89383147|NCT01381887|Placebo Comparator|001|Placebo Treatment A: Form=capsule route=oral administration. Capsule is taken once daily on Day 1 and Day 2 in 1 of 4 treatment periods.
89383148|NCT01381887|Experimental|002|"Canagliflozin 300mg/Placebo Treatment B: Type=1 unit=mg number=300 form=capsule route=oral use. Capsule is taken once on Day 1 in 1 of 4 treatment periods.~Form=capsule route=oral administration. Capsule is taken once on Day 2 in 1 of 4 treatment periods."
89383149|NCT01381887|Experimental|003|Canagliflozin 300mg Treatment C: Type=1 unit=mg number=300 form=capsule route=oral use. Capsule is taken once daily on Day 1 and Day 2 in 1 of 4 treatment periods.
89383150|NCT01381887|Experimental|004|"Canagliflozin 300mg/Canagliflozin 150mg Treatment D: Type=1 unit=mg number=300 form=capsule route=oral use. Capsule is taken once on Day 1 in 1 of 4 treatment periods.~Type=1 unit=mg number=150 form=capsule route=oral use. Capsule is taken once on Day 2 in 1 of 4 treatment periods."
89183882|NCT01515787|Active Comparator|Group 2|Patients receive 5FUCMT including chemotherapy and radiation therapy for 5.5 weeks. Patients will be given either 5-fluorouracil or capecitabine and radiation therapy. After the chemoradiation therapy is completed, patients will proceed directly to surgery. Post-surgery, patients will receive FOLFOX chemotherapy once every two weeks for 8 cycles total over a period of 16 weeks. Patient observation with follow up evaluations and event monitoring will occur up to 8 years post randomization.
89383151|NCT03680664|Experimental|Active tDCS + MBSR|"Excitatory bilateral stimulation to the frontal lobes, in particular the left and right DLPFC, will be applied. The anode will be placed at Fz and the cathode at Iz to achieve this bilateral frontal excitatory stimulation. Rubber electrodes will be inserted in 35-cm2 saline-soaked sponges and fixed with a headband. The direct current will be of 2 milliamps (mA) (current density = 0.57 A/m2) for 30 min per day.~After a brief orientation session, the MBSR sessions will be conducted in 8 weekly 2.5 hour classes plus a half-day retreat. Content includes instruction and guidance to mindfulness meditation practices, gentle mindful movement, and various exercises to enhance mindfulness in everyday life. Participants will get daily at-home assignments with Compact Discs-Read Only Memory (CD-ROMs) of meditative practice."
89383152|NCT03680664|Sham Comparator|sham tDCS + MBSR|"The same tDCS parameters as as the active condition will be used; however, the device will be turned off after 1 minute of active stimulation.~After a brief orientation session, the MBSR sessions will be conducted in 8 weekly 2.5 hour classes plus a half-day retreat. Content includes instruction and guidance to mindfulness meditation practices, gentle mindful movement, and various exercises to enhance mindfulness in everyday life. Participants will get daily at-home assignments with CDs of meditative practice."
89002925|NCT06035601|Active Comparator|Usual care|Patients will receive usual care through their providers.
89002926|NCT06034743|Experimental|2 mg baxdrostat|2 mg baxdrostat administered orally, once daily (QD).
89002927|NCT06034743|Experimental|1 mg baxdrostat|1 mg baxdrostat administered orally, once daily (QD).
89002928|NCT06034743|Placebo Comparator|Placebo|Placebo administered orally, once daily (QD).
89002929|NCT06032923|No Intervention|Healthy controls|This group will not receive the dietary supplement or placebo.
89002930|NCT06032923|Active Comparator|Subjects with SLE - Active|This study group will take the dietary supplement Nicotinamide Riboside capsules.
89002931|NCT06032923|Placebo Comparator|Subjects with SLE - Placebo|This study group will take the Placebo.
89002932|NCT06027216|Experimental|Field Expansion|Field of view on the nasal side (same side as the blind eye) with and without multiplexing prism
89002933|NCT06024668|Experimental|Detection of colliding pedestrian|Participants will perform a simulated walking task in which surrounding pedestrians will walk towards and make a collision. Participants will respond by pressing buttons to indicate the direction of the colliding pedestrians. Participants will perform the task with and without the multiplexing prism in random orders.
89002934|NCT06020950|Placebo Comparator|Control|Reduced calorie diet along with placebo (sunflower oil) pearls
89002935|NCT06020950|Active Comparator|Omega-3 supplementation|Reduced calorie diet along with omega-3 supplementation
89002936|NCT06020950|Experimental|Chia seed|Reduced calorie diet along with chia seed consumption
89183883|NCT01503866|Experimental|20 mg bardoxolone methyl|
89183884|NCT01467427|Experimental|NNC-0156-000-0009|
89383153|NCT04878471|Experimental|ASP5354|Three participants in three dose levels will receive a single intravenous dose of ASP5354 on Day 1 under fasting conditions.
89383154|NCT04878471|Placebo Comparator|ASP5354 Matching Placebo|One participant in three dose levels will receive a single intravenous dose of matching placebo on Day 1 under fasting conditions.
89383155|NCT03684720|Experimental|Discover followed by direct instruction [DD]|The intervention group which will be taught suturing using guided-discovery-learning
89383156|NCT03684720|No Intervention|Instruction followed by practice [IP]|The control group which will be taught suturing using traditional instructional teaching.
89383157|NCT04877379|Experimental|Part 1|Subjects will receive single doses of VNRX-7145 or VNRX-5024 alone and in combination. All subjects will receive study drug in the sequence specified by the randomization schedule.
89183885|NCT01461161|Experimental|20 mg bardoxolone methyl|
89183886|NCT01461161|Experimental|60 mg bardoxolone methyl|
89183887|NCT01461161|Experimental|80 mg bardoxolone methyl|
89183888|NCT01440244|Other|Single group assignment|Cervical mediastinoscopy
89383158|NCT04877379|Experimental|Part 2A|Multiple dose administration of VNRX-7145 q8h for 10 days
89183889|NCT01375530||1|Healthy adults 18 - 60 years old
89183890|NCT01351675|Placebo Comparator|Placebo|
89383159|NCT04877379|Placebo Comparator|Part 2B|Multiple dose administration of placebo q8h for 10 days
89383160|NCT04877379|Experimental|Part 3A|Multiple dose administration of low dose VNRX-7145 + VNRX-5024
89183891|NCT01351675|Experimental|Bardoxolone Methyl|
89383161|NCT04877379|Experimental|Part 3B|Multiple dose administration of high dose VNRX-7145 + VNRX-5024
89383162|NCT04877379|Placebo Comparator|Part 3C|Multiple dose administration of Placebo (matching VNRX-7145 + VNRX-5024)
89383163|NCT01382745|Experimental|Nimotuzumab|Patients will receive weekly injections of Nimotuzumab (200mg/injection) for 12 weeks and standard external beam radiotherapy
89183892|NCT01192464|Experimental|autologous CAR.CD30 EBV specific-CTLs|"Group One Dose (CTLs CAR.CD30) at Day 0: 2x10^7 cells/m2~Group Two Dose (CTLs CAR.CD30) at Day 0: 5x10^7 cells/m2~Group Three Dose (CTLs CAR.CD30) at Day 0: 1x10^8 cells/m2"
89183893|NCT01143558|Experimental|1|All cohorts undergo the same intervention with the study device.
89183894|NCT01056185||Influenza|Influenza A and subtypes such as H3N2 and 2009 H1N1 or influenza B
89183895|NCT01056185||Novel Respiratory Virus-1|MERS-CoV (Middle East Respiratory Syndrome Coronavirus
89183896|NCT01056185||Novel Respiratory Virus-2|SARS-CoV (Severe Acute Respiratory Syndrome Coronavirus)
89183897|NCT01053936|Experimental|Bardoxolone methyl: 5 mg|
89183898|NCT01053936|Experimental|Bardoxolone methyl: 10 mg|
89183899|NCT01053936|Experimental|Bardoxolone methyl: 15 mg|
89183900|NCT01053936|Experimental|Bardoxolone methyl: 30 mg|
89183901|NCT01053936|Experimental|Bardoxolone methyl: 2.5 mg|
89189352|NCT02545036|Experimental|TCM daycare model|30 patients will be assigned to this arm. The assignment depends on the patients' own will. After diagnosis by nephrology physician, these patients will be distributed to control group by their wills. The intervention is Traditional Chinese Medicine (TCM) daycare model, which provides multiple approaches of traditional Chinese medical treatment, including 5 tones of Chinese music, massage on meridians and collaterals, acupuncture, and patient education. The treatment course is one time a week, for 12 weeks (12 treatments in total). And the model will be provided by a team work clinical care system organized by doctors, nurses, pharmacists and case managers, also provide a comprehensive TCM care system for every visit.
89383164|NCT03684330|Active Comparator|Vitamin D supplementation|
89383165|NCT03684330|Placebo Comparator|Vitamin D placebo|
89383166|NCT04857489||Patients with Relapse Remitting Multiple Sclerosis|Blood sample
89383167|NCT04857489||Healthy Controls|Blood Sample
89383168|NCT03680430|Experimental|limb soft tissue sarcoma|
89399547|NCT02177240|Active Comparator|GRS (GlideRite®)|GlideScope® intubation with GRS® stylet of a simulated difficult airway
89399548|NCT02177240|Active Comparator|FIS (Flex-it® )|GlideScope® intubation with Flex-it® stylet of a simulated difficult airway
89399549|NCT02179658|Experimental|OPT-80 group|Oral
89399550|NCT02179658|Active Comparator|Vancomycin group|Oral
89399551|NCT02177318||Patients with COPD|
89383169|NCT03688386|Experimental|Language Intervention|"1. Review language and infant bonding curriculum 2. 1st LENA recording and heart rate variability of mother reading to infant 3. Provide LENA linguistic feedback and review curriculum 4. 2nd LENA recording and heart rate variability of mother reading to infant 5. Provide LENA linguistic feedback and review curriculum 6. 3rd LENA recording and heart rate variability of mother reading to infant 7. Provide LENA linguistic feedback~Assessments: 1. NICU Network Neurobehavioral Scale (NNNS) profile at 36 weeks 2. Fragile Infant Parent Readiness Evaluation at 36 weeks 3. Parent perception survey of reading and curriculum at 36 weeks and 12 months 4. Bayley Scales of Infant and Toddler Development at 12 and 24 months 5. DNA methylation of genes pre and post intervention"
89183902|NCT01044069|Experimental|Pts with B Cell Acute Lymphoblastic Leukemia|This is a phase I study. Patients with CD19+ ALL (CR, relapsed, MRD, or refractory) are eligible for enrollment. B-ALL patients in first CR will be enrolled but only treated if they develop MRD or a frank relapse, while patients with MRD or with documented relapsed/refractory disease are eligible for immediate treatment. The T cell doses originally proposed in this study were based on doses administered safely in prior autologous T cell adoptive therapy trials but the dose has been modified based on the toxicities observed in patients with morphologic evidence of disease. Patients will be treated with different doses of T cells depending on the amount of disease at the time of T cell infusion. Patients in Cohort 1 (<5% blasts in the BM) will continue to receive 10^6 19-28z+ T cells/kg as previously. Patients in Cohort 2 (≥5% blasts in the BM) will receive the reduced dose of 1x106 19-28z+ T cells/kg).
89183903|NCT00974415|Experimental|treatment|CO2 treatment
89383170|NCT03688386|Active Comparator|Infant bonding|"1. Review infant bonding curriculum with mother 2. 1st LENA recording and heart rate variability of mother holding infant 3. Review infant bonding curriculum 4. 2nd LENA recording and heart rate variability of mother holding infant 5. Review infant bonding curriculum 6. 3rd LENA recording and heart rate variability of mother holding infant 7. Provide linguistic feedback of all 3 LENA recordings~Assessments: 1. NICU Network Neurobehavioral Scale (NNNS) profile at 36 weeks 2. Fragile Infant Parent Readiness Evaluation at 36 weeks 3. Parent perception survey of reading and curriculum at 36 weeks and 12 months 4. Bayley Scales of Infant and Toddler Development at 12 and 24 months 5. DNA methylation of genes pre and post intervention"
89383171|NCT03684252|Other|Control|Treatment as usual
88856386|NCT01400958|Active Comparator|A: Nuvigil®|Study evaluation times correspond to standard follow-up evaluations for newly diagnosed malignant glioma patients. After 6 weeks of concurrent External Beam Radiation Therapy (EBRT) and Temozolomide (TMZ), there is typically a 4 week treatment break prior to the start of the 6 monthly cycles of TMZ. No further placebo or Nuvigil® will be given after the 6 week treatment regimen. Thus, study evaluations will occur at baseline (Week 0), immediately after completion of EBRT, TMZ, and Nuvigil® or placebo (Week 7), at the end of the 4 week washout period (Week 10), after the first 2 cycles of TMZ (Week 18), and after the 6th cycle of TMZ (Week 34).
88856387|NCT01400958|Placebo Comparator|B: Placebo|Study evaluation times correspond to standard follow-up evaluations for newly diagnosed malignant glioma patients. After 6 weeks of concurrent EBRT and TMZ, there is typically a 4 week treatment break prior to the start of the 6 monthly cycles of TMZ. No further placebo or Nuvigil® will be given after the 6 week treatment regimen. Thus, study evaluations will occur at baseline (Week 0), immediately after completion of EBRT, TMZ, and Nuvigil® or placebo (Week 7), at the end of the 4 week washout period (Week 10), after the first 2 cycles of TMZ (Week 18), and after the 6th cycle of TMZ (Week 34).
88856388|NCT01388166||Patients with COPD|
88856389|NCT01400412|Experimental|MVC Arm: DRV/r + MVC + FTC + TDF placebo|Darunavir 800 mg PO QD + Ritonavir 100 mg PO QD + Maraviroc 150 mg PO QD + Emtricitabine 200 mg PO QD + Placebo for Tenofovir disoproxil fumarate PO QD
88856390|NCT01400412|Experimental|TDF Arm: DRV/r + TDF + FTC + MVC placebo|Darunavir 800 mg PO QD + Ritonavir 100 mg PO QD + Emtricitabine 200 mg PO QD + Tenofovir disoproxil fumarate 300 mg PO QD + Placebo for Maraviroc PO QD
88856391|NCT01422876|Experimental|BI 10773/linagliptin FDC (high dose)|Patients receive BI 10773/linagliptin FDC (high dose) once daily
89183904|NCT00974415|Sham Comparator|sham|sham treatment
89183905|NCT00823654||Premenopausal Women with Early Stage Breast Cancer|
89383172|NCT03684252|Experimental|Intervention|CBT-based intervention
88856392|NCT01422876|Experimental|BI 10773/linagliptin FDC (low dose)|Patients receive BI 10773/linagliptin FDC (low dose) once daily
88856393|NCT01422876|Active Comparator|BI 10773 (high dose)|Patients receive BI 10773 (high dose) once daily
88856394|NCT01422876|Active Comparator|BI 10773 (low dose)|Patients receive BI 10773 (low dose) once daily
89383173|NCT03623802|Experimental|Local Movement Therapy|Group receiving treatment in form of Local Movement Therapy Program.
89383174|NCT03623802|Experimental|Integral Movement Therapy|Group receiving treatment in form of Integral Movement Therapy Program.
89383175|NCT03680118|Experimental|autogenous rings with GBR and autogenous graft with ti-mesh|Augmentation with autogenous onlay ring blocks covered by guided bone regeneration (GBR) using collagen membrane and autogenous bone graft using titanium mesh (ti-mesh) only
89183906|NCT00823654||Unaffected High Risk Women with BRCA mutations|
89183907|NCT00811889|Placebo Comparator|Placebo|
89183908|NCT00811889|Experimental|Bardoxolone Methyl (RTA 402): 75mg|
89183909|NCT00811889|Experimental|Bardoxolone Methyl (RTA 402): 150mg|
89183910|NCT00811889|Experimental|Bardoxolone Methyl (RTA 402): 25mg|
89183911|NCT00669188|Experimental|Information Type 1|genetic risk information
89183912|NCT00669188|Sham Comparator|Information Type 2|information absent
89183913|NCT00664027|Experimental|25 mg|25 mg RTA 402 (Bardoxolone methyl)/Stratum 1
89183914|NCT00664027|Experimental|75 mg|75 mg RTA 402 (Bardoxolone methyl)/Stratum 1
89383176|NCT04850469||trial group|Mesenchymal Stem Cell-Derived Exosomes
89383177|NCT04850469||control group|conventional treatment
89383178|NCT01783041|Placebo Comparator|5% dextrose|Infants randomized to the placebo group will receive 5% dextrose intravenously. If infant is receiving 100 cc/kg/day of enteral feeds before the supplementation endpoint, an equivalent volume of placebo (5% Dextrose) will be given to the study patients.
89383179|NCT01783041|Experimental|L-carnitine|Infants randomized to the study group will receive L-carnitine intravenously. If infant is receiving 100 cc/kg/day of enteral feeds before the supplementation endpoint, an equivalent dose of enteral L-carnitine will be given to the study patients.
89383180|NCT01569321|Experimental|Breast cancer|
89183915|NCT00664027|Experimental|150 mg|150 mg RTA 402 (Bardoxolone methyl)/Stratum 1
89183916|NCT00664027|Experimental|25/75 mg|25 mg -> 75 mg RTA 402 (Bardoxolone methyl)/Stratum 2
89183917|NCT00597805||1|Patients scheduled for a total, anterior or posterior pelvic exenteration
89383181|NCT01381809|Experimental|Epoetin alfa|Group 1: Epoetin alfa type = range unit= IU/Kg number= 337.5 to 1050 IU/Kg form= solution for injection route= subcutaneous use weekly injections (max 40 000 IU per week for first 8 weeks of treatment max 80 000 IU per week later) using pre-filled 1mL 40 000 IU syringes for 24 to 48 weeks
89383182|NCT01381809|Placebo Comparator|No treatment|Group 2: Placebo form= solution for injection route= subcutaneous use weekly injections for 24 to 48 weeks
89183918|NCT00565708|Experimental|acetylsalicylic acid|200mg OD for 3 years
89183919|NCT00565708|Placebo Comparator|Placebo|200mg OD for 3 years
89183920|NCT00550849|Experimental|1|RTA 402
89183921|NCT00550849|Experimental|2|RTA 402
89383183|NCT03679806|Experimental|Halliwick|Exercises were performed in a private pool owned by the local MS society twice in a week for 8 weeks. Pool depth was 120 cm 30-31°C Mental adjustment, sagittal rotation, transverse rotation, and combined rotation controls, balances in stillness steps of the Halliwick concept were included.
89383184|NCT03679806|Experimental|Aquatic Plyometric Exercise|Exercises were performed in a private pool owned by the local MS society twice in a week for 8 weeks. Pool depth was 120 cm 30-31°C. The three phases of each exercise; eccentric (or loading) phase, the amortization phase, and the concentric (or unloading) phase included.
89383185|NCT03679728||First trimester|Group of children from mother affected by Zika virus in the first trimester of pregnancy.
89383186|NCT03679728||Second trimester|Group of Children from mother affected by Zika virus in the second trimester of pregnancy.
88856395|NCT01422876|Active Comparator|Linagliptin|Patients receive linagliptin once daily
89183922|NCT00550849|Experimental|3|RTA 402
89183923|NCT00538343|Experimental|RTA 744|
89183924|NCT00535314|Experimental|RTA 402 Dose1|Dose1 of RTA 402 to be administered orally once daily for 28 consecutive days, for up to 18 months.
89383187|NCT03679572|Experimental|Robot assisted partial nephrectomy super-selective clamping|The Da Vinci robot (device) allows to use near-infrared fluorescence in order to clamp precisely the branches of the vascularization for the partial nephrectomy. The healthy parenchyma ischemia is avoided.
88856396|NCT01422720|Experimental|Eslicarbazepine Acetate tablets (800 mg)|
88856397|NCT01387932|Experimental|HepaSphere/QuadraSphere TACE|HepaSphere/QuadraSphere TACE
89183925|NCT00535314|Experimental|RTA 402 Dose2|Dose2 of RTA 402 to be administered orally once daily for 28 consecutive days, for up to 18 months.
89183926|NCT00529438|Experimental|Bardoxolone methyl capsules|"Bardoxolone methyl to be taken orally for 21 consecutive days, once a day, in the morning prior to food intake.~Patients to continue to receive treatment for the first 21 days of each 28-day cycle until they experience intolerable toxicity, show evidence of disease progression, or receive a maximum of 18 cycles (18 months)."
89383188|NCT03679572|Active Comparator|Robot assisted partial nephrectomy with renal artery clamping|The partial nephrectomy with robotic assistance is performed using a renal artery. It's the conventional method.
89383189|NCT03677466|Experimental|Pharmaco-invasive strategy|Fibrinolytic therapy (Streptokinase, Alteplasa, Tenecteplasa in standard dose) is conducted within 12 h of symptom onset in the pre-hospital setting if primary PCI cannot be performed within 120 min from STEMI diagnosis. Then PCI is performed to all of patients.
89383190|NCT03677466|Active Comparator|Primary PCI|Primary percutaneous coronary intervention (PCI) in patients with primary STEMI
89383191|NCT03196297|Experimental|Concizumab|Daily administration of concizumab to both on-demand and prophylaxis patients
89383192|NCT03677310|Experimental|3% sodium chloride|Subjects in this group will receive 3% sodium chloride over a period of 24 hours at a rate of 10 cc/hour beginning immediately prior to incision.
89383193|NCT03677310|Sham Comparator|Normal Saline|This group will receive normal saline over a period of 24 hours at a rate of 10 cc/hour beginning immediately prior to incision.
89383194|NCT03447132|Active Comparator|Fulvestrant 500mg + Palbociclib 125mg|+ Goserelin 3.6 mg if pre or peri menopausal patient - duration 4 months
88856398|NCT01387932|Active Comparator|Conventional TACE|Conventional TACE
88856399|NCT04413786|Experimental|oxytocin group|male subjects with oxytocin treatment
88856400|NCT04413786|Placebo Comparator|placebo group|male subjects with placebo treatment
88856401|NCT01422408|Experimental|Supportive care (fluocinonide cream)|Patients apply topical fluocinonide cream BID in weeks 1-2 and QD in weeks 3-4.
89183927|NCT00529113|Experimental|Phase 1 Cohort 1|Bardoxolone methyl 150 mg/day x 21 days and gemcitabine (1000 mg/m2 by intravenous infusion on Days 1, 9, and 15)
89183928|NCT00529113|Experimental|Phase 1 Cohort 2|Bardoxolone methyl 300 mg /day for 21 days and gemcitabine (1000 mg/m2 by intravenous infusion on Days 1, 9, and 15)
89183929|NCT00529113|Experimental|Phase 1 Cohort 3|Bardoxolone methyl 150 mg/day for 28 days and gemcitabine (1000 mg/m2 by intravenous infusion on Days 1, 9, and 15)
89183930|NCT00529113|Experimental|Phase 1 Cohort 4|Bardoxolone methyl 200 mg/day for 28 days and gemcitabine (1000 mg/m2 by intravenous infusion on Days 1, 9, and 15)
89183931|NCT00529113|Experimental|Phase 1 Cohort 5|Bardoxolone methyl 250 mg/day for 28 days and gemcitabine (1000 mg/m2 by intravenous infusion on Days 1, 9, and 15)
89183932|NCT00529113|Experimental|Phase 1 Cohort 6|Bardoxolone methyl 300 mg/day x 28 days and gemcitabine (1000 mg/m2 by intravenous infusion on Days 1, 9, and 15)
89383195|NCT03447132|Placebo Comparator|Fulvestrant 500mg + Placebos|+ Goserelin 3.6 mg if pre or peri menopausal patient - duration 4 months
89383196|NCT03677232||Hong Kong Chinese adolescents with CHD|Hong Kong Chinese adolescents with CHD aged 12-18 who are able to read and write chinese
89383197|NCT04133623|Experimental|Ketorolac|Administration of ketorolac 0.5 mg/kg up to 10 mg, one single dose at the enrollment. This group will receive also a placebo indistinguishable from the ibuprofen.
89383198|NCT04133623|Active Comparator|Ibuprofen|Administration of ibuprofen 10 mg/kg up to 600 mg, one single dose at the enrollment. This group will receive also a placebo indistinguishable from the ketorolac.
89383199|NCT03623724|Experimental|blended Cognitive-behavioral Therapy|The experimental condition refers to a blended treatment that integrates empirically-supported face-to-face cognitive-behavioral psychotherapy with a mobile phone application and a web platform - blended cognitive-behavioral therapy (bCBT). The intervention includes ten face-to-face cognitive-behavioral sessions combined with nine online sessions based on the self-help treatment modules of the Moodbuster (psychoeducation, exercise therapy, behavioral activation, problem solving, cognitive restructuring and relapse prevention) delivered over a period of 16 weeks. 50 patients will be integrated in this experimental condition.
89183933|NCT00529113|Experimental|Phase 1 Cohort 7|Bardoxolone methyl 350 mg/day x 28 days and gemcitabine (1000 mg/m2 by intravenous infusion on Days 1, 9, and 15)
89002937|NCT06017921|Active Comparator|Eszopiclone|Eszopiclone 3mg at bed time for 14 days
89002938|NCT06017921|Placebo Comparator|Placebo|Placebo at bed time for 14 days
89383200|NCT03623724|Active Comparator|Treatment-As-Usual|The control condition concerns the treatment-as-usual (TAU) that consists in routine care that patients receive when they are diagnosed with major depression in primary care. We will not interfere with treatments delivered in TAU, but the intervention will be tracked (e.g., medication). The psychiatrist of our team will monitor possible medicine intake (stabilized throughout the trial). 50 patients will be integrated in this condition.
89383201|NCT03192475|Active Comparator|Group Lifestyle Balance plus phone contacts|Group Lifestyle Balance is the core behavioral lifestyle intervention delivered from 0-4 months using an in-person group format. The active comparator receives 8 additional sessions of group interactive telephone contact delivered from 5-12 months
89383202|NCT03192475|Placebo Comparator|Group Lifestyle Balance plus newsletter contacts|Group Lifestyle Balance is the core behavioral lifestyle intervention delivered from 0-4 months using in-person group format. The placebo comparator receives 4 additional educational newsletters delivered from 5-12 months.
89383203|NCT03683862|Experimental|Thermoplastic Retainer|Impressions of the upper arch will be taken at the day of bracket debonding and the retainer will be delivered in 24 hours. TheraMon microchip will be embedded within the appliance and patients will be instructed to wear the appliance 24 hours/ day.
89383204|NCT03683862|Active Comparator|Hawley Retainer|Impressions of the upper arch will be taken at the day of bracket debonding and the retainer will be delivered in 24 hours. TheraMon microchip will be embedded within the appliance and patients will be instructed to wear the appliance 24 hours/ day.
89383205|NCT03189745|Experimental|MenACWY-TT Booster|10 year booster dose of MenACWY
89383206|NCT03188263|Experimental|Bright Light|Irradiance is 230 μW/m2 and lux is 500 lux.
89383207|NCT03188263|Placebo Comparator|Dim Light|irradiance is reduced from 230 μW/m2 to 3 μW/m2, and lux reduced from 500 lux to 7 lux
89383208|NCT03188185|Experimental|ALKS 5461|Sublingual tablets
89383209|NCT03188185|Placebo Comparator|ALKS 5461 Placebo|Sublingual tablets
89383210|NCT03288337||Hidradenitis Suppurativa Cohort|Patients with HS who are eligible to fill out the series of quality of life questionnaires
89383211|NCT03679182|Experimental|Olanzapine|Olanzapine 5 mg at 0, 12, 24 and 36 hours
89383212|NCT03679104|Active Comparator|Endoscopic clips|Closure of mucosotomy using endoscopic clips
89383213|NCT03679104|Active Comparator|OverStitch™ suturing device|Closure of mucosotomy using OverStitch™ suturing device
89383214|NCT03623568|Experimental|Treatment with Mavyret (glecaprevir/pibrentasvir) for HCV|12 weeks of treatment with Mavyret
89383215|NCT03683784||Males|Male diabetics or male subjects proved to be diabetics
89383216|NCT03683784||Female|Female diabetics or male subjects proved to be diabetics
89383217|NCT03186781|Experimental|Group 1: HA-F A/Sing (20 mcg), ages 18-47 Yrs|HA-F A/Sing injections (20 mcg) administered intramuscularly (IM) by Needle/Syringe (Day 0) in H2-naïve adults (adults with no pre-existing immunity to H2)
88856402|NCT01399788|Active Comparator|1.0|Test Myrin P Forte Contains 150mg Rifampicin, 75mg Isoniazid, 275mg Ethambutol, 400mg Pyrazinamide
89002939|NCT06016972|Experimental|QLS-111 ophthalmic solution|Qlaris' investigational product, QLS-111 ophthalmic solution, provided in 3 concentrations for this study (0.015%, 0.03%. and 0.075%), single use vials, masked, and preservative free (PF).
89002940|NCT06016972|Placebo Comparator|QLS-111 ophthalmic vehicle solution|Inactive control (0.00%). QLS-111 ophthalmic vehicle solution, single use vials, masked, PF.
89002941|NCT06013969|Experimental|GPP Patients|Generalized Pustular Psoriasis (GPP) patients with a recurrent flare following initial GPP flare treatment with intravenous (i.v.) spesolimab.
89002942|NCT06013020|Experimental|Guided NOAC and DAPT|"The first month: rivaroxaban 2.5 mg twice daily (if CR≥24) plus standard DAPT (ticagrelor 90 mg twice daily or clopidogrel 75 mg daily plus aspirin 100 mg daily).~The following 11 months: lower-dose ticagrelor 60 mg twice daily (45 mg twice daily if <50 kg, ≥75 yrs) or clopidogrel (75 mg daily) plus aspirin (100 mg daily)."
89002943|NCT06013020|Experimental|Unguided DAPT|The first month: standard DAPT. The following 11 months: lower-dose ticagrelor or clopidogrel plus aspirin.
89183934|NCT00529113|Experimental|Phase 2 Cohort 1|Bardoxolone methyl maximum tolerated dose(as determined in the Phase 1 portion of the study)/day x 28 days and gemcitabine (1000 mg/m2 by intravenous infusion on Days 1, 9, and 15)
89183935|NCT00529113|Placebo Comparator|Phase 2 Cohort 2|Placebo capsules/day x 28 days and gemcitabine (1000 mg/m2 by intravenous infusion on Days 1, 9, and 15)
88856403|NCT01399788|Active Comparator|2.0|Reference Single drug reference preparations contain Rifampicin, Isoniazid, Ethambutol, Pyrazinamide
88856404|NCT01387542|Experimental|Paliperidone Extended Release (ER)|Paliperidone ER 3 milligram (mg) or 6 mg or 9 mg or 12 mg oral tablets depending on investigator's discretion once daily for 10 weeks
88856405|NCT01387230|Experimental|GSK573719|active drug
89183936|NCT00527410|Experimental|RTA 744|RTA 744 injection administered intravenously for a maximum of 18 cycles (54 weeks). Dose escalation based on four dose levels and occurance of dose limiting toxicity (DLT).
89183937|NCT00526812|Experimental|Group A (RTA 744)|Receive study drug for three consecutive days, Cycle repeated every 21 days.
89183938|NCT00526812|Experimental|Group C (RTA 744 Injection)|Receive study drug once a week for four consecutive weeks. Repeat cycle every 5 weeks.
88810429|NCT06213506|Experimental|Infants_6W_Dose C_2 Group|Infants 6 weeks of age, part of the dose-finding cohort, randomized to receive 3 doses of the iNTS-GMMA Dose C vaccine at Day 1, Day 57 (during the Priming phase) and at Day 232 (during the Booster phase). These infants also receive an EPI vaccination with the following vaccines: Measles and Rubella Vaccine (MR-VAC) and Yellow Fever (YF) vaccine administered concomitantly during the last iNTS-GMMA administration at Day 232, and the pentavalent vaccine (DTPwHepB-Hib), the Pneumococcal conjugate vaccine, and the inactivated polio vaccine administered at the same time, at 6, 10 and 14 weeks of age, at the local EPI vaccination centers, and not part of the current clinical trial.
88856406|NCT01387230|Placebo Comparator|Placebo|no active drug
88856407|NCT01387074||botulinum toxin Type A|Botulinum toxin Type A treatment at a dose determined by the physician at Baseline followed by a second botulinum toxin Type A treatment approximately 12 weeks later if applicable.
88856408|NCT01386606|Experimental|Androxal 6.25 mg|Androxal 6.25 mg/day
88856409|NCT01386606|Experimental|Androxal 12.5 mg|Androxal 12.5 mg/day
88856410|NCT01386606|Experimental|Androxal 25 mg|Androxal 25 mg/day
88856411|NCT01386606|Active Comparator|AndroGel|AndroGel 5G topical testosterone
88856412|NCT01385748|Active Comparator|Clonidine Lauriad® 50µg|50µg muco-adhesive buccal tablets, once de day, every day up to 8 weeks
88856413|NCT01385748|Active Comparator|Clonidine Lauriad® 100µg|100µg muco-adhesive buccal tablets, once a day, every day up to 8 weeks
88856414|NCT01385748|Placebo Comparator|Placebo Lauriad®|Placebo muco-adhesive buccal tablets, once a day, every day up to 8 weeks
88856415|NCT01397448|Experimental|E3810 5 mg|
88856416|NCT01397448|Experimental|E3810 10 mg|
88856417|NCT01397448|Active Comparator|Teprenone 150 mg|
88856418|NCT01385202|Experimental|THERMOCOOL® SMARTTOUCH™ Catheter|
88856419|NCT05365932|Experimental|TMD Pain group|Arm included patients with TMD Pain intensity >3 on a VAS scale and with diagnosis of myofascial pain, either alone or in combination with arthralgia, headache attributable to TMD or with disc displacement with reduction. Participants had to be 18 years of age or older. All subjects had to wear the device for 6 months and it should not be used for more than 23 hours in a 24-hour period
88856420|NCT01384734|Experimental|Arm A: BMS-663068 (400mg) + Raltegravir + Tenofovir|Treatment Group 1
88856421|NCT01384734|Experimental|Arm B: BMS-663068 (800 mg) + Raltegravir + Tenofovir|Treatment Group 2
88856422|NCT01384734|Experimental|Arm C: BMS-663068 (600 mg) + Raltegravir + Tenofovir|Treatment Group 3
88856423|NCT01384734|Experimental|Arm D: BMS-663068 (1200 mg) + Raltegravir + Tenofovir|Treatment Group 4
88856424|NCT01384734|Active Comparator|Arm E: Atazanavir + Ritonavir + Raltegravir + Tenofovir|Treatment Group 1 (reference arm)
89183939|NCT00341939||1/Cancer Patients|Cancer patients previously enrolled on IRB approved clinical trials at NCI
88856425|NCT01396512|Experimental|IMOJEV™ Vaccine Group|Participants will receive a single dose of the Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV™) on Day 0.
88856426|NCT01396512|Active Comparator|CD.JEVAX ™ Vaccine Group|Participants will receive a single dose of the Japanese encephalitis live attenuated vaccine (SA14 14 2 vaccine), CD.JEVAX™ on Day 0
88856427|NCT01396434||Prevenar 13 patients|
88856428|NCT01383954|Other|Diclofenac gel|Diclofenac gel 4 grams (g) applied topically 4 times daily (QID) to the affected knee(s) for up to 4 weeks. Participants took a maximum dosage of 32 g/day.
88856429|NCT05365464|Active Comparator|Progesterone|Women receive prometrium 200 mg qhs for up to 8 weeks
88856430|NCT05365464|Active Comparator|hCG|A single shot of hCG (ovidril 250 ug) will be given as a subcutaneous injection 1 week after ovulation
88856431|NCT01383486|Experimental|Naproxen Sodium ER (BAYH6689) or Advil IR|Eligible subjects were provided with 24 Advil immediate-release (IR) caplets containing 200 mg Ibuprofen and Naproxen Sodium extended release (ER) tablets containing 660 mg Naproxen Sodium. Upon a single incidence of pain, subjects were instructed to review both packages and choose one product to use. Subject were not offered any additional instructions for use beyond what is on the packages.
88856432|NCT04766736||Tumors (T) samples of various etiologies (HBV, HCV, NASH, alcool)|The combination of the Tumors status of the sample combined with its etiology ((HBV, HCV, NASH, alcool)
88856433|NCT04766736||Non Tumors (NT) samples of various etiologies (HBV, HCV, NASH, alcool)|The combination of the Non Tumors status of the sample combined with its etiology ((HBV, HCV, NASH, alcool)
88856434|NCT01383174|Experimental|Peer Support Program|Nuevo Amanecer is the peer support program. Participants receive the peer support program as soon as possible after randomization.
88856435|NCT01383174|No Intervention|Wait-list Control|Waits six months, and at the end of the six months is offered the option of participating in the peer support program.
88856436|NCT01396278|Experimental|BI 54903 low dose|patient to receive Respimat inhaler containing low dose BI 54903 plus placebo matching hydrofluoroalkane (HFA) metered dose inhaler (MDI)
88856437|NCT01396278|Experimental|BI 54903 medium dose|Respimat inhaler containing medium dose BI 54903 plus placebo matching HFA MDI
88856438|NCT01396278|Experimental|BI 54903 high dose|Respimat inhaler containing high dose BI 54903 plus placebo matching HFA MDI
88856439|NCT01396278|Active Comparator|Fluticasone propionate 440 mcg BID|Fluticasone HFA MDI containing 440 mcg ICS plus placebo matching Respimat inhaler
89183940|NCT00076830||Enrolled cohort|All patients enrolled, as this is an evaluation/diagnostic study
89183941|NCT00034216||Healthy Volunteers|Healthy volunteers 18 years of age and older
88856440|NCT01396278|Active Comparator|Fluticasone propionate 88 mcg BID|Fluticasone HFA MDI containing 88 mcg ICS plus placebo matching Respimat inhaler
89183942|NCT00034216||Participants|Participants with cancer 18 years of age and older
89383218|NCT03186781|Experimental|Group 2: HA-F A/Sing (60 mcg), ages 18-47 Yrs|HA-F A/Sing injections (60 mcg) administered IM by Needle/Syringe (Day 0 and Week 16) in H2-naïve adults (adults with no pre-existing immunity to H2)
88856441|NCT05365152|Experimental|Meal replacement intervention group|"On the day of the patient's admission, the total calories required for the diabetic diet during the hospitalization period were calculated according to ideal weight * 25/kcal (BMI > 28, 80% of this value). Carbohydrates, fats, and proteins accounted for 50%, 30%, and 20% of the energy supply, respectively, and the calories of the three meals were distributed according to 1:2:2. The meal replacement intervention group replaced the daily meal with meal replacement on the basis of the conventional diabetic diet. About 400kcal calories in carbohydrates."
88856442|NCT05365152|No Intervention|diabetes diet group|"On the day of the patient's admission, the total calories required for the diabetic diet during the hospitalization period were calculated according to ideal weight * 25/kcal (BMI > 28, 80% of this value). Carbohydrates, fats, and proteins accounted for 50%, 30%, and 20% of the energy supply, respectively, and the calories of the three meals were distributed according to 1:2:2."
89383219|NCT03186781|Experimental|Group 3A: DNA A/Sing(4 mg)-HA-F A/Sing(60 mcg), ages 18-47 Yrs|DNA A/Sing injections (4 mg) administered IM by PharmaJet (Day 0); HA-F A/Sing injections (60 mcg) administered IM by Needle/Syringe (Week 16) in H2-naïve adults (adults with no pre-existing immunity to H2)
89383220|NCT03186781|Experimental|Group 3B: DNA A/Sing(4 mg)-HA-F A/Sing(60 mcg), ages 52-70 Yrs|DNA A/Sing injections (4 mg) administered IM by PharmaJet (Day 0); HA-F A/Sing injections (60 mcg) administered IM by Needle/Syringe (Week 16) in H2-exposed adults (may have some H2 immunity)
89383221|NCT03186781|Experimental|Group 4A: HA-F A/Sing (60 mcg), ages 18-47 Yrs|HA-F A/Sing injections (60 mcg) administered IM by Needle/Syringe (Day 0 and Week 16) in H2-naïve adults (adults with no pre-existing immunity to H2)
89383222|NCT03186781|Experimental|Group 4B: HA-F A/Sing (60 mcg), ages 52-70 Yrs|HA-F A/Sing injections (60 mcg) administered IM by Needle/Syringe (Day 0 and Week 16) in H2-exposed adults (may have some H2 immunity)
89383223|NCT03683706|Active Comparator|Intervention|Participants in this arm will receive 12 sessions of LTP in My Own Way Plus interventions.
89383224|NCT03683706|No Intervention|Treatment as Usual|Participants in this arm will be getting their usual treatment
89383225|NCT03623412|Experimental|One abnormal value|Women with only one abnormal value on OGTT (Oral Glucose Tolerance Test) during pregnancy
89383226|NCT03623412|Active Comparator|GDM|Women with two abnormal values on OGTT during pregnancy - diagnosis=GDM
88856443|NCT05365074||chloroprocaine anesthesia for arthroplasty|patients having predicted uncomplicated surgery for total or unicompartment knee arthroplasty of anterior access total hip arthroplasty, operated under spinal anesthesia with 50 mg of chloroprocaine
88856444|NCT01383096|Active Comparator|Cohort 1 - Treatment A: OZ439 800mg PIB, fed|OZ439 800 mg (as free base) as powder in a bottle (PIB)for reconstitution in a suspension prior to administration. Administered 30 minutes after a standard fatty breakfast.
88856445|NCT01383096|Experimental|Cohort 1 - Treatment D: OZ439 800 mg Prototype F1 fasted|OZ439 800 mg (as free base) as a prototype solution formulation 1. Administered fasted.
89183945|NCT00750152|Placebo Comparator|2|placebo
89183946|NCT00750152|Experimental|1|NAFT-500
88856446|NCT01383096|Experimental|Cohort 2 - Treatement H: OZ439 800 mg Prototype F2 fasted|OZ439 800 mg (as free base) as a prototype solution formulation 2. Administered fasted.
88856447|NCT01383096|Experimental|Cohort 3 - Treatement K: OZ439 400mg Prototype F1 fasted|Best Prototype Solution - OZ439 400 mg as prototype solution formulation 1. Administered fasted.
89383227|NCT02830165|Experimental|Treatment (SBRT)|Patients undergo 3 fractions of SBRT over 1-2 weeks, 2-4 weeks prior to radical prostatectomy.
89383228|NCT03184987|Experimental|FF/UMEC/VI 100/62.5/25 mcg closed triple therapy|Subjects will receive FF/UMEC/VI 100/62.5/25 mcg inhalation powder via ELLIPTA, once daily, 1 puff/time, in the morning. Subjects may receive salbutamol as a rescue medication when needed throughout the run-in and treatment period.
89183947|NCT02182089||Dialysis patients with greater than 20% IDH|"Study Population:~The sample will be enriched for subjects prone to IDH, defined as patients who experience IDH for greater than 20% of HD treatments in the past 2 months. The study population will consist of 48 patients total, 75% of patients (n=36) prone to IDH and 25% of patients with less than 10% of IDH during the last two months (n=12)."
89183948|NCT02182089||Patients with less than 10% IDH|"Study Population:~The sample will be enriched for subjects prone to IDH, defined as patients who experience IDH for greater than 20% of HD treatments in the past 2 months. The study population will consist of 48 patients total, 75% of patients (n=36) prone to IDH and 25% of patients with less than 10% of IDH during the last two months (n=12)."
89383229|NCT03184987|Experimental|FF/UMEC/VI 200/62.5/25 mcg closed triple therapy|Subjects will receive FF/UMEC/VI 200/62.5/25 mcg inhalation powder via ELLIPTA, once daily, 1 puff/time, in the morning. Subjects may receive salbutamol as a rescue medication when needed throughout the run-in and treatment period.
89383230|NCT03184519|Experimental|All patients|Patients will undergo 3 blood samples after IVF-ET (pregnancy test) to determine pregnancy.
89383231|NCT03184441|Experimental|Premie Pouch|All participants will receive the experimental treatment with the Premie Pouch device.
89383232|NCT05241145|Experimental|IVMED-6Wk|In Group 1 (IVMED-6Wk), patients instilled IVMED-80 eye drops into their study eye twice a day for 6 weeks and were followed for an additional 20 weeks without treatment (total 26 weeks)
89383233|NCT05241145|Experimental|IVMED-16Wk|In Group 2 (IVMED-16Wk), patients instilled IVMED-80 eye drops into their study eye twice a day for 16 weeks and were followed for an additional 10 weeks without treatment (total 26 weeks)
89383234|NCT05241145|Placebo Comparator|Placebo|In Group 3 (Placebo), patients instilled IVMED-80 vehicle solution eye drops into their study eye twice a day for 16 weeks and were followed for an additional 10 weeks without treatment (total 26 weeks)
89399552|NCT03693261||Coronary Artery Disease (CAD)|Patients with clinically and angiographically established coronary artery disease (CAD) who require CABG, as part of the standard medical care.
89183949|NCT02597192|Active Comparator|Active test group|probiotic oral hygiene products with Bacillus (PIP, Chrisal)
89183950|NCT02597192|Placebo Comparator|Placebo group|oral hygiene products without Bacillus
89183951|NCT05392790|Experimental|Aerobic exercise plus progressive resisted exercise group|Will receive aerobic exercise, progressive resisted exercise in addition to traditional care.
89183952|NCT05392790|Experimental|Aerobic exercise group|Will receive aerobic exercise plus traditional care.
89183953|NCT05392790|Experimental|Progressive resisted exercise group|Will receive progressive resisted exercise
89183954|NCT05392790|Other|Control group|Will receive traditional medical treatment in the form of Calcium, Vit D and Bi phosphnate.
89183955|NCT04071483|Experimental|Moderate stenosis|Moderate cervical neural foraminal stenosis is narrowest width of the neural foramen was >50% of the width of the width of the extraforaminal nerve root at the level of the anterior margin of the superior articular process.
89183956|NCT04071483|Active Comparator|Severe stenosis|Severe cervical neural foraminal stenosis is narrowest width of the neural foramen was ≤50% of the extraforaminal nerve root width
89183957|NCT05404802|Experimental|Experimental Group|"Training sessions~Each training session will last for 30-45 minutes, twice a week over a 10-week period in Week 1 to Week 10. Each session will be attended by a cluster of 4 to 6 participants, and each participant will have one PARO.~Free-play sessions~Two 15-30 minutes free-play sessions in each week of the 10 weeks are conducted on days when there are no training sessions."
89183958|NCT05404802|Experimental|Control Group|"Training sessions~Each training session will last for 30-45 minutes, once a week over a 2-week period after all assessments are completed. Each session will be attended by a cluster of 4 to 6 participants, and each participant will have one PARO.~There is no free-play sessions for control group."
89183959|NCT01387113||Acute ischemic stroke patients|All acute ischemic stroke patients receiving IV rt-PA within 6 hours of symptom onset
89183960|NCT02597036|Experimental|Part A LY3127804|Dose escalation of LY3127804 given intravenously (IV) every 2 weeks (Q2W) for 28 day cycle.
89183961|NCT02597036|Experimental|Part B LY3127804 + Ramucirumab Dose 1|Dose escalation of LY3127804 in combination with Ramucirumab given IV Q2W for 28 day cycle.
89183962|NCT02597036|Experimental|Part C LY3127804 + Ramucirumab Dose 2|LY3127804 in combination with Ramucirumab given IV Q2W for 28 day cycle.
89183963|NCT02597036|Experimental|Part D LY3127804 + Ramucirumab|LY3127804 and Ramucirumab given IV Q2W until participant qualifies for study discontinuation.
89183964|NCT02597036|Experimental|Part E LY3127804 + Ramucirumab + Paclitaxel|LY3127804 and Ramucirumab given IV Q2W and Paclitaxel given IV on day 1, 8, and 15 until participant qualifies for study discontinuation.
89183965|NCT04073355|Experimental|Physical Activity|Smartphone-delivered physical activity intervention
89183966|NCT04071639|Experimental|Group 1|Mild to moderate HD patients receive medicine treatment with different doses of Deutetrabenazine(Austedo), Risperidone, Zoloft+Idebenone, according to their symptoms. The mode of administration is oral. Capsules will be swallowed whole with water. Zoloft should be taken 50mg once in the morning and Risperidone 1mg once at night. Deutetrabenazine(Austedo) should be taken 6mg once a day, or increase dose according to AUSTEDO® tablets Prescribing Information. Idebenone should be taken 30mg three times a day. Study drug can be taken irrespective of meals. Duration:5 years.
89183967|NCT04071639|Experimental|Group 2|Mild to moderate HD patients receive medicine treatment with different doses of Haloperidol, Risperidone, Zoloft+Idebenone, according to their symptoms. The mode of administration is oral. Capsules will be swallowed whole with water. Haloperidol should be taken 0.5mg~1mg three times a day. The administration of Zoloft, Risperidone and Idebenone are same as group 1. Study drug can be taken irrespective of meals. Duration:5 years.
89183968|NCT04089176|Active Comparator|protocal A|Carbetocin versus placebo
89183969|NCT04089176|Active Comparator|protocal B|Oxytocin versus placebo
89183970|NCT02577081|Experimental|CAT scan|A CAT scan will be done for all participants. The scan will include the pelvis and 2 femurs.
89183971|NCT02596646|Active Comparator|Group A|Early Precut
89183972|NCT02596646|Active Comparator|Group B|Prolonged cannulation attempts
88856448|NCT01383096|Experimental|Cohort 1 - Treatement B: OZ439 800mg PIB fasted|OZ439 800 mg (as free base) as powder in a bottle (PIB) for reconstitution in a suspension prior to oral administration. Administered fasted.
89183973|NCT03972098||ra patients|The diagnosis of RA was based on the criteria developed by the American College of Rheumatology and European League Against Rheumatism (ACR/EULAR) in 2010 [8]. A drug history was obtained from every patient. All non-steroidal anti-inflammatory medications and disease-modifying antirheumatic drugs prescribed during the year before enrollment in the study were recorded. criteria included systemic diseases (renal failure, hepatic insufficiency, diabetes mellitus, other collagen vascular diseases, history of smoking and consumption of alcohol.In order to eliminate the possibility of any systemic disease therefore we choose that our control group as young.
89183974|NCT03972098||healthy control|healthy person, similar population
89183975|NCT00749996|Experimental|Investigational group|Single level herniectomy followed by placement of the DIAM™ Spinal Stabilization System
89183976|NCT00749996|Active Comparator|Control group|Single level herniectomy
89183977|NCT02577159|Experimental|Dapagliflozin|Diabetic patients who met the inclusion/exclusion criteria. Dapagliflozin is orally administered for 8 weeks in the dose of 5mg per day if there is no serious event included in termination criteria. If the effect for improving diabetes is insufficient, it is allowed to raise its dose up to 10mg/day.
89183978|NCT00916994|Experimental|SpaceGuard Balloon implantation|
89183979|NCT00749684||Adults with malignant melanoma at high risk of relapse|"Adults with malignant melanoma of the following stages:~II and III (>/= 1.5 mm Breslow thickness without distant metastases~melanoma with lymph node metastases"
89183980|NCT02575755|Experimental|Efficacy Study: Azithromycin plus piperaquine|At baseline, participants receive three daily doses (0, 24 and 48 hours) of i) 1 g azithromycin as 2 x film-coated 500 mg tablets ii) 960 mg piperaquine tetraphosphate tablets as 3 x 320 mg tablets
89183981|NCT02575755|Active Comparator|Efficacy Study Control: National Standard Treatment|At baseline, participants receive a single dose of sulfadoxine-pyrimethamine comprising 1,500 mg of sulfadoxine and 75 mg pyrimethamine in tablet form
89183982|NCT02575755|Experimental|Pharmacokinetic Study: Azithromycin plus piperaquine|At baseline, participants receive three daily doses (0, 24 and 48 hours) of i) 1 g azithromycin as 2 x film-coated 500 mg tablets ii) 960 mg piperaquine tetraphosphate tablets as 3 x 320 mg tablets
89183983|NCT02576769||Basal cell carcinoma|Basal cell carcinoma
88856449|NCT01383096|Experimental|Cohort 1 - Treatment C:OZ439 800mg PIB with milk|OZ439 800 mg (as free base) as powder in a bottle (PIB) for reconstitution in a suspension prior to oral administration. Administered following 200 mL milk.
88856450|NCT01383096|Experimental|Cohort 3 - Treatment J: OZ439 800mg Prototype F1 fasted|Best Prototype Solution - OZ439 800 mg (as free base) as prototype solution formulation 1. Administered fasted.
88856451|NCT01383096|Experimental|Cohort 1 - Treatement E: OZ439 800mg Prototype F1 with milk|OZ439 800 mg (as free base) as a prototype solution formulation 1. Administered with milk.
88856452|NCT01383096|Experimental|Cohort 2 - Treatement F: OZ439 800 mg PIB fasted|OZ439 800 mg (as free base) as powder in a bottle (PIB) for reconstitution in a suspension prior to oral administration. Administered fasted.
88856453|NCT01383096|Experimental|Cohort 2 - Treatement G: OZ439 800mg PIB with milk|OZ439 800 mg (as free base) as powder in a bottle (PIB) for reconstitution in a suspension prior to oral administration. Administered following 200 mL milk.
88856454|NCT01383096|Experimental|Cohort 2 - Treatement I: OZ349 800mg Prototype F2 with milk|OZ439 800 mg (as free base) as a prototype solution formulation 2. Administered with milk.
88856455|NCT04040244|Experimental|Exhaled Breath Analysis|Exhaled breathe condensate will be collected using R-tube and ReCIVA device over 5-10 minutes.
88856456|NCT01383018||AMS penile prosthesis receipients|Men for whom an AMS penile prosthesis is recommended
88856457|NCT01382940|Experimental|Rituximab|Rituximab intravenous (IV) infusions were administered over a 4.25-hour period on Day 1, and over a 2-hour period on Day 15 (first course) and on Days 168 and 182 (second course). All participants continued to receive methotrexate as prescribed by their treating physician. Premedication included methylprednisolone, an antihistamine and acetaminophen.
88856458|NCT01381926|Experimental|Exenatide then Placebo|"Study participants in phase1 will receive the study drug, exenatide, at a dose of 5mg subcutaneously twice daily 30 minutes before meals for one month. During the second month of the study, the dose of exenatide will be increased to 10mg subcutaneously twice daily before meals for one month. During the third month of the study, no study medication will be given and this will serve as a wash out period prior to the second phase of the study (placebo). During the fourth and fifth months, study participants will get placebo alternatives to exenatide 5mg and exenatide 10mg, respectively, subcutaneously twice daily before meals."
88856459|NCT01381926|Active Comparator|Placebo then Exenatide|"Study participants in phase1 will receive the saline placebo, at a dose of 5mcg subcutaneously twice daily 30 minutes before meals for one month. During the second month of the study, the saline placebo will be increased to 10mcg subcutaneously twice daily before meals for one month. During the third month of the study, no treatment will be given and this will serve as a wash out period prior to the second phase of the study. During the fourth month study participants will receive Exenatide 5mcg twice daily with meals. During the fifth month, study participants will receive exenatide 10mcg, subcutaneously twice daily before meals."
88856460|NCT01395888|Experimental|Relovair|Inhaled long-acting bronchodilator and corticosteroid combination
88856461|NCT01395888|Active Comparator|Tiotropium|Inhaled long-acting anticholinergic
88856462|NCT01395810|Experimental|Prophylaxis, high dose (once weekly)|
88856463|NCT01395810|Experimental|Prophylaxis, low dose (once weekly)|
88856464|NCT01395810|Experimental|On-demand|
88856465|NCT01395810|Experimental|Prophylaxis, high dose (every second week)|
89183984|NCT04071561||Non-conversion|In 13 patients, 14 posterior retroperitoneal adrenalectomy procedures were successfully completed and form the non-conversion group
89183985|NCT04071561||Conversion|Conversion to lateral transperitoneal adrenalectomy was necessary in 1 patient after starting posterior retroperitoneal adrenalectomy.
89183986|NCT04073277|Experimental|SCF-N-treated needle acupuncture|For each participant, one hand was randomly assigned to the experimental group with SCF-N-treated needle acupuncture .
88856466|NCT05363358||Ig-naive (New-to-class) Cohort|Participants who initiate GGL or one of the comparator IVIG products who have no record of previous use of any Ig product (Ig naive) for at least 6 months before study initiation will be include in this cohort.
88856467|NCT05363358||Ig-experienced (New-to-drug) Cohort|Participants who initiate either GGL or a comparator IVIG product with no record of previous use of that specific IVIG product but with previous use of any other Ig product (Ig experienced) in all available study data will be included in this cohort.
88856468|NCT01381692|Active Comparator|Arm I (rituximab, bortezomib, dexamethasone)|Patients receive rituximab IV over 30-60 minutes on days 1, 8, 15, and 22 (of courses 1 and 4 only) and bortezomib IV or SC and dexamethasone PO on days 1, 8, and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
88856469|NCT01381692|Experimental|Arm II (temsirolimus, rituximab, bortezomib, dexamethasone)|Patients receive temsirolimus IV over 30-60 minutes on days 1, 8, 15, and 22 and rituximab, bortezomib, and dexamethasone as in arm I. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
88856470|NCT01395030|Experimental|18F-fluoromethylcholine PET/CT|Patients undergo 18F-fluoromethylcholine positron emission tomography (PET)/ computed tomography (CT) scan within 14 days of surgical resection of liver tumor.
88856471|NCT01381068|Experimental|Monitored Arm|The end tidal CO2 sensor is placed in the respiratory circuit and the monitor is visible to the resuscitation team. The resuscitation team is instructed to adjust ventilation to keep EtCO2 levels between 40-55.
89183987|NCT04073277|Sham Comparator|untreated needle acupuncture|The other hand of participant in experimental group was assigned to the control group with untreated needle acupuncture.
89183988|NCT04073121|Experimental|Luminor DCB and Angiolite DES|Study Devices
89183989|NCT00746798|Experimental|ChimeriVax WN02 vaccine, low dose|Participants randomized to receive ChimeriVax WN02 vaccine, low dose
89183990|NCT00746798|Experimental|ChimeriVax-WN02 vaccine, medium dose|Participants randomized to receive ChimeriVax-WN02 vaccine, medium dose
89183991|NCT00746798|Experimental|ChimeriVax-WN02 vaccine, high dose|Participants randomized to receive ChimeriVax-WN02 vaccine, high dose
89183992|NCT00746798|Placebo Comparator|Placebo|Participants randomized to receive Placebo (Saline)
88856472|NCT01381068|Placebo Comparator|Control Arm|The end tidal CO2 sensor is placed in th respiratory circuit. The monitor is covered so the resuscitation team can not see the display. The resuscitation team is instructed to provide ventilation according to clinical judgment.
88856473|NCT01394952|Experimental|1.5 mg Dulaglutide|Administered once weekly, subcutaneously
88856474|NCT01394952|Placebo Comparator|Placebo|Administered once weekly, subcutaneously
88856475|NCT01394718|Placebo Comparator|Saline Placebo|Control subjects will receive saline as placebo at the time of skin closure intra-operatively and will continue to receive IV saline for 44 hours post-operatively. Doses will be administered every 6 hours (total of 8 doses).
89183993|NCT00716274|Experimental|Atomoxetine|Atomoxetine will be administered at 1.0 to 1.4 mg/kg/day given orally once daily in the morning for 16 weeks (study period II). Participants who complete the study period II will be re-randomized in the study period III of 16-week duration to assess maintenance of benefit following discontinuation of treatment with atomoxetine. Participants assigned to atomoxetine during the study period II will be re-randomized to either atomoxetine or placebo whereas participants previously assigned to placebo will receive atomoxetine.
89183994|NCT00716274|Placebo Comparator|Placebo|Placebo will be packaged in the same way as active comparator to enforce double-blind study design
89183995|NCT00746564|Experimental|Open Label|SJM Confirm Device
89183996|NCT02598908||NHS staff volunteer donors|Interested staff working within the Pathology Department at SWBH NHS Trust will be provided with written information regarding the proposed EQA scheme and the sample collection procedure. A consent form will be given to staff members, who will be asked to return the signed form within 1 week if they wish to participate. Each participating staff member will be assigned a unique patient identifier to allow for sample results to be anonymised.
89183997|NCT02598908||SWBH outpatient donors|A list of SWBH NHS Trust patient TPMT results will be gathered from the Pathology computer system (Telepath). Those with a TPMT activity of interest, measured in the past five years, will be contacted with the agreement of their hospital consultant. Information and consent forms will be sent to the patient either through the post or via their hospital consultant. Each participating patient will be assigned a unique patient identifier to allow for sample results to be anonymised.
89183998|NCT01298193|Experimental|Aprepitant|"Observational phase (first cycle):~Day 0 (Dexamethasone 8mg) Day 1 (5-HT3 antagonist, Ondansetron: 8 mg x2, Granisetron: 1mg x2,Tropisetron: 5 mg, Dexamethasone 24 mg) + Chemotherapy (Docetaxel 75mg/m2 and Cyclophosphamide 600mg/m2 ).~Days 2 and 3 (Dexamethasone 16 mg).~If not complete response:~Efficacy phase (second cycle):~Day 0 (Dexamethasone 8mg) Day 1 (Aprepitant: 125 mg,5-HT3 antagonist, Ondansetron: 8 mg x2, Granisetron: 1mg x2, Tropisetron: 5 mg, Dexamethasone 12 mg)+ Chemotherapy: Docetaxel 75mg/m2 and Cyclophosphamide 600mg/m2 .~Days 2 and 3 (Aprepitant: 1 capsule of 80 mg daily, Dexamethasone 8 mg)."
89183999|NCT02590536|Experimental|sildenafil citrate|Group A (45 patients): pregnancies affected by Fetal Growth Restriction (FGR) being treated with sildenafil citrate 25 mg of sildenafil citrate every 8 hours starting at diagnosis of FGR until delivery
89184000|NCT02590536|Placebo Comparator|placebo|Group B (45 patients): pregnancies affected by Fetal Growth Restriction (FGR) being treated with placebo every 8 hours starting at diagnosis of FGR until delivery.
89184001|NCT02576691||The PCI group|The PCI group was composed of patients who underwent PCI following the return of spontaneous circulation or after CA.
89184002|NCT02576691||Non-PCI group|Non-PCI group included patients who didn't undergo PCI or were subjected to PCI before CA
89184003|NCT03917589||Patients with corticosteroids|Patients who have systematically been treated by high-dose corticosteroids after the delivery
89184004|NCT03917589||Patients without corticosteroids|Patients who haven't been systematically treated by high-dose corticosteroids after the delivery.
89184005|NCT00719862|Placebo Comparator|Placebo Nasal Spray|0mg Placebo Nasal Spray
89184006|NCT00719862|Active Comparator|0.15% azelastine hydrochloride nasal spray|0.15% azelastine hydrochloride
89184007|NCT02578953|Experimental|Sequence 1-Dutasteride test product and then Reference product|Participants will receive treatment A in period 1 and treatment B in period 2. Where treatment A= dutasteride 0.5 mg capsule test product, treatment B= dutasteride 0.5 mg capsule reference product.
89184008|NCT02578953|Experimental|Sequence 2-Dutasteride reference product and then test product|Participants will receive treatment B in period 1 and treatment A in period 2. Where treatment A= dutasteride 0.5 mg capsule test product, treatment B= dutasteride 0.5 mg capsule reference product.
89184009|NCT04073589|Experimental|Treatment A|Single SC injection of Dose A
89184010|NCT04073589|Experimental|Treatment B|Single SC injection of Dose B
89184011|NCT04073589|Experimental|Treatment C|Single SC injection of Dose C
89184012|NCT04073589|Experimental|Treatment D|Single SC injection of Dose D
88856476|NCT01394718|Experimental|Intravenous Acetaminophen|Subjects will receive the first dose of intravenous (IV) acetaminophen (at 15 mg/kg, with maximum doses based on patient age and weight) at the time of skin closure intra-operatively and will continue to receive IV acetaminophen for 42 hours post-operatively. Doses will be administered every 6 hours (total of 8 doses).
88856477|NCT01394250|Experimental|Buzzy|If randomized to Buzzy®, the nurse will demonstrate the cold pack and the device just prior to the IV cannulation procedure. The device will be applied with a Velcro strap 5 centimeters proximal to the site of IV cannulation; it will remain in place until the IV cannula is inserted and secured. All nurses that work during the study hours will be trained on the device prior to beginning the study. Training includes direct one-one training with the device including return demonstration.
88856478|NCT01394250|Active Comparator|Topical Lidocaine 4% Cream|If randomized to topical lidocaine cream, subjects will have the cream placed on two or more potential IV sites as soon as possible after the consent procedure is complete. These subjects will undergo IV placement no less than 30 minutes after the cream is applied.
88856479|NCT01380990|Experimental|Gene Therapy|Infusion of autologous EFS-ADA LV CD34+ cells
89184013|NCT02578719|Placebo Comparator|drug: bupivacaine|Placebo comparator: bupivacaine first 3 months 0.5% 1 cc bupivacaine diluated with 1.5 cc saline enjection will be used in GON block once a month. If effectiveness is proved then blindness will be opened and all patients will be blocked by 0.5% 1 cc bupivacaine diluated with 1.5 cc saline once a month for 3 months.
88856480|NCT01380990|Other|Historical Control Group|Historical data from ADA-SCID patients who were treated with Hematopoietic Stem Cell Transplantation (HSCT)
88856481|NCT01380834|Active Comparator|treatment group|Group 1( treatment group ): 42 patients will have six paravertebral nerve blocks with ropivacaine 0.5 %, and incisional administration of placebo / normal saline at all four laparoscopic ports.
88856482|NCT01380834|Placebo Comparator|Placebo group|Group 2(control group): 42 patients will have placebo/normal saline in paravertebral space, same amount, and injection at incision sites for all four insufflation ports with ropivacaine 0.5%.
88856483|NCT04407702|Experimental|Control Group|The volunteers in this group will receive the same hygiene instructions as the other groups and will undergo both treatments, except that water will be used instead of the sealant and the laser device will be set to a power of 0 W. In other words, the same irradiation procedure will be performed but without the emission of light.
88856484|NCT04407702|Experimental|Sealant Group|The volunteers in this group will receive treatment with sealant (Permaseal - Ultradent), which is a photopolymerizable methacrylate-based resin.
88856485|NCT04407702|Experimental|Low-Level Laser Group|The volunteers in this group will receive irradiation with AsGaAl laser at a wavelength of 780 nm (Laser XT Therapy, DMC, São Carlos, SP, Brazil) with relative isolation.
88856486|NCT04407702|Experimental|Low Level Laser + Sealant Group|The volunteers in this group will receive the same irradiation administered to Low-level Laser Group. During the last session, these volunteers will also receive the same sealant applied in Sealant Group.
88856487|NCT04766658|Other|Water Swallow Intervention First|Subjects will complete voice recordings after water swallows and then perform voice recordings after gargle phonation.
88856488|NCT04766658|Other|Gargle Phonation Intervention First|Subjects will complete voice recordings after gargle phonation and then perform voice recordings after gargle phonation.
89399553|NCT03693261||controls|Control group will be formed by subjects, randomly selected, who will undergo cardiac surgery for aortic or mitral valve replacement as part of their standard medical care (these patients have no history, clinical signs of CAD, and show normal coronary arteries on coronary angiography).
88856489|NCT05360940||A|100 positive stool samples for H.pylori
88856490|NCT05360940||B|100 negative stool samples for H.pylori
88856491|NCT04407468||COVID|Patients with or without prone position
88856492|NCT05368740||median IPI group|IPI score level was between 5-7
88856493|NCT05368740||high IPI group|IPI score level was between 8-10
88856494|NCT05361330|Experimental|The experimental group: Shuganjieyu capsule|Shuganjieyu capsule combined with Fluoxetine
88856495|NCT05361330|Placebo Comparator|The control group: Shuganjieyu capsule simulator|Fluoxetine monotherapy
88856496|NCT05364060||patients followed in psychiatry|Quantitative questionnaires
88856497|NCT00214968|Experimental|Modafinil|Subjects began taking Provigil at a dosage of 100 mg/day (1 tablet) and increased their dosage by 100 mg/day each week for up to 4 weeks
88856498|NCT00210522|Experimental|001|RWJ 333369 Open-Label Extension: One 200 mg to 600mg tablet taken twice daily (up to a maximum of 1200mg/day) up to 1 year or the time that RWJ-333369 is available by prescription or the study is terminated by Sponsor.
88856499|NCT00214422|Experimental|Arm 1- 5040cGy to the lymph nodes|5040Gray (cGy) to the lymph nodes
88856500|NCT00214422|Experimental|Arm 2 - 5400cGy to the lymph nodes|5400Gray (cGy) to the lymph nodes
88856501|NCT00214422|Experimental|Arm 3 - 5900cGy to the lymph nodes|5900Gray (cGy) to the lymph nodes
88856502|NCT03024450||HER2 positive AGC treated with H+CT|HER2 expression was assessed by IHC first. In the cases with IHC 2+, fluorescence in situ hybridization (FISH) was used to detect HER2/neu amplification levels. Only patients with high level of HER2 expression (IHC 3+ or IHC 2+ plus FISH positive) were eligible in this study.
88856503|NCT03997422|Experimental|Vertical Sleeve Gastrectomy (VSG)|Bariatric surgical procedure
88856504|NCT05364528||clinical pregnancies with direct catheter|Clinical pregnancies occurred after fresh and frozen blastocyst transfers using direct technique.
88856505|NCT05364528||clinical pregnancies with afterload catheter|Clinical pregnancies occurred after fresh and frozen blastocyst transfers using afterload technique.
88856506|NCT04263090|Experimental|Rigosertib + Nivolumab|Rigosertib + Nivolumab in metastatic KRAS+ lung adenocarcinoma patients
88856507|NCT03832764||ANSPEC-PRO|These patients are selected (after randomized selection) to be monitored non-invasively for pain level via prototype ANSPEC-PRO - correlated to a NRS number given by the awake patient in PACU/ICU.
88856508|NCT03832764||MEDSTORM|These patients are selected (after randomized selection) to be monitored non-invasively for pain level via MEDSTORM - correlated to a NRS number given by the awake patient in PACU/ICU.
88856509|NCT05630508|Experimental|interactive mhealth Lifestyle behavior intervention|Receiving Standard care, LIVEN educational material and interactive LIVEN application
89399554|NCT03685695|Experimental|Supportive care (physical activity)|Participants wear Fitbit Charge 2 to monitor physical activity for 3 courses (9-12 weeks). Participants then increase their activity minutes to 30 minutes, 5 times a week or by 30% for 6 additional months.
89399555|NCT02177396|Experimental|Telmisartan|
89399556|NCT02177396|Active Comparator|Valsartan|
89383235|NCT05240443|Experimental|Bariatric Surgery + Medical Management for Chronic Kidney Disease|The intervention group will include medical management and bariatric surgery, which will consist of Roux-en-Y gastric bypass or sleeve gastrectomy performed according to local practice standards. Medical management for CKD will be directed by nephrologists at St. Joseph's Healthcare Hamilton. Comorbidities such as hypertension, dyslipidemia, and type 2 diabetes will be managed at the discretion of individual nephrologists. Generally, this can include anti-hypertensives (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers) for systolic blood pressure control below a target of <140/90 mmHg (<130/80 in patients with type 2 diabetes), statins in patients with dyslipidemia to target low-density lipoprotein <2mmol/L for the treatment of CKD.
89383236|NCT05240443|Active Comparator|Medical Management for Chronic Kidney Disease|Medical management for CKD will be directed by nephrologists at St. Joseph's Healthcare Hamilton. Comorbidities such as hypertension, dyslipidemia, and type 2 diabetes will be managed at the discretion of individual nephrologists. Generally, this can include anti-hypertensives (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers) for systolic blood pressure control below a target of <140/90 mmHg (<130/80 in patients with type 2 diabetes), statins in patients with dyslipidemia to target low-density lipoprotein <2mmol/L for the treatment of CKD.
89383237|NCT03026166|Experimental|Rovalpituzumab Tesirine and Nivolumab|"Participants will receive 2 doses of 0.3 mg/kg rovalpituzumab tesirine by intravenous (IV) infusion 6 weeks apart (Day 1 of Cycles 1 and 3), and 2 doses of 360 mg nivolumab IV 3 weeks apart beginning on Cycle 2 (Day 1 of Cycles 2 and 3).~Participants will then receive maintenance therapy with 480 mg nivolumab IV once every 4 weeks from Cycle 4 until disease progression."
89383238|NCT03026166|Experimental|Rovalpituzumab Tesirine and Nivolumab + Ipilimumab 1 mg/kg|"Participants will receive 2 doses of 0.3 mg/kg rovalpituzumab tesirine IV 6 weeks apart (Day 1 of Cycles 1 and 3), nivolumab 1 mg/kg every 3 weeks for 4 cycles beginning on Cycle 2 (Day 1 of Cycles 2-5), and ipilimumab 1 mg/kg IV every 3 weeks for 4 cycles beginning on Cycle 2 (Day 1 of Cycles 2-5).~After a 6-week washout, participants will then receive maintenance therapy with 480 mg nivolumab IV once every 4 weeks from Cycle 6 until disease progression."
89383239|NCT03026166|Experimental|Rovalpituzumab Tesirine and Nivolumab + Ipilimumab 3 mg/kg|"Participants will receive 2 doses of 0.3 mg/kg rovalpituzumab tesirine IV 6 weeks apart (Day 1 of Cycles 1 and 3), nivolumab 1 mg/kg every 3 weeks for 4 cycles beginning on Cycle 2 (Day 1 of Cycles 2-5), and ipilimumab 3 mg/kg IV every 3 weeks for 4 cycles beginning on Cycle 2 (Day 1 of Cycles 2-5).~After an 8-week washout, participants will then receive maintenance therapy with 480 mg nivolumab IV once every 4 weeks from Cycle 6 until disease progression."
89383240|NCT03683472|No Intervention|Treatment as usual (TAU)|Individuals will receive treatment as usual
89383241|NCT03683472|Active Comparator|TAU and Unwinding Anxiety Phone App|"The Unwinding Anxiety program focuses on teaching individuals 1) to understand how anxious worry is developed and perpetuated through reinforcement learning, 2) how to recognize these worry habit loops and 3) how to bring mindful awareness to moments of worry such that they can uncouple feelings of anxiety from reactive worry thinking and ride out habitual mind states that perpetuate and reinforce anxiety. Together, these help individuals unlearn/extinguish worry at a core mechanistic level."
89383242|NCT03676920|Experimental|Intervention Arm|This feasibility study includes only one arm. All enrolled patients will be asked to use the intervention.
89383243|NCT03683316||all infants|"There will be one arm for this study. All infants will receive a similar intervention during their routine kangaroo mother care (KMC). KMC is a national and international standard of care. This is an observational study of how infants breath while participating in KMC compared to how they breath while in a crib or incubator. Work of breathing will be measured at baseline and then during KMC. Mothers will participate in KMC regardless of participation in the study. Work of breathing will be measured by using Respiratory Inductance Plethysmography (RIP). This scientifically measures work of breathing (specifically phase angles) by placing soft bands around the abdomen and chest. The actual intervention is a standard of care and something that the mother infant dyad will do regardless of the study. Each mother / infants pair is expected to be actively enrolled for approximately 2 hours."
89383244|NCT03026088|Experimental|Bisoprolol|
89383245|NCT03676842|Experimental|FLEX Scoring Catheter plus DCB|This is a single-arm study. All patients will be treated with the FLEX Scoring Catheter followed by an IN.PACT Admiral Drug-Coated Balloon (Medtronic Vascular; Galway, Ireland).
89383246|NCT03678948|Active Comparator|Radiofrequency-Based Debridement|The Smith and Nephew WEREWOLF COBLATION System is indicated for all soft tissue types in the knee. The WEREWOLF COBLATION System is a FDA cleared bipolar, radiofrequency electrosurgical system designed for use in orthopaedic/arthroscopic surgical procedures.
89383247|NCT03678948|Active Comparator|Mechanical Debridement|
89383248|NCT03678792|Other|Buprenorphine-Naloxone|Standard of Care
89383249|NCT03678792|Experimental|Morphine|
89383250|NCT03678792|Experimental|Tramadol|
89383251|NCT03678714|Experimental|Exercise Intervention|Structured exercise intervention will be undertaken for 12 weeks
89383252|NCT03678714|Experimental|Lifestyle Physical Activity|Increased lifestyle physical activity undertaken for 12 weeks
89184014|NCT02578719|Placebo Comparator|placebo|first 3 months 2.5 cc saline enjection will be used in GON block once a month. If effectiveness is proved then blindness will be opened and all patients will be blocked by 0.5% 1 cc bupivacaine diluated with 1.5 cc saline once a month for 3 months.
89184015|NCT00742508|Experimental|SK&F-105517-D group|SK&F-105517-D 10-80 mg/day
89383253|NCT03678714|No Intervention|Control|Resting control
89383254|NCT03676686|Experimental|Nåva Foot Cream|Topical Nåva foot cream administered twice daily.
89383255|NCT03305094|Active Comparator|Control group|"Sham remote ischemic preconditioning on the right arm is induced with a blood pressure cuff inflation at 20 mm Hg for 5 min and followed by a 5 min reperfusion at 0 mm Hg. The sham ischemia-reperfusion cycle is performed 3 times for a total of 30 min. This procedure is done after anesthetic induction, but before the patient is placed on cardiopulmonary bypass.~A 20 mm Hg blood pressure cuff on the right arm does not induce ischemia."
88856510|NCT05630508|Sham Comparator|Sham group - app access only|Receiving standard care, LIVEN educational material and access to the application
89184016|NCT00742508|Other|Carvedilol-IR group|Carvedilol-IR 5-20 mg/day
89184017|NCT04085016||meibography of statin group|patients with regular HMG CoA reductase inhibitor (statin) treatment
89383256|NCT03305094|Experimental|Intervention group|Remote ischemic preconditioning on the right arm is induced with a blood pressure cuff inflation at 200 mm Hg for 5 min and followed by a 5 min reperfusion at 0 mm Hg. The ischemia-reperfusion cycle is performed 3 times for a total of 30 min. This procedure is done after anesthetic induction, but before the patient is placed on cardiopulmonary bypass.
88856511|NCT05630508|No Intervention|Control group - Standard care|Receiving Standard care only
88856512|NCT05368818||All patients|Included all patients prescribed an on-label secukinumab dose
88856513|NCT05368818||Patients with Psoriatic Arthritis (PsA)|Included patients classified as having a concomitant PsA diagnosis, if it was declared in the Baseline table
88856514|NCT05630274|Experimental|Selpercatinib (Dose level 1)|Selpercatinib administered as single dose orally.
88856515|NCT05630274|Experimental|Selpercatinib (Dose level 2)|Selpercatinib administered as single dose orally.
88856516|NCT05630274|Active Comparator|Moxifloxacin|Moxifloxacin administered as single dose orally.
88856517|NCT05630274|Placebo Comparator|Placebo|Placebo administered orally.
88856518|NCT04407624|Experimental|Intermittent Exercise Group|Warm-up, loading (walking, squat, sitting down on a chair, limb movements with weights, stepping on steps, walking on different floors), cooling and relaxation exercises
88856519|NCT04407624|Active Comparator|Control Group|Warm-up, loading (brisk walking at 60-85% of maximum heart rate), cooling and relaxation exercises
89399557|NCT02030054|Active Comparator|atorvastatin|Patients were randomly assigned to atorvastatin (40 mg day) or rosuvastatin (20 mg day) for 30 days. After 1-week wash-out period to avoid any carryover effect, cross-over was performed, and patients were switched to the other drug which was continued for 30 days.
88856520|NCT05632692|Experimental|Intervention|A menthol solution is going to be formulated by crushing and dissolving one noncalorific menthol candy drop (15 mg) in 150 ml of warm water, in order to obtain a solution with a concentration of 0.01%. Prior to use, solutions are going to be aliquoted for mouth rinse and warmed at room temperature. Then, it will be served to each participant on individual bottles in a total dose of 75 ml before exercise and 75 ml during exercise.
88856521|NCT05632692|Placebo Comparator|Placebo|A placebo beverage is going to be prepared using noncaloric berry-flavored sweetener consisting of sucralose candy drops, which will be crushed and dissolved in 150 ml of warm water. Prior to use, solutions are going to be aliquoted for mouth rinse and warmed at room temperature. Then, it will be served to each athlete on individual bottles in a total dose of 75 ml before exercise and 75 ml during exercise.
88856522|NCT04407312|Experimental|CILO group|"Intervention:~Suspected patients with AMI were loaded with 600-mg clopidogrel and 300-mg aspirin in the emergency room.~After 3 to 5 days post-PCI (before discharge), patients were randomly allocated to the CILO group or the placebo group (1:1 fashion) based on a computer-generated randomization sequence.~For the CILO group, cilostazol-SR 200 mg daily was added to dual antiplatelet therapy with aspirin (100 mg daily) and clopidogrel (75 mg daily).~Study drug is maintained for 30 days. Double blinded, Randomized, Placebo controlled Trial.~Drug:~Cilostazol-SR, Tablet, 200mg, once daily. Astrix, Capsule, 100mg, once daily. Plavix, tablet, 75mg, once daily."
88856523|NCT04407312|Placebo Comparator|Placebo group|"Intervention:~Suspected patients with AMI were loaded with 600-mg clopidogrel and 300-mg aspirin in the emergency room.~After 3 to 5 days post-PCI (before discharge), patients were randomly allocated to the CILO group or the placebo group (1:1 fashion) based on a computer-generated randomization sequence.~In the Placebo group, placebo tablet was administered on top of dual antiplatelet therapy with aspirin (100 mg daily) and clopidogrel (75 mg daily).~Study drug is maintained for 30 days. Double blinded, Randomized, Placebo controlled Trial.~Drug:~Placebo, Tablet, 200mg, once daily. Astrix, Capsule, 100mg, once daily. Plavix, tablet, 75mg, once daily."
88856524|NCT03993444|Experimental|communication and problem solving|Three smal group sessions (separate for employees (length 2 hours each) and for supervisors (length 2,5 hours each)) focused on training communication and problem solving skills.
88856525|NCT03993444|Active Comparator|psychoeducation|Two, 1 hour, lectures, one on the topic of pain and one on the topic of stress (for employees and supervisors combined).
88856526|NCT04326738|Placebo Comparator|normal saline (N) group|N group received corresponding intravenous normal saline of 1ml·kg-1.
88856527|NCT04326738|Active Comparator|midazolam (M) group|M group received intravenous injection of 0.03mg·kg-1 (1mg·ml-1) midazolam.
88856528|NCT03597126|Active Comparator|robot-assisted ISR|Patients with low rectal cancer undergo intersphincteric resection assisted by Robotic
88856529|NCT03597126|Active Comparator|laparoscopic ISR|Patients with low rectal cancer undergo laparosocopic intersphincteric resection
88856530|NCT04347486|Experimental|Sugammadex 2mg|Administer 2mg/kg of sugammadex on reappearance of T2 by Train-of-Four stimulation
88856531|NCT04347486|Experimental|Sugammadex 4mg|Administer 4mg/kg of sugammadex on reappearance of T2 by Train-of-Four stimulation
88856532|NCT04347486|Experimental|Sugammadex 8mg|Administer 8mg/kg of sugammadex on reappearance of T2 by Train-of-Four stimulation
88856533|NCT04347486|Active Comparator|Conventional reversal|Administer conventional neuromuscular reversal agent (0.02mg/kg of atropine and 0.03mg/kg of neostigmine) on reappearance of T2 by Train-of-Four stimulation
88856534|NCT03025152|Experimental|Hou Gu Mi Xi|Patients in this arm receive Hou Gu Mi Xi, with an oral dose of 10 g/day during entire follow up period (2 years).
88856535|NCT03025152|Placebo Comparator|placebo|Patients in this arm receive placebo, with an oral dose of 10 g/day during entire follow up period (2 years).
88856536|NCT05632458|Experimental|double stent retriever|
88856537|NCT05632458|Active Comparator|single stent retriever|
88856538|NCT05632224|Active Comparator|Aprepitant|Substance P inhibitor chemotherapeutic and also useable for prevention of postoperative nausea and vomiting
88856539|NCT05632224|Active Comparator|Granisetron|5- HT3( 5-hydroksitriptamine 3) antagonist drug for prevention of postoperative nausea and vomiting
88856540|NCT05632146|Active Comparator|Patients with hollow viscus perforation|
88856541|NCT05632146|Active Comparator|Patient with hollow viscus perforation|
88856542|NCT05366322||Cohort A: mRNA-1273 COVID Vaccine|Participants who have received 2 doses of the mRNA-1273 vaccine at least 14 days apart.
88856543|NCT05366322||Cohort B: BNT1262b2 COVID Vaccine|Participants who have received 2 doses of the BNT1262b2 vaccine at least 14 days apart.
88856544|NCT03024840|Experimental|sevoflurane|Sevoflurane is inhalated with 1%-2% after anesthesia induction until end of the surgery.
88856545|NCT03024840|Experimental|propofol|Propofol is injected with 9-15 mg/kg/h after anesthesia induction until end of the surgery.
88856546|NCT05366088|Experimental|Mindfulness-Based Cognitive Therapy|Group sessions 2 hours/week, for 8 weeks, based on the manualized protocol developed by co-I Dr. Segal and will be delivered by social workers (or equivalent) with ≥3 years of experience delivering MBCT and training for official certification from the Center for Mindfulness Studies (Toronto).
88856547|NCT05366088|Active Comparator|Health Enhancement Program|Group sessions 2 hrs/week for 8 weeks, and amount of home practice (~30 mins/day, 6 days/week). HEP will be delivered by social workers (or equivalent) who have received the official training course from HEP's developers at the University of Wisconsin.
88856548|NCT03595644|Experimental|SBRT plus TKI group|SBRT with photon and dose is 40-50Gy/5F after three months after EGFR-TKI treatment
88856549|NCT03595644|Active Comparator|TKI treatment group|Standard EGFR-TKI(Gefitinib, erlotinib or icotinib) Gefitinib: 250mg po Qd Erlotinib: 150mg po Qd Icotinib: 125mg po tid
88856550|NCT05631678|Experimental|the effect of oral rifampicin on the pharmacokinetics of ASK120067 tablets|Take ASK120067 tablets orally once on the first day at 160mg in fast condition；Take rifampicin capsules orally once on the days 8 to 17 at 600mg in fast condition, and a combination of 160mg ASK120067 and 600mg rifampicin were administrated on the 15th day in fast condition.
88856551|NCT05631678|Experimental|effect of oral itraconazole on the pharmacokinetics of ASK120067 tablets|Take ASK120067 tablets orally once on the first day at 80mg in fast condition；Take itraconazole capsules orally twice on the days 8 to 13 at 200mg in fed condition, and a combination of 80mg ASK120067 and 200mg itraconazole were administrated on the 11th day in fast condition.
88856552|NCT05631600|Experimental|Manuka honey|The intervention in this study was conducted in a split-mouth design, meaning that after completing the NSPT for each subject, Manuka honey was administered as an adjunct to the periodontal treatment in two randomly selected quadrants of the oral cavity around the teeth with a specially designed cannula. The cannula reached the bottom of the periodontal pocket and moved circumferentially around the tooth at 6 sites, and Manuka honey was extruded until the excess of the material was observed in the sulcus.
88856553|NCT05631522|Experimental|foot reflexology group|Patients who will receive foot reflexology before and throughout the MCDR procedure.
88856554|NCT05631522|No Intervention|control group|Patients who will receive the routine ICU care during the MCDR procedure.
88856555|NCT05631444|Placebo Comparator|Placebo group|Placebo group (n=10), which consisted of 15 injections of 1 mL of vehicle (1 mL saline solution with 2% of autologous serum) on periadventitial arteries in one dose at day 0.
88856556|NCT05631444|Experimental|Auto-BM-MNC|Auto-BM-MNC (n=7) were obtained from diabetic patients. Fifteen injections of 7.197x106 ± 2.984x106 cells/mL each with 2% of autologous serum were periadventitial arteries administrated in one dose at day 0.
88856557|NCT05631444|Experimental|Allo-WJ-MSCs|Allo-WJ-MSCs (n=7) were obtained from culturing the WJ from healthy cordon umbilical donors unrelated to the patient. Fifteen injections of 1.333x106 cells/mL each with 5% of human serum albumin serum were periadventitial arteries administrated in one dose at day 0.
88856558|NCT03599778|Experimental|treatment group|8 cycles of postoperative XELOX regimen (capecitabine: 1000 mg/m2 bid d1-14 q3w, oxaliplatin: 130 mg/m2 d1 q3w) + apatinib'MTD(maximum tolerated dose)
88856559|NCT03599778|Active Comparator|Control group|8 cycles of postoperative XELOX regimen (capecitabine: 1000 mg/m2 bid d1-14 q3w, oxaliplatin: 130 mg/m2 d1 q3w)
88856560|NCT03990012|Experimental|Patients referred for breast biopsy|Patients with Breast Imaging-Reporting and Data System (BI-RADS) 4C or 5 diagnosis who have been referred for breast biopsy based on the results of their standard diagnostic breast exam will undergo IR and 3D imaging of the breasts.
88856561|NCT03980418|Experimental|all included patients will have the same procedure|After the conventional DaTSCAN SPECT/CT exam in conventional camera, all patients included will have two recordings of DaTSCAN SPECT/CT in semiconductor CZT (cadmium zinc telluride) camera; one focused on the striatum and the other focused on the total brain
88856562|NCT03979404|Experimental|Active iTBS|iTBS will be delivered at 80% of resting motor threshold, consisting of a triplet of 50Hz bursts, repeated at 5Hz; 2 seconds on and 8 seconds off; 600 pulses per session; total duration of 3 minutes and 9 seconds, to the left dorsolateral prefrontal cortex.
88856563|NCT03599700||myeloproliferative neoplasms|"history taking~physical examination~laboratory investigations: Complete blood counts Bone marrow examination JAK2 V617F mutation. High-sensitivity C-reactive protein ESR Uric acid level LDH GGT BCR- ABL fusion gene IL-8 , TNF-Alpha Serum ferritin Serum albumin, transferrin, alpha feto protein Complement system: C3, C4."
89184018|NCT04085016||meibography of non-statin group|patients with recently diagnosed dyslipidemia who were eligible to undergo 3 to 6 months of lifestyle interventions before re-evaluation for starting statin therapy
89184019|NCT02590614|Experimental|800 IU Vitamin D|Participants will be taking 800 IU/d of vitamin D3 for two months
88856564|NCT04008264||Standard post operative pain regimen|There will be a 3 month pre-intervention phase where participants will be placed on a standard post-operative analgesic regimen consisting of an opioid, a NSAID, and acetaminophen. Patients will record their narcotic and non-opioid analgesic usage patterns in the two weeks following outpatient hand surgery.
89184020|NCT02590614|Placebo Comparator|Placebo|Placebo made by Vital Nutrients, Inc. to look exactly like the 800 IU/d caplets by the same company.
89184021|NCT02575443|Experimental|Moderate block (MB) group|
89184022|NCT02575443|Experimental|Deep block (DB) group|
89184023|NCT04071327||Pulmonary arterial hypertension (PAH)|Patients with newly diagnosed or established PAH, within 6 months of first outpatient visit to a PH Care Center
89383257|NCT03676608|Experimental|Bee wax mammary areolae|"Usual educational care plus the product.~The product to be valued are mammary areolae made by hand with organic beeswax. Despite its honey aroma, it does not contain honey. The wax used for the manufacture of the areolae is operculum. This wax is used and not another because it avoids possible residues and allergies that may contain other types of waxes. The operculum wax is used as a thickener in pharmacy and cosmetic products as a fat base in ointments and creams."
89383258|NCT03676608|Active Comparator|Control|Usual educational care.
89383259|NCT03678558|Experimental|Cytochalasin B supplemented vitrification medium|
89383260|NCT03678558|No Intervention|Vitrification medium with no supplementation|
89383261|NCT03672786|Active Comparator|Control Group|Sedentary: Multicentrum® 2 months. Subjects maintaining the multivitamin supplement (Multicentrum® (Pfizer, Spain) 1 tablet/day) during 2 months
89383262|NCT03672786|Experimental|Experimental Group|Athletes: Multicentrum® 2 months. Subjects maintaining the multivitamin supplement (Multicentrum® (Pfizer, Spain) 1 tablet/day) during 2 months
89383263|NCT03678480|Experimental|HTD1801 500 mg BID (twice daily), or 1000 mg/day|HTD1801 tablets in double-blind capsules, 250 mg
89383264|NCT03678480|Active Comparator|Ursodeoxycholic Acid (UDCA) 250 mg BID, or 500 mg/day|UDCA tablets in double-blind capsules, 250 mg
89383265|NCT03676530|No Intervention|Relative Rest (Control)|Male/Female Military Trainees with symptoms consistent with Tibial Stress Syndrome. No compression. Standard of care therapy includes relative extremity rest, stretches and graduated run program.
89383266|NCT03676530|Experimental|Compression Garments|Male/Female Military Trainees with symptoms consistent with Tibial Stress Syndrome. Standard of care therapy includes compression garments worn, stretches and graduated run program.
89383267|NCT03117985|Experimental|Antiretroviral therapy|Stopping antiretroviral therapy
89383268|NCT03678246|Experimental|LSFOI (Ramped)|LSFOI (Ramped)
89383269|NCT03678246|Active Comparator|LSFOI (Supine)|LSFOI (Supine)
89383270|NCT03672708|Other|Cresyl violet|
89383271|NCT03672552|Experimental|FFWP and Improved Oral Care|Receiving dental hygienist cleaning with supervised tooth brushing and FFWP (plain, unmodified water).
89383272|NCT03672552|No Intervention|Standard Care|This group has assessments and standard oral care with no dental hygienist cleaning, no FFWP or supervised tooth brushing and continuing with agreed upon diet texture and fluid modification.
89383273|NCT03678168|Other|Control|Standard care (Throat pack) which will be used as a control.
89383274|NCT03678168|Experimental|Intervention|Pharyngeal tampons which will be used as a comparator against throat pack.
89383275|NCT03678090|Active Comparator|tPA standard dosage|Tissue Plasminogen Activator (tPA) dose of 10 to 25 mg.
89383276|NCT03678090|Experimental|tPA low dosage|tPA dose of 2.5mg
89383277|NCT03678012|Active Comparator|Ferumoxytol/Hydrogen peroxide|1.5% Ferumoxytol / 3% Hydrogen Peroxide (H2O2) 1:1 ratio
89383278|NCT03678012|Placebo Comparator|Hydrogen peroxide|Sham Solution / 3% Hydrogen Peroxide (H2O2) 1:1 ratio
88856565|NCT04008264||Scopolomine group|During the observational phase, patients will be on scopolamine for a total 6 day course (one patch applied at time of surgery, prescription for one patch), and patients will record their narcotic and non-opioid analgesic usage patterns in the two weeks following outpatient hand surgery. The patients who incorporate scopolamine into their post operative analgesia regimen will be eligible for inclusion in the study.
88856566|NCT05631288||Cases|Periodontally compromised patients attending the Periodontology Department during periodontal diagnosis appointments at the point of first diagnosis.
88856567|NCT05631288||Controls|Periodontally healthy patients attending the remaining specialty departments ath the same clinic at the point of first diagnosis.
88856568|NCT03595410||Recurrence laryngeal cancer|
89383279|NCT03678012|Sham Comparator|Water|Sham solution (water; negative control)
89383280|NCT03676452|Experimental|Intervention group|Participants of the intervention group train for 16 weeks (three times per week) with a multicomponent virtual reality-based exergame at their home. The Active@Home exergame contains strength training with Tai Chi-based exercises, balance training with dancing and a cognitive training with specific cognitive-motor games. Each training session lasts about 30 to 40 minutes.
89383281|NCT03676452|No Intervention|Control group|Participants of the control group go on with their usual daily life. After post-measurements, they get the Active@Home exergame to use the training system at home. They don't have to follow a specific training plan.
89383282|NCT03676296|Experimental|Puerarin|Puerarin (90.2 mg daily) in granules
88856569|NCT03595410||No recurrence laryngeal cancer|
88856570|NCT03595254|Experimental|Thrive Intervention|Online cognitive behavior therapy program
89383283|NCT03676296|Placebo Comparator|Placebo|Placebo in granules
89383284|NCT03672474|Experimental|Photobiomodulation REGEnLIFE RGn530 device group|
89383285|NCT03672474|Sham Comparator|Sham REGEnLIFE RGn530 device group|
89383286|NCT03672240|Experimental|APL-1202|"APL-1202 will be administered orally at daily 750 mg (250 mg, TID) for 5-7 days prior to the first intravesical BCG treatment and continue for additional 11 weeks (a total 12 weeks of dosing with APL-1202).~Standard intravesical BCG induction course (once weekly for 6 weeks) 50 mg TICE BCG in 50 mL sterile saline (or a full dose standard vial of BCG) will be initiated on Week 2."
89383287|NCT03676140|Active Comparator|Separate Administration|'Albendazole on day 1' 'Ivermectin on day 1' 'Diethylcarbamazine on day 1' 'Azithromycin on day 8'
89383288|NCT03676140|Experimental|Co-Administration|'Albendazole on day 1' 'Ivermectin on day 1' 'Diethylcarbamazine on day 1' 'Azithromycin on day 1'
89383289|NCT03676062|Active Comparator|stabilization exercise group|Spinal stabilization exercise were applied all patients additional with hotpack, TENS application in this group accompanied by physiotherapist.
88856571|NCT03595254|No Intervention|Waitlist Control|Wait 8 weeks before receiving program access
89383290|NCT03676062|Active Comparator|yoga group|Yoga program were applied all patients in this group accompanied by physiotherapist. Sessions included selected breathing exercises, warm up, asana and relaxation.
89383291|NCT03676062|Active Comparator|home exercise group|Home exercise were applied all patients in this group supervised, controlled by physiotherapist every week.To make compliance easier for patients; a booklet including suggestions to prevent low back pain and description of exercises, were given. Prescribed exercises were selected in this booklet and checked&progressed in each control sessions.
89383292|NCT03675984|Experimental|asymmetrical stabilization exercise group|'asymmetrical stabilization exercise' patient learn asymmetrical stabilization exercise according to the asymmetrical paraspinal muscles weakness and curve type
89383293|NCT03677856|Experimental|Paravertebral Blockade|Anaesthesia to single side of the patient's chest
88856572|NCT05631210|No Intervention|Normal privacy agreement|This group was the control. They were given a normal privacy agreement to read and interpret.
88856573|NCT05631210|Experimental|Pictogram privacy agreement|This group was given the same privacy agreement of the control group, but with the addition of pictograms that summarized the information.
88856574|NCT03599466|Experimental|BF-Lisinopril Tablets 20mg|During the study session, the subjects will be administered a single dose of BF-Lisinopril Tablet 20mg after an overnight fast of approximately 10 hours.
88856575|NCT03599466|Active Comparator|Zestril Tab 20mg|During the study session, the subjects will be administered a single dose of Zestril Tab 20mg after an overnight fast of approximately 10 hours.
88856576|NCT03599388|Experimental|SASI|"Sleep Diaries (daily)~Fitbit 24/7~Phone/videoconference (weekly with study team)~Epworth Sleepiness Scale (weekly)~PROMIS fatigue scale-morning (weekly)~PROMIS fatigue scale-evening (weekly)"
88856577|NCT03595020||MDD group|The major depression group (MDD group) received antidepressant treatment but did not interfere with drug selection.
88856578|NCT03595020||HC group|The healthy control group (HC group) don't accept intervention and treatment.
88856579|NCT03599310|Experimental|Advance care planning|The intervention is a facilitator-based ACP process with a structured guide as a communication tool to aid the interventionists in broaching end-of-life care issues and eliciting patients' values and preferences in a consistent manner.
88856580|NCT03599310|Placebo Comparator|Usual care|A leaflet covering the concept of ACP and advance directives (AD), purposes and potential benefits will be distributed to all participants as part of usual information support to standardize the information provided. The health care team will encourage patients to discuss the matters with their family carers and/or significant others.
88856581|NCT03987672|Other|Assess Nutritional Effects of Nutritional Formula|Self-controlled study in which we will assess the nutritional effects of the Kate Farm Peptide 1.5 nutritional Formula in patients with gastroparesis, relative to their pre-enrollment nutritional formula regimen.
88856582|NCT03986970|No Intervention|Arm 1: Control|No PrEP.
88856583|NCT03986970|Experimental|Arm 2: FTC-TDF|FTC-TDF one day, 5 hours before circumcision.
88856584|NCT03986970|Experimental|Arm 3: FTC-TDF|FTC-TDF one day, 21 hours before circumcision.
88856585|NCT03986970|Experimental|Arm 4: FTC-TDF|FTC-TDF two days, 5 hours before circumcision.
88856586|NCT03986970|Experimental|Arm 5: FTC-TDF|FTC-TDF two days, 21 hours before circumcision.
88856587|NCT03986970|Experimental|Arm 6: FTC-TAF|FTC-TAF one day, 5 hours before circumcision.
88856588|NCT03986970|Experimental|Arm 7: FTC-TAF|FTC-TAF one day, 21 hours before circumcision.
88856589|NCT03986970|Experimental|Arm 8: FTC-TAF|FTC-TAF two days, 5 hours before circumcision.
88856590|NCT03986970|Experimental|Arm 9: FTC-TAF|FTC-TAF two days, 21 hours before circumcision.
88856591|NCT03594864||Hyper-reduced liver recipients.|Low-weight children who underwent live donor liver transplantation with ultrasound-guided in situ left lateral segment graft hyper-reduction.
88856592|NCT03594786|Experimental|endovascular aneurysm repair (EVAR) arm|every patients are in the same arm and have EVAR with supra-renal fixation
88856593|NCT03599232|Active Comparator|intervention( formative OSCE)|"students attended a formative objective structured clinical examination (OSCE) on the first day of their pediatric module to assess the competencies they gained from previous modules. the formative OSCE composed of 8 stations, which were both interactive and static. The interactive stations include history taking, examination, communication (counseling about breastfeeding), and procedural skills (pediatric basic life support) while non-interactive stations include data interpretation, management (linked-station) and a video-station (emergency).~assessed at end of the module(7 weeks) through summative OSCE"
88856594|NCT03599232|No Intervention|control|students in this group have attended pediatric module without formative OSCE and assessed at end of the module(7 weeks) through summative OSCE
88856595|NCT03978546|Experimental|Non-Glaucoma Patient Arm|All participants will complete the same assessments
88856596|NCT03978546|Experimental|Glaucoma Patient Arm|All participants will complete the same assessments
88875373|NCT05365854|Active Comparator|extended sigh then continuous positive airway pressure (CPAP)|"Patients assigned to this group will receive an ARM by extended sigh (e-sigh) during 50 seconds (driving pressure at 10cmH2O and successive PEEP levels at 10, 15, 20, 25 and 30cmH2O, with respiratory frequency fixed at 30/min in controlled pressure), followed by a 10-minute pause corresponding to a period of return to basal state.~Then they receive a CPAP ARM (40cmH2O during 50 seconds). Hemodynamic (blood pressure, cardiac output, stroke volume) and ventilatory measurements will be performed the last 10 seconds of each recruitment maneuver."
89383294|NCT03677856|Active Comparator|Thoracic epidural block|Anaesthesia to both sides of the patient's chest
89383295|NCT03677622|Experimental|Stroke volume (SV) group|"As bellow but with the addition of HES (Voluven (R)) to near maximal stroke volume of the heart:~A bolus injection of 200 ml Voluven® is given repeatedly with measurement of the SV until the increase in SV in response to the bolus is <10%.~The Case Report File give detailed instructions for the interpretation of the SV during changes in position of the patient during laparoscopic surgery."
89383296|NCT03677622|Active Comparator|Restricted group|"Preoperatively: Clear oral fluids until 2 h before surgery. During surgery: If preoperative fluid intake <500 ml, NaCl 0.9% is given until 500 ml.~Lost blood is replaced volume by volume with HES (Voluven®) with allowance of 500 ml extra.~Postoperative fluid: The rest of the day of surgery, fluid is given to meet the basic needs, i.e. 1000 ml K-Na-glucose, K-glucose or glucose 5%. The patient is encouraged to drink and eat as soon possible.~In the surgical department, fluid charts and weight changes monitor fluid balance. A body weight increase of two kilograms is allowed.~Fluid losses is replaced with a fluid having a similar electrolyte composition as the loss and in an equal volume. If the weight increases more than two kilogram, furosemide is given to increase the diuresis."
89383297|NCT03672162|Active Comparator|Gabapentin Group|Subjects will receive Gabapentin 600 mg (two capsules of Gabapentin 300 mg) at two hours prior to surgery with clear water 30 ml and undergo elective total abdominal hysterectomy
89383298|NCT03672162|Active Comparator|Celecoxib Group|Subjects will receive Celecoxib 400 mg (two capsules of Celecoxib 200 mg) at two hours prior to surgery with clear water 30 ml and undergo elective total abdominal hysterectomy
89383299|NCT03672162|Placebo Comparator|Placebo group|Subjects will receive Placebo (two capsules of placebo) at two hours prior to surgery with clear water 30 ml and undergo elective total abdominal hysterectomy
89383300|NCT04059120|Experimental|Experimental group|The physical load will be organized as follows: The experimental group (EG) will perform muscle strength exercises with intensities of 45 to 90% of 1RM in combination with specific stretching exercises, and aerobic resistance with efforts of 60 to 90% of the theoretical maximum heart rate, which will be controlled with a Polar brand heart rate monitor model FT7.
89383301|NCT04059120|Active Comparator|Control group|The physical load will be organized as follows: The control group (CG) will perform muscle strength exercises with intensities of 45 to 90% of 1RM in combination with single or general stretching exercises, and aerobic resistance with efforts of 60 to 90% of the theoretical maximum heart rate, which will be controlled with a Polar brand heart rate monitor model FT7.
89383302|NCT04059198|Experimental|Arm 1 - Inarigivir Soproxil Daily|Inarigivir Soproxil Alone 400 mg Inarigivir daily for 12 weeks followed by 400 mg daily in combination with TAF 25 mg daily for 12 weeks
89383303|NCT04059198|Experimental|Arm 2 - Inarigivir Soproxil 3 Times Weekly|400 mg Inarigivir 3 times weekly for 12 weeks followed by 400 mg 3 times weekly in combination with TAF 25 mg daily for 12 weeks
89383304|NCT04059198|Experimental|Arm 3 - Inarigivir Soproxil and TAF Daily|400 mg Inarigivir daily in combination with TAF 25 mg daily for 24 weeks
89383305|NCT04058964|Experimental|Treatment (pembrolizumab, PEGPH20)|Patients receive pembrolizumab IV over 10 minutes on day 1 and pegylated recombinant human hyaluronidase PH20 SC on days 1, 8, and 15. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity.
89383306|NCT03024606|Active Comparator|texting group|text messages focused on smoking cessation and pregnancy
89383307|NCT03024606|No Intervention|control group|No text messages
89383308|NCT03675906||preoperative albumin levels <3.8|
89383309|NCT03675906||preoperative albumin level >3.8|
89383310|NCT03675906||postoperative Day 2 albumin level <2.9|
89383311|NCT03675906||postoperative Day 2 albumin level >2.9|
89383312|NCT03675828|Experimental|Virtual Visit|In this arm, the 7-day post discharge visit will be completed by a scheduled virtual visit with a member of the study team using the Cleveland Clinic Online Express Care application on a computer or a tablet/phone.
89383313|NCT03675828|No Intervention|Outpatient Clinic|In this arm, the 7-day post discharge visit will be completed by a standard-of-care, in-person outpatient visit with a member of the study team in the heart failure clinic.
89383314|NCT03671772||FDRs of idiopathic RBD patients|First-degree relatives of idiopathic RBD patients
88856597|NCT03594396|Experimental|MEDIOLA|"Prior to the start of study medication, tumor tissue and blood will be collected as baseline. Olaparib 300mg bid will be started after the collection of tumor and blood. Olaparib will be given on days 1-28 days without rest.~Tumor tissue and blood will be collected on day 14 before administration of durvalumab, to see the change in biomarkers after 2 weeks of olaparib treatment. After the acquisition of tumor and blood, durvalumab will be given in a fixed one dose of 1.5 gram on day 15.~On day 29, there will be a third acquisition of tumor and blood, to see the change in biomarkers after combination treatment of olaparib and durvalumab. Tumor response will also be evaluated according to RECIST criteria version 1.1 based on CT."
88856598|NCT03599076||Manifest HD|
89383315|NCT03671772||FDRs of controls|First-degree relatives of controls
89383316|NCT02864160|Experimental|Health Coaching|The health coaching intervention group (n=100) will receive written educational materials on diabetes self-management in Spanish and the diabetes self-management tools (stretch band, a glucometer, and a diabetes cookbook in Spanish). In addition, patients in the intervention group will be assigned a health coach who will provide health coaching over the course of 6 months with 14 phone calls.
89383317|NCT02864160|Active Comparator|Comparison group|The comparison group (n=100) will receive the standard diabetes care that is offered at Heart of Ohio clinics including consultations with a primary care provider, a dietician, a pharmacist, and a diabetes educator. The comparison group will receive written educational materials on diabetes self-management in Spanish and diabetes self-management tools including a stretch band, a glucometer, and a diabetes cookbook in Spanish.
88856599|NCT03599076||Premanifest HD|
88856600|NCT03599076||Control|
88856601|NCT03598764|Other|Classic head extraction group|
89383318|NCT03671616|Experimental|IPV-Al SSI|Single arm trial. All subjects will receive the IPV-Al SSI as booster vaccination
89383319|NCT03675594|Experimental|intervention arm|the group of participants will take the CAD/CAM titanium denture bases and assessment during and after the first 3 months after delivery of the first type.
89383320|NCT03675594|Experimental|intervention arm 2|the same group of participants will take the CAD/CAM cobalt/chromium denture bases and assessment during and after the second 3 months after delivery of the second type.
89383321|NCT03675438|Experimental|Sub-epitheilal TCA Inlay|Implantation of a sub-epithelial presbyopia corrective inlay using TCA technology
89383322|NCT03180619|Experimental|Part A (Renal Impairment): Moderate or Severe Renal Impairment|Participants with chronic hepatitis B (CHB) and moderate or severe renal impairment who were virologically suppressed and taking tenofovir disoproxil fumarate (TDF), a TDF-containing anti-hepatitis B virus (HBV) regimen, or other oral antivirals (OAVs), will switch to tenofovir alafenamide (TAF) and receive TAF 25 milligram (mg) tablet once daily orally for 96 weeks.
89383323|NCT03180619|Experimental|Part A (Renal Impairment): End Stage Renal Disease|Participants with CHB and end stage renal disease who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or OAVs, will switch to TAF and receive TAF 25 mg tablet once daily orally for 96 weeks.
89383324|NCT03180619|Experimental|Part B: Hepatic Impairment|Participants with CHB and moderate or severe hepatic impairment who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or OAVs, will switch to TAF and receive TAF 25 mg tablet once daily orally for 96 weeks.
89383325|NCT03669744||Patients with trigeminal neuralgia resistant|a telephone survey will be conducted at 21 patients with trigeminal neuralgia resistant to usual treatments, according to the ICHD-3β criteria treating by one or more trigeminal nerve blocks at the peri operative pain management center of Limoges University Hospital between 2014 and 2018
88856602|NCT03598764|Other|External Pop out group|
88856603|NCT03594240|Active Comparator|intervention group|Intervention group included pediatric patients with diabetic nephropathy receiving oral vitamin B complex tablets( Neurorubine TM -Forte Lactab TM ) once daily.
89383326|NCT03671538|Experimental|Anlotinib Plus Pemetrexed and Cisplatin|pemetrexed 500mg/m2 and Cisplatin 75mg/m2 on day 1 of a 21-day cycle ;Anlotinib 12mg qd on day 1 to 14 of a 21-day cycle
89383327|NCT05426941|Experimental|Music Imagery|MI sessions will be delivered by board-certified music therapists with specialized training in MI and the study treatment protocol.The 8-session protocol has two stages. Stage 1 (sessions 1-4) is focused on learning to use music and imagery for self-regulation. Once the Veteran has demonstrated skill in using music for self-regulation, Stage 2 (sessions 5-8) shifts to identify and deepen their inner resources and how they can use those resources for self-care.
89383328|NCT05426941|Experimental|Music Listening|Following a one-time meeting with a music therapist, an electronic playlist will be compiled for the Veteran to listen to during the 12-week treatment period.
89383329|NCT05426941|No Intervention|Usual care|Participants in the usual care arm (as is the case for MI and ML groups) may receive analgesics and non-pharmacological treatments (e.g., physical therapy) for their chronic musculoskeletal pain.
89383330|NCT05420467|Active Comparator|TCbHP|HER2-positive breast cancer
88856604|NCT03594240|Placebo Comparator|Control group|Placebo group or control patients received placebo that were similar in appearance to vitamin B complex tablets and the administered dose was as the same schedule as vitamin B complex .
88856605|NCT03594006|Other|Cancer patients on active therapy|
88856606|NCT03593850|Experimental|Music group|"Patients in this arm listened through headphones to a song of 29 minutes and 32 seconds duration. The song was composed entirely by investigator Juan Martin-Saavedra and registered to copyright and authorship regulatory entities from Colombia under the name Occasio adolore (Musical piece No. 5-559-355 and Phonogram No. 12-105-295 of Colombia's Copyright authorship agency). Patients were instructed to avoid using cellphones or other activities during the time of the intervention. Patients receive the intervention in the same room as the Silence group, but for the intervention they were always alone. The room was located in a low transit place with low ambient noise."
88856607|NCT03593850|Active Comparator|Silence group|Patients on the silence group listened to a 29 minute and 32 second audio file that produced no sounds with headphones on. Patients were instructed to avoid using cellphones or other activities during the time of the intervention. Patients receive the intervention in the same room as the Music group, but for the intervention they were always alone. The room was located in a low transit place with low ambient noise.
88856608|NCT03024762|Experimental|Intervention arm|The intervention arm involves children and adolescents with unknown HIV status, aged between 6 weeks to 19 years, born to parents living with HIV/AIDS. These children will be identified for HIV testing through their parents diagnosed with HIV or receiving HIV care in the hospital.
88856609|NCT03024762|No Intervention|Control arm|The control arm involves children and adolescents with unknown HIV status, aged between 6 weeks to 19 years; consulting in the hospital for any motive. These children will be recruited for HIV testing at the outpatient department (OPD) and this through their accompany parents/guardians. Care providers will be advised to propose HIV testing systematically to all children and adolescents showing up at the OPD irrespective of the chief complaint.
89383331|NCT05420467|Experimental|nPCbHP|HER2-positive breast cancer
89383332|NCT05420467|Active Comparator|EC-T|Luminal breast cancer (HER2-, more than 4 lymph node metastases), and triple negative breast cancer
89383333|NCT05420467|Experimental|ddEC-wnP|Luminal breast cancer (HER2-, more than 4 lymph node metastases), and triple negative breast cancer
89383334|NCT05420467|Active Comparator|TC|Luminal breast cancer (HER2-, with 1-3 lymph nodes)
89383335|NCT05420467|Experimental|nPC|Luminal breast cancer (HER2-, with 1-3 lymph nodes)
88856610|NCT04747782||COVID positive|Patients admitted to the ICU with respiratory distress found to be COVID19 positive.
88856611|NCT04747782||COVID negative|Patients admitted to the ICU with respiratory distress found to be COVID19 negative
88856612|NCT04747782||COVID positive delayed|Patients admitted to the ICU for an indication other than respiratory distress, found to be COVID19 positive.
88856613|NCT04747782||never-ICU|Patients admitted to the internal medicine ward with respiratory distress found to be COVID19 positive.
88856614|NCT03593694|Other|Group 1|"Arm: Other: Group 1 Participants in this group will receive the culturally tailored education booklet titled Your Guide to Sugar Diabetes. In addition, subjects will complete 10 sessions of diabetes education delivered weekly via videoconferencing lasting 60 minutes each session as detailed above."
89383336|NCT03671460|Experimental|CD19-CAR-T Cells|Subjects will receive CD19-CAR-T Cells on Day 0 : 100% of total dose.
89383337|NCT03671382|Experimental|Intervention Arm|Communication Training Program and Patient Prompt Sheet
89383338|NCT03671382|No Intervention|Control Arm|Oncologists will not receive the communication skills training program and their patients will not receive the Patient Prompt Sheet
89383339|NCT02915874|Active Comparator|Acceptance and Commitment Therapy Behavioral Intervention|"Subjects randomized to the ACT Intervention group will attend a 1-day group workshop in which two broad areas will be covered:~Behavioral Change training will involve a) teaching subjects how to recognize ineffective patterns of behavior and habits, b) exploring and setting life goals and those related to mental and physical health, and c) promoting effective and committed actions to achieve these goals despite the urge to do otherwise;~Mindfulness and Acceptance Training will emphasize new ways of managing troubling thoughts, feelings, and physical sensations (i.e. learning how to recognize, and develop cognitive distances from unhelpful thoughts such as I can't take this anymore and learning how to willingly face experiences that cannot be changed). In-session exercises and practice will be heavily emphasized during the group intervention and handouts will be distributed for home use."
89383340|NCT02915874|No Intervention|Control|Subjects randomized to not receive treatment.
89383341|NCT03675048|Experimental|Intervention group|The intervention group will receive 5 drops (10^8 cfu Lactobacillus reuteri DSM 17938) twice daily during feeding for 4 weeks.
89383342|NCT03675048|Placebo Comparator|Placebo group|The placebo group will receive 5 drops twice daily during feeding for 4 weeks. Placebo composition will be identical to that of the study drug but will not contain L. reuteri.
89383343|NCT03675048|No Intervention|Control group|The infants from the control group will comply with the same requirements and will undergo the same procedures as participants from the main group except for randomization and treatment.
89383344|NCT03022578|Experimental|Treatment (LITT, lomustine)|Patients undergo LITT at baseline and receive lomustine PO on day 1. Treatment with lomustine repeats every 42 days for up to 6 cycles in the absence of disease progression or unaccepted toxicity.
89383345|NCT03669666||control group|10 normal healthy subjects are conducted for cardiac magnetic resonance imaging examination
89383346|NCT03669666||case group|25 patients with valvular heart disease diagnosed clinically and by echocardiography are conducted for cardiac magnetic resonance imaging examination
89383347|NCT03022422|Other|Group B: 18-30 yo identical twins (TIV)|Individual twins to receive Fluzone® standard TIV
89383348|NCT03022422|Other|Group C: 18-30 yo fraternal twins (TIV)|Individual twins to receive Fluzone® standard TIV
89383349|NCT03022422|Other|Group D: 40-64 yo identical twins (TIV)|Individual twins to receive Fluzone® standard TIV
89383350|NCT03022422|Other|Group E: 40-64 yo fraternal twins (TIV)|Individual twins to receive Fluzone® standard TIV
89383351|NCT03022422|Other|Group F: 65-100 yo identical twins (TIV)|Individual twins to receive Fluzone® standard TIV
89383352|NCT03022422|Other|Group F: 65-100 yo identical twins (High-Dose TIV)|Individual twins to receive High-Dose Fluzone® TIV
89383353|NCT03023826|Experimental|LY3202626 (R-Fasting)|Single oral dose of LY3202626 (R) capsule under fasting conditions.
89383354|NCT03023826|Experimental|LY3202626 (T1-Fasting)|Single oral dose of LY3202626 (T1) tablet under fasting conditions.
88875374|NCT05365620|Active Comparator|Catheter Suction|Patients in this arm were managed for 8 hours with Catheter Suction whenever the subject showed signs of airway secretion accumulation, as per standard clinical practice for those ICU's
89383355|NCT03023826|Experimental|LY3202626 (T1-Fed)|Single oral dose of LY3202626 (T1) following a high fat breakfast.
89383356|NCT03671070|Active Comparator|Low dose Epinephrine boluses|Patients suffering from acute hypo-tension will receive low dose IV epinephrine boluses ≤ 5 μg/kg/dose, 3 doses, within 3 hours
89383357|NCT03671070|Placebo Comparator|Traditional management of shock|Patients suffering from acute hypo-tension will be managed according to Traditional algorithm of Hypotension
89383358|NCT03670992||Pancreatic Metastases|Patients with only pancreatic metastases from RCC
89383359|NCT03670992||extra-pancreatic metastases|patients with extra pancreatic metastases from RCC
89383360|NCT03670758||Group 1|Will include 30 women with unexplained primary infertility; will be recruited from the outpatient infertility clinic
89383361|NCT03670758||Group 2|another 30 fertile women who got pregnant and delivered at least once in the previous year with no history of recurrent abortions; will recruited from outpatient gynecology clinic as control
89383362|NCT03674658|Experimental|A drug|Rhynorm(A drug)
89383363|NCT03674658|Active Comparator|B drug|Rytmonorm (B drug)
89383364|NCT03674580||Suicidal patients|No intervention. Follow-up of the suicidal patients
89383365|NCT03674502|Experimental|ADU-1604|ADU-1604 administered as an IV infusion
89383366|NCT03623256|Active Comparator|Spinal Fentanyl|Spinal dose of preservative-free fentanyl 25 mcg (Volume 0.5 mL)
89383367|NCT03623256|Active Comparator|Spinal Bupivacaine|Spinal dose of preservative-free 0.25% bupivacaine (Volume 0.5 mL)
89383368|NCT03623256|Active Comparator|Spinal Fentanyl and Bupivacaine|Spinal combination of preservative-free 0.25% bupivacaine (0.5 mL) and fentanyl 25 mcg (0.5 mL). (Total Volume 1 mL).
89383369|NCT03623256|Experimental|Epidural fentanyl /spinal bupivacaine|Spinal preservative-free 0.25% bupivacaine (Volume 0.5 mL) and epidural fentanyl 100 mcg (Volume 2 mL).
89383370|NCT02661672|Experimental|Patients with Brain Hemorrhage|Subjects will receive best medical management for ICH plus they will receive the MIES surgery and use of the Apollo or Artemis System for clot evacuation.
89383371|NCT03669510|Active Comparator|computer gaiuded IAN|Computer guided surgical technique
89383372|NCT03669510|Experimental|Classical technique|Non computer guided surgical technique
89383373|NCT03674190|Experimental|Anterior Lumbar Interbody Fusion|Surgical treatment Anterior Lumbar Interbody Fusion
89383374|NCT03674190|Active Comparator|Total disc replacement|Surgical treatment total disc replacement in the lumbar spine
89383375|NCT03674034||term|50 CTscan and MRI images of children aged at term
89383376|NCT03674034||one month|50 CTscan and MRI images of children aged one month
89383377|NCT03674034||two months|50 CTscan and MRI images of children aged two months
88856615|NCT03593694|Active Comparator|Group 2|"Arm: Active Comparator: Group 2 Participants in this group will receive as detailed above, the culturally tailored education booklet titled My Guide to Sugar Diabetes. In addition, subjects will complete 10 sessions of diabetes education delivered weekly via videoconferencing lasting 60 minutes each session. Patients will also be assigned the FORA Test-n-Go Series Blood Glucose and Blood Pressure monitors and provided glucose test strips to allow testing at least once a day during the initial face-to-face session."
88856616|NCT03593694|Experimental|Group 3|Arm: Experimental: Group 3 The intervention has 3 components: 1) diabetes education; 2) home telemonitoring; and 3) diabetes modified behavioral activation, delivered by nurses via smartphones. Trained nurses will deliver the TECH DM-BAT intervention via videoconferencing technology on smartphones.
88856617|NCT03593616||Lens Phacoemulsification Group|insertion of intra-ocular lens
88856618|NCT05632848|Experimental|Treatment arm|Chidamide and Zimberelimab
88856619|NCT03598374|Experimental|Inositol + Folic acid|"Couples with PCOS infertile women, diagnosed according to the Rotterdam criteria, who access infertility center with conception desire. These women will receive oral supplementation with Inositol (Myo-inositol and D-chiro-inositol at 40:1 ratio) plus Folic acid for 6 months.~Couples are required to have regular intercourse with the aim to achieve a spontaneous conception."
88856620|NCT03598374|Placebo Comparator|Folic acid|"Couples with PCOS infertile women, diagnosed according to the Rotterdam criteria, who access infertility center with conception desire. These women will receive oral supplementation with Folic acid for 6 months.~Couples are required to have regular intercourse with the aim to achieve a spontaneous conception."
88856621|NCT03593460|Experimental|sPIF 1 mg/kg (Starting Dose)|Patients will be administered a starting dose of sPIF 1mg/kg (n=10/cohort) for 14 days assessing safety, tolerability and clinical response based on the effect on ALT levels
88856622|NCT03593460|Experimental|sPIF 2 mg/kg|Patients will be dosed at 2mg/kg sPIF for 14 days assessing safety, tolerability and clinical response based on the effect on ALT levels.
88856623|NCT03593460|Experimental|sPIF 3 mg/kg|Patients will be administered a starting dose of sPIF 3mg/kg (n=10/cohort) for 14 days assessing safety, tolerability and clinical response based on the effect on ALT levels
88856624|NCT03593460|Experimental|sPIF 4 mg/kg|Patients will be administered a starting dose of sPIF 4mg/kg (n=10/cohort) for 14 days assessing safety, tolerability and clinical response based on the effect on ALT levels
88856625|NCT03593460|Experimental|sPIF 5 mg/kg|Patients will be administered a starting dose of sPIF 5mg/kg (n=10/cohort) for 14 days assessing safety, tolerability and clinical response based on the effect on ALT levels.
88856626|NCT03024294|Other|Patients undergoing VATS lobectomy or segmentectomy|Patients undergoing VATS lobectomy or segmentectomy performed by one of the surgeons in the Division of Thoracic Surgery who are then placed on this specific post-operative care pathway to determine the rate of discharge of these patients by post-operative day (POD) three.
88856627|NCT03593382||Female endurance athletes|Female endurance athletes recruited from Swedish and Danish national teams and competitive sport clubs
88856628|NCT04407078|Experimental|Sugammadex group|Sugammadex group receives the intravenous sugammadex of 2 mg/kg.
88856629|NCT04407078|Placebo Comparator|Neostigmine group|Neostigmine group receives the intravenous neostigmine 50 ug/kg and glycopyrrolate 10 ug/kg.
88856630|NCT04003116|Experimental|Supplementary oxygen|Supplementary oxygen added to conventional anticoagulant treatment.
88856631|NCT04003116|No Intervention|Standard medical therapy|Standard management.
89184024|NCT04071327||Chronic thromboembolic pulmonary hypertension (CTEPH)|Patients with newly diagnosed or established CTEPH, within 6 months of first outpatient visit to a PH Care Center
89184025|NCT04071327||Group 3 PH due to Developmental Lung Disease|Pediatric patients with newly diagnosed or established Group 3 PH due to developmental lung disease, within 6 months of first outpatient visit to a PH Care Center.
89184026|NCT03941184||SCAD cases|SCAD cases will be identified based on presence of at least one diagnosis code for SCAD followed by manual verification by a trained individual, OR, inclusion in the previously validated SCAD cohort (Tweet 2012).
88856632|NCT00218634|Experimental|CBT-AD|Cognitive behavioral therapy for adherence and depression
88856633|NCT00218634|Active Comparator|ETAU|Enhanced treatment as usual
88856634|NCT00217620|Experimental|sorafenib|sorafenib
88856635|NCT00217464|Experimental|Fulvestrant|Fulvestrant will be provided as 250 mg in 5 mL as a pre-tilled syringe. Fulvestrant will be administered as 500 mg, that is, 2 injections of 5 mL, one into each buttock im on day 0. A single 250 mg in 5 mL injection will be administered on day 14 followed by a single 250 mg in 5 mL dose on day 28 and monthly thereafter.
88856636|NCT00214500|Experimental|Migalastat|"Migalastat was administered orally during the 12-week treatment period and then during the optional 2 treatment extension periods.~Treatment Period:~Migalastat 25 mg BID for Weeks 1 and 2 (Day 1 through the morning dose on Day 14).~Migalastat 100 mg BID for Weeks 3 and 4 (Day 15 through the morning dose on Day 28).~Migalastat 250 mg BID for Weeks 5 and 6 (Day 29 through the morning dose on Day 42).~Migalastat 25 mg BID for Weeks 6 to 12 (Days 43 to 84).~Extension Period:~Migalastat 25 mg BID for Weeks 12 through 48.~Migalastat 50 mg QD for Weeks 48 through 96."
88856637|NCT04002726|Active Comparator|Group Aa|Allocated to do the app-based training. Allocated to do the app-based classroom IGA test first, and the slide-based test second.
89184027|NCT03941184||Controls without SCAD|Potential controls will be identified based on absence of any SCAD diagnosis codes.
89184028|NCT04071093|Other|Telemonitoring|
89184029|NCT04071093|No Intervention|Usual Care|
89184030|NCT02596334|Active Comparator|triple therapy|dolutegravir + abacavir + lamivudine (TRIUMEQ) : oral administration, one tablet daily during 48 weeks.
89184031|NCT02596334|Experimental|monotherapy|dolutegravir (TIVICAY) : 50 mg, oral administration, one tablet daily during 48 weeks.
88856638|NCT04002726|Active Comparator|Group As|Allocated to do the app-based training. Allocated to do the slide-based classroom IGA test first, and the app-based test second.
89184032|NCT00719706|Active Comparator|1|1000-3000mg/day of acetyl-l-carnitine PLUS 600-1800mg/day of alpha-lipoic acid
89184033|NCT00719706|Placebo Comparator|2|
89184034|NCT02575599|Active Comparator|Lifestyle counselling|Intervention group: Eighty six adults with type 2 diabetes will be recruited from the general practices where the trained nurses in Guided self-determination programme are working.
89184035|NCT02575599|No Intervention|Regular consultation|Control group: Eighty six adults with type 2 diabetes will be recruited from general practices with employed registered nurses without the Guided self-determination training.
89184036|NCT02575521|Placebo Comparator|Propofol-Dexmedetomidine group|this group is planned to receive intravenous anaesthesia only
89184037|NCT02575521|Active Comparator|Sevoflurane group|this group is planned to receive sevoflurane/fentanyl anaesthesia
89184038|NCT00742274|Experimental|1|TAG+BMT
89184039|NCT00742274|Active Comparator|2|BMT alone
89184040|NCT04711473|Active Comparator|Colonoscopy Only|Participants in this arm will receive a letter from their provider informing them they are overdue for colon cancer screening and requesting their participation in colonoscopy, and including a referral for the procedure at a local endoscopy center. Participants will be provided a phone number if interested in navigated colonoscopy scheduling.
89184041|NCT04711473|Experimental|Choice|Participants in this arm will receive a letter from their provider informing them they are overdue for colon cancer screening and requesting their participation in their choice of either colonoscopy or mailed fecal immunochemical testing (FIT). The letter will include both a referral for the colonoscopy at a local endoscopy enter and a FIT kit with a lab requisition and instructions for completion.
89184042|NCT04711473|Experimental|FIT Only|Participants in this arm will receive a letter from their provider informing them they are overdue for colon cancer screening and requesting their participation in FIT testing. The letter will include a FIT kit with lab requisition and instructions for completion.
89184043|NCT00917696|Active Comparator|1|ATP
89184044|NCT00917696|Placebo Comparator|2|Saline
89184045|NCT02576457|Experimental|BMS-936559|BMS-936559 Intravenous infusion on specified days
89184046|NCT02576457|Other|Placebo|Placebo on specified days
88856639|NCT04002726|Active Comparator|Group Sa|Allocated to do the slide-based training. Allocated to do the app-based classroom IGA test first, and the slide-based test second.
88856640|NCT04002726|Active Comparator|Group Ss|Allocated to do the app-based training. Allocated to do the slide-based classroom IGA test first, and the app-based test second.
88856641|NCT03597984|No Intervention|Arm A|Standard Radiotherapy: 4 Gy x 5 fractions (fr) to Whole vertebra
88856642|NCT03597984|Experimental|Arm B|"Intervention: Radiotherapy with Simultaneous Integrated Boost-SIB on macroscopic metastases~Delivery of a boost on macroscopic secondary lesion with Simultaneous Integrated Boost technique according this schedule:~- 5 Gy x 3 fr (Whole Vertebra) + SIB 10 Gy x 3 fr on the macroscopic disease Gross Tumor Volume - (GTV)"
88856643|NCT03597906|Experimental|Group A: Manifest|20 eyes will be treated using Contoura, topography guided ablation vision with the standard manifest refraction.
89184047|NCT05276102|Active Comparator|Repated exposure to antiseptic and treatment|Repeated exposure of forearm skin to antiseptic (once daily for 2 hours under occlusion, during three weeks) Emollient cream treatment 3 times a day
89184048|NCT05276102|Active Comparator|Sham irritation and treatment|Repeated exposure of forearm skin to deionized water (once daily for 2 hours under occlusion, during three weeks) Emollient cream treatment 3 times a day
89184049|NCT05276102|Active Comparator|No irritation and treatment|Intact skin on forearms Emollient cream treatment 3 times a day
89184050|NCT05276102|No Intervention|Repated exposure to antiseptic and no treatment|Repeated exposure of forearm skin to antiseptic (once daily for 2 hours under occlusion, during three weeks) No emollient cream treatment
89184051|NCT05276102|No Intervention|Sham irritation and no treatment|Repeated exposure of forearm skin to deionized water (once daily for 2 hours under occlusion, during three weeks) No emollient cream treatment
89184052|NCT05276102|No Intervention|No irritation and no treatment|Intact skin on forearms No emollient cream treatment
89184053|NCT01192971|Experimental|A: 850mg|A: Experimental apatinib 850 mg qd p.o, and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
89184054|NCT01192971|Experimental|B: 750mg|B: Apatinib 750 qd p.o. and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
89184055|NCT04090814|Experimental|Movement-Evoked Pain during TENS treatment|Participants performed several physical tasks while using the HeatTens device (HV-F311-E). During these tasks, participants needed to rate their pain.
89184056|NCT04090814|No Intervention|Movement-Evoked Pain|Participants performed several physical tasks during with their pain was assessed.
89184057|NCT01918215|Other|Device Implantation|A prospective, blocked, randomised, placebo-controlled trial of primary prophylaxis ICD therapy or implantable loop recorder (ILR) insertion in patients with LVEF 36-50% and Late Gadolinium Enhancement(LGE)on CMR
89184058|NCT01918215|No Intervention|Observational Registry|A prospective observational registry of patients with LVEF 36-50% and no LGE on CMR
89184059|NCT04090892||Persons with spasticity 4.0-20.11 years|Study personnel are not carrying out the surgical intervention but are assessing the outcomes of the surgery on gait and motor function.
89184060|NCT05412836|Experimental|One Treatment Arm|Subjects will receive a single intra-articular injection of AqueousJoint.
89184061|NCT00719472|Experimental|Rituximab 375 mg/m^2|Patients received 6 or 8 21-day cycles of CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone) or CVP (cyclophosphamide, vincristine, prednisone) in combination with rituximab 375 mg/m^2 administered by intravenous (IV) infusion on Day 1 of each cycle.
89184062|NCT02599064|Experimental|RXI-109|Intravitreal injections of RXI-109 in one eye given on Day 1 and at monthly intervals through Month 3 for a total of four doses
89383378|NCT03670290||Group 1|Group I will receive 30 ml of Bupivacaine 0.25% solution through the fascia iliaca compartment catheter. Catheter will be inserted with US.
89383379|NCT03670290||Group 2|Group II will receive, morphine 0.1 mg/ml via patient controlled analgesia pump. every pump will be set 1 mg dose morphine per use and 15 min lockout time.
89383380|NCT03670290||Group 3|Group III will receive 10 ml of Bupivacaine 0.25% solution through the epidural catheter.
89383381|NCT03166735|Experimental|BI 1467335 dose 1|
89383382|NCT03166735|Experimental|BI 1467335 dose 2|
89383383|NCT03166735|Experimental|BI 1467335 dose 3|
89383384|NCT03166735|Experimental|BI 1467335 dose 4|
89383385|NCT03166735|Placebo Comparator|Placebo|
89383386|NCT03082014|Active Comparator|Arm A|Amlodipine for 4 weeks, Losartan for 4 weeks, Atenolol for 4 weeks.
89383387|NCT03082014|Active Comparator|Arm B|Atenolol for 4 weeks, Amlodipine for 4 weeks, Losartan for 4 weeks.
89383388|NCT03082014|Active Comparator|Arm C|Losartan for 4 weeks, Atenolol for 4 weeks, Amlodipine for 4 weeks.
89383389|NCT02750605|Experimental|Drug eluting balloon angioplasty|Intervention with DEB angioplasty in long lesions of crural arteries
89383390|NCT02750605|Active Comparator|Plain old balloon angioplasty|Intervention with plain old balloon angioplasty POBA in long lesions of crural arteries
89383391|NCT03673566|Experimental|NICU Dashboard: Parent|"The parental intervention group will have access to the parent application on the NICU Dashboard. Parents will be able to view basic information about their baby's condition, educational material, and track core measures and developmental milestones.~Parents of NICU babies will be asked to complete questionnaires at baseline and within 48 hours of NICU discharge."
89383392|NCT03673566|No Intervention|Standard Care: Parent|The Parental Control group will receive standard of care without any study devices.
89383393|NCT03673566|Experimental|NICU Dashboard: Clinician|"The Clinician group will have access to the NICU Dashboard, which presents information from the EHR, bedside monitoring, and other systems of record through a pre-released FDA Class 2 clinical decision support rule-based system, to assist the appropriate evidence-based guidelines be integrated with team workflows. Caregivers educate and coach parents to facilitate integrating them into their infant's care.~NICU clinicians will be asked to complete questionnaires 1) prior to clinical go-live of the intervention (baseline), 2) at the study mid-way point, and 3) upon completion of parent recruitment."
89383394|NCT05320159||Overall cohort: Secukinumab|Included all the patients treated with secukinumab
89383395|NCT05320159||Bio-naive|Included PsO patients initiating treatment with secukinumab. Bio-naïve was defined as no observed treatment (i.e., injection, prescription or patient reported history) with any of the following biologic drugs of interest anytime pre-index: secukinumab, certolizumab, etanercept, adalimumab, infliximab, golimumab, ustekinumab, ixekizumab, brodalumab, abatacept, and guselkumab and risankizumab during all available history
89383396|NCT05320159||Bio-experienced|Included PsO patients initiating treatment with secukinumab. Patients had pre-index use of one or more of the biologic drugs of interest during all available history
89383397|NCT05320159||Systemic-naive|Included PsO patients initiating treatment with secukinumab. Systemic-naïve was defined as no observed treatment (i.e., injection, prescription or patient reported history) with any of the biologic treatments or with any of the following systemic (i.e., oral or injectable - no topical forms) drugs of interest pre-index: methotrexate, corticosteroids, acitretin or apremilast.
89383398|NCT05320159||Systemic-experienced|Included PsO patients initiating treatment with secukinumab. Systemic-experienced patients had pre-index use of one or more of the systemic drugs of interest.
89383399|NCT03670212|Placebo Comparator|Placebo|The placebo compound, Lactose Monohydrate Powder, was encapsulated in generic opaque capsules identical to the capsules used in the acute stress session. During the placebo session, two capsules were self-administered (swallowed) by each subject. At 11:45am, subjects self-administered a capsule containing 54mg of lactose. At 12:15pm, subjects self-administered a capsule containing 10mg of lactose.
89383400|NCT03670212|Experimental|Acute Stress|During the acute stress experimental session, subjects self-administered two generic opaque capsules. At 11:45am, subjects self-administered a capsule containing 54mg of Yohimbine Hydrochloride powder. At 12:15pm, subjects self-administered a capsule containing 10mg of Hydrocortisone.
89383401|NCT03673488||TephaFlex™ mid-urethral sling for SUI|P4HB material ( TephaFlex ™) will be implanted in 25 women with confirmed Stress Urinary Incontinence (SUI).
89383402|NCT03165955|Experimental|Oraxol|Subjects will receive Oraxol 205 mg/m2 daily x 3 days weekly for up to 16 weeks.
89383403|NCT03669978||Patients with chronic occlusive arthritis of the Lower Limbs|"Patients with chronic occlusive arthritis of the Lower Limbs with lesions on the femoro-popliteal stage and candidates for endovascular treatment of these lesions.~Creation of a bone and arterial panorama using EndoNaut® software."
89383404|NCT05263921|Active Comparator|Treatment A: PF-07321332/ritonavir|PF-07321332 ritonavir
89383405|NCT05263921|Experimental|Treatment B: PF-07321332/ritonavir|PF-07321332/ritonavir mixed with water
89383406|NCT05263921|Experimental|Treatment C: PF-07321332/ritonavir|PF-07321332/ritonavir mixed with applesauce
89383407|NCT05263921|Experimental|Treatment D: PF-07321332/ritonavir|PF-07321332/ritonavir mixed with vanilla pudding
89383408|NCT05192473|Experimental|Lithotripsy Treatment|"Pulse Intravascular Lithotripsy System~Device: Pulse Intravascular Lithotripsy Catheter"
89383409|NCT05184673|Active Comparator|hatha thermo-neutral|The hatha classes will hold each pose for 5 breaths in a room temperature (~70 degrees Fahrenheit) space. Yoga sessions will be led by a 500hr Registered Yoga Teacher. This reduces the risk for injury due to the extensive training the yoga teacher will have received and the knowledge of cuing and sequencing for best practice. All study personnel will be vaccinated against SARS-CoV-2, reducing the risk of spreading SARS-CoV-2.
89535107|NCT03092115|Experimental|HIV medication adherence app|Youth in this arm will receive a medication adherence application to help them remember to take their HIV treatment medication (antiretroviral therapy) as a supplement to current HIV standard of care.
88856644|NCT03597906|Experimental|Group B: partial TMR|20 eyes will be treated with Contoura vision, topography guided ablation using the topographic astigmatic power and axis and without change in the spherical power (using the same spherical power as the manifest refraction).
88856645|NCT03597906|Experimental|Group C: Full TMR|20 eyes will be treated with Contoura vision, topography guided ablation using the topographic astigmatic power and axis and modifying the spherical power to obtain the same spherical equivalent as the manifest refraction. This is done by subtracting half of the difference between topographic astigmatic power and the manifest astigmatic power from the spherical power (topography-modified treatment refraction).
88856646|NCT03597828||DEXMEDETOMIDINE|Dexmedetomidine infusion for pleuroscopy sedation. Rescue drugs will be midazolam for inadequate sedation and fentanyl for pain control
88856647|NCT03597828||MIDAZOLAM/FENTANYL|Midazolam for sedation and fentanyl for pain will be used for pleuroscopy monitored anesthesia care
89535108|NCT03230461|Experimental|Target compression depth 4.0-5.0 cm|The rescuer is asked to perform two minutes of chest compressions on a manikin, aiming to compress to the target depth at a rate of 100-120/min
89535109|NCT03230461|Experimental|Target compression depth 4.5-5.5 cm|The rescuer is asked to perform two minutes of chest compressions on a manikin, aiming to compress to the target depth at a rate of 100-120/min
88856648|NCT03597516|Experimental|RP-G28|galacto-oligosaccharide, spray-dried powder for reconstitution for oral administration, 7.5 grams 2 times per day
88856649|NCT03597516|Placebo Comparator|Placebos|maltodextrin, powder for reconstitution for oral administration, 7.5 grams 2 times per day
88856650|NCT03597282|Experimental|NEO-PV-01 + adjuvant + nivolumab|Nivolumab at a dose of 240 mg will be administered by intravenous infusion (IV) every 2 weeks throughout the study. At Week 12, all patients, regardless of their disease status, will receive NEO-PV-01 + adjuvant administered subcutaneously.
88856651|NCT03597282|Experimental|Nivolumab + adjuvant|Nivolumab at a dose of 240 mg will be administered by intravenous infusion (IV) every 2 weeks throughout the study. At Week 12, all patients, regardless of their disease status, will receive Poly-ICLC (adjuvant) administered subcutaneously.
88856652|NCT03597282|Experimental|NEO-PV-01 + adjuvant + nivolumab on alternate schedule|Nivolumab at a dose of 240 mg will be administered by intravenous infusion (IV) every 2 weeks throughout the study. At Week 12, all patients, regardless of their disease status, will receive NEO-PV-01 + adjuvant, administered on an alternative schedule, subcutaneously.
88856653|NCT03597282|Experimental|NEO-PV-01 + adjuvant + nivolumab + APX005M|Nivolumab at a dose of 240 mg will be administered by intravenous infusion (IV) every 2 weeks throughout the study. At Week 12, all patients, regardless of their disease status, will receive NEO-PV-01 + adjuvant administered subcutaneously. Patients on this arm will also receive APX005M at a dose of 0.1 mg/kg administered by IV infusion at Week 12, Week 15, and Week 19.
88856654|NCT03597282|Experimental|Nivolumab + APX005M|Nivolumab at a dose of 240 mg will be administered by intravenous infusion (IV) every 2 weeks throughout the study. At Week 12, Week 15, and Week 19, all patients, regardless of their disease status, will receive APX005M at a dose of 0.1 mg/kg administered by IV infusion.
88856655|NCT03597282|Experimental|NEO-PV-01 + adjuvant + nivolumab + ipilimumab|Nivolumab at a dose of 240 mg administered by intravenous infusion (IV) every 2 weeks throughout the study. At Week 12, all patients, regardless of their disease status, will receive NEO-PV-01 + adjuvant administered subcutaneously. Patients on this arm will also receive ipilimumab at a dose of 1.0 mg/kg administered by IV infusion at Week 12 and Week 19.
88856656|NCT03597282|Experimental|Nivolumab + ipilimumab|Nivolumab at a dose of 240 mg will be administered by intravenous infusion (IV) every 2 weeks throughout the study. At Week 12 and Week 19, all patients, regardless of their disease status, will receive ipilimumab at a dose of 1.0 mg/kg administered by IV infusion.
88856657|NCT03597204|Other|fecal immunochemical test (FIT)|Annual fecal immunochemical test (FIT) for selected high risk individuals to undergo CRC screening. And colonoscopy for those with FIT positive result
88856658|NCT03593304|Active Comparator|Experimental:Mecobalamin and Pyridoxine hydrochloride|Injection Mecobalamin (500mcg) three times a week (on day 1,3,5 of vincristine chemotherapy) for 5 weeks.Tablet Pyridoxine hydrochloride (25 mg) 2 tablets thrice daily for 5 weeks.
88856659|NCT03593304|Placebo Comparator|Placebo: normal saline and Oral placebo|Injection normal saline (1ml) three times a week (on day 1,3,5 of vincristine chemotherapy) for 5 weeks.Oral placebo pill 2 tablets thrice daily for 5 weeks.
89184063|NCT05410262||Mechanical power and risk of ventilator-induced lung injury in patients with ARDS|This study will prospectively evaluate patients consecutively admitted with ARDS, as defined according to the Berlin expert consensus
89535110|NCT03230461|Experimental|Target compression depth 5.0-6.0 cm|The rescuer is asked to perform two minutes of chest compressions on a manikin, aiming to compress to the target depth at a rate of 100-120/min
89535111|NCT05463653|Experimental|Experimental telemedicine|Patient's rehabilitation and compliance with the standard exercices will be guided and monitored through an ad hoc device developed specifically for this trial.
88856660|NCT00211536|Experimental|MiniMed Implantable insulin Pump (MIP)|The experimental group will receive intraperitoneally (IP) delivered insulin via the Medtronic MiniMed Implantable Pump (MIP). At the time of implant, the pump will be filled with Aventis HOE21PH U400 insulin and the subject will be treated with this insulin for the first 180 days post implant. During the refill procedure performed 180 days post implant, any insulin remaining in the pump will be removed and the pump will be refilled with Medtronic MiniMed Implantable Pump Human Recombinant Insulin.
89535112|NCT05463653|Active Comparator|Control|Patient's rehabilitation and compliance with the standard exercices will be monitored in the usual manner, at the monthly visits to the physical therapy clinic
89535113|NCT03078621|Experimental|Stem Cells|Intravenous and Intrathecal transplantation of specific populations of purified bone marrow-derived stem cells and mesenchymal stem cells.
89184064|NCT00579501|Experimental|Trabectedin|Trabectedin at a dose of 1.5 milligram per meter square (mg/m^2) will be given as an intravenous (iv) infusion (a fluid or a medicine delivered into a vein by way of a needle) over 24-hour every 3 weeks for a minimum of 3 and a maximum of 6 cycles prior to definitive surgery. Dexamethasone 20 mg iv will also be administered within 30 minutes before start of each trabectedin infusion.
89184065|NCT02590458|Experimental|Short Breast MRI (SBMRI)|Routine scheduled MRI with contrast performed on women at high risk of developing breast cancer. One day after routine MRI, short breast MRI (SBMRI) with contrast performed. After SBMRI, participant completes a questionnaire about their comfort level and experience of the research scan.
89184066|NCT02596178|Experimental|EIT Guided PEEP Therapy|
89184067|NCT04085952|Experimental|anterior colporrhaphy with dermal graft|Patients randomized to this arm underwent anterior colporrhaphy with dermal graft augmentation (ARUCS) during their surgery for pelvic organ prolapse.
89184068|NCT04085952|Active Comparator|anterior colporrhaphy suture based|Patients randomized to this arm underwent anterior colporrhaphy with suture based repair (native tissue) during their surgery for pelvic organ prolapse. This is and was the most common practice for anterior colporrhaphy.
89184069|NCT02589834|Active Comparator|Quran group|The patients listened to Quran recitation by a compact disc player through an occlusive headphone, started after induction of spinal anesthesia and continued throughout the entire cesarean section duration.
89184070|NCT02589834|No Intervention|Non-Quran group|Those patients did not listen to Quran and subjected to operative room noise throughout the surgery.
89184071|NCT02576301|Experimental|Phase 2 AML|OXi4503 at MTD plus cytarabine 1g/m2/day
89184072|NCT02576301|Experimental|Phase 2 MDS|OXi4503 at MTD plus cytarabine 1g/m2/day
89184073|NCT02576301|Experimental|OXi4503 dose escalation|MTD for OXi4503 will be determined
89184074|NCT02576301|Experimental|OXi4503 + cytarabine dose escalation|MTD of the combination of OXi4503 + cytarbine will be determined
89184075|NCT02589756|Experimental|The fatty fish group|Participants will eat fatty fish and avoiding nuts)
89184076|NCT02589756|Experimental|The nut group|Participants who will avoid fatty fish
89184077|NCT02589756|Placebo Comparator|The control group|Participants who will avoid both fatty fish and nuts
89184078|NCT00918762|Experimental|daVinci® Robotic Surgical System|Participants will undergo a planned surgical procedures via the robotic approach.
89184079|NCT04019067|Experimental|MCE first group|"Patients randomized to the MCE first group will have a MCE deployed as the first detection method."
89184080|NCT04019067|No Intervention|standard of care group|For patients randomized to the Standard Care Group, gastroenterologists choose which procedures to perform and when to perform them based on their interpretation of the patient's presentation.
89184081|NCT02575287||NERD group|(Digital chromoendoscopy with Optical Enhancement and without magnification; Digital chromoendoscopy with Optical Enhancement and with magnification; optical magnification without Digital chromoendoscopy: Optical Enhancement) Patients with reflux symptoms, without endoscopic lesions on the upper endoscopy with high definition white light or I-Scan and a positive ph-impedanciometry for reflux
89184082|NCT02575287||Control group|(Digital chromoendoscopy with Optical Enhancement and without magnification; Digital chromoendoscopy with Optical Enhancement and with magnification; optical magnification without Digital chromoendoscopy: Optical Enhancement) Patients with reflux symptoms, without endoscopic lesions on the upper endoscopy with high definition white light or I-Scan and a negative ph-impedanciometry for reflux
89184083|NCT04086186|Active Comparator|Adductor Canal Block Group|Standard method for peri-operative pain control. Adductor canal block is performed by anesthesiologist prior to surgery.
89184084|NCT04086186|Experimental|Liposomal Bupivacaine Group|Experimental method for peri-operative pain control. Liposomal bupivacaine peri-articular injection is performed by surgeon during surgery.
89184085|NCT00741338|Experimental|Cohort 1|Tolerance Induction Period (TIP): Cyclosporine A (CsA) starting at 5 milligram per kilogram (mg/kg) orally three times daily until the target trough concentration of at least 350 nanogram per milliliter (ng/mL) (preferably 400 ng/mL) achieved along with azathioprine (Aza) 2.5 mg/kg/day orally. Once target CsA trough level achieved and maintained for at least 1 week, participants received laronidase 0.058 mg/kg (low-dose) once weekly intravenous (IV) infusion (starting from Day 1) up to Week 12. CsA and Aza were gradually discontinued. Immune Challenge Period (ICP): following TIP, laronidase dose increased to 0.12 mg/kg once weekly IV infusion for 1 week followed by 0.25 mg/kg once weekly IV infusion for 1 week and then 0.58 mg/kg (full-dose) once weekly IV infusion up to Week 39.
89184086|NCT00741338|Experimental|Cohort 2|TIP: CsA starting at 6.7 mg/kg orally three times daily until the target trough concentration of at least 350 ng/mL (preferably 400 ng/mL) achieved along with Aza 5 mg/kg orally every other day. Once target CsA trough level achieved and maintained for at least 1 week, participants received laronidase 0.058 mg/kg (low-dose) once weekly IV infusion (starting from Day 1) up to Week 18. CsA and Aza were gradually discontinued. ICP: following TIP, laronidase dose increased to 0.12 mg/kg once weekly IV infusion for 1 week followed by 0.25 mg/kg once weekly IV infusion for 1 week and then 0.58 mg/kg (full-dose) once weekly IV infusion up to Week 45.
89184087|NCT02575131|Experimental|TNO whole wheat bread yeast basis|NBC-1: four slices of whole wheat bread yeast basis (98 grams) spread with 3 cups low-fat margarine (total 30 grams) consumed with 200 mL of black coffee (without milk and sugar) or 200 mL tea (no sugar) or 200 mL of water at TNO
89184088|NCT02575131|Active Comparator|TNO whole wheat sourdough bread|NBC-2- four slices of whole wheat sourdough bread (98 grams) with 3 cups low-fat margarine (total 30 grams) consumed with 200 mL of black coffee (without milk and sugar) or 200 mL tea (no sugar) or 200 mL of water. at TNO
89002944|NCT06012760|Experimental|Combined Iron Protocols group（CIP group）|Preoperative randomization was conducted, followed by a three-day regimen in the week preceding surgery, involving the administration of intravenous iron sucrose at a dosage of 200 mg per day, vitamin C at a dosage of 2 g per day, and subcutaneous administration of Human Erythropoietin Injection at a dosage of 150 IU per kilogram.
89383410|NCT05184673|Active Comparator|hatha hot|The hatha hot classes will hold each pose for 5 breaths in a room heated to 95 degrees Fahrenheit. Yoga sessions will be led by a 500hr Registered Yoga Teacher. This reduces the risk for injury due to the extensive training the yoga teacher will have received and the knowledge of cuing and sequencing for best practice. All study personnel will be vaccinated against SARS-CoV-2, reducing the risk of spreading SARS-CoV-2.
89383411|NCT05184673|Active Comparator|flow thermo-neutral|The flow hot classes will flow from each pose (one breath per movement) a room temperature (~70 degrees Fahrenheit) space. Yoga sessions will be led by a 500hr Registered Yoga Teacher. This reduces the risk for injury due to the extensive training the yoga teacher will have received and the knowledge of cuing and sequencing for best practice. All study personnel will be vaccinated against SARS-CoV-2, reducing the risk of spreading SARS-CoV-2.
89383412|NCT05184673|Active Comparator|flow hot|The flow hot classes will flow from each pose (one breath per movement) in a room heated to 95 degrees Fahrenheit. Yoga sessions will be led by a 500hr Registered Yoga Teacher. This reduces the risk for injury due to the extensive training the yoga teacher will have received and the knowledge of cuing and sequencing for best practice. All study personnel will be vaccinated against SARS-CoV-2, reducing the risk of spreading SARS-CoV-2.
89383413|NCT03055494|Experimental|Secukinumab|Eligible patients received secukinumab 300 mg s.c. at randomization, Weeks 1, 2, 3 and 4 followed by monthly dosing up to Week 48
89383414|NCT03055494|Placebo Comparator|Placebo|Eligible patients received placebo at randomization, Weeks 1, 2, 3, 4, and 8. At Week 12, patients were switched to treatment with secukinumab 300 mg s.c. at Weeks 12, 13, 14, 15, and 16 followed by monthly dosing up to Week 48
89383415|NCT03673410|Active Comparator|Laparoscopic revisional bariatric surgery|Patients requiring revisional bariatric surgery will be treated with a standard of care laparoscopic procedure.
89383416|NCT03673410|Experimental|Robotic revisional bariatric surgery|Patients requiring revisional bariatric surgery will be treated with the same procedure but performed robotically.
89383417|NCT02445768|Experimental|Cognitive multisensory rehabilitation|The treatment group will receive the cognitive multisensory rehabilitation that uses motor imagery and sensory discrimination exercises
89383418|NCT03673332|Experimental|treatment including immune checkpoint inhibitors|All patients included in this study will receive approved immune-checkpoint inhibitors therapies, such as CTLA-4, PD-1, and PD-L1 inhibitors.
88856661|NCT00211536|No Intervention|Subcutaneous insulin arm (SC)|The control group will remain on their current pre-study subcutaneous insulin therapy of either Multiple Daily Injections (MDI) or Continuous Subcutaneous Insulin Infusion (CSII - external insulin pump). The SC group will not be restricted to the type of insulin used, or be required to change or modify their current diabetes therapy for the purpose of the study.
88856662|NCT04001088|Experimental|Probiotic|Probiotics in a capsule.
88856663|NCT04001088|Placebo Comparator|Placebo|Non active ingredients in a capsule.
88856664|NCT03976128|Experimental|Nordic Walking training|20 sessions of 45 minutes x 2 times/week x 10 weeks using NW
88856665|NCT03976128|Active Comparator|Conventional endurance training|20 sessions of 45 minutes x 2 times/week x 10 weeks using treadmill and cycloergometer training.
88856666|NCT03596970|Experimental|Everolimus with MMF (TAC-withdrawal)|Everolimus (RAD001) with MMF and Steroids
88856667|NCT03596970|Active Comparator|Everolimus with reduced TAC|Everolimus (RAD001) with reduced TAC and Steroids
88856668|NCT03596892|Experimental|Decitabine + BUCY|For MLL+ acute leukemia undergoing allo-HSCT，Decitabine+BUCY conditioning regimen was Decitabine 20mg/m2/day on days -14 and -10； Busulfan (BU) 3.2 mg/kg/day on days -7 and -4；Cyclophosphamide (CY) 60 mg/kg/day on days -3 and -2.
89383419|NCT02914548|Experimental|0.3% OPA-15406|Subjects were treated with assigned 0.3% OPA-15406 ointment twice daily.
89383420|NCT02914548|Experimental|1% OPA-15406|Subjects were treated with assigned 1% OPA-15406 ointment twice daily.
89383421|NCT02914548|Placebo Comparator|Placebo|Subjects were treated with assigned 0% OPA-15406 ointment twice daily.
89383422|NCT03165721|Experimental|Patients ≥ 12 Years of Age w/Wild-Type GIST|"SGI-110 administered subcutaneously at 45mg/m^2/day x 5 days on a 28-day cycle~Gastrointestinal stromal tumor (GIST)"
88856669|NCT03596892|Active Comparator|BUCY|For MLL+ acute leukemia undergoing allo-HSCT，BUCY conditioning regimen was Busulfan (BU) 3.2 mg/kg/day on days -7 and -4；Cyclophosphamide (CY) 60 mg/kg/day on days -3 and -2.
88856670|NCT04199286|Active Comparator|Asymmetrical surgery|This asymmetrical horizontal muscle surgery done as recess-resect in one eye or 3 muscle surgery
88856671|NCT04199286|Active Comparator|Symmetrical|This symmetrical horizontal muscle surgery includes bilateral medial rectus recession in esotropia cases or bilateral lateral rectus recession in exotropia
88856672|NCT04198896||CAD-only|patients with diagnosed coronary artery diseases (CAD) without any other atherosclerotic cardiovascuar diseases at the entry of SHIP
88856673|NCT04198896||CAD with poly-arterial diseases|patients with diagnosed coronary artery diseases (CAD) with other atherosclerotic cardiovascuar diseases such as any of aortic and/or peripheral artery diseases at the entry of SHIP
89002945|NCT06012760|Active Comparator|Standard Medical Care group（SMC group）|Standard Medical Care (SMC) for the treatment of IDA. SMC as determined by the Investigator for the treatment of iron deficiency anemia (IDA).
89383423|NCT03165721|Experimental|Patients ≥ 12 Years of Age w/PHEO/PGL with SDH-deficient PHE|"SGI-110 administered subcutaneously at 45mg/m^2/day x 5 days on a 28-day cycle~Pheochromocytoma and Paraganglioma (PHEO/PGL) with succinate dehydrogenase (SDH)-deficient PHE"
89383424|NCT03165721|Experimental|Patients ≥ 12 Years of Age w/HLRCC-associated Renal Cell Ca|"SGI-110 administered subcutaneously at 45mg/m^2/day x 5 days on a 28-day cycle~Hereditary leiomyomatosis and renal cell carcinoma (HLRCC)-associated Renal Cell Ca"
89383425|NCT02224872|Experimental|Bone marrow transplant|Thymoglobulin on days -9 to -7 Fludarabine on days -6 to -2 Cyclophosphamide on days -6, -5, 3, 4 TBI on day -1 BMT on day 0 Mesna on days 3, 4 Tacrolimus on days 5-365 Mycophenolic acid mofetil on days 5-35
89383426|NCT02187198|Experimental|Buprenorphine low dose|Participants in this arm will receive a low dose (less than or equal to 8/2mg) of buprenorphine for 12 weeks.
88856674|NCT03592914||subjects with respiratory disease|This study is a comparative, single-center study. This is a minimal risk study using a non-significant risk device. A minimum of 60 and maximum of 70 subjects will be enrolled in the study. Subject participation will last approximately 1 hour(s).
88856675|NCT03592836|Active Comparator|Continuous infusion of loop diuretics|Furosemide continuous infusion: 125 or 250 mg die
88856676|NCT03592836|Active Comparator|Intermittent infusion of loop diuretics|Furosemide bolus intermittent: 125 or 250 mg die
88856677|NCT03592758||ultrasound assessment|all patient are evaluated by an ultrasound assessment before general anaesthesia
88856678|NCT03596580||Dehydrated participants|125 participants ≥ 65 years of age at the moment of the interviews; hospitalized in General Medicine; osmolarity ≥ 296 mOsm/L
88856679|NCT03596580||Hydrated participants|97 participants ≥ 65 years of age at the moment of the interviews; hospitalized in General Medicine; osmolarity < 296 mOsm/L
88856680|NCT03596502||Direct oral anticoagulants (DOACs)|Patients diagnosed with non-valvular atrial fibrillation who initiated their oral anticoagulation with a DOAC (apixaban, dabigatran or rivaroxaban) at cohort entry date, and did not have a previous prescription for any oral anticoagulant in the prior year.
88856681|NCT03596502||Warfarin|Patients diagnosed with non-valvular atrial fibrillation who initiated their oral anticoagulation with warfarin at cohort entry date, and did not have a previous prescription for any oral anticoagulant in the prior year.
88856682|NCT03592680|Active Comparator|Vitamin C|Vitamin C 1000mg PO from 5 days before surgery until 10 days after surgery
88856683|NCT03592680|Placebo Comparator|Placebo|Placebo as an alternative for Vitamin C tablets
88856684|NCT04198194||Participants with events|Individuals who have experienced any of the listed outcomes
88856685|NCT04198194||Participants without events|Individuals who have not experienced any of the listed outcomes
88856686|NCT04198038|Experimental|cognitively impaired children|This is a single-group study; all participants will be offered the songwriting intervention.
88856687|NCT03596346|Active Comparator|Test group|20 g of rapeseed ingredient (RI) daily
88856688|NCT03596346|Placebo Comparator|Control group|0 g of rapeseed ingredient (RI) daily
88856689|NCT03596190|Other|Assessment arm|
88856690|NCT03592446|Experimental|Active-raVNS|Transcutaneous electrical vagus nerve stimulation at ear.
88856691|NCT03592446|Sham Comparator|Sham-raVNS|Sham vagus nerve stimulation at ear.
88856692|NCT03596112|Experimental|polyacrylate wound pad|Use of cellulose and distinct layers of sodium-polyacrylate pad for wound care; frequency: twice a week
88856693|NCT03596112|Active Comparator|hydrocellular foam pad|Use of standard foam pad for wound care; frequency: twice a week
88856694|NCT04197570|Active Comparator|Opioid-based anesthetic|"Premedication~-midazolam 2mg IV x 1 as need for anxiety, at the discretion of the anesthesiologist~Induction~Fentanyl 2-4 mcg/kg IV bolus~Propofol 1-3 mg/kg IV~Paralytic and vasoactive medications at the discretion of the anesthesiologist~Maintenance~Fentanyl 1-2 mcg/kg IV bolus immediately prior to sternotomy & aortic cannulation~Fentanyl 1-2mcg/kg IV bolus immediately following removal of bypass cannula~Dexmedetomidine 0.4 mcg/kg/hr IV infusion~Isoflurane titrated at the discretion of the anesthesiologist~Vasoactive medications at the discretion of the anesthesiologist for hemodynamic management~During chest closure:~start Propofol 25-75mcg/kg/min IV infusion~continue dexmedetomidine 0.4mcg/kg/hr IV infusion~titrate off isoflurane~Acetaminophen 1000mg IV"
88856695|NCT04197570|Experimental|Opioid-free anesthetic|"Premedication~-midazolam 2mg IVx1 as needed for anxiety, at the discretion of the anesthesiologist~Induction~Dexmedetomidine 1mcg/kg IV~Propofol 1-3mg/kg IV~Paralytic and vasoactive medications at the discretion of the anesthesiologist~Maintenance~Dexmedetomidine 0.8-1.0 mcg/kg/hr IV infusion~Isoflurane titrated at the discretion of the anesthesiologist~May add propofol infusion if clinically indicated~Vasoactive medications at the discretion of the anesthesiologist for hemodynamic management~During chest closure:~start Propofol 25-75mcg/kg/min IV infusion~continue dexmedetomidine 0.4 - 1.0 mcg/kg/hr IV infusion~titrate off isoflurane~Acetaminophen 1000mg IV"
88856696|NCT04197882|Experimental|treatment|"This study consisted of 3 stage of neoadjuvant treatment, surgical, and adjuvant treatment. Neoadjuvant treatment period: OrienX010 intratumoral injection in combination with Toripalimab infusion. Toripalimab : 3 mg/kg, IV infusion: Once every 2 weeks for 6 doses ; OrienX010: Maximum injection volume 8 × 108 pfu, intratumoral injection: Once every 2 weeks for 6 doses ; Surgical treatment period: 2 weeks after the last dose of neoadjuvant treatment (± 7 days), the investigator designed the surgical protocol of the melanoma radical surgery according to the patient's individual disease, and performed postoperative care according to the patient's condition.~Adjuvant treatment period: 3 weeks after operation (± 7 days), the patient was given Toripalimab infusion. Toripalimab 3 mg/kg intravenously given every 3 weeks (every 3 weeks per cycle) for up to 1 year (the one-year duration will be counted from 1st dose in neoadjuvant treatment)."
88856697|NCT03591978||Healthy non smokers|Healthy subjects with no respiratory disease and never smokers
88856698|NCT03591978||Healthy smokers|Healthy subjects without respiratory disease and at least a cumulative tobacco consumption history of <10 pack-years
88856699|NCT03591978||COPD|COPD patients (diagnosed as recommended by GOLD 2017 strategy) former or current smokers with at least >10 pack-years
88856700|NCT04197414||Prostate cancer|Patients diagnosed as prostate cancer and have undergone prostatectomy
88856701|NCT04197414||Renal cell cancer|Patients diagnosed as renal cell cancer and have undergone partial or radical nephrectomy
88856702|NCT04197414||Bladder cancer|Patients diagnosed as bladder cancer and have undergone radical or partial cystectomy
88856703|NCT04197414||Ureter cancer|Patients diagnosed as ureter cancer and have undergone nephroureterectomy or ureterectomy
88856704|NCT04197024|Experimental|Traditional exercise capacity test|Patients of the Ministry of the Interior and Administration hospital in Głuchołazy with a diagnosed disease unit of Chronic Obstructive Pulmonary Disease (COPD).
88856705|NCT04197024|Experimental|Immersive virtual reality exercise capacity test|Healthy volunteers, Students of Department of Physical Education and Physiotherapy, Opole University of Technology, Opole, Poland
88856706|NCT03024060|Experimental|ALA 20 mW|ALA + IBL 10J at 20 mW (8min 20 sec)
88856707|NCT03024060|Experimental|ALA 10 mW|ALA + IBL 10J at 10 mW (16 min 40 sec)
88856708|NCT03024060|Placebo Comparator|Vehicle|Vehicle (VEH) group will be randomized (1:1) to be balanced for the two active groups; receiving light treatment delivered at 20 mW/cm2 OR 10 mW/cm2. Subjects receiving VEH will be considered a single treatment group
88856709|NCT03024216|Experimental|Arm 1|Atezolizumab1200 mg IV week 1 and week 4 followed by Sipuleucel-T administered weeks 6, 8, and 10
88856710|NCT03024216|Experimental|Arm 2|Sipuleucel-T administered week 1, 3, and 5 followed by Atezolizumab1200 mg IV weeks 7 and 10
88856711|NCT03596034|Experimental|JUUL 5%, Virginia Tobacco, ENDS product|Subjects participate in a 15 day product use period during which subjects will be requested to predominantly use the JUUL 5% product ad libitum as their primary source of nicotine. Subjects will be asked to report their daily use of the JUUL 5% product and combustibles per day (CPD) throughout the 15 day product use period.
88856712|NCT03595956||Medical Gender Affirmation (MGA) Cohort|Patients engaged in gender-affirming care.
88856713|NCT03981744|Experimental|Group 1: Ustekinumab + Placebo|Participants will receive body weight-range based IV dosing of approximately 6 milligram per kilogram (mg/kg) of ustekinumab at Week 0 followed by ustekinumab 90 milligram (mg) subcutaneously (SC) at Week 8 and every 8 Weeks (q8w) administrations through Week 72. At Week 24, participants will receive IV dosing of placebo.
88856714|NCT03981744|Placebo Comparator|Group 2: Placebo + Ustekinumab|Participants will receive IV dosing of placebo at Week 0 followed by placebo SC administrations at Weeks 8,16 and 24. At Week 24, participants will receive body weight-range based IV dosing of approximately 6 mg/kg of ustekinumab, followed by ustekinumab 90 mg SC q8w administrations Week 32 through Week 72.
88856715|NCT03591900|Active Comparator|daibetic thalassemic patients on SC insulin|"A pilot study will be done on 20 patients with abnormal glucose tolerance which will include:~A-Continuous glucose monitoring system (CGMS) : A glucometer will be given to each patient and will be asked to measure blood glucose before meals and snacks and record the valus in the CGMS for better calibration (Khammar A et al., 2009).~B-Therapeutic intervention:~Thalassemia patients who proved to have diabetes according to the ADA criteria will be put on sc insulin"
88856716|NCT03591900|Active Comparator|daibetic thalassemic patients on insulin pump|"A pilot study will be done on 20 patients with abnormal glucose tolerance which will include:~A-Continuous glucose monitoring system (CGMS) : A glucometer will be given to each patient and will be asked to measure blood glucose before meals and snacks and record the valus in the CGMS for better calibration (Khammar A et~B-Therapeutic intervention:~Thalassemia patients who proved to have diabetes according to the ADA criteria will be put on insulin pump"
89535114|NCT03230227|Active Comparator|Bupivacaine magnesium|( bupivacain 0.125% magnesium sulfate 5%) infusion in the presternum , for 48 hours
89535115|NCT03230227|Active Comparator|bupivacain only|bupivacaine 0.125% infusion in the presternum , for 48 hours
88856717|NCT03591744|Experimental|Treatment (daratumumab, bortezomib, chemotherapy)|Participants receive daratumumab IV on days 1, 8, 15, and 22, dexamethasone IV/PO on days 1, 2, 8, 9, 15, 16, 22, and 23, pegylated liposomal doxorubicin hydrochloride IV on day 8, lenalidomide PO daily on days 1-14, and bortezomib SC on days 1, 4, 8, and 11 of courses 1 and 2. Participants then receive daratumumab IV on days 1, and 15, dexamethasone IV/PO on days 1, 2, 8, 9, 15, 16, 22, and 23, pegylated liposomal doxorubicin hydrochloride IV on day 8, lenalidomide PO daily on days 1-14, and bortezomib SC on days 1, 4, 8, and 11 of courses 3 and 4. Courses repeat every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Participants may receive up to 8 courses at the discretion of treating physician.
88856718|NCT03595800|Experimental|haploidentical related donors|
88856719|NCT03595800|Active Comparator|Matched unrelated donor|
89383427|NCT02187198|Experimental|Buprenorphine high dose|Participants in this arm will receive a high dose (16-24mg) of buprenorphine for 12 weeks.
89383428|NCT03672942|Experimental|Communication Skills|Male and female participants will listen to a description of John Gottman's Gentle Start-up communication skills training exercise and practice the technique in the lab for approximately 8 minutes.
89383429|NCT03672942|Experimental|Mindfulness|Male and female participants will listen to a script about Acceptance/Willingness of unwanted emotions written by Amie Zarling and practice this technique in the lab for approximately 8 minutes.
89383430|NCT03672942|Placebo Comparator|Placebo|Male and female participants will listen to music in lieu for 8 minutes.
89383431|NCT02642029|Experimental|Intermittent TBS (iTBS)|Single session of intermittent theta-burst stimulation (600 pulses in blocks of 2s, separated by 8s of pause) to cerebellar vermis.
88856720|NCT03023670|Active Comparator|Group A|This group will include patients with low flow of mixed oxygen / air (1:1L) during the period of cardiopulmonary bypass
88856721|NCT03023670|Active Comparator|Group B|This group will receive low rate (4\min) with low tidal volume ( 2ml/kg ) during the period of cardiopulmonary bypass.
89383432|NCT02642029|Active Comparator|Continuous TBS (cTBS)|Single session of continuous theta-burst stimulation of 600 pulses to cerebellar vermis.
89383433|NCT02642029|Sham Comparator|Sham TBS|Single session, using the exact same procedures as the active arms but with a sham coil, which is designed to induce the same nonspecific sensory effects of TMS (auditory and somatosensory activation) without inducing the neuromodulatory magnetic fields.
89383434|NCT04058574|Active Comparator|ACL|"Intervention Group ACL: 30 patient, athletes, with ACL deficiency candidate to a surgical ACL reconstruction"
88856722|NCT03023592|Experimental|Iguratimod|Patients are treated with Iguratimod 25 mg Twice a day for 24 weeks.
89535116|NCT04493879|Experimental|Bioptron Light Therapy (BLT) group|Received Bioptron Light Therapy (BLT) ten minutes every day for one month plus the routine medical treatment of oral mucositis(Analgesics, anti-inflammatory medication and antimicrobial therapy for any new mouth infections
89535117|NCT04493879|Experimental|Routine medical care group|Received only the routine medical care of oral mucositis for one month this consists of analgesics, anti-inflammatory treatment, and antimicrobial treatment for any new mouth infections
89383435|NCT04058574|Placebo Comparator|Control|Control Group: 15 healthy volunteers, athletes.
89383436|NCT04058730|Experimental|LRYGBP|"Laparoscopic Roux en Y Gastric by pass surgery will be evaluated for patients of Type II DM with BMI between 27.5-32.5 kg/m2 Laparoscopic RYGB is primarily a restrictive procedure with a small element of malabsorption.~Glycosylated Haemoglobin will be used as a parameter to assess the status of Type II Diabetes for these patients to evaluate the effect of the intervention at 1 month, 3 months, 12 months and 24 months post discharge."
88856723|NCT03591666|Experimental|Study Group|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
89383437|NCT04058730|Experimental|LSG|Laparoscopic Sleeve Gastrectomy surgery will be evaluated for patients of Type II DM with BMI between 27.5-32.5 kg/m2 Laparoscopic Sleeve Gastrectomy is a pure restrictive procedure. Glycosylated Haemoglobin will be used as a parameter to assess the status of Type II Diabetes for these patients to evaluate the effect of the intervention at 1 month, 3 months, 12 months and 24 months post discharge
88856724|NCT04196946|Experimental|Group I|25 mcg fentanyl intrathecally
88856725|NCT04196946|Experimental|Group II|250 mcg alfentanil intrathecally
88856726|NCT04199208|Active Comparator|Standard Care Arm|Standard perioperative care is given.
88856727|NCT04199208|Experimental|Interventional Arm|Intervention of prehabilitation and immunonutrition is given prior to surgery
88856728|NCT03591588|Active Comparator|high-saturated fat diet|Diet high in saturated fat (~50% calorie from fat, ~25% from saturated fat)
88856729|NCT03591588|Active Comparator|low-fat diet|Diet with low fat (~25% calorie from fat)
88856730|NCT04194918|Experimental|Prevention (Flexiquit+, text message, handout)|Individuals will be recruited to use the Flexiquit+ program consisting of 6 sessions, each lasting approximately 25 minutes. Participants will also receive text messages providing motivational messages and review information discussed in the program. At the end of the intervention, participants will receive an email with all of the session handouts.
88856731|NCT04747938|Experimental|Energy accumulator|Energy Accumulator was a portable handheld device invented for local heat therapy for healthcare purpose. All subjects treated with thermal therapy using the Energy Accumulator by acupoint concepts.
88856732|NCT04747938|Experimental|Home exercise program|Home exercises aimed at providing gentle mobilization at the shoulder and were capable of carrying out at home. Patients were requested to perform the movements on a daily basis within the first 4 weeks of treatment. Four movements were involved: Movement 1 - Pendular Exercise, Movement 2 - Circle Exercise, Movement 3 - Wall Climbing Exercise, and Movement 4 - Lie on bed and move both arms up and down.
88856733|NCT03023904|Experimental|Treatment (nivolumab)|Patients receive nivolumab IV over 30 minutes on day 1. Courses repeat every 2 weeks for up to 2 years (104 weeks) in the absence of disease progression or unacceptable toxicity.
88856734|NCT03966768|Experimental|Duramesh suturable mesh for laparotomy closure|Patients undergoing a midline laparotomy for trauma or emergency surgery will be closed with Duramesh suturable mesh.
88856735|NCT03966768|Experimental|Conventional suture closure for laparotomy closure|Patients randomized to conventional laparotomy closure will be closed using size 1 slowly-absorbing polydiaxonone (PDS) single strand or looped suture, based on surgeon preference.
89383438|NCT04058730|Experimental|SMM|"Standard Medical Management will be evaluated for patients of Type II DM with BMI between 27.5-32.5 kg/m2 Standard Medical management will be as per the recommendation of ADA 2010 guidelines.~Glycosylated Haemoglobin will be used as a parameter to assess the status of Type II Diabetes for these patients 1 month, 3 months, 12 months and 24 months post consult"
88856736|NCT03966768|Experimental|Open abdomen group closed in delayed fashion with Duramesh|Patients undergoing delayed primary closure of an open abdomen will also be studied. 20 study patients undergoing delayed primary closure of an open abdomen will be closed with Number 1 or Number 2 Duramesh
88856737|NCT04406922|Experimental|Intervention group|Cold exposure in the morning and evening.
88856738|NCT03591198|Experimental|Qigong Training|
88856739|NCT03591198|Active Comparator|Cognitive Training|
88856740|NCT04196400|Active Comparator|Steroid injection|Steroid (betamethasone) 2 ml is injected subcutaneously after finishing the operation at the repair site.
88856741|NCT04196400|No Intervention|Control Group|
88856742|NCT04021758|Experimental|Peer to peer program intervention|The experimental condition for the proposed project is the Airman's Edge program, a peer to peer program in which peer mentors will be trained to provide a series of interventions aimed at reducing risk for suicidal behaviors both directly and indirectly through the targeting of emotion dysregulation, cognitive rigidity, and contextual risk factors (e.g., insomnia, meaning in life, social support, firearm availability).
88856743|NCT04021758|No Intervention|Wait list|
88856744|NCT04196322||Controlled|
88856745|NCT04196322||Uncontrolled|
88856746|NCT04196088|Active Comparator|Ultivision AI Software enhanced screening colonoscopy|Ultivision Artificial Intelligence enhanced screening colonoscopies will be performed.
88856747|NCT04196088|Placebo Comparator|No AI enhancement screening colonoscopy|Screening colonoscopies without Artificial Intelligence enhancement will be performed.
89383439|NCT02639923||Minor head injury CCT pos. group|Tbi patients with acute lesion on early cranial computed tomography. Patients consent to have 7ml peripheral blood to be drawn.
89383440|NCT02639923||Minor head injury CCT neg. group|Tbi patients without acute lesion on early cranial computed tomography. Patients consent to have 7ml peripheral blood to be drawn.
89383441|NCT02639923||Control Group (healthy volunteers)|Volunteers without history, signs or symptoms of acute traumatic injuries. Volunteers consent to have 7ml peripheral blood to be drawn.
89383442|NCT01314625||one arm|
88856748|NCT04196166||Cases|nested from on going retrospective cohort study. Participants who had change in their surgical plan after hospitalization.
88856749|NCT04196166||Controls|nested from on going retrospective cohort study. Participants who didn't have change in their surgical plan after hospitalization.
88856750|NCT03591042|Experimental|cervical length screening|cervical length screening
88856751|NCT03591042|No Intervention|no screening|no screening
88856752|NCT04195932|Experimental|Exercise|6 moths of supervised moderate intensity aerobic and resistive exercise training
88856753|NCT03590886||total response Group|The PBC patients show biochemical response for UDCA treatment more than 1 year according to Paris-I/II standard
89383443|NCT05239897|Experimental|postoperative delirium|We will use Confusion Assessment Method (CAM) to determine the incidence of postoperative delirium in participants twice per day. We will use the Memorial Delirium Assessment Scale(MDAS)and Mini-mental state examination(MMSE) to examine postoperative delirium severity.
88856754|NCT03590886||poor response group|The PBC patients show poor biochemical response for UDCA treatment more than 1 year according to Paris-I/II standard
88856755|NCT03972774|Other|Cardiac PET stress testing and test-dependent management|Subjects randomized to the cardiac PET stress test strategy will receive appropriate subsequent care depending on the outcome of the cardiac PET scan (i.e., depending on whether ischemia is present or not).
88856756|NCT03972774|Other|Management without stress-imaging|Subjects randomized to the CAC-only arm will receive appropriate non-PET driven medical clinical management and follow-up.
88856757|NCT03023436|Experimental|CRS + HIPEC + Systemic Chemotherapy|"Cytoreductive surgery(CRS) followed by Hyperthermic Intraperitoneal Chemotherapy(HIPEC) and systemic chemotherapy will be performed for the treatment of patients assigned to this group.~CF regimens or other first line regimens based on Fluoropyrimidine and Cisplatin according to the National Comprehensive Cancer Network（NCCN） Guidelines （Gastric Cancer，version 3.2016) are recommended.Regimens and dosing schedules are not limited in this trial."
88856758|NCT04020042|Experimental|Ultrasound imaging guidance|Determination of epidural needle site by using ultrasound guidance
88856759|NCT04020042|Active Comparator|Traditional landmark palpation|Depermination of epidural needle site by using traditional landmark method
88856760|NCT04026594|Experimental|Mindfulness Based Stress Reduction (MBSR)|"306 participants will be randomized in the MBSR program, consisting of 8 weekly sessions lasting 2 and half hours each. In addition to this, they will be asked to complete 30 minutes of home practice each day. In order to avoid forgetting techniques and to reinforce motivation, a MBSR recall session will be offered six month after intervention.~All the sessions may be carried out remotely, by videoconference. In this case, both programs should be conducted in this way in order to ensure comparability.."
88856761|NCT04026594|Active Comparator|Progressive Muscle Relaxation Training (PMRT)|"306 participants will be randomized in a relaxation program, consisting of 8 weekly sessions lasting 2 and half hours each. In addition to this, they will be asked to complete 30 minutes of home practice each day. In order to avoid forgetting techniques and to reinforce motivation, a relaxation recall session will be offered six month after intervention.~All the sessions may be carried out remotely, by videoconference. In this case, both programs should be conducted in this way in order to ensure comparability"
88856762|NCT04025424||Skin melanoma, retrospective|"1) Clinically and morphologically verified diagnosis of skin melanoma or melanoma metastases without an identified primary lesion;~2) The availability of basic clinical information about the patient and the course of his illness;"
88856763|NCT04025424||Hodgkin disease, retrospective|"1) Clinically and morphologically verified diagnosis of Hodgkin disease (any histological variant);~2) The availability of basic clinical information about the patient and the course of his illness;"
88856764|NCT04025424||Uveal melanoma, retrospective|"1) Clinically and morphologically verified diagnosis of uveal melanoma (any histological variant);~2) The availability of basic clinical information about the patient and the course of his il"
88856765|NCT04025424||Skin melanoma, proscpective|"1) Clinically and morphologically verified diagnosis of metastatic melanoma;~2) The availability of basic clinical information about the patient and the course of his illness;"
88856766|NCT04025424||Lung cancer, procpective|"1) Clinically and morphologically verified diagnosis of metastatic or inoperable squamous cell lung cancer;~2) The availability of basic clinical information about the patient and the course of his illness;~3) The presence of indications for therapy with a PD-1 or PD-L1 inhibitor in the standard dosage in monotherapy;"
88856767|NCT04023396|Experimental|ABX464 50mg|All subjects will receive ABX464 administered at 50 mg o.d for an overall period of 96 weeks.
88856768|NCT04195464|Experimental|DN|
88856769|NCT04195464|Sham Comparator|Sham-DN|
88856770|NCT04195464|No Intervention|Control|
88856771|NCT04195386|Experimental|Chemically activated Composite resin Alkasite|Single placement of composite resin on atypical cavities.
88856772|NCT04195386|Active Comparator|Resin-Modified Glass ionomer Cement|Single placement of Resin-Modified Glass ionomer Cement on atypical cavities.
88856773|NCT04195152||Difficult intubation group|An intubation is called difficult if a normally trained anesthesiologist needs more than 3 attempts or more than 10 min for a successful endotracheal intubation.
88856774|NCT04195152||Non difficult intubation group|An intubation is called non difficult if a normally trained anesthesiologist needs only one attempt for a successful endotracheal intubation.
88856775|NCT04195074|Experimental|ETV group|100 patients would receive treatment of oral entecavir (ETV) 0.5 mg once per day from baseline to life-long.
88856776|NCT04195074|Experimental|TDF group|100 patients would receive treatment of oral tenofovir disoproxil fumarate (TDF) 300 mg once per day from baseline to life-long.
88856777|NCT04195074|Experimental|TAF group|100 patients would receive treatment of oral tenofovir alafenamide (TAF) 25 mg once per day from baseline to life-long.
88856778|NCT04194762|Experimental|treadmill training|Three training sessions per week for two months of treadmill. The intensity of exercise is monitored through the heart rate (HR). Patients ought to maintain a HR between 40 and 50% of the reserve HR
88856779|NCT04194762|Active Comparator|Cycling|Three training sessions per week for two months of cycling. The intensity of exercise is monitored through the heart rate (HR). Patients ought to maintain a HR between 40 and 50% of the reserve HR
88856780|NCT03971838|Experimental|Intervention Arm|Women with a history of gestational diabetes will be offered 4-6 months of a diabetes prevention program.
88856781|NCT04029792|Experimental|Combination of Plant Extracts (BSL_EP028)|Volunteers will take twice at day for 8 weeks a capsule containing the combination of a plant extracts (BSL_EP028)
88856782|NCT04029792|Placebo Comparator|Placebo|Volunteers will take twice at day for 8 weeks a capsule containing maltodextrin.
88856783|NCT04029948|Active Comparator|laser ERBT|Laser En Bloc Resection Of bladder Tumor
88856784|NCT04029948|Active Comparator|electro-surgical ERBT|electro-surgical En Bloc Resection Of bladder Tumor
88856785|NCT03590262|Experimental|metformin|patients take metformin 500mg twice or three times a day as add-on therapy to insulin for 3 months ,using self-control method.
88856786|NCT03590184||patients with a biological prosthesis|patients who have received a biological prosthesis
88856787|NCT03590184||patients with a biosynthetic resorbable prosthesis|patients who have received a biosynthetic resorbable prosthesis
88856788|NCT04029636||Established LONIPC|The first cohort will comprise of patients with established LONIPCs and the investigative procedures in this study will provide data on the scope of abnormalities and pathology across the spectrum of these conditions.
88856789|NCT04029636||Trajectory of LONIPC|The second, prospectively followed, cohort will provide data on the sequence and temporal development of these abnormalities, and therefore provide information on the trajectory of LONIPCs
88856790|NCT04029402||Diabetic kidney disease|Patients with archived biopsies with a pathologic diagnosis of diabetic kidney disease, interstitial fibrosis/tubular atrophy, or nephrosclerosis.
88856791|NCT04029402||Healthy controls|Potential living donors with archived biopsies performed as part of their donor workup and with no diagnostic abnormalities
88856792|NCT04029558|Experimental|Combination of plant extracts (BSL_EP024)|The volunteers will take two capsules daily with a combination of plant extracts (BSL_EP024)
88856793|NCT04029558|Placebo Comparator|Placebo|The volunteers will take two capsules daily with maltodextrin.
88856794|NCT04194684|Experimental|Assigned Interventions|Nab-paclitaxel
88856795|NCT03590106|Experimental|Peer Recovery Support Program|"Patients enrolled in the Peer Recovery Support Program will:~Actively engage in the program as defined by meeting with a Peer Support Volunteer at least two times prior to discharge, and or use of resilience journal, and or review of NA book.~Demonstrate negative drug screens done randomly during their hospitalization.~Actively contact at least one outpatient recovery program that they might enroll in prior to discharge (information about recovery programs to be provided by unit SW).~Demonstrate appropriate changes in their SOCRATES 8D survey scores from admission to program to post discharge.~Participate in follow up phone call with completion of SOCRATES 8D survey at 30 and 60 days post discharge."
88856796|NCT04194294|Active Comparator|Liocaine|Group Lid
88856797|NCT04194294|Active Comparator|Na CL 0.9%|group C
88856798|NCT04029324|Active Comparator|Immediate implant placement|Implants are placed immediately after extraction
88856799|NCT04029324|Placebo Comparator|Early implant placement|Implants are placed 4-8 weeks after extraction
88856800|NCT04029090|Experimental|Sequence 1|Subjects will receive a single intravenous dose of MCI-186 as a 1-hour infusion in the treatment sequence: first Treatment A, then Treatment C, then Treatment B (Treatment A= 60 mg of MCI-186, Treatment B= 300 mg of MCI-186, treatment C=0.9% w/v saline)
88856801|NCT04029090|Experimental|Sequence 2|Subjects will receive a single intravenous dose of MCI-186 as a 1-hour infusion in the treatment sequence: first Treatment B, then Treatment A, then Treatment C (Treatment A= 60 mg of MCI-186, Treatment B= 300 mg of MCI-186, treatment C=0.9% w/v saline)
88856802|NCT04029090|Experimental|Sequence 3|Subjects will receive a single intravenous dose of MCI-186 as a 1-hour infusion in the treatment sequence: first Treatment C, then Treatment B, then Treatment A (Treatment A= 60 mg of MCI-186, Treatment B= 300 mg of MCI-186, treatment C=0.9% w/v saline)
88856803|NCT04193982|Experimental|Saraglitazar|Patients will receive Saraglitazar 4 mg once daily for 6 months
88856804|NCT04193982|Experimental|Vitamin E|Patients will receive Vitamin E 400mg twice daily for 6 months
88856805|NCT04193982|Experimental|Combination|Patients will receive combination of Saraglitazar 4 mg once daily and Vitamin E 400mg twice daily for 6 months
88856806|NCT04193982|Active Comparator|Lifestyle|Patients will follow instruction from dietician and life style changes advise as per protocol including targeting 7 to 10percent weight loss in 6 months
88856807|NCT04028778|Experimental|Gefitinib + Anlotinib|Patients will be treated with Gefitinib 250mg, p.o., qd and anlotinib hydrochloride capsule 12mg, p.o., qd, D1-D14; take on an empty stomach (take at the same time every day as possible), every 3 weeks for a cycle.
89002946|NCT06004726|Experimental|Experimental and control|Experimental group will get 4 module of intervention
88856808|NCT04028778|Placebo Comparator|Gefitinib + Placebo|Patients will be treated with Gefitinib 250mg, p.o., qd and placebo to simulate anlotinib hydrochloride capsule 12mg, p.o., qd, D1-D14; take on an empty stomach (take at the same time every day as possible), every 3 weeks for a cycle
88856809|NCT04028856||Continuous interferon treatment group|Patients with chronic hepatitis B treated with continuous interferon for 48 weeks
88856810|NCT04028856||Intermittent interferon treatment group|patients with chronic hepatitis B treated with intermittent interferon for 48 weeks, in which interferon therapy was intermittent for 3 months
88856811|NCT03594474|No Intervention|control group|Begins treatment with 0.5 g/kg per day of 20% Intravenous Lipid Emulsion (IVLE) after birth if the birth weight is less or equal 1000g or 1 g/kg per day if birth weight is more than 1000g. The IVLE dose in this group will be increased by 0.5 g/kg per day daily until reaching 3 g/kg per day.
88856812|NCT03594474|Experimental|experimental group|"The experimental group will begin treatment with 2 g/kg per day of 20% Intravenous Lipid Emulsion after birth.~The dose of IVLE will be increased directly from 2 to 3 g/kg per day the next day in this group."
88856813|NCT04028544|Experimental|The Treatment Group|standard treatment + Qishenyiqi dropping pills (QSYQ) (oral use, 1 bag each time, three times a day)
88856814|NCT04028544|Placebo Comparator|The Control Group|standard treatment + placebo (oral use, 1 bag each time, three times a day).
88856815|NCT04406220|Active Comparator|Small clog size|
88856816|NCT04406220|Active Comparator|Large clog size|
88856817|NCT04193592|Experimental|Oral Pirfenidone 2403 mg per day|Enrolled subjects will receive oral pirfenidone 801 mg taken three times a day. Pirfenidone will be supplied in 267 mg capsules.
88856818|NCT03964272|Experimental|ExAblate 4000 System|Exablate bilateral treatment for Parkinson's Disease Motor Features
88856819|NCT03963102|Active Comparator|Control Group 3 hours|Application of Ameluz for 3 hours.
88856820|NCT03963102|Experimental|Trial Group 4 hours|Application of Ameluz for 4 hours.
88856821|NCT03599856|No Intervention|"Before control group"|Control group with observation of current local standard of care with paper checklist available at the bedside during the ICU rounds of the ICU physicians (as usual)
88856822|NCT03599856|Experimental|"After Intervention group"|An mini Ipad providing TraceBook' intelligent dynamic clinical checklists during the ICU rounds of the ICU physicians.
88856823|NCT04193358|Experimental|FERTILIS HOMME® group (group A)|Group A will receive 2 FERTILIS HOMME capsules twice daily to be taken with meals for 3 months.
88856824|NCT04193358|Placebo Comparator|Placebo group (group B)|Group B will receive 2 placebo capsules twice daily to be taken with meals for 3 months
88856825|NCT04193748|Active Comparator|Control group|Topical triamcinolone acetonide 0.1% available commercially (Kenacort- in orabase) has been used. Topical corticosteroid treatment has be repeated four times per day for four weeks.
88856826|NCT04193748|Experimental|Group S|Topical pomegranate seeds extract treatment has been repeated four times per day for four weeks.
88856827|NCT04193748|Experimental|Group P|Topical pomegranate peel extract treatment has been repeated four times per day for four weeks.
88856828|NCT04028154|Experimental|ESP Block|
88856829|NCT04028154|Active Comparator|TLIP Block|
88856830|NCT04028076|Experimental|Peers LEAD|8-week educational behavioral intervention
88856831|NCT04027764|Experimental|Toripalimab Combined With S1 and Albumin Paclitaxel|
88856832|NCT04027842|Experimental|Prewarming group|Participants in Prewarming group was warmed with forced air warming device (WarmTouch WT 6000 Warming Unit, Medtronic, Minneapolis, MN, USA) over the entire body for 10 minutes before anesthesia was induced in the operating theater. All participants received active warming with forced air warming system from the initiation of anesthetic induction until end of surgery.
88856833|NCT04027842|No Intervention|Non-prewarming group|In Non-prewarming group, no active warming was conducted before induction of anesthesia. Only standard care was provided with introperative active warming with forced air warming system from the initiation of anesthetic induction until end of surgery.
88856834|NCT04192890|Experimental|IRE patients|patients who will underwent 'Focal irreversible electroporation of the prostate cancer'
88856835|NCT03592602|Experimental|arm movement|Male or female patients, age ≥ 18, who meet the indication of PICC placement and be able to move the arm (abducted and adducted) with compliance will be studied.
88856836|NCT04027530|Experimental|Ertugliflozin 15mg once daily|Once daily treatment with oral ertugliflozin (steglatro) 15mg for 4 consecutive weeks.
88856837|NCT04027530|Placebo Comparator|Placebo|Once daily treatment with a placebo pill for 4 consecutive weeks.
88856838|NCT03023358|Experimental|chidamide regimen|patients receive chidamide (30mg twice every week) po, cyclophosphamide (750mg/m2) iv on day 1, liposomal doxorubicin (30mg/m2) iv on day 1, vincristine (1.4mg/m2, max to 2mg) iv on day 1 and prednisone (100mg/d) po on day 1-5.
88856839|NCT03023358|Active Comparator|CDOP regimen|patients receive cyclophosphamide (750mg/m2) iv on day 1, liposomal doxorubicin (30mg/m2) iv on day 1, vincristine (1.4mg/m2, max to 2mg) iv on day 1 and prednisone (100mg/d) po on day 1-5.
88856840|NCT03023280||Patients undergoing radio frequency ablation|Patients undergoing radio frequency for large symptomatic heterotypic gastric mucosa
88856841|NCT04192812|Experimental|GnRHa|3,75 MG LEUPROLIDE ACETATE FOR EVERY 4 WEEKS THROUGHOUT 3 MONTHS BEFORE SURGERY
88856842|NCT04192812|Placebo Comparator|no GnRHa|NO TREATMENT
88856843|NCT04192578|Experimental|Unilateral upper limb 60mmHg RIC|RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on unilateral upper limb and inflated to 60 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeatedly for 5 times.
88856844|NCT04192578|Experimental|Bilateral upper limb 60mmHg RIC|RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on bilateral upper limb and inflated to 60 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeatedly for 5 times.
88856845|NCT04192578|Experimental|Unilateral upper limb 200mmHg RIC|RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on unilateral upper limb and inflated to 200 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeatedly for 5 times.
89002947|NCT06004726|No Intervention|Control|control group will not get intervention ,Information Booklet and video assisted teaching will be given after posttest
89002948|NCT05989048|Experimental|Zavegepant|Zavegepant intranasal 10 mg
89383444|NCT05239819|Experimental|Intervention group|We conducted a fully engaged inspiratory muscle training (IMT) program. The exercise group received the intervention threshold IMT from preoperative to postoperative undergoing upper abdominal surgery. The IMT was started before 3 weeks of operation and surveyed in the followed 4 weeks.
89383445|NCT05239819|Active Comparator|Usual care group|The Usual care group will receive regulated education.
89383446|NCT04969705|Active Comparator|Group A (spinal Dexmedetomidine)|. Spinal needles (22 G) will be introduced in sitting position after skin disinfection with povidine iodine, iliac crest will be palpated and thumb extended to meet the midline, feeling the space between L4 and L5. spinal needle penetrates through the dura matter, a pop will be felt and then after the needle puncture into the subarachnoid space and the appearance of clear cerebrospinal fluid, the intrathecal local anesthetic will be injected. All patients will be receiving 2 ml heavy bupivacaine 0.5% plus 5 µg dexmedetomidine to total volume of 2.5 ml.
89383447|NCT04969705|Active Comparator|Group B (spinal with transversus abdominus plane block)|Spinal needles (22 G) introduced in sitting position . patients receiving1.7 to 2.2 ml heavy bupivacaine 0.5%( according to weight and height ) + 1 ml normal saline = total volume of 2.5 ml then at surgery end under sonographic guide transducer placed in transverse plane above iliac crest.A 90 mm 22 G short beveled block needle inserted in-plane with transducer, in anterior-posterior direction. needle connected to syringe contains20 ml of bupivacaine 0.25%+10 µg dexmedetomidine to deposit local anesthetic deep into the fascial layer between internal oblique & transversus abdominis muscles on each side.
89383448|NCT04969705|Active Comparator|Group C ( controlled group ) Spinal Anesthesia only :|Patients will be anesthetized only with spinal anesthesia using Bupivacaine Hcl( 10 mg).
89383449|NCT03676374|Experimental|Prucalopride|Prucalopride 2mg once a day as add-on for PPI 2x/d
89383450|NCT03676374|Placebo Comparator|Placebo|Placebo once a day as add-on for PPI 2x/d
89383451|NCT03178669|Experimental|Cobitolimod Dose 2x31 mg|Dose 31 mg of cobitolimod at 2 occasions, placebo at 2 occasions
89383452|NCT03178669|Experimental|Cobitolimod Dose 2x125 mg|Dose 125 mg of cobitolimod at 2 occasions, placebo at 2 occasions
88856846|NCT04192578|Experimental|Bilateral upper limb 200mmHg RIC|RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on bilateral upper limb and inflated to 200 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeatedly for 5 times.
88856847|NCT04192578|Experimental|Unilateral lower limb 60mmHg RIC|RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on unilateral lower limb and inflated to 60 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeatedly for 5 times.
88856848|NCT04192578|Experimental|Bilateral lower limb 60mmHg RIC|RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on bilateral lower limb and inflated to 60 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeatedly for 5 times.
88856849|NCT04192578|Experimental|Unilateral lower limb 200mmHg RIC|RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on unilateral lower limb and inflated to 200 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeatedly for 5 times.
89383453|NCT03178669|Experimental|Cobitolimod Dose 2x250 mg|Dose 250 mg of cobitolimod at 2 occasions, placebo at 2 occasions
88856850|NCT04192578|Experimental|Bilateral lower limb 200mmHg RIC|RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on bilateral lower limb and inflated to 200 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeatedly for 5 times.
88856851|NCT04407000|Experimental|Test Drug|Loqular 200 mg Film Tablet containing 200 mg favipiravir (World Medicine İlaç-Turkey)
88856852|NCT04407000|Active Comparator|Reference drug|Avigan 200 mg Film Tablet containing 200 mg favipiravir (Toyama Chemical Industry Co.Ltd./Japan)
88856853|NCT04192656|Experimental|PAP plus medication|patients treated by both PAP and medication
89383454|NCT03178669|Experimental|Cobitolimod Dose 4x125 mg|Dose 125 mg of cobitolimod, at 4 occasions
89383455|NCT03178669|Placebo Comparator|Placebo|Placebo at four occasions
89002949|NCT05989048|Placebo Comparator|Placebo|Placebo
89002950|NCT05987566|Experimental|Morning Meal Challenge|
89002951|NCT05987566|Experimental|Late Night Meal Challenge|
89383456|NCT01330147||Tonsillectomy|Subjects undergoing tonsillectomy for non-cancer reasons including operations for: recurrent tonsillitis, asymmetric tonsils, snoring surgery or obstructive sleep apnoea.
89383457|NCT03178201|Experimental|TGR-1202|Patients with relapsed or refractory grade 1, 2, or 3A follicular lymphoma will receive TGR-1202.
89383458|NCT04833127|Active Comparator|Masibambane - Gender-Enhanced|"A virtual (online) group-based interactive Gender-Enhanced (GE) Workshop (using the WhatsApp® platform). The intervention has components that are conducted by participants on their own time as well as a real-time live interactive session."
89383459|NCT04833127|Other|Individually accessed|In this condition women are given access to a PrEP video and to websites that provide information on PrEP and on contraception options.
89383460|NCT03021642|Experimental|First Tepotinib Test, Then Tepotinib Reference|
89383461|NCT03021642|Experimental|First Tepotinib Reference, Then Tepotinib Test|
89383462|NCT01656564||Healthy Controls|Individuals with no known history of HIV
89383463|NCT01656564||Healthy Controls - Questionnaire Group|Individuals with no known history of HIV
89383464|NCT01656564||HIV|Individuals who acquired HIV in early life
89383465|NCT00354120|Experimental|1|Alentuzumab
89383466|NCT00354120|Active Comparator|2|Globulina antilinfocitaria
89383467|NCT04058808|Experimental|Participants with Atrial Fibrillation attending the clinic.|
88818628|NCT02703909|Experimental|deep NMB + 15 mm IP|participants will be given the muscle relaxant, rocuronium, iv to obtain a deep NMB which is defined as 0-1 posttetanic counts on a neuromuscular junction monitor and the initial insufflating pressure will be 15 mm Hg. The initial insufflation pressure for the laparoscopy will be 10 mm Hg pressure.
88818629|NCT05747651||Active SLE|"Patients will undergo regular follow-up where routine clinical examination and laboratory assessments will be conducted, and biological samples will be obtained. The patients will be instructed to contact their center whenever they develop a symptom suspicious of flare. In such cases, an unscheduled visit will be conducted for clinical examination, assessment and sampling similar to the last visit.~If a patient needs a major change in therapy at one of the scheduled visits or at an unscheduled visit, an early termination (ET) visit will be planned. Patients requiring a major change in therapy due to active disease (defined as BILAG A or B) from week 12 through week 52 will undergo two additional evaluations at week +26 and at week +52 from the time of early termination/new therapy initiation in order to determine biomarkers of secondary response after the change in therapy (herein termed secondary response) and persistent non- response (herein termed refractory disease)."
89383468|NCT00169806|Other|cohort|Subjects who are scheduled to undergo a percutaneous kidney stone removal who do not have complicated comorbidities
88818630|NCT03759561|Active Comparator|Videolaryngoscope group|In the videolaryngoscope group, tracheal intubation was performed using videolaryngoscope under cervical collar application.
89383469|NCT03669900|Other|a minimally invasive surgery (SERI)|The surgery consisted of varus traction, skin incision, metatarsal osteotomy and K- wire insertion. All the cases were done by the senior consultant orthopedic surgeon, including preoperative planning, the osteotomy itself and the follow up in the clinic. Another orthopedic surgeon was involved in collecting the data, doing all the measurements preoperative and postoperative and assisting the primary surgeon during the surgery.
88856854|NCT04192656|Active Comparator|medication|patients treated by medication only
88818631|NCT03759561|Active Comparator|Fiberoptic bronchoscope group|In the fiberoptic bronchoscope group, tracheal intubation was performed using fiberoptic bronchoscope via oral cavity under cervical collar application.
88856855|NCT04191954|Active Comparator|Fasudil eye drops (concentration 0.5 percent)|twice daily
88856856|NCT04191954|Placebo Comparator|receive artificial tears drop with the same frequency|
88856857|NCT04192032|Experimental|Preferred flavor (5% nicotine)|Preferred flavor Juul pod (5% nicotine)
88856858|NCT04192032|Active Comparator|Classic Tobacco Flavor|Control flavor (5% Classic Tobacco flavor Juul pod)
88856859|NCT04192032|Experimental|Preferred flavor with HWL|Preferred flavored Juul pod (5% nicotine) with HWL
88856860|NCT04192032|Experimental|Preferred flavor (3% nicotine)|Preferred flavored Juul pod (3% nicotine)
88856861|NCT04192032|Experimental|Preferred flavor (0% nicotine)|Preferred flavored Juul pod (0% nicotine)
88856862|NCT04027062|Other|Diabetes Continuing Education Program|"the physicians will be assessed before and after intervention~the intervention group will be enrolled to the intervention program proposed to be (lecture + interactive workshop + group discussion + role play)"
88856863|NCT04026828||Periodontitis Group|Chronic periodontitis and aggressive periodontitis patients
88856864|NCT04026828||Control Group|Both periodontal and medically healthy volunteers.
88856865|NCT04192188||ART-Group|Patients undergoing supportive periodontal therapy and independently antiresorptive therapy.
88856866|NCT04192188||Control Group|Patients undergoing supportive periodontal therapy without the need for antiresorptive therapy.
88856867|NCT04191408|Experimental|Mechanically ventilated patients after surgery|After ICU admission the patient's hemodynamics (MAP, HR, CO, PPV) will be measured in supine position. It will be remeasured after PEEP has been increased from +5 to +15 cmH20. Then the baseline measurement will be repeated. Then passive leg raise will be performed and all the parameters will be remeasured.
88856868|NCT04191564|Experimental|low perfusion|fluid restriction based on the goal directed fluid therapy is maintained during the whole case and a state of low perfusion is created by reducing the systolic blood pressure below 100 mmHg by vasoactive medications like cleviprex or nicardipine, by increasing positive end expiratory pressure (PEEP) and by a very short period of a high IAP of 20 mmHg only during firing.
88856869|NCT04191564|Experimental|normal perfusion|Perfusion pressure is maintained above 100 mmHg with free fluid loading iv and the lowest IAP possible during the whole procedure.
88856870|NCT04195620|Experimental|Low loneliness, low self-disclosure|Individuals in this arm report lower levels of loneliness than the mean level reported by similar individuals. They will start the study in the low self-disclosure group which involves questions that are unlikely to involve meaningful personal disclosure. All members of this group will also complete the high self-disclosure condition later in the study.
89383470|NCT03023046|Experimental|Treatment (chemotherapy)|Patients receive etoposide IV over 96 hours, doxorubicin IV over 96 hours, and vincristine sulfate IV over 96 hours on days 1-4. Patients also receive cyclophosphamide IV over 1 hour on day 5 and prednisone PO BID on days 1-5. Patients who are Ph+ also receive imatinib mesylate or dasatinib PO QD on days 1-14. Patients who are CD20+ also receive rituximab IV on day 1 or day 5. Cycles repeat every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity.
89383471|NCT03668262||0.15mg/ kg group|Administration method of cis-atracurium: the dose of the first patient is 0.15 mg / kg, and the ratio between adjacent doses is 1.5. If the laryngeal mask insertion condition of this patient is satisfactory, the next patient will use the lower dose. If the laryngeal mask insertion condition of this patient is not satisfactory, the next patient will use a higher dose. Starting from the first case of dissatisfaction, the number of observation units is counted. Dissatisfaction - satisfaction occurs at 7 exchange points and then the test ends.
89383472|NCT03668262||0.1mg/ kg group|Administration method of cis-atracurium: the dose of the first patient is 0.15 mg / kg, and the ratio between adjacent doses is 1.5. 0.15/1.5=0.1 ( If the laryngeal mask insertion condition of this patient is satisfactory, the next patient will use the lower dose. If the laryngeal mask insertion condition of this patient is not satisfactory, the next patient will use a higher dose. Starting from the first case of dissatisfaction, the number of observation units is counted. Dissatisfaction - satisfaction occurs at 7 exchange points and then the test ends.)
89383473|NCT03668262||0.07mg/ kg group|Administration method of cis-atracurium: the dose of the first patient is 0.15 mg / kg, and the ratio between adjacent doses is 1.5. 0.1/1.5=0.0667 ( If the laryngeal mask insertion condition of this patient is satisfactory, the next patient will use the lower dose. If the laryngeal mask insertion condition of this patient is not satisfactory, the next patient will use a higher dose. Starting from the first case of dissatisfaction, the number of observation units is counted. Dissatisfaction - satisfaction occurs at 7 exchange points and then the test ends.)
89383474|NCT03668262||0.05mg/ kg group|Administration method of cis-atracurium: the dose of the first patient is 0.15 mg / kg, and the ratio between adjacent doses is 1.5. 0.07/1.5=0.0466( If the laryngeal mask insertion condition of this patient is satisfactory, the next patient will use the lower dose. If the laryngeal mask insertion condition of this patient is not satisfactory, the next patient will use a higher dose. Starting from the first case of dissatisfaction, the number of observation units is counted. Dissatisfaction - satisfaction occurs at 7 exchange points and then the test ends.)
89399558|NCT02030054|Active Comparator|rosuvastatin|Patients were randomly assigned to atorvastatin (40 mg day) or rosuvastatin(20 mg day) for 30 days. After 1-week wash-out period to avoid any carryover effect, cross-over was performed, and patients were switched to the other drug which was continued for 30 days.
89399559|NCT02182622|Experimental|Dose Level -1|Docetaxel 60mg/m2 IV every 21 days Prednisone 5mg oral twice daily LDE225 200mg oral daily
88856871|NCT04195620|Experimental|Low loneliness, high self-disclosure|Individuals in this arm report lower levels of loneliness than the mean level reported by similar individuals. They will start the study in the high self-disclosure group which involves questions that are likely to involve meaningful personal disclosure. All members of this group will also complete the low self-disclosure condition later in the study.
88856872|NCT04195620|Experimental|high loneliness, low self-disclosure|Individuals in this arm report higher levels of loneliness than the mean level reported by similar individuals. They will start the study in the low self-disclosure group which involves questions that are unlikely to involve meaningful personal disclosure. All members of this group will also complete the high self-disclosure condition later in the study.
89383475|NCT03668262||0.03mg/ kg group|Administration method of cis-atracurium: the dose of the first patient is 0.15 mg / kg, and the ratio between adjacent doses is 1.5. 0.05/1.5=0.0333 ( If the laryngeal mask insertion condition of this patient is satisfactory, the next patient will use the lower dose. If the laryngeal mask insertion condition of this patient is not satisfactory, the next patient will use a higher dose. Starting from the first case of dissatisfaction, the number of observation units is counted. Dissatisfaction - satisfaction occurs at 7 exchange points and then the test ends.)
89383476|NCT03668262||0.02mg/ kg group|Administration method of cis-atracurium: the dose of the first patient is 0.15 mg / kg, and the ratio between adjacent doses is 1.5. 0.03/1.5=0.02( If the laryngeal mask insertion condition of this patient is satisfactory, the next patient will use the lower dose. If the laryngeal mask insertion condition of this patient is not satisfactory, the next patient will use a higher dose. Starting from the first case of dissatisfaction, the number of observation units is counted. Dissatisfaction - satisfaction occurs at 7 exchange points and then the test ends.)
89383477|NCT03669198|Active Comparator|NT-pro BNP group|Subjects who be included in NT-pro BNP group examined NT-pro BNP in the ED to determine the baseline level and prior to discharge for determine the percent decline from baseline level. Patients in the NT-pro BNP group can be discharged if the NT-pro BNP level decreased ≥ 30% from baseline. If the target percent decline is not met, we will do intensification of therapy according to the algorithm
89383478|NCT03669198|No Intervention|Control group|Patients in the control group were managed based on clinical judgment without use of NT-pro BNP testing. In the control group, the decision whether patient can be discharged or not was determined by cardiologist in charge of the patient based on clinical assessment.
89383479|NCT03019458|Experimental|MINGO|MINGO is a supplement consisting of local ingredients such as moringa, rice and mung beans, which can be added to any type of edible paste, food, and liquid. The experimental group is required to take 6 sachets per day for 12 weeks in addition to their regular diet. They are required to keep a daily food diary
89383480|NCT03019458|No Intervention|Control|The control group is required to eat their normal diet. They are also required to keep a daily food diary.
89383481|NCT04058340|Active Comparator|lactizole-placebo|A group of patients who will receive 3ml lactizole solution (150ppm) in nebulization twice a day for 4 weeks , and then for the next 4 weeks they will receive 2 times a day 3ml 0.9% NaCl solution in nebulization
89383482|NCT04058340|Active Comparator|placebo-lactizole|A group of patients who will receive 2 times a day for 4 weeks (0.9% NaCl solution in nebulization) for 4 weeks and will receive 3ml of lactizole solution (150ppm) in nebulization 2 times a day for 4 weeks
89383483|NCT03669120|Active Comparator|Arm I (mainstream instructional care)|Participants receive mainstream instructional care including brief advice on how to quit smoking, 10-week supply of NRT in the form of nicotine patches, and intensive print materials to promote smoking cessation.
89383484|NCT03669120|Experimental|Arm II (tailored intensive care)|Participants receive tailored intensive care including brief advice on how to quit smoking, NRT, and intensive print materials to promote smoking cessation as in Arm I. Participants also receive individualized text based messages to promote smoking cessation for 6 months.
89383485|NCT04058106||A patient who need the spine surgery|A patient who go the propofol based total intravenous anesthesia due to intraoperative neuromonitorung for spine surgery
88856873|NCT04195620|Experimental|high loneliness, high self-disclosure|Individuals in this arm report higher levels of loneliness than the mean level reported by similar individuals. They will start the study in the high self-disclosure group which involves questions that are likely to involve meaningful personal disclosure. All members of this group will also complete the low self-disclosure condition later in the study.
88856874|NCT03023982|Experimental|Pectoralic block group|After general anesthesia, 40ml of 0.25% Bupivacaine Hydrochloride will be administered before procedure Thoracotomy. Block will be administrated between pectoralis minor and serratus anterior muscle at the 3rd and 4th rib., in assistance of ultrasound for visualization anesthetic injection point.
88856875|NCT03023982|Active Comparator|Control group|Patients in this group will receive standard pain control with opioids and NSAIDs
88875375|NCT05365620|Experimental|Mechanical Inexsufflation|Patients in this are were managed for 8 hours with automatic inexsufflation treatments (CoughSync, Ruxin Medical Systems Company Ltd, Beijing, China) performed automatically every 30 minutes, and with Catheter Suction performed only if signs of airway secretion accumulation manifested
89383486|NCT04058262|Experimental|Meditation presential|
89383487|NCT04058262|Experimental|Reiki|
89383488|NCT04058262|Experimental|Meditation (app)|
89383489|NCT04058262|Placebo Comparator|round of conversation|
88875376|NCT05361876||Young Male|Healthy men with some sport experience
88875377|NCT05361876||Young Female|Healthy female with some sport experience
88875378|NCT05346276|Experimental|68Ga-DOTA-hLAG-3 PET/CT|Each participant receives a single intravenous injection of 68Ga-DOTA-hLAG-3, and undergo PET/CT imaging within the specified time.
88856876|NCT03951870|Experimental|Mesolimbic Neurofeedback|"Neuromodulation via fMRI Neurofeedback task: subjects (n=34) will participate in four fMRI-NF sessions, up-regulating activation of three mesolimbic reward nodes:~ventral tegmental area, and bilateral ventral striatum. ROIs are 5 mm spheres around peak activations in funcitonal localizer task (Monetary Incentive delay, reward anticipation contrast), within a predifned meta-analytic anatomical masks of the three regions.~anatomical masks: VTA (Midbrain): -4 -24 -10 *see below Right Nac: 12 10 -4 Left Nac: -10 10 -6 Oldham, Stuart, et al. Human brain mapping (2018).~* 23/08/22: Due to VTA complex contours, it was not restricted according to Oldham et al as mentioned above, but via more accurate VTA mask (Murty et al. 2014, NeuroImage). This was mistakenly left out of the original preregistration. It is noteworthy that, to date (23/8/22), ROI analyses haven't been performed.~Hepatitis B vaccination: subjects will receive vaccination against Hepatitis B."
88856877|NCT03951870|Active Comparator|Control Neurofeedback|"Neuromodulation via fMRI Neurofeedback task: subjects (n=34) will participate in four fMRI-NF sessions, up-regulating activation of regions comprising one of 4 control networks (5mm spheres around MNI coordinates):~Motor Imagery (Hétu, Sébastien, et al. Neurosci. & Biobehav Rev (2013)) R. Cerebellum: 32 -62 -28 L. Cerebellum: -32 -56 -30 L. Precentral Gyrus: -26 -2 58; Auditory imagery (McNorgan, Chris.Front in Human Neurosci 6 (2012)) R STG:64 -30 9 L IFG:-48 24 -5 L precentral Gyrus: -52 1 47; Arithmetic processing (Arsalidou, Marie, and Margot J. Taylor. Nuroimage (2011)) R. SPL: 29 -66 49 L. MFG (dlpfc): -45 32 29 L. precuneus: -28 -71 33; Spatial Navigation (Kühn, Simone, and Jürgen Gallinat. Human Brain Map. (2014)) R. hippocampus 26 -35 -11 L. hippocampus -26 -47 -9 L. Post. cingulate -15 -59 19~Hepatitis B vaccination: subjects will receive vaccination against Hepatitis B."
88856878|NCT03951870|Other|Natural history|"No brain manipulation (Assesment of natural history immune response).~Hepatitis B vaccination: subjects (n=17) will receive vaccination against Hepatitis B."
88856879|NCT04192110|Experimental|Diuretic initiation or augmentation|Participants will either initiate or increase the dose of a loop or thiazide-type diuretic
88856880|NCT04025736|Experimental|Patients received Tranexamic acid|The patient was assigned as intervention group, TXA will be aspirated into a syringe. In TXA group, TXA 1000 mg (20 mL) was given intravenously 10 minutes before surgery.
88856881|NCT04025736|Placebo Comparator|Patients received same volume of saline|In the control group, the patient received 20ml saline intravenous also 10 min before surgery.
88856882|NCT04766112|Experimental|Group I|Group I will receive yang style Tai chi exercises combined with mental imagery training which consist of 10 positions
88856883|NCT04766112|Active Comparator|Group II|Group B will receive yang style Tai chi exercise which consist of 10 positions
88856884|NCT04190940|Experimental|High Intensity Focused Ultrasound|Patients receiving high intensity focused ultrasound as a treatment will be asked to complete the behavioral task pre and post their treatment.
88856885|NCT04190940|Experimental|Deep Brain Stimulation|"Patients receiving deep brain stimulation as a treatment will be asked to complete the behavioral task while their DBS electrode is on and off."
88856886|NCT04195230|Experimental|Computerized Cognitive Training (Breakfast Game)|"Participants will undergo a pilot training protocol where they will have to perform two tasks concomitantly, in a multi-tasking fashion. The tasks are related to everyday activities as cooking and setting tables."
88856887|NCT04199598|Experimental|Treatment A (test product): Abediterol (2.4 μg)|Randomized subjects will receive single dose treatment of Abediterol nebuliser solution for inhalation via PARI LC SPRINT nebulizer following an overnight fast of at least 8 hours
88856888|NCT04199598|Experimental|Treatment B (Test Product): Abediterol (4.8 μg)|Randomized subjects will receive single dose treatment of Abediterol nebuliser solution for inhalation via PARI LC SPRINT nebulizer following an overnight fast of at least 8 hours
88856889|NCT04199598|Experimental|Treatment C(Test Product):Abediterol(2.4 μg)|Randomized subjects will receive single dose treatment of Abediterol nebuliser solution for inhalation via OMRON NE-C900-E nebulizer following an overnight fast of at least 8 hours
88856890|NCT04199598|Experimental|Treatment D (Reference Product): Abediterol (2.5 μg)|Randomized subjects will receive single dose treatment of Abediterol (as napadisylate) inhalation powder via dry powder inhaler (DPI) following an overnight fast of at least 8 hours
88875379|NCT04970004||Patients Diagnosed with HSCT-TMA|
89383490|NCT05654688|Experimental|Graston|Graston technique and traditional physical treatment (control)
89383491|NCT05654688|Experimental|Muscle energy technique|Muscle energy technique and traditional physical treatment
88856891|NCT04190784|Experimental|60 seconds stretching group|"Stretching exercises for upper Trapezius and Levator scapula .~From supine position , the examiner will passively place the participant's head into flexion, side-bending away and rotation towards the side to be stretched (for upper trapezius muscle) and flexion, side-bending away and rotation away from the side to be stretched (for levator scapula ). The patient introduces a light resisted effort to take the stabilized shoulder towards the ear and the ear towards the shoulder. The contraction is sustained for 10 seconds and, upon complete relaxation of effort, the therapist gently eases the head/ neck into an increased degree of side-bending and rotation, where it is stabilized, as the shoulder is stretched caudally. The examiner will depress the participant's shoulder with 100 Newton's of force measured with pressure dynamometer. Once the examiner achieved this level of force, he maintains the stretch for 60 seconds . The procedure is repeated three times."
89383492|NCT05654688|Active Comparator|Traditional physical therapy|Traditional physical therapy treatment as heat application
89383493|NCT03668964|Experimental|Vitamin B2|Daily dose of 75 mg Vitamin B2
89383494|NCT03668964|Experimental|Vitamin C|Daily dose of 500 mg Vitamin C
89383495|NCT03668964|Experimental|Vitamin B2 + C|Daily dose of 75 mg Vitamin B2 and 500 mg Vitamin C
89383496|NCT03668964|Experimental|Vitamin A|Daily dose of 250 µg Vitamin A
89383497|NCT03668964|Experimental|Vitamin D3|Daily dose of 60 µg Vitamin D3
88856892|NCT04190784|Experimental|30 seconds stretching group|The same procedures while the therapist will maintain the stretch for 30 seconds.
89383498|NCT03668964|Experimental|Vitamin E|Daily dose of 100 mg Vitamin E
89383499|NCT03668964|Placebo Comparator|Placebo|Daily dose of 575 mg microcrystalline cellulose
89383500|NCT03668886|Experimental|multimodal exercise program|Elderly in this group will receive multimodal exercise program. The duration of exercise is 60 minutes and frequency is 2 times/week.
89383501|NCT03668886|No Intervention|Control group|Elderly in this group will continue to attend community activity as usual. The activity includes active activity is 60 minutes and frequency is 2 times/week.
89383502|NCT02923830|Active Comparator|Control Group|Heparinized saline catheter flush - The control group will have their port catheters flushed with 20mL saline + 5mL heparin 100 units/mL; q 3 months
89383503|NCT02923830|Experimental|Intervention Group|Saline-only catheter flush - The intervention group will have their port catheters flushed with saline only.
88856893|NCT04190784|Experimental|15 seconds stretching group|The same procedures while the therapist will maintain the stretch for 15 seconds.
88856894|NCT04190784|Placebo Comparator|60 seconds placebo stretching group|The therapist will maintain the same manual contact without stretching force for 60 seconds
89383504|NCT03668730|Experimental|Reduced dose group|After 2 cycles of induction chemotherapy with Paclitaxel Liposome, Cisplatin and 5-Fluorouracil, patients undergo low-dose intensity-modulated radiotherapy (IMRT) 5 days per week for approximately 6 weeks (30 fractions). Patients also receive cisplatin once per three week for 3 cycles.
89383505|NCT03668730|Experimental|Standard dose group|After 2 cycles of induction chemotherapy with Paclitaxel Liposome,Cisplatin and 5-Fluorouracil, patients undergo standard-dose intensity-modulated radiotherapy (IMRT) 5 days per week for approximately 6 weeks (33 fractions). Patients also receive cisplatin once per three week for 3 cycles.
88856895|NCT04190784|Placebo Comparator|30 seconds placebo stretching group|The therapist will maintain the same manual contact without stretching force for 30 seconds
88856896|NCT04190784|Placebo Comparator|15 seconds placebo stretching group|The therapist will maintain the same manual contact without stretching force for 15 seconds
88856897|NCT03023748|Experimental|intravenous paricalcitol solutions|"Intravenous paricalcitol will be administered twice or thrice weekly post-hemodialysis with a dose based on the baseline iPTH level divided by 120.~For instance, with a baseline iPTH 1200pg/mL, an induction dose of 10mcg twice or thrice weekly will be given. The maximum weekly dose allowed is 30mcg. Subsequent dose titration may be required depending on the serum PTH level. Intravenous paricalcitol will be continued up to 24 months."
89184089|NCT02575131|Experimental|TNO Oatmeal|PepsiCo, Inc.-1 - One portion of Steel Cut oatmeal: 66.8 grams of oats boiled for 25 minutes in 500 grams of water and consumed with 307 grams of skimmed milk at TNO
89184090|NCT02575131|Active Comparator|TNO original Cheerios|PepsiCo, Inc.-2 - One portion of original Cheerios (ready to eat cereal): 70 grams prepared with 307 grams of skimmed milk and consumed with about 275 grams of water at TNO
89184091|NCT02575131|Experimental|TNO standard breakfast|"TNO breakfast: one slice of white bread with a fried egg and 200 mL orange juice. With spray oil a frying pan is prepared to fry an egg (medium size).~The breakfast is consumed at TNO"
89383506|NCT03623178||Assertive Community Treatment|"patients with DSM-5 Diagnosis of SUD and one of the following criteria (1) present important functional difficulties, in at least one of the following areas: everyday life activities and maintaining a supportive social network, for minimum two years.~or (2) difficulties to attend their health care appointments, during the last 3 months."
89383507|NCT03623178||Treatment As Usual|patients with DSM-5 Diagnosis of SUD which do not respond to ACT inclusion criteria
89383508|NCT03668652|Experimental|Focal prostate cancer treatment by HIFU|Patients with target lesion distance < 30 mm from the rectum will be treated with High Intensity Focused Ultrasound (HIFU) applied by FocalOne HIFU device and patients with lesion > 30 mm from the rectum will be treated with TULSA applied by TULSA-PRO.
89383509|NCT03668652|Active Comparator|Radical Prostatectomy|Robot assisted laparoscopic radical prostatectomy or open retro-pubic radical prostatectomy will be performed using validated radical prostatectomy technique. Nerve sparing surgery on side of cancer free prostate lobe will be performed and type of nerve sparing procedure will be specified.
89399560|NCT02182622|Experimental|Dose Level 1|Docetaxel 75mg/m2 IV every 21 days Prednisone 5mg oral twice a day LDE225 200mg oral daily
89399561|NCT02182622|Experimental|Dose Level 2|Docetaxel 75mg/m2 IV every 21 days Prednisone 5mg oral twice daily LDE225 400mg oral daily
88856898|NCT04190316|Other|Evaluation of patient and patient-care environment ESBL|ESBL-PE carriers included in the study will be sampled for evaluation of their fecal RA of ESBL-PE on day 0, 3, 5, 7, 10, 14 and weekly till day 30 or their discharge from ICU. Urine and respiratory samples will be collected on the same day to identify multiple-site colonization with ESBL-PE. Seven samples of patient care environment will be performed 2-times a week till day 30 or discharge of the patient from the ICU.
88856899|NCT04190160|Experimental|6 months treatment|replacement of whatever pre-existing hypoglicaemic therapeutic scheme, with or without insulin, with a single daily and flexible administration of IDegLira in a pilot little group of very old diabetic patients
89383510|NCT03668574|Experimental|Aerobic exercise group|Patients will firstly warm up for 5 minutes and begin training on the treadmill. There will be two weekly sessions, lasting 40 minutes, for 6 weeks, reaching a total of 12 sessions. The exercise intensity will vary from 60 to 90% of the maximum heart rate (HRmax) predicted by the percentage formula HR = HR rep + percentage (HRmax - HR rep), where HRmax = 220-age (years) and HR rep = HR obtained for five minutes of rest. Heart rate and level of subjective perception of the effort will be monitored during all sessions. Patients from this group will also be educated about their back pain by receiving a copy of The back Book.
88856900|NCT04190004|Experimental|vasopressin|All subjects will receive bot 40IU of vasopressin and saline placebo in counterbalanced design
88856901|NCT04190004|Placebo Comparator|Placebo|All subjects will receive bot 40IU of vasopressin and saline placebo in counterbalanced design
88856902|NCT04406298|Experimental|Small Quantity Paracentesis|Intermittent small quantity (upto 3L per day) paracentesis through an indwelling catheter for up to 5 days.
88856903|NCT04406298|Active Comparator|Large Volume Paracentesis|Large Volume Paracentesis > 5 litres
88856904|NCT04025892|Experimental|Tracking group|Participants will be asked to track weight daily for six weeks
88856905|NCT04406376|Active Comparator|Tapering Down of Steroids|Prednisone 1 mg/kg (max. 60 mg) daily for 7 days, 40 mg for 2 days, 20 mg for 2 days (Total 11 days)
89383511|NCT03668574|Placebo Comparator|Placebo Group|Patients will received a detuned pulsed 5-minute ultrasound and pulsed short-wave diathermy for 25 minutes, twice weekly for 6 weeks. The devices will be used with disconnected internal cables to obtain the placebo effect; however, it will be possible to manipulate the devices and adjust the doses and alarms as if they were connected, in order to simulate the pragmatism of clinical practice as well as to increase the credibility of the use of these devices in patients. Patients from this group will also be educated about their back pain by receiving a copy of The back Book.
88856906|NCT04406376|Active Comparator|No Tapering Down of Steroids|Prednisone 1 mg/kg (max. 60 mg) daily for 7 days (Total 7 days)
88856907|NCT04025268|Active Comparator|pregnant women receiving group prenatal care (GPNC)|Overweight/obese pregnant women will be recruited from the prenatal care clinic at the Lyndon B Johnson Tropical Medical Center (LBJTMC) in Pago Pago, American Samoa. These women will be randomized to receive the 10-session GPNC intervention.
88856908|NCT04025268|Active Comparator|pregnant women receiving standard of care (SOC)|Overweight/obese pregnant women will be recruited from the prenatal care clinic at the Lyndon B Johnson Tropical Medical Center (LBJTMC) in Pago Pago, American Samoa. These women will be randomized to continue with standard of care (SOC) prenatal care visits.
88856909|NCT04025346|Active Comparator|Capsimax|
88856910|NCT04025346|Placebo Comparator|Placebo|
88856911|NCT04025034|Experimental|Study Group|Use of SONOPET(R) to orbital surgery.
88856912|NCT04025112|Experimental|Armeo|Patients group (54 patients) for robotic therapy.
89184092|NCT02575131|Experimental|Home whole wheat bread yeast basis|NBC-1: four slices of whole wheat bread yeast basis (98 grams) spread with 3 cups low-fat margarine (total 30 grams) consumed with 200 mL of black coffee (without milk and sugar) or 200 mL tea (no sugar) or 200 mL of water at home
89184093|NCT02575131|Active Comparator|Home whole wheat sourdough bread|NBC-2- four slices of whole wheat sourdough bread (98 grams) with 3 cups low-fat margarine (total 30 grams) consumed with 200 mL of black coffee (without milk and sugar) or 200 mL tea (no sugar) or 200 mL of water at home
89383512|NCT03021018|Experimental|Brivaracetam (BRV) 100 mg|Two 5 ml vials of brivaracetam administered intravenously over a 2-minute period
89383513|NCT03021018|Experimental|Brivaracetam (BRV) 200 mg|Four 5 ml vials of brivaracetam administered intravenously over a 4-minute period
89399562|NCT02182622|Experimental|Dose Level 3|Docetaxel 75mg/m2 IV every 21 days Prednisone 5mg oral twice daily LDE225 800mg oral daily
88856913|NCT04025112|Active Comparator|Conventional|Patients group (54 patients) for conventional rehabilitation protocol.
88856914|NCT04024722|Experimental|Single ovary treatment|
89399563|NCT02182700|Experimental|Combivent® aerosol|
88856915|NCT04024722|Experimental|Dual ovary treatment|
88856916|NCT04024800|Experimental|Arm 1|AE37 peptide vaccine every 21 days for 5 doses + Pembrolizumab every 21 days for 2 years (Maximum 35 cycles)
88856917|NCT04406610|Experimental|GD2 CAR-T|Treated by GD2 CAR-T therapy intravenously
88856918|NCT04406610|No Intervention|Control|With no medical intervention
88856919|NCT04024176|Experimental|Moderate hemophiliac patients|Each participant will perform a gait analysis and clinical examination
88856920|NCT04024332|Experimental|Group A (healthy)|On Day 1, 8 healthy subjects will receive a single oral dose of 25 mg ACT-541468 in fasted condition.
88856921|NCT04024332|Experimental|Group B (severe renal function impairment)|On Day 1, 8 subjects with severe renal function impairment will receive a single oral dose of 25 mg ACT-541468 in fasted condition.
88856922|NCT04023864|Experimental|Platycodon Grandiflorus Extract(GCWB107) group|Once-daily, once a tablet, after meals (900 mg/day, 571 mg/day as a Platycodon Grandiflorus Extract(GCWB107))
88856923|NCT04023864|Placebo Comparator|Placebo group|Once-daily, once a tablet, after meals (900 mg/day, 0 mg/day as a Platycodon Grandiflorus Extract(GCWB107))
88856924|NCT03022890|Experimental|Hatha yoga|12 weeks of hatha yoga classes, once per week
88856925|NCT03022890|Placebo Comparator|Health education|12 weeks of health education classes, once per week
88856926|NCT04023786|Experimental|56 patients, one arm|All patients benefits of a passive leg raising test and a PEEP test to compare these two tests.
88856927|NCT04023630|Experimental|rivaroxaban plus ticagrelor|rivaroxaban 15 mg (or 10 mg for subjects with moderate renal impairment) once daily plus ticagrelor 90 mg tablet twice daily for 12 months
89383514|NCT03021018|Active Comparator|Lorazepam (LZP)|Lorazepam bolus is to be injected based on information from the patient leaflet/package insert. The rate of injection should not exceed 2.0 mg/min. The LZP dose will be determined according to the Investigator's clinical judgment.
89383515|NCT03669042|Experimental|Treatment|All patients will undergo a vascular repair or reconstruction surgery, which requires the use of PhotoFix. The surgical procedures will vary by patient and by underlying etiology. Therefore, PhotoFix implant sites will also vary. In all cases, PhotoFix will be implanted per the Instructions for Use (IFU).
89383516|NCT02509507|Experimental|Phase Ib/II Talimogene Laherparepvec|Talimogene Laherparepvec
89383517|NCT02509507|Experimental|Phase Ib/II Talimogene Laherparepvec + Pembrolizumab|Combination treatment of Talimogene Laherparepvec and Pembrolizumab
89383518|NCT03176407|Experimental|HemoPill acute|"Capsule is swallowed by the patient and an external study receiver records the capsule sensor data for 4 consecutive hours.~Capsule excretion is monitored for up to 4 days. If excretion is not recorded during that time, a follow-up examination of the patient is conducted after 10 days."
89383519|NCT03175549|Active Comparator|Apremilast (Otezla)|Fixed oral dose of 90 mg/d following the standard titration for a total dosing duration of 14 days.
89383520|NCT03175549|Placebo Comparator|Placebo|Identical placebo pills taken orally for 14 days
89383521|NCT03174925|Experimental|Tissue Stiffness by Elastography|Potentially cancerous thyroid nodules were assessed by elastrography, then a fine needle biopsy specimen or the surgically-excised nodule was assessed pathologically to determine cancer status.
89383522|NCT05216107||Hospital Universitario de Álava, Spain|large hospitals (>200 beds) with wards admitting older surgical patients where (a) electronic medical records are available, (b) have staff committed to recruiting a minimum of 100 participants with complete follow-up, and (c) give consent for the Lead statistician in Spain to access de-identified data for aggregated analysis.
89383523|NCT05216107||Hospital Universitario de Basurto, Spain|large hospitals (>200 beds) with wards admitting older surgical patients where (a) electronic medical records are available, (b) have staff committed to recruiting a minimum of 100 participants with complete follow-up, and (c) give consent for the Lead statistician in Spain to access de-identified data for aggregated analysis.
89383524|NCT05216107||Hospital Universitario de Cruces, Spain|large hospitals (>200 beds) with wards admitting older surgical patients where (a) electronic medical records are available, (b) have staff committed to recruiting a minimum of 100 participants with complete follow-up, and (c) give consent for the Lead statistician in Spain to access de-identified data for aggregated analysis.
89383525|NCT05216107||Hospital Universitario de Donostia, Spain|large hospitals (>200 beds) with wards admitting older surgical patients where (a) electronic medical records are available, (b) have staff committed to recruiting a minimum of 100 participants with complete follow-up, and (c) give consent for the Lead statistician in Spain to access de-identified data for aggregated analysis.
88856928|NCT04023630|Active Comparator|rivaroxaban plus clopidogrel|rivaroxaban 15 mg (or 10 mg for subjects with moderate renal impairment) once daily plus clopidogrel 75 mg tablet once daily for 12 months
88856929|NCT04199754|Experimental|Contrast Enhanced Cone Beam CT|60 seconds after the start of the administration of IV contrast, cone beam CT will be initiated.
88856930|NCT04023474|Experimental|Platelet Rich Fibrin (PRF) Group|Patients randomized to this group will receive treatment with a PRF graft in clinic at the time any pertinent post-operative complication is identified.
88856931|NCT04023474|No Intervention|No Platelet Rich Fibrin Group|Participants in the observational control group will be managed at the time of the complication by standard of care methods.
89383526|NCT05216107||Hospital San Pedro (Logroño), Spain|large hospitals (>200 beds) with wards admitting older surgical patients where (a) electronic medical records are available, (b) have staff committed to recruiting a minimum of 100 participants with complete follow-up, and (c) give consent for the Lead statistician in Spain to access de-identified data for aggregated analysis.
89383527|NCT05216107||Hospital of Navarra, Spain|large hospitals (>200 beds) with wards admitting older surgical patients where (a) electronic medical records are available, (b) have staff committed to recruiting a minimum of 100 participants with complete follow-up, and (c) give consent for the Lead statistician in Spain to access de-identified data for aggregated analysis.
89383528|NCT01314937|Experimental|Deworming at 12 months of age|
89383529|NCT01314937|Experimental|Deworming at 18 months of age|
89383530|NCT01314937|Experimental|Deworming at 12 and 18 months of age|
89383531|NCT01314937|Placebo Comparator|Usual care|
89383532|NCT04718155|Active Comparator|statin group|will receive atorvastatin for 48 hours
89383533|NCT04718155|Placebo Comparator|control|will receive placebo tablets for 48 hours
89383534|NCT04668859|Active Comparator|Midodrine Arm|Patients will receive the drug Midodrine
89383535|NCT04668859|Placebo Comparator|Placebo Arm|Patients will receive placebo.
89383536|NCT02320201|Experimental|Electrical stimulation|Transcutaneous Electrical Nerve Stimulator (TENS) will be applied to the foot via skin surface electrodes for a minimum of 2 hours per day for 1 week to 20 subjects. Subjects will be required to keep a daily voiding diary for one week before treatment to establish a control, during the treatment week and for one week after treatment. Subjects will also be asked to complete a validated questionnaire prior to treatment, during treatment week and one week after treatment. The primary outcomes of this study are improvement in objective measures of frequency as indicated by voiding diary and subjective symptom improvement based on questionnaire comparison.
88875380|NCT04946214|Other|Smart Water Bottle Intervention Arm|Patients will receive a smart water bottle, then instructed on bowel and bladder preparation for daily standard of care radiotherapy treatments for up to 10 weeks.
88818632|NCT05096975||Control group|"ADHD without emotion dysregulation (Control group) The group is composed of children with ADHD and with a score ≤ 180 at the CBCL-A-A-A when combining the Aggressive behaviors, Anxiety/Depression and Attention subscales."
88818633|NCT05096975||Deficit Emotion Self Regulation group|"ADHD without moderate emotion dysregulation (Deficit Emotion Self Regulation group) The group is composed of children with ADHD and with a score ≥180 and ≤ 210 at the CBCL-A-A-A when combining the Aggressive behaviors, Anxiety/Depression and Attention subscales."
89383537|NCT02261389|No Intervention|Arm A, usual follow-up practice|Imaging studies and serum markers (CEA, CA 15.3, others) performed according to local practice
88856932|NCT04023006||Edentulous Patients|The investigational device is part of a treatment concept for edentulous patients of all ages, gender and races. The incidence for tooth loss has not declined over years, and the prevalence for edentulism is significantly higher for adults 50 years and older. For this descriptive two-part survey, no minimum number of patients is defined, but to achieve a reasonable subject number, a minimum of five (5) patients will be enrolled, i.e. 10 dentures will be fabricated within this study.
88856933|NCT04022928|Experimental|PRP injection|Patients with symptomatic ankle OA for at least 6 months were recruited. Patients received a single injection of 3-ml of PRP into symptomatic ankles.
88856934|NCT04147104|Active Comparator|Standard-of-care plus invasive mechanical ventilation|Invasive mechanical ventilation for lung support and to facilitate exhalation via an endotracheal tube o tracheotomy.
88856935|NCT04147104|Experimental|ECCO2R plus invasive mechanical ventilation|Low-flow ECCO2R adjunct to standard-of-care and invasive mechanical ventilation.
88856936|NCT04147182|Experimental|Patient with low grade TCC|"Patients of 18 years or older able to sign informed consent~A previous diagnosis of low grade bladder cancer~A pyelographic imaging examination (CTU, MRU, IVP, antegrade/retrograde pyelography) showing normal upper urinary tract in the 12 months prior to inclusion~Serum creatinine levels ≤ 2.0 mg/dl~Serum sodium levels <146 mg/ml~Current bladder tumor diagnosed by endoscopy or imaging in the last 3 months~Patient is candidate for TURBT"
88856937|NCT04146792|Experimental|body acceptance program|
88856938|NCT04146792|Active Comparator|writing creativity program|
88856939|NCT04146948||COPD group|No intervention 40 years or older, clinical diagnosis of COPD (Global Initiative for Chronic Obstructive Lung Disease stages I to IV)
88856940|NCT04146948||healthy group|40 years or older, not with the clinical diagnosis of COPD
88856941|NCT04022304|Experimental|Sequence: Humulin® N- Biocon Insulin N-Humulin® N|"Period 1: 0.4 IU/kg of Humulin® N (100 IU/mL) administered once subcutaneously.~Period 2: 0.4 IU/kg of Biocon Insulin N (100 IU/mL) administered once subcutaneously.~Period 3: 0.4 IU/kg of Humulin® N (100 IU/mL) administered once subcutaneously.~The treatment periods will be separated by 5-7 days"
88856942|NCT04022304|Experimental|Sequence: Biocon Insulin N- Humulin® N- Humulin® N|"Period 1: 0.4 IU/kg of Biocon Insulin N (100 IU/mL) administered once subcutaneously.~Period 2: 0.4 IU/kg of Humulin® N(100 IU/mL) administered once subcutaneously.~Period 3: 0.4 IU/kg of Humulin® N (100 IU/mL) administered once subcutaneously.~The treatment periods will be separated by 5-7 days"
88856943|NCT04022304|Experimental|Sequence: Humulin® N- Humulin® N-Biocon Insulin N|"Period 1: 0.4 IU/kg of Humulin® N(100 IU/mL) administered once subcutaneously.~Period 2: 0.4 IU/kg of Humulin® N (100 IU/mL) administered once subcutaneously.~Period 3: 0.4 IU/kg of Biocon Insulin N (100 IU/mL) administered once subcutaneously.~The treatment periods will be separated by 5-7 days"
88856944|NCT04022304|Experimental|Sequence: Biocon Insulin N- Humulin® N- Biocon Insulin N|"Period 1: 0.4 IU/kg of Biocon Insulin N (100 IU/mL) administered once subcutaneously.~Period 2: 0.4 IU/kg of Humulin® N (100 IU/mL) administered once subcutaneously.~Period 3: 0.4 IU/kg of Biocon Insulin N (100 IU/mL) administered once subcutaneously.~The treatment periods will be separated by 5-7 days"
88856945|NCT04022304|Experimental|Sequence: Humulin® N-Biocon Insulin N- Biocon Insulin N|"Period 1: 0.4 IU/kg of Humulin® N (100 IU/mL) administered once subcutaneously.~Period 2: 0.4 IU/kg of Biocon Insulin N (100 IU/mL) administered once subcutaneously.~Period 3: 0.4 IU/kg of Biocon Insulin N (100 IU/mL) administered once subcutaneously.~The treatment periods will be separated by 5-7 days"
88856946|NCT04022304|Experimental|Sequence: Biocon Insulin N- Biocon Insulin N-Humulin® N|"Period 1: 0.4 IU/kg of Biocon Insulin N (100 IU/mL) administered once subcutaneously.~Period 2: 0.4 IU/kg of Biocon Insulin N (100 IU/mL) administered once subcutaneously.~Period 3: 0.4 IU/kg of Humulin® N (100 IU/mL) administered once subcutaneously.~The treatment periods will be separated by 5-7 days"
88856947|NCT04022382|Experimental|Restylane Defyne recipient|
88856948|NCT04021446|Active Comparator|Exercise|Will receive the exercise intervention
88856949|NCT04021446|No Intervention|Attention Control|Will not receive the exercise intervention
88856950|NCT03930654|Experimental|iPrEP Intervention|"iPrEP Intervention:~Women will receive the iPrEP intervention on an iPAD Air tablet device~iPrEP serves a dual role as a data collection instrument and an intervention--the survey incorporates brief, informational messages into a traditional survey instrument~iPrEP uses qualitative themes~iPrEP is divided into sections addressing factors with historical success at predicting pre-exposure prophylaxis (PrEP) adherence~Scales chosen to measure themes and sections were retained from the original HIV Prevention Trials Network (HPTN) 073 instrument~Scales were modified (in some cases) for cultural competency and tailoring to women"
88856951|NCT03930654|Active Comparator|Usual Care|"Control Intervention:~Women will receive usual care~Usual care includes an assessment visit with an emergency department (ED)-assigned social worker who specializes in substance use~Social worker will offer a list of substance abuse treatment referral agencies"
88856952|NCT04020900||Children <18 years, admitted for a general anesthesia.|Children <18 years, admitted for a general anesthesia.
88856953|NCT04020666||HUK group|On the basis of routine treatment for cerebral infarction, patients in the HUK group were also given Urinary Kallidinogenase at 0.15 PNA unit/day, for a 10-day course.
88856954|NCT04020666||control group|The control group were given routine treatment for cerebral infarction, including anti-platelet aggregation, anticoagulation, lipid-lowering and plaque stabilizing, free radical scavenging, nerve nutrition and brain protection.
88875381|NCT04945122|Experimental|Pitavastatin|Patients diagnosed AMI with abnormal glucose metabolism use pitavastatin (4mg po Qn) to control cholesterol for 6 months.
88818634|NCT05096975||Dysregulation Profile Group|"ADHD with severe emotion dysregulation (Dysregulation Profile Group) The group is composed of children with ADHD and with a score ≥ 210 at the CBCL-A-A-A when combining the Aggressive behaviors, Anxiety/Depression and Attention subscales."
89383538|NCT02261389|Experimental|Arm B, tumor markers assessment|Serum CEA and CA 15.3 performed every 3 months. No imaging studies allowed in asymptomatic patients: imaging studies (18 FDG-PET) performed only in case of critical increase of CEA and /or CA 15.3 serum levels (+100% for CEA and +75% for CA15.3), even if in the normal range.
89383539|NCT02924688|Experimental|FF/UMEC/VI (100/31.25/25) mcg closed triple therapy|Subjects will receive FF/UMEC/VI (100/31.25/25) mcg inhalation powder via DPI, once daily in the morning. Subjects may receive albuterol/salbutamol as a rescue medication when needed during the treatment period.
89383540|NCT02924688|Experimental|FF/UMEC/VI (100/62.5/25) mcg closed triple therapy|Subjects will receive FF/UMEC/VI (100/62.5/25) mcg inhalation powder via DPI, once daily in the morning. Subjects will also receive albuterol/salbutamol as a rescue medication when needed during the treatment period.
89383541|NCT02924688|Experimental|FF/UMEC/VI (200/31.25/25) mcg closed triple therapy|Subjects will receive FF/UMEC/VI (200/31.25/25) mcg inhalation powder via DPI, once daily in the morning. Subjects may receive albuterol/salbutamol as a rescue medication when needed during the treatment period.
89383542|NCT02924688|Experimental|FF/UMEC/VI (200/62.5/25) mcg closed triple therapy|Subjects may receive FF/UMEC/VI (200/62.5/25) mcg inhalation powder via DPI, once daily in the morning. Subjects may receive albuterol/salbutamol as a rescue medication when needed during the treatment period.
89383543|NCT02924688|Active Comparator|FF/VI (100/25) mcg dual combination therapy|Subjects will receive FF/VI (100/25) mcg inhalation powder via DPI, once daily in the morning. Subjects may receive albuterol/salbutamol as a rescue medication when needed during the treatment period.
89383544|NCT02924688|Active Comparator|FF/VI (200/25) mcg dual combination therapy|Subjects will receive FF/VI (200/25) mcg inhalation powder via DPI, once daily in the morning. Subjects may receive albuterol/salbutamol as a rescue medication when needed during the treatment period.
89383545|NCT03668496|Experimental|SHR-1210 +chemotherapy|subject will receive SHR-1210 200mg every 3 weeks, carboplatin AUC 5 on Day 1 of each 21 day, 4-6 cycles Paclitaxel 175mg/m2, Day 1 of each 21 day, 4-6 cycles
89383546|NCT03668496|Active Comparator|chemotherapy|carboplatin AUC 5 on Day 1 of each 21 day, 4-6 cycles Paclitaxel 175mg/m2, Day 1 of each 21 day, 4-6 cycles
89383547|NCT03668418||Colorectal cancer|Patients operated for colorectal cancer with or without liver metastasis undergoing a chemotherapy treatment after surgery
89383548|NCT03668418||Esophagus/gastric cancer|Patients operated for esophagus/gastric cancer undergoing a chemotherapy treatment after surgery
89383549|NCT03668418||Biliary duct cancer|Patients operated for biliary duct cancer undergoing a chemotherapy treatment after surgery
88818635|NCT04740411|Experimental|Common Elements Toolbox (COMET)|
89383550|NCT03668418||Pancreatic cancer|Patients operated for pancreatic cancer undergoing a chemotherapy treatment after surgery
89383551|NCT03666702|Experimental|Upper limb physiotherapy programme|A progressive, individualised four week upper limb physiotherapy intervention programme delivered via web-based physiotherapy lasting up to 30 minutes/session, five times per week + usual care.
89383552|NCT03666702|Active Comparator|Usual care|An average of 4 to 5 physiotherapy sessions per week, lasting approximately 45 minutes each.
89383553|NCT03011892|Placebo Comparator|Double Blind (DB): Vehicle BID|Participants applied vehicle cream twice daily (BID) for 8 weeks DB period.
89383554|NCT03011892|Active Comparator|DB: Triamcinolone (TAC) 0.1% BID/Vehicle Cream BID|Participants applied triamcinolone 0.1% cream BID for 4 weeks followed by vehicle cream for 4 weeks in DB period.
89383555|NCT03011892|Experimental|DB: Ruxolitinib 0.15% Once Daily (QD)|Participants applied ruxolitinib 0.15% cream QD for 8 weeks in DB period.
89383556|NCT03011892|Experimental|DB: Ruxolitinib 0.5% QD|Participants applied ruxolitinib 0.5% cream QD for 8 weeks in DB period.
89383557|NCT03011892|Experimental|DB: Ruxolitinib 1.5% QD|Participants applied ruxolitinib 1.5% cream QD for 8 weeks in DB period.
89383558|NCT03011892|Experimental|DB: Ruxolitinib 1.5% BID|Participants applied ruxolitinib 1.5% cream BID for 8 weeks in DB period.
89399564|NCT02182778|Experimental|Gemcitabine/Cisplatin group|Gemcitabine and cisplatin are infused on day1, 8. The cycle is repeated every 3 weeks.
88818636|NCT04740411|No Intervention|Wait-list control condition|
88818637|NCT02703987|Experimental|Group I|Fermented infant milk formula
88818638|NCT02703987|Active Comparator|Group II|Non-fermented infant milk formula
88818639|NCT01836185|Experimental|Evacetrapib (Healthy)|Group 1: 130 milligrams (mg) evacetrapib administered once, orally, to participants with normal hepatic function
88818640|NCT01836185|Experimental|Evacetrapib (Hepatic, Mild)|Group 2: 130 mg evacetrapib administered once, orally, to participants with mild hepatic impairment
88818641|NCT01836185|Experimental|Evacetrapib (Hepatic, Moderate)|Group 3: 130 mg evacetrapib administered once, orally, to participants with moderate hepatic impairment
88818642|NCT01836185|Experimental|Evacetrapib (Hepatic, Severe)|Group 4: 130 mg evacetrapib administered once, orally, to participants with severe hepatic impairment
88818643|NCT05073341|Experimental|experimental and control group and intervention is given in the experimental group|Nurse-led family intervention is given in the experimental group having three components i.e infarmation about the patient condition , guidance, and emotional support
88818644|NCT05073341|Other|control group|No intervention will be given in the control group
88818645|NCT02706249|Active Comparator|A: Standard Dose Enoxaparin|"Participants will receive Enoxaparin 40 mg subcutaneously once daily. On study Enoxaparin will be administered for up 14 days during hospitalization.~After the day 14 assessment, treatment arms will be un-blinded in order to appropriately schedule a bilateral lower extremity ultrasound for participants enrolled onto Arm A at day 17."
88818646|NCT02706249|Active Comparator|B: Weight Adjusted Enoxaparin|"Participants will receive Enoxaparin at 1mg/kg subcutaneously once daily with maximum dose of 100 mg daily. Participants who weigh more than 100kg will be capped at 100mg.~On study Enoxaparin will be administered for up 14 days during hospitalization."
88818647|NCT00559949|Experimental|Arm I|Patients receive oral selumetinib twice daily on days 1-28. Treatment repeats every 28 days in the absence of unacceptable toxicity or disease progression.
89383559|NCT03011892|Placebo Comparator|Open-Label (OL): Vehicle BID to Ruxolitinib 1.5% BID|Following DB Period, at Week 8, participants who met criteria (compliant with the protocol and no safety concerns) received open-label treatment with ruxolitinib 1.5% cream BID for 4 weeks.
89383560|NCT03011892|Active Comparator|OL: TAC BID/Vehicle BID to Ruxolitinib 1.5% BID|Following DB Period, at Week 8, participants who met criteria (compliant with the protocol and no safety concerns) received open-label treatment with ruxolitinib 1.5% cream BID for 4 weeks.
88856955|NCT04405986|Experimental|Electrophysiological procedure|Brainstem reflexes and neural conduction will be explored using Auditory Evoked Potentials (AEP) and blink and Masseter Inhibitory Reflex (MIR) in hospitalised patients with COVID infection
88856956|NCT04021992|Experimental|GVD with or without R|Gemcitabine 1000mg/m2, d1,d8, intravenous drip; Vinorelbine 50mg/m2, d1,d8, oral; Doxorubicin liposomes 30mg/m2, d1,intravenous drip; With or without rituximab 375 mg/m2, d0,intravenous drip; All patients received up to 6 treatment cycles of 21 days.
88856957|NCT04022070|Other|Dynamic Tape|To evaluate the evolution of this symptomatology prior to and thereafter the application of Dynamic Tape® bandage in a sample of subjects affected by plantar fasciitis.
88856958|NCT03593148|Other|Lifestyle treatment|Patients will be included in the Lifestyle treatment that is a existing treatment program at Vestfold Hospital Trust.
89184094|NCT02575131|Experimental|Home Oatmeal|PepsiCo, Inc.-1 - One portion of Steel Cut oatmeal: 66.8 grams of oats boiled for 25 minutes in 500 grams* of water and consumed with 307 grams of skimmed milk at home
88856959|NCT03022734|Experimental|chemotherapy with radiotherapy|Cetuximab or Bevacizumab, FOLFOX or FOLFIRI, radiotherapy
88856960|NCT04406532|Experimental|PT-Pal|Participants randomized to the 14-day intervention arm will receive exercise instructions via PT-Pal. The Pt-Pal is a mobile health technology used to facilitate communication between the Care Team and patients, by allowing the team to send from their web-portal, exercise routines, surveys and educational material to the patient's mobile device. The PT-Pal app then captures the patient activity adherence, and reports those results back to the team including a graphical summary about patients' condition and activity. Clinicians can send/receive HIPAA-secure messages with patients. The app was designed to work with intermittent data connectivity typically found in mobile networks by switching between store-and-forward and real-time mode of connectivity to ensure data delivery.
88856961|NCT04406532|Active Comparator|Self-guided exercises|Participants randomized to the 14-day control arm will be instructed by research staff on how to use the exercise manual provided at the time of their screening.
88856962|NCT04021836|Other|3d evaluation of naso labial changes using alar cinch suture|
88856963|NCT04021836|Other|3d evaluation of nasolabial change without Alar cinch|
88856964|NCT04020588|Active Comparator|Celecoxib|Celecoxib 200 mg twice a day
88856965|NCT04020588|Active Comparator|Minocycline|Minocycline 100 mg twice a day
88856966|NCT04020588|Placebo Comparator|Placebo|Placebo capsules twice a day
88856967|NCT04146402|Experimental|SCT-I10A + Chemotherapy|SCT-I10A, 200 mg intravenous (IV) on Day 1 of each 3-week cycle. Chemotherapy: cisplatin+5-FU
88856968|NCT04146402|Active Comparator|Placebo + Chemotherapy|Placebo, 200 mg intravenous (IV) on Day 1 of each 3-week cycle. Chemotherapy: cisplatin+5-FU
89184095|NCT02575131|Active Comparator|Home original Cheerios|PepsiCo, Inc.-2 - One portion of original Cheerios (ready to eat cereal): 70 grams prepared with 307 grams of skimmed milk and consumed with about 275 grams of water at home
88856969|NCT04146168||VenaSeal|Complete closure of previously treated veins will be assessed via ultrasound
88856970|NCT04146480|Experimental|Cardiac amyloidosis patients|
88856971|NCT03021876|Placebo Comparator|ordinary group|usual intake prior to liver surgery
88856972|NCT03021876|Active Comparator|carnitine group|treatment with oral L-carnitine, 1500 mg/body per day for 2 weeks prior to liver surgery
88856973|NCT04020354|Experimental|HABIT-ILE|Early HABIT-ILE (Hand and arm bimanual intensive therapy including lower extremities) will be applied over 2 weeks.
88856974|NCT04020354|Active Comparator|Usual Care|A two weeks period of usual customary care
88856975|NCT04145544|Experimental|Treatment arm|"Procedure will be performed under general anaesthesia. The patients will undergo a surgery that is identical to the one that was planned by the surgeon. At the end of the surgery, the investigator will use the ArtiFascia® patch. Implantation of the ArtiFascia® will be according to clinical discretion of the physician, and in compliance with ArtiFascia® instructions for use. Detailed instructions are in the instructions for use.~Post operation the subject will stay at the hospital according to site standards and physician discretion."
88856976|NCT04145544|Active Comparator|Control|"Same procedure as for the treatment arm but using a commercial suturable dural substitute.~Implantation of the commercial suturable dural substitute will be according to clinical discretion of the physician, and in compliance with each specific device instructions for use. Detailed instructions are in the instructions for use."
89184096|NCT02575131|Experimental|Home standard breakfast|"one slice of white bread with a fried egg and 200 mL orange juice. With spray oil a frying pan is prepared to fry an egg (medium size).~The breakfast is consumed at home"
89184097|NCT02598830|Experimental|Vitamin D3+str.training, COPD & Healthy|"Vitamin D3 capsules for 30 weeks:~weeks 1-2: 10000 IU/day (equivalent to 250 ug), accompanied by 1000 mg Ca2+~weeks 3-30: 2000 IU/day (equivalent to 50 ug), accompanied by 1000 mg Ca2+~Progressive unilateral strength training of the legs for 3+10 weeks (weeks 15-28); leg 1 = high-load training, leg 2 = low-load training, allocated to left and right foot in a randomized manner:~weeks 15-17, familiarization period~week 18, test period~weeks 19-28, intervention period~weeks 29-30, test period"
88856977|NCT04146558|Experimental|Internal ayurvedic treatment|"All possible internal preparations will be administered for a period of 12 months.~All administered preparations with its dosage and duration will be documented All preparations will be subjected to lab test for clearing heavy metal and pesticide content before the administration"
88856978|NCT04146558|Active Comparator|External ayurvedic treatment|Application of warm external oil (Ayyapala kera tailam) on affected parts twice daily
88856979|NCT03619044|Other|Patients with metastatic breast cancer|Patients with metastatic breast cancer treated with trastuzumab + pertuzumab + taxane in the metastatic first line.
88856980|NCT04146246||Adult|Adults aged 18 years or older. Collect whole blood sample via venous/arterial puncture and, where possible, finger stick.
88856981|NCT04146246||Neonate|Neonates gestational age >35 weeks or older. Collect whole blood sample via heel prick or, where an in dwelling line already exists, via arterial/umbilical draw.
88856982|NCT04020120||ADHD in professional activity|Adult ADHD patients in active employment at the time of inclusion or who were in employment within 3 months prior to inclusion
89383561|NCT03011892|Experimental|OL: Ruxolitinib 0.15% QD to Ruxolitinib 1.5% BID|Following DB Period, at Week 8, participants who met criteria (compliant with the protocol and no safety concerns) received open-label treatment with ruxolitinib 1.5% cream BID for 4 weeks.
89383562|NCT03011892|Experimental|OL: Ruxolitinib 0.5% QD to Ruxolitinib 1.5% BID|Following DB Period, at Week 8, participants who met criteria (compliant with the protocol and no safety concerns) received open-label treatment with ruxolitinib 1.5% cream BID for 4 weeks.
89383563|NCT03011892|Experimental|OL: Ruxolitinib 1.5% QD to Ruxolitinib 1.5% BID|Following DB Period, at Week 8, participants who met criteria (compliant with the protocol and no safety concerns) received open-label treatment with ruxolitinib 1.5% cream BID for 4 weeks.
88856983|NCT04145856|Placebo Comparator|Placebo|- Control arm
88856984|NCT04145856|Experimental|Probiotic|- Arm with active probiotic alone
88856985|NCT04145856|Experimental|Probiotic + Antispasmodic/Antifoam|- Arm with active probiotic combined to antispasmodic/antifoam drug
88856986|NCT04146090|Active Comparator|Low-pressure|Forty patients aged 18 to 65 years, with an ASA physical status I or II, who will be scheduled to undergo laparoscopic cholecystectomy
88856987|NCT04146090|Placebo Comparator|Standard pressure|Forty patients aged 18 to 65 years, with an ASA physical status I or II, who will be scheduled to undergo laparoscopic cholecystectomy
88856988|NCT04140786|Experimental|Daily IV Gentamicin|Once daily (for 24 days) IV infusions of 10 mg/kg gentamicin delivered over a 30-60 minute period.
88856989|NCT04140786|Experimental|Biweekly IV Gentamicin|Twice weekly (for 3 months or 24 total) IV infusions of 10 mg/kg gentamicin delivered over a 30-60 minute period.
88856990|NCT04147650|Experimental|0.05% Voclosporin Ophthalmic Solution (VOS)|0.05% VOS, in both eyes (OU) twice a day (BID) over 12 weeks
88856991|NCT04147650|Experimental|0.10% VOS|0.10% VOS, in both eyes (OU) twice a day (BID) over 12 weeks
88856992|NCT04147650|Experimental|0.20% VOS|0.20% VOS, in both eyes (OU) twice a day (BID) over 12 weeks
88856993|NCT04147650|Placebo Comparator|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution, in both eyes (OU) twice a day (BID) over 12 weeks
88856994|NCT04023942|Active Comparator|Low carb - App-based group|Low carb is defined as 30 energy percent from carbs and consist of 20 energy percent from protein. The daily energy requirement is calculated for each participant individually, based on his/hers resting metabolic rate and physical activity level. Daily energy intake should be 10% lower than the calculated daily energy requirement. Participants assigned to the app-based group works together with a personal coach via app, providing nutritional guidance and support during the 12-month weight maintenance step.
88856995|NCT04023942|Active Comparator|Low carb - Newsletter-based group|"Low carb is defined as 30 energy percent from carbs and consist of 20 energy percent from protein. The daily energy requirement is calculated for each participant individually, based on his/hers resting metabolic rate and physical activity level. Daily energy intake should be 10% lower than the calculated daily energy requirement. The newsletter intervention group gets regularly digital newsletters, in the same frequency as contacts take place in the app-based group."
88856996|NCT04023942|Active Comparator|Low fat - App-based group|Low fat is defined as 25 energy percent from fat and consist of 20 energy percent from protein. The daily energy requirement is calculated for each participant individually, based on his/hers resting metabolic rate and physical activity level. Daily energy intake should be 10% lower than the calculated daily energy requirement. Participants assigned to the app-based group works together with a personal coach via app, providing nutritional guidance and support during the 12-month weight maintenance step.
88856997|NCT04023942|Active Comparator|Low fat - Newsletter-based group|"Low fat is defined as 25 energy percent from fat and consist of 20 energy percent from protein. The daily energy requirement is calculated for each participant individually, based on his/hers resting metabolic rate and physical activity level. Daily energy intake should be 10% lower than the calculated daily energy requirement. The newsletter intervention group gets regularly digital newsletters, in the same frequency as contacts take place in the app-based group."
88856998|NCT04022226|Active Comparator|Methohexital|Standard of care anesthesia that does not affect slow wave characteristics
88856999|NCT04022226|Experimental|Ketamine|Standard of care anesthesia that suppresses slow wave characteristics
88857000|NCT04029012|Experimental|Penthrox|methoxyflurane inhaler (Penthrox) to be used 5 minutes (+/- 1 minutes) before procedure, and continuously breathing in the inhaler throughout the procedure.
89383564|NCT03011892|Experimental|OL: Ruxolitinib 1.5% BID to Ruxolitinib 1.5% BID|Following DB Period, at Week 8, participants who met criteria (compliant with the protocol and no safety concerns) received open-label treatment with ruxolitinib 1.5% cream BID for 4 weeks.
89383565|NCT03017742|Experimental|Test Group|The subjects enrolled in the test group will receive the pulse oximeter
89383566|NCT02125513|Active Comparator|Arm A: 3 courses|Patients will receive 3 courses of i.v. carboplatin AUC 5 and paclitaxel 175 mg/m2 every 3 weeks, followed by cytoreductive surgery within 6 weeks from the last cycle of chemotherapy. Alternatively, the Participating Centres can use the weekly paclitaxel schedule: carboplatin AUC 6 day 1 and paclitaxel 80 mg/m2 day 1-8-15.
89399565|NCT02182778|Experimental|Gemcitabine/Cisplatin /S-1 group|S-1 is given daily for 7 consecutive days and gemcitabine and cisplatin are infused on day1. The cycle is repeated every 2 weeks.
89399566|NCT03688971|Experimental|Omiganan Topical Gel|Omiganan 1.75%
88857001|NCT04025658|Active Comparator|Oxytocin 0.5IU|Patient is given 0.5IU of oxytocin intravenously over 1 minute, immediately upon delivery of the fetal head.
88857002|NCT04025658|Active Comparator|Oxytocin 1IU|Patient is given 1IU of oxytocin intravenously over 1 minute, immediately upon delivery of the fetal head.
88857003|NCT04025658|Active Comparator|Oxytocin 2IU|Patient is given 2IU of oxytocin intravenously over 1 minute, immediately upon delivery of the fetal head.
88857004|NCT04025658|Active Comparator|Oxytocin 3IU|Patient is given 3IU of oxytocin intravenously over 1 minute, immediately upon delivery of the fetal head.
88857005|NCT04025658|Active Comparator|Oxytocin 4IU|Patient is given 4IU of oxytocin intravenously over 1 minute, immediately upon delivery of the fetal head.
88857006|NCT04025658|Active Comparator|Oxytocin 5IU|Patient is given 5IU of oxytocin intravenously over 1 minute, immediately upon delivery of the fetal head.
88857007|NCT03605706|Experimental|SHR-1210|SHR-1210+FOLFOX4
88857008|NCT03605706|Experimental|CONTROL|SHR-1210+Placebo
88857009|NCT03924180|Experimental|GMP - Dietary Supplement for PKU patients|Glycomacropeptides -GMP Glytactin
89399567|NCT03688971|Active Comparator|Ketoconazole Topical Cream|Ketoconazole 2.0%
88857010|NCT03924180|Active Comparator|Control -Amino acids mixtures|Mixtures of conventional amino acids.
88857011|NCT05581680|Experimental|patients with facial palsy|
88857012|NCT05581680|Active Comparator|healthy volunteers|
88857013|NCT04023240|Experimental|68Ga-FAPI PET/CT|Patients receive 68Ga-FAPI IV and then undergo PET/CT approximately 1 hour later.
88857014|NCT05586438|Experimental|blood draws|All patients enrolled will have PK blood samples obtained around a colistin dosing
88857015|NCT05581524|Experimental|VELEX|Treatment of varicose veins of lower limbs by means of chemical ablation or empty-vein sclerotherapy
88857016|NCT04765878|Experimental|Humidification|
88857017|NCT04145232||NSCLC|This cohort will consist of 30 patients with non-small cell lung cancer (NSCLC).
88857018|NCT04144764|Experimental|Workplace-based exercise group|
88857019|NCT04144764|Sham Comparator|Control group|
88857020|NCT04029246|No Intervention|Letter only|
88857021|NCT04029246|Active Comparator|Letter plus phone call|
88857022|NCT04029246|Active Comparator|Letter plus incentive|
88857023|NCT04144920|Other|Block 1|Participants in this arm performed the conditions in this order: CS, HFLD, LFHD
88857024|NCT04144920|Other|Block 2|Participants in this arm performed the conditions in this order: CS, LFHD, HFLD
88857025|NCT04144920|Other|Block 3|Participants in this arm performed the conditions in this order: HFLD, CS, LFHD
88857026|NCT04144920|Other|Block 4|Participants in this arm performed the conditions in this order: HFLD, LFHD, CS
88857027|NCT04144920|Other|Block 5|Participants in this arm performed the conditions in this order: LFHD, CS, HFLD
88857028|NCT04144920|Other|Block 6|Participants in this arm performed the conditions in this order: LFHD, HFLD, CS
88857029|NCT04027452|Experimental|Traumatic memory reactivation|Audio recording of traumatic memory that triggers symptoms of PTSD, anxiety, depression, played before each ECT treatment.
88857030|NCT04027452|Placebo Comparator|Neutral memory reactivation|Audio recording of neutral (non-traumatic) memory played before each ECT treatment.
88857031|NCT04144452|Active Comparator|Patient Education Session|Educational session will be given twice a day for three months. Individualized instructional booklet about back care for each patient will be designed, reviewed and finalized by operating surgeons according to the needs of patients.
88857032|NCT04144452|Experimental|Therapeutic exercises plus educational sessions|Trunk and lower musculature strength and endurance training will be performed twice a week for three months. Therapeutic exercises incorporating mat exercises will be performed. Progression will be made according to patient status.
88857033|NCT03947190|Experimental|Group 1|Group 1 adults (n=20) will be receiving, 4 weeks apart, three doses of 10µg R21 /50µg Matrix M vaccine, and a CHMI intradermally (ID) by inoculation of 22,500 PfSPZ Challenge.
88857034|NCT03947190|Experimental|Group 2|Group 2 adults (n=20) will be receiving 5x10^10 vp ChAd63 ME-TRAP and 2x10^8 pfu MVA ME-TRAP vaccines, 8 weeks apart, and then a CHMI intradermally (ID) by inoculation of 22,500 PfSPZ Challenge, 4 weeks later.
88857035|NCT03947190|Experimental|Group 3|Group 3 adults (n=10) will be receiving, 4 weeks apart, three doses of 10µg R21 /50µg Matrix M vaccine, and a CHMI intravenously (DVI) by inoculation of 3,200 PfSPZ Challenge.
88857036|NCT03947190|Experimental|Group 4|Group 4 adults (n=14) will be the control group receiving no vaccine, only a CHMI intradermally (ID) by inoculation of 22,500 PfSPZ Challenge.
89399568|NCT03688971|Placebo Comparator|Vehicle|
88857037|NCT04144374|Experimental|Diabetic Wound Infection|Participants with a documented medical history of Type 1 or Type 2 diabetes and a mild to moderate (Grade 2 or 3) wound infection of the lower limb will receive 3 to 5 doses of omadacycline once daily, followed by sampling of interstitial tissue fluid at the margin of the wound by a microdialysis probe over 24 hours following the last dose (e.g., 48-72 hours).
88857038|NCT04144374|Active Comparator|Healthy Volunteers|Participants will be male or female healthy adult volunteers with no significant medical or medication history. Participants will receive 3 doses of omadacycline once daily, followed by sampling of interstitial tissue fluid at the margin of the wound by a microdialysis probe over 24 hours following the last dose (e.g., 48-72 hours).
88857039|NCT04026282|Experimental|GnRH-ant protocol|Recombinant FSH (Gonal-f®) will be administrated as routinely practiced by investigators. FSH doses will be adjusted according to the clinical experiences of investigators.The GnRH-ant (Cetrotide®) will be initiated in a fixed protocol on stimulation days 5 or 6 per the investigator's ART protocol.
88857040|NCT04026282|Active Comparator|GnRH-a long protocol|The GnRH-a (Diphereline® or Decapetyl®) 0.1mg will be administered for about 14 to 20 days for down-regulation. Gonal-f® will be administrated as routinely practiced by investigators. GnRH-a types, GnRH-a and FSH doses will be adjusted according to the clinical experiences of investigators in each site.
88857041|NCT04144296|Other|Study Arm|All patient will be included in this arm
88857042|NCT04144218|Placebo Comparator|Control group|
88857043|NCT04144218|Experimental|Experimental group|
89383567|NCT02125513|Experimental|Arm B: 6 courses|Patients will receive 6 courses of i.v. carboplatin AUC 5 and paclitaxel 175 mg/m2 every 3 weeks, followed by cytoreductive surgery within 6 weeks from the last cycle of chemotherapy. Alternatively, the Participating Centres can use the weekly paclitaxel schedule: carboplatin AUC 6 day 1 and paclitaxel 80 mg/m2 day 1-8-15.
89383568|NCT03667950|Experimental|hyperspectral imaging|diagnostic hyperspectral Imaging of the gastrointestinal anastomosis and calculating the anastomotic Perfusion measures
89383569|NCT03667872|Experimental|Device|MRI compatible and LFP recordable implantable stimulator
89383570|NCT03667794||PH patients|Patients with known or first diagnosis of PH
89383571|NCT03667794||healthy controls|Healthy controls had normal lung function testing including whole-body plethysmography and transfer factor, no previously diagnosed pulmonary disease as well as no respiratory symptoms.
88857044|NCT05580900|Experimental|Livestream Modality|The livestream modality is considered the treatment group for the purpose of this quasi-experimental study.
89383572|NCT03667794||non-healthy controls|Non-healthy controls were allowed to have stable pulmonary comorbidities including chronic obstructive pulmonary disease (COPD), sarcoidosis, asthma, or fibrosis as well as non-pulmonary comorbidities.
89383573|NCT03667638|Experimental|PRP Intervention|PRP injection into wound border
88857045|NCT05580900|Experimental|Live Modality|The live modality is considered the control group for the purpose of this quasi-experimental study.
88857046|NCT04021602|Active Comparator|Intervention 1 (Tx1) - DPP + Breastfeeding + Usual Care|Patients randomized to Tx1 will receive education in both the Diabetes Prevention Program (DPP) and in Breastfeeding. At baseline, this includes 16 DPP sessions (core curriculum), one 2-hour breastfeeding session, and participation in a professional peer support group. The 2-hour breastfeeding session is pre-recorded into four (4) 30-minute sessions and archived on a secure, private Facebook group. Participants will have access to all four breastfeeding sessions by week 24 of pregnancy and they need to complete all sessions by week 30 of pregnancy. At delivery, the patient will receive usual lactation support in the hospital, additional breastfeeding assessment and support (at day 3, day 10, week 3 and week 6), followed by 6 DPP sessions (post-core curriculum).
88857047|NCT04021602|Active Comparator|Intervention 2 (Tx2) - DPP Only + Usual Care|Patients randomized to Tx2 will receive education in only the Diabetes Prevention Program. At baseline, this includes 16 DPP sessions (core curriculum). At delivery, the patient will receive usual lactation support in the hospital, followed by 6 DPP sessions (post-core curriculum).
88857048|NCT04021602|Placebo Comparator|Intervention 3 (Tx3) - Usual Care Only|Patients randomized to Tx3 will receive only usual standard of care. At baseline, the patient will receive only regular prenatal care provided by their physician. At delivery, the patient will receive standard of care breastfeeding support provided by the hospital.
88857049|NCT05580822|Experimental|intra-arterial TNK infusion (0.4mg/min) via support/access catheter, over 15 minutes|
88857050|NCT05580822|Experimental|intra-arterial TNK infusion (0.25mg/min) via support/access catheter, over 15 minutes|
88857051|NCT05580822|Placebo Comparator|intra-arterial placebo infusion via support/access catheter, over 15 minutes|
88857052|NCT04026126|Experimental|Heat Therapy Treatment|This study will recruit subjects to participate in heat therapy treatment at the University of Kansas Medical Center (KUMC). After pre-screening, informed consent, and enrollment, all subjects will have baseline hemodynamic assessments as well as VO2max measurements. Subjects will complete 10 heat therapy treatments over the course of 14 days. Hemodynamics will be assessed with the use of the Clearsight© fingertip blood pressure cuff. Within 24-48 hours after the last heat therapy experience, hemodynamic assessments and VO2max will be performed. Blood samples will be collected pre- and post intervention and analyzed for levels of nitric oxide mediators, heat shock protein levels and pro-anti-inflammatory markers.
88857053|NCT05580354|Experimental|Arm 1|Patients will receive 17 cycles of Tislelizumab (200mg per cycle) in combination with BCG (6-week induction course of 120mg followed by maintenance with 3 weekly infusions of 120mg at months 3,6,12).
88857054|NCT04144062|Active Comparator|Zirconia crowns|
88857055|NCT04144062|Active Comparator|CAD/CAM crowns|
88857056|NCT04143906|Experimental|Vinorelbine/Carboplatin|Vinorelbine 25 mg/m2 d1,8; Carboplatin AUC=6 d1; q 3 weeks
88857057|NCT04143906|Experimental|Gemcitabine/Carboplatin|Gemcitabine 1000 mg/m2 d1,8; Carboplatin AUC=6 d1; q 3 weeks
88857058|NCT04143750|Experimental|[14C]Vicagrel|
88857059|NCT03022110|Active Comparator|plastic stent|Endoscopic Ultrasound-guided Drainage with plastic stent
88857060|NCT03022110|Experimental|lumen-apposing metal stent (LAMS)|Endoscopic Ultrasound-guided Drainage with lumen-apposing metal stent
88857061|NCT02708004|Experimental|ACT-132577|3 different dose levels
88857062|NCT02708004|Placebo Comparator|Placebo|Matching active drug
88857063|NCT03021720|Active Comparator|Femoral arterial access|Femoral arterial puncture for the uterine fibroid embolization procedure
88857064|NCT03021720|Experimental|Radial arterial access|Radial arterial puncture for the uterine fibroid embolization procedure
89383574|NCT03666546|Experimental|Laevolac crystals 20 g|Lactulose crystals, oral intake, 20 g single dose
89383575|NCT03666546|Experimental|Laevolac crystals 30 g|Lactulose crystals, oral intake, 30 g single dose
89383576|NCT03666546|Experimental|Laevolac liquid 20 g|Lactulose liquid, oral intake, 20 g single dose
88857065|NCT02708706|Experimental|physical therapy and hyaluronic acid|patient received ultrasound-guided hydrodilatation with hyaluronic acid plus physical therapy
88857066|NCT02708706|Active Comparator|physical therapy only|patient received physical therapy only
88857067|NCT04143672|Experimental|study group|"The following tests will be performed on the study subjects.~Pain catastrophizing scale~Hospital Anxiety and Depression scale-Anxiety Subscale (HADS-A)~Pain sensitivity questionnaire~Pain pressure threshold using electronic digital pressure algometer"
88857068|NCT04143828|Experimental|Mobile Mindfulness Programme|The mobile mindfulness program is delivered via a mobile application.
89383577|NCT03666546|Experimental|Laevolac liquid 30 g|Lactulose liquid, oral intake, 30 g single dose
89383578|NCT03666546|Active Comparator|Glucose 30 g|Glucose Monohydrate, oral intake, 33 g single dose
89383579|NCT03666546|Placebo Comparator|Water|Still water, oral intake, 250 mL single dose
89184098|NCT02598830|Placebo Comparator|Placebo+str.training, COPD & Healthy|"Placebo capsules for 30 weeks (the number of capsules ingested each day match those of the vitamin D3 group)~Progressive unilateral strength training of the legs for 3+10 weeks (weeks 15-28); leg 1 = high-load training, leg 2 = low-load training, allocated to left and right foot in a randomized manner:~weeks 15-17, familiarization period~week 18, test period~weeks 19-28, intervention period~weeks 29-30, test period"
88857069|NCT04143828|No Intervention|Wait-list control condition|When assigned to the control condition, participants will be wait-listed for 3 months during the study. After the final assessment participants will receive access to the mobile mindfulness program.
89184099|NCT02578251|Experimental|Paracetamol|Patients will receive paracetamol intravenously (1 g in 100 mL) over 15 minutes (single dose), as an analgesic during the first stage of labor, given by a member of the study team.
89184100|NCT02578251|Active Comparator|Pethidine|Slow intravenous administration of pethidine, 50 mg to be diluted in 10 mL of sterile water (single dose), as an analgesic during the first stage of labor, given by a member of the study team.
89184101|NCT00746330|Experimental|F12M - PL - F12D - MFF|Participants received a single dose of each treatment in the following order, separated by a washout period of 6-7 days: Period 1: Formoterol fumarate 12 μg via pMDI + placebo to formoterol fumarate via DPI; Period 2: Placebo to formoterol fumarate / mometasone furoate via pMDI + placebo to formoterol fumarate via DPI; Period 3: Placebo to formoterol fumarate / mometasone furoate via pMDI + formoterol fumarate via DPI; Period 4: Formoterol fumarate / mometasone furoate 10 μg / 100 μg via pMDI + placebo to formoterol fumarate via DPI. Participants were allowed to continue their regular asthma maintenance inhaled corticosteroid medication throughout the study and were supplied with the short-acting β2-agonist (SABA) salbutamol as rescue medication.
89383580|NCT03012828|Experimental|Moxidectin 4mg|10 subjects will receive a single oral dose of moxidectin 4mg
89184102|NCT00746330|Experimental|F12D - F12M - MFF - PL|Participants received a single dose of each treatment in the following order, separated by a washout period of 6-7 days: Period 1: Placebo to formoterol fumarate / mometasone furoate via pMDI + formoterol fumarate via DPI; Period 2: Formoterol fumarate 12 μg via pMDI + placebo to formoterol fumarate via DPI; Period 3: Formoterol fumarate / mometasone furoate 10 μg / 100 μg via pMDI + placebo to formoterol fumarate via DPI; Period 4: Placebo to formoterol fumarate / mometasone furoate via pMDI + placebo to formoterol fumarate via DPI. Participants were allowed to continue their regular asthma maintenance inhaled corticosteroid medication throughout the study and were supplied with the short-acting β2-agonist (SABA) salbutamol as rescue medication.
89184103|NCT00746330|Experimental|MFF - F12D - PL - F12M|Participants received a single dose of each treatment in the following order, separated by a washout period of 6-7 days: Period 1: Formoterol fumarate / mometasone furoate 10 μg / 100 μg via pMDI + placebo to formoterol fumarate via DPI; Period 2: Placebo to formoterol fumarate / mometasone furoate via pMDI + formoterol fumarate via DPI; Period 3: Placebo to formoterol fumarate / mometasone furoate via pMDI + placebo to formoterol fumarate via DPI; Period 4: Formoterol fumarate 12 μg via pMDI + placebo to formoterol fumarate via DPI. Participants were allowed to continue their regular asthma maintenance inhaled corticosteroid medication throughout the study and were supplied with the short-acting β2-agonist (SABA) salbutamol as rescue medication.
89184104|NCT00746330|Experimental|PL - MFF - F12M - F12D|Participants received a single dose of each treatment in the following order, separated by a washout period of 6-7 days: Period 1: Placebo to formoterol fumarate / mometasone furoate via pMDI + placebo to formoterol fumarate via DPI; Period 2: Formoterol fumarate / mometasone furoate 10 μg / 100 μg via pMDI + placebo to formoterol fumarate via DPI; Period 3: Formoterol fumarate 12 μg via pMDI + placebo to formoterol fumarate via DPI; Period 4: Placebo to formoterol fumarate / mometasone furoate via pMDI + formoterol fumarate via DPI. Participants were allowed to continue their regular asthma maintenance inhaled corticosteroid medication throughout the study and were supplied with the short-acting β2-agonist (SABA) salbutamol as rescue medication.
89184105|NCT00714207|Experimental|NOT Intervention|Students in this arm of the study were randomized to receive the reformatted NOT program
89184106|NCT00714207|Active Comparator|NOT controls|Students in this arm were randomized to receive a single group session on smoking cessation and were given youth oriented informational pamphlets on smoking cessation
89184107|NCT00714207|Experimental|KB intervention|Students in this arm of the study were randomized to receive the reformatted Kicking Butts intervention
88857070|NCT05587608|Active Comparator|ultrasound-guided thoracic segmental spinal group|given ultrasound-guided thoracic segmental spinal heavy Marcaine plus 25 ug fentanyl at the level of T10 interlaminar space.
88857071|NCT05587608|No Intervention|General anesthesia group|General anesthesia (control)
89184108|NCT00714207|Active Comparator|KB controls|Students in this arm were randomized to receive a single group session on smoking cessation and were given youth oriented informational pamphlets on smoking cessation
89184109|NCT02590224|Active Comparator|Ferrous bis-glycinate group|The patients will receive oral ferrous bis-glycinate fully reacted amino acid 27 mg tablets (Pharaferro 27 tablets) once daily for eight consecutive weeks.
89184110|NCT02590224|Active Comparator|Ferrous glycine sulphate group|The patients will receive 567.6 mg of ferrous glycine sulphate capsules (Ferrosanol duodenale capsules, Schwarz) once daily for eight consecutive weeks.
89184111|NCT00709449|Experimental|1|20 patients with age related macular degeneration
89383581|NCT03012828|Experimental|Moxidectin 8mg|10 subjects will receive a single oral dose of moxidectin 8mg
89383582|NCT03012828|Experimental|Moxidectin 16mg|10 subjects will receive a single oral dose of moxidectin 16mg
89383583|NCT03012828|Experimental|Moxidectin 24mg|10 subjects will receive a single oral dose of moxidectin 24mg
88857072|NCT02703714|Experimental|Pembrolizumab and GM-CSF|Patients receive pembrolizumab IV over 30 minutes on day 1. Patients also receive sargramostim subcutaneous injection (SC) on days 1-14 of courses 1-2 or 2-3. Treatment repeats every 21 days for up to 2 courses for sargramostim and for up to 35 courses (24 months) for pembrolizumab in the absence of disease or unaccepted toxicity.
88857073|NCT03919578|Experimental|Hep B Batch 1|1 dose of 1 mL Hepatitis B Batch 1
88857074|NCT03919578|Experimental|Hep B Batch 2|1 dose of 1 mL Hepatitis B Batch 2
88857075|NCT03919578|Experimental|Hep B Batch 3|1 dose of 1 mL Hepatitis B Batch 3
88818648|NCT04740021|Experimental|Experimental: LP002+EP|Participants recieve LP002 10 mg/kg intravenous (IV) on day 1 PLUS carboplatin titrated to an area under the plasma drug concentration-time curve [AUC] 5 IV on day 1 PLUS etoposide 100 mg/m^2 IV on days 1, 2 and 3 of each 21-day cycle
88818649|NCT05747417|Experimental|prism glasses|prisms glasses are advised with ranging of 4prism diopters to 10 prism diopters
88818650|NCT05747417|No Intervention|presbyopic glasses|simple presbyopia glasses according to age are advised
88818651|NCT03663387||Normal subjects|70
88818652|NCT01837901|Sham Comparator|Sham|OkuStim is used to determine the phosphene threshold, device is turned on but no stimulation is performed.
88818653|NCT01837901|Experimental|150%|OkuStim is used to determine the phosphene threshold, and then to administer transcorneal electrostimulation with a stimulation strength corresponding to 150% of the patient's phosphene threshold.
88818654|NCT01837901|Experimental|200%|OkuStim is used to determine the phosphene threshold, and then to administer transcorneal electrostimulation with a stimulation strength corresponding to 200% of the patient's phosphene threshold.
88818655|NCT02708433|Active Comparator|Buffered 1% lidocaine|"In week one each subject would receive either anesthetic (Buffered 1% lidocaine with 1/100,000 Epinephrine) or (Non-Buffered 2% lidocaine with 1/100,000 Epinephrine) to block the inferior alveolar, lingual, buccal nerves.~In week two the alternate anesthetic would be administered.~Mandibular molar and canine tested for pulpal anesthesia"
88818656|NCT02708433|Active Comparator|Non-Buffered lidocaine|"In week two each subject would receive the alternate anesthetic (Buffered 1% lidocaine with 1/100,000 Epinephrine) or (Non-Buffered 2% lidocaine with 1/100,000 Epinephrine) to block the inferior alveolar, lingual, buccal nerves.~Mandibular molar and canine tested for pulpal anesthesia"
88818657|NCT05038085|Experimental|experimental group application|progressive muscle relaxation exercise health education
88818658|NCT05038085|No Intervention|control group application|No intervention will be made in the control group.
88818659|NCT04339569||History of patellar tendinopathy|
89184112|NCT00709449|Experimental|2|20 patients with primary open angle glaucoma
89184113|NCT00709449|Experimental|3|20 age and sex matched control subjects
89383584|NCT03012828|Experimental|Moxidectin 36mg|10 subjects will receive a single oral dose of moxidectin 36mg
89383585|NCT03012828|Placebo Comparator|Placebo|10 subjects will receive a single oral dose of placebo
89383586|NCT03667560|Experimental|Dermacell ADM without basement membrane|Dermacell ADM without a basement membrane
88810430|NCT06213506|Active Comparator|Infants_6W_Control_2 Group|Infants 6 weeks of age, part of the dose-finding cohort, randomized to receive 3 doses of the MenACWY vaccine at Day 1, Day 57 (during the Priming phase) and at Day 232 (during the Booster phase). To allow completion of the vaccination schedule a fourth dose of the MenACWY vaccine is administered after the trial ends, as per the licensed indication and in private vaccination settings. These infants also receive an EPI vaccination with the following vaccines: Measles and Rubella Vaccine (MR-VAC) and Yellow Fever (YF) vaccine administered concomitantly during the last study intervention administration at Day 232, and the pentavalent vaccine (DTPw-HepB-Hib), the Pneumococcal conjugate vaccine, and the inactivated polio vaccine administered at the same time, at 6, 10 and 14 weeks of age, at the local EPI vaccination centers, and not part of the current clinical trial.
88810431|NCT06213493||Non end-stage heart failure|Measurement of tissutal RNAs in non end-stage heart failure patients undergoing to left ventricle reconstruction
88810432|NCT06213493||ACS patients|Measurement of circulating RNAs in acute coronary syndrome (ACS) patients treated with percutaneous angioplasty and undergoing to ventricle remodelling
88810433|NCT06213493||HF patients|Measurement of circulating RNAs in heart failure patients
88810434|NCT06213493||Controls|Measurement of RNAs in individuals not affected by cardiovascular diseases
88810435|NCT06213480|Experimental|Synbiotic Group|They will receive a 3-day antibiotic (Vancomycin 500 mg/3 times/day), followed by a 3-month symbiotic. The synbiotic that will be used in this trial contains the oligosaccharide-degrading probiotics, Akkermansia muciniphila and Bifidobacterium infantis; butyrate producers such as Clostridium beijerinckii, Anaerobutyricum hallii, and Clostridium butyricum; and chicory-derived inulin, a prebiotic dietary fiber.
88810436|NCT06213480|Placebo Comparator|Placebo Group|They will receive a 3-day antibiotic (Vancomycin 500 mg/3 times/day), followed by a 3-month placebo.
88810437|NCT06213467|Experimental|A and B|Each patient in which two implants have already been inserted are exposed, the first implant expose by using traditional methods , the second one expose by using diode laser 940nm .
88810438|NCT06213428|Active Comparator|Active: Probiotic|"Progressive Perfect Probiotic 120 Billion CFU containing the following strains will be used:~Lactobacillus plantarum, Lactobacillus rhamnosus, Lactobacillus acidophilus, Bifidobacterium animalis subsp.lactis, Bifidobacterium breve, Lactobacillus paracasei, Lactobacillus casei, Lactobacillus gasseri, Lactobacillus reuteri, Bifidobacterium bifidum, Bifidobacterium longum subsp. Longum.~Participants will be required to take one capsule a day, for 28 days."
88810439|NCT06213428|Placebo Comparator|Placebo Probiotic|A placebo that is identical in capsule size and colour to the active probiotic capsule will be used. This will ensure participants and experimenters are masked during each intervention period. Participants will be required to take one capsule a day for 28 days.
88810440|NCT06213415|Active Comparator|Oral steroids|Oral steroids only
88810441|NCT06213415|Active Comparator|Oral steroids plus intratympanic injections|Oral steroids plus intratympanic injections
88810442|NCT06213402||Sickle cell anaemia and other related sickle diseases|Patients with sickle cell disease and related diseases in current regular follow-ups in European-Union health centers
88810443|NCT06213402||Thalassemia and related diseases|Patients with Thalassemia disease and related diseases in current regular follow-ups in European-Union health centers, stratified by age, gender, and/or variants/type if applicable.
88810444|NCT06213402||Pyruvate Kinase Deficiency and related diseases|Patients with Pyruvate Kinase Deficiency and related diseases in current regular follow-ups in European-Union health centers, stratified by age, gender, and/or variants/type if applicable.
88810445|NCT06213402||Red Blood Cell membrane disorders and related diseases|Patients with Reb Blood Cell membrane disorders and related diseases in current regular follow-ups in European-Union health centers, stratified by age, gender, and/or variants/type if applicable.
88810446|NCT06213376|Experimental|Intervention|"20 sessions/4 weeks:~Video Feedback:~S1) Participant (P1) views recording of previous session with the clinician & judges whether the production is intelligible.~S2) S1 & the clinician identifies changes in motor movements that are influencing performance.~S3+S4) S1+S2 & given support from the clinician, P1 identifies techniques improving intelligibility & modifies behavior accordingly.~MIT:~Humming - Clinician introduces the target phrase by showing a visual cue, humming the phrase, then intoning (singing) the phrase while P1 taps left-hand.~Unison intoning - Clinician and P1 intone (sing) & tap the target phrase together.~Unison intoning with fading - Clinician & P1 begin to intone (sing) & tap the target phrase together. The clinician fades out, while P1 continues to sing the rest of the phrase accompanied by tapping.~Immediate repetition response to probe question - Following P1's successful repetition, the clinician intones a question and P1 intones the target."
88810447|NCT06213363|Experimental|TCR1672 tablet|TCR1672 tablet
88810448|NCT06213363|Placebo Comparator|TCR1672 placebo|TCR1672 placebo
88810449|NCT06213337|No Intervention|control group|No intervention will be applied to this group.
88810450|NCT06213337|Experimental|virtual classroom group|Participants in this group will be given virtual classroom training on foot care.
88810451|NCT06213337|Experimental|SMS support group|Information regarding foot care will be sent via SMS to the participants in this group.
88810452|NCT06213337|Experimental|SMS supported virtual classroom training group|Participants in this group will be given virtual classroom training with SMS support.
88818660|NCT04339569||Healthy controls|
88857076|NCT03919578|Active Comparator|Hep B (Bio Farma)|1 dose of 1 mL Hepatitis B (Bio Farma)
88857077|NCT03945864|Experimental|antimicrobial synthetic bone graft|This group will have parenteral antibiotics and antimicrobial (silver ions) synthetic bone graft
88857078|NCT03945864|Active Comparator|parenteral antibiotics with pure synthetic bone graft|This group will have parenteral antibiotics and pure synthetic bone graft
88857079|NCT04143048||The construction of Gene detection technology flow|At this stage, a small panel targeted high-throughput sequencing process for gastrointestinal stromal tumors was established, and the association of tumor-associated mutation profiles in different patients with clinical stage was initially explored. It is planned to collect about 100 cases of gastrointestinal stromal tumors after surgery (freezing tissue or FFPE sections), DNA extraction and high-throughput sequencing of small panels, and analysis of the relationship between the mutation spectrum of each sample and the corresponding patient clinical data (staging).
88857080|NCT04143048||Establishment of non-invasive gene testing technology process|In this stage, we plan to establish a small panel of peripheral blood cfDNA targeting high-throughput sequencing process, and verify the consistency of peripheral blood cfDNA and tissue gDNA in gene detection of gastrointestinal stromal tumors. About 50 patients were planned to be enrolled. Peripheral blood was collected once for each patient and the blood volume was 10mL. Meanwhile, the tumor tissue samples were collected within 5mm in diameter, depending on the size of the lesion . DNA extraction and small panel sequencing were performed for the two types of samples of the patients respectively, and the DNA sequencing results of the two types of samples were compared, and the clinical data of the corresponding patients were referenced to evaluate the consistency of the results of peripheral blood cfDNA and tissue gDNA for the gene detection of gastrointestinal stromal tumor.
89383587|NCT03667560|Active Comparator|FlexHD|FDA-approved FlexHD Pliable
89383588|NCT03666936|Experimental|Intervention|Social-health care intervention
89383589|NCT04598724||Bladder Cancer Patient Participants|Participants will be scheduled for one-on-one interviews that will occur over Zoom or telephone.
88857081|NCT04143048||Prospective cohort (double-blind recommended)|Peripheral blood of about 150 patients was collected once and the blood volume was 10mL . Meanwhile, the tumor tissue samples were collected within 5mm in diameter, depending on the size of the lesion. Patients focus on the early stage of stromal tumors or those whose size under gastroenteroscopy is between 2 and 5 cm. DNA extraction and small panel sequencing were conducted for each patient sample. Based on the indicator results of the previous mutation spectrum for each stage of gastrointestinal stromal tumor, the clinical stage classification of patients and the benign and malignant nodules were determined by the mutation spectrum, and compared with the real clinical data of patients.
88857082|NCT03904446|Experimental|Methylergonovine 0.2 mg|Standard Oxytocin Infusion at the time of Cesarean Section plus 0.2 mg of Intramuscular Methergine
88857083|NCT03904446|Placebo Comparator|Placebo (Normal Saline)|Standard Oxytocin Infusion at the time of Cesarean Section plus 1 milliliter (mL)of normal saline given intramuscular
88857084|NCT04143984|Active Comparator|Arm-C|Patients will receive induction chemotherapy followed by carbon-ion radiotherapy with a dose of 63 GyE in 21 fractions (the fraction size is 3 GyE).
88857085|NCT04143984|Experimental|Arm-CC|Patients will receive induction chemotherapy followed by carbon-ion radiotherapy and camrelizumab. In details, patients will receive carbon-ion radiotherapy with a dose of 63 GyE in 21 fractions (the fraction size is 3 GyE); in addition, patients will also receive camrelizumab of 200 mg (IV.), every 2 weeks, started with carbon-ion radiotherapy for a maximal period of 1 year.
88857086|NCT05583318||Part 1: Patients diagnosed with non-Hodgkin's lymphoma|Diagnosis period 2010-2018, from the hematological malignancy registries of Côte-d'Or, Gironde, Basse-Normandie
88857087|NCT05583318||Part 2: Patients diagnosed with live non-Hodgkin's lymphoma after vital status update|Update of vital status in December 2022
89383590|NCT04598724||Care Givers for Bladder Cancer Patient Participants|Participants will be scheduled for one-on-one interviews that will occur over Zoom or telephone.
88857088|NCT05582772|Active Comparator|GA+M Intervention|"GA+M intervention arm All participants in the GA+M intervention arm will undergo a standardized GA by a trained nurse and geriatrician. The GA will include 8 domains (comorbidity, medication review, function, falls risk, nutrition, social supports, cognition, and mood) similar to our 5C protocol.~Based on any detected abnormalities or issues, a standardized set of strategies will be implemented (e.g. increased falls risk will lead to detailed assessment of balance and gait, consideration of gait aid, and referral to outpatient physiotherapy). This follows the standard approach to implementing GA similar to recent trials in geriatric oncology including 5C. Monthly telephone follow-up by the nurse and review with the geriatrician as needed will be done to ensure identified issues have been addressed."
88857089|NCT05582772|Active Comparator|RSM Intervention|RSM Intervention All participants in the RSM intervention arm will receive once-weekly symptom monitoring via email-based surveys using the 9-item Edmonton Symptom Assessment Scale within a secure customized REDCap interface. If patients prefer, weekly telephone calls will be done instead by a research assistant to elicit If there are moderate or severe symptoms (score of 4+ out of 10), an oncology nurse will obtain more detailed symptom information and provide evidence-based symptom-targeted recommendations using the pan-Canadian Oncology Symptom Triage and Remote Support (COSTaRS) Practice Guide. Symptom monitoring will continue for 6 months or discontinuation of treatment.
88857090|NCT05582772|Active Comparator|GA+RSM intervention|GA+RSM Combination Participants will receive both strategies as detailed above, with a GA at baseline.
89184114|NCT05340816|Experimental|Manual Lymphatic Drainage|5 days, 30 minutes, Manual Lymphatic Drainage
89383591|NCT03010254|Experimental|DFT015|ACRYSOF® IQ Extended Depth of Focus Intraocular lens (IOL), bilateral implantation
89383592|NCT03010254|Active Comparator|SN60WF|ACRYSOF® IQ Monofocal IOL, bilateral implantation
89383593|NCT04050150|Experimental|Arm Training in Standing|Task-oriented, functional arm training completed in standing or during walking. All participants receive the same arm training intervention.
89383594|NCT03666468|Experimental|PlayMed|"PlayMed, a highly immersive role-playing computer game~- Focus on Paediatric Asthma and Seizure management"
89383595|NCT03666468|Active Comparator|Online Package (OP)|"Online package (OP) of NSW Health Guidelines~- Focus on Paediatric Asthma and Seizure management"
89383596|NCT03666468|Placebo Comparator|Paper Guidelines|"Paper NSW Health Guidelines~- Focus on Paediatric Asthma and Seizure management"
89383597|NCT03666390|Experimental|0.5mg/kg Ketamine|Anesthesia
88857091|NCT05582772|No Intervention|Control|Control Usual care consists of brief verbal education and a drug pamphlet to all patients when starting an ARAT. There is no GA+M and no RSM at either site. Patients have access to a 24x7 oncology nursing line or a 24/7 pharmacy line.
88857092|NCT03902652|Experimental|Intervention (21% oxygen during CC+SI)|"Infants randomized into the 21% oxygen CC+SI group will receive a SI with a PIP of 25-30 cmH2O while receiving chest compression.~The SI will be delivered over a period of 20 seconds. This will be followed by PEEP of 5-8 cm water fro 1sec. The use of 20sec SI will be repeated 3 times, which results to 60sec of chest compression. At that time the clinical team will perform an assessment of the newborn's heart rate.~If heart rate is >60/min continue with standard care as per local hospital policy (standard hospital practice guideline). If heart rate remains <60/min continue with CC+SI for another 20sec at which time a further assessment should be performed. If heart rate remains <60/min continue with CC+SI.~During CC+SI the clinical team will only use 21% oxygen."
88857093|NCT03902652|Active Comparator|Intervention (100% oxygen during CC+SI)|"Infants randomized into the 100% oxygen CC+SI group will receive a SI with a PIP of 25-30 cmH2O while receiving chest compression.~The SI will be delivered over a period of 20 seconds. This will be followed by PEEP of 5-8 cm water fro 1sec. The use of 20sec SI will be repeated 3 times, which results to 60sec of chest compression. At that time the clinical team will perform an assessment of the newborn's heart rate.~If heart rate is >60/min continue with standard care as per local hospital policy (standard hospital practice guideline). If heart rate remains <60/min continue with CC+SI for another 20sec at which time a further assessment should be performed. If heart rate remains <60/min continue with CC+SI.~During CC+SI the clinical team will only use 100% oxygen."
88857094|NCT03916692|Experimental|Standard Process - glucose balance|Standard Process - glucose balance formula (200 kcal)
88857095|NCT03916692|Experimental|Energy smart Carbohydrate blend|Energy smart carbohydrate blend (50 grams, 200 kcal)
88857096|NCT03916692|Active Comparator|Liquid Dextrose Control|Liquid dextrose solution in the form of TRUTOL ® Glucose Tolerance Test Beverage (50 grams, 200 kcal)
88857097|NCT04142970|Active Comparator|Mild renal impairment|Mild renal impairment (eGFR: 60-89 mL/min/1.73 m^2)
88857098|NCT04142970|Active Comparator|Moderate renal impairment|Moderate renal impairment (eGFR: 30-59 mL/min/1.73 m^2)
88857099|NCT04142970|Active Comparator|Subjects with normal renal functions|Subjects with normal renal functions (eGFR: ≥ 90 mL/min/1.73 m^2)
88857100|NCT03022344|Sham Comparator|Healthy|Patients in this cohort consist of 100 healthy patients
88857101|NCT03022344|Sham Comparator|Diabetes mellitus|Newly diagnosed (< 1 year) diabetes patients clinically classified as type-2 diabetes patients of both sex
88857102|NCT04142346|No Intervention|Uninterrupted sitting|Participants remained seated throughout 7 hours. During the protocol, participants were allowed to go to the bathroom in a wheelchair and al-libitum water was granted.
88857103|NCT04142346|Experimental|Sitting + moderate intensity breaks|Participants were instructed to sit throughout 7 hours, while interrupting the sitting position every 30 minutes to perform 2 minutes of moderate-intensity physical activity. The breaks consisted of walk up and down stairs and squats. Each person performed these exercise alternately. During the protocol, participants were allowed to go to the bathroom in a wheelchair and al-libitum water was granted.
88857104|NCT04142112|Experimental|Ohana IVF Sperm Preparation Kit|Samples in the Ohana IVF Sperm Preparation Kit group will undergo product-specific multistep processing in the lab prior to insemination.
88857105|NCT04142112|Active Comparator|Standard IVF Preparation Kit|Samples in the Standard IVF Sperm Preparation Kit group will undergo traditional processing in the lab prior to insemination.
88857106|NCT04143282|Experimental|Metformin group|Non Diabetic metastatic breast cancer Patients will take metformin 1 gm. twice daily (Nathan 2009) along with standard chemotherapy
88857107|NCT04143282|Other|control group|Non Diabetic metastatic breast cancer Patients will take standard chemotherapy only
88857108|NCT04142190||ELONVA|Patients stimulated with Elonva
88857109|NCT04142190||PUREGON|Patients stimulated with Puregon
88857110|NCT04149678|Experimental|Treatment Group A - Ozanimod|Subjects will receive a single oral dose of ozanimod 0.46 mg
88857111|NCT04149678|Experimental|Treatment Group B - Ozanimod plus Cyclosporine|Subjects will receive a single oral dose of ozanimod 0.46 mg plus a single oral dose of cyclosporine 600 mg
88857112|NCT05581992|Experimental|AMG 510 + Omeprazole|Participants will receive AMG 510 on Day 1, daily doses of omeprazole on Days 4 to 8, and a single dose of both omeprazole and AMG 510 on Day 9.
88857113|NCT03021174|Experimental|Exercise|Exercise for Cancer Patients (EXCAP©®), developed by Dr. Karen Mustian, involves face-to-face instruction and a prescription for an at-home progressive walking and resistance exercise program.
88857114|NCT03021174|Active Comparator|Nutrition Education Control|Nutrition education (control) involves equal time and attention as the exercise arm, but the content covers nutrition for cancer patients and lacks an exercise prescription.
88857115|NCT03020628|Experimental|NBP607-QIV 0.5mL|Quadrivalent Inactivated Cell Culture-derived Influenza Vaccine
88857116|NCT03020628|Active Comparator|NBP607-TIV 0.25mL|Trivalent Inactivated Cell Culture-derived Influenza Vaccine
88857117|NCT05581914|Experimental|Treatment group|Care as Usual and the MY LIFE treatment
88857118|NCT05581914|Active Comparator|Waitinglist Control group|Care as Usual
88857119|NCT05580198||BRH+|Acute ischemic stroke patients with brainstem raphe hypoechogenicity.
88857120|NCT05580198||BRH-|Acute ischemic stroke patients without brainstem raphe hypoechogenicity.
88875382|NCT04945122|Active Comparator|Atorvastatin|Patients diagnosed AMI with abnormal glucose metabolism use atorvastatin (20mg po Qn) to control cholesterol for 6 months.
88875383|NCT04873518||Cohort 1|These are the eldest children who entered kindergarten in September 2016.
88875384|NCT04873518||Cohort 2|These children entered kindergarten in September 2017.
88875385|NCT04873518||Cohort 3|These are the youngest children who entered kindergarten in September 2018
89383598|NCT03666390|Active Comparator|0.045mg/kg Midazolam|Benzodiazepine
89383599|NCT03008460|Experimental|Eziclen®/Izinova®|
89383600|NCT03008460|Active Comparator|Klean-Prep®|
89383601|NCT02914236|Experimental|Vivaer Stylus|Intervention: Procedure: thermal treatment of submucosal tissue including cartilage in the internal nasal valve area
89383602|NCT03623022|Experimental|Endotoxin, then Normal Saline|"Endotoxin challenge: Subjects will undergo inhalation of 20,000 EU CCRE. The Clinical Center Reference Endotoxin (CCRE) will be inhaled by subjects as a nebulized preparation using an ultrasonic nebulizer until the challenge solution is completely spent (generally 10 minutes).~Following a washout of 2 weeks to 3 months the participant will undergo a Saline Challenge: Subjects will undergo inhalation of 0.9% sodium chloride. The Normal saline will be inhaled by subjects as a nebulized preparation using an ultrasonic nebulizer until the challenge solution is completely spent (generally 10 minutes)."
89383603|NCT03623022|Experimental|Normal Saline, then Endotoxin|"Saline Challenge: Subjects will undergo inhalation of 0.9% sodium chloride. The Normal saline will be inhaled by subjects as a nebulized preparation using an ultrasonic nebulizer until the challenge solution is completely spent (generally 10 minutes).~Following a washout of 2 weeks to 3 months the participant will undergo an Endotoxin challenge: Subjects will undergo inhalation of 20,000 EU CCRE. The CCRE will be inhaled by subjects as a nebulized preparation using an ultrasonic nebulizer until the challenge solution is completely spent (generally 10 minutes)."
89184115|NCT05340816|Experimental|Transcutaneous Electrical Nerve Stimulation|5 days, 20 minutes, Transcutaneous Electrical Nerve Stimulation
89184116|NCT05340816|No Intervention|Control|no any intervention
89383604|NCT03666078||normal vaginal delivery|
89383605|NCT03666078||assisted vaginal delivery|
89383606|NCT03666078||elective cesarean delivery|
89383607|NCT03666078||emergency cesarean delivery|
89383608|NCT03666312||Cohort A|The study will include patients from the two main Italian liver transplantation centers (Ospedale Le Molinette, Torino and Azienda Ospedaliera Pisana, Pisa), allowing to enroll 220 patients in the first 18 months of the proposed study. More in details, all >18-years-old patients listed for and undergoing liver transplantation will be included in the study after signing an informed consent. Each patient will then be prospectively followed one year.
89383609|NCT03666312||Cohort B|A second cohort of 55 patients will then be enrolled in the following 6 months as internal validation sample, and will be analogously monitored until the end of the 3-years-long study.
89399569|NCT03536624|Experimental|Experimental group|"Participants will be involved in a short-term spa residential program of 6 days combining psychological intervention, physical activity, thermal spa treatment, health education and corrections of eating disorders.~After the program, participants will be followed for 12 months."
89399570|NCT03693027|Experimental|PTx800|Qualified subjects will dissolve one oral lozenge (PTx800 lozenges) by mouth 3 times a day (after breakfast, lunch and dinner) throughout the 6 week study.
89184117|NCT00746252|Experimental|1|risperidone
89184118|NCT00746252|Experimental|2|aripiprazole
89184119|NCT02574975|Active Comparator|Methacholine diagnosing group|Methacholine bronchial provocation test was performed by using Jaeger spirometry with Aerosol Provocation System
89184120|NCT02574975|Experimental|Adenosine monophosphate diagnosing group|Adenosine monophosphate bronchial provocation test was performed by using Jaeger spirometry with Aerosol Provocation System
89184121|NCT02574975|Experimental|Leukotriene D4 diagnosing group|Leukotriene D4 bronchial provocation test was performed by using Jaeger spirometry with Aerosol Provocation System
89184122|NCT02574975|Experimental|Astograh diagnosing group|Methacholine bronchial provocation test was performed by using Astograph Jupiter-21 airway reaction testing apparatus
88857121|NCT03645408|Experimental|Exenatide then Placebo|This is a within subjects design study in which each subject receives both study drug and placebo. Subjects in this arm received a 5 mcg dose of immediate release exenatide on the day of the first alcohol self-administration trial. The 5mcg dose of exenatide was approved as the first dose administered to patients at the start of their treatment with this drug for FDA-approved indications. Subjects in this arm then received a sham injection on the day of the second alcohol self-administration trial. The sham injection was a needle stick using a syringe with no drug injected. Note that the volume of fluid injected for a 5mcg dose is so small that subjects would not sense this volume of fluid (or lack thereof) during the injection. Subjects were shielded from seeing the injection to maintain the blind.
88857122|NCT03645408|Experimental|Placebo then Exenatide|This is a within subjects design study in which each subject receives both study drug and placebo. Subjects in this arm received a sham injection on the day of the first alcohol self-administration trial. The sham injection was a needle stick using a syringe with no drug injected. Subjects in this arm then received a 5 mcg dose of immediate release exenatide on the day of the second alcohol self-administration trial. The 5mcg dose of exenatide was approved as the first dose administered to patients at the start of their treatment with this drug for FDA-approved indications. Note that the volume of fluid injected for a 5mcg dose is so small that subjects would not sense this volume of fluid (or lack thereof) during the injection. Subjects were shielded from seeing the injection to maintain the blind.
88857123|NCT04141722|Experimental|Sleep|
88857124|NCT04141722|Experimental|Wake|
88857125|NCT04141488|Experimental|Experimantel Group|Electrotherapy program in our study 20 minutes, Hot-pack (HP) 20 minutes, 60-120 Hz frequency range 50-100 millisecond pulse time conventional TENS (Transcutaneous Electrical Nerve Stimulation) and 5 minutes 1.5 watt / cm2 treatment dosage 1 MHz ' ultrasound (US) treatment was applied. Exercise program; Eccentric and concentric strengthening and stretching of ECBR and ECBL muscles, terminal elbow flexion and extension, forearm pronation and supination exercises were given. Electrotherapy was given as 15 sessions for 6 weeks, 2 or 3 days a week, 1 session per day, and 30 sessions for 6 weeks, 5 days per week. Fifteen of these exercise sessions were supervised by the physiotherapist in the hospital and the remaining 15 patients did not come to the clinic on their own. The experimantel group was given strengthening exercises of the upper trapezoidal, middle trapezoidal and serratus anterior muscles with extra scapula muscles.
88857126|NCT04141488|Other|Control Group|Electrotherapy program in our study 20 minutes, Hot-pack (HP) 20 minutes, 60-120 Hz frequency range 50-100 millisecond pulse time conventional TENS (Transcutaneous Electrical Nerve Stimulation) and 5 minutes 1.5 watt / cm2 treatment dosage 1 MHz ' ultrasound (US) treatment was applied. Exercise program; Eccentric and concentric strengthening and stretching of ECBR and ECBL muscles, terminal elbow flexion and extension, forearm pronation and supination exercises were given. Electrotherapy was given as 15 sessions for 6 weeks, 2 or 3 days a week, 1 session per day, and 30 sessions for 6 weeks, 5 days per week. Fifteen of these exercise sessions were supervised by the physiotherapist in the hospital and the remaining 15 patients did not come to the clinic on their own.
88857127|NCT04141254|Experimental|Debriefing|"a standardized follow-up visit at one month associated with debriefing and enhanced educative component"
88857128|NCT04141254|Other|Without debriefing|"a standardized follow-up visit at one month alone (i.e.; without debriefing and educative component)"
88857129|NCT03914976||patient who will have a high risk digestive surgery|patient who will have a high risk digestive surgery: esophagectomy, major hepatectomy> 3 segments, duodeno cephalic pancreatectomy
88857130|NCT04149756||overweight or obese adults|overweight or obese adults who participate the trial (NCT03675191)
88857131|NCT04141098|Experimental|Total Nucleus Replacement|All patients that meet the inclusion/exclusion criteria will receive the PerQdisc® Nucleus Replacement Device.
88857132|NCT05586204|Experimental|Facilitate action narrowly|
88857133|NCT05586204|Experimental|Facilitate action broadly|
88857134|NCT05586204|Experimental|Boost intentions only|
89184123|NCT02574975|Experimental|budesonide /formoterol treatment group|budesonide 160μg and formoterol 4.5ug,1 inhalation ,twice daily ,for three month
89184124|NCT00718770|Experimental|Bexarotene|Open label - all patients receive intervention
88857135|NCT05586204|Experimental|Boost intentions and facilitate action narrowly|
88857136|NCT05586204|Experimental|Boost intentions and facilitate action broadly|
88857137|NCT05586204|No Intervention|Holdout|
88857138|NCT04149834|Active Comparator|Modified Minimally Invasive Surgical Technique|Comparator: Modified Minimally Invasive Surgical Technique The defect will be gained through the tiny buccal triangular ﬂap: from the buccal 'window' the soft tissue ﬁlling the defect (i.e. the so-called granulation tissue) will be sharply dissected from the papillary supra-crestal connective tissue and from the bony walls with a micro-blade and will be removed with a mini-curette (The soft tissue will be sharply dissected from the osseous defect)
88875386|NCT04803630|Experimental|Treatment of depression (thermal therapy)|Patients undergo thermal therapy over 2.5 hours.
88875387|NCT04445064|Experimental|Arm A: IO102 vaccine|Randomization between arm A and B. Patients in arm A will receive IO102 3 to 4 times prior to curative treatment
89184125|NCT00714363|Active Comparator|1|LASIK
89184126|NCT00714363|Active Comparator|2|SBK
88857139|NCT04149834|Other|Non- incised papilla surgical approach|intervention: Non- incised papilla surgical approach Apical horizontal incision on the buccal mucosa, as far as possible from the interdental papillae and marginal KT will be performed. Soft tissue will be reflected apico-coronally by a full-thickness flap showing the granulation tissue filling the bony defect after exposing the coronal limit of the intra-bony component of the defect, while the marginal tissue will be kept unaltered.
88857140|NCT04140474|Experimental|Archimedes procedure|All included patients will receive anesthesia consultation, biological assessment and chest CT scan in thin sections. A surgical treatment will always be planned after presentation of the file in a meeting of multidisciplinary consultation of thoracic oncology. The Archimedes® procedure will be performed during a bronchoscopy under general anesthesia. Immediate monitoring consisted in a chest x-ray 1hour after the procedure.
88857141|NCT04149444|Experimental|ARM 1|"Dose escalation cohort - First 10 patients enrolled on study.~Trifluridine/Tipiracil 30mg/m2 - to start, if no significant dose limiting side effects the dose will be increased to 35mg/m2 for the duration of the trial.~After first 10 patients enrolled on study - Trifluridine/Tipiracil 35mg/m2~Each cycle is 28 days. Two doses per day during days 1-5 with a two day rest for days 6 and 7. Then two doses per day for days 8-12, followed by a rest period for days 13-28 with the next cycle starting the day after day 28."
88857142|NCT03020706|Experimental|Magnesium|magnesium sulfate, injectable intravenous administration (50mg/kg diluted in 100ml normal saline) during general anesthesia
88857143|NCT03020706|No Intervention|Control|No intervention
88857144|NCT04149366||group 1 (Wrapround retainer)|
88857145|NCT04149366||Group 2 (Essix retainer 1mm)|
88857146|NCT04149366||Group 3 (Essix retainer 1.5 mm)|
88857147|NCT04149366||Group 3 (Essix retainer 2mm)|
88857148|NCT04148976|Placebo Comparator|Placebo (P)|The placebo consisted of 30g of calcium caseinate, 30g of maltodextrin, and 0.2g of flavoring. The placebo was provided in a dehydrated form in a packet containing 30g each provided twice a day. The content of each packet was dissolved in 250ml of water.
88857149|NCT04148976|Experimental|Dietary Portfolio (DP)|The DP included 25g of soy protein, 14g of dehydrated nopal,14g of oats, 4g of chia seeds, 4g of inulin, and 0.15g of flavoring. The DP was provided in a dehydrated form in a packet containing 30g each. The content of each packet was dissolved in 250ml of water.
88857150|NCT04140630||E-cigarette users and bystanders|Households with one e-cigarette user (adult (18 years old and above); e-cigarette exclusive user for at least 1 month; daily use of e-cigarettes inside home; cohabiting with at least one non-tobacco product nor e-cigarette user; other household members should not be users of any tobacco products or e-cigarettes) and one bystander cohabiting with the user
88857151|NCT04140630||Conventional cigarette smokers and bystanders|Households with one smoker (adult (18 years old and above; manufactured cigarette exclusive smoker for at least 6 months; daily smoking inside home; cohabiting with at least one non-tobacco product nor e-cigarette user; other household members should not be users of tobacco products or e-cigarettes) and one bystander cohabiting with the smoker
88857152|NCT04140630||Heated tobacco product users and bystanders|Households with one user of the heated tobacco product, HTP (adult (18 years old and above; • HTP exclusive user for at least 1 month; daily use of HTP inside home; cohabiting with at least one non-tobacco product nor e-cigarette user; other household members should not be users of tobacco products or e-cigarettes) and one bystander cohabiting with the user
88857153|NCT04140630||Non-smokers and non-users (control)|Smoke free households (participants should be adult (18 years old and above), non e-cigarette user (never or former e-cigarette user >1 month), non-user of any kind of tobacco product (never or former user >1 month), and other household members should not be users of tobacco products or e-cigarettes
88857154|NCT04149132||Patients without sepsis|Patients admitted and hospitalized for infections without sepsis and for other reasons in departments of Internal Medicine and Intensive Care Units
88857155|NCT03908892|Experimental|Combination group|Local use of 1% tetracycline ointment for the sick nail(s), 3 times a day, plus local application with zanthoxylum nitidum tincture soaked blocks for the sick nail(s) for 30 minutes, twice a day, till paronychia relief or progression.
88857156|NCT03908892|Active Comparator|Control group|Local use of 1% tetracycline ointment for the sick nail(s), 3 times a day, till paronychia relief or progression.
88857157|NCT04140318|Experimental|treatment|combination therapy of PD-1 and chemotherapy including: sintilimab 200mg iv, 30-60min, q3w; nab-paclitaxel 125mg/m2, iv, d1,d8, q3w
88857158|NCT03021408|Experimental|MIRT + Treadmill|In the context of MIRT, the gait training in this group will be performed by using a treadmill without cues.
88857159|NCT03021408|Experimental|MIRT + Treadmill Plus|In the context of MIRT, the gait training in this group will be performed by using a treadmill with visual and auditory cues.
88857160|NCT03021408|Experimental|MIRT + Virtual Reality|In the context of MIRT, the gait training in this group will be performed by using Virtual Reality with enhanced perceptions (visual, auditory, and haptic inputs).
88857161|NCT04140006|Active Comparator|Alendronate Gel (ALN)|After preparation, 0.05 ml of the gel containing 100 µg of ALN will be injected in the osteotomy site immediately before fixture insertion (20 fixtures)
88857162|NCT04140006|Active Comparator|Bone Morphogenic Protein Gel (BMP)|After preparation, 0.05 ml of the gel containing 100 µg of BMP will be injected in the osteotomy site immediately before fixture insertion (20 fixtures)
88857163|NCT04140006|Active Comparator|Mixture Gel of ALN and BMP|After preparation, 0.05 ml of mixture gel containing 50 µg of ALN and 50 µg of BMP will be injected in the osteotomy site immediately before fixture insertion (20 fixtures)
88857164|NCT04140006|Sham Comparator|Control|After preparation, the fixture will be inserted without topical application of any medication (20 fixtures)
88857165|NCT04140084|No Intervention|Translation, Redesign and Rapid prototyping with clinicians|This step includes a translation of the tools (English to French) and a redesign work of the original tools. Then, the study will include clinicians (at least 20) from two healthcare settings (CHU Sainte-Justine, and the CISSS-CA (Hotel-Dieu de Levis). After a presentation of the two tools during the Emergency Physicians' departmental meetings, the written comments about the prototype version will be collected. A revision of the prototypes is scheduled at the end of this step.
88875388|NCT04445064|No Intervention|Arm B: Control group|Randomization between arm A and B
88857166|NCT04140084|No Intervention|Rapid prototyping with patients|This step will include the assessment of the tools by patients (or parents of patients) that have had a previous mTBI at the CISSS-CA (Hotel-Dieu de Levis). The comments about the adult and pediatric prototypes (5 adult patients, 5 parents of pediatric patients) will be collected through interviews. A revision of the prototypes is scheduled at the end of this step.
88857167|NCT04140084|Experimental|Real-life clinical meetings|This step will include a presentation of the tools to 5 emergency physicians so that they can use the tools with patients (5 adults, 5 parents of pediatric patients) in a realistic setting to identify any problems of use. The clinicians and patients that had used the tools during the clinical encounters will be then met during cognitive interviews to collect their comments on the tools and to address any usability issues. A final revision of the prototypes is scheduled at the end of this step.
88857168|NCT04140084|No Intervention|Training session developement|This step includes the development of a training session on how to perform SDM with patients facing the decision to undergo head CTs for mTBI and about how to use our newly developed decision aids in this clinical setting. The content of the training session will be adapted to the needs, goals, strengths and limitations observed during the focus groups (departmental meetings) exploring health professionals' barriers to using a decision aid about head CTs in mTBI. The expertise of SAVIE (www.savie.ca) in producing online and interactive elearning programs will be mobilized in order to produce a training program that will integrate the content the investigators will have identified as the main skills, knowledge and competencies needing development among our health professionals to stimulate the use of SDM and our decision aids. SAVIE will produce a virtual elearning program adaptable to all media (PC, mobile device, tablet) and different health professionals.
88857169|NCT04140084|No Intervention|Retrospective analysis|This step will retrospectively analyze the medical records of traumatic brain injury adult patients (adult, 350, Hotel-Dieu de Levis) and pediatric patients (406, CHU de Sainte-Justine and Hotel-Dieu de Levis)) randomly selected throughout the year preceding this study in each of the two centers to determine the rate of head CT ordering, the head CT result and the appropriateness of having ordered the head CT based on the CCHR and PECARN criteria. One reviewer will judge the appropriateness of having done a CT scan according to the CCHR and PECARN criteria based on a structured extraction form that will previously be approved by the study's steering committee. To ensure validity, 10% of the analysis will be reviewed by an expert. The reviewer will look at prehospital data collection, triage information, physician's notes, nursing notes and head CT requisition form information to determine if any of the clinical decision rule criteria are present.
88857170|NCT04140240|Experimental|İntervention group|Experimental: İntervention group
88857171|NCT04140240|No Intervention|Control group|Control group: No intervention
88857172|NCT04146324||Adjuvant nivolumab therapy|Participants receiving nivolumab as an adjuvant therapy according to the market authorization in Australia
88857173|NCT03588936|Experimental|Nivolumab (0.25 mg/kg) and Tocilizumab|"Participant will receive tocilizumab 8 mg/kg IV (max dose 800 mg) on Day 0. On Day 1 participants will receive nivolumab IV (0.25 mg/kg based on dose escalation design).~Nivolumab will be given every ~2 weeks for up to 4 doses and a second dose of Tocilizumab will be given on ~Day 29 on the same day as Dose # 3 of Nivolumab."
88857174|NCT03588936|Experimental|Nivolumab (0.5 mg/kg) and Tocilizumab|"Participant will receive tocilizumab 8 mg/kg IV (max dose 800 mg) on Day 0. On Day 1 participants will receive nivolumab IV (0.5 mg/kg based on dose escalation design).~Nivolumab will be given every ~2 weeks for up to 4 doses and a second dose of Tocilizumab will be given on ~Day 29 on the same day as Dose # 3 of Nivolumab."
88857175|NCT03588624|Experimental|TearCare|All subjects in the study will undergo the TearCare procedure one time at the baseline visit. They will then be followed out to one month.
88857176|NCT03585582||PARDS survivors|"Children <18 years~diagnosed with PARDS, as defined by PALICC~admitted to the ICU at the CHUSJ, a pediatric tertiary care center"
88875389|NCT04445064|Experimental|Arm C: IO103|No randomization. Patients in arm C will receive IO103 3 to 4 times prior to curative treatment
88875390|NCT04227366|Experimental|Group 1|BCD-089
88875391|NCT04227366|Placebo Comparator|Group 2|Placebo
89184127|NCT02599142|Active Comparator|Group A: Closed-face shells|Cranial radiotherapy using the control closed-face immobilisation shell.
89184128|NCT02599142|Experimental|Group B: open-face shell|Cranial radiotherapy using the experimental open-face immobilisation shell
89184129|NCT02590302|Other|Dyads receiving the Implementation Phase|Dyad 1 (CHEO-YSB) Dyad 2 (CGH-CCH) Dyad 3 (WDMH-CCH) Dyad 4 (QCH-YSB)
89184130|NCT04561791|Experimental|Feasibility of TCE & Prevalence of BE|"Feasibility of using tethered capsule endomicroscopy as a screening method for Barrett's esophagus in the primary care practice environment~Determine the prevalence of Barrett's esophagus in a primary care practice cohort at MGH"
89189353|NCT02545036|No Intervention|Control group|30 patients will be assigned to this arm. The assignment depends on the patients' own will. After diagnosis by nephrology physician, these patients will be distributed to control group by their wills. The control group will only receive assessment and follow-up without intervention.
89189354|NCT02544958|Experimental|Er:YAG laser|4 treatments of 1 month interval
89189355|NCT00715572|Active Comparator|A|
89399571|NCT03693027|Placebo Comparator|Placebo|Qualified subjects will dissolve one oral lozenge (placebo control) by mouth 3 times a day (after breakfast, lunch and dinner) throughout the 6 week study.
89189356|NCT00715572|Active Comparator|B|
89189357|NCT02573298|Active Comparator|Ice|patients randomized to receive local ice on inflamed joint
89383610|NCT03665376|Experimental|ERAS arm|Preoperative: Counseling and education about the ERAS program; Oral intake until 6 hours before the surgery; Carbohydrate drinks load; No mechanical bowel preparation; Antithrombotic prophylaxis (Tinzaparin 3500 IU) Intraoperative: Spinal anaesthesia (15 mg hyperbaric Bupivacaine + 200mcg intrathecal Morphine); Intravenous Ceftriaxone 2g, Metronidazole 500mg / Gentamycin 160mg, Ondansetron 8mg and Dexamethasone 8mg; Crystalloid fluid 10 to 20ml/Kg; Adrenaline 200mcg in each 500 ml of intravenous fluid; Avoidance of abdominal drains; Postoperative: Early oral intake; Nasogastric tube and urinary catheter removed immediately after the surgery; Early enteral nutrition; Chewing gum for 2 to 4 hours after surgery; Oral sips 8 hours postoperatively; Intravenous fluids discontinued at four hours after transfer to the ward.
88857177|NCT03020862|Experimental|Placebo ---> Dietary beetroot|"Placebo was administrated in the first period of the cross-over trial, while the intervention beverage Dietary Beetroot juice was administrated in the second period of the trial.~The placebo: was an NO3- negligble drink from James White Drinks England (Beet-it), which was otherwise similar to the dietary beetroot juice in nutrient composition, smell and appearance. Dose: 2x70 mL consumed twice a day for six days.~Intervention beverage, Dietary beetroot juice:Consumed as beetroot juice from James White Drinks England (Beet-it) and contained 300 mg dietary nitrate. Dose: 2x70 mL consumed twice a day for six days."
89184131|NCT04084158|Experimental|Toripalimab+chemoradiation|"Induction immunotherapy: Toripalimab injection (JS001) 3mg/kg IV q 14 days x 2 cycles.~Concurrent Chemoradiotherapy: Starting within 4 weeks after the first cycle induction immunotherapy. carboplatin AUC = 2 + albumin-bound paclitaxel 60 mg/m2 or paclitaxel liposome 45 mg/m2 or paclitaxel 45 mg/m2 IV weekly x 6 weeks concurrent with radiation to a total dose of 50.4 Gy given in 1.8 Gy fractions daily x 28 fractions.~Progression of disease (PD): The progress of the disease will be assessed within 4 weeks after concurrent chemoradiotherapy. Patients without disease progression continue to receive consolidation and adjuvant therapy.~Consolidation chemotherapy: carboplatin AUC = 6 + albumin-bound paclitaxel 260 mg/m2 or paclitaxel liposome 135 mg/m2 or paclitaxel 135 mg/m2 IV q 21 days x 6 cycles.~Adjuvant immunotherapy:Toripalimab injection (JS001) 3mg/kg IV q 14 days up to 1 year."
89184132|NCT04084158|Active Comparator|chemoradiation|"Concurrent Chemoradiotherapy: carboplatin AUC = 2 + albumin-bound paclitaxel 60 mg/m2 or Liposome paclitaxel 45 mg/m2 or paclitaxel 45 mg/m2 IV weekly x 6 weeks concurrent with radiation to a total dose of 50.4 Gy given in 1.8 Gy fractions daily x 28 fractions.~Progression of disease (PD): The progress of the disease will be assessed within 4 weeks after concurrent chemoradiotherapy. Patients without disease progression continue to receive consolidation therapy.~Consolidation chemotherapy: carboplatin AUC = 6 + albumin-bound paclitaxel 260 mg/m2 or paclitaxel liposome 135 mg/m2 or paclitaxel 135 mg/m2 IV q 21 days x 6 cycles."
89184133|NCT00714441|Active Comparator|2|Computer Automated Self-Management (CASM). Please see description below for CASM.
89184134|NCT00714441|Active Comparator|3|Computer Automated Self-Management and Problem Solving Therapy (CAPS). Please see descriptions below for CAPS (also refer to CASM with is included in the CAPS program).
89184135|NCT00714441|Active Comparator|1|Lifestyle and Activities Education Program (LEAP-AHEAD). Please see description below for LEAP-AHEAD.
89184136|NCT00746096|Experimental|IKH-01|ethinyl estradiol 0.035mg and norethisterone 1mg
89184137|NCT00746096|Placebo Comparator|Placebo|Placebo for ethinyl estradiol 0.035mg and norethisterone 1mg
89184138|NCT04084236|Active Comparator|Active TENS|
89184139|NCT04084236|Sham Comparator|Sham TENS|
89184140|NCT00714519|Experimental|1|
89184141|NCT00714519|Placebo Comparator|2|
89184142|NCT00709527|Experimental|1|
89184143|NCT00715026|Other|Trilogy AB Acetabular Hip Implant System|Post Approval Study of Device.
89184144|NCT00714675|Experimental|1|Citrulline
89184145|NCT00714675|Active Comparator|2|Amino acids
89184146|NCT00714948|Experimental|1|This is a phase II trial of gemcitabine and Split-dose cisplatin plus sorafenib.
89184147|NCT02575053||Latex group|patients who report ( a high risk for) latex allergy and will be operated on
89184148|NCT00714831|Active Comparator|CG|Control Group
89184149|NCT00714831|Experimental|IG|Intervention Group
89184150|NCT00714870|Other|1|intervention: this group will attend the nutrition and exercise program control group: this group will not attend the nutrition and exercise program
89184151|NCT02575209||Women schiz.|Women with recent diagnosis of schizophrenia
89184152|NCT02575209||Men schiz.|Men with recent diagnosis of schizophrenia
89399572|NCT02179814|Experimental|AMPT|"Experimental:~alpha-methyl-paratyrosine (AMPT, trade name: Demser), body-weight adjusted dosage (40 mg/kg body weight, maximum 4000mg) at 4 time points over 24 hours"
89184153|NCT02575209||Women healthy|Women without diagnosis of schizophrenia or other neurological and/or psychiatric diagnosis
89184154|NCT02575209||Men healthy|Men without diagnosis of schizophrenia or other neurological and/or psychiatric diagnosis
89184155|NCT00714714|Experimental|Tretinoin and Adapalene gels|Adapalene facial gel and tretinoin facial gel applied daily for two weeks on opposite sides of the face (in a split-face model)
89184156|NCT00441337|Experimental|0.3 mg/kg MDX-1106 drug|0.3 milligrams (mg) MDX-1106 drug (nivolumab) per kilogram (kg) of body weight (mg/kg) was administered in a single intravenous (IV) infusion. If criteria were met, 2 additional doses could be administered (1 every 4 weeks).
89383611|NCT03665376|No Intervention|Control arm|Preoperative: No carbohydrate drink loads, no antithrombotic prophylaxis; Mechanical bowel preparation as needed; Spinal anaesthesia, fluid therapy and antibiotherapy done according to standard hospital practice. The urinary catheter and drains were removed at the discretion of the surgeon. Postoperative: Enteral feeding delayed by the auscultation of bowel sounds. The standard hospital practices involve keeping active the nasogastric tube, fasting patients postoperative, strict bed rest… Pain control was managed with medication of choice by surgeon and anesthesiologist.
89383612|NCT03003390|Experimental|Prophylaxis with enoxaparin|A clinical nurse will administer enoxaparin subcutaneously <24 hours after insertion of the central venous catheter and then give enoxaparin subcutaneously every 12 hours until the removal of the catheter.
89383613|NCT03003390|No Intervention|Control arm|Participants randomized to the control arm will receive no 'placebo' intervention.
89383614|NCT03003000|Experimental|ibuprofen + caffeine|Fixed Dose Combination
89383615|NCT03003000|Active Comparator|ibuprofen|
89383616|NCT03003000|Placebo Comparator|placebo|
88857178|NCT03020862|Experimental|Dietary beetroot juice --> Placebo|The intervention beverage Dietary beetroot juice was administrated in the first period of the cross-over trial, while placebo was administrated in the second period of the trail Intervention beverage, Dietary beetroot juice:Consumed as beetroot juice from James White Drinks England (Beet-it) and contained 300 mg dietary nitrate. Dose: 2x70 mL consumed twice a day for six days. The placebo: was an NO3- negligble drink from James White Drinks England (Beet-it), which was otherwise similar to the dietary beetroot juice in nutrient composition, smell and appearance. Dose: 2x70 mL consumed twice a day for six days.
89383617|NCT03665298|Experimental|Needle X|Smartphone application application to enhance access to sterile needles, naloxone overdose kits, and addiction treatment programs in New York City.
89383618|NCT03665220|Experimental|Ergonomic adjustment group|Ergonomic intervention program at home for post-stroke patients. The ergonomic adjustments made were based on a prior assessment of the patient's needs in this respect, using a purpose-made home inspection form.
88857179|NCT03586128||HIV serodiscordant couples|
89383619|NCT03665220|Experimental|Kinesiotherapy + ergonomics group|A Kinesiotherapy plus ergonomic adjustments program for post-stroke patients. This group received, in addition to the ergonomic adjustments described above, sessions of postural orientation and kinesiotherapy (therapeutic exercises).
89383620|NCT03665220|Active Comparator|Healthcare education|A conservative intervention program for post-stroke patients
88857180|NCT03569436||Metastatic head and neck participants in Japan|Study in Japan targeting recurrent/metastatic HNC patients who are treated with nivolumab
88857181|NCT03582462|Experimental|IONIS FXI-LRx|Ascending single and multiple doses of IONIS FXI-LRx by subcutaneous (SC) injection.
88857182|NCT03582462|Placebo Comparator|Placebo|Sterile Normal Saline (0.9% NaCl) calculated volume to match active comparator.
89383621|NCT03666156||Whole Sample|Female, caucasians, aged 18-65 years
89383622|NCT03514680|No Intervention|Period I|-Consented patients will complete electronic versions of the PRO-CTCAE CIPN severity and interference items, 0 - 10 worst CIPN pain numerical rating scale, and QLQ-CIPN20 via tablet prior to their clinician visit at the outpatient oncology center at three consecutive clinic visits: baseline, visit 2, visit 3.
89383623|NCT03514680|Experimental|Period II|"Consented patients will complete the same battery of assessments from the usual care period at the baseline, visit 2, and visit 3 time points.~Following patient completion of the screening questionnaires, study staff will provide the clinicians with a color-coded summary of the patients' responses to the screening questionnaires and the CIPN assessment and management algorithm"
89383624|NCT04055454|Experimental|MV-LASV low dose: treatment group A|In total 24 participants will receive two low dose treatments with MV-LASV on day 0 and 28.
89383625|NCT04055454|Experimental|MV-LASV high dose: treatment group B|In total 24 participants will receive two high dose treatments with MV-LASV on day 0 and 28.
89383626|NCT04055454|Placebo Comparator|Placebo: treatment group C|In total 12 participants will receive placebo treatment on day 0 and 28.
89383627|NCT03665844|Placebo Comparator|SmartSleep Boost Off|Participants wear the device for baseline data collection in boost off mode. There is no intervention. This is known as SmartSleep Boost Off mode.
89383628|NCT03665844|Active Comparator|SmartSleep Boost On|Participants wear the device for 3 weeks in boost on mode. This is known as SmartSleep Boost On mode.
89383629|NCT04056390|Active Comparator|Substrate Modification|After obtaining a voltage map of the LA, substrate modification by catheter ablation using an irrigated radio frequency current ablation catheter will be performed aiming at low-voltage areas (LVA) < 0.5mV.
89383630|NCT04056390|Active Comparator|LAA Isolation|Patients will undergo LAA-isolation using the cryoballoon (CB). Six weeks later patients will undergo re-mapping. In case of residual conduction LAA-reisolation will be performed. In case of durable LAA isolation, interventional LAA occlusion is recommended.
89383631|NCT03665766||IFN group received Cyclosporine|Living donor liver transplantation recipients with recurrent HCV received Peg IFN-α 2a and RBV as antiviral therapy and Cyclosporine A as primary immunosuppression ,this was routinely taken not as intervention according to local practice
88857183|NCT03580278|Experimental|Cohort 1:75 mg ABY-035/AFO2|Cohort 1: 75 mg ABY-035/AFO2, once daily for 14 days
89383632|NCT03665766||IFN group received tacrolimus|Living donor liver transplantation recipients with recurrent HCV received Peg IFN-α 2a and RBV as antiviral therapy and Tacrolimus as primary immunosuppression ,this was routinely taken not as interventing according to local practice
89383633|NCT03665766||Sof plus Rbv group received Cyclosporine|Living donor liver transplantation recipients with recurrent HCV received sofosbuvir and RBV as antiviral therapy and Cyclosporine as primary immunosuppression,this was routinely taken not as intervention according to local practice
89383634|NCT03665766||Sof plus Rbv received tacrolimus|Living donor liver transplantation recipients with recurrent HCV received sofosbuvir and RBV as antiviral therapy and Tacrolimus as primary immunosuppression,this was routinely taken not as intervention according to local practice
89383635|NCT03665766||Sof,dac pus ribavirin received cyclosporine|Living donor liver transplantation recipients with recurrent HCV received daclatasvir, sofosbuvir and RBV as antiviral therapy and Cyclosporine as primary immunosuppression,this was routinely taken not as intervention according to local practice
89383636|NCT03665766||sof,dac plus rbv received tacrolimus|Living donor liver transplantation recipients with recurrent HCV received daclatasvir, sofosbuvir and RBV as antiviral therapy and Tacrolimus as primary immunosuppression,this was routinely taken not as intervention according to local practice
89383637|NCT03002610|Active Comparator|PLS|The control group will receive PLS: text format with simple explanation of the survey topic main findings and is intended for lay audience.
89383638|NCT03002610|Experimental|Infographics|Infographics format of a Cochrane systematic review summary represents the experimental intervention in the trial, where the results are presented with text and pictures.
89383639|NCT03002610|Active Comparator|Scientific abstract|Scientific abstract is the text written for the academic population and practitioners. It is also intended for control group.
89383640|NCT03665142|Experimental|Kinesio taping|In this study, Kinesio Tape Tex Gold® kinesio tape over lateral ankle (5cm*5m) is used. 36 participants were taped for the TTH.50-mm wide and 0.5-mm thick KT was applied to the upper trapezius muscle with one I-shaped tape. The tape was measured from the acromion to the hairline at the back, and the upper trapezius fibers were extended in the extended position, ie the cervical vertebrae were flexed to the opposite side and applied to the same side in the flexion and rotation position.
89383641|NCT03665142|Placebo Comparator|Exercise|Upper trapezius muscle stretching exercise was applied to the control group.
89383642|NCT03005106|Experimental|StrataGraft Skin Tissue|
89383643|NCT01004861|Experimental|PLX3397|
89383644|NCT03637361|Placebo Comparator|Arm 1|100 mL Ocean Spray® Diet Cranberry Juice
89383645|NCT03637361|Experimental|Arm 2|REL-1017 5 mg in 100 mL of Ocean Spray® Diet Cranberry Juice
89383646|NCT03637361|Experimental|Arm 3|REL-1017 20 mg in 100 mL of Ocean Spray® Diet Cranberry Juice
89383647|NCT03637361|Experimental|Arm 4|REL-1017 60 mg in 100 mL of Ocean Spray® Diet Cranberry Juice
89383648|NCT03637361|Experimental|Arm 5|REL-1017 100 mg in 100 mL of Ocean Spray® Diet Cranberry Juice
89383649|NCT03637361|Experimental|Arm 6|REL-1017 150 mg in 100 mL of Ocean Spray® Diet Cranberry Juice
89383650|NCT00038675|Experimental|Imatinib|Imatinib mesylate 400 mg orally daily, and in HES patients start with imatinib mesylate 100 mg orally daily.
89383651|NCT02974907|Experimental|RGN-259|RGN-259: It is a preservative-free, sterile eye drop solution containing Tβ4
89383652|NCT02974907|Placebo Comparator|Placebo|It is composed of the same excipients as RGN-259 but does not contain Tβ4
89383653|NCT03254459|Experimental|Buprenorphine Sublingual Spray 0.5 mg|Buprenorphine Sublingual Spray 0.5 milligrams (mg) three times a day (TID) for 7 days.
89383654|NCT03254459|Active Comparator|Standard of Care Narcotic Therapy|Morphine intravenous (IV), 4 mg TID for 24 hours, followed by oxycodone hydrochloride tablet, 10 mg TID for 6 days.
88857184|NCT03580278|Experimental|Cohort 2: 150 mg ABY-035/AFO2|Cohort 2: 150 mg ABY-035/AFO2 once daily for up to 28 days
88857185|NCT03589950|Experimental|Anlotinib plus chemotherapy|Anlotinib (12mg QD PO d1-14, 21 days per cycle) + Docetaxel (75mg/m2 IV d1)/Pemetrexed (500 mg/m2 IV d1), q21d/S-1 (80-120mg/day,depending on body surface area; days 1-28 in a 6-week cycle)
88857186|NCT03589950|Active Comparator|Chemotherapy|Docetaxel (75mg/m2 IV d1)/Pemetrexed (500 mg/m2 IV d1), q21d/S-1 (80-120mg/day,depending on body surface area; days 1-28 in a 6-week cycle)
88857187|NCT03589872||Study Group|patients with parkinson disease
88857188|NCT03589716|Other|Participants with Vital Signs Within Normal Range|All participants will be asked to have an arm and finger measurement conducted and undergo vital sign measurements using the Vital Moto Mod and reference devices for blood pressure, heart rate, respiration rate, blood oxygen saturation, and temperature. Participants with vital signs within the normal physiological range will also be asked to perform an optional exercise testing and/or undergo arterial blood gas measurement.
88857189|NCT03589716|Other|Participants with Vital Signs Outside of Normal Range|All participants will be asked to have an arm and finger measurement conducted and undergo vital sign measurements using the Vital Moto Mod and reference devices for blood pressure, heart rate, respiration rate, blood oxygen saturation, and temperature. Participants with vital signs outside of the normal physiological range would be documented.
88857190|NCT03589638|Active Comparator|direct laryngoscope|Endotracheal intubation was applied by anesthesiologist with direct laryngoscope.
88857191|NCT03589638|Active Comparator|C-MAC videolaryngoscope|Endotracheal intubation was applied by anesthesiologist with C-MAC videolaryngoscope.
88857192|NCT03589638|Active Comparator|McGrath videolaryngoscope|Endotracheal intubation was applied by anesthesiologist with McGrath videolaryngoscope.
88857193|NCT03022500|Experimental|durvalumab + tremelimumab|Durvalumab: 1.5g Q4W plusTremelimumab: 75mg Q4W up to 4cycle then Durvalumab 750mg Q2W, till PD or unacceptable toxicity.
88857194|NCT04148742|Experimental|daily dose of DZD9008|daily dose of DZD9008
88857195|NCT03589560|Experimental|Biodentine|3-4 mm of Biodentine (Septodont, St. Maur-des-Fosses, France) was applied over the clot carefully in group I by using amalgam carrier. material was packed lightly with a moistened cotton pellet and Periapical radiograph was taken to confirm coronal seal in the second visit of dental pulp revascularization.
88857196|NCT03589560|Active Comparator|Mineral Trioxide Aggregate|3-4 mm of white Mineral Trioxide Aggregate (Angelus, Londrina, Brazil) was applied over the clot in group II by using amalgam carrier. material was packed lightly with a moistened cotton pellet and Periapical radiograph was taken to confirm coronal seal in the second visit of dental pulp revascularization.
88857197|NCT04148898|Experimental|osimertinb group|Osimertinib 80 mg oral daily
88857198|NCT04148898|Experimental|osimertinb combined with bevacizumab group|"Osimertinib 80 mg oral daily;~.bevacizumab 7.5 mg/kg intravenous every 3 weeks"
88857199|NCT04148820|Experimental|Once daily drug administration|Patients will be given cardiovascular drugs once daily
88857200|NCT04148820|Experimental|Twice daily drug administration|Patients will be given cardiovascular drugs twice daily
88857201|NCT03588312||simple heart defects|Newborns with hypoplastic aortic arch in simple congenital heart defects requiring aortoplasty
88857202|NCT03588312||complex heart defects.|Newborns with hypoplastic aortic arch in complex congenital heart defects requiring aortoplasty
88857203|NCT03588234||Type 1 diabetes|Individuals with type 1 diabetes (18-29 years old). They must complete a questionnaire. This group has approximately 26 extra questions to respond to compared to controls. The extra questions pertain to their diabetes history as well as their knowledge regarding diabetes.
88857204|NCT03588234||Matched controls without Type 1 diabetes|Individuals without type 1 diabetes (18-29 years old). They must complete the same questionnaire as the individuals with diabetes (without the diabetes-specific questions).
88857205|NCT03589404|Experimental|rso2|The regional oxymetry probe will be placed in the abdominal region of the umbilicus in the middle clavicular line before the disease operation begins.
88857206|NCT04148586|Experimental|One week Whole Breast Irradiation|WBI: 27 Gy/5 fractions/1 week. 5.4 Gy /fraction ± boost to tumor bed 5.4 Gy/ 1 fraction, 2 days after the end of WBI.
88857207|NCT04148586|Experimental|Once weekly Whole Breast Irradiation|WBI: 28.5 Gy/ 5 fractions/ 5 weeks. 5.7 Gy/fraction ± boost to tumor bed 5.7 Gy/ 1 fraction, one week after the end of WBI. WBI is given on the same day each week.
88857208|NCT04148586|Active Comparator|3 weeks Whole Breast Irradiation|WBI: 40.05 Gy/ 15 fractions/ 3 weeks. 2.67 Gy/ fraction ± boost to tumor bed 10 Gy/ 4 fraction / 4 days after the end of WBI
88857209|NCT03589248||GIF score|assess the AGI by gastrointestinal failure(GIF) score
88857210|NCT03589248||US score|assess the AGI by ultrasonography(US) score
88857211|NCT03588156|Experimental|Benapenem|Investigatial Product: Benapenem: 11 group : 62.5mg one dose; 125mg one dose;250mg one dose;500mg one dose 30min infusion;500mg one dose 60min infusion ;1000mg one dose 30min infusion; 1000mg one dose 60min infusion 2000mg one dose 30min infusion;2000mg one dose 60min infusion;3000mg one dose 60min infusion;4000mg one dose 60min infusion
88857212|NCT03588156|Placebo Comparator|Placebo|Placebo control 11 group : 62.5mg one dose;125mg one dose;250mg one dose;500mg one dose 30min infusion;500mg one dose 60min infusion ;1000mg one dose 30min infusion; 1000mg one dose 60min infusion 2000mg one dose 30min infusion;2000mg one dose 60min infusion;3000mg one dose 60min infusion;4000mg one dose 60min infusion
88857213|NCT03588000|Experimental|Strength group|Strengthen self-monitoring of blood glucose by Internet mobile terminal (APP)
88857214|NCT03588000|No Intervention|Control group|Voluntary self-monitoring of blood glucose
88857215|NCT03941808|Experimental|Drug|4 pills a day (1000mg) for 3 months then 2 pills a day (500 mg) for 3 months
88857216|NCT03941808|Placebo Comparator|Placebo|4 pills a day (1000mg) for 3 months then 2 pills a day (500 mg) for 3 months
88857217|NCT03587610|Active Comparator|Intervention arm|"if the patients vaccinations are up to date: no remedial vaccination is done and the patient is informed of the next remedial vaccination date~if the patients vaccinations are not up to date: remedial vaccination is realised in the unit in the absence of contraindication, in case of a temporary contraindication the vaccination will be performed on an outpatient basis by the patients primary care provider and he will be given a prescription at hospital discharge for the remedial vaccination."
88857218|NCT03587610|No Intervention|Standard care|"if the patients vaccinations are up to date: no remedial vaccination is done and the patient is informed of the next remedial vaccination date~if the patients vaccinations are not up to date: the patient will be informed that a remedial vaccination is necessary and that he should contact his primary care provider after hospital discharge."
88857219|NCT03589092||GDM Current|"Currently pregnant women diagnosed with GDM.~Next generation sequencing (NGS) methodologies will used on individuals suspected of genetic diabetes."
88857220|NCT03589092||GDM History|"Women with history of GDM (with negative GAD/IA2 antibodies if results available).~Next generation sequencing (NGS) methodologies will used on individuals suspected of genetic diabetes."
88857221|NCT03941496|Experimental|AZA Treatment|"In Phase Ib dose escalation stage, participants will receive subcutaneous (SQ) AZA once daily x 5 days. Results from Phase Ib are sent to FDA/IRB for approval before proceeding to Phase IIa. 36 subjects will receive AZA treatment in total (Phase Ib/IIa). All participants receive standard of care antibiotics against tuberculosis.~Dose Escalation Strategy to identify the lowest dose of AZA that decreases DNA methylation and restores immune function is listed below. Proceeding to Phase IIa will proceed if stopping criteria are met at any of the steps below and FDA/IRB approval is obtained:~5 mg/m^2 subcutaneous (SQ) once daily x 5 days for 8 individuals~15 mg/m^2 subcutaneous (SQ) once daily x 5 days for 8 individuals~30 mg/m^2 subcutaneous (SQ) once daily x 5 days for 8 individuals~50 mg/m^2 SQ once daily x 5 days for 8 individuals~75 mg/m^2 once daily x 5 days for 8 individuals"
88857222|NCT03895476|Active Comparator|control group|palatal wound will not be protected with any material
88857223|NCT03895476|Active Comparator|group 1|palatal wound will be protected with Platelet rich Fibrin
88857224|NCT03895476|Active Comparator|group 2|wound will consist of collagen protection with the additional layer of cyanoacrylate surgical glue.
88857225|NCT03895476|Active Comparator|group 3|wound will consist of collagen protection with the application
88857226|NCT03020394||Noninvasive ventilation|Noninvasive positive pressure ventilation is achieved by Philips Respironics V60/Vision ventilator. Choose bilevel positive airway pressure mode, and adjust the fraction of inspire oxygen(FiO2) or oxygen flow rate to maintain patient's oxygen saturation(SpO2) between 88% to 92%. Parameter adjustment and weaning of NPPV follow the protocols used before.
88857227|NCT03020394||Invasive ventilation|Intubated immediately and connected to the ventilator. Parameter adjustment and weaning of IPPV follow the protocols used before.
88857228|NCT03020394||High flow nasal cannula|High flow nasal cannula of different models (large, medium and small) are selected depending on the size and comfort of the patient's nostrils. Adjusting the oxygen flow rate (O2 Flow) maintains the patient's SpO2 88% to 92%. The flow was initially adjusted to 25 L/min and the flow was gradually adjusted to the patient's maximum tolerance. The inspiratory gas temperature (31 to 37 °C) was set to the patient's maximum tolerance level. If the patient's condition deteriorates and the tracheal intubation standard is met , the patient is recommended to undergo invasive ventilation treatment, but the choice of the final respiratory support method should be decided by the attending physician, patient and family.
88857229|NCT04406064|Experimental|Viral Specific T-cells (VSTs)|
88857230|NCT04405752||12-mm diameter metallic billiary stent|
88857231|NCT04405752||10-mm diameter metallic billiary stent|
88857232|NCT03894150|Experimental|F0002-ADC|
89383655|NCT03620591|Active Comparator|Lidocaine|"Intraoperative administration of lidocaine to patients undergo laparoscopic cholecystectomy.~Prior induction to anesthesia, lidocaine bolus 1.5 mg / kg will be administered to the lidocaine group and then patients will be connected to a continuous 2 mg / kg / h administration of lidocaine until the end of the procedure."
88857233|NCT05702892|Experimental|periodontitis|
88857234|NCT05702892|Experimental|gingivitis|
88857235|NCT05702892|Experimental|periodontal healthy|
88857236|NCT04765410||Patients with solid pancreatic masses|Patients with solid pancreatic masses
88857237|NCT04765254||control group|COVID-19 infected patients with no other comorbidities and they take the routine protocol from the Egyptian ministry of health
88857238|NCT04765254||diabetic group|COVID-19 infected patients with diabetes comorbidity and they receive the routine protocol for covid treatment in addition to their hypoglycemic drugs
88857239|NCT03581058|Experimental|Cannabis - Jean Guy|A participant will be administered 1g of Jean Guy strain of cannabis.
88857240|NCT03581058|Experimental|Cannabis - Churchill|A participant will be administered 1g of Churchill strain of cannabis.
88857241|NCT03581058|No Intervention|Sober|All participants will complete same tasks sober.
89189358|NCT02573298|Active Comparator|Cold gas|patients randomized to receive cold gas on inflamed joint
89383656|NCT03620591|Placebo Comparator|Placebo|Intraoperative administration of normal saline to patients undergo laparoscopic cholecystectomy.
89383657|NCT03637283|Experimental|anti-VEGF|vitreoretinal surgery combined with intraoperative anti-VEGF
89383658|NCT03637283|Active Comparator|fan-shaped photocoagulation|vitreoretinal surgery combined with fan-shaped photocoagulation
89383659|NCT04363463|No Intervention|Conventional positioning|semi-seated in bed or seated in a chair during the day. The prone position is not allowed during the day (it is allowed at night if it is the natural sleeping position).
89383660|NCT04363463|Experimental|Interventional positioning : prone position|Two sessions minimum of prone position over the day. With a total objective of at least 2h30 of cumulated duration over the day. The objective is to spend as much time as possible in prone position if the patient tolerates it well.
89383661|NCT05178953|Experimental|pentoxifylline group|"Group 1: Patients receiving pentoxifylline (TRENTAL 400 mg tablets, OSPS; 400 mg, twice daily) Infertile men referred to an infertility treatment center who have had unprotected sex for at least one year have not had normal fertility in their partner. These men are all married. According to WHO criteria, sperm motility abnormalities are observed in these patients.~These volunteers receive two pentoxifylline tablets(400 mg) daily for 3 month, (TRENTAL 400 mg modified release tablets, OSPS; 400 mg ,two times daily)~Other names:~Trental"
89383662|NCT05178953|Experimental|Zinc Sulfate group|"Infertile men referred to an infertility treatment center who have had unprotected sex for at least one year have not had normal fertility in their partner. These men are all married. According to WHO criteria, sperm motility abnormalities are observed in these patients. Candidates receive one zinc sulfate tablet(229 mg) daily for 3 month,(Zinc Sulfate 220mg Capsules)~Other Names:~zinc sulfate"
89383663|NCT05178953|Experimental|pentoxifylline+ zinc group|"Infertile men referred to an infertility treatment center who have had unprotected sex for at least one year have not had normal fertility in their partner. These men are all married. According to WHO criteria, sperm motility abnormalities are observed in these patients. Candidates receive one zinc sulfate(220mg) tablet+ two pentoxifylline tablets(400 mg) daily for 3 month (TRENTAL 400 mg modified release tablets, OSPS; 400 mg +Zinc Sulfate 220mg Capsules)~Other Names:~zinc sulfate"
89184157|NCT00441337|Experimental|1 mg/kg MDX-1106 drug|1 mg MDX-1106 drug (nivolumab) per kg of body weight (mg/kg) was administered in a single IV infusion. If criteria were met, 2 additional doses could be administered (1 every 4 weeks).
88857242|NCT03580980|Active Comparator|Drug: Morphine|Morphine Group C (n=30) was the control group who received IV morphine in a dose of 0.1 mg/kg after induction of anesthesia
88857243|NCT03580980|Active Comparator|Procedure/surgery:Caudal levobupivacaine|In Caudal Group (n=30), patients were placed in the lateral position and received caudal epidural block after induction of anesthesia with levobupivacaine 0.125% , 1.1 ml/kg and morphine 0.02 mg/kg with maximum 20ml.
88857244|NCT03580980|Active Comparator|Drug: Paracetamol and ketamine|The patients of Multimodal Group (n=30) received paracetamol infusion 10 mg/kg over 10 minutes and ketamine 0.5 mg/kg IV bolus followed by ketorolac 1 mg/kg infusion over 10 minutes.
88857245|NCT04405440||Healthy controls|The healthy control group will perform a well-validated avoidance (behavioral) task and will fill in some questionnaires about eating behaviors, emotions, and feelings.
88857246|NCT04405440||Anorexia Nervosa patients|As the healthy controls, the participants of the anorexia nervosa group will perform the same behavioral task and will fill in the same questionnaires
88857247|NCT02985060|Experimental|Therapeutic hypothermia group|Therapeutic hypothermia using surface cooling device (Arctic Sun) Stroke care based on international guidelines except therapeutic hypothermia using surface cooling device (Arctic Sun)
88857248|NCT02985060|Other|Control group|Stroke care based on international guidelines
88857249|NCT03587454|Experimental|Tele-Glaucoma arm|Subjects enrolled in tele-glaucoma arm for remote assessment
88857250|NCT03587376|Experimental|Participants with Elevated Liver Enzymes|Blood samples will be collected on Day 1 from participants previously treated with atabecestat and who had elevated liver enzymes while on atabecestat.
88857251|NCT03587376|Active Comparator|Participants Without Elevated Liver Enzymes|Blood samples will be collected on Day 1 from participants who completed at least 3 months of dosing with atabecestat and who did not have the elevated liver enzymes (adverse event) while on atabecestat.
88857252|NCT03587298||Group 1|NAFLK criteria met (by definition: sonographic fatty liver)
88857253|NCT03587298||Group 2|Control group: matched age; no NAFKL
88857254|NCT04148196|No Intervention|Control group|older people's who have a Standard Mini Mental Test score of 23 and above, living in nursing homes.
88857255|NCT04148196|Experimental|Experimental group|Intervention group: older people's who have a Standard Mini Mental Test score of 23 and above, living in nursing homes.The researcher will perform 16 sessions of progressive relaxation exercises twice a week for 8 weeks. Each PMR exercise was conducted under the guidance of the researcher. Before and after each session of the Progressive Muscle Relaxation They will be measured heart rate and blood pressure.
88857256|NCT03587220|Experimental|Capsaicin+UVB group|All subjects will be treated with capsaicin, placebo + UVB, or Capsaicin+UVB.
89184158|NCT00441337|Experimental|3 mg/kg MDX-1106 drug|3 mgs MDX-1106 drug (nivolumab) per kg of body weight (mg/kg) was administered in a single IV infusion. If criteria were met, 2 additional doses could be administered (1 every 4 weeks).
88857257|NCT03587220|Experimental|Capsaicin + EMLA group|All subjects will be pre-treated with lidocain cream before capsaicin application
88857258|NCT04148274||Patients|Patients with Ulcerative Colitis diagnosis
89184159|NCT00441337|Experimental|10 mg/kg MDX-1106 drug|10 mgs MDX-1106 drug (nivolumab) per kg of body weight (mg/kg) was administered in a single IV infusion. If criteria were met, 2 additional doses could be administered (1 every 4 weeks).
89184160|NCT00578877|Active Comparator|Arm 1|Gynol II (2% N-9 gel)
89002955|NCT05983133|Experimental|SGN-EGFRd2|SGN-EGFRd2 monotherapy
89184161|NCT00578877|Experimental|Arm 2|Buffer Gel
89002956|NCT05982275|Experimental|CARTemis-1|Dose escalation sequential cohorts CARTemis-1 will be self-administered intravenously one or two days, depending on the dose administered.
89002957|NCT05980624|No Intervention|Group A|nutrition counselling plus Standard chemotherapy only. Patients will undergo only standard chemotherapy for 3 months
89002958|NCT05980624|Experimental|Group B|nutrition counselling plus standard chemotherapy adding oral nutrition supplements as described in manufacturer label daily for 3 month and
89002959|NCT05973227|Experimental|interventional arm (use of TRIDENT system)|
89002960|NCT05972590|Other|50-75 years old volunteers cohort|Biological samples collection Blood drawing + faeces collection
89002961|NCT05964998|Experimental|Active stimulation|
89002962|NCT05964998|Sham Comparator|Sham stimulation|
89002963|NCT05955573||knee osteoarthritis|Knee osteoarthritis
89002964|NCT05954507|Other|Prospective cohort of patients|Patients with suspected cardiac sarcoidosis
89184162|NCT02590146|Experimental|Intervention Group|Patients in this group will participate in pain management counseling and choose non-pharmacologic pain control supports to use during their procedure in addition to the standard of care pain management offered in the office
89184163|NCT02590146|No Intervention|Control group|Patients in this group will receive standard of care pain management offered in the office.
89184164|NCT01032343|Active Comparator|Omega-3 PUFA capsule|
89184165|NCT01032343|Placebo Comparator|Gelatine capsule|
89189359|NCT00845260|Experimental|Internet CBT|Internet-based cognitive behavior therapy (CBT).
89189360|NCT00845260|Experimental|Group CBT|Group cognitive behavior therapy (CBT).
89189361|NCT00715806|Experimental|1|
88810453|NCT06213311|Experimental|Axicabtagene Ciloleucel (axi-cel) and Glofitamab|Participants will be assigned to a dose level of glofitamab based on when you join this study. The first group of participants will receive the lowest dose level. Each new group will receive a higher dose than the group before it, if no intolerable side effects were seen.
88810454|NCT06213298|Experimental|Kava|75mg of Kava taken three times daily for 14 days. Participants will then enter into a washout period of 14-28 days.
88810455|NCT06213298|Placebo Comparator|Placebo|The placebo will be taken three times daily for 14 days. Participants will then enter into a washout period of 14-28 days.
88810456|NCT06213272|Experimental|Aerobic Exercise Treatment (AET) combined with Phono-Motor Therapy (PMT)|Patients will receive 40, once-daily 2-hour intervention sessions administered 4-5 times per week by trained research assistants. Sessions will begin with a 5-min warm-up, followed by 20 min of aerobic exercise (cycling, 60% heart rate range), and a 5-min cool-down. Participants will rate their perceived effort every 5 minutes and complete a log at the end of each session to characterize their experience. When HR returns to near resting levels (i.e., 5-min after cool-down), participants will undertake the PMT for the remaining 90 min.
88810457|NCT06213272|Active Comparator|Stretching and PMT|Patients will receive 40, once-daily 2-hour intervention sessions administered 4-5 times per week by trained research assistants. Sessions will begin with a 5-min warm-up, followed by 20 min of stretching and a 5-min cool-down. Stretching activities will target the head/neck, shoulder, elbow/forearm, hand/wrist, trunk/hip, ankle/foot. Participants will complete a log at the end of each session to characterize their experience, and within 5 min of completing the last stretching activity, participants will undertake PMT for the remaining 90 min of a given session.
88810458|NCT06213246|Experimental|Sleep Hygiene Strategies (SHS)|In Week 3, the study participants will implement sleep hygiene strategies. Specifically, these sleep hygiene strategies will be applied for all seven days of Week 3 and will involve the guidelines recommended by the National Sleep Foundation.
88810459|NCT06213220||mood disorders group|Participants are requested to wear the wristbands throughout the experiment, and upload their data every three days. Additionally, the Hamilton Depression Rating Scale (HAMD) and the Young Mania Rating Scale (YMRS) are administered once a week for measurement.
88810460|NCT06213220||healthy control group|Participants are requested to wear the wristbands throughout the experiment, and upload their data every three days. Additionally, the Hamilton Depression Rating Scale (HAMD) and the Young Mania Rating Scale (YMRS) are administered once a week for measurement.
88810461|NCT06213168|Experimental|HFNC|Patients assigned to the control group will be continuously treated by HFNC. HFNC will be initiated within one hour following randomization.
88810462|NCT06213168|Experimental|HFNC with CPAP|Patients assigned to the intervention group will receive high flow nasal oxygen plus CPAP sessions
88810463|NCT06213142|Experimental|CBToolkit|CBToolkit includes two SSI modules: (1) Mindful Awareness, with the goal of increasing awareness and tolerance of physical sensations and emotional experiences using mindfulness practices and tips and (2) Flexible Problem Solving, with the goal of promoting cognitive flexibility, applying problem-solving strategies in difficult scenarios, and learning to modify behavioral action tendencies.
88810464|NCT06213116|Experimental|MADgic Atomizer|"Group M(MADgic) acting as Intervention Group:~Patients receiving Lignocaine 30mg (3 alliquotes) given via MADgic Laryngotracheal Atomization Device prior to endotracheal intubation."
88810465|NCT06213116|Active Comparator|Lignocaine Spray|"Group S (Spray) acting as Control Group:~Patients receiving Lignocaine 30 mg (3 puffs) given via 10mg Lignocain Pump Spray prior to endotracheal intubation."
89383664|NCT02736617|Experimental|Treatment (obinutuzumab and ibrutinib)|Patients receive obinutuzumab IV over 30 minutes on days 1, 8, and 15 of cycle 1, and day 1 of cycles 2-6. Patients also receive ibrutinib PO QD on days 1-28. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients who have PR continue to receive obinutuzumab IV every 2 months and ibrutinib PO QD for 2 years in the absence of disease progression or unacceptable toxicity.
89383665|NCT05178875||NDNS participants|Random participants from all the UK (including England, Scotland, Wales and North Ireland)
89383666|NCT05178719|Experimental|PMA-zeolite|All subjects receive the substance 3 times per day in a measuring spoon as powder
89383667|NCT05572619||Positive group|A patient diagnosed with large vessel occlusion after a non-contrast CT, CT perfusion and CT angiography
89383668|NCT05572619||Negative group|A normal person or a patient not diagnosed with intracranial haemorrhage after a non-contrast CT, CT perfusion and CT angiography
89383669|NCT04670393|Experimental|FertyBiotic Woman Plus|Participants received FertyBiotic Woman Plus one sachet a day
89383670|NCT04670393|Placebo Comparator|Placebo|Participants received 400 mcg of folic acid once a day
89383671|NCT05178251||Control group without Covid 19 pandemic|- Patients who underwent an appendectomy from March 17, 2018 to December 14, 2018 and from March 17, 2019 to December 14, 2019
89383672|NCT05178251||Test group with Covid 19 pandemic|- Patients who underwent an appendectomy from March 17, 2020 to December 14, 2020
89189362|NCT00715806|Active Comparator|2|
89383673|NCT03251963|Experimental|Fixed Dose Enoxaparin|Eligible patients will be administered 40 mg enoxaparin daily and will have steady state peak and trough anti-Xa levels drawn after the third enoxaparin dose.
89383674|NCT03251963|Experimental|Variable Dose Enoxaparin|Eligible patients will be administered 0.5 mg/kg enoxaparin daily and will have steady state peak and trough anti-Xa levels drawn after the third enoxaparin dose.
89383675|NCT03287219|Active Comparator|150 mg Methylene Blue-MMX tablets|take 6 x 25mg Methylene Blue-MMX tablets equivalent to 150 mg
89383676|NCT03287219|Active Comparator|200 mg Methylene Blue-MMX tablets|take 8 x 25mg Methylene Blue-MMX tablets equivalent to 200 mg
89383677|NCT03286751|Experimental|LY900014|Single dose of 7 units (U), 15 U, and 30 U of LY900014 administered subcutaneously (SC) in three of six periods.
89383678|NCT03286751|Active Comparator|Insulin Lispro (Humalog)|Single dose of 7 U, 15 U, and 30 U of insulin lispro administered SC in three of six periods.
89383679|NCT03249935|Experimental|Azithromycin|Azithromycin 1 gm PO single dose given as directly observed
89383680|NCT03622073|Experimental|Misoprostol treatment by Midwife|Administration of misoprostol by the midwife and assessment for the primary outcome.
88857259|NCT04148040|Experimental|G-POEM for infantile hypertrophic pyloric stenosis|The procedure includes four steps: a) a transversal mucosal incision was performed at the proximal antrum. b) a submucosal longitudinal tunnel was created across the pyloric ring. c) full-thickness pyloromyotomy was performed, with a little extension of the antrum. After pyloromyotomy, an ultrathin gastroscope was used to inspect the mucosa and pyloric outlet. d) after careful hemostasis, the mucosal entry was closed by clips.
88857260|NCT03586908|Experimental|PHP-201 0.5%|PHP-201 0.5%, ophthalmic solution, topical eye drop, OU
88857261|NCT03580746||Taping and posteromedial release|Children with clubfoots are treated by taping and posteromedial release
88857262|NCT03580746||Treatment by Ponseti|Children with clubfoots are treated by Ponseti
88857263|NCT04147572|Experimental|Inhaler A, Tiotropium Easyhaler|Placebo Tiotropium Easyhaler, type A
88857264|NCT04147572|Experimental|Inhaler B, Tiotropium Easyhaler|Placebo Tiotropium Easyhaler, type B
88857265|NCT04147572|Placebo Comparator|Reference product, Spiriva modified HandiHaler|Placebo Spiriva, hard capsule inhaled via modified HandiHaler device
88857266|NCT04147572|Experimental|Substudy Test product Placebo Tiotropium Easyhaler|The substudy subjects will demonstrate the use of the inhaler.
88857267|NCT04147572|Placebo Comparator|Substudy Reference product Placebo Spiriva® HandiHaler|The substudy subjects will demonstrate the use of the inhaler.
88857268|NCT05702580|Experimental|Standard thoracentesis followed by pre-aspiration fluid agitation|Participants will undergo the standard thoracentesis followed by the experimental pre-aspiration fluid agitation technique
88857269|NCT03580590|Experimental|1st group|20 patients will receive 90 mg oral Diltiazem 3 hours pre-operative
88857270|NCT03580590|Experimental|2nd group|20 patients will receive 90 mg oral Diltiazem 3 hours pre-operative+ 10 mg/kg IV Tranexamic Acid slow infusion with saline half an hour before the induction of anesthesia
88857271|NCT03580590|Placebo Comparator|3rd group|20 patients will receive oral placebo tablet 3 hours pre-operative
88857272|NCT03934944|Experimental|Phone application arm|Participants will have access to a educational video and foot alerts at weekly intervals to supplement usual Podiatry care and education.
88857273|NCT03934944|Other|Usual care|Participants will have Podiatry care and education.
88857274|NCT03192462|Experimental|Group A (Closed to New Patient Enrollment)|"Patients with locally advanced or metastatic pancreatic adenocarcinoma who are responding following 3 cycles of first line chemotherapy will receive 6 infusions with a fixed dose of multiTAA specific T cells beginning on the 4th week of the 4th cycle of chemotherapy. MultiTAA T cell infusions will occur on day 21 (a chemotherapy off week) of each chemotherapy cycle starting on chemotherapy cycle 4."
88857275|NCT03192462|Experimental|Group B (Closed to New Patient Enrollment)|Patients with locally advanced or metastatic pancreatic adenocarcinoma who have failed first line chemotherapy or are intolerant or ineligible to receive standard of care chemotherapy will be evaluated in the clinic and receive 6 infusions (administered at monthly intervals) with a fixed dose of multiTAA specific T cells.
89383681|NCT03622073|Active Comparator|Misoprostol treatment by Doctor|Administration of misoprostol by the doctor and assessment for the primary outcome.
88857276|NCT03192462|Experimental|Group C (Closed to New Patient Enrollment)|Patients with resectable pancreatic adenocarcinoma following completion of neoadjuvant chemotherapy, radiotherapy or combination. These patients will receive 6 infusions with a fixed dose of multiTAA specific T cells. One infusion will occur 4 weeks prior to surgical resection (with an option to infuse up to one week earlier) and after the completion of all pre-operative chemotherapy and/or radiation. The subsequent 5 infusions will occur at monthly intervals beginning 8 weeks post-surgery. Following surgery all patients will additionally receive 3 months of standard of care (SOC) chemotherapy starting week 9 after surgery. Hence, SOC chemo will occur weeks 9-11, 13-15, and 17-19 post-surgery and multiTAA T cell infusions will occur at weeks 8, 12, 16, 20, and 24 post-surgery.
88857277|NCT03586752|Experimental|On-line group|On-line program course
88857278|NCT03586752|Active Comparator|Standard group|Standard program course
88857279|NCT03891576|Experimental|Niraparib 200 mg|Niraparib will be administered every day as oral at a fixed dose of 200 mg
88857280|NCT03891576|Active Comparator|Niraparib 300 mg|Niraparib will be administered every day as oral at a fixed dose of 300 mg
88857281|NCT03891576|Other|Niraparib 200mg/300mg|Niraparib will be administered every day as oral at a fixed dose of 200 mg or 300 mg
88857282|NCT03586674|Active Comparator|Ursogal|Control group : Ursogal 10-20 mg/kg/d on 2 divided dose for four months with regular follow up.
88857283|NCT03586674|Experimental|Lipanthyl + Ursogal|Therapy group: Ursogal 10-20 mg/kg/d by mouth, on 2 divided dose, and lipanthyl 10-20 mg/kg/d by mouth,once per day, for four months with regular follow up.
88857284|NCT03586440||Rounded shoulder posture group|-distance between the on table and posterior aspect of lateral part of acromion process ≥ 2.5 cm
88857285|NCT03586440||forward head rounded shoulder posture|"craniovertebral angle (CVA) ≤ 50 degree~distance between on table and acromion ≥ 2.5 cm"
88857286|NCT03586440||normal posture group|"Craniovertebral angle> 50 degree~distance between on table and acromion < 2.5 cm"
88857287|NCT03586206||Mild-moderate C.difficile infection|
88857288|NCT03586206||severe C.difficile infection|
88857289|NCT03586206||severe complicated/fulminant C.difficile infection|
88857290|NCT05697588||MCI progression|MCI-P (Compared with the baseline, MMSE score declined > 4 points per year)
88857291|NCT05697588||MCI stabilization|MCI-S (Compared with the baseline, MMSE score decreased < 4 points per year）
88857292|NCT05702346|Experimental|Intervention|Participants will receive the EPA intervention.
88857293|NCT05702346|Active Comparator|Control|This is the control group who will receive written information about health.
89383682|NCT03285113|Experimental|Ultrahigh Frequency Stimulation|Patients with chronic lower limb pain will be treated with ultrahigh frequency stimulation via lead around DRG.
88857294|NCT03156348|Experimental|Intervented|The intervention group will receive in addition to the usual care, it will receive the Clinical Pharmacist Care during hospitalization, discharge and during 2 months post-discharge, through a home visit at 30 ± 5 days post-discharge and a telephone call at 60 ± 5 days.
89002965|NCT05954312|Experimental|VVD-130037 Dose Escalation|Participants will receive ascending doses of VVD-130037, orally, once daily in 21-day treatment cycles.
89383683|NCT03000348|Active Comparator|High Dose, Once per day|Patient takes one oral dose of Cysteamine (high dose) per day, in the morning. The patient takes two oral placebo doses, one at mid-day and one in the evening.
89383684|NCT03000348|Active Comparator|High Dose, Twice per day|Patient takes two oral doses of Cysteamine (high dose) per day, one in the morning and one in the evening. The patient takes one oral placebo dose, at mid-day.
89383685|NCT03000348|Active Comparator|High Dose, Three times per day|Patient takes three oral doses of Cysteamine (high dose) per day, one in the morning, one at mid-day and one in the evening.
89383686|NCT03000348|Placebo Comparator|Placebo|Patient takes three oral doses of placebo, one in the morning, one at mid-day and one in the evening.
89383687|NCT03000348|Active Comparator|Low Dose, Three times per day|Patient takes three oral doses of Cysteamine (low dose) per day, one in the morning, one at mid-day and one in the evening.
89383688|NCT03000348|Active Comparator|Mid-Range Dose, Three times per day|Patient takes three oral doses of Cysteamine (mid-range dose) per day, one in the morning, one at mid-day and one in the evening.
89383689|NCT03283709|Experimental|Full-contour monolithic Zirconia crowns|If participants assigned to this arm are in need of surveyed crowns on RPD abutment teeth they will be fabricated from multi-layered monolithic zirconia
89383690|NCT03283709|Other|Conventional abutment crowns|If participants assigned to this arm are in need of surveyed crowns on RPD abutment teeth they will be fabricated from type III gold or high-noble metal veneered with feldspathic porcelain
89383691|NCT03664986|Experimental|Exparel pudendal block|This group will have intra-operative pudendal block performed with Liposomal Bupivacaine (EXPAREL) solution.
88857295|NCT03156348|No Intervention|Control|"The control group will receive hospital care and discharge from a clinical team previously trained in geriatric clinical pharmacology, which includes epicrisis, indications that the physician deems pertinent to the discharge and prescriptions if necessary and a medical control at 15 days post-discharge.~Information will be collected that allows the characterization:~Sociodemographic~Morbid~Pharmaco-therapeutic~Functionality before (baseline), during and after hospitalization~A physician, a pharmacist and an occupational therapist, blind to the treatment assignment, will collect the records using a specially designed record. Post-discharge evaluations will be conducted through telephone interviews at 30, 60 and 90 days after hospital discharge."
88857296|NCT03580200|Experimental|Intervention Side|Each participant is to be randomly assigned an intervention side (side of the body that will receive trigger point dry needling) and a control side (side of the body that will not receive trigger point dry needling).
88857297|NCT03580200|No Intervention|Control Side|Each participant is to be randomly assigned an intervention side (side of the body that will receive trigger point dry needling) and a control side (side of the body that will not receive trigger point dry needling).
88857298|NCT03580122|Experimental|Asparten|Asparten (arginine aspartate) 5000mg/10mL 3x/day
89002966|NCT05952401|Active Comparator|Usual Care|Patients will receive general brief advice about smoking cessation at patient tobacco treatment needs assessment then receive the intervention at 3 months.
88857300|NCT03156426||Study population|Adults with a histological, clinical or radiological diagnosis of cirrhosis who are admitted to RIE over a 4-month period will be approached by a member of their clinical care team for potential participation. Eligible patients may be recruited from accident and emergency, the acute medical unit, hepatology ward, high dependency or intensive care units. Recurrent admissions are common, so only the first admission for each recruited patient will be included. Patients will be monitored to identify acute kidney injury (AKI) during admission.
88857301|NCT03585738|Experimental|Inositol + Folic acid|Couples with PCOS infertile women, diagnosed according to the Rotterdam criteria, who access infertility center with conception desire. These women will receive oral supplementation with Inositol (Myo-inositol and D-chiro-inositol at 40:1 ratio) plus Folic acid before spontaneous conception until delivery.
89189363|NCT00851500|Experimental|low dose K-604|
89189364|NCT00851500|Experimental|high dose K-604|
89383692|NCT03664986|No Intervention|Comparison group|This group will be those to receive current standard treatment with no pudendal block performed.
89383693|NCT03492918|Experimental|pembrolizumab group|Drug:Pembrolizumab Dose/Potency:200 mg Dose Frequency:Q3W Route of Administration:IV infusion Regimen/Treatment Period:Day 1 of each 3 week cycle Use:Experimental
89383694|NCT03247673|Experimental|CT-P16|CT-P16 will be administrated once in IV infusion of 5mg/KG to healthy male subjects
89383695|NCT03247673|Active Comparator|EU-approved Avastin|EU-approved Avastin will be administrated once in IV infusion of 5mg/KG to healthy male subjects
89383696|NCT03247673|Active Comparator|US-licensed Avastin|US-licensed Avastin will be administrated once in IV infusion of 5mg/KG to healthy male subjects
89383697|NCT03665610||Mandatory Safety Population|All subjects who enrolled in studies RPC01-1912, RPC01-1913, or RPC01-1914 and received at least one dose of ozanimod or IP (per parent studies), excluding subjects who discontinued during Period 1 of study RPC01-1913.
89383698|NCT03665610||Optional pharmacokinetic(s) and pharmacodynamics(s) population|Subjects in study RPC01-1913 have completed the study at least through Period 2 and completed the 7 ± 2 days postdose follow-up assessments; or subjects in study RPC01-1914 have completed the study through the 7 ± 2 days postdose follow-up and had no major protocol violations in the parent studies that are deemed to impact PK or PD assessments.
89383699|NCT03665532|Experimental|Interactive 2-way texting|Biweekly text message communications with counselors for problem solving
89383700|NCT03665532|Active Comparator|Passive text reminders|Automated weekly text message health care reminders
89383701|NCT03664908|Experimental|serum samples of SLE patients without LN|100 serum samples coming from systemic lupus erythematosus (SLE) patients without lupus nephritis (LN).
89383702|NCT03664908|Experimental|serum samples of Lupus nephritis (LN) patients|100 serum samples coming from systemic lupus erythematosus(SLE) patients with lupus nephritis (LN)
89383703|NCT03664908|Experimental|healthy voluntary blood donors (control group)|100 serum sample coming from 100 healthy voluntary blood donors (provided by Regional blood center of Reims). This arm will be our control group.
89383704|NCT03622944|Active Comparator|Muscle energy technic|post isometric relaxation technics were used as muscle energy technics.
89383705|NCT03622944|Active Comparator|Deep Friction Massage|Painful areas palpated and deep friction massage was applied.
89383706|NCT03622944|Active Comparator|exercise|Physiotherapist guided Spinal stabilization exercises were applied.
89383707|NCT03247517|Placebo Comparator|Placebo|Placebo, qd, oral capsule
89383708|NCT03247517|Experimental|200mg SPN-812|200mg SPN-812, qd, oral capsule
89383709|NCT03247517|Experimental|400mg SPN-812|400mg SPN-812, qd, oral capsule
89383710|NCT03665454|Experimental|PF-06412562|Subjects will receive 25 mg of PF-06412562 twice daily on study Days 2 and 3, along with placebo carbidopa/levodopa dosed at these times. Additional carbidopa/levodopa placebo capsules also will be administered according to the subject's home regimen.
89383711|NCT03665454|Active Comparator|Standard of Care carbidopa/levodopa|Subjects will take placebo tablets for the PF-06412562 twice daily on study Days 2 and 3, along with active carbidopa/levodopa (25/100 mg) administered at these times. Additional active carbidopa/levodopa capsules also will be administered according to the subject's home regimen.
89383712|NCT03664440|Placebo Comparator|continuation arm|patients who currently received TDF/3TC/NVP (group A) or TDF/FTC/NVP (group B) were block 4 randomly assigned (1:1) by computer-generated random numbers, to continue their current regimen of NVP 200 mg twice daily plus TDF/3TC (group A1) and plus TDF/FTC (groupB1)
89383713|NCT03664440|Active Comparator|switch arm|patients who currently received TDF/3TC/NVP (group A) or TDF/FTC/NVP (group B) were block 4 randomly assigned (1:1) by computer-generated random numbers to switch from NVP to RPV 25 mg once-daily plus TDF/3TC (group A2) and plus TDF/FTC (groupB2)
89383714|NCT04050306||Adolescents and young adults|Participants 12-19 years old without chronic diseases.
89383715|NCT03663738|Active Comparator|health mobile app for T2DM patients|It consists of a mobile app that will be provided to patients during a period of 12 months, the patient can also continue with the usual care. The application will be synchronized with a server where all the information is recorded for further analysis. The central focus of the application consists of continuous support and monitoring through the app that has a personalized and dynamic virtual coach that will help the patient to adopt healthy habits and change their behaviors through training plans in different areas: exercise physical, healthy eating, therapeutic education and emotional management
89383716|NCT03663738|No Intervention|Control|Receives the usual care as established in the Canary Islands Atherosclerotic Vascular Disease Prevention and Control Program (EVA)
89383717|NCT03283553|Experimental|Multicomponent Intervention|1.) A one-page paper-pencil agenda setting checklist completed immediately before a regularly scheduled medical oncology visit to elicit and align patient and companion perspectives regarding issues to discuss with the provider, and to stimulate discussion about the role of the companion in the visit, 2.) facilitated registration for the patient portal (for patient and family member, as desired by the patient), and 3.) education (as relevant) on access to doctor's electronic visit notes.
89383718|NCT03283553|Placebo Comparator|Usual Care|Care as usual with the medical oncologist.
89189365|NCT00851500|Placebo Comparator|placebo|
89189366|NCT00711204|Placebo Comparator|1|
89383719|NCT03664596|Experimental|Dietary supplement only|Participants will take a sublimated mare milk of 1 sachet 3 times a day during 2 months.
89383720|NCT03664596|Other|Dietary supplement and ursodeoxycholic acid therapy|Patients with non-alcoholic steatohepatitis will take ursodeoxycholic acid (2-3 times/day) combined with the mare's milk supplement (1 sachet, 3 times/day) for two months.
89383721|NCT03664596|Active Comparator|Ursodeoxycholic acid therapy only|Patients with verified diagnosis of non-alcoholic steatohepatitis would be given treatment of ursodeoxycholic acid (2-3 times/day) for a two-month period.
88857302|NCT03585738|Placebo Comparator|Folic acid|Couples with PCOS infertile women, diagnosed according to the Rotterdam criteria, who access infertility center with conception desire. These women will receive oral supplementation with Folic acid before spontaneous conception until delivery.
88857303|NCT03583164|Experimental|F901318|open-label single-arm of F901318 as treatment of invasive fungal infections due to Lomentospora prolificans, Scedosporium spp., Aspergillus spp., and other resistant fungi which are susceptible to F901318 in patients with limited treatment options.
88857304|NCT03589326|Experimental|Cohort A: Ponatinib 30 milligram (mg)|Ponatinib 30 mg, tablets, orally, once daily (QD), with vincristine 1.4 mg/m^2 (max 2 mg) intravenous (IV), on Days 1 and 14 and dexamethasone 40 mg (<60 years [yrs]) and 20 mg (≥60 yrs), orally, once on Days 1 to 4, Days 11 to 14 for up to 3 cycles (each cycle=28 days) in induction phase (reduced dose of ponatinib 15 mg upon achievement of MRD-negative CR at end of induction) followed by ponatinib last induction phase dose with cytarabine, 1000 mg/m^2 as 2-hour IV infusion (<60 yrs) and 250 mg/m^2 (≥60 yrs) every 12 hours, IV on Days 1, 3, 5 of Cycles 2,4,6 and methotrexate, 1000 mg/m^2 (<60 yrs) and 250 mg/m^2 (≥60 yrs), IV infusion, on Day 1 of cycles 1, 3, 5 in consolidation phase followed by ponatinib last consolidation phase dose with vincristine 1.4 mg/m^2 (max 2 mg), IV, on Day 1 and prednisone 200 mg (<60 yrs), 100 mg (≥60-69 yrs) and 50 mg(≥70 yrs) on Days 1 to 5 for up to 11 cycles in maintenance phase up to data cut-off date: 12 August 2022.
88857305|NCT03589326|Active Comparator|Cohort B: Imatinib 600 mg|Imatinib 600 mg, tablets, orally, QD, with vincristine 1.4 mg/m^2 (max 2 mg), IV, on Days 1 and 14 and dexamethasone 40 mg (<60 yrs) and 20 mg (≥60 yrs), orally, once on Days 1 to 4 and Days 11 to 14 in each 28-day cycle for up to 3 cycles in the induction phase followed by imatinib 600 mg, tablets, orally, QD, with cytarabine, 1000 mg/m^2 every 12 hours as a 2-hour-IV infusion (<60 yrs) and 250 mg/m^2 every 12 hours (≥60 yrs), IV on Days 1, 3, and 5 of each 28-day even cycles (Cycles 2, 4, and 6), and methotrexate, 1000 mg/m^2 (<60 yrs) and 250 mg/m^2 (≥60 yrs), IV infusion, on Day 1 of each 28-day odd cycles (Cycle 1, 3, and 5) in consolidation phase followed by imatinib 600 mg, tablets, orally, QD, along with vincristine 1.4 mg/m^2 (max 2 mg), IV, on Day 1 and prednisone 200 mg (<60 yrs), 100 mg (≥60-69 yrs) and 50 mg (≥70 yrs) on Days 1 through 5 in each 28-day cycle up to 11 cycles in maintenance phase up to data cut-off date: 12 August 2022.
88857306|NCT05684640|Experimental|Rodatristat ethyl|Part One: is 600 QD
88857307|NCT05684640|Placebo Comparator|Placebo|Part Two: Placebo match for Rodatristat ethyl
88857308|NCT03586362||Treatment Group A|Patients admitted for pneumonia whose MRSA nasal swab is negative for MRSA, and empiric vancomycin is discontinued within 24 hours of the MRSA nasal swab results being documented in the electronic health record.
88857309|NCT03586362||Treatment Group B|Patients admitted for pneumonia whose empiric vancomycin is continued for ≥24 hours after electronic health record documentation of negative MRSA nasal swab results.
88857310|NCT03585192|Experimental|Skin Group|Pulse oximeter probe is placed on right wrist of vigorous neonate after vaginal birth. If randomized to skin group, neonate will initiate skin-to-skin contact after umbilical cord is cut and dried with warm blankets on Mother's abdomen. Length of monitoring will be for first hour of life.
88857311|NCT03585192|Active Comparator|Warmer Group|Pulse oximeter probe is placed on right wrist of vigorous neonate after vaginal birth. If randomized to warmer group, neonate will initiate skin-to-skin contact after 20 minutes of observation under the radiant warmer. Length of monitoring will be for first hour of life.
88857312|NCT03585426|Experimental|Vancomycin 1g q12h|
88857313|NCT03585426|Experimental|Vancomycin 1g q8h|
88857314|NCT03585036|Active Comparator|dexketoprofen|"Drug: dexketoprofen Women will receive oral dexketoprofen 25mg 2 hours before the procedure~Drug: Placebo 1 Women will receive an oral placebo similar to Tramadol 2 hours before the procedure."
88857315|NCT03585036|Active Comparator|tramadol|"Drug: Tramadol Women will receive oral Tramadol 100 mg 2 hours before the procedure~Drug: Placebo 2 Women will receive an oral placebo similar to dexketoprofen 2 hours before the procedure~."
88857316|NCT03585036|Placebo Comparator|placebo|"Drug: Placebo 1 Women will receive an oral placebo similar to Tramadol 2 hours before the procedure.~Drug: Placebo 2 Women will receive an oral placebo similar to dexketoprofen 2 hours before the procedure"
88857317|NCT03584880|Experimental|Diode Laser disinfection|Diode laser disinfection Laser type: 940 nm diode laser Power: 1 Watt Tip: 200 micrometer fibre tip
88857318|NCT03584880|Placebo Comparator|Pseudo Diode Laser Disinfection|Inactivated Diode laser application in root canal
88857319|NCT03155568|Active Comparator|sciatic nerve block|ultrasound guided sciatic nerve block by injecting 30ml of 0.5% bupivacaine and visualized circumferentially spreading around the sciatic nerve
88857320|NCT03155568|Active Comparator|ankle block|ankle block performed by injecting 20 ml of 0.5% bupivacaine in equal amounts around the five major nerves supplying the foot
88857321|NCT03155568|Active Comparator|combined popliteal and ankle block|combined block performed by the use of 20 ml of 0.25% bupivacaine for sciatic nerve block followed by the ankle block with use of 20 ml of 0.5% bupivacaine both in the same manner as other two groups.
88857322|NCT03584802|Experimental|Experimental treatment of AE-IPF|The experimental group will receive a combination of: 1- Methylprednisolone bolus of 1g IV day 1, then 20 mg/day (or oral prednisolone equivalent) for 21 days; 2- Nine therapeutic plasma exchanges of 1,5x the estimated plasma volumes using albumin: saline (3:1) or fresh frozen plasma in case of an INR superior to 1,5, on days 1,2,3,5,7,9,11,13,15; followed by administration of low dose of intravenous immunoglobulin (100mg/kg) 3, Rituximab 1g IV on days 7 and 15 (after therapeutic plasma exchange and premedication) 4, Intravenous immunoglobulin 0,5g/kg/d on days 16 to 19,
88857323|NCT03584802|Active Comparator|Conventional treatment of AE-IPF|Intravenous methylprednisolone bolus of 10mg/kg on day1, 2 and 3, then 1mg/kg/d for 1 week, and 0,75 mg/kg/d for 1 week, then 0,5 mg/kg/d for 1 week, and 0,25 mg/kg/d for 1 week, and 0,125 mg/kg/d until day 90. Shift to oral prednisone as soon as the oral route is available.
89189367|NCT00711204|Active Comparator|2|
89383722|NCT03283319|Experimental|3.75 ug Panblok H7 plus AS03|Participants dosed intramuscularly (IM) on Days 1 and 29 with 3.75 ug Panblok H7 plus AS03
89383723|NCT03283319|Experimental|7.5 ug Panblok H7 plus AS03|Participants dosed intramuscularly (IM) on Days 1 and 29 with 7.5 ug Panblok H7 adjuvanted with AS03
89383724|NCT03283319|Experimental|15 ug Panblok H7 plus AS03|Participants dosed intramuscularly (IM) on Days 1 and 29 with 15 ug Panblok H7 adjuvanted with AS03
89383725|NCT03283319|Experimental|3.75 ug Panblok H7 plus MF59|Participants dosed intramuscularly (IM) on Days 1 and 29 with 3.75 ug Panblok H7 adjuvanted with MF59
89383726|NCT03283319|Experimental|7.5 ug Panblok H7 plus MF59|Participants dosed intramuscularly (IM) on Days 1 and 29 with 7.5 ug Panblok H7 adjuvanted with MF59
89383727|NCT03283319|Experimental|15 ug Panblok H7 plus MF59|Participants dosed intramuscularly (IM) on Days 1 and 29 with 15 ug Panblok H7 adjuvanted with MF59
89383728|NCT03549533||artificial insemination|Patient who perform his first artificial insemination will be included. Samples of sperm will be analyzed.
89383729|NCT01313975||1|Patients with non-traumatic subarachnoid hemorrhage
89383730|NCT01313975||2|Patients with severe traumatic brain injury
89383731|NCT03637829|Placebo Comparator|Control|250 mL of water
89002967|NCT05952401|Experimental|"Nudges to Quit"|Patients will receive a multilevel intervention that includes reminders to care team to increase tobacco treatment engagement.
89383732|NCT03637829|Active Comparator|White Chocolate|White chocolate (40 g)
89383733|NCT03637829|Experimental|Dark chocolate 1|Dark chocolate (40 g)
89383734|NCT03637829|Experimental|Dark chocolate 2|Dark chocolate (46 g) possibly containing caffeine and/or theobromine
89002968|NCT05949801|Experimental|Investigational drug group|Neucardin+standard basic therapeutic medication
89383735|NCT03282227|Experimental|M207 Microneedle System 3.8 mg|M207 Microneedle System 3.8 mg (1.9 mg/patch x 2 patches)
89383736|NCT04696835|Experimental|children with hearing aids|
89383737|NCT04696835|Sham Comparator|control group|
89383738|NCT05158127|Experimental|Treatment Group (AlloRx)|intravenous infusion and intralesional injection of 100 million cells
89383739|NCT05157035|Experimental|Mindfulness/Acceptance-Based Smartphone App (MABSA) Intervention Group|The intervention is 6 weeks in duration. Participants will be asked to listen daily to at least one audio-guided mindfulness meditation embedded in the app. They will also be asked to watch a weekly video lesson on mindfulness and acceptance and will be asked to write a reflection about the video. They will also receive weekly emotional and technical support during the duration of the intervention.
89383740|NCT05157035|No Intervention|Wait-List Control Group|The control group is a wait-list control group. Participants in the control group will be offered to use the app after 10 weeks of being in the study. The control group participants once they opted to use the app after 10 weeks will only have access to the app for 6 weeks.
89383741|NCT05571605|Experimental|Exercise Training|Participants will exercise 3 times a week on a stationary bicycle. Exercise intensity will begin at low levels (50% of maximal heart rate reserve) and increase as tolerated to a maximum of 80% of maximal heart rate reserve. Exercise time will progress from an initial 20 minutes per session to a maximum of 45 minutes per session.
89383742|NCT05571605|Placebo Comparator|Stretching|Participants will undergo progressive whole body stretching and balance exercises. This type of low intensity exercise is designed not to increase heart rate but rather to improve joint mobility and the ability to perform activities of daily living. This will serve as the control group to the exercise group. The control group will come in for stretching sessions 3 times per week for 20-45 minutes.
89383743|NCT03240575|Experimental|Tiotropium + Olodaterol fixed dose combination|
89383744|NCT03240575|Active Comparator|Fluticasone propionate + Salmeterol fixed dose combination|
89383745|NCT05571371||Epileptic seizure|Measuring inflammatory serum biomarkers in epileptic seizure patients and psychogenic non-epileptic seizure
89383746|NCT03385265|Experimental|DIPPer Academy|Parents randomized to this group will participate in the DIPPer Academy curriculum.
89383747|NCT03385265|Active Comparator|Standard of Care Control|Parents randomized to this group will receive care as usual from their child's diabetes provider
89383748|NCT03280121|Experimental|TIF using EsophyX ZR transoral device|Transoral incisionless fundoplication which is a minimally invasive treatment for gastroesophageal reflux disease (GERD) using EsophyX ZR transoral device
89383749|NCT03233009|Experimental|Test Product 1|Participants will topically apply test product 1 via semi occlusive patch.
89383750|NCT03233009|Experimental|Test Product 2|Participants will topically apply test product 2 via semi occlusive patch.
89383751|NCT03233009|Experimental|Test Product 3|Participants will topically apply test product 3 via semi occlusive patch.
89383752|NCT03233009|Experimental|Test Product 4|Participants will topically apply test product 4 via semi occlusive patch.
89383753|NCT03233009|Sham Comparator|Reference Product|Participants will topically apply Reference product via semi occlusive patch.
89002969|NCT05949801|Placebo Comparator|placebo group|Placebo + standard basic therapeutic medication
89002970|NCT05949593|Experimental|LBS-008, Tinlarebant|
89002971|NCT05949593|Placebo Comparator|Placebo|
89383754|NCT04034225|Experimental|SNS-301 added to pembrolizumab|"SNS-301~Pembrolizumab"
89189368|NCT04042870|Experimental|Joint Loosening Yoga|Yoga Intervention. Dose: 15 minutes, M-F for 4-weeks.
89189369|NCT05810857|Other|Motor Relearning Program|
89383755|NCT05571215|Experimental|Combined tDCS and PNE|This is a single-arm pilot study used to evaluate the treatment effects of combining pain neuroscience education (PNE) and transcranial direct current stimulation (tDCS). All participants will receive the same Intervention, which includes five sessions of tDCS to the left dorsolateral prefrontal cortex (DLPFC) plus PNE over two weeks.
89383756|NCT03690947|Experimental|Combination Therapy Group|
89383757|NCT03690947|Active Comparator|Intravitreal Ranibizumab Group|
89383758|NCT01313741|Experimental|Single arm shoulder arthroplasty|
89383759|NCT02999178|Experimental|Nintedanib|
89383760|NCT02999178|Placebo Comparator|Placebo|
89383761|NCT02959190|Experimental|120mg/120mg Galcanezumab - Episodic Migraine (EM)|240 milligram (loading dose) of Galcanezumab at first dosing visit followed by 120 milligram (mg) once a month for a year by subcutaneous (SC) injection. EM participants (pts) rolled over from CGAN (NCT02959177) 120 mg Galcanezumab.
89383762|NCT02959190|Experimental|240mg/240mg Galcanezumab - EM|240 mg Galcanezumab given SC once a month for a year. EM participants rolled over from CGAN (NCT02959177) 240 mg Galcanezumab.
89383763|NCT02959190|Experimental|Placebo/ 120mg Galcanezumab - EM|240 mg (loading dose) of Galcanezumab at first dosing visit followed by 120 mg once a month for a year by SC injection. EM participants rolled over from CGAN (NCT02959177) placebo.
89184166|NCT02573727|Experimental|Nor Adrenaline + Albumin|"Intravenous continous infusion of terlipressin at the dose of 2 mg every 24 hours with the maximum daily cumulative dose of 12 mg/day.~In case of no response the dose of the terlipressin will be progressively increased to the maximum infusion dose of 12 mg/24 hour.~Patients will be given 1g/Kg of albumin per day, which will be discontinued if CVP is more than 18 cm H2O."
89383764|NCT02959190|Experimental|Placebo/ 240mg Galcanezumab - EM|240 mg Galcanezumab given SC once a month for a year. EM participants rolled over from CGAN (NCT02959177) Placebo.
89383765|NCT02959190|Experimental|120mg Galcanezumab - CM|240 mg (loading dose) of Galcanezumab at first dosing visit followed by 120 mg once a month for a year by SC injection. Participants with CM were enrolled.
89383766|NCT02959190|Experimental|240mg Galcanezumab - CM|240 mg Galcanezumab given SC once a month for a year. Participants with CM were enrolled.
89383767|NCT02031614|Experimental|Phlebotomy|Subjects in this arm will undergo phlebotomy of 500 mL of blood.
89383768|NCT01344356|Other|Benign Tumors|Benign head and neck tumors will be treated with SBRT
89383769|NCT01344356|Other|Malignant Tumors|Malignant Head and Neck Tumors will be treated with SBRT.
89383770|NCT03640130|Experimental|Single Arm|Each participant will participate in several blocks (randomized order), to evaluate performance with and without behavioral gaze-contingent text enhancements.
89383771|NCT03618992|Active Comparator|Cohort 1|Subjects will be provided with containers of topical cholesterol-containing moisturizers to be applied to the skin and hair, identical except for labels designating left and right. Topical formulations will be purchased by Skin Actives Scientific (www.skinactives.com), and will consist of one container of intervention and one of vehicle only (see ingredients below), to be applied to the left or right arm as indicated by pre-randomization assignment. Patients will be instructed to begin a 1-week washout period in which they will stop all topicals, and will then begin daily application of the topical intervention products to the indicated sites. Patients will return for follow-up visits at 2, 6, 10, and 14 weeks after starting intervention.
89399573|NCT02179814|Sham Comparator|Diphenhydramine & placebo|Diphenhydramine (25mg, trade name in Switzerland: Benocten) at the first medication intake time point, placebo at the second to fourth intake time point (medication intake over 24 hours)
89184167|NCT02573727|Active Comparator|Terlipressin + Albumin|"Continuous IV infusion of NA starting at 0.5 mg/h with doubling of dose after every 4 hours designed to achieve an increase in MAP of at least 10 mmHg or an increase in 4-h urine output of more than 200 ml. When one of these goals was not achieved, the noradrenaline dose was increased every 4 h in steps of 0.5 mg/h, up to the maximum dose of 3 mg/h.~Patients will be given 1g/Kg of albumin per day, which will be discontinued if CVP is more than 18 cm H2O."
89184168|NCT00709683||A|
89184169|NCT04085874|Experimental|FBR group|weekly home visit and monthly group meeting for 12 weeks
89184170|NCT04085874|Active Comparator|non-FBR group|once nutrition counseling from standard health care services
89184171|NCT04510467||case group|RMD patients with COVID 19 infection
89184172|NCT04510467||control group|RMD patients without COVID 19 infection
88857324|NCT03584568|Experimental|Perspective Taking Reappraisal|This arm focuses on reappraisals with perspective taking with a limited amount of basic skill building
88857325|NCT03584568|Other|Basic Skill Building|This arm focuses on basic skill building only.
88857326|NCT03020238|Placebo Comparator|BiClamp group|BiClamp forcep (BiClamp® forcep, ERBE Elektromedizin, GmbH, Tuebingen, Germany) is used to dissect inferior hypogastric plexus
88857327|NCT03020238|Active Comparator|water jet group|water jet (ERBEJET®2, ERBE Elektromedizin, GmbH, Tuebingen, Germany) is used to dissect inferior hypogastric plexus
88857328|NCT03584412|Experimental|ACT OPEN|Acceptance and Commitment Therapy Online for Painful Peripheral Neuropathy (ACT OPEN).
88857329|NCT03584412|Other|Waiting List Control|Participants in this condition will not receive any change to their usual treatment for a period of 5 months, after which they will be given access to complete the ACT OPEN treatment.
88857330|NCT03155646|Active Comparator|DEXMEDETOMIDINE|patients will receive ultrasound-guided TAP block using 0.3 ml/kg levobupivacaine (0.125%) with a maximum volume of 20 ml each side + 0.5 ug/kg dexmedetomidine Hydrochloride dissolved in 2 ml normal saline (NaCl 0.9%).
88857331|NCT03155646|Active Comparator|CLONIDINE|patients will receive ultrasound-guided TAP block using 0.3 ml/kg levobupivacaine (0.125%) with a maximum volume of 20 ml + 0.5 ug/kg clonidine dissolved in 2 ml normal saline (NaCl 0.9%).
88857332|NCT03155646|Active Comparator|LEVOBUPIVACAINE|patients will receive ultrasound-guided TAP block using 0.3 ml/kg levobupivacaine (0.125%) with a maximum volume of 20 ml + 2 ml normal saline (NaCl 0.9%).
88857333|NCT03584178|Experimental|Mucosal Atomization Device|Budesonide via MAD Device
89184173|NCT00918840||DermaVir + HAART|"Dosage: 0.4 mg DNA~Dosage form: 3.2 mL DNA/PEIm nanomedicine~Administration with 4 DermaPrep patches~Frequency: every 4 weeks~Duration: 8 weeks (3 DermaVir treatments)"
89184174|NCT00918840||Placebo + HAART|"Dosage form: 3.2 mL Placebo~Administration with 4 DermaPrep patches~Frequency: every four weeks~Duration: 8 weeks (3 Placebo treatments)"
89189370|NCT05810857|Other|Mirror Therapy|
89189371|NCT05810844|Experimental|Motor Relearning Program (MRP)|
89189372|NCT05810844|Experimental|Neuro Development Treatment (NDT)|
89189373|NCT05810831|Experimental|Massage with post isometric relaxation exercises|
89189374|NCT05810831|Experimental|Massage|
89189375|NCT05810818|Experimental|Dry needling along stretches and soft tissues therapy|
88857334|NCT03584178|Experimental|Intranasals Saline Irrigation|Budesonide via Intranasals Saline Irrigation
88857335|NCT04405206||Group A:Clinical complete response (cCR)|Group A:Clinical complete response (cCR) Patients who achieve cCR when restaged by DRE-Endoscopy-MRI-CEA at 16 weeks following intensity modulated radiotherapy(IMRT) plus consolidation CapeOX(Capecitabine+Oxaliplatin) will receive Nonoperative Management(NOM).
88857336|NCT04405206||Group B:Near-cCR|Patients who achieve near-cCR when restaged by DRE-Endoscopy-MRI-CEA at 16 weeks following intensity modulated radiotherapy(IMRT) plus consolidation CapeOX(Capecitabine+Oxaliplatin) will receive Local Excision(LE) or Nonoperative Management(NOM).
88857337|NCT04405206||Group C:Residual tumor|Patients with residual tumor when restaged by DRE-Endoscopy-MRI-CEA at 16 weeks following intensity modulated radiotherapy(IMRT) plus consolidation
88857338|NCT03101046|Other|Group1: Arm A (standard arm) + Arm B (experimental arm)|"Arm A: Patients with docetaxel resistant mCRPC (defined as having ≥5 CTCs / 7.5 mL) will receive up to 8 additional cycles of docetaxel (75 mg/m² every 3 weeks) after randomization.~Arm B: Patients with docetaxel resistant mCRPC (defined as having ≥5 CTCs / 7.5 mL) will receive up to 10 cycles of cabazitaxel (20 mg/m² every 3 weeks) after randomization."
88857339|NCT03101046|Other|Group 2: Cohort|Patients with docetaxel sensitive mCRPC (defined as having <5 CTCs / 7.5 mL) will receive up to 8 additional cycles of docetaxel (75 mg/m² every 3 weeks)
88857340|NCT03152448||Early Stage Prostate Cancer|Recently diagnosed treatment-naïve patients with early stage localized prostate cancer
88857341|NCT03159936|Experimental|Tofacitinib citrate|All participants will take one 5 mg tablet by mouth in the morning and one tablet by mouth in the evening for the 6-month study duration.
88857342|NCT03027414|Experimental|Substudy 1 Active and Sham|HVs that receive TMS over the right dlPFC
88857343|NCT03027414|Experimental|Substudy 2 Active and Sham|HVs that receive TMS over the right dlFPC
88857344|NCT03027414|Experimental|Substudy 3 Active and Sham|HVs will receive offline TMS to the lest IPS (FPN)
88857345|NCT03156816|Experimental|Colchicine|The patients will receive an oral bolus of colchicine of 2 mg followed by 0.5 mg b.i.d. during 5 days.
88857346|NCT03156816|Placebo Comparator|Control arm|The patients will receive an oral bolus of placebo of 2 mg followed by 0.5 mg b.i.d. during 5 days.
88857347|NCT03157830||Ocrelizumab, OCREVUS|Patients eligible for this study will be receiving OCREVUS as part of their routine care for MS treatment, and undergo the standard monitoring tests and procedures for MS patients receiving treatment. In addition, they will complete the EDSS scale on 6 occasions over a 12-month period, and the MSIS-29 on three occasions during the 12 month period for research.
88857348|NCT03583944|Experimental|Eribulin Mesylate 1.23 mg|Participants will receive eribulin mesylate 1.23 mg intravenous (IV) infusion, given over 2 - 5 minutes on Days 1 and 8 of 21 days cycle for a total of 6 cycles.
88857349|NCT02841696||Hypertensive people|Hypertensive people recruited 10 years ago before any anti-hypertensive treatment
88857350|NCT04764786|Experimental|EVOO+POLY|Acute test meal
88857351|NCT04764786|Active Comparator|OO-POLY|Acute test meal
88857352|NCT03583476||CLA triple therapy|Patients with clarithromycin-containing triple therapy
88857353|NCT03583476||MET triple therapy|Patients with metronidazole-containing triple therapy
88857354|NCT03583476||Concomitant therapy|Patients with concomitant therapy
89189376|NCT05810818|Active Comparator|stretching and soft tissue mobilization|
88857355|NCT03583476||Sequential therapy|Patients with sequential therapy
88857356|NCT03583398||TAVI TAo|
88857357|NCT03583398||TAVI TF|
88857358|NCT03583398||AVR|
88857359|NCT03583320|Experimental|Arm A (Cardiac CT)|Patients randomised to Arm A i.e. the intervention arm will under go standard of care patient hospital management but will also have cardiac CT angiogram (CTCA) carried out. Their subsequent clinical management will be left to clinician discretion in light of the additional CTCA results.
88857360|NCT03583320|No Intervention|Arm B (Standard of care arm)|"Patients randomised to Arm B will receive usual standard of care management guided by serial troponin blood tests. These patients will also under go cardiac CT angiogram (CTCA) but these scans will not be used for the patients' in-hospital care.~Furthermore, unlike Arm A, CTCA interpretation followed by reporting will not take place in the acute hospital setting and therefore will be carried out within the following three weeks. Should the CTCA be found to have significant high risk CAD e.g. >50% stenosis in the left main (LM) coronary artery, and/or >50% stenosis in the proximal left anterior descending (LAD) coronary artery, they will be un-blinded and kept in a separate registry. Their results will be discussed with the hospital care team and if they have not had any invasive coronary imaging during the preceding hospital admission, an urgent cardiology out-patient referral will be made to enable further clinical management."
88857361|NCT03583242||DME treat with antiangiogenic|"3 Intravitreal injections of 0.05 ml of Aflibercept (40 mg/ml) during 3 months (one per month) The clinical management of the patients will be adapted to the treatment standards of the Ophthalmology Service of the Hospital de la Santa Creu and Sant Pau, without the realization of this study influencing such process.~1 Injection of dexamethasone intravitreal implant 0.7mg. The clinical management of the patients will be adapted to the treatment standards of the Ophthalmology Service of the Hospital de la Santa Creu and Sant Pau, without the realization of this study influencing such process."
88857362|NCT03078426|Experimental|Group 1 : UIP pattern|18 patients with UIP pattern at HRCT and IPF as a definite diagnosis.
88857363|NCT03078426|Experimental|Group 2 : possible UIP pattern|"7 patients with  possible  UIP pattern at HRCT with histopathology given by surgical lung biopsy making the diagnosis of IPF."
88857364|NCT03078426|Experimental|Group 3 : diagnosis of fibrosing sarcoidosis|15 patients with the diagnosis of fibrosing sarcoidosis after multidisciplinary discussion.
89189377|NCT05810805||Control group|
89189378|NCT05810805||Imflammtory bowel disease group|
89189379|NCT05810805||Irritable bowel syndrome group|
89189380|NCT05810805||Colorectal neoplasms group|
89189381|NCT05810805||Helicobacter pylori infection group|
89189382|NCT05810805||functional dyspepia group|
89383772|NCT03618992|No Intervention|Cohort 2|Pre-study randomization will assign patients to have measurements obtained from either the left or right side of the body. Baseline skin barrier measurements of the skin and lips will be obtained, including transepidermal water loss (TEWL), hydration, pH and sebum (oil). Photos of the skin, lips, eyebrows, eyelashes and scalp will be taken. On each side, samples of scalp (pluck 1), eyebrow (trim 1), and eyelash (trim 1) hairs will be obtained only at baseline and the final visit. Patients will return for follow-up visits at 1, 2, and 3 months after discontinuation of oral antifungal therapy.
89383773|NCT03618992|No Intervention|Cohort 3|Pre-study randomization will assign patients to have measurements obtained from either the left or right side of the body. Baseline skin barrier measurements of the skin and lips will be obtained, including transepidermal water loss (TEWL), hydration, pH and sebum (oil). Photos of the skin, lips, eyebrows, eyelashes and scalp will be taken. On each side of the body, samples of scalp (pluck 1, trim 1), eyebrow (pluck 1, trim 1), and eyelash (trim 1) hairs will be obtained at the baseline and final visit. Patients will return for follow-up visits at monthly intervals after initiation of oral antifungal therapy for up to 12 months.
89383774|NCT03510650||Patients|50 patients with sepsis versus 50 patients with HLH [anticipated]
89383775|NCT03722810|Active Comparator|Active comparator: patient interview|This intervention will be a structured in-depth interview with a patient with a chronic illness that has been chosen by the student's allocated GP teacher. The interview will be followed by a structured interview with the practice nurse and then a structured debriefing interview with the GP teacher.
89383776|NCT03722810|Sham Comparator|Sham comparator: document|In this intervention, the student's allocated GP teacher will give the student time to read a document that gives information about consultation skills, and asks questions that the student will need to discuss with the GP teacher.
89383777|NCT02236676|Active Comparator|Nap after rehearsal trials|A 30-minute daytime nap after training
89383778|NCT02236676|Placebo Comparator|Resting while awake|Placebo condition of 30 minutes between training and retesting in which the half hour is spent resting awake in bed.
89383779|NCT03618368|Experimental|Blinded THERANOVA-500 dialyzer|This group of 25 subjects is dialyzed with masked THERANOVA-500 dialyzer enabling Expanded Hemodialysis (HDx) therapy.
89383780|NCT03618368|Placebo Comparator|Blinded REVACLEAR-400 dialyzer|This group of 25 subjects is dialyzed with masked REVACLEAR-400 dialyzer enabling conventional hemodialysis (HD).
89383781|NCT03618368|Experimental|Unblinded THERANOVA-500 dialyzer|This group of 10 subjects is dialyzed with unmasked THERANOVA-500 dialyzer which enables Expanded Hemodialysis (HDx) therapy.
89383782|NCT03618368|Placebo Comparator|Unblinded REVACLEAR-400 dialyzer|This group of 10 subjects is dialyzed with unmasked REVACLEAR-400 dialyzer which enables conventional hemodialysis (HD).
89383783|NCT03618914||Non-anemic women|
89383784|NCT03618914||anemic women|anemia due to iron deficiency
89383785|NCT02956460|Active Comparator|fanfilcon A|Participants are randomized to wear fanfilcon A for two weeks during the cross over study.
89383786|NCT02956460|Active Comparator|senofilcon A|Participants are randomized to wear senofilcon A for two weeks during the cross over study.
89383787|NCT03618290||Acute ischemic stroke group|50 patients (expected) - Acute ischemic stroke (AIS)
89383788|NCT03618290||Non-neurological pathologies group|25 control subjects with non-neurological pathologies (Congestive heart failure (CHF), Chronic obstructive pulmonary disease ( COPD ) etc.)
89383789|NCT03618290||Non AIS-related brain injuries group|25 control subjects with traumatic or other non AIS-related brain injuries. These will include: Traumatic Brain Injury (TBI) defined as intracranial hemorrhage or contusion.
89383790|NCT02999100|Experimental|Group 1 -IH oxytocin|Women with an uncomplicated pregnancy in third stage of labour will be enrolled in the arm. Subjects will receive 400 micrograms (mcg) IH oxytocin. Subjects will be followed up in-person or via telephone within approximately 24 hr post dose and once between 7 days to 14 days
88857365|NCT03078426|Experimental|Group 4 : lung diseases without reticulations|20 patients with lung diseases without reticulations (acute or sub-acute hypersensitivity pneumonitis, organizing pneumonia, isolated pleural plaques) .
88857366|NCT03159312|Experimental|Assigned Interventions|20 individuals undergoing bariatric surgery and post surgery normal indications with moderate exercise program
88857367|NCT03159312|No Intervention|Control group|Control group: 23 individuals undergoing bariatric surgery and post surgery normal indications without exercise program
88857368|NCT05701410|Experimental|Study group|Patients with a history of lumbar spinal stenosis.
89383791|NCT02999100|Experimental|Group 1 -IM oxytocin|Women with an uncomplicated pregnancy in third stage of labour will be enrolled in the arm. Subjects will receive 10 I.U. IM oxytocin. Subjects will be followed up in-person or via telephone within approximately 24 hr post dose and once between 7 days to 14 days
89383792|NCT02999100|Experimental|Group 2 (IH and IV oxytocin)|Group 2 will enrol healthy, non-pregnant, non-lactating female subjects of childbearing potential, and each subject will participate in 2 dosing sessions. Group 2 will be divided into two cohorts: Cohort A will enrol women on a combined oral contraceptive, and Cohort B will enrol women who are not using a hormonal form of contraceptive. Group 2 subjects will randomized to receive IH oxytocin, and IV oxytocin in a cross fashion. Subjects will be followed up in-person once between 7 days to 21 days
89383793|NCT02749370|Experimental|Etanercept|Participants received etanercept 50 mg subcutaneously twice weekly for 12 weeks followed by 50 mg once weekly for an additional 12 weeks.
88857369|NCT03583008|Experimental|Anticoagulation (AC) Intervention|Providers in this arm will receive supportive tools including Anticoagulation (AC) Intervention--Prescribing Practices and Anticoagulation (AC) Intervention--Academic Detailing to help them assess their Anticoagulant (AC) prescribing practices and will also meet with the study investigators for academic detailing.
88857370|NCT03583008|No Intervention|Control|Providers in this arm will not receive any intervention.
88857371|NCT05703126|Other|The study group|The study group will include patients with acute myeloid leukemia receiving chemotherapy, aged 18 to 65 years, without clinical signs of heart failure, with an LV ejection fraction of more than 50% before the start of polychemotherapy, in whom in the course of chemotherapy treatment after the next course of treatment a decrease in global longitudinal strain of 15% or more relative to the initial values will be revealed.
89383794|NCT03622866|Active Comparator|Ultra-high pulse width|Ultra-high pulse width stimulation using the Algovita System
89383795|NCT03622866|Active Comparator|Traditional pulse width|Traditional pulse width stimulation using the Algovita System
89383796|NCT03619070|Experimental|Lower load resistance training (LL)|In the LL group, postmenopausal women will perform the resistance training with moderate volume (i.e. three sets per exercise performed until or close to failure) and low load (i.e. 30% of 1RM)
89383797|NCT03619070|Experimental|Higher load resistance training (HL)|In the HL group, postmenopausal women will perform the resistance training with moderate volume (i.e. three sets per exercise performed until or close to failure) and high load (i.e. 80% of 1RM)
89383798|NCT03619070|Experimental|Higher volume resistance training (HVHL)|In the HVHL group, postmenopausal women will perform the resistance training with high volume (i.e. six sets per exercise performed until or close to failure) and high load (i.e. 80% of 1RM)
89383799|NCT03619070|Other|Control group, (CG)|In CG, the postmenopausal women group will not perform exercise
89383800|NCT03618836||Cases. Preterm Births|Microbiological and biological patterns on vaginal samples in the first trimester of pregnancy among spontaneous preterm births between 22 and 36 weeks
89383801|NCT03618836||Controls. Term Births|Microbiological and biological patterns on vaginal samples in the first trimester of pregnancy among deliveries over ≥ 37 weeks
88857372|NCT05703126|Other|The control group|The control group will consist of patients with acute myeloid leukemia receiving chemotherapy, aged 18 to 65 years, without clinical signs of heart failure, with an LV ejection fraction of more than 50% before the start of polychemotherapy, in whom no signs of myocardial disease will be detected during chemotherapy. and endothelial dysfunction.
88857373|NCT03155334|Other|Prevalence of CCSVI in MS|Subjects with prevalence of CCSVI in Multiple Sclerosis and in Other Neurodegenerative Diseases - PIS User Testing
88857374|NCT03155334|Other|BVD Exploited Against MS|Subjects suffering from Brain venous drainage exploited against Multiple Sclerosis - PIS User Testing
88857375|NCT03582696|Other|No Arms|Participants are not assigned to randomized study arms or groups.
88857376|NCT03159390|Experimental|phenylacetate salt of ornithine|There are 4 study days of approximately 10 hours. Amino acid tracers (e.g., OP, PHE, TYR) will be provided via IV. The dosage of OP provided in this study 6 g in a period of 6 hours. 2 muscle biopsies will be completed on 2 of the study days.
88857377|NCT03159156|No Intervention|Blood Donation As Usual|Volunteer blood donors complete assessment materials, including assessment of respiratory activity, but otherwise undergo the typical blood donation procedure.
88857378|NCT03159156|Experimental|Applied Tension|Participants are taught a simple muscle tensing technique with a brief video presented on a notebook computer before giving blood. They are asked to engage in repeated gentle 5-sec on, 5-sec off cycles of whole body isometric muscle tension before and while giving blood.
88857379|NCT03159156|Experimental|Respiration Control|Participants are taught a simple respiration control technique with a brief video presented on a notebook computer before giving blood. They are asked to breathe in a gentle shallow but regular fashion aimed at reducing risk for hyperventilation before and while giving blood.
88857380|NCT03159156|Experimental|Applied Tension/Respiration Control|Participants are asked to practice both Applied Tension and Respiration Control before and while giving blood.
88857381|NCT03582306|Experimental|High chlorophyll diet - intervention 1st|Participants will complete the 4 week intervention, 4 week washout, then 4 week control period (monitor only)
88857382|NCT03582306|Experimental|High chlorophyll diet - control 1st|Participants will complete the 4 week control period (monitor only), 4 week washout, then 4 week intervention
88857383|NCT03582228|Experimental|Virtual Envrionment for Social Communication|"Once the intervention begins, participants will meet online from home for one-hour sessions twice a week (twelve sessions over six weeks).~Weekly sessions will follow a standardized format:~15 minutes- Social support group (guided discussion of experiences related to weekly topic)~20 minutes- Didactic instruction~15 minutes- Role playing~10 minutes- Debriefing and group feedback"
88857384|NCT03159234|Other|Diabetic pregnant women|
88857385|NCT03020316|No Intervention|Usual Care|"Subjects will be encouraged to follow-up with their primary physicians.~Subjects will be informed that they will be periodically contacted by telephone and/or email by the research team for future assessments."
88857386|NCT03020316|Active Comparator|Peer Mentor & Transcendental Meditation|"Subjects will be assigned a peer mentor (a volunteer with CAD). After initial contact, the peer mentor and subject will be encouraged to communicate at whatever frequency or medium they deem most appropriate. This may include speaking by telephone, personal email or meeting in person. Mentors (and subjects if willing) will be asked to keep a log of such contacts, which will be provided to the study staff at interval reassessments.~In addition to the peer mentor, subjects will be instructed in transcendental meditation (TM) in the standard manner by a trained TM instructor."
88857387|NCT03020316|Active Comparator|Peer Mentor|"We are no longer recruiting in this arm.~Subjects will be assigned a peer mentor (a volunteer with CAD). After initial contact, the peer mentor and subject will be encouraged to communicate at whatever frequency or medium they deem most appropriate. This may include speaking by telephone, personal email or meeting in person. Mentors (and subjects if willing) will be asked to keep a log of such contacts, which will be provided to the study staff at interval reassessments."
88857388|NCT03158844||HIV+ patients (Standard of care)|300 HIV-infected and hospitalized adult patients at the University Teaching Hospital (UTH) will be recruited.
89383802|NCT03435536|Experimental|Circulating tumor DNA|circulating tumor DNA rate at various times of pancreatic cancer resection
89383803|NCT03618602|Experimental|100mg Bisthianostat|100mg starting dose taken orally on Day 1, 4,7,11,14,18,21,25 and 28 of each cycle(4 weeks).
89383804|NCT03618602|Experimental|200mg Bisthianostat|200mg Bisthianostat taken orally on Day 1, 4,7,11,14,18,21,25 and 28 of each cycle(4 weeks).
89383805|NCT03618602|Experimental|400mg Bisthianostat|400mg Bisthianostat taken orally on Day 1, 4,7,11,14,18,21,25 and 28 of each cycle(4 weeks).
89383806|NCT03618602|Experimental|600mg Bisthianostat|600mg Bisthianostat taken orally on Day 1, 4,7,11,14,18,21,25 and 28 of each cycle(4 weeks).
89383807|NCT03723278||Healthy individuals|Young, male and healthy volunteers without any significant disease
89383808|NCT03618212||Myeloma patients|
89383809|NCT05001386|Experimental|Lymphoproliferative disorders|Patients followed in the haematology unit of Hospices Civils de Lyon for lymproliferative disorders as chronic lymphoid leukemia (CLL), non-Hodgkin lymphoma (NHL) or multiple myeloma (MM) .
88857389|NCT03158844||Health systems informants|15 key Zambian health systems informants and leaders who can discuss inpatient care and the process of linking hospitalized patients to HIV care.
88857390|NCT05628246|Active Comparator|In-person|Face to face at OPD
88857391|NCT05628246|Experimental|Telemedicine|Telemedicine
88857392|NCT05701332|Experimental|BCG|6 doses of intravesical BCG
88857393|NCT03582072|Experimental|letter|letter from the CMO: practice outside the top 20% of prescribers whose prescribing increased by > 4%, where GPs in the practice were sent a letter informing them their prescribing had increased
88857394|NCT03582072|No Intervention|control|practice outside of the top 20% of prescribers whose prescribing increase by >4%, GPs were not sent a letter
88857395|NCT03581994|No Intervention|Standard Practice|Not receiving any intervention/educational materials on drug-drug interaction testing
88857396|NCT03581994|Experimental|Compulsory DDI Testing|Receiving educational materials on drug-drug interaction testing and a sample test report when caring for patient cases.
88857397|NCT03581994|Experimental|Optional DDI Testing|Receiving educational materials on drug-drug interaction testing and given a sample test report if ordered when caring for patient cases.
88857398|NCT03581916|Experimental|18F-JNJ-64326067|Participants will receive single intravenous (IV) bolus injection of 18F-JNJ-64326067 on Day 1.
88857399|NCT03154866|Experimental|Lactobacillus kefiri LKF01 DSM32079|
88857400|NCT03154866|Placebo Comparator|Placebo|
88857401|NCT03581838||Acitve EoE|Observed eating session of Jimmy John's turkey or vegetarian sandwich with water among individuals who have EoE who have not been treated or have not achieved remission from treatment.
88857402|NCT03581838||Remission EoE|Observed eating session of Jimmy John's turkey or vegetarian sandwich with water among individuals who have EoE who are have achieved remission from treatment.
88857403|NCT03581838||Controls|Observed eating session of Jimmy John's turkey or vegetarian sandwich with water among individuals without EoE.
88857404|NCT03581682|Experimental|Tele-Visit Using Parental Home Echo|All parents will have hands-on echo training. We will test if a tele-visit using parental home echo is clinically reliable compared to an on-site clinic visit, costs less, and improves parental sense of empowerment.
88857405|NCT03157986|Active Comparator|Whole Body Vibration training|Balance Training on a Vibration platform
88857406|NCT03157986|Active Comparator|Conventional Balance training|Balance Training on a Balance board
88857407|NCT03158142|Experimental|Atropine group|One drop of Atropine Sulfate 1% Oph Soln will be administered either in the morning or at night in each eye. Study measurements will be taken approximately after 1, 12, 24 and 96 hours after drop instillation. After a 2 week wash out period with no eye drops, another drop of 1% atropine sulfate ophthalmic eye drops will be administered either in the morning or night (the visit that was not taken before) and study measurements will be scheduled approximately after 1, 12 24 and 96 hours after drop instillation
88857408|NCT05701176|Experimental|[18F]F-AraG PET procedures|All patients will undergo a total of 3 [18F]F-AraG PET scanning procedures at T=0, T=2 weeks and T=6 weeks.
88857409|NCT03154944|Experimental|Ostomy device 1|In this arm the subjects test a new ostomy device consisting of a known adhesive and a new top film
88857410|NCT03154944|Experimental|Ostomy device 2|In this arm the subjects test a new ostomy device consisting of a new adhesive and a known top film
88857411|NCT03154944|Experimental|Ostomy device 3|In this arm the subjects test a new ostomy device consisting of a known adhesive and a new top film
88857412|NCT03028740|Placebo Comparator|Placebo|Participants received cenicriviroc placebo-matching, tablet, orally, once daily for up to approximately 40 months.
88857413|NCT03028740|Experimental|Cenicriviroc 150 mg|Participants received cenicriviroc, 150 milligrams (mg), tablet, orally, once daily for up to approximately 40 months.
88857414|NCT03157596|Experimental|intervention group|"selected randomly from a list of all the 105 special education centers registered at the State Ministry of Education, and randomly allocated into intervention group.~all the children with developmental disabilities in enrolled in the school who met the eligibility criteria were examined and all their parents were interviewed.~Caregivers' baseline knowledge and attitudes towards the oral healthcare of their children was assessed by an interview questionnaire.~examination for the children with developmental disabilities was carried out to assess caregivers' practice by assessing the oral hygiene level and amount of unmet treatment needs.~educational intervention by an Oral Health Education Program for Caregivers of Children with developmental disabilities about the oral health care of Children with DD, in the form of a short video, accompanied by demonstration & followed by an interactive discussion .~the same evaluation was carried out again 3 months after the intervention."
88857415|NCT03157596|No Intervention|control group|Evaluation of the knowledge, attitude and practice of caregivers of children with developmental disabilities towards the oral health of their children at baseline and 3 months after without any intervention.
88857416|NCT03154632|Active Comparator|US Group|Ultrasound Therapy
88857417|NCT03154632|Active Comparator|DCD Group|Digital Capacitive Diathermy Therapy
88857418|NCT03027648|Other|patients with LNG-IUS|Placement of levonorgestrel-releasing intrauterine system
88857419|NCT05252520|Experimental|JNJ-77474462|Participants will receive a single subcutaneous (SC) Dose 1 of JNJ-77474462 on Day 1 in Cohort 1, a single SC Dose 2 of JNJ-77474462 on Day 1 in Cohort 2 and a single SC Dose 3 of JNJ-77474462 on Day 1 in Cohort 3.
88857420|NCT03886584|Experimental|Patients with with neuropsychiatric conditions|"In this arm, five groups :~Patients with DFT, diagnosed according Racovsky criteria~Patients with Lewi Body dementia, diagnosed according McKeith criteria~Patients with pre-demential Alzheimer, diagnosed according Dubois criteria~Patients with Alzheimer, diagnosed according MMSE~Patients with bipolar disorder, diagnosed according DSM 5"
88857421|NCT03886584|Active Comparator|Healthy subjects|Healthy controls appaired in age, sex and educational level
88857422|NCT01670448|Active Comparator|PECBLOCK performed with bupivacaine|Active drug given through PECBLOCK in these patients.
88857423|NCT01670448|Placebo Comparator|PECBLOCK performed with NaCl 0.9%|Placebo drug given through PECBLOCK in these patients
88857424|NCT01670682|Active Comparator|fascia fixation group|procedure: ischia spinous fascia fixation
88857425|NCT01670682|Active Comparator|mesh group|Procedure: Modified Pelvic Floor Reconstruction Surgery with mesh
88857426|NCT01670838||subarachnoid haemorrhage|nontraumatic subarachnoid haemorrhage
88857427|NCT01670994|Experimental|ALT-801|
88857428|NCT03157908|Experimental|Smartphone app|All participants in this pilot study will install the smartphone app for testing
88857429|NCT03028896|No Intervention|standard|In the neck flexed and the head extended position, hold mask like a pen with the index finger placed anteriorly at the junction of the cuff and tube, push the mask backwards maintaining pressure against the palate until resistance is felt.
88857430|NCT03028896|Experimental|rotational|After insertion of the entire cuff inside the mouth, the LMA FlexibleTM was rotated counter-clockwise through 90° and was advanced through the right side of the tongue until the resistance was felt, and then was returned back in the hypopharynx.
88857431|NCT03157206||DME patients treated with aflibercept|angiography by ultrawide field
88857432|NCT03154398||1|case control
88857433|NCT03156972|Active Comparator|Group a|
89189383|NCT05810779|Experimental|dynamic surface exercise with conventional therapy|the experimental group undergo conventional physical therapy and additional dynamic surface exercise training thrice a week for 2 months dynamic surface training will include gym balls , bolster or platform swing
88857434|NCT03156972|Active Comparator|Group b|
88857435|NCT01671072|Experimental|TissueGene-C|Single intra-articular injection to the damaged knee joint a dose of 1.8 x 10^7 cells
88857436|NCT01671072|Placebo Comparator|Normal Saline|Single intra-articular injection to the damaged knee joint at the same volume
88857437|NCT01671150|Placebo Comparator|Placebo control|half of the participants will receive a placebo control
88857438|NCT01671150|Active Comparator|Endotoxin (Inflammatory challenge)|
88857439|NCT03156738|Experimental|Dose 1|MT-2990 or Placebo
88857440|NCT03156738|Experimental|Dose 2|MT-2990 or Placebo
88857441|NCT03156738|Experimental|Dose 3|MT-2990 or Placebo
88857442|NCT03156738|Experimental|Dose 4|MT-2990 or Placebo
88857443|NCT03156738|Experimental|Dose 5|MT-2990 or Placebo
88857444|NCT01671228|Experimental|decision aid|The Yorkshire Dialysis Decision Aid (YoDDA). Delivered as a leaflet in clinic and a web resource outside the NHS.
88857445|NCT01671228|Experimental|Decision Aid + values task|The Yorkshire Dialysis Decision Aid (YoDDA) + values clarification questions. delivered as a leaflet in clinic and a web-based resource outside the NHS.
88857446|NCT01671228|Experimental|Decision Aid + patient stories|The Yorkshire Dialysis Decision Aid (YoDDA) + patient stories. Delivered as an web-based resource outside the NHS.
88857447|NCT01671228|No Intervention|usual predialysis education|The consultations and information usually provided by the predialysis health professionals
88857448|NCT01671306||Collateral, coronary disease|Patients are grouped into 2: Good and poor collateral development
88857449|NCT01671306||collateral|Patients are grouped into 2: Good and poor collateral development
88857450|NCT01671384|Active Comparator|Valproate, levocarnitine|"The patients will be randomized into two groups:~Group I (Physiotherapy + Placebos) Group II (Physiotherapy + Valproate and Levocarnitine)"
88857451|NCT01671384|Placebo Comparator|Placebo|"All patients will be randomized into two groups:~Group I (Physiotherapy + Placebos) Group II (Physiotherapy + Valproate and Levocarnitine)"
88857452|NCT01676454||Vasopressin levels.|"Cohort will consist of subjects with a minor injury or injuries defined as:~no episodes of systolic blood pressure < 90 mmHg between occurrence of injury and admission;~no blood transfusion requirement;~base deficit < 5 mEq/L;~no requirement for mechanical ventilation other than transiently during orthopedic surgery."
88857453|NCT01671540|Experimental|Intrapulmonary percussive ventilation|IPV is applied for 1 week (once a day) during the physical therapy treatment of the patient
88857454|NCT01671540|Active Comparator|standard airwy claerance regime|The standard treatment consists out of existing drainage techniques to remove secretion out of the lungs by means of breathing control exercises
88857455|NCT01671774|Experimental|IMAB362 + ZA|Participants received IMAB362 on Day 1 of each 3-week cycle (every 3 weeks). Participants received ZA on Day 1.
88857456|NCT01671774|Experimental|IMAB362 + ZA + IL-2 (1 million IU)|Participants received IMAB362 on Day 1 of each 3-week cycle (every 3 weeks). Participants received ZA on Day 1 and IL-2 on Days 1 to 3 of Cycles 1 and 3 only.
88857457|NCT01671774|Experimental|IMAB362 + ZA + IL-2 (3 million IU)|Participants received IMAB362 on Day 1 of each 3-week cycle (every 3 weeks). Participants received ZA on Day 1 and IL-2 on Days 1 to 3 of Cycles 1 and 3 only.
88857458|NCT01671774|Active Comparator|IMAB362|Participants received IMAB362 only on Day 1 of each cycle every 3 weeks.
88857459|NCT01671852|Active Comparator|Nasonex|The intervention group will receive mometasone nasal sprays at the dosage outlined below for 8 weeks. For patients that are between age 3 to 11 years and if they are randomized to the medicated group, they will use pediatric dosing of Mometasone nasal sprays, 1 spray (50 mcg) in each nostril once daily for 8 weeks. For patients that are older than age 12 and if they are randomized to the medicated group, they will use adult dosing of Mometasone nasal sprays, 2 sprays (100mcg) in each nostril twice daily for 8 weeks.
88857460|NCT01671852|Placebo Comparator|Saline|The placebo group will receive saline nasal sprays for 8 weeks.
88857461|NCT01671930||cardiac computed tomographic angiography|Patients refered for cardiac computed tomographic angiography by a cardiologist.
88857462|NCT01672086||Stelkast Surpass Patients|
88857463|NCT01672164||Liver Transplant Recipients|
88857464|NCT03153930|Placebo Comparator|Sitting Only (SIT)|In-Lab (full sample): children will sit continuously for 3 hours during an OGTT Free-living (sub-sample; N=12): children will complete their habitual sedentary behaviors over 4 days; they will also wear a continuous glucose monitor
88857465|NCT03153930|Experimental|Walking Breaks (WALK)|In-Lab (full sample): children will be asked to walk on a treadmill every 30 minutes for 3 minute bouts during a 3 hour OGTT Free-living (sub-sample; N=12): children will be prompted with an ActivPAL vtap monitor on the right thigh to perform 3-minute walking bouts whenever sedentary time has lasted longer than 30 minutes over 4 days; they will also wear a continuous glucose monitor
88857466|NCT05547750|Experimental|vitamin K2 arm|The vitamin K2 arm takes vitamin K2 180 μg/day at bedtime for 8 weeks.
89189384|NCT05810779|Active Comparator|trunk targeted training with conventional therapy|the group will receive conventional physical therapy and additional trunk targeted training thrice a week for 2 months.
89189385|NCT05810740|Experimental|Binimetinib 15 mg / Binimetinib 45 mg|2 periods
89189386|NCT05810740|Experimental|Binimetinib 45 mg / Binimetinib 15 mg|2 periods
88857467|NCT05547750|Placebo Comparator|Placebo|The placebo group takes a placebo at bedtime for 8 weeks.
89383810|NCT05001386|Sham Comparator|Control group|Patients followed in the medicine of aging unit in the Hospices Civils de Lyon without haematological malignancies, without chemotherapy and without immunosuppressive treatment (≤ 5 years)
89383811|NCT05001386|Experimental|Myeloproliferative disorders|Patients followed in the haematology unit of Hospices Civils de Lyon for myeloproliferative disorders as acute myeloid leukemia (AML) or chronic myeloid leukemia (CML).
88857468|NCT01672320||Phase II|An evaluation of long-term outcomes, patient reported outcomes, and radiographic analysis will be conducted prospectively on 500 patients
88857469|NCT01672320||Phase I|An analysis of post-operative component positioning will be evaluated for 500 patients, retrospectively.
88857470|NCT04370106|No Intervention|Control|Usual care for participants with existing VLU in the CG is defined as visiting the outpatient wound clinic/visits by the community care nurse as prescribed by the physician. Wound healing measurement, therapeutic adherence measurement, wound recurrence measurement, and questionnaires will be provided by the institute's nurses.
88857471|NCT04370106|Other|Social leg Program|Usual care as described for the CG will also be provided to the IG. Wound healing measurement, therapeutic adherence measurement, wound recurrence measurement, and questionnaires will be provided by the institute's nurses. After baseline data collection (T0) and random allocation to the intervention group, this usual care will be enhanced by frequenting a social leg program.
88857472|NCT04244682|Other|Healthy participants receiving rTMS|Participation will require up to three visits. One visit will take up to an hour, and the other visits will each take up to three hours each. During the first visit, participants will be consented, and their brains will be scanned using magnetic resonance imaging. Participants will receive rTMS during two study visits.
88857473|NCT04200768|Other|Standard|Standard of care
88857474|NCT04404816|Experimental|Group 1|premature infants born < 33 G.A. enrolled in the first 72 hours after birth, with respiratory distress syndrome, requiring non-invasive ventilation with FiO2 <0.4
88857475|NCT04404816|Experimental|Group 2|premature infants born < 33 G.A. with respiratory insufficiency requiring mechanical ventilation, after more than 1 failed extubation attempt
88857476|NCT04077372|Experimental|Serious illness conversation guide (SICG)|"Patients have serious illness conversation within 3 wks of randomization and every 3 months thereafter."
89383812|NCT02031848|Active Comparator|Healthy Weight Control Group|Subjects will complete the Assessments, Diet Intake, and MRI portions of the study
88857477|NCT04077372|Active Comparator|Conversations by treating team|Patients have conversations as determined by treating team (but not using SICG tool).
88857478|NCT04348968||Patient who received a Maxera Cup of large diameter|Patient received a Maxera Cup with an outer diameter of 64 mm or 66 mm between Nov 2011 and Feb 2018.
88857479|NCT01672398|Experimental|Intervention Group|Telemonitoring plus self-management support
88857480|NCT01672398|No Intervention|Usual Care Group|Usual Care
88857481|NCT01672476|Placebo Comparator|Placebo|1 capsule/day of placebo will be orally administered for the study period (8 weeks)
88857482|NCT01672476|Active Comparator|Valsartan 80mg|(As reference group) 80mg/day of Valsartan will be orally administered for the study period (8 weeks)
88857483|NCT01672476|Experimental|Fimasartan 30mg|30mg/day of Fimasartan will be orally administered for the study period (8 weeks)
88857484|NCT01672554|Other|Seroquel XR|Quetiapine XR will be titrated according to the following pattern: Seroquel XR 300 mg on day 1 and Seroquel XR 600 mg on day 2. On day 3, the dosage could be either maintained at 600 mg/day or continued up to 800 mg/day or if the 600 mg dose is not tolerated, the dose could then be reduced to 400 mg/day. Following this, subjects will be flexibly dosed, according to clinical judgment of the investigator, between 400 mg/day and 800 mg/day with minimum dose adjustments of 200 mg/day. This adjustment can be performed at anytime during the study but should not take place within a week from last cognitive assessment, planned at month 6. An overlap of at least 4 days but not more than 2 weeks with the previous antipsychotic will be allowed with decreasing doses on a two-week period.
88857485|NCT03153696|Experimental|Cellie Intervention|The Cellie Coping Kit intervention is grounded in empirical evidence regarding injury recovery. By utilizing parents as coaches, the Cellie Coping intervention can be initiated in the hospital and continued as the child recovers at home. The intervention's portable, engaging design and active partnership with parents as consistently available coaches, allows families to use the intervention anywhere (i.e., home, hospital, during procedures) ensuring the child is supported at the time the injury-related stressor arises. The Cellie Coping Intervention consists of 1) a stuffed toy to promote engagement, 2) caregiver book, and 3) coping cards. Skills are presented in a way usable by most parents and children without medical team support. In this condition, children and parents will be introduced to the Cellie Intervention immediately following the completion of the T1 measures.
89383813|NCT02031848|Active Comparator|Dieting Group|Subjects will complete the Assessments, Diet Intake, and MRI portions of the study and will be given the weight loss and weight maintenance diets, and will attend weekly behavioral meetings
89383814|NCT03617978|Experimental|None Elevation|Participant placed on a flat surface. Study participant connected to the measuring hemodynamic parameters device
89383815|NCT03617978|Experimental|Elevation angle of 20 degrees|Participant placed on a flat surface, lower limbs raised and supported at an angle of 20 degrees. Study participant connected to the measuring hemodynamic parameters device
88875392|NCT04113252|Experimental|Group 1--Diary and Possible Opioid Return Incentive|Participants in this arm will be given incentives upon return of completed diary and will have the possibility to earn incentives for returning any leftover tablets to the study team.
88875393|NCT04113252|Experimental|Group 2--Diary, Coaching, Possible Opioid Return Incentive|Participants in this arm will be given coaching. They will also be given incentives upon return of completed diary and will have the possibility to earn incentives for returning any leftover tablets to the study team.
88875394|NCT04113252|Experimental|Group 3--Diary and coaching|Participants in this arm will be given coaching. They will also be given incentives upon return of completed diary.
89383816|NCT03617978|Experimental|Elevation angle of 30 degrees|Participant placed on a flat surface, lower limbs raised and supported at an angle of 30 degrees. Study participant connected to the measuring hemodynamic parameters device
89383817|NCT03617978|Experimental|Elevation angle of 45 degrees|Participant placed on a flat surface, lower limbs raised and supported at an angle of 45 degrees. Study participant connected to the measuring hemodynamic parameters device
89383818|NCT03617900|Placebo Comparator|Placebo|
89383819|NCT03617900|Experimental|Ginger|
89383820|NCT03617900|Active Comparator|Paracetamol|
89383821|NCT05384366|Other|Neoadjuvant chemotherapy|Patients receiving neoadjuvant paclitaxel 175mg/m2 and carboplatin (AUC5) at three weekly interval by intravenous route
89383822|NCT05572385|Active Comparator|Patients with aphasia|Patients with a clinical aphasia (20 receptive, 20 expressive) with a specific logopedic treatment, with specific EEG measurement at start and end of treatment schedule.
89383823|NCT05572385|No Intervention|Patients without aphasia|Patients with comparable stroke characteristics, but without clinical aphasia.
89383824|NCT03616808|No Intervention|Conventional therapy|Intraoperative haemostatic treatment is based on conventional coagulation assays.
89383825|NCT03616808|Active Comparator|Goal-directed therapy|Thromboelastometry-guided haemostatic treatment is provided intraoperatively.
88857486|NCT03153696|Other|Cellie Wait-list Control|The Cellie Coping Kit intervention is grounded in empirical evidence regarding injury recovery. By utilizing parents as coaches, the Cellie Coping intervention can be initiated in the hospital and continued as the child recovers at home. The intervention's portable, engaging design and active partnership with parents as consistently available coaches, allows families to use the intervention anywhere (i.e., home, hospital, during procedures) ensuring the child is supported at the time the injury-related stressor arises. The Cellie Coping Intervention consists of 1) a stuffed toy to promote engagement, 2) caregiver book, and 3) coping cards. Skills are presented in a way usable by most parents and children without medical team support. In this condition, children and parents will be introduced to the Cellie Intervention via phone and mail following the completion of the T3 measures.
88857487|NCT03153540|Active Comparator|Active iTBS|"Device: MagPro X100 stimulator equipped with the B65 fluid-cooled coil for dominant Inferior Frontal Gyrus (IFG) stimulation (MagPro, Medtronic).~Intervention: 10 sessions daily of iTBS over 2 weeks. Active-iTBS consists of intermittent Theta Burst Stimulation to the dominant IFG (120% of resting motor threshold, bursts of 3 pulses at 50 Hz, bursts repeated at 5 Hz for 600 pulses total over 3 min)."
88857488|NCT03153540|Sham Comparator|Sham iTBS|"Device: MagPro X100 stimulator applied to dominant inferior frontal lobe.~Intervention: 10 sessions daily of sham iTBS over 2 weeks. Sham sessions involve a click replicating the sound of the magnetic discharge, without any magnetic pulse being delivered."
88857489|NCT01672632|Experimental|Overfeeding|We overfed 40 young, healthy adults by 40% of their baseline energy requirements for 8 weeks. The diet consisted of 41% carbohydrate, 44% fat, and 15% protein.
89383826|NCT03616652|Experimental|Non-deceptive placebo group (additional information)|Participants receive a placebo pill and are told that it is placebo. They receive additional information about the power of placebo effects via a film sequence before they take the placebo.
89383827|NCT03616652|Placebo Comparator|Non-deceptive placebo group (no additional information)|Participants receive a placebo pill and are told that it is placebo. They do not receive additional information about placebo effects. Instead, they watch a neutral film sequence about sleep.
89383828|NCT03618524|Experimental|Experimental|Lower limb hot water immersion
89383829|NCT02031926|Experimental|Positive expiratory pressure|
89383830|NCT03607994|Active Comparator|HIRREM-SOP (BCC|Acoustic stimulation linked to brainwave activity and continued current care.
89383831|NCT03607994|Other|nonspecific acoustic stimulation (NCC)|Continued current care and acoustic stimulation that is not linked to brainwave activity.
89383832|NCT03617510|Experimental|group1|Generic name:Felbinac Trometamol Injection;Placebo:normal saline Dosage form:Injection Dosage:47.13mg Volume:2.00ml Frequency:Multi-dose after single-dose Duration:5 days A total of 12 subjects,10 received the test drug and 2 received the placebo.
89383833|NCT03617510|Experimental|group2|Generic name:Felbinac Trometamol Injection;Placebo:normal saline Dosage form:Injection Dosage:94.25mg Volume:4.00ml Frequency:Multi-dose after single-dose Duration:5 days A total of 12 subjects,10 received the test drug and 2 received the placebo.
89383834|NCT03617510|Experimental|group3|Generic name:Felbinac Trometamol Injection;Placebo:normal saline Dosage form:Injection Dosage:188.50mg Volume:8.00ml Frequency:Multi-dose after single-dose Duration:5 days A total of 12 subjects,10 received the test drug and 2 received the placebo.
89383835|NCT03617510|Experimental|group4|Generic name:Felbinac Trometamol Injection;Placebo:normal saline Dosage form:Injection Dosage:259.16mg Volume:11.00ml Frequency:Multi-dose after single-dose Duration:5 days A total of 12 subjects,10 received the test drug and 2 received the placebo.
89383836|NCT03617432|Experimental|Experimental group|Experimental group will be treated by Chidamide combined CHOPE (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone and Etoposide ) regimen for 6 cycles.
89383837|NCT03617432|Experimental|Control group|Control group will be treated by CHOPE (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone and Etoposide ) regimen for 6 cycles.
89383838|NCT03464916|Experimental|CAR2 Anti-CD38 A2 CAR-T Cells|Relapsed or Refractory Multiple Myeloma
89383839|NCT05058716||COVID-19 positive patients|
89383840|NCT05058716||COVID-19 negative patients|
89383841|NCT04057950|Active Comparator|treating shampoo|treating shampoo (1% Selenium Disulfide (SeS2)/1% salicylic acid-based shampoo) 1144628 D cosmetic product
89383842|NCT04057950|Placebo Comparator|vehicle|1144781 cosmetic product
89383843|NCT03616340|Experimental|Ketorolac|
89383844|NCT03616340|Experimental|Kenalog|
89383845|NCT03663660||before the OIPP|Period 1 : Children hospitalized before the OIPP implementation
89383846|NCT03663660||after the OIPP implementation|Period 2 :Children hospitalized after the OIPP implementation
89399574|NCT03688893|Experimental|Laser Application|35% Hydrogen Peroxide (Whitening HP, FGM SC Brazil) 40 minutes divided in two phases of 20 minutes each one (5 minutes colocation, 10 minutes Laser Application and 5 minutes moving the product) from premolar to premolar in superior and inferior teeth. Experimental
89399575|NCT03688893|No Intervention|No Laser Application|35% Hydrogen Peroxide (Whitening HP FGM SC Brazil), 40 minutes divided in two phases of 20 minutes each one (5 minutes colocation, 10 minutes waiting and 5 minutes moving the product) from premolar to premolar in superior and inferior teeth. No Laser Application No Intervention
88857490|NCT04026984|Experimental|Rifamycin SV MMX plus ORT|One tablet contains 50 mg Rifamycin SV-MMX® plus standard of care Oral Rehydration Therapy (ORT). Two 50mg tablets will be administered twice daily.
88857491|NCT04026984|Placebo Comparator|Placebo tablets plus ORT|Matching placebo tablets plus standard of care Oral Rehydration Therapy (ORT)
88857492|NCT04019340|No Intervention|Control|Usual care for patients in the CG is defined as visiting the outpatient wound clinic as prescribed by the physician. Wound size measurement, wound care (including dressing and inspection), and questionnaires will be provided by the institute's nurses.
88857493|NCT04019340|Other|Education|Usual care as described for the CG will also be provided to the IG (visit to the outpatient wound clinic as prescribed by the physician). Wound size measurement, wound care (including dressing and inspection), and questionnaires will be provided by the institute's nurses. After baseline data collection (T0) and random allocation to the intervention group, this usual care will be enhanced by a pluridisciplinary educational program
88857494|NCT03153618|Experimental|VALIDATE subjects|Will be invited to interact with VALIDATE to determine if they meet referral indications for cancer predisposition assessment.
88857495|NCT03153618|No Intervention|Control|Current standard of care will be followed
88857496|NCT04404348|Experimental|Intervention|Three times per week for four weeks, participants will complete a computerized cognitive training session (approximately 30 minutes long).
88857497|NCT04404348|Placebo Comparator|Control|Three times per week for four weeks, participants will complete a computerized session (approximately 30 minutes long) that consists of inert computer games.
88857498|NCT03153228||Smokers of traditional cigarettes|29 healthy smokers of traditional cigarettes (min. 1 packyear)
88857499|NCT03153228||Smokers of e-cigarettes|29 healthy smokers of e-cigarettes (min. 1 packyear)
88857500|NCT03153228||Control|29 healthy volunteers.
88857501|NCT01672944|Experimental|TBCCN-developed educational materials|"Biobanking educational DVD and booklet kit developed by the Tampa Bay Community Network (TBCCN) Center. English kit is entitled Biobanking Hope for a Cancer Cure, and Spanish kit is entitled Biobanco: Una esperanza de cura para el cancer."
88857502|NCT01672944|Other|Control Group|"Biobanking educational Brochure developed by the National Cancer Institute. English brochure is entitled Providing your Tissue for Research: What you need to Know, Spanish brochure is entitled Lo que usted debe saber antes de dar sus tejidos para investigación médica."
88857503|NCT03152994||COPD patients with T2DM|"For it's an observational study, fasting blood glucose(FBG) will be checked every six months. The patients who will develope T2DM during the follow-up will be divided into the groupCOPD patients with T2DM."
88857504|NCT03152994||COPD patients without T2DM|"For it's an observational study, fasting blood glucose(FBG) will be checked every six months. The patients who won't develope T2DM during the follow-up will be divided into the groupCOPD patients without T2DM."
88857505|NCT02653248|Experimental|Cohort 1|Patients will receive 5 fractions of Stereotactic Body Radiation Therapy (SBRT). Dose per fraction is 8Gy. Total Dose: 40Gy. To escalate the dose of stereotactic radiotherapy to a tumoricidal dose without exceeding the maximum tolerated dose in patients with organ confined prostate cancer.
88857506|NCT02653248|Experimental|Cohort 2|Patients will receive 5 fractions of Stereotactic Body Radiation Therapy (SBRT). Dose per fraction is 9Gy. Total Dose: 45 Gy. To escalate the dose of stereotactic radiotherapy to a tumoricidal dose without exceeding the maximum tolerated dose in patients with organ confined prostate cancer.
89383847|NCT03617276||Outcome measurement|Each participant will be asked to complete each standardised outcome measure (SOM) three times and each trial will be videotaped by the researcher. The selected SOM's are the modified nine-hole peg test, the four square step test and the modified clinical test of sensory integration and balance. A doctor will watch the video on 2 separate occasions to evaluate intra-rater reliability. Inter-rater reliability will be assessed through asking three other neurofibromatosis specialist professionals (two NF2 consultants and one NF2 specialist nurse) to review the video and to score each measure completed. Once the filmed sessions have been analysed by the relevant clinician's the data will be destroyed in line with Trust policy. Each participant will also be required to complete the INFI-QOL questionnaire, the dynamic visual acuity test and provide information about the number of falls/near misses they have had over the past 12 months
89189387|NCT05810701|Active Comparator|NACT and CGA+ physical training intervention|Elderly (≥70 years) ovarian cancer patients referred for Neo-adjuvant treatment randomized to comprehensive geriatric assessment and individualised physical training.
89189388|NCT05810701|No Intervention|NACT no intervention|Elderly (≥70 years) ovarian cancer patients referred for Neo-adjuvant treatment randomized to standard of care
89383848|NCT05035004|Experimental|Post exercise hot water immersion|Moderate intensity cycling for 30 minutes, followed by a 10-minute transfer period and then 30 minutes of whole-body hot water immersion.
89383849|NCT05035004|Active Comparator|Exercise|Moderate intensity cycling for 30 minutes.
88857507|NCT02653248|Experimental|Cohort 3|Patients will receive 5 fractions of Stereotactic Body Radiation Therapy (SBRT). Dose per fraction is 10Gy. Total Dose: 50Gy. To escalate the dose of stereotactic radiotherapy to a tumoricidal dose without exceeding the maximum tolerated dose in patients with organ confined prostate cancer.
88857508|NCT03024528||CAM-ICU (+)|Delirious patients.
88857509|NCT03024528||CAM-ICU (-)|Non-delirious patients
88857510|NCT03153072|Other|A child with supraventricular tachycardia|
88857511|NCT03609372|Experimental|Single arm|These practices, which previously received the addition of performance feedback and provider prompts in the presence of communication skills training, will receive The STOP-HPV Trial 6: Maintenance
88857512|NCT05394948|Experimental|Group receiving dietary recommendations including experimental nutraceutic.|Experimental group will consume experimental nutraceutic instead of the habitual breakfast during 3 weeks and within a dietary recommendations.
88857513|NCT05394948|Active Comparator|Group receiving dietary recommendations including control nutraceutic.|Experimental group will consume control nutraceutic instead of the habitual breakfast during 3 weeks and within a dietary recommendations.
88857514|NCT01673412|Experimental|interventional arm|Psychological tests
88857515|NCT03153306|Experimental|"the bolus group"|10ml/kg of the natural colloid 5% albumin was given at 1 hrs.
88857516|NCT03153306|Experimental|"thecontinuous group"|10ml/kg of the natural colloid 5% albumin was given over 6 hrs
88857517|NCT03152916|Experimental|3D printing personalized plate|3D printing personalized plate will be used to guide the Kirschner wires in the joint fusion surgery.
88857518|NCT01673724|Experimental|pramipexole|dosage form: tablet dosage: pramipexole 0.125/0.25/0.5/1mg frequency: tid duration: 24weeks
88857519|NCT01673724|Active Comparator|Bromocriptine|bromocriptine dosage form: white round tablet
88857520|NCT04765098|Active Comparator|Etoposide|
88857521|NCT04765098|Experimental|Tamoxifen|
88857522|NCT01673880|Other|E2006 2.5 mg|
88857523|NCT01673880|Other|E2006 10mg|
88857524|NCT01673880|Other|E2006 25 mg|
88857525|NCT01673958|Experimental|Stair descending group|Stair descending exercise. Participants will carry out six weeks of stair descending training consisting of three exercise sessions per week.
88857526|NCT01673958|Experimental|Stair ascending group|Stair ascending exercise. Participants will carry out six weeks of stair descending training consisting of three exercise sessions per week.
88857527|NCT04777032||Liver transplant recipients|All liver transplant recipient in Denmark aged 18-100 years will be eligible for inclusion in the DACOLT study. Inclusion requires the individual to be able to understand the study information in either Danish or English and to be able to provide an informed consent.
88857528|NCT04777032||Control group 1_CGPS|The Copenhagen General Population Study (CGPS) is an ongoing observational population study with more than 110.000 participants from the greater Copenhagen area. All residents in the greater Copenhagen area > 40 years and 25% of 20-40 years old are invited to participate in the study and in follow-up examinations every decade. A random sample of 10.000 participants aged ≥ 40 years had a contrast enhanced CT of the chest including CT angiography of the heart performed. Of these, 6500 had a contrast enhanced CT of the abdomen.
88857529|NCT04777032||Control group 1_CCHS|The Copenhagen City Heart Study (CCHS) includes a random population sample included from the greater Copenhagen area. Health surveys have been repeated 5 times between 1976 and 2015. Almost 4000 participants were randomly selected for echocardiography.
88857530|NCT01674036|Experimental|Part 1 (GZFD00111/TDU12766): Genz-682452|Participants will receive a single oral dose of Genz-682452. Six ascending single doses and an optional seventh dose under fasted conditions will be used.
88857531|NCT01674036|Placebo Comparator|Part 1 (GZFD00111/TDU12766): Placebo|Participants will receive a single oral dose of placebo.
89383850|NCT05035004|Active Comparator|Hot water immersion|Whole-body hot water immersion for 30 minutes, followed by a 10-minute transfer period and then an additional 30 minutes of whole-body hot water immersion.
89383851|NCT02996682|Experimental|SOF/VEL|SOF/VEL for 12 weeks
89383852|NCT02996682|Experimental|SOF/VEL + RBV|SOF/VEL + RBV for 12 weeks
89383853|NCT03664284|Active Comparator|intervention group|
89383854|NCT03664284|No Intervention|control group|
89383855|NCT02873702|Experimental|Healing Period: Dexlansoprazole 60 mg|Dexlansoprazole 60 milligram (mg), delayed-release capsules, orally, once daily for up to 8 weeks in the Healing Period.
89383856|NCT02873702|Experimental|Healing Period: Lansoprazole 30 mg|Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks in the Healing Period.
88857532|NCT01674036|Experimental|Part 2 (GZFD00211/FED12767): Genz-682452|Participants will receive two single doses of Genz-682452 separated by a 7-day wash-out period, one dose given under fed (standardized high-fat breakfast) and one under fasted conditions. The dose will be based on the blind review of the safety/tolerability/pharmacokinetic data of single dose level cohorts in Part 1.
88857533|NCT04348578|No Intervention|control group|The root canal was prepared using the WaveOne Gold file reciprocation system with VDW Silver motor. WaveOne Gold #25 (0.07) file was used for instrumentation. For larger canals, #35 (0.06) and #45 (0.05) files were used after the #25 file. During instrumentation procedure, irrigation was applied with 5mL 2.5% NaOCl using a side-vented needles. The final irrigation was applied with 5mL NaOCl and 5mL sterile saline in the control group.The root canals were dried with sterile paper points and were filled with gutta-percha and AH Plus sealer with the cold lateral condensation method and the entry cavity was restored with composite. All treatments were performed following a standardized procedure by one operator. After completion of the root canal treatment, periapical radiographs were taken using the paralleling technique. All the patients were called for follow-up examination at 12 months, and were examined radiographically.
88857534|NCT04348578|Experimental|QMix 2in1|The root canal was prepared using the WaveOne Gold file reciprocation system with VDW Silver motor. WaveOne Gold #25 (0.07) file was used for instrumentation. For larger canals, #35 (0.06) and #45 (0.05) files were used after the #25 file. During instrumentation procedure, irrigation was applied with 5mL 2.5% NaOCl using a side-vented needles. The final irrigation was applied with 5mL Mix 2in1 and 5mL sterile saline in the experimental group.
88857535|NCT03378102|Experimental|Interferon (IFN)-gamma-secreting HAdV antigen specific T cells|"Virus-specific, antigen selected cells will be obtained using the CliniMACS® Prodigy System. The donor will be screened for their ability to produce an IFN-gamma- secretion response to HAdV by testing the donor's mononuclear cells with the Miltenyi Rapid Cytokine Inspector kit. Donors with appropriate IFN-gamma secretion response will undergo a steady state leukapheresis. The investigational product (IP) will be generated using the CCS-IFN enrichment program with an approximate duration time of 15 hours. IP will be suspended in 0.9 normal saline + 2.5% albumin and distributed for infusion and infused within 4 hours as a bolus on day 0.~Subjects will receive virus-specific, antigen selected T cells within a targeted range of 1 x 10^3- 2 x 10^5 per kg of recipient weight."
88857536|NCT01775046||DTA patients|160 patients presenting with a disease of descending thoracic aorta(DTA)with an indication for endovascular treatment with Valiant Thoracic Stent Graft with the Captivia Delivery System and who meet the inclusion/exclusion criteria are intended to participate in this non-interventional.
88857537|NCT03032328|Experimental|vitamin D supplement|patient's will be given a vitamin D
88857538|NCT02998164|Experimental|Technology-assisted language intervention|This intervention will incorporate augmentative and alternative communication software delivered on iPads into speech-language therapy
88857539|NCT02998164|Active Comparator|usual care|This group will be usual care children are already receiving.
89383857|NCT02873702|Experimental|Maintenance Period: Dexlansprazole 30 mg|Participants who will be healed at Week 8 will be randomized to receive dexlansoprazole 30 mg, delayed-release capsules, orally, once daily for up to 6 months in the Maintenance period.
88857540|NCT02980692|Experimental|SUNPG1623 dose I|low range dose
88857541|NCT02980692|Experimental|SUNPG1623 dose II|mid range dose
88857542|NCT02980692|Experimental|SUNPG1623 dose III|mid range dose
88857543|NCT02980692|Experimental|SUNPG1623 dose IV|mid range dose to high dose
88857544|NCT02980692|Placebo Comparator|Placebo|mid range dose to high dose
88857545|NCT04747392|Other|Sequence A|The test drug (SAL001) is administrated once by subcutaneous injection in the first period, and the reference drug (FORSTEO) is administrated once by subcutaneous injection in the second period.
88857546|NCT04747392|Other|Sequence B|The reference drug (FORSTEO) is administrated once by subcutaneous injection in the first period, and the test drug (SAL001) is administrated once by subcutaneous injection in the second period.
88857547|NCT01692444||COPD|15 patients with COPD from 1 to 4 according to the GOLD 2011
89535118|NCT04485169|Experimental|TPE Arm|In addition to standard care TPE was performed once daily using COBE Spectra Apheresis machine version 7 (Manufacturer TERUMO BCT, Lakewood, CO, USA INC) having continuous flow centrifugation. Venous access was achieved using an ultrasound guided double lumen catheter (Arrow - 12 FR) via femoral vein. Patient's total blood volume was calculated as per Nadler's formula. Anticoagulant acid dextrose ratio was 1:10 and flow rate 30-40 ml/minutes (Adjusted as per hemodynamic status). Patients' blood pressure, pulse, oxygen saturation was monitored throughout procedure. Duration of procedure varied from 2-4 hours and 1-1.5 times total plasma volume was removed during each procedure. Replacement fluid was fresh frozen plasma (FFP) and normal saline in 2:1 respectively. All procedures were performed in intensive care or high dependency unit by Apheresis Department of PEMH. TPE was continued till recovery
88857548|NCT01692444||Non smoker Control|15 patients without COPD and no smoking history
88857549|NCT01692444||Smoker Control|15 patients without COPD but a smoking history
88857550|NCT03728712||Never smokers|Participants with no history of cigarette smoking
88857551|NCT03728712||Active smokers|Participants with an active history of cigarette smoking AND at least 10 pack-years total smoking history
88857552|NCT01674192|Experimental|prucalopride|single dose of 2 mg prucalopride
88857553|NCT01674270|Experimental|Degarelix|Degarelix Alone
88857554|NCT01674270|Experimental|Degarelix + Casodex|Degarelix and Casodex
89535119|NCT04485169|No Intervention|NON TPE arm|Only supportive treatment offered including Vit C, Zinc, Vit D, famotidine, Enoxaparin and Methylprednisolone
88857555|NCT01674270|Active Comparator|LHRH Agonist + Casodex|LHRH Agonist and Casodex
88857556|NCT01674348|Active Comparator|P2202|"Two treatment arms in Stage I- P2202 (1000 mg) and placebo~Four treatment arms in stage II- P2202 (suggested dose levels 750 mg, 500 mg or 250 mg) or placebo"
88857557|NCT01674348|Placebo Comparator|Placebo|"Two treatment arms in Stage I- P2202 (1000 mg) and placebo~Four treatment arms in stage II- P2202 (suggested dose levels 750 mg, 500 mg or 250 mg) or placebo"
88857558|NCT01674504|Experimental|Montelukast sodium|Montelukast sodium chewable tablets 4mg and 5mg of Dr. Reddy's Laboratories Limited
88857559|NCT01674504|Active Comparator|SINGTJLAIR ®|SINGTJLAIR ® (containing Montelukast sodium)chewable tablets 5mg of Merck Sharp & Dohme Ltd., USA
88857560|NCT02431104|Experimental|Laser Treatment|Treatment to unwanted tattoo using a 532-nm KTP/1064-nm Nd:YAG Dual-Pulse Duration Laser
88857561|NCT02326116|Experimental|Group 1|Trachael Traction Exercises
88857562|NCT02326116|Placebo Comparator|Group 2|Trachael Massage
88857563|NCT01674582|Other|MRI, Neuropsychological testing|
88857564|NCT05353062|Active Comparator|Standard therapy|Endoscopic therapy with hemoclip +/- injection of epinephrine solution
88857565|NCT05353062|Experimental|Bipolar hemostatic forceps|Endoscopic therapy with bipolar hemostatic forceps
88857566|NCT01674660||volume status|volume status:group1 over volume status,group2 normal volume status,group3 low volume status
88857567|NCT01674660||night blood pressure|night blood pressure：group1 nondipper,group2 dipper,group3 extreme dipper,group4 riser
88857568|NCT01674660||interdialysis weight gain|interdialysis weight gain:group1 >5% dry weight,group2 <5% dry weight
88857569|NCT03152370|Experimental|E7046 in combination with Long Course Chemoradiotherapy (LCRT)|Participants will receive once daily (QD) doses of E7046 (recommended Phase 2 dose [RP2D] determined in the Dose-Escalation part of the study) for 10 weeks, starting on Day 1, 14 days prior to initiation of the radiotherapy. LCRT will be initiated on Day 15 and will consist of a total of 45 Grays (GY) radiation administered in 1.8 GY daily doses delivered for 5 days (Monday to Friday) every week for 5 weeks. Capecitabine (825 milligrams per meters squared [mg/m^2]) will be administered twice daily on the days of radiotherapy. Surgery will be performed 14 to 16 weeks from the first day of E7046 treatment.
88875395|NCT04087122|Experimental|Esophageal warming|Patients receive the Attune Medical Esophageal Heat Transfer Device
88875396|NCT03963492|Active Comparator|Continuous Walking|Participants in the Continuous Walking (CONT) arm will undergo training 2x/week for 6 weeks for a total plan of 12 training sessions. The intervention for the CONT group will be to complete a 6-minute long walk without rest breaks
89383858|NCT02873702|Experimental|Maintenance Period: Placebo|Participants who will be healed at Week 8 will be randomized to receive dexlansoprazole placebo-matching capsules, orally, once daily for up to 6 months in the Maintenance period.
89383859|NCT03617120|Experimental|Ergonomic Brace vs hard brace|"Ergonomic Brace is a new design of scoliosis brace, which consists of a knit bodice as base and also resin bones, paddings, straps and a pelvic belt as auxiliaries for spinal correction. The purpose of the bones is to keep the posture of patient upright. Paddings are placed at the convex regions of the spine while straps are used to input directional force onto the paddings. Pelvic belt, on the other hand, is for stabilizing the pelvis in order to achieve an effective spinal correction. The biomechanical principles for the correction of spine has considered both the frontal and sagittal planes, where the overall brace mechanism follows the Rigo classification.~Hard brace is the brace which the participants are currently using for their ongoing conservative treatment."
89383860|NCT03616262|Active Comparator|Phase 1|In Phase 1, subjects will receive either Treatment A (Lidocaine alone) or Treatment B (Botox+Lidocaine )
89383861|NCT03616262|Active Comparator|Phase 2|In Phase 2, subjects will receive either Treatment B (Botox+Lidocaine) or Treatment A (Lidocaine alone) -- the opposite of what was administered in Phase 1
89383862|NCT02236754|Other|Healthy Controls|Pancreatic 18F-FP-DTBZ uptake will be measured with PET scanning in healthy controls: subjects with predicted normal BCM (healthy, normal weight, non-diabetic individuals who have stimulated insulin and c-peptide levels within the normal range).
89383863|NCT02236754|Other|Patients with T1D|Pancreatic 18F-FP-DTBZ uptake will be measured with PET scanning in patients with longstanding T1D: subjects with predicted reduced beta cell mass (subjects with established T1DM who have low or no measurable stimulated insulin and c-peptide levels).
89383864|NCT03615950||Intervention Group|30 Children with eosinophilic esophagitis who are started on swallowed corticosteroids by their clinical provider.
89383865|NCT03615950||Control Group|30 children, 5-12 years of age, not taking swallowed corticosteroids. Age and sex matched 1:1 with intervention group.
89383866|NCT02911116|Experimental|Cohort 1 (Subcutaneous Only)|Subcutaneous injections of Ustekinumab at baseline.
89383867|NCT02911116|Experimental|Cohort 2 (IV and Subcutaneous)|Initial IV infusion of ustekinumab at baseline followed by one subcutaneous injection at Week 8. In participants who demonstrate an allergic reaction to the baseline IV infusion, the second dose at Week 8 can also be administered as an IV infusion instead of a subcutaneous injection.
89383868|NCT03664050|Experimental|Group A Letrozole group|2.5 mg letrozole oral tablets will be administered on the 2nd -3rd day of menses and then every day for 5 days.
89383869|NCT03664050|Active Comparator|Group B laparoscopic ovarian drilling group|bilateral laparoscopic ovarian drilling, each ovary will be cauterized at 4 points, each for 4 sec at 40 W, at a depth of 7-8 mm and a diameter of 3-5 mm, using a monopolar electrosurgical needle according to the size of each ovary.
89383870|NCT02998554|Experimental|SHP640|Participants instructed to instill 1 drop of SHP640 (Povidone-iodine [PVP-I] 0.6 percent [%] and Dexamethasone 0.1%) ophthalmic suspension in each eye 4 times daily (QID) (with a minimum of 2 hours between doses) for 7 days.
89383871|NCT02998554|Placebo Comparator|Placebo|Participants instructed to instill 1 drop of placebo ophthalmic solution in each eye QID for 7 days.
89383872|NCT02996448|Experimental|NDV 3A vaccine|Participants will receive a single dose of 0.5 mL (300 micrograms of rAls3) administered via IM injection.
89383873|NCT03663972|Active Comparator|Motoric Arm|Children will participate in an intervention based on traditional articulation approaches to speech therapy.
89383874|NCT03663972|Active Comparator|Phonologic Arm|Children will receive intervention that targets the conceptual representation of sounds.
89383875|NCT02995980|Experimental|Contrast enhanced mammography vs standard digital mammogram|Contrast-enhanced spectral mammography for the detection breast cancer .
89383876|NCT04058496||1|Coronary artery bypass surgery off-pump (n=24)
89383877|NCT04058496||2|Coronary artery bypass surgery on-pump (n=16)
89383878|NCT04058496||3|Coronary artery bypass surgery plus valve surgery (n=20)
89383879|NCT04055688||Participants with known or suspected high grade gliomas|
89383880|NCT02872142|Experimental|Albutein 5%|Plasma exchanges (PEs) with albutein 5% as a replacement solution during an intensive treatment phase of two PEs per week over 3 weeks followed by maintenance treatment phase of weekly PE for 21 weeks. The dose of albutein 5% for replacement following plasma removal was calculated based on gender, weight, and the hematocrit of the participant.
89383881|NCT02994654|Experimental|ReCell|All subjects will receive both ReCell and skin graft. Each patient serves as their own control. Their study treatment area (burn injury) will be divided into Area A and Area B. Investigational treatment will be randomly allocated to either Area A or Area B
89383882|NCT02994654|Experimental|Control|All subjects will receive both ReCell and skin graft. Each patient serves as their own control. Their study treatment area (burn injury) will be divided into Area A and Area B. Control, which is the Investigator's pre-determined graft plan will be randomly allocated to either Area A or Area B
89383883|NCT04882280|Experimental|Low room|Low intensity (80 lux) room light
89383884|NCT04882280|Experimental|Normal room|Normal intensity (150 lux) room light
89383885|NCT04882280|Experimental|Bright room|High intensity (500 lux) room light
89383886|NCT04882280|Experimental|Bright|Very high intensity (1000 lux) room light
89383887|NCT04055610|Experimental|H-MEX|10 participants with paraplegia will participate in explorative gait training using H-MEX powered exoskeleton.
88857570|NCT03152370|Experimental|E7046 in combination with SCRT followed by chemotherapy|Participants will receive QD doses of E7046 (RP2D determined in the Dose-Escalation part of the study) for 10 weeks, starting on Day 1, 14 days prior to initiation of the radiotherapy. Short course radiotherapy (SCRT) will be initiated on Day 15 and will consist of a total of 25 Gy radiation administered in 5 Gy daily doses for 5 days (Monday to Friday) for 1 week. Ten days after the end of radiotherapy, 3 cycles of the modified folinic acid/5-FU/oxaliplatin (mFOLFOX-6) regimen will be administered every 2 weeks for 2 consecutive days. Surgery will be performed 14 to 16 weeks from the first day of E7046 treatment.
88857571|NCT02187120|Experimental|Tranexamic Acid|"As soon as possible after injury, emergency medical services clinicians will administer 1g Tranexamic Acid (10ml ampoule containing 100mg/ml Tranexamic Acid in water for injection) delivered intravenously using a slow push of the syringe.~As soon as possible after the patient arrives at hospital, clinicians will administer 1g Tranexamic acid (10ml ampoule containing 100mg/ml Tranexamic Acid in water for injection) added to up to one litre 0.9%w/v Sodium Chloride and the entire volume infused intravenously over 8 hours."
88857572|NCT02187120|Placebo Comparator|Placebo|"As soon as possible after injury, emergency medical services clinicians will administer a 10ml ampoule containing 0.9%w/v Sodium Chloride via intravenous injection using a slow push of the syringe (ampoules containing Sodium Chloride appear identical to the ampoules containing Tranexamic Acid).~As soon as possible after the patient arrives at hospital, clinicians will administer a second 10 ml ampoule containing 0.9%w/v Sodium Chloride added to up to one litre 0.9%w/v Sodium Chloride and the entire volume infused intravenously over 8 hours."
88857573|NCT02335710||Smith & Nephew Journey II BCS TKA|Subjects must be implanted with a Smith & Nephew Journey II bi-cruciate stabilizing (BCS) total knee arthroplasty (TKA) implanted by Dr. Harold Cates
88857574|NCT02335710||Normal knee|Subjects must have a healthy, functioning knee with no osteoarthritis or knee pathologies
88857575|NCT01674738|Experimental|Pemetrexed, Cisplatin, Bevacizumab|Stratum A
89189389|NCT05810688|Experimental|Eating rehabilitation training group|The intervention group will receive eating rehabilitation training, including oral care, saliva gland massage, oral exercise, feeding strategy, and swallowing skill education
89189390|NCT05810688|No Intervention|Control group|The control group will receive only usual care.
89383888|NCT03615716|Experimental|Multi-level Violence Prevention Intervention - Boys|A study examining middle school boys who have a high potential of violence based on where they live. This arm will measure outcomes in the boys. as the result of the intervention, from the perspectives of the boys.
89383889|NCT03615716|Experimental|Multi-level Violence Prevention Intervention - Caregivers|In this study examining middle school boys who have a high potential of violence based on where they live, this arm will measure caregivers' perspectives of the boys ' outcomes. Caregivers will be surveyed pre-intervention and 4- and 6-month post intervention to explore the impact of the boys' intervention.
89383890|NCT04054284|Experimental|Intervention|Herbal Tea Mixture is consisted of: Vaccinium myrtillus L. folium, Morus nigra L. folium, Phaseolus vulgaris L. pericarpium, Viscum album L. herba, Urtica dioica L. radix, Gentiana lutea L. radix, Taraxacum officinale W. radix, Cichorium intybus L. herba, Teucrium chamaedrys L. herba, Stevia rebaudiana folium.
89399576|NCT03688815||Patients with ischemic heart disease|Patients with ischemic heart disease scheduled for myocardial perfusion scintigraphy were enrolled. Biomarkers were analysed form periferal blood. Patients outcome data were followed up to 5 years.
89383891|NCT04054284|Active Comparator|Control|Herbal Tea Mixture without antidiabetic properties is consisted of: Achillea millefolium L. herba, Teucrium montanum L. herba, Glechoma hederacea L. herba, Eupatorium cannabinum L. herba, Humulus lupulus L. lupulin, Artemisia absinthium L. herba, Salvia officinalis L.
89383892|NCT01067196||Observation and quality of life|Central Nervous System Tumors
89383893|NCT04494438|No Intervention|Steroid tapering.|
89383894|NCT04494438|Experimental|Rituximab|Single administration of Rituximab 375 mg/mq at a rate of 0.5 to 1.5 ml/min over approximately 6 hours, following the infusion of 2.5-5 mg of intravenous chlorfenamine maleate (based on the local protocol and patient tolerance), methylprednisolone (2 mg/Kg) in normal saline and oral paracetamol (8 mg/kg).
89383895|NCT03662490||patient|Patient who performed a High resolution oesophageal manometry (HRM) for the diagnosis of oesophageal motility disorder.
89383896|NCT04056936||Infants diagnosed with a tongue-tie and a frenotomy|If a tongue-tie is present at the routine newborn examination, the infant can be included in the study. If the infant also has breastfeeding problems and there is a decreased tongue mobility and poor sucking ability, the pediatrician may find indication for frenotomy. If the frenotomy is performed before discharge the infant is included in this group. All Mother-infant dyads will get breastfeeding support.
89383897|NCT04056936||Infants diagnosed with a tongue-tie and no frenotomy|The infants that are recruited to the tongue-tie cohort that do not receive treatment before discharge. The pediatrician evaluates that the tongue tie does not cause any functional problems and no treatment is performed before discharge. All Mother-infant dyads will get breastfeeding support.
89383898|NCT04056936||All infants born in Telemark and Vestfold Counties|All the infants born in the study period that will contribute to the prevalence study.
89383899|NCT03663426|Active Comparator|control group opioid anesthesia|standard anesthesia using opioids
88857576|NCT01674738|Experimental|Pemetrexed, Cisplatin, Bevazizumab|Stratum B:
88857577|NCT01674894||Group 1|Women treated with Menopur
88857578|NCT01674894||Group 2|Women treated with Menopur and Bravelle
88857579|NCT01674972||NAFLD|Patients with biopsy proven NAFLD
88857580|NCT01674972||Control|Matched healthy control subjects
89189391|NCT05810675|Experimental|Telehealth Early Intervention Program (TEIP) group|The TEIP group will also receive a 16-week telehealth intervention with guidance, digital learning platform, teaching parents to learn intervention skills to improve children's attention and play ability, social communication, cognition, perceptual movement, and improve parents' management of children's behavior problems.
89383900|NCT03663426|Experimental|study group opioid free anesthesia|opioid free anesthesia and high dose glucocorticoids
89383901|NCT03662412|Experimental|Sirolimus treatment|Oral solution of sirolimus, 2mg, once a day. The trial will be terminated when a serious adverse reaction occurred, or the tumor progressed rapidly twice in a row, or when the patient did not want to continue.
89383902|NCT03663270|Active Comparator|Intervention arm|HPI monitoring to predict hypotension
89383903|NCT03663270|No Intervention|Control arm|blinded HPI monitoring
89383904|NCT02870972|Experimental|Part 1: BCX7353 350 mg once daily|BCX7353 capsules, 350 mg dose administered once per day for 28 days
89383905|NCT02870972|Experimental|Parts 2 and 3: BCX7353 250 mg once daily|BCX7353 capsules, 250 mg dose administered once per day for 28 days
89383906|NCT02870972|Experimental|Parts 2 and 3: BCX7353 125 mg once daily|BCX7353 capsules, 125 mg dose administered once per day for 28 days
89383907|NCT02870972|Placebo Comparator|Parts 1, 2 and 3: Placebo|Placebo capsules, administered once per day for 28 days
89383908|NCT02870972|Experimental|Part 3: BCX7353 62.5 mg once daily|BCX7353 capsules, 62.5 mg dose administered once per day for 28 days
89383909|NCT03214367|Experimental|LY900014|LY900014 given subcutaneously (SC) 0-2 minutes before each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Preprandial insulin doses were individualized and titrated according to protocol-defined targets.
89383910|NCT03214367|Active Comparator|Insulin Lispro (Humalog)|Insulin lispro given SC 0-2 minutes before each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Preprandial insulin doses were individualized and titrated according to protocol-defined targets.
88857581|NCT01675206|Active Comparator|360 µg Vit K2|Administration of 360 µg of Vitamin K2 thrice weekly
88857582|NCT01675206|Active Comparator|720 µg Vit K2|Administration of 720 µg of Vitamin K2 thrice weekly
88857583|NCT01675206|Active Comparator|1080 µg Vit K2|Administration of 1080 µg of Vitamin K2 thrice weekly
88857584|NCT01537458||Isolated TI repair|Patients that underwent isolated tricuspid valve repair
88857585|NCT03150576|Active Comparator|Control|4 cycles of: Paclitaxel 80mg/m2 Day 1, 8 & 15, every 3 weeks, Carboplatin area under the curve (AUC) 5 Day 1, every 3 weeks
88857586|NCT03150576|Experimental|Research 1|4 cycles of: Paclitaxel 80mg/m2 on Days 1, 8 & 15 every 3 weeks, Carboplatin AUC 5 Day 1, every 3 weeks, Olaparib oral 150mg twice daily, Day -2 to Day 10 every 3 weeks
88857587|NCT03150576|Experimental|Research 2|4 cycles of: Paclitaxel 80mg/m2 on Days 1, 8 & 15 every 3 weeks, Carboplatin AUC 5 Day 1, every 3 weeks, Olaparib oral 150mg twice daily, Day 3 to Day 14 every 3 weeks
88857588|NCT04747080|Experimental|TAC and HD-DXM|"Dexamethasone 40 mg per day, 4 consecutive days (the 4-day course of dexamethasone is repeated in the case of lack of response by day 14).~Tacrolimus is given at a dose of 0.03mg/kg·d, and the dose is adjusted to maintain the trough concentration of tacrolimus at approximately 3-5 ng/mL for 12 weeks."
88857589|NCT04747080|Active Comparator|HD-DXM|Dexamethasone 40 mg per day, 4 consecutive days (the 4-day course of dexamethasone is repeated in the case of lack of response by day 14) .
88857590|NCT01675284|Experimental|Low Dosage AT-301|7.5 µg hemagglutinin (HA)
88857591|NCT01675284|Experimental|Middle Dosage AT-301|15 µg hemagglutinin (HA)
88857592|NCT01675284|Experimental|High Dosage AT-301|30 µg hemagglutinin (HA)
88857593|NCT01675362|Placebo Comparator|Control group|They will receive placebo
89383911|NCT03214367|Experimental|LY900014 Postmeal (Open Label)|LY900014 given SC 20 minutes after the start of each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Prandial insulin doses were individualized and titrated according to protocol-defined targets.
89189392|NCT05810675|No Intervention|Telephone group|The telephone group will receive 16-weeks of care and child development counseling through phone calls.
88857594|NCT01675362|Active Comparator|Antioxidant group|They will be receive vitamins A, C, E and selenium (Selenium ACE) Dosage: Two tablets before ESWL Then 2 tablets every 8 hours after ESWL for one week
89189393|NCT05810662|Active Comparator|Ringer lactate|Ringer's lactate solution, or lactated Ringer's solution, is a type of isotonic, crystalloid fluid further classified as a balanced or buffered solution used for fluid replacement. The contents of Ringer's lactate include sodium, chloride, potassium, calcium, and lactate in the form of sodium lactate, mixed into a solution with an osmolarity of 273 mOsm/L and pH of about 6.5.
89383912|NCT03214367|Experimental|LY900014 - Maximum Extended Enrollment (MEE)|LY900014 given subcutaneously (SC) 0-2 minutes before each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Preprandial insulin doses were individualized and titrated according to protocol-defined targets.
89383913|NCT03214367|Active Comparator|Insulin Lispro (Humalog)-MEE|Insulin lispro given SC 0-2 minutes before each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Preprandial insulin doses were individualized and titrated according to protocol-defined targets.
89383914|NCT03214367|Experimental|LY900014 Postmeal (Open Label)-MEE|LY900014 given SC 20 minutes after the start of each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Prandial insulin doses were individualized and titrated according to protocol-defined targets.
89383915|NCT02994108|Experimental|txt2protect|"Content was delivered in 2 phases over 36 weeks. During Phase 1 (weeks 1-3), participants received 10-12 messages daily. During Phase 2 (weeks 4-36), message frequency decreased to monthly messages. Phase 1 content was presented in 3 modules. Module 1 addressed information about HPV infection and HPV vaccination. Module 2 addressed motivation to receive HPV vaccine. Module 3 addressed behavioral skills and self-efficacy for initiating and completing the 3-dose series (e.g., talking with their doctor about the vaccine). Phase 2 booster messages largely reinforced Phase 1 content to foster continued engagement with the program.~txt2protect: Text messages sharing HIV/STI prevention information with a focus on HPV infection and vaccination."
89383916|NCT02994108|Active Comparator|Sexual Health Control|"Content was delivered in 2 phases over 36 weeks. During Phase 1 (weeks 1-3), participants received 10-12 messages daily. During Phase 2 (weeks 4-36), message frequency decreased to monthly messages. Phase 1 content was presented in 3 modules; however, unlike the treatment group, content was topic-based rather than theory-based and focused on general sexual health. Module 1 addressed basic facts about HIV and sexually transmitted infections (STI), including HPV. Module 2 addressed HIV/STI prevention (e.g., condom use, PrEP) and will included basic facts about HPV vaccination currently available online. Module 3 addressed tips for healthy relationships. Phase 2 booster messages largely reinforced Phase 1 content to foster continued engagement with the program.~Sexual Health Control: Text messages sharing HIV/STI prevention and healthy relationship building information, including information about HPV infection and vaccination."
89383917|NCT03663036|Experimental|FL-ASCR|Magnetic Resonance Imaging of the shoulder Radiograph of the shoulder
89383918|NCT03614000|Experimental|positive screenings|
89383919|NCT03251352||TKI Discontinuation Group|The enrolled patients will be undertaking TKI discontinuation under the conditions of informed consent and frequent monitoring according to the clinical guideline.
89383920|NCT02032160|Experimental|Engerix B|Engerix B IM injection - 20ug At 0, 1 and 6 months
89383921|NCT02032160|Experimental|Fendrix|Fendrix IM injection - 20ug At 0, 1 and 6 months
89383922|NCT03662958|Experimental|Lutrate|a novel leuprolide acetate 3.75mg depot
89383923|NCT03662958|Active Comparator|Enantone|market reference leuprolide acetate 3.75 mg depot
89383924|NCT02032082|No Intervention|Ex vivo without CO|
89383925|NCT02032082|Experimental|EX Vivo with carbone monoxide|During the Ex Vivo Lung Perfusion reconditioning,the lungs will be ventilated wit h Oxygen (21%) and Carbon Monoxide (250ppm).
89383926|NCT04057170|Experimental|mulligan method|Mulligan mobilization with mowement method every three days for six weeks
89383927|NCT04057170|Experimental|accelerated protocol|accelerated rehabilitation protocol every three days for six weeks
89383928|NCT03615638|Experimental|Fall prevention group|Fall prevention program
89383929|NCT03615638|No Intervention|Usual care group|Usual postoperative care
89383930|NCT03615638|No Intervention|Asymptomatic control|No intervention
89383931|NCT03636737||experimental group|Patients with Pyoderma gangrenosum
89184175|NCT02574897|Experimental|Electronic Symptom Survey|Patients randomized to the intervention arm will fill out the daily PRO-CTCAE electronic symptom survey. The intervention consists of sending the results of the surveys in the intervention arm to the clinical care team. The four symptom-specific PROMIS subsets (Anxiety, Depression, Fatigue, and Sleep Disturbance) will be filled out weekly while patients are admitted to the hospital. Patients will again complete the 6 minute walk distance testing, HRQoL surveys, and PASS assessment at the time of discharge. Patients in the intervention arm will complete a satisfaction survey at discharge. HRQoL (by mail) and PASS (by telephone) will be assessed for a third time 30 days after discharge.
88857595|NCT01675362|Active Comparator|Calcium channel Blockers|They will receive Verapamil (Isoptin 80 mg) Dosage: One tablet 2 hours before ESWL Then one tablet every 12 hours after ESWL for one week
88857596|NCT01675362|Active Comparator|Angiotensin receptor blocker group|They will receive Losartan (Cozaar 50 mg) Dosage: One tablet 2 hours before ESWL Then one tablet every day after ESWL for one week
88857597|NCT01675518|Experimental|Part-1 dose 1|
88857598|NCT01675518|Experimental|Part-1 dose 2|
88857599|NCT01675518|Experimental|Part-1 dose 3|
88857600|NCT01675518|Experimental|Part-1 dose 4|
88857601|NCT01675518|Experimental|Part-1 dose 5|
88857602|NCT01675518|Experimental|Part-1 dose 6|
88857603|NCT01675518|Placebo Comparator|Part-1 placebo|
88857604|NCT01675518|Experimental|Part-2 fed|
88857605|NCT01675518|Experimental|Part-2 fasted|
88857606|NCT03158532|Placebo Comparator|Placebo I/Placebo II|0,9% Saline 10 mL was given intra-arterially through the sheath at the start of a transradial procedure (right after sheath placement) and 0,9% Saline 10 mL was given intra-arterially through the sheath at the end of procedure (just before sheath removal).
88857607|NCT03158532|Experimental|Nitroglycerin I/Placebo II|500 microgram of Nitroglycerin (in 10 mL saline) was given intra-arterially through the sheath at the start of a transradial procedure (right after sheath placement) and 0,9% Saline 10 mL was given intra-arterially through the sheath at the end of procedure (just before sheath removal).
88857608|NCT03158532|Active Comparator|Placebo I /Nitroglycerin II|0,9% Saline 10 mL was given intra-arterially through the sheath at the start of a transradial procedure (right after sheath placement) and 500 microgram of Nitroglycerin (in 10 mL saline) was given intra-arterially through the sheath at the end of procedure (just before sheath removal).
88857609|NCT03158532|Experimental|Nitroglycerin I /Nitroglycerin II|500 microgram of Nitroglycerin (in 10 mL saline) was given intra-arterially through the sheath at the start of a transradial procedure (right after sheath placement) and 500 microgram of Nitroglycerin (in 10 mL saline) was given intra-arterially through the sheath at the end of procedure (just before sheath removal).
88857610|NCT04404738|Experimental|MicroPort® Surgical System|robot-assisted surgeries, for instance, prostatectomy, cystectomy or nephrectomy will be performed using MicroPort® surgical system
88857611|NCT04404738|Active Comparator|da Vinci Surgical System|robot-assisted surgeries, for instance, prostatectomy, cystectomy or nephrectomy will be performed using da Vinci surgical system
88857612|NCT03879876|Experimental|Human T Lymphoid Progenitor (HTLP) injection|Human T Lymphoid Progenitor cells (HTLPs) obtained after a brief period of ex vivo culture in the presence of the fusion protein DL-4, Retronectin® and a combination of cytokines
88857613|NCT01675986|Experimental|Pregabaline|Groups PREGABALINE : 150 mg de LYRICA®
89383932|NCT03615560||Preeclampsia (mild)|
88857614|NCT01675986|Experimental|Hydroxyzine|Groups HYDROXYZINE : 75 mg d'ATARAX®
88857615|NCT01675986|Placebo Comparator|Lactose|Groups placebo : 4 g de lactose
88857616|NCT03155490|Experimental|Leadership Training|Subjects are resident trainees with a role in the emergency department evaluation and management of trauma patients.
88857617|NCT03155490|No Intervention|Control|Subjects are resident trainees with a role in the emergency department evaluation and management of trauma patients.
88857618|NCT03876522||Lafora Disease Patients|Documented genetic diagnosis of Lafora disease; clinical diagnosis of Lafora disease and a sibling with a known mutation in EPM2A or EPM2B; clinical diagnosis of Lafora disease and a previously undescribed mutation in EPM2A or EPM2B; asymptomatic siblings if mutation positive prior to enrollment.
88857619|NCT03150186||SHS exposure in homes|Measurement of nicotine level in private homes
88857620|NCT03150186||SHS exposure in private cars|Measurement of nicotine level in private cars
88857621|NCT03150186||SHS exposure in outdoor settings|Measurement of nicotine level in outdoor settings (children playgrounds, terraces of hospitality venues, and entrances of primary school buildings)
88857622|NCT03875664|Active Comparator|Intervention|Receives 20 mL liposomal bupivacaine expanded with 10 mL of injectable sterile normal saline solution (0.9%) for a total of 30 mL injected in the posterior vaginal compartment in a standardized technique
88857623|NCT03875664|Placebo Comparator|Placebo|Receives 30 mL of injectable sterile normal 0.9% saline solution injected in the posterior vaginal compartment in a standardized technique
88857624|NCT01676064|Active Comparator|liberal fluid group|during surgery 7 ml/kg/hr RL during first intraoperative hr, 5 ml/kg/hr for the subsequent hours.After surgery ( PACU) 1,5 ml/kg/hr;After operation ward on the day of surgery 1,5 ml/kg/hr; Postoperative day 1- 1,5 ml/kg/hr RL, oral fluids;Postoperative day 2-oral fluids and solid food according to surgical allowance.
89383933|NCT03615560||Preeclampsia (severe)|
89383934|NCT03615560||Gestational hypertension|
89383935|NCT03615560||Control group|
88857625|NCT01676064|Active Comparator|restrictive fluid group|"during surgery-RL according to 4-2-1 4 ml/kg/hr for first 10 kg (=40ml/hr) then 2 ml/kg/hr for next 10 kg (=20ml/hr)then 1 ml/kg/hr for any kg over 20 kg of weight. This always gives 60ml/hr for first 20 kg then you add 1 ml/kg/hr for each kg over 20 kg.~After surgery (PACU):4-2-1 rule. After operation ward on the day of surgery 1,5 ml/kg/hr.Postoperative day 1:1,5 ml/kg/hr RL, oral fluids. Postoperative day 2:oral fluids and solid food according to surgical allowance."
88857626|NCT01670058||Belatacept treated adult kidney-only transplant recipients|All adult kidney-only transplant recipients treated with Nulojix (Belatacept)
88857627|NCT01670058||CNIs at transplantation|
88857628|NCT01670136|No Intervention|sildenafil, standard of care|Infants receiving sildenafil as standard of care
88857629|NCT01670136|Other|sildenafil administered for study|1 dose of sildenafil administered for study
88857630|NCT01670214|Active Comparator|Pulsed electromagnetic field|parameters of the pulsed electromagnetic field are frequency:10 Hz, intensity 4-5 mT, 6 sessions phase 1 treatment and added 6 sessions for phase 2 treatment (3 sessions per week)
89383936|NCT03662256|Active Comparator|Current Primary Care Referral Process|In communities randomized to the current primary care process, families will be notified if their children refer hearing screening in exactly the same method each preschool had been using previously. This process involves a letter home to the parents, either sent with the child or by mail, requesting that the parent/caregiver bring the child to village health clinic for an evaluation. Per current practice, most preschools also give the list of referred children to the Norton Sound Audiology Department, whose staff then reaches out to families to schedule appointments during the next available audiology clinic.
89383937|NCT03662256|Experimental|Expedited Telemedicine Referral|In communities randomized to the expedited telemedicine intervention, parents of children who screen positive will receive a phone call from the school or the clinic on the day of screening notifying them of the day and time of their child's telemedicine consultation appointment. Appointments will be made with community health aides (CHAs) who have dedicated time blocked off to perform telemedicine consults. Participating children who refer screening will be transported to clinic for their appointment with adult chaperones. Parent participation will be required unless parents direct otherwise. Nonparticipating children in communities assigned to the expedited telemedicine intervention arm will receive standard referral following the current school primary care referral process.
89383938|NCT03231371|Experimental|Study Arm|
88857631|NCT01670214|Placebo Comparator|pulsed electromagnetic field|patients are placed under off instrument while who is kept blind to know it for 6 sessions (3 sessions per week).
88857632|NCT01676142||Patients with NTM pulmonary infection|
88857633|NCT01676142||Patients with other pathogen related lung infection|
88857634|NCT01676142||Patient with NTM pulmonary colonization|
88857635|NCT04747002|Active Comparator|Administration Group|Patients who are injected with DSP-7888.
88857636|NCT04747002|No Intervention|Non-administration Group|Patients who are only under observation.
88857637|NCT03873480|Active Comparator|Intervention Arm|Participants randomized into the intervention group will receive an injection of 2.5 cc of 0.25% marcaine without epinephrine prior to the incision. The local anesthetic will be administered by the treating surgeon. All other aspects of the procedure will be kept in accordance with the standard of care for trigger thumb surgeries.
88857638|NCT03873480|No Intervention|Non-Intervention Arm|Those that are not randomized into the intervention group will receive the standard of care for a trigger thumb release, which is administration of 2.5 cc of 0.25% marcaine without epinephrine following completion of surgery. The local anesthetic will be administered by the treating surgeon.
88857639|NCT03872310|Active Comparator|Active comparator|Within group
88857640|NCT03872310|Sham Comparator|Sham comparator|Within group
88857641|NCT04404426|Experimental|L-citrulline|Administration of citrulline enterally for 7 days
88857642|NCT04404426|Placebo Comparator|Placebo|Administration of placeboenterally for 7 days
88857643|NCT04764084|Experimental|Treatment group|Niraparib-Anlotinib combination therapy
88857644|NCT03871530|Experimental|Coordinate A|"PIEB Next Bolus: 45 minutes, PIEB Interval: 50 minutes, and PIEB volume: 5 mL"
88857645|NCT03871530|Experimental|Coordinate B|"PIEB Next Bolus: 45 minutes, PIEB Interval: 40 minutes, and PIEB volume: 6.5 mL"
88857646|NCT03871530|Experimental|Coordinate C|"PIEB Next Bolus: 45 minutes, PIEB Interval: 50 minutes, and PIEB volume: 8 mL"
88857647|NCT03871530|Experimental|Coordinate D|"PIEB Next Bolus: 45 minutes, PIEB Interval: 60 minutes, and PIEB volume: 6.5 mL"
88857648|NCT03871530|Experimental|Coordinate E|"PIEB Next Bolus: 30 minutes, PIEB Interval: 40 minutes, and PIEB volume: 5 mL"
88857649|NCT03871530|Experimental|Coordinate F|"PIEB Next Bolus: 30 minutes, PIEB Interval: 40 minutes, and PIEB volume: 8 mL"
88857650|NCT03871530|Experimental|Coordinate G|"PIEB Next Bolus: 30 minutes, PIEB Interval: 60 minutes, and PIEB volume: 8 mL"
88857651|NCT03871530|Experimental|Coordinate H|"PIEB Next Bolus: 30 minutes, PIEB Interval: 60 minutes, and PIEB volume: 5 mL"
88857652|NCT03871530|Experimental|Coordinate I|"PIEB Next Bolus: 15 minutes, PIEB Interval: 50 minutes, and PIEB volume: 5 mL"
88857653|NCT03871530|Experimental|Coordinate J|"PIEB Next Bolus: 15 minutes, PIEB Interval: 40 minutes, and PIEB volume: 6.5 mL"
88857654|NCT03871530|Experimental|Coordinate K|"PIEB Next Bolus: 15 minutes, PIEB Interval: 50 minutes, and PIEB volume: 8 mL"
88857655|NCT03871530|Experimental|Coordinate L|"PIEB Next Bolus: 15 minutes, PIEB Interval: 60 minutes, and PIEB volume: 6.5 mL"
88857656|NCT03871530|Experimental|Coordinate M|"PIEB Next Bolus: 30 minutes, PIEB Interval: 50 minutes, and PIEB volume: 6.5 mL"
88857657|NCT03871530|Experimental|Coordinate N|"PIEB Next Bolus: 30 minutes, PIEB Interval: 50 minutes, and PIEB volume: 6.5 mL"
89383939|NCT03662880|Other|Cardiac Magnetic Resonance &Trans-esophageal echo|patients undergo Percutaneous Mitral Commissurotomy will do cardiac magnetic resonance and trans esophageal echo for detection of left atrial thrombus
89383940|NCT03613766|Experimental|Physical activity program|Before 3 to 6 months before the expected date of surgery, the experimental group, performed a 12-week monitored and supervised concurrent exercise program. Before and after of this period, body composition, anthropometric measures, physical fitness, cardiovascular risk, blood samples, Basal Metabolic Rate and health-related quality of life were measured in a laboratory under controlled conditions.
89383941|NCT03613766|No Intervention|Habitual care prescription|Before 3 to 6 months before the expected date of surgery, the control group, followed the habitual care prescriptions until the surgery
88857658|NCT02984826|Active Comparator|Strength training|Intervention with specific strength training program runs for 10 weeks.
88857659|NCT02984826|Active Comparator|Ergonomic and posture|Intervention, the control group will be trained in ergonomics and posture.
88857660|NCT03870048|Experimental|All Study Participants/tDCS or SHAM|"tDCS Block: The participant will receive tDCS for 20 min at an intensity of 2 mA while seated comfortably and quietly in a room. The intensity will start at 0 mA and will be incrementally increased to 2mA over the initial 30 seconds. At the 19:30 minute time point, the current will gradually be reduced from 2 mA to 0 mA.~Sham block: Identical to the tDCS block, except the participants will only receive the initial 30 seconds of ramp-up, after which the current will be set to 0 for the remainder of the 20 minutes."
88857661|NCT01676610||Infants presenting to the Clinic|Infants presenting to the Bilal and Bhains Colony Health Center. Devices used to measure Pulse Oximetry (PO) include Rad-5v by Masimo, TuffSat by GE, N-65 by Nellcor, PRO2 by Conmed, and Lifebox by Acare.
88857662|NCT03866538|No Intervention|Continued Budesonide|Patients in this arm continue budesonide at the dose they were taking at the time of enrollment in the trial
88857663|NCT03866538|Experimental|Withdrawal of Budesonide|Patients are weaned off of budesonide over 2 weeks and continued off of the medication for the duration of the trial
88857664|NCT03861624|Experimental|Intramedullary nailing|Patients receive definitive fixation of AO/OTA-42 open tibia diaphyseal fractures via Intramedullary nailing with standard SIGN nail.
88857665|NCT03861624|Active Comparator|External Fixation|Patients receive definitive fixation of AO/OTA-42 open tibia diaphyseal fractures External Fixation with uniplanar Dispofix external fixator.
88857666|NCT01677390|Experimental|Arm 1|SGN-75, everolimus
88857667|NCT03661086|Active Comparator|O2matic|Usual care plus O2matic controlled oxygen therapy for a maximum of 3 days or until weaning from oxygen supplementation
88857668|NCT03661086|No Intervention|Manual|Usual care plus manual controlled oxygen therapy by nursing staff. O2matic used in monitoring mode to measure SpO2 continuously.
88857669|NCT03658512||TUEDID cohort|
88857670|NCT03750864|Experimental|ACT-LCS Therapy|Intervention is psychosocial counseling utilizing Acceptance and Commitment Therapy for Lung Cancer Stigma (ACT-LCS) as a patient-focused intervention to reduce the self-blame, guilt and inhibited disclosure associated with lung cancer stigma.
88857671|NCT03749070|Active Comparator|Silymarin|Patients will receive 2 capsules containing a total of 700mg of silymarin, 8mg of vitamin E and 50mg of phosphatidylcholine, in addition to the excipient, which should be ingested daily for 12 weeks.
88857672|NCT03749070|Placebo Comparator|Placebo|Patients will also receive similarly 2 capsules per day, but without the bioactive principle tested (silymarin). Therefore, the capsules in the control group will contain only 700 mg of maltodextrin, a neutral food component derived from starch, in addition to the excipient and the same amount of vitamin E and phosphatidylcholine to balance the two groups.
88857673|NCT03748602|Experimental|TOD|Thoracic Outlet Decompression (TOD)
88857674|NCT03748602|No Intervention|Conservative therapy|Physiotherapy and pain relief
88857675|NCT01345656|Experimental|Arm 1|
88857676|NCT01345656|Experimental|Arm 2|
88857677|NCT01345656|Experimental|Arm 3|
88857678|NCT01345656|Experimental|Arm 4|
88857679|NCT01345656|Placebo Comparator|Arm 5|
88857680|NCT01345656|Active Comparator|Arm 6|
88857681|NCT01676922||Cohort|
88857682|NCT03744624|Experimental|With 3D Model|Patients in this arm will undergo laparoscopic liver resection with prior planning utilizing both 3D printed model and computed tomography (or/and magnetic resonance imaging)
88857683|NCT03744624|Active Comparator|Without 3D Model|Patients in this arm will undergo laparoscopic liver resection with prior planning utilizing only standard medical imaging computed tomography (or/and magnetic resonance imaging) without development of 3D printed model
88857684|NCT03743064|Experimental|100 mg anamorelin HCl|100 mg anamorelin HCl (administered as 100 mg tablets in the fasted condition)
88857685|NCT03743064|Placebo Comparator|Placebo|Placebo oral tablet (administered as matching placebo tablets in the fasted condition)
88857686|NCT01196832||Chronic obstructive pulmonary disease patients|"COPD patients with exacerbation will be recruited during hospitalization in Intensive care unit or as outpatients in the clinical investigation centre of the CHU de Bordeaux.~Inclusion visit: blood sample for fibrocytes analysis. Second visit 2 months ± 7 days after the exacerbation: clinical and functional evaluation (plethysmography, TLCO, arterial gaz), blood sample for fibrocytes analysis."
88857687|NCT01196832||Control group|Subjects without any history of lung disease and with normal lung function testing
88857688|NCT03737916|Experimental|dextrose group|"Procedure: Ultrasound-guided perineural injection with 5% dextrose. Ultrasound-guided perineural injection with 5% Dextrose (1cc) to ulnar nerve into the elbow, 2 and 4 cm before and after the elbow (total 5 cc).~Drug: 5% Dextrose 5% Dextrose could decrease the release of CGRP (Calcitonin Gene Related Peptide) and substance P to reduce the nerve inflammation"
88857689|NCT03737916|Placebo Comparator|control group|"Procedure: Perineural injection with normal saline Ultrasound-guided perineural injection with normal saline (1cc) to ulnar nerve into the elbow, 2 and 4 cm before and after the elbow (total 5 cc).~Drug: Normal Saline Normal saline is safe for perineural injection."
88857690|NCT04763460|Active Comparator|Baseline CRT programming|The comparator arm patients will remain at baseline CRT programming for the first 6 months, and then will crossover to the experimental arm and CRT device will be programmed to optimal settings derived from the electrocardiographic assessment for the following 6 months.
88857691|NCT04763460|Experimental|Electrocardiography-guided optimal CRT programming|The experimental arm patients will have CRT device programmed based on the electrocardiographic assessment for 12 months.
88857692|NCT04763616|Experimental|Isatuximab and Cemiplimab combined therapy|"Drug : Isatuximab~1 cycle : 10mg/kg IV every week. It is administered on Day 2, Day 9, Day 16, Day 23.~2~6 cycle : 10mg/kg every 2 weeks . It is administered on Day 2, Day 16.~7th cycle and beyond : 10mg/kg IV every 3 weeks. It is administered on Day 2.~Drug : Cemiplimab~1st - 6th cycle : 250mg IV every 2 weeks. It is administered on Day 1, Day 15.~7th cycle and beyond : 350mg every 3 weeks. It is administered on Day 1."
88857693|NCT04747158|Experimental|Convalescent plasma|COVID-19 convalescent plasma
88857694|NCT03652974|Experimental|sodium valproate with clozapine|"sodium valproate, dosage form: 250 mg, dosage and frequency:250 mg/d for 1 week, 500 mg/d for week 2 , 1000 mg/d for weeks 3, 4, 5, 6, 7 , 8, 9, 10, 11and 12; clozapine, dosage and frequency:300~600 mg/d; duration: 12 weeks.~Intervention: Drug: sodium valproate with Clozapine"
88857695|NCT03652974|Experimental|Modified electroconvulsive therapy with clozapine|"12 times MECT for 12 weeks，once a week for the 12 weeks; clozapine, dosage and frequency:300~600 mg/d; duration: 12 weeks.~Intervention: Device: modified electroconvulsive therapy(MECT) with Clozapine"
88857696|NCT03652974|Experimental|amisulpride|"amisulpride, dosage form: 200 mg, dosage and frequency:200 mg/d for 1 week, 400 mg/d for week 2,800 mg/d for weeks 3, 4, 5, 6, 7 , 8, 9, 10, 11and 12; clozapine, dosage and frequency:300~600 mg/d; duration: 12 weeks.~Intervention: Drug: amisulpride with Clozapine"
88857697|NCT03652974|Placebo Comparator|placebo|"The amisulpride and placebo tablets were identical in appearance. One placebo tablet for the first one week, two placebo tablets for the second week, four placebo tablets for weeks 3, 4, 5, 6, 7 , 8, 9, 10, 11and 12; clozapine, dosage and frequency:300~600 mg/d; duration: 12 weeks.~Intervention: Drug: placebo with Clozapine"
88857698|NCT03650244||Patients fitted with REMEEX|
88857699|NCT03649152|Experimental|Propagermanium then Placebo|"Propagermanium one capsule orally twice daily for 16 weeks. Compliance will be measured by drug accountability and completion of a participant diary.~Participants will receive 16 weeks propagermanium and 16 weeks placebo separated by a 6 week washout period."
88857700|NCT03649152|Experimental|Placebo then Propagermanium|"Propagermanium one capsule orally twice daily for 16 weeks. Compliance will be measured by drug accountability and completion of a participant diary.~Participants will receive 16 weeks placebo and 16 weeks propagermanium separated by a 6 week washout period."
88857701|NCT02082288|Experimental|Edessy ICSI Outcome Embryo Score|ICSI
88857702|NCT03849456|Experimental|GWP42006|Oral solution taken twice daily with food for 52 weeks.
88857703|NCT03645720|No Intervention|Metal needle gruop|puncture using metal needle
89184176|NCT02574897|Active Comparator|Blinded Electronic Symptom Survey|Patients in the control arm will only fill out the symptom survey at the time of admission and days 7, 10, and 14. The results of symptom surveys from the patients in the control arm will not be sent to providers, but will be used for data analysis purposes only. The four symptom-specific PROMIS subsets (Anxiety, Depression, Fatigue, and Sleep Disturbance) will be filled out weekly while patients are admitted to the hospital. Patients will again complete the 6 minute walk distance testing, HRQoL surveys, and PASS assessment at the time of discharge. HRQoL (by mail) and PASS (by telephone) will be assessed for a third time 30 days after discharge.
89383942|NCT04057092|Experimental|Intervention group|Eligible patients undergoing gynecologic oncology or general surgery will receive perioperative immunonutrition supplement INergy-FLD®. The operation should occur within 8 weeks from enrolment in the pilot study. Upon assessment and enrolment in the pilot study, patients will have a consultation with their physician in the preoperative clinic and will be provided with 10 days worth of INergy-FLD® beverages, 30 servings total.
88857704|NCT03645720|Experimental|plastic cannula|puncture using plastic cannula
88857705|NCT03645096|Experimental|Pregnenolone 500 > Pregnenolone 800 > Placebo|"3 exposures in order:~Pregnenolone 500 mg capsule by mouth, daily for 7 days followed by 14 day washout.~Pregnenolone 800 mg capsule by mouth, daily for 7 days followed by 14 day washout.~Matching placebo capsule by mouth, daily for 7 days."
88857706|NCT03645096|Experimental|Pregnenolone 500 > Placebo > Pregnenolone 800|"3 exposures in order:~Pregnenolone 500 mg capsule by mouth, daily for 7 days followed by 14 day washout.~Matching placebo capsule by mouth, daily for 7 days followed by 14 day washout.~Pregnenolone 800 mg capsule by mouth, daily for 7 days."
88857707|NCT03645096|Experimental|Pregnenolone 800 > Pregnenolone 500 > Placebo|"3 exposures in order:~Pregnenolone 800 mg capsule by mouth, daily for 7 days followed by 14 day washout.~Pregnenolone 500 mg capsule by mouth, daily for 7 days followed by 14 day washout.~Matching placebo capsule by mouth, daily for 7 days."
88857708|NCT03645096|Experimental|Pregnenolone 800 > Placebo > Pregnenolone 500|"3 exposures in order:~Pregnenolone 800 mg capsule by mouth, daily for 7 days followed by 14 day washout.~Matching placebo capsule by mouth, daily for 7 days followed by 14 day washout.~Pregnenolone 500 mg capsule by mouth, daily for 7 days."
88857709|NCT03645096|Experimental|Placebo > Pregnenolone 500 > Pregnenolone 800|"3 exposures in order:~Matching placebo capsule by mouth, daily for 7 days followed by 14 day washout.~Pregnenolone 500 mg capsule by mouth, daily for 7 days followed by 14 day washout.~Pregnenolone 800 mg capsule by mouth, daily for 7 days."
88857710|NCT03645096|Experimental|Placebo > Pregnenolone 800 > Pregnenolone 500|"3 exposures in order:~Matching placebo capsule by mouth, daily for 7 days followed by 14 day washout.~Pregnenolone 800 mg capsule by mouth, daily for 7 days followed by 14 day washout.~Pregnenolone 500 mg capsule by mouth, daily for 7 days."
89383943|NCT03613922|Experimental|Early Manual Therapy Group|Routine physiotherapy program plus Mulligan's Mobilization with Movement technique were applied.
88857711|NCT03734172||Paediatric diagnostic group|Paediatric diagnostic group
88857712|NCT03732300|Experimental|ASSIP + TAU goup|ASSIP psychotherapy intervention + treatment as usual (TAU)
88857713|NCT03732300|No Intervention|TAU|Treatment as usual
88857714|NCT04762524|Experimental|Initiation on CVVH|Patients in this arm were initiated on CVVH, rather than CVVHD
88857715|NCT04762524|Active Comparator|Initiation on CVVHD|Patients in this arm were initiated on CVVHD, rather than CVVHDH
88857716|NCT03642678|Experimental|Intervention group|"Participants identified as high-risk for malnutrition-related mortality by prediction model are cluster-randomized into study group.~Interventions: In this group, participants will be given common clinical screening for clinical or sub-clinical infection and also oral nutrition supplement (ONS) if albumin is < 3.8 g/dl. Parameters for outcome measurements are recorded monthly (such as biochemical data) or quarterly (such as Body Composition Monitor (BCM) or Malnutrition Inflammatory Score (MIS). Hospitalization or Mortality events will be recorded when happened."
89184177|NCT00714909||1|
89184178|NCT00918528|Active Comparator|1. Internal urethrotomy|
89184179|NCT00918528|Experimental|2. Internal urethrotomy + mitomycin C|
89383944|NCT03613922|Active Comparator|Routine Physiotherapy Group|Only routine physiotherapy program was applied
89383945|NCT03663114||Lenvatinib|Participants receiving lenvatinib capsules 12 milligrams (mg) based on participant's body weight greater than or equal to (>=) 60 kilograms (kg) or 8 mg based on participant's body weight less than (<) 60 kg, orally, once daily dose will be centrally registered and observed prospectively for up to 1 year after the administration of dose.
88857717|NCT03642678|No Intervention|Control group|Participants identified as high-risk for malnutrition-related mortality by prediction model are cluster-randomized into control group. In this group, participants will not be given any intervention, but only outcome measurements are recorded monthly (such as biochemical data) or quarterly (such as Body Composition Monitor (BCM) or Malnutrition Inflammatory Score (MIS). Hospitalization or Mortality events will be recorded when happened.
88857718|NCT03642210|Experimental|Levonorgestrel 52 mg intrauterine system|Levonorgestrel 52 mg intrauterine system, inserted for use up to 6 months
88857719|NCT03844386|Experimental|MVA.tHIVconsv3 (M3)|Participants in this arm receive one vaccine dose of MVA.tHIVconsv3 (M3) given IM at Day 0
88857720|NCT03844386|Experimental|MVA.tHIVconsv4 (M4)|Participants in this arm receive one vaccine dose of MVA.tHIVconsv4 (M4) given IM at Day 0
88857721|NCT03844386|Experimental|MVA.tHIVconsv3 (M3)+MVA.tHIVconsv4 (M4)|Participants in this arm receive a single combined dose containing each vaccine type MVA.tHIVconsv4 (M3) + MVA.tHIVconsv4 (M4) given IM at Day 0
88857722|NCT03844386|Placebo Comparator|Placebo|Participants in this arm receive one saline (placebo) dose given IM at Day 0
88857723|NCT02082678|Active Comparator|Ondansetron|Ondansetron will be given 0.5 mg twice a day (BID). The dose may be increased from 0.5 mg/BID to 1.0 mg/BID at week 4 for participants with less than 30% reduction in HAMD and/or alcohol use. An additional dose increase to 2.0 mg/BID and 4.0 mg/BID is allowed at weeks 8 and 10, respectively, for participants with less than a 50% reduction in HAMD scores and/or alcohol use.
88857724|NCT02082678|Placebo Comparator|Placebo|Placebo will be given 0.5 mg/ BID. The dose may be increased from 0.5 mg/BID to 1.0 mg/BID at week 4 for participants with less than 30% reduction in HAMD and/or alcohol use. An additional dose increase to 2.0 mg/BID and 4.0 mg/BID is allowed at weeks 8 and 10, respectively, for participants with less than a 50% reduction in HAMD scores and/or alcohol use.
88857725|NCT03836430|Experimental|Newborn Behavioral Observation|The Newborn Behavioral Observation-Family Wellness (NBO-FW) intervention is the experimental arm of this RCT. It consists of 3 NBOs - 2 during the birth hospitalization and the third at 6 weeks post-discharge as well as a journal with prompts for mothers to reflect on their infant's behavior and their own transition to motherhood. NBOs are clinical relationship-building tools used by trained clinicians/therapists to help parents understand their babies' unique language.
88857726|NCT03836430|No Intervention|Usual care|This arm is the usual care arm. Of note, both arms receive 2 parenting books, one at hospital discharge and one at 6 weeks post-discharge.
88857727|NCT04403958|Experimental|PRC|Total wrist arthrodesis with PRC and dorsal plate
88857728|NCT04403958|Active Comparator|TWA|Total wrist arthrodesis with dorsal plate
88857729|NCT04763850|Experimental|Walking decline|Walking decline on an instrumented treadmill under 3 different conditions
88857730|NCT01677468|Experimental|Intermediate embolization|TACE with substatsis using gelfoam
88857731|NCT01677468|Active Comparator|Complete embolization|TACE with complete embolization using gelfoam
88857732|NCT00003816|Experimental|Regimen 1|Patients receive busulfan IV over 2 hours every 6 hours on days -7 to -4 and cyclophosphamide IV over 2 hours on days -3 and -2.
88857733|NCT00003816|Experimental|Regimen 2|Patients receive cyclophosphamide IV over 2 hours on days -5 to -2 and anti-thymocyte globulin IV over 4-8 hours on days -5 to -3.
88857734|NCT00003816|Experimental|Regimen 3|Patients receive cyclophosphamide IV over 2 hours on days -5 and -4 and total-body irradiation (TBI) twice daily on days -3 to -1.
88857735|NCT00003816|Experimental|Regimen 4|Patients receive fludarabine IV over 30 minutes on days -6 to -2 and melphalan IV over 1 hour on days -3 and -2.
88857736|NCT00003816|Experimental|Regimen 5|Patients receive etoposide IV over 26 hours beginning on day -5, cyclophosphamide IV over 2 hours on day -4, and TBI twice daily on days -3 to -1.
88857737|NCT00003816|Experimental|Regimen 6|Patients receive cyclophosphamide IV over 24 hours, carboplatin IV over 24 hours, and thiotepa IV over 24 hours on days -7 to -4.
88857738|NCT00003816|Experimental|Regimen 7|Patients receive fludarabine IV over 30 minutes on days -5 to -1 and anti-thymocyte globulin IV over 4-8 hours on days -5 to -2.
88857739|NCT00003816|Experimental|Regimen 8|Patients receive cyclophosphamide IV over 2 hours on days -5 and -4, TBI twice daily on days -3 to -1, and anti-thymocyte globulin IV over 4-8 hours on days -3 to -1.
88857740|NCT00003816|Experimental|Regimen 9|Patients receive busulfan IV over 2 hours every 6 hours and anti-thymocyte globulin IV over 4-8 hours on days -7 to -4 and cyclophosphamide IV over 2 hours on days -3 and -2.
88857741|NCT03618654|Experimental|Arm A (durvalumab, metformin)|"Patients will take Metformin 500mg/day for 3 days. From day 4, 500mg twice daily and then in 3 days (day 7) dose escalation to 1000mg twice daily will be achieved. This will be taken until the day before surgery after dinner.~Patients will receive 1500mg durvalumab (MEDI4736) via IV infusion"
88857742|NCT03618654|Experimental|Arm B (durvalumab)|Patients will receive 1500mg durvalumab (MEDI4736) via IV infusion. Participants receive durvalumab as in Arm A in the absence of disease progression or unacceptable toxicity.
88857743|NCT03617874|Active Comparator|PC4PrEP- Intervention Clinics|Intervention clinics will receive the PC4PrEP intervention. The intervention includes Montefiore PrEP policy awareness, provider and patient education, pre-screening to identify PrEP eligible patients, and identifying high risk individuals in the community and providing referral and linkage to primary care.
88857744|NCT03617874|Placebo Comparator|Standard of Care Clinics|These clinics will not receive the PC4PrEP intervention but will continue with their standard of care model.
88857745|NCT03614910||Locally Advanced Pancreatic Cancer|"Patients with locally advanced unresectable pancreatic cancer. Unresectable tumors as defined by:~occlusion, thrombosis or several centimeters of encasement of the superior mesenteric vein or portal vein~tumor abutment greater than 180 degrees of the superior mesenteric artery or thrombosis of the artery~abutment or encasement of the celiac axis~involvement of lymph nodes outside the area of resection"
88857746|NCT03718104||Naltrexone|Pregnant women with opioid use disorder on prescribed oral or extended-release naltrexone and their infants. Biospecimens collected from this group will undergo pharmacokinetic analysis, genetic and epigenetic analysis, and breast milk analysis. This group will also receive safety and efficacy interventions.
88857747|NCT03718104||Buprenorphine/Naloxone|Pregnant women with opioid use disorder on prescribed buprenorphine/naloxone and their infants. Biospecimens collected from this group will undergo genetic and epigenetic analysis and the group will also receive safety and efficacy interventions.
89184180|NCT00714987||1: High level PEEP|
89184181|NCT00714987||2: Low level PEEP|
89383946|NCT03526679|Experimental|Experimental arm|The combination of lenvatinib and eribulin
88857748|NCT03718104||Naltrexone - alcohol use disorder|Pregnant women with alcohol use disorder on prescribed naltrexone (oral or extended-release) and their infants. Biospecimens collected from this group will undergo pharmacokinetic analysis, genetic and epigenetic analysis, and breast milk analysis. This exploratory group will also receive safety and efficacy interventions.
88857749|NCT03714750|Active Comparator|DK crush|Percutaneous revascularization of true coronary bifurcation stenosis (Medina 1,1,1 or 0,1,1) with double kissing and crush technique
88857750|NCT03714750|Experimental|Reverse TAP|Percutaneous revascularization of true coronary bifurcation Stenosis (Medina 1,1,1 or 0,1,1) with reverse T and protrusion technique
88857751|NCT01677078|Experimental|Neuronavigation system|"10 sessions of rTMS coupled with a neuronavigation system~Description of 1 session of the rTMS protocol :~Frequency: 20Hz~Intensity: 110% of motor threshold~80 train of 2 seconds duration~10 seconds between two trains~3200 pulses~Devices :~rTMS: System Mag Pro (Magventure, Denmark)~Neuronavigation system: Syneika One (Syneika, France)"
88857752|NCT01677078|Sham Comparator|Standard localisation method|"10 sessions of rTMS with manual localisation of the DLPFC using the standard localisation method (i.e. the '5-cm method')~Description of 1 session of the rTMS protocol :~Frequency: 20Hz~Intensity: 110% of motor threshold~80 train of 2 seconds duration~10 seconds between two trains~3200 pulses~Devices :~- rTMS: System Mag Pro (Magventure, Denmark)"
88857753|NCT04763070|Other|Ciprofloxacin|
88857754|NCT04763694|Experimental|Treatment arm|Subjects wore multifocal soft contact lenses for 12 months.
88857755|NCT04762914||Prehabilitation (PH)|Patients who underwent prehabilitation prior to colorectal cancer resection
88857756|NCT04762914||Non-Prehabilitation (NPH)|Patients who did not undergo prehabilitation prior to colorectal cancer resection
88857757|NCT03828318|Experimental|Patient Activation Arm|
88857758|NCT03828318|No Intervention|Standard Care Arm|
88857759|NCT03609060|Experimental|DEXAML|"Induction therapy:~Idarubicin 8 mg/m²/day, IV over 15 minutes, D1 to D5 + Cytarabine 100 mg/m²/d, IV continuous 24h-infusion D1 to D7 + Lomustine 200 mg/m²/d, orally at D1 + Dexamethasone 10 mg/12h, IV over 30 minutes, D1 to D3. Addition of midostaurin in patients with Fms-like tyrosine kinase 3-internal tandem ( FLT3-ITD) or Fms-like tyrosine kinase 3-tyrosine kinase domain (FLT3-TKD) mutations is allowed.~Post remission therapy:~Idarubicin 8 mg/m², IV over 15 minutes, D1 + Cytarabine 50 mg/m²/12h, subcutaneous, D1 to D5 + Dexamethasone 20 mg/d, IV over 30 minutes, D1. Addition of midostaurin in patients with FLT3-ITD or FLT3-TKD mutations is allowed. Intermediate dose cytarabine is allowed for patients with Core Binding Factor AML (CBF-AML).~Allogeneic stem-cell transplantation allowed after 2 to 4 cycles"
88857760|NCT03706794|Experimental|Clinical Decision Support Tool|Tailored education provided via a smartphone application
88857761|NCT03706794|Active Comparator|Headache Education|Non-tailored education provided via a smartphone application.
89184182|NCT00468481|Experimental|Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)|1 tablet 0.020 mg EE/3.0 mg DRSP/0.451 mg L-5-MTHF as calcium salt given orally/daily for 24 days followed by 1 tablet 0.451 mg L-5-MTHF as calcium salt given orally/daily for 4 days over a time period of 24 weeks
89399577|NCT02179970|Other|Plerixafor (Mozobil)|Plerixafor (Mozobil), continuous 7 day IV infusion. Starting at a dose of 20 ug/kg/hr, and subsequent dose levels of 40, 80 and 120 ug/kg/hr.
88857762|NCT03705234|Experimental|Inclisiran|Inclisiran sodium 300 milligrams (mg) will be administered as a SC injection at randomization, 3 months and then every 6 months.
88857763|NCT03705234|Placebo Comparator|Placebo|Placebo will be administered as SC injections of saline solution at randomization, 3 months and then every 6 months.
88857764|NCT03704766|Experimental|Inflamed/Infected Joint|Patients undergoing joint aspiration/debridement due to suspicion of septic joint or rheumatologic/inflammatory condition
88857765|NCT03704766|Active Comparator|Normative Control|Patient undergoing procedure unrelated to infection/inflammation
89383947|NCT03615092|Active Comparator|Test Group|"Active Comparator: gingival recession with a previous restored cervical lesion~the aim of this study is to compare if the acellular dermal matrix graft is as efficient as a substitute for the connective graft used in root coverage of gingival recessions with non carious cervical lesions."
89383948|NCT03615092|Placebo Comparator|Control Group|the aim of this study is to compare if the acellular dermal matrix graft is as efficient as a substitute for the connective graft used in root coverage of gingival recessions with non carious cervical lesions. The control group had no cervical lesion, and was treated with the same technique as the acelular dermal matrix graft
89383949|NCT04056780||Septic group|The septic group will be considered as patients that fulfill the 2018 ICM definition of PJI.
89383950|NCT04056780||Aseptic group|The aseptic group will be considered as patients that don't fulfill the 2018 ICM definition of PJI.
88857766|NCT03826992|Experimental|Venetoclax and Vyxeos combination|"Venetoclax will be given orally on Days per the assigned dose level. A single course consisting of 3 doses of Vyxeos and 7-21 doses of venetoclax depending on the assigned dose level will be administered to participants in this study. Vyxeos will be administered by central venous catheter over 90 minutes on Day 1, 3, and 5.~Venetoclax is given daily by mouth per assigned dose level."
88857767|NCT00004092|Experimental|Arm I (ACT) (closed to accrual as of 4/6/2006)|Patients receive doxorubicin IV over 24 hours on days -9 to -6, cyclophosphamide IV over 2 hours on day -5, and paclitaxel IV over 24 hours on day -2. PBSC are reinfused on days -2 and 0. G-CSF is administered beginning on day 0 and continuing until blood counts recover.
88857768|NCT00004092|Active Comparator|Arm II (STAMP V)|Patients receive cyclophosphamide IV, carboplatin IV, and thiotepa IV over 24 hours on days -7 to -4. PBSC are reinfused and G-CSF is administered as in arm I.
88857769|NCT00004146|Experimental|Treatment (RT and CAI)|"Patients receive induction therapy consisting of radiotherapy once daily 5 days a week plus oral carboxyamidotriazole once daily for 6 weeks followed by carboxyamidotriazole alone daily for 4 weeks. Patients continue on oral carboxyamidotriazole once daily as maintenance therapy in the absence of disease progression or unacceptable toxicity. Patients are followed monthly for survival.~Other: pharmacological study, radiation therapy"
88857770|NCT00004500|Experimental|Lucinactant|Lucinactant via bronchoaveolar lavage
88857771|NCT00004500|Other|Standard Care|Standard Care included the use of oxygen, CMV, sedation, paralysis, vasopressors, and/or alkalinization
88857772|NCT03606330||VP-SG 01|Study subjects that present MACE at the 36 months follow-up
88857773|NCT03606330||VP-SG 02|Study subjects that do not present MACE at the 36 months follow-up
88857774|NCT03605628|Other|abdominal wall length|Measurement of abdominal wall length during neuromuscular block with a measuring tape
89383951|NCT04844684||Obese/non-diabetic patients undergoing gastric bypass surgery|
88857775|NCT03701724|Experimental|Systematic maintenance rTMS (arm A)|Active rTMS treatment followed, for responders, by systematic maintenance rTMS Depression usual medical treatment (psychosocial approach and/or pharmacotherapy and/or, ECT…)
88857776|NCT03701724|Experimental|rTMS course in case of relapse (arm B)|Active rTMS treatment followed, for responders, by additional rTMS courses, in case of relapse Depression usual medical treatment (psychosocial approach and/or pharmacotherapy and/or, ECT…)
88857777|NCT03701724|Sham Comparator|Sham rTMS (arm C)|sham rTMS followed, for responders, by either systematic sham mTMS (50%) or additional sham rTMS course in case of relapse(50%) Depression usual medical treatment (psychosocial approach and/or pharmacotherapy and/or, ECT…)
88857778|NCT00745992||Fungal infections|"Patients with invasive fungal infections; and~Patients who receive PO or IV voriconazole for more than 3 days"
88857779|NCT03825198|Active Comparator|ESB group|"Erector Spinae plane block with 20 ml levobupivacaine 0,25% on each side. General anesthesia with 15 mcg sufentanil, 2-3 mg/kg propofol and 0,5 mg/kg Rocuronium Bromide during spine fusion surgery (1 or two intervertebral levels). Maintainance of general anesthesia with sevoflurane.~Postoperative analgesia with Ketorolac (0,5 mg/kg), paracetamol 1000 mg (4 times/ day) and Morphine PCA. Dexamethasone is administered for the prevention of nausea."
88857780|NCT03825198|Sham Comparator|SHAM group|Erector Spinae plane block with 20 ml NaCl 0,9% on each side General anesthesia with 15 mcg sufentanil, 2-3 mg/kg propofol and 0,5 mg/kg Rocuronium Bromide during spine fusion surgery (1 or two intervertebral levels). Maintainance of general anesthesia with sevoflurane.Postoperative analgesia with Ketorolac (0,5 mg/kg, paracetamol 1000 mg 4times/ day and Morphne PCA .Dexamethasone is administered for the prevention of nausea.
89383952|NCT03613688|Experimental|Deepure Group A|Visit 3: Warm water without Deepure; Visit 4: Warm water with 1 g Deepure; Visit 5: Warm water with 1.5 g Deepure; Visit 6: Warm water with 2 g Deepure.
89383953|NCT03613688|Experimental|Deepure Group B|Visit 3: Warm water with 1 g Deepure; Visit 4: Warm water with 1.5 g Deepure; Visit 5: Warm water with 2 g Deepure; Visit 6: Warm water without Deepure.
89383954|NCT03613688|Experimental|Deepure Group C|Visit 3: Warm water with 1.5 g Deepure; Visit 4: Warm water with 2 g Deepure; Visit 5: Warm water without Deepure; Visit 6: Warm water with 1 g Deepure.
89383955|NCT03613688|Experimental|Deepure Group D|Visit 3: Warm water with 2 g Deepure; Visit 4: Warm water without Deepure; Visit 5: Warm water with 1 g Deepure; Visit 6: Warm water with 1.5 g Deepure.
88857781|NCT03596658|Experimental|SHR9549 dose escalation and expansion(s)|Escalating dose of SHR9549 with intensive safety monitoring to ensure the safety of patients
88857782|NCT03690648||Saliva collection|"Clinical examination;~Quality of life survey;~Saliva collection for genetical analysis"
88857783|NCT03690648||Saliva and Blood collection|"Clinical examination;~Quality of life survey;~Saliva and blood collection for genetical analysis"
88857784|NCT01677156||Receiving Corus CAD (ASGES)|Patients receiving Corus CAD (ASGES) to aid in the diagnosis of obstructive CAD
88857785|NCT03689166|Active Comparator|Probiotics group|Probiotic drug
88857786|NCT03689166|Placebo Comparator|Control group|This group will receive placebo
88857787|NCT03684408|Other|RFID and Wire Localization|Part A of this project is for physician training to master the technique of RFID placement and retrieval. On the day of surgery prior to going to the operating room, all participants will have the RFID placed first to allow radiologists to become familiar with placement of the RFID localizer. Participants will then immediately undergo wire localization. Either ultrasound or mammogram guidance will be used for the localization at the discretion of the performing radiologist. Surgeons will use a reader to locate the RFID chip during surgery. The wire will be present in the event the area of concern cannot be adequately located with the reader.
88857788|NCT03684408|Experimental|RFID Localization|Participants will be stratified based on technique of localization (either US guidance or mammographic guidance). They will then be randomized to receive either the wire or RFID localization. There will be four visits: one pre-op breast surgery visit in which enrollment will occur, one radiology procedure visit for localization, one surgical visit, and one post-operative visit. This is the same number of visits as standard of care.
88857789|NCT03684408|Active Comparator|Wire Localization|Participants will be stratified based on technique of localization (either US guidance or mammographic guidance). They will then be randomized to receive either the wire or RFID localization. There will be four visits: one pre-op breast surgery visit in which enrollment will occur, one radiology procedure visit for localization, one surgical visit, and one post-operative visit. This is the same number of visits as standard of care.
88857790|NCT03681366|No Intervention|Single vision soft contact lens|single vision, spherical soft contact lens
88857791|NCT03681366|Experimental|DISC3.5 Plus lens|A soft contact lens that comprises of simultaneous distance optical prescription and myopic defocus areas.
88857792|NCT03591354|Experimental|Closed Loop Control (CLC)|"Participants randomized to the closed loop control (CLC) arm will use the t:slim X2 with Control-IQ Technology & Dexcom G6 Continuous Glucose Monitor (CGM) for 3 months.~Objective 1: This arm is participants who had 6 months of CLC in the primary trial (DCLP3 Pivotal Trial)~Objective 2: This arm is participants who had 6 months of sensor-augmented pump (SAP) in the primary trial (DCLP3 Pivotal Trial)~Objective 3: This arm is participants who had 3 months of CLC in the extension trial (DCLP3 Extension) will continue use of the Control-IQ Technology & Dexcom G6 CGM until the product is commercially available."
88857793|NCT03591354|Active Comparator|Predictive-Low Glucose Suspend (PLGS)|"Participants randomized to Predictive-Low Glucose Suspend (PLGS) will use the t:slim X2 with Basal-IQ & Dexcom G6 CGM for 3 months.~Objective 1: This arm is participants who had 6 months of PLGS in the primary trial (DCLP3 Pivotal Trial)~Objective 2: This arm is not applicable to objective 2~Objective 3: This arm is participants who had 3 months of PLGS in the extension trial (DCLP3 Extension) will continue use of the Control-IQ Technology & Dexcom G6 CGM until the product is commercially available."
88857794|NCT03582852|Active Comparator|promontory|Laparoscopic sacrocolpopexy, which consist in fixing a mesh between vaginal anterior wall
88857795|NCT03582852|Active Comparator|laparoscopic lateral suspension|The procedure consists in spreading out bilaterally, a subperitoneal T-shaped mesh in the anterior abdominal wall
88857796|NCT00006156|Experimental|Control|Control for FSH stimulation test
88857797|NCT00006156|Experimental|Drug: FSH|FSH Stimulation Test
88857798|NCT03677778|Placebo Comparator|Placebo group|After surgery, in the post-operative recovery room, patients randomized to both the intervention and control groups will have 10cc 0.5% ropivacaine bolused via their nerve catheters. After 30 minutes, the following will be measured/assessed: spirometry data, pain scores (using the Numeric Rating Scale), and, if time is sufficient, bilateral diaphragmatic excursion via ultrasonography and brachial plexus motor and sensory exams. This control group will have no normal saline injected into their nerve catheter (no intervention). Then, both the control and treatment groups will have the following measured/assessed after 5, 15 and 30 minutes: spirometry data, pain scores (using the Numeric Rating Scale), and, if time is sufficient, bilateral diaphragmatic excursion via ultrasonography and brachial plexus motor and sensory exams. Investigators will be blinded to whether the patient is in the intervention or treatment group.
88875397|NCT03963492|Experimental|Interval Walking|Participants in the Interval Walking (INT) arm will undergo training 2x/week for 6 weeks for a total plan of 12 training sessions. The intervention for the (INT) group will be to complete three 2-minute-long walks with 2-minute seated rest breaks between each walk
89184183|NCT00468481|Active Comparator|Drospirenone (DRSP)/Ethinylestradiol (EE)|1 tablet 0.020 mg EE/3.0 mg DRSP [YAZ] given orally/daily for 24 days followed by 1 placebo tablet given orally/daily for 4 days over a time period of 24 weeks
89383956|NCT04057326|Active Comparator|Oryz-Aspergillus Enzyme and Pancreatin Tablet Arm|Oryz-Aspergillus Enzyme and Pancreatin Tablet ,2 tablets/time, 3 times daily. Study drug will be administered orally.
89383957|NCT04057326|Placebo Comparator|Placebo Arm|Placebo,2 tablets/time, 3 timesdaily. Study drug will be administered orally.
89383958|NCT04573829|Experimental|Non-drug approaches at home|Non-drug approaches at home three visits per week during six months and psycho-education for the caregivers one time per week for six months.
89383959|NCT02870348|Experimental|Alpha-1 MP|Participants received IV infusion of 60 mg/kg Alpha-1 MP administered weekly for mean duration of 213 weeks.
89383960|NCT03615014|Other|Patients having trauma|Adults patients having trauma in the month before visiting emergency will fill questionnaires
89383961|NCT03614936||Inoperable squamous cell cancer of the head and neck|patients 70 years of age or older with ENT carcinoma
89383962|NCT03281720|Experimental|Targeted Axillary Dissection|"After patients have completed their neoadjuvant systemic therapy, they will have a Savi Scout® electromagnetic reflector placed into the clipped axillary lymph nodes.~The surgeon will then use the Savi Scout detector intraoperatively to identify and remove your clipped lymph nodes prior to removing the remainder of the axillary lymph nodes in a surgery called an axillary dissection."
89383963|NCT03613610|Active Comparator|Three needles group|
89383964|NCT03613610|Active Comparator|Single needle group|
89184184|NCT00714168|Active Comparator|1|Participants will take part in a standard behavioral weight loss program.
89184185|NCT00714168|Experimental|2|Participants will take part in a stepped-care weight loss program.
89383965|NCT03239873|Experimental|VARIVAX® PE34 Process + Measles, Mumps, Rubella (M-M-R) II®|VARIVAX® Passage Extension (PE34) Process vaccine 0.5 mL administered in the left arm or thigh and M-M-R II® vaccine 0.5 mL administered in the right arm or thigh by subcutaneous injection on Day 1 and Day 91
89383966|NCT03239873|Active Comparator|VARIVAX® 2016 Commercial Process + M-M-R II®|VARIVAX® 2016 Commercial Process vaccine 0.5 mL administered in the left arm or thigh and M-M-R II® vaccine 0.5 mL administered in the right arm or thigh by subcutaneous injection on Day 1 and Day 91
89184186|NCT02574819|Experimental|Drug|Methylnaltrexone (MNTX) nearly 0.15mg/kg administered every other day for 2 weeks.
89383967|NCT05384210|Active Comparator|Milnacipran|Patients will receive Milnacipran as a mono-therapy will be administered in increment doses for 3 months
89383968|NCT05384210|Active Comparator|Gabapentin|patients will receive Gabapentin as a mono-therapy will be administered in increment doses for 3 months
89383969|NCT05384210|Active Comparator|Combined gabapentin/milnacipran|Patients will receive combined gabapentin and milnacipran as a combination therapy will be administered in increment doses for 3 months
89383970|NCT03613376|No Intervention|No Compression|Patients in this group will not receive any compression after treatment
89383971|NCT03613376|Active Comparator|Compression|Patients in this group will use class II compression stockings continuously until next evening and then next 4 days during daytime.
89535120|NCT04493723||All participants|All eligible, consented participants, will be asked to give blood, tissue, and other biospecimens for research purposes
89184187|NCT02574819|Placebo Comparator|Placebo|Placebo administered every other day for 2 weeks.
89184188|NCT02591316||Breast cancer survivor|Inclusion criteria: Female breast cancer survivors (30-70yrs of age) that have completed primary treatment (chemotherapy, radiation therapy or both) within past 60 months
89383972|NCT03614780|Experimental|30 additional minutes outdoors|Participants were asked to go about their normal activities during the first 2 baseline days of participation. Participants were asked to spend an additional 30 minutes outdoors per day for the next 5 days of participation.
89383973|NCT04804592|Experimental|Group A: SiHy CL|Silicone hydrogel (SiHy) CL wear at least 3 days per week and at least 8 hours per day;
89383974|NCT04804592|Experimental|Group B: RGP CL|Rigid gas permeable (RGP) CL wear at least 3 days per week and at least 8 hours per day;
89383975|NCT04804592|Experimental|Group C: no CL wear|No current CL wear for at least 3 months;
88857799|NCT03677778|Active Comparator|Treatment group|After surgery, in the post-operative recovery room, patients randomized to both the intervention and control groups will have 10cc 0.5% ropivacaine bolused via their nerve catheters. After 30 minutes, the following will be measured/assessed: spirometry data, pain scores (using the Numeric Rating Scale), and, if time is sufficient, bilateral diaphragmatic excursion via ultrasonography and brachial plexus motor and sensory exams. This group will then have 30ml of normal saline injected into their nerve catheter. Then, both the control and treatment groups will have the following measured/assessed after 5, 15 and 30 minutes: spirometry data, pain scores (using the Numeric Rating Scale), and, if time is sufficient, bilateral diaphragmatic excursion via ultrasonography and brachial plexus motor and sensory exams. Investigators will be blinded to whether the patient is in the intervention or treatment group.
88857800|NCT03810534|Experimental|Connect-Home|Connect-Home intervention at the skilled nursing facility and at the subject's home.
89383976|NCT03213509||Perinatal Death With Pause Point(s) Observed, Intervention Arm|"Any perinatal death where one or more pause points was observed by BetterBirth staff (FADA) at 2 months or 6 months post-intervention launch, in the intervention arm of the BetterBirth Trial.~The study involves administering verbal and social autopsies to the mother or family member of a baby who is in this cohort."
89383977|NCT03213509||Perinatal Death With Pause Point(s) Observed, Control Arm|"Any perinatal death where one or more pause points was observed by BetterBirth staff (FADA) at 2 months or 6 months post-intervention launch, in the control arm of the BetterBirth Trial.~The study involves administering verbal and social autopsies to the mother or family member of a baby who is in this cohort."
89184189|NCT02591316||Control|Females (30-70yrs of age) with no previous cancer diagnosis.
89383978|NCT04802798|Experimental|Placebo, Fibre 1, Fibre 2|All three interventions will be provided in a randomized double-blind order. The interventions will consist of 8 grams per day of three different types of powdered food supplement that will be mixed with water and consumed for a 7-day period. The powdered food supplement will be either placebo (glucose), fibre 1 (derived from a plant-based food) or fibre 2 (derived from a different plant-based food).
89383979|NCT04802798|Experimental|Placebo, Fibre 2, Fibre 1|All three interventions will be provided in a randomized double-blind order. The interventions will consist of 8 grams per day of three different types of powdered food supplement that will be mixed with water and consumed for a 7-day period. The powdered food supplement will be either placebo (glucose), fibre 1 (derived from a plant-based food) or fibre 2 (derived from a different plant-based food).
89383980|NCT02032394|Experimental|Chlorhexidine|Washing of perineal area and proximal first 5 centimeters of catheter from mea, done by 15 ml of Chlorhexidine 0.2%, 3 times a day for 10 days.
89184190|NCT00715065||2|Healthy control subjects (who do not faint at the sight of blood)
88857801|NCT03810534|No Intervention|Control|Standard discharge planning at the skilled nursing facility only.
88857802|NCT05347836||Children diagnosed to have T1DM with a minimum duration of five years|
88857803|NCT05347836||Healthy children|
88857804|NCT05347758|Experimental|Group A|Drug: HRS-7535
88857805|NCT05347758|Placebo Comparator|Group B|Drug: Placebo
89184191|NCT00715065||1|People who faint at sight of blood
89184192|NCT00713700|Experimental|Device|
89184193|NCT03949153|Experimental|Experimental arm|Single Nivolumab 240 mg infusion at D0, followed by cryotherapy using interventional radiology of metastatic lymphadenopathy at D1 and in situ injection with ipilimumab at D2.
89184194|NCT00715221||1|Normal Weight
89383981|NCT02032394|Experimental|Povidone-Iodine|Washing of perineal area and proximal first 5 centimeters of catheter from mea, done by 15 ml of Povidone-iodine 10%, 3 times a day for 10 days.
89383982|NCT02032394|Active Comparator|Normal saline|Washing of perineal area and proximal first 5 centimeters of catheter from mea, done by 15 ml of Normal saline 0.9%, 3 times a day for 10 days.
89383983|NCT03239483|Experimental|Dapivirine gel|Participants will receive a single dose of dapivirine gel rectally, followed by 7 daily doses of dapivirine gel to be administered under direct observation in the clinic.
89383984|NCT03239483|Placebo Comparator|Placebo gel|Participants will receive a single dose of placebo gel rectally, followed by 7 daily doses of placebo gel to be administered under direct observation in the clinic.
89535121|NCT03078465|Experimental|Ticagrelor|Administration of ticagrelor 180mg/day for 12 months.
89184195|NCT00715221||2|Obese without diabetes
89184196|NCT00715221||3|Obese with diabetes
89184197|NCT00709917||A|
89184198|NCT02574741|Active Comparator|Aripiprazole|Aripiprazole oral solution (1mg/mL) for 12 weeks. dosages range from 2-10mg per day.
89184199|NCT02574741|Active Comparator|Placebo|50% will be randomized to placebo.
89184200|NCT02574741|Active Comparator|Behavioral Intervention|All subjects will receive behavioral therapy, in addition to either active study drug (aripiprazole) or placebo.
89383985|NCT02868554|No Intervention|Standard Invisalign Therapy|Patients receiving standard Invisalign therapy will be instructed to wear each aligner 24 hours day. Patients will be permitted to progress to the subsequent aligner after 14 days of compliant aligner wear.
88857806|NCT05347680|Active Comparator|intubating laryngeal Tube Suction|Fiberoptic Intubation through intubating laryngeal Tube Suction
89383986|NCT02868554|Experimental|Accelerated Invisalign|Patients receiving accelerated Invisalign therapy will be instructed to wear each aligner 24 hours day. Patients will be permitted to progress to the subsequent aligner after 4 days of compliant aligner wear.
89383987|NCT02868554|Experimental|Accelerated Invisalign and Vibration|In addition to the accelerated Invisalign protocol described in Arm #2, patients will undergo intraoral vibration therapy using an AcceleDent Aura device for a duration of 20 minutes per day.
88857807|NCT05347680|Active Comparator|Ambu AuraGain Laryngeal Mask|Fiberoptic Intubation through Ambu AuraGain Laryngeal Mask
89383988|NCT01068912|Experimental|1: Experimental|Low-dose favipiravir regimen: 1000 mg favipiravir twice a day (BID) x 1 day, and 400 mg favipiravir BID x 4 days
88857808|NCT03580434|Experimental|V-STRUT|V-STRUT implantation
89383989|NCT01068912|Experimental|2: Experimental|High-dose favipiravir regimen: 1200 mg favipiravir BID x 1 day, and 800 mg favipiravir BID x 4 days
89383990|NCT01068912|Placebo Comparator|Placebo|Placebo
89383991|NCT03614624|Experimental|Comparison of two devices|Patients receive clinical examination, electrocardiogramm and echocardiography.
89383992|NCT03614546|Other|A（surgery） group|Hepatectomy
88857813|NCT06125938|Experimental|tent pole technique|The screw tent-pole method is an effective technique to achieve initial reconstruction of alveolar bone deficiencies
88857814|NCT06125938|Active Comparator|autogenous bone block technique|Bone block graft has been the gold standard for restoring deficient regions.
88857815|NCT06125899|Experimental|Age emhGAP-IG|"Adapted emhGAP-IG;~Adapted Problem-Solving Therapy (PST-PC)~Support/supervision of lay providers~Links to social support resources."
88857816|NCT06125899|Active Comparator|Generic emhGAP-IG|Psychoeducation and stress reduction
88857817|NCT06125886|Experimental|high risk population|The enrolled patients underwent simultaneous transvaginal ultrasound examination and microscale endometrial sampling biopsy.
88857818|NCT06125873|Active Comparator|Metformin|Metformin 500mg taken orally twice daily
88857819|NCT06125873|Experimental|"Moringa+Metformin"|Metformin 500mg taken orally twice daily with Moringa Oliefera (MO) capsule 1g once daily before breakfast
88857820|NCT06125860|No Intervention|Arm 1 (control arm)|In Arm 1 (control arm), participants will receive the standard of antenatal care including iron and folic acid supplementation.
88857821|NCT06125860|Experimental|Arm 2 (Targeted BEP based on baseline nutritional status)|
88857822|NCT06125860|Experimental|Arm 3 (Targeted BEP by baseline nutritional status and monthly gestational weight gain monitoring)|
88857823|NCT06125860|Experimental|Arm 4 (universal BEP)|
88857824|NCT06125847|Experimental|NGGT006|3 doses of NGGT006 will be administered according to the principle of dose escalation
89383993|NCT03614546|Experimental|B1（SBRT） group|Stereotactic Body Radiation Therapy(SBRT), 40-55Gy/5-6F
89383994|NCT03614546|Experimental|B2a（TACE+ IMRT ） group|First，treat with intensity modulated radiation therapy (IMRT),50Gy/25F/5W, 4 weeks after IMRT，treat with transcatheter arterial chemoembolization（TACE） 2-4 times
89383995|NCT03614546|Experimental|B2b（TACE+ IMRT ） group|First，treat with transcatheter arterial chemoembolization（TACE） 2-4 times，4 weeks after TACE，treat with intensity modulated radiation therapy (IMRT),50Gy/25F/5W
89383996|NCT03614546|Experimental|C1（SBRT） group|Stereotactic Body Radiation Therapy, 40-55Gy/5-6F
89383997|NCT03614546|Experimental|C2a（TACE+ IMRT ） group|First，treat with intensity modulated radiation therapy (IMRT),50Gy/25F/5W, 4 weeks after IMRT，treat with transcatheter arterial chemoembolization（TACE） 2-4 times
89383998|NCT03614546|Experimental|C2b（TACE+ IMRT ） group|First，treat with transcatheter arterial chemoembolization（TACE） 2-4 times，4 weeks after TACE，treat with intensity modulated radiation therapy (IMRT),50Gy/25F/5W
89383999|NCT03229109|Experimental|Group 1|Age 18-25, males and females, Spectrophon dehydration body monitor was attached to subject's wrist
89384000|NCT03229109|Experimental|Group 2|Age 26-35, males and females, Spectrophon dehydration body monitor was attached to subject's wrist
89384001|NCT03229109|Experimental|Group 3|Age 36-45, males and females, Spectrophon dehydration body monitor was attached to subject's wrist
89384002|NCT03229109|Experimental|Group 4|Age 46-50, males and females, Spectrophon dehydration body monitor was attached to subject's wrist
89384003|NCT03614468|Experimental|Formula A|An experimental Infant Formula, Milk-Based Powder with Iron, for healthy term infants 0 to 12 months of age.
89384004|NCT03614468|Active Comparator|Formula B|A Commercially available Infant Formula, for healthy term infants 0 to 12 months of age (Enfamil TM, Milk-Based Powder with Iron)
89384005|NCT01314131|Experimental|Intervention group|
88857825|NCT06125834|Experimental|T-DM1 treatment group|Trastuzumab Emtansine (T-DM1), 3.6mg/kg, d1/21, IVD, until progressive diseases or intolerable adverse effects occurs
89535122|NCT03078465|Active Comparator|Clopidogrel|Administration of clopidogrel 150 mg/day for 12 months
89384006|NCT03614390|Other|MBCT group|"There is only 1 arm in the study.~The MBCT will be conducted according to the treatment manual. The program consists of eight weekly sessions. In between sessions, participants are advised to practice mindfulness meditations for 40-50 minutes every day.~The teachers of the program will teach on voluntary basis. The teachers must have attended the 1-year foundation course to teach mindfulness (available in the United Kingdom and Hong Kong), regular mindfulness practice and must have at least yearly mindfulness retreat. This is in accordance to the good practice guidelines developed in the UK for mindfulness teachers"
89384007|NCT04056234||Rheumatoid arthritis group|Patients with rheumatoid arthritis
89384008|NCT04056234||Control group|Patients with osteoarthritis / joint effusion.
89384009|NCT05181215|Experimental|Bafiertam|190 mg (2 x 95 mg) delayed-release capsules
89384010|NCT05181215|Active Comparator|Vumerity|462 mg (2 x 231 mg) delayed-release capsules
88857826|NCT06125821||questionnaire|Arabic Version Of Henry Ford Hospital Headache Disability Inventory Questionnaire : Cross Cultural Adaptation, Validity, And Reliabilit
89384011|NCT02032316|Experimental|Interventional|Placement of ureteral stent following post-ureteroscopy
89384012|NCT03613298|Experimental|HIFU (Focal One®) Treatment|"Subjects harboring an isolated recto-sigmoid deep invasive endometriosis (DIE) lesion with a persistence of symptoms despite hormonal treatment will be installed on the Focal One® device to:~Evaluate its ability to locate and assess the volume of the endometriosic lesion~Treat the targeted lesion by HIFU energy application. Real-time guided ultrasonography will be used to determine the location of the endometriosic nodule.~Patients will fill-out questionnaires on gynecological and intestinal symptoms and on quality of life before treatment and 1 and 6 months after HIFU. Imaging follow-up scans will be organized at 1 and 6 months and by a pelvic MRI scan at 3/6 months."
89002974|NCT05931497|Experimental|verum whole body hyperthermia|WBH will be completed with a Clearlight Sauna Dome and ancillary equipment to monitor core body temperature. For the verum WBH, participants will be brought to a core body temperature of 101.3°F.
89002975|NCT05931497|Sham Comparator|sham whole body hyperthermia|The sham condition will be identical to the active WBH condition. Time and other procedures will be consistent. Mild heat will be used to mimic an active WBH session.
89002976|NCT05930197|Experimental|Interventional|The oral suspension formulation of BSS will be used in this study. It is self administered at 1050mg 4 times per day (1 to 6 hours apart) for 2 days.
88857830|NCT06125782|Active Comparator|Omega-3 fatty acid|One Omega-3 fatty acid softgel capsule 1 gm for children at or below 25 kg and two Omega-3 fatty acid softgel capsule above 25 kg. In this intervention arm having 32 participants, half will have plasma Omega 3 fatty acid level within reference value and rest half below reference value.
88857831|NCT06125782|Placebo Comparator|Placebo|Placebo softgels having almost same color and shape, one softgel for children at or above 25 kg and two softgels for children above 25 kg. In this placebo arm having 32 participants, half will have plasma Omega 3 fatty acid fatty acid level within reference value and rest half below reference value.
89384013|NCT03212261|Experimental|3RP-Lymphoma|-An adapted version of the 3RP (3RP-Lymphoma) for lymphoma survivors recently completing cancer treatment. The adapted program incorporates the three prongs of the 3RP: RR elicitation, stress awareness, and adaptive strategies. It will be delivered in weekly sessions over the course of approximately 8 weeks.
89384014|NCT04056702||Prescribed triple combination|A group of 60 people with CF who are clinically prescribed elexacaftor-tezacaftor-ivacaftor and have chronic sinusitis
89384015|NCT04056702||Not eligible for modulators|A group of 10 patients with two class I/II mutations who are ineligible for elexacaftor-tezacaftor-ivacaftor based on their genotype and have chronic sinusitis.
89384016|NCT03613142|Experimental|Double tract anatomosis|After the proximal gastrectomy, the purse-string suture is tied at the esophagus stump, and the anvil head is inserted into the esophagus stump using an anvil clamp. A Roux-en-Y esophagojejunostomy (E-stomy) is performed by intracorporeal anastomosis with a circular stapler, and the jejunal stump is closed with a linear stapler. Next, side-to-side gastrojejunostomy (G-stomy), 15 cm below the E-stomy, is performed using 2 linear staplers. Finally, end-to-side jejunojejunostomy (J-stomy), 20 cm below the G-stomy, is performed by 2 linear staplers.
88857832|NCT06125756|Experimental|KL001 injection solution|Subjects will be dosed with three different dose of KL001 injection solution at 2.5x10^12 vg/kg to 1.0x10^13 vg/kg.
88857833|NCT06125717|Active Comparator|15 μg of the H1 influenza antigen|
88857834|NCT06125717|Active Comparator|7.5 μg of the H1 influenza antigen|
88857835|NCT06125717|Placebo Comparator|Placebo (no antigen)|
88857836|NCT06125652|Experimental|anti Tim-3/CD123 CAR-T cell therapy|Enrolled patients will receive prespecified dose of autologous CAR-T cells.
88857837|NCT06125639|Experimental|Sauna Group|
88857838|NCT06125639|No Intervention|Control Group|
88857839|NCT06125587|Experimental|Chiglitazar group|Chiglitazar, tablet, 32mg, taken orally once daily for 3 months
88857840|NCT06125587|Active Comparator|Metformin group|Metformin, tablet, 0.5g, taken orally twice daily for 3 months
88857841|NCT06125561||Diabetic|Diabetic patients with age ranges 18-60 years. Clinical Examination will be performed by CPTIN probe and questionnaire will be filled by participant's.
88857842|NCT06125561||Non diabetic|Non Diabetic patients with age ranges 18-60 years. Clinical Examination will be performed by CPTIN probe and questionnaire will be filled by participant's.
88857843|NCT06125496||Female|Forty one females with CLBP between the ages of 20-60 participated in the study. Pain management strategies were determined by Pain Coping Questionnaire (PCQ). Tampa Scale for Kinesiophobia for perception of kinesiophobia, Oswestry Disability Index for disability due to pain and International Physical Activity Questionnaire-Short Form (IPAQ-SF) for the physical activity level were used.
89384017|NCT03613142|Active Comparator|Esophagogastrostomy|After the proximal gastrectomy, the purse-string suture is tied at the esophagus stump, and the anvil head is inserted into the esophagus stump using an anvil clamp. Next, end-to-end or side to end esophagogastrostomy is performed with a circular stapler.
88857844|NCT06125496||Male|Forty one males with CLBP between the ages of 20-60 participated in the study. Pain management strategies were determined by Pain Coping Questionnaire (PCQ). Tampa Scale for Kinesiophobia for perception of kinesiophobia, Oswestry Disability Index for disability due to pain and International Physical Activity Questionnaire-Short Form (IPAQ-SF) for the physical activity level were used.
89384018|NCT03662802||ECG Data|Coded data including; wavelengths, amplitude, intervals, timing, frequence
89384019|NCT05384054||Low Erythroferron group|The lower concentration group will be Group1.
89384020|NCT05384054||High Erythroferron group|The higher concentration group will be Group2.
89384021|NCT03613064|Experimental|Congestive Heart Failure (CHF)|The CHF arm will include adults hospitalized with CHF who have been identified as being at high risk for readmission (in the top quintile of risk) by our readmission risk prediction algorithms, and who also have social vulnerabilities present. All subjects in the CHF arm will receive the Socially Enhanced Transitional Care Intervention.
89384022|NCT03613064|Experimental|Ischemic Heart Disease (IHD)|The IHD arm will include adults hospitalized with IHD who have been identified as being at high risk for readmission (in the top quintile of risk) by our readmission risk prediction algorithms, and who also have social vulnerabilities present. All subjects in the IHD arm will receive the Socially Enhanced Transitional Care Intervention.
89384023|NCT03612986|Active Comparator|A: Active comparator SYALOX® 300 Plus|"Active Nutraceutical containing HA and AKBA (SYALOX® 300 Plus)~1 tablet/day, oral administration"
89384024|NCT03612986|Placebo Comparator|B: Placebo|"Placebo~1 tablet/day, oral administration"
89384025|NCT03612440|Experimental|Group D|40 patients receive a loading infusion of dexmedetomidine (1ug/kg)for 20min follow by a maintenance infusion (0.4ug/kg/h) continued until the end of the surgery
89384026|NCT03612440|Placebo Comparator|Group C|40 patients receive matching placebo (normal saline)
89384027|NCT03662568|Experimental|Part A:Group A|Subjects will receive GLS4+RTV on Day 1,followed by ETV on Day11-21 and co-administration with GLS4+RTV on Day 21.
89384028|NCT03662568|Experimental|Part A:Group B|Subjects will receive ETV on Day 1,followed by GLS4+RTV on Day11-21 and co-administration with ETV on Day 21.
88857845|NCT06125470|Experimental|Intervention areas|Health facilities and other service delivery points including outreach health workers receiving FP supplies, trainings and renovations to create enabling environment at health and Family planning facilities Community engagement and creating creating adolescents friendly spaces roll out of Gender responsive strategies
89384029|NCT03662568|Experimental|Part B:Group C|Subjects will receive GLS4+RTV on Day 1,followed by TDF on Day11-21 and co-administration with GLS4+RTV on Day 21.
89384030|NCT03662568|Experimental|Part B:Group D|Subjects will receive TDF on Day 1,followed by GLS4+RTV on Day11-21 and co-administration with TDF on Day 21.
89384031|NCT03612362|Experimental|"Improved Injera Baking Biomass Stove"|"2750 eligible households with in 50 randomly selected clusters/Gotes are allocated into the improved Injera backing stove intervention arm."
89384032|NCT03612362|No Intervention|Control arm|"Similarly 2750 eligible households with in 50 randomly selected clusters/Gotes will continue to use the traditional Injera baking biomass stove and will be used as control arm."
89384033|NCT03661554|Experimental|single arm|"This clinical study, BCMA nano-antibody CAR-T cells in the treatment of refractory recurrent multiple myeloma clinical research, is a single center, single arm, open design. The aim is to study the safety and efficacy of BCMA nano antibody CAR-T in the treatment of MM. In this study, a 3 + 3 dose gradient climbing design was used. Three dosage groups, 5x106 / kg, 1x107 / kg and 1.5x107 / kg, were divided into three groups."
89384034|NCT02993250|Experimental|Cohort 1 (Chronic Hepatitis C Without Cirrhosis)|Participants will receive 800 milligram (mg) AL-335 +odalasvir (ODV) 25 mg+simeprevir (SMV) 75 mg once daily for 8 weeks in Cohort 1.
89384035|NCT02993250|Experimental|Cohort 2 (Chronic Hepatitis C With Compensated Cirrhosis)|Participants will receive AL-335 800 milligram (mg)+ODV 25 mg+SMV 75 mg once daily for 12 weeks in Cohort 2. Dosing in cohort 2 will be started according to decision of Data Review Committee (DRC).
88857846|NCT06125418|Experimental|Customized group|patients who received customized healing abutments following implant placement. customized healing abutments will be fabricated with different macrogeometry and different emergence angle
88857847|NCT06125418|Experimental|Standard group|patients who received standard titanium healing abutments following implant placement
88857848|NCT06125405|Experimental|Telitacicept group|Weekly administration (administration time can be within 1 week + 3 days). Body weight and dosage: for subjects with body weight greater than 10kg and less than or equal to 20kg, the dose of Telitacicept is 40mg; for subjects with body weight greater than 20kg and less than or equal to 40kg, the dose of Telitacicept is 80mg; for subjects with body weight greater than 40kg and less than or equal to 60kg, the dose of Telitacicept is 120mg; for subjects with body weight greater than or equal to 60kg, the dose of Telitacicept is 160mg. Treatment duration: 52 weeks.
89384036|NCT03612284|Experimental|Device Feasibility|"Scleral lens insertion solution study. This is not an interventional study, but a study to test a new contact lens solution. Primary FDA Classification: 21 CFR 886.5928 Soft (Hydrophilic) Contact Lens Care Products Product Code: LPN~Secondary FDA Classification: 21 CFR 886.5918 - Rigid gas permeable contact lens care products Product Code: MRC~The FDA has previously made risk determinations (class II, non-significant risk) for devices classified under 21 CFR 886.5928 and 21 CFR 886.5918. As a non-significant risk device, the GatorFil Contact Lens Saline Solution is exempt from the IDE regulation (21 CFR 812)."
89384037|NCT03612908||Normothyroid pregnant women|Healthy pregnant women with the TSH serum values within the recommended ranged per trimester of pregnancy.
89384038|NCT03612908||Patients with a thyroid disease|Patients with a thyroid disease named hypothyroidism or hyperthyroidism.
89384039|NCT03661476|Experimental|Oculo-Motor Exercises (OME)|10 repetitive four different oculomotor exercise protocols with eye stabilization were organized as home programs for 6 weeks, twice a day in the morning and evening each day of the week.
89384040|NCT03612830|Experimental|LECS|Laparoscopic and Endoscopic cooperative surgery,LECS resects the tumor completely by laparoscopy with the help of the precise positioning and guidance of endoscopy .
89384041|NCT03612830|Experimental|RECS|Robotic and Endoscopic cooperative surgery,RECS resects the tumor completely by Dan Vinchi robot with the help of the precise positioning and guidance of endoscopy .
88857849|NCT06125392||Invasive assessment of coronary masovomotor function|All lesions undergoing assessment of coronary microvascular dysfunction and coronary spasm using coronary pressure wires.
89384042|NCT03661788|Experimental|First placebo, than atomoxetin|Patients receive a placebo in the first of the two 14-day treatment intervals and atomoxetin in the second 14-day treatment intervals. Between the treatment intervals there is a wash-out phase of two weeks. The order of treatment is randomized.
88857850|NCT06125366|Experimental|Dose escalation of BAY1747846|
88857851|NCT06125366|Placebo Comparator|Matching Placebo|
88857852|NCT06125353|Active Comparator|intervention group|Participants in the Intervention group consumed one melatonin tablet per day, containing 1mg of melatonin, for a total of three months.
88857853|NCT06125353|No Intervention|placebo group|Participants in this group were instructed to consume one placebo tablet (with water) every day for a total of three months. Melatonin and placebo tablets were of similar physical and sensory properties.
88857854|NCT06125327|Placebo Comparator|Placebo Comparator|Idiopathic pulmonary fibrosis (IPF) patients were administered placebo matching SC1011 taken orally as tablets (matching the respective SC1011 tablets) twice daily, in the morning and in the evening for 52 weeks.
88857855|NCT06125327|Experimental|SC1011 200mg|Idiopathic pulmonary fibrosis (IPF) patients were administered SC1011 taken orally as tablets twice daily(200mg daily), in the morning and in the evening for 52 weeks.
88857856|NCT06125301|Experimental|Intervention group|Care as usual + weekly self-monitoring during one year follow-up and discussing app results with caregivers.
88857857|NCT06125301|No Intervention|Control group|Care as usual.
88857858|NCT06125249||Patients with AKI after heart transplantation|AKI occurs in patients after heart transplantation
88857859|NCT06125249||Patients did not develop AKI after heart transplantation|Patients who do not develop AKI after heart transplantation
88857860|NCT06125184|Placebo Comparator|Placebo group|Mean arterial pressure (MAP) will be increased from 65 mmHg to 85 mmHg with a blind drug (Placebo). If MAP does not increase norepinephrine will be titrated to reach the MAP target (85 mmHg).
88857861|NCT06125184|Active Comparator|Vasopressin group|Mean arterial pressure (MAP) will be increased from 65 mmHg to 85 mmHg with a blind drug (Vasopressin at 0.03 IU/min). If MAP does not increase norepinephrine will be titrated to reach the MAP target (85 mmHg).
88857862|NCT06125171|Experimental|Tucidinostat+Apatinib|
88857863|NCT06125158|Active Comparator|Control group|Participants in this group will receive conventional ankle interventions including ankle strength training and balance training. All treatments target the affected lower extremity for 40 minutes per session, once per day, 3 days per week for 6 weeks.
88857864|NCT06125158|Experimental|Experimental Group A|Participants in this group will be asked to perform conventional ankle training and hip strength training. The conventional ankle training routine for this group will have the same movements as the control group, but the volume of training will be half that of the control group, and the duration of training will be 20 min/session. Hip strength training will consist of elastic band resistance exercises, forward step-up and lateral step-up for 20 min/session. All treatments target the affected lower extremity for 40 minutes per session, once per day, 3 days per week for 6 weeks.
88857865|NCT06125158|Experimental|Experimental Group B|"Participants in this group will be asked to perform conventional ankle training and neuromuscular electrical stimulation. The conventional ankle training routine for this group will have the same movements as the control group, but the volume of training will be half that of the control group, and the duration of training will be 20 min/session. Neuromuscular electrical stimulation aims to stimulate the gluteus maximus and gluteus mediums muscles of the affected lower limb. The researcher chose the Neuromuscular Electrical Stimulation 1 mode for the treatment prescription (this prescription can output a variety of waveforms with frequencies varying continuously from 1 to 100 Hz to stimulate the target muscles alternately, effectively preventing muscle fatigue caused by a single stimulation) and set the stimulation time to 20 min per session. All treatments target the affected lower extremity for 40 minutes per session, once per day, 3 days per week for 6 weeks."
88857866|NCT06125106|Experimental|Blinatumomab Group|Haploidentical hematopoietic stem cell transplantation was performed using a Conditioning regimen containing Blinatumomab. 28ug of Blinatumomab was administered intravenously once a day for a total of 7 days, followed by a routine conditioning regimen and haploid hematopoietic stem cell transplantation.
88857867|NCT06125093|Experimental|Intervention group|"Those in the intervention group will participate in a weekly group-based online intervention for approximately 6 months (Incredible Years-Autism Spectrum and Language Delays Parent Program, IY-ASLD®).~Families allocated to the intervention group will also receive treatment as usual (TAU)."
88857868|NCT06125093|No Intervention|Treatment as usual (TAU) group|"The TAU condition involves outpatient appointments with different paediatric specialists in the hospitals of the 3 sites of the study.~Depending on the patients' needs, some cases will be assisted in early years centers or child mental health centers based in the community."
88857869|NCT06125080|Experimental|Utidelone+Tirelizumab+Bevacizumab|
88875398|NCT03945162|Experimental|0.7 mg/cm^2 Ruvidar® (TLD-1433) Bladder infusion and Photodynamic Therapy|A single instillation of Ruvidar® (TLD-1433) (at the therapeutic dose of 0.7 mg/cm^2) will be infused intravesically into the bladder for approximately 60 minutes. PDT treatment is performed after Ruvidar® (TLD-1433) has been rinsed from the bladder. Two Study Treatments will be performed, a primary Study Treatment at Day 0 and a maintenance Study Treatment at Day 180.
88875399|NCT03917316||ADHD|
88875400|NCT03917316||Control|
88875401|NCT03766386||Danon Disease Patients|Patients with a confirmed diagnosis of Danon disease who are currently alive (including patients who may or may not have undergone heart transplantation).
89384043|NCT03661788|Experimental|First atomoxetin, than placebo|Patients receive atomoxetin in the first of the two 14-day treatment intervals and a placebo in the second 14-day treatment interval. Between the treatment intervals there is a wash-out phase of two weeks. The order of treatment is randomized.
89384044|NCT03661398|Experimental|Transcatheter Mitral Valve Replacement|Patients with symptomatic mitral regurgitation (garde 3 or 4), determined to be a high risk for cardiovascular surgery, will be treated with the Caisson Transcatheter Mitral Valve Replacement (TMVR) System
89384045|NCT03612128|Other|control group|Children continued their traditional physiotherapy
89384046|NCT03612128|Active Comparator|intervention group|We applied mirror therapy in addition to traditional physiotherapy
89384047|NCT03612752|Experimental|Active arm|CMI-168
89384048|NCT03612752|Placebo Comparator|Placebo arm|Placebo
89384049|NCT03611660|Active Comparator|Traditional Lifestyle Program ONLY|Participants will receive an evidence-based 12-week family-based pediatric obesity program.
89384050|NCT03611660|Experimental|Traditional Lifestyle Program PLUS Mindfulness|Participants will receive an evidence-based 12-week family-based pediatric obesity program plus 6 sessions of mindfulness meditation instruction.
89384051|NCT03612674|Active Comparator|Standard colonoscopy (S)|A standard colonoscopy will be performed.
89384052|NCT03612674|Experimental|AEV assisted colonoscopy (E)|Colonoscopy with ARC Endocuff Vision attached to the top of the scope will be performed.
89384053|NCT02989194|Experimental|VIS410 low dose|Single intravenous fixed low dose of VIS410
89384054|NCT02989194|Experimental|VIS410 high dose|Single intravenous fixed high dose of VIS410
88857870|NCT06125041|Experimental|treatment group|"Administration regimen: adebelizumab 1200mg, IV, Q3W+ carboplatin AUC 5 d1+ etoposide 100mg/m2 D1, 2, 3; 21 days is a treatment cycle. After 4-6 cycles, patients with imaging evaluation CR/PR/SD (according to tumor RECIST1.1 standard) receive adebelizumab maintenance therapy and radiotherapy at the same time. Patients with imaging evaluation PD (according to tumor RECIST1.1 standard) can receive adebelizumab maintenance therapy combined with radiotherapy according to the clinical practice, or they can change other treatment schemes and continue to follow up.~After the induction treatment, the participants will continue to receive adebelizumab (20mg/kg, IV, Q3W) combined with concurrent radiotherapy (conventional radiotherapy SBRT chest lesions (2Gy*25f), brain (3Gy*10f)/ bone (3Gy*10f)/ suprarenal gland (3Gy*10-15f)/ liver (3YX)."
89384055|NCT02989194|Placebo Comparator|Placebo|Single intravenous placebo infusion
89384056|NCT03612518|Experimental|Text and Voice Messages|Participants will receive text messages and voice messages
89384057|NCT03612518|Experimental|Interactive Phone Call|Participants will receive interactive phone calls
89384058|NCT03612518|No Intervention|Control|Participants in this arm will not be exposed to any intervention.
89384059|NCT03661242|No Intervention|Standard of care|No intervention
88857871|NCT06125028|Experimental|[68Ga]Ga-PTF PET/CT|150 (+/-50) MBq [68Ga]Ga-PTF will be administered intravenously and PET/CT will be performed
88857872|NCT06125028|Active Comparator|[18F]FDG PET/CT|[18F]FDG will be administered once intravenously according to the SMPC and PET/CT will be performed
88857873|NCT06125002|Experimental|Intervention (placebo, corn starch tablets)|Treatment will occur by oral route, and everyone will ingest identical opaque capsules (750 mg). The treatment protocol will be applied before the start (pre-treatment) of the intense dynamic exercise sessions, once a day, during the two days before, and on the day (immediately before) the execution of the exercise protocol.
89384060|NCT03661242|Active Comparator|Shared care|Clinic visit with Clincal Exercise Physiologist or physical therapist who does assessment and prescripes individulized physical activity plan
89384061|NCT05383820|Placebo Comparator|Placebo|Placebo (calcined magnesia) in capsules, one capsule every 8 hours for 5 days.
89384062|NCT05383820|Experimental|Ketorolac|Ketorolac 10 mg capsules, one capsule every 8 hours (30 mg daily) for 5 days.
89384063|NCT05383820|Active Comparator|Paracetamol|Paracetamol capsules of 500 mg, one capsule every 8 hours (1.5 g per day) for 5 days.
89384064|NCT04055766||Meningitis/Encephalitis|Patients with clinical signs and symptoms suspected of meningitis/encephalitis
89384065|NCT04055766||Stroke|Patients with clinical signs and symptoms suspected of stroke
89384066|NCT04055766||Headache|Patients with clinical signs and symptoms suspected of headache
89384067|NCT04055766||Vertigo|Patients with clinical signs and symptoms suspected of vertigo
89384068|NCT03612050|Placebo Comparator|Enhanced Usual Care|facilitate any clinical interventions
89384069|NCT03612050|Experimental|Meaning Centered Psychotherapy|raise patients' sense of meaning/purpose
89384070|NCT03660774||Patients with hemophilia|Children and young adults with hemophilia A or B, all severities, treated in the hemophilia treatment center (comprehensive care) setting, including participation of caregivers/parents completing questionnaires designed to evaluate neurologic, neurocognitive and neurobehavioral function and development.
89384071|NCT03611894||hemorrhagic ischemia|comparison between clinical characteristics and the confirmed diagnosis by RMI (magnetic resonance Imaging)
89384072|NCT03611894||nonhemorrhagic ischemia|comparison between clinical characteristics and the confirmed diagnosis by RMI (magnetic resonance Imaging)
89384073|NCT03611894||intracerebral hematoma|comparison between clinical characteristics and the confirmed diagnosis by RMI (magnetic resonance Imaging)
89384074|NCT03622554|No Intervention|Control arm|Curist taking a spa treatment of 3 weeks in the usual conditions for each Center
89384075|NCT03622554|Experimental|Intervention|"Addition to the usual cure: -12 adapted physical activity (APA) sessions of 60 minutes to improve the balance , muscular strength, endurance and suppleness without creating additional fatigue for the curists~- personalized therapeutic patient education (ETP) with an individual assessment at the beginning of the treatment (1h), 3 group sessions (1h30) and an end-of-cure interview (1h) and an educational follow-up by phone at 3, 6 and 12 months"
89384076|NCT02032472|No Intervention|Health Center (usual practice)|Controlling arterial pressure in the health center (a common practice is carried out)
89384077|NCT02032472|Experimental|Collaboration of pharmacies|Pharmacies cooperate in Measurement of Arterial Pressure of patients
89384078|NCT03611504||Hemospray® group|Patients with gastrointestinal bleeding treated with Hemospray®.
88857874|NCT06125002|Experimental|Intervention (diosmin)|Treatment will occur by oral route, and everyone will ingest identical opaque capsules (750 mg). The treatment protocol will be applied before the start (pre-treatment) of the intense dynamic exercise sessions, once a day, during the two days before, and on the day (immediately before) the execution of the exercise protocol.
88857875|NCT06124976|Experimental|ST-02|ST-02 is a new gemcitabine formulation for instillation into the upper urinary tract. Eligible participants will be enrolled and receive ST-02 once weekly for six weeks in a retrograde or antegrade fashion at the discretion of the treating urologist.
88857876|NCT06124963|Experimental|WX390 + Toripalimab|Participants will receive WX390 continuous oral dosing (0.9 mg once a day) and Toripalimab fixed dose (240 mg, intravenous, Day 1, every 3 weeks).
88857877|NCT06124911|Experimental|Maximal-intent Resistance Training - 3x5 (MI3x5)|The max-intent group were instructed and encouraged to deliberately commit to exerting maximal effort and force during the concentric phase of the leg press with the intention of achieving the greatest velocity possible. This group completed 3 sets of 5 repetitions at 60% one-repetition maximum.
89384079|NCT03622710|Experimental|Different surfaces|Subjects are trained to walk over a walking track with different surfaces (WTDS) for 5 days over 4 weeks.
88857878|NCT06124911|Experimental|Maximal-intent Resistance Training - 5x5 (MI5x5)|The max-intent group were instructed and encouraged to deliberately commit to exerting maximal effort and force during the concentric phase of the leg press with the intention of achieving the greatest velocity possible. This group completed 5 sets of 5 repetitions at 60% one-repetition maximum.
88857879|NCT06124911|Experimental|Controlled-tempo Resistance Training - 3x5 (CT3x5)|The controlled-tempo group followed a metronome for both eccentric and concentric phases of the leg press with the intention of maintaining a steady three-second concentric and three-second eccentric. This group completed 3 sets of 5 repetitions at 60% one-repetition maximum.
88857880|NCT06124911|Experimental|Controlled-tempo Resistance Training - 5x5 (CT5x5)|The controlled-tempo group followed a metronome for both eccentric and concentric phases of the leg press with the intention of maintaining a steady three-second concentric and three-second eccentric. This group completed 5 sets of 5 repetitions at 60% one-repetition maximum.
88857881|NCT06124885|Experimental|AKI risk screening using RenaFAST POCT test kits|All consenting patients will have a real-time biomarker analysis done at 5 time-points during their course of drug therapy using the renaFAST kits.
89384080|NCT03622710|Active Comparator|overground|Subjects are trained to walk overground for 5 days over 4 weeks.
89384081|NCT02954510|Experimental|Intervention|Single arm utilizing ferumoxytol
89384082|NCT03060330|Experimental|LVMR|Modified Laparoscopic Ventral Mesh Rectopexy
89384083|NCT03060330|Experimental|LVMR with STARR|Modified Laparoscopic Ventral Mesh Rectopexy Combined with Stapled Trans-anal Rectal Resection
89384084|NCT02032784|Experimental|Octreotide|Octreotide 100mcg subcutaneous every 8 hours for 5 days
89384085|NCT02032784|Other|no octreotide|No Octreotide
88857882|NCT06124872||Community survey 1 (planned demographic/health survey)|"Households included in a planned demographic and health survey (DSS).~All participants included in this survey will be invited to respond to snakebite questions."
88857883|NCT06124872||Community survey 2 (Stand alone survey)|"25 households randomly selected for inclusion within each survey cluster.~Survey clusters will be randomly selected enumeration units within study Counties."
88857884|NCT06124872||Community survey 3 (Stand alone survey)|"25 households randomly selected for inclusion within each survey cluster.~Survey clusters will be randomly selected enumeration units within study Counties."
88857885|NCT06124872||Key informant interviews|Stakeholders in the process of healthcare decision making and research relevant to snakebite and snakebite envenoming
88857886|NCT06124859|Experimental|Patients with a diagnosis of COPD (GOLD II- V) or pulmonary fibrosis (>6 months).|
89384086|NCT03611426|Experimental|rhThrombin ( Topical )|Cohort 1:rhThrombin ( Topical ) 500IU /ml、1000IU/m and 2000IU/ml During segmental hepatectomy; Cohort 2:rhThrombin ( Topical ) 1000IU/m and 2000IU/ml with absorbable collagen sponge During segmental hepatectomy; Cohort 3:rhThrombin ( Topical ) 1000IU/m and 2000IU/ml used directly sprayed on hemorrhagic point During segmental hepatectomy;
89002977|NCT05926960|Experimental|Triplet|encorafenib and binimetinib in combination with pembrolizumab
89384087|NCT03611426|Placebo Comparator|placebo|Cohort 1: the same volume of saline during segmental hepatectomy; Cohort 2:the same volume of saline used withabsorbable collagen sponge during segmental hepatectomy; Cohort 3:the same volume of saline during segmental hepatectomy;
89384088|NCT03658824|Other|3 week wait|Participant waits for 3 weeks after their baseline assessment before commencing therapy.
89384089|NCT03658824|Other|4 week wait|Participant waits for 4 weeks after their baseline assessment before commencing therapy.
89384090|NCT03658824|Other|5 week wait|Participant waits for 5 weeks after their baseline assessment before commencing therapy.
89384091|NCT03658824|Other|6 week wait|Participant waits for 6 weeks after their baseline assessment before commencing therapy.
89384092|NCT03658824|Other|7 week wait|Participant waits for 7 weeks after their baseline assessment before commencing therapy.
89384093|NCT03658824|Other|8 week wait|Participant waits for 8 weeks after their baseline assessment before commencing therapy.
89184201|NCT00468169|Experimental|A: Cetuximab+FHX|Cetuximab [250mg/m2 (day 1, weekly x10)] + FHX (5-FU [CI: 600mg/m2/day; days 0-5 (120h total) every other week x5], Hydroxyurea [500 mg PO BID, days 0-5 (=11 doses), every other week x5] and twice-daily radiation [150 cGy per fraction - days 1-5, every other week x5 (70-72 Gy total dose)]). Total duration is 10 weeks.
89384094|NCT03658746|Experimental|Antimicrobial susceptibility guided therapy|"Patients in this group will receive a 14-day quadruple therapy for helicobacter pylori eradication. The regimen contains one proton pump inhibitor, colloidal bismuth pectin, and two sensitive antibiotics determined by antimicrobial susceptibility test. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole, levofloxacin, furazolidone and tetracycline will be evaluated.~Drugs: 1.one proton pump inhibitor: rabeprazole 10mg bid for 14d, 2.Colloidal Bismuth Pectin 200mg bid for 14d, 3.two sensitive antibiotics: amoxicillin 1000mg bid for 14d, clarithromycin 500mg bid for 14d, metronidazole 500mg tid for 14d, tinidazole 500mg tid for 14d, levofloxacin 500mg qd for 14d, furazolidone 100mg bid for 14d, tetracycline 500mg qid for 14d."
89384095|NCT03658746|Active Comparator|Empirical therapy according to medication history|"Patients in this group will receive a 14-day quadruple therapy based on personal medication history for helicobacter pylori eradication. The regimen contains one proton pump inhibitor, Colloidal Bismuth Pectin and two antibiotics chosen according to medication history. If the patient hasn't been treated with levofloxacin in the previous eradication regimen, he will be treated with amoxicillin and levofloxacin. Otherwise, he will be treated with amoxicillin and furazolidone.~Drugs: 1.one proton pump inhibitor: rabeprazole 10mg bid for 14d 2.Colloidal Bismuth Pectin 200mg bid for 14d 3.two antibiotics based on personal medication history: amoxicillin 1000mg bid and levofloxacin 500mg qd for 14d, amoxicillin 1000mg bid and furazolidone 100mg bid for 14d."
89384096|NCT02032862|Experimental|Sage tablets|Sage extract, 3400 mg , DER 1:17, in once daily application over 12 weeks treatment phase
88857887|NCT06124833||Newly Diagnosed Cohort|Patients who have been diagnosed with inflammatory bowel disease (IBD, including Crohn's disease and ulcerative colitis) for the first time within the last 6 months prior to study enrollment.
89384097|NCT02032862|Placebo Comparator|Placebo|Placebo, matching the verum in size and appearance, in once daily application over 12 weeks treatment phase
89384098|NCT03611192|Experimental|Multicomponent exercise group|
89384099|NCT03611192|Active Comparator|Home-program exercise group|
89384100|NCT02990910|Other|Individualized opioid analgesia|One group: positive result 10μg/kg morphine; negative result 50μg/kg morphine.Scored every 10 minutes until CHEOPS<=6 and Aldrete score>9.
89384101|NCT02990910|Other|conventional opioid analgesia|Another group: all received 25μg/kg morphine .Scored every 10 minutes until CHEOPS<=6 and Aldrete score>9.
89384102|NCT04056000|Experimental|Exercising following the ingestion of a high-carbohydrate br|60 minutes of cycling, with the ingestion of a high-carbohydrate breakfast and 200 mg of caffeine.
88857888|NCT06124833||Disease Progression Cohort|Patients who were previously diagnosed with IBD and have been followed for over a year to understand disease progression and prognosis.
88857889|NCT06124833||Drug Cohort|Patients with IBD who, during their tracking observations, begin using biological agents and small molecule drugs for the first time.
88857890|NCT06124833||Familial IBD cohort|Cases where there are 2 or more diagnosed IBD patients among the patient's first-degree relatives (≥ 2 IBD-affected First Degree Relatives, FDR).
88857891|NCT06124833||Family Control Group|First-degree blood relatives of the patient who have never been diagnosed with IBD up to the point of study enrollment and who reside with the patient.
88857892|NCT06124820|Experimental|Treatment Arm|Intravaginal micro-ablative fractional CO2 laser technology Deka SmartXide Touch C60 (MonaLisa Touch) will be administered intravaginally over a course of 5 cycles
88857893|NCT06124820|Sham Comparator|Control Arm|Sham treatment -Participants receiving sham treatment will have the probes advanced in the same manner without the use of a laser energy device.
88857894|NCT06124781|Experimental|Patient with patch test reactions|Patient with at least one positive/doubtful patch test reaction for nickel, limonene hydroperoxide and/or linalool hydroperoxide
88857895|NCT06124768||Mixed type DVT treated by PMT through the modified access|Anterograde venography shows patients with mixed type DVT. PMT is performed via ipsilateral distal calf venous access or contralateral femoral access.
88857896|NCT06124768||Mixed type DVT treated by PMT through the traditional access|Anterograde venography shows patients with mixed type DVT. PMT is performed via ipsilateral popliteal venous access.
88857897|NCT06124768||Central type DVT treated by PMT|Anterograde venography shows patients with central type DVT. PMT is performed via any access, such as ipsilateral femoral venous access or ipsilateral popliteal venous access.
89184202|NCT00468169|Experimental|B: Cetuximab + PX|Cetuximab [250 mg/m2 (day 1, weekly x7)] + PX (Cisplatin [100mg/m2 (week 1 & 4 on day 1 (or 2))], Accelerated fraction radiotherapy with concomitant boost [AFX-CB (72 Gy/42 F/6 W) (3-D or IMRT based)]). Total duration: 7 weeks.
89384103|NCT04056000|Experimental|Exercising following the ingestion of caffeine only|60 minutes of cycling, with the ingestion of 200 mg of caffeine.
89384104|NCT04056000|Experimental|Exercising in the absence of breakfast or caffeine ingestion|60 minutes of cycling, without the ingestion of breakfast, or caffeine.
89384105|NCT03611348|Active Comparator|Microneedling + latanoprost|patient will receive topical application of latanoprost 0.005% eye drops solution twice daily for 3 months preceded by microneeding in sessions by dermapen every 2 weeks for 3 months (totally 6 sessions).
89384106|NCT03611348|Active Comparator|latanoprost|Patient will receive topical application of latanoprost 0.005% eye drops solution only twice daily for 3 months (active control side).
89384107|NCT04055532||Mild Cognitive Impairment|
88857898|NCT06124755|Experimental|Viabahn endoprosthesis group|Femoropopliteal lesions treated with Viabahn endoprosthesis.
88857899|NCT06124755|Active Comparator|Drug-coated balloon group|Femoropopliteal lesions treated with drug-coated balloon endoprosthesis.
88857900|NCT06124742||clear aligners|The aim of this study is to assess the gustatory perception and alteration in patients using either clear aligners or fix orthodontics treatment.
88857901|NCT06124729||Bevacizumab Combined With PD-1 Monoclonal Antibody in Preoperative Neoadjuvant Therapy|
88857902|NCT06124690|Active Comparator|Pulmonary vein isolation (no low voltage)|Patients without the presence of low voltage areas receive pulmonary vein isolation only.
88857903|NCT06124690|Active Comparator|Pulmonary vein isolation only (evidence of low voltage areas)|Patients with the evidence of low voltage areas are randomized to either pulmonary vein isolation only or PVI plus ablation of low voltage areas.
88857904|NCT06124690|Active Comparator|Pulmonary vein isolation plus ablation of low voltage areas|Patients with the evidence of low voltage areas are randomized to either pulmonary vein isolation only or PVI plus ablation of low voltage areas.
88857905|NCT06124664||Symptomatic pelvic varicose veins (PVV)|40 patients will include patients with symptomatic PVV (pelvic pain, dyspareunia, heaviness in the hypogastrium) and without symptoms and signs of CVD.
88857906|NCT06124664||Asymptomatic PVV|40 pdtients will consist of women with asymptomatic PVV with signs of CVD.
88857907|NCT06124664||varicose veins of the lower limb|10 patients with varicose veins of the lower limb without PVV and pelvic congestion syndrome (PCS)
88857908|NCT06124651|Active Comparator|CR knee|This type of total knee arthroplasty retains the posterior cruciate ligament.
88857909|NCT06124651|Active Comparator|PS knee|This type of total knee sacrifices the posterior cruciate ligament and cam and post mechanism replaces its function.
88857910|NCT06124612||Atrial fibrillation|Patients already enrolled in main OCEANIC-AF study.
89184203|NCT02589990|Experimental|Strength training|Strength training, 4 rep of 4RM x 4 sets in leg press.
89184204|NCT04015830|Experimental|Older Adults with HIV (N = 60)|African Americans and Whites age 50 and older
88857911|NCT06124599||Women who have developed menstrual staphylococcal toxic shock|"Clinical diagnosis of staphylococcal toxic shock syndrome: confirmed or probable according to CDC criteria :~The 5 CDC clinical criteria for Staphylococcal Toxic Shock are:~a fever above 39°C,~arterial hypotension,~generalized scarlatiniform erythroderma~intense desquamation of the palms or soles of the feet 7 to 14 days later,~and systemic manifestations (at least three):~Digestive: vomiting, diarrhea~Muscular: myalgias, increased serum creatine phospho-kinase~Vaginal, oropharyngeal and conjunctival mucosal hyperemia~Renal: hyperuricemia, hypercreatininemia, leukocyturia without urinary infection,~Hepatic: increased transaminases~Hematological: thrombocytopenia (< 100,000 platelets/mm3)~Neurological: excluding episodes of fever or hypotension such as disorientation or altered consciousness.~If 4 criteria are met, the case is considered probable, and if 5 criteria are met, confirmed."
88857912|NCT06124599||Control healthy women|Women over 13 years of age, menstruating and using internal sanitary protection with No history of menstrual toxic shock for controls
88857913|NCT06124573|Experimental|Reference group|After an overnight fasting of at least 10.00 hours prior to start of high-fat and high-calorie (approximately 800 to 1000 calories) breakfast, subjects were administered a single-dose of the reference product along with 250 mL of 20% glucose in water solution at room temperature.
88857914|NCT06124573|Experimental|Test group|After an overnight fasting of at least 10.00 hours prior to start of high-fat and high-calorie (approximately 800 to 1000 calories) breakfast, subjects were administered a single-dose of the test product along with 250 mL of 20% glucose in water solution at room temperature.
88857915|NCT06124560|Experimental|Reference group|After an overnight fasting of at least 10.00 hours prior to dosing, subjects were administered a single-dose of the reference product along with 250 mL of 20% glucose in water solution at room temperature.
88857916|NCT06124560|Experimental|Test group|After an overnight fasting of at least 10.00 hours prior to dosing, subjects were administered a single-dose of the test product along with 250 mL of 20% glucose in water solution at room temperature.
88857917|NCT06124547|Experimental|Reference group|After an overnight fasting of at least 10.00 hours prior to start of high-fat and high-calorie (approximately 800 to 1000 calories) breakfast, subjects were administered a single-dose of the reference product along with 250 mL of 20% glucose in water solution at room temperature.
88857918|NCT06124547|Experimental|Test group|After an overnight fasting of at least 10.00 hours prior to start of high-fat and high-calorie (approximately 800 to 1000 calories) breakfast, subjects were administered a single-dose of the test product along with 250 mL of 20% glucose in water solution at room temperature.
88857919|NCT06124495|Experimental|Reference group|After an overnight fasting of at least 10.00 hours prior to dosing, subjects were administered a single-dose of the reference product along with 250 mL of 20% glucose in water solution at room temperature.
89002978|NCT05926960|Active Comparator|Doublet|ipilimumab and nivolumab
89184205|NCT00918606|Experimental|LIPO-102|
89184206|NCT03949218||bipolar disorder(BD)|hospitalized patients BD patients in SMHC from 2009 to 2018; meet ICD-10 diagnosis of F31 bipolar disorder criteria and its subtype (mental examination was conducted by three levels of doctors including at least one attending physician and one chief physician in psychiatric); available relevant HIS system biochemical data; hospitalized patients need to the first admission; age and gender is not limited
89184207|NCT03949218||major depressive disorder（MDD）|hospitalized patients MDD patients in SMHC from 2009 to 2018; meet ICD-10 diagnosis of F32 depressive disorder criteria and its subtype (mental examination was conducted by three levels of doctors including at least one attending physician and one chief physician in psychiatric); available relevant HIS system biochemical data; hospitalized patients need to the first admission; age and gender is not limited
89184208|NCT05685030|Placebo Comparator|Placebo|product vehicle (sunflower oil)
89184209|NCT05685030|Experimental|Limosilactobacillus reuteri CCT 7862|Limosilactobacillus reuteri CCT 7862 - 1 x 10e9 UFC/ daY.
89184210|NCT05685030|Experimental|Bifidobacterium lactis CCT 7858 + Lactobacillus rhamnosus CCT 7863|Blend: Bifidobacterium lactis CCT 7858 + Lactobacillus rhamnosus CCT 7863 - 1 x 10e9 UFC/ day.
89184211|NCT05334576|Other|Single Arm: Crizanlizumab|Single-arm: Patients with sickle cell disease and increased risk of silent cerebral infarcts
89384108|NCT04055532||Alzheimer's Disease|
89384109|NCT04055532||Dementia with Lewy Bodies|
88857920|NCT06124495|Experimental|Test group|After an overnight fasting of at least 10.00 hours prior to dosing, subjects were administered a single-dose of the test product along with 250 mL of 20% glucose in water solution at room temperature.
88857921|NCT06124469||Benign lymph nodes|Categories UNN-RADS 1 and 2 (test negative)
88857922|NCT06124469||Metastatic lymph nodes|Categories UNN-RADS 3, 4, and 5 (test positive).
88857923|NCT06124443||Cases|Infants & children of diabetic mothers
89184212|NCT02959320|Active Comparator|Direct Anterior Approach|All patients receiving a hip hemiarthroplasty through a Direct Anterior Approach (DAA) will have their surgeries performed with the aid of fluoroscopy on an OSI Hana table that allows the operative limb to be manipulated through range of motion and traction while keeping the pelvis stabilized. This table also has a radiolucent platform about the pelvis, enabling the surgery to be fluoroscopically assisted. The incision for the DAA will extend from a proximal point about 2 cm distal and 2 cm lateral to the ASIS to a point 8-12 cm distal and slightly lateral to this.
89184213|NCT02959320|Active Comparator|Anterolateral Approach|All patients receiving a hip hemiarthroplasty through an the Anterolateral Approach (ALA) will have their surgeries performed on a standard OR table in a contralateral lateral decubitus position. With the leg in the position of sleep, a straight 8-12 cm incision will be made, centered over the greater trochanter and femoral shaft with 1/3 of the incision extending superior to the tip of the greater trochanter.
89384110|NCT04055532||Frontotemporal Lobar Dementia|
89384111|NCT04055532||Parkinson's Disease with Dementia|
88857924|NCT06124443||Controls|Infants & children of non-diabetic mothers
88857925|NCT06124430||Control Group|Students will take part in the ECOS of the departments scheduled at the end of their internship. Students will use the various revision methods usually offered to them by the faculty or in the emergency department, apart from the ECOX tool. Revision methods are left to their own discretion.
88857926|NCT06124430||ECOX Interventional Group|Students will take part in the ECOS of the departments scheduled at the end of their internship. Students will use the ECOX tool available in the emergency department to practice before taking the on-duty OSCEs.
88857927|NCT06124417|Experimental|Treatment group|The Hamilton Rating Scale for Depression (HAMD) will be applied to assess the depressive status of all enrolled patients. This scale consists of 24 survey items, each with a score of 0-4. Patients will be assigned to the treatment group if their score was ≥8. Patients were given sertraline for antidepressant treatment in the treatment group. The initial dose ranged from 25 to 50 mg, taken orally once daily, and the dosage was adjusted based on the patient's response to the medication.
88857928|NCT06124417|No Intervention|Control group|Patients will be assigned to the control group if their HAMD score was <8.
89184214|NCT02589444|Experimental|Participants with vitamin D deficiency - treatment group|Participants with 25-hydroxyvitamin D (25(OH)D) ≤30 ng/mL taking oral high-dose vitamin D3 (50,000 IU) once a week and providing stool and sputum sample at screening and 3 months after screening.
89384112|NCT04055532||Transient Epileptic Amnesia|
89384113|NCT04055532||Temporal Lobe Epilepsy|
89384114|NCT04055532||Spinocerebellar Ataxia|
89384115|NCT04055532||HIV-Associated Neurocognitive Disorder|
89384116|NCT04055532||Amyotrophic Lateral Sclerosis|
89384117|NCT04055532||Primary Lateral Sclerosis|
88857929|NCT06124365|Experimental|study group|
88857930|NCT06124365|Active Comparator|Control group|
89384118|NCT04055064|Experimental|Intervention|patients received nutrition education and nutritional supplements
89384119|NCT04055064|No Intervention|Control|patients did not receive any intervention
89384120|NCT02033018|Experimental|Aflibercept injection|Myopic eyes with retinal neovascularization submitted a aflibercept intravitreal injection
89384121|NCT02033096||Cohort 1: Stannsoporfin 1.5 mg/kg|Cohort 1: Received one 1.5 mg/kg stannsoporfin injection (with phototherapy as needed) during participation in an earlier interventional trial (NCT00850993)
89384122|NCT02033096||Cohort 2: Stannsoporfin 3.0 mg/kg|Cohort 2: Received one 3.0 mg/kg stannsoporfin injection (with phototherapy as needed) during participation in an earlier interventional trial (NCT00850993)
89384123|NCT02033096||Cohort 3: Stannsoporfin 4.5 mg/kg|Cohort 3: Received one 4.5 mg/kg stannsoporfin injection (with phototherapy as needed) during participation in an earlier interventional trial (NCT00850993)
89384124|NCT02033096||Cohort 4: Placebo Control|Cohort 4: Received one sterile saline injection (with phototherapy as needed) during participation in an earlier interventional trial (NCT00850993)
89384125|NCT03658590|Active Comparator|Group D|including 51 women who will receive a prefilled syringe with two milliliters (8 mg) of dexamethasone intravenously.
89384126|NCT03658590|Placebo Comparator|Group P|including 51 women who will receive a prefilled syringe with two milliliters of distilled water intravenously.
88857931|NCT06124339|Active Comparator|Cognitive activity - VR spatial navigation only|VR spatial navigation program will consist of a spatial navigation program that increases difficulty and length per trial over time. Spatial navigation is the ability to navigate between multiple elements/landmarks widely used in computer games. A trial is a test of performance or quality of someone or something.
88857932|NCT06124339|Active Comparator|Physical activity - Cycling only|The physical activity program will consist of a stationary bike cycling program. Each day will consist of a cycling program of varying levels of difficulty for 20-50 minutes.
88857933|NCT06124339|Experimental|Combined, simultaneous physical and cognitive activity|The combined physical and cognitive activity VR program will consist of a spatial navigation program that increases difficulty and length per trial over time.
88857934|NCT06124326|Experimental|Premenstrual Syndrome Supplement|"During the first menstrual cycle, participants will take the supplement as needed (pro re nata) when they feel symptoms of PMS, such as cramping or bloating.~For the second and third menstrual cycles, Participants will take 2 capsules per day with water for 1 week, starting 4 days before their menstrual cycle and finishing on Day 3 of their cycle."
88857935|NCT06124300|Experimental|Female Hormone Balance Supplement|Participants will add 1 scoop of the powder to a drink of choice every morning.
88857936|NCT06124274|Experimental|Mid-Follicular Phase|7-11 days after onset of menses.
88857937|NCT06124274|Experimental|Mid-Luteal Phase|5-9 days after ovulation (as confirmed with ovulation test kits).
88857938|NCT06124274|Experimental|Active pill phase|10-20 days after starting new pill cycle.
88857939|NCT06124274|Experimental|Withdrawal phase|48hrs after last pill (during placebo pill phase).
88857940|NCT06124222|Active Comparator|Group A|Patients who have not received RT in their oncologic treatment (non-irradiated).
88857941|NCT06124222|Experimental|Group B|Patients who have received RT in their oncologic treatment (irradiated).
88857942|NCT06124170||Total knee arthroplasty (TKA)|Total knee arthroplasty
88857943|NCT06124170||Unicompartmental knee arthroplasty (UKA)|Unicompartmental knee arthroplasty
88857944|NCT06124170||High tibial osteotomy (HTO)|High tibial osteotomy
88857945|NCT06123975||Adenomyosis Cohort|Infertile patients with adenomyosis who met the inclusion and exclusion criteria, after signing the informed consent form, the researchers recorded the clinical information of the patients and initiated the IVF-ET procedure. Peripheral blood was collected on the day of embryo transfer. And if the pregnancy test was positive at 14 days after embryo transfer, peripheral blood was collected at 21 days after the transfer and every 2 weeks thereafter until 12 weeks of gestation.
88857946|NCT06123910|Experimental|Colostrum bovine|Subjets taking a colostrum supplement
88857947|NCT06123910|Placebo Comparator|Placebo|Subjets taking a commercial dairy product
88857948|NCT06123884|Experimental|BAT1308|Strength 100 mg/4 mL, intravenous drip, recommended dose 300 mg, administered every 3 weeks (21 days) (Q3W)
88857949|NCT06123884|Placebo Comparator|BAT1308 monoclonal antibody|Strength 100 mg/4 mL, intravenous drip, recommended dose 300 mg, administered every 3 weeks (21 days) (Q3W)
88857950|NCT06123832||Experimental Group|Liposomal Amphotericin B for Injection (Ampicillin®)
88857951|NCT06123832||Control Group|Liposome of Amphotericin B for Injection (Fungoxone®), Cholesteryl Sulfate Complex of Amphotericin B for Injection (Amphotericin®), Amphotericin B for Injection
88857952|NCT06123702|Experimental|Cannabidiol|600 mg oral cannabidiol
88857953|NCT06123702|Placebo Comparator|Placebo|Placebo capsules
88857954|NCT06123676|Other|Single arms|Single arm study
88857955|NCT06123650|Placebo Comparator|Control group (GA)|Group (A) will receive conventional Oropharyngeal physical therapy program for dysphagia including; Exercise therapy for the oropharyngeal and tongue muscles , neuromuscular electrical stimulation in addition to sham transcranial magnetic stimulation on the contralesional cerebral hemisphere.
88857956|NCT06123650|Active Comparator|Study group (GB)|Group (B) will received low frequency (1 Hz) repetitive transcranial magnetic stimulation to the contralesional cerebral hemisphere in addition to the same Oropharyngeal physical therapy program for dysphagia as in group A.
88857957|NCT06123637|Experimental|Analgesia nociception index group|
88857958|NCT06123637|Placebo Comparator|Standard group|
88857959|NCT06123624|Experimental|Desflurane group|
88857960|NCT06123624|Placebo Comparator|Sevoflurane group|
88857961|NCT06123585|Experimental|Invisalign® SmileView™|
88857962|NCT06123585|Active Comparator|Invisalign aligners|
88857963|NCT06123364|Active Comparator|Active treatment arm|Patients in this study arm will receive 50 mg of mirabegron daily in the form of tablets, which is used to treat OAB according to current treatment guidelines. Additionally they will twice a week receive an actual extracorporeal electromagnetic stimulation in the duration of 20 minutes, for 8 weeks.
88857964|NCT06123364|Sham Comparator|Sham treatment arm|Patients in this study arm will receive 50 mg of mirabegron daily in the form of tablets, which is used to treat OAB according to current treatment guidelines. Additionally they will twice a week receive a sham extracorporeal electromagnetic stimulation in the duration of 20 minutes, for 8 weeks.
88857965|NCT06122948|Active Comparator|(Group M)|The midazolam group will receive intranasal midazolam (0.1 mg/kg)
88857966|NCT06122948|Experimental|(Group MK)|Midazolam ketamine group will receive intranasal midazolam (0.1mg/kg) and ketamine (3mg/kg)
88857967|NCT06122142|Active Comparator|Study personnel distribution channel|SR product will be delivered by paid study personnel.
88857968|NCT06122142|Experimental|Voucher distribution channel|Voucher which will be used to redeem for SR product(s) on a monthly basis for each head of household.
88857969|NCT06122142|Experimental|Village health team distribution channel|Village health teams will distribute SR products.
88857970|NCT06121466|Experimental|Abdominal wall injections for abdominal wall pain|Patients with abdominal pain who are suspected of having abdominal wall pain.
88875402|NCT03766386||Deceased Danon Disease Patients|Patients with a confirmed diagnosis of Danon disease who are deceased (including patients who may or may not have undergone heart transplantation).
89384127|NCT03622476|Experimental|PK research|Interventional studies were performed in the 1-7 year old subgroup, and the children received a comprehensive assessment and PK test every 3 months. After the 72-hour washout period, 50 IU/kg of concentrated FVIII was administered in a single dose, and blood was taken within half an hour before the infusion and 1 h, 9 h, 24 h, and 48 h after the infusion, and the samples were centrifuged. If the assessment considers that the treatment is inadequate, then the valley concentration target is upgraded.
89384128|NCT03658434|Experimental|feasibilty|Palliative Radiotherapy
89384129|NCT03227861|Experimental|DRV 800 mg + COBI 150 mg + FTC 200 mg + TAF 10 mg FDC|Participants will receive oral tablet containing Darunavir 800 milligram (mg)/ Cobicistat 150 mg/ Emtricitabine 200 mg/ Tenofovir Alafenamide 10 mg (D/C/F/TAF) fixed-dose combination (FDC) once daily within 24 hours of the screening/baseline visit.
89384130|NCT03451955|Experimental|Intervention group|Patients in the intervention group follow a gluten-free diet for six months.
89384131|NCT03451955|No Intervention|Control group|Patients in the control group follow their usual diet for six months
89384132|NCT03428945|Experimental|Hydroxychloroquine|Hydroxychloroquine compound for oral use
89384133|NCT03428945|Placebo Comparator|Placebo|Placebo tablet matching active drug
89384134|NCT03409289||ROSC RUSH Exam|The study population will include out of hospital cardiac arrest (both traumatic and non-traumatic causes) with return of spontaneous circulation after the cardiac arrest while in the emergency department .
89384135|NCT05180747|Other|Burst group|Patients received two physical therapy sessions weekly for 6 weeks.
89384136|NCT05180747|Other|Spaced Group|Patients received one physical therapy sessions every 2 weeks for 6 months.
89384137|NCT01336712|Experimental|Myeloablative Haploidentical Transplant|Haplo transplant
89384138|NCT03208127|Experimental|Treatment with Direct Acting Antiviral (DAA) Fixed Dose Combination|12 weeks of HCV treatment with medically appropriate direct acting antiviral
89384139|NCT02865122|Experimental|NTRA-9620-A|NTRA-9620 Dose 1 To be dosed orally for 24 weeks, 4 times/day
89384140|NCT02865122|Experimental|NTRA-9620-B|NTRA-9620 Dose 2 To be dosed orally for 24 weeks, 4 times/day
89384141|NCT02865122|Placebo Comparator|Placebo|Placebo To be dosed orally for 24 weeks, 4 times/day
89384142|NCT03611114|Experimental|Blood orange juice|Subjects will be asked to consume blood orange juice (400 ml/day) for 2 weeks.
89384143|NCT03611114|Placebo Comparator|Control drink|Subjects will be asked to consume a control drink (400 ml/day) for 2 weeks.
89384144|NCT02033330|Active Comparator|phenolics form orange peel, type 1|1 dose of 500 mg of phenolics from orange peel, orally ingested
89384145|NCT02033330|Active Comparator|phenolics from orange peel, type 2|1 dose of 500 mg of phenolics from orange peel, orally ingested
89384146|NCT02033330|Experimental|phenolics from orange peel, type 3|1 dose of 500 mg of phenolics from orange peel, orally ingested
89384147|NCT03611036|Experimental|Strength|Patients will follow the pulmonary rehabilitation program associated with upper limbs strength training for a duration of 4 weeks
89384148|NCT03611036|Active Comparator|Endurance|Patients will follow the pulmonary rehabilitation program associated with upper limbs endurance training for a duration of 4 weeks
89384149|NCT03610958|Experimental|Epitomee Device arm|"A non-surgical, non-pharmacologic, medical Device designed to enhance the feeling of satiety. The Device is composed of a 000 size standard capsule and the Tulip's proprietary Device, encapsulated within it.~The Device components are produced from approved pharmaceutical excipients / food additives / generally recognized as safe (GRAS )/ food contact materials which are used at high grade"
89384150|NCT04603157|No Intervention|Standard of Care Group|Subject with diagnosed with postural orthostatic tachycardia syndrome will continue to follow the treatment recommendations of the primary care physician
89384151|NCT04603157|Experimental|Hybrid Exercise Training Group|Subject with diagnosed with postural orthostatic tachycardia syndrome will follow a hybrid exercise training program
89384152|NCT05453747|Experimental|Ankle injury basketball player|Athletes included in the study; They were divided into two groups as those with and without ankle injury . The same exercise program was applied to the same group in both groups.
88875403|NCT03560466|Experimental|Dupilumab|Doses of dupilumab will be administered every 2 weeks or every 4 weeks added to current controller medications for 52 weeks
89384153|NCT05453747|Active Comparator|Basketball player|The same exercise program was applied to the same group in both groups.
89384154|NCT05432687|Other|patient before Robotic-assisted Radical Prostatectomy|evaluation of deep abdominal wall before surgery : cough test + ulstrasonography of transversus abdominis
89384155|NCT03913481|Experimental|ANH|Best available treatments plus ANH, performed withdrawing a volume of blood before the CPB. The volume will be personalized for every patient, but it'll be at least 650ml.
89384156|NCT03913481|Other|Standard care|No ANH
89384157|NCT03661944||Symptomatic group|There is no intervention in this group, only functional assessments and general physical examinations will be done
89384158|NCT03661944||Healthy control group|There is no intervention in this group, only functional assessments and general physical examinations will be done
89384159|NCT02864498|Experimental|1g DS107|1g DS107 (2 DS107 capsules and 2 placebo capsules) orally administered once-daily for 8 weeks.
89384160|NCT02864498|Experimental|2g DS107|2g DS107 (4 DS107 capsules) orally administered once-daily for 8 weeks.
88857971|NCT06121193|Active Comparator|Patients - Wait-List Control|"Complete questionnaires at baseline (administered electronically or by mail). Follow-up measures will be administered at 3-months after the clinic visit electronically and by mail.~• A PREVENT action plan (behavior change prescription, community resources, and education) will be provided to the patient via email after the completion of the follow-up measurement."
88857972|NCT06121193|Experimental|Experimental: Patients - PREVENT Tool|"Complete questionnaires at baseline (administered electronically or by mail). Follow-up measures will be administered immediately following the clinic visit, and monthly for 3-months after the clinic visit electronically and by mail~• At the clinic visit, the provider will use the PREVENT tool to discuss CVH risk and deliver a tailored behavioral change plan inclusive of patient-centered community resources."
88857973|NCT06121193|No Intervention|Providers|-All eligible providers will be sent questionnaires electronically to their email at baseline, following provider training and follow-up. Providers will be invited to attend a training session to educate them on the PREVENT tool at baseline.
88857974|NCT06121167||study group|patients with acute kidney injury
88857975|NCT06121167||control group|patients who do not develop acute kidney injury
88857976|NCT06120712|Experimental|Participants with advanced malignant melanoma using cryopreserved GC101 TIL|A tumor sample is resected from each participant and cultured ex vivo to expand the population of autologous tumor infiltrating lymphocytes injection (GC101 TIL). After lymphodepletion, patients are infused GC101 TIL followed Pembrolizumab.
88857977|NCT06120101|Experimental|Experimental|Reflexology will be applied in a total of 3 sessions and the final test will be applied to the patients by phone 24 hours after the last reflexology application. At the end of the study, 3 reflexology sessions and 2 test measurements will be performed on the experimental group. Each reflexology session takes approximately 30-40 minutes. Sessions will be performed in a private room within the neurology clinic, on ergonomic and repositionable beds. Each session started with the right foot and will continue with the left foot. Primary relaxation techniques will be applied to both feet, followed by reflexology techniques to all system organs.
88857978|NCT06120101|No Intervention|Control|No application will be applied to the control group.
88857979|NCT06119893|Active Comparator|Control Group|Patient received an indication periodontal flap surgery. In this randomized controlled split mouth study, the patient underwents periodontal flap surgery in their mandibular. Following local anesthesia (2% lidocaine and 1:100,000 epinephrine), sulcular incisions were made. Vertical incision was not used in any operation. The mucoperiosteal flap was elevated until the buccal and lingual bone defects were adequately exposed. Defects were thoroughly debrided firstly by using periodontal curettes, and then cleaned by piezoelectric ultrasonic scaler to ensure all granulation tissues were thoroughly removed. Buccal and lingual flaps were closed primarily. In the control group, 2 mL 0.9% isotonic sodium chloride (saline) with 27-gauge single-type disposable syringes was applied to the buccal surface of flap after the operation
88857980|NCT06119893|Active Comparator|Test Group|Patient received an indication periodontal flap surgery. In this randomized controlled split mouth study, the patient underwents periodontal flap surgery in their mandibular. Following local anesthesia (2% lidocaine and 1:100,000 epinephrine), sulcular incisions were made. Vertical incision was not used in any operation. The mucoperiosteal flap was elevated until the buccal and lingual bone defects were adequately exposed. Defects were thoroughly debrided firstly by using periodontal curettes, and then cleaned by piezoelectric ultrasonic scaler to ensure all granulation tissues were thoroughly removed. Buccal and lingual flaps were closed primarily. In the test group, 8 mg (2 mL) submucosal dexamethasone with 27-gauge single-type disposable syringes was applied to the buccal surface of flap after the operation
89184215|NCT02589444|Sham Comparator|Participants with vitamin D deficiency - placebo group|Participants with 25-hydroxyvitamin D (25(OH)D) concentrations ≤30 ng/mL taking a sham comparator (placebo) once a week and providing stool sample and sputum sample at screening and 3 months after screening.
89184216|NCT02589444|Other|Participants without vitamin D deficiency|Participants with 25-hydroxyvitamin D (25(OH)D) concentrations > 30 ng/mL with no intervention and providing stool sample and sputum sample at screening and 3 months after screening.
89384161|NCT02864498|Placebo Comparator|Placebo|Placebo (4 placebo capsules) orally administered once-daily for 8 weeks.
89384162|NCT03238781|Placebo Comparator|Placebo|Participants randomized to Placebo were administered 6 subcutaneous (SC) injections on day 1 and weeks 2, 4, 6, 8 and 10 during the 12 week double-blind treatment period.
88857981|NCT06118619||Experimental|Ingaron 500,000 IU intramuscularly 1 time per day daily or every other day for 2 months (60 days) - a total of 30 or 60 injections + basic anti-tuberculosis therapy
88857982|NCT06118619||No Intervention|only basic anti-tuberculosis therapy
88857983|NCT06118463||study group|Women aged 20-60; There is a definite pathological diagnosis of cervical cancer
88857984|NCT06118463||Healthy control group|Women aged 20-60; No tumors in the uterus or other parts of the body; No inflammatory disease; Blood routine and blood biochemical tests are normal.
88857985|NCT06118164|Experimental|experimental group -pursing- lip breathing combined with aerobic walking exercise|"For the pursed-lip breathing combined with aerobic walking exercise group (experimental group), subjects were taught to coordinate their breathing with their walking. They were instructed to inhale for two steps and exhale with pursed lips for four to five steps. Initially, they were allowed to walk at a pace that felt comfortable to them, and then gradually increase their walking speed until they reached the target aerobic heart rate, calculated using the formula: (220 - age) × 55-65% of maximum heart rate.~During the walking exercise, a pulse oximeter was used to monitor their heart rate and blood oxygen saturation. Training sessions were conducted daily from the first day after surgery until the fifth day, with three sessions each day, and each session lasting for 15 minutes."
88857986|NCT06118164|Active Comparator|Control group 1-pursed-lip breathing|"For the group receiving single pursing- lip breathing training (control group 1), subjects were taught to perform deep inhalation through the nose (counting mentally from 1 to 2) while in a seated or standing position. They were then instructed to purse their lips and exhale slowly and steadily (counting mentally from 1 to 4).~During the walking exercise, a pulse oximeter was used to monitor their heart rate and blood oxygen saturation. Training sessions were conducted daily from the first day after surgery until the fifth day, with three sessions each day, and each session lasting for 15 minutes."
89384163|NCT03238781|Experimental|AMG 301 210 mg Q4W|Participants randomized to AMG 301 210 mg every fourth week (Q4W) received a total of 3 AMG 301 subcutaneous (SC) injections (70 mg/mL in each injection) plus 3 matching placebo injections on day 1 and weeks 4 and 8. Participants also received 6 SC placebo injections on weeks 2, 6, and 10 during the 12 week double-blind treatment period.
88857987|NCT06118164|Active Comparator|Control group 2 -aerobic walking exercise|"For the single aerobic walking exercise group (control group 2), subjects were taught to start with their own acceptable stride and pace and then gradually increase their walking speed until they reached the target aerobic heart rate. Pulse oximeters were used to monitor their heart rate and blood oxygen saturation levels during the process.~During the walking exercise, a pulse oximeter was used to monitor their heart rate and blood oxygen saturation. Training sessions were conducted daily from the first day after surgery until the fifth day, with three sessions each day, and each session lasting for 15 minutes."
88857988|NCT06116942|Experimental|Active stimulation - Placebo stimulation|Participants will undergo a 2 intervention periods. The first intervention period will consist of a 2-week course of rTMS followed by BCI-mediated training. This intervention will be succeeded by a 4-week washout period to mitigate any carry-over effects. The second intervention period will entail 2 weeks of sham rTMS followed by BCI-mediated training.
88857989|NCT06116942|Experimental|Placebo stimulation - Active stimulation|Participants will undergo the same interventions as the first arm but delivered in inverse order. The first intervention period will consist of 2 weeks of sham rTMS followed by BCI-mediated training. The second intervention period will entail 2 weeks of rTMS prior to BCI-mediated training and will start after a 4-weeks washout period.
88857990|NCT06114667|Experimental|Nasal high flow|"Nasal high flow will be administered through a heated humidifier (Airvo 3, Fisher and Paykel healthcare) and applied through large bore binasal prongs.~Initial gas flow rate will be set at 60 l/min, FiO2 will be adjusted to maintain an SpO2 88-92% and Initial temperature will be set at 37° and reduced according to patient's tolerance.~Ventilatory support will be applied in 2h sessions and resumed as needed according to international guidelines for NIV treatment"
88857991|NCT06114667|Active Comparator|Non invasive ventilation|"NIV will be delivered through a face mask connected to a ventilator with pressure support applied in a noninvasive ventilation mode.~The Pressure-support level will be adjusted to obtain an expired tidal volume of 6-8 ml/kg of predicted body weight and a respiratory rate of 25-30 b/min. PEEP (range 5-10 cm of water) and FiO2 will be adjusted to maintain an SpO2 88-92% and to patient's comfort.~Ventilatory support will be applied in 2h sessions and resumed as needed according to international guidelines for NIV treatment."
88857992|NCT06112249|No Intervention|Control Group|
88857993|NCT06112249|Experimental|Peer Intervention|Receives curriculum taught by Peer Interventionist
88857994|NCT06112249|Experimental|Staff Delivered|Receives curriculum taught by staff
88857995|NCT06110143|Other|PrePROBE|Periodontal treament during pregnancy
88857996|NCT06110143|Other|PostPROBE|Peridontal treatment postpartum
88857997|NCT06108323|Experimental|Action observation plus exercise|Therapeutic exercise plus action observation training
88857998|NCT06108323|Sham Comparator|Sham observation plus exercise|Therapeutic exercise plus sham action observation training
88875404|NCT03376698|Active Comparator|Colchicine 0.5 mg|
88875405|NCT03376698|Active Comparator|Colchicine 0.25 mg|
88875406|NCT03376698|Placebo Comparator|Placebo|
88875407|NCT03084666|Experimental|Treatment Group|The treatment will receive 200 mmHg of pressure from a Zimmer automatic tourniquet system (ATS) for three 5 minute intervals.
88875408|NCT03084666|Experimental|Control Group|Our control group will receive 20 mmHg of pressure from a Zimmer automatic tourniquet system (ATS) for three 5 minute intervals.
89184217|NCT05325684|Experimental|PD-L1 rechallenge|
89184218|NCT00435487|Experimental|A|
89184219|NCT00435487|Active Comparator|B|
89184220|NCT00918918|Experimental|Treatment B|Vodka + orange juice
89184221|NCT00918918|Placebo Comparator|Treatment A|Orange juice
89384164|NCT03238781|Experimental|AMG 301 420 mg Q2W|Participants randomized to AMG 301 420 mg every second week (Q2W) received a total of 6 AMG 301 subcutaneous (SC) injections (70 mg/mL in each injection) on day 1 and weeks 2, 4, 6, 8, and 10 during the 12 week double-blind treatment period.
88857999|NCT06105957|Experimental|Core+Facilitated Weekly Group Sessions+Counselor Crafted Feedback+Individual Coaching Calls|"Behavioral: Core The core intervention will include 24 online weekly behavioral modules, an online interactive discussion board, a physical activity tracker, an e-scale with recommendations for daily self-weighing, dietary self-monitoring via an app, as well as weekly calorie and physical activity goals.~Behavioral: Facilitated Weekly Group Sessions Participants will receive 24, 60-minute facilitated online video-conference-based weekly group sessions.~Behavioral: Counselor Crafted Feedback Participants will receive up to 24 weekly messages that are crafted by a trained professional based on their dietary, physical activity, and weight monitoring for the week as well as their completion of online modules, to construct an individualized feedback message.~Behavioral: Individual Coaching Calls Participants will receive 3 30-minute online one-on-one coaching calls to focus on identifying and addressing challenges to successful behavior change and weight loss."
88858000|NCT06105957|Experimental|Core+Facilitated Weekly Group Sessions+Pre-Scripted Feedback|"Behavioral: Core The core intervention will include 24 online weekly behavioral modules, an online interactive discussion board, a physical activity tracker, an e-scale with recommendations for daily self-weighing, dietary self-monitoring via an app, as well as weekly calorie and physical activity goals.~Behavioral: Facilitated Weekly Group Sessions Participants will receive 24, 60-minute facilitated online video-conference-based weekly group sessions.~Behavioral: Pre-Scripted Feedback Participants will receive up to 24 weekly messages constructed from a bank of pre-scripted messages that align with success, partial success, or absence of self-monitoring related to diet monitoring, physical activity, and self-weighing, as well as on weekly module engagement."
88858001|NCT06105957|Experimental|Core+Facilitated Weekly Group Sessions+Pre-Scripted Feedback+Individual Coaching Calls|"Behavioral: Core The core intervention will include 24 online weekly behavioral modules, an online interactive discussion board, a physical activity tracker, an e-scale with recommendations for daily self-weighing, dietary self-monitoring via an app, as well as weekly calorie and physical activity goals.~Behavioral: Facilitated Weekly Group Sessions Participants will receive 24, 60-minute facilitated online video-conference-based weekly group sessions.~Behavioral: Pre-Scripted Feedback Participants will receive up to 24 weekly messages constructed from a bank of pre-scripted messages that align with success, partial success, or absence of self-monitoring related to diet monitoring, physical activity, and self-weighing, as well as on weekly module engagement.~Behavioral: Individual Coaching Calls Participants will receive 3 30-minute online one-on-one coaching calls to focus on identifying and addressing challenges to successful behavior change and weight loss."
88858002|NCT06105957|Experimental|Core+Facilitated Weekly Group Sessions+Counselor Crafted Feedback|"Behavioral: Core The core intervention will include 24 online weekly behavioral modules, an online interactive discussion board, a physical activity tracker, an e-scale with recommendations for daily self-weighing, dietary self-monitoring via an app, as well as weekly calorie and physical activity goals.~Behavioral: Facilitated Weekly Group Sessions Participants will receive 24, 60-minute facilitated online video-conference-based weekly group sessions.~Behavioral: Counselor Crafted Feedback Participants will receive up to 24 weekly messages that are crafted by a trained professional based on their dietary, physical activity, and weight monitoring for the week as well as their completion of online modules, to construct an individualized feedback message."
88858003|NCT06105957|Experimental|Core+ Counselor Crafted Feedback+Individual Coaching Calls|"Behavioral: Core The core intervention will include 24 online weekly behavioral modules, an online interactive discussion board, a physical activity tracker, an e-scale with recommendations for daily self-weighing, dietary self-monitoring via an app, as well as weekly calorie and physical activity goals.~Behavioral: Counselor Crafted Feedback Participants will receive up to 24 weekly messages that are crafted by a trained professional based on their dietary, physical activity, and weight monitoring for the week as well as their completion of online modules, to construct an individualized feedback message.~Behavioral: Individual Coaching Calls Participants will receive 3 30-minute online one-on-one coaching calls to focus on identifying and addressing challenges to successful behavior change and weight loss."
88858004|NCT06105957|Experimental|Core+ Counselor Crafted Feedback|"Behavioral: Core The core intervention will include 24 online weekly behavioral modules, an online interactive discussion board, a physical activity tracker, an e-scale with recommendations for daily self-weighing, dietary self-monitoring via an app, as well as weekly calorie and physical activity goals.~Behavioral: Counselor Crafted Feedback Participants will receive up to 24 weekly messages that are crafted by a trained professional based on their dietary, physical activity, and weight monitoring for the week as well as their completion of online modules, to construct an individualized feedback message."
88858005|NCT06105957|Experimental|Core+Pre-Scripted Feedback+Individual Coaching Calls|"Behavioral: Core The core intervention will include 24 online weekly behavioral modules, an online interactive discussion board, a physical activity tracker, an e-scale with recommendations for daily self-weighing, dietary self-monitoring via an app, as well as weekly calorie and physical activity goals.~Behavioral: Pre-Scripted Feedback Participants will receive up to 24 weekly messages constructed from a bank of pre-scripted messages that align with success, partial success, or absence of self-monitoring related to diet monitoring, physical activity, and self-weighing, as well as on weekly module engagement.~Behavioral: Individual Coaching Calls Participants will receive 3 30-minute online one-on-one coaching calls to focus on identifying and addressing challenges to successful behavior change and weight loss."
89184222|NCT02589678|Other|MMR/Tdap-IPV|Participants receiving MMR vaccine (Measles, mumps, and rubella) at 0 months/at enrollment, followed by Tdap-IPV vaccine (Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis) at 3 months.
89384165|NCT02033408|Experimental|Antibiotics in addition to steroids|"methylprednisolone-1.5mg/kg up to 60mg daily in two divided doses and in addition the following antibiotics:~PO Vancomycin 250mg 4 times a day for 3 weeks (children under age 8 125mgX4/d for 3 weeks)~PO Amoxycillin 50mg per Kg divided by 3 (up to 500mg 3 times a day) - for 3 weeks~PO Metronidazole 5mg per Kg 3 times a day (up to 250mg 3 times a day) - for 3 weeks~PO Doxycycline 2mg per kg twice a day (up to 100mg twice a day) - for 3 weeks; OR- For children younger than 7 years: PO Ciprofloxacin 10mg per Kg twice a day (up to 250mg twice a day) for 3 weeks"
88858006|NCT06105957|Experimental|Core+Pre-Scripted Feedback|"Behavioral: Core The core intervention will include 24 online weekly behavioral modules, an online interactive discussion board, a physical activity tracker, an e-scale with recommendations for daily self-weighing, dietary self-monitoring via an app, as well as weekly calorie and physical activity goals.~Behavioral: Pre-Scripted Feedback Participants will receive up to 24 weekly messages constructed from a bank of pre-scripted messages that align with success, partial success, or absence of self-monitoring related to diet monitoring, physical activity, and self-weighing, as well as on weekly module engagement."
89384166|NCT02033408|Active Comparator|Steroids only|methylprednisolone-1.5mg/kg up to 60mg daily in two divided doses
89384167|NCT02033408|Other|Open arm|either the antibiotics and/or FMT (fecal microbiome transplant) may be administered in a non-randomized, uncontrolled open-label arm to any resistant IBD patients
89384168|NCT02033252|Experimental|Acupuncture|A series of acupuncture sessions within four weeks from the baseline with concurrent conventional medications for asthma
89384169|NCT02033252|No Intervention|Waiting|Participants who will be allocated to waitlist will receive no acupuncture treatments throughout the 4 weeks while receiving other conventional managements for asthma. After 4 weeks, if participants choose to try the acupuncture treatment, the active acupuncture treatment will be provided for 4 weeks (3 sessions/week).
89384170|NCT03610880|Experimental|TG-2349 (400 mg) plus DAG181 (200 mg)|Dosing period 1 (Day 1 to 7): TG-2349 alone；Dosing period 2 (Day 8 to 14): TG-2349+DAG181
89384171|NCT03610880|Experimental|DAG181 (200 mg) plus TG-2349 (400 mg)|Dosing period 1 (Day 1 to 7): DAG181 alone；Dosing period 2 (Day 8 to 14): TG-2349+DAG181
89384172|NCT02097121|Experimental|Botox 25 U|Participants randomized to receive 25 Units (U) BOTOX (not to exceed 6 U/kg), administered via cystoscopy as 20 intradetrusor injections of 0.5 mL each, sparing the trigone. Posttreatment follow-up clinic visits occurred at Weeks 2, 6, and 12. Participants could request retreatment from Week 12 and 12 weeks after each subsequent treatment for up to 4 cycles. The retreatment dose was determined by the Investigator and could be at the same dose or at the next higher dose compared with the preceding treatment.
89384173|NCT02097121|Experimental|Botox 50 U|Participants randomized to receive 50 Units (U) BOTOX (not to exceed 6 U/kg), administered via cystoscopy as 20 intradetrusor injections of 0.5 mL each, sparing the trigone. Posttreatment follow-up clinic visits occurred at Weeks 2, 6, and 12. Participants could request retreatment from Week 12 and 12 weeks after each subsequent treatment for up to 4 cycles. The retreatment dose was determined by the Investigator and could be at the same dose or at the next higher dose compared with the preceding treatment.
89384174|NCT02097121|Experimental|Botox 100 U|Participants randomized to receive 100 Units (U) BOTOX (not to exceed 6 U/kg), administered via cystoscopy as 20 intradetrusor injections of 0.5 mL each, sparing the trigone. Posttreatment follow-up clinic visits occurred at Weeks 2, 6, and 12. Participants could request retreatment from Week 12 and 12 weeks after each subsequent treatment for up to 4 cycles. The retreatment dose was determined by the Investigator and could be at the same dose or at the next higher dose compared with the preceding treatment.
89384175|NCT02033486|Experimental|TOBI + DBT|TOBI + DBT of women presenting for breast imaging.
89384176|NCT05298215|Experimental|5 mg/kg UB-221|Total of 2 doses on Day 0 (week 1) and 84 (Week 12), respectively, by intravenous (IV) infusion.
89384177|NCT05298215|Experimental|10 mg/kg UB-221|Total of 2 doses on Day 0 (week 1) and 84 (Week 12), respectively, by intravenous (IV) infusion.
89002979|NCT05921084|Placebo Comparator|Control arm|Usual medical care (including general dietary advice).
89002980|NCT05921084|Active Comparator|MIND diet intervention arm|Usual medical care plus the MIND diet intervention.
89384178|NCT05298215|Placebo Comparator|Placebo|sterile saline solution (0.9% NaCl) for intravenous (IV) infusion
89384179|NCT02747420|Experimental|Post Tibial Nerve Stimulation Group (PTNS)|
89384180|NCT02747420|Sham Comparator|Sham Group|
89384181|NCT03238001|Experimental|All qualified participants|Participants received DCTclock, Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), and a battery of other traditional pen and paper neuropsychological assessments.
89384182|NCT02747108|Experimental|Blood Test Group|Patients will complete an HbA1c test and then receive brief counseling and written information about their test result based on the American Diabetes Association and National Diabetes Prevention Program guidelines.
89384183|NCT02747108|Active Comparator|Brochure Group (usual care)|Patients will not complete an HbA1c test and will instead receive brief counseling and written information about recommended screenings and immunizations.
88858011|NCT06095154|Experimental|New-mode reduced CTVp|Patients with newly diagnosed, non-metastatic NPC was given New-mode reduce-volume target IMRT. The CTVp was defined as a subclinical disease consisting of 10 mm margin surrounding GTVnx (not including all nasopharyngeal mucosa)
88858012|NCT06095154|No Intervention|Conventional CTVp|Patients with newly diagnosed, non-metastatic NPC was given conventional reduce-volume target IMRT. The CTVp was defined as GTVnx + entire nasopharynx mucosa + 10 mm + corresponding anatomical structures.
88858013|NCT06094218|Active Comparator|Treatment as Usual (TAU)|TAU may include (1) routine suicide risk screening and assessment; (2) safety planning with means restriction; and (3) the Collaborative Assessment and Management of Suicidality (CAMS), an evidence-based approach to managing and treating suicidal patients.
88875409|NCT02928978|Experimental|Ruxolitinib|Participants will receive ruxolitinib 20 mg by mouth twice daily for 15 days (+/- 5 days). Ruxolitinib will be supplied as four, 5 mg tablets.
89384184|NCT05256095|Experimental|Immediate Assignment to Intervention Group|This group will begin to receive the intervention immediately upon entering the study. Thinking in Speech is a novel cognitive therapy that helps children with autism independently cope with everyday events that cause stress, by developing their ability to use inner speech. Participants will complete two sessions per week for eight week, for a total of sixteen sessions. Sessions will be conducted by speech-language pathologists who are trained in Thinking in Speech. Sessions will be conducted via a secure Zoom platform.
89384185|NCT05256095|Experimental|Waitlist Assignment to Intervention Group|The Waitlist group will begin to receive the intervention 10 weeks after entering the study. Thinking in Speech is a novel cognitive therapy that helps children with autism independently cope with everyday events that cause stress, by developing their ability to use inner speech. Participants will complete two sessions per week for eight week, for a total of sixteen sessions. Sessions will be conducted by speech-language pathologists who are trained in Thinking in Speech. Sessions will be conducted via a secure Zoom platform.
89384186|NCT02075671|Experimental|Levulan and Blu-U Light|Entire face treated with 20% Aminolevulinic Acid (Levulan) and Blu-U light
89384187|NCT02075671|Sham Comparator|Vehicle and Blu-U Light|Entire face treated with vehicle substance only and Blu-U light
89384188|NCT02075671|Placebo Comparator|Vehicle Only|Entire face treated with vehicle substance only
89384189|NCT05206643||A cohort as an area probability sample of Shanghai City|
89384190|NCT02560298|Experimental|Arm A (cisplatin, fluorouracil or capecitabine)|Patients receive cisplatin IV over 1-4 hours on day 1 and fluorouracil IV continuously over 24 hours on days 1-4. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity. Patients with complications associated with the central venous access which prevent further infusion of fluorouracil and only after discussion with the Chief Investigator receive capecitabine BID on days 1-4.
89384191|NCT02560298|Experimental|Arm B (paclitaxel, carboplatin)|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15 and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
89384192|NCT02033642|Experimental|Family Based Behavioral Intervention|Family Based Behavioral Intervention (FBBI) is a 24-session lifestyle intervention designed to: (1) educate adolescent/young adult participants and their parents in principles of good nutrition and physical activity, and (2) train parents to implement lifestyle changes at home to facilitate weight loss in their child.
89384193|NCT02033642|Experimental|Maintenance|The Maintenance condition in this study is a 12-session intervention designed to extend FBBI and continue to teach adolescent/young adult participants and their parents to continue practicing lifestyle behaviors at home.
89384194|NCT03226769|Active Comparator|Thermalon|Participants received application of Thermalon dry eye compress on Days 0 and 7 followed by daily use as per label instructions.
89384195|NCT03226769|Experimental|TrueTear™|Participants received TrueTear™ device intranasally for approximately 8 minutes on Day 0, for approximately 3 minutes on Day 7 followed by daily use of TrueTear™ per participant guide.
89384196|NCT01330615|Active Comparator|Cryotherapy with EMLA|EMLA applied before cryotherapy
89384197|NCT01330615|Placebo Comparator|Cryotherapy with placebo analgesia|Placebo cream applied instead of EMLA
89384198|NCT03636529|Active Comparator|Tart cherry juice (TCJ)|Participants randomized to consume either placebo beverage or tart cherry juice at beginning of the study followed by a 4 week washout then switch over to the alternate beverage to account for timing and order effects.
89384199|NCT03636529|Placebo Comparator|Placebo|Participants randomized to consume either placebo beverage or tart cherry juice at beginning of the study followed by a 4 week washout then switch over to the alternate beverage to account for timing and order effects.
89384200|NCT05034029|Experimental|Metformin|Metformin hydrochloride sustained release tablet will administer orally in escalating doses to reduce side-effects and maintain masking: 0.5 g/day for the first two weeks, 1 g/day for the next 2 weeks, and then 2 g/day until the end of the study if tolerated. If the subject cannot tolerate the maximum dose (2 g/day), take their maximum tolerable dose. In case of adverse reaction, the researchers can determine whether the subject needs to reduce or stop the drug based on their discretion.
89384201|NCT05034029|Placebo Comparator|Placebo|Placebo will administer the same as the experimental drug.
89384202|NCT03637127|Experimental|Order air-hypoxia|"The participants will be exposed to shamed hypoxia (FiO2: 20.9% equivalent to sea level and consecutively to simulated altitude (FiO2: 15.1% equivalent to 2500m above sea level) administered by an altitude Simulator (Altitrainer, SMTEC), simulated altitude (FiO2: 15.1%), with a facemask."
89384203|NCT03637127|Experimental|Order hypoxia-air|"The participant will be exposed to hypoxia (FiO2, 15.1% equivalent to 2500m above sea level), simulated altitude (FiO2: 15.1%), and consecutively to shamed hypoxia (FiO2, 20.9%) administered by an altitude simulator (Altitrainer, SMTEC) with a facemask."
89384204|NCT02864342|Active Comparator|BreatheMate device and application|BreatheMate Bluetooth device that attaches to Symbicort pressurized Metered Dose Inhaler (pMDI) and cell phone with application that sends medication and refill reminders and reminders to complete a COPD questionnaire
89384205|NCT02864342|Placebo Comparator|BreatheMate device without application|BreatheMate Bluetooth device that attaches to Symbicort pressurized Metered Dose Inhaler (pMDI) and cell phone without any reminders or alerts.
89384206|NCT03237065|Experimental|Iron isomaltoside/ferric derisomaltose|Administered IV
88858014|NCT06094218|Experimental|Brief Cognitive Behavioral Therapy (BCBT)|BCBT consists of 12 outpatient individual psychotherapy sessions scheduled weekly or biweekly. The first session is 90 minutes and subsequent sessions are 60 minutes. BCBT is divided into three phases. In phase 1 (5 sessions), the therapist conducts a detailed assessment of the patient's most recent suicidal episode or suicide attempt, identifies patient-specific factors that contribute to and maintain suicidal behaviors, provides a cognitive-behavioral conceptualization, collaboratively develops a crisis response plan, and teaches basic emotion regulation skills. In phase 2 (5 sessions), the therapist teaches cognitive restructuring skills to build cognitive flexibility. In phase 3 (2 sessions), a relapse prevention task is conducted, and participants must demonstrate the ability to successfully complete this task in order to terminate the treatment. Additional sessions are conducted until participants demonstrate the ability to successfully complete this task.
88858015|NCT06093321|Experimental|SYB PDO Thread|PDO Thread
88858016|NCT06093321|Active Comparator|MINT lift®|PDO Thread
89384207|NCT03237065|Active Comparator|Ferric carboxymaltose|Administered IV
89384208|NCT05121077|Experimental|Moderate continuous training|Participants will continuously exercise at a workload between 50-60% of VO2peak on a bicycle ergometer.
89384209|NCT05121077|Experimental|Interval training|Participants will exercise at a varying workload between 50-60% of VO2peak during recovery and 80-90% of VO2peak during bouts of interval training on a bicycle ergometer.
89384210|NCT03171415|Experimental|RZL-012|"A single-time injection, multiple subcutaneous injections of RZL-012 administered into 8-36 sites (0.1mL per site):~40mg RZL-012 -administered at 8 sites~80mg RZL-012 - administered at 16 sites~120mg RZL-012 - administered at 24 sites~180mg RZL-012 - administered at 36 sited"
89384211|NCT03171415|Placebo Comparator|Placebo|A single-time injection, multiple subcutaneous injections of Placebo administered into 8-36 sites (0.1mL per site)
89384212|NCT03829241|Experimental|Troriluzole|"Randomization phase (Weeks 1 through 8): Participants received troriluzole 100 mg capsules twice daily (BID) orally for up to 8 weeks in the double-blind (DB) randomization phase.~Extension phase (Weeks 9 through 56): Participants, who completed the randomization phase and for whom the investigator believed open-label (OL) treatment could offer an acceptable risk-benefit profile, entered the extension phase and received OL troriluzole capsules (continuing on the same dose and regimen that was taken at the end of the randomization phase) for up to additional 48 weeks."
89384213|NCT03829241|Placebo Comparator|Placebo|"Randomization Phase (Weeks 1 through 8): Participants received troriluzole matching placebo capsules BID orally for up to 8 weeks in the DB randomization phase.~Extension Phase (Weeks 9 through 56): Participants, who completed the randomization phase and for whom the investigator believed OL treatment could offer an acceptable risk-benefit profile, entered the extension phase and received OL troriluzole capsules (continuing on the same dose and regimen that was taken at the end of the randomization phase) for up to additional 48 weeks."
89384214|NCT05210959||Preterm or term born infants|Premature or term born infants between the aged 3-18 months were recruited in this study.
89384215|NCT05090423|Experimental|Experimental: balance training alone|The subjects will receive the balance training twice a week for 6 weeks.
89384216|NCT05090423|Experimental|Experimental: balance training and neurodynamic intervention for the common peroneal nerve|The subjects will receive the balance training and neurodynamic intervention for the common peroneal nerve twice a week for 6 weeks.
89384217|NCT01984879||Inflammatory bowel diseases|Patients who have inflammatory bowel diseases and who give consent to participate in the survey
89384218|NCT05056493|Experimental|Clinical Providers|Clinical provider site champions will be invited to participate in web-based quantitative surveys and a semi-structured interview
89384219|NCT05056493|Experimental|Parent/Caregivers|Patient and parent/caregiver subjects from the participating clinic sites will be enrolled. These participants are all adults - parents or caregivers of children and youth with special health care needs (CYSHCN) and adult patients with multiple chronic conditions (MCC) who are already receiving care at Duke Health.
88858017|NCT06087276|Experimental|Parallel Design: ulixacaltamide arm|Double-blind Part: Oral dosing, once daily in the morning with titration over 14 days to 60 mg ulixacaltamide: 7 days of 20 mg, 7 days of 40 mg, 70 days of 60 mg
88858018|NCT06087276|Placebo Comparator|Parallel Design: placebo arm|Double-blind Part: Oral dosing, once daily in the morning: 84 days of placebo
89384220|NCT01314781|Experimental|solifenacin 5mg, PFMT and WBVT|Patients randomized to group A will receive solifenacin 5mg tablet once daily and a training programme for PFMT and WBVT once a week.
89384221|NCT01314781|Active Comparator|solifenacin 5mg|Subjects randomised to group B will receive solifenacin 5mg tablet once daily.
89384222|NCT01330693|Active Comparator|Atomoxetine|Atomoxetine is FDA-approved for the treatment of ADHD symptoms in children
89384223|NCT01330693|Placebo Comparator|Placebo|Sugar pill
88858019|NCT06087276|Experimental|Randomized Withdrawal|"Double-blind Part: Oral dosing, once daily in the morning with titration over 14 days to 60 mg ulixacaltamide: 7 days of 20 mg, 7 days of 40 mg, 42 days of 60 mg~Randomized Withdrawal Part: Following double-blind part: 1:1 randomization to placebo or 60 mg ulixacaltamide for 28 days"
88858020|NCT06087276|Experimental|Long-term Safety Study: Essential1 rollovers|Open-label Part: Oral dosing, once daily in the morning up to one year (365 days) of 60 mg ulixacaltamide
89184223|NCT02589678|Other|Tdap-IPV/MMR|Participants receiving Tdap-IPV vaccine (Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis) at 0 months/at enrollment, followed by MMR vaccine (Measles, mumps, and rubella) at 3 months.
89384224|NCT01913977|Experimental|Treatment with mechanical ventilation|Abylcap system with the oxygenator Lilliput2 as CO2 remover (Bellco, Italy).
89384225|NCT01330771||hMG-HP/r-FSH|Patients with a condition
89384226|NCT03164551|Active Comparator|GERI+ Incubator|
89384227|NCT03164551|Other|Conventional incubator|
89384228|NCT02863328|Experimental|14 mg oral semaglutide|
89384229|NCT02863328|Active Comparator|25 mg empagliflozin|
89384230|NCT03040141|Experimental|VIS410 low dose|Single intravenous infusion of fixed low dose of VIS410 in addition to oseltamivir
89384231|NCT03040141|Experimental|VIS410 high dose|Single intravenous infusion of fixed high dose of VIS410 in addition to oseltamivir
89384232|NCT03040141|Placebo Comparator|Placebo|Single intravenous infusion of placebo in addition to oseltamivir
89384233|NCT02033564|Active Comparator|Macintosh/Miller Laryngoscope|Macintosh or Miller laryngoscopy blade, preference left up to practitioner conducting intubation. These are the gold standards currently used in laryngoscopy.
89384234|NCT02033564|Active Comparator|Glidescope Laryngoscope|Glidescope video-guided laryngoscopy blade
88858021|NCT06087276|Experimental|Long-term Safety Study: Parallel Design and Randomized Withdrawal rollovers|"Open-label Part for patients previously on placebo: Oral dosing, once daily in the morning with titration over 14 days to 60 mg ulixacaltamide: 7 days of 20 mg, 7 days of 40 mg, up to 351 days of 60 mg~Open-label Part for patients previously on 60 mg ulixacaltamide: Oral dosing, once daily in the morning up to 365 days 60 mg ulixacaltamide"
88858022|NCT06085326|No Intervention|Pre-Intervention Phase|PICU patients who are intubated without the Smart checklist
88858023|NCT06085326|Active Comparator|Post-Intervention Phase|PICU patients who are intubated after implementation of the Smart checklist in the pediatric intensive care unit.
88858024|NCT06082518|Experimental|Immediate start of hyperbaric treatments|HBOT treatments will be scheduled to start immediately after referral.
88858025|NCT06082518|Experimental|Delayed start of hyperbaric treatments|HBOT treatments will be scheduled to start 60 days after referral.
88858026|NCT06075979|Experimental|Lumbar disc herniation group|Patients undergoing surgery for lumbar disc herniation
88858027|NCT06075979|Experimental|Lumbar spinal stenosis group|Patients undergoing surgery for lumbar spinal stenosis
88858028|NCT06075966|Experimental|Non-fusion group|Patients who have undergone the INTRA-Spine dynamic stabilization system insertion surgery for lumbar spondylosis and have complete follow-up data and meet the standards completed at the First Affiliated Hospital of Shandong First Medical University.
88858029|NCT06075966|Active Comparator|Fusion group|Patients who have undergone lumbar spine fusion surgery due to lumbar spondylosis and meet the standards and have complete follow-up data completed at the First Affiliated Hospital of Shandong First Medical University.
88858030|NCT06067438|Experimental|Arm I (amiodarone hydrochloride)|Patients receive amiodarone hydrochloride IV for 4 days and then via a feeding tube for 3 days on study.
88858031|NCT06067438|Placebo Comparator|Arm II (normal saline)|Patients receive normal saline IV for 4 days on study.
88858032|NCT06057974||Pre-intervention|The patient and their parents who are admitted to the NICU before the NICU starts implementing the intervention.
88858033|NCT06057974||Post-intervention|The patient and their parents who are admitted to the NICU after the NICU implements the intervention.
88858034|NCT06057753|No Intervention|Standard Education|Standard stroke patient education as per the medical providers
88858035|NCT06057753|Experimental|MyStroke|Access to a personalized video-based stroke educational platform
88858036|NCT06050954|Other|Maintenance Therapy 200mg Pembrolizumab|Participants who have radiographical or ctDNA progression after 3-6 cycles of standard-of-care platinum-based chemotherapy will be offered 200mg Pembrolizumab every six weeks via IV infusion.
88858037|NCT06050954|Other|Maintenance Therapy 400mg Pembrolizumab|Participants who have radiographical or ctDNA progression after 3-6 cycles of standard-of-care platinum-based chemotherapy will be offered 400mg Pembrolizumab every six weeks via IV infusion..
88858038|NCT06050954|Other|Active Surveillance|Participants who are deemed ctDNA responders (reduction in ctDNA by 50% or more) on post-chemo testing will undergo active surveillance and continued serial ctDNA testing at regular intervals as defined by the study protocol. Patients will also undergo surveillance imaging as defined in the study protocol. At the time of first radiographic or ctDNA progression (to be assessed every 12 weeks in conjunction with radiographic assessment), the patient will be offered treatment with pembrolizumab.
88858039|NCT06050369|Experimental|GTS group|This arm will be studied to get some electrophysiological marker of tics. The patients will be their own control (periods with symptoms vs. free symptoms periods).
88858040|NCT06050369|Experimental|OCD group|This arm will be studied to get some electrophysiological marker of compulsions. The patients will be their own control (periods with symptoms vs. free symptoms periods).
88858041|NCT06031428|Active Comparator|Control|All participants in the study will receive diabetes education mailers. This includes monthly mailings of diabetes education, based off the American Diabetes Association guidelines for Diabetes Education.
89384235|NCT02937701|Experimental|ABP 710|"Participants randomized to receive a 3 mg/kg intravenous (IV) infusion of ABP 710 on day 1, at weeks 2 and 6, and every 8 weeks thereafter until week 22.~At week 22 participants continued receiving 3 mg/kg ABP 710 every 8 weeks through week 46."
88858042|NCT06031428|Experimental|MANAGe-DM|Participants assigned to MANAGe-DM will receive the standard diabetes education mailing in addition to a novel nurse case management intervention. MANAGe-DM will include NCM services tailored to the health needs of Black men with recent release from incarceration and T2DM. MANAGe-DM will include three components: 1) diabetes education and skills training; 2) healthcare navigation and 3) basic needs navigation. . Each month of the study period, the NCM will conduct two phone call intervention sessions with individual participants.
88858043|NCT06027723|Experimental|Nicotine|Participants will follow a standard vape protocol designed to deliver the approximate nicotine typically consumed from 1 cigarette (1.25 mg)
88858044|NCT06027723|Placebo Comparator|Placebo|Participants will follow a standard vape protocol that is equal inhalation to that used in the nicotine condition.
88858045|NCT06013579|Active Comparator|Continuous Moderate Exercise (CME)|Following a 4 minute warm-up at 50% VO2peak, the participant walks for up to 42 continuous minutes at 60% VO2peak172, followed by a 4 minute cool-down. The total exercise time is 50 minutes.
88858046|NCT06013579|Active Comparator|High-Intensity Interval Training (HIIT)|Following a 5-minute warm-up at 50% VO2peak, high and moderate-intensity exercise bouts alternate, progressing to five bouts of 4-minute high-intensity exercise (90% VO2peak), alternating with four 3-minute bouts of moderate-intensity exercise (50% VO2peak) by week 8, followed by a 5 minute cool-down. The total exercise time is 42 minutes.
88858047|NCT06004492|Placebo Comparator|blended learning program|8 hours of workshops and four months of practical learning on technology platforms
88858048|NCT06004492|No Intervention|conventional education|conventional education
88858049|NCT06002347|Experimental|STAC Parent Module|
88858050|NCT06001112|Experimental|acupuncture group|subjects will received cheek acupuncture for one time
88858051|NCT06001112|Active Comparator|etoricoxib|subjects will received etoricoxib 120mg for one time
88858052|NCT05994235|Experimental|Subcutaneous Mosunetuzumab and Oral Tazemetostat|50 patients will be enrolled and treated with standard dosing of subcutaneous mosunetuzumab, and with oral tazemetostat by mouth twice daily at standard dosing (800 mg twice daily) beginning at the same time as mosunetuzumab initiation.
88858053|NCT05991427|Experimental|Experimental vaccine group, low dose, Intramuscular injection(IM)|2 doses of ChAdOX1-VZV vaccine (1 × 10^10 vp) on Day 0 and Month 4
89384236|NCT02937701|Active Comparator|Infliximab|"Participants randomized to receive a 3 mg/kg IV infusion of infliximab on day 1, at weeks 2 and 6, and every 8 weeks thereafter until week 22.~At week 22 participants were re-randomized in a 1:1 ratio to either continue receiving 3 mg/kg infliximab every 8 weeks or transition to receive 3 mg/kg ABP 710 every 8 weeks through week 46."
89384237|NCT05186623||Patients with confirmed ulcerative colitis|Patients with confirmed ulcerative colitis, who are going to receive vedolizumab therapy (n=100: development cohort n=70 and validation cohort n=30), ustekinumab therapy (n=100: development cohort n=70 and validation cohort n=30), or tofacitinib therapy (n=100: development cohort n=70 and validation cohort n=30), will be enrolled.
88858054|NCT05991427|Active Comparator|Control vaccine group, low dose, IM|2 doses of Shingrix vaccine (0.5ml) on Day 0 and Month 4
88858055|NCT05991427|Experimental|Experimental vaccine group, high dose, IM|2 doses of ChAdOX1-VZV vaccine (5 × 10^10 vp) on Day 0 and Month 4
88858056|NCT05991427|Active Comparator|Control vaccine group, high dose, IM|2 doses of Shingrix vaccine (0.5ml) on Day 0 and Month 4
88858057|NCT05991427|Experimental|Experimental vaccine group, Aerosol, Inhalation(IH)|2 doses of ChAdOX1-VZV vaccine (2 × 10^10 vp) on Day 0 and Month 4
88858058|NCT05991427|Placebo Comparator|Saline group, Aerosol, IH|2 doses of saline (0.2ml) on Day 0 and Month 4
88858059|NCT05990569|Experimental|Arm A|Bupivacaine
88858060|NCT05990569|Experimental|Arm B|Bupivacaine with methylene blue
88858061|NCT05990192|Other|SBRT followed by Niraparib|"SBRT treatment will commence within 7 days post randomisation and will be administered as detailed in the SOPRANO Radiotherapy Planning and Delivery Guidelines document. Doses will vary between 3 fractions over 5 days to 8 fractions over 19 days depending on the location of the lesions being treated.~Niraparib treatment will start 4 weeks post completion of SBRT treatment and will continue daily until disease progression or other discontinuation criteria are met. Niraparib comes in oral tablet form and the starting dose will be 200mg per day (once a day) or 300mg per day (once a day) calculated by participant's weight and platelet count."
88858062|NCT05990192|Other|SBRT alone|SBRT treatment will commence within 7 days post randomisation and will be administered as detailed in the SOPRANO Radiotherapy Planning and Delivery Guidelines document. Doses will vary between 3 fractions over 5 days to 8 fractions over 19 days depending on the location of the lesions being treated.
88858063|NCT05987020|Experimental|pre-specified group|"The experimental group received aromatherapy, an intervention using lavender essential oil compound, while the control group received a placebo, sweet almond oil. The research tools include: Basic Demographic Information,  The Chinese version of the Pittsburgh Sleep Quality Index, CPSQI , The World Health Organization Quality of Life Questionnaire -Taiwan Version and The World Health Organization Quality of Life Questionnaire -old."
88858064|NCT05987020|Placebo Comparator|subgroup of participant|"The control group received a placebo, sweet almond oil. The research tools include: Basic Demographic Information,  The Chinese version of the Pittsburgh Sleep Quality Index, CPSQI , The World Health Organization Quality of Life Questionnaire -Taiwan Version and The World Health Organization Quality of Life Questionnaire -old."
88858065|NCT05982158|Active Comparator|Cognitive Behavioural Therapy (CBT)|The standard therapy arm will be based on a focused cognitive behavioural therapy (CBT) protocol for AVHs. Sessions will involve discussing the characteristics of participant's AVHs, before applying core CBT approaches, adapted to the AVH experience, to conduct a thorough cognitive behavioural assessment with a focus on coping strategy enhancement and cognitive restructuring.
88858066|NCT05982158|Experimental|Avatar Therapy|The experimental arm will use avatar therapy. Sessions will involve generating an audio-visual avatar as a virtual representation of the primary 'voice' that the participant hears. This will be used to recreate AVHs experientially and allow participants to practice alternative ways of responding to the 'voice'. This innovative approach will be combined with the use of broader CBT methods.
89384238|NCT01330849|Experimental|Toolkit intervention|
89384239|NCT01330849|No Intervention|Waiting List Control Group|Children eligible for the study according to the inclusion criteria, but randomly allocated to the waiting list control group are promised to receive the intervention AFTER the study is finished.
89384240|NCT04602845|Experimental|Remimazolam group|"Drug administration: 50ug fentanyl and 50mg flurbiprofen at the beginning of induction and pre-prepared drugs labeled inducers, which contained 3 mg/2ml remimazolam.~Successful sedation is defined as MOAA/S score less than or equal to 4 points during the whole process of the treatment. If MOAA/S score was greater than 4 points, a single dose of Remimazolam (1 mg) is allowed to deepen sedation. if three times of deepen sedation within 15 minutes still can not achieve successful sedation, this progress will define as failure sedation."
89384241|NCT04602845|Active Comparator|Midazolam group|"Drug administration: 50ug fentanyl and 50mg flurbiprofen at the beginning of induction and pre-prepared drugs labeled inducers, which contained 2.5 mg/2ml midazolam.~Successful sedation is defined as MOAA/S score less than or equal to 4 points during the whole process of the treatment. If MOAA/S score was greater than 4 points, a single dose of Midazolam (1 mg) is allowed to deepen sedation. if three times of deepen sedation within 15 minutes still can not achieve successful sedation, this progress will define as failure sedation."
89184224|NCT02590848|No Intervention|Group with no intervention|This group will receive healthy recommendations of eating fresh fruits
89384242|NCT01330927|Experimental|VA106483 0.5 mg|
89384243|NCT01330927|Experimental|VA106483 1 mg|
89384244|NCT01330927|Experimental|VA106483 2 mg|
89384245|NCT01330927|Experimental|VA106483 4 mg|
89384246|NCT01330927|Placebo Comparator|Sugar pill|
89384247|NCT04966325|Experimental|Treatment T (Therapeutic dose)|Single oral dose of 200 mg LC350189 (1 × 200 mg tablet) and 2 × placebo tablets.
89384248|NCT04966325|Experimental|Treatment ST (Supratherapeutic dose)|Single oral dose of 600 mg LC350189 (3 × 200 mg tablets).
89384249|NCT04966325|Placebo Comparator|Treatment P (Placebo)|Single oral dose of 3 × placebo tablets.
88858067|NCT05979688|Experimental|Yogic breathing exercise|Participation in a 6 weekly virtual yogic breathing exercise training with 1-3 sessions per week.
88858068|NCT05979688|No Intervention|Waitlist control|Participation in usual daily activities
88858069|NCT05977049|Other|Takotsubo Support Group|Participants diagnosed with Takotsubo Syndrome will be enrolled into the study.
89384250|NCT04966325|Active Comparator|Treatment M (positive control)|Single oral dose of moxifloxacin 400 mg (1 × 400 mg tablet; open label)
88858070|NCT05972512|Placebo Comparator|Placebo|The test treatment will be taken two times a day.
88858071|NCT05972512|Experimental|Botanical Extract of standardised for biotin (1250 mcg)|The standardised botanical extract of biotin is specially formulated for healthier hair and skin. Biotin promotes the hair growth.
88858072|NCT05972512|Experimental|Botanical Extract of standardised for biotin (1250mcg) + 10 mg Silica|The standardised botanical extract of biotin and silica is specially formulated for healthier hair. The combination of biotin and silica will helpful in hair growth, reduces shedding, and improves the health of hair.
88858073|NCT05970796|Experimental|Telehealth group|The telehealth group will receive eight sessions of individualized pelvic floor muscle training provided by a physical therapist via telehealth in 12 weeks.
88858074|NCT05970796|Active Comparator|Face-to-face group|The face-to-face group will be supervised by a female physical therapist who will provide pelvic floor muscle training twice a week for 12 weeks.
88858075|NCT05970718|Experimental|IV Dose Level 1|Randomized 6:2 for single ascending IV dose
88858076|NCT05970718|Experimental|IV Dose Level 2|Randomized 6:2 for single ascending IV dose
88858077|NCT05970718|Experimental|IV Dose Level 3|Randomized 6:2 for single ascending IV dose
88858078|NCT05970718|Experimental|IV Dose Level 4|Randomized 6:2 for single ascending IV dose
88858079|NCT05970718|Experimental|IV Dose Level 5|Randomized 6:2 for single ascending IV dose
88858080|NCT05970718|Experimental|IV Dose Level 6|Randomized 6:2 for single ascending IV dose
88858081|NCT05970718|Experimental|SC Dose Level 1|Randomized 6:2 for single ascending SC dose
88858082|NCT05970718|Experimental|SC Dose Level 2|Randomized 6:2 for single ascending SC dose
88858083|NCT05970718|Experimental|SC Dose Level 3|Randomized 6:2 for single ascending SC dose
89384251|NCT05096377||ESP block group|Diaphragmatic excursion was measured using M-mode ultrasound during normal breathing, deep breathing and with the sniff manoeuvre.
88858084|NCT05970718|Experimental|Optional Cohort 1|Randomized 6:2 for single ascending dose This is an optional cohort, that may be IV or SC and will not exceed highest dose level
88858085|NCT05970718|Experimental|Optional Cohort 2|Randomized 6:2 Randomized 6:2 for single ascending dose This is an optional cohort, that may be IV o SC and will not exceed highest dose level
88858086|NCT05949957|Experimental|Intervention group|"LvL UP App (Smarphone-based conversational agent-delivered holistic lifestyle intervention for the prevention of type 2 diabetes, and common mental disorders [anxiety, depression]).~HAPPY App (Health promotion information, and display health data collected)~Oura ring and Oura App (activity-tracking wearable that collects lifestyle data [physical activity, sleep and heart rate])."
88858087|NCT05949957|Active Comparator|Control group|"HAPPY App (Health promotion information, and display health data collected)~Oura ring and Oura App (activity-tracking wearable that collects lifestyle data [physical activity, sleep and heart rate])."
88858088|NCT05949710|Experimental|aerobic exercise(AE), group A|3 times a week, normal weight
88858089|NCT05949710|No Intervention|control group, group B|control group, normal weight
88858090|NCT05949710|Experimental|aerobic exercise(AE) , group C|3 times a week, overweight
88858091|NCT05949710|Experimental|aerobic exercise(AE), group D|5 times a week, overweight
88858092|NCT05949710|No Intervention|control group, group E|control group, overweight
88858093|NCT05944302|Experimental|Intervention group (EMDR)|"Since the aim of the study was to examine the effect of EMDR on pain, the pain levels of 32 the patients in the intervention group were examined before the first session and after the last session EMDR application. The control measurement was made 1 month after the last session of EMDR. To the initiative group; The first EMDR session was applied after the Personal Information Form and VAS were applied.~The Personal Information Form was applied only once before the first session. Each EMDR session lasts between 45 and 90 minutes. EMDR was applied to the patients between 3-12 sessions. After the last EMDR session, VAS and Individual In-depth Interview Question Form . were applied."
88858094|NCT05944302|No Intervention|Control group|Pre-test (VAS) and post-test (VAS), and 1 month later, control measurement (VAS) data collection forms were applied simultaneously with the admitted 32 the patients. No application was made to the patients except for routine follow-up, anamnesis and medical treatment.
88858095|NCT05933174|Experimental|Prompt-sheet|Question-prompt group patients will receive a simple prompt sheet with the questions with which they will encouraged to use to guide a conversation with their provider at their next visit for routine diabetes care. These questions are based on recommendations from the Agency for Healthcare Research and Quality's Question Builder App and also on recommendations from the Canadian Deprescribing Network which specifically addresses SU use.
89384252|NCT03169153|Other|Lotrafilcon B, then senofilcon C|Lotrafilcon B contact lenses worn first, followed by senofilcon C contact lenses, as randomized. Each product worn bilaterally (in both eyes) for a total duration of 30 (+ 3) days under a daily wear modality for the specific study period. The lenses will be removed every night and cared for with the subject's habitual lens care solution.
88858096|NCT05933174|Active Comparator|Usual education|Control group patients will be sent an information brochure with content from the NIDDK about diabetes medications (https://www.niddk.nih.gov/health-information/diabetes/overview/insulin-medicines-treatments).
88858097|NCT05921565|Experimental|Single Behavioral Arm|Everyone in the study will receive the same type of treatment. They will all receive a treatment period that will last for 8 weeks. All participants will be given a 3% total weight loss goal, a daily calorie goal ranging from 1200-2000 kcal/day based on body weight, and a daily fat goal based on 25% of total daily calories from fat, and an option to stop their food/energy intake at 6pm every day without altering any other meal times. .Participants will also be asked to use two meal replacements per day. Participants will also be given a physical activity goal of 100 minutes per week.
88858098|NCT05913791|Experimental|Nutrients-fortified egg|Each subject will be provided with 2 nutrients-fortified eggs from N&N Agriculture Pte Ltd to consume daily for 12 weeks. They will be instructed to consume the eggs for breakfast with the following preparation methods: hard-boiling, half-boiling and steaming. Subjects are to continue their usual diet.
89184225|NCT02590848|Experimental|Group with walnut intake|This group will receive healthy recommendation of eating fresh fruits + 30 g of walnut kernels per day during 6 months.
89384253|NCT03169153|Other|Senofilcon C, then lotrafilcon B|Senofilcon C contact lenses worn first, followed by lotrafilcon B contact lenses, as randomized. Each product worn bilaterally (in both eyes) for a total duration of 30 (+ 3) days under a daily wear modality for the specific study period. The lenses will be removed every night and cared for with the subject's habitual lens care solution.
89384254|NCT03168919|Experimental|Chemoradiation with MRI assessment|This study has only one arm. The eligible subjects will receive standard of care fractionated radiation therapy along with concomitant temozolomide, which will NOT be changed based on the MRI scans obtained as a part of this study. There is no control or sham group.
89384255|NCT05089669|Experimental|interactive e-book|The experimental group will read an interactive e-book for 90 minutes to learn nasogastric tube feeding.
89384256|NCT05089669|Active Comparator|comparison group|The comparison group will read a paper textbook for 90 minutes to learn nasogastric tube feeding.
89384257|NCT04108819|Experimental|Ketogenic Diet|Participants will receive the ketogenic diet.
89384258|NCT03205163|Experimental|Low Dose Cohort: Advate 25 IU/kg Then BIVV001 25 IU/kg|Participants received a single intravenous (IV) dose of Advate 25 international units per kilogram (IU/kg) on Day 1 of Advate treatment period (3 days) followed by a single IV dose of BIVV001 25 IU/kg in BIVV001 treatment period (BTP) (28 days). Advate treatment period (ATP) consisted of a washout of at least 72 hours which was started from the time of Advate dosing.
89384259|NCT03205163|Experimental|High Dose Cohort: Advate 65 IU/kg Then BIVV001 65 IU/kg|Participants received a single IV dose of Advate 65 IU/kg on Day 1 of ATP (4 days) followed by a single IV dose of BIVV001 65 IU/kg in BTP (28 days). ATP consisted of a washout of at least 96 hours which was started from the time of Advate dosing.
89384260|NCT01781143|Experimental|Perform echo at home.|A group of women that follows an IVF treatment, will perform their echoes at home, instead of always make an appointment in the clinic.
89384261|NCT03681145|Experimental|Group A-Intervention|Participants will receive the study intervention immediately after study enrollment has been completed. The intervention will be delivered in 12, 20-30 minute sessions and text messaging over 4 months (1st session in person, remaining 11 sessions will be remote). The investigators will asses feasibility, acceptability and preliminary clinical outcomes of the Y2TEC intervention at 4 months and 6 months. During the waiting period, participants will receive text messages.
89384262|NCT03681145|Experimental|Group B-Wait-list|Participants will be placed in a waitlist group for four months after study enrollment. Participants will receive the revised study intervention in 12, 20-30 minute sessions and text messaging over 4 months( all sessions remote). The investigators will asses feasibility, acceptability and preliminary clinical outcomes of the Y2TEC intervention at 4 months and 6 months. During the waiting period, participants will receive text messages.
89384263|NCT01759537|Experimental|Implants placed at sub-crestal position.|Ankylos dental endosseous implants-Sub-crestal
89384264|NCT01759537|Active Comparator|Epi-crestal implants.|Ankylos dental endosseous implants-Epi-crestal
88858099|NCT05913791|Placebo Comparator|Regular egg|Each subject will be provided with 2 regular eggs to consume daily for 12 weeks. They will be instructed to consume the eggs for breakfast with the following preparation methods: hard-boiling, half-boiling and steaming. Subjects are to continue their usual diet.
88858100|NCT05908695|Experimental|GV-971|
88858101|NCT05908695|Placebo Comparator|Placebo|
88858102|NCT05895266|Experimental|Part 1: Period 1|In Period 1 on Day 1, participants will receive liquid midazolam.
88858103|NCT05895266|Experimental|Part 1: Period 2|In Period 2 on Day 1, participants will receive ABBV-903 oral tablets. In Period 2 on Day 10, participants will receive liquid midazolam and ABBV-903 oral tablets. Participants will be followed-up for approximately 30 days.
88858104|NCT05895266|Experimental|Part 2: Period 1|In Period 1 on Day 1, participants will receive liquid midazolam.
88858105|NCT05895266|Experimental|Part 2: Period 2|In Period 2 on Day 1, participants will receive ABBV-903 oral tablets. In Period 2 on Day 5, participants will receive liquid midazolam and ABBV-903 oral tablets. Participants will be followed-up for approximately 30 days.
89384265|NCT03204539|Experimental|Alternative Treatment|Half of the participants will be randomized to blinded individualized lot selection for ITI.
89384266|NCT03204539|Other|Standard Treatment|The other half of the participants will receive random lot selection for ITI.
89184226|NCT05234970|Active Comparator|Active Comparator: App 1 Study group (Wysa)|"Wysa App~Wysa provides free, 24/7, emotional support to users through an app-based AI chatbot system. All Wysa chats are anonymous. The AI-based bot responds to the users' emotions and uses CBT, DBT, meditation, breathing, yoga, motivational interviewing, and micro-actions to help the user manage their emotions and encourage mental well-being. In addition, there are over a hundred AI-guided self-care exercises which are backed by science and handpicked by therapists."
89184227|NCT05234970|Placebo Comparator|Placebo Comparator: App 2 Study Group (Harvard College Mobile)|"Harvard College Mobile App~Harvard College Mobile is an informational app developed by the Harvard University, and is designed to help students navigate resources on campus including professional and peer support groups, but does not allow direct messaging through the app. All Harvard students have full access to the contents of this application."
89384267|NCT01331317|Other|Paricalcitol|Crossover study between paricalcitol and placebo
89184228|NCT05319288|Active Comparator|Distal acupoints only group|The DPOG (n=51) will receive acupuncture of distal acupoints only(SI3, EX-UE7) for ALBP.
89184229|NCT05319288|Active Comparator|Local acupoints mainly combined with distal acupoints group|LPMG (n=51) will receive acupuncture of local acupoints mainly(BL23, BL25, BL32) combined with distal points(BL40) for ALBP.
89384268|NCT03638947|No Intervention|Standard of Care|Patient will receive by mail a kit containing swab for the nares, armpit and groin.
89384269|NCT03638947|Active Comparator|Swab kit plus povidone-iodine soap|Patient will receive by mail a kit containing swab for the nares, armpit and groin. In addition the patient will receive decolonization treatment including povidone-iodine soap for presurgical cleansing two days prior to surgery.
89384270|NCT01722019|Active Comparator|radiofrequency ablation with VNUS closure fast|Radiofrequency ablation will be performed with VNUS closure fast.
89384271|NCT01722019|Experimental|laser ablation and Tulip fiber|Laser ablation with a 1470 nm wave length in combination with a new fiber, the Tulip fiber.
89384272|NCT01666873||total knee prosthesis|Patients that undergo a total knee prosthesis.
89184230|NCT04084782||Onychomycosis group|Subjects in this group suffer from onychomycosis of the toenail, who chose to self treat by purchasing the product from an online platform.
89384273|NCT03502681|Experimental|Maximum tolerated dose (MTD) cohort|"The initial 9-12 patients (MTD cohort) will be enrolled to determine safety of avelumab in combination with eribulin mesylate.~Upon determination of maximum tolerated dose (MTD), 12 additional patients will be enrolled in an expansion cohort (efficacy cohort) to determine objective response rate (ORR) at 6 months."
88858109|NCT05880485|Experimental|Online Adaptive Radiotherapy|Patients receive online adaptive radiotherapy with 5-10mm PTV margin. The CTV contours of the following areas: gross tumor volume (GTV), cervix (if not already encompassed by the GTV), uterus, parametria, ovaries, vaginal tissue, obturator nodal chain, internal iliac nodal chain, external iliac nodal chain, presacral nodal chain and common iliac nodal chain. The upper border of CTV is at the level of aortic bifurcation. A dose of 50.4Gy is delivered to CTV with online adaptive radiotherapy.
88858110|NCT05876390||Patients undergoing oncological breast surgery|"mastectomy + reconstruction~simple quadrantectomy~quadrantectomy + sentinel lymph node biopsy~quadrantectomy + axillary hollowing~bilateral interventions will also be considered"
89384274|NCT02860130|Experimental|Prismocitrate 18|
88875410|NCT02928978|Placebo Comparator|Placebo|Participants will receive a placebo (sugar pill) that is designed to mimic ruxolitinib. The placebo will be supplied as four, 5 mg tablets. Participants assigned to this arm will take four, 5 mg tablets by mouth twice daily for 15 days (+/- 5 days).
89384275|NCT02860130|Active Comparator|No Regional Anticoagulation of CRRT Circuit|
89384276|NCT05051605||Vaccinated group|Fifty living donor liver transplantation recipients on maintenance immunosuppressive regimen who would receive COVID-19 vaccine at least 3 months postoperatively.
89384277|NCT04938817|Experimental|Coformulation Pembrolizumab/Quavonlimab|Participants receive pembrolizumab/quavonlimab (coformulation of pembrolizumab 400 mg and quavonlimab 25 mg) administered by intravenous (IV) infusion once every 6 weeks (Q6W) for up to 18 infusions (up to approximately 2 years) or until progressive disease or discontinuation.
89399578|NCT03538028|Experimental|INCAGN02385|Part 1: INCAGN02385 at the protocol-defined starting dose administered every 2 weeks (Q2W), with dose escalation to determine the maximum tolerated dose or pharmacologically active dose. Part 2: INCAGN02385 administered Q2W or Q4W at the recommended dose(s) from Part 1.
89399579|NCT03537950|Experimental|PLC, CBD, CBDV|Dose order: PLC, CBD, CBDV
88875411|NCT02868684||mild traumatic brain injury|
88875412|NCT02868684||Healthy controls|
89184231|NCT02591004|Experimental|Magesium sulphate|"Patients in group A will receive Magesium sulphate 4 gm intravenous (I.V) loading dose over 30 mins & 1 gm/ hour maintenance dose for 24 hours, or till labor occurs ( whichever occurs first).~Doppler on fetal middle cerebral artery"
89384278|NCT04938817|Experimental|Coformulation Pembrolizumab/Quavonlimab + Lenvatinib|Participants receive pembrolizumab/quavonlimab (coformulation of pembrolizumab 400 mg and quavonlimab 25 mg) PLUS lenvatinib 20 mg. Pembrolizumab/quavonlimab will be administered by intravenous (IV) infusion once every 6 weeks (Q6W) for up to 18 infusions (up to approximately 2 years) or until progressive disease or discontinuation. Lenvatinib will be administered orally once-daily (QD) until progressive disease or discontinuation.
88858111|NCT05866757|No Intervention|Continuation - Group 1: Detectable disease|Continuing Maintenance Therapy- Patients with biochemically detectable disease who have failed to achieve Complete remission (CR) or Very good Partial Remission (VGPR) by IMWG criteria and/or MRD-positive and/or high risk features. They will continue maintenance therapy until disease progression with monitoring every 3 months as per standard of care (SOC), or more often if required. In case of disease progression these patients will be switched to a different treatment and withdraw from the study. QOL will be assessed.
89384279|NCT04938817|Experimental|Coformulation Pembrolizumab/Quavonlimab + MK-4830|Participants receive pembrolizumab/quavonlimab (coformulation of pembrolizumab 400 mg and quavonlimab 25 mg) PLUS MK-4830 800 mg. Pembrolizumab/quavonlimab will be administered by intravenous (IV) infusion once every 6 weeks (Q6W) for up to 18 infusions (up to approximately 2 years) or until progressive disease or discontinuation. MK-4830 will be administered by IV infusion once every 3 weeks (Q3W) for up to 36 infusions (up to approximately 2 years) or until progressive disease or discontinuation.
88858112|NCT05866757|No Intervention|Continuation - Group 2 Subgroup A: Remission|"Continuing Maintenance Therapy- Patients in biochemical remission, who meet IMWG criteria for very good partial response (VGPR) or complete response (CR and and sustained MRD (defined as MRD-negative at two time points that are at least 1 year apart) without high risk features. High-risk cytogenetics abnormalities defined as per IMWG criteria (del(17p) and/or t(4;14) and/or t(14;16)) , or any other features suggestive of high risk disease: extramedullary disease, poor response to first line therapy, plasma cell leukaemia, organomegaly secondary to infiltration by multiple myeloma.~Maintenance will continue until disease progression, monitored every 3 months as per SOC or more often if required. In case of disease progression these patients will be switched to a different treatment and withdraw from the study. QOL will be assessed."
88858113|NCT05866757|Other|Discontinuation - Group 2 Subgroup B|Patients who prefer to discontinue maintenance therapy. Patients who have discontinued maintenance therapy earlier than 2 years due to side effects but also achieved sustained MRD negative CR might be also included in this subgroup. This subgroup will be monitored and per SOC with blood tests, and BM MRD by NGF. In case of detectable disease in any of the samples (blood or BM) they will be offered to restart on maintenance therapy. Changing to a different type of treatment could be also offered to these patients, after discussion with treating physician. In case of being switched to a different treatment patient will withdraw from the study. QOL will be assessed
88858114|NCT05865158|Experimental|Institionalized group|Group of institutionalized people with chronic cardiovascular diseases.
88858115|NCT05865158|Experimental|Community-dwelling group|Group of community-dwelling people with chronic cardiovascular diseases.
88858116|NCT05854745|Experimental|Virtual HBB Teaching|HBB Virtual Training (Intervention): Participants will receive a blend of virtual training and telesimulation delivered by pediatricians from Ethiopia. The intervention consists of one day of virtual lectures and didactics from the HBB curriculum and skill assessments using neonatal mannequins.
88858117|NCT05854745|Active Comparator|In-person HBB Teaching|Participants will receive in-person HBB instruction by pediatricians from Ethiopia. The control consists of one day of HBB lectures and didactics and skill assessments using neonatal mannequins.
88858118|NCT05849181|Active Comparator|Moona Active Group|Participants in the Moona Active Group will placed the device between the pillow and the pillow cover, under their head and neck.
88858119|NCT05849181|Sham Comparator|Moona Inactive Group|Participants in the Moona Inactive Group will placed the device between the pillow and the pillow cover, under their head and neck.
88858120|NCT05845021|Experimental|Surgeon-Initiated Bone Health Referral Pathway|Patients assigned in the endocrinology bone health referral pathway would be formally referred by the surgeon to see endocrinology for clearance before undergoing lower extremity arthroplasty. In addition to normal labs, the surgeon will initiate additional bone health labs in these patients before consultation with endocrinology. Endocrinology providers will be available for a virtual consultation to review the patients DEXA and bone health labs; start the patient on the appropriate medication; and provide patient education regarding osteoporosis and bone health. For those undergoing evaluation by endocrinology, these providers will let the surgical team know when and whether the patient has initiated treatment.
89184232|NCT02591004|Active Comparator|Nifedipine|"Patients in group B will receive Nifedipine ( Epilat 10mg ® EIPICO Egypt ), as there is no recommended dose for the use of nifedipine as neuroprotectant, the dose given in this study will be same as that used for tocolysis. Nifedipine wil be given in a loading dose of 40 mg in the 1st hour (10mg will be given every 15 min), then a maintenance dose of 60mg /24 hours, divided in 3 doses.~Doppler on fetal middle cerebral artery"
89384280|NCT04938817|Experimental|Coformulation Favezelimab/Pembrolizumab|Participants receive favezelimab/pembrolizumab (coformulation of favezelimab 800 mg and pembrolizumab 200 mg) administered by intravenous (IV) infusion once every 3 weeks (Q3W) for up to 36 infusions (up to approximately 2 years) or until progressive disease or discontinuation.
89184233|NCT05310786|Other|Site Staff|Providers, Pharmacists, Pharmacy Technicians, Administrators to receive survey assessments
89184234|NCT05310786|Other|Patients|Subset of patients receiving PrIMO care to receive survey assessments
89384281|NCT04114994||Alzheimer's Disease|
89384282|NCT04114994||Mild Cognitive Impairment|
89384283|NCT04114994||Frontotemporal Dementia|
89384284|NCT04114994||Vascular Dementia|
89384285|NCT04114994||Parkinson Disease|
89384286|NCT04114994||Traumatic Brain Injury (TBI)|
89384287|NCT04114994||Multiple Sclerosis|
89384288|NCT04114994||No diagnosis|
89384289|NCT01366729|Experimental|TheraTogs|
89384290|NCT01366729|Active Comparator|Cane walking|
89384291|NCT04485325|Active Comparator|Tofacitinib|Tofacitinib (Xeljanz®; 5 mg twice daily, p.o.)
89384292|NCT04485325|Active Comparator|Etanercept|Etanercept (Enbrel®; 50 mg once per week, s.c.)
89184235|NCT04085562|Experimental|Amlodipine|Hypertensive patients on dialysis receiving Amlodipine 5-10 mg tablet daily alone or as part of antihypertensive regimen.
89184236|NCT04085562|Experimental|Bisoprolol|Hypertensive patients on dialysis receiving Bisoprolol 5-10 mg tablet daily alone or as part of antihypertensive regimen.
89184237|NCT02591160|Other|HCTZ cessation|Patients will stop taking HCTZ for 3 months while submitting serial blood and 24 hour urine samples
89184238|NCT05307978|Experimental|Cohort 1|Participants will receive a single dose of 5 mg of ALXN1910 IV or Placebo IV.
89184239|NCT05307978|Experimental|Cohort 2|Participants will receive a single dose of 15 mg of ALXN1910 SC or Placebo SC.
88875413|NCT02594826|Experimental|Culturally appropriate intervention|Culturally appropriate, church-based intervention focused on cervical cancer and navigation assistance.
89184240|NCT05307978|Experimental|Cohort 3|Participant will receive a single dose of 15 mg of ALXN1910 IV or Placebo IV.
89184241|NCT05307978|Experimental|Cohort 4|Japanese participants will receive a single dose of 15 mg of ALXN1910 SC or Placebo SC.
88875414|NCT02594826|Active Comparator|General health education control|General health and cancer education on nutrition, regular check-ups, tobacco use, and cancer screening.
88875415|NCT02595684|Experimental|Tadalafil|Tadalafil capsules
88875416|NCT02595684|Placebo Comparator|Placebo|Calcined magnesia capsules
88875417|NCT02599194|Experimental|18F-FSPG and 18F-FDG Intragroup Comparision|Participants sequentially receive radioimaging agents 18F-FSPG and 18F-FDG IV followed by PET/CT scan with 60 minutes.
88875418|NCT02604810|Active Comparator|IGIV-C 10%|IV dose of Immune Globulin Injection (Human), 10% Caprylate/Chromatography Purified (Grifols)
89184242|NCT05307978|Experimental|Cohort 5|Participants will receive a single dose of 45 mg of ALXN1910 SC or Placebo SC.
89384293|NCT03610178|Active Comparator|very tight glycemic targets|
89184243|NCT05307978|Experimental|Cohort 6|Participants will receive a single dose of 135 mg of ALXN1910 SC or Placebo SC.
89184244|NCT04084002||Patients with subacute chronic stroke|Patients with subacute chronic stroke
89184245|NCT04084002||Control group|Healthy control group age and sex matched
89184246|NCT04082832|Active Comparator|Cu(II)ATSM|Cu(II)ATSM Powder for Oral Suspension, 36 mg, to be reconstituted with Diluent (15 mL of sugar-free flavored pharmaceutical syrup) to provide an oral suspension for immediate consumption. Specified dose is 72 mg (2 bottles) taken fasting, before breakfast each day.
89384294|NCT03610178|Active Comparator|tight-moderate glycemic targets|
89384295|NCT03610178|No Intervention|Control group|Only observation in women with normal glucose tolerance
89384296|NCT02033798|Experimental|Tamsulosin|The dosage form of Tamsulosin is tablet, dosage is 0.2mg, frequency is once daily and duration is 6 months.
89384297|NCT03609632|Experimental|OGTT with 13C-labelled leucine|Intake of 75g of glucose with 1g of 13C leucine pre-feeding
89384298|NCT04491110|Experimental|Experimental: Carer music.|Listening to pre-recorded and selected music preferred by the carer, half an hour for 7 days.
89384299|NCT04491110|Sham Comparator|Sham Comparator: Carer.|Basic therapeutic education repetition performed to all carer through earphones, half an hour for 7 days.
89384300|NCT02986854|Experimental|Menveo-Menveo Group|Approximately 300 subjects, who were vaccinated with a single dose of Menveo 4 to 6 years before, will receive one dose of MenACWY-CRM at Day 1.
89384301|NCT02986854|Experimental|Menactra-Menveo Group|Approximately 300 subjects, who were vaccinated with a single dose of Menactra 4 to 6 years before, will receive one dose of MenACWY-CRM at Day 1.
89384302|NCT02986854|Active Comparator|Naive Group|Aproximately 100 subjects, of similar age to subjects enrolled in other primed groups, who have not received any meningococcal vaccination, will receive one dose of MenACWY-CRM at Day 1.
89384303|NCT02887183|Other|LCZ696(sacubitril/valsartan)|"Subjects received sacubitril/valsartan (LCZ696) on Day 1. The initial dose was determined by the investigator and per the approved indication described in the United States prescribing information/package insert (USPI). The three doses available were: 24/26 mg (Dose Level 1), 49/51mg (Dose Level 2) and 97/103mg (Dose Level 3).~Titration of the dosage were performed per USPI at 2 to 4 week intervals as clinically tolerated until maximal tolerated or target dosage was achieved. Target dosage was sacubitril/valsartan 97/103 mg twice daily."
89384304|NCT03167359|Experimental|Participants with Stage 0-III breast cancer|Women with Stage 0-III breast cancer, treated with breast conserving surgery or mastectomy and clear margins, will receive 15 doses of radiation over three weeks.
89384305|NCT03658356|Placebo Comparator|Verbal Instruction on Urine collection|"At initial prenatal visit, pregnant patients will be given verbal instructions on how to collect a urinary sample for culture.~Intervention: Pt will be given verbal instruction to collect urine"
89384306|NCT03658356|Active Comparator|Video instruction on urine collection|"At initial prenatal visit, pregnant patients will watch a video on how to collect a urinary sample for culture~Intervention: Patient will be asked to watch a video on how to collect a urine sample"
89384307|NCT03660462|Active Comparator|FeSO4 fortified rice test meal|
89384308|NCT03660462|Experimental|FePO4 fortified rice test meal|
89384309|NCT03660462|Experimental|HiFePO4 1 fortified rice test meal|
89384310|NCT03660462|Experimental|HiFePO4 2 fortified rice test meal|
88858121|NCT05845021|No Intervention|Standard of Care|The control arm will be composed of patients identified in the osteoporotic range like the endocrinology bone health referral pathway. These patients will be told by the surgeon that the patient has osteoporosis based on the DEXA scan and will be told to follow-up these results with the patient's primary care provider. These patients do not need bone health clearance before undergoing surgery. Only serum 25-hydroxyvitamin D levels will be added on to the patient's standard of care pre-operative labs. The control arm is the current standard of care. Comparing this pathway to the endocrinology referral pathway permits an assessment on the efficacy of the new pathway.
88858122|NCT05836779|Experimental|CBL-514 up to 320mg|Participants will receive up to 320 mg per treatment session at intervals of approximately 4 weeks for up to a maximum of 2 treatments.
89384311|NCT01331395|No Intervention|IVF-No Acupuncture|IVF with no Traditional Chinese Medicine: Acupuncture
89384312|NCT01331395|Active Comparator|IVF-Acupuncture|IVF with Traditional Chinese Medicine: Acupuncture
89384313|NCT03660306||opioid anesthesia|classical anesthesia using sufentanil to block sympathetic reactions during surgery. This decision is based on the anesthesiologist experience and not determined by the patient or procedure.
88858123|NCT05834309|No Intervention|Control group|Patients in this group will receive clinical usual care.
88858124|NCT05834309|Experimental|Exercise training group|An individualized multicomponent exercise program including resistance, aerobic, balance and flexibility exercises.The duration of the sessions will be 45 minutes, and the duration of the whole program will be 6 weeks, equivalent to 12 sessions.
88858125|NCT05819827||Patients with genitourinary cancers|Genitourinary medical oncologists and study coordinators will identify patients with genitourinary cancers (i.e., bladder cancer, prostate cancer, and testicular cancer) who will receive moderate to high emetogenic chemotherapy regimen.
89384314|NCT03660306||opioid free anesthesia|anesthesia using non opioids like dexmedetomidine, lidocaine, magnesium and ketamine to block sympathetic reactions during surgery. This decision is based on the anesthesiologist experience and not determined by the patient or procedure.
89399580|NCT03537950|Experimental|PLC, CBDV, CBD|Dose order: PL, CBDV, CBD
89399581|NCT03537950|Experimental|CBD, PLC, CBDV|Dose order: CBD, PLC, CBDV
89002981|NCT05918718|Experimental|methotrexate|The first group will receive a single dose (50 mg/m2) of methotrexate The beta-hcg level is measured on the first day, and the hcg serum level is routinely measured on the fourth, seventh and fourteenth day.
89399582|NCT03537950|Experimental|CBD, CBDV, PLC|Dose order: CBD, CBDV, PLC
89399583|NCT03537950|Experimental|CBDV, PLC, CBD|Dose order: CBDV, PLC, CBD
89384315|NCT04859257||Disease Group|Cohort 1 (Disease Group) of the study will collect blood and urine samples from participants who are either diagnosed with Chronic Fatigue Syndrome (CFS) or Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome (ME/CFS) or experience symptoms of profound fatigue based on the cohort specific inclusion criteria.
89384316|NCT04859257||Control Group|Cohort 2 (Control Group) of the study will collect blood and urine samples from participants who have NOT been diagnosed with Chronic Fatigue Syndrome (CFS) or Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome (ME/CFS) or experience symptoms of profound fatigue based on the cohort specific exclusion criteria.
88858126|NCT05816473|Experimental|Large Language Model-based Interaction|LLM-powered chatbot with the machine learning dashboard to provide the risk assessment and provide rationale based on interpretability metrics provided by the dashboard in which study participants can directly interact with using natural language. Participants will be provided the Generative Pre-trained Transformer (GPT) chatbot powered machine learning model dashboard.
88858127|NCT05816473|No Intervention|Machine Learning Dashboard|Machine learning algorithm output with an interactive dashboard that can be used to explain, or interpret the input factors that contribute most towards the generated risk score. Participants will have access to the machine learning dashboard only.
88858128|NCT05811364|Active Comparator|VBX Device Group|Subject in this group will receive treatment with the GORE VIABAHN® VBX Balloon Expandable Endoprosthesis (VBX)
88858129|NCT05811364|Active Comparator|BMS Control Group|Subjects in this group will receive treatment with a commercially available bare metal stent (BMS) that is approved for treatment of the disease
88858130|NCT05806138|Experimental|Vericiguat plus optimal medical therapy|For patients randomized to vericiguat, a starting dose of 2.5mg will be initiated at the randomization visit. At pre-specified titration visits, subjects will be up-titrated to vericiguat 5mg and then to the target dose of vericiguat 10mg using titration criteria based on mean systolic blood pressure and evaluation for clinical symptoms. Vericiguat will be administered in the background of optimal medical therapy for cardiomyopathy/heart failure.
88858131|NCT05806138|Active Comparator|Optimal medical therapy|For patients randomized to the control group, optimal medical therapy for cardiomyopathy/heart failure will be instituted throughout the study period.
88858132|NCT05789368|Placebo Comparator|Placebo sachet|consume 1 sachet per day
88858133|NCT05789368|Experimental|VeCollal sachet|consume 1 sachet per day
88858134|NCT05789368|Active Comparator|Collagen sachet|consume 1 sachet per day
88858135|NCT05788692|Experimental|electric toothbrush using a toothbrushing assisting application|Children will be brushing with an electric toothbrush two times/day using a toothbrushing assisting application
88858136|NCT05788692|Experimental|electric toothbrush without the application|Children will be brushing with an electric toothbrush two times/day without the toothbrushing assisting application
88858137|NCT05788692|Experimental|manual toothbrush using a toothbrushing assisting application|Children will be brushing with a manual toothbrush two times /day using a toothbrushing assisting application
88858138|NCT05788692|Experimental|manual toothbrush without using the application during brushing|Children will be brushing with a manual toothbrush two times /day without using the toothbrushing assisting application
88858139|NCT05786768|Active Comparator|Rituximab 375 mg/m2|single infusion of Rituximab (375 mg/m2)
88858140|NCT05786768|Experimental|Obinutuzumab 300 mg/1.73 m2|single infusion of Obinutuzumab 300 mg/1.73 m2
89384317|NCT03658200|Active Comparator|FAST software|Patient referred for chest CT and scanned with delay based on bolus tracking with FAST software. intervention: FAST START Software delay
89399584|NCT03537950|Experimental|CBDV, CBD, PLC|Dose order: CBDV, CBD, PLC
88858141|NCT05777343|Experimental|Intervention 1|Participants will receive exercise, PNE and online cognitive training sessions.
88858142|NCT05777343|Active Comparator|Intervention 2|Participants will receive exercise and pain neuroscience education (PNE).
88858143|NCT05777343|Active Comparator|Intervention 3|Participants will receive online cognitive training sessions.
88858144|NCT05765084|Experimental|Single arm|Standard of care chemotherapy, complemented with atezolizumab and WT1/DC vaccination
88858145|NCT05763056|Active Comparator|McGrath videolaryngoscopy|It is a portable videoryngoscope weighing only 325 grams. The CameraStickTM component consists of a light source and a miniature camera, and the image is displayed on a 1.7 inch LCD (Liquid Crystal Display) screen mounted on top of the laryngoscope handle. At the same time, the LCD screen maintains visual contact with the patient and the laryngoscope, can be rotated up to 90°, allowing the user to work in a comfortable posture while performing tracheal intubation. The blade length is suitable for children over 5 years old and adults, thus reducing the trouble of storing different sized blades in the emergency intubation trolley. The blades are sterile and there is no risk of contamination as they are disposable.
88858146|NCT05763056|Active Comparator|C-MAC videolaryngoscopy|Considering the importance of first attempt success in intubation, their use in emergency airway management has increased due to the high first attempt success rate in C-MAC VLs. In patients with cervical spine injury, semi-rigid collars used to prevent neck extension and neck movements cause poor laryngeal vision with Direct laryngoscope and difficulty intubation. C-MAC Video laryngoscope provides a better laryngeal view in these patients
88858147|NCT05763056|Active Comparator|Direct laryngoscopy|Macintosh laryngoscopy is still one of the most commonly used advanced airway methods today. For an ideal glottis view in direct laryngoscopy, the mouth and larynx should be in alignment. For this, longitudinal flexion and head extension maneuvers are performed. Reasons such as the clinical situation during intubation and the anatomical variation in the patient may prevent this maneuver from being performed.
89184247|NCT04082832|Placebo Comparator|Placebo Powder for Oral Suspension|Placebo Powder for Oral Suspension, to be reconstituted with Diluent (15 mL of sugar-free flavored pharmaceutical syrup) to provide an oral suspension for immediate consumption. Specified dose is 72 mg (2 bottles) taken fasting, before breakfast each day.
89184248|NCT05038488|Experimental|MIB-626|Oral administration of MIB-626 substantially raises the intracellular NAD+ levels and activates signaling mechanisms that regulate inflammation and cell survival, downregulates the NLRP3 inflammasome, and attenuates the inflammatory response in a number of experimental models, and protects against tissue damage induced by pro-inflammatory cytokines.
89184249|NCT05038488|Placebo Comparator|Placebo Tablet|"A placebo control will be supplied. Participants randomized to placebo will receive matching tablet.~Matching placebo tablets will be provided by the study's Sponsor, Metro International Biotech, LLC."
89184250|NCT05038488|Other|Home Treatment|Participants, who are discharged from the hospital before the completion of the 14-day intervention period, will be provided sufficient study medication to take home with them so they can continue to take the medication twice daily for the remaining duration of the 14-day intervention period.
89184251|NCT05036850||Incident and Prevalent Patients|Incident and prevalent patients diagnosed with a kidney disease at participating centres
89184252|NCT02589366|Experimental|Lymphoseek plus Vital Blue Dye|Lymphoseek plus Vital Blue Dye: Single dose of 50 µg Lymphoseek radiolabeled with 75 MBq Tc 99m injected pre-operatively followed by next day intra-operative administration of vital blue dye.
89384318|NCT03658200|Active Comparator|Control|Patient referred for chest CT and scanned with delay based on bolus tracking without FAST software. Intervention: Manual bolus tracking delay
89384319|NCT03661008||Adolescents with paternal involvement|
89384320|NCT03661008||Adolescents without paternal involvement|
89384321|NCT03659994|Experimental|Vitabeard High Dose|3 capsules of multivitamin Vitabeard
89002982|NCT05918718|Experimental|Letrozole BD|The first group will receive letrozole is given in the form of 2.5 mg tablets twice a day for 10 days. And on the fourth, seventh and fourteenth day, the HCG level is measured.
89002983|NCT05918718|Experimental|Letroozole TDS|letrozole is given in the form of 2.5 mg tablets 3 times a day for 5 days, and hCG levels are measured on days 4, 7, and 14.
89002984|NCT05916313|Experimental|BI 764532: Part A - Dose escalation cohort|
89002985|NCT05916313|Experimental|BI 764532: Part B - Dose expansion cohort|
89002986|NCT05904990|Experimental|traditional exercise therapy only|This 50-minute program included a 10-minute warm-up phase (treadmill walking at a comfortable speed), 30 minutes of stretching exercises for (glutei, paraspinal muscles, hamstring, pectoralis, scalenus, intercostal muscles, and trapezius), and a 10-minute cool-down involving self-stretching and respiratory exercises.
89002987|NCT05904990|Experimental|HILT alongside traditional exercise therapy,|pulsed Nd: YAG laser device (HIRO 3.0; ASA Laser, Arcugnano, Italy). This equipment delivers pulsed laser light at a wavelength of 1,064 nm, with a very high peak power of 3 kW and energy density ranging from 360 to 1,780 mJ/cm2.
89002988|NCT05904080|Active Comparator|Arm A (nivolumab, ipilimumab)|Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo CT or MRI at baseline, every 3 cycles on treatment, and every 8-12 weeks during follow-up. Patients may also undergo collection of blood samples at baseline, day 1 of cycle 2, and at progression or end of treatment.
89002989|NCT05904080|Experimental|Arm B (nivolumab, ipilimumab, cabozantinib)|Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 1 and cabozantinib S-malate PO daily on days 1-28 of each cycle. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients may continue with cabozantinib S-malate after 2 years per treating investigator. Patients undergo CT or MRI at baseline, every 3 cycles on treatment, and every 8-12 weeks during follow-up. Patients may also undergo collection of blood samples at baseline, day 1 of cycle 2, and at progression or end of treatment.
89002990|NCT05903378|Experimental|Relational touch group|Touch in care aims to improve the patient's perception of potentially painful or anxiety-provoking acts of care. It is based on techniques of skin contact, developing and deepening.
89002991|NCT05903378|No Intervention|Standard care group|Routine care without relational touch practice.
89002992|NCT05902767|Experimental|Nut Group|Participants will receive a supply of mixed nuts containing: 1 Brazil nut (~3g), walnuts (15g), hazelnuts (7g), and almonds (7g) to be consumed daily for 90 days. They will also receive dietary counselling on how to follow the Australian Dietary Guidelines.
89002993|NCT05902767|Other|Control Group|Participants will follow the same protocol as the Nut group regarding appointments and collection of information. At the visits, they will receive dietary counselling on how to follow the Australian Dietary Guidelines
89002994|NCT05895786|Experimental|PF-06823859|Participants will receive PF-06823859 via intravenous infusion every 4 weeks.
89002995|NCT05895786|Placebo Comparator|Placebo|Participants will receive placebo via intravenous infusion every 4 weeks.
89184253|NCT05218044|Other|Cryoablation|Phase I, single-arm study to evaluate the ability of cryoablation to achieve complete ablation of DCIS in the cryoablation zone of necrosis as a potential alternative to surgery.
89184254|NCT00919230|No Intervention|no treatment|no iron given
89184255|NCT00919230|Experimental|ferrous sulphate|iron given
89184256|NCT02589132|No Intervention|Standard of Care|Families receiving Standard of Care
89184257|NCT02589132|Experimental|Mobile-Thrive application|Standard care plus Mobile-Thrive app
89384322|NCT03659994|Experimental|Vitabeard Mid-Dose|2 Capsules of multivitamin Vitabeard, 1 Capsule of Placebo
89384323|NCT03659994|Experimental|Vitabeard Low-Dose|1 Capsule of multivitamin Vitabeard, 2 Capsules of Placebo
89384324|NCT03659994|Placebo Comparator|Placebo|3 Capsules of Placebo
89384325|NCT01068600|Experimental|Indacaterol 75 µg|"Indacaterol 75 µg inhaled once daily in the morning via Concept1, a single dose dry powder inhaler (SDDPI), for 12 weeks.~Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) albuterol was available for rescue use throughout the study."
89002996|NCT05890079|Active Comparator|Subcostal transversus abdominis plane block group|The patients in subcostal transversus abdominis plane block group will be received subcostal transversus abdominis plane block and patient controlled analgesia with morphine for postoperative analgesia
89184260|NCT00918996|Experimental|No Bladder Flap Group|Uterine incision made 1 cm above the vesico-uterine reflection without incision and dissection of the bladder peritoneum.
89184261|NCT00918996|No Intervention|Bladder Flap Group|Standard cesarean section technique with incision and dissection of a bladder flap prior to uterine incision.
89384326|NCT01068600|Placebo Comparator|Placebo|"Placebo to indacaterol inhaled once daily in the morning via Concept1, a SDDPI, for 12 weeks.~Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) albuterol was available for rescue use throughout the study."
89384327|NCT01067976|Experimental|Gadobutrol (Gadavist, BAY86-4875)|Patients first received an unenhanced MRM, followed by a gadobutrol-enhanced MRM. Gadobutrol was administered at the standard dose of 0.1 mmol/kg bw [0.1 ml/kg bw] as an intravenous injection (i.v.) injection at a rate of 2 ml/sec. UMRM and CMRM image sets were evaluated in a randomized fashion. After the evaluation of the UMRM or CMRM the respective XRM was added and evaluated together with the UMRM images.
89384328|NCT02858492|Experimental|Subjects receiving GSK2982772 60 mg|Enrolled subjects will receive GSK2982772 60 mg thrice daily (approximately 8 hours apart) for 84 days.
89184262|NCT00919308||Control, traditional bedside training|Postgraduate year 1 and 2 residents who are trained in central venous catheter insertion according to the traditional, bedside apprenticeship model.
89184263|NCT00919308||Simulation training|Postgraduate year 1 and 2 residents who complete a hands-on ultrasound guided simulation training protocol on a partial task training simulator until competence is achieved as measured by: the ability to cannulate a simulated vein under ultrasound guidance on first pass in five consecutive attempts and correct insertion of a central venous cannulator on a partial task training simulator with no technical errors.
89384329|NCT02858492|Experimental|Subjects receiving Placebo|Enrolled subjects will receive placebo thrice daily (approximately 8 hours apart) for 84 days.
88858148|NCT05754125|Experimental|Di-Leucine supplement|Participants will consume a amino acid supplement containing Di-Leucine following resistance exercise and their whole body anabolism will be determined over the subsequent 6 hours
89384330|NCT01067508|Experimental|Fiji Water|Participants are asked to consume one liter of this silicon-rich water daily for three months.
89384331|NCT01067508|No Intervention|Aquafina Water|Participants are asked to drink one liter of this deionized water daily for three months.
89384332|NCT03609554|Experimental|Pilates|The Pilates exercise programme was implemented over 6 weeks, with 2 sessions/week (55 minutes/session).
89384333|NCT03609554|No Intervention|Control|Adolescents assigned to the CG did not receive any structured exercise programme; they just attended their usual Physical Education sessions.
89384334|NCT01067352|Experimental|Group A (A1)|Participants were allocated to Group A if were still third percentile for height (according to the Tanner reference table) at the age of 4-6 years. Group A would be then randomized to receive Saizen at the daily dose of 0.035 milligram (mg)/kilogram (kg) (Group A1) or no treatment (Group A2) for two years.
89384335|NCT01067352|No Intervention|Group A (A2)|Participants were allocated to Group A if were still third percentile for height (according to the Tanner reference table) at the age of 4-6 years. Group A would be then randomized to receive no treatment (Group A2) for two years.
89384336|NCT01067352|No Intervention|Group B|Participants were allocated to Group B being third percentile (thus showing a spontaneous catch-up growth).
89384337|NCT02986074|Experimental|Anatomical midline lead first|subjects in this group will receive stimulation first using an anatomical midline placed lead and subsequently using a paresthesia mapping placed lead
89384338|NCT02986074|Experimental|Paresthesia mapping lead first|subjects in this group will receive stimulation first using a paresthesia mapping placed lead and subsequently using an anatomical midline placed lead
89384339|NCT03658122|Experimental|Parent-Child Care Treatment|Participants receive PC-CARE treatment immediately following the pre-treatment assessment.
89384340|NCT03658122|Other|Waitlist Control then Parent-Child Care|Participants wait approximately 2 months with no intervention before completing another pre-treatment assessment (post-waitlist assessment) and receiving PC-CARE treatment.
88858149|NCT05754125|Experimental|BCAA Supplement|Participants will consume a amino acid supplement containing branched chain amino acids (BCAA) following resistance exercise and their whole body anabolism will be determined over the subsequent hours
88858150|NCT05754125|Experimental|Collagen Supplement|Participants will consume a amino acid supplement containing collagen protein following resistance exercise and their whole body anabolism will be determined over the subsequent hours
89184264|NCT02588196|Experimental|treatment of dexamethasone group|
89184265|NCT02588274|Experimental|Acupuncture|Zhongliao (BL 33), Shenshu (BL 23), Huiyang (BL 35), and Sanyinjiao (SP 6) acupuncture points (Table 1). After patients are in prone position with relax, the investigators will use 75% alcohol pads to sterile the skin around the acupuncture points, and then insert steel needles (Huatuo, Suzhou, China 0.3mm*40mm/0.3mm*75mm) into the acupuncture points. For bilateral Zhongliao (BL 33), the needle will be inserted into about 50-60mm with 45 degree, for Huiyang (BL 35), the needle will be inserted into 50-60mm. for Shenshu (BL 23) and Sanyinjiao (SP 6), the needles will be inserted vertically to a depth of 25-30 mm. The treatment sessions are 24 after baseline, 3 times a week, and the each time the patients will accept a 30 minutes treatment.
89184266|NCT02588274|Placebo Comparator|placebo needle|The participants in placebo needle group will receive placebo needle at the same acupuncture points to treatment group. Investigators will use a sort of blunt needle that cannot penetrate skin and stimulate deep tissues while the thrusting and twisting manipulation will be used by acupuncturists to mock the treatment procedure and blind the patients. The duration and frequency of sessions are same to the treatment group.
89184267|NCT02588820|Experimental|Antiretroviral treatment|
89384341|NCT02920242|Experimental|Rifaximin|Patients received Rifaximin 200 mg tablet 3 times per day for 3 days.
89384342|NCT02920242|Active Comparator|Xifaxan|Patients received Xifaxan 200 mg tablet 3 times per day for 3 days.
89384343|NCT02920242|Placebo Comparator|Placebo|Patients received placebo tablet 3 times per day for 3 days.
89384344|NCT02985996|No Intervention|Phase I/Pre-Drug|Ten participants will be asked to complete study phase 1. Participants will be asked to provide blood and urine samples and undergo penile, urethral, and rectal swabs. Up to 12 rectal biopsies will be taken.
88875419|NCT02604810|Experimental|IGSC 20%|Immune Globulin Subcutaneous (Human), 20% Caprylate/Chromatography Purified (Grifols)
88858151|NCT05747274||The Divat COHORT|"The DIVAT cohort (Computerized and Validated Data in Transplantation) developed by the Immunology and Nephrology Department of the University Hospital of Nantes (France) , is a biocollection database linked to clinical data and plasma, serum, blood cells and urines of all kidney recipients from Nantes, Paris-Necker, and Lyon centres. The clinical and biological parameters are collected at 3 months, 6 months, 1 year and then every year.~All available specimens in the DIVAT cohort that:~meet inclusion and exclusion criteria of this study AND~are usable in terms of quality, integrity, and quantity. will be analysed for this study in order to maximise the power and generalisability of the results."
88858152|NCT05745350|Experimental|Treatment|
89384345|NCT02985996|Experimental|Phase II/Genvoya|Participants will receive one dose Genvoya. Participants will be asked to provide blood and urine samples and undergo penile, urethral, and rectal swabs. Up to 12 rectal biopsies will be taken.
89384346|NCT02985996|Experimental|Phase II/Truvada|Participants will receive one dose of Truvada. Participants will be asked to provide blood and urine samples and undergo penile, urethral, and rectal swabs. Up to 12 rectal biopsies will be taken.
89384347|NCT02985996|Experimental|Phase III/Genvoya|Participants will receive Genvoya once daily for ten days. Participants will be asked to provide blood and urine samples and undergo penile, urethral, and rectal swabs. Up to 12 rectal biopsies will be taken.
89384348|NCT02985996|Experimental|Phase III/Truvada|Participants will receive Truvada once daily for ten days. Participants will be asked to provide blood and urine samples and undergo penile, urethral, and rectal swabs. Up to 12 rectal biopsies will be taken.
89384349|NCT03225833|Experimental|WVE-120101 (Dose A) or placebo|
89384350|NCT03225833|Experimental|WVE-120101 (Dose B) or placebo|
88858153|NCT05735366|Experimental|Part1: Dose Escalation part|Patients will receive SAIL66 as a IV infusion at escalated doses.
88858154|NCT05735366|Experimental|Part2: Expansion part|Patients will receive SAIL66 as a IV infusion at the recommended dose.
88858155|NCT05734508|Experimental|MVA-BN vaccine|2 doses of 0.5 mL MVA-BN vaccine injected subcutaneously and given at least 28 days apart
88858156|NCT05731193|Experimental|Exposed group (EXP)|Exposed group (EXP) - 35 students. EXP group will learn pathological and nonpathological sounds for 3 days.
88858157|NCT05717387|Experimental|Time-restricted eating|Participants in the TRE group will be instructed to eat during a window of 8 h/d (8 am to 4 pm)
89384351|NCT03225833|Experimental|WVE-120101 (Dose C) or placebo|
89384352|NCT03225833|Experimental|WVE-120101 (Dose D) or placebo|
89384353|NCT03225833|Experimental|WVE-120101 (Dose E) or placebo|
89384354|NCT03659838||Participants|Schoolchildren from the canton of Zürich aged 6 to 16 years
88858158|NCT05717387|Experimental|the 5:2 diet|Participants in the 5:2 diet group will be instructed to consume 500-600 kcal/d on fast days and eat ad libitum on feast days.
89384355|NCT03659760|Experimental|Group Isolated|Group Isolated (Group II) (eyes closed with patch and ear plugged; between 24:00-06:00)
88858159|NCT05717387|No Intervention|Control|Participants in the control group will receive a general lifestyle counseling.
89384356|NCT03659760|No Intervention|Group Disrupted|Group Disrupted (Group I) (exposed to ambient light and noise)
89384357|NCT03659682|Active Comparator|semaglutide|Ozempic- 1.0 mg administered subcutaneously once weekly
89384358|NCT03659682|Placebo Comparator|placebo|Placebo, 1.0 mg administered subcutaneously once weekly
89384359|NCT03203447|Active Comparator|Active|Lucentis (0.5 mg/0.05 mL), IVT injection + CLS-TA (4 mg/0.10 mL), SC injection or Avastin (1.25 mg/0.05 mL), IVT injection + CLS-TA (4 mg/0.10 mL), SC injection
89384360|NCT03203447|Sham Comparator|Control|Lucentis (0.5 mg/0.05 mL), IVT injection + sham SC procedure or Avastin (1.25 mg/0.05 mL), IVT injection + sham SC procedure
89384361|NCT03659526||Control|Healthy volunteers or if they have had normal invasive or CT coronary arteriography or other functional imaging test
89384362|NCT03659526||Deformation imaging|Significant coronary disease (diameter stenosis >50%) has been diagnosed on arteriography or on CT angiography. Fractional flow reserve will be measured as the reference criterion.
89384363|NCT03659526||High p(CAD)|Intermediate-to-high probability of significant epicardial coronary disease (>50%).
89384364|NCT03659526||All comers|Probability of severe disease ranging from 15 to 85%.
89384365|NCT02858726|Experimental|CR845 0.5mcg/kg|Part A of study: IV CR845 0.5 mcg/kg administered after each dialysis session (3 times/week)
89384366|NCT02858726|Experimental|CR845 1 mcg/kg|Part A of study: IV CR845 1 mcg/kg administered after each dialysis session (3 times/week)
89384367|NCT02858726|Experimental|CR845 1.5mcg/kg|Part A of study: IV CR845 1.5 mcg/kg administered after each dialysis session (3 times/week)
88858160|NCT05717075|Other|Group A (Parents Round, then no special round)|Parents of enrolled patient receive the intervention for two weeks after the consent to the study (Period I). For two weeks after the intervention in Period I, the parents do not receive the intervention (Period II).
88858161|NCT05717075|Other|Group B (no special round, then Parents Round)|Parents of enrolled patient receive no intervention for two weeks after the consent to the study (Period I). For two weeks after Period I, the parents receive the intervention (Period II).
88858162|NCT05711134|Experimental|Serial In-Person Feedback|Providers are given recurring individualized in-person feedback on their practice patterns.
88858163|NCT05711134|Experimental|In-Person Feedback with Serial Electronic Feedback|Providers are given one-time individualized in-person feedback on their practice patterns, followed by recurrent individualized electronic feedback.
89384368|NCT02858726|Placebo Comparator|Placebo|Part A of study: IV Placebo administered after each dialysis session (3 times/week)
89384369|NCT03203291|Experimental|Tethered Pelvic Assist Device (TPAD) Treatment|All participants will receive 5 consecutive days of training with the TPAD (tethered pelvic assist device) with testing completed before training, on completion of training and at a 1-week follow up.
89384370|NCT03609476|Active Comparator|Standard of care group|No saline instillation
89384371|NCT03609476|Active Comparator|Room temperature saline group|room temperature saline instillation
89384372|NCT03609476|Active Comparator|Warmed saline group|warmed saline instillation
89384373|NCT04549610|Experimental|HMB supplementation|"The experimental procedure for each participant in this group includes a one week HMB supplementation.~HMB will be administered in the form of blinded capsules containing 0.5 g HMB per capsule. The capsules will be ingested with at least 250 mL of water. Each athlete will ingest 8 capsules (4 x 2 capsules) of HMB in a split dose per day. On training days the supplements will be taken in the morning (2 capsules), 1.5 hours before training session (2 capsules), immediately after training (2 capsules) and before sleep (2 capsules). On rest days the supplements will be taken in the morning (2 capsules), around midday (2 capsules), in the afternoon (2 capsules) and before bedtime (2 capsules) at possibly similar (approx. 4 hours) intervals during the day."
89384374|NCT04549610|Placebo Comparator|Placebo treatment|The experimental procedure for each participant in this group includes a one-week placebo (PLA) administration. PLA (corn starch) will be placed in the blinded capsules form. PLA will be ingested with at least 250 mL of water. Each participant in this group will ingest 8 placebo capsules a day. On training days the PLA capsules will be taken in the morning (2 capsules), 1.5 hours before training session (2 capsules), immediately after training (2 capsules) and before sleep (2 capsules). On rest days the supplements will be taken in the morning (2 capsules), around midday (2 capsules), in the afternoon (2 capsules) and before bedtime (2 capsules) at possibly similar (approx. 4 hours) intervals.
88858164|NCT05711134|No Intervention|Control|Providers are not given any feedback on their practice patterns.
89384375|NCT01068678|Experimental|IDeg 3 times weekly (3TW)|
88858165|NCT05706376|Experimental|Promoting Positive Family Futures|
88858166|NCT05706376|Active Comparator|Treatment as Usual|
88858167|NCT05701150||MIN Data Set|Patients who did not receive a targeted therapy based on NGS results (outside of a clinical trial)
88858168|NCT05701150||EXT Data Set|Patients who received a targeted therapy based on NGS results (outside of a clinical trial)
88858169|NCT05700448|Experimental|Sugemalimab+PGemOx|Participants receive sugemalimab 1200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle (Q3W) PLUS PGemOx regimen Q3W (pegaspargase 2000-2500 IU/m^2 via intramuscular injection on Day 1, gemcitabine 1000 mg/m^2 via IV infusion on Days 1 & 8 and oxaliplatin 130 mg/m^2 via IV infusion on Day 1.
88858170|NCT05700448|Placebo Comparator|Placebo+PGemOx|Participants receive placebo via intravenous (IV) infusion on Day 1 of each 3-week cycle (Q3W) PLUS PGemOx regimen Q3W (pegaspargase 2000-2500 IU/m^2 via intramuscular injection on Day 1, gemcitabine 1000 mg/m^2 via IV infusion on Days 1 & 8 and oxaliplatin 130 mg/m^2 via IV infusion on Day 1.
88858171|NCT05700084|Experimental|Utidelone Capsule (Part 1)|Utidelone Capsule, available as 10 mg/capsule and 15 mg /capsule. Doses between 50 mg/m2/d and 120 mg/m2/d administered orally will be explored. Patients will be dosed for 5/7 consecutive days in a 21 day cycle.
88858172|NCT05700084|Experimental|Utidelone Capsule/Utidelone Injection (Group A-B, Part 2)|At cycle 0, patients will take Utidelone Capsule in fasted status at 60 mg/m2/d. At cycle 1, patients will be administered Utidelone Injection by iv drip at 30 mg/m2/d. At Cycle 2, patients will take Utidelone Capsule (after meals) at 60 mg/m2/d.
88858173|NCT05700084|Experimental|Utidelone Injection/Utidelone Capsule (Group B-A, Part 2)|At cycle 0, patients will be administered Utidelone Injection by iv drip at 30 mg/m2/d. At cycle 1, patients will take Utidelone Capsule in fasted status at 60 mg/m2/d. At cycle 2, patients will take Utidelone Capsule (after meals) at 60 mg/m2/d.
88858174|NCT05692596||All participants|Participants include patients scheduled to see the clinical team in the Pancreas Interception Center (PIC) which will be housed in the Moffitt GI Clinic.
88858175|NCT05691231||Simplify Disc|Extended follow-up of subjects treated with the Simplify Disc during IDE study NCT03123549 and followed in the post-approval study NCT04980378.
88858176|NCT05688540|Experimental|e book|a multi-media model through e-book for preoperative care of CIED intervention.
89384376|NCT01068678|Active Comparator|IGlar OD|
89384377|NCT03202511|Active Comparator|Control|The control phase will consist of subjects taking 600/400 mg oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) on day 1 (2 tablets) followed by 300/200 mg (1 tablet) doses on days 2 and 3.
89384378|NCT03202511|Experimental|Treatment|The treatment phase will consist of subjects taking 600/400 mg oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) (2 tablets) along with a 2 gram oral probenecid (PRO) dose (4 tablets, 500 mg each) on day 1.
89384379|NCT03609710|Experimental|PSTLAR|Combined application of left colic artery preservation, anastomotic reinforcing sutures and postoperative transanal tube placement in robotic low anterior resection for rectal cancer
88858177|NCT05688540|Experimental|traditional education booklet|traditional education booklet of CIED intervention.
88858178|NCT05681000|Experimental|Utidelone Capsule at 25 mg/m2/d for 5 days|Cohort 1: 2 subjects are planned to take Utidelone Capsule at 25 mg/m2/d by QD for 5 consecutive days in a 21-day cycle.
88858179|NCT05681000|Experimental|Utidelone Capsule at 50 mg/m2/d for 5 days|Cohort 2: 2 subjects are planned to take Utidelone Capsule at 50 mg/m2/d by QD for 5 consecutive days in a 21-day cycle.
88858180|NCT05681000|Experimental|Utidelone Capsule at 75 mg/m2/d for 5 days|Cohort 3: 3-6 subjects are planned to take Utidelone Capsule at 75 mg/m2/d by QD for 5 consecutive days in a 21-day cycle.
88858181|NCT05681000|Experimental|Utidelone Capsule at 100 mg/m2/d for 5 days|Cohort 4: 3-6 subjects are planned to take Utidelone Capsule at 100 mg/m2/d by QD for 5 consecutive days in a 21-day cycle.
88858182|NCT05681000|Experimental|Utidelone Capsule at 100 mg/m2/d for 7 days|Cohort 5: 3-6 subjects are planned to take Utidelone Capsule at 100 mg/m2/d by QD for 7 consecutive days in a 21-day cycle.
88858183|NCT05681000|Experimental|Utidelone Capsule at 120 mg/m2/d for 7 days|Cohort 6: 3-6 subjects are planned to take Utidelone Capsule at 120 mg/m2/d by QD for 7 consecutive days in a 21-day cycle.
88858184|NCT05679154|Experimental|Team-focused Implementation|
88858185|NCT05679154|Active Comparator|Standard Implementation|
88858186|NCT05666102|Other|Focus Groups|Focus groups will occur during the course of the study period.
88858187|NCT05662865|Experimental|Single, Experimental Group|SGLT2i + adaptive study diet of progressive dietary carbohydrate reduction
88858188|NCT05630365|Experimental|Nasal sampling/Testing (Professional Use)|operators will collect one mid-turbinate nasal swab sample from both nostrils from each subject. The collected mid-turbinate nasal swab will be tested with the Panbio™ Rapid Panel by an operator at the study site in a Near Patient Testing setting (e.g. GP centre or hospital clinic). After the mid-turbinate nasal sampling, the operators will collect one NP swab sample from one nostril of each subject.UTM samples will be shipped to the Core Laboratory for testing with RT-PCR protocols for Flu A, Flu B and SARS-CoV-2, as per the laboratory manual
88858189|NCT05629533||Phase 1|"Subjects to undergo right heart catheterization SimpleSense data collected from the first set of subjects and associate the data from SimpleSense to the right heart catheterization values.~Undergoing right heart catheterization for a clinical indication including but not limited to :~Prognosis of advanced heart failure~During endomyocardial biopsy~Candidacy for heart transplant~Management of cardiogenic shock"
88858190|NCT05629533||Phase 2|Subjects to undergo right heart catheterization SimpleSense data collected from the second set of subjects and evaluate the algorithms developed to estimate cardiac output from SimpleSense data. The second set of subjects are from within the sample population that are sequestered from the first set used for association of data from SimpleSense to the data from the right heart catheterization.
88858191|NCT05622071|Experimental|SINGLE ARM|Tislelizumab 200 mg will be administered every 3 weeks IV. Treatment will be continued until progression or limiting toxicities, for a maximum duration of 2 years and with an average duration of 4 months
88858192|NCT05618054|Other|Adolescents with POTS|
88858193|NCT05618054|Other|Adolescents without POTS|
88858194|NCT05613036|Experimental|Cohort 1: Formulation 1 (Cycle 1) then BI 907828 (Cycle 2 onwards)|
88858195|NCT05613036|Experimental|Cohort 2: BI 907828 (T) then Formulation 2 (R) (Cycle 1) then BI 907828 (Cycle 2 onwards)|
88858196|NCT05606146|Experimental|Treatment|IUB SEAD procedure
88858197|NCT05601219|Experimental|ADA-011 Monotherapy Dose Escalation|ADA-011 monotherapy will be administered intravenously (IV), every 3 weeks (Q3W) at escalating doses starting with Cycle 1, Day 1, until participant withdrawal. Participants enroll with histologically or cytologically confirmed solid tumors.
88858198|NCT05601219|Experimental|ADA-011 Monotherapy Dose Expansion|ADA-011 monotherapy with the preliminary recommended phase 2 dose (RP2D) of ADA-011, in participants with histologically or cytologically confirmed solid tumors.
88858199|NCT05601219|Experimental|Combination Therapy Dose Escalation|Combination therapy with ADA-011 and PD(L)-1 inhibitor (at escalating ADA-011 doses) will be administered IV Q3W, starting with Cycle 1, Day 1 in participants with histologically or cytologically confirmed solid tumors.
88858200|NCT05591352|Placebo Comparator|Placebo sachet|consume 1 sachet per day
88858201|NCT05591352|Experimental|Chenopodium formosanum extracts sachet|consume 1 sachet per day
88858202|NCT05589883|Experimental|EMPOWER-Latinx intervention|Informal caregivers will meet with the interventionist one-on-one via telepsychiatry (e.g., WebEx, Zoom) for 6, 15-20 minute modules to be completed within about 2-3 days from initiation of the first module, not including the booster modules. Informal caregivers will complete study assessments as per the schedule of assessments.
88858203|NCT05584696|Experimental|Green Light Exposure Group|"When patients enter the clinic, toss a coin to determine which group they will belong to. Before the patient puts on the green glasses, the anxiety level is measured with the help of VAS. Then the patient is seated in the dental unit and green glasses will be put on. After 10 minutes the anxiety level will be measured again with the help of VAS.~The level of pain felt during surgery was determined by VAS. All operations will be performed by a single experienced surgeon. Since the patients enter the clinic, their heart rate, oxygen saturation and blood pressure will be measured continuously."
88858204|NCT05584696|Placebo Comparator|Control Group|"When patients enter the clinic, toss a coin to determine which group they will belong to. Before the patient puts on transparent glasses, the anxiety level is measured with the help of VAS. Then the patient is seated in the dental unit and transparent glasses will be put on. After 10 minutes the anxiety level will be measured again with the help of VAS.~The level of pain felt during surgery was determined by VAS. All operations will be performed by a single experienced surgeon. Since the patients enter the clinic, their heart rate, oxygen saturation and blood pressure will be measured continuously."
88858205|NCT05584618|Experimental|intervention|The women allocated in experimental group will be given antenatal education for 6 weeks
88858206|NCT05584618|No Intervention|control|The women allocated for the control group will receive prenatal care services routinely provided at the outpatient clinics of the same hospital
88858207|NCT05582681|Active Comparator|HCV Education|The intervention of HCV education will be performed at the addiction care setting for video- based patient education. Health care provide delivered patient education is the standard of care referral approach. HCV Education will include HCV disease overview, HCV screening, taking Glecaprevir/Pibrentasivir (G/P), and post study drug assessment and management. Participants may be randomized to either the video-based patient education or the HCV delivered patient education.
88858208|NCT05582681|Experimental|Point of Care (POC) HCV Viremia (RNA) testing|All participants will have standardized laboratory assessments for HCV Viremia (RNA testing) as well as Cepheid POC HCV Viremia (RNA) test. The Cepheid Xpert HCV Viral Load (VL) Fingerstick assay is a test designed for the quantitation (amount) of Hepatitis C Virus (HCV) DNA in human whole blood. The HCV RNA result will be compared to standardized laboratory assessment for HCV Viremia. The Cepheid test is being conducted for research use only and will not be used for HCV diagnosis or treatment decisions.
89384380|NCT03609710|Active Comparator|NORLAR|Traditional robotic low anterior resection for rectal cancer without left colic artery preservation, anastomotic reinforcing sutures or postoperative transanal tube placement
89384381|NCT03637049|Experimental|PBI-4050 and midazolam|Midazolam 2 mg solution once (Period 1), PBI-4050 1200 mg (3 x 400 mg tablets) once per day for 5 days and midazolam 2 mg solution once on last day (Period 2).
89384382|NCT03636971|Experimental|hyaluronic acid with mannitol|
89384383|NCT03636971|Experimental|hyaluronic acid with sorbitol|
89384384|NCT03636971|Active Comparator|saline|
89384385|NCT03610100|Experimental|Acelarin (NUC-1031)|"825 mg/m2 administered intravenously over 15 to 30 minutes on days 1, 8 and 15 of a 28 day cycle.~Patients will be seen on a weekly basis during the time they are on active treatment and will be treated until disease progression."
88858209|NCT05566054|Experimental|VAC group|Chidamide 10mg orally daily for 7 days (d1-d7), AZA 75mg/m2 daily for 7 days (d1-d7) and VEN orally once daily (100 mg d1, 200 mg d2, 400 mg d3-28); If the bone marrow assessment is CR/CRi/MLFS/PR/NR on the 21th-28th day in the first cycle, the second cycle of treatment will be started; If the bone marrow assessment is PR/NR, the patient needs to withdraw from the trial, If the bone marrow assessment is CR/CRi/MLFS, the patient will start post-remission therapy. For post-remission therapy, if the patients ineligible for intensive chemotherapy, continue with the same regimen until progression or recurrence of the disease, and the patients need to withdraw from the trial. If the patients were fit for intensive chemotherapy, patients will receive consolidation chemotherapy with other regimens or transplantation, and the patients needs to withdraw from the trial if progression or recurrence of the disease.
89384386|NCT03610100|Active Comparator|Gemcitabine|"Gemcitabine: 1000mg/m2 administered intravenously as a 30 minute infusion on days 1, 8 and 15 of a 28 day cycle.~Patients will be seen on a weekly basis during the time they are on active treatment and will be treated until disease progression."
89384387|NCT03657966|Experimental|Standard of care chemotherapy + DCVAC/Ov|Standard-of-care carboplatin/gemcitabine or carboplatin/paclitaxel followed by DCVAC/OvCa
89384388|NCT03659370|Active Comparator|Fumigation Full|Full Fumigation after acupuncture, 2 times per week, for 4 weeks.
89384389|NCT03659370|Active Comparator|Fumigation 1/16|1/16 Fumigation after acupuncture, 2 times per week, for 4 weeks.
89384390|NCT03659370|Active Comparator|Acupuncture|Acupuncture only, 2 times per week, for 4 weeks.
89384391|NCT03659292|Experimental|GEA+PCEA|General anesthesia combined with epidural anesthesia will be performed during surgery and patient-controlled epidural analgesia (PCEA) will be provided after surgery.
89384392|NCT03659292|Other|GA+PCIA|General anesthesia will be performed during surgery and patient-controlled intravenous analgesia (PCIA) will be provided after surgery.
89384393|NCT03659058|Active Comparator|study group|200 patients with compensated liver cirrhosis (F4) by fibroscan; Child Turcotte Pugh score A, after achieving sustained virological response will be treated by anti-fibrotic agents
88875420|NCT02606604|Experimental|FES Cycling|The intervention consists of electrical stimulation to five lower extremity muscle groups (quadricep, hamstring, anterior tibialis, gluteal, and gastrocnemius muscle groups) while cycling for 45 minutes, 3 times per week for 8 weeks. Outcome measures will be collected at baseline, 4 weeks, 8 weeks and 4 weeks after training is completed).
88875421|NCT02606604|Active Comparator|Cycling Only|The intervention consists of lower extremity cycling for 45 minutes, 3 times per week for 8 weeks. Electrical stimulation will not be applied to any muscles. Outcome measures will be collected at baseline, 4 weeks, 8 weeks and 4 weeks after training is completed.
89384394|NCT03659058|Placebo Comparator|control group|200 patients with compensated liver cirrhosis (F4) by fibroscan; Child Turcotte Pugh score A, after achieving sustained virological response will be followed up without any intervention
89384395|NCT01331473|Active Comparator|Carotid Artery Stenting without Protection|Subjects will undergo carotid artery angioplasty and stenting with any CE-certificated carotid stent and without embolic protection device
89384396|NCT01331473|Active Comparator|Carotid Artery Stenting with Proximal Protection|Subjects will undergo carotid artery angioplasty and stenting with any CE-certificated carotid stent and with a proximal embolic protection device provided by the GORE Neuro Protection System
89384397|NCT03635905|Experimental|Gabapentin|Gabapentin (Neurontin)- 600 mg oral administered pre-operatively at the time of cervical preparation
89384398|NCT03635905|Placebo Comparator|Placebo|
89384399|NCT02960113|Experimental|scopolamine patch|Scopolamine patch will be placed on the skin behind the right ear 1 hour before initiation of the regional anesthesia for the duration of surgery.
89384400|NCT02960113|Experimental|acupressure point P6|Acupressure point P6 stimulation will be placed on the distal right forearm just above the crest of the wrist.
89384401|NCT02960113|Experimental|scopolamine patch + acupressure point P6|Will receive both scopolamine patch and acupressure point P6 stimulation, as described above.
89384402|NCT04850365|Other|Abdominal sacral hysteropexy|The approach involves suspending the cervix to the anterior longitudinal ligament on the sacrum using permanent sutures or polypropylene mesh.
89384403|NCT04850365|Other|Vaginal sacrospinous hysteropexy|"This transvaginal extraperitoneal technique involves suspending the sacrospinous ligament to the cervix using either a dissolvable or permanent suture. The suspension is performed in a unilateral fashion.~The outcomes will be obtained as follow;"
89384404|NCT02919696|Experimental|Abemaciclib Dose Level 1|Abemaciclib 150 milligram (mg) administered every 12 hours, orally, cycle 1 and then in cycle 2. Participants may continue to receive treatment until discontinuation criteria are met. One cycle is defined as 28 days. (Cycle 1: 32 days), with modifications during Cycle 1 to enable pharmacokinetic (PK) sampling following a single dose and repeated doses.
89535123|NCT03325595|Active Comparator|Experimental: AEF0117|Subjects in Cohorts 1 through 4 receive active treatments. Subjects in Cohorts 1 through 4 will receive a single dose of 0.2, 0.6, 2 and 6mg respectively of AEF0117 on Day1.
89384405|NCT02919696|Experimental|Abemaciclib Dose Level 2|Abemaciclib 200 mg administered every 12 hours, orally, cycle 1 and then in cycle 2. Participants may continue to receive treatment until discontinuation criteria are met. One cycle is defined as 28 days. (Cycle 1: 32 days), with modifications during Cycle 1 to enable PK sampling following a single dose and repeated doses.
89384406|NCT02740452|Other|Ligamys technique|Ligamys technique (device) or standard technique
89384407|NCT02740452|Other|standard technique|Ligamys technique (device) or standard technique
89384408|NCT02935673|Experimental|Regimen A (Placebo)|Participants of part 1 and part 2 will receive a single loading dose (LD) (Dose 1) followed by 9 maintenance doses (MDs) (Doses 2 to 10) of matching placebo, administered twice daily.
89384409|NCT02935673|Experimental|Regimen B (low-dose lumicitabine)|Participants of part 1 and part 2 will receive a single 750 mg LD (Dose 1) followed by nine 250 mg MDs (Doses 2 to 10) of lumicitabine, administered twice daily.
89384410|NCT02935673|Experimental|Regimen C (High-dose lumicitabine)|Participants of part 2 will receive a single 1000 mg LD (Dose 1) followed by nine 500 mg MDs (Doses 2 to 10) of lumicitabine, administered twice daily.
88858210|NCT05566054|Active Comparator|VA group|AZA 75mg/m2 daily for 7 days (d1-d7) and VEN orally once daily (100 mg d1, 200 mg d2, 400 mg d3-28); If the bone marrow assessment is CR/CRi/MLFS/PR/NR on the 21th-28th day in the first cycle, the second cycle of treatment will be started; If the bone marrow assessment is still PR/NR, the patient needs to enter VEN+AZA+Chidamide group. If the bone marrow assessment is CR/CRi/MLFS, the patient will start post-remission therapy. For post-remission therapy, if the patients ineligible for intensive chemotherapy, continue with the same regimen until progression or recurrence of the disease, and the patient needs to withdraw from the trial. If the patients fit for intensive chemotherapy, patients will receive consolidation chemotherapy with other regimens or transplantation, and the patient needs to withdraw from the trial if progression or recurrence of the disease.
88858211|NCT05560932|Experimental|HIV Medications and Alcohol Use|Participants with HIV who take 5 or more medications and currently (within the past month) consume alcohol
88858212|NCT05557760|Experimental|Cognitive Control Training Group|
88858213|NCT05557760|Experimental|Cognitive Control Training + Booster Sessions Group|
88858214|NCT05552001|Experimental|Single arm receiving sacituzumab govitecan|
88858215|NCT05540288|Experimental|Nalmefene|
88858216|NCT05540288|Placebo Comparator|Placebo|
88858217|NCT05537285|Experimental|Individualized Accelerated Intermittent Theta Burst Stimulation (Ind-aiTBS)|Patients will receive individualized unilateral accelerated theta-burst stimulation to the left dorsal lateral prefrontal cortex for 5 consecutive days, with a total of 10 hours a day. Treatment will be 10min with 50min of breaks in between the 10 sessions. The target for stimulation will be individualized using the participant's fMRI scans by finding the region of the DLPFC most anti-correlated with the subgenual anterior cingulate cortex (sgACC). This target will be determined using e-field modeling and theta-gamma coupling.
88858218|NCT05537285|Active Comparator|Standard Accelerated Intermittent Theta Burst Stimulation (Std-aiTBS)|Patients will receive unilateral accelerated theta-burst stimulation to the left dorsal lateral prefrontal cortex for 5 consecutive days, with a total of 10 hours a day. Treatment will be 10min with 50min of breaks in between the 10 sessions.
88858219|NCT05537285|Sham Comparator|Sham Accelerated Intermittent Theta Burst Stimulation (sham)|Patients will receive sham unilateral accelerated theta-burst stimulation to the left dorsal lateral prefrontal cortex for 5 consecutive days, with a total of 10 hours a day. Treatment will be 10min with 50min of breaks in between the 10 sessions.
88858220|NCT05522972|Experimental|Video Games|Participants will be required to play video games for a period of time: 1-2 hrs per session, 4-5 sessions/week for ~1-6 months
88858221|NCT05522972|Experimental|Perceptual learning|Participants will be required to practice a visual discrimination task (e.g. visual acuity, position acuity, contrast sensitivity, & stereoacuity) for a period of time: 1-2 hrs per session, 4-5 sessions/week for ~1-6 months
88858222|NCT05522972|Active Comparator|Occlusion therapy|Participants will be required to cover the dominant eye during the day in order to push the brain to use the fellow amblyopic eye: 1-2 hrs per session, 4-5 sessions/week for ~1-6 months
88858223|NCT05512806|Experimental|Treatment A|Participants will receive Dose A orally as a film-coated tablet.
88858224|NCT05512806|Experimental|Treatment B|Participants will receive Dose A orally as a film-coated tablet.
89384411|NCT03622398|Experimental|HXLPE|"This side of knee implanted with HXLPE(highly crosslinked polyethylene) liner while undergoing total knee arthroplasty. This group will receive the intervention, Total knee arthroplasty with HXLPE liner."
89384412|NCT03622398|Active Comparator|Conventional|"This side of knee implanted with conventional polyethylene while undergoing standard total knee arthroplasty. This group will receive the intervention, Total knee arthroplasty with conventional polyethylene liner."
89384413|NCT03201809|Experimental|On-Q Catheter|On-Q catheters placed within the implant pocket; infusion of 0.2% Ropivacaine at 4 mL/h for a total of 400 mL (about 4 days).
89384414|NCT03201809|Active Comparator|Ultrasound Guided Pectoral Nerve Block|Single Shot Pre-operative injections of 10 mL of 0.25% Ropivicaine for the Pecs 1 injection, and 20 mL of 0.25% Ropivacaine for the pecs 2 injection
89384415|NCT04458324|Experimental|NIV + Buspar|Subjects will perform 6 months of FES-row-training while receiving NIV and taking Buspar.
89384416|NCT04458324|Placebo Comparator|NIV + placebo|Subjects will perform 6 months of FES-row-training while receiving NIV and taking placebo.
88858225|NCT05512806|Experimental|Treatment C|Participants will receive Dose B orally as a film-coated tablet.
88858226|NCT05512806|Experimental|Treatment D|Participants will receive Dose B orally as an oral solution.
88858227|NCT05512806|Experimental|Treatment E|Participants will receive Dose C orally as a film-coated tablet.
88858228|NCT05512806|Experimental|Treatment F|Participants will receive Dose C orally as a film-coated tablet.
88858229|NCT05503927||Participants Exposed to Wegovy|Pregnant participants exposed to Wegovy during the first trimester (T1) (that is, estimated conception date - 35 days through <14 weeks gestational age [WGA]) and their linked infants will be observed in this retrospective observational study.
88875422|NCT02606838|Experimental|Persons with Diabetes|Untrained Persons with Diabetes used the Styx Lancing Device System to obtain fingerstick and Alternate Site palm capillary blood.
88875423|NCT02607618|Experimental|iclaprim|iclaprim 80 mg intravenous every 12 hours
89384417|NCT04458324|Sham Comparator|sham NIV + Buspar|Subjects will perform 6 months of FES-row-training while receiving sham NIV and taking Buspar.
89384418|NCT04458324|Active Comparator|sham NIV + placebo|Subjects will perform 6 months of FES-row-training while receiving sham NIV and taking placebo.
89384419|NCT02858154|Other|HFNC and low flow oxygen by nasal cannula|All subjects will receive 3-4 hours of experimental treatment (HFNC) during a research portion of a PSG and then for the 6-8 hours of clinically ordered PSG will receive active comparator (low flow oxygen by nasal cannula)
89384420|NCT03657420|Experimental|ABI-009 + Pomalidomide + Dexamethasone|"Pomalidomide is given orally daily on days 1-21, 7 days off~ABI-009 is given intravenously on days 1, 8, and 15~Dexamethasone is given orally weekly on days 1, 8, 15, 22"
89384421|NCT02684214|Experimental|Food secure families|high and marginal household food security
89384422|NCT02684214|Experimental|Food insecure families|low and very low household food security
89384423|NCT03657498|Experimental|Study group|Combined orthodontic-orthognathic treatment
89384424|NCT03657498|No Intervention|Control Group I|No intervention
89384425|NCT03657498|Active Comparator|Control Group II|Standard orthodontic treatment
88858230|NCT05503927||Participants Exposed to Anti-obesity Medication (AOM)|Pregnant participants exposed to other Anti-obesity Medication (AOM) (phentermine, diethylpropion, benzphetamine, phendimetrazine, orlistat, or bupropion/naltrexone) during the first trimester (start of exposure identification window based on five times the half-life of each AOM through <14 WGA) and their linked infants will be observed in this retrospective observational study.
88875424|NCT02607618|Active Comparator|vancomycin|vancomycin 15 mg/kg intravenous every 12, 24 or 48 hours based on creatinine clearance
89184268|NCT04083768|Placebo Comparator|Supine group|After the patient completes the spinal anesthesia, the cesarean section is completed in the supine position.
89184269|NCT04083768|Active Comparator|15° group|After the patient completed the spinal anesthesia, the preoperative preparation (about 10 minutes) was completed with a left tilt of 15°, and the cesarean section was completed using the supine position after the skin was cut.
89184270|NCT04083768|Active Comparator|30° group|After the patient completed the spinal anesthesia, the preoperative preparation (about 10 minutes) was completed with a left tilt of 30°, and the cesarean section was completed using the supine position after the skin was cut.
89384426|NCT03657186|Experimental|ProbioSatys™|
89384427|NCT03657186|Placebo Comparator|Placebo|
89384428|NCT03657030|Active Comparator|Single Ascending Dose|The planned dose levels will be 1, 5, 25, 75, and 225 mg CVN424 and matching placebo.
89384429|NCT03657030|Active Comparator|Multiple Ascending Dose|The planned dose levels will be 25, 75, and 150 mg CVN424 and matching placebo.
89384430|NCT02908464|Experimental|Lumosity (CT Group)|"Patients in the Lumosity arm will be prescribed a perioperative neurocognitive training program created in collaboration with Lumos Labs, Inc. The program will contain brain games that focus on enhancing cognitive abilities in working memory, attention, and processing speed. Participants will be expected to complete at least 2, but no more than 3, 15 minute sessions of training per day. The protocol will be prescribed for 10 days preoperatively, and then for four weeks postoperatively."
89384431|NCT02908464|No Intervention|Usual Care (Control Group)|Patients in the usual care arm will undergo current standard of care for cardiac surgery and postoperative recovery. They will be asked to refrain from acquiring a Lumosity account.
89384432|NCT02907216|Experimental|Co-administration Group|Subjects aged 6 to 12 weeks who receive the Squarekids vaccine (diphtheria, tetanus, pertussis and inactivated poliovirus [DPT-IPV] vaccine) according to a 3, 4, 6 month schedule and the liquid Rotarix vaccine (oral live attenuated human rotavirus [HRV] vaccine) according to a 2, 3 month schedule. The HRV vaccine is administered orally while the DTP-IPV vaccine is administered subcutaneously in the upper arm or upper thigh.
89384433|NCT02907216|Active Comparator|Staggered Group|Subjects aged 6 to 12 weeks who receive the Squarekids vaccine (diphtheria, tetanus, pertussis and inactivated poliovirus [DPT-IPV] vaccine) according to a 3, 4.5, 6 month schedule and the liquid Rotarix vaccine (oral live attenuated human rotavirus [HRV] vaccine) according to a 2, 3.5 month schedule. The HRV vaccine is administered orally while the DTP-IPV vaccine is administered subcutaneously in the upper arm or upper thigh.
89384434|NCT02984982|Active Comparator|Standard of Care|Statin therapy (atorvastatin or rosuvastatin) will be administered with or without non-statin lipid modifying therapies (LMTs). Non-statin LMTs will be adjusted by physicians to achieve the LDL-C target level <100 milligrams per deciliter (mg/dL).
89384435|NCT02984982|Experimental|Alirocumab|Alirocumab will be given subcutaneously every 2 weeks on top of stable dose statin therapy (atorvastatin or rosuvastatin) with or without stable dose non-statin LMTs.
89384436|NCT04357158|Other|Patients referred for colonoscopy|
89384437|NCT03622242|Experimental|Pain threshold index group|Adjust infusion rate of remifentanil and propofol according to pain threshold index and wavelet index in 'pain threshold index group'.
89384438|NCT03622242|Active Comparator|Control group|As conventional management, adjust infusion rate of remifentanil and propofol according to wavelet index and conventional vital signs
89384439|NCT03656796|Experimental|PD with freezing of gait (FOG)|Intervention will include treadmill training with auditory cues (AC) and treadmill training without auditory cues (NC).
88858231|NCT05503927||Overweight/Obese Participants|Pregnant participants with obesity or overweight and 1 or more comorbid condition without exposure to Wegovy or other AOM during pregnancy will be observed in this retrospective observational study.
89384440|NCT03656796|Experimental|PD without freezing of gait (FOG)|Intervention will include treadmill training with auditory cues (AC) and treadmill training without auditory cues (NC).
89384441|NCT03656796|Experimental|Healthy subjects (Control)|Intervention will include treadmill training with auditory cues (AC) and treadmill training without auditory cues (NC).
89384442|NCT03656484|Active Comparator|Tetracycline-Metronidazole (TM) group|Topical administration (in the periodontal pocket of affected teeth), for 30 consecutive days of 3%Tetracycline and 3%Metronidazole paste (TM), n=25 patients, considered control group.
89384443|NCT03656484|Experimental|TM-Melatonin-Hyaluronic acid (TM-MHa) group|Topical administration (in the periodontal pocket of affected teeth), for 30 consecutive days of 3% Tetracycline, 3% Metronidazole, 0.18% Melatonin and 3% Hyaluronic Acid (TM-MHa) paste, n=25 patients, considered experimental group.
89384444|NCT04309578|Experimental|treatment arm|Single arm
89384445|NCT03656952|Experimental|Seq 1|PF-06700841-> placebo-> moxifloxacin
89384446|NCT03656952|Experimental|Seq 2|PF-06700841->moxifloxacin->placebo
89384447|NCT03656952|Experimental|Seq 3|Placebo->PF-06700841->moxifloxacin
88858232|NCT05494034|Experimental|"implantable cardiac monitoring device (Reveal LINQTM)"|All included patients will have long-term heart rate monitors (Reveal LINQ; Medtronic)
88858233|NCT05483075|Experimental|HCP-Guided Exercise|"Participants will schedule twice-weekly in-person visits to conduct health care provider (HCP)-supervised exercise activity for a minimum of 30 minutes. At least 3 additional times per week, participants will conduct self-directed exercise at home. Activity and other outcomes will be monitored with an Actigraph Centrepoint Insight Watch.~The HCP guided therapy will continue on a weekly basis for at least 2 weeks and up to a maximum of 4 weeks."
89384448|NCT03656952|Experimental|Seq 4|Placebo->moxifloxacin->PF-06700841
89384449|NCT03656952|Experimental|Seq 5|Moxifloxacin->PF-06700841->placebo
89384450|NCT03656952|Experimental|Seq 6|Moxifloxacin->placebo->PF-06700841
89384451|NCT02237976|Experimental|Self-hypnosis|Patients are trained to practice self-hypnosis wen they are listed for lung transplantation. They are encourage to practice it before and after transplantation.
89384452|NCT02237976|Active Comparator|Routine practice|No specific intervention
89384453|NCT03656250||Chemo Patients with Nasopharyngeal cancer|The standard chemoradiation treatment (total 7000 cGy in 35 fractions at 200 cGy/fraction) for 7 weeks with 3 cycles of chemo followed by 3-month chemotherapy.
89384454|NCT02981472|Experimental|Apixaban|
89384455|NCT02981472|Active Comparator|LMWH/VKA|
89384456|NCT03656172||Haemoglobin measure|Anaemic adult Patients eligible to iron Treatment supported within the ICO for a solid tumor, untreated or treated by chemotherapy and/or radiotherapy and/or surgery, having benefited of a blood test (NFS, reticulocytes with RET-He , a martial blood test (iron, transferrin and Ferritin), a CRP, vitamins B12 and B9, a creatinine, a haptoglobin, a TSH) before and after iron treatment.
89384457|NCT03656094|Experimental|Pembrolizumab plus chemotherapy|Pembrolizumab (200 mg) plus chemotherapy (physicians' choice among docetaxel, pemetrexed, or vinorelbine) every 3 weeks
89384458|NCT03656094|Active Comparator|Placebo plus chemotherapy|Placebo plus chemotherapy (physicians' choice among docetaxel, pemetrexed, or vinorelbine) every 3 weeks
89384459|NCT04298034|Experimental|Treatment|The patients randomized to the treatment group will have an antihypertensive medication prescribed to them. The specific medication will be either labetalol or nifedipine based on allergies and clinically appropriateness of the medication. The patient will be instructed on the dosing, timing, and possible adverse effects.
89384460|NCT04298034|No Intervention|No-treatment|
89384461|NCT02982720|Experimental|Pembrolizumab and Sylatron|Pembrolizumab will be administered intravenously at a dose of 200 mg every 3 weeks starting week 4. Sylatron will be administered at a dose of 200mcg subcutaneously weekly starting at week 1.
88858234|NCT05483075|No Intervention|Control|Participants will not participate in the HCP-guided exercise intervention but will wear the Actigraph Centrepoint Insight Watch.
88858235|NCT05482542|Other|Cyclophosphamide/ATG Conditioning Regimen|Cyclophosphamide (200 mg /kg) / rabbit antithymocyte globulin (6.0 mg/kg)
88858236|NCT05482542|Other|Cyclophosphamide/Rituximab Conditioning Regimen|Cyclophosphamide (200 mg/kg) / rituximab (1000 mg).
88858237|NCT05478824||Allergic Asthma|BMI ≥ 30 kg/m2
89384462|NCT03656640||Patients Receiving Gammanorm®|Patients Receiving Gammanorm®
89535124|NCT03325595|Placebo Comparator|Placebo Comparator: Placebo|Subjects in Cohorts 1 through 4 will be randomly assigned in an 6:2 allocation to receive active or placebo treatments.
89535125|NCT03228199|Other|Presbyopic Glasses/ Intervention Group|Immediate provision of a free pair of spherical presbyopic glasses to correct the worker's vision for optimal picking distance as measured using a chart placed at the top of a typical tea bush.
89535126|NCT03228199|Other|Control Group|Will be deferred to receive spectacles as above, after the 12 weeks evaluation period.
88858238|NCT05478824||Non-allergic Asthma|BMI ≥ 30 kg/m2
88858239|NCT05471518||Pre-menopausal women with CKD|Age 18-44 years CKD stage 3-4 (eGFR 15-59 ml/min/1.73m2)
88858240|NCT05471518||Post-menopausal women with CKD|Age 55-75 years CKD stage 3-4 (eGFR 15-59 ml/min/1.73m2)
88858241|NCT05471518||Pre-menopausal healthy women|Age 18-44 years Regular menstrual cycle (25-35 d)
88858242|NCT05471518||Post-menopausal healthy women|Age 55-75 years
88858243|NCT05470777|Experimental|CD22/CD19 CAR T and auto-HSCT sandwich strategy as consolidation therapy for B-ALL|
88858244|NCT05458960|Experimental|Arm 1: Social needs navigator program|Participants will be paired with a community health worker who will provide tailored support to address unmet social needs. The number and frequency of calls will be limited only by participants' needs, interest, and willingness to interact. The type of contact could include phone calls, or home/community visits. The community health worker will: (1) identify and assess patients' unmet social needs; (2) jointly generate solutions; (3) help prioritize among multiple needs; (4) identify community resources that could help resolve the problem(s); (5) determine eligibility for services; (6) help patients access available resources by scheduling appointments and providing appointment reminders; (7) prepare patients to interact with service agencies and/or act as an advocate; (8) provide support such as arranging transportation; (9) oversee follow-up problem-solving actions; and (10) review progress made towards resolving unmet social needs and adapt solutions.
88858245|NCT05458960|Active Comparator|Arm 2: Enhanced usual care|Participants will receive verbal referral to a federally funded, free, 24-hr assistance hotline, United Way 2-1-1, which connects callers with community services to help address unmet social needs.
88858246|NCT05458960|No Intervention|Arm 3: Clinic provider|4 WUSM colposcopy providers, 4 staff members, and 1 community health worker will be surveyed to assess potential for dissemination.
88858247|NCT05456295|No Intervention|NoCDO|Participants will be tested with no CDO
88858248|NCT05456295|Experimental|CUFF-A|The first study CDO will be designated CUFF-A
88858249|NCT05456295|Experimental|CUFF-B|The first study CDO will be designated CUFF-B
88858250|NCT05456295|Experimental|CUFF-C|The first study CDO will be designated CUFF-C
88858251|NCT05456295|Experimental|CUFF-D|The first study CDO will be designated CUFF-D
88858252|NCT05453617|Experimental|The TRE group|Participants in the TRE group will be instructed to eat during a window of 8 h/d (8 am to 4 pm).
88858253|NCT05453617|Experimental|The 5:2 diet group|Participants in the 5:2 diet group will be instructed to consume 500-600 kcal/d on fast days and eat ad libitum on feast days.
88858254|NCT05453617|No Intervention|Control|Participants in the control group will receive a general lifestyle counseling.
88858255|NCT05448209|Experimental|Experimental|Intervention Group Afterwards, patients taking paclitaxel-paclitaxel-herceptin will be given a nurse-led Motivational Interview about CIPN, physical activity and regular physical activity-walking. Patients will be instructed that the goal is to beat the previous number of steps each time. If he/she has problems/shortness of breath, chest pain, palpitation complaints during walking, he/she will be told to take a break from walking and rest. The study will be conducted under the supervision of a Medical Oncology specialist throughout the study, as well as the controls of patients with ongoing symptoms. Participants will be given a pedometer for regular follow-up, its use will be explained, and it will be told to mark it on the walking tracking chart. It will be emphasized that rhythmic walking is important for the pedometer to count correctly. Motivational Interview sessions will be conducted face-to-face at the beginning, week 4 and week 8.
88858256|NCT05448209|No Intervention|control group|control group will receive standard practice
88858257|NCT05432778|Experimental|Study Group|All patients in the Study Group will receive virostatic prophylaxis with letermovir 480 mg qd (We will be utilizing Letermovir oral formulation of 240 mg or 480 mg as available).
88858258|NCT05432778|No Intervention|Control Group|Patients in Controls will receive standard-of-care virostatic prophylaxis with valgancyclovir 450 mg bid.
89184271|NCT00579345|Experimental|cTIV|Cell culture derived seasonal trivalent influenza vaccine (cTIV)
89535127|NCT03324815|Active Comparator|Morphine- Methadone|Morphine 5mg/6h plus metadone: 2,5mg/12h
89535128|NCT03324815|Active Comparator|Morphine|Morphine: 5mg/6h
88858259|NCT05429736|Experimental|MST + TSS|Individuals will participate in 6 training sessions of MST combined with TSS.
88858260|NCT05429736|Sham Comparator|MST + ShamTSS|Individuals will participate in 6 training sessions of MST while receiving shamTSS.
88858261|NCT05421832||PD Cohort 1|PD patients assessed via the Hoehn & Yahr (H&Y) Scale to be in Stages 1-2 of PD (inclusive)
88858262|NCT05421832||PD Cohort 2|PD patients assessed via the H&Y Scale to be in Stages 3-4 of PD (inclusive)
88858263|NCT05421832||Prodromal PD|Patients who meet PI-defined criteria for prodromal PD, i.e., the latent phase of disease progression during which clinical PD symptoms have yet to manifest
89184272|NCT00579345|Active Comparator|eTIV_a|Influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free; eTIV_a)
88858264|NCT05421832||Age and Sex-matched Healthy Control|Age & sex matched healthy control subjects who have not been diagnosed with PD
88858265|NCT05421780|Placebo Comparator|Control biscuits group|For each MTT, subjects are to consume 90 g control biscuits as their breakfast within 15 mins.
88858266|NCT05421780|Experimental|autoclaved BSG-containing group|For each MTT, subjects are to consume 90 g autoclaved BSG-containing biscuits as their breakfast within 15 mins.
88858267|NCT05421780|Experimental|bio-transformed BSG-containing group|For each MTT, subjects are to consume 90 g bio-transformed BSG-containing biscuits as their breakfast within 15 mins.
88858268|NCT05417126|Experimental|Experimental-vMCO-010|Participants receive 1.2E11gc/eye of vMCO-010
89002997|NCT05890079|Active Comparator|External oblique intercostal plane block group|The patients in External oblique intercostal plane block group will be received external oblique intercostal plane block and patient controlled analgesia with morphine for postoperative analgesia
89184273|NCT00579345|Experimental|FLU (cTIV or eTIV_a)|Cell culture derived seasonal trivalent influenza vaccine (cTIV) or influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free; eTIV_a).
89184274|NCT00579345|Active Comparator|FLU (cTIV or eTIV_a) + PV|23-valent Pneumococcal vaccine (PV) concomitantly administered with cell culture derived seasonal trivalent influenza vaccine (cTIV) or influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free; eTIV_a).
89184275|NCT00715377|Experimental|1|
89184276|NCT04083924|Experimental|Basic cardiac ultrasound training|Single group education intervention study. No control group. Pre-post educational outcomes only.
89184277|NCT00718497||ALS|Subjects having either definite or probable ALS by El Escorial Criteria.
88818661|NCT04339647|Experimental|The SIMS Programme|The SIMS programme is a community-based intervention which improvised the usual care (defined as the existing preschool oral health programme) offered by the Ministry of Health. The target group is 5-6-year-old preschool children and their parents. Apart from the usual care, the 5-6-year-old children receive interventions carried out by teacher in school and home tooth brushing supervision by parents. In addition, parents/guardians will receive OHE from the DT team, free toothbrush and toothpaste (1000ppm F) for child home tooth brushing and supervised child home tooth brushing for 6 months.
88818662|NCT04339647|No Intervention|Control|The control group receives the usual care from the preschool oral health programme. The usual care is described as a DT team visiting the school to do an oral examination, provides OHE to the children, and applies fluoride varnish (20,000 ppmF) twice/year.
88818663|NCT04986683|Experimental|Patients with drug-resistant epilepsy|All patients who undergo two-stage epilepsy surgery will receive two longitudinal evaluations of brain MRI and neuropsychology test: a month before surgery and 1.5 years after surgery.
88818664|NCT02708745|Placebo Comparator|Placebo Arm|Parent participants will receive a placebo survey about their attitudes toward common child health topics before their child's health supervision visit.
88818665|NCT02708745|Experimental|Intervention Arm|Parent participants will also receive the intervention survey about their attitudes toward childhood vaccines before their child's health supervision visit.
88818666|NCT05251779|Experimental|Cang-Ai Group|The test group inhaled the volatile oil of Cang-Ai at a concentration of 1% by inhalation once a day for 30 minutes
88818667|NCT05251779|Active Comparator|Bergamot group|The control group inhaled the bergamot essential oils at a concentration of 1% by inhalation once a day for 30 minutes
88818668|NCT00559637|Experimental|Methoxy polyethylene glycol-epoetin beta|Methoxy polyethylene glycol-epoetin beta will be administered subcutaneously once a month. The starting dose will be 1.2 mcg/kg of body weight. Further dose adjustments will be performed during the study depending on the hemoglobin value. Total duration of treatment will be 9 months for all participants in the study and up to 11 months for participants who will be shifted to the dialysis.
88818669|NCT03349281|Experimental|Dose Level 1: Pevonedistat 15 + VXLD|"Pevonedistat: 15 mg/m2 intravenously (IV)~Vincristine: 1.5 mg/m2/dose IV push~Dexamethasone: 10 mg/m2/day divided twice daily~PEG-asparaginase: 2000 IU's/m2/day, capped at maximal dose of 3750 IU's.~Doxorubicin: 60 mg/m2/day IV~Intrathecal (IT) chemotherapy via injection per protocol:~All subjects: Cytarabine 70 mg ;~For central nervous system (CNS) negative subjects: Methotrexate 15 mg;~For CNS positive subjects (Triple IT Therapy): Cytarabine 30 mg, Methotrexate 15 mg, and Hydrocortisone 15 mg."
88818670|NCT03349281|Active Comparator|Dose Level -1: Pevonedistat 10 + VXLD|"Pevonedistat: 10 mg/m2 IV~Vincristine: 1.5 mg/m2/dose IV push~Dexamethasone: 10 mg/m2/day divided twice daily~PEG-asparaginase: 2000 IU's/m2/day, capped at maximal dose of 3750 IU's.~Doxorubicin: 60 mg/m2/day IV~Intrathecal (IT) chemotherapy via injection per protocol:~All subjects: Cytarabine 70 mg ;~For CNS negative subjects: Methotrexate 15 mg;~For CNS positive subjects (Triple IT Therapy): Cytarabine 30 mg, Methotrexate 15 mg, and Hydrocortisone 15 mg."
88818671|NCT03349281|Active Comparator|Dose Level 2: Pevonedistat 20 + VXLD|"Pevonedistat: 20 mg/m2 IV~Vincristine: 1.5 mg/m2/dose IV push~Dexamethasone: 10 mg/m2/day divided twice daily~PEG-asparaginase: 2000 IU's/m2/day, capped at maximal dose of 3750 IU's.~Doxorubicin: 60 mg/m2/day IV~Intrathecal (IT) chemotherapy via injection per protocol:~All subjects: Cytarabine 70 mg ;~For CNS negative subjects: Methotrexate 15 mg;~For CNS positive subjects (Triple IT Therapy): Cytarabine 30 mg, Methotrexate 15 mg, and Hydrocortisone 15 mg."
88818672|NCT00367809|Experimental|1|
88818673|NCT00367809|Active Comparator|2|
88818674|NCT00367809|No Intervention|3|
88818675|NCT02713425|Experimental|Single Arm - Entertaining Video Game|The children in this study will have a single visit. During this visit they will be introduced to the game. The child will then interact with the game and after they have finished, they will be asked questions about their experience with the game. Parents will observe and provide their own feedback about the game.
88818676|NCT01840319||1|Patients previously included in the initial protocol WYETH 3074A1-4448 / B1811030. (To collect only status survival data 30 days after the last dose of treatment)
88818677|NCT03206151|Experimental|CMAB009 + FOLFIRI|"Drug: CMAB009(recombinant chimeric anti-EGFR monoclonal antibody injection), will be administered every 7 days at an initial dose of 400mg/m^2 and 250mg/m^2 for subsequent infusions until progression of disease , withdrawal of consent, or unacceptable toxicity.~Drug: Irinotecan bi-weekly irinotecan infusion of 180mg/m^2 on Day 1. Drug: Folinic Acid infusion 400mg/m^2 of folinic acid in on Day 1. Drug: 5-Fluorouracil bolus 5-Fluorouracil bolus of 400mg/m^2 followed by a 46-48 h continuous infusion of 2400mg/m^2.~every 2 weeks until progression of disease , withdrawal of consent, or unacceptable toxicity."
88818678|NCT03206151|Active Comparator|FOLFIRI|"FOLFIRI Drug: Irinotecan bi-weekly irinotecan infusion of 180mg/m^2 on Day 1. Drug: Folinic Acid infusion 400mg/m^2 of folinic acid in on Day 1. Drug: 5-Fluorouracil bolus 5-Fluorouracil bolus of 400mg/m^2 followed by a 46-48 h continuous infusion of 2400mg/m^2.~every 2 weeks until progression of disease , withdrawal of consent, or unacceptable toxicity."
88818679|NCT04339725||Fecal DNA|Extraction fecal DNA and compare disease group to normal group
88818680|NCT01841021|Experimental|Brentuximab Vedotin Treatment|Brentuximab vedotin will be given intravenously with a dose of 1.8 mg/kg every 21 days, over 30 minutes for 16 cycles in the clinic.
88818681|NCT02713659|Experimental|Early Literacy Promotion|Parents and children randomized to the Early Literacy Promotion arm.
88818682|NCT02713659|Active Comparator|Standard Literacy Promotion|Parents and children randomized to the Standard Literacy Promotion arm.
88818683|NCT01842815|Experimental|755nm Alexandrite Laser Single Pass (Right Side).|755nm Alexandrite Laser for Treatment of unwanted, non cosmetic tattoos. The right side will be treated once within the same visit.
89384463|NCT00849667|Active Comparator|Farletuzumab (1.25 mg/kg)|Participants will receive farletuzumab 1.25 milligram per kilogram (mg/kg) administer as an intravenous (IV) infusion weekly, followed by taxane (paclitaxel [175 milligram per meter square {mg/m^2}] or docetaxel [75 mg/m^2]), administer as IV infusion and followed by carboplatin (to maintain area under curve [AUC] 5-6 milligram per milliliter per minute [mg/mL/minute]), administer as IV infusion, every three weeks, on Day 1 of each 21-day cycle for 6 cycles (combination therapy). Following completion of combination therapy, maintenance treatment with farletuzumab 1.25 mg/kg, administer as IV infusion, weekly is given until disease progression.
89384464|NCT00849667|Active Comparator|Farletuzumab (2.5 mg/kg)|Participants will receive farletuzumab 2.5 mg/kg administer as an IV infusion weekly, followed by taxane (paclitaxel [175 mg/m^2] or docetaxel [75 mg/m^2]), administer as IV infusion and followed by carboplatin (to maintain AUC 5-6 mg/mL/minute), administer as IV infusion, every three weeks on Day 1 of each 21-day cycle for 6 cycles (combination therapy). Following completion of combination therapy, maintenance treatment with farletuzumab 2.5 mg/kg, administer as IV infusion, weekly is given until disease progression.
89384465|NCT00849667|Placebo Comparator|Placebo|Participants will receive farletuzumab-matched placebo (0.9 percent [%] saline) administer as an IV infusion weekly, followed by taxane (paclitaxel [175 mg/m^2] or docetaxel [75 mg/m^2]), administer as IV infusion and followed by carboplatin (to maintain AUC 5-6 mg/mL/minute), administer as IV infusion, every three weeks on Day 1 of each 21-day cycle for 6 cycles (combination therapy). Following completion of combination therapy, maintenance treatment with farletuzumab-matched placebo (0.9% saline), administer as IV infusion, weekly is given until disease progression.
89384466|NCT03201419|Experimental|FE 201836 500 μg (Randomized Treatment Period)|FE 201836 500 μg oral solution and placebo orally disintegrating tablet (ODT), administered once daily
89384467|NCT03201419|Experimental|FE 201836 350 μg (Randomized Treatment Period)|FE 201836 350 μg oral solution and placebo ODT, administered once daily
88858269|NCT05394051|Experimental|PARK Now|"6-Week Self-Guided Program: PARK Positive Emotion Skills: The skills will be delivered over approximately 6 weeks, and individuals can participate from any device and location with internet access. A week will consist of 1-2 days of didactic material and 5-6 days of real-life skills practice and reporting. The maximum amount of time engaged in the PARK program for any participant is 5 hours over the 6-week period, plus completion of the REDCap surveys assessments (burnout, well-being, health behaviors). The intervention will focus on developing the following skills that will be supplemented by home practice: (1) positive events, capitalizing, gratitude; (2) mindfulness; (3) positive reappraisal; (4) personal strength and achievable goals; (5) and self-compassion.~PARK is delivered through the BrightOutcome online platform."
88858270|NCT05394051|No Intervention|Wait List Control-PARK Later|Wait list controls will be assessed at similar time intervals and will be offered PARK at end of follow-up.
88858271|NCT05391828|Experimental|Total Knee Arthroplasty (TKA) performed using a medial congruent articular bearing surface design|
88858272|NCT05391828|Active Comparator|Total Knee Arthroplasty (TKA) performed using a posterior stabilized bearing design|
89384468|NCT03201419|Experimental|FE 201836 250 μg (Randomized Treatment Period)|FE 201836 250 μg oral solution and placebo ODT, administered once daily
89384469|NCT03201419|Experimental|FE 201836 150 μg (Randomized Treatment Period)|FE 201836 150 μg oral solution and placebo ODT, administered once daily
89384470|NCT03201419|Experimental|FE 201836 100 μg (Randomized Treatment Period)|FE 201836 100 μg oral solution and placebo ODT, administered once daily
89384471|NCT03201419|Experimental|FE 201836 50 μg (Randomized Treatment Period)|FE 201836 50 μg oral solution and placebo ODT, administered once daily
89384472|NCT03201419|Experimental|Placebo (Randomized Treatment Period)|Placebo oral solution and placebo ODT, administered once daily
89184278|NCT00718575|Experimental|1|Deceased liver donors that are randomized to this arm will receive the Glucose/Ischemic Preconditioning pre-treatment intra-operatively prior to starting cold preservation of the organ
89384473|NCT03201419|Experimental|Desmopressin 25 μg (Randomized Treatment Period)|Desmopressin 25 μg ODT and placebo oral solution, administered once daily (female subjects)
89384474|NCT03201419|Experimental|Desmopressin 50 μg (Randomized Treatment Period)|Desmopressin 50 μg ODT and placebo oral solution, administered once daily (male subjects)
89384475|NCT01331551||men with inflammatory bowel disease|Men between the ages of 18-55 with inflammatory bowel disease who are taking mesalamine medication.
89384476|NCT01331629|Experimental|ART-THERAPIE|supported in art therapy with other supportive care available in the facility
89384477|NCT01331629|No Intervention|standard group|standard care (supportive care available in each facility)
89384478|NCT02924389|Other|Anti-retroviral (ARV) Naïve Males|Males diagnosed with HIV will undergo serial blood and tissue rectal sampling for twelve weeks after initiating ARV therapy as prescribed by their physician. Participants will be treated with either Triumeq or Truvada with dolutegravir.
89384479|NCT02924389|Other|Anti-retroviral (ARV) Naïve Females|Females diagnosed with HIV will undergo serial blood and tissue rectal sampling for twelve weeks after initiating ARV therapy as prescribed by their physician. Participants will be treated with either Triumeq or Truvada with dolutegravir.
89384480|NCT05440981|Experimental|Temporarily implanted nitinol device (iTind) group|Subjects will undergo iTind for the treatment of male LUTS.
89384481|NCT01315093|Experimental|Heparin, Low-Molecular-Weight group|LMWH was administered during an IVF cycle using either the GnRH - agonist or antagonist protocol in poor responders. Drug was started at the beginning of the cycle and stopped at the time of pregnancy test if negative, or continued if pregnancy occurred until the 32th weeks of gestation
89384482|NCT01315093|Active Comparator|Non Heparin, Low-Molecular-Weight group|IVF cycle using either the GnRH - agonist or antagonist protocol in poor responders.
88858273|NCT05390736|Experimental|STEADI Intervention|For those assigned to the STEADI intervention arm, the clinical research nurse conducted standardized assessments to identify a patient's risk factors for falls. The STEADI assessments included: 1) a review of comorbidities; 2) medication review; 3) review of patient's falls history; 4) assessment of feet and footwear; 5) assessment of visual acuity; and 6) assessment of gait and balance; 7) review of home safety risks; and 8) assessment of potential vitamin D deficiency. Nurses would use assessment results to make recommendations which would then be relayed to the patient through their provider at their upcoming primary care visit.
89384483|NCT03235349|Experimental|Glecaprevir/Pibrentasvir|Participants received oral glecaprevir/pibrentasvir 300 mg/120 mg once daily (QD) for 12 or 16 weeks. Participants received treatment for 12 weeks with the exception of treatment-experienced, genotype 3-infected participants who received treatment for 16 weeks.
89384484|NCT01331707|Active Comparator|Promus Element|
89384485|NCT01331707|Active Comparator|Resolute Integrity|
89384486|NCT03235115|Active Comparator|Methafilcon A IV|Subjects are randomized to wear Methafilcon A IV for 1 hour during the cross over study.
89384487|NCT03235115|Active Comparator|Ocufilcon B|Subjects are randomized to wear Ocufilcon B for 1 hour during the cross over study.
89384488|NCT03235115|Active Comparator|Omafilcon A|Subjects are randomized to wear Omafilcon A for 1 hour during the cross over study.
89384489|NCT03953807|Experimental|Ozurdex|OZURDEX implant 700 μg
89384490|NCT03662711|Active Comparator|Long-acting beta-agonist (LABA) or LABA/LAMA|long-acting bronchodilator agents (LABD, LAMA or LABA/LAMA) but no inhaled steroids plus usual care for comorbidities
88858274|NCT05390736|No Intervention|Control|After being enrolled in the study, the patient would receive usual care from their provider.
88858275|NCT05390736|Experimental|Physical Therapy Assessment Only|For those assigned to the PT assessment only arm, the clinical research nurse would only conduct gait and balance assessments and would make recommendations about need for physical therapy services, conveyed to primary care provider for referrals.
88858276|NCT05390736|Experimental|Medical management assessment only|For those assign to the medical management assessment arm, only patients' medication usage would be assessed for polypharmacy (using 5 or more medications) or use of pharmaceutical classes that increase risk for falls. Recommendations for making changes to dosing levels or reducing number of medications would be conveyed to primary care provider.
89384491|NCT03662711|Experimental|Long-acting muscarinic antagonist (LAMA) and/or LABA plus ICS|Bronchodilator agents LAMA and/or LABA with inhaled steroids plus usual care for comorbidities
89384492|NCT02923531|Experimental|X4P-001 Plus Nivolumab|Participants will receive X4P-001 400 milligrams (mg) (as 4 capsules of 100 mg each) orally once daily in combination with nivolumab 240 mg intravenous (IV) infusion (over 60 minutes) every 2 weeks. Study medication will be administered in 28-day cycles and will continue until treatment-limiting toxicity or disease progression.
89384493|NCT02934503|Experimental|Cisplatin or carboplatin, Etoposide, Pembrolizumab & Radiation|"Cohort A: cisplatin (75 mg/m^2) + carboplatin (AUC 6) + etoposide (100mg/m^2) for four to six, 3-week cycles + pembrolizumab (200 mg) followed by radiation. Pembrolizumab will be started with first cycle of chemotherapy and continued for up to 2 years.~Cohort B: Pembrolizumab (200 mg) will be added to standard therapy with cisplatin (75 mg/m2) or carboplatin (AUC 6) and etoposide (100 mg/m2) (and radiation, if appropriate), after one 3- week cycle of standard therapy and continued for up to 2 years.~Cohort C: 200 mg IV infusion of Pembrolizumab every 3 weeks over about 30 minutes after completion of standard chemotherapy with cisplatin (75 mg/ m2) and etoposide (100 mg/m2). Treatment with pembrolizumab will continue for up to 2 years.~Cohort D: Pembrolizumab 200 mg IV infusion every 3 weeks in vein after completion of standard chemotherapy and radiation. Pembrolizumab will start within 6 weeks of completing radiation therapy and continue for up to 2 years."
89384494|NCT03636217|Experimental|LGI-Milk Breakfast|Low glycemic index and milk content (LGI-Milk) breakfast as a test meal
89384495|NCT03636217|Experimental|LGI-Kefir Breakfast|Low glycemic index and kefir content (LGI-Kefir) breakfast as a test meal
89384496|NCT03636217|Experimental|HGI-Kefir Breakfast|High glycemic index and kefir content (HGI-Kefir) breakfast as a test meal
89384497|NCT04563247||Asymptomatic frontline HCWs for COVID 19|All healthcare workers who worked in high exposure areas of hospital dealing with COVID 19.
89384498|NCT02937545|Experimental|PGx Only|Patients will receive pharmacogenetic testing. Pharmacists will make recommendations for drug/dose changes based on PGx results.
88858277|NCT05380856|Active Comparator|IPG turned ON|Continous neuromodulation
88858278|NCT05380856|Placebo Comparator|IPG turned OFF|No neuromodulation
89384499|NCT02937545|Experimental|PGx + MTM|Patients will receive pharmacogenetic testing along with medication therapy management. Two MTM sessions will be conducted: one at the time testing is ordered and the testing sample is collected, and one when results are returned to the patient. Pharmacists will make recommendations for drug/dose changes based on medication action plan developed during MTM and the PGx results.
89384500|NCT03636139|Experimental|Anodal stimulation|transcranial DC stimulation : anodal
89384501|NCT03636139|Sham Comparator|Sham stimulation|transcranial DC stimulation : sham
89384502|NCT05435131|Experimental|Periodontal Health|Full-mouth clinical periodontal measurements recorded and GCF, saliva serum obtained.
89384503|NCT05435131|Experimental|Gingivitis|Full-mouth clinical periodontal measurements recorded and GCF, saliva serum obtained.
89384504|NCT05435131|Experimental|Stage II grade B Periodontitis|Full-mouth clinical periodontal measurements recorded and GCF, saliva serum obtained.
89384505|NCT05435131|Experimental|Stage III grade B Periodontitis|Full-mouth clinical periodontal measurements recorded and GCF, saliva serum obtained.
89384506|NCT05435131|Experimental|Stage III grade C Periodontitis|Full-mouth clinical periodontal measurements recorded and GCF, saliva serum obtained.
89384507|NCT01314209|Experimental|dexmedetomidine|
89384508|NCT05434429|Experimental|Intervention|Participants have access to short-term and long-term interventions.
89384509|NCT05434429|No Intervention|Control|Given access to all interventions at the end of the 5 weeks of the trial.
89384510|NCT04709393|Experimental|Pre-screening|Receiving FRAX+SARC-F questionnaire pre-screening results on estimated fracture risk
89384511|NCT04709393|No Intervention|Control|Not receiving FRAX+SARC-F questionnaire pre-screening preliminary results on estimated fracture risk
89384512|NCT03758417|Experimental|LCAR-B38M Chimeric Antigen Receptor T Cell|"Participants will receive LCAR-B38M CAR-T cells as a single infusion which consists of autologous T lymphocytes transduced with LCAR-B38M, a lentiviral vector to express a chimeric antigen receptor targeting the human B cell maturation antigen (anti-BCMA CAR).~In addition, participants will enroll in additional cohort to further characterize the safety profile and accumulate efficacy data of LCAR-B38M CAR-T cells."
88858279|NCT05354115|Other|Sampling|"Every second participant will be instructed to blow their nose. Study personnel will then collect one nasal swab from both nostrils and two NP swabs, one from each nostril from each participant.~Nasal samples must always be collected prior to the Nasopharyngeal sampling. A minimum of 90 Flu A positive subjects, a minimum of 90 Flu B positive subjects and a minimum of 100 SARS-CoV-2 positive subjects will be enrolled. In addition, a minimum of 385 negative subjects will be enrolled."
88858280|NCT05353751|Experimental|Kind Minds Program -Family|In the Family condition (KMP-Fam), both caregiver and adolescent will receive the KMP intervention via an online mindfulness program, augmented by weekly video conference support from a Community Health Worker (CHW) Kindness Coach
88858281|NCT05353751|Active Comparator|Kind Minds Program -Teen Only|In the Teen-Only condition (KMP-TO), only the adolescent will receive the KMP intervention via an online mindfulness program augmented by weekly video conference support from a CHW Kindness Coach.
88858282|NCT05353283|Experimental|Intervention Arm|POC adherence testing by a urine tenofovir assay with motivational interviewing counselling
88858283|NCT05353283|No Intervention|Standard of Care|Adherence counselling provided by the participant's PrEP care provider
88858284|NCT05352009|Experimental|Sling exercise training group|Participants will practice core muscle exercise in different positions with sling systems (Redcord®, Norway).
88858285|NCT05352009|Active Comparator|Conventional training group|Participants will practice balance exercise, including sit-to-stand, forward reaching, postural training on the therapeutic ball, maintaining standing balance with eyes open and progress to eyes close, and tandem stance.
88858286|NCT05344209|Experimental|anti-PD-1/PD-L1 treatment + UV1 vaccination|anti-PD-1/PD-L1 treatment + UV1 vaccination (and sagramostim)
88858287|NCT05344209|Other|anti-PD-1/PD-L1 treatment|anti-PD-1/PD-L1 treatment
89384513|NCT01329835|Experimental|Written information via brochure|Written information by a brochure
89384514|NCT01329835|No Intervention|standard care|standard prenatal care
89384515|NCT01329835|Experimental|Lifestyle counseling|Psycho-education based on principles of motivational interviewing and positive reinforcement
89384516|NCT03636659|Experimental|Amphotericin B Liposome|Amphotericin B Liposome for Injection 50 mg/vial, intravenous infusion at a dose of 3 mg/kg/day, OD for 5 days
89384517|NCT03636659|Active Comparator|AmBisome Liposome|AmBisome Liposome for Injection 50 mg/ vial, intravenous infusion at a dose of 3 mg/kg/day, OD for 5 days
88858288|NCT05335148|No Intervention|Standard of care arm - placebo colchicine pill|The standard of care arm will receive a placebo colchicine pill once a day
88858289|NCT05335148|Experimental|Experimental arm - oral colchicine once a day|The experimental arm will receive 0.6 mg of oral colchicine once a day
88858290|NCT05327764|Active Comparator|40:20|Walking for 40 minutes, resting for 20
88858291|NCT05327764|Experimental|20:10|Walking for 40 minutes, resting for 20
88858292|NCT05309577|Experimental|Caregiver Intervention|Behavioral self-monitoring of sleep and activity up to 6 weeks, using the myRhythmWatch app, and motivational health coaching.
88858293|NCT05299931|Other|Subcutaneous (SC) ustekinumab every 8 weeks (Q8w)|"Patients previously enrolled to the ustekinumab 90 mg SC Q8w-arm will continue ustekinumab 90 mg SC Q8w if they are Q8w responders at the end of REScUE~Patients treated with a OLE treatment regimen of ustekinumab 90 mg SC Q8w will be able to cross-over to a OLE treatment regimen of ustekinumab 90 mg SC Q4w if they meet the criteria of CD worsening at week 12 or at any timepoint beyond week 12 after entering REScUE-OLE"
89184279|NCT00718575|No Intervention|2|Neither donors nor recipients receive any intervention. All procedures will be performed according to our institution's standard of care.
89384518|NCT04892173|Experimental|Arm A|NBTXR3, as an intratumoral/intranodal injection, activated by investigator's choice of RT alone or RT in combination with cetuximab. NBTXR3 is given as a single intratumoral injection as a dose of 33% of the Gross Tumor Volume
89384519|NCT04892173|Active Comparator|Arm B|Investigator's choice of RT alone or RT in combination with cetuximab
89384520|NCT03199391|Experimental|BioWick SureLock Implant|All subjects are part of a single arm. All subjects received the BioWick SureLock implant.
89384521|NCT01329913|Experimental|GT1-HCV 200 mg|
89384522|NCT01329913|Experimental|GT1-HCV 400 mg|
89384523|NCT01329913|Experimental|GTI-HCV 800 mg|
89384524|NCT01329913|Experimental|GT3-HCV 200 mg|
88858294|NCT05299931|Other|Subcutaneous (SC) ustekinumab every 4 weeks (Q4w)|"Patients previously enrolled to the ustekinumab 90 mg SC Q8w-arm will switch to ustekinumab 90 mg SC Q4w (Cross-over) if they are Q8w non-responders at the end of REScUE OR Patients previously enrolled to the ustekinumab 90 mg SC Q4w-arm will continue ustekinumab 90 mg SC Q4w if they are Q4w responders at the end of REScUE"
88858295|NCT05295628|Experimental|EMBLOK™ Embolic Protection System|"Device Description:~The EMBLOK™ Embolic Protection System (EMBLOK EPS) is a sterile, single use system designed to capture and remove debris (e.g., thrombus, calcium, atheroma) dislodged during transcatheter aortic valve replacement (TAVR) procedures. The device is currently for investigational use only.~When Device Will Be Used:~Roll-in: Prior to enrollment of the first randomized subject at each site, each site will enroll 2 Roll-In subjects, who will not be randomized but will receive the EMBLOK EPS during TAVR.~Randomized: Up to 422 subjects meeting eligibility criteria will be randomized 1:1. The experimental intervention arm is utilizing EMBLOK EPS during TAVR (up to 211 subjects).~Nested registry: Up to 50 subjects who meet clinical eligibility criteria and are anatomically suitable for the EMBLOK EPS, but whose anatomy precludes the use of the SENTINEL CPS."
88858296|NCT05295628|Active Comparator|SENTINEL™ Cerebral Protection System|"Device Description:~The control comparator is the commercially-available SENTINEL™ Cerebral Protection System (SENTINEL CPS) (Boston Scientific Corp., Marlborough, MA, US), a dual-filter protection device designed to capture and remove debris dislodged during TAVR procedures.~The SENTINEL CPS is indicated for use as an embolic protection device to capture and remove thrombus/debris while performing TAVR procedures. The diameters of the arteries at the site of filter placement should be between 9.0 mm - 15.0 mm for the brachiocephalic and 6.5 mm - 10.0 mm in the left common carotid.~When Device Will Be Used:~In the randomized cohort, up to 422 subjects meeting eligibility criteria will be randomized 1:1 (stratified by operative risk and study site). The active comparator control arm is utilizing SENTINEL CPS during TAVR (up to 211 subjects)."
88858297|NCT05280067|Experimental|Investigational Device The ZetaFuse™ Bone Graft|The ZetaFuse™ Bone Graft is percutaneously implanted into the bone defect created by the metastatic tumor in a spinal vertebral body. The ZetaFuse™ Bone Graft is only for implantation into the vertebral body.
88858298|NCT05277740||CIS|Diagnosis of Clinically Isolated Syndrome (CIS) with abnormal MRI.
88858299|NCT05277740||RRMS|Diagnosis of Relapsing-Remitting MS (RRMS).
88858300|NCT05277740||Healthy Control|Participant with no evidence or history of significant neurodegenerative disorder affecting brain function.
88858301|NCT05260892||Narrow GM|Patients presenting at least onde edentulous site rehabilitated with Narrow GM implant
88858302|NCT05258435||Simplify Disc|Extended follow-up of subjects treated with the Simplify Disc during IDE G140154 and followed in the post-approval study NCT04630626.
88858303|NCT05246566||Subjects covered for suspected or SE diagnosis|"Patients covered for suspected or SE diagnosis defined by one of the following:~a prolonged generalized tonic-clonic crisis lasting more than 5 minutes and accompanied by impaired consciousness or at least 2 generalized tonic-clonic crisis without return to normal consciousness between crisis.~a focal convulsive crisis (motor or not) with disturbances of consciousness which lasts beyond 10 minutes or crisis which are repeated (≥ 2) at short intervals without recovery of interictal consciousness.~a focal convulsive crisis (motor or not) without alteration of consciousness that lasts beyond 10 to 15 minutes.~an absence-type crisis that lasts longer than 10 to 15 minutes.~a myoclonic, clonic and tonic crisis that lasts longer than 10 to 15 minutes.~a coma with an epileptic cause diagnosed on an EEG."
88858304|NCT05244304|Experimental|Tinlarebant|5 mg tablet taken orally once a day
88858305|NCT05244304|Placebo Comparator|Placebo|Placebo tablets for tinlarebant 5 mg are prepared similarly but use microcrystalline cellulose, NF, in place of the active drug substance and will be identical in size and appearance.
88858306|NCT05235321|Active Comparator|Standard GAT|This is the standard method for IOP measurement in clinical practice
89384525|NCT01329913|Experimental|GT3-HCV 400 mg|
89384526|NCT01329913|Experimental|GT3-HCV 800 mg|
89384527|NCT01329991|Active Comparator|oral dose of 200 mg PLX5622|6 subjects will be randomized to take an oral dose of PLX5622 for 14 days and 2 subjects will be randomized to take placebo.
89384528|NCT01329991|Active Comparator|oral dose of 400 mg PLX5622|6 subjects will be randomized to take an oral dose of PLX5622 for 14 days and 2 subjects will be randomized to take placebo.
89384529|NCT01329991|Active Comparator|oral dose of 800 mg PLX5622|6 subjects will be randomized to take an oral dose of PLX5622 for 14 days and 2 subjects will be randomized to take placebo.
89384530|NCT01329991|Active Comparator|oral dose of PLX5622-dose to be determined|6 subjects will be randomized to take an oral dose of PLX5622 for 14 days and 2 subjects will be randomized to take placebo.
89384531|NCT01329991|Placebo Comparator|Placebo Comparator|2 patients per cohort will be randomly assigned to take placebo. 8 patients total will be randomized to take placebo in this study.
89384532|NCT01569009||Observational|Patients are asked to continue with their normal daily activities.
89384533|NCT01382667||GLP-2 and symptom evaluation|Before starting and at the end of the chemotherapy, along with a blood withdrawal for GLP-2 evaluation, a GSRS (gastrointestinal symptom rate scale) questionnaire will be filled by each patient to account for GI symptoms. In addition, minor complaints such as warm sensation after chemotherapy, susceptibility to nausea under specific condition, sweating and weakness will scored by visual analog score (VAS). Lastly, the NCI-CTC score for mucositis will be performed.
89384534|NCT03198767|Experimental|Part A: LIK066 + P1: 50% CHO / P2: 25% CHO / P3: 0% CHO|Period 1 (Day 1-3): Daily dose of 50 mg LIK066 + 50% carbohydrate (CHO) Period 2 (Day 9-11): Daily dose of 50 mg LIK066 + 25% carbohydrate Period 3 (Day 17-19): Daily dose of 50 mg LIK066 + 0% carbohydrate
89384535|NCT03198767|Experimental|Part A: LIK066 + P1: 25% CHO / P2: 0% CHO / P3: 50% CHO|Period 1 (Day 1-3): Daily dose of 50 mg LIK066 + 25% carbohydrate (CHO) Period 2 (Day 9-11): Daily dose of 50 mg LIK066 + 0% carbohydrate Period 3 (Day 17-19): Daily dose of 50 mg LIK066 + 50% carbohydrate
89384536|NCT03198767|Experimental|Part A: LIK066 + P1: 0% CHO / P2: 50% CHO / P3: 25% CHO|Period 1 (Day 1-3): Daily dose of 50 mg LIK066 + 0% carbohydrate (CHO) Period 2 (Day 9-11): Daily dose of 50 mg LIK066 + 50% carbohydrate Period 3 (Day 17-19): Daily dose of 50 mg LIK066 + 25% carbohydrate
89384537|NCT03198767|Experimental|Part A: LIK066 + P1: 8% CHO|Period 1 (Day 1-3): Daily dose of 50 mg LIK066 + 8% carbohydrate (CHO) PROTOCOL DEVIATION: subjects received 8% CHO in error and were discontinued after Period 1.
89384538|NCT03198767|Experimental|Part B: LIK066 + 50% CHO + P1: NS / P2: PS / P3: CC|Period 1 (Day 1-3): Daily dose of 50 mg LIK066+50% carbohydrate + no supplement (NS) Period 2 (Day 9-11): Daily dose of 50 mg LIK066+50% carbohydrate + 6 g psyllium (PS) Period 3 (Day 17-19): Daily dose of 50 mg LIK066+50% carbohydrate +1g calcium carbonate (CC)
89384539|NCT03198767|Experimental|Part B: LIK066 + 50% CHO + P1: PS / P2: CC / P3: NS|Period 1 (Day 1-3): Daily dose of 50 mg LIK066+50% carbohydrate + 6 g psyllium (PS) Period 2 (Day 9-11): Daily dose of 50 mg LIK066+50% carbohydrate +1g calcium carbonate (CC) Period 3 (Day 17-19): Daily dose of 50 mg LIK066+50% carbohydrate + no supplement (NS)
89384540|NCT03198767|Experimental|Part B: LIK066 + 50% CHO + P1: CC / P2: NS / P3: PS|Period 1 (Day 1-3): Daily dose of 50 mg LIK066+50% carbohydrate +1g calcium carbonate (CC) Period 2 (Day 9-11): Daily dose of 50 mg LIK066+50% carbohydrate + no supplement (NS) Period 3 (Day 17-19): Daily dose of 50 mg LIK066+50% carbohydrate + 6 g psyllium (PS)
89384541|NCT03162055|Experimental|Experimental|glycopyrronium/formoterol fumarate 7.2/4.8 μg per actuation, twice daily
89384542|NCT03162055|Active Comparator|Active comparator|umeclidinium/vilanterol 62.5/ 25μg per inhalation, once daily
89384543|NCT02927145|Active Comparator|Group 1-Phase Ia|The study is designed to assess a 'standard' protein-in-adjuvant vaccination regimen- 2µg RH5.1/ 0.5mL AS01- of 3 doses given four weeks apart, with dose escalation to assess the best dose in healthy adults.
89384544|NCT02927145|Active Comparator|Group 2- Phase Ia|"The dose used will be- 10µg RH5.1/ 0.5mL AS01. The total number of volunteers recruited to Groups 1 and 2 will be decided based on the immunogenicity of the vaccines at the 2 µg and 10 µg doses.~If the doses are immunogenic the groups (1 and 2) will be recruited to a total of 12 volunteers."
89384545|NCT02927145|Active Comparator|Group 3-Phase Ia|"Group 3 will receive 50µg RH5.1/ 0.5mL AS0~The ultimate aim is to assess the safety and immunogenicity of giving the 'standard' first two doses of the vaccine followed by a delayed fractional dose (10 µg)."
89184280|NCT02572713||Early PD|20 early PD not requiring dopamine replacement therapy have been enrolled.
89384546|NCT02927145|Active Comparator|Group 4-Phase Ia|Group 3 and 4 will be recruited simultaneously. The dose of vaccine for this group is same as that of 3 (50µg RH5.1/ 0.5mL AS01)
89384547|NCT02927145|Active Comparator|Group 5-Phase IIa|The vaccination dose for Group 5 was decided following the analysis of safety and exploratory immunology assays from Groups 1, 2 and 4. The dose of vaccine for this group is the same as that of group 2 (10µg RH5.1/ 0.5mL AS01).
89384548|NCT02927145|No Intervention|Group 6-Phase IIa|"Group 6 volunteers will be infectivity controls, so will not receive any vaccinations.~Groups 5 and 6 will only be recruited once at least 6 volunteers in Group 4 have completed all vaccinations."
89384549|NCT02927145|Active Comparator|Group 7-Phase IIa|Group 7 are Group 5 volunteers who will receive a fourth dose of IMP (10µg RH5.1/ 0.5mL AS01)
89384550|NCT02927145|No Intervention|Group 8 -Phase IIa|Group 8 are infectivity controls who were originally in Group 6.
89384551|NCT02927145|No Intervention|Group 9 -Phase IIa|Group 9 are new infectivity controls
89535129|NCT05006469|Experimental|BAd treatment|Bendamustine 70-90mg/m2, d1, d2 Liposome Adriamycin 15-20mg/m2, d1 or Adriamycin 10mg d1-d4 Dexamethasone 40mg qw po. (20mg, >70 years old) There is a course of treatment every 28 days, and a total of 6 courses are completed.
88818684|NCT01842815|Experimental|755nm Alexandrite Laser Double Pass (Left Side)|755nm Alexandrite Laser for Treatment of unwanted, non cosmetic tattoos. The left side of the tattoo will be treated twice within the same visit 20 minutes apart.
88818685|NCT02714283||Non-CF bronchiectasis patients|Complete national 2006-2014 Medicare data from Part A, B and D will be obtained from CMS. We will use bronchiectasis ICD-9 codes 494.0 and 494.1 to identify patients with bronchiectasis within Medicare. From this identified bronchiectasis cohort, we will exclude patients with cystic fibrosis (ICD-9 codes 277.00-277.09), HIV infection (042), and a history of organ transplant (V42.0, V42.1, V42.6, V42.7, V42.8).
88818686|NCT04810949|Experimental|serum vitamin D levels >20ng/ml (Group 1)|Patients with serum vitamin D levels >20ng/ml that will receive Vitamin D supplementation
88818687|NCT04810949|Experimental|serum vitamin D levels >20ng/ml ( Group 2)|Patients with vitamin D levels >20ng/ml that will receive diet and hygiene measures
88818688|NCT04810949|Other|serum vitamin D3 levels < 20ng/ml (Group3)|Patients with Vitamin D levels<20ng/ml will receive vitamin D3 supplementation according to primary care discresion
88818689|NCT02718963|Experimental|Control group|"control group(N=10): who does not have dysphagia symptom~apply Synchronized Electrical Stimulation Device~before apply the synchronized electrical stimulation device, we will evaluate the high resolution manometry for evaluation of deglutition function~during apply the synchronized electrical stimulation device, we will evaluate the high resolution manometry for evaluation of deglutition function"
88818690|NCT02718963|Experimental|Experimental group|"experimental group(N=10): who have dysphagia symptoms~apply Synchronized Electrical Stimulation Device~before apply the synchronized electrical stimulation device, we will evaluate the high resolution manometry for evaluation of deglutition function~during apply the synchronized electrical stimulation device, we will evaluate the high resolution manometry for evaluation of deglutition function"
88818691|NCT04795583|Experimental|Prednisone|"Treatment adjusted by weight. Prednisone 25 mg capsules:~≤ 50kg = 2 capsules QD x 7 days (maximum dose = 50mg/day)~50 - 80kg = 3 capsules QD x 7 days (maximum dose = 75mg/day)~> 80kg = 4 capsules QD x 7 days (maximum dose = 100mg/day)"
88818692|NCT04795583|Placebo Comparator|Placebo|Capsules with the same appearance as Prednisone
88818693|NCT05746949|No Intervention|jet ventilation group|Jet ventilation
88818694|NCT05746949|Experimental|Optiflow group|High flow nasal oxygen
88858307|NCT05235321|Experimental|Fixed-force GAT|From the patient perspective, this method will feel identical to the standard GAT. The eye is given topical fluorescein/anesthetic. The GAT dial is set at 1.8 or 2.0, a C-MOS camera is connected to one of the oculars of the slit lamp machine and under blue light illumination, the GAT prism contacts the eye while the CMOS camera makes a video of the mire appearance through the ocular. The diameters of the recorded mire images are measured and the IOP is calculated based on the mire diameter
88858308|NCT05235321|Experimental|Upright applanating prototype|With this prototype, an applanating prism (custom manufactured with medical grade acrylic in an ISO-13485 certified facility) is attached to a fixed-force spring that creates a force equivalent to 1.8 or 2.0 on the GAT dial. Blue LED lights on the prototype are used to create the blue illumination similar to the blue light used in clinical practice on the slit lamp or Perkins tonometer. A C-MOS camera is aligned with the GAT prism to image the applanation mires. The eye is given topical fluorescein/anesthetic. Like fixed-force GAT, the GAT prism contacts the eye while the CMOS camera makes a video of the mire appearance. The diameters of the recorded mire images are measured and the IOP is calculated based on the mire diameter
88858309|NCT05235321|Experimental|Supine Applanating Prototype|With this method, a 5 gram clear acrylic cylinder (custom manufactured with medical grade acrylic in an ISO-13485 certified facility) is aligned with the lens of the CMOS camera and the distal tip of the cylinder is illuminated with blue light using an LED similar to the blue light used in clinical practice on the slit lamp or Perkins tonometer. The eye is given topical fluorescein/anesthetic. While the CMOS camera is recording, the 5 gram weight will rest upon the eye and circular applanation mires are recorded. The diameters of the recorded mire images are measured and the IOP is calculated based on the mire diameter
88858310|NCT05216809|Active Comparator|Young Adults|Equal sex distribution (10M/10F); ages 18-35 years old.
88858311|NCT05216809|Active Comparator|Older Adults|Equal sex distribution (6M/6F); ages 60-80 years old.
88858312|NCT05216432|Experimental|RLY-2608 for patients with unresectable or metastatic solid tumors|Multiple doses of RLY-2608 for oral administration.
88858313|NCT05216432|Experimental|RLY-2608 + fulvestrant combination for HR+ HER2- locally advanced or metastatic breast cancer|Oral dose of RLY-2608 in addition to fulvestrant as determined during Part 1 Dose Escalation.
88858314|NCT05216432|Experimental|RLY-2608+fulvestrant+palbociclib 125 mg for HR+ HER2- locally advanced or metastatic breast cancer|Oral dose of RLY-2608 in addition to fulvestrant and palbociclib 125mg as determined during Part 1 Dose Escalation.
88858315|NCT05216432|Experimental|RLY-2608+fulvestrant+ribociclib 400 mg for HR+ HER2- locally advanced or metastatic breast cancer|Oral dose of RLY-2608 in addition to fulvestrant and ribociclib 400mg as determined during Part 1 Dose Escalation.
89184281|NCT02572713||Moderate PD|20 moderate PD on dopamine replacement therapy without motor fluctuations have been enrolled.
88858316|NCT05216432|Experimental|RLY-2608+fulvestrant+ribociclib 600 mg for HR+ HER2- locally advanced or metastatic breast cancer|Oral dose of RLY-2608 in addition to fulvestrant and ribociclib 600mg as determined during Part 1 Dose Escalation.
89184282|NCT02572713||Advanced PD|21 advanced PD with motor fluctuations have been enrolled.
89184283|NCT02572713||Healthy Controls|21 healthy controls have been enrolled.
89184284|NCT00710073|Experimental|A|Combined sono-electro-magnetic therapy
89184285|NCT04070937||study group|all patients at least 18 years of age who present bilateral vestibulopathy on vestibular investigations according to the Barany criteria
88858319|NCT05200559|Experimental|E7777 + Pembrolizumab|"Phase l:~E7777: Dose Level 1, 3 µg/kg; Dose Level 2, 6 µg/kg; Dose Level 3, 9 µg/kg; Dose Level 4, 12 µg/kg Day 1-3 - given up to 8 cycles (dose-limiting toxicities assessed for first two cycles, only)~Pembrolizumab: 200 mg, IV on Day 1 (21-day cycle)~Phase ll:~E7777: administered on Day 1-3 at Phase 2 Recommended Dose (P2RD); Day 1-3 up to 8 cycles~Pembrolizumab: 200 mg, IV on Day 1 (21-day cycle)"
88858320|NCT05194722|Experimental|Orthopedic spine patients|In addition to participating in semi-structured interviews and usability testing of the study interventions, participants in this arm will receive one month of access to Wysa. They will complete measures of clinical effectiveness and hypothesized behavioral targets at baseline and one-month follow-up.
88858321|NCT05185622|Experimental|Treatment Group 1|Patients in Treatment Group 1 must be ages 2-<4 years and will receive Vamorolone at 2.0 mg/kg/day for the duration of the study. Treatment Group 1 will be enrolled prior to Treatment Group 2.
88858322|NCT05185622|Experimental|Treatment Group 2|Patients in Treatment Group 2 must be ages 2-<4 years and will receive Vamorolone at 6.0 mg/kg/day for the duration of the study. Treatment Group 2 will be enrolled after Treatment Group 1.
88858323|NCT05185622|Experimental|Treatment Group 3|Patients in Treatment Group 3 must be ages 7-<18 years and must be steroid untreated at entry. Treatment Group 3 will receive Vamorolone at 2.0 mg/kg/day for the duration of the study.
88858324|NCT05185622|Experimental|Treatment Group 4|Patients in Treatment Group 4 must be ages 7-<18 years and must be on a stable dose of steroid for 3 months prior to entry. Treatment Group 4 will receive Vamorolone at 2.0 mg/kg/day for the duration of the study.
88858325|NCT05185622|Experimental|Treatment Group 5|Patients in Treatment Group 5 must be ages 7-<18 years and must be steroid untreated at entry. Treatment Group 5 will receive Vamorolone at 6.0 mg/kg/day for the duration of the study.
89184286|NCT04070937||control group|DFNA9 patients carrying the p.P51S mutation in COCH gene presenting bilateral vestibulopathy according to the Barany criteria
89184287|NCT00715455|Active Comparator|Unfractionated Heparin|Unfractionated Heparin
89184288|NCT00715455|Experimental|REG1 Partial Rev.|REG1 with partial reversal
89184289|NCT00715455|Experimental|REG1 Total Rev.|REG1 with total reversal
89384552|NCT03980535|Experimental|Device Feasibility (MRI, MRSI)|Patients undergo an additional investigational MRI or MRSI sequence along with the standard MRI or MRSI. Healthy volunteers undergo an investigational MRI or MRSI sequence. Healthy volunteers may also undergo an additional standard sequence if there is one that can be compared to the investigational sequence. All MRI or MRSI procedures, including the standard MRI or MRSI, are no longer than 60 minutes.
89384553|NCT03688919|No Intervention|Comparison|Adolescents and their families in this group will not receive any of the interventions.
89384554|NCT03688919|Experimental|Self-Regulation Intervention|This arm will use a computer-based working memory training game (NBack) targeting Executive Functioning and in-person relaxation and biofeedback training targeting Emotion Regulation. As well, adolescents will receive Future Orientation training by being asked to envision and describe future events they are looking forward to, using concrete, vivid descriptive language.
89384555|NCT01331785|Experimental|Midodrine|
89535130|NCT04485247|Active Comparator|Conventional group|conventional laparoscopic appendectomy with 3-ports
89184290|NCT02574663|Experimental|TGR-1202|TGR-1202 daily dose
89184291|NCT02574663|Experimental|TGR-1202 + nab-paclitaxel + gemcitabine|TGR-1202 oral daily dose + nab-paclitaxel + gemcitabine both as an IV infusion
89184292|NCT02574663|Experimental|TGR-1202 + FOLFOX|TGR-1202 oral daily dose + oxaliplatin IV infusion + leucovorin IV infusion followed by 5-fluorouracil IV bolus followed by 5-FU IV infusion (FOLFOX regimen)
89184293|NCT02574663|Experimental|TGR-1202 + FOLFOX + Bevacizumab|TGR-1202 oral daily dose + oxaliplatin IV infusion + leucovorin IV infusion followed by 5-fluorouracil IV bolus followed by 5-FU IV infusion (FOLFOX regimen) + bevacizumab IV infusion
89384556|NCT01382589|Experimental|Arm A: Afamelanotide + NB-UVB|Subject in this arm will receive both afamelanotide implants (one implant administered every 28 days, 6 implants in total) and NB-UVB light (administered thrice weekly, 72 treatments in total)
89384557|NCT01382589|Active Comparator|Arm B: NB-UVB alone|Subjects in this arm B will receive NB-UVB light only (administered thrice weekly, 72 treatments in total)
89384558|NCT01381653|Experimental|Motivational Interviewing|Eight 30-minute sessions utilizing Motivational Interviewing will be delivered to reduce substance use and sexual risk in a group of high risk young men who have sex with men.
89384559|NCT03671759|Experimental|Experimental: N-of-1|"Participants will be randomized in two-day blocks to consume then avoid caffeine (Start: On Caffeine) or avoid then consume caffeine (Start: Off Caffeine). Using an N-of-1 strategy delivered by the NIH-funded, UCSF-run Eureka platform utilizing a mobile smartphone-based application, participants will receive instructions and answer questions to help us understand the relationship between caffeine and heart rhythm."
89384560|NCT01384227|Experimental|Proflavine Hemisulfate|
89384561|NCT01315171|Experimental|Medium chain supplemented diet|Subjects will have a diet during which all meals are supplemented with 4 tablespoons of medium chain triglyceride oil.
89384562|NCT01315171|No Intervention|Standard group|Subjects will continue with a standard western diabetes diet.
89184294|NCT00710151||1|Subjects with PCNSL who have survived disease-free for 2 years or more. Treatments will vary depending upon site of enrollment and will include chemotherapy, blood brain barrier disruption (BBBD) with chemotherapy, radiation, and stem cell transplantation.
89184295|NCT00718653|Experimental|1|lutein
89184296|NCT00718653|Experimental|2|Lutein plus green tea extract
89384563|NCT04631835|Experimental|HS-10352|There are five escalating dose cohorts
89384564|NCT04646369|Active Comparator|"screening as usual"|"Participants in the screening as usual' group will have a symptoms scores report of results sent to their provider based on their Screening Wizard responses."
89384565|NCT04646369|Experimental|Screening Wizard 2.0|Participants in the Screening Wizard 2.0 Report group will have a symptoms scores report of results and treatment preferences, barriers, and recommendations sent to their provider based on their Screening Wizard responses.
89384566|NCT04646369|Experimental|Screening Wizard 2.0 + SOVA|Participants in the Screening Wizard 2.0 + SOVA group will have a symptoms scores report of results and treatment preferences, barriers, and recommendations sent to their provider based on their Screening Wizard responses. This group will also receive access to the SOVA website aimed at addressing perceptions about mental health providing support to teens through peer interaction.
89384567|NCT02888119|Active Comparator|High Risk for Osteoarthritis|"High risk of developing knee OA has been defined by having knee pain but normal radiographs (Kellgren-Lawrence score 0 i.e. KL0) on both knees but at least one abnormal finding on clinical MR protocol such as overweight, prior knee injury (ligaments or menisci) or traumatic bone marrow edema lesions."
89384568|NCT02888119|Active Comparator|Mild Osteoarthritis|
89384569|NCT02888119|Active Comparator|Healthy Controls|Controls will be age/gender matched to patients within 2 years of age.
89384570|NCT03631329||Uncomplicated cesarean delivery|Uncomplicated singleton full-term parturients undergoing cesarean delivery
89184297|NCT00718731|Experimental|1|Subject on active drug
89184298|NCT00718731|Placebo Comparator|2|Subject on placebo
89184299|NCT04083846|Experimental|Group 1|"Period 1: Reference drug~Period 2: Test drug 1~Period 3: Test drug 2"
89184300|NCT04083846|Experimental|Group 2|"Period 1: Test drug 2~Period 2: Reference drug~Period 3: Test drug 1"
89184301|NCT04083846|Experimental|Group 3|"Period 1: Test drug 1~Period 2: Test drug 2~Period 3: Reference drug"
89384571|NCT03684447|Experimental|Propofol High Dose|high propofol injectable, individually dosed, three times per week
89384572|NCT03684447|Experimental|Propofol Low Dose|low propofol injectable, individually dosed, three times per week
89384573|NCT04505059|Experimental|Precision cardiac anesthesia|Remifentanil (TCI) for intra-operative analgesia Propofol (TCI) for intra-operative sedation
89384574|NCT04505059|Active Comparator|Conventional cardiac anesthesia|Institutional standard of care.
89384575|NCT01382433|Experimental|Chronic Cannabis Users|
89384576|NCT01382433|Experimental|Control|Neurotypical subjects
89384577|NCT01333657||SIRS|"temperature >38 ℃ or <36℃;~pulse rate>90 beats/min;~ventilatory rate>20 breaths/min or hyperventilation with partial pressure of arterial carbon dioxide (PaCO2)<32mmHg;~white blood cell count>12,000μL-1 or <4000μL-1 or >10% immature cells"
89384578|NCT01333657||Sepsis|"sepsis: SIRS plus infection;~severe sepsis: sepsis associated with organ dysfunction, hypoperfusion, or hypotension;~septic shock: sepsis with arterial hypotension, despite adequate ﬂuid resuscitation."
89184302|NCT04083846|Experimental|Group 4|"Period 1: Test drug 2~Period 2: Test drug 1~Period 3: Reference drug"
89184303|NCT04083846|Experimental|Group 5|"Period 1: Test drug 1~Period 2: Reference drug~Period 3: Test drug 2"
89184304|NCT04083846|Experimental|Group 6|"Period 1: Reference drug~Period 2: Test drug 2~Period 3: Test drug 1"
89384579|NCT03549299|Experimental|LSC2; 7.5 x 10^4 cells|Single dose of LSC2, 7.5 x 10^4 cells per patient
89384580|NCT03549299|Experimental|LSC2; 3.0 x 10^5 cells|Single dose of LSC2, 3.0 x 10^5 cells per patient
89384581|NCT03549299|Experimental|LSC2; 8.0 x 10^5 cells|Single dose of LSC2, 8.0 x 10^5 cells per patient
89384582|NCT03549299|Experimental|LSC2; 1.2 x 10^6 cells|Single dose of LSC2, 1.2 x 10^6 cells per patient
89384583|NCT01315327|Experimental|Omega-3 Fatty Acids|Omega-3 Fatty Acids (fish oil), flexibly titrated up to 6000 mg/day.
89384584|NCT01315327|Placebo Comparator|Placebo|Olive oil placebo, looks and tastes identical to active intervention.
89384585|NCT01314599|Experimental|Arm 1|PM01183 will be administered i.v. as a 1-hour infusion through a pump device at escalating doses according to the respective dose level, on Days 1 and 8 of each treatment phase.
89384586|NCT04243863|Experimental|VNRX-7145|Oral dosing
89384587|NCT04243863|Placebo Comparator|Placebo|Oral dosing
89384588|NCT02635633|Experimental|continuous thetaburst stimulation|Transcranial magnetic stimulation over the epileptogenic focus using a cTBS stimulation protocol.
89384589|NCT03197129|Experimental|SADE waiting room|children that will wait in the SADE waiting room
89384590|NCT03197129|No Intervention|Traditional waiting room|children that will wait in the traditional waiting room
89384591|NCT01333735||Patients with chemotherapy group|Patients with breast or colon cancer must beginning a chemotherapy (colon group was ended)
89384592|NCT01333735||Patients without chemotherapy group|patient with breast or colon cancer should not receive chemotherapy (colon group was ended)
89384593|NCT04217135|Active Comparator|conventional treatment|This group will receive conventional evidence-based medications with up-titration to maximal tolerable dose. The evidence-based medications include angiotensin converting enzyme inhibitor/angiotensin receptor blocker, beta-blocker, mineralocorticoid receptor antagonist, ivabradine and entresto. Which evidence-based medications will be started first depends on the decision of in-charge doctors without strict regulation. However, all evidence-based medications should be up-titrated to maximal tolerable dose. (Excuse me! Up-titration of evidence-based medications in heart failure isn't multiple intervention. Those medications should be prescribed in each heart failure case if no contraindication was noted.)
89384594|NCT04217135|Active Comparator|high-dose hydralazine group|another group will receive low-dose hydralazine initially with rapid up-titration, if no adverse effect including hypotension with worsening low cardiac output sign, skin rash and joint pain occurred. Since the half-life of hydralazine is around 4-6 hours and 3-5 half-life achieves the steady blood concentration, up-titration of hydralazine will be done per 1-2 days. For example, initial dose of hydralazine would be 25 mg tid and the dose would be 50 mg bid next day if no adverse effect occurred. Following this rule, one week is enough to reach high-dose hydralazine with daily dose of 300-400 mg.
89384595|NCT01337401|Experimental|Blinded Cediranib|
89384596|NCT01337401|Placebo Comparator|Blinded Placebo|
89384597|NCT01331863|Experimental|single arm surgery|Airway and/or pulmonary Vessels Transplantation
89184305|NCT02574507|Experimental|Couples-Based Behavioral Weight and Symptom Management|Participants will receive 12 session (6 weekly and 6 biweekly) of a behavioral weight and symptom management intervention.
89384598|NCT04178603|Experimental|Acute Exercise Trial|Lean control subjects and insulin resistant subjects perform an acute bout of one-legged knee-extensor exercise. Glucose metabolism is investigated before exercise (basal), during exercise and for 120 min of recovery.
89384599|NCT04178603|Experimental|Insulin Sensitivity post Exercise|Lean control subjects and insulin resistant subjects perform an acute bout of one-legged knee-extensor exercise and insulin action is investigated 4 hours after cessation of exercise. Insulin action is investigated by a 120 min euglycemic-hyperinsulinemic euglycemic clamp.
89384600|NCT01333891|Active Comparator|Sodium-Nitroprusside|Nipruss®, Sanol-Schwarz, Monheim, Germany 0, 0.5, 1 and 2 µg/kg/min, each infusion step for 5 minutes, total infusion period of 20 minutes
89384601|NCT01333891|Active Comparator|Phenylephrine|Neosynephrine®, Winthrop Breon Laboratories New York, NY, USA 0, 0.5, 1 and 2 μg/kg/min, each infusion step for 5 minutes, total infusion period of 20 minutes
89384602|NCT01333891|Active Comparator|Suction Cup|suction force of 25, 50, 75, and 100 mmHg
89384603|NCT04427605||ketamine group|ketamine intravenous infusion in pediatric patients refractory to conventional analgesic-sedative strategy lasted more than 12 hours (dose range 10-50 mcg/Kg/min)
89384604|NCT04853875|Experimental|Group A (Tetracycline, Metronidazole, and Bismuth)|Intraluminal Therapy for Helicobacter pylori Infection - Single dose medicament containing Tetracycline 2g, Metronidazole 2g, and Bismuth subcitrate 480 mg
89384605|NCT04853875|Active Comparator|Group B (Amoxicillin, Metronidazole, and Clarithromycin)|Intraluminal Therapy for Helicobacter pylori Infection - Single dose medicament containing Amoxicillin 3g, Metronidazole 2g, and Clarithromycin 1g
89384606|NCT03196973|Experimental|DF289 plus DF277|Otic solution
89384607|NCT03196973|Active Comparator|DF289|Otic solution
89384608|NCT03196973|Active Comparator|DF277|Otic solution
89384609|NCT01333969|Active Comparator|Ishcemic Preconditioning|In the study group, the patients' operative limb will be preconditioned by inflating the tourniquet for 5 minutes, followed by deflation and a 5-minute reperfusion period. Subsequently, the tourniquet will be inflated for the entire length of the operation (before skin incision to after insertion of the final components).
89384610|NCT01333969|No Intervention|Control|In the control group, the tourniquet will be used for the entire length of the operation without a preconditioning phase.
89384611|NCT03196505|Active Comparator|Liposomal Bupivacaine|Liposomal bupivacaine (Exparel) 20mL of injectable saline diluted with 60 ml of 0.25% Marcaine and 20 ml of saline for a total of 100 ml. After induction of anesthesia, the patients will receive a 20 ml mixture locally infiltrated at each trocar incision site (5 sites).
89384612|NCT03196505|Active Comparator|Control|60 milliliters (ml) of 0.25% bupivacaine diluted with 40 ml of saline for a total of 100 ml. After induction of anesthesia, the patients will receive 20 ml mixture locally infiltrated at each trocar incision site (5 sites).
89384613|NCT01334047|Experimental|DC vaccine|Dendritic cells loaded with amplified ovarian cancer stem cell mRNA, hTERT and Survivin.
89384614|NCT01337479||Participants of specific phase III entecavir studies|Those who participated in the specific Phase III entecavir studies as described; all had Hepatitis B infections
89384615|NCT01337557|Experimental|Bepotastine|
89384616|NCT01337713|Experimental|Swedish Massage|
89384617|NCT01337713|Sham Comparator|Light Touch|
89384618|NCT03196349|Active Comparator|Warfarin|Subjects randomized to Warfarin will have warfarin administered daily in order to maintain a target INR of 2-3
89384619|NCT03196349|Active Comparator|Apixaban|Subjects randomized to Apixaban will have apixaban administered study drug of 2.5mg twice daily
89384620|NCT03196349|Active Comparator|Rivaroxaban|Subjects randomized to Rivaroxaban will have rivaroxaban administered study drug of 10 mg daily
89384621|NCT01331941|Experimental|Group 1|Cancer subjects with normal renal function.
89384622|NCT01331941|Experimental|Group 3|Cancer subjects with moderate renal impairment.
89384623|NCT01331941|Experimental|Group 4|Cancer subjects with severe renal impairment.
89384624|NCT01331941|Experimental|Group 2|Cancer subjects with mild renal impairment.
89384625|NCT02886715|Experimental|Test|Tazarotene Cream 0.1% (Fougera Pharmaceuticals Inc.)
89384626|NCT02886715|Active Comparator|Reference|TAZORAC® (tazarotene) Cream, 0.1% (Allergan, Inc.)
89384627|NCT02886715|Placebo Comparator|Placebo|Placebo (Vehicle of test product) (Fougera Pharmaceuticals Inc.)
89384628|NCT04403737|No Intervention|Usual Care|Patients in the control arm will have a Rothman Index calculated but this will not be visible to providers.
89384629|NCT04403737|Experimental|Intervention|Patients in the intervention arm will have a Rothman Index calculated and will be visible to providers. Providers will be given a set of clinician-specific recommended-use protocols that they will be encouraged to follow based on the RI thresholds achieved by patients.
89384630|NCT05186389||"Control Group"|"15 non-obese participants considered metabolically-healthy : control group"
89384631|NCT05186389||Obese group (Ob)|"15 severely obese participants, candidates for bariatric surgery, but without T2D: obese group (Ob)"
89384632|NCT05186389||Obese and Type 2 Diabetes group (ObD)|"15 participants who are both severely obese, candidates for bariatric surgergy and diagnosed with T2D: obese and diabetic group (ObD)."
89384633|NCT04360837|Experimental|PEEP incremental-decremental alveolar recruitment|"installing EIT belt over the chest at the level of the 5th intercostal space and adjustment of the default recruitment settings in pressure control ventilation mode: pressure control 15 cmH20, PEEP 10 cmH2O, fraction of inspired oxygen (FiO2) and respiratory rate according to the discretion of the attending physician, recording basal parameters~implementation of recruitment:~increment phase: increasing PEEP by 3 cmH2O in every two minutes from 10 cmH2O until top of PEEP 25 cmH2O~decrement phase: decreasing PEEP by 3 cmH20 in every two minutes from 25 cmH20 until the basal PEEP 10 cmH20~end inspiratory hold manoeuvre at every PEEP level~recording closing parameters~Repeating the above detailed intervention once daily as long as the patient is controlled ventilation."
89384634|NCT01337791|No Intervention|control|
89384635|NCT01337791|No Intervention|telbivudine|
89384636|NCT01334203|Experimental|Ranolazine|
89384637|NCT01334203|Placebo Comparator|Placebo|
89384638|NCT03085797|Experimental|Mepolizumab 100 mg SC + MF|Participants will receive total thirteen doses of 100 mg SC of mepolizumab in thigh, abdomen or upper arm every 4 weeks for 52 weeks on top of SoC which includes daily nasal spray of mometasone furoate.
89384639|NCT03085797|Placebo Comparator|Placebo SC + MF|Participants will receive total thirteen doses of SC matching placebo in thigh, abdomen or upper arm every 4 weeks for 52 weeks on top of SoC which includes daily nasal spray of mometasone furoate.
89384640|NCT04262791|Experimental|Healthy Volunteers|Healthy participants will be monitored overnight for two consecutive nights at an inpatient setting to collect wrist actigraphy and videography data. Sleep headband (at sites where polysomnography (PSG) is available and performed) data will be collected on Night 2.
88858326|NCT05185622|Experimental|Treatment Group 6|Patients in Treatment Group 6 must be ages 7-<18 years and must be on a stable dose of steroid for 3 months prior to entry. Treatment Group 6 will receive Vamorolone at 6.0 mg/kg/day for the duration of the study.
89384641|NCT04262791|Experimental|Participants With Atopic Dermatitis (AD)|Participants with AD will be monitored overnight for two consecutive nights at an inpatient setting to collect wrist actigraphy and videography data. Sleep headband (at sites where polysomnography (PSG) is available and performed) data will be collected on Night 2. Participants will also be monitored at home via wrist actigraphy, sleep headband when available in the outpatient setting for 7 consecutive nights.
89384642|NCT02560597|Experimental|repetitive transcranial magnetic stimulation|rTMS delivered over the epileptogenic focus
89384643|NCT01334281||Blood: Undergoing Desensitization|Transplant subjects give blood at specified time points. Sensitization to HLA antigens is a barrier to transplant. Several U.S. institutions have protocols for desensitization where patients are treated with IV immunoglobulins (IVIg) and plasmapheresis (PP) to reduce circulating HLA-directed antibody levels. Labs provide doctors information on circulating donor-specific antibody (DSA) levels. These results are the main indicator whether to proceed with transplant. However, no information is given on the fate of the B cells that produce the DSA.
89384644|NCT01334281||Blood: NOT Undergoing Desensitization|Transplant subjects give blood at specified time points. Sensitization to HLA antigens is a barrier to transplant. Several U.S. institutions have protocols for desensitization where patients are treated with IV immunoglobulins (IVIg) and plasmapheresis (PP) to reduce circulating HLA-directed antibody levels. Labs provide doctors information on circulating donor-specific antibody (DSA) levels. These results are the main indicator whether to proceed with transplant. However, no information is given on the fate of the B cells that produce the DSA.
89384645|NCT01334359|Experimental|Treatment Group|Participants randomized to the afterschool intervention
89384646|NCT01334359|Placebo Comparator|Wait List Group|Participants in this group partake in their regular afterschool activities, without intervention from the study staff.
89384647|NCT01569165|Experimental|washing after 30 min|washing with water after 30 min following APF treatment
89384648|NCT01569165|Experimental|washing after 15 min|washing with water after 15 min following APF treatment
89384649|NCT01569165|Experimental|immediately washing with water|immediately washing with water after APF treatment
89384650|NCT01569165|Experimental|cleansing teeth with cotton roll|cleansing teeth with cotton roll immediately following APF treatment
89384651|NCT01569165|No Intervention|no fluoride therapy|control group
89384652|NCT01569243|Other|Usual care group|Subjects in this group will receive the usual standard of care available at MGH.
89384653|NCT01569243|Experimental|Text messaging group|Subjects in this group will be enrolled to receive text messages aimed at providing bite-sized coaching based on measured step count to help improve activity levels and providing reminder, educational and motivation messages aimed at helping patients to meet their diabetes self-management goals.
89384654|NCT03157531|Experimental|B-Laser™ Atherectomy System|B-Laser™ Atherectomy System
89384655|NCT01382355||Kidney transplant|
89384656|NCT02535091|Experimental|YKP3089|Multiple dose
89384657|NCT01382277|Experimental|Rosuvastatin 20 mg|Rosuvastatin 20 mg for 76 weeks.
89384658|NCT03630939|Experimental|ESR-114 1.5%|ESR-114 1.5% Topical Gel BID for 6 weeks
89384659|NCT03630939|Experimental|ESR-114 5.0%|ESR-114 5.0% Topical Gel BID for 6 weeks
89384660|NCT03630939|Placebo Comparator|Vehicle Gel|Placebo Topical Gel BID for 6 weeks
88858327|NCT05185622|Experimental|Treatment Group 7|Patients in Treatment Group 7 must be ages 12-<18 years and must be on a stable dose of steroid for 3 months prior to entry. Treatment Group 7 will receive Vamorolone at 6.0 mg/kg/day for the duration of the study.
88858328|NCT05178732|Experimental|Protein and early|
89384661|NCT02507791|Experimental|Early Fitbit|"Patients will receive Fitbit in the first phase of the study. In addition to attending weekly weight management classes, patients will wear Fitbit Charge HR devices to track heart rate, active minutes, steps taken, calories burned, and sleep patterns. Patients will receive weekly phone calls to review this data, and further recommendations will be given to encourage additional physical activity as clinically indicated based on time spent being physically active. The goal will be for individuals to reach 10,000 steps per day, though if subjects are significantly under that goal, realistic goal-setting (recommended increases of physical activity of 10% at a time). Patients will continue this intervention for 12 weeks. After 12 weeks, they will return for reassessment. This coincides with the completion of the weight loss program. Subjects will then be followed remotely for another 12 weeks and phone call interventions will continue before returning for a final study visit."
89535131|NCT04485247|Experimental|TULAA group|An operator extracts and ligates appendix through umbilical port.
88858329|NCT05178732|Experimental|Protein and late|
88858330|NCT05178732|Experimental|Protein-polyphenol and early|
88858331|NCT05178732|Experimental|Protein-polyphenol and late|
88858332|NCT05173987|Experimental|Pembrolizumab|Participants receive pembrolizumab 400 mg via IV infusion on Day 1 of each 6-week cycle (Q6W) for up to 18 cycles (up to approximately 2 years).
89184306|NCT04069845||liposomal doxorubicin treatment|intravenous liposomal doxorubicin
89184307|NCT04070625||Communication book group|Speech therapy with communication book
89184308|NCT04070625||Control group|Simple speech therapy
89184309|NCT02573805||erectile dysfunction group|International Index of Erectile Function (IIEF-5) questionnaire≥22 Rigiscan test are performed for two nights
89184310|NCT02573805||control group|International Index of Erectile Function (IIEF-5) questionnaire<22 Rigiscan test are performed for two nights
89184311|NCT04068987||Healthy Volunteers|"Healthy volunteers~Recruited from the public~Patients who have scheduled imaging scans for non-cardiac reasons and without a prior history or suspected history of cardiac disease"
89184312|NCT04068987||Children undergoing clinically indicated cardiac MRI|Patients who are scheduled to have a clinically indicated cardiac MRI
89184313|NCT02574585|Experimental|Treated group|Twenty subjects will be randomly assigned to receive two percutaneous injections of mesenchymal stem cells, with a 3-month interval between the injections.
89184314|NCT02574585|No Intervention|Control group|Twenty subjects will be randomly assigned to be clinically followed, without any specific intervention.
89184315|NCT05198466|Active Comparator|Active E-Stim|Subjects will receive a sham electrical stimulation device to wear for 1 hour daily for 4 weeks (phase II).
89184316|NCT05198466|Sham Comparator|Electrical Stimulation - Sham|Subjects will receive a sham electrical stimulation device to wear for 1 hour daily for 4 weeks (phase II).
89184317|NCT00919074|Active Comparator|Pancreatic duct stent|Placement of a pancreatic duct stent to facilitate bile duct cannulation
89184318|NCT00919074|Active Comparator|Pancreatic wire|Placement of a guidewire into the pancreatic duct to facilitate bile duct cannulation.
89184319|NCT05196126|Active Comparator|Group A - PACEMAKER|According with ESC indications for elective pacemaker implantation due to SND will referred for PM implantation.
89184320|NCT05196126|Experimental|Group B - CARDIONEUROABLATION|According with ESC indications for elective PM implantation due to SND will referred for ICM/ILR implantation or prolonged ECG monitoring. Within 4 weeks patient will be screened by interdisciplinary team and autonomic tests (including atropine tests) will be performed. Than, based on atropine tests, electrophysiologic study and extracardiac vagal nerve stimulation, final indication for cardioneuroablation will be established. Biatrial, binodal cardioneuroablation will be performed with anatomical approach with bilateral extra cardiac vagal nerve stimulation during general anesthesia. Than, patient will be closely monitored and indication for PM implantation will be verified.
89184321|NCT05012592|Active Comparator|Intervention Group|Health assessment (health checkup) and health awareness program to reduce malnutrition and helminth infestation among primary school children
88858333|NCT05173987|Active Comparator|Carboplatin+paclitaxel|Participants receive a combination of paclitaxel 175 mg/m^2 on Day 1 of each 3-week cycle (Q3W) and carboplatin AUC 5 or 6 on Day 1 Q3W for 6 cycles (up to approximately 4 months). Participants who experience a severe hypersensitivity reaction to paclitaxel or an adverse event (AE) requiring discontinuation of paclitaxel may receive docetaxel 75 mg/m^2 in place of paclitaxel on Day 1 Q3W after Sponsor consultation. Participants who experience a severe hypersensitivity reaction to carboplatin or an AE requiring discontinuation of carboplatin may receive cisplatin 75 mg/m^2 in place of carboplatin on Day 1 Q3W after Sponsor consultation.
88858334|NCT05171179|Other|Intravenous lidocaine|Intravenous (IV) lidocaine infusion without Pecs block (standard of care per ERAS protocol)
88858335|NCT05171179|Active Comparator|Blocks+Bupivacaine|Use of Pecs block types I and II with bupivacaine as local anesthetic
88858336|NCT05171179|Experimental|Blocks+Bupivacaine+Exparel|Use of Pecs block types I and II with mixture of bupivacaine and Exparel* (*Must include bupivacaine at lower dose to decrease intra-operative variability in pain control due to delayed onset of Exparel and in ability to use lidocaine infusion with injection of Exparel)
88858337|NCT05161754|Experimental|Treatment 1|Participants left tonsil: cold dissection and hot hemostasis. Participants right tonsil: cold dissection and cold hemostasis.
88858338|NCT05161754|Experimental|Treatment 2|Participants right tonsil: cold dissection and hot hemostasis. Participants left tonsil: cold dissection and cold hemostasis.
88858339|NCT05160922|Other|crizotinib|crizotinib oral treatment
88858340|NCT05149443|Experimental|Effectiveness of the Move it, Move ID app|All participants will receive the Move it, Move ID app.
88858341|NCT05139615|Experimental|APD418 (Part A: Dose Cohort 1-5)|
88858342|NCT05139615|Experimental|APD418 (Part B: Dose Group 1 and 2)|
88858343|NCT05139615|Placebo Comparator|Placebo (Part A: Cohort 1-5 and Part B)|
88858344|NCT05133037||Adolescent girls between 12-16 years old|Parental history of eating pathology or no parental history of eating pathology
88858345|NCT05115292|Experimental|Arm1|BJ-005 dose escalation
88858346|NCT05115292|Experimental|Arm 2|BJ-005 cohort expansion
88858347|NCT05111223|Experimental|TMS targeting anterior OFC networks|Participants will receive TMS and sham targeting the anterior OFC network.
88858348|NCT05111223|Experimental|TMS targeting posterior OFC networks|Participants will receive TMS and sham targeting the posterior OFC network.
88858349|NCT05105399|No Intervention|Morphine|
88858350|NCT05105399|Active Comparator|Continuous|
88858351|NCT05105399|Active Comparator|Single|
89184322|NCT05012592|No Intervention|Comparison group|Health assessment (health checkup) was provided but no health educational intervention during the intervention period
88858352|NCT05100004|Active Comparator|Left Dorsolateral Prefrontal Cortex (L-DLPFC)|The accelerated theta burst stimulation protocol will be applied to the left dorsolateral prefrontal cortex (DLPFC)
88858353|NCT05100004|Sham Comparator|Sham Stimulation|Sham (non-active) stimulation will be applied to the left dorsolateral prefrontal cortex (DLPFC) region
88858354|NCT05074381|Experimental|Dry needling|A single dry needling session will be performed with the subject lying in prone position. A trained physiotherapist will penetrate the needle into skin surface, fascia,into the muscle tissue at the MTrP location of the M. Obliquus Capitis Inferior, and will move the needle up and down to elicit local twitch responses.In case local twitch responses are elicited, this will be repeated until the local twitch responses are extinct. Afterwards, a rotational muscle energy technique will be applied to the atlanto-axial level.
88858355|NCT05074381|Sham Comparator|Sham needling|A single sham needling session will be performed with the subject lying in prone position. A trained physiotherapist will penetrate the needle into the skin surface at the MTrP location. The fascia and muscle tissue will not be penetrated. Afterwards, a rotational muscle energy technique will be applied to the atlanto-axial level.
88858356|NCT05066672|Experimental|NV-5138 400 mg oral capsules|Either 2 or 4 400 mg oral capsules administered once daily
88858357|NCT05066672|Placebo Comparator|matched placebo|2 or 4 oral capsules administered once daily
88858358|NCT05064865|Experimental|Freeze-dried table grape powder|The intervention group will consume 46 g/day of a freeze-dried table grape powder.
88858359|NCT05064865|Placebo Comparator|Placebo grape powder|The control group will consume the same amount of a placebo with a similar taste to the table grape powder.
88858360|NCT05047419||Pregnant Participants with Asthma|Participants will be asked to use peak flow meter each day from enrollment to 6 weeks post due date and send peak flow and FEV1 values to the research team via text message. Also, every 3 months participants will be asked to send in a PDF of the values from the peak flow meter app for the previous 7 days via email as a validation of the text message values.
88858361|NCT05047419||Not Pregnant Participants with Asthma|Participants will be asked to use peak flow meter each day from enrollment to 9 months and send peak flow and FEV1 values to the research team via text message. Also, every 3 months participants will be asked to send in a PDF of the values from the peak flow meter app for the previous 7 days via email as a validation of the text message values.
88858362|NCT05044351|Experimental|(A): NIRAF-assisted surgery|Patients undergoing NIRAF-assisted hemithyroidectomy
88858363|NCT05044351|Active Comparator|(B): Conventional surgery|Patients undergoing conventional hemithyroidectomy without NIRAF-assistance
88858364|NCT05041621|Experimental|Sensor augmented MDI therapy plus mobile application with reinforcement learning algorithm|Participants with type 1 diabetes will undergo sensor-augmented MDI therapy for 4 months using a freestyle libre glucose sensor (Abbott Diabetes Care) and a mobile application integrated with the reinforcement learning algorithm.
89184323|NCT00715689|Experimental|A|
89184324|NCT00715689|Experimental|B|
89184325|NCT00715689|Experimental|C|
89184326|NCT00715689|Experimental|D|
88858365|NCT05041127|Experimental|Treatment (cetuximab)|Patients receive cetuximab IV over 60-120 minutes QW in the absence of disease progression or unacceptable toxicity.
88858366|NCT05028101|Active Comparator|Control (Standard of Care (SOC))|Reconstructive surgical technique, delayed autologous breast reconstruction, and usual local anesthesia and analgesia during hospital stay.
88858367|NCT05028101|Experimental|SOC + Functional Medicine|"Reconstructive surgical technique, delayed autologous breast reconstruction, and usual local anesthesia and analgesia during hospital stay.~Perioperative nutrition and lifestyle-based interventions along with select dietary supplements."
88858368|NCT05020912|Experimental|Photodynamic therapy (PDT)|"Each participant will serve as their own control, receiving PDT for one tumor, no PDT for the second tumor (untreated control).~Visit 1:~Informed consent~Blood draw~Lesion(s) Photographed~(ALA) applied for4 hours~PpIX measured in lesions (PpIX buildup monitored every 30 minutes over a 4 h period)~PDT with blue light~Visit 2 (scheduled for within one of the following time intervals: 1-3 days, 4-7 days, or 8-14 days post-PDT):~Blood draw~Lesion(s) Photographed~Mohs surgery~After procedure, excess frozen BCC tissue will be saved for analysis"
88858369|NCT05008172|Experimental|Splenic Artery Embolization (SAE)|If a patient is randomized to the SAE arm, the Interventional Radiology (IR) team will be notified of the patient's enrollment. The timing of embolization is left to the IR team but will occur within 6-12 hours of enrollment.
88858370|NCT05008172|No Intervention|Observation|Patients assigned to the observation arm will be transferred from the trauma bay to floor or the ICU for monitoring and continuous care under the Trauma team.
88858371|NCT04987346|Experimental|Treadmill walking|Participants will be asked to walk at different gait velocities for 1 minute. The treadmill speed will be increased incrementally at 0.1m/s intervals until just before running.
88858372|NCT04963738|Experimental|Group 1: JNJ-73763989|Participants with moderate renal impairment will receive a single subcutaneous (SC) injection of JNJ-73763989 on Day 1.
88858373|NCT04963738|Experimental|Group 2: JNJ-73763989|Participants with severe renal impairment or end-stage renal disease (ESRD) will receive a single SC injection of JNJ-73763989 on Day 1.
88858374|NCT04963738|Experimental|Group 3: JNJ-73763989|Participants with normal renal function will receive a single SC injection of JNJ-73763989 on Day 1.
88858375|NCT04959396|Experimental|Treatment|IUB SEAD procedure
88858376|NCT04951050|Experimental|Drug eluting stent|
88858377|NCT04944836|Placebo Comparator|Control|All patients will receive non-labeled pills identical in appearance from our pharmacy, to be taking once every other day. In the control group, these will be placebo. These will be taken every other day for seven months beginning four week prior to surgery and extending for six months after surgery.
88858378|NCT04944836|Experimental|Clomiphene|All patients will receive non-labeled pills identical in appearance from our pharmacy, to be taking once every other day. In the study group, these will contain 50 mg of clomiphene citrate. These will be taken every other day for seven months beginning four week prior to surgery and extending for six months after surgery.
88858379|NCT04923477|Experimental|Exercise Group|Therapeutic exercise of resistance and mobility training delivered by a trained health professional x 8 weeks.
88858380|NCT04918615|Experimental|Sirolimus coated balloon catheter|Manufacturer: Shanghai MicroPort Medical Group Co, Ltd.
88858381|NCT04918615|Active Comparator|Paclitaxel coated balloon catheter|Manufacturer: Liaoning Yinyi Biotechnology Co., Ltd
88858382|NCT04890171|Active Comparator|Endoscopic treatment arm|Endoscopic submucosal dissection
88858383|NCT04890171|Active Comparator|Surgical treatment group|Gastrectomy with lymph node dissection
88858384|NCT04866914|Experimental|ACT for Insomnia|
88858385|NCT04866914|Active Comparator|CBT for Insomnia|
88858386|NCT04866914|No Intervention|Wait List|
88858387|NCT04865419|Experimental|Module 1: AZD0466 monotherapy|Participants will receive intravenous infusion of AZD0466 monotherapy once weekly during Cycle 1 (35 days), Cycle 2 (28 days) and Cycle 3 (28 days) and also beyond Cycle 3 until progressive disease, unacceptable toxicity, or withdrawal of consent.
88858388|NCT04865419|Experimental|Module 2: AZD0466 + Voriconazole|Participants may receive IV infusion of AZD0466 in combination with or without voriconazole during Cycle 1 (21 days), and Cycle 2 (28 days) and Cycle 3 (28 days) and also beyond Cycle 3 until progressive disease, unacceptable toxicity, or withdrawal of consent.
88858389|NCT04861818|Experimental|Morning group|Participant are assigned to the morning group (7-9am) for 30-min exercise/rest interventions.
88858390|NCT04861818|Experimental|Afternoon group|Participant are assigned to the afternoon group (3-5pm) for 30-min exercise/rest interventions.
88858391|NCT04837586|Active Comparator|Standard Care|Individuals in this arm will receive standard care for their obesity in the Pediatric Weight Management Clinic
88858392|NCT04837586|Active Comparator|Simple Scale|Individuals in this arm will receive standard care for their obesity in the Pediatric Weight Management Clinic and will be encouraged to self-weigh daily utilizing a simple scale.
88858393|NCT04837586|Active Comparator|EHR-Connected Scale|Individuals in this arm will receive standard care for their obesity in the Pediatric Weight Management Clinic and will be encouraged to self-weigh daily utilizing a Smart scale that is connected to the Electronic Health Record (EHR).
88858394|NCT04827966|Active Comparator|Fluoride Varnish|Clinpro® is 5% sodium fluoride varnish and is indicated to be used for hypersensitive as well as for demineralized teeth. It flows smoothly on moist teeth and binds firmly to their surfaces. 1ml of Clinpro® contain 50 mg of sodium fluoride. 0.2-0.5ml of the varnish is applied onto the tooth surface after through cleaning. One coats of the varnish will be applied and patient will be instructed not to rinse with water or eat for 30 minutes. This is based on the manufacturer's instructions.
88858395|NCT04827966|Active Comparator|Tooth Mousse|Tooth Mousse® contains Casein phosphopeptide-Amorphous calcium phosphate (CPP - ACP) is product from the milk casein. This delivers the necessary Calcium and Phosphate ions to the tooth, which will reduce the risk of caries and white spot by enhancing tooth remineralization. One tube of the Tooth Mousse will be prescribed to the patient. Patient will be instructed to apply the product using finger every night after brushing and flossing. This is continued till the prescribed product is finished. This is approximately calculated to be about 8 to 12 weeks.Patient is instructed to leave the paste for about 3 minutes and then rinse. This is based on the manufacturer's instructions.
89184327|NCT05012046|Experimental|Orange juice|Treatment beverage
89184328|NCT05012046|Experimental|Orange flavoured drink|Treatment beverage
89384662|NCT02507791|Active Comparator|Late/Delayed Fitbit|These subjects will follow a similar pattern except they will not receive Fitbit Charge HR devices until the second phase of the study (specifically after completion of the 12 week weight loss program). In the first phase, these subjects will receive weekly phone calls to offer them the same attention as the experimental group, but instead of reviewing Fitbit data, these subjects will subjectively report their physical activity in minutes and by qualifying their physical activity as light, moderate, or vigorous. These individuals, after 12 weeks, will return for reassessment. At that time, these individuals will receive Fitbits and receive weekly telephone calls for an additional 12 weeks before returning for a final study visit.
88858396|NCT04827966|Active Comparator|MI Paste|MI Paste® which is Casein phosphopeptide-Amorphous calcium phosphate fluoride (CPP-ACPF) additional contains fluoride in addition to CPP-ACP. The level of fluoride is 900ppm which approximates that in adult strength toothpastes. Recent studies have investigated the remineralization potential of CPP-ACP combined with fluoride and have found a synergistic effect when these are administered together, which is the composition in MI paste. One tube of the MI Paste will be prescribed to the patient. Patient will be instructed to apply the product using finger every night after brushing and flossing. This is continued till the prescribed product is finished. This is approximately calculated to be about 8 to 12 weeks.Patient is instructed to leave the paste for about 3 minutes and then rinse. This is based on the manufacturer's instructions.
88858397|NCT04827966|Active Comparator|Acidulated phosphate fluoride gel|A stable thixotropic gel providing 1.23% fluoride ion. This is only for professional use and applied by the dentist. The teeth is cleaned and polished and the gel is applied onto a tray. It is filled upto one third of the tray according to manufacturer's instructions. The tray is then inserted into the mouth and the patient is asked to gently bite down lightly for 1 to 4 minutes.The tray is then removed and patient is asked to expectorate any material in the mouth. The patient is instructed not to eat, rinse or drink for 30 minutes.
88858398|NCT04827966|Active Comparator|Fluoride Mouthrinse|Listerine® Sodium fluoride (0.2%) mouth rinses are effective in reducing caries and inhibit carbohydrate utilization of oral microorganisms by blocking enzymes involved in the bacterial glycolytic pathway studies have shown sodium fluoride mouth rinse to be effective in reducing S. mutans counts.
88858399|NCT04818359|Experimental|Interventional Arm|Supervised exercise program: MoviS Training. Lifestyle (nutrition and exercise) counseling based on WCRF 2018 recommendations; psychological well-being counseling which comprises evaluation for anxiety and depression.
88858400|NCT04818359|No Intervention|Control Arm|Lifestyle (nutrition and exercise) counseling based on WCRF 2018 recommendations; psychological well-being counseling which comprises evaluation for anxiety and depression.
88858401|NCT04796974|Experimental|Cention|Alcasite restorative material
88858402|NCT04796194|Experimental|LTX-315 in combination with pembrolizumab|"LTX-315 will be injected directly into the selected tumor lesion(s).~Pembrolizumab will be dispensed and administered as an IV infusion."
88858403|NCT04790799|Experimental|Intervention group|Treatment in a hospital setting at Gentofte Hospital skin department with patient education, glove counselling, personal product screening by a chemistry engineer, extended allergy testing and the standard treatment of hand eczema.
88858404|NCT04790799|No Intervention|Control group|Treatment as usual (at a dermatologist office).
88858405|NCT04780776|Experimental|UVB treatment arm|The treatment group will first undergo an evaluation of each individual's sensitivity to the Solius Photobiological System UVB using the device titration system for the first 5 weeks. Once determined after the 5 weeks, the subjects will be enrolled in a 16-week study where they will be exposed to their individualized titration evaluation.
88858406|NCT04780776|Sham Comparator|Sham comparator arm|The sham comparator group will undergo the procedures as the treatment group with the exception that the Solius Photobiological System will only be turned on to emit visible radiation.
88858407|NCT04766710|Experimental|Community-based ART delivery (CAD)|The CAD model intervention will take place for 24 months. A total of 2000 registered stable people living with HIV will form into the CAD group. The investigators have developed the implementation guide, monitoring tools, quality assurance checklist, and lists of people living with HIV in selected ART clinics for the CAD model intervention. The first step will be to extract the data disaggregated by gender, age, and type of sub-populations, including adolescents, female entertainment workers, men who have sex with men, transgender women, and people who use drugs from the national database using the definitions introduced by the WHO. Once the list is completed with patient ART codes, a consultative meeting combined with the project orientation will be convened. Providers from the selected ART clinics and implementing partners at each site will divide stable people living with HIV into their respective groups based on the ART sites.
88858408|NCT04766710|Active Comparator|ART multi-month dispensing (MMD)|A total of 2000 registered stable people living with HIV will form into the control group and received standard services under the MDD model. The control-arm participants will visit the ART clinics and collect their ARVs from the facility-based staff.
88858409|NCT04763031|Experimental|Intra-operative Radiation Therapy - IORT|Intra-operative Radiation Therapy - IORT
88858410|NCT04756570|Active Comparator|Control|25 stroke patients between the ages of 18-80, stroke duration of less than 2 months and not more than 2 years whose Mini-Mental State Examination (MMSE) scores equal or above the 25 will be included in this study. Modified Ashworth Scale (MAS), Barthel Index, The Modified Rankin Scale, Berg Balance Scale , &-min walk test, and Stroke-Specific Quality of Life Scale (SSQOL) assessments will be applied just before the rehabilitation program, after the application and at the end of 6 weeks
89184329|NCT05012046|Experimental|Water|Treatment beverage
89184330|NCT00919542|Active Comparator|prednisolone|standard course of prednisolone given in a reducing regimen over 16 weeks
89184331|NCT00919542|Experimental|Ciclosporin|ciclosporin reducing regimen lasting 16 weeks (additional prednisolone given for the first four weeks)
89184332|NCT00715845|Experimental|2|
89184333|NCT00719121|No Intervention|A|No Treatment
89184334|NCT00719121|Active Comparator|B|R115866 (0.35% gel)
89184335|NCT00719121|Active Comparator|C|R115866 Vehicle gel
89184336|NCT00719121|Active Comparator|D|Differin™, 0.1% adapalene gel
89184337|NCT00715923|Experimental|1|Modified consent form
88858411|NCT04756570|Active Comparator|Robotic 1|25 stroke patients between the ages of 18-80, stroke duration of less than 2 months and not more than 2 years whose MMSE scores equal or above the 25 will be included in this study. Modified Ashworth Scale (MAS), Barthel Index, The Modified Rankin Scale, Berg Balance Scale , &-min walk test, and Stroke-Specific Quality of Life Scale assessments will be applied just before the rehabilitation program, after the application and at the end of 6 weeks
88858412|NCT04756570|Active Comparator|Robotic 2|25 stroke patients between the ages of 18-80, stroke duration of less than 2 months and not more than 2 years whose MMSE scores equal or above the 25 will be included in this study. Modified Ashworth Scale (MAS), Barthel Index, The Modified Rankin Scale, Berg Balance Scale , &-min walk test, and Stroke-Specific Quality of Life Scale assessments will be applied just before the rehabilitation program, after the application and at the end of 6 weeks
88858413|NCT04752137|Other|ICG Dye and use of SPY-PHI Imaging|ICG will be administered in the pre-operative unit via IV injection at the time that they present to the pre-operative unit, which is approximately 4 hours before surgery. ICG Angiography (SPY PHI) will be performed to detect any residual signal
88858414|NCT04741256|Experimental|Tracheostomy discharge protocol|"All head and neck cancer patients regardless of participation in the study will receive the standard of care: A copy of a tracheostomy education booklet and standardized discharge training for patients and their caregivers by nursing staff during their inpatient stay.~Research personnel will provide protocol training to the inpatient nurses who are to provide training to caregivers.~Pre-implementation phase: Eligible patient participants identified & healthcare utilization recorded. Nursing staff participants complete nursing survey to capture volume of tracheostomy-related questions received.~Protocol-phase: Caregiver participants will complete a survey prior to patient tracheostomy, on day of patient discharge, and one week following discharge~Post-implementation phase: Nursing staff participants will complete an additional survey similar to the one in the pre-implementation phase. EMR will be reviewed for implementation fidelity."
88858415|NCT04739865|Experimental|25 mg COMP360 Psilocybin|25 mg COMP360 Psilocybin
88858416|NCT04722341|Experimental|Time-Restricted Eating (TRE)|8-hour daily eating period, starting 1-3 hours after waking up
88858417|NCT04722341|Active Comparator|Control|More than equal to a 12-hour daily eating period
88858418|NCT04705467|Other|Patients|Device: Gynecological brachytherapy requiring an Interstitial or ring and tandem insert involves insertion of the needle and applicators with no standard real-time image guidance. Occasionally 2-dimensional ultrasound is used, but it greatly limited by its flat nature, preventing a volumetric view of the needle pathways. Interstitial brachytherapy is done under general anesthesia. The trans-abdominal and trans-rectal standard 2D ultrasound that are used in some cases, will be expanded to 3D dimensional imaging through the use of an investigational device. Pre-procedure imaging in the form of MRI is used to help guide needles insertion as well as the clinical exam. Post-procedure CT is done for radiation planning.
88858419|NCT04680715|Experimental|Per-Operative Radiotherapy technique by Papillon +TM|Per-Operative Radiotherapy (1x20Gy) technique by Papillon +TM
88858420|NCT04656028|Active Comparator|Group 1 - without genetic testing; subgroup without motivational counseling|Group 1 - without genetic testing; subgroup without motivational counseling
88858421|NCT04656028|Experimental|Group 1 - without genetic testing; subgroup with motivational counseling|Group 1 - without genetic testing; subgroup with motivational counseling
88858422|NCT04656028|Experimental|Group 2 - with genetic testing; subgroup without motivational counseling|Group 2 - genetic testing has been performed; subgroup without motivational counseling.
88858423|NCT04656028|Experimental|Group 2 - with genetic testing; subgroup with motivational counseling|Group 2 - genetic testing has been performed; subgroup with motivational counseling.
88858424|NCT04639336||Patients with Pompe disease|
88858425|NCT04638465||A - Surgery Only|"Participants with the following diagnosis will receive transoral robotic surgery with neck dissection:~Base of Tongue/Non-Tonsil Oropharynx - Stage: cT1-2, cN0 or N1 (single node)~Tonsil - Stage: cT1-3, cN0 or N1 (single node)~Unknown primary - Stage: cT0 N1 (single node)~Radiation also given if indicated by intermediate or high risk features following surgery."
88858426|NCT04638465||B - Surgery with Adjuvant Therapy|"Participants with the following diagnosis will receive surgery followed by 6 Cycles of Cisplatin 40 mg/m2:~Base of Tongue/Non-Tonsil Oropharynx - Stage: cT1-2, cN1 (2-4 nodes) or N2~Tonsil - Stage: cT1-3, N1 (2-4 nodes)~Radiation also given if indicated by intermediate or high risk features following surgery."
88858427|NCT04638465||C - Concurrent Chemo/Radiation Therapy - Dose Level 1|"Participants with the following diagnosis will receive 6 Cycles of Cisplatin 40 mg/m2 + 60 Gy Radiation:~Tonsil - Stage: cT1-3, N2~Unknown Primary - Stage: cT0, N2"
88858428|NCT04638465||D - Concurrent Chemo/Radiation Therapy - Dose Level 2|"Participants with the following diagnosis will receive 7 Cycles of Cisplatin 40 mg/m2 + 70 Gy Radiation:~Base of Tongue/Non-Tonsil Oropharynx - Stage: cT3-4, any N~Base of Tongue/Non-Tonsil Oropharynx - Stage: cAny T, N3~Tonsil - Stage: cT1-3, N3~Tonsil - Stage: cT4, any N~Unknown Primary - Stage: cT0, N3"
88858429|NCT04630522|Experimental|JMT103- 120 mg SC Q4W|Eligible patients will receive JMT103 120 mg SC Q4W for up to 13 cycles.
88858430|NCT04630522|Experimental|JMT103- 120 mg SC Q8W|Eligible patients will receive JMT103 120 mg SC Q8W for up to 7 cycles.
88858431|NCT04630522|Experimental|JMT103- 180 mg SC Q8W|Eligible patients will receive JMT103 180 mg SC Q8W for up to 7 cycles.
88858432|NCT04623996|Experimental|Single Arm TP-0184|TP-0184 is administered orally once a day
88858433|NCT04615013|Experimental|Treatment (NBTXR3, IMRT, chemotherapy)|Patients receive NBTXR3 IT or IN on day 1. Beginning day 15, patients undergo IMRT 5 days per week for 6 weeks for a total of 28 fractions, in the absence of disease progression or unacceptable toxicity. Concurrent with IMRT, patients receive a chemotherapy regimen consisting of either fluorouracil and oxaliplatin with or without leucovorin, oxaliplatin and capecitabine, docetaxel and fluorouracil with or without leucovorin, docetaxel and paclitaxel, or carboplatin and paclitaxel per physician discretion.
88858434|NCT04597190|Active Comparator|SSRI Then Augmentation by WET|Prescribers will prescribe one of three SSRIs (sertraline, fluoxetine or paroxetine). Patients who do not respond to treatment by four months will have their treatment augmented by Written Exposure Therapy (WET) delivered by an integrated behavioral health consultant.
88858435|NCT04597190|Active Comparator|SSRI Then Switch to SNRI|Prescribers will prescribe one of three SSRIs (sertraline, fluoxetine or paroxetine). Patients who do not respond to treatment by four months will have their treatment switched to the SNRI (serotonin-norepinephrine reuptake Inhibitor) venlafaxine.
88858436|NCT04597190|Active Comparator|WET Then Switch to SSRI|Integrated behavioral health consultants will deliver WET. Patients who do not respond to treatment by four months will be switched to one of three SSRIs (sertraline, fluoxetine or paroxetine).
88858437|NCT04582578|No Intervention|Control Group|The control group will be treated with practice guideline optimal medical therapy for HF.
88858438|NCT04582578|Experimental|BiV-CRT|The experimental group will be treated with CRT in addition to optimal medical therapy for HF. In addition, the trial will further compare two methods of delivering CRT. One experimental group will receive BiV-CRT, while the second experimental group will receive Conduction System(CS)-CRT.
88858439|NCT04582578|Experimental|CS-CRT|The experimental group will be treated with CRT in addition to optimal medical therapy for HF. In addition, the trial will further compare two methods of delivering CRT. One experimental group will receive BiV-CRT, while the second experimental group will receive Conduction System(CS)-CRT.
88858440|NCT04577170||Fabry disease|
88858441|NCT04577170||Healthy|age and sex matched
88858442|NCT04576130|Experimental|ICD-implantation|Implantation of an ICD either during admission or within 4 weeks after discharge from index event.
88858443|NCT04576130|No Intervention|Standard care|Guideline directed medical therapy
88858444|NCT04575961|Other|Pembrolizumab + Chemotherapie|pembrolizumab in combination with platinum-based chemotherapy (investigator's choice: carboplatin + gemcitabine or carboplatin + pegylated liposomal doxorubicin)
88858445|NCT04575363|Experimental|pancreatic adenocarcinoma patient|patient with pancreatic ductal adenocarcinoma
88858446|NCT04550728|Experimental|FES+robot|Participants in this group will have FES during ankle robot training
88858447|NCT04550728|Active Comparator|Robot|Participants in this group will have ankle robot training only
88858448|NCT04549519||Stable group|Participants display knee valgus less or equal to 15° at 45° knee flexion in the descending phase of the squat on both legs
88858449|NCT04549519||Unstable group|Participants display knee valgus greater than 15° at 45° knee flexion in the descending phase of the squat on one leg or both legs
88858450|NCT04545840||Study group|Zirconia Implants will be placed. More than one implant can be placed in the same patient, as long as the subject presents natural teeth adjacent to the implant site.
88858451|NCT04537364||pediatric patients with CAKUT|"This cohort is composed of pediatric children diagnosed of CAKUT from Shanghai peri-conceptional parent-offspring cohort (SPCC) clinic research related outpatient and high-risk newborns referral outpatient, and those who are enrolled in nephrology department and urinary surgery department with CAKUT diagnosis.~By diagnostic tests for predicting renal parenchymal damage in this cohort, data of kidney images, urinary biomarkers and disease genes can be collected."
89384663|NCT01382199|Experimental|Ven100|Recombinant Human Lactoferrin Administered Orally for the Prevention of Antibiotic Associated Diarrhea in Adult Patients
89384664|NCT01337869|Active Comparator|Bascom Cleft Lift Technique|
89384665|NCT01337869|Active Comparator|Limberg Flap Technique|
89384666|NCT01381497||Employed migraine sufferers|Diagnosed adult migraine sufferers who are employed at least 30 hours per week during a daytime shift
89384667|NCT01384149|Active Comparator|standart slt|gonioscopic selective laser trabeculoplasty
89384668|NCT01384149|Experimental|external slt|perilimbal ,above trabecular meshwork 180 degrees ,100 laser dots
89384669|NCT04451317||Experimental|Patients involved in a Sport-Health initiative Visit once by telephone and then ask to fill in 3 questionnaires on a digital platform within 48 hours after the telephone interview.
89384670|NCT04451317||Control|Healthy sport subjects. Visit once by telephone and then ask to fill in 3 questionnaires on a digital platform within 48 hours after the telephone interview.
88858452|NCT04535271|Experimental|Single arm|Trabectedin 24 h CIV 0.5 mg/m2 D1 and D8 Gemcitabine i.v. 250 mg/m2 D1 and D8 Dacarbazine i.v. 250 mg/m2 D1 and D8
88858453|NCT04533997|Active Comparator|Intravenous furosemide|
88858454|NCT04533997|Experimental|Hypertonic saline solution plus intravenous furosemide|
89184338|NCT00715923|Active Comparator|2|Standard consent form
89384671|NCT01381419|Experimental|Part A, Cohort 1|In Cohort 1, four subjects (two on active and two on placebo for first dose, and then three on active and one on placebo for subsequent doses) will be included. Subjects will be dosed at least 30 minutes apart over the dosing day and only doses administered where the predicted plasma concentration will remain below those corresponding to the MABEL.
89384672|NCT01381419|Experimental|Part A, cohort 2|In Cohort 2, 10 subjects will be included (8 active : 2 placebo). Dosing will start once the previous cohort (Cohort 1) has completed the Treatment Phase. For Cohort 2 and any subsequent cohorts, dosing will take place on two different days when a new dose is administered such that no more than one subject receives the agreed ascending dose on the first dosing day. Doses may be split in up to three divided doses given 2 to 3 hours apart. Dosing for the first four sessions in each cohort will be staggered over 2 days. On the first day of each dosing session, only one subject will receive the highest dose for that dosing session and at least one subject each will receive placebo. The remaining subjects in the cohort will be dosed on the second day according to the randomisation plan.
89184339|NCT00719199|Experimental|1|IMO 2055 is a novel phosphorothioate oligodeoxynucleotide that is an agonist of Toll-like Receptor 9 (TLR9).
89184340|NCT04068675|Experimental|Group counseling arm|There is only one(1) arm in this study. All patients that enroll in the study will receive the group counseling intervention and be compared to historical controls.
89184341|NCT02589288|Active Comparator|Continuous Infusion|Patients receive a postoperative continuous infusion of Ropivacaine 0,2% at 6 ml/h and 4 ml PCA bolus, lockout 20 minutes via electronic infusion pump (Micrel device, Greece).
89184342|NCT02589288|Experimental|Automatic Intermittent Bolus|Patients receive a postoperative Automatic Intermittent Bolus of 6 ml Ropivacaine 0,2% and 4 ml PCA bolus, lockout 20 minutes every hour via electronic infusion pump (Micrel device, Greece).
88858455|NCT04511052|Experimental|Carotenoid + Probiotic|"Carotenoid: 1 capsule daily of a mixed carotenoid (~ 20 mg total carotenoids) supplement~Probiotic: 1 capsule daily containing 10 x 10^9 CFU of a proprietary strain~Total duration: 10 weeks"
88858456|NCT04511052|Placebo Comparator|Carotenoid + Placebo|"Carotenoid: 1 capsule daily of a mixed carotenoid (~ 20 mg total carotenoids) supplement~Placebo: 1 capsule daily containing the same carrier material of the probiotic, that is also similar in size, shape, and taste.~Total duration: 10 weeks"
88858457|NCT04506814|Active Comparator|Endocardial PVI|Endocardial complete PVI
88858458|NCT04506814|Experimental|Epicardial Posterior Wall Isolation + LAA Exclusion + Endocardial PVI|Minimally invasive surgical hybrid ablation using the convergent approach plus LAA exclusion using the clip
88858459|NCT04495543|Experimental|Brief-Skills for Safer Living (Brief-SfSL)|Participants with current suicidal ideation (Beck Suicide Scale >10) will undergo Brief-SfSLtherapy
88858460|NCT04486742|Experimental|Itch CBT Arm|Participants randomized to the Itch CBT Arm will participate in 4 weekly telehealth sessions with a therapist to address common areas of anxiety related to atopic dermatitis.
88858461|NCT04486742|No Intervention|Usual Care Arm|Participants randomized to the Usual Care Arm of the study will receive standard of care eczema educational materials that are typically provided by their health care provider after a clinic (or telehealth) visit.
88858462|NCT04473833|Experimental|Participants in the Kentucky Ovarian Cancer Screening Program|Participants from the Kentucky Ovarian Cancer Screening Program who choose to participate in this trial will undergo further serial transvaginal ultrasonography (TVS) screening.
88858463|NCT04472195|Experimental|Experimental|The experimental group will review a pre-induction airway management plan for their upcoming case and undergo a scripted 10-minute RCDP session with an airway coach within 1 hour of patient intubation. The intubation approach (DL vs. video assisted DL) will be chosen by the primary case attending and communicated to the airway coach to simulate the planned laryngoscopy attempt. The experimental group will then proceed with their scheduled case with a member of the research team observing the laryngoscopy attempt(s) to capture data.
88858464|NCT04472195|No Intervention|Control|The trainees in the control group will have no interventions by the research team, only observation of the intubation and documentation of the same details.
88858465|NCT04446832||Liver transplantation candidates|
88858466|NCT04442893|Experimental|Experimental group|The experimental group would be provided with a 6- session RFCBT program for 12 weeks (60-90 mins, once every two weeks).
88858467|NCT04442893|Other|Control group|The control group would receive a 6- session Health Education program for 12 weeks (60-90 mins, once every two weeks)
88858468|NCT04439331|Experimental|Treatment (defactinib)|Patients receive defactinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88858469|NCT04439279|Experimental|Treatment (trametinib)|Patients receive trametinib dimethyl sulfoxide PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88858470|NCT04428788|Experimental|Administration of CC-94676, CC1083611, and CC1083610|
88858471|NCT04409847||COVID+ PCR|Subjects who are SARS-CoV-2 PCR+ve and/or have diagnostic CXR or CT chest features of COVID -19
88858472|NCT04409847||COVID- PCR|subjects admitted with COVID-19 like symptoms but are SARS-CoV-2 PCR-ve and have CXR or CT chest that show low probability of COVID-19 will form the control group
89184343|NCT00710463||Control group|patients receive a hospital based comprehensive pulmonary rehabilitation programme, including endurance training, physiotherapy, medical therapy, and long term oxygen treatment when indicated.
89184344|NCT00710463||NIV treatment group|patients receive a hospital based comprehensive pulmonary rehabilitation programme, including endurance training, physiotherapy, medical therapy, and long term oxygen treatment when indicated, plus newly introduced nocturnal non invasive ventilation.
89184345|NCT00716001|Active Comparator|NAC|
89184346|NCT00716001|Placebo Comparator|nonNAC|
89184347|NCT00716157||Observation|Adult patients receiving both radiation therapy and chemotherapy
89184348|NCT02574429|Experimental|Cognitive Processing Therapy|Individuals who have either completed Standard Dialectical Behavior Therapy (DBT) for Borderline Personality Disorder (BPD) and/or are currently enrolled in DBT who have co-occuring PTSD.
89184349|NCT00710229|Active Comparator|A|Intravitreal injectin of Ranibizumab (3 monthly injection followed by monthly injectins as long as required
89184350|NCT00710229|Active Comparator|B|Intravitreal injectin of Bevacizumab (3 monthly injection followed by monthly injectins as long as required
89184351|NCT05684406||Group I|patients with type 2 diabetes mellitus
88858473|NCT04409652|Placebo Comparator|Control group|The endotracheal extubation is performed in head on bed without pillow.
88858474|NCT04409652|Active Comparator|Head elevation group|The endotracheal extubation is performed in head elevation on pillow (slight flextion of neck on chest) .
89002998|NCT05889845|Experimental|Candin treatment|Candida albicans Skin Test Antigen for Cellular Hypersensitivity will be administered as a 0.5 mL injection at the region of the interdigitated base of the treatment wart (epidermal/dermal junction) every 2 weeks for up to 10 injections
89184352|NCT05684406||Group II|apparently healthy controls with no chronic illness of matched age and sex
89184353|NCT00710541|Experimental|NPPV group|Subjects in this arm receive standard COPD treatment, LTOT if indicated, and NPPV with ventilators designed for 'non invasive ventilation'(Resmed VPAP III ST-A, Weinmann Ventimotion, Tyco Healthcare Knight Star 330)
89184354|NCT00710541|No Intervention|control gorup|Subjects in this arm receive standard COPD treatment and LTOT if indicated.
89002999|NCT05889845|Placebo Comparator|Placebo|Matching placebo (sterile saline) will be administered as a 0.5 mL injection at the region of the interdigitated base of the treatment wart (epidermal/dermal junction) every 2 weeks for up to 10 injections
89003000|NCT05883800|Experimental|Intervention|Intervention: daily on-couch adaptive radiotherapy
89003001|NCT05882929|Experimental|Experiment 1: Watching Cartoons|Watching Cartoon Movies will be performed after the child comes to the service after the operation and prepares for the postoperative period (taking vital signs, putting on clothes, controlling bleeding, telling the feeding time, etc.). Interventions will be implemented for a total of 15 minutes. Physiological Parameters Follow-up Form and Wong-Baker Faces Pain Scale will be filled in before the interventions are applied, 10 minutes during the intervention and 5 minutes after the intervention is completed.
89003002|NCT05882929|Experimental|Experiment 1: ball spin|ball squeezing will be applied after the child comes to the service after the operation and the postoperative period preparation is made (taking the vital signs, putting on the clothes, controlling the bleeding, telling the feeding time, etc.). Interventions will be implemented for a total of 15 minutes. Physiological Parameters Follow-up Form and Wong-Baker Faces Pain Scale will be filled in before the interventions are applied, 10 minutes during the intervention and 5 minutes after the intervention is completed.
89003003|NCT05882929|No Intervention|Control|In the control group, the 10th and 20th minute physiological parameters and Wong-Baker Faces Pain Scale will be evaluated after the child comes to the service after the operation and is prepared for the postoperative period (taking vital signs, putting on clothes, controlling bleeding, telling the feeding time, etc.).
89003004|NCT05881239||Subjective Cognitive Concerns (SCC)|The composition of the proposed study population will reflect that of subjects recruited through the Longitudinal Cohort of the Massachusetts Alzheimer's Disease Research Center and that of patients treated by neurologists at the Memory and Movement Disorders Clinics at MGH as well as participants from the community.
89003005|NCT05881239||Mild Cognitive Impairment (MCI)|The composition of the proposed study population will reflect that of subjects recruited through the Longitudinal Cohort of the Massachusetts Alzheimer's Disease Research Center and that of patients treated by neurologists at the Memory and Movement Disorders Clinics at MGH as well as participants from the community.
89003006|NCT05881239||Mild Behavioral Impairment [prominent apathy] (MBI)|The composition of the proposed study population will reflect that of subjects recruited through the Longitudinal Cohort of the Massachusetts Alzheimer's Disease Research Center and that of patients treated by neurologists at the Memory and Movement Disorders Clinics at MGH as well as participants from the community.
89003007|NCT05881239||Age-matched Controls|We will utilize community sampling to recruit 100 age-matched controls.
89003008|NCT05880524|Active Comparator|Pulmozyme|Dornase alfa; intravenous administration; 500 µg/kg
89003009|NCT05880524|Placebo Comparator|Isotonic Saline Solution|NaCl 0,9 %; intravenous administration; 0,5 ml/kg
89003010|NCT05870111|Experimental|Citicoline|2000mg/day citicoline for 4 weeks, administered orally
89003011|NCT05870111|Placebo Comparator|Placebo|placebo capsule daily for 4 weeks, matched in appearance to citicoline to preserve double-blind, administered orally
89003012|NCT05869903|Experimental|Orforglipron Dose 1|Participant will receive orforglipron administered orally.
89003013|NCT05869903|Experimental|Orforglipron Dose 2|Participant will receive orforglipron administered orally.
89003014|NCT05869903|Experimental|Orforglipron Dose 3|Participant will receive orforglipron administered orally.
89003015|NCT05869903|Placebo Comparator|Placebo|Participants will be given placebo.
89003016|NCT05867056|Experimental|Part 1: Single Ascending Dose (SAD)|SAD will be approximately 10 weeks for each participant, comprising a maximum 42-day screening period, a 1-day treatment period involving a single administration of IMC-I109V and a 28-day follow-up period, for a total of 8 visits. Visits will take place on Day -1 and Days 1, 2, 3, 8, 15, 22, and 29. Follow-up may be extended in participants who achieve a decrease in HBsAg of > 0.5 log10 IU/mL at Day 29.
89003017|NCT05867056|Experimental|Part 2: Multiple Ascending Doses (MAD)|MAD will be approximately 54 weeks for each participant, comprising a maximum 42-day screening period, a 24-week treatment period involving weekly administration of IMC-I109V, and a 24-week follow-up period, with a total of 29 visits. Visits will take place on Day -1 and Days 1, 3 and 8, Weeks 3 (Day 15) through 24, Weeks 28, 36, 48 and 49. Participants who have achieved HBsAg <100 IU/mL at end of Week 24 may be considered for further study treatments of up to Week 48 and follow-up visits every 12 weeks to Week 72. Treatment will be discontinued at Week 16 in participants who have not shown evidence of a response to IMC-I109V, in order to minimize unnecessary drug exposure in participants who are unlikely to achieve reductions in viral biomarkers with further doses.
89003018|NCT05867056|Experimental|Part 3: HBV HCC Module MAD|Enrollment into Part 3 may begin at the discretion of the Sponsor and will involve a maximum 42-day screening period, a treatment period comprising weekly administration of the target dose until the criteria for treatment discontinuation are met. Visits will take place on Day 1-2 and Day 8, Week 3 (Day 15), with this cycle being repeated until treatment stops, then 30 and 90 days post-last dose, then every 3 months after last dose, after which there will be a safety follow-up period of 30 days.
89003019|NCT05864846|Experimental|Cannabidiol Oral Solution|Participants who will receive the Cannabidiol Oral Solution (CBD-OS) titrated up to a dose of 12.5 mg/kg administered twice daily for a total dose of up to 25 mg/kg/day for 26 consecutive weeks. Participants will have the option to continue receiving the CBD-OS for an additional 26 weeks, for a total of 52 weeks.
89003020|NCT05864300|Active Comparator|Hourly Neurochecks|Patients awakened for neurological exams every hour
89003021|NCT05864300|Active Comparator|Every-Other-Hour Neurochecks|Patients awakened for neurological exams every-other-hour
89003022|NCT05859776|Experimental|Low Dose|AXT107 0.125 mg/eye
89003023|NCT05859776|Experimental|Mid Dose|AXT107 0.250 mg/eye
89003024|NCT05859776|Experimental|High Dose|AXT107 0.500 mg/eye
89184355|NCT00710619||A|
89003025|NCT05858905|Experimental|JAVELIN Study Catheter|The JAVELIN catheter will be used to treat subjects with moderate to severely calcified peripheral artery disease (PAD) with target lesion located in a native, de novo superficial femoral, popliteal or infrapopliteal artery.
89184356|NCT00710697|Experimental|Single Arm|Picoplatin
88858475|NCT04400981|Experimental|Intervention arm: RIC plus standard medical therapy|"Remote ischemic conditioning (RIC) will be applied immediately after randomization in the Emergency Department, through a standard blood pressure cuff placed around the non-paretic arm. The protocol includes 4 cycles of intermittent manually induced upper limb ischemia, alternating 5 minutes of inflation (20mmHg above systolic blood pressure) and 5 minutes of deflation.~Patients randomized to remote ischemic conditioning will also receive standard medical therapy"
89384673|NCT01381419|Experimental|Part B|Part B of the study will consist of a Screening Visit (up to 30 days before the dosing session), three PET scans (where possible, all three scans may be performed in one visit when subject is admitted overnight) and a Follow-up Visit. Each subject will receive an oral dose of study drug. The dose may be split in up to three divided doses given 2 to 3 hours apart.
89384674|NCT03635827|Active Comparator|NBTX-001|
88858476|NCT04400981|Active Comparator|Control arm: Standard medical therapy alone|"Standard medical therapy will be administered immediately after randomization in the Emergency Department. Standard medical therapy comprises single antiplatelet therapy, either aspirin given in a total dose ranging between 100 to 300 mg per day on days 1-5 and followed by aspirin 100mg/day on days 1-5 followed by aspirin 100mg/day, or Clopidogrel 75mg/day (at the discretion of the patient's attending physician), unless an indication for early anticoagulation (e.g. atrial fibrillation, mechanical heart valve, deep venous thrombosis, pulmonary embolism, antiphospholipid antibody syndrome, hypercoagulable state) or dual antiplatelet therapy (e.g. early carotid stenting) is present.~All patients will receive standard deep venous thrombosis (DVT) prevention therapy together with appropriate treatment for blood pressure control, glycemic control and cholesterol reduction."
88858477|NCT04395274||Current E-Cigarette Users|Monitoring current e-cigarette users
88858478|NCT04395274||Never E-Cigarette / Tobacco Users|Monitoring never users of any tobacco or e-cigarette products.
88858479|NCT04395157||Veterans engaged in VA mental health rehabilitation/recovery|Veterans must be within 6 weeks of discharge from or current receive mental health treatment services in a VA San Diego Healthcare System psychosocial rehabilitation and recovery center (PRRC), mental health residential rehabilitation treatment program (RRTP), general mental health outpatient treatment, or recent acute mental health inpatient hospitalization.
88858480|NCT04369573|Active Comparator|Early intra-aortic balloon pump (IABP) implantation|IABP implantation within 6 hours since cardiogenic shock symptoms onset
88858481|NCT04369573|Other|Standard of care as vasoactive agent|Any agent (inotropes and vasopressors) will be allowed. However, the following guide is provided to increase uniformity: 1) vasopressors allowed will be either epinephrine or norepinephrine; 2) as inotropic agent milrinone or dobutamine or levosimendan could be used; 3) dopamine will be allowed in association with milrinone or dobutamine or levosimendan; 4) the maximum inotropic score allowed will be 20
89003026|NCT05856526|Placebo Comparator|Placebo|
89003027|NCT05856526|Experimental|Spesolimab|
89384675|NCT03635827|Placebo Comparator|Placebo|
89384676|NCT04530201|Other|Sample collection|Women will self-collect two first-void urine samples at home, the day prior to colposcopy. During the colposcopy visit, the clinician will collect an additional cervical smear. Colposcopy and histology results (when available) will be used as reference test.
89384677|NCT01382121|Experimental|Peer modeling|Participants watch a video geared to increase confidence in ability to preform fitness test. Male participants will watch a video of a male adolescent completing the fitness test and talking about coping mechanisms used to preform to the best of his ability. Female participants will watch a video of a female adolescent completing the fitness test and talking about coping mechanisms used to preform to the best of her ability.
89384678|NCT01382121|Active Comparator|Control|Participants watch a video unrelated to the fitness test and self-efficacy. The video depicts healthy food and nutrition options.
89384679|NCT04095403|Experimental|Tarp assisted cooling|Whole body cooling in a small amount of 20'C water.
89384680|NCT04095403|Sham Comparator|Passive cooling|Supine lying
89384681|NCT01332175|Active Comparator|Provent|
89003028|NCT05855343|Experimental|BIDI Stick e-cigarette|
89384682|NCT01332175|Placebo Comparator|Placebo-Provent|
89384683|NCT01332175|Active Comparator|CPAP|
89384684|NCT03159091|Experimental|Rengalin|Oral administration. Two tablets per intake. The tablet should be held in the mouth until complete dissolution. 2 tablets 3 times a day without food (i.e. 15-30 min prior to meal or 15-30 min after meal).
89384685|NCT03159091|Placebo Comparator|Placebo|Oral administration. Two tablets per intake. The tablet should be held in the mouth until complete dissolution. 2 tablets 3 times a day without food (i.e. 15-30 min prior to meal or 15-30 min after meal).
89384686|NCT03196193|Experimental|ZNN CM Asia with AS2 technique|"Open Reduction and Internal Fixation with AS2 Trochanteric Fracture treated by Open Reduction and Internal Fixation using with ZNN CM Asia nail.~Bone fragment will be stabilized by additional screw fixation (Anterior Support Screw)."
89384687|NCT03196193|Active Comparator|ZNN CM Asia without AS2 technique|Trochanteric Fracture treated by Open Reduction and Internal Fixation using with ZNN CM Asia nail without additional screw fixation.
89384688|NCT01337947||exercise training|12 weeks of exercise treatment/program for DM1 subjects
89384689|NCT01338103|Experimental|Rituximab|
89384690|NCT03529877|Experimental|allo-APZ2-EB|intravenous infusion, three doses of allo-APZ2-EB (2 x 10^6 cells/kg)
89384691|NCT03621761|Active Comparator|Cognitive Behavioral Therapy|8 weekly telephone-based sessions and 2 booster sessions
89384692|NCT03621761|Active Comparator|Modafinil|50-400 mg per day (oral)
89384693|NCT03621761|Active Comparator|Cognitive Behavioral Therapy + Modafinil|Telephone-based cognitive behavioral therapy (8 weekly therapy sessions and 2 booster sessions) + Modafinil 50-400 mg per day (oral)
89003029|NCT05852938|Experimental|BION-1301|600mg subcutaneous administration every 2 weeks for 104 weeks
89003030|NCT05852938|Placebo Comparator|Placebo|subcutaneous administration every 2 weeks for 104 weeks
89003031|NCT05850104||classical prosthesis group|the effects of classical Chopart prosthesis on socket comfort, satisfaction level and quality of life in patients with unilateral Chopart amputation
89003032|NCT05850104||silicone prosthesis group|the effects of silicone prosthesis on socket comfort, satisfaction level and quality of life in patients with unilateral Chopart amputation
89003033|NCT05849454|Experimental|Messy Memories Intervention|All participants enrolled in the study will be assigned to the experimental arm and participate in the Messy Memories intervention.
89003034|NCT05848518|Experimental|Concurrent rehabilitation program|Endurance plus resistance exercises
89003035|NCT05848518|Experimental|Endurance rehabilitation program|Endurance exercises
89003036|NCT05848518|Experimental|Strength rehabilitation program|Resistance exercises
89003037|NCT05848518|No Intervention|Control group|No exercise
89003038|NCT05848011|Experimental|Lorigerlimab + Docetaxel and Prednisone|Lorigerlimab 6 mg/kg IV (up to 2 years) and docetaxel 75 mg/m^2 IV every 3 weeks (up to 7 months) and prednisone 5 mg orally twice daily (up to 7 months).
89003039|NCT05848011|Other|Standard of care docetaxel and prednisone|Docetaxel 75 mg/m^2 IV every 3 weeks and prednisone 5 mg orally twice daily.(up to 7 months)
89003040|NCT05846230|Experimental|BI 1291583 low dose arm|
89003041|NCT05846230|Experimental|BI 1291583 medium dose arm|
89003042|NCT05846230|Experimental|BI 1291583 high dose arm|
89003043|NCT05845775||percutaneous dilatational tracheostomy|Patients assigned to percutaneous dilatational tracheostomy
89003044|NCT05841693|Active Comparator|Experimental ( Carb Group)|Preoperative education will be provided by researchers to the patients on the ward before fluid intake.Solid food and drinking will be forbidden after 24:00 p.m the day before surgery. The Carb group will consume carbonhydrate fluid two hours before the surgery.
89003045|NCT05841693|Placebo Comparator|Standard Care (Non-carb Group)|Preoperative education will be provided by researchers to the patients on the ward before fluid intake. Solid food and drinking will be forbidden after 24:00 p.m the day before surgery.The Non-carb Group will consume same amount of placebo fluid as Carb Group two hours before the surgery
89003046|NCT05840484||Cohort-1|Participants with localized very low- or low-risk prostate cancer meeting consensus criteria for active surveillance
89184357|NCT05684250|Experimental|The time course group|The time course of the effect of biofeedback training in young adults wearing MFCLs. Subjects will receive one episode of auditory biofeedback training and accommodation will be measured before the training and after the training on a weekly basis for 3 weeks.
89184358|NCT05684250|Experimental|The repetition group|Subjects will receive one episode of auditory biofeedback training every week for 3 weeks and accommodation will be measured before the training and after the training on a weekly basis.
89184359|NCT05684250|Experimental|The longer duration group|Subjects will receive one episode of auditory biofeedback training for twice as long every week for 3 weeks and accommodation will be measured before the training and after the training on a weekly basis.
89184360|NCT00710775|Other|1|Patients undergoing surgical aortic valve replacement on cardiopulmonary bypass.
89003047|NCT05840484||Cohort-2|Participants with NCCN intermediate-risk localized prostate cancer requesting active surveillance (per patient and clinician shared decision making);
89003048|NCT05840484||Cohort-3|"Participants with severe medical comorbidities (defined as CCI estimated 10-year survival < 50% and agreed by treating clinician) and high- or very high-risk group localized prostate cancer.~Clinical trial investigators and staff will make every effort to integrate study visits with the subjects' clinic visits during participation."
89003049|NCT05839600|Experimental|BI 1821736: Dose escalation cohort|
89003050|NCT05837091|Experimental|Low Soduim Oxybate for Idiopathic Hypersomnia|Subjects prescribed with low sodium oxybate for idopathic hypersomnia will have a 24-hour polysomnography, wear an Axivity wristband and Nextsense EEG earbuds to evaluate total sleep time.
89003051|NCT05835973|Experimental|Sleep activity|"Actigraphy : Patient will wear actinometers on the wrist for 1 year continuously. In the study, MotionWatch 8 actimeters will be used, a class 1 medical device with CE mark (EN ISO 13485:2016 standard). They will be provided by the company camntech.~Ancillary Study:~DREEM 3 headband : a subgroup of patients will wear the headband during 2 nights every 3 months."
89003052|NCT05829265||Intervention group in the feasibility study.|There will only be one group in the feasibility study (i.e. all 50 patients recruited will receive the intervention).
89003053|NCT05827549|Experimental|Single group study|Apply Blinatumomab Cycle 1,2, S cycle 1, 2 (High Risk Group)- 4 weeks to patients before transplantation
89003054|NCT05818124|Experimental|Panel A: Molnupiravir Post-Exposure Prophylaxis (Part 2)|Molnupiravir 800 mg every 12 hours Day 0 PM through Day 5 AM, placebo molnupiravir every 12 hours Day 5 PM through Day 6 PM
89003055|NCT05818124|Experimental|Panel B: Molnupiravir Treatment (Part 2)|Placebo molnupiravir every 12 hours Day 0 PM through Day 1 PM, molnupiravir 800 mg every 12 hours Day 2 AM through Day 6 PM
89003056|NCT05818124|Active Comparator|Panel C: Oseltamivir Treatment (Part 2)|Placebo oseltamivir Day 0 PM through Day 1 PM, oseltamivir 75 mg plus placebo so the total number of capsules is always 4 per dose every 12 hours Day 2 AM through Day 6 PM
89003057|NCT05818124|Placebo Comparator|Panel D: Molnupiravir Placebo (Part 2)|Placebo molnupiravir every 12 hours Day 0 PM through Day 6 PM
89003058|NCT05818124|Experimental|Virus Inoculation (Part 1 & 2)|Influenza A challenge virus given once by intranasal administration
89003059|NCT05808699||Fundus camera image|Subjects imaged with a fundus camera
89003060|NCT05804526|Experimental|RC88+Sintilimab Injection|RC88+Sintilimab Injection Arm
89003061|NCT05804370|Experimental|Patients Receiving Gleolan|All patients in this arm will receive Gleolan and undergo intraoperative imaging
88858482|NCT04365868|Experimental|belapectin 2 mg/kg lean body mass (LBM)|"Phase 2b: Belapectin 2 mg/kg lean body mass administered intravenously (IV) every other week for 78 weeks (18 months)~Phase 3: The patient will be switched to the optimal dose"
88858483|NCT04365868|Experimental|belapectin 4 mg/kg lean body mass (LBM)|"Phase 2b: Belapectin 4 mg/kg lean body mass administered intravenously (IV) every other week for 78 weeks (18 months)~Phase 3: The patient will be switched to the optimal dose"
89184361|NCT02572245|Active Comparator|PF-06410293 PFS (Prefilled Syringe)|PF-06410293 40 mg administered by Prefilled Syringe (PFS)
89184362|NCT02572245|Active Comparator|PF-06410293 PFP (Prefilled Pen)|PF-06410293 40 mg administered by Prefilled pen
89184363|NCT05192460|Experimental|neoantigen tumor vaccine with or without PD-1/L1|In dose escalation phase, subject will only receive neoantigen tumor vaccine. In dose expansion phase, subject will receive neoantigen tumor vaccine combination with PD-1/L1.
89184364|NCT00719433|Experimental|1|
89184365|NCT00719433|Active Comparator|2|
89184366|NCT02589054||Patients|
89184367|NCT03897699|Experimental|active tDCS + Mindful Breathing Training|20 minutes of active or sham stimulation will be applied at 2.0 mA in parallel with mindful breathing training
89384694|NCT03221387|Other|Nasal high flow with oxygen|While in the clinic High Flow Nasal Cannula oxygen will be passed through a heated humidifier (AIRVO-2, Fisher and Paykel Healthcare) and applied continuously through large-bore binasal prongs (Optiflow+ Fisher and Paykel Healthcare), with a gas flow rate of 20-35 liters per minute or as high as the patient will tolerate and an FiO2 to keep arterial oxygen saturation (SaO2) > 90%. Temperature will be adjusted based on patient's comfort and range from 34-37 degrees based on prior experience. The subject will be discharged to home and instructed to use the high flow nasal cannula system at night and during the daytime while at home and resting.
88858484|NCT04365868|Placebo Comparator|Placebo|"Phase 2b: Placebo, administered intravenously (IV) every other week for 78 weeks (18 months)~Phase 3:Placebo, administered intravenously (IV) every other week for 78 weeks (18 months)"
88858485|NCT04343859|Experimental|IMMH-010|"After Dose escalation study, Dose expansion study will be conducted :~360mg and above,IMMH-010, QD or BID,Cycle1Day1-CycleN."
88858486|NCT04340895|Experimental|Intervention arm|"Treatment optimization (escalation/de-escalation) performed by the investigator based on participant self-monitoring of FC values and/or clinical symptoms (patient-reported outcome-2 [PRO-2] scoring).~The FC Test and/or PRO-2 scoring will be done by the participant at home every month during active disease, every 3 months in remission, or when a participant feels the need/presents clinical symptoms."
88858487|NCT04340895|Active Comparator|Reference arm|"Treatment optimization (escalation/de-escalation) performed by the investigator based on clinical symptoms (PRO-2 scoring) only.~The PRO-2 scoring will be assessed during clinic visits every 3-months during active disease, every 6 months during remission, or when a participant feels the need; as per recommended standard practice."
88858488|NCT04335487|Experimental|ICBT for PTSD Tailored for PSP|Therapist-guided, Internet-delivered cognitive behavioral therapy for PTSD tailored specifically for Canadian public safety personnel.
88858489|NCT04335487|Experimental|Transdiagnostic ICBT Tailored for PSP|Therapist-guided, transdiagnostic Internet-delivered cognitive behavioral therapy tailored specifically for Canadian public safety personnel.
88858490|NCT04329676|Experimental|Deep Brain Stimulation|Patients will undergo bilateral implant of directSTIM system in the STN.
88858491|NCT04328116||Study Group|Neodent GM Zygomatic Dental Implants will be placed. Multiple implants may be placed in a single subject.
88858492|NCT04308941|Active Comparator|Scleral Tonopen|The first 10 subjects will be randomly chosen for the first cohort (scleral TonoPen)
88858493|NCT04308941|Active Comparator|Scleral Pneumatonometer|The second 10 subjects will be randomly chosen for the second cohort (scleral pneumatonometry)
88858494|NCT04308941|Active Comparator|Diaton|The third 10 subjects will be randomly chosen for the third cohort (Diaton).
88858495|NCT04294966|Placebo Comparator|Placebo|
88858496|NCT04294966|Active Comparator|7.5 mg THC|
88858497|NCT04294966|Active Comparator|15 mg THC|
88858498|NCT04294576|Experimental|Arm 1; BJ-001|Phase 1a Part 1, Part 2, and Part 4: dose escalation for BJ-001 as single agent
88858499|NCT04294576|Experimental|Arm 2; BJ-001 and pembrolizumab|"Phase 1a Part 3 and Part 5: dose escalation for BJ-001 in combination with Pembrolizumab~Phase 1b: expansion cohorts for the combination of BJ-001 and pembrolizumab"
88858500|NCT04277546|Experimental|Brazikumab Maintenance Dose|Administer at 4-week intervals through Week 52 Participants who receive IV induction dosing will be administered brazikumab SC at 4-week intervals starting Week 12 through Week 52
88858501|NCT04277546|Experimental|Brazikumab Induction Dose|Administer at Week 0, Week 4, and Week 8
88858502|NCT04274361|Experimental|Ketamine arm|Early ketamine infusion therapy at a rate of 3 mcg/kg/min. All ketamine infusions will be calculated based on ideal body weight (IBW), unless actual body weight is less than ideal. Ketamine infusion therapy will be continued for 48 hours. At 2-4 hours post-infusion the patient's pain will be reassessed. If the NPS is more than 5 the infusion will be increased to 5mcg/kg/min. Following each change in the infusion rate the patient's pain will be reassessed at 2-4 hours and adjustments made accordingly. Maximum infusion rate will be set at 9mcg/kg/min. Conversely, The RAAPS team should be notified if neurologic symptoms (hallucinations, delusions, disturbing dreams, vertigo) are developing and, at the discretion of the RAAPS service, a single dose of lorazepam or midazolam may be utilized. The infusion can be decreased from in 2 mcg/kg/min increments if there are symptoms believed to be related to the infusion that do not respond to benzodiazepines.
88858503|NCT04274361|Placebo Comparator|Placebo arm|The 65 patients randomized to the control arm will receive placebo saline solution at a rate equivalent.
88858504|NCT04218825|Experimental|Adult patients with early stage MF-CTCL (stage IA-IB)|Patients are treated with Chlormethine gel (CL) gel. In case of any skin drug reaction, allergic test will be carried out. Patients not allergic to CL gel will continue at reduced application frequency, with the addition of topical steroid if necessary.
88858505|NCT04214990|Active Comparator|Aspirin|Enteric coated aspirin
88858506|NCT04214990|Placebo Comparator|Placebo|Enteric coated aspirin placebo
88858507|NCT04211740|Active Comparator|OCH-NCNP1 3 mg|
88858508|NCT04211740|Placebo Comparator|Placebo|
88858509|NCT04198727|Experimental|DPD activity|
88858510|NCT04166864|Experimental|SCC-Determined TMS|
88858511|NCT04128072|Experimental|Mogamulizumab + Total Skin Electron Beam Therapy (TSEB)|"Treatment with mogamulizumab will be continued until disease progression or the occurrence of another withdrawal criterion as specified in the protocol.~TSEB will start 28 days after mogamulizumab cycle 2 day 1 at a dose of 12 Gy in 8 fractions over two weeks (4 fractions per week)."
88858512|NCT04123548|Experimental|StrataGraft|On Day 1, participants received a single application of up to 1:1 meshed StrataGraft skin tissue on up to 3 DPT wound(s) totaling no more than approximately 2000 square centimeters (cm^2) in area.
88858513|NCT04101396|Other|4 points blood glucose monitoring|4 points of self monitoring blood glucose which comprises of fasting, 1 hour post breakfast, 1 hour post lunch and 1 hour post dinner
88858514|NCT04101396|Other|7 points blood glucose monitoring|7 points of self monitoring blood glucose which comprises of fasting,1 hour post breakfast, 1 hour pre and post lunch, 1 hour pre and post dinner, pre bed at 10 pm
88858515|NCT04097548|Experimental|CenteringPregnancy group prenatal care|Pregnant women who were randomized to receive CenteringPregnancy group prenatal care.
88858516|NCT04097548|No Intervention|Traditional individual prenatal care|Pregnant women who were randomized to receive traditional individual prenatal care.
89184368|NCT03897699|Sham Comparator|sham tDCS + Mindful Breathing Training|The sham condition will apply stimulation only for the first and last 30 seconds of the 20-minute session
89184369|NCT02589210|Experimental|EpiFix Mesh|Weekly application of EpiFix Mesh and standard of care (moist wound therapy and offloading)
89184370|NCT04069689|Experimental|EPX-100|Single and multiple doses of 20, 40, 80mg of EPX-100 (Clemizole Hydrochloride)
88858517|NCT04095364|Experimental|Arm I (paclitaxel, carboplatin, letrozole)|Patients receive paclitaxel IV over 3 hours and carboplatin IV on day 1. Cycles repeat every 21 days for up to 6 cycles. Patients then receive letrozole PO QD in the absence of disease progression or unacceptable toxicity. Patients undergo blood collection and tumor biopsy during screening as well as medical imaging throughout the study.
88858518|NCT04095364|Experimental|Arm II (letrozole)|Patients receive letrozole PO QD. Cycles repeat every 21 days for up to 6 cycles. Patients then receive letrozole orally PO QD in the absence of disease progression or unacceptable toxicity as maintenance therapy. Patients undergo blood collection and tumor biopsy during screening as well as medical imaging throughout the study.
88858519|NCT04066374|Experimental|Treatment Arm|Intrathoracic placement of neurostimulation device
88858520|NCT04063826|Other|PET MRI Scan|Imaging scan of the liver
88858521|NCT04061720|Experimental|Enhanced Chronic Care|Enhanced Chronic Care provides ongoing, phone-based motivational interventions and interpersonal support to promote readiness to quit, with facilitated access to evidence-based smoking treatment.
89384695|NCT04527575|Experimental|"EpiVacCorona (An Open Study)"|Group 1: 14 volunteers who will be vaccinated with the EpiVacCorona vaccine twice spaced 21 days apart, intramuscularly, at a dose of 0.5 ml
88858522|NCT04061720|Active Comparator|Standard Care|Standard Care provides phone-based brief advice to quit once per year.
88858523|NCT04022733|Placebo Comparator|Moderate NMB group|
88858524|NCT04022733|Experimental|Deep NMB group|
88858525|NCT03976154|Experimental|Dermabond|Catheter fixation will be performed after appropriate placement of a thoracic epidural with Dermabond. The investigator performing the thoracic epidural will distribute the Dermabond at the catheter insertion site in a space no greater than a 2 cm circle around the site. Once the Dermabond is allowed to dry, mastisol will be applied to the surrounding skin and a clear Tegaderm dressing will be used to cover the catheter. Catheter depth at the skin will be recorded at that time. An Epidural catheter infusion pump with 1/8thpercent Bupivacaine and 2mcg/ml Fentanyl will be attached to the catheter and started by the primary anesthesia with a goal rate of 6ml/hr.
88858526|NCT03976154|Active Comparator|Mastisol|Catheter fixation will be performed after appropriate placement of a thoracic epidural with Mastisol spray. The investigator performing the epidural placement will distribute Mastisol spray both in close proximity to the catheter insertion site as well as around the insertion site. Once the Mastisol is allowed to dry, a clear Tegaderm dressing will be used to cover the catheter. Catheter depth at the skin will be recorded at that time. An Epidural catheter infusion pump with 1/8thpercent Bupivacaine and 2mcg/ml Fentanyl will be attached to the catheter and started by the primary anesthesia team with a goal rate of 6ml/hr.
88858527|NCT03976154|Active Comparator|Grip-lock|Catheter fixation will be performed after appropriate placement of a thoracic epidural with a Grip-Lok fixation bandage. The investigator performing the epidural placement will place the fixation bandage one centimeter caudal from the insertion site. Mastisol will be applied to the surrounding skin and a clear Tegaderm will then be used to cover the catheter. Catheter depth at the skin will be recorded at that time. An Epidural catheter infusion pump with 1/8thpercent Bupivacaine and 2mcg/ml Fentanyl will be attached to the catheter and started by the primary anesthesia team in the operating room with a goal rate of 6ml/hr.
88858528|NCT03969420|Experimental|Lead-In Cohort: Arm 1|Refractory (i.e., failed to achieve a CR/CRi or achieved a CR/CRi with duration <90 days)
88858529|NCT03969420|Experimental|Lead-In Cohort: Arm 2|Relapsed (i.e., reoccurrence of disease following a CR/CRi with duration ≥90 days).
88858530|NCT03969420|Experimental|Stage 1: Arm 1|Refractory (i.e., failed to achieve a CR/CRi or achieved a CR/CRi with duration <90 days)
88858531|NCT03969420|Experimental|Stage 1: Arm 2|Relapsed (i.e., reoccurrence of disease following a CR/CRi with duration ≥90 days).
88858532|NCT03921242||Metformin Cohort|Group of study participants having both Type 2 Diabetes and Chronic Kidney disease and meeting the study's inclusion criteria for whom metformin was prescribed at baseline for this first time in each patient's medical history.
89384696|NCT04527575|Experimental|"EpiVacCorona (A Simple, Blind, Randomized Study)"|Group 2: Administration of the EpiVacCorona vaccine, intramuscularly, twice, 21 days spaced apart, at a dose of 0.5 ml (43 volunteers)
88858533|NCT03921242||Sulfonylurea Cohort|Group of study participants having both Type 2 Diabetes and Chronic Kidney disease and meeting the study's inclusion criteria for whom sulfonylurea was prescribed at baseline for this first time in each patient's medical history.
88858534|NCT03921242||DPP4 Inhibitor Cohort|Group of study participants having both Type 2 Diabetes and Chronic Kidney disease and meeting the study's inclusion criteria for whom a DPP4 Inhibitor was prescribed at baseline for this first time in each patient's medical history.
88858535|NCT03921242||SGLT2 Inhibitor Cohort|Group of study participants having both Type 2 Diabetes and Chronic Kidney disease and meeting the study's inclusion criteria for whom an SGLT2 Inhibitor was prescribed at baseline for this first time in each patient's medical history.
88858536|NCT03921242||GLP1 Receptor Agonist Cohort|Group of study participants having both Type 2 Diabetes and Chronic Kidney disease and meeting the study's inclusion criteria for whom a GLP1 receptor agonist was prescribed at baseline for this first time in each patient's medical history.
88858537|NCT03914443|Experimental|Cohort A|"Nivolumab: 360 mg, every 3 week 5-FU: 800 mg/m^2, every 3 week CDDP: 80 mg/m^2, every 3 week "
88858538|NCT03914443|Experimental|Cohort B|"Nivolumab: 240 mg lead-in followed by 360 mg, every 3 week 5-FU: 800 mg/m^2, every 3 week CDDP: 80 mg/m^2, every 3 week "
88858539|NCT03914443|Experimental|Cohort C|"Nivolumab: 360 mg, every 3 week 5-FU: 750 mg/m^2, every 3 week CDDP: 70 mg/m^2, every 3 week DTX: 70mg/m^2, every 3 weeks"
88858540|NCT03914443|Experimental|Cohort D|"Nivolumab: 240 mg lead-in followed by 360 mg, every 3 week 5-FU: 750 mg/m^2, every 3 week CDDP: 70 mg/m^2, every 3 week DTX: 70mg/m^2, every 3 weeks"
88858541|NCT03867617|Experimental|Study group|Treatment with regulatory T cells, donor bone marrow and tocilizumab in addition to immunosuppressive drug therapy in kidney transplant recipients
89184371|NCT04069689|Placebo Comparator|Placebo|Single and multiple doses of 20, 40, 80mg of placebo
88858542|NCT03867617|Active Comparator|Control group|Immunosuppressive drug therapy without treatment with regulatory T cells, donor bone marrow and tocilizumab in kidney transplant recipients
88858543|NCT03861767|Experimental|SPRY: Metformin LD-SC (low-dose, short course)|"LD-SC (low-dose, short course)~Participants take Metformin ER 500 mg daily for 7-28 days prior to their elective surgical procedure as determined by the patient's scheduling of their surgery. Participants take this same dose of Metformin ER for 90 days after their surgical procedure."
88858544|NCT03861767|Experimental|SPRY: Metformin LD-IC (low-dose, intermediate course)|"LD-IC (low-dose, intermediate course)~Participants take Metformin ER 500 mg daily for 29-90 days prior to their elective surgical procedure as determined by the patient's scheduling of their surgery. Participants take this same dose of Metformin ER for 90 days after their surgical procedure."
88858545|NCT03861767|Experimental|SPRY: Metformin LD-LC (low-dose, long course)|"LD-LC (low-dose, long course)~Participants take Metformin ER 500 mg daily for 90+ days prior to their elective surgical procedure as determined by the patient's scheduling of their surgery. Participants take this same dose of Metformin ER for 90 days after their surgical procedure."
88858546|NCT03861767|Experimental|SPRY: Metformin ID-SC (intermediate-dose, short course)|"ID-SC (intermediate-dose, short course)~Participants take Metformin ER 1000 mg daily for 7-28 days prior to their elective surgical procedure as determined by the patient's scheduling of their surgery. Participants take this same dose of Metformin ER for 90 days after their surgical procedure."
88858547|NCT03861767|Experimental|SPRY: Metformin ID-IC (intermediate-dose, intermediate course)|"ID-IC (intermediate-dose, intermediate course)~Participants take Metformin ER 1000 mg daily for 29-90 days prior to their elective surgical procedure as determined by the patient's scheduling of their surgery. Participants take this same dose of Metformin ER for 90 days after their surgical procedure."
88858548|NCT03861767|Experimental|SPRY: Metformin ID-LC (intermediate-dose, long course)|"ID-LC (intermediate-dose, long course)~Participants take Metformin ER 1000 mg daily for 90+ days prior to their elective surgical procedure as determined by the patient's scheduling of their surgery. Participants take this same dose of Metformin ER for 90 days after their surgical procedure."
88858549|NCT03861767|Experimental|SPRY: Metformin HD-SC (high-dose, short course)|"HD-SC (high-dose, short course)~After a 7 day run-in of Metformin ER 1000 mg, participants take Metformin ER 1500 mg daily for 7-28 days prior to their elective surgical procedure as determined by the patient's scheduling of their surgery. Participants take this same dose of Metformin ER for 90 days after their surgical procedure."
88858550|NCT03861767|Experimental|SPRY: Metformin HD-IC (high-dose, intermediate course)|"HD-IC (high-dose, intermediate course)~After a 7 day run-in of Metformin ER 1000 mg, participants take Metformin ER 1500 mg daily for 29-90 days prior to their elective surgical procedure as determined by the patient's scheduling of their surgery. Participants take this same dose of Metformin ER for 90 days after their surgical procedure."
88858551|NCT03861767|Experimental|SPRY: Metformin HD-LC (high-dose, long course)|"HD-LC (high-dose, long course)~After a 7 day run-in of Metformin ER 1000 mg, participants take Metformin ER 1500 mg daily for 90+ days prior to their elective surgical procedure as determined by the patient's scheduling of their surgery. Participants take this same dose of Metformin ER for 90 days after their surgical procedure."
88858552|NCT03861767|Placebo Comparator|SPRY: Placebo|Participants are randomized to receive dose matched placebo to take daily for either short-, intermediate-, or long-course.
88858553|NCT03758625|Experimental|ARM A|a1DC + inactivated whole autologous HIV vaccine given as six monthly doses of approximately 10e7 DC per dose
88858554|NCT03758625|Experimental|ARM B|a1DC + conserved HIV peptides vaccine given as six monthly doses of approximately 10e7 DC per dose
88858555|NCT03758625|Active Comparator|ARM C|a1DC + no antigen vaccine given as six monthly doses of approximately 10e7 DC per dose
88858556|NCT03758625|Experimental|ARM D|pgDC + inactivated whole autologous HIV vaccine given as six monthly doses of approximately 10e7 DC per dose
88858557|NCT03758625|Experimental|ARM E|pgDC + conserved HIV peptides vaccine given as six monthly doses of approximately 10e7 DC per dose
88858558|NCT03758625|Active Comparator|ARM F|pgDC + no antigen vaccine given as six monthly doses of approximately 10e7 DC per dose
88858559|NCT03756298|Experimental|Combination|Atezolizumab + capecitabine combination arm
88858560|NCT03756298|Active Comparator|Control|Capecitabine alone arm
88858563|NCT03716349|Experimental|System A|Tokuyama Universal Bond (TUB) single component self-etching 1-step adhesive system w/Tokyuama supra-nanofilled dental composite (ECM) (Tokuyama Dental Corp., Japan), informed consent signed, release of medical information signed, oral exam, health Questionnaire completed and/or updated, xray obtained if needed, pulp vitality testing, Tooth shade determination, photos of teeth, local and/or topical anesthetic applied as necessary, rubber dam isolation, tooth surface cleaned, cavity preparation performed as usual for caries removal, Enamel margins beveled, infinite invisible margins created, adhesive systems applied, dental composite placed, shade selection using Easy Shade 5. Light curing, restoration will be contoured and polished. teeth assessment, clinical assessment
88858564|NCT03716349|Active Comparator|System B|ScotchBond Universal one-step adhesive system with Filtek Supreme Ultra™, nanofilled dental composite (3M) will randomly be applied to the other tooth informed consent signed, release of medical information signed, oral exam, health Questionnaire completed and/or updated, xray obtained if needed, pulp vitality testing, Tooth shade determination, photos of teeth, local and/or topical anesthetic applied as necessary, rubber dam isolation, tooth surface cleaned, cavity preparation performed as usual for caries removal, Enamel margins beveled, infinite invisible margins created, adhesive systems applied, dental composite placed, shade selection using Easy Shade 5. Light curing, restoration will be contoured and polished. teeth assessment and clinical assessment at periodic timepoints.
88858565|NCT03710343|Experimental|Metformin|Metformin oral tablet will be taken by mouth or through a gastrostomy tube, once or twice a day for 16 weeks.
88858566|NCT03691935|Experimental|Ropivicaine|Erector Spinae Block of 20ml 0.5% ropivicaine bolus, connected to a pump containing 0.2% ropivicaine receiving 15ml every 3 hrs.
88858567|NCT03691935|Sham Comparator|Normal Saline|Erector Spinae Block of 20ml normal saline placebo bolus, then connected to pump of normal saline receiving 15ml every 3 hrs.
89184372|NCT00719511|Experimental|1|Patch allergen dose 1
89184373|NCT00719511|Experimental|2|Patch allergen dose 2
89184374|NCT00719511|Experimental|3|Patch allergen dose 3
89184375|NCT00719511|Experimental|4|Placebo
88858568|NCT03686345|Experimental|Core binding factor acute myeloid leukemia (CBF-AML)|Patients must have an unequivocal diagnosis of de novo-CBFL, prior to start midostaurin, documented by rearrangement of Core Binding Factor (CBF) genes, namely AML1-ETO and CBFB-MYH11. The experimental arm involves the administration of Midostaurin orally 50 mg (two 25 mg tablets) twice a day, from the end of induction chemotherapy, for 14 days. Patients should take Midostaurin at approximately 12 hours intervals. During all consolidation cycles, Midostaurin 50 mg (two 25 mg tablets) is administered orally twice a day, on days 8-21. Patients in complete remission after 3 cycles of remission consolidation therapy, will receive Midostaurin continuation therapy for 12 months. Midostaurin 50 mg (two 25 mg tablets) will be given orally twice a day for 12 months.
88858569|NCT03677141|Experimental|Phase Ib: Mosunetuzumab (M)-CHOP Dose Finding|Participants will receive M-CHOP up to the phase II recommended dose (RP2D).
88858570|NCT03677141|Experimental|Phase Ib: M-CHP-Pola Dose-Finding|Participants will receive M-CHP-Pola up to the RP2D.
88858571|NCT03677141|Experimental|Phase II: M-CHOP Previously Untreated (1L) DLBCL Safety Cohort|Participants with 1L DLBCL will receive mosunetuzumab at the RP2D in combination with CHOP.
88858572|NCT03677141|Experimental|Phase II: M-CHP-Pola 1L DLBCL|Participants with 1L DLBCL will receive M-CHP-Pola at a dose determined in the dose finding stage.
88858573|NCT03677141|Active Comparator|Phase II: Rituxumab (R)-CHP-Pola 1L DLBCL|Participants with 1L DLBCL will receive R-CHP-Pola at a dose determined in the dose finding stage.
88858574|NCT03677141|Experimental|Phase II: M-CHOP 1L DLBCL|Participants with 1L DLBCL will receive M-CHOP at a dose determined in the dose finding stage.
88858575|NCT03636074||Hearth-valve surgery|
88858576|NCT03636074||Hearth bypass surgery|
88858577|NCT03617679|Active Comparator|Active Ingredient|1:1 Randomization. Participants in this arm receive the active ingredient medication.
88858578|NCT03617679|Placebo Comparator|Placebo|1:1 Randomization. Participants in this arm receive the placebo medication. (Placebos do not contain active ingredients).
88858579|NCT03616821|Experimental|Brazikumab Dose 1|Intravenous brazikumab on day 1, day 15, and day 43 followed by Subcutaneous brazikumab every 4 weeks beginning on day 71 through week 50
88858580|NCT03616821|Experimental|Brazikumab Dose 2|Intravenous brazikumab on day 1, day 15, and day 43 followed by Subcutaneous brazikumab every 4 weeks beginning on day 71 through Week 50
88858581|NCT03616821|Placebo Comparator|Placebo|Intravenous placebo on day 1, day 15, and day 43 followed by Subcutaneous every 4 weeks beginning on day 71 through Week 50.
88858582|NCT03593915|Experimental|Ph 1b and 2: MDS|"Patients with previously untreated MDS~Patients with MDS who have received <6 cycles of HMAs (during dose escalation only)~Patients with de novo (cause unknown) or secondary MDS (treatment-related) who are not eligible for intensive induction chemotherapy or stem cell transplant~All French-American-British (FAB) subtypes~Intermediate and above per IPSS-R groups"
88858583|NCT03577327||Adults with vitiligo|
88858584|NCT03577327||Healthy adults|
88858585|NCT03572634|Experimental|Group 1-TP 0903 monotherapy|"Adult patients with CLL/SLL who:~are intolerant to, or have had progressive disease on B-cell receptor antagonists, BCL-2 antagonists or other investigational treatments for CLL/SLL"
88858586|NCT03572634|Experimental|Group 2-TP-0903 and ibrutinib combination therapy|"Adult patients with CLL/SLL who:~have progression of disease on ibrutinib, yet the treating provider considers continuation of ibrutinib therapy to be in the best interest of the patient"
88858587|NCT03541850|Experimental|Treatment (SBRT, ADT)|Patients undergo SBRT QOD for 14 days. Patients may also receive ADT comprised of a luteinizing hormone-releasing hormone agonist or a gonadotropin-releasing hormone antagonist, and an oral anti-androgen for 6 months at the discretion of the treating physician.
88858588|NCT03535272|Active Comparator|Intervention Group|Bismuth subsalicylate 4 tablets po bid (2.1 grams total of BSS)
88858589|NCT03535272|Placebo Comparator|Placebo|Placebo oral tablet 4 bid
88858590|NCT03517137|Experimental|Treatment|
88858591|NCT03511534|Active Comparator|Psychotherapy|Participants will receive evidenced based psychotherapy by a trained psychologist
88858592|NCT03511534|Active Comparator|Pharmacotherapy|Participants will receive pharmacotherapy by a psychiatrist
89184376|NCT04984122|Other|Control|GA group intravenous 2-3 μ/kg fentanyl followed by 2 mg/kg propofol. were administered for anesthesia induction. After a laryngeal mask insertion anesthesia was maintained by inhalation of sevoflurane in an oxygen (60%) and nitrous oxide (40%) mixture to maintain a minimal alveolar concentration (MAC) of 0.8%-1.3%.
89184377|NCT04984122|Other|Study|In the LA group, after positioning of the patient, 50 mg of lidocaine spray (5 pumps, 10 mg in each pump) were applied to the ectocervix, then 2 mL bupivacaine hydrochloride was injected submucosally using a 27-gauge needle tip at the 3, 6, 9, and 12 o'clock locations in the ectocervix.
89184378|NCT00719589||1|Patient who have had implantation of an interstim.
89184379|NCT00795821|Experimental|LY2216684|"10-week Acute Treatment Phase: Day after Week 0=start of 6 milligram (mg) once daily (QD) dosing; Week 1=all participants titrated to 9 mg QD; After Week 1=dose increased, maintained, or decreased to a minimum of 6 mg QD and maximum of 18 mg QD, depending on participant's tolerance of study drug.~1-year Long-term Extension Phase: Day after Week 10=start of same LY2216684 dose participant was taking at the end of acute treatment phase; After Week 11=dose increased, maintained, or decreased to minimum of 6 mg QD and maximum of 18 mg QD based on investigator's judgment of safety and tolerability (up to Week 62)."
89184380|NCT00795821|Placebo Comparator|Placebo|"10-week Acute Treatment Phase: 3 tablets QD for 10 weeks~1-year Long-term Extension Phase: Day after Week 10=6 mg LY2216684 dose; After 1 week=dose escalated to 9 mg QD; After Week 11=dose increased, maintained, or decreased to minimum of 6 mg QD and maximum of 18 mg QD based on investigator's judgment of safety and tolerability (up to Week 62)."
89184381|NCT00710853|Experimental|1|YiRen Qi gong weekly class for 8 weeks
89184382|NCT00710853|Experimental|2|Tai Chi weekly class for 8 weeks
89184383|NCT00710853|Active Comparator|3|Hatha yoga weekly class for 8 weeks
89184384|NCT00716235||DCD|Children with a diagnosis of DCD
89184385|NCT00716235||Autism|Children with a diagnosis of Autism disorder
89184386|NCT00716235||ADHD|Children with a diagnosis of ADHD
89184387|NCT00716235||Control|Control group - children with no neurological or psychiatric problems
89184388|NCT00711165|Placebo Comparator|Placebo|Placebo, 2 puffs, bid
89184389|NCT00711165|Experimental|Memetasone|Mometasone
89184390|NCT00719745|Active Comparator|1|
88858593|NCT03500081||Cancer Patients|Cancer patients with any solid tumor type planning to undergo a course of radiation therapy. Seventy-five patients in this group with any solid tumor type will consent to the genomic biomarker sub-study, which will be conducted with biopsy tissue samples to determine how genomic predictors of radiation response may correlate with tumor changes as seen on MRIs acquired during treatment.
88858594|NCT03500081||Healthy Volunteers|Faculty members in the Department of Radiation Oncology have volunteered to participate in this research project. They are investigators and are interested in the abilities of this new machine(MR-Linac) and the potential benefits to patients who will be treated in their department. These scans will be used to optimize scanning parameters for various body sites and to identify appropriate positioning methods for future patient treatments.
88858595|NCT03452007|Experimental|Bladder Mapping and Training|Individuals already implanted with a spinal cord epidural stimulator will receive epidural stimulation targeted at enhancing both the storage and voiding phase of micturition cycle.
88858596|NCT03442309|Experimental|Simple Prevention|"One drop (0.05 ml) of silver diamine fluoride (Advantage ArrestTM) solution at 38% concentration (2.24 F-ion mg/dose) will be dispensed per child. Posterior tooth surfaces to be treated will be dried, after which the SDF will be applied with a micro-brush to all asymptomatic carious lesions and to all pits and fissures on bicuspids and molar teeth for thirty seconds. Fluoride varnishes (5% NaF) will then be applied to all teeth.~Dosage frequency will be twice-yearly."
88858597|NCT03442309|Active Comparator|Complex prevention|"Pits and fissures on all bicuspids and molar teeth will be sealed with glass ionomer sealants (GC Fuji IX). Glass ionomer sealants (interim therapeutic restorations) will also be placed on all frank asymptomatic carious lesions. Fluoride varnishes (5% NaF) will then be applied to all teeth.~Dosage frequency will be twice-yearly."
88858598|NCT03396809|Experimental|Punctal Plugs|This arm of the study receives punctal plug intervention.
88858599|NCT03384836|Experimental|Treatment (propranolol hydrochloride, pembrolizumab)|Patients receive propranolol hydrochloride PO BID and pembrolizumab IV over 30 minutes of day 1. Courses repeat every 3 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
88858600|NCT03336333|Experimental|Cohort 1: Bendamustine + Rituximab|Participants will receive bendamustine plus rituximab for up to six 28-day cycles (Arm B)
88858601|NCT03336333|Experimental|Cohort 1: Zanubrutinib|Participants will receive zanubrutinib until unacceptable toxicity or disease progression (Arm A)
88858602|NCT03336333|Experimental|Cohort 1a (China only): Bendamustine + Rituximab|Participants will receive bendamustine plus rituximab for up to six 28-day cycles (Arm B, China only)
88858603|NCT03336333|Experimental|Cohort 1a (China only): Zanubrutinib|Participants will receive zanubrutinib until unacceptable toxicity or disease progression (Arm A, China only)
88858604|NCT03336333|Experimental|Cohort 2: Zanubrutinib|Participants will receive zanubrutinib until unacceptable toxicity or disease progression (Arm C)
88858605|NCT03336333|Experimental|Cohort 3: Venetoclax + Zanubrutinib|Approximately 110 participants, 50 without del17p and 60 with del[17p] or TP53 mutation will receive zanubrutinib plus venetoclax; Participants will also receive zanubrutinib starting on Cycle 1 Day 1 then daily for a minimum of 27 cycles, or until unacceptable toxicity or disease progression, whichever occurs first. Participants will receive venetoclax starting Cycle 4 Day 1 according to a 5-week dose-up schedule then daily until unacceptable toxicity, disease progression, or for a maximum of 24 cycles. Each cycle is 28 days. (Arm D)
88858606|NCT03329521|Experimental|Multicomponent intervention|A multicomponent intervention will be provided at chronic kidney disease (CKD) programs.
88858607|NCT03329521|No Intervention|Usual Care|CKD programs will continue to support access to kidney transplantation and living kidney donation as they usually do for CKD patients.
88858608|NCT03298737||Correct to normal vision population|
88858609|NCT03250767||Integra Titan Modular Shoulder System 2.5|
88858610|NCT03240874|Experimental|Usability - Focus Group|"Mobile Application Usability Testing: SweetMama Focus Groups~Focus groups: Women with a confirmed intrauterine pregnancy or postpartum until 12 weeks after delivery with gestational diabetes mellitus or type 2 diabetes mellitus will be recruited to undergo a single 1-hour focus group."
88858611|NCT03240874|Experimental|Usability - Individual Testing|"Mobile Application Usability Testing: SweetMama Individual Testing~Individual testing: Women with a confirmed intrauterine pregnancy (any gestational age) or who are up to 4 weeks postpartum, with gestational diabetes mellitus or type 2 diabetes mellitus, will be recruited to use SweetMama for 2 weeks and provide feedback."
88858612|NCT03240874|Experimental|Feasibility - Pilot Randomized Trial, SweetMama arm|"Mobile Application Feasibility Testing: SweetMama Pilot Trial, SweetMama arm~Women recruited to the pilot RCT phase will enroll in the study upon initiation of prenatal care for diabetes, which could be early in pregnancy at the time of first prenatal visit, or at a later point if they have transferred care to this site. Women randomized to receive SweetMama care will be oriented to use of SweetMama and will then use the intervention (messages, library, goal setting, and appointment reminders) throughout pregnancy and the first 8 weeks postpartum, at which point they will undergo surveys and interviews."
88858613|NCT03240874|No Intervention|Feasibility - Pilot Randomized Trial, usual care arm|"Mobile Application Feasibility Testing: SweetMama Pilot Trial, usual care arm~Women recruited to the pilot RCT phase will enroll in the study upon initiation of prenatal care for diabetes, which could be early in pregnancy at the time of first prenatal visit, or at a later point if they have transferred care to this site. Women randomized to usual care will be undergo entry and exit surveys (at 6-8 weeks postpartum) but will not interact with SweetMama."
88858614|NCT03240068|Experimental|Angiotensin-(1-7)|Subjects will receive intravenous infusion of five ascending doses of angiotensin-(1-7). The doses are: 1, 2, 4, 8, and 12 ng/kg/min. Each dose will be maintained for 10 minutes, for a total infusion period of 50 minutes.
88858615|NCT03240068|Placebo Comparator|Saline|Subjects will receive intravenous infusion of saline that is matched in volume to the angiotensin-(1-7) arm. Saline infusion will be maintained for a total infusion period of 50 minutes.
88858616|NCT03136445|Experimental|Intervention Arm|Tranexamic acid (TXA). Dose schedule TXA 1g every eight hours IV or 1.5g every eight hours PO.
88858617|NCT03136445|Placebo Comparator|Control Arm|Placebo (saline) if administration is IV. Placebo tablet matched for appearance to TXA if oral.
88858618|NCT03121469|Experimental|Per-Operative Radiotherapy|Technique of Per-Operative Radiotherapy (RPO) by Papillon +TM
88858619|NCT03089554|Experimental|Therapeutic Intervention|Therapeutic Intervention
88858620|NCT03083665|Placebo Comparator|Placebo|"12 weeks Treatment Period: Subjects will receive Placebo~4 weeks Down-Titration Period: Subjects will receive Placebo"
88858621|NCT03083665|Experimental|BRV 50 mg/day|"12 weeks Treatment Period: Subjects will receive BRV 50 mg/day~- Subjects entering into the Long term follow up (LTFU) study or managed access program (MAP): 2 weeks Transition Period: Subjects will receive BRV 50 mg/day followed by LTFU or MAP: Subjects will receive BRV 100 mg/day~- Subjects not entering into the LTFU study or MAP: 4 weeks Down-Titration Period: Subjects will receive BRV 25 mg/day for 1 week followed by Placebo for 3 weeks, followed by a Study Drug-Free Period"
88858622|NCT03083665|Experimental|BRV 200 mg/day|"12 weeks Treatment Period: Subjects will receive BRV 200 mg/day~- Subjects entering into the Long term follow up (LTFU) study or managed access program (MAP): 2 weeks Transition Period: Subjects will receive BRV 150 mg/day followed by LTFU or MAP: Subjects will receive BRV 100 mg/day~- Subjects not entering into the LTFU study or MAP: 4 weeks Down-Titration Period: Subjects will receive BRV 150 mg/day for 1 week followed by BRV 100 mg/day for 1 week, followed by BRV 50 mg/day for 1 week, followed by BRV 25 mg/day for 1 week followed by a Study Drug-Free Period"
88858625|NCT03059030|Experimental|Subjects with thrombocytopenia secondary to cirrhosis|Evaluate the safety and efficacy of 90Y radioembolization for the management of thrombocytopenia.
88858626|NCT03045276|Active Comparator|Arm 1 - No Feedback, Minimum Incentive|Subjects will receive daily text message reminders and report real-time treatment adherence with photos. They will receive compensation to encourage real-time adherence reporting. Subjects will also be able to log into a personal dashboard with a visual display of their weekly adherence performance and educational resources related to their primary disease. Every month, participants will receive a text encouraging them to visit their personal dashboard. The dashboard is able to track usage of the modules by individual. Parents/legal guardians will have access to these same educational materials via their own portals. Additionally, to mitigate the minimal risk of this study, parents/legal guardians will be notified if their child is excessively non-adherent.
88875425|NCT02609100|Active Comparator|Video Capsule Endoscopy|Randomization arm one is to video capsule endoscopy (VCE) a non-invasive procedure in which a patient swallows a disposable 1.0 X 2.5 cm 'pill' containing a camera electronically linked to equipment outside the patient which records images as it passes from the esophagus through the entire tract and is excreted in feces. It images the small intestine in areas beyond the reach of upper GI endoscopy and the terminal ileum and is similarly beyond the reach of colonoscopy. Its greatest use is in identifying points of bleeding and ulcers.
89184391|NCT00719745|Experimental|2|
89184392|NCT02587416|Experimental|Gemcabene 300 mg|Gemcabene 300 mg
89184393|NCT02587416|Experimental|Gemcabene 900 mg|Gemcabene 900 mg
89184394|NCT02587416|Active Comparator|Atorvastatin 80 mg|Atorvastatin 80 mg
89184395|NCT00719823|Other|1|
89184396|NCT00919776|Experimental|ciclosporin|ciclosporin reducing regimen lasting 16 weeks (additional prednisolone given for the first four weeks)
89184397|NCT00919776|Active Comparator|Prednisolone|standard course of prednisolone given in a reducing regimen over 16 weeks
89184398|NCT00719979|Experimental|iCBT and TeleCoaching|Participants received the technology-assisted behavioral intervention (iCBT + TeleCoaching).
89184399|NCT00719979|Experimental|iCBT(MoodManager)|Participants received Internet-based cognitive behavioral therapy only.
89184400|NCT00719979|Active Comparator|Treatment as usual / Wait-list control|Participants received treatment as usual . For wait-list control, participants were not provided any intervention for 6 weeks, after which they were allowed to choose coached or self-directed moodManager.
89384697|NCT04527575|Placebo Comparator|"Placebo (A Simple, Blind, Randomized Study)"|Group 3: Тhe use of placebo (sodium chloride, solvent for the preparation of dosage forms for injection 0.9%) intramuscularly twice space 21 days apart at a dose of 0.5 ml (43 volunteers)
89384698|NCT03318861|Experimental|Dose Escalation: 3 x 10^7 KITE-585|Participants with relapsed/refractory multiple myeloma (RRMM), will receive conditioning chemotherapy consisting of cyclophosphamide 300 mg/m^2/day and fludarabine 30 mg/m^2/day intravenous (IV) infusion for 3 days followed by a single infusion of KITE-585 at a dose of 3 x 10^7 autologous anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cells on Day 0. Participants may also receive an optional bridging therapy at the investigator's discretion, up to 7 days before initiation of conditioning chemotherapy. Participants will then have a post-treatment assessment period and long-term follow-up period from Week 2 to Month 3 and after Month 3 to Year 15, respectively.
88875426|NCT02609100|Active Comparator|Next Day Colonoscopy|Randomization arm two is to colonoscopy, a test that allows the doctor to look at the inner lining of the large intestine (rectum and colon). He or she uses a thin, flexible tube called a colonoscope to look at the colon.
88875427|NCT02610972||CLINICALLY CONFIRMED PREECLAMPSIA|Women clinically diagnosed with preeclampsia (severe, mild or superimposed) during pregnancy will provide a urine sample in the postpartum period to determine the presence or absence of proteinuria using the Congo Red test GV-005.
89384699|NCT03318861|Experimental|Dose Escalation: 1 x 10^8 KITE-585|Participants with RRMM, will receive conditioning chemotherapy consisting of cyclophosphamide 300 mg/m^2/day and fludarabine 30 mg/m^2/day IV infusion for 3 days followed by a single infusion of KITE-585 at a dose of 1 x 10^8 autologous anti-BCMA CAR T cells on Day 0. Participants may also receive an optional bridging therapy at the investigator's discretion, up to 7 days before initiation of conditioning chemotherapy. Participants will then have a post-treatment assessment period and long-term follow-up period from Week 2 to Month 3 and after Month 3 to Year 15, respectively.
88858627|NCT03045276|Active Comparator|Arm 2 - Feedback, Maximum Incentive|Subjects will receive daily text message reminders and report real-time treatment adherence with photos, and will have web access to the educational modules through their portal. Every month, participants will receive a text encouraging them to visit their portals. In contrast to Arm 1, they will receive their weekly performance results by text to their phone with tailored feedback. In Arm 2, subjects will receive a larger incentive if they perform their desired treatment behavior. Incentive notification will be texted to participants. Similarly to Arm 1, parents/legal guardians will have access to the same educational materials via their own WTH portals. Additionally, to mitigate the minimal risk of this study, parents/legal guardians will be notified if their child is excessively non-adherent.
88858628|NCT03033342|Experimental|Oral single doses of MRX-4|Single escalating oral doses of MRX-4 from 250 mg to 3000 mg
88858629|NCT03033342|Experimental|Oral multiple doses of MRX-4|Twice daily escalating oral doses of MRX-4 for 10 days: 500 mg, 750 mg, 1000 mg, and 1500 mg
88858630|NCT03033342|Experimental|MRX-4 co-administered with omeprazole|Impact of concomitant food or omeprazole on the pharmacokinetics of oral MRX-4.
88858631|NCT03033342|Placebo Comparator|Oral single doses of placebo|Single oral doses of placebo to match MRX-4
88858632|NCT03033342|Placebo Comparator|Oral multiple doses of placebo|Multiple oral doses of placebo given twice daily for 10 days to match MRX-4
88858633|NCT03033342|Placebo Comparator|Placebo co-administered with omeprazole|Oral placebo given on Day 1, Day 7 to match MRX-4 dosing with omeprazole
88858634|NCT02958670|Experimental|18F-AV-1451-PET|All subjects receive a Scan for assessment of TAU with the radiotracer 18-F-AV-1451
88858635|NCT02957968|Experimental|Cohort A: Triple Negative Breast Cancer (TNBC)|Triple Negative Breast Cancer (Cohort A): Decitabine IV over 60 minutes on 4 days and pembrolizumab IV over 30 minutes on days 8 and 22. Four cycles of dose-dense doxorubicin and cyclophosphamide (AC), followed by 12 doses of weekly paclitaxel and carboplatin.
88858636|NCT02957968|Experimental|Cohort B: HER2-negative hormone receptor-positive tumors|HER2-negative hormone receptor-positive tumors (Cohort B): Decitabine IV over 60 minutes on 4 days and pembrolizumab IV over 30 minutes on days 8 and 22. Four cycles of dose-dense doxorubicin and cyclophosphamide (AC), followed by 12 doses of weekly paclitaxel.
88858637|NCT02957968|Experimental|Cohort A2: Triple Negative Breast Cancer (TNBC) with Extended Pembrolizumab|Triple Negative Breast Cancer (Cohort A2). Decitabine IV over 60 minutes on 4 days and pembrolizumab IV over 30 minutes on days 8 and 22. Four cycles of dose-dense doxorubicin and cyclophosphamide (AC), followed by 12 doses of weekly paclitaxel and carboplatin, and pembrolizumab every 3 weeks.
88858638|NCT02918032||NLSD / TGCV|Patients who are diagnosed with NLSD / TGCV
88858639|NCT02819518|Experimental|Part 1: Pembrolizumab + Nab-paclitaxel|Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 21-day cycle PLUS nab-paclitaxel 100 mg/m^2 IV on Days 1, 8 and 15 of each 28-day cycle.
88858640|NCT02819518|Experimental|Part 1: Pembrolizumab + Paclitaxel|Participants receive pembrolizumab 200 mg IV on Day 1 of each 21-day cycle PLUS paclitaxel 90 mg/m^2 IV on Days 1, 8 and 15 of each 28-day cycle.
88858641|NCT02819518|Experimental|Part 1: Pembrolizumab + Gemcitabine/Carboplatin|Participants receive pembrolizumab 200 mg IV on Day 1 of each 21-day cycle PLUS gemcitabine/carboplatin 1000 mg/m^2 (gemcitabine) and an Area Under the Curve (AUC) 2 (carboplatin) on Days 1 and 8 of each 21-day cycle.
88858642|NCT02819518|Experimental|Part 2: Pembrolizumab + Chemotherapy|Participants receive pembrolizumab 200 mg IV on Day 1 of each 21-day cycle PLUS one of three background chemotherapy regimens at investigator's discretion: 1) nab-paclitaxel 100 mg/m^2 IV on Days 1, 8 and 15 of each 28-day cycle, 2) paclitaxel 90 mg/m^2 IV on Days 1, 8 and 15 of each 28-day cycle, OR 3) gemcitabine/carboplatin 1000 mg/m^2 (gemcitabine) and an AUC 2 (carboplatin) on Days 1 and 8 of each 21-day cycle.
88858643|NCT02819518|Active Comparator|Part 2: Placebo + Chemotherapy|Participants receive placebo (normal saline) IV on Day 1 of each 21-day cycle PLUS one of three background chemotherapy regimens at investigator's discretion: 1) nab-paclitaxel 100 mg/m^2 IV on Days 1, 8 and 15 of each 28-day cycle, 2) paclitaxel 90 mg/m^2 IV on Days 1, 8 and 15 of each 28-day cycle, OR 3) gemcitabine/carboplatin 1000 mg/m^2 (gemcitabine) and an AUC 2 (carboplatin) on Days 1 and 8 of each 21-day cycle.
88858644|NCT02759133|Active Comparator|A - A standard Localization technique|A standard Localization technique : Metal wire as localization technique for breast cancer surgery
88858645|NCT02759133|Experimental|B - Experimental Localization technique|Experimental Localization technique: Radioactive Iodine seed as localization technique for breast cancer surgery
88858646|NCT02718066|Experimental|HBI-8000 in combination with nivolumab|HBI-8000 dose escalation 20mg, 30mg, 40mg, orally, twice weekly; in combination with Nivolumab 240mg intravenous infusions every 2 weeks for Phase 1b and in accordance with the manufacturer package insert and institution's prescribing practice for Phase 2.
88858647|NCT02661022|Experimental|Phase 1, SL-401 7 µg/kg/day|Dose Level 1: single-agent SL-401 7 µg/kg/day on Days 1-5 during the initial 28-day run-in cycle followed by a combination of SL-401/pomalidomide/dexamethasone (pom/dex) if there was no dose-limiting toxicity during the run-in cycle
88858648|NCT02661022|Experimental|Phase 1, SL-401 9 µg/kg/day|Dose Level 2: SL-401 9 µg/kg/day in combination with pom/dex
88858649|NCT02616796|Experimental|Social gaze training|Appropriate social gaze behavior will be reinforced using the principles of Applied Behavior Analysis.
88858650|NCT02616796|No Intervention|No Training|Appropriate social gaze behavior will not be reinforced.
88858651|NCT02599363|Experimental|Dose Escalation Treatment Arm|
88858652|NCT02578797|Experimental|Apalutamide|Prostate Cancer participants will receive the study drug on an outpatient basis except for Cycle 1 (Day 1 and Day 2) and Cycle 3 (Day 1), when intake must occur at study site under overnight fasted conditions.
88858653|NCT02505750|Active Comparator|EBRT 45 Gy/capecitabine + EBRT boost|"3D conformal EBRT 45 Gy (1.8Gy/fraction/5 weeks) with concurrent chemotherapy using capecitabine (825 mg/m2 bid, on radiation days).~A cone down EBRT targeting the GTV will deliver a boost dose of 9 Gy in 5 fractions. On week 14 after the start of treatment, the tumour response evaluation will guide the final strategy: surgery (radical TME or local excision) or watch-and-wait (W-W)."
88858654|NCT02505750|Experimental|EBRT 45 Gy/capecitabine + CXB boost|"Arm B divided in 2 subgroups depending on the tumour diameter:~B1: If the tumour is < 3 cm, a CXB boost dose (90Gy/3 fractions/4 weeks) will be initially delivered to the tumour. After 2 weeks rest, patients will receive 3D conformal EBRT 45 Gy (1.8 Gy/fraction/5 weeks) with concurrent chemotherapy using capecitabine (825 mg/m2 bid, on radiation days). Clinical evaluation will be performed 3 weeks after the end of irradiation (week 14) and will guide the final strategy (surgery or W-W) as in arm A.~B2: If the tumour is ≥ 3 cm, patients will receive EBRT first 45 Gy (1.8 Gy/fraction/5 weeks) with concurrent chemotherapy using capecitabine (825 mg/m2 bid, on radiation days).~A CXB boost dose (90 Gy/3 fractions/4 weeks) will be delivered to residual tumour, after a rest of 2 weeks. On week 14 after the start of treatment, the tumour response evaluation will guide the final strategy (surgery or W-W) as in arm A. Adjuvant chemotherapy will be left to institution choice."
88858655|NCT02464046|Experimental|JNJ-42847922 then Placebo|Participants receive 2*20 milligram (mg) tablet of JNJ-42847922 orally once daily from Day 1 to Day 5 of period 1. After a washout period of 5 to 9 days participants will receive matching placebo from Day 1 to Day 5 of period 2.
88858656|NCT02464046|Experimental|Placebo then JNJ-42847922|Participants will receive matching placebo from Day 1 to Day 5 of period 1. After a washout period of 5 to 9 days participants will receive 2*20 mg tablet of JNJ-42847922 orally once daily from Day 1 to Day 5 of period 2.
88858657|NCT02413736|Experimental|Imatinib|Imatinib 400 mg/day for 24 months.
88858658|NCT02413736|No Intervention|No imatinib|No further imatinib.
88858659|NCT02407119|Active Comparator|7 day H.pylori eradication|Treatment: Omeprazole 20 mg or Rabeprazole 10 mg bid + clarithromycin 500 mg and amoxicillin 1,000 mg bid for 7 days
88858660|NCT02407119|Placebo Comparator|Placebo|Omeprazole 20 mg or Rabeprazole 10 mg bid + Placebo for two antibiotics (clarithromycin and amoxicillin) bid for 7 days
88858661|NCT02369406|Experimental|Antepartum Cohort|"40 children who test HIV-positive within 96 hours after birth (antepartum HIV infection) and are able to initiate ART < 7 days after birth. This cohort will include at least 15 children who start ART < 3 days after birth.~All infants in the antepartum cohort will initiate ART with Nevirapine, Zidovudine, Lamivudine, and later switch to Kaletra, Zidovudine, Lamivudine."
88858662|NCT02369406|Experimental|Peripartum Cohort|"10 children who test HIV-negative within 96 hours after birth but test HIV-positive <57 days after birth (peripartum HIV infection) and who are able to initiate ART <57 days after birth. This cohort will include at least 10 children who start ART < 21 days after birth.~The majority of infants in the peripartum cohort will be able to start Kaletra, Zidovudine, Lamivudine as their first regimen, but a minority may start Nevirapine, Zidovudine, Lamivudine and then switch to Kaletra, Zidovudine, Lamivudine."
88858663|NCT02369406|No Intervention|Control Cohort|25 HIV-infected children who initiated ART at later age ranges (30-365 days for antepartum infection, 57-365 days for peripartum infection or for those with unknown timing of infection) will be enrolled for a single visit that will occur between 24 and 36 months of age. These children will serve as a control group for virologic and immunologic comparisons with children in the prospective cohorts.
88858664|NCT02251665||Acute ischemic stroke, acute ICH, TIA|Consecutive patients with acute ischemic stroke, intracerebral hemorrhage, and transient ischemic attack who are emergently managed in the stroke care unit or stroke units in the National Cerebral and Cardiovascular Center
88858665|NCT02232126|No Intervention|Usual Care|
88858666|NCT02232126|Experimental|Intervention|
88858667|NCT02127073|Experimental|Oxytocin|Subjects would receive 4 IU of intranasal oxytocin; one spray in each nostril, single-use.
88858668|NCT02112214|Active Comparator|Intervention group|10-day bismuth-based quadruple therapy for H. pylori positive subjects
88858669|NCT02112214|Placebo Comparator|Placebo group|Placebo for H. pylori positive subjects
88858670|NCT02095808|Experimental|Surgery|"The 13C-glucose solution will be given intravenously. It will be started at about the same time as the start of surgery, according to the study guidelines.~The 13C-glucose IV solution will be stopped once the surgeon has removed the tumor tissue."
88858671|NCT02078544||All cancer|
88858672|NCT02074267|Experimental|Carbatin|Carbatin is initiated at 100 mg at night and slowly titrated to 300~800 mg three times/day over 4 to 25 days
88858673|NCT02074267|Active Comparator|Neurontin|Neurontin is initiated at 100 mg at night and slowly titrated to 300~800 mg three times/day over 4 to 25 days
88858674|NCT01905813|Experimental|INCB040093|
88858675|NCT01905813|Experimental|INCB040093 in combination with itacitinib (INCB039110)|
88858676|NCT01901562|Experimental|Ductoscopic papillectomy|Ductoscopic papillectomy to treat pathological nipple discharge
88858677|NCT01678027|Placebo Comparator|Placebo|Placebo for LAC triple therapy
88858678|NCT01678027|Active Comparator|LAC triple therapy|PPI (Lansoprazole), Clarithromycin, Amoxicilline
88858679|NCT01658670|Active Comparator|Enhanced Usual Care (EUC) exercise group|The EUC group is provided paid access to the exercise facility and has access to regular facility staff for the 18 month study period.
89384700|NCT03318861|Experimental|Dose Escalation: 3 x 10^8 KITE-585|Participants with RRMM, will receive conditioning chemotherapy consisting of cyclophosphamide 300 mg/m^2/day and fludarabine 30 mg/m^2/day IV infusion for 3 days followed by a single infusion of KITE-585 at a dose of 3 x 10^8 autologous anti-BCMA CAR T cells on Day 0. Participants may also receive an optional bridging therapy at the investigator's discretion, up to 7 days before initiation of conditioning chemotherapy. Participants will then have a post-treatment assessment period and long-term follow-up period from Week 2 to Month 3 and after Month 3 to Year 15, respectively.
88875428|NCT02610972||CLINICALLY HEALTHY|Women with a delivery of a healthy normal baby at term (induction of labor or an elective Caesarean Section) will provide a urine sample in the postpartum period to determine the presence or absence of proteinuria using the Congo Red test GV-005.
88875429|NCT02612688|Experimental|ACP Video Program|Facility asked to implement ACP Video Program
88875430|NCT02612688|No Intervention|Usual ACP procedures|Facility follows usual ACP procedures
88858680|NCT01658670|Experimental|HEART Camp (HC) Intervention group|The HC intervention group will be provided paid access to the exercise facility for the 18 month study period and will also receive the cognitive-behavioral intervention (knowledge, attitudes, self-efficacy, behavioral self-management skills and social support) delivered using both group-based and individual-based strategies.
88858681|NCT01121588|Experimental|Crizotinib|
88858682|NCT00930319||1|Patients with Advanced Hormone-dependent Prostate Carcinoma treated with Firmagon according to SPC
88858683|NCT00819247|Experimental|Degarelix 80/80 + 40|Loading doses of Degarelix 80 mg (20 mg/mL) on Days 0 and 3. Maintenance doses of 40 mg (20 mg/mL) given on days 28, 56, 84, 112 and 140.
88858684|NCT00819247|Experimental|Degarelix 40/40 + 40|Loading doses of Degarelix 40 mg (20 mg/mL) on Days 0 and 3. Maintenance doses of 40 mg (20 mg/mL) given on days 28, 56, 84, 112 and 140.
88858685|NCT00819247|Experimental|Degarelix 80 + 20|Loading dose of Degarelix 80 mg (20 mg/mL) on Day 0. Maintenance doses of 20 mg (10 mg/mL) given on days 28, 56, 84, 112 and 140.
88858686|NCT00739986|Experimental|1|Semapimod 60 mg IV x 1 day, placebo IV x 2 days
89384701|NCT03318861|Experimental|Dose Escalation: 1 x 10^9 KITE-585|Participants with RRMM, will receive conditioning chemotherapy consisting of cyclophosphamide 300 mg/m^2/day and fludarabine 30 mg/m^2/day IV infusion for 3 days followed by a single infusion of KITE-585 at a dose of 1 x 10^9 autologous anti-BCMA CAR T cells on Day 0. Participants may also receive an optional bridging therapy at the investigator's discretion, up to 7 days before initiation of conditioning chemotherapy. Participants will then have a post-treatment assessment period and long-term follow-up period from Week 2 to Month 3 and after Month 3 to Year 15, respectively.
88858687|NCT00739986|Experimental|2|Semapimod 60 mg IV x 3 days
88858688|NCT00739986|Placebo Comparator|3|Placebo comparator IV x 3 days
88858689|NCT00716976|Experimental|STS Arm (sodium thiosulfate treatment)|Patients receive sodium thiosulfate IV (dosage 16 g/m2 or 533 mg per kg for patients whose therapeutic protocol administers cisplatin on a per kg basis due to young age or small body) over 15 minutes beginning 6 hours after the completion of each cisplatin infusion. Treatment with sodium thiosulfate continues until the completion of cisplatin therapy.
88858690|NCT00716976|Experimental|Observation Arm (No sodium thiosulfate treatment)|Patients do not receive sodium thiosulfate.
88858691|NCT00670709||1|Subjects with mild or moderate Huntington's Disease
88858692|NCT00670709||2|Normal Controls
88858693|NCT00634634|Experimental|Sorafenib and Letrozole|
88858694|NCT00509353|Experimental|Single Group|
88858695|NCT00049595|Active Comparator|ABVD|8 cycles of ABVD
88858696|NCT00049595|Experimental|BEACOPP|4 cycles of BEACOPP Escalated + 4 cycles of BEACOPP Baseline
88858697|NCT03578796||Persons with ALS|Persons With possible ALS-specific cognitive impairment will be tested With ECAS-N, MoCA, CDR and a questionnaire at 4 months (baseline) and 8 months (1. follow-up). Further evaluation will be with the questionnaire and CDR at each follow-up until 3 years or use of permanent ventilation support or Death. Information about use of advanced life-prolonging therapy will be collected from patient journal.
88858698|NCT03668106|Active Comparator|swim up method|Measure volume using a sterile 2 mL pipet.Transfer specimen from a plastic cup to a sterile 15 mL- conical centrifuge tube. Gently mix the specimen with equal volume of Sperm Washing Media. Centrifuge the tubes at 1500 rpm for 10 minutes.Carefully aspirate the supernatant without disturbing the pellet and resuspend the pellet in 50mcm of fresh washing medium, then place layer of 0.5 ml of washing medium gently on the surface. Incubate the tubes at a 45° angle for 1 hour for swim-up in vertical rack in a 37°C incubator. After the incubation period, aspirate the entire supernatant from the round bottom tube. Aliquots of the detached sperm were analyzed by halosperm assay for DNA fragmentation another aliquots of same supernatant were used for ICSI then fertilization, division, blastulation, pregnancy and implantation rates were tabulated and statistically tested.
88858699|NCT03668106|Active Comparator|sperm gradient centrifugation|"PureSperm gradients 40 % and 80 % were used for the experiment. All procedures were conducted under sterile conditions. Using a sterile pipette, 2.0 mL of the lower layer (80% PureSperm gradient) was transferred into a conical centrifuge tube.~Using a new sterile pipette, 2.0 mL of the upper layer (40% PureSperm gradient) was gently dispensed on top of the lower layer. A liquefied semen sample was then placed on top of the upper layer and the tube was centrifuged for 20 minutes at 300g. The upper and lower layers were carefully aspirated without disturbing the pellet. Using a transfer pipette, 2-3 mL of Ham's F10 +10% HAS was added to the pellet and the resuspended pellet was centrifuged for 7 minutes at 300g. The supernatant was then removed and the pellet was suspended in a volume of 0.5 mL of Ham's F10 + FCS 10%. Aliquots of the detached sperm were dealt with like previous arm"
88858700|NCT03668106|Active Comparator|zeta method|"sperm samples were diluted 5 million in 1 ml. To induce a positive charge, the tube was placed inside a latex glove up to the cap and grasping the cap, the tube was rotated two or three turns and rapidly pulled out. Each tube was kept at room temperature for 1 minute to allow adherence of the charged sperm to the wall of the centrifuge tube.~Tubes were hold by the cap to avoid grounding of the tube. After 1 minute the tubes were centrifuged at 200g for 5 minutes. Then, the medium and pellet were discarded in order to discard non adhering sperm and other cells. The surface of tube was washed by 0.2ml of Ham's F10+ FCS 10% in order to neutralize the charge on the wall of the tube and detach the adhering sperm.~The collected medium at the bottom of each tube was repipetted and used to rinse the wall of the same tube several times to increase the number of recovered sperm . Aliquots of the detached sperm were dealt with like previous arm"
88858701|NCT03807336|Experimental|Experiential Condition|This group will receive an experiential version of the program Emotion-Focused Skills Training for Parents, meaning they will engage in tasks that are supposed to activate the parents emotional system, providing them with a deeper sense of understanding towards their child.
88858702|NCT03807336|Active Comparator|Psychoeducational version|This group will receive a non-experiential, psychoeducational version of the program Emotion-Focused Skills Training for Parents, meaning they will not engage in tasks that are meant to activate the parents emotional system.
88858703|NCT03575052|Experimental|Drug - Pimavanserin|
88858704|NCT03575052|Placebo Comparator|Placebo|
88858705|NCT04762056||COVID-19 patients after ICU discharge|Patients who suffered COVID-19 pneumonia and stayed in ICU and discharged
89384702|NCT03318861|Experimental|Dose Expansion (Renal Impairment): 3 x 10^7 KITE-585|RRMM participants with moderate renal impairment (creatinine clearance 30 to 59 mL/min [Grade 2 chronic kidney disease]) will receive a conditioning chemotherapy consisting of cyclophosphamide 300 mg/m^2/day and fludarabine 24 mg/m^2/day IV infusion for 3 days followed by a single infusion of KITE-585 at a tolerable dose of 3 x 10^7 autologous anti-BCMA CAR T cells on Day 0. Participants may also receive an optional bridging therapy at the investigator's discretion, up to 7 days before initiation of conditioning chemotherapy. Participants then had a post-treatment assessment period and long-term follow-up period from Week 2 to Month 3 and after Month 3 to Year 15, respectively.
89384703|NCT01381341|Experimental|linifanib|
89384704|NCT01384071|Experimental|Unstable shoes (MBT)|MBT shoes (Masai Barefoot Technology, Switzerland)
89384705|NCT01384071|Sham Comparator|Stable shoes (Adidas)|Adidas stable shoes (Adidas Bigroar2)
89384706|NCT01379391|Active Comparator|TPO|Patients received myeloablative Allo-HSCT with platelet lower than 20G/L on +14d post-transplantation. Patient enrolled in TPO arm will recieved Recombinant Human Thrombopoietin (rHTPO) treatment fro 14 days.
89384707|NCT01379391|No Intervention|TPO-Free Arm|No TPO intervention
89384708|NCT03631251|Experimental|Open Placebo|Open placebo in addition to the standard course of opioids. Opioids are given consistent with standard care.
89384709|NCT04152213|Experimental|Low GI diet group|"The components of the Low GI diet group include:~(1) A one-off, 60-minute, face-to-face, educational session conducted by the research nurse for GI knowledge input. (2) An informational booklet will be given out during the education session. (3) Three follow-up telephone calls of fifteen minutes will be conducted by the research nurse at the 2nd, 5th , and 8th weeks after completing the face-to-face education session."
89384710|NCT04152213|Placebo Comparator|Control group|"The components of the control group include:~(1) Pamphlets from the Department of Health about obesity and a balanced diet based on the food pyramid will be distributed. (2)Three follow-up telephone calls of fifteen minutes will be conducted by the research nurse at the 2nd, 5th , and 8th weeks after receiving the pamphlets."
88858706|NCT04761900||participants were followed for the incidence of T2DM in a cohort study|performed a cohort analysis for T2DM. For incident T2DM cases, calculate the follow-up time from the date of enrollment into our study to the date of T2DM diagnosis.
88858707|NCT04761900||participants were followed for the incidence of hypertension in a cohort study|performed a cohort analysis for hypertension. For incident hypertension cases, calculate the follow-up time from the date of enrollment into our study to the date of hypertension diagnosis.
88858708|NCT04761900||participants were followed for the incidence of carotid atherosclerotic plaque in a cohort study|performed a cohort analysis for carotid atherosclerotic plaque. For incident carotid atherosclerotic plaque cases, calculate the follow-up time from the date of enrollment into our study to the date of carotid atherosclerotic plaque diagnosis.
88858709|NCT03804528|Experimental|Exercise group|Each participant will engage in 60 minute daily sessions delivered 3 times/week for 8 consecutive weeks (a total of 24 sessions).
88858710|NCT03556020|Experimental|High Dose Group|Maximally tolerated dose Drug: Pemziviptadil (PB1046), Once Weekly Subcutaneous Injection
88858711|NCT03556020|Experimental|Low Dose Group|Minimally effective dose Drug: Pemziviptadil (PB1046), Once Weekly Subcutaneous Injection
88858712|NCT03570918|Experimental|MGD014 0.1 micrograms/kilogram (mcg/kg)|a single 2-hour infusion
88858713|NCT03570918|Experimental|MGD014 0.3 mcg/kg|a single 2-hour infusion
88858714|NCT03570918|Experimental|MGD014 1.0 mcg/kg|a single 2-hour infusion
88858715|NCT03570918|Experimental|MGD014 3.0 mcg/kg|a single 2-hour infusion
88858716|NCT03570918|Experimental|MGD014 10.0 mcg/kg|a single 2-hour infusion
88858717|NCT03570918|Experimental|MGD014 30.0 mcg/kg|a single 2-hour infusion
88858718|NCT03570918|Experimental|MGD014 100.0 mcg/kg|a single 2-hour infusion
88858719|NCT03570918|Experimental|MGD014 300.0 mcg/kg|a single 2-hour infusion
88858720|NCT03570918|Experimental|MGD014 300.0 mcg/kg multiple doses|2-hour infusion every 2 weeks for 3 infusions
88858721|NCT05347524||Case arm - Gastric cancer with peritoneal metastasis|Baseline blood samples will be collected from gastric cancer participants with peritoneal metastasis.
88858722|NCT05347524||Control arm - Gastric cancer without peritoneal metastasis|Baseline blood samples will be collected from gastric cancer participants without peritoneal metastasis.
88858723|NCT01677546|Experimental|CSII+BC+CL|Patients using insulin pump (CSII) bolus calculator (BC) wirelessly connected with blood glucose meter Contour Link (CL)
89384711|NCT03084315|Sham Comparator|E-Cig Zero Nicotine|E-Cigarette with no nicotine added
88858724|NCT01677546|Experimental|CSII+BC|Patients using insulin pump (CSII) bolus calculator (BC) without wireless connection with blood glucose meter (CL)
88858725|NCT01677546|No Intervention|CSII (insulin pump only)|Patients using insulin pump (CSII) without BC and connection with CL
88858726|NCT04403724|Active Comparator|premixed injection|will receive an intrathecal injection of 2.4 ml hyperbaric bupivacaine 0.5%, 20 µg fentanyl, and 100 µg preservative-free morphine mixed together.
88858727|NCT04403724|Active Comparator|sequential injections|will receive an intrathecal injection of 2,4 ml hyperbaric bupivacaine 0.5% followed immediately by the opioid mixture by two separate syringes.
88858728|NCT04403646|Experimental|TREATED|"Participants will receive a supply of 28 -- 390 mg ARBOX capsules for 14 days. Patients will be supplemented with 2 capsules of ARBOX per day and standard therapy.~Standard treatment includes: Antipyretics or Lopinavir / Ritonavir, Azithromycin and Hydroxychloroquine, as appropriate (treatment currently recommended by the department of Infectious Diseases of the Hospital de Clínicas that could undergo to modifications). In addition, if necessary: supplemental O2, non-invasive ventilation, antibiotic therapy."
88858729|NCT04403646|Placebo Comparator|CONTROL|"Participants will receive placebo supply for 14 days. The placebo will be administrated with the identical dose as described for the test product.~Beside patients will receive the standard theraphy, which includes Antipyretics or Lopinavir / Ritonavir, Azithromycin and Hydroxychloroquine, as appropriate (treatment currently recommended by the department of Infectious Diseases of the Hospital de Clínicas that could undergo to modifications). In addition, if necessary: supplemental O2, non-invasive ventilation, antibiotic therapy."
88858730|NCT04403568|Experimental|Ursolic Acid|Administration of Ursolic Acid to subjects who are scheduled to undergo radical prostatectomy
89384712|NCT03084315|Active Comparator|E-Cig 24mg Nicotine|E-cigarette with 24mg of nicotine added
88858731|NCT04403568|Experimental|Curcumin|Administration of Curcumin to subjects who are scheduled to undergo radical prostatectomy
88858732|NCT04403568|Experimental|Ursolic Acid and Curcumin|Administration of Ursolic Acid and Curcumin to subjects who are scheduled to undergo radical prostatectomy
88858733|NCT03552822||ERAS Implemented Group|Enhanced recovery after surgery (ERAS) protocol implementation for patients undergoing cesarean delivery.
88858734|NCT03552822||Pre-ERAS - Non-ERAS Implemented Group|Non-Enhanced recovery after surgery (ERAS) protocol implementation for patients undergoing cesarean delivery.
88858735|NCT03551028|Other|HPV self collection|Pairing self-collection of HPV samples for DNA testing with women seeking mobile mammography.
88858736|NCT03547986|Experimental|Duplex Ultrasound (DUS)|Standard angiography and DUS are performed on the same patients (paired data)
88858737|NCT03547986|Experimental|IVUS with Intraarterial pressure measurement (IAP)|Standard angiography and Intra-Vascular Ultrasound (IVUS) with Intraarterial pressure measurement (IAP) are performed on the same patients (paired data)
88858738|NCT03546738|Experimental|Burst SCS|Burst Spinal cord stimulation. SCS system implanted and burst stimulation given
88858739|NCT03546738|Sham Comparator|Sham SCS|Sham spinal cord stimulation. SCS system implanted but no stimulation given.
88858740|NCT03564756|Experimental|Iron + Vitamin C|One iron tablet once a day plus a 500 mg vitamin C tablet twice a day until delivery.
89384713|NCT03187301|Experimental|APL-130277|APL-130277 at the dose determined in the dose titration phase
89384714|NCT03187301|Placebo Comparator|Placebo|Placebo
89384715|NCT03187301|Active Comparator|moxifloxacin|moxifloxacin at a single 400mg dose
89384716|NCT01379313|Active Comparator|1:2 group|conventional I:E ratio group, inspiratory time : expiratory time = 1:1
88858741|NCT03564756|No Intervention|Iron + Placebo|One iron tablet once a day plus a placebo tablet twice a day until delivery.
89384717|NCT01379313|Experimental|1:1 group|1:1 I:E ratio group, inspiratory time : expiratory time = 1:1
89384718|NCT01379313|Experimental|2:1 group|inverse ratio group, inspiratory time : expiratory time = 2:1
89384719|NCT01379313|Active Comparator|1:2 PEEP group|I:E ratio of 1:2 with external PEEP of 5 cm H2O
89384720|NCT01381263|Experimental|Behavioural medicine|
89384721|NCT01381263|Active Comparator|Standard treatment|Standard treatment includes muscle strengthening, stretching, posture training, training of relaxation techniques and information about pain according to the best empirical praxis
89384722|NCT02963285||0 to 6 months|
89384723|NCT02963285||7 months to less than 1 year|
89384724|NCT02963285||1 to less than 2 years|
89384725|NCT02963285||2 to less than 6 years|
89384726|NCT02963285||6 to 12 years|
89384727|NCT01381185|No Intervention|Standard therapy|standard dose of 100mg aspirin qd and 1x75mg Clopidogrel will be given
89384728|NCT01381185|Active Comparator|ASA/CLP increase|According to 2 platelet monitoring assays HPR confirmation aspirin will be increased to 200mg qd, clopidogrel to 2x75mg qd
89384729|NCT01383837|Experimental|STYLEnS|Multifamily Group HIV/STI Prevention intervention or Single Family Dyad (youth and a parent)
89384730|NCT01383837|Active Comparator|Health Promotion|Health Promotion Intervention - Adolescents only
89384731|NCT02946047|Experimental|Ixazomib 1 mg|Cohort A: Patients will receive ixazomib 1mg 3 times monthly for 12 weeks, then weekly for 12 weeks.
89384732|NCT02946047|Experimental|Ixazomib 2 mg|Cohort B: Patients will receive ixazomib 2mg 3 times monthly for 12 weeks, then weekly for 12 weeks.
89384733|NCT02946047|Experimental|Ixazomib 3 mg|Cohort C: Patients will receive ixazomib 3 mg 3 times monthly for 12 weeks, then weekly for 12 weeks.
89384734|NCT02946047|Experimental|Ixazomib 4 mg|Cohort D: Patients will receive ixazomib 4mg 3 times monthly for 12 weeks, then weekly for 12 weeks.
89384735|NCT05422443||Chronic pain group|Children with chronic pain
89384736|NCT05422443||Health group|children without chronic pain
89384737|NCT05422287|Experimental|Virtual Reality Glasses (VRG) Group|The participants in this group were started to watch videos by wearing virtual reality glasses about 2 minutes before the catheterization process was started and the process was continued until the end. Then, catheterization was performed by detecting the tourniquet by the emergency department nurse. Upon completion of the catheterization procedure, VRG was removed from the procedure area by the researcher. This process took an average of 5 minutes. After the procedure was completed, the pain and satisfaction status of the patients were scored on the VAS by the same nurse.
89384738|NCT05422287|Experimental|Thermomechanical Stimulation Device (Buzzy ®) Group|1 minute before starting the catheterization procedure in this group, a cold and vibration application was placed in the operation area by the researcher using the apparatus of the Buzzy ® device and started. The procedure was performed after evaluating the vein and determining the appropriate right or left arm. At the end of this time, the Buzzy ® has been shifted approximately 5 cm above the processing zone. Then, catheterization was performed. Upon completion of the catheterization procedure, Buzzy ® was removed from the procedure area by the researcher. This process took an average of 4 minutes. After the procedure was completed, the pain and satisfaction status of the patients were scored on the VAS by the same nurse.
88858742|NCT03561246|Active Comparator|Personalized training effect on SSWS|"Determine the efficacy of motor control deficit guided personalized training on SSWS compared to non-personalized and CONTROL interventions.~Incline treadmill walking Decline treadmill walking"
88858743|NCT03561246|Active Comparator|Personalized training effect on Pp|"Determine the efficacy of motor control deficit guided personalized training on increasing symmetry of Pp compared to non-personalized and CONTROL interventions.~Incline treadmill walking Decline treadmill walking"
88858744|NCT03561246|Active Comparator|Positive response|"Determine if the personalized intervention increase the positive response rate compared to non-personalized and CONTROL interventions, and to further advance personalize interventions by identifying factors that predict response.~Incline treadmill walking Decline treadmill walking"
88858745|NCT03462966|Experimental|Therapeutic|40 subjects with diarrhea-predominant IBS (IBS-D) or mixed IBS (IBS-M) will be enrolled in the study. At the first clinic visit, subjects will undergo rectal sensitivity testing, as well as lactulose breath testing. Subjects will be asked to record their symptoms and bowel habits in a diary over the next 7 days. During the second clinic visit, subjects will receive a 14-day course of rifaximin (550 mg PO TID). During these 14 days, subjects will record their symptoms and bowel habits. Subjects will return to the clinic after completion of the medication and will undergo repeat evaluation via rectal sensitivity testing to assess for change in rectal sensitivity.
88858746|NCT03462654|Active Comparator|individual LiFE (iLiFE)|In iLiFE, LiFE activities to increase strength, improve balance, and promote physical activity as well as habitualization strategies are introduced and taught in 7 highly individualized, one-to-one home visits.
88858747|NCT03462654|Experimental|group LiFE (gLiFE)|In gLiFE, the same LiFE activities as performed in iLiFE are introduced and taught in 7 group sessions with 8 to 12 participants. Implementation and habitualization strategies will be addressed within the group setting, making use of group dynamics and processes.
88858748|NCT01678872|Other|Long Term Follow up|Long Term follow up of patients who received RetinoStat in a previous study.
88858749|NCT03535818|Active Comparator|Redo pulmonary vein isolation|
88858750|NCT03535818|Active Comparator|Ganglionated plexus ablation + redo pulmonary vein isolation|
88858751|NCT03794700|No Intervention|Control|
88858752|NCT03794700|Other|Intervention|Participants will receive hospice decisional support materials and be asked to review them. Participants will provide feedback on tools and complete feasibility, efficacy and knowledge assessments.
88858753|NCT04403412|Experimental|Left atrial appendage closure group|
88858754|NCT04403412|Experimental|Radiofrequency ablation group|
88858755|NCT04403412|Experimental|LAAC combined with radiofrequency ablation group|
88858756|NCT03458598|Experimental|Single shot rectus sheath block|The treatment group will have pre-operative ultrasound-guided single shot bilateral rectus sheath blocks with 20 ml of a ropivacaine / bupivacaine mixture per side.
88858757|NCT03458598|Sham Comparator|Placebo Control|The control group will have a pre-operative sham ultrasound-guided subcutaneous injection of 1ml saline per side.
89384739|NCT05422287|No Intervention|Control group|Peripheral intravenous catheterization was performed by the same emergency department nurse in accordance with the procedure. The process took an average of 3 minutes. There was no application to the patients in the control group except for the standard procedure. After the procedure was completed, the pain and satisfaction status of the patients were scored on the VAS by the same nurse.
89384740|NCT05421897|Experimental|Rapid infusion of dinutuximab with chemotherapy|Patients will receive chemotherapy and dinutuximab via rapid infusion
89384741|NCT03077919|Active Comparator|Stellate Ganglion Block (SGB)|7-10 mL 0.5% ropivacaine injected under ultrasound visualization ventral to right longus coli muscle (around and into the ventral fascia) and into the longus coli immediately dorsal to the presumed ventral fascia, at the level of the C6 anterior tubercle (landmarks for stellate ganglion).
88858758|NCT01672242|Experimental|HFNC|High Flow Nasal Cannula (HFNC) oxygen.
88858759|NCT01672242|Experimental|CPAP|Continuous Positive Airway Pressure (CPAP)
88858760|NCT03791736|Experimental|Sandostatine|Injection of Sandostatine
88858761|NCT01672008|Experimental|NOX-100/Placebo|"After enrollment, subjects will be randomly assigned to one of the following treatment sequences in a 1:1 ratio.~Sequence A: NOX-100 treatment phase followed by Placebo treatment phase Sequence B: Placebo treatment phase followed by NOX-100 treatment phase"
88858762|NCT01672008|Experimental|Placebo/NOX-100|"After enrollment, subjects will be randomly assigned to one of the following treatment sequences in a 1:1 ratio.~Sequence A: NOX-100 treatment phase followed by Placebo treatment phase Sequence B: Placebo treatment phase followed by NOX-100 treatment phase"
88858763|NCT01676376|Active Comparator|eSVS Mesh treated saphenous vein graft|Each subject will be randomized to an eSVS Mesh treated SVG to the right or left coronary system.
88858764|NCT01676376|Sham Comparator|Control saphenous vein graft|Each subject will be randomized to an untreated (no eSVS Mesh) SVG to the right or left coronary system.
88858765|NCT01676376|Active Comparator|Single Vessel Treatment|Each subject with receive one SVG with eSVS Mesh either to the right or left coronary system.
88858766|NCT01677234||Pregnant women|Pregnant women undergoing a cesarean section
88858767|NCT01679964|Other|Raltegravir switch|Isentress (400mg) bid + 2 NRTI (at least 2 nucleoside or nucleotide reverse transcriptase inhibitors and no other protease inhibitors)
88858768|NCT02404818||Survivors of Hodgkin's lymphoma|Cardiac Magnetic Resonance Imaging and Echocardiogram
88858769|NCT05346822|Experimental|integrated rehabilitation program for total knee arthroplasty|the intervention was performed in one KMUH affiliated facility
88858770|NCT05346822|No Intervention|normal total knee arthroplasty clinical pathway|no integrated rehabilitatoin program for total knee arthroplasty patients with our conventional clinical pathway
88858771|NCT03524898|Experimental|nab-paclitaxel and gemcitabine|Treatment consists of the combination treatment of nab-paclitaxel and gemcitabine, which is given every 2 weeks during 28-day cycle intervals until disease progression.
88858772|NCT03524820|Experimental|Metastatic colorectal cancer patients|Metastatic colorectal cancer patients receiving third line cetuximab treatment
88858773|NCT03524508|Experimental|5-FU/LV/Onivyde|Onivyde 70 mg/m2 (90 minutes), dl-LV 400mg/m2 or l-LV 200mg/m2 (30 minutes), 5-FU 2400 mg/m2 (46 hours) IV every 2 weeks.
88858774|NCT03524508|Active Comparator|5FU/LV|dl-LV 400mg/m2 or l-LV 200mg/m2 (30 minutes), 5-FU 2400 mg/m2 (46 hours) IV every 2 weeks.
88858775|NCT03521856|Experimental|shoulder exercise intervention|A home exercise intervention for strengthening and stretching the shoulders - Strengthening and Optimal Movement for Painful Shoulders (STOMPS) - performed 3 times per week for 12 weeks.
88858776|NCT03521856|Active Comparator|education-only control|Subjects watched a 1 hour educational video on shoulder anatomy, mechanisms of shoulder injury and pain, and hints for managing shoulder pain
88858777|NCT03457818|Experimental|Treatment Group|Denosumab 60 mg/ml [Prolia] SC at baseline and 6 months.
88858778|NCT03457818|Placebo Comparator|Control Group|Placebo SC at Baseline and 6 months.
88858779|NCT01676844|Experimental|Oral thin film therapy|One or more oral thin films (OTFs) containing potassium acid phosphate administered to the inside cheek, tongue or palate at a dose of 0.5 mmol/kg body weight twice daily. Dosages will be rounded to the nearest 0.1 mM/kg. Where more than one OTF is required to achieve a dosage of 0.5mmol/kg, strips will be administered consecutively with time allowed between doses to allow for complete dissolving of the previous strip. Treatment will continue until the participant has received OTF therapy for 14 consecutive days.
88858780|NCT01676844|Active Comparator|Standard therapy|Standard oral phosphate supplementation as per NHS Greater Glasgow and Clyde Guidelines. An oral solution containing potassium acid phosphate (1 mmol/mL) will be administered at a dosage of 0.5 mM/kg body weight twice daily. Dosages will be rounded to the nearest 0.1 mM/kg. Standard therapy will continue until the participant has received treatment for 14 consecutive days.
88858781|NCT04403334|Experimental|Intracameral levofloxacin|0.5% unpreserved solution
88858782|NCT04403334|Experimental|Intracameral moxifloxacin|0.5% unpreserved solution
88858783|NCT03779646|Experimental|bisoprolol fumarate|In this arm, the participants will receive different dose of bisoprolol fumarate.
88858784|NCT03779646|No Intervention|Control|In the control (no beta blocker) group, the patients not taking beta blocker will receive outpatient clinic or video visit every 8 weeks and provide their cardiac symptoms, heart rate, blood pressure and ECG. After 12 months , the patients will repeat cardiac MR besides heart rate, blood pressure, symptoms, ECG,BNP and echocardiography records.
88858785|NCT03500016|Experimental|Acute exercise and high intensity interval training|Euglycemic-hyperinsulinemic clamp, IVGTT, DXA scan, VO2max, plasma samples, fat and muscle biopsies before and after 8 weeks supervised high intensity interval training (HIIT). Before the 8 weeks HIIT-protocol the participants will also perform an 1-h acute exercise with plasma samples and musce samples before and immediately after the exercise bout and 4 hours into recovery
88858786|NCT03499080||Patients in medication free treatment|Inpatient unit dedicated to medication free treatment. This is an inpatient treatment unit for voluntary, planned treatment. The unit is staffed for a patient group that can be managed within a regime of open doors, voluntary treatment and low supervision. This means that high suicidal risk, severe acting out, active drug abuse etc. is excluded. They have an 8 week treatment program including Illness managment an recovery (IMR), Feedback informed treatment (FIT) and Affect consciousness treatment (ABT).
88858787|NCT03499080||Patients in treatment as Usual Åråsen|Inpatient unit colocated with the medication free unit. Same level of care. Similar treatment program, shorter treatment duration (on average 3 weeks).
88858788|NCT03499080||Patients in treatment as Usual Myrvegen|Inpatient unit on a different location from the others. Same Level of care. Different treatment program. Intermediate treatment duration (mainly 4-6 weeks).
88858789|NCT05346744|Experimental|Zirconia|10 crowns made of zirconia from 10 individual were milled, post-processed and occlusal adjusted in patients' mouth.
88858790|NCT05346744|Experimental|Celtra Duo|10 crowns made of Celtra Duo from 10 individual were milled, post-processed and occlusal adjusted in patients' mouth.
88858791|NCT05346744|Experimental|e.max CAD|10 crowns made of e.max CAD from 10 individual were milled, post-processed and occlusal adjusted in patients' mouth.
88858792|NCT05346744|Experimental|Lici UPCERA|10 crowns made of Lici from 10 individual were milled, post-processed and occlusal adjusted in patients' mouth.
88858793|NCT05346744|Experimental|Enamic|10 crowns made of Enamic from 10 individual were milled, post-processed and occlusal adjusted in patients' mouth.
88858794|NCT05346744|Experimental|Runci UPCERA|10 crowns made of Runci from 10 individual were milled, post-processed and occlusal adjusted in patients' mouth.
88858795|NCT00089778|Experimental|Grp A-Measurable metastatic disease (no immediate aldesleukin)|"Patients who do not need or are ineligible for treatment with interleukin-2 (IL-2) and patients who have previously had IL-2 therapy.~A3 FGF-5 (Fibroblast growth factor 5): 172-176/217-220 peptide - two 1 ml injections in the anterior thigh deep subcutaneous tissue within 2c of each other."
88858796|NCT00089778|Experimental|Grp B - Measurable metastatic disease that require aldesleukin|"Patients who require immediate treatment with IL-2. A2 FGF-5: 117-126 peptide + HD (high dose) IL-2 (prior cycle 1)- two 1 ml injection in the anterior thigh deep subcutaneous tissue within 2c of each other.~720,000 IU/kg as an intravenous bolus over a 15 minute period every 8 hours beginning on the day after immunization and continuing for up to 4 days (a maximum of 12 doses)."
88858797|NCT00089778|Experimental|Grp C - High-risk loco-regional disease|"Patients whose cancer has been surgically removed but who are at risk for recurrence and local disease and who are seeking experimental adjuvant therapy.~A2 FGF-5: 117-126 peptide (adjuvant); A3 FGF-5: 172-176/217-220 peptide (adjuvant)"
89384742|NCT03077919|Sham Comparator|Sham Treatment|1-2 mL preservative-free normal saline, injected under ultrasound visualization anterolateral to right anterior tubercle of C6.
89384743|NCT01377675||Usual curriculum education program|Third year internal medicine residents
88875431|NCT05732064|Experimental|Dexmedetomidine and esketamine|Dexmedetomidine 0.5 microgram/kg (300 microgram/ml) and esketamine 0.2 mg/kg (25 mg/ml) are administered via nasal cavity at 20:00 pm the day before surgery, the day of surgery, and the first day after surgery.
88875432|NCT05732064|Placebo Comparator|Normal saline|Same volumes of normal saline are administered via nasal cavity at 20:00 pm the day before surgery, the day of surgery, and the first day after surgery.
89384744|NCT01380951|Experimental|telbivudine|
88858798|NCT00089544|Experimental|Cohort A (chemotherapy, radiation, thalidomide, surgery)|Patients receive doxorubicin, ifosfamide, and dacarbazine IV continuously on days 1-3, 22-24, and 43-45. Patients receive G-CSF subcutaneously beginning on days 4, 25, and 46 and continuing until blood counts recover. Patients undergo radiotherapy once daily on days 7-11, 14-18, 21, 28-32, 35-39, and 42. Patients receive oral thalidomide once daily on days 7-21 and 26-42. Patients undergo surgical resection between days 84 and 98. Beginning 2 weeks after surgery, patients receive oral thalidomide once daily for 12 months in the absence of unacceptable toxicity.
88858799|NCT00089544|Experimental|Cohort B (thalidomide, radiation, surgery)|Patients receive oral thalidomide once daily beginning on day 1 and continuing until 1 week before surgery. Patients undergo radiotherapy once daily, 5 days a week, on weeks 1-5. Patients undergo surgical resection between days 77 and 91. Beginning 2 weeks after surgery, patients receive oral thalidomide once daily for 6 months in the absence of unacceptable toxicity.
88858800|NCT00089076|Experimental|Treatment (ipilimumab)|"PHASE I: Patients receive MDX-010 IV over 90 minutes on day 1. Treatment repeats every 28 days for a total of 4 courses in the absence of disease progression or unacceptable toxicity.~Cohorts of 6 patients from each group receive escalating doses of MDX-010 until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity.~PHASE II: Patients receive MDX-010 as in phase I at the MTD."
88858801|NCT03774654|Experimental|CD19.CAR-aNKT cells (cohort A, non-ALL)|This cohort is for patients without refractory/relapsed B-cell NHL or leukemia (ALL). Three dose levels will be evaluated. Patients will also receive lymphodepletion chemotherapy consisting of cyclophosphamide and fludarabine followed by the CD19.CAR-aNKT cell infusion.
88858802|NCT03774654|Experimental|CD19.CAR-aNKT cells (cohort B, ALL).|This cohort is for patients with refractory/relapsed B-cell NHL or leukemia (ALL). Three dose levels will be evaluated. Patients will also receive lymphodepletion chemotherapy consisting of cyclophosphamide and fludarabine followed by the CD19.CAR-aNKT cell infusion.
88858803|NCT00088374|Experimental|Von Hippel-Lindau (VHL) associated renal tumors|
88858804|NCT03773250|Experimental|Behavioral Intervention|Children and families in the intervention group will received the FAMILY program developed according to evidence-based guidelines.The intervention content regarding healthy sleep will emphasize the importance of having a consistent sleep schedule, establishing a regular bedtime routine, and creating an environment only for sleeping. The physical activity content will emphasize at least 60 minutes/day of moderate-to-vigorous intensity physical activity, reduction of sedentary behavior, and screen time limited to 2 hours/day. The nutrition content will emphasis the replacement of sugar-sweetened beverages, increased fruit and vegetable as well as water intake, consumption of regular meals, and reduction of discretionary food groups.
88858805|NCT03773250|Other|Control|An active placebo control intervention was designed which did not apply evidence-based lifestyle recommendations effective in weight loss and focused on vegetable education.
88858806|NCT03493620|Experimental|Device arm|Gastric endosuturing will be performed until the entire gastric body is sutured in the form of a tube.
88858807|NCT03493620|Sham Comparator|Sham arm|Group II is a control group (only the endoscopist will know which group each patient belongs to)
88858808|NCT03772548||Patients with spinal cord injury|
88858809|NCT03772548||Healthy subjects|
88858810|NCT00087594|Experimental|Direct Observed Therapy|Participants will receive the peginterferon alfa-2a plus ribavirin at the clinic as: subcutaneous peginterferon alfa-2a 180 microgram (mcg) (once in a week) for 24 weeks for Genotype 2 or 3 (G2/3), and for 48 weeks for Genotype 1 (G1); oral ribavirin 800 milligram (mg)/day (twice in a day) for 24 weeks for G2/3, and 1000 or 1200 mg/day (twice in a day) for 48 weeks for G1.
88858811|NCT00087594|Experimental|Self-Administration Therapy|Participants will receive the peginterferon alfa-2a plus ribavirin at home as: subcutaneous peginterferon alfa-2a 180 mcg (once in a week) for 24 weeks for G2/3, and for 48 weeks for G1; oral ribavirin 800 mg/day (twice in a day) for 24 weeks for G2/3, and 1000 or 1200 mg/day (twice in a day) for 48 weeks for G1.
88858812|NCT03770286|Active Comparator|Fluoride Varnish alone|5% sodium fluoride varnish will be applied to all teeth the day of acceptance into the study and then at 3 months, 6 months, and 12 months.
88858813|NCT03770286|Experimental|SDF with Super Floss|SDF will be applied to target interproximal lesions with the use of Super Floss for 1 minute. 5% sodium fluoride varnish will then be applied to all teeth. Both will occur the day of acceptance into the study and then at 3 months, 6 months, and 12 months.
88858814|NCT03770286|Experimental|SDF without Super Floss|SDF will be applied to around the (buccal, lingual, and occlusal) embrasures of the target interproximal lesions with the use of a microbrush for 1 minute. 5% sodium fluoride varnish will then be applied to all teeth. Both will occur the day of acceptance into the study and then at 3 months, 6 months, and 12 months.
88858815|NCT03492528|Experimental|Cardiovascular patients treated for a cancer|
88858816|NCT03769350|Experimental|Smartphone-delivered CBT for MDD|8-week Smartphone delivered CBT for MDD.
88858817|NCT03769350|Other|8 Week Waitlist Control|8-week waitlist control. (Note: participants will be crossed over to 8-week Smartphone-delivered CBT for MDD following the 8-week waitlist control).
88858818|NCT05347056||Vertebral Body Tethering Group|Vertebral Body Tethering applied to the lumbar region, with or without fusion to the thoracic region
88858819|NCT05347056||Selective Thoracic Fusion Group|selective thoracic fusion was applied, no intervention was applied to the lumbar region
88858820|NCT00087516|Active Comparator|Sitagliptin 100 mg/100 mg|Phase A and B: Oral tablets of sitagliptin 100 mg Once a Day (q.d )
88858821|NCT00087516|Active Comparator|Sitagliptin 200 mg/200 mg|Phase A and B: Oral tablets of sitagliptin 200 mg q.d
88858822|NCT00087516|Placebo Comparator|Placebo/Sitagliptin 100 mg|Phase A: Oral tablets of placebo matching sitagliptin 100 mg q.d. Phase B: Oral tablets of sitagliptin 100 mg q.d.
89384745|NCT01377597|Experimental|ranibizumab intravitreal injection|
89384746|NCT03220217|Experimental|5-20μg/40-80 MBq, 30-45μg/100-140 MBq|Subjects will receive a first intravenous (i.v.) injection of satoreotide trizoxetan with a peptide mass dose range of 5 to 20 μg and a radioactivity dose range 40 to 80 MBq. After 15 to 21 days the subjects will receive a second i.v. injection of satoreotide trizoxetan with a peptide mass dose range of 30-45 μg and a radioactivity dose range 100 to 140 MBq.
89384747|NCT03220217|Experimental|5-20μg/100-140 MBq, 30-45μg/160-200 MBq|Subjects will receive a first i.v. injection of satoreotide trizoxetan with a peptide mass dose range of 5 to 20 μg and a radioactivity dose range 100 to 140 MBq. After 15 to 21 days the subjects will receive a second i.v. injection of satoreotide trizoxetan with a peptide mass dose range of 30-45 μg and a radioactivity dose range 160 to 200 MBq.
88858823|NCT00087516|Placebo Comparator|Placebo/Sitagliptin 200 mg|Phase A: Oral tablets of placebo matching sitagliptin 200 mg q.d. Phase B: Oral tablets of sitagliptin 200 mg q.d.
88858824|NCT03768960|Experimental|Daratumumab|Participants will receive 16 milligram per kilogram (mg/kg) of daratumumab as intravenous (IV) infusion every week (QW) in Cycles 1 and 2 (Days 1, 8, 15 and 22) and every 2 weeks (Q2W) in Cycle 3 to 6 (Days 1 and 15) each cycle is of 28 days.
88858825|NCT00087126|Experimental|Topotecan|Topotecan weekly
88858826|NCT03767946||Group 1|"Children both genders according to age:~*1-year old children (12 months -1/+4 months); n=125 at the date of recruitment."
88858827|NCT03767946||Group 2|"Children both genders according to age:~*2-year-old children (24 months -1/+4 months); n=125 at the date of recruitment."
88858828|NCT03767946||Group 3|"Children both genders according to age:~*5-year old children (60 months +/- 6 months); n=125 at the date of recruitment."
88858829|NCT03767946||Group 4|"Children both genders according to age:~*12-years old children (12 years old +/- 6 months); n=125 at the date of recruitment."
88858830|NCT03490734|Active Comparator|Beverage A (Sweetened)|"One quarter of the group to receive black cherry and orange flavored beverage with added sugar for 3 weeks.~MRIs will be performed before starting and then after 3 weeks of daily beverage consumption wherein participants will be presented with visual stimuli of two beverage logos, one representing a water solution and another representing the assigned beverage. Each 1-second presentation signals impending delivery of 3 mL of the associated beverage via a plastic mouthpiece during MRI."
88858831|NCT03490734|Active Comparator|Beverage B (Sweetened)|"One quarter of the group to receive strawberry kiwi & lemonade flavored beverage with added sugar for 3 weeks.~MRIs will be performed before starting and then after 3 weeks of daily beverage consumption wherein participants will be presented with visual stimuli of two beverage logos, one representing a water solution and another representing the assigned beverage. Each 1-second presentation signals impending delivery of 3 mL of the associated beverage via a plastic mouthpiece during MRI."
88858832|NCT03490734|Active Comparator|Beverage A (Unsweetened)|"One quarter of the group to receive black cherry and orange flavored beverage no added sugar for 3 weeks.~MRIs will be performed before starting and then after 3 weeks of daily beverage consumption wherein participants will be presented with visual stimuli of two beverage logos, one representing a water solution and another representing the assigned beverage. Each 1-second presentation signals impending delivery of 3 mL of the associated beverage via a plastic mouthpiece during MRI."
88858833|NCT03490734|Active Comparator|Beverage B (Unsweetened)|"One quarter of the group to receive strawberry kiwi & lemonade flavored beverage no added sugar for 3 weeks.~MRIs will be performed before starting and then after 3 weeks of daily beverage consumption wherein participants will be presented with visual stimuli of two beverage logos, one representing a water solution and another representing the assigned beverage. Each 1-second presentation signals impending delivery of 3 mL of the associated beverage via a plastic mouthpiece during MRI."
88858834|NCT04763382|Other|Experimental grups: Training of caregivers|"Application of data collection:~Tools as pre-test, post-test and retention test to participants in the experimental group,~Education:It includes the training given to the caregivers in the experimental group, delivery of the guide booklet at the end of the training~Android phone application: Installing on the phones of the caregivers in the experimental group of the android application, which includes the frequency of CIC application, the CIC application process steps and hospital appointments, created by the nurse for the caregivers in the experimental group and the software is made by the computer engineer.~One home visit and three phone calls were made in order to solve the problems that the caregivers in the experimental group experienced with the use of CIC or android use.~Urinalysis for children who are inserted and put into the study:All participants in the study were asked to give urine tests three times with an interval of one month after discharge."
88858835|NCT04763382|Other|Control: Control grups|"As in the experimental group, the caregivers in the control group were pre-tested and post-tested using data collection tools.~No intervention was made to the caregivers in the control group.~However, caregivers in the control group performed urinalysis three times with an interval of one month after discharge."
88858836|NCT03489564||Active|Physically active will be defined by self-report and confirmed by step counts >8,000 per day from activity monitoring.
88858837|NCT03489564||Sedentary|Sedentary lifestyle will be defined by self-report and confirmed by step counts <5,000 per day from activity monitoring.
88858838|NCT04763304|Active Comparator|PPE-G (gown) followed by PPE-C (coverall)|"Placement of PPE-G (personal protective equipment including a gown for body protection) fluorescent solution full-body spray, removal of PPE-G and assessment of self-contamination through ultraviolet light scanning.~Placement of PPE-C (personal protective equipment including a coverall for body protection), fluorescent solution full-body spray, removal of PPE-C and assessment of self-contamination through ultraviolet light scanning."
88875433|NCT05731752|Experimental|HX009|Study treatment: HX009 administered every 2 weeks (14 [±3] days) via intravenous infusion.
88875434|NCT05731674|No Intervention|Control|
88875435|NCT05731674|Experimental|Intervention|
88875436|NCT05731206|Experimental|hydrolized protein formula|hydrolysed protein formula
89384748|NCT03220217|Experimental|5-20μg/160-200 MBq, 30-45μg/40-80 MBq|Subjects will receive a first i.v. injection of satoreotide trizoxetan with a peptide mass dose range of 5 to 20 μg and a radioactivity dose range 160 to 200 MBq. After 15 to 21 days the subjects will receive a second i.v. injection of satoreotide trizoxetan with a peptide mass dose range of 30-45 μg and a radioactivity dose range 40 to 80 MBq.
88875437|NCT05731206|Placebo Comparator|Control formula|commercially available hypoallergenic infant formula
89384749|NCT03204695|Experimental|WaveCrest®|Implant of WaveCrest® Left Atrial Appendage Occlusion System
88858839|NCT04763304|Active Comparator|PPE-C (coverall) followed by PPE-G (gown)|"Placement of PPE-C (personal protective equipment including a coverall for body protection), fluorescent solution full-body spray, removal of PPE-C and assessment of self-contamination through ultraviolet light scanning.~Placement of PPE-G (personal protective equipment including a gown for body protection), fluorescent solution full-body spray, removal of PPE-G and assessment of self-contamination through ultraviolet light scanning."
88858840|NCT00086346|Active Comparator|A|
88858841|NCT00086346|Active Comparator|B|
88858842|NCT00085566|Experimental|Everolimus (RAD-001) and Gefitinib|"•Phase I: Patients receive oral everolimus on day 1 and oral gefitinib once daily on days 8-21. Beginning on day 22, patients receive oral everolimus once weekly and oral gefitinib once daily. Treatment with the combination continues in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of everolimus until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.~•Phase II (prostate cancer patients only) (closed to accrual as of 10/19/2006): Patients receive oral everolimus (at the MTD determined in phase I) once weekly and oral gefitinib once daily. Treatment continues in the absence of disease progression or unacceptable toxicity."
88858843|NCT00085098|Experimental|Regimen A (radiotherapy only)|Within 52 days of surgery, patients will undergo standard-dose radiation therapy 5 days a week for approximately 5-6 weeks.
88858844|NCT00085098|Experimental|Regimen B (chemotherapy plus radiotherapy)|"Courses 1 and 2: Patients receive carboplatin IV over 1 hour on days 1 and 2 and etoposide IV over 2 hours on days 1-3. Treatment repeats every 21 days for 2 courses.~Within 3 weeks of completing chemotherapy, patients with CR undergo low-dose radiation therapy 5 days a week for 5 weeks. Patients with MRD, a PR, or SD receive chemotherapy courses 3 and 4 as outlined below.~Courses 3 and 4: Patients receive cisplatin IV over 6 hours on day 1, cyclophosphamide IV over 1 hour on days 2 and 3, and filgrastim (G-CSF), subcutaneous (SC) or IV beginning on day 4 and continuing until blood counts recover.~Treatment repeats every 21 days for 2 courses. Patients achieving a CR or MRD proceed to reduced-dose radiotherapy. Patients with a PR, SD, or progressive disease (PD) are restaged and may undergo standard radiation therapy as in regimen A. Reduced-dose radiation therapy: Within 6 weeks of starting course 4, patients undergo lower-dose radiation therapy once daily on days 1-5 for 5 weeks"
88858845|NCT00084864|Experimental|Stage 1, Arm I|Patients receive oral dexamethasone once daily on days 1-4 and oral calcitriol once daily on days 2-4 weekly for 4 weeks before surgery.
88858846|NCT00084864|Experimental|Stage 1, Arm II|No study drugs before surgery.
88858847|NCT00084864|Experimental|Stage 1 Arm 3|Patients receive oral dexamethasone once daily on days 1-4.
88858848|NCT00084864|Experimental|Stage 1, Arm 4|Patients receive oral calcitriol once daily on days 2-4.
88858849|NCT03487302||cCHD|
88858850|NCT03487302||CONTROLS|
88858851|NCT01677702|Active Comparator|Yili Lactoferrin ShuHua Milk (lactoferrin 5mg/100ml)|Total 250mL milk (with lactoferrin 5mg/100ml) will be taken once per day at 10am daily during the 84 days intervention.
88858852|NCT01677702|Active Comparator|Yili Lactoferrin ShuHua Milk (lactoferrin 10mg/100ml)|Total 250mL milk (with lactoferrin 10mg/100ml) will be taken once per day at 10am daily during the 84 days intervention.
89384750|NCT03979391|Experimental|Children with CIS or RIS|The detection of supernumerary oligoclonal bands (OCBs) in tears will be performed
88858853|NCT01677702|Placebo Comparator|Recombined low-protein milk|Total 250mL placebo milk will be taken once per day at 10am daily during the 84 days intervention.
88858854|NCT01677780|Experimental|RO5045337|Participants will continue the most similar dose and formulation available (which does not exceed the MTD or the maximum safely administered dose for that formulation during Phase 1) and the same schedule of RO5045337 treatment that they were receiving at the time of transitioning from their respective parent clinical study protocols: NO21279 (NCT00623870), NO21280 (NCT00559533), NP25299 (NCT01164033), NP28021 (NCT01605526) or NP28023 (NCT01635296).
88858855|NCT05346978|Experimental|Nasturtium (NT)|5g freeze-dried nasturtium leaf powder ; Each participant was supplemented with 15 grams of freeze-dried nasturtium leaf powder (NT) or placebo (PLC) per wk during 4 wk. Each participant received 3 envelopes per wk with 5 g NT each or 3 g PLC. In total each participant was given 24 envelopes (12 NT and 12 PLC) packaged in the same way to be indistinguishable from each other. The participants were instructed to take three days at wk one NT or PLC envelope diluted in 300 ml (about 10.14 oz) in chilly water in a bottle provided for the study
88858856|NCT05346978|Placebo Comparator|Placebo (PLC)|3g collagen colored with green pigment used in the food industry; Each participant was supplemented with 15 grams of freeze-dried nasturtium leaf powder (NT) or placebo (PLC) per wk during 4 wk. Each participant received 3 envelopes per wk with 5 g NT each or 3 g PLC. In total each participant was given 24 envelopes (12 NT and 12 PLC) packaged in the same way to be indistinguishable from each other. The participants were instructed to take three days at wk one NT or PLC envelope diluted in 300 ml (about 10.14 oz) in chilly water in a bottle provided for the study
88858857|NCT03485196||MSI-H group|We use the immunohistochemical expression of mismatch repair proteins (MutS protein homolog 2( MSH2),MutS protein homolog 6( MSH6) and PMS2（postmeiotic segregation increased 2 ）) to Determine the MSI status . When one antibodies or more show negative nuclear staining of the tumor cells, the MSI state can be defined as Microsatellite instability high (MSI-H).
88858858|NCT03485196||MSI-L group|We use the immunohistochemical expression of mismatch repair proteins (MLH1, MSH2, MSH6 and PMS2) to Determine the MSI status . when all the four antibodies show positive nuclear staining of the tumor cells, the MSI state can be defined as Microsatellite stable (MSI-L).
88875438|NCT05730738|Active Comparator|dalfampridine|patients received dalfampridine ER 10mg twice daily
88875439|NCT05730738|Placebo Comparator|Placebo|patients received placebo
89384751|NCT03192137|Experimental|ISV-305|0.1% dexamethasone in DuraSite® 2
89384752|NCT03192137|Placebo Comparator|Vehicle|DuraSite® 2 Vehicle
89384753|NCT03618095|Experimental|Main Cohort|Transcatheter Aortic Valve Replacement (TAVR) with the LOTUS Edge Valve System
89384754|NCT03618095|Experimental|Roll-In Cohort|Transcatheter Aortic Valve Replacement (TAVR) with the LOTUS Edge Valve System
89384755|NCT03618095|Experimental|Bicuspid Cohort|Transcatheter Aortic Valve Replacement (TAVR) with the LOTUS Edge Valve System
89384756|NCT04542785|Experimental|Lenient rate control|Treating physicians will target a resting heart rate between 80 and 110 beats per minute on a 12-lead resting ECG measured over 1 minute after 5 minutes of rest.
89384757|NCT04542785|Active Comparator|Strict rate control|Treating physicians will target a resting heart rate a mean resting heart rate < 80 bpm on a 12-lead resting ECG measured over 1 minute after 5 minutes of rest.
89384758|NCT03287375|Experimental|PIPAC|Peritoneal metastases (PM) from colorectal or appendiceal cancer will be treated with Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) using oxaliplatin 92 mg/m2 in 150 ml dextrose. Peritoneal metastases (PM) from other GI or gynecologic cancers will be treated with Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) using cisplatin 7.5 mg/m2 in 150 ml saline combined with doxorubicin 1.5 mg/m2 in 50 ml saline. PIPAC is performed during a standard laparoscopy with a capnoperitoneum of 12 mmHg and the aerosolised chemotherapy will be nebulized at a maximum pressure of 200 PSI and a flow rate of 0.5 ml/min. There is no upper number of allowed PIPAC treatments, but they will be planned in series of 3 with 4-6 weeks interval (6-7 weeks if combined with systemic chemotherapy).
88858859|NCT03485196||MSS group|We use the immunohistochemical expression of mismatch repair proteins (MLH1, MSH2, MSH6 and PMS2) to Determine the MSI status . when all the four antibodies show positive nuclear staining of the tumor cells, the MSI state can be defined as Microsatellite stable (MSS).
88858860|NCT01473108|Experimental|Finerenone (20 mg solution)|3-fold crossover of single dose 20 mg BAY 94-8862 solution, placebo and 50 mg eplerenone. The challenge drug fludrocortisone was given 2 h prior to administration of BAY 94-8862, eplerenone, and placebo.
88858861|NCT01473108|Experimental|Finerenone (10 mg solution)|3-fold crossover of single dose 10 mg BAY 94-8862 solution, placebo and 50 mg eplerenone. The challenge drug fludrocortisone was given 2 h prior to administration of BAY 94-8862, eplerenone, and placebo.
88858862|NCT01473108|Experimental|Finerenone (5 mg solution)|3-fold crossover of single dose 5 mg BAY 94-8862 solution, placebo and 50 mg eplerenone. The challenge drug fludrocortisone was given 2 h prior to administration of BAY 94-8862, eplerenone, and placebo.
88858863|NCT01473108|Experimental|Finerenone (20 mg as tablets)|3-fold crossover of single dose 20 mg BAY 94-8862 as 2 x 10 mg tablet, placebo and 50 mg eplerenone. The challenge drug fludrocortisone was given 2 h prior to administration of BAY 94-8862, eplerenone, and placebo.
88858864|NCT01473108|Experimental|Finerenone (2.5 mg solution)|3-fold crossover of single dose 2.5 mg BAY 94-8862 solution, placebo and 50 mg eplerenone. The challenge drug fludrocortisone was given 2 h prior to administration of BAY 94-8862, eplerenone, and placebo.
88858865|NCT00084318|Experimental|RT + cisplatin + cetuximab|Loading dose of cetuximab followed by radiation therapy with weekly cisplatin and cetuximab.
88858866|NCT00084318|Experimental|RT + docetaxel + cetuximab|Loading dose of cetuximab followed by radiation therapy (RT) with weekly docetaxel and cetuximab.
88858867|NCT00084084|Experimental|Agalsidase alfa (Cohort 1)|Cohort 1: Patients who completed TKT023.
88858868|NCT00084084|Experimental|Agalsidase Alfa (Cohort 2)|Cohort 2: Treatment-naive patients.
88858869|NCT00083616|Experimental|Panitumumab|Participants received panitumumab 6 mg/kg once every 2 weeks weeks administered by intravenous (IV) infusion until progressive disease, inability to tolerate the investigational product, or discontinuation of treatment for other reasons.
88858870|NCT04402710|Active Comparator|Control Group|Session 1: Participants will meet individually with a research assistant to discuss their type 2 risk and discuss benefits of engaging in 150 minutes of moderate-to-vigorous physical activity per week. Ideal Care will involve: Session 2: Introductions and Goal setting/planning. Session 3: Action-Coping Planning and Monitoring Physical Activity Session 4: Goal re-visitation and adjustment and building self-efficacy. Session 5: Physical Activity Enjoyment and Barriers/Solutions. Session 6: Relapse prevention and commitment to exercise. The last 30 minutes of sessions 2-6, control participants will receive 30-minutes of non-self-compassion or physical activity related health education (i.e., sleep, screen time, antibiotic use, oral health, osteoporosis and vitamin D).
89384759|NCT03881059|Placebo Comparator|Part A: Placebo|
89384760|NCT03881059|Experimental|Part A: BMS-986165 Dose A|
89384761|NCT03881059|Experimental|Part A: BMS-986165 Dose B|
88858871|NCT04402710|Experimental|Intervention Group|Session 1: Participants will meet individually with a research assistant to discuss their type 2 risk and discuss benefits of engaging in 150 minutes of moderate-to-vigorous physical activity per week. First 30 minutes of each subsequent session will be ideal care (as described above in the control group). Last 30 minutes of sessions 2-6, self-compassion condition participants will learn to apply self-compassion to their prediabetes experience and physical activity. Session 2: Learn about fear of self-compassion and the benefits of self-compassion. Session 3: Yin and Yang of self-compassion. Session 4: Mindfulness. Session 5: Dealing with difficult emotions, loving Kindness and Self-Compassionate motivation. Session 6: Living deeply, self-appreciation and stages of progress.
88875440|NCT05730660|Experimental|Intervention group|
88875441|NCT05730660|Placebo Comparator|Placebo group|
88875442|NCT05725434|Experimental|CT-P47 SC (tocilizumab)|CT-P47 (tocilizumab) by subcutaneous (SC) injection
89384762|NCT03881059|Experimental|Part B: Ustekinumab + BMS-986165 Placebo|
89384763|NCT03881059|Experimental|Part B: BMS-986165 Dose A + Ustekinumab Placebo|
89384764|NCT03881059|Experimental|Part B: BMS-986165 Dose B + Ustekinumab Placebo|
89384765|NCT01338337|No Intervention|Support treatment|Transfusional support will be applied for symptomatic anaemia using clinical discretion and chelation therapy when ferritin is ≥ 1000 μgr/ml with the chelating agents allowed.
89384766|NCT01338337|Experimental|Azacitidine|Azacitidine 75 mg/m2, for 5 days of each 20 day cycle. Transfusional support will be applied for symptomatic anaemia using clinical discretion and chelation therapy when ferritin is ≥ 1000 μgr/ml with the chelating agents allowed
89384767|NCT02861534|Experimental|Vericiguat|Participants receive a starting dose of 2.5 mg of vericiguat taken orally once daily with food, on a background of HF standard of care. The vericiguat dose will be uptitrated to 5 mg and to 10 mg.
89384768|NCT02861534|Placebo Comparator|Placebo|Participants receive a starting matching placebo dose of 2.5 mg taken orally once daily with food, on a background of HF standard of care. The matching placebo dose will be uptitrated to 5 mg and to 10 mg.
89384769|NCT01191151||Orthopedic injury, osteoarthritis|All eligible patients receiving orthopedic, sports medicine, arthroscopy and related surgery or nonoperative treatment
89384770|NCT02034032|Active Comparator|Regenexx SD|Regenexx-SD (Same Day) is a bone marrow based injection procedure.
89384771|NCT02034032|Active Comparator|Exercise Therapy|Subjects in the Exercise Therapy group will attend an initial session with a trained Physical Therapist. During that session the physical therapist will instruct the subject in a home exercise program and instructions about activity limitations. The subject's progress will also be followed by the Physical Therapist during the 6 week follow-up visit with further instructions provided.
89384772|NCT02034188|Experimental|Umbilical cord mesenchymal stem cells|
89384773|NCT03167255|Experimental|NS-065/NCNP-01 40mg/kg|Patients receiving 40mg/kg in the NS-065-NCNP-201 study will continue their current dose for an additional 192 weeks or until enrollment in a separate long-term follow up program of NS-065/NCNP-01, whichever is earlier.
89184401|NCT00720135|Experimental|Arm I|Patients receive DI-Leu16-IL2 immunocytokine IV over 4 hours on 4 consecutive Wednesdays. Patients with detectable CD20-positive B-cells pretreatment also receive rituximab IV on 4 consecutive Tuesdays. Treatment repeats every 6-8 weeks for up to a maximum of 4 courses in the absence of disease progression or unacceptable toxicity.
89384774|NCT03167255|Experimental|NS-065/NCNP-01 80mg/kg|Patients receiving 80mg/kg in the NS-065-NCNP-201 study will continue their current dose for an additional 192 weeks or until enrollment in a separate long-term follow up program of NS-065/NCNP-01, whichever is earlier.
89384775|NCT03140969|Experimental|QR-110|Administered every 3 months
88858872|NCT00083226|Experimental|Treatment (doxorubicin+bortezomib)|Patients receive doxorubicin IV over 5-15 minutes on days 1 and 8. Patients also receive bortezomib at a dose of 1.3 mg/m^2 IV over 3-5 seconds on days 1, 4, 8, and 11. Treatment repeats every 21 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. Patients with no disease progression may continue to receive bortezomib alone in the absence of disease progression or unacceptable toxicity.
88858873|NCT05346510|Experimental|ALND Group|ALND is performed in patients with positive axillary lymph nodes on CT scan and on AAUS.
88858874|NCT05346510|Experimental|pALND Group|pALND is performed in patients with negative axillary lymph nodes on CT scan but positive on AAUS.
88858875|NCT05346510|Experimental|SLNB Group|SLNB will be performed for those with negative axillary lymph nodes on CT scan and on AAUS.
88858876|NCT00082758|Experimental|Disease Measurable by Standard Criteria(hu14.18-interleukin-2)|"Patients with residual/refractory neuroblastoma and readily measurable residual/refractory disease using standard radiographic criteria. Standard radiographic criteria for CT/MRI Lesions will use the definitions of measurable disease from the Response Evaluation Criteria In Solid Tumors (RECIST) from the National Cancer Institute.~hu14.18-Interleukin-2 fusion protein : Given IV"
88858877|NCT00082758|Experimental|Disease Eval by MIBG or BM Histology (hu14.18-interleukin-2)|"Patients with residual/refractory neuroblastoma with disease that is not measurable by standard radiographic criteria, but is evaluable by meta-iodobenzylguanidine (MIBG) scanning and/or by bone marrow (BM) histology.~hu14.18-Interleukin-2 fusion protein : Given IV"
88858878|NCT00082758|Experimental|Disease Identified by BM Immunohistochemistry Only|"Patients with residual/refractory neuroblastoma that do not have disease that is measurable by standard radiographic techniques or evaluable by meta-iodobenzylguanidine (MIBG) scanning or bone marrow (BM) histology, however, disease is identified and quantified by BM immunohistochemistry (>5 neuroblastoma cells per 1,000,000 nucleated marrow cells).~hu14.18-Interleukin-2 fusion protein : Given IV"
88858879|NCT01678014|Experimental|Anorexia|Anorexia patients
88858880|NCT04403178||Children who develops hip displacement|Patient group 1 includes children who developed a Migration Percentage of > 40 % in either hip over a follow-up period of three years.
88858881|NCT04403178||Children who do not develops hip displacement|Patient group 2 includes children who did not develop a Migration Percentage of > 40 % on either hip over a follow-up period of three years
88858882|NCT03424512|Experimental|Group Metacognitive Therapy|Group metacognitive therapy (MCT) is a brief psychological intervention designed to be delivered in small groups of 4-8 patients over a course of six, 90 minute sessions conducted on a weekly basis
88858883|NCT03424200|Other|Coaching plus Routine Care|Participants will receive coaching plus routine care
88858884|NCT03424200|Other|Routine Care|Participants will receive the routine care
88858885|NCT03438318|Experimental|Part A (CMP-001, Atezolizumab and Optional Radiation Therapy)|Participants will receive CMP-001 5 milligrams (mg) SC once weekly for 2 weeks, then 10 mg IT once weekly for 3 weeks, followed by every 3 weeks thereafter until discontinuation of treatment in combination with atezolizumab SC every 3 weeks starting at Week 2. Route of administration (IT/SC) for CMP-001 beyond Week 5 will be determined by Investigator. Participants enrolled in Part A who progressed per RECIST v1.1 on combination of CMP-001 and atezolizumab have opportunity to enroll in Part A optional radiation therapy add-on after documented disease progression per CT/MRI or PET scan. After CMP-001 washout period of 10 days, participants will be treated with radiation consisting of 20 grays in 5 fractions for 5 days then resume CMP-001 treatment.
88858886|NCT03438318|Experimental|Part B (Radiation Therapy, CMP-001 and Atezolizumab)|Participants will be treated with radiation therapy consisting of 20 grays in 5 fractions for 5 days, then participants will receive CMP-001 5 mg SC once weekly for 2 weeks, then 10 mg IT once weekly for 3 weeks, followed by dosing every 3 weeks thereafter until discontinuation of treatment. The route of administration (that is, IT or SC) for CMP-001 beyond Week 5 will be determined by the Investigator. First dose of CMP-001 will be administered within 2 days of radiation therapy. Atezolizumab will be administered SC in combination with CMP-001 every 3 weeks starting at Week 2.
88858887|NCT03087942|Experimental|Group 1|ESRD patients
88858888|NCT03087942|Experimental|Group 2|healthy volunteers
88858889|NCT03087942|Experimental|Group 3|severe and moderate renal impaired patients
88858890|NCT03087942|Experimental|Group 4|mild renal impaired patients
88858891|NCT04402320||Control group|extubated and weaning from the ventilator and followed our routine protocol of management post extubation without mechanical ventilation or BIPAP machine
89003062|NCT05802004|Experimental|Stim, then Sham, then daily Stim|For the 2 overnights in the sleep lab, this arm will be randomized to complete acoustic stimulation (STIM) on the first overnight and no acoustic stimulation (SHAM) on the second overnight and then daily acoustic stimulation (STIM2) during the ~2 weeks at-home.
89184402|NCT02574273|Active Comparator|Secret Agent Society (SAS) Program|The Secret Agent Society (SAS) Program is an intervention which involves subjects participating in 9 weekly two-hour therapy groups ('Club meetings') with 3 to 6 other children. The SAS intervention includes a number of components to help children apply the skills that they learn in the session to home. Parents will attend weekly parent support training sessions. 3 and 6 month booster sessions are conducted with both parents and children to help families with maintaining the skills that they have learned and to problem-solve new challenges that arise. Parent and child assessments will be completed at pre and post treatment (Wk 1 and Wk 10) and at 3-month and 6-month follow-up booster visits, for both parent and child participants.
89003063|NCT05802004|Experimental|Stim, then Sham, then daily Sham|For the 2 overnights in the sleep lab, this arm will be randomized to complete acoustic stimulation (STIM) on the first overnight and no acoustic stimulation (SHAM) on the second overnight and then no daily acoustic stimulation (SHAM2) during the ~2 weeks at-home.
89003064|NCT05802004|Experimental|Sham, then Stim, then daily Stim|For the 2 overnights in the sleep lab, this arm will be randomized to complete no acoustic stimulation (SHAM) on the first overnight and acoustic stimulation (STIM) on the second overnight and then daily acoustic stimulation (STIM2) during the ~2 weeks at-home.
89384776|NCT03083847|Experimental|Pilot (1a): 1 injection of 5x10^4 PfSPZ Challenge+pyrimethamine|Pilot Phase - 1 injection of 5x10^4 sporozoites of PfSPZ Challenge (NF54) with 50mg of pyrimethamine dosed on days 2 and 3 after injection
89384777|NCT03083847|Experimental|Pilot (1b):1 injection of 1x10^5 PfSPZ Challenge+pyrimethamine|Pilot Phase - 1 injection of 1x10^5 sporozoites of PfSPZ Challenge (NF54) with 50mg of pyrimethamine dosed on days 2 and 3 after injection
88858892|NCT04402320||Invasive ventilation group|reconnected to mechanical ventilator before extubation for one hour with sedation with midazolam 3-5 milligram/hour intravenous infusion to achieve score 0 or -1on Richmond Agitation - Sedation Scale (RASS). 20 minutes before the end of this hour midazolam infusion discontinued and patients awaked. Patient put on mechanical ventilation (MV) with the following parameters, FIO2 40%, pressure SIMV mode, PEEP 8 cmH2O, Pressure support 15 cmH2O, Respiratory rate 14/min, Peak inspiratory pressure (PIP) of 35 cmH2O. Then patients extubated and followed our previous protocol without the use of NIV.
88858893|NCT04402320||non invasive ventilation group|following the same previous protocol done after extubation with immediate connection to NIV with BIPAP mode for 1 hour and repeated every 12hours for 48 hours, BIPAP adjusted in our study by FIO2 40%, PEEP 8 cmH2O, Pressure support of 15 cmH2O.
88858894|NCT03436056|Other|Dose escalation cohort - DOSE LEVEL 1|Intervention: One dose pembrolizumab 200 mg (week 1) followed by lung Stereotactic Body Radiotherapy (SBRT) 30 Gy 3 fractions (#) in week 3. Treatment with pembrolizumab 200 mg will be continued given every 3 weeks.
88858895|NCT03436056|Other|Dose escalation cohort - DOSE LEVEL 2|Intervention: One dose of pembrolizumab 200 mg (week 1) followed by lung Stereotactic Body Radiotherapy (SBRT) 54 Gy 3 fractions (#) in week 3. Treatment with pembrolizumab 200 mg will be continued given every 3 weeks.
88858896|NCT03436056|Other|Part B - Expansion cohort|Intervention: One dose of pembrolizumab 200 mg (week 1) followed in by lung Stereotactic Body Radiotherapy (SBRT) dosed at the maximum tolerated dose determined in Part A in week 3, dosed at the maximum tolerated dose determined in Part A. Treatment with pembrolizumab 200 mg will be continued given every 3 weeks.
88858897|NCT03088176|Experimental|Combination|"Talimogene laherperepvec intratumoral injection up to 4ml of 10^6 PFU/mL on Day 1, followed by up to 4mL of 10^8 PFU/mL 3 weeks later, followed by every 2 weeks thereafter for up to two years.~Dabrafenib 150mg orally twice daily for up to two years Trametinib 2mg orally once daily for up to two years"
88858898|NCT00087984|Experimental|MB-002-003|
88858899|NCT01678404|Experimental|131I-rituximab|131I-rituximab treatment interval at least 4 weeks up to maximum 6 cycles
88858900|NCT03087864|Experimental|Atezolizumab and Chemoradiation|Atezolizumab 1200 mg i.v. day 1-22-43-64-85 Carboplatin AUC = 2 i.v day 1-8-15-22-29 Paclitaxel 50 mg/m2 i.v day 1-8-15-22-29 Radiotherapy 23 x 1.8 Gy
88858901|NCT03087630|Experimental|Reasoned-Based Intervention|Receives reason-based intervention.
88858902|NCT03087630|Experimental|Social-Based Intervention|Receives social-based intervention.
88858903|NCT03087630|Experimental|Integrated Intervention|Receives integrated intervention.
88858904|NCT03087630|Experimental|Attention Control|Receives attention control feedback.
88858905|NCT01678482|Experimental|lession count reduction post treatment|"A total of 50 subjects were included.~The majority are female (62 %)~At baseline the average number of lesions was 20.5±7.1, ranging from 6 to 36 lesions.~All subjects demonstrated a reduction in lesion count.~The average improvement after one month was 56.7%±8.9%, and remained similar also after 3 months 57.7%±9.4%.~The percent of responders (with at least 40% of reduction) was 94% after 1 month and 96% after 3 months~The Percent of responders is similar for males & females and similar for cheeks & front."
88858906|NCT01678716|Active Comparator|Essential Health Care (EHC) only|This arm is the basic comparison arm, which will receive the standard package of health services offered through BRAC's essential health care (basic antenatal care, basic counseling on health and nutrition through health worker home visits. In addition, a nationwide mass media campaign on IYCF practices will ensure exposure to some messages about IYCF behaviors in this arm.
88858907|NCT01678716|Experimental|EHC + Micronutrient Powders|This arm will be based on the EHC platform but will also include EHC platform health workers promoting and selling the micronutrient powders.
88858908|NCT01678716|Experimental|EHC + BCC|This arm will have a behavior chance communications intervention to improve infant and young child feeding practices. The intervention will be delivered primarily by the frontline health workers who will visit mothers in their homes and counsel them on essential IYCF practices.
88858909|NCT01678716|Experimental|EHC + BCC + Micronutrient powders|This arm will contain both the behavior change communication and the micronutrient powder sales intervention.
88858910|NCT00081510|Experimental|Lonafarnib plus Anastrozole|Participants receive lonafarnib 200 mg orally (PO) twice per day (BID) beginning on Day 1 Cycle 1 and continuing until Progression of Disease, unacceptable toxicity, or other discontinuation criteria are met; and anastrozole 1 mg, PO, once per day (QD) for as long as the participant is receiving lonafarnib
89184403|NCT02574273|Other|Waitlist Group / Treatment As Usual|Participants may be randomly allocated to the wait list control condition, where participants will receive treatment as usual during the 3 month period when the intervention group will participate in the SAS Program. The wait-list group will then be given the opportunity to participate in the SAS intervention at their treating clinic. The wait list control condition includes the treatment participants are already receiving (which may include but is not limited to: individual therapy, group therapy, and/or medication management). Therefore, the wait list control condition consists of treatment which is individually tailored for each participant. Parent and child assessments will be completed at pre and post treatment (Wk 1 and Wk 10) and at 3-month and 6-month follow-up booster visits.
88858911|NCT00081510|Active Comparator|Placebo plus Anastrozole|Participants receive placebo to lonafarnib PO BID beginning on Day 1 Cycle 1 until Progression of Disease, unacceptable toxicity, or other discontinuation criteria are met; and anastrozole, 1mg PO QD for as long as the participant is receiving placebo
89384778|NCT03083847|Experimental|Pilot (1d):1 injection of 2x10^5 PfSPZ Challenge+pyrimethamine|Pilot Phase - 1 injection of 2x10^5 sporozoites of PfSPZ Challenge (NF54) with 50mg of pyrimethamine dosed on days 2 and 3 after injection
88858912|NCT00088452|Active Comparator|Ethosuximide|"Ethosuximide~Frequency and Duration: twice a day, every day for the duration of the study treatment~Formulation: Two formulations were used (actual formulation used was dependent on the patient's weight and ability to swallow): 250mg Zarontin capsules OR 250 mg/5 mL Zarontin syrup~Dosing: Ethosuximide was titrated in predetermined increments every 1-2 weeks during a 16-week titration period. The titration continued until the patient a) achieved seizure freedom by clinical and EEG criteria, b) reached the maximal allowed study drug dose, c) reached the maximal tolerated dose, or d) developed dose-exiting criteria (treatment failure), whichever came first. Maximum allowed dose: 60 mg/kg/day or 2000 mg/day (whichever was lower)"
88858913|NCT00088452|Active Comparator|Lamotrigine|"Lamotrigine~Frequency and Duration: twice a day, every day for the duration of the study treatment~Formulation: Three formulations were used (actual formulation used was dependent on the patient's weight): 5mg Lamictal chewable tablets OR 25 mg Lamictal chewable tablets OR 25 mg (Lamictal tablets~Dosing: Lamotrigine was titrated in predetermined increments every 1-2 weeks during a 16-week titration period. The titration continued until the patient a) achieved seizure freedom by clinical and EEG criteria, b) reached the maximal allowed study drug dose, c) reached the maximal tolerated dose, or d) developed dose-exiting criteria (treatment failure), whichever came first. Maximum allowed dose: 12 mg/kg/day or 600 mg/day (whichever was lower)."
88858914|NCT00088452|Active Comparator|Valproic acid|"Valproic acid~Frequency and Duration: twice a day, every day for the duration of the study treatment~Formulation: Two formulations were used (actual formulation used was dependent on the patient's weight): 250mg Depakote capsules OR 125mg Depakote sprinkles.~Dosing: Depakote was titrated in predetermined increments every 1-2 weeks during a 16-week titration period. The titration continued until the patient a) achieved seizure freedom by clinical and EEG criteria, b) reached the maximal allowed study drug dose, c) reached the maximal tolerated dose, or d) developed dose-exiting criteria (treatment failure), whichever came first. Maximum allowed dose: 60 mg/kg/day or 3000 mg/day (whichever was lower)"
88858915|NCT03417570|Experimental|Arm 1: EGD with cap first, followed by EGD without cap|-Participants in the first arm will undergo EGD with cap first, followed by EGD without cap in the same procedural period.
88858916|NCT03417570|Experimental|Arm 2: EGD without cap first, followed by EGD with cap|-Participants in the second arm will undergo EGD without cap first, followed by EGD with cap in the same procedural period.
88858917|NCT03087552||Transradial balloon aortic valvuloplasty|Consecutive patients with severe aortic stenosis and receiving as first attempt balloon aortic valvuloplasty by transradial access.
88858918|NCT03087474||VKA patients|Vitamin K antagonist (VKA) patients
88858919|NCT03087474||NOAC patients|nonvitamin K antagonist oral anticoagulants (NOAC) patients
88858920|NCT01679106|Placebo Comparator|Fentanyl IV PCA and placebo TAP catheter|Patients will receive Fentanyl IV PCA and placebo TAP catheter.
88858921|NCT01679106|Active Comparator|TAP catheter with continuous infusion of Ropivicaine|Patients will receive TAP catheter with continuous infusion of Ropivicaine for up to 48 hours after surgery.
88858922|NCT04403100|Active Comparator|Hydroxychloroquine Sulfate|Hydroxychloroquine 400 mg. Loading oral dose of 800 mg followed by orally dose of 400 mg/ day for the following 10 days
88858923|NCT04403100|Active Comparator|Lopinavir/ Ritonavir|Lopinavir Ritonavir 200/ 50 mg Loading oral dose of 800/ 200 mg twice a day on day 1 followed by 400/100 mg orally twice a day for the following 9 days
88858924|NCT04403100|Active Comparator|Hydroxychloroquine plus Lopinavir/ Ritonavir|"Hydroxychloroquine 400 mg. Loading oral dose of 800 mg followed by orally dose of 400 mg/ day for the following 10 days~Plus~Lopinavir Ritonavir 200/ 50 mg Loading oral dose of 800/ 200 mg twice a day on day 1 followed by 400/100 mg orally twice a day for the following 9 days"
88858925|NCT04403100|Placebo Comparator|Placebo|"Placebo~Twice a day from day 1 through day 10."
88858926|NCT03087318|Experimental|Rehabilitation medical center|"Physical activity:~3 sessions / week at least~at least during 30 minutes each session~at least at 50% of the maximal HR(heart rate) measured during the exercise stress testing (from the screening)~during 3 months."
88858927|NCT03087318|Experimental|Private sport club|"Physical activity:~3 sessions / week at least~at least during 30 minutes each session~at least at 50% of the maximal HR(heart rate) measured during the exercise stress testing (from the screening)~during 3 months."
88858928|NCT03087318|Experimental|Sport association|"Physical activity:~3 sessions / week at least~at least during 30 minutes each session~at least at 50% of the maximal HR(heart rate) measured during the exercise stress testing (from the screening)~during 3 months."
88858929|NCT03086538|Experimental|Pemetrexed+Tarceva|Pemetrexed 500 mg/m2 IV Q 3 weeks Tarceva 100mg once daily, continous
88858930|NCT04761276||Lucidis Intra-ocular lens (IOL)|Adult patients with significant reduction in visual acuity and/or visual comfort from cataract who will receive Lucidis Intra-ocular lens
88858931|NCT03473730|Experimental|Cohort 1 Renal (daratumumab, biopsy, surgery)|Patients receive daratumumab IV over 8 hours for the first dose and then over 4 hours for all doses thereafter during weeks 1-8. Treatment repeats every week for up to 8 weeks in the absence of disease progression or unacceptable toxicity. Patients then undergo biopsy, nephrectomy, or metastasectomy during weeks 10-12. Patients may then restart treatment with daratumumab beginning 2 weeks after biopsy or 4-6 weeks after nephrectomy or metastasectomy. Cycles repeat every 2 weeks for 4 months and then monthly for 1 year in the absence of disease progression or unacceptable toxicity.
88858932|NCT03473730|Experimental|Cohort 2 Bladder (daratumumab)|Patients receive daratumumab IV over 8 hours for the first dose and then over 4 hours for all doses thereafter beginning at week 1. Cycles repeat every week for up to 4 weeks in the absence of disease progression or unacceptable toxicity.
88858933|NCT01679262|Other|Optimal size of OPAs|
88858934|NCT02984748||Cochlear Implant Recipients|
88858935|NCT03081858|Experimental|TSD-001 Administration Part 1, Cohort 1|Part 1, Cohort 1: For the first 3 subjects enrolled, the initial dose will be 10 mg in Sterile Water for Injection (SWFI). TSD-001 will be retained in the bladder for 2 hours (1 hour or more will be acceptable, depending on subject's tolerability of the procedure). If Dose Limiting Toxicity(DLT) does not develop, intravesical instillation 14 days later will be titrated up according to the schedule (25, 50, 75, 100, 150 mg in SWFI) until DLT (defined as any grade 3 or 4 toxicity or prolonged [greater than 14 days] grade 2 toxicity) is observed.
88858936|NCT03081858|Experimental|TSD-001 Administration Part 1, Cohort 2|"Part 1, Cohort 1: For the next 3 subjects enrolled, the initial dose will be 90 mg in SWFI. TSD-001 will be retained in the bladder for 2 hours (1 hour or more will be acceptable, depending on subject's tolerability of the procedure). If DLT does not develop, intravesical instillation 14 days later will be titrated up according to the schedule (180, 270, 360, 450, and 540 mg in SWFI) until DLT (defined as any grade 3 or 4 toxicity or prolonged [greater than 14 days] grade 2 toxicity) is observed.~If no DLT is observed in the first 6 subjects (cohorts 1 and 2) after titration up to 540 mg, then the maximum deliverable dose (MDD) will be defined and dose recommended for part 2 of the study."
88858937|NCT03081858|Experimental|TSD-001 Administration Part 2|"In part 2, the dose will be selected as the MTD/MDD, established in part 1 and provided weekly via the intravesical route.~During part 2, up to 10 additional subjects will receive intravesical instillations of TSD-001 via urethral catheterization of the urinary bladder at the MTD/MDD established in part 1 at weekly intervals for 6 consecutive weeks. TSD-001 will be retained in the bladder for 2 hours (1 hour or more will be acceptable, depending on subject's tolerability of the procedure)."
88858938|NCT03082560||Group 1|Healthy adult patients with lichen planopilaris
88858939|NCT01679340|Experimental|S-1+oxaliplatin|S-1: 80mg/m2, 3weeks/cycle(take for 14d, rest for 7d oxaliplatin: 65mg/m2, D1,D8, 3weeks/cycle after 6 cycles, then mono S-1 for 2-4 cycles, total 8-10 cycles.
88858940|NCT01679340|Active Comparator|S-1+cisplatin|S-1: 80mg/m2, 3weeks/cycle(take for 14d, rest for 7d) cisplatin: 75mg/m2, D1, every 3 weeks After 6 cycles, then mono S-1 for 2-4 cycles, total 8-10 cycles.
88858941|NCT03087084|Experimental|Cardiac Pacing and Impedance Measurement system|
88858942|NCT03089814|Active Comparator|Healthy volunteers|Healthy male volunteers will receive ischemic conditioning (4 cycles of 5-min ischemia followed by 5-min reperfusion on upper extremity) while measuring changes in tissue microcirculation at the thenar muscle.
88858943|NCT03089814|Active Comparator|Cardiac surgery patients|Patients scheduled for cardiac surgery will receive ischemic conditioning (4 cycles of 5-min ischemia followed by 5-min reperfusion on upper extremity) while measuring changes in tissue microcirculation at the thenar muscle.
88858944|NCT03089970||Healthy asthma|Asthmatic patients not with an exacerbation, i.e., stable asthmatics
88858945|NCT03089970||Rhinovirus-infected asthmatics|Asthmatics with an exacerbation and associated rhinovirus infection
88858946|NCT03089970||Influenza A-infected asthmatics|Asthmatics with an exacerbation and associated influenza A infection
89384779|NCT03083847|Experimental|Pilot (5a): 1 injection of 1x10^5 PfSPZ Challenge+chloroquine|Pilot Phase - 1 injection of 1x10^5 sporozoites of PfSPZ Challenge (NF54) with 1000mg of chloroquine (loading dose) 2 days prior to injections and 500mg (maintenance dose) 5 days post injection
88858947|NCT03089892||Gynecologic cancer patients|Gynecologic cancer patients under chemotherapy
88858948|NCT03087006|Active Comparator|Automatic Self Transcending Meditation|Automatic Self Transcending Meditation (ASTM) may help with depression, anxiety, stress, PTSD, and may have a positive impact on quality of life of participants diagnosed with dry eye disease. ASTM is a class of meditation that helps quiet the mind and induces physiological and mental relaxation whilst the eyes are shut. It utilizes a specific sound value (mantra) to draw attention inward and permit the mind to experience a restful but alert state of consciousness.
88858949|NCT03087006|Placebo Comparator|Treatment as Usual (TAU)|Participants continue to receive treatment as usual including dry eye disease medications.
88858950|NCT01679574|Experimental|letrozole|Letrozole tablets (Femara; Novartis Pharma, Switzerland) 2.5 mg letrozole daily from day 3 of the menses for 5 days
88858951|NCT01679574|Active Comparator|Metformin and clomiphene|".Drug: metformin (Cidophage®; CID,Cairo, Egypt) metformin 1500 daily for 3 months~Drug: CC (Clomid®; Global Napi Pharmaceuticals, Cairo, Egypt) 100 mg CC for 5 days starting from day 3 of menstruation"
88858952|NCT01679652|Experimental|Nebivolol|Tablet Nebivolol 5 mg (oral use) for 5 days
88858953|NCT01679652|Placebo Comparator|Placebo|Inactive placebo given as tablet for 5 days
88858954|NCT01679730||irritable bowel syndrome patients|
88858955|NCT03086928|Experimental|lava ultimate|lava ultimate is Resin nano-ceramic which is a mixture of a resin composite matrix and nano-ceramic fillers of approximately 80% by weight. The main advantages of this material over the glass ceramics are the stress absorbing action or stress distribution by having modulus of elasticity near to the tooth dentin and can be individualized intra-orally or extra-orally, either before or after definitive cementation.
89384780|NCT03083847|Experimental|Pilot (5b): 1 injection of 2x10^5 PfSPZ Challenge+chloroquine|Pilot Phase - 1 injection of 2x10^5 sporozoites of PfSPZ Challenge (NF54) with 1000mg of chloroquine (loading dose) 2 days prior to injections and 500mg (maintenance dose) 5 days post injection
89384781|NCT03083847|Experimental|Main (2a):3 doses of 2x10^5 PfSPZ Challenge+pyrimethamine+NF54|Main Phase - 3 monthly doses of 2x10^5 sporozoites of PfSPZ Challenge + pyrimethamine on days 2 and 3 post injection + homologous controlled human malaria infection (CHMI) with 3.2x10^3 PfSPZ Challenge (NF54) at 12 weeks after third injection
89384782|NCT03083847|Experimental|Main (2b):3 doses of 2x10^5 PfSPZ Challenge+pyrimethamine+7G8|Main Phase - 3 monthly doses of 2x10^5 sporozoites of PfSPZ Challenge + pyrimethamine on days 2 and 3 post injection + heterologous CHMI with 3.2x10^3 PfSPZ Challenge (7G8) at 12 weeks after third injection
88858956|NCT03086928|Active Comparator|E.max cad|E.max is lithium disilicate glass ceramic, composed of quartz, lithium dioxide, phosphor oxide, alumina oxide, and potassium oxide with superior mechanical and optical properties if used for laminate veneers
88858957|NCT04761744|Experimental|Nivolumab|
88858958|NCT01679886|Experimental|Rubidium PET|Rubidium PET
88858959|NCT04402476|Experimental|Device and Control|"Device:~Powder Free Polychloroprene Surgical Gloves, Sterile. Low Dermatitis Potential, Tested for use with Chemotherapy Drugs.~Approximately 2cm x 2cm square positioned to ensure that the inside portion of the test material maintained skin contact.~Positive Control:~0.4% Sodium Lauryl Sulfate (SLS) Dose. 0.2 ml"
88858960|NCT03089736|Experimental|TAU + Education and self care|Treatment as usual (TAU; i.e. pharmacological treatments and advices) + structured education + instructions on self care
88858961|NCT03089736|Other|Treatment as usual (TAU)|Treatment as usual (TAU; i.e. pharmacological treatments and advices)
88858962|NCT03432000|Experimental|subjects with schizophrenia|Performances on temporal task Subjective alterations of time perception in patients with an adapted scale (EAWE) Global symptomatology with PANSS (positive and negative symptom scale)
88858963|NCT03432000|Sham Comparator|healthy subjects|Evaluate the links (correlation) between perception of temporal sequencing and perception of causality using an adapted experimental paradigm (Michotte paradigm) and to compare performance between healthy subjects and controls Investigate the existence of a correlation between these alterations and the peculiarities of the subjective experience of time (EAWE scale) in the group of subjects with schizophrenia
88858964|NCT03089502|Experimental|Exercise Rehabilitation|The intervention group will participate in the exercise rehabilitation program for a total of 12 weeks. This includes performing aerobic training five times per week and resistance training two to three times per week. Participants will also be expected to attend the education sessions following their supervised exercise rehabilitation sessions each week.
88858965|NCT03089502|No Intervention|Usual Care|Participants in the control group will be encouraged to continue with their regular physical activity routine and will receive regular standard of care by their Cardiologist and Oncologist.
88858966|NCT03089190|Active Comparator|DC7-2 alone|Administration of DC7-2, a meat-derived octapeptide.
88858967|NCT03089190|Active Comparator|DC7-2 + potato protein isolate|Administration of DC7-2, a meat-derived octapeptide, combined with potato protein isolate that protects DC7-2 from degradation in the GI tract.
88858968|NCT03089190|Active Comparator|Potato protein isolate + placebo|Administration of potato protein isolate combined with inactive whey protein as placebo.
88858969|NCT03089190|Placebo Comparator|Placebo|administration of inactive whey protein
88858970|NCT03089424|Placebo Comparator|Placebo PBMT|Application of PBMT (Photobiomodulation Therapy) without any dose (0 Joule) and The Back Book (educational information booklet).
88858971|NCT03089424|Active Comparator|PBMT active|Application of PBMT (Photobiomodulation Therapy) active and The Back Book (educational information booklet).
88858972|NCT03089346|Other|Asthma|"Patients with diagnosis of asthma according to 2016 Global Strategy for Asthma Management and Prevention (GINA) definition"
88858973|NCT03081234|Experimental|Ribociclib + adjuvant endocrine therapy|Ribociclib in combination with standard adjuvant endocrine therapy
88858974|NCT03081234|Active Comparator|Placebo + adjuvant endocrine therapy|Placebo in combination with standard adjuvant endocrine therapy
88858975|NCT03417492|Experimental|Sildenafil Citrate|Open label treatment with forced titration of sildenafil citrate.
88858976|NCT03080922|Experimental|hematopoietic stem cell|high dose of donor granulocyte colony-stimulating factor（G-CSF）mobilized peripheral blood hematopoietic stem cell are infused to patient received normal chemotherapy
88858977|NCT04402164|Active Comparator|Dentally anchored Herbst group|Herbst appliance will be anchored on the mandibular dentition
88858978|NCT04402164|Active Comparator|Skeletally anchored Herst group|Herbst appliance will be anchored on mini-plates placed in the para symphesial areas
89535132|NCT03324737|No Intervention|Standard Care Arm|Subjects in the standard care arm will be informed of their increased risk of developing type 2 diabetes in the future, and given general lifestyle verbal advice to maintain a healthy weight, eat a well-balanced diet and do regular exercise during their 6 week postnatal visit. Women found to have impaired fasting glucose (6.1-6.9 mmol/L) or impaired glucose tolerance (2H post glucose of 7.8-11.0 mmol/L) will be issued a letter reinforcing lifestyle changes namely weight loss (if raised BMI), diet, exercise, and encouragement to consult a family physician to discuss the appropriateness of starting medications that can prevent the progression to type 2 diabetes, or restore the blood glucose to normal levels. Those with a normal OGTT result will just be informed that it is normal.
88858979|NCT03080532||european population|
88858980|NCT03080766|Experimental|decitabine|"Decitabine is a white to almost white powder for concentrate for solution for infusion. It is supplied as a lyophilized preparation in a clear colorless 20ml glass vial containing 50 mg decitabine.~The concentrate should be aseptically reconstituted with 10 ml of water for injections. After reconstitution, the concentrate must be diluted within 15 minutes using cooled infusion fluids and completely administered to patients within 5 hours.~The drug will then be administrated intravenously.~Dosage 20 mg/m2~28-day course, for each course, receive decitabine for 10 days"
88858981|NCT03080688||Prizma|Measurement of oxyhemoglobin saturation by OSM-3 oximeter and Prizma oxygen saturation measurement
88858982|NCT03080298|Experimental|Treatment with BP101|
88858983|NCT03080298|Placebo Comparator|Treatment with placebo|
88858984|NCT04401618||Class V RMGI Restorations|Resin-modified glass ionomer (RMGI - Fuji 2 LC) Class V restorations performed by by 3rd and 4th-year dental students in adult patients of Schulich dental clinic over the last three years will be evaluated using mirrors and probes.
88858985|NCT04401618||Class V Glass ionomer - GIC Restorations|Glass ionomer (GI - Fuji 9) Class V restorations performed by by 3rd and 4th-year dental students in adult patients of Schulich dental clinic over the last three years will be evaluated using mirrors and probes.
88858986|NCT03080376|Experimental|Web-based intervention without support|3 months Web-based intervention without support
88858987|NCT03080376|Experimental|Web-based intervention with support|3 months Web-based intervention with support (e-mails)
88858988|NCT03080376|Active Comparator|Traditional intervention|3 months of Printed-based intervention
89384783|NCT03083847|Experimental|Main (3):3 doses of 2x10^5 PfSPZ Challenge+chloroquine+7G8|Main Phase - 3 monthly doses of 2x10^5 sporozoites of PfSPZ Challenge + weekly chloroquine (1000mg given 2 days prior to injections and 500mg given 5 days post injection and weekly thereafter until 5 days post third injection) + heterologous controlled human malaria infection (CHMI) with 3.2x10^3 PfSPZ Challenge (7G8) at 12 weeks after third injection
89384784|NCT03083847|Experimental|Main Phase (4a) - Infectivity Control: NF54 (homologous) CHMI|Main Phase - Infectivity Control with one dose of 3.2x10^3 sporozoites of PfSPZ Challenge (NF54) (homologous) controlled human malaria infection (CHMI)
89384785|NCT03083847|Experimental|Main Phase (4b) - Infectivity Control: 7G8 (heterologous) CHMI|Main Phase - Infectivity Control with 3.2x10^3 sporozoites of PfSPZ Challenge 7G8 (heterologous) controlled human malaria infection (CHMI)
89384786|NCT01377519|Active Comparator|MR Guided Focused Ultrasound|
89384787|NCT01377519|Placebo Comparator|Placebo MR Guided Focused Ultrasound|
88858989|NCT03080844|Experimental|Practice|Participants will be asked to delay time to smoking first cigarette of the day for up to two weeks.
88858990|NCT03080844|Active Comparator|No Practice|Participants will continue with their normal smoking behavior.
88858991|NCT03392064|Experimental|AMG 119 Treatment|AMG 119 administered as a one-time intravenous infusion at different cell dose levels
88858992|NCT03080064|Experimental|Health Coach Intervention|The investigators connected participants at enrollment (median gestation of 12.5 weeks, IQR: 11-15) with a trained health coach who called participants every 2-3 weeks until 36 weeks of gestation. During these phone calls, health coaches helped participants adopt and maintain new healthful lifestyle behaviors that were evidence-based, simple, and easy to track. Goals aimed to promote appropriate gestational weight gain and covered several domains including diet, physical activity, screen time, and sleep.
88858993|NCT04761354||University Medical Center Utrecht|Patients who underwent adrenalectomy for primary aldosteronism in case of an aldosterone-producing-adenoma
88858994|NCT04761354||University Medical Center Groningen|Patients who underwent adrenalectomy for primary aldosteronism in case of an aldosterone-producing-adenoma
88858995|NCT04761354||Vu University Medical Center Amsterdam|Patients who underwent adrenalectomy for primary aldosteronism in case of an aldosterone-producing-adenoma
88858996|NCT04761354||University Medical Center Maastricht|Patients who underwent adrenalectomy for primary aldosteronism in case of an aldosterone-producing-adenoma
88858997|NCT04761354||Academic Medical Center Amsterdam|Patients who underwent adrenalectomy for primary aldosteronism in case of an aldosterone-producing-adenoma
88858998|NCT04761354||Istituto di Semeiotica Chirurgica Roma|Patients who underwent adrenalectomy for primary aldosteronism in case of an aldosterone-producing-adenoma
88858999|NCT04761354||University of California San Francisco|Patients who underwent adrenalectomy for primary aldosteronism in case of an aldosterone-producing-adenoma
88859000|NCT04761354||Northwestern Memorial Hospital|Patients who underwent adrenalectomy for primary aldosteronism in case of an aldosterone-producing-adenoma
88859001|NCT04761354||Weill Cornell Medical Center|Patients who underwent adrenalectomy for primary aldosteronism in case of an aldosterone-producing-adenoma
88859002|NCT04761354||Columbia University Medical Center|Patients who underwent adrenalectomy for primary aldosteronism in case of an aldosterone-producing-adenoma
88859003|NCT04761354||University of Chicago Medical Center|Patients who underwent adrenalectomy for primary aldosteronism in case of an aldosterone-producing-adenoma
88859004|NCT04761354||M.D. Anderson Cancer Center|Patients who underwent adrenalectomy for primary aldosteronism in case of an aldosterone-producing-adenoma
88859005|NCT04761354||Boston Medical Center|Patients who underwent adrenalectomy for primary aldosteronism in case of an aldosterone-producing-adenoma
88859006|NCT04761354||University Health Network Toronto|Patients who underwent adrenalectomy for primary aldosteronism in case of an aldosterone-producing-adenoma
88859007|NCT04761354||Montreal General Hospital - McGill University|Patients who underwent adrenalectomy for primary aldosteronism in case of an aldosterone-producing-adenoma
88859008|NCT04761354||University of Sydney|Patients who underwent adrenalectomy for primary aldosteronism in case of an aldosterone-producing-adenoma
88859009|NCT03089112|Experimental|Seguence 1|Period 1 : HGP1607 Period 2 : HGP1501 Period 3 : HGP1607+HGP1501
88859010|NCT03089112|Experimental|Seguence 2|Period 1 : HGP1607 Period 2 : HGP1607+HGP1501 Period 3 : HGP1501
88859011|NCT03089112|Experimental|Seguence 3|Period 1 : HGP1501 Period 2 : HGP1607 Period 3 : HGP1607+HGP1501
88859012|NCT03089112|Experimental|Seguence 4|Period 1 : HGP1501 Period 2 : HGP1607+HGP1501 Period 3 : HGP1607
88859013|NCT03089112|Experimental|Seguence 5|Period 1 : HGP1607+HGP1501 Period 2 : HGP1607 Period 3 : HGP1501
88859014|NCT03089112|Experimental|Seguence 6|Period 1 : HGP1607+HGP1501 Period 2 : HGP1501 Period 3 : HGP1607
88859015|NCT03083886|Active Comparator|Usual PCP led care|
88859016|NCT03083886|Experimental|Identify, Coordinated, Enhanced (ICE) Decision Making|
88859017|NCT03083886|Experimental|Individualized Postural Therapy (IPT)|
88859018|NCT04279626||LETS-M|Women who were older than 20 years old and had not reached menopause, with symptomatic uterine myomas, such as hypermenorrhea, infertility, a mass effect-related urinary frequency, and constipation, received LETS-M.
88859019|NCT03088956||bvFTD|Participants with behavioral variant frontotemporal dementia (bvFTD) (n=37)
88859020|NCT03088956||Healthy|Healthy Participants (n=10)
88859021|NCT03088722|Experimental|Community health extension workers|Community health extension workers providing contraceptive implants
88859022|NCT03088722|No Intervention|Nurses and midwives|Nurses and midwives providing contraceptive implants (existing care)
88859023|NCT03088644|Experimental|Part A: 18F-JNJ-64413739|Subjects will receive an intravenous (IV) bolus injection of 18F-JNJ-64413739 at a dose between 150 and 185 megaBecquerel (MBq) on Day 1 of Part A to investigate the total body biodistribution and measure the radiation dosimetry.
88859024|NCT03088644|Experimental|Part B: 18F-JNJ-64413739|Subjects will receive an IV bolus injection of 18F-JNJ-64413739 at a dose between 150 and 185 MBq on Day 1 of Part B to measure the uptake, distribution, and clearance in brain.
88859025|NCT03088644|Experimental|Part C: 18F-JNJ-64413739|Subjects will receive an IV bolus injection of 18F-JNJ-64413739 for a PET/MR scan on Day 1 and a repeat 18F-JNJ-64413739 PET/magnetic resonance (MR) scan at least 1 week later to determine the test-retest variability in V[t]. 18F-JNJ-64413739 doses will be between 150 and 185 MBq.
88859026|NCT03088644|Experimental|Part D: JNJ-54175446 + 18F-JNJ-64413739|Subjects will have a baseline 18F-JNJ-64413739 PET/MR scan on Day 1. On Day 2 they will receive JNJ-54175446 (maximum 600 milligram [mg]) orally (after light breakfast) and then an IV injection of 18F-JNJ-64413739 four hours after dosing for a PET/MR scan. At least 1 week later, they will receive another dose of JNJ-54175446, and then an IV injection of 18F-JNJ-64413739 four hours later for a second post-treatment PET/MR scan. 18F-JNJ-64413739 doses will be between 150 and 185 MBq.
88859027|NCT03088254|Experimental|Group I|Treatment of Telmisartan 80 mg, Amodipine 10 mg, Rosuvastatin 20 mg for 8 weeks
88859028|NCT03088254|Active Comparator|Group II|Treatment of Telmisartan 80 mg, Amodipine 10 mg, Rosuvastatin placebo for 8 weeks
88859029|NCT03088254|Active Comparator|Group III|Treatment of Telmisartan 80 mg, Amodipine placebo, Rosuvastatin 20 mg for 8 weeks
88859030|NCT03088488||Periodontally healthy subjects|
88859031|NCT03088488||Chronic periodontitis patients|
88859032|NCT05685420|Experimental|open-label|Herombopag plus standard of care
88859033|NCT04279080||1|rectal cancer patients
88859034|NCT04279080||2|ovarian cancer patients
88859035|NCT05689086||Program Participants|"Patients with HFrEF (LVEF<40%) & NYHA class II-III who are referred to and consent to participate in the Virtual Heart Failure Optimization Program"
88859036|NCT03086772|Experimental|Tai Chi|Individuals in the Tai Chi intervention group participated in a 12-week Tai Chi program.
88859037|NCT03086772|Active Comparator|Light Exercise|Individuals in the exercise control group performed a 12-week light exercise program.
88859038|NCT05689008|No Intervention|control|Participants will receive standard therapy, including oxygen therapy，glucocorticoid and other antiinflammatory drugs and supportive treatments according the ninth edition of Chinese guidelines for the treatment of COVID-19 infection.
88859039|NCT05689008|Experimental|UC-MSCs treatment|Participants will receive two doses of UC-MSCs instillation at the first and fourth day after the assignment on the basis of standard treatment.
88859040|NCT05688930|Experimental|PENMT (Experimental Group)|The neuromuscular injury prevention intervention protocol contains field work activities that involve proprioceptive exercises, flexibility, and specific and general muscle strength of the MMII and trunk.
88859041|NCT05688930|Active Comparator|FIFA 11+ (Control Group)|Treatment or experimental condition. 1: FIFA 11+ Program
88859042|NCT05684484|Active Comparator|conventional treatment group|Group 1 (n=26): Patients will receive conventional treatment only of ulcerative colitis for 3 months.
88859043|NCT05684484|Experimental|experimental treatment group|Patients will receive previous conventional treatment and Roflumilast (500 mcg ) orally once daily for 3 months
88859044|NCT03391908||MP - SG 01|Patients with unstable angina type acute coronary syndrome: patients aged at least 18 years, who have signed the informed consent, and present an unstable angina-type acute coronary syndrome with maximum 48h before presentation, defined as the presence of typical angina pain, with duration of more than 5 minute, accompanied by ECG changes.
88859045|NCT03391908||MP - SG 02|Patients with acute myocardial infarction (STEMI or NSTEMI) that occurred 30 days before randomization: patients aged at least 18 years, who have signed the informed consent, and present with acute myocardial infarction (STEMI or NSTEMI) defined as typical changes on the ECG (ST elevation of minimum 1 mm in at least 2 consecutive leads - STEMI; ST-T changes for NSTEMI) accompanied by increased levels of cardiac troponin I or T, or CK-MB of more than 2x the normal reference value of the laboratory.
88859046|NCT03086382|Experimental|Treatment A - B|Single administration of Treatment A (single dose of Lacosamide (LCM) 200 mg, given as 2 tablets of LCM 100 mg under fasting conditions, followed by a Wash-Out Period of at least 7 days and a single administration of Treatment B (single dose of LCM 200 mg given as syrup) under fasting conditions
88859047|NCT03086382|Experimental|Treatment B - A|Single administration of Treatment B (single dose of LCM 200 mg given as syrup) under fasting conditions, followed by a Wash-Out Period of at least 7 days and a single administration of Treatment A (single dose of Lacosamide (LCM) 200 mg, given as 2 tablets of LCM 100 mg) under fasting conditions
88859048|NCT04401696|Experimental|Group A|Use of Bubble CPAP for management of respiratory distress
88859049|NCT04401696|Active Comparator|Group B|Use of Oxygen via nasal cannula for respiratory distress
88859050|NCT05680428|Experimental|early feeding group|after stoma reversal in patients in this group oral feeding was started with in 12 hrs after surgery
88859051|NCT05680428|Active Comparator|conventional feeding group|after stoma reversal in patients in this group oral feeding was started 48hrs after surgery
88859052|NCT03086304|Experimental|TEAS group|Choose several acupoints,give 2/10 hz dilatational wave stimulation.Complete the 30 minutes intervention after extubation and 1-3 days after surgery.Give a health education on the first postoperative day.
88859053|NCT03086304|Experimental|no TEAS group|The choice of acupoints are same with TEAS group,tape over the electrode but don't give electroacupuncture stimulation,the others steps are same with TEAS group.
88859054|NCT04279002||Respiratory rehabilitation course|Patients who has completed at least one respiratory rehabilitation course at the Espace du Souffle (Tours France) within the 5 years prior to inclusion
89184404|NCT02588118||male group|Propofol 2 mg/kg (t0) followed by cisatracurium 0.1 mg/kg 1 min (t2). Patients will be monitored using bispectral index monitoring for propofol and Relaxometer mechanomyograph neuromuscular monitoring for cisatracurium. Serial arterial blood samples (5 ml) were withdrawn in EDTA-tubes before cisatracurium administration, 1, 3, 5, 7, 10, 13, 16, 19, 22, 25, 30, 60 and 90 min following administration. Blood samples were assayed in duplicate using high performance liquid chromatograph for Pharmacokinetic analysis.
88859055|NCT03414996|Experimental|High-intensity interval training|Following 5 min warm-up at 30 % of maximal aerobic power (MAP) obtained at the cardiopulmonary exercise test, patients performed 2 sets of 10 minutes of repeated phases of 15 seconds at 100 % MAP alternating with 15 seconds of passive recovery. The 2 sets were separated by 4 min of passive recovery (no pedalling). Patients performed 5-minutes of recovery period at 30 % MAP after the second set. Total time duration was 34 minutes.
88859056|NCT03414996|Active Comparator|Moderate-intensity continuous exercise training|Duration was adjusted to match total energy expenditure of the high-intensity interval training session. Following 5 min warm-up at 30 % of maximal aerobic power (MAP), patients performed continuous exercise at 60 % MAP during 24 minutes. Patients performed 5-minutes of recovery period at 30 % MAP after the second set. Total time duration was 34 minutes.
88859057|NCT03086226|Experimental|Fosravuconazole 300 mg|"Given throughout the study for 12 months as the experimental arm.~Both experimental arms will be evaluated at 3 months. At this time-point, one of the study arms will be dropped according to the drop-the-loser design, based on efficacy or toxicity."
88859058|NCT03086226|Experimental|Fosravuconazole 200 mg weekly|"Given throughout the study for 12 months as the experimental arm.~Both experimental arms will be evaluated at 3 months. At this time-point, one of the study arms will be dropped according to the drop-the-loser design, based on efficacy or toxicity."
88859059|NCT03086226|Active Comparator|Itraconazole 400mg daily|Given throughout the study for 12 months as the comparator arm.
88859060|NCT03085992|Experimental|Single Arm|INDUCTION TREATMENT WITH FOLFOXIRI PLUS BEVACIZUMAB FOLLOWED BY PREOPERATIVE CHEMORADIOTHERAPY PLUS BEVACIZUMAB
88859061|NCT03362424|Experimental|Mesenchymal stem cell group|rotator cuff repair stem cells
88859062|NCT03362424|Active Comparator|Control group|rotator cuff repair
88859063|NCT03086070|Experimental|Treatment arm|omeprazole 20 mg capsule once daily for 8 weeks
88859064|NCT03086070|Placebo Comparator|Placebo arm|matching placebo capsules ones daily for 8 weeks
88859065|NCT03086148|Experimental|ketamine group|
88859066|NCT03086148|Placebo Comparator|normal saline group|
88859067|NCT03359538|Placebo Comparator|placebo|Patients assigned to this arm will take Riluzole as usual + placebo tablets
88859068|NCT03359538|Active Comparator|Rapamycin 1 mg/m2|Patients assigned to this arm will take Riluzole as usual + tablets corresponding to a Rapamycin dose of 1 mg/m2/day
88859069|NCT03359538|Active Comparator|Rapamycin 2 mg/m2|Patients assigned to this arm will take Riluzole as usual + tablets corresponding to a Rapamycin dose of 2 mg/m2/day
88859070|NCT04272138|Experimental|Calm Meditation|Participants in the intervention group will be exposed to 10 minutes per day of meditation via a smartphone application for 4 weeks. Participants will log their meditation participation in an online weekly log.
88859071|NCT04272138|Active Comparator|Educational Podcast Control|Participants in the control group will be exposed to 10 minutes per day of health education podcasts via a smartphone application for 4 weeks. Participants will log their podcast participation in an online weekly log.
88859072|NCT05345808|Other|Formulated Posterior Sub Tenon Triamcinolone|All the eyes received single dose 40 mg of Triamcinolone Acetonide (TA) and VISCOAT which is 20 mg sodium chondroitin sulphate and 15 mg sodium hyaluronate (0.5 ml) through posterior subtenon route using NAGATA subtenon canula.
88859073|NCT04401228||covid ICU patients|
88859074|NCT04401228||covid conventionnal ward|
88859075|NCT02336958|Active Comparator|ropivacaine|Ultrasound guided intermediate cervical plexus block: 20ml ropivacaine 0.75%. Ultrasound guided perivascular/pericarotidal infiltration: 5ml ropivacaine 0.75%.
88859076|NCT02336958|Placebo Comparator|saline|Ultrasound guided intermediate cervical plexus block: 20ml ropivacaine 0.75%. Ultrasound guided perivascular/pericarotidal infiltration: 5ml saline 0.9%.
88859077|NCT03409926|Active Comparator|Microcrystalline Cellulose (MCC) 10 grams/day|non-fermentable active control
89384788|NCT03082677|Experimental|ixazomib|Ixazomib beginning between day +100 to +150 at a dose of 4 mg orally once per week (3 weeks on/ 1 week off). The patients will continue on this same dose until taper off from immunosuppressants or 1 year post-HSCT is reached (whichever occurs first) or until the patient develops GVHD or malignant disease relapse/progression occurs.
88859078|NCT03409926|Experimental|Acacia Gum 5 grams/day|fermentable dietary fiber
88859079|NCT03409926|Experimental|Acacia Gum 10 grams/day|fermentable dietary fiber
88859080|NCT04760886||Urban trauma cohort|All paediatric trauma admissions in an urban, MTC treated operatively, isolated from a departmental trauma list between 1st April 2019- 1st April 2021
88859081|NCT04760886||Rural trauma cohort|All paediatric trauma admissions in a rural district general, treated operatively, isolated from a departmental trauma list between 1st April 2019- 1st April 2021
88859082|NCT03085602|Experimental|CBT Treatment|Participants receive Cognitive behavioral therapy (CBT). Participants will receive 4 one hour CBT treatments.
88859083|NCT03085602|Active Comparator|Control Group|Participants receive health education treatment. Participants will attend treatment sessions that match the CBT Treatment arm with respect to time and contact.
88859084|NCT03085602|No Intervention|Control Group - Scans|Participants in this new arm to the study will receive no intervention and will receive three scans.
88859085|NCT04401306|Experimental|Self-regulated simulation training|
88859086|NCT04401306|Active Comparator|Instructor-regulated simulation training|
88859087|NCT03356496|Experimental|Intervention|Patient provided with instructions and video for the use of an incentive spirometry device. Patient instructed to use incentive spirometry device as frequently as every hour while awake but at least 4 times daily for at least 10 breathing cycles for 1-3 weeks before surgery. Patient instructed to record usage and any physical complaints in a diary.
88859088|NCT03356496|No Intervention|Control|Patient receives only usual care as provided by perioperative healthcare providers.
88859089|NCT03085446|Experimental|PDM nutritional intervention|
88859090|NCT03085446|Experimental|control|General information on nutrition and health
88859091|NCT03085368|Experimental|EC→PL(Epirubicin+Cyclophosphamide--Docetaxel+lapatinib)|Epirubicin 80 mg/ IV day M2 Cyclophosphamide 600 mg/m2 day IV 21 days for a total of 1 cycles, with a total of 4 cycles sequential Docetaxel 100mg/m2 IV day 1 21 days for a total of 1 cycles, with a total of 4 cycles Lapatinib 1000mg/d Po (fasting) every 30 days for a cycle Note: lapatinib in the first injection of docetaxel drug taking, once a day, oral dose of 1000mg, a total of over 1 years;
89003065|NCT05802004|Experimental|Sham, then Stim, then daily Sham|For the 2 overnights in the sleep lab, this arm will be randomized to complete no acoustic stimulation (SHAM) on the first overnight and acoustic stimulation (STIM) on the second overnight and then no daily acoustic stimulation (SHAM2) during the ~2 weeks at-home.
89003066|NCT05800145|Experimental|resource referral|will receive a tailored list of information about community resources. The list will include information about local emergency food resources (e.g. local food pantries) and government programs to address Food Insecurities (FI) Supplemental Nutrition Assistance Program (SNAP).
89003067|NCT05800145|Active Comparator|community health worker (CHW) intervention|assist participants in addressing FI and supporting them in their blood pressure management
89003068|NCT05800145|Active Comparator|medically tailored meals (MTM)|Participants will receive 10 medically tailored meals delivery to their home weekly for 3 months
89003069|NCT05799950||AcrySof single-piece IOL|Pseudophakic subjects previously implanted with an AcrySof single-piece IOL
89003070|NCT05799950||AcrySof multi-piece IOL|Pseudophakic subjects previously implanted with an AcrySof multi-piece IOL
89003071|NCT05799638||Heart Failure Patients who were tolerable to GDMT|Guideline-Directed Medication Treatment contains ACEI/ARB/ARNI, β blocker, SGLT2i and MRA. The patients in this group were tolerable to all the medications and accepted GDMT.
88859092|NCT03085368|Experimental|PEL(Paclitaxel+epirubicin+Lapatinib)|80mg/ M2 day 1 IV epirubicin Paclitaxel 150mg/m2 IV day 1 14 days for a total of 1 cycles (intensive chemotherapy), with a total of 6 cycles Also given Lapatinib 1000mg/d Po (fasting) every 30 days for a cycle Note: lapatinib in the first injection of paclitaxel drug taking, once a day, oral dose of 1000mg, a total of over 1 years;
89003072|NCT05799638||Heart Failure Patients who were intolerable to GDMT|The patients in this group were intolerable to one or more medication in GDMT due to hypotension, hyperkalemia or renal insufficiency.
89003073|NCT05796453|Experimental|Clareon Vivity IOL - Non Toric|Implantation with Clareon Vivity IOLs in both eyes 3-6 months prior to enrollment, with at least one of the eyes implanted with a non-toric Clareon Vivity IOL.
89003074|NCT05796453|Experimental|Clareon Vivity IOL - Toric|Implantation with Clareon Vivity IOLs in both eyes 3-6 months prior to enrollment, with at least one of the eyes implanted with a toric Clareon Vivity IOL.
89003075|NCT05796453|Experimental|Clareon PanOptix IOL - Non Toric|Implantation with Clareon PanOptix IOLs in both eyes 3-6 months prior to enrollment, with at least one of the eyes implanted with a non-toric Clareon PanOptix IOL.
89003076|NCT05796453|Experimental|Clareon PanOptix IOL - Toric|Implantation with Clareon PanOptix IOLs in both eyes 3-6 months prior to enrollment, with at least one of the eyes implanted with a toric Clareon PanOptix IOL.
89003077|NCT05796141|Experimental|Condition 1|1) Core BWL Intervention
89384789|NCT03136055|Experimental|Part A: Pembrolizumab only|Participants will receive 200 mg of pembrolizumab via IV over 30 minutes every 3 weeks for 24 months or 35 administrations (whichever comes first).
89384790|NCT03136055|Experimental|Part B: Pembrolizumab + Chemotherapy|Participants will receive 200 mg of pembrolizumab via IV over 30 minutes every 3 weeks for 24 months or 35 administrations (whichever comes first) and chemotherapy treatment of 125 mg/m^2 of irinotecan via IV on days 1 and 8 of each 21-day cycle or paclitaxel via IV on days 1, 8, and 15 of each 21-day cycle per physician discretion
89384791|NCT01380873|Experimental|Group1|
89384792|NCT01380873|Experimental|Group2|
89384793|NCT01380873|Experimental|Group3|
89384794|NCT03789045||Obese men and women|Metabolic thresholds and fat oxidation points relationship in Obese males and females, age 18-60y, body fat > 30%
89384795|NCT03789045||Male and female athletes|Metabolic thresholds and fat oxidation points relationship in Athletic males and females, age 18-60y.
89384796|NCT03789045||Sedentary females and males|Metabolic thresholds and fat oxidation points relationship in Sedentary females and males, age 18-60y,
89384797|NCT03221309||Adults infected with HCV|"Phase 1 (first 100 enrolled participants) HCV-infected adults with on-going injection drug use use with opioids with 3 months of screening~Phase 2 (enrolled participants 101-200) HCV-infected adults with on-going opioid misuse of non-prescription opioids within twelve months of screening"
89384798|NCT01379235|Experimental|Intervention group|Intervention group: will receive 12 weeks of pilatis exercise 3 times a week.
89384799|NCT01379235|Other|control group|The control group will be offered the same intervention (pilatis exercise) at the end of the study period.
89384800|NCT05421117||transumbilical (TU) routes|For the TU group, a surgical glove was created bag during the operation as follows: a sterile, surgical latex glove (size 8.5) was double tied at the level of the wrist, the fingers were removed, and a 75-cm purse-string suture was made using a symmetrical knot to form a bag. The glove bag took an average of 10 min to make. It was lubricated with normal saline to remove the talcum powder and then introduced through the 10-mm umbilical port (optic port). The fingers of the glove were removed to facilitate its insertion with the 10-mm trocar and for ease of movement in the abdominal cavity.
89535133|NCT03324737|Active Comparator|Interactive Smartphone App Arm|"Participants will download the INTERACTIVE SMARTPHONE APP and will be briefed on its use by our team of nutritionists/dieticians, exercise physiologists and life style coaches. Weight: Participants will be reminded that the goal is satisfactory weight loss.~NUH occupational therapist-trained lifestyle coaches, exercise physiotherapists, and clinical nutritionist/ dietician will interact with participants through real-time chats channels via the APP; all culturally appropriate and customized to the Singapore context."
89003078|NCT05796141|Experimental|Condition 2|1) Core BWL Intervention; 2) Home Environment Modifications
89003079|NCT05796141|Experimental|Condition 3|1) Core BWL Intervention; 2) Autonomy Support Training
89003080|NCT05796141|Experimental|Condition 4|1) Core BWL Intervention; 2) Autonomy Support Training; 3) Home Environment Modifications
89003081|NCT05796141|Experimental|Condition 5|1) Core BWL Intervention; 2) Joint Feedback
89003082|NCT05796141|Experimental|Condition 6|1) Core BWL Intervention; 2) Joint Feedback; 3) Home Environment Modifications
89003083|NCT05796141|Experimental|Condition 7|1) Core BWL Intervention; 2) Joint Feedback; 3) Autonomy Support Training
89003084|NCT05796141|Experimental|Condition 8|1) Core BWL Intervention; 2) Joint Feedback; 3) Autonomy Support Training; 4) Home Environment Modifications
89003085|NCT05796141|Experimental|Condition 9|1) Core BWL Intervention; 2) Dyadic Action Planning
88859093|NCT03085368|Active Comparator|EC→PH(Epirubicin+Cyclophosphamide--Docetaxel+herceptin)|Table 80mg/ day 1 IV Cyclophosphamide 600 mg/m2 day IV 21 days for a total of 1 cycles, with a total of 4 cycles Docetaxel 100mg/m2 IV day 1 21 days for a total of 1 cycles, with a total of 4 cycles Trastuzumab 2mg/kg IV QW (first dose 4 mg/kg) Note: trastuzumab was administered at the beginning of the first injection of paclitaxel, with an injection dose of 2mg/kg, 1 times a week, for a total of up to 1 years; followed by trastuzumab 2mg/kg IV, once every 3 weeks for a total of one year
88859094|NCT03085368|Active Comparator|EPH(Paclitaxel+epirubicin+herceptin)|80mg/ M2 day 1 IV epirubicin Paclitaxel 150mg/m2 IV day 1 14 days for a total of 1 cycles, with a total of 6 cycles Also given Trastuzumab 2mg/kg IV QW (first dose 4 mg/kg) Note: trastuzumab was administered at the beginning of the first injection of paclitaxel, with an injection dose of 2mg/kg, 1 times a week, for a total of up to 1 years; followed by trastuzumab 2mg/kg IV, once every 3 weeks for a total of one year
88859095|NCT03085290|Experimental|Group A|Subjects assigned to this arm will receive autologous serum eye drops first, followed by a washout period and then allogeneic serum eye drops.
88859096|NCT03085290|Experimental|Group B|Subjects assigned to this arm will receive allogeneic serum eye drops first, followed by a washout period and then autologous serum eye drops.
88859097|NCT05687760|Active Comparator|calcium hydroxide arm|intracanal medication of calcium hydroxide paste
88859098|NCT05687760|Experimental|bromelain arm|intracanal medication of bromelain paste (Bromelain powder with enzymatic activity of 2400 Gelatin digestion unit per Gram was mixed with saline in 1:1 proportion 1 g powder was mixed with 1 ml distilled water)
88859099|NCT03409380|Experimental|Arginine|Arginine drink provided 1 time. There is about 10 g of arginine in the product.
88859100|NCT03409380|Placebo Comparator|Placebo|Placebo drink provided 1 time.
88859101|NCT03085134|Experimental|Test infant formula with HMOs|Extensively hydrolysed infant formula with HMOs taken by infant according to age, weight and appetite.
88859102|NCT03085134|Active Comparator|Control infant formula without HMOs|Extensively hydrolysed infant formula without HMOs taken by infant according to age, weight and appetite
88859103|NCT03084978|Active Comparator|General Anesthesia|Subjects will undergo general anesthesia with endotracheal intubation.
88859104|NCT03084978|Experimental|Conscious Sedation|Subjects will undergo conscious sedation anesthesia.
88859105|NCT03084744|Experimental|Schema therapy|Schema therapy in an individual format will be implemented by clinical psychologists. The treatment period will be 2 years with biweekly 50-minute sessions (up to 48 sessions).
88859106|NCT03084744|Placebo Comparator|Active monitoring|Active monitoring by telephone will be implemented by clinical psychologists. The treatment period will be 2 years with monthly 10-minute sessions (up to 24 sessions).
88859107|NCT03084588|Active Comparator|Methadone|Patients in the methadone group will receive a single dose of methadone 0.2 mg/kg at induction of anesthesia
88859108|NCT03084588|Active Comparator|Interscalene block|Patients in the intersclene block group will receive an interscalene block prior to induction of anesthesia
88859109|NCT03408366|Experimental|Women having a Laparotomy|The first 10 patients enrolled will undergo skin closure with staples. The next 10 patients enrolled will undergo skin closure with a running subcuticular suture.to evaluate skin perfusion using the Spectrum NIR imaging system following intravenous injection of ICG in all patients. Patients will be assigned skin closure with either running subcuticular suture or skin staples in a sequential, nonrandomized fashion before the procedure. After the planned surgical procedure is complete, ICG will be injected intravenously. Video of the incision will be recorded. After skin closure is complete, a second intravenous bolus of ICG (same dose as previously injected) will be given. Video of the incision will again be recorded. Measurement of perfusion will subsequently be performed by video analysis at the previously described three predefined points along the incision after surgery is complete and again after skin closure.
88859110|NCT03084276|Experimental|High-fat meal|
88859111|NCT03084276|Active Comparator|Low-fat meal|
89184405|NCT02588118||female group|Propofol 2 mg/kg (t0) followed by cisatracurium 0.1 mg/kg 1 min (t2). Patients will be monitored using bispectral index monitoring for propofol and Relaxometer mechanomyograph neuromuscular monitoring for cisatracurium. Serial arterial blood samples (5 ml) were withdrawn in EDTA-tubes before cisatracurium administration, 1, 3, 5, 7, 10, 13, 16, 19, 22, 25, 30, 60 and 90 min following administration. Blood samples were assayed in duplicate using high performance liquid chromatograph for Pharmacokinetic analysis.
89184406|NCT00716391|Active Comparator|Group A|TPF plus concomitant treatment with cisplatin and conventional radiotherapy.
89184407|NCT00716391|Experimental|Group B|TPF plus concomitant treatment with cetuximab and conventional radiotherapy
89184408|NCT00919386||1 Direct ureteric measurement|This is determined by using a 5 French Pollack Open-Ended Flexi-Tip Ureteral catheter (Cook, Spencer, Indiana) to cannulate the ureteral orifice. A retrograde pyelogram will be done at the conclusion of the procedure and the Pollack will be advanced to the pyeloureteral junction (PUJ) under fluoroscopy. At this point the length of the distance between the PUJ and vesicoureteral junction (VUJ) will be recorded and stent length determined based on this measurement.
88859112|NCT03084432||caffeine group|22 preterm infants received caffeine (starting from day 2 of life and received for more than 7 days) for apnea prophylaxis or treatment according to protocol of Ain Shams University neonatal intensive care unit [apnea prophylaxis for preterm ≤32 weeks gestation and apnea treatment for those 33 or 34 weeks gestation]. Dual Energy X-ray Absorptiometry was done 5th-6th week post-natal age
88859113|NCT03084432||control group|20 preterm infants for whom caffeine was not given, either it was not indicated, not available or parents refused its use.Dual Energy X-ray Absorptiometry was done 5th-6th week post-natal age
88859114|NCT05345574|Active Comparator|dexmedetomidine infusion group|dexmedetomidine infusion (loading dose of 1 ㎍/kg over 10 min and continuous infusion of 0.3-0.6 ㎍/kg/h) during the surgery
89535134|NCT03084783|Experimental|Intervention group|Participants receive dexamethasone 10mg intravenously 6 hourly for 4 days.
88859115|NCT05345574|Active Comparator|remifentanil infusion group|remifentanil of 0.05 ㎍/kg/h during induction, followed by remifentanil infusion (0.05-0.3 ㎍/kg/h) during the surgery
88859116|NCT03084198|Active Comparator|Control group|Standard care for ALF
88859117|NCT03084198|Experimental|Experimental group|Continuous treatment with the hiHep bioartificial liver support system.
88859118|NCT05598606|Experimental|Denosumab|1 ml (60 mg) of denosumab (Prolia; Amgen, Inc) subcutaneous injection plus intravenous placebo every 6 months
88859119|NCT05598606|Active Comparator|zoledronate|Intravenous zoledronic acid 5 mg plus subcutaneous placebo every 12 months.
88859120|NCT03350880|Experimental|PNF in Water - PNFW|Flexibility training was carried out over a period of six weeks, with two sessions per week, totaling 12 sessions.
88859121|NCT03350880|Active Comparator|PNF on Land - PNFL|Flexibility training was carried out over a period of six weeks, with two sessions per week, totaling 12 sessions.
88859122|NCT03084120|Other|Gastric bypass surgery|"Pregnant women having undergone a Gastric bypass surgery before the pregnancy.~Collection of bloods samples for the mother.~Retrieval of umbilical cord blood.~Retrieval of placenta.~Collection of newborn's and mother's lock of hair.~Dietetic patient outcomes questionnaires for the mother.~Parental questionnaires : ASQ (Ages & Stages questionnaires) and CFQ (Child Feeding Questionnaire)."
88859123|NCT03084120|Other|Reference group|"Pregnant women having a body mass index <25 kg/m2 at the early pregnancy.~Collection of bloods samples for the mother.~Retrieval of umbilical cord blood.~Retrieval of placenta.~Collection of newborn's and mother's lock of hair.~Dietetic patient outcomes questionnaires for the mother.~Parental questionnaires : ASQ (Ages & Stages questionnaires) and CFQ (Child Feeding Questionnaire)."
88859124|NCT03084120|Other|Overweight|"Pregnant women having a body mass index 25-30 kg/m2 at the early pregnancy.~Collection of bloods samples for the mother.~Retrieval of umbilical cord blood.~Retrieval of placenta.~Collection of newborn's and mother's lock of hair.~Dietetic patient outcomes questionnaires for the mother.~Parental questionnaires : ASQ (Ages & Stages questionnaires) and CFQ (Child Feeding Questionnaire)."
88859125|NCT03084120|Other|Obesity|"Pregnant women having a body mass index > 30 kg/m2 at the early pregnancy.~Collection of bloods samples for the mother.~Retrieval of umbilical cord blood.~Retrieval of placenta.~Collection of newborn's and mother's lock of hair.~Dietetic patient outcomes questionnaires for the mother.~Parental questionnaires : ASQ (Ages & Stages questionnaires) and CFQ (Child Feeding Questionnaire)."
88859126|NCT03084042||Depression patients (MDD)|Patients with diagnosis of major depression according to DSM criteria
89184409|NCT00919386||2 Based on patient height|"We will use the height measurement criteria used by Lee et al in their study. Patients less than 5'2 will receive a 22 cm stent, 5'3-5'7 will get a 24 cm stent, 5'8-5'10 will get a 26 cm stent, 5'11 to 6'1 will get a 28 cm stent, and all patients greater than 6'2 will receive a 30 cm stent."
88859127|NCT03084042||Anxiety patients (GAD)|Patients with generalized anxiety disorder according to DSM criteria
88859128|NCT03084042||Healthy controls|Demographically matched healthy controls.
88859129|NCT04400916|Experimental|Topical tranexamic acid|
88859130|NCT04400916|Placebo Comparator|Topical BSS|
88859131|NCT03406104|Experimental|GS010-treated Eyes|Lenadogene nolparvovec Intravitreal ocular unilateral Injection Each participant will have one eye randomly selected to receive a single injection of GS010 and the other eye will receive a sham injection. GS010-treated Eyes: GS010 is a recombinant adeno-associated viral vector serotype 2 (rAAV2/2) containing the wild-type ND4 gene (rAAV2/2-ND4). Participants will receive a single dose of GS010 in one of their randomly selected eyes, via intravitreal injection containing 9E10 viral genomes in 90μL balanced salt solution (BSS) plus 0.001% Pluronic F68®.
88859132|NCT03406104|Sham Comparator|Sham-treated Eyes|Sham Intravitreal ocular unilateral Injection Each participant will have one eye randomly selected to receive GS010 and the other eye will receive a sham injection. Eyes receiving sham injection will undergo the same preparatory procedures as eyes receiving GS010 injection, including pupillary dilation, topical anti-infection and topical anesthetic procedures. Sham intravitreal injection will be performed by applying pressure to the eye at the location of a typical intravitreal injection procedure using the blunt end of a syringe without a needle.
88859133|NCT04761042|Experimental|Wilderness program|A one-week (8 days) wilderness program, 3-month online support, and a follow-up visit for four days.
88859134|NCT04761042|Other|Holiday program (Attention control)|A one-week (8 days) holiday program, 3-month online contact, and a follow-up visit for four days.
88859135|NCT04400526|Other|Phase 1: A video competition for anti-drug abuse|Phase 1 aims to increase the public awareness of hazardous effects of drug abuses and existing resources available for drug abusers through a video competition. We will co-organize a video competition for anti-drug abuse with C.H.O.I.C.E. The competition will appeal to the participation of all children (aged 13-18) living in the four targeted districts.
89184410|NCT00919386||3 Based on a predetermined formula|We will use the formula described by Wieder. Stent length in cm= patients height in inches - 42.
89184411|NCT02588898||Patients with type 2 diabetes|Patients (both men and women) with diagnosed type 2 Diabetes for at least 5 years. Blood collection and electrophysiological tests were performed.
89184412|NCT02588898||Controls free of diabetes|Controls (both men and women) are people of the same age who are free of Diabetes. Blood collection and electrophysiological tests were performed.
89184413|NCT04068129||Burma|Patients from remote Burma clinic
89535135|NCT03084783|No Intervention|Control group|Participants receive standard care and no dexamethasone.
88859136|NCT04400526|Other|Phase 2: Developing a community-based network|Phase 2 aims to develop a community-based network through training anti-drug ambassadors (ADAs). We target to recruit a total of 150 children aged 13 - 18 as ADAs through secondary schools and community centres in the four targeted districts by sending invitation letters. The content of the workshop will be designed by our expert panel. The content of the workshop will include (1) hazardous effects of drug abuse especially less psychotropic drugs such as Cannabis, (2) signs and symptoms of drug abuse particularly less psychotropic drugs like Cannabis, (3) alternatives to drug abuse, (4) community resources available, and (5) how to refer drug abusers. Besides, all children will be taught to use the AWARD model for referrals in the workshop.
88859137|NCT04400526|Other|Phase 3: A mass promotional campaign|Phase 3 aims to engage the public to join the community-based network through anti-drug activities organized by anti-drug ambassadors. They are encouraged to design their own promotional activities for community members in the targeted districts.Types of activities can include but not limited to health talks, booths, outreaching activities, games, posters, leaflets and websites.
88859138|NCT05686746|Experimental|Baricetinib 4 mg|4 mg oral tablet daily
88859139|NCT05686746|Experimental|Baricetinib 2 mg|2 mg oral tablet daily
88859140|NCT05686746|Active Comparator|MMF|MMF 500 mg tablet twice daily
88859141|NCT03083574|Experimental|Photopheresis Theraflex ECP™|All patients will initially be treated by 6 cycles of extracorporeal photopheresis (i.e. extracorporeal photopheresis on two consecutive days) administered every 2 weeks. Patients will then be evaluated after 3 months and treatment continuation will be decided based on response.
88859142|NCT03832452|Experimental|Part A: Treatment 1|A single oral dose of 2000 mg lucerastat on Day 1 and of 4000 mg lucerastat on Day 3
88859143|NCT03832452|Placebo Comparator|Part A: Treatment 2|A single oral dose of placebo on Day 1 and 3
88859144|NCT03832452|Active Comparator|Part B: Treatment A|A single oral dose of 400 mg moxifloxacin
88859145|NCT03832452|Experimental|Part B: Treatment B|A single oral dose of 1000 mg lucerastat
88859146|NCT03832452|Experimental|Part B: Treatment C|A single oral dose of 4000 mg lucerastat
88859147|NCT03832452|Placebo Comparator|Part B: Treatment D|A single oral dose of placebo
88859148|NCT03343860|Active Comparator|Conventional|PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. Inducibility will be tested but no ablation will be carried out and a DCC post AT mapping will be performed if necessary. The procedure will end up after these steps.
88859149|NCT03343860|Active Comparator|Non inducibility|PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. Then inducibility will be tested and all inducible AT will be mapped and ablated (max 5 consecutive AT) .
88859150|NCT03083496|Active Comparator|Potassium Oxalate 5%|Prophylaxis of the teeth; an application every 48 hours; 4 sessions
88859151|NCT03083496|Active Comparator|Potassium Oxalate 10%|Prophylaxis of the teeth; an application every 48 hours; 4 sessions
88859152|NCT03083418|Experimental|Control group|No EDP treatment.
88859153|NCT03083418|Experimental|EDP therapy group|30 minutes continuous stimulation each time, two times a day, a total of one weeks of treatment .Parameters: 30min stimulation time, pacing frequency of 9 beats / min, pulse frequency is 40 hertz, the stimulus intensity (output pulse amplitude) is in the range of 0~30 units, which should be adjusted according to the daily maximum tolerance (patients with no pain and tension).
88859154|NCT05548920||Ultrasound guided Superior Vena Cava Collapsibility Index (SVC - CI)|Preoperative ultrasound guided Superior Vena Cava collapsibility Index will be measured with patient breathing spontaneously and on deep inspiration.
88859155|NCT05548920||Ultrasound Guided Inferior Vena Cava Collapsibility Index (IVC -CI)|Preoperative Ultrasound guided Inferior Vena Cava collapsibility Index will be measured with patient breathing spontaneously and on deep inspiration.
88859156|NCT03083340|Experimental|Deprexis|Participants will complete 8 weeks of online treatment via a web-based program, Deprexis.
88859157|NCT04279938|Other|Safety Run in & Main Efficacy Part|"Part 1 (safety run-in) aims to evaluate the maximum tolerated dose (MTD) of tinostamustinein combination with pembrolizumab (200mg Q3W) and rituximab (375mg/m2 Q3W). The dose of tinostamustineestablished to be safe and tolerable in this combination will be used in part 2 of the trial (main efficacy part).~The aim of part 2 is to detect signals of anti-tumour activity and to further assess the safety of this combination treatment in r/r DLBCL. The study has a strong focus on correlative research in order to identify mechanisms of response and resistance to pembrolizumab and the pembrolizumab/R-tinostamustinecombination."
88859158|NCT05686434|Experimental|Osimertinib adjuvant therapy group|Patients must be enrolled within 10 weeks of complete surgical excision and receive oral Osimertinib at a dose of 80 mg once a day for a planned duration of 3 years (156 weeks).
88859159|NCT03083106|Other|Elevoplasty treatment|Single Group Compared to Baseline, Non-Randomized, Multi-Center, Prospective
88859160|NCT03338244|Active Comparator|Azithro|Communities will receive four rounds of biannual mass azithromycin.
88859161|NCT03338244|Placebo Comparator|Placebo|Communities will receive four rounds of biannual mass placebo.
88859162|NCT03083028|Active Comparator|Non Operative|"Non-Operative~Patients who are treated non-operatively will be treated with a walking boot and allowed WBAT. Discharge from hospital will be determined by the patient walking 25m unaided by standby assistance. All patients will be reviewed between 7 and 14 days post injury with repeat x-rays by the treating surgeon."
88859163|NCT03083028|Active Comparator|Operative|The specific procedure for each patient managed operatively, both in the observational study and the RCT, will be determined by the operating surgeon. Any adverse intra-operative or post-operative event will be recorded. This includes but is not limited to death, infection and neurovascular injury. Post operatively, all patients will be NWB (non weight bearing) and placed in a POP (plaster of paris) below knee cast or walking boot. Discharge from hospital will be determined by the patient walking 25m unaided by standby assistance. The treating surgeon will review the patients after 10-14 days for a wound review, removal of sutures and change of cast to a fibreglass cast or walking boot (cam walker). The patient will be WBAT (weight bearing as tolerated) for a further 4 weeks
88859164|NCT03082950||1|human papilloma Virus (hpv) associated vulvar cancer incl. preinvasive lesions
88859165|NCT03082950||2|non-human papilloma Virus (hpv) associated vulvar cancer incl. preinvasive lesions
88859166|NCT03082794|Experimental|Study group I|Study group I (53 participants) received the NCD (details of diet: 15% protein, 75% carbohydrates, 10% fat). Both groups had 15% caloric restriction from their maintenance energy requirements.
88859167|NCT03082794|Experimental|Study group II|Study group II (51 participants) received the LCD or healthy weight maintenance diet (details of diet: 15% protein, 55% carbohydrates, 30% fat).Both groups had 15% caloric restriction from their maintenance energy requirements.
88859168|NCT05685888||The Ursodeoxycholic acid (UDCA) group|The Ursodeoxycholic acid (UDCA) group was defined as individuals who have received regular Ursodeoxycholic acid treatments during the two weeks before diagnosed COVID-19 infection (The frequency and dosage of UDCA were also recorded). Subjects matching the characteristics of this group were screened from the database according to inclusion and exclusion criteria, and characteristics of this group were collected and recorded for subsequent analysis.
88859169|NCT05685888||The non-Ursodeoxycholic acid (non- UDCA) group|The non-Ursodeoxycholic acid (non- UDCA) group was defined as individuals who didn't received regular Ursodeoxycholic acid treatments during the two weeks before diagnosed as COVID-19 infection. Subjects matching the characteristics of this group were screened from the database according to inclusion and exclusion criteria, and characteristics of this group were collected and recorded for subsequent analysis.
89384801|NCT05421117||transvaginal (TV) routes|A curette was placed into the uterine cavity and stabilized with a tenaculum for manipulation of the uterus. After separation of the adnexal mass ligaments, the manipulator was removed to perform TV retrieval. A vaginal retractor was inserted into the vagina to view the cervix and allow removal of the mass via the TV route. The posterior lip of the cervix was grasped with an Allis forceps and then pulled superiorly to expose the posterior vaginal dome. The sampler was inserted into the vagina and pushed gently against the vaginal wall to define the posterior fornix between the uterosacral ligaments. A 1-2-cm transverse TV posterior colpotomy was performed under laparoscopic control using a 3-mm monopolar hook. The sample was pulled into the vagina by holding the bag mouth from the colpotomy with ring forceps. The bag mouth was opened in the vaginal canal and the sample was transferred from the vagina.
89384802|NCT05421039||Group (1)|With the exposure
88859172|NCT04348188|Experimental|Supervised exercise group|Supervised intervention group: 3 weekly sessions of 1 hour during 6 weeks of therapeutic exercise in which aerobic physical activity will be combined with exercise strength of different muscle groups plus stretches on a supervised basis and strengthening of self-care.
88859173|NCT04348188|Active Comparator|Not supervised exercise group|Unsupervised intervention group: The same therapeutic exercise protocol will be scheduled which will be carried out autonomously without supervision with telephone tracking.
88859174|NCT03082404|Experimental|Inspiratory muscle training group|Six times a week (three supervised at hemodialysis unit and other three times at home), 5 series, 10 repetitions, two-minutes interval or according to the patient tolerance.
88859175|NCT03082404|No Intervention|Control group|The patients in this group will be evaluated at baseline and reassessed after five weeks of follow-up.
88859176|NCT03334344|Experimental|Intervention Arm|Subjects whose surgeon will be viewing VR models in connection with the in addition to the source CT/MR image
88859177|NCT03334344|No Intervention|Control Arm|Subjects whose surgeon will only be viewing CT/MR images in connection with the case
89003086|NCT05796141|Experimental|Condition 10|1) Core BWL Intervention; 2) Dyadic Action Planning; 3) Home Environment Modifications
89184414|NCT04068129||Alaska|Patients in pediatric ophthalmology clinic
89184415|NCT00716469|Experimental|LS11 Administration|"Treatment will be given with a standard 3+3 light dose escalation. The Treatment Period will be 28 days. The LS11 dose will be 30mg/m2. The initial light dose will be 50 J/cm. If criteria for dose escalation are met, then the light dose will be escalated to 100J/cm, 150J/cm and 200J/cm. Once the maximum light dose is determined, up to 6 additional patients will be treated at that level to gain further experience with this modality prior to phase II testing. In particular, at least 3 subjects <12 years of age will be enrolled at the maximum tolerable dose (MTD) to allow for further evaluation of safety in younger children. If grade 3 or 4 toxicities are noted at light dose level #1, the LS11 dose will be decreased to 20mg/m2 (2/3 of the standard dose)."
89184416|NCT00711321||2|AFFITOPE AD02 with adjuvant
89184417|NCT00711321||1|AFFITOPE AD02 without adjuvant
89184418|NCT04082598|Experimental|Tooth extraction and antibiotic treatment|Tooth extraction and Amoxicillin- clavulanic acid 875/125 mg, twice a day, for 6 days
89184419|NCT04082598|Experimental|tooth extraction and antibiotic treatment + dietary supplement|Tooth extraction and Amoxicillin- clavulanic acid 875/125 mg, twice a day, for 6 days + Bifidobacterium longum and Lactoferrin twice a day for 6days
89184420|NCT04082598|No Intervention|Tooth extraction|tooth extraction without antibiotics and/or Bifidobacterium longum and Lactoferrin
89184421|NCT02587494|Active Comparator|Early cardiac catheterization|Cardiac catheterization performed as early as possible, within 12h post ROSC following OHCA, with possible PCI during mild therapeutic hypothermia or apyrexia
89184422|NCT02587494|No Intervention|Medical arm|Initial therapy does not include cardiac catheterization. Cardiac catheterization with possible PCI is allowed after completion of mild therapeutic hypothermia or apyrexia for >24h post ROSC.
89184423|NCT04095195||Familial pancreatic cancer relatives|
89184424|NCT04095195||Peutz-Jeghers syndrome|
89184425|NCT04095195||BRCA 1/2, PALB2, p16 mutations with familiarity for PC|Known genetic mutation and at least 1 1st- or 2nd-degree relative suffering from PC
89184426|NCT04095195||Lynch syndrome with familiarity for pancreatic cancer|
89184427|NCT04095195||FAMMM syndrome|
89184428|NCT04095195||Hereditary and genetic pancreatitis|
89184429|NCT00716547|Experimental|1|
89184430|NCT00716547|Experimental|2|
89184431|NCT00716547|Active Comparator|3|
89184432|NCT00716547|Placebo Comparator|4|
89384803|NCT05421039||Group (2)|Without the exposure
89384804|NCT03609398|Experimental|RVF Vaccine|1.0 mL dose given SQ in upper arm
89535136|NCT02452645|Experimental|Intervention|The intervention will integrate: a) support from peer counselors with child care experience who will serve as team leaders for groups of FCCPs; b) tailored print and video materials; and c) a set of portable active toys to elicit changes to the nutrition and physical activity environments of family child care homes.
89384805|NCT03426657|Experimental|Durvalumab + Tremelimumab + RT|Durvalumab (1500 mg,q4W) + Tremelimumab (75 mg, q4W / since Amendment 3: 300 mg absolute dose d5) for up to a maximum of 4 doses/cycles combined with radiotherapy (35 x 2.0/1.8/1.6 Gy) followed by durvalumab monotherapy 1500mg via IV infusion q4W, starting 4 weeks after the last infusion of the combination, for up to a maximum of 8 additional durvalumab doses.
89384806|NCT02858180|Experimental|Heart Failure Cohort|"Harvoni (sofosbuvir/ledipasvir fixed dose combination)~1 pill once daily Includes 400 mg sofosbuvir (SOF) and 90 mg ledipasvir (LDV)"
89384807|NCT02858180|Experimental|Lung Disease Cohort|"Harvoni (sofosbuvir/ledipasvir fixed dose combination)~1 pill once daily Includes 400 mg sofosbuvir and 90 mg ledipasvir"
89384808|NCT03082599|Active Comparator|Emmetropia both eyes (OU) group|Symfony Toric IOL target refraction both eyes emmetropia (±0.25D).
88859178|NCT04348344|Experimental|intervention group|"health education of pulmonary rehabilitation pulmonary rehabilitation including aerobic exercise，strength training and breath training.~Patients in stable stages using the home-based rehabilitation exercise prescription, taking home exercise, using the sports bracelet and special respiratory rehabilitation app software, the home management system integrating home rehabilitation training, detection and feedback is mainly adopted, which is a combination of aerobic endurance training, intermittent strength training and inspiratory muscle training."
88859179|NCT04348344|No Intervention|control group|health education of pulmonary rehabilitation
88859180|NCT05505864|Experimental|Intervention Group|"Participants in the intervention group will be asked to wear an ACTIVPAL4 at week 0, 5, and 11.~Participants in the intervention group will be asked to fill out questionnaires assessing key variable (demographics, sedentary behaviour, and quality of life) on the SEMA3 app at week 0, 2, 4, 6, and 12.~Participants in the intervention group will receive a one-on-one behavioural counselling session online through zoom at week 0 to create personalized action plans and coping strategies to reduce and break up sedentary behaviour. The participant will update these action plans and coping strategies at the end of week 2 and 4 on the SEMA3 app.~Participants in the intervention group will receive tailored text messages the day after receiving their one-on-one counselling session for a 6-week period.~Participants in the intervention will receive one-on-one qualitative interview on zoom at week 6 to explore participants overall experience engaging in the intervention."
89384809|NCT03082599|Experimental|Nanovision group|Symfony Toric IOL target refraction for the dominant eye will be plano (±0.25D) and for the non-dominant eye -0.50 ±0.16 D.
88859181|NCT05505864|No Intervention|Control Group|"Participants in the control group will be asked to wear an ACTIVPAL4 at week 0, 5, and 11.~Participants in the control group will be asked to fill out questionnaires assessing key variable (demographics, sedentary behaviour, and quality of life) on the SEMA3 mobile app at week 0, 2, 4, 6, and 12."
88859182|NCT03832218|Other|Mitochondrial disease|Psychiatric assessment
88859183|NCT05454228||Delirium|
88859184|NCT05454228||Non-delirium|
88859185|NCT03082092|Experimental|Methylprednisolone Group|The intervention group will receive a single dose intravenous 125mg methylprednisolone diluted in 2.1ml of diluent on induction of total knee replacement.
88859186|NCT03082092|Placebo Comparator|Placebo Group|The placebo group will receive a single dose intravenous 2.1ml of 0.9% IV saline, which is transparent and has no difference in appearance to methylprednisolone, on induction of total knee replacement
88859187|NCT04401852|Active Comparator|MgSO4 group|will receive a single bolus dose of 4g MgSO4 slowly intravenous over 15-20 minutes without maintenance dose
88859188|NCT04401852|Placebo Comparator|placebo group|will receive an equal volume of isotonic 0.9% saline over 15-20 minutes
88859189|NCT03081936|Active Comparator|A1 formula|Oral consumption of Nutricia Aptamil Stage 1 formula (traditional cow milk)
88859190|NCT03081936|Experimental|A2 formula|Oral consumption of a2® Platinum Stage 1 formula (containing 100% A2® beta -casein)
88859191|NCT03081936|Active Comparator|Breast feeding|Oral consumption of breast milk
88859192|NCT03318120|Experimental|Progressive Resistance Training|Participants assigned to this arm will receive progressive resistance training under the supervision of a personal trainer at a gym facility close to their home. They will be required to perform these exercises twice a week for the first six months. They will be monitored with an activity monitor.
88859193|NCT03318120|No Intervention|Control Arm|The control arm offered to subjects with dystonia and other involuntary muscle disorders, participants will be followed at baseline and 6 months similar to what will be done in active exercise arm but this arm will not receive exercise. They will be monitored with an activity monitor.
89384810|NCT04232384|Active Comparator|Standard paracentesis group (SPG)|The patients will be asked to lie supine for 10 minutes and no changes in posture will be allowed for this period. Abdominal paracentesis will be done either by blind technique (in case the ascites is clinically detectable) or ultrasonography-guided (in cases the ascites is not clinically detectable).
88859194|NCT03398538|Experimental|Mirragen Wound Matrix Dressing|MIRRAGEN™ Advanced Wound Matrix is intended for the use in the management of wounds including diabetic ulcers. Wound matrix dressing to be used per manufacturer instructions for use on diabetic foot wounds in conjunction with offloading and Additional (outer) Dressing Application with moisture retention dressing
88859195|NCT03398538|Active Comparator|Fibracol Wound Dressing|A commercially available wound dressing to be used per manufacturer's instructions for use on diabetic foot wounds in conjunction with offloading and Additional (outer) Dressing Application with moisture retention dressing moisture retention dressing
88859196|NCT03081780|Experimental|FATE NK-100|
89003087|NCT05796141|Experimental|Condition 11|1) Core BWL Intervention; 2) Dyadic Action Planning; 3) Autonomy Support Training
89003088|NCT05796141|Experimental|Condition 12|1) Core BWL Intervention; 2) Dyadic Action Planning; 3) Autonomy Support Training 4) Home Environment Modifications
89384811|NCT04232384|Experimental|Rollover paracentesis group (ROG)|Patients with ascites will be rolled over thrice in bed laterally upto 90 degrees on either side (Figure 1) and ascitic fluid sample is drawn within 1 minute of the last rollover. There will be four steps to this i.e roll over to one side at 90 degrees and then 180 degrees to the other side, then back to the first side and then back to the center (to complete three turns). This will be done after the disinfection and cleaning of the anterior abdominal wall have been done and the personnel involved in the procedure are ready for the paracentesis. The ascitic paracentesis will be initiated within one minute of the completion of the turn. One assistant will maintain a stopwatch during this period to ensure compliance with this.
88859197|NCT04278612|Experimental|Intervention|"Provision of comprehensive care including the following:~Baby:~Measure weight and length Plot on appropriate growth charts in Road to Health Card (RTHC) Discuss with mother about the growth of the baby Identification of malnutrition and appropriate management Age-appropriate nutrition counselling Immunisation Developmental screening Vitamin A supplementation Deworming HIV Care: If mother is HIV positive -~Polymerase chain reaction (PCR) test for the baby repeated at 10 weeks~Nevirapine for the baby for six weeks~Mother:~Cervical cancer screening Provide family planning Screening tuberculosis (TB) and sexually transmitted infections (STIs)~HIV Care:~HIV positive mothers - provide ART for the mother and adherence support~HIV negative mothers- HIV test every three months while breastfeeding"
88859198|NCT04278612|Active Comparator|Control|Routine maternal and child care service delivery
88859199|NCT05430282|Active Comparator|Vestibular rehabilitation|Patients in the vestibular rehabilitation group will be asked to do vestibular exercises 3 times a day for 20 minutes, every day for one month.
88859200|NCT05430282|Experimental|Cervical exercise in addition to vestibular rehabilitation|Patients in this group will receive the same vestibular exercise program and will be asked to do additional neck exercises and they will be asked to do these exercises twice a day for ten minutes.
89384812|NCT01346501||Adalimumab|"Participants with Rheumatoid Arthritis (RA) who continued adalimumab treatment after completion of study M06-859, participated in the observational period of studies P12-069 and P12-707.~Other name for adalimumab is Humira."
89384813|NCT01346501||Non-adalimumab|Patients who discontinued adalimumab treatment after completion of the study M06-859.
89384814|NCT02034344||Group 1: Healthy participants|20 healthy participants will be enrolled.
89384815|NCT02034344||Group 2: DLE/SCLE without SLE|30 participants with Discoid Lupus Erythematosus/Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) without Systemic Lupus Erythematosus (SLE) will be enrolled.
88859201|NCT03082482|Active Comparator|Standard Treatment|Participants randomized to Standard Treatment will receive a smartphone with active service, brief advice to quit smoking (self-help materials), and 8-week supply of nicotine replacement therapy (patches), and provided 5 proactive phone counseling sessions by a trained Certified Tobacco Treatment Specialist.
88859202|NCT03082482|Experimental|Automated Treatment|Participants randomized to Automated Treatment will receive smartphone-delivered automated treatment that will provide tailored smoking cessation treatment by way of video clips, text and graphical messages. Participants will receive notifications on the study provided smartphone once a week for an 8-week treatment period. Content delivered will be specific to the participants smoking status and motivation to quit.
88859203|NCT03082170|Other|Data review|The investigators will go over the data from the test summary of participants who have already undergone post operative swallowing assessment.
88859204|NCT03082170|Experimental|FEES and SDQ|The participants will undergo six months or more after surgery swallowing assessment which will include the FEES test and the SDQ questionnaire.
88859205|NCT05096598|Experimental|ZP8396|Up to 10 single dose cohorts are planned with 8 subjects in each; 6 participants in each cohort will receive active treatment.
88859206|NCT05096598|Placebo Comparator|Placebo (ZP8396)|In each of the 10 single dose cohorts, 2 subjects will receive placebo.
88859207|NCT03081624||Preterm Preschoolers|Preterm children who haven't attend school.
88859208|NCT03081624||Term Preschoolers|Term children who haven't attend school.
88859209|NCT03308916|Experimental|Liver stiffness measurement|Transient elastography in fasting state
88859210|NCT03081702|Experimental|Hydroxychloroquine and Itraconazole|"Hydroxychloroquine, orally (by mouth), at a dose of 100 mg, 200 mg, 400 mg, or 600 mg, twice a day, every day.~Itraconazole, orally (by mouth) at 300 mg, twice a day, every day."
88859211|NCT03081546||Mild Cognitive Impairment (MCI)|"Persons with age-related Mild Cognitive Impairment (MCI) according to clinical diagnosis, consistent with Alzheimer's Association (AA) and the National Institute on Aging (NIA) diagnostic criteria.~Must be concurrently enrolled in the Rocky Mountain Alzheimer's Disease Center Bio-AD study (clinicaltrials.gov identifier: NCT02612376)."
88859212|NCT03081546||Healthy Controls|Community dwelling controls older than 55 years of age that are concurrently enrolled in the Rocky Mountain Alzheimer's Disease Center Bio-AD study (clinicaltrials.gov identifier: NCT02612376).
88859213|NCT05345964|Active Comparator|Single-dose experimental group|5mg,15mg,30mg,60mg,90mg,120mg,150mg and 180mg need to complete a single-dose clinical study. The first two dose groups had 4 subjects in each group (3 received GST-HG151 and 1 received placebo，randomly assigned), and the rest are 10 ubjects in each group (8 received GST-HG151 and 2 received placebo， randomly assigned)
88859214|NCT05345964|Placebo Comparator|Single-dose control group|5mg,15mg,30mg,60mg,90mg,120mg,150mg and 180mg need to complete a single-dose clinical study. The first two dose groups had 4 subjects in each group (3 received GST-HG151 and 1 received placebo，randomly assigned), and the rest are 10 ubjects in each group (8 received GST-HG151 and 2 received placebo， randomly assigned)
88859215|NCT05345964|Active Comparator|Multi-dose experimental group|According to the results of the SAD, it is planned to carry out multiple-dose studies in 2 to 3 dose groups. Continuous administration, 12 subjects in each group(10 received GST-HG151 and 2 received placebo， randomly assigned)
88859216|NCT05345964|Placebo Comparator|Multi-dose control group|According to the results of the SAD, it is planned to carry out multiple-dose studies in 2 to 3 dose groups. Continuous administration, 12 subjects in each group(10 received GST-HG151 and 2 received placebo， randomly assigned)
89003089|NCT05796141|Experimental|Condition 13|1) Core BWL Intervention; 2) Dyadic Action Planning; 3) Joint Feedback
89384816|NCT02034344||Group 3: DLE/SCLE with SLE|30 participants with DLE/SCLE with SLE will be enrolled.
89384817|NCT02745587|Experimental|Prostate(bed) only|external beam radiotherapy limited to the prostate(bed)
89384818|NCT02745587|Active Comparator|Prostate(bed) and pelvis|external beam radiotherapy to the prostate(bed) and pelvic lymph node regions
89384819|NCT02691845|Other|BA|Brief advice to exercise. This serves as a control condition.
89384820|NCT02691845|Active Comparator|BA + SHE + HE|Brief advice to exercise + supervised & home-based exercise + health education
89384821|NCT02691845|Experimental|BA + SHE + CBEX|Brief advice to exercise + supervised & home-based exercise + cognitive-behavioral sessions focused on increasing and maintaining exercise
88859217|NCT05345964|Active Comparator|Food Impact Study Group A|According to the results of the SAD, it is planned to select 1 dose group，10 subjects(8 received GST-HG151 and 2 received placebo， randomly assigned)，two cycles, crossover
88859218|NCT05345964|Active Comparator|Food Impact Study Group B|According to the results of the SAD, it is planned to select 1 dose group，8 subjects，two cycles, crossover
88859219|NCT04399824|Experimental|Arm I (SBRT)|Patients undergo SBRT in 5 fractions over 14 days in the absence of disease progression or unacceptable toxicity.
88859220|NCT04399824|Experimental|Arm II (HDR brachytherapy)|Patients undergo HDR brachytherapy on day 1 and a second fraction within 14 days in the absence of disease progression or unacceptable toxicity.
88859221|NCT04279782||Exclusion group|Patients with two consecutive negative results of detection for 2019 Novel Coronavirus nucleic acid from pharyngeal swabs
88859222|NCT04279782||Confirmed group|Patients with positive result of detection for 2019 Novel Coronavirus nucleic acid from pharyngeal swab
88859223|NCT05397210||Infinity-Lock™ Button System|Participants diagnosed with acute or chronic Grade Ill-VI ACJ dislocation who require treatment with an Infinity-Lock Button System who meet the inclusion criteria and none of the exclusion criteria.
88859224|NCT05393076|Experimental|Cohort 1 (Moderate hepatic impairment participants)|Eligible participants to receive single dose of linerixibat.
88859225|NCT05393076|Experimental|Cohort 2 (Matched healthy control participants)|Eligible participants to receive single dose of linerixibat
88859226|NCT05385510|Experimental|Group 1 - children with HIV|100 5-36 month old children with confirmed HIV infection.
88859227|NCT05385510|Experimental|Group 2 - children without HIV|20 5-36 month old children without HIV infection.
89184433|NCT02573025|Experimental|Test Followed by Reference|Participants will receive PEG-IFN alfa-2a BA-free formulation (Test) in Period 1, followed by PEG-IFN alfa-2a market formulation (Reference) in Period 2 on Day 1 of each period with a washout period of 14 to 21 days.
88859228|NCT05381220|Experimental|early mobilization in stroke patients|"The first day is to elevate the head of the bed and sit for 5 minutes The second day is to elevate the head of the bed for 10 minutes and sit on the edge of the bed for 5 minutes.~The third day, sit on the edge of the bed for 10 minutes, get out of bed and stand for 10 minutes, and standing still for 5 minutes. The activity time is about 25 minutes each time, and the activity frequency is 2 times a day for 3 days."
88859229|NCT05381220|No Intervention|usual care in stroke patients|usual care
89384822|NCT05336357|Experimental|Goal-Directed Therapy Group|Patients allocated to the Goal-Directed Therapy group will be monitored by the ClearSight™ System (Edwards Life Sciences, Irvine, CA, USA) in the first 24 hours after randomization, where the parameters Cardiac Index (CI), Stroke Volume (SV), Systolic Blood Pressure (SBP) and Mean Arterial Pressure (MAP) will be acquired continuously.
89535137|NCT02452645|Active Comparator|Comparison|The comparison intervention will provide print materials and videos on literacy and school readiness to children and books in both English and Spanish. Participants will also receive support from peer counselors with child care experience.
88859232|NCT04347876||Group A|COVID-19 positive with positive tuberculin test
88859233|NCT04347876||Group B|COVID-19 positive with negative tuberculin test
88859234|NCT05059704|Experimental|Circuit Class Training|Patients will participate in a total of 1.5hour/day for 8 weeks with a 1:3 (therapist to patient). The circuit will be divided into 5 specific stations, 5 to 10 minutes for warm-up tasks and 15 to 20 minutes on each station as tailored to the patient's activity level
88859235|NCT05059704|Active Comparator|Individual Task specific training|Patients will participate in a total of 1.5hour/day for 8 weeks with 1:1 (therapist to patient) ratio. During each session, all patients will perform 5 to 10 minutes warm-up tasks, then practiced the selected tasks for the rest of the time.
88859236|NCT05006352|Experimental|DNL343 (High Dose)|
88859237|NCT05006352|Experimental|DNL343 (Low Dose)|
88859238|NCT05006352|Placebo Comparator|Placebo|
88859239|NCT05418192|Experimental|Group A|Intervention Given: Enriched Environment (age-appropriate) + NDT + Therapeutic Dosing
88859240|NCT05418192|Other|Group B|Traditional Physical Therapy consisting of NDT
88859241|NCT04399434||normal pregnancy|pregnancy with a normal fetal size
89184434|NCT02573025|Experimental|Reference Followed by Test|Participants will receive PEG-IFN alfa-2a market formulation (Reference) in Period 1, followed by PEG-IFN alfa-2a BA-free formulation (Test) in Period 2 on Day 1 of each period with a washout period of 14 to 21 days.
89184435|NCT00720291|Active Comparator|Metronidazole|Subjects who are randomly assigned to receive metronidazole 500 mg po for a period of 7 days following diagnosis of asymptomatic BV.
88859242|NCT04399434||fetal growth restriction|fetal birth weight is below two standard deviations of the average weight for the same gestational age, or below the 10th percentile of normal weight for the same age
88859243|NCT04399434||fetal macrosomia|fetal birth weight ≥ 4000g
88859244|NCT04760574||Case group|HIV infected men who have sex with men
88859245|NCT04760574||Control group|HIV non-infected men
88859246|NCT03237390|Experimental|Treatment (gemcitabine hydrochloride, ribociclib)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and ribociclib PO QD on days 8-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
88859247|NCT05328804|Experimental|rhTPO|rhTPO will be injected subcutaneously at 300 u/kg daily for 14 days.
88859248|NCT05328804|Experimental|Herombopag|Herombopag will be taken orally at 5 mg daily for 28 days.
88859249|NCT05328804|Experimental|Herombopag in combination of rhTPO|Herombopag will be taken orally at 5 mg daily for 28 days，while rhTPO will be injected subcutaneously at 300 u/kg daily for 14 days
88859250|NCT05348850||Study Group|"Athletes with patellofemoral pain syndrome will be selected Muscle contractile properties and functional performance will be assessed for athletes with patellofemoral pain syndrome .~Data will be collected from all athletes regarding age, gender, training intensity running experience and previous injuries.~By the end of the assessment it will be detected if muscle contractile properties of vastus medialis and vastus lateralis is a determinant factor that influence functional performance in runners with patellofemoral pain syndrome."
88859251|NCT05340348|Other|Patient library|All the patients are included in one arm. They will undergo various type of samples.
88859252|NCT03293238|Active Comparator|Joint Line Ultrasound|Patients assigned to this group receive a standard medial or lateral joint line injection of Euflexxa aided by ultrasound guidance while sitting up.
88859253|NCT03293238|Sham Comparator|Joint Line Landmark|Patients assigned to this group receive a standard medial or lateral joint line injection of Euflexxa without ultrasound guidance while sitting up.
88859254|NCT03293238|Active Comparator|Suprapatellar Ultrasound Guided|Patients assigned to this group receive an injection of Euflexxa while lying down into the suprapatellar pouch aided by ultrasound guidance.
88859255|NCT03293238|Sham Comparator|Suprapatellar Landmark|Patients assigned to this group receive an injection of Euflexxa while lying down into the suprapatellar pouch without ultrasound guidance.
88859256|NCT03292068|Experimental|Acupuncture, acupressure|"Intervention with Pyonex-needles & Usual care; applied to the acupoints LI4 , LI11, PC6 and ST36 bilaterally before surgery. Pyonex needles are embedded in a 2 mm round plastic piece sitting on a round, skin friendly patch of about 8 mm in diameter. The patch can remain for seven days. The needle can be stimulated by gently touches the plastic bubble by the patch.~Intervention Acupressure & Usual care; a 'kulplåster (1.5 mm a ball on a small piece of adhesive tape) both ears before postoperative drug administration. Kulplåster can remain for ten days or until they fall off. Children and their parents will be asked to fill in a diary of when the needle is stimulated, for what reason and when the symptoms are alleviated. In the diary is also filled in on the kulplåster remains."
88859257|NCT03292068|Experimental|Timbal diet|"Timbal diet including ice cream & Usual care.The specially designed diet, originally made for patients suffering of dysphagia, named timbalkost will be used. The specially designed food/diet, timbalkost will be given as lunch and dinner. The consistency of timbalkost is smooth. It does not require more thorough processing of the mouth. As a snack, a protein-enriched ice cream, made with egg yolks and cream, will be made available. The food will be given to the child for 3-7 days depending on how quickly the child can return to normal food. A powder that jellify liquids to facilitate swallowing will also be used if and when needed. The children or their parents will be asked to fill in a food diary during one week after surgery."
88859258|NCT03292068|Other|Extended telephone counseling|Extended telephone counseling & Usual care : A nurse will contact the child, or the child´s parents, by telephone on day 1, 3, 5 and 10 for extended telephone counseling postoperatively (POD), to provide support and information. The child's well-being will be assessed, response given to queries and concerns, advice and explanations related to the problems expressed or identified, proper interventions will be promoted and reassurance provided. The nurse will fill in a protocol on what topics the counseling was about at each call and the child and/or parent a diary.
88859259|NCT04400136|No Intervention|GROUP A - no PPI|no PPI treatment (control group)
88859260|NCT04400136|Experimental|GROUP B PPI 1/day for 6 months|(standard dose-long term): Lansoprazole oral tablets 30 mg once daily (before breakfast on an empty stomach) for 6 months
88859261|NCT04400136|Experimental|GROUP C PPI 1/day for 3 months|(standard dose-short term): Lansoprazole oral tablets 30 mg once daily (before breakfast on an empty stomach) for 3 months
88859262|NCT04941066|Experimental|Active neurofeedback|Receiving feedback signals from the rumination-related brain functional connectivity.
88859263|NCT04941066|Sham Comparator|Sham neurofeedback|Receiving artificially generated feedback signals.
88859264|NCT04938336||expert healthcare professionals|Delphi Procedure
88859265|NCT04938336||healthcare professionals, patients and informal carers|interviews
88859266|NCT04932252|Experimental|A4368 - Dose 1|Single dose of A4368 or placebo tablet, orally administered
88859267|NCT04932252|Experimental|A4368 - Dose 2|Single dose of A4368 or placebo tablet, orally administered
88859268|NCT04932252|Experimental|A4368 - Dose 3|Single dose of A4368 or placebo tablet, orally administered
88859269|NCT04932252|Experimental|A4368 - Dose 4|Single dose of A4368 or placebo tablet, orally administered
88859270|NCT04932252|Experimental|A4368 - Dose 5|Single dose of A4368 or placebo tablet, orally administered
88859271|NCT04932252|Experimental|A4368 - Dose 6|Single dose of A4368 or placebo tablet, orally administered
88859272|NCT04932252|Experimental|A4368 - Dose 1 repeated|Multiple dose of A4368 or placebo tablet, orally administered daily for 14 consecutive days
89535138|NCT03228355|Active Comparator|Levcromakalim|
88859273|NCT04932252|Experimental|A4368 - Dose 2 repeated|Multiple dose of A4368 or placebo tablet, orally administered daily for 14 consecutive days
88859274|NCT04278300||case|patient with age-related exudative macular degeneration
88859275|NCT04278300||control|Patient with no macular disorder and in need of cataract surgery
89535139|NCT03228355|Placebo Comparator|Saline|
89535140|NCT05232617||Rheumatological rehabilitation training|
88859276|NCT02984436||ED Patients with Acute Chest Pain|Emergency Department (ED) Patients with Acute Chest Pain will have blood samples collected for High sensitivity cardiac troponin T (hs-CTnT) analysis. Results from this analysis will be integrated into the HEART Score/Pathway. It will later be seen if integration of the hs-cTnT outperforms the use of HEART Score/Pathway alone.
88859277|NCT05266014|Experimental|tinlarebant|Daily, oral administration of one tinlarebant.
88859278|NCT03693144|Experimental|Intervention Group 1 Full LIITA3H App|Participants were given the LIITA3H app, which is a combination product consisting of 3 main features that tracked their visits to fast food restaurants (using the ELI feature), sent tailored text messages to prompt healthy choices when they were in a fast food restaurant (using the POP feature), and allowed them to submit pictures of their food (using the SNAP feature).
88859279|NCT03693144|Active Comparator|Control Group 2 Partial LIITA3H App|Participants were given the LIITA3H app that tracked their visits to fast food restaurants (using the ELI feature) and they submitted pictures of their food (using the SNAP feature). However, they did not receive tailored text messages.
88859280|NCT03693144|Other|Control Group 3 LIITA3H Location only|Participants were given the LIITA3H app that tracked their visits to fast food restaurants (using the ELI feature) but they did not receive tailored messages or submit pictures of their food.
88859281|NCT04902768||Adults with congenital heart disease|
88859282|NCT02984670|Experimental|Behavior Therapy|
88859283|NCT02984670|Experimental|Cognitive Therapy|
89384823|NCT05336357|No Intervention|Conventional Therapy Group|Patients allocated to the Conventional Therapy Group will be treated according to the assistant team of the Emergency Unit, where will be measured the following parameters: invasive or non-invasive blood pressure (decided by the assistant team), peripheral oximetry, heart and respiratory rate, urinary output, in association with clinical history, complete physical examination and laboratory and imaging tests.
88859284|NCT02984670|Other|Waitlist|
88859285|NCT02984592||Group 1|The participants in group 1 will state that they participate regular exercise programs in the previous 6 months
88859286|NCT02984592||Group 2|The participants in group 2 will state that they do not perform any regular exercise in previous 6 months.
88859287|NCT04857840|Experimental|Arm A: Investigational Product /Period 1,2 and 3 if any (open label)|Firibastat 1000 mg tablets QD - 12 weeks
89184436|NCT00720291|Placebo Comparator|Placebo|Subjects who are randomly assigned to receive a placebo for a period of 7 days following the diagnosis of asymptomatic BV.
89384824|NCT03160885|Experimental|Initial treatment period - Tralokinumab Q2W|"Week 0 to Week 16~Two subcutaneous (SC) injections of tralokinumab as a loading dose on Day 0, followed by a SC injection of tralokinumab Q2W regimen for 16 weeks"
88859288|NCT04857840|Placebo Comparator|Arm B: Placebo/Period1 only|Placebo tablets QD 12 weeks in Period 1 only, followed by open label Period 2 and 3 if any.
88859289|NCT04582968|Experimental|Pyrotinib Plus Capecitabine combined with brain radiotherapy|Fractionated stereotactic radiotherapy(FSRT) or whole brain radiation therapy (WBRT) Drug: Pyrotinib combined with capecitabine pyrotinib 400 mg once daily; Capecitabine 1000 mg/m2 per day on day 1 through 14, every 21 days.
88859290|NCT04834284||Helicopter Emergency Medical Services (HEMS)|Patients transported to the comprehensive stroke centre at least in some part by a HEMS unit
88859291|NCT04834284||Ground Emergency Medical Services (GEMS)|Patients transported to the comprehensive stroke centre solely by an ambulance
88859292|NCT04563468|Experimental|Strength inspiratory muscle training group|Strength IMT
88859293|NCT04563468|Sham Comparator|Endurance inspiratory muscle training group|Endurance IMT
88859294|NCT03261570|Active Comparator|Pyridostigmine and Placebo|Pyridostigmine 60mg by mouth one day and Placebo (Lactulose 50mg) by mouth on a different day
88859295|NCT03261570|Active Comparator|Digoxin and Placebo|Digoxin 0.5mg (500mcg) by mouth one day and Placebo (Lactulose 50mg) by mouth on a different day
88859296|NCT05292612|Experimental|Standard therapist-guided iCT-SAD vs. Waitlist|"to examine if standard iCT-SAD delivered in Chinese is superior to waitlist.~participants in the experimental group would receive iCBT(C&W) for SAD under the guidance of trained therapist."
88859297|NCT05292612|Experimental|Guided self-help iCT-SAD vs. Waitlist|"to examine if guided self-help iCT-SAD delivered in Chinese is superior to waitlist.~participants in the experimental group would receive iCBT(C&W) for SAD under the guidance of trained coaches."
89184437|NCT00711399||group A|Study group
89184438|NCT00711633|Experimental|1|the fermented preterm formula (FPF)
89184439|NCT00711633|Placebo Comparator|2|formula adapted for preterm infants (PF)
89535141|NCT05021289|Experimental|Guided İmagery|• participants were given one session of guided imagery.
88859298|NCT05292612|Experimental|Standard therapist-guided iCT-SAD vs. Guided self-help iCT-SAD|"to examine if guided self-help iCT-SAD is noninferior to standard iCT-SAD.~participants would be randomised into two groups. one group of participants would receive iCBT(C&W) for SAD under the guidance of trained therapist while the other group of participants would receive iCBT(C&W) for SAD under the guidance of trained coaches."
89184440|NCT05684016|Active Comparator|Control|A control population (Non RRMS) will include a minimum of 20 age and gender matched healthy patients from the George Washington University (GWU) neurology outpatient clinic (being compared with those RRMS patients being treated with Gilenya® ) for whom Brain MRI's are being ordered as a result of their having headaches, dizziness, or other conditions where there is no physical evidence for neurologic impairment. All control patients will only be recruited by the full time Neurology Faculty at the GWU Medical Faculty Associates (MFA). Control patients will be asked to consent to have NeuroQuant added to their routine Brain MRI which will add 7 minutes to their time in the MRI scanner to obtain additional image data.
88859299|NCT03227562|Other|Responder|The 2 arms will be created according to the early response to risperidone (responder vs. non responder)
88859300|NCT03227562|Other|Non responder|The 2 arms will be created according to the early response to risperidone (responder vs. non responder)
88859301|NCT04277364|Active Comparator|High dose phosphatidic acid|750mg of phosphatidic acid per day for 8 weeks
88859302|NCT04277364|Active Comparator|Low dose phosphatidic acid|375mg of phosphatidic acid per day for 8 weeks
88859303|NCT04277364|Placebo Comparator|Placebo|750mg of corn starch per day for 8 weeks
88859304|NCT05276778||People with type 2 diabetes|People diagnosed with type 2 diabetes age 18-70
88859305|NCT04557228|Placebo Comparator|Placebo|Study participants will receive 4 weeks of supplementation with 900mg placebo supplements
88859306|NCT04557228|Experimental|Phosphatidylserine Supplementation|Study participants will receive 4 weeks of supplementation with 900mg phosphatidylserine supplements.
88859307|NCT04278378|Active Comparator|Riboflavin|1.6 mg riboflavin / day for 24 weeks
88859308|NCT04278378|Experimental|Folic Acid|0.4 mg folic acid/ day for 24 weeks
88859309|NCT04278378|Experimental|Riboflavin + Folic Acid|1.6mg Riboflavin + 0.4 mg Folic Acid / day for 24 weeks
88859310|NCT04278378|Placebo Comparator|Placebo|
88859311|NCT04399512|Active Comparator|Patients with liver cirrhosis|prevalence of apical periodontitis will be checked and non-surgical root canal treatment will be given to the patients with apical periodontitis and change in MELD(model for end stage liver disease) will be checked after treatment.
88859312|NCT04399512|Active Comparator|Normal healthy patients|prevalence of apical periodontitis will be checked and non-surgical root canal treatment will be given to the patients with apical periodontitis
88859313|NCT04399278|Other|Group A|The EEO test will be applied first over 15 seconds and secondly over 30 seconds (each EEO test separated by 1 minute wash-out period)
88859314|NCT04399278|Other|Group B|The EEO test will be applied first over 30 seconds and secondly over 15 seconds (each EEO test separated by 1 minute wash-out period)
88859315|NCT04797468|Experimental|HLX23|HLX23 administered IV.
89384825|NCT03160885|Placebo Comparator|Initial treatment period - Placebo|"Week 0 to Week 16 (Initial treatment period):~Two subcutaneous (SC) injections of placebo as a loading dose on Day 0 followed by a SC injection of placebo Q2W regimen for 16 weeks"
89384826|NCT03160885|Experimental|Maintenance treatment period - Tralokinumab Q2W|"Week 16 to Week 52~Tralokinumab responders from the initial treatment period re-randomised at Week 16 and administered tralokinumab maintenance subcutaneous injection regimen Q2W for 36 weeks"
89384827|NCT03160885|Experimental|Maintenance treatment period - Tralokinumab Q4W|"Week 16 to Week 52~Tralokinumab responders from the initial treatment period re-randomised at Week 16 and administered tralokinumab maintenance subcutaneous injection regimen Q4W for 36 weeks.~Participants in this group receive alternating doses of tralokinumab SC injection and placebo SC injection every 2 weeks"
88859316|NCT04785924|Other|Observation Treatment Group|All patients observed while treated with IMI/REL.
88859317|NCT04514562|Other|Intervention|NeVa Stent Retrievers
89003090|NCT05796141|Experimental|Condition 14|1) Core BWL Intervention; 2) Dyadic Action Planning; 3) Joint Feedback; 4) Home Environment Modifications
89003091|NCT05796141|Experimental|Condition 15|1) Core BWL Intervention; 2) Dyadic Action Planning; 3) Joint Feedback; 4) Autonomy Support Training
88859318|NCT04509180|Experimental|Catheter ablation group|Patients undergoing catheter procedure will be put under conscious sedation and local anesthesia. Pulmonary vein isolation and posterior wall isolation will be performed with a radiofrequency ablation catheter (20-45W, open-tip irrigation). Ablation index will be used for the lesion formation guidance (450-500 on anterior aspects; 350-400 on the posterior aspects). A wide antral circumferential ablation will be performed for pulmonary veins and a box lesion set for the posterior left atrial wall. Voltage mapping and signal analysis performed by the operator will be used to assess electrical isolation of the pulmonary veins and posterior wall and to identify gaps in ablation lines. At the end of procedure, an implantable loop recorder will be inserted in the left parasternal region.
88859319|NCT04509180|Active Comparator|Convergent group|Patients undergoing convergent procedure will be put under general anesthesia. A minimally invasive epicardial radiofrequency ablation (30W, 90s) of posterior wall will be performed through a subxiphoid window. Monitoring of the esophageal temperature will be performed with an esophageal temperature probe set at 38°C. Next, an endocardial radiofrequency ablation (20-40W, open-tip irrigation; ablation index 450-500 anteriorly and 350-400 posteriorly) of pulmonary veins in a wide antral circumferential fashion will be performed. Voltage mapping and signal analysis performed by the operator will be used to assess the electrical isolation of the pulmonary veins and posterior wall and to identify the gaps in ablation lines. At the end of procedure, an implantable loop recorder will be inserted in the left parasternal region.
88859320|NCT04509024|Experimental|Incidental training|Participants undergo novel non-linguistic incidental category learning training.
88859321|NCT04509024|Active Comparator|explicit training|Participants undergo traditional explicit language learning.
88859322|NCT04348110|Placebo Comparator|Placebo tablets|
88859323|NCT04348110|Experimental|Blueberry Chewable Tablets|
88859324|NCT04506294|Experimental|eScreen Group|After randomization at baseline, use eScreen system (child screening component and parent information component) for 6 weeks.
88859325|NCT04506294|No Intervention|Usual Care Group|Treatment as usual from baseline. Optional access to the game only (no screening, no parent information component) after completion of T3 assessment (~12 weeks)
88859326|NCT05251818|Active Comparator|Acupressure grubu|"The first thing after the operation is to apply the thumb tool for approximately seven minutes, with 15 seconds of preparation and 1.5 minutes of application at each point of the LI4 and TH6 acupuncture points (the equivalent of working each point).The second application will be repeated three hours after the first application, with the same procedure.~By the researcher, hourly monitoring will be done until the bowel sounds of the puerperant are heard, and the puerperant will be followed up until the gas and defecation output. The gas and defecation time of the puerperants will be questioned every 12 hours, and the information will be obtained by making a phone call with those who are discharged without defecation."
88859327|NCT05251818|Active Comparator|Control Group|"No application will be made to the control group.. From the first postoperative hour, the researcher will follow the bowel sounds every hour until the first bowel sounds of the patient are heard.~Postpartum women will be followed until gas and defecation are released. The gas and defecation time of the puerperants will be questioned every 12 hours, and the information will be obtained by making a phone call with those who are discharged without defecation."
88859328|NCT04398810|Experimental|the low-pressure pneumoperitoneum during surgery|"A. Inclusion criteria Patients who underwent elective gallbladder surgery~Cholelithiasis~Chronic cholecystitis~Gallbladder polyps~Gallbladder adenoma~Porcelain gallbladder~The experimental group controls the CO2 flow that is injected into the abdominal cavity during surgery and maintains the pressure in the abdominal cavity at a low level of 5 mmHg to perform the surgery."
88859329|NCT04398810|Experimental|the standard-pressure pneumoperitoneum during surgery|"A. Inclusion criteria Patients who underwent elective gallbladder surgery~Cholelithiasis~Chronic cholecystitis~Gallbladder polyps~Gallbladder adenoma~Porcelain gallbladder~In the case of the control group, surgery is performed while maintaining the pressure in the abdominal cavity at 12 mmHg as generally performed during surgery."
88859330|NCT02084628|Experimental|Gadoxetate disodium (Eovist/Primovist, BAY86-4873)|Participants to receive single dose of Eovist/Primovist as a manual injection at a dose of 0.1 milliliter per kilogram (mL/kg) body weight (BW) (0.025 millimole [mmol]/kg BW), followed by a flush of at least 5 mL saline (sodium chloride 0.9 percent [%] solution) manually.
88859331|NCT04760418|Experimental|4 week baseline|Participants in this arm are randomized to a 4-week baseline period with repeated weekly assessment after the initial intake. This is followed by 12 sessions of weekly individual manualized Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure (COPE)
88859332|NCT04760418|Experimental|6 week baseline|Participants in this arm are randomized to a 6-week baseline period with repeated weekly assessment after the initial intake. This is followed by 12 sessions of weekly individual manualized Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure (COPE)
88859333|NCT04277520|Active Comparator|Continous rotation|instrumentation was done in continuous rotation motion
88859334|NCT04277520|Active Comparator|Reciprocation|instrumentation was done in reciprocation motion
88859335|NCT04277520|Active Comparator|Adaptive motion|instrumentation was done in adaptive motion
88859336|NCT04399902|Experimental|Study blanket|Two standard warmed hospital blankets will be placed on top of the patient and the study blanket on top of the standard warmed blankets, covering as much of the patient as possible, at the discretion of the care team. At all times, clinicians should ensure that the study blanket does not touch the patient's bare skin.The blanket will remain on the patient through their path of care, and removed from the patient at arrival to the ICU/final phase of care, or if the patient temperature exceeds 38˚C at any point.
88859337|NCT04277754||two-year-old children with typical development|
88859338|NCT04451772|Experimental|Part 1: Elsubrutinib Dose A and Upadacitinib Dose A|Participants will receive Elsubrutinib Dose A and Upadacitinib Dose A once daily (QD).
88859339|NCT04451772|Experimental|Part 2: Elsubrutinib Dose A and Upadacitinib Dose B|Participants will receive Elsubrutinib Dose A and Upadacitinib Dose B QD.
88859340|NCT04451772|Experimental|Part 3: Elsubrutinib Dose A and Upadacitinib Placebo|Participants will receive Elsubrutinib Dose A and Upadacitinib placebo QD.
88859341|NCT04451772|Experimental|Part 4: Elsubrutinib Placebo and Upadacitinib Dose A|Participants will receive Elsubrutinib placebo and Upadacitinib Dose A QD.
88859342|NCT03831984|Active Comparator|0,09% Bromfenac|Topical 0,09% Bromfenac twice daily 3 days before surgery
89384828|NCT03160885|Placebo Comparator|Maintenance treatment period - Placebo|"Week 16 to Week 52~Tralokinumab responders from initial treatment period randomised at Week 16 and administered placebo subcutaneous maintenance injection for 36 weeks"
89384829|NCT03160885|Placebo Comparator|Maintenance treatment period - Placebo (tralokinumab naive)|"Week 16 to Week 52~Placebo responders from the initial treatment period re-assigned at Week 16 and administered placebo maintenance subcutaneous injection regimen Q2W for 36 weeks"
88859343|NCT03831984|Placebo Comparator|0,1% sodium hyaluronate|Topical 0,1% sodium hyaluronate twice daily 3 days before surgery
89384830|NCT03160885|Experimental|Open-label treatment - Tralokinumab 300 mg Q2W + optional TCS|"Week 16 to Week 52~Subjects receiving initial treatment with tralokinumab Q2W or placebo Q2W assigned to open-label treatment at Week 16 and administered tralokinumab subcutaneous (SC) injection + optional TCS* regimen Q2W~OR~Subjects receiving maintenance treatment with tralokinumab Q2W/Q4W or placebo assigned to open-label treatment after Week 16 and administered tralokinumab SC injection + optional TCS regimen Q2W~• TCS = topical corticosteroids"
89384831|NCT00730717|Experimental|1|Patients who are not concurrently receiving methotrexate treatment for pyoderma gangrenosum
88859344|NCT02084706|Active Comparator|Triamcinolone (20 g) and 2% Lidocaine injection over A1 pulley|Group one subjects will receive an injection of 0.5mL (20 g) of Triamcinolone and 0.5 mL of 2% Lidocaine over the A1 pulley.
88859345|NCT02084706|Experimental|J-tip lidocaine administration, then steroid injection|"Group two subjects will receive a needle free J-tip administration of 0.5mL of 2% lidocaine prior (2-10 minutes) to needle injection of 0.5mL of Triamcinolone (20 g) over the A1 pulley."
88859346|NCT04447014||Cohort 1|Subjects with confirmed adrenocortical cancer (ACC)
88859347|NCT04686084|Experimental|CT scan|CT scan (MDCT, standard of care) and DE-CBCT (Investigational)
88859348|NCT04433988|Placebo Comparator|Control group|100 patients will receive standard treatment plus placebo
88859349|NCT04433988|Experimental|Pentoxifylline group|100 patients will receive standard treatment plus pentoxifylline 1200 mg/day
89384832|NCT00730717|Experimental|2|Patients who are receiving concurrent methotrexate for pyoderma gangrenosum
89384833|NCT01332409||Patients prescribed salmeterol and fluticasone|Patients with chronic obstructive pulmonary disease prescribed salmeterol and fluticasone during study period
89384834|NCT03181451|Active Comparator|30 mg Ferric Maltol|12 subjects will receive 30 mg Ferric Maltol twice daily for 9 days (Days 1-9) plus a final 30mg dose on the morning of Day 10. PK study Day 1 & Day 10.
88859350|NCT04425408|Experimental|Positional pillow followed by vibrating belt|26 patients with positional sleep apnea will be randomized to spend 3 nights using a positional pillow followed by a vibrating belt. The time spend on supine position will be monitored on each device and a satisfaction questionnaire as well as a sleep quality questionnaire will be performed after the use of each device.
88859351|NCT04425408|Experimental|Vibrating belt followed by positional pillow|26 patients with positional sleep apnea will be randomized to spend 3 nights using a vibrating belt followed by a positional pillow. The time spend on supine position will be monitored on each device and a satisfaction questionnaire as well as a sleep quality questionnaire will be performed after the use of each device.
88859352|NCT04685538|Experimental|Chloroprocaine 3%|All the eligible patients will be administrated by Chloroprocaine 3 % according to the randomization criteria.
88859353|NCT04685538|Active Comparator|Tetracaine 0.5%|All the eligible patients will be administrated by Tetracaine 0.5% according to the randomization criteria.
89384835|NCT03181451|Active Comparator|16.6 mg Ferric Maltol|12 subjects will receive 16.6 mg Ferric Maltol twice daily for 9 days (Days 1-9) plus a final 16.6mg dose on the morning of Day 10. PK study Day 1 & Day 10.
89384836|NCT03181451|Active Comparator|7.8 mg Ferric Maltol|12 subjects will receive 7.8 mg Ferric Maltol twice daily for 9 days (Days 1-9) plus a final 7.8mg dose on the morning of Day 10. PK study Day 1 & Day 10.
88859354|NCT03255798|Other|G2 and G3 implantation|Two iStent inject stents and one iStent Supra stent
88859355|NCT04746222|Experimental|Treatment|Single dose of 30 oral capsules containing FMT from a stool bank
88859356|NCT04746222|Placebo Comparator|Placebo|Single dose of 30 oral placebo capsules
88859357|NCT04746768|Experimental|exercise and nutritional support|exercise and nutritional support program during an active support phase (0 to 6 months) followed by an empowerment phase (from 6 to 12 months)
88859358|NCT04344678|Placebo Comparator|Control group|Escitalopram 20 mg tablet plus one placebo tablet
88859359|NCT04344678|Experimental|Sildenafil group|Escitalopram 20 mg tablet plus one Sildenafil 50 mg tablet
88859360|NCT03212118|Other|Treatment as usual|"Treatment as usual untouched. This is the standard The Norwegian Labour and Welfare Administration (NAV) procedure."
88859361|NCT03212118|Active Comparator|Two talks|Two standard talks (not including elements from motivational interviewing)
88859362|NCT03212118|Experimental|Motivational interviewing|Two standard talks with a motivational interviewing content.
88859363|NCT04056312|Experimental|Group memory retraining|Experimental group will be receiving memory retraining exercises via lap top twice a week for 5 weeks. Four people in a group.
88859364|NCT04056312|Placebo Comparator|Placebo|Experimental group will be receiving memory retraining exercises via lap top twice a week for 5 weeks. Four people in a group.
88859365|NCT03249558|Active Comparator|Morphine, Duloxetine|Subjects will take a maximum dose of 60 mg/day of extended release morphine capsules and 60 mg of duloxetine capsules.
89384837|NCT01334593||Rectal Cancer|
89384838|NCT03495973||Participants with Crohn's Disease (CD)|Participants with CD will be assessed for the effectiveness of ustekinumab in accordance with national guidelines and routine standard of care. Data will be prospectively collected with the aid of the Swedish inflammatory bowel disease (IBD) registry, SWIBREG and medical records of each participant. Data will also be collected retrospectively from SWIBREG and other databases including national databases such as the participant registry in which cases the national databases will be considered source data.
89384839|NCT00406783|Experimental|5-mg Desloratadine tablet|
89384840|NCT00406783|Placebo Comparator|Placebo tablet|
89384841|NCT03179891|Experimental|Interictal Period|All subjects received 12.5 mg DBF during the interictal state.
89384842|NCT03179891|Experimental|Ictal/Peri-ictal Period|All subjects received 12.5 mg DBF during the ictal/peri-ictal state.
88859366|NCT03249558|Placebo Comparator|Morphine, Placebo Duloxetine|Subjects will take a maximum dose of 60 mg/day of extended release morphine capsules and placebo duloxetine capsules.
88859367|NCT03249558|Placebo Comparator|Placebo Morphine, Duloxetine|Subjects will take placebo morphine capsules and 60 mg of duloxetine capsules.
88859368|NCT03246828|Experimental|Omission of gliclazide|
88859369|NCT04746300||Group 1: no sequencing|Participants in this group, for which DNA sequencing could not be reported due to a variety of (quality/technical) reasons, will be treated with standard of care therapy. This group is therefore comparable to patients treated outside the Radboudumc.
88859370|NCT04746300||Group 2: no druggable aberration|Participants in this group received a DNA sequencing report identifying no biomarkers to which a logical treatment option can be connected. These participants will also receive standard of care therapy.
88859371|NCT04746300||Group 3: allocated to personalized treatment|Participants in this group received a DNA sequencing report which identified presence of a biomarker allowing the participant to be treated with a personalized therapy. This therapy could range from immunotherapy, or PARP inhibitors, to other medication.
88859372|NCT02476812|Experimental|Positive Piggy Bank|"Patients randomized to this group will meet with a research assistant who provides an overview of the intervention, explains the rationale for this treatment, and then gives the patients the instructions, piggy bank, and currency slips. Participants in this group will receive instructions. At the end of the monitoring period, 30 days, they are to close their account by opening the piggy bank and reviewing all of the slips of paper.~Study personnel will contact patients within 72 hours to answer questions. Participants will also be contacted at 30 days to let patients know that they should read all of their currency slips in one sitting. They are also told that the intervention part of the study is over and are asked they complete the follow up questionnaires. Then, study personnel will call again to let the participant know that the second set of questionnaires will be arriving by mail."
88859373|NCT02476812|No Intervention|Waitlist Control|The control group will serve to show the relative benefits of the Positive Piggy Bank intervention. Those in the control group who meet study criteria will also receive regular care after their epidural steroid injection (e.g., physician visits, medication maintenance, standard patient education). These patients will follow the same questionnaire follow up procedures as listed above including phone calls. The phone call at 72 hours will be to simply thank them for their participation in the study. At the end of the study period, approximately three months, Wait List control patients will also be offered the Positive Piggy Bank intervention along with the supportive phone calls. Should they choose to try the Positive Piggy Bank intervention, they will be required to return to the center to pick up supplies and receive instruction. They will also complete study questionnaires by mail at 30 days to assess intra-individual change.
88859374|NCT04316442|Experimental|STI-6129 infusion|Intravenous infusion to be given with prophylaxis for infusion reactions if necessary.
88859375|NCT02090712||Reperfusion strategies|Patients submitted to thrombolysis with tenecteplase after acute myocardial infarction will be transferred to a tertiary center and angiography with the intention to treat the culprit artery will be performed in 3 - 48 hours (preferably first 24 hours).
88859376|NCT02090712||Primary PCI|Patients with contra-indication to thrombolytics or able to reach the catheterization laboratory within 90 minutest will be transferred for primary angioplasty, according to current guidelines.
88859377|NCT03206190|Experimental|Mutation carrier|The participants will be tested genetically if they carry a disease causing mutation or not. Depending on their genetic test result they will at the end of the study divided into two groups. The clinician will be blinded throughout the entire study to the genetic results.
88859378|NCT03206190|Experimental|Non-mutation carrier|The participants will be tested genetically if they carry a disease causing mutation or not. Depending on their genetic test result they will at the end of the study divided into two groups. The clinician will be blinded throughout the entire study to the genetic results.
88859379|NCT03206190|Experimental|Known-mutation carriers but presymptomatic|In a third arm (open arm) we will also include positive predictive tested participants which know that they are carrying a known mutation but are at inclusion into the study asymptomatic (according to the inclusion / exclusion criteria).
88859380|NCT04277052|Experimental|Group 1|Muscle disorders
88859381|NCT04277052|Experimental|Group 2|Disc displacements
88859382|NCT04277052|Experimental|Group 3|Other common joint disorders
88859383|NCT04277052|Experimental|Group 4|Mix type
88859384|NCT04277052|Experimental|Group 5|Healthy individuals
88859385|NCT03204396|Active Comparator|Intervention group|Dulaglutide (Trulicity®) 1.5 mg in 0.5 ml, via pen s.c. once weekly for 12 weeks.
88859386|NCT03204396|Placebo Comparator|Placebo group|0.5 ml normal saline (0.9% sodium chloride (NaCl)), injection s.c. via syringe once weekly for 12 weeks.
88859387|NCT04398498||Cohort A: Clinical Practice|Subjects more than 60 days post-transplant
88859388|NCT04398498||Cohort B: Long Term Follow-Up|Subjects who are at least 2 years post transplant up to 5 years post-transplant
88859389|NCT03631680||'Bilateral Oophorectomy Surgery' Group|Premenopausal women planning to undergo a laparoscopic, elective bilateral oophorectomy surgery.
88859390|NCT03631680||'Comparative (Control)' Group|Premenopausal women with normal menstrual cycles from a previously completed study at Pennington Biomedical Research Center [NCT01748994] will serve as a comparator (control) group.
88859391|NCT03174132|Experimental|Restylane Perlane Lidocaine|Restylane Perlane Lidocaine will be injected into one side of the nasolabial fold at day 1
88859392|NCT03174132|Active Comparator|Restylane Perlane|Restylane Perlane will be injected into the opposite side of the nasolabial fold on day 1
89003092|NCT05796141|Experimental|Condition 16|1) Core BWL Intervention; 2) Dyadic Action Planning; 3) Joint Feedback; 4) Autonomy Support Training; 5) Home Environment Modifications
89003093|NCT05793138|Placebo Comparator|Usual Care|Participants will receive usual dialysis care for 12 months, then they will receive the geriatric care model.
89003094|NCT05793138|Active Comparator|Geriatric Care Model|While specifics of the intervention will be finalized after aim 2, the investigators anticipate participants will complete the GOLD and telehealth prioritization visit. Information gathered will guide the research geriatric team's recommendation report to the participants' dialysis care team. The dialysis teams will receive training on how to use the recommendation report and local resources to initiate geriatric problem management.
88859393|NCT04271904|Sham Comparator|Placebo Diet|Participants on the placebo diet will be given a meal plan and recipes by the study dietitian. The dietitian will assist in developing a diet that is isocaloric to the anti-inflammatory diet and healthy (for the sake of the participants' well-being, and to blind participants), while allowing many foods that are (counterintuitively) pro-inflammatory (e.g. whole wheat bread, white beans, oats, soy, eggplant, raspberries, pumpkin seeds, popcorn, etc). There are many counter-intuitive restrictions in the anti-inflammatory diet that we will be using (banned foods include white beans, soy, eggplant, oats, raspberries, strawberries, prunes, walnuts, cashews, soy milk. Allowed foods include maple syrup, honey, lean beef, lamb, brown rice, feta cheese, butter). Therefore, even fairly astute and educated participants may have trouble discerning which diet they are consuming (anti-inflammatory or placebo).
88859394|NCT04271904|No Intervention|Non-dieting Control|Those in the non-dieting control condition will not be asked to alter their diet in any way.
88859395|NCT04233528|Experimental|healthy volunteers|metabolically healthy eutrophic individuals (BMI ≥18.5 and <25 kg / m2) without any IDF criteria for metabolic syndrome
88859396|NCT04233528|Experimental|metabolically healthy obesity|obese individuals (BMI ≥ 30.0 kg / m2) meeting the criteria for metabolically healthy obesity
88859397|NCT04233528|Experimental|metabolically unhealthy obesity|volunteers diagnosed with metabolically unhealthy obesity
88859398|NCT01680510|Experimental|Alga Dunaliella Bardawil 9-cis beta Carotene Rich Powder|50 patients will receive first the capsules containing the alga Dunaliella Bardawil 9-cis beta-Carotene rich powder and after 24 weeks of washout period will receive capsule containing placebo (Starch).
88859399|NCT01680510|Placebo Comparator|Placebo (Starch)|The other 50 Patients will receive first the placebo (Starch) capsules and after 24 weeks of washout period will receive capsules containing the alga Dunaliella Bardawil 9-cis beta-Carotene rich powder .
88859400|NCT04398186||Study group 1|Hiperandrogenism + ultrasonographic PCO
88859401|NCT04398186||Study group 2|Menstruel cycle irregular + ultrasonographic PCO
88859402|NCT04398186||Study group 3|Menstruel cycle irregular + ultrasonographic PCO + hyperandrogenism
88859403|NCT04398186||Control group|Do not have PCOS
89384843|NCT01334671|Experimental|group 1, Atorvastatin|STEMI patients will be randomly divided into three groups Group 1 which has been give 80mg atorvastatin before PCI will be administered with atorvastatin 40mg per day for one month,then 20mg per day until the end of the trial
89384844|NCT01334671|Experimental|group 2 , Atorvastatin|Group 2 will be administered with atorvastatin 40mg per day for one month,then 20mg per day until the end of the trial
88859404|NCT03818802|Active Comparator|Nicotinamide Riboside|NR is a single chemical moiety containing nicotinamide and ribose. The investigational product is a synthetic NR that is nature-identical to naturally-occurring NR, does not induce flushing or pruritus and has no effect on lipid levels.
88859405|NCT03818802|Placebo Comparator|Placebo|Correspondent placebo, a pill not containing the active component.
88859406|NCT04213326||Cancer Cohort|Subjects interested in the cancer cohort, will sign an informed consent, complete an optional survey, and have 60mLs of blood draw by a licensed phlebotomist.
88859407|NCT04213326||Non-Cancer Cohort|Subjects interested in the non-cancer cohort, will sign an informed consent, complete an optional survey, and have 60mLs of blood draw by a licensed phlebotomist.
88859408|NCT03817632||A Standard|Computer assisted primary total knee replacement with OrthoPilot FS 101 navigation system and Software 5.1
88859409|NCT03817632||B Elite|Computer assisted primary total knee replacement with OrthoPilot Elite navigation system and Software 6.0
88859410|NCT04398108|Experimental|Margetuximab & Chosen Chemotherapy|The dosage and administering of margetuximab is 15 mg/kg IV every 21 days. Investigators need to choose one of the 3 chemotherapies based on patient conditions.
88859411|NCT01625286|Experimental|Part A: Intermittent schedule (2/5)|See intervention description below.
88859412|NCT01625286|Experimental|Part A: Intermittent schedule (4/3)|See intervention description below.
88859413|NCT01625286|Active Comparator|Part B: AZD5363 combined with paclitaxel|See intervention description below.
88859414|NCT01625286|Placebo Comparator|Part B: paclitaxel combined with placebo|See intervention description below.
88859415|NCT04277130|Experimental|Intervention group|Intervention with active video games
88859416|NCT04277130|No Intervention|Control group|No intervention
88859417|NCT03801174|Experimental|Partner-assisted intervention|Patients and partners will receive intervention
88859418|NCT03801174|Active Comparator|Patient-only intervention|Patients will receive intervention
88859419|NCT05158062|Experimental|pembrolizumab and bevacizumab with PBC followed by pembrolizumab, bevacizumab and olaparib|Participants will continue treatment period up to 6 cycles and enter maintenance period after treatment period. Study treatment will be continued until progressive disease (PD) based on RECIST 1.1, death, unacceptable toxicity, or participant withdrawal from the study.
88859420|NCT01076868|Experimental|Primaquine|Primaquine 14 days
88859421|NCT05151432|Experimental|Pulsed US + Exercise Group|Twenty subjects will receive PUT, plus an exercise program.
88859422|NCT05151432|Experimental|Pulsed Electromagnetic + Exercise Group|Twenty subjects will receive PEMF, plus an exercise program.
88859423|NCT05151432|Experimental|Pulsed US + Pulsed Electromagnetic + Exercise Group|Twenty subjects will receive PUT, PEMF, plus an exercise program.
88859424|NCT05151432|Experimental|Sham + Exercise group|Twenty subjects will receive sham PEMF and sham PUT plus exercises program.
88859425|NCT04195776|Experimental|Three TFV Medicated Douche Sequences|Once enrolled, participants will complete a baseline sampling session and then three sequences of study product administration, along with sRAI and administration of autologous seminal fluid. Sequence A will be 1 TFV douche followed by sRAI; Sequence B will be one dose of TFV douche followed sRAI then a tap water douche; Sequence C will be 1 tap water douche followed sRAI then by a single dose of TFV douche. There will be a washout period of at least 14 days between sequences. Participants will have sequences administered in clinic or a research unit, followed by imaging and various specimen collections over 8 hours.
89003095|NCT05785767|Experimental|A: fianlimab+cemiplimab|Phase 2: fianlimab (HD) Phase 3: fianlimab (chosen dose)
89003096|NCT05785767|Experimental|B: fianlimab+cemiplimab|Phase 2: fianlimab (LD) Phase 3: fianlimab (chosen dose)
89384845|NCT01334671|Experimental|group 3 , Atorvastatin|Group 3 will be administered with atorvastatin 20mg per day until the end of the trial
89384846|NCT01338571||Healthly children|Children will be given yogurt twice a day for four weeks. The dose for an adult is 8 ounces of yogurt twice a day. The dose will be scaled to the children based upon surface area dosing charts, but will not exceed a resistant starch load of 1 gram per year of age plus 10 grams10.
89384847|NCT01332565|Experimental|Single Arm|All subjects will receive a 50 mg single dose of GSK1349572
88859426|NCT03708588|Experimental|Experimental: Chewed ticagrelor|Drug: Ticagrelor chewed pills. The loading dose will be administered as soon as possible by Catheterization Lab staff after a baseline P2Y12 platelet reaction units (PRU) level is drawn and before the end of the PCI. Patients will be asked to chew, but not swallow, allowing for sublingual absorption. (Loading dose 180mg)
88859427|NCT03708588|Active Comparator|Active Comparator: Integral pill|Drug: Ticagrelor integral pills. The loading dose will be administered as soon as possible by Catheterization Lab staff after a baseline P2Y12 platelet reaction units (PRU) level is drawn and before the end of the PCI. Patients will swallow the loading dose followed by 25-50mL (milliliter) of water. (180mg)
88859428|NCT04276662|Experimental|Cohort 1: Mild hepatic impairment|Participants who have mild hepatic impairment as assessed by National Cancer Institute Organ Dysfunction Working Group (NCI-ODWG) criteria.
88859429|NCT04276662|Experimental|Cohort 2: Moderate hepatic impairment|Participants who have moderate hepatic impairment as assessed by National Cancer Institute Organ Dysfunction Working Group (NCI-ODWG) criteria.
88859430|NCT04276662|Experimental|Cohort 3: Healthy participants|Healthy participants who have normal hepatic function with sex, age (±10 years [y]), and weight (±20%) matching with the mild and moderate hepatic impairment cohorts.
88859431|NCT04130802|Experimental|OCS-01 1.5% mg/mL QD|eye drops
88859432|NCT04130802|Experimental|OCS-01 1.5% mg/mL BID|eye drops
88859433|NCT04130802|Placebo Comparator|Placebo (Vehicle) BID|eye drops
88859434|NCT04276350|Experimental|Acupuncture|"Acupuncture Regime:~2-3 sessions per week, each lasting an hour, over a period of 10 weeks (with deviation of 2 weeks for scheduling), total of 30 sessions"
88859435|NCT04276350|Active Comparator|Best medical therapy|"Best Medical Therapy Regime:~3 sessions to be completed over a period of 10 weeks (with deviation of 2 weeks for scheduling), with subjects learning and practicing biofeedback exercises daily"
88859436|NCT03613740|Experimental|Fucoxanthin|12 mg Fucoxanthin capsule, once a day before breakfast during 90 days.
88859437|NCT03613740|Placebo Comparator|Placebo|Homologated magnesium sterate capsule, once a day before breakfast during 90 days.
88859438|NCT03166098||Diagnosis of Schizophrenia|
88859439|NCT03166098||Diagnosis of Bipolar Disorder|
88859440|NCT03166098||Unaffected siblings of the SZ groups|
88859441|NCT03166098||Unaffected siblings of the BP group|
88859442|NCT03166098||Healthy control (HC) comparison group|
88859443|NCT03087162|Experimental|Once daily dose dexlansoprazole|Group 1 Dexlansoprazole 60 mg by oral once daily for 14 days (Levofloxacin 500 mg by oral once daily for 14 days Amoxicillin 1000 mg by oral bid for 14 days Bismuth 1048 mg by oral bid for 14 days)
88859444|NCT03087162|Active Comparator|Twice daily dose dexlansoprazole|Group 2 Dexlansoprazole 60 mg oral bid 14 Days (Levofloxacin 500 mg od oral 14 Days Amoxicillin 1000 mg bid oral 14 Days Bismuth 1048 mg bid oral 14 Days)
88859445|NCT03165942|Experimental|Alcoholic Beverage|Participants will complete an MRI and oral alcohol session.
88859446|NCT03165942|Placebo Comparator|Non-Alcoholic Beverage|Participants will complete an MRI and oral non-alcoholic session.
88859447|NCT03163992|Experimental|pembrolizumab|Pembrolizumab (MK-3475) 200 mg every 3 weeks (Q3W)
88859448|NCT04397328|Experimental|Hydroxychloroquine 200mg|Regular Dose 400mg orally once, followed in 8 hours by 400mg, then 200mg twice a day for 4 consecutive days (5 days in total) Modified Dose 400mg orally once, followed in 8 hours by 400mg, then 200mg once a day for 4 consecutive days (5 days in total) Modified doses are for individuals with body weight below 40 kg, renal impairment with a creatinine clearance less than 10mls/min or QTc interval greater than 480 but less than 500.
88859449|NCT04397328|Placebo Comparator|Placebo Arm|The placebo arm will be matched to study drug to maintain the study blind. Regular Dose Placebo 2 tabs once, followed in 8 hours by 2 tabs, then 1 tab twice a day for 4 consecutive days (5 days in total) Modified Dose Placebo 2 tabs once, followed in 8 hours by 2 tabs, then 1 tab once a day for 4 consecutive days (5 days in total) Modified doses are for individuals with body weight below 40 kg, renal impairment with a creatinine clearance less than 10mls/min or QTc interval greater than 480 but less than 500.
89384848|NCT02973815|Experimental|NU-HOME Intervention|Participants randomized to the intervention condition will receive the NU-HOME family intervention program that includes group sessions with other families focused on nutrition education, cooking skills, and physical activity. The intervention program also includes individual goal setting phone calls with parents and online, complementary materials.
88859450|NCT04100538|Experimental|Intervention group|The intervention group will receive the technology-assisted program by health coach twice a week during the 10-week treatment period. The health coach will be an experienced master-prepared nurse who has extensive and in-depth knowledge about fibromyalgia and has previously worked in direct contact with patients with fibromyalgia in a research project.
88859451|NCT04100538|No Intervention|control group|The control group will receive technology-assisted informational support twice a week during the 10-week treatment period. Each technology-assisted informational support will last for approximately 10-30 min consisting of 15-min questions-and-answers regarding the educational materials and 15-min debriefing.
89384849|NCT02973815|No Intervention|Delayed Intervention|Participants randomized to the delayed intervention condition will not receive any educational materials or training until after the final data collection. Once all data collection is completed, they will receive a shortened version of the NU-HOME intervention program that was offered to the intervention families.
88859452|NCT03163602|Active Comparator|Control Group 1|Access flap, implant surface decontamination (saline), systemic antibiotics (amoxicillin 500 mg and metronidazole 400 g, 3 x day for 7 days)
89384850|NCT01338727|Experimental|Breastfeeding Peer Counseling|
89384851|NCT01338727|No Intervention|Standard Care|
89384852|NCT01332643|Active Comparator|Test|The test group will consist of patients undergoing blastocyst biopsy followed by vitrification (embryo freezing), and in which the biopsied cells will be analyzed with a comprehensive chromosome analysis technique (array Comparative Genome hybridization or aCGH) and only one chromosomally normal embryo will be replaced in a thawed cycle.
89384853|NCT01332643|No Intervention|control|The control group will consist of patients in which one embryo will be replaced on day 5 based on morphological and developmental characteristics, and the other embryos reaching blastocyst stage will be vitrified. If patient does not become pregnant, successive embryo transfers of frozen embryos will be performed, but not as part of the study.
88859453|NCT03163602|Active Comparator|Test Group 2|Access flap, implant surface debridement, systemic antibiotics (amoxicillin 500 mg, metronidazole 400 g, 3 x day for 7 days), bovine bone substitute material (BioOss®) and collagen membrane (BioGide®)
88859454|NCT04398576|No Intervention|Support as usual|"There will be no interventions, only support as usual. All GPs receive an information package by post or via e-mail containing:~Belgian guidelines on the management of hazardous and harmful alcohol use~A summary card about EIBI for hazardous and harmful alcohol consumption.~Internet links to documentation of the medical association and the Flemish centre of expertise on alcohol and drugs(31).~An EHR-update allows the use of an extra e-form permitting standardised introduction of screening results from the Alcohol Use Disorders Identification Test (-Consumption) (AUDIT(-C)), alcohol-related diagnoses and actions including provision of oral brief advice/intervention, referral to a digital-based system for advice and/or referral to another health care provider."
88859455|NCT04398576|Active Comparator|Training and support|"All GPs receive an information package by post or via e-mail containing:~Belgian guidelines on the management of hazardous and harmful alcohol use~A summary card about EIBI for hazardous and harmful alcohol consumption.~Internet links to documentation of the medical association and the Flemish centre of expertise on alcohol and drugs(31).~An EHR-update allows the use of an extra e-form permitting standardised introduction of screening results from the Alcohol Use Disorders Identification Test (-Consumption) (AUDIT(-C)), alcohol-related diagnoses and actions including provision of oral brief advice/intervention, referral to a digital-based system for advice and/or referral to another health care provider.~There shall be tailored training and support for the general practioners. At the start of the study, this group receives two face-to-face educational trainings of two hours each. Another two face-to-face booster sessions will follow at 6 and at 12 months."
88859456|NCT04398576|Active Comparator|Training and support and community actions|In this group, GPs receive the same training and support as in the second arm (training and support). There will also be embedded community-based actions within a local strategy.
88859457|NCT03081468||Healthy volunteers|Fifty healthy volunteers. Each participant will attend for a single study visit, lasting approximately 1 hour in duration. Participants will undergo pupillometry examination using the binocular OCT prototype and Konan RAPDx.
88859458|NCT03081468||Participants with confirmed relative afferent pupillary defect|Fifty participants with with eye disease (retinal disease, glaucoma, and neuro-ophthalmic conditions) and confirmed relative afferent pupillary defect. Each participant will attend for a single study visit, lasting approximately 1 hour in duration. Participants will undergo pupillometry examination using the binocular OCT prototype and Konan RAPDx.
88859459|NCT03392376|Experimental|Haloperidol injection|"Haloperidol 2,5mg x 3 daily, with additional as needed doses to a maximum of 20mg/daily.~Other name: Serenase"
88859460|NCT03392376|Placebo Comparator|Normal Saline|Saline (0,9%)
88859461|NCT05243628|Experimental|Afrezza + Automatic Insulin Delivery|Subjects in this group will use Afrezza for their bolus (mealtime) insulin and a CSII pump with an AID algorithm using RAA for their basal and correction insulin coverage.
88859462|NCT05243628|Experimental|Afrezza + Insulin Degludec|Subjects in this group will use Afrezza for their bolus (mealtime and correction) insulin and insulin degludec for basal insulin coverage.
88859463|NCT05243628|Active Comparator|AID Control|Subjects in this group will use a CSII pump with an AID algorithm using RAA for all bolus (mealtime and correction) and basal insulin coverage (control group).
88859464|NCT05249478|Active Comparator|epidural catheter inserted before spinal anesthesia.|"As for the epidural analgesia, it will be performed under complete aseptic precautions, by introducing a needle between the lumbar vertebrae at level of L3-L4 or L4-L5 and injecting anesthetic medication into the epidural space, via the epidural catheter inserted through the needle into the epidural space.~A small amount of air (1 to 2 mL) may be injected into the epidural space, avoid injecting larger amounts of air as this may contribute to patchy anesthesia."
89003097|NCT05785767|Experimental|C: cemiplimab monotherapy+placebo|Phase 2 and Phase 3
89003098|NCT05774951|Active Comparator|Arm A: standard endocrine therapy of investigator´s choice|Continue standard endocrine therapy of investigator's choice (aromatase inhibitors [AI; exemestane, letrozole, anastrozole] or tamoxifen)
89003099|NCT05774951|Experimental|Arm B: camizestrant|Camizestrant
89384854|NCT05185765|Active Comparator|Brown bread (commercially available)|Participants consume half a slice, and masticate and expectorate 1/4th of rectangular bottom part
89384855|NCT05185765|Active Comparator|Wholemeal bread (commercially available)|Participants consume half a slice, and masticate and expectorate 1/4th of rectangular bottom part
88859465|NCT05249478|Active Comparator|ultrasound guided femoral nerve catheter inserted before spinal anesthesia.|"As for the femoral nerve block, it will be performed under complete aseptic precautions, using a transportable Sonosite M-Turbo ultrasound system with linear transducer placed on the femoral crease to obtain the images of the femoral nerve & artery.~The needle used for the block will be an echogenic needle of 18 Gauge and 3.5 inches. Before proceeding, skin infiltration with local anesthesia will be done using a syringe containing 5ml of 1% lidocaine, Once the femoral nerve is visualized, the needle will be inserted in-plane in a lateral to medial orientation and advanced towards the nerve. Once the tip placed adjacent to the nerve, the catheter is introduced through it, then the needle is removed, the location of the catheter can be confirmed by visualization of the catheter and spread of local anesthetic (LA)."
88859466|NCT05249478|Active Comparator|ultrasound guided adductor canal block inserted before spinal anesthesia.|As for the adductor canal block,using a transportable Sonosite M-Turbo ultrasound system with linear transducer placed perpendicular to the thigh at the midpoint between the anterior superior iliac spine and the base of the patella,The needle used for the block will be an echogenic needle of 18 Gauge and 3.5 inches. Before proceeding, skin infiltration with local anesthesia will be done using a syringe containing 5ml of 1% lidocaine, the saphenous nerve is identified as it lies adjacent proximally lateral then distally superior to the femoral artery. Saphenous nerve is followed distally as it becomes more superficial, traveling with an arterial branch just deep to the sartorius muscle. Using an in-plane approach, after negative aspiration, the tip of the needle is placed deep to the sartorius muscle, at the lateral border of the artery, Once the needle is in position, the catheter is introduced through it, then the needle is removed.
88859467|NCT04083222|Placebo Comparator|Placebo|Participants received ISIS 757456-matching placebo, subcutaneous (SC) injection, once-weekly for 8 weeks and an additional loading dose on Day 3.
88859468|NCT04083222|Experimental|ISIS 757456|Participants received ISIS 757456 80 mg, SC injection, once-weekly for 8 weeks and an additional loading dose on Day 3.
88859469|NCT05249946|Experimental|Intervention group|"increasing provision of vegetables and sustainable fish in food offered in early childhood education and care (ECEC) and adjusting intake of meat and milk to reasonable levels to meet recommendations~advancing food education, reducing food waste and assessing the climate and financial impacts of the shift towards a more plant-based diet"
88859470|NCT05249946|No Intervention|Control group|Food supply and food education continue as usual.
88859471|NCT04276506|Experimental|information booklet group|information session before the coronary angiography
88859472|NCT04276506|Experimental|music group|music session before the coronary angiography
88859473|NCT04276506|No Intervention|control group|No information or music session before the coronary angiography
88859474|NCT03148080||Observational|Participants complete a Current Medical Conditions Form, the CogState web-based cognitive assessment, and a Self-Report Questionnaire administration over 45-60 minutes containing measures of work ability and other work-related measures, cognitive, physical, and psychosocial symptoms, and characteristics of workplace environment. Self-report measures of individual and family characteristics, resources, and demands are also included.
88859475|NCT05246124|Experimental|Intervention group|This study used Zumba dance exercise done 3 times a week during 2-week self-isolation period, with each session lasting for 50 minutes. The participants did exercise by following instructions from Zumba video shown
88859476|NCT05246124|No Intervention|Control group|No intervention during 2-week self-isolation period
88859477|NCT05244252|Experimental|Group A|Two drugs dexmeditomidine and bupivacaine will be given in TAP block
88859478|NCT05244252|Active Comparator|Group B|One drug bupivacaine will be given in TAP block
88859479|NCT05249790|Experimental|'Recommended algorithm' cohort|COVID-19 patients treated at home by their family doctors according to the proposed recommendations
88859480|NCT05249790|Active Comparator|Usual care|COVID-19 patients treated at home by their family doctors according to their usual clinical practice expected to be in accordance with AIFA recommendations
88859481|NCT03370224|Experimental|Experimental Group|The experimental group will receive memory retraining exercises administered on a laptop computer twice a week for 5 weeks (10 training sessions).
88859482|NCT03370224|Placebo Comparator|Placebo|The placebo group will receive placebo control memory exercises administered on a laptop computer twice a week for 5 weeks (10 training sessions).
88859483|NCT03304314|Experimental|Pseudotumor cerebri (PTC) patients|
88859484|NCT03304314|Experimental|Control|
88859485|NCT03286842|Experimental|Olaparib|Olaparib 150mg tablets administered orally twice daily continuously
88859486|NCT05243784|Experimental|Intervention|The design of the MOVI-HIIT intervention is framed within the socio-ecological model of behavior modification, in such a way that it will be designed to intervene in the individual, family and school environment. It will have a duration of 8 weeks and will consist of two 5-minute daily physical activity breaks based on intervallic training, five days a week.
88859487|NCT05243784|No Intervention|Control|Students in the control group (CG) will receive mandatory lessons on Spain (one 45-minute session of Psychomotor/Physical Education), and the usual classroom teaching methodology. Teachers in the CG schools will be asked not to make any changes to their methodology during the time of the study, with the promise by the research team to share and explain the MOVI-HIIT program once the interventions are completed.
88859488|NCT05245188|Experimental|Experimental Product 1|Consumption of 200 ml of product 1. Subjects will take this amount only on the day of the visit that they are to consume this product.
88859489|NCT05245188|Experimental|Experimental Product 2|Consumption of 200 ml of product 2. Subjects will take this amount only on the day of the visit that they are to consume this product.
88859490|NCT05245188|Experimental|Experimental Product 3|Consumption of 200 ml of product 3. Subjects will take this amount only on the day of the visit that they are to consume this product.
88859491|NCT05245188|Experimental|Experimental Product 4|Consumption of 200 ml of product 4. Subjects will take this amount only on the day of the visit that they are to consume this product.
88859492|NCT05240274|Active Comparator|Metformin|metformin 500mg OD
88859493|NCT05240274|Placebo Comparator|Placebo|placebo 500mg OD
88859494|NCT05240196|No Intervention|Control|participant will receive standard care only
89384856|NCT05185765|Active Comparator|Wholemeal bread without crust (commercially available)|Participants consume half a slice, and masticate and expectorate 1/4th of rectangular bottom part
88859495|NCT05240196|Other|Binaural music|Participants will listen to binaural music whilst having a routine mammogram
88859496|NCT05240196|Other|Non-binaural music|Participants will listen to non-binaural music whilst having a routine mammogram
88859497|NCT05244018|Active Comparator|Group 1(Treatment group)|
88859498|NCT05244018|Active Comparator|Group 2(Control group)|
88859499|NCT04396314|Experimental|Basic Body Awareness Therapy|Basic Body Awareness Therapy (BBAT), a health oriented, multi-perspective and person-centred approach with a focus on the patient's resources, is a movement awareness training approach in physiotherapy, aiming to promote movement quality in daily life through self-exploration and self-experience enabling the learning of new movement habits. BBAT consists of a broad scope of movements in the following positions: lying, sitting, standing and walking. Relational movements are practiced in therapy with components such as rhythm, form, elasticity, flow, intention and voice
88859500|NCT04396314|Active Comparator|Control|The control group will be treatment for usual for PTSD. Pharmacological treatment is based in fluoxetine, paroxetine, sertraline and venlafaxine. Regarding non-pharmacological treatment the strongly recommendations are cognitive-behavioural therapy, cognitive processing therapy, cognitive therapy and prolonged exposure therapy
88859501|NCT03066726||CPR less than the 10%le|Group of patients with fetuses with cerebroplacental ratio less than 10%le
88859502|NCT03066726||CPR greater or equal than 10%le|Group of patients with fetuses with cerebroplacental ratio greater or equal than 10%le
88859503|NCT04276818|Active Comparator|PRP group|Second-degree superficial burn group treated with PRP
88859504|NCT04276818|Active Comparator|conventional treatment group|second-degree superficial burn group treated with cream containing silver sulfadiazine
88859505|NCT04396392|Experimental|VR-based training|receiving only VR intervention
88859506|NCT04396392|Active Comparator|text-based training|receiving only text-based intervention
88859507|NCT04396392|Experimental|VR- and text-based training|receiving both VR intervention and text-based intervention
88859508|NCT04396392|No Intervention|waiting list|waiting list in phase 1 and text-based training after 3 weeks
88859509|NCT02391402|Experimental|CABA|CABA uses Behavioral Activation (BA) to identify meaningful goals and activities while learning cognitive skills to aid in working toward those goals. Early sessions of CABA focus on learning about mTBI, PTSD, and lifestyle skills that can improve thinking abilities and mood. Cognitive skills taught each week include internal and external skills to help manage problems with memory, attention, and regulation of thinking processes. Investigators and patients will spend a part of each session applying the cognitive skills to managing real life situations and getting patients active in the service of personal goals.
88859510|NCT02391402|Placebo Comparator|TAU|"Treatment as Usual (TAU) is the usual care that patients would normally receive at the VA. TAU care involves psychotherapy (counseling) provided by a specialist in the treatment of PTSD. Patients will be offered individual appointments with an experienced provider on the PTSD Clinical Team (PCT). Beyond this, the specific approach will be determined by the patient and his/her provider and may include skills for managing PTSD and/or a chance for the patient to process his/her traumatic experiences. Additional treatments may be offered to patients, such as group classes and medications. TAU care may also include additional evaluation and/or treatment of mTBI, provided by the usual care offered in Portland or Seattle's respective neuropsychology clinics. Treatment for mTBI includes individual or group sessions, and is based on clinical need."
88859511|NCT04397640|Other|Sonovue|ICU patients with sepsis and septic shock who are eligible for myocardial contrast echocardiography with sulphur hexafluoride microbubbles contrast Sonovue (Bracco, Milan, Italy) injection.
88859512|NCT02398500|Experimental|LMG324|SAD: LMG324 administered as a single IVT injection in 1 eye (study eye) in 1 of 4 doses, with 15-day follow-up
88859513|NCT02398500|Experimental|LMG324 + sham|Expansion: LMG324 administered as a single IVT injection in 1 eye (study eye), followed by sham injections, until implementation of SoC therapy as specified in the protocol, for 24 weeks
88859514|NCT02398500|Active Comparator|Lucentis + sham|Expansion: Ranibizumab 0.5 mg administered as monthly IVT injections in 1 eye (study eye) with interim sham injections, for 24 weeks
88859515|NCT03042858||Infants with PPV|During laparoscopy for pyloric stenosis, the surgeon will turn the camera downward to answer the first question, whether the inguinal canal is patent or closed. If a PPV is present, the subject will be followed for up to 18 years of age.
88859516|NCT03042858||Infants without PPV|During laparoscopy for pyloric stenosis, the surgeon will turn the camera downward to answer the first question, whether the inguinal canal is patent or closed. If there is no PPV, meaning they have normal anatomy, the patient demographic data will be recorded and this will terminate their participation.
88859517|NCT03039660|Experimental|RefreshMD|An online course for sleep improvement in medical students
88859518|NCT03039660|Placebo Comparator|Bond Between Us|An online course covering communication skills and the physician-patient relationship
88859519|NCT03037476|Experimental|Web-Based PFI|Participants randomized to the web-based PFI in Study 2 receive a 5 component Personalized Feedback Tool. The first component is presented immediately after the baseline survey and a link to each of the remaining 4 components is sent to participants spaced 1 to 2 weeks apart. The PFI components cover: 1) Stimulants, 2) Marijuana, 3) PSM and unwanted effects, 4) Academics, and 5) Alcohol. Each component is comprised of personalized feedback presented in text and graphic format, and each component includes links to tips for making changes if and when the participant is contemplating or ready to commit to change. These tips include general relapse prevention strategies, as well as information about the importance of regular class attendance, study habits, and sleep habits for academic success. General educational tips/strategies for time management, as well as tips for initiating behavior change are also included. Each component takes approximately 5-10 minutes to review.
88859520|NCT03037476|Other|Assessment Only|The Assessment Only group receives assessment on substance use, health behaviors, and academic behaviors at baseline, 6-month follow-up, and 12-month follow-up in Study 2.
89384857|NCT05185765|Active Comparator|White bread, water based (commercially available)|Participants consume half a slice, and masticate and expectorate 1/4th of rectangular bottom part
89384858|NCT05185765|Active Comparator|White hard roll (commercially available)|Participants consume half a roll, and masticate and expectorate half of 1 cm thick slice
89384859|NCT05185765|Active Comparator|Brown hard roll (commercially available)|Participants consume half a roll, and masticate and expectorate half of 1 cm thick slice
89384860|NCT05185765|Active Comparator|White soft bun (commercially available)|Participants consume half a bun, and masticate and expectorate 1/8th of a bun
88859521|NCT04276896|Experimental|pathogen-specific DC and CTLs|Patients will receive approximately 5x10^6 LV-DC vaccine and 1x10^8 CTLs via sub-cutaneous injections and iv infusions, respectively.
88859522|NCT02984514|Experimental|Type 1 diabetes|Positron emission tomography with tracer 18F-deoxy glucose
88859523|NCT04276428|Experimental|LY3209590|LY3209590 administered subcutaneously (SC).
88859524|NCT04276428|Active Comparator|Insulin Degludec|Insulin degludec administered SC.
88859525|NCT05248932|Active Comparator|infusion|patients will receive an infusion of norepinephrine that will be started at 2.5μg/min immediately after intrathecal injection and then manually adjusted according to monitoring of blood pressure (bp), heart rate, fluid responsiveness (thoracic volume variations and stroke volume variations), cardiac index and systemic vascular resistance by using cardiometry, with the objective of maintaining values near baseline
88859526|NCT05248932|Active Comparator|bolus|patient with no prophylactic vasopressor and a bolus of 5 μg norepinephrine will be given whenever systolic BP decreases to <80% of the baseline value.
88859527|NCT05246826|Experimental|Clinical Pilates Exercises|Pilates exercises will be performed 3 days a week, for a total of 18 sessions for 6 weeks.
88859528|NCT05246826|Experimental|Clinical Pilates Exercises and Conventional Treatment|In addition to Pilates exercises, conventional treatment will be performed 3 days a week, for 6 weeks, a total of 18 sessions.
88859529|NCT05247528|Placebo Comparator|Placebo Comparator|"Subjects randomized to the placebo arm, will receive a single subcutaneous injection each morning daily.~Intervention: Placebo"
88859530|NCT05247528|Experimental|MANP|"Subjects randomized to the experimental arm, will receive a single subcutaneous injection each morning daily. (multiple ascending dose cohorts)~Intervention: Drug: MANP"
88859531|NCT03140514|Experimental|Intervention|Urine CXCL10-chemokine levels will be monitored at specific time points post-transplant. Sustained elevated levels will trigger performance of a renal allograft biopsy. Any rejection will be treated. Rejection treatment according to clinical standard-of-care
89384861|NCT05185765|Active Comparator|Brown soft bun (commercially available)|Participants consume half a bun, and masticate and expectorate 1/8th of a bun
89384862|NCT05185765|Active Comparator|Ciabatta (commercially available)|Participants consume half a mini ciabatta, and masticate and expectorate half of 1 cm thick slice
88859532|NCT03140514|No Intervention|Control|Urine CXCL10-chemokine levels will be monitored at specific time points post-transplant, but the values are concealed.
88859533|NCT02395614|Experimental|Chlorhexidine irrigation|0.05% chlorhexidine solution (IrriSept®) commercially prepared in 450 ml bottles for irrigation. Each patient will receive triple antibiotic solution on one breast and the CHG on the other breast.
88859534|NCT02395614|Active Comparator|triple antibiotic irrigation|triple antibiotic solution will contain 1 g of cefazolin, 50,000 U of bacitracin, and 80 mg of gentamicin in 500 mL of normal saline (NS). If the patient is allergic to either component - the allergen will not be used in the solution - for irrigation. Each patient will receive triple antibiotic solution on one breast and the CHG on the other breast.
88859535|NCT04396938|Experimental|Lamotrigine|Single dose of Lamotrigine (300mg - capsule). In healthy volunteers.
88859536|NCT04396938|Placebo Comparator|Placebo|Placebo capsule: identical appearance to experimental capsule. In healthy volunteers.
89384863|NCT05185765|Active Comparator|Croissant (commercially available)|Participants consume half a croissant, and masticate and expectorate half of 1 cm thick slice
89384864|NCT05185765|Active Comparator|Whole wheat bread produced by bakery, proofing time 65 min, ambient cooling|Participants consume half a slice, and masticate and expectorate 1/4th of rectangular bottom part
89384865|NCT05185765|Active Comparator|Whole wheat bread produced by bakery, proofing time 85 min, ambient cooling|Participants consume half a slice, and masticate and expectorate 1/4th of rectangular bottom part
89384866|NCT05185765|Active Comparator|Whole wheat bread produced by bakery, proofing time 105 min, ambient cooling|Participants consume half a slice, and masticate and expectorate 1/4th of rectangular bottom part
89384867|NCT05185765|Active Comparator|Whole wheat bread produced by bakery, proofing time 65 min, vacuum cooling|Participants consume half a slice, and masticate and expectorate 1/4th of rectangular bottom part
89384868|NCT05185765|Active Comparator|Whole wheat bread produced by bakery, proofing time 85 min, vacuum cooling|Participants consume half a slice, and masticate and expectorate 1/4th of rectangular bottom part
88859537|NCT00639678|Experimental|1|
88859538|NCT00639678|Experimental|2|
88859539|NCT00639678|Placebo Comparator|3|
88859540|NCT00639678|Placebo Comparator|4|
89384869|NCT05185765|Active Comparator|Whole wheat bread produced by bakery, proofing time 105 min, vacuum cooling|Participants consume half a slice, and masticate and expectorate 1/4th of rectangular bottom part
89535142|NCT05021289|No Intervention|control group|No intervention was applied on the control group patients.
89535143|NCT03228277|Experimental|Olmutinib|Single arm of Olmutinib, staring dose of 800 mg
88859541|NCT02914158|Experimental|Ovarian Suppression and aromatase inhibitors|"Ovarian Suppression：Goserelin 3.6 mg or Leuprolide 3.75 mg administered intravenously every 28 days, for 5 years.~AI: no restriction of specific drugs, oral by standard dose of post-menopause breast cancer, for 5 years."
88859542|NCT02914158|Active Comparator|Ovarian Suppression and tamoxifen|"Ovarian Suppression：Goserelin 3.6 mg or Leuprolide 3.75 mg administered intravenously every 28 days, for 5 years.~Tamoxifen: 20mg oral for every day, for 5 years."
88859543|NCT02765802|Experimental|Lambda 180 μg|Lambda 180 μg once weekly, administered by subcutaneous (SC) injection, for a total of 48 weeks.
88859544|NCT02765802|Experimental|Lambda 120 μg|Lambda 120 μg once weekly, administered by subcutaneous (SC) injection, for a total of 48 weeks.
88859545|NCT05241132|Experimental|BMCUP treated with Tislelizumab and chemotherapy|"Patients with bone metastases from cancer of unknown primary (BMCUP) diagnosed according to the criteria defined in the 2015 European Society of Medical Oncology (ESMO) clinical Practice Guidelines and with bone metastases confirmed by imaging and histology that cannot be completely resected~Cisplatin: 100mg/m2, injected intravenously every 3 weeks, 8 cycles (period 21 days)~Paclitaxel (albumin-bound) : paclitaxel, 175mg/m2, given intravenously every 3 weeks for 8 cycles (period 21 days).~Tislelizumab: 200mg, given intravenously every 3 weeks until disease progression or unacceptable toxicity or death or subject withdrawal of informed consent."
88859546|NCT03132792|Experimental|Autologous genetically modified AFPᶜ³³²T cells|
88859547|NCT05241054|Active Comparator|Bupivacaine|Patients will receive local anesthesia by paranasal infiltration at the incision site with 2.5 ml of 0.5% bupivacaine with 1:100000 epinephrine.
88859548|NCT05241054|Active Comparator|Nitroglycerine|Patients will receive an infusion of Nitroglycerine (TNG) (0.2-1μg/kg/min) will be started and adjusted to maintain mean arterial blood pressure between 55-65 mmHg.
88859549|NCT05240820|Placebo Comparator|Vicryl+Prolene|wound closure using polyglactin 910 (Vicryl®, Ethicon, Johnson and Johnson Ltd., NJ, USA) and polypropylene (Prolene®, Ethicon)
88859550|NCT05240820|Active Comparator|PDS+Dermabond|wound closure using polydioxanone (StratafixTM Spiral PDS® Plus) and combination of 2-octyl cyanoacrylate and polyester mesh (Dermabond Prineo®)
88859551|NCT03182400|Experimental|Healthy volunteer|Neurophysiological assessment Neuropsychological assessment
88859552|NCT00638508|Active Comparator|Ketorolac|Patients will receive Ketorolac at 5 mg/hr not to exceed 120 mg/day
88859553|NCT00638508|Experimental|Ketorolac with Ropivacaine|Patients will receive Ketorolac 5 mg and Ropivacaine 0.5% (Group 2) via an infusion catheter at the incision site
88859554|NCT05240430||stem cell application; Group I disease 0-7. days,|In mesenchymal stem cell application, according to the diagnosis of COVID 19 and the day of stem cell application; Group I disease 0-7. days,
88859555|NCT05240430||stem cell application; Group II; 8-14 days of the disease. days|In mesenchymal stem cell application, according to the diagnosis of COVID 19 and the day of stem cell application; Group II; 8-14 days of the disease. days
88859556|NCT05240430||stem cell application; Group III; those applied on the 15th day and after.|In mesenchymal stem cell application, according to the diagnosis of COVID 19 and the day of stem cell application; Group III; It will be divided into 3 groups as those applied on the 15th day and after.
88859557|NCT00637806|Active Comparator|1|Megestrol acetate concentrated suspension 110 mg/mL
88859558|NCT00637806|Active Comparator|2|Megestrol acetate concentrated suspension 60 mg/mL
88859559|NCT00637806|Placebo Comparator|3|
88859560|NCT05240118||HFmrEF Group|"HFmrEF (Heart failure with mildly reduced ejection fraction): ESC Guideline heart failure 2021: patients with LVEF 41-49%.~non-cardiac events group versus cardiac events (cardiac death or heart failure-related rehospitalization) group"
88859561|NCT04396782|Experimental|physiotherapy rehabilitation with IVR|This program includes: static bicycle with virtual reality glasses, analytical lower limb exercises, global lower limb exerciseswith virtual reality glasses and activities to be done at home.
88859562|NCT04396782|Active Comparator|standard physiotherapy rehabilitation|static bicycle, analytical lower limb exercises, global lower limb exercises and activities to be done at home.
88859563|NCT00637728|Active Comparator|1|Megestrol acetate concentrated suspension 110 mg/mL
88859564|NCT00637728|Placebo Comparator|2|Placebo suspension
88859565|NCT01922466|Experimental|Bee Venom Acupuncture|
88859566|NCT01922466|Experimental|Loxoprofen|
88859567|NCT01922466|Experimental|EWCT : Bee Venom Acupucture and Loxoprofen|
88859568|NCT00637572|Experimental|Megestrol acetate oral suspension nanocrystal dispersion|Megestrol acetate oral suspension nanocrystal dispersion formulation 115 mg/mL
88859569|NCT00637572|Active Comparator|Megestrol acetate oral suspension micronized formulation|Megestrol acetate oral suspension micronized formulation 60 mg/mL
88859570|NCT00637416|Active Comparator|Lansoprazole and dietary control|Lansoprazole and dietary control
88859571|NCT00637416|Placebo Comparator|Placebo and dietary control|Dietary control and placebo
88859572|NCT01922544||Conventional group|In this group CS lead was implanted in a conventional manner.
88859573|NCT01922544||EP-catheter group|In this group coronary sinus was canulated using a steerable electrophysiology catheter.
88859574|NCT03154320|Active Comparator|Standard Group|On Day 0 (day of HIV diagnosis and study enrollment) participants will receive a chest x-ray and provide a sputum specimen for spot Xpert Ultra testing (48-hour results). Those with high clinical/radiographic suspicion for TB will start same-day TB treatment. On Day 2, participants will return for results of Xpert Ultra testing (spot specimen) and to provide a specimen for early morning Xpert Ultra testing. Those who are Xpert Ultra positive will start TB treatment. Those who are not diagnosed with TB will start ART on Day 7, after testing and treatment for other opportunistic infections. A liquid TB culture will be performed on both the spot and early morning specimens.
88859575|NCT03154320|Experimental|Same-Day Treatment Group|On Day 0 (day of HIV diagnosis and study enrollment) participants will receive a chest x-ray and Xpert Ultra testing with same-day results. Based on clinical symptoms, Xpert Ultra results, and chest x-ray, physician will determine whether or not the participant has tuberculosis. Those who are diagnosed with TB will start same-day TB treatment. Those who are not diagnosed with TB will start same-day ART.
88859576|NCT00636792|Experimental|1|This is a phase 2, single-arm, open label, multicenter study evaluating the efficacy and safety of the combination of VELCADE, bendamustine, and rituximab in subjects with relapsed or refractory follicular lymphoma, who have received 4 or more doses of rituximab. Subjects may be sensitive or refractory to prior therapies, including rituximab.
88859577|NCT03558984|Experimental|D-PLEX + SOC|For subjects randomized to the investigational treatment arm, D-PLEX treatment will be applied at the end of the index surgery just before closing the chest, as an adjunct to the SOC prophylactic antibiotic treatment.
88859578|NCT03558984|Other|Standard of Care|For subjects randomized to the control arm, the surgical treatment will be as per the SOC.
88859579|NCT03108924|Experimental|Moderate RI|Participants with moderate renal insufficiency (RI) are treated with a single 50 mg dose of gefapixant
88859580|NCT03108924|Experimental|Severe RI|Participants with severe RI are treated with a single 50 mg dose of gefapixant
88859581|NCT03108924|Other|Healthy Matched Controls|Healthy, participants matched for age and body weight are treated with a single 50 mg dose of gefapixant
88859582|NCT03108924|Experimental|ESRD Requiring HD|Participants with end stage renal disease (ESRD) requiring hemodialysis (HD), are treated in Period 1 with a single 50 mg dose of gefapixant immediately after the scheduled HD, followed in Period 2 with a single 50 mg dose of gefapixant two hours prior to HD. Between the Periods 1 and 2 MK-7264 dose administrations there was approximately a 7-day washout period with 3 dialysis sessions.
88859583|NCT04506918|Experimental|IVR survey|Participants will receive an IVR survey
88859584|NCT04506918|Experimental|SMS survey|Participants will receive an SMS survey
88859585|NCT04499508|Experimental|Treatment with Optima Balt Coils|The APPLY study is a single-arm prospective study which means that everyone enrolled in the clinical trial will be/has been treated with the Optima Balt Coils.
88859586|NCT01922778|Experimental|Endometrial Biopsy|"Recruits from the Bariatric Surgery Program will be interviewed by a study investigator prior to their bariatric surgery. If the patient consents to the procedure, then this will usually be a D&C performed in one setting at the time of her bariatric surgery under general anesthesia. In the case where a patient is diagnosed with complex atypical endometrial hyperplasia or early endometrial prior to her bariatric surgery, an IUD device can be inserted at the time of her bariatric surgery.~For patients not undergoing bariatric surgery, an endometrial biopsy will be performed in the clinic or office setting. If the biopsy cannot be performed due to technical difficulty (cervical stenosis) or inadequate sampling, we will try again on a different day after a trial of vaginal misoprostol (Cytotec) 400 or 600 mcg per vagina the night before."
88859587|NCT00636636|Experimental|G-ER|Gabapentin - Extended Release
88859588|NCT00636636|Placebo Comparator|Placebo|Sugar pill
88859589|NCT05244954|Experimental|Intermittent Screening and Treatment (IST)|Students will be screened for infection using a higher sensitivity malaria rapid diagnostic test and treated if positive. Treatment will be with DP (females less than 10 years old and all males) or chloroquine (females 10 years old or older).
88859590|NCT05244954|Experimental|Intermittent Preventive Treatment (IPT)|All students are treated at each intervention. Treatment will be with DP (females less than 10 years old and all males) or chloroquine (females 10 years old or older).
88859591|NCT05244954|No Intervention|Control|Students will not receive preventive treatment.
88859592|NCT00635778|Experimental|dalotuzumab 2.5/2.5 mg/kg|Participants received a loading dose of dalotuzumab 2.5 mg/kg administered by intravenous (IV) infusion. Two weeks following completion of the loading dose, participants received a maintenance dose of dalotuzumab 2.5 mg/kg administered by IV infusion every two weeks for up to 18 months.
88859593|NCT00635778|Experimental|dalotuzumab 5.0/5.0 mg/kg|Participants received a loading dose of dalotuzumab 5.0 mg/kg administered by IV infusion. Two weeks following completion of the loading dose, participants received a maintenance dose of dalotuzumab 5.0 mg/kg administered by IV infusion every two weeks for up to 18 months.
88859594|NCT00635778|Experimental|dalotuzumab 10.0/5.0 mg/kg|Participants received a loading dose of dalotuzumab 10.0 mg/kg administered by IV infusion. Two weeks following completion of the loading dose, participants received a maintenance dose of dalotuzumab 5.0 mg/kg administered by IV infusion every two weeks for up to 18 months.
88859595|NCT00635778|Experimental|dalotuzumab 15.0/5.0mg/kg|Participants received a loading dose of dalotuzumab 15.0 mg/kg administered by IV infusion. Two weeks following completion of the loading dose, participants received a maintenance dose of dalotuzumab 5.0 mg/kg administered by IV infusion every two weeks for up to 18 months.
88859596|NCT00635778|Experimental|dalotuzumab 20.0/5.0 mg/kg|Participants received a loading dose of dalotuzumab 20.0 mg/kg administered by IV infusion. Two weeks following completion of the loading dose, participants received a maintenance dose of dalotuzumab 5.0 mg/kg administered by IV infusion every two weeks for up to 18 months.
89384870|NCT03160573|Active Comparator|Test-Unflavored Rinse then Placebo Unflavored Rinse|Participants will receive CloSYS unflavored rinse containing 0.1% stabilized chlorine dioxide (sodium chlorite) in an aqueous solution for 3 weeks,. After a washout period of 2 weeks, they will then receive Placebo unflavored rinse containing containing NO 0.1% stabilized chlorine dioxide for 3 weeks.
88859597|NCT00635778|Experimental|dalotuzumab 15.0/10.0 mg/kg|Participants received a loading dose of dalotuzumab 15.0 mg/kg administered by IV infusion. Two weeks following completion of the loading dose, participants received a maintenance dose of dalotuzumab 10.0 mg/kg administered by IV infusion every two weeks for up to 18 months.
88859598|NCT00635778|Experimental|dalotuzumab 15.0/15.0 mg/kg|Participants received a loading dose of dalotuzumab 15.0 mg/kg administered by IV infusion. Two weeks following completion of the loading dose, participants received a maintenance dose of dalotuzumab 15.0 mg/kg administered by IV infusion every two weeks for up to 18 months.
88859599|NCT04396470|Experimental|tVNS treatment|
88859600|NCT04396470|Sham Comparator|tVNS sham treatment|
88859601|NCT01929252|Active Comparator|Dexmedetomidine|%0.25 40 ml levobupivacaine and 2 mcg/kg dexmedetomidine administered via wound infiltration just before the incision.
88859602|NCT01929252|Active Comparator|Levobupivacaine|%0.25 40 ml levobupivacaine administered via wound infiltration prior to incision.
88859603|NCT04275960|Experimental|Arm_25 + 75 mg (Fasted)|Healthy male participants receive a single dose of 25 mg selitrectinib (Period 1) and 75 mg selitrectinib (Period 2) in fasted state.
88859604|NCT04275960|Experimental|Arm_50 + 50 mg (Fasted/Fed)|Healthy male participants receive a single dose of 50 mg selitrectinib in fasted state (Period 1) and 50 mg selitrectinib in fed state (Period 2).
88859605|NCT04275960|Experimental|Arm_100 + 150 mg (Fasted)|Healthy male participants receive a single dose of 100 mg selitrectinib (Period 1) and 150 mg selitrectinib (Period 2) in fasted state.
88859606|NCT04276038|Active Comparator|Active LLLT|"Patients will self-treat at home (active or sham), twice a day (excluding Weekends) for 1 month. The duration of each session will be 15-20 minutes and will include treatment over painful point on the knee and over regional lymph nodes (popliteal, inguinal). The treatment dose should be initiated gradually for the first week until reaching the maximum dose of 6-8 minutes per treatment point. This is the recommended dose for near infrared lasers for the indication of knee pain by the World Association for Laser Therapy (WALT). In the first days an increase in pain may be felt before the reduction in pain. If the increase in pain continues for more than a week under graded dosimetry, the treatment must be stopped.~Laser therapy will be administered to the patients in addition to standard of care therapy as customary in our institution."
88859607|NCT04276038|Sham Comparator|Sham LLLT|Half of the LLT devices will be not activated at random before the application to the patients. Sham activated devices will give outward signs of normal function but will not generate a signal. The investigators will be unaware of the device's functionality. The patients will not be able to determine whether the device is working or not. At study completion, device serial numbers will be used to determine which patients received a working device.
88859608|NCT04275804|Active Comparator|Control group: conventional dressing|Alternate day dressing in a designated clinic by a trained nurse specialized in wound care Dressing by a specialized wound-nurse is the current gold-stand of treatment for diabetic ulcers.
88859609|NCT04275804|Experimental|Vibration group: conventional dressing and LMHFV|Alternate day dressing in a designated clinic by a trained nurse specialized in wound care Alternate dat 20-week course of whole-body vibration therapy Alternate day 20min sessions on a self-designed vibration platform with low-magnitude high-frequency vibration (35Hz, 0.3g peak-to-peak displacement <0.1mm). Since the participants will return for dressing change on alternate days, the vibration group will also undergo the LMHFV on the same attendance.
88859610|NCT00634920|Experimental|Everolimus (CNI-free)|Patients in this group were converted to everolimus immunosuppressive therapy. The patients in the everolimus group were treated with everolimus, off-label (CNI-free) use, and EC-MPS and corticosteroids in accordance with local practice and approved label. Conversion to everolimus was as follows: Day 1: begin everolimus 3 mg in the evening. Usual morning dose of CsA and 50% reduced evening dose of CsA Day 2: everolimus 2 mg in the morning and 2 mg in the evening, complete discontinuation of CsA Day 3 or 4, and onwards: everolimus according to trough level 6-10 ng/mL.The given total daily dose of the immunosuppressive drugs (everolimus) was divided into two (equal) doses, applied 12 hours apart.
88859611|NCT00634920|Active Comparator|Control (CsA)|Patients in the control group continued on an immunosuppressive regimen. The patients in this Control group were treated with CsA, EC-MPS and corticosteroids in accordance with local practice and approved label. The given total daily dose of the immunosuppressive drugs (CsA and EC-MPS) was divided into two (equal) doses, applied 12 hours apart.
88859612|NCT01923012|Experimental|Vitamin K2|
89384871|NCT03160573|Active Comparator|Test-Flavored Rinse then Placebo Flavored Rinse|Participants will receive CloSYS mint-flavored rinse containing 0.1% stabilized chlorine dioxide (sodium chlorite) in an aqueous solution for 3 weeks. After a washout period of 2 weeks, they will then receive Placebo flavored rinse containing NO 0.1% stabilized chlorine dioxide for 3 weeks.
89535144|NCT03324659|Experimental|Exercise and Meditation|The Exercise and Meditation group will practice mindfulness meditation immediately before walking treadmill exercise, five days per week for four weeks.
88859613|NCT01923090|Experimental|Finasteride|Finasteride treatment 5mg for 3 weeks
88859614|NCT01923090|Experimental|Dutasteride|Dutasteride treatment 0.5mg for 3 weeks
89003100|NCT05773794|Experimental|Dietary flavonoids (soymilk, green tea, or blueberry) consumption|Each subject takes breakfast with 460 ml of soymilk, green tea, or blueberry in a single dose, and samples (plasma, urine, and stool samples) at different time points were collected following the administrations of soymilk, green tea, or blueberry blend.
89003101|NCT05773794|Placebo Comparator|Control group|Each subject takes breakfast with 460 ml of milk or water in a single dose, and samples (plasma, urine, and stool samples) at different time points were collected following the administration of milk or water.
88859615|NCT01929330|Experimental|Sequence AB|Subjects will be hospitalized to the clinical unit on the evening of Day -1. All subjects will receive 1 x 0.5mg oral dose of dutasteride (Sequence A), in the morning; Subjects will remain in the clinical unit until completion of all assessments at 24 hours post-dose on Day 2 including collection of the 24 hour post-dose PK sample. Subjects will return to the unit for the remaining PK samples at 36, 48 and 72 hours. The subject will receive or 5 x 0.1mg oral dose of dutasteride (Sequence B) in similar fashion as that of Sequence A. The two treatment sequences will be separated by a minimum washout period of 28 days to ensure that dutasteride is effectively eliminated from the subject between dosing occasions.
88859616|NCT01929330|Experimental|Sequence BA|Subjects will be hospitalized to the clinical unit on the evening of Day -1. All subjects will receive 5 x 0.1mg oral dose of dutasteride (Sequence B) in the morning; Subjects will remain in the clinical unit until completion of all assessments at 24 hours post-dose on Day 2 including collection of the 24 hour post-dose PK sample. Subjects will return to the unit for the remaining PK samples at 36, 48 and 72 hours. The subjects will receive 1 x 0.5mg oral dose of dutasteride (Sequence A) in similar fashion as that of Sequence B, The two treatment sequences will be separated by a minimum washout period of 28 days to ensure that dutasteride is effectively eliminated from the subject between dosing occasions.
88859617|NCT01929564|Active Comparator|Beneforte broccoli|Four x 100g portions of Beneforte broccoli will be consumed each week for twelve weeks, on top of the participants habitual diet.
88859618|NCT01929564|Placebo Comparator|Parthenon broccoli|Four x 100g portions of Parthenon broccoli will be consumed each week for twelve weeks, on top of the participants habitual diet.
88859619|NCT00634842|Experimental|FPG 70-90 mg/dL|Aggressive FPG (fasting plasma glucose) titration target range group
88859620|NCT00634842|Experimental|FPG 80-110 mg/dL|Conventional FPG (fasting plasma glucose) titration target range group
88859621|NCT04396548|Active Comparator|Group A (midodrine group)|Midodrine will be given orally with small sips of water one hour before arrival in the operation room before spinal anesthesia
88859622|NCT04396548|Placebo Comparator|Group B (placebo group):|Inert tablet containing sugar (placebo) will be given orally with small sips of water one hour before arrival in the operation room before spinal anesthesia
88859623|NCT01923246|Experimental|Single WEB intervention|Web intervention recieved once.
88859624|NCT01923246|Experimental|Repeated WEB intervention|Web intervention recieved twice.
88859625|NCT01923246|Experimental|Single IVR intervention|IVR intervention recieved once
89184441|NCT05684016|Active Comparator|MS Subject on Gilenya|All the RRMS patients will have their Brain MRI with the addition of NeuroQuant. The 30 patients that are taking Gilenya® will have serial NeuroQuant/MRI and Neuropsychological testing (which is like an IQ test) using Automated Neuropsychological Assessment Matrices (ANAM) whether they are or are not experiencing cognitive issues. In addition, each study patient will undergo Extended Disability Status Score (EDSS) evaluation by a physician or a physician assistant at baseline and at 1 and 2 years. A group of 20 RRMS patients will undergo a second Brain MRI (not standard of care) with NeuroQuant evaluation 7 to 14 days after the initial study in order to confirm the reproducibility of this imaging technique. The cost for this repeat MRI will not be charged to you but will be borne by the sponsors of this study
89184442|NCT05684016|Active Comparator|MS Subject not on Gilenya|All the RRMS patients will have their Brain MRI with the addition of NeuroQuant.
89184443|NCT04842006|Experimental|TNT + precision|
89184444|NCT04842006|Active Comparator|Conventional|
89184445|NCT00578643|Experimental|Allogeneic unrelated transplant|Conditioning from Day -9 to Day -1. Stem cells given on Day 0. Busulfan, alemtuzumab, cyclophosphamide, fludarabine, cyclosporine, stem cell infusion.
89184446|NCT04082286|Experimental|Radioimmunotherapy|Children affected by high risk malignant disorders will be receiving increasing infused activity of a radio-immune conjugated antibody as part of their conditioning regimen prior to alleogeneic stem cell transplantation
89184447|NCT02587884|Active Comparator|Group TACE|Patients will treated with TACE after resection.
89184448|NCT02587884|No Intervention|Group Control|Patients will treated without TACE after resection.
88859626|NCT01923246|Experimental|Repeated IVR intervention|IVR intervention recieved twice
88859627|NCT01923246|No Intervention|Control group|Untreated Control Group.
88859628|NCT01923324|Experimental|Physician telephone consultation|Received direct telephone consultation with pain physician about index patient
88859629|NCT01923324|Active Comparator|Usual family physician care|Usual family physician care (without direct telephone consultation with pain physician)
88859630|NCT01923402||Exclusive cigarette smokers|
88859631|NCT01923402||Exclusive moist snuff consumers|
88859632|NCT01923402||Non-tobacco consumers|
89184449|NCT00716703|Experimental|1|cohort = pediatric patients in the ED (3-18 yo) with abdominal pain suspicious for appendicitis that are to undergo CT scan
88859633|NCT04395456|Experimental|AMY-101|
88859634|NCT04395456|Placebo Comparator|Placebo|
88859635|NCT01929720|Experimental|Arm I (CBT for worry, uncertainty & insomnia)|Patients wear a wrist actigraph and complete a sleep diary and worry record daily in weeks 1 and 5. Patients participate in a Behavioral Intervention (cognitive-behavioral therapy) in which they receive education on the components of anxiety (physical cognitive, and behavioral) and practice relaxation techniques and behavioral sleep strategies in weeks 2-5.
88859636|NCT01929720|Active Comparator|Arm II (wait-list control)|Patients wear a wrist actigraph and complete a sleep diary and worry record daily in weeks 1 and 5. This is a wait-list comparison, so after six weeks, patients in the control group complete the behavioral (cognitive-behavioral therapy)intervention for worry, uncertainty, and insomnia.
88859637|NCT01929798|Experimental|Optimized basal/bolus with artificial pancreas|Portable artificial pancreas with optimization
89184450|NCT02588508|Experimental|Warm packs|The warm packs are held in the mother's perineum during birth. The warm packs are changed as needed to maintain warmth.
89184451|NCT02588508|Experimental|Perineal massage|"The perineal massage will be gently held in the longitudinal direction of the muscle fibers, with movements of the thumb and forefinger, like count coins."
89184452|NCT02588508|No Intervention|Hands off|Hands off group does not receive any perineal manipulation and they are only observed.
89535145|NCT03324659|Sham Comparator|Control|The Control group will listen to an audio book followed by quiet rest, five days per week for four weeks.
89384872|NCT03160573|Placebo Comparator|Flavored Oral Rinse-Placebo then Test-Flavored Rinse|Participants will receive CloSYS mint flavored rinse containing NO 0.1% stabilized chlorine dioxide for 3 weeks. After a washout period of 2 weeks, they will then receive CloSYS mint-flavored rinse containing 0.1% stabilized chlorine dioxide (sodium chlorite) in an aqueous solution for 3 weeks.
88859638|NCT01929798|No Intervention|Nominal basal/bolus treatment|Portable artificial pancreas without optimization.
88859639|NCT01929954|Experimental|Gintuit|Subjects with a posterior tooth (molar or premolar) socket created by atraumatic extraction will be grafted with freeze-dried bone allograft (ie, MinerOss™). The primary wound bed will consist of exposed alveolar bone and bone graft imbedded in coagulum of blood from the socket for both treatments. The test treatment GINTUIT will be inlayed within the defect over the socket graft material, and stabilized with resorbable tacking sutures. An additional single layer of GINTUIT will cover the entire surface of the extraction socket at approx. 2-3 mm beyond the margins of the wound and fixed with non-resorbable sutures. The lower layer of this additional layer should be in contact with the previously applied GINTUIT.
88859640|NCT01929954|Active Comparator|Bio-Gide|Subjects with a posterior tooth (molar or premolar) socket created by atraumatic extraction will be grafted with freeze-dried bone allograft (ie, MinerOss™). The primary wound bed will consist of exposed alveolar bone and bone graft imbedded in coagulum of blood from the socket for both treatments. The control treatment will be a collagen membrane (ie, Bio-Gide, applied per the Package Insert) inlayed within the defect over the socket graft material, and stabilized with resorbable tacking sutures. Crossed suspensory type sutures should also be placed over Bio-Gide, depending on the degree of stabilization needed. In all subjects, care should be taken in suturing to avoid advancement of the buccal gingival flap.
88859641|NCT04395690|Active Comparator|Inferior Alveolar Block Nerve (IABN)|Inferior Alveolar Block Nerve (IABN) anesthesia technique before posterior mandibular implant placement.
88859642|NCT04395690|Experimental|Infiltration (INF)|Infiltration (INF) anesthesia technique before posterior mandibular implant placement.
88859643|NCT00633984|Active Comparator|Cognitive Behavioral Group Therapy + D-Cycloserine|Participants received Cognitive Behavioral Group Therapy and 50mg D-Cycloserine.
88859644|NCT00633984|Placebo Comparator|Cognitive Behavioral Group Therapy + Placebo|Participants received Cognitive Behavioral Group Therapy and 50mg Placebo.
88859645|NCT04395612|Experimental|Treatment arm1|niraparib 200mg/day and brivanib 400mg/day
88859646|NCT04395612|Experimental|Treatment arm2|niraparib 200mg/day and toripalimab 240mg/21 days
88859647|NCT01923558|Experimental|Donepezil Hydrochloride Tablets, 23 mg|Donepezil Hydrochloride Tablets, 23 mg of Dr.Reddy's Laboratories Ltd
88859648|NCT01923558|Active Comparator|Aricept|Aricept® 23 mg tablet of Eisai Inc
88859649|NCT01920048|Experimental|Percutaneous Coronary Intervention and Optimal Medical Therapy|
88859650|NCT01920048|Active Comparator|Optimal Medical Therapy alone|
88859651|NCT01923480|Experimental|15% CLINISOL 0.04 g/kg/hr|15% CLINISOL- Sulfite-Free (Amino Acid)Injection 0.04 g/kg/hr to be administered. Each treatment session is expected to last 7 hours with the first 3 hours of basal infusion followed by 4 hours of 15% CLINISOL - Sulfite-Free (Amino Acid) Injection.
88859652|NCT01923480|Experimental|15% CLINISOL 0.08 g/kg/hr|15% CLINISOL- Sulfite-Free (Amino Acid)Injection 0.08 g/kg/hr to be administered. Each treatment session is expected to last 7 hours with the first 3 hours of basal infusion followed by 4 hours of 15% CLINISOL - Sulfite-Free (Amino Acid) Injection.
88859653|NCT01923480|Experimental|15% CLINISOL 0.13 g/kg/hr|15% CLINISOL- Sulfite-Free (Amino Acid)Injection 0.13 g/kg/hr to be administered. Each treatment session is expected to last 7 hours with the first 3 hours of basal infusion followed by 4 hours of 15% CLINISOL - Sulfite-Free (Amino Acid) Injection.
88859654|NCT01921218|Experimental|Treatment|Belatacept (Nulojix) IV
88859655|NCT01921218|Active Comparator|Control|Calcineurin inhibitor based therapy (cyclosporine or tacrolimus)
88859656|NCT03831828||Lymph node metastasis Positive|good prognosis; without Lymph node metastasis.
88859657|NCT03831828||Lymph node metastasis Negative|poor prognosis; with Lymph node metastasis.
88859658|NCT01920438|Experimental|PEG|Percutaneous Endoscopic Gastrostomy
89384873|NCT03160573|Placebo Comparator|Unflavored Oral Rinse-Placebo then Test-Unflavored Rinse|Participants will receive CloSYS unflavored rinse containing NO 0.1% stabilized chlorine dioxide for 3 weeks. After a washout period of 2 weeks, they will then receive unflavored rinse containing 0.1% stabilized chlorine dioxide (sodium chlorite) in an aqueous solution for 3 weeks.
88859659|NCT01920438|Experimental|RIG|Radiologically-guided Insertion of Gastrostomy
88859660|NCT00633750|Experimental|Tarceva|
88859661|NCT01922856|Experimental|Challenge (Vaccinated)|"The vaccine will be administered via the ID route to alternating upper arms on days 0, 21, and 42.~On the morning of challenge, subjects will drink 120 mL of bicarbonate buffer. Approximately 1 minute later, subjects will drink a solution of virulent H10407 bacteria suspended in the remaining 30 mL of bicarbonate buffer (2 x 10P7P cfu)."
88859662|NCT01922856|Experimental|Challenge (Unvaccinated)|On the morning of challenge, subjects will drink 120 mL of bicarbonate buffer. Approximately 1 minute later, subjects will drink a solution of virulent H10407 bacteria suspended in the remaining 30 mL of bicarbonate buffer (2 x 10P7P cfu).
88859663|NCT00633360|Experimental|Drospirenone and ethinyl estradiol|
88859664|NCT00633360|Placebo Comparator|Placebo|
88859665|NCT01923714||Glaucoma|Patients with open-angle glaucoma (OAG) that require topical intraocular pressure lowering therapy and that were scheduled to switch current therapy to preservative-free DTFC.
88859666|NCT00988260|Experimental|Ganirelix 0.125 mg|
88859667|NCT00988260|Experimental|Ganirelix 0.25 mg|
88859668|NCT00988260|Experimental|Ganirelix 0.5 mg|
88859669|NCT00633126|Experimental|A|ceftaroline
88859670|NCT00989664|Experimental|open-label single arm|Tositumomab and Iodine-131 Tositumomab radioimmunotherapy for chemotherapy-refractory low-grade B-cell lymphomas and low-grade lymphomas that have transformed to higher grade histologies.
88859671|NCT01923792||Placebo|Subjects previously randomised to receive placebo in study TH002
88859672|NCT01923792||ToleroMune HMD Group 1|Subjects previously randomised to receive ToleroMune HDM in study TH002
88859673|NCT01923792||ToleroMune HDM Group 2|Subjects previously randomised to receive ToleroMune HDM in study TH002
89535146|NCT03228121|Experimental|Cohort A|Cohort A (Treatment Then Placebo group) will receive three days of cell therapy using the venous procedure (three consecutive days of blood harvest, cell separation and cell application). Cohort A will return in three months and receive three consecutive days of placebo.
89535147|NCT03228121|Experimental|Cohort B|Cohort B (Placebo Then Treatment group) will receive three consecutive days of placebo. Cohort B will return in three months and receive three consecutive days of cell therapy using the venous procedure.
89535148|NCT03325361|Experimental|TD|
89535149|NCT03325361|No Intervention|NTD|
88859674|NCT01923870|Experimental|Moderate Hepatic Impairment|Males age 18-70 with a BMI between 25-42 kg/m^2 with moderate hepatic impairment (Child-Pugh Class B)
88859675|NCT01923870|Experimental|Healthy Volunteers|Males age 18-70 with a BMI between 25-42 kg/m^2
88859676|NCT03492060||Variant in a hnRNP gene|Individuals with a variant in any hnRNP gene who present with neurodevelopmental abnormalities are eligible for the study.
88859677|NCT03492060||Variant in other gene|Individuals with a confirmed variant in other genes who present with neurodevelopmental abnormalities are eligible for the study.
88859678|NCT00632736|Active Comparator|Ropinirole XL (formerly CR)|Ropinirole XL (formerly CR)
88859679|NCT01923948|Active Comparator|Pregabalin|Single, 150 mg pre-operative oral dose of Pregabalin
88859680|NCT01923948|Placebo Comparator|Sugar Pill|Single, placebo pre-operative dose
88859681|NCT01924026||Affected MHP|With Phe between 360 and 600 micromoles/L
88859682|NCT01924026||Unaffected Siblings|With normal Phe levels
88859683|NCT00989196|Experimental|Human-cl rhFVIII|
88859684|NCT00989196|Active Comparator|Kogenate FS|
88859685|NCT04288362|Experimental|Intervention Group|
88859686|NCT04288362|Active Comparator|Control Group|
88859687|NCT03100110|Experimental|NeuroCognitive Communicator|
88859688|NCT00632502|Experimental|Navarixin|Navarixin (MK-7123, SCH 527123) 30 mg capsule, to be taken by mouth once daily in the morning for 4 weeks
88859689|NCT00632502|Placebo Comparator|Placebo|Placebo capsule to match navarixin, to be taken by mouth once daily in the morning for 4 weeks
88859690|NCT00632424|Experimental|1|
88859691|NCT00631488|Experimental|MK-0893 + Sitagliptin|
88859692|NCT00631488|Experimental|MK-0893 + Metformin|
88859693|NCT00631488|Active Comparator|Sitagliptin + Metformin|
88859694|NCT01924104|Active Comparator|Low Molecular Weight Heparin|Low molecular weight heparin, 2500 milli-International unit/day, subcutaneously
88859695|NCT01924104|Active Comparator|Low dose aspirin|Low dose aspirin, 75mg/day, orally
88859696|NCT01924104|Active Comparator|Heparin & Aspirin|Heparin (40 mg/day, subcutaneously) and aspirin (70 mg/day, orally)
88859697|NCT01924104|Placebo Comparator|Sodium chloride (NaCl)|Equivalent volume of NaCl 0.9%, subcutaneously
88859698|NCT03098862||1|Direct EBOV exposure risk controls
88859699|NCT03098862||2|EVD fatal cases
88859700|NCT03098862||3|EVD survivor cases
88859701|NCT03098862||4|No known EBOV exposure population controls
88859702|NCT00988884|Experimental|Concomitant Vaccination|V503 given as a 0.5 mL intramuscular injection in the deltoid muscle of the non-dominant arm on Day 1, Month 2, and Month 6, and Menactra™ and Adacel™ each given as a 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm on Day 1
88859703|NCT00988884|Experimental|Non-concomitant Vaccination|V503 given as a 0.5 mL intramuscular injection in the deltoid muscle of the non-dominant arm on Day 1, Month 2, and Month 6, and Menactra™ and Adacel™ each given as a 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm at Month 1
88859704|NCT00631020|Experimental|CBME +/- NRT|6 weeks CBME with optional 4 weeks NRT
88859705|NCT00987402|Active Comparator|Plain soap and water|Surgical hand preparation with plain soap and water
88859706|NCT00987402|Active Comparator|Alcohol based hand rubs|Surgical hand preparation with alcohol based alcohol hand rub
88859707|NCT00630864|Experimental|1|Fx-1006A 20mg soft gelatin capsules once daily for 12 months
88859708|NCT01924338|Experimental|Skin types I and II|"Volunteers classified as skin types I and II according to the Fitzpatrick Scale~Procedures: dental cast creation, MRI scan, laser scan"
88859709|NCT01924338|Experimental|Skin type III|"Volunteers classified as skin type III according to the Fitzpatrick Scale~Procedures: dental cast creation, MRI scan, laser scan"
88859710|NCT01924338|Experimental|Skin type IV|"Volunteers classified as skin type IV according to the Fitzpatrick Scale~Procedures: dental cast creation, MRI scan, laser scan"
88859711|NCT01924338|Experimental|Skin types V and VI|"Volunteers classified as skin types V and VI according to the Fitzpatrick Scale~Procedures: dental cast creation, MRI scan, laser scan"
88859712|NCT01924416|Experimental|Enhanced Care|Enhanced Care: Decision aid; QL-PRO immediate summary results; chemotherapy cycles and imaging studies as needed
88859713|NCT01924416|Active Comparator|Usual Care|Usual Care: Routine chemotherapy cycles and imaging studies
88859714|NCT00630786|Experimental|Panitumumab plus conatumumab|Participants received 10 mg/kg conatumumab and 6 mg/kg panitumumab administered on the same day by sequential intravenous (IV) infusions once every 2 weeks until progressive disease, intolerability, withdrawal, or death.
88859715|NCT00636480|Experimental|CHG 2%-26 ml|Chlorhexidine gluconate in an aqueous base, 26 ml applicator
88859716|NCT00636480|Active Comparator|ChloraPrep 26 ml|ChloraPrep One-Step 26 ml Active drug contains chlorhexidine gluconate and alcohol
88859717|NCT00636480|Placebo Comparator|Sterile Saline|Sterile salt water administered topically.
88859718|NCT01924494||Endoscopy procedures|Patients undergoing elective flexible gastrointestinal endoscopy procedures
88859719|NCT01924572|No Intervention|Immediate cord clamping|provider clamps and cuts the cord within 10 seconds after birth
89535150|NCT03223051|Experimental|Evaluation|"Included patients will be invited to participate in 1 session, to be evaluated with the Motor Function Measure and the new test of space exploration, during 2 hours maximum, to compare scores with these 2 tests.~An occupational therapist will be required to install the patient in front of the table and to give the instructions."
88859720|NCT01924572|Experimental|cord clamping at 2 minutes|Provider places infant on maternal abdomen and cuts cord at 2 minutes after birth
88859721|NCT01924572|Experimental|cord clamping at 5 minutes|Provider places the infant on maternal abdomen and clamps and cuts cord at 5 minutes
88859722|NCT01924572|Experimental|cord milking|provider milks the cord 5 times from placenta to infant
88859723|NCT01924728|Active Comparator|Magnetic stimulation|Active magnetic stimulation delivered to the pelvic floor muscles
88859724|NCT01924728|Sham Comparator|Sham magnetic stimulation|Sham magnetic stimulation delivered to the pelvic floor muscles
88859725|NCT00985686|Experimental|Study Arm|Arm where participants began the LEAP Project intervention upon recruitment for an 8 week period.
88859726|NCT00985686|Active Comparator|Waitlist Arm|"Arm where participants received the LEAP Project intervention after an 8 week wait period.~At 8 weeks, the results from the wait-list arm (no intervention) were compared to the results of the study arm (intervention completed)."
88859727|NCT01924884||Prospective|Patients newly referred to the Principal Investigator for intra-abdominal surgery and for whom the Principal Investigator anticipates using Negative-Pressure Wound Therapy.
88859728|NCT01924884||Retrospective|Patients who underwent intra-abdominal surgery by the Principal Investigator between January 1, 2011 and May 9, 2013 will be identified through patient medical records. Living patients will be contacted via letter from the Principal Investigator introducing the study along with the study's consent form for the patients' review. Interested patients will be consented either in person at the patient's next clinic visit or via telephone by a member of the study staff.
88859729|NCT01924884||Historical Controls|Patients who underwent intra-abdominal surgery without Negative-Pressure Wound Therapy by the Principal Investigator prior to January 1, 2011 will be enrolled as Historical Controls.
88859730|NCT01924884||De-Identified Retrospective|Patients who underwent intra-abdominal surgery by the Principal Investigator between January 1, 2011 and May 9, 2013 and are deceased or do not consent to be in the study will be enrolled in the De-Identified Retrospective Case Cohort.
88859731|NCT00635934|Experimental|A-MAV™disc|
88859732|NCT00630552|Placebo Comparator|Placebo + Gemcitabine|
88859733|NCT00630552|Experimental|AMG 655 + Gemcitabine|
88859734|NCT00630552|Experimental|AMG 479 + Gemcitabine|
88859735|NCT01924962|No Intervention|medical therapy|patients are treated with medical therapy only, intervention (stent) of other than (chronic occluded) target-vessel is allowed.
88859736|NCT01924962|Active Comparator|revascularisation|revascularisation and stent-implantation of chronic occluded coronary artery
88859737|NCT03098394|Experimental|Rapid Turnaround Test|Patients randomized to this arm will be tested for a sexually transmitted infection (STI) with both the rapid nucleic acid amplification test (NAAT) as well as the conventional polymerase chain reaction (PCR) test. The results from the rapid turnaround test will guide providers on treatment decisions for a possible STI. The results from the PCR test will be used to verify the results of the rapid turnaround test.
88859738|NCT03098394|Active Comparator|Usual Care|Patients randomized to this arm will be tested for a sexually transmitted infection (STI) using the conventional PCR test. The results from the PCR test normally take approximately 48-72 hours and these patients will likely receive treatment based on the decision of the clinical provider. The results from the PCR test will be used to verify the decision of the clinical provider to treat or withhold treatment for a possible STI.
88859739|NCT01920126|Experimental|Sodium bicarbonate group|Sodium bicarbonate group
88859740|NCT01920126|Placebo Comparator|Saline group|Saline group
88859741|NCT00984594|Other|Primary injury site|CR-Plug will be placed in the site of the primary injury
88859742|NCT00984594|Other|Backfill site|Autograft will be placed in the site of the primary injury; CR Plug will be placed in the harvest site
88859743|NCT01925118|Experimental|High-dose IL-2|
88859744|NCT01925352|Experimental|Ad-HGF|5×10(9)pfu adenovirus hepatocyte growth factor was delivered by transendocardial injection in patients with ischemic heart disease into five left ventricular sites once.
88859745|NCT01925430||Comparative product|A device which monitors sleep/wake states
88859746|NCT01925430||Screening device|This device will screen for sleep-breathing disorders
88859747|NCT01920204|Experimental|Midostaurin|Treatment with Midostaurin, twice daily 100 mg orally for 6 months continuously.
88859748|NCT00984204|Experimental|Treatment arm|
88859749|NCT04508010|Experimental|IVR survey|Participants will receive an IVR survey
88859750|NCT04508010|Experimental|CATI survey|Participants will receive a CATI survey
88859751|NCT00983892|Experimental|CarePartners+|Patients receive automated telephonic symptom assessment and symptom management advice; caregivers receive the intervention (Intervention = access to a caregiver Web site that updates them on patient's symptoms and provides tailored problem solving advice).
88859752|NCT00983892|No Intervention|CarePartners-|Patients receive automated telephonic symptom assessment and symptom management advice; caregivers receive nothing (i.e. no access to the caregiver website, or 'intervention').
88859753|NCT02984202|Experimental|Safety/Efficacy|Patients will be implanted with the AMI and evaluated for safety and efficacy over a 2-year period. The placement of the AMI array into the inferior colliculus will also be evaluated.
88859754|NCT04275258|Experimental|Intervention group|"Subjects will receive standard trauma discharge plan and no more than a 2-week supply of opioids. Subjects will complete surveys at baseline, 12-week, and 24-week post hospital discharge. In addition, subjects will receive:~A face-to-face meeting prior to discharge where the PA will discuss with the subject their individualized pain management plan and individualized opioid taper plan.~PA will contact subject on the phone within the first week after hospital discharge to ensure subject plans to follow up with PCP and to troubleshoot any subject concerns related to pain management."
88859755|NCT04275258|No Intervention|Control group|Subjects will receive standard trauma discharge plan and no more than a 2-week supply of opioids. Subjects will complete surveys at baseline, 12-week, and 24-week post hospital discharge.
88859756|NCT01925664|Experimental|Doula|Mothers received doula home visiting services in addition to normal prenatal and obstetric clinical care and had access to social work case management.
89384874|NCT01314677|Experimental|Group A (FDG PET/CT between RT fractions 5-6)|"Patients undergo a baseline FDG PET/CT scan and receive standard radiotherapy (RT) for 28 fractions with concurrent chemotherapy.~Patients undergo a FDG PET/CT scan between RT fractions 5-6 (before course 2 of chemotherapy).~Approximately 6 weeks after completion of CRT, patients undergo a FDG PET/CT scan and undergo standard tumor resection."
88859757|NCT01925664|No Intervention|Usual Care|Mothers received normal prenatal and obstetric clinical care and had access to social work case management.
88859758|NCT01925742|Experimental|Low Risk of aneuploidy|Integrated prenatal screening for Down's syndrome (with follow-up fetal karyotype if positive); Serum QUAD Assay for aneuploidy screening; Semiconductor MPSS NIPT assay using ccfDNA in maternal blood; Optical-based MPSS NIPT assay using ccfDNA in maternal blood; Harmony™ Test (Ariosa Diagnostics)
88859759|NCT01925742|Experimental|High risk of aneuploidy|Integrated prenatal screening for Down's syndrome (with follow-up fetal karyotype if positive); Serum QUAD Assay for aneuploidy screening; Semiconductor MPSS NIPT assay using ccfDNA in maternal blood; Optical-based MPSS NIPT assay using ccfDNA in maternal blood; Harmony™ Test (Ariosa Diagnostics) (subset)
88859760|NCT01925820|Experimental|Arm 1|180 mcg Peg-IFN alfa-2a (Pegasys) once a week for 48 weeks. Entecavir daily will also be administered concurrently for 48 weeks and then given as monotherapy for an additional 96 weeks
88859761|NCT01925820|Active Comparator|Arm 2|Entecavir daily for 144 weeks.
88859762|NCT01925820|Active Comparator|Arm 3|180 mcg Peg-IFN alfa-2a once a week for 48 weeks
88859763|NCT01925898|Experimental|Ketamine|Oral ketamine
88859764|NCT01925898|Active Comparator|Midazolam|Oral Midazolam
88859765|NCT00983580|Experimental|Arm I (acetylsalicylic acid and eflornithine)|Patients receive acetylsalicylic acid PO once daily and eflornithine PO twice daily on days 1-28.
88859766|NCT00983580|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO three times daily on days 1-28.
88859767|NCT01920672|Experimental|Timed Planned Activity (TPA)|The TPA provides meaningful activities delivered at specific times in the daily diurnal cycle; it is theory-based, its components have been tested in pilot work; and it is portable and replicable (e..g, protocols are standardized). It involves involved 8 contacts (6 home visits and 2 phone calls) over 4 days. At baseline the CG completes the Pleasant Event Activity Survey. From the survey a careplan of meaningful activities are developed for the CG to administer. The suggested activities match the capabilities of an individual with moderate stage AD ie., based on repetitive motion (e.g., folding towels) and integrating multi-sensory stimulation (e.g., soft music, objects pleasant to touch). CG are instructed to introduce these activities during the late morning and early evening.
88859768|NCT01920672|Active Comparator|Home Safety and Education Program|The active comparator intervention will be delivered by interventionists who will provide social attention, empathy and engagement similar to that afforded to the experimental group. The length of time spent will be comparable to the length of time spent in the treatment arm. The attention-control group will involve 6 in-home visits in the afternoon and 2 brief telephone education sessions in the morning. Control group subjects will be provided a copy of Mace and Rabins, The 36-Hour Day, a well-known practical guidebook for families caring for AD patients. Each contact will provide helpful education based on a specific book chapter including information about home safety, health promotion, and advanced care planning
88859769|NCT00982878|Experimental|Maraviroc|
88859770|NCT00982488|Other|Dasatinib, 50 mg QD to 120 mg BID, Chronic phase|Participants with chronic phase disease continued on the previous study dose of dasatinib, ranging from 50 mg once daily (QD) to 120 mg twice daily (BID).
88859771|NCT00982488|Other|Imatinib, 400 mg BID, Chronic phase|Participants with chronic phase disease received 400 mg of imatinib twice BID.
88859772|NCT00982488|Other|Dasatinib, 50 mg QD to 120 mg BID, Advanced phase, AP|Participants with advanced phase disease, accelerated phase (AP), continued on the previous study dose of dasatinib, ranging from 50 mg QD to 120 mg BID.
88859773|NCT00982488|Other|Dasatinib, 50 mg QD to 120 mg BID, Advanced phase, MBP|Participants with advanced phase disease, myeloid blast cell (MBP), continued on the previous study dose of dasatinib, ranging from 50 mg QD to 120 mg BID.
88859774|NCT00982488|Other|Dasatinib, 50 mg QD to 120 mg BID, Advanced phase, Ph+ ALL|Participants with advanced phase disease, Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), continued on the previous study dose of dasatinib, ranging from 50 mg QD to 120 mg BID.
88859775|NCT00982410|Experimental|Arm 1|cognitive-behavioral treatment (CBT) interventions to manage pain and decrease substance use abuse/misuse
88859776|NCT00982410|Placebo Comparator|Arm 2|educational supportive group
88859777|NCT00982020|Experimental|Olanzapine/standard behavioral weight intervention|
88859778|NCT00982020|Experimental|Olanzapine/intense behavioral weight intervention|
88859779|NCT01926054|Active Comparator|Acthar Gel 80 IU SC BIW|80 IU administered subcutaneously BIW for 6 months
89384875|NCT01314677|Experimental|Group B (FDG PET/CT between RT fractions 10-11)|"Patients undergo a baseline FDG PET/CT scan and receive standard radiotherapy (RT) for 28 fractions with concurrent chemotherapy.~Patients undergo a FDG PET/CT scan between RT fractions 10-11 (before course 3 of chemotherapy).~Approximately 6 weeks after completion of CRT, patients undergo a FDG PET/CT scan and undergo standard tumor resection."
88859780|NCT01926054|Active Comparator|Acthar Gel 80 IU SC TIW|80 IU administered subcutaneously TIW for 6 months
88859781|NCT01926132|Experimental|ascorbic acid 10g/20ml|Normal Saline 130ml+ ascorbic acid 10g/20ml , covered bottle for the blind allocation
88859782|NCT01926132|Active Comparator|Normal Saline 150ml|Normal Saline 150ml, covered bottle
89384876|NCT01314677|Experimental|Group C (FDG PET/CT between RT fractions 15-16)|"Patients undergo a baseline FDG PET/CT scan and receive standard radiotherapy (RT) for 28 fractions with concurrent chemotherapy.~Patients undergo a FDG PET/CT scan between RT fractions 15-16 (before course 4 of chemotherapy).~Approximately 6 weeks after completion of CRT, patients undergo a FDG PET/CT scan and undergo standard tumor resection."
89384877|NCT05185687|Experimental|First Come, First Served|"Respondents will view the following description: The US government will make 500 million COVID-19 home tests available for free. US residents can ask for tests by entering their home address in a website. It is likely that more people will want tests than will be available. How should the government decide who will receive tests, when there are not enough for all who want them? One plan that is being considered is this one:~Below this statement, respondents will view the First Come, First Served plan description."
88859783|NCT02984358|Placebo Comparator|Animal protein based diet|Seven day fully controlled normocaloric diet (1.2 g/ kg body weight of protein per day), with the main protein source at the two main meals (lunch and dinner) being provided by animal products (meat and fish).
88859784|NCT02984358|Active Comparator|Low-nucleotide mycoprotein based diet|Seven day fully controlled normocaloric diet (1.2 g/ kg body weight of protein per day), with the main protein source at the two main meals (lunch and dinner) being provided by nucleotide-depleted mycoprotein products (commercial Quorn products).
88859785|NCT02984358|Active Comparator|High-nucleotide mycoprotein based diet|Seven day fully controlled normocaloric diet (1.2 g/ kg body weight of protein per day), with the main protein source at the two main meals (lunch and dinner) being provided by nucleotide-rich mycoprotein products.
88859786|NCT01920906|Experimental|Biopsy and blood tests|All subjects will undergo a skin biopsy and blood tests
88859787|NCT01926210|Experimental|mild ovarian stimulation|Patients are stimulated with mild ovarian stimulation protocol,i.ed, from cycle day 3 to 7, letrozole 5mg per day are administrated and recombinant FSH 150 IU are given on day 4 and 6 . On cycle day 8, serum FSH LH, and estradiol levels are measured, and after then, the dose of recombinant FSH is adjusted according to the ovarian response and the maxim recombinant FSH dose is 150 IU/d. The GnRH-antagonist (Cetrotide) 0.25mg per day is administrated when the estradiol level reaches 200 pg/ml and the serum LH level rises above 2 times of basal LH level.
88859788|NCT01926210|Active Comparator|controlled ovarian stimulation|Patients are stimulated using controlled ovarian stimulation protocol,i.e., from cycle day 18-22 (day 7 after ovulation) of previous cycle, all participants are given short-acting GnRH agonist (Triptorelin 0.05mg/d) for 14 days, then after checking serum FSH, LH and estradiol to make sure that complete downregulation is achieved, exogenous gonadotropin (recombinant FSH) 300 IU/d is given for 5 days, then the dose of recombinant FSH is adjusted according to ovarian response.
88859789|NCT01926288|Other|HBeAg positive group|"Entecavir maleate tablets (1) + blank Baraclude tablets (1),once a day Empty stomach (at least 2 hours after a meal or fasting), treatment for 48 weeks, then enter the open-label trial extended to 240 weeks .~Blank maleate entecavir tablets (1) + Baraclude tablets (1),once a day Empty stomach (at least 2 hours after a meal or fasting), treatment for 48 weeks, then enter the open-label trial extended to 240 weeks ."
88859790|NCT01926288|Other|HBeAg-negative group|"Entecavir maleate tablets (1) + blank Baraclude tablets (1),once a day Empty stomach (at least 2 hours after a meal or fasting), treatment for 48 weeks, then enter the open-label trial extended to 240 weeks .~Blank maleate entecavir tablets (1) + Baraclude tablets (1),once a day Empty stomach (at least 2 hours after a meal or fasting), treatment for 48 weeks, then enter the open-label trial extended to 240 weeks ."
88859791|NCT01926366|Experimental|Experimental: AZD6423|Subjects will participate in 1 of 8 groups and receive single or multiple doses of AZD6423 or matching placebo. In each group 6 subjects will receive AZD6423 and 2 subjects will receive matching placebo.
88859792|NCT01926366|Placebo Comparator|Placebo to match AZD6423|Subjects will participate in 1 of 8 groups and receive single or multiple doses of AZD6423 or matching placebo. In each group 6 subjects will receive AZD6423 and 2 subjects will receive matching placebo.
88859793|NCT00981084|Experimental|armodafinil and placebo|All participants will receive one dose of armodafinil and one dose of placebo in a cross-over design
88859794|NCT00980148|Experimental|Arm2|Doxycycline 100 mg oral twice a day (BID) for 7 days; 153 subjects
88859795|NCT00980148|Experimental|Arm 1|Azithromycin 1 gm oral single dose; 153 subjects
88859796|NCT03064854|Experimental|Group A: squamous, gem/cis+PDR001|
88859797|NCT03064854|Experimental|Group B: non-squamous, pem/cis+PDR001|
88859798|NCT03064854|Experimental|Group C: paclitaxel/carbo+PDR001|
88859799|NCT03064854|Experimental|Group E: non-squamous, pem/cis (or carbo)+PDR001+canakinumab|
88859800|NCT01926600||PO|administrated by per oral
88859801|NCT01926600||IV|Administrated by intravenous
88859802|NCT01926600||SL|administrated by sublingual
88859803|NCT01921530|Active Comparator|Interbody Fusion|
88859804|NCT01921530|Active Comparator|Posterolateral Fusion|
88859805|NCT01926678|Experimental|Swedish massage therapy|Swedish massage therapy once per week for 6 weeks
88859806|NCT01926678|Active Comparator|Light touch therapy|Light touch therapy once per week for 6 weeks
88859807|NCT01926678|Other|Wait list|A 6 week wait list, followed by randomization to massage therapy or light touch therapy once per week for 6 weeks
88859808|NCT01926756|Other|Straight catheterization (control)|The control arm is the current practice at our hospital (to perform straight catheterization for short procedures).
88859809|NCT01926756|Active Comparator|No straight catheterization|The experimental arm will void preoperatively and will not be straight catheterized intraoperatively. This is a change from the current practice at our hospital.
88859810|NCT01926834|Experimental|Erigeron Injection|Erigeron Injection, 30ml,qd,i.v., for 7 days
88859811|NCT01926834|Placebo Comparator|placebo|normal saline, 500ml,i.v.,qd, for 7 days
88859812|NCT01926834|No Intervention|health volunteers|health volunteers, no drug to be given.
88859813|NCT01921608|Experimental|PrePex™ device|Adult male circumcision by the PrePex™ device
88859814|NCT01926912||Participants with schizophrenia|
88859815|NCT04395378||Flying pilots|Flying pilots holding class 1 and class 2 certificates
89384878|NCT05185687|Experimental|Random|"Respondents will view the following description: The US government will make 500 million COVID-19 home tests available for free. US residents can ask for tests by entering their home address in a website. It is likely that more people will want tests than will be available. How should the government decide who will receive tests, when there are not enough for all who want them? One plan that is being considered is this one:~Below this statement, respondents will view the Random plan description."
89384879|NCT05185687|Experimental|Disadvantaged Priority & Random|"Respondents will view the following description: The US government will make 500 million COVID-19 home tests available for free. US residents can ask for tests by entering their home address in a website. It is likely that more people will want tests than will be available. How should the government decide who will receive tests, when there are not enough for all who want them? One plan that is being considered is this one:~Below this statement, respondents will view the Disadvantaged Priority & Random plan description."
89384880|NCT02736227|Experimental|Tacrolimus Withdrawal and Everolimus Monotherapy|Tacrolimus will be tapered while continual use of everolimus.
88859816|NCT03385512|Experimental|OPEN High Touch|Participants in this arm will experience the OPEN High Touch intervention.
89384881|NCT01334905|Experimental|Part A group|fasted condition then fed condition
89384882|NCT01334905|Experimental|Part B group|fed condition then fasted condition
89384883|NCT02623985|Experimental|Sofia|Patients who presented with sore throat will be performed throat swab and sent for Sofia which is rapid test.
88818718|NCT02055963|Experimental|Minocycline|"Participants take study medication twice daily, starting 2 days prior to surgery, and continue for 3 weeks postsurgery. The final day of study medication will be the 21st day after surgery.~Minocycline100 mg given orally every 12 hours on Day -2, (i.e., 2 days prior to surgery) and continuing for 3 weeks postsurgery.~Questionnaire completion 2 days before surgery, on day of surgery, 1 and 3 days after surgery, then twice a week until follow up visit on day 21."
89384884|NCT02623985|Experimental|QuickVue|Patients who presented with sore throat will be performed throat swab and sent for QuickVue which is rapid test.
88818719|NCT02055963|Placebo Comparator|Placebo|"Participants take study medication twice daily, starting 2 days prior to surgery, and continue for 3 weeks postsurgery. The final day of study medication will be the 21st day after surgery.~Placebo 100 mg given orally every 12 hours on Day -2, (i.e., 2 days prior to surgery).~Questionnaire completion 2 days before surgery, on day of surgery, 1 and 3 days after surgery, then twice a week until follow up visit on day 21."
88818720|NCT01848041|Experimental|RVL-1201 once daily|RVL-1201 0.1% ophthalmic solution dosed one full drop per eye in the morning; one full drop of vehicle (placebo) per eye approximately 8 hours after the morning dose
88818721|NCT01848041|Experimental|RVL-1201 twice daily|RVL-1201 0.1% ophthalmic solution dosed one full drop per eye BID; approximately 8 hours between the morning dose and the afternoon dose
88818722|NCT01848041|Placebo Comparator|RVL-1201 vehicle (placebo)|RVL 1201 ophthalmic solution vehicle (placebo) dosed one full drop per eye BID; approximately 8 hours between the morning dose and the afternoon dose
88818723|NCT02724033|Active Comparator|Group A|Group A - regional nerve block
88818724|NCT02724033|Active Comparator|Group B|Group B - antiemetic
88818725|NCT02724033|Active Comparator|Group C|Group C - block and antiemetic
88818726|NCT05011539||Ovarian cancer|The patients with ovarian cancer
88818727|NCT05011539||Control group|
88818728|NCT02267447||Derivation cohort|Eligible respondents to the combined 2001, 2003 and 2005 Canadian Community Health Surveys, conducted by Statistics Canada.
88818729|NCT02267447||Validation cohort|Eligible respondents to the 2007 and 2009 Canadian Community Health Surveys.
88818730|NCT02724423|Experimental|NRL-1 Ictal|During the ictal or peri-ictal setting, a single intranasal dose of NRL-1 will be administered at either 5 mg, 10 mg, 15 mg, or 20 mg based on the subject's body weight.
88818731|NCT02724423|Experimental|NRL-1 Inter-Ictal|During the inter-ictal setting, a single intranasal dose of NRL-1 will be administered at either 5 mg, 10 mg, 15 mg, or 20 mg based on the subject's body weight.
88818732|NCT02267837|Experimental|OrthoPulse™|Subjects assigned to this group receive full mouth fixed orthodontic appliance treatment in conjunction with receiving daily OrthoPulse™ treatments.
88818733|NCT02267837|No Intervention|Control|Subjects assigned to this group receive full mouth fixed orthodontic appliance treatment only, and no OrthoPulse™ treatments.
88818734|NCT05745311|Experimental|low-dose group （The KPCXM18 injection）|Intravenous infusion of 20 mg twice daily at intervals of 12±2 hours for 10 days.
88818735|NCT05745311|Experimental|middle-dose group （The KPCXM18 injection）|Intravenous infusion of 60 mg twice daily at intervals of 12±2 hours for 10 days.
88818736|NCT05745311|Experimental|high-dose group （The KPCXM18 injection）|Intravenous infusion of 100 mg twice daily at intervals of 12±2 hours for 10 days.
88818737|NCT05745311|Placebo Comparator|Placebo|Intravenous infusion twice a day with an interval of 12±2 hours for 10 days.
88818738|NCT02726451|Placebo Comparator|Basic Skin Care|Subjects use a basic skin care regimen.
88818739|NCT02726451|Active Comparator|Active Skin Care|Subjects use the Sensi Peel®, Rejuvenating Serum, and C&E Strength Max skin care products in additional to a basic skin care regiment.
88818740|NCT02989259|Experimental|apatinib|apatinib 500mg p.o. qd
88818741|NCT02730663|Experimental|Niti-S SPAXUS Stent|Niti-S SPAXUS Stent (TaeWoong Medical Co., Ltd. Korea)
88818742|NCT05743205|Experimental|Educational Intervention|Educational intervention
88818743|NCT04985253||Operable breast neoplasm cohort|Operable breast cancer (OBC) ER +/Her2 neg or triple negative breast cancer patients diagnosed and treated at Tata Memorial Centre, Mumbai from 01 Jan 2010 to 31 Dec 2013 with a five-year follow up or events within the 5 years.
88818744|NCT01848821|Other|OASIS half of wound|OASIS will be applied to one half of the wound and standard of care consisting of wound vac only will be applied to the other half.
88818745|NCT01848821|Other|Standard therapy half of wound|Standard therapy to half of wound will consistent of non-stick mesh and wound VAC application.
88818746|NCT04950621|Experimental|Remimazolam|In remimazolam group, a 0.1 mg/kg dose of intravenous remimazolam was administered for induction, and 0.3-0.7 mg/kg/h infusion for maintenance after intubation.
89384885|NCT02623985|Experimental|Throat swab culture|Patients who presented with sore throat will be performed throat swab and sent for throat swab culture which is gold standard.
89384886|NCT01332877|Experimental|enriched breakfast|high carbohydrate, high protein breakfast providing 600 kcal, 50% carbohydrate, 20% protein, 30% fat
88859817|NCT03385512|Experimental|OPEN High Tech|Participants in this arm will experience the OPEN High Tech intervention.
88859818|NCT03385512|Experimental|ASK Poster|Participants in this arm will experience the ASK intervention.
88859819|NCT01921764|Experimental|Workplace physical exercise|Physical exercise (kettlebells, elastic bands, exercise balls) performed at the workplace with coaching
88859820|NCT01921764|Active Comparator|Home physical exercise|Physical exercise performed at home with elastic bands and bodyweight exercises with instruction to follow the exercises at http://www.jobogkrop.dk/Oevelser-til-nakke-og-ryg/Oevelser
88859821|NCT00983814|Experimental|Droxidopa+Carbidopa|Droxidopa (L-dihydroxyphenylserine (L-DOPS)) (200, 400, or 600mgs TID) in combination with carbidopa (25mg or 50mg TID)
88859822|NCT00983814|Placebo Comparator|Placebo|Placebo
88859823|NCT01921842|Experimental|Nutrition and Physical Activity Training|NAP-SACC Child Care Wellness program administered in year 1 of study
88859824|NCT01921842|Other|Delayed Intervention Group|NAP-SACC Child Care Wellness Program is administered in year 2 of study.
88859825|NCT03088332|Experimental|Endoscopic gastroplasty|Make a gastric tube similar to that obtained in surgical gastroplication however it will be created using intragastric endoscopic sutures.
88859826|NCT01921920|Active Comparator|Omeprazole 20mg aqueous|Treatment A: a single oral dose of omeprazole 20-mg aqueous-solvent based capsules (AstraZeneca - test)
88859827|NCT01921920|Active Comparator|Omeprazole 20mg organic|Treatment B: a single oral dose of omeprazole 20-mg organic-solvent based capsules (Merck - reference for Treatment A)
88859828|NCT01921920|Active Comparator|Omeprazole 40mg aqueous|Treatment C: a single dose of omeprazole 40-mg aqueous-solvent based capsules (AstraZeneca - test)
88859829|NCT01921920|Active Comparator|Omeprazole 40mg organic|Treatment D: a single dose of omeprazole 40-mg organic-solvent based capsules (Merck - reference for Treatment C)
89384887|NCT05095337|Experimental|[14C]SHR1459|
89384888|NCT01335139|Experimental|SCIT + Placebo|Subcutaneous immunotherapy (SCIT) + sublingual immunotherapy (SLIT) placebo
89384889|NCT01335139|Experimental|SLIT + Placebo|Sublingual immunotherapy (SLIT) + subcutaneous immunotherapy (SCIT) placebo
89384890|NCT01335139|Placebo Comparator|Placebo + Placebo|Sublingual immunotherapy (SLIT) placebo + subcutaneous immunotherapy (SCIT) placebo
89384891|NCT05030129|Experimental|Ergoloid mesylates (EM) and 5-hydroxytryptophan (5-HTP)|Ergoloid mesylates (EM) 1 mg three times daily and 5-hydroxytryptophan (5-HTP) 100 mg three times daily for 4 weeks
89384892|NCT05030129|Placebo Comparator|Placebo|2 placebo capsules three times daily for 4 weeks
88859830|NCT04275414|Experimental|bevacizumab plus standard care|Under ECG monitoring, give bevacizumab 500mg + 0.9% sodium chloride solution 100ml via intravenous drip, time is no less than 90min.
88859831|NCT04395924||Pregnant women COVID-19 positive by RT-PCR|Pregnant women COVID-19 positive by RT-PCR on nasopharyngeal swabs and/or by serology or with previous history of SARS-Cov-2 positive during the pregnancy coming to the maternity to deliver
88859832|NCT04395144|Experimental|Awake prone positioning|Prone positioning of patients on nasal high-flow oxygen therapy
88859833|NCT04395144|Active Comparator|Standard care|Standard decubitus positioning of patients on nasal high-flow oxygen therapy
88859834|NCT04395768|Experimental|Vitamin C|"Participants will receive vitamin C in addition to active comparator treatment:~Inpatients: IV Vitamin C (Sodium Ascorbate) 50mg/kg every 6hrs on day 1 followed by 100mg/kg every 6hrs (4x per day; 400mg/kg/day) for 7 days (average 28g/day; maximum dose of 50g/24hrs for those weighing more than 125kg). Can be converted to 1 gram three times per day PO on hospital discharge) Outpatients: Vitamin C Outpatient trial: 200mg/kg x1 IV, then 1 gram PO three times per day for 7 days;~Plus Active Comparator treatment:~Hydroxychloroquine Hydroxychloroquine 400mg (2x200mg) PO for 1 day, followed by 200mg PO per day for 6 days Azithromycin 500 mg PO on day 1 followed by 250 mg PO once daily for 4 days Zinc Citrate 30mg elemental zinc PO daily Vitamin D3 5,000iu PO daily for 14 days Vitamin B12 (Methylcobalamin) 500mcg PO daily for 14 days"
88859835|NCT04395768|Active Comparator|Control|Hydroxychloroquine Hydroxychloroquine 400mg (2x200mg) PO for 1 day, followed by 200mg PO per day for 6 days Azithromycin 500 mg PO on day 1 followed by 250 mg PO once daily for 4 days Zinc Citrate 30mg elemental zinc PO daily Vitamin D3 5,000iu PO daily for 14 days Vitamin B12 (Methylcobalamin) 500mcg PO daily for 14 days
88859836|NCT04396158|Experimental|intervention|
88859837|NCT01927146||Resectable gastric cancer|No intervention
88859838|NCT01927224|Experimental|Nifurtimox (Group 1)|Descriptive pharmacokinetic group
88859839|NCT01927224|Experimental|Nifurtimox (Group 2)|The assessment of bioequivalence of the two formulation (30mg vs.120mg)
88859840|NCT03831750|Experimental|Stress Reduction Intervention|Participants will receive the standard of care for IBD and training and access to an online stress reduction intervention.
88859841|NCT03831750|No Intervention|Control|Participants will receive the standard of care for IBD.
89384893|NCT05030129|Experimental|Ergoloid mesylates (EM) and placebo|Ergoloid mesylates (EM) 1 mg three times daily and 1 placebo capsule three times daily for 4 weeks.
89384894|NCT05030129|Experimental|5-hydroxytryptophan (5-HTP) and placebo|5-hydroxytryptophan (5-HTP) 100 mg three times daily and 1 placebo capsule three times daily for 4 weeks.
89384895|NCT01335217|Other|Open-label TNS treatment|There is only one arm in this open label treatment of MDD co-occuring with PTSD.
89384896|NCT05239559||bubble CPAP arm|"Oxygen will be delivered by Bubble CPAP device, which will have three components:~Continuous gas flow into the circuit: The gas flow rate required to generate CPAP is usually 5-10 L/min.~A nasal interface connecting the child's airway with the circuit: short nasal prongs are generally used to deliver nasal CPAP. They must be carefully fitted to minimize leakage of air (otherwise, CPAP will not be achieved) .~An expiratory arm with the distal end submerged in water to generate end-expiratory pressure: in bubble CPAP, the positive pressure is maintained by placing the far end of the expiratory tubing in water. The pressure is adjusted by altering the depth of the tube under the surface of the water."
89384897|NCT01338961|No Intervention|Normothermic CPB|Standard management. Patients will be kept at normothermia throughout the procedure (>36oC).
89384898|NCT01338961|Active Comparator|Hypothermic CPB|Patients will be cooled to 31-32oC (nasopharyngeal) after the beginning of CPB. Rewarming will begin 10-15 min before release of aortic cross-clamp. The gradient between heat-exchanger and nasopharynx during rewarming will be maintained at 3oC. The rewarming will be stopped at 36,5oC.
89384899|NCT01339039|Experimental|Part 1|Maximum Tolerated Dose Determination of Plerixafor (3 weeks on, 1 week off) and Bevacizumab (every 2 weeks)
89384900|NCT01339039|Experimental|Part 2|Surgical Arm: Safety evaluation of Plerixafor (3 weeks on, 1 week off) and Bevacizumab (every 2 weeks)
88859842|NCT01921998||Biomarker and health economics|Biomarkers will be taken throughout cycle 1. Health economics will be recorded using a patient side effect diary, a details of admission form, and a patient survey of healthcare use.
88859843|NCT01927458|Experimental|anodal tDCS with treadmill training|Each subject will receive 4 weeks gait treadmill training at least 3 days per week in combination with anodal transcranial Direct Current Stimulation over the primary motor cortex up to 20 min
88859844|NCT04396080|Experimental|Onlays behaviour depending on materials|Patients who require it as treatment option will be treated with posterior partial restorations, and will have clinical follow-up to obtain a comparison of the behavior of subsequent restorations based on the material.
88859845|NCT01927536||Night Vision|White LED Flashlight, Red/Green Green Dominant LED Flashlight
88859846|NCT01927614||Cohort 1|20 patients 1-year post heart transplant will undergo standard of care invasive cardiac catheterization but will also have intravascular ultrasound performed to measure the maximal intimal thickness of the proximal left anterior descending artery. Patients will be dichotomized into those with MIT <0.5mm (10 patients) and those with MIT >0.5mm (10 patients). All 20 patients will undergo both cardiac CT and cardiac MRI with perfusion imaging.
88859847|NCT01927614||Cohort 2|10 patients 1 year post heart transplant classified as CAV grade 0 by standard cardiac catheterization will undergo both cardiac CT and cardiac MRI with perfusion imaging.
88859848|NCT01927614||Cohort 3|10 patients with a diagnosis of CAV grade 1 as assessed by routine coronary angiogram at any time point post heart transplantation, will undergo cardiac CT and cardiac MRI with perfusion imaging
88859849|NCT01927692||MG subjects|MG subjects will have serum acetylcholine receptor (AChR) antibodies
88859850|NCT01922154|Experimental|intravitreal ranibizumab|Ranibizumab was injected into vitreous cavity in the study eye once (0.5 mg/0.05 ml) at least 1 week before performing trabeculectomy with mitomycin C.
88859851|NCT04554576|Experimental|6-week self-management and remote feedback for 6 months|All participants will receive the 6-week self-management program and after, half the group will be randomized to an every 6th week healthcare provider feedback phone or video visit session for 6 months (4 visits over 24 months).
88859852|NCT04554576|Active Comparator|6-week self-management and control group for 6 months|All participants will receive the 6-week self-management program and after, half will be randomized to a 6 month control grup
88859853|NCT03060642||Barrett's esophagus|Barrett's esophagus, without or with dysplasia or adenocarcnoma
88859854|NCT03060642||Controls|Non-BE endoscopic controls
88859855|NCT01927848|Experimental|Rosehip|Dosage: 3 capsules once daily with meals (daily dose: 2.25 g powder).
88859856|NCT01927848|Placebo Comparator|Placebo|Dosage: 3 capsules once daily with meals
88859857|NCT01927926|Experimental|Whey-protein & polydextrose snack|Whey-protein & polydextrose snack bar.
88859858|NCT01927926|Placebo Comparator|Control snack|Control snack bar containing minimal protein and not polydextrose.
88859859|NCT01922310|Other|Communication intervention|This study uses a single arm design with current 'controls' to explore an intervention, the procedure for providing information and requesting consent for donation, that uses new agreed best practice procedures led by specially trained intensive care health professionals. The study intervention is a staff education and training module intended to provide a framework and preparation for select critical care staff to conduct organ donation discussions in line with best practice.
88859860|NCT04552470|Placebo Comparator|Placebo|
88859861|NCT04552470|Experimental|PF-06882961 40 mg|Participants will be titrated up to 2 weeks to reach desired dose level
88859862|NCT04552470|Experimental|PF-06882961 80 mg|Participants will be titrated up to 4 weeks to reach desired dose level
88859863|NCT04552470|Experimental|PF-06882961 120 mg|Participants will be titrated up to 6 weeks to reach desired dose level
88859864|NCT04550130|Experimental|low dose (1.8 L)|Patients in this arm will be treated with one column (Leukapheresis) and 1.8 L blood will be filtered.
88859865|NCT04550130|Experimental|high dose (3.6 L)|Patients in this arm will be treated with Two column (Leukapheresis) and 3.6 L blood will be filtered.
88859866|NCT04556916|Experimental|Men over 40 being suspicious of prostate cancer|Per patient 49 ml of peripheral blood sample after signing consent and performing before the 1st prostate biopsy
88859867|NCT04556916|Experimental|Men over 40 with no suspicion of prostate cancer|Per patient 49 ml of peripheral blood sample after signing consent
88859868|NCT03423342|Experimental|Nicotinamide Riboside|Nicotinamide riboside will be supplied as 250mg capsules, to be administered orally. The initial dose will be 1 capsule twice daily, followed by weekly up-titration by 1 capsule/dose to a final dose of 4 capsules (1000mg) twice daily at the end of Week 4. Participants will be continued on the final dose up to the final follow up visit (week 12). If, at any step, a dose increase is not tolerated, the maximum previously-tolerated dose will be continued through to week 12.
89003102|NCT05769309|Active Comparator|Erector spinae block group|the patients will be administered bilateral Erector spinae block with 20 ml of 0.25 % bupivacaine
89003103|NCT05769309|Other|control group|no block will be done but only IV analgesia.
89384901|NCT01339039|Experimental|Part 3|Safety and tolerability of Plerixafor (daily) at MTD dose from Part 1 and Bevacizumab (every 2 weeks)
89384902|NCT03176459|Experimental|EXPAREL+bupivacaine TAP infiltration|Receive a single 20-mL dose of EXPAREL 266 mg expanded in volume with 20 mL normal saline plus 20 mL 0.25% bupivacaine for a total volume of 60 mL.
89384903|NCT03176459|Active Comparator|Active bupivacaine TAP infiltration|Receive 20 mL 0.25% bupivacaine expanded in volume with 40 mL normal saline for a total volume of 60 mL
89384904|NCT01339117|Experimental|High fermentable substrate diet|High fermentable substrate diet provided for two days
89384905|NCT01339117|Experimental|Low fermentable substrate diet|Low fermentable substrate diet provided for two days
89384906|NCT05239481|Experimental|intervention|Before the examination, the nurse chose the appropriate colonoscopy position size sheet according to the patient's age and body size and spread it on the examination bed; instructed the patient to lie in the designated area according to the body size.Description: ① take off your shoes; ② follow the bed chart; ③ fade your pants to your knees.
89384907|NCT05239481|Placebo Comparator|control|Traditional disposable cleaning sheets were used during control colonoscopy.Before the examination, the nursing staff took a unified and simple language to guide the patient, the following: ① please remove the shoes; ② please sit on the end of the bed mattress; ③ please lie to the left side; ④ please put the head close to the pillow; ⑤ please fade the pants to the knee; ⑥ please put the knee close to the abdomen.
88859869|NCT03423342|Placebo Comparator|Placebo|Matching placebo will be supplied as 250mg capsules, to be administered orally. The initial dose will be 1 capsule twice daily, followed by weekly up-titration by 1 capsule/dose to a final dose of 4 capsules (1000mg) twice daily at the end of Week 4. Participants will be continued on the final dose up to the final follow up visit (week 12). If, at any step, a dose increase is not tolerated, the maximum previously-tolerated dose will be continued through to week 12.
89384908|NCT01332955|Experimental|Telaprevir-pegIFN alfa-2a-ribavirine|Single Group Assignment
89384909|NCT05224895||General Anesthesia in Trendelenburg position for robotic prostatectomy|
89384910|NCT01335373||Group 1|
88859870|NCT01928160|Experimental|Arm I (chemotherapy, erlotinib hydrochloride)|Patients receive erlotinib hydrochloride PO QD on days 1-21, pemetrexed disodium IV and carboplatin IV or cisplatin IV on day 1. Treatment repeats every 21 days for 4 courses. Patients then receive maintenance erlotinib hydrochloride PO QD on days 1-21 and pemetrexed disodium IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
88859871|NCT01928160|Experimental|Arm II (chemotherapy)|Patients receive pemetrexed disodium and carboplatin or cisplatin as in Arm I. Treatment repeats every 21 days for 4 courses. Patients then receive maintenance pemetrexed disodium as in Arm I. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
88859872|NCT04274946|Active Comparator|RAI+PB+US|Sentinel lymph node mapping with dual tracer (radioisotope and patent blue) and intraoperative ultrasound to identify SLN in the breast cancer patients
88859873|NCT04274946|Experimental|RAI+ICG+US|Sentinel lymph node mapping with dual tracer (radioisotope and ICG) and intraoperative ultrasound to identify SLN in the breast cancer patients
88859874|NCT04274946|Experimental|RAI+PB+ICG+US|Sentinel lymph node mapping with triple tracer (radioisotope,ICG and patent blue) and intraoperative ultrasound to identify SLN in the breast cancer patients
88859875|NCT04274946|Experimental|PB+ICG+US|Sentinel lymph node mapping with triple tracer (ICG and patent blue) and intraoperative ultrasound to identify SLN in the breast cancer patients
88859876|NCT01928238|Experimental|Arm 1|"Patients will have two 20-minute noninvasive periods :~Noninvasive neurally adjusted ventilatory assist (NIV-NAVA) and then Noninvasive pressure support ventilation (NPSV)"
88859877|NCT01928238|Experimental|Arm 2|"Patients will have two 20-minute noninvasive periods :~Noninvasive pressure support ventilation (NPSV) and then Noninvasive neurally adjusted ventilatory assist (NIV-NAVA)"
88859878|NCT01928316|Experimental|Sequence A|Healthy male volunteers will receive single oral dose of 10 mg imported mizolastine tablet on Day 1 and single oral dose of 10 mg domestic (made in China) mizolastine tablet on Day 8.
88859879|NCT01928316|Experimental|Sequence B|Healthy male volunteers will receive single oral dose of 10 mg domestic (made in China) mizolastine tablet on Day 1 and single oral dose of 10 mg imported mizolastine tablet on Day 8.
88859880|NCT04346472||Gliomes de grade II initial|Gliomes de grade II initial
88859881|NCT04551846|Experimental|Oligomeric enteral feeding group|Oligomeric enteral nutrition will be administered according to the study protocol
88859882|NCT04551846|Active Comparator|Polymeric enteral feeding group|Polymeric enteral nutrition will be administered according to the study protocol
88859883|NCT04550520|Experimental|study part 1: healthy adult volunteers|22 Healthy volunteers: The half of the study group will start with test day A (injection of glucagon), followed by test day B (injection of placebo) and the other half will start with test day B (injection of placebo), followed by test day A (injection of glucagon).
88859884|NCT04550520|Experimental|study part 2: adult patients with primary polydipsia or central diabetes insipidus|If results of study part 1 suggest that glucagon stimulates copeptin (proof of concept),10 patients with primary polydipsia and 10 patients with central diabetes insipidus will be additionally included (study part 2): The half of the study group will start with test day A (injection of glucagon), followed by test day B (injection of placebo) and the other half will start with test day B (injection of placebo), followed by test day A (injection of glucagon).
88859885|NCT01928550||PDR patients|Patients suspected to have Proliferative Diabetic Retinopathy or PDR
88859886|NCT04759482||Patients with sleep apnea|We selected 150 patients recorded by polysomnography between january 2019 and june 2020 in the Center for Sleep Medecine and Research in Nancy.
88859887|NCT01928628|Active Comparator|Lercanidipine 10mg|1 Tablet of Zanidip ® 10mg + 1 Tablet of L10/V80 Placebo + 1 Tablet of L10/V160 Placebo (8wks)
89384911|NCT05221463|Experimental|Educational group|Video-assisted breastfeeding training was given to the educational group.
89384912|NCT05221463|Other|Control group|Only the hospital's routine general breastfeeding training was given to the control group, and no other intervention was made.
89384913|NCT03204721|Active Comparator|Extracorporeal photophoresis|The treatment procedure of ECP consists of three steps. First, the leukocytes are removed by apheresis; second, the mononuclear cells are primed with the photosensitizing agent 8-methoxypsoralen; then third, these cells are exposed to radiation with ultraviolet A light before they are re-infused into the patient.
89384914|NCT03204721|No Intervention|Controll|No procedure
89384915|NCT05218811|Experimental|Treatment group|Patients underwent Cryotheapy assisted partial nephrectomy
89384916|NCT05185219|Experimental|Valerian|generic name: XIE CAO CONC dosage form: capsule dosage: 500 mg/capsule, 6 capsules a day frequency: 3 times a day after each meal, 2 capsules each time duration: 30 days
89384917|NCT05185219|Placebo Comparator|Control|generic name: placebo (Caramel Colors dyed starch) dosage form: capsule dosage: 500 mg/capsule, 6 capsules a day frequency: 3 times a day after each meal, 2 capsules each time duration: 30 days
89384918|NCT01315483|Experimental|Low fat, high carb weight loss diet|Ornish-like weight loss dietary pattern
88818747|NCT04950621|Active Comparator|Propofol|In propofol group, a 2 mg/kg dose of intravenous propofol was administered for induction, and 4-12 mg/kg/h infusion for maintenance after intubation.
88859888|NCT01928628|Experimental|Lercanidipine10mg /Valsartan 80mg|1 Tablet of Zanidip ® 10mg Placebo +1 Tablet of L10/V80 + 1 Tablet of L10/V160 Placebo (8wks)
88859889|NCT01928628|Experimental|Lercanidipine 10mg /Valsartan 160mg|1 Tablet of Zanidip ® 10mg Placebo + 1 Tablet of L10/V80 Placebo + 1 Tablet of L10/ V160 (8wks)
88859890|NCT01928706|Experimental|Denture liner Mucopren Soft; Group 1|The existing mandibular dentures were relined with a soft silicone-based denture liner (Mucopren Soft; Group 1; n=22).
88859891|NCT01928706|Active Comparator|Denture liner Kooliner; Group 2|The existing mandibular dentures were relined with a a hard acrylic resin based denture liner (Kooliner; Group 2 n=22).
88859892|NCT01928784|Experimental|Specific pain spot|Radial Extracorporeal Shock Wave Therapy 2000 impulses, Patients with specific pain spot for low back pain
88859893|NCT01928784|Experimental|No specific pain spot|Radial Extracorporeal Shock Wave Therapy 4000 impulses, Patients without specific pain spot for low back pain
88859894|NCT03084900|Experimental|Patient-Centered Decision Support|Intervention - computer decision support in diabetes clinic. Investigators will use a computerized decision support system to aid clinicians to provide standard of care management while introducing patient-centered guidelines and outcomes measures. The intervention is the use of an electronic decision support tool. The decision support tool consists of a series of questions answered by the patients that will then allow the health care provider to address specific needs during the visit.
88859895|NCT03084900|No Intervention|Standard Care|Standard pediatric diabetes care will be compared to the computerized decision support system.
88859896|NCT01929096|Experimental|Low-dose group|Compound Edaravone Injection, 12.5mg/dose (Edaravone 10mg, (+)-Borneol 2.5mg), one dose every 12 hours, continue for 14 days
88859897|NCT01929096|Experimental|Medium-dose group|Compound Edaravone Injection, 37.5mg/dose (Edaravone 30mg, (+)-Borneol 7.5mg), one dose every 12 hours, continue for 14 days
88859898|NCT01929096|Experimental|High-dose group|Compound Edaravone Injection, 62.5mg/dose (Edaravone 50mg, (+)-Borneol 12.5mg), one dose every 12 hours, continue for 14 days
88859899|NCT01929096|Active Comparator|Control group|Edaravone Injection，30 mg/dose, one dose every 12 hours, continues for 14 days
88859900|NCT01929174||Controls|Patients undergoing catheterization for other reasons who have a normal biventricular heart.
88859901|NCT01929174||Single ventricle Fontan|"Patients with a single functional ventricle (excluding hypoplastic left heart syndrome) palliated with a Fontan type operation involving passive blood flow to the lungs."
88859902|NCT05600790|Experimental|the MIED+TAU group|Intervention description: provide standard audio instructions for mindfulness exercises, introduce the nature and law of anxiety, depression and other emotions, the source of anxiety, depression and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems.
88859903|NCT05600790|No Intervention|the TAU-only group|TAU consisted of all medicinal and psychological treatments received between baseline and follow-up (about five months). Medicinal treatments included receiving Lorazepam, Olanzapine, Paroxetine Hydrochloride, Sertraline, etc. Psychological treatments included receiving cognitive behavior therapy or psychodynamic therap
88859904|NCT03059004|Experimental|1. Home Exercise Program|The Home Exercise group receives the TeMPO Home Exercise Program (including a set of weights, a DVD showing how to complete the TeMPO exercises, and a pamphlet outlining instructions on how to complete the exercises and how often should they be done).
88859905|NCT03059004|Experimental|2. Home Exercise Program + SMS Messages|Subjects in this arm receive the TeMPO Home Exercise Program and motivational SMS messages to encourage them to adhere to the TeMPO Home Exercise regimen.
88859906|NCT03059004|Experimental|3. In-Clinic Topical Therapy|Subjects in this arm receive the TeMPO Home Exercise Program, motivational SMS messages to encourage them to adhere to the TeMPO Home Exercise Program, and 14 in-clinic sessions with a trained physical therapist. The therapist will apply topical therapies: ultrasound, gel, and manual therapy.
88859907|NCT03059004|Experimental|4. In-Clinic Exercise Therapy|Subjects in this arm will receive the TeMPO Home Exercise Program, SMS motivational messages to encourage them to adhere to the TeMPO Home Exercise Program and 14 in-clinic sessions with a trained physical therapist. The therapist will supervise the participant in a rigorous set of strengthening and stretching exercises.
88859908|NCT04554888|Experimental|Doxepin Application|During the session each forearm of the subject will be divided into four squared areas (2.5x2.5 cm), see Figure 4. Four of the areas will be treated with doxepin for 1 hour and 30 minutes (with a patch to deposit 1.2 grams of cream). Each patch will be covered with Tegaderm I.V., an occlusive, adhesive dressing (3M), for at least 1½ hours 48. At the end of the pre-treatment period, the patches will be removed and the skin will be cleaned with alcohol.
88859909|NCT04554888|Experimental|Itch Induction|After Doxepin removal, Then tests with papain, cowhage, histamine or vehicle will be conducted. Each substance will be randomly applied in two areas, one pretreated with doxepin and one with no pre-treatment.
88859910|NCT04553016|Experimental|1: Vaccine|"At Week 0, volunteers receive 5.0 x 10^10 virus particles (vp) of ChAdOx1.tHIVconsv1 (C1) administered intramuscularly (IM). The dose is divided in 2 and administered in the deltoid muscle of each arm.~At week 4,1.0 x 10^8 Plaque forming units (PFU) of MVA.tHIVconsv3 (M3) administered IM and 0.9 x 10^8 PFU of MVA.tHIVconsv4 (M4) are administered IM simultaneously, one into the deltoid muscle of each arm."
88818748|NCT01578135||Phase I|
88818749|NCT01578135||Phase II|
88818925|NCT02270645|Experimental|Treatment: 595/1064 multiplex laser|"Subjects in the treatment arm will receive 3 treatments using the 595/1064 multiplex laser spaced by a four week interval (+/- 3 days), administered in an outpatient clinic setting. If a subject in the treatment arm has multiple BCCs satisfying inclusion criteria, all BCCs will be treated.~Four weeks (+/- 3 days) after the last treatment (Day 84) both treatment and control patients will be assessed for final clinical appearance, measurement, and evaluation of the lesion by a dermatologist.~Subjects will also undergo deep excisional biopsy encompassing the entire lesion to determine residual tumor cell presence. If histologic examination of the tissue reveals residual BCC, then the subject will receive standard of treatment."
89384919|NCT01315483|Experimental|Low carb, high fat weight loss diet|South-Beach-like weight loss diet pattern
89384920|NCT01315483|No Intervention|Control|Usual care
89384921|NCT01333267|Experimental|PTHrP group|Subjects receive PTHrP(1-36) starting with doses of 2 picomoles (pmols)/kg/hr for one week. Subsequent dosing groups are determined by the response to PTHrP doses.
89384922|NCT01333267|Experimental|PTH dosing group|Subjects receive PTH(1-34) starting with doses of 2 picomoles (pmols)/kg/hr for one week. Subsequent dosing groups are determined by the response to PTH doses.
89384923|NCT03155269|Experimental|Group 1- Protein rich beverage powder fortified with MMN|Participants will be administered orally two doses of cereal based fortified beverage (30 grams powder made up in 200 milliliter (mL) water) daily in the morning and evening for 6 months.
89384924|NCT03155269|Other|Group 2 -Low protein non-fortified iso-caloric beverage powder|Participants will be administered orally two doses (in morning and evening) of low protein non fortified isocaloric beverage (30 grams powder made up in 200 mL water) daily for 6 months.
89384925|NCT02906670|Experimental|1 mg/kg Q1W|Phase 1a: Patients are administered a weekly dose of 1 mg/kg of Sym013 until unacceptable toxicity, progressive disease, termination of the trial or patient decision to withdraw.
89384926|NCT02906670|Experimental|2 mg/kg Q1W|Phase 1a: Patients are administered a weekly dose of 2 mg/kg of Sym013 until unacceptable toxicity, progressive disease, termination of the trial or patient decision to withdraw.
89384927|NCT02906670|Experimental|4 mg/kg Q1W|Phase 1a: Patients are administered a weekly dose of 4 mg/kg of Sym013 until unacceptable toxicity, progressive disease, termination of the trial or patient decision to withdraw.
89384928|NCT02906670|Experimental|6 mg/kg Q1W + Prophylaxis|"Phase 1a: Patients are administered a weekly dose of 6 mg/kg of Sym013 + premedication until unacceptable toxicity, progressive disease, termination of the trial or patient decision to withdraw.~Premedications for infusion-related reactions included glucocorticoids and an antihistamine (H1 antagonist) prior to each dose of Pan-HER from the beginning of the study. As of Protocol Amendment 5, additional premedications were added which included montelukast, dexamethasone, antihistamine (H2 antagonist), and acetaminophen."
89384929|NCT02906670|Experimental|9 mg/kg Q1W + Prophylaxis|"Phase 1a: Patients are administered a weekly dose of 9 mg/kg of Sym013 + premedication until unacceptable toxicity, progressive disease, termination of the trial or patient decision to withdraw.~Premedications for infusion-related reactions included glucocorticoids and an antihistamine (H1 antagonist) prior to each dose of Pan-HER from the beginning of the study. As of Protocol Amendment 5, additional premedications were added which included montelukast, dexamethasone, antihistamine (H2 antagonist), and acetaminophen."
89384930|NCT02906670|Experimental|6 mg/kg Q2W|Phase 1a: Patients are administered a dose of 6 mg/kg of Sym013 every second week until unacceptable toxicity, progressive disease, termination of the trial or patient decision to withdraw.
89384931|NCT02906670|Experimental|9 mg/kg Q2W|Phase 1a: Patients are administered a dose of 9 mg/kg of Sym013 every second week until unacceptable toxicity, progressive disease, termination of the trial or patient decision to withdraw.
89384932|NCT02906670|Experimental|9 mg/kg Q2W + Prophylaxis|"Phase 1a: Patients are administered a dose of 9 mg/kg of Sym013 + premedication every second week until unacceptable toxicity, progressive disease, termination of the trial or patient decision to withdraw.~Premedications for infusion-related reactions included glucocorticoids and an antihistamine (H1 antagonist) prior to each dose of Pan-HER from the beginning of the study. As of Protocol Amendment 5, additional premedications were added which included montelukast, dexamethasone, antihistamine (H2 antagonist), and acetaminophen."
89384933|NCT02906670|Experimental|12 mg/kg Q2W + Prophylaxis|"Phase 1a: Patients are administered a dose of 12 mg/kg of Sym013 + premedication every second week until unacceptable toxicity, progressive disease, termination of the trial or patient decision to withdraw.~Premedications for infusion-related reactions included glucocorticoids and an antihistamine (H1 antagonist) prior to each dose of Pan-HER from the beginning of the study. As of Protocol Amendment 5, additional premedications were added which included montelukast, dexamethasone, antihistamine (H2 antagonist), and acetaminophen."
89384934|NCT02906670|Experimental|15 mg/kg Q2W + Prophylaxis|"Phase 1a: Patients are administered a dose of 15 mg/kg of Sym013 + premedication every second week until unacceptable toxicity, progressive disease, termination of the trial or patient decision to withdraw.~Premedications for infusion-related reactions included glucocorticoids and an antihistamine (H1 antagonist) prior to each dose of Pan-HER from the beginning of the study. As of Protocol Amendment 5, additional premedications were added which included montelukast, dexamethasone, antihistamine (H2 antagonist), and acetaminophen."
89384935|NCT02906670|Experimental|Phase 2a Dose-Expansion Cohort A|Part 2 is a Phase 2a dose-expansion with Sym013 at the RP2D and regimen. One (1) of 4 tumor types to be evaluated in this arm of the trial will be selected based upon findings from Part 1, additional preclinical data, and additional clinical data available at that time from other agents inhibiting these targets.
89384936|NCT02906670|Experimental|Phase 2a Dose-Expansion Cohort B|Part 2 is a Phase 2a dose-expansion with Sym013 at the RP2D and regimen. One (1) of 4 tumor types to be evaluated in this arm of the trial will be selected based upon findings from Part 1, additional preclinical data, and additional clinical data available at that time from other agents inhibiting these targets.
88859911|NCT04553016|Placebo Comparator|2. Placebo|Normal sterile saline (0.9% Sodium Chloride solution) administered IM as Placebo, the volume is matched to that of the vaccines and administered in the deltoid muscle of each arm at Week 0 and at week 4 .
88859912|NCT03374592|Active Comparator|Conventional Radiotherapy|8Gy in 1 fraction or 20Gy in 5 fractions
88859913|NCT03374592|Experimental|Volumetric Intensity-Modulated Arc Therapy|8Gy in 1 fraction or 20Gy in 5 fractions
88859914|NCT04553406|Experimental|SPR720 low dose|SPR720 500 mg administered orally once daily for 28 days.
88859915|NCT04553406|Experimental|SPR720 high dose|SPR720 1000 mg administered orally once daily for 28 days.
88859916|NCT04553406|Placebo Comparator|Placebo|Placebo administered orally once daily for 28 days
88859917|NCT04553406|Active Comparator|Standard of Care (SOC)|Standard of Care regimen per the Investigator's discretion.
88859918|NCT04759638||Rectal Cancer|Rectal Cancer
88859919|NCT04395300||Healthcare workers|Physicians, Nurses, Laboratory workers, radiology technicians
89384937|NCT02906670|Experimental|Phase 2a Dose-Expansion Cohort C|Part 2 is a Phase 2a dose-expansion with Sym013 at the RP2D and regimen. One (1) of 4 tumor types to be evaluated in this arm of the trial will be selected based upon findings from Part 1, additional preclinical data, and additional clinical data available at that time from other agents inhibiting these targets.
89384938|NCT02906670|Experimental|Phase 2a Dose-Expansion Cohort D|Part 2 is a Phase 2a dose-expansion with Sym013 at the RP2D and regimen. One (1) of 4 tumor types to be evaluated in this arm of the trial will be selected based upon findings from Part 1, additional preclinical data, and additional clinical data available at that time from other agents inhibiting these targets.
88859920|NCT04124796|Experimental|target subjects|"target subjects patients are expected, corresponding to the average population received each year for a CBCa in the unit."
89384939|NCT01339195|Experimental|Behavioral|Behavioral: French adaptation of NINDS-Canadian Stroke Network battery
89384940|NCT01339351|No Intervention|Usual Psychosocial Care|Participants are free to use any psychosocial care available to cancer patients. No restrictions to participation in other groups or services.
89384941|NCT01339351|Experimental|Therapeutic Group by teleconference|ten 90 minute group sessions by teleconference. Lead by social workers. Sessions focus on information, story sharing and coping.
88859921|NCT04124796|Active Comparator|health care team|the health care team managing these patients
88859922|NCT04124718||high caries experience|80 adults will be allowed in the high caries experience group according to DMFT index DMFT>13.9
88859923|NCT04124718||low caries experience|80 adults will be allowed in the high caries experience group according toDMFT index DMFT≤4
88859924|NCT04394052||Soft-tissue tumors|Benign and malignant soft tissue masses
88859925|NCT04394052||Bone tumors|Benign and malignant bone focal bone lesions
88859926|NCT05605002|Active Comparator|Waiting list group|This group will include 30 patients with MDD who will be treated with oral SSRIs only, the dosage of which will be determined by the psychiatrist. After 6 weeks, patients could choose 6 weeks' intradermal acupuncture treatments free of charge.
88859927|NCT05605002|Sham Comparator|SIA+SSRIs group|This group will include 30 patients with MDD who will be treated with sham intradermal acupuncture combined with SSRIs. Acupoints related to MDD will be stimulated by acupuncturists and the dosage of oral SSRIs will be determined by the psychiatrist.
88859928|NCT05605002|Experimental|AIA+SSRIs group|This group will include 30 patients with MDD who will be treated with active intradermal acupuncture combined with SSRIs. Acupoints related to MDD will be stimulated by acupuncturists and the dosage of oral SSRIs will be determined by the psychiatrist.
88859929|NCT05604846|Experimental|Probiotic group|Probiotic group: 0,5 g per day of ProPrems®, including a combination of Bifidobacterium infantis Bb-02 (DSM 33361) 300 million, Bifidobacterium lactis (BB-12®) 350 million and Streptococcus thermophilus (TH-4®) 350 million. Mixed with 3 mills of breastmilk
89384942|NCT01335451|Experimental|Active|Each cohort will have 6 subjects that will receive AZD5213
88859930|NCT05604846|Placebo Comparator|Control group|Control group receives 3 mills of breastmilk without additives
88859931|NCT05604768||Normal parturient group|20 normal parturients who had undergone antenatal examination and delivery in Beijing Ditan Hospital were fully informed of the risks and volunteered to join the study and signed the informed consent form.
88859932|NCT05604768||Pregnant women with threatened premature delivery group|20 pregnant women with threatened preterm labor who had undergone antenatal examination and delivery in Beijing Ditan Hospital were fully informed of the risks and volunteered to join the study and signed the informed consent form.
88859933|NCT03034512||Patients with Alpers-Huttenlocher|Patients confirmed to have Alpers Huttenlocher Syndrome
88859934|NCT03034512||Siblings|Siblings of patients with Alpers Huttenlocher Syndrome
88859935|NCT04124484|Experimental|50mg group|Participants received one 50mg of DBPR108 tablet and two placebos matching DBPR108 100mg under fasted conditions for one day.
88859936|NCT04124484|Experimental|100mg group|Participants received one 100mg of DBPR108 tablet and two placebos matching DBPR108 50mg and 100mg under fasted conditions for one day.
88859937|NCT04124484|Experimental|200mg group|Participants received two 100mg of DBPR108 tablets and one placebo matching DBPR108 50mg under fasted conditions for one day.
88859938|NCT04124484|Placebo Comparator|placebo group|Participants received two placebo matching DBPR108 100mg and one placebo matching DBPR108 50mg
88859939|NCT04124016|Experimental|Inulin|Inulin_ extract of chicory fermentable fiber
88859940|NCT04124016|Experimental|green tea extract|green tea extract_rich in tri-hydroxylated flavan-3-ol monomers (1 mmol of PVL precursor)
88859941|NCT04124016|Experimental|grape seed|grape seed extract - rich in di-hydroxylated flavan-3-ol monomers (1 mmol of PVL precursors)
88859942|NCT04124016|Experimental|grape seed exctract|grape seed extract - rich in di-hydroxylated flavan-3-ol oligomers (1 mmol of PVL precursors)
88859943|NCT04124094|Experimental|Fluticasone propionate 100 mcg and salmeterol xinafoate 50 mcg|Test Product
88859944|NCT04124094|Active Comparator|SERETIDE DISKUS 100/50|reference Product
88859945|NCT05604612|Experimental|Experimental|
88859946|NCT05604612|No Intervention|Active Comparator|
88859947|NCT05604378||EBV-positive gastric cancers|
88859948|NCT05604378||EBV-negative gastric cancers|
88859949|NCT04123782|Active Comparator|Group A (F-ESWT group)|3 sessions, one per week, of electromagnetic focused extracorporeal shockwave treatment (3000 impulses at 0.12 mJ/mm2 per session)
89384943|NCT01335451|Placebo Comparator|Placebo|Each cohort will have 2 subjects that will receive placebo
88859950|NCT04123782|Placebo Comparator|Group B (placebo group)|3 sessions, one per week, of electromagnetic focused extracorporeal shockwave treatment (3000 impulses at 0.01 mJ/mm2 per session)
89384944|NCT01335529|Experimental|Boceprevir, PegIFN alfa 2b, Ribavirin|"Standard Treatment :~Peg-Interferon (PegIFN) alfa 2b by subcutaneous injection 1,5 µg/kg/week~Ribavirin capsules 200mg: dosage delivered in weight categories (< 65 kg: 800 mg ; 65-80 kg: 1000 mg; 81-105 kg: 1200mg; > 105 kg: 1400mg)~Three-drug-regimen:~Peg-Interferon alfa 2b by subcutaneous injection 1,5 µg/kg/week~Ribavirin capsules 200mg: dosage delivered in weight categories like in standard treatment~Boceprevir tablets 200mg: 800 mg 3 times a day (2400 mg/j) with food"
89384945|NCT01335607|Active Comparator|Part A: Samatasvir cap→tab→tab; Part B: cap|Part A: Samatasvir capsule as a single dose on Day 1 (fasting state) followed by samatasvir tablet as a single dose on Day 8 (fasting state) followed by samatasvir tablet as a single dose on Day 15 (fed state); Part B: samatasvir capsule as a single dose on Day 1 (fed state)
89384946|NCT01335607|Active Comparator|Part A: Samatasvir tab→cap→tab; Part B: cap|Part A: Samatasvir tablet as a single dose on Day 1 (fasting state) followed by samatasvir capsule as a single dose on Day 8 (fasting state) followed by samatasvir tablet as a single dose on Day 15 (fed state); Part B: samatasvir capsule as a single dose on Day 1 (fed state)
89384947|NCT02906358|Active Comparator|Community-based pain self-management|Community-based pain self-management: two, one-hour meetings monthly for the first three months (6 meetings) and one meeting per month for the last three months (total 9 meetings)
89384948|NCT02906358|Active Comparator|Clinic-based pain self-management|Clinic-based pain self-management: 30-45 minute individualized meetings once monthly for 6 months (total 6 meetings)
88859951|NCT04274868||Children and adolescents with liver tumor|Patients treated after 01/01/1990 for a primary liver tumor before the age of 18.
88859952|NCT03831438|Other|Dose escalation|"Sequential escalating doses of AVID200 when administered once every 2 weeks (Q2W) by 1-hour intravenous (IV) infusion to patient cohorts with diffuse cutaneous systemic sclerosis (dcSSc).~Each 2-week dosing period equals 1 cycle; patients may receive up to 3 cycles of AVID200 (i.e., dosing on D1, 15, and 29 of overall 6 week treatment period)."
88859953|NCT04123392|Experimental|Decitabine + BUCY|For TP53+ myeloid tumors undergoing allo-HSCT, Decitabine +BUCY conditioning regimen was Decitabine 20mg/m2/day on days -14 and -10, Busulfan (BU) 3.2 mg/kg/day on days -7 and -4, Cyclophosphamide (CY) 60 mg/kg/day on days -3 and -2.
88859954|NCT04123392|Active Comparator|BUCY|For TP53+ myeloid tumors undergoing allo-HSCT, BUCY conditioning regimen was Busulfan (BU) 3.2 mg/kg/day on days -7 and -4, Cyclophosphamide (CY) 60 mg/kg/day on days -3 and -2.
88859955|NCT04393038|Experimental|ABX464|ABX464 - Capsules + Standard of Care (SOC)
88859956|NCT04393038|Placebo Comparator|Placebo|Placebo - Capsules + Standard of Care (SOC)
88859957|NCT05601258||patients with higher lipase level|patients with higher lipase levels (higher than the laboratory upper limits) in the course of SARS-CoV-2 infection
88859958|NCT05601258||Control|patients with normal lipase levels in the course of SARS-CoV-2 infection
88859959|NCT04760262||Group Propofol|anesthesia was maintained with TIVA (intravenous 125-250 µg/kg/min propofol + 0.1-0.25 µg/kg/min remifentanil infusion)
88859960|NCT04760262||Group Sevoflurane|anesthesia was maintained with inhalation (sevoflurane concentration of 1-2% in 50-50% O2-air mixture).
88859961|NCT04127292|Experimental|Emotional Self Awareness Group (Clinician participants)|Virtual Human Interaction (VHI) to train outpatient clinicians in emotional self-awareness (ESA) and receive clinician-focused, comprehensive feedback in ESA
88859962|NCT04127292|No Intervention|Emotional Self Awareness Group (Patient participants)|Patients provided care by clinicians trained in ESA
88859963|NCT04127292|Sham Comparator|Control Group (Clinician participants)|The Control group CPs will engage in the same two VHI scenarios and will complete the TRQ-SF in response to each scenario without receiving the ESA feedback
88859964|NCT04127292|No Intervention|Control Group (Patient participants)|Patients provided care by clinicians not receiving ESA feedback
89384949|NCT02186834|Experimental|Selinexor, Liposomal Doxorubicin and Dexamethasone|"Combination Therapy: Phase I Dose Escalation followed by Phase 2 treatment at Recommended Phase 2 Dose (RP2D).~After the initial screening visit and registration in the study, participants will receive Selinexor orally at a dose of 80 mg along with dexamethasone for 1 day. One week later, patients will receive weekly selinexor at a starting dose from 60 mg once a week to 80 mg twice a week in combination with pegylated liposomal doxorubicin at a starting dose of 20 mg/m², and dexamethasone 40 mg orally weekly."
89535151|NCT03324503|Experimental|Glucocorticoid ≥ 30 mg/day|≥ 30 mg/day prednisone or prednisolone as per local clinical practice of sarcoidosis initial induction therapy will be taken orally preferably before, during, or immediately after meals or with food or milk, at approximately the same time of day for 8 weeks.
89535152|NCT03229993|Experimental|OCT guided PCI|
88859965|NCT04123002|Experimental|Interventional group|Miswak chewing sticks would be provided to the participants and they would be explained the method of use
88859966|NCT04123002|No Intervention|Comparison group|They would use only tooth brush and paste
88859967|NCT04123236||Oral Health Impact Profile|To evaluate the Oral Health-related Quality of Life, Turkish version of Oral Health Impact Profile-14 was used. Responses were made on a scale 0 (never), 1(hardly ever), 2 (occasionally), 3 (fairly often),and 4 (very often).Oral Health-related Quality of Life impairment was characterized by the Oral Health Impact Profile-14 summary score (the sum of all 14 items, potential range 0-56). Higher Oral Health Impact Profile-14 scores mean worse Oral Health-related Quality of Life and vice versa.
88859968|NCT04123236||Helkimo's anamnestic dysfunction index|As a method based on patient feedback for the determination of the degree of temporomandibular disorders, anamnestic index was used. For this purpose eight questions were asked to the patients that includes answers as 'yes' or 'no'. (Table 2) The analyses of the questionnaire was done according to anamnestic scale as 0: no symptoms; I: mild symptoms (sensation of the jaw fatigue, jaw stiffness, and temporomandibular joint sounds as clicking or crepitus) and II:severe symptoms (included one or more of the following: Difficulty in the mouth opening, jaw locking, mandible dislocation and its painful movement and painful temporomandibular joint region and/or masticatory muscles)
89535153|NCT03229993|Experimental|OCT guided medicine|
88859969|NCT04123236||Visual analog scale (VAS) for facial pain:|Facial pain was measured by asking the patients if they had had any pain during last 12 months and made them mark the intensity of the pain on a visual analog scale which had the anchor points at the left (no pain) and right (worse pain) ends of a 10 cm horizontal line. The analyses of the facial pain was done as fallowing: if the patient marked no facial pain the Visual analog scale value was accepted as 0 and if the patient marked any level of facial pain Visual analog scale value was accepted as 1.
88859970|NCT04123236||Helkimo's clinical dysfunction index (DI):|Maximum opening of mandible, deviation during opening, dysfunction of temporomandibular joint, pain in the temporomandibular joint and pain in the masticatory muscles was evaluated
88859971|NCT02994420||Lean women|BMI 18-25, weight in kg / height in m2
88859972|NCT02994420||Obese women|BMI 30-35, weight in kg / height in m2
88859973|NCT03047928|Experimental|Patient group|"All patients receive the same treatment. Patients included in the protocol are treated with Nivolumab according to usual guidelines, implying outpatient IV infusions of 3 mg/kg biweekly until progression.~The vaccine is administered on the same day as the administration start of Nivolumab. The vaccination is given biweekly for a total of 6 times, then every fourth week up to week 47, whereupon no additional vaccines will be given. In total, 15 vaccines will be administered. A vaccine consist of 100 μg IDO long peptide, 100 μg PD-L1 long1 peptide and 500 microliters Montanide as adjuvant.~Patients who complete all vaccines will continue Nivolumab treatment after standard guidelines."
88859974|NCT04122846|Experimental|Treatment (Emotional Awareness and Expression Therapy)|Internet-based Emotional Awareness and Expression Therapy
88859975|NCT05607810||No Intervention - Subjects who received ADVM-022 in prior clinical study|
88859976|NCT02990988||Iron repletion|Subjects participating in the associated study under the Iron Repletion arm will also provide stool collection and answers to questionnaire and diet diary.
88859977|NCT02990988||Placebo|Subjects participating in the associated study under the Placebo arm will also provide stool collection and answers to questionnaire and diet diary.
88859978|NCT05607654|Active Comparator|active iTBS|The active group of TRD will receive the accelerated intermittent TBS(iTBS).The iTBS cycles including 10 bursts of three pulses at 50 Hz were delivered in 2-second trains. Each iTBS session comprised 60 x 2 second trains, with an 8-second intertrain interval and total duration of 10-minutes.Treatment sessions were administered hourly 10 times a day totaling 18,000 pulses/day. Patients received this treatment protocol for 5 consecutive days (90,000 pulses in total).
88859979|NCT05607654|Sham Comparator|sham rTMS|The sham group of TRD will receive sham rTMS stimulation.
88859980|NCT04127682||Physicians|Physicians dealing with cases of pediatrics' acute URIs at PHC units either urban or rural, insurance hospitals or Assiut university hospitals.
88859981|NCT04122144|Experimental|Intervention|ENHANCED-SPS intervention implemented
88859982|NCT04122144|No Intervention|Control|Standard of care maintained. These are procedures conducted during the routine HIV care visits at the health facilities include ART card documentation as required, general/routine counseling, and adherence counseling to the non suppressors, ART drug supply based on the clinicians prescription and laboratory monitoring.
88859983|NCT04122066||respiratory symptoms reported in studied patients|If Sofosbuvir\Daclatasvir regimen has respiratory side effects or not and the factors increase incidence of respiratory complications
88859984|NCT03228264|Experimental|High teleSLT frequency|During four weeks all patients will do a daily two-hour training session with a tablet computer (consisting of teleSLT and teleCT) at their home. In the experimental group 80% of the training time will be devoted to teleSLT and 20% to teleCT. Both groups receive the same amount of ucSLT.
88859985|NCT03228264|Active Comparator|Low teleSLT frequency|During four weeks all patients will do a daily two-hour training session with a tablet computer (consisting of teleSLT and teleCT) at their home. In the control group 20% of the training time will be devoted to teleSLT and 80% to teleCT. Both groups receive the same amount of ucSLT.
88859986|NCT05607264|Experimental|Kinsiotaping|patients who received kinesiotaping plus conventional treatment for chronic shoulder impingement syndrome.
88859987|NCT05607264|Experimental|Virtual Reality training|patients who received VR training plus conventional treatment for chronic shoulder impingement syndrome.
88859988|NCT05607264|Active Comparator|conventional treatment|patients who received conventional treatment for chronic shoulder impingement syndrome only.
88859989|NCT04122300|Experimental|Euphrasia arm|Euphrasia eye drops® (Weleda AG, Arlesheim) is administrated at a dose of one drop in each eye four times a day over a period of 96 hours.
88859990|NCT04122300|Placebo Comparator|Placebo arm|Placebo (0.9% NaCl) is administrated at a dose of one drop in each eye four times a day over a period of 96 hours.
89003104|NCT05768139|Experimental|Part 1.1: Dose Escalation (Advanced Solid Tumors and Breast)|"Cohort A0: Advanced Solid tumors expressing PI3Kα mutations.~Cohort A1: HR+/HER2- breast cancer expressing PI3Kα H1047X mutations or other kinase domain mutations."
89535154|NCT03229993|No Intervention|SPECT guided PCI|
89535155|NCT03229993|No Intervention|SPECT guided medicine|
89535156|NCT05006547||Young adults|18<age<35
89384950|NCT03144687|Experimental|Cohort A|Participants with MF who were tolerating a ruxolitinib dose of less than 20 milligrams (mg) daily with no dose increase or no dose modification in the 8 weeks before screening visit received a combination of the itacitinib at the dose of 200 mg, orally, once daily (QD) and ruxolitinib, orally, twice daily (BID) at their previous stable dose (must had been < 20 mg daily). Participants continued study treatment until disease progression, unacceptable toxicity, withdrawal of consent, or other Protocol-specified criteria to stop treatment are met.
89384951|NCT03144687|Experimental|Cohort B|Participants with MF who progressed after initial reduction in spleen with ruxolitinib treatment, progressed or discontinued for hematologic toxicities received treatment with itacitinib alone at the dose of 600 mg QD. Participants continued study treatment until disease progression, unacceptable toxicity, withdrawal of consent, or other Protocol-specified criteria to stop treatment are met.
89384952|NCT04335890|Experimental|DC IKKb|Vaccination with IKKb matured RNA loaded Dendritic Cells
89384953|NCT01624532|Experimental|GC1109|"Step1: GC1109 0.3 mL or 0.5 mL or 0.1mL administered in Multi Intramuscular Doses (3 times) to Healthy Subjects~Step2: GC1109 1.0 mL administered in Multi Intramuscular Doses (4 times) to Healthy Subjects"
89384954|NCT01624532|Placebo Comparator|Placebo of GC1109|"Step1: Placebo of GC1109 0.5mL administered in Multi Intramuscular Doses (3 times) to Healthy Subjects~Step2: Placebo of GC1109 1.0 mL administered in Multi Intramuscular Doses (4 times) to Healthy Subjects"
89384955|NCT03608930|Experimental|rotary polypectomy snare|All colorectal polyps found are removed using a rotary polypectomy snare (Disposable Polypectomy Snare). The technique is hot snare resection of the polyp with electrocautery. Details are as follows: (1) insert the snare into the colonoscopy; (2) connect the snare with the high-frequency device;(3) advance sliding handle to open the loop; (4) adjust the direction of the snare by rotating the handle as required, rotate the loop until the loop reaches target polyp; (6) encircle the target polyp with loop; (7) pull the sliding handle, lasso the target polyp;(8) resect the polyp with electrocautery, then inhaling the transected polyp into a trap followed by submission to the histological evaluation. The hemostatic clipping is used after hot snare polypectomy if removing a flat polyp or bleeding on the wound after treatment.
89535157|NCT05006547||Middle aged adults|50<age<65
89535158|NCT03229681|Experimental|Baduanjin exercise group|Participants in this group received routine rehabilitation training and Baduanjin exercise
89535159|NCT03229681|Active Comparator|Routine rehabilitation group|Participants in this group only received routine rehabilitation training
89535160|NCT05020431|Experimental|One arm|One arm nonrandomized clinical trial
89535161|NCT03222739|Other|Device Arm|This is a single arm study comparing an ultrasound with the industry standard of x-ray to detect and monitor scoliosis curvature.
88859991|NCT04121910|Experimental|Savolitinib and/or Itraconazole|Treatment Period 1: Single administration of savolitinib (200 mg) will occur on Study Day 1 after a high-fat, high-calorie breakfast followed by PK sampling for 48 hours Treatment Period 2: Itraconazole will be administered (200 mg BID) on Study Day 15, and (200 mg QD) on Study Days 16 and 17, 1 hour before breakfast (and before dinner, when applicable) Treatment Period 3: A single combination of itraconazole (200 mg) 1 hour before breakfast + savolitinib (200 mg) after a high-fat, high-calorie breakfast on Study Day 18, and a single dose of itraconazole (200 mg) on Study Day 19, 1 hour before breakfast
88859992|NCT04274478|Other|Single group|
88859993|NCT04274634||Conditions with predisposition to lens oscillations|Marfan Syndrome and Pseudoexfoliation
89384956|NCT03608930|No Intervention|regular polypectomy snare|All colorectal polyps found are removed using a regular polypectomy snare (polypectomy snare, symmetrical). The technique is hot snare resection of the polyp with electrocautery. Details are as follows: (1) insert the snare into the colonoscopy; (2) connect the snare with the high-frequency device;(3) advance sliding handle to open the loop; (4) adjust the bending section angulation of the colonoscopy as required, advance the snare until the loop reaches target polyp; (6) encircle the target polyp with loop; (7) pull the sliding handle, lasso the target polyp;(8) resect the polyp with electrocautery, then suction of the transected polyp into a trap followed by submission to the histological evaluation. The hemostatic clipping is performed after hot snare polypectomy if a flat polyp or bleeding on the wound after treatment.
89384957|NCT01578356||Radical Retropubic prostatectomy (RRP)|Men who underwent open radical prostatectomy in the past at our centre.
88859994|NCT04274634||Age-matched with normal axial lengths|
88859995|NCT04274634||Age-matched with extreme axial lengths|
88859996|NCT04274634||Intraocular lens|
88859997|NCT04274634||Pre- and post- cataract surgery|
88859998|NCT04274634||Normals|
88859999|NCT03830736|Placebo Comparator|Control product|A glucose solution (glucose and water) based on 42 gram carbohydrates.
88860000|NCT03830736|Experimental|Oat Beverage 1|The test product is an oat based beverage with added vegetable oil. The test portion is based on 42 gram available carbohydrates and consumed as a breakfast meal prior to determinations of test variables in the morning.
88860001|NCT03830736|Experimental|Oat Beverage 2|The test product is an oat based beverage with added vegetable oil. The test portion is based on 42 gram available carbohydrates and consumed as a breakfast meal prior to determinations of test variables in the morning.
88860002|NCT03830736|Experimental|Oat Beverage 3|The test product is an oat based beverage with added vegetable oil. The test portion is based on 42 gram available carbohydrates and consumed as a breakfast meal prior to determinations of test variables in the morning.
88860003|NCT03830736|Experimental|Oat Beverage 4|The test product is an oat based beverage. The test portion is based on 42 gram available carbohydrates and consumed as a breakfast meal prior to determinations of test variables in the morning.
88860004|NCT04393818|Experimental|Intervention App|Participants allocated to the intervention App will receive access to a fully operational mobile phone App. The App will be used to deliver psychoeducational materials (written and audio-visual), including: emotional training (mindfulness, moral harm, skills to manage emotions), lifestyles behaviour promotion (physical activity, diet, substance abuse, sleep), work environment, and social support.
88860005|NCT04393818|Sham Comparator|Control App|Participants allocated to the control App will receive access to a a fully operational mobile phone App with limited contents about management and prevention of mental health problems. Although this group will also receive psychoeducation, the content will be reduced to general, written recommendations.
88860006|NCT04393896|Experimental|intervention group|Participants in the intervention group will receive the usual financial benefits of the Reward Policy as well as the WIFI program which will include three key components: psycho-education through WOA publications, peer-support through a WeChat chat group, and professional support through WeChat private chat and video call.
88860007|NCT04393896|No Intervention|control group|Participants in the control group will receive the usual financial benefits of the Reward Policy and receive payment from the Changsha psychiatric hospital. However, they will not have access to the WIFI program since they cannot scan the WeChat barcode for the research.
88860008|NCT04129788|Experimental|bisacodyl|bisacodyl 5mg tablet, once a day on three consecutive days
88860009|NCT04129788|Placebo Comparator|placebo|tablet, once a day on three consecutive days
88860010|NCT03831126||betamethasone treatment|
88860011|NCT04073784|Experimental|Gemcitabine combined with Apatinib and Toripalimab|Subjects receive Apatinib for oral administration, 250mg, once a day, gemcitabine 1000mg/m2 (Day 1 and Day 8) and Toripalimab , 240mg, (Day 1) of each 21days for at most 6 cycles, followed by Toripalimab 240mg every three weeks (Q3W) and Apatinib 250mg once a day maintenance for the remainder of the study or until documented PD.
88860012|NCT05606796|Experimental|Preserved latanoprost|"Benzalkonium chloride (BAK) preserved latanoprost 0.005%.~1 drop will be instilled into the conjunctival sac of both eyes of patient, at about 9pm daily, to reduce intraocular pressure."
88860013|NCT05606796|Experimental|Preservative-free latanoprost|"Preservative-free (Benzalkonium chloride-free) latanoprost 0.005%.~1 drop will be instilled into the conjunctival sac of both eyes of patient, at about 9pm daily, to reduce intraocular pressure."
88860014|NCT04121208|Active Comparator|Active drug: JNJ-40346527|"A single initial randomisation site will be set up for Part 1 that will assign participants to JNJ-40346527 300 mg Bis in die - twice a day (BID) or placebo in a 2:1 ratio.~A second randomisation site will be setup for Part 2 depending on which scenario is adopted.~Either a Part 2, Scenario 1 site will assign participants to JNJ-40346527 150 mg BID, JNJ-40346527 50 mg BID or placebo in a 2:2:1 ratio or a Part 2, Scenario 2 site will assign participants to JNJ-40346527 150-50 mg BID or placebo in a 2:1 ratio."
88860015|NCT04121208|Placebo Comparator|Placebo|Non-active study drug
88860016|NCT03831204||AHF/HFpEF|AHF with preserved ejection fraction Acoustic cardiography was performed for all participants using the BIOPAC Prognostic scores were calculated for every patient
88860017|NCT03831204||AHF/HFrEF|AHF with reduced ejection fraction Acoustic cardiography was performed for all participants using the BIOPAC Prognostic scores were calculated for every patient
88860018|NCT05606640||Haemophilia|Adult males with severe or moderate haemophilia A or B
89384958|NCT01578356||Robot-assisted laparoscopic prostatectomy (RALP)|Men who undergo robot-assisted laparoscopic prostatectomy at our centre.
89184453|NCT00716781||1 (first year)|Asymptomatic infants born to GBS-positive mothers or to mothers with risk factors and incomplete prophylaxis were managed according to the CDC protocol. Blood cultures and CBC were performed and the infant was observed for 48 hours. Participating hospital were free to perform any additional test, such as CRP, MiniESR, etc
88860019|NCT04129710|Experimental|I-MRE|"Ibrutinib 560 mg/day daily (starting dose) between days 4 and 28 of each cycle for six cycles. Then Ibrutinib is continued until disease progression, intolerable toxicity, death or up to two years.~Methotrexate (standard hydration/leucovorin support) 3.5 g/m2 (0.5 g/m2 in 15 min+ 3 g/m2 in 3-hr infusion) d2.~Rituximab 375 mg/m2 conventional infusion d1.Etoposide 250 mg/m2 over 3 hours on day3.~Every 4 weeks for 1 cycle, 6 cycles will be prescribed as protocol."
88860020|NCT04129710|Experimental|L-MRE|"Oral lenalidomide 25mg/day (starting dose) between days 4 and 24 of each cycle for six cycles.Then lenalidomide is continued until disease progression, intolerable toxicity, death or up to two years.~Methotrexate (standard hydration/leucovorin support) 3.5 g/m2 (0.5 g/m2 in 15 min+ 3 g/m2 in 3-hr infusion) d2.~Rituximab 375 mg/m2 conventional infusion d1.~Etoposide 250 mg/m2 over 3 hours on day3.~Every 4 weeks for 1 cycle, 6 cycles will be prescribed as protocol."
88860021|NCT04129710|Active Comparator|MRE|"Methotrexate (standard hydration/leucovorin support) 3.5 g/m2 (0.5 g/m2 in 15 min+ 3 g/m2 in 3-hr infusion) d2.~Rituximab 375 mg/m2 conventional infusion d1.~Etoposide 250 mg/m2 over 3 hours on day3.~Every 4 weeks for 1 cycle, 6 cycles will be prescribed as protocol.~Patients who will not achieve SD or better after the 4th course, as well as those who will experience Progressive Disease (PD) at any time will be randomly allocated to the Experimental groups."
88860022|NCT03200808|Experimental|treatment group|"Methylene blue compound injection are mixed by Methylene Blue injection, Dexamethasone powder-injection, Ropivacaine injection and Normal saline injection. Each individual component can help in a very wide range of medical conditions without serious side effects.~Every patient received intradermal mixed methylene blue compound injection twice. All patients were observed during the hospitalization at the first injection, and two weeks later they received the second injection at the outpatient department."
88860023|NCT05603598|Placebo Comparator|Placebo|IV infusion of saline, approximately 5.5 hours
88860024|NCT05603598|Experimental|Liver-enriched antimicrobial peptide 2|IV infusion of LEAP2, approximately 5.5 hours
88860025|NCT04121130|Active Comparator|Group A (F-ESWT Group)|3 F-ESWT sessions, 1 per week (0,10 mJ/mm2; 2000 impulses; 5 Hz) in the most painful tender and/or trigger points of the upper trapezius muscle.
88860026|NCT04121130|Placebo Comparator|Group B (sham F-ESWT):|3 sham F-ESWT sessions, 1 per week (0,01 mJ/mm2; 2000 SW; 5 Hz) in the most painful tender and/or trigger points of the upper trapezius muscle.
88860027|NCT04129476|Experimental|Cooperative Education Program|We explore the effects of a cooperative education program based on precede-proceed model during pregnancy on preventing postpartum depression.
88860028|NCT04129476|No Intervention|Control|We provide routine care for these people during pregnancy
88860029|NCT04128852|Other|MagnetOs Putty|MagnetOs Putty will be applied according to the latest Instructions For Use (IFU) approved in Europe. Specifically, MagnetOs Putty will be used as bone void filler.
88860030|NCT04129008|Experimental|Indobufen|
88860031|NCT04129008|Active Comparator|Aspirin|
88860032|NCT04121052|Experimental|Treatment Sequence 1|Participants will receive JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 1; followed by JNJ-64417184 oral tablet in fed conditions (low-fat meal) in treatment period 2; followed by JNJ-64417184 oral tablet in fed conditions (Ensure Original) in treatment period 3; followed by JNJ-64417184 oral tablet in fed conditions (standard meal) in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
88860033|NCT04121052|Experimental|Treatment Sequence 2|Participants will receive JNJ-64417184 oral tablet in fed conditions (low-fat meal) in treatment period 1; followed by JNJ-64417184 oral tablet in fed conditions (standard meal) in treatment period 2; followed by JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 3; followed by JNJ-64417184 oral tablet in fed conditions (Ensure Original) in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
88860034|NCT04121052|Experimental|Treatment Sequence 3|Participants will receive JNJ-64417184 oral tablet in fed conditions (standard meal) in treatment period 1; followed by JNJ-64417184 oral tablet in fed conditions (Ensure Original) in treatment period 2; followed by JNJ-64417184 oral tablet in fed conditions (low-fat meal) in treatment period 3; followed by JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
88860035|NCT04121052|Experimental|Treatment Sequence 4|Participants will receive JNJ-64417184 oral tablet in fed conditions (Ensure Original) in treatment period 1; followed by JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 2; followed by JNJ-64417184 oral tablet in fed conditions (standard meal) in treatment period 3; followed by JNJ-64417184 oral tablet in fed conditions (low-fat meal) in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
88860036|NCT04121052|Experimental|Treatment Sequence 5|Participants will receive JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 1; followed by JNJ-64417184 oral tablet in fed conditions (low-fat meal) in treatment period 2; followed by JNJ-64417184 oral tablet under fasted condition in treatment period 3; followed by JNJ-64417184 oral tablet in fed conditions (standard meal) in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
88860037|NCT04121052|Experimental|Treatment Sequence 6|Participants will receive JNJ-64417184 oral tablet in fed conditions (low-fat meal) in treatment period 1; followed by JNJ-64417184 oral tablet in fed conditions (standard meal) in treatment period 2; followed by JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 3; followed by JNJ-64417184 oral tablet under fasted condition in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
89184454|NCT00716781||2 (second year)|Asymptomatic infants born to GBS-positive mothers or to mothers with risk factors and incomplete prophylaxis were managed with clinical observation only. Clinical surveillance was based on 3 signs: 1. Skin appearance (pink, pale, mottled, cyanotic); 2. Respiratory rate (>50 or <50 breaths per minute); 3. Dyspnea (Yes / No)
89184455|NCT02587806|Experimental|Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC)|Super selective intravenous administration of 50 million Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and intrathecal administration of BM-MNCs in dose of 100 million along with liberation therapy (when associated with CCSVI)
89184456|NCT00720525||1|Patients with diastolic heart failure
89184457|NCT00720525||2|Patients without diastolic heart failure
89184458|NCT04828824|Experimental|COCR Arm|Participants in the COCR arm will receive three packs of combined oral contraceptive pills (35mcg ethinyl estradiol/norgestimate) and a specific protocol for their use for bothersome bleeding.
89184459|NCT04828824|No Intervention|SOC Arm|Participants in the SC arm will be offered care according to our standardized protocol, which may include STI testing, reassurance and monitoring, prescription of COCs if desired, or removal.
89184460|NCT00578565|Experimental|1|open label, all subjects will receive rituximab
89184461|NCT04082208|Experimental|Intervention Group|High Flow nasal cannula (HF)
89184462|NCT04082208|Active Comparator|Standar Care Group|Standar Care: low flow device (LF)
89184463|NCT00716937|Experimental|1|Excision of the cyst and Karydakis flap
89184464|NCT00716937|Experimental|2|Excision of the cyst and laying open
89184465|NCT02572089|Experimental|2mg Intranasal Naloxone|Administer 0.1mL spray of the 20 mg/mL formulation in one nostril
89184466|NCT02572089|Experimental|4mg(a) Intranasal Naloxone|Administer 0.1mL spray of the 20 mg/mL formulation in both nostrils
89384959|NCT03608852||Banked-money group|This group will have $50 placed in a 'bank account' for every clinic visit where their tests reveal abstinence from smoking. As a modified commitment contract, the Banked-Money Group can only withdraw the accrued money at the end of the trial if they complete the trial by quitting smoking for the entire 6 months.
89384960|NCT03608852||Reward group|This group will directly receive $50 for every clinic visit where their tests reveal abstinence from smoking.
89184467|NCT02572089|Experimental|4mg(b) Intranasal Naloxone|Administer 0.1mL spray of the 40mg/mL formulation in one nostril
89184468|NCT02572089|Experimental|8mg Intranasal Naloxone|Administer 0.1mL spray of the 40mg/mL formulation in both nostrils
89184469|NCT02572089|Experimental|Intramuscular Naloxone|Administer 1mL of 0.4mg/mL formulation intramuscularly
89184470|NCT00919620|Experimental|case management (4 yrs)|4-year case management and standard care
89184471|NCT00919620|Active Comparator|case management (2 yrs) and standard care (2 yrs)|2-year case management and standard care
89184472|NCT00919620|No Intervention|standard care (4 yrs)|standard care for 4 years
89184473|NCT04069377||Manuel chest compression|Manuel chest compressions will be handled by human efforts.
88860038|NCT04121052|Experimental|Treatment Sequence 7|Participants will receive JNJ-64417184 oral tablet in fed conditions (standard meal) in treatment period 1; followed by JNJ-64417184 oral tablet under fasted condition in treatment period 2; followed by JNJ-64417184 oral tablet in fed conditions (low-fat meal) in treatment period 3; followed by JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
88860039|NCT04121052|Experimental|Treatment Sequence 8|Participants will receive JNJ-64417184 oral tablet under fasted condition in treatment period 1; followed by JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 2; followed by JNJ-64417184 oral tablet in fed conditions (standard meal) in treatment period 3; followed by JNJ-64417184 oral tablet in fed conditions (low-fat meal) in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
88860040|NCT04121052|Experimental|Treatment Sequence 9|Participants will receive JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 1; followed by JNJ-64417184 oral tablet in fed conditions (low-fat meal) in treatment period 2; followed by JNJ-64417184 oral tablet under fasted condition in treatment period 3; followed by JNJ-64417184 oral tablet in fed conditions (Ensure Original) in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
88860041|NCT04121052|Experimental|Treatment Sequence 10|Participants will receive JNJ-64417184 oral tablet in fed conditions (low-fat meal) in treatment period 1; followed by JNJ-64417184 oral tablet in fed conditions (Ensure Original) in treatment period 2; followed by JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 3; followed by JNJ-64417184 oral tablet under fasted condition in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
88860042|NCT04121052|Experimental|Treatment Sequence 11|Participants will receive JNJ-64417184 oral tablet in fed conditions (Ensure Original) in treatment period 1; followed by JNJ-64417184 oral tablet under fasted condition in treatment period 2; followed by JNJ-64417184 oral tablet in fed conditions (low-fat meal) in treatment period 3; followed by JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
88860043|NCT04121052|Experimental|Treatment Sequence 12|Participants will receive JNJ-64417184 oral tablet under fasted condition in treatment period 1; followed by JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 2; followed by JNJ-64417184 oral tablet in fed conditions (Ensure Original) in treatment period 3; followed by JNJ-64417184 oral tablet in fed conditions ( low-fat meal) in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
88860044|NCT04121052|Experimental|Treatment Sequence 13|Participants will receive JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 1; followed by JNJ-64417184 oral tablet in fed conditions (standard meal) in treatment period 2; followed by JNJ-64417184 oral tablet under fasted condition in treatment period 3; followed by JNJ-64417184 oral tablet in fed conditions (Ensure Original) in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
88860045|NCT04121052|Experimental|Treatment Sequence 14|Participants will receive JNJ-64417184 oral tablet in fed conditions (standard meal) in treatment period 1; followed by JNJ-64417184 oral tablet in fed conditions (Ensure Original) in treatment period 2; followed by JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 3; followed by JNJ-64417184 oral tablet under fasted condition in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
88860046|NCT04121052|Experimental|Treatment Sequence 15|Participants will receive JNJ-64417184 oral tablet in fed conditions (Ensure Original) in treatment period 1; followed by JNJ-64417184 oral tablet under fasted condition in treatment period 2; followed by JNJ-64417184 oral tablet in fed conditions (standard meal) in treatment period 3; followed by JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
89184474|NCT04069377||Mechanical chest compression|In the study, chest compression in the mechanical cardiopulmonary resuscitation group was performed with the Lund University Cardiopulmonary Assist System (LUCAS) Chest Compression System (LUCAS 2).
89184475|NCT02588742|Experimental|melatonin group|Patients in the melatonin group are given 5mg of melatonin at 8 pm the day before surgery, POD#0, POD#1, POD#2, POD#3, POD#4, and POD#5.
89184476|NCT02588742|Placebo Comparator|control group|Patients in the control group are given placebo at 8 pm the day before surgery, POD#0, POD#1, POD#2, POD#3, POD#4, and POD#5.
89184477|NCT04936854|Active Comparator|Sirolimus|Patients with active thyroid eye disease will receive 2 mg Sirolimus (two 1 mg tablets) on the first day, followed by 0,5 mg Sirolimus (half 1 mg tablet) per day for 12 weeks.
89184478|NCT04936854|Active Comparator|Corticosteroids|Patients with active thyroid eye disease will receive 500 mg Methylprednisolone intravenously once a week for 6 weeks, followed by 250 mg once a week for 6 weeks.
89184479|NCT00711789|Active Comparator|Angiotensin II|
88860047|NCT04121052|Experimental|Treatment Sequence 16|Participants will receive JNJ-64417184 oral tablet under fasted condition in treatment period 1; followed by JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 2; followed by JNJ-64417184 oral tablet in fed conditions (Ensure Original) in treatment period 3; followed by JNJ-64417184 oral tablet in fed conditions (standard meal) in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
88860048|NCT04120896|Experimental|Karate group|
88860049|NCT04120896|Active Comparator|Kung Fu group|
88860050|NCT04128930|Experimental|Fixed CPAP titration at home|"Patients will start CPAP treatment with a pressure that is calculated by the following formula (predicted pressure = (0.13 x BMI) + (0.16x neck circumference in cm) + (0.04 x AHI)) with a maximal pressure of 10 cmH2O. After 3 nights and after 7 nights, CPAP data will be remotely evaluated and pressure will be adapted based on the following rules:~After 3 nights: median obstructive AHI<5/h: decrease pressure with 2 cmH2O; median obstructive AHI>5/h: increase with 2cmH2O~After 7 nights: median obstructive AHI>5/h of 4 nights after last adaptation: increase with 2 cmH2O"
88860051|NCT04128930|Active Comparator|APAP titration at home|Patients will start CPAP treatment with an auto-adjusting CPAP device with pressure levels between 4 and 12 cmH2O. After 7 nights of titration, the optimal pressure will be determined by analyzing the median of the nightly pressure that included 95% of the periods (percentile 95). CPAP treatment will be continued with this fixed optimal pressure.
88860052|NCT04128462|Experimental|MNK6105 + SoC|"Participants will receive standard of care (SoC), along with MNK-6105 delivered by continuous intravenous (IV) infusion as follows:~Loading dose: 20 g infused over 6 hours~Intermediate dose: 15 g infused over 18 hours~Maintenance dose: 15 g infused over 24 hours for up to 4 days"
88860053|NCT04128462|Placebo Comparator|Placebo + SoC|Participants will receive SoC, along with continuous IV infusion of matching placebo for 5 days.
88860054|NCT04394520|No Intervention|Control|No change will be made to the introduction content or the consent mode (active opt-in and active opt-out) from other related trials
88860055|NCT04394520|Experimental|Modified Intro, Standard Consent|Modified introductory language will be used, but the consent structure (active opt-in and active opt-out) will remain the same.
88860056|NCT04394520|Experimental|Modified Intro, Active Opt-in|Modified introductory language will be used, and the consent mode will be changed to active opt-in only.
88860057|NCT04394520|Experimental|Modified Intro, Active Opt-out|Modified introductory language will be used, and the consent mode will be changed to active opt-out only.
88860058|NCT04394520|Experimental|Modified Intro, Passive Opt-in|Modified introductory language will be used, and the consent mode will be changed to passive opt-in only.
88860059|NCT04128618|Experimental|Active NMES|
88860060|NCT04128618|Sham Comparator|Modified NMES sham|
88860061|NCT03309306|No Intervention|Phase 1: Lab Testing (Visit 1, Day 0)|Participants will test the FoodImage App and Pen-and-paper Records with in a Laboratory Kitchen. Participants will use the FoodImage app and food records to measure food waste during simulated shopping trip and kitchen clean-out. Measurements will be collected by participants with both methods while lab personnel directly weigh foods to provide the criterion value.
88860062|NCT03309306|Active Comparator|Phase 2: RCT Stress Management|Participants will use the FoodImage app to capture data on food purchases, food waste that occurs during food preparation, food waste that is present after eating, and food waste from food purges in free-living conditions. Participants will capture baseline data for 4-7 days. After a 1-week break, participants will use the app to record food waste for approximately 4-7 days over the subsequent week. They will also receive information on stress management
88860063|NCT03309306|Experimental|Phase 2: RCT Food Waste Reduction|"Phase 2 will occur in participants' natural environment (free-living conditions). Participants will use the FoodImage app to capture data on food purchases, food waste that occurs during food preparation, food waste that is present after eating, and food waste from food purges. Participants will use the app to record food waste for approximately 4-7 days over the subsequent week. They will also be provided with the following:~Feedback on the amount of food waste their household created during the first week,~A goal to reduce the next week's food waste by 20% or more, and~Tips on how to reduce household food waste adapted from current consumer campaigns"
88860064|NCT04120662|Active Comparator|Group A: Surgery group|Surgical procedure according to the injury type
88860065|NCT04120662|Active Comparator|Goup B: Shockwave group|3 weekly sessions of Focused Shock Wave Treatment (F-ESWT), using an electrohydraulic device set to an energy flux density (EFD) of 0.21 mJ/mm2 and 2000 impulses
88860066|NCT04120506|Experimental|Rapid infusion of Vpriv|: Infusions at Baseline and during step-wise rate increases and End-of-study will be performed in the Shaare Zedek Medical Center (SZMC) by the Study Nurse who will monitor vital signs (see below) for a total of 8 visits at SZMC. Home therapy will be approved if the patient so desires for 5 infusions in Phase 1 and for the first 5 infusions in Phase 3. All routine hematological and biochemical tests will be performed in the SZMC clinical labs. Abdominal quantitative MR Imaging (MRI) for spleen and liver volumes will be performed at SZMC
88860067|NCT04120350|Experimental|R2-MTX-LEN|"Phase Ib：Experimental arm will be treated with R2-MTX regimen for 6 cycles as initiate induction, the dose of lenalidomide was escalated from 15mg， 20mg， 25mg to test DLT by 3+3 design, meanwhile the dose of rituximab and methotrexate is fixed. If the patients achieved CR or PR by MRI and CSF evaluation, they processed to lenalidomide maintenance for 2 years.~Phase II: the patients will be treated by fixed dose of R2-MTX regimen (established lenalidomide dose from phase Ib study) for 6 cycles. the efficiency evaluation will be performed every 2 cycles, the patients who achieved CR or PR will finish the total 6 cycles of induction therapy, then begin the stage of lenalidomide maintenance for 2 years. Follow-ups should be taken for 5 years."
89003105|NCT05768139|Experimental|Part 1.2-DE: Dose expansion at MTD|"Cohort A2: Gynecologic cancers~Cohort A3: HNSCC~Cohort A4: Other solid tumors not included in Cohorts A0, A1, or A2~Mutations for Cohorts A2, A3, and A4: PI3Kα H1047X mutations or other kinase domain mutations~Cohort A5: Solid tumors expressing PI3Kα helical domain mutations (E542/E545)"
89184480|NCT00711789|Placebo Comparator|Placebo|
88860068|NCT04394598|Experimental|CRT with Dendrobium Huoshanense|"Dendrobium Huoshanense Granules: 3g tid per day for 5weeks~Concurrent Chemoradiotherapy:~Radiation: 50Gy/25Fx; Capecitabine: 625mg/m2 bid Monday-Friday per week; Irinotecan: 80mg/m2 (UGT1A1*28 6/6) or 65mg/m2 (UGT1A1*28 6/7)~Chemotherapy in Interval Between CRT and Surgery:~Capecitabine: 1000mg/m2 bid d1-14; Irinotecan: 200mg/m2 d1~Surgery:~Scheduled 6-8 weeks after the completion of CRT Adjuvant Chemotherapy: depends on patients pathological review."
88860069|NCT04394598|Placebo Comparator|CRT with Placebo|"Placebo: 3g tid per day for 5weeks~Concurrent Chemoradiotherapy:~Radiation: 50Gy/25Fx; Capecitabine: 625mg/m2 bid Monday-Friday per week; Irinotecan: 80mg/m2 (UGT1A1*28 6/6) or 65mg/m2 (UGT1A1*28 6/7)~Chemotherapy in Interval Between CRT and Surgery:~Capecitabine: 1000mg/m2 bid d1-14; Irinotecan: 200mg/m2 d1~Surgery:~Scheduled 6-8 weeks after the completion of CRT Adjuvant Chemotherapy: depends on patients pathological review."
88860070|NCT04120272||Delirium group|Group of patients with postoperative delirium
88860071|NCT04120272||Non delirium group|Group of patients without postoperative delirium
88860072|NCT04394832|Experimental|Baseline phase, followed by intervention phase|"Within the baseline phase, measurements of the primary outcome measure (frequency of intrusive memories of trauma) were collected in a pen-and-paper diary for up to three weeks (dependent on baseline length). Individual baseline phases will be used as control periods.~In the intervention phase the participant was offered around five intervention sessions with a researcher. Each session the participant chose which intrusive memory they would like to focus on and the cognitive task was completed. The intervention included a memory reminder cue, a 10-minute time gap and then around 20 minutes playing the mobile phone game Tetris, using mental rotation instructions. Participants were given instructions to continue to use the technique self-guided in the subsequent week. Measurements of the primary outcome measure (frequency of intrusive memories of trauma) were collected in a pen-and-paper diary."
88860073|NCT04127760|No Intervention|control|Follow-up at several time frames
88860074|NCT04127760|Experimental|treatment|Radiotherapy would be carried out. Follow-up at the same time frames as the control arm
88860075|NCT03302130|Experimental|Imaging healthy volunteers|Mood induction: positive, negative, neutral mood (using subjects own memories) Arterial spin labeling MRI Physiological monitoring
88860076|NCT04127370|Experimental|Obese Patients With NAFALD Undergoing Bariatric Surgeries|
88860077|NCT02984046|Experimental|acute bronchiolitis|Prospective, monocentric, case-control and study Primary end-point: correlation between serum CC16 level and severity of the bronchiolitis, evaluated by a clinical scoring system
88860078|NCT04127526|Active Comparator|Baseline Period of 2 weeks|2 participants will be randomly allocated to a baseline of 2 weeks before commencing CONNECT intervention.
88860079|NCT04127526|Active Comparator|Baseline Period of 3 weeks|2 participants will be randomly allocated to a baseline of 3 weeks before commencing CONNECT intervention.
88860080|NCT04127526|Active Comparator|Baseline Period of 4 weeks|2 participants will be randomly allocated to a baseline of 4 weeks before commencing CONNECT intervention.
88860081|NCT05602428|Experimental|The observation group A|The use of esketamine sub-anesthetic dose combined with hip capsule peripheral nerve block. The patients were subjected to local anesthesia and punctured through the left radial artery for invasive arterial blood pressure monitoring. Anesthesia induction: the observation group followed by intravenous injection of ketamine 0.2mg/kg, sufentanil 0.3μg/kg, Cyclophenol 0.3mg/kg, midazolam 2mg, rocuronium 0.6mg/kg. After the onset of the drug endotracheal intubation, connect anesthesia machine control breathing. Anesthesia was maintained with 1%~2% sevoflurane inhalation, remifentanil infusion rate was 0.2~0.3 μg/kg·min, sevoflurane was stopped 30 min before the end of the operation. Patient-controlled intravenous analgesia pump (PCIA) was given for postoperative analgesia. PCIA formula: sufentanil 100ug+ondansetron 8mg+ketorolac tromethamine 60mg+saline to 100ml, pump speed 2ml/h, automatic single dose 3ml, lock time 20min.
88860082|NCT05602428|Active Comparator|the control group B|Esketamine subanesthetic dose combined with lumbar plexus block was used. The patient was placed in the healthy lateral decubitus position and ultrasound-guided puncture was performed 4 cm beside the 3rd and 4th lumbar vertebrae (Figure 1B、C). The frequency of the ultrasound probe was 2-5 MHz, and the probe was adjusted until the images below the transverse processes of the 3rd to 5th lumbar vertebrae and the psoas muscle were clearly displayed, and the needle was inserted close to the probe and retracted in the lumbar plexus, and sufentanil 0.5 μg/kg, propofol 1.5 mg/kg, and rocuronium 0.6 mg/kg were injected after no blood extraction. General anesthesia was then performed using a subanesthetic dose of esketamine and the same maintenance and postoperative analgesic measures were used as in group A.
88860083|NCT05602428|Active Comparator|the control group C|general anesthesia was performed with esketamine subanesthetic dose. The same maintenance and postoperative analgesia measures were used as in group A.
88860084|NCT02983890|Active Comparator|Arm of study1|Dicloxacillin tablets.
88860085|NCT02983890|Placebo Comparator|Arm of study 2|No treatment
88860086|NCT03022968|Experimental|Alzheimer disease|[18F]T807 PET
88860087|NCT03022968|Experimental|Benson disease|[18F]T807 PET
88860088|NCT03022968|Experimental|Healthy volunteer|[18F]T807 PET
88860089|NCT04129944|Placebo Comparator|Placebo|
88860090|NCT04129944|Experimental|UBX0101 0.5 mg|
88860091|NCT04129944|Experimental|UBX0101 2.0 mg|
88860092|NCT04129944|Experimental|UBX0101 4.0 mg|
88860093|NCT05602350|Experimental|Treatment|Survey respondents will self-administer three survey sections in a tablet: (1) antisocial behaviors, (2) depression symptoms, and (3) anxiety symptoms
88860094|NCT05602350|Placebo Comparator|Control|Survey respondents will have the survey questions on the three sections administered by an enumerator
89003106|NCT05768139|Experimental|Part 1.2-DS: RP2D Selection (Breast)|"Recommended Phase 2 dose (RP2D)~Cohort A1: HR+/HER2- breast cancer expressing PI3Kα H1047X mutations or other kinase domain mutations."
89003107|NCT05768139|Experimental|Part 1.3: RP2D Expansion (Breast)|Cohort A1: HR+/HER2- breast cancer expressing PI3Kα H1047X mutations or other kinase domain mutations.
88860095|NCT04124172|Active Comparator|Real rTMS|"rTMS (Magstim Super Rapid, Magstim Company, Whitland, Wales, UK) with eight-shaped coil (1 Hz, 1500 stimuli) in M1of the contralateral hemisphere to the lesion (healthy side). M1 is defined like the hot spot to elucidated a motor evoked potential in the Abductor Pollicis Brevis (APB) muscle of the contralateral hand. Intervention will be performed before one hour rehabilitation session of the upper limb according to our clinical protocol, completing 15 sessions."
88860096|NCT04124172|Sham Comparator|Sham rTMS|"Sham rTMS (Magstim Super Rapid, Magstim Company, Whitland, Wales, UK) with eight-shaped coil (1 Hz, 1500 stimuli) in M1of the contralateral hemisphere to the lesion (healthy side). Investigators will make the simulation disconnecting the coil but keeping its position during the same time as the real one. Intervention will be performed before one hour rehabilitation session of the upper limb according to our clinical protocol, completing 15 sessions."
88860097|NCT04393194|Experimental|Vaginal estrogen cream|subjects will be treated with the prescribed vaginal medication, 1g per time, q d for the first 2 weeks and then 1g per time, twice a week.
88860098|NCT04393194|Placebo Comparator|vaginal placebo cream|Subjects will be treated with the prescribed vaginal medication, 1g per time, q d for the first 2 weeks and then 1g per time, twice a week.
88860099|NCT04126980||ED group|The ED group who had less than 72 hours of hospitalization (including the preparation period which commonly took approximately 1 day) for the surgery.
88860100|NCT04126980||Comparison group|The comparison group who were hospitalized for more than 72 hours but less than 12 days.
88860101|NCT04127058|Other|CYP2D6 non-poor metabolizers|titrated up to 24 mg daily (12 mg b.i.d.)
88860102|NCT04127058|Other|CYP2D6 poor metabolizers|titrated up to 12 mg daily (6 mg b.i.d.)
89384961|NCT03080961|Experimental|Before and after VIBLOK|The degree to which HSV-2 is blocked by the VIBLOK cream is determined by comparing the amount of HSV in the external genital area before and after application of the cream. So participants are their own control.
88860103|NCT05600010||Study group|Detection of microplastics/nanoplastics in heart tissue and the blood of patients undergoing cardiac surgery
88860104|NCT03012360|Placebo Comparator|no antibiotic treatment for VAT|3 days of placebo
88860105|NCT03012360|Experimental|antibiotic treatment for 3 days|"Patients randomized in one of the two experimental groups will receive 3 days of antimicrobials. Antibiotic treatment is standardized, based on the time of onset of VAT, and presence of risk factors for MDR bacteria:~patients with early-onset VAT (< 5 days of mechanical ventilation), with no risk factor for MDR will receive ceftriaxone .~patients with late-onset VAT (≥5 days of mechanical ventilation), or with at least one risk factor for multidrug resistant bacteria will receive imipenem , and ciprofloxacin as empirical treatment.~When methicillin-resistant Staphylococcus aureus (MRSA) is suspected linezolid will be added to empirical treatment.~3 days of imipenem and ciprofloxacin with optional linezolid, followed by 4 d of placebo"
88860106|NCT04121598||Normal Weight Control|Adolescents with a BMI percentile under 85%.
88860107|NCT04121598||Overweight/Obese Control|Adolescents with a BMI percentile at 85% or higher.
88860108|NCT04121598||Overweight/Obese Experimental|Adolescents with a BMI percentile at 85% or higher, who report loss of control eating episodes.
88860109|NCT05609838|Experimental|Experimental group|A 15 minutes hot water foot bath was applied to the experimental group patients 3 hours after the cesarean section.Data collection tools were applied at the 5th minute, 1st hour and 2nd hour after the hot water footbath and the gas output was questioned.
88860110|NCT05609838|No Intervention|Control Group|The control group was given routine post-cesarean care without any intervention and data collection tools were applied at the same time as the experimental group.
88860111|NCT04392882|Experimental|Legume enriched diet group|"Replacing 1/3 refined rice intake with legumes three times per day~Vegetable intake at least six units (30-70 g/unit) per day for sufficient dietary fiber intake~Regular 30-min walk after dinner each day"
88860112|NCT04392882|No Intervention|Usual diet group|"Maintaining usual diet~Vegetable intake at least six units (30-70 g/unit) per day for sufficient dietary fiber intake~Regular 30-min walk after dinner each day"
88860113|NCT04126668|Experimental|Period 1: fasted control → Period 2: fed control|Period 1: administration of CM082 200 mg at 7:30am, without the breakfast；Period 2: administration of CM082 200 mg at 7:30am, 30 minutes after the breakfast
88860114|NCT04126668|Experimental|Period 1: fed control → Period 2: fasted control|Period 1: administration of CM082 200 mg at 7:30am, 30 minutes after the breakfast；Period 2: administration of CM082 200 mg at 7:30am, without the breakfast
88860115|NCT04126434|Sham Comparator|no masking|not wearing facemask
89384962|NCT01379157|Active Comparator|Conventional arm|Infusion of 0.5 g of imipenem for 0.5 hr every 6 hr for 3-5 days
88860116|NCT04126434|Active Comparator|masking|wearing facemask
88860117|NCT04126512||Bedside ligation|Infants admitted to St. Orsola-Malpighi Hospital (SOM) NICU had their PDA ligated at bedside, with a timing of surgery dependent on the time schedule of the surgeons and anaesthesiologists.
88860118|NCT04126512||Referred to specialist paediatric cardiac surgery centre|Due to the unavailability of local cardiac surgery, infants admitted to the Cambridge University Hospital (CUH) NICU were referred to specialist paediatric cardiac surgical centres, where PDA ligation was performed. In these cases, the surgical timing depended on both bed availability at the referral centre and the availability of the neonatal transfer team.
88860119|NCT02979678|Experimental|Questionnaire|Breast cancer
88860120|NCT04758936|Experimental|Clonidine|Given that agitated delirium requires rapid medical intervention, α-2 agonist therapy (clonidine) will be administered as soon as possible, The sedative and analgesic treatments will be administered and titrated according to the scales on the usual protocol of the service (evaluation of sedation (NICS) and analgesia (VAS, BPS, BPS-NI). In case of excessive sedation assessed by the scores and administration of combined treatments (α-2 agonist and other sedatives), the reduction of the doses of other sedatives will be preferred over the α-2 agonist treatment. In case of insufficient sedation despite maximal doses of α-2 agonist, other sedatives (choosen by the attending physician) will administered and titrated according to the scales for pain and sedation evaluation.
89003108|NCT05768139|Experimental|Part 2.1: RP2D Selection|Cohort B: HR+/HER2- breast cancer expressing PI3Kα H1047X mutations or other kinase domain mutations.
89003109|NCT05768139|Experimental|Part 2.2: RP2D Expansion|Cohort B: HR+/HER2- breast cancer expressing PI3Kα H1047X mutations or other kinase domain mutations.
89384963|NCT01379157|Experimental|Extended infusion arm|Infusion of 1 g of imipenem for 4 hr every 8 hr for 3-5 days
89384964|NCT01538966|Active Comparator|High dose SRL + weekly Pegvisomant|"High dose of SRL monthly~Octreotide LAR 30mg~Lanreotide 120mg~Weekly Pegvisomant (40-120mg/week)"
89384965|NCT01538966|Active Comparator|Low dose SRL + daily Pegvisomant|"Low dose of SRL monthly~Octreotide LAR 10mg~Lanreotide 60mg~Daily Pegvisomant (15-60mg/day)"
89384966|NCT01538966|Active Comparator|Low dose SRL + weekly Pegvisomant|"Low dose of SRL monthly~Octreotide LAR 10mg~Lanreotide 60mg~Weekly Pegvisomant (40-120mg/week)"
89384967|NCT01377285|Experimental|ARB & Pentoxifylline|angiotensin receptor blockers(ARB)and Pentoxifylline 400mg tablet (If CKD3 1# BID(Bi in die=two times a day); CKD4 1# QD(quaque die=one time a day); CKD5(estimated Glomerular filtration rate,eGFR<15ml/min/1.73 m2) 1# QOD(Every other day).
88860121|NCT04758936|Experimental|Dexmedetomidine|Given that agitated delirium requires rapid medical intervention, α-2 agonist therapy (dexmedetomidine) will be administered as soon as possible. The α-2 agonist treatment that will be started will depend on the allocation of the previously randomized unit. The sedative and analgesic treatments will be administered and titrated according to the scales on the usual protocol of the service (evaluation of sedation (NICS) and analgesia (VAS, BPS, BPS-NI). In case of excessive sedation assessed by the scores and administration of combined treatments (α-2 agonist and other sedatives), the reduction of the doses of other sedatives will be preferred over the α-2 agonist treatment. In case of insufficient sedation despite maximal doses of α-2 agonist, other sedatives (choosen by the attending physician) will administered and titrated according to the scales for pain and sedation evaluation.
88860122|NCT03830814||Cases|Patients with heart failure with reduced ejection fraction (HRrEF) who have indications for the use of sacubitril/valsartan as recommended by recent guidelines
89184481|NCT04082052|Experimental|Single Session Intervention for Self-Dislike|A 30-45 minute intervention delivered in a web browser that focuses on reducing self-dislike using facts about the brain, testimonials from peers, and writing exercises.
89384968|NCT01377285|Active Comparator|ARB & Placebo|angiotensin receptor blockers(ARB) and Placebo tablet(If CKD3 1# BIDBi in die=two times a day); CKD4 1# QD(quaque die=one time a day); CKD5(estimated Glomerular filtration rate,eGFR<15ml/min/1.73 m2) 1# QOD(Every other day).
88860123|NCT04126044|Active Comparator|Reference: bevacizumab - EU|
88860124|NCT04126044|Experimental|Test: PF-06439535 (CN)|
89384969|NCT03609242|Experimental|Intervention|Arm 1 will receive the STOP-HPV bundle intervention
88860125|NCT03822390||Patients|Patients older than 18 years undergoing colonoscopy in one the participating centres.
88860126|NCT03829878|Experimental|CP101|CP101 (Full Spectrum Microbiota) Capsule
88860127|NCT03829878|Placebo Comparator|Placebo|Placebo for CP101
88860128|NCT03829800|Experimental|Ensure® Abbott Nutrition|A standard nutritional formula not specific for diabetics
88860129|NCT03829800|Experimental|Glucerna® Abbott Nutrition|A formula with a patented blend of slow-digesting carbohydrates including resistant maltodextrin and sucromalt
88860130|NCT03829800|Experimental|Diasip® Nutricia Advanced|A formula whose composition has isomaltulose and resistant starch
88860131|NCT03829800|Active Comparator|Glicolab®|Glucose solution
88860132|NCT04125810|Experimental|Probiotic|Probiotic
88860133|NCT04125810|Placebo Comparator|Placebo|Placebo
89184482|NCT04082052|Placebo Comparator|Single Session Intervention for Feelings Disclosure|A 30-45 minute intervention delivered in a web browser that focuses on encouraging feelings disclosure using facts about the brain, testimonials from peers, and writing exercises.
88860134|NCT04758858|Active Comparator|VLCHF (Very Low CHO High Fat) Diet|10% of energy from CHO, 15% proteins, and 75% lipids
88860135|NCT04758858|Active Comparator|Low-CHO Diet|30% of energy from CHO, 15% proteins and 55% lipids
89184483|NCT00717171|Placebo Comparator|1|
89184484|NCT00717171|Experimental|2|
89184485|NCT00741260|Experimental|Neratinib and Capecitabine (Dose Level 1)|Neratinib 160 mg and Capecitabine 1500 mg/m^2
89384970|NCT03609242|No Intervention|Control|Arm 2 will receive standard of care
89384971|NCT03630861||GBM|Primary glioblastoma (GBM)
89384972|NCT03630861||PCNSL|Primary CNS lymphomas (PCNSL)
89384973|NCT03630861||Brain metastases|Brain metastases (BM)
89384974|NCT03630861||Cerebral Stroke|Cerebral Stroke (CS)
89384975|NCT03630861||Healthy Volunteers|Healthy Volunteers (HV)
89384976|NCT03609164|Experimental|Suture-spanning augmentation of single-row repair|
89384977|NCT03609164|Active Comparator|single-row repair|
89384978|NCT03630783|Experimental|Cognitive Bias Modification (Group-E)|Participants were subjected to Combined Cognitive Bias Modification in each session. During the attentional bias modification phase, photographs of neutral or threatening (disgusted) faces were used. In each trial, a pair was shown for 500 ms. Then, a sign of arrow appeared and participants were asked to indicate the direction of the arrow. In %80 of the trials, the arrow was in the same area with the neutral photograph. During the interpretational bias modification phase a threatening or positive word, as the interpretation of a sentence, appeared, then, a relevant sentence with ambiguous meaning appeared, and later, participants were asked to indicate if the word and the sentence were related. After their response a feedback (right/wrong) was given and the next trial was started.
89535162|NCT03325283|Experimental|Protembo device treatment|Patients who consent to participate in the PROTEMBO SF Trial and in whom the ProtEmbo Cerebral Protection System is used or is attempted to be used.
89535163|NCT03324347|Experimental|Therapydog|A certified therapydog (together with a certified dog-handler) will be present in the dental clinic while the child will undergo a clinical dental examination by licenced pediatric dentist.
88860136|NCT04758858|Placebo Comparator|Control Diet|50% of energy from CHO, 15% proteins and 35% lipids
88860137|NCT04125888||AIT Cohort|Allergic rhinitis patients with and without asthma treated with AIT
88860138|NCT04125888||Control Cohort|Allergic rhinitis patients with and without asthma not treated with AIT
88860139|NCT04759092|Experimental|Treatment with tDCS|Home based treatment with tDCS for four months
88860140|NCT02975310|Experimental|Endoscopic polypectomy in clinic (EPIC)|Patients assigned to this arm of the study will undergo the In Clinic Polypectomy Performed in Clinic
88860141|NCT02975310|Active Comparator|Endoscopic Sinus Surgery (ESS)|Patients assigned to this arm will undergo endoscopic sinus surgery (ESS),
88860142|NCT04394208|Placebo Comparator|Group 1|Patients with COVID-19 pneumonia receiving standard of care as per Ministry of Health Protocol of Treatment plus placebo
88860143|NCT04394208|Experimental|Group 2|patients with COVID-19 pneumonia receiving standard of care as per Ministry of Health Protocol of Treatment + Silymarin Oral 420mg/day in 3 divided doses
88860144|NCT05608980|Active Comparator|Treatment arm|0.01%hypochlorous acid group
88860145|NCT05608980|Placebo Comparator|Placebo|eyelid wipes
88860146|NCT03829566|Experimental|Hematopoietic Stem Cell Transplantation|Hematopoietic Stem Cell Therapy will be performed as follows: Autologous stem cells will be infused after conditioning with rituximab, cyclophosphamide, mesna, rATG (rabbit), and methylprednisolone. Granulocyte-colony stimulating factor (G-CSF) and intravenous immunoglobulin (IVIg) will be administered post-transplant.
88860147|NCT04274400||Patients referred for polysomnography|Patients referred for polysomnography will be classified according to the presence of OSA, insomnia or both.
88860148|NCT04125576||Burn patients|The subjects complaine of severe neuropathic pain that is rated at least 5 on the visual analogue scale (VAS), despite treatments with gabapentin medication and other physical modalities.
88860149|NCT04125576||Healthy controls|age and sex matched healthy controls
88860150|NCT04125654|Experimental|Patients with ascites enrolled for mNGS testing|Patients with ascites will be enrolled in this study in order to analyze the clinical utility of mNGS for pathogen detection. There is no control group for this study (Investigators will identify historical controls by retrospective clinical documents).
88860151|NCT04394442|Experimental|Hydroxycholoroquine group|
88860152|NCT04394442|No Intervention|Control group|
88860153|NCT04125264|Experimental|Intense therapeutic Ultrasound|"During the trial two applications of 1000 pulses each one (day one and day thirty) will be applied. Pulse regulation could be modified from 4 to 5 joules depending the presence or not of pain.~Conservative treatment of plantar fasciitis include: custom made foot orthosis with the same general characteristics plus plantar fasciia and achilles tendon stretching."
88860154|NCT04125264|No Intervention|Control group|Non ITU application. Conservative treatment of plantar fasciitis include: custom made foot orthosis with the same general characteristics plus plantar fasciia and achilles tendon stretching.
88860155|NCT02972424|Experimental|Teriparatide Prefilled Syringe|TPTD is supplied as a sterile, colorless, clear, isotonic solution in a glass cartridge which is pre-assembled into a disposable delivery device (pen) for subcutaneous injection. Each prefilled delivery device is filled with 2.7 mL to deliver 2.4 mL. Each mL contains 250 mcg teriparatide (corrected for acetate, chloride, and water content), 0.41 mg glacial acetic acid, 0.1 mg sodium acetate (anhydrous), 45.4 mg mannitol, 3 mg Metacresol, and Water for Injection. In addition, hydrochloric acid solution 10% and/or sodium hydroxide solution 10% may have been added to adjust the product to pH 4.
88860156|NCT02972424|Placebo Comparator|Placebo|Placebo is supplied as a sterile, colorless, clear, isotonic solution in a glass cartridge which is pre-assembled into a disposable delivery device (pen) for subcutaneous injection. Each prefilled delivery device is filled with 2.7 mL to deliver 2.4 mL. Each mL contains 0.41 mg glacial acetic acid, 0.1 mg sodium acetate (anhydrous), 45.4 mg mannitol, 3 mg Metacresol, and Water for Injection. In addition, hydrochloric acid solution 10% and/or sodium hydroxide solution 10% may have been added to adjust the product to pH 4.
88860157|NCT04393428||COVID-19 patients with urinary samples|COVID-19 patients with urinary samples
88860158|NCT05608590|Experimental|Direct HSG during fertility work-up|Tubal flushing at HSG with Lipiodol® (oil-based contrast medium) (max. 15mL) incorporated in the fertility work-up
88860159|NCT05608590|Active Comparator|Delayed HSG 6 months after completing fertility work-up|Tubal flushing at HSG with Lipiodol® (oil-based contrast medium) (max. 15mL) after a 6 months waiting period after completion of fertility work-up
88860160|NCT04393584|Experimental|FOLFIRINOX|Irinotecan 180mg/m2 d1, d1-2 5-FU 2450 mg/m², d1 Leucovorin 200 mg/m², d1 Oxaliplatin 85 mg/m², d1 every two weeks (q2w) 4 cycles (4-8 weeks) pre-OP and 4 cycles (6-12 weeks) post-OP
88860161|NCT04393584|Active Comparator|FLOT|d1 Docetaxel 50mg/m2, d1-2 5-FU 2600 mg/m², d1 Leucovorin 200 mg/m², d1 Oxaliplatin 85 mg/m² every two weeks (q2w) 4 cycles (4-8 weeks) pre-OP and 4 cycles (6-12 weeks) post-OP
88860162|NCT02316366|Experimental|Warm fluid|Patients in this arm of the study receive intravenous saline warmed to 37.5 degrees Celsius by Astoflo Plus fluid warmer
88860163|NCT02316366|No Intervention|Room temperature Fluid|Patients receive intravenous saline at room temperature (22-24 degrees Celsius)
88860164|NCT03828864|Active Comparator|Active Pulsed Shortwave therapy|Application of the medical device emitting pulsed shortwave therapy. The medical device is used over the site of pain.
88860165|NCT03828864|Placebo Comparator|Placebo Pulsed Shortwave therapy|Application of the medical device that does not emit pulsed shortwave therapy. The medical device is used over the site of pain.
88860166|NCT02315352|Experimental|Period 1 and 2|A-B or B-A where A: L-PZQ ODT (MSC 2499550A) put on tongue; B: Rac-PZQ ODT (MSC1028703A) put on the tongue
88860167|NCT02315352|Experimental|Period 3, 4 and 5|C-D-E; C-E-D; D-E-C; D-C-E; E-C-D; E-D-C where C: L-PZQ ODT (MSC 2499550A) dispersed in water; D: Rac-PZQ ODT (MSC1028703A) dispersed in water; E: Cesol® 150 mg crushed in water
89535164|NCT03324347|No Intervention|No therapydog|No therapydog will be present in the dental clinic while the child will undergo a clinical dental examination by licenced pediatric dentist.
88860168|NCT04125108|Experimental|pulmonary rehabilitation group|The experimental group was to participate in a 12-week pulmonary rehabilitation program supplemented with an individualized and supervised exercise-training program.
88860169|NCT04125108|No Intervention|control group|The control group was to participate in a 12-week conventional rehabilitation program.
88860170|NCT05608356|Experimental|intervention group|"Intervention group subjects will receive injectable platelet rich fibrin (i-prf) . The (i-prf) will be injected in the periodontal ligament of maxillary anterior teeth during en masse retraction.The injection sites will be the sites of bone compression to target the surfaces of the bone where osteoclastogenesis and bone resorption occurs during en masse retraction.~Considering that the obtained (i-prf) after centrifuging would be 4 ml, 1 ml will be injected intraligamentally distal to the right and left canines, and 0.5 ml will be injected intraligamentally palatal to each incisor. The study group will receive i-PRF intraligamentally in the periodontal ligament space of the maxillary six anterior teeth three times as follow, just before anterior teeth retraction, and after 21 days of the retraction, and after 42 days of the retraction. Before each time of injection, an anesthetic solution will be administered for pain control."
88860171|NCT05608356|Sham Comparator|control group|Subjects in the control group will only receive sham (placebo) injection three successive times with and interval of 21days between each injection, similar to the timepoints of (i-prf) injection in the intervention group. Also the sites of injection will be similar to the sites of injection of the intervention group; 1 ml of the placebo agent will be injected intraligamentally distal to the right and left canines, and 0.5 ml will be injected intraligamentally palatal to each incisor. An anesthetic solution will be administered for pain control before the administration of the sham injections.
88860172|NCT03142308||Surgeons|Young surgeons in all surgical specialities
88860173|NCT03828474|Experimental|Acetazolamide 125mg twice daily|Acetazolamide pill 125mg twice daily by mouth, started the night prior to ascent and continued for 3 total doses
88860174|NCT03828474|Experimental|Acetazolamide 62.5mg twice daily|Acetazolamide pill 62.5mg twice daily by mouth, started the night prior to ascent and continued for 3 total doses
88860175|NCT04394364||BIS monitor group|Patients under monitoring of BIS
88860176|NCT02983812||Activity Monitoring - Smartphone|Patients in the activity monitoring - smartphone group will be randomly assigned to track their data using a smartphone app (which collects step counts) for 6 months. There will be no intervention for either group, both are being passively monitored.
88860177|NCT02983812||Activity Monitoring - Wearable|Patients in the activity monitoring - wearable device group will be randomly assigned to track their data using a wearable activity tracker (which collects step counts and sleep patterns/duration). There will be no intervention for either group, both are being passively monitored.
88860178|NCT05608122||unstable intracranial aneurysms|Unstable intracranial aneurysms are defined as the intracranial aneurysms that grows or ruptures.
88860179|NCT05608122||stable intracranial aneurysms|Stable intracranial aneurysms are defined as the intracranial aneurysms that have no significant morphological changes.
88860180|NCT04120818||SIOL group|aphakic children diagnosed with congenital cataract who underwent secondary IOL implantation
88860181|NCT04120818||PIOL group|children with congenital cataract who underwent lensectomy and anterior vitrectomy and primary IOL implantation
88860182|NCT03822156||Cavitary Pulmonary Tuberculosis|The patients who are diagnosed with the cavitary pulmonary tuberculosis
88860183|NCT03822156||Endobronchial Tuberculosis|The patients who are diagnosed with the endobronchial tuberculosis
88860184|NCT03822234|Experimental|Modified ileal conduit|With our modified ileal conduit technique
88860185|NCT03822234|No Intervention|Conventional ileal conduit|Conventional ileal conduit
88860186|NCT03827928|Experimental|Yoga/meditation|A 6-week yoga/meditation intervention.
88860187|NCT03827928|No Intervention|Wait list|A wait list control period.
88860188|NCT04392414|Experimental|COVID-19 convalescent hyperimmune plasma|Moderately and severely ill COVID-19 patients treated with convalescent hyperimmune plasma. Patients will be infused with two units of 300 ml
88860189|NCT04392414|Placebo Comparator|Non-convalescent fresh frozen plasma (Standard plasma)|Moderately and severely ill COVID-19 patients treated with non-convalescent fresh frozen plasma (standard plasma). Patients will be infused with two units of 300 ml
88860190|NCT03828084|Experimental|Formulation A|3 test capsules of combination decitabine/THU (5 mg/250 mg per capsule; Formulation A) given as a single oral dose with approximately 240 mL (8 fluid ounces) of ambient temperature water.
88860191|NCT03828084|Experimental|Formulation B|3 test capsules of combination decitabine/THU (5 mg/250 mg per capsule; Formulation B) given as a single oral dose with approximately 240 mL (8 fluid ounces) of ambient temperature water.
88860192|NCT03828084|Experimental|Formulation C|3 test capsules of combination decitabine/THU (5 mg/250 mg per capsule; Formulation C) given as a single oral dose with approximately 240 mL (8 fluid ounces) of ambient temperature water.
88860193|NCT03828084|Active Comparator|Reference Formulation|3 capsules of THU (250 mg per capsule) given as a single oral dose with approximately 240 mL of ambient temperature water, followed by a single oral dose of 3 capsules of decitabine (5 mg per capsule) given 1 hour later with approximately 240 mL of ambient temperature water.
88860194|NCT03827772|Experimental|Intervention Arm: Fecal microbiota transplantation|30 grams of stool homogenized with 100 mL of normal saline administered a single time via nasojejunal tube.
88860195|NCT03827772|Other|Control Arm|Nutritional supplementation, supportive management
88860196|NCT03822000||Elderly Patients with Femoral Fracture|Elderly patients with fall-induced femoral fracture. Patients were categorized into two groups: death (n = 42) and survival (n = 2,365).
88860197|NCT02315430|Experimental|Treatment (cabozantinib-s-malate)|Patients receive cabozantinib-s-malate PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89003110|NCT05761171|Experimental|Regimen A (revumenib, 3-drug re-induction, FLA)|See Detailed Description.
89184486|NCT00741260|Experimental|Neratinib and Capecitabine (Dose Group 2)|Neratinib 240 mg and Capecitabine 1500 mg/m^2
89184487|NCT00741260|Experimental|Neratinib and Capecitabine (Dose Group 3)|Neratinib 240 mg and Capecitabine 2000 mg/m^2
89184488|NCT00741260|Experimental|Neratinib and Capecitabine (Dose Group 4)|Neratinib 200 mg and Capecitabine 2000 mg/m^2
89184489|NCT00741260|Experimental|Neratinib and Capecitabine (Dose Group 5)|Neratinib 160 mg and Capecitabine 2000 mg/m^2
88860198|NCT04274244|Experimental|Cross-Linked Hyaluronate Gel Prefilled Syringe 30 MG/3ML|"The study participants will first undergo SCALE AND ROOT PLANING. This procedure is the same as that used in the active comparator group and the control group.~Eight weeks following the initial therapy, reevaluation of the intrabony defects in the interproximal sites with a clinical probing depth >5 mm will be performed by radiographs as well as by using William's graduated periodontal probe to confirm the indication for periodontal surgery. Pairs of premolar and molar teeth in the maxilla or the mandible will be randomized to receive the test treatment (REGENERATIVE PERIODONTAL SURGERY with adjunctive hyaluronic acid gel application) or to serve as active comparators (regenerative periodontal surgery with adjunctive enamel matrix derivative application)."
88860199|NCT04274244|Active Comparator|Enamel Matrix Proteins|"SCALE AND ROOT PLANING~REGENERATIVE PERIODONTAL SURGERY: Application of enamel matrix derivative."
88860200|NCT04274244|No Intervention|Scale and root planning|Control group: Just SCALE AND ROOT PLANING is performed
88860201|NCT04274322||Cohort 1|High NUTRIC score
88860202|NCT04274322||Cohort 2|low NUTRIC score
88860203|NCT04273698|Experimental|Clinical intervention|The project involved recruiting families, with children under the age of five years old, who were experiencing one or more difficulties, and these families were offered five therapeutic sessions, based on a psychodynamic parent-infant psychotherapy approach.
88860204|NCT04274166|Experimental|Experimental|2 s.c. secukinumab 150 mg injections
88860205|NCT04274088||Tecnis;|Patients who received the Tecnis multifocal IOL.
88860206|NCT04274088||Diffractiva|Patients who received the Diffractiva multifocal IOL.
88860207|NCT02983734|Active Comparator|D-cycloserine|"To compare efficacy of the novel therapeutic approach of DCS in improving cognitive functioning in GW veterans with GWI.~DCS = d-cycloserine~Dosage: 100mg~Dosage form: Pill, administered orally~Frequency: Daily for four weeks"
88860208|NCT02983734|Placebo Comparator|Placebos|To provide a control group to compare efficacy of the novel therapeutic approach of DCS in improving cognitive functioning in GW veterans with GWI.
88860209|NCT03821454|Experimental|Capecitabine|The experimental group received oral capecitabine for eight cycles.
88860210|NCT03821454|Placebo Comparator|Placebo|The placebo group received oral placebo for eight cycles.
88860211|NCT03827148|Experimental|Intervention: Pharmacist-delivered pharmaceutical care|The intervention consist of a pharmacist providing pharmaceutical care with aim to improve the treatment outcomes. It will be in the form of a single face-to-face session by pharmacist. Moreover, a specially designed rheumatoid arthritis disease education literature will be provided in both Urdu and English languages to patients for home use. The patients will be provided a contact number at which the pharmacist will be available at all times for the next three months (week 12). A specially designated counselling area in the pharmacy department of the hospitals served as venues for intervention.
88860212|NCT03827148|No Intervention|Control: Usual Care|The patient in control group will have usual care without pharmacist intervention.
89535165|NCT05006001||Case|Cases were defined as patients with an event of renal impairment during follow-up, such as acute kidney injury.
88860213|NCT04392492||Patients undergoing transfemoral TAVI with MANTA closure|Patients undergoing transfemoral transcatheter aortic valve replacement with femoral access site closure using the novel plug-based vascular closure device (MANTA, Teleflex/Essential Medical Inc., Malvern, Pennsylvania, USA).
88860214|NCT04392570||Fasting group|patients with type 2 diabetes who prefer to fast during Ramadan
88860215|NCT04392570||Non-fasting group|patients with type 2 diabetes who are otherwise healthy and have no contraindications for fasting but prefer not to fast
88860216|NCT03827304|Experimental|Burns dressings patients|Virtual Reality pain distraction games scenarios
88860217|NCT03820674|Experimental|Energy Conservation plus Problem Solving Therapy Intervention|Receiving experimental intervention
88860218|NCT03820674|Active Comparator|Health Education Intervention|Receiving control intervention
88860219|NCT03820518|Experimental|High-dose|Receiving 60 ng/kg/day of calcitriol and 30 mg/kg/day of elemental phosphorus.
88860220|NCT03820518|Experimental|Low-dose|Receiving 20 ng/kg/day of calcitriol and 30 mg/kg/day of elemental phosphorus.
88860221|NCT03820440|Experimental|Treatment - hemodynamic tests|"Treatment - hemodynamic tests:~The EEOT is performed by interrupting the mechanical ventilation for 30 seconds, by using and end-expiratory hold on the ventilator.~The LRM is performed by using a single act of mechanical ventilation in pressure-controlled mode at 30 cmH20 for 30 seconds"
88860222|NCT01453764|Experimental|Adipose SVF IV Infusion|IV Infusion of Autologous Adipose Derived Stromal Vascular Fraction Intervention: Intravenous Infusion
88860223|NCT03820206|Active Comparator|Tranexamic acid group|1 g (10 mL) tranexamic acid (Kapron, Amoun, Egypt; stored in a dry container at 15 °C-30 °C) diluted in 20 mL of 5% glucose slowly administered intravenously 15 minutes before skin incision over a 5-minute period.
88860224|NCT03820206|Placebo Comparator|Control group|30 mL of 5% glucose slowly administered intravenously 15 minutes before skin incision over a 5-minute period.
88860225|NCT02955654|Experimental|Acceptance and commitment therapy|Patients randomized to ACT will receive weekly 45-50 minute sessions delivered over 8 weeks by a therapist. ACT will include mindfulness,learning new methods to handle problems，acceptance of thoughts and feelings, learning to disempower thoughts and feelings, and values-based committed action.
88860226|NCT02955654|Active Comparator|Aripiprazole|Patients randomized to aripiprazole group will be treated with aripiprazole at the dose of 10-20mg/day for 8 weeks.
88860227|NCT02955654|Other|Stress management training|Patients randomized to SMT group will be received 2 introductory sessions and 15 treatment sessions. SMT will include training of stress manage-ment skills, progressive muscle relaxation,positive imagery, assertiveness training, and problem solving.
88860228|NCT01453842|Experimental|Diet oil|
88860229|NCT01453842|Active Comparator|Olive oil|
88860230|NCT01453842|Placebo Comparator|Carrot|
88860231|NCT03826836|No Intervention|Control Group|Treatment as usual (i.e. best medical treatment).
88860232|NCT03826836|Experimental|Mindfulness-based stress reduction|Treatment as usual (i.e. best medical treatment) in combination with an eight-week mindfulness-based stress reduction programme.
89184490|NCT00741260|Experimental|Neratinib and Capecitabine MTD (Dose Group 6)|Neratinib and Capecitabine Maximum Tolerated Dose without prior lapatinib
88860233|NCT04392648|Experimental|Escalation:TAK-573 0.1-1.5mg/kg+Bortezomib+Dexamethasone|TAK-573 0.1 to 1.5 milligram per kilogram (mg/kg), infusion, intravenously, once, every 3 weeks in a 21-days treatment cycle, along with bortezomib 1.3 milligram per square meter (mg/m^2), injection, subcutaneously, once on Days 1, 4, 8, and 11 and dexamethasone 40 milligram (mg) (20 mg if aged more than 75 years), tablets, orally on Days 1, 8, and 15 in each 21-days treatment cycle from Cycle 1 through Cycle 8. For participants who continue beyond Cycle 8, TAK-573 will be given as an infusion, intravenously, once, every 3 weeks in a 21-days treatment cycle with dexamethasone 40 mg (20 mg if aged more than 75 years), tablets, orally from Cycle 9 through Cycle 17.
88860234|NCT04392648|Experimental|Escalation:TAK-573 0.05-0.75mg/kg+Pomalidomide+Dexamethasone|TAK-573 0.05 to 0.75 mg/kg, infusion, intravenously, once, every 4 weeks in a 28-days treatment cycle, along with pomalidomide 4 mg, capsules, orally, once daily from Days 1 through 21 and dexamethasone 40 mg (20 mg if aged more than 75 years), tablets, orally, once on Days 1, 8, 15, and 22 in each 28-days treatment cycle from Cycle 1 through Cycle 17.
89384979|NCT03630783|Placebo Comparator|Placebo Control (Group-C)|Participants in this group were subjected to the same procedure as the experimental group. However, during the Combined Cognitive Bias Modification process, the sign of arrow appeared at even rates (%50 - %50) after neutral and disgusted facial impressions; and during the interpretational bias modification, sentences and relevant words were superficially related or were not related at all.
89384980|NCT03630627|Experimental|SB26 for Part 1|SB26: various single doses, administered to various cohorts
89384981|NCT03630627|Experimental|SB26 for Part 2|SB26: various multiple doses, administered to various cohorts
88860235|NCT04392648|Experimental|Escalation:TAK-573 0.1-1.5mg/kg+Cyclophosphamide+Dexamethasone|TAK-573 0.1 to 1.5 mg/kg, infusion, intravenously, once, every 4 weeks in a 28-days treatment cycle, along with cyclophosphamide 300 mg/m^2, tablets, orally, once on Days 1, 8, and 15 and dexamethasone 40 mg (20 mg if aged more than 75 years), tablets, orally, once on Days 1, 8, 15, and 22 in each 28-days treatment cycle from Cycle 1 through Cycle 17.
88860236|NCT04392648|Experimental|Expansion: TAK-573 + Bortezomib + Dexamethasone|TAK-573, infusion, intravenously, once, every 3 weeks in a 21-days treatment cycle, along with bortezomib 1.3 mg/m^2, injection, subcutaneously, once on Days 1, 4, 8, and 11 and dexamethasone 40 mg (20 mg if aged more than 75 years), tablets, orally, once on Days 1, 8, and 15 in each 21-days treatment cycle until disease progression, intolerable toxicity, withdrawal from study, or death (up to 3 years). The dose of TAK-573 for Dose Expansion Phase will be the RP2D and recommended dose for expansion (RAD) determined in the previous Dose Escalation Phase.
88860237|NCT04392648|Experimental|Expansion: TAK-573 + Pomalidomide + Dexamethasone|TAK-573, infusion, intravenously, once, every 4 weeks in a 28-days treatment cycle, along with pomalidomide 4 mg, capsules, orally, once daily from Days 1 through 21 and dexamethasone 40 mg (20 mg if aged more than 75 years), tablets, orally, once on Days 1, 8, 15, and 22 in each 28-days treatment cycle until disease progression, intolerable toxicity, withdrawal from study, or death (up to 3 years). The dose of TAK-573 for Dose Expansion Phase will be the RP2D and RAD determined in the previous Dose Escalation Phase.
88860238|NCT04392648|Experimental|Expansion: TAK-573 + Cyclophosphamide + Dexamethasone|TAK-573, infusion, intravenously, once, every 4 weeks in a 28-days treatment cycle, along with cyclophosphamide 300 mg/m^2, tablets, orally, once on Days 1, 8, and 15 and dexamethasone 40 mg (20 mg if aged more than 75 years), tablets, orally, once on Days 1, 8, 15, and 22 in each 28-days treatment cycle until disease progression, intolerable toxicity, withdrawal from study, or death (up to 3 years). The dose of TAK-573 for Dose Expansion Phase will be the RP2D and RAD determined in the previous Dose Escalation Phase.
88860239|NCT03826602|Experimental|Tucatinib plus metformin|Tucatinib administered twice daily on Days 2-8. Metformin administered as a single dose on Days 1 and 8. Iohexol administered via IV push on Days 1 and 8
88860240|NCT03820128|Active Comparator|Very early refeeding|"Very early diet intervention: refeeding within 24 hours from the hospital admission.~Participants will be encouraged to start eating immediately after the time of admission. They will be able to choose the meal from the list with no amount or calories restriction.They will be asked to conduct the daily diet diary - time of feeding, quality and quantity of the foods ingested. Laboratory tests will be performed at the study entry, on the day of 3 and 5 of hospitalization and on the day of discharge."
88860241|NCT03820128|Active Comparator|Early refeeding|"Early diet intervention: refeeding after 24 hours from the hospital admission .~During the first 24 hours after admission participants will be on fluid only (orally and/or intravenously). Later on they will be encouraged to start eating. They will be able to choose the meal from the list with no amount or calories restriction.They will be asked to conduct the daily diet diary - time of feeding, quality and quantity of the foods ingested. Laboratory tests will be performed at the study entry, on the day of 3 and 5 of hospitalization and on the day of discharge."
88860242|NCT01453920|Active Comparator|Treat-and-extend|Ranibizumab injection every 3 months, with follow-up assessments at each visit (every 3 months)
89384982|NCT03630627|Placebo Comparator|Placebo for Part 1|SB26 matching placebo: various single doses, administered to various cohorts
88860243|NCT01453920|Experimental|Treat-and-observe'|No injection, follow-up assessments every month
88860244|NCT03821220|Active Comparator|Group A|Patients will receive an activity tracker and written information for pre-diabetic, on top of their usual care.
88860245|NCT03821220|Active Comparator|Group B|Patients will receive an activity tracker, written information for pre-diabetic, and personalized physical activity prescription, on top of their usual care.
89184491|NCT00741260|Experimental|Neratinib and Capecitabine MTD (Dose Group 7)|Neratinib and Capecitabine Maximum Tolerated Dose with prior lapatinib
89384983|NCT03630627|Placebo Comparator|Placebo for Part 2|SB26 matching placebo: various multiple doses, administered to various cohorts
89384984|NCT02905266|Experimental|Nivolumab and Ipilimumab Concomitant Administration|Followed by Nivolumab monotherapy
89384985|NCT02905266|Experimental|Nivolumab and Ipilimumab Sequential Administration|Followed by Nivolumab monotherapy
89384986|NCT03889899|Experimental|DaRT Seeds|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds
89384987|NCT01380795|Other|Circulating Tumor Cell|blood sample CTC monitoring and CTC EGFR/K-ras status determination
89535166|NCT05006001||Control|Cases were defined as patients without an event of renal impairment during follow-up, such as acute kidney injury.
89535167|NCT05006001||Exposure|Exposure was defined as patients with colchicine and NSAIDs combination therapy.
89384988|NCT04339998||Patients with Suspected or Confirmed COVID-19|Patients 18 years of age and older under investigation for COVID-19 and those patients that are positive for COVID-19 at University of Minnesota Medical Center and Bethesda Hospital. Informed consent will be obtained from the patient or decision maker prior to study inclusion
89384989|NCT01380717|Active Comparator|Standard treatment|Patients with CKD 3-4, hypertension, treated for 18 months with beta-blocker and if needed ACE-inhibitor or ARB.
88860246|NCT03821220|Active Comparator|Group C|Patients will receive an activity tracker, written information for pre-diabetic, personalized physical activity prescription, three sessions of motivational interview support from trained physician assistants, and two session of dietitian support, on top of their usual care.
89384990|NCT01380717|Active Comparator|Intensive vasodilation|Patients with CKD 3-4 and hypertension, randomized to treatment with calcium channel blocker and if needed ACE-inhibitor or ARB for 18 months
89384991|NCT04292652||EVAR group|Individuals undergoing endovascular aortic repair. n=40
89384992|NCT04292652||OR group|Individuals undergoing open repair. n=40
89384993|NCT01569399|Active Comparator|active rTMS|High frequency (10HZ) on the left DLPFC
89184492|NCT02587260|Active Comparator|Sequence I|Ticagrelor in the period I Prasugrel in the period II Clopidogrel in the period III
89384994|NCT01569399|Placebo Comparator|sham rTMS|
89384995|NCT02982018|Experimental|Investigational Contact Lens with UV Blocker|Subjects will be dispensed the investigational contact lens with UV blocker to wear daily for a period of 12 weeks with follow-up visits occurring after 1, 2, 4, 8, and 12 weeks. Afterwards, the subjects will wear their habitual contact lenses for a period of two weeks with weekly visits.
89384996|NCT02982018|Active Comparator|Marketed Contact Lens|Subjects will be dispensed the marketed contact lens to wear daily for a period of 12 weeks with follow-up visits occurring after 1, 2, 4, 8, and 12 weeks. Afterwards, the subjects will wear their habitual contact lenses for a period of two weeks with weekly visits.
89384997|NCT03080493|Active Comparator|Gabapentin|"Gabapentin 600 mg PO - first dose in clinic prior to osmotic dilator placement, second dose 8 hours later (at home)~Will receive standard regimen of acetaminophen/codeine and ibuprofen to take as needed for pain overnight"
88860247|NCT03820908|Experimental|Bisantrene|patients will receive bisantrene 250mg/m2/d for 7 days
88860248|NCT02953548|Experimental|GWP42003-P|Administered orally, titrating to a target dose of 40 mg/kg/day. Participants continue at the target dose, or the highest tolerated dose up to the target dose, for the remainder of the 2-week treatment period.
88860249|NCT02952456||Bereaved families|Person who have lost a loved one from an epilepsy-related death with interview with a psychologist
88860250|NCT02952456||Patients with épilepsy|Patients with épilepsy with interview with a psychologist
88860251|NCT02952456||Relatives of patients with epilepsy|Relatives (Parents / spouse/ Husband) of patients with epilepsy with interview with a psychologist
88860252|NCT02952222|Active Comparator|Propofol (Group P)|Propofol only
88860253|NCT02952222|Active Comparator|Propofol with Dexmedetomidine (Group DP)|Propofol with Dexmedetomidine
89384998|NCT03080493|Placebo Comparator|Placebo oral capsule|"Matched placebo~Will receive standard regimen of acetaminophen/codeine and ibuprofen to take as needed for pain overnight"
89384999|NCT03655626|Experimental|Sepsis Watch on Duke University Hospital ED Adults|Patients older than 18 years old at time of presentation to Duke University Hospital emergency department.
89385000|NCT01339910|Experimental|Reduced Intensity Conditioning (RIC)|One of two different regimens in RIC will be administered; fludarabine and busulfan, or fludarabine and melphalan.
89385001|NCT01339910|Active Comparator|Myeloablative Conditioning Regimen (MAC)|One of three different regimens in MAC will be administered; busulfan and fludarabine, busulfan and cyclophosphamide, or cyclophosphamide and total body irradiation.
89385002|NCT03622164|Active Comparator|Non-experimental intervention|Radiotherapy to the bilateral neck lymphatics and tumor bed (radiotherapy to both sides of the neck).
89385003|NCT03622164|Experimental|Experimental intervention|Radiotherapy to ipsilateral neck lymphatics and tumor bed (radiotherapy to one side of the neck).
89385004|NCT01377207|Experimental|Female Arm|Female gender diagnosed with ST segment Elevation Myocardial Infarction (STEMI)
89385005|NCT01377207|Active Comparator|Male Arm|Male Gender diagnosed with ST segment Elevation Acute Myocardial Infarction (STEMI)
89385006|NCT03654222||Cardiac surgery|Direct procedures in heart
89385007|NCT03654222||Organ preservation|Mainly renal autograft
89385008|NCT03654222||Bypass|Revascularization of affected organs or segments with Woven Dacron graft
89385009|NCT03654222||Exclusion|Resection of an affected organ (nephrectomy)
88860254|NCT03826446|Other|Open Surgery|Patients diagnosed as operable right sided colon cancer were enrolled in this study and did open complete mesocolic excision procedures
88860255|NCT03826446|Other|Laparoscopic Surgery|Patients diagnosed as operable right sided colon cancer were enrolled in this study and did laparoscopic complete mesocolic excision procedures
88860256|NCT03826056|Active Comparator|Current standard education group|A study team member will use the current hospital standard educational material to explain the discharge diagnosis to the patient, the treatment, and the follow up needed. The study team member will also give a survey with a preaddressed envelope to each participant to complete at his or her convenience.
89385010|NCT03654222||Replacement|Replacement of affected aortic segment with a Woven Dacron graft
89385011|NCT03654222||Other|Any surgery that does not include the previous ones
89385012|NCT02237066|Experimental|Chocolate PTA Balloon|Chocolate PTA Balloon Angioplasty
89385013|NCT02237066|Active Comparator|Standard PTA Balloon|Standard PTA Balloon Angioplasty
89385014|NCT03655392|Experimental|Intervention Group|64 adult asthmatic patients (18-70 years old) were randomized into two groups: intervention group (IG) (n=38) or control group (CG) (n=26). IG patients were submitted to a individualized educational program: three 30-minutes intervention of a shortterm educational program delivered by a nurse at 3 monthly visits. CG group did not receive educational intervention. All patients were submitted to a spirometry, induced sputum collection, nitric oxide measure, exhaled breath condensate air measurement, and answered the questionnaires ACT, ACQ, AQLQ, BDI: Asthma Control Test (ACT), Asthma Control Questionnaire (ACQ), Asthma Quality Life Questionnaire (AQLQ), Beck Depression Inventory (BDI). All participants also answered a symptoms diary about asthma symptoms and peak flow measure.
89385015|NCT03655392|Experimental|Control Group|64 adult asthmatic patients (18-70 years old) were randomized into two groups: intervention group (IG) (n=38) or control group (CG) (n=26). IG patients were submitted to three 30-minutes intervention of a shortterm educational program delivered by a nurse at 3 montly visits. CG group did not receive educational intervention. All patients were submitted to a spirometry, induced sputum collection, nitric oxide measure, exhaled breath condensate air measurement, and answered the questionnaires: Asthma Control Test (ACT), Asthma Control Questionnaire (ACQ), Asthma Quality Life Questionnaire (AQLQ), Beck Depression Inventory (BDI). All participants also answered a symptoms diary about asthma symptoms and peak flow measure.
89385016|NCT03655314|Active Comparator|Newborn Weight Tool (NEWT)|The electronic medical record will display the Newborn Weight Tool along with a banner flagging newborn weight loss greater than or equal to the 75th centile of birth weight
89385017|NCT03655314|Placebo Comparator|Usual care|As with usual care, the electronic medical record will display the weight only as weight in grams and percent weight lost from birth weight
89385018|NCT03608618|Experimental|Cohort 1|3-6 subjects will receive a starting dose of MCY-M11 via intraperitoneal infusion once weekly for 3 weeks
89385019|NCT03608618|Experimental|Cohort 2 and 2i|3-6 subjects will receive a higher dose of MCY-M11 via intraperitoneal infusion once weekly for 3 weeks (cohort 2); 3-6 subjects will receive MCY-M11 and cyclophosphamide preconditioning (cohort 2i)
89385020|NCT03608618|Experimental|Cohort 3 and 3i|3-6 subjects will receive a higher dose of MCY-M11 via intraperitoneal infusion once weekly for 3 weeks (cohort 3); 3-6 subjects will receive MCY-M11 and cyclophosphamide preconditioning (cohort 3i)
89385021|NCT03608618|Experimental|Cohort 4 and 4i|3-6 subjects will receive a higher dose of MCY-M11 via intraperitoneal infusion once weekly for 3 weeks (cohort 4); 3-6 subjects will receive MCY-M11 and cyclophosphamide preconditioning (cohort 4i)
89385022|NCT03655158|Experimental|ozone group|After gingivectomy and gingivoplasty, right quadrants of the surgical areas were assigned to receive ozone therapy in all patients
89385023|NCT03655158|No Intervention|non-ozone group|placebo application, left quadrants received regular air from the ozone generator.
89184493|NCT02587260|Active Comparator|Sequence II|Ticagrelor in the period I Clopidogrel in the period II Prasugrel in the period III
89385024|NCT03654924|Experimental|Laryngeal Mask|A pressure gauge will be connected to the LMA using a small cable to measure the LMA cuff pressure continuously.
89385025|NCT03654846|No Intervention|Conventional emergency call|"Emergency call with conventinal cell phone:~verbal description of location~telephone-assisted CPR"
89385026|NCT03654846|Experimental|EmergencyEye emergency call|"Emergency call with EmergencyEye App on cell phone:~automated geolocalisation~video-assisted CPR"
89385027|NCT04184648||There was no adverse systems outcome after PMA36 weeks|Premature infants at PMA36 weeks did not show the following conditions (1) before follow-up tracheotomy; (2) the duration of hospital stay exceeds 50 weeks of PMA; (3) continuous or intermittent use of oxygen and respiratory support for more than 12 months after birth; (4) readmission ≥2 times due to respiratory factors within 12 months. (5) death
89385028|NCT04184648||Death or adverse respiratory outcome after 36 weeks of pma|Premature infants at PMA36 weeks presented the following conditions (1) before tracheotomy during follow-up; (2) the duration of hospital stay exceeds 50 weeks of PMA; (3) continuous or intermittent use of oxygen and respiratory support for more than 12 months after birth; (4) readmission ≥2 times due to respiratory factors within 12 months. (5) death
89385029|NCT04203290|Active Comparator|General anesthesia|Patients will be applyed 0.03 mg/kg midazolam, 2 mcg/kg fentanyl, propofol until reaching the appropriate anesthetic depth by observing entropy value (40-60) and 0.5 mg/kg rocuronium for anesthesia induction, after intubation sevoflurane will be used for anesthesia maintenance with low flow anesthesia (0.5 l/min).
89385030|NCT04203290|Active Comparator|General anesthesia combined with thoracic epidural anesthesia|Before anesthesia induction epidural catheter will be inserted giving 7 ml bupivacaine %0.25 in saline + 50 mcg fentanyl after confirming the location of catheter, following 15 minutes the standard anesthesia induction will be applied ( 0.03 mg/kg midazolam, 2 mcg/kg fentanyl, propofol until reaching the appropriate anesthetic depth by observing entropy value (40-60) and 0.5 mg/kg rocuronium ). For anesthesia maintenance epidural infusion will be applied ( 7ml/h %0.25 bupivacaine solution) together with low flow (0.5 l/min) sevoflurane anesthesia.
89385031|NCT02237144|Experimental|Cash transfer|1500 taka ($18.75) per household distributed monthly
89385032|NCT02237144|Experimental|Food transfer|30 kg rice, 2 kg lentils, and 2 kg micro-nutrient fortified cooking oil per household distributed monthly
89385033|NCT02237144|Experimental|Food and cash transfer|15 kg of rice; 1 kg of lentils and 1 kg of micronutrient fortified cooking oil and 750 taka cash per household, distributed monthly
89385034|NCT02237144|Experimental|Cash transfer + BCC|1500 taka ($18.75) per household distributed monthly Weekly, one hour meetings on maternal and child nutrition, sanitation and health knowledge, attitudes and practice Occasional home visits
89385035|NCT02237144|Experimental|Food transfer + BCC|30 kg rice, 2 kg lentils, and 2 kg micro-nutrient fortified cooking oil per household distributed monthly Weekly, one hour meetings on maternal and child nutrition, sanitation and health knowledge, attitudes and practice Occasional home visits
89184494|NCT02587260|Active Comparator|Sequence III|Prasugrel in the period I Ticagrelor in the period II Clopidogrel in the period III
89184495|NCT02587260|Active Comparator|Sequence IV|Prasugrel in the period I Clopidogrel in the period II Ticagrelor in the period III
89184496|NCT02587260|Active Comparator|Sequence V|Clopidogrel in the period I Ticagrelor in the period II Prasugrel in the period III
88860257|NCT03826056|Experimental|New personalized education group|A study team member will use the new personalized educational materials to explain the discharge diagnosis to the patient, the treatment, and the follow up needed. The study team member will also give a survey with a preaddressed envelope to each participant to complete at his or her convenience.
88860258|NCT03821688|Experimental|SAS-JB|laparoscopic single anastomosis sleeve jejunal bypass
89184497|NCT02587260|Active Comparator|Sequence VI|Clopidogrel in the period I Prasugrel in the period II Ticagrelor in the period III
89184498|NCT02572011|No Intervention|Control|Participants in the control (CON) group will not complete any formalised balance training as part of the current study.
89184499|NCT02572011|Experimental|Experimental|Participants in the experimental group will complete the Home-based Games Console Balance Training intervention.
89184500|NCT02596256|Experimental|control group|Apatinib Mesylate Tablets (500 mg qd p.o.) and Docetaxel (60mg/m2 i.v. d1 q21d)
89184501|NCT02596256|Active Comparator|contrast group|Docetaxel (60mg/m2, i.v. d1 q21d)
89184502|NCT00717483||Type 1 diabetes|children with type 1 diabetes
89184503|NCT04934358|Experimental|Physical activity program and motivational intervention|Physical activity program agreed with the patient / family and according to functional status (based on the 6-minute walk test) and motivational intervention. In addition to the care provided in usual care, a progressive physical exercise program based on basal functional capacity is prescribed. The exercise will be developed at home.
89184504|NCT04934358|Active Comparator|Treatment as usual|Multidisciplinary rehabilitation provided by professionals in the hospital and primary care settings, according to the individual needs of patients at different times of their recovery and the accessibility and availability of services in the different care settings.
89184505|NCT04090580|Experimental|Daily dosage of dapagliflozin and metformin|Subjects enrolled will be randomized 1:1 to either receive a daily dosage of 10 mg dapagliflozin and 2000 mg metformin for 12 weeks
89184506|NCT04090580|Experimental|Daily dosage of metformin|Subjects enrolled will be randomized 1:1 to either receive a daily dosage of 2000 mg metformin for 12 weeks
89184507|NCT02571933||Grammar English|Patients who primarily speak Grammar English. Patients will answer the FPS-R in Grammar English both before and after administration of routine analgesia for pain (analgesia to be administered regardless of enrollment in study). Study participants will answer a series of questions - the cognitive interview - after second FPS-R to assess for ease of use and how well it is understood.
89184508|NCT02571933||Pidgin English|Patients who primarily speak Pidgin English. Patients will answer the FPS-R in Pidgin English both before and after administration of routine analgesia for pain (analgesia to be administered regardless of enrollment in study). Study participants will answer a series of questions - the cognitive interview - after second FPS-R to assess for ease of use and how well it is understood.
89184509|NCT02571933||French|Patients who primarily speak French. Patients will answer the FPS-R in French both before and after administration of routine analgesia for pain (analgesia to be administered regardless of enrollment in study). Study participants will answer a series of questions - the cognitive interview - after second FPS-R to assess for ease of use and how well it is understood.
89184510|NCT04089722|Other|Open-Label: Deoxycholic Acid Injections|Deoxycholic Acid Injections (dose strength: 2 mg/cm2) via subcutaneous injections into posterior and/or anterior axillary roll adiposity. Patients will receive 10 mL or less (≤100 mg) of study drug per treatment administered in 0.2-mL injections with a 30-gauge, 0.5-in needle attached to a 1-mL syringe at 1.0-cm spacing using a customized grid. Up to 6 treatments (30 ± 7 days apart) will be permitted, but fewer can be allowed because of efficacy (insufficient BSF to inject, patient satisfaction with treatment) or safety/tolerability concerns.
89385036|NCT02981082|Active Comparator|Dimethyl Fumarate (DMF)|Twice daily oral doses of Dimethyl Fumarate (DMF) 120mg for the first 7 days followed by the maintenance dose of Dimethyl Fumarate (DMF) 240mg twice a day. Subjects will be dosed for 24 weeks
88860259|NCT03821688|Active Comparator|MGB|laparoscopic mini gastric bypass
89385037|NCT02981082|Placebo Comparator|Placebo|Twice daily oral doses of placebo for 12 weeks
89385038|NCT02237222||Gait rehabilitation|"Multi-modal therapy program including physiotherapy with the aim of gait improvement, Lokomat or treadmill training, strength training, sports therapy.~Frequency and intensity are individually assigned."
88860260|NCT03821688|Active Comparator|LSG|laparoscopic sleeve gastrectomy
88860261|NCT03826368||TBI Controls|Adult men and women between 18 and 55. No prior history of traumatic brain injury. Experienced taking hemp-derived botanicals.
88860262|NCT03826368||TBI HDS|Adult men and women between 18 and 55. History of traumatic brain injury. Experienced taking hemp-derived botanicals.
88860263|NCT03825354|Experimental|Brief Intervention and contact (BIC)|Brief education about suicidal behaviour and follow up contacts for 6 months in addition to treatment as usual. follow up will occur at the following time points post discharge: weeks 1, 2, 4, 6, 8, 12, 16 and 20. this will occur in addition to treatment as usual.
88860264|NCT03825354|No Intervention|control|control will continue treatment as usual which is whatever the clinical team decides upon post discharge. data will be collected on repeated suicidal behaviour through medical records with consent.
89385039|NCT02034266|Experimental|Omega-3 supplementation|Participants will take an oral 5 mL serving (1 tbsp) of mammalian omega-3 seal oil (375 mg EPA, 280 mg DPA and 510 mg DHA) (Auum Inc., Timmons, On) twice daily. Total daily essential fatty acid load - 2330 mg.
89385040|NCT03654612|Experimental|Apatinib+S-1|Patients with recurrent/metastatic head and neck malignancies received apatinib plus S-1 as second-line therapy.
89385041|NCT03654534|Experimental|oral nutritional supplements|NutrenOpimum administration was recommended with a dosage of 400 kcal/400 ml per day within 7 days postoperatively and was continued for 3 months postoperatively.
89385042|NCT03654534|No Intervention|standard diet|The control group was given no additional postoperative nutritional supplementation (standard diet).
88860265|NCT04391478|Active Comparator|milrinone|Milrinone is a phosphodiesterase inhibitor typ3 used in treatment of PPHN. used in dose (0.25 to 0.75 mg/kg/min) intravenous infusion compared with nasogastric sildenafil.
89385043|NCT01066104|Placebo Comparator|Xolair placebo|Xolair placebo 150-375 mg is administered subcutaneously (SC) every 2 or 4 weeks depending on the patient's baseline serum total IgE level (IU/mL), measured before the start of treatment, and body weight (kg) ). Doses of more than 150 mg are divided among more than one injection site to limit injections to not more than 150 mg per site.
89385044|NCT01066104|Active Comparator|Xolair (omalizumab)|Xolair (omalizumab) 150-375 mg is administered subcutaneously (SC) every 2 or 4 weeks depending on the patient's baseline serum total IgE level (IU/mL), measured before the start of treatment, and body weight (kg). Doses of more than 150 mg are divided among more than one injection site to limit injections to not more than 150 mg per site.
89385045|NCT02736968|Experimental|E. histolytica- Active|N=34, 6mg auranofin daily x 7 days
89385046|NCT02736968|Placebo Comparator|E. histolytica- Placebo|N=34, 6mg placebo daily x 7 days
89385047|NCT02736968|Experimental|Giardia- Active|N=34, 6mg auranofin daily x 5 days
89385048|NCT02736968|Placebo Comparator|Giardia- Placebo|N=34, 6mg placebo daily x 5 days
89385049|NCT02980224|Experimental|OmegaD|OmegaD Softgels
89385050|NCT02980224|Placebo Comparator|Placebo|Placebo Softgels
89385051|NCT03653910|Experimental|Airtraq|Patients received DLT intubation by Airtraq videolarygoscope
89385052|NCT03653910|Active Comparator|Macintosh|Patients received DLT intubation by Macintosh laryngoscope
88860266|NCT04391478|Active Comparator|sildenafil|Sildenafil is a phosphodiesterase inhibitor typ 5 used in treatment of PPHN. used in dose (0.2 to 0.5 mg/kg/6h) by nasogastric tube compared with intravenous milrinone infusion.
88860267|NCT03828006|Experimental|Active Group|One tablet per day through oral administration of a dietary supplement containing red rice yeast as the main active ingredient
88860268|NCT03828006|Placebo Comparator|Placebo Group|One tablet per day of placebo.
89385053|NCT03608306|Experimental|Resin-modified glass ionomer|Activa Bioactive-Restorative is an enhanced resin modified glass ionomer (RMGI) with an ionic resin matrix, a shock-absorbing resin component, and bioactive fillers that mimic the physical and chemical properties of natural teeth.
89385054|NCT03608306|Active Comparator|Bulk-fill glass hybrid restorative|EQUIA Forte is a bulk-fill, fluoride-releasing restorative system that combines EQUIA Forte Fil, which is a high strength glass hybrid restorative, and EQUIA Forte Coat, a wear-resistant, self-adhesive, light-cured resin coating.
88860269|NCT03823014|Experimental|External Erectile Prosthesis|Study participants will be recruited as couples (transgender man + sexual partner.) Couples will use an external erectile prosthesis (Elator) over the course of 1 month and keep track of their experiences. 20 men and their partners will be enrolled.
88860270|NCT04346706|Experimental|Immediate implantation|Tooth extraction, immediate insertion of an implant with immediate temporization
88860271|NCT04346706|Experimental|Delayed implantation|Implant inserted in a healed socket with immediate temporization
88860272|NCT03825900|Active Comparator|Active tDCS|Active transcranial direct current stimulation
88860273|NCT03825900|Sham Comparator|Sham tDCS|Sham transcranial direct current stimulation
88860274|NCT03826134|Experimental|[11C]-PXT012253|
88860275|NCT03825978|Active Comparator|Intervention|An individual and comprehensive prenatal genetic counseling was given to all pregnant women in the intervention group, including all screening tests and diagnostic tests for prenatal diagnosis and screening tests at the first antenatal visit.
89385055|NCT03654144|Experimental|Study group|women will receive dienogest
89385056|NCT03654144|Active Comparator|control group|women used combined oral contraceptive pills
89385057|NCT03654456||Sepsis patients with OSA|Sepsis patients who received a prior polysomnography showing an apnea-hypopnea index at least 5/hr with compatible symptoms
89385058|NCT03654456||Sepsis patients without OSA|Sepsis patients who received a prior polysomnography showing an apnea-hypopnea index less than 5/hr
89385059|NCT02591615|Active Comparator|Arm A|"For Squamous Carcinoma Carboplatin AUC = 6 IV day 1 every 21-days for up to 4 cycles Paclitaxel 200 mg/m2 IV day 1 every 21-days for up to 4 cycles~OR~For Non-squamous Carcinoma Carboplatin AUC = 6 IV day 1 every 21-days for up to 4 cycles Pemetrexed 500 mg/m2 IV day 1 every 21-days for up to 4 cycles"
88860276|NCT03825978|No Intervention|Control|There was no intervention from the first antenatal visit in the control group. Routine clinical information was given about prenatal screening and diagnostic tests.
88860277|NCT03826212|Experimental|Soybean Germ Extract|Soybean Germ Extract 1,600 mg/day for 12 weeks.
88860278|NCT03826212|Placebo Comparator|Placebo|Placebo 1,600 mg/day for 12 weeks.
88860279|NCT03078348|Active Comparator|Targeted Psychoeducational Photo Novella|"Fecal Immunochemical Test (FIT) Kit + Culturally targeted Photo Novella Booklet + culturally targeted reminders. This study involves participation at distinct time points:~Baseline~6 month follow-up"
88860280|NCT03078348|Active Comparator|Standard Brochure Intervention|"FIT Kit + Screen for Life Brochure + standard reminders. This study involves participation at distinct time points:~Baseline~Post 6 month follow-up"
88860281|NCT03829956|Other|Snoring and mild OSA|This cohort of participants has been diagnosed with primary snoring or mild obstruction sleep apnoea. A medical device (intra-oral tongue stimulation device) will be introduced for 6 weeks and the effects will be assessed by comparing the outcome measures before and after the intervention.
88860282|NCT04391868|Active Comparator|Viagra tablet|Subjects receive a single dose of 50 mg Viagra tablet followed by plasma sampling for 14 hours.
88860283|NCT04391868|Experimental|Sildenafil citrate ODF without water|Subjects receive a single dose of 50 mg sildenafil ODF without water followed by plasma sampling for 14 hours.
88860284|NCT04391868|Experimental|Sildenafil citrate ODF with water|Subjects receive a single dose of 50 mg sildenafil ODF with water followed by plasma sampling for 14 hours.
88860285|NCT03827616|Active Comparator|2,5 Gy|hypofractionated dosing 28 fractions x 2,5 Gy over 38 days (prostate 28 x 2,5Gy - 70Gy, seminal vesicles 28 x 2Gy - 56 Gy, node lympaticus ( if Rouch formula> 15% or N1) 28 x 1,8 Gy - 50,4 Gy).
88860286|NCT03827616|Active Comparator|3 Gy|hypofractionated dosing 20 fractions x 3 Gy over 26day (prostate 20 x 3Gy - 60Gy, seminal vesicles 20 x 2,5Gy - 50 Gy, node lympaticus ( if if Rouch formula> 15% or N1 ) 20 x 2,2 Gy - 44 Gy).
88860287|NCT03823794||Prevalent case of atopic dermatitis|People with atopic dermatitis meeting the inclusion criteria and registered with one of the study practices for one or more years during the study period.
88860288|NCT03823794||Controls|Age, gender and primary care practice-matched controls without a diagnosis of atopic dermatitis or another exclusion condition (psoriasis, photodermatitis, or ichthyosis) and registered with one of the study practices for one or more years during the study period.
88860289|NCT03821532|No Intervention|Control group|Each family will receive a randomized packet containing educational information, rewards charts and an adult literacy test. The treatment plan will be determined based on recommendations from the clinical guidelines for the Evaluation and Treatment of Functional Constipation Infants and Children as published by the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition. At the first visit, the parent(s) will complete an adult literacy test and an initial paper questionnaire regarding symptoms, adherence to the treatment plan and demographics. At 1 month, the primary investigator will call each family and administer a phone survey regarding symptoms and adherence to the treatment plan in the past month. At 3 months, the families will return for a follow up visit with their 3 month reward charts and complete a final paper survey regarding the child's symptoms and adherence to the treatment plan.
88860290|NCT03821532|Experimental|Experimental group|Each family will receive a randomized packet containing educational information, rewards charts, an adult literacy test and a constipation action plan tool. The treatment plan will be determined based on recommendations from the clinical guidelines for the Evaluation and Treatment of Functional Constipation Infants and Children as published by the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition. At the first visit, the parent(s) will complete an adult literacy test and an initial paper questionnaire regarding symptoms, adherence to the treatment plan and demographics. At 1 month, the primary investigator will call each family and administer a phone survey regarding symptoms and adherence to the treatment plan in the past month. At 3 months, the families will return for a follow up visit with their 3 month reward charts and complete a final paper survey regarding the child's symptoms, adherence to the treatment plan, and action plan utility.
88860291|NCT03821766||Heart failure|Patients suffering from heart failure regardless to the etiology will undergo cardiac catheterization according to their medical condition. the SCG and BCG signals will be recorded along with the intracavitary pressure profiles detected invasively with the cardiac catheterization.
88860292|NCT01454310|Experimental|Acellular skin substitute|
88860293|NCT01454310|Active Comparator|Autologous skin graft|
88860294|NCT03825666|Experimental|Active|Intervention with drink pre surgery and chewing gum post surgery. No subgroups, combined intervention will be assessed. ProvideXtra® Fresenius Kabi plus standard consumer xylitol chewing gum.
88860295|NCT03825666|No Intervention|Control|control group following standard guidelines
88860296|NCT01454388|Active Comparator|PEG plus breakfast|patients are allowed to have a low residue breakfast the day prior to colonoscopy
88860297|NCT01454388|No Intervention|PEG without breakfast|
88860298|NCT01454388|Active Comparator|picosalax plus breakfast|patients are allowed to have a low residue breakfast the day prior to colonoscopy
88860299|NCT01454388|No Intervention|picosalax without breakfast|
88860300|NCT01454544|Experimental|ALK house dust mite tablet 6 DU|
88860301|NCT01454544|Experimental|ALK house dust mite tablet 12 DU|
88860302|NCT01454544|Placebo Comparator|Placebo|
88860303|NCT03824730||Endovascular occlusions group|Group of patients with aorto-iliac occlusive disease (TASC B, C, D) in whom stenting of the Common and/or External Iliac Arteries were performed
88860304|NCT03824886|Experimental|Implementation of skin care algorithm|In the interventional nursing homes, a structured skin care prevention package based on a newly developed evidence-based skin care algorithm will be implemented at the nursing homes and delivered by nurses.
88860305|NCT03824886|No Intervention|Standard Care|In the control group, no additional intervention will be implemented. PU and IAD prevention and basic hygiene and skin care activities are routinely conducted in German nursing homes. This is considered as 'usual practice'.
88860306|NCT02983188|Active Comparator|Berberine|Patients will receive berberine pills in additional to current atypical antipsychotic agents
88860307|NCT02983188|Placebo Comparator|Placebo|Patients will receive placebos pills in additional to current atypical antipsychotic agents
88860308|NCT01450176|Active Comparator|Pataday once daily|15 subjects will administer Pataday once daily for 2 weeks. Then these subjects will administer Bepreve twice daily for 2 weeks.
88860309|NCT01450176|Active Comparator|Bepreve twice daily|Bepreve twice daily for 2 weeks, then subjects will use Pataday once daily for 2 weeks
89535168|NCT05006001||Non-Exposure|Non-Exposure was defined as patients with other gout therapy.
88860310|NCT01450254|Experimental|Experimental|These patients will carry out a therapy program with the study intervention device.
88860311|NCT01450254|Active Comparator|Control|The patients in this group will not carry out a therapy program with the study intervention device.
88860312|NCT01454622|Experimental|Treatment Sequence AB|
89535169|NCT03227965|Other|ELITE|
89003111|NCT05761171|Experimental|Regimen B (revumenib, FLA)|"COMBINATION CYCLES 1-2: Patients receive revumenib PO or via NG, ND, NJ, or G-tube every 12 hours continuously, FLA IV on days 1-5, MTX IT, hydrocortisone IT, and cytarabine IT on day 0 and optionally on days 8, 15, and 22 of each cycle. Cycles repeat every 28 days for 2 cycles.~MONOTHERAPY: Patients receive revumenib PO or via NG, ND, NJ, or G-tube every 12 hours continuously. Treatment repeats every 28 days for up to 12 cycles on study in the absence of disease progression or unacceptable toxicity. Patients may also receive MTX IT, hydrocortisone IT, and cytarabine IT on days 0, 8, 15 and 22 as clinically indicated.~All patients also undergo ECHO or MUGA, collection of blood and CSF samples, lumbar puncture, and bone marrow aspiration throughout the trial."
89003112|NCT05759728|Experimental|CNA3103 Monotherapy|Single intravenous dose of CNA3103 at Day 0
89003113|NCT05758415|Experimental|Secukinumab|"Name and Strength: 2 X Secukinumab 150 mg / 1 mL~Pharmaceutical Dosage Form: Solution for subcutaneous (s.c.) injection~Randomized in a 1:1 ratio"
89003114|NCT05758415|Placebo Comparator|Placebo|"Name and Strength: 2 X Placebo / 1 mL~Pharmaceutical Dosage Form: Solution for subcutaneous (s.c.) injection~Randomized in a 1:1 ratio"
89003115|NCT05756322|Experimental|Dose Finding and Expansion Phase|Phase 1: Dose finding Phase 2: Optimal dose identified by phase 1 (dose finding) administrated to subject.
89003116|NCT05755100|Other|Pilot study of I MOVE!+UP among Veterans with PTSD and BMI of 30 or greater.|Single arm pilot trial.
89003117|NCT05752799|Active Comparator|Opioid Based Anaesthesia|"This arm will receive:~2 mcg/kg fentanyl in 10 ml volume~0.2 mL/kg/h remifentanil infusion~0.1 mg/kg morphine"
89003118|NCT05752799|Active Comparator|Opioid Free Anaesthesia|"This arm will receive~40 mg/kg magnesium sulfate in 100 ml N/S infusion~0.4 mcg/kg dexmedetomidine, max total dose 50mcg in 50 ml N/S infusion~0.3 mg/kg ketamine in 10 ml volume~0.2 ml/kg of the Multimix regimen in 100 ml N/S infusion as a bolus (The Multimix regimen consists of 50mcg dexmedetomidine, 500 mg lidocaine and 50mg ketamine).~0.2 ml/kg/h of the Multimix regimen in 100 ml N/S infusion as a continuous infusion"
89003119|NCT05751772|Experimental|"Patient therapeutic education group"|The intervention group will benefit from a pharmacist-led therapeutic education intervention on the knowledge of hospitalized heart failure patients and usual hospital care (medical and nursing care)
89003120|NCT05751772|No Intervention|"Usual hospital care group"|The control group do only benefit from the usual hospital care (any medical and nursing care giving to an acute heart failure inpatient) and won't benefit from the pharmacist's educational intervention.
89003121|NCT05748171|Experimental|Inotuzumab ozogamicin|"Each participant in the InO arm will receive 1 course (3 doses) of InO, as follows:~Day 1: 0.8 mg/m2~Days 8 (±1 day) and Day 15 (±1 day): 0.5 mg/m2/dose"
89003122|NCT05748171|Active Comparator|ALLR3|"Mitoxantrone 10 mg/m2 on Days 1 and 2 Vincristine 1.5 mg/m2 (max single dose 2 mg) administered on Days 3, 10, 17 and 24 Dexamethasone 20 mg/m2/day administered orally (or IV) divided into two daily doses (maximum 40 mg/day) as two 5-day blocks on Days 1-5 and Days 15-19.~PEG-asparaginase 1000 units/m2 IV administered on Days 3 and 17"
89003123|NCT05742945|Experimental|ILR|Breast cancer patients receiving axillary lymph node dissection and immediate lymphatic reconstruction
89003124|NCT05742945|No Intervention|non-ILR|Breast cancer patients receiving only axillary lymph node dissection
89003125|NCT05742880|Sham Comparator|Without Facemask|Wearing no mask.
89003126|NCT05742880|Active Comparator|Wearing a Facemask|Wearing a surgical facemask
89003127|NCT05742880|Active Comparator|Wearing a FFP2-Mask|Wearing a FFP2- Mask
89003128|NCT05734001|Active Comparator|Conventional Haemostatic Tests|"Conventional Haemostatic Tests:~If INR: > 2.5 FFP will be transfused at 15 ml/kg~If Platelet Count is 20,000/mm3-50,000/mm3 RDPC will be transfused at 10 ml/kg~If Fibrinogen < 80 mg/dl Cryoprecipitate will be transfused at 5 ml/kg"
89189394|NCT05810662|Active Comparator|5%dextrose in 0.9%saline|"5% Dextrose and 0.45% Sodium Chloride Injection, USP solution is sterile and nonpyrogenic. It is a large volume parenteral solution containing dextrose and sodium chloride in water for injection intended for intravenous administration.~Each 100 mL of 5% Dextrose and 0.45% Sodium Chloride Injection, USP contains dextrose, hydrous 5 g and sodium chloride 0.45 g in water for injection. Electrolytes per 1000 mL: sodium (Na+), 77 mEq; chloride (Cl-) 77 mEq. The osmolarity is 406 mOsmol/L (calc.), which is hypertonic. The caloric value is 170 kcal/L.~The pH is 4.3 (3.5 to 6.5). 5% Dextrose and 0.45% Sodium Chloride Injection, USP contains no bacteriostat, antimicrobial agent or added buffer and is intended only as a single-dose injection."
88860313|NCT01454622|Experimental|Treatment Sequence BA|
88860314|NCT01450332|Experimental|study|
88860315|NCT01454856||Surgical cancer patients|No modification of the treatment
88860316|NCT01454856||Non-surgical cancer patients|No modification of the treatment
88860317|NCT01454856||Surgical non-cancer patients|No modification of the treatment
88860318|NCT01454856||Non-surgical non-cancer patients|No modification of the treatment
88860319|NCT01450410|Active Comparator|Nicotinic Acid|
88860320|NCT01450410|Placebo Comparator|Placebo|
88860321|NCT02950818|Experimental|Take Heart self-management program|Group and telephone-based educational program to enhance self-management of heart disease and related risk factors.
88860322|NCT02950818|No Intervention|Waitlist control|Control group participants will be offered the opportunity to participate in Take Heart following the conclusion of their study involvement.
88860323|NCT03824418||Chromoendoscopy follow-up|
88860324|NCT03824418||Autofluorescence follow-up|
88860325|NCT04391712|Experimental|Experimental|Participants will receive MLS laser treatment along with regular inpatient medical care.
88860326|NCT04391712|Active Comparator|Control Group|Participants will receive regular inpatient medical care.
88860327|NCT04391634|Other|Mechanical ventilation|Preterm infants on mechanical ventilation
88860328|NCT01450488|Experimental|masitinib 3 mg/kg/day|
88860329|NCT01450488|Experimental|masitinib 6 mg/kg/day|
88860330|NCT01450566|Experimental|Lidocaine|Use of lidocaine
88860331|NCT01450566|Placebo Comparator|No lidocaine|No lidocaine/standard of care
88860332|NCT03824262|Experimental|Group I|HICO-VARIOTHERM 550 and Mistral-Air Plus forced-air warming device
88860333|NCT03824262|Active Comparator|Group II|Mistral-Air Plus forced-air warming device
88860334|NCT03043014|Experimental|Mifépristone group|
88860335|NCT03043014|Active Comparator|misoprostol group|
88860336|NCT01450644|Other|Fast track|If patients are randomised to fast-track, their information will be passed to the H2H nurse to organise a case conference within one week of discharge.
88860337|NCT01450644|Other|Waiting list|If patients are in the control arm, they will continue to receive Standard Best Practice (SBP) and their data will be held by the researcher until after the second interview (4 weeks). After this time, they will be contacted by the H2H nurse to receive the intervention and will be interviewed and followed up as for the fast track group.
88860338|NCT01455168||No treatment|Capsular tension ring is not used in the group.
88860339|NCT01455168||CTR simply implanted|Capsular tension ring is simply implanted in the group.
88860340|NCT01455168||CTR with the eyelets closed|Capsular tension ring is implanted and closed by tying both eyelets in the group.
88860341|NCT02983344|Active Comparator|fascia iliaca compartment block|Patient will receive 40ml of ropivacaine 0.375% at the fascia iliaca compartment under the guidance of ultrasound. It will be given 20 minutes before patient is positioned for spinal anaesthesia
88860342|NCT02983344|Active Comparator|intravenous fentanyl|Patient will receive 0.5 mcg/kg of intravenous fentanyl. It will be given 5 minutes before patient is positioned for spinal anaesthesia
88860343|NCT01450878|Experimental|Graft with EPO|intravenous 1000 000UI beta-epoietin one hour before organe retrieval.
88860344|NCT01450878|No Intervention|graft without EPO|no injection befoe organ retrieval
88860345|NCT01451034|Active Comparator|WHYX cancer group|WHYX cancer diagnosed by pathologic report
88860346|NCT01451034|Placebo Comparator|non-WHYX cancer group|all cancer except WHYX cancer diagnosed by pathologic report
88860347|NCT03824340|Active Comparator|Doxycycline before ICSI|extra medications (Doxycycline ) group before ICSI : in which Women who will receive the Doxyxycline before ICSI Intervention : Women will receive Doxycycline before ICSI
88860348|NCT03824340|No Intervention|control group|control group : No intervention : in which Women willnot receive the extra medications (Doxycycline ) before ICSI
88860349|NCT03824028||Clareon IOL AutonoMe|Prior implantation with Clareon intraocular lenses (IOLs) using the Clareon® IOL AutonoMe™ automated preloaded delivery system
88860350|NCT03823872|Experimental|Overweight|Participants with BMI 25-29.9 kg/m2 undergo structured exercise for weight loss. They are randomized to the following interventions: 1) time restricted feeding = only eat between 12pm-8pm or 2) normal feeding= eat on normal schedule.
88860351|NCT03823872|Experimental|Obese|Participants with BMI 29.9-34.9 kg/m2 undergo structured exercise for weight loss. They are randomized to the following interventions: 1) time restricted feeding = only eat between 12pm-8pm or 2) normal feeding= eat on normal schedule.
88860352|NCT01455246|Experimental|Daptomycin + Meropenem|30 patients with cirrhosis and nosocomial SBP
88860353|NCT01455246|Active Comparator|Ceftazidime|30 patients with cirrhosis and nosocomial SBP
88860354|NCT01455324||Lower Limb Amputees|Those with lower limb amputations
88860355|NCT01451112|Experimental|Treated|
88860356|NCT02910648|Experimental|Approach/Inhibit group|"Participants in the experimental group and control sham sound cues group will complete the Modified Go/No-Go Task.~Following completion of post-training assessment measures, participants will be given the opportunity to take a 90-minute while undergoing real-time sleep monitoring.~White noise will be played via headphones. Upon entering Stage N3 sleep and/or after having been asleep for 20 minutes and currently in any stage sleep other than N1, sound cues will be played to participants via headphones based on their randomization to 1 of 3 experimental groups."
88860357|NCT02910648|Sham Comparator|Sham sound cues group|"Participants in the experimental group and control sham sound cues group will complete the Modified Go/No-Go Task.~Following completion of post-training assessment measures, participants will be given the opportunity to take a 90-minute while undergoing real-time sleep monitoring.~White noise will be played via headphones. Upon entering Stage N3 sleep and/or after having been asleep for 20 minutes and currently in any stage sleep other than N1, sound cues will be played to participants via headphones based on their randomization to 1 of 3 experimental groups."
88860358|NCT02910648|Sham Comparator|Sham go/no-go group|"Participants in the control sham go/no-go group will complete a modified Go/No-Go Task with sham approach and inhibit items.~Following completion of post-training assessment measures, participants will be given the opportunity to take a 90-minute while undergoing real-time sleep monitoring.~White noise will be played via headphones. Upon entering Stage N3 sleep and/or after having been asleep for 20 minutes and currently in any stage sleep other than N1, sound cues will be played to participants via headphones based on their randomization to 1 of 3 experimental groups."
88860359|NCT01455480|Experimental|RPh201|
88860360|NCT03823950|Experimental|Receive G-CSF 72 hours following chemotherapy|"Children will be enrolled during the first four rounds of chemotherapy. Upon enrollment, children will receive G-CSF at 24 hours following chemotherapy. G-CSF will be discontinued when absolute neutrophil count (ANC) has increased post nadir in accord with G-CSF administration guidelines. Parents and children will then complete questionnaires to determine rates of side effects and needle distress at the end of G-CSF during their next regular outpatient oncology clinic visit.~Following children's next course of chemotherapy, G-CSF will be started 72 hours after completion of chemotherapy."
88860361|NCT03823950|No Intervention|Historical Controls|Four matched historical controls who received G-CSF at 24 hours following chemotherapy for each patient enrolled will be selected as each enrolled patient completes G-CSF therapy.
88860362|NCT01451190|Experimental|Treated|
88860363|NCT01451268|Experimental|Panobinostat Arm A|
88860364|NCT01451268|Experimental|Panobinostat Arm B|
88860365|NCT01451346|Placebo Comparator|Placebo|Placebo sachets contained 5 grams of Maltodextrin only.
88860366|NCT01451346|Experimental|B Infantis 35624|Each 5gram freeze-dried powder contained ≥1*1010 Colony forming units (CFU) of B. infantis 35624/sachet.
88860367|NCT03823638|Experimental|D-Mannitol|Oral Supplement of the investigated substance: D-Mannitol powder (manufacturer Roquette)
88860368|NCT03823638|Placebo Comparator|Placebo|Oral Supplement of the placebo: Dextrose monohydrate powder (manufacturer Roquette)
88860369|NCT01455558|Experimental|Cilostazol|
88860370|NCT01455714||A, B, C|Group A- 40 patients without symptoms of heart failure Group B- 40 patients with exertional dyspnoea Group C - 40 patients with overt heart failure
88860371|NCT02884908|Experimental|Pregabalin + BBCET - NI/I/II type|This group will be comprised of subjects with the NI/I/II type who receive study medication (Pregabalin) and Brief Behavioral Compliance Enhancement Treatment (BBCET).
88860372|NCT02884908|Experimental|Pregabalin + BBCET - NI/NI type|This group will be comprised of subjects with the NI/NI type who receive study medication (Pregabalin) and Brief Behavioral Compliance Enhancement Treatment (BBCET).
88860373|NCT02884908|Placebo Comparator|Placebo + BBCET - NI/I/II type|This group will be comprised of subjects with the NI/I/II type who receive placebo and Brief Behavioral Compliance Enhancement Treatment (BBCET).
88860374|NCT02884908|Placebo Comparator|Placebo + BBCET - NI/NI type|This group will be comprised of subjects with the NI/NI type who receive placebo and Brief Behavioral Compliance Enhancement Treatment (BBCET).
88860375|NCT01451658|No Intervention|EVL or GVS treatment|"Endoscopic treatment alone is used for 2nd prevention of gastroesophageal variceal bleeding in patients with HCC.~endoscopic variceal ligation (EVL) or Gastric Variceal Sclerotherapy (GVS)"
88860376|NCT01451658|Experimental|Endoscopic treatment combined propranolol|Endoscopic treatment alone versus combined propranolol is used for 2nd prevention of gastroesophageal variceal bleeding in patients with HCC.
88860377|NCT01455792|Experimental|MRI and soft image fusion biopsy|Preoperative MRI and soft image ultrasound guided biopsy.
88860378|NCT01455792|Active Comparator|Gold standard biopsy|Gold standard TRUS biopsy
88860379|NCT01451892|Experimental|Dance therapy|overweight individuals participating in a patient education program for obese people combined with specific dance-therapy
88860380|NCT01451892|Active Comparator|Education|overweight individuals participating in a patient education ambulatory program for obese people
88860381|NCT04392258||Status post resuscitation|Patients or dataset that underwent resuscitation
89184511|NCT05093166|Experimental|Urethral reduced functionality and/or lesions due to previous hypospadias treatment failure|"The first step consists in a small oral mucosa biopsy collection by surgeon under general anaesthesia. The biopsy will be processed in a laboratory of a regenerative medicine manufacturing site where the epithelial cells will be isolated, expanded and prepared as final graft to be implanted.~The treatment for urethra reconstruction required a two stage urethroplasty:~First stage: application of Holour on the wound bed prepared according to standard surgery The penis will be immobilized for some days after this operation.~Second stage: surgical procedure for urethral tubularization and penile reconstruction according to standard surgical procedure.~The surgical procedures may be followed by a post-implantation treatment (if necessary) with corticosteroids and antibiotics."
89184512|NCT00720837|Experimental|Laser Interstitial Thermal Therapy|Laser Interstitial Thermal Therapy (LITT) - An intraoperative biopsy and placement of applicator for laser treatment. Treatment will last between 5 and 10 minutes.
89184513|NCT00712023|Active Comparator|1|warming by circulating-water mattress
89184514|NCT00712023|No Intervention|2|Forced-air warming mattress
89184515|NCT05683314||Acetabular_Pelvic_Sacral fracture with open reduction and internal fixation|
89184516|NCT05683314||Acetabular_Pelvic_Sacral fracture with minimally invasive internal fixation|
89184517|NCT02598986|Placebo Comparator|white pita bread|Pita bread made of white wheat flour
88860382|NCT01455948|Active Comparator|Balloon Sinuplasty™ System|
88860383|NCT01455948|Active Comparator|Functional Endoscopic Sinus Surgery|
88860384|NCT02851056|Experimental|Survivin Vaccine and Autologous HCT|Dendritic Cell Survivin Vaccine (DC:AdmS) and Autologous Hematopoietic Cell Transplantation (HCT). Participants will receive 1 pre-transplant survivin vaccine, 7-30 days prior to stem cell apheresis collection. After the first survivin vaccination, participants will be mobilized with Granulocyte-colony Stimulating Factor (G-CSF). A second survivin vaccine will be administered on day +21 (between day+20 and +34) after HCT. All participants will be co-immunized with Prevnar 13 at each time they receive the survivin vaccine.
88860385|NCT02937948|Experimental|Adaptative Treatment plans|A Library of treatment plans will be generated for each patient before starting radiochemotherapy (standard treatment). This Library will be created using CT-Scans with variable bladder filling (and hence different uterine positions). Each day of radiotherapy treatment, an appropriate plan is chosen based on Imaging that day.
88860386|NCT02936466|Experimental|Interventional group|Bipolife group
88860387|NCT02936466|No Intervention|Control group|No specific intervention, treatment as usual
88860388|NCT02935374|Active Comparator|Amoxicillin|The children with acute otitis media will be treated with amoxicillin mixture, 100mg/ml, 40mg/kg/d, divided to two daily doses for 7 days.
88860389|NCT02935374|Active Comparator|Amoxicillin-Potassium Clavulanate|The children with acute otitis media will be treated with amoxicillin-clavulanate mixture, 80mg/ml, 45mg/kg/d, divided to two daily doses for 7 days.
88860390|NCT02935374|No Intervention|Wait and see|The children with acute otitis media will be monitored without antimicrobial treatment.
88860391|NCT02935374|Other|Macrolide|The children with acute otitis media with known allergy to amoxicillin or amoxicillin-clavulanate will be treated with macrolide and monitored as a separate group, outside randomization.
88860392|NCT01452204|Experimental|Pulsed Electromagnetical Field|
88860393|NCT01452204|Placebo Comparator|Placebo|
88860394|NCT01452282||Ankle Brachial Index|
88860395|NCT01452360||Collection of CKD patient group|
88860396|NCT01452360||Collection of CKD high-risk group|
88860397|NCT01452360||Collection of healthy control group|
88860398|NCT01452438||MenACYW-CRM vaccinated children|All children between the age of 2 to 10 years old who have received of MenACYW-CRM vaccine during the study period.
88860399|NCT01452594||Diphenylcyclopropenone|topical gel administration to skin
88860400|NCT01452750|Experimental|TAK-438 10 mg QD|
88860401|NCT01452750|Experimental|TAK-438 20 mg QD|
88860402|NCT01452750|Active Comparator|Lansoprazole 15 mg QD|
88860403|NCT04273308|Experimental|whole-body vibration training|a 12-week whole-body vibration training that conducted 3 times per week, with 5-min continuous vibration at 12-Hz frequency and 3-mm amplitude each time.
88860404|NCT01452828|Experimental|Renal Impairment Nondialyzed|
88860405|NCT01452828|Experimental|Renal Impairment Dialyzed|
88860406|NCT01452828|Experimental|Matched Control|
88860407|NCT01452906|Experimental|PA21 and Omeprazole with food|
88860408|NCT01452906|Experimental|No PA21; Omeprazole with food|
88860409|NCT01452906|Experimental|PA21 with food, Omeprazole 2 hrs later|
88860410|NCT01452984||Single Retrospective Interviews|Each retrospective interview will be conducted by the Principal Investigator and/or Project Manager to collect denmographic information and experiential narratives from the patient, using open-ended questions and structured probes based on individual responses. Retrospective interviews will be recorded and scheduled at the patients' convenience either in the clinic, at the home, or at a place that is convenient to them.
88860411|NCT01452984||Prospective Observations|Prospective Observations of clinic visits will be combined with informal interview to document conversations with their treating physicians about concerns emerging from appearance, function, and other factors that may impinge on clinical decision making and experience including quality of life. The Project Manager will be present for the clinical visit during which the Mohs surgery takes place and record field observations as well as informal interview notes in a notebook.
88860412|NCT01453218|No Intervention|Basiliximab|Historical comparable cohort treated with Basiliximab 20mg iv administered at 0 and 4th day post-transplant
88860413|NCT01453218|Active Comparator|ATeGe-Fresenius|
88860414|NCT02837250|Experimental|Pos4Health|Pos4Health is a 6 Core Internet intervention focusing on improving adherence to ART among nonadherent substance users living with HIV in non urban areas. Pos4Health Cores each present a topic, show videos of HIV+ peers discussing that topic, and how they have coped with it, and use interactions to teach about the topic and to develop knowledge and skills. Each core ends with tips to try that include tips mentioned by peers or from expert material. Content is personalized to the user and users receive tailored feedback. Cores are metered out weekly after each Core is completed.
88860415|NCT02837250|Active Comparator|Patient Education|Patient Education is a static (unchanging) website that presents accurate information about the same topics in Pos4Health, but without personalization, peer videos, or interactivity.
88860416|NCT02795598|Active Comparator|Single Injection Supraclavicular Block|Patients scheduled for surgery distal to the elbow will have an ultrasound guided single injection supraclavicular nerve block for surgical anesthesia.
88860417|NCT02795598|Active Comparator|Double Injection Supraclavicular Block|Patients scheduled for surgery distal to the elbow will have an ultrasound guided double injection supraclavicular nerve block for surgical anesthesia.
88860418|NCT03849378|Experimental|Sargassum Horneri Extract group|This group takes Sargassum Horneri Extract for 12 weeks.
88860419|NCT03849378|Placebo Comparator|Placebo group|This group takes Placebo Extract for 12 weeks.
88860420|NCT02730780|Other|African-American|40 healthy African-American subjects will be enrolled and each will undergo study procedures at 4 separate visits, with each visit occurring 7-days apart. After a baseline visit, the subject will begin either a low-salt or high-salt diet, based upon randomization assignment to one of the two following dietary protocols: A) low-salt diet, washout, then high-salt diet; or B) high-salt diet, washout, then low-salt diet. Each dietary or washout period lasts for 7 days.
88860421|NCT02730780|Other|Whites|40 healthy white subjects will be enrolled and each will undergo study procedures at 4 separate visits, with each visit occurring 7-days apart. After a baseline visit, the subject will begin either a low-salt or high-salt diet, based upon randomization assignment to one of the two following dietary protocols: A) low-salt diet, washout, then high-salt diet; or B) high-salt diet, washout, then low-salt diet. Each dietary or washout period lasts for 7 days.
88860422|NCT03823092||Normal|phakic participants with no evidence of eye disorders
88860423|NCT03823092||Cataract|participants with cataract
88860424|NCT03823092||AMD|participants with age related macular degeneration
88860425|NCT03823092||Pseudophakic|particpiants who have had cataract surgery with intraocular lens implant
88860426|NCT03823092||other macula|participants with macular ddisorders other than AMD
88860427|NCT03823092||DR|participants with diabetic retinopathy
89385060|NCT02591615|Active Comparator|Arm B|"MK-3475 200 mg/m2 IV every 21-days for up to 4 cycles~Patients with CR, PR, or SD by irRC will then be treated with:~For Squamous Carcinoma:~Carboplatin AUC = 6 IV day 1 every 21-days for up to 4 cycles Paclitaxel 200 mg/m2 IV day 1 every 21-days for up to 4 cycles~OR~For Non-squamous Carcinoma~Carboplatin AUC = 6 IV day 1 every 21-days for up to 4 cycles Pemetrexed 500 mg/m2 IV day 1 every 21-days for up to 4 cycles"
88860428|NCT03823248|Experimental|MoLuoDan and Sanchi powder group|Experiment group: oral administration of Moluodan concentrated pills with warm water before meal for 8 pills each time for three times a day, + oral administration of Sanchi powder mixing with warm water before meal for 3g each time for twice a day, + oral administration of Folic Acid Tablet simulation half a hour after meal for 5 mg each time for 3 times a day. The medication period was 24 weeks.
89385061|NCT03077607|Experimental|Arm A|Subjects will receive a 0.5 mg talazoparib and 100 mg itraconazole.
88860429|NCT03823248|Active Comparator|Folic Acid Tablet group|Control group: oral administration of Moluodan simulation medicine with warm water before meal for 8 pills each time for three times a day, + oral administration of Sanchi powder simulation medicine mixing with warm water before meal for 3g each time for twice a day, + oral administration of folic acid tablets half a hour after meal for 5 mg each time for 3 times a day. The medication period was 24 weeks.
88860430|NCT03822936|Experimental|Preoperatory chemoradiation therapy with carbon ions|Chemoradiation followed by surgery
88860431|NCT03822624|Experimental|Probiotic group|
88860432|NCT03822624|Placebo Comparator|Placebo group|
88860433|NCT03822546|Experimental|Conventional cigarette|The subject's preferred brand of commercially available conventional cigarette
88860434|NCT03822546|Active Comparator|myblu 25 mg freebase|myblu pod-system containing 25 mg nicotine ('freebase') tobacco flavour
88860435|NCT03822546|Active Comparator|myblu 16 mg nicotine salt|myblu pod-system containing 16 mg nicotine salt tobacco flavour
88860436|NCT03822546|Active Comparator|myblu 25 mg nicotine salt|myblu pod-system containing 25 mg nicotine salt tobacco flavour
88860437|NCT03822546|Active Comparator|myblu 40 mg nicotine salt|myblu pod-system containing 40 mg nicotine salt tobacco flavour
88860438|NCT03822546|Active Comparator|blu PRO 48 mg nicotine salt|blu PRO open-system containing 48 mg nicotine salt tobacco flavour
88860439|NCT04391088||hospitalized people living with diabetes|hospitalized people living with diabetes
88860440|NCT04273152||children with allergy|children with allergies
88860441|NCT04273152||healthy control|healthy control (non allergic children)
88860442|NCT01453452|Experimental|Exercise and Lifestyle counseling|Patients will receive behavioral dietary intervention & counseling intervention by phone, exercise intervention at Curves(R) facility, and take a quality-of-life assessment online.
88860443|NCT02910024|Active Comparator|Real-rTMS|Repetitive transcranial magnetic stimulation (rTMS) of the primary motor cortex in the lesioned hemisphere using the intermittent theta-burst-stimulation protocol (iTBS; application of 3 pulses with a frequency of 50 Hz, in a theta-rhythm of 5 Hz for 2 seconds, repeated every 10 seconds, duration of one session: about 3,5 minutes) before physiotherapy for 8 days
88860444|NCT02910024|Sham Comparator|Sham-rTMS|Repetitive transcranial magnetic stimulation (rTMS) in sham position (tilted coil over parieto-occipital vertex) before physiotherapy for 8 days
88860445|NCT01453686|Experimental|Hydrocortisone 1%|
89385062|NCT03077607|Experimental|Arm B|Subjects will receive 1 mg talazoparib and 600 mg rifampin.
89385063|NCT03608462|Sham Comparator|rTMS targeting the right DLPFC|60 patients will be randomly allocated into this group,half of them will receive iTBS on the right DLPFC,while the other half will receive sham stimulation.
88860446|NCT01453686|Experimental|Clobetasol Propionate 0.05%|
88860447|NCT02983266|Experimental|Group 1: Low Hertz|"Participants will receive 10 hertz stimulation to the left auricular branch of the vagus nerve, delivered in one 15 minute session.~Device: InTENsity MicroCombo"
88860448|NCT02983266|Experimental|Group 1: High Hertz|"Participants will receive 30 hertz stimulation to the left auricular branch of the vagus nerve, delivered in one 15 minute session.~Device: InTENsity MicroCombo"
88860449|NCT02983266|Sham Comparator|Group 1: Control|"Participants will receive 30 hertz stimulation to a non-vagally innervated region of the left ear, delivered in one 15 minute session.~Device: InTENsity MicroCombo"
88860450|NCT02983266|Experimental|Group 2: Pre-stressor|"Participants will receive 10 or 30 hertz stimulation to the left auricular branch of the vagus nerve, delivered in one 15 minute session prior to receiving experimental sympathetic induction.~Device: InTENsity MicroCombo"
88860451|NCT02983266|Experimental|Group 2: Post-stressor|"Participants will receive 10 or 30 hertz stimulation to the left auricular branch of the vagus nerve, delivered in one 15 minute session after experimental sympathetic induction.~Device: InTENsity MicroCombo"
88860452|NCT02983266|Placebo Comparator|Group 2: Control|"Participants will receive 10 or 30 hertz stimulation to a non-vagally innervated region of the left ear, delivered in one 15 minute session prior to receiving experimental sympathetic induction.~Device: InTENsity MicroCombo"
88860453|NCT02983266|Experimental|Group 3: 30 Hz|"Participants will receive 10 or 30 hertz stimulation to the left auricular branch of the vagus nerve, delivered in one 15 minute session.~Device: InTENsity MicroCombo"
89385064|NCT03608462|Sham Comparator|rTMS targeting the left LPC|60 patients will be randomly allocated into this group,half of them will receive iTBS on left LPC,while the other half will receive sham stimulation.
88860454|NCT02983266|Experimental|Group 4: 30 Hz|"Participants will receive 10 or 30 hertz stimulation to the left auricular branch of the vagus nerve, delivered in one 15 minute session. Participants will also receive stimulation on a subsequent session prior to urodynamic testing.~Device: InTENsity MicroCombo"
88860455|NCT02983266|Experimental|Group 1: Response|"Participants will receive 10-30 hertz stimulation to the left auricular branch of the vagus nerve, delivered over the course of 1 hour.~Device: InTENsity MicroCombo"
88860456|NCT01459926|Experimental|Dose 1|
88860457|NCT01459926|Experimental|Dose 2|
88860458|NCT01459926|Experimental|Dose 3|
88860459|NCT01459926|Experimental|Placebo|
88860460|NCT01456182|Other|Dose arm 1|
88860461|NCT01456182|Other|Dose arm 2|
89385065|NCT03608462|No Intervention|Observation group|To investigate the abnormalities of hippocampal neurogenesis in patients with early schizophrenia(n=30) compared to healthy controls(n=30)
88860462|NCT01456182|Other|Dose arm 3|
88860463|NCT01456182|Other|Dose arm 4|
88860464|NCT01456182|Other|Dose arm 5|
88860465|NCT01455870|Experimental|ITCA 650 60 mcg/day|ITCA 650 is exenatide in DUROS
88860466|NCT01455870|Active Comparator|sitagliptin|sitagliptin 100 mg/day
88860467|NCT01456260|Experimental|TAK-438 10 mg QD|
88860468|NCT01456260|Experimental|TAK-438 20 mg QD|
88860469|NCT01456260|Active Comparator|Lansoprazole 15 mg QD|
88860470|NCT01452516|Other|nanOss Bioactive Bone void filler|Lumbar fusion using interbody cages with autograft in conjunction with instrumented posterolateral gutter fusions using nanOss Bioactive bone void filler
88860471|NCT01890408|Experimental|ropivacaine|patients scheduled to undergo open liver resection Age > 18 years Free from pain in preoperative period
88860472|NCT01890408|Placebo Comparator|placebo|patients scheduled to undergo open liver resection Age > 18 years Free from pain in preoperative period
88860473|NCT01890564||Bariatric surgery|Patients undergoing bariatric surgery.
88860474|NCT01456338|Experimental|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) is a non-exposure based, manual-guided individual therapy. CBT for PTSD consists of 3 learning and skill components designed to improve PTSD symptoms and substance use: 1) Patient education about PTSD and its relation to substance use and treatment; 2) Breathing retraining: A behavioral anxiety reduction skill; and 3) Cognitive restructuring: A cognitive approach and functional analysis of the link among emotions, cognitions and situations.
88860475|NCT01456338|Active Comparator|Individual Addiction Counseling|Individual Addiction Counseling (IAC) was adapted from the Individual Drug Counseling (IDC) manual used in the NIDA Cocaine Collaborative Study. IAC is a manual-guided treatment that focuses on substance use and history of use, consequences of use and denial, developing strategies for relapse prevention, and facilitation of connection with peer recovery support groups, specifically twelve step groups. The current adaptation of IAC modified the IDC manual by broadening the focus to include drugs other than cocaine, as well as alcohol.
88860476|NCT01890798|Experimental|Drisapersen (DMD117402)|The protocol is open only to the subjects who completed GSK protocol DMD114876 and participated in protocol DMD115501, United States citizens who have completed protocol DMD114044, or United States citizens who are participating in protocol DMD114349 outside the United States and want to end their participation in the DMD114349 study. Eligible subjects will receive drisapersen 6 milligram (mg)/kilograms (kg) once a week via subcutaneous (SC) injection.
88860477|NCT01456416||Glatiramer Acetate|GA administered SQ daily in MS patients who met all Inclusion-Exclusion Criteria and were approved by their Health Care Plans for GA treatment.
88860478|NCT01890876|Active Comparator|Low altitude|Walking uphill Walking downhill
88860479|NCT01890876|Active Comparator|High altitude|Walking uphill Walking downhill
88860480|NCT04844658|Experimental|standard treatment + NASAFYTOL®|"Minimum 25 patients will receive NASAFYTOL® as a supportive supplementation to standard treatment of hospitalized patients infected with COVID-19.~For each patient, 8 capsules of NASAFYTOL® taken orally per day (4 capsules in the morning and 4 capsules in the evening before meal ,with a full glass of water. ) in support of the standard COVID-19 treatment in force in the hospital from the day after the randomization (day1) and during the period of hospitalization and maximum for 14 days"
89535170|NCT04493489|Placebo Comparator|BCG|After TURBT, the first year: once a week for 6 times, from the 7th week, once every 2 weeks, and 3 times. Administer once a month starting from the 13th week and continue to give 10 times. Second and third years: once a month, 12 times a year.
88860481|NCT04844658|Active Comparator|standard treatment + FULTIUM® - D3 800|"Minimum 25 patients will receive vitamin D , FULTIUM® - D3 800 as a supportive supplementation to standard treatment of hospitalized patients infected with COVID-19.~For each patient,1 capsule of Vitamin D taken orally per day (1 capsule in the morning) in support of the standard COVID-19 treatment in force in the hospital from the day after the randomization (day1) and for the duration of the hospitalization and maximum for 14 days"
88860482|NCT04841538|Experimental|Cohort 1|ES101 is administered via intravenous infusion, 0.3mg/kg，once every 14 days, every 28 days as a treatment cycle.
88860483|NCT04841538|Experimental|Cohort 2|ES101 is administered via intravenous infusion, 1mg/kg，once every 14 days, every 28 days as a treatment cycle.
88860484|NCT04841538|Experimental|Cohort A1|ES101 is administered via intravenous infusion, RP2D (to be determined)，once every 14 days, every 28 days as a treatment cycle.
88860485|NCT04841538|Experimental|Cohort A2|ES101 is administered via intravenous infusion, RP2D (to be determined)，once every 14 days, every 28 days as a treatment cycle.
88860486|NCT04841538|Experimental|Cohort B|ES101 is administered via intravenous infusion, RP2D (to be determined)，once every 14 days, every 28 days as a treatment cycle.
88860487|NCT04841538|Experimental|Cohort C|ES101 is administered via intravenous infusion, RP2D (to be determined)，once every 14 days, every 28 days as a treatment cycle.
88860488|NCT04849650|Experimental|Renal Impairment Subjects|10mg dose of IV Amisulpride, followed 24 hours by a 10mg oral dose of Amisulpride
88860489|NCT04849650|Experimental|Healthy Subjects|10mg dose of IV Amisulpride, followed 24 hours by a 10mg oral dose of Amisulpride
88860490|NCT01891032||the patients with open partial nephrectomy|the adult patients with open partial nephrectomy
88860491|NCT01891032||laparoscopic|the adult patients with laparoscopic partial nephrectomy
88860492|NCT01891032||VAMS|the adult patients with VAMS partial nephrectomy
88860493|NCT01891032||robotic|the adult patients with robotic partial nephrectomy
88860494|NCT05587140|Experimental|Acupuncture like TENS|The study would use acupuncture like TENS for 30 minutes
88860495|NCT05587140|Experimental|Conventional TENS|The study would use conventional TENS for 30 minutes
88860496|NCT05587140|Experimental|Sham TENS|The study would use sham TENS for 30 minutes
88860497|NCT01456728|Experimental|Progastria|One chewable tablet of the study product is to be taken once per day giving a dose of L. reuteri of 2x108 CFU/day together with omeprazole 2x20mg. The study product and omeprazole will be taken daily for 28 consecutive days.
88860498|NCT01456728|Placebo Comparator|Placebo|The placebo will have identical appearance and taste with the study product only lacking the bacteria. All subjects from this group will receive 2 x 20 mg omeprazole per day and Placebo 1 chewable tablet per day for 28 days.
88860499|NCT01891110|Experimental|ES of the abdominal muscles|ES with surface electrodes, fixed stimulation parameters and individual mA
89184518|NCT02598986|No Intervention|Whole grain pita bread|no macronutrient supplementation
88860500|NCT01891110|Experimental|ES of limbs & abdomen|The combination of the ES of the lower limb muscles and the abdominal muscles.
88860501|NCT01891110|Experimental|ES of the limb muscles|Lower limb muscles were stimulated to produce a milking mechanism from the distal to proximal part of the limb to pump the venous blood from the peripheral to the central part of the body
88860502|NCT01891266|Experimental|Non-tourniquet assisted TKA|
88860503|NCT01891266|Other|Tourniquet assisted TKA|
88860504|NCT01891500|Experimental|Early inhaled nitric oxide|Patients randomized to receive iNO at OI 10-15.
88860505|NCT01891500|Placebo Comparator|Bioinert inhaled gas (nitrogen gas)|Patients randomized to bioinert inhaled gas at OI 10-15.
89184519|NCT02598986|Experimental|Restored white pita bread|macronutrient supplementation
89184520|NCT02598986|Experimental|Fortified white pita bread|macronutrient supplementation 2
89184521|NCT00717561|Experimental|Arm 1|
89184522|NCT00717561|Active Comparator|Arm 2|
89184523|NCT00720915|Other|No Anticoagulant Therapy|No Anticoagulant Therapy
89184524|NCT00720915|Other|Anticoagulant Therapy|Continue on anticoagulant therapy
89184525|NCT00717639|Experimental|1|single arm study, all patients will undergo Vasovist-enhanced MRA
89184526|NCT02571699|Active Comparator|Subgluteal sciatic block|Subgluteal block with similar volume
89184527|NCT02571699|Experimental|Subgluteal block|Subgluteal block with decreasing volume
89184528|NCT02571855|Experimental|Part A: ACT-541468 multiple ascending doses|Six young adults will receive ACT-541468 in the morning from Day 1 to Day 5 at each dose level in a sequential manner (total number of subjects = 18). Planned dose levels are 10, 25 and 75 mg per day
89184529|NCT02571855|Placebo Comparator|Part A: Placebo|For each ACT-541468 dose level tested in Part A, 2 young adults will receive matching placebo in the same conditions (total number of subjects = 6)
89184530|NCT02571855|Experimental|Part B: ACT-541468 single ascending doses|Six elderly will receive ACT-541468 in the morning of Day 1 at each dose level in a sequential manner (total number of subjects = 18). Planned dose levels are 5, 15 and 25 mg
89184531|NCT02571855|Placebo Comparator|Part B: Placebo|For each ACT-541468 dose level tested in Part B, 2 elderly will receive matching placebo in the same conditions (total number of subjects = 6)
89184532|NCT02571855|Experimental|Part C: repeated dose of ACT-541468|Sixteen young adults and eight elderly will receive ACT-541468 (planned dose: 25 mg) in the evening for 7 days (8 days for 6 of the 16 young adults).
89184533|NCT02571855|Placebo Comparator|Part C: Placebo|Four young adults and 2 elderly will receive matching placebo in the same conditions as subjects receiving the active compound in Part C
89184534|NCT00712101|Experimental|1|Abciximab bolus administration intracoronary
89184535|NCT00712101|Active Comparator|2|Abciximab bolus intravenously
89184536|NCT00717717|No Intervention|Control|No intervention except repeated measurements of physical capacity
89184537|NCT00717717|Experimental|Intervention|Intervention: One-year rehabilitation program including weekly supervised and group-based physical exercise, home-based physical activity, individual and group-based coaching (narrative therapy), and expert educational talks/lectures
89184538|NCT04082130|Experimental|(XCM)+(CAF)|"Surgical protocol for test treatment with CAF + XCM:~After local anesthetizing the recipient site,CAF elevation will be done using (De Sanctis & Zucchelli 2007) design.Horizontal incisions will be done at the recession site,another two slightly divergent vertical incisions will be done at the end of previous incisions extending to the mucogingival junction.The resulting flap will be split thickness in the surgical papillae area,then will be full thickness exposing 3-4 mm of the bone apically of the dehiscence and after that it will be split thickness in the apical direction,all the muscle insertions will be eliminated,the root surface will be prepared by curettes and chemically treated with 24% EDTA gel.De-epithelialization of the interdental papillae will be done.The XCM will be trimmed and fix onto the root surface 1-2mm coronally of the CEJ using absorbable sutures,and the flap will be coronally advanced to fully cover the XCM and then sutured to the de-epithelialized papillae."
89535171|NCT04493489|Experimental|Propranolol plus BCG|After TURBT administered for 2 consecutive years, oral propranolol, starting dose 10mg, tid, then 20mg, tid,lastly increased to 40mg, bid. After the last BCG infusion, propranolol was gradually reduced, in the order of 20 mg, tid to 10 mg, tid.
88860506|NCT01891500|Active Comparator|Crossover iNO|Patients who deteriorate (OI >20 on two consecutive blood gases) will be unblinded. If they are receiving placebo gas, they will be started on iNO and make up the crossover cohort.
88860507|NCT02862132|Experimental|Vedolizumab|IV Vedolizumab 177mg/m2 Body Surface Area (BSA), max. 300mg Induction regimen: 0,2,6 and then every 8 weeks
88860508|NCT02859402|Experimental|Experimental Arm|Conditioning chemotherapy: Fludarabine and Busulfan followed by Allogeneic stem cell transplantation
88860509|NCT02857374|Experimental|Diagnostic (intravital microscopy)|Patients receive indocyanine green and fluorescein sodium injection IV and then undergo intravital microscopic observation over 15-20 minutes during standard of care sentinel node biopsy.
88860510|NCT04273074|Other|preoperative sonographic assessment group|preoperative sonographic assessment to airway
88860511|NCT04843722|Experimental|Cohort 1: hAd5-S-Fusion+N-ETSD at 5 × 10e10 IU/dose Subcutaneous|Cohort 1 (n=20): hAd5-S-Fusion+N-ETSD at 5 × 10e10 IU/dose Subcutaneous on Day 1
88860512|NCT04843722|Experimental|Cohort 2: hAd5-S-Fusion+N-ETSD at 5 × 10e10 IU/dose Subcutaneous and 1 × 10e10 IU/dose Sublingual|Cohort 2 (n=20): hAd5-S-Fusion+N-ETSD at 5 × 10e10 IU/dose Subcutaneous and 1 × 10e10 IU/dose Sublingual on Day 1
89184539|NCT04082130|Active Comparator|(SCTG)+(CAF)|"The surgical protocol in the control group will be identical with test group protocol with these exceptions:~The entire flap will be elevated as split thickness instead of split-full-split thickness flap.~A SCTG harvested from the palate will be used to cover the exposed denuded root surface in lieu of placement of XCM in the test group. And absorbable sutures will be used to stabilize it 2 mm coronally from the CEJ.~As in the test group the mucosal flap will coronally advanced to completely cover the SCTG then sutured to the de-epithelialized papillae."
89184540|NCT02574351||obese asthmatic|Participants from this group will be included in this study. A blood draw, breathing test will be performed to see if there is a difference in the t-regulatory cells amongst this group.
89535172|NCT05005923|No Intervention|Periodontal healthy|
88860513|NCT04844268|Experimental|Cohort 1|Intramuscular (IM) injection of VACCINE RNA MCTI CIMATEC HDT(HDT-301) at a dose of 1 µg. Participants will be randomized (4:1 ratio for active vaccine:placebo) with equal probability of receiving a schedule of two doses, of the same concentration, on days 1 and 28 (group 1) or 1 and 56 (group 2), or a schedule of single-dose administration (group 3).
88860514|NCT04844268|Experimental|Cohort 2|Intramuscular (IM) injection of VACCINE RNA MCTI CIMATEC HDT(HDT-301) at a dose of 5 µg. Participants will be randomized (4:1 ratio for active vaccine:placebo) with equal probability of receiving a schedule of two doses, of the same concentration, on days 1 and 28 (group 1) or 1 and 56 (group 2), or a schedule of single-dose administration (group 3).
88860515|NCT04844268|Experimental|Cohort 3|Intramuscular (IM) injection of VACCINE RNA MCTI CIMATEC HDT(HDT-301) at a dose of 25 µg. Participants will be randomized (4:1 ratio for active vaccine:placebo) with equal probability of receiving a schedule of two doses, of the same concentration, on days 1 and 28 (group 1) or 1 and 56 (group 2), or a schedule of single-dose administration (group 3).
89385066|NCT04215588|Active Comparator|Individualized heparin and protamine titration|The device Hemostasis Management System Plus (Medtronic, Minneapolis, MN) will be used to determine the patients' sensitivity to heparin and its concentration in whole blood. Then, it will automatically calculate the necessary dose for anticoagulation during bypass. The protamine dose to eliminate heparin effect will be calculated from the remaining heparin concentration (0.75mg/100 International Units circulating heparin).
89385067|NCT04215588|Active Comparator|Activated Clotting Time guided heparin and protamine dose|Heparin initial dose will be determined according to the patients' weight to achieve a required Activated Clotting Time (ACT) to initiate cardiopulmonary bypass. Subsequent doses of heparin will be administered according to ACT and protamine dose will be calculated from total heparin dose (0.75mg protamine/100 International Units heparin)
89385068|NCT03608228||Parkinson's Disease|
89385069|NCT03622086|Experimental|7-10 years old|Children-caregiver pairs will participate in a 24-week pilot that includes 2 phases, 12 weeks of usual care, followed by 12 weeks of Foundations of Fitness Program.
89385070|NCT03622086|Experimental|11-13 years old|Children-caregiver pairs will participate in a 24-week pilot that includes 2 phases, 12 weeks of usual care, followed by 12 weeks of Foundations of Fitness Program.
89385071|NCT02977572|Experimental|Non-Invasive ventilation (NIV group)|For the NIV group, a BiPAP Vision was used, by setting the Inspiratory Positive Airway Pressure (IPAP) at a level that was required to achieve a tidal volume of approximately 8-10 ml/kg. Also an Expiratory Positive Airway Pressure (EPAP) was set at a minimum of 5 cmH20 during the first hour, gradually increasing until there was a clinical improvement. Fraction inspiratory of oxygen (FiO2) was applied to maintain a transcutaneous arterial oxygen saturation (SaO2) of 92%-94%. NIV was continuously applied until there was a clinical and/or a gasometrical improvement, at which time they were replaced by a Venturi mask with FiO2 of 0.4.
89535173|NCT05005923|Active Comparator|Periodontitis Stage III Grade B|The patients were subjected to quadrant-wise full-mouth subgingival scaling and root planning under local anesthesia. The entire non-surgical periodontal treatment of periodontitis groups was completed in a total of 4 sessions in two weeks.
88860516|NCT04844268|Placebo Comparator|Placebo|Intramuscular (IM) injection of saline (0.9% sodium chloride). Participants will be randomized (4:1 ratio for active vaccine:placebo) with equal probability of receiving a schedule of two doses, of the same concentration, on days 1 and 28 (group 1) or 1 and 56 (group 2), or a schedule of single-dose administration (group 3).
88860517|NCT04842552|Active Comparator|Hydralazine hydrochloride 25mg|Hydralazine hydrochloride (25mg tablets) every eight hours (TDS)
88860518|NCT04842552|Placebo Comparator|Placebo|Placebo tablets (identical in shape to the active comparator) every eight hours (TDS)
88860519|NCT01891656|Experimental|Motivational Interviewing|"Participants randomized to the MI group will receive a single 60-minute MI session focused on motivation to initiate and engage in treatment. The MI session will be organized around the Check-Up format, with additional planning components as desired by the client."
88860520|NCT01891656|No Intervention|Supervision As Usual|Participants randomized to the SAU group will receive the standard agency intake process as well as baseline and follow-up research interviews, but will not receive any additional intervention as part of the study. They will be referred to a treatment program as per the normal routine.
88860521|NCT01891656|Experimental|Motivational Computer|Participants randomized to the MC group will complete a 60 minute computer intervention focused on motivation to initiate and engage in treatment. The program will be self-guided, interactive, and to the extent possible, will mirror the features of MI session. The MC program will have two main components: a motivation component and a planning component.
88860522|NCT04390932|Experimental|Enhanced TA|Therapeutic exercise protocol accompanied by an enhanced TA.
88860523|NCT04390932|Active Comparator|Neutral therapeutic alliance|Therapeutic exercise protocol accompanied by an limited TA
88860524|NCT01456884|Experimental|Live - Vibroacoustic|Treatment order A: live guitar and vocal music therapy on day one, vibroacoustic music therapy on day two.
88860525|NCT01456884|Experimental|Vibroacoustic - Live|Treatment order B: vibroacoustic music therapy live guitar on day one, and vocal music therapy on day two.
88860526|NCT02813928|Experimental|ccfDNA analysis|The level of circulating ccfDNA, defined as extra cellular DNA, increases in CRC patients. The Inplex® method could validate the use of ccfDNA as a cancer biomarker in terms of prognosis and surveillance.
88860527|NCT01891812|Experimental|Nitrous oxide 50%|Nitrous oxide 50% administered for 15 minutes.
88860528|NCT01457274|Experimental|"light sedation"|"In this study the depth of sedation will be guided by the Bispectral Index monitor (BIS monitor). A BIS value of 70-80 will be targeted in the light sedation arm."
88860529|NCT01457274|Active Comparator|"deep sedation"|"In this study the deep sedation arm will have a BIS value of less than 60 targeted."
88860530|NCT01892046|Experimental|SNX-5422|Open label administration of SNX-5422 capsules every other day (QOD) for 21 days of a 28 day cycle. Dose escalation will be based on safety outcomes defined as 1 or less dose limiting toxicities during the first 28 day cycle at any dose level. During the dose escalation phase, subjects will receive carboplatin and paclitaxel once every 21 days for a total of 4 courses. During the maintenance phase, SNX-5422 at the MTD will be dosed every other day (QOD) for 21 days of a 28 day cycle.
88860531|NCT04389996||Patients with cancer|Survey
88860532|NCT01892124|Experimental|Motivational Interviewing/Cognitive Behavioral-based Therapy|Receives an immediate weekly 10 session intervention based on a culturally-adapted, motivational interviewing and Cognitive Behavioral Therapy grounded protocol.
88860533|NCT01892124|Experimental|Wait-List Control|Receives a weekly 10 session intervention based on a culturally-adapted, motivational interviewing and Cognitive Behavioral Therapy grounded protocol after a three month, no-intervention waiting period.
88860534|NCT01892358|Active Comparator|SKIN Intervention|Participants will receive the SKIN intervention at Baseline and 1-mo interviews.
88860535|NCT01892358|Placebo Comparator|Assessment-Only|Participants in this arm will receive treatment-as-usual
88860536|NCT04840836||Telehealth-supported LARC provision|"Patients who receive care at the SBHC provide informed consent for care, as well as record review for quality assurance purposes. Analyses will include female patients who have a reproductive health visit, which includes contraceptive counseling, contraceptive management, or contraceptive method initiation, during the study period. Patients who have a telehealth consultation with a SBHC medical provider for LARC services (conservatively estimated n=113) will be considered enrolled patients once the data are extracted from the EHR."
88860537|NCT04272684|Experimental|Interventional|Driving Assessment
88860538|NCT01457664|Placebo Comparator|Placebo|
88860539|NCT01457664|Experimental|RO4995819|
88860540|NCT04390464|Active Comparator|Standard of care|Standard of care
88860541|NCT04390464|Experimental|Ravulizumab + Standard of care|Ravulizumab IV (adjusted to weight, Day 1 only)
88860542|NCT04390464|Experimental|Baricitinib + Standard of care|Baricitinib PO OD (4mg, Days 1-14)
88860543|NCT04390542|Experimental|Psychoeducation intervention|Psychoeducatoinal intervention
89184541|NCT02574351||normal asthmatic|Participants from this group will be included in this study. A blood draw, breathing test will be performed to see if there is a difference in the t-regulatory cells amongst this group
88860544|NCT04390542|No Intervention|Usual care|Information from healthcare providers
88860545|NCT04845750|Experimental|Rodeo Micro Mapping Catheter|Determination of pulmonary vein isoation during cryoablation procedure
89184542|NCT02574351||obese control|Participants from this group will be included in this study. A blood draw, breathing test will be performed to see if there is a difference in the t-regulatory cells amongst this group.
89184543|NCT02574351||normal control|Participants from this group will be included in this study. A blood draw, breathing test will be performed to see if there is a difference in the t-regulatory cells amongst this group.
89184544|NCT02587182|Experimental|Dry needling|Dry needling in the masseter and temporalis muscles
89184545|NCT00712257|Other|Spectranetics Laser plus Gore Viabahn Endoprosthesis|Spectranetics Laser for optimal debulking followed by adjunctive PTA plus GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface placement
89184546|NCT00740792|Experimental|azelastine HCl/fluticasone propionate|nasal spray
89184547|NCT00740792|Active Comparator|azelastine HCL|nasal spray
89184548|NCT00740792|Active Comparator|fluticasone propionate|nasal spray
89184549|NCT00740792|Placebo Comparator|placebo|nasal spray
89184550|NCT00919698||Sedated mechanically ventilated patients|
89184551|NCT00720993||1|Control group - patients scheduled for routine colonoscopy procedures with no self or family history or other GI conditions.
89184552|NCT00720993||2|Case group - patients with confirmed colorectal carcinoma scheduled for surgery or observed during routine colonoscopy screening.
89184553|NCT03728049|Experimental|CT-ADP group|PVR assessment with the standard methods and with the CT-ADP that will be provided to the operator in real-time during TAVI. The decision to undertake corrective procedure will be left at the discretion of the operator and based on the results of the CT-ADP on top of the standard methods of PVR assessment.
89003129|NCT05734001|Experimental|ROTEM Based tests|"The second group will undergo ROTEM based correction. ROTEM correction will be based on the following protocol :~EXTEM CT > 80 sec - FFP will be transfused at 15 ml/kg MCF < 35 mm- Platelet will be transfused at 10 ml/kg~FIBTEM MCF < 7 mm- Cryoprecipitate will be transfused at 5 ml/kg"
89184554|NCT03728049|Other|Control group|PVR assessment with standard methods only (at discretion of the operator excluding CT-ADP and transesophageal echocardiography). CT-ADP will not be provided to the operator at the time of TAVI. The decision to undertake corrective procedure will be left at the discretion of the operator according to the results of the standard methods of PVR assessment.
89184555|NCT02595788||Supine position|Examination in the supine position
89184556|NCT02595788||Prone position|Change from supine to prone position
89184557|NCT00721071|Experimental|1|
89184558|NCT00917774|Active Comparator|Standard LPS Flex|Nexgen LPS-Flex total knee design used for TKA
89184559|NCT00917774|Experimental|Gender specific LPS-Flex|Gender specific LPS flex design used for TKA in female patients
89184560|NCT00721305|Experimental|1|In this arm, subjects will receive 40 mg of Lovastatin (2 tablets of 20 mg each, p.o.), in a daily doses, during twelve months
89184561|NCT00721305|Placebo Comparator|2|In this arm, subjects will receive placebo (2 tablets which will look externally identical to lovastatin: wrapped in the same way, with the same size, shape and color)
89184562|NCT00717951|Experimental|A|"Arm A is docetaxol+capecitabine chemotherapy"
89184563|NCT00717951|Experimental|B|"Arm B is docetaxol+cisplatin chemotherapy"
89184564|NCT00721383|Experimental|Treatment|Physical activity and caregiver skill-building
89184565|NCT00721383|Active Comparator|Control|caregiver skill-building
89184566|NCT00721461|Experimental|1|V930
88860546|NCT04844424|Experimental|Part 1A: Treatment Sequence ABC|Participants will receive a single oral Dose 1 of milvexian as direct compression (DC) tablets under fasting conditions (Treatment A) in Treatment Period 1, followed by a single oral Dose 1 of milvexian as roller compacted (RC) tablets under fasting conditions (Treatment B) in Treatment Period 2 and then a single oral Dose 1 of milvexian Phase 2 oral capsules under fasting conditions (Treatment C) in Treatment Period 3 on Day 1 of each Treatment Period during Part 1A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
88860547|NCT04844424|Experimental|Part 1A: Treatment Sequence BCA|Participants will receive Treatment B in Treatment Period 1, followed by Treatment C in Treatment Period 2 and then Treatment A in Treatment Period 3 on Day 1 of each Treatment Period during Part 1A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
89385072|NCT02977572|Placebo Comparator|Continuous Positive AirwayPressure CPAP|The CPAP was applied by using a flow generator with adjustable fractional inspired oxygen (FiO2). This was connected to the Positive End-Expiratory Pressure (PEEP) valve that was placed in the face mask. In the second instance, the CPAP system that was used was a Boussignac CPAP System Flow Jet. The Boussignac valve takes gas from a single source and splits it in order to create four high flow jets. These jets converge in the chamber creating a virtual valve. A initial level of 5cmH20 of PEEP was recommended for the first hour of ventilation, with subsequent increments (up to 15cmH20) until a clinical improvement was obtained. CPAP was continuously applied until there was a clinical and/or a gasometrical improvement, at which time it was replaced by a Venturi mask.
89385073|NCT02746874|Active Comparator|Active Group|Radiofrequency ablation procedure of the three articular branches of the knee joint. The targets will be thermally lesioned for 2 minutes 30 seconds thereby causing neurolysis.
89385074|NCT02746874|Sham Comparator|Placebo Group|Simulated Radiofrequency Ablation procedure of the three articular branches of the knee joint.The targets will be not be thermally lesioned for 2 minutes 30 seconds therefore not causing neurolysis.
89385075|NCT01377129|Active Comparator|Single Bundle|These patients are operated using a single bundle technique.
89385076|NCT01377129|Experimental|Double bundle|These patients are operated using a double bundle technique.
89385077|NCT02558075|Experimental|MoodLifters Program|A program to provide evidence-based education and skills to reduce psychological distress and enrich people's lives.
89385078|NCT01377051|Active Comparator|Bronchodilator|Indacaterol maleate 300 mcg will be administered by a third independent investigator following a randomization list.
89385079|NCT01377051|Placebo Comparator|Placebo|Will be administered with the same device by a third independent investigator
89385080|NCT03217175|Active Comparator|Bihormonal Bionic Pancreas|Bihormonal bionic pancreas exercise visit - subjects will participate in the outpatient bihormonal bionic pancreas run in period, and will use the bihormonal bionic pancreas for their exercise visit at the end of the run in. The glucagon pump of the bionic pancreas will be filled with glucagon.
89385081|NCT03217175|Placebo Comparator|Insulin Only Bionic Pancreas|Insulin-only bionic pancreas exercise visit - Bihormonal bionic pancreas exercise visit - subjects will participate in the outpatient bihormonal bionic pancreas run in period, and will use the insulin-only bionic pancreas for their exercise visit at the end of the run in. The glucagon pump of the bionic pancreas will be filled with placebo (normal saline).
89385082|NCT01379079|Experimental|aspirin at bedtime|
88860548|NCT04844424|Experimental|Part 1A: Treatment Sequence CAB|Participants will receive Treatment C in Treatment Period 1, followed by Treatment A in Treatment Period 2 and then Treatment B in Treatment Period 3 on Day 1 of each Treatment Period during Part 1A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
88860549|NCT04844424|Experimental|Part 1A: Treatment Sequence ACB|Participants will receive Treatment A in Treatment Period 1, followed by Treatment C in Treatment Period 2 and then Treatment B in Treatment Period 3 on Day 1 of each Treatment Period during Part 1A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
88860550|NCT04844424|Experimental|Part 1A: Treatment Sequence BAC|Participants will receive Treatment B in Treatment Period 1, followed by Treatment A in Treatment Period 2 and then Treatment C in Treatment Period 3 on Day 1 of each Treatment Period during Part 1A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
89385083|NCT01379079|Active Comparator|aspirin on awakening|
89385084|NCT02034968|Experimental|Nimotuzumab & nab-paclitaxel & cisplatin|"Nimotuzumab: 200mg,IV once a week during chemotherapy.~Nab-paclitaxel: 125mg/m2,(IV over 30 min) (days 1 and 8) on 21 day cycle~Cisplatin: 75mg/m2,IV on 21 day cycle"
89385085|NCT03652506|Active Comparator|Group A|The regional oxymetry probe will be placed in the abdominal region of the umbilicus in the middle clavicular line before the disease operation begins.
89385086|NCT03652506|Active Comparator|Group E|Thoracic Epidural block +The regional oxymetry probe will be placed in the abdominal region of the umbilicus in the middle clavicular line before the disease operation begins.
89385087|NCT03652506|Active Comparator|Group Q|Ultrasound guided unilateral anterior Quadratus Lumborum block +The regional oxymetry probe will be placed in the abdominal region of the umbilicus in the middle clavicular line before the disease operation begins.
89385088|NCT03607760||ECMO|severe respiratory failure with ECMO
89385089|NCT03607760||conventional mechanical ventilation|severe respiratory failure with conventional mechanical ventilation
89385090|NCT01380561|Experimental|Single Arm Study|asimadoline
89385091|NCT05182983||People with digestive tract diseases|
89385092|NCT05182983||Healthy people|
89385093|NCT02522429|Experimental|Low Intensity Focused Ultrasound Device|15 acute DOC patients, 15 chronic DOC patients
88860551|NCT04844424|Experimental|Part 1A: Treatment Sequence CBA|Participants will receive Treatment C in Treatment Period 1 followed by Treatment B in Treatment Period 2 and then Treatment A in Treatment Period 3 on Day 1 of each Treatment Period during Part 1A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
88860552|NCT04844424|Experimental|Part 1B: Treatment Sequence DEF|Participants will receive a single oral Dose 1 of milvexian as DC oral tablets under fed conditions (Treatment D) in Treatment Period 1, followed by a single oral Dose 1 of milvexian as RC oral tablets under fed conditions (Treatment E) in Treatment Period 2 and then a single oral Dose 1 of milvexian as Phase 2 oral capsules under fed conditions (Treatment F) in Treatment Period 3 on Day 1 of each Treatment Period during Part 1B. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
88860553|NCT04844424|Experimental|Part 1B: Treatment Sequence EFD|Participants will receive Treatment E in Treatment Period 1, followed by Treatment F in Treatment Period 2 and then Treatment D in Treatment Period 3 on Day 1 of each Treatment Period during Part 1B. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
88860554|NCT04844424|Experimental|Part 1B: Treatment Sequence FDE|Participants will receive Treatment F in Treatment Period 1, followed by Treatment D in Treatment Period 2 and then Treatment E in Treatment Period 3 on Day 1 of each Treatment Period during Part 1B. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
88860555|NCT04844424|Experimental|Part 1B: Treatment Sequence DFE|Participants will receive Treatment D in Treatment Period 1, followed by Treatment F in Treatment Period 2 and then Treatment E in Treatment Period 3 on Day 1 of each Treatment Period during Part 1B. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
88860556|NCT04844424|Experimental|Part 1B: Treatment Sequence EDF|Participants will receive Treatment E in Treatment Period 1, followed by Treatment D in Treatment Period 2 and then Treatment F in Treatment Period 3 on Day 1 of each Treatment Period during Part 1B. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
88860557|NCT04844424|Experimental|Part 1B: Treatment Sequence FED|Participants will receive Treatment F in Treatment Period 1, followed by Treatment E in Treatment Period 2 and then Treatment D in Treatment Period 3 on Day 1 of each Treatment Period during Part 1B. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
88860558|NCT04844424|Experimental|Part 2A: Treatment Sequence GH|Participants will receive twice daily (BID) oral Dose 1 of milvexian DC oral tablets (Treatment G) in Treatment Period 1, followed by BID oral Dose 1 of milvexian Phase 2 oral capsule (Treatment H) in Treatment Period 2 up to Day 5 in each Treatment Period during Part 2A. There will be a wash-out period of more than 5 days between the evening dose of Day 5 of Treatment Period 1 and the morning dose of Day 1 of Treatment Period 2.
88860559|NCT04844424|Experimental|Part 2A: Treatment Sequence HG|Participants will receive Treatment H in Treatment Period 1, followed by Treatment G in Treatment Period 2 up to Day 5 in each Treatment Period during Part 2A. There will be a wash-out period of more than 5 days between the evening dose of Day 5 of Treatment Period 1 and the morning dose of Day 1 of Treatment Period 2.
88860560|NCT04844424|Experimental|Part 2B: Treatment Sequence IJ|Participants will receive BID oral Dose 2 of milvexian DC oral tablet (Treatment I) in Treatment Period 1, followed by BID oral Dose 2 of milvexian Phase 2 oral capsule (Treatment J) in Treatment Period 2 up to Day 5 in each Treatment Period during Part 2B. There will be a wash-out period of more than 5 days between the evening dose of Day 5 of Treatment Period 1 and the morning dose of Day 1 of Treatment Period 2.
88860561|NCT04844424|Experimental|Part 2B: Treatment Sequence JI|Participants will receive Treatment J in Treatment Period 1, followed by Treatment I in Treatment Period 2 up to Day 5 in each Treatment Period during Part 2B. There will be a wash-out period of more than 5 days between the evening dose of Day 5 of Treatment Period 1 and the morning dose of Day 1 of Treatment Period 2.
88860562|NCT04844424|Experimental|Part 3A: Treatment Sequence KLM|Participants will receive single oral Dose 1 of milvexian as oral Tablet 1 under fasting conditions (Treatment K) in Treatment Period 1, followed by single oral Dose 1 of milvexian oral Tablet 2 under fasting conditions (Treatment L) in Treatment Period 2 and then single oral Dose 1 of milvexian as Phase 2 oral capsules under fasting conditions (Treatment M) in Treatment Period 3 on Day 1 in each Treatment Period during Part 3A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
88860563|NCT04844424|Experimental|Part 3A: Treatment Sequence LMK|Participants will receive Treatment L in Treatment Period 1, followed by Treatment M in Treatment Period 2 and then Treatment K in Treatment Period 3 on Day 1 of each Treatment Period during Part 3A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
88860564|NCT04844424|Experimental|Part 3A: Treatment Sequence MKL|Participants will receive Treatment M in Treatment Period 1, followed by Treatment K in Treatment Period 2 and then Treatment L in Treatment Period 3 on Day 1 in each Treatment Period during Part 3A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
88860565|NCT04844424|Experimental|Part 3A: Treatment Sequence KML|Participants will receive Treatment K in Treatment Period 1, followed by Treatment M in Treatment Period 2 and then Treatment L in Treatment Period 3 on Day 1 in each Treatment Period during Part 3A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
88860566|NCT04844424|Experimental|Part 3A: Treatment Sequence LKM|Participants will receive Treatment L in Treatment Period 1, followed by Treatment K in Treatment Period 2 and then Treatment M in Treatment Period 3 on Day 1 in each Treatment Period during Part 3A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
88860567|NCT04844424|Experimental|Part 3A: Treatment Sequence MLK|Participants will receive Treatment M in Treatment Period 1, followed by Treatment L in Treatment Period 2 and then Treatment K in Treatment Period 3 on Day 1 in each Treatment Period during Part 3A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
89003130|NCT05727930|Experimental|High-intensity, task-specific (i.e., walking) interventions|30 1-hour (hr) sessions of walking training targeting higher cardiovascular intensities over approximately 2 months
89385094|NCT02974140|Experimental|CRS|First surgical eye randomized to Cataract Refractive Suite with second surgical eye (fellow eye) assigned to standard manual technique. Second eye surgery conducted within 7-14 days of the first eye surgery.
89385095|NCT02974140|Active Comparator|Manual|First surgical eye randomized to standard manual technique with second surgical eye (fellow eye) assigned to Cataract Refractive Suite. Second eye surgery conducted within 7-14 days of the first eye surgery.
89385096|NCT02311725|Experimental|aTAU + sTVi|"Antidepressant Treatment as Usual (aTAU): All participants will receive antidepressant treatment as usual provided by their primary care doctor during the study.~Storytelling Video Intervention (sTVi): We will develop a series of 4 videos, each episode approximately 30 minutes long, which will illustrate the key principles of Acceptance and Commitment Therapy.~In addition, we will develop an accompanying personal journal for participants that includes a brief self-help guide which encourages participants to write about what they learned in the videos and how they will take similar steps in their own lives to cope with depression."
89385097|NCT02311725|Active Comparator|aTAU + Attention Control Videos|"Antidepressant Treatment as Usual (aTAU): All participants will receive antidepressant treatment as usual provided by their primary care doctor during the study.~Attention Control Videos: Control participants will view videos about general mental health and well-being. Specifically, we plan to give participants 4 30-minute videos on topics including nutrition, stress reduction, movement and recreation, and becoming an educated patient. The series comes with an accompanying course guidebook. We will provide videos on the same schedule as sTVi."
89385098|NCT03653754||typically developing|Intervention: Measurement of growth and body composition. Growth (height, body weight), and body composition was measured at school.
89385099|NCT03653754||neurodisabilities|Intervention: Measurement of growth and body composition. Growth (height, body weight), and body composition was measured at school.
89385100|NCT02237300|Experimental|VR based cue-exposure therapy|Throughout the six sessions, participants (n=30) will be exposed to different VR environments related to binge behavior, according to a previously constructed hierarchy. During exposure, patients will face high risk situations to diminish or to extinguish the conditioned response of anxiety when exposed to food related cues. In each session, the patient will be exposed to the corresponding step of the hierarchy. During the exposure session, the patient can handle the virtual foods using the laptop's mouse but cannot eat the foods (exposure with response prevention). Exposure will end when the anxiety level decreased by 40% in relation to the level registered at the initiation of the exposure session or after 60 minutes of exposure.
89385101|NCT02237300|Active Comparator|Additional Cognitive-behavioral treatment|Participants (n=30) in this condition will receive six CBT booster sessions (two sessions per week) over the course of three weeks to improve the output of treatment. CBT sessions are based on the approach described by by Eldredge and colleagues (Eldredge et al.,1997). In this treatment program, patients are trained to self-monitor their food patterns and to identify and manage thoughts, emotions, and environmental factors related to disrupted eating behaviors.
89385102|NCT04932005|Experimental|DZD2269|This study includes two parts. In Part A, a single dose of DZD2269 at different dose levels will be given. In Part C, DZD2269 at selected dose levels will be given twice daily for 7 days.
89385103|NCT04932005|Placebo Comparator|Placebo|In Part A, a single oral dose of placebo will be given. In Part C, placebo will be given twice daily for 7 days.
89003131|NCT05727930|Active Comparator|High-intensity, non-specific physical therapy interventions|30 1-hr sessions of general physical therapy interventions (strengthening, balance training, aerobic cycling, transfers, walking) targeting higher cardiovascular intensities over approximately 2 months
89003132|NCT05727930|Active Comparator|Low-intensity, task-specific physical therapy interventions|30 1-hr sessions of general physical therapy interventions (strengthening, balance training, aerobic cycling, transfers, walking) targeting lower cardiovascular intensities over approximately 2 months
89003133|NCT05727930|Active Comparator|Low-intensity, non-specific physical therapy interventions|30 1-hr sessions of general physical therapy interventions (strengthening, balance training, aerobic cycling, transfers, walking) targeting lower cardiovascular intensities over approximately 2 months
89003134|NCT05724134|Active Comparator|Maintenance hyperinsulinemia (MH) protocol|The basal insulin infusion rate (IIR) necessary to maintain participants' mean basal fasting plasma glucose (mbFPG) will be determined during the basal titration period. Then, during the intervention period, the IIR will remain at 100% of basal for the full duration (225 min). The IIR and resulting insulin levels are expected to be relatively high (cf. hyperinsulinemia) because of underlying insulin resistance.
89003135|NCT05724134|Experimental|Reduction toward euinsulinemia (RE) protocol|The basal insulin infusion rate (IIR) necessary to maintain participants' mean basal fasting plasma glucose (mbFPG) will be determined during the basal titration period. Then, during the intervention period, the basal IIR will be reduced by up to 40%. Thus, the basal hyperinsulinemia expected due to underlying insulin resistance will be reduced toward euinsulinemia.
89385104|NCT02974842||Pre-Salpingo-Oophorectomy|Women with pelvic mass suspicious for malignancy or have BRCA1 or BRCA2 mutations that will undergo pre-salpingo-oophorectomy.
89385105|NCT03653676||Subjects with SCA|Children and adolescents with SCA confirmed by hemoglobin analysis randomized to either moderate or vigorous intensity exercise test (CIIT)
89535174|NCT05005923|Active Comparator|Periodontitis Stage III Grade C|The patients were subjected to quadrant-wise full-mouth subgingival scaling and root planning under local anesthesia. The entire non-surgical periodontal treatment of periodontitis groups was completed in a total of 4 sessions in two weeks.
89535175|NCT03227809|Experimental|Handbook condition|Parents in this condition receive a handbook designed for parents of first-year college-going students the summer before school starts
89535176|NCT03227809|Experimental|Handbook plus condition|Parents in this condition receive a handbook designed for parents of first-year college-going students the summer before school starts plus a series of text messages during students' first year of college
89535177|NCT03227809|No Intervention|Control|Parents receive treatment as usual of incoming university student parents
89535178|NCT02490683|Experimental|Luna Rich X|Luna Rich X©: 500 mg/ day in 4 pills of lunasin-enriched soy protein concentrate Reliv Now: 19 grams of powder/day, that subject will mix and consume daily with water or a beverage they commonly drink
89535179|NCT02490683|Experimental|Reliv Now|19 grams of power/day, that subjects will mix and consume daily with water or a beverage they commonly drink
89385106|NCT03653676||Controls without SCA|Children and adolescents without SCA or sickle cell trait randomized to either moderate or vigorous intensity exercise test (CIIT)
89535180|NCT02490683|Placebo Comparator|Placebo|Placebo pills containing starch (provided by Reliv International, Inc.)
89385107|NCT03536247|Active Comparator|Intraductal lithotripsy|Cholangioscopy enables therapeutic intervention including intracorporeal electro-hydraulic and laser lithotripsy for biliary stone disease with favorable efficacy and safety.
89385108|NCT03536247|Active Comparator|Papillary Balloon dilation|Balloon dilation of the Ampulla of Vater after a small sphincterotomy is an alternative technique that allows for removal of large bile duct stones in a safe and effective manner.
89385109|NCT03172481|Experimental|Active Treatment|PRC-063 25, 35, 45, 55, 70 or 85 mg
89385110|NCT03172481|Placebo Comparator|Placebo Treatment|
89385111|NCT01163487|Experimental|Dichloroacetate (DCA)|25 mg/kg/day, 37.5 mg/kg, or 50 mg/kg/day oral DCA.
89385112|NCT02855450|Experimental|rhNGF|rhNGF (Recombinant Human Nerve Growth Factor) 180 μg/ml eye drops solution
89385113|NCT02855450|Placebo Comparator|Vehicle|Ophthalmic Placebo solution
89385114|NCT03477045|Active Comparator|Fish oil|Fish oil providing 450 mg of eicosapentaenoic acid plus docosahexaenoic acid per dose
89385115|NCT03477045|Experimental|Camelina seed oil|Camelina seed oil providing 450 mg of eicosapentaenoic acid plus docosahexaenoic acid per dose
89385116|NCT01379001|Experimental|Young|Young healthy controls, aged 21-35
89385117|NCT01379001|Experimental|Older|Older healthy controls, aged 65-80
89385118|NCT02035124|Experimental|BKM120 and Cabazitaxel|"BKM 120 orally once daily;~Cabazitaxel 25 mg/m2 IV every 3 weeks"
89385119|NCT03172325|Experimental|CinnaGen adalimumab|CinnoRA® (adalimumab Prefilled Syringe produced by CinnaGen Company) 40 mg/0.8 ml Every other week 40 mg Adalimumab, will be subcutaneously administered to rheumatic patients during six months. Along with, 15 mg weekly methotrexate, at least 1 mg daily Folic acid and 7.5 mg daily Prednisolone over six months.
89385120|NCT03172325|Active Comparator|AbbVie adalimumab|Humira® (adalimumab Prefilled Syringe produced by AbbVie Company) 40 mg/0.8 ml Every other week 40 mg Adalimumab, will be subcutaneously administered to rheumatic patients during six months. Along with, 15 mg weekly methotrexate, at least 1 mg daily Folic acid and 7.5 mg daily Prednisolone over six months.
89385121|NCT03653520|Active Comparator|diazepam only (group 1)|Patients are given 5 or 10mg of diazepam for sedation before surgery for sedation
89385122|NCT03653520|Active Comparator|diazepam/tramadol/ondansetron (group 2)|Patients are given 5 or 10mg of diazepam, 50 or 100mg of tramadol and 4 or 8mg of ondansetron orally before surgery for sedation
89003144|NCT05707429||Healthy control group|will include patient's relatives or volunteers, who accept to participate in the study through invitation or posters which send or spread it to all staff hospitals about importance of the study.
89003145|NCT05707429||IBD patients inactive group|"IBD patients group: they will be recruited from outpatient clinic and inpatient with CD or UC at the Gastroenterology department at Alrajhi hospital.~CD patients will be assessed by the Crohn's Disease Activity Index a score of less than 150 corresponds to relative disease quiescence (remission); 150 to 219, mildly active disease; 220 to 450, moderately active disease; and greater than 450, severe disease (9)."
89003146|NCT05707377|Experimental|Part 1 and Part 2: Zanubrutinib High dose|Participants will receive Zanubrutinib twice daily
89385123|NCT03653520|Experimental|MKO only (group 3)|Patients are given 1 or 2 MKO melts (each contain 3mg midazolam, 25mg ketamine, 2mg ondansetron) sublingually before surgery for sedation
89385124|NCT01378923|Experimental|Values-based mindfulness group|The Re-entry values and mindfulness program (REVAMP) is an 8 session group intervention designed for jail inmates nearing release into the community
89003147|NCT05707377|Experimental|Part 2: Zanubrutinib Low Dose|Participants will receive Zanubrutinib once daily
89003148|NCT05707377|Active Comparator|Tacrolimus|Participants will receive tacrolimus capsules for 64 weeks
89385125|NCT01378923|Other|Treatment as usual|has access to standard jail interventions and programs
89385126|NCT02034734|Experimental|1: ASP3652|Multiple doses of ASP3652
89385127|NCT01376973||group A|Not received any oral device (Control)
89385128|NCT01376973||Group B and Group C|Group B - Used Michigan Occlusal Splint (MOS); Group C - Used Planas Oral Appliance (POA).
89385129|NCT03608072|Experimental|Dose group 1|
89385130|NCT03608072|Experimental|Dose group 2|
89385131|NCT03608072|Experimental|Dose group 3|
89385132|NCT03630471|Active Comparator|Control|Enhanced usual care (problem-solving booklets only).
89385133|NCT03630471|Experimental|Intervention|PRIDE 'Step 1' problem-solving intervention.
89385134|NCT04054986|Experimental|Breast Cancer|Breast cancer
89385135|NCT03653286|Experimental|NMES and Run|NMES and run
89385136|NCT03653286|Other|Only Run|Only Run
89385137|NCT01208090|Experimental|Investigational drug - Dose 1|
89385138|NCT01208090|Experimental|Investigational drug - Dose 2|
89385139|NCT01208090|Placebo Comparator|Matching placebo|
89385140|NCT03085017|Active Comparator|Ostene|Application of Ostene onto cut sternal site for hemostasis.
89385141|NCT03085017|Experimental|BoneSeal|Application of BoneSeal onto cut sternal site for hemostasis.
89385142|NCT04210050|Other|Usual care|Usual care follows the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines.
89385143|NCT04210050|Active Comparator|Usual care plus NIPPV group only|Usual care for COPD based on Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines plus use of nocturnal ventilator device using the Breas VIVO 50 home ventilator, Breas Medical (or any newer models as available).
88860568|NCT04844424|Experimental|Part 3B: Treatment Sequence NOP|Participants will receive single oral Dose 1 of milvexian oral Tablet 1 under fed conditions (Treatment N) in Treatment Period 1, followed by single oral Dose 1 of milvexian oral Tablet 2 under fed conditions (Treatment O) in Treatment Period 2 and then single oral Dose 1 of milvexian Phase 2 oral capsule under fed conditions (Treatment P) in Treatment Period 3 on Day 1 in each Treatment Period during Part 3B. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
88860569|NCT04844424|Experimental|Part 3B: Treatment Sequence OPN|Participants will receive Treatment O in Treatment Period 1, followed by Treatment P in Treatment Period 2 and then Treatment N in Treatment Period 3 on Day 1 in each Treatment Period during Part 3B. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
88860570|NCT04844424|Experimental|Part 3B: Treatment Sequence PNO|Participants will receive Treatment P in Treatment Period 1, followed by Treatment N in Treatment Period 2 and then Treatment O in Treatment Period 3 on Day 1 in each Treatment Period during Part 3B. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
89385144|NCT03653130|Experimental|Intervention Program|Participants will receive an instrument (violin, viola, or cello). Intervention sessions will take place twice a week at the Domiciliary and once per week at the Domiciliary or at a community location (Richard L. Roudebush VA Medical Center or Regenstrief Institute). Each session will include: thirty minutes of group music instruction by an experienced music educator with skills in adult music education followed by thirty minutes of weekly adult ensemble experience.
89385145|NCT03653130|No Intervention|Usual Care Control|Usual care at VA Domiciliary including participation in Domiciliary recreational therapy electives (if eligible).
89385146|NCT03653130|No Intervention|Retrospective Chart Review|Retrospective chart reviews case-matched to intervention participants for age and biological sex factors.
89385147|NCT03215771|Experimental|MyoPro + Motor Learning-Based Therapy|Subjects received 9 weeks of motor learning-based therapy in combination with use of MyoPro myoelectric elbow wrist hand orthosis, followed by 9 weeks of home use with a customized exercise program.
89385148|NCT04266990|Experimental|Epilepsy patients|Epilepsy patients admitted for clinical purposes in the EEG monitoring units at the UZ
89385149|NCT04266990|Active Comparator|Healthy volunteers|Healthy volunteers recruited from among colleagues from the department and hospital staff
89385150|NCT01380483|Experimental|A|Subjects received the Par formulated product
89385151|NCT01380483|Active Comparator|B|Subjects received the Oclassen Pharmaceuticals formulated product.
89385152|NCT02745392|Experimental|ZP-Zolmitriptan 1 mg|ZP-Zolmitriptan 1 mg patch single administration
89385153|NCT02745392|Experimental|ZP-Zolmitriptan 1.9 mg|ZP-Zolmitriptan 1.9 mg patch single administration
89385154|NCT02745392|Experimental|ZP-Zolmitriptan 3.8 mg|ZP-Zolmitriptan 3.8 mg (1.9 mg x 2 patches) single administration
88860571|NCT04844424|Experimental|Part 3B: Treatment Sequence NPO|Participants will receive Treatment N in Treatment Period 1, followed by Treatment P in Treatment Period 2 and then Treatment O in Treatment Period 3 on Day 1 in each Treatment Period during Part 3B. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
88860572|NCT04844424|Experimental|Part 3B: Treatment Sequence ONP|Participants will receive Treatment O in Treatment Period 1, followed by Treatment N in Treatment Period 2 and then Treatment P in Treatment Period 3 on Day 1 in each Treatment Period during Part 3B. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
88860573|NCT04844424|Experimental|Part 3B: Treatment Sequence PON|Participants will receive Treatment P in Treatment Period 1, followed by Treatment O in Treatment Period 2 and then Treatment N in Treatment Period 3 on Day 1 in each Treatment Period during Part 3B. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
88860574|NCT04844424|Experimental|Part 4 A: Treatment Sequence QRS|Participants will receive single oral Dose 1 of milvexian as Phase 3 oral tablets under fasting conditions (Treatment Q) in Treatment Period 1, followed by single oral Dose 1 of milvexian as Phase 3 oral tablets under fed conditions (Treatment R) in Treatment Period 2 and then single oral Dose 1 of milvexian as Phase 3 oral tablets under fed conditions (Treatment S) in Treatment Period 3 on Day 1 of each Treatment Period during Part 4A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
89385155|NCT02745392|Placebo Comparator|Placebo|Placebo (either single or double patch) single administration
89385156|NCT03622008|Experimental|FEP-TAZ 4 g|FEP-TAZ 4 g (2 g cefepime + 2 g tazobactam) IV treatments as a q8h infusion (90 min) regimen for 10 days
89385157|NCT03622008|Placebo Comparator|Placebo|placebo IV
89385158|NCT03225183||1|Framingham Heart Study participants
89385159|NCT04063202||Non-cases|Secondary school students (seventh to tenth years of education) without probable depression at baseline interview.
89385160|NCT01378845|Placebo Comparator|Prostavasin|
89385161|NCT01378845|Active Comparator|Prostavasin + Bosentan|
89535181|NCT03324269|Other|NOL|"After tracheal intubation and before surgical incision, a calibration Tetanus test of 100Hz, 60 mAmp during 30 sec at remifentanil level (Ce) of 4 ng/ml will be done (starting NOL below 10).~According to the NOL response, there will be an increment of 1 ng/ml of RemiCe if NOL gradient ≥ 20 or decrement of 1 ng/ml if NOL gradient < 10. Ideal remifentanil Ce is the remifentanil Ce at which the variation of NOL index will be less than 10 units at a NOL starting value below 10. Thus this individual remifentanil Ce will be the remifentanil level programmed before surgical incision. NOL and hemodynamic responses will be recorded during the entire duration of surgery."
89535182|NCT03228043|Experimental|Apatinib group|Apatinib combined with CAPEOX program. Apatinib tablets: 500 mg po qd from the second cycle of chemotherapy. Oxaliplatin: Day 1, 130mg/m2, IV infusion. Capecitabine: Day 1-14, 1000mg/m2 Twice Daily, po. A total of 6 cycles, 3 weeks apart of chemotherapy.
89535183|NCT03228043|Placebo Comparator|Control group|CAPEOX program. Oxaliplatin: Day 1, 130mg/m2, IV infusion. Capecitabine: Day 1-14, 1000mg/m2 Twice Daily, po. A total of 6 cycles, 3 weeks apart of chemotherapy.
89535184|NCT03119857|Active Comparator|Antiandrogen|Antiandrogen (bicalutamide 150 mg x 1) p.o. alone,
89385162|NCT03606122|Experimental|PD P 506 A-PDT|The study medication will be applied to each study lesion for 4 hours. After removal of the study medication the study lesions will be illuminated with red light of defined wavelength (PDT). Second PDT of the lesions will be performed 6-14 days after the first PDT.
89385163|NCT03606044||MIS-PN|Participants approved for elective robot-assisted partial nephrectomy with T1a or T1b renal tumours.
89385164|NCT03605888|Experimental|RCT Intervention|Overweight or obese (BMI ≥ 25 kg/m2) participants randomized to the Koa Family. intervention
89385165|NCT03605888|No Intervention|RCT Control|Overweight or obese (BMI ≥ 25 kg/m2) participants randomized to the control group.
89385166|NCT03605888|Other|Exploratory|Normal-weight mothers (BMI 18.5-24.9 kg/m2) assigned to the Koa Family intervention.
89385167|NCT03076515|Active Comparator|Nerivio Migra active|This arm will use the active device for acute treatment of migraine at the migraine symptoms onset. the device will be applied on the upper arm and controlled by a dedicated smartphone application.
89385168|NCT03076515|Sham Comparator|Nerivio Migra placebo|This arm will use the sham device for acute treatment of migraine at the migraine symptoms onset. the device will be applied on the upper arm and controlled by a dedicated smartphone application.
89385169|NCT03605810||eGFR-population|To be included in the eGFR-population, patients have to have at least one recorded eGFR value in the OPTUM CDM database between January 1, 2007 and December 31, 2016, be adults (>18 years of age at the time of eGFR test) and have at least 370/180 days (180 days serves as sensitivity analysis) of continuous enrollment in medical and pharmacy insurance plans since eGFR test date.
89385170|NCT03605810||Atrial fibrillation (AF) sub-population|"To be included in the AF sub-population patients need to satisfy the inclusion criteria for the eGFR-population; have two inpatient or outpatient diagnoses for AF or atrial flutter on two different days within the study period irrespective of time points when eGFR is measured.~Patients with at least one inpatient or outpatient diagnosis or procedure code for mitral stenosis and prosthetic valves within the study period will be excluded."
89385171|NCT03605810||Coronary artery disease (CAD) sub-population|To be included in the CAD sub-population patients need to satisfy the inclusion criteria for the eGFR-population; have at least one inpatient CAD diagnosis within the study period irrespective of time points when eGFR is measured.
88860575|NCT04844424|Experimental|Part 4A: Treatment Sequence RSQ|Participants will receive Treatment R in Treatment Period 1, followed by Treatment S in Treatment Period 2 and then Treatment Q in Treatment Period 3 on Day 1 of each Treatment Period during Part 4A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
88860576|NCT04844424|Experimental|Part 4A: Treatment Sequence SQR|Participants will receive Treatment S in Treatment Period 1, followed by Treatment Q in Treatment Period 2 and then Treatment R in Treatment Period 3 on Day 1 of each Treatment Period during Part 4A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
88860577|NCT04844424|Experimental|Part 4A: Treatment Sequence QSR|Participants will receive Treatment Q in Treatment Period 1, followed by Treatment S in Treatment Period 2 and then Treatment R in Treatment Period 3 on Day 1 of each Treatment Period during Part 4A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
88860578|NCT04844424|Experimental|Part 4A: Treatment Sequence RQS|Participants will receive Treatment R in Treatment Period 1, followed by Treatment Q in Treatment Period 2 and then Treatment S in Treatment Period 3 on Day 1 of each Treatment Period during Part 4A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
88860579|NCT04844424|Experimental|Part 4A: Treatment Sequence SRQ|Participants will receive Treatment S in Treatment Period 1, followed by Treatment R in Treatment Period 2 and then Treatment Q in Treatment Period 3 on Day 1 of each Treatment Period during Part 4A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
89385172|NCT03605810||Type 2 diabetes mellitus (T2DM) sub-population|To be included in the T2DM sub-population patients need to satisfy the inclusion criteria for the eGFR-population; have at least two inpatient or outpatient diagnosis of T2DM on two different days within the study period irrespective of time points when eGFR is measured.
89385173|NCT03605732|Experimental|intervention|Intervention group: They will receive an educational app designed to improve sleep, and will receive self-help training in a six-week training package.
89385174|NCT03605732|Active Comparator|Patient education|Patients will receive written weekly information on accurate and relevant information regarding insomnia symptoms, physiological controls of sleep, sleep hygiene practices, healthy sleep behaviors
89385175|NCT04951635|Experimental|Almonertinib|
89385176|NCT04951635|Placebo Comparator|Placebo Almonertinib|
89385177|NCT03605576|Experimental|Fu's subcutaneous needling|In this arm, the subjects will receive the intervention of FSN on Day1, Day2 and Day4, in total 3 treatments and will be arrange to take efficacy two assessment on Day8 and Day15, separately.
88860580|NCT04844424|Experimental|Part 4B: Treatment Sequence TU|Participants will receive single oral Dose 1 of milvexian as Phase 3 oral tablet under fed conditions (Treatment T) in Treatment Period 1, followed by single oral Dose 2 of milvexian as Phase 3 oral tablet under fed conditions (Treatment U) in Treatment Period 2 on Day 1 of each Treatment Period during Part 4B. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
89385178|NCT03605576|Active Comparator|Transcutaneous electrical nerve stimulation|In this arm, the subjects will receive the intervention of TENS on Day1, Day2 and Day4, in total 3 treatments and will be arrange to take efficacy two assessment on Day8 and Day15, separately.
89385179|NCT01378767|Active Comparator|Krill oil capsules|Two grams per day daily for 21 days
89385180|NCT01378767|Placebo Comparator|Coconut oil capsules|Two grams per day for 21 days
89385181|NCT03607604||Autoantibody Negative|"Patients who are autoantibody negative (could potentially be either MODY or type 2 diabetes patients)~Suspected MODY patients will be candidates for next generation sequencing (NGS)"
89385182|NCT03607604||Diabetes Mellitus, Type 1|"Patients diagnosed with type 1 diabetes mellitus~Patients with positive UCPCR and negative autoantibodies results will be suspected with MODY and will be candidates for next generation sequencing (NGS)"
89385183|NCT03607604||Non Diabetic|Individuals not diagnosed with any type of diabetes (but could be diagnosed with IFG and/or IGT)
89385184|NCT04868721|No Intervention|control side|Conventional side Canine retraction was commenced without micro-osteoperforations.
89385185|NCT04868721|Experimental|single Micro-osteoperforations side|Three flapless micro-osteoperforations (MOPs) was performed for one time only distal to the maxillary canine before starting retraction.
89385186|NCT04868721|Experimental|Multiple Micro-osteoperforations side|Three flapless micro-osteoperforations (MOPs) was performed on repeated basis distal to the maxillary canine evey 28 days before canine retraction.
89385187|NCT03605420|Experimental|Experimental group|Receiving one family visit prior to hospital admission
89385188|NCT03605420|No Intervention|Control group|Without receiving one family visit prior to hospital admission
89385189|NCT03170609|Experimental|Lowest dose formulation a|Multivalent group B streptococcus vaccine
89385190|NCT03170609|Experimental|Middle dose formulation a|Multivalent group B streptococcus vaccine
89385191|NCT03170609|Experimental|Highest dose formulation a|Multivalent group B streptococcus vaccine
89385192|NCT03170609|Experimental|Lowest dose formulation b|Multivalent group B streptococcus vaccine
89385193|NCT03170609|Experimental|Middle dose formulation b|Multivalent group B streptococcus vaccine
89385194|NCT03170609|Experimental|Highest dose formulation b|Multivalent group B streptococcus vaccine
89385195|NCT03170609|Placebo Comparator|Placebo|Saline control
89385196|NCT03605186|Experimental|Chamomile oral cryotherapy|"The infusion of chamomile will be prepared in the clinic with 400 mL of distilled water and 10 g of chamomile flowers (Chamomile classic infusion, Royal Herbs).~Ice cubes will be prepared in special ice trays placed in the chemotherapy center for this purpose.~Patient will receive a cup of ice cubes which is continuously replenished before being emptied.~Patients will be instructed to swish the ice cubes around their oral cavities starting 5 minutes before chemotherapy infusion, continuing 30 minutes throughout the session and for additional 35 minutes after completion of intravenous chemotherapy session."
89385197|NCT03605186|Active Comparator|Oral cryotherapy|"The plain icecubes will be prepared in the clinic with 400 mL of distilled water.~Ice cubes will be prepared in special ice trays placed in the chemotherapy center for this purpose.~Patient will receive a cup of ice cubes which is continuously replenished before being emptied.~Patients will be instructed to swish the ice cubes around their oral cavities starting 5 minutes before chemotherapy infusion, continuing 30 minutes throughout the session and for additional 35 minutes after completion of intravenous chemotherapy session."
89385198|NCT01314755|Experimental|immune-enhancing feed IMPACT|immune-enhancing feed IMPACT
88860581|NCT04844424|Experimental|Part 4B: Treatment Sequence UT|Participants will receive Treatment U in Treatment Period 1, followed by Treatment T in Treatment Period 2 on Day 1 of each Treatment Period during Part 4B. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
88860582|NCT04844424|Experimental|Subpart 4A: Treatment Sequence VW|All participants of Subpart 4A will undertake a mandatory taste assessment on Day 5 of period 3 or Day 15 before the discharge and will receive milvexian tablet dispersed in water without a sweetener orally via syringe (Treatment V) in Treatment Period 1, followed by milvexian tablet dispersed in water with sucralose sweetener orally via syringe (Treatment W) in Treatment Period 2. Participants will cleanse their palates using 2 rinse of mineral water and one unsalted cracker and wait for a time interval of at least 1-2 hours from start of dosing before the next taste round.
88860583|NCT04844424|Experimental|Subpart 4A: Treatment Sequence WV|All participants of Subpart 4A will undertake a mandatory taste assessment on Day 5 of period 3 or Day 15 before the discharge and will receive Treatment W in Treatment Period 1, followed by Treatment V in Treatment Period 2. Participants will cleanse their palates using 2 rinse of mineral water and one unsalted cracker and wait for a time interval of at least 1-2 hours from start of dosing before the next taste round.
88860584|NCT04844424|Experimental|Part 5: Treatment Sequence XYZ|Participants will receive a single oral Dose 1 of milvexian as DC whole tablets under fasting conditions (Treatment X) in Treatment Period 1 followed by a single oral Dose 1 of milvexian as DC tablets dispersed in water and then mixed with apple sauce under fasting conditions (Treatment Y) in Treatment Period 2 and then a single oral Dose 1 of milvexian as DC tablets dispersed in water administered through a nasogastric (NG) tube under fasting conditions (Treatment Z) in Treatment Period 3 on Day 1 of each Treatment Period during Part 5. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
88860585|NCT04844424|Experimental|Part 5: Treatment Sequence YZX|Participants will receive Treatment Y in Treatment Period 1 followed by Treatment Z in Treatment Period 2 and then Treatment X in Treatment Period 3 on Day 1 of each Treatment Period during Part 5. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
89385199|NCT01314755|Active Comparator|control arm|iso-nitrogenous, iso-caloric control feed
89385200|NCT03605108|Active Comparator|Probiotic|"• Probiotic fomula per capsule:~2 Billion CFUs HU36 - 30 mg HU58 - 20 mg Bacillus clausii -25 mg Bacillus coagulans 10B - 35 mg Prepro - 22 mg. The prebiotic that is to be used in the proprietary blend is a vegetable grade cellulose."
89385201|NCT03605108|Placebo Comparator|Placebo|Rice flour only
89385202|NCT04904549|Experimental|Stage 1: SARS-CoV-2 vaccine|2 injections of monovalent SARS-CoV-2 vaccine at Day 1 and Day 22
89385203|NCT04904549|Placebo Comparator|Stage 1: Placebo|2 injections of placebo at Day 1 and Day 22
89385204|NCT04904549|Experimental|Stage 2: SARS-CoV-2 vaccine|2 injections of bivalent SARS-CoV-2 vaccine at Day 1 and Day 22
89385205|NCT04904549|Placebo Comparator|Stage 2: Placebo|2 injections of placebo at Day 1 and Day 22
89385206|NCT03605030|Active Comparator|Novel Lead Based Armboard|
89385207|NCT03605030|Placebo Comparator|Standard Armboard|
89385208|NCT02237378|Experimental|FDG PET scan|A PET scan using F-18 FDG, N-13 Ammonia will be performed
89385209|NCT03607916|Experimental|Cohort 1 : HB Prilocaine 2%,(60mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2% will be administered at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). The dose range will be from 45 to 70mg.
89385210|NCT03607916|Experimental|Cohort 2 : HB Prilocaine 2%,(45-70mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2% will be administered at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). The dose range will be from 45 to 70mg.
88860586|NCT04844424|Experimental|Part 5: Treatment Sequence ZXY|Participants will receive Treatment Z in Treatment Period 1 followed by Treatment X in Treatment Period 2 and then Treatment Y in Treatment Period 3 on Day 1 of each Treatment Period during Part 5. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
88860587|NCT04844424|Experimental|Part 5: Treatment Sequence XZY|Participants will receive Treatment X in Treatment Period 1 followed by Treatment Z in Treatment Period 2 and then Treatment Y in Treatment Period 3 on Day 1 of each Treatment Period during Part 5. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
88860588|NCT04844424|Experimental|Part 5: Treatment Sequence YXZ|Participants will receive Treatment Y in Treatment Period 1 followed by Treatment X in Treatment Period 2 and then Treatment Z in Treatment Period 3 on Day 1 of each Treatment Period during Part 5. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
88860589|NCT04844424|Experimental|Part 5: Treatment Sequence ZYX|Participants will receive Treatment Z in Treatment Period 1 followed by Treatment Y in Treatment Period 2 and then Treatment X in Treatment Period 3 on Day 1 of each Treatment Period during Part 5. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
88860590|NCT01892748|Active Comparator|Cholecalciferol 50.000IU/week|patients will receive vitamin D3 (50.000 IU/week) for 24weeks
88860591|NCT01892748|Placebo Comparator|Placebo|patients receive placebo in similar capsules of cholecalciferol for 24weeks
88860592|NCT01892826|Experimental|hCG group|
88860593|NCT01892826|No Intervention|LH pic|
88860594|NCT01892904|Experimental|EE20/DRSP(BAY86-5300)-flexibel extended regimen|One tablet [0.02 mg of ethinylestradiol (β-CDC) and 3 mg of drospirenone] / day with flexible extended regimen (24-day to 120-day active tablet intake followed by 4-day tablet free interval)
88860595|NCT01892904|Active Comparator|EE20/DRSP(BAY86-5300)-28 days cyclic regimen|One tablet [0.02 mg of ethinylestradiol (β-CDC) and 3 mg of drospirenone] / day with 28-day cyclic regimen (24-day active tablet intake followed by 4-day placebo tablet intake)
88860596|NCT01892982|Experimental|Problem Solving Education tailored to NICU|NICU-PSE integrates motivational interviewing and problem solving, with ongoing monitoring and linkage to mental health services for mothers with worsening depressive symptoms over time. The intervention is provided over six sessions, including three tailored, post-discharge sessions, which address issues common to families of preterm infants: caregiver burden, complexity of medical follow-up, and social reintegration following hospitalization.
88860597|NCT01892982|No Intervention|Control|Both study groups receive standard NICU medical, social work, and nursing services. At each study site, attending neonatologists and pediatrics residents constitute the medical team, and all families are assigned a social worker.
88860598|NCT01893060|Experimental|Povidone-Iodine|Umbilical stump care. Povidone-Iodine, USP, Swabstick Singles, applied twice a day to cord stump while umbilical line(s) are in place
88860599|NCT01893060|Experimental|Chlorhexidine|Umbilical stump care. ChloraPrep® Chlorhexidine Gluconate 2% w/v; 70% Isopropyl Alcohol v/v Swabstick Single, applied twice a day to cord stump while umbilical line(s) are in place
88860600|NCT01893060|Experimental|Pluronic Cream|Umbilical stump care. Pluronic gel - (F68, Polymyxin, Nystatin, Nitrofurantoin), applied twice a day to cord stump while umbilical line(s) are in place
88860601|NCT01893060|Sham Comparator|Control|No product is applied to cord stump while umbilical line(s) are in place. This is the current standard of care at UVA.
88860602|NCT01457742|Active Comparator|Pulsed Radio Frequency (PRF)|
88860603|NCT01457742|Sham Comparator|Sham|Use of Sham device for 15 minutes simulated treatment twice per day
88860604|NCT02314650|Experimental|Transcutaneous acupoint stimulation|Electrical stimulation was given through electrodes attached to skin at Ximen and Shenmen acupoint during anesthesia
88860605|NCT02314650|Placebo Comparator|Non-acupoint stimulation|Electrical stimulation was given through electrodes attached to skin at shoulder (non-acupoint) during anesthesia
88860606|NCT02314650|Sham Comparator|Control|patients were with electrodes attached but no stimulation was given
89385211|NCT03607916|Experimental|Cohort 3 : HB Prilocaine 2%,(45-70mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2% will be administered at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). The dose range will be from 45 to 70mg.
89385212|NCT03607916|Experimental|Cohort 4 : HB Prilocaine 2%,(45-70mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2% will be administered at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). The dose range will be from 45 to 70mg.
89385213|NCT03607916|Experimental|Cohort 5 : HB Prilocaine 2%,(45-70mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2% will be administered at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). The dose range will be from 45 to 70mg.
89535185|NCT03119857|Experimental|Antiandrogen + docetaxel|Antiandrogen (bicalutamide 150 mg x 1) p.o. + Docetaxel 75 mg/m2 (maximum 2.0 m2 ) i.v. q 3 weeks x up to 8-10 cycles.
88860607|NCT01457820|Experimental|Allopurinol High dose|
88860608|NCT01457820|Experimental|Allopurinol Low dose|
88860609|NCT01457820|Placebo Comparator|Placebo|
88860610|NCT01457898|Experimental|VPAP II®|VPAP II® Group
88860611|NCT01893216||with depression or anxiety|Hospital Anxiety and Depression Scale score over 9 points
88860612|NCT01893216||without depression or anxiety|Hospital Anxiety and Depression Scale score less than 8 points
88860613|NCT04758156|Experimental|CleanViewAL|1L polyethylene glycol+ascorbic acid split dose
88860614|NCT04758156|Placebo Comparator|SUPREP|Oral sulfate solutiom
88860615|NCT01457976||Members of the US public, non-probability sample|
88860616|NCT01457976||Members of the German public, non-probability sample|
88860617|NCT01457976||Members of the US public, probability sample|
88860618|NCT05020782|Experimental|Intervention Arm|INTERVENTION DRUG: BELIMUMAB 10 MG/KG
89184567|NCT02574117|Experimental|flap with corticotomy and bone allograft|Maxillary expansion with quad helix appliance was applied to posterior teeth with cross bite. Then corticotomy surgical procedure associated with addition of commercially available bone allograft; demineralized freeze-dried bone allograft on the buccal surface of maxillary 1st premolar, 2nd premolar and 1st molar areas.
89184568|NCT02572947|Experimental|Dolutegravir monotherapy|10 patients will be simplified to monotherapy of dolutegravir tablet 50mg once daily for 24 weeks
89184569|NCT00712491|Experimental|1|
89184570|NCT00712491|Experimental|2|
89184571|NCT04083066|Experimental|Rituximab combined with formoterol, pemetrexed, dexamethasone|Rituximab 375mg/m2D0 is soluble in 0.9% NS, concentration 1mg/ml, micro pump is pumped for 4h Fotemustine 100mg/m2 D1 dissolved in 250mL 0.9% NS, intravenously for 1h, protected from light Pemetrexed 600mg/m2 D1 dissolved in 100ml 0.9% NS, intravenously 1h Dexamethasone 40mg D1-5 Dissolved in 100 ml 5% GS, intravenously (21 days is a cycle)
89184572|NCT04070547|Experimental|Early tVNS|First 2 weeks this group will receive transcutaneous vagal nerve stimulation 4 hours a day (day 1 to day 14). Then participants will be followed for another 2 weeks (day 15 to day 28) without any intervention. Laboratory testing will be carried out three times with average of 14 days between sessions: on day 1 (pre-intervention), on day 14 (post-intervention) and on day 28 (follow-up).
89184573|NCT04070547|Experimental|Early Sham|First 2 weeks this group will receive sham stimulation 4hours a day (day 1 to day 14). Then participants will be followed for another 2 weeks (day 15 to day 28). Laboratory testing will be carried out three times with average of 14 days between sessions: on day 1 (pre-intervention), on day 14 (post-intervention) and on day 28 (follow-up).
89184574|NCT04070547|Experimental|Late tVNS|First 2 weeks this group will be on a waiting list (day 1 to day 14). Then participants will receive transcutaneous vagal nerve stimulation 4hours a day (day 15 to day 28). Laboratory testing will be carried out three times with average of 14 days between sessions: on day 1 (waiting), on day 14 (pre-intervention) and on day 28 (post-intervention).
89184575|NCT04070547|Experimental|Late Sham|First 2 weeks this group will be on a waiting list (day 1 to day 14). Then participants will receive sham stimulation 4hours a day (day 15 to day 28). Laboratory testing will be carried out three times with average of 14 days between sessions: on day 1 (waiting), on day 14 (pre-intervention) and on day 28 (post-intervention).
89184576|NCT04069455|Experimental|EPRO group|Clinical usual care plus ePRO App self-management online during postoperative adjuvant chemotherapy
89184577|NCT04069455|No Intervention|Control group|Clinical usual care during postoperative adjuvant chemotherapy
89184578|NCT05683782|Active Comparator|Test Group|"Split-thickness Apically Positioned Flap with topical Erythropoietin (Test group):~A split thickness horizontal incision will be done at the mucogingival junction of the targeted area to be augmented with a scalpel with blade number 15C. Around the teeth, the gingiva stays intact coronal to the horizontal incision. The horizontal incision will extend mesio-distally in accordance with the area to be augmented.(Mandibular anterior or premolar teeth).~A split-thickness flap is elevated, and the dissection is extended as far as necessary in the apical direction. The flap is secured to the periosteum with simple interrupted bio absorbable sutures.~A Chitosan based Erythropoietin gel will be prepared. 1 mL of EPO-loaded with chitosan 5% and β-glycerophosphate disodium salt (GP) 20% gel will be used. The patient will be instructed to use the gel on the surgical site two times daily for 14 days."
89184579|NCT05683782|Active Comparator|Control Group|"Split-thickness Apically Positioned Flap without Erythropoietin :~Local anesthesia is administered by infiltration technique. The same surgical procedure is performed with the application of Chitosan gel without being loaded with erythropoietin."
89184580|NCT00712569||1|Patients in Category 1 are those who report before the visit that they intend to discuss cancer-related internet information and report after the visit that they did discuss such information.
89184581|NCT00712569||2|Patients in Category 2 are those who report before the visit that they intend to discuss cancer-related internet information, but report after the visit that they did not discuss such information.
89184582|NCT00712569||3|Patients in Category 3 are those who report before the visit that they do not intend to discuss cancer-related internet information and do not discuss it.
89184583|NCT04877184|Experimental|Transcranial ultrasound stimulation and rehabilitation|The investigators expect to enroll 10 people in the experimental group.
89184584|NCT04877184|Active Comparator|Rehabilitation|The investigators expect to enroll 10 people in the control group.
89184585|NCT00740714|Experimental|A|Randomized to active treatment (Coenzyme Q10 2400 mg/day with vitamin E 1200 IU/day)
89184586|NCT00740714|Experimental|B|Randomized to active treatment (Coenzyme Q10 1200 mg/day with vitamin E 1200 IU/day)
89184587|NCT00740714|Placebo Comparator|C|Placebo (with vitamin E 1200 IU/day)
89184588|NCT04068285|Active Comparator|High intensity interval exercise|"Participants with type 2 Diabetes mellitus in High intensity interval exercise (HIIE) group will make aerobic exercise using bicycle at high intensity followed by low intensity periods under observation in the hospital.~exercise"
89184589|NCT04068285|Active Comparator|Moderate intensity continuous exercise|"Participants with type 2 Diabetes mellitus in Moderate intensity continuous exercise (MIC) group will make aerobic exercise using bicycle at moderate intensity during the session under observation in the hospital.~exercise"
89184590|NCT04068285|No Intervention|No Intervention: Control group|The participants with type 2 Diabetes mellitus in the control group will make stretching exercise at home
89184591|NCT02588352|Experimental|Healthy volunteers|Open label administration of salt tablets for one week
89184592|NCT00721773|Experimental|ACE inhibitor, benazepril|Benazepril will be started at 10 mg/day and will be up-titrated to 20 mg/day according to BP control and tolerability.
89184593|NCT00721773|Experimental|Angiotensin receptor blocker, valsartan|Valsartan will be started at 80 mg/day and will be up-titrated to 160 mg/day according to BP control and tolerability.
89003149|NCT05703971|Experimental|Phase 1|"Up to 2 sequential dose selection cohorts will be treated with quaratusugene ozeplasmid (intravenous (IV) administration once every 21 days) plus atezolizumab (1200 mg IV administration once every 21 days) until disease progression or unacceptable toxicity.~Quaratusugene ozeplasmid doses will be evaluated (0.09 [starting dose], and 0.12 mg/kg) until the RP2D is identified."
89003150|NCT05703971|Experimental|Phase 2|Patients will be treated with the RP2D of quaratusugene ozeplasmid (IV administration once every 21 days) plus atezolizumab (1200 mg IV administration once every 21 days) until disease progression or unacceptable toxicity
89003151|NCT05701371||Centenarian cohort|
89003152|NCT05696717|Active Comparator|Ampreloxetine (Open Label)|Participants will receive ampreloxetine as a single, oral, daily dose of active drug for 12 weeks.
89003153|NCT05696717|Placebo Comparator|Ampreloxetine (Randomized Withdrawal)|After completing the open label, participants are randomized to either ampreloxetine or placebo receiving a single, oral, daily dose of active drug or placebo for a further 8 weeks.
89003154|NCT05696717|Active Comparator|Long-Term Extension Period|Participants will receive ampreloxetine as a single, oral, daily dose of active drug for 104 weeks.
89003155|NCT05695170|Active Comparator|Individual intervention condition|"PreventT2 individual lifestyle intervention curriculum (2021 revised National DPP curriculum, freely available from the CDC)"
89003156|NCT05695170|Experimental|Couple-based intervention condition|"PreventT2 Together (couple-based adaptation of PreventT2; approved by the CDC in November 2022 as an Alternate Curriculum for use in the National DPP)"
89003157|NCT05694858|Experimental|Lignocaine-Embedded Microneedle Patch|A biodegradable maltose microarray needle (MAN) patch loaded with 12.5 mg lignocaine will be applied on the dorsum of the participant's hand for 30 minutes. Intravenous cannulation will be carried out after 30 minutes.
89003158|NCT05694858|Active Comparator|EMLA 5% Patch|1 finger-tip unit (FTU) of EMLA containing 12.5 mg lignocaine and 12.5 mg prilocaine will be applied on the dorsum aspect of the participant's hand. This will then be covered by a Polyvinyl Alcohol (PVA)-Polyethylene Terephthalate (PET) adhesive and left in place for 30 minutes. Intravenous cannulation will be carried out after 30 minutes.
89003159|NCT05687136|Experimental|Treatment (peposertib, tuvusertib)|Patients receive peposertib PO in combination with tuvusertib PO QD or BID daily on days 1-14 of each cycle. Cycles repeat every 28 days in the absence of disease progression, pregnancy, non-compliance, unacceptable toxicity, termination of the study or the study drug is no longer available. Patients also undergo tumor biopsy before C1D1, C1D10 and at progression and blood sample collection during prestudy and weeks 1, 2, 3, 4, 5, 6, and at progression. Patients additionally undergo PET, CT, and MRI at baseline and are repeated every 8 weeks for 24 weeks then every 12 weeks unless clinically indicated.
89003160|NCT05686265||Patients|Patients with SAH (see eligibility criteria below).
89003161|NCT05686265||Controls|Healthy controls (see eligibility criteria below).
89003162|NCT05685225|Experimental|Naltrexone-Acetaminophen|Subjects take a single dose for a Qualifying Migraine
89003163|NCT05685225|Active Comparator|Naltrexone|Subjects take a single dose for a Qualifying Migraine
89003164|NCT05685225|Active Comparator|Acetaminophen|Subjects take a single dose for a Qualifying Migraine
89003165|NCT05685225|Placebo Comparator|Placebo|Subjects take a single dose for a Qualifying Migraine
89003166|NCT05679401|Experimental|Imlifidase and Standard-of-Care (SoC)|"Imlifidase is administered IV as one dose of 0.25 mg/kg over 15 minutes.~SoC consists of a standardized combination of PLEX, CYC, and glucocorticoids."
89003167|NCT05679401|Active Comparator|Standard-of-Care (SoC)|SoC consists of a standardized combination of PLEX, CYC, and glucocorticoids.
89003168|NCT05675059|Active Comparator|Group 1: STRONG Intervention|The STRONG program includes consultation with a Moffit dietician, logging intake of food daily into a food diary with a Fitbit smartphone app, and completing questionnaires.
89003169|NCT05675059|Active Comparator|Group 2: Usual Care|Participants will be referred to dieticians based on clinical discretion. Participants will also be asked to wear a Fitbit for 12 weeks to passively collect data on activity level.
89003170|NCT05669586|Experimental|Organoid-Guided Antitumor therapy|lung cancer specimens are obtained from lung tumor surgery or biopsy or malignant pleural effusion are used to grow organoids. Then organoids are used for drug sensitivity tests to obtain the sensitivity to drugs. Patients will receive a relatively sensitive antitumor regimen based on the test results.
89003171|NCT05669586|No Intervention|Physician-decided Antitumor therapy|According to the National Comprehensive Cancer Network's (NCCN) Guidelines for lung Cancer, physicians will determine antitumor protocols or case report. They're also not sure what the drug susceptibility test says.
89003172|NCT05665504||High-Risk for Recurrence That Accept Adjuvant Chemotherapy|Participants whose gene assay show that they are at a higher risk of recurrence will be offered to receive postoperative chemotherapy. If participants also have a special mutation on the tumor (EGFR), investigators will recommend that the participant also receive the oral anti-EGFR pill (TagrissoTM) daily for 3 years after completing the chemotherapy. The administration of standard postoperative chemotherapy is not considered part of the study. Only the results of the DetermaRx test is a part of this study.
89003173|NCT05665504||High-Risk for Recurrence That Decline Adjuvant Chemotherapy|Participants whose gene assay show that they are at a higher risk of recurrence will be offered to receive postoperative chemotherapy. If participant declines, investigators will followup with participants periodically every 6-12 months over 5 years.
89003174|NCT05665504||Low-Risk for Recurrence|Participants whose gene assay show that they are at a lower risk of recurrence will not be offered additional treatment after resection. Investigators will followup with participants periodically every 6-12 months over 5 years.
89003175|NCT05661552|Experimental|Evolocumab treatment group|The experimental group will receive Rosuvastatin 5 mg, Ezetimibe 10 mg, and evolocumab by subcutaneous injection. Evolocuumab will be administered at a dose of 140 mg once during the study period.
89003176|NCT05661552|Active Comparator|Group not receiving evolocumab|The control group receives Rosuvastatin 5 mg and Ezetimibe 10 mg.
89003177|NCT05654168||Professional dancers|Professional dancers with and without groin pain
89003178|NCT05651828|Active Comparator|A: Continuous Vismodegib|Participants will receive continuous 150 mg by mouth daily vismodegib as per commercially available package insert.
89003179|NCT05651828|Experimental|Arm B: Fixed Intermittent Vismodegib|Participants will receive intermittent 150 mg dose vismodegib by mouth with a 12 weeks on/8 weeks off regimen. Participants will take vismodegib for first 12 weeks, then off 8 weeks, and alternate in fixed cycles.
89003180|NCT05651828|Experimental|Arm C: Personalized Intermittent Vismodegib (Adaptive)|Participants will start with an 8-week run in period with vismodegib 150 mg dose by mouth daily. Participants will take vismodegib for the first 8 weeks, then start personalized dosing based on specific model.
89184594|NCT00721773|Experimental|RAS inhibitors, benazepril+valsartan|Benazepril will be started at 10 mg/day and will be up-titrated to 20 mg/day, and valsartan will be started at 80 mg/day and will be up-titrated to 160 mg/day according to BP control and tolerability.
89003181|NCT05651828|Experimental|Arm D: Personalized Intermittent Vismodegib (TGI model)|Participants will start with an 8-week run in period with vismodegib 150 mg dose by mouth daily. Participants will take vismodegib for the first 8 weeks, then start personalized dosing based on TGI model.
89184595|NCT00721773|Active Comparator|non-RAS inhibitors, control|Drug: antihypertensive agents, except ACE inhibitors and ARBs. Administration of antihypertensive agents will select as follows: CCB→β-blocker→α-blocker.
89184596|NCT02572869||segmental mandibulectomy and free fibular flap reconstruction|Patients who underwent segmental mandibulectomy and free fibular flap reconstruction at MSK between 1987 and 2014
89184597|NCT00718107||ALS|Subjects having either definite or probable ALS by El Escorial Criteria.
89184598|NCT04377945|Experimental|Part 1, JM-010 component Group A|Part 1, JM-010 component Group A
89184599|NCT04377945|Experimental|Part 1, JM-010 component Group B|Part 1, JM-010 component Group B
89184600|NCT04377945|Experimental|Part 1, JM-010 component Group C|Part 1, JM-010 component Group C
89184601|NCT04377945|Placebo Comparator|Part 1, Placebo Group|Part 1, Placebo Group
89184602|NCT04377945|Experimental|Part 2, JM-010 combination Group A|Part 2, JM-010 combination Group A
89184603|NCT04377945|Experimental|Part 2, JM-010 combination Group B|Part 2, JM-010 combination Group B
89184604|NCT04377945|Experimental|Part 2, JM-010 component Group C|Part 2, JM-010 component Group C
89184605|NCT04377945|Placebo Comparator|Part 2, Placebo Group|Part 2, Placebo Group
89184606|NCT00718185||A|Patients receiving sildenafil as standard of care
89184607|NCT04070469|Experimental|Patient reveiving amoxycillin|all patient included in this study
89184608|NCT00712647|Active Comparator|1|Asbestos-exposed participants and heavy smokers
89184609|NCT00712647|Placebo Comparator|2|Asbestos-exposed participants and heavy smokers
89184610|NCT00788957|Experimental|Part 1: Panitumumab + Rilotumumab|Participants received panitumumab 6 mg/kg and rilotumumab 10 mg/kg by intravenous infusion once every 2 weeks until progressive disease, intolerability, withdrawal, death or sponsor decision.
89184611|NCT00788957|Active Comparator|Part 2: Panitumumab Alone|Participants received panitumumab 6 mg/kg and placebo by intravenous infusion once every 2 weeks until progressive disease, intolerability, withdrawal, death or sponsor decision.
89184612|NCT00788957|Experimental|Part 2: Panitumumab + Rilotumumab|Participants received panitumumab 6 mg/kg and rilotumumab 10 mg/kg by intravenous infusion once every 2 weeks until progressive disease, intolerability, withdrawal, death or sponsor decision.
89184613|NCT00788957|Experimental|Part 2: Panitumumab + Ganitumab|Participants received panitumumab 6 mg/kg and ganitumab 12 mg/kg by intravenous infusion once every 2 weeks until progressive disease, intolerability, withdrawal, death or sponsor decision.
89184614|NCT04067817|Experimental|norepinephrine|Blood pressure is generally maintained at value not less than 80% of baseline during intraoperative period. If the blood pressure is within normal range and SVV is less than 9, patient will be given a continuous infusion of crystalloid solution. However, when blood pressure drops and SVV is greater than 13, a bolus of 200mL colloid will then be quickly administered. If the blood pressure doesn't recover back to normal range within 5 minutes after bolus, norepinephrine will be given through the central venous catheter. If SVV is between 9 and 13, a bolus of crystalloid at 8mL/kg/h will be administered
89184615|NCT04067817|Experimental|phenylephrine|Blood pressure is generally maintained at value not less than 80% of baseline during intraoperative period. If the blood pressure is within normal range and SVV is less than 9, patient will be given a continuous infusion of crystalloid solution. However, when blood pressure drops and SVV is greater than 13, a bolus of 200mL colloid will then be quickly administered. If the blood pressure doesn't recover back to normal range within 5 minutes after bolus, phenylephrine will be given through the central venous catheter. If SVV is between 9 and 13, a bolus of crystalloid at 8mL/kg/h will be administered.
89184616|NCT00740636|Experimental|75 mg/m2/day Temozolomide|75 mg/m2/day Temozolomide for 21 days (7 days off treatment). 28 day cycles.
89184617|NCT00740636|Experimental|200 mg/m2/day Temozolomide|200 mg/m2/day Temozolomide for 5 days (23 days off treatment). 28 day cycles.
89184618|NCT00718341|Active Comparator|1|
89184619|NCT00718341|Placebo Comparator|2|
89184620|NCT03973970||Test Arm 1- T-SPOT.TB assay|Test Arm 1: T-SPOT.TB test using density gradient isolation (Leucosep) For each subject recruited in the study, cells will be isolated using Leucosep Tubes and T-Cell Xtend reagent according to package insert. For each subject recruited in the study, the T-SPOT.TB assay will be run according to the assay package insert.
89184621|NCT03973970||Test Arm 2-QuantiFERON-TB Gold Plus assay|Test Arm 2: QuantiFERON-TB Gold Plus For each subject recruited in the study, the QuantiFERON-TB Gold Plus (QFT-Plus) assay will be run according to the assay package insert.
89184622|NCT00721929|Experimental|adrenal mass group|
89184623|NCT02595632||Healthy|Healthy subjects with no apparent lung disease and normal lung function testing.
89184624|NCT02572635|Experimental|Cohort 1|50 µg of PnuBioVax
89184625|NCT02572635|Experimental|Cohort 2|200 µg of PnuBioVax
89184626|NCT02572635|Experimental|Cohort 3|500 µg of PnuBioVax
89184627|NCT02572635|Placebo Comparator|Placebo|Placebo
89385214|NCT03607916|Experimental|Cohort 6 : HB Prilocaine 2%,(45-70mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2% will be administered at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). The dose range will be from 45 to 70mg.
89385215|NCT03607916|Experimental|Cohort 7 : HB Prilocaine 2%,(45-70mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 paturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2% will be adminitrated at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). The dose range will be from 45 to 70mg.
89385216|NCT03607916|Experimental|Cohort 8 : HB Prilocaïne 2%,(45-70mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2% will be administered at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). The dose range will be from 45 to 70mg.
89385217|NCT03607916|Experimental|Cohort 9 : HB Prilocaine 2%,(45-70mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2% will be administered at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). The dose range will be from 45 to 70mg.
88860619|NCT05029986|Experimental|All participants|This is a single-arm trial. All participants will receive (1) a control condition (socialization phase, 2 weeks) and (2) an intervention condition (speech breathing intervention, 4 weeks). Group sessions will take place once a week, and participants will be instructed to practice their exercises every day at home during the study duration.
89385218|NCT03607916|Experimental|Cohort 10 : HB Prilocaine 2%,(45-70mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2% will be administered at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). The dose range will be from 45 to 70mg.
89385219|NCT04709627||60 minute surgery|Patients completing at least 60 minutes of surgery
89385220|NCT01141712|Other|Autologous transplant|Patients will receive BCNU 300 mg/m^2 Day -6, Etoposide 100 mg/m^2 BID Days -5 to -2, Cytarabine 100 mg/m^2 BID Days -5 to -2, and Melphalan 140 mg/m^2 Day -1 followed by autologous HCT.
89385221|NCT02034656||imatinib resistance|All mutation data from CML and Ph positive ALL patients who developed imatinib resistance during the year 2001-2009
89385222|NCT00145145|Experimental|MAGE-3.A1 Peptide mixed with CpG 7909|Patients were vaccinated every two weeks on six occasions. On each vaccination day, the MAGE-3.A1 peptide (300 mcg) mixed with CpG 7909 (5 mg) was administered twice intradermally (10% of the dose each) and twice subcutaneously (40% of the dose each) in the arms and thighs.
89385223|NCT03607448||Diabetes Mellitus Type 1 and Type 2|Subjects will wear the Abbott Sensor Based Glucose Monitoring Systems and expected to perform at least 8 capillary BG test per day. Site Staff will determine when subject will undergo either a hypoglycemia induction or a hyperglycemia induction. Study staff will perform IV blood draw to obtain blood plasma for YSI sampling every 15 min when glucose as measured by YSI is above 70mg/dL and below 240 mg/dL.
89385224|NCT02034890|Experimental|hyaluronic acid|intravesical instillation of 40 mg of hyaluronic acid at 6 specific time points: 1,2,3 and 4 weeks postoperatively 2 and 3 months postoperatively
88860620|NCT01893294|Experimental|Treatment (gemcitabine hydrochloride)|Patients receive gemcitabine hydrochloride IT on day 1. Within 33 hours, patients receive standard chemotherapy comprising fluorouracil IV on days 1, 8, 15, 22, 29, and 36 and undergo standard radiation therapy 5 days a week for 6 weeks.
88860621|NCT01458054|Experimental|Treatment A|GSK2336805 60mg x 1 dose (fasted) [Reference Treatment]
88860622|NCT01458054|Experimental|Treatment B|Omeprazole 40 mg q24h x 4 days (fed)
88860623|NCT01458054|Experimental|Treatment C|GSK2336805 60 mg x 1 dose and Omeprazole 40 mg on Day 1 (fasted) [Test Treatment]
88860624|NCT01458054|Experimental|Treatment D|GSK2336805 30mg x 1 dose (fasted) [Reference Treatment]
89385225|NCT02034890|No Intervention|retrospective control patients|retrospective control patients
88860625|NCT01458054|Experimental|Treatment E|Ritonavir 100mg q12h x 4 days (fed)
88860626|NCT01458054|Experimental|Treatment F|GSK2336805 30 mg x 1 dose (fasted) and ritonavir 100mg q12h on Day 1 (fasted) [Test Treatment]
88860627|NCT01458054|Experimental|Treatment G|Ritonavir 100mg q12h x 1 day
89003182|NCT05649969|Experimental|STRONG Program|the STRONG program includes consultations with a Moffitt dietician, logging intake of food daily into a food diary with a Fitbit smartphone app, and completing questionnaires.
89003183|NCT05642676|Experimental|Interventions clinics to be remodeled|
89003184|NCT05626530|Other|single arm|This is an open label single arm study
89003185|NCT05624190|Experimental|TNK group|Patients of this group will receive IA rhTNK-tPA plus Best Medical Management (BMM) after successful mechanical thrombectomy (MT) recanalization
89003186|NCT05624190|Active Comparator|control group|Patients of this group will receive Best Medical Management (BMM) alone after successful mechanical thrombectomy (MT) recanalization
89385226|NCT02015351|Experimental|Anti-VEGF and Immunosuppression|"Bevacizumab: Dosage 1.25mg/0.05ml; Frequency monthly injections; Duration at least 3 months.~Immunosuppression: cyclosporine and/or azathioprine"
89385227|NCT03604796|Active Comparator|Continuous IV Acetaminophen|Intravenous Infusion
89385228|NCT03604796|Active Comparator|Rectal Acetaminophen|Rectal Solution
89385229|NCT03607292|Experimental|Group A|Anterior sciatic nerve block
89385230|NCT03607292|Experimental|Group P|Posterior sciatic nerve block
89385231|NCT05134259|Active Comparator|Study Group|The children in this group will receive traditional treatment of hemiplegic CP including medical treatment and physiotherapy in addition to repetitive transcranial magnetic stimulation sessions for 4 weeks.
89385232|NCT05134259|No Intervention|Control Group|The children in this group will receive traditional treatment of hemiplegic CP including medical treatment and physiotherapy for 4 weeks.
89385233|NCT03604484|Active Comparator|Tricuspid annuloplasty|Patient treated with tricuspid annuloplasty at the moment of the mitral valve surgery
89385234|NCT03604484|No Intervention|No Tricuspid annuloplasty|Control patients
89385235|NCT02311049|Experimental|Arm 1|16 fractions à rato of 4 fractions a week over 4 weeks
89385236|NCT02311049|Experimental|Arm 2|25 fractions à rato of 5 fractions a week over 5 weeks
88860628|NCT05028270||Balloon technology|The femoral artery is introduced after the patient is fully anesthetized. First, the 5F-VETERBRAL is introduced under the guidance of the guidance. The common carotid artery and internal carotid artery will be received laterally. After whole-body heparinization, micro-catheter and guide wire technology are used. In the figure below, the proximal end of the 4mm super-form occlusion ball is marked far away from the eye, plugged and sealed, and the guide tube is pushed around in the internal carotid artery. When the occlusion is finished, the internal carotid artery and the ophthalmic artery are not accompanied far away, and the plot is good. The guiding catheter drives the injection of drugs, topotecar, and topotecan for 5 minutes (the suction balloon is opened and blocked, and the infusion is continuous) to complete the infusion.
89385237|NCT02237534|Active Comparator|Calcium carbonate|Start at a dose of 1,500 mg/day, and adjust it to lower serum phosphate concentration <4.5 mg/dL. Maximum dose is 3,000 mg/day.
89385238|NCT02237534|Experimental|Lanthanum carbonate|Start at a dose of 750 mg/day, and adjust it to lower serum phosphate concentration <4.5 mg/dL. Maximum dose is 1,500 mg/day. For patients with calcium carbonate at inclusion, calcium carbonate will be replaced with lanthanum carbonate of 750 mg/day.
89385239|NCT03607214|Experimental|Positive Expectations Group|Participants receive a nasal spray that is in fact a placebo. However, they are told that it protects from experiencing negative emotions and generally improves their mood. They take the nasal spay in the laboratory and on seven consecutive days. Participants watch two film sequences that are supposed to induce sadness.
89385240|NCT03607214|No Intervention|No-treatment control group|Participants do not receive the nasal spray. Participants watch two film sequences that are supposed to induce sadness.
89385241|NCT03602456||Kentucky HEALTH|This group will consist of 90% of eligible beneficiaries who will receive Kentucky HEALTH benefits throughout the 5-year demonstration waiver.
89385242|NCT03602456||Traditional Medicaid (control)|This group will consist of 10% of eligible beneficiaries who will continue receiving traditional Medicaid benefits as in place before July 1, 2018 throughout the 5-year demonstration waiver.
89385243|NCT03607136|Experimental|exercise training|Participants in the exercise training group received a 12-week exercise training.
88860629|NCT05028270||Microcatheter technology|The tip of the Marathon microcatheter is placed at the opening of the ophthalmic artery. After the contrast agent is confirmed by hand, the chemotherapeutic drugs The femoral artery is introduced after the patient is fully anesthetized. First, the 5F-VETERBRAL is introduced under the guidance of the guidance. Maphalan, carboplatin, and topotecan are injected sequentially for 30 minutes. Make sure that the tip position of the catheter is not maintained during the injection process. verb: move. After the operation is completed, the blocking balloon is pulled out under the guidance of the guide wire, the arterial sheath is removed, and the femoral artery puncture point is pressed to stop bleeding.
88860630|NCT01458444|Active Comparator|BIPAP|Non invasive ventilation (VNI) by BIPAP® vision
88860631|NCT01458444|Experimental|OPTIFLOW|OPTIFLOW system
88860632|NCT05029518|Experimental|Treatment A: SMP-100 dissolved in water administered under fasting conditions|12 subjects，For Treatment A, SMP-100 will be dissolved in a total of 240 mL of water and administered orally to each subjects, and a hand and mouth check will be performed to ensure consumption of the medication. Subjects will be required not to wear dentures or mouth piercing at the time of dosing. No food will be allowed from at least 10 hours before dosing until at least 4 hours post-dose.
88860633|NCT05029518|Experimental|Treatment B: SMP-100 tablets administered under fasting conditions|12 subjects，For Treatment B, SMP-100 tablets will be administered to each subject with 240 mL of water and a hand and mouth check will be performed to ensure consumption of the medication. The dosing procedure must be completed within 2 minutes. In the event that subjects cannot swallow all tablets with 240 mL of water, additional water may be allowed up to a maximum total volume of 400 mL. No food will be allowed from at least 10 hours before dosing until at least 4 hours post-dose.
89003187|NCT05604209|Experimental|C62|C62 administered at Day 0 and M4 on Day 28
89003188|NCT05604209|Experimental|C1C62|C1C62 administered at Day 0 and M3M4 on Day 28
89003189|NCT05604209|Placebo Comparator|Placebo|Placebo administered on Day 0 and Day 28
89003190|NCT05603312|Experimental|AAV-GAD Dose 1 treatment group|Eligible participants will receive bilateral infusion of AAV-GAD Dose 1 into the STN
89003191|NCT05603312|Experimental|AAV-GAD Dose 2 treatment group|Eligible participants will receive bilateral infusion of AAV-GAD Dose 2 into the STN
89385244|NCT03607136|No Intervention|control|Participants in the control group did not receive any specific training programs instead of maintaining their usual activities of daily living.
89385245|NCT03604328|Experimental|PA5108|PA5108 ocular implant (study eye) and topical prostaglandin analogue therapy (non-study eye)
89003192|NCT05603312|Sham Comparator|Sham treatment group|Eligible participants will undergo a sham surgical procedure
89385246|NCT03606902|Active Comparator|(Group f):|"Intervention:~Procedure: Epidural catheter insertion~Drug: Epidural 15 ml of 0.0625%bupivacaine with 1 µg /Kg Fentanyl ,then continuous epidural infusion of fixed volume 10 ml of 0.0625% bupivacaine +1 µg/Kg/h Fentanyl for the next 6 hours ."
89385247|NCT03606902|Active Comparator|(Group Lf):|"Intervention:~Procedure:Epidural catheter insertion~Drug: Epidural injection 15 ml of 0.0625%bupivacaine with 1 µg/Kg Fentanyl initial bolus, then 1st hour continuous IV infusion of 10ml of 0.0625%bupivacaine +1 µg/Kg/h Fentanyl ,2nd hour 10ml of 0.0625%bupivacaine + 0.5 µg/Kg/h Fentanyl , then next 4 hours10 ml of 0.0625%bupivacaine with + 0.25 µ g/Kg/h Fentanyl."
89535186|NCT04434339|Experimental|group 1|"ESP block group ,Patients received preoperative US guided ESP block on BOTH sides to be operated upon 30 minutes before being transferred to the OR"
89003193|NCT05603000|No Intervention|Waitlist (delayed intervention)|No treatment will be administered to participants in this arm until after the 4-month follow-up in-lab assessment is completed.
89003194|NCT05603000|Experimental|EFFT intervention|Treatment (6-week group Emotion Focused Family Therapy) will be administered to participants in this arm.
89003195|NCT05599646|Experimental|traditional pedometer group|
89003196|NCT05599646|Experimental|gamified smartphone pedometer group|
89003197|NCT05599646|No Intervention|control group|
89003198|NCT05599503|Experimental|SimpleC Wellness Platform with Social Robot Interaction|Participants in the Social Robot condition will have access to personal media, reminders, televisit, messaging, news, and wellness programs in their own room via the Companion. Participants will also will have access to social and health reminders as well as social and wellness programs facilitated by a virtual robot agent in their own room via the Companion, social and health reminders as well as social and wellness programs facilitated by a physical robot in the community area and a staff member (likely the activity director).
89003199|NCT05599503|Active Comparator|SimpleC Wellness Platform|Participants in the SimpleC Wellness Platform condition will have access to personal media, reminders, televisit, messaging, news, and wellness programs in their own room via the Companion.
89003200|NCT05597020|Experimental|50 mg daridorexant|Daridorexant will be taken orally, once daily in the evening within approximately 30 min before going to bed.
89003201|NCT05597020|Placebo Comparator|Placebo|Matching placebo will be taken orally, once daily in the evening within approximately 30 min before going to bed.
89385248|NCT03604250|Experimental|Lifestyle plus prebiotics|Research participants will be asked to wear health monitoring devices, including a continuous glucose monitoring device and an Apple watch. They may be prompted to perform lifestyle modifications aimed at better understanding their health parameters, based on the results obtained from the wearable devices and other tests. During the last 3 weeks of the study, research participants may be asked to take a personalized prebiotic supplement, up to once/day.
89385249|NCT03604094||Group I|0-1 month old newborns
89385250|NCT03604094||Group II|1 month-2 year-old pediatric patients
89003205|NCT05583825|Experimental|Rebozo Applied Group|"Those who are in the latent phase (cervical opening 1-4 cm) will be provided to sign the informed consent form by making a statement regarding the research. The Personal Information Form will be filled and the anxiety levels of women with a cervical dilation of 3-4 cm will be determined with the State Anxiety Inventory and the pain level will be determined with the Visual Analog Scale, and rebozo techniques will be applied two or three times. After the application, the level of pain will be re-evaluated.~When the cervical dilation is 6-7 cm (active phase), the pain level will be determined with the Visual Analog Scale, Rebozo Techniques will be applied two or three times and the pain level will be re-evaluated after the application.~When the cervical opening is 8-9 cm (transition phase), the pain level will be determined, Rebozo Techniques will be applied two or three times, and anxiety and pain levels will be evaluated after the application."
89003206|NCT05583825|No Intervention|Standard Care Group|"Pregnant women who will not be subjected to any application other than routine hospital applications, who are in the latent phase (cervical opening 1-4 cm), will be provided to sign the informed consent form by making a statement about the research. Afterwards, by filling out the Personal Information Form, the anxiety levels of women with a cervical dilation of 3-4 cm will be determined with the State Anxiety Inventory, and their pain levels will be determined with the Visual Analog Scale.~When the cervical opening is 6-7 cm (active phase), the level of pain will be determined.~When the cervical dilation is 8-9 cm (transition phase), anxiety and pain levels will be determined.~The Travay Follow-up Form will be used in the period from the admission of women to labor until the end of the action.~Evaluation of birth experience will be done in the fourth stage of labor using the birth experience scale."
89003207|NCT05582187|Experimental|Cohort 1: Fosmanogepix participants with mild hepatic impairment|Participants with mild hepatic impairment will receive a single dose of fosmanogepix, administered orally as 1 fosmanogepix tablet under fasted conditions.
89184628|NCT02603159|Experimental|Capecitabine-5 weeks-radiotherapy|Capecitabine 5 weeks : 625mg/m2, bid d1-5; q1w, po,5 weeks in total, radiotherapy： 50Gy ，2 Gy/d，5d/w.
89184629|NCT02603159|Active Comparator|Capecitabine-10 weeks-radiotherapy|Capecitabine 10 weeks : 625mg/m2, bid d1-5; q1w, po,10 weeks in total, radiotherapy： 50Gy ，2 Gy/d，5d/w.
89385251|NCT03602378||Parents of children with disability|parents of children with developmental disabilities (Down syndrome, autism spectrum disorder, pervasive developmental disorder, cerebral palsy), age 20-50, salivary cortisol, Holter Medilog AR12 Plus, Polar V800, AGE reader
89385252|NCT03602378||Parents of children with chronic disease|parents of children chronic disease (diabetes mellitus type 1, epilepsy, asthma), age 20-50, salivary cortisol, Holter Medilog AR12 Plus, Polar V800, AGE reader
89385253|NCT03602378||Parents of healthy children|parents of healthy children, age 20-50, salivary cortisol, Holter Medilog AR12 Plus, Polar V800, AGE reader
89385254|NCT03602300|Active Comparator|Ravidasvir reference formulation|Ravidasvir 200 mg oral single dose manufactured by EEPI
89385255|NCT03602300|Experimental|Ravidasvir test formulation|Ravidasvir 200 mg oral single dose manufactured by Doppel
89385256|NCT03606824|Placebo Comparator|Pivastatin and placebo|After randomization, patients in Pivastatin + placebo group will receive pitavastatin and placebo.
89385257|NCT03606824|Experimental|Pivastatin and LT-4|After randomization, patients in combination group will receive pitavastatin as the lipid-lowering therapy and take levothyroxine as the thyroid hormone supplement.
89385258|NCT03602222|Active Comparator|In-person training LGBT mental health|In-person training LGBT mental health: Participants randomized to the in-person condition will receive training in LGBT-affirmative mental health counseling face-to-face.
89385259|NCT03602222|Experimental|Mobile training LGBT mental health|Mobile training LGBT mental health: Participants randomized to the mobile training condition will receive training in LGBT-affirmative mental health counseling while on the web.
89385260|NCT03604016|Experimental|Besifovir dipivoxil+L-carnitine|Besifovir dipivoxil 150 mg and L-carnitine 330 mg
89385261|NCT03604016|Active Comparator|Tenofovir Alafenamide|Tenofovir Alafenamide 25mg
89385262|NCT03219333|Experimental|Enfortumab vedotin|Enfortumab vedotin on days 1, 8 and 15 every 28 days
89385263|NCT03168867|No Intervention|Standard Educational Control|Participants in the standard educational control group will be provided with standard care regarding type 1 diabetes management during their routine clinic visits as usual. The standard care will be consistent with diabetes education provided by each of the study sites.
89385264|NCT03168867|Experimental|The 3Ms Intervention + Standard Care|Parents will complete the first intervention session in the diabetes clinic immediately after baseline data collection and randomization. The subsequent two intervention sessions will also be conducted during regularly scheduled diabetes clinic visits.
89385265|NCT01064622|Active Comparator|Arm I (gemcitabine hydrochloride and placebo)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15 and placebo PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. At the time of disease progression, patients are unblinded and may crossover to arm II.
88860634|NCT05029518|Experimental|Treatment C: SMP-100 tablets administered under fed conditions|"12 subjects，For Treatment C, SMP-100 tablets will be administered to each subject with 240 mL of water and a hand and mouth check will be performed to ensure consumption of the medication. The dosing procedure must be completed within 2 minutes. In the event that subjects cannot swallow all tablets with 240 mL of water, additional water may be allowed up to a maximum total volume of 400 mL.~After a supervised fast of at least 10 hours, subjects will be served a high-fat, high-calorie meal of approximately 800 to 1000 calories (approximately 50% of total caloric content of the meal derived from fat). This test meal should derive approximately 150, 250, and 500-600 calories from protein, carbohydrate, and fat, respectively. Subjects should start the meal approximately 30 minutes prior to drug administration. Subjects will be required to completely eat the meal in 30 minutes or less. No food will be allowed until at least 4 hours post-dose."
88860635|NCT02784756|Other|Quantiferon-CMV assay|All patients will receive a CMV-immunity test at specific time points during the study. This is a single arm design
88860636|NCT01893450|Active Comparator|methimazole|methimazole 30 mg daily during one year
88860637|NCT01893450|Active Comparator|methimazole, bromocriptine|methimazole 30 mg daily during one year, bromocriptine 5 mg twice a day during one year
88860638|NCT01893450|Active Comparator|pentoxifylline|methimazol 30 mg daily and pentoxifylline 400 mg twice a day during one year
89184630|NCT02595554|Active Comparator|Concurrent chemoirradiation (CCRT)|Concurrent chemoirradiation
89385266|NCT01064622|Experimental|Arm II (gemcitabine hydrochloride and vismodegib)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15 and vismodegib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89385267|NCT01376895|Experimental|POWER|Power is a 3 session intervention delivered through the internet in real time by a trained health educator. It focuses on reducing HIV risk. Each session last from 1 to 2 hours.
89385268|NCT01376895|Active Comparator|Power Health|Power Health is a 1 session general health promotion program designed to be delivered via the internet in real time by a trained health educator. The sessions focus on healthy life styles, cardiovascular health, and prostate health. Participants also receive information regarding safe sex.
89385269|NCT01380405|No Intervention|without health education|the normal practices without specific intervention
89385270|NCT01380405|Experimental|individual health education|"The study intervention is an individual education in the correct use of inhalers and it will be carried out in so-called inhalation workshops. The room in which the inhalation workshop will be located has to meet the necessary comfort conditions for the patient to feel relaxed and be able to carry out learning. The lesson included inhalation devices, explanatory leaflets"
89535187|NCT04434339|Experimental|group 2|"TAB group ,Patients received bilateral lower TAB 30 min before being transferred to the OR"
89535188|NCT04434339|No Intervention|group 3|"the control group, Patients will not receive any block."
89385271|NCT01380405|Experimental|health education group|"The study intervention is education in group in the correct use of inhalers and it will be carried out in so-called inhalation workshops. The room in which the inhalation workshop will be located has to meet the necessary comfort conditions for the patient to feel relaxed and be able to carry out learning. In addition to the necessary furniture and teaching material that will be required (slide projector, over-head-projector, projection screen, video, etc.), the physical space given over to this purpose should consist of an area in which material can be left which will be used to complete the teaching and patient information (inhalation devices, explanatory leaflets, small monographs, slides, etc.)."
89385272|NCT04850391|Active Comparator|Lean-overweight|BMI 18.5 - 30 kg/m2
89385273|NCT04850391|Active Comparator|Obese|BMI > 30 kg/m2
89385274|NCT04850391|Active Comparator|Obese OSA|OSAS patients with BMI > 30 kg/m2
89385275|NCT04163718|Experimental|Treatment with Umbralisib|
89385276|NCT04171635||Patients with transfusional iron overload|The subject population of patients with transfusional iron overload awaiting liver transplant has been chosen because of the clinical indication for MRI examination every three months and the availability of liver explants for analysis after transplant. Explants will receive QSM or R2* MRI to provide a quantitative biophysical connection to liver iron concentration (LIC).
89385277|NCT04171635||Healthy subjects|Healthy control subjects over the age of 21 with no known hematological or liver disease and no contraindications for MRI
89385278|NCT01378689|Experimental|Online video|Participants in this arm are shown a brief video (~5 minutes) after ordering a refill for their glucocorticoid use. The video includes real patients telling their own story about the possible side effects of prolonged use of glucocorticoids.
89385279|NCT01378689|No Intervention|No video|
89385280|NCT03630549|Active Comparator|Standard of Care|"Offer of home-based same-day ART initiation~Clinic-based ART visit/refill Who: Nurse Where: Nurse-led health facility When: Follow-up interval of max. 3 months What: TB screening, Screening for other opportunistic infections, Screening for ART-related toxicities, adherence assessment, assessment whether patient visited any medical facility since last appointment, addressing basic psychosocial problems, ART (+CTX/IPT) dispensing~No SMS intervention"
89385281|NCT03630549|Experimental|Village-based ART refill|"Offer of home-based same-day ART initiation~Offer of Village-based ART visit/refill Who: VHW Where: At VHW's home* When: Follow-up interval of max. 3 months What: TB screening, Screening for other opportunistic infections, Screening for ART-related toxicities, adherence assessment, assessment whether patient visited any medical facility since last appointment, addressing basic psychosocial problems, ART (+CTX/IPT) dispensing~*Except at 6 and 12 months follow-up: visit at health facility for laboratory assessment (viral load)~Offer of Individually customized SMS~Monthly reminder SMS: to pick up ART~SMS communicating VL result"
89385282|NCT04153539|Experimental|Walking along a busy road|Participants in this group will be asked to walk along a busy road for 4.5 hours.
89385283|NCT04153539|Active Comparator|Walking in a traffic-free park|Participants in this group will be asked to walk in a traffic-free park for 4.5 hours.
89385284|NCT01063764|Experimental|Levetiracetam|Open-label, single-arm
89385285|NCT04117815||study group|"Patients with breast or gynecological cancer planning to undergo chemotherapy Chemotherapy can be neoadjuvant, adjuvant or palliative Up to two lines of chemotherapy are allowed. Adjuvant therapy counts as one line.~Chemotherapy regime is associated with alopecia. Chemotherapy must be planned for at least 4 cycles of taxane or antracycline- based chemotherapy regimen No alopecia of any reason (up-front) No overt cognitive impairment and fluent in German Written informed consent Age 18 and older"
89385286|NCT04117815||reference group|"For the purpose of comparison, a reference sample will be included in the study applying to the following inclusion criteria:~Patients with breast or gynecological cancer planning to undergo chemotherapy Chemotherapy can be neoadjuvant, adjuvant or palliative Up to two lines of chemotherapy are allowed. Adjuvant therapy counts as one line.~Chemotherapy regime is associated with alopecia. Chemotherapy must be planned for at least 4 cycles of taxane or antracycline- based chemotherapy regimen Refuse to undergo scalp cooling Patients who have been excluded for the study group for the reason of migraine Written informed consent Age 18 and older~Patients from the reference group complete the same survey as the study group. Group comparisons will be adjusted for baseline body image and reasons for refusal."
89385287|NCT03073629|Active Comparator|Clinical Pathway Cohort|Patients with isolated RV failure will be evaluated and managed in a specialized cardiovascular clinic.
89385288|NCT03073629|No Intervention|Standard Care|Patients with isolated RV failure will receive standard care and follow up.
89385289|NCT03652350|Experimental|Use CT-guided microwave ablation in Ground Glass Nodules ≤ 3cm|Patients with Ground Glass Nodules ≤ 3cm were treated with CT-guided microwave ablation
89385290|NCT02880189|Other|Single|All subjects will be receiving the Orbera Intragastric Balloon and will be undergoing Endoscopic Ultrasound guided core liver biopsy.
89385291|NCT04053972|Experimental|treatment group|adjuvant lenvatinib
89385292|NCT04053972|No Intervention|control group|no intervention
89385293|NCT01380249|Experimental|PDM08|To assess the tolerability and safety of increasing multiple doses administration of PDM08: 560 μg, 1.12 mg, 2.24 mg, 3.5 mg and 14 mg, 28 mg and 56 mg administered twice a week for four weeks in patients with advanced solid tumours for which there is no standard therapy or the patient is refractory to it.
89385294|NCT04054518|Experimental|Durvalumab|1500 mg durvalumab (MEDI4736) via IV infusion Q4W <<for up to a maximum of 12 months (up to 13 doses/cycles) with the last administration on week 48>> or <<until confirmed disease progression>> unless there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met.
88860639|NCT05027100|Experimental|exploratory research|Anlotinib 10mg QD with 2W stop 1W tiselizumab injection 200mg Q3W Irinotecan (2 cycles) 100mg/m2,d1,d8,Q3W
88860640|NCT02374944|Experimental|Hardware Removal|Removal of hardware at 6 months.
88860641|NCT02374944|No Intervention|Hardware Retention|Retention of hardware at 6 months
88860642|NCT02887794|Experimental|30 patients with schizophrenia|Measure the correlation between the score on the scale psychometric AHRS (Auditory Hallucination Rating Scale) to measure HAV and performance scores discrimination test psychoacoustic Tone Matching Task in subjects suffering from schizophrenia and HAV.
89535189|NCT04493801||with nasoseptal flap|patient who undergo a pituitary gland surgery with nasoseptal flap
89385295|NCT01378611|Placebo Comparator|active control group|The active control group is stimulated with: Output current 0.25 milliampere, Pulse width 0.1 milliseconds, Frequency 1 Hz, Duty cycle: 14 sec on 60 min off (duty cycle <0.5%)
89385296|NCT01378611|Experimental|treatment group|The high stimulation group is stimulated with output current 0.25 milliampere, Pulse width 0.5 milliseconds, Frequency 30 Hz, Duty cycle: 30 sec on 5 min off in the treatment group the current was stepwise increased with two week intervals to the maximally tolerated output current (maximum 1.75 mA).
89385297|NCT03652896|Experimental|anatomical liver resection|resect the tumor located liver segment or lobe
89385298|NCT03652896|Experimental|resection margin based liver resection|non-anatomical liver resection, but insure adequate resection margin
89385299|NCT04113330||Study Group|Participant vaccinated with CYD Dengue Vaccine and classified as seronegative or undetermined at baseline in previous dengue studies in Colombia
89385300|NCT04565847|Active Comparator|Healthy Control - Active Arm|Healthy Controls Mannitol-Induced Cough Challenges on Visit 2 to determine elligibility (cough response). Mannitol delivered via inhalation. Dosage: 0, 5, 10, 20, 40 mg capsules. 80 and 160 mg doses delivered with two and four capsules, respectively. Nebulized salbutamol (5mg/mL) given prior to Mannitol-Induced Cough Challenges on Visit 3 or 4.
89385301|NCT04565847|Placebo Comparator|Healthy control - Placebo Arm|Healthy Controls Mannitol-Induced Cough Challenges on Visit 2 to determine elligibility (cough response). Mannitol delivered via inhalation. Dosage: 0, 5, 10, 20, 40 mg capsules. 80 and 160 mg doses delivered with two and four capsules, respectively. Nebulized 0.9% Saline given prior to Mannitol-Induced Cough Challenges on Visit 3 or 4.
89385302|NCT04103073||Study group|The patient with OSAS 35-70 years of age, clinically stabile, symptoms such as snoring, breathing cessations, and daytime sleepiness, and polysomnographic evidence consistent with mild (5<apnea hypopnea index (AHI)< 15) to moderate (16 < AHI < 30) OSAS.
89385303|NCT03075891|Experimental|Ivermectin 1% cream + Doxycycline 40 mg MR capsules|
89385304|NCT03075891|Placebo Comparator|Ivermectin 1% cream + Oral placebo capsules|
89385305|NCT02013167|Experimental|Blinatumomab|"Participants received blinatumomab by continuous intravenous infusion (CIVI) over 4 weeks followed by a 2 week treatment-free interval for 2 induction cycles. Participants who achieved a bone marrow response, complete remission, or complete remission with partial or incomplete hematologic recovery (CR/CRh*/CRi) within 2 induction cycles of treatment could receive up to 3 additional consolidation cycles of blinatumomab.~Participants who received 2 induction and up to 3 consolidation cycles of therapy and continued to have a bone marrow response or CR/CRh*/CRi could continue to receive blinatumomab for an additional 12 months (4 cycles), where 1 cycle consisted of 4 weeks of CIVI followed by an 8-week treatment-free period.~The initial dose of blinatumomab was 9 μg/day for the first 7 days of treatment, increased to 28 μg/day starting on day 8 through day 29 and for all subsequent cycles."
89385306|NCT02013167|Active Comparator|Standard of Care Chemotherapy|"Participants received one of four prespecified, investigator-chosen chemotherapy regimens for 2 induction cycles. Participants who achieved a bone marrow response, CR/CRh*/CRi within 2 induction cycles of treatment could receive up to 3 additional consolidation cycles of SOC chemotherapy.~Participants who received 2 induction and up to 3 consolidation cycles of therapy and continued to have a bone marrow response or CR/CRh*/CRi could continue to receive SOC therapy for an additional 12 months."
89385307|NCT03630237||Intensive care population|All patients admitted to any of the three adult intensive care units (general, cardiac & neurosciences) at a large teaching hospital. These patients will have a high sensitivity troponin added onto biochemistry samples requested by the clinical team.
89385308|NCT03805737|Experimental|Indoor Daylight PDT Therapy|Ameluz will be applied to skin. This will be followed by a 30-minute incubation period. Subsequently, you will be exposed to natural sunlight through a window for 2 hours. Post-treatment assessments will be performed and you will be given instruction on appropriate sun protection methods.
89385309|NCT03805737|Active Comparator|FDA Approved Standard Light Therapy Treatment|Ameluz will be applied to skin. This will be followed by a 30-minute incubation period. Subsequently, you will receive Red Light Treatment for 10 minutes. Post-treatment assessments will be performed and you will be given instruction on appropriate sun protection methods.
88860643|NCT05027568|Experimental|Drug: IOA-289 single dose|Single oral dose of IOA-289 liquid filled capsule formulation - ascending doses
88860644|NCT05027568|Placebo Comparator|Placebo single dose|Single oral dose of placebo liquid filled caspule formulation
89385310|NCT01378533|Experimental|AC-T（dose-dense）|AC-T(dose-dense) EPI（Pharmorubicin） CTX（cyclophosphamide） PTX（Paclitaxel） G-CSF
89385311|NCT01378533|Experimental|chemotherapy:PC|PTX（Paclitaxel） CBP（carboplatin）
89385312|NCT02630199|Experimental|AZD6738 + paclitaxel|The PART A will be in combination with paclitaxel; the starting dose of 40 mg AZD6738 OD will be escalated to reach a maximum tolerated dose in patients with advanced solid malignancies, as defined by dose-limiting toxicity. The PART B will be an independent parallel PK expansion cohort with cycle 0 of AZD6738 on D1, D8~D21 monotherapy followed by combination therapy with weekly paclitaxel from cycle 1.
88860645|NCT02775162|Experimental|Normothermic Machine Perfusion (NMP)|Following the routine retrieval procedure of the liver, it will be placed on the OrganOx metra for Normothermic Machine Perfusion (NMP) for transport per the Investigational Plan and the Instructions For Use.
88860646|NCT02775162|Other|Standard of Care (Ice)|Following the routine retrieval procedure of the liver, it will be placed in ice-cold perfusion solution within an ice box for transport as dictated by logistics and local policy.
88860647|NCT01458600|Active Comparator|diclofenac|12 months treatment with diclofenac 50 mg 1x2 in addition to regular treatment for thyrotoxicosis.
88860648|NCT01458600|Other|without diclofenac|12 months treatment without diclofenac in addition to regular treatment for thyrotoxicosis.
88860649|NCT01893528|Experimental|REGN2009 dose level 1|Cohort A - REGN2009 or placebo; Cohort B - Patients on existing (non-exclusionary) medications + (REGN2009 or placebo)
88860650|NCT01893528|Experimental|REGN2009 dose level 2|Cohort C - REGN2009 or placebo; Cohort D - Patients on existing (non-exclusionary) medications + (REGN2009 or placebo)
88860651|NCT01893528|Experimental|REGN2009 dose level 3|Cohort E - REGN2009 or placebo; Cohort F - Patients on existing (non-exclusionary) medications + (REGN2009 or placebo)
89385313|NCT01378455|Experimental|ICHTP group|In ICHTP (interactive computerized handwriting training program) group, they received the training of visual-perception .visual-motor integration skill of children and modulate muscle strength of grasp through ICHTP software
89385314|NCT01378455|Active Comparator|THTP group|The THTP (traditional handwriting training program)group ,they received the training of paper-pencil activities with visual-perception and visual-motor integration skills
89385315|NCT03759951|Experimental|Control|No intervention. Participated only in measurements at baseline, at 6 months and at 12 months.
89385316|NCT03759951|Experimental|DoIT-1|Participated in a supervised 1-year workout exercise training program once per week and in measurements at baseline, at 6 months and at 12 months.
89385317|NCT03759951|Experimental|DoIT-2|Participated in a supervised 1-year workout exercise training program twice per week and in measurements at baseline, at 6 months and at 12 months.
89385318|NCT03759951|Experimental|DoIT-3|Participated in a supervised 1-year workout exercise training program thrice per week and in measurements at baseline, at 6 months and at 12 months.
89385319|NCT04563065|Experimental|Exercise group|"The design of the physical exercise program will be supported by the Canadian and Spanish Guidelines for exercise throughout pregnancy (11,13) and published by Barakat model (10).~Frequency: The program will consist of three weekly sessions. The duration of every session will be 55-60 minutes. The intensity of the workload will be 55-60% of the maximum maternal Heart Rate, and controlled by Polar monitor (FT60). Likewise, once a week, the Borg Scale of Perceived Effort will be administered to participants, in order to have a more reliable assessment of the intensity of the activities, 12-14 (moderate; out of a 20 point scale) will be the level used.~The minimum adherence required for the participants will be 80% of the total sessions (approximately 80 sessions)."
89385320|NCT04563065|No Intervention|Control group|"Women randomly assigned to the control group (CG) received general advice from their health care provider about the positive effects of physical activity. Participants in the CG had their usual visits with health care providers during pregnancy, which were equal to the exercise group. Women were not discouraged from exercising on their own. However, women in the CG were asked about their exercise once each trimester using a Decision Algorithm (by telephone)."
89385321|NCT02588781|Experimental|Pemetrexed|Pemetrexed 500 mg/m2 IV Q 3 weeks
89385322|NCT01380171||Cleft lip/palate|Patients who have had surgical intervention for cleft lip/palate since 1998 at Children's Healthcare of Atlanta at the Center for Craniofacial Disorders
89385323|NCT01063062|Experimental|tocilizumab|Participants received an 8 mg/kg tocilizumab intravenous (IV) infusion once every 4 weeks for 24 weeks (6 infusions). Participants taking concomitant methotrexate (MTX) at Baseline remained on a stable dose as per standard of care at the Investigator's discretion.
89385324|NCT04418739|No Intervention|Control Arm|Standard intraoperative fluid regime
89385325|NCT04418739|Experimental|Treatment Arm|Intravenous human albumin 1g/kg at skin incision running at 100ml/hour
89385326|NCT01314989|Active Comparator|Cyproheptadine|Cross-over study
89003208|NCT05582187|Experimental|Cohort 2: Fosmanogepix Participants with moderate hepatic impairment|Participants with moderate hepatic impairment will receive a single dose of fosmanogepix, administered orally as 1 fosmanogepix tablet under fasted conditions.
89184631|NCT02595554|Experimental|NACT+Surgery|Neoadjuvant chemotherapy with Paclitaxel and Cisplatin (3 cycles), followed by radical surgery
88860652|NCT02771028|Experimental|Intervention group|Patients assigned to intervention group receive an 8-week EFT-program
88860653|NCT02771028|No Intervention|Control group|Patients assigned to control group are placed on a waitlist for a period of 8 weeks
89385327|NCT01314989|Placebo Comparator|Sugar pill|Cross-over study
88860654|NCT02764788|Experimental|Specific auriculotherapy|Auriculotherapy on specific points with needles
88860655|NCT02764788|Sham Comparator|Non-specific auriculotherapy|Auriculotherapy on non-specific auriculotherapy points with needles
89385328|NCT04483115|Experimental|TPN171H 2.5mg group|TPN171H 2.5mg tablet + Placebo 10mg tablet
88860656|NCT02764788|Placebo Comparator|Seed auriculotherapy|Auriculotherapy on non-specific auriculotherapy points with seeds
88860657|NCT04272528|Experimental|experimental group|Nurses provide uniform care to patients according to the quality standards.
88860658|NCT04272528|Placebo Comparator|control group|Nurses provide the routine care to patients.
88860659|NCT01458756||liver transplant patients|Population of adult patients awaiting liver transplant, status on the waiting list in the transplant center of University Hospital of Lille.
88860660|NCT02839278|Experimental|Immune-mediated inflammatory disease|Patients with an immune-mediated inflammatory disease. A blood sample is achieved at T0 (no follow-up).
88860661|NCT02832570|Experimental|Sildenafil|Single sildenafil oral intake (100 mg) approximately 2 hours before the treadmill test.
88860662|NCT02832570|Placebo Comparator|Placebo|Single placebo intake approximately 2 hours before the treadmill test.
88860663|NCT02832492||PNR+|Patients who will show pupil near response during PNR assessment.
88860664|NCT02832492||PNR-|Patients who will not show pupil near response during PNR assessment.
88860665|NCT02763150|Experimental|Lifestyle Intervention|Intervention group will receive a comprehensive, multicomponent weight loss intervention targeting diet, physical activity, and behavioral strategies.
88860666|NCT02763150|Active Comparator|Health Promotion|Health promotion group will receive education on healthy eating and activity before pregnancy.
89385329|NCT04483115|Experimental|TPN171H 5mg group|TPN171H 5mg tablet + Placebo 10mg tablet
89385330|NCT04483115|Experimental|TPN171H 10mg group|TPN171H 10mg tablet + Placebo 5mg tablet
89385331|NCT04483115|Placebo Comparator|Placebo group|Placebo 5mg tablet+ Placebo 10mg tablet
89385332|NCT04483115|Active Comparator|tadalafil 20mg group|tadalafil tablet 20mg
89385333|NCT04483115|Active Comparator|tadalafil 40mg group|tadalafil tablets 20mg *2
89535190|NCT04493801||without nasoseptal flap|patient who undergo a pituitary gland surgery without nasoseptal flap
89003209|NCT05582187|Experimental|Cohort 3: Fosmanogepix Participants with severe hepatic impairment|Participants with severe hepatic impairment will receive a single dose of fosmanogepix, administered orally as 1 fosmanogepix tablet under fasted conditions.
89003210|NCT05580653|Experimental|1) Beef then half beef and half pinto bean then pinto bean|
89535191|NCT03120169|Active Comparator|treadmill endurance training|
89003211|NCT05580653|Experimental|2) Half pinto bean and half beef then pinto bean then beef|
89003212|NCT05580653|Experimental|3) Pinto Bean then Beef then half pinto bean and half beef|
89003213|NCT05580653|Experimental|4) Egg then half Egg and half black bean then black bean|
89003214|NCT05580653|Experimental|5) Half egg and half black bean, then black bean then egg|
89003215|NCT05580653|Experimental|6) Black bean then egg then half black bean and half egg|
89003216|NCT05569174|Experimental|secukinumab|AIN457 300 mg subcutaneously (s.c.) for 12 weeks
89003217|NCT05569174|Placebo Comparator|Placebo|Placebo subcutaneously for 12 weeks
89003218|NCT05567406|Experimental|Belumosudil|Participants will receive belumosudil orally, once daily (QD) or twice daily (BID) if they are taking strong CYP3A4 inducers or proton pump inhibitors.
89003219|NCT05566795|Experimental|Arm #1|DAY101
89003220|NCT05566795|Active Comparator|Arm #2|"Investigator's choice of one of the following current standard of care for pediatric patients with low-grade gliomas:~Children's Oncology Group - Vincristine/Carboplatin (COG-V/C)~International Society for Paediatric Oncology - Low-Grade Glioma Vincristine/Carboplatin (SIOPe-LGG-V/C)~Vinblastine (VBL)"
89003221|NCT05565742|Experimental|LY3819469 Dose 1|Participants will receive LY3819469 subcutaneously (SC).
89003222|NCT05565742|Experimental|LY3819469 Dose 2|Participants will receive LY3819469 SC.
89003223|NCT05565742|Experimental|LY3819469 Dose 3|Participants will receive LY3819469 SC.
89535192|NCT03120169|Active Comparator|cycling endurance training|
89003224|NCT05565742|Experimental|LY3819469 Dose 4 + Placebo|Participants will receive LY3819469 SC and placebo.
89003225|NCT05565742|Placebo Comparator|Placebo|Participants will receive placebo.
89003226|NCT05564754|Active Comparator|Sedation, temperature device and high MAP|Continuous deep sedation for 36 hours Fever management with a feedback-controlled device if temperature above 37.7°C. A mean arterial pressure target of >85mmHg.
89003227|NCT05564754|Active Comparator|Sedation, no temperature device and high MAP|Continuous deep sedation for 36 hours. Fever management without a feedback-controlled device. A mean arterial pressure target of >85mmHg.
89003228|NCT05564754|Active Comparator|Sedation, temperature device and low MAP|Continuous deep sedation for 36 hours. Fever management with a feedback-controlled device if temperature above 37.7°C. A mean arterial pressure target of >65mmHg.
89003229|NCT05564754|Active Comparator|Sedation, no temperature device and low MAP|Continuous deep sedation for 36 hours. Fever management without a feedback-controlled device. A mean arterial pressure target of >65mmHg.
89003230|NCT05564754|Active Comparator|Minimal sedation, temperature device and high MAP|Minimal sedation (and early extubation if possible). Fever management with a feedback-controlled device if temperature above 37.7°C. A mean arterial pressure target of >85mmHg.
89003231|NCT05564754|Active Comparator|Minimal sedation, no temperature device and high MAP|Minimal sedation (and early extubation if possible). Fever management without a feedback-controlled device. A mean arterial pressure target of >65mmHg.
89003232|NCT05564754|Active Comparator|Minimal sedation, temperature device and low MAP|Minimal sedation (and early extubation if possible). Fever management with a feedback-controlled device if temperature above 37.7°C. A mean arterial pressure target of >65mmHg.
89003233|NCT05564754|Active Comparator|Minimal sedation, no temperature device and low MAP|Minimal sedation (and early extubation if possible). Fever management without a feedback-controlled device. A mean arterial pressure target of >65mmHg.
89003234|NCT05564390|Experimental|MM1OA-EA02 Regimen 1 (azacitidine, venetoclax)|"INDUCTION: Patients receive azacitidine IV or SC on days 1-7 of each cycle and venetoclax PO on days 1-28 of each cycle. Treatment repeats every 28 days for up to 2 cycles or until patient achieves remission, whichever comes first, in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Patients receive azacitidine IV or SC on days 1-7 and venetoclax PO on days 1-28 of each cycle. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.~Patients undergo bone marrow biopsy and aspiration as well as blood sample collection on the trial."
89003235|NCT05564390|Experimental|MM1OA-EA02 Regimen 2 (azacitidine, venetoclax, gilteritinib)|"INDUCTION: Patients receive azacitidine IV or SC on days 1-7 and venetoclax and gilteritinib PO on days 1-28 of each cycle. Treatment repeats every 28 days for up to 2 cycles or until patient achieves remission, whichever comes first, in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Patients receive azacitidine IV or SC on days 1-5, venetoclax PO on days 1-7 and gilteritinib PO on days 1-28 of each cycle. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.~Patients undergo bone marrow biopsy and aspiration as well as blood sample collection on the trial."
89184632|NCT04069065|Experimental|Conversion to Once-daily Tacrolimus|Conversion to TacroBell slow-release cap.(Once-daily Tacrolimus) at least one year after liver transplantation
89184633|NCT00722085||Observational|
89184634|NCT00735254|Active Comparator|Pulsed dye laser|PDL Patient will be have scar treated with pulsed dye laser.
89184635|NCT00735254|Active Comparator|Affirm laser|Patient will be have scar treated with Affirm Laser
89184636|NCT00735254|Active Comparator|combined PDL and Affirm Lasers|Patient will be have scar treated with combined Affirm + PDL
89184637|NCT00735254|Placebo Comparator|Placebo|Patient will be have scar treated with Placebo
89184638|NCT04067583||Physicians with recent aflibercept experience|Ophthalmologists who have prescribed and/or administered aflibercept in the past 6 months
89184639|NCT04070391|Experimental|vitamin B6|One pill (100 mg) ingested daily for 4 weeks.
89184640|NCT04070391|Placebo Comparator|control|One vinegar pill ingested daily for 4 weeks
89535193|NCT03325205|Experimental|Active tDCS|Participants receive anodal tDCS over DLPFC. Each sessions lasts for 20 minutes, with a total of 15 stimulations: 6 acute sessions, 9 maintenance sessions.
89535194|NCT03325205|Sham Comparator|Sham tDCS|Participants receive sham tDCS over DLPFC. Each sessions lasts for 20 minutes, with a total of 15 stimulations: 6 acute sessions, 9 maintenance sessions.
89385334|NCT03569865|Experimental|Active AVS-1|Active AVS-1 consists of a 30-minute pulsing lights (red, green, blue) and sounds that gradually descend from alpha (10 Hz) to delta (2 Hz).
89385335|NCT03569865|Experimental|Active AVS-2|Active AVS-2 consists of a 30-minute pulsing lights (red, green) and sounds that gradually descend from alpha (10 Hz) to delta (2 Hz).
88860667|NCT02761746|Experimental|Intervention Condition (MESA)|MESA involves two sessions (ACASI assessment and intervention), one at study entry (prior to beginning ART) and one a month later. Then, participants will complete ACASI assessments only at 3, 6, 9, and 12 months. The first MESA session is tailored based on how important and how confident the person feels about taking medications as prescribed. The participant is also offered personalized feedback regarding immune status and HIV knowledge with actual adherence feedback provided in the second session. Finally, the participant may engage in goal setting. The second MESA session focuses on adherence behavior over the previous month and the consequences (good or bad) of that behavior.
88860668|NCT02761746|No Intervention|Control Condition (SH)|The SH control condition involves two sessions (ACASI assessment and control condition), one at study entry (prior to beginning ART) and one a month later. Then, participants will complete ACASI assessments only at 3, 6, 9, and 12 months. The first SH session targets healthy eating and physical activity and is matched for dose and length of time of the intervention session. Feedback and education are provided, if desired. Finally, the participants may engage in goal setting for healthy eating and physical activity. The second SH session focuses on the goals set during the first session and behavior over the previous month.
88860669|NCT02759484|Experimental|Home Based Enhanced Education|The Home Based Enhanced Education arm consists of a diabetes self-management curriculum delivered by Community Health Workers in the participant's home.
88860670|NCT02759484|Active Comparator|Clinic Based Enhanced Education|The Clinic Based Enhanced Education arm consists of group diabetes self-management education, delivered by a Certified Diabetes Educator, plus mailed diabetes self-management education.
89385336|NCT03569865|Placebo Comparator|Placebo AVS|The placebo control AVS program consists of 30 minutes of constant dim light that slowly changes in color, and a steady monotone at ultra-low (<1 Hz) frequency (outside of the entrainment range).
89385337|NCT04054362|Experimental|With Cisplatin|Paclitaxel Protein bound, Cisplatin, and Gemcitabine until stable or progressive disease, at which point Paricalcitol will be introduced.
89385338|NCT04054362|Experimental|Without Cisplatin|Paclitaxel Protein bound and Gemcitabine until stable or progressive disease, at which point Paricalcitol will be introduced.
89385339|NCT04467281|Experimental|89Zr-DFO-daratumumab PET/CT|"Pre treatment evaluation: 1) Standard of Care (SoC) labs, imaging, blind bone marrow biopsy. 2) Baseline research 89 Zr DFO daratumumab PET/CT 3) Possible biopsy of 89 Zr DFO daratumumab avid lesion Treatment: Daratumumab containing combination therapy (up to 12 cycles, 4 weeks/cycle). SoC labs, imaging, and blind bone marrow biopsies until complete response (CR) is suspected or 12 cycles are completed.~Post treatment evaluation:1) SoC labs, imaging, and blind bone marrow biopsy 2) SoC minimal residual disease (MRD) analysis by next generation sequencing 3) Follow up research 89 Zr DFO daratumumab PET/CT 4) Possible biopsy of 89 Zr DFO daratumumab avid lesion"
89385340|NCT04350879||Diabetic patients|Women between 18 and 40 years old with type 1 and type 2 diabetes
89385341|NCT03652194||Reference strain ATCC|1 strain sensitive to all antifungals
89385342|NCT03652194||Clinical isolates sensitive to all antifungal agents|10 clinical isolates sensitive to all
89385343|NCT03652194||Echinocandin-resistant clinical isolates|10 echinocandin-resistant clinical isolates (Eucast, Caspofungin > 8µg/ml)
89385344|NCT04322019||"Amikacin treatment group"|Intensive care patients on renal replacement therapy with Amikacin treatment
89385345|NCT04315467|Experimental|SGM-101|SGM-101 (5-10 mg) will be administered intravenously over 30 minutes followed by a 50 mL flush of isotonic saline to account for the dead volume of the tubing. SGM-101 will be administered 3 to 5 days (+/-1 day) prior to surgery. As a prophylactic measure to ensure the possibility of allergic reaction is absolutely minimized, 25 mg of IV Benadryl may be given the subject prior to the infusion of SGM-101 at the discretion of the Principal Investigator.
89385346|NCT01785342||Indeterminate Pulmonary Nodule|The goal will be accomplished by recruiting 500 smokers with indeterminate pulmonary nodules (0.7cm - 3.0cm) on chest CT who will undergo fiberoptic bronchoscopy and will be followed for 2 years until a final diagnosis is made. Biosample and imaging collection will be done.
89385347|NCT01378143|Experimental|OCZ103-OS, mFOLFOX6 or FOLFIRI|OCZ103-OS in combination with mFOLFOX6 or FOLFIRI as standard of care
89385348|NCT05073107|Experimental|Test: With Dental Monitoring|"Dental Monitoring (DM) Kit + 2-month DM subscription~Required to take intra-oral videos (which will be translated into photographs) using the DM application weekly and it will be monitored by the delegated team members:~Day 0 (To be taken at the clinic)~Day 7 (To be taken in the evening after brushing teeth)~Day 14 (To be taken in the evening after brushing teeth)~Day 21(To be taken in the evening after brushing teeth)~Day 28 (To be taken before study Visit 2)~There is a window period of +1 day for the intra-oral videos."
89385349|NCT05073107|No Intervention|Control: Without Dental Monitoring|No DM Kit
89535195|NCT05013723||Intervention|Patients who received casirivimab-imdevimab antibody infusion
89535196|NCT05013723||Control|Matched control group who did not receive MAb, matched on diagnosis date, age, gender and Utah COVID-19 Risk Score
89535197|NCT03230071|Placebo Comparator|Placebo|placebo identified to TMBCZG,0.1g per pill which contains 0mg TMBCZG，3 pills per time, 2 times per day for 24 weeks.
89535198|NCT03230071|Experimental|TMBCZG-high dose|TMBCZG, 0.1g per pill which contains 14mg TMBCZG, 3 pills per time, 2 times per day for 24 weeks.
89535199|NCT03230071|Experimental|TMBCZG-medium dose|TMBCZG( 0.1g per pill which contains 14mg TMBCZG) and placebo identified to TMBCZG(0.1g per pill which contains 0mg TMBCZG), 2 TMBCZG pills and 1 placebo pill per time, 2 times per day for 24 weeks.
89535200|NCT03230071|Experimental|TMBCZG-low dose|TMBCZG( 0.1g per pill which contains 14mg TMBCZG) and placebo identified to TMBCZG(0.1g per pill which contains 0mg TMBCZG), 1 TMBCZG pills and 2 placebo pill per time, 2 times per day for 24 weeks.
89385350|NCT02973048|Placebo Comparator|Hyperbaric bupivacaine|Hyperbaric bupivacaine 0.5% will be administered at the dose of 10 mg intrathecally associated with 100 µg of morphine and 2.5 µg of sufentanyl.
89385351|NCT02973048|Active Comparator|Hyperbaric prilocaine|Hyperbaric prilocaine 2% will be administered at the dose of 50 mg intrathecally associated with 100 µg of morphine and 2.5 µg of sufentanyl.
89385352|NCT05028413|No Intervention|Participants Blinded to BrAC reading (Control)|Participants randomized to this arm will consume three weight-based doses of alcohol with a target BAC of 0.10 and comple breathalyzer measurements every 20 minutes until a BAC of 0.03 is reached. They will complete a visual analog scale (the Self-Reported intoxication Survey) on their perceived fitness to drive and be blinded to their breath alcohol readings with the BACtrack Mobile Pro device.
89385353|NCT05028413|Experimental|Participants Aware of their BrAC reading|Participants randomized to this arm will consume three weight-based doses of alcohol with a target BAC of 0.10 and comple breathalyzer measurements every 20 minutes until a BAC of 0.03 is reached. They will be shown their breath alcohol readings with the BACtrack Mobile Pro device before completing a visual analog scale (the Self-Reported intoxication Survey) on their perceived fitness to drive.
89385354|NCT04110405|Experimental|Stepped Care|To assess the effectiveness of the stepped care model with 420 women who have depression and potential co-occurring anxiety, recruited from 12 primary care clinics in Tajikistan.
89385355|NCT04110405|Active Comparator|Standard of Care plus Healthy Lifestyle|To compare standard of care plus healthy lifestyle materials with 210 women recruited from 6 primary care clinics in Tajikistan.
89385356|NCT02932943|Experimental|Rapastinel 450 mg|Rapastinel 450 milligram (mg) weekly intravenous (IV) injections. Each participant will continue to take the same dose of antidepressant therapy the participant was receiving prior to entering this study throughout treatment.
89385357|NCT02932943|Placebo Comparator|Placebo|Placebo-matching rapastinel weekly IV injections. Each participant will continue to take the same dose of antidepressant therapy the participant was receiving prior to entering this study throughout treatment.
89385358|NCT04054206|Active Comparator|Sequence 1|"Two participants will be randomly assigned to sequence 1 comprising 3 treatments (ER fasted, ER fed, and IR fasted) in a crossover design, administered one week apart:~Day 1-7: ER fasted; Day 8-15: ER fed Day 15-22: IR fasted"
89385359|NCT04054206|Active Comparator|Sequence 2|Two participants will be randomly assigned to sequence 2 comprising 3 treatments in a crossover design, administered one week apart: Day 1-7: ER fed; Day 8-15: IR fasted; Day 15-22: ER fasted
89385360|NCT04054206|Active Comparator|Sequence 3|"Two participants will be randomly assigned to sequence 3 comprising 3 treatments in a crossover design, administered one week apart:~Day 1-7: IR fasted; Day 8-15: ER fasted; Day 15-22: ER fed"
89385361|NCT04054206|Active Comparator|Sequence 4|"Two participants will be randomly assigned to sequence 4 comprising 3 treatments in a crossover design, administered one week apart:~Day 1-7: IR fasted; Day 8-15: ER fed; Day 15-22: ER fasted"
88860671|NCT02757300|Experimental|Hypopharyngeal packing|"Patients with indication for surgery of the sinuses were randomly assigned to one of the two study groups.~After standardized anaesthetic management and PONV prophylaxis routinely applied the patients were screened for mucosal injury on second postoperative day. Furthermore, the amount of analgetic and anti-emetic drugs and the severity of pain and PONV were recorded throughout the hospital stay."
88860672|NCT02757300|Active Comparator|Without hypopharyngeal packing|"Patients with indication for surgery of the sinuses were randomly assigned to one of the two study groups.~After standardized anaesthetic management and PONV prophylaxis routinely applied the patients were screened for mucosal injury on second postoperative day. Furthermore, the amount of analgetic and anti-emetic drugs and the severity of pain and PONV were recorded throughout the hospital stay."
88860673|NCT02509260|Experimental|Prevena™ incisional NPWT|Prevena wound management system: Post op application of the Prevena™ wound management system will be applied.
88860674|NCT02509260|Active Comparator|Standard Wound Dressings|Standard Wound Dressings: Control patients with standard wound dressings will have gauze and tape dressings applied.
88860675|NCT01458834|Experimental|Active attention training condition|
88860676|NCT01458834|Placebo Comparator|Control condition|
88860677|NCT01458912|Experimental|BI 54903 HD q.d.|Patients receive 2 puffs BI 54903 HD q.d. via Respimat inhaler (p.m.) combined with 2 puffs placebo (a.m.)
88860678|NCT01458912|Placebo Comparator|Placebo|Patients receive 2 puffs Placebo b.i.d. via Respimat inhaler
88860679|NCT01458912|Experimental|BI 54903 MD b.i.d.|Patients receive 2 puffs BI 54903 MD b.i.d.via Respimat inhaler
89385362|NCT04054206|Active Comparator|Sequence 5|"Two participants will be randomly assigned to sequence 5 comprising 3 treatments in a crossover design, administered one week apart:~Day 1-7: ER fasted; Day 8-15: IR fasted; Day 15-22: ER fed"
89385363|NCT04054206|Active Comparator|Sequence 6|"Two participants will be randomly assigned to sequence 6 comprising 3 treatments in a crossover design, administered one week apart:~Day 1-7: ER fed; Day 8-15: ER fasted; Day 15-22: IR fasted"
89385364|NCT03603938|Experimental|bedtime dosing ARB for hypertension|potassium losartan has benefit for the nondipping BP pattern
89385365|NCT03603938|Experimental|bedtime dosing ARB for the prognosis|bedtime administration of potassium losartan has benefit for the prognosis of CKD patients
89385366|NCT03652116|Active Comparator|Bupivacaine Group|Patients delivered by cesarean section followed by wound infiltration by bupivacaine.
89385367|NCT03652116|Active Comparator|Pethidine Group|Patients delivered by cesarean section followed by wound infiltration by pethidine.
89385368|NCT03602144|Active Comparator|Carbohydrate|Participants will receive a carbohydrate-based smoothie every morning for 6 weeks (42 days).
88860680|NCT02747862||Attenuated Familial Adenomatous Polyposis|Chart review study to evaluate the outcomes of subjects with Attenuated Familial Adenomatous Polyposis (AFAP) who have not undergone surgical resection of the colon.
89385369|NCT03602144|Experimental|Protein|Participants will receive a protein-based smoothie every morning for 6 weeks (42 days).
88860681|NCT02747862||Deleterious Familial Adenomatous Polyposis|Chart review study to evaluate the outcomes of subjects with Deleterious Familial Adenomatous Polyposis (FAP) who have not undergone surgical resection of the colon.
88860682|NCT02743728||All Infants|Each infant will receive an Magnetic Resonance Imaging, then Transcranial Magnetic Stimulation Cortical Excitability testing, and General Movement Assessment. These 3 different components of the one arm in which all infants are involved will be collectively assessed.
88860683|NCT02743338|Experimental|Sleep Restriction followed by additional CBT-i components|Sleep Restriction treatment during 5+5 weeks. Followed by being offered an additional intervention consisting of other ICBT-i components during 10 weeks.
88860684|NCT02743338|Active Comparator|Sleep Compression followed by additional CBT-i components|Sleep Compression treatment during 5+5 weeks. Followed by being offered an additional intervention consisting of other ICBT-i components during 10 weeks.
89184641|NCT04089800|Experimental|Intervention|For 9 months, each of the 40 women in the intervention condition will use their phones to access the multimedia-based antenatal videos and audios tailored to their pregnancy stages. Participants will use the prototype until six weeks after giving birth. The intervention implementation is estimated to take 9 months including a 6 weeks follow-up after delivery, which implies that the implementation will be completed by November/ December 2019. The investigators will install the final prototype on a phone and give each participant in the intervention group a phone with a prototype installed, and explain how it works. Women will get support in resolving technical issues that may arise with the application between March and May 2019.
89184642|NCT04089800|No Intervention|Control|The 40 women in the control condition will receive the usual standard care of antenatal check-up and counselling but no multimedia intervention.
89184643|NCT04070235|Experimental|SH229/DCV 400mg/60mg|HCV GT 1-6 participants were medicated with SH229 tablets 400 mg once daily and DCV tablets 60 mg once daily QD (n=40) for 12weeks
89184644|NCT04070235|Experimental|SH229/DCV 600mg/60mg|HCV GT 1-6 participants were medicated with SH229 tablets 600 mg once daily and DCV tablets 60 mg once daily (n=40).
89184645|NCT04070235|Experimental|SH229/DCV 800mg/60mg|HCV GT 1-6 participants were medicated with SH229 tablets 800 mg once daily and DCV tablets 60 mg once daily (n=40).
89184646|NCT04070235|Experimental|SH229/DCV|HCV GT 1-6 participants were medicated with SH229 tablets 400 mg,600 mg or 800 mg once daily and DCV tablets 60 mg once daily
89184647|NCT02593760|Active Comparator|Placebo + Ruxolitinib|Participants will receive placebo (PO QD) in combination with ruxolitinib (dose will depend on the participant's baseline platelet count) for up to 48 weeks.
89184648|NCT02593760|Experimental|Vismodegib + Ruxolitinib|Participants will receive vismodegib (150 mg PO QD) in combination with ruxolitinib (dose will depend on the participant's baseline platelet count) for up to 48 weeks.
89184649|NCT02604329|Experimental|intervention|"Radiation : use of Oncolase Digi therapy laser diode"
89184650|NCT00712803|Experimental|1|One subcutaneous vaccination (10^3 dose of vaccine) of rDEN3-3'D4delta30 vaccine into the deltoid region of either arm.
89184651|NCT00712803|Experimental|2|One subcutaneous vaccination (10^5 dose of vaccine or placebo) of rDEN3-3'D4delta30 vaccine into the deltoid region of either arm OR one subcutaneous vaccination (10^1 dose of vaccine or placebo) of rDEN3-3'D4delta30 vaccine into the deltoid region of either arm.
89184652|NCT00795509||Tolterodine tartrate.|Patients taking Tolterodine tartrate.
89385370|NCT03603782|Experimental|1|
89385371|NCT03603782|Experimental|2|
89385372|NCT03603782|Experimental|3|
89385373|NCT03603782|Experimental|4|
89385374|NCT01946867|Experimental|NBTXR3 IntraTumoral injection (IT)|Single intratumor injection
89385375|NCT03967340||Lung transplant|
89385376|NCT01550315|Active Comparator|High Sodium - POTS & Controls|Subjects will receive a high sodium diet for 4-5 days prior to study day. Procedures include: blood work, urine collection, Pulsitile Arterial Tonometry (PAT), PAT analysis, Calf Blood Flow in Reactive Hyperemia (CBF-RH), & evaluation of forearm-mediated dilation.
89385377|NCT01550315|Other|Low Sodium Diet (POTS & Controls)|"Participants will consume a very low sodium diet (10 mEq/day) for 4-5 days prior to study day.~Procedures include: blood work, urine collection, Pulsitile Arterial Tonometry (PAT), PAT analysis, Calf Blood Flow in Reactive Hyperemia (CBF-RH), & evaluation of forearm-mediated dilation."
89385378|NCT02972658|Experimental|AZES Lanabecestat 20 milligrams (mg)/AZFD Lanabecestat 20 mg|Participants who received Lanabecestat 20 mg in the feeder study (AZES) were randomized to receive Lanabecestat 20 mg.
89385379|NCT02972658|Experimental|AZES Lanabecestat 50 mg/AZFD Lanabecestat 50 mg|Participants who received Lanabecestat 50 mg in the feeder study (AZES) were randomized to receive Lanabecestat 50 mg.
88860685|NCT02743338|Active Comparator|Sleep Restriction followed by no intervention|Sleep Restriction treatment during 5+5 weeks. Followed by NOT being offered or informed of an additional intervention consisting of other ICBT-i components during 10 weeks.
88860686|NCT02743338|Active Comparator|Sleep Compression followed by no intervention|Sleep Compression treatment during 5+5 weeks. Followed by NOT being offered or informed of an additional intervention consisting of other ICBT-i components during 10 weeks.
88860687|NCT02742324|Experimental|Ruxolotinib and peg-IFN alpha -2a|"Phase I~LeveL 1 Ruxolotinib 10 mg BID and peg-IFN alpha -2a 45 mcg weekly increasing doses to level 9 : Ruxolotinib 20 mg BID and peg-IFN alpha -2a 135 mcg weekly~Phase II~Ruxolotinib and peg-IFN alpha -2a randomized between selected doses from phase I"
88860688|NCT01459146|Experimental|AL plus ABZ; Arm 1|Artemether-Lumefantrine combination 20mg/120mg 12 hourly for 3 days oral, plus albendazole 400mg stat oral
88860689|NCT01459146|Active Comparator|AL plus PZQ plus ABZ; Arm 2|artemether-lumefantrine combination 120mg/20mg 12 hourly for 3 days; plus praziquantel 40mg/kg stat; plus albendazole 400mg stat oral
88860690|NCT01459146|Active Comparator|ABZ plus PZQ; Arm 3|Albendazole 400mg stat plus Praziquantel 40mg/kg stat oral
88860691|NCT05028894||IPF|Participants diagnosed with idiopathic pulmonary fibrosis
88860692|NCT05024136|Active Comparator|Placebo|Subjects take 30 mins aromatherapy of Limon essential oil per time, a total of 3 times for the month.
88860693|NCT05024136|Experimental|Experimental|Subjects take 30 mins aromatherapy of vetiver essential oil per time, a total of 3 times for the month.
89385380|NCT02972658|Experimental|AZES Placebo/AZFD Lanabecestat 20 mg|Participants who received placebo in the feeder study (AZES) were randomized to receive Lanabecestat 20 mg.
89385381|NCT02972658|Experimental|AZES Placebo/AZFD Lanabecestat 50 mg|Participants who received placebo in the feeder study (AZES) were randomized to receive Lanabecestat 50 mg.
89385382|NCT02853032|Active Comparator|Active rTMS to the right DLPFC|Active repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm. In this arm, active rTMS will be delivered at 20 Hertz (Hz) in 2 sec trains with 14 sec inter-train intervals, 20 minutes/session (i.e. 1,600 pulses/session), 7 days/week for 20 consecutive days.
89385383|NCT02853032|Placebo Comparator|Sham rTMS to the right DLPFC|Sham repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm. In this arm, sham rTMS will be delivered at 20 Hz in 2 sec trains with 14 sec inter-train intervals, 20 minutes/session (i.e. 1,600 pulses/session), 7 days/week for 20 consecutive days.
89385384|NCT02232087|Experimental|test product A|salmeterol and fluticasone propionate, 2 puffs
89385385|NCT02232087|Active Comparator|reference product D|salmeterol and fluticasone propionate, 2 puffs
89385386|NCT02232087|Experimental|test product B|salmeterol and fluticasone propionate, 6 puffs
89385387|NCT02232087|Active Comparator|reference product E|salmeterol and fluticasone propionate, 6 puffs
89385388|NCT02232087|Experimental|test product C|salmeterol and fluticasone propionate, 12 puffs
89385389|NCT02232087|Active Comparator|reference product F|salmeterol and fluticasone propionate, 12 puffs
89385390|NCT03168425|Experimental|Tailored|Participants will be prescribed an opioid based on a formula derived from inpatient opioid use
89385391|NCT03168425|Other|Control|Participants will be prescribed 30 tablets of oxycodone 5mg, which is the average prescription currently given to our population.
88860694|NCT05026398|Experimental|Fenfluramine|Drug: Fenfluramine - 15mg twice daily oral solution for seven days
89385392|NCT00004445|Experimental|Implanted Neuroprosthesis|"Volunteers are evaluated for appropriateness for inclusion in the study on an intent-to-treat basis. Qualifying candidates all receive the implanted neuroprosthesis and participate in post-operative training and follow-up procedures.~Interventions include:~Procedure/Surgery Rehabilitation/Exercise~Device includes:~IRS-8 Stimulating Electrodes External Controller"
89385393|NCT01380015|Placebo Comparator|Placebo Control|Participants will consume two cups of commercial spearmint tea per day (300 mL in the morning and 300 mL in the evening, providing a total of approximately 20 mg of rosmarinic acid per day) for a total of 4 months.
88860695|NCT05026398|Placebo Comparator|Placebo|Placebo - 15mg twice daily oral solution for seven days
88860696|NCT01895244|Experimental|Conditioning with CYC/ antithymocyte globulin (ATG)|Each patient receives stem cell transplantation open label with cluster of differentiation (CD)34 selected stem cells mobilisation and conditioning depending on manifestation If cardiac manifestation: Conditioning with CYC 2 x 50mg + thiotepa 2x5mg + ATG If no cardiac manifestation: Conditioning with 4 x 50mg CYC + ATG
88860697|NCT01895244|Experimental|Conditioning with CYC/Thiotepa/ATG|In patients with cardiac manifestations as defined in the protocol the conditioning for stem cell transplantation is changed to Cyclophosphamide (CYC), thiotepa and ATG
88860698|NCT02724930|No Intervention|Standard Implementation|Standard COPES implementation consists of provider education including brief in-person presentations and written material.
88860699|NCT02724930|Experimental|Implementation Facilitation|"Enhanced facilitation of COPES implementation.~All clusters start in the standard implementation group and cross-over from the control group to the intervention group in a randomized stepped-wedge fashion at 7 time points over the course of the 33 week implementation."
89385394|NCT01380015|Experimental|Experimental|Participants will consume two cups of a high rosmarinic acid spearmint tea per day (300 mL in the morning and 300 mL in the evening, providing a total of approximately 300 mg of rosmarinic acid per day) for a total of 4 months.
88860700|NCT05586828||different controlling nutritional status score|
89385395|NCT03603704|Experimental|LY3209590|"Insulin naïve participants with Type 2 Diabetes Mellitus received 5 mg and 10 mg LY3209590 administered subcutaneously (SC) in Cohort 1 and 2 respectively.~Participants with T2DM received 20 mg LY3209590 administered subcutaneously in Cohort 3."
88860701|NCT05586750|Experimental|STAREE Statin group|
89385396|NCT03603704|Active Comparator|Placebo|Participants from Cohort 1 and 2 received Placebo administered SC.
88860702|NCT05586750|Placebo Comparator|STAREE Placebo group|
88860703|NCT01893606|Placebo Comparator|Starch capsule|During the two weeks screening phase of the study, the daily dose of 3 tablets will be taken before breakfast, lunch and supper.
88860704|NCT01893606|Experimental|N-acetyl-D-glucosamine|During the 8-week treatment phase of the study,the dose of 100mg(3 tablets)per day will be taken.
88860705|NCT02085720|Experimental|Chinese elderly OSAS|Subjects will be recruited in the community elderly center with home sleep study done. Those with significant OSAS will be prescribed with CPAP therapy and subsequent compliance is monitored.
88860706|NCT02716974|Experimental|chemohormonal and definitive therapy|(1st) Systemic chemo-hormonal therapy with up to 6-months (~24 weeks) of neoadjuvant androgen deprivation (Leuprolide Acetate) and up to 6 cycles of chemotherapy (Docetaxel), (2nd) definitive local tumor control with prostatectomy +/- adjuvant radiation therapy, and (3rd) consolidative stereotactic radiation to oligometastatic lesions. The men will receive a total of 1 year of androgen deprivation. Androgen blockade (Bicalutamide) will be the same throughout the course of treatment.
88860707|NCT01890096|Experimental|HDR 2 fractions|HDR brachytherapy of 27 Gy delivered in 2 fractions one week apart
88860708|NCT01890096|Experimental|HDR 1 fraction|HDR brachytherapy of 19 Gy delivered in a single fraction
88860709|NCT01890174||AMD with macular drusen|Patients diagnosed with dry AMD with macular drusen
89184653|NCT02603003|Placebo Comparator|Cisplatin|Cisplatin
88860710|NCT01459380|Experimental|Regimen I (intermittent veliparib)|Patients receive veliparib PO BID on days 1-7, and pegylated liposomal doxorubicin hydrochloride IV over 1 hour and carboplatin IV over 30 minutes on day 1.
89184654|NCT02603003|Placebo Comparator|Pemetrexed|Pemetrexed
88860711|NCT01459380|Experimental|Regimen II (continuous veliparib)|Patients receive veliparib PO BID on days 1-28, and pegylated liposomal doxorubicin hydrochloride and carboplatin as in Regimen I.
88860712|NCT04346004|Placebo Comparator|Control group|Participants in this group are administered N/S.
88860713|NCT04346004|Experimental|Iron isomaltoside group|Participants in this group are administered Iron isomaltoside & Vitamin B12.
88860714|NCT02680314|Active Comparator|Single Dose|single dose of misoprostol
88860715|NCT02680314|Active Comparator|Multiple Dose|multiple doses of misoprostol
88860716|NCT05586672||ASD group|Participants aged from 3 years to 4 years and half at inclusion will be clinically evaluated with standardized scales and tests and will performed an EEG-HR recording while listening to successive soundtracks at several times.
88860717|NCT05586672||Control group|Participants aged from 3 years to 4 years and half at inclusion will be clinically evaluated with standardized scales and tests and will performed an EEG-HR recording while listening to successive soundtracks in inclusion visit.
88860718|NCT02707692|Other|Pneumococcal, then Influenza, then Placebo vaccination|Participants first received a 0.5 mL injection of Pneumococcal vaccine (Pneumovax-23®). After a washout period of at least 6 weeks, they then received a 0.5 mL injection of Influenza vaccine (Fluarix®, GSK). After another washout period of at least 6 weeks, the participant received a 0.5 mL injection of saline (placebo).
88860719|NCT02707692|Other|Pneumococcal, then Placebo, then Influenza vaccination|Participants first received a 0.5 mL injection of Pneumococcal vaccine (Pneumovax-23®). After a washout period of at least 6 weeks, they then received a 0.5 mL injection of saline (placebo). After another washout period of at least 6 weeks, the participant received a 0.5 mL injection of Influenza vaccine (Fluarix®, GSK).
88860720|NCT02707692|Other|Influenza, then Pneumococcal, then Placebo vaccination|Participants first received a 0.5 mL injection of Influenza vaccine (Fluarix®, GSK). After a washout period of at least 6 weeks, they then received a 0.5 mL injection of Pneumococcal vaccine (Pneumovax-23®). After another washout period of at least 6 weeks, the participant received a 0.5 mL injection of saline (placebo).
88860721|NCT02707692|Other|Influenza, then Placebo, then Pneumococcal vaccination|Participants first received a 0.5 mL injection of Influenza vaccine (Fluarix®, GSK). After a washout period of at least 6 weeks, they then received a 0.5 mL injection of saline (placebo). After another washout period of at least 6 weeks, the participant received a 0.5 mL injection of Pneumococcal vaccine (Pneumovax-23®).
88860722|NCT02707692|Other|Placebo, then Pneumococcal, then Influenza vaccination|Participants first received a 0.5 mL injection of saline (placebo). After a washout period of at least 6 weeks, they then received a 0.5 mL injection of Pneumococcal vaccine (Pneumovax-23®). After another washout period of at least 6 weeks, the participant received a 0.5 mL injection of Influenza vaccine (Fluarix®, GSK).
88860723|NCT02707692|Other|Placebo, then Influenza, then Pneumococcal vaccination|Participants first received a 0.5 mL injection of saline (placebo). After a washout period of at least 6 weeks, they then received a 0.5 mL injection of Influenza vaccine (Fluarix®, GSK). After another washout period of at least 6 weeks, the participant received a 0.5 mL injection of Pneumococcal vaccine (Pneumovax-23®).
88860724|NCT02706678|Experimental|Tacrolimus sustained-release capsule group|Oral
88860725|NCT02703948|Other|Restylane Silk with Lidocaine|
88860726|NCT01459536||Rotator Cuff Tear-surgical|
88860727|NCT01459536||Health Older Adult Control|
88860728|NCT01459536||Rotator cuff tear - non surgical|
88860729|NCT02666742|Experimental|DOAC (Direct Oral Anticoagulant)|Participants will be asked to take standard dose approved for stroke prophylaxis
88860730|NCT02666742|Active Comparator|Aspirin|Participants will be asked to take 81 milligrams by mouth once per day.
88860731|NCT04390776|Experimental|Treatment Sequence 1|PF-06651600 100 mg Tablets (fasted, Period 1), followed by Capsules (fasted, Period 2), and followed by Capsules (fed, Period 3).
88860732|NCT04390776|Experimental|Treatment Sequence 2|PF-06651600 100 mg Capsules (fasted, Period 1), followed by Tablets (fasted, Period 2), and followed by Capsules (fed, Period 3).
88860733|NCT04390776|Experimental|Treatment Sequence 3|PF-06651600 100 mg Tablets (fasted, Period 1), followed by Capsules (fasted, Period 2).
88860734|NCT04390776|Experimental|Treatment Sequence 4|PF-06651600 100 mg Capsules (fasted, Period 1), followed by Tablets (fasted, Period 2).
88860735|NCT01893762|Experimental|16 rowers|Adult rowers, aged between 18 and 25, training >6 times a week are subjected to both an aerobic and a an anaerobic exercise challenge. Between the two challenges there must a pause of at least a week.
89184655|NCT02603003|Experimental|Jinfukang|Jinfukang
89184656|NCT00722163|Experimental|1|behavioural
89184657|NCT00722163|Active Comparator|2|befriending
89184658|NCT00722163|No Intervention|3|TAU
89184659|NCT04106141|Other|control group|
89184660|NCT04106141|Active Comparator|intervention group|
89184661|NCT00722241||A|Adult subjects (at least 18 years of age) with a diagnosis of type 1 diabetes (~80%) or insulin-treated type 2 diabetes (~20%); method of insulin delivery may be multiple daily injections (MDI) or continuous subcutaneous insulin infusion (CSII)
89184662|NCT04106297|Experimental|GLPG3970 SAD|Single doses of GLPG3970 at up to 6 dose levels in ascending order
88860736|NCT01893684|Experimental|Protein + Exercise|PRO diet recommendations will include high quality proteins with an emphasis on lean meats, with protein being targeted for every meal and snack. PRO will provide dietary protein (1.6 g.kg-1.d-1; ~30% of energy intake) with a ratio of carbohydrate/protein of <1.5 and dietary lipids at ~ 30% energy intake. Energy deficit will be determined by reducing estimated daily energy needs by ~500 kcal/d. The prescribed diet will include a minimum of one serving of beef per day, which is approximately 3 to 3.5 ounces or ~100 grams. The exercise program will require attendance of 3 nonconsecutive days per week. A program that combines flexibility and balance activities, weight bearing endurance exercise (walking) and resistance training to preserve lean mass will be prescribed. Each session will last ~75 min with a 35 min warm-up/aerobic exercise of mild to moderate intensity, ~30 min of resistance training, and finally, a ~10 min of balance and flexibility exercises during the cool-down period.
88860737|NCT01893684|Experimental|Protein|PRO diet recommendations will include high quality proteins with an emphasis on lean meats, with protein being targeted for every meal and snack. PRO will provide dietary protein (1.6 g.kg-1.d-1; ~30% of energy intake) with a ratio of carbohydrate/protein of <1.5 and dietary lipids at ~ 30% energy intake. Energy deficit will be determined by reducing estimated daily energy needs by ~500 kcal/d. The prescribed diet will include a minimum of one serving of beef per day, which is approximately 3 to 3.5 ounces or ~100 grams.
88860738|NCT01893684|Experimental|Carbohydrate + Exercise|Diet will provide dietary protein at 0.8 g.kg-1.d-1 (~ 18% of energy intake) with a ratio of carbohydrates/protein > 3.5 and dietary lipids at ~30% energy intake. Again, energy deficit will be determined by reducing estimated daily energy needs by ~500 kcal/d. The exercise program will require attendance of 3 nonconsecutive days per week. A program that combines flexibility and balance activities, weight bearing endurance exercise (walking) and resistance training to preserve lean mass will be prescribed. Each session will last ~75 min with a 35 min warm-up/aerobic exercise of mild to moderate intensity, ~30 min of resistance training, and finally, a ~10 min of balance and flexibility exercises during the cool-down period.
88860739|NCT02686320||Rheumatoid arthritis >65 years old|
88860740|NCT02686320||Rheumatoid arthritis <50 years old|
88860741|NCT02684292|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg administered intravenously (IV) on Day 1 of each 3-week cycle for up to 35 cycles.
88860742|NCT02684292|Active Comparator|Brentuximab vedotin|Participants receive BV 1.8 mg/kg (maximum 180 mg per dose) IV on Day 1 of each 3-week cycle for up to 35 cycles.
88860743|NCT04391010|Other|Health care providers with beard|
88860744|NCT04391010|Other|Health care providers without beard|
88860745|NCT02983032|Experimental|Brief behavioural treatment for insomnia (BBTI)|A behavioural therapy for improving symptoms of insomnia in older adults focussing on sleep-related behaviour such as napping and when a person gets up and goes to bed.
88860746|NCT01459692|No Intervention|Control group - No Music Exposure|Subjects that were assigned to the control group of the study were not exposed to music.
88860747|NCT01459692|Experimental|Music Exposure|The treatment subjects were randomly assigned to receive nightly exposure to music at periodic intervals between the hours of 9:00 PM and 8:00 AM.
88860748|NCT04390074||COVID-19|Patients with COVID-19 who have received or are receiving Intensive Care in Sweden. Patients are identified in the Swedish Intensive care registry, to which all Swedish intensive care units (ICU) are reporting all intensive care patients.
88860749|NCT04390074||Control|Age- and sex-matched controls are drawn from all residents of Sweden by Statistics Sweden.
88860750|NCT02649426|Experimental|Ultrasound Renal Denervation|Subjects in the TRIO or SOLO cohorts that are randomized to treatment, will receive renal denervation following a renal angiogram
88860751|NCT02649426|Sham Comparator|Sham Procedure|For subjects in TRIO or SOLO cohorts that randomize to the sham procedure, the diagnostic renal angiogram intervention will be considered the sham procedure.
88860752|NCT01459770|Active Comparator|control|"usual care for hospital discharge:~CKD group~ESRD group"
88860753|NCT01459770|Active Comparator|intervention|"pharmacist administered medication information transfer intervention~CKD group~ESRD group"
88860754|NCT02377206|Experimental|Alzheimer Disease|Alzheimer Disease People ADAS-Cog evaluation PET imaging with [18F]DPA-714
88860755|NCT01894074|Placebo Comparator|Placebo|Lifestyle counseling:standard dietary education and counseling with a goal of reducing calories to 1500-1800 kcal/day
89184663|NCT04106297|Placebo Comparator|Placebo SAD|Single doses of placebo
89184664|NCT04106297|Experimental|GLPG3970 MAD|Multiple doses of GLPG3970 at up to 4 dose levels in ascending order, daily for 14 days
89184665|NCT04106297|Placebo Comparator|Placebo MAD|Multiple doses of placebo
88860756|NCT01894074|Active Comparator|Intensive Dietary Intervention|Intensive Dietary Intervention employing very low energy diet (800 kcal/day) x 12 weeks followed by transition to regular foodstuffs over 4-6 weeks.
88860757|NCT02639988||rheumatoid arthritis and type 2 diabetes|
88860758|NCT02639988||osteoarthritis and type 2 diabetes|
88860759|NCT01459848|Active Comparator|block play|30 minutes of block play with parent
88860760|NCT01459848|Experimental|baby dvd|watch baby dvd with parent
88860761|NCT04390854|Active Comparator|Induced blood clot scaffold|
88860762|NCT04390854|Experimental|Induced blood clot scaffold combined with Platelet rich fibrin|
88860763|NCT02630316|Placebo Comparator|Placebo|Matching placebo inhaled using an ultrasonic nebulizer four times daily
88860764|NCT02630316|Active Comparator|Inhaled Treprostinil|Active Treprostinil for inhalation solution (0.6 mg/mL) delivered via an ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath. Inhaled four times daily and titrated up to a maximum of 12 breaths four times daily
88860765|NCT02875704||Stargardt disease, AMD, DR patients|Stargardt disease, Age Related Macular Degeneration, Diabetic Retinopathy patients
88860766|NCT02875704||Controls|Patients without retinal disease who will be undergoing cataract surgery
89184666|NCT04106297|Experimental|GLPG3970 FE-rBA|Single dose of GLPG3970 in fed and fasted state
88860767|NCT02354820|No Intervention|Control|Patients are identified by the pre-screener form given to parents as having constipation or encopresis. No intervention is given to providers to help them with constipation management.
88860768|NCT02354820|Experimental|Experimental|Patients are identified by the pre-screener form given to parents as having constipation or encopresis. Evidence based reminders and patient educational materials are given to providers to help them with constipation management.
88860769|NCT02624544|Experimental|Group A|Proton Pump Inhibitor esomeprazole 40 mg twice a day
88860770|NCT02624544|Active Comparator|Group B|desonide
88860771|NCT02620410|Other|Axonics SNM System|Axonics SNM Therapy for urinary control is indicated for the treatment of urinary retention and the symptoms of overactive bladder, including urinary urge incontinence and significant symptoms of urgency-frequency alone or in combination, in patients who have failed or could not tolerate more conservative treatments.
88860772|NCT01893840|Experimental|FlowOx|5 minutes of pulsating negative pressure (10 sek og -40mmHg/7 sek of athmospheric pressure) will be Applied to the patient's leg
88860773|NCT01452048||Obese Sedentary Adults, but otherwise healthy|
88860774|NCT02613936|Experimental|Active anodal tDCS + cognitive training|In this arm, patients with mmTBI will undergo 10 sessions of active tDCS x 30 minutes combined with simultaneous cognitive training on consecutive weekdays.
88860775|NCT02613936|Sham Comparator|Placebo anodal tDCS + cognitive training|In this arm, patients with mmTBI will undergo 10 sessions of placebo tDCS x 30 minutes combined with simultaneous cognitive training on consecutive weekdays.
88860776|NCT02603328|Active Comparator|Treatment|Atorvastatin 80mg OD (optimal dose). Treatment dose will be de-escalated to 40mg based on reported adverse events.
88860777|NCT02603328|Placebo Comparator|Placebo|Identically looking capsules containing no active ingredient
89184667|NCT04106297|Experimental|GLPG3970 FE|Single dose of GLPG3970 in fed and fasted state
89385397|NCT03652584|Experimental|High Protein Diet|Low glycemic index dietary plan with 1.6 g/kg/day of protein for 6 months
89385398|NCT03652584|Active Comparator|Control Diet|Low glycemic index dietary plan with 0.8 g/kg/day of protein for 6 months
88860778|NCT02335788|Other|Single arm - EMBA PED|The EMBA Peripheral Embolization Device when indicated for arterial and venous embolization in the peripheral vasculature.
88860779|NCT02327286|Experimental|Intervention|Promote and support healthy behaviors
88860780|NCT02327286|No Intervention|Control|Conventional care for women with prior GDM.
88860781|NCT01451970|Other|High Monounsaturated Fat Diet|Subjects will adhere to their specific diet for four weeks. The diet will be a weight-maintaining diet, and the target nutrient composition for diets will be 55% carbohydrate, 30% fat, 15% protein. For the monounsaturated fat treatment (M diet) approximately 10% of all lipids ingested will be saturated.
88860782|NCT01451970|Other|High Saturated Fat Diet|Subjects will adhere to their specific diet for four weeks. The diet will be a weight-maintaining diet, and the target nutrient composition for diets will be 55% carbohydrate, 30% fat, 15% protein. For the saturated fat treatment (S diet) approximately 40% of all lipids ingested will be saturated.
88860783|NCT02598258|Experimental|Sauna + Cold Water Bath|Subjects will first spend 10 minutes in a dry sauna at 85 degrees celtius. Immediately after , subjects will be immersed in a cold water bath (ICool , Australia) at a temperature of 5 degrees celtius for approximately one minute. Blood pressure , ecg , gaz exchange and thoracic impedance will be measured during sauna and cold water bath.
88860784|NCT01450722|Active Comparator|drug eluting stent|Paclitaxel eluting stent for long superficial femoral artery obstruction
88860785|NCT01450722|Active Comparator|bypass operation|femoropopliteal artery bypass operation by using synthetic PTFE graft
88860786|NCT01456104|Experimental|vaccine|This is a single-arm phase I trial in patients with AJCC stage IIB, IIC, III, and IV (MIa) melanoma in which autologous human Langerhans-type dendritic cells (CD34+hematopoietic progenitor cell (HPC)-derived Langerhans cells, or LCs) will be electroporated with mRNA encoding full-length murine tyrosinase-related peptide 2 (TRP2). LCs will also be loaded with control antigens (HLA-A*0201-restricted flu matrix peptide).
88860787|NCT01451736|Experimental|paliperidone palmitate (Invega Sustenna)|Participants will be provided paliperidone palmitate (Invega Sustenna), administered in injectible long-acting form, plus group skills training and case management
88860788|NCT01451736|Active Comparator|oral risperidone|Participants will be provided oral risperidone, plus group skills training and case management
88860789|NCT02310594||Ancillary-Correlative (blood banking)|Samples of blood are collected before, during, and within two weeks after radiation therapy and then stored for analysis of anti-tumor immunity.
88860790|NCT02868918|Experimental|biodentine|bioactive dentin substitute used to act like natural dentin in insulating the pulp against external stimuli intervention
89184668|NCT04106297|Experimental|GLPG3970 in psoriasis subjects|
89184669|NCT04106297|Experimental|Placebo in psoriasis subjects|
89184670|NCT04105673||Shaken Baby Syndrome|Realization of a clinical examination and survey on children with a past history of a Shaken Baby Syndrome
89184671|NCT04067193||old geriatric inpatients|usability assessment after 24 to 72 hours of possible use of the device (PARADE CONNECT shoes)
89385399|NCT03330561|Experimental|PRS-343|
89385400|NCT03603626|Experimental|Preemptive pregabalin|
89385401|NCT03603626|Placebo Comparator|Placebo|
89385402|NCT03652038|Experimental|TD-8236 for SAD (Part A)|6 out of 8 subjects per cohort (up to 5 cohorts) will be randomized to receive TD-8236
89385403|NCT03652038|Placebo Comparator|Placebo for SAD (Part A)|2 out of 8 subjects per cohort (up to 5 cohorts) will be randomized to receive placebo
88860791|NCT02868918|Active Comparator|glass ionomer cement|high viscosity glass ionomer used as a base material comparator other name : - fuji ix
88860792|NCT02378766|Experimental|Website A|Patients assigned to this arm will be invited to complete a web-based tailored intervention called TAVIE en santé.
88860793|NCT02378766|Other|Website B|Patients assigned to this arm will be invited to consult a validated list of five predetermined websites.
88860794|NCT04757844|Experimental|Young healthy voluntary adults|30 young healthy voluntary adults
88860795|NCT04758078|Experimental|Corticosteroids|Patients will receive inhaled corticosteroids (Budesonide 2 mL = 1000 microgram)
88860796|NCT04758078|Placebo Comparator|Placebo|Patients will receive nebulized 0.9% saline
88860797|NCT01450956|Experimental|Sevoflurane|Patients will receive 2% sevoflurane via oxygenator during CPB
88860798|NCT01450956|No Intervention|Control|Patients will receive only oxygen and air through oxygenator
88860799|NCT02300922|Experimental|several cohorts|"All patients will receive 3 injections of TF2 (the first: 14 mg/m², the second and the third:75 mg/m²). One day after each injection of TF2, the patient will receive a radiolabelled peptide (IMP-288) with Yttrium for therapeutic injectionThe First cohort will receive 555 MBq/m2 X 2 of 90-Y-IMP-288.:~All patient will receive 180 MBq of 111-In-IMP-288 for dosimetry analysis"
88860800|NCT02297724||all subjects|For all subjects, administration of oxygen will last for no more than 10 min, with flow rate 15L/min via non-rebreather facial mask. Each subject will have once of the administration per scan. Data collection will start about 10 min before the administration of oxygen, and last throughout the oxygen exposure, then continue for about 10 min after oxygen exposure for each subject.
88860801|NCT01453530|Active Comparator|Sugammadex|A single dose of sugammadex 2 mg/kg iv. Dose calculation will be based on the patient's actual body weight. No dose adjustments are allowed
88860802|NCT01453530|Active Comparator|Neostigmine/glycopyrrolate|A single dose of neostigmine 0.04 mg/kg iv plus glycopyrrolate 0.01 mg/kg iv. Dose calculation will be based on the patient's actual body weight. No dose adjustments are allowed.
88860803|NCT01453530|Placebo Comparator|No reversal agent|No treatment
88860804|NCT02983422|Active Comparator|Group aminophylline|To increase the dose of frusemide until 15mg/h with Syringe pumps. If the urine doesn't reach 1ml/kg/h,then combined with Aminophylline(loading dose of 5mg/kg，and maintenance dose of 0.5mg/kg)
88860805|NCT02983422|Placebo Comparator|Group frusemide|Use frusemide with Syringe pumps,maximum dose to 15mg/h，with placebo bolus followed by IV infusions of normal saline (0.9%) every hour (matched by volume and appearance to the treatment group)
88860806|NCT02295540|Experimental|Treatment (hypofractionated IMRT, surgery)|Patients undergo hypofractionated IMRT every other day for up to 5 treatments. Patients then undergo surgery 7-14 days after the last radiation treatment.
88860807|NCT02019654||1|Mild or moderate TBI within the past 30 days
88860808|NCT05585892|Other|Intervention items 1-15|Students in this arm were exposed to intervention and control items in the 10 weekly e-seminars. Assignment of item types was the exact opposite of that in group B.
88860809|NCT05585892|Other|Intervention items 16-30|Students in this arm were exposed to intervention and control items in the 10 weekly e-seminars. Assignment of item types was the exact opposite of that in group A.
88860810|NCT05585814|Experimental|Pembrolizumab+ Bevacizumab + CAPOX as neoadjuvant treatment for 4 cycles|"CapOx: Capecitabine is given orally at 1500mg / m² twice a day from day1-14 every 3 weeks for 4 cycles and Oxaliplatin is given by intravenous infusion at 200mg / m2 on Day 1 every 3 weeks for 4 cycles;~Bevacizumab：Bevacizumab is given intravenously at 10mg/kg on day 1 every 3 weeks for 4 cycles;~Pembrolizumab：Pembrolizumab is given intravenously at 200 mg on day 1 every 3 weeks for 4 cycles"
88860811|NCT02566200||IM group|Patients admitted in intensive care for a myocardial infarction
88860812|NCT02563080||First attack of acute pancreatitis|50 patients with first attack of moderately severe or severe acute pancreatitis treated in Helsinki University Hospital.
88860813|NCT02000232||Diagnosis with Gout and use of colchicine|Observational study age 18+
88860814|NCT05585736|Other|Cycloplegic refraction|All refractions were measured before and after cycloplegic addition to the eye.
89385404|NCT03652038|Experimental|TD-8236 for MAD (Part B)|6 out of 8 subjects per cohort (up to 6 cohorts) will be randomized to receive TD-8236.
88860815|NCT01989780|Active Comparator|Arm A|weekly paclitaxel + bevacizumab
88860816|NCT01989780|Experimental|Arm B|"endocrine therapy* + bevacizumab then back to weekly paclitaxel + bevacizumab therapy~(*Letrozole, Anastrozole, Exemestane, Fulvestrant, LHRH Analogs + Aromatase inhibitors.)"
88860817|NCT02265588|No Intervention|Care as usual|Care as usual means receiving their regular medical care. This consists of the regular follow up visits at the gastroenterologist every 3 months.
88860818|NCT02265588|Experimental|Cognitive Behavioral Therapy|The intervention group receives regular medical care (care as usual) AND a cognitive behavioral therapy program called PASCET-PI. The therapy sessions will be performed by trained psychologist.
88860819|NCT02549898|Experimental|Vascular inflammation|Subjects with habitual unilateral migraine without aura, undergo a baseline MRI scan, undergo pharmacological induction of a migraine attack, and subsequently are MRI scanned prior to (BBI-MRI) and after Feraheme infusion (USPIO-MRI ).
88860820|NCT02549898|Experimental|Effect of sumatriptan|Subjects with habitual unilateral migraine without aura, undergo a baseline MRI scan and then undergo pharmacological induction of a migraine attack. Sumatriptan is given and subjects subsequently undergo MRI scans prior to (BBI-MRI) and after Feraheme infusion (USPIO-MRI).
88860821|NCT02549898|Experimental|Pilot w/o cilostazol|Subjects without habitual unilateral migraine without aura undergo a baseline MRI scan. Subjects are then MRI scanned prior to (BBI-MRI) and after Feraheme infusion (USPIO-MRI).
88860822|NCT02549898|Experimental|Pilot w/ cilostazol|Subjects without habitual unilateral migraine without aura undergo a baseline MRI scan and then receive cilostazol. Subjects are then MRI scanned prior (BBI-MRI) to and after Feraheme infusion (USPIO-MRI).
88860823|NCT02545608|Experimental|Restylane Vital in both hands|Open group used to develop a proper use of injection technique for Restylane Vital
88860824|NCT02545608|Other|Restylane Vital and No treatment|Split-hand design: Restylane Vital in one hand and initially no treatment in the other hand
89385405|NCT03652038|Placebo Comparator|Placebo for MAD (Part B)|2 out of 8 subjects per cohort (up to 6 cohorts) will be randomized to receive placebo.
89385406|NCT03652038|Experimental|TD-8236 for Biomarker (Part C)|8 subjects in each of 2 biomarker cohorts will be randomized to receive TD-8236.
89385407|NCT03652038|Placebo Comparator|Placebo for Biomarker (Part C)|8 subjects in 1 biomarker cohort will be randomized to receive placebo.
89385408|NCT03651960|Experimental|Robot|ROBOT PROTOTYPE
89385409|NCT01377909|Experimental|statin|
89385410|NCT04053660|No Intervention|Control|Periodontally healthy group
89385411|NCT04053660|Experimental|Chronic Periodontitis|Patients with chronic periodontitis
89385412|NCT01731522|Experimental|EF condition|
89385413|NCT05463159|Experimental|Group A|participants in this group will be given with TENS to spastic Hams, Adductor and TA along with stretchings and ROM as baseline treatment
89385414|NCT05463159|Active Comparator|Group B|participants in this group will be given with TENS to opposite of spastic muscles, i.e. quards, abductor and dorsiflexors along with stretchings and ROM as baseline treatment
89385415|NCT05463159|Active Comparator|Group C|participants in this group will be given with TENS to both spastic muscles and opposite of spastic muscle along with stretchings and ROM as baseline treatment
89385416|NCT05463159|Active Comparator|Group D|participants in this group will be given with stretchings and ROM as baseline treatment
89385417|NCT02972502|Active Comparator|Metoclopramide (Reglan)|Patients will receive 10 mg of intravenous (IV) metoclopramide following a 1-liter bolus of normal saline (NS) and 25 mg of IV diphenhydramine.
89385418|NCT02972502|Experimental|Haloperidol (Haldol)|Patients will receive 2.5 mg of intravenous (IV) haloperidol following a 1-liter bolus of normal saline (NS) and 25 mg of IV diphenhydramine.
89385419|NCT05462067|Active Comparator|Binocular EDOF IOL|Binocular EDOF IOL for treatment of cataract
89385420|NCT05462067|Experimental|Combined Edof and Trifocal IOL|Combined EDOF and Trifocal IOL - EDOF in the distance dominant eye / Trifocal in the non-dominant eye
89385421|NCT05461911||The Study Group|30 adult patients aged 30-75 years to receive a specialized tube feeding product Nutrison Advanced Cubison (20% protein energy 100 kcal, 5.5 g protein, 0.85 g arginine, 38 mg of vitamin C and 2 mg of zinc) in a volume not exceeding 1.5 liters / day and, if necessary, to replenish nutritional needs based on the total daily intake of 30-35 kcal / kg / day and 1.2-1.5 g of protein / kg body weight / day according to the recommendations for nutritional support for patients with pressure ulcers during the entire observation period
89385422|NCT05461911||The Control Group|30 patients aged 30-75 years to receive a standard (available in the clinic) tube feeding product (energetically similar to the product in group 1) with a standard content of arginine, vitamins and minerals from calculating the total daily intake of 30-35 kcal / kg / day and 1.2-1.5 g protein / kg body weight / day according to the recommendations for nutritional support for patients with pressure ulcers during the entire observation period
88860825|NCT01894464|Experimental|Teacher led intervention|Teachers will conduct teacher-led interventions that are individualized for each student to prevent emerging truancy among elementary students.
88860826|NCT01894464|No Intervention|Control Group|
88860827|NCT02260362||HTAP of Congenital Heart Disease|
88860828|NCT01981044|Experimental|SERI® Surgical Scaffold|It is a prospective, multicenter, single-arm, post-market on-label clinical study of a 510(k)-cleared device.
88860829|NCT04756986|Experimental|malic acid group|patients will receive a topical spray containing 1% malic acid
88860830|NCT04756986|No Intervention|placebo group|patients will receive a topical placebo spray
89184672|NCT04067193||unformal caregivers|usability assessment after 24 to 72 hours of possible use of the device (PARADE CONNECT shoes) by their relative
88860831|NCT02513784|Experimental|Antibacterial mouthwash|Subjects will be randomized to twice daily chlorhexidine gluconate mouthwash for 21 days.
88860832|NCT02513784|No Intervention|No intervention|Subjects will be randomized to no intervention for 21 days.
88860833|NCT02510742|Active Comparator|SPG neurostimulation|SPG neurostimulation of frequency 20 Hz
88860834|NCT02510742|Sham Comparator|Control|Sham neurostimulation of amplitude=0
88860835|NCT02283996|Experimental|Physical Therapy with Steroid Injection|Patients will undergo regular physical therapy as defined by the standard of care at Massachusetts General Hospital for Adhesive Capsulitis (Frozen Shoulder). If they are in the inflammatory phase of the condition, they will receive 40 mg of depot methylprednisolone in solution with 2 cc of 1% lidocaine.
88860836|NCT02283996|Experimental|Watchful Waiting with Steroid Injection|Patients will undergo no therapeutic intervention outside of steroid injection. If they are in the inflammatory phase of the condition, they will receive 40 mg of depot methylprednisolone in solution with 2 cc of 1% lidocaine.
88860837|NCT05586282||Patients with a circulatory failure|All patients hospitalized in ICU with a circulatory failure due to septic shock, cardiogenic shock, or post-resuscitation syndrome.
88860838|NCT02369484|Other|Afatinib|Afatinib 40 mg p.o./day until tumour progression or lack of tolerability
89385423|NCT01569477|Experimental|Treatment incentives|Incentives for biochemical verification visits, treatment engagement, and abstinence
89385424|NCT01569477|Active Comparator|Attendance incentive|Incentives for only attending the biochemical verification visits
89385425|NCT03601988|Active Comparator|Chemotherapy|Adjuvant chemotherapy group receive 8 cycles of XELOX (Oxaliplatin 130mg/m2, ivdrip, D1,capecitabine 1000mg po, Bid, D1-14, Q21D)
88860839|NCT04390152|Experimental|Mesenchymal stem cell|WJ MSC 50*10e6, two doses plus standard treatment with hydroxychloroquine + Lopinavir/Ritonavir or Azithromycin and ventilation support.
88860840|NCT04390152|Active Comparator|Control group|Hydroxychloroquine, lopinavir/ritonavir and ventilation support plus placebo
88860841|NCT04390230||Patient with peniale implantation|All patients who underwent implantation with either Coloplast or Boston Scientific - AMS IPPs between 2014 and 2019, by 2 surgeons of the University Hospital of Nice, France.
88860842|NCT02238834|Experimental|SAD Cohorts 1-8 Experimental Arm|
88860843|NCT02238834|Placebo Comparator|SAD Cohorts 1-8 Placebo Arm|
88860844|NCT02238834|Experimental|MAD Cohorts 1 through 4 Experimental Arm|Note: The planned MAD portion of the study was not conducted. Evaluation of FP-025 MAD is being conducted under a separate protocol (Study No. FP02C-17-001).
88860845|NCT02238834|Placebo Comparator|MAD Cohorts 1 through 4 Placebo Arm|Note: The planned MAD portion of the study was not conducted. Evaluation of FP-025 MAD is being conducted under a separate protocol (Study No. FP02C-17-001).
88860846|NCT02238054||ABSORB BVS|All patients with a coronary angioplasty procedure and the implantation of at least one ABSORB BVS
88860847|NCT02498730|Active Comparator|Interval Training|6 stimulous (30 s) at 100% VO2Max/ 1 min 30 s to rest, 19 minutes (total exercise), 3 times/ week, 12 weeks
88860848|NCT02498730|Active Comparator|Continuous Training|Running at 60% VO2Max, 25 minutes (total exercise), 3 times/week, 12 weeks
88860849|NCT02498730|Sham Comparator|Control|Only Dependent Variables Measures
88860850|NCT02496936|Experimental|Saturated Fat (SFA)|30 grams saturated fat in the form of heavy whipping cream will be provided to subject in a smoothie drink
88860851|NCT02496936|Experimental|Monounsaturated Fat (MUFA)|30 grams monounsaturated fat in the form of high oleic canola oil will be provided to subject in a smoothie drink
88860852|NCT02496936|Experimental|Polyunsaturated Fat Linoleic (PUFA-LA)|30 grams polyunsaturated fat in the form of high linoleic sunflower oil will be provided to subject in a smoothie drink
88860853|NCT02496936|Experimental|Polyunsaturated Fat Alpha-Linolenic (ALA)|30 grams polyunsaturated fat in the form of flaxseed oil will be provided to subject in a smoothie drink
88860854|NCT02496936|Experimental|Polyunsaturated Fat Long Chain Omega-3 (LCn3)|30 grams polyunsaturated fat in the form of fish oil (Coromega Omega3 Squeeze) will be provided to subject in a smoothie drink
88860855|NCT02496780|Placebo Comparator|placebo|once or 3x daily injectable placebo (insulin diluent)
88860856|NCT02496780|Experimental|basal insulin levemir|once daily basal insulin therapy with insulin levemir
88860857|NCT02496780|Experimental|rapid-acting insulin Novolog|pre-meal rapid-acting insulin 3x/day with insulin novolog
88860858|NCT01953588|Active Comparator|Arm I (anastrozole)|Patients receive anastrozole daily for 6 cycles followed by surgery. A treatment cycle is 4 weeks in length. After completion of analysis of endocrine resistant data, patients will continue treatment as defined in the protocol.
89184673|NCT04067193||professional caregivers|usability assessment after the possible use of the device (PARADE CONNECT shoes) by 40 hospitalzed old patients in the geriatrics ward
88860859|NCT01953588|Active Comparator|Arm II (fulvestrant)|Patients receive fulvestrant on days 1 and 15 of cycle 1 and day 1 of cycles 2-6 followed by surgery. A treatment cycle is 4 weeks in length. After completion of analysis of endocrine resistant data, patients will continue treatment as defined in the protocol.
88860860|NCT01953588|Active Comparator|Arm III (anastrozole and fulvestrant)|Patients receive anastrozole daily in combination with fulvestrant on days 1 and 15 of cycle 1, and on day 1 of cycles 2-6 followed by surgery. A treatment cycle is 4 weeks in length. After completion of analysis of endocrine resistant data, patients will continue treatment as defined in the protocol.
88860861|NCT01953510|Active Comparator|A: 3+1 PCV10|PCV10 administered at 2, 3, 4 and 9 months of age
88860862|NCT01953510|Experimental|B: 3+0 PCV10|PCV10 administered at 2, 3 and 4 months of age
88860863|NCT01953510|Experimental|C: 2+1 PCV10|PCV10 administered at 2, 4 and 9 months of age
88860864|NCT01953510|Experimental|D: 1+1 PCV10|PCV10 administered at 2 and 6 months of age
88860865|NCT01953510|Experimental|E: 2+1 PCV13|PCV13 administered at 2, 4 and 9 months of age
88860866|NCT01953510|No Intervention|F: control|No infant PCV vaccination. PCV10 administered at 18 and 24 months of age
88860867|NCT01953510|No Intervention|G: control|Recruited at 18 months of age (non-randomised). PCV10 administered at 24 months of age
88860868|NCT02475252|Active Comparator|Experts|Surgically experienced gynecologists with a personal history of at least 50 hysteroscopy procedures will perform a hysteroscopy on a training model.
88860869|NCT02475252|Experimental|Novices|Medical students will perform a hysteroscopy on a training model.
88860870|NCT01893918||COPD patients|COPD patients, males and females, older than 65 years, with smoking history > 20 pack/years
88860871|NCT02188602||High Chloride Dose|Patients receiving high dosing of chloride
88860872|NCT02188602||Low Chloride Dose|Patients receiving low dosing of chloride
88860873|NCT02177058|Experimental|Immediate INTERACT implementation|INTERACT Quality improvement program training and implementation between APR 2013 and MAR 2014
88860874|NCT02177058|Active Comparator|Delayed intervention with reporting|Quarterly surveys/data reporting between APR 2013 and MAR 2014. They receive INTERACT training starting on MAR 2014.
88860875|NCT02177058|No Intervention|Delayed intervention not reporting|No data collected from these nursing homes for one year since baseline. They receive INTERACT training starting on MAR 2014.
88860879|NCT02157480|No Intervention|control|usual follow-up for 6 weeks
88860880|NCT02157480|Experimental|electrostimulation 3 days per week|20 minutes ambulatory bi-quadricipital electrostimulation sessions three times per week for 6 weeks
88860881|NCT02157480|Experimental|electrostimulation 5 days per week|20 minutes ambulatory bi-quadricipital electrostimulation sessions five times per week for 6 weeks
88860882|NCT05578950|Active Comparator|group A pulse therapy of itraconazole|patients with pulse therapy group recieved oral itraconazole 100 mg, two capsules twice daily for 7 days a month
88860883|NCT05578950|Active Comparator|group B continous therapy of terbinafine|patients with continous therapy group , recieved continous oral 250 mg terbinafine once daily for 12 weeks continously
88860884|NCT05586126||Sevoflurane|patients admitted because of respiratory insufficiency due to COVID-19 with need for invasive mechanical ventilation that are sedated by using sevoflurane
88860885|NCT05586126||Control|patients admitted because of respiratory insufficiency due to COVID-19 with need for invasive mechanical ventilation that are sedated by means of intravenous medication, such as propofol, midazolam, esketamine of fentanyl
88860886|NCT01893996|Experimental|Adalimumab|Active Study Drug is Adalimumab (Humira) which is FDA approved to treat rheumatoid arthritis since 2003.
88860887|NCT01893996|Placebo Comparator|Placebo|Placebo is inert and matches study drug, including the pre-filled syringe, and is supplied by Abbvie, the study drug manufacturer.
88860888|NCT02442180|Experimental|G-CSF + steroid in partial responder|Patients who are randomized to prednisolone plus G-CSF treatment group in patients with partial responder to prednisolone therapy.
88860889|NCT02442180|Placebo Comparator|Placebo + steroid in partial responder|Patients who are randomized to prednisolone plus placebo treatment group in patients with partial responder to prednisolone therapy.
88860890|NCT02442180|Experimental|G-CSF in null responder to steroid|Patients who are randomized to G-CSF treatment group in patients with null responder to prednisolone therapy.
88860891|NCT02442180|Placebo Comparator|Placebo in null responder to steroid|Patients who are randomized to placebo treatment group in patients with null responder to prednisolone therapy.
88860892|NCT01924260|Experimental|Treatment (alisertib, gemcitabine)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15 and alisertib PO BID on days 1-3, 8-10, and 15-17. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88860893|NCT02439762|Experimental|Cognitive Behavioral Therapy (CBT)|The CBT condition will cover topics such as orienting the patient to the cognitive model of suicidal thoughts, plans and behaviors and the role of substance use in increasing the likelihood of suicidal behaviors and presenting tools to help patients better manage responses to suicide-related triggers.
88860894|NCT02439762|Active Comparator|Supportive Psycho-education (SPC)|The SPC condition is designed to match the CBT condition in terms of level of attention and the non-specific aspects of receiving support for a suicidal crisis and substance misuse. Specific content related to suicide risk will consist of general information about suicide-related resources available, while content related to substance use is based on a modified psycho-educational attention control treatment for alcoholism. The sessions will help patients to better understand the resources available during a suicidal crisis and how substance use impacts in their life. However, topics related to identifying thoughts and behaviors associated with suicidal crises and possible coping mechanisms will not be a part of the formal content of these SPC sessions.
88860895|NCT02983110||Cohort B|Group B will be HIV Infected post-menopausal women who are not receiving hormonal therapy to provide tissue, blood, and cells
88860896|NCT02983110||Cohort C|Group C will be HIV infected transgendered women receiving hormone therapy to provide tissue and blood
88860897|NCT02983110||Cohort E|Group E will be HIV infected men
88860898|NCT02432742|Experimental|Restylane Perlane|Single injection and optional touch up injection with Restylane Perlane in NLF
88860899|NCT02432742|Active Comparator|Restylane|Single injection and optional touch up injection with Restylane in NLF
88860900|NCT02430558|Experimental|OD-PHOENIX|treatment of 1 to 5 osteochondral allograft cylinders in mosaic
88860901|NCT05585970|Active Comparator|healthy Control individuals|
88860902|NCT05585970|Active Comparator|CKD patients|
89184674|NCT00722319||A|Patients on long-term oral anticoagulation who are submitted to PCI-S because of acute coronary syndrome or stable angina. No further groups nor interventions are anticipated since the study is observational
89184675|NCT02603081|Placebo Comparator|Placebo|0 mg SPI-1005 bid po x 21d
88860903|NCT05585970|Active Comparator|ESRD on regular hemodialysis|
88860904|NCT02086500|Experimental|Prehospital Tranexamic Acid|1 gram of Tranexamic Acid will be given during emergency medical transport
89003236|NCT05564390|Experimental|MM1OA-EA02 Regimen 3 (azacitidine, venetoclax, gilteritinib)|"INDUCTION: Patients receive azacitidine IV or SC on days 1-7 and venetoclax PO on days 1-28, and gilteritinib PO on days 8-21 of each cycle. Treatment repeats every 28 days for up to 2 cycles or until patient achieves remission, whichever comes first, in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Patients receive azacitidine IV or SC on days 1-5, venetoclax PO on days 1-14 and gilteritinib PO on days 8-21 of each cycle. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.~Patients undergo bone marrow biopsy and aspiration as well as blood sample collection on the trial."
89003237|NCT05564390|Experimental|MM1YA-CTG01 Arm I (daunorubicin, cytarabine, venetoclax)|Patients receive daunorubicin IV, cytarabine IV, and venetoclax PO on study and undergo bone marrow aspiration and collection of blood samples on study and as clinically indicated.
89003238|NCT05564390|Experimental|MM1YA-CTG01 Arm II (azacitidine, venetoclax)|Patients receive azacitidine IV or SC and venetoclax PO on study and undergo bone marrow aspiration and collection of blood samples on study and as clinically indicated.
89003239|NCT05564390|Active Comparator|MM1YA-CTG01 Arm III (daunorubicin, cytarabine)|Patients receive daunorubicin IV and cytarabine IV on study and undergo bone marrow aspiration and collection of blood samples on study and as clinically indicated.
89003240|NCT05564390|Active Comparator|MM1YA-S01 Arm I (cytarabine, daunorubicin)|Patients receive cytarabine IV and daunorubicin IV per standard approach on study. Patients also undergo a bone marrow aspiration and collection of blood throughout the trial.
89003241|NCT05564390|Experimental|MM1YA-S01 Arm II (cytarabine, daunorubicin, venetoclax)|Patients receive cytarabine IV and daunorubicin IV with venetoclax PO on study. Patients also undergo a bone marrow aspiration and collection of blood throughout the trial.
89003242|NCT05564390|Experimental|MM1YA-S01 Arm III (azacitidine, venetoclax)|Patients receive azacitidine SC or IV and venetoclax PO on study. Patients also undergo a bone marrow aspiration and collection of blood throughout the trial.
89003243|NCT05564390|Experimental|MM1YA-S01 Arm IV (Vyxeos)|Patients receive Vyxeos IV on study. Patients also undergo a bone marrow aspiration and collection of blood throughout the trial.
89003244|NCT05564390|Active Comparator|MM2YA-EA01 Arm A (cytarabine)|Patients receive cytarabine IV on study. Patients undergo bone marrow aspiration and biopsy on study. Patients may also undergo ECHO and/or MUGA as clinically indicated.
89003245|NCT05564390|Experimental|MM2YA-EA01 Arm B (cytarabine, venetoclax)|Patients receive cytarabine IV and venetoclax PO on study. Patients undergo bone marrow aspiration and biopsy on study. Patients may also undergo ECHO and/or MUGA as clinically indicated.
89003246|NCT05564390|Experimental|MM2YA-EA01 Arm C (Vyxeos, venetoclax)|Patients receive Vyxeos IV and venetoclax PO on study. Patients undergo bone marrow aspiration and biopsy on study. Patients may also undergo ECHO and/or MUGA as clinically indicated.
89003247|NCT05564390|Experimental|MM2YA-EA01 Arm D (azacitidine, venetoclax)|Patients receive azacitidine IV or SC and venetoclax PO on study. Patients undergo bone marrow aspiration and biopsy on study. Patients may also undergo ECHO and/or MUGA as clinically indicated.
89003248|NCT05564390|Experimental|Screening (mutation carrier screening)|Patients undergo bone marrow aspiration and collection of blood on study. Patients' bone marrow and blood specimens undergo rapid genetic testing. Patients are then assigned to a specific protocol containing a therapy targeted to the patient's mutational profile. If there is no targetable mutation, the patient is placed on a protocol testing novel combinations that do not contain a target-specific drug.
89003249|NCT05559580|Experimental|Avenciguat (BI 685509)|Avenciguat (BI 685509)
89003250|NCT05559580|Placebo Comparator|Placebo|Placebo
89003251|NCT05552976|Experimental|MeziKd (Mezigdomide + Carfilzomib + Dexamethasone)|
89003252|NCT05552976|Active Comparator|Kd (Carfilzomib + Dexamethasone)|
89003253|NCT05543733|Experimental|Home exercise program|
89003254|NCT05539963|Experimental|STIMULAN VG|Participants will receive STIMULAN VG on Day 1 following surgical debridement. Systemic antibiotics for 3 days ± 2 days following the debridement surgery.
89003255|NCT05539963|Active Comparator|Standard of Care|Participants will receive Systemic antibiotics for 4-6 weeks following the debridement surgery.
89003256|NCT05538065|No Intervention|No Alert (Usual Care)|Providers randomized to usual care will receive no intervention.
89003257|NCT05538065|Experimental|Open Encounter + Pre-commitment|There will be an enhanced EHR alert, known as a Best Practice Advisory [BPA], which will appear on each provider's EHR screen. We will also test a two-staged pre-commitment BPA in which the providers are prompted to discuss risks of the high-risk medications and share a handout about risks with their patients.
89003258|NCT05538065|Experimental|Open Encounter + Follow-up booster|There will be an enhanced EHR alert, known as a Best Practice Advisory [BPA], which will appear on each provider's EHR screen. We will add a boostering option in the enhanced BPA, which is a provider-directed option for a follow-up in-basket message sent 4 weeks after the BPA is triggered.
89003259|NCT05536440|Experimental|Cohort 1 active|Dose A
89003260|NCT05536440|Placebo Comparator|Cohort 1 placebo|Dose A
89003261|NCT05536440|Experimental|Cohort 2 active|Dose B
89003262|NCT05536440|Placebo Comparator|Cohort 2 placebo|Dose B
89003263|NCT05536440|Experimental|Cohort 3 active|Dose C
89003264|NCT05536440|Placebo Comparator|Cohort 3 placebo|Dose C
89003265|NCT05536440|Experimental|Cohort 4 active|Dose D
89003266|NCT05536440|Placebo Comparator|Cohort 4 placebo|Dose D
89003267|NCT05536440|Experimental|Cohort 5 active|Dose E
89003268|NCT05536440|Placebo Comparator|Cohort 5 placebo|Dose E
89003269|NCT05536440|Experimental|Cohort 6 active|Dose F
89003270|NCT05536440|Placebo Comparator|Cohort 6 placebo|Dose F
89003271|NCT05536440|Experimental|Cohort 7 active|Dose G
89003272|NCT05536440|Placebo Comparator|Cohort 7 placebo|Dose G
89003273|NCT05536440|Experimental|Cohort 8 active|Dose H
89003274|NCT05536440|Placebo Comparator|Cohort 8 placebo|Dose H
89003275|NCT05536154|Experimental|EAP regimen|The combination regimen of etoposide, cytarabine and PEG-rhG-CSF.
89184676|NCT02603081|Active Comparator|Low dose|200 mg SPI-1005 bid po x 21d
89184677|NCT02603081|Active Comparator|Mid dose|400 mg SPI-1005 bid po x 21d
89184678|NCT02603081|Active Comparator|High dose|600 mg SPI-1005 bid po x 21d
89385426|NCT03601988|Experimental|Chemo-radiotherapy|Adjuvant chemo-radiotherapy group receive 6 cycles of XELOX (Oxaliplatin 130mg/m2, ivdrip, D1, capecitabine 1000mg po, Bid, D1-14, Q21D) and concurrent chemo-radiotherapy (capecitabine 825mg po, Bid, d1-5, QW)
89385427|NCT03606590|Experimental|TTFields in combination with sorafenib|Patients will be treated continuously with TTFields, in addition to sorafenib
89385428|NCT02971800|Experimental|sodium fluorescein|"Once hysterectomy completed, a 10 % solution of sodium fluorescein at a 0,25 ml dose (25 mg) is injected before performing diagnostic cystoscopy for all patient.~Name: Fluorescite Injection 10%, contains sodium fluorescein (equivalent to fluorescein 10% w/v) Dosage : 25 mg Frequency: only once"
89385429|NCT03601910|Experimental|A group|"Period 1: D308 10mg Tab. 1T~Period 2: CKD-380 10mg Tab. 1T"
89385430|NCT03601910|Experimental|B group|"Period 1: CKD-380 10mg Tab. 1T~Period 2: D308 10mg Tab. 1T"
89385431|NCT03163667|Active Comparator|CB-839 + Everolimus|CB-839 is administered as oral tablets twice daily (BID) in combination with standard daily (QD) everolimus in 28 day cycles.
89385432|NCT03163667|Placebo Comparator|Placebo + Everolimus|Placebo is administered as oral tablets BID in combination with standard QD everolimus in 28 day cycles.
89385433|NCT03651570|Experimental|PTSD Coach|PTSD Coach is a mobile mental health app developed by US Veterans Affairs translated into French by Veterans Affairs Canada in partnership with the Department of National Defence and the Canadian Mental Health Association. It was developed for a male population (92% of veterans are men), as is predominantly found in HNC, and addresses the issue of mental health and stigma as found in our HNC patients. PTSD Coach can be used as a stand-alone education and symptom management and contains 4 modules: 1) Learn- Module, 2) Self-Assessment-Module, 3) Manage Symptoms-Module and 4) Find Support-Module. The content of the first and last modules were adapted to the oncological population.
89385434|NCT03651570|Placebo Comparator|Game application|Patients will be assigned to three apps involving playing a game (i.e., Candy Crush, Tetris, or Solitaire), during the waiting time before and between medical treatments in the hospital, on the same weekly schedule as the experimental group. The game apps contain no element of intervention and were selected based on popularity and capacity to interests.
89385435|NCT03651570|No Intervention|Usually Care Control Group|The Otolaryngology - Head and Neck Surgery (OHNS) Departments do not offer systematic interventions on anxiety and self-management, neither does any intervention address stigma. However, participating recruitment centres are already offering a best-of-care approach with well-established psychosocial oncology services, including psychiatrists, psychologists, social workers, nurses, and volunteers. All participants will be free to use hospital- or community-based support throughout the study, which will be tracked in all groups via questionnaire and chart review.
89385436|NCT03603548|Active Comparator|Advagraf|
89385437|NCT03603548|Experimental|Envarsus|
89385438|NCT03954782|Experimental|Nintedanib|Oral treatment of Nintedanib 150 mg soft capsule
89385439|NCT03954782|Placebo Comparator|Placebo|Oral treatment of placebo soft capsule
89385440|NCT01330199|Experimental|TDF 150mg + MVC 150mg|Subjects will receive a single dose of tenofovir 150 mg and maraviroc 150 mg.
89385441|NCT01330199|Experimental|TDF 300mg + MVC 300mg|Subjects will receive a single dose of tenofovir 300 mg and maraviroc 300 mg.
89385442|NCT01330199|Experimental|TDF 600mg +MVC 600mg|Subjects will receive a single dose of tenofovir 600 mg and maraviroc 600 mg.
89385443|NCT01330199|Experimental|FTC 100mg + RAL 200mg|Subjects will receive a single dose of emtricitabine 100 mg and raltegravir 200 mg.
89385444|NCT01330199|Experimental|FTC 200mg + RAL 400mg|Subjects will receive a single dose of emtricitabine 200 mg and raltegravir 400 mg.
89385445|NCT01330199|Experimental|FTC 400mg + RAL 800mg|Subjects will receive a single dose of emtricitabine 400 mg and raltegravir 800 mg.
89385446|NCT03651726|Experimental|THX-110 (dronabinol plus PEA)|"Double-blind phase and extension open label phase:~Dose range of 2.5 mg to 10 mg dronabinol (1 to 4 capsules) plus 800 mg PEA (2 tablets) taken orally once daily; starting dose is 2.5 mg dronabinol plus 800 mg PEA. Up-titration is performed within maximal 3 weeks. The titration phase is followed by a maintenance phase of 9 weeks at stable dose."
89385447|NCT03651726|Placebo Comparator|Placebo|"Double-blind phase:~Range of 1 to 4 dronabinol placebo capsules plus 2 PEA placebo tablets taken orally once daily; starting dose is 1 dronabinol placebo capsule plus 2 PEA placebo tablets. Up-titration is performed within maximal 3 weeks. The titration phase is followed by a maintenance phase of 9 weeks at stable dose."
89385448|NCT01781039||low HIN difficulty- anesthetized|Subjects with normal OHC function and who will be undergoing an previously scheduled anesthetized procedure will be assigned into 2 groups based on their self-perceived HIN difficulty (high and low difficulty), and then undergo a test battery consisting of auditory threshold tests, objective HIN assays, OHC measurements, cognitive processing, and central auditory processing evaluations. Immediately after anesthetization, electrocochleography (ECochG) will be used to measure CAP amplitudes, which will be correlated with measurements obtained from unanesthetized subjects as described below. This aim will determine the optimal CAP recording method with the strongest correlation with HIN performance in humans
88860905|NCT02086500|Placebo Comparator|Control|Identical volume of saline during emergency medical transport
89184679|NCT04105829|Experimental|Tooth color measurement|Tooth color changes between times (before retainer bonding, after retainer bonding, in 1 month, 3 months, 6 months and a year)
89385449|NCT01781039||high HIN difficulty- anesthetized|Subjects with normal OHC function and who will be undergoing an previously scheduled anesthetized procedure will be assigned into 2 groups based on their self-perceived HIN difficulty (high and low difficulty), and then undergo a test battery consisting of auditory threshold tests, objective HIN assays, OHC measurements, cognitive processing, and central auditory processing evaluations. Immediately after anesthetization, electrocochleography (ECochG) will be used to measure CAP amplitudes, which will be correlated with measurements obtained from unanesthetized subjects as described below. This aim will determine the optimal CAP recording method with the strongest correlation with HIN performance in humans
89385450|NCT01781039||Hearing Aid fitting: MAD|Microphone adaptive directionality (MAD) feature will be activated, the WDC set to linear, and the DNR minimized
89385451|NCT01781039||Hearing Aid fitting: WDC|Wide dynamic compression (WDC) feature will be set to target levels, the MAD feature set to omnidirectional, and the DNR minimized.
89385452|NCT01781039||Hearing Aid fitting: DNR|Digital noise reduction (DNR) set to maximum, MAD set to omnidirectional, and WDC set to linear
89385453|NCT01781039||Hearing Aid fitting: Positive control|All hearing aid features enables
89385454|NCT01781039||Hearing Aid fitting: Negative control|All hearing aid features disabled
89385455|NCT03603470|Other|Patients with previous prothesis instability|
89385456|NCT03603470|Other|Patients without prothesis instability|
89385457|NCT00107250|Experimental|AZD2171 + Standard chemotherpay regimens|
89385458|NCT03606434|Experimental|Hypoxic Exposure|Men, and women in early or late follicular phase of menstrual cycle will be exposed to acute and intermittent hypoxic episodes.
89385459|NCT03603392|Experimental|Physical activity program|Before and after a 5-months of a supervised exercise program were performed in post bariatric patients, body composition, physical fitness and cardiovascular risk factors were measured.
89385460|NCT03651258||Experimental group|patient who can benefit from the ALIJEU for certain meals
89385461|NCT03651258||Group of witnesses|patient who did not benefit from the ALIJEU
89385462|NCT03167411|Experimental|Bexagliflozin alone|
89385463|NCT03167411|Active Comparator|Bexagliflozin with exenatide injection|
89385464|NCT02035436|Experimental|Non-sedation|Non-sedation supplemented with pain management during mechanical ventilation.
89385465|NCT02035436|Active Comparator|Sedation|Current gold standard: Sedation with a daily wake-up trial.
89385466|NCT03601754|Experimental|Closed Loop Stimulation (CLS)|Prior to enrollment, the patient would have received Biotronik pacemaker with His bundle lead placement for at least 30 days and CLS will be programmed ON for at least 7 days as part of routine care.
89385467|NCT02237768|Experimental|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET of Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey one tablet, once
89385468|NCT02237768|Experimental|DYNABAC 250 MG ENTERIC COATED TABLET|DYNABAC 250 MG ENTERIC COATED TABLET of Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey, two tablets, once
89385469|NCT03606278|Experimental|Structured debriefing assisted by video|In the structured debriefing assisted by video, the process was based on the immediate review of the video, stopping and rewinding the recording as required.
89385470|NCT03606278|Active Comparator|Structured oral debriefing|In the structured oral debriefing, the process was based by the mental search of their memories of what occurred.
89385471|NCT01952847|Placebo Comparator|mTOR Inhibitor Patient Group - Placebo|Participants receive placebo beginning on Day 1 of an mTOR inhibitor based therapy. Placebo taken as a sugary drink by mouth. Participant will take the drink twice daily starting first day anti-cancer therapy received. Participant to swish the drink for 10 seconds and swallow. Four weeks of treatment constitute 1 cycle for participants on mTOR inhibitor therapy.
89385472|NCT01952847|Experimental|mTOR Inhibitor Patient Group - Glutamine|Glutamine taken as a sugary drink by mouth. Participant will take the drink twice daily starting first day anti-cancer therapy received. Participant to swish the drink for 10 seconds and swallow. Four weeks of treatment constitute 1 cycle for participants on mTOR inhibitor therapy.
89385473|NCT01952847|Placebo Comparator|Radiation Therapy to Esophagus Patient Group - Placebo|Placebo taken as a sugary drink by mouth. Participant will take the drink twice daily starting first day radiation therapy to the esophagus received. Participant to swallow the drink in small amounts several times.
89385474|NCT01952847|Experimental|Radiation Therapy to Esophagus Patient Group - Glutamine|Glutamine taken as a sugary drink by mouth. Participant will take the drink twice daily starting first day radiation therapy to the esophagus received. Participant to swallow the drink in small amounts several times.
89385475|NCT03597932||baseline or control group|All participant anesthesiologists do intraoperative handover of anesthesia care according to a usual process or without checklist for 2-week to 1-month baseline data collection.
89385476|NCT03597932||Checklist group|All participant anesthesiologists do intraoperative handover of anesthesia care by using a standardized handover checklist for another 2-week to 1-month data collection.
89385477|NCT02237846|Active Comparator|Intra-articular knee injection of UC-MSC|Human umbilical cord tissue-derived mesenchymal stem cells administered into the knee joint once
89385478|NCT02237846|Active Comparator|IV injection of UC-MSC|Human umbilical cord tissue-derived mesenchymal stem cells administered once per day for 3 consecutive days
89385479|NCT03601676|Active Comparator|Intervention|
89385480|NCT03601676|No Intervention|Control|
89385481|NCT05461833|Experimental|Fecal transplantation group|Fecal transplantation of frozen prepared feces from healthy donor. Application by colonoscope in proximal half of colon.
89385482|NCT05461833|Active Comparator|Standard-care group|FODMAP diet, Otilonium Bromide, oral, (40mg, 1 tablet TID) and a multi-strain probiotic, oral, (1 capsule BID)
89385483|NCT01560585|Experimental|Open label|All participants will receive Isotretinoin for 24 weeks
89385484|NCT03603236||preeclampsia|18-40 aged diagnosed with preeclampsia
89385485|NCT03603236||control|18- 40 aged healthy females over 37. weeks of pregnant with no history of preeclampsia
89385486|NCT05462847|Experimental|Volume loading|
89385487|NCT05462847|Active Comparator|Control|
89385488|NCT03601598|Experimental|SHR-1210 + SHR6390|SHR-1210 was administered 200mg iv every 2 weeks in combination with SHR6390 150mg or 100mg oral daily with 3 weeks on and 1 week off
89385489|NCT05462691|Experimental|Patients without tuberosity reconstruction|patients undergoing reverse shoulder arthroplasty because a proximal humeral fracture with suturing of the tuberosities
89385490|NCT05462691|Active Comparator|Patients with tuberosity reconstruction|patients undergoing reverse shoulder arthroplasty because a proximal humeral fracture without suturing of the tuberosities
89385491|NCT03597152|Experimental|Treatment|WelTract
89385492|NCT03597152|Placebo Comparator|Control|Inert Placebo
89385493|NCT03601364||Group 1|1.Mechanical ventilator closed group (Mechanical ventilator off)
89385494|NCT03601364||Group 2|"Tidal Voltage 3-4ml / kg (TV),~FIO2 50%, Flow: 2L / min,~Frequency; 10-12 applied group."
89385495|NCT03601364||Group 3|"1. PEEP: 5 cm H2O basınç,~Tidal Voltage 3-4ml / kg (TV),~FIO2 50%, Flow: 2L / min,~Frequency; 10-12 applied group."
89385496|NCT03075501|Active Comparator|Paired|Individuals receive drug (stimulant, or sedative) on two separate occasions and placebo on two separate occasions. Individuals receive drug in only one room.
89385497|NCT03075501|Other|Unpaired|Individuals receive drug (stimulant, or sedative) on two separate occasions and placebo on two separate occasions. Individuals receive drug in both rooms.
89385498|NCT03597074||1|Patients without AKI progression Use of color Doppler Ultrasound derived Renal Resistive Index (RI) and semi-quantitative evaluation of intra-renal vascularization for early prognosis of AKI progression
89385499|NCT03597074||2|Patients with Transient AKI Use of color Doppler Ultrasound derived Renal Resistive Index (RI) and semi-quantitative evaluation of intra-renal vascularization for early prognosis of AKI progression
89385500|NCT03597074||3|Patients with Persistent AKI Use of color Doppler Ultrasound derived Renal Resistive Index (RI) and semi-quantitative evaluation of intra-renal vascularization for early prognosis of AKI progression
89385501|NCT03596528|Other|Lung biopsy|Lung biopsy
89385502|NCT05462535||Single arm, Single group(No interventional)|Observational
89385503|NCT03596216|Experimental|Percutaneous Electrial Stimulation (PES group).|"This intervention consisted in the application of an asymmetric biphasic rectangular current. The subject lay prone with her feet outside the table. The FHL muscle was located at 50% of the distance between the fibular head and inferior border of the lateral malleolus on the posterior aspect of the fibular by ultrasound machine (cross-section) (Logiq, GE Healthcare, USA) and then, a needle (0.30mm x 0.40mm) was inserted, perpendicular to the surface of the skin, until the muscle belly. Prior to inserting a neddle, the underlying skin was cleaned with isopropyl alcohol. The intensity of the current was necessary to cause an exacerbated muscle contraction, during 1.5 min acording to the Valera and Minaya protocol´s.~This intervention was performed once in each participant, on one leg only (stance limb), It's only once, it was not a treatment"
89385504|NCT03596216|Experimental|Transcutaneous Electrial Stimulation (TENS group)|"This intervention consisted in the application of an asymmetric biphasic rectangular current. The subject lay prone with her feet outside the table. The FHL muscle was located at 50% of the distance between the fibular head and inferior border of the lateral malleolus on the posterior aspect of the fibular by ultrasound machine (cross-section) (Logiq, GE Healthcare, USA),and then, one self-adhesive electrode was placed on the back of the leg and the other on the sole of the foot. The intensity of the current was necessary to cause an exacerbated muscle contraction, during 1.5 min.~This intervention was performed once in each participant, on one leg only (stance limb), It's only once, it was not a treatment"
89385505|NCT05461443|Active Comparator|Wild-type|Supplementation with the wild-type of the LGG strain
89385506|NCT05461443|Experimental|Low-pill|Supplementation with the low-pili LGG strain
89385507|NCT05461443|Experimental|High-pili|Supplementation with the high-pili LGG strain
89385508|NCT05461365|Experimental|intranasal insulin|For each selected participant (n=27), a baseline olfactory measurement was performed with Sniffin Sticks® (12 items) and a capillary glucose measurement was obtained with Dextrostix® NF before and after the intervention, in order to guarantee patient safety and reduce the risk of hypoglycemia. The initial and final measurements were divided into three subsections with a different number of correct answers for each section Subsequently, Gelfoam® cottonoids soaked in 40 IU of NPH insulin were placed on the nasal roof (between the nasal septum and the middle meatus) of each nostril. These remained in place for 15 minutes and were later removed. This procedure was performed in three visits one week apart. During the fourth and last visit (one week after the previous visit), olfaction was reevaluated using the measures previously described.
89385509|NCT03602846||Good Outcome|Good outcome is defined as the safe delivery of the newborn.
89385510|NCT03602846||Poor Outcome|Poor outcome is defined as the incidence of fetal demise during pregnancy.
88860906|NCT04757064|Experimental|Standard Rehabilitation Group|"Standard Rehabilitation Group: will receive the standard protocol of king Hussein hospital 6 weeks post-operative which is:~Start aggressive knee flexion exercises and increase the extensor strength. Consider CPM/dynasplint if flexion <60_ MUA contraindicated.~Examination under anesthesia can be done to assess the cause of limited knee flexion. Surgical release is indicated if knee flexion is < 60 degrees at six months after surgery."
89385511|NCT02317991|Experimental|nab-paclitaxel and ramucirumab|"All patients will receive 125 mg/m^2 of nab-Paclitaxel intravenously (IV) on Days 1, 8, and 15 of a 28-day cycle (weekly for 3 weeks, with 1 week of rest).~Patients will receive ramucirumab 8mg/kg IV in combination with nab-paclitaxel on Days 1 and 15 of the 28-day cycle."
89385512|NCT03602768|Experimental|Goal Management Training|The online version of GMT with a therapist on the back-end monitoring progress and giving feedback throughout the program. Online GMT takes 5-9 weeks (self-paced) to complete 9 modules involving instructional video with interactive content, practice of cognitive strategies through games, and between-module exercises.
89385513|NCT03602768|Experimental|Memory & Aging Program|The online version of MAP with a therapist moderator on the course discussion pages. MAP takes 5-9 weeks (self-paced) to complete 8 modules involving instructional video with interactive content and practice of memory strategies through various exercises.
89385514|NCT03602768|Placebo Comparator|Cambridge Brain Sciences Training|This is a commercial and research brain training platform, composed of 7 games that are online adaptations of the standard measures of cognition including working memory and spacial planning.
89385515|NCT03602768|No Intervention|Waitlist|Participants randomized to this arm will receive no additional information or access to intervention programs until after the follow up testing measures are collected, at which point they will be given access to the intervention of their choosing.
89385516|NCT00861549|Experimental|cohort 1|1mg / 0.5 tablet
89385517|NCT00861549|Experimental|cohort 2|2mg / 1 tablet; crossover with Phencynonate hydrochloride (2mg/1 tablet) made in China
89385518|NCT00861549|Experimental|cohort 3|4mg / 2 tablets
89385519|NCT03602690|Experimental|Dolutegravir + Darunavir/ritonavir + optimized NRTI|"All patients will receive ART regimen every day including:~Dolutegravir 50mg once daily Darunavir/ritonavir 600/100 twice daily Optimized NRTI recycling with lamivudine and one other NRTI (zidovudine or tenofovir or abacavir)"
89385520|NCT01330511||Bilateral Hydronephrosis Grade I-II|Patients with Bilateral Hydronephrosis Grade I-II
88860907|NCT04757064|Experimental|Supervised Rehabilitation Group|Supervised Rehabilitation Group: will receive supervised rehabilitation program 1 session / week for 45 minutes-1 hour.
88860908|NCT01894386|Experimental|Sequence 1|Subjects will receive treatment A, B, C, D in each dosing periods 1, 2, 3, and 4 respectively (one per period). A - FF/UMEC/VI 400/500/100; B - FF/UMEC/VI 400/250/100; C - FF/VI 400/100; D - UMEC/VI 250/100
89385521|NCT01330511||Bil. Hydronephrosis Grade III-IV, Other|Patient with Bilateral Hydronephrosis Grade III-IV and others with any hydronephrosis and distended bladder or MCKD
89385522|NCT01330511||Unilateral Hydronephrosis Grade I-II|Patients with Unilateral Hydronephrosis Grades I-II
89385523|NCT01330511||Unilateral Hydronephrosis Grade III-IV|Patients with Unilateral Hydronephrosis Grade III-IV
89385524|NCT01379547|Active Comparator|Conventional Treatment|Patients who will be randomized to arm 1 will receive antibiotic therapy with a duration based on conventional practice
89385525|NCT01379547|Experimental|procalcitonin-guided antibiotics treatment|Patients who will be randomized to arm 2 will receive antibiotics therapy with a duration based on procalcitonin-guided algorithm.
89385526|NCT02237612|Experimental|Diagnostic (diffusion-weighted MRI)|Patients undergo diffusion-weighted MRI of the pelvis.
89385527|NCT02978495|Experimental|A- BRCA Mutation|"Doxorrubicin 60 mg/m2 concomitantly with Cyclophosphamide 600mg/m2, every 3 weeks, for 4 cycles followed by:~Paclitaxel 80 mg/m2 once a week, for 12 weeks, concomitant to Carboplatin AUC 1,5 once a week, for 12 weeks."
89385528|NCT02978495|Active Comparator|B- BRCA Mutation|"Doxorrubicin 60 mg/m2 concomitantly with Cyclophosphamide 600mg/m2, every 3 weeks, for 4 cycles followed by:~Paclitaxel 80 mg/m2 once a week, for 12 weeks."
89385529|NCT02978495|Experimental|C- BRCA wild-type|"Doxorrubicin 60 mg/m2 concomitantly with Cyclophosphamide 600mg/m2, every 3 weeks, for 4 cycles followed by:~Paclitaxel 80 mg/m2 once a week, for 12 weeks, concomitant to Carboplatin AUC 1,5 once a week, for 12 weeks."
89385530|NCT02978495|Active Comparator|D- BRCA wild-type|"Doxorrubicin 60 mg/m2 concomitantly with Cyclophosphamide 600mg/m2, every 3 weeks, for 4 cycles followed by:~Paclitaxel 80 mg/m2 once a week, for 12 weeks."
89385531|NCT02237690|Experimental|doxorubicin hydrochloride liposome（Libaoduo）|Use the test drug(doxorubicin hydrochloride liposome-Libaoduo,from Fudan-Zhangjiang ),then use the reference drug(doxorubicin hydrochloride liposome，from Sunpharma) after at least 4-weeks.
89385532|NCT02237690|Active Comparator|doxorubicin hydrochloride liposome|Use the reference drug(doxorubicin hydrochloride liposome，from Sunpharma),then use the test drug drug(doxorubicin hydrochloride liposome-Libaoduo,from Fudan-Zhangjiang) after at least 4-weeks.
89385533|NCT03602534||cases with variable acne severity scores|"group will include 50 females~Clinical examination including acne grade assessment using Global Acne Grading Scale (GAGS)~Assessment of body mass index (BMI)~blood serum samples will be collected from all patients to do thyroid function test"
89385534|NCT03602534||healthy controls|"group will include 29 females~Assessment of body mass index (BMI)~blood serum samples will be collected from all healthy controls to do thyroid function test"
89385535|NCT03601208|Experimental|Blood sample|Venepuncture vs fingerprick test using Mitra volumetric absorptive microsampling (VAMs)
89385536|NCT04788017|Active Comparator|ziresovir|"The study drugs will be administered to subjects by CRU staff at approximately 8:00 a.m. (± 1 hour), following an overnight fast.~Immediately following administration of the assigned dose of the study drugs, subjects will be given water such that their water consumption is approximately 240 mL as follows:~If administered 60 mL as the study drug dose, follow with approximately 180 mL water.~If administered 120 mL as the study drug dose, follow with approximately 120 mL water.~If administered 180 mL as the study drug dose, follow with approximately 60 mL water."
89385537|NCT04788017|Placebo Comparator|placebo|"The study drugs will be administered to subjects by CRU staff at approximately 8:00 a.m. (± 1 hour), following an overnight fast.~Immediately following administration of the assigned dose of the study drugs, subjects will be given water such that their water consumption is approximately 240 mL as follows:~If administered 60 mL as the study drug dose, follow with approximately 180 mL water.~If administered 120 mL as the study drug dose, follow with approximately 120 mL water.~If administered 180 mL as the study drug dose, follow with approximately 60 mL water."
89385538|NCT03601130|Other|No Bone Graft|Open Wedge High Tibial Osteotomy with medial plate fixation (without bone grafting)
89385539|NCT03601130|Active Comparator|HydroxyColl Bone Graft Substitute|Open Wedge High Tibial Osteotomy with medial plate fixation (with bone grafting) using Hydroxycoll bone graft substitute.
89385540|NCT02942615|Experimental|Heart safety management|limit heart dose more frequent follow up of cardiac function professional management of cardiac toxicity
89385541|NCT02942615|No Intervention|Control group|without any restrict heart dose limitation for RT Follow up of cardiac function Observation and without any special management of cardiac toxicity
89385542|NCT03600974||Endoscopy-E(+)|Subjects with positive endoscopy finding:erosive esophagitis or Barrett esophagus.For subjects of this group, PPIs, Stretta,Laparoscopic Nissen fundoplication is considered.
89385543|NCT03600974||Endoscopy-E(-)|Subjects with negative endoscopy finding:NERD.
89385544|NCT03600974||Acid-A(+)|Subjects with DeMeester scores>14.72.For subjects of this group, PPIs, Stretta,Laparoscopic Nissen fundoplication is considered.
89385545|NCT03600974||Acid-A(-)|Subjects with DeMeester scores<14.72
88860909|NCT01894386|Experimental|Sequence 2|Subjects will receive treatment B, D, A, C in each dosing periods 1, 2, 3, and 4 respectively (one per period). A - FF/UMEC/VI 400/500/100; B - FF/UMEC/VI 400/250/100; C - FF/VI 400/100; D - UMEC/VI 250/100
88860910|NCT01894386|Experimental|Sequence 3|Subjects will receive treatment C, A, D, B in each dosing periods 1, 2, 3, and 4 respectively (one per period). Subjects will receive treatment B, D, A, C in each dosing periods 1, 2, 3, and 4 respectively (one per period). A - FF/UMEC/VI 400/500/100; B - FF/UMEC/VI 400/250/100; C - FF/VI 400/100; D - UMEC/VI 250/100
89385546|NCT03600974||impedance-I（+）W/S|Subjects with total reflux number > 80 in 24h pH-impedance monitoring. W means weakly acid reflux account for above 50% in total reflux number. G means gas reflux account for above 50% in total reflux number.For subjects of this group,probiotic agent is considered.
89385547|NCT03600974||impedance-I（-）|Subjects with total reflux number < 80 in 24h pH-impedance monitoring.
89385548|NCT03600974||Reflux-symptom association-S(+)|Subjects with positive reflux-symptom association.For subjects of this group, PPIs, Stretta, neuromodulators are considered.
89385549|NCT03600974||Reflux-symptom association-S(-)|Subjects with negative reflux-symptom association
89385550|NCT03600974||motility-M(+)|Subjects with motility disorders according to Chicago v3.0.For subjects of this group, prokinetic motility agents are considered.
89385551|NCT03600974||motility-M(-)|Subjects without motility disorders according to Chicago v3.0
89385552|NCT03600974||lower oesophageal sphincter-L(+)|Subjects with abnormal LES pressure or EGJ type III or hiatus hernia.For subjects of this group, Stretta,Laparoscopic Nissen fundoplication is considered.
89385553|NCT03600974||lower oesophageal sphincter-L(-)|Subjects with normal LES pressure and EGJ type I~II
89385554|NCT03600974||psychology-P(+)|Subjects with normal psychology condition.For subjects of this group,neuromodulators are considered.
89385555|NCT03600974||psychology-P(-)|Subjects with abnormal psychology condition
89385556|NCT03075267|Experimental|PT010 (BGF MDI) 320/14.4/9.6 µg|PT010 Budesonide, Glycopyrronium and Formoterol Fumurate Metered Dose Inhaler (BGF MDI) 320/14.4/9.6 µg
88860911|NCT01894386|Experimental|Sequence 4|Subjects will receive treatment D, C, B, A in each dosing periods 1, 2, 3, and 4 respectively (one per period). Subjects will receive treatment C, A, D, B in each dosing periods 1, 2, 3, and 4 respectively (one per period). Subjects will receive treatment B, D, A, C in each dosing periods 1, 2, 3, and 4 respectively (one per period). A - FF/UMEC/VI 400/500/100; B - FF/UMEC/VI 400/250/100; C - FF/VI 400/100; D - UMEC/VI 250/100
88860912|NCT02104986|Experimental|3 courses of Velbe-Bleomycin-Cisplatin|3 VBP (Velbe-Bleomycin-Cisplatin) Risk-adapted strategy - reduction of the number of chemotherapy courses
88860913|NCT02104986|Experimental|4 courses of Velbe-Bleomycin-Cisplatin|4 VBP (Velbe-Bleomycin-Cisplatin) Risk-adapted strategy - reduction of the number of chemotherapy courses
88860914|NCT02104986|Experimental|3 courses Vepeside-ifosfamide-Cisplatin|3 VIP (Vepeside-ifosfamide-Cisplatin) Risk-adapted strategy - reduction of the number of chemotherapy courses
88860915|NCT02104986|Experimental|4 courses Vepeside-ifosfamide-Cisplatin|4 VIP (Vepeside-ifosfamide-Cisplatin) Risk-adapted strategy - reduction of the number of chemotherapy courses
88860916|NCT01894932|Experimental|MBCT Group for stress patient|Mindfulness-based cognitive Group therapy will be administered on stress patient.
89385557|NCT03075267|Experimental|PT010 (BGF MDI) 160/14.4/9.6 µg|PT010 (BGF MDI) 160/14.4/9.6 µg
89385558|NCT03075267|Experimental|PT003 (GFF MDI) 14.4/9.6 µg|PT003 (GFF MDI) 14.4/9.6 µg
89385559|NCT03600896|Experimental|Phase 1: Recombinant Human Interleukin-7 (CYT107)|"In Part 1 of the study, 3 dose levels of CYT107 will be tested in this study. Up to 3 participants will be enrolled in each dose level. The first group of participants will receive the lowest dose level. The next group will receive a higher dose than the first group, if no intolerable side effects were seen. The third group will receive an even higher dose than the second, if no intolerable side effects were seen. Based on the results seen, 1 of the 3 doses will be selected as the recommended dose.~In Part 2 of the study, an additional 25 participants will be enrolled to receive CYT107 at the recommended dose found in Part 1."
89385560|NCT03600896|Experimental|Phase 2: Recombinant Human Interleukin-7 (CYT107)|In Part 2 of the study, an additional 25 participants will be enrolled to receive CYT107 at the recommended dose found in Part 1.
89385561|NCT03600662|Experimental|TriRec|Trileaflet Reconstruction of the Aortic Valve
89385562|NCT03600662|Experimental|Aortic valve replacement|Biological prosthesis, Device: St. Jude Medical Trifecta GT
89385563|NCT03600584|Experimental|One-layer duct-to-mucosa Group|Modified one-layer duct-to-mucosa pancreaticojejunostomy is used after pancreaticoduodenectomy.
89385564|NCT03600584|Active Comparator|Invagination Group|Invagination pancreaticojejunostomy is used after pancreaticoduodenectomy.
89385565|NCT03600506|Active Comparator|Dexmedetomidine|Intervention drug of the study
88860917|NCT01894932|Experimental|MBCT Group for depression patient|Mindfulness-based cognitive Group therapy will be administered on depression patient.
88860918|NCT01894932|Experimental|SR group for stress patient|psycho-physiological stress regulation group will be administered on stress patient.
88860919|NCT01894932|Experimental|SR group for depression patient|psycho-physiological stress regulation group will be administered on depression patients.
89385566|NCT03600506|Placebo Comparator|Placebo|Normal Saline (Placebo)
89385567|NCT05266677|Experimental|EXPL|Liquid oral supplement comprising a blend of glycerides at certain proportions
89385568|NCT05266677|Other|CTRL|Liquid oral supplement comprising glycerides used in current formulas
89385569|NCT03593486|Experimental|Active Stimulation|Participants will receive active EMF stimulation through the study device for 60 minutes during the procedure.
89385570|NCT03593486|Sham Comparator|Sham Stimulation|The participant will be positioned in the stimulator, but no EMF stimulation will be delivered.
89385571|NCT03593330|Experimental|Transitional Care Programme|The primary intervention of the Transitional Care Programme (TCP) will be additional patient education, framing of expectations for the hospital course and length of stay, coordinated team preparation for discharge, a dedicated discharge appointment, and a follow up phone call.
89385572|NCT03593330|No Intervention|Standard of Care|Patients are admitted without a pre-determined discharge date. They do not receive a dedicated discharge appointment, and will not receive a follow up phone call 48 hours after discharge.
89385573|NCT03590834|Experimental|Center-based intervention|In-person, child-focused intervention taking place only at the Head Start centers
89385574|NCT03590834|Experimental|Center-and-home-based intervention|In-person, child-focused intervention taking place only at the Head Start centers. Delivered in-person at Head Start centers and the family home.
89385575|NCT03590834|Active Comparator|Active Control|Active comparison group
89385576|NCT03600272|Experimental|Combined spinal-epidural analgesia|The combined spinal epidural analgesia technique was used to maintain analgesia for parturients in the combined spinal-epidural analgesia group. First, the investigator injected a dose of 5 ug sufentanil into cerebrospinal fluid. If no adverse effects were observed 10 minutes after the first dose, the parturient then received mixed liquids of 0.075% ropivacaine and 0.2ug/ml sufentanil citrate through a patient-controlled epidural analgesia (PCA) pump, which provided patients themixed solution at 8-10ml/h to optimize their pain relief until the delivery of neonates.
89385577|NCT03600272|Other|Epidural analgesia|The epidural analgesia technique was used to maintain analgesia for parturients in the epidural analgesia group, which involved placing a thin catheter through a needle inserted into the epidural space. First, the investigator injected a test dose of 5ml 1% lidocaine through it. If not adverse effects were observed 10 minutes after the test dose, the parturient then received a bolus injection of an initial dose of 8-10 ml mixed liquids of 0.075% ropivacaine and 0.2ug/ml sufentanil citrate. We then connected the catheter with a patient-controlled epidural analgesia (PCA) pump, which provided patients the same mixed solution at 8-10ml/h to optimize their pain relief until the delivery of neonates.
89385578|NCT05082597|Experimental|ESWT|Receive low energy extracorporeal shock wave therapy
89385579|NCT03600038|Experimental|Experimental|This is the experimental arm of the study. This includes receiving the novel/experimental smoking cessation smartphone app. Therapy description of experimental app withheld to protect the integrity of the study.
89385580|NCT03600038|Active Comparator|Control|This is the control arm of the study. This includes receiving the standard of care smoking cessation smartphone app. Therapy description of standard of care app withheld to protect the integrity of the study.
89385581|NCT03913286|Experimental|Intervention|The participant will be implanted with the Blackrock Microsystems MultiPort system.
89385582|NCT04856943|Experimental|smartconsent group|Intervention group: : the principal investigator upon receiving the tablet enters with his/her user and password, registers his/her signature, selects the patient (anonymized), selects the intervention and then the tablet will be given to the patient and he/she will be instructed to follow the indications in order to be able to project the video and digitally sign the informed consent.
89385583|NCT04856943|Placebo Comparator|control group|Control group: The informed consent paper document (official format) will be printed with the patient's name, signed by the physician (principal investigator) and given to the patient to read and sign.
89385584|NCT03599336|Other|Nonoperative Treatment|Subjects will have nonoperative treatment to treat proximal humerus fracture that is broken into 3 or 4 parts.
89385585|NCT03599336|Other|Operative Course for rTSA|Subjects will have shoulder replacement surgery to treat proximal humerus fracture that is broken into 3 or 4 parts.
89385586|NCT03074331|Experimental|SOF/VEL|SOF/VEL for 12 weeks
89385587|NCT03599024|Experimental|PCEA Group|The patients randomized into this arm were able to control the administration of analgesics, according to their subjective condition.
89385588|NCT03599024|Active Comparator|Non-PCEA Group|The patients randomized into this arm were receiving analgesics according to the physician's prescription.
89385589|NCT02237924|Experimental|endostar + IMRT|
88860920|NCT01894932|No Intervention|normal|normal, no intervention.
88860921|NCT01894932|No Intervention|Drug treatment remission patient|Drug treatment remission patient
88860922|NCT04757532|Experimental|Bupropion|Subjects receive a single-dose treatment. Urine samples will be collected until 3 days after administration in 6 fractions: 0-4h, 4-8h, 8-12h, 12-24h, 24-48h, 48-72h post-administration.
88860923|NCT04757532|Experimental|Anastrozole|Subjects receive a single-dose treatment. Urine samples will be collected until 7 days after administration in 7 fractions: 0-24h, 24-48h, 48-72h, 72-96h, 96-120h, 120-144h, 144-168h post-administration.
88860924|NCT04757532|Experimental|Testosterone cyclopentylpropionate|Subjects receive a single-dose treatment. Urine samples will be collected until 20 days after administration in 20 fractions: first urine of the day, every day.
88860925|NCT04757532|Experimental|Danazol|Subjects receive a single-dose treatment. Urine samples will be collected until 2 days after administration in 6 fractions: 0-4h, 4-8h, 8-12h, 12-24h, 24-36h, 36-48h post-administration.
88860926|NCT04757532|Experimental|Chlorthalidone|Subjects receive a single-dose treatment. Urine samples will be collected until 3 days after administration in 4 fractions: 0-12h, 12-24h, 24-48h y 48-72h post-administration.
89385590|NCT02237924|Active Comparator|DDP + IMRT|
89385591|NCT04855227||Laparoscopic ventral hernia repair|These subjects will undergo a laparoscopic primary umbilical or incisional hernia repair.
89385592|NCT04855227||Robotic-assisted ventral hernia repair|These subjects will undergo a robotic-assisted primary umbilical or incisional hernia repair.
89385593|NCT02238002||normal angle|normal anterior chamber and open angle eyes underwent cataract surgery
89385594|NCT02238002||narrow angle|shallow anterior chamber and narrow angle eyes underwent cataract surgery
88860927|NCT01890954|Active Comparator|DiAs-closed-loop system|eight hours using Closed Loop Control (DiAs) under both, miss insulin bolus for 30 grams of carbohydrates snack or under bolus for an 80 grams of carbohydrates lunch
88860928|NCT01890954|No Intervention|Sensor Augmented Pump|8 hours observational under both, missed insulin bolus for 30 gr carbohydrates snack and under bolus for an 80 gr carbohydrates lunch. Sensor augmented pump used the patients own insulin settings (basal rate, meal boluses and correction boluses) and a CGM provided by the study team to be used during admission. No DiAs use during this admission.
89385595|NCT04615533||Frail older adults, assessment|Frail older adults, assessment Frail'BESTest, Clinical Frailty Scale, Mini BESTest, Berg Balance Scale, Tinetti Blance and Gait Scale
89385596|NCT04561089||COVID-19 asymptomatic population|COVID-19 asymptomatic Illumina personnel
89385597|NCT03825302||Males with asthma|Induced sputum, methacholine challenge, and mannitol challenge will be performed.
89385598|NCT03825302||Females with asthma|Induced sputum, methacholine challenge, and mannitol challenge will be performed.
89385599|NCT04851795|Experimental|supervised physical exercise sessions|Participants assigned to the supervised exercise group will perform a supervised routine of approximately 30 minutes, 2 days per week (Monday and Wednesday at the Txagorritxu hospital, and Tuesday and Thursday at the Santiago hospital from 7:15 to 7:45 and from 15:15 to 15:45).
89385600|NCT04851795|Other|unsupervised physical exercise sessions|For the non-supervised group, we will propose climbing the stairs from floor 0 to floor 7 three times during the working day and doing planks and stretching exercises outside of work. For the latter, an educational session will be given at the beginning of the study to explain how to perform them correctly.
89385601|NCT02238392|Active Comparator|Group A|Adenosine testing after PVI and elimination of dormant conduction
89385602|NCT02238392|Active Comparator|Group B - Termination of AF|Termination of atrial fibrillation by catheter ablation
89385603|NCT02260193|Experimental|AKB-6548, starting dose 1|
89385604|NCT02260193|Experimental|AKB-6548, starting dose 2|
89385605|NCT02260193|Experimental|AKB-6548, starting dose 3|
89385606|NCT05763147|Experimental|PosiFlush™ Pre-filled flush syringes (Suzhou Becton Dickinson Medical Devices Co., Ltd.)|PosiFlush™ Pre-filled flush syringes (Suzhou Becton Dickinson Medical Devices Co., Ltd.)
89385607|NCT05763147|Active Comparator|PosiFlush™ Pre-filled Flush Syringes (BD, USA)|PosiFlush™ Pre-filled Flush Syringes (BD, USA)
89385608|NCT03587402|Experimental|Transcutaneous perineal stimulation|Patient is asked to lie down with legs slightly bend and two adhesive electrodes are attached transcutaneous on base of penis and on perineum. Stimulation current is administrated half time with a fixed frequency of 30 Hz and half time with 50 Hz. Pulse increased until the patient perceives the current. Sessions lasted for 30 minutes weekly for 10 weeks.
89385609|NCT03587402|Active Comparator|Anal stimulation|Patient is asked to lie down with legs slightly bend and an electrical probe is inserted into the anus. Stimulation current is administrated half time with a fixed frequency of 30 Hz and half time with 50 Hz. Pulse increased until the patient perceives the current. Sessions lasted for 30 minutes weekly for 10 weeks.
88860929|NCT02065830|Experimental|Robot Safety and Efficacy|"The subjects will undergo inpatient rehabilitation consisting of a treatment cycle of 30/40 training section using the robot EKSO system device, according to individually tailored exercise scheduling.~The practice will include robot-assisted walking at variable speeds for 45/60 min and balance training."
88860930|NCT02064114|Active Comparator|Intervention group|Start of optimal management of risk factors, every 2 weeks for 6 months after atrial fibrillation ablation. And followed for a period of 3,6 and 12 months after the procedure.
88860931|NCT02064114|Active Comparator|control group|conventional treatment, followed for a period of 3,6 and 12 months after the procedure.
88860932|NCT04756830|Other|Vaccination|All participants will receive two doses of the inactivated adsorbed vaccine against COVID-19.
88860933|NCT02063022|Active Comparator|Standard treatment (as per ISG SSG III protocol)|"Standard treatment for non metastatic Ewing's Sarcoma (as defined by the ISG/SSG III protocol).~It is based on a 6 drugs pre-local treatment (Vincristin, dactinomycin, cyclophosphamide,ifosfamide,etoposide and doxorubicin) followed by local treatment (surgery and/or radiotherapy)and by a maintenance treatment based on induction response"
89385610|NCT02035514|Experimental|Arm 1|A single infusion of up to 1 million cells per Kg of autologous MSC stem cells vs placebo. The treatment will be on day 0 and placebo on month 6.
88860934|NCT02063022|Experimental|Intensified treatment|Dose intense treatment for non metastatic Ewing's Sarcoma It is based on a 3 drug pre-local treatment (Vincristin, ifosfamide and doxorubicin)followed by local treatment (surgery and/or radiotherapy)and by a maintenance treatment based on induction response
88860935|NCT02059668||Biomarker analyses head & neck cancer tissue, blood specimen|Validation of prognostic biomarkers for local tumor control in definitive and adjuvant treatment of head and neck cancer.
88860936|NCT01895010|Experimental|Acupoint and tropisetron|acupoint electric stimulation combined with tropisetron 6mg before TACE
88860937|NCT01895010|Active Comparator|tropisetron|treated with tropisetron 6mg before TACE
88860938|NCT02039388|Other|High risk patients for breast and/or ovarian cancer|
89385611|NCT02035514|Experimental|Arm 2|A single infusion of up to 1 million cells per Kg of autologous MSC stem cells vs placebo. The treatment will be on month 6 and placebo on day 0.
89385612|NCT04819035||CBC-Diff Monocyte Volume Width Distribution|Monocyte Volume Width Distribution (MDW) is part of the CBC with Differential
89385613|NCT02238236||Patients with allergic rhinitis, eczema/dermatitis, urticaria|
88860939|NCT04389528|Experimental|tDCS active arm|
88860940|NCT04389528|Placebo Comparator|tDCS placebo|
88860941|NCT05413356|Experimental|treatment group|Ruxolitinib twice daily treatment, combined with steroids 1mg/kg/day for two weeks, and tampering 0.25 mg/kg/day every week
89385614|NCT04306029|No Intervention|Pre-Intervention|
89385615|NCT04306029|Experimental|Post-Intervention|"Postpartum staff has received the Postpartum Family Planning Package, which consists of provider education on contraceptive delivery in the immediate postpartum period and promotion of the WHO MEC/PFP Compendium mobile application."
88860942|NCT00603330|Experimental|1|MSC infusion for steroid-refractory grade II-IV acute GVHD. In this arm, 4 x 10E6 MSC/Kg BW of the recipient will be injected during the first hour after thawing.
88860943|NCT00603330|Experimental|2|MSC infusion for poor graft function. In this arm, 2 x 10E6 MSC/Kg BW of the recipient will be injected during the first hour after thawing.
88860944|NCT00603330|Experimental|3|MSC + DLI for poor donor T-cell chimerism after allogeneic HCT. In this arm, 2 x 10E6 MSC/Kg BW of the recipient will be injected during the first hour after thawing.
88860945|NCT01896336|Experimental|5mg sublingual Zolpidem hemitartrate|1 QD
88860946|NCT01896336|Active Comparator|10 mg oral Zolpidem hemitartrate|1 QD.
88860947|NCT04293666|Experimental|Kefir drink|(2) The first phase of Kefir, the second phase of the placebo group (hereinafter referred to as group B
88860948|NCT04293666|Placebo Comparator|placebo|(1) first-stage placebo and second-stage Kefir group (hereinafter referred to as group A).
89385616|NCT02849678|Active Comparator|Lidocaine|"Lidocaine will be infused through a catheter placed in the thoracic paravertebral space to block the transmission of pain signals at the level of the spinal nerves from the abdominal incision.~At a concentration of 0.5%, Lidocaine has been deemed safe to use for peripheral nerve blocks and analgesia.Compared to ropivacaine, lidocaine is shorter-acting, less cardiotoxic, and safer to use."
89385617|NCT02849678|Active Comparator|Ropivacaine|"Ropivacaine is a local anesthetic used as the standard drug in paravertebral nerve blocks at our institution. It is also used in other nerve block infusions at our hospital and institutions across the country. It will be used as the standard drug to which lidocaine is compared.~Ropivacaine has been safely used in the paravertebral nerve blocks at our institution for several years."
89385618|NCT04295577||Cohort 1: Retrospective Cohort|"This cohort will include:~Patients who have previously commenced maintenance Niraparib prior to the MONITOR study opening at the site and are still receiving Niraparib but in whom quality of life data are not available.~Patients who have previously commenced Niraparib prior to the MONITOR Study opening at the site but are now deceased but will be eligible for retrospective data collection without the need for informed consent.~Patients who have previously commenced maintenance Niraparib prior to the MONITOR study opening at the site but have discontinued treatment.~Data in respect of AEs, SAEs, ADRs and AESIs will be recorded in Case Report Forms and be identified via the patient's medical records. There is no requirement to complete trial specific SAE reporting forms in this cohort."
89385619|NCT04295577||Cohort 2: Prospective Cohort|"This cohort will include:~Patients who have previously commenced maintenance Niraparib prior to the MONITOR study opening at the site and are still receiving Niraparib and in whom quality of life data is available.~Patients who are due to commence maintenance Niraparib treatment."
89385620|NCT02238158||Chronic Obstructive Pulmonary Disease|
88860949|NCT00556218|Other|Tibetan Meditation|
88860950|NCT00556218|Other|No Meditation|
88860951|NCT00532740||All Patients|Patients with metastatic cancer of the liver who are not surgical resection candidates and who will be treated with TheraSphere per institutional standard of care.
88860952|NCT00508794|Experimental|Group 1 Yoga Program|3 sessions of yoga each week for 6 weeks. Questionnaire evaluating treatment-related symptoms during the middle of radiotherapy.
89184680|NCT00787787|Experimental|Treatment (sunitinib malate and capecitabine)|Patients receive sunitinib malate PO QD on days 1-21 and capecitabine PO BID on days 1-14. Courses repeat every 21 days in the absence or disease progression or unacceptable toxicity.
89385621|NCT02238314|Experimental|Tipranavir low dose|
89385622|NCT02238314|Experimental|Tipranavir high dose|
89385623|NCT03587168||Patients with Parkinson's Disease|Patients with Parkinson's Disease Parkinson's Disease (Hoehn and Yahr stage 1-4)
89385624|NCT03587168||Healthy Controls|Healthy People
88860953|NCT00508794|Experimental|Group 2 Stretching Program|3 sessions of stretching each week for 6 weeks. Questionnaire evaluating treatment-related symptoms during the middle of radiotherapy.
88860954|NCT00508794|Other|Group 3 Waitlist Control Group|Option of participating in the yoga or stretching program after the study has ended. Questionnaire evaluating treatment-related symptoms during the middle of radiotherapy.
88860955|NCT04253652||Oral iron|These patients will have diagnosed with iron deficiency anaemia and been prescribed oral iron supplements as part of their treatment from their doctor. This will be in accordance with the NICE guidelines; 200mg capsules containing 65mg elemental iron, 2-3 times a day for a period of atleast 1 month.
88860956|NCT04253652||Intravenous iron|These patients will have diagnosed with iron deficiency anaemia and been prescribed intravenous iron as part of their treatment from their doctor. Participants will receive an infusion of either 1000mg or 1500mg
88860957|NCT02087748|Active Comparator|1% diclofenac sodium gel|Diclofenac sodium 1% gel 4 grams applied topically Q6 hour for 48 hours
88860958|NCT02087748|Placebo Comparator|Placebo|Placebo gel 4gm applied topically Q6 hour for 48 hours
88860959|NCT04755738|Experimental|Almonertinib plus Microwave ablation group|Patients in the group were treated with both targeted therapy and microwave ablation. Patients were treated with Almonertinib with the dose of 110mg once daily firstly. When the best response achieved, microwave ablation was conducted in the primary tumors, and then followed by Almonertinib treatments.
88860960|NCT04755738|Active Comparator|Almonertinib group|Patients in the group were treated with Almonertinib with the dose of 110mg once daily until disease progression, death or intolerable adverse events.
88860961|NCT04755270|Experimental|vr-supported hypnofertility|Relaxation, visualization, imagination and affirmation and techniques based on the hypnofertility philosophy were applied to women in the experimental group in four stages
88860962|NCT04755270|No Intervention|Control|Any initiative was not applied to the control group
88860963|NCT04755504|Experimental|EEG evaluation|All patients will be evaluated during 1 night by standard polysomnography and additionally EEG will be evaluated by 2 electrodes behind each ear connected to a recording device (Sensor Dot)
89184681|NCT02571387|Experimental|Mindfulness|Computerized mindfulness-based intervention. 10 minutes per day, every day for 12 months of MP3 listening. Guidelines are in line with main mindfulness-based interventions (MBSR, MBCT, ACT). Participants can choose between 4 audio recordings (sessions): awareness of the breathing, awareness of postures and bodily sensations, acceptance of thoughts and emotions, and awareness of bodily sensations and related thoughts and emotions while executing 5 squats.
89184682|NCT02571387|Sham Comparator|Sham meditation|"Computerized sham meditation intervention. 10 minutes per day, every day for 12 months of MP3 listening. The unique guideline is to meditate at the beginning of each session. Participants can choose between 4 audio backgrounds: forest, night, beach, and river."
89184683|NCT02571387|No Intervention|Treatment as usual|Usual care in a nutrition pole in France: nutrition, diet, exercise.
88860964|NCT01490502|Active Comparator|Low-dose vitamin D3|
88860965|NCT01490502|Active Comparator|High-dose vitamin D3|
88860966|NCT01895712||Orsiro|
88860967|NCT02317692|Active Comparator|Standard ADHD parent training|8 sessions of evidence-based parent training plus school intervention
88860968|NCT02317692|Experimental|Culturally-modified ADHD parent training|8 sessions of culturally-modified parent training plus school intervention
89184684|NCT02571309|Other|Smartphone app - Asthmatuner|"The app Asthmatuner contains four different modes;~Lung function testing with Bluetooth connection of external spirometry~Symptom evaluation~Actual treatment plan, based om lung function and symptoms~Trend views of lung function, symptoms and asthma control"
89184685|NCT02571309|Other|Conventional|Conventional treatment and Asthmatuner will be stratified and harmonized into categories of asthma management and current state-of-art at each health care centre. Each group harmonized group will include 43 subjects.
89184686|NCT00722475|Experimental|IvIg|Repeated infusions of intravenous immunoglobulin in early pregnancy
89184687|NCT00722475|Placebo Comparator|placebo|infusion of human albumin CSL Behring 5%
89184688|NCT04108169|Active Comparator|Active Comparator|
89184689|NCT04108169|No Intervention|Sham Comparator|
89184690|NCT00713037|Experimental|(18F)-FMISO/CT|The study utilizes PET/CT scanning with (18F)-FMISO/CT in addition to standard used CT and MRI. Patients enrolled in this trial completed 2 PET/CT investigations, the first before proton radiation therapy and the second at a dose of approximately 30 Gy (24-36 Gy).
89184691|NCT04067349|Active Comparator|laparoscopic liver resection|Patients undergoing laparoscopic liver resection
89184692|NCT04067349|Active Comparator|open liver resection|Patients undergoing open liver resection
89184693|NCT00787319||AMD|
89184694|NCT03997721||Perforation|Patients undergoing primary emergency laparotomy/laparoscopy due to suspicion of intestinal perforation or ( small intestine, large intestine), perforated ventricular or duodenal ulcer
89184695|NCT03997721||Obstruction|Patients undergoing primary emergency laparotomy/laparoscopy due to suspicion of intestinal obstruction
89184696|NCT03997721||Anasomotic leak|Patients undergoing primary emergency laparotomy/laparoscopy due to suspicion of anastomotic leak following elective surgery.
88860969|NCT01435746|Experimental|Liberal Transfusion|Patients in the liberal transfusion group will receive red blood cell transfusions when their hemoglobin concentration drops below 10 g/dl. The aim should be to reach a hemoglobin concentration between 10 and 12 g/dl.
88860970|NCT01435746|Active Comparator|Conservative Transfusion|Patients in the conservative transfusion group will receive red blood cell transfusions when their hemoglobin concentration drops below 8 g/dl. The aim should be to reach a hemoglobin concentration between 8 and 10 g/dl.
89184697|NCT02571231|Experimental|HFV+vg|volume guarantee given
89184698|NCT02571231|Experimental|HFV-VG|Volume guarantee not given
89184699|NCT00915239|Active Comparator|Pantoprazole|
89535201|NCT05020041|Experimental|Intervention|"The implementation of painted games will consist of adapting a space destined for recreation, designing a psychomotor circuit that does not require contact between peers, or manipulation of objects to maintain COVID-19 sanitary and safety protocols.~The schools in the intervention group will receive the online educational talk aimed at schoolchildren and a talk aimed at Physical Education teachers."
88860971|NCT01428024|Experimental|Restylane Lip Volume|Submucosal injections with Restylane Lip Volume. Treatment of up to 1,5 ml product for upper and lower lip, respectively at week 0 and optional at week 2 and 12.
88860972|NCT01428024|Experimental|Restylane Lip Refresh|Submucosal injections with Restylane Lip Refresh. Treatment of up to 0,5 ml product for upper and lower lip, respectively at week 0 and optional at week 2 and 12.
88860973|NCT01895790|Experimental|Pancreatic Duct|Consecutive adult patients (18-80 years of age) with cytopathologic diagnosis of unresectable pancreatic cancer complaining of pain due to pancreatic duct obstruction will receive a pancreatic duct stent.
88860974|NCT01412970|Other|study group|comparison of ability to predict volume responsiveness and precision of measurement of stroke volume variation assessed by electrical impedance tomography in comparison to clinically established invasive hemodynamic monitoring devices, i.e. arterial pulse contour analysis during volume loading procedures
88860975|NCT01935414|Experimental|geko™|geko™ use continually post-surgery for 48hrs and then a minimum of 4hrs/day until discharge
89385625|NCT03629769|Experimental|Patients with prostatitis-like symptoms|Cohort of patients with CP/CPPS (abacterial prostatitis)
89385626|NCT03589742|Experimental|Radiofrequency ablation patients|Single-Arm study, all patients included will undergo RF ablation using AblaView® Ablation Catheter
89385627|NCT02238470||Oral anticoagulants|Patients who will receive oral anticoagulants indefinitely for the secondary prevention of cardioembolic stroke
89385628|NCT03581708||advanced lung cancer|Patients diagnosed with advanced lung cancer
89385629|NCT04119375|Active Comparator|Control|The standard-of-care protocol in Kenya includes diagnosis, the provision of medications - typically administered for a 1-2 week period at which point patients are expected to return to the clinical site - periodic on-the-ground follow-up by community health volunteers (CHVs)(at the discretion of local clinicians and CHVs) and nutritional support, as is sometimes provided.
89385630|NCT04119375|Experimental|SMS-Only|"Patients in the SMS reminder group will receive a single, medication reminder SMS once daily at their indicated treatment time. The reminder message will read Please take the medication on time consistent with messages used by Liu and colleagues (2015)."
89385631|NCT04119375|Experimental|Social Behavior Change Communication (SBCC)|"Patients assigned to this intervention will have access to a mobile health platform that provides reminders, information and motivation - designed with behaviorally-informed strategies - but no follow up support from a human beyond what the standard of care allows. Further details of the intervention can be found in the study protocol section.~The intervention will send automated motivational messages and regular prompts for patients to self-verify their adherence. Messages include reminders about the community benefits of adherence, and a measure of the patient's adherence performance relative to successful peers. Clinicians can view individual or aggregate patient histories to leverage limited resources."
89385632|NCT04119375|Experimental|Keheala|"An automated system sends motivational messages and regular prompts for patients to self-verify their adherence. Messages include reminders about the community benefits of adherence, and a measure of the patient's adherence performance relative to successful peers. If a patient fails to correctly verify her compliance, the system automatically alerts the support-sponsor, who then intervenes with a supportive dialogue. Clinicians can view individual or aggregate patient histories to leverage limited resources.~Further details of the intervention can be found in the study protocol section."
89385633|NCT03586934|Other|Traditional (Standard) Protocol|Preoperative Single shot interscalene block (30 mL 0.5 ropivacaine), postoperative morphine patient controlled analgesia (1 mg/10 min/30 mg) with Hydrocodone-Acetaminophen (oral, 5/325 mg, 1 tab q4h pro re nata (PRN) for pain score of 1-3), Hydrocodone-Acetaminophen (oral, 10/325 mg, 1 tab q4h PRN for pain score of 4-6) Morphine injectable solution (2 mg IV q3h PRN for pain score 7-10), and oxycodone hydrochloride (oral, 10 mg q12h x2 doses) through postoperative day one. Discharged from hospital with hydrocodone bitartrate and acetaminophen (Norco) (5/325 mg or 10/325 mg, 1-2 oral tabs q4-6h PRN pain) script.
88860976|NCT01935414|Active Comparator|TEDS stockings|TEDS use continually post-surgery for 48hrs and then a minimum of 4hrs/day until discharge
89385634|NCT03586934|Experimental|Multimodal Anesthesia and Analgesia|"Under age 75: Preop: acetaminophen 1000 mg oral, celecoxib 400 mg oral. Interscalene block (30 ml 0.5% ropivacaine with 1:200,000 epinephrine). Intraop: ketorolac 15 mg IV, acetaminophen injectable product. Postop: acetaminophen 500 mg oral, oxycontin 10 mg oral. Breakthrough: ketorolac 15 mg IV, oxycodone 10 mg oral. Floor: tramadol 100 mg q6h oral, acetaminophen 1 g q8h oral, celecoxib 200 mg q12h oral, ketorolac 15 mg IV q6h. Breakthrough: Pain scores 4-6: oxycodone 5 mg q4h PRN oral, pain scores 7-10: oxycodone 10 mg q4h PRN oral. Discharge: acetaminophen 1 g q8h oral, tramadol 100 mg q8h oral, celecoxib 200 mg q12h oral or meloxicam 15 mg daily oral, oxycodone 5 mg q4h PRN oral.~75 or older: Same except: Preop: celecoxib 200 mg oral. PACU meds: acetaminophen 500 mg oral. No OxyER."
89385635|NCT01596257|Active Comparator|bulk SCT|Patients receive reduced intensity or myeloablative conditioning regimen, GVHD prophylaxis, and undergo T cell depleted or no T cell depleted allogeneic SCT on day 0. After completion of study treatment, patients are followed up every 6-8 weeks for up to 24 months
89385636|NCT01596257|Experimental|fractionated SCT|Patients receive reduced intensity or myeloablative conditioning regimen, GVHD prophylaxis, and undergo T cell depleted or no T cell depleted allogeneic SCT on days 0, 2, 4, and 6. After completion of study treatment, patients are followed up every 6-8 weeks for up to 24 months
89385637|NCT04749017|Experimental|Experimental group|Avena Sativa L. consumption of 900 mg for 60 days.
89385638|NCT04749017|Placebo Comparator|Control group|Identically appearing placebo capsules consumed for 60 days.
89385639|NCT02035592|Active Comparator|Full dose blueberry|"26g of freeze dried blueberry powder; equivalent to 2 portions of fresh blueberries per day.~Frequency: 26g per day.~Total duration: 6-month."
89385640|NCT02035592|Active Comparator|Half dose blueberry|"26g of freeze dried powder; containing 13g of freeze dried blueberry powder and 13g of placebo comparator material; equivalent to 1 portion of fresh blueberries per day.~Frequency: 26g per day.~Total duration: 6-month."
89385641|NCT02035592|Placebo Comparator|Control|"Matched control powder; matched for appearance, taste and sugar content.~Frequency: 26g per day.~Total duration: 6-month."
89385642|NCT03586856|Active Comparator|Nasal mask interface|The CPAP interface will be applied and adjusted by experienced staff blinded to the outcome variable; leakage. Measures to reduce/minimize leakage are tested in an unblinded observational part after the intervention.
89385643|NCT03586856|Active Comparator|Nasal prongs interface|The CPAP interface will be applied and adjusted by experienced staff blinded to the outcome variable; leakage. Measures to reduce/minimize leakage are tested in an unblinded observational part after the intervention.
89385644|NCT03586154|Other|Group A|patients were subjected to ultrasound guided SGB using 1 ml ketamine in a dose of 0.5mg/kg plus 5ml bupivacaine 0.5% in total volume 10 ml
88860977|NCT01896414|Experimental|EPA (marine fatty acids)|Subjects will receive EPA , four 1 gram capsules daily.
88860978|NCT01896414|Placebo Comparator|Placebo|Subjects will be randomized to receive placebo, four 1 gram capsules daily.
88860979|NCT01412190|Other|Untreated|
88860980|NCT01412190|Active Comparator|Restylane Vital Light|Restylane Vital Light administered at 3 treatment sessions 4 weeks apart
89184700|NCT00915239|Placebo Comparator|Placebo|
89385645|NCT03586154|Active Comparator|Group B|patients were subjected to ultrasound guided SGB using 1 ml ketamine in a dose of 0.5mg/kg plus 5ml bupivacaine 0.5% in total volume 10 ml plus posterior approach shoulder injection with PRP.
89385646|NCT04658693|Experimental|Multi contact electrode implant and implanted electromyography recording electrodes|"Fifteen subjects with lower limb amputation will receive implanted multicontact stimulating nerve cuff electrodes connected to temporary percutaneous leads.~During experimental testing, a small amount of stimulation will be applied to the nerves through the contacts of the multichannel cuff electrode."
89385647|NCT03975621|Experimental|Immediate Intervention|The immediate intervention group will receive the intervention at the time of consent (baseline) and will be enrolled in the intervention for a total of 6 months. Patients will receive the tablet, a pedometer and an exercise band. Patients will use Nurse AMIE while receiving weekly phone calls from a patient navigator. After 90 days of the intervention observation will take place for 90 days, the patient will be asked to continue using Nurse AMIE without a patient navigator's presence.
88860981|NCT01895868|Active Comparator|Simulation-based training|Participants in the intervention group receive simulation training using two types of ultrasound simulators: The Scantrainer (Medaphor) and the BluePhantom (CAE). All participants are training to pre-established proficiency-criteria.
89184701|NCT02604485|Other|Cohort|XOMA 358 dose level A, dose level B, dose level C, and dose level D.
89385648|NCT03975621|Experimental|Delayed Intervention|The delayed intervention group will receive the intervention 3 months after consent (6 months of intervention with 3 months delay total of 9 months); the patient will then follow the same pattern as listed above. The only difference is we will ask the delayed intervention group to wear a FitBit device for 1 week following consent in order to gain baseline data as to their activity/movement.
89385649|NCT01413815|Active Comparator|L-arginine|L-Arginine
89385650|NCT01413815|Placebo Comparator|corn starch|Placebo: Corn Starch
89385651|NCT03585920|Active Comparator|Positive Control (standard fat)|Expanded Corn Snack. Positive control (13 g oil per 40 g snack portion)
89385652|NCT03585920|Experimental|Negative Control (reduced fat)|Expanded Corn Snack. Negative control (<8 g oil per 40 g snack)
89385653|NCT03585920|Experimental|Reduced Fat Sensory Matched|Expanded Corn Snack. Reduced fat optimised (<8 g oil, matched sensory signals)
89385654|NCT04646603|Experimental|MRG-001|Multiple SC dose of 0.0066 mL/kg MRG-001 (n=20) will be administered every other day for the duration of 13 days totaling 7 injections.
89385655|NCT04646603|Placebo Comparator|Placebo|Single SC dose of 0.0066 mL/kg Sterile Injectable Saline (n=20) will be administered every other day for the duration of 13 days totaling 7 injections.
89385656|NCT03579992|Experimental|60-minute Isometric|60-min Isometric MyCI training: EMG-controlled game training for 60-minutes per session
89385657|NCT03579992|Experimental|90-minute Isometric|90-min Isometric MyCI training: EMG-controlled game training for 90-minutes per session
88860982|NCT01895868|No Intervention|Control|Clinical training alone.
89385658|NCT03579992|Experimental|90-minute Movement|90-min movement MyCI training: EMG-controlled game training for 90-minutes per session
89385659|NCT03629847|Experimental|Everolimus & Radiolabeled Lu-177|Drug: Everolimus will be administrated in combination with the intravenous radiolabelled Lu-177 DOTATATE therapy.
89385660|NCT01330589|Experimental|AB: Placebo (A); St. Johns Wort (B)|Receive placebo for 7 days, 7 days washout and 7 days of St. Johns Wort
89385661|NCT01330589|Experimental|BA: St. Johns Wort (B); Placebo (A)|Receive St. Johns Wort for 7 days, 7 days washout and 7 days of placebo
89385662|NCT03577886|Experimental|CDX-6114|0.225, 0.75, 2.25 and 7.5 g
88860983|NCT02319174|Experimental|Sphygmo|All subjects will have blood pressure measured by both the research device (Sphygmo) and the commercially available device. All clinical decisions will be made using measurements from the commercially available device.
88860984|NCT01393314|Active Comparator|Honeywell HomMed Telemonitor|TeleCareOhio Monitor (Honeywell HomeMed) system provides in-home medical monitoring for patients with chronic disease such as heart failure.
88860985|NCT01393314|No Intervention|Usual care|These participants receive usual care which consists of usual home-care with educational package.
88860986|NCT01341444|Experimental|Prevena Incision Management System|Negative Pressure Therapy Device
88860987|NCT01341444|Placebo Comparator|Standard of Care for Surgical Incisions|Sterile gauze and a non-penetrable barrier
88860988|NCT01331148|Active Comparator|Vitamin D|10,000 IU per caplet, with vitamin D dose based on weight, ranging from 240,000 IU to 600,000 IU. Patients will receive calcium/vitamin D daily soft chew as well.
88860989|NCT01331148|Placebo Comparator|Placebo|placebo only, all patients will receive calcium/vitamin D chew
89184702|NCT00722631|Experimental|1|up to 30 mg pioglitazone, tablet, orally, once daily
89184703|NCT00722631|Active Comparator|2|up to 4 mg/day glimepiride, tablet, orally, once daily
89184704|NCT02604095|Experimental|Melatonin|Take one table at bedtime.
89184705|NCT02571543|Experimental|Intervention|"2 Stage study design. Stage 1: 8 patients will be treated with the lower dose of 400mg of Ibuprofen. Should the efficacy be insufficient (3 or less patients) then the study will stop and stage 1 will recommence with 800mg.~Stage 2: 17 patients will be treated either with the lower dose of 400mg or the higher dose of 800mg of Ibuprofen should the respective stage 1 have been successful (4 or more patients showing an effect)."
89385663|NCT03577886|Placebo Comparator|Placebo|Phosphate Buffer Diluent solution
89385664|NCT01314833|Experimental|TC*6|6 cycles of (Docetaxel 75mg/m2 ivgtt d1+ Cyclophosphamide 600 mg/m2 iv d1, 21 days per cycle) .
89385665|NCT01314833|Experimental|CEF*3-T*3|3 cycles of CEF (Epirubicin 100 mg/m2 ivgtt d1+Cyclophosphamide 500 mg/m2 iv d1+ 5-fluorouracil 500 mg/m2 iv d1, 21 days per cycle) followed by 3 cycles of Docetaxel (Docetaxel 100mg/m2, ivgtt d1, 21 days per cycle)
89385666|NCT01314833|Experimental|EC*4-wP*12|4 cycles of EC (Epirubicin 90 mg/m2 ivgtt d1+Cyclophosphamide 600 mg/m2 iv d1, 21 days per cycle) followed by 4 cycles of Paclitaxel (Paclitaxel 80mg/m2, ivgtt d1,8,15, 21days per cycle)
89385667|NCT05763927|Experimental|Fruquintinib& Toripalimab& SRT|"Induction treatment:~Fruquintinib 5mg d1-d14； Toripalimab 240 mg intravenously d1；~Consolidation treatment:~SRT: 25 Gy in 5 fractions d22-d26； Fruquitinib 5mg d22-d35，43-56,64-77； Toripalimab 240 mg intravenously d22、43、64；~Surgery: Surgical resection will be performed according to the principles of TME(total mesorectal excision) 2-4 weeks after the last dose administration of Fruquintinib；~Adjuvant chemotherapy: Standard chemotherapy or observation according to the judgement of Principle Investigator and patients' willing."
89385668|NCT03579836|Experimental|Phase I-1 (#4 Cohort)|BEY1107 monotherapy, 4 Cohorts, 4 weeks (administered on a 3-week-on and 1-week-off)
89385669|NCT03579836|Experimental|Phase I-2 (#3 Cohort)|BEY1107 in combination with Gemcitabine, 3 Cohorts, 4 weeks (administered on a 3-week-on and 1-week-off)
89385670|NCT03579836|Experimental|Phase II (#1 Cohort)|BEY1107 in combination with Gemcitabine, 6 Cycles / 24 weeks (administered on a 3-week-on and 1-week-off)
89385671|NCT04577781|Experimental|GLPG3970|Participants received 400 milligrams (mg) GLPG3970 oral solution, once daily (QD) for a period of 6 weeks.
89385672|NCT04577781|Placebo Comparator|Placebo|Participants received GLPG3970 matching placebo oral solution, QD for a period of 6 weeks.
89385673|NCT02737826|Experimental|Phase - Buprenorphine Initiation|"In Phase I, we will determine buprenorphine tolerability using a one-day outpatient buprenorphine initiation protocol up to 16mg sublingually over an up to 8 hour induction window. Buprenorphine tolerability will be defined as pain level ≤ to baseline, withdrawal measures ≤ to baseline, and willingness to continue with taper."
89385674|NCT02737826|Active Comparator|Phase II - Gabapentin + Buprenorphine|Subjects who tolerate sublingual buprenorphine initiation in Phase I will proceed to Phase II, which will involve randomization to gabapentin or placebo, 2 week stabilization period, and up to 8 week buprenorphine tapering period. Those randomized to gabapentin will receive up to 1600mg oral gabapentin (double blinded) divided three times daily, titrated over the 2 week stabilization period and continued during the buprenorphine tapering period. During the 2 week stabilization period, buprenorphine will also be titrated up to 24mg as needed/tolerated.
89385675|NCT02737826|Placebo Comparator|Phase II - Placebo + Buprenorphine|Subjects who tolerate sublingual buprenorphine initiation in Phase I will proceed to Phase II, which will involve randomization to gabapentin or placebo, 2 week stabilization period, and up to 8 week buprenorphine tapering period. Those randomized to placebo will receive up to 1600mg oral placebo (double blinded) divided three times daily, titrated over the 2 week stabilization period and continued during the buprenorphine tapering period. During the 2 week stabilization period, buprenorphine will also be titrated up to 24mg as needed/tolerated.
89385676|NCT02737826|Experimental|Phase II - Buprenorphine taper|After a 2 week stabilization period where sublingual buprenorphine is titrated up to 24 mg/day and oral gabapentin/placebo is titrated up to 1600mg/day, subjects will enter a buprenorphine tapering period lasting up to 8 weeks. The suggested buprenorphine taper will be determined by stabilizing dose, but able to be altered by prescriber or participant based on symptoms.
89385677|NCT05761977||Patient with extensive small-cell lung cancer|extensive small-cell lung cancer
89385678|NCT03367715|Experimental|Nivolumab + Ipilimumab + Short-course radiation therapy|within 6 weeks of the first diagnostic surgery for glioblastoma, all subjects will initiate study treatment on Day 1
89385679|NCT03963063|Active Comparator|Non Goal-directed Care Group|
89385680|NCT03963063|Experimental|Goal-directed Care Group|
89385681|NCT03577808||Arm|Patients with locally advanced rectal cancer will receive neoadjuvant chemoradiation. The radiation procedure and concurrent chemotherapy drugs will base on clinical practice. Organoids bio-bank of pre-treatment tumor biopsies will be established and exposed to irradiation and the same chemotherapy drugs as the corresponding patient.
89385682|NCT05762913|Experimental|Diaphragm release|The therapist passes his fingers under the costal arch, during inspiration the therapist accompanies the movement of the ribs, while during expiration he takes his fingers deeper, increasing his pressure. The therapist progresses progressively deeper into the costal arch with each breath. The maneuver will be performed in two sets of 10 deep breaths. The diaphragm release technique will be applied in 3 sessions, with 2 days of rest in between.
89003276|NCT05524402|Experimental|TOR-C 1|TOR-C 1 is an active intervention adapted from the original Toolkit for Optimal Recovery program, adjusted for patients with mTBI and anxiety. The TOR-C 1 sessions address mind-body skills, including eliciting the relaxation response (eg, body scan, deep breathing, mindfulness), cognitive-behavioral strategies (eg, reframing), acceptance and commitment skills (eg, acceptance), and skills for returning to activity (eg, goal setting, activity pacing). The format is a 4-week program delivered over live video with weekly sessions and home practice.
89003277|NCT05524402|Active Comparator|TOR-C 2|TOR-C 2 is an active intervention teaching educational information on key modifiable factors relating to recovery after concussion, such as return to activity, the role of nutrition and sleep, and the relationship between concussion and anxiety. The format is a 4-week program delivered over live video with weekly sessions.
88860990|NCT01311492|Placebo Comparator|Healthy Lifestyle Program|The purpose of the healthy lifestyle group is to control for general levels of staff and participant time and attention, in addition to general secular and seasonal effects that could influence the outcomes of interest.
88860991|NCT01311492|Active Comparator|Physical Activity Intervention|The physical activity program includes aerobic, strenth, flexibility and balance training.
88860992|NCT04969302|Experimental|Intervention Group|"Skin preparations will performe using Povidone 10% 1000 mL solution (Turkuaz Chemistry, İstanbul, Turkey) Povidone-iodine will heat to 37°C using a gel warmer (KGW-1 Keewell Medical Technology, Foshen, China) in the warm group.~The day before the operation, the patient will be met and informed about the study and verbal and written consent will be obtained stating that they are willing to participate in the study.~The weight tracking of the patients will be determined using a digital weight meter provided by the researcher. Patient evaluation will be made with NRS-2002 in terms of malnutrition risk.~Antibiotic prophylaxis of 1000 mg available in the operating room will be administered 30-60 minutes before the operation.~Before the incision, a wound culture sample will be taken with sterile transport swap and sent to the laboratory for culture study."
89385683|NCT03585218|Experimental|Experimental Group|The Experimental Group participants will be submitted to the inhalation of the hedonic aroma during the chemotherapeutic treatment, this being the intervention of the study.The control group is not subject to intervention.
89385684|NCT03585218|No Intervention|Control Group|The control group is not subject to intervention.
89385685|NCT01330667|Experimental|Formula Supplementation|Participants will supplement feedings with early limited formula following nursing.
89385686|NCT01330667|No Intervention|Control|Participants will be instructed to continue exclusively breastfeeding with no formula supplementation.
89385687|NCT04064931||recurrent abortion|women of childbearing age who have spontaneous abortion within 20 weeks of pregnancy for 2 or more consecutive times.
89385688|NCT04064931||normal pregnancy history|Women of childbearing age who had a normal pregnancy history and are not in pregnancy status now.
89385689|NCT04064931||general population|Women of childbearing age in general examination.
89385690|NCT03577652|Experimental|Ticagrelor, 90mg, 12h|
89385691|NCT03577652|Experimental|Ticagrelor, 90mg, 24h|
89385692|NCT03577652|Experimental|Ticagrelor, 180mg, 24h|
89385693|NCT03620513|Placebo Comparator|Normal Saline nasal spray|Two spray (via atomizer) of normal saline in each nostril five minutes prior to fiberoptic procedure
89385694|NCT03620513|Experimental|Decongestant (Oxymetazoline 0.05%)|Two sprays via atomizer (about 0.18 ml) of oxymetazoline 0.05% (Nasivion) in each nasal cavity five minutes prior to fiberoptic procedure. Two sprays will be given at the gap of ten seconds.
89385695|NCT03620513|Experimental|Anesthesia (lidocaine 15%, Nummit)|Two sprays of 15% lidocaine (Nummit) will be give in each nasal cavity five minutes prior to fiber optic procedure. Two sprays will be given at the gap of ten seconds.
89003280|NCT05516706|Active Comparator|Dynamic stretching|This group performed warm up and dynamic stretching exercise for six weeks.
89003281|NCT05516706|Active Comparator|Plyometric push up|This group performed Warm up and plyometric push up for six weeks.
89003282|NCT05514535|Experimental|Insuline glargine U100 (reduced) + semaglutide|Participants will initially receive 0.25 milligrams (mg) once-weekly semaglutide subcutaneously (s.c.) and the dose will be gradually escalated to 2 mg as an add-on to dose-reduced insulin glargine s.c. given once-daily. Insulin glargine U100 will be reduced by 10 U at the initiation of semaglutide and then again at each semaglutide dose escalation. Insulin glargine dose will be adjusted based on the mean of three pre-breakfast self-measured plasma glucose (SMPG) values (target SMPG: 4.4-7.2 millimoles per litre (mmol/L)).
89535202|NCT05020041|No Intervention|Control|The schools participating in the control group will receive an online educational talk aimed at promoting healthy habits and the benefits of physical activity inside and outside the school environment.
89535203|NCT02488577|Active Comparator|TAMIS TME|T2 N0 Cases which undergo transanal minimally invasive total mesorectal excision.
89003283|NCT05514535|Active Comparator|Insuline glargine U100 (titrated)|Participants will receive titrated insuline glargine U100 s.c. once-daily. Insulin glargine U100 dose will be adjusted based on the mean of three pre-breakfast SMPG values (target SMPG: 4.4-7.2 mmol/L).
89003284|NCT05513001|Experimental|Arm 1: LOU064 (blinded)|LOU064 (blinded) taken orally for 24 weeks, followed by cycles of either LOU064 (open-label) taken orally for a maximum of 5 cycles of 24 weeks each OR treatment-free observation cycles. Randomized in a 1:1 ratio (arm 1:arm 2)
89003285|NCT05513001|Placebo Comparator|Arm 2: LOU064 Placebo (blinded)|LOU064 placebo (blinded) taken orally for 24 weeks, followed by cycles of either LOU064 (open-label) taken orally for a maximum of 5 cycles of 24 weeks each OR treatment-free observation cycles. Randomized in a 1:1 ratio (arm 1:arm 2)
89003286|NCT05513001|Experimental|Arm 3: LOU064 (Open Label)|LOU064 (open-label) taken orally for 24 weeks per treatment cycle (Arm 3)
89003287|NCT05512377|Experimental|brigimadlin (BI 907828) treatment arm|
89003288|NCT05509595|Experimental|Treatment|Patients receiving treatment
89003289|NCT05501119|Experimental|SUPPORT-D Group|
89003290|NCT05494749|Experimental|Test group|
89003291|NCT05494749|Active Comparator|Control|
89003292|NCT05492500|Experimental|Main cohort: ponsegromab low dose|Participants will receive a low dose Q4W SC
89003293|NCT05492500|Experimental|Main cohort: ponsegromab medium dose|Participants will receive a medium dose Q4W SC
89003294|NCT05492500|Experimental|Main cohort: ponsegromab high dose|Participants will receive a high dose Q4W SC
89003295|NCT05492500|Placebo Comparator|Main cohort: placebo|matched placebo
89385696|NCT03620513|Experimental|Decongestant and Anesthesia|In this group decongestants and anesthesia (oxymetazoline and lidocaine) sprays will be used. Decongestant (Oxymetazoline 0.05%) will be give as described above. After two minutes, lidocaine 15% (Nummit) spray will be given as described above. Procedure will be done after five minutes of decongestant.
89385697|NCT03585062|Experimental|S-1 combined with Paclitaxel-albumin|S-1 combined with Paclitaxel-albumin S-1:40~60mg bid, day 1~14 (S-1: BSA <1.25m2, 40mg bid , 1.25m2 ≤ BSA ≤1.5m2, 50mg bid, BSA>1.5m2, 60mg bid， for 2 weeks, rest a week) Paclitaxel-albumin: 125 mg/m2, intravenous infusion for 30 minutes, Day1 and Day 8.
89385698|NCT03854331|Experimental|Resilience program|The resilience program consists of different modules that are based on research on mentalization, mindfulness, parent management training, improving self-control and self-efficacy, cognitive behaviour therapy, social learning theory and neuroscience. The MyResilience program is also informed by cognitive bias modification and self-control training research. These techniques have been found to be effective in improving engagement in health behaviours and reducing symptoms and negative behaviours in clinical groups
89385699|NCT03854331|No Intervention|Standard care|Danish antenatal standard care is 3 visits at the general practitioner, 5 midwife controls and 2 ultrasound scans
89535204|NCT02488577|Active Comparator|TAMIS-Local|T2 N0 Cases which will undergo transanal minimally invasive locoregional resection.
89535205|NCT03227887|Active Comparator|Good chewing ability|
89535206|NCT03227887|Experimental|Impaired chewing ability|
89385700|NCT03584906|Experimental|De-epithelialized gingival graft (DGG)|A harvesting approach where the a graft is obtained from the superficial palate and then extra-orally de-epithelialized in order to obtain a connective tissue graft (DGG harvesting approach) Then the DGG is used for treating gingival recessions (root coverage procedure)
89535207|NCT03323957||Patients|all infants admitted for care
88860993|NCT04969302|No Intervention|Control Group|"Skin preparations will performe using Povidone 10% 1000 mL solution (Turkuaz Chemistry, İstanbul, Turkey) Povidone-iodine will heat to 20°C using a gel warmer (KGW-1 Keewell Medical Technology, Foshen, China) in the room heat group.~The day before the operation, the patient will be met and informed about the study and verbal and written consent will be obtained stating that they are willing to participate in the study.~The weight tracking of the patients will be determined using a digital weight meter provided by the researcher. Patient evaluation will be made with NRS-2002 in terms of malnutrition risk.~Antibiotic prophylaxis of 1000 mg available in the operating room will be administered 30-60 minutes before the operation.~Before the incision, a wound culture sample will be taken with sterile transport swap and sent to the laboratory for culture study."
88860994|NCT01862718|Experimental|1|Ablation plus radiation
89184706|NCT02571543|No Intervention|Control|The control group will consist of a no-treatment group of patients undergoing Intrauterine Insemination (IUI) or Timed Sexual intercourse (TSI), to verify the delay between LH-Peak onset and ovulation. 42h after Beta-HCG injection inducing LH-Peak, ovulation will be determined by ultrasound examination.
88860995|NCT01286922|Experimental|Interval Training|"The target intensity for the INT group is 2 min at about 95% of baseline VO2max followed by 2 min of recovery at 40-50% of VO2max. Regardless of the training method each participant will be locked into a weekly energy expenditure of 12 kilocalories per kilogram of body weight per week (KKW)."
88860996|NCT01286922|Placebo Comparator|Aerobic Conditioning|During the first AER training condition, we will train all participants at an energy expenditure of 12 kcal/kg/wk (KKW). The target exercise intensity for the AER group will be 50%-70% of baseline V02max.
88860997|NCT01855464|Experimental|wedge resection+parietal pleurectomy|Surgical treatment includes parietal pleurectomy and wedge resection of the tip of the lung.
88860998|NCT01855464|Active Comparator|parietal pleurectomy|Surgical therapy is limited to parietal pleurectomy.
88860999|NCT00273624|Experimental|olanzapine|10 mg Olanzapine
88861000|NCT00273624|Placebo Comparator|placebo|Placebo
88861001|NCT01253070|Experimental|Treatment (daunorubicin, cytarabine, sorafenib tosylate)|"INDUCTION THERAPY: Daunorubicin hydrochloride 60 mg/m^2/day by IV push or short IV on days 1-3, cytarabine 100 mg/m^2/day by continuous IV on days 1-7, and sorafenib tosylate orally every 12 hours on days 1-7.~CONSOLIDATION THERAPY - Every 28 days for 2 cycles: Cytarabine 2 g/m^2/day by IV on days 1-5 and sorafenib tosylate 400 mg orally every 12 hours on days 1-28.~MAINTENANCE - Every 28 days for up to 12 cycles: Sorafenib tosylate 400 mg orally every 12 hours on days 1-28."
88861002|NCT01252914|Experimental|One iStent Supra Stent and medication|The study assesses the efficacy and safety of one iStent Supra stent in the reduction of intraocular pressure associated with primary open-angle glaucoma
88861003|NCT04756284||Bladder Tumor Positive|Patients with previous bladder cancer diagnosis; any stage and histological type, undergoing cystoscopy or suspected bladder tumor undergoing surveillance cystoscopy.
88861004|NCT04756284||Bladder Tumor Negative|Patients with no suspected bladder tumor.
88861005|NCT01840956|Experimental|HAVG|Surgical placement of HAVG
88861006|NCT02087514|Active Comparator|Transfusion of PRBC stored for 1 week|Subjects will receive blood transfusion with packed red blood cells stored for 1 week.
88861007|NCT02087514|Experimental|Transfusion of PRBC stored for 2 weeks|Subjects will receive blood transfusion with packed red blood cells stored for 2 weeks.
88861008|NCT02087514|Experimental|Transfusion of PRBC stored for 3 weeks|Subjects will receive blood transfusion with packed red blood cells stored for 3 weeks.
88861009|NCT02087514|Experimental|Transfusion of PRBC stored for 4 weeks|Subjects will receive blood transfusion with packed red blood cells stored for 4 weeks.
88861010|NCT02087514|Experimental|Transfusion of PRBC stored for 5 weeks|Subjects will receive blood transfusion with packed red blood cells stored for 5 weeks.
88861011|NCT02087514|Experimental|Transfusion of PRBC stored for 6 weeks|Subjects will receive blood transfusion with packed red blood cells stored for 6 weeks.
88861012|NCT01212822|Experimental|Treatment (bevacizumab, FOLFOX)|"NEOADJUVANT THERAPY: Patients receive bevacizumab IV over 30-90 minutes on day 1. Patients also receive FOLFOX chemotherapy comprising oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV continuously over 46 hours on days 1-2. Treatment with bevacizumab repeats every 2 weeks for 4 courses and treatment with FOLFOX repeats every 2 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.~SURGERY: Patients then undergo planned surgical resection 4-6 weeks after 6 courses of chemotherapy and at least 8 weeks since the last dose of bevacizumab.~ADJUVANT THERAPY: Beginning 8-10 weeks after surgery, patients receive bevacizumab IV, oxaliplatin IV, leucovorin calcium IV, and fluorouracil IV as in neoadjuvant therapy. Treatment repeats every 2 weeks for 6 courses in the absence of disease progression or unacceptable toxicity."
88861013|NCT00163566|Placebo Comparator|Placebo gel|Placebo gel twice per day
88861014|NCT00163566|Active Comparator|0.7% DHT gel, Dose 1|0.7% DHT gel twice per day, 35 mg/day
88861015|NCT00163566|Active Comparator|0.7% DHT gel, Dose 2|0.7% DHT gel twice per day, 70 mg/day
89184707|NCT02574039|Experimental|Oat bran|66g oat bran made up in 350ml skimmed milk
89184708|NCT02574039|Placebo Comparator|Control|Refined grain product and 350ml skimmed milk
89184709|NCT04107779|Experimental|JUUL 5% Virginia Tobacco ENDS|JUUL 5% Virginia Tobacco flavored ENDS product [6 days] in confinement.
88861016|NCT04389606|Experimental|Study Formula (SF)|New infant formula for term infants
88861017|NCT04389606|Active Comparator|Comparator Formula (CF)|Commercially available infant formula for term infants
88861018|NCT04389606|No Intervention|Human Milk Reference Group|Human milk
88861019|NCT00074568||1|Patients with scleroderma and their family members (parents, brothers, and sisters)
88861020|NCT00074568||2|Healthy volunteers with no autoimmune disease and without a first-degree relative with a systemic autoimmune disease
88861021|NCT00033774||1|Eligible healthy volunteers 18 and older
88861022|NCT04705662|Other|Ferrous Sulphate|This is a single arm study, all participants will take Ferrous sulphate 200mg (65mg elemental iron) for 4 weeks (+/- 2 days). Participants will be required to take 2 tablets per day.
89003296|NCT05492500|Experimental|Open-label, PK Cohort: ponsegromab low dose|Participants will receive a low dose Q4W SC
89184710|NCT04107779|Experimental|JUUL 3% Virginia Tobacco ENDS|JUUL 3% Virginia Tobacco flavored ENDS product [6 days] in confinement.
88818780|NCT05731505|Experimental|KOLCABA COMFORT THEORY APPLİED TO PARENTS OF CHİLDREN WİTH CEREBRAL PALSY|During the training given by the researcher, the children continued their routine education in the rehabilitation center. Although the education to be done is for the child and their parents, the education was given directly to the parents, since the mental perception levels of the children may not be sufficient and mostly children with CP live dependent on their parents. The parent who will be involved in the research is the primary caregiver who is most interested in the child.
89385701|NCT03584906|Experimental|Envelope technique (ET)|"A harvesting approach where only one horizontal incision is performed on the palate (ET harvesting approach) for harvesting a connective tissue graft.~Then the connective tissue graft is used for treating gingival recessions (root coverage procedure)"
89385702|NCT03584906|Experimental|Trap door technique (TDT)|"A harvesting approach where one horizontal and two vertical incisions are performed on the palate (TDT harvesting approach) for harvesting a connective tissue graft.~Then the connective tissue graft is used for treating gingival recessions (root coverage procedure)"
89385703|NCT03584906|Experimental|Maxillary tuberosity (MT)|"A harvesting approach that obtains an epithelialized gingival graft from the maxillary tuberosity (MT harvesting approach) which is then extra-orally de-epithelialized in order to obtain a connective tissue graft.~Then the connective tissue graft is used for treating gingival recessions (root coverage procedure)"
89385704|NCT03584360|Experimental|betamethasone-calcipotriol versus placebo|In this arm we will compared the application association of betamethasone-calcipotriol foam in an area versus a placebo foam in an other area during 4 weeks.
89184711|NCT04107779|Experimental|JUUL 5% Mint ENDS|JUUL 5% Mint flavored ENDS product [6 days] in confinement.
89385705|NCT03584360|Experimental|betamethasone-calcipotriol versus betamethasone|In this arm we will compared the application association of betamethasone-calcipotriol foam in an area versus a betamethasone pomade in an other area during 4 weeks.
89385706|NCT03584360|Experimental|betamethasone-calcipotriol versus propionate of clobetasol|In this arm we will compared the application association of betamethasone-calcipotriol foam in an area versus a propionate of clobetasol pomade in an other area during 4 weeks.
89385707|NCT01330745|Other|aortic valve replacement|
89385708|NCT02809443|Experimental|GLS-5700 at 1 mg|DNA/dose
89385709|NCT02809443|Experimental|GLS-5700 at 2 mg|DNA/dose
89385710|NCT03584282|No Intervention|Standard of Care|Participants in this group will receive the standard of care for PrEP follow-up and no additional research interventions.
89385711|NCT03584282|Active Comparator|Text Messaging|Participants in this group will receive the text messaging intervention.
89385712|NCT03584282|Active Comparator|Peer Navigation|Participants in this group will receive the peer navigator intervention.
89385713|NCT03584282|Active Comparator|Text Messaging and Peer Navigation|Participants in this group will receive both the text messaging and peer navigation interventions.
88818781|NCT04457219|Active Comparator|Conventional dressing with 120 minutes external compression|A standard absorbent dressing is placed on the radial access site, following the transradial angiographic procedure. A radial compression device is then applied to secure patent haemostasis, once the radial sheath is removed. The compression device remains in place for a minimum of 2 hours, as per protocol. This is the standard radial care currently in use at Liverpool Heart and Chest Hospital.
88818782|NCT04457219|Experimental|Conventional dressing with 60 minutes external compression|A standard absorbent dressing is placed on the radial access site, following the transradial angiographic procedure. A radial compression device is then applied to secure patent haemostasis, once the radial sheath is removed. The compression device remains in place for a minimum of 1 hour, as per protocol.
88818783|NCT04457219|Experimental|Haemostatic dressing with 60 minutes external compression|A haemostatic absorbent dressing is placed on the radial access site, following the transradial angiographic procedure. This consists of a mineral-based dressing that accelerates local haemostasis. A radial compression device is then applied to secure patent haemostasis, once the radial sheath is removed. The compression device remains in place for a minimum of 1 hour, as per protocol.
88818784|NCT04450979|Active Comparator|Bioactive hydrolysate|20 g of hydrolysed rice protein
88818785|NCT04450979|Placebo Comparator|Placebo|20 g micro crystalline cellulose
88818786|NCT02732145|Placebo Comparator|Normal vulva|"The Normal vulva group consisted of patients without vulvar discomfort (ISSVD Questionnaire), and without any vulvar lesion (Clinical examination) undergoing planned labioplasty. For each patient with vulvar dermatosis, the first consecutive patient with normal vulva was taken for comparison.~Interventions: Three Rings Vulvoscopy, Vulvar Biopsy, and Histopathology."
88818787|NCT02732145|Placebo Comparator|Impaired vulvar skin|"The group of Impaired vulvar skin was formed by the patients without vulvar symptoms (ISSVD Questionnaire), but with some non-specific vulvar lesions (Clinical examination) undergoing planned labioplasty, before surgery. For each patient with vulvar dermatosis, the first consecutive patient with impaired vulvar skin was taken for comparison.~Interventions: Three Rings Vulvoscopy, Vulvar Biopsy, and Histopathology."
88818788|NCT02732145|Placebo Comparator|Vulvodynia|"The Vulvodynia group consisted of patients with vulvar discomfort (ISSVD Questionnaire), who fulfilled Friedrich's criteria (Clinical examination). Non-specific lesions found with TRIV were not relevant for the diagnosis of vulvodynia. For each patient with vulvar dermatosis, the first consecutive patient with vulvodynia was taken for comparison.~Interventions: Three Rings Vulvoscopy, Vulvar Biopsy, and Histopathology."
88818789|NCT02732145|Active Comparator|Vulvar dermatosis|"The group of Vulvar Dermatosis was formed by the patients with vulvar discomfort (ISSVD Questionnaire) and vulvar lesion specific for dermatosis (Clinical examination).~Interventions: Three Rings Vulvoscopy, Vulvar Biopsy, and Histopathology."
88818790|NCT04372979|Experimental|SARS-CoV-2 patients treated with convalescent plasma|Subjects will receive an intravenous injection of SARS-CoV-2 Convalescent Plasma.
88818791|NCT04372979|Active Comparator|SARS-CoV-2 patients treated with standard plasma|Subjects will receive an intravenous injection of standard Plasma.
88818792|NCT01852175|Active Comparator|Prasugrel|Prasugrel 60mg loading dose and 10 mg maintenance dose
88818793|NCT01852175|Active Comparator|Ticagrelor|Ticagrelor 180mg loading dose and 90mg bid maintenance dose
88818794|NCT02429934|Active Comparator|Abatacept also known as Orencia also known as CTLA4Ig|32 SLE patients to be treated with subcutaneous abatacept 125mg sq once a week for 16 weeks.
89385714|NCT01330823|Active Comparator|L-Carnitine|L-Carnitine 4 g daily for Intervention
89385715|NCT01330823|Placebo Comparator|Placebo|Placebo (tartaric acid)
89385716|NCT03636191|Experimental|Probiotic|
89385717|NCT03636191|Placebo Comparator|Placebo|
89385718|NCT03579758|Active Comparator|Arm I (capecitabine)|Participants undergo re-resection (including partial liver resection and portal lymph node dissection). Participants then receive capecitabine PO BID on days 1-14. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity.
89385719|NCT03579758|Experimental|Arm II (chemotherapy, capecitabine)|Participants receive cisplatin IV over 1 hour and gemcitabine IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Within 10 weeks of chemotherapy, participants undergo re-resection (including partial liver resection and portal lymph node dissection). Participants then receive capecitabine PO BID on days 1-14. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity.
88861023|NCT04687020|Other|Non-interventional (United States) / Low-interventional (Canada) : Viltolarsen|Patients will receive viltolarsen (recommended dose 80mg/kg/week) during a treatment period up to 120 months.
88861024|NCT04784286|Active Comparator|Telemedicine 30-day follow-up visit|"The Center for Connected Care will arrange for 30-day post-op telemedicine visits via a secured video application. When there is a telemedicine visit, the Center of Connected Care will connect the patient and then page the midlevel provider and dietitian after the electronic rooming process is complete & the patient is ready.~A survey about post-operative care visits within 7-14 days after that visit. The survey will focus on the following aspects: baseline familiarity with technology, patients' satisfaction with the post-op care they received, patients' preference of in-person vs telemedicine visits, patients' estimation of additional costs for care outside of the direct medical costs, along with an open question asking for comments & feedback about their overall experience with their follow-up appointment."
88861025|NCT04784286|Active Comparator|In-person 30-day follow-up visit|"Standard practice of having bariatric surgery patients follow up with the bariatric surgery midlevel providers as well as with dietitians within 30-days after their bariatric procedure. The bariatric surgery midlevel providers are staffed and supported by our bariatric surgeons in case if they have questions or concerns.~Participants will be contacted via telephone and will be surveyed about their post-operative care visits within 7-14 days after that visit. The survey will focus on the following aspects: baseline familiarity with technology, patients' satisfaction with the post-operative care they received, patients' preference of in-person vs telemedicine visits, patients' estimation of additional costs for their care outside of the direct medical costs, along with an open question that will ask patients to provide comments and feedback about their overall experience with their follow-up appointment."
88861026|NCT05391984|Experimental|Activity oriented|Activity-oriented therapy will be given to 15 patients which will train the structures around the shoulder in different activities of daily life.
88861027|NCT05391984|Experimental|Structural oriented|Structural-oriented therapy will be given to 15 patients including a fixed sequence of physiotherapy techniques.
88861028|NCT04783818||One Stage Reconstruction With Adjuvant Radiotherapy|
88861029|NCT04783818||Two Stage Reconstruction With Adjuvant Radiotherapy|
88861030|NCT04783818||Autologous Reconstruction With Adjuvant Radiotherapy|
88861031|NCT04783818||One Stage Reconstruction Without Adjuvant Radiotherapy|
88861032|NCT04783818||Two Stage Reconstruction Without Adjuvant Radiotherapy|
89385720|NCT03636113||ICU nurses -manual|Standard method of Urine Output monitoring
88810476|NCT06213077|Active Comparator|Nitric Oxide|"Upon enrollment, patients will complete the IIEF questionnaire, EHS Score questionnaire and the Quality of Life survey.~Patients will be sent home with instructions to take 2 Berkeley Life capsules once daily (in this case Active NO), in combination with their existing treatment protocol (Tadalafil) and then return on day 60, returning all unused test product.~After 60 days of taking the active ingredient + tadalafil, patients will repeat the IIEF questionnaire, EHS Score questionnaire and the Quality of Life survey.~After a 4 week wash out, patients will be crossed over to the placebo group and given the other combination.~After 60 days of both combinations, placebo and active, patients will repeat the IIEF questionnaire, EHS Score questionnaire and the Quality of Life survey"
88861033|NCT04783818||Autologous Reconstruction Without Adjuvant Radiotherapy|
89385721|NCT03636113||ICU nurses -automated|Device- Clarity RMS Electronic sensor
89385722|NCT03577574|Active Comparator|retrobulbar anesthesia group|2% lidocaine 4ml injected into retrobulbar space
89385723|NCT03577574|Active Comparator|peribulbar anesthesia group|2% lidocaine 4 to 8ml injected into peribulbar space
89385724|NCT03577574|Experimental|two step anesthesia group|conjunctival cul-de-sac anesthetized with 0.5% proparacaine hydrochloride drops three times + 2% lidocaine 0.6 to 0.8ml subconjunctival injection
89385725|NCT03070431|Experimental|High-precision RT 5x5 Gy in 1 week|Patients with motor deficits of the lower extremities due to metastatic spinal cord compression (MSCC) will receive 5x5 Gy of high-precision RT in 1 week.
89385726|NCT02238548|Placebo Comparator|Control group|Regular cholera vaccination
89385727|NCT02238548|Experimental|Milk bolus|Cholera vaccination - raw milk - bolus
89385728|NCT02238548|Experimental|Milk controlled|Cholera vaccination - raw milk - controlled intake
89385729|NCT01330901|Experimental|Ustekinumab|Ustekinumab 90 mg subcutaneously at week 0, 4 and 16
89385730|NCT02428647|Active Comparator|micronutrient powder (MNP)|preventive zinc supplements provided as MNP (containing 10 mg zinc and 14 other nutrients, including 6 mg iron, 0.56 mg copper, 17 μg selenium, 90 μg iodine, 400 μg RE vitamin A, 5 μg vitamin D, 5 mg vitamin E, 30 mg ascorbic acid, 0.5 mg vitamin B1, 0.5 mg vitamin B2, 6 mg niacin, 0.5 mg vitamin B6, 0.9 μg vitamin B12, and 150 μg folate,) plus ORS and therapeutic placebo supplements for diarrhea
89385731|NCT02428647|Placebo Comparator|placebo powder|placebo powder plus ORS and therapeutic placebo supplements for diarrhea
89385732|NCT02428647|Active Comparator|preventive zinc supplements|preventive zinc supplements provided as dispersible zinc tablets (containing 7 mg zinc, to be given between meals) plus ORS and therapeutic placebo supplements for diarrhea
88861034|NCT04783116|Experimental|Plant stanols (3g/day)|Consumption of plant stanol chews
88861035|NCT04783116|Placebo Comparator|Control|Consumption of placebo chews (without plant stanols)
88861036|NCT04782960|Active Comparator|20 patients receive Subconjunctival bupivacaine of the end of the surgery|20 patients receive Subconjunctival bupivacaine in the end of operation and monitoring postoperative pain score
88861037|NCT04782960|Placebo Comparator|20 patients receive Subconjunctival placebo in the end of operation|20 patients receive Subconjunctival placebo in the end of operation and monitoring postoperative pain score
88861038|NCT01075230|Active Comparator|Standard TKA|Subjects in this arm will receive total knee replacement as standard of care without Platte Rich Plasma
88861039|NCT01075230|Active Comparator|Standard TKA with PRP|Subjects in this arm will receive total knee replacement as standard of care with Platte Rich Plasma
88861040|NCT04480242||Asthma Research in Children and Adolescents - Spanish Cohort|Groups defined according to treatments prescribed during regular clinical practice and to the exposure to inhalation techniques monitoring
88861041|NCT01026012|Experimental|Combined Protocol|patient with submaximal symptom limited maximal exercise testing will also be administered regadenoson pharmacological stress test.
88861042|NCT02088216|Active Comparator|N-Acetylcysteine group|Participants received 600 mg of oral N-acetylcysteine BID for 12 months.
88861043|NCT02088216|Other|Control group|Participants received as-needed therapy.
88861044|NCT04782882|Experimental|intervention group|In the first session of the researcher (S.K.), the participants were explained the effects of anxiety and stress on the treatment in simple terms for 5 min. Then, information was given about the effects of laughter therapy and progressive muscle relaxation on the body. Laughter therapy was applied for 15-20 min. Then, the lights were turned off and progressive muscle relaxation exercises were performed for 15-20 min under candlelight and accompanied by music. The procedures were received as a group (2-6 people) in 3-4 face-to-face sessions.
88861045|NCT04782882|No Intervention|Control group|The control group then received routine care
88861046|NCT01014936|Experimental|MSC2156119J Regimen 1|Subjects will be administered with micronized or non-micronized MSC2156119J in dose ranging from 30 mg to 400 mg (capsule formulation) once daily for 14 days, followed by 7 days with no treatment (21-day cycle) in Regimen 1.
88861047|NCT01014936|Experimental|MSC2156119J Regimen 2|Subjects will be administered with micronized or non-micronized MSC2156119J in dose ranging from 60 mg to 315 mg (capsule formulation) once daily 3 times per week for 3 weeks (21-day cycle) in Regimen 2.
88861048|NCT01014936|Experimental|MSC2156119J Regimen 3|Subjects will be administered with micronized MSC2156119J in dose ranging from 300 mg to 1400 mg (capsule or tablet formulation) once daily for 21 days (21-day cycle) in Regimen 3.
89385733|NCT02428647|Active Comparator|therapeutic zinc supplements|preventive placebo supplements provided as dispersible tablets plus ORS and dispersible therapeutic zinc tablets (containing 20 mg zinc) for diarrhea
88861049|NCT01896180|Experimental|ALZ-1101|ALZ-1101 ophthalmic solution dosed as 1 drop, once daily in the evening via topical ocular adminstration
88861050|NCT01896180|Active Comparator|Latanoprost|Latanoprost 0.005% ophthalmic solution dosed as 1 drop, once daily in the evening via topical ocular administration
88861051|NCT00981162|Experimental|Treatment (sorafenib tosylate and everolimus)|Patients receive everolimus PO once daily and sorafenib tosylate PO twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88861052|NCT00960102|Active Comparator|bilateral cochlear implant|
88861053|NCT00960102|Active Comparator|cochlear implant and hearing aid|
89184712|NCT04107779|Experimental|JUUL 3% Mint ENDS|JUUL 3% Mint flavored ENDS product [6 days] in confinement.
89385734|NCT01071395|Experimental|Amantadine|Amantadine 100mg tab BID or TID for duration of study
89385735|NCT01071395|Placebo Comparator|Placebo|Placebo one tab BID or TID for duration of study
89385736|NCT02970942|Experimental|Semaglutide 0,1 mg|
89385737|NCT02970942|Experimental|Semaglutide 0,2 mg|
89385738|NCT02970942|Experimental|Semaglutide 0,4 mg|
89385739|NCT02970942|Placebo Comparator|Placebo 1|
88861054|NCT00960102|Active Comparator|bilateral hearing aid|
88861055|NCT04755894|Experimental|group A|
88861056|NCT04755894|Active Comparator|group B|
88861057|NCT04782024|Placebo Comparator|Placebo|
88861058|NCT04782024|Experimental|7-Keto 50mg|
88861059|NCT04782024|Experimental|7-Keto 25mg|
88861060|NCT04389762|Experimental|PS128|daily ingestion of Lactobacillus plantarum PS128 capsules
88861061|NCT04346160||Patients with bilateral conjunctivitis|Hospitalized patient affected by COVID-19 disease with bilateral conjunctivitis defined as red eyes (macroscopic signs of conjunctival congestion)
89184713|NCT04107779|Experimental|JUUL 5% Menthol ENDS|JUUL 5% Menthol flavored ENDS product [6 days] in confinement.
89385740|NCT02970942|Placebo Comparator|Placebo 2|
89385741|NCT02970942|Placebo Comparator|Placebo 3|
89385742|NCT05433311|Active Comparator|Exercises|Neutral position training, transversus abdominis/multifidius/abdominal/back extensors strengthening exercise, bridge exercise, cat-camel exercise, lumbal extensor/hamstring/gastrosoleus/latissimus dorsi/gluteal stretching exercises
89385743|NCT05433311|No Intervention|Routine|Only routine treatment
88861062|NCT04346160||Patients without conjunctivitis|Hospitalized patient affected by COVID-19 disease without any signs of conjunctivitis defined as red eyes (macroscopic signs of conjunctival congestion)
88861063|NCT04346160||Healthy control group|group of healthy patients considered as controls
88861064|NCT04755348|Experimental|Product usage order ABFCED|Subjects will use each of the 6 products (ABFCED) during an familiarization period, followed by a 4 hour Test Session
88861065|NCT04755348|Experimental|Product usage order BCADFE|Subjects will use each of the 6 products (ABECD) during an familiarization period, followed by a 4 hour Test Session
88861066|NCT04755348|Experimental|Product usage order CDBEAF|Subjects will use each of the 6 products (CDBEAF) during an familiarization period, followed by a 4 hour Test Session
88861067|NCT04755348|Experimental|Product usage order DECFBA|Subjects will use each of the 6 products (DECFBA) during an familiarization period, followed by a 4 hour Test Session
88861068|NCT04755348|Experimental|Product usage order EFDACB|Subjects will use each of the 6 products (EFDACB) during an familiarization period, followed by a 4 hour Test Session
88861069|NCT04755348|Experimental|Product usage order FAEBDC|Subjects will use each of the 6 products (FAEBDC) during an familiarization period, followed by a 4 hour Test Session
88861070|NCT04754958|Experimental|VR|In addition to standard care during MRI scan, patient receives VR intervention.
88861071|NCT04754958|No Intervention|No VR|Standard of care during MRI scan.
88861072|NCT00909012|Placebo Comparator|1|
88861073|NCT00909012|Experimental|2|
88861074|NCT00909012|Experimental|3|
88861075|NCT00909012|Experimental|4|
88861076|NCT00909012|Experimental|5|
88861077|NCT00875004|Experimental|Erythropoietin beta|
88861078|NCT04781790||Patients with Bone marrow failure|Standard of care of patients with bone marrow failure
88861079|NCT05320692|Experimental|Treatment group|TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib).
88861080|NCT05320692|Active Comparator|Control group|TACE Alone.
88861081|NCT01895166|Experimental|EBUS-GS group|The EBUS probe and GS are confirmed to reach the lesion by EBUS images alone, cytologic and pathologic specimens are obtained without fluoroscopic guidance.
88861082|NCT01895166|Active Comparator|EBUS-GS-X-ray group|The EBUS probe and GS are confirmed to reach the lesion by EBUS images and radiograph fluoroscopy, cytologic and pathologic specimens are obtained under fluoroscopic guidance.
88861083|NCT01763580|Experimental|Tacrolimus with low-dose corticosteroid|Oral
88861084|NCT01763580|Active Comparator|High-dose corticosteroid alone|Oral
88861085|NCT04754724|Experimental|GIMate|Individuals with suspected lactose intolerance who start with GIMate use first
88861086|NCT04754724|Active Comparator|H2 Check|Individuals with suspected lactose intolerance who start with H2 Check use first
88861087|NCT01896258||Regional emergency centers|
88861088|NCT01896258||Local emergency centers|
88861089|NCT00857922||Neurosurgical patient|Neurosurgical patient of the Mischer Neuroscience Institute, 18 years and over
88861090|NCT00857922||Family members|Family members of specific vascular, trauma, brain tumor and functional disorder cohorts
88861091|NCT00826098|Experimental|1 (PRP)|Total knee replacement with PRP
88861092|NCT00826098|No Intervention|2 (non-PRP)|Total knee replacement without PRP
88861093|NCT01753830|Experimental|Durolane|Single intraarticular injection of Durolane
88861094|NCT01753830|Placebo Comparator|PBS|Single intraarticular injection of PBS
88861095|NCT03990948||Patients with obesity|In 100 patients with obesity, blood samples will be collected.
88861096|NCT03990948||Patients with a Sleeve Gastrectomy|In 100 patients with a Sleeve Gastrectomy, blood samples will be collected.
88861097|NCT03990948||Patients with a Roux-en-Y Gastric Bypass|In 100 patients with a Roux-en-Y Gastric Bypass, blood samples will be collected.
88861098|NCT01745250|Experimental|Emervel Lips|Emervel Lips
88861099|NCT01745250|Experimental|Juvederm Ultra Smile|Juvederm Ultra Smile
88861100|NCT00760812|Experimental|ESI--Individual PII First Condition|This group will first receive the Early Social Interaction (ESI) model individual parent-implemented intervention (PII) for 9 months, followed by the ESI model group information, education, and support (IES) intervention for 9 months.
88861101|NCT00760812|Experimental|ESI--Group IES First Condition|The group will first receive ESI group IES condition for 9 months, followed by ESI individual PII for 9 months.
88861102|NCT01740492|Experimental|LDK1: Low dose Ketamine (0.15mg/kg)|"Participants randomized to the first group, LDK1, will receive an intravenous injection of low dose ketamine (0.15mg/kg).~All participants, regardless of the group, will receive a dose of morphine(0.15mg/kg) at the same time the study drug is administered."
88861103|NCT01740492|Experimental|LDK2: Low dose Ketamine (0.3mg/kg)|"Participants randomized to the second group, LDK2, will receive an intravenous injection of low dose ketamine (0.3mg/kg).~All participants, regardless of the group, will receive a dose of morphine(0.15mg/kg) at the same time the study drug is administered."
88861104|NCT01740492|Placebo Comparator|0.9% Normal Saline|This group will receive a placebo injection of 0.9% normal saline of a similar volume (0.05ml/kg)
88861105|NCT04780386|Experimental|NVP-1805|NVP-1805
88861106|NCT04780386|Active Comparator|NVP-1805-R1 and NVP-1805-R2|coadministration of NVP-1805-R1 and NVP-1805-R2
88861107|NCT04780308||1 medial 1 lateral K-wire|Pediatric Gartland Type 3 supracondylar humeral fractures fixed by 1 medial 1 lateral K-wire
88861108|NCT04780308||1 medial 2 lateral K-wire|Pediatric Gartland Type 3 supracondylar humeral fractures fixed by 1 medial 2 lateral K-wire
88861109|NCT04780308||2 medial 1 lateral K-wire|Pediatric Gartland Type 3 supracondylar humeral fractures fixed by 2 medial 1 lateral K-wire
88861110|NCT04780308||2 lateral K-wire|Pediatric Gartland Type 3 supracondylar humeral fractures fixed by 2 lateral K-wire
88861111|NCT04780308||3 lateral K-wire|Pediatric Gartland Type 3 supracondylar humeral fractures fixed by 3 lateral K-wire
88861112|NCT01738464||Pelvic Pain|Interstitial Cystitis or Chronic Prostatitis/Chronic Pelvic Pain Syndrome, Lower Urinary Tract Symptoms, and Overactive Bladder patients will be compared to Healthy and Depressed patients.
88861113|NCT01738464||Controls|Healthy patients will be used as controls to compare to patients diagnosed with Interstitial Cystitis, Chronic Prostatitis, Chronic Pelvic Pain Syndrome, Lower Urinary Tract Symptoms, Overactive Bladder, and Depressed patients.
89184714|NCT04107779|Experimental|JUUL 3% Menthol ENDS|JUUL 3% Menthol flavored ENDS product [6 days] in confinement.
88861114|NCT01738464||Major Depression|Major Depression patients will be compared to Controls and Pelvic Pain cohorts.
89535208|NCT05020119|Experimental|Low dose of neoantigen-based cell therapy (N=3+3)|(1±20%) × 109cells/200 mL every 14 days for 10 doses
88861115|NCT04780854|Active Comparator|Metformin group|1 gm metformin tablet administered twice daily for 3 months
88861116|NCT04780854|Placebo Comparator|Metformin-free|1 placebo tablet administered twice daily for 3 months
88861117|NCT04780152|Experimental|tDCS arm|Participants receive 10 consecutive sessions followed by 1 session per week 10 weeks of tDCS (30 minutes and 2 mA) + fluoxetine (10 mg daily 2 weeks followed by 20 mg daily).
88861118|NCT04780152|Placebo Comparator|Control arm|Participant receive 10 consecutive sessions followed by 1 session per week 10 weeks of placebo (30 minutes of placebo-simulation tDCS) + fluoxetine (10 mg daily 2 weeks followed by 20 mg daily).
88861119|NCT01737528||TAVR Patients|Will include all patients 18 years or over who undergo Transcatheter Aortic Valve Replacement (TAVR) for severe aortic stenosis. The sample size will include all patients entered into the Registry.
88861120|NCT04779840||period 2011|
89535209|NCT05020119|Experimental|Medium dose of neoantigen-based cell therapy (N=3+3)|(3±20%) × 109cells/200 mL every 14 days for 10 doses
88861121|NCT04779840||period 2018|
88861122|NCT01735656|Experimental|DK-culotte & Resolute stents|Double kissing culotte technique for true bifurcation lesion with Resolute stents
88861123|NCT01735656|Active Comparator|DK-crush & Resolute stents|Double kissing crush technique for true bifurcation lesion with Resolute stents
88861124|NCT00644280|Active Comparator|Ranibizumab|Ranibizumab (0.5 mg in 0.05 mL) administered intravitreally at 3 time points: 9 days before Ahmed tube insertion for open-angle glaucoma, 1 month post-surgery, and 2 months post-surgery
88861125|NCT00644280|No Intervention|Usual care|Standard of care Ahmed tube insertion for open-angle glaucoma without injections of Ranibizumab
88861126|NCT00641316|Experimental|1|Teeth extraction followed by natural healing
88861127|NCT00641316|Experimental|2- FDBA/TCP|
88861128|NCT00641316|Experimental|3 FDBA/TCP+PRP|
88861129|NCT00641316|Experimental|4 FDBA/TCP + PDGF|
88861130|NCT04779762|Experimental|Group 1|Standard induction regimen of Ustekinumab with the Crohn's disease exclusion diet (CDED)
88861131|NCT04779762|Active Comparator|Group 2|Standard induction regimen of Ustekinumab as above without diet
88861132|NCT04778202||first group (control group)|25 normal health control women apparently healthy. blood samples will be obtained after getting informed consent
89184715|NCT04107779|Experimental|JUUL 5% Mango ENDS|JUUL 5% Mango flavored ENDS product [6 days] in confinement.
89184716|NCT04107779|Experimental|JUUL 3% Mango ENDS|JUUL 3% Mango flavored ENDS product [6 days] in confinement.
89535210|NCT05020119|Experimental|High dose of neoantigen-based cell therapy (N=3+3)|(9±20%) ×109cells/400 mL every 14 days for 10 doses
89535211|NCT02488499|Active Comparator|Individualized Treatment|Individualized Treatment: 15 sessions of individualized treatment (i.e., parent-child) that target areas of presenting concern identified during assessment. These may include social problem-solving, emotion regulation, parent-child difficulties.
89535212|NCT02488499|Experimental|Coping Power|Coping Power: 15 sessions of concurrent parent and child group treatment. The child group focuses on developing problem-solving and emotion regulation skills. The parent group focuses on developing parenting skills and problem-solving strategies to manage and reduce their children's disruptive behaviour.
89535213|NCT03229603|Other|Cluster of 3000 women|Cluster will be selected from an existing cervical, breast, and oral cancer screening program in Mumbai, India and its surrounding semi-urban and rural areas.
88861133|NCT04778202||Second group (breast cancer patient group)|25 female patients referred to radiology departement at South Egypt Cancer Institute or Assiut University Hospital diagnosed as breast cancer patients as evidenced by clinical examination , mammography and histopathology
88861134|NCT04778280||Group A|1-Group A(Healty group with negative Giardia lamblia or control group) 96 samples
88861135|NCT04778280||Group B|2- Group B(Cases group with positive Giardia lamblia )96 sample
88861136|NCT04777968|No Intervention|Control Group (A) : RMGI restoration without SDF and KI.|• RMGI restoration without SDF and KI.
88861137|NCT04777968|Experimental|Intervention Group (B): Pretreatment with SDF and KI prior to RMGI restoration.|• Pretreatment with SDF and KI prior to RMGI restoration.
88861138|NCT04779606|Experimental|Chloroprocaine|Chloroprocaine 3% ocular gel (30 mg/mL), 3 drops instilled at a 1 min ± 15 sec interval.
88861139|NCT04779606|Placebo Comparator|Placebo|Vehicle for chloroprocaine 3% ocular gel, 3 drops instilled at a 1 min ± 15 sec interval.
88861140|NCT05295654|Experimental|Kinect validation|Kinect measurements will be compared with the vicon measurements to validate the kinect system.
88861141|NCT01722708|Experimental|clindamycin|
88861142|NCT01722708|Experimental|metronidazole|
88861143|NCT04779450|Experimental|Synchronous Telemonitoring|The sessions will be supervised by a therapist and conducted via video call using the WhatsApp® application, lasting 50 minutes, 3 times a week, for 6 consecutive weeks, the exercises will basically consist of active stretching, mobilization and scapular stabilization, and active shoulder exercises with gradual range of motion.
88861144|NCT04779450|Experimental|Asynchronous Telemonitoring|An explicative schedule with the exercises to be performed asynchronously during the week will be delivered weekly via e-mail and WhatsApp®. The exercises will be the same as those performed by the synchronous telemonitoring group, and the participant will be free to ask any questions about the protocol to the therapist at any time via text message or e-mail.
89184717|NCT04107779|Experimental|Dual-use of JUUL 5% and UB of Combustible Cigarette|JUUL 5% Virginia Tobacco, Mint, Menthol, or Mango flavored ENDS product and usual brand of combustible cigarette [6 days] in confinement.
89184718|NCT04107779|Active Comparator|UB of Combustible Cigarette|Usual brand combustible cigarette [6 days] in confinement.
89184719|NCT04107779|Other|Tobacco/Nicotine Abstention|Smoking abstention (no smoking) [6 days] in confinement.
89184720|NCT04067505|Experimental|Rivaroxaban|Participants will receive rivaroxaban 15mg twice daily for three weeks, then 20mg oral once daily after operation.
89385744|NCT03577496|Experimental|Peppermint oil|A cotton ball with three drops of peppermint oil will be waved under the patient's nares upon arrival to the recovery room. The patients will be assessed for PONV for up to an hour in the post anesthesia care unit (PACU) or until their discharge, whichever is first.
89385745|NCT05429723|Experimental|HS-10383|HS-10383 was administered at 8 am on the first day, 4 dose levels
89385746|NCT05429723|Placebo Comparator|HS-10383 Placebo|Matching placebo to HS-10383 was administered at 8 am on the first day, 4 dose levels
89385747|NCT03073005|No Intervention|Traditional VAD training|Patients and caregivers will receive traditional training for their VAD via a video produced by the VAD manufacturer.
89385748|NCT03073005|Experimental|Simulation-based VAD training|Patients and caregivers will receive traditional training for their VAD via a video produced by the VAD manufacturer and then participate in simulation-based mastery learning for VAD management
89385749|NCT03577340||Novices|Novices: Trainee cardiologists implanting cardiac devices as per guidelines under supervision
89385750|NCT03577340||Experts|Experts: Device implanting cardiologists implanting cardiac devices as per guidelines
89385751|NCT03582878|Active Comparator|mycophenolate mofetil|mycophenolate mofetil dosing 1g before transplantation and 1g bid afterwards
89385752|NCT03582878|Experimental|Sirolimus|Sirolimus oral product Dosing 5mg orally 2-6h before transplantation Target trough levels between 5-10ng/ml
88861145|NCT04779450|Active Comparator|Control Group|Will receive only a booklet of usual guidelines for women after breast cancer, such as skin care, return to activities, upper limb functionality, self-care, lymphedema and physical activity practice.
88861146|NCT04777890|Active Comparator|suboccipital inhibition technique group|
88861147|NCT04777890|Experimental|INYBI group|Participants in this group will be treated with the INYBI, an instrument designed for treating the suboccipital area, in a more precise way than the manual technique.
88861148|NCT04777890|Experimental|combined treatment group|Participants in this group will be first treated with the INYBI and then receive an upper cervical manipulation
88861149|NCT04778124|Other|Patients with hemorrhoidal disease undergoing HAL-RAR|This is a single-arm trial, in which all patients with grade II hemorrhoidal disease resistant to conservative treatment, grade III and IV hemorrhoidal disease underwent HAL RAR surgery.
88861150|NCT02316678||anti-TNF - no intervention|Patients who are new users of anti-TNF therapy
88861151|NCT02316678||Corticosteroids - no intervention|Patients initiating corticosteroids
88861152|NCT03726528|Experimental|Experimental intervention|
88861153|NCT04777578|Experimental|DN|
89184721|NCT04067505|Active Comparator|Warfarin/Nadroparin|Participants will receive nadroparin 1mg/kg twice daily (subcutaneous), plus warfarin 3mg oral once daily for 5 days after the operation, later warfarin(oral) at individually titrated doses(0.75mg to 18mg) to achieve a target international normalized ratio (INR) of 2.0 to 3.0, once daily until 6 months.
89184722|NCT00794963|Experimental|Integrated care|Provide on-site internal medicine evaluation, treatment and follow up of metabolic syndrome for patients in Clozapine Clinic
89184723|NCT00794963|Other|Usual Care|Follow the 8-month outcome of schizophrenia patients with metabolic syndrome treated in the community
89184724|NCT00713271|Experimental|1|Low dose
88861154|NCT04777578|No Intervention|Control|
88861155|NCT04754568|Experimental|Virtual reality instructional design|Completion of virtual reality simulation of an outpatient physical therapy evaluation.
88861156|NCT04754568|Active Comparator|Role-playing instructional design|Completion of traditional role-playing of a scripted outpatient physical therapy evaluation
88861157|NCT01896492|Active Comparator|N-acetyl cystien and clomiphen citrate|N-acetyl cystien and clomiphen citrate,in induction of ovulation in newly diagnosed PCOS,1-2gm schats of NAC PLUS 100 mg of cc in the therd day of the cycle till day 8,with monitoring of follicular growth usin ultrasonography.HCG is giving to trigger of ovulation fo follicular size 18mm or more.
88861158|NCT01896492|Placebo Comparator|Clomiphen citrate and placebo|CC plus placebo compared to cc and NAC in induction of ovulation in PCOS new cases.
88861159|NCT01896492|No Intervention|N-acetyl cystien|In addition to the CC, each patient was selected randomly to receive either NAC (Sedico, Cairo, ARE), in a dose of 1.2 g/d orally, or a placebo (sugar) of the same volume twice daily from day 3 until day 7
88861160|NCT01711632|Experimental|Vemurafenib|Eligible patients will receive vemurafenib at a dose of 960mg orally twice daily (b.i.d.) continuously in cycles of 4 weeks (28 days).
88861161|NCT04756206|Active Comparator|Dutasteride|Dutasteride of 0.5 mg once daily was given for 3 months compared to a placebo.
89385753|NCT01331057||1:Sri Lankais|Children aged of four to six years old, in the nursery school and if their first language is unique : tamil.
89385754|NCT01331057||2: Algerian|Children aged of four to six years old, in the nursery school and if their first language is unique : arabic.
89385755|NCT01331057||3: Mali|Children aged of four to six years old, in the nursery school and if their first language is unique : SONINKE.
89385756|NCT03579524|Active Comparator|ESPB group|Erector Spinae Plane Block administered group
89385757|NCT03579524|Active Comparator|SAPB group|Serratus Anterior Plane Block administered group
89385758|NCT02238704|Experimental|Regimen A|500mg elemental calcium (as CaCO3) + 200 microgram Vit D per administration, administered 2 times a day, at least 2hours apart with one administration of 60mg elemental iron (as FeSO4) at any time of the day
89385759|NCT02238704|Active Comparator|Regimen B|500mg elemental calcium (as CaCO3) + 200 microgram Vit D per administration, administered 3 times a day, at least 2hours apart with one administration of 60mg elemental iron (as FeSO4) at any time of the day
89385760|NCT03577262|Experimental|Healthy subjects [11C]-UCB-J|Net dose of approximately 370 megabecquerel (MBq) of [11C]-UCB-J, Total injected mass of UCB-J per will not to exceed 10 µg for each dose given on Days 1 and 28
89385761|NCT03577262|Experimental|AD patients [11C]-UCB-J|Net dose of approximately 370 megabecquerel (MBq) of [11C]-UCB-J, Total injected mass of UCB-J per will not to exceed 10 µg for each dose given on Days 1 and 28
89385762|NCT01331135|Experimental|sirolimus treatment|Dose escalation of sirolimus with starting dose at 1 mg/m2 and increasing to a possible 3 mg/m2.
89535214|NCT03083535|Active Comparator|Tooth Brushing|Tooth brushing with dentifrice and standardized tooth brush
89535215|NCT03083535|Experimental|Aloe vera massaging|Tooth brushing with dentifrice and standardized tooth brush followed by massaging with aloe vera gel
89385763|NCT02849171|Experimental|high-grade glioma|Eligible patients must have undergone standard radiation (typically 60Gy in 30 fractions), with or without concurrent drug therapy, and have MRI findings consistent with tumor progression and/or pseudoprogression within 24 weeks after completion of radiation. Eligible patients will undergo an 11C-CH PET study within 2 weeks of the standard of care MRI that shows changes concerning for tumor progression vs. pseudoprogression. All patients will then be followed with surveillance brain MRI with and without contrast as per standard of care for a period of 11 months, to assess further progression or stabilization of the lesion. Initial MRI changes are considered to represent pseudoprogression/treatment related changes if the lesion stabilizes or becomes smaller without a change in tumor-related therapy. Otherwise, it will be considered a recurrence should there be progessive radiographic changes.
89385764|NCT03888885|Experimental|Sport Education Group|Participants participated in the required physical education lessons which were delivered in a season of sport education model for 10 lessons.
89385765|NCT03888885|No Intervention|Control Group|Participants received no intervention treatment. They were asked to attend in normal physical education classes for the same period of time.
89385766|NCT02848664||Dysphagia retraining with device|Participants with dysphagia received baseline testing of dysphagia and dysphagia handicap. Then received training on how to use a vibrotactile device for self training at home. They used the device for 3 months and returned for re-evaluation on testing of dysphagia and feedback on the device
89385767|NCT03635879|Active Comparator|MCTprocal medical food|Vitaflo MCTprocal, single dose (20 g MCT)
89385768|NCT03635879|Active Comparator|Milk/tricaprilin oil blend|Lactose-free milk and tricaprilin oil, blended,single dose (20 g tricaprilin)
89385769|NCT03635879|Active Comparator|AC-1207|AC-1207 liquid, single dose (20 g tricaprilin)
89385770|NCT03635879|Active Comparator|AC-1205|AC-1205 liquid, single dose (20 g tricaprilin)
89385771|NCT03635879|Active Comparator|AC-1206|AC-1206 liquid, single dose (20 g tricaprilin)
89385772|NCT03635879|Experimental|AC-1202|AC-1206 liquid, single dose (20 g tricaprilin)
89385773|NCT03651180||Amphilimus eluting stent|Diabetic patients treated with Cre8 Amphilimus eluting stent
89385774|NCT03651180||Non Amphilimus eluting stent|Diabetic patients treated with any other drug eluting stent
89385775|NCT02238860|Active Comparator|Entacavir|Entacavir 0.5 mg (OD) for 48 weeks
89385776|NCT02238860|Active Comparator|Tenofovir|Tenofovir 300 mg ,OD for 48 weeks
89385777|NCT01333709|Experimental|Arm A: immediate rectal surgery|"Very good responder patients will be randomly assigned to proctectomy within 2-4 weeks after the end of the induction chemotherapy."
89385778|NCT01333709|Other|Arm B: RCT Cap 50 and then rectal surgery|"Very good responder patients will be randomly assigned to receive chemoradiotherapy combining the administration of oral capecitabine (1600 mg/m2/day, BID) and radiotherapy at a total dose of 50 grays (2Gy/day, 5 days a week, 5 weeks, boost 6 Gy)."
88861162|NCT04756206|Placebo Comparator|Placebo|same form and color of Dutasteride tablet was given at the same regimen to act as a placebo
89385779|NCT01333709|Other|Arm C: RCT Cap 50 and then rectal surgery|"Good or poor responder patients will be randomly assigned to receive chemoradiotherapy combining the administration of oral capecitabine (1600 mg/m2/day, BID) and radiotherapy at a total dose of 50 grays (2Gy/day, 5 days a week, 5 weeks, boost 6 Gy)."
89385780|NCT01333709|Experimental|Bras D: RCT Cap 60 and then rectal surgery|"Good or poor responder patients will be randomly assigned to receive chemoradiotherapy combining the administration of oral capecitabine (1600 mg/m2/day, BID) and radiotherapy at a total dose of 60 grays (2Gy/day, 5 days a week, 6 weeks, boost 14 Gy)."
89385781|NCT02239172|Experimental|12.5 µg + Alhydrogel|vaccine
89385782|NCT02239172|Experimental|25 µg + Alhydrogel|vaccine
89385783|NCT02239172|Experimental|50 µg + Alhydrogel|vaccine
89385784|NCT02239172|Experimental|100 µg + Alhydrogel|vaccine
88861163|NCT04777500|Experimental|taVNS Group1|This group will receive taVNS for 4 weeks.
88861164|NCT04777500|Experimental|taVNS Group 2|This group will receive taVNS for 4 weeks.
89385785|NCT05202717|Experimental|PHENIX U4+|Electrical stimulation treatment for patients with urinary incontinence using a new type of pelvic floor therapy instrument
89385786|NCT05202717|Active Comparator|Traditional pelvic floor electrical stimulation therapy instrument|Electrical stimulation treatment for patients with urinary incontinence using traditional pelvic floor therapy instrument
89385787|NCT02969382|Experimental|SEP-363856|SEP-363856 capsule (50 mg or 75 mg) once daily
89385788|NCT02969382|Placebo Comparator|Placebo|Placebo capsule once daily
89385789|NCT03579368|Other|Symfony Implantation|Patients undergoing bilateral IOL implantation with the Tecnis Symfony Extended Range of Vision IOL at a single surgical site
89385790|NCT01333787|Active Comparator|Dietary Fiber Mixture|The dietary fiber mixture was composed of six different types of fibers. It was used for treatment of chronic constipation in children.
89385791|NCT01333787|Placebo Comparator|Maltodextrine|Blinded control group
89385792|NCT03574922|Active Comparator|Balance Exercises|Balance Exercises
88861165|NCT04777188|Experimental|Hypertrophic Obstructive Cardiomyopathy|Left ventricular systolic function by speckle tracking echocardiography before and after percutaneous intramyocardial septal radiofrequency ablation for hypertrophic obstructive cardiomyopathy.
88861166|NCT04745598||Control group: Dental model|Patients diagnosed with periodontal disease stage I/II/III
88861167|NCT04745598||Computer-assisted teaching format group|Patients diagnosed with periodontal disease stage I/II/III
89385793|NCT03574922|Active Comparator|Core Stabilization Exercises|Balance and core stabilization exercises
89385794|NCT03574922|No Intervention|Control|Assessments only
89385795|NCT02239250|Experimental|Water filter and cookstove|All household that appear on Government approved lists as belonging to ubudehe 1 & 2 categories in the 72 sectors randomised as intervention sectors will be eligible to receive one free water filtering device and one free cookstove. All households will be given instructions of how to use the intervention.
89385796|NCT02239250|No Intervention|Control|All household that appear on Government approved lists as belonging to ubudehe 1 & 2 categories in the 24 sectors randomised as control sectors will continue with their traditional cooking methods and drinking practices.
89385797|NCT03651414||Control|Patients hospitalized ab initio in Internal Medicine or similar for at least one night
89385798|NCT03651414||Outlier|Patients spending at least one night in a ward different from Internal Medicine despite the presence of medical diseases, due to lack of available beds
89385799|NCT01989104||Children|6-12 years of age
89385800|NCT01989104||Adolescents|13-17 years of age
89385801|NCT01989104||Young adults|18-20 years of age
89385802|NCT03077789|Experimental|TRABECULOTOMY|
89385803|NCT00175136|Active Comparator|I-beam|I-beam stem design of tibial component for Total Knee Arthroplasty.
89385804|NCT00175136|Active Comparator|wedge|Wedge stem design of tibial component for Total Knee Arthroplasty.
89385805|NCT02589509|Experimental|Direct-Metacognitive|Direct attention training followed by metacognitive strategy training
89385806|NCT02589509|Experimental|Metacognitive-Direct|Metacognitive strategy training followed by direct-attention training
89385807|NCT02239406||Metal-on-Metal Revision|Patients who have a failed metal on metal total hip implant and are presenting for revision surgery
89385808|NCT02903238|Experimental|Placebo|placebo capsule
88861168|NCT04745598||Plaque-disclosing group|Patients diagnosed with periodontal disease stage I/II/III
88861169|NCT04745598||Intra-oral Camera group|Patients diagnosed with periodontal disease stage I/II/III
88861170|NCT04779060|Active Comparator|fentanyle group|
88861171|NCT04779060|Active Comparator|dexamethasone group|
88861172|NCT04779060|Placebo Comparator|control group|
89385809|NCT01331369|Active Comparator|Control|Usual care. It means routine medical care that include free demand consultation and free medicines.
89385810|NCT01331369|Experimental|Intervention|Intensification of care. Besides routine medical care that include free demand consultation and free medicines, subjects were invited to have 6 structured medical encounters based on a social-psychological approach. Doctors must follow a protocol to conduct the encounter that have around 30 minutes each.
89385811|NCT03621852||Endoultrasound guided FNB|Patients with tumors of the pancreas, submucosal tumors or lymphnode disease of the upper gastrointestinal tract, which have to undergo EUS guided FNB.
89385812|NCT03651024|Other|Treating Patients with ED|Treatment of patients with ED
89385813|NCT01329809|Experimental|JX-594 Intravenous infusion|JX-594 will be administered intravenously to patients with measurable intra-hepatic disease who are not eligible for intratumoral injection of JX-594.
89385814|NCT01329809|Experimental|JX-594 Intratumoral Injection|JX-594 will be injected directly into the liver tumor of patients who have at least two measurable intra-hepatic tumors, one of which must be at least 1.5cm in diameter and safety injectable.
89385815|NCT02847260|Experimental|Remodulin|Remodulin will be initiated, whilst subjects are hospitalized (minimum of 72 hours) and under medical supervision, at approximately 2 ng/kg/min as a continuous SC infusion with dose increments of 1-2 ng/kg/min applied approximately every 12 hours according to clinical response and tolerability. Following discharge, dose rate increments are permitted at 1-2 ng/kg/min with a minimum of 24 hours between each dose up-titration. Once a dose rate of 20 ng/kg/min is achieved, the dose increments can be increased up to 4 ng/kg/min with dose increments separated by at least 24 hours. The aim is to achieve a target dose of 10, 20, and 30 ng/kg/min by the end of weeks 1, 4 and 12, respectively.
89385816|NCT02872571|Experimental|Intramuscular Islet Autograft|Intramuscular Islet Autograft After Extensive Pancreatectomy
89385817|NCT03650946||1|men with high or intermediate risk localized disease who are about to undergo definitive surgery or radiotherapy
89385818|NCT03650946||2|men with rising PSA after local definitive treatments
89385819|NCT03650946||3|m0CRPC with a PSA >1.0 or 2.0
89385820|NCT03574844|Experimental|Saccharomyces cerevisiae, dose 500|Saccharomyces cerevisiae CNCM I-3856, 500 mg per day (2 capsules), for 4 weeks
89385821|NCT03574844|Experimental|Saccharomyces cerevisiae, dose 1000|Saccharomyces cerevisiae CNCM I-3856, 1 g per day (2 capsules), for 4 weeks
89385822|NCT03574844|Placebo Comparator|Placebo|Maize starch and magnesium stearate, 1 g per day (2 capsules), for 4 weeks
89385823|NCT03649620|Experimental|unripe Bokbunja Extract|tablet(1 tablet/d, 600 mg/d) for 12 weeks
88861173|NCT04778826|Active Comparator|Lung Lobectomy with standard ipsilateral lymphadenectomy|Lung lobectomy with ipsilateral lymphadenectomy
88861174|NCT04778826|Active Comparator|Lung Lobectomy with VAMLA|Lung lobectomy combined with video-assisted mediastinal lymphadenectomy through the neck (VAMLA). The approach is similar to transcervical mediastinoscopy and allows for a radical bloc dissection of all mediastinal lymph node stations. Besides the benefit of bilateral lung ventilation during this phase of the operation a bilateral mediastinal lymphadenectomy offers improved surgical radicality.
88861175|NCT04777110|Experimental|Esketamine injection group (0.25mg/kg)|The main anesthesiologist standing on the right side of the patient gave successive injections of esketamine (0.25 mg/kg), and 1 minute later, injected propofol (1.5 mg/kg) for 30 s
89385824|NCT03649620|Placebo Comparator|Placebo|Placebo for 12 weeks
89535216|NCT03083535|Experimental|SRP with aloe vera massaging|Scaling and root planning was done with ultrasonic scalar. It was followed by aloe vera massaging on half arch for 3 minutes daily
88861176|NCT04777110|Sham Comparator|Saline injection group(0.05ml/kg)|The main anesthesiologist standing on the right side of the patient sequentially injects normal saline (0.05ml/kg), and 1 minute later injects propofol (1.5 mg/kg), the injection time is 30 seconds
88861177|NCT04776876|Experimental|Treatment (retifanlimab, telotristat ethyl)|Patients receive retifanlimab IV over 30-60 minutes on day 1 and telotristat ethyl PO TID on days 1-28. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
88861178|NCT01694940||Mitochondrial Disease Patients|Patients with possible or known mitochondrial disorders. Patients who are known carriers of mitochondrial or nuclear DNA mutations involved in mitochondrial function.
89385825|NCT02968563|Experimental|Tirabrutinib + Idelalisib|Tirabrutinib 80 mg (4 x 20 mg tablets/2 x 40 mg tablets/1 x 80 mg tablet) once daily + idelalisib 100 mg (1 x 100 mg tablet) once daily for up to 104 weeks.
89385826|NCT02968563|Experimental|Tirabrutinib + Idelalisib + Obinutuzumab|Tirabrutinib 80 mg (4 x 20 mg tablets/ 2 x 40 mg tablets/ 1 x 80 mg tablet) once daily + idelalisib 100 mg (1 x 100 mg tablet) once daily for up to 104 weeks + obinutuzumab 100 mg on Day 1, 900 mg on Day 1 or 2, and 1000 mg subsequently for up to 8 doses on Day 1 of Weeks 2, 3, 5, and then every 4 weeks through Week 21.
89385827|NCT01329887|Other|administration of ketanserin|
89385828|NCT01334099|Experimental|Radiation combined with CP-675,206|
89385829|NCT03650868|No Intervention|Control Group|No intervention will be applied to control group
89385830|NCT03650868|Experimental|TPVB group|Thoracal paravertebral block will be performed with 20cc of 0,25% bupivacaine preoperatively.
89385831|NCT03579134|Experimental|partial overlay denture|removable partial denture with a metal extension over the remaining posterior teeth raising their height to the newly proposed vertical dimension and occlusal plane
89385832|NCT03579134|Active Comparator|fixed temporary crowns|fixed crowns made from temporary material placed on the prepared posterior teeth to the new occlusal plane level elevating the vertical dimension to the newly proposed level
89385833|NCT01331525|Experimental|Single stage non-randomised|"Patients will receive Carboplatin and Etoposide. Both Chemotherapy drugs will be delivered as a 21 day cycle (q21) with up to a maximum of 6 cycles delivered according to response unless progressive disease (RECIST Version 1.0) and or excessive toxicity.~Ipilimumab will be administered at a dose of 10mg/kg IV on day 1 of cycles 3-6 of Chemotherapy.~In the absence of immune related progression of disease or unacceptable toxicity, subsequent maintenance doses of Ipilimumab will be delivered every 12 weeks starting at week 30 at a dose of 10 mg/kg until unacceptable toxicity or immune related disease progression"
89385834|NCT03650790|Active Comparator|preeclamptic obese pregnancy|CTRP 9 level will be assessed by 40 obese preeclamptic gestational ELISA methods that meet the latest ACOG criteria.
89385835|NCT03650790|Active Comparator|preeclamptic non-obese pregnancy|CTRP 9 level will be assessed by 40 non-obese preeclamptic gestational ELISA methods that meet the latest ACOG criteria.
89385836|NCT03650790|Active Comparator|normal pregnancy|CTRP 9 level will be assessed by 40 normal gestational ELISA methods
89385837|NCT03792165|Experimental|Action observation therapy and exercise|Video of normal human movement and Strengthening and stretching exercises for hip and knee muscles
89385838|NCT03792165|Active Comparator|Exercise|Strengthening and stretching exercises for hip and knee muscles, balance and proprioceptive exercises
89385839|NCT03649542|Active Comparator|Fluidotherapy® plus exercises group (FLO)|The Fluidotherapy® Unit and exercises group (FLO). They were required to complete wrist exercises in Fluidotherapy® Unit box for 15 minutes with the following exercises finger abduction/adduction, finger flexion/extension, forearm supination/pronation, wrist flexion/extension, and wrist radial deviation/ulnar deviation. Each patient performed two sets of fifteen repetitions for each exercise, totaling 15-minutes.
89385840|NCT03649542|No Intervention|Exercises only group (EX)|They were required to complete wrist exercises in the air for 15 minutes, including abduction/adduction, finger flexion/extension, forearm supination/pronation, wrist flexion/extension, and wrist radial deviation/ulnar deviation. Each patient performed two sets of fifteen repetitions for each exercise, totaling 15-minutes.
89385841|NCT03576950||Uterine rupture|Women with uterine rupture occurred during pregnancy.
89385842|NCT01334177|Experimental|Treatment (immunotherapy and monoclonal antibody therapy)|Patients receive cetuximab IV over 60-120 minutes on days -28, -21, -14, -7 of weeks -4 to -1. Patients then receive cetuximab IV on days 1, 8, 15, and 22 and TLR8 agonist VTX-2337 SC on days 1, 8, 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89385843|NCT03578978||Neonates with suspected LONS and/or NEC|A group of 150 neonates with suspected LONS and/or NEC will be recruited. No intervention will be given to the subjects. Blood sampling will be obtained from subjects at 4 time points (Hour 0, 24, 48 and 72) for analysis of the sepsis biomarkers of interest.
89385844|NCT03578978||Healthy neonates|A group of 50 neonates who are clinically well, admitted to the NICU for reasons other than neonatal sepsis or NEC will be recruited into the study to explore the kinetics and concentrations of the panel of biomarkers in healthy subjects comparing to subjects with suspected LONS/NEC. No intervention will be given to the subjects. Blood sampling will be obtained from subjects at 4 time points (Hour 0, 24, 48 and 72) for analysis of the sepsis biomarkers of interest.
89385845|NCT03574766|Experimental|Meditation Group|Twenty minutes of daily meditation for 7 days. Routine lactation support.
89385846|NCT03574766|No Intervention|Control Group|Routine lactation support.
89003297|NCT05492500|Experimental|Open-label, PK Cohort: ponsegromab medium dose|Participants will receive a medium dose Q4W SC
89385847|NCT03649386|Active Comparator|Control|Heated breathing circuit will turned off.
89385848|NCT03649386|Experimental|Heat|Heated breathing circuit will be turned on.
89003298|NCT05492500|Experimental|Open-label, PK Cohort: ponsegromab high dose|Participants will receive a high dose Q4W SC
89385849|NCT01331603||MDS and primary myelofibrosis patients|patients with in iron overloaded MDS patients (low and high risk ), and also patients with primary myelofibrosis. The risk stratification of these patients will be calculated according to the IPSS (International Prognostic Scoring System).
89385850|NCT03574688|Experimental|Water intervention|The participants increase their habitual daily water intake with 1.5 Liters of tap water per day during 6 weeks.
89385851|NCT05763537|Experimental|Standard Doula Care Plus the PMAD Intervention|Participants in this arm will receive standard perinatal doula care provided by doulas trained in the DONA International doula training in addition to PMAD-specific care from their doulas.
89385852|NCT05763537|Active Comparator|Standard Doula Care|Participants in this arm will receive standard perinatal doula care provided by doulas trained in the DONA International doula training.
89385853|NCT05763537|No Intervention|Standard Maternal Care|In this arm participants will receive standard perinatal medical care and will not receive care from a doula.
89003299|NCT05490888|Experimental|single dose of PHIN-214|single ascending dose of PHIN-214
89003300|NCT05490888|Experimental|multiple daily dosing of PHIN-214|multiple doses of PHIN-214, daily for 28 days
89003301|NCT05483218|Experimental|wrist orthosis|group benefiting from an orthosis that supports the wrist by covering the palm of the hand only
89003302|NCT05483218|Experimental|wrist-hand-finger orthosis|group benefiting from an orthosis that supports the wrist by covering the palm of the hand and the fingers
89385854|NCT05762523|Experimental|"Group 1 VAC∆6: оnce at a dose of 10⁶ PFU (plaque-forming units)"|15 healthy volunteers of both sexes aged 18-40 years who had not been vaccinated against smallpox, had no vaccine marks and anti-smallpox virus neutralizing antibodies in their sera as well as those who met the inclusion criteria and did not have any exclusion criteria
89385855|NCT05762523|Experimental|"Group 2 VAC∆6: once at a dose of 10⁷ PFU"|15 healthy volunteers of both sexes aged 18-40 years who had not been vaccinated against smallpox, had no vaccine marks and anti-smallpox virus neutralizing antibodies in their sera as well as those who met the inclusion criteria and did not have any exclusion criteria
89385856|NCT05762523|Experimental|"Group 3 VAC∆6: twice at a dose of 10⁶ PFU"|15 healthy volunteers of both sexes aged 18-40 years who had not been vaccinated against smallpox, had no vaccine marks and anti-smallpox virus neutralizing antibodies in their sera as well as those who met the inclusion criteria and did not have any exclusion criteria
89385857|NCT05762523|Experimental|"Group 4 OspaVir® + live smallpox vaccine"|15 healthy volunteers of both sexes aged 18-40 years who had not been vaccinated against smallpox, had no vaccine marks and anti-smallpox virus neutralizing antibodies in their sera as well as those who met the inclusion criteria and did not have any exclusion criteria
89385858|NCT02796261|Experimental|Eflornithine + Lomustine|Eflornithine dosed on a 2 weeks on, 1 week off schedule + Lomustine dosed every 6 weeks
89385859|NCT02796261|Active Comparator|Lomustine|Lomustine dosed every 6 weeks
89385860|NCT02904096|Experimental|"Grade 4 Hands group"|"Grade 4 Hands group will be subjects with hand grading of grade 4 (very severe loss of fatty tissue, marked visibility of veins and tendons in the dorsal hand). Grade 4 Hands group subjects will receive Radiesse injectable implant and 2% lidocaine HCL up to 3 cc (2 syringes) per hand per treatment. Subjects in Grade 4 Hands group can have up to three retreatments over an 18 month period."
89385861|NCT02904096|Experimental|"Grade 2 or 3 Hands group"|"Grade 2 or 3 Hands group will be subjects with hand grading of grade 2 or grade 3 (moderate to severe loss of fatty tissue, mild to moderate visibility of veins and tendons in the dorsal hand). Grade 2 or 3 Hands group subjects will receive Radiesse injectable implant and 2% lidocaine HCL up to 3 cc (2 syringes) per hand per treatment. Subjects in Grade 2 or 3 Hands group can have up to three retreatments over an 18 month period."
89385862|NCT01569711||Deep brain stimulation|
89385863|NCT05202171|Experimental|Exercise group|Exercise group will be performed cervical stabilization exercise training applied with telerehabilitation and standard treatment ( preventive/symptomatic oral drug therapy routinely in the clinic and suggestions for triggering factors in migraine) for 8 weeks
89385864|NCT05202171|Active Comparator|Standard treatment group|Standard treatment group will be given preventive/symptomatic oral drug therapy routinely in the clinic and suggestions for triggering factors in migraine for 8 weeks.
89385865|NCT04053348|Experimental|Intervention|Participants allocated to the intervention group will receive their home-based rehabilitation program using mobile app installed in the mobile device.
89385866|NCT04053348|Active Comparator|Control|Those assigned to the control group will receive the same home-based rehabilitation program but with information and instructions delivered through the use of paper-based handouts.
89385867|NCT03648762|Other|Heart failure patients|Patients diagnosis with heart failure will be assessed for the study
89003303|NCT05476926||Faricimab for nAMD|
89385868|NCT02586675|Experimental|Tamoxifen and Ribociclib with Goserelin|Phase I dose escalation followed by Phase Ib dose expansion. Tamoxifen and Ribociclib, with Goserelin added for premenopausal or peri-menopausal participants. Ribociclib: Capsules/Tablets for oral use 400 mg OR 600 mg Days 1-21 of each 28 day cycle or daily. Tamoxifen: Tablets for oral use 20 mg daily (all days of every cycle without interruption). Goserelin: Subcutaneous injection 3.6 mg Day 1 of each 28 day cycle.
89385869|NCT03648528|Experimental|cholecaciferol|one 5000 IU tablet of 25VD taken during dialysis (3 pills per week) for a period of 12 weeks
89385870|NCT03648528|Placebo Comparator|placebo|one tablet of placebo taken during dialysis (3 pills per week) for a period of 12 weeks
89385871|NCT05201625|Active Comparator|control group|Healthy control group
89385872|NCT05201625|Active Comparator|ICU COVID 19 patients|ICU COVID 19 patients
89385873|NCT05201625|Active Comparator|non-ICU covid 19 patients|non-ICU covid 19 patients
89385874|NCT04053114||Retrospective cohort|Tissue samples
89385875|NCT03629691||gastric cancer lung metastatic|One of the study tumors.Between February 1, 2015 and May 19, 2018, 356adult patients with gastric adenocarcinoma, multiline chemotherapy failure and lack of standard treatment, received oral apatinib 250 mg daily at the Affiliated Hospital of Qingdao University, of them, 110 patients with lung metastasis. 28 patients with lung cavitation
89385876|NCT03629691||NSCLC|One of the study tumors.Between February 1, 2015 and May 19, 2018, 77 adult patients with primary lung cancer, multiline chemotherapy failure and lack of standard treatment, received oral apatinib 250 mg daily at the Affiliated Hospital of Qingdao University. 30 of 77 were squamous cell carcinoma and 47 of 77 were adenocarcinoma. 28 patients with lung cavitation.
89385877|NCT03648138|Active Comparator|Calorie label|"This arm will display a Calories per Bottle label on all beverages, not just sugary beverages. This label is identical to the American Beverage Association's current Clear on Calories labels (as of 2018)."
89003304|NCT05476926||Faricimab for DME|
89385878|NCT03648138|Experimental|Text warning label|This arm will display similar text proposed in a recent sugary drink warning label bill in California. Sample text: WARNING: Drinking beverages with added sugar(s) contributes to obesity, type 2 diabetes, and tooth decay. The calorie label will also appear on all beverages.
89003305|NCT05476926||Port Delivery System with Ranibizumab for nAMD|
89385879|NCT03648138|Experimental|Sugar graphic warning label|"This arm will graphically display the amount of sugar in each sugary beverage along with the same text used in the text warning label arm. The calorie label will also appear on all beverages."
89385880|NCT03648138|Experimental|Health graphic warning label|"This arm will graphically display potential negative health effects of over consuming sugary drinks for each sugary beverage, along with the same text used in the text warning label arm. The calorie label will also appear on all beverages."
89535217|NCT03323879|Experimental|LDR/HDR|MRI planned LDR boost to DIL with concurrent whole gland 19 Gy HDR. LDR dose will be sequentially escalated from 50 Gy to 80 Gy
89003306|NCT05476497|Experimental|Part A - Group A1|4 parallel cohorts (1-4) of adult healthy subjects. Each cohort will receive 6 ascending subcutaneous administrations of VLP Peanut.
89003307|NCT05476497|Experimental|Part A - Group A2|Adult peanut allergic subjects, will undergo skin prick tests with ascending concentrations of VLP Peanut.
89184725|NCT00713271|Experimental|2|intermediate dose
89385881|NCT03161405|Experimental|TAK-906 maleate 25mg;Itraconazole 200mg + TAK-906 maleate 25mg|TAK-906 maleate 25 milligram (mg), capsule, orally, once on Day 1 of First Intervention Period, followed by a minimum of 4-day washout period, further followed by Itraconazole 200 mg, solution, orally, once daily on Days 1 to 5 along with TAK-906 maleate 25 mg, capsule, orally on Day 4 of Second Intervention Period.
89385882|NCT03648060|Experimental|Experimental group|Home-based rehabilitation sessions performed with the digital kinematic biofeedback system. Patients will be instructed to perform exercise sessions in at least 5 days per week, but compliance to this schedule is not mandatory per protocol.
89385883|NCT01813929|Experimental|Metformin|
89385884|NCT01813929|Placebo Comparator|Placebo|
89385885|NCT05284968|Experimental|Cell injection|Cell injection
89385886|NCT03650166|Active Comparator|Enhanced usual care|Participants receive a personal, validated home BP monitor with oral and written instruction.
89385887|NCT03650166|Experimental|MyBP|Participants receive a personal, validated home BP monitor with oral and written instruction. In addition patients receive instruction on, and access to, MyBP. This program provides high BP education through online videos and automated, bidirectional text messaging to assist in continuous home BP self-monitoring.
89385888|NCT04053738|No Intervention|Baseline|Participants slept in the anti-snoring bed in the laboratory, but the bed did not provide any intervention
89385889|NCT04053738|Experimental|Anti-snoring Intervention|Participants slept in the anti-snoring bed in the laboratory, and the bed moved the trunk of the participant
89385890|NCT01502085|Experimental|Vorinostat, Lenalinomide, Dexamethasone|"Vorinostat: 400 mg po days 1-7 and 15-21 Lenalidomide: 25 mg po days 1-21~* Lenalidomide dose for patients with renal impairment (CrCL<50ml/min) has be dose adjusted according to package insert Dexamethasone: 40mg po days 1, 8, 15 and 22 for patients aged less than 75 years, 20mg for those aged 75 years and above"
88861179|NCT04776642||MARK_AF|MARKers of ATrial Remodeling in Patietns with Atrial Fibrillation. Patients with paroxysmal and persistent atrial fibrillation undergoing thoracoscopic atrial fibrillation ablation surgery
88861180|NCT04776642||INDICO AF|Atrial Fibrillation in Patients With an Implantable Cardioverter Defibrillator and Coronary Artery Disease. Investigate the incidence of new-onset AF in patients with coronairy artery disease and an impaired LVEF, who will receive a single chamber ICD as primary prevention for sudden cardiac death.
88861181|NCT04776642||PREDICT AF|PREDICT AF, Tissue, Blood and biomarkers to predict future Atrial Fibrillation. Patients without a history of atrial fibrillation undergoing cardiothoracic surgery
88861182|NCT04776642||WEIGHTLOSS AF|The change of adipose tissue characteristics upon drastic weight loss: Implications for atrial fibrillation.
88861183|NCT04776642||MAD AF|(123I-mIBG And Defibrillation for Atrial Fibrillation) Enhanced sympathetic activity as a mechanism of Atrial Fibrillation. Patients will undergo 123I-mIBG scintigraphy within 7 days before and six week after an elective cardioversion is performed.
88861184|NCT04776642||Adapt Biobank - AF surgery|Patients with Atrial Fibrillation who only donate blood and tissue for the biobank. Patients undergo thorascopic surgery, LAA will be amputated, blood will be collected.
89385891|NCT04052802|Experimental|Bioactive resin (Giomer)|"This group of patients will receive a bioactive resin Beautifil flow plus X (Shofu Dental) for treatment of their demineralized fissures"
89385892|NCT04052802|Experimental|Conventional resin|"This group of patients will receive a conventional resin Filtek Z350xt Flowable composite (3M ESPE) for treatment of their demineralized fissures"
89385893|NCT03648684|Experimental|Caffeine-Based Expectancy Challenge|Participants will ingest caffeine under the guise of Adderall prior to completing tasks. They will engage in an expectancy challenge intervention designed to both challenge expectancies for prescription stimulants and promote safe caffeine use for cognitive/mood enhancement.
88861185|NCT04776642||Adapt Biobank - blood|Patients with cardiac arrhythmias who only donate blood for the ADAPT biobank.
88861186|NCT01982058|Experimental|Intimacy-Enhancing Couples|Patients and their partners receive communication and intimacy-enhancing intervention (IEC) once a week comprising the following five 90-minute sessions: Orientation and Stories of the Cancer Experience; Communication and Listening to Partner's concerns; Communication and Coping with Cancer Issues as a Team; Being Supportive to Solve Concerns; and Reflecting on Changes and Future Adaptation.
88861187|NCT01982058|Active Comparator|General Health and Wellness|Patients and their partners receive a General Health and Wellness intervention focusing on nutrition and physical activity once a week comprising of five 90-minute sessions: Introduction and Nutrition Basics; Nutrition and Prevention of Recurrence; Nutritional Review and Introduction to Relaxation; Physical Activity Basics; Aerobics and Resistance Exercises and Wrap up.
88861188|NCT01982058|Other|Usual Care|Patients and their partners receive standard psychological and emotional care (usual care [UC]) (i.e., social work consultations and referral to a psychiatrist or psychologist, if requested or deemed necessary by the attending physician).
89184726|NCT00713271|Experimental|3|high dose
89003308|NCT05476497|Experimental|Part B - Cohorts 1-4|4 parallel cohorts (1-4) of peanut allergic subjects. Each cohort will receive 6 ascending subcutaneous administrations of VLP Peanut.
89184727|NCT00713271|Placebo Comparator|4|
89385894|NCT03648684|Placebo Comparator|Placebo-Based Expectancy Challenge|Participants will ingest placebo under the guise of Adderall prior to completing tasks. They will engage in an expectancy challenge intervention designed to challenge expectancies for prescription stimulants.
89385895|NCT03648684|No Intervention|Control|
89385896|NCT03647982|Experimental|botulinum toxin 1U|
89385897|NCT03647982|Experimental|botulinum toxin 3U(25U/1ml)|
89385898|NCT03647982|Experimental|botulinum toxin 5U|
89385899|NCT03647982|Experimental|botulinum toxin 10U|
89385900|NCT03647982|Experimental|botulinum toxin 3U(50U/1ml)|
89385901|NCT03647982|Experimental|botulinum toxin 3U(12.5U/1ml)|
89385902|NCT03647904|Experimental|SEMS Project|A comprehensive modular intervention consisting of wellness, fatigue management, cognitive remediation and psychological treatment. Treatment will consist of a total of 12 weeks.
89385903|NCT03647904|Other|Wait List Control|Individuals in the wait list control arm will serve as controls for the first intervention group, but will receive the treatment following their three month assessment. The intervention following the waitlist control will be a comprehensive modular intervention consisting of wellness, fatigue management, cognitive remediation and psychological treatment. Treatment will consist of a total of 12 weeks.
89385904|NCT02901054|Experimental|open label infusion ondansetron|"A single 4-mL CSF sample per subject.~Serial blood sampling at 0 (pre-infusion), 15, 30, 60, 120, and 180 min after ondansetron administration"
89385905|NCT03068715|Experimental|Active TBS-DLPFC|The active group will receive theta-burst TMS stimulation.
89385906|NCT03068715|Sham Comparator|Sham TBS-DLPFC|The sham group will receive sham theta-burst TMS stimulation.
89385907|NCT04053036|Experimental|Placebo Then MDMA|Participants first receive placebo at their first session in the laboratory. Then will return to the laboratory 72 hours later and will receive MDMA (1.5 mg/kg)
89385908|NCT04053036|Experimental|MDMA Then Placebo|Participants first receive MDMA (1.5 mg/kg) at their first session in the laboratory. Then will return to the laboratory 72 hours later and will receive placebo.
88861189|NCT04753944|Active Comparator|Probiotic group|Patients will be introduced for 5 weeks with probiotic therapy (in the study group). They will take Ecologic®Barrier (Winclove Probiotics BV, Amsterdam, The Netherlands), consisting of Bifidobacterium bifidum W23, Bifidobacterium lactis W52, Lactobacillus acidophilus W37, Lactobacillus brevis W63, Lactobacillus casei W56, Lactobacillus salivarius W24, Lactococcus lactis W19 and Lactococcus lactis W58. The probiotic dose is going to be 4 capsules daily (one capsule contains 500 million CFUs of living probiotic strains). The treatment will be administered two times a day, during breakfast and supper. The probiotic formula will be Provided by polish distributor of Winclove products, namely Sanprobi sp. z o. o. sp. k
88861190|NCT04753944|Placebo Comparator|Placebo group|Patients will be introduced for 5 weeks with placebo that consist of maize starch, maltodextrins and vegetable protein. The placebo dose is going to be 4 capsules daily (one capsule). The treatment will be administered two times a day, during breakfast and supper.
89385909|NCT03647670|Other|Sequence 1|In Sequence 1, Period 1, subjects will be dosed with a single administration of midazolam 2 mg oral solution on Day 1. Midazolam PK will then be assessed over the next 24 hours (hr). Period 1 will be immediately followed by Period 2 with no washout, in which subjects will be dosed with 200 mg PF-04965842 orally once daily (QD) for 7 days. Midazolam 2 mg oral solution will be administered on the morning of Day 2 and Day 7 within 5 minutes after PF-04965842 dosing. Midazolam PK will be assessed for 24 hr following dosing.
89385910|NCT03647670|Other|Sequence 2|In Sequence 2, Period 1, subjects will be dosed with 200 mg PF-04965842 orally QD for 7 days. Midazolam 2 mg oral solution will be administered on the morning of Day 2 and Day 7 within 5 minutes after PF-04965842 dosing. Midazolam PK will be assessed for 24 hr following dosing. Subjects will then undergo a washout period of at least 7 days. In Period 2 subjects will be dosed with a single administration of midazolam 2 mg oral solution on Day 1. Midazolam PK will then be assessed over the next 24 hr.
88861191|NCT01895400|Active Comparator|Renexin|Renexin 1T bid for 12 weeks
89385911|NCT05202951||Patients with hemophilia|all adult patients follow-upin Hospital for hemophilia
89385912|NCT02966340|Experimental|Prazosin 1st visit, Placebo 2nd visit|All participants receive 2mg prazosin and placebo in a cross-over design (e.g., one pill per visit). The order of prazosin vs placebo is counterbalanced between subjects (e.g., half participants receive prazosin at study visit 1 and half participants receive placebo at study visit 1).
89385913|NCT02966340|Experimental|Placebo 1st visit, Prazosin 2nd visit|All participants receive 2mg prazosin and placebo in a cross-over design (e.g., one pill per visit). The order of prazosin vs placebo is counterbalanced between subjects (e.g., half participants receive prazosin at study visit 1 and half participants receive placebo at study visit 1).
88861192|NCT01895400|Placebo Comparator|Placebo|Placebo 1T bid for 12 weeks
88861193|NCT04754178||Down syndrome|Down syndrome patients and their parents
88861194|NCT04754178||Control group|Healthy children and their parents
88861195|NCT04753866|Experimental|Rehabilitated|Initial lip support condition of the patient when presents himself/herself at the office with indication for full arch implant rehabilitation. Then, the patient is facially scanned before and after the implant surgery.
89385914|NCT05200689|Experimental|Thoracotomy, KT|Patients in this group will undergo the same analgesia protocol as other groups. They will undergo the thoracotomy protocol, alongside the KT protocol.
89385915|NCT05200689|Experimental|Thoracoscopy, KT|Patients in this group will undergo the same analgesia protocol as other groups. They will undergo the thoracoscopy protocol, alongside the KT protocol.
89535218|NCT02452567|Experimental|Metabolically abnormal lean|Moderate (8-10%) diet-induced weight loss.
88861196|NCT05605626||Simulator training before|group exposed directly to simulator training without knowing the topic of obstetric emergency
89385916|NCT05200689|No Intervention|Thoracotomy, Non-KT|Patients in this group will undergo the same analgesia protocol as other groups. They will undergo the thoracotomy protocol, without the KT protocol.
89184728|NCT02573961|Active Comparator|laser|Subjects will receive 24 activated laser acupuncture group treatments. The laser will be applied for 10 seconds to each of the selected acupuncture points. In addition they will be instructed to take a tailored low caloric diet
89385917|NCT05200689|No Intervention|Thoracoscopy, Non-KT|Patients in this group will undergo the same analgesia protocol as other groups. They will undergo the thoracoscopy protocol, without the KT protocol.
89385918|NCT03647748|No Intervention|Cellulize 532nm|Cellulize device using 532nm Green Light.
89385919|NCT03647748|Sham Comparator|Cellulize Placebo (Sham Comparator)|"Cellulize modified to appear as if it is running, but does not use the 532nm light.~Sham Device, or Placebo."
89385920|NCT05207007||posterior polar cataracts|"Phacomulsification lens removal cataract surgery with Intraocular lens(IOL) implantation were performed in these patients.~Drug: Subconjunctival dexamethasone and general anesthesia All patients received subconjunctival dexamethasone (2 mg) during surgery, and all surgeries were performed under general anesthesia."
88861197|NCT05605626||lesson before simulation training|group undergoing formal lecture before the vacuum delivery simulation on mannequin
88861198|NCT04753554|Active Comparator|Conventional group|The patient group that whose oxygenation will be managed by blood gas analysis.
88861199|NCT04753554|Experimental|ORI group|The patient group that whose oxygenation will be managed by ORI values
88861200|NCT05272098|Experimental|Group A|myofascial release therapy
88861201|NCT05272098|Active Comparator|Group B|endurance training of the trunk extensor muscles
89385921|NCT05207007||posterior lenticonus|"Phacomulsification lens removal cataract surgery with Intraocular lens(IOL) implantation were performed in these patients.~Drug: Subconjunctival dexamethasone and general anesthesia All patients received subconjunctival dexamethasone (2 mg) during surgery, and all surgeries were performed under general anesthesia."
89385922|NCT05284734|Experimental|Caudal block group|A 22 gauge 50 mm echogenic block needle placed through the sacrococcygeal membrane into the sacral canal in the longitudinal position, using the in-plane technique Negative aspiration was then performed 0.125% bupivacaine at a dose of 1 ml/kg was administered
89385923|NCT05284734|Experimental|Erector spinae block group|The erector spinae muscle and the transverse process were identified, and a 22 G, 80 mm echogenic block needle was advanced towards the transverse process until contact. Following hydrodissection, 1 ml/kg of 0.125% bupivacaine was injected deep into the erector spinae muscle
89385924|NCT05206851|Experimental|Manual Lymphatic Drainage and Hot pack|
89385925|NCT05206851|Active Comparator|Hot Pack|
89385926|NCT03067311|Experimental|I-CAT|A novel therapeutic intervention combining strategies to improve stress reactivity and increase meaningful coping given by trained clinicians.
89385927|NCT03067311|Active Comparator|Treatment as Usual|Usual treatment provided at the University of North Carolina at Chapel Hill (UNC) Outreach and Support Intervention Services (OASIS) Clinic by trained clinicians.
89385928|NCT05185713||Ctrl HPV (-)|Patients with normal cervix and HPV negative
89385929|NCT05185713||Ctrl HPV (+)|Patients with normal cervix and HPV positive
88861202|NCT04753476|Experimental|Secretome-MSCs (n=24)|This group will be given Covid-19 standard therapy with intramuscular Hypoxic S-MSC secretome
89385930|NCT05185713||LSIL group|Patients with low-grade squamous Intraepithelial lesion
89385931|NCT05185713||HSIL group|Patients with high-grade squamous Intraepithelial lesion
89385932|NCT05185713||ICC group|Patients newly diagnosed invasive cervical cancer
89385933|NCT05762289|Experimental|Change in range of motion and within the weight bearing group|. Subjects in Group A or treatment group were seated and given thrust manipulation using belt. Cervical spine was placed in neutral position and belt was stabilized on C4-C5 which is the part that causes most stiffness and pain and lost of range. Patient placed belt in left hand for left sided thrust and caudal force was applied , therapist held other end of the belt and applied stretch in the line of eye ball. The cervical spine of patient was guided in left rotation until resistance was felt and than thrust of high velocity low amplitude was given by therapist . This was done for both sides if the cavitation sound was not heard manipulation was tried for a second time after 10 minutes by repositioning the patient but no more than two times in a day. Therapist performing manipulation was skilled in giving belt thrust manipulation.
89535219|NCT05013489|Experimental|Mindfulness, compassion and intercare based Intervention|An Eight week mindfulness and intercare group online program.
89535220|NCT05013489|No Intervention|Waiting list|Psychological support if needed. No other intervention.
89535221|NCT03320603|Other|Phase 1|Prospective collection of data on a standard eCRF (without reminders of recommendations). Prothrombin Complex Concentrate given as standard of care.
88861203|NCT04753476|Other|Control (n=24)|This group will receive standard Covid-19 therapy with the best supportive care
88861204|NCT05605392|Experimental|Deinstitutionalization|
88861205|NCT05171946|Experimental|Cohort 1|Low-Dose, 1mg, 3 doses 21 days apart
88861206|NCT05171946|Experimental|Cohort 2|Mid-Dose, 2 mg, 2 doses 21 days apart
88861207|NCT05171946|Experimental|Cohort 3|High-Dose, 4 mg, 2 doses 21 days apart
88861208|NCT05605314||pSS-DED|DED patients who visited the dry eye clinic of Peking University Third Hospital from 2021 to May 2028. The pSS-DED patients further accepted the diagnosis of rheumatology department. All enrolled DED participants met the criterion of TFOS DEWS II Definition and Classification Report and pSS-DED group also met 2016ACR/EULAR pSS diagnosis and classification consensus.
88861209|NCT05605314||nss-DED|DED patients who visited the dry eye clinic of Peking University Third Hospital from 2021 to May 2028.
88861210|NCT04775940|Experimental|Perforated collagen membrane|
88861211|NCT04775940|Active Comparator|Occlusive collagen membrane|
88861212|NCT02089464|Active Comparator|NBS-rTMS + task-oriented rehabilitation|NBS-guided rTMS + task-oriented rehabilitation
88861213|NCT02089464|Sham Comparator|Sham rTMS + task-oriented rehabilitation|Sham rTMS + task-oriented rehabilitation
88861214|NCT04775862|Experimental|RAS wild type; investigator choice re-challenge with anti EGFR Rx|
89385934|NCT05762289|Active Comparator|Control|While Group B received manipulation in supine position by maitland's traditional thrust. Where the neck is slightly flexed by therapist hand on the occipit where therapist is standing behind the head. Neck is guided in right side flexion and opposite rotation and at the end of rang high velocity low amplitude thrust is applied. This was done for both sides if the cavitation sound was not heard manipulation was tried for a second time after 10 minutes by repositioning the patient but no more than two times in a day
89385935|NCT05174949|Experimental|Anodal stimulation|Anodal stimulation targeting hemisphere
89385936|NCT05174949|Experimental|Cathodal stimulation|Cathodal one at the contralesional hemisphere
89385937|NCT05174949|Experimental|Sham stimulation|Sham stimulation to the brain
89385938|NCT05200611||Fecal Immunochemical Test|People in this group with positive fecal immunochemical test results were further examined by colonoscopy.
89385939|NCT05206461||Hemiparetic CP|Trunk control, hand function and quality of life were evaluated with the Trunk Control Measurement Scale, 9-Hole Peg Test and Pediatric Quality of Life Inventory in Hemiparetic CP
89385940|NCT05206461||Diparetic CP|Trunk control, hand function and quality of life were evaluated with the Trunk Control Measurement Scale, 9-Hole Peg Test and Pediatric Quality of Life Inventory in Diparetic CP
89385941|NCT05206149|Experimental|Intranasal Administration of Glucagon|Intranasal administration of glucagon in healthy subjects
89385942|NCT05206149|Placebo Comparator|Intranasal Administration of Placebo|Intranasal administration of placebo (isotonic saline solution) in healthy subjects
89385943|NCT05206071|Experimental|SL 19+22 CAR-T|
89385944|NCT03629457|Experimental|Intervention group 4s (mindfulness)|Abbreviated program of 4 weeks: will consist of 4 weekly sessions of 2 hours. Participants must practice at home for 15 minutes a day
89385945|NCT03629457|Experimental|Intervention group 8s (mindfulness)|Program of 8 weeks: The format will be 8 weekly sessions of 2 hours. Participants must practice at home for 30 minutes a day
88861215|NCT04775862|Active Comparator|RAS mutant; investigator choice of SOC third line Rx|
88861216|NCT05605158|Active Comparator|Group 1 (Pioglitazone group; n=28)|Non-diabetic patients with non-alcoholic steatohepatitis will receive 30mg/day pioglitazone for 24 weeks.
88861217|NCT05605158|Active Comparator|Group 2 (Empagliflozin group; n=28)|Non-diabetic patients with non-alcoholic steatohepatitis will receive 10mg/day empagliflozin for 24 weeks.
88861218|NCT01896648||Type 2 diabetic women|
88861219|NCT04754880||non-CTO|This group was defined as no chronic obstruction, except for non-critical stenosis, who underwent coronary angiography with the diagnosis of stable angina pectoris.
88861220|NCT04754880||CTO|This group was defined as the presence of complete occlusion in one artery and no critical lesions (> 50%) in the other arteries undergoing coronary angiography with the diagnosis of stable angina pectoris.
88861221|NCT05598762|Active Comparator|Children with mild atopic dermatitis|"age 1-8 years old~mild degree of atopic dermatitis"
88861222|NCT05598762|Active Comparator|Children with moderate-severe atopic dermatitis|"age 1-8 years old~moderate or severe degree of atopic dermatitis"
88861223|NCT05598762|Active Comparator|Children with food allergy and moderate-severe atopic dermatitis|"age 1-8 years old~moderate or severe degree of atopic dermatitis~IgE mediated food allergy"
88861224|NCT05598762|Active Comparator|Adult with atopic dermatitis|"age 18-60 years old~mild-severe atopic dermatitis"
88861225|NCT05598762|Active Comparator|Healthy|"age 1-60 years old~no history of atopic diseases"
88861226|NCT05598762|Active Comparator|Healthy with Asthma|"age 1-8 years old~doctor diagnosed asthma~no history of chronic or chronic relapsing eczema"
88861227|NCT01053234|Experimental|Insulin aspart|
88861228|NCT01053234|Experimental|NPH insulin|
89385946|NCT03629457|No Intervention|Control group|The participants will only receive a one-hour information session and will be invited to complete the questionnaires provided in two moments of the time (coinciding with the interventions in the experimental groups)
89535222|NCT03320603|Other|Phase 2|Prospective collection of data on expert data collection tool (expert eCRF reminding recommendations at each step of the management of severe bleeding). Prothrombin Complex Concentrate given as standard of care.
89535223|NCT03227653||Efavirenz|Children using efavirenz-based cART for at least 6 months
89535224|NCT03227653||Non-efavirenz|Children using non-efavirenz-based cART (nevirapine or Lopinavir-Ritonavir Drug Combination) for at least 6 months.
89535225|NCT04434183|Active Comparator|isokinetic exercise|The group (isokinetic exercise group, n = 25) was given isokinetic exercise.
88861229|NCT02090088||All Subjects|All Subjects
88861230|NCT03433170|Experimental|Quadrupled semitendinosus graft|Autologous quadrupled semitendinosus graft is used to reconstruct the ACL injury
88861231|NCT03433170|Active Comparator|ST-Gracilis graft|Both gracilis and semitendinosus autologous graft are used to reconstruct the ACL injury
89535226|NCT04434183|Active Comparator|home exercise|The group(home exercise group, n=25) was given home exercise program.
88861232|NCT04775238|Active Comparator|Group 1 (Staphylococcus aureus)|Staphylococcus aureus is an example of gram positive bacteria which is a strong biofilm producer and highly resistant to antibiotics. Staphylococcus aureus will be exposed to silver nanoparticles and copper nanoparticles separately to study their antibacterial and biofilm inhibiting properties and their synergistic effect in combination with antibiotics.
88861233|NCT04775238|Active Comparator|Group 2 (Pseudomonas aeruginosa )|Pseudomonas aeruginosa is an example of gram negative bacteria which is a strong biofilm producer and highly resistant to antibiotics. Pseudomonas aeruginosa will be exposed to silver nanoparticles and copper nanoparticles separately to study their antibacterial and biofilm inhibiting properties and their synergistic effect in combination with antibiotics.
88861234|NCT05595798||Geriatric population|patient with ages above 65-yr
88861235|NCT05595798||Pediatric population|patient with ages between 4-8 year old
88861236|NCT01896882|Experimental|Intervention|Nutritional education on sodium restriction diet.
88861237|NCT01896882|No Intervention|Control|Standard treatment.
89385947|NCT05156619||Cohort#1|new annual breast cancer cases and cases of recurrence at Hadassah University hospital between 2018-2021 (700)
89385948|NCT05156619||Cohort#2|Retrospective study - all clinical trial patients in the Sharett institute of oncology between 1.1.12-30.6.21 (300)
89535227|NCT04434261||Patients tested for SARS-CoV-2|Patients who underwent the preoperative screening program for SARS-CoV-2
88861238|NCT05580042|Experimental|Patients with Granuloma Annulare|4-week treatment and 2-week follow-up period (without treatment)
88861239|NCT04775160|No Intervention|Control group|The control group will be monitored using smartphone-based active and passive Ecological Momentary Assessment through the MEmind and eB2 mobile applications, and will receive treatment as usual, which will consist of psychiatric follow-up (scheduled appointments with their psychiatrist) in an outpatient Secondary Suicide Prevention Programme, with predetermined clinical reviews according to the Brief Intervention Contact recommendations (1, 2, 4, 7 and 11 weeks, and 4, 6, 9 and 12 months)
88861240|NCT04775160|Experimental|Intervention group|The intervention group will receive an Ecological Momentary Intervention called SmartSafe, will be monitored using smartphone-based active and passive Ecological Momentary Assessment through the MEmind and eB2 mobile applications, and their treatment as usual, which will consist of psychiatric follow-up (scheduled appointments with their psychiatrist) in an outpatient Secondary Suicide Prevention Programme, with predetermined clinical reviews according to the Brief Intervention Contact recommendations (1, 2, 4, 7 and 11 weeks, and 4, 6, 9 and 12 months)
88861241|NCT03288480|Other|PT-112|This is a single arm study of PT-112, which is administered to patients with relapsed or refractory MM
88861242|NCT01895478|Experimental|PACCI-ED|PACCI-ED attendings were given the PACCI-ED use intervention.
88861243|NCT01895478|No Intervention|Control|Control attendings were not given the PACCI-ED use intervention.
88861244|NCT03095742|Placebo Comparator|Low MAP|Low mean arterial pressure. 30 patients were blindly randomized to normal range (MAP 65 mmHg) during the peri-cardiac arrest period.
88861245|NCT03095742|Active Comparator|High MAP|High mean arterial pressure. 30 patients were blindly randomized to intervention group (MAP 75 mmHg) during the peri-cardiac arrest period.
88861246|NCT03094026|Experimental|Intervention|The arm will begin the Lumosity program at enrollment in the study.
88861247|NCT03094026|Active Comparator|Wait List Control|The arm will begin the Lumosity program 3 months after enrollment in the study.
88861248|NCT04774770|Experimental|HED-Start Intervention arm|Participants assigned to the intervention arm will undergo 4 sessions of the HED-Start program. Each session is 2 hours long and will be conducted fortnightly.
88861249|NCT04774770|No Intervention|Standard care arm|Participants assigned to the standard care arm will proceed with routine standard care.
88861250|NCT05433558|Experimental|Experimental group|enter the experiment directly
88861251|NCT05433558|Experimental|Waiting group|enter the experiment after waiting eight weeks
88861252|NCT04774614|Experimental|VITA ENAMIC multiColor anterior laminate veneers|
88861253|NCT04774614|Active Comparator|IPS e.max CAD anterior laminate veneers|
88861254|NCT05074134|Experimental|[14C]-TNP-2092|
88861255|NCT05421546|Active Comparator|Spermidine arm|This arm will enrol 20 volunteers aged 65 years of age or older (65-90) who have received two doses of the Coronavirus vaccine, with the vaccination course completed more than 8 weeks before recruitment. Following a baseline venous blood sample, participants will receive Spermidine supplements 6mg/day and oral administration once daily. A research appointment and venous blood sample will be requested at the point of recruitment, 5 weeks, 13 weeks and 37 weeks after recruitment of the participant.
88861256|NCT05421546|Placebo Comparator|Placebo arm|This arm will enrol 20 volunteers aged 65 years of age or older (65-90) who have received two doses of the Coronavirus vaccine, with the vaccination course completed more than 8 weeks before recruitment. Following a baseline venous blood sample, participants will receive placebo oral administration once daily. A research appointment and venous blood sample will be requested at the point of recruitment, 5 weeks, 13 weeks and 37 weeks after recruitment of the participant.
88861257|NCT05390970|Experimental|Platelet-rich Plasma|These subjects will have the active PRP injected into their anterior vaginal wall.
88861258|NCT05390970|Placebo Comparator|Placebo (saline)|These subjects will have a saline placebo injected into the anterior vaginal wall.
88861259|NCT04773756|Other|Sofosbuvir / Daclatsvir|A drug used in the treatment of HCV infection, given in the same dose 400mg and 60 mg respectively once daily for 14 days
89385949|NCT05156619||Cohort#3|all newly diagnosed recurrent/metastatic disease during the study period (200)
89385950|NCT03629379|Active Comparator|ustekinumab arm|First 10 patients who are switched from anti-TNF to ustekinumab because of psoriasiform skin lesions refractory to 12 weeks of topical therapy.
89385951|NCT03629379|Active Comparator|vedolizumab arm|First 10 patients who are switched from anti-TNF to vedolizumab because of psoriasiform skin lesions refractory to 12 weeks of topical therapy.
89385952|NCT03629301|Experimental|ID-DPP group|Internet-delivered intervention based on the DPP
89385953|NCT03629301|Other|Wait-list Group|
89385954|NCT05123079|Experimental|Single Oral Dose of 25 mg administered as 1 x 25 mg tablet, Fasted (Without Food)|Oral Dose
89385955|NCT05123079|Experimental|Single Oral Dose of 25 mg administered as 1 x 25 mg tablet, Fed (With food)|Oral Dose
89385956|NCT05123079|Experimental|Single Oral Dose of 25 mg administered as 2 x 7.5 and 2 x 5.0 mg tablets, Fasted (Without Food)|Oral Dose
89385957|NCT05129163|Placebo Comparator|Exercise|The control group received weekly one-hour group exercise training for 3 months.
89385958|NCT05129163|Experimental|Exercise and nutrition|The intervention group had weekly one-hour group exercise training the same as the control and an additional weekly one-hour group nutrition session for 3 months.
89385959|NCT05761665||Alzheimer|Kinesiophobia, Balance, Falling,Walking Speed and Fragility Will be Evaluated with Tests.
89385960|NCT05761665||Physically Fragile|Kinesiophobia, Balance, Falling,Walking Speed and Fragility Will be Evaluated with Tests.
89385961|NCT05761665||Healthy|Kinesiophobia, Balance, Falling,Walking Speed and Fragility Will be Evaluated with Tests.
89184729|NCT02573961|Active Comparator|high protein low carbohydrate diet|Subjects will be instructed to take a tailored high protein/low carbohydrate/low caloric diet.
89385962|NCT01569789|Active Comparator|Ear Stimulation|Comparing cytokine levels pre and post stimulation of the nerve in the ear
88861260|NCT03012984|Experimental|Dexmedetomidine group|Dexmedetomidine supplemented morphine analgesia will be provided for patients in this group in the form of patient-controlled intravenous analgesia. The formula contains a mixture of morphine (0.5 mg/ml) and dexmedetomidine (1.25 ug/ml), diluted with normal saline to a total volume of 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time from 6 to 8 minutes.
88861261|NCT03012984|Placebo Comparator|Control group|Morphine analgesia will be provided for patients in this group in the form of patient-controlled intravenous analgesia. The formula contains morphine (0.5 mg/ml), diluted with normal saline to a total volume of 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time from 6 to 8 minutes.
88861262|NCT01574118|Experimental|Brief Enhanaced Exposure Therapy|"The following interventions are included in this arm:~Psycho-education addressing common reactions to trauma~Revisiting the Trauma memories~Processing the trauma memories~In vivo Exposure homework~*Use of a brief pre-exposure trauma memory retrieval trial~Exposure to video clips related to the patient's trauma~Compound extinction - simultaneously exposing patient to trauma video clips while they listen to their trauma script"
88861263|NCT01574118|Active Comparator|Standard Prolonged Exposure Therapy|"The following interventions are included in this arm:~Psycho-education addressing common reactions to trauma~Revisiting of the Trauma memories~Processing the trauma memories~Breathing retraining~In vivo Exposure homework"
88861264|NCT01574118|No Intervention|Delayed Treatment Control|Patients assigned to this arm receive assessment only (Week 0, 3, and 6) prior to receiving standard prolonged exposure therapy using the Foa et al treatment manual.
88861265|NCT04773990|Other|Experimental Group|Group (A) twenty-five patients will receive biodex balance training
89385963|NCT01569789|Placebo Comparator|Calf Stimulation|Comparing cytokine levels pre and post stimulation of the placebo area on the calf
89385964|NCT05043285|Experimental|20 µg dose, 18-59 years of age (phase 1/2)|
89385965|NCT05043285|Experimental|20 µg dose, ≥60 years of age (phase 1/2)|
89385966|NCT05043285|Experimental|40 µg dose, 18-59 years of age (phase 1/2)|
89385967|NCT05043285|Experimental|40 µg dose, ≥60 years of age (phase 1/2)|
89385968|NCT05043285|Placebo Comparator|Placebo, 18-55 years of age (phase 1/2)|
89385969|NCT05043285|Placebo Comparator|Placebo, ≥60 years of age (phase 1/2)|
89385970|NCT04380519|Experimental|RPH -104 80 mg|Subject randomized to receive subcutaneous single injection of 2 ml solution of RPH-104 on Day 1, in addition to standard therapy
89385971|NCT04380519|Experimental|Olokizumab 64 mg|Subject randomized to receive subcutaneous single injection of 0,4 ml solution of Olokizumab on Day 1, in addition to standard therapy
89385972|NCT04380519|Placebo Comparator|Placebo|Subject randomized to receive subcutaneous single injection of 2 ml solution of Placebo on Day 1, in addition to standard therapy
89385973|NCT05760963||Adult with lumbar echography indication|Adult with lumbar echography indication will be included.
89385974|NCT05004051||Patients who are booked for and then subsequently have undergone endovascular repair.|
89535228|NCT02452333|Experimental|Evidence-based Oncoplastic Algorithm|Oncoplastic Approach Excisional Breast Biopsy, Tezel Method of Breast Volume Measurement and Cosmetic Assessment
89535229|NCT02452333|Experimental|Control|- Conventional Excisional Breast Biopsy, Tezel Method of Breast Volume Measurement and Cosmetic Assessment
89385975|NCT05004051||Patients with infrarenal AA without indications for repair undergoing serial monitoring|
89385976|NCT01569867||statin|
89385977|NCT04980573|Experimental|Intervention|Participants receive a bottle of plant-based oil to inhale twice daily for 14 days.
89385978|NCT04980573|Placebo Comparator|Placebo|Participants receive a bottle of inert oil to inhale twice daily for 14 days.
89385979|NCT02847182|Experimental|Cord Blood Infusion (best source)|Subjects will be randomized to receive a cord blood infusion at the baseline or 6 month visit. The cord blood will be autologous (if available) or unrelated cord blood.
89535230|NCT03320525|Experimental|Experimental|The active substance used in the T-ChOS capsule formulation is a chitooligosaccharide blend.
89535231|NCT03320447|Experimental|MAL-PDT|Patients were randomly assigned to receive either AFL-PDT or MAL-PDT in a 1:1 ratio. As result, the patients were randomized to treatment with AFL-PDT or MAL-PDT
89535232|NCT03320447|Experimental|AFL-PDT|Patients were randomly assigned to receive either AFL-PDT or MAL-PDT in a 1:1 ratio. As result, the patients were randomized to treatment with AFL-PDT or MAL-PDT
88861266|NCT04773990|Other|Controlled Group|twenty-five patients will receive a physical therapy exercise protocol
88861267|NCT05051202|Experimental|25g Sugars From Fiber per day|Administered in 50 g Flapjacks containing 25 g Fiber (from Sugars from Fiber), taken 3 times per day, after meals, for a 14 day period
88861268|NCT05051202|Active Comparator|25g Resistant Maltodextrin per day|Administered in 50 g Flapjacks containing 25 g Resistant Maltodextrin, taken 3 times per day, after meals, for a 14 day period
88861269|NCT05051202|Experimental|35g Sugars From Fiber per day|Administered in 50 g Flapjack containing 35 g Fiber (from Sugars from Fiber), taken 3 times per day, after meals, for a 14 day period
88861270|NCT05051202|Active Comparator|35g Resistant Maltodextrin per day|Administered in 50 g Flapjacks containing 35 g Resistant Maltodextrin, taken 3 times per day, after meals, for a 14 day period
88861271|NCT05051202|Experimental|45g Sugars From Fiber per day|Administered in 50 g Flapjacks containing 45 g Fiber (from Sugars from Fiber), taken 3 times per day, after meals, for a 14 day period
88861272|NCT05051202|Active Comparator|45g Resistant Maltodextrin per day|Administered in 50 g Flapjacks containing 45 g Resistant Maltodextrin, taken 3 times per day, after meals, for a 14 day period
88861273|NCT05290974|Active Comparator|In-person group|Conventional in-person standardized teaching
88861274|NCT05290974|Experimental|Online group|Independent learning with online educational material
88861275|NCT02866344|Experimental|Microwave ablation|Patients will be given general anesthesia. A laparoscopic trocar and additional ports will be placed under direct visualization and pneumoperitoneum will be established. Once the operating surgeon determines that the lesions as evaluated on intraoperative ultrasound remain amenable to MWA, ablations will be performed with a 2.45-gigahertz (GHz) generator with a 1.8-mm-diameter transcutaneous antenna (Acculis pMTA Accu2i; AngioDynamics Inc., Denmead, Hampshire, UK). Additional ablations will be performed sequentially. Laparoscopic core needle biopsy of lesions will be performed and submitted for permanent pathologic sectioning per current treatment standards. At the conclusion of the ablation, a collapsed titanium clip will be inserted into the microwave antenna tract as a radiographic fiducial marker. Hemostasis of the ablation track will be ensured using a combination of microwave energy, monopolar electrocautery, and/or topical hemostatics.
88861276|NCT02866344|Active Comparator|Hepatic resection|General anesthesia will be induced. A laparoscopic trocar and additional ports will be placed under direct visualization and pneumoperitoneum will be established. The liver will be evaluated with intraoperative ultrasound (BK Medical A/S, Herlev, Denmark). Laparoscopic core needle biopsy of lesions will be performed. Partial hepatectomy may be carried out with parenchymal precoagulation with radiofrequency electrosurgical devices such as the LigaSure™ (Covidien, Medtronic; Minneapolis, MN), Harmonic® (Ethicon Endosurgery; Cincinnati, OH), or saline-coupled radiofrequency ablation device (Aquamantys™; Covidien/Medtronic; Minneapolis, MN); hepatic parenchymal transection can be performed as above or with the use of stapling devices to ligate and divide parenchyma. Hepatic vascular inflow occlusion will be performed at the surgeon's discretion. A topical hemostatic may be used along the transected hepatic parenchyma. Resected specimens will be preserved in formalin for pathology.
88861277|NCT04773132|Experimental|Low Protein Diet|All subjects will be given a low protein/protein-free diet in order to deplete the label protein pool. The diet provided will meet the daily energy requirements of all the subjects.
88861278|NCT01565382|Experimental|Independent, blinded reader trainees|Seven practicing nuclear medicine physicians with no prior training in reading scans from florbetapir-PET, or other amyloid imaging agents.
88861279|NCT04773444|Experimental|Eccentric cycling training|Moderate intensity cycling training in eccentric type
88861280|NCT04773444|Experimental|Concentric cycling training|Moderate intensity cycling training in concentric type (intensity matched the eccentric training)
88861281|NCT04773444|No Intervention|Control group|without receiving any exercise training
88861282|NCT01545180||HTPcap in IC|HTPcap active and passive in a population of stable patients with heart failure (left ventricular ejection fraction impaired or preserved) and / or valvular disease who received a left right heart catheterization as part of their care.
88861283|NCT01895556|Experimental|Information|Information about male circumcision and HIV risk
88861284|NCT01895556|Placebo Comparator|Control|Control
88861285|NCT02744430|Active Comparator|Arm 1 - Active|Mirabegron 50 mg orally once every 24 hours starting immediately
88861286|NCT02744430|Placebo Comparator|Arm 2 - Placebo|Placebo orally once every 24 hours starting immediately
88861287|NCT05208138|Experimental|Intervention|Bariatric operation with the Senhance surgical system
88861288|NCT05204706|Active Comparator|Intervention arm|Women who meet study inclusion criteria and consent to study participation will be randomised using sealed envelope randomisation and online database for clinical trials to one of two groups in a 1:1 ratio.
89535233|NCT04485091|Experimental|Group A: 20% TCM and PBM|21 participants will be included in this group. Application of chemical peel of 20% trichloroacetic acid solution (TCM) in association with photobiomodulation (PBM) with red spectrum LED (660nm) on the back of the hands.
89535234|NCT04485091|Placebo Comparator|Group B: 20% TCM and PBM placebo|21 participants will be included in this group. Application of chemical peel of 20% trichloroacetic acid solution (TCM) in association with simulated photobiomodulation on the back of the hands.
89535235|NCT04433715||patients with UI symptoms|All participants completed all three questionnaires: ICIQ-SF, UDI-6 and IIQ-7.
88861289|NCT05204706|No Intervention|Control arm|Women allocated to the control arm will receive standard care and no digital intervention. This includes self-monitoring blood glucose and lifestyle advice (diet, physical activity, optimal body weight) by a multidisciplinary team.
88861290|NCT04772976||Patient group|Patients with Ankylosing Spondylitis
88861291|NCT04772976||Healthy controls|Healthy controls
88861292|NCT00054756|Experimental|Thyrotropin Releasing Hormone|Subjects receiving TRH (Thyrotropin Releasing Hormone)
88861293|NCT04772430|No Intervention|Control group|The baby whose height and weight measurements will be taken will be taken to the stretcher, and the vaccine will be administered after the pain score is measured before the procedure. Pain scores will be recorded during and after the procedure
89535236|NCT04433715||patients without UI symptoms|All participants completed all three questionnaires: ICIQ-SF, UDI-6 and IIQ-7.
89184730|NCT02573961|Sham Comparator|control|Subjects in the control group will undergo sham laser acupuncture treatment with no laser power output. In addition they will be instructed to take a tailored low caloric diet .
89385980|NCT02847182|Placebo Comparator|Placebo Infusion|Subjects will be randomized to receive a placebo infusion at the baseline or 6 month visit. The placebo is an acellular media product similar in both appearance and odor.
89385981|NCT03578900|Experimental|Xeros Group - Lozenge|"Application of Xeros system for 15 days. Lozenge (Malic acid 28.56 mg, Xylitol 421,98 mg, Sodium fluoride 0.55 mg) or Spray (Malic acid 1%, Xylitol 10%, Sodium fluoride 0.05%) 4 times a day. Effects on Xerostomia and Quality of Life were determined before and after application by answering the questionnaires.~Effects of lozenge on hyposalivation and pH variation determined by saliva collection with pre-weighed falcon and a ph electrode at predetermined times during a 20 minute period."
89385982|NCT03578900|Active Comparator|Mouthwash group|"Application of citric acid based Mouthwash (0,33% citric acid) for 15 days four times a day. Effects on Xerostomia and Quality of Life were determined before and after application by answering the questionnaires.~Effects of mouthwash on hyposalivation and pH variation determined by saliva collection with pre-weighed falcon and a pH electrode at predetermined times during a 20 minute period."
89385983|NCT03578900|Experimental|Xeros Group - Mouthwash|"Application of Xeros system for 15 days. Mouthwash (Betaine 1.33%, Xylitol 3.30%, Sodium fluoride 0.05%, Allantoin 0.10%) 2 times a day.~Effects on Xerostomia and Quality of Life were determined before and after application by answering the questionnaires."
89385984|NCT03578900|Experimental|Xeros Group - Gel|"Application of Xeros system for 15 days. Gel (Betaine 1%, Aloe Vera 0.05%, Xylitol 10%, Sodium Fluoride 0.0033%) before bed.~Effects on Xerostomia and Quality of Life were determined before and after application by answering the questionnaires."
89385985|NCT03578900|Experimental|Xeros Group - Toothpaste|"Application of Xeros system for 15 days. Toothpaste (Betaine 4%, Xylitol 10%, Sodium Fluoride 0.33%, Allantoin 0.10%) 3 times a day.~Effects on Xerostomia and Quality of Life were determined before and after application by answering the questionnaires."
89385986|NCT03576872|Experimental|Psychoeducational intervention|"Psychoeducational will be conducted prior to chemotherapy.~Teach session will occur prior and during administration of chemo~A small quiz will be conducted to asses understanding of the educational binder"
89385987|NCT02550002||Strict treatment regimen with aflibercept|Treatment intervals with aflibercept in the strict retinal fluid treatment regimen will be extended by two weeks only if no SRF in the central subfoveal field and no IRF can be detected SD-OCT examination.
89385988|NCT02550002||Relaxed treatment regimen with aflibercept|Treatment intervals with aflibercept in the relaxed retinal fluid treatment regimen will be extended by two weeks only if SRF in the central subfoveal field is ≤100 μm in a vertical extent and no IRF is detected on SD-OCT examination.
89385989|NCT03574532||Hospitalized adults with RSV, hMPV and influenza A infections|Respiratory Syncytial Virus (RSV)/Human Metapneumovirus (hMPV) and Influenza A Infected adults that required hospitalization or were infected by these viruses while being hospitalized during the prespecified recent past season(s) will be retrospectively observed to describe the proportion and burden of the different types of respiratory pathogens. The primary data source for this study will be the medical records of each participating participant.
89385990|NCT03574532||Hospitalized infants/children with RSV or hMPV infection|Respiratory Syncytial Virus (RSV)/Human Metapneumovirus (hMPV) and Infected Infants/Children that required hospitalization or were infected by these viruses while being hospitalized during the prespecified recent past season(s) will be retrospectively observed to describe the proportion and burden of the different types of respiratory pathogens. The primary data source for this study will be the medical records of each participating participant.
89385991|NCT03574376|Active Comparator|Bupivacaine Liposome Injection [Exparel]|Patients will receive a nerve block with a medication called liposomal bupivacaine, also called Exparel. Once assigned, a University of Illinois surgeon, or resident surgeon, will administer the nerve block. The nerve block is expected to provide pain relief from 72 to 96 hours. During this time, patients may request oral or intravenous pain medication for breakthrough pain. Patients will remain in the hospital until discharged by the attending physician.
89385992|NCT03574376|Active Comparator|Epidural 0.125% bupivicaine|"Patients will receive pain relief through a 0.125% bupivacaine epidural in the upper back by an assigned anesthesiologist. This epidural will remain in place for an uncertain amount of time. The decision to remove the epidural will be determined by the physicians and will be based on level of pain and injury.~However, pain data will only be recorded by the research team for no longer than 96 hours after the epidural is placed. Patients are able to request intravenous and oral pain medications for breakthrough pain. After the epidural is removed, they will remain in the hospital until discharged by the attending physician."
89385993|NCT03576794|Active Comparator|Leflunomide treatment|Patients will receive prednisolone 15 mg once daily and will be randomized within 4 weeks of the start of glucocorticoid therapy (prednisolone). Prednisolon will be tapered according to a short fixed protocol with a slow gradual taper till 0 in week 27. During the first 2 weeks after randomization patients will receive Leflunomide 20 mg every other day in order to prevent early drug withdrawal due to side effects. After 2 weeks Leflunomide will be increased to 20 mg once daily and this therapy will be continued during 12 months.
89385994|NCT03576794|Placebo Comparator|Placebo control|Patients will receive prednisolone 15 mg once daily and will be randomized within 4 weeks of the start of glucocorticoid therapy (prednisolone). Prednisolon will be tapered according to a short fixed protocol with a slow gradual taper till 0 in week 27. During the first 2 weeks after randomization patients will receive placebo 20 mg every other day in order to prevent early drug withdrawal due to side effects. After 2 weeks placebo will be increased to 20 mg once daily and this therapy will be continued during 12 months.
89535237|NCT03323645||Patients with penile prostheses|
89385995|NCT02846558|Experimental|Calorie Restriction - Frequent Patient Communication|MS patients receiving monthly natalizumab infusions will use the LoseIt! smartphone application to log daily food consumption. Data from the app will be collected at follow-up visits. Patients will receive initial training in using the app, and then receive weekly supportive messages encouraging them to adhere to the calorie restriction diet between 3- and 6-month followup visits. Results will be compared primarily to those collected from the Standard of Care arm.
88861294|NCT04772430|Experimental|Experimental group|The baby whose height and weight measurements will be taken will be taken to the stretcher, after the pain score is measured before the procedure, the snow globe will be operated and the vaccine will be applied. The snow globe will continue to work until the application is completed. Pain scores will be recorded during and after the procedure.
89385996|NCT02846558|Experimental|Timing Restriction|MS patients receiving monthly natalizumab infusions who are ineligible for the calorie restriction portion of the study (the Frequent Patient Activation and Standard of Care arms) will be offered the option to enroll in the second part of the study, assessing differences in outcomes between daily 16-hour fasting periods and no dietary changes. Patients in the second part of the study randomized to this arm will consume their normal daily food intake, but restrict eating to an 8-hour period during the day. Results will be compared to patients who do not make any changes to their diet, the No Change arm.
89385997|NCT02846558|Placebo Comparator|Calorie Restriction - Communication Standard of Care|MS patients receiving monthly natalizumab infusions will use the LoseIt! smartphone application to log daily food consumption. Data from the app will be collected at follow-up visits. Besides initial training with the application and 3- and 6-month follow up exams, participants will not receive additional support or interaction from the study team.Results will be compared with those collected from the Frequent Patient Interaction arm.
89385998|NCT02846558|No Intervention|No Diet Change|MS patients receiving natalizumab infusions who were ineligible for the calorie restriction portion of the study (e.g. body mass index < 25 kg/m^2) or did not wish to participate in calorie restriction, may elect to be part of the second portion of the study. If so, they may be randomized to this arm, in which no changes are made to amount or timing of daily food intake. Results will be compared with the experimental Timing arm
89385999|NCT04362813|Experimental|Canakinumab|Canakinumab 450 mg for body weight 40-<60 kg, 600 mg for 60-80 kg or 750 mg for >80 kg in 250 mL of 5% dextrose infused IV over 2 hours. Single dose on Day 1.
89386000|NCT04362813|Placebo Comparator|Placebo|250 mL of 5% dextrose infused IV over 2 hours. Single dose on Day 1.
89386001|NCT03578822|Experimental|Group A|Recombinant human urokinase(rhPro-UK) and Aspirin simulation agent
89386002|NCT03578822|Other|Group B|rhPro-UK simulation agent and Aspirn
89386003|NCT03578744|Experimental|Interventional|Group A patients will be treated with conventional flap surgery. The furcation defects will be debrided and autologous platelet-rich fibrin will be paced as a graft and membrane. Later the flap will be sutured.
89386004|NCT03578744|Experimental|Interventional Comparator|Group B patients will be treated with conventional flap surgery. The furcation defects will be debrided and Hyaluronic acid (Gengigel) will be placed as a graft. Amniotic membrane (Tata Memorial Hospital Mumbai) will be placed over the graft and later the flap will be sutured.
89386005|NCT03576638|Active Comparator|Sinemet|Controlled Release 25/100
89386006|NCT03576638|Experimental|AP CD/LD|
89386007|NCT04284657|No Intervention|ARM I: Control group|Standard therapy alone
89386008|NCT04284657|Active Comparator|ARM II: PRAVASTATIN|Standard therapy and PRAVASTATIN 40 mg QD
88861295|NCT04772508|Sham Comparator|Group A|15 sites received only scaling and root planing
88861296|NCT04772508|Active Comparator|Group B|15 sites received scaling and root planing with subgingival placement of amnion membrane
88861297|NCT04772508|Active Comparator|Group C|15 sites received scaling and root planing with subgingival placement of amnion membrane hydrated with Taurine
88861298|NCT01896960|Active Comparator|2 ml Bupivacaine|2 ml Bupivacaine with 15 micrograms of fentanyl
88861299|NCT01896960|Active Comparator|1.5 ml Bupivacaine|1.5 ml Bupivacaine with 15 micrograms of fentanyl
88861300|NCT02091102|Experimental|755nm Alexandrite Laser|755nm Alexandrite Laser
88861301|NCT00055692|Experimental|Treatment (bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes on day 1. Treatment continues every 2 weeks in the absence of disease progression or unacceptable toxicity.
88861302|NCT05043012|Experimental|Group 1|will have an mpMRI scan with a flexible AIR coil.
88861303|NCT05043012|Experimental|Group 2|will have an mpMRI scan with an endorectal coil
88861304|NCT04772352|Experimental|Experimental group: Lifestyle intervention + febuxostat (40mg, once a day, orally)|participants accept febuxostat treatment in addition to lifestyle intervention for 0-48 week.
89184731|NCT04105361|Experimental|Study group|We will do posterior nasal neurectomy in patients with allergic rhinitis after FESS in one side of the nose
89386009|NCT04284657|Active Comparator|ARM III: PRAV + Sodium Citrate|Standard therapy and PRAVASTATIN 40 mg QD and Sodium Citrate (up to 30 mL TID)
89386010|NCT03578666|Experimental|Massage Group|Recreational active runners recruited from local running clubs (n= 16) will receive 40 minutes of massage therapy.
89535238|NCT04434105|Experimental|PRP group|patients received ultrasound-guided injection of 2 mL PRP into the affected carpal tunnel.patients will be injected twice with 2 weeks intervals
89535239|NCT04434105|Active Comparator|Steroid group|patients received ultrasound-guided injection of 2 mL steroids (40 mg triamcinolone acetonide). into the affected carpal tunnel. patients will be injected twice with 2 weeks intervals
89535240|NCT04434105|Placebo Comparator|Control group|patients received ultrasound-guided injection of 2 mL saline patients will be injected twice with 2 weeks intervals
89535241|NCT02451631|Active Comparator|Traditional care|Traditional care with paper(SMBG) and healthcare staff advice in office
89535242|NCT02451631|Experimental|Health-On G App.+ Physician web portal|Patient self-mgmt using Health-On G Application on smartphone; Healthcare staffs monitoring through physician web to review data
89535243|NCT02488421||Patient treated with Apixaban|
89535244|NCT02488421||Patient treated with Rivaroxaban|
89184732|NCT04105361|Experimental|Control group|We will do FESS only in the other side of the nose
89535245|NCT02488421||Patient treated with Dabigatran|
89386011|NCT03578666|Experimental|Cold water immersion group|Recreational active runners recruited from local running clubs(n= 16) will immerse for 10 minutes in a cold water bath
89386012|NCT03578666|No Intervention|Control group|Recreational active runners recruited from local running clubs will rest passively in a sitting position for 30-min period
89386013|NCT05205135||Caregivers|Caregivers of persons with dementia supported by the Carer Matters programme
89386014|NCT05205135||Nurses|Ward nurses who collaborate with the Carer Matters team
89386015|NCT05205135||Programme facilitators|Facilitators of programmes organised through Carer Matters
89386016|NCT05205135||Care Support Nurses|Nurses trained to deliver support and assistance as part of Carer Matters Programme
89386017|NCT05205135||Community partners and hospital leaders|Key policy makers and community leaders who partner with the Carer Matters programme to ensure its success
89386018|NCT05205135||Other clinicians (e.g. Social workers, Physiotherapists, doctors)|Other clinicians who refer caregivers to the Carer Matters programme
89386019|NCT03574220|Experimental|Pembrolizumab + Stereotactic Body Radiotherapy|"Lung SBRT 50 Grays (Gy) in 5 fractions over 5-14 days, or 60 Gy in 3 fractions over 8-15 days.~Adjuvant Therapy:~Pembrolizumab 200mg IV every 21 days for 6 months"
89386020|NCT03574142|Experimental|Epanova|Epanova® capsule, per oral
89386021|NCT03578588|Experimental|Banapenem B1 group|Dose in the 1st period 250mg; Dose in the 2nd period 500mg; Dose in the 3rd period 1000mg
89386022|NCT03578588|Experimental|Banapenem B2group|Dose in the 1st period 500mg; Dose in the 2nd period 1000mg; Dose in the 3rd period 250mg
89386023|NCT03578588|Experimental|Banapenem B3group|Dose in the 1st period 1000mg; Dose in the 2nd period 250mg; Dose in the 3rd period 500mg
89386024|NCT03578588|Experimental|Banapenem C1group|250mg Once daily for 7 consecutive days
89386025|NCT03578588|Experimental|Banapenem C2group|500mg Once daily for 7 consecutive days
89386026|NCT04876677|Experimental|CHF5993|Beclometasone Dipropionate (BDP) 100 μg/inhalation + Formoterol Fumarate (FF) 6 μg/inhalation + Glycopyrronium Bromide (GB) 12.5 µg/inhalation
89386027|NCT02966028|Experimental|SNF472 300 mg|Dose 1 arm (300 mg): 1 vial of physiological saline and 1 vial of active (10 mL SNF472 at 30 mg/mL)
89386028|NCT02966028|Experimental|SNF 472 600 mg|Dose 2 arm (600 mg): 2 vials of active (10 mL SNF472 at 30 mg/mL)
89386029|NCT02966028|Placebo Comparator|Matching Placebo|Placebo arm: 2 vials of physiological saline
89386030|NCT03578432|Experimental|Supportive care (everolimus, saliva output testing)|Participants receive everolimus PO QD for 5 days beginning 2 weeks after radiation treatment. Participants also undergo saliva output testing at baseline prior to radiation or chemoradiation treatment, after 3 weeks of RT/chemoRT, after 6 weeks of RT/chemoRT, prior to everolimus administration, at completion of the 5 day everolimus course, and at 1, 3, and 6 months after the completion of radiation or chemoradiation therapy.
89386031|NCT03578354|Experimental|4-AP|15 mg 4-aminopyridine twice daily
88861305|NCT04772352|Active Comparator|Control group: Lifestyle intervention|participants receive lifestyle intervention for 0-24 week. If the results of the 0-24 week study showed that the liver fat content of subjects in the experimental group was significantly lower than that in the control group, control group will accept febuxostat treatment in addition to lifestyle intervention in the next 25-48 week.
88861306|NCT00056472|Active Comparator|olanzapine/sertraline combination|sertraline plus olanzapine
88861307|NCT00056472|Placebo Comparator|olanzapine plus placebo|olanzapine (5 - 20mg/day) plus placebo
88861308|NCT00056550|Experimental|Recombinant Human Antithrombin (rhAT) infusion|Loading and continuous infusion dose of rhAT to target and maintain an AT activity level > 80% and < 120% of normal.
88861309|NCT04752930|Experimental|ctDNA monitoring|ctDNA monitoring will be performed at protocol-specified intervals and requirement
88861310|NCT04752930|Active Comparator|Imageology (SOC)|Imaging examination will be performed at protocol-specified intervals and requirement
88861311|NCT04271826|Experimental|cases with normal CT|evaluate level of bilirubin and phospholipase A2 and their relation to positive or negative appendicitis
88861312|NCT04271826|Experimental|cases with proven appendicitis on CT|evaluate level of bilirubin and phospholipase A2 and their relation to positive or negative appendicitis
88861313|NCT04771884||Treatment(meropenem vancomycin ceftazidime ceftriaxone ceftizoxime linezolid)|The use of antimicrobial agents depends on the clinical practice.
88861314|NCT02538744|Placebo Comparator|placebo|placebo po 1x/day from day -12 through 4
88861315|NCT02538744|Active Comparator|doxazosin 8 mg|day -12 through -9: Doxazosin 1 mg po 1x/day day -8 through -5: Doxazosin 2 mg po 1x/day day -4 through -1: Doxazosin 4 mg po 1x/day day 1 through 4: Doxazosin 8 mg po 1x/day
88861316|NCT00060528|Experimental|no GM|No granulocyte macrophage colony stimulating factor (GM-CSF) was given
88861317|NCT00060528|Experimental|Rec-hGM|Recombinant human GM-CSF (Sargramostim) was administered at 100mcg/day on days 1-4 following each vaccine. Given subcutaneously (s.c.) at site of vaccine.
88861318|NCT00060528|Experimental|rF-GM (10^7pfu)|recombinant fowlpox GM-CSF was given on day one at 10^7 in last two arms. Given subcutaneously (s.c.) at site of vaccine.
89184733|NCT05673135|Other|Non-obese hypertensive pregnant women|
89184734|NCT05673135|Other|Obese hypertensive pregnant women|
89386032|NCT03578354|Experimental|Atenolol|25 mg atenolol twice daily
89386033|NCT03578354|Placebo Comparator|Placebo|Masked placebo twice daily
89386034|NCT02239718|Experimental|2-unit cantilevered resin bonded bridge|Use one tooth as abutment tooth to replace one adjacent missing tooth
89535246|NCT02488421||Patient treated with vitamin K antagonists|
89535247|NCT03208075|Experimental|Normal Phosphorus Diet|Diet containing 1500mg of phosphorus per day
89535248|NCT03208075|Experimental|Low-phosphorus Diet|Diet containing 500mg of phosphorus per day
89386035|NCT02239718|Active Comparator|3-unit fixed movable resin bonded bridge|Use teeth from both side of the missing tooth space to replace a tooth. The prosthesis is cast in two piece and connected with a fixed-movable joint (semi-precision, allow degree of movement).
89535249|NCT03208075|Experimental|High-phosphorus Die|Diet containing 2300mg of phosphorus per day
89535250|NCT03320291|Experimental|Regjoint|
89535251|NCT03078777|Experimental|Pre-Dialysis|Patients will take 120 mg of fexofenadine three hours prior to dialysis and plasma concentration measured three hours following dosing.
88861319|NCT00060528|Experimental|rF-GM (10^8)|recombinant fowlpox GM-CSF was given on day one at 10^8 in last two arms. Given subcutaneously (s.c.) at site of vaccine.
88861320|NCT02255838|Experimental|Disposable bronchoscope first (aScope IV), then Reusable bronchoscope (Storz 8402 2x)|the bronchoscope will be re-inserted and advanced to the basal segmental bronchi of the right lower lobe. The tip of the bronchoscope will be brought into wedge position in one of the basal segments for broncho-alveolar lavage (BAL). A saline flush of 20 ml will be administered. The flow of saline will be observed at the distal tip of the bronchoscope. After 10 seconds of maintaining a wedge position, gentle suction will be applied to collect the lavage specimen in the collection trap. This step will be repeated 4 more times (total of 80ml) to obtain an adequate specimen.
89386036|NCT02925741|Experimental|Silk-Like Linens|Patients in the experimental arm will be cared for on silk-like bed linens.
89386037|NCT02925741|No Intervention|Standard Cotton Linens|Patients in the standard of care arm will be cared for on standard cotton bed linens.
89386038|NCT03576482||Transport on foot|Patients go to operating room walking with their families and with their normal clothes
88861321|NCT02255838|Active Comparator|Reusable bronchoscope first (Storz 8402 2x), then Disposable bronchoscope (aScope IV)|the bronchoscope will be re-inserted and advanced to the basal segmental bronchi of the right lower lobe. The tip of the bronchoscope will be brought into wedge position in one of the basal segments for broncho-alveolar lavage (BAL). A saline flush of 20 ml will be administered. The flow of saline will be observed at the distal tip of the bronchoscope. After 10 seconds of maintaining a wedge position, gentle suction will be applied to collect the lavage specimen in the collection trap. This step will be repeated 4 more times (total of 80ml) to obtain an adequate specimen.
88861322|NCT04696224|Active Comparator|INTRAVENOUS|30 patients who will receive 15mg / kg of TXA intravenous in 100ml salina solution (0,9%), after anesthetic induction and before incising the skin (administered in 10 minutes). For masking purposes, these patients will also receive at the end of the surgery, and before performing the plan closure, a compress soaked in 80ml of saline solution (0.9%), which will fill all the plans of the incision, and will be kept for 5 minutes.
88861323|NCT04696224|Active Comparator|LOCAL|30 patients who, at the end of the surgery, and before the suture in layers, will receive a compress soaked in a solution of 1.5 g of tranexamic acid (six ampoules of Transamin®, Zydus Nikkho) diluted in 50 ml of saline solution (0.9 %) (total volume of 80ml), which will fill all the plans of the incision and will be maintained for 5 minutes. For masking purposes, these patients will also receive 100ml of saline solution (0.9%) after anesthetic induction and before incising the skin.
88861324|NCT04696224|Placebo Comparator|PLACEBO|30 patients who will not receive the TXA, but will receive a 100ml intravenous saline solution 0,9% after anesthetic induction and before incising the skin (such as group 1) and a compress soaked in saline solution as used in group 2.
88861325|NCT04690452|Experimental|Intervention condition|Intervention group that receive a standardized 8 weeks Compassion Cultivation Training from a faculty member certified CCT© instructor (https://www.compassioninstitute.com/about-us/teacher-directory/)
88861326|NCT04690452|Other|Waitlist control condition|"The participants assigned to the waitlist control will fill in the same questionnaires as the intervention group at the different time points (i.e., pre, post, 2-month and 6-month follow-ups).~Two months after finishing the intervention, will become participants of a CCT© program themselves given by the same faculty member certified CCT© teacher as for the experimental group."
88861327|NCT04689438||Healthy control groups|clinically healthy gingiva BOP score less than 10%
88861328|NCT04689438||Gingivitis groups|BOP score of 10% or greater
88861329|NCT04689438||Periodontitis groups|interdental AL ≥5 mm, PD≥6 mm
88861330|NCT04688580|Experimental|XW10172|
88861331|NCT04753008|Experimental|Dopamine group|Cardiac surgery patients receiving dopamine to support their cardiac function (as part of the routine post-operative care).
88861332|NCT04753008|No Intervention|Control group|Cardiac surgery patients receiving no positive inotrope drug.
88861333|NCT04771494|Experimental|Trained|Participants with at least 6 months of training with unstable devices
88861334|NCT04771494|Experimental|Untrained|Participants with no previous instability experience
88861335|NCT04771104|Active Comparator|Allocated to intervention at first experimental day|
88861336|NCT04771104|Placebo Comparator|Allocated to intervention at second experimental day|
88861337|NCT00060606|Experimental|Prenatal Surgery Group|Fetal surgery to close spina bifida defect prior to 26 weeks of gestation with delivery by C-Section at approximately 37 weeks of gestation.
89386039|NCT03576482||Transport by stretcher on wheels|Patients go to operating room by stretcher on wheels and with hospital clothes. Normal routine of our hospital.
89535252|NCT03078777|Experimental|Post-Dialysis|Patients will take 120 mg of fexofenadine at the end of their dialysis session and plasma concentration measured three hours following dosing.
89535253|NCT03227497|Active Comparator|Walnut|"At the beginning of the study, subjects are randomly assigned to receive either intervention treatment (whole walnuts) or no treatment (control arm).~Treatment arm includes 56 g of whole walnuts daily."
89535254|NCT03227497|No Intervention|Control|At the beginning of the study, subjects are randomly assigned to receive either intervention treatment (whole walnuts) or no treatment (control arm).
89386040|NCT04189731||supra-scapular block|Patient will have a short ISB (between 2h and 4h) relayed by a supra-scapular block (SSB) long (72h) through the placement of a perineural catheter thus allowing a continuous diffusion of Naropein® by an elastomeric pump
89386041|NCT02239796|Experimental|TPTNS|"12 stimulation sessions of 30 minutes duration, delivered twice weekly over a 6 week period using a NeuroTrac continence stimulator.~Two surface electrodes are applied to the non-hemiparetic ankle, where appropriate, or the right ankle where no hemiparesis exists. The electrical stimulator is pre-programmed to safely deliver 30 minutes of continuous stimulation with a pulse frequency of 10 hertz and pulse width 200µs22. The intensity of the current will depend on the stroke survivor's perception threshold and individual comfort and is self-adjusted at each session, but will normally range between 15 and 40 milliamps."
89535255|NCT03078309|Experimental|healthy|All subjects will undergo a full ocular exam and visual functions will be assessed before and after the administration of a single dose of cannabis (THC:CBD 1:40). On the second study day all subjects will receive a single dose of cannabis (THC:CBD 1:1) and undergo the full ocular exam again.
88861338|NCT00060606|Active Comparator|Postnatal Surgery Group|Standard postnatal closure of the spina bifida defect when the baby is medically stable, usually within 48 hours of birth by C-section.
88861339|NCT00063570|Experimental|A|
88861340|NCT00063570|Experimental|B|
88861341|NCT01897038|Experimental|Cohort 1 (Onartuzumab)|
88861342|NCT01897038|Experimental|Cohorts 2/3 (Onartuzumab + Sorafenib)|
88861343|NCT04770792|Experimental|Experimental group|2% chlorhexidine gluconate with mineral trioxide aggregate.
88861344|NCT04770792|Active Comparator|Control group|Mineral trioxide aggregate.
88861345|NCT00064038|Experimental|Arm I|Patients receive induction therapy comprising oral dexamethasone (DM) on days 1-4, 9-12, and 17-20 and oral lenalidomide on days 1-28. Treatment repeats every 35 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients then receive maintenance therapy comprising oral DM on days 1-4 and 15-18 and oral lenalidomide on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88861346|NCT00064038|Active Comparator|Arm II|Patients receive induction therapy comprising DM as in arm I induction and oral placebo on days 1-28. Treatment repeats as in arm I induction. Some patients may then receive maintenance therapy comprising oral DM as in arm I maintenance and oral placebo on days 1-21. Courses repeat as in arm I maintenance.
88861347|NCT04770558|Experimental|Exergame group|The exergame group will receive exergame training for 12 weeks, 2 times a week and 60 min per session.
88861348|NCT04770558|No Intervention|Control group|The control group will not receive any intervention and maintain their lifestyle for 12 weeks.
88861349|NCT01960530|No Intervention|Endogenous Cortisol|No Study medication will be given during this study period, however various blood, urine and saliva samples will be taken in order to measure normal levels of hormones and other chemicals at several time-points.
88861350|NCT01960530|Other|Dexamethasone|1mg Dexamethasone will be administered at 22:00 on Day 1 and at 06:00 and 12:00 on Day 2. Various blood, urine and saliva samples will be taken in order to measure normal levels of hormones and other chemicals at several time-points. Dexamethasone is considered a challenge agent and therefore a non-IMP
88861351|NCT01960530|Experimental|Infacort®|20mg Infacort® will be administered on Day 2 at 07:00. Dexamethasone is a challenge agent and will be taken to suppress endogenous adrenocorticotropic Hormone (ACTH) and cortisol. 1mg Dexamethasone will be administered at 22:00 on Day 1 and 06:00 and 12:00 on Day 2. Various blood, urine and saliva samples will be taken in order to measure normal levels of hormones and other chemicals at several time-points.
89003309|NCT05472389|Other|Patients, adults and children, with Dravet Syndrome|An homogenous population of patients with DS. The patients will have a prospective baseline period of 3 to 6 months duration in order to collect seizure frequency. After this period, all patients will then undergo a 24-48 hours video-EEG recordings and a full-night polysomnography
88818795|NCT02429934|Placebo Comparator|Placebo|32 SLE patients to be treated with subcutaneous placebo once a week for 16 weeks. Injection will be vehicle injected subcutaneously once a week for 16 weeks
88818796|NCT01852799|Experimental|PAD Followed by ASCT|"Drug: Bortezomib, Adriamycin (Doxorubicin) /Epidoxorubicin(EPI), Dexamethasone.~After received induction therapy, patients will proceed to receive ASCT based on the willing of the patients and the decision of the investigators."
88818797|NCT02429856|Active Comparator|PCS|SCORPIO™ Posterior Cruciate Ligament Substituting TKA prosthesis
88818798|NCT02429856|Active Comparator|PCR|SCORPIO™ Posterior Cruciate Ligament Retaining TKA prosthesis
88818799|NCT02429778|Experimental|BREATHE|4 weeks DVD-delivered relaxation intervention program called breathe. The experimental intervention includes progressive muscle relaxation, diaphragmatic breathing, and home practice of the skills. Following the 4 weeks of treatment, participants will be asked to continue to practice at home for 4 weeks.
88818800|NCT02429778|No Intervention|Wait List|8 week wait list period. Participants assigned to wait list will have the opportunity to receive BREATHE arm after 8 weeks if interested.
88818801|NCT02403180|Other|DACP MF, then PROCLEAR 1D MF|DACP MF (nelfilcon A) multifocal contact lenses worn in Period 1, followed by PROCLEAR 1D MF (omafilcon A) multifocal contact lenses worn in Period 2. Both products were worn bilaterally (in both eyes) for 5 ±1 days in a daily wear, daily disposable modality.
88818802|NCT02403180|Other|PROCLEAR 1D MF, then DACP MF|PROCLEAR 1D MF (omafilcon A) multifocal contact lenses worn in Period 1, followed by DACP MF (nelfilcon A) multifocal contact lenses worn in Period 2. Both products were worn bilaterally (in both eyes) for 5 ±1 days in a daily wear, daily disposable modality.
88818803|NCT01852955|Active Comparator|IV acetaminophen|Administration of IV acetaminophen 1000 mg over 15 minutes at the start of surgical closure.
88818804|NCT01852955|Placebo Comparator|Placebo|Administration of placebo (sterile normal saline)group-same volume of saline solution administered in the same fashion as the acetaminophen
88818805|NCT01854281||Patent foramen ovale dive A group|Divers with a previously diagnosed patent foramen ovale observed after Dive A.
88818806|NCT01854281||Closure dive A group|Divers with a patent foramen ovale previously closed by a catheter-based procedure observed after Dive A.
88818807|NCT01854281||patent foramen ovale dive B group|Divers with a previously diagnosed patent foramen ovale observed after Dive B.
88818808|NCT01854281||closure dive B group|Divers with a patent foramen ovale previously closed by a catheter-based procedure observed after Dive B.
88818809|NCT00558467|Other|Pramipexole|
88818810|NCT00558467|Placebo Comparator|Placebo|
88818811|NCT02402166|Experimental|Single Arm|There are 4 periods in this study: 1)screening and washout; 2) Dose Optimization; 3) Dose Maintenance; 4) Safety Follow-up. SPD489 will be used to treat all subjects.
88818812|NCT02378220|No Intervention|"Controls (not tested)"|Treatment as usual (e.g. review of potential drug-drug interactions via Lexicomp Online)
88818813|NCT02378220|Active Comparator|"Intervention (tested)"|"Patients in the tested group will receive pharmacogenetic testing via YouScript® Personalized Prescribing System. The study pharmacist will review drug-drug interactions (DDI), drug-gene interactions (DGI), and drug-drug-gene interactions (DDGI) using YouScript® to provide drug therapy recommendations to prescribers."
88818814|NCT02401308|Active Comparator|Awake DBS Surgery|"Deep brain stimulation surgery: Parkinson's patients undergoing traditional awake DBS surgery utilizing microelectrode recordings and intra-operative stimulation"
88818815|NCT02401308|Active Comparator|Asleep DBS Surgery|Deep brain stimulation surgery:Parkinson's patients undergoing DBS surgery under general anesthesia utilizing intraoperative imaging to verify the stereotactic accuracy of DBS electrodes placement at the time of surgery.
88818816|NCT02401230|Active Comparator|Rectal Gel Lubricant|Subjects will insert 5 mL of lubricant in rectum for seven consecutive days
88818817|NCT02401230|Active Comparator|Truvada|Subjects will take one Truvada tablet orally for seven consecutive days
88818818|NCT02401230|Active Comparator|Rectal Gel Lubricant + Truvada|Subjects will insert 5 mL of lubricant in rectum and take one Truvada tablet orally for seven consecutive days
88818819|NCT01854359|Other|Active treatment|Idebenone (150mg tablets) administered orally as five tablets, three times per day with food.
88818820|NCT01854593|Active Comparator|Bevacizumab injection and vitrectomy|0.16 mg/0.05 ml bevacizumab intravitreal injection one day before vitrectomy.
88818821|NCT01854593|Sham Comparator|Sham injection and vitrectomy|Sham injection one day before vitrectomy.
88818822|NCT02429310|No Intervention|Supervised Exercise Only|This is the cohort of patients with Intermittent Claudication that will receive standard care of a supervised exercise programme only.
89184735|NCT02602925|Experimental|Dose decrease|Patients receive daily practice care, but doses of etanercept, adalimumab or ustekinumab will be lowered: intervals of drug-administration will be prolonged stepwise with tight control of disease activity and DLQI. First, the dose will be decreased to 66-70% of the normal dose (by interval prolongation with a factor 1.5). If patients remain in a state of low disease activity, the dose will be further reduced to 50% (by doubling the original interval). Each step will be analyzed after three months, or when the patient visits earlier due to complaints.
89184736|NCT02602925|Other|Usual care|Patients will continue treatment with the normal dose and treatment regimens will be based on usual daily practice care. Treatment decisions are made at the discretion of the treating physician.
89184737|NCT00722709|Experimental|LA|Use of Ropivacaine
89184738|NCT00722709|Placebo Comparator|Placebo|Use of 0.9% saline
89184739|NCT00722943|Active Comparator|DMT group|These infants will receive tactile stimulation and developmental massage by a licensed therapist. This intervention will be done behind a screen in order to blind the therapy to NICU staff and parents.
89184740|NCT00722943|Placebo Comparator|SHAM control|These infants will have no tactile stimulation or developmental massage done. The therapist will stand behind a screen but will not touch the infant. The screen will blind the NICU staff and parents to the study arm.
89386042|NCT02239796|Sham Comparator|Sham TPTNS|"The sham stimulation group will self- or carer-deliver a similar programme of twelve, 30 minute sessions twice weekly for 6 weeks NeuroTrac continence stimulator.~The surface electrodes will be positioned on the lateral malleolar area of the ankle, not the medial aspect, to avoid the posterior tibial nerve.~The stimulation intensity will be increased until sensation is reported, then turned down to 4mA for the 30 minute session, ensuring that despite avoiding the posterior tibial nerve, there is no therapeutic stimulation provided."
89386043|NCT02964312|Other|Latera Implant|Unilateral or bilateral placement of the Latera nasal implant for support of the lateral nasal wall cartilage.
89386044|NCT04155333|Experimental|Active anodal stimulation|active anodal stimulation at F3, cathode placed on contralateral bicep
89386045|NCT04155333|Experimental|Active cathodal stimulation|active cathodal stimulation at F3, anode placed on contralateral bicep
88861352|NCT01960530|Active Comparator|Hydrocortisone Tablet|20mg Hydrocortisone Tablet will be administered on Day 2 at 07:00. Dexamethasone is a challenge agent and will be taken to suppress endogenous ACTH and Cortisol. 1mg Dexamethasone will be administered at 22:00 on Day 1 and 06:00 and 12:00 on Day 2. Various blood, urine and saliva samples will be taken in order to measure normal levels of hormones and other chemicals at several time-points.
89386046|NCT04155333|Sham Comparator|Sham stimulation|sham stimulation that will be counterbalanced between subjects such that half will receive sham stimulation configured as condition 1 (anode F3, cathode bicep) and half will receive condition 2 (cathode F3, anode bicep)
89184741|NCT04105205|Experimental|Apramycin injection in escalating doses|Apramycin, solution for infusion.
89184742|NCT04105205|Placebo Comparator|Placebo|Physiological saline, solution for infusion.
89184743|NCT00794573|Experimental|Varenicline|0.5 mg tablet once a day for the first three days, a 0.5 mg tablet twice a day for the following four days, and a 1.0 mg tablet twice a day for the remainder of the 12-week treatment.
89184744|NCT00794573|Placebo Comparator|Sugar pill|placebo for 0.5 mg tablet once a day for the first three days, a 0.5 mg tablet twice a day for the following four days, and a 1.0 mg tablet twice a day for the remainder of the 12-week treatment.
88861353|NCT01960530|Active Comparator|i.v Hydrocortisone Injection|20mg i.v. Hydrocortisone Injection will be administered on Day 2 at 07:00. Dexamethasone is a challenge agent and will be taken to suppress endogenous ACTH and Cortisol. 1mg Dexamethasone will be administered at 22:00 on Day 1 and 06:00 and 12:00 on Day 2. Various blood, urine and saliva samples will be taken in order to measure normal levels of hormones and other chemicals at several time-points.
88861354|NCT01897350||CMR following ST segment myocardial infarction|
88861355|NCT01737060|Active Comparator|Angular stable plate Philos|Open Reduction and Osteofixation with Philos plate and TiCron cerclages
88861356|NCT01737060|Experimental|Reverse Total Shoulder Artroplasty|Intervention group
88861357|NCT04389372|Experimental|Mindfulness by Smartphone|mindfulness therapy by smart phone
88861358|NCT04753632||Cerebral palsy patients and caregivers|Cerebral palsy patients and caregivers
88861359|NCT04753632||Healthy people and their caregivers|Healthy people and their caregivers
88861360|NCT04770168|Experimental|CBT Curriculum - First Cohort|Students will receive the 3-month cognitive behavioral therapy curriculum in the first half of the academic year.
88861361|NCT04770168|Experimental|CBT Curriculum - Second Cohort (Waitlist Controls)|Students will receive the current school board curriculum as usual for the first half of the academic year, serving as wait-list controls. Since this is a stepped wedge trial, the winter cohort will receive the identical intervention as the fall cohort in the second half of academic year.
88861362|NCT01897428|Active Comparator|Reference arm|Treated with Reference (bepotastine besilate 10 mg)
88861363|NCT01897428|Experimental|Test arm|Treated with Test (bepotastine salicylate 9.64 mg)
88861364|NCT05606562|Experimental|Dental treatment|All participants will be offered dental treatment for free.
88861365|NCT00067236|Experimental|PG-116800 tablet|PG-116800 tablet (200 mg) taken twice daily for 90 days
88861366|NCT00067236|Placebo Comparator|Placebo tablet|Placebo tablet taken twice daily for 90 days
88861367|NCT04753398|Experimental|Telemonitoring group|Additional telemonitoring devices: Blood Pressure Monitor, medication dispenser, telemonitoring technology
88861368|NCT04753398|No Intervention|Control group|usual care, without telemonitoring
88861369|NCT00007644|Other|Radical Prostatectomy|Surgical removal of the prostate
89386047|NCT05204979||Misopristol|Group A: vaginal misoprostol will be taken Group B: sublingual misoprostol will be taken
88861370|NCT00007644|No Intervention|Watchful Waiting|Closely watching, waiting and treating symptoms if and when cancer progresses
88861371|NCT00068718|Experimental|Treatment (DLI)|Patients undergo unirradiated DLI over 15-30 minutes on day 0. Patients then undergo restaging on day 28 and may undergo a second DLI after at least 4 weeks if no significant GVHD develops and disease status worsens or after at least 8 weeks if disease status is unchanged and persistent donor T-cells are documented.
88861372|NCT00024102|Active Comparator|Standard Chemotherapy|"Patient/Physician choice of cyclophosphamide + MTX + 5-FU~OR~Cyclophosphamide + doxorubicin"
89535256|NCT03078309|Experimental|Retinitis Pigmentosa|All subjects will undergo a full ocular exam and visual functions will be assessed before and after the administration of a single dose of cannabis (THC:CBD 1:40). On the second study day all subjects will receive a single dose of cannabis (THC:CBD 1:1) and undergo the full ocular exam again.
88861373|NCT00024102|Experimental|Capecitabine|Treatment with capecitabine
88861374|NCT05606016|Experimental|Facilitated Self-Sampling Intervention (FSSI)|Participants in the FSSI arm will receive education on COVID-19 testing and be provided with rapid antigen tests. Participants will also receive pre and post surveys.
88861375|NCT05606016|Experimental|Testing Navigation Intervention (TNI).|Participants in the TNI arm will receive COVID-19 testing education and be navigated to PCR testing sites. Participants will also receive pre and post surveys.
88861376|NCT05606016|Active Comparator|Control|Participants in the Control Group arm will receive a CDC-designed COVID-19 testing brochures, and pre and post surveys only.
88861377|NCT00074802|Experimental|Paroxetine Continuation|Participants who showed only partial response to paroxetine in Phase 1 will receive continued treatment with paroxetine for 16 additional weeks.
88861378|NCT00074802|Experimental|Paroxetine with CBT Augmentation|Participants who showed only partial response to paroxetine in Phase 1 will receive continued treatment with paroxetine plus cognitive behavioral therapy (CBT) for 16 additional weeks.
88861379|NCT05605938|Experimental|Tenoten for children|1 tablet 3 times daily for 12 weeks. Route of administration: sublingual, the tablet should be held in the mouth until completely dissolved.
88861380|NCT05605938|Placebo Comparator|Placebo|As per the Tenoten for children dosing regimen.
88861381|NCT05605782||Participants initiating treatment with ozanimod|
88861382|NCT05605782||Participants initiating an sphingosine-1 phosphate (S1P) modulator|
88861383|NCT05605782||Participants initiating other non-S1P-receptor modulators disease modifying treatments (DMTs)|
89386048|NCT03576404|Experimental|Eligible participants|The intervention of patient-centered pharmacist care included a comprehensive interview patients conducted at month 3 and 5 ,which included and reviewing all their medications using concepts of MTM and MI All study participants were assessed at baseline and on monthly basis for the changes in the study outcomes.
89386049|NCT03647514|Experimental|Abraxane Combined With Xeloda|Tailored neoadjuvant chemotherapy with 4 cycles of PX(weekly Abraxane 125mg/m2, Q3week Xeloda 1250mg/m2, 21day/cycle) is planned for early breast cancer patients(stage of T2-4N0-3M0) who are eligible for primary systemic therapy.
88861384|NCT00156390|Experimental|1|echo-guided LV lead placement
88861385|NCT00156390|Other|2|LV lead placement as per standard of care (without echo-guidance)
88861386|NCT00029172|Experimental|Nurse Case management|
88861387|NCT04592562|Experimental|GAE Arm|Patients who meet study eligibility will be scheduled to undergo the Genicular Artery Embolization procedure and will subsequent be followed for 12 months after their procedure.
88861388|NCT00030264|Experimental|Methotrexate & Vinblastine|Methotrexate and Vinblastine will be given once a week for the first 26 weeks and then every two weeks for the next 26 weeks or until disease progression (whichever occurs first).
88861389|NCT00036738|Experimental|Treatment (allogeneic nonmyeloablative HSCT)|See Detailed Description
89003310|NCT05467904|Active Comparator|Xltranplus|Xltanplus is a full hemp flower formulation with cannabinoids and terpenes
89386050|NCT05759871|Experimental|FSH only (no GnRH antagonist)|Women receive only FSH starting on day 2 of the cycle. The starting dose of FSH is 225-300 IU s.c. for the first 4 days adjusted thereafter according to the ovarian response.
89386051|NCT05759871|Active Comparator|FSH + GnRH antagonist|Women receive 225-300 IU s.c. FSH, and a GnRH antagonist from day 6 of FSH treatment at the dose of 0.25 mg per day until the triggering day. The GnRH antagonist in group 2 is injected each time immediately after the injection of FSH.
89386052|NCT02239952|Experimental|sunitinib|
89386053|NCT02239952|Experimental|vandetanib|
89386054|NCT02239952|Experimental|Erlotinib|
89386055|NCT03647436||Exposed group|"Elderly patients with hospital admission due to hip fracture and score less than 12 points in the short-MNA at the moment of hospital admission.~Intervention:~Comprehensive Geriatric Assesment (CGA). Both groups.~CGA includes measuring of:~Previous functional assessment of daily life activities (Barthel and Lawton index), a cognitive screening (MiniMental State Examination), the turn-based assessment of the presence of delirium (Confusion Assessment Method) and in case of presence of delirium will be measured the duration and intensity of the symptoms (Delirium Rating Scale-Revised-98). Likewise, the presence of frailty (Clinical Frailty Scale) and walking ability (Functional Ambulation Categories) will be evaluated."
89386056|NCT03647436||Control group|"Elderly patients with hospital admission due to hip fracture and score equal or higher than 12 points in the short MNA at the moment of hospital admission~Intervention:~Comprehensive Geriatric Assesment (CGA). Both groups.~CGA includes measuring of:~Previous functional assessment of daily life activities (Barthel and Lawton index), a cognitive screening (MiniMental State Examination), the turn-based assessment of the presence of delirium (Confusion Assessment Method) and in case of presence of delirium will be measured the duration and intensity of the symptoms (Delirium Rating Scale-Revised-98). Likewise, the presence of frailty (Clinical Frailty Scale) and walking ability (Functional Ambulation Categories) will be evaluated."
89386057|NCT03646734||Guided Bone Regeneration with Particulate graft|patients who had inadequate alveolar crest (crest width <4mm) and requested of dental implant placement, treated with guided bone regeration with particulate graft
89386058|NCT03646734||Guided Bone Regeneration with block graft|patients who had inadequate alveolar crest (crest width <4mm) and requested of dental implant placement, treated with guided bone regeration with block graft
89386059|NCT03576326|Experimental|Incentive Drawing|Eligible to earn a weekly drawing entry with different winning probabilities during the 6-month incentive intervention period. Possible winnings depend on toothbrushing performance: low adherence threshold (brushing child's teeth once per day for 7 days in a week) will have an 18% chance of winning $25 and a 1% chance of winning $50 (expected $5 payout); high adherence threshold (brushing twice per day for 14 days in a week) will have a 34% chance of winning $25 and a 3% chance of winning $50 (expected $10 payout).
89386060|NCT03576326|No Intervention|Control - Delayed Incentive|No rewards during the first 12 months, but information on toothbrushing performance. After the Month 12 follow-up visit, may opt to participate in a delayed 6-month open label extension to earn the same monetary rewards the intervention group could earn Baseline through Month 6. Not a formal part of this trial, but rather a necessary condition to assure all participating parents/caregivers have the chance to earn the same monetary incentives.
89386061|NCT04739475|Other|Non surgical Periodontal Therapy NPT|"Conventional staging debridement (CSD) according to the severity of periodontal disease in 2 to 4 appointments at day 0, 7, 14 and 21.~Supra and subgingival scaling and polishing will be performed by the use of manual and ultrasonic instruments and oral hygiene instructions will be given. Patients will be instructed to use interdental brushes with appropriate size interdental brushes or dental floss when interdental embrasures will not allow for interdental brushing."
89003311|NCT05467904|Active Comparator|Xltran|Xltran contains terpenes extracted from the hemp flower
89003312|NCT05467904|Placebo Comparator|Placebo|Placebo will be an inactive formulation of water, sunflower lecithin and polysorbate
89386062|NCT03647280|Experimental|Abraxane Combined With Epirubicin|Tailored neoadjuvant chemotherapy with 4 cycles of PE(weekly Abraxane 125mg/m2, Q3week Epirubicin 100mg/m2, 21day/cycle) is planned for early breast cancer patients(stage of T2-4N0-3M0) who are eligible for primary systemic therapy.
89386063|NCT03576248|Experimental|In-phase 6 Hz prefronto-parietal tACS|6 Hz stimulation (1000 μA) with transcranial Alternative Current Stimulation (tACS) will be applied simultaneously over the left prefrontal dorso-lateral cortex (F3 of the 10-20 international scalp EEG system) and the left parietal cortex (P3 of the 10-20 international scalp EEG system, with a return electrode in Cz) for 20 minutes. The phase difference between the two stimulation sites will be 0°.
88818823|NCT02429310|Experimental|NMES + Supervised Exercise|This cohort of patients with Intermittent Claudication will receive the standard care of supervised exercise plus the use of a Revitive IX neuromuscular electrical stimulation device (Intervention) as per the protocol. The adjunctive benefit of the latter intervention compared to standard treatment alone will then be assessed.
89003313|NCT05461352|Experimental|5 mg|Period in which participants received repeated doses of 5 mg TS-142 prior to bedtime
89386064|NCT03576248|Sham Comparator|Sham prefronto-parietal tACS|The same stimulation as in in-phase transcranial Alternative Current Stimulation tACS (6 Hz F3 and P3 stimulation with 0° phase difference) will start with a current intensity of 1000 μA lasting for 30 seconds. Afterwards, the intensity will progressively decrease over 20 seconds until cessation. The whole session duration is 20 minutes.
89386065|NCT03576248|Experimental|2 mA left prefrontal tDCS|2000 μA anodal transcranial Direct Current Stimulation (tDCS) will be applied over the left prefrontal dorso-lateral cortex (F3 of the 10-20 international scalp EEG system with a right supraorbital return electrode (Fp2 of the 10-20 international scalp EEG system) during 20 minutes.
88818824|NCT04017143|Experimental|HPV App group|Participants will be assigned to receive an HPV app.
88818825|NCT04017143|No Intervention|Usual Care|This is a usual care group that receives a brochure that is usually distributed by a clinic.
88818826|NCT01854905||Patients Attending Consultation for LASIK|Patients attending consultation for LASIK on Day 1. No intervention or treatment is administered during the study.
89003314|NCT05461352|Experimental|10 mg|Period in which participants received repeated doses of 10 mg TS-142 prior to bedtime
89003315|NCT05451810|Experimental|Main Cohort: Epcoritamab Diffuse Large B-Cell Lymphoma (DLBCL)|Participants with relapsed or refractory (R/R) DLBCL will receive subcutaneous (SC) epcoritamab in 28 day cycles.
89386066|NCT03576248|Sham Comparator|Sham left prefrontal tDCS|The same stimulation as active transcranial Direct Current Stimulation (tDCS) (anodal F3 and return in Fp2) will start at 2 mA intensity for 30 seconds. Afterwards, the intensity will progressively decrease over 20 seconds until cessation. The whole session duration is 20 minutes.
89386067|NCT04721769|Active Comparator|Endoscopic strip craniectomy with the use of lateral osteotomies|Patients will have lateral osteotomies incorporated into their surgical procedure following suturectomy of the fused sagittal suture.
89386068|NCT04721769|Experimental|Endoscopic strip craniectomy without the use of lateral osteotomies|Patients will NOT have lateral osteotomies incorporated into their surgical procedure following suturectomy of the fused sagittal suture.
89386069|NCT03646032|Experimental|Intervention group|Intervention group (n=200) - will consist of 100 AAA males / 100 AAA females randomly selected participants who will receive a download of the SAAFE game and play for at least 30 minutes and as long as an hour, if desired.
89386070|NCT03646032|Active Comparator|Control group|Control group (n=200) - will consist of 100 AAA males / 100 AAA females randomly selected participants. This group will receive the standard of care by launching a mobile app that will play a dating sim game (called Choices). They will also receive pamphlets that provide information on the testing location and care if they have HIV/STI.
89386071|NCT03578120||iMAP2 participants where their mothers received REPEVAX|Children who participated in iMAP2 study whose mothers received a pertussis-containing vaccine during pregnancy called REPEVAX
89386072|NCT03578120||iMAP2 participants where their mothers received BOOSTRIX-IPV|Children who participated in iMAP2 study whose mothers receives a pertussis-containing vaccine during pregnancy called BOOSTRIX-IPV
89386073|NCT03578120||iMAP2 participants where their mothers received no vaccine|Children who participated in iMAP2 study whose mothers did not receive a pertussis-containing vaccine during pregnancy
89386074|NCT03576170|Active Comparator|aromatherapy-scent|
89386075|NCT03576170|Active Comparator|aromatherapy-touch|
89386076|NCT03576170|No Intervention|wait-list control|
89386077|NCT01566747|Experimental|Pazopanib|Pazopanib 800mg day to be given continuously until disease progression.
89386078|NCT03621462|Experimental|Acquisition of Lesion Images with AIDA|Subjects presenting with atypical skin lesions referred for biopsy will have their lesion imaged using the Artificial Intelligence Dermatology Assistant (AIDA™) study device
89386079|NCT03578042|Active Comparator|LosanetAMplus|Patients taking the fixed triple combination
89386080|NCT03578042|Other|standard of care|Patients taking 2 or 3 free combinations containing 3 drugs for hypertension as decided by the treating physician
89386081|NCT03646500|Experimental|Retrobulbar block|Retrobulbar block administered prior to Transcleral Diode Procedure
89386082|NCT03646500|Active Comparator|Remifentanil|Conscious IV sedation administered prior to Transcleral Diode Procedure.
89386083|NCT03574064|Experimental|GLP-2|Glucagon-Like Peptide-2 (GLP-2)
89386084|NCT03574064|Experimental|GIP|Glucose-dependent Insulinotropic polypeptide (GIP)
89386085|NCT03574064|Experimental|GLP-2+GIP|GLP-2+GIP
89386086|NCT03574064|Placebo Comparator|Placebo|Placebo
89386087|NCT05204745||Case|Subjects with subjective gait impariment according to questionnaire answers.
89386088|NCT05204745||Control|Subjects without subjective gait impariment according to questionnaire answers.
89386089|NCT03918408|Experimental|Pulsed, accelerated|18 mW, 5 sec, 5 sec off, 10 minutes of illumination
89386090|NCT03918408|Active Comparator|Conventional|9 mW, continuous 10 minutes of illumination
89386091|NCT03573986|Experimental|Arm A|
89386092|NCT05204433||normal control|healthy volunteers
89386093|NCT05204433||adenoma|pathologically reported colorectal adenoma
89386094|NCT05204433||colorectcal cancer|pathologically reported colon cancers
89386095|NCT05204433||High risk group|pathologically reported inflammatory bowel diseases
89386096|NCT03573674|Experimental|Cognitive ergonomics Intervention|
89386097|NCT03573674|Active Comparator|Stress management Intervention|
89386098|NCT03573674|No Intervention|Passive control|"Passive Control groups receive no intervention at all."
89386099|NCT03959592|Active Comparator|Lutein, zeaxanthin and mesozeaxanthin|Patients will be asked to consume 1 pill daily with a meal, for six months. The pills will contain 22 mg total of the carotenoids lutein (10 mg), zeaxanthin (2 mg), and mesozeaxanthin (10 mg).
89535257|NCT02488031|Experimental|Error-reduction|The participants in the error-reduction group will participate in a 4-week home-based training intervention during the month between their pre- and post-test visits. During pre- and post- training visits, Cooperative Ataxia Rating Scale (ICARS) and the Scale for the Assessment and Rating of Ataxia (SARA), Purdue Pegboard, Brief Test of Attention, 6-minute Walk, Hand Grip Dynamometer, Physical Performance Function, Digit Span, SARA, Montreal Cognitive Assessment, Beck Depression Inventory 2nd Ed, Stroop and biomechanical gait analysis tests will be administered. Also biomechanical assessments of dysmetria and neurophysiological assessment of brain activity will be conducted to evaluate the impact of the training on SCA individuals.
89386100|NCT03959592|Placebo Comparator|Placebo|Patients will be asked to consume 1 pill daily with a meal, for six months. The pills will contain only sunflower oil (placebo).
89386101|NCT04087395|Experimental|RHA®4 with new anesthetic agent|"Split-face injection of RHA®4 with new anesthetic agent in the nasolabial fold of one side of the face and RHA®4-Lidocaine in the nasolabial fold of opposite side of the face.~Up to 3 mL injected per side."
89386102|NCT04087395|Experimental|RHA®4-Lidocaine|"Split-face injection of RHA®4 with new anesthetic agent in the nasolabial fold of one side of the face and RHA®4-Lidocaine in the nasolabial fold of opposite side of the face.~Up to 3 mL injected per side."
89386103|NCT03573596|Other|dasatinib|2 years of dasatinib treatment before discontinuation if MR 4 is achieved for at least 1 year
89386104|NCT03621618|Other|dobutamine|Cardiac failure
89386105|NCT03621618|Other|norepinephrine|Sepsis
89386106|NCT04038333||Children|Interviewees are parents or grandparents of children aged between 6 to 59 months.
89386107|NCT04038333||Elderly|Interviewees are the elderly aged 60 years old or above.
89386108|NCT04038333||Chronic disease patients|Interviewees are adult patients with chronic diseases aged below 60 years old.
89386109|NCT04038333||Vaccination and health care personnel|Interviewees are vaccination and health care personnel in each study site.
89386110|NCT05204277|Active Comparator|In-office bleaching|40% hydrogen peroxide in-office bleaching (Opalescence™ boost™ PF 40%, Ultradent Products, Inc., South Jordan, UT, USA)
89386111|NCT05204277|Active Comparator|microabrasion|6.6% hydrochloric acid and silicon carbide microparticles microabrasion paste (Opalustre™, Ultradent Products, Inc., South Jordan, UT, USA)
89386112|NCT05204277|Active Comparator|Remineralization|casein phosphopeptide amorphous calcium fluoride phosphate (CPP-ACFP) remineralizing tooth crème (MI-Paste Plus®, GC America Inc., USA).
89386113|NCT05204277|Active Comparator|Microabrasion + In-office bleaching|teeth were treated with enamel microabrasion followed by in-office bleaching.
89386114|NCT05204277|Active Comparator|In-office bleaching + Remineralization|In-office bleaching was applied followed by MI-Paste Plus®
89386115|NCT05204277|Active Comparator|Microabrasion + Remineralization|microabrasion was applied followed by MI-Paste Plus®
88861390|NCT00038610|Experimental|Hyper-CVAD + Imatinib|Imatinib 600 mg orally days 1-14, course 1, & 600 mg daily days 1-14 (daily if tolerated course 1), even courses. Cyclophosphamide 300 mg/m^2 intravenous (IV) for 6 doses days 1-3, odd courses. Doxorubicin 50 mg/m^2 IV day 4; Vincristine 2 mg IV days 4 & 11; & Dexamethasone 40 mg IV or orally daily days 1-4 & 11-14 odd courses 1, 3, 5, 7. Methotrexate 12 mg intrathecally (6 mg if via Ommaya reservoir) day 2, odd courses and 200 mg/m^2 IV over 2 hours followed by 800 mg/m^2 over 22 hours day 1 of even courses. Cytarabine 100 mg intrathecally day 7 for odd courses and 3 gm/m^2 IV every 12 hours for 4 doses days 2-3 for even courses. Mesna 600 mg/m^2 IV daily, odd courses. G-CSF 10 mcg/kg/day after completion of chemotherapy until neutrophil recovery to 1 x 109/L or higher for all courses.
89386116|NCT05204277|Active Comparator|Microabrasion + In-office bleaching + Remineralization|teeth were treated with microabrasion followed by inoffice bleaching and lastly MI-Paste Plus®
89386117|NCT05204277|No Intervention|Control|no treatment (control)
88861391|NCT00156936|Experimental|Medisorb naltrexone 380 mg (VIVITROL)|
88861392|NCT00156936|Experimental|Oral naltrexone to Medisorb naltrexone 380 mg (VIVITROL)|
89386118|NCT03619278|Experimental|HIVACAR|Participants will receive 5 vaccines of personalized RNA vaccine (HIVACAR01), 2 dose of 10-1074 antibodies and 3 doses of romidepsin
88861393|NCT00076050|Experimental|1|Participants will receive a 200-mg dose of soy isoflavones daily over 2 years.
89386119|NCT03619278|Placebo Comparator|Placebo|Participants will receive 5 doses of placebo, 2 doses of 10-1074 antibodies and 3 doses of romidepsin
89386120|NCT05204121|Experimental|Elpida 40 mg once weekly|elsulfavirine 40mg orally once weekly for 8 weeks
89386121|NCT05204121|Experimental|Elpida 80 mg once weekly|elsulfavirine 80mg orally once weekly for 8 weeks
89386122|NCT05204121|Experimental|Elpida 160 mg once weekly|elsulfavirine 160mg orally once weekly for 8 weeks
89386123|NCT04697901|Experimental|Active Stimulation|Active tDCS stimulation will be applied.
89386124|NCT04697901|Sham Comparator|Sham Stimulation|Sham tDCS stimulation will be applied.
89386125|NCT02899962|Active Comparator|LEO 90100 aerosol foam|Topical application twice weekly for 52 weeks
88861394|NCT00076050|Placebo Comparator|2|Participants will receive placebo daily over 2 years.
88861395|NCT00046566|Active Comparator|Soy protein-milk protein-carbohydrate|Participants received 40 grams of soy protein daily for 8 weeks, 40 grams of milk protein daily for 8 weeks, and 40 grams of carbohydrate daily for 8 weeks.
88861396|NCT00046566|Experimental|Milk protein-carbohydrate-soy protein|Participants received 40 grams of milk protein daily for 8 weeks, 40 grams of carbohydrate daily for 8 weeks, and 40 grams of soy protein daily for 8 weeks.
88861397|NCT00046566|Placebo Comparator|Carbohydrate-soy protein-milk protein|Participants received 40 grams of complex carbohydrate daily for 8 weeks, 40 grams of soy protein daily for 8 weeks, and 40 grams of milk protein daily for 8 weeks.
88861398|NCT00077922|Experimental|LMB-2 in chronic lymphocytic leukemia|40 micrograms/kg every other day (QOD) x 3 every 4 weeks in patients with chronic lymphocytic leukemia, the most prevalent form of adult leukemia.
89386126|NCT02899962|Placebo Comparator|LEO 90100 aerosol foam vehicle|Topical application twice weekly for 52 weeks
89386127|NCT03647202|Experimental|Sequence ABC|Participants receive milademetan in a fasted condition (A), then with a high-calorie, high-fat breakfast (B), then with a standard breakfast (C) - with a washout period between treatments.
89386128|NCT03647202|Experimental|Sequence ACB|Participants receive milademetan in a fasted condition (A), then with a standard breakfast (C), then with a high-calorie, high-fat breakfast (B) - with a washout period between treatments.
89386129|NCT03647202|Experimental|Sequence BAC|Participants receive milademetan with a high-calorie, high-fat breakfast (B), then in a fasted condition (A), then with a standard breakfast (C) - with a washout period between treatments.
89386130|NCT03647202|Experimental|Sequence BCA|Participants receive milademetan with a high-calorie, high-fat breakfast (B), then with a standard breakfast (C), then in a fasted condition (A) - with a washout period between treatments.
89386131|NCT03647202|Experimental|Sequence CAB|Participants receive milademetan with a standard breakfast (C), then in a fasted condition (A), then with a high-calorie, high-fat breakfast (B) - with a washout period between treatments.
89386132|NCT03647202|Experimental|Sequence CBA|Participants receive milademetan with a standard breakfast (C), then with a high-calorie, high-fat breakfast (B), then in a fasted condition (A) - with a washout period between treatments.
89386133|NCT03646344|Active Comparator|Active Group|Will receive Heme Arginate (IMP) at a dose of 3mg/kg over 30mins. Participants will receive infusions of the IMP at 2 time-points, the first prior to surgery (transplantation), and the second 20-28 hours later. At each infusion, the IMP will be followed by a 100ml infusion of 0.9% Sodium Chloride over 15mins.
89386134|NCT03646344|Placebo Comparator|Placebo Group|Will receive a 100ml infusion of 0.9% Sodium Chloride (placebo) over 30mins. Participants will receive infusions at 2 time-points, the first prior to surgery, and the second 20-28 hours later. At each infusion, the placebo will be followed by a further 100ml infusion of 0.9% Sodium Chloride over 15mins.
89386135|NCT01569945|Active Comparator|Tablets|Clomifen (5 days) followed by Ethinyl Estradiol (5 days)
89386136|NCT01569945|Active Comparator|human menopausal gonadotropins|Daily Injections
89386137|NCT03645876|Experimental|SHR-1210+BP102+XELOX|Participants receive SHR-1210 200mg,BP102 7.5mg/kg and oxaliplatin 130mg/m2 in day 1 intravenously every 3week, capecitabine by oral bid in day1-14 every 3 week until disease progression or unacceptable toxicity
89386138|NCT03645798|Experimental|"Three good things therapy group"|"The experimental group received a six-month Wechat-basedthree good things positive psychotherapy from August 2015 to January 2016. Participants were directed to record three good things that went well each day. These things could be minor, ordinary, or important. Next to each good things, participants were required to answer the question: Why did this good thing happen?"
89386139|NCT03645798|Other|Normal psychological instruction group|The control group only received normal psychological instruction from the hospital
89386140|NCT03646266|Experimental|Rocuronium|Titration of rocuronium bromide until tidal volume of 6ml/kg predicted body weight (PBW) is reached
89386141|NCT03646266|No Intervention|Control|Standard of care
89386142|NCT02899338|Experimental|BI695501 Autoinjector|
89386143|NCT02899338|Active Comparator|BI695501 Prefilled syringe|
89386144|NCT04052100|Active Comparator|Usual care|Patients following the standard preoperative policies of opur institution
89386145|NCT04052100|Experimental|Prehabilitation|Patients following the standard preoperative policies of opur institution and the multimodal prehabilitation program
88861399|NCT01897194||Coma Patients|Observation of EEG patterns in coma patients.
88861400|NCT01897974||Seizure disorder|Patients that are on medications for seizure disorder.
88861401|NCT00161382|Experimental|Intervention Group|HIV, STD, and pregnancy prevention curriculum
88861402|NCT00161382|Experimental|Control Group|Standard sexual education curriculum
88861403|NCT00079326|Experimental|Treatment (trastuzumab, ixabepilone)|Patients receive trastuzumab IV over 30-90 minutes and ixabepilone IV over 3 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
88861404|NCT01898052|Experimental|multimodal drug injection|Multimodal drug injection Levobupivacaine 150 mg, epinephrine(1:1000) 0.6 mL(0.6 mg), morphine sulfate 5 mL(5 mg), ketorolac 1 mL (30 mg) and mixed with normal saline up to 100 mL
88861405|NCT01898052|Active Comparator|Single anaesthetic drug|Single anaesthetic drug levobupivacaine 150 mg and epinephrine (1:1000) 0.6 ml (0.6 mg)
88861406|NCT00051168|Experimental|Travatan|Travoprost (0.004%)
88861407|NCT00083382|Experimental|Thalidomide + Bisphosphonate|200 mg/day Thalidomide + 90 mg Pamidronate OR 4 mg Zometa every 2 weeks for 2 months and then every 4 weeks as maintenance therapy
88861408|NCT04506840|Experimental|Training group|Participants will participate in a program of physical exercise during the adjuvant chemotherapy treatment
88861409|NCT04506840|No Intervention|Not training group|Participants will not do any intervention, they only will be perform the pre and post-tests.
88861410|NCT00167388|No Intervention|group 1|All babies <1250 gm at the time of the study are enrolled into this arm, and randomized to be NPO during the PRBC transfusion
88861411|NCT00167388|Active Comparator|group 2|Babies <1250 gm at the time of the study are enrolled into this arm, and randomized to be fed during the PRBC transfusion
89386146|NCT04052178|Active Comparator|Repetitive transcranial magnetic stimulation (rtMS)|"Acute repetitive transcranial magnetic stimulation on the pharyngeal sensory cortex. Applied intensity 90% of the resting motor threshold, 1250 pulses at 5 Hz.~Each treatment arm was placebo/sham compared with a time separation of one week. The assignment to either active or sham was randomized."
89386147|NCT04052178|Active Comparator|Intrapharyngeal electrical stimulation (PES)|"Intrapharyngeal electrical stimulation applied to an intensity of 75% of the tolerance threshold with 0.2 ms pulses at 5 Hz during 10 min.~Each treatment arm was placebo/sham compared with a time separation of one week. The assignment to either active or sham was randomized."
89386148|NCT04052178|Active Comparator|Capsaicin|"100 mL of oral capsaicin solution at a concentration of 10-5M.~Each treatment arm was placebo/sham compared with a time separation of one week. The assignment to either active or sham was randomized"
89386149|NCT03645642|Experimental|Midodrine|Midodrine (5 mg TDS) along with albumin(20g/l) and diuretics. The dose of Midodrine will titrated according to the Mean arterial pressure (75-90mmhg). The dose will be increased to a maximum of 12.5 mg thrice daily.
88861412|NCT00167388|No Intervention|group 3|All babies >1250 gm at the time of the study are enrolled into this arm, and randomized to be fed during the PRBC transfusion
88861413|NCT00167388|Experimental|group 4|All babies <1250 gm at the time of the study are enrolled into this arm, and randomized to be fed during the PRBC transfusion
88861414|NCT00167544|Experimental|1|1. Tapering dose of hydrocortisone every 12 h over 7 day period
88861415|NCT00167544|Placebo Comparator|2|2. Identical-appearing saline placebo
88861416|NCT00167934|Placebo Comparator|Placebo|50% of participants will receive placebo
88861417|NCT00167934|Experimental|Experimental|50% of participants will receive Depakote ER
88861418|NCT00168324|Experimental|700 µg Dexamethasone|700 µg dexamethasone intravitreal implant administered on Day 0 and Day 180.
89386150|NCT03645642|Active Comparator|Albumin with diuretics|Albumin(20g/l) and diuretics.
89386151|NCT05284422|Active Comparator|Traditional technique|Peripheral venous catheters inserted to the participants in this arm are inserted with a palpation/visualization guided technique in their hand, arm, foot or head.
89386152|NCT05284422|Experimental|Ultrasound-guided technique|Peripheral venous catheters inserted to the participants in this arm are inserted with an ultrasound-guided technique in their forearm.
89386153|NCT03066609|Experimental|Secukinumab 150mg|Secukinumab 150mg s.c.
89386154|NCT03066609|Experimental|Secukinumab 300mg|Secukinumab 300mg s.c.
89386155|NCT03066609|Placebo Comparator|Placebo|Placebo to secukinumab s.c
89386156|NCT03645486|Experimental|Lentiviral TYF-CGD-modified autologous stem cells|Autologous hematopoietic stem cells transduced with lentiviral TYF vector carrying the functional gene
89386157|NCT03646110|Experimental|single-incision MIE|Esophageal cancer patients received single-incision Minimally invasive esophagectomy
89386158|NCT03646110|Active Comparator|multi-incision MIE|Esophageal cancer patients received multi-incision Minimally invasive esophagectomy
89386159|NCT05204043|Experimental|Peter Hess® sound massage|Peter Hess® sound massage using bowls dedicated to this technique.
89386160|NCT05204043|Experimental|Music relaxation Music Care®|The patient chooses his music preferences and receive the music relaxation.
89386161|NCT03611790|Experimental|Intervention|NeVa VS
89386162|NCT05757921|Experimental|Non-surgical mechanical treatment with Perisolv® (A)|The test group will receive the following treatment: In the deepened pockets to be treated, Perisolv is initially applied according to the manufacturers recommendation.Then subgingival debridement is performed. This is performed with piezoelectric ultrasound (EMS) while rinsing water and completed with subgingival manual instrumentation. In addition an aliquot of Perisolv was left after final debridement.
89386163|NCT05757921|Active Comparator|Non-surgical mechanical treatment without Perisolv® (B)|The control group will receive the following treatment: In the deepened pockets to be treated, subgingival debridement is performed. This is performed with piezoelectric ultrasound (EMS) while rinsing water and completed with subgingival manual instrumentation.
89386164|NCT03946761|Experimental|Cancer goggle system|"The surgical procedure will be performed according to standard practice, with the exception of microdosing of ICG & visualization of biliary/liver anatomy using the cancer goggles system~The surgeon will start with a peripherally injected microdose of 0.02 mg of ICG & will inject an additional 0.02mg every 5 minutes until a noticeable fluorescent change in the liver is observed. If a change is not observed after 0.14 mg has been injected then the microdosing regimen will stop. Output video from the cancer goggles will be recorded and saved for post-surgical analysis.~Following resection of the liver parenchyma, the portal area and the cut surface of the liver will be analyzed for the identification of bile ducts leaks with or without cancer goggles."
89386165|NCT02964234|Experimental|Empowerment|Behavior: Empowerment
89386166|NCT02964234|Experimental|Education|Behavior: Education
89386167|NCT03921255|Active Comparator|TAF Incongruent (TAF-INC)|Active condition (TAF-INC) cognitive bias modification for interpretations (CBM-I), incorporates an obsessional thought meant to elicit either moral or likelihood TAF, followed by a sentence incongruent to TAF bias and meant to reduce the impact of the previous statement. Before moving on, participants must fill-in and correctly solve a key word important in the interpretation of the sentence. Participants then must correctly solve a short yes/no comprehension question to ensure understanding of the scenario.
89386168|NCT03921255|Placebo Comparator|TAF Congruent (TAF-CON)|Maintenance/Control condition (TAF-CON) CBM-I, differs in that participants are provided with a sentence congruent with TAF bias. Again, participants were only able to move on when they correctly solved the key word and the accompanying yes/no comprehension question.
89386169|NCT03921255|Placebo Comparator|Stress Management Psychoeducation|In the stress management psychoeducation (SMP) psychoeducation about stress and stress management are provided, similar in length to the obsessional thought and interpretations presented in the TAF-INC and TAF-CON. Like the other conditions there is a key word to solve, and participants were only able to move on when they correctly solved the key word and the accompanying yes/no comprehension question.
89386170|NCT03645252|Active Comparator|Vein first|Tumor-draining pulmonary vein is interrupted first and before any surgical manipulation.
89386171|NCT03645252|Active Comparator|Arteries before vein|Lobar arteries (+/- bronchus and inter-lobar fissures) are interrupted before tumor-draining pulmonary vein.
89386172|NCT03645174|Active Comparator|Aintree catheter|Fiberoptic-guided intubation through LMA, using Aintree catheter
89386173|NCT03645174|Experimental|Long tube|Fiberoptic-guided intubation through LMA, using long tube
89386174|NCT03773328|Experimental|CK0801, 50ml|"All subjects will receive adoptive therapy with an infusion of unrelated cord blood-derived regulatory T cells: CK0801. Subjects will receive one 50mL intravenous dose of CK0801 (Treg cells) on study Day 0. A total of three cohorts will be evaluated.~Cohort dosing will be as follows:~Dose level 1 = 1x10e6/kg Treg cells per kg recipient ideal body weight (IBW); Dose level 2 = 3x10e6/kg Treg cells per kg recipient ideal body weight (IBW); Dose level 3 = 1x10e7/kg Treg cells per kg recipient ideal body weight (IBW)."
89386175|NCT03645018|Experimental|diagnosis with tomosynthesis (DTS)|"Single arm.~Population: Subjects enrolled in previously closed SOS trial (high risk subjects for lung cancer) without confirmed lung cancer."
89386176|NCT03644394|Other|Implantation|Surgical Implantation of IMES sensors
89386177|NCT05203809||Observation group|Group of participants wearing continuous temperature monitoring device
89386178|NCT03644940|Experimental|Subpopulation-specific Algorithm|
89386179|NCT03644940|No Intervention|Control Algorithm|
89386180|NCT03864081|Other|Enrolled Subjects (PSR)|Patients who meet the study's inclusion and exclusion criteria, including signing the informed consent form, subjects will undergo signal acquisition prior to their scheduled cardiac catheterization on the day of the procedure.
89386181|NCT01345188|Active Comparator|Ranolazine|1000 mg Ranexa orally once daily titrated as tolerated after 1 week up to taking 1000 mg twice daily.
89386182|NCT01345188|Placebo Comparator|Placebo|1000 mg placebo orally once daily titrated as tolerated after 1 week up to taking 1000 mg twice daily.
89386183|NCT03852459|Experimental|Active Arm|S-Ibuprofen Topical Gel 5%
89386184|NCT03852459|Placebo Comparator|Placebo Arm|Vehicle Topical Gel
89386185|NCT03580902|Active Comparator|Standard Buprenorphine|Participants assigned to this arm will received buprenorphine treatment consistent with standard practice at the study site. This includes induction by a physician, regular meetings with a physician for medical management, urine monitoring, and prescription of buprenorphine, with access to behavioral support services.
88861419|NCT00168324|Experimental|350 µg Dexamethasone followed by 700 µg Dexamethasone|350 µg dexamethasone intravitreal implant administered on Day 0 and 700 µg dexamethasone intravitreal implant on Day 180.
88861420|NCT00168324|Sham Comparator|Sham Injection followed by 700 µg Dexamethasone|Sham injection on Day 0 and 700 µg dexamethasone intravitreal implant on Day 180.
88861421|NCT00084552|Active Comparator|Arm I|Patients undergo conventional intensity-modulated radiotherapy (IMRT) once daily 5 days a week for approximately 7.5 weeks.
88861422|NCT00084552|Experimental|Arm II|Patients undergo IMRT with dose restriction to erectile tissue once daily 5 days a week for approximately 7.5 weeks.
89184745|NCT00584844|Experimental|F tularensis Vaccine (0.0025 mL)|Subjects receive a small amount of F tularensis vaccine (0.0025mL) placed on a cleansed site on the skin on the volar surface of the forearm. A bifurcated needle was used to make 15 superficial punctures at the vaccination site to permit percutaneous penetration of the vaccine.
89184746|NCT02587104|Experimental|EpiFix|Weekly application of EpiFix and standard of care (moist wound therapy and offloading)
89184747|NCT05068908||Low-impact chronic painful temporomandibular disorder (TMD) cases|Participants whose chronic painful TMD is determined to be low-impact. Visits include a standardized clinical examination using the Diagnostic Criteria for TMD (DC/TMD) protocol, psychosocial questionnaires completion, sensory and endogenous pain modulation (EPM) testing and a multi-modal Magnetic Resonance Imaging (MRI) data acquisition.
89184748|NCT05068908||High- impact chronic painful temporomandibular disorder (TMD) cases|Participants whose chronic painful TMD is determined to be high-impact. Visits include a standardized clinical examination using the Diagnostic Criteria for TMD (DC/TMD) protocol, psychosocial questionnaires completion, sensory and endogenous pain modulation (EPM) testing and a multi-modal Magnetic Resonance Imaging (MRI) data acquisition.
89184749|NCT05068908||Pain-free controls|Participants without chronic painful TMD. Visits include a standardized clinical examination using the Diagnostic Criteria for TMD (DC/TMD) protocol, psychosocial questionnaires completion, sensory and endogenous pain modulation (EPM) testing and a multi-modal Magnetic Resonance Imaging (MRI) data acquisition.
89184750|NCT05068908||Pilot study-MRI optimization group|"A pilot study will be conducted separately from the main project for optimization of MRI parameters, where up to five participants will be recruited as a separate group to undergo only MRI sessions (single study visit). The goal is to optimize the parameters of the main project's MR imaging protocol in order to minimize imaging distortions related to the presence of the thermodes in close proximity to the field of view for the brain."
89184751|NCT02587728||Carpal Tunnel Blood Draw|Participants with confirmed diagnosis of Carpal Tunnel Syndrome who will undergo blood draw for laboratory analysis for amyloidosis.
89184752|NCT00919464|Other|Needle Insertion into Femur|Data gathering with monitoring of pressures in the thigh via via needle in femur.
89184753|NCT00723333||Affected Group|Patients > 60 years of age with Primary Myelofibrosis that have undergone an allogeneic transplant
89184754|NCT05373693|Placebo Comparator|Control group|The subjects are randomized to wear SV lens
89184755|NCT05373693|Experimental|experimental group +2D|The subjects are randomized to wear special designed lens with +2D Peripheral Defocus.
89184756|NCT05373693|Experimental|experimental group +3D|The subjects are randomized to wear special designed lens with +3D Peripheral Defocus.
89184757|NCT05373693|Experimental|experimental group +4D|The subjects are randomized to wear special designed lens with +4D Peripheral Defocus.
89386186|NCT03580902|Experimental|Standard Buprenorphine plus CBT4CBT-Buprenorphine|Participants in this condition will receive Standard Buprenorphine as described above, with the addition of access to the CBT4CBT-Buprenorphine program, which is a web-based program that covers basic knowledge about buprenorphine treatment as well as teaches cognitive and behavioral coping skills.
89386187|NCT03744390|Experimental|AG-221|Subjects enrolled will receive continuous 28-day cycles of AG-221 - 100 mg.
89003316|NCT05451810|Experimental|Main Cohort: Epcoritamab Classic Follicular Lymphoma (cFL)|Participants with R/R cFL will receive SC epcoritamab in 28 day cycles.
89184758|NCT02570451||undergoing any elective SDA surgical procedure|500 patients Patient Survey Independent Activities of Daily Living Score Sheet Geriatric Depression Scale Short Form Activities of Daily Living Score Sheet Grip Strength Mini Cog RAND 36-Item Short Form Health Survey Confusion Assessment Method (CAM)
89184759|NCT02570451||scheduled for elective joint replacement surgery|Patient Survey Independent Activities of Daily Living Score Sheet Geriatric Depression Scale Short Form 211 patients Activities of Daily Living Score Sheet Grip Strength Mini Cog RAND 36-Item Short Form Health Survey Confusion Assessment Method (CAM)
89184760|NCT04018911|Active Comparator|Hearing Aid standard NR_1|Hearing Aid with standard Noise Reduction (NR) serves as reference condition.
89184761|NCT04018911|Experimental|Hearing Aid with NR_2|NR_2: Noise Reduction principle 2
89184762|NCT04018911|Experimental|Hearing Aid with NR_3|NR_3: Noise Reduction principle 3
89184763|NCT04018911|Experimental|Hearing Aid with NR_4|NR_4: Noise Reduction principle 4
89003317|NCT05451810|Experimental|Diversity Enriched Cohort: Epcoritamab DLBCL|Participants with R/R DLBCL will receive SC epcoritamab in 28 day cycles.
89003318|NCT05451810|Experimental|Diversity Enriched Cohort: Epcoritamab cFL|Participants with R/R cFL will receive SC epcoritamab in 28 day cycles.
89003319|NCT05450328|Placebo Comparator|Normal Saline|The control group will receive a saline solution (8mL) as a placebo, before CPB start.
89184764|NCT04070079|Other|Tenofovir Alafenamide|Tenofovir Alafenamide 25mg, Dosed orally, once daily with or without food.
89386188|NCT03644316|Experimental|BandGrip|Topical skin closure device
89386189|NCT03629145|Experimental|Live Music Therapy|Twenty minutes of live, preferred music played on guitar and voice
89386190|NCT03629145|Placebo Comparator|Recorded Music|Twenty minutes of recorded music, also on guitar and voice, previously recorded by investigator
89386191|NCT05759715||2-0 darkbown-green (2-0 bg)|Those with distinctively dark brown in the central area, slightly green in the peripheral area,
89386192|NCT05759715||1-0 lightbrown-green (1-0 bg).|Those with slightly dark brown in the central area and green in the peripheral area,
89386193|NCT05759715||dark brown (1-1 db)|Eyes with the same color structure in the central iris and the peripheral iris.
88861423|NCT02091882|Experimental|Aripiprazole IEM Tablet + Placebo IEM Tablet + MIND1 System|"Participants were placed a patch by the clinical staff prior to each ingestible event marker (IEM) tablet ingestion. Participants received one IEM tablet approximately every 2 hours, for a total of 4 ingestions on Day 1 at 0, 2, 4 and 6 hours.~Following placement of the patch by clinic staff, participants ingested one 10 mg aripiprazole-embedded IEM tablet without food at Hour 0, one placebo-embedded IEM tablet without food at approximately Hour 2, one placebo-embedded IEM tablet with a high fat meal at approximately Hour 4, and one placebo-embedded IEM tablet without food at approximately Hour 6. Clinic staff recorded the time of each ingestion of an IEM and the time detected by MIND1 System."
88861424|NCT00085254|Experimental|Arm 1 (Safety Run In)|"INITIATION COURSE: Patients receive cilengitide IV over 1 hour on days 1 and 4. Treatment repeats weekly for 10 weeks. Patients also receive oral temozolomide and undergo radiotherapy one hour later on days 1-5 of weeks 1-6.~MAINTENANCE COURSES: Patients receive oral temozolomide once daily on days 1-5 in courses 1-6. Patients also receive cilengitide IV on days 1, 4, 8, 11, 15, 18, 22, and 25. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Doses of cilengitide: 500mg, 1000mg and 2000mg~Temozolimide, Radiation Therapy, laboratory biomarker analysis, pharmacological study"
88861425|NCT00085254|Experimental|Phase II (Arm1-500mg)|"INITIATION COURSE: Patients receive cilengitide (500mg) IV over 1 hour on days 1 and 4. Treatment repeats weekly for 10 weeks. Patients also receive oral temozolomide and undergo radiotherapy one hour later on days 1-5 of weeks 1-6.~MAINTENANCE COURSES: Patients receive oral temozolomide once daily on days 1-5 in courses 1-6. Patients also receive cilengitide IV (500mg) on days 1, 4, 8, 11, 15, 18, 22, and 25. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~cilengitide, Temozolimide, Radiation Therapy, laboratory biomarker analysis, pharmacological study"
88861426|NCT00085254|Experimental|Phase II (Arm 2 -2000mg)|"INITIATION COURSE: Patients receive cilengitide (2000mg) IV over 1 hour on days 1 and 4. Treatment repeats weekly for 10 weeks. Patients also receive oral temozolomide and undergo radiotherapy one hour later on days 1-5 of weeks 1-6.~MAINTENANCE COURSES: Patients receive oral temozolomide once daily on days 1-5 in courses 1-6. Patients also receive cilengitide IV (2000mg) on days 1, 4, 8, 11, 15, 18, 22, and 25. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~cilengitide,Temozolimide, Radiation Therapy, laboratory biomarker analysis, pharmacological study"
88861427|NCT01897272||Splinting After Surgery|This group will be fitted for a splint and given instructions on wearing their splint after their short-incision Carpal Tunnel Release
88861428|NCT01897272||No Splinting After Surgery|This group will not be splinted after the short-incision carpal tunnel release
88861429|NCT00253890|Active Comparator|Trazodone|50-150mg (50mg capsules) at bedtime for 90 days
88861430|NCT00253890|Placebo Comparator|Placebo|1-3 capsules at bedtime for 90 days
88861431|NCT00254592|Experimental|AC with GM-CSF and Carboplatin/Nab-Paclitaxel|"Doxorubicin and cyclophosphamide (AC) administered intravenously every 14 days up to a total of 4 cycles, with GM-CSF on days 4-13, depending on tumor response.~Two weeks after the completion of AC, weekly doses of carboplatin/nab-paclitaxel will be given for 3 weeks, followed by 1 week of rest, for a total of 9-12 doses. Subjects who receive 4 cycles of AC will receive 9 doses of nab-paclitaxel and subjects who receive 2 cycles of AC will receive 12 weeks of nab-paclitaxel. In addition, subjects will receive trastuzumab weekly (12-16) doses if they are Her-2 positive and bevacizumab (6-8) doses every 2 weeks if they are Her-2 negative. Each clinic visit will last approximately ½ hour."
88861432|NCT00255684|Experimental|Conditioning therapy followed by TBI|Fludarabine, Cyclophosphamide; Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil
88861433|NCT00256776|Experimental|Thal + Dex + Velcade|
88861434|NCT00256776|Active Comparator|Thal + Dex|Standard treatment
88861435|NCT00257322|Experimental|GM-CSF|Granulocyte-macrophage colony-stimulating factor (GM-CSF) 250ug/m^2 SQ QD with a cap of 500mcg SQ QD
88861436|NCT00258180|Experimental|severe autoimmune enteropathy|Young patients with severe autoimmune enteropathy receive cyclophosphamide IV over 1 hour on days 1-4. Patients then receive filgrastim (G-CSF) IV or subcutaneously once daily beginning on day 10 and continuing for 3 days or until blood counts recover
88861437|NCT01899222||fundus imaging|retinal photograph obtained at visit
88861438|NCT00176202|Active Comparator|Risperidone|Risperidone is an antimanic medication and is a second generation antipsychotic
89386194|NCT05759715||light brown (1-1 lb)|Eyes with the same color structure in the central iris and the peripheral iris.
89386195|NCT05759715||dark brown (2-0 b)|Those with distinctively dark brown in the central iris area compared to the periphery .
89386196|NCT05759715||slightly dark brown (1-0 b)|Those with slightly dark brown (1-0 b) in the central iris area compared to the periphery .
89386197|NCT03644784||Yamaguchi University Hospital|
89386198|NCT03644784||Erasmus Medical Center|
88861439|NCT00176202|Active Comparator|Divalproex sodium|Divalproex sodium is an antiepileptic medication and is a mood stabilizer
88861440|NCT00176592|Active Comparator|Betaseron|Betaseron 250 micrograms SQ every other day and Triple-Dose Gadolinium at each MRI
88861441|NCT00176592|Active Comparator|Copaxone|Copaxone 20 mg daily SQ and Triple-Dose Gadolinium at each MRI
88861442|NCT00176826|Experimental|Intent-To-Treat|Patients who were treated with chemotherapies (myeloablative conditioning regimen) and stem cell transplant. Busulfan intravenously for 4 days followed by cyclophosphamide intravenously for 4 days. Rabbit ATG is given intravenously for 4 doses pre-transplant.
88861443|NCT00176904|Experimental|Treated Patients|All patients treated with protocol regimen (chemotherapy and surgery).
88861444|NCT00179478|Experimental|Immediate Treatment Group|Initiation of treatment with Interferon Beta 1a IM once weekly immediately after onset of a first demyelinating syndrome in high risk individuals
89386199|NCT03644784||Academic Medical Center - Amsterdam|
89386200|NCT03644784||Segeberger Kliniken Gruppe|
89386201|NCT03644784||McGill University - Montreal|
89386202|NCT05283798|Experimental|rate of missed threads in the first 6 weeks|To compare efficacy safety & side effects of multiload 375 IUD versus copper T 380 IUD when inserted during elective CS
89386203|NCT05283798|Other|number of bleeding days in first 6 weeks|compare numbers of bleeding days in first 6 weeks and first 6 month
89386204|NCT02896296|Experimental|RBP-6000 (100/300 mg Flex)|"On Day 1 of the study all eligible subjects received a single subcutaneous (SC) injection of RBP-6000. Participants returned to the site for monthly injection visits every 28 days (-2/+7 days) for a total of up to 6 injections. Participants were not required to complete all 6 injections and could choose to terminate from the study at any time.~For each injection, participants could receive either a dose of 100 mg RBP-6000 or 300 mg RBP-6000, based on the medical judgement of the investigator."
89386205|NCT03643614|Experimental|study group|Injection of autologous regenerative cells of adipose tissue for treatment of radiation induced rectovaginal fistulas
89386206|NCT05262348|Active Comparator|Phase 1a - conventional stimulation|Stimulation will be delivered bilaterally to the STN or the GPi. The stimulation parameters will be based upon standard practice by the neurologist.
89386207|NCT05262348|Experimental|Phase 1b - adaptive stimulation|Stimulation will be delivered bilaterally to the STN or the GPi, with the neurologist-set therapeutic window (which corresponds to the upper and lower limits for aDBS amplitude). The stimulation will be automatically adapted according to the personalized algorithm based on real time LFP analysis.
89386208|NCT03643536|Experimental|12-WPEP in subjects with reduce LVEF|Intervention: a 12 week physical exercise program in the health-related quality of life of CABG or PCI subjects with LVEF by 2D-echocardiography between 30-54%. The quality of life was measured using SF-36 questionnaire
89386209|NCT03643536|Active Comparator|12-WPEP in subjects with normal LVEF|Intervention: a 12 week physical exercise program in the health-related quality of life of or PCI subjects with LVEF by 2D-echocardiography≥ 55% (control group)The quality of life was measured using SF-36 questionnaire
89386210|NCT03643458||Transfused infants|Preterm infants undergone red blood cell transfusion during hospital stay.
89386211|NCT03740919|Active Comparator|Insulin Lispro (Humalog)|Participants received 100 units per milliliter (U/mL) insulin lispro (Humalog) administered subcutaneously (SC), 0 to 2 minutes before each meal with once or twice daily basal insulin. Preprandial insulin doses were individualized and titrated according to protocol-defined targets.
89386212|NCT03740919|Experimental|LY900014|Participants received 100 U/mL LY900014 administered SC, 0 to 2 minutes before start of the meal.
89386213|NCT03740919|Experimental|LY900014 Postmeal|Participants received 100 U/mL LY900014 administered SC, up to 20 minutes after the start of the meal.
89386214|NCT01335685|Experimental|Arm A: Ixazomib 3.0 mg|Ixazomib 3.0 mg, capsules, orally, on Days 1, 4, 8, 11, 22, 25, 29, 32 plus melphalan 9 mg/m^2, tablets, orally on Days 1 to 4 and prednisone 60 mg/m^2, tablets, orally on Days 1 to 4 in 42-day cycle for up to 9 cycles in induction phase followed by ixazomib at dose last tolerated in induction, orally, on Days 1, 8, 15 in 28-day cycle for up to 12 cycles or until disease progression or unacceptable toxicity if deriving benefit in maintenance phase (up to 23 maintenance cycles; overall up to 32 cycles [34 months]).
89386215|NCT01335685|Experimental|Arm A: Ixazomib 3.7 mg|Ixazomib 3.7 mg, capsules, orally, on Days 1, 4, 8, 11, 22, 25, 29, 32 plus melphalan 9 mg/m^2, tablets, orally on Days 1 to 4 and prednisone 60 mg/m^2, tablets, orally on Days 1 to 4 in 42-day cycle for up 9 cycles in induction phase followed by ixazomib at dose last tolerated in induction, orally, on Days 1, 8, 15 in 28-day cycle up to 12 cycles or until disease progression or unacceptable toxicity if deriving benefit in maintenance phase (up to 10 maintenance cycles; overall up to 19 cycles [21 months]).
89386216|NCT01335685|Experimental|Arm B: Ixazomib 3.0 mg|Ixazomib 3.0 mg, capsules, orally, on Days 1, 8, 15 plus melphalan 6 mg/m^2, tablets, orally on Days 1 to 4 and prednisone 60 mg/m^2, tablets, orally on Days 1-4 in 28-day cycle for up to 13 cycles in induction phase followed by ixazomib at dose last tolerated in induction, orally, on Days 1, 8, 15 in 28-day cycle up to 12 cycles or until disease progression or unacceptable toxicity if deriving benefit in maintenance phase (up to 15 maintenance cycles; overall up to 27 cycles [25 months]).
89386217|NCT01335685|Experimental|Arm B: Ixazomib 4.0 mg|Ixazomib 4.0 mg, capsules, orally, on Days 1, 8, 15 cycle plus melphalan 6 mg/m^2, tablets, orally on Days 1 to 4 and prednisone 60 mg/m^2, tablets, orally on Days 1-4 in 28-day cycle for up to 13 cycles in induction phase followed by ixazomib at dose last tolerated in induction, orally, on Days 1, 8, 15 in 28-day cycle up to 12 cycles or until disease progression or unacceptable toxicity if deriving benefit in maintenance phase (up to 49 maintenance cycles; overall up to 61 cycles [58 months]).
89386218|NCT01335685|Experimental|Arm B: Ixazomib 5.5 mg|Ixazomib 5.5 mg, capsules, orally, on Days 1, 8, 15 plus melphalan 6 mg/m^2, tablets orally on Days 1 to 4 and prednisone 60 mg/m^2, tablets, orally on Days 1-4 in 28-day cycle for up to 13 cycles in induction phase followed by ixazomib at dose last tolerated in induction, orally, on Days 1, 8, 15 in 28-day cycle up to 12 cycles or until disease progression or unacceptable toxicity if deriving benefit in maintenance phase (up to 12 maintenance cycles; overall up to 24 cycles [24 months]).
89386219|NCT01335685|Experimental|Arm C: Ixazomib 3.0 mg|Ixazomib 3.0 mg, capsules, orally, on Days 1, 8, 15, 22, and 29 plus melphalan 9 mg/m^2, tablets orally on Days 1 to 4 and prednisone 60 mg/m^2, tablets, orally on Days 1 to 4 in 42-day cycle for up to 9 cycles in induction phase followed by ixazomib at dose last tolerated in induction, orally, on Days 1, 8, 15 in 28-day cycle up to 12 cycles or until disease progression or unacceptable toxicity if deriving benefit in maintenance phase (up to 30 maintenance cycles; overall up to 39 cycles [40 months]).
89386220|NCT01335685|Experimental|Arm C: Ixazomib 4.0 mg|Ixazomib 4.0 mg, capsules, orally, on Days 1, 8, 15, 22, and 29 plus melphalan 9 mg/m^2, tablets, orally on Days 1 to 4 and prednisone 60 mg/m^2, tablets, orally on Days 1 to 4 in 42-day cycle for up to 9 cycles in induction phase followed by ixazomib at dose last tolerated in induction, orally, on Days 1, 8, 15 in 28-day cycle up to 12 cycles or until disease progression or unacceptable toxicity if deriving benefit in maintenance phase (up to 12 maintenance cycles; overall up to 21 cycles [24 months]).
89386221|NCT01335685|Experimental|Arm D: Ixazomib 4.0 mg|Ixazomib 4.0 mg, capsules, orally, on Days 1, 8, 22, and 29 plus melphalan 9 mg/m^2, tablets, orally on Days 1 to 4 and prednisone 60 mg/m^2, tablets, orally, on Days 1 to 4 in 42-day cycle for up to 9 cycles in induction phase followed by ixazomib at dose last tolerated in induction, orally, on Days 1, 8, 15 in 28-day cycle up to 12 cycles or until disease progression or unacceptable toxicity if deriving benefit in maintenance phase (up to 28 maintenance cycles; overall up to 37 cycles [38 months]).
89184765|NCT00739934|Experimental|Children aged 2 to <12 years|Immunocompromised children aged 2 to <12 years who are at high risk for systemic fungal infection.
88861445|NCT00179478|Active Comparator|Delayed Treatment Group|Delayed initiation of of Interferon beta-1a IM once weekly at diagnosis of clinically definite MS, at conclusion of initial CHAMPS study or during long term observation
89386222|NCT01335763|Other|Insulin glargine|10 units at bedtime of insulin glargine will be prescribed to the patients who has HbA1c levels of 7.5-11%. Insulin glargine dose is going to be titrated by increments of 1 unit daily by the patient to achieve a morning fasting glucose of <=5.5mmol/L
89386223|NCT01339507||Bepreve|Subjects with a history of allergic conjunctivitis.
89386224|NCT01339507||Lastacaft|Subjects with a history of allergic conjunctivitis.
88861446|NCT02134782|Experimental|Individualized Yoga Intervention Group|Yoga will be administered individually by a trained yoga instructor, and offered daily for 21 days (5 days per week or 15 days in total). There will be a common structure for all sessions that will include relaxation and breathing exercises. Additional poses focused on strength, flexibility, and balance will be incorporated at low, moderate or high intensity levels based upon the wishes and abilities of the child and parent and the judgment of the yoga instructor. The target intensity will be documented and may change with each yoga session. Each yoga session will vary in duration between 15 and 45 minutes. Modifications will be made to accommodate devices such as central venous lines, particularly if accessed. For children who are in isolation, the research team will follow hospital policies and procedures.
88861447|NCT02134782|Active Comparator|iPad Activity Control Group|For those randomized to the control group, visits by the same yoga instructors will occur at the same schedule as the yoga intervention. Contact will be offered daily (5 days per week) for 21 days. The yoga instructor will offer games, music, movies or books on a study-supplied iPad. The instructor will offer to interact with the child (for example, read to, or play games with the child) for a maximum of 45 minutes (the maximum length of yoga sessions). This approach will allow us to control for contact frequency and the individual providing contact, and consequently, to better measure the independent effect of yoga. These children will not receive yoga during the 3 week iPad activity period; instructors will receive specific training to ensure that no yoga occurs during this time frame. Use of child or hospital supplied iPad activities will be permitted instead of the study-supplied iPad activities.
88861448|NCT00182754|Experimental|Arm I|Patients receive octreotide subcutaneously (SC) once on day 1.
89184766|NCT00713505|Experimental|Arm I (parent intervention program and usual care)|Child participants and their families may access multidisciplinary psychosocial services (i.e., usual care). Parents also receive 8 weekly face-to-face training sessions (75-90 minutes each) with a therapist over approximately 2-3 months. Phone support/assistance is provided by the therapist within 2-3 days following each training session and then every 2 weeks for up to 6 months after completion of the training sessions.
89386225|NCT02926209|Active Comparator|Aer-O-Scope First|Patients in this arm will undergo colonoscopy using the Aer-O-Scope followed by colonoscopy using a conventional colonoscope
89386226|NCT02926209|Active Comparator|Conventional Colonoscope First|Patients in this arm will undergo colonoscopy using a conventional colonoscope followed by colonoscopy using the Aer-O-Scope
89386227|NCT04466163|Experimental|Schema Therapy and the Healthy Adult|For this study the ST-HA protocol outlined by Broersen & Claassen (2019) will be followed, consisting of ten one-and-a-half hour individual sessions across ten weeks with daily homework assignments (30-60 minutes). The ST-HA protocol is based on three pillars, aimed at improving self-compassion, well-being and positive affect. First psycho-education about compassionate affect regulation is given and patients learn to recognize the importance of self-caring behavior in stimulating the soothing- affect system to buffer against stress. The second pillar of the ST-HA protocol concerns the development of personal values and committed action as well as getting insight in values of important others. The third pillar concerns developing self-compassion
88861449|NCT00182754|Placebo Comparator|Arm II|Patients receive placebo SC once on day 1.
89184767|NCT00713505|Active Comparator|Arm II (wait-list/usual care control [UCC])|Child participants and their families undergo usual care as in arm I and are placed on a wait-list.
89184768|NCT02586948|Experimental|extracorporeal CO2 removal|extracorporeal CO2 removal initiated shortly after intubation, using the veno-venous Hemolung device
89184769|NCT00723411|Active Comparator|A|This arm will receive 2 subcutaneous injections with 20 µg Diamyd on Days 1 and 30, i.e., 1 prime and 1 booster dose, followed by 2 additional single doses with Diamyd 20 µg on Days 90 and 270.
89184770|NCT00723411|Active Comparator|B|This arm will receive 2 subcutaneous injections with 20 µg Diamyd on Days 1 and 30, i.e., 1 prime and 1 booster dose, followed by 2 additional single doses with placebo on Days 90 and 270.
89184771|NCT00723411|Placebo Comparator|C|This arm will receive 4 injections of placebo, 1 each on Days 1, 30, 90, and 270.
89184772|NCT02586558|Active Comparator|Experimental Infant Formula|Milk-based infant formula with prebiotics
89184773|NCT02586558|Placebo Comparator|Reference group|Milk-based infant formula without prebiotics
89184774|NCT02586636|Other|OCT1 -/-|Cohort of patients with two loss of function alleles for OCT1. The participants within this group will receive metformin at increasing dose to a maximum tolerated dose over two distinct four week treatment periods. The concurrent treatment order of omeprazole and placebo will be randomised within the cohort.
89386228|NCT04466163|No Intervention|Baseline|Outcome variables will be measured repeatedly in a pre-treatment baseline condition (2-5 weeks). Patients are randomly assigned to a pre-treatment/baseline phase. In the present study a restricted randomisation is chosen (Heyvaert & Onghena, 2014a). A minimum length of the phases is decided a priori in order to prevent for the assignment of too few measurements per phase and to ensure that the full treatment protocol can be offered
89386229|NCT03635671||Intensified blood glucose control|Patients with diabetes mellitus type 2 and poor blood sugar control that are introduced to insulin or GLP-1 therapy
89386230|NCT03635671||Nephropathy|Patients that are introduced to hemodialysis or renal transplantation secondary to renal failure
89386231|NCT04462965|Experimental|Test group|Toripalima Combined with Temozolomide and Cisplatin. Toripalima3 mg/kg intravenous infusion, administered once every 2 weeks (1 treatment cycle every 2 weeks) for a maximum of 1 year. Temozolomide, Oral 200mg/m2 1-5 days and Cisplatin, Iv infusion 25 mg/m2/d for a period of 1 to 3 days, 28 days for 1 cycle, lasting 6 cycles;
89386232|NCT04462965|Placebo Comparator|Placebo group|Placebo Combined with Temozolomide and Cisplatin. Toripalima3 mg/kg intravenous infusion, administered once every 2 weeks (1 treatment cycle every 2 weeks) for a maximum of 1 year. Temozolomide, Oral 200mg/m2 1-5 days and Cisplatin, Iv infusion 25 mg/m2/d for a period of 1 to 3 days, 28 days for 1 cycle, lasting 6 cycles;
89386233|NCT01339585|Experimental|Timing of tDCS|
89386234|NCT01339585|Experimental|Alternative timing of tDCS|
89386235|NCT04004325|Experimental|Cohort A|
89386236|NCT04004325|Experimental|Cohort B|
89386237|NCT05185063||Out of Hospital Cardiac Arrest|
88861450|NCT00183456|Experimental|Intervention Condition: CHAT|Participants received the program over the course of five small group sessions and one individual session based on a harm reduction philosophy. Participants were trained as Peer Mentors and were encouraged to talk to their family, friends, and sex partners about a range of sex risk reduction options.
88861451|NCT00183456|Active Comparator|Comparison Condition: Standard of Care|The comparison condition consisted of one group session. The session focused on HIV and STIs transmission and risk reduction information.
88861452|NCT00183456|No Intervention|Network Participants|Index participants generated a list of network members during their baseline visits and were asked to recruit eligible network members into the study. These network participants completed study interviews but did not participate in the intervention.
88861453|NCT00183456|No Intervention|Non-randomized Baseline index participants|This arm includes those index participants that did not show up for randomization or did not recruit a network member were thus not eligible to be randomized into a study condition.
88861454|NCT00184548|Experimental|rFVIIa, Blunt Trauma|
88861455|NCT00184548|Placebo Comparator|Placebo, Blunt Trauma|
89386238|NCT01339663|Experimental|Treatment (dose-escalation, T-APC boost, CTL)|"INFUSION I: Patients receive high-dose cyclophosphamide IV on day days -4 and -3 and low-dose IL-2 SC BID on days 0-14. Patients also receive CTL IV on day 0.~INFUSION II: Beginning 6-48 hours later, patients receive high-dose cyclophosphamide, low-dose IL-2, and CTL as in Infusion I. Patients also receive T-APC vaccine IV within 18-36 hours following CTL infusion and in week 4, and IL-2 SC BID on days 0-14 following second T-APC vaccination."
88861456|NCT00184548|Experimental|rVIIa, Penetrating Trauma|
88861457|NCT00184548|Placebo Comparator|Placebo, Penetrating Trauma|
88861458|NCT00085410|Experimental|Arm I|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11.
89386239|NCT03066999|Active Comparator|Cystoscopy|will have catheter placement using the cystoscopy method
89386240|NCT03066999|Active Comparator|DirectVision|will have catheter placement using DirectVision.
89386241|NCT01335841|Experimental|3D fluoroscopy and navigation station|
89386242|NCT01335841|Active Comparator|2D and anatomical landmarks|
89386243|NCT03737565||Coronary Artery Disease|
89386244|NCT02889133|Active Comparator|Iron repletion|Subjects will donate blood donation and undergo 24-hour PTR and receive IV iron-dextran. After 5 months, subjects will donate blood again, receive IV saline and undergo 24-hour PTR.
89386245|NCT02889133|Placebo Comparator|Placebo|Subjects will donate blood donation and undergo 24-hour PTR and receive IV saline. After 5 months, subjects will donate blood again, receive IV iron-dextran and undergo 24-hour PTR.
89386246|NCT01333423|Experimental|Doxil + Seliciclib|Doxil (Liposomal doxorubicin) 40 mg/m2 intravenous (IV) over 2 -3 hours on Day 4 and Seliciclib starting dose 200 mg orally twice a day on Days 1 - 3 of 28 day cycle
89535258|NCT02488031|Experimental|Best Medical Management|The participants in the best medical management group will undergo identical testing sessions (two visits one month apart) as those in the error-reducing group but will not receive the 4-week error reducing intervention. They will be administered the International Cooperative Ataxia Rating Scale (ICARS) and the Scale for the Assessment and Rating of Ataxia (SARA) assessments and the following tests: Purdue Pegboard, Brief Test of Attention, 6-minute Walk, Hand Grip Dynamometer, Physical Performance Function, Digit Span, SARA, Montreal Cognitive Assessment, Beck Depression Inventory 2nd Ed, Stroop and biomechanical gait. Biomechanical assessments of dysmetria and neurophysiological assessment of brain activity will be conducted at both visits.
89535259|NCT03082911|Experimental|Phone call|"A brief telephone intervention at the same time of sending the invitation letter plus the habitual invitation process used in the screening program (described in control group).~Calls will be made by the administrative staff of the Screening Technical Office, which is experienced in telephone attention.~Each phone call will last approximately 5 minutes."
89535260|NCT03082911|Active Comparator|Standard procedure|The habitual invitation strategy used in the screening program . Three letters are send by post: 1- An invitation letter plus an information leaflet and a list of pharmacies in which people can obtain the screening test. 2- A reminder letter for those who have not participated after 5 weeks of sending the first letter. 3- A second reminder letter for those who have collected the kit in the pharmacy but have not returned it with the sample.
89535261|NCT03227341|Other|patients with uncontrolled asthma.|8 week pulmonary rehabilitation program
89535262|NCT03227341|Other|patients with partially controlled asthma|8 week pulmonary rehabilitation program
89535263|NCT04410861|Active Comparator|Minimal Micropulse Arm|"Wavelength 810 577 Power 0.75 W 0.15 W DC 5% 5% Spot size 125um 100um Duration 0.3 sec 0.3 sec Number of spots 100-120 100-120~."
89535264|NCT04410861|Experimental|Panmacular Micropulse Arm|Wavelength 810 577 Power 1.7 W 0.425 W DC 5% 5% Spot size 500um 500um Duration 0.3 sec 0.3 sec Number of spots 400-450 400-450
89535265|NCT02488265|Experimental|Motor training|Balance training, Screening to prevent falls
89535266|NCT02488265|Experimental|Balance RhytmicalTraining|Balance training, Screening to prevent falls
88861459|NCT00186498|Placebo Comparator|Placebo Oral Capsule|Patients received a placebo capsule starting the day before ECT begins and while receiving ECT
88861460|NCT00186498|Experimental|memantine|Patients receive memantine starting the day before ECT begins and while receiving ECT
88861461|NCT00265200|Experimental|zoledronic acid|3.0-4.0 mg by IV (in the vein), once a month for 6 months
88861462|NCT00087672|Experimental|CC-5013|
89386247|NCT03554187|Experimental|Lactibiane Buccodental, probiotics|"For one tablet : Lactobacillus paracasei LA 802 (109 UFC), Vitamine D3 (1,5 µg), Vitamine C (24 mg) Dosage : 2 tablets daily for 6 weeks tablet to suck after the meal and brushing teeth (one in the morning and one in the evening)~Interventions :~Ultrasonic periodontal debridement, with appropriate device : D+1 / Analyzes of periodontopathogenic bacteria : D-14, D+1, D+45, D+90 / IL1B test : D-14 / Salivary sampling : D+1, D+45, D+90 / Halitosis measure : D+1, D+45, D+90"
89184775|NCT02586636|Other|OCT wt/wt|"Cohort of patients with two normal or wild type alleles for OCT1. The participants within this group will receive metformin at increasing dose to a maximum tolerated dose over two distinct four week treatment periods. The concurrent treatment order of omeprazole and placebo will be randomised within the cohort."
88861463|NCT00265512|Active Comparator|Telephone Case Monitoring Aftercare|Telephone Case Monitoring Aftercare
88861464|NCT00265512|Active Comparator|Continuing Care as Usual|Continuing Care as Usual
88861465|NCT00265980|No Intervention|Weight initial|Subjects undergo studies at their usual body weight which is used as a baseline against which to compare subjects following weight loss with or without leptin repletion.
88861466|NCT00265980|Placebo Comparator|Weight -10% placebo|Subjects are studied while at a 10% reduced body weight and receiving placebo injections for 5 weeks.
89386248|NCT03554187|Placebo Comparator|Placebo|"With no metabolic action ; identical in appearance to experimental probiotics Dosage : 2 placebo tablets daily for 6 weeks tablet to suck after the meal and brushing teeth (one in the morning and one in the evening)~Intervention(s) :~Ultrasonic periodontal debridement, with appropriate device : D+1 / Analyzes of periodontopathogenic bacteria : D-14, D+1, D+45, D+90 / IL1B test : D-14 / Salivary sampling : D+1, D+45, D+90 / Halitosis measure : D+1, D+45, D+90"
88861467|NCT00265980|Experimental|Weight -10% leptin|Subjects are studied while at a 10% reduced body weight and receiving leptin injections for 5 weeks.
88861468|NCT00187200|Active Comparator|Simultaneous VV Pacing|Programmed to simultaneous biventricular pacing
88861469|NCT00187200|Active Comparator|Sequential VV Pacing|Programmed to sequential biventricular pacing
88861470|NCT00088218|Active Comparator|Clofarabine|Clofarabine intravenous (IV) 30 mg/m^2 daily times 5 days
88861471|NCT00088218|Active Comparator|Clofarabine Plus Ara-C|Clofarabine IV 30 mg/m^2 daily times 5 days + Ara-C 20 mg/m^2 subcutaneously daily times 14 days.
88861472|NCT00189228|Experimental|xolair|This is a single arm, parallel study examining differences of therapeutic outcomes of Xolair. Xolair is being examined as an intervention that might change the outcome of immunization.
89184776|NCT00739310|Experimental|Vest Treatment (HFCWO)|Patients will receive Vest treatments for airway clearance therapy 2 x daily for 12 months. These data will be compared to 12 months of data prior to Vest initiation.
89184777|NCT04089644|Active Comparator|manual group|Hypotension will be corrected by manual infusion of norepinephrine
89184778|NCT04089644|Experimental|closed-loop group|Hypotension will be corrected by closed-loop control of norepinephrine infusion
89184779|NCT00713739|Experimental|1|Alfuzosin 10mg daily
89184780|NCT00713739|Active Comparator|2|Nifedipine XL 30mg daily
89184781|NCT00713739|Active Comparator|3|Doxazosin 4 mg daily
89184782|NCT00713739|Active Comparator|4|Prazosin 1 mg BID
89189395|NCT05810636||ADHD group|"Inclusion criteria:~DSM-5 Attention-deficit hyperactivity disorder~7~18 years old~Willing to carry smartwatch and smartphone most of the time during one-month study period~Exclusion criteria:~- Comorbid with major psychiatric disorders (i.e., schizophrenia, bipolar disorder) or neurodevelopmental disorders (i.e., intellectual disability, autism spectrum disorder)"
89386249|NCT01333579|Active Comparator|Active rTMS|1Hz active rTMS delivered to the unaffected hemisphere
89386250|NCT01333579|Placebo Comparator|Placebo rTMS|1Hz placebo rTMS delivered to the vertex
89386251|NCT04399473||Control group: Usual PT Care|
89386252|NCT04399473||Experimental group: PNE + Usual PT Care|Participants in this arm will receive PNE education in addition to Usual PT Care
89386253|NCT01339741|Active Comparator|Vitamin D|
89386254|NCT01339741|Placebo Comparator|Placebo|
89386255|NCT05184829|Active Comparator|systemic lymph node dissection group|systemic lymph node dissection group
89386256|NCT05184829|Experimental|selective lymph node dissection|selective lymph node dissection
88861473|NCT00091260|Experimental|revlimid|lenalidomide 15 mg/day, for 21 days with 7 days rest (28 day cycle) with or without dexamethasone 20 mg daily (10 mg BID) on Days 1-4, 9-12, and 17-20 of every other 28-day cycle.
89386257|NCT01482195|Experimental|Subretinal Injection of rAAV2-VMD2-hMERTKRecombinant Adeno-Associated Virus|Single arm of 6 patients undergoing subretinal injection of Gene Therapy using rAAV2-VMD2-hMERTKRecombinant Adeno-Associated Virus. Each patient received the injection in one eye.
89386258|NCT01482195|No Intervention|fellow eye without intervention|fellow eye without intervention
89386259|NCT01341613|Experimental|Cardioviva™ supplement capsule|
89386260|NCT01341613|Placebo Comparator|Placebo capsule|
89386261|NCT01339819|Experimental|Arm 1|Dabigatran Therapy
89386262|NCT01339819|Active Comparator|Arm 2|Phenprocoumon Therapy
89386263|NCT05208255|Experimental|Exercise Group1|"The telerehabilitation-based neurocognitive exercise group~6 weeks, 2 sessions per week Session duration: 60 minutes"
89386264|NCT05208255|Experimental|Exercise Group2|"The telerehabilitation-based neurocognitive exercise+motor imagery training group~6 weeks, 2 sessions per week Session duration: 60 minutes (45 minutes-neurocognitive exercise; 15 minutes-motor imagery training)"
89386265|NCT05208255|Active Comparator|Control Group|"The medication group - Participants who voluntarily participated in the study but did not want to participate in exercise groups.~6 weeks of medication use"
89386266|NCT02963922|Experimental|liraglutide 3.0 mg|
89386267|NCT02963922|Placebo Comparator|Placebo|
89386268|NCT01339975||Group A. Surgically treated patients|Patients having a radical or partial nephrectomy.
89386269|NCT01339975||Group B. Patients treated with targeted therapies|Patients treated by RCC-directed targeted therapy
89386270|NCT01340131|Experimental|CKD-828(Fixed Dose Combination)|Single oral dose of a FDC tablet consisting of Telmisatan 40mg/S-Amlodipine 5mg Intervention
89386271|NCT01340131|Active Comparator|Free combination Therapy|Co-administration of single oral doses of a 40mg tablet of Telmisatan and a 5 mg tablet of S-Amlodipine
89386272|NCT01335919||Neonate|Subjects admitted for surgery or to the pediatric intensive care unit (PICU) or neonatal intensive care unit (NICU) who require daily and/or multiple blood samples for hemoglobin measurement.
89386273|NCT05207787|Experimental|Multiple doses of HS-10365 and 160mg BID (recommended Phase 2 dose)|Phase 1 : Multiple doses of HS-10365 for oral administration. Phase 2 : 160 mg BID of HS-10365
89386274|NCT03643380|Experimental|Investigational SNS device|
89386275|NCT01336075|Active Comparator|Mini invasive thoracoscopic radiofrequency ablation|Video-assisted thoracoscopic radiofrequency ablation
88861474|NCT00193128|Experimental|Cohort 1|"Oxaliplatin 40 mg/m2 intravenously (IV) over 2 hours and docetaxel 20 mg/m2 IV over 30 minutes on days 1, 8, 15, 22, and 29. Radiation therapy began concurrently with day 1 of chemotherapy at a dose of 1.8 Gy/d Monday through Friday to a total of 45 Gy (25 fractions).~Patients were to have esophageal resection after completion of preoperative therapy during weeks 9 to 12 and after all treatment-related side effects were resolved."
88861475|NCT00193128|Experimental|Cohort 2|"Oxaliplatin 40 mg/m2 intravenously (IV) over 2 hours and docetaxel 20 mg/m2 IV over 30 minutes on days 1, 8, 15, 22, and 29. Capecitabine was administered 1000 mg/m2 orally twice daily on days 1 to 7, 15 to 21, and 29 to 35. Radiation therapy began concurrently with day 1 of chemotherapy at a dose of 1.8 Gy/d Monday through Friday to a total of 45 Gy (25 fractions).~Patients were to have esophageal resection after completion of preoperative therapy during weeks 9 to 12 and after all treatment-related side effects were resolved."
88861476|NCT00193596|Experimental|Regimen A|"Paclitaxel 200 mg/m2 by 1-hour IV infusion, day 1~Carboplatin area under the curve (AUC) 6.0 IV, day 1~Etoposide 50 mg alternating with 100 mg by mouth, days 1 and 10~Regimen A was repeated at a 21-day interval"
89189396|NCT05810636||Neurotypical group|"Inclusion criteria:~7~18 years old without a diagnosis of Attention-deficit hyperactivity disorder~Willing to carry smartwatch and smartphone most of the time during one-month study period~Exclusion criteria:~Have a diagnosis of major psychiatric disorders (i.e., schizophrenia, bipolar disorder) or neurodevelopmental disorders (i.e., intellectual disability, autism spectrum disorder)~Unable to use smartwatch and smartphone"
89386276|NCT01336075|Active Comparator|Percutaneous ablation|Percutaneous radiofrequency catheter ablation
89386277|NCT05214261|Experimental|TAP block group|Patiens undergo laparoscopic-guided TAP block installation for laparoscopic clolorectal surgery
89386278|NCT05214261|Active Comparator|Epidural analgesia group|Patients undergo epidural catheters placement for laparoscopic colorectal surgery
89386279|NCT03644238|Experimental|Experimental intervention|Oral Glucose Tolerance Test and physical activity
88861477|NCT00193596|Experimental|Regimen B|"Irinotecan 100 mg/m2 IV, days 1 and 8~Gemcitabine 1000 mg/m2 IV, days 1 and 8~Regimen B was repeated at a 21-day interval"
88861478|NCT01899378|Experimental|daily probiotic|10^8 CFU Lactobacillus reuteri DSM 17938 and 10^9 Bifidobacterium longum infantis daily for one month
88861479|NCT01899378|Experimental|weekly probiotic|10^8 CFU Lactobacillus reuteri DSM 17938 and 10^9 Bifidobacterium longum infantis weekly for one month
88861480|NCT01899378|Experimental|bi-weekly probiotic|10^8 CFU Lactobacillus reuteri DSM 17938 and 10^9 Bifidobacterium longum infantis bi-weekly for one month
88861481|NCT01899378|No Intervention|control|
89386280|NCT03644238|Other|Control intervention|Oral Glucose Tolerance Test and inactivity.
89386281|NCT03619785|Experimental|Experimental (SAPB)|Patients randomized to the experimental arm receive an ultrasound-guided serratus anterior plane block for their rib fracture pain.
89386282|NCT03619785|Active Comparator|Control|Patients randomized to the control arm receive usual pain control treatment in the emergency department.
89386283|NCT03643302||Therapy of bronchoalveolar lavage group|Patients with bronchiectasis exacerbations treat with fundamental treatment combining with the therapy of airway clearance and bronchoalveolar lavage.
89386284|NCT03643302||Fundamental treatment group|In the control group,fundamental treatment was adopted according to the guidelines
89386285|NCT02881567|Experimental|Daclizumab|
89386286|NCT02962674|Other|Treatment|
89386287|NCT03280797|Other|Control|
89386288|NCT03280797|Other|Rheumatoid arthritis patients|
89386289|NCT05184595|Active Comparator|Carfilzomib delivered in OH only|"Patients receive the whole treatment in OH. Primary and secondary endpoints are collected at day 1 of cycle 3, 6, 9, 12, 18 and one month after.~Patients leave the protocol prematurely due to treatment failure, toxicity or patient wishes. For those patients, the end of study visit will be done one month after ending treatment."
89535267|NCT03208309|Active Comparator|Diacerein|Diacerein 50 mg immediate release capsule, once daily for the starting 28 days and Diacerein 50 mg immediate release capsule twice a day for the remainder of the study.
89535268|NCT03208309|Placebo Comparator|Placebo|Placebo capsules once a day for the starting 28 days and two times daily for the remainder of the study.
89535269|NCT02488187|Other|ABUS vs MRI (ultrasound when indicated)|To compare the overall sensitivity and specificity of ABUS versus MRI (and hand-held breast ultrasound when clinically indicated) for the ipsilateral and contralateral breast in newly diagnosed breast cancer patients.
89386290|NCT05184595|Experimental|Carfilzomib delivered in OH and HaH combined|"Patients receive the first cycle of treatment in OH. Then, they are randomized between exclusive OH treatment and combined treatment in OH and at home with HaH services.~For the HaH patients group, the first injection of each cycle is delivered in OH. The rest of the cycle is delivered at home by HaH after a clinical examination (by nurse or general practitionner).~Primary and secondary endpoints are collected at day 1 of cycle 3, 6, 9, 12, 18 and one month after.~Patients leave the protocol prematurely due to treatment failure, toxicity or patient wishes. For those patients, the end of study visit will be done one month after ending treatment."
89386291|NCT05213793||ischemic stroke|The cohort includes patients with acute stroke who underwent CTP, multi-delay ASL, DWI, CTA or TOF-MRA scanning.All patients will be examined within 24 hours of onset. CBF, CBV, MTT and Tmax cerebral blood flow parameter images of CTP will be obtained. CBF, CBV and ATT cerebral blood flow parameter images in multi-delay ASL will be obtained by the quantitative evaluation system. The volume of reversible ischemic tissue will be calculate according to CTP and multi-delay ASL respectively.
89386292|NCT03643068|Experimental|KSP-QRH-E3-IRDye800 (Peptide 919288G) 0.6 mg subjects 1-3|The first three subjects will receive lyophilized powder reconstituted with 5 mL of 0.9% NaCl, 0.6 mg of KSP-QRH-E3-IRDye800 (Peptide 919288G) total. For the first three subjects, 3.34 mL of KSP-QRH-E3-IRDye800 (Peptide 919288G)will be discarded. The 1.66 mL of KSP-QRH-E3-IRDye800 (Peptide 919288G)remaining in the syringe will be administered by squirting it into the mouth of the subject.
89386293|NCT03643068|Experimental|KSP-QRH-E3-IRDye800 (Peptide 919288G) 1.8 mg subjects 4-25|Following a safety review of the first three subjects receiving 0.6 mg dose, the remaining 22 subjects will receive the full 1.8 mg dose of KSP-QRH-E3-IRDye800 (Peptide 919288G) reconstituted in 5 mL 0.9% NaCl. These 22 subjects will receive all 5 mL of the peptide solution in a syringe for administration. The agent will not be reconstituted until the subject is ready to squirt the peptide into his or her mouth via syringe. They will be asked to wait 5 minutes and then drink at least 4-8 oz of tap water.
89386294|NCT05184517|Experimental|Arm I|Oph1 0.5% CsA ophthalmic formulation followed by Restasis 0.05% CsA ophthalmic formulation
89386295|NCT05184517|Experimental|Arm II|Restasis 0.05% CsA ophthalmic formulation followed by Oph1 0.5% CsA ophthalmic formulation
89386296|NCT05207475|Experimental|RIC group|RIC treatment and regular treatment.
89386297|NCT05207475|No Intervention|Regular treatment|Regular treatment alone.
89386298|NCT03644628|Active Comparator|Sacropexy group (SCP)|Anterior and apical repair with laparoscopic sacropexy
89386299|NCT03644628|Experimental|Lateral suspension group (LLS)|Anterior and apical repair with laparoscopic lateral suspension
88861482|NCT01899534|No Intervention|Paper-based screening|Paper-based screening. Women will complete a mental health screening tool on paper (usual care).
88861483|NCT01899534|Experimental|E-screening|Women will complete mental health screening on a tablet
88861484|NCT00091962|Experimental|Depressed Intervention|Telephone-based, nurse-delivered Collaborative Care program for depression; Involving: Psychoeducation; workbook for depression self-care; initiation or adjustment of antidepressant pharmacotherapy prescribed under their PCPs' direction; referral to mental health specialist
88861485|NCT00091962|Active Comparator|Depressed Usual Care|"Usual care for depression; feedback of the depression finding by the study team"
88861486|NCT00091962|No Intervention|Non-Depressed Control Group|Non-depressed control group
88861487|NCT00194532|Experimental|Cefpodoxime|Cefpodoxime 100mg twice a day(BID)for 3 days
88861488|NCT00194532|Active Comparator|Ciprofloxacin|Ciprofloxacin 250mg twice a day (BID)for 3 days
88861489|NCT00194610|Experimental|Botox injection|Subjects were injected with Botulinum toxin A in a mix of 50 U diluted in 2 cubic centimeters of normal saline. With the subjects in the dorsal lithotomy position, one injection of 25 international units was given into the bladder neck at the 3 o'clock position and another of 25 international units was given into the 9 o'clock position
88861490|NCT00194610|Placebo Comparator|Normal saline|Subjects were injected in the bladder neck with 1 cubic centimeter normal saline into the 3 o'clock and 6 o' clock positions in the perineum, while in the dorsal lithotomy position
88861491|NCT00093756|Experimental|Treatment (bortezomib, paclitaxel, carboplatin)|"PHASE I: Cohorts of 3-6 patients receive escalating doses of study medications until the maximum tolerated dose (MTD) is determined. PHASE II: Patients receive as in phase I at the MTD. Patients also undergo radiotherapy as in phase I.~3-dimensional conformal radiation therapy bortezomib: Given IV paclitaxel: Given IV carboplatin: Given IV"
88861492|NCT04389138|No Intervention|Comparison|In this arm participants will attend 3 study visits to complete study questionnaire and assessments. In between these visits, participants will be asked to wear an activity monitor and record an activity diary for one week. Other than this, participants will continue to receive only standard of care treatment.
88861493|NCT04389138|Experimental|Intervention arm|In this arm participants will attend the same 3 study visits to complete study questionnaires and assessments. Participants will be asked to wear an acitvity monitor and record an activity diary for one week after the study visits. In between baseline and 6 month follow up, intervention arm participants will receive study physiotherapy. This will consist of an individual assessment and 4 additional sessions of physiotherapy.
88861494|NCT04145154|Experimental|Plasma|Subjects to whom platelet rich plasma is applied
88861495|NCT04145154|No Intervention|Advanced cure|Subjects to whom advanced healing is performed
89184783|NCT04081662|Experimental|compACT Intervention|"At every time-point of the study, participants will complete self-reports of stress, (as measured by the PSS-4) distress (as measured by the PHQ-2), and activity through the mobile app Lorevimo. After completing these assessments, participants will be randomly assigned to either receive one additional ACT-based microintervention question or receive no additional question.~The microintervention will consist of one of 84 prompts that aim to target one of 6 processes targeted in ACT (contacting the present moment, defusion, acceptance, self-as-context, values, and committed action).~The ACT-based questions were developed by the research team as a unique intervention for the current study. They are based upon core themes of acceptance and commitment therapy: engagement, awareness, and openness."
89184784|NCT03971006||Immunocompetent ARDS patients|(n=50) Patients with moderate-to-severe pneumonia-associated Acute Respiratory Distress Syndorme (ARDS) and no immunosuppression (excluding patients with HIV infection, solid tumor or hematological malignancies, organ transplant or taking steroids since more than 4 weeks).
89184785|NCT03971006||Immunosuppressed ARDS patients|(n=50) Patients with moderate-to-severe pneumonia-associated Acute Respiratory Distress Syndorme (ARDS) (Berlin definition (2)) and previously known immunosuppression (as listed above). These patients will allow comparing the cell defects observed in the study population to those observed in immunosuppressed patients.
89184786|NCT03971006||Controls|(n=10) Patients undergoing a bronchoscopy with Bronchoalveolar Liquid (BAL) as part of routine care but having neither ARDS nor active lung infection, infiltrating lung disease or immunosuppression. These patients will allow quantifying normal levels of the studied biomarkers in the alveolar and blood compartments.
88861496|NCT04118556|Experimental|Decidua Stroma Cells (DSC)|"Placenta derived decidua stroma cells (DSC). In the first phase I part, two different dose levels will be used, 1x10^6/kg and 3x10^6/kg. Two doses, one week apart, will be given. The decision to proceed to the next dose level will depend on results observed at the previous dose level.~The dose in the randomized part will be based on the findings in the phase I part. In the Phase II study all patients will receive 2 doses, one week apart. Depending on response, up to 6 doses in total may be given. Additional doses (beyond the first 2 doses) may be given one week apart until response."
88861497|NCT04118556|Active Comparator|Best Available Treatment (BAT)|The BAT in this study will freely be identified by the Investigator prior to patient randomization and may include treatments such as: anti-thymocyte globulin (ATG), extracorporeal photopheresis (ECP), low-dose methotrexate (MTX), mycophenolate mofetil (MMF), mTOR inhibitors (everolimus or sirolimus), etanercept, vedolizumab, ruxolitinib or infliximab. Dose and frequency will depend on label (where approved) and institutional guidelines for various BAT.
88861498|NCT00267696|Experimental|Gemcitabine/carboplatin/bevacizumab|A regimen consisting of gemcitabine(1000 mg/m2)/carboplatin(AUC 3) / bevacizumab(Avastin®)(10mg/kg) will be administered on day 1 and day 15 of a 28 day cycle.
88861499|NCT00267774|Experimental|FFR guided PCI|
88861500|NCT00267774|Active Comparator|Angio-guided PCI|
88861501|NCT00195624|Experimental|Relapsed severe aplastic anemia|Subjects diagnosed with relapsed severe aplastic anemia
88861502|NCT00195624|Experimental|Refractory severe asplastic anemia|Subjects diagnosed with refractory severe aplastic anemia
88861503|NCT00195624|Experimental|Relapse after Alemtuzumab|Subjects who relapse after initial response to alemtuzumab therapy will have cyclosporine added to the regimen after the 6 month visit.
88861504|NCT00195702|Experimental|DB adalimumab 20 mg ew|Subjects received 20 mg adalimumab subcutaneously (SC) once weekly (ew) and concomitant methotrexate (MTX) during the double-blind (DB) phase.
88861505|NCT00195702|Experimental|DB adalimumab 40 mg eow|Subjects received 40 mg adalimumab subcutaneously (SC) every other week (eow) and concomitant methotrexate (MTX) during the double-blind (DB) phase. Subjects received placebo injections SC and concomitant MTX on the alternate weeks during the DB phase.
88861506|NCT00195702|Placebo Comparator|DB placebo ew|Subjects received placebo subcutaneously (SC) once weekly (ew) and concomitant methotrexate (MTX) during the double-blind (DB) phase.
88861507|NCT00195702|Experimental|DB adalimumab 20 mg ew/OL adalimumab 40 mg eow|Subjects received adalimumab 20 mg subcutaneously (SC) once weekly (ew) during the double-blind (DB) phase, then adalimumab 40 mg SC every other week (eow) during the open-label (OL) extension phase, along with concomitant methotrexate (MTX).
88861508|NCT00195702|Experimental|DB adalimumab 40 mg eow/OL adalimumab 40 mg eow|Subjects received adalimumab 40 mg subcutaneously (SC) every other week (eow) with placebo on alternate weeks during the double-blind (DB) phase, then adalimumab 40 mg SC eow during the open-label (OL) extension phase, along with concomitant methotrexate (MTX).
88861509|NCT00195702|Experimental|DB placebo ew/OL adalimumab 40 mg eow|Subjects received placebo subcutaneously (SC) once weekly (ew) during the double-blind phase, then adalimumab 40 mg SC every other week (eow) during the open-label (OL) extension phase, along with concomitant methotrexate (MTX).
88861510|NCT00196716|Experimental|Fabrazyme|Open-label study. Patients received 1.0 mg/kg Fabrazyme every two weeks for approximately six months followed by 0.3 mg/kg Fabrazyme every two weeks for approximately 18 months.
88861511|NCT00197184|Experimental|Twinrix Junior|Subjects previously received 3 doses of combined hepatitis A / hepatitis B vaccine (junior formulation).
88861512|NCT00197184|Active Comparator|Twinrix Adult|Subjects previously received 2 doses of combined hepatitis A / hepatitis B vaccine (adult formulation).
88861513|NCT00198042|Experimental|Surgical Reconstruction of the ACL|
89184787|NCT05373069|Experimental|Group intervention|PIM - DIEP
89184788|NCT02595476|Experimental|BIS 55|"Induction:~TCI propofol (6 µg/ml) - remifentanil (4 ng/ml) Atracurium IV (0.5 mg/kg)~Orotracheal Intubation~Remifentanil target decreased to 1 ng/ml~Propofol target adjustment to reach BIS 55~10 minutes steady state~Tetanic stimulation (ulnar nerve): 100 Hz, 60 milliamps, 5 seconds~Pupillary dilation recording (videopupillometer Algiscan)"
89184789|NCT02595476|Active Comparator|BIS 25|"Induction:~TCI propofol (6 µg/ml) - remifentanil (4 ng/ml) Atracurium IV (0.5 mg/kg)~Orotracheal Intubation~Remifentanil target decreased to 1 ng/ml~Propofol target adjustment to reach BIS 25~10 minutes steady state~Tetanic stimulation (ulnar nerve): 100 Hz, 60 milliamps, 5 seconds~Pupillary dilation recording (videopupillometer Algiscan)"
89184790|NCT00723567||Affected Group|Family members of northern European descent in which members have different erythrocyte morphology ranging from atypical HPP to HE to normal and a novel Sp mutation.
89184791|NCT02586402|Experimental|Pegolsihematide|Participants received Pegolsihematide by intravenous injection once every 4 weeks ; the dose was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 grams per deciliter (g/dL).
89184792|NCT02586402|Active Comparator|Epoetin Alfa|Epoetin Alfa administration 1 to 3 times per week. The dose was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 g/dL.
89184793|NCT00713895|Active Comparator|Standard Self-Help|receive a standard self-help manual in Chinese and English of the participants' choice at baseline
89184794|NCT00713895|Experimental|Expert System|receive an expert system intervention that included the Pathway-To-Change self-help manual and a series of 3 individualized feedback reports at baseline, 3, and 6 months.
89184795|NCT00734630|Active Comparator|Nebivolol|Nebivolol 5 mg, 5 mg nontrade tablets, oral administration Nebivolol 10 mg, 10 mg nontrade tablets, oral administration Nebivolol 20 mg, 20 mg nontrade tablets, oral administration Nebivolol 40 mg (two 20 mg nontrade tablets), oral administration
89184796|NCT00734630|Placebo Comparator|Placebo|Matching placebo tablets, oral administration
89184797|NCT02570997|Active Comparator|CT1812|"In cohorts 1-6, 8 subjects will be enrolled. 6 subjects will receive CT1812. Doses will be escalated in the following sequence: 10mg, 30mg, 90mg, 180mg, 360mg, 650mg.~Should an MTD not be identified, additional cohorts at higher doses may be enrolled. The maximum dose administered will not exceed 1350mg."
88861514|NCT00201240|Experimental|CD34+ selection with CliniMACS device|T cell depletion using Miltenyi device
89184798|NCT02570997|Placebo Comparator|Matching Placebo|In cohorts 1-6, 8 subjects will be enrolled. 6 subjects will receive matching placebo.
89184799|NCT00713973||1|Submitted to the American protocol for prophylaxis of deep vein thrombosis
89184800|NCT00713973||2|Submitted to the Brazilian protocol for prophylaxis of deep vein thrombosis
89184801|NCT00713973||3|Submitted to the SBCP modified protocol for prophylaxis of deep vein thrombosis
89184802|NCT02570529|Experimental|Albis®|The intervention group
89184803|NCT02570529|Placebo Comparator|Placebo|The placebo comparator group
89184804|NCT05372835|Experimental|mouthwash|The 15 mL of commercially available La Chlogen mouthwash (Republic of China Patent No. M616466) was used for intervention to rinse in mouth for 5 minutes. The main ingredient in the mouthwash is low-concentration high-purity HOCl (100 ppm) solution.
89184805|NCT05372835|Experimental|mouthwash and periodontal flosser|The 15 ml of commercially available La Chlogen mouthwash (Republic of China Patent No. M616466) in conjunction with the La Chlogen periodontal flosser (Republic of China Patent No. M590033) were used for intervention in the mouth for 5 minutes. The main ingredient in the mouthwash is low-concentration high-purity HOCl (100 ppm) solution.
88861515|NCT00098670|Experimental|Treatment (alemtuzumab, rituximab, fludarabine phosphate)|"Patients receive induction therapy comprising rituximab IV over 4 hours on days 1, 3, and 5 of course 1 and day 1 of all subsequent courses and fludarabine IV over 30 minutes on days 1-5. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression.~Approximately 4 months after completion of induction therapy, patients achieving a partial response, nodular partial response, or stable disease receive consolidation therapy comprising alemtuzumab subcutaneously on days 1-3. Treatment repeats weekly for up to 6 courses in the absence of disease progression."
88861516|NCT00099372||Abdominal Sacral Colpopexy with no Burch colposuspension|Participants had an Abdominal Sacral Colpopexy without Burch colposuspension for treatment of pelvic organ prolapse
88861517|NCT00099372||Abdominal Sacral Colpopexy with Burch Colposuspension|Participants had an Abdominal Sacral Colpopexy with Burch colposuspension for treatment of pelvic organ prolapse
88861518|NCT04098588|Experimental|BEAST|There are 3 parts to BEAST. Part 1 involves the Behavioral Nudge technique using previously collected injunctive and descriptive norms from a National Guard sample. Soldiers will be given a customized feedback form that shows norms relevant to the target behavior they selected. The soldier will be given a chance to ask any follow-up questions. Part 2 of the intervention focuses on the principle of targeting others, considering how a change would impact those closest to them. Part 3 will utilize the Reciprocal Concessions procedure combined with the Reducing Barriers technique.
88861519|NCT04098588|Active Comparator|Descriptive Feedback|This condition will involve a presentation of descriptive data based on the soldiers' tests scores and an opportunity to ask any follow-up questions. This process is a component of some behavioral change interventions (e.g., motivational interviewing); therefore this should be a more useful control condition (mirroring parts 1 and 2 of the active condition) versus a more passive or waitlist control condition. Participants in the control condition will also be given standard referral information to the USM Psychology Clinic (mirroring part 3 of the active condition).
88861520|NCT00100230|Experimental|1.|Oral Docosahexaenoic acid, dosage based on body weight
88861521|NCT00100230|Placebo Comparator|2|corn/soy oil placebo; oil not containing DHA...dosage based on body weight
88861522|NCT00201864|Experimental|single-arm study|Combination of daily exemestane 25 mg with monthly 250 mg Fulvestrant injection
88861523|NCT00202722|Active Comparator|Remifentanil IVPCA|Bolus dose steps of 0.15 microgr/kg, with a 2-min lock-out time
88861524|NCT00100698|Active Comparator|1|recombinant human growth hormone subcutaneously once a day
88861525|NCT00100698|Placebo Comparator|2|placebo subcutaneously once a day
88861526|NCT00103116|Experimental|Autologous dendritic cell cancer vaccine|Open label nonrandomized
88861527|NCT00205374|Active Comparator|Cidofovir|"Cidofovir (Vistide) is a commercially available agent approved by the FDA for the treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS). The drug is not FDA approved for the treatment of RRP at this time. However, recent case reports have been encouraging with regard to the effectiveness of the agent in the treatment of RRP. The FDA has granted this study a safe to proceed designation with IND 58,481."
88861528|NCT00205374|Placebo Comparator|Placebo|On the baseline study day, patients will be randomized into either a treatment group (cidofovir injection) or a placebo group. A restricted randomization procedure, in groups of 4, will be used to encourage uniformity in sample sizes between groups.
88861529|NCT00103194|Experimental|Treatment (lapatinib ditosylate)|Patients receive lapatinib ditosylate PO daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88861530|NCT00277524||Overall|All patients enrolled in OMNI. Patient sub-groups include device type, history of atrial fibrillation (AF), history of investigate atrioventricular (AV) block, implant indication, and managed ventricular pacing (MVP) enabled.
88861531|NCT00278538|Experimental|Hematopoietic Stem Cell Transplant Regimen 2|Autologous Hematopoietic Stem Cell Transplantation: Rituximab, rATG and Cyclophosphamide regimen
88861532|NCT00208026|Experimental|Pimecrolimus 1% Cream|Treatment with drug/Elidel. Single arm-open-label treatment arm. A Pilot Study of the Efficacy and Safety of Pimecrolimus Cream 1% for the Treatment of Netherton Syndrome:
88861533|NCT00208494|Active Comparator|A|Ceramic-on-metal total hip implant
88861534|NCT00208494|Active Comparator|B|Metal-on-metal total hip implant
88861535|NCT00106392|Experimental|Tacrolimus|Preoperatively: Tacrolimus 2 mg oral daily from 4 to 10 days prior to surgery through hospital discharge; Postoperatively: Tacrolimus 3 mg oral daily at time of hospital discharge through 6 months of follow up.
88861536|NCT00106392|Placebo Comparator|Placebo|Preoperatively: Matching placebo oral daily from 4 to 10 days prior to surgery through hospital discharge; Postoperatively: Matching placebo oral daily at time of hospital discharge through 6 months of follow up.
88861537|NCT00211692|Active Comparator|Group A consensus interferon+rbv 52 wks|Daily CIFN (15 mcg/day SQ) and RBV (1-1.2 g/d PO) given 52 weeks (group A)
88861538|NCT00211692|Experimental|Group B CIFN variable duration|CIFN (15 mcg/day SQ) and RBV (1-1.2 g/d PO) given for 52-72 weeks (from time of viral response +48 weeks) (group B)
88861539|NCT01899690|Experimental|antibiotic|7 days of preventive antibiotics after surgery
88861540|NCT01899690|No Intervention|No antibiotic|No preventive postoperative antibiotics
88861541|NCT01897584|Experimental|Inverse IE|in only one group, inspiration to expiration ratio 1:2 to 1:1 will be applied during pneumoperitoneum
88861542|NCT01899846|Experimental|Cohort 1|Hydroxyprogesterone caproate 250 mg/ml. Detailed pharmacokinetic evaluation following first dose
88861543|NCT01899846|Experimental|Cohort 2|Hydroxyprogesterone caproate 250 mg/ml. Detailed pharmacokinetic evaluation 24 - 28 weeks gestation
88861544|NCT01899846|Experimental|Cohort 3|Hydroxyprogesterone caproate 250 mg/ml. Detailed pharmacokinetic evaluation 32 - 36 weeks gestation
88861545|NCT00214890|Active Comparator|Tenofovir|As part of this study visit, you participants will be assigned by chance to receive either TDF alone or ABC alone
88861546|NCT00214890|Active Comparator|Abacavir|As part of this study visit, you participants will be assigned by chance to receive either TDF alone or ABC alone
88861547|NCT00216060|Experimental|Experimental Arm|Daily oral risedronate combined with androgen deprivation
88861548|NCT00216060|Placebo Comparator|Placebo Arm|daily oral placebo combined with androgen deprivation
88861549|NCT00106938|Active Comparator|1|"CAS group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).~Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years."
89184806|NCT05372835|Placebo Comparator|control|The pure water without HOCl chemical was applied in this intervention to rinse in mouth for 5 minutes.
88861550|NCT00106938|Active Comparator|2|"CEA group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).~Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years."
88861551|NCT02100072|Experimental|Nd:YAG 1440 nm laser|
88861552|NCT00110136|Experimental|St. John's Wort|Patient given one 300mg St. John's Wort tablet three times per day
88861553|NCT00282672|Sham Comparator|LGD Sham Procedure first then LGD Radiofrequency Ablation|"Sham procedure plus anti-secretory medication. Subjects with Low Grade Dysplasia (LGD) receive proton pump inhibitor (PPI) with dose of Esomeprazole 40 mg BID.~At 12 month, subjects crossover to receive radiofrequency ablation."
89386300|NCT01336153|Experimental|MLC601|MLC601 (NeuroAideTM) is a TCM which is used extensively in China to improve recovery after stroke. It combines several herbal and animal components.
89386301|NCT01336153|Placebo Comparator|Placebo|
89386302|NCT03629067|Experimental|Sequence A|"Period 1(Treatment R) - Period 2(Treatment R) - Period 3(Treatment T)~There will be a 14 washout of days between the each period."
88861554|NCT00282672|Active Comparator|LGD:Radiofrequency ablation|Ablation System plus anti-secretory medication. Subjects with Low Grade Dysplasia (LGD) undergo an upper endoscopy with sizing of the esophageal diameter followed by radiofrequency ablation plus standard anti-secretory therapy (proton pump inhibitor, PPI-dose: Esomeprazole 40 mg BID.)
88861555|NCT00282672|Sham Comparator|HGD Sham Procedure first then HGD Radiofrequency Ablation|"Sham procedure plus anti-secretory medication. Subjects with High Grade Dysplasia (HGD) with proton pump inhibitor (PPI) dose: Esomeprazole 40 mg BID.~At 12 month, subjects crossover to receive radiofrequency ablation."
89386303|NCT03629067|Experimental|Sequence B|"Period 1(Treatment R) - Period 2(Treatment T) - Period 3(Treatment R)~There will be a 14 washout of days between the each period."
89386304|NCT03629067|Experimental|Sequence C|"Period 1(Treatment T) - Period 2(Treatment R) - Period 3(Treatment R)~There will be a 14 washout of days between the each period."
89386305|NCT03644082|Experimental|Epilepsy Patients|
89386306|NCT01340287|Active Comparator|1 = Tested product|
89386307|NCT01340287|Sham Comparator|2 = Control product|
89386308|NCT05207319|Experimental|the MRDI group (Moral Reasoning Development Intervention)|The MRDI is comprised of 4 components that are run concurrently: moral reasoning, strategies of anger management and problem-solving and social skills.
89386309|NCT05207319|No Intervention|the control group|The control group is the Treatment as Usual (TAU).
89386310|NCT01341691|Placebo Comparator|Placebo 20mg|
89386311|NCT01341691|Active Comparator|K2CG 60 mg extender|
88861556|NCT00282672|Active Comparator|HGD:Radiofrequency ablation|Ablation System plus anti-secretory medication. Subjects with High Grade Dysplasia (HGD) undergo an upper endoscopy with sizing of the esophageal diameter followed by radiofrequency ablation plus standard anti-secretory therapy (proton pump inhibitor, PPI-dose: Esomeprazole 40 mg BID.)
88861557|NCT00282828|Experimental|Sertraline & Clonazepam|"Phase I non-responders randomized to this group remained on sertraline at the same dose level as at entry into Phase 2 with the addition of clonazepam up to 3.0mg per day.~Dosing was flexible, permitting clinicians to slow or suspend the titration of the medication because of side effects or response, but patients had to receive no less than 0.5mg of clonazepam per day in order to remain in the study."
88861558|NCT00282828|Experimental|Venlafaxine|"Phase I non-responders randomized to this group switched to venlafaxine with flexible titration up to 225 mg per day.~Dosing was flexible, permitting clinicians to slow or suspend the titration of the medication because of side effects or response, but patients had to receive no less than 75 mg venlafaxine per day in order to remain in the study."
88861559|NCT00282828|Experimental|Sertraline & Placebo|"Phase I non-responders randomized to this group remained on sertraline at the same dose level as at entry into Phase 2 with the addition of placebo.~Dosing was flexible, permitting clinicians to slow or suspend the titration of the medication because of side effects or response, but patients had to receive no less than 1 capsule of placebo per day in order to remain in the study."
89386312|NCT01341691|Active Comparator|K2CG 60 mg|
89386313|NCT01341691|Active Comparator|K2CG 20mg extender|
89386314|NCT01341691|Active Comparator|K2CG 20mg|
89386315|NCT01341691|Placebo Comparator|Placebo 60mg|
89386316|NCT05213403||Patient G1|Correlation between surgery and scoring system
89386317|NCT05213403||Patients G2|Incongruence between surgery and scoring system
89386318|NCT05213325||Cases|Children with acute diarrhea
89386319|NCT05213325||Control|Healthy control children
89386320|NCT03166371|Experimental|Liposomal Glutathione (GSH)|Participants will be randomized to receive two teaspoons containing 840 mg GSH (420 mg/tsp) twice daily for 90 days after discharge from Emory University Hospital (EUH).
88861560|NCT00112242|Experimental|1. Melan-A ELA|500 mcg Melan-A ELA analog peptide + 1 ml Montanide ISA-51
89386321|NCT03166371|Placebo Comparator|Placebo|Participants will be randomized to receive a placebo product identical to liposomal glutathione (GSH) twice daily for 90 days after discharge from Emory University Hospital (EUH).
89386322|NCT05207241||Control group|Under the professional guidance of doctors, participating women (1) breastfeed individually without using a breast pump; (2) massage their breasts 4 times a day for 15 minutes each time; (3) breastfeeding time is scientifically matched with infant's schedule; (4) alternative breastfeed, ensuring emptying one breast within 24 hours. Doctors follow up once a month via WeChat. Participants complete the questionnaires. A breast ultrasound will be performed every three months. The infant weight will be measured and recorded 6 months after breastfeeding
88861561|NCT00112242|Experimental|2. Melan-A ELA + NY-ESO-1b + MAGE-A10|500 mcg Melan-A ELA analog peptide + 500 mcg NY-ESO-1b(A) analog peptide + 500 mcg MAGE-A10 peptide + 1 ml Montanide ISA-51
89386323|NCT02962908|Experimental|Group 1|(n=74): FLU-v on Day 0 and Day 21
89386324|NCT02962908|Experimental|Group 2|(n=74): adjuvanted FLU-v on Day 0, saline (0.5mL) on Day 21
89386325|NCT02962908|Placebo Comparator|Group 3|(n=37): saline solution (0.5ml) on Day 0 and Day 21
89386326|NCT02962908|Placebo Comparator|Group 4|(n=37): Adjuvanted placebo on Day 0, saline (0.5mL) on Day 21
89386327|NCT03642756|Placebo Comparator|20 gauge|
89386328|NCT03642756|Active Comparator|22 gauge|
89386329|NCT03642756|Active Comparator|24 gauge|
89386330|NCT02962284|Experimental|YONSA with Methylprednisolone|Aberaterone Acetate 500 mg (4 x 125 mg qd) with Methylprednisolone (4 mg bid)
89386331|NCT03642600|Active Comparator|dietary advice plus myo-inositol and folic acid|2gram myo-inositol and folic acid twice daily orally lack of consistent evidence for myo-inositol as treatment of women with PCOS
89386332|NCT03642600|Active Comparator|dietary advice plus liraglutide pen injector|liraglutide starting at 0.6 mg, gradually increasing up to a dose of 3 mg daily after four weeks no evidence for weight loss in women with PCOS
89386333|NCT03642522|Experimental|1 Hz rTMS|30 minutes of 1 Hz rTMS to the right dorsolateral prefrontal cortex (R_DLPFC)
89386334|NCT03642444|Active Comparator|Phase A cane walking (assistive walking-device a cane)|9-12 weeks usual cane-walking to establish baseline values. Patients walk with their usual assistive-walking device - a cane.
89386335|NCT03642444|Active Comparator|Phase B elasticated orthotic-garment - TheraTogs|9-19 weeks : assistive walking-device which is an elasticated orthotic-garment worn throughout the day (product name TheraTogs). Cane use maximally reduced during his period.
89386336|NCT03642444|No Intervention|Phase C follow-Up|9-10 weeks individually determined follow-up: subjects determine whether they walk independently (without assistive device) or with the elasticated orthotic-garment (TheraTogs) or with a cane.
89386337|NCT03642288|Experimental|CRE-induced SBO|Patients with CRE-induced SBO received GG challenge.
89386338|NCT03642288|Active Comparator|ASBO|Patients with adhesive SBO (ASBO) received GG challenge.
89386339|NCT03641352|Experimental|CKD-501 0.5mg|CKD-501 0.5mg
89386340|NCT03641352|Placebo Comparator|Placebo|Placebo
89386341|NCT03641274||Frequent users of emergency departement|FUEDs receiving the CM intervention in sites participating in the research project will be assessed over time on clinical variables (see inclusion and exclusion criteria)
89386342|NCT03644004||Women with medical history of gestational diabetes|Patients followed at the hospital of Vienne for gestational diabetes in 2016.
89386343|NCT03621384||Bb Genotype|Subjects with Bb genotype of BsmI polymorphisms in vitamin D receptor gene
89386344|NCT03621384||bb Genotype|Subjects with bb genotype of BsmI polymorphisms in vitamin D receptor gene
89386345|NCT03643926|Experimental|Arthroscopic Brostrom|
89386346|NCT03643926|Active Comparator|Open Brostrom|
89386347|NCT03640884||Xueshuantong-Injection|Patients who received the Xueshuantong-Injection for treatment will be consecutive included in this registry. The investigators will record all the information about ADR, application of Xueshuantong-Injection and the combined medications, etc.
89386348|NCT03641040|Experimental|VOG group|Measurement: Video-oculography(VOG) measure and analyze angles of ocular deviations between dominant and non-dominant eye using VOG with alternate cover.
88861562|NCT00112242|Experimental|3. Melan-A ELA + NY-ESO-1b + MAGE-A10 + CpG|500 mcg Melan-A ELA analog peptide + 500 mcg NY-ESO-1b(A) analog peptide + 500 mcg MAGE-A10 peptide + 1 ml Montanide ISA-51 + 2.5 mg CpG-7909/PF-3512676
89386349|NCT03641040|Active Comparator|APCT group|Measurement: Alternative prism cover test(APCT) measure and analyze angles of ocular deviations between dominant and non-dominant eye using APCT
89386350|NCT03642054||Pelvic Organ Prolapse|Patients having vaginal hysterectomy who demonstrate grade III-IV uterovaginal prolapse.
89386351|NCT03642054||Non Pelvic Organ Prolapse|Patients having vaginal hysterectomy who do not demonstrate uterovaginal prolapse.
88861563|NCT00112242|Experimental|4. Melan-A EAA/ELA + NY-ESO-1lp + MAGE-A10+ CpG|"If patient is HLA-A2 positive: 100 mcg Melan-A EAA native peptide (during first cycle) or 100 mcg ELA analog peptide (during other cycles) + 500 mcg NY-ESO-1lp long peptide + 100 mcg MAGE-A10 peptide + 1 ml Montanide ISA-51 (no Montanide during cycle 3) + 2.5 mg CpG-7909/PF-3512676~If patient is HLA-A2 negative: 500 mcg NY-ESO-1lp long peptide+ 1 ml Montanide ISA-51 (no Montanide during cycle 3) + 2.5 mg CpG-7909/PF-3512676"
89184807|NCT02570763|Experimental|Active Stimulation|Active tDCS administration during the first 20 minutes of each of the six therapy sessions.
89184808|NCT02570763|Sham Comparator|Sham Stimulation|Sham tDCS administration during the first 20 minutes of each of six therapy sessions.
89184809|NCT04079556|Experimental|Tobacco LHW|Quit Smoking For a Healthy Family - family-based psycho-education intervention using lay health worker (LHW) outreach.
89386352|NCT03641976|Experimental|Arm I (A-FOLFOXIRI)|Patients receive irinotecan hydrochloride IV over 1 hour, oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and bevacizumab IV on day 1. Patients also receive fluorouracil IV continuously over 48 hours beginning on day 1.
89386353|NCT03641976|Active Comparator|Arm II (A-FOLFOX/A-FOLFIRI)|Patients receive irinotecan hydrochloride IV over 1 hour (or oxaliplatin IV over 2 hours), leucovorin calcium IV over 2 hours, fluorouracil IV bolus, and bevacizumab IV on day 1. Patients also receive fluorouracil IV continuously over 48 hours beginning on day 1.
89386354|NCT01069692|Placebo Comparator|Arm 1|Placebo
89386355|NCT01069692|Experimental|Arm 3|
89386356|NCT01069692|Experimental|Arm 2|
89386357|NCT01069692|Experimental|arm 4|SBR759A
89386358|NCT01069692|Experimental|arm 5|
89386359|NCT03621228|Experimental|MindfulGarden|Standard care + exposure to an interactive digital device
89386360|NCT03621228|No Intervention|Control|Standard care only
89386361|NCT03641898||Morphometric assessment of FNLs|After FFR-guided PCI, the morphometric characteristics of FNLs (FFR>0.8) are assessment by intravascular ultrasound.
89386362|NCT01344876|Experimental|OPB-51602|OPB-51602 1, 2, 4 and 6 mg/day oral once daily (QD) in a 4 week cycle
89386363|NCT03641586|Experimental|Stage I|Approximately 25-35 Chinese subjects with local advanced or metastatic malignant solid tumor will be enrolled in the dose escalation stage of BGB-283 until maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D) determination
89386364|NCT03641586|Experimental|Stage II|Approximately 15-30 melanoma subjects will be enrolled in dose expansion stage of BGB-283
89386365|NCT03641586|Experimental|Stage III|20 subjects will be enrolled for food effect stage of BGB-283
89386366|NCT05183178|Active Comparator|Ticagrelor|Current standard of care
89386367|NCT05183178|Experimental|Prasugrel|New standard of care
89386368|NCT03640806|Experimental|PHYSICAL ACTIVITY|Standard support for 12 months (HAS 2010, EULAR 2016) 3 fibromyactiv workshops per week during the first 6 months, or 72 sessions. Each workshop lasts 2 hours of physical activity.
89386369|NCT03640806|No Intervention|CONTROL|Standard care for 12 months (HAS 2010, EULAR 2016) with Pain Consultation every 3 months.
89386370|NCT03572426||Bipolar|Diagnosed as having at least 1 lifetime manic episode by the MINI
89386371|NCT03572426||Depression|Diagnosed as having at least 1 Major Depressive Episode by the MINI
89386372|NCT03572426||Healthy Controls|Does not meet Criteria for any mood disorder diagnosis (MDD, BD, dysthymia)
89386373|NCT02846324|Experimental|GBT440 600 mg Dose|Parts A and B
89386374|NCT02846324|Experimental|GBT440 900 mg Dose|Part A
89386375|NCT02846324|Experimental|GBT440 1500 mg Dose|Part B
89184810|NCT00584454|Experimental|Q Fever Vaccine (NDBR 105)|Volunteers will receive and intradermal dose of 0.1 ml of the skin test antigen (Q fever Skin Test Antigen, Henzerling Strain, Phase 1, MNLBR 110) in the volar aspect of the arm. Skin test will be evaluated; if erythema occurs after the skin test, it is medically contraindicated to vaccinate that volunteer. Volunteers with skin test reactions will not be vaccinated and withdrawn from the study.
89386376|NCT02846324|Placebo Comparator|Placebo|Parts A and B
89386377|NCT02240342|Experimental|Poor ovarian reserve women|
89386378|NCT03576092||Normal Pregnancy|Healthy gestational age-matched pregnant patients from 32 - 41 weeks without a diagnosis of preeclampsia.
89386379|NCT03576092||Preeclampsia Pregnancy|Pregnant patients from 32 - 41 weeks with a diagnosis of preeclampsia based on standard criteria as outlined by the American Congress of Obstetrics and Gynecology (ACOG).
89386380|NCT03161093|Experimental|Fasinumab dosing regimen 1|Fasinumab Subcutaneous (SC) dosing regimen 1 and naproxen-matching placebo oral
89386381|NCT03161093|Experimental|Fasinumab dosing regimen 2|Fasinumab SC dosing regimen 2 and naproxen-matching placebo oral
89386382|NCT03161093|Experimental|Fasinumab-matching placebo and naproxen|
89386383|NCT03161093|Experimental|Fasinumab-matching placebo and naproxen-matching placebo|
89386384|NCT02847650|Placebo Comparator|Placebo|
89386385|NCT02847650|Experimental|PF-06649751|
88861564|NCT00112242|Experimental|5. Melan-A EAA/ELA + NY-ESO-1lp + MAGE-A10+ CpG+ IL-2|"If patient is HLA-A2 positive: 100 mcg Melan-A EAA native peptide (during first cycle) or 100 mcg ELA analog peptide (during other cycles) + 500 mcg NY-ESO-1lp long peptide + 100 mcg MAGE-A10 peptide + 1 ml Montanide ISA-51 (no Montanide during cycle 3) + 2.5 mg CpG-7909/PF-3512676 + low dose IL-2~If patient is HLA-A2 negative: 500 mcg NY-ESO-1lp long peptide+ 1 ml Montanide ISA-51 (no Montanide during cycle 3) + 2.5 mg CpG-7909/PF-3512676 + low dose IL-2"
88861565|NCT00284154|Experimental|Intervention|Patients received vinflunine 320 mg/m2 every 21 days as a 15- to 20-minute infusion.
89386386|NCT03573440|No Intervention|no mindful eating education|"Subject will be asked to eat their meal with an investigator present.~They will inform the investigator verbally when they are feeling full.~After they have decided to end their meal, they will be asked to fill out a questionnaire"
89386387|NCT03573440|Experimental|mindful eating education|"After receiving a brief education session on mindful eating, subject will be asked to eat their meal with an investigator present.~They will inform the investigator verbally when they are feeling full.~After they have decided to end their meal, they will be asked to fill out a questionnaire"
89386388|NCT03573284|Experimental|Asthma group|Patients with chronic nonproductive cough for more than 8 weeks based on physician's opinion will be subjected to FeNO, impulse oscillometry(IOS) and pulmonary function. Receiver operating characteristic (ROC) curves to evaluate the clinical value of FeNO and small airways indices in CVA diagnosis. The optimal cutoff point for the level of FeNO and IOS is also determined.
89386389|NCT03576014|Experimental|BD03|"This study will be comprised of 3+3 dose escalation design with three dose levels, 0.6mg (cohort1), 2mg(cohort2), 6mg(cohort3).~Decision to increase dose will be guided by occurrence of DLT (dose limiting toxicity) evaluated 1week after the second injection (5weeks after first injection)"
89386390|NCT03575858|Experimental|Barrel shaped interdental brushes|test group
89386391|NCT03575858|Active Comparator|Tapered interdental brushes|control group
89386392|NCT03575780|Experimental|KX2-391 Ointment|KX2-391 ointment 1% will be administered once daily over 5 consecutive days
89386393|NCT01334255|Experimental|0.5 mg of iSONEP (sonepcizumab/LT1009)|iSONEP (sonepcizumab/LT1009) is a humanized murine monoclonal antibody to sphingosine 1-phosphate
89386394|NCT01334255|Experimental|2.0 mg of iSONEP (sonepcizumab/LT1009)|iSONEP (sonepcizumab/LT1009) is a humanized murine monoclonal antibody to sphingosine 1-phosphate
89386395|NCT03575624|Experimental|Nutrition, goal-setting, yoga|Behavioral: Nutritional and goal-setting education, yoga to promote achievement of change in health behaviors. SMART goal setting was used to guide nutritional and physical activity change to decrease disease risk and promote well-being.
88861566|NCT00285246||Group 1|Army Reserve and National Guard soldiers deploying to a hazardous deployment from Fort Dix, NJ and Camp Shelby, MS
88861567|NCT01899924|Experimental|Event Related Potentials|
89386396|NCT03573128|Experimental|Intervention|Students with Autism Accessing General Education (SAAGE). Teaching staff work with a study team coach to identify areas of concern for individual students, create goals and implement a modular behavioral intervention using an active teaching/feedback loop model.
89386397|NCT03573128|Active Comparator|Enhanced Services As Usual|Teaching staff access in-service training sessions hosted by study team and are provided with print materials from which the modules for the active intervention were created.
89386398|NCT01334333|Active Comparator|Prograf®|Prograf® is a twice daily formulation of tacrolimus
89386399|NCT01334333|Experimental|Advagraf®|Advagraf® is a once daily formulation of tacrolimus
89386400|NCT03573050|Experimental|RIV-TDS 13.3 mg/24 h (Test)|5 consecutive patch applications of Test (each patch to be applied for 24 hours)
89386401|NCT03573050|Active Comparator|Exelon® 13.3 mg/24 hours transdermal patch (Reference)|5 consecutive patch applications of Reference (each patch to be applied for 24 hours)
89386402|NCT03575312|Experimental|Enrofloxacin|enrofloxacin by dermal route, by inhalation, oral adminstration
89386403|NCT05186441|Active Comparator|DMPFC iTBS|DMPFC iTBS group has 30 patients. Each receive 20 times DMPFC iTBS therapy. During the iTBS, a 5-min train treatment(110%RMT, 2s on and 8s off, 900 pulses in total）was applied to the left DMPFC.
89386404|NCT05186441|Active Comparator|DLPFC iTBS|DLPFC iTBS group has 30 patients. Each receive 20 times DMPFC iTBS therapy. During the iTBS, a 5-min train treatment(110%RMT, 2s on and 8s off, 900 pulses in total）was applied to the left DMPFC.
89386405|NCT05186441|Sham Comparator|placebo|The placebo research received similar pseudo-stimulation treatment, which was the same as the treatment site and method of true stimulation, but during stimulation, the coil used B65 8 zigzag coil, which was flipped 180 degrees, and only produced stimulation sound during treatment, but did not produce irritating magnetic field. It can produce a placebo effect.
89386406|NCT03572816|No Intervention|Current standard|"mobilization without weight bearing for 6 weeks starting with the day of either decision-making for non-operative therapy or open reduction and internal fixation, if needed a cast or another kind of orthosis as a Static Walker are applied, then 4 weeks 15-20 kg, 2 weeks 35-45 kg, after that transition to full-weight bearing (always only if possible)~X-ray after 6 and 12 weeks; depending on the results, the schedule for weight bearing may be adjusted to the need in case of delayed healing or complications related to implants"
88861568|NCT00223236|Active Comparator|Citicoline|Citicoline is an over the counter supplement that may have neuroprotective properties and may have antidepressant effects.
88861569|NCT00223236|Placebo Comparator|Placebo|Inactive ingredient matching the active medication in appearance
88861570|NCT00223704|Experimental|HOE 140|Bradykinin receptor antagonist
88861571|NCT00223704|Active Comparator|Aminocaproic Acid|Antifibrinolytic
88861572|NCT00223704|Placebo Comparator|Placebo|Placebo
88861573|NCT00224952||Patients receiving Carbamazepine or Valproic Acid|
88861574|NCT00225420|Other|Single Arm Intervention|Single Arm Intervention where after enrollment (or prior to enrollment but before starting radiotherapy) patients will initially receive leuprolide acetate (Lupron®) intramuscular (IM). Patients will begin adaptive external-beam radiation therapy 2-3 months following the initiation of hormonal therapy. Each patient receives a dose of docetaxel at 10 mg/m2 intravenously over 1 hour weekly for eight weeks, for a total of eight weeks.
88861575|NCT00225498|Experimental|1|ziprasidone
88861576|NCT00225498|Active Comparator|2|risperidone or olanzapine
88861577|NCT00225732|Active Comparator|intravenous ibuprofen|
88861578|NCT00225732|Placebo Comparator|normal saline|
88861579|NCT02096718|Experimental|Afatinib in moderate renal impaired|Single Dose Afatinib in moderate renal impaired subjects
88861580|NCT02096718|Experimental|Afatinib in severe renal impaired|Single Dose Afatinib in severe renal impaired subjects
88861581|NCT02096718|Other|Afatinib in healthy subjects|Single Dose Afatinib in healthy subjects matched by gender, race, age and BMI to moderate and severe renal impaired subjects
88861582|NCT00113022|Experimental|Org 24448|Blinded, active experimental compound
89386407|NCT03572816|Experimental|Intervention|"mobilization with the custom-made heel-unloading orthosis ('Settner shoe') without pads for 6 weeks, then 2 weeks one pad, 2 weeks 2 pads, 2 weeks 3 pads, after that full-weight bearing without any support (always only if possible)~X-ray after 6 and 12 weeks; depending on the results, the schedule for weight bearing may be adjusted to the need in case of delayed healing or complications related to implants"
89386408|NCT01337453||Flu-like symtoms, incidence|The frequency of FLS will be estimated by number of patients and number of Botox treatments.
89386409|NCT02847494|Active Comparator|Control|Metoclopramide 10mg IV+ dexamethasone 10mg IM
89386410|NCT02847494|Active Comparator|Experimental|Metoclopramide 10mg IV + methylprednisolone acetate 160mg IM
89386411|NCT03572270|Experimental|case|PLWH
89386412|NCT03572270|Other|control|HIV negative women, going to medically assisted procreation consultation for male infertility
89386413|NCT02554253|Active Comparator|ketamine|Ketamine induction
89386414|NCT02554253|Active Comparator|Propofol|Propofol induction
88861583|NCT00113022|Placebo Comparator|Placebo|Blinded placebo
88861584|NCT02097732|Active Comparator|B: No induction|Participants will undergo stereotactic radiosurgery (SRS) followed 2-3 weeks later by ipilimumab, which is given once every 3 weeks for a total of 4 doses.
88861585|NCT02097732|Experimental|A: Induction|Patients will receive 2 doses of ipilimumab, which is given once every 3 weeks, prior to stereotactic radiosurgery (SRS), followed by 2 more doses of ipilimumab, for a total of 4 doses.
88861586|NCT04752306||residents|"10 residents~Minimum 1x > 1week had experience with incontinence material~MMSE score >23~good verbal communication"
88861587|NCT04752306||healthcare workers|8 healthcare workers working in setting, no exclusion criteria
89386415|NCT02239484|Experimental|Sequence 1|Tadalafil→Tamsulosin→Tadalafil+Tamsulosin
88861588|NCT04752306||policymakers|2 policymakers responsible for the purchase of incontinence material
88861589|NCT02028468|Active Comparator|Anterolateral Approach|Patient Operated with Watson Jones Approach
88861590|NCT02028468|Active Comparator|Trans-gluteal Approach|Patient operated with Trans-gluteal Hardinge Approach
88861591|NCT00113334|Experimental|ABT-510 (Thrombospondin)|Fixed dose level of thrombospondin 100 mg subcutaneously twice daily.
88861592|NCT00286182|Experimental|Erythropoietin alpha|Subcutaneous erythropoietin will be administered once weekly to achieve a target hemoglobin of 13 g/dL. Subjects will be dosed with the study drug for 24 weeks. The administration of study drug will be performed according to a pre-specified treatment algorithm that adjust erythropoietin dosages based on the rate of rise of the hemoglobin.
89386416|NCT02239484|Experimental|Sequence 2|Tadalafil+Tamsulosin→Tadalafil→Tamsulosin
89386417|NCT02239484|Experimental|Sequence 3|Tamsulosin→Tadalafil+Tamsulosin→Tadalafil
89386418|NCT01331759|Experimental|Immediate Neuropattern™|The experimental group will undergo Neuropattern™ stress diagnostics immediately after inclusion in the study.
89386419|NCT01331759|Placebo Comparator|Later Neuropattern™|The control group will undergo Neuropattern™ stress diagnostics three months after inclusion in the study.
89386420|NCT03575234|Experimental|Treatment (nivolumab, cyclophosphamide, IRX-2, surgery)|Participants receive nivolumab IV over 60 minutes on days 1 and 15, cyclophosphamide IV on day 1, and IRX-2 SC over 10 consecutive days between days 4-21 in the absence of disease progression or unacceptable toxicity. Beginning days 25-30, participants undergo surgery.
89386421|NCT01337531|Experimental|gonadotropin|recombinant or highly purified gonadotropin
88861593|NCT00286182|Placebo Comparator|Placebo|Placebo consists of saline injections.
88861594|NCT00286728|Experimental|Arm 1|Intensive referral to dual-focused self-help groups
88861595|NCT00286728|No Intervention|Arm 2|Usual care
88861596|NCT00113880||1|5-8 years of age, estimated to be approximately 4,000 new FluMist vaccinees per season
88861597|NCT00113880||2|9-17 years of age, estimated to be approximately 5,000 new FluMist vaccinees per season
88861598|NCT00113880||3|18-49 years of age, estimated to be approximately 6,000 new FluMist vaccinees per season.
89386422|NCT01337531|Active Comparator|Gonadotropins|recombinant versus highly purified gonadotropin
89386423|NCT03572114||Sporadic Dystonia|3 Tesla MRI Burke-Fahn-Marsden Dystonia Rating scale MDS-United Parkinsons Disease Rating Scale, Part III Beck Depression Inventory MoCA: Montreal Cognitive Assessment
89386424|NCT03572114||Familial Dystonia|3 Tesla MRI Burke-Fahn-Marsden Dystonia Rating scale MDS-United Parkinsons Disease Rating Scale, Part III Beck Depression Inventory MoCA: Montreal Cognitive Assessment
88861599|NCT00226590|Experimental|Combined Therapy|In this trial we adopted the approach of using both induction and concurrent chemotherapy together with TRT planned conformally to a tumor dose of 74 Gy.
88861600|NCT00114114|Experimental|Group 1: 0 g/day|Zoladex plus Placebo Testosterone (T) gel
88861601|NCT00114114|Experimental|Group 2: 1.25 g/day|Zoladex plus 1.25 g/day T gel
88861602|NCT00114114|Experimental|Group 3: 2.5 g/day|Zoladex plus 2.5 g/day T gel
89386425|NCT03572114||Parkinson´s disease, juvenile|3 Tesla MRI Burke-Fahn-Marsden Dystonia Rating scale MDS-United Parkinsons Disease Rating Scale, Part III Beck Depression Inventory MoCA: Montreal Cognitive Assessment
88861603|NCT00114114|Experimental|Group 4: 5 g/day|Zoladex plus 5 g/day T gel
88861604|NCT00114114|Experimental|Group 5: 10* g/day|Zoladex plus 10* g/day T gel. *Note that the 10 g/day dose was reduced to 7.5 g/day part-way through the trial
88861605|NCT00114114|Experimental|Group 6: Placebo/Placebo (PBO/PBO)|Placebo Zoladex plus Placebo T gel (controls)
88861606|NCT00227760|Experimental|Treatment (cediranib maleate)|Patients receive cediranib maleate PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88861607|NCT00227994|Experimental|Galantamine|Galantamine for 12 weeks
88861608|NCT00227994|Experimental|Donepezil|Donepezil for 12 weeks
88861609|NCT04250454|No Intervention|Control|Elsass Standard Care
88861610|NCT04250454|Active Comparator|Intervention|Enriched eviroment, Feed back training, Electrical stimulation, nutrition
88861611|NCT00114504|Experimental|Simvastatin group|Patients with FDG-positive plaque who received simvastatin and diet therapy
88861612|NCT00114504|No Intervention|Control group|Patients FDG-positive plaque who received diet therapy alone
89003320|NCT05450328|Active Comparator|Combination of inhaled Epoprostenol and Milrinone|The experimental group will receive simultaneously 4mg of Milrinone (1mg/mL, 4mL) and 60 mcg of Epoprostenol (15 mcg/mL, 4mL) before CPB initiation.
89386426|NCT03572114||Neurodegeneration with brain iron acc.|3 Tesla MRI Burke-Fahn-Marsden Dystonia Rating scale MDS-United Parkinsons Disease Rating Scale, Part III Beck Depression Inventory MoCA: Montreal Cognitive Assessment
88861613|NCT04247802|Experimental|Backwards Walking (BW) programme|This group will undertake a routine course of one to one out-patient physiotherapy which will include a BW programme. The BW programme will be prescribed by a physiotherapist and the participant will carry it out, along with other prescribed exercises, in their own home. Each participant will initially be prescribed a 5 minute BW programme to be completed once a day. The length of the BW programme and intensity will be progressed or regressed as deemed appropriate by the treating clinician with the aim for patients to achieve at least 10 minutes of BW every day of the week.
89386427|NCT03572114||mitochondrial disease|3 Tesla MRI Burke-Fahn-Marsden Dystonia Rating scale MDS-United Parkinsons Disease Rating Scale, Part III Beck Depression Inventory MoCA: Montreal Cognitive Assessment
89386428|NCT03572114||Healthy Controls|3 Tesla MRI Burke-Fahn-Marsden Dystonia Rating scale MDS-United Parkinsons Disease Rating Scale, Part III Beck Depression Inventory MoCA: Montreal Cognitive Assessment
89386429|NCT04563611|No Intervention|Muscle strength|Participants hamstring muscle strengths will be evaluated with ISOMED 2000 isokinetic dynamometer
89386430|NCT04563611|No Intervention|Hamstring Flexibility|In this study, Individuals' evaluations of hamstring flexibility will be assessed by the active knee extension test (ICC: 0.96) with maximum hip flexion.
89386431|NCT04563611|No Intervention|Cognitive Function|The lower (reaction time and visual-perceptual ability) and upper level (working memory, inhibitory control, and cognitive flexibility) cognitive functions of the individuals participating in the study will be evaluated with the computer assisted CNSVS test battery
88861614|NCT04247802|Active Comparator|Usual Care|This group will undertake a routine course of one to one out-patient physiotherapy over 12 weeks. To allow comparison between the two groups the control group will also have up to four review appointments where their home exercise programme can be progressed or regressed. The physiotherapy treatments will be not be restricted (apart from no BW programme) to allow for a pragmatic approach based on the treating clinician's clinical judgement, however their content will be recorded on treatment logs.
89386432|NCT04563611|No Intervention|Injury risk|Injury risk analysis of individuals will be made using the strength differences between the two sides, H: Q ratios (conventional and functional ratio) and functional movement screen (FMS), which will be obtained from the isokinetic measurement results.
88861615|NCT00118248|Experimental|Treatment (chemotherapy)|Patients receive tanespimycin IV over 2-6 hours on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
88861616|NCT04245384|Experimental|Internet-based treatment|Internet-based dietetic treatment with video calls, no physical meetings
88861617|NCT04245384|Active Comparator|Standard treatment|Dietetic treatment with physical meetings
88861618|NCT00230022|Experimental|Brief computer-delivered intervention|A 20-minute interaction with software designed to partially replicate the experience of a brief motivational intervention with a therapist or health care professional. Included decisional balance, normed feedback, and optional goal-setting.
88861619|NCT00230022|No Intervention|Assessment only|Participants in this arm only completed assessment section, same as intervention group, but then was done.
88861620|NCT01898676|Active Comparator|Divalproex Sodium Extended Release 250mg|Treatment A: A single 2-tablet dose of divalproex sodium extended-release tablet, 250mg. Each subject will have 2 treatments with this medication and two treatments with a single 2-tablet dose of DEPAKOTE 250mg tablet.
88861621|NCT01898676|Active Comparator|DEPAKOTE 250mg|Treatment B: A single 2-tablet dose of DEPAKOTE ER tablet, 250mg. Each subject will have 2 treament period with this medication and 2 treatment periods with a single 2-tablet dose of Divalproex Sodium Extended-Release 250mg tablet.
88861622|NCT04243902|Experimental|1 - standard manual valve (without leg-bag)|"The valve will initially be tested in 8 participants who currently use a standard manual valve (without leg-bag).~This first group will include a safety cohort of participants (n=4). All safety data will be reviewed from the initial 4 participants before further participants can undergo the study investigation."
88861623|NCT04243902|Experimental|2 - drainage bag with free drainage|The valve will then be tested with participants (n=8) who currently use a drainage bag with free drainage.
88861624|NCT00230802|Active Comparator|2 tablet increase|Patients will increase their current levothyroxine dose by 2 extra tablets per week (~29% increase)
88861625|NCT00230802|Active Comparator|3 tablet increase|Patients will increase their levothyroxine dosage by 3 extra tablets per week (~43%).
89386433|NCT04563611|Experimental|Nordic hamstring exercise|To perform this exercise, participants will be asked to stand in an upright position on their knees. The hands and arms will be positioned on the chest and held by the physical therapist at the heels of the individuals. The individual will then be asked to lower the upper body forward as slowly as possible. Verbal commands will be given throughout the movement so that the hip and trunk smoothness is not disturbed
89386434|NCT04563611|Experimental|Supine Sliding Leg Curls|The persons will be started to exercise in the hook position, with hands-on their back, with their knees next to the body, in a flexion position of approximately 60 °. Participants will be asked to first build a bridge, then maintain this position and slowly slide the slippery apparatus under their feet to bring their knees to full extension.
88861626|NCT00288366|Active Comparator|1|aripiprazole (Abilify)
88861627|NCT00288366|Active Comparator|2|ziprasidone (Geodon)
88861628|NCT00288600|Experimental|Experimental group|Intravenous Immunoglobulin
88861629|NCT00288600|Placebo Comparator|CONTROL GROUP|Normal Saline solution
88861630|NCT00290472|Experimental|Arm I|Patients receive CCI-779 IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients are followed every 8 weeks.
88861631|NCT04752852|Experimental|Dexamethasone|Patients with odd numbers were assigned to group A. 8 mg/2 ml dexamethasone was injected intravenously sixty minutes before the induction of anaesthesia
88861632|NCT04752852|Placebo Comparator|Placebo|Patients with even numbers were assigned to group B. Two millilitres (ml) normal saline (0.9%) was given intravenously 60 minutes before the induction of anaesthesia.
88861633|NCT00291876|Experimental|Havrix Group|Subjects who received during the primary study 2 doses of Havrix™ at Day 0 and at Month 12.
89003321|NCT05445713||Cohort 1|Asymptomatic subjects found to be PCR/antigen/antibody-positive during routine screening for SARS-CoV-2 infection
89386435|NCT04563611|Experimental|Turkish Get-up exercise|TG exercise, in 7 different steps (1. Starting position, 2. Supine girya lifting, 3. Elbow supported kettlebell lifting, 4. Hand supported kettlebell lifting, 5. High bridge, 6. Half above knee and lunge position, 7. Standing up) and the return of these different steps.
89386436|NCT04563611|No Intervention|Agility|Agility performances of individuals will be evaluated with the Agility T-test.
89386437|NCT02240420|Active Comparator|Life Style counseling (Star-Mama)|Star-Mama intervention group will receive during 6 months weekly phone calls with queries and narratives about health habits. The participant's answers will be sent to a health coach who will follow up with the participant, and develop a plan with the participant to address her needs.
89386438|NCT02240420|No Intervention|Educational Resource Support|Participants in the control group of the study will receive a set of educational materials with information about their health and the health of their babies.
89386439|NCT04508855||Cancer patients with atrial fibrillation|"All patients will be assigned to receive subcutaneous LMWH in therapeutic doses~More specifically the regimens will be as follows:~Tinzaparin 175 units/Kg once daily; Enoxaparin 1unit/kg twice daily; Fondaparinux <50 kg, 5 mg SC once daily, 50-100 kg, 7.5 mg SC once daily, >100 kg, 10 mg SC once daily; Bemiparin 115 IU/kg once daily; <50kg, 5000IU, 50-70kg, 7.500 IU, >70kg, 10000IU Nadroparin: Patients weighing 40 to 100 kg: SC, 171 anti-factor Xa IU per kg of body weight once a day; patients weighing over 100 kg will not receive nadroparin because a treatment dosage has not been established; Dalteparin: 200 units IU/kg SC daily for 30 days, then 150 units IU/Kg SC daily Dose adjustments will occur only in case of renal insufficiency according to the medicine's SPC The treatment with the LMWH will last at least during the period of active antineoplastic therapy of cancer patients"
89386440|NCT03575078|Experimental|Maximum tolerated dose of ARQ761 in combination with Olaparib.|ARQ761: weekly infusion. Olaparib Dose 1 D-7 administered orally twice daily
89386441|NCT02259842|Experimental|BI 34021 FU2 solution|single rising doses, dose groups 3 and 5 double-dosing (fed and fasted)
89386442|NCT02259842|Experimental|BI 34021 FU2 tablet|dose group 4 only
88861634|NCT01899144|Experimental|Albuterol Spiromax 90 mcg|"At each treatment visit, participants receive 1 actuation from each of 4 pre-arranged device combinations comprising 2 dry powder inhalers (DPIs) and 2 metered-dose inhalers (MDIs) in order to maintain the study blind.~In this arm, one of the DPIs contains Albuterol Spiromax 90 mcg; the other three devices contained placebo."
88861635|NCT01899144|Experimental|Albuterol Spiromax 180 mcg|"At each treatment visit, participants receive 1 actuation from each of 4 pre-arranged device combinations comprising 2 dry powder inhalers (DPIs) and 2 metered-dose inhalers (MDIs) in order to maintain the study blind.~In this arm, both of the DPIs contain Albuterol Spiromax 90 mcg for a total dose of 180 mcg; the MDIs contained placebo."
88861636|NCT01899144|Active Comparator|ProAir HFA 90 mcg|"At each treatment visit, participants receive 1 actuation from each of 4 pre-arranged device combinations comprising 2 dry powder inhalers (DPIs) and 2 metered-dose inhalers (MDIs) in order to maintain the study blind.~In this arm, one of the MDIs contains ProAir HFA 90 mcg; the other three devices contained placebo."
88861637|NCT01899144|Active Comparator|ProAir HFA 180 mcg|"At each treatment visit, participants receive 1 actuation from each of 4 pre-arranged device combinations comprising 2 dry powder inhalers (DPIs) and 2 metered-dose inhalers (MDIs) in order to maintain the study blind.~In this arm, both of the MDIs contain ProAir HFA 90 mcg for a total dose of 180 mcg; the DPIs contained placebo."
88861638|NCT01899144|Placebo Comparator|Placebo|At each treatment visit, participants receive 1 actuation from each of 4 pre-arranged device combinations comprising 2 dry powder inhalers (DPIs) and 2 metered-dose inhalers (MDIs) in order to maintain the study blind. In this arm, all devices contain placebo.
89184811|NCT04081194||case group, Melanoma Patients|"15 patients of with Melanoma, Age between 40 and 90 years.~-Withdrawal of Blood sample, Isolation of Exosomes:~Bradford protein assay And Qubit protein assay.~Bioanalyzer.~Real time PCR."
89184812|NCT04081194||control group|"10 Persons without Melanoma, age > 40 years~-Withdrawal of Blood sample, Isolation of Exosomes:~Bradford protein assay And Qubit protein assay.~Bioanalyzer.~Real time PCR."
89184813|NCT02586324|Other|global medium|
89184814|NCT02586324|Experimental|SSM|
89184815|NCT04081272||G6PD-normal|Donated blood from G6PD-normal subjects
89184816|NCT04081272||G6PD-deficient|Donated blood from G6PD-deficient subjects
89184817|NCT02586246|Experimental|CDP870 group from Study 275-08-002|Subjects with active rheumatoid arthritis who are participating in Study 275-08-002 of CDP870
89184818|NCT02586246|Experimental|CDP870 group from Study 275-08-004|Subjects with active rheumatoid arthritis who are participating in Study275-08-004 of CDP870
89184819|NCT00578175|Experimental|Group A|Subjects received refrigerator-stored Priorix-Tetra™ (MMRV vaccine 208136 formulation A) co-administered with Havrix® and Prevnar® at Day 0 and a second dose of Havrix® at Day 180
89184820|NCT00578175|Experimental|Group B|Subjects received freezer-stored Priorix-Tetra™ (MMRV vaccine 208136 formulation B) co-administered with Havrix® and Prevnar® at Day 0 and a second dose of Havrix® at Day 180
89184821|NCT00578175|Active Comparator|Group C|Subjects received ProQuad® co-administered with Havrix® and Prevnar® at Day 0 and a second dose of Havrix® at Day 180
89184822|NCT00723879||Patients with hepatitis C|Patients receiving a patient assistance program during therapy for hepatitis C will be enrolled into this study. All patients will receive PegIntron plus Rebetol (according to the label) and the patient assistance program.
89184823|NCT00435409|Experimental|A|
89184824|NCT00435409|Active Comparator|B|
89184825|NCT00724035|Experimental|Infraclavicular|This group will receive an ultrasound-guided infraclavicular brachial plexus block.
89184826|NCT00724035|Active Comparator|Axillary|This group will receive an ultrasound-guided axillary brachial plexus block.
89184829|NCT04126824|Active Comparator|Bupivacaine|During the Uterine Artery Embolization (UAE) procedure, participants in this arm receive bupivacaine and contrast to enable visualization of the nerve block under fluoroscopy.
89386443|NCT02259842|Placebo Comparator|Placebo|
89386444|NCT03377036|Experimental|DBT+s2D|Digital breast tomosynthesis plus synthesized 2D mammograms
89386445|NCT03377036|Active Comparator|2D-FFDM|2D full-field digital mammography
88861639|NCT00234078|Experimental|0.5% OPC-12759|0.5% OPC-12759 (rebamipide) ophthalmic suspension
88861640|NCT00234078|Experimental|1% OPC-12759|1% OPC-12759 (rebamipide) ophthalmic suspension
88861641|NCT00234078|Experimental|2% OPC-12759|2% OPC-12759 (rebamipide) ophthalmic suspension
88861642|NCT00234078|Placebo Comparator|placebo|placebo of OPC-12759 (rebamipide) ophthalmic suspension
88861643|NCT00118404|Experimental|1|Participants received acute phase and continuation phase cognitive therapy
88861644|NCT00118404|Placebo Comparator|2|Participants received acute phase cognitive therapy and continuation phase pill placebo
88861645|NCT00118404|Active Comparator|3|Participants received acute phase cognitive therapy and continuation phase fluoxetine
88861646|NCT00121836|Experimental|1|
88861647|NCT01898910|Active Comparator|PVI+renal denervation+OMT|
88861648|NCT01898910|Active Comparator|PVI+GP ablation+OMT|
89184830|NCT04126824|Experimental|Bupivacaine and Triamcinolone|During the Uterine Artery Embolization (UAE) procedure, participants in this arm receive bupivacaine plus triamcinolone mixed with contrast to enable visualization of the nerve block under fluoroscopy.
89184831|NCT00724113|Active Comparator|1|infiltration intra articular
89184832|NCT00724113|Experimental|2|ARTHRO distension plus intensive mobilisation
89184833|NCT04581330|Experimental|DEKA SmartXide C02 laser|One half of the subject's neck will be treated with ablative fractional CO2 laser.
89184834|NCT04581330|No Intervention|Control|The other half of the subject's neck will not be treated with the ablative fractional CO2 laser.
89184835|NCT05683236|Experimental|intervention group|The patients in the intervention group received multidisciplinary collaborative team care combined with palliative care.
89184836|NCT05683236|Active Comparator|control group|The control group was given routine nursing intervention.
89184837|NCT02584374||Patients|with suspected iliac vein compression, but with no signs of compression on venography and if venography with balloon occlusion test is performed.
89184838|NCT02584374||Healthy controls|"Healthy subjects between 18-45 years of age~Venography with balloon occlusion test will be performed."
89184839|NCT04070001|Active Comparator|Ibuprofen group|Ibuprofen group received 1-dose 400-mg Ibuprofen 1 hour before elastomeric separator placement
89184840|NCT04070001|Active Comparator|Laser group|Laser groups received a single irradiation of low-level laser immediately after elastomeric separator placement.
89184841|NCT04070001|Placebo Comparator|Control group|Control group received placebo lactose tablets 1 hour before elastomeric separator placement.
89184842|NCT04081506|Experimental|Group A|Individualized care
88861649|NCT00237666|Experimental|Ziprasidone|Ziprasidone monotherapy, 20-60 mg BID.
89184843|NCT04081506|No Intervention|Group B|Conventional care
89184844|NCT00724191||A|Evaluation of new MRI methods that measure information related to the chemical makeup of the brain in patients undergoing therapy for brain tumors.
89184845|NCT02573649|Active Comparator|CLS-ON first|Closed-loop Stimulation on first
89184846|NCT02573649|Active Comparator|CLS-OFF first|Closed-loop Stimulation off first
89184847|NCT00467857|Active Comparator|InteguSeal* and standard surgical preparation solutions|InteguSeal* microbial skin sealant was applied to surgical sites prior to incision after standard surgical skin preparation in patients undergoing coronary artery bypass graft (CABG) surgery
89184848|NCT00467857|Other|Standard surgical skin preparation alone|Prior to incision, standard surgical skin preparation in patients undergoing coronary artery bypass graft (CABG) surgery
89184849|NCT02573571||Clostridium difficile infection|Patients with Clostridium difficile-associated diarrhea for development of biomarkers
89184850|NCT05328219|Experimental|Chewing gums with PEG solution|The investigator provide the chewing gums with PEG solution to the experimental group.
89184851|NCT05328219|Active Comparator|Standard of Care|Care provided as per the standard existing routine.
89184852|NCT00724269|Active Comparator|Opti Free RepliniSH|Opti Free RepliniSH
89184853|NCT00724269|Active Comparator|ReNu Multi-Plus|ReNu Multi-Plus
89184854|NCT05315661|Experimental|Treatment Arm|injected with 3x10^7 cells/2mL of ET-STEM to intraventricular space via an Ommaya reservoir. repeated 3 times at 4 week intervals
89184855|NCT00435019|Experimental|insulin detemir|insulin detemir + insulin aspart
89184856|NCT00435019|Experimental|NPH insulin|NPH insulin + insulin aspart
89184857|NCT00714129|Experimental|1|Weight loss diet - normal diet
88861650|NCT00296322|Active Comparator|Mitomycin-C, Doxifluridine|Mf: Mitomycin-C 20mg/m2 intravenously (3-6 weeks after surgery) Doxifluridine 460-600mg/m2/day per oral for 3 months (started 4 weeks after surgery)
89184858|NCT00714129|Experimental|2|Weight loss diet - low in simple sugars (specifically fructose)
89184859|NCT01028989|Other|Reduced Glycemic Load Diet|"36-40% fat; 40-42% carbohydrate; 18-22% protein~Glycemic Load <=46 per 1000 calories"
89184860|NCT01028989|Other|Standard Diet|"25-27% fat; 55-57% carbohydrate; 18-22% protein~Glycemic Load >=77 per 1000 calories"
89184861|NCT01029067|Active Comparator|Cognitive Remediation|Computerized cognitive remediation (CogPack training). A fixed series is administered, which covers a wide range of neuropsychological exercises involving memory, reasoning, selective attention and psychomotor speed. The difficulty level for each patient is adapted automatically depending on to the subject's performance on prior exercises. At the end of each session, the patient receives individual feedback on his or her performance. To match with group MCT, eight sessions are administered. Each session lasts approximately 45-60 minutes.
88861651|NCT00296322|Active Comparator|Mitomycin-C, Doxifluridine, Cisplatin|iceMFP: Cisplatin 100mg with 1L of normal saline intraperitoneally for 2 hours during surgery Mitomycin-C 15mg/m2 intravenously (1 day after surgery) Doxifluridine 460-600mg/m2/day per oral(started at 4 weeks after surgery and administered a total of 12 months) Cisplatin 60mg/m2 intravenously monthly for 6 months (started at 4 weeks after surgery)
88861652|NCT00297102|Active Comparator|Roflumilast|500 mcg, once daily, oral administration in the morning
88861653|NCT00297102|Placebo Comparator|Placebo|once daily
88861654|NCT00123162|Experimental|Sildenafil Citrate|A single vaginal dose of Viagra 100 mg.
88861655|NCT00123162|Placebo Comparator|Placebo|A single vaginal dose of placebo.
88861656|NCT01897818|Experimental|ALS patients|
88861657|NCT04751838||Survivor cohort; Non-survivor Cohort|All patients were categorized according to the state of departure from the hospital, named survivor or non-survivor.
89184862|NCT01029067|Experimental|Metacognitive Training|The group metacognitive training program (MCT) is fully documented (Moritz, Woodward, & Metacognition Study Group, 2007; VanHam Campus Press) and can be obtained in more than 15 languages cost-free via the following link: www.uke.de/mkt. The group program is delivered to groups of 3-10 patients by trained psychologists addressing delusion-related metacognitive biases (e.g., jumping to conclusions). The eight modules are presented via a video projector using pdf-converted Power-Point slides. Each group session lasts approximately 45-60 minutes. Individualized MCT (MCT+) follows group sessions and accords to the general guidelines for cognitive-behavioral therapy. For each patient, 8 one-to-one sessions were carried in addition to one session relating to the medical history.
89184863|NCT05188599||Amputee patients|age between 18-65 years, (b) time after amputation ≥ 6 months, (c) unilateral or bilateral amputation above the ankle level
89184864|NCT00724581|Experimental|A|
89184865|NCT02570841|Active Comparator|Capsaicin|Treatment with Topical High dose Capsaicin
89184866|NCT02570841|Placebo Comparator|Placebo|Treatment with Topical Placebo
89184867|NCT05079009|Experimental|ECCO2R pulsatile configuration|Adult patients hospitalized in the medical ICU for whom a treatment by ECCO2R has been indicated.
89184868|NCT02570919|Active Comparator|IGRT 45 Gy in 5 fractions of 9 Gy|Arm A: Hypofractionated IGRT at a prescription dose of 45 Gy in 5 fractions of 9 Gy delivered in five consecutive days
89184869|NCT02570919|Experimental|IGRT 24 Gy single dose|Arm B: single fraction IGRT at a prescription dose of 24 Gy
89184870|NCT04732416|Experimental|HM15136 active|Cohort A / Cohort C
89184871|NCT00724659|Experimental|Ultrasound Pre-Arthrogram|Ultrasound of the joint(s) before the clinically scheduled arthrogram of the same joint(s)
89184872|NCT00724659|Experimental|Ultrasound Post-Arthrogram|Ultrasound of the joint(s) after the clinically scheduled arthrogram of the same joint(s), performed while the body still has a contrast agent in it from the arthrogram. The contrast agent varies with different joint areas, but is usually iodine based (like Ultravist.)
89184873|NCT02586168|Experimental|Gemcabene 900 mg|Gemcabene 900 mg
89184874|NCT02586168|Placebo Comparator|Placebo|Placebo
89184875|NCT04079478||AI|Artificial Intelligence colonoscopy
89184876|NCT04079478||Control|White light colonoscopy
89386446|NCT03157583|Active Comparator|Reference product (for SPFi calculation)|This arm will include all the test sites on the participants back where reference product (P3 standard sunscreen) will be applied.
89386447|NCT03157583|Experimental|Test product 1|This arm will include all the test plates used for UVAPF testing and test sites on the participants back where test product 1 will be applied for SPF testing.
89386448|NCT03157583|Experimental|Test product 2|This arm will include all the test plates used for UVAPF testing and test sites on the participants back where test product 2 will be applied for SPF testing.
89386449|NCT03157583|Experimental|Test product 3|This arm will include all the test plates used for UVAPF testing and test sites on the participants back where test product 3 will be applied for SPF testing.
88861658|NCT04751838||Training Cohort, Validation Cohort|the eligible patients randomly (7:3) into training cohort and validation cohort. The training cohort were used to build nomogram model, while the validation cohort validated the model.
88861659|NCT00123630|Placebo Comparator|placebo|placebo group
88861660|NCT00123630|Experimental|omalizumab|Xolair group
88861661|NCT00124176|Experimental|1|Nebulized levalbuterol 10mg/hr given continuously
89184877|NCT04081116|Experimental|MI-E testing symmetric settings|Symmetric settings is one of 3 different settings that will be tested on the same day but in randomized order.
89184878|NCT04081116|Experimental|MI-E testing assymetric settings|Asymmetric settings is one of 3 different settings that will be tested on the same day but in randomized order.
89184879|NCT04081116|Sham Comparator|Settings in use|Settings in use is one of 3 different settings that will be tested on the same day but in randomized order
89184880|NCT00724737|Active Comparator|fMRI of the brain, no surgery|Healthy volunteers will undergo an fMRI (functional MRI of the brain).
89184881|NCT00724737|Experimental|fMRI of the brain, presurgical|Patients scheduled to have brain surgery will undergo an fMRI (functional MRI of the brain).
89184882|NCT04019223||anti-tissue transglutaminase group|serum IgA-tissue transglutaminase antibody (tTG) was analyzed in serum using a quantitative automated ELISA method by means of a commercially available detection kit using recombinant human tTG as antigen recommended cut-off by the manufacturer > 8 U/mL).
89184883|NCT04019223||biopsy group|upper gastrointestinal endoscopic examination will be done and the jejunal histopathological examinations will be done at the Histopathology Laboratory. The features consistent with CD included: hyperplasia of crypts, atrophy of villous, and increase of intraepithelial lymphocytes.Duodenal samples will be processed using haematoxylin/eosin staining and CD3 immunophenotyping. The number of intra-epithelial lymphocytes (IEL), the architecture of villi, and the inflammatory cell infiltration of the lamina propria will be assessed. Histopathological changes will be classified according to the Marsh-Oberhuber criteria.Lymphocytic enteropathy (Marsh 1 lesion) was defined as 25 or more IEL per 100 epithelial nuclei, and normal villous architecture.
89184884|NCT04962789||with compaction|those whose endometrial thickness is calculated to decrease by the time of embryo transfer compared with the thickness at the day of ovulation trigger, analyzed according to the degree of compaction, i.e., 5%, 10%, 15%, or 20% decrease thickness
89184885|NCT04962789||without compaction|those who had an increase in their endometrial thickness or whose thickness decreased less than 5%
89184886|NCT04956627|Experimental|BMS-986166|
89386450|NCT03157583|Experimental|Test product 4|This arm will include all the test plates used for UVAPF testing and test sites on the participants back where test product 4 will be applied for SPF testing.
89386451|NCT03157583|No Intervention|Negative control (for SPFi calculation)|This arm will include all the test sites on the participants back which will be left unprotected.
89386452|NCT03157583|Active Comparator|Reference (for UVAPFi calculation)|This arm will include test plates treated with reference sunscreen formulation S2.
89386453|NCT03157583|Other|Blank control (for UVAPFi calculation)|This arm will include blank test plates treated with glycerin.
89386454|NCT03570710|Placebo Comparator|normal saline arm group|110 ml normal saline IV just before skin incision plus topical application of 200 ml normal saline applied on the pelvic bed after Cesarean hysterectomy
88861662|NCT00124176|Active Comparator|2|Racemic albuterol 20mg/hr given continuously
89386455|NCT03570710|Active Comparator|intravenous tranexamic acid group|1 gm tranexamic acid (2 ampoules of Capron 500 mg /5 ml; Amoun, Cairo, Egypt) intravenous just before skin incision plus110 ml normal saline IV just before skin incision plus topical application of 200 ml normal saline applied on the pelvic bed after Cesarean hysterectomy
89386456|NCT03570710|Active Comparator|Topical tranexamic acid group|2 gm topical tranexamic acid ( 4 ampoules of Capron 500 mg/5 ml applied typically) in 200 ml normal saline applied on the pelvic bed after Cesarean hysterectomy plus110 ml normal saline IV just before skin incision plus topical application of 200 ml normal saline applied on the pelvic bed after Cesarean hysterectomy plus In topical tranexamic acid group gauze soaked with 2g tranexamic acid (20 ml) diluted in 200 ml of sodium chloride 0.9% or placebo (120ml of sodium chloride 0.9%.) applied on the pelvic bed after Cesarean hysterectomy. To ensure a sufficiently high concentration, the tranexamic acid was diluted only to a volume sufficient to moisten a large wound surface. 20 ml moisten at least 1500 cm2.
89386457|NCT01315379||PTSD without TBI|"children and adolescents with a diagnosis of PTSD and without head injury, following a motor vehicle accident.~This group will be treated using the Prolonged Exposure Therapy protocol."
89386458|NCT01315379||PTSD with m-TBI|"children and adolescents with a diagnosis of PTSD and a diagnosis of mild traumatic brain injury, following a motor vehicle accident.~This group will be treated using the Prolonged Exposure Therapy protocol."
89386459|NCT01337765|Experimental|BEZ235 + MEK162|
89386460|NCT01334489|No Intervention|Usual management|Usual management of monochorionic pregnancy without the pessary placement
89386461|NCT01334489|Other|Arabin Cervical Pessary|"The pessary will be inserted 24 hours after fetal surgery in the exploration room. This procedure does not need anaesthesia and it does not need to be done in a surgery room. During the following explorations the correct placement of the pessary is assessed, and if it does not, it can be easily adjusted.~The pessary will be removed at 37 weeks of gestation, or before if any unexpected event occurs."
89386462|NCT02842736|Experimental|Endometrial Cryoablation|
88861663|NCT00240162|Experimental|PTK787/ZK 222584|Initially patients will receive a dose of 500mg (2, 250mg tablets) in the morning and 250mg (1, 250mg tablet) in the afternoon for 2 weeks (cycle 1, days 1-14), then 500mg (2, 250mg tablets) bid for 2 weeks (cycle 1, days 15-28) and finally 750mg (3, 250mg tablets) in the morning and 500mg (2, 250mg tablets) in the afternoon for the remainder of treatment duration (cycle 2, day 1 and onwards). Each 28 days of drug administration will constitute one cycle of therapy.
88861664|NCT00299988|Experimental|IVIG|ivig
88861665|NCT00299988|Placebo Comparator|Placebo|
88861666|NCT04226352|Experimental|Dose 1|60 mg DXM a day for 28 days
88861667|NCT04226352|Experimental|Dose 2|300 mg DXM every 2 weeks for 28 days.
88861668|NCT04226352|Experimental|Dose 3|300mg DXM once, with 60mg DXM daily afterwards
88861669|NCT00300456|Active Comparator|A|ABT-335 + 20 mg simvastatin
88861670|NCT00300456|Active Comparator|B|ABT-335 + 40 mg simvastatin
88861671|NCT00300456|Placebo Comparator|C|ABT-335 monotherapy
88861672|NCT00300456|Placebo Comparator|D|20 mg simvastatin monotherapy
88861673|NCT00300456|Placebo Comparator|E|40 mg simvastatin monotherapy
88861674|NCT00300456|Placebo Comparator|F|80 mg simvastatin monotherapy
88861675|NCT00125034|Experimental|Cetuximab Plus FOLFOX-4|
88861676|NCT00125034|Active Comparator|FOLFOX-4 Alone|
88861677|NCT02100930|Experimental|Neuroblastoma|This is a single-arm, open label, open access study to provide the anti-GD2 murine IgG3 MoAb 3F8 combined with granulocyte-macrophage colony stimulating factor (GM-CSF) to patients with high-risk neuroblastoma (NB). This immunotherapy has shown efficacy against minimal residual disease (MRD) in such patients.
89184887|NCT04956627|Experimental|BMS-986166 + Itraconazole|
89184888|NCT04956627|Experimental|BMS-986166 + Phenytoin|
89184889|NCT04956627|Experimental|BMS-986166 + Gemfibrozil|
89184890|NCT00920088|Experimental|Cohort 1|GSK2248761 with LPV/RTV arm and probes
89184891|NCT00920088|Experimental|Cohort 2|GSK2248761 with DRV/RTV
89386463|NCT01307033|Active Comparator|MK-954H (L50/H12.5)|One combination tablet daily, orally, for 8 weeks. Each tablet contains Losartan 50 mg (L50) and 12.5 mg of hydrochlorothiazide (H12.5). Participants will then receive open label MK-0954A (L100/H12.5) orally, once daily for 44 weeks (extension)
89386464|NCT01307033|Experimental|MK-0954A (L100/H12.5)|One combination tablet daily, orally, for 8 weeks. Each tablet contains Losartan 100 mg (L100) and 12.5 mg of hydrochlorothiazide (H12.5). Participants will continue to receive MK-0954A orally, once daily for 44 week extension
89386465|NCT02844920||Fibroid Treatment|Intrauterine ultrasound guided radio-frequency ablation
89386466|NCT04446143|Other|Application of mindfulness meditation prior to UDS|Those in the mindfulness medication group will listen to an audio-taped mediation, which takes 10 mins to complete.
89386467|NCT04446143|Active Comparator|No meditation prior to UDS|The control group will be seated in a quiet empty room where they wait for 10 min.
89386468|NCT02244398|Experimental|FP and HTC services|VHTs in the intervention arm provide both family planning and HTC services between May 2012 and September 2013, then return to providing family planning only at the end of the project. Services are made available to all adults in VHTs' communities. HIV testing is done using the national rapid testing algorithm. Clients who test positive for HIV are referred to a health center for care and treatment and receive disclosure support and information on peer support groups.
89386469|NCT02244398|Active Comparator|FP services|VHTs in the control arm only provide family planning services.
89386470|NCT04475705|Active Comparator|Sevoflurane group|patients in this group will receive inhalation anaesthesia with sevoflurane at Minimal Alveolar Concentration 0.7-1.3 as the main anaesthetic to achieve Bispectral Index 40-60. Other anaesthetic management will be standardised.
89386471|NCT04475705|Active Comparator|propofol group|patients in this group will receive intravenous propofol using Target Controlled Infusion 'Paedfusor' model 2-5 as the main anaesthetic to achieve Bispectral Index 40-60. Other anaesthetic management will be standardised.
89386472|NCT03572036||Arm 1|aged 18 and older, participated in 001-H-0088 and 04-H-0161 and 1) a diagnosis of SCD 2) a diagnosis of PH 3) prescribed and/ or reported taking PDE5-I therapy for a duration of >16 weeks.
89386473|NCT03569150|Other|Intervention (Rosebud)|The intervention is: Native Americans patients with a serious life-limiting illness will have an advance care planning discussion with an interdisciplinary healthcare professional trained in the culturally-adapted COMFORT Communication Curriculum.
88861678|NCT00241176|Experimental|Aripiprazole|
88861679|NCT00125658|Active Comparator|Control|FTP: 30 sessions (90 minute sessions, 3 times per week, 10 weeks) followed by POWER: 30 sessions (90 minute sessions, 3 times per week, 10 weeks)
88861680|NCT00125658|Experimental|Experimental|POWER: 30 sessions (90 minute sessions, 3 times per week, 10 weeks) followed by FTP: 30 sessions (90 minute sessions, 3 times per week, 10 weeks)
88861681|NCT02102100|Experimental|Menthol-Preferring Smokers|Each subject in this arm received a random sequence of 3 different inhaled menthol conditions across 3 test sessions (a single menthol condition for each test session). In each test session, a random order of one saline, and 2 nicotine (0.25 mg and 0.5 mg /70 kg) infusions were given one hour apart, concurrent with the randomized menthol inhalation condition for that test session.
88861682|NCT02102100|Experimental|Non-Menthol Preferring Smokers|Each subject in this arm received a random sequence of 3 different inhaled menthol conditions across 3 test sessions (a single menthol condition for each test session). In each test session, a random order of one saline, and 2 nicotine (0.25 mg and 0.5 mg /70 kg) infusions were given one hour apart, concurrent with the randomized menthol inhalation condition for that test session.
88861683|NCT02094534|Experimental|ORMD-0801 Capsules|API (recombinant human insulin USP), in Oramed's proprietary formulation in capsules, ORMD-0801
88861684|NCT02094534|Placebo Comparator|Placebo|Fish oil in capsules, identical in appearance to ORMD-0801
88861685|NCT00242502|Experimental|Bevacizumab + Erlotinib|Bevacizumab 10 mg/kg intravenous every 14 days, repeat cycle every 28 days; Erlotinib 150 mg orally every day continuous dosing.
88861686|NCT04389060|Active Comparator|GSE group|Subjects took a single dose of 600 mg GSE in capsule form through ingestion 2 hours prior to testing
88861687|NCT04389060|Placebo Comparator|Placebo group|Subjects took a single dose of 600 mg starch in capsule form through ingestion 2 hours prior to testing
89003322|NCT05445713||Cohort 2|Symptomatic outpatients who were confirmed to have COVID-19 through a positive PCR/antigen test
89386474|NCT03569150|No Intervention|Control (Pine Ridge)|In the control group, Native American patients with a serious life-limiting illness will receive usual care. The healthcare professionals have not undergone training in the culturally-adapted COMFORT Communication Curriculum.
89386475|NCT03158311|Experimental|QVM149 150/50/80 μg|QVM149 150/50/80 μg o.d. delivered via Concept1
89386476|NCT03158311|Experimental|QVM149 150/50/160 μg|QVM149 150/50/160 μg o.d. delivered via Concept1
89386477|NCT03158311|Active Comparator|Salmeterol/fluticasone 50/500 μg plus tiotropium 5 μg|Salmeterol/fluticasone 50/500 μg b.i.d. delivered via Accuhaler® plus tiotropium 5 μg o.d. delivered via Respimat®
89386478|NCT01331915|Experimental|Theravac|Theravac® is a recombinant adenylate cyclase toxin from Bordetella pertussis that has been detoxified by mutation of its catalytic domain, and which has been coupled to the Tyrosinase.A2 epitope YMDGTMSQV.
89386479|NCT02244866|Active Comparator|Pergoveris (FSH and LH)|150 IU of recombinant FSH and 75 IU of recombinant LH (Pergoveris) daily subcutaneous injection
89386480|NCT02244866|Active Comparator|Follitropin alpha (FSH)|150 IU of recombinant FSH (follitropin alpha or Gonal-F) daily subcutaneous injection
89386481|NCT01334567|Experimental|Tenofovir DF|
89386482|NCT03570398|Other|Abdominal CT|
89386483|NCT03570398|Other|Abdominal Ultrasound|
89535270|NCT02488187|Other|ABUS vs mammography (ultrasound when indicated)|To compare the sensitivity and specificity of ABUS versus mammography (and hand-held breast ultrasound when clinically indicated) for the ipsilateral and contralateral breast in newly diagnosed breast cancer patients when MRI is not performed.
89386484|NCT01337843|Active Comparator|Control Group|Control Group participants will receive a well-regarded book for back pain patients.
89386485|NCT01337843|Experimental|Wellnes Workbook|Participants will receive the Wellness Workbook, a web-based cognitive behavioral pain management intervention to help individuals with chronic low back pain (CLBP) learn adaptive coping and pain management skills, increase their physical activity and manage stress with relaxation and mindfulness training
89535271|NCT03091803||Arm I (QSM, T1WI, gadobenate dimeglumine, GOCART DCE MRI)|Patients undergo standard of care QSM and T1WI. Patients then receive gadobenate dimeglumine IV and undergo GOCART DCE MRI over 60 minutes.
88861688|NCT01899066|Experimental|Lucentis; chemotherapy|"Lucentis: 0.5mg/0.05 ml;Other Name: Ranibizumab;monthly for the first six months.~Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first six months."
89386486|NCT04398329|Experimental|Phase 1b (Cohort 1)|Fixed dose of HTX-034.
89386487|NCT04398329|Experimental|Phase 1b (Cohort 2)|Individualized dose of HTX-034.
89386488|NCT04398329|Experimental|Phase 2 (Expansion): Low Dose|Fixed dose of HTX-034.
89386489|NCT04398329|Experimental|Phase 2 (Expansion): High Dose|Individualized dose of HTX-034.
89386490|NCT04398329|Active Comparator|Phase 1b and Phase 2|Bupivacaine HCl.
89386491|NCT03568916||Rivaroxaban vs dabigatran|Patients diagnosed with non-valvular atrial fibrillation who initiated their oral anticoagulation with rivaroxaban or dabigatran at cohort entry date, and did not have a previous prescription for any oral anticoagulant in the prior year.
89386492|NCT03568916||Apixaban vs dabigatran|Patients diagnosed with non-valvular atrial fibrillation who initiated their oral anticoagulation with apixaban or dabigatran at cohort entry date, and did not have a previous prescription for any oral anticoagulant in the prior year.
89386493|NCT03568916||Apixaban vs rivaroxaban|Patients diagnosed with non-valvular atrial fibrillation who initiated their oral anticoagulation with apixaban or rivaroxaban at cohort entry date, and did not have a previous prescription for any oral anticoagulant in the prior year.
88861689|NCT01899066|Active Comparator|chemotherapy|chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first six months.
88861690|NCT01890720|Experimental|iNPWT|Negative Pressure Wound Therapy (NPWT) is a mechanical wound care treatment using controlled sub-atmospheric pressure to assist and accelerate wound healing. Incisional Negative Pressure Wound Therapy (iNPWT) is a new NPWT devices, which can be used over clean closed surgical incisions. The device behaves in a similar fashion to existing conventional NPWT devices, i.e. transmission of negative pressure levels at the wound bed, tissue contraction and establishing a characteristic pattern of peri-wound blood flow and that it reduces and normalises tissue stresses at the incision
88861691|NCT01890720|Active Comparator|Standard wound dressing|The standard postoperative wound dressing is a normal wound dressing, used over clean closed incisions.
89386494|NCT03571880|Experimental|CNSLBP group|
88861692|NCT00244140|Experimental|Iopromide 370 mg I/mL|Iopromide (Ultravist 370 mg I/mL) administered intravenously
89386495|NCT03571880|Active Comparator|Healthy control group|
89386496|NCT03635593|Active Comparator|CBD|10mg capsules Cannabidiol (CBD)
89386497|NCT03635593|Active Comparator|CBD+THC|10mg capsules Cannabidiol (CBD) +THC tetrahydrocannabinol (CBD 5mg + (THC)
88861693|NCT00244140|Experimental|Iopromide 300 mg I/mL|Iopromide (Ultravist 300 mg I/mL) administered intravenously
88861694|NCT00126750|Other|Arm 1|
88861695|NCT00127062|Experimental|Asthma|Asthma patients ranging from mild to severe
88861696|NCT00127062|Other|Healthy Non-Smokers|
88861697|NCT00127218|Experimental|1|any statin plus niacin
89386498|NCT03635593|Placebo Comparator|Placebo|10mg capsules placebo
89386499|NCT04373915|No Intervention|Standard Bedside Rounding|
88861698|NCT00127218|Placebo Comparator|2|any statin plus placebo
88861699|NCT00127530|Placebo Comparator|Placebo- sugar pill|Placebo control
88861700|NCT00127530|Experimental|Fampridine-SR|10 milligram (mg) tablet b.i.d.
88861701|NCT04346238||Patients with Friedriech Ataxia genetically confirmed|Patients with Friedriech Ataxia genetically confirmed
88861702|NCT00250926|Experimental|Bortezomib, Dexamethasone, Rituximab|A cycle of therapy consisted of bortezomib 1.3 mg/m(2) intravenously; dexamethasone 40 mg on days 1, 4, 8, and 11; and rituximab 375 mg/m(2) on day 11. Patients received four consecutive cycles for induction therapy and then four more cycles, each given 3 months apart, for maintenance therapy.
88861703|NCT00251238|Experimental|Ginkgo biloba extract EGb 761|Receiving daily Ginkgo biloba extract EGb 761
89386500|NCT04373915|Experimental|Remote Bedside Rounding|Parents of infants on one care team will have the opportunity to participate in rounds via secure remote video software.
88861704|NCT00251238|Placebo Comparator|Placebo|Receiving daily placebo
88861705|NCT00251862|Experimental|Decision aid plus YourDiseaseRisk|Patients viewed the decision aid and completed the Your Disease Risk risk assessment tool prior to visit with their primary care provider.
88861706|NCT00251862|Experimental|Decision aid alone|Patient's viewed decision aid only prior to a visit with their primary care provider.
88861707|NCT00251862|Sham Comparator|III|Standard care
89003323|NCT05445713||Cohort 3|Inpatients surviving hospitalisation for severe COVID-19 and who were PCR/antigen-positive
89386501|NCT03571490|Active Comparator|TQL Ropivacaine(active)|Bilateral Single shot of ropivacaine 0.325% 30 mL. In total 60 mL of 0.325% ropivacaine
89386502|NCT03571490|Placebo Comparator|TQL saline (placebo)|Bilateral single shot of saline 0.9% 30 mL. in Total 60 mL of saline 0.9%
89386503|NCT01336231||patients group|Patients with a metastatic kidney cancer and must beginning a treatment by antiangiogenic
89386504|NCT05754801|Experimental|Active treatment (Yunzhi Essence)|Subjects will take 2 Yunzhi capsules, 4 times daily, for 6 months.
89386505|NCT05754801|Placebo Comparator|Placebo|Subjects will take 2 placebo capsules, 4 times daily, for 6 months
89386506|NCT01331993|Experimental|1|Treatment order : A, B, C
89386507|NCT01331993|Experimental|2|Treatment order : B, C, A
89386508|NCT01331993|Experimental|3|Treatment order : C, A, B
89386509|NCT01331993|Experimental|4|Treatment order : A, C, B
89386510|NCT01331993|Experimental|5|Treatment order : B, A, C
89386511|NCT01331993|Experimental|6|Treatment order : C, B, A
89386512|NCT03424694|Experimental|2 fractions of 14.5 Gy HDR Brachytherapy|"High Dose Rate (HDR) Brachytherapy as monotherapy at a dose of 29 Gy is delivered in 2 fractions of 14.5 Gy, minimum 6 hours a part, delivered on a single implant procedure with 2 MRI assisted plannings and dosimetries.~HDR brachytherapy implant is done under anesthesia with ultrasound guidance as an out-patient procedure."
88861708|NCT00303966|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
88861709|NCT00304512|Experimental|Migalastat Low Dose 50 mg|Migalastat 50 mg was administered orally QOD during the 12-week treatment period and then during the optional 36-week treatment extension period.
88861710|NCT00304512|Experimental|Migalastat Middle Dose 150 mg|Migalastat 150 mg was administered orally QOD during the 12-week treatment period and then during the optional 36-week treatment extension period.
88861711|NCT00304512|Experimental|Migalastat High Dose 250 mg|Migalastat 250 mg was administered orally QOD during the 12-week treatment period and then during the optional 36-week treatment extension period.
88861712|NCT00304746|Active Comparator|testosterone gel|AndroGel (1% testosterone transdermal gel), 2.5 g to 10 g daily
88861713|NCT00304746|Placebo Comparator|placebo gel|Placebo gel
88861714|NCT05267730|Experimental|Modern board and card games group|"Conectar Jugando Game Program: The program consisted of 12 one-hour intervention sessions. The sessions were biweekly with a total duration of 6 weeks. The modern board and card games used in the program were Bee Alert (Knizia, 2012), Monster Match (Gruhl & Weir, 2018), Kaleidos Junior (Albertarelli, 1997), Sherlock Express (Kermarrec, 2019), Alles Kanone! (Knizia, 2007), Halli Galli (Shafir, 1990), Bananazul (Warsch, 2019), Blurble (Bernard, 2013), La Morada Maldita (Ortiz, 2020), Dice Academy (Gobert, 2019) and Streams (Itsubaki, 2011). Play sessions will be held in subgroups of 3-5 children within the class group. In each session, each subgroup will play two games. The games used in the program have an average duration of approximately 20-30 minutes (filler games).~All subgroups will play all games in the program the same number of times with the same rules. The game program will be the same in all participating centers to guarantee the homogeneity of its implementation"
88861715|NCT05267730|No Intervention|Wait-list group|Wait-list. They will do the usual classes without modern board games. At the end of the postintervention evaluation, the Conectar Jugando Game Program will be implemented under the same conditions as the experimental group.
88861716|NCT05267418|Active Comparator|automated nasal oxygen titration with FreeO2 alone|The participant received automated nasal oxygen titration administered by a closed loop system (FreeO2) during the 3-min constant speed shuttle test (3-min CSST) and endurance shuttle walking test (ESWT). The objective of this system is maintain SpO2 a the pre-specified target level (94% in this study) with an automatic adjustment of oxygen flow second by second.
88861717|NCT05267418|Active Comparator|automated nasal oxygen titration with FreeO2 with high-flow nasal O2 therapy|In addition to nasal oxygen titration administered by a closed loop system (FreeO2), the participant received high flow nasal therapy (Airvo2) set at 60 liters per minute with nasal canula during the 3-min CSST and endurance shuttle walking test.
88861718|NCT05267418|Active Comparator|Fixed-flow oxygen therapy|The participant received oxygen by nasal canula at a fixed flow of 2 liters per minute during the 3-min constant speed shuttle test (3-min CSST) and endurance shuttle walking test (ESWT). In patients already on home oxygen, the O2 flow during exercise was set at 1 L/min above the usual flow used at home .
89386513|NCT03424694|Experimental|1 fraction of 19.5 Gy HDR brachytherapy|"HDR Brachytherapy as monotherapy at a dose 19.5 Gy is delivered in 1 fraction. Treatment is done on a single ultrasound guided implant, post implant MRI assisted planning and dosimetry.~HDR brachytherapy implant is done under anesthesia with ultrasound guidance as an out-patient procedure."
89386514|NCT01340365|Other|Usual Care|
89386515|NCT01340365|Experimental|Tai Chi|Individuals will take part in community-based Tai Chi classes twice a week for 6 months as well as practice Tai Chi outside of class twice a week for the same 6 month period.
89386516|NCT01337999||HE-4 levels, healthy premenopausal women|
89386517|NCT03571412|Experimental|5Hz Left Dorsolateral Prefrontal Cortex|This group will receive 5Hz Left Dorsolateral Prefrontal Cortex repetitive Transcranial Magnetic Stimulation. Once a day on monday to friday. Until complete 15 sessions.After complete acute phase intervention (15 sessions) subject will have a 5 week clinical follow up.
88861719|NCT00134004|Experimental|Mini-haplo Transplant|Non-myeloablative haploidentical bone marrow transplant with a fludarabine, cyclophosphamide (Cy), TBI (total body irradiation) preparative regimen and post-transplant Cy, mycophenolate mofetil (MMF), and tacrolimus as GVHD prophylaxis.
88861720|NCT00135798|Experimental|LADR Treatment, Genotypes 1,4,6|Subjects randomized to low accelerating dose regimen (LADR) treatment
88861721|NCT00135798|No Intervention|Standard care|Subjects randomized to Standard Care group, Genotypes 1,4,6
88861722|NCT00135798|Experimental|LADR treatment, Genotypes 2,3|Subjects randomized to low accelerating dose regimen (LADR) treatment.
88861723|NCT00136812|No Intervention|enhanced usual care control|NRT during hospitalization with brief advice to stay quit once discharged
88861724|NCT00136812|Experimental|stage-tailored intervention|NRT during hospitalization with brief advice to stay quit once discharged plus a computer-delivered stage-tailored smoking cessation intervention with manual and counseling plus 10-weeks of nicotine patch available post-hospitalization
88861725|NCT00137280|Experimental|Collaborative Chronic Illness Care Model|Collaborative Chronic Illness Care Model: A care model that integrates greater availability of clinical information, reorganizes the practice system and provider roles, fosters care coordination, and focuses on evidence-based protocols--specifically supported employment and wellness services for individuals with schizophrenia.
89184892|NCT02570685|Experimental|Reflective Interpersonal Gratitude|An interpersonal gratitude journal, designed to foster gratitude for one's existing social relationships, by writing and reflecting on people and positive daily encounters for which one is grateful.
88861726|NCT00137280|No Intervention|Usual Care|Usual Care
88861727|NCT01790334||Spontenous Ventilation (Group S)|ultrasonography of Right internal jugular vein
88861728|NCT01790334||Pressure control Ventilation (Group P)|ultrasonography of Right internal jugular vein
88861729|NCT01790334||Volume control ventilation (Group V)|ultrasonography of Right internal jugular vein
88861730|NCT00138294|Experimental|Intervention Cities|Children 4 years of age and older in the intervention cites (Temple, Belton, Academy, Troy, Salado, Rogers, and Holland) with be offered live attenuated or inactivated influenza vaccines through a school-based research vaccination program.
88861731|NCT00138294|Active Comparator|Comparison Cities|Children living in the comparison cities (Waco, Bryan and College Station) which are within 90 miles of the intervention cites will received their influenza vaccines (live attenuated or inactivated influenza vaccines) by the local healthcare providers.
88861732|NCT02103114|Experimental|Anti-thrombin III|
88861733|NCT02103114|Placebo Comparator|Placebo|
88861734|NCT00140244|Active Comparator|r-MetHuLeptin|r-MetHuLeptin SubQ once daily
88861735|NCT00140244|Placebo Comparator|Placebo|SubQ once daily
88861736|NCT02103270|Placebo Comparator|Oat Flour 600 mg|Arm C that is maintained on placebo (oat flour) throughout the study; this arm will receive 600 mg oat flour beginning on week 104. This will be true even if a subject in the placebo group meets criteria at week 104
88861737|NCT02103270|Active Comparator|Peanut Protein 4,000mg|Arm A on peanut OIT until week 104 (maintenance) and once meeting criteria [i.e. 1) on OIT treatment for minimum 104 weeks, 2) taking daily maintenance dose of 4,000 mg protein for at least 13 weeks, 3) no severe reactions to home dosing from Week 91-Week 104, and 4) no reactions at the Week 104 DBPCFC] will be assigned to avoid peanut (i.e. will consume 600 mg oat flour daily) and will proceed to tolerance and desensitization phase.
88861738|NCT02103270|Active Comparator|Peanut Protein 300 mg|Arm B on peanut OIT until week 104 and once meeting criteria specified in description of Arm A, will be assigned to be maintained on 300 mg peanut protein (i.e. 600 mg peanut flour) daily and will proceed to the tolerance and desensitization testing phase.
89184893|NCT02570685|Experimental|Reflective-Behavioral Gratitude|An interpersonal gratitude journal, designed to foster gratitude for one's existing social relationships, by writing and reflecting on people and positive daily encounters for which one is grateful. In addition participants are asked to choose a friend express this gratitude to them at the end of each week.
89184894|NCT02570685|Active Comparator|Neutral Control Journal|Write about and reflect on things that occurred over the course of the day.
88861739|NCT01790412|Experimental|Exercise group|"Three sessions per week:~Supervised exercise program"
88861740|NCT01790412|No Intervention|Control|Sedentary pregnant women
88861741|NCT01790022|Experimental|Methylprednisolone 500 mg|Methylprednisolone 500 mg administered intravenously at baseline
88861742|NCT00140556|Experimental|ChemoRadiotherapy|Radiation Therapy concurrent with cisplatin chemotherapy, Avastin and Tarceva
88861743|NCT05215392|Experimental|Smartphone Application|Family members in the experimental group of this study will receive an ecological momentary intervention (EMI) derived from an ecological momentary assessment (EMA) via the Family Connections smartphone app.
88861744|NCT05215392|Active Comparator|Treatment As Usual|Family members in this condition will receive the manual of Family Connections which contains all the information on the program sessions conducted and the skills training strategies in writing.
88861745|NCT00142116|Experimental|Thalidomide and Rituximab|"Thalidomide 200mg orally once a day for 14 weeks if that dosage is tolerated well, it will be increased to 400mg for up to 50 weeks~Rituximab Given intravenously once weekly for 4 weeks beginning the second week of study treatment. If tolerated well, this may be repeated 8 weeks later."
88861746|NCT05201430|Experimental|A: FOLFOXIRI|Neoadjuvant chemotherapy with 3-4 cycles of FOLFOXIRI regimen, followed by surgery
88861747|NCT05201430|Experimental|B: CapeOX|Neoadjuvant chemotherapy with 2-3 cycles of CapeOX regimen, followed by surgery
88861748|NCT05188560|Experimental|AOT+MI|participants who, in addiction to standard rehabilitation program after surgery, underwent a single pre-operative training session of action observation therapy associated with motor imagery.
88861749|NCT05188560|No Intervention|Control group|Participants who was not subjected to any pre-operative activity. They received standard rehabilitation program after surgery too.
88861750|NCT00142506|Active Comparator|1|radiotherapy with hormones, questionaire assessments
88861751|NCT00142506|Placebo Comparator|2|radiotherapy without hormones, questionaire assessments
88861752|NCT05266794|No Intervention|Control|25 hemodialysis patients who received their routine therapy only.
88861753|NCT05266794|Active Comparator|Selenium|23 hemodialysis patients who received Selenium 200µg once daily with their routine therapy just after the dialysis sessions for 3 months.
88861754|NCT05266794|Active Comparator|Alpha Lipoic acid|20 hemodialysispatients who received Alpha Lipoic acid (ALA) (Thiotex fort®) 600mg once daily with their routine therapy just after the dialysis sessions for 3 months.
89184895|NCT04018833||ranibizumab|Patients nonresponsive to bevacizumab that were switched to ranibizumab
89184896|NCT04018833||aflibercept|Patients nonresponsive to bevacizumab that were switched to aflibercept
89184897|NCT04066803|Experimental|MTX group with folic acid|the group with optimal MTX dose (gradually increased from 0 to 12weeks，appropriate folic acid，and stable original other DMARDs
89184898|NCT04066803|Active Comparator|control group without folic acid|the group with stable MTX 10mg/w dose and maximum DMARDs doses（graduallly increased from 0 to 12 weeks）without folic acid
88861755|NCT00142818|Experimental|Naltrexone plus modafinil|Nal + Mod
88861756|NCT00142818|Experimental|Naltrexone|Nal
88861757|NCT00142818|Experimental|Modafinil|Mod
88861758|NCT00142818|Placebo Comparator|Placebo|Placebo
88861759|NCT05266716|Experimental|Primary Arm|The study will involve a total of approximately 48 individuals enrolled during a six-week period as participants in the field test of the Affect digital therapeutic platform
88861760|NCT00147030|Active Comparator|cooled|Whole body mild induced hypothermia for 72 hours, starting by 6 hours of age, in addition to standard intensive care. After 72 hours of cooling, rewarming by a maximum of 0.5 degree C / hour to normothermia.
88861761|NCT00147030|No Intervention|non-cooled|Standard intensive care
88861762|NCT05266560|Active Comparator|Propofol injection group (1.5mg/kg)|The patients in the propofol group were given intravenous injection of propofol 1.5 mg/kg and succinylcholine 1 mg/kg in turn, and the interval between each drug administration was 1 minute, and electroconvulsive therapy was performed after the patients were anesthetized.
88861763|NCT05266560|Experimental|Ciprofol injection group(0.4mg/kg)|The patients in the ciprofol group were given intravenous injection of ciprofol 0.4 mg/kg and succinylcholine 1 mg/kg in turn. The interval between each drug administration was 1 minute, and the patients received electroconvulsive therapy after anesthesia.
89184899|NCT02570373|Experimental|Guselkumab|Participant will receive a single intravenous (IV) infusion of guselkumab at a dose of 10 milligram per kilogram (mg/kg) over 60 minutes on Day 1.
89184900|NCT02569827|Placebo Comparator|Cohort 1|"Placebo Q6H for 5 days~A total of 72 participants (18 participants per group assuming up to two drop-outs per group) will be assigned in a randomised double-blind fashion."
88861764|NCT00147966|Experimental|ritxumab|all patients get treatment
88861765|NCT04528212|Experimental|Group I|Glimepiride (4 mg) per Day
88861766|NCT04528212|Experimental|Group II|Glimepiride (4 mg) plus Fenofibrate (160 mg) per Day
88861767|NCT04528212|Experimental|Group III|Glimepiride (4 mg) plus Curcumin (1100 mg) With 5mg Black Pepper per Day
88861768|NCT05265936|Active Comparator|Guidewire through DJ stent|Patients who underwent lithotripsy after guidewire insertion through a previously placed double j stent.
88861769|NCT05265936|Sham Comparator|DJ stent remove + guidewire|Patients who underwent lithotripsy after double j stent removal and guidewire placement.
88861770|NCT05265858||Patients with hip osteoarthritis|Patients with hip osteoarthritis who will undergo total hip arthroplasty
88861771|NCT00148668|Active Comparator|Arm 1|Herceptin/navelbine
88861772|NCT00148668|Active Comparator|Arm 2|Taxotere/carboplatin/herceptin
88861773|NCT05265780|Experimental|kinesiotape|kinesiotaping group
88861774|NCT05265780|Sham Comparator|control|sham group
88861775|NCT00149838|Experimental|Active prefrontal rTMS phase1|Phase I participants receiving rTMS
89535272|NCT03091803||Arm II (QSM, T1WI, gadoterate meglumine, GOCART DCE MRI)|Patients undergo standard of care QSM and T1WI. Patients then receive gadoterate meglumine IV and undergo GOCART DCE MRI over 60 minutes.
89535273|NCT03207685|Other|All Subjects|This is a single arm study With a device intervention of Additional Seizure Monitoring
89535274|NCT03320135|Active Comparator|Enamel matrix derivative proteins|Open flap debridement to enamel matrix derivative application in proximal class-II furcation.
89535275|NCT03320135|Active Comparator|Open Flap Debridement|Open flap debridement in proximal class-II furcation.
89535276|NCT03227575|Experimental|Post-Meal Walking Group|"Following a 30-minute digestion period, the Post-Meal Walking Group will be instructed to walk following breakfast, lunch, and dinner at least 4 times per week (180 minutes of moderate intensity exercise/week). Participants will walk at a brisk pace for 15 minutes, as demonstrated in a previous study. A Garmin VivoFit activity monitor will measure their physical activity across the four-week intervention. The Garmin VivoFit activity monitor must be returned during the Follow-up Study Visit."
88861776|NCT00149838|Placebo Comparator|Sham rTMS phase 1|Phase I participants receiving sham stimulation
88861777|NCT00149838|Experimental|rTMS extension|rTMS. Phase II participants, all of whom did not meet remission requirements after phase 1. They all receive active open label rTMS
88861778|NCT00149838|Experimental|Open label antidepressant regimen|All patients who met remission who were then transitioned to medications after the TMS trial was completed.
88861779|NCT01790646||patients undergoing general anesthesia|every elective patient undergoing general anesthesia for neurosurgical procedures with endotracheal intubation
88861780|NCT04410822||Patients enrolled|an age older than 18 years old and symptoms of FI according to Rome IV criteria.
88861781|NCT00324870|Experimental|Arm I|"Phase I: Patients receive oral SAHA twice daily on days 1-14 and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of SAHA until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. An additional 6 patients are treated at the MTD.~Phase II: Patients receive SAHA at the MTD determined in phase I and bevacizumab as in phase I."
88861782|NCT00151320|Experimental|Arm 1|"Standard CHOP chemotherapy administered every 21 days (full dose) for six cycles~Rituximab administered (375 mg/m2) day 1 of each cycle (with usual premedications)~VELCADE (Bortezomib) is administered prior to rituximab and CHOP on day 1 of each cycle. The dose of VELCADE will be determined by a dose escalation schedule."
88861783|NCT00326196|Active Comparator|PCI|Percutaneous coronary intervention
88861784|NCT00326196|Active Comparator|CABG|Coronary artery bypass graft (CABG)
88861785|NCT04332198|Experimental|ALS patients|
88861786|NCT00328770|Experimental|Sirolimus based immunosuppression|Sirolimus given intravenously or orally to achieve serum level of 12-20ug/l
88861787|NCT05105568|Experimental|Process-based therapy|
89184901|NCT02569827|Active Comparator|Cohort 2|Modipafant 50 mg Q12H alternating with placebo Q12H for 5 days (total of 10 modipafant doses = 500 mg)
89184902|NCT02569827|Active Comparator|Cohort 3|Modipafant 100 mg Q12H alternating with placebo Q12H 5 days (total of 10 modipafant doses = 1000 mg)
88861788|NCT04281654|Experimental|Ballroom Dance|The Dance group participants will take part in ballroom dance lessons twice/week for 45-minutes/session for 10 weeks
88861789|NCT04281654|Experimental|Ukulele|The Music group participants will take part in ukulele lessons twice/week for 45-minutes/session for 10 weeks
88861790|NCT04281654|Active Comparator|Control|The Control group participants will meet 2 times per week for 45-minutes/session for 10 weeks to participate in a social conversational group for 10 weeks
88861791|NCT04952376|Active Comparator|Short message service (SMS)|Subjects will receive vaccine availability and appointment information via SMS.
88861792|NCT04952376|Experimental|Personalized text message|Subjects will receive vaccine availability and appointment information via a personalized message text from the primary care provider (PCP).
88861793|NCT04952376|Experimental|Interactive or 2-way SMS|Subjects will receive vaccine availability and appointment information via interactive 2-way SMS options.
88861794|NCT04177680|Experimental|Omega-3 pentaenoic acid (MAT9001)|2g MAT9001 capsules twice daily with meals
88861795|NCT04177680|Active Comparator|Icosapent ethyl (Vascepa)|2g Vascepa capsules twice daily with meals
88861796|NCT01790724|Experimental|Walking exercise|Participants will be instructed in safe walking exercise. They will participate in an eight week, tapered, on-site program. Participants will also attend group workshops where they will learn self-regulatory skills such as goal-setting, self-monitoring, barrier trouble-shooting, rewarding, and relapse prevention and recovery.
88861797|NCT01790724|Active Comparator|Metabolic health education|Participants will complete an eight-week online metabolic health education course. Topics will include glucose control, insulin, weight management, nutrition, physical activity, eye/kidney/foot health, stress reduction, and doctor-patient communication.
88861798|NCT00330876|Experimental|Pitavastatin 2 mg QD|Pitavastatin 2 mg once daily
88861799|NCT00330876|Experimental|Pitavastatin 4 mg QD|Pitavastatin 4 mg once daily
88861800|NCT01792206|Active Comparator|Zemplar|Zemplar 1 mcg or placebo to be taken once daily with breakfast for 3 months
88861801|NCT01792206|Placebo Comparator|Placebo|Zemplar 1 mcg or placebo to be taken once daily with breakfast for 3 months
88861802|NCT00333606|Experimental|Verum acupuncture|Acupuncture of specific acupuncture points
88861803|NCT00333606|Sham Comparator|Sham acupuncture|Acupuncture of non-specific acupuncture points
88861804|NCT04947852|Experimental|Investigation Mask|Bi Level CPAP Mask
88861805|NCT04947852|Active Comparator|Comparator Mask|Bi Level CPAP Mask
88861806|NCT00334074|Experimental|Clofarabine and Cytarabine|Five consecutive days of clofarabine 40 mg/m^2 IVI over 1 hour followed 4 hours later by cytarabine 1000 mg/m^2 IVI over 2 hours
88861807|NCT00335478|Experimental|Daptomycin|
88861808|NCT01790802|Experimental|Active laser|Twelve 2RT nanosecond laser shots in two arcs of 6 shots superiorly and 6 shots inferiorly, inside the retinal vascular arcades at an approximate distance from the fovea of 3000 microns, with approximately one laser spot diameter between them.
88861809|NCT01790802|Sham Comparator|Sham laser procedure|The maximum illumination button on hte 2RT laser will be briefly pressed by the operating physician at each of the 12 locations where and when the laser would normally be applied. The laser remains in standby mode preventing accidental laser firing.
89184903|NCT02569827|Active Comparator|Cohort 4|Celgosivir 150 mg Q6H for 5 days (total of 20 doses = 3000 mg total).
88816440|NCT02404350|Placebo Comparator|Placebo arm 1 (Group 4)|"Placebo to Secukinumab sc injection every week for 4 weeks followed by placebo to Secukinumab every 4 weeks until week 16. Non-responders will be switched to Secukinumab either 150 or 300 mg sc injection every four weeks until week 100. Responders at week 16 continued receiving placebo until week 24, then were switched to secukinumab 150 or 300 mg sc injection every 4 weeks until week 100. PLEASE NOTE: Placebo arms 1 and 2 belong to the same placebo group (group 4)~Beginning at Week 52, for subjects whose signs and symptoms were not fully controlled, and who the investigator believed may improve further with an increase in dose, may have had the secukinumab dose increased to 300mg s.c. every 4 weeks."
88861810|NCT01790880|Active Comparator|ORLA|Practice on ORLA (Oral Reading for Language in Aphasia), a computer-based virtual therapy system, for 90 minutes per day, 6 days per week for 6 weeks.
88861811|NCT01790880|Experimental|ORLA + Writing|"Practice on ORLA + writing computer program, 90 minutes per day, 6 days per week, for 6 weeks."
88861812|NCT02103816|Experimental|SmartLipo Triplex laser system along with the SideLaze800 hand|
88861813|NCT04870164|Experimental|ensovibep dose 1 (infusion)|
88861814|NCT04870164|Experimental|ensovibep dose 2 (infusion)|
88861815|NCT04870164|Experimental|ensovibep dose 3 (infusion)|
88861816|NCT04870164|Placebo Comparator|placebo (infusion)|
88861817|NCT04870164|Experimental|ensovibep dose 4 (IV bolus)|
88861818|NCT04870164|Experimental|ensovibep dose 5 (IV bolus)|
88861819|NCT04870164|Experimental|ensovibep dose 6 (SC injection)|
88861820|NCT04870164|Experimental|ensovibep dose 7 (SC injection)|
88861821|NCT04870164|Experimental|ensovibep dose 8 (SC injection)|
88861822|NCT04870164|Experimental|ensovibep dose 9 (SC injection)|
88861823|NCT04870164|Experimental|ensovibep dose 10 (IM injection)|
88861824|NCT04870164|Experimental|ensovibep dose 11 (IM injection)|
88861825|NCT04870164|Experimental|ensovibep dose 12 (IM injection)|
88861826|NCT04870164|Experimental|ensovibep dose 13 (IM injection)|
88861827|NCT01791036|Experimental|Adductor Canal Block Group|Adductor Canal Block
88861828|NCT01791036|Active Comparator|Femoral Nerve Block Group|Femoral Nerve Block
89184904|NCT05648565|Experimental|Radiofrequency ablation (RFA)|
89184905|NCT00725439|Experimental|A|Talarozole
89386518|NCT03571412|Experimental|5Hz Dorsomedial Prefrontal Cortex|This group will receive 5Hz Dorsomedial Prefrontal Cortex Transcranial Magnetic Stimulation, once a day on monday to friday. Until complete 15 sessions.After complete acute phase intervention (15 sessions) subject will have a 5 week clinical follow up.
89386519|NCT01341769|Placebo Comparator|Control Test Food|Snack base
89386520|NCT01341769|Experimental|Experimental Test Food 1|Snack Base containing ingredient 1
88861829|NCT04345926|Experimental|Dose-response|"- Concentration of propofol at the loss of consciousness (LOS) will be recorded in the presence of remifentanil (7.5 ng/mL) (LOS time).~- Patients will be intubated and remifentanil will be decreased to 4 ng/mL.~- Concentration of propofol that caused the LOS will be maintained for 20 minutes (Baseline time).~- Propofol will be increased in steps of 0.3 mcg/mL for 7 minutes until an episode of burst suppression will be observed (Burst suppression time).~EEG activity will be acquired using a SedLine® monitor during the complete protocol."
88861830|NCT03974646|Experimental|intervention group|Participants assigned to the intervention group will receive both will receive usual care (standard clinical and medical services) provided to individual with CKD stages 3-4 who attend the CKD clinic at medical outpatient department on their clinic follow up , and a 12- weeks self-management intervention delivered by two dedicated and trained renal nurse educators. The intervention will involve three group-based sessions, CKD booklet and three follow-up phone calls.
88861831|NCT03974646|No Intervention|control group|Participants randomized to the control group in this study will receive usual care (standard clinical and medical services) provided to individual with CKD stages 3-4 who attend the CKD clinic at medical outpatient department on their clinic follow up. Usual care consisted of brief verbal information (2-5 minutes) about taking medications, reducing salt, smoking cessation and reducing alcohol consumption. There will no structured program but only the provision of written material to patients.
88861832|NCT00337350|Active Comparator|rosiglitazone|rosiglitazone 4mg/day
88861833|NCT00337350|Placebo Comparator|placebo|matched placebo for 4mg rosiglitazone
88861834|NCT00338598|Experimental|Glycine|Glycine, 0.8 gr per kg given in two daily doses
88861835|NCT00338598|Placebo Comparator|placebo|placebo will be administered.
88861836|NCT00338988|Experimental|Capecitabine + Oxaliplatin|Combination of intravenous (IV) oxaliplatin 100 mg/m^2 Day 1 and oral (PO) capecitabine 750 mg/m^2 twice daily (total daily dose 1500 mg/m2) on Days 1-14.
88861837|NCT00343044|Experimental|Treatment|Subjects received standard topotecan with the addition of bevacizumab. Cycles were 28 days and continued until toxicity, progression or subject wish to discontinue treatment. Topotecan administered 4 mg/m2 IV on days 1, 8 and 15 and bevacizumab IV 10 mg/kg, days 1 and 15 of each cycle.
88861838|NCT04724304|Experimental|Healthy adults|Healthy adults will have blood flow to the heart evaluated using s Real-Time Myocardial Echocardiography (RTMPE) and magnetic resonance image (MRI) to the heart.
88861839|NCT00344370|Experimental|Pitavastatin|Pitavastatin 4 mg QD
88861840|NCT00344370|Active Comparator|Atorvastatin|Atorvastatin 40 mg
88861841|NCT00344682|Experimental|memantine|memantine (5-20mg a day)
88861842|NCT00344682|Placebo Comparator|Placebo|placebo (5-20mg a day)
88861843|NCT00345384|Placebo Comparator|Normal Saline|One group (placebo comparator) will receive a normal saline infusion, set at a rate as if it were the active drug.
89184906|NCT00920166|Experimental|Modilac Pétunia 1|Formula with reduced total protein concentration, enriched in alpha-lactalbumin and containing a symbiotic
89184907|NCT00920166|Active Comparator|Modilac 1|Regular milk
89184908|NCT02570217|Experimental|HHHFNC|The patients receive respiratory support by mean of Heated Humidified High Flow Nasal cannula
89184909|NCT02570217|Active Comparator|NCPAP|Patients receive respiratory support by Nasal Continuous Positive Airways Pressure(NCPAP)
89386521|NCT01341769|Experimental|Experimental Test Food 2|Snack base containing ingredient 2
89386522|NCT01341769|Experimental|Experimental Test Food 3|Snack base containing ingredients 1 and 2
89386523|NCT04344431|Experimental|HBO group|
89386524|NCT04344431|No Intervention|Non-HBO group|
88861844|NCT00345384|Active Comparator|Dexmedetomidine|The second group (the study group) will receive a continuous infusion of dexmedetomidine titrated from 0.1 - 0.5 mics/kg/h to control pain for up to 24 hours after they are admitted to an open nursing unit after discharge from the PACU or ICU
89535277|NCT03227575|Experimental|Traditional Exercise Group|"The Traditional Exercise Group will perform aerobic and light resistance training exercise over the 4-week intervention. A group of trained Exercise and Sports Physiology students will conduct the aerobic exercise and light resistance training program three times per week (180 minutes of moderate to high intensity exercise/week). Garmin VivoFit activity monitors will measure their physical activity across the four-week intervention. The Garmin VivoFit activity monitor must be returned during the Follow-up Study Visit."
88861845|NCT01791114|Experimental|Cold water consumption|Subjects will participate in two trials as part of this protocol: a) cold water (4 °C) consumption and b) tepid (36 °C) water consumption
88861846|NCT01791114|Experimental|Meal consumption|Subjects will participate in two trials as part of this protocol: a) High calorie meal consumption and two weeks later b) no meal consumption.
88861847|NCT01791114|Experimental|Cold exposure|Participants will complete three studies: a) cold exposure study (above their individually determined shivering threshold ~ 16°C); b) Cold exposure plus 0.5mg/kg up to 40mg propranolol at the beginning of the metabolic study and again after 4-6 hrs; c) thermoneutral conditions (26 - 28°C).
88861848|NCT01791114|Experimental|Exercise|Subjects between 18 and 35 years old will be asked to participate in two trials: a) Exercise, i.e. four times for 10 min- at 85% VO2max (maximal oxygen consumption). with 15-min breaks between each bout b) and two weeks later rest.
88861849|NCT04271592|Experimental|Part 1: SAD Cohorts 1-7 ABI-H3733 Liquid Form|A single dose of ABI-H3733 liquid oral dosage form administered on Day 1. Cohort 1 will receive a 100-mg dose. Subsequent cohorts 2-7 will receive a ≤3-fold increase in dose from the previous cohort; the dose will be determined by evaluation of safety and PK data from previous cohorts.
88861850|NCT04271592|Placebo Comparator|Part 1: SAD Cohorts 1-7 Placebo Liquid Form|A single dose of placebo matching ABI-H3733 liquid oral dosage form will be administered on Day 1. Cohort 1 will receive a 100-mg dose. Subsequent cohorts 2-7 will receive a ≤3-fold increase in dose from the previous cohort; the dose will be determined by evaluation of safety and PK data from previous cohorts.
88861851|NCT04271592|Experimental|Part 1: MAD Cohorts 8-10 ABI-H3733 Liquid Form|Once-daily doses of ABI-H3733 liquid oral dosage form will be administered from Day 1 to Day 5. Cohort 8 will receive a dose determined from evaluation of the data from the SAD cohorts. Subsequent cohorts 9 and 10 will receive a ≤3-fold increase in dose from the previous cohort; the dose will be determined by evaluation of safety and PK data from previous cohorts.
88861852|NCT04271592|Placebo Comparator|Part 1: MAD Cohorts 8-10 Placebo Liquid Form|Once-daily doses of placebo matching ABI-H3733 liquid oral dosage form will be administered from Day 1 to Day 5. Cohort 8 will receive a dose determined from evaluation of the data from the SAD cohorts. Subsequent cohorts 9 and 10 will receive a ≤3-fold increase in dose from the previous cohort; the dose will be determined by evaluation of safety and PK data from previous cohorts.
88861853|NCT04271592|Experimental|Part 2: Single Dose Fasted Cohort 11 ABI-H3733 Solid Form|A single dose of ABI-H3733 solid oral dosage form will be administered in a fasted state on Day 1. The decision to proceed with Part 2 and the dose administered will be determined after evaluation of cumulative safety and PK data from Part 1.
88861854|NCT04271592|Placebo Comparator|Part 2: Single Dose Fasted Cohort 11 Placebo Solid Form|A single dose of placebo matching ABI-H3733 liquid oral dosage form will be administered in a fasted state on Day 1. The decision to proceed with Part 2 and the dose administered will be determined after evaluation of cumulative safety and PK data from Part 1.
88861855|NCT04271592|Experimental|Part 2: Single Dose Fed Cohort 12 ABI-H3733 Solid Form|A single dose of ABI-H3733 solid oral dosage form will be administered after a high-fat meal on Day 1. The decision to proceed with Part 2 and the dose administered will be determined after evaluation of cumulative safety and PK data from Part 1.
88861856|NCT04271592|Placebo Comparator|Part 2: Single Dose Fed Cohort 12 Placebo Solid Form|A single dose of placebo matching ABI-H3733 solid oral dosage form will be administered after a high-fat meal on Day 1. The decision to proceed with Part 2 and the dose administered will be determined after evaluation of cumulative safety and PK data from Part 1.
88861857|NCT04271514|Experimental|COMPLETED ENROLLMENT -- Single Dose Escalation Part A - active|Increasing doses of RPT193 will be administered to healthy volunteers
88861858|NCT04271514|Placebo Comparator|COMPLETED ENROLLMENT -- Single Dose Escalation Part A - placebo|Matching placebo will be administered to healthy volunteers
88861859|NCT04271514|Experimental|COMPLETED ENROLLMENT -- Multiple Dose Escalation Part B - active|Increasing doses of RPT193 will be administered once/day for 7 days to healthy volunteers
88861860|NCT04271514|Placebo Comparator|COMPLETED ENROLLMENT -- Multiple Dose Escalation Part B - placebo|Matching placebo will be administered once/day for 7 days to healthy volunteers
88861861|NCT04271514|Experimental|COMPLETED ENROLLMENT -- Expansion Part C - active|RPT193 will be administered daily for 28 days to patients with atopic dermatitis
88861862|NCT04271514|Placebo Comparator|COMPLETED ENROLLMENT -- Expansion Part C - placebo|Matching placebo will be administered daily for 28 days to patients with atopic dermatitis
88861863|NCT01791192|Experimental|FTY720|Fingolimod
88861864|NCT01791192|Active Comparator|Oral Corticosteroid|Oral Corticosteroid
88861865|NCT01793766|Experimental|Brain modulation|10 sessions of brain modulation with Eldith/Neuroconn transcranial Direct Current Stimulation device
88861866|NCT01793766|Placebo Comparator|Placebo (sham modulation)|10 placebo sessions where no brain modulation takes place
88861867|NCT00346476||Participants|Individuals in the Masiphumelele Township of Cape Town, South Africa, who have been potentially exposed to TB and/or HIV
88861868|NCT01793844||A (R-CHOP21)|"CHOP combined with Rituximab regimen（R-CHOP21）~Treatment Arm A(R-CHOP21): Rituximab 375mg/m2 for injection on day1; cyclophosphamide(C), 750mg/m2 for injection on day2; doxorubicin(H), 50mg/m2 for injection on day2; and Vincristine(O), 1.4mg/m2 for injection on day2, prednisone(P) 60mg/m2 orally on days 2 to 6. The therapy was repeated every 21 days for a total of 6 cycles."
88861869|NCT01793844||B (CHOP14)|Biweekly CHOP regimen （CHOP14） Treatment Arm B (CHOP14): cyclophosphamide(C), 750mg/m2 for injection on day1; doxorubicin(H), 50mg/m2 for injection on day1; and Vincristine(O), 1.4 mg/m2 for injection on day1, prednisone(P) 60mg/m2 orally on days 1 to 5. The therapy was repeated every 14 days for a total of 6 cycles.PS: G-CSF 1.0-2ug/kg/ d for subcutaneous injections will be administered on day 6 for a total use of 6-8 days.
88861870|NCT01793844||C （R-CHOP14)|Biweekly CHOP combined with Rituximab regimen（R-CHOP14） Treatment Arm C (R-CHOP14): Rituximab 375mg/m2 for injection on day1; cyclophosphamide(C), 750mg/m2 for injection on day2; doxorubicin(H), 50mg/m2 for injection on day2; and Vincristine(O), 1.4mg/m2 for injection on day2, prednisone(P),60mg/m2 orally on days 2 to 6. The therapy was repeated every 14 days for a total of 6 cycles.PS: G-CSF 1.0-2ug/kg/ d for subcutaneous injections will be administered on day 7 for a total use of 6-8 days patients with bulky disease or extranodal lesion wil be received radiotherapy after finishing the chemotherapy.
88861871|NCT04019418|Placebo Comparator|No Carbohydrate Drink + Rest|Participants will consume the no carbohydrate drink (300ml water) followed by a rest session
89184910|NCT03205761|Experimental|olaparib|Patients with a positive methylation status on at least one of the two genes and lacking of known deleterious or suspected deleterious mutations in both genes could be included in the study to receive olaparib tablet formulation at 600 mg total daily dose (given in two oral administrations of 300 mg every 12 hours approximately). Patients will continue to receive their treatment until objective disease progression, symptomatic deterioration, unacceptable toxicity, death or withdrawal of consent, whichever occurs first.
88861872|NCT04019418|Active Comparator|No Carbohydrate Drink + Exercise|Participants will consume the no carbohydrate drink (300ml water) followed by an exercise session (75% VO2 max on a cycle ergometer)
88861873|NCT04019418|Active Comparator|Carbohydrate Drink + Rest|Participants will consume the carbohydrate drink (300ml water + 75g maltodextrin) followed by a rest session
89184911|NCT02584218|Experimental|Non-invasive resin based caries sealing|Application of resin based sealant after acid etching of carious occlusal surface
89184912|NCT02584218|Active Comparator|Invasive resin based restoration|Application of resin based resin restoration after operative intervention of caries lesion, excavation and preparation on occlusal surface
89184913|NCT03933540||Pediatric Asthma Patients|"Participants are ages 8 years through 17 years and have partially controlled or uncontrolled asthma.~No intervention is included in this study."
88861874|NCT04019418|Experimental|Carbohydrate Drink + Exercise|Participants will consume the carbohydrate drink (300ml water + 75g maltodextrin) followed by an exercise session (75% VO2 max on a cycle ergometer)
88861875|NCT00347022|Experimental|Xenetix|The patient receive one injection of Xenetix 300 (300 mg of iodine/ml)
88861876|NCT00347022|Active Comparator|Visipaque|The patient receive one injection of Visipaque 270 (270 mg of iodine/ml)
88861877|NCT04714866|Experimental|Interventional group|Cognitive behavioral therapy for ADHD
88861878|NCT04714866|No Intervention|waiting list group|No Intervention for the waiting list group
88861879|NCT00350142|Experimental|Stereotactic Body Radiotherapy|Patients will have a 4D pancreatic protocol CT and a FDG PET scan scan, both for planning purposes. An SBRT treatment plan will be developed based on tumor geometry and location. All patients will receive a single fraction of 25 Gy dose of Stereotactic Body Radiotherapy on Trilogy Linear Accelerator, followed by weekly Gemcitabine.
88861880|NCT00350220|Active Comparator|1|High Hemoglobin group; goal Hb >13g/dl. 10cc/kg RBCs are transfused for any hemoglobin value under 13g/dl regardless whether clinical indication for transfusion exists.
88861881|NCT00350220|Active Comparator|2|Low Hb transfusion group; goal to not transfuse unless the Hb <9.0 g/dl. 10cc/kg RBCs are transfused only if the Hemoglobin is under 9.0g/dl and clinical indications for transfusion exist.
88861882|NCT01791348|Other|d2 test of attention|
88861883|NCT03962400|Active Comparator|Control|Subjects will have warfarin dose determined in the usual fashion by a health care provider.
88861884|NCT03962400|Experimental|Treatment|Subjects will have warfarin dose determined using a reinforcement learning computer model.
88861885|NCT04588272||2 liters|40 patients will receive O2 supply at rate of 2 liters per minute and then cabnographic and other measures will be recorded through out the procedure.
88861886|NCT04588272||4 liters|40 patients will receive receive O2 supply at rate 4 liters per minute and then cabnographic and other measures will be recorded through out the procedure.
88861887|NCT04588272||6 liters|: 40 patients will receive O2 supply at rate 6 liters per minute and then cabnographic and other measures will be recorded through out the procedure.
88861888|NCT03860610||Patient group 1 after THA|Patients who have already received a THA (N=30) for OA will be assessed 1 year postoperatively (Visit A); Interventions in this Group: 'Muscle strength test', 'Dynamic stability test during level and uphill walking', 'Postural stability test', 'EuroQol Group Health questionnaire (EQ-5D-5L)', 'HOOS/ KOOS', ' Muscle activity test', 'Passive range of motion'
88861889|NCT03860610||Patient group 2 after TKA|Patients who have already received a TKA (N=30) for OA will be assessed 1 year postoperatively (Visit A); Interventions in this Group: 'Muscle strength test', 'Dynamic stability test during level and uphill walking', 'Postural stability test', 'EuroQol Group Health questionnaire (EQ-5D-5L)', 'HOOS/ KOOS', ' Muscle activity test', 'Passive range of motion'
88861890|NCT03860610||Patient group 3 before THA|Patients with severe hip OA (N=30) scheduled to receive a THA will be assessed preoperatively (Visit 1), 12 weeks postoperative (Visit 2) and 1 year postoperative (Visit 3). Interventions in this Group: 'Muscle strength test', 'Dynamic stability test during level and uphill walking', 'Postural stability test', 'EuroQol Group Health questionnaire (EQ-5D-5L)', 'HOOS/ KOOS', ' Muscle activity test', 'Passive range of motion'
89184914|NCT00725517|Experimental|1|Icodextrin group
89184915|NCT00725517|No Intervention|2|Glucose group
89184916|NCT00920751|Experimental|Water infusion|Water infusion in lieu of air insufflation during colonoscope insertion
89184917|NCT00920751|Active Comparator|Air insufflation|Conventional air insufflation colonoscopy
89184918|NCT00725595||E, 2, III|To treat CSR with ASV and Bilevel ventilators
89184919|NCT04620291|Experimental|Cohort A|250 mg UB-421 SC: ART-treated subjects
89184920|NCT04620291|Experimental|Cohort B|500 mg UB-421 SC: ART-treated subjects
88861891|NCT03860610||Patient group 4 before TKA|Patients with severe knee OA (N=30) scheduled to receive a TKA will be assessed preoperatively (Visit 1), 12 weeks postoperative (Visit 2) and 1 year postoperative (Visit 3). Interventions in this Group: 'Muscle strength test', 'Dynamic stability test during level and uphill walking', 'Postural stability test', 'EuroQol Group Health questionnaire (EQ-5D-5L)', 'HOOS/ KOOS', ' Muscle activity test', 'Passive range of motion'
89386525|NCT05709080|Experimental|family-professional collaboration practice model|"Physical therapists in the family-professional collaboration practice model group will receive instructions in the collaborative intervention, following the process and the strategies of the family-professional collaboration practice model to enhance the collaboration during physical therapy sessions.~The instruction conducted online in two sessions for six hours (3 hours per session).~the therapists in this group will treat the children according to steps of family-professional collaboration practice model: Step 1: Mutually agreed-upon goals, Step 2: shared planning, Step 3:Shared implementation, and Step 4: Shared evaluation of child and family outcomes."
89386526|NCT05709080|No Intervention|conventional therapy|"Physical therapists in the conventional therapy group will not receive any instructions related to the collaborative intervention process.~the therapists in this group will treat the children as conventional therapy"
89386527|NCT05184127|Experimental|MIR 19 ®|Study participants from experimental groups, in addition to standard COVID-19 therapy, received the MIR 19 ® (2 inhalations per day with a single dose of 1.85 or 5.55 mg at intervals of 7-8 hours for 14 days).The standard therapy in this group included symptomatic treatment without use of any etiotropic drugs such as Favipiravir, Umifenovir, Remdesivir, convalescent plasma and interferon α-2b
89386528|NCT05184127|Active Comparator|Standard COVID-19 therapy|In the comparison group, therapy was carried out in accordance with the current version of the temporary methodological recommendations of the Ministry of Health of the Russian Federation for the treatment of COVID-19 infection.The standard therapy included symptomatic treatment as well as etiotropic drugs such as Favipiravir, Umifenovir, Remdesivir, convalescent plasma and interferon α-2b. In the experimental groups treated with MIR 19 ®, the therapy included symptomatic treatment without use of any etiotropic drugs such as Favipiravir, Umifenovir, Remdesivir, convalescent plasma and interferon α-2b.
89386529|NCT01338077|Experimental|Sodium alginate|Oral suspension, 50 mg/ml
89386530|NCT01338077|Active Comparator|Omeprazole|20 mg/cap
88861892|NCT03860610||Healthy control group|Age-matched healthy control subjects (N=30);Interventions in this Group: 'Muscle strength test', 'Dynamic stability test during level and uphill walking', 'Postural stability test', 'EuroQol Group Health questionnaire (EQ-5D-5L)', 'HOOS/ KOOS', ' Muscle activity test', 'Passive range of motion'
88861893|NCT01791426|Experimental|Artelac Rebalance|Artelac Rebalance ophthalmic solution contains 0.15% hyaluronic acid, is unpreserved and presented in single dose units with a fill volume of 0.5 mL.
88861894|NCT01791426|Active Comparator|Vismed|Vismed ophthalmic solution, contains 0.18% sodium hyaluronate, is unpreserved and presented in single dose units with a fill volume of 0.3 mL.
88861895|NCT03821844|Experimental|Music and Memory|Music and Memory is a personalized music program in which nursing home staff provide people with dementia with music playlists tailored to their personal history of music preferences.
88861896|NCT03821844|No Intervention|Usual Care|Usual care for managing agitated and/or aggressive behaviors in the nursing home setting.
89386531|NCT03570320|No Intervention|Control group|The first treatment group will be our control arm. On discharge following their surgery, these patients will receive a single prescription for 225 Morphine Milligram Equivalents (MMEs). This corresponds to #30 pills of 5mg oxycodone/acetaminophen, #45 pills of 5mg hydrocodone/acetaminophen, or #30 pills of 7.5mg Morphine.
88861897|NCT00350532|Active Comparator|Neuropathic Pain Subjects|Chronic Pain Participants will be trained to accurately estimate pain by way of thermal heat testing. Next a small amount of spinal fluid will be withdrawn from each participant to measure the amounts of naturally-made chemicals in the participants' cerebrospinal fluid. Participants then will receive an injection of clonidine. After the injection, additional samples of spinal fluid will be taken to measure chemical changes in the fluid.
88861898|NCT00350532|Active Comparator|Healthy Subjects|Healthy Participants will be trained to accurately estimate pain by way of thermal heat testing. Next a small amount of spinal fluid will be withdrawn from each participant to measure the amounts of naturally-made chemicals in the participants' cerebrospinal fluid. Participants then will receive an injection of clonidine. After the injection, additional samples of spinal fluid will be taken to measure chemical changes in the fluid.
89386532|NCT03570320|Experimental|Interventional Arm|Patients who are randomized into the second group will also receive prescriptions for 225 MME's on discharge following their surgery, however their medications will be broken up equally into 3 separate scripts, each for 75 MME's. This corresponds to 3 scripts for #10 pills of 5mg oxycodone/acetaminophen, 3 scripts for #15 pills of 5mg hydrocodone/acetaminophen, or 3 scripts for #10 pills of 7.5mg Morphine. Each script will be post-dated to ensure that patients wait the appropriate amount of time between filling their scripts, and that they cannot fill multiple scripts on the same day or at the same time.
89386533|NCT01315561|Experimental|acupuncture|MSAT is a treatment method in which the patient is exposed to active or passive movement and exercise during acupuncture, as opposed to conventional acupuncture.
89386534|NCT01315561|Active Comparator|injections of diclofenac|the control group was treated with intramuscular injections of diclofenac(NSAID). All administrations were limited to 1 session
89386535|NCT04328129|Experimental|Primary case|Subject with laboratory-confirmed coronavirus SARS-CoV-2 infection by polymerase chain reaction (PCR)
89386536|NCT04328129|Experimental|Family contact|Subject who lived in the household of the primary case while the primary case was symptomatic
89386537|NCT01336309||Focus Group|We conducted three focus groups per site, at three sites, with around eight people each. These data were used to guide refinement and selection of the items we developed for Phase III data collection. We will administer the Yoga Research Tool.
88861899|NCT00351936|Active Comparator|Aripiprazole|aripiprazole 15mg/day
88861900|NCT00351936|Placebo Comparator|placebo|matched placebo for aripiprazole 15mg/day
89184921|NCT04620291|Experimental|Cohort C|700 mg UB-421 SC: ART-treated subjects
89386538|NCT01336309||Cognitive Interviews|We conducted cognitive interviews at three different sites, with about ten in each group. These data were used to guide refinement and selection of the items we developed for Phase III data collection. We collected this data via a large, online survey and administered the Yoga Research Tool.
89386539|NCT01336309||Survey Prototype Administration|We administered a prototype of the study measure to a large group of yoga students, with about 450 total participants. These data were used to further inform the refinement and selection of items to be used in the final measure.
89386540|NCT01336309||Reliability and Validity Testing|We are conducting yoga classes at community partner facilities near each site, with about ten participants in each class. Participants at each class will complete the study measure and related questionnaires, in order to test the reliability and validity of the study measure.
89386541|NCT03571178|Experimental|Treatment|Patients who will receive physical therapy
89386542|NCT04266665|Active Comparator|Dexmedetomidine|Dexmedetomidine 2 μg/ml will be given as bolus 1mg/kg for 10 minutes with a maintenance dose of 0.8μg/kg/h until surgery completion
89386543|NCT04266665|Placebo Comparator|Normal saline|Normal saline (NaCl 0.9%) administration will start 10 minutes after anesthesia induction and maintained throughout the surgical procedure.
89386544|NCT05182021||Case group|The case group represented by 50 primigravida women aged 35 y or more during their pregnancy or at the time of delivery
89386545|NCT05182021||Control group|The control group represented by 50 primigravida women aged 20 y : 34 y during their pregnancy or at the time of delivery
89386546|NCT03571100|Active Comparator|Povidine-Iodine|Bilateral injections patients receiving Povidine-Iodine in right eye, chlorhexidine in the left eye
89386547|NCT03571100|Active Comparator|Chlorhexidine|Bilateral injections patients receiving Povidine-Iodine in left eye, chlorhexidine in the right eye
89386548|NCT01338311|Active Comparator|salbutamol|
89386549|NCT01338311|Placebo Comparator|placebo|200mcg twice daily for a total of 7 doses
89386550|NCT01336387|Experimental|Arm I (retinoid 9cUAB30)|Participants receive retinoid 9cUAB30* PO on days 1-28.
89386551|NCT01336387|Placebo Comparator|Arm II (placebo)|Participants receive placebo* PO on days 1-28.
89386552|NCT00501800||Caucasian|
89386553|NCT00501800||African American|
88861901|NCT00352794|Experimental|Lenalidomide + Prednisone|Lenalidomide oral 10 mg daily/days 1-21 of 28 day cycle. Prednisone starting dose oral 30 mg/day during cycle 1, 15 mg/day during cycle 2, and 15 mg every other day during cycle 3, and then it will be discontinued.
88861902|NCT04421118||standard portal pressure gradient measurement and CT scan|"Procedure/Surgery:~Portal pressure gradient measurement and CT imaging examination. Three-dimensional models reconstructing and fluid dynamics simulation."
88861903|NCT00353418|Experimental|PEG-IFN Alfa-2a 180 μg + Ribavirin 800 mg|
89386554|NCT00501800||Chinese|
89386555|NCT00501800||Latina (Mexican or Central American)|
89386556|NCT00501800||Filipina|
89386557|NCT01334879|Active Comparator|With Loading Doses|5 patients will receive intravitreal injections every 30 days (+/- 7 days) for the first 4 months and every month thereafter until month 12 (maximum of 12 injections)
89386558|NCT01334879|Active Comparator|Physician Discretion|5 patients will receive intravitreal ranibizumab every 30 days (+/- 7 days) on as needed basis based on the criteria defined in the study.
89386559|NCT05354492|Experimental|Active Program Participant|You will actively take part in the group program via Zoom with our program facilitators.
88861904|NCT00353418|Active Comparator|PEG-IFN Alfa-2a 180 μg + Ribavirin 1000 or 1200 mg|
89386560|NCT05354492|No Intervention|Program Wait List|You will be placed on a wait list to take part in the program.
89386561|NCT01315717||Group 1|Healthy subjects
89386562|NCT01315717||Group 2|Patients with Mild Cognitive Impairment
89535278|NCT03227575|No Intervention|Case Control Group|"The participant will be instructed to maintain their current diet and levels of physical activity for four weeks. Participants in this group will wear an ambulatory blood pressure monitor at baseline and at follow-up. Any change in diet and physical activity level might significantly affect the study results. The Control Group will maintain their current lifestyle for four weeks. Garmin VivoFit activity monitors will measure their physical activity throughout the 4-week intervention. The Garmin VivoFit activity monitor must be returned during the Follow-up Study Visit."
89184922|NCT04620291|Experimental|Cohort D|500 mg UB-421 SC: Treatment naive subjects
89184923|NCT04620291|Experimental|Cohort E|700 mg UB-421 SC: Treatment naive subjects
89386563|NCT01315717||Group 3|Patients with Mild AD
89386564|NCT01315717||Group 4|Patients with Moderate AD
89386565|NCT03570242|No Intervention|Control group (palliative treatment)|"usual care control group (includes patients undergoing palliative Treatment) receives individualized nutritional support (dietary advices: daily protein intake1,2 - 1,5 g/kg bodyweight)"
89386566|NCT03570242|Experimental|WB-EMS group (palliative treatment)|"physical exercise group (includes patients undergoing palliative Treatment) receives regular WB-EMS training (2 EMS trainings per week; each session for 20 min)~+ individualized nutritional support (dietary advices: daily protein intake 1,2-1,5 g/kg bodyweight)"
89386567|NCT03570242|No Intervention|Control group (curative treatment)|"usual care control group (includes patients undergoing curative treatment 3-4 weeks before surgery) receives individualized nutritional support (dietary advices: daily protein intake1,2 - 1,5 g/kg bodyweight)"
89386568|NCT03570242|Experimental|WB-EMS group (curative treatment)|"physical exercise group (includes patients undergoing adjuvant treatment 3-4 weeks before surgery) receives regular WB-EMS training (2 EMS trainings per week; each session for 20 min)~+ individualized nutritional support (dietary advices: daily protein intake 1,2-1,5 g/kg bodyweight)"
89386569|NCT01315795|Experimental|Symptomatic polycystic liver disease (PCLD) patients|Symptomatic polycystic liver disease (PCLD) patients
89386570|NCT03570164|Experimental|Sevoflurane|Anesthesia is maintained with sevoflurane.
89386571|NCT03570164|Experimental|Desflurane|Anesthesia is maintained with desflurane.
89386572|NCT05181943|Experimental|Laser irradiation (Test group)|laser irradiation over lesion
89386573|NCT05181943|Active Comparator|Conventional treatment (Control group|
89386574|NCT01315951|Experimental|Petroleum Jelly|Every patient will be applying petroleum jelly to the affected areas per protocol.
89386575|NCT01340443||Cohort|
89386576|NCT01391234|Experimental|STAT RT planning and delivery workflow|single arm
89386577|NCT05184049|Experimental|Epalrestat|oral epalrestat (50mg/ time, 3 times/day) + conventional hypoglycemia + oral mecobalamin (0.5mg/ time, 3 times/day) for half a year
89386578|NCT05184049|Experimental|The control group|conventional hypoglycemia + oral mecobalamin (0.5mg/ time, 3 times/day) for half a year
89386579|NCT01336543|Experimental|Active Treatment|"ACTIVE TREATMENT intervention below:~NSCLC (Non-Small Cell Lung Cancer)~PE (Cisplatin 50mg/m2 on days 1,8,29,36 Etoposide 60 mg/m2 days 1-3 and 29-31)~Radiation 59.4 Gy with 2 cycles of PE~(Non-squamous histology) Pemetrexed consolidation 500mg/m2 every 21 days for 4 cycles~(Squamous histology) Gemcitabine consolidation 1000mg/m2 days 1,8, every 21 days for 4 cycles"
89386580|NCT03570086||migraineurs without aura|
89386581|NCT03570086||health controls|
89386582|NCT01341847|Active Comparator|Water method colonoscopy|This technique allow only water infusion (air pump is turned off) through the adaptor on the biopsy channel of the colonoscope during insertion since the scope is inserted into the anus until reach the cecum. Water will be infused as needed under endoscopist judgement through the adaptor on biopsy channel with endoscopic washer pump. The usual air insufflation will be used during colonoscope withdrawal to facilitate mucosal examination and perform any other intervention, such as biopsy
89386583|NCT01341847|Other|air method colonoscopy|This technique only use usual air insufflation technique during colonoscope insertion and shortening maneuvers.
89386584|NCT03568370|Experimental|olive oil|use one drop olive oil on each nipple after each feeding
89386585|NCT03568370|No Intervention|breast milk|use breast milk on each nipple after each feeding
89386586|NCT03568214|Experimental|Individualized moderate + high-intensity|"12 weeks of moderate-intensity continuous training (MICT) combined with high-intensity interval training (HIIT)~4 days per week of MICT for 50 minutes per session~1 day per week of HIIT for 35 minutes per session~Exercise intensity for MICT will be established according to ventilatory thresholds one and two (VT1 and VT2)~The HIIT protocol will consist of eight, 60 second intervals at 100% maximal oxygen uptake (VO2max), separated by 150 seconds active recovery"
89386587|NCT03568214|Experimental|Standardized moderate-intensity|"12 weeks of MICT~5 days per week of MICT for 50 minutes per session~Exercise intensity for MICT will be established according to 40-65% heart rate reserve (HRR)"
89386588|NCT03568214|No Intervention|Control|non-exercise control group testing at baseline and post-program (12 weeks)
89386589|NCT03568136|Experimental|Treatment Arm A|Patients in treatment arm A receive 300 mg Secukinumab administered as 2 subcutaneous injections of 150 mg (i.e. 2x 150 mg) at baseline day 1 and week 1, 2, 3, 4, 8, 12 and injections with placebo at week 5, 6, 7 and 16. For assessments of the study endpoints were followed up visits at week 20 and 24. Placebo will be administered as 2 subcutaneous injections.
89386590|NCT03568136|Placebo Comparator|Treatment Arm B|Patients in treatment arm B receive placebo until visit 3 (week 3) and will switch to Secukinumab 300 mg s.c. up from visit 4 (week 4), visit 5, 6, 7, 8, 12 and16. For assessments of the study endpoints were followed up visits at week 20 and 24.
89386591|NCT01336621|Experimental|Retigabine IR|Open label flexible dose between 300 mg/day (Minimum) and 1200 mg/day (maximum).
89386592|NCT05187481|Experimental|Experimental Group|The experimental group will take Jianpi Huatan dispensing granule while receiving chemotherapy and/or targeted therapy, once a day in the morning and evening, 30 days as a course of treatment, a total of 3 courses.
89184924|NCT00725673||1|GOLD II COPD patients with osteoporosis
89386593|NCT05187481|Placebo Comparator|Control Group|The experimental group will take Placebo granule (containing 1/10 of the formula dose of Jianpi Huatan Granule) while receiving chemotherapy and/or targeted therapy, once a day in the morning and evening, 30 days as a course of treatment, a total of 3 courses.
89386594|NCT00383435|Experimental|MF/F MDI 400/10 mcg BID|
89386595|NCT00383435|Experimental|MF/F MDI 200/10 mcg BID|
89386596|NCT00383435|Experimental|MF MDI 400 mcg BID|
89386597|NCT00383435|Active Comparator|Formoterol MDI 10 mcg BID|
89386598|NCT00383435|Placebo Comparator|Placebo MDI BID|
89386599|NCT01336699|Experimental|Cohort A|WRSs2 vaccine 1x10^3 colony-forming units (cfu) orally (8 patients), WRSs3 vaccine 1x10^3 cfu orally (8 patients), Placebo 30 ml orally (2 patients)
89386600|NCT01336699|Experimental|Cohort B|WRSs2 vaccine 1x10^4 colony-forming units (cfu) orally (8 patients), WRSs3 vaccine 1x10^4 cfu orally (8 patients), Placebo 30 ml orally (2 patients)
89386601|NCT01336699|Experimental|Cohort C|WRSs2 vaccine 1x10^5 colony-forming units (cfu) orally (8 patients), WRSs3 vaccine 1x10^5 cfu orally (8 patients), Placebo 30 ml orally (2 patients)
89386602|NCT01336699|Experimental|Cohort D|WRSs2 vaccine 1x10^6 colony-forming units (cfu) orally (8 patients), WRSs3 vaccine 1x10^6 cfu orally (8 patients), Placebo 30 ml orally (2 patients)
89386603|NCT01336699|Experimental|Cohort E|WRSs2 vaccine 1x10^7 colony-forming units (cfu) orally (8 patients), WRSs3 vaccine 1x10^7 cfu orally (8 patients), Placebo 30 ml orally (2 patients)
89386604|NCT03698123|Experimental|Dietary Modification|On the first night of the study, participants can eat and drink as they normally would (no dietary intervention). On second and third nights participants will be provided meals, snacks and drinks with specific macronutrient composition, encouraged to only eat and drink study meals, snacks and drinks, and to avoid eating after 10:00 hours. The composition of the study foods and drinks on nights 2 and 3 will be different.
89386605|NCT01340599|Experimental|Arm I (Polyphenon E)|Patients receive defined green tea catechin extract PO once daily QD for 4-10 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo radical prostatectomy between days 28-70.
89184925|NCT00725673||2|GOLD II COPD patients with a normal bone mineral density
89184926|NCT04434417||Cohort tested|The cohort will include patients or health professionals who patients who were suspected of being infected with 2019-nCoV
89184927|NCT02586714||Normal weight|
89184928|NCT02586714||Overweight|
89386606|NCT01340599|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD for 4-10 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo radical prostatectomy between days 28-70.
89386607|NCT01335035|Experimental|ICL670|
89386608|NCT01340677|Experimental|001|Canagliflozin 100 mg Type=1 unit=mg number=100 form=tablet route=oral use. Tablet is taken once without food during 1 of 3 treatment periods.,Canagliflozin 300 mg Type=1 unit=mg number=300 form=tablet route=oral use. Tablet is taken once without food during 1 of 3 treatment periods.,Canagliflozin 50 mg Type=1 unit=mg number=50 form=tablet route=oral use.Tablet is taken once without food during 1 of 3 treatment periods.
89386609|NCT05164315|Experimental|Tailored surgery|Arm 1 will receive tailored surgery. If there are no cancer cells or the margin is negative in the local excision/biopsy during surgery, the operation will be terminated. And if the final pathology result is T2-4, or cancer cells and margin are positive in the frozen section during surgery, or the result of digital rectal examination and visual examination using anoretractor under general anesthesia is not suitable for local excision (visible and palpable tumor nodules), a total mesorectal excision will be performed.
89386610|NCT05164315|Active Comparator|Total mesorectal excision (TME)|Arm 2 will receive TME. Surgery including high ligation of the inferior mesenteric artery and total mesorectal excision will be performed under the lithotomy position. After pelvic dissection, double-stapled anastomosis or transanal anastomosis will be performed, followed by diverting stoma. Abdominoperineal resection with permanent stoma is included.
89386611|NCT01335269|Experimental|Treatment arm|BI 853520 once daily in a dose escalation schedule
89386612|NCT05183815|Experimental|massage|
89386613|NCT01335347|Experimental|Experimental Low Dose|Biological: One dose of a live replication incompetent adenovirus given in a capsule
89386614|NCT01335347|Experimental|Experimental Medium Dose|"Biological: One or two doses of replication incompetent adenovirus given in a capsule~Other: Placebo capsules of the same size and shape"
89386615|NCT01335347|Experimental|Experimental High Dose|Biological: One dose of replication incompetent adenovirus in a capsule
89386616|NCT01335347|Placebo Comparator|Placebo Control|Capsules of the same size and shape as the experimental
89184929|NCT02586714||Obese|
89386617|NCT05164003|Experimental|CORETOX®|
89386618|NCT05164003|Active Comparator|BOTOX®|
89386619|NCT05163535|Experimental|VM-1500A-LAI (1200 mg, 1200 mg, 1200 mg)|VM-1500A-LAI 3 i / m injections with an interval of 4 weeks (1200 mg, 1200 mg, 1200 mg) during daily therapy with 2NRTIs for 12 weeks
89386620|NCT05163535|Experimental|VM-1500A-LAI (1200 mg, 900 mg, 900 mg)|VM-1500A-LAI 3 i / m injections with an interval of 4 weeks (1200 mg, 900 mg, 900 mg) during daily therapy with 2NRTIs for 12 weeks
89386621|NCT05163535|Experimental|VM-1500A-LAI (1200 mg, 600 mg, 600 mg)|VM-1500A-LAI 3 i / m injections with an interval of 4 weeks (1200 mg, 600 mg, 600 mg) during daily therapy with 2NRTIs for 12 weeks
88861905|NCT00353652|Active Comparator|Study#1: chlorthalidone (CTD) first then spironolactone (SP)|Participants in study #1 only received 2 interventions. All subjects are randomized to receive 3 months of chlorthalidone first (12.5-25 mg/d), using a single-blind 2-phase crossover design. Then, the subject is transitioned to treatment with spironolactone (25-75 mg/d)without washout period for 3 months. Following 3 month treatment period, the procedures listed below were performed. After completion of the study procedures, the medication is discontinued.
89386622|NCT05163535|Other|ELPIDA®|ELPIDA®, 20 mg capsules and 2NRTIs, daily therapy for 12 weeks
88861906|NCT00353652|Active Comparator|Study #1: spironolactone (SP) first, then chlorthalidone (CTD)|Participants in study #1 only received 2 interventions. All subjects are randomized to receive 3 months spironolactone first (25-75 mg/d), using a single-blind 2-phase crossover design. Then, the subject is transitioned to treatment with chlorthalidone(12.5-25 mg/d) without washout period. Following 3 month treatment period, the procedures listed below were performed. After completion of the study procedures, the medication is discontinued.
89184930|NCT02059551|Experimental|Intervention|"In case of positive D-dimer testing or in patients with a high clinical probability of PE, these patients have MRI protocol combined with venous ultrasonography of the legs. MRI includes 2 different sequences: Unenhanced steady-state-free precession sequences (SSFP) sequences and angiography sequences. (please see \\\intervention section\\\ for more details). MRI readings will be performed centrally by two independent readers blinded to the results of diagnostic reference standard. Venous ultrasonography of the legs will be interpreted locally."
89386623|NCT01338467|Experimental|EYEOP Treatment|Open label, all subject treated by the EYEOP device
89386624|NCT01340755|Experimental|Transanal endoscopic surgery|Laparoscopy-assisted transanal endoscopic rectosigmoid resection
89386625|NCT01336777||Insulin resistant group|there is no intervention
89386626|NCT01336777||Insulin sensitive group|There is no intervention
89386627|NCT04434209|Experimental|NephroCheck-guided interventions|
89386628|NCT04434209|Active Comparator|Standard of Care|Standard of Care assessment and treatment
89386629|NCT01341925|Placebo Comparator|Placebo Supplement and No PEP|Will receive two capsules by mouth, two times daily matched for odor and appearance with the active intervention.
89386630|NCT01341925|Experimental|Omega-3 and PEP|"Omega-3 Supplementation will receive 1000 mg Ω3 (two 500 mg capsules, each containing 350 mg EPA: 50 mg DHA; 100 other Ω3)by mouth, two times daily.~Psychoeducational Psychotherapy (PEP)Therapy sessions occur twice a week for up to 24 sessions of manualized treatment."
89386631|NCT01341925|Experimental|Omega-3 and No PEP|Omega-3 Supplementation will receive 1000 mg Ω3 (two 500 mg capsules, each containing 350 mg EPA: 50 mg DHA; 100 other Ω3)by mouth, two times daily.
89386632|NCT01341925|Experimental|Placebo Supplement and PEP|"Placebo Supplement will receive two capsules by mouth, two times daily matched for odor and appearance with the active intervention.~Psychoeducational Psychotherapy (PEP)Therapy sessions occur twice a week for up to 24 sessions of manualized treatment."
89386633|NCT01338545||Cohort|
89386634|NCT01342003||Subtype 1a|subtype 1a patients treated with peginterferon plus ribavirin
89386635|NCT01342003||subtype 1b|subtype 1b patients treated with peginterferon plus ribavirin
89386636|NCT01338623|Experimental|Tansulosine|
89386637|NCT01340833|Experimental|Study Medication|GSK2118436
89386638|NCT01332383||Patients prescribed AMERGE|Patients with migraine disorders prescribed AMERGE during study period
88861907|NCT00353652|Active Comparator|Study# 2 CTD alone 1st, CTD+ SP 2nd, CTD+IR 3rd|Subjects are randomized to receive 3 months of fixed-dose chlorthalidone (CTD, 25 mg/d) alone first, using a single-blind 3-phase crossover design. Then, subjects are treated with fixed-dose CTD (25 mg/d) plus fixed-dosespironolactone (SP) 25 mg daily for 3 months, then fixed-dose CTD (25 mg/d) plus fixed-dose irbsesartan (IR, 150 mg daily) for 3 months. After completion of the study procedures, the medication is discontinued.
88861908|NCT00353652|Active Comparator|Study# 2 CTD alone 1st, CTD+IR 2nd, CTD+SP3rd|Subjects are randomized to receive 3 months of fixed-dose chlorthalidone (CTD, 25 mg/d) alone first, using a single-blind 3-phase crossover design. Then, subjects are treated with fixed-dose CTD 25 mg/d plus fixed-dose irbsesartan (IR, 150 mg daily) for 3 months, followed by fixed-dose CTD (25 mg/d) plus fixed-dose spironolactone (SP) 25 mg daily for 3 months. After completion of the study procedures, the medication is discontinued.
88861909|NCT00353652|Active Comparator|Study# 2 CTD+SP1st, CTD alone 2nd, CTD+IR 3rd|Subjects are randomized to receive fixed-dose CTD (25 mg/d) plus fixed-dose spironolactone (SP) 25 mg daily for 3 months, using a single-blind 3-phase crossover design. Then, subjects are treated with fixed-dose CTD 25 mg/d alone for 3 months, then fixed-dose CTD 25 mg/d plus fixed-dose irbsesartan (IR, 150 mg daily) for 3 months. After completion of the study procedures, the medication is discontinued.
88861910|NCT00353652|Active Comparator|Study# 2 CTD+SP1st, CTD+IR 2nd, CTD alone 3rd|Subjects are randomized to receive fixed-dose CTD (25 mg/d) plus fixed-dose spironolactone (SP) 25 mg daily for 3 months, using a single-blind 3-phase crossover design. Then, subjects are treated with fixed-dose CTD 25 mg/d plus fixed-dose irbsesartan (IR, 150 mg daily) for 3 months, then fixed-dose CTD 25 mg/d alone for 3 months. After completion of the study procedures, the medication is discontinued.
88861911|NCT00353652|Active Comparator|Study# 2 CTD+IR 1st, CTD alone 2nd, CTD+SP 3rd|Subjects are randomized to receive fixed-dose CTD 25 mg/d plus fixed-dose irbsesartan (IR, 150 mg daily) for 3 months, using a single-blind 3-phase crossover design. Then, subjects are treated with fixed-dose CTD 25 mg/d alone for 3 months, then fixed-dose CTD (25 mg/d) plus fixed-dose spironolactone (SP) 25 mg daily for 3 months. After completion of the study procedures, the medication is discontinued.
88861912|NCT00353652|Active Comparator|Study# 2 CTD+IR 1st, CTD+SP 2nd, CTD alone 3rd|Subjects are randomized to receive fixed-dose CTD 25 mg/d plus fixed-dose irbsesartan (IR, 150 mg daily) for 3 months, using a single-blind 3-phase crossover design. Then, subjects are treated with fixed-dose CTD (25 mg/d) plus fixed-dose spironolactone (SP) 25 mg daily for 3 months, followed by fixed-dose CTD 25 mg/d alone for 3 months. After completion of the study procedures, the medication is discontinued.
88861913|NCT01792362|Experimental|AMH|obese PCOS patients who underwent weight loss diet
88861914|NCT03740880|Active Comparator|Late trigger|dual trigger (10.000 IU hCG i.m. and 0.3 mg Deca) once the leading follicle is 17 mm
88861915|NCT03740880|Experimental|Early trigger|dual trigger (10.000 IU hCG i.m. and 0.3 mg Deca) once the leading follicle is 14 mm
88861916|NCT02982798|Experimental|Group I|Period I: administration of Metformin + Rosuvastatin Period II: JLP-1310
88861917|NCT02982798|Experimental|Group II|Period I: JLP-1301 Period II: administration of Metformin + Rosuvastatin
88861918|NCT03709914|Experimental|ZTI-01 Cohort 1 ≥ 6 to <12 years of age|ZTI-01 (fosfomycin IV) 100 mg/kg (single dose) Subjects weighing within the 3rd to < 97th percentile for age
88861919|NCT03709914|Experimental|ZTI-01 Cohort 2 ≥ 2 to <6 years of age|ZTI-01 (fosfomycin IV) 100 mg/kg (single dose) Subjects weighing within the 3rd to < 97th percentile for age
88861920|NCT03709914|Experimental|ZTI-01 Cohort 3a Birth to < 3 mos of age|ZTI-01 (fosfomycin IV) 75 mg/kg (single dose) Subjects weighing within the 3rd to < 97th percentile for age
88861921|NCT03709914|Experimental|ZTI-01 Cohort 3b ≥ 3 to < 6 mos of age|ZTI-01 (fosfomycin IV) 100 mg/kg (single dose) Subjects weighing within the 3rd to < 97th percentile for age
88861922|NCT03709914|Experimental|ZTI-01 Cohort 3c ≥ 6 to < 24 mos of age|ZTI-01 (fosfomycin IV) 100 mg/kg (single dose) Subjects weighing within the 3rd to < 97th percentile for age
88861923|NCT03921840|Experimental|Intervention|Based on the self-efficacy theory, participants in the intervention arm will receive personalized, circadian-based activity guidelines, a 2-hour in person education session, real time physical activity self-monitoring, interactive prompts, biweekly phone consultation with the research team, and financial incentives for achieving weekly physical activity goal.
89184931|NCT02585856|Experimental|PDT+stent|Patients with unresectable CCA are performed PDT and biliary stent with ERCP
89184932|NCT02585856|Placebo Comparator|stent|Patients with unresectable CCA are performed biliary stent with ERCP alone
89386639|NCT01338701|Experimental|Auricular (Ear) Acupuncture|Auricular (Ear) Acupuncture is administered in a step-wise, algorithmic acupuncture approach in which needles are inserted at specific auricular landmarks. The sequence and location of needled points is determined by the participant's severity of headache pain at presentation and response to needling. Between six and nine points are needled in each treatment session depending on the individual's response (i.e., a decrease or persistence of headache pain). In-dwelling ASP needles are inserted at the end of each session. Participants are instructed to remove the needles after 3 days, or sooner if pain or redness developed at a needle site. Ten 45-minute acupuncture treatment sessions are administered over 6 weeks.
89386640|NCT01338701|Experimental|Traditional Chinese Acupuncture (TCA)|A semi-standardized form of Traditional Chinese Acupuncture (TCA) is administered, incorporating the insertion of up to 22 acupuncture needles associated with each individual participant's: (1) primary headache pattern (up to three pairs of points); (2) secondary headache pattern (up to 2 pairs of points); (3) Ah-Shi or tender points (up to 4 points); (4) constitutional points (source points on two meridians); and, (5) up to 2 pairs of additional points from a selected list. Point selection was reassessed every two weeks per TCM diagnostic and treatment principles. While the majority of points were located on the limbs, points also included local points of tenderness to the head, as well as the front and back of the torso. Ten 60-minute TCA sessions are administered over 6 weeks.
89386641|NCT01338701|Other|Usual Care|All study participants continue to receive routine usual care for their TBI, headaches and associated symptoms as determined by their clinical team.
88861924|NCT03921840|Placebo Comparator|Control|The control group will receive general education on physical activity for older adults and continue daily activity and healthcare routine. Participants will also receive a Go4Life program book from the National Institute on Aging.
88861925|NCT01794078|Placebo Comparator|Control|Oral placebo, administered as single dose during simulated altitude episodes Cycle 1 and Cycle 2
88861926|NCT01794078|Experimental|Aminophylline 400 mg|Oral aminophylline 400 mg, administered as single dose during simulated altitude episodes Cycle 1 and Cycle 2
88861927|NCT01794078|Experimental|ambrisentan 5 mg|Oral ambrisentan 5 mg, administered as single dose during simulated altitude episodes Cycle 1 and Cycle 2
88861928|NCT01794078|Experimental|Combined aminophylline 400 mg and ambrisentan 5 mg|Oral combined aminophylline 400 mg and ambrisentan 5 mg, administered as single doses during simulated altitude episodes Cycle 1 and Cycle 2
88861929|NCT03436680|Experimental|Group I (neurofeedback)|Participants complete at least neurofeedback training sessions over 30 minutes 2 times a week for up to 5 weeks.
88861930|NCT03436680|Active Comparator|Group II (standard of care)|Participants receive standard of care.
88861931|NCT01791504|Experimental|TissuGlu Surgical Adhesive|Standard wound closure techniques plus TissuGlu and no drains.
88861932|NCT01791504|No Intervention|Control - Standard of Care|Standard wound closure techniques with drains.
88861933|NCT00354978|Experimental|FOLFIRI plus Bevacizumab|FOLFIRI [folinic acid (leucovorin) 400 mg/m^2 by vein (IV) Day 1; 5-FU 400 mg/m^2 IV injection Day 1 immediately followed by 2.4 g/m^2 IV over 46 hours over Days 1-3; Irinotecan 180 mg/m^2 IV on Day 1] + Bevacizumab 5 mg/kg over 90 minutes on Day 1 administered alone then 5 mg/kg IV on Day 1 of 14 day cycle.
89184933|NCT00794417|Experimental|Phase 1: Aflibercept 6 mg/kg and Pemetrexed and Cisplatin|Participants received intravenous infusion of aflibercept 6 mg/kg followed by pemetrexed 500 mg/m^2 and then cisplatin 75 mg/m^2 on Day 1 of each 3 week cycle (1 Cycle = 21 Days in this study) until disease progression, unacceptable toxicity, withdrawal of consent or if another study withdrawal criterion has been met.
88861934|NCT01792440||non-cystic fibrosis bronchiectasis|patients with non-cystic fibrosis bronchiectasis will be evaluated cross-sectionally
88861935|NCT01792440||healthy control subjects|healthy control subjects will be evaluated cross-sectionally
89535279|NCT02638623|Active Comparator|Drug Lactated Ringer|Covered two liters of body temperature warmed lactated ringer's in the immediate preoperative setting of subjects undergoing total knee or total hip replacement
89535280|NCT02638623|Placebo Comparator|Placebo|Covered empty bag with no hydration supplement
88861936|NCT01794156|Active Comparator|Cognitive behavior therapy|"The cognitive-behavioral model is presented and individualized.~Cognitive correction: beliefs are addressed by explaining their roles in maintaining cognitive biases. Next, clients are trained to identify and to challenge their key beliefs~Exposure and response prevention (ERP) using imaginal and in vivo exposure and to both over and covert neutralization is implemented according to hierarchies developed following the individual assessment. Extended periods of exposure permits emotional discomfort to dissipate.~Combined phase: continues ERP while making explicit links to the cognitive targets.~Relapse prevention included a written individualized guide to encourage the maintenance of treatment gains. Self-directed ERP continues."
88861937|NCT01794156|Active Comparator|Mindfulness-based stress reduction (MBSR)|The entire intervention is based on systematic and intensive training in MBSR following Santorelli and Kabat-Zinn and their applications to everyday life. The program is divided in 8 consecutive blocks with daily homework in mindfulness-based stress reduction skills. The main activity of MBSR is a cognitive and intervention-based process characterized by self-regulation of attention to the present moment and an open and accepting orientation towards one's experience.
89003324|NCT05445713||Cohort 4|Participants vaccinated in clinical trials in 2020 prior to widespread community exposure, and hence protected from severe COVID-19 (and possibly Long-COVID) if subsequently infected.
89386642|NCT01340911|Active Comparator|Part 1A, Cohorts 1-6|"Approximately 48 healthy male subjects will be enrolled into 6 separate cohorts (8 subjects per cohort). Each Cohort of subjects will be dosed sequentially, approximately one week apart, at escalating doses. Within each cohort, 6 subjects will be randomized to receive a single dose of SRT3025, and 2 will be randomized to receive a single dose of placebo.~The following are the planned doses for Cohorts 1-6, with Cohort 1 being the lowest dose and Cohort 6 being the highest dose: 50, 150, 500, 1000, 2000, and 3000mg of SRT3025. Dose level may be altered as appropriate during the study based on real time analysis of the safety, tolerability, and /or PK data. Dose adjustment may involve an increase or decrease in dose or dividing the total daily dose allowing for twice-daily dosing. Total daily dosing will not exceed 3000mg."
89386643|NCT01340911|Active Comparator|Part 1B, Cohorts 7-8|One to two of the doses administered in Part 1A may be selected for administration with food, based on expected changes in SRT3025 exposures with food, as well as safety, tolerability, and PK data from Part 1A. If initiated, the effect of a single dose of SRT3025 with a moderate fat/calorie meal may be initiated concurrently with a cohort in Part 2 of the study. Approximately 6 subjects would be enrolled into each cohort in Part 1B.
89386644|NCT01340911|Active Comparator|Part 2A, Cohorts 9-11|Approximately 16-24 healthy subjects will be enrolled into 2 to 3 cohorts (8 subjects per cohort) in Part 2A. Within each cohort, 6 subjects will be randomized to receive multiple doses of SRT3025, and 2 will be randomized to receive multiple doses of placebo. The repeat dosing component of the study will be initiated, and doses selected, based on the evaluation of safety, tolerability, and PK data from Part 1A. Subjects in Part 2A will be randomized to receive 14 consecutive days of dosing with SRT3025 or matched-placebo. Subjects in these Cohorts will be dosed sequentially (in the fasted state) approximately two weeks apart.
89386645|NCT01340911|Active Comparator|Part 2B, Cohorts 12-13|If initiated, the effect of repeat doses of SRT3025 with moderate fat/calorie meals would occur in Part 2B (Cohorts 12 and 13). Each of these cohorts would enroll approximately 6 subjects.
89386646|NCT01340989|Experimental|4% oxygen|addition of 4% oxygen to the CO2 pneumoperitoneum
89386647|NCT01340989|Experimental|full conditioning|full conditioning of the peritoneal cavity by the laparoscopic gas: 4% oxygen, 10% nitrous oxide, humidification and set temperature of 32°C
89386648|NCT01340989|Active Comparator|CO2 pneumoperitoneum|standard laparoscopy with CO2 pneumoperitoneum
89386649|NCT01337011|Experimental|intra-coronary administration|Application of stem cells using the intra-coronary route.
89386650|NCT01337011|Experimental|intra-myocardial administration|Application of stem cells using the intra-myocardial route.
89386651|NCT05162209|Experimental|Synbiotic|Lactobacillus acidophilus, Lactobacillus rhamnosus, Bifidobacterium bifidum, Bifidobacterium longum, Enterococcus faecium (total 2.5 x10 9CFU/sachet), fructooligosaccharydes (FOS) 625 mg, oral sachet daily, for 12 weeks
89386652|NCT05162209|Placebo Comparator|Placebo|Oral sachet daily for 12 weeks
89386653|NCT01342159|Active Comparator|Intravitreal bevacizumab injection|
89386654|NCT01342159|Active Comparator|Intravitreal Triamcinolone injection|
89386655|NCT01342159|Active Comparator|intravitreal bavacizumab with triamcinolone|
89386656|NCT01342237|Experimental|topotecan|
89386657|NCT01337323||New prescription for fluticasone furoate nasal spray|patients receiving their first prescription for fluticasone furoate nasal spray and who have active seasonal allergic rhinitis with a history of using another intranasal steriod (INS) and other concomitant allergic rhinitis medications to treat their seasonal allergy symptoms.
89386658|NCT03157037|Experimental|Imlifidase|Imlifidase 0.25 mg/kg body weight intravenous infusion
88861938|NCT01794156|Experimental|Inference-based therapy|"The inference-based therapy will be delivered in 10-step~The client will:~learn that the compulsions, anxiety and discomfort are driven by an initial obsessional doubt~learn why this doubt is 100% irrelevant here and now~learn the inferential confusion process~have to recognize that the doubt originates from him/her~have to identify/describe the narrative leading him/her to the doubt~have to identify the cross-over point when he/she leaves reality~learn to be aware of the reasoning devices~learn how personal themes dictate the idiosyncratic nature of the person's obsession~explore and reinforced an alternative self-view~be trained to use properly his/her senses in the face of obsessional triggers situations"
88861939|NCT04194060|Experimental|Enhanced recovery after surgery group|"ERAS GROUP~Tracheal intubation.~Short acting anesthetic agents,avoid opioid agents~Omental patch repair with placement of sub hepatic drain~Bilateral Transverse abdominis plane block/ Rectus sheath block immediately after surgery.~Post operative nausea and vomiting prophylaxis.~Encourage to mobilize out of bed after effect of general anesthesia has weaned off.~Initiation of feeding-Oral sips on day 1, step up day 2 onward~Removal of nasogastric tube-immediately after surgery after aspirating the gastric content through nasogastric tube.~Removal of urinary catheter-after weaning from the effect of general anesthesia.~Sub hepatic drain removal -anytime within 24 hours;drain will not be removed if fluid is bilious or pus.~Avoid opiod analgesics."
88861940|NCT04194060|Active Comparator|Conventional group|"CONVENTIONAL GROUP~Tracheal intubation~Short acting anesthetic agents, avoid opiod anesthesia agents.~Omental patch repair along with sub hepatic drain placement.~Post operative nausea and vomiting prophylaxis.~Ambulation-as per patients' own request.~Initiation of oral feed- after passage of 1st flatus.~Nasogastric tube removal-output <300ml/day with resolution of ileus.~Removal of urinary catheter- when patient sits on bed side/ambulate.~Removal of sub hepatic drain-when patient tolerates unrestricted amount of liquid diet and drain output is less than 200 ml /day.~Patient will receive opiod analgesics.~I"
88861941|NCT00355914|Active Comparator|Group 1 Without Steroids|Lumbar Facet Joint Nerve Block with Local Anesthetic (0.5 mL of 0.25% Bupivacaine with/without 0.5 mL of Sarapin)
88861942|NCT00355914|Experimental|Group 2 With Steroids|Lumbar Facet Joint Nerve Block with Local Anesthetic (0.5 mL of 0.25% Bupivacaine with/without 0.5 mL of Sarapin) and 0.15 mg of non-particulate betamethasone)
88861943|NCT01792596|Other|pasta|1. Plain pasta
88861944|NCT01792596|Other|pasta with protein|Pasta with protein
88861945|NCT01792596|Other|pasta with fiber|Pasta with Fiber
88861946|NCT00356304|Experimental|1|Participants will receive motivational interviewing in addition to their antidepressant therapy
88861947|NCT00356304|Active Comparator|2|Participants will receive treatment as usual
88861948|NCT03138096|Experimental|Group 1 - five Pb(PfCS@UIS4)-infected mosquitoes|(Group 1) will be exposed to bites of five Pb(PfCS@UIS4)-infected mosquitoes
89386659|NCT04830943|Experimental|Olfactory and gustatory disorders after covid 19 infection (n = 150)|Cerebrolysin Dose:5 ml ampoule (1ml contains 215.2 mg cerebrolysin) once daily through intramuscular injection five times per week, for a total of 40 treatments (for at least 8 weeks after presentation), after which the cycle was repeated again according to the each patient response to therapy for a maximum of 24 weeks.
89386660|NCT04830943|No Intervention|control group (n = 100)|no drug intervention, just olfactory training using at least 4 strong odors to smell twice daily for at least 15 minutes (every time), for at least 8 weeks after presentation.
89386661|NCT01341145|Experimental|Aerobic Exersice|12-week moderate aerobic exercise program
89386662|NCT01341145|Active Comparator|Relaxation|12-week at home progressive muscle relaxation program
88861949|NCT03138096|Experimental|Group 2 - 25 Pb(PfCS@UIS4)-infected mosquito bites|(group 2) will be exposed to 25 Pb(PfCS@UIS4)-infected mosquito bites
88861950|NCT03138096|Experimental|Group 3 - 75 Pb(PfCS@UIS4)-infected mosquito bites|(group 3) will be exposed to 75 Pb(PfCS@UIS4)-infected mosquito bites
88861951|NCT03138096|Other|Group 4 - Infectivity control group of Phase 1|Infectivity control group of Phase 1
88861952|NCT03138096|Other|Group 5 - Infectivity control group of Phase 2|Infectivity control group of Phase 2
88861953|NCT02855892|Placebo Comparator|Control Group|- Placebo, two-week interval, intradermal administration
88861954|NCT02855892|Experimental|Study Group 1|- GV1001 0.4 mg, two-week interval, intradermal administration
88861955|NCT02855892|Experimental|Study Group 2|- GV1001 0.56 mg, two-week interval, intradermal administration
88861956|NCT02855892|Experimental|Study Group 3|"- GV1001 0.56 mg, four-week interval, intradermal administration~: Should be visited every two weeks (GV1001 0.56 mg or placebo is administered alternately at every visit.)"
88861957|NCT02816580|Experimental|elderly subjects|
88861958|NCT02713854|Experimental|Endometrial biopsy group|Women who have an endometrial biopsy 2-3 months prior to IVF
88861959|NCT04182516|Experimental|Dose Escalation Part|Patients with histologically confirmed diagnosis of locally advanced/metastatic HER2 negative breast cancer, epithelial ovarian cancer, castration-resistant prostate cancer (CRPC) or pancreatic cancer.
88861960|NCT04182516|Experimental|Dose Expansion Part - Epithelial Ovarian Cancer|Patients with gBRCA mutation and epithelial ovarian cancer.
88861961|NCT04182516|Experimental|Dose Expansion Part - Pretreated HER 2 Neg. Breast Cancer|Patients with gBRCA mutation and HER2 negative breast cancer previously treated with a PARP inhibitor.
88861962|NCT04182516|Experimental|Dose Expansion Part - No Pretreated HER 2 Neg. Breast Cancer|Patients with gBRCA mutation and HER2 negative breast cancer who have not received prior therapy with a PARP inhibitor.
89386663|NCT01338779||Group 1 - kidney tolerant|Renal allograft recipients showing functional tolerance (normal and stable renal function) after discontinuation of immunosuppressive medications for at least 1 year (or based on the investigator's discretion).
89386664|NCT01338779||Group 2 - acceptor|Enrollment for group 2 was closed. Renal transplant recipients with functioning allografts (not on dialysis) who had not received immunosuppressive medications for at least 1 year (or at investigator's discretion) but who had moderately impaired or gradually deteriorating renal function, defined as creatinine clearance (CrCl) < 40 mL/min and/or creatinine > 50% above baseline value, and thus did not qualify for group 1.
88861963|NCT04182516|Experimental|Dose Expansion Part - CRPC|Patients with gBRCA mutation and castration-resistant prostate cancer (CRPC).
88861964|NCT04182516|Experimental|Dose Expansion Part - Pancreatic Cancer|Patients with gBRCA mutation and pancreatic cancer who have not received prior therapy with a PARP inhibitor.
88861965|NCT01794234||Cohort|
88861966|NCT00357162|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive belinostat IV over 30 minutes on days 1-5. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
88861967|NCT00358332|Experimental|Group 1: FMP2.1/AS02A 10 mcg dose or rabies vaccine.|20 children will be randomized to receive either the 10 mcg dose of FMP2.1/AS02A (n=15) or rabies vaccine (n=5) on study days 0, 30 +/- 7, and 60 +/- 7.
88861968|NCT00358332|Experimental|Group 2: FMP2.1/AS02A 25 mcg dose or rabies vaccine.|40 children will be randomized to receive either the 25 mcg dose of FMP2.1/AS02A (n=30) or rabies vaccine (n=10) on study days 0, 30 +/- 7, and 60 +/- 7.
88861969|NCT00358332|Experimental|Group 3: FMP2.1/AS02A 50 mcg dose or rabies vaccine.|40 children will be randomized to receive either the 50 mcg dose of FMP2.1/AS02A (n=30) or rabies vaccine (n=10) on study days 0, 30 +/- 7, and 60 +/- 7.
88861970|NCT01792908|Experimental|KT group|The KT group received ankle KT on the lateral ligament in the non-dominant leg and a recommendation guide. The Kinesio tape procedure was carried out by the same certified athletic therapist to ensure consistency throughout the study.
88861971|NCT01792908|No Intervention|Control group|Any intervention has been applied. Using another kind of tape or a different KT application for control group may increase cutaneous information, undermining our goal.
88861972|NCT02442414|Experimental|KBP-5209|Dose escalation for KBP-5209 will initially follow a modified accelerated titration design with a starting dose of 20 mg QD. Early dose escalation will proceed with one-patient cohorts and 100% dose increments (ie, dose doubling) until a patient experiences a DLT, at which point the cohorts will move to a 3+3 design. Treatment will continue until there appears evidence of progressive disease, intolerable toxicity, or the subject discontinues from the study treatment for other reasons. A cycle is defined as continuous treatment for 28 days.
88861973|NCT01773486|Active Comparator|Hesperidin|Subjects will receive oral hesperidin 500 mg/day
88861974|NCT01773486|Placebo Comparator|Placebo|subjects will receive matching placebo to hesperidin daily for 1 month
88861975|NCT03984240|Experimental|Brain eloquent area glioma group|The brain eloquent area glioma will be diagnosed by MRI scan.
88861976|NCT03984240|Active Comparator|control group|Healthy volunteers without intracranial diseases.
88861977|NCT00359736|Experimental|Sildenafil|Sildenafil 20 mg tid orally
88861978|NCT00359736|Placebo Comparator|Placebo|Identical Placebo 20 mg tid orally
89386665|NCT01338779||Group 3 - kidney graft loss|Enrollment for group 3 is closed. These were renal transplant recipients who had subsequently rejected and lost function of their transplanted kidney.
89386666|NCT01338779||Group 4 - kidney monotherapy|Renal transplant recipients showing stable and normal renal function after receiving only prednisone 10 mg/day for at least 1 year (or based on the investigator's discretion).
88861979|NCT00360360|Experimental|Bevacizumab/Paclitaxel/Carboplatin/Erlotinib|Bevacizumab 15mg/kg IV infusion,Day 1 Paclitaxel 175mg/m2, 1-3 hour IV infusion,Day 1 Carboplatin AUC 6.0 IV Day 1 Erlotinib 150 mg by mouth daily
89386667|NCT01338779||Group 5 - kidney standard immunotherapy|Enrollment for group 5 is closed. Stable renal transplant recipients currently on standard immunosuppression.
88861980|NCT01552590|Active Comparator|Tolvaptan|Tablet, QD, 2 weeks
88861981|NCT01552590|Placebo Comparator|Placebo|Tablet, QD, 2 weeks
88861982|NCT01496664|Experimental|Result of combined CABG and PCI treatment|The registry is to assess results of combined operative and catheter based (hybrid procedure) treatment of patients with significant coronary artery disease using essential clinical and angiographic parameters.
88861983|NCT01105884|Active Comparator|Group 1|
88861984|NCT01105884|Active Comparator|Group 2|
88861985|NCT01105884|Active Comparator|Group 3|
88861986|NCT01105884|Active Comparator|Group 4|
88861987|NCT01105884|Active Comparator|Group 5|
88861988|NCT00549978|Other|1|Two compartments with cross-over and parallel
88861989|NCT00549978|Other|2|Two compartments with cross-over and parallel
88861990|NCT03983226|Experimental|Surgery|"Intervention:~Procedure: Maximum effort cytoreductive surgery combined with Niraparib maintenance Drug: Platinum-based chemotherapy and Niraparib"
88861991|NCT03983226|Active Comparator|No surgery|Intervention: Drug: Platinum-based chemotherapy and Niraparib
88861992|NCT04346082|Experimental|online mindfulness group|
89386668|NCT01338779||Group 6 - kidney chronic rejector|Enrollment for group 6 is closed. Chronic allograft nephropathy group.
89386669|NCT01338779||Group 7 - kidney identical twin|Enrollment for group 7 is closed.
89386670|NCT01338779||Group 8 - living kidney donors|Corresponding to recipients in group 1 or 4.
88861993|NCT00360672|Experimental|Revlimid|Revlimid 25 mg/day, orally for 21 days with 7 days rest (28 day cycle).
88861994|NCT00360828|Experimental|Irinotecan Treatment|Participants were given irinotecan at a fixed dose: [350 mg/m2 in patients either not on anti-seizure drugs or on anti-seizure drugs which do not interfere with the metabolism of Irinotecan; 600 mg/m2 in patients on anti-seizure drugs which interfere with the metabolism of Irinotecan] once every 21 days. Depending on how many side effects were experienced with the first cycle [first 21 days], the dose of both drugs may remain the same or may be decreased to make the treatment better tolerated with less side effects. The irinotecan was given to through a vein over 90 minutes.
88861995|NCT00361140|Experimental|AUC 6000|"Busulfan AUC Level 1: 6000 +/- 600 uM-min~Fludarabine 40mg/m2 IV over 1 hour"
88861996|NCT00361140|Experimental|AUC 7500|"Busulfan AUC Level 2: 7500 +/- 750 uM-min~Fludarabine 40mg/m2 IV over 1 hour"
89386671|NCT01338779||Group 9 - healthy controls|Enrollment for group 9 is closed.
88861997|NCT00361140|Experimental|AUC 9000|"AUC Level 3: 9000 +/- 900 uM-min~Fludarabine 40mg/m2 IV over 1 hour"
88861998|NCT01794468|Experimental|study group-Dermal blood flow measurements|Dermal blood flow was measured with the Dermal Blood Flow (DBF) monitor
88861999|NCT00361374|Experimental|EPA|Eicosapentaenoic acid (EPA) Omega-3, 1g/day
88862000|NCT00361374|Experimental|DHA|Docosahexaenoic acid (DHA) Omega-3, 1g/day
88862001|NCT00361374|Placebo Comparator|Placebo|Placebo capsule (980mg soybean oil)
88862002|NCT00362466|Active Comparator|A|50-180 mg once daily (QD)
88862003|NCT00362466|Active Comparator|B|200-800 mg QD
88862004|NCT00305682|Active Comparator|Arm 1-Previous Autologous Transplant|Arm 1 - hematologic malignancy patients who have received a previous autologous transplant or ≥ 2 cycle of multiagent chemotherapy within the last 3 months previous to umbilical cord blood transplant (UCBT). Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation without anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.
89386672|NCT01338779||Group 10 - liver tolerant|Enrollment for group 10 is closed. Liver allograft recipients with functional tolerance (stable and normal liver function) after cessation of immunosuppressive medications for at least three years (or at investigator's discretion).
89386673|NCT01338779||Group 11 - liver standard immunotherapy|Enrollment for group 11 is closed. Subjects with a liver transplant who never had an attempt made to discontinue gradually their immunosuppression and who are currently taking standard immunosuppressive medications and have stable and normal liver allograft function after at least 1 year of receiving these drugs.
89535281|NCT03323567|Experimental|MD Muscle Collagen group|Group with collagen intramuscular injections
88862005|NCT00305682|Active Comparator|Arm 2 - No Prior Autologous Transplant|Arm 2 - hematologic malignancy patients who have not been treated with prior autologous transplant or ≤ 1 cycle of chemotherapy in the 3 months previous to umbilical cord blood transplant (UCBT), and who should receive anti-thymocyte globulin as conditioning regimen. Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation with anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.
88862006|NCT00305682|Active Comparator|Arm 3 - Refractory Leukemia/Lymphoma|Arm 3 - patients with refractory leukemia or lymphoma who have been rendered aplastic either by induction chemotherapy or radioimmunoconjugated monoclonal antibody therapy. Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation with anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.
88862007|NCT00305682|Active Comparator|Arm 4: MT2006-01 coenrolling patients|Arm 4 - hematologic malignancy patients enrolled in MT2006-01. Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation with or without anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.
88862008|NCT00305682|Active Comparator|Arm 5 - Previous Autologous Transplant|Arm 5 - hematologic malignancy patients who have received a previous autologous transplant or ≥ 2 cycle of multiagent chemotherapy within the last 3 months previous to umbilical cord blood transplant (UCBT). Conditioning Fludarabine dose of 30 mg/m2/day x 5, cyclophosphamide and total body irradiation without anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.
88862009|NCT00305682|Active Comparator|Arm 6 - No prior autologous transplant|Arm 6 - hematologic malignancy patients who have not been treated with prior autologous transplant or ≤ 1 cycle of chemotherapy in the 3 months previous to umbilical cord blood transplant (UCBT), and who should receive anti-thymocyte globulin as conditioning regimen. Conditioning Fludarabine dose of 30 mg/m2/day x 5, cyclophosphamide and total body irradiation with anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.
88862010|NCT00305760|Experimental|Cyclophosphamide, Pancreatic Tumor Vaccine, Cetuximab|
88862011|NCT00309738|Experimental|Pitavastatin 4 mg QD|Pitavastatin 4 mg once daily
88862012|NCT00309738|Active Comparator|Simvastatin 40 mg QD|Simvastatin 40 mg once daily
88862013|NCT00310050|Experimental|Pemetrexed in combination with concomitant radiotherapy|Patients will receive Pemetrexed plus Radiotherapy.
89184934|NCT00794417|Experimental|Phase 1: Aflibercept 2 mg/kg and Pemetrexed and Cisplatin|Participants received intravenous infusion of aflibercept 2 milligrams per kilogram (mg/kg) followed by pemetrexed 500 mg/square meter (m^2) and then cisplatin 75 mg/m^2 on Day 1 of each 3 week cycle (1 Cycle = 21 Days in this study) until disease progression, unacceptable toxicity, withdrawal of consent or if another study withdrawal criterion has been met.
89184935|NCT00794417|Experimental|Phase 1: Aflibercept 4 mg/kg and Pemetrexed and Cisplatin|Participants received intravenous infusion of aflibercept 4 mg/kg followed by pemetrexed 500 mg/m^2 and then cisplatin 75 mg/m^2 on Day 1 of each 3 week cycle (1 Cycle = 21 Days in this study) until disease progression, unacceptable toxicity, withdrawal of consent or if another study withdrawal criterion has been met.
89535282|NCT03323567|Experimental|Lidocaine 2% group|Group with 2% Lidocaine intramuscular injections
89535283|NCT03323567|Placebo Comparator|Saline|Group with 0,9% NaCl intramuscular injections
89535284|NCT03227185|Experimental|Real - sham anodal tDCS|"Session 1: 20 min of 1 mA anodal tDCS applied via 5x7 cm rubber electrodes over the DLPFC (current density: 0.028 mA/cm2). Additional ramp-up and ramp-down phase at beginning and end of stimulation lasting for 15 s. Electrodes remain attached to the participant's head for the duration of the encoding phase.~Session 2: 30 s of 1 mA anodal tDCS applied via 5x7 cm rubber electrodes over the DLPFC (current density: 0.028 mA/cm2). Additional ramp-up and ramp-down phase at beginning and end of stimulation lasting for 15 s. Electrodes remain attached to the participant's head for the duration of the encoding phase."
88862014|NCT00363168|Experimental|A|0.3 mg/0.05 ml dose of ranibizumab
88862015|NCT00363168|Experimental|B|0.5 mg/0.05 ml dose of ranibizumab
88862016|NCT03723798|Experimental|Group 1|SA001 Low dose
88862017|NCT03723798|Experimental|Group 2|SA001 Mid dose
88862018|NCT03723798|Experimental|Group 3|SA001 High dose
88862019|NCT03723798|Placebo Comparator|Placebo|Placebo
88862020|NCT01794546|Experimental|Immediate Telehealth|"The immediate intervention group will receive the telehealth intervention during the first 6 months of the study timeline."
88862021|NCT01794546|Active Comparator|Wait List Control|"The wait list control group will receive the telehealth intervention during months 6 through 12 of the study timeline."
88862022|NCT00365274|Experimental|SGN-30 + Combination Chemotherapy|"Monoclonal antibody SGN-30 monotherapy: SGN-30 12 mg/kg weekly intravenously(IV) over 2 hours once weekly for 3 weeks.~SGN-30 and CHOP chemotherapy: Beginning 1 week after completion of monoclonal antibody SGN-30 monotherapy, SGN-30 12 mg/kg IV over 2 hours on day 1 and CHOP chemotherapy comprising cyclophosphamide IV over 1 hour, doxorubicin hydrochloride IV over 15 minutes, and vincristine IV over 15 minutes on day 1 and oral prednisone once daily on days 1-5. Treatment repeats every 21 days for 6-8 courses."
88862023|NCT00310362|Experimental|Usual Care with nurse phone call|Usual Care--Nurses telephoned patients 7 days prior to appointment to remind patients about scheduled GI appointment and to answer any questions.
88862024|NCT00310362|Experimental|interactive voice response 3 days prior|Interactive voice response system was used to remind patients 3 days before a scheduled appointment and to educate them about preparation procedures for the appointment (IVR3)
88862025|NCT00310362|Experimental|interactive voice response 7 days prior|Interactive voice response system was used to remind patients 7 days before a scheduled appointment and to educate them about preparation procedures for the appointment (IVR7)
88862026|NCT00311376|Experimental|1|botulinum toxin Type A (200U)
88862027|NCT00311376|Experimental|2|botulinum toxin Type A (300U)
88862028|NCT00311376|Other|3|placebo; botulinum toxin Type A (200U)
88862029|NCT00311376|Other|4|placebo; botulinum toxin Type A (300U)
88862030|NCT03238170|Experimental|MR-Simulation|Patients will have 1 MRI scan appointment, using the Siemens Aera® (Siemens AG Healthcare, Erlangen, Germany) on the same day as their treatment planning CT scan. The MR scan will be performed in the radiotherapy treatment position.
88862031|NCT02104830|Experimental|Empegfilgrastim 6 mg|Patients will receive a single administration of empegfilgrastim at a dose of 6 mg subcutaneously, 24 h after the chemotherapy and placebo #2 in a dose of 0.0083 ml/kg in 24-27 hour after chemotherapy, then patient received placebo #2 in dose 0.0083 ml/kg until ANC ≥ 10x109/L or during 14 days
88862032|NCT02104830|Experimental|Empegfilgrastim 7.5 mg|Patients will receive a single administration of empegfilgrastim at a dose of 7.5 mg subcutaneously, 24 h after the chemotherapy and placebo #2 in a dose of 0.0083 ml/kg in 24-27 hour after chemotherapy, then patient received placebo #2 in dose 0.0083 ml/kg until ANC ≥ 10x109/L or during 14 days
88862033|NCT02104830|Active Comparator|Filgrastim|Patients will receive filgrastim at a dose of 5 μg/kg subcutaneously daily (until ANC 10 000/μL or for 14 days, whichever occurred first), starting 24 h after the chemotherapy and placebo #1 in dose 1.0 ml subcutaneously, 24 h after the chemotherapy.
88862034|NCT00311766|Placebo Comparator|1|Placebo comparator gel does not contain any active drug. Topical administration of 0.0% Thymosin Beta 4 gel, once a day (qd) up to 56 days
88862035|NCT00311766|Active Comparator|2|Topical Administration of 0.01%, 0.03%, and 0.1% Thymosin Beta 4 gel once a day (qd) up to 56 days
88862036|NCT00313560|Experimental|Erlotinib and EBRT after pancreatectomy|"Adjuvant treatment with erlotinib 100 mg plus Capecitabine 800 mg/m2 PO BID (5 days on/ 2 days off regimen) and External Beam Radiation Therapy (EBRT) at doses of 50.4 Gy in 28 fractions after pancreatectomy (Dosing for capecitabine and erlotinib was amended after considering the toxicity profile of the first 6 patients).~Approximately 4-8 weeks after the conclusion of chemoradiation, it is recommended patients will continue treatment with 4 cycles of gemcitabine 1000 mg/m2 days 1, 8, and 15 every 28 days plus daily erlotinib 100 mg."
88862037|NCT01791738|Experimental|Acetabular positioning system|Pre-operative planning through 3D software with design and fabrication of patient specific instruments for placement of a guide pin to be used to aid in bone preparation for insertion of an acetabular cup in total hip arthroplasty
88862038|NCT01791738|No Intervention|Standard total hip arthroplasty|Each surgeon will use their standard methods of pre-operative planning using pre-operative x-rays, and complete the procedure using standard surgical instruments for total hip arthroplasty.
88862039|NCT00314106|Experimental|TBI 1200 cGy + TIL +HD IL-2, prior IL-2|Patients that received prior interleukin 2 (IL-2) therapy will receive a myeloablative lymphocyte depleting preparative regimen consisting of cyclophosphamide (60 mg/kg/day x 2 days intravenous (IV)), fludarabine (25mg/m^2/day IV X 5 days) and 1200 cGy total body irradiation (TBI). Following the lymphodepleting regimen, patient will receive intravenous adoptive transfer of tumor reactive lymphocytes (minimum 3 X 10 (9) and up to a maximum of 3 X 10(11) lymphocytes) followed by high-dose intravenous (IV) IL-2 (720,000 IU/kg/dose every 8 hours for up to 15 doses).
88862040|NCT00314106|Experimental|TBI 1200 cGy + TIL +HD IL-2, no prior IL-2|Patients that have not received prior interleukin 2 (IL-2) therapy will receive a myeloablative lymphocyte depleting preparative regimen consisting of cyclophosphamide (60 mg/kg/day x 2 days intravenous (IV)), fludarabine (25mg/m^2/day IV X 5 days) and 1200 cGy total body irradiation (TBI). Following the lymphodepleting regimen, patient will receive intravenous adoptive transfer of tumor reactive lymphocytes (minimum 3 X 10 (9) and up to a maximum of 3 X 10(11) lymphocytes) followed by high-dose intravenous (IV) IL-2 (720,000 IU/kg/dose every 8 hours for up to 15 doses)
88862041|NCT00315120|Other|A (Active OMT and active (UST)|Subjects in this group received active osteopathic manipulation and active ultrasound physical therapy
88862042|NCT00315120|Other|B (Sham OMT and active UST)|Subjects in this group received sham osteopathic manipulation and active ultrasound physical therapy
88862043|NCT00315120|Other|C (Active OMT and sham UST)|Subjects in this group received active osteopathic manipulation and sham ultrasound physical therapy
88862044|NCT00315120|Other|D (Sham OMT and sham UST)|Subjects in this group received sham osteopathic manipulation and sham ultrasound physical therapy
88862045|NCT00315588|Experimental|Islet Transplantation|Islet Transplantation in subjects with a previous kidney transplant.
88862046|NCT01793064|Experimental|Adaptive Intervention Group (AI)|Adaptive Intervention Group (AI) receives adaptive step goals and feedback/incentives based on personal physical activity performance.
88862047|NCT01793064|Active Comparator|Static Intervention group (SI)|"Static Intervention group (SI) receives a static usual care goal of 10,000 steps/day and feedback/incentives for uploading their pedometer to the study website."
88862048|NCT00367380|Experimental|Group 1|6 volunteers to be challenged with the infected with +/-3 mosquito bites from batch 413ABM
88862049|NCT00367380|Experimental|Group 2|6 volunteers to be challenged with the infected with +/-3 mosquito bites from batch 414WRR
88862050|NCT00367380|Experimental|Group 3|6 volunteers to be challenged with the infected with +/-3 mosquito bites from batch 418JAL
88862051|NCT00368316|Experimental|S. sonnei conjugate vaccine|Shigella sonnei O-specific polysaccharide covalently bound to recombinant exoprotein A of Pseudomonas aeruginosa
88862052|NCT00368316|Experimental|S. flexneri 2a conjugate vaccine|Shigella flexneri 2a O-specific polysaccharide covalently bound to recombinant exoprotein A of pseudomonas aeruginosa
88862053|NCT00368940|Experimental|PATH|Participants will receive PATH for 12 weeks
88862054|NCT00368940|Active Comparator|ST-CI|Participants will receive ST-CI for 12 weeks
89184936|NCT00794417|Experimental|Phase 2: Aflibercept 6 mg/kg and Pemetrexed and Cisplatin|Participants received intravenous infusion of aflibercept 6 mg/kg followed by pemetrexed 500 mg/m^2 and then cisplatin 75 mg/m^2 on Day 1 of each 3 week cycle (1 Cycle = 21 Days in this study) for 6 cycles.
88862055|NCT00369564|Experimental|Arm I Glutamic Acid|Patients receive oral glutamic acid 3 times daily beginning prior to the first dose of vincristine and continuing through week 5 (stratum 2) or week 10 (stratum 1).
89184937|NCT04066101||high caries risk|100 adults will be allowed in the high caries risk group according to DMFT index (DMFT ≥ 14)
89184938|NCT04066101||low caries risk|100 adults will be allowed in the low caries risk group according to DMFT index (DMFT ≤ 5)
88862056|NCT00369564|Placebo Comparator|Arm II Placebo|Patients receive oral placebo 3 times daily beginning prior to the first dose of vincristine and continuing through week 5 (stratum 2) or week 10 (stratum 1).
88862057|NCT00315822|Placebo Comparator|30% oxygen|Subjects undergoing surgery will receive routine administration of oxygen
88862058|NCT00315822|Active Comparator|80% oxygen|Subject undergoing surgery will receive supplemental oxygen
88862059|NCT01794624|Active Comparator|Cognitive Therapy|Cognitive Therapy for Catastrophizing
88862060|NCT01794624|Active Comparator|Behavioral Therapy|Behavioral Therapy for Sleep Continuity Disturbance
88862061|NCT01794624|No Intervention|TMJD Education|6-sessions of TMJD disease education/support control
88862062|NCT00316524|Experimental|GP 1: two x 1x10E08 TCID, MVA-BN® s.c., vaccinia naive|vaccinia naive subjects receiving two subcutanenous vaccinations with 0.5ml MVA-BN® IMVAMUNE (1x10E08 TCID)
88862063|NCT00316524|Experimental|GP 2: 1x10E08 TCID, MVA-BN®, 1x Placebo, s.c., vaccinia naive|vaccinica naive subjects receiving one vaccination with 0.5ml MVA-BN® IMVAMUNE(1x10E08 TCID), followed by one vaccination Placebo (0.5ml Tris Buffer)
88862064|NCT00316524|Placebo Comparator|GP 3: two x Placebo, s.c., vaccinia naive|vaccinia naive subjects, receiving two subcutaneous vaccinations with Placebo (0.5ml Tris Buffer).
88862065|NCT00316524|Experimental|GP 4: 1x10E08 TCID, MVA-BN®, s.c., vaccinia experienced|vaccinia experienced subjects, receiving one subcutaneous vaccination with 0.5ml MVA-BN® IMVAMUNE (1x10E08 TCID).
88862066|NCT02994498|Experimental|DCB-BO1301 1 capsule|DCB-BO1301 1 capsule, tid (around 1 hour before meal) for at most 48 weeks
88862067|NCT02994498|Experimental|DCB-BO1301 2 capsules|DCB-BO1301 2 capsules, tid (around 1 hour before meal) for at most 48 weeks
88862068|NCT02994498|Experimental|DCB-BO1301 3 capsules|DCB-BO1301 3 capsules, tid (around 1 hour before meal) for at most 48 weeks
88862069|NCT00317226|Experimental|Ferric Carboxymaltose (FCM)|maximum dose of 1,000 mg over 15 minutes IV administered within 7 days of the qualifying visit
88862070|NCT05288010|Other|Active Group|Patients of the clinic receiving cannabis treatment for non cancer chronic pain, who have been invited to join the study and have agreed and consented to join study.
88862071|NCT01793298|Experimental|Healthy Subjects - ASM-024 Single Administration|Single administration of ascending doses of ASM-024
88862072|NCT01793298|Placebo Comparator|Healthy Subjects - Placebo|Single administration of placebo
88862073|NCT01793298|Experimental|Healthy Subjects - ASM-024 Repeat Administration|Repeat administration of ascending doses of ASM-024
88862074|NCT01793298|Placebo Comparator|Healthy Subjects - Placebo Repeat Administration|Repeat administration of ascending doses of placebo
88862075|NCT01793298|Experimental|Subjects with Asthma|Repeat administration of ascending doses of ASM-024 or placebo in a crossover fashion
88862076|NCT02973126|Other|FFRct versus SPECT|Comparison of the diagnostic performance of FFRct and SPECT in subjects with suspected stable CAD
88862077|NCT05287854|Experimental|Local anesthesia + Virtual Reality|In addition to local standard anaesthesia, patients benefit from a virtual reality session during the operation using a virtual reality headset
88862078|NCT05287854|No Intervention|Local anesthesia alone|Patients benefit only from a local anaesthesia is provided according to the standard procedure
88862079|NCT05287776|Experimental|15 patients with vitiligo subjected to NB-UVB|Patients will be subjected to NB-UVB sessions 3 times weekly. The UVB dosing scheme in the patients receiving only NB-UVB treatment entailed initial dosing at 0.5 J/cm2 with increasing increments by 0.3 J/cm 2 every other session until faint erythema occurs.
88862080|NCT05287698|Experimental|Cold vapor group|Cold vapor will be applied to the experimental group patients for 15 minutes in the recovery room. For the study, Nebtime UN600A Ultrasonic Nebulizer Device will be used to apply cold steam to the patients which used in the hospital and calibrated (https://elmaslarmedikal.com.tr/urunler/nebtime-un600a-ultrasonik-nebulizator/). The parameters to be set on the device for the cold vapor to be applied to the patients in the early postoperative period will be vapor intensity level 5 (1-10), air blowing intensity 5 (1-10), heater intensity 1 (+10C), and timer 15 minutes. The patients will be evaluated by the researchers in terms of sore throat and dysphagia before and 15 minutes after the cold vapor application in the recovery room and at the 6th, 12th, and 24th hours after the cold vapor application in the postoperative service.
88862081|NCT05287698|No Intervention|Control group|Patients in the control group will receive standard care that includes all medical and non-medical treatments in the hospital. Nursing care, which is routinely applied to patients in the postoperative period, both in the recovery room and in the service, will be continued within the standard care. The patients will be evaluated by the researchers in terms of sore throat and dysphagia when they come to the recovery room and at the 6th,12th, and 24th hours after the surgery in the postoperative service.
88862082|NCT01794858|Experimental|Therapeutic Hypothermia|"Primary - Organ specific outcome at 28 days Logistic Organ Dysfunction Score (LOD) will be compared before and after TH. Change in LOD will reflect LOD day 4 minus LOD day 1 (Ehrmann, Can J Anesth 2006).~Secondary~Lab values: D-Dimer, IL-6, CRP~APACHE II Scores Day 1 and after TH (day 4)~Length of stay in the ICU and hospital~Prevalence of infections~28-day mortality~Hypothermia-related side effects: cardiac arrhythmia, electrolyte balance, hyperglycemia, bleeding, acute pancreatitis"
88862083|NCT00318708|Experimental|clarithromycin + fluticasone|clarithromycin 500 mg twice daily (Biaxin) + fluticasone propionate 88 mcg twice daily (Flovent® HFA 44 mcg two puffs twice daily)
88862084|NCT00318708|Active Comparator|placebo + fluticasone|placebo clarithromycin twice daily + fluticasone propionate 88 mcg twice daily (Flovent® HFA 44 mcg two puffs twice daily)
88862085|NCT00319644|Experimental|Minibal Arm|Using Mini bronchoalveolar lavage
88862086|NCT00319644|No Intervention|Tracheal Aspirates|standard of care for ICU.
88862087|NCT02422446|Experimental|EPA arm|EPA arm will receive 4 grams per day of EPA (icosapent ethyl) taken twice a day
88862088|NCT02422446|No Intervention|Control|Control group will not receive EPA
88862089|NCT05287386|Experimental|Pemigatinib|Selective FGFR1-3 inhibitor
88862090|NCT02056704|No Intervention|Angiography|Evaluation by angiography only.
88862091|NCT02056704|Experimental|Angiography with IVUS|Evaluation with angiography and intravascular ultrasound.
88862092|NCT03617640||Hirschsprung's disease patients|Children diagnosed with Hirschsprung's disease or Hirschsprung's disease associated enterocolitis
88862093|NCT03617640||control patients|Children diagnosed and treated for miscellaneous bowel diseases
88862094|NCT05286606||Focus groups|Health Care Professionals (HCP), facilitators, participants in the exercise program will be invited to participate in focus groups to comment on usability/acceptability.
88862095|NCT05286606||App users|Users of the exercise program with musculoskeletal conditions have been referred to the exercise program via the charities, all will be participating in a three-month program using the beta version of the app. They will be invited to participate in the program evaluation
88862096|NCT05286606||Facilitators|Facilitators of the exercise program: The facilitators for the virtual groups have been recruited equally by the charities and are working for GoodBoost to facilitate the exercise program for the app users. They will be invited to participate in the program evaluation
88862097|NCT04271670|Experimental|Warm water footbath with ginger powder|Footbath with ginger powder with a maximum duration of 20 minutes.
88862098|NCT04271670|Experimental|Warm water footbath with mustard powder|Footbath with mustard powder with a maximum duration of 20 minutes.
88862099|NCT04271670|Active Comparator|Warm water only footbath|Warm water only footbath with a maximum duration of 20 minutes.
88862100|NCT04750746|Active Comparator|Control Group|Control group will get conventional treatment.
88862101|NCT04750746|Experimental|Experimental Group|This group will get base line treatment with exer gaming.
88862102|NCT04750668|Experimental|Multisensory Balance Training Group|Multisensory balance training manipulate sensory inputs of vision, vestibular and proprioception.
88862103|NCT04750668|No Intervention|Control Group|Participants in control group maintain their regular activity without any intervention.
88862104|NCT04750590|Experimental|en bloc resection group|Patients scheduled for laser en bloc tumor resection with subsequent morcellation of exophytic part of the tumor
89184939|NCT01459107|Experimental|Treatment (Transplantation)|Hand/arm transplantation in combination with a novel donor bone marrow cell-based therapy followed by single-drug immunosuppression with potential weaning.
89386674|NCT03067610|Experimental|Radiation Therapy|Intensity modulated radiation therapy (IMRT) with or without chemotherapy (if given, either cisplatin, cetuximab, or carboplatin-paclitaxel)
88862105|NCT04750590|Experimental|piecemeal resection group|Patients scheduled for piecemeal bladder tumor TUR with subsequent removing of tissue using the instrument loop or Janet's syringe.
88862106|NCT04750200|No Intervention|Control Arm|Patients randomized to the control arm will undergo institutional standard of care treatment (surgical drainage and/or medical management for the CSDH.
88862107|NCT04750200|Experimental|Interventional Arm|Patients randomized to the interventional arm will undergo institutional standard of care treatment (surgical drainage and/or medical management for the CSDH as per the standard of care in the institution. These patients will then undergo EMMA within 48 hours after finishing the surgical drainage. The embolic agent and use of general anesthesia vs conscious sedation will be left to operators' preference and the institutional protocol. All patients will be followed as per the institutional standard of the care. Any peri-procedural complications and change in clinical status will be recorded.
88862108|NCT00321594|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive belinostat IV over 30 minutes on days 1-5. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
88862109|NCT04751136|Active Comparator|Intervention Arm|infants were given Cerebrolysin®, manufactured by Neuro Pharma Gmbh, in a dose of 0.1 ml / kg body weight once weekly intramuscular injection for 12 month (total of 48 injections).
88862110|NCT04751136|No Intervention|Non-intervention Arm|No medication was given
88862111|NCT04750980||Food allergy|Childen with food allergy
88862112|NCT04750980||Respiratory allergy|Children with respiratory allergy
88862113|NCT04750980||Healthy controls|Healthy subjects
88862114|NCT00390234|Experimental|Treatment (ziv-aflibercept)|Patients receive ziv-aflibercept IV over 1 hour on day 1. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity.
88862115|NCT00391716|Experimental|gabapentin 900mg daily|900mg gabapentin daily for 12 weeks and weekly concomitant manualized behavioral counseling for 12 weeks.
88862116|NCT00391716|Experimental|gabapentin 1800mg daily|1800 mg gabapentin daily for 12 weeks and weekly concomitant manualized behavioral counseling for 12 weeks
88862117|NCT00391716|Placebo Comparator|placebo daily|placebo capsules daily for 12 weeks and weekly concomitant manualized behavioral counseling for 12 weeks.
88862118|NCT00392496|Experimental|Arm I|This is a non-randomized, open-label, multicenter study. Patients receive sunitinib malate orally once daily on days 1-28. Treatment repeats every 4 weeks for a maximum of 12 courses in the absence of disease progression or unacceptable toxicity.
88862119|NCT01958190|Active Comparator|Tacrolimus|Patient received standard-dose of Tracrolimus Advagraf (5-10 ng/ml) and 7.5 mg prednison; lower or discontinue steroids after day 180 at the discretion of the treating physician
88862120|NCT01958190|Experimental|combination Tacrolimus and Sirolimus|Patients receive combination of low-dose extended release Tacrolimus and low-dose Sirolimus
88862121|NCT01795326||Germany|A sample of physicians who were targeted to receive the metabolic educational materials and either currently prescribe or have the potential to prescribe SEROQUEL® or SEROQUEL® XR.
88862122|NCT01795326||United Kingdom|A sample of physicians who were targeted to receive the metabolic educational materials and either currently prescribe or have the potential to prescribe SEROQUEL® or SEROQUEL® XR.
88862123|NCT01795326||Spain|A sample of physicians who were targeted to receive the metabolic educational materials and either currently prescribe or have the potential to prescribe SEROQUEL® or SEROQUEL® XR.
89003325|NCT05439421|Experimental|With Claim 0% Tar|Package or digital marketing advertisement containing claim of interest
88862124|NCT01795326||Hungary|A sample of physicians who were targeted to receive the metabolic educational materials and either currently prescribe or have the potential to prescribe SEROQUEL® or SEROQUEL® XR.
88862125|NCT01795326||Netherlands|A sample of physicians who were targeted to receive the metabolic educational materials and either currently prescribe or have the potential to prescribe SEROQUEL® or SEROQUEL® XR.
88862126|NCT01795326||Sweden|A sample of physicians who were targeted to receive the metabolic educational materials and either currently prescribe or have the potential to prescribe SEROQUEL® or SEROQUEL® XR.
88862127|NCT01795326||Romania|A sample of physicians who were targeted to receive the metabolic educational materials and either currently prescribe or have the potential to prescribe SEROQUEL® or SEROQUEL® XR.
88862128|NCT01795326||Italy|A sample of physicians who were targeted to receive the metabolic educational materials and either currently prescribe or have the potential to prescribe SEROQUEL® or SEROQUEL® XR.
88862129|NCT01571778|Experimental|Donning Gloves without Hand Hygiene|In this arm, healthcare workers will be assigned to don non-sterile gloves prior to patient contact WITHOUT first performing hand hygiene. Samples will be obtained from hands prior to donning gloves and from the gloves after donning to determine total aerobic colony counts and to identify important hospital pathogens
88862130|NCT01571778|No Intervention|Hand Hygiene before donning Non-Sterile Gloves|In this arm, healthcare workers will be assigned to first perform hand hygiene before donning non-sterile gloves prior to patient contact (This is usual,expected practice). Samples will be obtained from hands prior to donning gloves and from the gloves after donning to determine total aerobic colony counts and to identify important hospital pathogens
88862131|NCT04388982|Experimental|MSCs-Exos Dosage 1|MSCs-Exos. low-dose group
88862132|NCT04388982|Experimental|MSCs-Exos Dosage 2|MSCs-Exos mid-dose group
88862133|NCT04388982|Experimental|MSCs-Exos Dosage 3|MSCs-Exos high-dose group
88862134|NCT05286216|Experimental|Experimental group|"Patient diagnosis form with CHB and related scales (Patient Diagnosis Form with Chronic Hepatitis B, Medication Adherence Report Scale-5), Medication Adherence Report Scale (MedTake Test), Chronic Liver Disease Quality of Life Scale 2.0 (Liver Disease Symptom Index 2.0 (LDSI 2.0), Health-Related Quality of Life Scale SF-12 (12 Item Short Form Health Survey) (Short Form 12 - SF 12), Patient Learning Needs Scale will be applied before the intervention. The training will be in two modules and two different sessions. The effectiveness of the training will be evaluated by re-applying the scales 12 weeks and 24 weeks after the training."
88862135|NCT05286216|No Intervention|Control group|"Patient diagnosis form with CHB and related scales (Patient Diagnosis Form with Chronic Hepatitis B, Medication Adherence Report Scale-5), Medication Adherence Report Scale (MedTake Test), Chronic Liver Disease Quality of Life Scale 2.0 (Liver Disease Symptom Index 2.0 (LDSI 2.0), Health-Related Quality of Life Scale SF-12 (12 Item Short Form Health Survey) (Short Form 12 - SF 12), Patient Learning Needs Scale in the first evaluation, 12 weeks and 24 weeks later, the scales were re-applied and the education was improved. effectiveness will be evaluated."
88862136|NCT01793454|Active Comparator|40% oxygen|Patients in this group will be ventilated with fraction of inspired oxygen 40% during the surgery.
88862137|NCT01793454|Active Comparator|80% oxygen|Patients in this group will be ventilated with a fraction of inspired oxygen 80% during the surgery.
88862138|NCT00393978|Placebo Comparator|Quetiapine and Placebo|Quetiapine and Placebo
88862139|NCT00393978|Active Comparator|Quetiapine and Topiramate|Quetiapine and Topiramate
88862140|NCT00397020|Experimental|1 Divalproex ER|Divalproex ER
88862141|NCT00397020|Active Comparator|2 Quetiapine Fumarate|quetiapine fumarate
88862142|NCT00371436|Active Comparator|Progressive Audiologic Tinnitus Management (PATM)|"The program follows a five-level progressive intervention model that addresses the various needs of tinnitus patients in a systematic and hierarchical manner-from initial contact with a VA provider through long-term treatment."
88862143|NCT00371436|Other|Usual Care (UC)|Typical audiologic care that would be received in a VA Audiology Clinic.
88862144|NCT00397878|Experimental|Treatment (saracatinib)|Patients receive oral AZD0530 once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88862145|NCT00400686|Experimental|Epoetin Alfa - 80,000 U sc|Epoetin Alfa will be administered 80,000 units subcutaneously every week beginning on Day 1. On Day 28, the dose was adjusted based upon patients' Hemoglobin Levels
88862146|NCT05215938||Study I: Multi-organ sodium imaging with B1 field correction|"The scan will be performed in four area of interests (AOFs) to acquire sodium level signal form the thigh, heart, kidneys, and brain. Between each AOF the sodium receive coil will be moved to cover the specific organ. Determination of the sodium imaging method robustness is performed with a series of MRI sequences.~The scans at the four AOFs are repeated to evaluate repeatability. The scan time with repositioning of coils is approximately 15 min per station (total scan time 2 hours).~If needed the participants are able to have a break between scan stations."
88862147|NCT05215938||Study II: Circadian sodium level variation in the kidney measured with MRI|"Participation requires one full day at the MR Centre. MRI scans will be performed three times at the same day within the following time periods: 6.30-8.00 am. (before breakfast), 12.30-14-00 pm. (after lunch) and 21.00-22.00 pm. (after dinner). The scan time is expected to be 30-40 min at each scan (three scans are performed on one examination day), which requires a total scan time ~1½ hours.~Participants are not allowed to perform excessive physical exercise the day before and during the study day. Lighter physical exercise as walking, biking etc. is accepted. Alcohol consuming is not allowed the day before and during the study day. The participants can drink and eat as usual, but all fluid intake and urinations shall be documented in a liquid urination schedule. Blood pressure will be measured at each scan session and urine samples are collected just after each scan session to assess the osmolarity."
88862148|NCT00373386|Experimental|Growth Hormone|Growth hormone treatment 0.3 mg/kg/min
89003326|NCT05439421|Experimental|Without Claim 0% Tar|Package or digital marketing advertisement without claim of interest
89003327|NCT05439421|Experimental|With Claim No Chemicals|Package or digital marketing advertisement containing claim of interest
89003328|NCT05439421|Experimental|Without Claim No Chemicals|Package or digital marketing advertisement without claim of interest
89003329|NCT05439421|Experimental|With Claim Apple Image|Package or digital marketing advertisement containing claim of interest
89386675|NCT01338935|Experimental|Part I|Ascending dose tolerance, PK, and estimation of ED95 for CW 002
89003330|NCT05439421|Experimental|Without Claim Apple Image|Package or digital marketing advertisement without claim of interest
89003331|NCT05439421|Experimental|With Claim 100% Food Grade Glycerin|Package or digital marketing advertisement containing claim of interest
89386676|NCT01338935|Experimental|Part II|Safety, efficacy and PK of increasing bolus doses and infusions of CW 002, and exploration of Neostigmine reversal
89386677|NCT01338935|Experimental|Part III|Intubation with CW 002 and Neostigmine reversal
89386678|NCT04455295|Experimental|Active Stimulation 0.5|0.5mA, 30Hz intermittent transdermal vagus nerve stimulation of the auricle vagus. Stimulation 30 second on/30 seconds off for five cycles.
89386679|NCT04455295|Placebo Comparator|Lobe Control|0.5mA, 30Hz intermittent transdermal vagus nerve stimulation of the earlobe. Stimulation 30 second on/30 seconds off for five cycles.
89386680|NCT04455295|Placebo Comparator|Sham Stimulation|0.5mA, 5Hz intermittent transdermal vagus nerve stimulation of the auricle vagus. Stimulation 30 second on/30 seconds off for five cycles.
89386681|NCT04455295|Placebo Comparator|Nonstimulation|Placement of electrode without any stimulation.
89386682|NCT03567902|Experimental|Group A|C-MAC videolaryngoscope intubation -> Direct laryngoscope intubation
89386683|NCT03567902|Experimental|Group B|Direct laryngoscope intubation -> C-MAC videolaryngoscope intubation
89386684|NCT05186701|Experimental|Kinesio taping and Conventional Physical Therapy|Standardized therapeutic kinesio taping (I shaped with 50-100% tension for 72 hours on both shoulders) along with Conventional Physical Therapy including Thermotherapy, myofacial release, exercise therapy (active isolated unilateral stretching of pectoralis minor muscle and strengthening of shoulder retractors).
89386685|NCT05186701|Active Comparator|Conventional Physical Therapy|Thermotherapy, myofacial release, exercise therapy (active isolated unilateral stretching of pectoralis minor muscle and strengthening of shoulder retractors).
88818827|NCT01855997||Adult CHB Participants Treated With Peg-IFN Alfa-2a|Adult participants with CHB infection, and who have completed at least 24 weeks of Peg-IFN alfa-2a with/without nucleoside analogue therapy and at least 24 weeks of follow-up, will be included. Participants will be recruited from Roche clinical trials or general practice; no treatment will be administered in this non-interventional study.
88818828|NCT02734953|Experimental|Intervention|Determination of non-invasive pulmonary pressures by CardioMems device interrogation pre- and post-administration of inhaled nitric oxide at 0.075 mg/kg IBW/hr
88818829|NCT00573729|Experimental|Pulsed Dye Laser 577 nm|Pulsed Dye Laser Treatment 577 nm treatment of Port Wine Stain Birthmarks
88818830|NCT00573729|Experimental|Pulsed Dye Laser 595 nm|Pulsed Dye Laser Treatment 595 nm treatment of Port Wine Stain Birthmarks
88818831|NCT00555711||Modulated Imaging|Modulated Imaging
88818832|NCT02428608|Experimental|Botulinum toxin, Tyoe A|DWP-450 (Botulinum toxin, Type A)
88818833|NCT02735187|Active Comparator|group30|Treatment of the target area with 30 minutes of blue light at 453nm compared to Vitamin D creme Daivonex on contralateral Plaque of same patient.
88818834|NCT02735187|Active Comparator|group15|Treatment of the target area with 15 minutes of blue light at 453nm compared to Vitamin D creme Daivonex on contralateral Plaque of same patient.
88818835|NCT02428296|Experimental|Patients with PIK3CA gene mutation treated with Sirolimus|This is a single-arm, non-randomized, open-label study for the treatment of segmental overgrowth disorders (somatic PIK3CA gene mutation) with Sirolimus in thirty-nine patients.
88818836|NCT01856933|Experimental|PSMA ADC|2.5 mg/kg, IV, over 60 minutes every 3 weeks
88818837|NCT02427984||Metal on Metal (MoM)|Patients wearing MoM hip prosthesis
88818838|NCT02427984||Ceramic on Ceramic (CoC)|Patients wearing CoC hip prosthesis
88818839|NCT02427984||Controls|Patients free from hip devices
88818840|NCT02643225||pregnant women with gestational diabetes|case group
88818841|NCT02643225||non diabetic pregnant women|control group
88818842|NCT02264249||Split dose colonoscopy preparation|Esophagogastroduodenoscopy and colonoscopy - split dose - ½ evening before and ½ early AM (4L volume or 2L volume bowel preparation)
88818843|NCT02264249||Evening before colonoscopy preparation|Esophagogastroduodenoscopy and colonoscopy - Evening before (4L, 2L or miralax bowel preparation)
88818844|NCT02264249||Same day prep colonoscopy preparation|Esophagogastroduodenoscopy and colonoscopy - Same day prep (4L volume or 2L volume or Miralax bowel preparation)
88818845|NCT01857713|Active Comparator|Reza Band UES Assist Device|Patient is own control. Compare baseline to last follow-up after using device
88818846|NCT02643459|No Intervention|Conventional|no suPAR measurement. Standard care.
88818847|NCT02643459|Experimental|suPAR|suPAR measurement and education of doctors working in the Emergency department in the meaning of low or elevated levels of suPAR. Since suPAR is measured on all patients regardless of disease the investigators cannot define a single intervention. A possible intervention depends on the clinical situation.
88818848|NCT02643615|Experimental|VEP under TIVA|Patients undergoing prone spine surgery will receive an anesthesia regimen using propofol (TIVA) for maintenance
88818849|NCT02643615|Experimental|VEP under balanced anesthesia|Patients undergoing prone spine surgery will receive an anesthesia regimen using Desflurane as part of balanced general anesthesia
88818850|NCT02643849|Experimental|Spanner|
88818851|NCT02265341|Experimental|Treatment (ponatinib hydrochloride)|Patients receive ponatinib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88818852|NCT02989103||Hyperthyroidism Follow-up Cohort Study|Hyperthyroid patients enrolled and treated between 1946 and 1964 in 25 U.S. and 1 UK site
88818853|NCT01859195||Focus Group Stage|~20-24 participants, to comprise 3-6 focus groups
88818854|NCT01859195||Cognitive Interview Stage|~12-16 participants in individual cognitive interviews
88818855|NCT01421186|Experimental|Phase 1 dose escalation|"Part A: MOR03087 dose escalation; biweekly treatment~Part B: MOR03087 dose escalation; weekly treatment~Part C: MOR03087 dose escalation (weekly treatment) + dexamethasone~Part D: MOR03087 weekly treatment in combination with pomalidomide + dexamethasone~Part E: MOR03087 weekly treatment in combination with lenalidomide + dexamethasone~For all parts, patients will be treated until disease progression (PD) or until a maximum of 3 years after first treatment."
89386686|NCT03570008|Experimental|Sp-Ex|a 9 days spa residential program including physical activity. 3 sessions of 10 minutes per day of physical exercise for bone health improvements supervised by a professional of adapted physical activity. Participants will benefit advices from national plan for physical activity and nutrition (NPPN)
89386687|NCT03570008|Active Comparator|Sp-alone|Participants will benefit a short term spa residential program of 9 days. In addition they will benefit advices from national plan for physical activity and nutrition (NPPN)
89386688|NCT03570008|Active Comparator|Ex-alone|Participants will benefit 3 sessions of 10 minutes per day of physical exercise for bone health improvements supervised by a professional of adapted physical activity. Participants will benefit advices from national plan for physical activity and nutrition (NPPN)
89386689|NCT02246426|Experimental|Experimental Treatment|Computerized plasticity-based adaptive cognitive training requiring a total maximum of 40 treatment sessions, 3-5 times weekly, 45-60 minutes per session.
89386690|NCT02246426|Active Comparator|Active Comparator|Commercially available computerized training requiring a total maximum of 40 treatment sessions, 3-5 times weekly, 45-60 minutes per session.
89386691|NCT00381485|Experimental|MF/F MDI 400/10 mcg BID|"Mometasone Furoate 400 mcg and formoterol 10 mcg fixed dose combination taken twice daily~Participants received 2 to 3 weeks (approximately) of open-label, run-in medication with MF MDI 400 mcg BID prior to the 12-week double-blind treatment period"
89386692|NCT00381485|Experimental|MF/F MDI 200/10 mcg BID|"Mometasone Furoate 200 mcg and formoterol 10 mcg fixed dose combination taken twice daily~Participants received 2 to 3 weeks (approximately) of open-label, run-in medication with MF MDI 400 mcg BID prior to the 12-week double-blind treatment period"
89386693|NCT00381485|Active Comparator|MF MDI 400 mcg BID|"Mometasone Furoate 400 mcg taken twice daily~Participants received 2 to 3 weeks (approximately) of open-label, run-in medication with MF MDI 400 mcg BID prior to the 12-week double-blind treatment period"
89386694|NCT05183269|Experimental|Virtual reality|Normal procedure with the use of a virtual reality monitor
89386695|NCT05183269|No Intervention|no virtual reality|Normal procedure without the use of a virtual reality monitor
89386696|NCT01335503|Active Comparator|AN-PEP with low caloric meal|
89386697|NCT01335503|Active Comparator|AN-PEP with high caloric meal|
89386698|NCT01335503|Placebo Comparator|Placebo with low caloric meal|
89386699|NCT01335503|Placebo Comparator|Placebo with high caloric meal|
89386700|NCT01341379|Experimental|N-carbamylglutamate (Carbaglu)|
89386701|NCT01332539||drug-resistant partial epilepsy|
89386702|NCT01332539||controlled partial epilepsy|
89386703|NCT01335659||ostial lesion|ostial lesion will be evaluated by IVUS and FFR
89386704|NCT05182957|Experimental|Anti-PD-1 monoclonal antibody+Lenalidomide+Azacitidine|Anti-PD-1 monoclonal antibody plus Lenalidomide, Azacitidine
89386705|NCT02840474|Experimental|Part A: VRC01LS (40 mg/kg)|VRC-HIVMAB080-00-AB (VRC01LS) - (40 mg/kg) - administered intravenously (IV) at Day 0
89386706|NCT02840474|Experimental|Part B: VRC07-523LS (40 mg/kg)|VRC-HIVMAB075-00-AB (VRC07-523LS) - (40 mg/kg) - administered IV at Day 0
89386707|NCT04777981|Experimental|CBDRA60 supplement|Daily sublingual tablet containing 30mg Cannabidiol and 30mg Red Algae, a total of 60mg per dose. Participants will take 2 tablets per day, sublingually and with food, taken approximately and at least, 8 hours apart, daily for 28 days. Participants will be mailed a supply of pills by an overnight courier service.
89386708|NCT04777981|Placebo Comparator|Placebo|Control subjects will receive daily oral placebo tablets of identical appearance and taste containing no CBDRA60.
88818900|NCT01485380|Experimental|Active study arm|Subjects recruited into this study will be required to undergo two magnetic resonance imaging- positron emission tomography (MRI-PET) scans of the brain in addition to high density electroencephalogram (EEG) acquisition. The first scan will be a baseline scan while the second scan will be performed while dexmedetomidine is being infused.
88818901|NCT05445297|Other|Amiodarone group|
88818902|NCT05445297|Other|Refralon group|
89386709|NCT01335737|Experimental|aerobic training|12 weeks of aerobic training, 4 times/week
89386710|NCT01335737|Placebo Comparator|wait list control|wait list control condition, 12 weeks + 4 to parallel the deconditioning protocol in active intervention group
89386711|NCT04889599|Experimental|BH009 (Docetaxel Injection)|Patients will receive single dose BH009 75 mg/m2, as a 1-hour IV infusion.
89386712|NCT04889599|Active Comparator|Docetaxel Injection|Patients will receive single dose Docetaxel Injection 75 mg/m2, as a 1-hour IV infusion.
88818903|NCT01539980|Experimental|Sericin scaffold|
88818904|NCT05445063|Experimental|Participants receiving intervention|Participants will receive autologous transplantation of induced pluripotent stem cell-derived retinal pigment epitheliums.
88818905|NCT00556673|Experimental|Indacaterol/mometasone - Placebo|In Treatment Period 1 (Day 1) participants received 2 inhalations of indacaterol maleate 250 μg / mometasone furoate 200 μg once a day in the morning via the Twisthaler device. In Treatment Period 2 (Day 8) participants received 2 inhalations of placebo via the Twisthaler device once a day in the morning. In Treatment Period 3 (Day 15) participants received fluticasone proprionate 250 μg / salmeterol xinafoate 50 μg twice a day delivered via dry-powder inhaler. Each treatment period was separated by a minimum washout period of 7 days.
88818906|NCT00556673|Experimental|Placebo - indacaterol/mometasone|In Treatment Period 1 (Day 1) participants received 2 inhalations of placebo in the morning via the Twistheler device. In Treatment Period 2 (Day 8) participants received 2 inhalations of indacaterol maleate 250 μg / mometasone furoate 200 μg via the Twisthaler device in the morning. In Treatment Period 3 (Day 15) participants received fluticasone proprionate 250 μg / salmeterol xinafoate 50 μg twice a day delivered via dry-powder inhaler. Each treatment period was separated by a minimum washout period of 7 days.
88818907|NCT05437029|Experimental|Q-Griffithsin Group 1: 3.0 mg daily spray|In Group 1, up to 12 participants will receive a dose of 3.0 mg intranasal Q-GRFT administered once daily, as 2 sprays (100 µL/ spray) in each nostril, for 7 days.
88818908|NCT05437029|Experimental|Q-Griffithsin Group 2: two 3.0 mg sprays per day|In Group 2, up to 12 participants will be enrolled to receive a total of 6.0 mg intranasal Q-GRFT administered as 3.0 mg twice daily (3.0 mg BID), with 2 sprays (100 µL/ spray) in each nostril approximately every 12 hours, for 7 days.
89386713|NCT03476213|Experimental|Group TCI|induction and anesthesia will be held by using target-controll infusion
88862149|NCT05154552|Experimental|group A/ routine physical therapy and PNF|"In group A, PNF based gait training (15 minutes) and conventional physical therapy (45 minutes) will be performed.~PNF exercises involved PNF pelvic patterns (pelvic interior elevation and posterior depression), PNF lower extremity D1 Flexion and PNF lower extremity D1 extension (Unilateral during 1st to 3rd week and bilateral from 4th week onwards). Exercises will progress from rhythmic initiation and then progress to slow reversal and agonistic reversal up to 6th week of therapy and continues until 12th week. Each exercise will be repeated for 10 to 20 times.~Conventional physiotherapy will be administered according to the European Physiotherapy guidelines for Parkinson's disease.~Other exercises include:~Range of motion exercises~Stretching exercises~Upper and lower limb strengthening exercises"
88862150|NCT05154552|Active Comparator|group B/ routine physical therapy|"Conventional physical therapy (45 minute session) will be performed in group B.Conventional physiotherapy will be administered according to the European Physiotherapy guidelines for Parkinson disease.~Other exercises include:~Range of motion exercises~Stretching exercises~Upper and lower limb strengthening exercises"
88862151|NCT01796574|Experimental|Ketogenic diet|Patients will receive the ketogenic diet as a formula delivered via feeding tube. Once able to tolerate food by mouth, patients will be switched to a modified Atkins diet.
89386714|NCT03476213|Active Comparator|Group TIVA|induction and anesthesia will be held by manual dosing of propofol and sufentanil
89386715|NCT03567746|Experimental|Underwater EMR|The patients randomized in this arm will be treated by endoscopic resection assisted by the filling of the colonic lumen using water instead of air and avoiding the formation of a submucosal cushion
89386716|NCT03567746|Active Comparator|Conventional EMR|The patients randomized in this arm will be treated by endoscopic resection following the traditional technique. It means, by assistance of selective submucosal saline injection to create a submucosal cushion below the polyp.
89386717|NCT01342627|Experimental|Sorafenib|"Sorafenib will be orally administered at a daily dose of 400 mg taken twice daily without food, at least one hour before or two hours after eating. Four weeks of treatments will be considered as a cycle. Each patient enrolled in the study will received medications for topical therapy. Dermatological medications will be provided free.~In case of toxicities, dose reduction/interruption is permitted according to protocol.~In case of disease progression Sorafenib administration will be discontinued."
89386718|NCT04384393|Experimental|ThisCART19 cells injections|In this study, allogeneic anti-CD19 CAR T Cells(ThisCART19 cells) is used to treat patients with refractory or relapsed CD19 positive B cell malignancies.
89386719|NCT03570944||Patients undergoing elective HRS or KRS|Adult patients undergoing elective HRS or KNS
89386720|NCT01343641|Experimental|MK-0677|The oral agent MK-677 is spiropiperidine, Merck L-163 191, GH secretagogue ghrelin mimetic which increases GH and IGF-I secretion, fat free mass and energy expenditure76-79. It is produced by Merck & Co, Inc.
89386721|NCT01343641|Placebo Comparator|Placebo|Inactive Pill used as a comparator
89386722|NCT03155945|Experimental|Olorinab 25 mg TID|Participants received olorinab 25 milligrams (mg) tablet by mouth, three times daily (TID) for 8 weeks
89386723|NCT03155945|Experimental|Olorinab 100 mg TID|Participants received olorinab 100 mg oral tablets TID for 8 weeks
89386724|NCT03570866||Early stage endometrial cancer|Women with diagnosis of intermediate and high-risk early stage endometrial cancer.
89386725|NCT01342705|Experimental|phlebotomy|
89386726|NCT01342705|No Intervention|control|
89386727|NCT03569930|Experimental|Standard|standard of care (diet rich in water and vegetable fibers, hygienic)
89386728|NCT03569930|Experimental|ProtFlav|oral supplements (flavonoid-based supplements - ProtFlav) will be added to standard of care
89386729|NCT03569930|Experimental|ProtCent|anal application of a Centella based cream (Centella asiatica - ProtCent) will be added to standard of care
89386730|NCT01335815||elective knee and limb endoprothesis|
88862152|NCT01795404|Experimental|Inquiry Based Stress Reduction (IBSR) Program|During a 12-week intervention program, participants will be encouraged to identify and inquire their stressful thoughts. Through the use of self-inquiry practices participants are taught to increase awareness of their thoughts and feelings, to observe their emotional and physical responses during situations perceived by them as stressful, and allow their mind to return to its true, peaceful, creative nature. Through the process of self-inquiry, participants take an active role in investigating their stressful thoughts, and by this regulating their stress and managing symptoms and emotions, thus enabling them to cope better with the distress related to the possibility of cancer.
88862153|NCT01795404|No Intervention|Control group|Waited-list control
88862154|NCT04271124|Active Comparator|PR|
88862155|NCT04271124|Experimental|PR+ET|
89386731|NCT01343719|Experimental|BI 661051 low dose, low|solution for oral administration, single dose
89386732|NCT01343719|Experimental|BI 661051 low dose, medium|solution for oral administration, single dose
89386733|NCT01343719|Experimental|BI 661051 low dose, high|solution for oral administration, single dose
89386734|NCT01343719|Experimental|BI 661051 medium dose, low|solution for oral administration, single dose
89386735|NCT01343719|Experimental|BI 661051 medium dose, medium|solution for oral administration, single dose
89386736|NCT01343719|Experimental|BI 661051 medium dose, high|solution for oral administration, single dose
89386737|NCT01343719|Experimental|BI 661051 high dose, low|solution for oral administration, single dose
89386738|NCT01343719|Experimental|BI 661051 high dose, medium|solution for oral administration, single dose
89386739|NCT01343719|Experimental|BI 661051 low dose|tablet
89386740|NCT01343719|Experimental|BI 661051 medium dose|tablet
89386741|NCT01343719|Placebo Comparator|Placebo|solution for oral administratrion
89386742|NCT03569852|Experimental|Experimental Group 1|Order of treatment, time restrictive feeding (16 hours fasting and 8 hours eating) followed by traditional eating pattern (12 hours fasted and 12 hours eating).
89386743|NCT03569852|Experimental|Experimental Group 2|Order of treatment, traditional eating pattern (12 hours fasted and 12 hours eating) followed by time restrictive feeding (16 hours fasting and 8 hours eating).
89386744|NCT01316731|Experimental|Exercise|
89386745|NCT03160703|Experimental|Test dentifrice 1 (RDA~58)|Participants will apply experimental dentifrice containing 0.454% SnF2 / 5% STP.
89386746|NCT03160703|Experimental|Test dentifrice 2 (RDA~77)|Participants will apply experimental dentifrice containing 0.454% SnF2 / 5% STP.
89386747|NCT03160703|Other|Reference dentifrice 1 (RDA~80)|Participants will apply dentifrice containing 1000 parts per million (ppm) fluoride as Sodium Monofluorophosphate (SMFP).
89386748|NCT03160703|Active Comparator|Reference dentifrice 2 (RDA~120)|Participants will apply dentifrice containing 0.454% SnF2.
89386749|NCT03569774|Experimental|Individualized PEEP|Individualized PEEP will be identified by performing a decremental PEEP protocol which will determine the level of PEEP that correlates with maximal lung compliance in each subject. Subjects will receive one-lung ventilation with individualized PEEP
89386750|NCT03569774|Active Comparator|Low PEEP|Subjects will receive One-lung ventilation with low PEEP (5 cmH2O)
89386751|NCT01342861|Sham Comparator|Observational period|A first period of follow-up on the 400 patients was designed to survey and evaluate current nutrition administration policy
89386752|NCT01342861|Experimental|Intervention period|The second period of follow-up on the 400 patients was designed to evaluate the impacts of adding milky food to the breakfast and of educating health care professionals on the early detection of undernutrition.
89386753|NCT01316965|Experimental|multifaceted prevention program|
89386754|NCT01316965|No Intervention|usual care|
89386755|NCT01332617|Experimental|Treatment with combination therapy|Treatment with combination therapy of Simvastatin, Zoledronic Acid, Bortezomib, Bendamustine, and Methylprednisolone.
89386756|NCT03569696|Experimental|Nivolumab|Nivolumab will be administered intravenously every 2 weeks in a dose of 240mg over 30 minutes for 8 cycles and then 480mg every 4 weeks for two years (cycle 9-30)to a maximum of 30 doses whichever comes first.
89386757|NCT01342939||MODY2|Also called GCK (glucokinase) MODY. They have a specific mutation in the GCK gene.
89386758|NCT01342939||MODY3|Also called HNF1 alfa MODY. They have a specific mutation in the HNF1 alfa gene.
89386759|NCT01342939||Healthy control subjects|
89386760|NCT03392090|Experimental|More Good Days video&brief questionnaire|"Participants will watch the More Good Days video and will be given a brief questionnaire and wallet card to help identify their goals and preferences about information and care~The More Good Days video is developed to help patients with advanced cancer think about what a good day means to them and to help them think about questions they may have for their physicians when discussing treatments.~The 3-page brief questionnaire is designed to help patients identify their preferences about information and care and to help encourage a conversation between patients and their doctors and health care team about their goals and preferences~The wallet card will help patients think about questions they may want to ask their providers when considering treatments."
88818909|NCT01422434|Active Comparator|LEO 90105 ointment|LEO 90105 ointment applied once daily for 4 weeks.
88818910|NCT01422434|Active Comparator|Dovonex® ointment|Applied twice daily for 4 weeks.
89386761|NCT01315535||Fast Titration|
89386762|NCT01315535||Regular Titration|
89386763|NCT01315535||Fast Tritation Including Mandibular Exercises|
89386764|NCT01315535||Regular Tritation Including Mandibular Exercises|
89386765|NCT04376983|No Intervention|Control|Patients will get no intervention
88818911|NCT01422434|Active Comparator|Rinderon® - DP ointment|Applied once daily for 4 weeks
89386766|NCT04376983|Experimental|Intervention|Patients will transmit their CRT data every week (first 6 weeks) and then every two week to the Heart Centre Hasselt. The physical activity data will be used to deliver a tailored motivational message to the patient to increase physical activity in this group.
88818912|NCT02402322|Active Comparator|Non-scheduled support|Participants received an Web-based cognitive behavioral treatment for Panic Disorder with the support of a therapist via phone when they required it.
89386767|NCT01332695|Experimental|ST101|ST101 oval tablets
89386768|NCT01332695|Placebo Comparator|Placebo|oval tablets to match ST101 tablet
88818913|NCT02402322|Experimental|Scheduled support|Participants received an Web-based cognitive behavioral treatment for Panic Disorder with the support of a therapist via phone weekly.
88818914|NCT02402322|No Intervention|Waiting list|Participants in a waiting list.
88818915|NCT01861457|Experimental|Nozin® Nasal Sanitizer®|Non-antibiotic, alcohol-based antiseptic
88818916|NCT01861457|Placebo Comparator|Phosphate-buffered saline|Placebo
88818917|NCT02651103||Posterior spinal fusion|Patients undergoing spinal fusion surgery
88818918|NCT01861925||Normal eye|Astigmatism smaller than 1.5 diopters
88818919|NCT01861925||Large regular astigmatism|Astigmatism of > 1.5 diopters, regular astigmatism.
88818920|NCT01861925||Large irregular astigmatism|Astigmatism of > 1.5 diopters, irregular astigmatism.
88818921|NCT02269631|Experimental|Legume diet group|Meals will include approximately 1 ½ cups of cooked legumes, such as pinto, baked and navy beans as part of your 2 daily main dishes (lunch and dinner) and additional foods and snacks, preferably from the recommended healthy foods list. The smartpill will be administered at the end of the study.
88818922|NCT02269631|Active Comparator|Control diet group|Meals will be healthy, typical American foods (without legumes) for 2 daily main dishes and additional foods and snacks, preferably from the recommended healthy foods list.The smartpill will be administered at the end of the study.
88818923|NCT02270255|Sham Comparator|Control group|Sham procedure. Subcutaneous injection of 5cc of 1% Xylocaine in the periumbilical region.
88818924|NCT02270255|Experimental|Sup Hypogastric Nerve block group|Superior hypogastric nerve block performed during UFE. 20cc of 0.75% Ropivacaine injected at the superior hypogastric nerve plexus.
88818926|NCT02270645|No Intervention|Control|"Subjects in the control arm will receive 3 regular study visits spaced 4 weeks (+/- 3 days) apart. If a subject in the control arm has multiple BCCs satisfying inclusion criteria, all BCCs will not be treated.~Four weeks (+/- 3 days) after the last (Day 84) both treatment and control patients will be assessed for final clinical appearance, measurement, and evaluation of the lesion by a dermatologist.~Subjects will also undergo deep excisional biopsy encompassing the entire lesion to determine residual tumor cell presence. If histologic examination of the tissue reveals residual BCC, then the subject will receive standard of treatment."
89386769|NCT03569540|Experimental|Treated Patients|Patients who will receive Glibenclamide 05mg daily for 21 days, orally or by nasogastric tube.
89386770|NCT03569540|Placebo Comparator|Control Group|Patients who will receive amylum 05mg daily for 21 days, orally or by nasogastric tube.
89386771|NCT04376437|Experimental|medical cannabis|All patients will start with 250mcg cannabis flos BID and will follow the titration plan of dose modification according to CIPN relief and adverse events. Maximum dose of 2,000mcg per day is prescribed at the end of titration period, which is continuous for 15 days (about 2 weeks).On 10 weeks visit all patients will be discontinued from the treatment. In case of worsening of neuropathy at any point during the 4 weeks of FU, patients might be able to restart with inhaled MC treatment for no more than 4 weeks. Total treatment in this study will be for no more than 14 weeks.
89386772|NCT01335893|Experimental|ICG injection group|This group will receive a single dose of ICG, diluted in saline solution, prior to surgery. Then, during their surgery, they will be imaged with the camera and imaging probe we have developed.
89386773|NCT03567278|Experimental|ACURATE TA™|Patients implanted with ACURATE TA™ Bioprosthesis
89386774|NCT01339169|Experimental|YF476 treatment|
89386775|NCT05251441|Experimental|F50|Patients in the group in which fortification was started when enteral nutrition reached 50 cc/kg
89386776|NCT05251441|Active Comparator|F100|Patients in the group in which fortification was started when enteral nutrition reached 100 cc/kg
89386777|NCT03567200|Experimental|Single-Arm Feasibility|9-week, 1x/week, 90-minute face-to-face sessions.
89386778|NCT01332773|Experimental|Artery first group|"The basic principle of the artery first approach is the early identification of the SMA at its origin at the aorta with the further resection then being guided by its anatomic course.~The dissection is carried cephalad along the aorta until the origin of the SMA is reached. The posterior and right aspect of the SMA is then dissected over a few centimeters. On the right side of the SMA a replaced or accessory right hepatic artery, if present, will be identified and preserved. This maneuver should be done, if infiltration of the SMA is suspected as the procedure can be terminated at this point. Once the situation at the SMA is assessed and resectability is confirmed resection will be done."
88862156|NCT00373698|Experimental|Three Component Model|Three Component Model of Collaborative Care: Patients randomized to 3CM will receive telephone care management along with usual care by VA clinicians.
89386779|NCT01332773|Active Comparator|Conventional Group|A wide Kocher manoeuver is performed to fully mobilize the duodenum and the head of the pancreas. The colonic mesentery on the right side is separated from the anterior surface of the duodenum and the head of the pancreas. The size of the tumor and its relation to the superior mesenteric artery, the celiac trunk, the mesentery, the portal vein, and the superior mesenteric vein is assessed. If resectability is given a Kausch-Whipple's resection is performed.
89386780|NCT04371679||Endotracheal intubation and ventilation|Patients admitted at ICU that are intubated and ventilated
88862157|NCT00373698|No Intervention|Usual Care|"Patients randomized to Usual Care will receive care as usual by VA clinicians."
88862158|NCT00374088|Placebo Comparator|Placebo|These patients receive a placebo infusion of D5W prior to and after surgery
88862159|NCT00374088|Experimental|N-Acetylcysteine|These patients receive a loading dose of N-Acetylcysteine 100 mg/kg in D5W IV 1 hour prior to surgery. They receive a maintenance infusion of N-Acetylcysteine 10 mg/kg/hr in D5W IV for 24 hours after surgery.
88862160|NCT00401622|Experimental|OneTouch® Ultra®2 system|Test care group assigned to OneTouch® Ultra®2 system
88862161|NCT00401622|Active Comparator|Standard care|Control group receiving standard care with a traditional blood glucose monitoring system
88862162|NCT04270890|Experimental|Study participants|Patients will be dual scanned; one with 4D-CT in free-breathing and one wearing the compression belt.Organ motion will then be quantified using Eclipse. This facilitates a direct comparison to determine the efficacy of the compression belt. Patients with reduction in organ motion will be treated wearing the abdominal compression belt. The alignment scale will be recorded to facilitate accurate placement each fraction. The belt will be inflated to a tolerable level by the patient and recorded for consistency each fraction. The position of the belt will be referenced to the anterior and lateral tattoos to ensure accurate and consistent placement each fraction.
88862163|NCT00374244|Placebo Comparator|1|placebo pimozide
88862164|NCT00374244|Active Comparator|2|active pimozide
88862165|NCT04270812|Experimental|Sleep Treatment|This arm consists of the sleep treatment that will be administered to all participants in the single-arm open trial.
88862166|NCT00377832|No Intervention|1|
88862167|NCT00377832|Active Comparator|2|Acetaminophen 975 mg once
88862168|NCT00401778|Active Comparator|1|RAD001 5 mg/day for 21 days sequentially.
89386781|NCT04371679||Non-Invasive Ventilation|Patients admitted at ICU who are non-invasively ventilated
89386782|NCT03567512|Experimental|Intervention group|The Intervention administered to this group will focus on Quit Smoking of parental and household smokers and Reduction of Secondhand Smoke Exposure among the Children.
89386783|NCT03567512|Placebo Comparator|Control group|The placebo intervention will be administered in this group.
89386784|NCT01339325|Active Comparator|LESS cholecystectomy|Laparo-endoscopic single site cholecystectomy, the entire surface of the patient's abdomen is covered by plaster at the end of the operation. Patient does not know which kind of procedure he underwent before discharge.
89386785|NCT01339325|Active Comparator|Standard LAP-CHOLE|Standard laparoscopic cholecystectomy. The entire surface of the patient's abdomen is covered by plaster at the end of the operation. Patient does not know which kind of procedure he underwent before discharge.
89386786|NCT01339325|Active Comparator|LESS Cholecystectomy not blind|Laparo-endoscopic single site cholecystectomy. The patient is aware of the procedure he underwent.
89386787|NCT03569462|Experimental|"Mobile WeChat intervention"|Participants will watch a demonstration of HIV self-testing, receive HIV self-testing kits, and receive access to a mobile health application that delivers content to promote HIV-self testing and reduce HIV-related risk behavior.
89386788|NCT03569462|Active Comparator|Control condition|Participants will watch a demonstration of HIV self-testing and receive HIV self-testing kits.
89386789|NCT05708690|Experimental|Tranexamic Acid Topical|The treatment of interest was application of Topical Tranexamic Acid (5 gram in 50 mL warm normal saline). The topical will be poured into the pericardial and mediastinal cavities (after protamine administration), and sternum (before chest closure)
89386790|NCT05708690|Placebo Comparator|Placebo|The control group is given 100 mL of warm normal saline. The topical will be poured into the pericardial and mediastinal cavities (after protamine administration), and sternum (before chest closure).
89386791|NCT01343875||surgery, biceps tear|
89386792|NCT04851821|Experimental|Quercetix group|Each patient included, after signing the consent, will have a treatment for ten days: one tablet twice a day 30 minutes before the meal.
89386793|NCT04851821|Placebo Comparator|Placebo Group|Each patient included, after signing the consent, will have a treatment for ten days: one tablet twice a day 30 minutes before the meal.
89386794|NCT01315457||Alemtuzumab|Patients treated with alemtuzumab
89386795|NCT03567122|Experimental|Internal Focus of Attention|30 subjects will be randomized to this arm. Only internal focus of attention feedback instructions will be given during the execution and training performing the Cranio-Cervical Flexion Test. The subjects allocated to this arm will not be allowed to use the visual feedback traditionally provided during the Cranio-cervical Flexion Test.
88862169|NCT00401778|Active Comparator|3|RAD001 10 mg/day for 21 days sequentially.
89386796|NCT03567122|Experimental|External Focus of Attention|30 subjects will be randomized to this arm. Only external focus of attention feedback instructions will be given during the execution and training performing the Cranio-Cervical Flexion Test. The subjects allocated to this arm will not be allowed to use the visual feedback traditionally provided during the Cranio-cervical Flexion Test. In addition, they will use just a laser point attached to the head to guide their cranio-cervical flexion.
89386797|NCT03567122|Active Comparator|Control|30 subjects will be randomized to this arm. The participants allocated to this arm will be instructed as traditionally during the Cranio-Cervical Flexion Test. They will be given visual feedback while have their attention guided to the inner neck movement.
88862170|NCT00401778|No Intervention|Control|Patients who are eligible for the study but choose not to receive RAD001 treatment.
88862171|NCT00402714|Active Comparator|1|Extracorporeal photopheresis, pentostatin and total body irradiation
88862172|NCT00402714|Active Comparator|2|Pentostatin and total body irradiation
88862173|NCT00405288||Proctofoam-HC®|Women in the third trimester of pregnancy prescribed Proctofoam-HC® aerosol foam canister for 36 applications for treatment of symptoms of hemorrhoids. One applicatorful is to be applied into the anus (or on the perianal area) two or three times daily and after bowel evacuation.
88862174|NCT00405288||Control|Control group of women in the third trimester of pregnancy who were not exposed to any teratogens during the course of the pregnancy, and to Proctofoam-HC any of its components, or any other topical corticosteroids or local anaesthetics during the course of their pregnancy.
88862175|NCT00458406|Active Comparator|Bi-Flex|"Subjects randomized to this arm will undergo a clinical Bi-Flex sleep study. Following a baseline polysomnography, subjects in this arm will undergo bilevel positive airway pressure with pressure release technology (Bi-Flex) therapy.~In this randomized, double-blinded clinical trial, patients with obstructive sleep apnea will be randomized to Bi-Flex or CPAP, and repeat polysomnography will be performed on pressure at 3 months. Objective adherence data will be obtained at 1 and 3 months."
88862176|NCT00458406|Active Comparator|CPAP|"Subjects randomized to this arm will undergo a clinical CPAP titration sleep study.~Subjects in this arm received standard continuous positive airway pressure (CPAP) therapy.~In this randomized, double-blinded clinical trial, patients with obstructive sleep apnea will randomized to CPAP or Bi-Flex, and repeat polysomnography will be performed on pressure at 3 months. Objective adherence data will be obtained at 1 and 3 months."
88862177|NCT00381810|Experimental|Rituximab 1000 mg|Participants will receive rituximab 1000 mg intravenously twice, 14 days apart at study entry and again 6 months later. Participants will also receive methylprednisolone 100 or 125 mg IV, acetaminophen 1000 mg orally, and diphenhydramine 50 mg orally prior to study drug infusion.
88862178|NCT00458952|Experimental|Dose Escalation|Dosing of Ultratrace iobenguane I 131 began at 6.0 mCi/kg and escalated in 1.0 mCi/kg increments in order to establish the MTD. The MTD is the dose immediately below the level at which escalation stops due to dose-limiting toxicity (DLT). An additional 3 patients are to be treated at the MTD, for a total of 6.
88862179|NCT00459732|Placebo Comparator|Placebo Capsule|placebo capsule, similar in size, shape and color to zinc capsule, taken once daily for 18 months
88862180|NCT00459732|Active Comparator|Zinc (25 mg/d)|25 mg of elemental Zinc as zinc sulphate taken once daily for 18 months
88862181|NCT00405522|Experimental|Propofol 2.0 mg/kg + Remifentanil 1.5 ug/kg|
88862182|NCT00405522|Experimental|Propofol 4.0 mg/kg + Remifentanil 0.5 ug/kg|
88862183|NCT00381966|Experimental|Robotic placement device|The intervention involves use of a robotic template to assist in placement of needles for prostate brachytherapy.
88862184|NCT00461292|Experimental|1|botulinum toxin Type A (200U)
88862185|NCT00461292|Experimental|2|botulinum toxin Type A (300U)
88862186|NCT00461292|Other|3|placebo; botulinum toxin Type A (200U)
88862187|NCT00461292|Other|4|placebo; botulinum toxin Type A (300U)
88862188|NCT00382590|Active Comparator|5-Aza + VPA|5-Azacytidine (5-Aza) 75 mg/m^2 subcutaneously daily + Valproic Acid (VPA) 50 mg/m^2 orally daily, each for 7 days
88862189|NCT00382590|Active Comparator|Ara-C|Low-Dose Ara-C 20 mg twice daily subcutaneously for 10 days.
89386798|NCT03569384|Experimental|"Intervention group tele-rehabilitation"|"Video Consultation (VC) Sessions: Each patient will have the opportunity to have minimum one VC per week the first month, one VC each second week the second month one VC a month Retraining breath: Patients will also be instructed to use different techniques to breath during the video consultations with the physiotherapist. Chat Sessions: Each patient has the opportunity to chat with the physiotherapist any time via the chat module of the system. Workout Sessions with a Virtual Physiotherapist Agent (VPA):~The patient will train according to what is decided by the physiotherapist and the patient in the VC or chat meetings. Normally, the patients will train 10-20 minutes daily at home with its individual and tailored VPA. Patients' security: In order to minimize the risks of possible accidents while performing the exercises, the patient will answer questions before and after each exercise performance that the physiotherapist can follow in real time."
89386799|NCT03569384|Active Comparator|Control|COPD patients in the control group will undergo the conventional standardized rehabilitation program as implemented at the Department of Respiratory Medicine and Allergy, Aarhus University Hospital. The program is an 8 weeks program consisting of 2 weekly group training sessions at the hospital with instruction by a physiotherapists and 6 hours of education about COPD and its treatment.
89386800|NCT01343953|Experimental|Cord Blood Transplantation|
89386801|NCT05140291|Experimental|Dry needling|Experimental Group
89386802|NCT05140291|Sham Comparator|Sham Needling|Sham Group
89386803|NCT03567044|Experimental|Blood Collection|Patients will be asked to have blood draws at specific time points during their whole breast irradiation.
89386804|NCT02247128|Active Comparator|Aspirin + Clopicogrel (Cohort A)|Cohort A: patients will receive clopidogrel (75mg quaque die (qD), 3 months) on top of low-dose aspirin (≤100mg qD, at least 1 year but recommended lifelong). When a patient in Cohort A doesn't already takes aspirin, a loading dose of 300mg will be given within 24 hours prior to TAVI. The loading dose for clopidogrel is 300mg, and will be given within 24 hours prior to TAVI.
89386805|NCT02247128|Active Comparator|Aspirin monotherapy (Cohort A)|Cohort A: patients will receive low-dose aspirin (≤100mg qD, at least 1 year but recommended lifelong). When a patients doesn't already takes aspirin, a loading dose of 300mg will be given within 24 hours prior to TAVI. It is recommended to omit other antiplatelet therapy (e.g. clopidogrel) at least 5 days prior to the TAVI procedure.
89386806|NCT02247128|Active Comparator|OAC + Clopicogrel (Cohort B)|Cohort B: patients will receive clopidogrel (75mg qD, 3 months) on top of OAC (according to its indication). The loading dose for clopidogrel is 300mg, and will be given within 24 hours prior to TAVI. It is recommended to omit other antiplatelet therapy (e.g. aspirin) at least 5 days prior to the TAVI procedure.
89386807|NCT02247128|Active Comparator|OAC monotherapy (Cohort B)|Cohort B: patients will receive OAC according to its indication. It is recommended to continue the OAC therapy peri-procedural (International Normalized Ratio aimed at 2.0). It is recommended to omit antiplatelet therapy (e.g. clopidogrel) at least 5 days prior to the TAVI procedure.
89386808|NCT01339481||Subjects with RA initiating abatacept treatment regimen|Subjects naïve to both abatacept and belatacept
89386809|NCT01344031|Experimental|Arm A (anastrozole and Akt inhibitor MK2206)|"Patients receive anastrozole PO on days 1-28. Beginning in course 2, patients receive Akt inhibitor MK2206 PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~NOTE: As of 8/19/2015, patients no longer receive Akt inhibitor MK2206."
89386810|NCT01344031|Experimental|Arm B (Akt inhibitor MK2206 and anastrozole)|"The RPTD of Akt inhibitor MK2206 with anastrozole is determined after 3 courses, administered as in Arm A.~NOTE: As of 8/19/2015, patients no longer receive Akt inhibitor MK2206."
89386811|NCT01344031|Experimental|Arm C (Akt inhibitor MK2206 and fulvestrant)|"Patients receive Akt inhibitor MK2206 PO on days 1, 8, 15, and 22, fulvestrant IM on day 1and day 15 of course 1 and then on day 1 of each course in each subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~NOTE: As of 8/19/2015, patients no longer receive Akt inhibitor MK2206."
89386812|NCT01344031|Experimental|Arm D (Akt inhibitor MK2206, anastrozole, fulvestrant)|"Patients receive Akt inhibitor MK2206 PO as in Arm A, anastrozole PO on days 1-28 and fulvestrant IM on day 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~NOTE: As of 8/19/2015, patients no longer receive Akt inhibitor MK2206."
88818927|NCT02651259|Experimental|Cohort 1 (pregnant women enrolled in the second trimester)|Participants received 12 directly observed once-weekly doses of RPT, INH, and pyridoxine (vitamin B6) at study entry and at 11 weekly follow-up visits.
88818928|NCT02651259|Experimental|Cohort 2 (pregnant women enrolled in the third trimester)|Participants received 12 directly observed once-weekly doses of RPT, INH, and pyridoxine (vitamin B6) at study entry and at 11 weekly follow-up visits.
88818929|NCT02271425|Experimental|Evacetrapib Tablet + Evacetrapib Intravenous|A single oral dose of 130 milligrams (mg) evacetrapib tablet + a single intravenous (IV) dose of 175 micrograms (μg)[¹³C₈] evacetrapib administered over a 4 hour infusion.
88818930|NCT01862159||Operated patients|Patients undergoing laparoscopic gastric bypass surgery between 1st of May 2007 until 30th of september 2012
88818931|NCT02651337|Experimental|Drainage with Alivio in-line Flusher|Volume of saline needed to drain CSF using the Alivio in-line Flusher historically compared with volume of saline needed to drain CSF using a standard syringe
88818932|NCT01863017|Sham Comparator|Sham tDCS|Five consecutive sessions of no tDCS. Each session will last approximately 30 minutes. Current will be applied for 20 minutes. Less than 3 minutes of tDCS has been shown to induce no lasting effects. Normal weight control participants will receive one sham session and one active session.
88818933|NCT01863017|Experimental|Active tDCS|Five consecutive sessions of tDCS administered. Each session will take about 30 minutes. Normal weight control participants will receive one sham session and one active session.
88818934|NCT05442411|Experimental|post operative pain score|post operative pain score at 1hour, 2 hour, 4 hour, 6 hour, and 12 hour
88818935|NCT05442411|Experimental|morphine requirement|post operative PCA morphine requirement
88818936|NCT03390569|Experimental|Exercise in GBM|All patients will be assigned a three-month exercise intervention according to their own capabilities and current activity levels
88818937|NCT05444829|Experimental|specific screw holes locating surgical guide and pre-bent plates|Put the specific screw holes locating device in place and drill the screw holes, remove the screw holes locating device and mobilize the segments then apply the pre-bent plates and fix it with screw for passive reduction of the segments. Then suture the mentalis muscle then the mucosa.
88818938|NCT05444829|Other|classical reduction and fixation|mobilize the broken segment first, Arch bar was made to achieve proper occlusion put the compression plate on the inferior border and remove it for further bending using plate pliers for further accommodation of the plate on the inferior border the fix it in place using compression and tension plate.
88818939|NCT01423760|Experimental|Tecemotide (L-BLP25)|
88818940|NCT01423760|Other|Observational|
88818941|NCT02651415|Experimental|Regorafenib and Perindopril|Phase II, open label, single arm trial of patient with refractory mCRC treated with regorafenib (10 mg/day) and perindopril (4 mg/day). There will be no stratification in this study.
88818942|NCT00555425|Active Comparator|1|Buprenorphine/naloxone maintenance (Mtn) is designed to reflect usual care by primary care physicians and includes weekly drug counseling (DC) and referral to ancillary services.
88818943|NCT00555425|Experimental|2|Buprenorphine/naloxone detoxification (Dtx) is identical to Mtn for the first 4 weeks (stabilization) following randomization. In Mtn, Bup will continue unchanged for the remainder of the study. In Dtx, the dosage of Bup will be tapered to zero over the next 3 weeks, and patients will not receive additional Bup for the remainder of the study. Dtx patients will be offered thrice-weekly DC beginning during the taper and naltrexone will be offered 7 days following the last dose of Buprenorphine/naloxone.
88818944|NCT01485770|Experimental|Placebo, Then ADX-N05|Participants first receive a placebo to match ADX-N05 once a day for 2 consecutive weeks (Weeks 1 and 2). They will then receive ADX-N05 150 mg tablet once a day for seven days (Week 3) followed by 300 mg (2 tablets) once a day for seven days (Week 4).
88818945|NCT01485770|Placebo Comparator|ADX-N05, Then Placebo|Participants first receive ADX-N05 150 mg tablet once a day for seven days (Week 1) followed by 300 mg (2 tablets) once a day for seven days (Week 2). They will then receive a placebo to match ADX-N05 once a day for 2 consecutive weeks (Weeks 3 and 4).
88818946|NCT01863563|Experimental|QuickClot|QuickClot sponge will be applied for one minute each site of tonsillectomy and Adenoidectomy.
88818947|NCT05444673|Experimental|Paprizumab combined with cisplatin and 5-FU|Patients received four cycles of paprizumab (200mg iv, 21-day cycle) in combination with 5-fu (500mg/m2 iv) plus cisplatin (80mg/m2 iv, 21-day cycle). Reassessment after completion of neoadjuvant chemotherapy was performed in operable patients.
88818948|NCT05444439|Other|One group of naive H.Pylori infection will submitted for upper endoscopy.|"Upper endoscopy will be done under complete septic condition and multiple gastric biopsies from corpus and antrum will be taken for :~Histopathological examination.~Culture and sensitivity of endoscopic biopsies.~detection of vacuolating cytotoxin A (Vac A) and cytotoxin-associated gene A (Cag A) virulent Helicobacter Pylori genotypes by polymerase chain reaction amplification(PCR).~Then start empirical antibiotics regimens."
88818949|NCT01424072|No Intervention|Control Group|Control Group didn't receive any treatment and was evaluated at the same time and the same way of interventions group
88818950|NCT01424072|Experimental|Auriculotherapy by needles|The investigators used 3 points, Shenmen, Kidney, and Brain Stem with semi-permanent needles of 1.8 mm, 1 time per week for 8 sessions.
88818951|NCT01424072|Experimental|Auriculotherapy by seeds|The investigators used the three points Shenmen, Kidney, and Brain Stem with mustard seeds, 1 time per week for 8 sessions.
88818952|NCT04738929|Experimental|Normal weight|Normal weight subjects (BMI=18.5-25)
88818953|NCT04738929|Experimental|Obese|Obese subjects (BMI=30-34.99)
88818954|NCT01540370||Patients with OAG and/or OHT|Patients with OAG and/or OHT
88818955|NCT04338633|Active Comparator|Conventional calcium hydroxide paste|Application of Conventional calcium hydroxide paste
88818956|NCT04338633|Experimental|Calcium hydroxide nanoparticle|Application of Calcium hydroxide nanoparticle
88818957|NCT04338633|Experimental|Combined Calcium hydroxide with silver nanoparticle|Application of Combined Calcium hydroxide with silver nanoparticle
88818958|NCT01866839|Experimental|CD34+ cell positively selected graft stem cell recipient|Recipients received a myeloablative conditioning regimen of cyclophosphamide (120 mg/kg total), fludarabine (125 mg/m2 total) and total body irradiation (1200 cGy with lung shielding to 600 cGy), followed by an infusion of a stem cell product selected for CD34+ progenitors using the Miltenyi CliniMACS® system. Older subjects will receive a lower dose of irradiation (800 or 600 cGy based on age) to reduce the regimen intensity.
88818959|NCT01487954|Experimental|Arm I: alkaline water|Patients undergo external beam radiation therapy QD, 5 days a week for 6 weeks. Patients drink 8 ounces of alkaline water within 30 minutes immediately prior to and after undergoing radiation therapy.
88818960|NCT01487954|Active Comparator|Arm II: distilled water|Patients undergo external beam radiation therapy as in arm I. Patients also drink 8 ounces of distilled water within 30 minutes immediately prior to and after undergoing radiation therapy
88818961|NCT00368511|No Intervention|1|Listening to music and posture changes
88818962|NCT01541384|Experimental|Medication Dosage Reminders|Subject will receive electronic pill bottle that will track adherence. They will also be able to activate available dosage reminders (text message, phone message, email).
88818963|NCT01541384|Experimental|Medicaiton Dosage Reminders + Coordinator Support|Subject will receive electronic pill bottle that will track adherence. They will also be able to activate available dosage reminders (text message, phone message, email). The study coordinator will also check adherence every 2 weeks and alert the transplant team when it drops below 90%. The transplant team will determine the next best course of action.
88818964|NCT01541384|Other|Usual Care with GlowCap|Subject will receive electronic pill bottle that will track adherence but all reminders will be deactivated.
88818965|NCT05413395|Experimental|Protocol|"Standard-of-care (SOC), over-the-counter (OTC) topical colloidal oatmeal formulation with a modified plant oil (Activated Oil, AO) applied to designated target lesion sites and non-lesion sites (study sites) twice per day for 14 days, followed by a 7-day regression durability period during when no product is applied."
88818966|NCT05413395|Active Comparator|Control|"Standard-of-care (SOC), over-the-counter (OTC) topical colloidal oatmeal formulation amended with deionized water to match the colloidal oatmeal concentration of the Protocol arm applied to designated target lesion sites and non-lesion sites (study sites) twice per day for 14 days, followed by a 7-day regression durability period during when no product is applied."
88818967|NCT01488188|Active Comparator|Influenza vaccine-Nasal|Nasal administration
88818968|NCT01488188|Active Comparator|Influenza vaccine -Sublingual|Sublingual administration
88818969|NCT05406609||General|Shoulder surgery under general anesthesia
88818970|NCT05406609||Regional|Shoulder surgery under regional anesthesia
88818971|NCT01489670||Lumigan® 0.01%|Patients with primary open-angle glaucoma or ocular hypertension treated with Lumigan® 0.01% in clinical practice.
88818972|NCT04738851|Experimental|healthy volunteers|Virtual mirror therapy task : TMV Classic mirror therapy task : TMC Control task :TC
88818973|NCT01542398|Experimental|Family-Focused Psychosocial Intervention|Intervention Group
88818974|NCT01542398|No Intervention|Waiting List Control|
89386813|NCT01332929|Experimental|Bevacizumab|first level dose : 5 mg/kg Second level dose : 10 mg/kg Third level dose : 15 mg/kg
89386814|NCT04660279|Other|Validate|D-WB PET/CT scans + arterial blood sampling.
88862190|NCT00382824|Active Comparator|CoQ10|Half of the enrolled patients will be randomized into the the CoQ10 arm and will receive a dosage of 2400mg/day of Coenzyme Q10
88862191|NCT00382824|Placebo Comparator|Placebo|Half of the enrolled patients will be randomized into the the Placebo arm and will receive a matching dose of placebo that resembles the 2400mg/day dose of the CoQ10 arm.
88862192|NCT00462228|Experimental|Memantine|Subjects will be titrated up to 20 mg of memantine per day for 12 weeks, followed by placebo for 12 weeks
89386815|NCT01316029||laying-on-of-hands|44,587 Japanese volunteers with/without illness, who were interested in receiving laying-on-of-hands
89386816|NCT05185193|Experimental|radiofrequency stimulation|Participants received radiofrequency stimulation three times a day for 30 minutes once a day. After the end of the first session intervention, there was a washout period and the next intervention was started at a time point when the next menstruation was not likely (8-18 days after the onset of menstruation).
88862193|NCT00462228|Placebo Comparator|Placebo|Subjects will be titrated up to 20 mg of placebo per day for 12 weeks, followed by memantine for 12 weeks
88862194|NCT00408564|Experimental|Gemcitabine,Oxaliplatin and Cetuximab|"Gemcitabine will be given on day 1 of every 2 week cycle. Oxaliplatin will be given day 2 of every 2 week cycle. Cetuximab will be given every week for 12 weeks.~After chemotherapy, patient will be assessed for resectability. Patients will have either surgery or daily radiation and capceitabine Monday-Friday for a total of 5 and a half weeks."
88862195|NCT02110758||Pilot Practices Patient Survey Cohort|Patients with any active drug therapy treatment for cancer receiving care at pilot practice in southeastern Pennsylvania
88862196|NCT02110758||Comparison Practices Patient Survey Cohort|Patients with any active drug therapy treatment for cancer receiving care at comparison practice in southeastern Pennsylvania
88862197|NCT02110758||Pilot Practices Utilization Cohort|Patients with an evaluation & management claim attributed to a medical oncology pilot practice in southeastern Pennsylvania
88862198|NCT02110758||Comparison Practices Utilization Cohort|Patients with an evaluation & management claim attributed to a medical oncology comparison practice in southeastern Pennsylvania
88862199|NCT02110758||Pilot Practices Quality Measures Cohort|Patients with a new diagnosis of cancer in the past two years
88862200|NCT02111772|Experimental|Asthmatic subjects|Subjects with Asthma whose cold and chest symptoms will be evaluated one week before and 4 weeks after an inoculation with rhinovirus.
88862201|NCT02111772|Active Comparator|Without Asthma|Subjects without asthma whose cold and chest symptoms will be evaluated one week before and 4 weeks after an inoculation with rhinovirus
88862202|NCT00383448|Experimental|Treated Patients|Patients receiving chemotherapy (Hydroxyurea, Alemtuzumab, Clofarabine, Melphalan), Hematopoietic Stem Cell Transplantation and radiation therapy (Total body Irradiation) mycophenylate mofetil and cyclosporine A.
88862203|NCT00383760|Experimental|Treatment (eribulin mesylate)|Patients receive E7389 IV on days 1 and 8.
88862204|NCT00384774|Experimental|Lasmiditan|Participants received escalating doses of 2.5 mg, 5 mg, 10 mg, 20 mg, 30 mg and 45 mg of lasmiditan as intravenous injection.
88862205|NCT00384774|Placebo Comparator|Placebo|Participants received intravenous infusion of placebo solution.
88862206|NCT00410280|Other|1|
88862207|NCT00410826|Experimental|Arm I (chemo, radiotherapy, enzyme inhibitor/radiosensitizer)|Patients receive cisplatin IV on days 1, 22, and 43 and undergo 3-dimensional conformal or intensity modulated radiotherapy once daily, 5 days per week, on days 1-47. Patients also receive erlotinib hydrochloride PO once daily on days -7 to 47.
89386817|NCT05185193|Sham Comparator|sham stimulation|Participants received a sham stimulation similar to a radiofrequency stimulation three times a day for 30 minutes once a day. After the end of the first session intervention, there was a washout period and the next intervention was started at a time point when the next menstruation was not likely (8-18 days after the onset of menstruation).
89386818|NCT04580953|Experimental|Treatment with CardiaCareTM RR2|
89386819|NCT01344109||Breast cancer patients|Newly diagnosed patients with breast cancer presenting with operable breast tumor prior to initiation of of neoadjuvant chemotherapy (choice of chemotherapy will be the the treating physician's discretion)
89386820|NCT01344109||Healthy volunteers|Adult women without a cancer diagnosis.
89386821|NCT03569306|Experimental|ENB-EBUS-GS group|ENB is used in this group.EBUS and GS are inserted into bronchi in the assistance of ENB. The EBUS probe and GS are confirmed to reach the lesion by EBUS images.
89386822|NCT03569306|Active Comparator|EBUS-GS group|ENB isn't used in this group.EBUS and GS are inserted into bronchi according to the chest CT that judged by the doctor. The EBUS probe and GS are confirmed to reach the lesion by EBUS images.
88862208|NCT00410826|Active Comparator|Arm II (chemotherapy, radiotherapy)|Patients receive cisplatin and radiotherapy as in Arm I.
88862209|NCT00464646|Experimental|1|"Cohort A: Women with unresected locally advanced breast cancer (clinical Stage IIIA, IIIB, and IIIC)~Cohort B: Women with resected pN2 or pN3 (pathologic Stage III) breast cancer"
88862210|NCT00385008|Other|Arm 1|open-label active drug
88862211|NCT00385008|Other|Arm 2|open-label active drug
89386823|NCT01317121||Subjects at risk for psychosis|Identification and clinical characterization of subjects with prodromal symptoms will be done in the early diagnosis outpatient center of the University Department of Psychiatry in Hamburg, Germany. Subjects At Risk Mental State (ARMS) for psychosis will be identified if they meet the criteria of the Structured Interview for Prodromal Syndromes (SIPS) (McGlashan et al 2001).
89386824|NCT01317121||Patients with a first episode of schizophrenia|Patients with a first episode of schizophrenia will be recruited from inpatients at the Clinic for Psychiatry and Psychotherapy at the University Hospital (UKE) in Hamburg, Germany. All patients have to meet criteria for DSM-IV and ICD-10 diagnosis for schizophrenia.
89386825|NCT01317121||Healthy control subjects|Healthy control subjects will be recruited from the hospital staff and students at the University Hospital Hamburg-Eppendorf (UKE), Hamburg, Germany. They have to be free from any neurological or psychiatric disorder, according to DSM-IV and ICD-10 criteria.
88862212|NCT00466206|Experimental|3MP - Treatment Arm|Magnetic Mini-Mover Procedure using the Magnimplant and Magnatract
88862213|NCT00410904|Experimental|Arm I|Patients receive oral AZD2171 once daily on days 1-28 in course 1 and on days 1-21 in course 2 and all subsequent courses. Patients also receive pemetrexed disodium IV over 10 minutes on day 8 in course 1 and on day 1 in course 2 and all subsequent courses. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.
88862214|NCT00385788|Experimental|Gemcitabine + Fludarabine + Melphalan|Gemcitabine 800 mg/m^2 intravenous (IV) over 30 minutes for one day; Fludarabine 33 mg/m^2 IV for 4 days; Melphalan 70 mg/m^2 IV over 30 minutes for 2 days. Antithymocyte Globulin 2 mg/kg IV for 2 days before stem cell transplantation. If receiving transplant from matched unrelated donor (not blood relative), a mismatched related donor (a blood relative, but not a full match), or receiving a cord blood transplant, infusion of stem cells on Day 0. Tacrolimus 0.03 mg/kg by vein over 24 hours following infusion; beginning Day +7 Filgrastim (G-CSF) injection under skin once daily and Methotrexate 5 mg/m2 by vein on Days +1, +3, +6, and +11.
89386826|NCT03566888||Single Group|85 eligible study participants
89386827|NCT01344265||consecutive patients|there is only one group in our study
89386828|NCT03159611|Experimental|Tenoten for children|
88862215|NCT00385788|Experimental|Fludarabine + Melphalan|Fludarabine 33 mg/m^2 IV for 4 days; Melphalan 70 mg/m^2 IV over 30 minutes for 2 days. Antithymocyte Globulin 2 mg/kg IV for 2 days before stem cell transplantation. If receiving transplant from matched unrelated donor (not blood relative), a mismatched related donor (a blood relative, but not a full match), or receiving a cord blood transplant, infusion of stem cells on Day 0. Tacrolimus 0.03 mg/kg by vein over 24 hours following infusion; beginning Day +7 Filgrastim (G-CSF) injection under skin once daily and Methotrexate 5 mg/m2 by vein on Days +1, +3, +6, and +11.
88862216|NCT00411684|Experimental|CDB-2914|A Prospective, Open-Label, Single Arm, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of CBD-2914 as Emergency Contraception When Taken Between 48 Hours and 120 Hours of Unprotected Intercourse
88862217|NCT00386256|Experimental|Health Buddy outpatient|Received home telehealth monitoring by Health Buddy
88862218|NCT00386256|Experimental|Telephone outpatient|
88862219|NCT00386256|Experimental|health buddy inpatient|
88862220|NCT00386256|Experimental|telephone inpatient|
88862221|NCT00412074|Active Comparator|Control 400 IU vitamin D3|400 IU vitamin D3/day given to lactating women and 400 IU vitamin D3/day given as oral supplement to infant in dyad
88862222|NCT00412074|Experimental|2400 IU vitamin D3 (cholecalciferol)|2400 IU vitamin D3 given to lactating mother: 400 IU vitamin D3 from a prenatal vitamin and 2000 IU vitamin D3 and 0 IU vitamin D3 (placebo) given to her breastfeeding infant
88862223|NCT00412074|Experimental|6400 IU vitamin D3 (cholecalciferol)|6400 IU vitamin D3 given to lactating mother: 400 IU vitamin D3 from a prenatal vitamin and 6000 IU vitamin D3 and 0 IU vitamin D3 (placebo) given to her breastfeeding infant
88862224|NCT00466752|Experimental|Treatment (enzyme inhibitor) 48hr stop|Patients receive sorafenib tosylate PO BID on days 1-14. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Beginning 2 days after completion of sorafenib tosylate, patients undergo radical prostatectomy on approximately day 43.
88862225|NCT00466752|Experimental|Treatment (enzyme inhibitor) 24hr stop|tients receive sorafenib tosylate PO BID on days 1-14. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Beginning 1 day after completion of sorafenib tosylate, patients undergo radical prostatectomy on approximately day 43.
89386829|NCT03159611|Placebo Comparator|Placebo|
88862226|NCT02115750|Active Comparator|Enbrel (etanercept)|Enbrel 50mg weekly times 24 weeks.
88862227|NCT02115750|Experimental|CHS-0214|CHS-0214 50mg weekly times 24 weeks.
88862228|NCT02115828|Experimental|Vismodegib|Vismodegib Treatment arm will receive Vismodegib by mouth 150 mg daily up to 1 year.
88862229|NCT02115984|Experimental|Chemotherapy & Panagen|Panagen 5 mg tablet by mouth every 2-3 h (six times a day) for 18 days. Patients start to receive the preparation immediately after the chemotherapy and take three tablets during 6 h, that is one tablet every 2 h. Then the patients stop taking the preparation and resume its administration after 42 h, that is, 48 h after the chemotherapy (Day 3) and continue its administration for 17 days (to Day 20 after the chemotherapy).
89386830|NCT03000374|Experimental|Panitumumab + mFOLFOX-6|"- Modified FOLFOX-6 regimen: 5-Fluorouracil (5-FU), oxaliplatin and leucovorin will be administered intravenously once every 14 days, according to the mFOLFOX-6 regimen:~Day 1: Oxaliplatin 85 mg/m² in IV infusion of 250-500 mL and leucovorin 200 mg/m² IV, both injected over two hours, followed by 5-FU 400 mg/m2 in IV bolus and a 46-hour infusion of 5-FU 2400 mg/m².~- Panitumumab will be administered intravenously (IV) in a dose of 6 mg/kg on day 1 every 14 days. Panitumumab will be supplied to sites by the study sponsor in 5-mL and 20-mL vials, at a concentration of 20 mg/mL.~Treatment will continue until 6 cycles have been administered, followed by surgery, 5 weeks +/- 1 week after the last dose of neoadjuvant treatment"
89386831|NCT04323943|Experimental|Carbon-AFO (C-AFO)|Manufactured carbon ankle foot orthosis (C-AFO) Sprystep (Thuasne) will be provided to patients. A familiarization with C-AFO will be performed before doing the tests.
89386832|NCT04323943|Active Comparator|Custom-made thermo-plastic orthosis (CM-AFO)|Own custom-made thermo-plastic orthosis (CM-AFO) of patients. A familiarization will be performed also before doing the tests.
89386833|NCT04323943|No Intervention|Without orthosis (NO)|No orthosis - patient will wear only their shoes
89386834|NCT03566654|Experimental|remote ischemic conditioning|Receiving remote ischemic conditioning (RIC) treatment with pressure set at 200 mmHg.
89386835|NCT03566654|Sham Comparator|placebo remote ischemic conditioning|Receiving sham RIC treatment with pressure set at 50~60 mmHg
89386836|NCT03635359||positive for fetal aneuploidy|
89386837|NCT03635359||negative for fetal aneuploidy|
89386838|NCT01339637||Diabetes risk factors|Very dark skin subjects with with diabetes risk factors
88818975|NCT01427504|Experimental|Sequence 1a|Sequence 1,2,3: boceprevir only, then etravirine only, then both boceprevir and etravirine.
88818976|NCT01427504|Experimental|Sequence 1b|Sequence 1,3,2: boceprevir only, then both boceprevir and etravirine, then etravirine only.
88818977|NCT01427504|Experimental|Sequence 2a|Sequence 2,1,3: etravirine only, then boceprevir only, then both boceprevir and etravirine.
88818978|NCT01427504|Experimental|Sequence 2b|Sequence 2,3,1: etravirine only, then both boceprevir and etravirine, then boceprevir only.
88818979|NCT01427504|Experimental|Sequence 3a|Sequence 3,1,2: both boceprevir and etravirine, then boceprevir only, then etravirine only.
88818980|NCT01427504|Experimental|Sequence 3b|Sequence 3,2,1: Both boceprevir and etravirine, then etravirine only, then boceprevir only.
88818981|NCT03183323|Experimental|Telerehabilitation|In addition to optimal medical treatment: 3 months of twice weekly group-based telerehabilitation through a video-conferencing on a tablet platform. In addition access to instruction videos for further self-training through the same platform and throughout the whole 2-year period. Electronic devices to trace activity.
88818982|NCT03183323|No Intervention|Standard care|In addition to optimal medical treatment: Advice on physical activity. Electronic devices to trace activity.
88818983|NCT02265965|Experimental|Intravenous Nitroglycerin|Subjects will receive IV nitroglycerin at the time of Hysterotomy. Infusion will be stopped once neonate is delivered
88818984|NCT02265965|No Intervention|Intravenous Saline|Subjects will receive IV saline at the time of Hysterotomy. Infusion will be stopped once neonate is delivered
88818985|NCT03021083|Experimental|IONSYS Administration|"Patients who have elective multi-level spinal fusions under general anesthesia (who do not receive methadone) will be enrolled. In addition, all patients will receive Pepcid 20 mg, dexamethasone 10 mg, and ondansetron 4 mg.~When patients will arrive in the post anesthesia care unit (PACU), pain will initially be controlled with IV hydromorphone to achieve an NRS score of 3 or less. Once transferred to the step down unit (SDU), the IONSYS patch will be applied. IONSYS should be utilized when they have pain, but rescue analgesia will be available. If severe pain continues, the chronic pain service will be consulted, to potentially change the medications.~Patients will be assessed for pain at rest and with PT in the AM and PM of POD 1 and POD 2. The IONSYS system will be discontinued after 48 hours, and a total dose of fentanyl received per 24 hours will be recorded. PT milestones for discharge will be assessed on the afternoon of POD 1 and POD 2."
88818986|NCT03000257|Experimental|ABBV-181 plus Venetoclax|Venetoclax will be taken once daily beginning 7 days prior to cycle 1 and continuing daily for a 28 day cycle and ABBV-181 will be administered every 4 weeks.
88818987|NCT03000257|Experimental|ABBV-181|ABBV-181 will be administered at escalating dose levels in 28-day dosing cycles (2 doses per cycle). Based on available safety, pharmacokinetic, and pharmacodynamic data from the dose-escalation part of the study, participants will be enrolled in dose-expansion cohorts to further evaluate ABBV-181 at a dose level which is at or below the Maximum tolerated dose (MTD). In the Monotherapy Expansion portion of the study, ABBV-181 will be administered in 28-day dosing cycles at either 1 dose per cycle or 2 doses per cycle. Based on available safety, PK and PD data from the single agent dose-escalation part of the study, a dose for ABBV-181 will be selected to evaluate in combination with Rovalpituzumab Tesirine or venetoclax.
88818988|NCT03000257|Experimental|ABBV-181 plus Rovalpituzumab Tesirine|Rovalpituzumab Tesirine will be given once every six weeks times two doses and ABBV-181 will be administered every 3 weeks.
88818989|NCT02654769|Active Comparator|Active Comparator Picato®|Picato® (ingenol mebutate) gel, 0.05% (Leo Pharma Inc.) [Reference Listed Drug (RLD)]
88818990|NCT02654769|Experimental|Generic Ingenol Mebutate|Generic ingenol mebutate gel, 0.05% [Test]
88818991|NCT02654769|Placebo Comparator|Vehicle Foam|Vehicle gel of the test product
88818992|NCT02945813|Experimental|Arm A: Metformin|"Metformin - 850mg PO BID; 48 weeks~Salvage radiotherapy SRT - 35 x 2Gy; 7 weeks"
88818993|NCT02945813|Active Comparator|Arm B: Salvage Radiotherapy|- Salvage radiotherapy SRT - 35 x 2Gy; 7 weeks
88818994|NCT05443581|Experimental|Intervention group|"Participations in this group are required to follow a healthy vegetarian diet （avoid meat, poultry, fish, dairy） during the 24-weeks trail.~Daily energy intake = BMR(basal metabolic rate) × 1.25-500kcal；BMR = 370 + 21.6 × Lean body mass(kg) Requirements of energy supply ratio: protein 15%-20%; fat 20%-25%; carbohydrate 50%-60%."
88818995|NCT05443581|Active Comparator|Control group|"Participations in this group are required to follow a healthy omnivorous diet (No restriction on food sources) during the 24-weeks trail.~Daily energy intake = BMR × 1.25-500kcal；BMR = 370 + 21.6 × Lean body mass(kg) Requirements of energy supply ratio: protein 15%-20%; fat 20%-25%; carbohydrate 50%-60%."
88818996|NCT02865707|Experimental|Prebiotic|Prebiotic group will take 15 grams of prebiotic product Synergy-1 per day for 6 months. Synergy-1 is chicory-derived β-fructans inulin plus FOS (1:1). During the first two weeks the patient is advised to take 7.5 g of the product at breakfast only. Starting in week 3 until the end of the treatment the participant will take 7.5 g at breakfast and 7.5 g at dinner for a total of 6 months, or until you experience a flare.
88862230|NCT02115984|Placebo Comparator|Chemotherapy & Placebo|Placebo tablet by mouth every 2-3 h (six times a day) for 18 days. Patients start to receive the placebo tablets immediately after the chemotherapy and take three tablets during 6 h, that is one tablet every 2 h. Then the patients stop taking the preparation and resume its administration after 42 h, that is, 48 h after the chemotherapy (Day 3) and continue its administration for 17 days (to Day 20 after the chemotherapy).
88862231|NCT00413166|Experimental|Induction ATRA + ATO + Idarubicin|"All-Trans Retinoic Acid (ATRA) + Arsenic Trioxide (ATO)~ATRA 45 mg/m2 daily by mouth beginning day 1; ATO 0.15 mg/kg by vein daily beginning on day 1; Idarubicin 12 mg/m2 x 1 dose; Methylprednisolone 50 mg daily for 5 days starting on day 1."
89386839|NCT03566576|Experimental|Anlotinib Plus Pemetrexed|"This study will include a sequential evaluation of 3 subjects per cohort. Cohort 1: Anlotinib 8mg per day and Pemetrexed. Cohort 2: Anlotinib 10mg per day and Pemetrexed. Cohort 3: Anlotinib 12mg per day and Pemetrexed.~A dose limiting toxicity (DLT) event is defined as any of the following events:~CTCAE Grade 4 event (ANC<1000/ul, body temperature≥38.5°C);~Grade 3 non-hematologic toxicity (except for nausea and vomiting that could be improved with optimal supportive care, escalation of alkaline phosphatase) If a DLT is experienced in any cohort, the cohort will be expanded to 6 subjects. If 2 DLTs are experienced in any cohort, the dose escalation ceased. The MTD was defined as the dose having at most two out of six patients experience DLT."
89386840|NCT03566576|Experimental|Anlotinib Plus Docetaxel|"This study will include a sequential evaluation of 3 subjects per cohort. Cohort 1: Anlotinib 8mg per day and Pemetrexed. Cohort 2: Anlotinib 10mg per day and Pemetrexed. Cohort 3: Anlotinib 12mg per day and Pemetrexed.~A dose limiting toxicity (DLT) event is defined as any of the following events:~CTCAE Grade 4 event (ANC<1000/ul, body temperature≥38.5°C);~Grade 3 non-hematologic toxicity (except for nausea and vomiting that could be improved with optimal supportive care, escalation of alkaline phosphatase) If a DLT is experienced in any cohort, the cohort will be expanded to 6 subjects. If 2 DLTs are experienced in any cohort, the dose escalation ceased. The MTD was defined as the dose having at most two out of six patients experience DLT."
88862232|NCT00413166|Experimental|Maintenance|"All-Trans Retinoic Acid (ATRA) + Arsenic Trioxide (ATO)~ATO 0.15 mg/kg by vein over 2 hours Monday-Friday for 4 weeks, then a 4-week break. ATRA 45 mg/m2 by mouth every day for 2 weeks, followed by 2 additional weeks of no study drug. Continue ATRA until treatment with ATO complete."
88862233|NCT00413166|Experimental|Induction ATRA + ATO + GO|"All-Trans Retinoic Acid (ATRA) + Arsenic Trioxide (ATO) + Gemtuzumab Ozogamicin (GO)~ATRA 45 mg/m2 daily po (in 2 divided doses) beginning day 1; ATO 0.15 mg/kg IV daily beginning on day 1; GO 9 mg/m2 on day 1 Methylprednisolone 50 mg daily for 5 days followed by rapid taper starting on day 1.~Theophylline 100mg p.o. bid days 1-3, 200 mg p.o. bid days 4-6, and 300 mg p.o. bid thereafter during periods when patient is receiving ATRA or ATO. Theophylline administration continues until therapy with ATO and ATRA is completed."
88862234|NCT00386880||Subjects with episodic migraine with allodynia|These are subjects with episodic migraine with allodynia
88862235|NCT00386880||Subjects with episodic migraine without allodynia|Subjects with episodic migraine without allodynia
88862236|NCT00413400|Placebo Comparator|Placebo|
88862237|NCT00413400|Active Comparator|Etanercept|
88862238|NCT00413478|Experimental|5-Azacytidine|5-Azacytidine 75mg/m^2 subcutaneously daily for seven days. Treatment cycles will be repeated every 3-8 weeks.
88862239|NCT00413634|Experimental|Younger Participants (18-50 years)|
88862240|NCT00413634|Experimental|Elderly Participants (≥65 years)|
88862241|NCT00467298|Experimental|Self-management|Novel intensive self-management education and exercise program of four weeks
88862242|NCT00467298|No Intervention|Usual care|Usual care- cardiac or pulmonary rehabilitation exercise program of 8 weeks duration
88862243|NCT00467844|Experimental|1|1 mg GTx-024
88862244|NCT00467844|Experimental|2|3 mg GTx-024
88862245|NCT00467844|Placebo Comparator|3|Placebo
88862246|NCT00387036|Other|1|Arm 1: drug, crossing over to Pbo comparator
88862247|NCT00387036|Other|2|Arm 2: Pbo comparator, crossing over to drug
88862248|NCT04388592|Experimental|Nurse practitioner (NP)-led care arm|The patient randomized to the NP intervention arm will be contacted by the NP to be scheduled for an NP appointment within 4 to 6 weeks from the date of the referral. The NP consultation will include patient history, physical examination, symptomatic management strategies as appropriate (eg: bladder and bowel management strategies, fatigue management, depression, anxiety, spasticity etc), discussion of mental and physical health resources for symptomatic treatment, support, physical and mental health resources to optimize functioning (eg: home care, physical/occupational therapy referral) and quality of life. There will be NP followup, in person or by phone or videoconferencing at 3 months, and 6 months. The NP will be using the electronic medical record offered by Alberta Health Services.
88862249|NCT04388592|No Intervention|Usual Care Arm|Those patients randomized to the usual care arm (community neurologist and registered nurses) will be contacted by the NP to be scheduled for an NP appointment in 6 months, so that every participant is given the opportunity to meet with the NP, after their involvement in the study has concluded. During the six-month period, patients randomized to the control group will receive usual care from community neurologists and MS registered nurses or family physicians. The care will be delivered according to standard practices, and follow-up visits will be conducted according to the various neurologists' or family physicians' practices.
88862250|NCT00470106|Active Comparator|Cognitive Remediation|cognitive remediation
89386841|NCT04377997|Experimental|Therapeutic Anticoagulation Group|"Patients identified as eligible through discussions with the primary care team and review of the electronic medical record will be approached and consented as described above in Subject Enrollment and Procedures for obtaining consent.~For research purposes, 20ml of blood will be drawn and stored for biobanking at the following timepoints: at baseline (i.e., after enrollment and before randomization), 5-7 days post-randomization, and on the day of discharge. The blood sample taken at baseline will also be used to conduct a pregnancy test for women of childbearing age.~After enrollment and blood collection, patients will then be randomized to therapeutic anticoagulation (LMWH for most subjects but UFH for those with morbid obesity or moderate to severe renal dysfunction as noted below) or standard of care anticoagulation. Those assigned to the therapeutic anticoagulation group will receive a higher dose of heparin."
89386842|NCT04377997|Active Comparator|Standard of Care Anticoagulation Group|"Patients identified as eligible through discussions with the primary care team and review of the electronic medical record will be approached and consented as described above in Subject Enrollment and Procedures for obtaining consent.~For research purposes, 20ml of blood will be drawn and stored for biobanking at the following timepoints: at baseline (i.e., after enrollment and before randomization), 5-7 days post-randomization, and on the day of discharge. The blood sample taken at baseline will also be used to conduct a pregnancy test for women of childbearing age.~After enrollment and blood collection, patients will then be randomized to therapeutic anticoagulation or standard of care anticoagulation. Those assigned to the standard of care anticoagulation group will receive the normal dose of heparin as per the Mass General guidelines."
89386843|NCT03566498|Experimental|Immediate hydration|They will be allowed to start oral fluids immediately (within the first 2 hours post operatively) beginning with water or clear fluids (but not milk or soda containing drinks), the amounts will be according to their needs, solid food will be given gradually after tolerating the drinks and intravenous fluids will be given beside all of that and till the return of intestinal movements.
89386844|NCT03566498|Active Comparator|Early hydration|They will receive the routine intravenous fluids and the oral fluids will be given after 8 hours post operatively and gradually, solid food will be allowed after that gradually too and the intravenous fluids will be stopped after return of intestinal movements.
89386845|NCT01336049|Experimental|Nimotuzumab|
89386846|NCT04758949|Experimental|FL-101 Monotherapy|30 patients will receive FL-101 prior to surgery.
89386847|NCT04758949|Experimental|FL-101 + Nivolumab|30 patients will receive FL-101 and Nivolumab prior to surgery.
89386848|NCT04758949|Active Comparator|Nivolumab + Placebo|30 patients will receive Nivolumab and placebo prior to surgery.
89386849|NCT03566342||GROUP A|The PCEA solution will contain 0.1% Bupivacaine + 2.85 mcg/cc of Fentanyl. Basal infusion 7 ml/hour Demand dose 8ml Lockout ( number of doses per hour) 2 Lock out interval 30 minutes
89386850|NCT03566342||GROUP B|The PCEA solution will contain 0.1% Bupivacaine + 2.85 mcg/cc of Fentanyl. Basal infusion 7 ml/hour Demand dose 5ml Lockout ( number of doses per hour) 4 Lock out interval 15 minutes
88862251|NCT00470106|Experimental|Social Cognitive Skills Training|social cognitive skills training
88862252|NCT00470106|Active Comparator|Hybrid Intervention|combined social cognitive and cognitive remediation training
88862253|NCT00470106|Other|Skills Training|control training
88862254|NCT00387660|Experimental|Metastatic SCLC|Irinotecan 200 mg/m2, every 21 days (intravenous) + Carboplatin AUC = 5 mg/ml x min (intravenous), every 21 days for 6 cycles
88862255|NCT00387660|Experimental|Relapsed SCLC|Irinotecan 150 mg/m2 (intravenous), every 21 days + Carboplatin AUC = 5 mg/ml x min (intravenous, every 21 days for 6 cycles
88862256|NCT00472056|Experimental|BEAM + Standard Rituximab|"Arm 1 BEAM Chemotherapy (Carmustine, Etoposide, Cytarabine, Melphalan) + Standard Rituximab with Standard Rituximab for Cohort 1 or 2~Cohort 1 for 65 years of age or younger BEAM: Carmustine 300 mg/m2 intravenous (IV) over 1 hour on day -6, cytarabine 200 mg/m2 IV twice a day on days -5 through -2 (total 8 doses), etoposide 200 mg/m2 IV twice a day on days -5 through -2 (total 8 doses), and melphalan 140 mg/m2 IV on day -1.~Cohort 2 for older than 65 years of age BEAM: Carmustine 300 mg/m2 IV over 1 hour on day -6, cytarabine 100 mg/m2 IV twice a day on days -5 through -2 (total 8 doses), etoposide 100 mg/m2 IV twice a day on days -5 through -2 (total 8 doses), and melphalan 140 mg/m2 IV on day -1.~Standard Rituximab: 375 mg/m^2 IV Days +1, +8 after Stem Cell Infusion on Day 0."
88862257|NCT00472056|Experimental|BEAM + High Rituximab|"BEAM Chemotherapy (Carmustine, Etoposide, Cytarabine, Melphalan) + High Dose Rituximab~Cohort 1 for 65 years of age or younger BEAM: Carmustine 300 mg/m2 intravenous (IV) over 1 hour on day -6, cytarabine 200 mg/m2 IV twice a day on days -5 through -2 (total 8 doses), etoposide 200 mg/m2 IV twice a day on days -5 through -2 (total 8 doses), and melphalan 140 mg/m2 IV on day -1.~Cohort 2 for older than 65 years of age BEAM: Carmustine 300 mg/m2 IV over 1 hour on day -6, cytarabine 100 mg/m2 IV twice a day on days -5 through -2 (total 8 doses), etoposide 100 mg/m2 IV twice a day on days -5 through -2 (total 8 doses), and melphalan 140 mg/m2 IV on day -1.~High Dose Rituximab: 1000 mg/m^2 IV Days +1, +8 after Stem Cell Infusion on Day 0"
88862258|NCT00415506|Experimental|Scleritis|Subjects with Scleritis
88862259|NCT00415506|Experimental|Orbital Inflammation|Subjects with Orbital Inflammation
88862260|NCT00389532|Experimental|1|aged 19 to 59 years
88862261|NCT00389532|Experimental|2|aged ≥ 60 years
88862262|NCT01795092|No Intervention|Control|Those in the control group do not obtain a dermatology evaluation and will be assessed and treated by their primary care provider. We will perform a chart review two weeks after presentation to assess for admission versus discharge home from clinic and outcome.
89003332|NCT05439421|Experimental|Without Claim 100% Food Grade Glycerin|Package or digital marketing advertisement without claim of interest
89386851|NCT03566342||GROUP C|The PCEA solution will contain 0.1% Bupivacaine + 2.85 mcg/cc of Fentanyl. Basal infusion 7 ml/hour Demand dose 3ml Lockout ( number of doses per hour) 6 Lock out interval 10 minutes
89386852|NCT03566342||GROUP D|The PCEA solution will contain 0.1% Bupivacaine + 2.85 mcg/cc of Fentanyl. Basal infusion 14 ml/hour Demand dose 0 ml Lockout ( number of doses per hour) 0 Lock out interval 0 minutes
88862263|NCT01795092|Experimental|Dermatology consultation|Patients randomized to the treatment group will obtain a dermatology evaluation at the primary care physician's office and will be sent to the Emergency Department (ED) or discharged home with outpatient dermatology follow-up in 2-3 days to assess their condition. Patients who are evaluated by a dermatologist and require hospitalization will have their transition to the ED managed by the dermatologist. Patients who are admitted after the initial outpatient discharge or at the follow-up visit will be considered treatment failures. A medical record review will be performed for patients in the treatment group two weeks after initial evaluation at the internal medicine clinic.
88862264|NCT00475878|Placebo Comparator|placebo|
88862265|NCT00475878|Active Comparator|escitalopram|
88862266|NCT01795170||Test Group|Patients receiving a lysine restricted diet adjunct to pyridoxine therapy will be considered as participants in the 'exposure'/test group
88862267|NCT01795170||Control Group|Patients on pyridoxine mono-therapy will be participants in the 'control' group
88862268|NCT01796886|Experimental|patient's neurological status|
88862269|NCT00477204|Active Comparator|Simvastatin|Zocor(simvastatin)(20 mg)daily for 6 months along with Placebo (sugar pill)of active comparator (Vytorin [simvastatin] + Zetia [ezetimibe].
88862270|NCT00477204|Active Comparator|Ezetimibe/Simvastatin|Vytorin(simvastatin [Zocor} + ezetimibe [Zetia])(20 mg)daily for 6 months along with placebo (sugar pill)of comparator (Vytorin [simvastatin]).
88862271|NCT00528450|Experimental|Tretinoin and Arsenic Trioxide With or Without Idarubicin|See Outline for details
88862272|NCT00478218|Experimental|Lenalidomide/Cyclophosphamide/Dexamethasone|
88862273|NCT00479154|Experimental|Botulinum Toxin A|Injection of onabotulinumtoxinA
88862274|NCT00479154|Placebo Comparator|Placebo (saline)|Injection of saline placebo
88862275|NCT04270656|Experimental|Insulin pump therapy|
88862276|NCT04270656|Active Comparator|Multi-injection treatment ( MDI ).|
88862277|NCT00422448|Experimental|Nevi from participants|Benign nevi dermoscopically sub-classified into 4 dermoscopic types (i.e., with globular, reticular, mixed pattern with globules in the center and mixed pattern with globules at the periphery) were excised from healthy volunteers for further genetical analysis
88862278|NCT00424554|Experimental|Temozolomide treatment|
88862279|NCT00424554|No Intervention|No treatment|
88862280|NCT02117310|Experimental|ICG|Angiography with administered ICG
88862281|NCT00425802|Other|treatment|This is a phase 2 study of a treatment regimen consisting of a non-myeloablative (NMA) conditioning regimen incorporating low dose chemotherapy and low dose radiation as well as peri-transplant Rituximab and the transplantation of peripheral blood stem cells (PBSC) or bone marrow if PBSC collection not possible from an HLA compatible related or unrelated donor in patients with B cell lymphoid malignancies including diffuse large cell (DLC) and mantle cell non-Hodgkin's lymphoma (NHL), indolent B cell NHL, or chronic lymphocytic leukemia (CLL).
88862282|NCT00530634|Experimental|Gemcitabine + Cisplatin|Surgical resection followed by (within 60 days) by chemotherapy (Gemcitabine at 1000 mg/m2 IV over 30 minutes on days 1 and 8 of a 21 day cycle and Cisplatin at 75 mg/m2 IV over 1 hour on day 8 of a 21 day cycle) followed by radiation therapy (treated using linear accelerator with photon beam energy of 6-21 MV) upon completion of 3 cycles of chemotherapy.
88862283|NCT02113410|Experimental|Sit 'N' Fit Chair Yoga (SNFCY)|Willing and eligible subjects randomized to Sit 'N' Fit Chair Yoga attended twice-weekly 45-minute yoga sessions for 8 weeks, for a total of 16 sessions.
88862284|NCT02113410|Active Comparator|Health Education Program (HEP)|Willing and eligible subjects randomized to the Health Education Program (HEP) will attended twice-weekly 45-minute health education sessions for 8 weeks, for a total of 16 sessions.
88862285|NCT00531882|Experimental|1-pioglitazone|Pioglitazone
89184940|NCT02602847||Patients with alcoholic or hepatitis C virus related disease|cccDNA assay on liver biopsy in patients with liver transplantation for alcoholic disease or hepatitis C virus (HCV) related disease, without contact with HBV
89184941|NCT02602847||Hepatitis B core antibody positive donors|cccDNA assay on liver biopsy in patients who receive liver from hepatitis B core antibody positive donors
88862286|NCT00531882|Experimental|2-simvasatin|Simvastatin
88862287|NCT00531882|Active Comparator|3-Ibuprofen 1000-1600 mg/day|Ibuprofen 1000-16-- mg/day, maximum 3200 mg/day
88862288|NCT00428298|Experimental|Active Treatment Valacyclovir|Subjects dispensed 500 mg capsules. Subjects take two 500 mg capsules twice daily for 16 weeks.
88862289|NCT00428298|Placebo Comparator|Placebo Treatment|Subjects dispensed 500 mg capsules. Subjects take two 500 mg capsules twice daily for 16 weeks.
88862290|NCT00486018|Sham Comparator|Sham injection|
88862291|NCT00486018|Experimental|Ranibizumab injection 0.3 mg|
88862292|NCT00486018|Experimental|Ranibizumab injection 0.5 mg|
88862293|NCT00486642|Experimental|Arm A (pazopanib hydrochloride)|"Patients receive pazopanib hydrochloride PO QD on days 1-28.~."
88862294|NCT00486642|Experimental|Arm B (pazopanib hydrochloride, bicalutamide)|Patients receive pazopanib hydrochloride PO QD on days 1-28. Patients also receive bicalutamide PO QD on days 8-28 of course 1 and on days 1-28 in all subsequent courses.
88862295|NCT04388514|Experimental|Blood ozonization|Blood ozonization plus BAT
88862296|NCT04388514|No Intervention|Standard of Care|"BAT only~To note that the BAT are therapy with antiretroviral therapy (lopinavir/ritonavir 2 tablets every 12 hours or darunavir/cobicistat 1 tablet per day) and hidrossycloroquine 400 mg every 12 hours then first day, followed by 200 mg every 12 hours for other 4 days."
88862297|NCT00428922|Experimental|Trastuzumab, Bevacizumab, and Docetaxel|Trastuzumab [6mg/kg], Bevacizumab [15mg/kg], and Docetaxel [75 mg/M²]
88862298|NCT00533442|Active Comparator|Tacrolimus plus MMF plus Steroids|Patients randomized to this arm were scheduled to receive maintenance therapy consisting of Tacrolimus, Mycophenolate Mofetil (MMF), and Steroids. Patients in both treatment arms received dual induction therapy consisting of Rabbit Anti-thymocyte Globulin (Thymoglobulin) plus Daclizumab.
89003333|NCT05439421|Experimental|With Claim Ultra Light|Package or digital marketing advertisement containing claim of interest
89184942|NCT02602847||HBV patients|cccDNA assay on liver biopsy in patient with liver transplantation for chronic hepatitis B, with or without HBV replication
89184943|NCT04391907|Active Comparator|IPL group|Subject who have intense pulsed light (IPL) laser 2 twice 1-6 weeks before cataract surgery
89184944|NCT04391907|No Intervention|Non-IPL group|Subject who do not have intense pulsed light (IPL) laser before cataract surgery
89184945|NCT00725829|Experimental|1|simvastatin 40g + ezetimibe 10g once a day
89184946|NCT00725829|Placebo Comparator|2|simvastatin 40g + placebo once a day
89184947|NCT02603939||Participants with Advanced Knee OA|People with advanced knee osteoarthritis requiring joint replacement surgery are being assessed for their pain responses before and after joint replacement surgery
89184948|NCT02603939||Participants with Early Knee OA|Participants with osteoarthritis with early disease who do not require joint replacement surgery are being assessed for pain
89184949|NCT02584296|No Intervention|Usual care control|Phase 1 will be observation only, and will be considered a usual care control group, activity at home.
89184950|NCT02584296|Experimental|Biobehavioral self management approach|Phase 2 participants will receive the Biobehavioral self management approach (BSMA) intervention aligned with the IMB model; introduced over three days of each five-day consolidation chemotherapy hospital admission.
89184951|NCT04321317|Other|Undernourished Patients|All patients included will be included in the unique arm of the study
89184952|NCT04079322|Experimental|Exercise|During the exercise arm, volunteers will complete a planned workout, as prescribed by the coach. The workout will be designed to be strenuous and induce an inflammatory response.
89184953|NCT04079322|Experimental|Rest|"The rest arm will be coordinated with a planned non-workout day, as prescribed by the coach, where volunteers are either scheduled to not run or go for an easy recovery run (<6 miles at a self-described easy pace) later in the afternoon."
89184954|NCT02583438|Experimental|Lifestyle intervention|
89184955|NCT02570061|Experimental|telephone|Information about the Calmette study was given by telephone
89184956|NCT02570061|Active Comparator|face-to-face|Information about the Calmette study was given face-to-face at a consultation at the hospital
89184957|NCT03929874||18 ≤ age ≤ 40|18 ≤ age ≤ 40
89184958|NCT03929874||age ≥ 60|age ≥ 60
89184959|NCT00725907|Experimental|1|PGRF
89184960|NCT00725907|Placebo Comparator|2|saline
89184961|NCT02583750|Experimental|OGTT after deprived sleep first|Participants came to the lab to perform the oral glucose tolerance test after three nights of sleep deprivation, then another test after three nights of sufficient sleep
89003334|NCT05439421|Experimental|Without Claim Ultra Light|Package or digital marketing advertisement without claim of interest
89184962|NCT02583750|Experimental|OGTT after sufficient sleep first|Participants came to the lab to perform the oral glucose tolerance test after three nights of sufficient sleep, then another test after three nights of deprived sleep
89184963|NCT02603861|Placebo Comparator|Placebo|Placebo matching LY3154207 administered once orally in one of four periods.
89184964|NCT02603861|Experimental|LY3154207 - Dose 1|LY3154207 administered orally in no more than one of the four periods.
89184965|NCT02603861|Experimental|LY3154207 - Dose 2|LY3154207 administered orally in no more than one of the four periods.
89184966|NCT02603861|Experimental|LY3154207 - Dose 3|LY3154207 administered orally in no more than one of the four periods.
89184967|NCT02603861|Active Comparator|Modafinil|200 mg modafinil administered orally in no more than one of the four periods.
89184968|NCT02569905|Active Comparator|Groups Parecoxib sodium|Fifty-one, American Society of Anesthesiologists' (ASA) physical status1or2, patients, undergoing colorectal operation were selected in the clinical study.
89184969|NCT02569905|Active Comparator|Groups Flurbiprofen|Fifty-two, American Society of Anesthesiologists' (ASA) physical status1or2, patients, undergoing colorectal operation were selected in the clinical study.
89184970|NCT02569905|Placebo Comparator|Group Saline|Fifty-one, American Society of Anesthesiologists' (ASA) physical status1or2, patients, undergoing colorectal operation were selected in the clinical study.
89184971|NCT02603783|Active Comparator|Capsaicin|1,5 mg capsaicin in 30 minutes
89184972|NCT02603783|Placebo Comparator|Placebo|75 ml placebo (0,9 % saline) in 30 minutes
89184973|NCT04110275|Experimental|low dose group|"Recombinant human tissue-type plasminogen activator derivative(rPA) for injection: 18 mg, Intravenous injection for 2 minutes or more.~A separate venous access should be used for bolus injection,a common venous access shared with other drugs is not allowed for injection. And no other drugs mixed with test drug during the injection."
89184974|NCT04110275|Experimental|high dose group|"Recombinant human tissue-type plasminogen activator derivative (rPA) for injection: the first injection of 18 mg rPA is pushed slowly for 2 minutes or more,the second injection of 9mg rtPA is pushed for 1 minute or more.The interval between the two injections should be controlled accurately about 30 minutes.~A separate venous access should be used for bolus injection,a common venous access shared with other drugs is not allowed for injection. And no other drugs mixed with test drug during the injection."
89184975|NCT04110275|Active Comparator|comparative group|Recombinant tissue plasminogen activator for injection: continuous intravenous injection for 2 hours.
89184976|NCT04250883|Experimental|Experimental group: Low Impact laparoscopy|low impact laparoscopy (low pressure (8 mmHg) and deep NMB (PTC 1-2)
89184977|NCT04250883|Active Comparator|Control group: Standard laparoscopy|standard laparoscopy (standard pressure (14 mmHg) and moderate NMB (TOF 1-2)
89184978|NCT04469634|Experimental|antibody response and memory B-cell|Regular blood draws to measure antibody responses and memory B-cell responses Regular swab collection to test for re-infection
89184979|NCT04465500|Other|Treatment|
89184980|NCT05432076||experimental group|In the study, sleep bands and white noise will be used for sleep for the babies in the experimental group
89184981|NCT05432076||control group|while the control group will not be interfered with
89184982|NCT04080726|Experimental|HIP1601+HGP1705 Placebo|HIP1601+HGP1705 Placebo for 4weeks. if not fully cured, take HIP1601+HGP1705 Placebo for addtional 4weeks
89386853|NCT03566342||GROUP E|The PCEA solution will contain 0.1% Bupivacaine + 2.85 mcg/cc of Fentanyl. Basal infusion 7 ml/hour Demand dose 7ml Lockout ( number of doses per hour) 3 Lock out interval 20 minutes
89386854|NCT04320979|Experimental|internal mammary nodal irradiation|chest wall and supraclavicular nodal+-axillary plus internal mammary nodal irradiation
89386855|NCT04320979|Active Comparator|no-internal mammary nodal irradiation|ipsilateral chest wall and supraclavicular +-axillary nodal irradiation
89386856|NCT03564860||HBP device data collection group|Device electrograms and 12-lead ECG will be collected from patients over the age of 18 years who have been previously implanted with a permanent His Bundle pacing lead and an Abbott pacemaker, defibrillator, or cardiac resynchronization therapy device during a standard-of-care device follow-up visit.
89386857|NCT05708456|Experimental|Intervention Group|Application of data collection forms for the initial evaluation. Teaching the use of the mobile application, monitoring the use of the mobile application in the experimental group by the researcher for 12 weeks, and applying the data collection forms to the patients in the 6th and 12th weeks.
89386858|NCT05708456|No Intervention|Control Group|Application of data collection forms for the initial evaluation. Application of data collection forms to the patients in the 6th and 12th weeks. No intervention will be made to the patients in the control group other than the routine service provided in the outpatient clinic.
89386859|NCT01344343|Experimental|Accelerated hip fracture surgery|Arrival in the operating room within 6 hours of diagnosis of a hip fracture requiring surgical repair
89386860|NCT01344343|No Intervention|Standard care|Surgical hip fracture repair according to the standard timing
89386861|NCT03566186|Experimental|Active phototherapy group|(n=12) Phase 2 training + active phototherapy Dosage applied was 30J per site (180J per muscle) to six sites on the quadriceps The MR4 LaserShower 50 4D emitter (MultiRadiance Medical, USA). The optical power was calibrated before irradiationin each participant using a Thorlabs thermal power meter(Model S322C, Thorlabs, Newton, NJ, USA).
89386862|NCT03566186|Placebo Comparator|Placebo group|(n=14) Phase 2 training + placebo phototherapy group
89386863|NCT03566186|Other|non-treatment control group|(n=13) Phase 2 training + control group
88862299|NCT00533442|Experimental|Tacrolimus plus Rapamycin plus Steroids|Patients randomized to this arm were scheduled to receive maintenance therapy consisting of Tacrolimus, Rapamycin (Sirolimus), and Steroids. Patients in both treatment arms received dual induction therapy consisting of Rabbit Anti-thymocyte Globulin (Thymoglobulin) plus Daclizumab.
89386864|NCT01344421||hip dysplasia|Patients with hip dysplasia
89386865|NCT01344421||Healthy people|Enrolled from the patients acquaintance circle
89386866|NCT03566030||Tenofovir Disoproxil Fumarate 300 mg QD|Administered Tenofovir Disoproxil Fumarate 300 mg QD
89386867|NCT03566030||Tenofovir Alafenamide|Administered Tenofovir Alafenamide 25 mg QD
89386868|NCT04312711|Experimental|intervention|All participants received 3D-TOF-MRA and ultrasound examination, and DSA is used as golden reference
89386869|NCT03565952|Experimental|Cranial massage|Manual cranial therapy consisting of massage and cranial relaxing techniques, lasting 30 minutes each session approximately, for 3 weeks and one month follow-up. Manual therapy consists of a prone and supine cranial massage.
88862300|NCT00533910|Placebo Comparator|Placebo|Will be given placebo and follow the exact procedures as the experimental section
88862301|NCT00533910|Experimental|Drug|
88862302|NCT01954524|Experimental|IV bolus injection of Sildenafil|CTP class B cirrhosis: A single 5 and 10 mg IV bolus injections of Sildenafil. CTP class C cirrhosis: A single 2.5, 5, 8 and 10 mg IV bolus injections of Sildenafil.
89386870|NCT03565952|Active Comparator|Control Group|The control group does not receive treatment.
89386871|NCT03565796|Experimental|Group A|Personalized active referral plus financial incentive+ AWARD advice + referral card + warning leaflet+ COSH booklet
89386872|NCT03565796|Experimental|Group B|AWARD advice + COSH booklet
89386873|NCT01333007||Cohort|
89386874|NCT04256005|No Intervention|Control|Participants will attend the laboratory and complete no exercise. The participants will remain seated for the 29 minutes of the session.
89386875|NCT04256005|Experimental|105% VO2Peak|Participants will complete ten intervals at a work rate which equates to 105% VO2peak with a 1:1 work rest ratio. The recovery period will involve free cycling against no resistance. The duration of the interval and recovery periods will vary between trials so that the total work done during each trial, excluding CON, will be the same, the duration of intervals will be determined by the 50% ∆ trial which will be set at 60 s for work and recovery intervals.
89386876|NCT04256005|Experimental|50% ∆ Gas Exchange Threshold|Participants will complete ten intervals at a work rate which equates to 50% ∆ GET with a 1:1 work rest ratio. The recovery period will involve free cycling against no resistance. The duration of the interval and recovery periods will vary between trials so that the total work done during each trial, excluding CON, will be the same, the duration of intervals will be determined by the 50% ∆ trial which will be set at 60 s for work and recovery intervals.
88862303|NCT00535002|Other|Cocaine Females, Yohimbine then Placebo|Cocaine dependent females, received yohimbine day 1 and placebo day 2
88862304|NCT00535002|Other|Cocaine Females, Placebo the Yohimbine|Cocaine dependent females, received placebo day 1 and yohimbine day 2
88862305|NCT00535002|Other|Cocaine Males, Yohimbine then Placebo|Cocaine dependent males, received yohimbine day 1 and placebo day 2
88862306|NCT00535002|Other|Cocaine Males, Placebo thenYohimbine|Cocaine dependent males, received placebo day 1 and yohimbine day 2
88862307|NCT00535002|Other|Control Females, Yohimbine then Placebo|Non-dependent females, received yohimbine day 1 and placebo day 2
88862308|NCT00535002|Other|Control Females, Placebo then Yohimbine|Non-dependent females, received placebo day 1 and yohimbine day 2
88862309|NCT00535002|Other|Control Males, Yohimbine then Placebo|Non-dependent males, received yohimbine day 1 and placebo day 2
88862310|NCT00535002|Other|Control Males, Placebo then Yohimbine|Non-dependent males, received placebo day 1 and yohimbine day 2
88862311|NCT02117934|Experimental|HEPLISAV|0.5 mL HEPLISAV (20 mcg HBsAg and 3000 mcg 1018) administered intramuscularly in the deltoid muscle at Weeks 0, 4, and placebo (saline injection) at Week 24, followed by a 52-week safety follow-up from the last active dose of HEPLISAV.
88862312|NCT02117934|Active Comparator|Engerix-B|1.0 mL Engerix-B (20 mcg HBsAg adsorbed on 500 mcg of aluminum hydroxide) administered intramuscularly in the deltoid muscle at Weeks 0, 4, and 24, followed by a 32-week safety follow-up from the last dose of Engerix-B.
88862313|NCT00429702|Experimental|Benadryl® Ativan® Decadron® (BAD) Pump|Patients receive ondansetron hydrochloride IV twice daily and saline IV twice daily beginning 30-60 minutes prior to the start of chemotherapy. Patients also receive diphenhydramine hydrochloride, lorazepam, and dexamethasone by continuous infusion pump.
88862314|NCT00429702|Active Comparator|Control Arm Saline|Patients receive ondansetron hydrochloride IV twice daily and dexamethasone IV twice daily beginning 30-60 minutes prior to the start of chemotherapy. Patients also receive saline by continuous infusion pump.
88862315|NCT00535392|Experimental|Levetiracetam|
88862316|NCT00535782|Experimental|TCZ + MTX|Participants received 8 mg/kg tocilizumab (TCZ) by intravenous infusion (IV) every 4 weeks plus methotrexate (MTX) 7.5-25 mg (oral or parenteral) weekly for the first 24 weeks. From Week 24 to Week 104, participants received open-label TCZ 8 mg/kg every 4 weeks plus 7.5-25 mg MTX weekly.
88862317|NCT00535782|Placebo Comparator|Placebo + MTX|Participants received placebo intravenous infusion (IV) every 4 weeks plus methotrexate (MTX) 7.5-25 mg (oral or parenteral) weekly for the first 24 weeks. From Week 24 to 104, participants received open-label tocilizumab (TCZ) 8 mg/kg every 4 weeks plus 7.5-25 mg MTX.
88862318|NCT00431184|Active Comparator|Pentazocine then Lorazepam|In the first leg of the study, pentazocine will be given to subjects randomly assigned to this group. On Day 1, subjects will receive 50mg of pentazocine followed by a second dose of 50mg two hours later. On Day 2, subjects in this group will be given 0.25mg of Lorazepam followed by a second dose of 0.25mg two hours later.
88862319|NCT00431184|Active Comparator|Lorazepam then Pentazocine|In the first leg of the study, lorazepam will be given to subjects randomly assigned to this group. On Day 3, subjects in this group will be given 0.25mg of Lorazepam followed by a second dose of 0.25mg two hours later. On Day 2, subjects will receive 50mg of pentazocine followed by a second dose of 50mg two hours later.
88862320|NCT00433992||ABC/3TC|HIV-infected subjects were given Abacavir-Lamuvidine
88862321|NCT00433992||TDF/FTC|HIV-infected patients were given tenofovir DF-emtricitabine
88862322|NCT00535938||Naïve to Botox® treatment|Initiating treatment with BOTOX® upon entry to the project.
88862323|NCT00535938||Non-naïve to Botox® treatment|Receiving ongoing treatment with BOTOX® upon entry to the project.
88862324|NCT00537576|Experimental|Low dose LACTIN-V applicator|Low dose LACTIN-V applicator (150 mg LACTIN-V, 5.0 x 10^8 CFU), administered vaginally once a day for 5 consecutive days
88862325|NCT00537576|Experimental|Medium dose LACTIN-V applicator|Medium dose LACTIN-V applicator (300 mg LACTIN-V, 1.0 x 10^9 CFU), administered vaginally once a day for 5 consecutive days
88862326|NCT00537576|Experimental|High dose LACTIN-V applicator|High dose LACTIN-V applicator (600 mg LACTIN-V, 2.0 x 10^9 CFU), administered vaginally once a day for 5 consecutive days
88862327|NCT00537576|Placebo Comparator|Low dose Placebo applicator|Low dose Placebo applicator (150 mg Placebo), administered vaginally once a day for 5 consecutive days
88862328|NCT00537576|Placebo Comparator|Medium dose Placebo applicator|Medium dose Placebo applicator (300 mg Placebo), administered vaginally once a day for 5 consecutive days
88862329|NCT00537576|Placebo Comparator|High dose Placebo applicator|High dose Placebo applicator (600 mg Placebo), administered vaginally once a day for 5 consecutive days
88862330|NCT01795794|Experimental|LOSEC|"LOSEC will be given 20 mg X 1/day for 6 months and then for the next 6 months the same group will be the control group of herself."
88862331|NCT01795950|Experimental|0.5 M PLX-PAD|0.5 million (M) PLX-PAD cells per kg body weight
88862332|NCT01795950|Experimental|1 M PLX-PAD|1.0 million (M) PLX-PAD cells per kg body weight
88862333|NCT01795950|Experimental|2 M PLX-PAD|2.0 million (M) PLX-PAD cells per kg body weight
88862334|NCT01796028|Placebo Comparator|Arm A : TAXOTERE® + Metformin placebo|Docetaxel (TAXOTERE®) will be administered at 75 mg/m2. Metformin (or placebo) is formulated into 850 mg tablets for oral administration and is to be dispensed twice a day on a continuous daily dosing schedule
88862335|NCT01796028|Experimental|Arm B : TAXOTERE® + Metformin|Docetaxel (TAXOTERE®) will be administered at 75 mg/m2. Metformin is formulated into 850 mg tablets for oral administration and is to be dispensed twice a day on a continuous daily dosing schedule
88862336|NCT00491244|Experimental|Peginterferon alfa-2a and ribavirin|Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week plus ribavirin (Copegus, F. Hoffman-LaRoche) 200 mg/day for 24 to 48 weeks (genotype 1: 48 weeks, genotype 2: 24 weeks)
88862337|NCT00491244|Experimental|Peginterferon alfa-2a|Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week for 24 to 48 weeks (genotype 1: 48 weeks, genotype 2: 24 weeks)
88862338|NCT00492336|Active Comparator|Rasagiline|Treatment with Rasagiline
88862339|NCT00492336|Placebo Comparator|Inactive pill|Treatment with Placebo
88862340|NCT00538434|Experimental|Reslizumab 1 mg/kg|reslizumab 1 mg/kg intravenous (IV) on Day 0 of each 28-day (+/-7 days) cycle, for up to 4 cycles
88862341|NCT00538434|Experimental|Reslizumab 2 mg/kg|reslizumab 2 mg/kg IV on Day 0 of each 28-day (+/-7 days) cycle, for up to 4 cycles
88862342|NCT00538434|Experimental|Reslizumab 3 mg/kg|reslizumab 3 mg/kg IV on Day 0 of each 28-day (+/-7 days) cycle, for up to 4 cycles
88862343|NCT00538434|Placebo Comparator|Placebo|saline placebo IV on Day 0 of each 28-day (+/-7 days) cycle, for up to 4 cycles
88862344|NCT00538512|Active Comparator|TIV|the trivalent inactivated influenza vaccine - Fluzone, manufactured by Sanofi-Pasteur
88862345|NCT00538512|Active Comparator|LAIV|live-attenuated influenza vaccine Flumist, manufactured by MedImmune
88862346|NCT00538512|Placebo Comparator|Placebo|Physiologic saline administered as a nasal spray or intramuscular injection
88862347|NCT00538824|Experimental|DexTR (all patients)|All patients were treated with the DexTR (dexamethasone / thalidomide, lenalidomide (Revlimid®)), which consisted of lenalidomide 25mg/day during days 1-21, dexamethasone 40mg/day on days 1-4, 9-12, and 17-20, and thalidomide 50mg/day for the first 7 days, followed by 100mg/day for all subsequent days, for a total of 4 cycles of 28 days each.
88862348|NCT00539526|Experimental|1|bimatoprost 0.03%
88862349|NCT00539526|Active Comparator|2|travoprost 0.004%
88862350|NCT00539526|Active Comparator|3|latanoprost 0.005%
88862351|NCT01796106|Experimental|Resin infiltration|Enrolled proximal early caries lesions will be treated using the resin infiltrant Icon (DMG, Germany).
88862352|NCT01796106|Active Comparator|Fluoride varnish & Oral hygiene instruction|Oral hygiene instruction and topical fluoridation therapy (Duraphat Fluoride Varnish, Colgate, USA) will be provided.
88862353|NCT03371004|Experimental|DM-CHOC-PEN + Radiation|4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) - 39-89.7 MG/M2 iv once and then 3-weeks later radiation - 15-30 Gy will be administered
88862354|NCT00541242|Active Comparator|1|bimatoprost 0.03% eye drops
88862355|NCT00541242|Active Comparator|2|latanoprost 0.005% eye drops
88862356|NCT00438204|Experimental|Bevacizumab, gemcitabine hydrochloride|"Bevacizumab 10mg/kg IV over 90 ± 15 minutes every 14 days~Gemcitabine 1200 mg/m2 intravenously over 30 minutes following the pemetrexed disodium every 14 days~Pemetrexed 400 mg/m2 intravenously over 10 minutes every 14 days."
88862357|NCT00438750|Experimental|Independent Home Exercises|Subjects who learn their therapy exercises from the surgeon and practice them independently at home.
88862358|NCT00438750|Experimental|Formal Therapy|Subjects who follow the conventional protocol of seeing a therapist to learn and guide them in their exercises.
88862359|NCT00439296|Experimental|Dose Level 1|"Treatment Dose of ABT-751 is 80 mg/m2/day~Tx Course 1:~• ABT-751, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, IT Methotrexate~Tx Course 2:~• Cyclophosphamide, 6-Thioguanine, IT Methotrexate, Cytarabine, PEG-asparaginase, ABT-751~Tx Courses 3-12 (maintenance courses):~• ABT-751, IT Methotrexate"
88862360|NCT00439296|Experimental|Dose Level 2|"Treatment Dose of ABT-751 is 100 mg/m2/day~Tx Course 1:~• ABT-751, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, IT Methotrexate~Tx Course 2:~• Cyclophosphamide, 6-Thioguanine, IT Methotrexate, Cytarabine, PEG-asparaginase, ABT-751~Tx Courses 3-12 (maintenance courses):~• ABT-751, IT Methotrexate"
88862361|NCT00439296|Experimental|Dose Level 3|"Treatment Dose of ABT-751 is 125 mg/m2/day~Tx Course 1:~• ABT-751, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, IT Methotrexate~Tx Course 2:~• Cyclophosphamide, 6-Thioguanine, IT Methotrexate, Cytarabine, PEG-asparaginase, ABT-751~Tx Courses 3-12 (maintenance courses):~• ABT-751, IT Methotrexate"
88862362|NCT00439296|Experimental|Dose Level 4|"Treatment Dose of ABT-751 is 150 mg/m2/day~Tx Course 1:~• ABT-751, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, IT Methotrexate~Tx Course 2:~• Cyclophosphamide, 6-Thioguanine, IT Methotrexate, Cytarabine, PEG-asparaginase, ABT-751~Tx Courses 3-12 (maintenance courses):~• ABT-751, IT Methotrexate"
88862363|NCT00439296|Experimental|Dose Level 5|"Treatment Dose of ABT-751 is 175 mg/m2/day~Tx Course 1:~• ABT-751, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, IT Methotrexate~Tx Course 2:~• Cyclophosphamide, 6-Thioguanine, IT Methotrexate, Cytarabine, PEG-asparaginase, ABT-751~Tx Courses 3-12 (maintenance courses):~• ABT-751, IT Methotrexate"
89003335|NCT05439421|Experimental|With Claim Fresh Hookah Tobacco|Package or digital marketing advertisement containing claim of interest
89184983|NCT04080726|Experimental|HGP1705+HIP1601 Placebo|HGP1705+HIP1601 Placebo for 4weeks. if not fully cured, take HGP1705+HIP1601 Placebo for addtional 4weeks
89184984|NCT04080570|Experimental|Remote Visit|After an initial physical in-home visit, the physician will see home hospitalized patients by facilitated video each day.
89184985|NCT04080570|No Intervention|In-Home Visit|The physician will see home hospitalized patients physically in their homes each day, as is usual care.
89184986|NCT02585544|Other|Genital prolapse|Single arm: i.e., all patients
89184987|NCT00726219|Other|1|Insertion distance of femoral catheter: 3cm
89184988|NCT00726219|Other|2|Insertion distance of femoral catheter: 7cm
89184989|NCT00920322|Active Comparator|five times weekly|Patients will receive rTMS on each weekday for 4 weeks (5 x weekly)
89184990|NCT00920322|Experimental|three times weekly|Patients will receive rTMS three times weekly for four weeks
89184991|NCT02585466||BIS25|BIS 25 levels were subsequently maintained via propofol TCI 0.2 microg mL-1 TCI adjustments. Stable BIS values that showed no further decline and remained within BIS ±5 ofBIS 25 of the previous BIS value were considered an indicator of pseudo-steady state plasma effect-site equilibration
89184992|NCT02585466||BIS50|BIS 50 levels were subsequently maintained via propofol TCI 0.2 microg mL-1 TCI adjustments. Stable BIS values that showed no further decline and remained within BIS ±5 of either BIS 50 levels of the previous BIS value were considered an indicator of pseudo-steady state plasma effect-site equilibration
89184993|NCT00726843|Active Comparator|1|8 weeks of Yoga, followed by 8 weeks of follow-up
89184994|NCT00726843|Active Comparator|2|8 weeks of follow-up, followed by 8 weeks of yoga
88862364|NCT00439296|Experimental|Dose Level 0|"Treatment Dose of ABT-751 is 65 mg/m2/day~Tx Course 1:~• ABT-751, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, IT Methotrexate~Tx Course 2:~• Cyclophosphamide, 6-Thioguanine, IT Methotrexate, Cytarabine, PEG-asparaginase, ABT-751~Tx Courses 3-12 (maintenance courses):~• ABT-751, IT Methotrexate"
88862365|NCT00439296|Experimental|Dose Level -1|"Treatment Dose of ABT-751 is 50 mg/m2/day~Tx Course 1:~• ABT-751, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, IT Methotrexate~Tx Course 2:~• Cyclophosphamide, 6-Thioguanine, IT Methotrexate, Cytarabine, PEG-asparaginase, ABT-751~Tx Courses 3-12 (maintenance courses):~• ABT-751, IT Methotrexate"
89386877|NCT05353946|Active Comparator|Elective Rotational Atherectomy|"Operators can decide elective use of rotational atherectomy (RA) or conventional angioplasty according to the calcification patterns of the coronary lesion evaluated by Intravascular ultrasound (IVUS) or by angiography if the IVUS cannot cross the lesion.~Procedure is performed with a Rotablator system, consisting of a rotating olive-shaped burr whose leading hemisphere is coated with microscopic diamond chips. The proximal end of the device has a housing unit containing the burr advancer, a fiberoptic tachometer cable, an irrigation port, and a nitrogen gas delivery hose, which permits the rapidly rotating of the burr. The RA catheter is introduced into the coronary artery over a stainless steel 0.09-inch wire to cross the lesion, then advanced with a slow pecking motion at a speed of 160,000 to 190,000 rpm with each ablation run <15 seconds is performed. Burr size was with a burr/vessel ratio of 0.7. After RA, all patients received IVUS-guided percutaneous coronary intervention."
89386878|NCT05353946|Active Comparator|Bailout Rotational Atherectomy|The operators began with conventional angioplasty (non-compliant balloon dilatation) regardless of the calcification patterns in the coronary lesion, and rotational atherectomy (RA) can be used only as a bailout.
89386879|NCT03565718|Active Comparator|Standard Group|Participants in this group will receive counseling, informational materials, and recipes for following a vegan diet. Participants in this group will receive gift cards to go shopping at their local supermarkets and follow the diet for 3 weeks. At the end of the 3 week period each participant will have a follow-up meeting and provide feedback to the study personnel. The Dietary Intervention: Standard/Grocery includes intervention meetings and dietary counseling.
89386880|NCT03565718|Experimental|Restaurant Group|"Participants in this group will receive counseling, informational materials, and recipes for following a vegan diet. Participants in this group will receive gift cards to go and eat out a few times a week at local vegan soul food restaurants and follow the diet for 3 weeks. At the end of the 3 week period each participant will have a follow-up meeting and provide feedback to the study personnel.~The Dietary Intervention: Restaurant condition includes intervention meetings and dietary counseling."
89386881|NCT01344499|Experimental|Adept|1000ml Adept will be left in the abdomen and measured over time
89386882|NCT01344499|Active Comparator|Ringer-lactate|1000 ml of Ringer lactate left in the abdomen and measured over time
89386883|NCT03565562|No Intervention|Control group|Local authorities allocated to this group won't implement any promotion of the e-health tool for the 12 first months. Free access to StopBlues.
89386884|NCT03565562|Active Comparator|Group experimental 1 promotion|Local authorities allocated to this group will have to implement the promotion of the e-health tool: the promotion at the local authority level. They will promote the e-health tool using their usual communication methods (local newspapers, local website, bulletin and billboards, posters in the local shops and in the bus stops…). Free access to StopBlues.
89386885|NCT03565562|Active Comparator|Group experimental 2 promotion|Local authorities allocated to this group will have to implement promotion of the e-health tool: the promotion at local authority and GPs' waiting room level. Local authorities will promote the e-health tool using their usual communication methods (local newspapers, local website, bulletin and billboards, posters in the local shops and in the bus stops...). (similarly to group experimental1) as well as leaflets and posters in GPs' waiting room. Free access to StopBlues.
89386886|NCT05065879|Experimental|Hypertension group|Hypertension group will enroll 330 subjects with hypertension (aged 60 years or older).
88862366|NCT00542490|Experimental|Vaginal Cuff Brachytherapy|
88862367|NCT03117660|Experimental|Vitamin A|Subjects will receive 3-4weeks of vitamin A
88862368|NCT03117660|No Intervention|Control|Subjects will receive no treatment
88862369|NCT00439374|Active Comparator|17 alpha-hydroxyprogesterone caproate|250 mg of 17 alpha-hydroxyprogesterone caproate given by weekly injection until 37 weeks gestation or delivery
88862370|NCT00439374|Placebo Comparator|Placebo|Placebo oil given by weekly injection until 37 weeks gestation or delivery.
88862371|NCT00439608|Experimental|Treatment|Cetuximab, paclitaxel, and carboplatin weekly for 6 weeks with 50.4 Gy radiation.
88862372|NCT01797042|Active Comparator|Fructose 9%|Sugar sweetened milk consumed in an amount that added sugar provides 9% of calories required for weight maintenance
88862373|NCT01797042|Active Comparator|Glucose 9%|Sugar sweetened milk consumed in an amount that added sugar provides 9% of calories required for weight maintenance
88862374|NCT01797042|Active Comparator|High fructose corn syrup 18%|Sugar sweetened milk consumed in an amount that added sugar provides 9% of calories required for weight maintenance
88862375|NCT01797042|Active Comparator|Sucrose 18%|Sugar sweetened milk consumed in an amount that added sugar provides 9% of calories required for weight maintenance
88862376|NCT00500448|No Intervention|No Treatment|No treatment was delivered to this arm. Participants went about activities of daily living
88862377|NCT00500448|Experimental|Electrical Stimulation|Neuromuscular electrical stimulation treatments 3 times per week for 4 weeks
88862378|NCT04750122|Experimental|Neoadjuvant therapy base on PTC drug screenning|Patients will receive neoadjuvant therapy including trastuzumab, pertuzumab, and chemotherapy based on PTC drug screening.
88862379|NCT04749576|Active Comparator|Low dose saffron|healthy, mild-moderate ulcerative colitis for low dose
88862380|NCT04749576|Active Comparator|High dose Saffron|healthy, mild-moderate ulcerative colitis for high dose
88862381|NCT04749576|Placebo Comparator|Placebo|healthy, mild-moderate ulcerative colitis for placebo
88862382|NCT00441558|Experimental|flibanserin|flexible dosing of either 50 or 100mg every evening, or 25 or 50mg twice daily.
88862383|NCT00443352|Experimental|Duloxetine|Duloxetine 120mg daily for 12 weeks.
88862384|NCT00445302|Active Comparator|Normal renal function|Participants with normal renal function (creatinine clearance (CLcr) > 90 ml/min) who serve as the study control. Participants treated with one dose of plerixafor (240 µg/kg) administered by subcutaneous (SC) injection.
88862385|NCT00445302|Experimental|Mild renal impairment|Participants have mild renal impairment (creatinine clearance (CLcr) = 51 to 80 mL/min). Participants treated with one dose of plerixafor (240 µg/kg) administered by subcutaneous (SC) injection.
88862386|NCT00445302|Experimental|Moderate renal impairment|Participants have moderate renal impairment (creatinine clearance (CLcr) = 31 to 50 mL/min). Participants treated with one dose of plerixafor (240 µg/kg) administered by subcutaneous (SC) injection.
88862387|NCT00445302|Experimental|Severe renal impairment|Participants have severe renal impairment (creatinine clearance (CLcr) < 31 mL/min, not requiring dialysis). Participants treated with one dose of plerixafor (240 µg/kg) administered by subcutaneous (SC) injection.
88862388|NCT00502944|Experimental|Counselor-based HIV screening|
88862389|NCT00502944|Active Comparator|Emergency staff member-based HIV screening|
88862390|NCT00504504|Experimental|Rituximab + ABVD Chemotherapy|Rituximab 375 mg/m^2 by vein (IV) over 3 to 8 hours weekly for 6 weeks in a row. ABVD Chemo: Adriamycin 25 mg/m^2 IV, Bleomycin 10 U/m^2 IV, Vinblastine 6 mg/m^2 IV, DTIC 375 mg/m^2 IV. Each but Rituximab over 3 hours every other week for a total of 12 treatments.
88862391|NCT00504660|Active Comparator|1: Anaplastic Tumors|Anaplastic Tumors - 6-TG 80 mg/m^2 orally (PO) every 6 hours Day 1-3; Temozolomide 150 mg/m^2 PO daily Days 4-8, after 6 day rest Capecitabine 825 mg/m^2 and Celebrex 400 mg PO every 12 hours Day 14-27 for 28 day course.
88862392|NCT00504660|Active Comparator|2: Anaplastic Tumors|"Anaplastic Tumors - 6-TG 80 mg/m^2 PO every 6 hours Day 1-3, Lomustine 100 mg/m^2 PO on Day 4; Capecitabine 825 mg/m^2 PO every 12 hours Days 11-24, and Celebrex 400 mg PO every 12 hours Days 11-24.~Participants if previously received Temozolomide but not Lomustine (CCNU) will receive Lomustine; or if had Gliadel wafers and Temozolomide with radiotherapy (XRT) will receive Temozolomide."
88862393|NCT00504660|Active Comparator|3: Glioblastoma Multiforme|"Glioblastoma Multiforme - 6-TG 80 mg/m^2 PO every 6 Hours Day 1-3; Capecitabine 825 mg/m^2 PO every 12 hours Days 14-27 and Celebrex 400 mg PO every 12 hours Day 11-24; Temozolomide 150 mg/m^2 PO daily Days 4-8 OR CCNU (Lomustine) 100 mg/m2 orally Day 4 of each 42-day cycle.~Participants receive Temozolomide if not had previous treatment and if had prior CCNU. Those previously treated with Temozolomide but not CCNU receive CCNU, and those that had Gliadel and Temozolomide with XRT receive Temozolomide."
88862394|NCT00505362|Active Comparator|Rectus muscle closure|Two-layer uterine closure, peritoneal closure, fascial and skin closure and reapproximation of the rectus muscles with three-interrupted sutures.
88862395|NCT00505362|No Intervention|Rectus muscle non-closure|Two-layer uterine closure, peritoneal closure, fascial and skin closure, and rectus muscles non-closure.
88862396|NCT00544674|Experimental|PR104|PR104 will be administered once every 21 days by IV
88862397|NCT00544908|Experimental|Dasatinib|Dasatinib 70 mg po bid (1 cycle=28 days)
88862398|NCT00447330|Experimental|1|
88862399|NCT04388280|Other|Imaging|Echocardiography combined with coronary flow reserve (CFR) and strain imaging, or computed tomography (CT) angiography with direct visualization of coronary arteries.
88862400|NCT04388280|No Intervention|Observation|No imaging for the estimation of coronary artery disease
88862401|NCT02115048|Active Comparator|Arm A|Continuous regimen of oral Letrozole 2.5 mg daily
88862402|NCT02115048|Experimental|Arm B|Continuous regimen of oral Letrozole 2.5 mg daily plus oral Afatinib 30 mg daily
88862403|NCT00546156|Active Comparator|HR+, HER2-|Patients with Hormone Receptor Positive, HER2 negative Breast Cancer. A single dose of Bevacizumab 10mg/kg, followed two weeks later by Adriamycin60 mg/m2 and Cyclophosphamide 600 mg/m2 with Bevacizumab 10mg/kg every 2 weeks x4, followed by Taxol 175 mg/m2 with Bevacizumab 10 mg/kg every 2 weeks x3, followed by Taxol 175 mg/m2 x1.
88862404|NCT00546156|Active Comparator|Triple Negative Breast Cancer Cohort|Hormone receptor negative, HER2 negative Cohort. Receive same drug protocol as Arm A.
88862405|NCT00508716|No Intervention|A|Usual Care - Education about CHF by Primary Nurse on discharge. No teach-back is used in this arm.
88862406|NCT00508716|Experimental|B|"Tailored Intervention for patients with low health literacy and nurse-directed teachback: Educational leaflet which has been developed for low-health literacy patients. Adminstered by dedicated Nurse-educator. Nurse-educator asks Patient for teachback after Intervention. This means that the Patient repeats in his/her own words the Information received. Education ends once Patient has been able to repeat the Information back."
89003336|NCT05439421|Experimental|Without Claim Fresh Hookah Tobacco|Package or digital marketing advertisement without claim of interest
89003337|NCT05439421|Experimental|With Claim Lower Nicotine Tobacco|Package or digital marketing advertisement containing claim of interest
89003338|NCT05439421|Experimental|Without Claim Lower Nicotine Tobacco|Package or digital marketing advertisement without claim of interest
88862407|NCT00509496|Experimental|anti-gp100:154-162 TCR PBL + HD IL-2|"fludarabine phosphate-25 mg/m^2/day intravenous piggy back over 30 minutes for 5 days~cyclophosphamide-60 mg/kg/day x 2 days intravenous~Anti-gp100:154-162 TCR-engineered peripheral blood lymphocyte (PBL) cell preparation - minimum of approximately 5 X 10^8 cells and up to 3 x10^11 anti-gp100:154-162 TCR engineered TIL or PBL. The cells are infused intravenously over 20-30 minutes.~aldesleukin-720,000 IU/kg intravenously over 15 minutes every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses)"
88862408|NCT00509496|Experimental|anti-gp100:154-162 TCR TIL + HD IL-2|"fludarabine phosphate-25 mg/m^2/day intravenous piggy back over 30 minutes for 5 days~cyclophosphamide-60 mg/kg/day x 2 days intravenous~Anti-gp100:154-162 TCR-engineered tumor infiltrating lymphocytes (TIL) cell preparation- minimum of approximately 5 X 10^8 cells and up to 3 x10^11 anti-gp100:154-162 TCR engineered TIL or PBL. The cells are infused intravenously over 20-30 minutes~aldesleukin-720,000 IU/kg intravenously over 15 minutes every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses)"
88862409|NCT00547638|Experimental|Dermabond Protape|DERMABOND PROTAPE (Prineo) Topical Skin Adhesive
88862410|NCT00547638|Active Comparator|Dermabond HVD|DERMABOND HVD Topical Skin Adhesive
88862411|NCT00510744|Experimental|pancreatic enzyme supplementation|3 month supplementation in those gastric bypass patients shown to have a fat absorption less than 80%
88862412|NCT00548418|Experimental|I|"Cisplatin 50 mg/m2 IV day 1 of a 21 day cycle~Topotecan 0.75 mg/m2 IV Days 1, 2, 3 of a 21 day cycle~Bevacizumab 15 mg/kg day 1 of a 21 day cycle"
88862413|NCT00511914|Experimental|cTIV (Adults)|Received one dose of cell-culture derived trivalent influenza vaccine (cTIV).
88862414|NCT00511914|Experimental|cTIV (Elderly)|Received one dose of cell-culture derived trivalent influenza vaccine (cTIV).
88862415|NCT00511992|Experimental|Avastin|
88862416|NCT00451698|Placebo Comparator|3|acyanotic placebo
88862417|NCT00451698|Experimental|4|acyanotic erythropoietin
88862418|NCT01796262|Placebo Comparator|Wheat germ oil|Wheat germ oil 250 mg pearl b.i.d. for six months
88862419|NCT01796262|Active Comparator|docosahexaenoic acid|DHA Richoil 250 mg pearl (DMF srl): b.i.d. for six months
88862420|NCT01796340|Experimental|Food cue exposure|
88862421|NCT01796340|Active Comparator|Psycho-education|
88862422|NCT00548652|No Intervention|1|standard nutrition counselling
88862423|NCT00548652|Experimental|2|MOVE -weight loss intervention
88862424|NCT00548652|Experimental|3|MOVE plus medical crisis counselling
88862425|NCT00548652|Experimental|4|MOVE plus methylphenidate
88862426|NCT00548652|Experimental|5|MOVE plus methyphenidate plus medical crisis counselling
88862427|NCT01797354|Experimental|Cognitive-behavioral therapy and hypnosis group|Patients will receive (in groups of 6) fifteen 120-min sessions of group therapy including cognitive-behavioral techniques and hypnosis.
88862428|NCT01797354|Active Comparator|Support group|Patients will receive (in groups of 6) fifteen 120-min support group session.
88862429|NCT00549042|Experimental|OROS hydromorphone|OROS hydromorphone tablets administered orally once daily in total daily doses of 12, 16, 24, 32, 40, 48, or 64 mg
88862430|NCT00549042|Placebo Comparator|placebo|Matching placebo tablets orally once daily (number and dosage of tablets to match the number and dosage of the stable dose of OROS hydromorphone obtained in the Conversion and Titration phase).
88862431|NCT00452868|Experimental|Donepozil|Donepezil 5 milligrams a day for 6 weeks
88862432|NCT00453336|Experimental|Single Arm|
88862433|NCT00549822|Experimental|Intermittent letrozole therapy|Letrozole 2.5 mg administered by mouth daily during each 28 day treatment cycle. Treatment is intermittent with possible breaks between each 28 day treatment cycle based on CA 15-3 or CA 27.29 levels. Letrozole is administered until the participant has disease progression as determined by RECIST (Response Evaluation Criteria In Solid Tumors), experiences severe side effects, or decides to stop treatment.
88862434|NCT00550290|Active Comparator|Cefazolin Preoperatively|Participants received Cefazolin 2 grams intravenously within 30 minutes prior to incision
88862435|NCT00550290|Experimental|Cefazolin Postoperatively|Participants received Cefazolin 2 gram intravenous within 30 minutes prior to incision and 1 gram Cefazolin every 8 hours for the first 24 hours post-op
88862436|NCT03255408|Active Comparator|CBF Lowering and Normoxia Sleep|Study participants will take drug lowering Cerebral Blood Flow (CBF) and sleep under room air i.e. normoxia exposure.
88862437|NCT03255408|Experimental|CBF Lowering and IH Sleep|Study participants will take drug lowering Cerebral Blood Flow (CBF) and sleep under Intermittent Hypoxia (IH) exposure.
88862438|NCT03255408|Sham Comparator|Placebo and Normoxia Sleep|Study participants will take Placebo that has no effect on Cerebral Blood Flow (CBF) and sleep under room air i.e. normoxia exposure.
88862439|NCT03255408|Placebo Comparator|Placebo and IH Sleep|Study participants will take Placebo that has no effect on Cerebral Blood Flow (CBF) and sleep under Intermittent Hypoxia (IH) exposure.
88862440|NCT01797198|Experimental|gemfibrozil + ASP3652|Multiple doses of gemfibrozil and single dose of ASP3652
88862441|NCT01797198|Experimental|ASP3652 + repaglinide|Multiple doses of ASP3652 and the single dose of repaglinide
88862442|NCT00550368|Experimental|Helicobacter pylori negative|Persons who tested negative for H. pylori by both serology and Urea breath test. All participants will receive the Biological intervention: Enteropathogenic E. coli.
89003339|NCT05439421|Experimental|With Claim Premium Shisha Tobacco|Package or digital marketing advertisement containing claim of interest
89184995|NCT00726531|Experimental|OEP|Home based exercise programme (OEP) This exercise programme consists of a 30 minute programme of leg muscle strengthening and balance retraining exercises progressing in difficulty to be performed at home at least three times per week, and a walking plan to be undertaken at least two times per week for 24 weeks. . Trained peer mentors will contact and visit the patients at their home to start the exercise programme with them and will follow-up with up to three more home visits / exercise sessions as the participants require
89386887|NCT05065879|Experimental|Diabetes group|Diabetes group will enroll 330 subjects with diabetes (aged 60 years or older).
88862443|NCT00550368|Experimental|Helicobacter pylori positive|Persons who tested positive for H. pylori by both serology and Urea breath test. All participants will receive the Biological intervention: Enteropathogenic E. coli.
88862444|NCT00551070|Experimental|Treatment (selumetinib sulfate)|Patients receive selumetinib sulfate PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88862445|NCT00552786|Experimental|Acetin|
89386888|NCT05065879|Experimental|Combined Diseases group|Combined Diseases group will enroll 300 subjects with both hypertension and diabetes (aged 60 years or older).
88862446|NCT00552786|Placebo Comparator|Glucose|
88862447|NCT01797744|Experimental|Vestibular rehabiliation|Vestibular rehabiliation
88862448|NCT01797744|No Intervention|Control group|Usual rehabilitation whitout additional vestibular exercises
88862449|NCT00517530|Experimental|Phase I, NHL|Participants in this NHL arm received multiple ascending doses between 50 and 2000 mg via intravenous infusion of obinutuzumab.
88862450|NCT00517530|Experimental|Phase I, CLL|Participants in this CLL arm received multiple ascending doses between 400 and 2000 mg via intravenous infusion of obinutuzumab.
88862451|NCT00517530|Experimental|400/400 mg - Phase II, iNHL|Participants in this iNHL arm received an intravenous infusion of obinutuzumab 400 mg on Days 1 and 8 of Cycle 1 and obinutuzumab 400 mg on Day 1 of Cycles 2-8 for a maximum of 8 cycles and 9 infusions. Each cycle was 21 days.
88862452|NCT00517530|Experimental|1600/800 mg - Phase II, iNHL|Participants in this iNHL arm received an intravenous infusion of obinutuzumab 1600 mg on Days 1 and 8 of Cycle 1 and obinutuzumab 800 mg on Day 1 of Cycles 2-8 for a maximum of 8 cycles and 9 infusions. Each cycle was 21 days.
88862453|NCT00517530|Experimental|400/400 mg - Phase II, aNHL|Participants in this aNHL arm received an intravenous infusion of obinutuzumab 400 mg on Days 1 and 8 of Cycle 1 and obinutuzumab 400 mg on Day 1 of Cycles 2-8 for a maximum of 8 cycles and 9 infusions. Each cycle was 21 days.
88862454|NCT00517530|Experimental|1600/800 mg - Phase II, aNHL|Participants in this aNHL arm received an intravenous infusion of obinutuzumab 1600 mg on Days 1 and 8 of Cycle 1 and obinutuzumab 800 mg on Day 1 of Cycles 2-8 for a maximum of 8 cycles and 9 infusions. Each cycle was 21 days.
88862455|NCT00517530|Experimental|1000/1000 mg - Phase II, CLL|Participants in this CLL arm received an intravenous infusion of obinutuzumab 1000 mg on Days 1, 8, and 15 of Cycle 1 and obinutuzumab 1000 mg on Day 1 of Cycles 2-8 for a maximum of 8 cycles and 10 infusions. Each cycle was 21 days.
88862456|NCT00517530|Experimental|Retreated Participants|Participants who might benefit from retreatment who were allowed to be treated again via intravenous infusion of obinutuzumab at the request of the investigator.
88862457|NCT00518154|Experimental|A|Patients will be taking oral Pyridostigmine 30mg tid, as well as their usual antiretroviral treatment
89003340|NCT05439421|Experimental|Without Claim Premium Shisha Tobacco|Package or digital marketing advertisement without claim of interest
89003341|NCT05439421|Experimental|With Claim High Quality Shisha Tobacco|Package or digital marketing advertisement containing claim of interest
89184996|NCT00726531|Experimental|Fame|Community based exercise programme (FaME) FaME includes and extends the OEP. It will comprise one hour PSI delivered group exercise class in a local community centre for a maximum of 15 participants, and two 30 minute home exercise sessions (based on the extended OEP) per week for 24 weeks. Participants will also be advised to walk at least twice per week for up to 30 minutes at a moderate pace.
89184997|NCT00726531|No Intervention|TAU|Treatment as usual
89184998|NCT02583516|Experimental|A - Continuous Administration|960 mg of vemurafenib po, bid, days 1 to 28 and 60 mg of cobimetinib po, od, days 1 to 21, for each 28-days' cycle.
89184999|NCT02583516|Experimental|B - Intermittent Administration|960 mg of vemurafenib po, bid, days 1 to 28 and 60 mg of cobimetinib po, od, days 1 to 21, for each 28-days' cycle, during 12 weeks. After that period, patients will be treated with both drugs at the same doses indicated previously, but with an intermittent pattern: vemurafenib days 1 to 28 followed by 14 days off (4 weeks on and 2 weeks off) and cobimetinib days 1 to 21 followed by 21 days off (3 weeks on and 3 weeks off)
89386889|NCT05065879|Active Comparator|Healthy people group|Healthy people group will enroll 480 subjects with no medical history of hypertension or diabetes (aged 60 years or older).
89386890|NCT01344577||Group1#|bone graft material used: Apatos Cortical® (porcine cortical bone 600-1000 µm)
89386891|NCT01344577||Group2#|bone graft material used: MP3® (porcine cortic-cancellous collagenated bone mix 600-1000 µm)
89386892|NCT01344577||Group3#|control group
89003342|NCT05439421|Experimental|Without Claim High Quality Shisha Tobacco|Package or digital marketing advertisement without claim of interest
89003343|NCT05439421|Experimental|With Claim Don't blow smoke - blow clouds|Package or digital marketing advertisement containing claim of interest
89386893|NCT01333085|Experimental|RAD001-paclitaxel-carboplatin|RAD001: 20,30 or 50 mg PO 9 weekly cycles Paclitaxel: 60 mg/m²IV, in 1 hour, 9 weekly cycles Carboplatin AUC2 IV in 1 hour,9 weekly cycles
89386894|NCT01344655|Experimental|Formoterol 12 μg pMDI (Atimos®)|
89386895|NCT01344655|Active Comparator|Salmeterol 25 µg pMDI HFA (Serevent™)|
89386896|NCT01344655|Placebo Comparator|Matched Placebo|
89386897|NCT03565484|Experimental|Antimicrobial susceptibility testing guided therapy|14d bismuth quadruple therapy based on susceptibility test.
88862458|NCT00553098|Experimental|Treatment (chemotherapy, low dose radiation)|"CONDITIONING REGIMEN: *Patients with no life-threatening viral or fungal infections within 1 month before the planned HCT receive alemtuzumab IV over 6 hours on day -10 and fludarabine phosphate IV over 30 minutes on days -4 to -2. They also undergo low-dose TBI on day 0. Patients with HLH, IPEX syndrome, DiGeorge syndrome, or life-threatening viral or fungal infections within 1 month before the planned HCT receive fludarabine phosphate IV over 30 minutes on days -4 to -2 and undergo 2 low doses of TBI on day 0.~HEMATOPOIETIC CELL TRANSPLANTATION: Patients undergo HCT on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine IV or PO 2-3 times daily beginning on day -3 and continuing until day 100 followed by a taper until day 180. They also receive mycophenolate mofetil IV or PO 3 times daily beginning on day 0 and continuing until day 40 followed by a taper until day 96."
88862459|NCT00553410|Active Comparator|Continuous letrozole|Continuous letrozole: 5 years continuously (2.5 mg Letrozole daily)
88862460|NCT00553410|Experimental|Intermittent letrozole|Intermittent letrozole: 48 months over 5 yrs: 4 x 9 months (9 mo followed by 3 mo treatment-free interval in yrs 1-4, -> 36 mo) plus 1 x 12 mo in yr 5 -> 48 months
88862461|NCT00554970|Other|Treatment 1 then Treatment 2|Subjects received Treatment 1 in period 1 followed by a 7 day washout period and then Treatment 2 in period 2. Treatment 1 was a single dose of MAP0010 low dose delivered by nebulization twice daily for 7 days as per protocol. Treatment 2 was a single dose of Pulmicort Respules® 0.25mg dose delivered by nebulization twice daily for 7 days as per protocol.
88862462|NCT00554970|Other|Treatment 2 then Treatment 1|Subjects received Treatment 2 in period 1 followed by a 7 day washout period and then Treatment 1 period 2. Treatment 1 was a single dose of MAP0010 low dose delivered by nebulization twice daily for 7 days as per protocol. Treatment 2 was a single dose of Pulmicort Respules® 0.25mg dose delivered by nebulization twice daily for 7 days as per protocol.
89386898|NCT03565484|Experimental|Personal medication history guided therapy|14d bismuth quadruple therapy based on previous medication history.
89386899|NCT03565484|Other|Salvage therapy for negative culture|14d bismuth quadruple therapy based on previous medication history.
89386900|NCT03565484|Other|Salvage therapy for failed eradication|14d bismuth quadruple therapy for salvage treatment.
89386901|NCT01336127|Experimental|occupational therapy|10 weeks occupational therapy according to a protocol (OTiP protocol) based on the Dutch guidelines of occupational therapy in Parkinson's disease
89386902|NCT01336127|No Intervention|No occupational therapy|Patients and their caregivers in the control group will have no occupational therapy intervention until their last measurement has taken place (6 months).
89386903|NCT03565406|Experimental|Unresectable Stage III or Stage IV Melanoma|
88862463|NCT00554970|Other|Treatment 3 then Treatment 4|Subjects received Treatment 3 in period 1 followed by a 7 day washout period and then Treatment 4 period 2. Treatment 3 was a single dose of MAP0010 high dose delivered by nebulization twice daily for 7 days as per protocol. Treatment 4 was a single dose of Pulmicort Respules® 0.5mg dose delivered by nebulization twice daily for 7 days as per protocol.
88862464|NCT00554970|Other|Treatment 4 then Treatment 3|Subjects received Treatment 4 in period 1 followed by a 7 day washout period and then Treatment 3 in period 2. Treatment 3 was a single dose of MAP0010 high dose delivered by nebulization twice daily for 7 days as per protocol. Treatment 4 was a single dose of Pulmicort Respules® 0.5mg dose delivered by nebulization twice daily for 7 days as per protocol.
88862465|NCT00520884|Placebo Comparator|Healthy 70+ Women Placebo Infusion|Healthy and Frail Women 70 and Older Receive a 3 hour Placebo Infusion of Saline administered in a stepwise fashion in amounts equivalent to the ghrelin infusion.
89185000|NCT00790907|Experimental|Open label fondaparinux background and standard dose UFH|Subjects indicated for PCI and randomized to receive standard dose UFH
89185001|NCT00790907|Experimental|Open label fondaparinux background and low dose UFH|Subjects indicated for PCI and randomized to receive low dose UFH
89185002|NCT00790907|Other|Open label fondapaparinux|Subjects not indicated for PCI and not randomized
89386904|NCT01333163|Active Comparator|GLP-1|
89386905|NCT01333163|Placebo Comparator|Placebo|
89386906|NCT04734379|Experimental|Treatment|Oral fasudil 180 mg/day
89386907|NCT03565250|Experimental|ADHD patients|children aged 8-12 ans with ADHD
89386908|NCT03565250|Active Comparator|control|children aged 8-12 ans without ADHD
89386909|NCT05352620|Experimental|Implant assisted maxillary overdenture|Horseshoe Maxillary Complete overdenture construction (Stabilizing and connecting the Smart Box housing)
89386910|NCT04163887|Other|laparoscopic liver resection|Laparoscopy allows some surgical procedures to be performed through small incisions that enable the operator to access the abdominal cavity, often at the pubic area, and surgical instruments are introduced through these small incisions. This technique avoids large abdominal incisions and significantly reduces the duration of hospitalization.
89386911|NCT04163887|Other|open liver resection|standard of care
89386912|NCT01333241|Experimental|Lifestyle behavior intervention group|The 6-month lifestyle behavior intervention includes group education and individual teaching and coaching.
89386913|NCT01333241|Sham Comparator|Control group|Disaster Preparedness/Home Safety group education and teaching
89386914|NCT03565094|Experimental|Lu AF28996|"Lu AF28996 solution, cohort depending dose~Part A:~Cohort 1: single oral dose of Lu AF28996~Cohorts 2-6: two single ascending oral doses of Lu AF28996 with a washout in between~Possibility of 4 additional cohorts (Cohorts 7 to 10), allowing for the investigation of a potential 13 additional subjects~Part B: 8 subjects (randomised to one of four treatment sequences)"
89386915|NCT01339871|Experimental|Pazopanib + Vorinostat|Starting doses Pazopanib 400 mg orally daily and Vorinostat 100 mg orally daily
89386916|NCT01339949|Experimental|24 Gy radiation|
89386917|NCT01339949|Sham Comparator|Sham 24 Gy radiation|
89386918|NCT04693429|Experimental|PRO-172|PRO-172 Ophthalmic Solution QID (four times per day). Single arm.
89386919|NCT05353712|Experimental|Group T: ABCDEF|Participants will receive all six blind-coded samples, in the order A, B, C, D, E, F. There will be a minimum of 7 days washout between samples.
89386920|NCT05353712|Experimental|Group V: FABCDE|Participants will receive all six blind-coded samples, in the order F, A, B, C, D, E. There will be a minimum of 7 days washout between samples.
89185003|NCT02569983||Observational cohort|Observational study - all suspected or confirmed ovarian cancer patients
88862466|NCT00520884|Placebo Comparator|Frail 70+ Women Placebo Infusion|Frail Women 70 and Older Receive a 3 hour Placebo Infusion of Saline administered in a stepwise fashion in amounts equivalent to the ghrelin infusion.
88862467|NCT00520884|Active Comparator|Healthy 70+ Women Ghrelin Infusion|Healthy Women 70 and Older are administered a 3 hour graded Ghrelin Infusion (the first hour of the ghrelin infusion a dose of 2.5 pmol/kg/min, increased to a dose of 5.0 pmol/kg/min for one hour, and then increased to the dose of 10 pmol/kg/min for the final hour of the infusion).
88862468|NCT00520884|Active Comparator|Frail 70+ Women Ghrelin Infusion|Frail Women 70 and Older are administered a 3 hour graded Ghrelin Infusion (the first hour of the ghrelin infusion at a dose of 2.5 pmol/kg/min, increased to a dose of 5.0 pmol/kg/min for one hour, and then increased to the dose of 10 pmol/kg/min for the final hour of the infusion).
88862469|NCT00521352|Active Comparator|Active rTMS|Active Repetitive Transcranial Magnetic Stimulation (rTMS)
88862470|NCT00521352|Sham Comparator|Sham rTMS|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)
88862471|NCT00521976||Chest pain|Men and women admitted with chest pain and suspected acute coronary syndrome (ACS).
88862472|NCT00523302|Active Comparator|Active TMS|Since cortical stimulation can be performed non-invasively by active Transcranial Magnetic Stimulation (TMS), Participants in the active TMS group, receive five 20 minute active TMS treatment sessions per week for two weeks.
88862473|NCT00523302|Sham Comparator|Sham TMS|To prevent unwanted cortical activation, Sham TMS will be employed in the Sham TMS group. For the Sham TMS group, a specially designed sham TMS coil will be used for all sham conditions. This sham TMS coil produces auditory signals identical to active TMS coils but is shielded so that actual stimulation does not occur. This approach is currently the state-of-the-art approach to sham TMS procedures and is employed in high-quality clinical TMS trials. Participants in the sham TMS group receive five 20 minute Sham TMS treatment sessions per week for two weeks.
89386921|NCT05353712|Experimental|Group W: EFABCD|Participants will receive all six blind-coded samples, in the order E, F, A, B, C, D. There will be a minimum of 7 days washout between samples.
88862474|NCT00523614||1: Cases|
88862475|NCT00523614||2: Controls|
88862476|NCT00524472|Experimental|Hyperinsulinemic-normoglycemic clamp|Patients will be randomized to receive the hyperinsulinemic-normoglycemic clamp titrating the blood glucose to 80-110 mg/dL.
88862477|NCT00524472|Other|Insulin at the standard of care levels|Group B will be administered insulin at the standard of care levels established by the participating institution.
88862478|NCT00524940|Experimental|Study Group|
88862479|NCT00525174|Active Comparator|Patching|2 hours daily patching of the sound eye plus one hour near activities while patching
88862480|NCT00525174|Active Comparator|Bangerter filters|Bangerter filter worn on sound eye spectacles lens full time plus at least one hour near activities
88862481|NCT04166916|Active Comparator|Slow waves enhancing acoustic stimulation|During non-rapid eye movement (NREM) sleep, acoustic stimuli will be played to increase slow wave amplitude.
88862482|NCT04166916|Sham Comparator|SHAM: no application of acoustic stimuli|During NREM sleep no acoustic stimuli will be played.
88862483|NCT04166916|Active Comparator|Slow waves decreasing acoustic stimulation|During NREM sleep acoustic stimuli will be played to decrease/modulate slow waves amplitude in a dose-dependent way (e.g. less pronounced than arm 1).
88862484|NCT00555048|Experimental|Alemtuzumab|Alemtuzumab given together with busulfan and cyclophosphamide followed by a donor stem cell transplant.
88862485|NCT00525798|Active Comparator|1|SMC021 - Oral Calcitonin
88862486|NCT00525798|Placebo Comparator|SMC021- Placebo|SMC021 - placebo
88862487|NCT00555360|Experimental|Arm 1|Veterans with heart failure that can identify an out-of-home informal caregiver
88862488|NCT00555360|Active Comparator|Arm 2|Veterans with heart failure that can identify an out-of-home informal caregiver
88862489|NCT00525876|Experimental|Matched Sibling Transplant|Allogeneic Stem Cell Transplantation With Rituximab Containing Nonablative Conditioning Regimen: Cyclophosphamide 750 mg/m^2 given intravenously on Day -3, 4 hours after completion of Fludarabine 30 mg/m^2 given intravenously on Days -5 and -3 before transplantation. Rituximab 375 mg/m^2 given intravenously on Days -13, -6 before transplantation and Days 16, 8 after transplantation.
88862490|NCT00525876|Experimental|Allo MUD & MM|Allo MUD & MM = Allogeneic Stem Cell Transplantation, Matched unrelated donor or mismatched sibling donor transplantations: Cyclophosphamide 1000 mg/m^2 given intravenously on Day -3, 4 hours after completion of Fludarabine 30 mg/m^2 given intravenously on Days -5 and -3 before transplantation. Rituximab 375 mg/m^2 given intravenously on Days -8, -1 before transplantation and Days 6, 13 after transplantation. Alemtuzumab 15 mg per day given intravenously days 1 through 3 after transplantation.
88862491|NCT00555750|Experimental|eszopiclone (3mg)|active medication (eszopiclone 3mg tablet) by mouth nightly 30 min before bed
88862492|NCT00555750|Placebo Comparator|placebo|identical placebo tablet by mouth nightly 30 min before bed
88862493|NCT00526188|Experimental|Gadoxetic Acid Disodium (Primovist, BAY86-4873)|Bolus injection of 0.025 mmol/kg body weight (0.1 ml/kg BW) of Gadoxetic Acid Disodium (Primovist, BAY86-4873). Single i.v. injection during MRI procedure, with one contrast-enhanced MRI procedure per patient
88862494|NCT00556140|Experimental|Major Depression with Psychotic Features|
88862495|NCT00527124|Experimental|Arm I|Patients receive oral cediranib maleate once daily on days 1-21, docetaxel IV over 1 hour on day 1, and oral prednisone twice daily on days 1-21.
88862496|NCT00527124|Active Comparator|Arm II|Patients receive docetaxel and prednisone as in arm I.
88862497|NCT00527592|Experimental|Travoprost|Travoprost assigned to one eye, with latanoprost assigned to the fellow eye for intra-individual control. One drop, single dose. The eye, and the order in which the first test medicine was instilled (either travoprost or latanoprost), was randomly assigned.
88862498|NCT00527592|Active Comparator|Latanoprost|Latanoprost assigned to one eye, with travoprost assigned to the fellow eye for intra-individual control. One drop, single dose. The eye, and the order in which the first test medicine was instilled (either travoprost or latanoprost), was randomly assigned.
88862499|NCT02121912|Experimental|FPH Pilairo Q CPAP mask|The Sleep Technician will fit the FPH Pilairo Q CPAP mask to the participant.
88862500|NCT02121912|Active Comparator|Any other market released nasal or nasal-pillow CPAP mask|The Sleep Technologist will fit the participant with any market released nasal or nasal-pillow CPAP mask
89386922|NCT05353712|Experimental|Group X: DEFABC|Participants will receive all six blind-coded samples, in the order D, E, F, A, B, C. There will be a minimum of 7 days washout between samples.
88862501|NCT00556452|Experimental|Clo/BU4|"Study will start at the 2nd dose level of three Clofarabine levels, in combination with Busulfan. The Clofarabine level that each subsequent patient is treated at is determined by a method using continual reassessment.~After pre-conditioning, subjects will receive a peripheral blood stem cell transplant."
89386923|NCT05353712|Experimental|Group Y: CDEFAB|Participants will receive all six blind-coded samples, in the order C, D, E, F, A, B. There will be a minimum of 7 days washout between samples.
89386924|NCT05353712|Experimental|Group Z: BCDEFA|Participants will receive all six blind-coded samples, in the order B, C, D, E, F, A. There will be a minimum of 7 days washout between samples.
89386925|NCT01336283|Active Comparator|COPD with emphysema|Analyze what type of training is more appropriate and beneficial as the patient characteristics that apply to you.
89386926|NCT01336283|Active Comparator|COPD non-emphysema|compare the efficacy of endurance, strength, and the combination of strength and endurance exercise training in patients with COPD.
89386927|NCT03916549|Experimental|Group 1|The patients with bowel dysfunction following low anterior resection performed at least 1 year ago will undergo acupuncture. The acupuncture procedure is performed by one well trained person, 1 time per week in total of 10 weeks on the same day time. Sterile, disposable, stainless steel acupuncture needles (40x0.25 mm diameter) were inserted to corporal acupoints, with initial gentle stimulation by quick rotation of 1080°, after then leaving needle in located place for twenty minutes. Needling deep - 0.5-1 cm. If the intent was to invigorate - the needle was inserted to the flow of energy; if harmonization needed - the needle was placed perpendicular to the point flow of energy; if sedation was needed, needles were placed against to the flow of energy on channel. The selection of acupoints was based according by traditional Chinese medicine, literature findings.
89386928|NCT05353634||Infected patients with mNGS|If the patient is suspected of infection, mNGS is performed for testing.
89386929|NCT05353634||Infected patients without mNGS|The patient is suspected of being infected, and no mNGS test was performed, only other tests were performed.
89386930|NCT03564704|Experimental|PDT-ALL-LBL|The intervention of PDT-ALL-LBL consists of diagnostic test (bone marrow aspiration, flow immunophenotyping, karyotyping，FISH, NGS, Flow-MRD, PET-CT scan), induction regimen (chidamide, dexamethasone, vincristine, cyclophosphamide, idarubicin, pegaspargase), consolidation regimen (chidamide, prednisone, cytarabine, methotrexate, cyclophosphamide, etoposide, adriamycin, 6-mercaptopurine, pegaspargase), MRD assessment and maintenance regimen (chidamide, prednisone, vincristine, methotrexate, 6-mercaptopurine), intrathecal injection chemotherapy (methotrexate, cytarabine, dexamethasone), radiation therapy (for mediastinum- and/or central nervous system-involved lymphoma/leukemia) and allogeneic hematopoietic stem cell transplantation for patients with donor.
89386931|NCT03564548|Experimental|PPP001|Inhaled cannabinoids (PPP001)
89386932|NCT03564548|Active Comparator|Morphine sulfate or Hydromorphone or Oxycodone|Oral morphine sulfate or hydromorphone or oxycodone at the previous stabilized dosage
89386933|NCT03159455|Experimental|BI 1467335|
89386934|NCT03159455|Placebo Comparator|Placebo|
89386935|NCT05353010|Experimental|Period 1: A; Period 2: B and C|A: Oral Administration of Tacrolimus 5mg once / B: Oral Administration of IN-A001(Tegoprazan) 50mg QD for 7 days / C: Oral Administration of IN-A001(Tegoprazan) 50mg + Tacrolimus 5mg once
89386936|NCT05352854|Experimental|Health control|emmetropia/low myopia (equivalent spherical lens > -3.00d, astigmatism ≤ 1.5d), best corrected visual acuity ≥1.0
89386937|NCT05352854|Experimental|High myopia|Equivalent spherical lens ≤-6.00D or axial length ≥26.5mm
89386938|NCT05352854|Experimental|Primary open angle glaucoma|emmetropia/low myopia (equivalent spherical lens > -3.00d, astigmatism ≤ 1.5d), diagnosed as POAG
89386939|NCT05352854|Experimental|HM-POAG|Equivalent spherical lens ≤-6.00D or axial length ≥26.5mm，diagnosed as POAG
89386940|NCT01841177|Experimental|Therapeutic Drug Monitoring|The intervention is [1] regular measurement of milrinone levels; [2]physician feedback of plasma levels in experimental arm by the ICU pharmacist ( this process currently occurs for other drugs such as vancomycin).
88862502|NCT03158376|Experimental|gabapentin group|"the day before surgery : gabapentin 400 mg orally~preoperatively (2 hours before surgery) : 3 capsules each containing 400 mg gabapentin (total gabapentin dose 1200 mg) and intravenous infusion of 50 ml of normal saline solution~postoperative day 1 to 10 : 400 mg x 3 ( gabapentin 1200 mg daily)"
88862503|NCT03158376|Placebo Comparator|placebo group|"The day before surgery: 1 placebo capsule orally~preoperatively (2 hours before surgery) : 3 placebo capsules and intravenous infusion of 75 mg hydroxyzine~postoperative day 1 to 10: 1 placebo capsule x 3"
89386941|NCT01841177|Active Comparator|Standard Care|Standard care involves titration of milrinone infusion based on clinical examination by the treating team. The control group will receive standard care: with milrinone dose modification on clinical assessment. Control patients will have milrinone plasma levels drawn but not analysed until the end of the study.
88862504|NCT01797510|Experimental|Coaching|Interventional web based coaching study
88862505|NCT01797510|No Intervention|Usual Care|
88862506|NCT02126748|Experimental|Intrapulmonary Percussive Ventilation|20 min of IPV administered to the patient inhalation 4ml hypertonic saline 3% 3x/day
88862507|NCT02126748|Active Comparator|Assisted Autogenic Drainage|20 min of AAD administered to the patient inhalation 4ml hypertonic saline 3% 3x/day
88862508|NCT02126748|No Intervention|control|20 min of bouncing administered tot the patient inhalation 4ml hypertonic saline 3% 3x/day
88862509|NCT05622630|Active Comparator|Four-cell bathroom|Four-cell bath:Treatment with direct current
89003344|NCT05439421|Experimental|Without Claim Don't blow smoke - blow clouds|Package or digital marketing advertisement without claim of interest
89386942|NCT01336361||Physical Therapists|Physical Therapists who are members of the American Physical Therapy Association (APTA) and live in the United States .
89386943|NCT05184647||Children under 18 years olds with total splenectomy for non Malignant hemoglobinopathie|Children under 18 years olds with total splenectomy for non Malignant hemoglobinopathie
89386944|NCT05184647||Children under 18 years olds with partial splenectomy for non Malignant hemoglobinopathie|Children under 18 years olds with partial splenectomy for non Malignant hemoglobinopathie
89386945|NCT02838134|Experimental|Group A: Deep Neuromuscular blockade|An extra bolus of rocuronium after intubation followed by infusion
88862510|NCT05622630|Active Comparator|Gravel bath|Gravel bath:In this procedure, the patients are given a footbath with heated stones (granules) of different sizes for a period of 20 minutes, during which the patients are encouraged to move their feet (and, if applicable, hands) evenly.
88862511|NCT01797900|Experimental|Inductive + concurrent chemotherapy|Inductive chemotherapy :paclitaxel 175mg/m2 d1+ cisplatin 80mg/m2d1, every 21 days for two cycles concurrent chemotherapy:cisplatin 80mg/m2 on week 1, 4, 7 radiotherapy: IMRT
88862512|NCT01797900|Active Comparator|concurrent + adjuvant chemotherapy|concurrent chemotherapy: cisplatin 80 mg/m2, on week 1, 4, 7 adjuvant chemotherapy: paclitaxel 175mg/m2 + cisplatin 75mg/m2, every 21 days for 4 cycles radiotherapy: IMRT
88862513|NCT03746808|Placebo Comparator|EMA only|Phase I will use smartphones and passive sensing to monitor geolocation, psychosocial variables (e.g., stress, urge to drink), and alcohol use in a group of 80 homeless adults with an AUD who are receiving shelter-based treatment.
88862514|NCT03746808|Active Comparator|EMA + App/Treatment Messages|Phase III will pilot test the newly developed app for utility, satisfaction, and preliminary effectiveness in a group of 40 homeless adults with an AUD who are receiving shelter-based treatment. The investigators will compare Phase III participants (i.e., received Metrocare, EMAs, and tailored treatment messages) to Phase I participants (i.e., received Metrocare and EMAs only) to examine the preliminary effectiveness of the app.
88862515|NCT04747704|Experimental|Intervention|Participants receiving Three-Principles Counseling
88862516|NCT05622552|Active Comparator|active group|"tDCS stimulation, which was performed once a day sessions of active anodal tDCS to the right dorsolateral prefrontal cortex and cathode to the left OFC (2 mA, 20 minutes, 10 sessions over 2 weeks).~In the active group, current stimulations were gradually ramped up to 2 mA (in 30 seconds) intensity for 20 minutes, once a day, for 10 days."
88862517|NCT05622552|Sham Comparator|sham group|"tDCS stimulation, which was performed once a day sessions of sham anodal tDCS to the right dorsolateral prefrontal cortex and cathode to the left OFC (2 mA, 20 minutes, 10 sessions over 2 weeks).~For sham stimulation, the procedure was identical, except that the current was gradually ramped up to 2mA and rapidly down to zero (in 30 seconds), thus leading to the same initial sensations of tDCS."
88862518|NCT03572790|Experimental|Prucalopride|
88862519|NCT03572790|Placebo Comparator|Placebo|
88862520|NCT05622474|Experimental|IC plus CC plus IMRT|Induction chemotherapy followed by Intensity-modulated radiotherapy plus concurrent chemotherapy
88862521|NCT05622474|Active Comparator|CC plus IMRT|Intensity-modulated radiotherapy plus concurrent chemotherapy alone
88862522|NCT03428802|Experimental|Treatment (pembrolizumab)|Participants receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Participants with disease progression may continue pembrolizumab for up to 1 year.
88862523|NCT03379194|Experimental|'Antibiotic stewardship program'|Physicians receive quarterly over 24 months, first in January 2018 postal mail a feedback on their antibiotic prescriptions and updated antibiotic resistance information from the community. With the first letter, educational material, evidence-based guidelines for conditions leading to most outpatient prescriptions in primary care and leaflets for on using antibiotics wisely are provided. Additional material is made available on a study website that can be accessed by each physician in the intervention group by an unique access code.
88862524|NCT03379194|No Intervention|Control|No intervention
88862525|NCT02319486|Experimental|CEV with/without carboplatin|CEV chemotherapy(CEV Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first six months) together with/without 20mg/2ml carboplatin periocular injection
88862526|NCT03271554||Alectinib|Participants with ALK-positive, locally advanced or metastatic non-small cell lung cancer, who are treated with alectinib in accordance with local clinical practice and local labeling, are observed in this study.
88862527|NCT03093636|Experimental|Continuous Glucose Monitor (CGM)+Decision Support System (DSS)|Continuous Glucose Monitor (CGM)+Decision Support System (DSS) study participants will use the inControl Advice App, study insulin, and study CGM at home for 12 weeks.
88862528|NCT03093636|Placebo Comparator|Continuous Glucose Monitor (CGM) alone|Continuous Glucose Monitor (CGM) alone study participants will use study insulin and the study CGM alone at home for 12 weeks.
88862529|NCT05622162|Experimental|Interventional and Comparator|The subject participation in the study consists from performing of one non-contrast enhanced PET/CT with Investigational Product (18F-JK-PSMA-7) and of one PET/CT with Comparator (18F-Fluorocholine) This sequence of administration is established in advance as the organizational model, linked to the availability and management of the radiopharmaceutical, not allow to perform a randomization.
89003345|NCT05439421|Experimental|With Claim Contains natural, unwashed tobacco leaf|Package or digital marketing advertisement containing claim of interest
89003346|NCT05439421|Experimental|Without Claim Contains natural, unwashed tobacco leaf|Package or digital marketing advertisement without claim of interest
89185004|NCT03109353|Experimental|ALA-ECP|Extracorporeal photopheresis (ECP) with 5-aminolevulinic acid replacing psoralen
89185005|NCT04066569|Active Comparator|OGTT Tests and Placebo Test|Patients with acromegaly
89185006|NCT04066569|Active Comparator|OGTT Tests|age and sex matched healthy volunteers
89386946|NCT02838134|Sham Comparator|Group B: Moderate neuromuscular Blockade|Moderate neuromuscular Blockade No additional rocuronium after intubation.
89386947|NCT03150589|Experimental|SB11 (Proposed ranibizumab biosimilar)|
89386948|NCT03150589|Active Comparator|Lucentis (ranibizumab)|
89386949|NCT05708378|Experimental|Rocker board training|"Stretching Exercises (Heel drop, heel raises, Hamstring stretch, quad stretch, half kneel, IT band stretch, half squats). Hold the stretch for 20 seconds and repeat 10 times.~Isometric Strengthening Exercises of calves, hamstrings, quads, hip flexors, gluteus, dorsiflexors and plantarflexors. Hold for 20 seconds and repeat 10 times.~Pelvic Bridging Exercises. Trunk control exercises on Rocker Board in standing position first in medio-lateral direction for 10 min and then in anterio-posterior direction for 10 min with breaks in between."
88862530|NCT00546390|Experimental|Ischemic Preconditioned Group (rIP)|A 15-cm sterile blood pressure cuff was placed around the right thigh and connected to the inflating device, and the patient was draped obscuring the visibility of the cuff. Subsequently, the patient was randomly allocated (by opening of an envelope) to RIPC consisting of four 5-min cycles of lower limb ischemia-reperfusion induced by a tourniquet inflated to 300 mmHg
89386950|NCT05708378|Other|Stable surface training|"Stretching Exercises (Heel drop, heel raises, Hamstring stretch, quad stretch, half kneel, IT band stretch, half squats). Hold the stretch for 20 seconds and repeat 10 times.~Strengthening Exercises calves, hamstrings, quads, hip flexors, gluteus, dorsiflexors and plantarflexors. Hold for 20 seconds and repeat 10 times.~Pelvic Bridging Exercises. Trunk balance exercise (flexion, extension of lower and upper trunk, rotation of lower and upper trunk, forward and lateral reach) on plain surface."
89386951|NCT03519217||Diabetic patients under the age of one year|All cases which are diagnosed with diabetes mellitus under the age of one year will be subjected for blood glucose level, glycated haemoglobin, fasting C-peptide, anti-insulin and anti-islets auto-antibodies, and who have negative tests for anti-insulin and anti-islets auto-antibodies, will be subjected to do genetic study for KCJN11 and ABCC8
89386952|NCT05340452|Experimental|Test Group|Single oral dose of 20 ml of Test (Klaribact 125mg/5ml Suspension) will be given with the aid of graduated cup.
89386953|NCT05340452|Active Comparator|Reference Group|Single oral dose of 20 ml of Reference (Klaricid 125mg/5ml Suspension) will be given to volunteers with the aid of graduated cup.
89386954|NCT01344733||MDD|Patients with treatment resistant major depressive disorder will be evaluated in order to assess the presence of hypomanic symptoms as cause of resistance.
89386955|NCT02835092|Active Comparator|Self-directed Control|
89386956|NCT02835092|Experimental|Take Shape For Life Program|
89386957|NCT02835092|Experimental|Medifast Direct Program|
89386958|NCT03564392|Experimental|Treatment|Ten weekly modules will be delivered through an e-learning platform (i.e., Coursesites). Each module includes a video presentation of material synchronized with a slideshow illustrating session material with interactive features, and directed assignments to be completed throughout the week. At the end of every two weeks, a brief (i.e., 20 min) telephone call with a member of the study team will be scheduled to discuss and clarify the content of the session, discuss how the participant utilized skills demonstrated in the session, problem-solve difficulties in utilizing the skills, and review homework. Participants will be required to weigh themselves weekly (data will be transferred wirelessly to the laboratory) and feedback regarding weight losses will be provided during the phone call. The interventionist will provide individualized feedback on food records via email.
89386959|NCT03564392|No Intervention|Wait List Control|The Wait-List Control (WLC) condition does not receive any intervention during the study period. They receive the intervention after completing the study.
89386960|NCT03145207|Other|name brand patch|name brand lidocaine patch
89386961|NCT03145207|Other|generic patch|generic lidocaine patch
88862531|NCT00546390|No Intervention|No Cuff|No rIP
89386962|NCT03145207|Other|name brand patch-early|name brand lidocaine patch-early
89386963|NCT03145207|Other|name brand patch-late|name brand lidocaine patch-late
89386964|NCT03145207|Other|generic patch-early|generic lidocaine patch-early
89386965|NCT03145207|Other|generic patch-late|generic lidocaine patch-late
88862532|NCT00860652|Experimental|Adjuvant Radiotherapy (RT)|Adjuvant Radiotherapy (64Gy in 32 Fractions to the prostate bed)
89386966|NCT03145207|Other|both patches|brand name and generic lidocaine patch
89386967|NCT02836652|Experimental|Treatment Arm|Warfarin (INR Target 2.0-2.5, median 2.25, per standard of patient care) + placebo (1 pill/day) post HeartMate II implant
89386968|NCT02836652|Active Comparator|Control Arm|Warfarin (INR Target 2.0-2.5, median 2.25, per standard of patient care) + acetylsalicylic acid (ASA) therapy (81mg/day) post HeartMate II implant
89386969|NCT04335175||Tourette Syndrome|Individuals previously diagnosed with Tourette syndrome (TS). Participants must be 18 years of age or older.
89386970|NCT04335175||Obsessive Compulsive Disorder|Individuals previously diagnosed with obsessive compulsive disorder (OCD). Participants must be 18 years of age or older.
89386971|NCT04335175||Healthy Controls|Individuals with no past or current neurologic or psychiatric illness. Participants must be 18 years of age or older.
88862533|NCT00860652|Experimental|Active Surveillance with Early SalvageRT|Active Surveillance with Early Salvage Radiotherapy
88862534|NCT04039074|Experimental|Integrative Yoga|"A 12-week Integrative Yoga intervention which has meditative and psycho-educational components corresponding to traditional yoga practice."
88862535|NCT04039074|Active Comparator|Iyengar yoga|A 12-week established, predominantly body-oriented yoga intervention (Iyengar yoga).
88862536|NCT04039074|Active Comparator|Mindfulness|A 12-week mindfulness intervention designed for the healthy handling of stress.
88862537|NCT00556842|Active Comparator|1|Participants will undergo total hip arthroplasty.
88862538|NCT00556842|Active Comparator|2|Participants will undergo hemi-arthroplasty.
89185007|NCT04071795|Experimental|Opt Out|Training and Academic Detailing
89185008|NCT04071795|Experimental|Opt In|Training and Academic Detailing
89185009|NCT04066179|Experimental|Prednisolone+G-CSF|Prednisolone 40 mg/day for initial 7 days G-CSF300 microgram daily for 7 days
88862539|NCT00558012|Experimental|Active Medication Group|One-time dose: Intravenous Zoledronic Acid 5.0 mg; Vitamin D (800 IU/daily); Calcium 1200 mg/daily (supplement plus diet)
89185010|NCT04066179|Active Comparator|Prednisolone|Prednisolone 40 mg/day for 7 days
89185011|NCT04066179|Experimental|Granulocytes-Colony Stimulating Factor|Granulocytes-Colony Stimulating Factor 300 mcg for 7 days followed by 300 mcg every 3 days
88862540|NCT00558012|Placebo Comparator|Placebo|One-time dose: intravenous saline; Vitamin D (800 IU/daily); 1200 mg calcium (supplement plus diet)
88862541|NCT00558246|Experimental|I|On same patient, one breast is randomized to control and one breast is randomized to experimental arm. Patient is own control.
88862542|NCT00558246|Active Comparator|II|On same patient, one breast is randomized to control and one breast is randomized to experimental arm. Patient is own control.
88862543|NCT00558792|Experimental|Isovue 370, 70 mL|iopamidol injection 370, 70 mL
88862544|NCT00558792|Experimental|Isovue 370, 80 mL|iopamidol injection 370, 80 mL
88862545|NCT00558792|Experimental|Isovue 370, 90 mL|iopamidol injection 370, 90 mL
88862546|NCT03884634||Dabir Microsurface Overlay Group|Patients undergoing cardiac surgery with the Dabir Micropressure Overlay in place and turned ON (in addition to standard operating room table mattress and heating/cooling gel pad).
88862547|NCT03884634||Control Group|Patients undergoing cardiac surgery with the Dabir Micropressure Overlay in place and turned OFF (in addition to standard operating room table mattress and heating/cooling gel pad).
88862548|NCT00561600|Active Comparator|A|ASR™-XL Modular Acetabular Cup System stem
88862549|NCT00561600|Active Comparator|B|Pinnacle™ acetabular shell, with a 28mm or 36mm ULTAMET® metal liner, and a 28mm or 36mm Articul/eze M head.
88862550|NCT00561834|Experimental|Ranibizumab|To determine the mean change in best corrected visual acuity (BCVA) using the Early Treatment Diabetic Retinopathy Study testing system at 6 months in NAION patients treated as needed (PRN) with ranibizumab.
88862551|NCT04388202|Experimental|Sertraline|Sertraline 100-200 mg daily for 8 weeks
88862552|NCT04388202|Active Comparator|Escitalopram|Escitalopram 10-20 mg daily for 8 weeks
88862553|NCT02128074|Experimental|KRX-0502|KRX-0502 (ferric citrate)
88862554|NCT02128230|Experimental|Total Therapy 5b|Induction, optional bridging, first transplant, optional bridging, inter-therapy, optional bridging, second transplant, optional bridging, consolidation, maintenance
88862555|NCT03416244|Experimental|A: Nivolumab / Ipilimumab combination treatment|Nivolumab 240 mg fixed dose IV every 2 weeks; Additionally, after 7 week safety assessment Ipilimumab 1mg/kg IV every 6 weeks
88862556|NCT03416244|Experimental|B. Nivolumab monotherapy|Nivolumab 240 mg fixed dose IV every 2 weeks
88862557|NCT05560776|Experimental|2 passes per target on EBUS|
88862558|NCT05560776|Experimental|3 passes per target on EBUS|
88862559|NCT05560620|Experimental|Sleep Deprivation and Caffeine Intervention|Participants randomized into the sleep deprivation group and then randomized into receiving caffeinated coffee the next morning. Participant is blinded to the caffeine intervention.
88862560|NCT05560620|Sham Comparator|Sleep Deprivation and no Caffeine intervention|Participants randomized into the sleep deprivation group and then randomized into receiving de-caffeinated coffee the next morning. Participant is blinded to the caffeine intervention.
88862561|NCT05560620|Active Comparator|Control and Caffeine|Participants randomized into the control group, who will sleep regularly, and then randomized into receiving caffeinated coffee the next morning. Participant is blinded to the caffeine intervention.
88862562|NCT05560620|Sham Comparator|Control and No Caffeine|Participants randomized into the control group, who will sleep regularly, and then randomized into receiving de-caffeinated coffee the next morning. Participant is blinded to the caffeine intervention.
88862563|NCT04388124|Placebo Comparator|Placebo|Patient will receive placebo for 56 days: 2 capsules of 62.5 mg per day for 27 days +/-1 day, 2 capsules of 125 mg per day for 27 days +/-1 day.
88862564|NCT04388124|Experimental|Bosentan|Patient will receive Bosentan for 56 days: 2 capsules of 62.5 mg per day for 27 days +/-1 day, 2 capsules of 125 mg per day for 27 days +/-1 day.
88862565|NCT05560152|Experimental|Experimental group|"Experimental: Experimental group Subjects will receive Yiqihuayu Decotion, combined with guidelines-based standard care.~Interventions:~Drugs: Yiqihuayu Decotion Other: Standard care (e.g. antiplatelet drugs and statins)"
88862566|NCT05560152|No Intervention|Control group|"No Intervention: Control group Subjects will receive guidelines-based standard care.~Interventions:~Other: Standard care (e.g. antiplatelet drugs and statins)"
88862567|NCT02130258|Other|>30% Pain Relief|All subjects have radicular pain and are scheduled to receive an epidural steroid injection (ESI) as a treatment. The ESI treatment is conducted by the subject's clinical physician and is not given as part of the research study procedures. Quantitative Sensory Testing (QST) will be conducted before and after the ESI treatment. QST consists of hot and cold temperature testing using the QST device. This group of subjects received greater than 30% pain relief.
88862568|NCT02130258|Other|<30% Pain Relief|All subjects have radicular pain and are scheduled to receive an epidural steroid injection (ESI) as a treatment. The ESI treatment is conducted by the subject's clinical physician and is not given as part of the research study procedures. Quantitative Sensory Testing (QST) will be conducted before and after the ESI treatment. QST consists of hot and cold temperature testing using the QST device. This group of subjects received less than 30% pain relief.
89003347|NCT05439421|Experimental|With Claim We only use ingredients which are FDA approved|Package or digital marketing advertisement containing claim of interest
89003348|NCT05439421|Experimental|Without Claim We only use ingredients which are FDA approved|Package or digital marketing advertisement without claim of interest
89003349|NCT05439421|Experimental|With Claim Passing flavored tobacco smoke through water cools and purifies it|Package or digital marketing advertisement containing claim of interest
89003350|NCT05439421|Experimental|Without Claim Passing flavored tobacco smoke through water cools and purifies it|Package or digital marketing advertisement without claim of interest
88862569|NCT03172416|Other|Oxaliplatin|"3+3 dose escalation of oxaliplatin~This is a single arm phase I trial in a 3 + 3 dose escalation and cohort expansion design evaluating the safety and tolerability of PIPAC using oxaliplatin.~The pre-planned dose levels of oxaliplatin are 45mg/m2 (Cohort 1), 60mg/m2 (Cohort 2), 90mg/m2 (Cohort 3),120mg/m2 (Cohort 4) and 150mg/m2 (Cohort 5) administered as PIPAC. Successive cohorts of patients (3 participants/cohort) will be enrolled and started on a fixed dose of oxaliplatin. The protocol specifies oxaliplatin 45mg/m2 once every 6 weeks for Cohort 1. Dose escalation continues until dose-limiting toxicities (DLT) are observed in one-third of participants. If no DLT occurs, the next cohort will be enrolled at the next planned dose level. If 1 DLT occurs in a cohort, another 3 patients will be treated with the same dose level.~Oxaliplatin every 6 weeks with IV nivolumab every 2 weeks~PIPAC oxaliplatin at 90mg/m2 every 6 weeks with IV nivolumab at 240mg every 2 weeks"
89185012|NCT04110119|Active Comparator|Control: Drug-Only Group|Patients with acute lower-back pain who have undergone routine conventional drug treatment at the first visit to the emergency department (49 patients). The drug treatment consists of analgesic-anti-inflammatory (diclophenac sodium 75 mg IM) and myorelaxant (thiocolchicoside 4 mg IM), administered only once.
88862570|NCT03033420|Experimental|Intervention group|A smartphone-based monitoring system including a) an integrated feedback loop between patients and clinicians and b) context-aware CBT modules
88862571|NCT03033420|No Intervention|Control group|Treatment-as-usual
88862572|NCT01798212|Other|full thickness gastroplication|
88862573|NCT05560074|Experimental|Buzzy|Buzzy®: It is a 8x5x2.5 cm sized, noninvasive device used for pain control in adults and children, developed by the pediatrician Ammy Baxter, with a plastic battery and vibration motor. A cold ice pack is placed under Buzzy. It has a local cold application and vibration effect. It is placed 3~5 cm above the injection site for 15~30 sec before and during the procedure, making local cold application and vibrations. One should be sure about the definite contact of Buzzy® with the skin. The ice pack is kept in a deep freezer and placed in the device before the procedure. After the procedure is completed, the ice pack is wiped with 70% alcohol, and kept and chilled again in the deep freezer. http://www.buzzy4shots.com/)
88862574|NCT05560074|Experimental|DistractionCards|"DistrACTION® Cards consisted of visual cards of 5 cm × 8 cm, covered with various pictures and shapes. In this method, the children first carefully examine the cards. Then, the PhD-qualified nurse researcher asks some questions about those cards to be answered by the children, such as How many ladybugs are there in the picture? How many apes are there in the picture? or Can you see the comet? The distraction procedure via distraction cards begin just before the venous blood specimen collection and continue until the end of the blood specimen collection"
88862575|NCT05560074|No Intervention|Control|Controll group: Venous blood will be taken as usual on the blood collection room without applying an intervention to the children in the Control group. Children will follow the standard blood draw procedure.
88862576|NCT05559996|Experimental|Hyaluronic acid injection|Hyaluronic acid injection
88862577|NCT05559918||Preloading with clopidogrel|
88862578|NCT05559918||In-hospital loading with clopidogrel|
88862579|NCT05559840|Active Comparator|Group I|The control group (Group I) will be treated with condom catheter tamponade by inflating the condom with saline according to national protocol.
88862580|NCT05559840|Experimental|Group II|The study group (Group II) will receive condom catheter that will be inflated with air
88862581|NCT02812212|Experimental|Open-label|"Device: ultrasonography and diuretic renography Bilateral ultrasonography to measure the antero-posterior renal pelvic diameter (APRPD) in both positions.~Diuretic renography to measure the cortical transit time"
88862582|NCT02601378|Experimental|LXS196 as a single agent|About 68 patients will be enrolled in dose escalation and expansion
88862583|NCT02601378|Experimental|LXS196 in combination with HDM201|about 44 patients to be enrolled in dose escalation and expansion
88862584|NCT02434848|Active Comparator|Engerix B|15 subjects per group (n = 30 in total)
88862585|NCT02434848|Active Comparator|Fendrix|15 subjects per group (n = 30 in total)
89185013|NCT04110119|Experimental|Case: Drug and Chiropractic Group|Patients, who received chiropractic treatment immediately after the conventional drug treatment as in the control group (49 patients). The chiropractic treatment consists of high speed and low amplitude spinal manipulation techniques, applied only once.
88862586|NCT05559762||Day Shift|Nurses regularly working 12hr day shifts
88862587|NCT05559762||Night Shift|Nurses regularly working night shift
88862588|NCT05559528||Public health system|Group with patients treated in the public health system in Brazil. They will be stratified according to whether or not CDK 4/6 inhibitors are used in therapy.
88862589|NCT05559528||Private health system|Group with patients treated in the private health system in Brazil. They will be stratified according to whether or not CDK 4/6 inhibitors are used in therapy.
88862590|NCT05559450|Experimental|Blinatumomab arm|On the 1st to 3rd day, Blinatumomab should be continuous intravenous use for 24 hours with 9ug/ day for those whose weight are equal to or greater than 45kg, and 5ug/ m2 / day for those whose weight are less than 45kg (maximum dosage is 9ug/ day) per 24 hours. On the 4th to 14th day, for the patients who are equal to or greater than 45kg, they will receive Blinatumomab at the dose of 28ug/ day with continuous intravenous administration, and those below 45kg are given a 24h continuous infusion of 15ug/ m2 / day (maximum dose is 28ug/ day). Bucy-based myeloablative conditioning regimen will be performed on the 15th day.
88862591|NCT05559450|Other|Conventional therapy|Bucy-based myeloablative conditioning regimen will be given to those patients are enrolled into control group.
88862592|NCT01669200|Placebo Comparator|Placebo Oil|Differential changes will be compared in the test group versus the control group at one month and six months with respect to BHB and insulin levels, and at six months with respect to cognitive scores.
88862593|NCT01669200|Experimental|Medium Chain Triglyceride Oil|Differential changes will be compared in the test group versus the control group at one month and six months with respect to BHB and insulin levels, and at six months with respect to cognitive scores.
88862594|NCT05559294|Experimental|Professional development|"The intervention consists of a nine months long professional development program with an interchange between three e-learning modules and three group workshops starting with an e-learning module and ending with a workshop. Each workshop is 3 hours with approximately 100 participants. The e-learning modules are completed individually by ECEC staff. Between workshops, each day nursery and/or kindergarten center will receive a two-hour supervisory visit from UCL staff to support professional development. The daily leader at the day nursery and/or kindergarten center sets the theme for each supervisory visit to enhance development as much as possible.~The intervention is being designed as a collaboration between UCL and Odense municipality"
88862595|NCT05559294|Active Comparator|Usual professional development|Education and Care as Usual entails a standing offer from the municipality of Odense for Usual Competence development within the area of nature, outdoor life and natural phenomena visits from a learning consultant to support the ECEC staff's work with digital technology at the day nursery and/or kindergarten center. It is up to the day nursery and/or kindergarten center if the use the offer or not. This offer is extended to all day nursery and/or kindergarten centers.
88862596|NCT05559138||hemodialysis patients with omicron infection|hemodialysis patients with omicron infection
88862597|NCT05559138||non-hemodialysis patients with omicron infection|non-hemodialysis patients with omicron infection
88862598|NCT00564954|Experimental|Dex-methylphenidate hydrochloride (Focalin XR)|20 mg capsule orally once a day for 7 days
88862599|NCT00564954|Placebo Comparator|Placebo|orally once a day for 7 days
88862600|NCT00565110|No Intervention|Enhanced Usual Care|EUC patients receive medical center standard oncology care and supportive services routinely provided to all patients with cancer. In addition, EUC patients are given a patient focused and a family focused educational pamphlet on depression and cancer and a listing of financial and community resources (in Spanish for Spanish-speaking patients). With patient consent, as described in the informed written consent, the treating oncologist is informed via medical chart note if EUC patients screen positive for major depression. Treating oncology attending physicians, fellows and residents are invited to attend a didactic session led by the study psychiatrist on treating depression in cancer patients.
89003351|NCT05439421|Experimental|With Claim Natural flavor|Package or digital marketing advertisement containing claim of interest
89003352|NCT05439421|Experimental|Without Claim Natural flavor|Package or digital marketing advertisement without claim of interest
89003353|NCT05439421|Experimental|With Claim Shisha or hookah tobacco is unique and completely unlike that found in cigarettes|Package or digital marketing advertisement containing claim of interest
88862601|NCT00565110|Experimental|ADAPt-C intervention|Intervention patients receive: first-line choice of antidepressant medication management,psychotherapy or both; depression education, and maintenance/relapse prevention counseling based on a stepped care depression treatment algorithm, treatment follow-up and feedback to the oncologist, and systems navigation; a psychiatric consultant who prescribes antidepressant medication for individual patients; and a didactic for oncologists on depression management. Cultural adaptations include: patient choice of first line treatment and degree of family participation in their depression care; PST tailored for literacy and patients with cancer; bilingual, bicultural CDCS; Spanish educational materials.
88862602|NCT06299488|Experimental|Intervention: Montmorency Cherry + Apocynum Venetum|Sip2Sleep® is a proprietary formula of Montmorency tart cherry extract and Venetron®, a purified, powdered extract derived from Apocynum Venetum. Recommended dose is ¼ teaspoon which contains 553 mg (1:5 fruit extract) of Montmorency tart cherry and 25mg of Venetron® leaf extract. The compound was prepared as an oral dropper, consumed alone or in water 30-60 minutes prior to bedtime. The study was conducted over a period of four weeks, consisting of two weeks without intervention and two weeks with intervention as follows: (1 week off (baseline) - 1 week on - 1 week off - 1 week on) for each participant
88862603|NCT06299488|No Intervention|No intervention: Typical Sleep Routine|"The study was conducted over a period of four weeks, consisting of two weeks without intervention and two weeks with intervention (ABAB) as follows: (1 week off (baseline) - 1 week on - 1 week off - 1 week on) for each participant.~Participants did not consume any intervention or placebo during this time."
88862604|NCT06299475|Experimental|Online counseling and invitation|Participants receive structured online contraceptive counseling and an online invitation to a clinic for contraceptive provision
88862605|NCT06299475|No Intervention|Control|Participants receive standard praxis i.e. no contraceptive counseling or online invitation
88862606|NCT06299462|Experimental|Matched-sibling donor transplants|Matched sibling transplants will receive PTCy + ATG2.5 ± ATG1.5
88862607|NCT06299462|Experimental|Matched unrelated donor transplants|Unrelated transplants will receive PTCy + ATG5.0
88862608|NCT06299410|Experimental|Cohort A1: 10 mg ITI-1284|
88862609|NCT06299410|Experimental|Cohort A2: 20 mg ITI-1284|
88862610|NCT06299384|Experimental|Lyssn Crisis|"To compare LyssnCrisis to SAU, we will use a standard randomized design in which call-takers will have services-as-usual (SAU) and LyssnCrisis phases. All call-takers will start with a 4-week baseline period of SAU where LyssnCrisis is operating in the background, but does not provide AI feedback on suicide risk assessment. Lyssn team members will on-board and train the participating call-takers on the Lyssn software (i.e., reviewing calls, sharing and accessing calls for supervision), using a similar method used in the pilot field trial. After a 4-week baseline phase, call-takers will be randomly assigned to continue SAU or begin feedback with LyssnCrisis (LC) for 12 weeks.~LC arm participants will have access to LyssnCrisis feedback tools for the duration of the 12 week period and will receive onboarding support for LyssnCrisis fidelity feedback tools."
88862611|NCT06299384|No Intervention|Services As Usual|"To compare LyssnCrisis to SAU, we will use a standard randomized design in which call-takers will have services-as-usual (SAU) and LyssnCrisis phases. All call-takers will start with a 4-week baseline period of SAU where LyssnCrisis is operating in the background, but does not provide AI feedback on suicide risk assessment. Lyssn team members will on-board and train the participating call-takers on the Lyssn software (i.e., reviewing calls, sharing and accessing calls for supervision), using a similar method used in the pilot field trial. After a 4-week baseline phase, call-takers will be randomly assigned to continue SAU or begin feedback with LyssnCrisis (LC) for 12 weeks.~Participants in the SAU arm will continue services-as-usual for an additional 12-week period,where participants receive ProtoCall's regular supervision and feedback. Following this period (16 total weeks of SAU), SAU arm participants will receive LyssnCrisis for 12 weeks."
88862612|NCT06299371|Experimental|neoadjuvant immuno-chemotherapy|Adebrelimab plus paclitaxel for injection (albumin bound) and platinum chemotherapy
88862613|NCT06299358|Experimental|Foot massage group|"Foot massage will be performed by the researcher for 10 minutes on two consecutive days a week in the infants' own homes. In foot massage, euphlorage, petrisage and friction techniques will be used in the appropriate order.~Infants in the foot massage group will be visited five times in total, two times each in the first encounter, first and second weeks. Related forms (Infantile colic and newborn comfort behavior scale) will be filled out by the researcher three times in total, once for the first encounter and once for each week. A total of two forms related to crying and sleep, one for each week, will be completed by the mother at the end of the study. The maternal state-trait anxiety scale will be completed twice, at the first encounter and at the end of the intervention."
88862614|NCT06299358|Experimental|Mother heart sound group|"For the group to listen to the mother's heart sounds, the heart sounds of the mothers of the babies will be recorded on an mp3 player in a quiet environment (in their own homes) with the help of hand-held doopes. The volume (65 decibels) and distance of the mp3 player will be determined by the researcher with the help of a decibel meter and the appropriate distance will be determined. The mother will play this sound to the infant for half an hour every day for two weeks, in coordination with the hours of the intervention in the other groups.~The infants in this group will be visited three times in total, once at the first encounter and once at the end of the first and second weekends, and the relevant forms (Infantile colic and newborn comfort behavior, state-trait anxiety scale) will be applied. Forms related to crying and sleep will be completed by the mother two times in total, one for each week."
88875443|NCT05665842|Experimental|Music Application Group|"After explaining the purpose of the study and the way it was applied to the adolescents in the music practice group, the Introductory Characteristics Form for Adolescents, PedsQL and AIQ will be applied.~After, the predetermined instrumental music will be shared with the adolescents every evening for 15 days via social media by the researcher and participants will be asked to listen to these music. Participants will listen to the instrumental music sent by the researcher for at least 20 minutes every evening during the music application. This whole process will be reminded to the adolescents with messages every evening and they will be asked to listen the music before the normal bedtime (before 23:00 at night). At the end of the music application (after 15 days), the Introductory Characteristics Form for Adolescents, PedsQL and AIQ will be reapplied."
88862615|NCT06299358|Experimental|Foot massage and mother heart sound group (mixed group)|For the group in which maternal heart sounds and foot massage will be applied, the heart sounds of the mothers of the babies will be recorded on an mp3 player in a quiet environment (in their own homes) with the help of hand-held doopes. The sound (65 decibels) and distance of the mp3 player will be determined by the researcher with the help of a decibel meter. The researcher will perform foot massage as in the massage group and the mother's heart sound will be played for a total of half an hour with the massage. The infants in this group will be visited five times in total, once in the first encounter and twice each in the first and second week, and the relevant forms (Infantile colic, neonatal comfort behavior scales will be applied 3 times for infants; state-trait anxiety scale will be applied twice for the mother, once at the beginning and twice at the end). A total of two forms related to crying and sleep will be completed by the mother, one for each week.
88862616|NCT06299332|Experimental|Device Treatment|Eligible subjects will receive 6 weekly treatments with the Forma Applicator according to the study protocol and will return for two follow up visits 1- and 3-months post treatment. Two further telephone feedback checks will be carried out 6 months and 12 months following the last treatment visit.
88862617|NCT06299319|Experimental|Experimental: Psilocybin 25 mg|Participants will receive a 25 mg dose of psilocybin, twice throughout the trial, with two weeks in between doses.
88862618|NCT06299293||Cases|Participants with Anorexia Nervosa
88862619|NCT06299293||Controls|Participants with a healthy weight
88862620|NCT06299267|Other|effect of dual task|effect of dual task
88862621|NCT06299254||Participants with obesity|Participants affected by obesity (the level of body mass index (BMI) higher or equal to 30).
88862622|NCT06299254||Healthy-weight participants|As controls, not-hospitalized participants with a healthy weight
88862623|NCT06299228|Experimental|Experimental Group|The experimental group will receive sensorimotor intervention and traditional hand therapy
88862624|NCT06299228|Experimental|Control Group|Control Group will receive Hand Therapy only
88862625|NCT06299202|Experimental|Patients with localized breast cancer|Patients with localized breast cancer (stage II or III, HER 2, triple-negative) eligible for a neoadjuvant chemotherapy and not presenting contraindication to angiomammography.
88862626|NCT06299189|Experimental|A self-guided internet delivered intervention|MinADHD: 7 self-help modules Interventions: Behavioural
88862627|NCT06299176|Experimental|Whole Heart Radiation Therapy|Whole heart radiotherapy, 5 Gy in 1 fraction
88862628|NCT06299163|Experimental|NM32-2668|
88862629|NCT06299150|Active Comparator|direct resin composite mini-veneer|Composites resins have become the first choice for direct anterior and posterior restorations. The great popularity is related to their esthetic appearance and reduced need of sound tissue removal as compared with former treatments. Several studies have demonstrated that composite restorations may last long in clinical service. Composite restorations have demonstrated a good clinical performance with annual failure rates varying from 1% to 3% in posterior teeth and 1% to 5% in anterior teeth.
88862630|NCT06299150|Experimental|IPS e.max CAD|"IPS e max likely refers to a type of dental material or technology. IPS e.max is a popular brand of lithium disilicate glass-ceramic used in dentistry for the fabrication of dental restorations such as crowns, veneers, inlays, onlays, and bridges.~IPS e.max restorations are known for their excellent esthetics, strength, and durability. They are designed to closely mimic the natural appearance of teeth while providing reliable performance and longevity. Dentists often choose IPS e.max restorations for their patients due to their versatility and ability to meet both esthetic and functional requirements."
88862631|NCT06299111|Experimental|REGN9933|Randomized 1:1:1
88862632|NCT06299111|Experimental|REGN7508|Randomized 1:1:1
88862633|NCT06299111|Placebo Comparator|Placebo|Randomized 1:1:1
88862634|NCT06299085|Other|50 adult patients suffering from severe or morbid obesity|"50 adult patients suffering from severe or morbid obesity (BMI ≥ 35 kg/m2 in the presence of comorbidities and BMI ≥ 40 kg/m2, respectively), male and female, candidates for bariatric surgery (Sleeve Gastrectomy and Roux-en-Y Gastric Bypass).~Two timepoints: T0 (pre-hospitalization) and T1 (follow-up 12 months +/- 1 month).~Expected assessments at T0 and T1:~Blood chemistry tests to monitor metabolic markers involved in dietary and metabolic changes.~Bone densitometry for body composition analysis (DEXA).~Analysis of pre-intervention walking and the ability to recover motor activity after bariatric surgery using gait analysis."
88862635|NCT06299033|Experimental|hNPC01 therapy|1.5×10^7 hNPC01 cells; 3.0×10^7 hNPC01 cells; 6.0×10^7 hNPC01 cells
88862636|NCT06299020|No Intervention|Non fasting|Non fasting arm: usual diet and behavior
88862637|NCT06299020|Experimental|Fasting|Intermittent fasting
88862638|NCT06299007||Group 1|Patients who were admitted due to upper gastrointestinal bleeding and had anemia
88862639|NCT06298994||study group|Patients with Chronic Obstructive Pulmonary Disease
88862640|NCT06298994||control group|Aged-matched healthy controls
89185014|NCT04052061|Experimental|CD19 t-haNK|CD19 t-haNK will be administered to patients with Diffuse Large B-Cell Lymphoma who have received 2 or more lines of therapy and are ineligible for transplant.
88862641|NCT06298968|Experimental|Combined therapy using GC, Lenvatinib and Adebrelimab|GC chemotherapy every 3 weeks,with a total of 6 cycles. Lenvatinib 8 mg once daily (QD) oral dosing. Adebrelimab 1200mg intravenously every 3 weeks.
88862642|NCT06298955|Experimental|OMS906 study drug|OMS906 study drug repeat-dose 5 mg/kg IV administration at 8-week intervals.
88862643|NCT06298942|Experimental|natural band|to use an round ligament as a natural band in stead of synesthetic band with sleeve gastrectomy
88862644|NCT06298942|Active Comparator|silicone band|to use a synesthetic band with sleeve gastrectomy
88862645|NCT06298929|Active Comparator|Group 1|patients with PAET who will receive unilateral or bilateral MR fenestration
88862646|NCT06298929|Active Comparator|Group 2|patients with PAET who will receive unilateral or bilateral MR recession
88862647|NCT06298916|Experimental|Experimental Part 1|"Six patients with metastatic sarcoma will receive 8 ± 1 millicurie (mCi) (~50 μg mass dose) of 64Cu-LNTH-1363S (64Cu Radiolabeled FAPi PET/CT Imaging Agent).~Six patients with metastatic sarcoma will receive 8 ± 1 millicurie (mCi) (~90 μg mass dose) of 64Cu-LNTH-1363S (64Cu Radiolabeled FAPi PET/CT Imaging Agent)."
89003354|NCT05439421|Experimental|Without Claim Shisha or hookah tobacco is unique and completely unlike that found in cigarettes|Package or digital marketing advertisement without claim of interest
89003355|NCT05439421|Experimental|With Claim water in the shisha effectively cools and filters the smoke, making smooth and light|Package or digital marketing advertisement containing claim of interest
89003356|NCT05439421|Experimental|Without Claim water in the shisha effectively cools and filters the smoke, making smooth and light|Package or digital marketing advertisement without claim of interest
89003357|NCT05438940|Experimental|STRONG-GEC|Participants will receive individually tailored, bi-weekly nutrition counseling from a dietician via telehealth and remote monitoring through a smart phone app and wearable sensor to allow participants to log food intake while sharing their data with a dietician.
89003358|NCT05438927|Experimental|Nutritional Support|Participants will receive individually tailored, bi-weekly nutrition counseling from a dietician via telehealth and remote monitoring through a smart phone app and wearable sensor to allow participants to log food intake while sharing data with a dietician
89003359|NCT05436444|Experimental|1|All participants receive challenge virus
89003360|NCT05435014|Experimental|T-ACE Oil|TAE/TACE treatment was performed with T-ACE Oil.
89003361|NCT05435014|Active Comparator|Lipiodol|TAE/TACE treatment was performed with Lipiodol.
89003362|NCT05429970|Experimental|PSRB|Participants will receive mind-body resilience training/MBRT, music therapy, propranolol and etodolac pre and post operatively. Postoperative Psychological Interventions may occur between POD 1-7 if needed.
89003363|NCT05429970|No Intervention|Standard of Care|Participants will receive usual care (study interventions not specifically recommended)
89003364|NCT05428332|No Intervention|No Brace Group|50% of the participants in the study that will not be receiving a TCU brace.
89003365|NCT05428332|Experimental|Tri-Compartment Unloader Brace Group|50% of the participants in the study that will be receiving a TCU brace.
89003366|NCT05425940|Experimental|Experimental Arm|Subjects with mCRC will receive XL092 + atezolizumab
89003367|NCT05425940|Active Comparator|Control Arm|Subjects with mCRC will receive active comparator of regorafenib
89003368|NCT05423717|Experimental|Daridorexant 10 mg|
89003369|NCT05423717|Experimental|Daridorexant 25 mg|
89003370|NCT05423717|Experimental|Daridorexant 50 mg|
89003371|NCT05423717|Placebo Comparator|Placebo|
89003372|NCT05420259|Experimental|Combined Exercise and Dietary Intervention|Intervention aimed at conveying a supervised combined moderate aerobic and resistance training, once a week with a duration of 40-60 minutes plus daily home exercise, personalized according to patients' age and functional status. Dietary intervention aimed at a one-on-one nutritional counseling. In the first visit a dietary plan is designed and one daily oral nutritional supplement (Fortimel Compact®, Nutricia) is given to meet the European Society of Parenteral and Enteral Nutrition (ESPEN) recommended intake.
89003373|NCT05420259|Other|Control|Standard Care
89003374|NCT05415215|Other|Arm A: Pertuzumab IV and Trastuzumab IV Plus Investigator's Choice of Chemotherapy|During the neoadjuvant phase, the enrolled participants randomized to this arm will receive treatment with pertuzumab and trastuzumab intravenously (PH IV) plus investigator's choice of chemotherapy (Option 1, 2, or 3). With chemotherapy Option 1, PH IV will be administered at each cycle from Cycles 1 to 6 (1 cycle is 3 weeks); with chemotherapy Options 2 and 3, PH IV will be administered once per cycle from Cycles 5 to 8 (1 cycle is 3 weeks).
89003375|NCT05415215|Other|Arm B: PH FDC SC Plus Investigator's Choice of Chemotherapy|During the neoadjuvant phase, the enrolled participants randomized to this arm will receive treatment with the fixed dose combination of pertuzumab and trastuzumab for subcutaneous use (PH FDC SC) plus investigator's choice of chemotherapy (Option 1, 2, or 3). With chemotherapy Option 1, PH FDC SC will be administered at each cycle from Cycles 1 to 6 (1 cycle is 3 weeks); with chemotherapy Options 2 and 3, PH FDC SC will be administered once per cycle from Cycles 5 to 8 (1 cycle is 3 weeks).
89003376|NCT05415215|Experimental|Arm C: Adjuvant PH FDC SC in Hospital, Then at Home|During the adjuvant phase, participants who have achieved pCR after surgery will be treated with 2 cycles of PH FDC SC in the hospital (run-in period). After completion of the last cycle of radiotherapy and the last cycle of PH FDC SC (run-in period), participants will then be randomized with a ratio of 1:1 into one of two treatment arms (Arm C or D) in a cross-over treatment period to receive the next 6 cycles of PH FDC SC treatment. Participants in Arm C will receive 3 cycles of PH FDC SC in the hospital and then 3 cycles of PH FDC SC in the home setting. After the cross-over treatment period, participants will receive the remaining PH FDC SC treatment cycles required to complete the planned 18 cycles of HER2-directed therapy, unless of disease recurrence, unacceptable toxicity, or withdrawal. Study treatment during this treatment continuation period will be administered either in the hospital or in the home setting as selected by the participant at the end of the crossover period.
89185016|NCT04019691|Active Comparator|Mix-and-Match group|Cataract surgery and implantation of a Tecnis ZKB00 multifocal IOL with +2.75 D add power (Abbott Medical Optic Inc., Santa Ana, CA) in the dominant eye, and a Tecnis ZLB00 multifocal IOL with +3.25 D add power (Abbott Medical Optics Inc.) in the non-dominant eye.
89003377|NCT05415215|Experimental|Arm D: Adjuvant PH FDC SC at Home, Then in Hospital|During the adjuvant phase, participants who have achieved pCR after surgery will be treated with 2 cycles of PH FDC SC in the hospital (run-in period). After completion of the last cycle of radiotherapy and the last cycle of PH FDC SC (run-in period), participants will then be randomized with a ratio of 1:1 into one of two treatment arms (Arm C or D) in a cross-over treatment period to receive the next 6 cycles of PH FDC SC treatment. Participants in Arm D will receive 3 cycles of PH FDC SC in the home setting and then 3 cycles of PH FDC SC in the hospital. After the cross-over treatment period, participants will receive the remaining PH FDC SC treatment cycles required to complete the planned 18 cycles of HER2-directed therapy, unless of disease recurrence, unacceptable toxicity, or withdrawal. Study treatment during this treatment continuation period will be administered either in the hospital or in the home setting as selected by the participant at the end of the crossover period.
89185017|NCT04019691|Active Comparator|EDOF group|Cataract surgery and implantation of Tecnis Symfony ZXR00 trifocal IOLs (Abbot Medical Optics Inc.) in both eyes.
88862648|NCT06298916|Experimental|Experimental Part 2|Part 2 will evaluate 64Cu-LNTH-1363S (64Cu Radiolabeled FAPi PET/CT Imaging Agent) correlation with FAP expression measured by IHC (SUVmax and SUVmean vs IHC score) in 20 evaluable patients with non-metastatic, operable, supposed FAP-expressing solid tumors (sarcomas, esophageal, gastric, pancreatic, colorectal) planned for surgery within 60 days (from study imaging).
88862649|NCT06298903|Active Comparator|Hip activation|Participants will perform a hip muscle activation program 2 days per week for 8 weeks. The HEP consists of 5 exercises that target the gluteal muscles.
88862650|NCT06298903|Experimental|Hip activation + Single leg balance|Participants will perform a hip muscle activation program as in the active comparator group, plus a single leg balance training HEP 2 days per week for 8 weeks. The hip HEP consists of 5 exercises that target the gluteal muscles. The single leg balance HEP consists of a variety of eyes open and eyes closed single leg balance exercises.
88862651|NCT06298890||Patients who will be using artificial tears before and after cataract surgery|Patients will receive artificial tears 7 days before the cataract surgery and continue to use them for 3 months after the surgery.
88862652|NCT06298890||Patients who will not be using any artificial tears neither before nor after the cataract surgery.|Patients will not receive any artificial tears neither before nor after the cataract surgery.
88862653|NCT06298864|Experimental|Internet-based Cognitive Behavioral Therapy (Internet-CBT)|Internet-CBT following ACS is exposure-based, centering on exposure to cardiac related symptoms and situations. The CBT is therapist-guided and lasts for 8 weeks.
88862654|NCT06298864|Active Comparator|Internet-based Cardiac Lifestyle intervention (Internet-CL)|Internet-CL is based on strategies for behavioral change and guidelines on health promoting lifestyle modifications following ACS. The Internet-CL is therapist-guided and lasts for 8 weeks.
88862655|NCT06298851|Experimental|Neural Mobilization Group (NMG)|Participants of NMG performed sciatic, femoral and peroneal nerve and lumbar region gliding. All glides include 4 sets of 10 repetitions, with each gliding cycle lasting 6 seconds, and a 1-minute rest between sets for both extremities.
88862656|NCT06298851|Experimental|Dynamic Stretching Group (DSG)|"4 sets of 10 repetitions will be performed, each exercise cycle lasting 6 seconds, and a 1-minute rest period will be given between sets. All stretching exercises will be performed in two circuits.~Exercises:~Walking on toes Walk and keep the right knee on the ground Walk and do not touch the left knee to the ground Walking with the knee flexed to 90° and abducting and adducting the hip Walking with the knee fully extended and hip flexion leaning forward Jogging and 90° forward flexion of the right/left hip Jogging and right/left hip adduction"
88862657|NCT06298851|Experimental|Static Stretching Group (SSG)|"4 sets of 4 repetitions will be applied to the lumbar extensor, hamstring, quadriceps and gastrocnemius muscles of both extremities, each stretching lasting 15 seconds, and a 1-minute rest period will be left between sets.~Static Stretching Exercises:~Standing quadriceps stretch Modified hamstring stretching Gastrocnemius stretching Adductor stretching Lumbar stretching"
88862658|NCT06298812|Other|REFLECT|Enrolled patients are treated with the REFLECT Scoliosis System. This is an HDE-approved device.
88862659|NCT06298799|Other|Collection of DNA/RNA samples|Type 2 Diabetic participants cohort or Healthy participants cohort who will perform Collection of DNA/RNA samples
88862660|NCT06298786||Healthy Subjects|Subjects with TMD Screener score < 3
88862661|NCT06298786||TMD subjects|Subjects with TMD screener score ≥ 3
88862662|NCT06298734|Experimental|Group A: High-Intensity Exercise (EX)|"10 participants will complete:~In-office baseline visit.~Virtual exercise sessions 3x weekly.~Post-intervention in-office visit."
88862663|NCT06298734|Experimental|Group B: High-Fiber Diet (DT)|"10 participants will complete:~In-office baseline visit.~1x weekly appointment with research staff to review to review diet adherence.~Post-intervention in-office visit."
88862664|NCT06298734|Experimental|Group C: Combined High-Intensity Exercise and High-fiber Diet (COMB)|"10 participants will complete:~In-office baseline visit.~Virtual exercise sessions 3x weekly.~1x weekly appointment with research staff via Zoom platform to review to review diet adherence. Diet appointment may be combined with exercise session appointment.~Post-intervention in-office visit."
88862665|NCT06298734|No Intervention|Group D: Attention Control (AC)|"10 participants will complete:~In-office baseline visit.~Participants will receive a general healthy lifestyle guidebook.~Pot-intervention in-office visit."
88862666|NCT06298721|Active Comparator|Standard of Care TKA|Patients scheduled to undergo TKA at Cleveland Clinic will follow the standardized TKA Care Pathway as part of Standard of care. Patients enter the TKA care path after consenting to undergo TKA for symptomatic knee pain that has not relieved with nonoperative measures. They stay in the care path until 90-days after the operation is complete. The TKA care path guides the care delivered through the preoperative, intraoperative and postoperative phases.
88862667|NCT06298721|Experimental|Standard of Care TKA + Personalized Outcome Prediction Tool with targeted interventions|"Patients who are identified to have a TKA PROMs phenotype which includes lower than median scores for VR-12 MCS will be further screened for:~Distress ➔ using the NCCN Distress Thermometer (DT) Depression ➔ using the Patient Health Questionnaire-9 Those patients with a score ≥ 8 on the DT, or a score ≥ 10 on the PHQ-9, or any response other than 0 to question 9 on the PHQ-9 will have a consult with Psychiatry and Behavioral Science to determine a mental health diagnosis.~Patients who are identified to have a TKA PROMS phenotype which includes lower than median scores for KOOS-PS (score of =<51.5) will be scheduled for a 4 to 8 week intervention of pre-rehabilitation. All patients who undergo the PT intervention will have a an assessment before and after the rehab TKA."
88862668|NCT06298695|Experimental|Individual Schema Therapy|A maximum of 40 sessions of individual schema therapy within one year
88862669|NCT06298695|Active Comparator|Treatment As Usual (TAU)|Treatment as usual in treatment-resistant anxiety disorders (psychological and/or psychiatric).
89003378|NCT05415215|Other|Arm E: Adjuvant Trastuzumab Emtansine|Participants with pathological evidence of residual invasive carcinoma in the breast or axillary lymph nodes following completion of preoperative therapy and surgery will enter Arm E to receive trastuzumab emtansine for 14 cycles. Trastuzumab emtansine will be administered IV in the hospital as per prescribing information.
89185018|NCT04019691|Active Comparator|Trifocal group|Cataract surgery and implantation of FineVision PodFT IOLs (PhysIOL SA) in both eyes.
89185019|NCT00726687|Experimental|single|Single arm designed to elicit Maximum Tolerated Dose
89185020|NCT03950115|Experimental|Group 1|IPL therapy will be performed with the M22® (Lumenis, Dreieich, Germany). IPL treatment is going to be administered to the skin below the lower eyelid. Before treatment, the eyes will be protected with opaque goggles. Ultrasound gel is going to be applied to the patient's face from tragus to tragus including the nose in order to conduct the light, help to spread the energy evenly, and provide a degree of protection. The intensity of the IPL treatment will range from 9.8J/cm2 to 13J/cm2 according to Fitzpatrick Skin Type Grading.
89185021|NCT00727077||IntronA/Rebetol|Children age 3 to 17, with chronic hepatitis C, treated in clinical practice at 10 German sites
89185022|NCT00726765||Referral Strategy 1|"Patient meets at least one of the following three criteria:~Inflammatory back pain~Human leukocyte antigen B27 (HLA-B27)~Sacroiliitis demonstrated by imaging (X-ray, magnetic resonance imagining [MRI], bone scan [if previously available])"
89185023|NCT00726765||Referral Strategy 2|"Patient meets at least two of the following six criteria:~Inflammatory back pain~HLA-B27~Sacroiliitis (on imaging)~Family history of AS~Good response of back pain to nonsteroidal anti-inflammatory drugs (NSAIDs)~Known Extra Articular Manifestations (Uveitis, Iridocyclitis, Psoriasis, Inflammatory Bowel Disease)"
88862670|NCT06298669|Experimental|Biventricular Pacing followed by Right Ventricular Pacing|Subjects will be randomly assigned to the order of pacing interventions. After baseline testing (with their CRT device still in the subjects' baseline pacing modality), subjects assigned to BiV-first will have their CRT device reprogrammed to BiV pacing modality in the clinic. After undergoing three months of treatment in this pacing modality, they will return to clinic for retesting. The CRT device will then be reprogrammed to RV pacing for the next 3 months. Subjects will then again return to clinic for retesting, and their CRT device will be reprogrammed to their baseline pacing modality.
88862671|NCT06298669|Experimental|Right Ventricular Pacing followed by Biventricular Pacing|Subjects will be randomly assigned to the order of pacing interventions. After baseline testing (with their CRT device still in the subjects' baseline pacing modality), subjects assigned to RV-first will have their CRT device reprogrammed to RV pacing modality in the clinic. After undergoing three months of treatment in this pacing modality, they will return to clinic for retesting. The CRT device will then be reprogrammed to BiV pacing for the next 3 months. Subjects will then again return to clinic for retesting, and their CRT device will be reprogrammed to their baseline pacing modality.
88862672|NCT06298643||Transfusion dependent|Participants that received ≥2 units of red blood cell transfusion during the 8 weeks after initial myelodysplastic syndrome diagnosis date.
88862673|NCT06298643||Non-transfusion dependent|Participants that received 0 units or <2 units of red blood cell transfusion during the 8 weeks after initial myelodysplastic syndrome diagnosis date.
88862674|NCT06298591|Other|subcision|
88862675|NCT06298578||In person follow up|
88862676|NCT06298578||mobile app follow up|
88862677|NCT06298565||efgartigimod cohort|patients treated with efgartigimod
88862678|NCT06298565||non-efgartigimod cohort|patient treated with other MG medication
88862679|NCT06298552|Experimental|Efgartigimod IV|Patients receiving efgartigimod IV in both part A and part B
88862680|NCT06298552|Placebo Comparator|Placebo|Patients receiving placebo during part A and receiving efgartigimod IV during part B
88862681|NCT06298513||Patient after first acute myocardial infarction|
88862684|NCT06298461|Active Comparator|OSS|
88862685|NCT06298461|Active Comparator|2L PEG|
88862686|NCT06298448||eGPA|Eosinophilic granulomatosis with polyangiitis patients before and after treatment with mepolizumab will be compared
88862687|NCT06298448||GPA|Comparator group not treated with mepolizumab
88862688|NCT06298448||Asthma|Asthma patients before and after treatment with mepolizumab
88862689|NCT06298448||CRSwNP|Chronic rhinosinusitis patients before and after treatment with mepolizumab
88862690|NCT06298448||Healthy|Healthy comparator group
88862691|NCT06298435||GA group|Adult patients having undergone surgery under general anesthesia with IPPV in the UMCG between 01-01-2018 and 01-04-2023
88862692|NCT06298396|Experimental|MAPs on Cochlear™ Nucleus® 7, Nucleus® 8 and Kanso® 2 Sound Processors|Participants will receive four different MAPs to use during two take-home periods and will then complete hearing assessments using each MAP.
89386972|NCT01344811|Experimental|Telemonitoring group|"A Smartphone, body composition analyzer and Pedometer will be provided~transmitting the results to the Smart Care Server via Smartphone~At Smart care Center,care manager will provide remote body weight and activity monitoring and individual obesity case management"
89386973|NCT01344811|Other|Control group|"A weighing scale and Pedometer will be provided~recording in a self diary of body weight and the number of steps"
89386974|NCT01344889||Cohort|
89386975|NCT02836496|Experimental|Mepolizumab|Enrolled subjects will receive either mepolizumab 300 mg or placebo subcutaneous (SC) every 4 weeks while continuing their HES therapy.
89386976|NCT02836496|Placebo Comparator|Placebo|Enrolled subjects will receive either mepolizumab 300 mg or placebo SC every 4 weeks while continuing their HES therapy.
89386977|NCT04213807|Experimental|MAA868|Subcutaneous injection on Day 1 with two subsequent monthly injections
89386978|NCT04213807|Placebo Comparator|Placebo|Subcutaneous injection: Placebo on Day 1 with two subsequent monthly injections
89386979|NCT05065099|Experimental|OnTRACK Intervention|"In the intervention condition, HCPs will be trained in the usage of the OnTRACK system.~They will be oriented to the educational videos, the symptom tracking, and the interpretation of the data that is provided by the patients and families, and the associated management strategies based on that data. Additionally, patients and parents will be trained to use the OnTRACK smartphone app on their phone from diagnosis to recovery (or 12 weeks if not recovered), including daily exertional monitoring symptom ratings and use of the educational videos. School personnel will be introduced to the OnTRACK app and the data summary features in the school dashboard and the associated supports that can be provided to the student based on that data."
89386980|NCT05065099|No Intervention|Treatment as Usual|"In the control condition, the HCP provides usual/standard care to the patients and parents as is the practice within the specific clinic. The OnTRACK app and the educational modules are not provided."
89386981|NCT01344967|Experimental|Zometa, Bone Suppression, Active Ingredient|
89386982|NCT05250661|Experimental|Aqueous propolis extract|The individuals in the intervention group were asked to gargle with 5 ml aqueous propolis extract four times a day after meals (morning, noon, evening and night before bedtime) and wait average one minute in the mouth and then spit, in addition to the standard practice of the clinic. According to the standard practice of the clinic, it was performed tanflex (3x1) and/or sodium bicarbonate (1x1) to the patients in the prevention of oral mucositis with the request of the physician. The patients were followed for 21 days. The 21-day period is consistent with the duration of mucositis healing in the literature. Follow-up and evaluation of patients who were discharged early were performed by home visits and made a phone call everyday.
89386983|NCT05250661|No Intervention|Control|Standard procedures of the clinic were applied to control group. According to the standard practice of the clinic, it was performed tanflex (3x1) and/or sodium bicarbonate (1x1) to the patients in the prevention of oral mucositis with the request of the physician. Follow-up and evaluation of patients who were discharged early were performed by home visits and made a phone call everyday.
89386984|NCT04176913|Experimental|Anti-CD20 Allogeneic CAR-T Cell Therapy|An open label, single arm Phase I study to evaluate the safety, tolerability, and pharmacokinetics of LUCAR-20S CAR-T cells in relapsed or refractory CD20+ diffuse large B-cell, follicular, mantle cell and small lymphocytic lymphoma.
89386985|NCT03268213|Experimental|Fecal microbial transplantation|Treated with fecal microbial transplantation
89003379|NCT05407714|Experimental|SpaceOAR Treatment Arm|Single arm, up to 20 subjects with a pathologically confirmed diagnosis of clinical stage T1 or T2 prostate cancer indicated for radiotherapy will be enrolled, for there are chances of missing data in the real world study. A sample of 14 subjects provides at least 90% power for the primary objective.
89003380|NCT05406921|Experimental|Intervention Arm: PLWD|150 community-residing PC patients with an ADRD diagnosis will be enrolled and receive MIND coordination services for 3 months to test program implementation feasibility in PC practice settings.
89386986|NCT05050279|Placebo Comparator|Placebo|Delgocitinib placebo capsule
89386987|NCT05050279|Experimental|Active dose 1|Delgocitinib capsule (Dose 1)
89386988|NCT05050279|Experimental|Active dose 2|Delgocitinib capsule (Dose 2)
89386989|NCT05050279|Experimental|Active dose 3|Delgocitinib capsule (Dose 3)
89386990|NCT05050279|Experimental|Active dose 4|Delgocitinib capsule (Dose 4)
89386991|NCT03074227|Active Comparator|Allogeneic faecal transplantation|Faecal transplantation of donor stool
89386992|NCT03074227|Placebo Comparator|Autologous faecal transplantation|Faecal transplantation of own stool
89386993|NCT04072861|Experimental|Cohort 1|9 mg RBT-9, single dose
89386994|NCT04072861|Experimental|Cohort 2, Healthy Volunteers|27 mg RBT-9, single dose
89386995|NCT04072861|Experimental|Cohort 3, Healthy Volunteers|90 mg RBT-9, single dose
89386996|NCT04072861|Experimental|Cohort 4, Subjects with CKD Stage 3|27 mg RBT-9, single dose
89003381|NCT05406921|No Intervention|Data Validation Arm|An additional 100 PLWD will serve as a data validation arm to demonstrate the feasibility of collecting and validating data from large health systems.
89003382|NCT05406921|Experimental|Intervention Arm: PLWD CPs|150 Care Partners (CPs) of the 150 community-residing PC patients with an ADRD diagnosis will be enrolled and receive MIND coordination services for 3 months to test program implementation feasibility in PC practice settings.
89386997|NCT04072861|Experimental|Cohort 5, Subjects with CKD Stage 3|90 mg RBT-9, single dose
89386998|NCT04072861|Experimental|Cohort 6, Subjects with CKD Stage 4|27 mg RBT-9, single dose
89386999|NCT04072861|Experimental|Cohort 7, Subjects with CKD Stage 4|90 mg RBT-9, single dose
88862693|NCT06298383|Experimental|Trypsin, Bromelain and Rutoside (TBR) Group|patients will receive Trypsin, Bromelain and Rutoside combination (2 tablets of flamogen a combination of Trypsin 48mg, Bromelain 90mg and Rutoside 100mg) as a single oral dose 1 hour before treatment.
88862694|NCT06298383|Active Comparator|NSAIDs Group|Patients will receive diclofenac potassium (50mg) as a single oral dose 1 hour before treatment.
88862695|NCT06298383|Active Comparator|Steroid Group|Patients will receive a single oral dose of a steroid drug (30 mg prednisolone) 1 hour before treatment.
88862696|NCT06298383|Placebo Comparator|Placebo group|Patients will receive a single oral dose of placebo (compressed tablets of powdered milk) 1 hour before treatment
88862697|NCT06298370|Active Comparator|Group P|Patients in this group will undergo ultrasound-guided block using a linear or convex ultrasound probe in the supine position before intrathecal bupivacaine. The block procedure will involve the use of a local anesthetic solution (10-20 ml of 0.25% bupivacaine and 2 mg dexamethasone) and a 22 Gauche 80 mm block needle. Subsequently, intrathecal drug will be administered at the L3-L4 intervertebral level with 10-15 mg of bupivacaine while the patient is in a sitting position.
88862698|NCT06298370|Active Comparator|Group M|Patients will receive intrathecal bupivacaine plus morphine without Pericapsular Nerve Group block. Intrathecal drugs will be administered at the L3-L4 intervertebral level by adding 10-15 mg bupivacaine with 100 μg of morphine.
88862699|NCT06298370|Active Comparator|Group P+M|Patients will undergo ultrasound-guided block using a linear or convex ultrasound probe in the supine position before intrathecal bupivacaine plus morphine. The block procedure will involve the use of a local anesthetic solution (10-20 ml of 0.25% bupivacaine and 2 mg dexamethasone) and a 22 Gauche 80 mm block needle. Intrathecal drugs will be administered at the L3-L4 intervertebral level by adding 10-15 mg bupivacaine with 100 μg of morphine.
88862700|NCT06298357|Experimental|Immediate Start|Program starts in the hospital and lasts for 8 weeks after hospital discharge.
88862701|NCT06298357|Active Comparator|Waitlist Control|After 8 weeks after hospital discharge, these participants start the 8 week intervention.
88862702|NCT06298344|Experimental|Thiamine|Patients with left to right shunt congenital heart disease who undergone transcatheter closure Intervention: Daily Thiamine 100 mg in 28 days.
88862703|NCT06298344|No Intervention|Placebo|Patients with left to right shunt congenital heart disease who undergone transcatheter closure Interventions: Daily Placebo oral (Manufactured to mimic Thiamine) in 28 days.
88862704|NCT06298331|Experimental|Aerobic Exercise and Abdominal Massage|"Aerobic Exercise: Aerobic exercise training will be given for 8 weeks, 3 days a week on the treadmill in the clinic under the supervision of a physiotherapist, and 8 weeks, the other 2 days a week outside the clinic. The duration of the walking session is 50 minutes (5 minutes warm-up - 40 minutes load - 5 minutes cool down).~Abdominal Massage: Abdominal massage will be performed manually by applying baby oil to the patient's abdomen and while the patient is in the supine position. This application will take approximately 15 minutes. The massage will be performed by the physiotherapist in the clinic 3 days a week for 8 weeks and by the patient outside the clinic 2 days a week for 8 weeks as self-massage."
88862705|NCT06298331|Active Comparator|Abdominal Massage|Abdominal Massage: Abdominal massage will be performed manually by applying baby oil to the patient's abdomen and while the patient is in the supine position. This application will take approximately 15 minutes. The massage will be performed by the physiotherapist in the clinic 3 days a week for 8 weeks and by the patient outside the clinic 2 days a week for 8 weeks as self-massage.
88862706|NCT06298292||ZeroTP minis|Intervention: Tyrosine-free and Phenylalanine-free protein substitute in tablet form. Subjects who currently take a protein substitute for the dietary management of either tyrosinaemia I, II, III or alkaptonuria will be recruited. Subjects will take the study product for 7 days. Subjects will replace some or their entire usual protein substitute with the new product. The amount of tablets prescribed will be calculated to provide the same amount of protein as their usual protein substitute.
88862707|NCT06298292||ZeroMet minis|Intervention: Methionine-free and Cystine-enriched protein substitute in tablet form. Subjects who currently take a protein substitute for the dietary management of homocystinuria will be recruited. Subjects will take the study product for 7 days. Subjects will replace some or their entire usual protein substitute with the new product. The amount of tablets prescribed will be calculated to provide the same amount of protein as their usual protein substitute.
88862708|NCT06298292||ZeroVIL minis|Intervention: Valine-, Isoleucine- and Leucine-free protein substitute in tablet form. Subjects who currently take a protein substitute for the dietary management of MSUD will be recruited. Subjects will take the study product for 7 days. Subjects will replace some or their entire usual protein substitute with the new product. The amount of tablets prescribed will be calculated to provide the same amount of protein as their usual protein substitute.
88862709|NCT06298279|Experimental|Tunneled Delivery/Standard Resources|"In this arm, participants will be guided through the Self-Guided PSP Wellbeing Course in a predetermined order and using predetermined timing. Future lessons will unlock as previous lessons are completed.~Participants receiving the standard resources will be presented with resources that are typically presented in PSPNET courses. This includes lesson slides case stories, do-it yourself guides, and frequently asked questions pages."
88862710|NCT06298279|Experimental|Tunneled Delivery/Enhanced Social Learning Resources|"In this arm, participants will be guided through the Self-Guided PSP Wellbeing Course in a predetermined order and using predetermined timing. Future lessons will unlock as previous lessons are completed.~Participants receiving the enhanced social learning resources will receive the same resources offered in the standard conditions (i.e., lesson slides, case stories, do-it-yourself guides, and frequently asked questions pages) and will also receive additional resources. Additional resources will include homework records to accompany the case stories, de-identified quotations from previous clients for each lesson, and a motivational video encouraging them to engage with the course."
88862711|NCT06298279|Experimental|Personalized Delivery/Standard Resources|"In this arm, participants will be able to navigate through the course modules in whichever order and at whatever pace they like. Participants will not have to complete one lesson in order to gain access to the following lesson.~Participants receiving the standard resources will be presented with resources that are typically presented in the course. This includes lesson slides, case stories, do-it yourself guides, and frequently asked questions pages."
89185024|NCT04080336|Experimental|dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia & Upjohn, Puurs, Belgium) inserted by the study nurse 3 hours before IUD insertion.
88862712|NCT06298279|Experimental|Personalized Delivery/Enhanced Social Learning Resources|"In this arm, participants will be able to navigate through the course modules in whichever order and at whatever pace they like. Participants will not have to complete one lesson in order to gain access to the following lesson.~Participants receiving the enhanced social learning resources will receive the same resources offered in the standard conditions (i.e., lesson slides, case stories, do-it-yourself guides, and frequently asked questions pages) and will also receive additional resources. Additional resources will include homework records to accompany the case stories, de-identified quotations from previous clients for each lesson, and a motivational video encouraging them to engage with the course."
89387000|NCT05250349||Isolated HF Group|Patients with echocardiography - confirmed Heart Failure (HFmrEF and HFrEF) and clinical symptoms (NYHA I-III).
89387001|NCT05250349||HF + CS group|Patients with echocardiography - confirmed Heart Failure (HFmrEF and HFrEF) with NYHA I-III symptoms, who were diagnosed with flow limiting Carotid Stenosis on carotid Doppler ultrasound.
89387002|NCT05250349||Control group|A cohort of patients without Heart Failure or other significant cardiac pathology and without Carotid Stenosis (a paired propensity match will be performed).
89387003|NCT04044781|Experimental|Test Group|Stage 1 safety assessments will be performed before and after the administration of a single, 185 MBq (5mCi) dose of T2310 in up to three healthy volunteers. Stage 2 will evaluate the relationship between plasma concentration of BPN14770, an investigational PDE4D modulator, and brain target occupancy in up to six healthy volunteers.
89387004|NCT04044469|Experimental|Immunization-enhancement|This group receives an immunization-promoting manipulation aimed at triggering negative appraisals of the medical information received and questioning the validity of the medical reassurance. For this purpose, a standardized information text is presented to the participants after receipt of the doctor's report, in which it is stated that the standard medical diagnosis in gastroenterology is often not particularly accurate and that serious diseases are from times to times overlooked. As a further factor contributing to the non-detection of diseases, it is mentioned that doctors are often under time pressure and thus do not have sufficient time to ask patients for all important information. It is believed that communicating this information will result in participants continuing to report high probabilities of serious illness despite the previously received findings report.
89387005|NCT04044469|Experimental|Immunization-inhibition|The aim of the immunization-inhibiting manipulation is to increase the probability that the normal test results obtained will be used to reduce worries about a serious illness. The participants of this group receive - analogous to the immunization-promoting group - a standardized information text which states that the standard medical diagnosis in gastroenterology is very accurate and that the physicians are very often correct in their initial diagnostic assessment, especially with regard to the assessment of a serious organic disease. This is supported by two scientific publications. The aim of this information is to increase the value of the results obtained, so that the participants are more reassured as a result of the inconspicuous test results and use them to correct their health-related concerns.
89387006|NCT04044469|Experimental|Control group|This group does not receive additional information after the doctor's report.
89387007|NCT04634383|Experimental|WFMA Cortical Visual Prosthesis Single-arm Study|The WFMA is an electronic device that is implanted in the cortical vision processing regions of the brain to produce artificial vision.
89387008|NCT01345279||cisplatin|
89387009|NCT01345279||cisplatin + topotecan|
89387010|NCT01345279||cisplatin + paclitaxel|
89387011|NCT05232019||Infertile females|No less than 20 years old who were attending our clinical center for the first time were enlisted
89387012|NCT00577577|Experimental|rhIGF-I/rhIGFBP-3|
89387013|NCT00577577|Placebo Comparator|Placebo|
89387014|NCT02833844|Experimental|Double-Blind Placebo SC QM/Open-Label Evolocumab 420 mg SC QM|Double-blind placebo subcutaneous (SC) injection every 4 weeks (QM) for 24 weeks, followed by open-label evolocumab 420 mg SC QM for 24 weeks.
89387015|NCT02833844|Placebo Comparator|Double-Blind Evolocumab 420 mg SC QM/Open-Label Evolocumab 420 mg SC QM|Double-blind evolocumab SC injection QM for 24 weeks, followed by open-label evolocumab 420 mg SC QM for 24 weeks.
89387016|NCT01345357|Experimental|CEP-9722 in combination with Gemcitabine and Cisplatin|Study drugs will be administered in cycles of 21 days for up to 6 cycles. CEP-9722 treatment will be initiated at cycle 2. After cycle 3, patients may discontinue gemcitabine and/or cisplatin for reasons of tolerability, at the discretion of the investigator.
88862713|NCT06298266|Experimental|infusion of GPRC5D-CD19 CAR T injection|Infusion of GPRC5D-CD19 CAR T cells injection by dose of 1.0×10^6 /kg±20 % CAR-T ，3.0×10^6 /kg±20%、6.0×10^6 /kg±20%. Administration method: intravenous infusion. Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
89387017|NCT01333631|Experimental|Valporoic acid + chemoradiotherapy|
89387018|NCT05014789|Experimental|Control-IQ 2.0 technology 2.0 on the t:slim X2 insulin pump|"Each subject will use different combinations of new features of the system each week, in random order, over the next 4 weeks, using the t:slim X2 insulin pump with Control-IQ technology 2.0.~The first 5 subjects in the study will complete a 48 hour session with multiple challenges during use of Control-IQ technology 2.0, before moving on the outpatient portion of the trial."
89387019|NCT01345435|Experimental|Telemonitoring group|"A Smart Care PC, blood glucose meter and body composition analyzer will be provided~transmitting the results to the Smart Care Server via Smart Care PC~At Smart care Center,care manager will provide remote blood glucose monitoring and individual diabetes case management"
89387020|NCT01345435|Experimental|Telemonitoring & Telemedicine group|"A Smart Care PC, blood glucose meter and body composition analyzer will be provided~transmitting the results to the Smart Care Server via Smart Care PC~At Smart care Center,care manager will provide remote blood glucose monitoring and individual diabetes case management~taking telemedicine through video telephone instead of visiting hospital"
89387021|NCT01345435|Other|Control group|"Blood glucose meter and body composition analyzer will be provided~Self-monitoring Blood Glucose (SMBG)"
89387022|NCT04611763|Experimental|Pre FA Group|
89387023|NCT04611763|Active Comparator|Post FA Group|
89387024|NCT03564002||obese subjects|
89387025|NCT03564002||lean subjects|
89387026|NCT05329064|Other|10mcg of BNT162b2 (Pfizer-BioNTech/Comirnaty®)|10mcg of BNT162b2 (Pfizer-BioNTech/Comirnaty®) for each dose. Two doses will be given at 2 months apart between doses.
89387027|NCT05186935|Experimental|Single arm|This is a multi-center, pivotal, non-randomized, prospective, open-label clinical investigation.
89387028|NCT04568629|Experimental|Algorithm Arm|Participants received prognostic advice from a prognostic algorihm.
89387029|NCT04568629|Experimental|Clinician arm|Participants recieved prognostic advice from another clinician.
89387030|NCT04973917|Experimental|conventional ventilation mode|respiratory support after cardiac surgery. Vt < 6 ml/kg PBW, driving pressure < 13 cmH2O
89387031|NCT04973917|Experimental|intelectual mode - Intelivent ASV|closed loop mode of mechanical ventilation Vt < 6 ml/kg PBW, driving pressure < 13 cmH2O
89387032|NCT03985033|Experimental|L-PRF|Post-extraction sockets will be filled with autologous leucocyte and platelet-rich fibrin (L-PRF) clot.
89387033|NCT03985033|No Intervention|Control|Post-extraction sockets will be left to heal spontaneously with natural blood clot.
89387034|NCT01341782|Experimental|Paricalcitol|Participants received paricalcitol at an initial dose of 2 µg, and maxacalcitol placebo administered 3 times per week at each hemodialysis via intravenous catheter for 12 weeks. After 2 weeks the dose could be adjusted ± 1 µg based on protocol-specified criteria up to a maximum of 7 µg.
89185025|NCT04080336|Active Comparator|misoprostol|1 vaginal tablet of misoprostol (200 mcg) (Misotac®; Sigma Pharma, SAE, Egypt) inserted by the study nurse 3 hours before IUD insertion.
88862714|NCT06298240|Experimental|Experimental group|Application of a consensual nursing guide with 5 reasons for health consultation where an autonomous role can be applied. Users who come to the emergency center during the first fifteen days of each month are assigned to the experimental group until the necessary sample of 156 subjects is reached.
88862715|NCT06298240|No Intervention|Control group|Users who come to the emergency center in the second fortnight of each month are assigned to the non-intervention (control) group where the usual medical visit is applied until the required sample of 156 subjects is reached.
88862716|NCT06298214|No Intervention|Usual Care|Subjects will see doctors as normal during first year postpartum with no assistance.
88862717|NCT06298214|Experimental|Her Health Program|Her Health is a patient navigation intervention delivered by community health workers across the first postpartum year. Her Health has two interspersed components: Navigation and Education. Her Health Navigation is delivered through weekly and monthly check-ins between participant and navigator. Her Health navigators will deliver historically informed and culturally competent education designed to promote self-efficacy and self-advocacy within the healthcare system.
88862718|NCT06298201|Experimental|E-Based Physical Exercise Intervention|A randomized controlled trial (RCT) aimed at evaluating the effects of an e-based PE intervention at home in addition to conventional PE on the disability progression of pwMS comorbid conditions.
88862719|NCT06298201|No Intervention|Conventional Physical Exercise|Conventional Physical Exercise will receive no e-based PE intervention
88862720|NCT06298188|Experimental|Risankizumab|Induction regimen: 0,4,8 IV and then every 8 weeks sc
88862721|NCT06298175|Experimental|Intervention Group|The study group received 8 weeks of self-management training. Reflections, prepared using Power Point, were used in all sessions. The study employed various methods, including the question-answer and audio-visual methods, as well as performance feedback when necessary during the sessions. Final evaluations were conducted for both groups after eight weeks.
88862722|NCT06298175|Active Comparator|Control Group|The control group was informed about self-management for 1 week. General information was given about approaches to improving self-management. Final evaluations were conducted for both groups after eight weeks.
88862723|NCT06298162||RYGB, successful weight loss (TWL >35%)|TWL = total weight loss
88862724|NCT06298162||RYGB, unsuccessful weight loss (TWL <25%)|
88862725|NCT06298149|Experimental|Turtle Island Tales|All participating families will receive a monthly lesson targeting a healthy behavior (increase fruit/vegetable intake, decrease added sugar intake, increase physical activity, decrease sedentary/screen time, promote healthy sleep, and promote emotional regulation) over the course of one year.
88862726|NCT06298136|Experimental|Online mindfulness-based intervention (MBI)|The research team have developed an online family MBI (arm 1) for parents and their children with ADHD. It integrates psychoeducation videos (each 3-7 minutes) with audio mindfulness exercises (each 5-15 minutes). The content includes: (1) mindfulness and attention, (2) mindfulness and physical sensation, (3) mindfulness and parental stress, and (4) mindfulness and parental self-care. The majority of the exercises in the first four modules are for parents, but five of them include guidance for child-parent mindfulness exercises. The fifth module targets children with ADHD and the length of video and audio of mindfulness exercises for children, each last 3-5 mins.
88862727|NCT06298136|Active Comparator|Psychoeducation|The psychoeducation program is based on the Parent Training for Child ADHD Program developed by Russell Barkley for children with ADHD and other behavioral disorders. It includes: (1) understanding ADHD symptoms, (2) general behavior management principles, (3) positive reinforcement and attending skills, (4) the use of a reward and token system, and (5) child problem-solving skills.
88862728|NCT06298097|Other|stroke patients|Resting-state networks obtained through electroencephalography will be analyzed in a group of stroke patients.
89185026|NCT04080336|Placebo Comparator|placebo|one tablet of placebo inserted by the study nurse 3 hours before IUD insertion.
89185027|NCT00727155|Experimental|1|Treatment
89185028|NCT00727155|No Intervention|2|Waitlist
89387035|NCT01341782|Active Comparator|Maxacalcitol|Participants received maxacalcitol at an initial dose of 5 µg (iPTH < 500 pg/mL at Screening) or 10 µg (iPTH ≥ 500 pg/mL at Screening), and paricalcitol placebo administered 3 times per week at each hemodialysis via intravenous catheter for 12 weeks. After 2 weeks the dose could be adjusted ± 2.5 µg based on protocol-specified criteria up to a maximum of 20 µg.
89387036|NCT01345747|Experimental|laryngeal tube|laryngeal tube suction has suction port
89387037|NCT01345747|Experimental|endotracheal tube|
89387038|NCT05150509||Patients with Progressive Disease and without Progressive Disease|"Patients with Progressive Disease Patients with metastasis and/or recurrent OSCC were considered as a group of subjects with progressive disease.~Patients with without Progressive Disease Patients without metastasis and/or recurrent OSCC were considered as a group of subjects without progressive disease."
89387039|NCT02250157|Experimental|Part 1|"Part 1 of this study is a 3+3 design to define the MTD of Oratecan in up to 60 evaluable subjects. It will be conducted in 2 parts; 1A will test the oral liquid formulation and 1B will test the oral tablet formulation of irinotecan."
89387040|NCT02250157|Experimental|Part 2|Part 2 will enroll an additional 10 subjects at the Part 1 MTD to further characterize the safety, tolerability, pharmacokinetics, and activity of Oratecan at that dose.
89387041|NCT03952429|Active Comparator|Active Cognitive Bias App|Participants will receive the Anti-Alcohol App with the Active Cognitive Bias modification, as well as participant diaries assessing alcohol consumption and several questionnaires.
89387042|NCT03952429|Placebo Comparator|Inactive Cognitive Bias Modification|Participants will receive the Anti-Alcohol App with the Inactive Cognitive Bias Modification, as well as participant diaries assessing alcohol consumption and several questionnaires.
89387043|NCT05107531||Parkinson's Patients with Motor Freezing|Individuals with Parkinson's Disease with motor freezing were included in this group.
88862729|NCT06298097|Other|healthy participants|Resting-state networks obtained through electroencephalography will be analyzed in a group of healthy participants.
89535285|NCT03227185|Experimental|Sham - real anodal tDCS|"Session 1: 30 s of 1 mA anodal tDCS applied via 5x7 cm rubber electrodes over the DLPFC (current density: 0.028 mA/cm2). Additional ramp-up and ramp-down phase at beginning and end of stimulation lasting for 15 s. Electrodes remain attached to the participant's head for the duration of the encoding phase.~Session 2: 20 min of 1 mA anodal tDCS applied via 5x7 cm rubber electrodes over the DLPFC (current density: 0.028 mA/cm2). Additional ramp-up and ramp-down phase at beginning and end of stimulation lasting for 15 s. Electrodes remain attached to the participant's head for the duration of the encoding phase."
89535286|NCT03091647|Experimental|acupressure intervention|Practice acupressure at home and complete daily logs
89535287|NCT03091647|Placebo Comparator|usual care|Receive usual care and complete daily logs
88862733|NCT06298071|Experimental|Group 1|Injection; strength: 4mg.
88862734|NCT06298071|Experimental|Group 2|Injection; strength: 8mg.
88862735|NCT06298071|Experimental|Group 3|Injection; strength: 12mg.
88862736|NCT06298058|Experimental|SIBP-A13|SIBP-A13: injection; strength: 1, 2, 4, 5, 6 or 8 mg; dose escalation and the first group is 1mg (intravenous infusion).
88862737|NCT06298032|Experimental|Olamkicept - Part A|
88862738|NCT06298032|Placebo Comparator|Placebo - Part A|
88862739|NCT06298032|Experimental|Olamkicept - Part B|
89387044|NCT05107531||Parkinson's Patients Without Motor Freeze|Individuals with Parkinson's Disease without motor freeze were included in this group.
89387045|NCT05107531||Healthy Controls|Healthy individuals who did not have any neurological problems that would affect gait were included.
89387046|NCT01345825|Experimental|resistance training|
89387047|NCT01345903|Experimental|Treatment (surgery)|Patients undergo robotic-assisted surgery using the da Vinci robot
88862740|NCT06298032|Placebo Comparator|Placebo - Part B|
88862741|NCT06298019|Experimental|Active Intervention with CAR T|All participants in the trial will receive an infusion of autologous, genetically modified CAR T cells specific for the CD19 antigen
88862742|NCT06298006||PASC24 study participants|100 patients with residual cognitive and psychiatric symptoms after COVID-19 infection who undergo follow-up.
89387048|NCT01341470|Experimental|Single IV dose LY2495655|Single 70 milligram (mg) dose LY2495655 administered intravenously (IV)
88862743|NCT06297993||Adult patients with a confirmed diagnosis of large duct PSC.|"Adult patients between 18 and 75 years of age (inclusive) who can comprehend instructions, follow the study procedures and are willing to sign an Informed Consent Form (ICF).~Confirmed clinical diagnosis of large duct PSC based on current AASLD Guidelines."
88862744|NCT06297980|Experimental|Personalized treatment|We will test an intervention that includes up to four personalized adjustments to food intake, insulin dose and glycemic algorithms by menstrual cycle phase, based on the three months of observational data collected.
88862745|NCT06297980|No Intervention|Standard Care|In this arm, women will continue with their usual insulin dose, food intake and glycemic algorithms as determined by their provider
88862746|NCT06297954|Experimental|Metoclopramide|Patients will be randomized to receive metoclopramide 20 mg IV single dose.
88862747|NCT06297954|Placebo Comparator|Placebo|Patients will be randomized to receive placebo 10 ml IV single dose.
88862748|NCT06297941|Experimental|REM-422|"Dose Escalation: Participants will receive escalating doses of REM-422 to determine Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D)-422, oral capsule administered once daily~Dose Expansion: Participants will receive REM-422 at the identified RP2D Treatment will continue until disease progression, therapy intolerance, or participant withdrawal Safety evaluation will continue until 30 days of last administration of REM-422"
89185029|NCT00793871|Experimental|sunitinib|single agent sunitinib, single arm
89185030|NCT04065945||Couples undergoing ART treatment|Couples in reproductive age undergoing ART treatment in Women's Hospital School of Medicine Zhejiang University, The International Peace Maternity & Child Health Hospital, and Changhai Hospital of Shanghai.
89185031|NCT04065945||Couples getting pregnant naturally|Couples who get pregnant naturally and want to deliver the babies in Women's Hospital School of Medicine Zhejiang University, The International Peace Maternity & Child Health Hospital, and Changhai Hospital of Shanghai.
89185032|NCT02585154|Experimental|Closed-loop Deep Brain Stimulation|Closed-loop Deep Brain Stimulation
89185033|NCT02585154|Active Comparator|Open loop Deep Brain stimulation|Open loop Deep Brain stimulation
89185034|NCT02585154|Other|No Deep Brain Stimulation|No Deep Brain Stimulation
89387049|NCT01341470|Experimental|Multiple SC dose 17.5 mg LY2495655|17.5 mg of LY2495655 administered subcutaneously (SC) every 2 weeks for 8 weeks (total of 5 doses)
89387050|NCT01341470|Experimental|Multiple SC dose 140 mg LY2495655|140 mg of LY2495655 administered subcutaneously (SC) every 2 weeks for 8 weeks (total 5 doses)
89387051|NCT01341470|Experimental|Multiple SC dose 420 mg LY2495655|420 mg dose of LY2495655 administered subcutaneously (SC) every 2 weeks for 8 weeks (total 5 doses)
89387052|NCT01341470|Placebo Comparator|Single IV dose placebo|Single Placebo dose administered intravenously (IV)
89387053|NCT01341470|Placebo Comparator|Multiple SC dose placebo|Placebo dose administered subcutaneously (SC) every 2 weeks for 8 weeks (total of 5 doses)
89387054|NCT03564158|Experimental|meropenem 2 g- vaborbactam 2 g|Approved Dose
89387055|NCT03564158|Experimental|meropenem-vaborbactam (dose TBD)|Supratherapeutic Dose
89387056|NCT03564158|Active Comparator|Moxifloxacin 400 mg|Active Control
89387057|NCT03564158|Placebo Comparator|Normal Saline (placebo)|Placebo
89387058|NCT02677298|Experimental|Botulinum toxin A|Botulinum Toxin A (Clostridium botulinum toxin type A) will be administered in double blind fashion in cycle 1. 20 Units will be administered (divided in five 0.1 mL i.m. injections) into the glabellar area.
89387059|NCT02677298|Placebo Comparator|Placebo|Placebo will be administered in double blind fashion in cycle 1. divided in five 0.1 mL i.m. injections into the glabellar area.
89185035|NCT04105283|Experimental|Tc99m-MAA|"Tc99m-MAA will be administered by selective or supra-selective arterial injection via the bronchial artery or branches thereof.~Administration will occur over a period of 30-240 seconds"
89185036|NCT02584062|Experimental|no-touch fluid-air exchange group|All patients in no-touch fluid-air exchange group will have a surgery of vitrectomy metrectomy and internal membrane peeling and gas tamponed.In this surgery ,investigator will not touch the macular area,especially the area of the macular hole and investigator will not have the fluid-air exchange of the macular area.
88862749|NCT06297902|Experimental|Dose painting|Radiation dose will be escalated to the hypermetabolic part of the tumor (maximum point dose 83.3 Gy), shown in pre-treatment FDG-PET images. Dose escalation will be applied to these regions during the first half of the fractionated treatment (17 of 34 fractions).
89387060|NCT02677298|Experimental|Botulinum toxin A Open Label Extension Arm|"Open Label Extension Arm where all Subjects from Arm 1 and 2 can receive Experimental Treatment in up to 3 treatment cycles.~20 Units will be administered (divided in five 0.1 mL i.m. injections) into the glabellar area."
89387061|NCT03143101|Experimental|FluMist trivalent (2015-2016)|Participants will receive intranasal spray of 0.2 milliliter (mL) (total dose in both nostrils) FluMist trivalent vaccine on Days 1 and 28. Each 0.2 mL dose contained 10^7±0.5 fluorescent focus units (FFU) of each vaccine strain. Strains included in the trivalent vaccine were: A/H1N1 (A/Bolivia/559/2013), A/H3N2 (A/Switzerland/9715293/2013), and B/Phuket/3073/2013 (B/Yamagata-lineage).
89387062|NCT03143101|Experimental|FluMist Quadrivalent (2015-2016)|Participants will receive intranasal spray of 0.2 mL (total dose in both nostrils) FluMist quadrivalent vaccine on Days 1 and 28. Each 0.2 mL dose contained 10^7±0.5 FFU of each vaccine strain. Strains included in the vaccine were A/H1N1 (A/Bolivia/559/2013), A/H3N2 (A/Switzerland/9715293/2013), B/Phuket/3073/2013 (B/Yamagata-lineage), and B/Brisbane/60/2008 (B/Victoria-lineage).
89387063|NCT03143101|Experimental|FluMist Quadrivalent (2017-2018)|Participants will receive intranasal spray of 0.2 mL (total dose in both nostrils) FluMist quadrivalent vaccine on Days 1 and 28. Each 0.2 mL dose contained 10^7±0.5 FFU of each vaccine strain. Strains included in the vaccine were the new A/H1N1 (A/Slovenia/2903/2015), A/H3N2 (A/New Caledonia/71/2014), B/Phuket/3073/2013 (B/Yamagata-lineage), and B/Brisbane/60/2008 (B/Victoria-lineage).
88862750|NCT06297902|No Intervention|Standard radiotherapy|Homogeneous dose to the tumor.
88862751|NCT06297876|Experimental|Storytelling|Participants will view short video narratives of community members speaking about why they chose to get vaccinated against Coronavirus Disease of 2019 (COVID-19) and how they overcame hesitancy. Participants will also view the informational videos described below.
88862752|NCT06297876|Other|Learn More|Participants will view short informational videos that provide factual information on the COVID-19 vaccines.
89387064|NCT01345981|Experimental|lidocaine 20 mg|intravenous lidocaine
89387065|NCT01345981|Experimental|lidocaine 40 mg|intravenous lidocaine 40 mg
89387066|NCT01345981|Placebo Comparator|normal saline|2 ml
89387067|NCT00871351|Experimental|Ezetimibe + Atorvastatin|Participants with hypercholesterolemia receiving atorvastatin 10 mg and ezetimibe 10 mg for 12 weeks after a 4-week washout and 4 weeks of daily atorvastatin 10 mg
89387068|NCT00871351|Active Comparator|Atorvastatin|Participants with hypercholesterolemia receiving atorvastatin 20 mg for 12 weeks after a 4-week washout and 4 weeks of daily atorvastatin 10 mg
89387069|NCT00871351|Active Comparator|Rosuvastatin|Participants with hypercholesterolemia receiving rosuvastatin 2.5 mg for 12 weeks after a 4-week washout and 4 weeks of daily atorvastatin 10 mg
89387070|NCT04920331|Experimental|Erenumab|Subjects with episodes of status migrainosus will receive a single dose of IV erenumab
89387071|NCT02745080|Experimental|Secukinumab 300 mg s.c.|Secukinumab 300 mg administered at Baseline, Weeks 1, 2, 3 and 4, followed by dosing every 4 weeks until Week 48.
89387072|NCT02745080|Active Comparator|Adalimumab 40 mg s.c.|Adalimumab 40 mg administered at Baseline followed by dosing every 2 weeks until Week 50.
89387073|NCT01346137|Experimental|meloxicam|15 mg versus 30 mg per day P.O for 15 days, during 3 menstrual cycles
89535288|NCT04492709|Experimental|Treatment|The subjects will receive oral midazolam solution of 2 mg as a single dose on 2 occasions, 6 days apart (Days 1 and 7). The first dose will be prior to dosing with oral AZD5718 tablet and the second dose after five administrations of AZD5718 under fasted conditions.
89003383|NCT05400473|Active Comparator|Therapeutic exercise group|1.Movements of flexion, extension, inclinations, and rotations of the cervical region at maximum amplitude and without load. 2.Neural mobilization of the cervical nerve roots. 3.Contraction of the deep muscles of the flexors, extensors, and rotators of the cervical region without performing spinal movements, using the movement of the eyes to aid in the accomplishment of these exercises. 4.Isometric contraction of the flexor muscles, inclinators, and rotators against manual resistance of the physiotherapist. 5.Isometric contraction of the cervical extensors of the cervical region against gravity. 6.Contraction of the flexor muscles, extensors, and incliners of the cervical region against the resistance of elastic bands.
89387074|NCT04537507||Patients underwent coronary angiography|We reviewed medical notes of patients hospitalized for coronary angiography because of exacerbated angina (recurrent chest pain, classical stable angina, long history of chest pain/angina or other symptoms such as dyspnea). We excluded patients with acute coronary syndromes (ACS), Tako-tsubo cardiomiopathy and history of ischemic heart disease, as well as those referred for coronary angiography before heart valve surgery. Prior cardiosurgical valve replacement was also the exclusion criterion.
89387075|NCT00521599|Experimental|MF DPI 2 x 100 mcg BID|2 inhalations of mometasone furoate dry powder inhaler (MF DPI) 100 mcg plus 1 inhalation of placebo matching MF DPI 200 mcg twice daily (BID) for 8 weeks
89387076|NCT00521599|Experimental|MF DPI 1 x 200 mcg BID|1 inhalation of mometasone furoate dry powder inhaler (MF DPI) 200 mcg plus 2 inhalations of placebo matching MF DPI 100 mcg twice daily (BID) for 8 weeks
89387077|NCT00521599|Placebo Comparator|Placebo|2 inhalations of placebo matching mometasone furoate dry powder inhaler (MF DPI) 100 mcg plus 1 inhalation of placebo matching MF DPI 200 mcg twice daily (BID) for 8 weeks
89387078|NCT00442897|Experimental|1|
89387079|NCT00442897|Active Comparator|2|
89387080|NCT01346215|Experimental|Actparin® - Laboratorio Bergamo|
89387081|NCT01346215|Active Comparator|Heparin sodium - APP Pharmaceuticals|
89387082|NCT02834390|Experimental|Quizartinib 20 mg/day|"Participants who received 20 mg quizartinib once daily in the morning under fasting conditions.~For the Induction phase, cytarabine (100 mg/m^2/day IV) and either idarubicin (12 mg/m^2/day IV infusion) or daunorubicin (60 mg/m^2/day IV) were co-administered with quizartinib.~For the Consolidation phase, cytarabine (3.0 g/m^2/12 hours IV) was co-administered with quizartinib."
89387083|NCT02834390|Experimental|Quizartinib 40 mg/day|"Participants who received 40 mg quizartinib once daily in the morning under fasting conditions.~For the Induction phase, cytarabine (100 mg/m^2/day IV) and either idarubicin (12 mg/m^2/day IV infusion) or daunorubicin (60 mg/m^2/day IV) were co-administered with quizartinib.~For the Consolidation phase, cytarabine (3.0 g/m^2/12 hours IV) was co-administered with quizartinib."
89387084|NCT03141151|Experimental|COACH: Healthy Bodies|This will be a staged intensity behavioral intervention. The intensive phase will last 15 weeks and consist of weekly, 90 minute, skills-building sessions. The content will focus on diet, physical activity, sleep, media use, and parenting. Behavior change techniques will include goal-setting, self-monitoring, and problem solving. Following the intensive phase, participants will enter a maintenance phase, consisting of monthly phone calls from a health coach for 3 months.
89387085|NCT03141151|Active Comparator|COACH: Strong minds|This will be a school-readiness intervention for the 3-5 year old children involved, which will meet twice a month for 3 months. Group sessions will focus on building social support around literacy skills for parents and children, as well as school advocacy.
89387086|NCT01317355||cancer patients|in and out patients of 5 German university hospitals currently undergoing cancer treatment
89387087|NCT01317433|Experimental|Arm A|Intensified FOLFIRI plus Cetuximab + Doxycycline 100 mg daily per os to start 7 days before Cetuximab for 6 weeks + skin moisturizers (Dexeryl), sun protection.
89185037|NCT02584062|Experimental|the tradional group|All patients in no-touch fluid-air exchange group will have a surgery of vitrectomy metrectomy and internal membrane peeling and gas tamponed.In this surgery ,investigator will touch the macular area and investigator will have the fluid-air exchange.
89387088|NCT01317433|Active Comparator|Arm B|Intensified FOLFIRI plus Cetuximab + skin moisturizers (Dexeryl), sun protection.
89387089|NCT01358708|Experimental|LACTEOL® 340 mg|
89387090|NCT01358708|Placebo Comparator|PLACEBO|
89387091|NCT01346449|Active Comparator|Visual cue absent|
89387092|NCT01346449|Experimental|Calorie information present|
89387093|NCT01346449|Active Comparator|Calorie information absent|
89387094|NCT01346449|Experimental|Visual cue present|
89387095|NCT01346527||Type 2 diabetes|"Women will be diagnosed with type 2 DM (pre-gestational, White classification B or C class). Since the majority of women with B or C class DM are on insulin therapy in our clinic, we will recruit only women on insulin therapy (i.e. no oral diabetes medications).~HbA1C ≤ 8 for greater than 3 months32, 33.~All women will have confirmed singleton pregnancies.~Receive care at the Women's Health Clinic at Barnes Jewish Hospital.~Pre-pregnancy BMI is anticipated to be >30 (i.e. obese) from the data regarding the patient population of our clinic. Women with pre-pregnancy BMI between 23-40 will be included."
89387096|NCT01346527||Healthy, obese pregnant controls|"No diagnosis of type 1 or 2 diabetes or previous gestational DM.~Women with pre-pregnancy BMI between 30-45: control participants will be BMI matched to women with DM.~A normal routine, standard of care 1 hour 50 gram gestational diabetes screen.~Receive care at the Women's Health Clinic at Barnes Jewish Hospital.~Patients will have a singleton pregnancy with no fetal abnormalities (as determined by routine standard of care ultrasonography)."
89387097|NCT01346527||Healthy, Lean Controls|No diagnosis of type 1 or 2 diabetes or previous gestational DM. 2) Women with pre-pregnancy BMI between 21-25.9 3) A normal routine, standard of care 1 hour 50 gram gestational diabetes screen.
89387098|NCT03563768|Experimental|One-stop strategy group|Percutaneous coronary intervention (PCI) will be performed on the same operating table immediately after the endovascular aortic repair (EVAR)
89185038|NCT02947971|Experimental|OFDI Imaging|Experimental OFDI Imaging
89185039|NCT04105127|Active Comparator|Anterior builds-ups|Intervention orthodontic - fixed orthodontic treatment in patients with overbite reduction: fixed orthodontic treatment with resin build-ups bonded to the palatal surfaces of central upper incisors
89387099|NCT03563768|No Intervention|Staging strategy group|PCI will be performed several days after EVAR
89387100|NCT01317511|Experimental|Protein|Protein drink
89387101|NCT01317511|Placebo Comparator|Placebo|water
89387102|NCT03563924||Historical cohort|Patients with venous thromboembolism and cancer who follow traditional management of venous thromboembolism
89387103|NCT03563924||AlloTC cohort|"Patients with venous thromboembolism and cancer who follow AlloTC specific management. AlloTC specific care path way develop a personalized care plan (PPS) and ensure the transmission of data (to all the interlocutors: patients and caregivers) at each step of the patient care path."
89387104|NCT01346605||CCTA patients|Prior stress SPECT with intermediate to high likelihood to be referred to the cardiac catheterization laboratory for an invasive coronary angiogram or patients presenting with chest pain and clinical indication of Coronary CT Angiography and an initial calcium score above 300
89387105|NCT03563846|Experimental|RP-G28 administered in the fasted state|RP-G28, 15 g dissolved in water, administered in the fasted state
89387106|NCT03563846|Experimental|RP-G28 administered in the fed state|RP-G28, 15 g dissolved in water, administered immediately following the consumption of a standard non-dairy meal
89387107|NCT03635281|Experimental|PEEP group|In this group the a PEEP level will be added after 20 minutes from OLV. PEEP values will be chosen according to the best static compliance with an incremental trial (i.e. starting from ZEEP, the PEEP values will be increased in step of 2 cmH2O each until the best compliance is reached)
89387108|NCT03635281|Experimental|RM+PEEP group|"Recruitment maneuvers will be performed as follow Recruitment maneuvers~set FIO2 at 1.0~Ppeak limit at 45 cmH2O~Respiratory rate set at 6~I:E set at 1:1~Raise the VT at step of 2 ml/kg PBW until the Pplat is between 30-40 cmH2O~If the maximum VT is set without rasing the Pplat, raise PEEP~Allow three respiratory cycles with Pplat between 30 and 40 cmH2O~End of RM~The recruitment manouvers will be performed after 20 minutes of OLV. At the end of the RM, the VT will be set back to 5 ml/kg while the PEEP will be chosen according to the best static compliance with a decremental trial (from 16 cmH2O, lowering PEEP with steps of 2 cmH2O each until the best compliance is reached)."
89387109|NCT01346761|Experimental|Telephone genetic counseling|Participants randomly assigned to telephone counseling are mailed packets that included a sealed envelope containing an educational brochure about hereditary breast and ovarian cancer (HBOC) genetic counseling with visual aids. At the time of their session, participants open their envelope and counselors use the visual aids to explain breast-ovarian cancer genetics and administer BRCA1/BRCA2 genetic counseling. Women receiving in-person counseling are given these same materials during their session at the community clinic. In-person and telephone counseling are delivered by the same five board-certified genetic counselors.
89387110|NCT01346761|Active Comparator|In-person genetic counseling|In-person BRCA1/BRCA2 genetic counseling is delivered by board-certified genetic counselors using a guide-line-concordant semistructured protocol that allows for personalization of counseling and is similar to that used by others. All sessions are audiotaped for treatment fidelity assessments. In-person and telephone counseling are delivered by the same five board-certified genetic counselors.
89387111|NCT01356602|Experimental|Canakinumab, pre-filled syringes (PFS)|Patients on this arm received 150 mg subcutaneously (s.c.) at randomization and upon new flare. The doses were provided as pre-filled syringes. The patients were given 3 injections: two placebo and one active drug.
89387112|NCT01356602|Active Comparator|Canakinumab, lyophilizate (LYO)|The patients on this arm received 150 mg s.c. at randomization and upon new flare. The doses were provided as lyophilized powder and had to be reconstituted with water for injection before application. The patients were given 3 injections: two placebo and one active drug.
89387113|NCT01356602|Active Comparator|Triamcinolone Acetonide|The patients on this arm received 40 mg intramuscular (i.m.) at randomization and upon new flare. The patients were given 3 injections: two placebo and one active drug.
89387114|NCT01347775|Sham Comparator|Sham inspiratory muscle training|Patients in the sham group used the threshold trainer (Threshold at IMT device URES HS730, Respironics, New Jersey, Inc, Cedar Grove, NJ, USA), with the diaphragm removed.
89387115|NCT01347775|Experimental|Inspiratory muscle training|Inspiratory muscle training will be by a threshold trainer (Threshold at IMT device URES HS730, Respironics, New Jersey, Inc, Cedar Grove, NJ, USA), a commercially available spring-loaded inspiratory muscle training device. It will be set at 40% of the subjects baseline maximal inspiratory pressure and increased by 10% each week by an unblinded assistant. All subjects were trained with these devices for 8-10 breaths, 3 times a day, everyday for 6 weeks
89387116|NCT01347853|Experimental|Ketorolac tromethamine|
89387117|NCT01347853|Placebo Comparator|Placebo|
89387118|NCT01346917|Experimental|Lidocaine|
89387119|NCT01346917|Placebo Comparator|Placebo|
89387120|NCT01343017|Other|Increased tidal volume (IVT)|In the group with increased tidal volume (IVT), initial plateau pressure (Pplateau) will be monitored and then tidal volume will be increased until Pplateau was 0.04 cm H2O/kg over the initial Pplateau. The PETCO2 will be then adjusted to 4.5 kPa with a flexible corrugated hose placed between the Y-piece of the anaesthesia circle system and the heat and moisture filter (HME) attached to the endotracheal tube.
89387121|NCT01343017|Other|Normal tidal volume (NVT), with PEEP|In the group with normal tidal volume (NVT), a PEEP to10 cmH2O will be applied. When required, VT will then adjusted to maintain PETCO2 at 4.5 kPa
89387122|NCT03563612|Active Comparator|cpap first, differential ventilation later|
89387123|NCT03563612|Active Comparator|differential ventilation first, cpap late|
89387124|NCT01348009|Experimental|Tesetaxel-capecitabine-cisplatin|
89387125|NCT03620305||Description of treatment of septic pseudarthrosis|chirurgical and medical treatment
89387126|NCT01343173|Experimental|Patients|
89387127|NCT05309954||Observational (With Bone Scan)|Individuals with a Family history of Paget's disease of bone (PDB) affecting first degree relative such as a parent or sibling that have not already diagnosed with PDB
89387128|NCT05309954||Observational (Without Bone scan)|Individuals, that are spouses, friends and/or non blood relatives of the individuals with a family history of PDB.
89387129|NCT01346995|Experimental|Experimental Knee Pain|Experimental knee pain induced by injections of 1 ml hypertonic saline in to the infrapatellar fat pad
89387130|NCT01346995|Active Comparator|Control|non-painful injections of isotonic saline into the infrapatellar fatpad.
89387131|NCT02830880|Experimental|FACBC|Participants with biopsy-proven primary or recurrent castration-resistant prostate carcinoma with skeletal and/or nodal involvement will undergo an FACBC PET-CT scan.
89387132|NCT03141307|Active Comparator|Intervention|The EICI intervention group will receive an electronic interactive tool with movie clips and external links available through the tool. The movie intervention group will watch the educational consent movie and receive the standard paper-based brochure.
89387133|NCT03141307|Placebo Comparator|Control|This group will receive the standard of care currently used (paper-based brochure)
89387134|NCT01347151|Experimental|Glide scope|
89387135|NCT01347151|Experimental|Pentax airway scope|
89387136|NCT01348243|Experimental|Clodronate 200 mg|
89387137|NCT01348243|Active Comparator|Clodronate 100 mg|
89387138|NCT01348321|Experimental|Azithromicine plus levamisole|
89387139|NCT01348321|Experimental|Azithromicin|
89387140|NCT03772951|Active Comparator|Cognitive Remediation Therapy|The study group received antipsychotic drugs Clozapine combined with Computerized Cognitive Remediation Therapy for 4 times/week for 45 minutes each time. For a total of 12 weeks. Clozapine, dosage, dosage form, and frequency :300~600 mg/d; po; duration: 12 week.
89387141|NCT03772951|Placebo Comparator|Clozapine|Clozapine, dosage, dosage form, and frequency :300~600 mg/d; po; duration: 12 week.
89387142|NCT01343329|Experimental|Subjects Receiving Esmolol|The Esmolol arm is defined as a 48-hour intravenous infusion of esmolol (Brevibloc 20mg/ml), which will be started on enrollment.
89387143|NCT01343329|Active Comparator|Subjects receiving Propranolol|The comparison arm will be comprised of oral propranolol, starting with 20mg PO every 6 hours prn (as needed) to reduce heart rate into target range. If 20mg is ineffective, the dose will be doubled at each dosing interval until an adequate dose is found, not to exceed 120mg four times daily. (ex: 20mg, 40mg, 80mg, 120mg)
89387144|NCT01317589|Active Comparator|fentanyl|active pain treatment with fentanyl patch
88862753|NCT06297863|Experimental|HEAD DOWN TILT -10° to -15° (HDT15)|"HDT15 will be applied in the intervention group in 2 different settings:~in the Emergency Room, by tilting the stretcher to lower the head by -10° to -15° relative to the body of the patient; the degree of tilting will be checked using a dedicated digital inclinometer or a mobile phone app~in the Angiography Suite, by tilting the angiography table to lower the head by -10° to -15° relative to the body of the patient, depending on the actual technology of the angiography system of each clinical site; the degree of tilting will be automatically checked using the angiography system HDT15 will start as soon as possible following randomisation in the Emergency Room (i.e. after vascular neuroimaging), and will be maintained during the transfer to the Angiography Suite, as well as during the entire thrombectomy procedure. HDT15 will end after the completion of mechanical thrombectomy."
88862754|NCT06297863|No Intervention|USUAL POSITIONING|Patients randomised in the control group will be maintained in the usual position during the emergency room phase (0° to +30°) and on the angiography table (0°), according to standard practice. Mechanical thrombectomy will be performed as per usual care.
88862755|NCT06297824|Other|ERGT-A|12 session emotion regulation treatment in group format. Psychoeducation and homework assignments. Subjects taught are the function of deliberate self-harm (DSH), functionality of emotions, negative consequences of emotional avoidance, non-avoidant emotion regulation.
88862756|NCT06297811|Experimental|Trilaciclib group|
88862757|NCT06297811|Active Comparator|Control group|
88862758|NCT06297785|Other|Nurse-delivered, gut-directed hypnotherapy|
88862759|NCT06297759||healthcare professionals who care for patients with dementia|Participants will be selected by healthcare professionals who care for patients with dementia. At the first meeting, participants will be informed about the study, will be screened for inclusion criteria, and a written informed consent form will be obtained before testing.
88862760|NCT06297733||Physiotherapy Students|The population of the research consists of undergraduate students of the physiotherapy and rehabilitation department.
88862761|NCT06297720|Experimental|Oral hydration|wet swab-ice cube-small amount of water
88862762|NCT06297720|No Intervention|No hydration|According to routine care, no oral fluid supplementation is provided.
89387145|NCT01317589|Experimental|methadone|active pain treatment with methadone
89387146|NCT01347385|Experimental|Barbed suture|
89387147|NCT01347385|Active Comparator|Traditional suture material|
89387148|NCT01348399||XIENCE PRIME stents|
89387149|NCT01348477|Experimental|Elliptical domed mesh technique|84 adult patients with primary uncomplicated inguinal hernia, treated with an open preperitoneal elliptical mesh technique
89387150|NCT01348477|Active Comparator|Lichtenstein technique|84 adult patients with primary uncomplicated inguinal hernia treated with the Lichtenstein technique (gold standard)
89387151|NCT01347463||Traditional|
89387152|NCT01347619|Active Comparator|Arm 1. Toolkit only with Web Access|NHs in this arm will receive the toolkit only and web access to the materials.
88862763|NCT06297707|Experimental|experimental group|aquatic high intensity resistive training
88862764|NCT06297707|Active Comparator|control group|usual care
88862765|NCT06297681||newly diagnosed M-protein related cardiac disease group|M-protein related cardiac disease aged 18 and above (at least one of the following criteria is met): (1) Systemic amyloidosis of the affected heart; (2) Presence of M component and presence of arrhythmia, cardiac enzyme abnormalities, cardiac function abnormalities, and exclusion of other diagnosable cardiac diseases. It is expected to include 40 patients with M-protein related cardiac disease. The treatment medication for enrolled patients must comply with the treatment regimen of Daratumumab + Bortezomib + Dexamethasone. All patients were given Dapagliflozin 10mg/day at the beginning of treatment (creatinine clearance rate greater than 20ml/min).
88862766|NCT06297668|Experimental|Treatment Sequence 1: ABC|Participants will be randomized to one of the 6 different treatment sequences. Each participant will receive 3 single-dose treatments of BGF MDI HFA with spacer (Treatment A), followed by BGF MDI HFO with spacer (Treatment B), and then BGF MDI HFO without spacer (Treatment C) with single dose (4 puffs) on Day 1 of all treatment periods.
89387153|NCT01347619|Active Comparator|Arm 2.Toolkit, Audit/Feedback, Education|NHs in the second arm will receive the toolkit, web access, periodic audit and feedback reports of antipsychotic prescribing to NH leadership, and faxed educational messages adapted from the AHRQ atypical antipsychotic CERSG to prescribers.
89387154|NCT01347619|Active Comparator|Arm 3. All above plus academic detailing|NHs in the third arm will receive the previous items plus face-to-face academic detailing.
89387155|NCT01343563|Active Comparator|Low frequency to High|For the first six weeks, subjects randomized to this group will receive low frequency stimulation. At the six week point, the low frequency group subjects will be crossed over to high frequency for the remaining six weeks.
89387156|NCT01343563|Active Comparator|High frequency|Subjects randomized to this group will receive high frequency stimulation for the entire 12 weeks of the first phase of this study.
89387157|NCT01348555|Experimental|V0162|
89003384|NCT05400473|Experimental|Therapeutic exercise group + photobiomodulation|This group will consist of 30 participants. Initially, photobiomodulation will be applied on the cervical region. A low-power infrared laser therapy unit (Therapy XT - ANVISA RDC Standard 185/2001 - DMC, São Paulo, SP, Brazil) will be used to carry out the photobiomodulation protocol. The infrared laser therapy unit to be used has the characteristics: continuous optical output of 100 mW, with a wavelength of 808 nm, beam size area of 0.028 cm2, power density 1.78 W/cm2, with 7 Joules per point, with a duration of 70 seconds of application for each point.For application, the individual will be seated. With the cervical region bare, the therapist will position the tip of the laser therapy unit perpendicularly on each of the 12 predefined points along the cervical region (6 points laterally to the right and 6 points laterally to the left).
89387158|NCT01348555|Placebo Comparator|Placebo|
89387159|NCT04437277|Experimental|Patients consenting|
89387160|NCT00687986|Active Comparator|primary surgery|primary surgical resection
89387161|NCT00687986|Experimental|stereotactic radiotherapy|primary stereotactic radiotherapy
89387162|NCT01348633||Sub-study 1|The Quantitative, Doppler SD-OCT Blood Flow Technology will be validated and calibrated by manipulating end-tidal blood gases using the computer-controlled gas sequencer (Slessarev et al, 2005) in 15 healthy controls. Homeostatic inner retina blood flow values and the magnitude of vascular reactivity will be compared between Doppler SD-OCT blood flow technology and the Canon Laser Blood Flowmeter, an established standard, at specific locations within the retinal vascular tree.
89387163|NCT01348633||Sub-study 2|The Quantitative, Hyper-Spectral Imaging Derived Oxygen Saturation Maps of the major retinal vessels and capillary beds will be validated and calibrated in human volunteers using our novel and exact technique that allows the precise control of the partial pressure of oxygen (PO2) to induce controlled and safe levels of hypoxia. Oxygen saturation values will be compared to measured PO2 values (i.e. recognized standard) for various levels of hypoxia and will be used to provide in-sight into the properties of the data output e.g. effective operating range, linearity of response. At the end of the study, subjects will be returned to normoxic conditions to assess reproducibility of oxygen saturation maps.
89387164|NCT01348633||Sub-study 3|Subjects with symptoms of branch and central retinal artery and vein occlusion within the past 2 months will be used to validate the Doppler SD-OCT blood flow technology and the hyperspectral imaging derived oxygen saturation maps. In cases of central retinal vein and artery occlusion, imaging values (i.e. inner retinal and choroidal blood flow, oxygen saturation values of the major retinal vessels and the capillary beds of the retina and ONH) will be compared between the affected and unaffected eyes. In cases of branch occlusion, imaging values will be compared between the affected and unaffected quadrants of the affected eye and between the affected and unaffected eyes. The difference in inner retinal and choroidal blood flow for each eye will be calculated and compared between eyes.
89387165|NCT01348633||Sub-study 4|Calibration for retinal melanin, crystalline lens absorption, macular pigment, morphological variation and pre-retinal autofluorescence in healthy subjects (n=20 per decade, range 40 to 80yrs). Established reflectometric techniques to derive absorption values and autofluorescence techniques will be used to calculate correction values for each parameter that influences the hyper-spectral retinal and ON oxygen saturation imaging data (Keilhauer and Delori, 2006; Delori et al, 2007).
89387166|NCT01348633||Sub-study 5|Establishment of a database of healthy control imaging values (n=20 per decade, range 40 to 80yrs). A database of healthy control values will be established for each technology taking into account extraneous factors such as age (range 40 to 70 years) and gender. The healthy control database will be compared to the results of each individual patient in the prospective study phase of this proposed Research Program (see Prospective Study Phase, 3, Control group). Statistical confidence limits for abnormality at each time point, and for progression overtime, will be established. Measurements will be repeated at separate visits to establish repeatability.
89387167|NCT03563378|Experimental|Lactated ringers solution|Participants in this group will receive Lactated Ringer's solution during the intraoperative period.
89387168|NCT03563378|Experimental|Normal saline solution|Participants in this group will receive Normal saline solution during the intraoperative period.
89387169|NCT01352455|Experimental|5 days per week hemodialysis|5 days per week, 2 hours 20 minutes per session versus 3 days per week, 4 hours per session
89003385|NCT05398809|Experimental|Ruxolitinib/APECED-AA Patients|All participants receiving IP through this protocol (APECED-AA patients)will receive ruxolitinib.
89387170|NCT02829944|Experimental|Ropivacaine|Subjects will receive 440 mg ropivacaine and 30 mg ketorolac. Infusion of study medication will start after the skin is sutured and will continue for 48 hours after cesarean delivery.
89387171|NCT02829944|Placebo Comparator|Placebo|Subjects will receive saline placebo. Infusion of study medication will start after the skin is sutured and will continue for 48 hours after cesarean delivery.
89387172|NCT03563300|Active Comparator|Wheat flour|Wheat flour will be administered blindly versus placebo for 7 days
89387173|NCT03563300|Placebo Comparator|Rice flour|Placebo will be administered blindly versus wheat flour for 7 days
89387174|NCT04014842|Other|RapidShock|Patients receiving xseries device with rapid shock enabled
89387175|NCT04014530|Experimental|Phase I dMMR and pMMR|2-4 groups of 3 patients treatment with 200mg i.v. Pembrolizumab q3w and dose escalation of Ataluren in order to determine the Ataluren MTD. These patients can either be pMMR/dMMR CRC and dMMR EC patients.
89387176|NCT04014530|Experimental|Phase II dMMR|Mismatch repair deficient CRC or EC patients treated with 200mg i.v. pembrolizumab q3w and Ataluren at MTD.
89387177|NCT04014530|Experimental|Phase II pMMR|Mismatch repair proficient CRC patients treated with 200mg i.v. pembrolizumab q3w and Ataluren at MTD.
89387178|NCT03563534|Active Comparator|silver diamine fluoride|38% silver diamine fluoride applied to cavitated primary molars twice per week to arrest caries
89387179|NCT03563534|Active Comparator|interim restorative therapy|Resin modified glass ionomer applied to cavitated primary molars
89535289|NCT03222271|Active Comparator|I) Extubation to NIV (S/T mode)|"The patients will receive NIV using S/T mode after extubation with the following parameters:~Expiratory Positive Airway Pressure (EPAP): 4-8 centimeter water (cmH2O).~Inspiratory Positive Airway Pressure (IPAP): 12-20 cmH2O.~Respiratory rate (RR): 10-12 breath/minute."
88862767|NCT06297668|Experimental|Treatment Sequence 2: ACB|Participants will be randomized to one of the 6 different treatment sequences. Each participant will receive 3 single-dose treatments of BGF MDI HFA with spacer (Treatment A), followed by BGF MDI HFO without spacer (Treatment C), and then BGF MDI HFO with spacer (Treatment B) with single dose (4 puffs) on Day 1 of all treatment periods.
88862768|NCT06297668|Experimental|Treatment Sequence 3: BAC|Participants will be randomized to one of the 6 different treatment sequences. Each participant will receive 3 single-dose treatments of BGF MDI HFO with spacer (Treatment B), followed by BGF MDI HFA with spacer (Treatment A), and then BGF MDI HFO without spacer (Treatment C) with single dose (4 puffs) on Day 1 of all treatment periods.
88862769|NCT06297668|Experimental|Treatment Sequence 4: BCA|Participants will be randomized to one of the 6 different treatment sequences. Each participant will receive 3 single-dose treatments of BGF MDI HFO with spacer (Treatment B) followed by BGF MDI HFO without spacer (Treatment C), and then BGF MDI HFA with spacer (Treatment A) with single dose (4 puffs) on Day 1 of all treatment periods.
89387180|NCT02824562|Other|Intervention|The intervention group will receive treatment as usual plus a chronic pain self-management program which includes six one-on-one sessions facilitated by a trained interventionist and six group sessions facilitated by a trained interventionist and a peer. A peer is an HIV-infected patient living with chronic pain, who has completed all ten of the one-on-one sessions offered, received training to co-facilitate the six group sessions with the interventionist, and is successfully self-managing his/her chronic pain. The participants will complete an outcome assessment within 30 days of the last group session.
89535290|NCT03222271|Experimental|II) Extubation to NIV (iVAPS) mode|"The patients will receive NIV using iVAPS mode after extubation with the following parameters:~Patient's height in cm..~Target alveolar ventilation (Va): adjusted provided that tidal volume is 8 ml/kg of ideal body weight (IBW).~Expiratory Positive Airway Pressure (EPAP) :4-8 cmH2O~Minimum and maximum Pressure Support (PS) :8-16~Respiratory rate :10-12 breath/min."
88862770|NCT06297668|Experimental|Treatment Sequence 5: CAB|Participants will be randomized to one of the 6 different treatment sequences. Each participant will receive 3 single-dose treatments of BGF MDI HFO without spacer (Treatment C), followed by BGF MDI HFA with spacer (Treatment A), and then BGF MDI HFO with spacer (Treatment B) with single dose (4 puffs) on Day 1 of all treatment periods.
88862771|NCT06297668|Experimental|Treatment Sequence 6: CBA|Participants will be randomized to one of the 6 different treatment sequences. Each participant will receive 3 single-dose treatments of BGF MDI HFO without spacer (Treatment C), followed by BGF MDI HFO with spacer (Treatment B), and then BGF MDI HFA with spacer (Treatment A) with single dose (4 puffs) on Day 1 of all treatment periods.
88862772|NCT06297655|Experimental|Recombinant human activated coagulation factor Ⅷ for injection|Each subject in this study receive on-demand treatment with recombinant human coagulation factor VIII for injection for 180 days, with an increase in medication frequency based on the relief after medication.
88862773|NCT06297629|Experimental|Group 1|If participants test positive for minimal residual disease (MRD), participants will be enrolled in Group 1. MRD refers to small numbers of cancer cells that remain in the body during or after treatment. Participants in this group will receive ASTX727 and DLI. If participants are enrolled in Group 1, the participant will take ASTX727 on Days 1-4 of each cycle.
88862774|NCT06297629|Experimental|Group 2|If participants do not test positive for MRD, you will be enrolled in Group 2. Participants in this group will only receive ASTX727. If participants are enrolled in Group 2, the participant will take ASTX727 on Days 1-3 of each cycle.
88862775|NCT06297616|Experimental|LY3841136|LY3841136 administered subcutaneously (SC)
88862776|NCT06297616|Placebo Comparator|Placebo|Placebo administered SC
88862777|NCT06297603|Experimental|Retatrutide Dose 1|Participants will receive retatrutide administered subcutaneously (SC).
88862778|NCT06297603|Experimental|Retatrutide Dose 2|Participants will receive retatrutide administered SC.
88862779|NCT06297603|Experimental|Retatrutide Dose 3|Participants will receive retatrutide administered SC.
88862780|NCT06297603|Placebo Comparator|Placebo|Participants will receive placebo administered SC.
88862781|NCT06297564|Active Comparator|Progesterone primed endometrial protocol|The cases were received soft progesterone capsules (brand name: Utrogestan, 100 mg, Laboratories Besins International, France) 100 mg and 150 IU of human menopausal gonadotropin (hMG) concomitantly from the menstrual cycle (MC) day 3 until the trigger day
88862782|NCT06297564|Experimental|Gonadotropin-releasing hormone antagonist protocol|The cases were received the gonadotropin-releasing hormone antagonist (GnRH-ant) protocol consisting of HMG 150 IU's daily injection from MC 3 until the trigger day. GnRH-ant (Cetrotide, 0.25 mg, MerckSerono) was started when at least one of the following criteria were met: LH >10 IU/L, the presence of at least one follicle with mean diameter >14 mm, or serum E2 level >600 pg/mL.
88862783|NCT06297538|Experimental|gamma transcranial alternating current stimulation|
88862784|NCT06297538|Sham Comparator|sham transcranial alternating current stimulation|
88862785|NCT06297512|Experimental|pGBM patients therapy|"Whole therapy radiation therapy~Temozolomide concomitant~After 1 month adjuvant Temozolomide,~After 3 months Doxorubicine~adjuvant Temozolomide"
88862786|NCT06297486|Experimental|Cohort A (Primary Cohort)|Participants with severe or moderately severe hemophilia A without FVIII inhibitors using routine FVIII prophylaxis
88862787|NCT06297486|Experimental|Cohort B|Participants with severe or moderately severe hemophilia A without FVIII inhibitors using on-demand FVIII replacement therapy
88862788|NCT06297486|Experimental|Cohort C|Participants with severe or moderately severe hemophilia A without FVIII inhibitors using emicizumab prophylaxis
88862789|NCT06297473|Experimental|Telephone-/video follow-up|Yearly routine review of patients status will take place by using telephone- or video consultation.
88862790|NCT06297473|Active Comparator|Standard|Yearly routine review of patients status will take place as an in-person interview
88862791|NCT06297460|Experimental|STEPPS program|The only condition is the experimental one. Participants receive the STEPPS program
88862792|NCT06297434|Experimental|J2H-1702 A mg|
88862793|NCT06297434|Experimental|J2H-1702 B mg|
88862794|NCT06297434|Experimental|J2H-1702 C mg|
89535291|NCT03081507|Experimental|LHW-led small media intervention arm (SM-LHW)|
89535292|NCT03081507|Experimental|LHW-led plus small media intervention arm (PN-LHW)|
88862795|NCT06297434|Placebo Comparator|Placebo|
89185040|NCT04105127|Active Comparator|Posterior builds-ups|Intervention orthodontic - fixed orthodontic treatment in patients with overbite reduction: fixed orthodontic treatment with resin build-ups bonded to the occlusal surfaces of first or second upper/lower molars
89387181|NCT02824562|Other|Control|"The control group will receive treatment as usual. The treatment as usual or control group refers to the standard of care that patients receive for their chronic pain. This standard of care allows patients to discuss chronic pain with their providers at their discretion. Although highly variable, providers can recommend and prescribe pharmacologic (e.g., opioid and other pain medication), non-pharmacologic (e.g., physical therapy, referral to psychology) approaches for pain. This study will not interfere in any way with usual care. No additional treatment will be provided to participants allocated to the control group. The participants will complete an outcome assessment within 30 days of the last group session."
89387182|NCT03835598||Patients with cardiac biological prosthesis|
89387183|NCT02744066|Other|Neonates|Neonates admitted to the NICU will be fitted for NEATCAP, non-invasive novel hearing protection device.
89387184|NCT03563456|Experimental|EXPERIMENT (EXP)|Subjects conduct the structured combined exercise in form of combination of High Intensity Interval Training and Resistance Training
89387185|NCT03563456|Active Comparator|CONTROL (KTR)|Subjects conduct structured exercise of cardiorespiratory training in form of lower-volume continuous cardiorespiratory exercise.
89387186|NCT03827330||Patients|Patients who had Candida species growth from blood cultures drawn at the National Institutes of Health
89185041|NCT02583906|Other|cpap treatment|patients randomized to the 'no cpap' arm will not be treated by CPAP
89185042|NCT02583906|No Intervention|no cpap|patients randomized to the 'cpap' arm will be treated by CPAP
89185043|NCT04066257|Active Comparator|Tegoprazan 50 mg|Oral administration of Tegoprazan 50 mg twice daily for 7 days
89185044|NCT04066257|Active Comparator|Tegoprazan 50 mg+MTN 500 mg+TCL 500 mg+BIS 300 mg|Oral administration of Tegoprazan 50 mg twice daily, Metronidazole 500 mg three times daily, and Tetracycline hydrochloride 500 mg & Tripotassium bismuth dicitrate 300 mg four times daily for 7 days
89387187|NCT03563144|Experimental|NANT Pancreatic Cancer Vaccine|"in subjects with ECOG=2 or subjects with ECOG=0 or 1~A combination of agents will be administered to subjects in this study:~cyclophosphamide, bevacizumab, oxaliplatin, capecitabine, 5-fluorouracil, leucovorin, nab-paclitaxel, aldoxorubicin HCl, avelumab, ALT-803, haNK, GI-4000, GI-6207, GI-6301, ETBX-011, ETBX-021, ETBX-051, ETBX-061."
89387188|NCT03563144|Active Comparator|Gemcitabine and Nab-paclitaxel|Gemcitabine plus Nab-paclitaxel will be administered to subjects with ECOG=2
89387189|NCT03563144|Active Comparator|Gemcitabine|Gemcitabine will be administered to subjects with ECOG=0 or 1
89387190|NCT04763720||Dyadic Developmental Psychotherapy|Families being treated with DDP at either of the centres
89387191|NCT01338818|Experimental|Ritalin LA|All participants started with Ritalin LA 20 mg/day and increased at weekly intervals in increments of 20 mg/day until reaching the patient's optimal dose 40, 60 or 80 mg/day).
89387192|NCT02823470|Experimental|Arm A: activated smart device alerts and feedback|LUM/IVA: LUM 400 mg q12h/IVA 250 mg q12h through Week 48.
89387193|NCT02823470|Experimental|Arm B: de-activated smart device alerts/feedback features|LUM/IVA: LUM 400 mg q12h/IVA 250 mg q12h through Week 48.
89387194|NCT04748510|Active Comparator|Functionally aligned Total Knee Arthroplasty|Knee arthroplasty performed using a functional alignment theory
89387195|NCT04748510|Active Comparator|Mechanical axis aligned Total Knee Arthroplasty|Knee arthroplasty performed using a mechanical alignment theory
89387196|NCT05238584|No Intervention|Total omentectomy|Total or subtotal gastrectomy with D2 lymphadenectomy and total omentectomy.
89387197|NCT05238584|Experimental|Partial omentectomy|Total or subtotal gastrectomy with D2 lymphadenectomy and partial omentectomy.
89387198|NCT03821948||Average CRC Risk Group|Stool sample collection and blood draw in men and women aged 40 and older with average CRC risk undergoing a standard of care colonoscopy procedure
89387199|NCT03821948||Increased CRC Risk Group|Stool sample collection and blood draw in men and women aged 40 and older with increased CRC risk undergoing a standard of care colonoscopy procedure
89387200|NCT03562910|Experimental|Intervention|All enrolled subjects will be given access to the HelpSteps application, either via their personal cell phone or to a provided tablet.
89387201|NCT03562754|Active Comparator|Control|
89387202|NCT03562754|Experimental|Prometheus System|
89387203|NCT02259920|Active Comparator|Treatment A|KUC 4783 CL, immediate release tablets
89387204|NCT02259920|Experimental|Treatment B|KUC 4783 CL delivered as a particulate formulation to the distal small bowel
89387205|NCT02259920|Experimental|Treatment C|KUC 4783 CL delivered as a particulate formulation to the ascending colon
89387206|NCT02259920|Experimental|Treatment D|KUC 4783 CL delivered as a solution formulation to the ascending colon
89387207|NCT02259920|Experimental|Treatment E|KUC 4783 CL delivered as a solution formulation to the descending colon
89185045|NCT04066257|Active Comparator|MTN 500 mg+TCL 500 mg+BIS 300 mg|Oral administration of Metronidazole 500 mg twice daily, Tetracycline hydrochloride 500 mg & Tripotassium bismuth dicitrate 300 mg four times daily for 7 days
89185046|NCT00915707|Experimental|Baseline|Subjects are tested under normal sleep conditions for carbohydrate metabolism and appetite regulation.
89185047|NCT00915707|Experimental|Sleep restriction|Subjects are tested under sleep restriction for carbohydrate metabolism and appetite regulation.
89185048|NCT00915707|Experimental|Reduced sleep quality|Subjects are tested under a poor sleep quality condition for carbohydrate metabolism and appetite regulation.
89185049|NCT04080102|Experimental|High intensity interval training (HIIT)|
89185050|NCT04080102|Experimental|Essential Amino Acid Supplement|
89185051|NCT04080102|Experimental|High intensity interval training + Essential Amino Acid|
89185052|NCT04080102|No Intervention|Control|
89185053|NCT02604251|Experimental|Treatment with KLOX BioPhotonic WoundGel System|One breast will be randomized to be treated with KLOX BioPhotonic WoundGel System.
89535293|NCT03207997|Experimental|Mild pulmonary fibrosis|mild pulmonary fibrosis (VFC> 75% theoretical and DLCO / VA> 55%) 2 additional unenhanced MR sequences
89535294|NCT03207997|Experimental|Moderate pulmonary fibrosis|moderate pulmonary fibrosis (VFC 50-75% and DLCO 36-55%) 2 additional unenhanced MR sequences
89387210|NCT01371656|Experimental|Arm I (levofloxacin)|Patients receive levofloxacin PO or IV over 60-90 minutes once or twice daily beginning on day 3 during 2 consecutive courses of chemotherapy or beginning on day -2 during HSCT and continuing until blood counts recover.
89387211|NCT01371656|No Intervention|Arm II (standard of care)|Patients receive established standard of care and receive chemotherapy or HSCT as patients in Arm I.
89387212|NCT01354106|Experimental|3M Kind Removal Silicone Tape|"investigational medical Silicone tape, 1 x 1.5 sample, applied on time, worn for 24 hours."
89387213|NCT01354106|Other|3M Micropore Medical Tape|"Commercially available Medical Paper Tape, 1 x 1.5 sample, applied on time, worn for 24 hours. Study Control."
89387214|NCT01354028|Experimental|Massage therapy|Massage therapy for 10 minutes during quiet alert state following 9 AM feeding. Actigraph in place to measure sleep for 3 hours.
89387215|NCT01354028|No Intervention|No massage therapy|This was a crossover trial with two arms. On one day, infants received massage therapy for 10 minutes. On the other day, infants were monitored as usual with the Actigraph to measure sleep efficiency, but received no massage therapy. This was the control or no intervention arm.
89387216|NCT03065582|Experimental|Sunscreen application|All subjects will undergo topical application of 3 products and an additional site will serve as a control
89387217|NCT04541888|Experimental|Experimental Group|322 subjects will be treated with CsA eye gel: 0.3 g: 0.15 mg, 1 times daily, The treatment period is 12 weeks. The basic medicine is Hypromellose Eye Drops, 3 times daily for 12 weeks.
89387218|NCT04541888|Placebo Comparator|Control group|322 subjects will be treated with Placebo : 0 g: 0mg, 1 times daily, The treatment period is 12 weeks. The basic medicine is Hypromellose Eye Drops, 3 times daily for 12 weeks.
89387219|NCT01354964|Experimental|Vitamin D|Participants received weekly oral vitamin D drops using a weight-based calculated dosage for up to six months.
89387220|NCT01354964|Placebo Comparator|Placebo|Participants received weekly oral placebo drops (similar in taste and appearance to vitamin D) for up to six months.
89185054|NCT02604251|Active Comparator|Treatment with silicone sheets|The second breast will be randomized to be treated with silicone sheets.
89387221|NCT03562676|Experimental|weightlessness|
89387222|NCT02673476|Placebo Comparator|Placebo|Identical Placebo Comparator
89387223|NCT02673476|Experimental|ALS-008176|ALS-008176 tablets
89387224|NCT01354496|Experimental|Cohort 1 - LY2409021 reference form|A 20 milligram (mg) LY2409021 dose, reference form administered orally in the fasted state
89387225|NCT01354496|Experimental|Cohort 1 - LY2409021 medium test form fed|Single 20 mg LY2409021 test form with medium particle size administered orally immediately after ingestion of a standardized high-fat meal
89387226|NCT01354496|Experimental|Cohort 1 - LY2409021 medium test form fasted|Single 20 mg LY2409021 test form with medium particle size administered orally in the fasted state
89387227|NCT01354496|Experimental|Cohort 2 - LY2409021 low test form fasted|Single 20 mg LY2409021 test form with low particle size administered orally in the fasted state
89387228|NCT01354496|Experimental|Cohort 2 - LY2409021 medium test form fasted|Single 20 mg LY2409021 test form with medium particle size administered orally in the fasted state
89387229|NCT01354496|Experimental|Cohort 2 - LY2409021 high test form fasted|Single 20 mg LY2409021 test form with high particle size administered orally in the fasted state
89387230|NCT04164134||Retinoblastoma patients (children)|Children that are currently diagnosed with a retinoblastoma. Blood will be collected and a short questionnaire has to be filled by the parent or legal guardian. Samples will be taken together with standard care blood draw, so no extra venepuncture is required.
89387231|NCT04164134||Controls (children)|Children with an unrelated problem/condition for which surgery is needed Blood will be collected and a short questionnaire has to be filled by the parent or legal guardian. Samples will be taken during standard care blood draw, so no extra venepuncture is required.
89387232|NCT04164134||Retinoblastoma survivors (adults)|"Adults that carry a RB1 germline mutation and were diagnosed and treated for retinoblastoma in the past.~Blood will be collected and a short questionnaire has to be filled."
89387233|NCT04164134||Controls (adults)|Healthy adult controls Blood will be collected and a short questionnaire has to be filled.
89387234|NCT04164134||Retinoblastoma survivors with Secondary primary malignancies|"Adults that carry a RB1 germline mutation, were treated for retinoblastoma in the past, and are currently diagnosed with a secondary primary malignancy.~Blood will be collected and a short questionnaire has to be filled. Tumor tissue will be collected during surgery."
89387235|NCT02259998|Experimental|Persantin® new formulation|
89387236|NCT02259998|Active Comparator|Persantin® commercial formulation|
89387237|NCT04009460|Experimental|Part A dose escalation|ES101 will be escalated in patients with advanced solid tumors.
89387238|NCT04009460|Experimental|Part B expansion|Subjects with solid tumors will be treated with single-agent ES101 at either specified dose levels or RP2D.
89387239|NCT02035826|Active Comparator|Arm 1|Arm (Expected Value) 2 Digit Match 1st Digit Match 2nd Digit Match Arm 1 ($2.80) $100 $10 $10
89387240|NCT02035826|Active Comparator|Arm 2|Arm (Expected Value) 2 Digit Match 1st Digit Match 2nd Digit Match Arm 2 ($1.40) $50 $5 $5
89387241|NCT02035826|Active Comparator|Arm 3|Arm (Expected Value) 2 Digit Match 1st Digit Match 2nd Digit Match Arm 3 ($0.70) $25 $5 $0
89387242|NCT02035826|No Intervention|Arm 4|Control Arm
89387243|NCT02035904|Experimental|Levobupivacaine|Levobupivacaine Patient Controlled Infusion 5 ml 0,25%, lock out 2 hours
89387244|NCT02035904|Placebo Comparator|Saline|patient controlled infusion 5 ml bolus, lock out 2 hours
89535295|NCT03207997|Experimental|Severe pulmonary fibrosis|severe pulmonary fibrosis (VFC <50% theoretical or DLCO / VA <35%). 2 additional unenhanced MR sequences
89535296|NCT03207997|Active Comparator|Control group|2 additional unenhanced MR sequences
89535297|NCT05006235|Active Comparator|Salbutamol Group|included babies who had received nebulized B2 agonist salbutamol (0.15 mg/kg) + 4ml normal saline
89535298|NCT05006235|Active Comparator|Epinephrine Group|included babies who had received nebulized epinephrine (0, 05 ml/Kg) + 4ml normal saline
89535299|NCT05006235|Placebo Comparator|Saline Group|include babies who had received nebulized 0.9% saline
89387245|NCT04110080|Experimental|Enhanced recovery after surgery|Preoperatively, patients will be counseled on optimization of physical and nutritional status. They will receive carbohydrate loading drinks prior to surgery. Intraoperatively, standard ASA monitors will be utilized, and patients will receive general anesthesia. Goal directed fluid management will be enforced with bolus options based on hemodynamics. Transabdominal plane and rectus sheath block will be performed in the operating room by the regional anesthesia team. Post-operatively pain management will include multimodal analgesic medications. Regular diet will be allowed and encouraged on post-operative day 0 (POD). Lines and drains will be minimized to encourage early mobilization and bowel function. Patients will be counseled on expectations of discharge criteria POD0.
89387246|NCT04110080|Active Comparator|Standard of care|Patients will receive traditional care for donor nephrectomy. Patients will be instructed to fast for 24 hours preoperative. On day of surgery, standard monitors will be used, and intraoperative management per anesthesiologists discretion including pain management. Post-operative, patients will receive pain medications, including opioids, as needed. Intravenous fluids will be continued until patients tolerate liquids per os. Bowel regimen will be ordered as needed. Patients will be discharged once meeting pre-set criteria.
88862796|NCT06297421|Experimental|Homogenized Prescription Enterobacteria Capsule|Oral Homogenized Prescription Enterobacteria Capsule，0.4 ml biologics/capsule Take 20 capsules daily, 10 capsules in the morning and 10 capsules in the evening for 6 consecutive days and rest for 1 day. This is a cycle. Take it for three consecutive cycles.
89387247|NCT03562520|Experimental|Adolescents with bipolar disorder|Forty adolescents (aged 13-21) with BD (type I, II, or not otherwise specified/other specified and related disorder) will be enrolled in the behavior change counseling intervention.
88862797|NCT06297421|Placebo Comparator|Placebo|Oral Placebo Capsule，0.4ml formulation/capsule Take 20 capsules daily, 10 capsules in the morning and 10 capsules in the evening for 6 consecutive days and rest for 1 day. This is a cycle. Take it for three consecutive cycles.
88862798|NCT06297408|Experimental|Relma-cel|Evaluate the safety and tolerability of Relma-cel in moderate to severe active systemic lupus erythematosus (SLE) and determine the Phase II Recommended Dose (RP2D)
89185055|NCT02583126|Experimental|Music Group|Prescribed medical/chemotherapy treatment plus standard care + Guided Imagery and Music
89387248|NCT02035982|Active Comparator|Cholinesterase Inhibitor|Participants randomized into the cholinesterase inhibitor arm will continue receiving their cholinesterase inhibitor at the same dosage.
89387249|NCT02035982|Placebo Comparator|Placebo|Participants randomized into the placebo arm will be tapered off their cholinesterase inhibitor for the first 2 weeks. For the remaining 6 weeks of their study they will be receiving only placebo, and no cholinesterase inhibitor.
89387250|NCT05707832|Experimental|Amphotericin B cholesteryl Sulfate Complex for Injection|Subjects will receive ABCD intravenous injection.
89387251|NCT02822222|Experimental|RMJH-111b|Four (4) RMJH-111b (magnesium citrate, tribasic anhydrous) soft gelatin capsules (110 mg elemental magnesium/capsule) orally bid for 7 days
89387252|NCT02822222|Placebo Comparator|Placebo|Four (4) placebo soft gelatin capsules (0 mg elemental magnesium/capsule) orally bid for 7 days
89387253|NCT02821910|Experimental|High dose, fed|1 fixed dose combination (FDC) tablet vs. 4 single tablets under fed conditions
89387254|NCT02821910|Experimental|High dose, fasted|1 fixed dose combination (FDC) tablet vs. 4 single tablets under fasted conditions
89387255|NCT02821910|Experimental|Low dose, fed|1 fixed dose combination (FDC) tablet vs. 4 single tablets under fed conditions
89387256|NCT05707910|Experimental|Treatment Cohort|EBV immunological agent administration on day 1,7,14,28 and 60 for Intradermal Injection
89387257|NCT03972956||Colorectal cancer or gastric cancer patient|Patients suffering from CRC or gastric cancer scheduled to have surgical resection of colon/rectum or stomach.
89387258|NCT03972956||Non-malignant disease patient|Patients suffering from non-malignant disease scheduled to have surgery.
89185056|NCT02583126|No Intervention|Control Group|Prescribed medical/chemotherapy treatment plus standard care
89185057|NCT00730119||Neonates|Subjects ages birth to 30 days
89387259|NCT02817776|Experimental|Treatment group|Pulmonary vein isolation (PVI) by RF ablation treatment with the THERMOCOOL SMARTTOUCH® SF catheter in persistent AF population.
89387260|NCT03138655|Experimental|UC: <30 kg Participants, Vedolizumab 100 mg|Participants with UC having baseline weight of <30 kg were randomized to this low dose group and received vedolizumab 100 mg IV infusion on Day 1 and at Weeks 2, 6 and 14.
89387261|NCT03138655|Experimental|UC: <30 kg Participants, Vedolizumab 200 mg|Participants with UC having baseline weight of <30 kg were randomized to this high dose group and received vedolizumab 200 mg IV infusion on Day 1 and at Weeks 2, 6 and 14.
89387262|NCT03138655|Experimental|CD: <30 kg Participants, Vedolizumab 100 mg|Participants with CD having baseline weight of <30 kg were randomized to this low dose group and received vedolizumab 100 mg IV infusion on Day 1 and at Weeks 2, 6 and 14.
89387263|NCT03138655|Experimental|CD: <30 kg Participants, Vedolizumab 200 mg|Participants with CD having baseline weight of <30 kg were randomized to this high dose group and received vedolizumab 200 mg IV infusion on Day 1 and at Weeks 2, 6 and 14.
88862799|NCT06297382|Experimental|Experimental|In the 2023-2024 academic year, those in the experimental group will be determined by randomization among the students who are senior students at the faculty of nursing, who have not received ChatGPT training before and who agree to participate in the research. Students in the experimental group will have data collection forms filled out. Then, 4 hours of ChatGPT based nursing process training will be given. Measurements will be taken again after the training and 6 weeks after the training.
88862800|NCT06297382|No Intervention|Control|In the 2023-2024 academic year, students who are senior students at the faculty of nursing, who have not received ChatGPT training before and who agree to participate in the research, will be determined by randomization and those in the control group will be determined. Students in the control group will fill out data collection forms. Students in the control group will not be given any training. Data collection forms will be applied again 6 weeks after the training.
88862801|NCT06297369|No Intervention|control group|a. Group 1 (Control group, N = 30 patients) which will include patients who will receive cisplatin chemotherapy starting from 75mg/m2 for 4 cycles (21-28 days and or fractionated)
88862802|NCT06297369|Active Comparator|treatment group|b. Group 2 (N = 30 patients) will receive N-acetylcysteine 600 mg twice daily (Acetylcystein ® 600 mg effervescent instant granules sachets, Sedico, Egypt) with cisplatin chemotherapy for 4 cycles (21-28 days and or fractionated)
88862803|NCT06297356|Experimental|intervention|This group will use a stress ball during nebuliser therapy. This process will be repeated at least twice a day.It will be a single application since the patients' current dyspnea and anxiety levels will be evaluated.
88862804|NCT06297356|No Intervention|Control|Patients in this group will receive nebuliser therapy at least twice a day. However, no intervention will be made in the meantime. Measurements will be taken before and after any nebulizer treatment.
88862805|NCT06297343||Adult patients with chronic renal failure|Adult patients with chronic renal failure for whom arteriovenous fistula creation is planned
88862806|NCT06297330|Experimental|Sleep intervention|One arm : All volunteers will receive a sleep management intervention.
88862807|NCT06297317||Experienced long-distance trail runners|"All the participants of the First 'Trail Scientifique de Clécy 2021. This was a multidisciplinary protocol to investigate the mechanisms that contribute to performance during an ultradistance trail race (156-km)"
88862808|NCT06297291||Prospective Ultrasound Renal Denervation Treatment|Hypertension patients that meet the eligibility criteria for treatment with Recor Medical Paradise Ultrasound Renal Denervation System will be enrolled and followed post-procedure for 5 years.
88862809|NCT06297291||RADIANCE CAP Transfer|Subjects enrolled in the RADIANCE Continued Access Protocol (CAP) study that are still active and have already completed their post-procedure 12-month follow-up visit are invited to participate in US GPS for long-term annual follow-up visits. These subjects will have already received the ultrasound Renal Denervation treatment under the RADIANCE CAP protocol and will not receive the procedure under the US GPS protocol.
88862810|NCT06297265|Experimental|Supportive care (MLD breast massage)|Patients undergo MLD breast massage over 30-60 minutes BIW for the duration of SOC radiation therapy and for 1 month thereafter.
88862811|NCT06297252|Experimental|Pregnant adults|Adults women with an ongoing pregnancy who are scheduled for a T2 ultrasound, regardless of known history or pregnancy context (normal or pathological).
88862812|NCT06297213|Other|Open Label|Probiotic
88862813|NCT06297200|Experimental|Pain, Craving, and Anxiety measures|Multi visit - LIFU/Sham. Participants will complete pain, craving, and anxiety measures pre and post intervention.
88862814|NCT06297187||CUSA Excel®|Subjects having had treatment for Vulvar Intraepithelial Neoplasia (VIN) and/or condyloma acuminata using CUSA® Excel system.
88862815|NCT06297187||CUSA Clarity®|Subject having had treatment for Vulvar Intraepithelial Neoplasia (VIN) and/or condyloma acuminata using CUSA® Clarity system.
88862816|NCT06297174|Experimental|Generic Racecadotril 100 mg Capsules|Generic Racecadotril 100 mg Capsules (test drug)
88862817|NCT06297174|Active Comparator|HIDRASEC®|HIDRASEC® (Racecadotril 100 mg Capsules (reference drug))
88862818|NCT06297161||Patients with newly diagnosed CP Ph+ CML|Patients newly-diagnosed with chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML)
88862819|NCT06297135|Experimental|Behavioral intervention group|Parents who enroll in the program will receive a series of 6 videos (~7 minutes each), 1 video at a time, generally every 3 days. Parents will also receive daily written texts, which include implementation tips and an assessment of a target (transition) behavior.
88862820|NCT06297109|Experimental|Intervention|Participants treated with patient-specific implants for Le Fort I osteotomy and genioplasty in bimaxillary orthognathic surgery.
88862821|NCT06297109|Active Comparator|Control|Participants treated with conventional mini-plates for Le Fort I osteotomy and genioplasty in bimaxillary orthognathic surgery.
89185058|NCT00730119||Infants|Subjects aged >30 days to 2 years
89185059|NCT00730119||Adults|Subjects aged 18 years of age or older
89185060|NCT00920712|Experimental|Weiqi decoction|
89185061|NCT00920712|Placebo Comparator|low dose of Weiqi decoction|
89185062|NCT03655821|Active Comparator|Arm A (BSA-based dosing)|Dosing of pemetrexed is based on BSA according drug label
89185063|NCT03655821|Experimental|Arm B (renal function based dosing)|Dosing of pemetrexed is based on renal function, calculated to reach the target AUC.
89185064|NCT04104971||with complications|children who did liver transplantation and develop complications
89185065|NCT04104971||without complications|children who did liver transplantation and do not develop complications
89185066|NCT02585076||Cohort 1|Patients aged 60 years or older regardless of gender and race with a documented diagnosis of hypertension will be enrolled into this study after the decision for electrocardiographic screening for AF has been made by the investigator
89185067|NCT00733863|Experimental|1|
89185068|NCT00733863|Placebo Comparator|2|
89185069|NCT04524702|Experimental|Treatment (paricalcitol, hydroxychloroquine, chemotherapy)|Beginning day -14, patients receive paricalcitol IV three times weekly and hydroxychloroquine PO BID. Patients also receive gemcitabine IV over 30 minutes and nab-paclitaxel IV over 30 minutes on days 1, 8, 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89387264|NCT03138655|Experimental|UC: >=30 kg Participants, Vedolizumab 150 mg|Participants with UC having baseline weight of >=30 kg were randomized to this low dose group and received vedolizumab 150 mg IV infusion on Day 1 and at Weeks 2, 6 and 14.
89387265|NCT03138655|Experimental|UC: >=30 kg Participants, Vedolizumab 300 mg|Participants with UC having baseline weight of >=30 kg were randomized to this high dose group and received vedolizumab 300 mg IV infusion on Day 1 and at Weeks 2, 6 and 14.
89387266|NCT03138655|Experimental|CD: >=30 kg Participants, Vedolizumab 150 mg|Participants with CD having baseline weight of >=30 kg were randomized to this low dose group and received vedolizumab 150 mg IV infusion on Day 1 and at Weeks 2, 6 and 14.
89387267|NCT03138655|Experimental|CD: >=30 kg Participants, Vedolizumab 300 mg|Participants with CD having baseline weight of >=30 kg were randomized to this low dose group and received vedolizumab 300 mg IV infusion on Day 1 and at Weeks 2, 6 and 14.
89387268|NCT02036138|Active Comparator|Advanced Medical Therapy Patients.|Advanced medical therapy is deﬁned as the use of the latest lifestyle guidelines set forth by the American Diabetes Association to optimize weight loss and glycaemic management, frequent home monitoring/titration strategies, use of latest FDA approved drug therapy (incretin analogues, insulin sensitizers, etc.)
89387269|NCT02036138|Experimental|Bariatric Surgery Patients - Roux-en-Y gastric by- pass|
89387270|NCT02036138|Experimental|Bariatric Surgery Patients -Laparoscopic sleeve gastrectomy|
89387271|NCT03562442|Experimental|Smokers|"Healthy caucasian smokers who are willing to quit smoking are investigated before cessation (Visit 1) and 6 weeks after cessation (Visit 2).~Intervention: Smoking cessation"
89387272|NCT03562442|No Intervention|Never-Smokers|Healthy caucasian volunteers who never smoked are investigated once only (Visit 1)
89387273|NCT05707520||MPA|Immunosuppressant with enteric-coated mycophenolate sodium
88862822|NCT06296524|Experimental|Footcore exercises and conventional therapy|Participants received Footcore exercises along with conventional therapy for 4 weeks, twice a day Footcore exercises includes toe yoga, toe spreads, foot doming, calf stretch, ball rolling. + conventional therapy
89387274|NCT05707520||None MPA|Immunosuppressant without enteric-coated mycophenolate sodium
89387275|NCT04412785|Experimental|Single Arm|Cyclosporine; oral or IV route of administration, per investigator discretion. Duration of administration up to 14 days, as tolerated.
89387276|NCT03689101|Experimental|Endometrial biopsies|Endometrial biopsy was performed precisely 7 days after LH surge (LH+7) to count endometrial CD138.
89387277|NCT02820038|Active Comparator|Other CMI Only|Approximately 75 participants will be assigned to this study group. Participants will ONLY receive medication guides, or other comparable Consumer Medication Information (CMI), for rheumatoid arthritis medications.
89387278|NCT02820038|Experimental|Other CMI & SMART Program|Approximately 75 participants will be assigned to this study group. Participants will receive medication guides, or other comparable Consumer Medication Information (CMI), for rheumatoid arthritis medications AND will be enrolled into the Strategic Memory Advanced Reasoning Training (SMART) Program.
88862823|NCT06296524|Active Comparator|Conventional Therapy|Participants received conventional physiotherapy treatment, which includes toe curl, picking of small object, heel raise (For 4 weeks, twice a day).
88862824|NCT06295562|Experimental|atomoxetine 80mg combined with oxybutynin 5mg, then placebo|Participants will receive atomoxetine 80mg combined with oxybutynin 5mg once (1 h before polysomnographic study). After a washout period of at least 7 days, they will receive placebo once (1h before polysomnographic study).
88862825|NCT06295562|Experimental|venlafaxine 37.5mg, then placebo|Participants will receive venlafaxine 37.5mg once (1 h before polysomnographic study). After a washout period of at least 7 days, they will receive placebo once (1h before polysomnographic study).
88862826|NCT06295562|Experimental|atomoxetine 80mg combined with trazodone 100mg, then placebo|Participants will receive atomoxetine 80mg combined with trazodone 100mg once (1 h before polysomnographic study). After a washout period of at least 7 days, they will receive placebo once (1h before polysomnographic study).
88862827|NCT06295562|Experimental|placebo, then atomoxetine 80mg combined with oxybutynin 5mg|Participants will receive placebo once (1 h before polysomnographic study). After a washout period of at least 7 days, they will receive atomoxetine 80mg combined with oxybutynin 5mg once (1h before polysomnographic study).
88862828|NCT06295562|Experimental|placebo, then venlafaxine 37.5mg|Participants will receive placebo once (1 h before polysomnographic study). After a washout period of at least 7 days, they will receive venlafaxine 37.5mg once (1h before polysomnographic study).
88862829|NCT06295562|Experimental|placebo, then atomoxetine 80mg combined with trazodone 100mg|Participants will receive placebo once (1 h before polysomnographic study). After a washout period of at least 7 days, they will receive atomoxetine 80mg combined with trazodone 100mg once (1h before polysomnographic study).
88862830|NCT06295302|Experimental|HWH486|
88862831|NCT06295302|Placebo Comparator|Placebo|
88862832|NCT06295159|Experimental|Arm A: Nivolumab|PD-L1 positive patients will be given Nivolumab 480 mg I.V. over 30 minutes (-/+ 10 minutes) every 4 weeks (every cycle) for 2 a total of 2 cycles.
89185070|NCT00727389|Other|groups of women|To evaluate the capacity of muscular function and articular amplitude in the aged women
89387279|NCT02820038|Experimental|Drug Facts Boxes Only|Approximately 75 participants will be assigned to this study group. Participants will ONLY receive Drug Facts Boxes for rheumatoid arthritis medications.
89387280|NCT02820038|Experimental|Drug Facts Boxes & SMART Program|Approximately 75 participants will be assigned to this study group. Participants will receive Drug Facts Boxes for rheumatoid arthritis medicationsAND will be enrolled into the Strategic Memory Advanced Reasoning Training (SMART) Program.
89387281|NCT01348867|No Intervention|Usual Care|These 120 controls will undergo a comprehensive assessment at baseline then again at 12 months, which is similar to the intervention group. However, in between these 2 time points the 'control' patients will receive usual care and hence will not be monitored under the structured care protocol by a diabetes nurse consultant led team.
89387282|NCT01348867|Experimental|Structured Care|"120 patients will be randomised to the structured care group, and these patients will receive repeated follow-ups and contact with the structured care team in between the two comprehensive assessments at week 0 and week 52.~Patients will be seen by Diabetes Nurse Consultant at week 0, 6, 12, 24 38 during the year. At each visit, clinical and laboratory measurements will be performed; treatment compliance and self care will be assessed and medications will be adjusted to optimise metabolic and cardiovascular risk factors control.~Patients will be seen by the doctors in their clinic follow up at week 0, 24 and 52.~Technical service assistance will telephone patient at week 18, 30 and 44 to reinforce patient to take medications, attend clinical follow up."
89387283|NCT01352611|Experimental|baclofen, intrathecal|A single injection of 50 micrograms of baclofen between the 4th and 5th lumbar vertebrae into the spinal fluid.
89387284|NCT01352689|Experimental|CKD-828(Fixed Dose Combination)|Single oral dose of a FDC tablet consisting of Telmisatan 80mg/S-Amlodipine 2.5mg
89387285|NCT01352689|Experimental|Free combination Therapy|Co-administration of single oral doses of a 80mg tablet of Telmisatan and a 2.5 mg tablet of S-Amlodipine
89387286|NCT03688399|Experimental|IOL Implantation experimental|hydrophobic, trifocal intraocular lens POD L GF with light distribution far > intermediate > near
89387287|NCT03688399|Active Comparator|IOL Implantation Comparator|hydrophobic, trifocal intraocular lens POD F GF with light distribution far > near > intermediate
89387288|NCT01357213|Placebo Comparator|Arm 2|Placebo in all three cohorts
89387289|NCT01357213|Experimental|Arm 1|XOMA 3AB in 3 dose levels/cohorts A, B or C.
89387290|NCT01348945|Experimental|Stump Preserving ACL Surgery|Patients of partial tear ACL injury fulfilling inclusion criteria received stump preserving ACL surgery, entered conventional ACL reconstruction rehabilitation program
89387291|NCT01348945|Active Comparator|ACL Reconstruction|Patients with complete tear ACL injury received ACL reconstruction entered conventional ACL rehabilitation program
89387292|NCT01357291|Experimental|Recidivism Reduction Program|Inmates who were assigned to the RRP intervention.
89387293|NCT01357291|Active Comparator|Business-as-usual|Business-as-usual are those inmates not assigned to RRP and who receive standard inmate programming.
89387294|NCT01352767|Experimental|InsuPad Device|Use of the InsuPad which heats the injection site.
89387295|NCT01352767|No Intervention|CONTROL|no treatment
89387296|NCT02819804|Experimental|Treatment (dasatinib, nivolumab)|Patients receive dasatinib PO QD on days 1-28 and nivolumab IV over 30 minutes on days 8 and 22 of course 1 and on days 1 and 15 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89387297|NCT02819726|Experimental|SAIT101|In Part A, each patient will receive one course of two 1000 mg SAIT101 infusions: one on Day 1 and the second on Day 15. In Part B, patients with an inadequate response (<50% improvement from Baseline in swollen and tender joint count at Week 24) will be eligible for a further course of two 1000 mg infusions of SAIT101 on Week 24 and Week 26.
89387298|NCT02819726|Active Comparator|Rituxan|In Part A, each patient will receive one course of two 1000 mg Rituxan infusions: one on Day 1 and the second on Day 15. In Part B, patients with an inadequate response (<50% improvement from Baseline in swollen and tender joint count at Week 24) will be randomised in a 1:1 ratio to receive Rituxan or SAIT101 10000 mg infusions on Week 24 and Week 26.
88862833|NCT06295159|Experimental|Arm B: Nivolumab- Relatlimab-rmbw|PD-L1 negative patients will be given a combination of Nivolumab 480 mg with Relatlimab 160 mg I.V. over 60 minutes (-/+ 10 minutes) every 4 weeks (every cycle) for a total of 2 cycles.
88862834|NCT06295159|Experimental|Arm C: Nivolumab plus ipilimumab|PD-L1 negative patients will be given 3 mg/kg of Nivolumab plus 1 mg/kg of Ipilimumab I.V. each given over 30 minutes (-/+ 10 minutes) every 4 weeks (every cycle) for a total of 2 cycles.
89387299|NCT02819726|Active Comparator|MabThera|In Part A, each patient will receive one course of two 1000 mg MabThera infusions: one on Day 1 and the second on Day 15. In Part B, patients with an inadequate response (<50% improvement from Baseline in swollen and tender joint count at Week 24) will be eligible for a further course of two 1000 mg infusions of MabThera on Week 24 and Week 26.
89387300|NCT02816138|Experimental|Transdermal nicotine patch|Transdermal nicotine patch, administered on awakening and removed at bedtime (16h/d). Dosing 3.5mg patch/daily, titrated over study to maximum dose of 21mg patch/daily.
89387301|NCT02036216||Hepatocellular Carcinoma|The mutation will be found in the DNA samples from the plasma and solid tumor tissues in the patients with HCC.
89387302|NCT02036060|Experimental|Arm A|docetaxel 75 mg/m2 + prednisone 10 mg/d + abiraterone 1000 mg/d
89003386|NCT05396157||Patients with an active hematological malignancy admitted to ICU|"All patients 18 years and older admitted to an adult intensive care unit during the current admission episode and that also had an active HM / HCT diagnosis.~We plan to the analyze patients outcomes according to:~Thrombocytopenia We will analyze bleeding and thrombosis risk taking into account platelets levels.~Patients receiving thromboprophylaxis (VTE vs Bleeding)"
89003387|NCT05395195|Experimental|Erythropoietin|Intravenous or subcutaneous injections of erythropoietin (500 U/kg/dose). Total of 9 doses will be administered. First dose will be given within 6 hours of birth. Second dose between 12 to 24 hours from the first dose. Subsequent 7 doses every 24 hours from the second dose.
89387303|NCT02036060|Active Comparator|Arm B|docetaxel 75 mg/m2 + prednisone 10 mg/d
89387304|NCT02815670|Experimental|Idarucizumab|
89387305|NCT02037152|No Intervention|Waitlist|Participants randomized to this arm are instructed that they will have access to the study intervention after four weeks. Waitlist group participants are prompted to answer weekly questionnaires.
89387306|NCT02037152|Experimental|Active treatment|"The active treatment group will be instructed to use the app-guided body scan exercise daily for six days per week over a period of four weeks. The body scan includes 20 minutes of guided audio-- the pre-recorded voice of a narrator instructs the user to systematically direct attention to various parts of the body. Before and after each use of the body scan, users complete a single-item scale measuring pain intensity/distress. Users are prompted to complete all other questionnaires at weekly or four-week intervals. The app includes access to a graphical display showing changes in average pain level. Subjects also have access to a section of frequently asked questions about the practice."
89387307|NCT02036918|Active Comparator|Arm A|Pre-treatment control group will be randomized to immediate lymph node biopsy followed by sipuleucel-T immunotherapy.
89387308|NCT02036918|Experimental|Arm B|Post-treatment experimental group will be randomized to immediate sipuleucel-T immunotherapy followed by lymph node biopsy.
89387309|NCT02809976|Experimental|Ruxolitinib 1.5% phosphate cream|Ruxolitinib 1.5% phosphate cream twice daily to vitiligo patches.
89387310|NCT03816098||elderly patients with dysphagia|
89387311|NCT03816098||elderly patients without dysphagia|
89387312|NCT02036528|Experimental|AppliGel-G with oral Ciprofloxacin and Doxycycline|AppliGel-G (Gentamicin Topical Gel) in conjunction with oral Ciprofloxacin and Doxycycline
89387313|NCT02036528|Active Comparator|Oral Ciprofloxacin and Doxycycline only|Ciprofloxacin and Doxycycline
89387314|NCT02047682|Experimental|Biopsychosocial|Biopsychosocial intervention with Individually tailored physical exercises and stress management
89387315|NCT02047682|Active Comparator|Reference|"Reference group receiving usual care in terms of standard workplace ergonomics and physical exercises"
89387316|NCT02880865|Experimental|Group 1 - MMR and CD-JEV|Participants receiving one dose of CD-JEV vaccine and one dose of MMR vaccine concurrently at Day 0; Group 1 will also receive a second dose of MMR per the routine immunization schedule at Day 84 (12 months of age).
89387317|NCT02880865|Experimental|Group 2 - MMR then CD-JEV|Participants receiving one dose of MMR vaccine at Day 0 and one dose of CD-JEV 56 days later. Group 2 will receive a second dose of MMR per the routine immunization schedule at Day 84 (12 months of age).
89387318|NCT01352923|Experimental|peripheral blood|healthy voluntary donors
89387319|NCT03635125|No Intervention|Background treatment phase|A 12- week Amlodipine 10 mg background treatment phase
89387320|NCT03635125|Active Comparator|Low Dose Treatment Phase-Nebivolol I|4-week low dose Nebivolol10 mg/Metoprolol 50 mg treatment phase
89387321|NCT03635125|Active Comparator|High dose treatment Phase-Nebivolol II|4-week High dose Nebivolol 20 mg/Metoprolol 100mg treatment phase
89387322|NCT03635125|Other|Baseline Washout Phase|2 to 4 week Baseline Washout Phase
89387323|NCT01854385|Experimental|Sumatriptan|Open label study of sumatriptan to treat post-traumatic headache. Subjects will use sumatriptan 100 mg at the onset of headache pain and may repeat the dose if not pain-free in 2 hours. Subjects will receive a maximum of 18 pills for use over two months. Subjects will maintain a daily headache diary.
89387324|NCT02809118|Placebo Comparator|Placebo|Placebo gel for intratympanic use
89387325|NCT02809118|Experimental|AM-111 0.4 mg/ml|AM-111 gel for intratympanic use (0.4 mg/ml AM-111)
89387326|NCT02809118|Experimental|AM-111 0.8 mg/ml|AM-111 gel for intratympanic use (0.8 mg/ml AM-111)
89387327|NCT01353001|Experimental|Diet Only|
89387328|NCT01353001|Experimental|Diet plus Aerobic Training|
89387329|NCT01353001|Experimental|Diet plus Resistance Training|
89387330|NCT02047760||MS patients|All MS sub-types
89387331|NCT02047760||Controls|sex- and age-matched controls
89387332|NCT01349023|Experimental|Standard Energy content/Standard ED|
89387333|NCT01349023|Experimental|Standard Energy content/Reduced ED|
89003388|NCT05395195|Sham Comparator|Control|Mock administration of injections (pretend) behind a screen by a dedicated personal
89387334|NCT01349023|Experimental|Reduced Energy content/Standard ED|
89387335|NCT01349023|Experimental|Reduced Energy content/Reduced ED|
89387336|NCT02036606||mood disorders|Questionary and neuropsychological tasks will be administered
89387337|NCT02036606||control|Questionary and neuropsychological tasks will be administered
89387338|NCT01353157||patients with elective cardiac surgery|
89387339|NCT02047838||Cases.|Patients with recurrent unilateral endometrioma who were previously operated for the same condition.
89387340|NCT02047838||Controls.|Patients previously operated for unilateral endometrioma without recurrence.
89387341|NCT01318681|Experimental|Pollen provocation with systemic treatment|Subjects are treated with Cetirizine 10 mg after a nasal challenge with a pollen solution
89387342|NCT01318681|Experimental|Pollen provocation with topical treatment|treatment with 25ug fluticasone furoate after a nasal pollen challenge
89387343|NCT01318681|Placebo Comparator|placebo treatment after pollen challenge|Placebo treatment after a nasal challenge with pollen solution
89387344|NCT01318681|No Intervention|control condition|A placebo drug is administered after a sham nasal challenge with a pollen solution
89387345|NCT02036684|No Intervention|Healthy Lifestyle Booklet|Standard care for radical prostatectomy (RP) patients includes the provision of preoperative information from a urology nurse educator. Usual care (UC) participants will be given generic instructions by the research coordinator about pelvic floor muscle exercises (PFMX), mobilization and general timeframes for a return to normal activities. The UC group will receive the same PFMX prescription as the PREHAB (Experimental) group and will receive weekly communication from the research coordinator regarding compliance with the PFMX prescription to provide an attentional-control. These instructions are provided in a healthy lifestyle booklet for men with prostate cancer.
89530171|NCT03249805|Experimental|MiracleFeet Foot Abduction Brace (mFAB)|The study will follow the subject for 6 months after their enrollment, beginning at first FAB use. The MiracleFeet Foot Abduction Brace (mFAB) is an injected plastic molded bar with fabric shoes that clip off and on. The shoes have laces and a strap. Both FABs provide 10 degrees of dorsiflexion and 45 or 65 degrees of abduction, and will be equipped with sensors to measure at-home FAB compliance. After the last cast is removed, a brace will be worn for 23 hours/day for the first 3 months and the time will be gradually decreased thereafter to a 'nights and naps' protocol for a total of 12 hours/day. At follow-up appointments the brace will be checked for fit and Pirani score recorded.
89185071|NCT00727467|Experimental|A|"On Days 1-8 of the trial, participants in Group A will be given the iPod with some music on the device to allow all participants to become familiar with the device i.e. turning device on and off, increasing and decreasing the volume. They will be instructed to use the device only when sitting at home, and that the device should not be turned on when walking or performing any mobility related or daily tasks.~On Days 8-15, participants in Group A will be allocated to the 'intervention' phase. Each participant will be given an iPod containing an auditory cue in the form of a continuous metronome beat, individualised to the patient's walking frequency (less 10%).Participants will be instructed to listen to the cueing when they are performing any mobility related tasks. On Days 15-23, participants in Group A will be allocated to the 'control' phase. During this time period, participants will be provided with the iPod shuffle containing no music or metronome beat."
89185072|NCT00727467|Active Comparator|B|"On Days 1-8 of the trial, participants in Group B will be given the iPod with some music on the device to allow all participants to become familiar with the device. They will be instructed to use the device only when sitting at home, and that the device should not be turned on when walking or performing any mobility related or daily tasks.~On Days 8-15, participants in Group B will be allocated to the 'control' phase. During this time period, participants will be provided with the iPod shuffle containing no music or metronome beat. On Days 15-23, participants in Group B will be allocated to the 'intervention phase'. Each participant will be given an iPod containing an auditory cue in the form of a continuous metronome beat, individualised to the patient's walking frequency (less 10%).Participants will be instructed to listen to the cueing when they are performing any mobility related tasks."
89185073|NCT00733941|Experimental|High frequency training|24 interval exercises performed 8 times per week
89185074|NCT00733941|Experimental|Normal frequency training|24 interval exercises performed 3 times per week
89185075|NCT04080258|Experimental|Osteopathic Manipulative Therapy|Osteopathic Manipulative Therapy (OMTh). Patients in the OMTh group will receive 5 Osteopathic manipulative therapies: the first at baseline, the second after 1 week, the third after 3 weeks, and then 2 more treatments on a monthly basis. The protocol will last for three months.
89185076|NCT04080258|Sham Comparator|Light Touch Therapy|Participants to the LTT group will receive the protocol at the same date of the OMTh group.
89185077|NCT04018443||patients admitted ti surgical ICU after major surgery|patient admitted to surgical ICU after major surgery for post-operative close monitoring, assessment and resuscitation of the intravascular volume status
89185078|NCT02583984||Thoracic Surgery with Lung Resection|General anesthesia and lung separation Thoracic Surgery with Lung Resection, such as lobectomy, segmentectomy
89185079|NCT02583984||Thoracic Surgery without Lung Resection|General anesthesia and lung separation Thoracic Surgery without Lung Resection, such as esophageal surgery, mediastinal surgery
89185080|NCT02569203|Placebo Comparator|control group|standard enteral nutrition
89185081|NCT02569203|Experimental|test group I|high-protein enteral nutrition of immune modulating nutrients enriched with β-glucan
89185082|NCT02569203|Experimental|test group II|high-protein enteral nutrition of immune modulating nutrients without β-glucan
89185083|NCT00920478|Active Comparator|Control Group|Inflammatory disease activity assessed using DAS28
89185084|NCT00920478|Experimental|Ultrasound Group|Inflammatory disease activity assessed using musculoskeletal ultrasound (gray scale and power doppler)
89185085|NCT00730197|Experimental|1|NISOLDIPINE EXTENDED-RELEASE TABLETS, 40 MG
89185086|NCT00730197|Active Comparator|2|Sular® Extended Release 40 mg tablets
89185087|NCT00727545|Experimental|1|
89530172|NCT03122249|Other|OASIS|Patients that meet the eligibility criteria will be enrolled in the study and will receive the advanced cancer symptom management intervention
89003389|NCT05390541|Active Comparator|Educational Control|Participants will receive a generic standard of care via a combination of videos, audio, and text/graphics across 5 sessions during 4 weeks.
89185088|NCT00730431|Experimental|IDX184 5 mg|Healthy participants will be administered a single 5 mg dose of IDX184.
89185089|NCT00730431|Experimental|IDX184 10 mg|Healthy participants will be administered a single 10 mg dose of IDX184.
89185090|NCT00730431|Experimental|IDX184 25 mg|Healthy participants will be administered a single 25 mg dose of IDX184.
89185091|NCT00730431|Experimental|IDX184 50 mg|Healthy participants will be administered a single 50 mg dose of IDX184.
89185092|NCT00730431|Experimental|IDX184 75 mg|Healthy participants will be administered a single 75 mg dose of IDX184.
89185093|NCT00730431|Experimental|IDX184 100 mg|Healthy participants will be administered a single 100 mg dose of IDX184.
89185094|NCT00730431|Placebo Comparator|Placebo|Healthy participants will be administered placebo matching IDX184.
89530173|NCT03255421||Patients enrolled|"Patients over 18 years old, consulting for lower urinary tract symptoms and performing an urodynamic examination with a cystometry in a tertiary center are included.~First pressure measurement in the bladder during the classic cystometry. Second measurement of bladder pressures during the bladder emptying."
89530174|NCT03122327||Newly diagnosed MM patients|newly diagnosed MM patients who fulfilled the inclusion criteria for this study
89003390|NCT05390541|Experimental|Empowered to Test Yourself|There will be 5 tailored web based sessions of the intervention over 4 weeks, all of which will follow the same format.
89535300|NCT03323411||Intervention and attention control|the Advance Care Treatment Plan experimental group received education on dementia cardiopulmonary resuscitation and tube feeding. The attention control group received education on exercise stress control diabetes and hypertension
89535301|NCT03319823|Experimental|Thiazide Therapy Group|• Group (1): Thiazide Therapy Group: Men without diabetes, and mild hypertension - a sleeping systolic blood pressure of 125-139 mm Hg, and an awake average blood pressure of < 160 mm Hg
88862837|NCT06294327|Experimental|Reactive static air support surfaces (Repose®)|"Intervention with Repose® devices~Standard repositioning protocol is applied."
88862838|NCT06294327|No Intervention|Alternating air pressure mattress (ArjoHuntleigh® Alpha Response)|"Standard care with mattress type: ArjoHuntleigh® Alpha Response~Standard repositioning protocol is applied."
88862839|NCT06294093||treadmill group|healthy subjects who run regularly at least twice a week for half an hour, over 80% of the training on treadmill.
88862840|NCT06294093||road group|healthy subjects who run regularly at least twice a week for half an hour, over 80% of the training on road.
88862841|NCT06293417||Treatment group|Statin+Ezefeno
88862842|NCT06293417||Control group|Statin doubling
88862843|NCT06293222||Participants with personal experience of sickle cell disorder.|Participants with personal experience of sickle cell disorder (parents, affected children or siblings).
88862844|NCT06293222||Researchers|Researchers working with children with life limiting or life changing conditions
88862845|NCT06293222||Members of a patient advocacy organisation|Members of a patient advocacy organisation (Sickle Cell Society)
88862846|NCT06292546|Experimental|Group A|Vonorason 20 mg bid + amoxicillin 0.75 g qid for 14 days, followed by 2 doses of bacillus subtilis enteric-coated capsules for 14 days.
88862847|NCT06292546|Experimental|Group B|Vonorason 20 mg bid + amoxicillin 0.75 g qid+ 2 doses of bacillus subtilis enteric-coated capsules for 14 days.
88862848|NCT06292546|Experimental|Group C|2 doses of bacillus subtilis enteric-coated capsules for 14 days, followed by vonorason 20 mg bid + amoxicillin 0.75 g qid for 14 days.
88862849|NCT06292546|Active Comparator|Group D|Vonorason 20 mg bid + amoxicillin 0.75 g qid for 14 days.
88862850|NCT06292247|Experimental|Cognitive behavioral therapy group|CBT is based on the principle that, the way we think profoundly impacts the way we feel and behave. Therefore, learning to think differently can enable the child to feel and act differently. It is a multi-component therapy that companies cognitive (cognitive restructuring) and behavioral (relaxation and distraction) interventions to change these maladaptive cognitions, which change the emotional distress and problematic behaviors. The following techniques were used in our research in a row, unrelated play, animated video modeling, stress-ball relaxation technique, audio music therapy, and positive reinforcement. These have been used effectively to manage children's anxiety during the dental appointment.
88862851|NCT06292247|Experimental|Auricular Plaster Therapy group|APT intervention involves the application of plaster with seeds on specific points of the outer ear, known as auricular points (acupoints). According to Traditional Chinese Medicine, these points correspond to various regions of the body. Applying pressure to these points (acupressure) will stimulate and regulate energy flow throughout the body. This process is believed to restore balance and harmony within the body's system and achieve a therapeutic effect e.g. (anxiety reduction)
88862852|NCT06292247|Experimental|Control group (Tell show do)|TSD is considered the cornerstone of behavior management techniques. It aims to introduce the child to the dental setting before commencing any procedure. With the TSD technique, the child should be informed about the process with a demonstration of the dental procedure using a simulator.
88862853|NCT06290856||Advanced gastrointestinal malignancy|Pancreatic cancer, Colorectal cancer, Cholangiocarcinoma
88862854|NCT06290674|Active Comparator|Study Group (A) (ESWT)|30 participants will receive Extracorporeal Shockwave (one session per week for 6 weeks), in addition to a balanced low-calorie diet (1500 k/cal for 6 weeks).
88862855|NCT06290674|Placebo Comparator|Control Group (B)|30 participant will receive Balanced low-calorie diet (1500 k/cal for 6 weeks), only.
88862856|NCT06290362|No Intervention|Control|Any intervention applied. Following the completion of the research, the need for psychosocial support among the control group participants was assessed, and it was found that none of the students in the control group required such support.
88862857|NCT06290362|Experimental|Cognitive Behavioural Theory-based group consultation|"Cognitive Behavioural Theory-based group consultation was given to the intervention group through an Instagram as online social media platform. This approach has been developed with the philosophy of Cognitive Behavioral Theory (Eskin, 2009). For three days a week over eight weeks of intervention conducted with synchronized psychoeducation sessions, online posts, surveys, personal sharing messages, and group interaction tools.~Introduction and warm-up,~Problem orientation-identifying the problem,~Identifying prior problems-Which one I want to start?~Recognizing the losses caused by problems and complaints,~Setting reachable and realistic goals,~Generating alternatives-What can I do?~Regulating emotions,~Experimenting and exploring. Sessions were completed in approximately one hour as semi-structured interactive group training according to group dynamics."
88862858|NCT06286982||People aged 65 years and older with a Clinical Frailty Score (CFS) ≥5|The Oral Symptom Assessment Scale will be administered to participants. A feedback questionnaire will also be administered.
88862859|NCT06286046|Experimental|Mitapivat 100 mg|Participants will receive mitapivat 100 milligrams (mg) tablet, orally, twice daily (BID) for up to 24 months.
89535302|NCT03319823|Experimental|Combination Therapy Group|• Group (2): Combination Therapy Group: Men with diabetes, or with more severe hypertension - a sleeping blood pressure of ≥ 140 mm Hg, or an awake average blood pressure of ≥ 160 mm Hg.
89535303|NCT03207919|Experimental|Lullaby Project|
89535304|NCT03207919|No Intervention|Control Group|
89535305|NCT03323333|Experimental|Intervention|
89535306|NCT04961151|Experimental|Conductive Wrap Warming|Esophageal warming will be discontinued first
89535307|NCT04961151|Experimental|Esophageal Warming|Conductive wraps will be discontinued first
89387346|NCT02036684|Experimental|Prehabilitation (PREHAB)|The prehabilitation (PREHAB) program focuses on total-body physical exercises and pelvic floor muscle exercises (PFMX). The total-body exercise prescription will consist of 60 minutes of home-based, unsupervised exercise on 3-4 days per week, alternating between aerobic and resistance training. Each session will include: a 5-minute warm-up, 25 minutes of aerobic exercise, 25 minutes of resistance training (5 exercises targeting major muscle groups), and a 5-minute cool-down. Training intensity progression will occur throughout the intervention. Participants will be provided with resistance bands, a stability ball, and an exercise mat. The PFMX prescription will include a gradual increase in PFMX exercises from 60 per day during weeks 1-2, 120 per day during weeks 3-4, and 180 per day during weeks 5-6 until the surgery date. The total number of repetitions of the PFMXs will be divided equally between the rhythmic and sustained contractions.
89387347|NCT03562286|Experimental|Experimental Fetoscopy|All participants will undergo fetoscopic repair of open spina bifida
89387348|NCT03604159|Experimental|Buprenorphine Extended-Release|XRB is a 300mg pre-mixed subcutaneous injectable formulation to be administered monthly. XRB is for abdominal subcutaneous injection only. Participants in the XRB treatment arm will be given 1 or more XRB injections prior to release from jail and one more at week 5 post-release, depending on their release date.
89387349|NCT03604159|Active Comparator|Sublingual Buprenorphine|SLB (SUBOXONE, Zubsolv, or generic tablets) is a daily sublingual film or tablet ranging from 8-24mg/day or equivalent (Zubsolv is dosed 5.7-17.1 mg/day). The film or tablet is placed under the tongue for 5 to 10 minutes until dissolved completely. Participants in the SLB treatment arm will be provided SLB daily by observed dosing in-jail (controlled substances are not self-administered in-jail) and and encouraged to continue SLB treatment in weekly, bi-weekly, or monthly quantities for unobserved, daily, self-administration through week 5. Patients may also elect to obtain SLB care free-of-charge from the Bellevue Hospital Center Addiction Medicine clinic or from non-NYU/Bellevue providers and pharmacies per usual care standards. SLB will not be provided via the study.
89387350|NCT03686930|Active Comparator|Cohort 1 - FP-045 oral solution|FP-045 powder for oral solution, will be reconstituted once daily (QD) dose, administered for 7 consecutive days.
89387351|NCT03686930|Placebo Comparator|Cohort 1 - Placebo for FP-045 oral solution|Placebo oral solution that is identical to the test product, but without FP-045.
89387352|NCT03686930|Active Comparator|Cohort 2 - FP-045 oral solution|FP-045 powder for oral solution (escalated dose), will be reconstituted once daily (QD) dose, administered for 7 consecutive days.
89387353|NCT03686930|Placebo Comparator|Cohort 2 - Placebo for FP-045 oral solution|Placebo oral solution that is identical to the test product, but without FP-045.
89387354|NCT03686930|Active Comparator|Cohort 3 - FP-045 oral solution|FP-045 powder for oral solution (escalated dose), will be reconstituted once daily (QD) dose, administered for 7 consecutive days.
89387355|NCT03686930|Placebo Comparator|Cohort 3 - Placebo for FP-045 oral solution|Placebo oral solution that is identical to the test product, but without FP-045.
89387356|NCT02047916||Normal Neonates > 33 weeks gestation|"Neonates >33 weeks gestational age~Postnatal age <72 hours;~Parental informed consent;~Inpatient at the Royal Sussex County Hospital (RCSH): either receiving special care on the Trevor Mann Baby Unit (TMBU) or normal care on the postnatal ward"
89387357|NCT01353235|Sham Comparator|usual care|
89387358|NCT01353235|Active Comparator|Prednisolone|1mg/kg/day prednisolone for the entire ICU stay and a maximum of 10 days
89387359|NCT02048228|Experimental|genotyping guided therapy|Patients randomized to the genotyping guided therapy arm will have their CYP2C19*2 carrier status determined at the time before antiplatelet therapy with subsequent alteration in antiplatelet therapy for *2 carriers.CYP2C19*2 carriers will be given 90 mg ticagrelor twice daily, and non-carriers will be given 75 mg clopidogrel daily.
89387360|NCT02048228|Active Comparator|Standard Therapy|Patients randomized to the Standard Therapy arm will not undergo genotyping. All patients will be administrated with clopidogrel 75 mg daily for 5 consecutive days.
89387361|NCT05701046||Anterior and oblique interbody fusion (ALIF, OLIF + Posterior fixation (open or MIS) or stand-alone)|
89387362|NCT05701046||Posterior interbody fusion (TLIF or PLIF) (open or MIS)|
89387363|NCT03046927|Experimental|Ergocalciferol|Oral administration of 50,000 IU of ergocalciferol one capsule per week for 2 months; and then once every 2 weeks for 10 months in 20 subjects of 10-21yr with newly diagnosed T1D
89387364|NCT03046927|Placebo Comparator|Placebo|Oral administration of placebo one capsule per week for 2 months; and then once every 2 weeks for 10 months in 20 subjects of 10-21yr with newly diagnosed T1D
89387365|NCT02036762|Active Comparator|Treatment Group|The group submitted to stretching exercises in the respiratory muscles and treadmill exercises
89387366|NCT02036762|Sham Comparator|Control Group|The control group received stretching exercises in the fist and ankle muscles and treadmill exercises
89387367|NCT01357369||Ondansetron/Cefazolin treatment|Pregnant women undergoing uncomplicated cesarean section deliveries who have consented to participate, and will receive Ondansetron and Cefazolin in the course of their clinical care will have PK blood samples drawn.
89387368|NCT02037308|Placebo Comparator|Control white bread|
89387369|NCT02037308|Experimental|Beetroot bread|
89387370|NCT03589105|Experimental|Ocrelizumab Treatment Cycles|Each participant will receive an initial dose of two 300 mg infusions of Ocrelizumab each separated by 14 days followed by one single dose of 600 mg 24 weeks after the initial dose.
89387371|NCT02048306|Experimental|Family-based PR group|
89387372|NCT02048306|Active Comparator|Conventional PR group|
89387373|NCT01357447|Experimental|Dornase alfa (Pulmozyme)|Dornase alfa is a highly purified solution of recombinant human deoxyribonuclease I (rhDNase), an enzyme which selectively cleaves DNA.
89387374|NCT01357447|Placebo Comparator|Saline|Normal saline 0.9% solution
89387375|NCT02048384|Experimental|A - metformin alone|metformin alone Arm A patients will receive metformin 850mg orally twice a day on a 28 day cycle.
89387376|NCT02048384|Active Comparator|B - metformin + rapamycin|metformin + rapamycin Arm B patients will receive 850mg orally twice a day and rapamycin 4mg orally once a day on a 28 day cycle.
88862860|NCT06285396|No Intervention|Control|The myometrial samples are bathed in physiological salt solution (PSS) only.
88862861|NCT06285396|Active Comparator|Ephedrine|The myometrial samples are bathed in physiological salt solution (PSS) with increasing concentrations of ephedrine.
89185095|NCT02583204|No Intervention|Control - standard care|Participants will receive standard care regarding nail toxicity. This entails advice to keep nails trim and the provision of a nail oil to massage into the nail daily. Participants will also receive advice in relation to general healthy living.
89185096|NCT02583204|Experimental|Intervention - Oncolife drops|Participants will receive the same standard care as the control arm, except for the nail drops. The participants will also receive Onicolife nail drops to be applied twice daily.
89185097|NCT02583204|Experimental|Intervention - Nail polish|Participants will receive the same standard care as the control arm, except for the nail drops. The participants will also receive a dark coloured nail polish to be applied as instructed.
89185098|NCT00727701|Experimental|1|Will receive usual wound prevention care, aftercare summaries, and regular surveillance.
89185099|NCT00727701|No Intervention|2|Will receive usual wound prevention and surveillance only.
89185100|NCT00727701|No Intervention|3|Will receive usual wound prevention only.
89185101|NCT02582892|Other|Vit D|Vit D 20 mg/day
89185102|NCT00734175|Experimental|1|Participants will receive 2 doses of vaccine 4 to 8 weeks (28-62 days) apart
89185103|NCT04079946|Active Comparator|patients for whom Complete mesocolic excision will be done|
89185104|NCT04079946|Active Comparator|patients had conventional surgery before|
89185105|NCT00734331||IBD|Inflammatory bowel disease patients
89185106|NCT00734331||Control|Average risk patients undergoing screening colonoscopy
89185107|NCT04512456|Experimental|Active HIV-infected patients|Exercise training
89185108|NCT04512456|No Intervention|Inactive HIV-infected patients|No intervention.
89185109|NCT04512456|No Intervention|Healthy subjects|No intervention.
89185110|NCT02584764|Experimental|CBT with Internet support|16 sessions of Cognitive behavior therapy in group with Internet support between group sessions
89185111|NCT04764513|Experimental|Patients with hematological malignancies after allo-HSCT|"Patients with negative minimal residual disease or stable disease:~After inclusion, patients will receive or not receive chemotherapy. Subsequently, patients will be dosed with γδ T cell.~Patients with positive minimal residual disease but not hematologic relapse:~After inclusion, patients will receive chemotherapy. Subsequently, patients will be dosed with γδ T cell.~Patients with hematologic relapse:~After inclusion, patients will receive chemotherapy. Subsequently, patients will be dosed with γδ T cell."
89185112|NCT02584530|No Intervention|Standard procedure group|PICC line insertion using anatomical landmarks guidance and tip placement confirmation by X-ray
89185113|NCT02584530|Experimental|Interventional group|Ultrasound guidance for PICC line placement and X-ray
89185114|NCT00727779|Experimental|metabolic syndrome|intervention is to undergo eight weeks of progressive strength training; metabolic syndrome subjects will have baseline and post-intervention assessments including muscle biopsies and insulin clamps
89185115|NCT00727779|Active Comparator|control subjects|intervention is to undergo eight weeks of progressive strength training; non-obese sedentary subjects will have the same assessments as the metabolic syndrome subjects and exercise training simultaneously.
89185116|NCT02582736||Olanzapine|Exposure to olanzapine will be defined as a prescription for olanzapine on the date of cohort entry.
88862862|NCT06285396|Active Comparator|Phenylephrine|The myometrial samples are bathed in physiological salt solution (PSS) with increasing concentrations of phenylephrine.
89185117|NCT02582736||Other atypical antipsychotics|Exposure to atypical antipsychotics will be defined as a prescription for an atypical antipsychotic other than olanzapine (clozapine, quetiapine, ziprasidone, paliperidone, or aripiprazole) on the date of cohort entry.
89185118|NCT02582736||Typical antipsychotics|Exposure to typical antipsychotics will be defined as a prescription for a typical antipsychotic (chlormezanone, chlorpromazine, chlorprothixene, flupenthixol, fluphenazine, fluspirilene, haloperidol, levomepromazine, loxapine, mesoridazine, methotrimeprazine, perphenazine, pimozide, pipotiazine, tetrabenazine, thiopropazate, thioproperazine, thioridazine, thiothixene, trifluoperazine or zuclopenthixol) on the date of cohort entry.
89185119|NCT02582736||Risperidone (reference)|Exposure to risperidone will be defined as a prescription for risperidone on the date of cohort entry.
88862863|NCT06285396|Active Comparator|Norepinephrine|The myometrial samples are bathed in physiological salt solution (PSS) with increasing concentrations of norepinephrine.
88862864|NCT06285396|Active Comparator|Control + oxytocin|The myometrial samples are bathed in physiological salt solution (PSS) and oxytocin.
89185120|NCT00734565|Experimental|1|
89185121|NCT04503564|Experimental|Achilles Infusion Set|Coil-reinforced soft polymer indwelling cannula
89185122|NCT00730587||1|Full-term healthy infants ages 5 months to 3 years.
89185123|NCT04019652|Experimental|10 mg CS-3150 (Treatment Sequence 1)|Participants will receive the following treatment sequence (1 treatment per Period): a single oral 10-mg dose of CS-3150, a 40-mg dose of CS-3150, a 400-mg dose of moxifloxacin, followed by placebo.
89185124|NCT04019652|Experimental|40 mg CS-3150 (Treatment Sequence 2)|Participants will receive the following treatment sequence (1 treatment per Period): a single oral 40-mg dose of CS-3150, placebo, a 10-mg dose of CS-3150, followed by a 400-mg dose of moxifloxacin.
89185125|NCT04019652|Experimental|Moxifloxacin (Treatment Sequence 3)|Participants will receive the following treatment sequence (1 treatment per Period): a single oral 400-mg dose of moxifloxacin, 10-mg dose of CS-3150, placebo, 40-mg dose of CS-3150.
89185126|NCT04019652|Experimental|Placebo (Treatment Sequence 4)|Participants will receive the following treatment sequence (1 treatment per Period): a single oral dose of placebo, 400-mg dose of moxifloxacin, 40-mg dose CS-3150, 10-mg dose of CS-3150.
89185127|NCT00734721|Active Comparator|A|Presentation of factual information video
89185128|NCT00734721|Active Comparator|B|Presentation of injection syringe/needle
89185129|NCT00734721|Active Comparator|C|Presentation of emotional information video
89185130|NCT00734721|Active Comparator|D|Stress relaxation music
89185131|NCT04400370||Pediatric patients undergoing lung resection|
89185132|NCT00734955|Experimental|Reduction Mammoplasty|Patients undergoing reduction mammoplasty
89530175|NCT03255343|Experimental|IMDENDRIM|
88862865|NCT06285396|Active Comparator|Ephedrine + oxytocin|The myometrial samples are bathed in physiological salt solution (PSS) with increasing concentrations of ephedrine and oxytocin..
89387377|NCT01353391|Active Comparator|Metformin|
89185133|NCT00734955|Experimental|Mastectomy|Patients undergoing mastectomy
89185134|NCT00734955|Experimental|Lumpectomy|Patients undergoing a lumpectomy
89185135|NCT04078464|Experimental|Acute Physical Activity + Mindfulness training|20 minutes of walking on a treadmill at a moderate pace while listening to a pre-recorded guided mindfulness meditation.
89185136|NCT04078464|Experimental|Mindfulness training|Participants will lie down and listen to a pre-recorded guided mindfulness meditation for 20 minutes.
89185137|NCT04078464|Experimental|Acute Physical Activity|20 minutes of walking on a treadmill at a moderate pace.
89185138|NCT00735111|Experimental|Karnofsky Performance Status Score|
89185139|NCT00735189|Experimental|1|Patient continues to receive anticoagulation care from the Anticoagulation Management Service
89185140|NCT00735189|Active Comparator|2|Patient receives anticoagulation care from their usual primary care physician
89185141|NCT00735345|Experimental|Treatment Arm|Chemo induction therapy followed by chemoradiotherapy and surgical resection or definitive radiotherapy
89185142|NCT00735501||A|
89185143|NCT00728013|Experimental|A|intensive statin group
89185144|NCT00728013|Experimental|B|moderate statin group
89185145|NCT02569749||Group 1|Patients with pacemaker indication (pacemaker already implanted or to be implanted)
89185146|NCT02569749||Group 2|Patients with ICD or CRTD therapy indication (device already implanted or to be implanted)
89185147|NCT02569749||Group 3|Patients with heart failure an preserved LVEF (40-50%)
89185148|NCT02569749||Group 4|Patients with heart failure and reduced LVEF (<40%)
89185149|NCT00735579||Study group|Patients undergoing major abdominal surgery
89185150|NCT00577707|Experimental|Patients With Stage IB-IIIA NSCLC With EGFR Mutations|This is a open label, single center, phase II trial for patients with clinical stage IB-IIIA NSCLC (T1-3N0-2M0) who have resectable tumors that harbor EGFR activating mutations. Patients will receive erlotinib x 3 weeks prior to initiation of concurrent erlotinib and chemotherapy.
89185151|NCT00728325|Active Comparator|1|Standard Vocational Rehabilitation (VRP)
89185152|NCT00728325|Experimental|2|Supported Employment (SE)
89185153|NCT00730743|Experimental|1|Intermittent clamp group
89185154|NCT00730743|No Intervention|2|No clamp group
89185155|NCT00728403|Experimental|1|American Ginseng and American Red Ginseng Capsules
89185156|NCT00728403|Experimental|2|American Ginseng Capsules
89185157|NCT00728403|Placebo Comparator|3|Placebo Capsules
89185158|NCT00730821|Experimental|1|
89387378|NCT01353391|Placebo Comparator|Placebo|
88862866|NCT06285396|Active Comparator|Phenylephrine + oxytocin|The myometrial samples are bathed in physiological salt solution (PSS) with increasing concentrations of phenylephrine and oxytocin..
88862867|NCT06285396|Active Comparator|Norepinephrine + oxytocin|The myometrial samples are bathed in physiological salt solution (PSS) with increasing concentrations of norepinephrine and oxytocin..
88862868|NCT06284096|Experimental|Intervention group|The intervention group, on the other hand, is aimed at participating in both the psychoeducation program conducted by the researcher and these routine practices within the institution.
88862869|NCT06284096|No Intervention|Control Group|The control group is planned to participate only in the routine Community Mental Health Center activities within the institution, such as handicraft activities, art, music, computer courses, etc.
88862870|NCT06283030|Experimental|Hypoglossal nerve stimulation|
88862871|NCT06283017|Experimental|Hypoglossal nerve stimulation|Device-mediated stimulation of the hypoglossal nerve
89185159|NCT00728559|Experimental|1|preemptive trocar site analgesia
89185160|NCT00728559|Experimental|2|trocar site pre skin closure analgesia
89185161|NCT00728559|No Intervention|3|control
89185162|NCT00735813|Experimental|A|Tunneled central venous catheters locked with Taurolock
89185163|NCT00735813|Active Comparator|B|Tunneled central venous catheter locked with heparin
89185164|NCT00736047|Active Comparator|1|
89185165|NCT00736047|Placebo Comparator|2|
89185166|NCT04064775|Experimental|Smart snacking intervention|In intervention 2 participants took part in a 4-week intervention on Instagram. Participants saw images of fictitious peers' snacks or beverages three times per week, and saw snack information images three times per week. Peer snack images were posted on days 2,4 and 6 of each week, and snack information images were posted on days 1,3 and 5 of each week. Images were posted between 10-11am each day. Participants also completed quizzes related to snacking at the end of weeks 1-3. Participants completed a survey at baseline and intervention end to assess their ideal portion sizes to allow for examination of the effectiveness of the intervention.
89185167|NCT04064775|No Intervention|Control|Participants in the control received no intervention. They completed the questionnaires at the end of weeks 1, 2 and 3, and also completed the surveys at baseline and intervention end.
89185168|NCT04064619|Active Comparator|sudden stopping|patients were followed up after 1 and 3 months from stopping the drug,
89185169|NCT04064619|Experimental|Weaning|patients were followed up after 1and 3 months from the end of gradual weaning
89185170|NCT00728637|Experimental|1|Participants took part in the Family Passport to Heart Health Program.
89185171|NCT00728637|Active Comparator|2|Participants took part in a control group.
89185172|NCT00730977|Experimental|single|single arm, open label, 4 doses tested.
89387379|NCT01349335|Experimental|1. tolvaptan|15 mg, P.O., Qd, for 7 days,
89387380|NCT01349335|Experimental|2 tolvaptan|30 mg, P.O., Qd, for 7 days,
89387381|NCT01349335|Experimental|3. Placebo|30mg,P.O.,Qd, for 7 days.
89387382|NCT02048462||Cyclists|
89387383|NCT03040921|Experimental|Uterine Transposition|Patients submitted to uterine transposition.
89387384|NCT03009487|Experimental|Amlodpine, Olmesartan, Rosuvastatin|co-administration of Olmesartan, Amlodipine and Rosuvastatin
89387385|NCT03009487|Placebo Comparator|Olmesartan, Rosuvastatin|co-administration of Olmesartan and Rosuvastatin
89387386|NCT03009487|Placebo Comparator|Amlodipine, Olmesartan|co-administration of Amlodipine and and Olmesartan
89387387|NCT02048540|Experimental|bevacizumab plus DOF|patients receive bev +DOF pre and post surgery up to total 6 cycles
89387388|NCT02048540|Active Comparator|DOF|patients receive DOF pre and post surgery up to total 6 cycles
89387389|NCT01353469|Experimental|Insuman Comb 25|Insuman Comb 25 will be self-injected subcutaneously twice daily 30-45 minutes before breakfast and dinner. The dose will be adjusted individually by monitoring the blood glucose values and symptoms, and following China guideline.
89387390|NCT01353469|Active Comparator|Novolin® 30R|Novolin® 30R will be self-injected subcutaneously twice daily within 30 minutes before breakfast and dinner. The dose will be adjusted individually by monitoring the blood glucose values and symptoms, and following China guideline and the package insert of Novolin® 30R
89387391|NCT02050022||Exacerbation|Patients experiencing acute exacerbation of COPD.
89387392|NCT02050022||Non-Exacerbation|COPD patients not experiencing acute exacerbation of COPD.
89387393|NCT02050100||Lung Cancer|Early-late stage primary lung cancer
89387394|NCT02050100||Lung Neoplasm|Benign non-calcified pulmonary nodules
89387395|NCT03562130|Experimental|Revestive|Revestive® (teduglutide)is administered in children sub cutaneous injection at 0.05 mg/kg body weight once daily
89387396|NCT02050178|Experimental|Drug: OMP-54F28, Nab-Paclitaxel and Gemcitabine|
89387397|NCT02050256|Other|general practioner|
89387398|NCT02037074|Experimental|Experimental: EVP-6308; Arm 1|low dose, Capsule, Twice Daily, Day 1 through Day 14
89387399|NCT02037074|Experimental|Experimental: EVP-6308; Arm 2|intermediate dose, Capsule, Once Daily, Day 1 through Day 14
89387400|NCT02037074|Experimental|Experimental: EVP-6308; Arm 3|high dose, Capsule, Once Daily, Day 1 through Day 14
89387401|NCT02037074|Placebo Comparator|Placebo Comparator; Arm 4|Placebo, Capsule, Once Daily, Day 1 through Day 14
89387402|NCT02048618|Experimental|GLPG0634 200 mg QD|2 tablets of 100 mg GLPG0634 in the morning
89387403|NCT02048618|Experimental|GLPG0634 100 mg QD|1 tablet of 100 mg GLPG0634 and 1 placebo tablet in the morning
89387404|NCT02048618|Placebo Comparator|Placebo QD|2 placebo tablets in the morning
89387405|NCT02047448|No Intervention|Control Group|The control group will receive the current standard of care including medication reconciliation during hospitalization performed by a nurse or physician and education about discharge medications provided by the inpatient nurse. There will not be a pharmacist discharge care plan developed for this group. The patients will not be required to choose a participating community pharmacist and no counseling and education appointments will be scheduled. Any medication-related problems identified by the pharmacists and will be communicated as appropriate and resolved as is the standard of care. Any other interaction between the patient and their pharmacist will be according to the current standard of care.
89387406|NCT02047448|Experimental|Pharmacist Counseling|The hospital pharmacist will meet with the patient and complete medication reconciliation, assess the patient's understanding of the medications, and identify medication-related problems. The hospital pharmacist will complete a pharmacist discharge care plan and a copy will be sent to the participating community pharmacist. The patients will be scheduled for the first meeting with their community pharmacist within 1 week of hospital discharge. The community pharmacist will interview the patient about their general health and any current symptoms of heart failure or COPD, identify any additional medication-related problems, follow-up on any issues as described in the pharmacist discharge care plan, and provide patient education. The patients will then meet with their community pharmacist for counseling and patient education at monthly intervals for 6 months following hospital discharge.
89387407|NCT02050412|Other|Cat fur scratch test|
89003391|NCT05389956||Ulsan University Hospital-Health Screening Cohort (UUH-HEALS)|Ulsan University Hospital-Health Screening Cohort is a prospective cohort of participants who participated in general health screening programs at the Health Promotion Center of Ulsan University Hospital (Ulsan, South Korea). This cohort includes health screening participants aged 19 years and older from community and workplace. The purpose of this cohort is to offer relevant and useful data on health risk factors in the field of non-communicable diseases such as cardiovascular disease and malignancy.
89387408|NCT02048696|Experimental|Exercise training|Secondary prevention and cardiac rehabilitation clinic of the Montreal Heart Institute. Subjects will undergo twice weekly exercise training with high intensity interval training for a period of 12 weeks.
89185173|NCT00728715|Experimental|A|Medium Dose of budesonide-formoterol
89185174|NCT00728715|Active Comparator|B|High dose of inhaled budesonide (1600 mcg/day)
89387409|NCT02048696|No Intervention|control|Individuals in this group are offered current ACC/AHA recommendations on physical activity in patients post-myocardial infarction.
89387410|NCT02050568||Anterior genital prolapse|Women with anterior genital prolapse ≥ grade 2, who are awaiting genital prolapse surgery.
89387411|NCT02050568||Posterior genital prolapse|Women with posterior genital prolapse ≥ grade 2, who are awaiting genital prolapse surgery.
89387412|NCT03810638||Heart Failure Patients|All Heart Failure Patients seen at 3 major academic medical centers.
89387413|NCT02047526||1|
89387414|NCT02048774|Active Comparator|High Social Position|The investigators will randomly assign a participant to a higher social position.
89387415|NCT02048774|Experimental|Low Social Position|The investigators will randomly assign a participant to a lower social position.
89387416|NCT02048852|Experimental|Reduced Nicotine Content -Non Menthol|Switch from own brand of cigarette to SPECTRUM research cigarettes (NRC 200-Reduced Nicotine Content cigarette) which contain 0.07mg nicotine yield without menthol.
89387417|NCT02048852|Experimental|Reduced Nicotine Content- Menthol|Switch from own brand of cigarette to Reduced Nicotine Research Cigarettes which contain 0.07mg nicotine yield with Menthol
89387418|NCT02048852|Active Comparator|Conventional Nicotine Content- Menthol|Allow own brand of Conventional Nicotine-Menthol Cigarette. No research cigarettes used.
89387419|NCT02048852|Experimental|Conventional Nicotine Content- Non Menthol|Switch from own brand of cigarette to SPECTRUM research cigarette (NRC-600 Conventional Nicotine )which contains conventional nicotine yield.
89387420|NCT03561974|Experimental|Humidification|
89387421|NCT03561974|No Intervention|Control group without humidification|
89387422|NCT02048930||Initiation cohort|Receive their first prescription for ICS therapy as one of the study drugs
88862872|NCT06282848|Active Comparator|Atropine 0.05%|Group receiving atropine treatment for 18 months after 6 months of monitoring without intervention
88862873|NCT06282848|Experimental|DIMS lens|Group receiving DIMS lens treatment for 18 months after 6 months of monitoring without intervention
88862874|NCT06282757|Experimental|Placebo group|The placebo intervention group will be shown an online educational VR video.
88862875|NCT06282757|Active Comparator|Nocebo group|The nocebo intervention group will be shown an online educational VR video.
89185175|NCT00731289|Experimental|1|single intraarticular injection of hyaluronan 3 ml (Durolane®, 20 mg/ml non-animal stabilized hyaluronic acid (NASHA) in buffered physiological sodium chloride solution pH 7 in one pre-filled glass syringe in sterile pack
89185176|NCT00731289|Active Comparator|2|single intraarticular injection of triamcinolone 1 ml (Volon A10®, 10mg triamcinolone acetonide, 10mg/ml)
89185177|NCT00736203||A|non-smokers
89387423|NCT02048930||Step-up cohort|Receive a prescription for one of the study drugs at a dose ≥50% that of their prescribed ICS dose during baseline.
88862878|NCT06281509|Experimental|Patients with Dupuytren disease|120 individuals diagnosed with Dupuytren disease (primary or recurrent).
88862879|NCT06281509|Experimental|Healthy controls|120 participants with no other medical conditions affecting the function of the hand (musculoskeletal pathology, vascular or neurological conditions such as CRPS, rheumatoid arthritis and paralysis).
89387424|NCT02048930||Switch cohort|switch from BUD DPI (other) to BUD EH or continue on BUD DPI (other) with no change in ICS dose
88862881|NCT06277869|Experimental|Thermal Jacket|As a intervention, the enrolled preterm or low birthweight neonates gets the thermal jacket as well as Kangaroo Mother Care for thermal care.
88862882|NCT06277869|Active Comparator|Kangaroo Mother Care|As a control, the enrolled preterm or low birthweight neonates gets the conventional Kangaroo Mother Care only.
88862883|NCT06277609|Experimental|Part A: Lu AF28996 with Enzyme Inhibitors|Participants will receive repeated single doses of Lu AF28996 and enzyme inhibitors.
88862884|NCT06277609|Experimental|Part B: Lu AF28996 with Antibiotics|Participants will receive single doses of Lu AF28996 and amoxicillin/clavulanic acid.
88862885|NCT06277050|Experimental|Maintenance Therapy with Toripalimab and Capecitabine|Capecitabine maintenance therapy (1000 mg/m2 orally twice daily on days 1-14) every 3 weeks. Maintenance therapy of Toripalimab (240 mg, every 3 weeks). The total treatment time of oral chemotherapy is 12 months.
88862886|NCT06277050|Active Comparator|Maintenance Therapy with Capecitabine alone|Capecitabine maintenance therapy (1000 mg/m2 orally twice daily on days 1-14) every 3 weeks. The total treatment time of oral chemotherapy is 12 months.
88862887|NCT06276478|Experimental|Trial group|
88862888|NCT06276478|Active Comparator|Control group|
88862889|NCT06276322|Experimental|Low Back Pain Group|Low back pain group will be evaluated the kinematics of all spine segments in 3 planes while performing the tasks that patients with chronic low back pain often describe as painful in their daily lives,
89387425|NCT02049008|Experimental|Photodynamic Therapy|
89387426|NCT02049008|Sham Comparator|Sham Photodynamic Therapy|
89387427|NCT02808338|Active Comparator|Philips BiPAP AutoSV Advanced System One|"The Bi-Level Positive Airway Pressure system will be used and will be configured with these settings.~P max: 30 EPAP min: 4 EPAPmax: 15 Pressure Support (PS) min: 0 Pressure Support (PS) max: 15 BiFlex: 2 Rate: Auto"
88862890|NCT06276322|Active Comparator|Healthy Group|Healthy Group's results will be compared them with low back pain group
88862891|NCT06276166||Older adults|Older adults without clear diagnosis of any type of dementia, neurological diseases, and mental disorders that affecting cognitive function.
88862892|NCT06274619|Experimental|Healthy Volunteers|Healthy volunteers aged 65-75 years undergoing controlled human infection with RSV Memphis 37
89387428|NCT02808338|Experimental|Modified Philips BiPAP ASV|The modified Philips BiPAP ASV will be configured with these settings P max: 30 EPAP min: 4 EPAPmax: 15 PS min: 0 PS max: 15 BiFlex: 2 Rate: Auto
88862893|NCT06272175|Experimental|Open Kinetic Chain Activity Group|Open kinetic chain activity will involve Flexion-Abduction-External Rotation and Flexion-Adduction-External Rotation patterns from the Proprioceptive Neuromuscular Facilitation (PNF). During the application, participants will lie on their back, and the pattern will be initiated from the opposite direction of the targeted movement. Participants will be encouraged to perform the movement as actively as possible. Assistance will be provided if the participant cannot complete the pattern. No other PNF techniques will be applied. Both patterns will be practiced for 10 repetitions. Resting periods will be provided as needed to prevent fatigue. The entire application is planned to last approximately 5 minutes.
88862894|NCT06272175|Experimental|Closed Kinetic Chain Activity Group|For closed kinetic chain activity of the upper extremity, an activity involving weight shifting onto the hands on a table while standing with the elbows in extension will be used. Participants will be asked to shift weight onto the hemiplegic upper extremity for 30 seconds. After a 30-second rest period, the weight shifting will be repeated for a second time.
88862895|NCT06271395|Experimental|The observation group|This group will be given Left cricopharyngeal muscle botulinum toxin injection, Injectable Type A Botulinum Toxin (National Medical Products Administration Approval Number S10970037) 100 unit, diluted with 1ml of 0.9% sodium chloride solution for injection and kept ready for use. Only once.
88862896|NCT06270875|Experimental|Coached: Basic pain education + self-care + basic communication & Self-led: spirituality|1 telephone weekly session on pain psychoeducation, lay coach-led self-care and relaxation tips, 1 session on social support and communication coaching, self-guided spirituality and meaning coping
88862897|NCT06270875|Experimental|Coached: Basic pain education + self-care + basic communication + spirituality|1 telephone weekly session on pain psychoeducation, lay coach-led self-care and relaxation tips, 1 session on social support and communication coaching, coach-led spirituality and meaning coping
88862898|NCT06270875|Experimental|Coached: Basic pain education + self-care + advanced communication & Self-led: spirituality|1 telephone weekly session on pain psychoeducation, lay coach-led self-care and relaxation tips, 2 sessions on social support and communication coaching, self-guided spirituality and meaning coping
89387429|NCT02808338|Active Comparator|ResMed S7 VPAP Adapt|"This is an FDA approved device and the following settings will be administered:~End-expiratory Pressure (EEP): 4 PSmin: 3 PSMax: 16"
89387430|NCT02808338|Active Comparator|ResMed S9 VPAP Adapt|"This is an FDA approved device and the following settings will be administered:~EPAP min: 4 EPAPmax: 15 PS min: 0 PS max: 20 Max Ramp: Off"
89387431|NCT02050646|Experimental|Low salt/ Liberal salt Diet|Cross-over trial of liberal salt and low salt diet.
88862899|NCT06270875|Experimental|Coached: Basic pain education + self-care + advanced communication + spirituality|1 telephone weekly session on pain psychoeducation, lay coach-led self-care and relaxation tips, 2 sessions on social support and communication coaching, coach-led spirituality and meaning coping
89387432|NCT02050646|Experimental|Liberal salt/Low salt diet|Cross-over trial of low salt and liberal salt diet
89387433|NCT02037386|Experimental|H-side branch stent|H-side branch stent group
89387434|NCT02049086|Experimental|SBIRT-PM|Screening, Brief Intervention and Referral to Treatment with Pain-Management advice (SBIRT-PM)
89387435|NCT02049086|Active Comparator|Pain Module Only|The pain module of SBIRT-PM with no substance abuse focus (Pain Module Only)
89387436|NCT02049086|No Intervention|No Additional Referral|No intervention.
89387437|NCT02049242|Active Comparator|Triple tourniquet|
88862900|NCT06270875|Experimental|Coached: Basic pain education + basic communication & Self-led: self-care + spirituality|1 telephone weekly session on pain psychoeducation, self-guided self-care and relaxation tips, 1 session on social support and communication coaching, self-guided spirituality and meaning coping
88862901|NCT06270875|Experimental|Coached: Basic pain education + basic communication + spirituality & Self-led: self-care|1 telephone weekly session on pain psychoeducation, self-guided self-care and relaxation tips, 1 session on social support and communication coaching, coach-led spirituality and meaning coping
88862902|NCT06270875|Experimental|Coached: Basic pain education + advanced communication & Self-led: self-care + spirituality|1 telephone weekly session on pain psychoeducation, self-guided self-care and relaxation tips, 2 sessions on social support and communication coaching, self-guided spirituality and meaning coping
89189397|NCT05810623|Experimental|SI Chemotherapy|Patients randomized to the experimental arm will receive a SI within 24h after diagnostic URS. In case of multiple diagnostic URS during the follow-up (including 2nd look for incomplete ablation, non-diagnostic first URS or UTUC recurrence) patients randomized to the interventional arm will receive a SI after each diagnostic URS for 2 years after the day of first diagnostic URS.
89387438|NCT02049242|Active Comparator|Single tourniquet|
89387439|NCT02049320||Remifentanil|Patients sedated using Remifentanil
88862903|NCT06270875|Experimental|Coached: Basic pain education + advanced communication + spirituality & Self-led: self-care|1 telephone weekly session on pain psychoeducation, self-guided self-care and relaxation tips, 2 sessions on social support and communication coaching, coach-led spirituality and meaning coping
88862904|NCT06270875|Experimental|Coached: advanced pain education + self-care + basic communication & Self-led: spirituality|2 telephone weekly sessions on pain psychoeducation, lay coach-led self-care and relaxation tips, 1 session on social support and communication coaching, self-guided spirituality and meaning coping
88862905|NCT06270875|Experimental|Coached: advanced pain education + self-care + basic communication + spirituality|2 telephone weekly sessions on pain psychoeducation, lay coach-led self-care and relaxation tips, 1 session on social support and communication coaching, coach-led spirituality and meaning coping
88862906|NCT06270875|Experimental|Coached: advanced pain education + self-care + advanced communication & Self-led: spirituality|2 telephone weekly sessions on pain psychoeducation, lay coach-led self-care and relaxation tips, 2 sessions on social support and communication coaching, self-guided spirituality and meaning coping
88862907|NCT06270875|Experimental|Coached: advanced pain education + self-care + advanced communication + spirituality|2 telephone weekly sessions on pain psychoeducation, lay coach-led self-care and relaxation tips, 2 sessions on social support and communication coaching, coach-led spirituality and meaning coping
89189398|NCT05810623|No Intervention|Observation|Patient randomized to the observational arm will be treated and followed according to institutional own standards.
89387440|NCT02050724|Experimental|CT guided labelling|CT guided radioactive labelling of pulmonary nodules followed by handheld-SPECT guided thoracoscopic surgery.
89387441|NCT02050724|Experimental|Electromagnetic bronchoscopic labelling|Electromagnetic guided bronchoscopic labeling of pulmonary nodules followed by handheld-SPECT guided thoracoscopic surgery.
89387442|NCT02260076|Experimental|PEG 400|multiple rising doses
89387443|NCT02260076|Placebo Comparator|Placebo|
89387444|NCT02807948|Other|Pacemaker, ICD, or CRT device patients|Subjects who need a non-thoracic clinically indicated scan
89387445|NCT02050802|Experimental|Treatment sequence BCAD|Subjects received study medication in the sequence BCAD. Treatment A: moxifloxacin positive control (3 placebo tablets once daily on Days 1-7, and on Day 8 moxifloxacin 400 mg tablet and 2 macitentan-matching placebo tablets). Treatment B: macitentan 10 mg (1 macitentan 10 mg tablet and 2 placebo tablets once daily on Days 1-8). Treatment C: macitentan 30 mg (3 macitentan 10 mg tablets once daily on Days 1-8). Treatment D: placebo (3 placebo tablets on Days 1-8). There was a wash-out period of at least 10 days between the last study drug administration of the previous treatment and the first study drug administration of the following treatment.
89387446|NCT02050802|Experimental|Treatment sequence ABDC|Subjects received study medication in the sequence ABDC. Treatment A: moxifloxacin positive control (3 placebo tablets once daily on Days 1-7, and on Day 8 moxifloxacin 400 mg tablet and 2 macitentan-matching placebo tablets). Treatment B: macitentan 10 mg (1 macitentan 10 mg tablet and 2 placebo tablets once daily on Days 1-8). Treatment C: macitentan 30 mg (3 macitentan 10 mg tablets once daily on Days 1-8). Treatment D: placebo (3 placebo tablets on Days 1-8). There was a wash-out period of at least 10 days between the last study drug administration of the previous treatment and the first study drug administration of the following treatment.
89530176|NCT03249961|Experimental|Placebo Brain stimulation|Participants will receive Sham TDCS, and Transcranial Magnetic Stimulation (TMS)
89530177|NCT03249961|Experimental|Excitatory Brain Stimulation|Participants will receive Anodal TDCS, and Transcranial Magnetic Stimulation (TMS)
89530178|NCT02455999|Experimental|SYL1001 eye drops dose C|SYL1001 eye drops dose C administration via the ophthalmic route
89387447|NCT02050802|Experimental|Treatment sequence DACB|Subjects received study medication in the sequence DACB. Treatment A: moxifloxacin positive control (3 placebo tablets once daily on Days 1-7, and on Day 8 moxifloxacin 400 mg tablet and 2 macitentan-matching placebo tablets). Treatment B: macitentan 10 mg (1 macitentan 10 mg tablet and 2 placebo tablets once daily on Days 1-8). Treatment C: macitentan 30 mg (3 macitentan 10 mg tablets once daily on Days 1-8). Treatment D: placebo (3 placebo tablets on Days 1-8). There was a wash-out period of at least 10 days between the last study drug administration of the previous treatment and the first study drug administration of the following treatment.
89387448|NCT02050802|Experimental|Treatment sequence CDBA|Subjects received study medication in the sequence CDBA. Treatment A: moxifloxacin positive control (3 placebo tablets once daily on Days 1-7, and on Day 8 moxifloxacin 400 mg tablet and 2 macitentan-matching placebo tablets). Treatment B: macitentan 10 mg (1 macitentan 10 mg tablet and 2 placebo tablets once daily on Days 1-8). Treatment C: macitentan 30 mg (3 macitentan 10 mg tablets once daily on Days 1-8). Treatment D: placebo (3 placebo tablets on Days 1-8). There was a wash-out period of at least 10 days between the last study drug administration of the previous treatment and the first study drug administration of the following treatment.
89189399|NCT05810610||Adult with stenosis ≥40% on CCTA|Adult patient,- with no diagnosed coronary status or history of stenting or bypass surgery- whose CCTA evaluation by the local radiologist results in at least an intermediate stenosis ≥40% on at least one vessel with indication for FFR measurement.- Who has not expressed opposition to the use of their data.
89387449|NCT02050802|Experimental|Treatment sequence DBAC|Subjects received study medication in the sequence DBAC. Treatment A: moxifloxacin positive control (3 placebo tablets once daily on Days 1-7, and on Day 8 moxifloxacin 400 mg tablet and 2 macitentan-matching placebo tablets). Treatment B: macitentan 10 mg (1 macitentan 10 mg tablet and 2 placebo tablets once daily on Days 1-8). Treatment C: macitentan 30 mg (3 macitentan 10 mg tablets once daily on Days 1-8). Treatment D: placebo (3 placebo tablets on Days 1-8). There was a wash-out period of at least 10 days between the last study drug administration of the previous treatment and the first study drug administration of the following treatment.
89387450|NCT02050802|Experimental|Treatment sequence ADCB|Subjects received study medication in the sequence ADCB. Treatment A: moxifloxacin positive control (3 placebo tablets once daily on Days 1-7, and on Day 8 moxifloxacin 400 mg tablet and 2 macitentan-matching placebo tablets). Treatment B: macitentan 10 mg (1 macitentan 10 mg tablet and 2 placebo tablets once daily on Days 1-8). Treatment C: macitentan 30 mg (3 macitentan 10 mg tablets once daily on Days 1-8). Treatment D: placebo (3 placebo tablets on Days 1-8). There was a wash-out period of at least 10 days between the last study drug administration of the previous treatment and the first study drug administration of the following treatment.
89387451|NCT02050802|Experimental|Treatment sequence CABD|Subjects received study medication in the sequence CABD . Treatment A: moxifloxacin positive control (3 placebo tablets once daily on Days 1-7, and on Day 8 moxifloxacin 400 mg tablet and 2 macitentan-matching placebo tablets). Treatment B: macitentan 10 mg (1 macitentan 10 mg tablet and 2 placebo tablets once daily on Days 1-8). Treatment C: macitentan 30 mg (3 macitentan 10 mg tablets once daily on Days 1-8). Treatment D: placebo (3 placebo tablets on Days 1-8). There was a wash-out period of at least 10 days between the last study drug administration of the previous treatment and the first study drug administration of the following treatment.
88862908|NCT06270875|Experimental|Coached: advanced pain education + basic communication & Self-led: self-care+ spirituality|2 telephone weekly sessions on pain psychoeducation, self-guided self-care and relaxation tips, 1 session on social support and communication coaching, self-guided spirituality and meaning coping
89387452|NCT02050802|Experimental|Treatment sequence BCDA|Subjects received study medication in the sequence BCDA. Treatment A: moxifloxacin positive control (3 placebo tablets once daily on Days 1-7, and on Day 8 moxifloxacin 400 mg tablet and 2 macitentan-matching placebo tablets). Treatment B: macitentan 10 mg (1 macitentan 10 mg tablet and 2 placebo tablets once daily on Days 1-8). Treatment C: macitentan 30 mg (3 macitentan 10 mg tablets once daily on Days 1-8). Treatment D: placebo (3 placebo tablets on Days 1-8). There was a wash-out period of at least 10 days between the last study drug administration of the previous treatment and the first study drug administration of the following treatment.
89387453|NCT02051504||Type 1 diabetes, HbA1c <7%|"Patients with Type 1 diabetes and adequate glycemic control: HbA1c <7% at the entrance in the study.~Intervention:~Incremental maximal exercise Near-Infra Red-Spectroscopy at vastus lateralis and pre-frontal cortex (during exercise) Gas exchanges (VO2, VCO2) during exercise Combined DLCO/DLNO (at rest) Venous and arterialised blood sampling (rest and exercise) Muscle biopsy at the vastus lateralis (rest) Diet questionnaire, quality-of-life questionnaires, physical activity questionnaires Accelerometry over one week Dual energy X-ray Absorptiometry"
89530179|NCT02455999|Experimental|SYL1001 eye drops dose D|SYL1001 eye drops dose D administration via the ophthalmic route
89530180|NCT02455999|Placebo Comparator|Placebo|Placebo eye drops administration via the ophthalmic route
88862909|NCT06270875|Experimental|Coached: advanced pain education + basic communication + spirituality & Self-led: self-care|2 telephone weekly sessions on pain psychoeducation, self-guided self-care and relaxation tips, 1 session on social support and communication coaching, coach-led spirituality and meaning coping
88862910|NCT06270875|Experimental|Coached: advanced pain education + advanced communication & Self-led: self-care+ spirituality|2 telephone weekly sessions on pain psychoeducation, self-guided self-care and relaxation tips, 2 sessions on social support and communication coaching, self-guided spirituality and meaning coping
88862911|NCT06270875|Experimental|Coached: advanced pain education + advanced communication + spirituality & Self-led: self-care|2 telephone weekly sessions on pain psychoeducation, self-guided self-care and relaxation tips, 2 sessions on social support and communication coaching, coach-led spirituality and meaning coping
88862912|NCT06261827|Active Comparator|Control group|Oxygen-air mixture without NO after extubation within 5 days after surgery 2 times a day for 30 min
88862913|NCT06261827|Experimental|200 ppm|NO will be supplemented at 200-ppm concentration after extubation within 5 days after surgery 2 times a day for 30 min
88862914|NCT06261060|Experimental|Arm 1|Participants will visit the study clinic 2 times during Week 1, one (1) time during Weeks 2-4, and then 1 time every 2 weeks after that (Weeks 6, 8, 10, and so on) until Week 22 (Month 6). Then participants will have a follow-up visit at Week 24 and again at Week 52 (Month 12). Participants will take sirolimus by mouth every day, at about the same time each day. Swallow the tablet(s) whole with a full glass of water (about 1 cup). Do not crush or chew the tablet(s). Participants may take sirolimus with or without food.
88862915|NCT06260852||Premium presbyopia surgery|Participants that underwent uncomplicated pseudophakic presbyopia correction with bilateral premium intraocular lenses (IOL) implantation
88862916|NCT06260605|Experimental|nursing students|Nursing students&#39; education
88862917|NCT06259721|Experimental|Combination Treatment|
88862918|NCT06249022|Experimental|The observation group|Both groups of patients were provided with routine treatments, including pharmacological treatment, rehabilitation therapy.Based on this, the patients in the observation group were given enteral nutrition support with Intermittent Oro-esophageal Tube Feeding (Medical Device No. 20010234, developed by the Swallowing Disorders Research Institute of Zhengzhou University).
88862919|NCT06249022|Active Comparator|The control group|Both groups of patients were provided with routine treatments, including pharmacological treatment, rehabilitation therapy. The patients in the control group were provided nutrition support with Nasogastric tube feeding , while the feeding process strictly followed the relevant guideline
88862920|NCT06248970|Experimental|the observation group|Both groups of patients were provided with routine treatments, including pharmacological treatment, rehabilitation therapy.Based on this, the patients in the observation group were given enteral nutrition support with Intermittent Oro-esophageal Tube Feeding (Medical Device No. 20010234, developed by the Swallowing Disorders Research Institute of Zhengzhou University).
88862921|NCT06248970|Active Comparator|the control group|Both groups of patients were provided with routine treatments, including pharmacological treatment, rehabilitation therapy. The patients in the control group were provided nutrition support with Nasogastric tube feeding , while the feeding process strictly followed the relevant guideline
88862922|NCT06248840|Experimental|The observation group|During the 15-day treatment, both groups of patients are hospitalized, while conventional care and enteral nutrition support are provided to the two groups. Specifically, conventional care includes health education, dietary adjustments, nasopharyngeal hygiene, management of risk factors (blood pressure and lipid control, etc.), exercise rehabilitation, and psychological support. The frequency and content of these interventions are arranged based on health condition. The observation group receives IOE for enteral nutrition support
88862923|NCT06248840|Active Comparator|The control group|During the 15-day treatment, both groups of patients are hospitalized, while conventional care and enteral nutrition support are provided to the two groups. Specifically, conventional care includes health education, dietary adjustments, nasopharyngeal hygiene, management of risk factors (blood pressure and lipid control, etc.), exercise rehabilitation, and psychological support. The frequency and content of these interventions are arranged based on health condition.The control group receives NGT for enteral nutrition support
88862924|NCT06246734|Experimental|Treatment, Immediate Robot Pet Companion|Participants will receive a Hasbro Joy for All robotic pet. These are low cost (< $150), life-like cats and dogs that respond to human interaction by making sounds or turning their head for eye contact. The robot companion pets are designed as supports for older people with cognitive impairment. In this trial, the older person can treat it like a pet or ignore it. Family caregivers will report on engagement with the pet and effects on mood.
88862925|NCT06246734|No Intervention|Control, Delayed Robot Pet Companion|During the 6-8 week trial, this group will not receive the robot pet companion but will complete baseline and follow-up assessments on teh same schedule as the treatment arm. Participants in this arm will receive the robot pet after the trial.
88862926|NCT06245083|Active Comparator|PQQ supplement|Pyrroloquinoline quinone (PQQ) 20 mg/day
88862927|NCT06245083|Placebo Comparator|Placebo|Placebo supplement with soybean oil 20 mg/day
88862928|NCT06244732|Experimental|RSB|In patients in the RSB Group, repeated blocks of the abdominal wall will be performed using special catheters positioned bilaterally in the rectus muscle fascia using ultrasound guidance (Ropivacaine 0.375% 20 ml per side, administered every 12 hours: at T0, T12 and T24)
88862929|NCT06244732|Active Comparator|EA|Patients of EA Group will receive analgesia via epidural catheter (Ropivacaine 0.15% with double initial bolus and subsequent continuous infusion 5 ml/h via elastomeric pump)
89530181|NCT04488445|Experimental|Strength Training|The intervention group performs a resistance training based on a resistance exercise of 3 sets of 3 to 5 repetitions (90% of an estimated 1 RM) and 3 minutes of resting time between sets.
89530182|NCT04488445|Placebo Comparator|Stretching|The control group performs 3 exercises of stretching and balance during one minute each and three sets. One minute of resting time between sets.
89189400|NCT05810571|Placebo Comparator|patient controlled analgesia|this group of patients received no block, received only postoperative patient-controlled analgesia with morphine
89387454|NCT02051504||Type 1 diabetes, HbA1c >8%|"Patients with Type 1 diabetes and inadequate glycemic control: HbA1c >8% at the entrance in the study.~Intervention:~Incremental maximal exercise Near-Infra Red-Spectroscopy at vastus lateralis and pre-frontal cortex (during exercise) Gas exchanges (VO2, VCO2) during exercise Combined DLCO/DLNO (at rest) Venous and arterialised blood sampling (rest and exercise) Muscle biopsy at the vastus lateralis (rest) Diet questionnaire, quality-of-life questionnaires, physical activity questionnaires Accelerometry over one week Dual energy X-ray Absorptiometry"
89530183|NCT04502459|Active Comparator|Cement only|The tourniquet was inﬂated just before cement application and deﬂated after its hardening
88862934|NCT06240065|Experimental|Short Bowel Syndrome Arm|Patients with SBS will be initiated on green bean purees added to enteral formula recipes, based on kilocalories of enteral formula over 3 weeks. During week 1 subjects will prepare and add 50 mL green bean puree per 1000kcal of enteral feed (5%) to their formula mixture, increasing to 100ml (10%) and 150ml (15%) during weeks 2 and 3, respectively.
88862935|NCT06240065|Active Comparator|Control Arm|Patients without SBS will be initiated on green bean purees added to enteral formula recipes, based on kilocalories of enteral formula over 3 weeks. During week 1 subjects will prepare and add 50 mL green bean puree per 1000kcal of enteral feed (5%) to their formula mixture, increasing to 100ml (10%) and 150ml (15%) during weeks 2 and 3, respectively.
88862936|NCT06236880|Experimental|Low Dose to High Dose of GM-2505|
88862937|NCT06236880|Experimental|Moderate Dose to High Dose of GM-2505|
88862938|NCT06236425|Other|TIL Harvest/Standard of care Treatment Phase|Participants will undergo tumor harvest for TIL and then receive 2 to 3 cycles of pembrolizumab or pembrolizumab/platinum chemotherapy (cisplatin or carboplatin / 5-FU) as per standard of care.
88862939|NCT06236425|Experimental|TBio-4101 Treatment|Participants without radiographic response (progressive disease) after pembrolizumab or pembrolizumab/platinum chemotherapy, and who meet eligibility requirements, will transition to receive TBio-4101. Participants will receive TBio-4101 infusion and after completion of TBio-4101 infusion, IL-2 will be administered every 8 hours, for up to 6 doses. Finally, pembrolizumab will be administered on Day 14, Day 35, and Day 56 and Q6W (beginning Week 12) thereafter for up to 2 years until discontinuation.
88862940|NCT06235905|Other|SPN-820 6 x 400 mg capsules|
88862941|NCT06229002|Experimental|Active tACS stimulation|Transcranial alternative current stimulation (tACS) at alpha frequency Single session of tACS : 30 minutes, 2mA, frequency = 10Hz, both electrodes located on the dorsolateral prefrontal cortex (left and right)
88862942|NCT06229002|Placebo Comparator|Sham stimulation|Single session of tACS sham stimulation : both electrodes located on the dorsolateral prefrontal cortex (left and right) ; real current delivered for the first and last 30s of the total stimulation time (ramp-in and ramp-out)
88862943|NCT06226727|Experimental|Sequence Group A|"The investigational products will be administered according to the treatment groups assigned to each sequence group in Period 1~4.~*Sequence Group A [Period 1, 3] Co-administration of BR1019-1(R1) and BR1019-2(R2). [Period 2, 4] Administration of BR1019(T)"
88862944|NCT06226727|Experimental|Sequence Group B|"The investigational products will be administered according to the treatment groups assigned to each sequence group in Period 1~4.~*Sequence Group B [Period 1, 3] Administration of BR1019(T) [Period 2, 4] Co-administration of BR1019-1(R1) and BR1019-2(R2)."
88862945|NCT06225505|Experimental|Experimental arm|In the experimental arm, patients and their treating physician will be made aware of the molecular relapse (positive ctDNA detection results) in study steps 1 (ctDNA monitoring). To locate metastatic deposits, patients will be offered to undergo a whole-body imaging with 18F-FDG PET-CT and 68Ga-FAPI-46-PET-CT, in addition to any other workup considered as relevant by their treating physician.
88862946|NCT06225505|Sham Comparator|Control arm|In the control arm, patients and their treating physician will not be made aware of the molecular relapse and will continue the standard surveillance with repeated ctDNA test every 3 months (blinded). ). At the time of the clinical/radiological diagnosis of relapse, similar procedures will be performed (18F-FDG PET-CT, 68Ga-FAPI-46-PET-CT, and tumor genetic landscape assessment by ctDNA analysis).
88862947|NCT06224270|Experimental|Adults with IBD|
88862948|NCT06220214|Experimental|CEDM + CEDBT|Participants undergo CEDM + CEDBT imaging after every 4-6 cycles of neoadjuvant chemotherapy prior to surgery (imaging may occur up to 2 times)
88862949|NCT06219356|Experimental|Dose Escalation of GLB-002 in Participants with R/R NHL-Phase 1a|Part 1a (Dose Escalation) of the study will enroll R/R NHL participants and will evaluate the safety, tolerability, PK, PD and preliminary efficacy of GLB-002 administered orally, and determine the maximum tolerated dose (MTD) and/or recommended expansion doses (RED) in R/R NHL patients who are eligible for dose limiting toxicity (DLT) evaluation.
88862950|NCT06219356|Experimental|Dose Expansion of GLB-002 in Participants with R/R FL (Grade 1, 2, 3a)-Phase 1b Cohort 1|Part 1b (Dose Expansion) Cohort 1 will confirm tolerability of the selected doses and schedules and evaluate whether efficacy is in a range that warrants further clinical development for R/R Follicular Lymphoma (Grade 1、2、3a).
88862951|NCT06219356|Experimental|Dose Expansion of GLB-002 in Participants with R/R DLBCL and FL (Grade 3b)-Phase 1b Cohort 2|Confirm tolerability of the selected doses and schedules and evaluate whether efficacy is in a range that warrants further clinical development for R/R Diffuse Large B-cell Lymphoma and R/R Follicular Lymphoma (Grade 3b).
88862952|NCT06219356|Experimental|Dose Expansion of GLB-002 in Participants with other R/R NHL-Phase 1b Cohort 3|Part 1b (Dose Expansion) Cohort 3 will confirm tolerability of the selected doses and schedules and evaluate whether efficacy is in a range that warrants further clinical development for other R/R NHL, including, but not limited to Mantle-cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Small Lymphocytic Lymphoma (SLL) /Chronic Lymphocytic Leukemia (CLL) and Peripheral T-cell Lymphoma (PTCL).
88862953|NCT06217068|Experimental|Sedentary Individuals - Acute Moderate-Intensity Exercise|8 minutes of elliptical exercise at a moderate intensity based on heart rate reserve. There will be a 2-minute warm-up and 2-minute cool down period in addition to the 8 minutes at moderate-intensity.
88862954|NCT06217068|Experimental|Active Individuals - Acute Moderate-Intensity Exercise|8 minutes of elliptical exercise at a moderate intensity based on heart rate reserve. There will be a 2-minute warm-up and 2-minute cool down period in addition to the 8 minutes at moderate-intensity.
89530184|NCT04502459|Active Comparator|Skin to Cement|Inﬂation of tourniquet before skin incision and its deﬂation after hardening of cement
89530185|NCT04502459|Active Comparator|Skin to Skin|Inflate of tourniquet before incision and deflate following completion of skin closure
89387455|NCT02051504||Healthy controls, Groupe 1|"Healthy controls for patients with Type 1 diabetes and adequate glycemic control matched on age, sex, body composition and physical activity level.~Intervention:~Oral Glucose Tolerance Test Incremental maximal exercise Near-Infra Red-Spectroscopy at vastus lateralis and pre-frontal cortex (during exercise) Gas exchanges (VO2, VCO2) during exercise Combined DLCO/DLNO (at rest) Venous and arterialised blood sampling (rest and exercise) Muscle biopsy at the vastus lateralis (rest) Diet questionnaire, quality-of-life questionnaires, physical activity questionnaires Accelerometry over one week Dual energy X-ray Absorptiometry"
89387456|NCT02051504||Healthy controls, Group 2|"Healthy controls for patients with Type 1 diabetes and inadequate glycemic control matched on age, sex, body composition and physical activity level.~Intervention:~Oral Glucose Tolerance Test Incremental maximal exercise Near-Infra Red-Spectroscopy at vastus lateralis and pre-frontal cortex (during exercise) Gas exchanges (VO2, VCO2) during exercise Combined DLCO/DLNO (at rest) Venous and arterialised blood sampling (rest and exercise) Muscle biopsy at the vastus lateralis (rest) Diet questionnaire, quality-of-life questionnaires, physical activity questionnaires Accelerometry over one week Dual energy X-ray Absorptiometry"
89387457|NCT02049398||Oral microbiome cohort|a cohort of 40 adults willing to provide oral samples approximately every two months forone year
89387458|NCT02051582||Surgeons using fluoroscopy with laser pointer|"Surgeons will attempt to obtain a perfect anterior-posterior (AP) and axillary views of a cadaver wrist using a mini-fluoroscopy unit equipped with a laser pointer.~A perfect view is considered the ability to obtain perfect circle views through a cannulated mini acutrak screw that will have been placed into the cadaver prior to data collection.~Surgeons will also be asked to wear three dosimeter badges: one on the collar, one on the waist, and a ring badge under a pair of regular sterile surgical gloves."
89387459|NCT02051582||Surgeons using fluoroscopy without laser pointer|"Surgeons will attempt to obtain a perfect anterior-posterior (AP) and axillary views of a cadaver wrist using a mini-fluoroscopy unit equipped without a laser pointer.~A perfect view is considered the ability to obtain perfect circle views through a cannulated mini acutrak screw that will have been placed into the cadaver prior to data collection.~Surgeons will also be asked to wear three dosimeter badges: one on the collar, one on the waist, and a ring badge under a pair of regular sterile surgical gloves."
89387460|NCT02051660|Experimental|Manualized CALM Intervention|
89387461|NCT02051660|Active Comparator|Non-manualized supportive intervention|
89387462|NCT02051738|Experimental|Treatment Sequence AB|A single 500 mg dose of mebendazole fast-disintegrating chewable tablet will be administrated under fasted condition (Treatment A) in Treatment Period 1; In Treatment Period 2, the same medication will be administrated under fed condition (Treatment B).
89387463|NCT02051738|Experimental|Treatment Sequence BA|A single 500 mg dose of mebendazole fast-disintegrating chewable tablet will be administrated under fed condition (Treatment B) in Treatment Period 1; In Treatment Period 2, the same medication will be administrated under fasted condition (Treatment A).
89387464|NCT02050880||Normal eyes|Eyes without pathology.
89387465|NCT02050880||Glaucoma|Eyes with Glaucoma.
89387466|NCT02050880||Retinal|Eyes with Retinal Disease.
89387467|NCT02050880||Corneal|Eyes with corneal disease including a kerato-refractive group.
89387468|NCT02050958|Experimental|OXP001|OXP001
89387469|NCT02050958|Active Comparator|Ibuprofen|Brufen
89387470|NCT02037464|Experimental|Capsaicin Supplement|
89387471|NCT02049554|No Intervention|Usual Care|
89387472|NCT02049554|Experimental|Preconception Care Screener Group|Women's Health Screener and Clinician discussion
89387473|NCT02049710|Active Comparator|Sexual Behavior Intervention|Video based intervention based on changing risky behavior associated with sexual behavior.
89387474|NCT02049710|Active Comparator|Driving behavior intervention|Video based intervention based on changing risky behavior associate with driving
89387475|NCT01353625|Experimental|CC-115|
89387476|NCT01357603|Experimental|Glaritus arm|Insulin glargine (Glaritus: 100 U/ml), Penfill® cartridges 3.0ml
89387477|NCT01357603|Active Comparator|Lantus arm|Insulin glargine (Lantus: 100 U/ml), Penfill® cartridges 3.0ml
89387478|NCT02051894||HIE Group|
89387479|NCT01357681|Experimental|(2)-epigallocatechin-3-gallate (EGCG)|Month 01:400 mg /day (200-0-200) p.o. Month 02:800 mg /day (400-0-400) p.o. Month 03 -12: 1200 mg /day (600-0-600) p.o.
89387480|NCT01357681|Placebo Comparator|Placebo|Placebo
89387481|NCT02049788|Active Comparator|low calorie/fat diet|The low calorie/fat diet group, obese children aged 9-16, received conventional behavioural lifestyle modification instructions x 1/month for 6 months about low-calorie (approximately 1200-1300 kcal/day), low-fat (25% of total calories from fat) and about physical activity (increase non-weight bearing exercise 30 minutes/day at least x 3 times/week, increase physical activity in their routine and decrease sedentary activity).
89387482|NCT02049788|Experimental|Low glycaemic index diet|Low glycaemic index diet group, obese children of both sexes aged 9-16, received experimental behavioural lifestyle modification instructions x 1/month for 6 months about low glycaemic index diet (selection of low-GI carbohydrates with the caloric distribution of carbohydrate 50-55%: protein 15-20%: fat 30-35%, instruction by two-hour small classes with parental participation low GI cooking demonstration and food labeling guidance) and about physical activity (increase non-weight bearing exercise 30 minutes/day at least x 3/week, increase physical activity in their routine and decrease sedentary activity).
89387483|NCT02037932|Experimental|Balloon Assisted Coiling|Balloon Assisted Coiling using MicroVention second-generation hydrogel coils and MicroVention Scepter Occlusion Balloon Catheter.
89387484|NCT01543633|Experimental|Active Study Arm|Subjects recruited into this study will be required to undergo a base MRI scan of the brain. On a separate day propofol will be administered with concurrent EEG while subjects respond to stimuli.
89387485|NCT03561740|Experimental|Metronomic Capecitabine Group|Patients in experimental group (also Metronomic Capecitabine Group) will receive additional metronomic chemotherapy of capecitabine (500mg TID po), begin after the completion of standard adjuvant chemotherapy or surgery if neoadjuvant chemotherapy were administrated, until three weeks after the last cycle of trastuzumab (6mg/kg every 3 weeks).
88862955|NCT06214221|Experimental|Signos System|For all consented participants, the Signos app will use CGM data to provide recommendations customized to users for promoting general health and wellness.
89387486|NCT03561740|No Intervention|Control Group|Patients in control group will receive standard therapy only, as per the guidelines.
88862956|NCT06214221|Active Comparator|Standard Lifestyle Education|"The Active Comparator: Standard Lifestyle Education arm in the clinical trial refers to a control group that receives conventional lifestyle modification advice instead of the experimental Signos System."
88862957|NCT06214208|Experimental|30 Hz Frequency|Intervention will be applied with a 30 Hz frequency.
88862958|NCT06214208|Experimental|50 Hz Frequency|Intervention will be applied with a 50 Hz frequency.
88862959|NCT06214208|Experimental|80 Hz Frequency|Intervention will be applied with an 80 Hz frequency.
88862960|NCT06213233|Placebo Comparator|Placebo|
88862961|NCT06213233|Experimental|Cannabidiol|
88862962|NCT06212271|Experimental|Colchicine|Colchicine (0.6 mg oral daily for 4-weeks) will be the drug administered in this study.
88862963|NCT06212271|Placebo Comparator|Placebo|This arm is a matching placebo that will be administered in the same fashion as the experimental arm.
88862964|NCT06208514|Experimental|Brief pain exposure therapy (BPET)|
88862965|NCT06207799|Experimental|Elranatamab|"Induction therapy - This is given to decrease the number of MM cells in the bone marrow.~Purging - This is done to remove leftover MM cells after induction therapy.~Stem cell mobilization - This is done to move stem cells from your bone marrow into the blood, so they can be collected for the autologous stem cell transplant.~Conditioning therapy - This is given to help prepare the body to receive the stem cell transplant.~Autologous stem cell transplant~Maintenance therapy - This is given to help control the disease after the stem cell transplant."
88862966|NCT06207110|Experimental|Regulation of Cues|The ROC program provides psychoeducation, coping skills, self-monitoring and experiential learning targeting increasing satiety responsiveness and decreasing food cue responsiveness.
88862967|NCT06207110|Active Comparator|Family-Based Treatment|The FBT program provides nutrition and physical activity education, behavior therapy skills, and parenting skills targeting changes in energy balance.
88862968|NCT06207110|Experimental|Regulation of Cues +|The ROC+ program includes all of the components of ROC as well as nutrition education and reducing energy intake
88862969|NCT06207110|Active Comparator|Health Education|The HE program provides information about nutrition, physical activity, sedentary behavior, sleep, emotions, and stress.
88862970|NCT06206681||Ultrapulse Carbon Dioxide Laser|The study investigates the use of the Ultrapulse Carbon Dioxide Laser for the excision of eyelid lesions, including xanthelasma, pigmented nevi, keratoses, and so on.
88862971|NCT06206226|Experimental|Oh Happy Day Class-Digital Connections (OHDC-DC)|
88862972|NCT06196138|Experimental|Gum|Patients who will chew gum after surgery will constitute this group
88862973|NCT06196138|Experimental|Hot Compress|Patients who will undergo hot compress after surgery will constitute this group
88862974|NCT06196138|No Intervention|Control|Patients who will undergo routine protocol will constitute this group
88862975|NCT06191796|Experimental|Dose-finding Cohort A: Zanzalintinib + AB521|Participants with solid tumors will receive zanzalintinib + AB521
88862976|NCT06191796|Experimental|Dose-finding Cohort B: zanzalintinib + AB521 + nivolumab|Participants with ccRCC will receive zanzalintinib + AB521 + nivolumab
88862977|NCT06191796|Experimental|Expansion Cohort 1: Zanzalintinib + AB521|Participants with ccRCC will receive zanzalintinib + AB521
88862978|NCT06191796|Experimental|Expansion Cohort 2: zanzalintinib + AB521 + nivolumab|Participants with ccRCC will receive zanzalintinib + AB521 + nivolumab
88862979|NCT06189807|Other|Control Group -|
88862980|NCT06189807|Experimental|Intervention Group - Decision aid|
88862981|NCT06189703|Active Comparator|Group A: Treatment Arm|The same device placement will be used for sham as in the active arm.
88862982|NCT06189703|Sham Comparator|Group B: Sham-Control Arm|The same device placement will be used for sham as in the active arm.
88862983|NCT06188910|Experimental|Neurofeedback|3 weekly 30-minute neurofeedback sessions per week for 12 weeks
88862984|NCT06188910|Active Comparator|Control|Health education, a 25-minute session, on mobile phone addiction and promotion of healthy lifestyles
88862985|NCT06182722||Major Depressive Disorder (MDD)|Patients with major depressive disorder. These patients consisted of two cohorts. The first cohort is expected to consist of 15 participants for nested cohort study. The rest form the second cohort.
88862986|NCT06182722||Healthy controls|Healthy normal volunteers.
88862987|NCT06181968|Active Comparator|Treatment arm|Congestive therapy will be guided by findings on daily cardiac- and lung ultrasound
88862988|NCT06181968|Sham Comparator|Control Arm|This arm will have the same ultrasound exams done daily as the treatment arm, but information will not be available for the treating physician for guiding therapy
88862989|NCT06181929|Experimental|intervation group|LDCT screening exam
88862990|NCT06180382|Experimental|Adalimumab with optimisation|Patients with Crohn's disease will be included. They will have Adalimumab with optimisation as treatment.
88862991|NCT06180382|Experimental|Vedolizumab|Patients with Crohn's disease will be included. They will have Vedolizumab as treatment.
88862992|NCT06179875|Experimental|VRDN-001 10 mg/kg|5 infusions of VRDN-001 10 mg/kg
88862993|NCT06178055|Experimental|KUS121 high dose group|
88862994|NCT06178055|Experimental|KUS121 low dose group|
88862995|NCT06178055|Sham Comparator|Control group|
89189401|NCT05810571|Active Comparator|erector spina plane block|this group of patients received erector spina plane block preoperatively, received only postoperative patient-controlled analgesia with morphine
89189402|NCT05810571|Active Comparator|quadratus lumborum block|this group of patients received erector spina plane block preoperatively, received only postoperative patient-controlled analgesia with morphine
88862996|NCT06177704||Patients with diagnosis of probable/definite DRT after LAAO|"Patients with diagnosis of probable/definite DRT after LAAO detected by transesophageal echocardiography (TEE) or cardiac computed tomography (CT).~In all patients after the LAAO procedure, a first imaging evaluation at 45 to 90 days, and a second imaging evaluation at 12 months is recommended.~In case of DRT diagnosis, and following the recent SCAI/HRS recommendations, a repeat imaging at 45- to 90-day intervals is recommended to assess for DRT resolution with eventual cessation of anticoagulation.~In case of DRT resolution, a sequential imaging evaluation at ±90-day, ±180-day, and ±365 days after the imaging test where DRT was resolved is recommended"
89387487|NCT03494647|Active Comparator|Cheetah Heel Cup|Subjects randomly assigned to this group will receive the Cheetah Heel Cup at their initial visit.
89387488|NCT03494647|Active Comparator|The X Brace|Subjects randomly assigned to this group will receive the X Brace at their initial visit.
89387489|NCT02037698|Experimental|Pre-PCI CT scan group|Pre-PCI CT scan
89387490|NCT02037698|No Intervention|Control group|Control
89387491|NCT01357759|Experimental|Escalating doses of MORAb-022|Subjects with RA will be randomized into Cohorts 8 to 11, with each cohort consisting of five RA subjects per cohort (four active and one placebo).
89387492|NCT01357759|Placebo Comparator|Placebo|Subjects with RA will be also randomized into Cohorts 8 to 11, with each cohort consisting of five RA subjects per cohort (four active and one placebo).
89387493|NCT02053454|Active Comparator|patisiran (ALN-TTR02)|
89387494|NCT02053454|Active Comparator|Sterile Normal Saline (0.9% NaCl)|
89387495|NCT02052050|Experimental|core stability|Stabilized muscle program will consist of two months of individual physical training that it will be conducted 3 times/week for 90 min each. A correct progression to improve stabilization of deep abdominal muscles will be made.
88862997|NCT06176989|Experimental|1|Participants with IDH2 mutated (R140/R172) malignant sinonasal and skull base tumors.
88862998|NCT06176196|Experimental|VX-548|Participants will receive VX-548 up to 12 weeks.
88862999|NCT06176196|Placebo Comparator|Placebo|Participants will receive placebo matched to VX-548 up to 12 weeks.
88863000|NCT06173687|Experimental|All participants|
88863001|NCT06172257|Experimental|OCS-01|dexamethasone ophthalmic suspension,1.5% [15 mg/mL]
88863002|NCT06172257|Placebo Comparator|Vehicle ophthalmic suspension|Vehicle of OCS-01
88863003|NCT06171945|Experimental|AYA Connect|Adolescent and young adult cancer survivors receive AYA Connect intervention.
88863004|NCT06171945|Experimental|AYA Connect-PP|Adolescent and young adult cancer survivors receive AYA Connect-PP intervention.
88863005|NCT06171945|Experimental|AYA Connect-PP+|Adolescent and young adult cancer survivors receive AYA Connect-PP+ intervention.
88863006|NCT06171659||Open Surgical Procedure (Arthroplasty)|"PPSP subjects who have undergone hip (or knee) joint arthroplasty (i.e., open surgical procedure for joint replacement).~6 month post-op scans~12 month post-op scans~18 month post-op scans"
89387496|NCT02052050|No Intervention|control group|usual care
89387497|NCT02931097|Active Comparator|Pedunculopontine stimulation|Deep brain stimulation of the pedunculopontine area
89387498|NCT02931097|Active Comparator|Pontomesencephalic stimulation|Deep brain stimulation of the pontomesencephalic area
89387499|NCT02931097|Sham Comparator|Sham stimulation|No deep brain stimulation
89387500|NCT02052128|Experimental|onapristone 10 mg BID mg|onapristone 10 mg BID extended-release tablets
89387501|NCT02052128|Experimental|onapristone 20 mg BID|onapristone 20 mg BID extended-release tablets
89387502|NCT02052128|Experimental|onapristone 30 mg BID|onapristone 30 mg BID extended-release tablets
89387503|NCT02052128|Experimental|onapristone 40 mg BID mg|onapristone 40 mg BID mg extended-release tablets
89387504|NCT02052128|Experimental|onapristone 50 mg BID|onapristone 50 mg BID extended-release tablets
89387505|NCT02052128|Experimental|onapristone 100 mg QD|onapristone 100 mg QD immediate-release tablets
89387506|NCT01349413|Placebo Comparator|Placebo|Identical looking placebo (once daily)
89387507|NCT01349413|Experimental|Esomeprazole 20mg daily|Esomeprazole 20mg daily Oral for 8 weeks
89387508|NCT01349647|Experimental|Vaccine and Chemotherapy|This is a pilot trial evaluating the safety and immunogenicity of a pentavalent vaccine for patients with small cell lung cancer (SCLC). Patients with SCLC who have completed all planned initial therapy and have maintained a partial or complete response will be enrolled.
89387509|NCT01349647|Experimental|Vaccine Alone|Patients will be vaccinated with the pentavalent vaccine comprised of KLH conjugates of GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid plus OPT-821 adjuvant.
89387510|NCT01317979||Diabetes group I|metabolic surgery, laparoscopicly
89387511|NCT01318057||Wild-Type|Wild-Type are those individuals who were non-carriers of any functional (loss-of-function)variant in CYP2C9 and/or VKORC1 genes
88863007|NCT06171659||Less Invasive Procedure (Arthroscopy)|"PPSP subjects who have undergone hip (or knee) arthroscopy (i.e., less invasive joint surgical procedure involving scopes and lower profile surgical tools)~- 6 month post-op scans"
88863008|NCT06171659||Asymptomatic: Had Total Joint Replacement (Arthroplasty)|"Asymptomatic subjects who have undergone total hip or total knee arthroplasty.~- single scan during one study visit (up to 3.5 hours)"
88863009|NCT06171659||Asymptomatic: Less Invasive Procedure (Arthroscopy)|"Asymptomatic subjects who have undergone hip or knee arthroscopy.~- single scan during one study visit (up to 3.5 hours)"
89189403|NCT05810558|Placebo Comparator|Arm 1 Ultrasonic|Subjects will receive cleaning of the peri-implant sulcus using ultrasonic instrumentation
89189404|NCT05810558|Experimental|Arm 2 Glycine|Subjects will receive cleaning of the peri-implant sulcus using glycine powder air-powered debridement
89189405|NCT05810532|Active Comparator|4H group|fasting more than 4 hours before sedation
89387512|NCT01318057||Carriers|Those patients who were identified as having any functional CYP2C9 and/or VKORC1 polymorphism
89387513|NCT06273735||radical prostatectomy patients with versus without MINS|The cohort consists of open and robotic-assisted radical prostatectomy patients. The rate of MINS is determined by laboratory chemistry as part of the study as well as clinically through routine visits and postoperatively through questionnaires. Intervention is not performed according to the study protocol but is part of the normal clinical course, if necessary.
89387514|NCT06273722||D-OCT scanned patients|This diagnostic cohort study will include patients (18+ years) who underwent a biopsy and D-OCT scan for lesions suspect for BCC skin cancer. Patient data was retrieved from a pre-existing registry (METC: 2022-3555). All D-OCT scans were obtained at the outpatient dermatology clinic of Maastricht University Medical Center+ (MUMC+) using a Vivosight Multi-beam Swept-Source Frequency Domain OCT scanner (Michelson Diagnostics Maidstone, Kent, UK; resolution <7.5 µm lateral, <5 µm axial; depth of focus 1.0 mm; scan area 6 × 6 mm). All scanned lesions were histopathologically examined by a dermatopathologist blinded to D-OCT scans and D-OCT assessment.
89387515|NCT06273709||OCT scans without clinical/dermoscopic photographs|OCT scans will be used from a pre-existing registry. The OCT scans are made of lesions clinically suspect for BCC. All patients underwent punch biopsy conform regular care.
89387516|NCT06273709||OCT scans with clinical/dermoscopic photographs|The same OCT scans will be used . OCT assessment is performed in conjunction with clinical and dermoscopic photographs.
89387517|NCT06273696||Circumcision clients|Participants who underwent the ShangRing circumcision procedure
89387518|NCT06273670||Service providers|General practitioners, specialists, nurses, and social workers.
89387519|NCT06273670||Clients|All clients who were attending family planning centers in public health facilities at the study period will be included if they have had a postpartum LARC method (Copper IUD, Progestin-releasing IUS or Subdermal implant) or willing to use it in the first year after delivery.
89387520|NCT06273657|Experimental|Medisinstart|
89387521|NCT06273657|No Intervention|Control|
89387522|NCT06273644|Experimental|60-65 E% Carbohydrates|Diet plan A with 60-65 E% Carbohydrates in 4 weeks
89387523|NCT06273644|Active Comparator|40-45% Carbohydrates|Diet plan B with 40-45 E% Carbohydrates in 4 weeks
89387524|NCT06273631|Experimental|multiple-diverse carbohydrate diet|"Carbohydrate provides 50~55% of total dietary energy, protein 10~15%, and fat 20 ~30%. Among them, 45~50% of carbohydrate supply sources are refined grains, 45~50% of carbohydrate supply sources are whole grains, beans or potatoes.~The total energy is divided into 6 meals per day. The breakfast provides 15~20% of total energy, lunch 20~25%，dinner 15~20%，and each of 3 extra meals provide 10~15% of total energy."
89387525|NCT06273631|Experimental|middle carbohydrate diet|"Carbohydrate provides 50~55% of total dietary energy, protein 10~15%, and fat 20 ~30%. 90~95% of the carbohydrate supply comes from refined grains.~The total energy is divided into 3 meals per day. The breakfast provides 25~30% of total energy, lunch 30~40%，and dinner 30~35%."
89387526|NCT06273592|Active Comparator|Plant-based|"The plant-based arm consists of consuming one plant-based meat meal and then using the Rigiscan™ device to measure the frequency, rigidity, and duration of nocturnal erections.~The meal in the plant-based arm and the meal in the animal-based arm will differ only by whether the meal contains plant-based meat or animal meat."
89387527|NCT06273592|Active Comparator|Animal-based|"The animal-based arm consists of consuming one animal meat meal and then using the Rigiscan™ device to measure the frequency, rigidity, and duration of nocturnal erections.~The meal in the plant-based arm and the meal in the animal-based arm will differ only by whether the meal contains plant-based meat or animal meat."
89387528|NCT06273579|No Intervention|Tutored by AI|26 participants allocated. During their second, third, fourth, and fifth repetition of the practice subpial brain tumor resection scenario, participants will receive verbal ICEMS feedback when the system detects an error on their performance.
89387529|NCT06273579|Experimental|Tutored by human instructor using AI's words|26 participants allocated. During their second, third, fourth, and fifth repetition of the practice subpial brain tumor resection scenario, participants will receive verbal feedback from an expert instructor. The expert instructor will deliver this feedback using the same words as the ICEMS.
89387530|NCT06273579|Experimental|Tutored by human instructor using wording of choice|26 participants allocated. During their second, third, fourth, and fifth repetition of the practice subpial brain tumor resection scenario, participants will receive verbal feedback from an expert instructor. The expert instructor will deliver this feedback using any wording they feel is appropriate to correct the error.
89387531|NCT06273553|Experimental|RG002 Injection|In Part A, subjects with histologically confirmed Cervical Intraepithelial Neoplasia Grade 2 or 3 (CIN2/3) associated with Human Papillomavirus (HPV) 16 or 18, will be allocated to three dose cohorts that are 25µg,75µg and 150µg. In Part B, subjects with histologically confirmed Cervical Intraepithelial Neoplasia Grade 2 or 3 (CIN2/3) associated with Human Papillomavirus (HPV) 16 or 18, will be allocated to 1 or 2 dose levels according to the results of Part A. All subjects will receive a total of three RG002 Injections, administered intramuscularly at assigned dose level, with a dosing frequency of every 2 weeks (D1, D15, and D29).
89387532|NCT06273540|Experimental|STP7 (mavoglurant) modified release film-coated tablet|"Participants will take STP7 (mavoglurant) twice a day (BID) from Days 3 to 9 according to the following dosing schedule:~Day 3: 50 mg BID;~Day 4: 100 mg BID;~Days 5-9: 200 mg BID,~Day 10: 200 mg only the morning dose.~Morning STP7 (mavoglurant) doses must be taken within 30 minutes of beginning a meal."
89387533|NCT06273540|Placebo Comparator|Placebo|Participants will take matched placebo on a dosing schedule identical to that of STP7 (mavoglurant) and morning doses must be taken within 30 minutes of beginning a meal.
89387534|NCT06273527|Experimental|COGENT - Cognitive Training Intervention Program|Computer-administered cognitive training program. COGENT is a modified working memory capacity task designed to train cognitive functioning. COGENT was designed to contain high interference across trials. By requiring repeated practice with utilization of interference control across trials, COGENT is thought to enhance plasticity of cognitive systems and improve performance. That is, training is based on the premise that learning-based neural changes will occur via repeated exposure to a task demanding cognitive control resources
89189406|NCT05810532|Experimental|1H group|oral hydration (water) is allowed 1 hour before sedation, while other food must be fasted more than 4 hours before sedation
88863010|NCT06170788|Experimental|MK-2870 + Pembrolizumab|Participants receive MK-2870 via intravenous (IV) infusion on Days 1, 15 and 29 of each 6-week cycle + 400 mg Pembrolizumab every 6 weeks (q6w) via IV infusion on Day 1 of each 6-week cycle for 18 cycles. Additionally, participants receive diphenhydramine (or equivalent), an H2 antagonist of investigator's choice, acetaminophen (or equivalent), and dexamethasone (or equivalent) per each drug's product label prior to the first 4 infusions of MK-2870. At subsequent infusions, the H2 antagonist and dexamethasone are optional, at the discretion of the investigator.
88863011|NCT06170788|Active Comparator|Pembrolizumab|Participants receive 400 mg Pembrolizumab via IV infusion q6w on Day 1 of each 6-week cycle for 18 cycles
88863012|NCT06168747|Experimental|İntervention|In the study group, wrist mediolateral glide, 1st MCP joint anteroposterior glide, CMC joint mediolateral, and anteroposterior glide were applied to the individuals by an experienced physiotherapist. Applications were made 6 times with 3 repetitions
88863013|NCT06168747|Sham Comparator|Sham Mobilization|In the sham mobilization group, individuals were placed in the same position, but no mobilization application was performed.
88863014|NCT06166966|Experimental|flipped training|flipped training
88863015|NCT06166966|Experimental|Course success|Course success
88863016|NCT06165250|Experimental|BR1018A-1 + BR1018B + BR1018C|
88863017|NCT06165250|Active Comparator|BR1018A + BR1018B-1 + BR1018C|
88863018|NCT06165250|Active Comparator|BR1018A-1 + BR1018B + BR1018C-1|
88863019|NCT06163326|Experimental|Arm 1|"Participants who previously received 1 ritlecitinib 50 mg capsule QD orally from BL to Week 52 in Study B7981040.~Ritlecitinib 50 mg or Ritlecitinib 100 mg or Placebo will be assigned."
88863020|NCT06163326|Experimental|Arm 2|Participants who previously received 1 placebo 50 mg capsule QD orally from BL to Week 52 in Study B7981040 Ritlecitinib 50 mg or Ritlecitinib 100 mg or Placebo will be assigned
88863021|NCT06163261|Other|Intervention group|This group will receive an individualized and person-centred prescription of physical activity and exercise in addition to standard care.
88863022|NCT06163261|No Intervention|Control group|This group will receive standard care.
88863023|NCT06162403|Experimental|Peripheral Nerve Stimulation|Participants will be asked to have PNS leads inserted via a needle, which will provide a mild, stimulating electrical current to the effected nerves 24 hours a day for up to 60 days. Participants will have study visits during and after this time.
88863024|NCT06160752|Experimental|Phase 1 Part A and Part B|TYRA-200 taken once daily by mouth in 28-day cycles
88863025|NCT06158958|Experimental|ABBV-303 Dose Escalation: Part 1A Monotherapy|Participants with (R)/refractory (R) solid tumors will receive ABBV-303 in escalating doses as a monotherapy until the maximum tolerable dose (MTD) is determined as part of the 3 year study duration.
88863026|NCT06158958|Experimental|ABBV-303 Dose Expansion: Part 2A Monotherapy|Participants with R/R NSCLC will receive ABBV-303 at the recommended phase 1 expansion dose (RP1ED) as a monotherapy as part of the 3 year study duration.
88863027|NCT06158958|Experimental|ABBV-303 Dose Expansion: Part 3A Monotherapy|Participants with R/R RCC will receive ABBV-303 at the RP1ED as a monotherapy as part of the 3 year study duration.
88863028|NCT06158958|Experimental|ABBV-303 Dose Expansion: Part 4A Monotherapy|Participants with R/R HNSCC will receive ABBV-303 at the RP1ED as a monotherapy as part of the 3 year study duration.
88863029|NCT06158958|Experimental|ABBV-303 Dose Expansion: Part 5A Monotherapy|Tissue agnostic with R/R participants with MET amplification by any commercially available test will receive ABBV-303 at the RP1ED as a monotherapy as part of the 3 year study duration.
88863030|NCT06158958|Experimental|ABBV-303 Dose Escalation: Part 1B Combination|Participants with R/R solid tumors will receive ABBV-303 in combination with budigalimab at or below the MTD as part of the 3 year study duration.
88863031|NCT06158958|Experimental|ABBV-303 Dose Expansion: Part 2B Combination|Participants with R/R NSCLC will receive ABBV-303 at or below the MTD in combination with budigalimab as part of the 3 year study duration.
88863032|NCT06151418||Novel hormonal therapy cohort|Patients initiating novel hormonal therapy (abiraterone, apalutamide or enzalutamide) for mCSPC
88863033|NCT06150638|Experimental|Biofeedback|
88863034|NCT06150638|Placebo Comparator|Placebo|
89185178|NCT00736281|No Intervention|Placebo Food Drops|The patients enrolled in our study will present with food allergy symptoms and diagnostic tests will provide the specific information regarding their food allergies. Once the diagnosis has been made and consent for treatment has been obtained, participants will be randomly assigned to either the group that receives the food allergy intervention with SLIT ( food allergens mixed with 50% glycerin in a vial) or the group that receives the control SLIT (glycerin only). The patients are truly blinded to their treatment because all the SLIT food allergy vials are identical and contain no distinguishing features that could reveal their contents. There is also no difference in taste between a vial containing glycerin and food allergens and a vial containing only glycerin.
88863035|NCT06150183|Experimental|BNT314 Monotherapy|Escalating dose levels and backfill cohorts
88863036|NCT06150183|Experimental|BNT314 + pembrolizumab|The BNT314 starting dose for the SRI combination therapy will be one DL lower than the RP2D/MTD/maximum administered dose (MAD) determined from the monotherapy dose escalation.
88863037|NCT06148896|Experimental|Group Exercise with acceptance and commitment therapy|Combining physiotherapy group exercise with acceptance and commitment therapy delivered by physiotherapist (GrExPACT)
88863038|NCT06148896|Active Comparator|Group Physiotherapy Exercise alone|Group Physiotherapy exercise alone (GrEx)
88863039|NCT06148038|Experimental|CBD Oral|CBD Oral 350mg twice daily for 28 days
88863040|NCT06148038|Placebo Comparator|Placebo control|Placebo control Oral twice daily for 28 days
88863041|NCT06145243|Active Comparator|Visual brochure based resistive home exercise group,|In the 8-week exercise training, the exercise resistance of the patients will start with 60-70% according to1 Repetition Maximum in the first 4 weeks and will be increased to 70-80% according to 1 Repetition Maximum in the last 4 weeks according to the American College of Sports Medicine safe exercise intensity guideline for elderly individuals.
88863042|NCT06145243|Active Comparator|Video-based resistive home exercise group|In the 8-week exercise training, the exercise resistance of the patients will start with 60-70% according to 1 Repetition Maximum in the first 4 weeks and will be increased to 70-80% according to 1 1 Repetition Maximum in the last 4 weeks according to the American College of Sports Medicine safe exercise intensity guideline for elderly individuals.
89387535|NCT06273527|Sham Comparator|Non-Training Program|The non-training condition requires participants to complete a similar computer task for the same length of time. The non-training is a modified working memory capacity task designed to be inert. The non-training condition was designed to contain relatively less interference demands across trials.
89387536|NCT06273514|Experimental|TECAR|TECAR therapy is a non-invasive method for treating musculoskeletal system disorders based on the application of high-frequency current (300 kHz - 1 MHz)
89387537|NCT06273514|Experimental|Dry needling|Dry needling, a form of intramuscular stimulation, is a therapeutic intervention employed in physiotherapy and sports medicine. It entails the precise insertion of fine needles into specific myofascial trigger points, taut bands of skeletal muscle, or connective tissue without the administration of pharmacological agents.
89387538|NCT06273475|Experimental|Intervention|Training facilitated through body weight unloading robotic technology yielding a dynamic unloading force applied to the body centre of mass.
89387539|NCT06273475|Active Comparator|Active Control|Training facilitated without the use of body weight unloading robotic technology, thereby only allowing manual assistance from physiotherapists.
89387540|NCT06273462|Experimental|Palmitoylethanolamide|Participants randomized to the experimental arm will receive the supplement Palmitoylethanolamide (PEA) at a dose of 600mg twice a day
89387541|NCT06273462|Placebo Comparator|Placebo|Participants randomized to the placebo arm will receive a visually identical placebo capsule
89387542|NCT06273449|No Intervention|Group 1|"Conventional:~The Standard of Care (SOC) workflow, which will act as a baseline compared to the other 2 groups.~Teeth Profile Capture Method: Physical impression RPD Design Method: Based on stone model, using wax pattern RPD Fabrication Method: Lost wax casting"
89387543|NCT06273449|Experimental|Group 2|"Partial Digital:~Similar to the SOC, Group 2 adopts the same teeth profile capture method, where a physical impression of teeth profile is taken from the subject. However, instead of using physical wax pattern on the stone model for design, the stone model is scanned and, on the scan, the design is performed digitally. For fabrication of RPD in Group 2, instead of using lost wax casting as per the SOC, the digital design is used for additive manufacturing."
89387544|NCT06273449|Experimental|Group 3|"SmartRPD Digital:~Group 3 adopts a different teeth profile capture method by using the intraoral scanner to digitally scan and save the subject's teeth profile. From the intraoral scan, a digital model of the subject's teeth profile is created. Similar to Group 2, but on the digital model instead, the design of RPD is digitally performed. The digital design, as per Group 2, is used for additive manufacturing."
89387545|NCT06273436|No Intervention|Usual Care|AIM (AIM Alliance for Innovation on Maternal Health) safety bundles delivered in-person
89387546|NCT06273436|Experimental|Usual Care plus Listening to Women and Pregnant and Postpartum People (LTWP)|LTWP is designed to provide the AIM (Alliance for Innovation on Maternal Health) Postpartum Discharge Transition education systematically and to frequently monitor women for signs and symptoms of postpartum complications using simple, patient-centered technology (text/phone).
89387547|NCT06273423|Experimental|Group dance fitness, OULA|Mind-body dance fitness group
89387548|NCT06273423|No Intervention|Waitlist Control|Waitlist control group
89387549|NCT06273410|Experimental|Cention N without adhesive.|
89387550|NCT06273410|Experimental|Cention N with adhesive|
89387551|NCT06273410|Active Comparator|Filtek Bulk Fill posterior composite|
88863043|NCT06145243|Experimental|Supervised resistance exercise group|In the 8-week exercise training, the exercise resistance of the patients will start with 60-70% according to 1 Repetition Maximum in the first 4 weeks and will be increased to 70-80% according to 1 Repetition Maximum in the last 4 weeks according to the American College of Sports Medicine safe exercise intensity guideline for elderly individuals.
88863044|NCT06145035|Placebo Comparator|control group|Four doses of vehicle (Plasma-Lyte A supplemented with 1% HSA) will be given 2 months apart. Each dose will be infused IV at a rate of 1 ml/min for a total of 60 ml over 60 minutes.
89387552|NCT06273384||Intervention group|Patients aged 18 years and older who present with peptic ulcer hemorrhage, confirmed by esophagogastroduodenoscopy (EGD).
89530186|NCT05585177|Experimental|Growth hormone pretreatment+IVF/ICSI|After 3 months of Growth hormone treatment (2 units daily), IVF/ICSI was performed
88863045|NCT06145035|Experimental|single-dose group|One dose of UC-MSCs (100 x 106 cells) will be infused IV at a rate of 1 ml/min for a total of 60 ml over 60 minutes (1.6 million cells/ml/min). This will be followed by three IV infusions of placebo (same volume and rate) 2, 4, and 6 months later.
88863046|NCT06145035|Experimental|repeated-dose group|Four doses of UC-MSCs (100 x 106 cells each) will be given 2 months apart. Each dose will be infused IV at a rate of 1 ml/min for a total of 60 ml over 60 minutes (1.6 million cells/ml/min).
89530187|NCT05585177|No Intervention|IVF/ICSI|IVF/ICSI was performed
89530188|NCT03249883|Active Comparator|SACH first|Will use a SACH foot for the first three weeks of prosthetic gait training , and a 1M10 foot for the second three weeks of prosthetic gait training
89530189|NCT03249883|Active Comparator|1M10 first|Will use a 1M10 foot for the first three weeks of prosthetic gait training , and a SACH foot for the second three weeks of prosthetic gait training
88863047|NCT06144892|Experimental|Intervention first|Patients will undergo proactive therapy first, followed by the buffer period, and finally the conventional APAP therapy.
88863048|NCT06144892|Experimental|Control first|Patients will undergo the conventional APAP therapy first, followed by the buffer period, and finally the proactive therapy.
89185179|NCT00736281|Active Comparator|Food Drops|Group 2 (intervention group) will receive sublingual immunotherapy (escalation followed by maintenance) with vials containing glycerin and the previously diagnosed food allergens (peptides).
89185180|NCT00736437|Experimental|1|ME-609
89185181|NCT00736437|Placebo Comparator|2|Vehicle
89530190|NCT04501835||Cardiac implantable electronic device infections|Patients hospitalised in Nancy University Hospital for suspected cardiac implantable electronic device infections
89530191|NCT03250039|Experimental|Mass Balance|Cumulative recovery of radioactivity in urine and feces
89530192|NCT03250039|Experimental|Absolute Bioavailability|Oral absolute bioavailability
88818997|NCT02865707|Placebo Comparator|Placebo|Placebo group will take 15 grams of maltodextrin per day for 6 months. Maltodextrin is a sugar adsorbed in the small bowel with no effect on the colonic intestinal microbiota. During the first two weeks the patient is advised to take 7.5 g of the product at breakfast only. Starting in week 3 until the end of the treatment the participant will take 7.5 g at breakfast and 7.5 g at dinner for a total of 6 months, or until you experience a flare.
88818998|NCT02656485|Experimental|Dose I|B244 Dose 1 (dose level [cells/mL] 20,000,000,000)
88818999|NCT02656485|Experimental|Dose II|B244 Dose 2 (dose level [cells/mL] 40,000,000,000)
88819000|NCT02656485|Experimental|Dose III|B244 Dose 3 (dose level [cells/mL] 80,000,000,000)
88819001|NCT02656485|Placebo Comparator|Placebo|Placebo to Match B244
88819002|NCT05392413||reactive group|According to the treatment effect, the patients were divided into two groups: reactive and non-reactive.
88819003|NCT05392413||non-reactive group|According to the treatment effect, the patients were divided into two groups: reactive and non-reactive.
88819004|NCT05443269|Experimental|Jump Start Program|The intervention consists of following the Jump Start plan for 7 days
88819005|NCT05443113||Children (<11 years) with pectus excavatum|All pediatric PE patients aged younger than 11 years upon first visit of our outpatient clinic
88819006|NCT02656875|Experimental|TRV130|"For clinician-administered bolus dosing, TRV130 initial dose is administered and supplemental dosing is available, if clinically indicated. Subsequent doses may be administered every 1 to 3 hours as needed.~For PCA dosing, the TRV130 regimen consists of a loading dose, a demand dose, and a lockout interval."
88819007|NCT05442801|Active Comparator|Cyclopentolate arm|"To study the effect of cyclopentolate 1% for cycloplegic refractions in pediatric populations:~Firstly, we instilled an anesthetic drop into patients' eyes. Secondly, 2 drops of cyclopentolate 1% (cyclogel) 5 minutes apart were instilled.~Autorefraction was taken at 60 minutes after first drop instillation. Primary outcome: spherical equivalent (SE) of cycloplegic refraction at 60 minutes."
88819008|NCT05442801|Active Comparator|Tropicamide arm|"To study the effect of tropicamide 1% for cycloplegic refractions in pediatric populations:~Firstly, we instilled an anesthetic drop into patients' eyes. Secondly, 2 drops of tropicamide 1% (mydriacil) 5 minutes apart were instilled. Autorefraction was taken at 30 minutes after first drop instillation. Primary outcome: spherical equivalent (SE) of cycloplegic refraction at 30 minutes."
88819009|NCT05442723|Other|Case|Patients with extensive LAD disease treated with off-pump CABG
88819010|NCT05442723|Other|Control|Patients with extensive LAD disease treated with on-pump CABG
88819011|NCT04739631|Experimental|acupuncture group|The acupuncture group and the sham-controlled group will receive three therapeutic sessions each week for four weeks, and another two sessions each week for four weeks (a total of 20 sessions at eight weeks). Each group will be followed-up for four weeks, to evaluate the persistent efficacy of acupuncture.The needle set for the sham acupuncture group and the real acupuncture group will use the CASOON Acupuncture Needle (Wuxi Jiajian Medical Instrument Company, limited), which needle size is 0.3 mm×30 mm. The depth of needling varied based on the patient's body sizes. After insertion, the needles were manually manipulated to obtain the De Qi sensation, which was defined as the acupuncturist feeling a tugging or grasping sensation from the needle manipulation and the patient feeling soreness, fullness, heaviness, or local distension at local needling sites.
88819012|NCT04739631|Placebo Comparator|sham-controlled group|The sham acupuncture group will be performed by superficial needling with less than 4mm depth. The needling location is about 0.5 cm away from the acupoints. Both the real acupuncture group and the sham acupuncture group received the same treatment protocol.
88819013|NCT04739631|No Intervention|waitlist-control group|As an waitlist-control group, no acupuncture will be performed.
88819014|NCT05339373|Other|Sequence TR|18 subjects assigned to the sequence TR will receive a single 100 mg dose of the test product Aceclofenac (1 x 100 mg tablet), marked as T in the sequence, in Period 1 and a single 100 mg dose of the reference product Airtal ® (1 x 100 mg tablet), marked as R in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
88819015|NCT05339373|Other|Sequence RT|18 subjects assigned to the sequence RT will receive a single 100 mg dose of the test product Airtal ® (1 x 100 mg tablet), marked as R in the sequence, in Period 1 and a single 100 mg dose of thetest product Aceclofenac (1 x 100 mg tablet), marked as T in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
88819016|NCT05439993|Experimental|Tepotinib plus paclitaxel arm|
88819017|NCT04739553|Experimental|His Pacing|Implant of a supplementary His pacing lead in addition to a traditional RV pacing lead.
88819018|NCT05439135|Experimental|midgut|A soft TET tube is inserted into the colon via the paraffin-lubricated gastroscope channel. If patients cannot tolerate endoscopy or anesthesia, or it is difficult to confirm the bypass intestine under endoscopy, a nasojejunal tube will be inserted under digital fluoroscopy.
88819019|NCT05439135|Experimental|colonic|A soft TET tube is inserted into the colon via the paraffin-lubricated colonoscope channel.
88819020|NCT05300997||Haemorrhagic Stroke [N=100]|Haemorrhagic stroke subjects presenting within 24 hours from symptom onset will have serial whole blood and saliva drawn a) in the emergency department (if available) or hospital within 24 hours of the onset of symptoms; b) 18 hours +/- 6 hours from symptom onset (if available); and c) 30 hours+/- 6 hours from symptom onset (if available).
89387553|NCT06273358||Over 45 year old|"Before surgery All preoperative patients will have Preoperative Stop Bang, Pittsburghb Sleep Quality Index, and Mini Mental tests for sleep quality and consciousness monitoring. This will be based on sleep the day before surgery and mini-mental exams before surgery.~The intraoperative phase Our clinical approach is to admit patients under general anesthesia after regular assessment and monitoring. The following parameters will be recorded intraoperatively.~After surgery As usual, patients are brought to the PACU after awakening. It will be measured Pittsburghb Sleep Quality Index on 3 days, QoR-15 on the last day, and 3D CAM or ICU-CAM for 3 days postoperatively. Patients will stay in the ward and intensive care unit for 72 hours and be called for 72 hours after release."
89387554|NCT06273358||Over 65 year old|"Before surgery All preoperative patients will have Preoperative Stop Bang, Pittsburghb Sleep Quality Index, and Mini Mental tests for sleep quality and consciousness monitoring. This will be based on sleep the day before surgery and mini-mental exams before surgery.~The intraoperative phase Our clinical approach is to admit patients under general anesthesia after regular assessment and monitoring. The following parameters will be recorded intraoperatively.~After surgery As usual, patients are brought to the PACU after awakening. It will be measured Pittsburghb Sleep Quality Index on 3 days, QoR-15 on the last day, and 3D CAM or ICU-CAM for 3 days postoperatively. Patients will stay in the ward and intensive care unit for 72 hours and be called for 72 hours after release."
89387555|NCT06273345||Single arm|
89387556|NCT06273332|Experimental|AI-assisted registration|3D model registration will be carried out using artificial intelligence
89387557|NCT06273332|Active Comparator|Point-based registration|3D model registration will be carried out using point-based approach
89387558|NCT06273319|Placebo Comparator|Group 1: Patients who will receive 15 litres oxygen therapy|: Patients who will receive 15 litres oxygen therapy, will be applied throughout the transaction.Patient saturation and complications such as bronchospasm and laryngospasm respiratory arrest will be recorded throughout the procedure.
89387559|NCT06273319|Active Comparator|Group 2: Patients who will receive 30 litres oxygen therapy|Patients who will receive 30 litres oxygen therapy,will be applied throughout the transaction.Patient saturation and complications such as bronchospasm and laryngospasm respiratory arrest will be recorded throughout the procedure.
89387560|NCT06273306|Experimental|Digital care|User of mobile APP for telemonitoring
89387561|NCT06273306|No Intervention|Traditional care|Monitoring in face-to-face visits
89387562|NCT06273280|Active Comparator|Standard of Care|Up-titration of GDMT at the discretion of the treating physician.
89387563|NCT06273280|Experimental|Intervention|Uptitration of GDMT according to the renal-based approach postulated by the Heart Failure Association of the European Society of Cardiology (HFA-ESC)
89387564|NCT06273267||Patients|AP-HP patients followed by the pediatric palliative care teams of Ile de France (metropolitan area of Paris) between January 2020 and December 2022 and suffering from a serious non-progressive neurological disease.
89387565|NCT06273254|Experimental|Test Product|Sacubitril and Valsartan Tablets 49mg/51mg to be orally administered
89387566|NCT06273254|Active Comparator|Reference product|Entresto® (48.6 mg sacubitril and 51.4 mg valsartan as sodium salt complex) to be orally administered
89387567|NCT06273241|Placebo Comparator|Berberine intake in fasted condition|Intake of 1000 mg berberine in the fasted condition (intake of last meal: before 20:00 on the day before the study visit)
88863049|NCT06140940|Experimental|active stimulation group: 20 participants with aphantasia will receive a session of active HD-tDCS|Participants will receive a session of active HD-tDCS at a current intensity of 4 mA for a duration of 15min. The placement of electrodes will be determined to specifically target the primary motor cortex (4 x 1 montage with the anode over C4). During the stimulation, participants will be engaged in a mental training task (sequential finger tapping-task).
88863050|NCT06140940|Placebo Comparator|placebo stimulation group: 20 participants with aphantasia will receive a session of sham HD-tDCS|"High-definition transcranial direct current (HD-tDCS), sham condition. Participants will receive a session of sham HD-tDCS, which will be delivered following the same procedures as active HD-tDCS but the intensity of the current will be set at 4mA during the 30 first seconds at the beginning of the 15-min period of the stimulation, and equal to 0 mA for the reminding period of stimulation to simulate the tingling sensation often experienced by individuals during active stimulation.~The placement of electrodes will be determined to specifically target the primary motor cortex (4 x 1 montage with the anode over C4). During the stimulation, participants will be engaged in a mental training task (sequential finger tapping-task)."
88863051|NCT06135519|Experimental|Mesenchymal stem cells|Mesenchymal Stem Cells taken from adipose tissue will be used
88863052|NCT06135519|Experimental|Homogenized fat|Adipose tissue will be harvested and used
89387568|NCT06273241|Active Comparator|Berberine intake after a low caloric meal|Intake of 1000 mg berberine after a light caloric meal (intake of last meal: before 20:00 on the day before the study visit)
88863054|NCT06125340|Experimental|Short-course treatment|5 days of placebo (after participants already received 3-5 days of antibiotics)
88863055|NCT06125340|Active Comparator|Standard-duration treatment|5 days of amoxicillin (after participants already received 3-5 days of antibiotics)
88863056|NCT06124105|Other|urine PO2|
88863057|NCT06123767|Experimental|CAS + Intravascular measuring the pressure gradient|"Patients with internal carotid stenosis qualified for angioplasty with stent implantation.~Standard CAS procedure with additional intravascular pressure measurements"
88863058|NCT06123767|Active Comparator|CAS (standard)|"Patients with internal carotid stenosis qualified for angioplasty with stent implantation.~Standard CAS procedure."
89387569|NCT06273241|Active Comparator|Berberine intake after a high caloric meal|Intake of 1000 mg berberine after a high caloric meal (intake of last meal: before 20:00 on the day before the study visit)
88863059|NCT06123611|No Intervention|Standard Care|In the pre-implementation period, all trauma patients will receive standard routine care. Which may include some screening and counseling on gun safety.
89387570|NCT06273228|Experimental|Parent participants|Parents receive access to the FCU Online website and telehealth coaching/ support provided by a trained mental health provider. The FCU Online website includes a brief 5-minute assessment, feedback on parents' responses, and online tools to support parenting in areas that were identified as challenges by the assessment. These tools include animated videos, parenting tips, and interactives to help practice parenting skills. Telehealth coaching will focus on Wellness and Self-Care, Parenting and Substance Use, Positive Parenting, Proactive Parenting, and Supervision and Limit Setting.
89387571|NCT06273215|Experimental|Non-obese T2DM|
89387572|NCT06273215|Experimental|Obese T2DM|
88863060|NCT06123611|Experimental|ACTFAST Intervention|During the implementation and maintenance periods, all trauma patients will receive study activities including firearm access screening, counseling on safe storage practices, and referral to safe storage and other community resources as appropriate.
89387573|NCT06273215|Experimental|Elderly T2DM|
89387574|NCT06273215|Experimental|T1DM|
89387575|NCT06273202|Experimental|Massage|Infants will be randomized to receive infant massage or not. Infant massage will be performed three times a day (10 minutes per session) until they reach the 35th week of post-conceptional age (35+6) by the two departmental physical therapists (ADP and ADV).
89387576|NCT06273202|No Intervention|Control group (standard care)|Infants in this group will receive standard care.
89387577|NCT06273189|Experimental|Lindeman|BSSO were performed with Lindeman and round bur
88863061|NCT06122298||Individuals with gambling problems|"This group includes individuals suffering from gambling addiction as defined by the DSM-5, and individuals suffering from problem gambling, just below the DSM-5 diagnostic threshold."
88863062|NCT06122298||Healthy control individuals|Matched healthy individuals
88863063|NCT06118983|Experimental|I-TRANSFER-HF|This is a 1-year long intervention period when I-TRANSFER-HF is in operation.
88863064|NCT06118983|No Intervention|Standard of Care (usual care)|This is a baseline period of usual care (UC) with no intervention.
88863065|NCT06114888|Experimental|MeMed BV|
89185182|NCT00736515|Experimental|Combination therapy|The subjects allocated into this arm will receive the combination therapy of oral administration of 60~120mg Gliclazide MR (Diamicron MR) and subcutaneous injection of basal insulin (Insulin Glargine Injection, Lantus) once daily for 3 months
89185183|NCT00736515|Active Comparator|monotherapy|The patients allocated into this arm will receive the monotherapy of subcutaneous injection of premixed insulin (Biosynthetic Human Insulin Injection, Novolin 30R) twice daily for 3 months.
89387578|NCT06273189|Active Comparator|Bone scalpel|BSSO were performed unilaterally using an ultrasonic bone scalpel
89387579|NCT06273176||Awake mapping|Awake mapping: Tumor resection with intraoperative awake motor or language mapping
89387580|NCT06273176||Asleep mapping|Asleep mapping: Tumor resection with intraoperative asleep motor mapping
88863066|NCT06114888|Active Comparator|Usual Care|
88863067|NCT06112314|Experimental|Arm A: IMC-F106C Low Dose + Nivolumab|Participants receive IMC-F106C Low Dose once weekly (QW) for the first 12 weeks, then every 2 weeks (Q2W) through Week 51, and then every 4 weeks (Q4W) until Week 101. Nivolumab is given Q4W until Week 101.
88863068|NCT06112314|Experimental|Arm B: IMC-F106C High Dose + Nivolumab|Participants receive IMC-F106C High Dose QW for the first 12 weeks, then Q2W through Week 51, and then Q4W until Week 101. Nivolumab is given Q4W until Week 101.
88863069|NCT06112314|Active Comparator|Arm C: Nivolumab OR Nivolumab + Relatlimab|Participants receive nivolumab 480 mg monotherapy, or nivolumab 480 mg + relatlimab 160 mg, Q4W until Week 101.
88863070|NCT06112106|No Intervention|Control group|Surgeons assigned to the control group will be asked (to continue) to apply the ergonomic recommendations in the daily practice introduced three months ahead of trial start.
88863071|NCT06112106|Experimental|Intervention group|Surgeons
88863072|NCT06111742|Experimental|Interactive Gaming Group|Subjects will utilize an interactive gaming platform via the Bedside Entertainment and Relaxation Theater (BERT) directly prior to and during induction of anesthesia.
89387581|NCT06273176||No mapping|No mapping: Tumor resection without intraoperative mapping
89387582|NCT06273150||DRPLA-mutation carrier|Subjects with a positive genetic test for a pathological expansion in the ATN1 gene.
89387583|NCT06273150||Volunteer control|Subjects without neurological conditions (other than primary headache disorders), without a family history of DRPLA or a previous negative genetic test for pathological expansions in the ATN1 gene.
88863073|NCT06111742|No Intervention|Standard of Care|Subjects will be offered standard of care interventions to improve preoperative anxiety. The interactive gaming system under investigation will not be available to this group.
88863074|NCT06109311|Experimental|Orforglipron Dose 1|Participants will receive orforglipron orally.
88863075|NCT06109311|Experimental|Orforglipron Dose 2|Participants will receive orforglipron orally.
89387584|NCT06273137|Experimental|Positive affect treatment|PAT is a 15-week cognitive-behavioral therapy that focuses on increasing reward motivation and sensitivity at the neural, behavioral, and affective levels of analysis. These observed effects occur through PAT's effects on reward sensitivity and positive affect. Participants will be assigned to a therapist with training in cognitive-behavioral therapy who will meet with them weekly via telehealth.
89387585|NCT06273137|No Intervention|Waitlist|
89387586|NCT06273111|Experimental|5% simvastatin ointment|Participants will be applied 5% simvastatin ointment on IH lesion
88863076|NCT06109311|Experimental|Orforglipron Dose 3|Participants will receive orforglipron orally.
88863077|NCT06109311|Placebo Comparator|Placebo|Participants will receive placebo orally.
88863078|NCT06099210||Moderate traumatic brain injury|Intervention: Glasgow coma scale
88863079|NCT06099210||Healthy control group|
88863080|NCT06094998||children born after ART|120 children born after assisted reproductive technologies
88863081|NCT06094998||children conceived spontaneously|132 children conceived spontaneously
89185184|NCT00731367|Active Comparator|Gelled|Aquacel Ag gelled.
89185185|NCT00731367|Active Comparator|Adherent|Aquacel Ag adherent
89387587|NCT06273098|Experimental|Bladder Health Education|Participants in this arm will receive the intervention
89387588|NCT06273098|No Intervention|No Bladder Health Education|Participants in this arm will not receive the intervention
89387589|NCT06273059||Diabetic patients and Healthy controls|Diabetic patients and Healthy controls
89387590|NCT06273046|Experimental|Biofeedback|
89387591|NCT06273046|Placebo Comparator|Placebo|
89387592|NCT06273020|Experimental|Intravenous thrombolysis and cerebrolysin|"Group 1: 20 patients with previous intravenous thrombolysis (IVT) in the qualifying stroke and who agreed to receive and got selected (through randomization) cerebrolysin.~Cerebrolysin would be prepared according to manufacturer's instructions: 30 mL of cerebrolysin in 100 ml of saline solution every 24 hours to a minimum of 10 days and a maximum of 14 days"
89387593|NCT06273020|Active Comparator|Intravenous thrombolysis without cerebrolysin|Group 2 : 20 patients with previous IVT in the qualifying stroke and who agreed to receive cerebrolysin but they were not choose through randomization.
89387594|NCT06273020|Other|Patients with cerebrolysin without IVT|"Group 3: 20 patients that they were not candidates to receive IVT (out of therapeutic window) but agreed to receive cerebrolysin (randomization not used)~Cerebrolysin would be prepared according to manufacturer's instructions: 30 mL of cerebrolysin in 100 ml of saline solution every 24 hours to a minimum of 10 days and a maximum of 14 days"
89387595|NCT06273007|Experimental|woman in labor|"All women in labour during the study period (3 months baseline and the 3rd-6th month of the intervention) will be included for this pre- vs post-study of the PartoMa intervention.~The following subgroups will be studied in-depth:~All stillbirths~5th Minute APGAR score <7~All maternal deaths~All women with severe obstetric complication (postpartum hemorrhage, hypertensive disorders of pregnancy, uterine rupture, obstructed labor)"
89387596|NCT06273007|Experimental|Birth attendants|All health care providers (physicians and midwives) working at the department of obstetrics during the study period will be invited to participate in knowledge tests of obstetric care and qualitative study. participant observations as well as in-depth interviews regarding quality of intrapartum care. This is a part of evaluating the use and effectiveness of the PartoMa intervention.
89387597|NCT06272929||45 patients with behcet disease|
89387598|NCT06272929||45 healthy participants|
89387599|NCT06272916||sample size of 630 cases was calculated, divided equally into three groups.|"For sample size calculation using Yousefshahi et al. (14) as a reference, a sample size of 630 cases was calculated, divided equally into three groups. This sample size achieves 80% power when the effect size is moderate (=0.12) and using 2 degrees of freedom Chi-Squared test with a significant level of 0.05. Using computer generated randomization program, patients were randomly divided into three equal groups.~Group 1: patient received 100 ml IV infusion of normal saline (control group). Group 2: patient received Aminophylline 1.5 mg/kg IV infusion diluted in normal saline with a total volume of 100 ml.~Group 3: patient received 50 mg/ kg Magnesium sulfate IV infusion diluted in normal saline with a total volume of 100ml."
89387600|NCT06272903|Experimental|Benzocaine 20% Topical Anesthesia Arm|"Participants will be assigned this arm either to their right or left hand side of their mouth. They will receive benzocaine 20% topical anesthesia prior to the placement of elastomeric orthodontic separators.~The topical anesthesia will be applied according to standard clinical practice. Pain and discomfort levels associated with the placement of separators will be assessed immediately after the procedure."
89387601|NCT06272903|Placebo Comparator|Placebo (Children's Toothpaste) Arm|"The other side of the mouth will receive a placebo, which consists of children's toothpaste, prior to the placement of elastomeric orthodontic separators.~The toothpaste will be applied according to standard clinical practice. Pain and discomfort levels associated with the placement of separators will be assessed immediately after the procedure."
89387602|NCT06272890|Experimental|intervention group|The intervention group will receive online motivational interviewing (MI) consisting of five sessions. The sessions are planned to take place on the same day and time every week. Each session will last an average of 40 minutes. In the literature, PD sessions with groups of 5-8 people have been evaluated as adequate and effective. Before the MG, a WhatsApp group will be established to provide faster and easier communication to the intervention group and communication about the sessions will be handled in this group.
89387603|NCT06272890|No Intervention|control group|No treatment will be applied to the control group during the study period.
89387604|NCT06272877|Experimental|Experimental Group|Fluidotherapy will be applied to the group in addition to the conservative rehabilitation program received by the control group. Fluidotherapy will be applied 20 minutes a day, 5 days a week for 4 weeks.
89387605|NCT06272877|Active Comparator|Control group|Only the conventional rehabilitation program will be applied by a physiotherapist for 6 weeks.
89387606|NCT06272864||Cohort 1 (Breast cancer)|patients with locally recurrent, unresectable or metastatic breast cancer
89387607|NCT06272864||Cohort 2 (NSCLC)|patients with unresectable stage III or metastatic non-small cell lung cancer
89387608|NCT06272864||Cohort 3 (Melanoma)|patients with unresectable or metastatic melanoma
89387609|NCT06272864||Cohort 4 (Sarcoma)|patients with locally advanced or metastatic sarcoma
89387610|NCT06272851||diabetics|Type 2 DM patients aged 30 to 80 years
89387611|NCT06272851||non diabetics|non-diabetic healthy individuals
89387612|NCT06272838|Experimental|Experimental Group|In addition to conventional balance exercises, the exercise program, which includes games to improve balance, performed with the help of a Biodex balance device, will be given in a total of 20 sessions, 5 days a week, for 4 weeks..
89387613|NCT06272838|Active Comparator|Control Group|The conventional balance exercise program will be applied by a physiotherapist for 4 weeks, 5 days a week, in a total of 20 sessions.
89387614|NCT06272825|Experimental|Experimental Group|In addition to the conventional rehabilitation program at the hospital, virtual reality exercise will be applied in 15 sessions, 5 days a week.
89387615|NCT06272825|Active Comparator|Control group|The conventional rehabilitation program at the hospital will be implemented in 15 sessions, 5 days a week.
88863082|NCT06094621||Pre-operative Visit Arm|Eligible participants for the interview and surveys will be those who have undergone a virtual visit by the head and neck surgery nurse practitioners before their scheduled surgical procedure.
89387616|NCT06272812|Experimental|MTBVAC|MTBVAC
89387617|NCT06272812|Placebo Comparator|Placebo|Placebo
89185186|NCT00736593|Experimental|1|
88863083|NCT06094621||No Pre-operative Visit Arm|Patients who also underwent surgical resection for head and neck cancer with free flap reconstruction at the University of Michigan through the Department of Otolaryngology but did NOT receive a pre-operative virtual visit. This cohort is a retrospective chart review study
88863084|NCT06093958|Experimental|Chest wall loading|All patients who are receiving mechanical ventilation and are passive on the ventilator will have chest wall loading performed to identify whether there is a paradoxical decrease in lung compliance.
88863085|NCT06093672|Experimental|Givinostat|
88863086|NCT06093672|Active Comparator|Hydroxyurea|
88863087|NCT06093074|Experimental|intervention group|Feasibility trial study group.
88863088|NCT06087185|Experimental|Mindful Eating Group|Mindful Eating practices will be taught during a weekly meeting lasting 150 minutes and individuals will be encouraged to integrate the practices learned into their daily lives, for at least 15 minutes a day, being progressively integrated into the other practices that will be taught in subsequent weeks. There will be a WhatsApp group with reminders during the week and audio for guided practice.
88863089|NCT06087185|Active Comparator|Video Group|"Composed of 5 videos sent weekly produced by trained professionals. The topics discussed will be relevant to the management of anxiety in general and lifestyle changes.~Video 1: Psychoeducation of anxiety. Video 2: Healthy eating. Video 3: Sleep hygiene. Video 4: Physical activity. Video 5: Substance use. This protocol used as a control was effective as a Psychoeducation Group in improving anxiety symptoms in patients with generalized anxiety disorder."
88863090|NCT06085638|Experimental|Arm1: Cohort 1: Azacitidine + Tamibarotene|Participants will receive azacitidine on Days 1-7 of each cycle and tamibarotene 2 times a day every day. Up to 20 participants will be enrolled in Cohort 1.
88863091|NCT06085638|Experimental|Arm2: Cohort 2,3: Azacitidine + Tamibarotene + Venetoclax|"Participants will receive azacitidine on Days 1-7 of each cycle, tamibarotene 2 times a day every day, and venetoclax on either Days 1-7 or Days 1-14 of each cycle, depending on the dose level you are assigned at enrollment. Up to 12 participants will be enrolled in Cohort 2.~Once Cohort 2 is complete, Cohort 3 will begin. Participants in Cohort 3 will receive the recommended dosing schedule found in Cohort 2 (azacitidine on Days 1-7, tamibarotene 2 times a day every day, and venetoclax on either Days 1-7 or Days 1-14"
88863092|NCT06071494|Experimental|Tropical Fruits|patient will be consuming the chosen fruits, according to the size of the serving following Malaysian Dietary Guideline 2020
88863093|NCT06071494|No Intervention|Normal diet|patient will consume normal diet as usual
88863094|NCT06070337|Experimental|H-Guard|Participants receiving H-Guard Intervention.
88863095|NCT06068881|Experimental|Tazverik (Tazemetostat)|800mg tablet orally twice daily in continuous 28-day cycles
88863096|NCT06061822|Experimental|AI-planned images acquired|
88863097|NCT06061822|Active Comparator|Radiographer-planned images acquired|
88863098|NCT06059248|No Intervention|head sniffing position group|The sniffing position group used the conventional method of endotracheal intubation, the operation method was the same as that of the elevation position group, after the anterior part of the tracheal tube was inserted into the glottis, the head was still kept in the backward position, and the tube core was pulled out by another anesthesiologist (the core extubation force was less than 10N), and the endotracheal tube was inserted at the same time.
88863099|NCT06059248|Experimental|head elevation position group|"The operation methods of the research group are: left hand laryngoscope, inserted into the laryngeal cavity, fully exposed glottis, right hand tracheal tube from the right corner of the mouth into the mouth, direct vision to insert the anterior part of the endotracheal tube into the glottis, and then the assistant pulls out the tube core (the strength of the extubation core is less than 10N), so that the patient's jaw is adducted, the head remains in the elevation position, and the endotracheal tube is inserted at the same time"
88863100|NCT06058299|Experimental|TBAJ876 25 mg|TBAJ876 25 mg + pretomanid 200 mg + linezolid 600 mg for 8 weeks followed by HR for 7 to 18 weeks
88863101|NCT06058299|Experimental|TBAJ876 50 mg|TBAJ876 50 mg + pretomanid 200 mg + linezolid 600 mg for 8 weeks followed by HR for 7 to 18 weeks
88863102|NCT06058299|Experimental|TBAJ876 100 mg|TBAJ876 100 mg + pretomanid 200 mg + linezolid 600 mg for 8 weeks followed by HR for 7 to 18 weeks
88863103|NCT06058299|Active Comparator|BPaL|Bedaquiline 200 mg + pretomanid 200 mg + linezolid 600 mg for 8 weeks followed by bedaquiline 100 mg + pretomanid 200 mg + linezolid 600 mg for 18 weeks
88863104|NCT06058299|Active Comparator|2HRZE/4HR|Isoniazid (H) + rifampicin (R) + pyrazinamide (Z), ethambutol (E) for 8 weeks followed by HR for 18 weeks (dose based on participant's weight).
88863105|NCT06056479|Active Comparator|external oblique intercostal block after induction|"After induction of general anesthesia, external oblique intercostal blocks will be performed with patients positioned in the supine position with their ipsilateral arm abducted.~Initially the probe is placed in a cephalad to caudad paramedian direction at the anterior axillary line, and the external oblique muscle identified at the level ribs 6 and 7 in line with the xiphoid process. To confirm correct identification of the external oblique muscle, With 17gauge echogenic ultrasound needle will be advanced in plane from a superomedial-to-inferolateral direction, through the external oblique muscle.30 ml of bupivacaine 0.25% will be administered incrementally."
89387618|NCT06272799||Retrospective cohort|80 patients will form the retrospective cohort, considering consecutively all patients treated according to clinical practice outside of studies randomized
88863106|NCT06056479|No Intervention|postoperative morphine per patient request|In this group no block will be done only morphine will be given intraoperatively- according to hemodynamic change and postoperative by morphine per patient request
88863107|NCT06055244|Experimental|Amantadine|Subjects will be treated with amantadine.
88863108|NCT06055244|Placebo Comparator|Placebo|Subjected received placebo identical to amantadine in appearance.
88863109|NCT06054555|Experimental|ABP 206|Subjects will receive Dose A of ABP 206 via intravenous (IV) infusion.
88863110|NCT06054555|Active Comparator|Nivolumab|Subjects will receive Dose A of Nivolumab via IV infusion.
88863111|NCT06053801||Xolair|Chinese adolescents with Chronic Spontaneous Urticaria (CSU) inadequately controlled with H1 antihistamines
88863112|NCT06048757|Experimental|Experimental app intervention group|The intervention in the experimental group will center around the use of a mobile application (i.e., device), namely the Diactive-1 app.
89387619|NCT06272799||Prospectively cohort|Additional 80 patients who meet the inclusion criteria will be enrolled prospectively
88863113|NCT06048757|No Intervention|Waiting-list control group|This arm will not complete an intervention. Participants will be instructed to continue to follow their normal daily diabetes care plan (i.e., standard care). This group will be granted access to the app following the intervention.
89387620|NCT06272786|Experimental|Experimental Group|In addition to the conventional physiotherapy program, patients in the intervention group will receive a suprascapular nerve block with musculoskeletal USG guidance available in our clinic at the beginning of rehabilitation. Bupivacaine hydrochloride will be used in this injection. 5 ml of bupivacaine hydrochloride 5% and 5 ml of saline will be drawn into a 10 ml syringe and ejection will be performed from the superior of the suprascapular noch under USG guidance.
88863114|NCT06047626|Experimental|Fatigue Reduction Diet- FRD|3 months of individualized counseling of the FRD delivered by registered dietitians, over 8 sessions by phone/video conferencing on fatigue, quality of life, and associated symptoms in persistently fatigued lymphoma cancer survivors
88863115|NCT06047626|Active Comparator|General Health Curriculum- GHC|3 months of individualized counseling of the attention control (matched for time and frequency of interactions with the FRD) the General Health Curriculum (GHC)
88863116|NCT06038214||core exercises grup|"Core Exercise Group Exercises The exercise program was planned as warm-up, core exercises and cool-down periods, 2 days a week, 30 minutes a day and 8 weeks.~In the warm-up and cool-down program, each exercise was planned as 3 sets of 10 seconds.~The first 2 weeks of exercises were planned as 6 repetitions, the next 2 weeks the exercises 10 repetitions and the last 4 weeks the exercises were planned as 12 repetitions."
88863117|NCT06038214||home exercises grup|"At the beginning of the study, it is planned to give a home exercise program for 30 minutes, 2 days a week for 8 weeks, with information and teaching home exercises at the beginning of the study. The content of the home exercise program will be therapeutic exercises, stretching and relaxation exercises.~Evaluations will be evaluated for each group at the same time of the day before the exercise program starts and 1 day after the last session after completing 2 sessions a week for 8 weeks."
89387621|NCT06272786|Active Comparator|Control roup|Patients in the control group will only receive a conventional physiotherapy program.
89387622|NCT06272760|Experimental|Tele-HABIT|Children in the experimental group are going to receive intensive bimanual activity-based occupational therapy, known as Home-Based HABIT (H-HABIT). This therapy is going to be administered remotely. Each session will last for 2 hours and was conducted 5 times a week. The total duration of this intervention is 3 weeks.
88863118|NCT06036745|Experimental|Pembrolizumab + SOX|
88863119|NCT06031233|Experimental|Nivolumab|If no infusion reaction has occurred after 2 cyclues, infusion time will stepwise be shortened to 10 minutes in the following cycles.
88863120|NCT06031233|Experimental|Pembrolizumab|If no infusion reaction has occurred after 2 cyclues, infusion time will stepwise be shortened to 10 minutes in the following cycles.
88863121|NCT06031233|Experimental|ipilimumab|If no infusion reaction has occurred after 2 cyclues, infusion time will stepwise be shortened to 10 minutes in the following cycles.
88863122|NCT06031233|Experimental|Durvalumab|If no infusion reaction has occurred after 2 cyclues, infusion time will stepwise be shortened to 10 minutes in the following cycles.
88863123|NCT06031233|Experimental|Atezolizumab|If no infusion reaction has occurred after 2 cyclues, infusion time will stepwise be shortened to 10 minutes in the following cycles.
88863124|NCT06031233|Experimental|bevacizumab|If no infusion reaction has occurred after 2 cyclues, infusion time will stepwise be shortened to 10 minutes in the following cycles.
88863125|NCT06031233|Experimental|Trastuzumab|If no infusion reaction has occurred after 2 cyclues, infusion time will stepwise be shortened to 10 minutes in the following cycles.
89387623|NCT06272760|Active Comparator|In-laboratory-HABIT|Children in the control group are going to receive bimanual activity-based tasks. These tasks are of the same intensity and duration as those are going to be administered to the experimental group. However, unlike the experimental group, the treatment for the control group is going to be conducted in a hospital setting. The duration of this intervention is also 3 weeks, with sessions lasting 2 hours each and occurring 5 times a week.
89387624|NCT06272747|Experimental|Experimental: A (XH-S003)|Participants will receive XH-S003 once or twice daily on scheduled day(s)
88863128|NCT06022328||Patients with ET|"45 patients with ET:~15 without thrombotic event (neither at diagnosis nor during follow-up)~15 with thrombotic events (thrombosis at diagnosis or within 2 years of diagnosis)~15 who progressed to myelofibrosis or AML during follow-up"
89387625|NCT06272747|Placebo Comparator|Placebo Comparator: B (Placebo)|Participants will receive matching placebo once daily on scheduled day(s)
88863129|NCT06022328||Patients with PV|"45 patients with PV~15 without thrombotic event (neither at diagnosis nor during follow-up)~15 with thrombotic event (thrombosis at diagnosis or within 2 years of diagnosis)~15 who progressed to myelofibrosis or AML during follow-up"
88863130|NCT06022328||Patients with PMF|"20 patients with PMF:~10 without transformation into AML~10 patients who progressed to AML"
88863131|NCT06022328||Patients without MPN|10 patients without MPN
88863132|NCT06019559|Experimental|K-757+K-833|
88863133|NCT06019559|Experimental|K-757 alone|
88863134|NCT06019559|Experimental|Placebo to K-757 and K-833|
88863135|NCT06018623||grup 1.Optimum range|Group 1 BMI = 18.5-24.9,
88863136|NCT06018623||Group 2.Overweight|BMI = 25-29.9,
88863137|NCT06018623||Group 3.Class I obesity|BMI=30-34.9
88863138|NCT05996536||Non-lipodystrophic controls|Non-lipodystrophic controls
88863139|NCT05996536||Partial Lipodystrophy|Partial Lipodystrophy
88863140|NCT05996315||Adults >18 years with distal end radius fracture|Adults > 18 years with distal end radius fracture requiring closed reduction in Emergency Department
88863141|NCT05994794|Experimental|Alpha-GPC, Creatine and Ashwagandha (Sensoril®)|"Two servings (12 capsules) of study products will be taken twice per day with meals, one serving in the morning and one serving the afternoon/evening. One serving consists of 6 capsules. The time difference between the two servings must be at least 6 hours.~One serving:~One capsule of Alpha GPC supplement~Four capsules of Creatine monohydrate supplement~One capsule of Sensoril (ashwagandha) supplement"
88863142|NCT05994794|Placebo Comparator|Placebo|Participants will consume one serving (6 capsules), twice per day, with meals at least 6 hours apart.
88863143|NCT05988918|Experimental|Cohort 1|Pancreatic adenocarcinoma
88863144|NCT05988918|Experimental|Cohort 2|Pancreatic or gastrointestinal neuroendocrine neoplasms with Ki-67 > 20%
88863145|NCT05988918|Experimental|Cohort 3|Neuroendocrine prostate carcinoma with Ki-67 > 20%
88863146|NCT05981092||BAG3 DCM|A single arm observational trial where all participants will undergo the same schedule of assessments.
88863147|NCT05977946|Experimental|Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)|
89387626|NCT06272734|Experimental|Reprieve System|Subjects will receive personalized and optimized diuretic and saline infusion using the study device during the course of the treatment.
89387627|NCT06272721|Other|Group 1: Children of women with overt hypothyroidism during pregnancy|31 children undergoing neuropsychological testing for clinical practice, having their 31 mothers exhibited overt hypothyroidism during pregnancy.
89530193|NCT05584943||84 patients on ASA chronic treatment|A total of 84 patients on chronic treatment with low-dose ASA (enteric coated, Cardio aspirin 100 mg/die Bayer, Milan, Italy) once daily (o.d.) for at least 1 month
88863148|NCT05977946|Experimental|Transcutaneous Auricular Neurostimulation (tAN)|
88863149|NCT05973643|Other|Electroconvulsive therapy|simple-blind, any adult patient presenting a characterized depressive episode in the context of unipolar major depressive disorder or bipolar disorder who consents and requires an ECT treatment. study including 50 patients.
88863150|NCT05973630|Experimental|Cohort 1|ATA-200 Dose level 1: 1.0E+14 vg/Kg, solution for injection, single IV infusion over 2h
88863151|NCT05973630|Experimental|Cohort 2|ATA-200 Dose level 2: 3.0E+14 vg/Kg, solution for injection, single IV infusion over 2h
88863152|NCT05969665|Experimental|Wearing a smartwatch and glucose measuring device|The intervention will be wearing a smart watch as well as continuous glucose monitoring with direct feedback via an application. Participants will wear these devices for 3 months.
88863153|NCT05969665|No Intervention|Standard care|The control group will be given the standard recommendations that all patients completing cardiac rehabilitation receive.
88863154|NCT05968521|Experimental|Cardiac Rehabilitation (Intervention)|Participants allocated to the intervention group will receive a cardiac rehabilitation (CR) programme which will involve education, exercise, and a psychological component.
89185187|NCT02569359|Experimental|Shea nut oil|100% shea nut oil extract with 75% triterpene esters. Daily dosage is three 750 mg soft gel capsules (2250 mg/per day) taken in the morning for 3 months
89185188|NCT02569359|Placebo Comparator|Placebo|placebo which comprised 100% canola oil or starch mixed soybean oil
88863155|NCT05968521|Active Comparator|Treatment as usual (Control)|Participants allocated to the control group will receive treatment as usual.
89185189|NCT00736671||Observational Parkinson's Disease|Observational study of subjects with Parkinson disease
89387628|NCT06272721|Active Comparator|Group 2: Children of women without overt hypothyroidism during pregnancy|21 children undergoing neuropsychological testing outside of clinical practice, as their 21 mothers did not exhibit overt hypothyroidism during pregnancy.
89387629|NCT06272695|Experimental|35 mg Volagidemab|Volagidemab 35 mg will be administered by subcutaneous (SC) injection once weekly for 6 weeks.
89387630|NCT06272682|Experimental|Branch A: Local corticosteroid infiltration under ultrasound|One dose. 1 ml Betamethasone acetate 6mg/2ml + Betamethasone disodium phosphate 6mg/2ml
89387631|NCT06272682|Experimental|Branch B: treated with intramuscular corticosteroid injection|One dose. 2 ml Betamethasone acetate 6mg/2ml + Betamethasone disodium phosphate 6m/2ml.
89387632|NCT06272669|Experimental|Active-tDCS vs Sham-tDCS|"During the active- and sham-tDCS conditions, the participants will receive current with ramp up and ramp down mode for 10 seconds, eliciting a tingling sensation on the scalp that fades over seconds. Following that, the tasks will be initiated five minutes subsequent to the stimulation mode and terminated prior to its end for active-tDCS condition. Whereas, the sham condition with the same placement and intensity will only receive 30s initial stimulation and then discontinue. Throughout the active / sham-tDCS condition, participants are required to sit still and focus their attention on a + displayed on a computer monitor during the five-minute rest. After that, they will undergo active-tDCS (1mA, 20 min) to the left DLPFC or sham stimulation over 10 sessions in 2 weeks, while performing the executive function training tasks."
89387633|NCT06272669|Other|Crossover trial|Participants in the sham-tDCS group will receive 10-day active tDCS and assessments will be performed before and after the 10-tDCS session.
89387634|NCT06272669|Experimental|Booster effect|All tDCS responders (>10% reduction in SRS scores) will enrol on a 6 months follow-up phase in which they will be randomized to receive either bimonthly 20-minute booster tDCS sessions, or bimonthly 20-minute booster sham tDCS sessions for 3 months, followed by monthly 20-minute booster tDCS, monthly 20-minute booster sham tDCS, for another 3 months, with a maximum of 9 (sham) tDCS booster sessions.
89387635|NCT06272656||HCC Patients treated with TACE|HCC patients who have received initial diagnosis and treatment in our hospital and are planning to receive TACE.
89387636|NCT06272643||Patients with Left Main Coronary Artery lesion (25-60%)|
89387637|NCT06272617|Experimental|treatment group|verum acupuncture
89387638|NCT06272617|Sham Comparator|control group|sham acupuncture
89387639|NCT06272604|No Intervention|No Intervention Control Group|The control group will not receive any specific intervention, continuing with their usual asthma management routine.
89387640|NCT06272604|Experimental|Exercise Rehabilitation Group|The experimental group will participate in a 12-week exercise intervention program.
89387641|NCT06272591||Pregnant women with induction indication|Any pregnant woman, with a singleton pregnancy, giving birth at Saint-Etienne University Hospital, with an indication for induction of labour from 37SA will be included. The indications may be for a maternal pathology, a maternal wish or a foetal pathology.
88863156|NCT05963568|Experimental|Intervention|Patients allocated to the experimental arm will receive Two (2) (Polycap ®) taken orally once a day. A capsule of Polycap ® contains 100mg of Aspirin, 20mg of simvastatin, 12.5mg hydrochlorothiazide, 5mg of ramipril and 50mg of atenolol. Patients assigned to Polypill will have their antihypertensive agents, lipid modifiers and anti-thrombotic agents withdrawn & replaced with the Polypill if they are already receiving such treatments before enrollment.
88863157|NCT05963568|No Intervention|Control arm|Patients allocated to the usual care arm will receive standard of care therapies for secondary prevention with drugs and doses left at the discretion of the treating physicians. Since our focus is to isolate the effect of the polypill strategy itself & create equipoise, at study inception providers for patients in both study arms will receive a brief one-time (Skype-based) training & a one time email synopsis on guideline recommended biomarker targets after stroke.
88863158|NCT05963022|Experimental|Tirzepatide Dose 1|Participants will receive tirzepatide subcutaneously (SC).
89387642|NCT06272565||CON(Non diabetes control group)|Non diabetes patients undergoing phacoemulsification surgery
89387643|NCT06272565||NDR(Non diabetes retinopathy diabetes patients)|Non DR diabetes patients undergoing phacoemulsification surgery
89387644|NCT06272565||NPDR (non proliferative diabetes retinopathy)|DR patients with no sign of any neovascularization suggested by fluorescein sodium angiography and receiving intravitreal injection surgery
88863159|NCT05963022|Experimental|Tirzepatide Dose 2|Participants will receive tirzepatide SC.
88863160|NCT05963022|Experimental|Tirzepatide Dose 3|Participants will receive tirzepatide SC.
88863161|NCT05963022|Placebo Comparator|Placebo|Participants will receive placebo.
88863162|NCT05962229|Experimental|S-nicotine (tobacco) as the starting condition|Participants will spend 8 hours in the hospital research ward where they will vape e-liquid containing 100% (S)-nicotine.
88863163|NCT05962229|Experimental|R-nicotine (synthetic) as the starting condition|Participants will spend 8 hours in the hospital research ward where they will vape e-liquid containing 100% (R)-nicotine.
88863164|NCT05962229|Experimental|Racemic (50:50 S- and R- nicotine) as the starting condition|Participants will spend 8 hours in the hospital research ward where they will vape e-liquid containing 50% (S)-nicotine and 50% (R)-nicotine.
88863165|NCT05958264||Preschool children|10 preschool children with T1D aged 3-5,9 years.
88863166|NCT05958264||Children of younger school age|10 children of younger school age aged 6-10,9 years with T1D.
88863167|NCT05958264||Children in puberty|10 children in puberty aged 11-14,9 years with T1D
88863168|NCT05958264||Postpubertal adolescents|10 postpubertal adolescents aged 15-18,9 years with T1D
88863169|NCT05957406|Other|SMART TRENDS Arm|Acumen HPI Smart Alerts and Smart Trends Software Feature to guide hemodynamic management in moderate-to-high-risk noncardiac surgery.
89387645|NCT06272565||PDR (proliferative diabetes retinopathy)|DR patients with neovascularization suggested by fluorescein sodium angiography and receiving intravitreal injection surgery
89387646|NCT06272552|Experimental|PROMs and PREMs|
89387647|NCT06272552|Active Comparator|PREMs|
89387648|NCT06272552|Active Comparator|Control|
89387649|NCT06272552|Other|Healthcare professionals|
89387650|NCT06272539|Active Comparator|Spinal Cord Stimulation|Spinal cord stimulation (SCS) involves an implantable pulse generator with the potential for enhanced therapeutic success through stimulation algorithms and parameters (28). Spinal cord stimulation (SCS) targeting distal areas, such as the dorsal root ganglion, may offer greater anatomical specificity in therapy. Subthreshold stimulation, utilizing high-frequency or burst energy delivery, has the potential to eliminate noxious and off-target paresthesiae. Recent studies have demonstrated that subthreshold stimulation at high frequencies and/or utilizing different stimulation paradigms can provide equal or even superior pain relief compared to standard SCS (29). The procedure entails the placement of two octapolar electrodes inserted through the epidural space, positioned beneath the dorsal area posterior to the spinal cord's posterior horn.
89387651|NCT06272539|Experimental|Spinal Cord Stimulation+Exercise|The experimental group will perform a Lumbo-pelvic core stability training program combined with motor control exercises through specific therapeutic exercises of the lumbopelvic centre combined with neurostimulation treatment. The exercise will be adapted according to the phases based on the results already published, the following intervention plan has been designed. Additionally, in each of the phases, the exercises were designed, limiting the degree of flexion/extension and lumbar traction of the exercises. Two weekly sessions will be scheduled during 8 weeks with a total of 24 sessions, each one of 60 minutes of duration. A certified physiotherapist in exercised with at least 10 years of clinical practice has applied treatment.
89387652|NCT06272526|Experimental|Guided Web-Based Intervention|Participants in this group will use the web-based intervention (https://kendikendineyardim.org) with guidance support.
89387653|NCT06272526|No Intervention|Waitlist|The waiting list control group participants will be controlled for time and assessed during the first 7-week period. Participants will have no contact with the study team during the waiting period. Immediately after the waiting period, they will receive the internet-based intervention with the experimental group.
89387654|NCT06272500|Placebo Comparator|Group A|receives only oral administration of a compound digestive enzyme capsule, with one capsule taken three times a day.
89387655|NCT06272500|Experimental|Group B|receives only oral administration of apple cider vinegar, with 15ml of apple cider vinegar with an acidity of ≥3.5g/100ml consumed after each meal.
88863170|NCT05955586|Experimental|SPR720|Healthy participants will receive SPR720 1000 mg capsule, orally, for 7 days.
89387656|NCT06272500|Experimental|Group C|receives oral administration of both the compound digestive enzyme capsule and apple cider vinegar simultaneously.
89387657|NCT06272474|Active Comparator|Buccal interocclusal records|
88863171|NCT05950334|Experimental|Regimen A|Participants receive FT522 in combination with rituximab (or a rituximab biosimilar approved by a local health authority) with chemotherapy.
88863172|NCT05950334|Experimental|Regimen B|Participants receive FT522 in combination with rituximab (or a rituximab biosimilar approved by a local health authority) without chemotherapy.
88863173|NCT05948267|Active Comparator|Propofol (P) group|Propofol(2mg/kg) prepared as will be mixed with 2 mL Lidocaine (40 mg) for concentration 10mg/ml and fentanyl (1mic/kg) prepared for concentration 10mg/ml in 2 separate syringes.
88863174|NCT05948267|Active Comparator|Ketamine-Dexmedetomidine (KD5) group|ketamine (1mg/kg) prepared for concentration 10mg/ml, Dexmedetomidine (0.5microg/kg slow IV) prepared for concentration of 5mic /ml in 2 separate syringes.
89387658|NCT06272474|Experimental|Lateral interocclusal records|
89387659|NCT06272448|Experimental|Intervention|Telerehabilitation for 3 months
89387660|NCT06272435|Experimental|Water, Multiplier, Sugar with Amino Acids, and Sugar Free|Subjects will follow control diet for 24 hours prior to visit. At the study visit, baseline measures will be collected prior to treatment. Subjects will then consume the assigned treatment (one treatment per visit in order above) and additional experimental measurements will be collected.
88863175|NCT05948267|Active Comparator|Ketamine-Dexmedetomidine (KD3) group|ketamine (1mg/kg) prepared concentration 10mg/ml, Dexmedetomidine (0.3microg/kg slow IV) prepared for concentration of 3mic /ml in 2 separate syringes.
88863176|NCT05945849|Experimental|CD33KO-HSPC followed by CART33|All subjects will receive CD33KO-HSPC, followed by 1-3 CART-33 infusions
89185190|NCT00736671||Observational Normal Control aubjects|Observational study of normal control subjects
89387661|NCT06272435|Experimental|Water, Multiplier, Sugar Free, and Sugar with Amino Acids|Subjects will follow control diet for 24 hours prior to visit. At the study visit, baseline measures will be collected prior to treatment. Subjects will then consume the assigned treatment (one treatment per visit in order above) and additional experimental measurements will be collected.
89530194|NCT05584943||Healthy subject|9 healthy subjects, not on ASA treatment, as controls.
89185191|NCT00731523|Experimental|1|
89387662|NCT06272435|Experimental|Water, Sugar with Amino Acids, Multiplier, and Sugar Free|Subjects will follow control diet for 24 hours prior to visit. At the study visit, baseline measures will be collected prior to treatment. Subjects will then consume the assigned treatment (one treatment per visit in order above) and additional experimental measurements will be collected.
89387663|NCT06272435|Experimental|Water, Sugar with Amino Acids, Sugar Free, and Multiplier|Subjects will follow control diet for 24 hours prior to visit. At the study visit, baseline measures will be collected prior to treatment. Subjects will then consume the assigned treatment (one treatment per visit in order above) and additional experimental measurements will be collected.
89387664|NCT06272435|Experimental|Water, Sugar Free, Multiplier, and Sugar with Amino Acids|Subjects will follow control diet for 24 hours prior to visit. At the study visit, baseline measures will be collected prior to treatment. Subjects will then consume the assigned treatment (one treatment per visit in order above) and additional experimental measurements will be collected.
89387665|NCT06272435|Experimental|Water, Sugar Free, Sugar with Amino Acids, and Multiplier|Subjects will follow control diet for 24 hours prior to visit. At the study visit, baseline measures will be collected prior to treatment. Subjects will then consume the assigned treatment (one treatment per visit in order above) and additional experimental measurements will be collected.
89387666|NCT06272435|Experimental|Multiplier, Water, Sugar with Amino Acids, and Sugar Free|Subjects will follow control diet for 24 hours prior to visit. At the study visit, baseline measures will be collected prior to treatment. Subjects will then consume the assigned treatment (one treatment per visit in order above) and additional experimental measurements will be collected.
89387667|NCT06272435|Experimental|Multiplier, Water, Sugar Free, and Sugar with Amino Acids|Subjects will follow control diet for 24 hours prior to visit. At the study visit, baseline measures will be collected prior to treatment. Subjects will then consume the assigned treatment (one treatment per visit in order above) and additional experimental measurements will be collected.
89387668|NCT06272435|Experimental|Multiplier, Sugar with Amino Acids, Water, and Sugar Free|Subjects will follow control diet for 24 hours prior to visit. At the study visit, baseline measures will be collected prior to treatment. Subjects will then consume the assigned treatment (one treatment per visit in order above) and additional experimental measurements will be collected.
89387669|NCT06272435|Experimental|Multiplier, Sugar with Amino Acids, Sugar Free, and Water|Subjects will follow control diet for 24 hours prior to visit. At the study visit, baseline measures will be collected prior to treatment. Subjects will then consume the assigned treatment (one treatment per visit in order above) and additional experimental measurements will be collected.
89387670|NCT06272435|Experimental|Multiplier, Sugar Free, Water, and Sugar with Amino Acids|Subjects will follow control diet for 24 hours prior to visit. At the study visit, baseline measures will be collected prior to treatment. Subjects will then consume the assigned treatment (one treatment per visit in order above) and additional experimental measurements will be collected.
89387671|NCT06272435|Experimental|Multiplier, Sugar Free, Sugar with Amino Acids, and Water|Subjects will follow control diet for 24 hours prior to visit. At the study visit, baseline measures will be collected prior to treatment. Subjects will then consume the assigned treatment (one treatment per visit in order above) and additional experimental measurements will be collected.
89387672|NCT06272435|Experimental|Sugar with Amino Acids, Water, Multiplier, and Sugar Free|Subjects will follow control diet for 24 hours prior to visit. At the study visit, baseline measures will be collected prior to treatment. Subjects will then consume the assigned treatment (one treatment per visit in order above) and additional experimental measurements will be collected.
89387673|NCT06272435|Experimental|Sugar with Amino Acids, Water, Sugar Free, and Multiplier|Subjects will follow control diet for 24 hours prior to visit. At the study visit, baseline measures will be collected prior to treatment. Subjects will then consume the assigned treatment (one treatment per visit in order above) and additional experimental measurements will be collected.
89387674|NCT06272435|Experimental|Sugar with Amino Acids, Multiplier, Water, and Sugar Free|Subjects will follow control diet for 24 hours prior to visit. At the study visit, baseline measures will be collected prior to treatment. Subjects will then consume the assigned treatment (one treatment per visit in order above) and additional experimental measurements will be collected.
89387675|NCT06272435|Experimental|Sugar with Amino Acids, Multiplier, Sugar Free, and Water|Subjects will follow control diet for 24 hours prior to visit. At the study visit, baseline measures will be collected prior to treatment. Subjects will then consume the assigned treatment (one treatment per visit in order above) and additional experimental measurements will be collected.
89387676|NCT06272435|Experimental|Sugar with Amino Acids, Sugar Free, Water, and Multiplier|Subjects will follow control diet for 24 hours prior to visit. At the study visit, baseline measures will be collected prior to treatment. Subjects will then consume the assigned treatment (one treatment per visit in order above) and additional experimental measurements will be collected.
89387677|NCT06272435|Experimental|Sugar with Amino Acids, Sugar Free, Multiplier, and Water|Subjects will follow control diet for 24 hours prior to visit. At the study visit, baseline measures will be collected prior to treatment. Subjects will then consume the assigned treatment (one treatment per visit in order above) and additional experimental measurements will be collected.
89387678|NCT06272435|Experimental|Sugar Free, Water, Multiplier, and Sugar with Amino Acids|Subjects will follow control diet for 24 hours prior to visit. At the study visit, baseline measures will be collected prior to treatment. Subjects will then consume the assigned treatment (one treatment per visit in order above) and additional experimental measurements will be collected.
89387679|NCT06272435|Experimental|Sugar Free, Water, Sugar with Amino Acids, and Multiplier|Subjects will follow control diet for 24 hours prior to visit. At the study visit, baseline measures will be collected prior to treatment. Subjects will then consume the assigned treatment (one treatment per visit in order above) and additional experimental measurements will be collected.
89185192|NCT02569125|Experimental|Everolimus (RAD001) 4.5 mg/m² daily over|Everolimus (RAD001) 4.5 mg/m² daily over 12 months. Patients will be on Everolimus (RAD001) therapy for 12 months; discontinuation can be necessary due to intolerable toxicity, withdrawal of consent, death or termination of the trial. After 12 months treatment is stopped. If there is progress of disease (see below) after end of therapy, re-start with Everolimus (RAD001) on a compassionate use is possible.
88863177|NCT05945732||Trastuzumab deruxtecan (T-DXd)|Participants with HER2-low expressing unresectable and/or metastatic breast cancer who will be treated with trastuzumab deruxtecan and part of the enrolled participants will receive conventional chemotherapy. The participants on conventional chemotherapy will be analyzed exploratory only.
88863178|NCT05942651|Active Comparator|active ccPAS4-ms|"Device: Magstim BiStim 2002 (The Magstim Company Ltd., Spring Gardens, Whitland, UK) and two small coils (40mm, figure-of-eight coils, Alpha B.I).~Coil 1 was positioned over right IFC at a 20° angle to the coronal plane with the handle pointing anteriorly, and coil 2 was positioned over right pre- SMA perpendicular to the midline.~The first stimulation will be applied to the IFC and the second to the pre-SMA, with an interstimulation interval set at 4 ms. A total of 180 stimulation pairs will be delivered every 2 s. (5Hz) for a total duration of 15 minutes at an intensity of 120% of rMT"
88863179|NCT05942651|Sham Comparator|Control condition ccPAS100-ms.|"Device: Magstim BiStim 2002 (The Magstim Company Ltd., Spring Gardens, Whitland, UK) and two small coils (40mm, figure-of-eight coils, Alpha B.I).~Coil 1 was positioned over right IFC at a 20° angle to the coronal plane with the handle pointing anteriorly, and coil 2 was positioned over right pre- SMA perpendicular to the midline.~The first stimulation will be applied to the IFC and the second to the pre-SMA, with an interstimulation interval set at 100 ms. A total of 180 stimulation pairs will be delivered every 2 s. (5Hz) for a total duration of 15 minutes at an intensity of 120% of rMT"
88863180|NCT05937750|Experimental|Imlifidase|Imlifidase administered in the 20-HMedIdeS-19 (PAES) study
88863181|NCT05937750|Experimental|Non-Comparative Concurrent Reference Cohort|Best available treatment administered in the 20-HMedIdeS-19 (PAES) study
88863182|NCT05936307|Active Comparator|15 healthy participants active then placebo|15 healthy participants will receive a session of active HD-tDCS and then a session of placebo HD-tDCS.
88863183|NCT05936307|Placebo Comparator|15 healthy participants placebo then active|15 healthy participants will receive a session of placebo HD-tDCS and then a session of active HD-tDCS.
88863184|NCT05935150|Experimental|OMSLNB|
88863185|NCT05933785||transanal endoscopic ISR|
88863186|NCT05933785||traditional ISR|
88863187|NCT05933525|Active Comparator|Travelan|IMM-124E (Travelan) is the investigational product. Travelan 1200mg will be taken orally for 7 days.
88863188|NCT05933525|Placebo Comparator|Placebo|ProMilk 85 milk powder is the placebo. Placebo has been manufactured into tablets using the same manufacturing process as Travelan. 1200mg will be taken orally for 7 days.
88863189|NCT05931718||Autoimmune hemolytic anemia|AIHA patients will be enrolled at diagnosis and stratified according to AIHA type (i.e. warm, cold, mixed, and atypical forms), sampled for peripheral blood for cytokine and NGS studies, and for feces for microbiome studies. If clinically indicated, bone marrow evaluation will be performed and a sample for single cell analysis will be collected. Patients will be followed up to collect treatments, responses, relapses, and complications (particularly thromboses and infections).
88863190|NCT05931718||Immune thrombocytopenia|ITP patients will be enrolled at diagnosis and sampled for peripheral blood for cytokine and NGS studies, and for feces for microbiome studies. If clinically indicated, bone marrow evaluation will be performed and a sample for single cell analysis will be collected.Patients will be followed up to collect treatments, responses, relapses, and complications (particularly thromboses and infections).
88863191|NCT05931718||Chronic idiopathic neutropenia/Autoimmune neutropenia|CIN/AIN patients will be enrolled at diagnosis and sampled for peripheral blood for cytokine and NGS studies, and for feces for microbiome studies. If clinically indicated, bone marrow evaluation will be performed and a sample for single cell analysis will be collected.Patients will be followed up to collect treatments, responses, relapses, and complications (particularly infections).
88863192|NCT05931718||Myelodysplastic syndromes|MDS patients will be enrolled at diagnosis and sampled for peripheral blood for cytokine and NGS studies, and to evaluate red cell metabolism. If clinically indicated, bone marrow evaluation will be performed and a sample for single cell analysis will be collected. Patients will be followed up to collect treatments, responses, relapses, and outcome.
88863193|NCT05930951|Active Comparator|OBT076 only|OBT076, administration at 3mg/kg, (IV ≥ 3h infusion) on Day 1 every 21 days (3-week cycle) until disease progression, unacceptable toxicity, intercurrent conditions that preclude continuation of treatment or patient refusal whichever comes first.
88863194|NCT05930951|Experimental|OBT076 -Balstilimab|3 cycles of OBT076, administration at 3mg/kg, IV (≥ 3h infusion) on Day 1 every 21 days (3-week cycle) followed by Balstilimab, administration at 450mg, IV, on Day 1 every 21 days (3-week cycle) until disease progression, unacceptable toxicity, intercurrent conditions that preclude continuation of treatment or patient refusal whichever comes first.
89185193|NCT00731601|Experimental|1|pantoprazole 40mg/q6h IV infusion for three days
89387680|NCT06272435|Experimental|Sugar Free, Multiplier, Water, and Sugar with Amino Acids|Subjects will follow control diet for 24 hours prior to visit. At the study visit, baseline measures will be collected prior to treatment. Subjects will then consume the assigned treatment (one treatment per visit in order above) and additional experimental measurements will be collected.
89387681|NCT06272435|Experimental|Sugar Free, Multiplier, Sugar with Amino Acids, and Water|Subjects will follow control diet for 24 hours prior to visit. At the study visit, baseline measures will be collected prior to treatment. Subjects will then consume the assigned treatment (one treatment per visit in order above) and additional experimental measurements will be collected.
89387682|NCT06272435|Experimental|Sugar Free, Sugar with Amino Acids, Water, and Multiplier|Subjects will follow control diet for 24 hours prior to visit. At the study visit, baseline measures will be collected prior to treatment. Subjects will then consume the assigned treatment (one treatment per visit in order above) and additional experimental measurements will be collected.
89387683|NCT06272435|Experimental|Sugar Free, Sugar with Amino Acids, Multiplier, and Water|Subjects will follow control diet for 24 hours prior to visit. At the study visit, baseline measures will be collected prior to treatment. Subjects will then consume the assigned treatment (one treatment per visit in order above) and additional experimental measurements will be collected.
89387684|NCT06272422||total hip arthroplasty (THA)|Standard THA, the head and neck of the femur are cut.
89387685|NCT06272422||Total hip prosthesis with femoral neck preservation|A total hip replacement is performed, but the neck of the femur is preserved and the head of the femur is cut off.
89387686|NCT06272422||Hip resurfacing|the head and neck of the femur are preserved.
89387687|NCT06272409|Experimental|DEP114|DEP114 administered once (01) time a day, by morning, for 5 (+2) days.
89387688|NCT06272409|Active Comparator|DESLORATADINE|Desloratadine administered once (01) time a day, by morning, for 5 (+2) days.
89387689|NCT06272396|Experimental|Smart watch|ECG done with smart watch
89387690|NCT06272383|Experimental|0.15mg/kg dexamethasone|Treatment with one dose of oral dexamethasone (0.15 mg/kg per dose; maximum single dose 3 mg)
89387691|NCT06272383|Active Comparator|Standard practice of 0.6mg/kg dexamethasone|Treatment with one dose of oral dexamethasone (0.6 mg/kg per dose; maximum single dose 12 mg)
89387692|NCT06272370|Other|Enhanced Usual Care|"Participants will be asked to use an online Asthma Symptom Monitoring tool to enhance communication with the medical team as well as self-awareness of their asthma symptoms. There are no study drugs in this arm. All 4 arms of the study will use these tools"
89387693|NCT06272370|Active Comparator|Rescue Inhaled Corticosteroids|Participants in this arm will either have budesonide/formoterol (Symbicort) or mometasone/formoterol (Dulera), or a stand-alone ICS (beclomethasone/QVAR, or budesonide/Pulmicort, or fluticasone Flovent HFA, Flovent Diskus, ArmonAir RespiClick, Arnuity Ellipta, or mometasone, Asmanex HFA, Asmanex Twisthaler or ciclesodine Alvesco HFA) added to the participants usual treatment or a combination inhaler of corticosteroid and albuterol (AirSupra) that was recently approved
89387694|NCT06272370|Active Comparator|Azithromycin|Participants will use azithromycin (Zithromax) 500mg three times a week (10mg.kg for participants under 50Kg) which can be dropped to 250 mg three times a week for dose related side effects
89387695|NCT06272370|Active Comparator|Rescue Inhaled Corticosteroids and azithromycin|This arm includes both the inhaled corticosteroid comparator and the azithromycin comparator as described in those two arms Participants in this arm will either have budesonide/formoterol (Symbicort) or mometasone/formoterol (Dulera), or a stand-alone ICS (beclomethasone/QVAR, or budesonide/Pulmicort, or fluticasone Flovent HFA, Flovent Diskus, ArmonAir RespiClick, Arnuity Ellipta, or mometasone, Asmanex HFA, Asmanex Twisthaler or ciclesodine Alvesco HFA) added to the participants usual treatment or a combination inhaler of corticosteroid and albuterol (AirSupra) that was recently approved AND Participants will use azithromycin (Zithromax) 500mg three times a week (10mg.kg for participants under 50Kg) which can be dropped to 250 mg three times a week for dose related side effects
89387696|NCT06272344|Experimental|Teleconsultation|Teleconsultation at 6 months
89387697|NCT06272331|Other|Low-protein plant-based drink|Ingestion of a low-protein plant-based drink.
88863195|NCT05930938|Placebo Comparator|Placebo-RT-cetuximab|3 cycles of placebo (matching oral solution from Day 1 to 14, per 3-week cycle) + IMRT (69.96 Gy in 33 fractions, 2.12 Gy/fraction) + cetuximab (loading dose of 400 mg/m² IV on Day -7, followed by weekly dose of 250 mg/m² IV until the end of the RT), followed
88863196|NCT05930938|Experimental|Xevinapant-RT-cetuximab|3 cycles of xevinapant (oral solution 200 mg/day from Day 1 to 14, per 3-week cycle) + IMRT (69.96 Gy in 33 fractions, 2.12 Gy/fraction) + cetuximab (loading dose of 400 mg/m² IV on Day -7, followed by weekly dose of 250 mg/m² IV until the end of the RT), followed by 3 cycles of monotherapy of xevinapant (200 mg/day from Day 1 to 14, per 3-week cycle)
88863197|NCT05926661|Other|Parent/Caregiver of high-risk children with heart disease|"The parent/caregivers of high-risk children with heart disease coming to the Nemours Cardiac Center for care will be offered a support tool and will be asked for it's acceptance and feasibility through their experience."
88863198|NCT05922904|Experimental|Part A: Pembrolizumab and Brentuximab +AD|
88863199|NCT05922904|Experimental|Part B: De-Escalation|
88863200|NCT05922904|Experimental|Part C: Standard Risk Arm|
89387698|NCT06272331|Other|High-protein plant-based drink|Ingestion of a high-protein plant-based drink
89387699|NCT06272331|Other|Cow's milk|Ingestion of cow's milk.
89387700|NCT06272292|Experimental|Symptomatic CAM-FAI patients|33 patients that exhibit symptomatic CAM-FAI on medical imaging (Alpha angle >60) and have reduced hip internal rotation (IR<15). All participants in this group will be males aged between 21 and 35 years old.
89387701|NCT06272292|Experimental|Asymptomatic CAM-FAI patients|33 healthy control that exhibit asymptomatic CAM on x-ray scans (Alpha angle >60). All participants in this group will be males aged between 21 and 35 years old.
89387702|NCT06272292|Experimental|Healthy controls|33 healthy control that exhibit no symptoms or abnormal morphologies of the proximal femur (Alpha angle >60 , IR>15). All participants in this group will be males aged between 21 and 35 years old.
89387703|NCT06272279|Experimental|Spinal cord stimulation|Spinal cord stimulation will be administered to participants for 15 min.
89387704|NCT06272279|Sham Comparator|Shamspinal cord stimulation|Sham spinal cord stimulation will be administered to participants for 15 min.
89387705|NCT06272266|Active Comparator|COVID-19 group|This group included 32 people aged 18-55 who had previously had COVID-19. Individuals' physical activity levels were measured with the IPAQ short form. Peripheral muscle strength (quadriceps muscle strength, triceps strength, hand grip strength) was measured. The exercise capacities of the individuals were evaluated with a standard exercise tolerance test using a bicycle ergometer. At the end of the test, Borg Scale, test duration, maximum heart rate, maximum work (W) and MET values were recorded. VO2peak levels and VO2peak prediction values were calculated. CPET was applied to 14 people in this group. At the end of the test, the individual's Respiratory Exchange Rate, Anaerobic Threshold, VO2peak, VO2AT (Maximum Oxygen Capacity at Respiratory Anaerobic Threshold), Carbon Dioxide Ventilation Equivalent, heart rate recovery, heart rate recovery in the 1st minute were measured. Aerobic exercise training was given to 14 people in this group. measurements were repeated.
89387706|NCT06272266|Active Comparator|control group|This group included 32 people aged 18-55 who had not previously had COVID-19. The physical activity levels of the individuals were measured with the IPAQ short form. Peripheral muscle strength (quadriceps muscle strength, triceps strength, hand grip strength) was measured. The exercise capacities of the individuals were evaluated with a standard exercise tolerance test using a bicycle ergometer. At the end of the test, Borg Scale, test duration, maximum heart rate, maximum work (W) and MET values were recorded. VO2peak levels and VO2peak prediction values were calculated. CPET was applied to 15 people in this group. At the end of the test, the individual's Respiratory Change Rate, Anaerobic Threshold, VO2peak, VO2AT (Maximum Oxygen Capacity at Respiratory Anaerobic Threshold), Carbon Dioxide Ventilation Equivalent, heart rate recovery, Heart rate recovery at 1 minute was measured.
89387707|NCT06272253|Experimental|INAVAC (Vaksin Merah Putih - UA-SARS CoV-2 (Vero Cell Inactivated) 5 μg|Study product are provided in the form of liquid in vial single dose (0.5 ml). The vaccine will be given 1 dose (0.5 ml) once.
89387708|NCT06272227|Experimental|alfacalcidol|alfacalcidol plus denosumab
89387709|NCT06272227|Placebo Comparator|placebo|placebo + denosumab
89387710|NCT06272214|Experimental|Adjuvant radiotherapy|Following surgery, patients start adjuvant radiotherapy 4-6 weeks after the operation, with a radiation dose of 45Gy/25F/5W, completed no later than 8 weeks post-surgery. Two weeks after completing radiotherapy, patients continue with immunotherapy maintenance therapy for up to 1 year (17 cycles Q3W) or until tumor progression.
89387711|NCT06272214|Active Comparator|Observation|Patients receive surgery after neoadjuvant chemotherapy combined with immunotherapy for esophageal cancer, followed by active survillance and maintenance therapy with PD1/PDL1 inhibitors for up to 1 year (17 cycles Q3W) or until tumor progression.
89387712|NCT06272201|Experimental|Treatment|POSE2.0 Treatment with Lifestyle Modification
89387713|NCT06272201|No Intervention|Control|Lifestyle Modification alone
88863201|NCT05916170|Experimental|Intervention - Health Warnings|Half of the cafés in the intervention arm will be randomly assigned to display a text-only warning and the other half with display a pictorial warning (text + image).
89387714|NCT06272188|Experimental|Experimantal group|Couples applying to municipal marriage offices will be invited to participate in a study after obtaining permission. Those agreeing will be briefed by researchers about the study's purpose and methods, signing the IVCF afterward. Using a random number table, couples will be grouped as experimental or control. A month post-wedding, couples receive a call to confirm an online interview appointment. On the set date, a Zoom link for the interview will be shared. During this session, couples complete forms like IIF, PRRA, PCHLS, and PPHBS, followed by online preconception counseling lasting approximately an hour. This counseling, based on relevant literature and standardized by the research team, addresses risks identified during the Preconceptional Period Risk Assessment Form. After three months, couples revisit the PCHLS and PPHBS assessments.
89387715|NCT06272188|No Intervention|Control group|No application will be made to the control group. Note: To act ethically, online preconception care counselling will be given to the participants in the control group after the data are obtained from the experimental and control groups. In addition, the website sagliklibaslangiclar.com will be introduced and it will be explained that they will be able to log in to the website with the username and password they will be given.
89387716|NCT06272162|Experimental|Intervention arm|Patients in the intervention arm will receive locally ablative stereotactic MRgRT in addition to standard of care, consisting of 5 times 10 Gy MR guided radiotherapy.
89387717|NCT06272162|No Intervention|Control arm|Patients randomized to the control arm will continue standard of care as described without additional local treatment.
89387718|NCT06272149|Experimental|type II Gaucher disease|This is a single-center, open, dose-climbing investigator-sponsored exploratory clinical study that included a dose-climbing phase and a dose-expanding phase. The sponsor plans to explore two dose levels in dose-climbing phase (one subject each cohort), then have additional 2~4 subjects in dose-expanding phase
89387719|NCT06272136|Experimental|Interventional arm|Induction of hyperglycaemia states via meal intake and measurements of transcutaneous spectral data with the investigational device and reference blood glucose values measured by Super GL and Freestyle Libre 3.
89387720|NCT06272123||Chronic Sinusitis|
89387721|NCT06272123||Controls|
89387722|NCT06272110||Post-visit survey of Patients/Caregivers (pre-implementation)|
89387723|NCT06272110||H+H EHR reports of Patients (pre-implementation)|
89387724|NCT06272110||Community survey of Community members (pre-implementation)|
88863202|NCT05916170|Experimental|Control - No Warnings|No warnings posted in the hookah café
88863203|NCT05909566|Experimental|HHFNC + Clinical decision Support|Standardized HHFNC weaning coupled with clinical decision support consisting of electronic record embedded reminders to the clinical team to wean HHFNC
89185194|NCT00731601|Active Comparator|2|pantoprazole 8mg/h for three days
89387725|NCT06272110||Key stakeholder interviews of Patients/Caregivers/Community Members (pre-implementation)|
89387726|NCT06272110||Key stakeholder interviews of NYC H+H Leadership/Providers/Staff (pre-implementation)|
89387727|NCT06272110||Key stakeholder interviews of CBO Leadership/Staff (pre-implementation)|
89387728|NCT06272110||Post-visit survey of Patients/Caregivers (post-implementation)|
89387729|NCT06272110||H+H EHR reports of Patients (post-implementation)|
88863204|NCT05909566|Active Comparator|HHFNC Weaning|Team does not receive clinical decision support reminders to wean the HHFNC
89387730|NCT06272110||Community survey of Community members (post-implementation)|
89387731|NCT06272110||Key stakeholder interviews of Patients/Caregivers/Community Members (post-implementation)|
89387732|NCT06272110||Key stakeholder interviews of NYC H+H Leadership/Providers/Staff (post-implementation)|
89387733|NCT06272110||Key stakeholder interviews of CBO Leadership/Staff (post-implementation)|
89387734|NCT06272097|Experimental|Intervention group|The intervention group will receive an intervention plan based on the TIME CDST tool led by wound specialist nurses at each dressing change.
89387735|NCT06272097|Other|Control group|The control group receives a routine wound care program of wound cleaning and dressing changes at each dressing change.
89387736|NCT06272084||TPE Treatments|Patients with indication for TPE treatment according to American Society for Apheresis (ASFA) guideline
89387737|NCT06272032|Active Comparator|High-intensity focused ultrasound (HIFU)|"The High-Intensity Focused Ultrasound (HIFU) knife, also known as the High-Intensity Focused Ultrasound Tumor Treatment System or HIFU ablation therapy, abbreviated as the HIFU knife, is a non-invasive and non-intrusive tumor treatment method utilizing high-intensity focused ultrasound technology. This technology was successfully developed by the Ultrasound Medical Engineering Research Institute of Chongqing Medical University in 1997."
89387738|NCT06272032|Placebo Comparator|Placebo|For patients in the Placebo treatment group, treatment is provided based on the severity of their symptoms, following the protocols outlined in the Allergic Rhinitis (AR) diagnosis and treatment guidelines. Patients are administered intranasal corticosteroids, oral antihistamines, oral leukotriene receptor antagonists, and intranasal antihistamines, as appropriate, in accordance with the severity of their symptoms.
88863205|NCT05901792|Experimental|Virtual Reality Games|VRGs group will receive games that focus on changing the position of the body center of gravity and improving balance levels.
88863206|NCT05901792|Other|Control group|As the control group, the cases on the waiting list will be evaluated.
88863207|NCT05901519|Experimental|Patients treated with Prednisone|Prednisone will be administered for three days before starting RT, and during the first three fractions of RT. Following an interim analysis of the decrease in sTNFR1 level, a decision will be made whether to administer prednisone for seven days prior to RT, and to continue for additional seven days during RT.
89387739|NCT06272019|Experimental|Gargle method|the participant will use 0.2% iodine gargle with gargle method by hold in mouth 30 second and gargle 30 seconds after that spit out
89387740|NCT06272019|Experimental|Swab method|the participant will use 0.2 iodine gargle with swab method by the researcher apply on mouth 1 minute without spit out
89387741|NCT06272006|Experimental|Coronally Positioned Flap (CPF) with Connective Tissue Graft (CTG)|Participants in this arm will receive a Coronally Positioned Flap (CPF) surgery combined with a Connective Tissue Graft (CTG). The CPF technique involves surgically repositioning the gum tissue to cover exposed root surfaces, while the CTG procedure involves transplanting connective tissue to the area of gingival recession to encourage regeneration and coverage of exposed roots. This arm aims to evaluate the effectiveness of CPF with CTG in improving gingival recession and periodontal health.
89387742|NCT06272006|Experimental|Modified Coronally Advanced Tunnel (MCAT) with Connective Tissue Graft (CTG)|This arm involves participants receiving the Modified Coronally Advanced Tunnel (MCAT) procedure along with a Connective Tissue Graft (CTG). The MCAT technique is a less invasive approach that creates a tunnel under the gum through which the connective tissue graft is placed without making significant incisions. This method aims to treat gingival recession by encouraging gum regeneration over the exposed roots, with the goal of improving periodontal outcomes and reducing recession.
89387743|NCT06271941|Experimental|EMR + h-APC + complete defect closure|Standard endoscopic mucosal resection (EMR) technique will be used for the primary removal of all polyps, utilizing submucosal injection. Electrocautery snare technique will be facilitated using standard microprocessor-controlled electrocautery (e.g., ERBE VIO Endocut 3-1-6). Ablation of the margin and base of the polypectomy site will be performed using h-APC (Erbe Hybrid APC). Once resection and thermal ablation are considered complete, the mucosal defect will be completely closed.
89387744|NCT06271941|Active Comparator|EMR + h-APC + no defect closure|Standard endoscopic mucosal resection (EMR) technique will be used for the primary removal of all polyps, utilizing submucosal injection. Electrocautery snare technique will be facilitated using standard microprocessor-controlled electrocautery (e.g., ERBE VIO Endocut 3-1-6). Ablation of the margin and base of the polypectomy site will be performed using h-APC (Erbe Hybrid APC). Once resection and thermal ablation are considered complete, the mucosal defect will be left without complete closure.
89387745|NCT06271941|Active Comparator|EMR + STSC + complete defect closure|Standard endoscopic mucosal resection (EMR) technique will be used for the primary removal of all polyps, utilizing submucosal injection. Electrocautery snare technique will be facilitated using standard microprocessor-controlled electrocautery (e.g., ERBE VIO Endocut 3-1-6). Ablation of the margin of the polypectomy site will be performed using STSC. Once resection and thermal ablation are considered complete, the mucosal defect will be completely closed.
89530195|NCT03259477|Experimental|precise segmental clamping|These participants with clinical T1 renal cell carcinoma(RCC) undergo precise segmental renal arterial clamping during laparoscopic partial nephrectomy.
88863208|NCT05901285|Experimental|VAX014|Dose escalation of VAX014 [recombinant bacterial minicells (rBMCs)] intratumoral injections alone for subjects with solid tumors relapsed and/or refractory to standard treatment and appropriate for injection of a nodal, subcutaneous, or cutaneous tumor via palpation or with the assistance of ultrasound. In dose expansion, injection may be in metastatic tumors with or without the need for interventional radiology.
88863209|NCT05899816|Experimental|Rocatinlimab|Rocatinlimab every 4 weeks (Q4W) for 24 weeks with a loading dose at Week 2.
88863210|NCT05899816|Placebo Comparator|Placebo|Placebo every 4 weeks (Q4W) for 24 weeks with a loading dose at Week 2.
89387746|NCT06271941|Active Comparator|EMR + STSC + no defect closure|Standard endoscopic mucosal resection (EMR) technique will be used for the primary removal of all polyps, utilizing submucosal injection. Electrocautery snare technique will be facilitated using standard microprocessor-controlled electrocautery (e.g., ERBE VIO Endocut 3-1-6). Ablation of the margin of the polypectomy site will be performed using STSC. Once resection and thermal ablation are considered complete, the mucosal defect will be left without complete closure.
89387747|NCT06271928|Experimental|Treatment group|Once enrolled, participants will be administrated Yijing Keli and followed by a 3-month medication cycle. The usage of this herbal compound is to take orally twice a day(two sacks per). Add it to about 200ml warm water and take it half an hour before breakfast in the morning and half an hour before bedtime in the evening except menstrual period.
88863211|NCT05898230||Subjects who have been implanted with the Carbomedics OptiForm Mitral Heart Valve|Mitral Valve Replacement with Carbomedics OptiForm Mitral Heart Valve
88863212|NCT05895045|Experimental|1.1: 8-12 yoga first|
88863213|NCT05895045|Experimental|1.2: 13-18 yoga first|
88863214|NCT05895045|Experimental|2.1: 8-12 yoga second|
88863215|NCT05895045|Experimental|2.2: 13-18 yoga second|
88863216|NCT05890404|Experimental|Materials Only|The Materials Only arm will have access to a digital suite of online training materials for LGBTQ-Affirmative CBT prepared by the research team.
88863217|NCT05890404|Experimental|Direct Training|In addition to receiving access to the online training materials, the Direct Training arm will receive 12 weekly 1-hour live webinars on delivering LGBTQ-affirmative CBT led by our four expert trainers.
88863218|NCT05890404|Experimental|Local Supervision|In addition to receiving the online training materials and live webinars, the Local Supervision arm will receive guidance from an on-site clinical supervisor, who will be nominated by the center director as someone with substantial CBT experience.
88863219|NCT05887557|Other|Low-barrier drop-in and mobile care|This is a single-arm trial of a set of implementation strategies to encourage uptake of drop-in and mobile HIV care for people living with HIV who experience barriers to engage in usual scheduled appointments.
88863220|NCT05886777|Experimental|Group 1|Combination [RSVpreF+BNT162b2] + Quadrivalent influenza vaccine (QIV)
88863221|NCT05886777|Experimental|Group 2|Combination [RSVpreF+BNT162b2] + placebo
88863222|NCT05886777|Active Comparator|Group 3|BNT162b2 + placebo
88863223|NCT05886777|Active Comparator|Group 4|RSVpreF + placebo
88863224|NCT05886777|Active Comparator|Group 5|QIV + placebo
88863225|NCT05886777|Experimental|Group 6|Coadministration RSVpreF + bivalent BNT162b2 + placebo
88863226|NCT05886777|Experimental|Group 7|Coadministration RSVpreF + bivalent BNT162b2 + QIV
89387748|NCT06271915|Experimental|lateral epicondilitis with SNAG's|The intervention group, will receive mulligan's technique on C4-C7 cervical region and eccentric exercises to the affected forearm interventions done 2 times per week, 45 minutes each session for 4 weeks
88863227|NCT05886348|Experimental|Model-A Novel Spectacle lens|
88863228|NCT05886348|Experimental|Model-B Novel Spectacle lens|
88863229|NCT05886348|Other|Single Vision Spectacle lens|
89387749|NCT06271915|Active Comparator|lateral epicondylitis|"control group will receives only localized treatment as eccentric exercise, stretching of forearm extensors, cross-friction massage and ultrasound with frequency 3 MHz and intensity 2 W/cm2, 100% duty cycle on the affected forearm.~interventions done 2 times per week, 45 minutes each session for 4 weeks"
89387750|NCT06271902|Experimental|Intervention group|Participants will be instructed to perform YoSO-IPP at a recommended frequency of two times per week for 12 weeks and attend an online 45-minute educational workshop in Week 1
89387751|NCT06271902|Active Comparator|Control group|Participants will be instructed to perform the lower body stretching program at a recommended frequency of two times per week.
89185195|NCT02568969|Experimental|Lactate monitoring|The patients in the group will be subjected to the continuous perioperative monitoring of the venous blood lactate
89185196|NCT02569593|Other|RYGB-patient|Patients with a planned RYGB at UZ Leuven will be recruited. Iron supplements, more specific Ferrodyn and Vista Ferrum will be administrated in these patients before and 1, 3, 6 and 12 months post-RYGB with at least 7 days between the administration of the different supplements.
88863232|NCT05879887|Experimental|Basic palliative care coaching + financial coaching + outpatient visit + 1 monthly follow-up call|4 telehealth sessions on principles of problem solving, self-care, symptom management, and advanced care planning, 1 telehealth session on strategies to address healthcare-related financial toxicity, one-time Comprehensive Specialty Outpatient Palliative Care Clinic guided by the National Consensus Project for Quality Palliative Care Guidelines, and a single monthly follow-up call
88863233|NCT05879887|Experimental|Basic palliative care coaching + financial coaching + outpatient visit + 4 monthly follow-up calls|4 telehealth sessions on principles of problem solving, self-care, symptom management, and advanced care planning, 1 telehealth session on strategies to address healthcare-related financial toxicity, one-time Comprehensive Specialty Outpatient Palliative Care Clinic guided by the National Consensus Project for Quality Palliative Care Guidelines, and monthly follow-up calls for 4 months
88863234|NCT05879887|Experimental|Basic palliative care coaching + outpatient visit + 1 monthly follow-up call|4 telehealth sessions on principles of problem solving, self-care, symptom management, and advanced care planning, one-time Comprehensive Specialty Outpatient Palliative Care Clinic guided by the National Consensus Project for Quality Palliative Care Guidelines, and a single monthly follow-up call
88863235|NCT05879887|Experimental|Basic palliative care coaching + outpatient visit + 4 monthly follow-up calls|4 telehealth sessions on principles of problem solving, self-care, symptom management, and advanced care planning, one-time Comprehensive Specialty Outpatient Palliative Care Clinic guided by the National Consensus Project for Quality Palliative Care Guidelines, and monthly follow-up calls for 4 months
88863236|NCT05879887|Experimental|Advanced palliative care coaching + financial coaching + outpatient visit + 1 monthly follow-up call|8 telehealth sessions on principles of self-care, symptom management, and advanced care planning: This component level will expand the depth and topic range of content offered in the 4 sessions into eight 20-30 minute sessions, 1 telehealth session on strategies to address healthcare-related financial toxicity, one-time Comprehensive Specialty Outpatient Palliative Care Clinic guided by the National Consensus Project for Quality Palliative Care Guidelines, and a single monthly follow-up call
89387752|NCT06271889|No Intervention|Control|Control group pregnant women will be selected using randomization. their babies' fetal voice will not be listened.
89387753|NCT06271889|Active Comparator|Intervention|Pregnant women in the intervention group will be selected using randomization. the fetal voice of their babies will be listened to for about 3-5 minutes with a Non-stress Tester.
89387754|NCT06271876|Experimental|Inspiratory muscle fatigue group|The EG (experimental group) will perform the diaphragmatic fatigue protocol using a specific inspiratory endurance test, in which volunteers, one-on-one, and in a single session, will breathe against submaximal inspiratory loads equivalent to 60% of their MIP (Maximum Inspiratory Pressure) through a threshold valve device. The participants will follow a free pattern of breathing until they are unable to establish flow during at least 3 maximum inspiratory efforts.
89387755|NCT06271876|No Intervention|Control group|they will not receive any intervention. Just sit and wait the same amount of time that the intervention and the activation group needs to finish their protocol (around 10 minutes)
89387756|NCT06271876|Active Comparator|Inspiratory muscle activation group|The activation group will perform the protocol of 2 sets of 30 repetitions at 40% of their MIP, one-on-one, and in a single session, breathing against submaximal inspiratory loads using a threshold valve device. The participants will follow a free pattern of breathing until complete the protocol.
89387757|NCT06271837|Experimental|Trastuzumab deruxtecan|
89387758|NCT06271798|Experimental|Group A (Resistive exercise group):|They will receive life style modification advice, in addition to performing resistive exercise three times per week for six weeks.
89387759|NCT06271798|Experimental|Group B (Aerobic exercise group):|They will receive the same life style modification advice, in addition to performing aerobic exercise three times per week for six weeks.
89387760|NCT06271772|Experimental|RB-PDT Plus Early Steroids|
89387761|NCT06271772|Experimental|Sham RB-PDT Plus Early Steroids|
89387762|NCT06271759|Experimental|Fragrance 1 Group|"At-home administration of one of the four active stimuli (fragrances), according to the following protocol:~Participants will complete a series of psychological scales (pre-measurements), tapping into mood, affective states, well-being.~Participants will inhale the fragranced stimulus for approximately 10 minutes.~After the completion of step 2, participants will engage in a neutral activity for about 15 minutes.~Participants will complete a series of psychological scales (post-measurements).~Participants will repeat this protocol one week apart."
89387763|NCT06271759|Experimental|Fragrance 2 Group|"At-home administration of one of the four active stimuli (fragrances), according to the following protocol:~Participants will complete a series of psychological scales (pre-measurements), tapping into mood, affective states, well-being.~Participants will inhale the fragranced stimulus for approximately 10 minutes.~After the completion of step 2, participants will engage in a neutral activity for about 15 minutes.~Participants will complete a series of psychological scales (post-measurements).~Participants will repeat this protocol one week apart."
89387764|NCT06271759|Experimental|Fragrance 3 Group|"At-home administration of one of the four active stimuli (fragrances), according to the following protocol:~Participants will complete a series of psychological scales (pre-measurements), tapping into mood, affective states, well-being.~Participants will inhale the fragranced stimulus for approximately 10 minutes.~After the completion of step 2, participants will engage in a neutral activity for about 15 minutes.~Participants will complete a series of psychological scales (post-measurements).~Participants will repeat this protocol one week apart."
89387765|NCT06271759|Experimental|Fragrance 4 Group|"At-home administration of one of the four active stimuli (fragrances), according to the following protocol:~Participants will complete a series of psychological scales (pre-measurements), tapping into mood, affective states, well-being.~Participants will inhale the fragranced stimulus for approximately 10 minutes.~After the completion of step 2, participants will engage in a neutral activity for about 15 minutes.~Participants will complete a series of psychological scales (post-measurements).~Participants will repeat this protocol one week apart."
89387766|NCT06271759|No Intervention|No Fragrance Group|"At-home administration of the neutral/no-odor stimulus, according to the following protocol:~Participants will complete a series of psychological scales (pre-measurements), tapping into mood, affective states, well-being.~Participants will inhale the non-fragranced stimulus for approximately 10 minutes.~After the completion of step 2, participants will engage in a neutral activity for about 15 minutes.~Participants will complete a series of psychological scales (post-measurements).~Participants will repeat this protocol one week apart."
89387767|NCT06271746|Active Comparator|Treatment with active FibroNova device|Treatment of Fibromyalgia pain and symptoms with active FibroNova device. Participants will treat with an active device twice a day.
89387768|NCT06271746|Placebo Comparator|Treatment with Sham FibroNova device|Treatment of Fibromyalgia pain and symptoms with Sham FibroNova device. Participants will treat with a sham device twice a day.
89387769|NCT06271720|Active Comparator|visceral manipulation|Palpation will be applied and the pressure will directly to the skin, into the direction of restriction just until resistance (tissue barrier) is felt. Once found, the collagenous barrier will be engaged for 90 to 120 seconds for each technique without sliding over the skin or forcing the tissue until the fascia complex starts to yield and a sensation of softening is achieved.
89530196|NCT03259477|Active Comparator|complete clamping|These participants with clinical T1 renal cell carcinoma(RCC) undergo complete renal arterial clamping during laparoscopic partial nephrectomy.
88863237|NCT05879887|Experimental|Advanced palliative care coaching + financial coaching + outpatient visit + 4 monthly followup calls|8 telehealth sessions on principles of self-care, symptom management, and advanced care planning: This component level will expand the depth and topic range of content offered in the 4 sessions into eight 20-30 minute sessions,1 telehealth session on strategies to address healthcare-related financial toxicity, one-time Comprehensive Specialty Outpatient Palliative Care Clinic guided by the National Consensus Project for Quality Palliative Care Guidelines, and monthly follow-up calls for 4 months
89189407|NCT05810506||Healthy|Healthy individuals; they were required to sign the voluntary consent form, not consume alcohol, be between 30-64 years old, and not have any acute or chronic diseases. Individuals outside these criteria were not included in the study. In the study, biochemical parameters will be taken from the anthropometric measurements and files of the patients without any intervention.
89387770|NCT06271720|Active Comparator|integrated neuromuscular inhibition|The practitioner first identifies TrPs to be treated within the upper trapezius muscle. The subjects will be placed in a supine position. Their arm will be positioned in slight shoulder abduction with the elbow bent and their hand resting on their stomach. Using a pincer grasp, the practitioner will move throughout the fibers of the upper trapezius and make note of any active TrPs. Once the TrPs were identified, treatment began. The first technique applied will be ischemic compression. The therapist again utilized a pincer grasp, placing the thumb and index finger over the active TrP. Slow, increasing levels of pressure will be applied until the tissue resistance barrier is identified. The pressure will be maintained until a release of the tissue barrier is felt. At that time, pressure will again be applied until a new barrier is felt. This process will be repeated until tension or tenderness is unable to be identified or 90 seconds have elapsed.
89387771|NCT06271707|Experimental|Group 1|ultrasound with bupivacaine
89387772|NCT06271707|Sham Comparator|Group 2|Ultrasound with saline
89387773|NCT06271694|Other|Standard Vestibular Rehabilitation|All participants will receive standard vestibular rehabilitation
89387774|NCT06271681|Other|All participants|This will be a single population open label trial evaluating immune response to PCV15 followed by PPSV23 8 weeks later in subjects with immunocompromising conditions or receiving immunosuppressive medications.
89387775|NCT06271655|Experimental|SPOTFIRE Arm|The intervention involves the use of a rapid point-of-care multiplex PCR test to identify viral etiology in patients with acute respiratory illness. This approach aims to provide timely and accurate diagnostic information to guide treatment decisions. Specimen samples will be collected by research staff at the time of ED presentation by NPAAS. Upon collection, the sample will be promptly prepared for testing on the SPOTFIRE R Panel device. In this trial, all providers will view Spotfire results before prescribing antibiotics ; failure to so so will be a protocol violation.
89387776|NCT06271642|Experimental|Bluetooth Haptic Device (Experimental Frequency) + Needle Sham|Bluetooth Haptic Device with experimental vibrating frequency will be placed on the arm of the participant, with weighted pinpricks with fixed stimulus intensities will be applied.
89387777|NCT06271642|Sham Comparator|Bluetooth Haptic Device (Control Frequency) + Needle Sham|Bluetooth Haptic Device with control vibrating frequency will be placed on the arm of the participant, with weighted pinpricks with fixed stimulus intensities will be applied.
89387778|NCT06271603|Experimental|Intervention Arm: Management performed with an initial diagnosis based on the LC-OCT device|The interventional procedure involves the management of BCC with an initial diagnosis based on the deepLive™ device. The imaging is performed by placing the probe tip in contact with the patient&#39;s skin after applying an immersion oil (paraffin) to the imaging area. The examination lasts only a few minutes and is painless. An integrated dermoscopic targeting system allows the operator to ensure proper positioning of the probe on the lesion and to ensure that the entire lesion has been captured for an accurate diagnosis. The images are displayed in real-time during the examination and directly evaluated by the investigator, who has the option to save images/videos at their discretion. A final evaluation with the deepLive™ device will also be performed during the 1-year follow-up, and intermediate evaluations may also be performed with the deepLive™ device depending on the initial management of BCC.
89387779|NCT06271603|Active Comparator|Control Arm: Standard management with an initial diagnosis based on skin biopsy|The control procedure corresponds to standard management of BCC with an initial diagnosis based on skin biopsy (standard management arm). The biopsy will be performed according to the standard practice of each center, using a 2 to 6 mm punch or shave biopsy, with prior injection of a local anesthetic. A final evaluation with the deepLive™ device will also be performed during the 1-year follow-up.
88863238|NCT05879887|Experimental|Advanced palliative care coaching + outpatient visit + 1 monthly follow-up call|8 telehealth sessions on principles of self-care, symptom management, and advanced care planning: This component level will expand the depth and topic range of content offered in the 4 sessions into eight 20-30 minute sessions, one-time Comprehensive Specialty Outpatient Palliative Care Clinic guided by the National Consensus Project for Quality Palliative Care Guidelines, and a single monthly follow-up call
88863239|NCT05879887|Experimental|Advanced palliative care coaching + outpatient visit + 4 monthly follow-up calls|8 telehealth sessions on principles of self-care, symptom management, and advanced care planning: This component level will expand the depth and topic range of content offered in the 4 sessions into eight 20-30 minute sessions, one-time Comprehensive Specialty Outpatient Palliative Care Clinic guided by the National Consensus Project for Quality Palliative Care Guidelines, and monthly follow-up calls for 4 months
88863240|NCT05879887|Experimental|Basic palliative care coaching + financial coaching + 1 monthly follow-up call|4 telehealth sessions on principles of problem solving, self-care, symptom management, and advanced care planning, 1 telehealth session on strategies to address healthcare-related financial toxicity, and a single monthly follow-up call
88863241|NCT05879887|Experimental|Basic palliative care coaching + financial coaching + 4 monthly follow-up calls|4 telehealth sessions on principles of problem solving, self-care, symptom management, and advanced care planning, 1 telehealth session on strategies to address healthcare-related financial toxicity, and monthly follow-up calls for 4 months
88863242|NCT05879887|Experimental|Basic palliative care coaching + 1 monthly follow-up call|4 telehealth sessions on principles of problem solving, self-care, symptom management, and advanced care planning, and a single monthly follow-up call
88863243|NCT05879887|Experimental|Basic palliative care coaching + 4 monthly follow-up calls|4 telehealth sessions on principles of problem solving, self-care, symptom management, and advanced care planning, and monthly follow-up calls for 4 months
88863244|NCT05879887|Experimental|Advanced palliative care coaching + financial coaching + 1 monthly follow-up call|8 telehealth sessions on principles of self-care, symptom management, and advanced care planning: This component level will expand the depth and topic range of content offered in the 4 sessions into eight 20-30 minute sessions, 1 telehealth session on strategies to address healthcare-related financial toxicity, and a single monthly follow-up call
88863245|NCT05879887|Experimental|Advanced palliative care coaching + financial coaching + 4 monthly follow-up calls|8 telehealth sessions on principles of self-care, symptom management, and advanced care planning: This component level will expand the depth and topic range of content offered in the 4 sessions into eight 20-30 minute sessions, 1 telehealth session on strategies to address healthcare-related financial toxicity, and monthly follow-up calls for 4 months
89387780|NCT06271590|Experimental|MagicTouch Sirolimus-Coated Balloon (SCB)|Magic TouchTM is a Sirolimus Coated Balloon catheter intended to be used in coronary applications, treats the atherosclerosis of the coronary arteries by eluting the immunosuppressant agent Sirolimus without leaving behind a metallic scaffold.
89387781|NCT06271590|Active Comparator|Drug eluting stents (DES)|Everolimus eluting stents (EES) or Zotarolimus eluting stents (ZES)
89387782|NCT06271564|Experimental|Magnetite Zno Composite Nanoparticles|5% topical ZnO-Fe3O4 Magnetic Composite NPs gel applied 3 times per day for 6 weeks
89387783|NCT06271564|Placebo Comparator|Topical Placebo Gel|Topical Placebo Gel containing water, glycerin and Hydroxypropyl methylcellulose applied 3 times per day for 6 weeks
89387784|NCT06271278|Experimental|Emotional Freedom Techniques group|The Nurse Introduction Form, Subjective Discomfort Unit, Alarm Fatigue Scale, and Work Stress Scale were administered to the experimental group prior to patient care. The Emotional Freedom Technique was explained, and the nurses were instructed to apply it before and after their shifts for one week. One week later, the Subjective Discomfort Unit, Alarm Fatigue Scale, and Work Stress Scale were applied again.
88863246|NCT05879887|Experimental|Advanced palliative care coaching + 1 monthly follow-up call|8 telehealth sessions on principles of self-care, symptom management, and advanced care planning: This component level will expand the depth and topic range of content offered in the 4 sessions into eight 20-30 minute sessions, and a single monthly follow-up call
89387785|NCT06271278|No Intervention|Control group|No applications were administered to nurses working in the surgical intensive care unit. In the control group, data was collected before patient care using the Nurse Introduction Form, Subjective Discomfort Unit, Alarm Fatigue Scale, and Work Stress Scale. No interventions were performed. One week later, the Subjective Discomfort Unit, Alarm Fatigue Scale, and Work Stress Scale were applied again.
88863247|NCT05879887|Experimental|Advanced palliative care coaching + 4 monthly follow-up calls|8 telehealth sessions on principles of self-care, symptom management, and advanced care planning: This component level will expand the depth and topic range of content offered in the 4 sessions into eight 20-30 minute sessions and monthly follow-up calls for 4 months
89387786|NCT06270641|Experimental|Intervention ExerciseRx-MS|"Participants use the ExerciseRx app to meet personalized daily step targets and weekly goals. They will receive MS Exercise and Physical Activity Recommendations and complete in-app surveys about barriers to being active and physical activity level. The ExerciseRx app will adjust the personalized step count goals based on percentage met of the previous week goal and providers will send supportive messages based on participant activity. Participants will complete validated self-report assessments.~Providers may also provide participants with additional guidance, make referrals, or schedule telemedicine or in-person clinic follow ups if needed to support the participant's physical activity progression."
89387787|NCT06270641|No Intervention|Usual care|"Participants receive MS Exercise and Physical Activity Recommendations, will continue typical physical activity, and complete validated self-report assessments.~At the end of 26 weeks, staff will offer the participants the ExerciseRx intervention protocol."
89387788|NCT06270277|Experimental|Inflammatory bowel disease group|Adolescents with Inflammatory bowel diseases will be administered Pediatric Quality of Life Inventory (PedsQL) and Strengths and Difficulties Questionnaire (SDQ).
89387789|NCT06270277|Active Comparator|Control group|Adolescents without known diseases in same age group will be administered Pediatric Quality of Life Inventory (PedsQL) and Strengths and Difficulties Questionnaire (SDQ) as control group
88863248|NCT05877027|Active Comparator|Intervention Group 1|The patients in the Exercise group will be treated with a structured exercise program. The exercises will be applied by the research physiotherapist for 6 weeks, 2 days a week. Each training session is planned to last approximately 30 minutes.
88863249|NCT05877027|Active Comparator|Intervention Group 2|The patients in the topical agent group were prescribed by the orthopedist. they will use the topical agent. Diclofenac in gel form was chosen as a topical agent in the light of the literature. In this context, patients in both groups will apply the topical agent around the knee joint 4 days a week, 2 times a day (every 12 hours) in the morning and evening for 6 weeks.
88863250|NCT05877027|Active Comparator|Intervention Group 3|The PRP procedure with the same characteristics will be used in the treatment of patients in the PRP group. The PRP application will be prepared by the orthopedics and traumatology specialist physician in the research team, using the kits provided within the scope of the project. In order to collect venous blood for the PRP production procedure, gamma sterile vacuum tubes and blood collection set in special kits without the risk of contamination will be used. A total of 3 doses will be administered to the patients, with a one-week interval between doses.
88863251|NCT05873868||Patients|Patients hATTR with neurological and cardiac damages treated with Patisiran or Vutrisiran
88863252|NCT05870930|Experimental|Carob beverage|
88863253|NCT05870930|Other|Sucrose beverage|
89387790|NCT06269783|Experimental|sipIT|Participants will receive an educational handout about physical activity, a connected water bottle with its companion mobile application. For months 1-3, participants will receive lapse-contingent reminders to drink delivered by text message.
89387791|NCT06269770|Active Comparator|Tramadol|Tramadol will be administered in a multimodal analgesic approach to manage postoperative pain.
89387792|NCT06269770|Active Comparator|Tapentadol|Tapentadol will be administered in a multimodal analgesic approach to manage postoperative pain.
88863254|NCT05868330|Active Comparator|Interscalene Catheter|One of the current standard of care for shoulder replacement surgery at our institution is to receive an interscalene catheter for pre-operatively
88863255|NCT05868330|Active Comparator|Exparel Single Shot Interscalene Block|One of the current standard of care for shoulder replacement surgery at our institution is to receive a pre-operative single shot interscalene block with Exparel
89189408|NCT05810506||NAFLD|NAFLD patients included in the study should sign a voluntary consent form, do not consume alcohol, be between 30-64 years old, have been diagnosed with NAFLD by applying to the gastroenterology outpatient clinic, have no other diseases, and should not use medication. In the study, biochemical parameters will be taken from the anthropometric measurements and files of the patients without any intervention.
89387793|NCT06269224||There are 3 groups. 2 groups consist of runners and 1 group consists of sedentary individuals.|Participants were recreational runners who run between 20 to 50 km weekly; one group consisted of 35 runners who had been RTY, the second group consisted of 35 runners who had been running for RSM; the third group was composed of 35 sedentary individuals identified using the Sedentary Behavior Questionnaire. Participants were within the age range of 30 to 45. Exclusion criteria encompassed a history of lower extremity or lumbar-related surgery within the last year and a body mass index (BMI) exceeding the normal threshold of 24.5 kg/m².
89387794|NCT06268782|Experimental|The intervention group|All participants belonged to the intervention group. The participants were asked to answer for the pretest questionnaire before the intervention, then accomplish the six-week intervention, answer to the posttest questionnaire after the intervention and answer to the follow-up questionnaire six months after the intervention.
89387795|NCT06268392||Expert sonographer|Expert sonographers ultrasound examination.
89387796|NCT06268392||Control Group (CG)|Control group ultrasound examination with no AI support.
89387797|NCT06268392||Feedback group 1 (FG1)|Feedback group 1 ultrasound examination with basic black box AI support.
89387798|NCT06268392||Feedback group 2 (FG2)|Feedback group 2 ultrasound examination with detailed explainable AI support.
89387799|NCT06268132||Long-living individuals|Long-living individuals at least 90 years of age from the Central Federal District of Russia
89387800|NCT06268054|Experimental|DEH113|The patient must take two (2) DEH113 tablets, if pain, up to three times a day.
89387801|NCT06268054|Placebo Comparator|Control|The patient must take two (2) DEH113 placebo tablets, if pain, up to three times a day.
89387802|NCT06268015|Experimental|Treatment|botensilimab + balstilimab until disease progression, then botensilimab + balstilimab + mFOLFOX6 (leucovorin, fluorouracil, oxaliplatin) + {bevacizumab or panitumumab}
89387803|NCT06267456|Other|handball players|Handball players aged between 18 and 35 who have been playing for a minimum of 3 years.
89387804|NCT06267456|Other|volleyball players|volleyball players aged between 18 and 35 who have been playing for a minimum of 3 years.
89387805|NCT06267456|Other|basketball players|Basketball aged between 18 and 35 who have been playing for a minimum of 3 years.
88863258|NCT05860647|Experimental|Intermittent theta burst stimulation|All subjects will receive treatment with intermittent theta burst stimulation (iTBS). There will be a total of 5 treatments over a 2-week period. All subjects will receive iTBS to the right TGd region. TBS treatment will also be provided for two additional sites within the large-scale brain networks (LSBNs) that is found to contain the greatest number of connectivity anomalies. Total participation will be 8-10 weeks.
88863260|NCT05859048|Active Comparator|Investigational arm guided by NT-proBNP result|NT-proBNP drawn and if level elevated (>125 pg/ml) a study visit with artificial intelligence (AI) echocardiogram, electrocardiogram (ECG), and heart failure (HF) focused examination conducted
88863261|NCT05859048|No Intervention|Routine care arm|Participants will be remotely monitored for number of heart failure events
88863262|NCT05857735||ACS patients|Patients admitted to hospital with diagnosis of ACS.
89185197|NCT02569281|Experimental|US-guided percutaneous electrolysis|Patients will receive one weekly session for 5 weeks including best-evidence manual therapy and an eccentric loading exercise program for the shoulder musculature, particularly the supraspinatus and infraspinatus muscles. The exercise program will be asked to be performed on an individual basis twice every day. The therapeutic protocol will be applied for 5 weeks. In addition, they will receive one session of US-guided percutaneous electrolysis. This intervention consists of the application of a galvanic electrical current with an acupuncture needle in the soft tissue, in this case the supraspinatus tendon.
89387806|NCT06267404|Experimental|Iliopsoas positional release|Group A (Iliopsoas positional release group) Positional release therapy will be administered on both Iliopsoas muscles, three sets on each side with 30 seconds hold on tender point. A rest of 15 seconds will be given between all sets.
89387807|NCT06267404|Active Comparator|Conventional therapy|Group B (Conventional therapy) Conventional Physical therapy i.e. Ultrasonic therapy 3 min 1 MHz, TENS 10 min, hot pack for 10 min and back strengthening exercises.
89387808|NCT06266182|Experimental|ACT intervention|Participants in the ACT intervention arm will learn new adaptive ways to cope with difficulties (including difficult thoughts or feelings).
89387809|NCT06266182|Other|Education|Participants in the Education arm will become familiar with post-HCT recommendations. This will be a minimally enhanced usual care.
89387810|NCT06265233|Experimental|ERP combined with Improv Group Therapy|Participants will attend 90-minute ERP + improv group therapy sessions for 12 consecutive weeks. They will also complete homework between sessions, answer questions, and complete questionnaires.
89387811|NCT06265012|Experimental|Group A, Low Dose PHV01|Group A (10 subjects) PHV01 @ 10^5 pfu/dose
89387812|NCT06265012|Experimental|Group B, Medium Dose PHV01|Group B (10 subjects) PHV01 @ 10^6 pfu/dose
89387813|NCT06265012|Experimental|Group C, Hjigh Dose PHV01|Group C (10 subjects) PHV01 @ 10^7 pfu/dose
89387814|NCT06265012|Placebo Comparator|Group D, Placebo|Group D (6 subjects) Placebo
89387815|NCT06264713|Experimental|Experimental Immersive Virtual Reality|Patients will undergo nine sessions of 20 minutes for three sessions/week, for a total of three weeks of treatment. The training consists of 3 different virtual reality tasks specifically designed for neglect training.
89387816|NCT06264713|Active Comparator|Sham Immersive Virtual Reality|Patients will undergo nine sessions of 20 minutes for three sessions/week, for a total of three weeks of treatment. The training consists of 3 different virtual reality tasks specifically designed for neglect training.
88863266|NCT05856214|Experimental|Couple-based violence prevention education(CBVPE)|Couples in the intervention group will receive trainings on gender based violence, intimate partner violence, Consequences of violence during pregnancy, common triggers of intimate partner violence, a healthy relationship in marriage ,couples communication and conflict management
88863267|NCT05842967|Experimental|Substudy A - RSVpreF|Participants will receive a single 120-µg dose of RSVpreF at Visit 1
89387817|NCT06264596|Experimental|Epinephrine|The epinephrine group will have two 3-L normal saline solution bags prepared for each case with 1 mL of 1:1000 epinephrine in each bag (epinephrine concentration 1:3,000,000 for each bag).
89387818|NCT06264596|Placebo Comparator|Normal saline|The control group will have two 3-L normal saline solution bags prepared with no additive
88863268|NCT05842967|Placebo Comparator|Substudy A - Placebo|Participants will receive placebo at Visit 1
88863269|NCT05842967|Experimental|Substudy B - RSVpreF|Participants will receive 120-µg doses of RSVpreF at Visit 1 and Visit 2 (open label, single arm only)
88863270|NCT05831189|Experimental|RBX2660|
88863271|NCT05829005|Active Comparator|Active arm|The location and number of pulses will be set. The intensity of stimulation will be felt by the subject. 120 stimuli - including at least 20 supra (motor) threshold stimuli causing movement of the affected limb.
88863272|NCT05829005|Sham Comparator|Inactive/control arm|The location and number of pulses have been set at the same as the active treatment. The intensity of stimulation will necessarily be less but will still result in a stimulus that is felt by the subject to maximise chances of successful blinding. 120 stimuli - no stimuli of sufficient intensity to produce movement.
88863273|NCT05827887||Ubrogepant|Participants will receive ubrogepant as prescribed by their physician in routine clinical practice.
88863274|NCT05827887||Atogepant|Participants will receive atogepant as prescribed by their physician in routine clinical practice.
88863275|NCT05824936|Experimental|Pilot study arm for technology-enhanced asthma intervention|All participants will be in the pilot arm for technology-enhanced intervention program.
88863276|NCT05824754|Experimental|JITAI|"Experimental: Within-participant micro-randomization~Twice daily in the study, a participant is assigned to receive a message or no message. The micro-randomization will be performed by a reinforcement learning algorithm based on the participant's engagement with the intervention."
88863277|NCT05822830|Experimental|Tirzepatide|Participants will receive tirzepatide subcutaneously (SC).
88863278|NCT05822830|Active Comparator|Semaglutide|Participants will receive semaglutide SC.
88863279|NCT05818033|Experimental|Intervention group|CARE1.02
88863280|NCT05818033|Active Comparator|Control group|Single-vision spectacle lens
89387819|NCT06264531|Experimental|bevacizumab|Bevacizumab 5 mg/kg as a slow infusion over 90 minutes every 14 days for a total of 6 injections
89387820|NCT06264531|Placebo Comparator|placebo|NaCl 0.9% as a slow infusion over 90 minutes every 14 days for a total of 6 injections
89387821|NCT06261775|Other|Control|Lacto-ovo-vegetarian meal
89387822|NCT06261775|Experimental|Test|Red meat-based meal
89387823|NCT06258811|Experimental|Experimental arm|Neoadjuvant immunochemotherapy (albumin paclitaxel+cisplatin+tislelizumab) + radical surgery + adjuvant therapy (radiation/chemoradiation + tislelizumab maitainance)
89387824|NCT06258811|No Intervention|Control arm|Standard therapy of radical surgery +adjuvant therapy (radiation/chemoradiation)
88863281|NCT05817942||Arm A: Filgotinib|Participants diagnosed with moderately or severely active UC taking filgotinib according to local treatment guidelines or routine clinical practice and product information.
88863282|NCT05813925|Experimental|CagriSema 2.4 mg/2.4 mg|Participants will receive 2.4 milligrams (mg) cagrilintide and 2.4 mg semaglutide subcutaneously (s.c.) once-weekly (OW) after a dose escalation period of 16 weeks (0.25 mg of cagrilintide and 0.25 mg of semaglutide from weeks 0-4, 0.5 mg of cagrilintide and 0.5 mg of semaglutide from weeks 5-8, 1 mg of cagrilintide and 1 mg of semaglutide from weeks 9-12 and 1.7 mg of cagrilintide and 1.7 mg of semaglutide from weeks 13-16) during the maintenance period for 52 weeks
88863283|NCT05813925|Active Comparator|Semaglutide 2.4 mg|Participants will receive semaglutide s.c. 2.4 mg and placebo matched to semaglutide OW after a dose escalation period of 16 weeks (0.25 mg for weeks 0-4, 0.5 mg for weeks 5-8, 1 mg for weeks 9-12 and 1.7 mg for weeks 13-16) during the maintenance period for 52 weeks
88863284|NCT05809817||Intervention (Periodontal treatment)|Patients with T2DM under follow-up in the PSCV will receive the usual periodontal therapy performed at the CEMO Villa Sur in the commune of Pedro Aguirre Cerda and at the CESFAM Puerto Varas in the context of PSCV. The care protocols and national evidence establish that the standard treatment of periodontitis consists of 4 or more sessions of scaling and root planing per sextant, depending on the severity of the disease.
88863285|NCT05809817||Control (Matched, non-active intervention)|Patients with T2DM under follow-up in the PSCV, with non-active control (withouth periodontal treatment) that will be matched in a ratio of 1:1 through Propensity Score Matching according to baseline HbA1c levels and demographic baseline data (age, sex).
88863286|NCT05808166|Experimental|Pregnant participant receiving Hecolin®|"1 (N=1,104): Pregnant participants receiving Hecolin® (n=150 immunogenicity subset).~For Arm 1, pregnant participants will receive 2 doses of Hecolin® at a 4 weeks interval and the third dose will be administered postpartum, approximately 20 weeks after the second dose."
88863287|NCT05808166|Placebo Comparator|Pregnant participants receiving placebo|"Arm 2 (N=1,104): Pregnant participants receiving placebo (n= 150 immunogenicity subset).~For Arm 2, pregnant participants will receive 2 doses of placebo at a 4 weeks interval and the third dose will be administered postpartum, approximately 20 weeks after the second dose."
88863288|NCT05808166|Active Comparator|Non-Pregnant participants receiving Hecolin®|"Arm 3 (N=150): Non-Pregnant participants receiving Hecolin® (n= 150 immunogenicity subset).~For Arm 3, non-pregnant participants will receive Hecolin® at 0-1-6 months schedule."
88863289|NCT05798520|Experimental|Part 1: BIIB091 High Dose + Matching Placebo for DRF|Participants will receive BIIB091 high dose and matching placebo for DRF, orally, for up to 48 weeks.
89387825|NCT06257563|Experimental|Isle of TEND Intervention|All participants will engage in the Isle of TEND Intervention.
89387826|NCT06255093|Other|Pre-Surveys Only|Pre-surveys only (did not meet referral criteria based on screening assessment) and receive online wellness education and anxiety treatment options information
89387827|NCT06255093|Other|Pre-Surveys, Recreational Program Referral, Post Surveys|Pre-surveys, meet referral criteria, referred to a program, post-surveys. Post-surveys will occur at the end of the out-of-school program, or 4 months after joining the program (whichever comes first).
89387828|NCT06254898|Active Comparator|Child life standard of care|Child life standard of care
89387829|NCT06254898|Experimental|Child life standard of care + incentives provided with conditional agreement.|Child life standard of care + incentives provided with conditional agreement.
89387830|NCT06254898|Experimental|Child life standard of care + incentive provided unconditionally.|Child life standard of care + incentive provided unconditionally.
89387831|NCT06251193|Experimental|E-CBSST|E-CBSST is the experimental arm in this study.
89387832|NCT06250842||Long-term benzodiazepine use group|Continuous use of benzodiazepines for ≥3 months
89387833|NCT06250842||Non-benzodiazepine use group|No history of prior benzodiazepine use
89387834|NCT06250842||Healthy Controls|Healthy Controls
89387835|NCT06249048|Experimental|Phase 1 Monotherapy (STX-001)|A Phase 1, first-in-human (FIH), multiple ascending STX-001 dose administration to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity in patients with advanced cancers. Consists of 4 planned dose escalation cohorts (Cohorts 1m) of STX-001 with new patients enrolled in each dose escalation cohort.
89387836|NCT06249048|Experimental|Phase 1 Combination (STX-001 with Pembrolizumab)|A Phase 1, first-in-human (FIH), multiple ascending STX-001 dose administration, in combination with pembrolizumab, to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity in patients with advanced cancers. Consists of 4 planned dose escalation cohorts (Cohorts 1c) of STX-001 with new patients enrolled in each dose escalation cohort.
89387837|NCT06249048|Experimental|Phase 2 Combination (STX-001 with Pembrolizumab)|Phase 2 consists of dose expansion cohorts in patients with 2 defined cancer types: triple negative breast cancer (TNBC) and melanoma. Phase 2 will evaluate STX-001 in combination with pembrolizumab; the recommended Phase 2 dose (RP2D) of STX-001 will be selected based on analysis of the totality of data from Phase 1.
89387838|NCT06248515|Experimental|Sacituzumab|
89387839|NCT06248437||Healthy participants|Healthy participants (n = 10). At that time, they were explained how they should eat the nutraceutical food (HIC1®), starting the next day and for five consecutive days. During those 5 days, a nurse made contact calls to verify that the participant took the corresponding dose for the day. After 5 days of ingesting the nutraceutical compound, a blood sample was taken again to quantify post-ingestion levels of ORAC units, amino acids, vitamin B12, vitamin D, phosphorus, magnesium, calcium, and the lipid profile.
89387840|NCT06248437||Patients with COPD|Patients with COPD (n = 10). At that time, they were explained how they should eat the nutraceutical food (HIC1®), starting the next day and for five consecutive days. During those 5 days, a nurse made contact calls to verify that the participant took the corresponding dose for the day. After 5 days of ingesting the nutraceutical compound, a blood sample was taken again to quantify post-ingestion levels of ORAC units, amino acids, vitamin B12, vitamin D, phosphorus, magnesium, calcium, and the lipid profile.
89387841|NCT06248437||Patients in the Intensive Care Unit (ICU)|"Patients receiving mechanical ventilation in the Intensive Care Unit (ICU) (n=10)~At that time, they were explained how they should eat the nutraceutical food (HIC1®), starting the next day and for five consecutive days. During those 5 days, a nurse made contact calls to verify that the participant took the corresponding dose for the day. After 5 days of ingesting the nutraceutical compound, a blood sample was taken again to quantify post-ingestion levels of ORAC units, amino acids, vitamin B12, vitamin D, phosphorus, magnesium, calcium, and the lipid profile. In the case of the participants in the ICU, control visits were made to the unit to verify that the dose was delivered to the participant"
89387842|NCT06248008|Experimental|ASC40 50mg|ASC40 50mg, up to 40 weeks of treatment.
89387843|NCT06245395|Active Comparator|Virtual Reality Arm|Pediatric patient receiving Virtual Reality during the otologic procedure.
89387844|NCT06245395|No Intervention|Standard of Care Arm|
89387845|NCT06244992|Experimental|PTT-936 Dose Level 1|PTT-936 will be administered every other day (QOD)
89387846|NCT06244992|Experimental|PTT-936 Dose Level 2|PTT-936 will be administered every other day (QOD)
89387847|NCT06244992|Experimental|PTT-936 Dose Level 3|PTT-936 will be administered every other day (QOD)
89387848|NCT06244992|Experimental|PTT-936 Dose Level 4|PTT-936 will be administered every other day (QOD)
89387849|NCT06244992|Experimental|PTT-936 Dose Level 5|PTT-936 will be administered every other day (QOD)
89387850|NCT06244992|Experimental|PTT-936 Dose Level 6|PTT-936 will be administered every other day (QOD)
89387851|NCT06244992|Experimental|PTT-936 Dose Level 7|PTT-936 will be administered every other day (QOD)
89387852|NCT06244992|Experimental|PTT-936 Dose Level 8|PTT-936 will be administered every other day (QOD)
89387853|NCT06244992|Experimental|PTT-936 Dose Level 9|PTT-936 will be administered every other day (QOD)
89387854|NCT06244992|Experimental|PTT-936 and anti-PD-1/L1 combination therapy|PTT-936 to be administered every other day (QOD) in combination with a standard-of-care (SOC) regimen of an anti-PD-1/L1 agent every three weeks (Q3W)
89387855|NCT06244264|Experimental|Autoblood transfusion + leukocyte filter group|In our department open surgery is considered as the standard procedure. The patients underwent open surgery, with autologous blood transfusion combined with a leukocyte filter. Blood transfusion based on bleeding during surgery.
89387856|NCT06244264|No Intervention|Allogeneic blood transfusion group|In our department open surgery is considered as the standard procedure. The patients receives open surgery with allogeneic blood transfusion. Blood transfusion based on bleeding during surgery.
89387857|NCT06242925|Experimental|ABCLO Group|The cohort (interventional) patients will receive the standard of care (Lahey bag, Ioban and closed suction drains) in addition to the study intervention (AbCLO Device).
89387858|NCT06242925|No Intervention|Historical Controls|"The control group is retrospective patients that were previously managed at the same center, regardless of the technique or the device used to close the OA.~At TMC, we have a previously collected data bank of all open abdomen managed at our center. This data bank is approved by IRB. This data bank has 170 patients in total. we will use 45 patients from the data bank to be matched to the interventional group (15 patients) to have a total of 60 patients from TMC.~As of LAC+USC Medical Center, they will provide historical controls from the trauma registry."
89387859|NCT06241560|Experimental|BI 1015550, then Pirfenidone + BI 1015550|
89387860|NCT06231264|Experimental|treatment group|Subjects will be trained to use the devices at the treatment sites and receive treatment twice a day for 8 weeks.
89387861|NCT06231264|Placebo Comparator|shame group|Subjects will be trained to use the devices at the sham sites and receive sham treatment twice a day for 8 weeks.
89387862|NCT06230484|Active Comparator|IFPE patients|patients receiving IFPE treatment
89387863|NCT06230484|Active Comparator|(control group): RME patients|patients receiving conventional rapid maxillary expansion treatment
89387864|NCT06228703|No Intervention|Airvo 3 high-flow nasal cannula device with flow set at 20 L/min|A new high-flow nasal cannula device (Airvo 3) will be used in the study, with the flow set at 20 L/min
89387865|NCT06228703|No Intervention|HFT 750 high-flow nasal cannula device with flow set at 20 L/min|A new high-flow nasal cannula device (HFT 750) will be used in the study, with the flow set at 20 L/min
89387866|NCT06228703|Experimental|Airvo 3 high-flow nasal cannula device with flow set at 40 L/min|Airvo 3 will be used with the flow set at 40 L/min
89387867|NCT06228703|Experimental|Airvo 3 high-flow nasal cannula device with flow set at 60 L/min|Airvo 3 will be used with the flow set at 60 L/min
89387868|NCT06228703|Experimental|HFT 750 high-flow nasal cannula device with flow set at 40 L/min|HFT 750 will be used with the flow set at 40 L/min
89387869|NCT06228703|Experimental|HFT 750 high-flow nasal cannula device with flow set at 60 L/min|HFT 750 will be used with the flow set at 60 L/min
89387870|NCT06228560|Experimental|LP-003 group 1|Participants received LP-003 subcutaneously during the 24-week treatment period
89387871|NCT06228560|Experimental|LP-003 group 2|Participants received LP-003 subcutaneously during the 24-week treatment period
89387872|NCT06228560|Experimental|LP-003 group 3|Participants received LP-003 subcutaneously during the 24-week treatment period
88863290|NCT05798520|Experimental|Part 1: BIIB091 Low Dose + Matching Placebo for DRF|Participants will receive BIIB091 low dose and matching placebo for DRF, orally, for up to 48 weeks.
88863291|NCT05798520|Active Comparator|Part 1: DRF + Matching Placebo for BIIB091|Participants will receive DRF standard dose and matching placebo for BIIB091, orally, for up to 48 weeks.
88863292|NCT05798520|Experimental|Part 2: BIIB091 + DRF Standard Dose|Participants will receive selected dose of BIIB091 (based on Part 1 data) and DRF standard dose, orally, for up to 48 weeks.
88863293|NCT05798520|Experimental|Part 2: BIIB091 + DRF Low Dose|Participants will receive selected dose of BIIB091 (based on Part 1 data) and DRF low dose, orally, for up to 48 weeks.
88863294|NCT05798520|Active Comparator|Part 2: DRF + Matching Placebo for BIIB091|Participants will receive DRF standard dose and matching placebo for BIIB091, orally, for up to 48 weeks.
89387873|NCT06228560|Active Comparator|Omalizumab|Participants received omalizumab 300 mg subcutaneously every 4 weeks during the 24-week treatment period
89387874|NCT06228560|Placebo Comparator|Placebo|Participants received placebo subcutaneously every 4 weeks during the 24-week treatment period
88863295|NCT05795426||Female volleyball players|Female volleyball players were included in the first group.
88863296|NCT05795426||Male volleyball players|Male volleyball players are included in the second group
88863297|NCT05787834|Active Comparator|Group I (low resistance RMT Group)|Patients receive usual care for 12 weeks on study and a Respiratory Muscle training Device with small breathing resistance
89387875|NCT06228248||medical worker|Medical workers working in clinical settings, including nurses, doctors, and Health care worker.
89387876|NCT06228248||health population|Healthy individuals who do not engage in medical work
89387877|NCT06227780|Experimental|Fragile X Syndrome|Fragile X Syndrome with full FMR1 mutations (>200 CGG repeats; at least partial FMR1 gene methylation)
89387878|NCT06227780|Active Comparator|Autism Spectrum Disorder Controls|Age and sex-matched with FXS cohort
89387879|NCT06227780|Active Comparator|Typically Developing Controls|Subjects with neither disorder who have met normal developmental milestones
89387880|NCT06226818||experimental group|Women cared for in a women's centre
89387881|NCT06226818||comparator group|Women in a health centre or family planning centre.
89387882|NCT06225713|Experimental|intervention group|In intervention group, participants will receive the whole peri-renal fat modification therapy (including peri-renal fat ultrasonic measurement and localization, focused ultrasound treatment parameters setting and initiating)
89387883|NCT06225713|Sham Comparator|sham-control group|In sham control group, participants will receive the sham control therapy (including peri-renal fat ultrasonic measurement and localization, focused ultrasound treatment parameters setting), however, without initiating the focused ultrasound equipment.
89387884|NCT06225648|Experimental|Threonine in Adults > 60|Threonine: all subjects will receive up to 7 threonine test levels, in random order.
89387885|NCT06223971|Experimental|Patients with history of COVID-19 infection and still experiencing symptoms (Long-COVID)|Participants with a diagnosis of Long- COVID will receive a single dose of [11C]CPPC (370 megabecquerel (MBq) (X±1 mCi)) intravenously and subsequent positron emission tomography (PET) scan.
89387886|NCT06223971|Experimental|Healthy Participants with history of COVID-19 infection but not experiencing any symptoms.|Healthy participants (without any history of post-COVID symptoms) will receive a single dose of [11C]CPPC (370 megabecquerel (MBq) (X±1 mCi)) intravenously and subsequent positron emission tomography (PET) scan.
88863298|NCT05787834|Experimental|Group II (Moderate to highter resistance RMT)|Patients undergo RMT using a respiratory muscle training device with moderate to higher breathing resistance for 12 weeks on study.
88863299|NCT05786482|No Intervention|Waitlist Control|
88863300|NCT05786482|Experimental|Online Program|Online program (mindful movement, meditation, breathwork, psychology-based coping skills program)
89387887|NCT06222099|Active Comparator|Standard Care (Control)|Device installed at home, capturing data without sending health alerts or measurement data to RPMC.
89387888|NCT06222099|Experimental|Direct-to-patient health alerts|Device provides direct health alerts to patients/family, but does not transmit measurement data to RPMC.
89387889|NCT06222099|Experimental|RPMC Care Only|Device transmits measurement data to RPMC without direct patient alerts.
89387890|NCT06222099|Experimental|RPMC + Direct-to-Patient Health Alerts|Device sends measurement data to RPMC and provides direct alerts to patients/family.
89387891|NCT06220864|Experimental|Dose Escalation|
89387892|NCT06220864|Experimental|Dose Expansion|
89387893|NCT06210035|Experimental|Belly-focus concentration meditation|Participants will engage in concentration meditation for 40 minutes every day for a week while recording heart rate. They will focus on the sensations around the belly.
89387894|NCT06210035|Experimental|Belly-focus concentration meditation with slow breathing|Participants will engage in concentration meditation and slow breathing for 40 minutes every day for a week while recording heart rate. They will focus on the sensations around the belly while breathing slowly.
89387895|NCT06210035|No Intervention|No-intervention control|Participants will rest quietly for 40 minutes every day for a week while recording heart rate.
89387896|NCT06201754||ICU patients|We will include all ICU inpatients who undergo bedside air quality monitoring
89185198|NCT02569281|Active Comparator|Eccentric exercise|Patients will receive one weekly session for 5 weeks including best-evidence manual therapy and an eccentric loading exercise program for the shoulder musculature, particularly the supraspinatus and infraspinatus muscles. The exercise program will be asked to be performed on an individual basis twice every day. The therapeutic protocol will be applied for 5 weeks.
89387897|NCT06199349|Experimental|GMDTC group|The subjects assigned to the GMDTC group will be administered once every morning after eating a standard breakfast on D1-D3 and D8-D10.
89387898|NCT06199349|Placebo Comparator|Normal saline group|The subjects assigned to the placebo group will be administered once every morning after eating a standard breakfast on D1-D3 and D8-D10.
89387899|NCT06196528|Experimental|WristArt implantation|
89387900|NCT06194318|Experimental|group 1 (SCB-1019 90µg with Alum; young adults)|4 young adults (18-59 years old) will receive low dose SCB-1019 (90µg, with Alum) at Day 1
89387901|NCT06194318|Placebo Comparator|group 2 (Placebo; young adults)|2 young adults (18-59 years old) will receive Placebo at Day 1
89387902|NCT06194318|Experimental|group 3 (SCB-1019 360µg with Alum; young adults)|4 young adults (18-59 years old) will receive high dose SCB-1019 (360µg, with Alum) at Day 1
89387903|NCT06194318|Placebo Comparator|group 4 (Placebo; young adults)|2 young adults (18-59 years old) will receive Placebo at Day 1
89387904|NCT06194318|Experimental|group 5 (SCB-1019 90µg without Alum; older adults)|10 older adults (60-85 years old) will receive low dose SCB-1019 (90µg, without Alum) at Day 1
89387905|NCT06194318|Experimental|group 6 (SCB-1019 90µg with Alum; older adults)|10 older adults (60-85 years old) will receive low dose SCB-1019 (90µg, with Alum) at Day 1
89387906|NCT06194318|Placebo Comparator|group 7 (Placebo; older adults)|4 older adults (60-85 years old) will receive Placebo at Day 1
89387907|NCT06194318|Experimental|group 8 (SCB-1019 360µg without Alum; older adults)|10 older adults (60-85 years old) will receive high dose SCB-1019 (360µg, without Alum) at Day 1
89387908|NCT06194318|Experimental|group 9 (SCB-1019 360µg with Alum; older adults)|10 older adults (60-85 years old) will receive high dose SCB-1019 (360µg, with Alum) at Day 1
89387909|NCT06194318|Placebo Comparator|group 10 (Placebo; older adults)|4 older adults (60-85 years old) will receive Placebo at Day 1
89387910|NCT06192342||Patients with acute neurological injury|Patients ≥ 16 years of age with ANI requiring mechanical ventilation for neurological causes, without baseline lung injury, defined by a PaO2/FiO2 ≥ 300 and with a normal chest x-ray
89387911|NCT06184126|Experimental|Active Immersive Virtual Reality|Patient with sickle cell disease experiencing acute vaso-occlusive crisis randomized to this arm will participate in an active immersive application on the virtual reality headset with hand-held controllers. The active immersive application will allow the user to interact directly with the application and move through the virtual environment .The patient will be able to use the active immersive application on the device for a maximum of two hours.
89387912|NCT06184126|Experimental|Passive Immersive Virtual Reality|Patient with sickle cell disease experiencing acute vaso-occlusive crisis randomized to this arm will participate in a passive immersive application on the virtual reality headset with hand-held controllers. The passive immersive application will not allow the user to interact directly with the application or move through the virtual environment .The patient will be able to use the passive immersive application on the device for a maximum of two hours.
89387913|NCT06184126|Placebo Comparator|Blindfold and Ear Plugs|Patient with sickle cell disease experiencing acute vaso-occlusive crisis randomized to this arm will wear a blindfold and ear plugs. The patient will be able to remain blindfolded and earplugs for a maximum of two hours.
89387914|NCT06181123||healthy group|Demographic data, clinical characteristics, exercise capacity (6 MWT, 3 min. Step test), functionality (vertical jump test, functional reach test), respiratory parameters (Respiratory muscle strength, pulmonary function test, MMRC scale), physical activity level (IPAQ, short form).
89387915|NCT06181123||Patient group|Demographic data, clinical characteristics, exercise capacity (6 MWT, 3 min. Step test), functionality (vertical jump test, functional reach test), respiratory parameters (Respiratory muscle strength, pulmonary function test, MMRC scale), physical activity level (IPAQ, short form).
89387916|NCT06178588|Experimental|Treatment (Sacituzumab govitecan)|Patients receive sacituzumab govitecan IV over 1-3 hours on days 1 and 8 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo tumor biopsy, PET/CT or MRI scans, and blood sample collection throughout the study.
89387917|NCT06175312|Experimental|Manipulations of graded feature salience (Expt 1.1)|Participants will view stimuli made salient based on feature contrast in one feature dimensions (color or motion direction; or checkerboard luminance contrast). The degree to which a location is salient will be manipulated based on the feature contrast across multiple values
89387918|NCT06174220|Active Comparator|Tideglusib|Randomization to Tideglusib 1g po daily or matching placebo
89387919|NCT06174220|Placebo Comparator|Placebo|Randomization to matching placebo 1g po daily
89387920|NCT06166017||Full-arch implant-supported restorations for fully edentulous patients|No interventions will be administered. Instead, clinical parameters will be collected (see detailed description) as well as radiographs of the implants.
89387921|NCT06157151|Experimental|PRGN-2009 plus Pembrolizumab|PRGN-2009 at a dose of 5 x 10^11 PU q3W for 3 administrations, then q6w, plus Pembrolizumab, 400mg q6w
88863301|NCT05786482|Experimental|Online Program + Weekly Check-ins|Online program (mindful movement, meditation, breathwork, psychology-based coping skills program) + brief 1-to-1 weekly check-ins with a study team member
89387922|NCT06157151|Active Comparator|Pembrolizumab alone|Pembrolizumab, 400mg q6w
89387923|NCT06157008||healthy volunteers|
89387924|NCT06157008||patients with prolonged disorders of consciousness|
89387925|NCT06156072||Patient requiring blood culture|After the request of treating physician of blood culture, each patient deemed eligible, will undergo the prescirbed couple of peripheral blood samples. The first one will be done with the classical blind technique, while the second one with ultrasound guidance.
89387926|NCT06155721|Experimental|Virtual Reality Cognitive Stimulation Program|"Participants with MCI undergo 8 VR sessions, using Oculus Quest 2 headsets for immersive cognitive exercises. Activities include a Supermarket Shopping Task for memory, a Payment Task for cognitive flexibility, and a Recipe Sequencing Task for problem-solving. Additionally, 360-degree videos with visuo-verbal stimulation are used to engage attention and episodic memory, monitored by therapists.~The investigators employ Oculus Quest 2 VR headsets with hand tracking technology to provide a seamless and immersive experience, especially beneficial for participants with Mild Cognitive Impairment (MCI)."
89387927|NCT06155149|Experimental|EXPERIMENTAL GROUP|All of the families constituting the sample of the study (30 mobile application-study group) will be told about burn prevention and first aid practices with a training (powerpoint presentation) prepared by the executive researcher in line with the literature and their questions will be answered. Then, the training to be given with the mobile application will be downloaded to the phones of the families in the experimental group and the training will continue through the application.
89387928|NCT06155149|Sham Comparator|CONTROL GROUP|All of the families constituting the sample of the study (30 control group) will be told about burn prevention and first aid practices with a training (powerpoint presentation) prepared by the executive researcher in line with the literature and their questions will be answered.
88863302|NCT05786131|Experimental|culprit-lesion-only revascularization|Patients will receive optimal medical therapy without further revascularization of non-culprit lesions (neither during index hospitalization nor during follow-up). Angina pectoris will be treated medically as recommended in the chronic coronary syndrome guidelines. Revascularization of non-culprit lesions will only be permitted if at least one bailout criteria is met.
88863303|NCT05786131|Experimental|multivessel complete revascularization|Patients will receive complete revascularization of all angiographically significant non-culprit lesions, either during the index procedure, the index hospitalization, or staged within 45 days after PCI of the culprit lesion.
88863304|NCT05780879|Experimental|Venetoclax + FLAG or CLAG induction chemotherapy|Induction chemotherapy with FLAG starting on day 1 and venetoclax given on days 3-16. The G-CSF component of FLAG will continue until count recovery (ANC at least > 1000). FLAG dosing will be standard and uniform for all patients and venetoclax dosing will be determined according to institutional guidelines based on the prophylactic antifungal therapy chosen for use during induction therapy. Given the national shortage of Fludarabine, Cladrabine (5mg/m2/day IV over 2 hours) has been substituted (CLAG) with similar toxicity profile.
88863305|NCT05777096||registered|"Paragliding pilots over the age of 18. Registered at the Fédération Française de Vol Libre (FFVL) in the year 2022 and/or 2023 Paragliding in the year 2022 and/or 2023"
88863306|NCT05770895|Experimental|Cohort 1: GS-2829 Dose A or Placebo|Healthy participants will receive GS-2829 Dose A or placebo for GS-2829.
88863307|NCT05770895|Experimental|Cohort 2: GS-6779 Dose B or Placebo|Healthy participants will receive GS-6779 Dose B or placebo for GS-6779.
88863308|NCT05770895|Experimental|Cohort 3: GS-2829 Dose A or Placebo + GS-6779 Dose B or Placebo|Healthy participants will receive GS-2829 Dose A or placebo for GS-2829 and GS-6779 Dose B or placebo for GS-6779.
88863309|NCT05770895|Experimental|Cohort 4: GS-2829 Dose C or Placebo + GS-6779 Dose D or Placebo|Healthy participants will receive GS-2829 Dose C or placebo for GS-2829 and GS-6779 Dose D or placebo for GS-6779.
88863310|NCT05770895|Experimental|Cohort 5: GS-2829 Dose A or Placebo + GS-6779 Dose B or Placebo|Participants with Chronic Hepatitis B (CHB) who are virally suppressed will receive GS-2829 Dose A or placebo for GS-2829 and GS-6779 Dose B or placebo for GS-6779.
88863311|NCT05770895|Experimental|Cohort 6: GS-2829 Dose C or Placebo + GS-6779 Dose D or Placebo|Participants with Chronic Hepatitis B (CHB) who are virally suppressed will receive GS-2829 Dose C or placebo for GS-2829 and GS-6779 Dose D or placebo for GS-6779.
88863312|NCT05770895|Experimental|Cohort 7: GS-2829 Dose C or Placebo + GS-6779 Dose D or Placebo|Participants with CHB who are virally suppressed will receive GS-2829 Dose C or placebo for GS-2829 and GS-6779 Dose D or placebo for GS-6779.
89387929|NCT06154265|Active Comparator|Default TEE|The TEE probe is placed after going under general anesthesia and a breathing tube is placed. TEE issued to take pictures of the heart before and after a CABG surgery. If randomized to this group, the TEE probe will remain in place throughout the surgery.
89387930|NCT06154265|Other|As-needed TEE|The TEE probe is placed only in situations where a surgeon requires information that can only be obtained by ultrasound imaging of the heart.
89387931|NCT06153290|Experimental|Genuine/real|15 participants receiving genuine/real chiropractic adjustment
89387932|NCT06153290|Sham Comparator|Simulated/sham|"15 participants receiving simulated/sham adjustment"
89387933|NCT06153199|Active Comparator|Self-management|Participants will review short video modules on pain self-management without medication and ergonomic work adjustment Participants will be asked to select 1 self-management option and 1 ergonomic option to use for 10 weeks
88863313|NCT05770895|Experimental|Cohort 8: GS-2829 Dose C or Placebo + GS-6779 Dose D or Placebo|Healthy participants will receive GS-2829 Dose C or placebo for GS-2829 and GS-6779 Dose D or placebo for GS-6779.
88863314|NCT05769855|Experimental|HR18034|
89387934|NCT06153199|Experimental|Self-management and Guided Participatory Ergonomics|Participants will review short video modules on pain self-management without medication and ergonomic work adjustment Supervisors in these work settings will also discuss options to adjust work processes and ways to support workers implement ergonomic strategies Participants will be asked to select 1 self-management option and 1 ergonomic option to use for 10 weeks. This group will receive options guided by their self-identified most difficult work activities due to pain and options that they are not using regularly.
89387935|NCT06146504|Experimental|CanXida Supplement|"All participants will adhere to the following treatment regime:~Day 1-7: 1 tablet per day Day 8-22: 2 tablets per day Day 23- 84: 3 tablets per day~The product should always be taken with the first meal of the day."
88863315|NCT05769855|Active Comparator|ropivacaine HCl|
88863316|NCT05769855|Placebo Comparator|Sodium Chloride Physiological Solution|
89387936|NCT06146504|Placebo Comparator|Placebo|"All participants will adhere to the following treatment regime:~Day 1-7: 1 tablet per day Day 8-22: 2 tablets per day Day 23- 84: 3 tablets per day~The product should always be taken with the first meal of the day."
89387937|NCT06146452||Pediatric palliative care|pediatric palliative care patients hospitalized in the Pediatric Palliative Care Clinic
89387938|NCT06144294|Experimental|Group 2 - Cohort 2a|Healthy women or transgender men 18-50 years of age, <6 months postpartum
89387939|NCT06144294|Experimental|Group 2 - Cohort 2b|Women and transgender men 18-50 years of age, <6 months postpartum, meeting criteria for a major depressive episode in the postpartum period on the MINI
89387940|NCT06144294|Experimental|Group 2 - Cohort 2c|Healthy adults of both sexes 18-50 years of age
89387941|NCT06144294|Experimental|Group 2 - Cohort 2d|Adults of both sexes 18-50 years of age meeting criteria for an episode of major depression or generalized anxiety disorder on the MINI
89387942|NCT06144294|Experimental|Group 3 - Cohort 2a|Healthy women or transgender men 18-50 years of age, <6 months postpartum
89387943|NCT06144294|Experimental|Group 3 - Cohort 2b|Women and transgender men 18-50 years of age, <6 months postpartum, meeting criteria for a major depressive episode in the postpartum period on the MINI
89387944|NCT06144294|Experimental|Group 3 - Cohort 2c|Healthy adults of both sexes 18-50 years of age
89387945|NCT06144294|Experimental|Group 3 - Cohort 2d|Adults of both sexes 18-50 years of age meeting criteria for an episode of major depression or generalized anxiety disorder on the MINI
89387946|NCT06143228||Whiplash Associated Disorder with Directional Preference|Movements that reduce, abolish, or centralize the patient symptoms are recognized as a directional preference. Directional preference is ultimately used to guide the treatment of neck pain related to derangement syndrome.If the patient neck impairments are related to a Derangement syndrome, the patient will be instructed to perform the movements in the identified directional preference every 2-3 hours for 10-12 repetitions or to hold the cervical spine in a sustained position for 1-2 minutes. If the response to the intervention plateaus, the exercise intensity is progressed through the application of patient self-overpressure. If warranted clinician overpressure and mobilization may be utilized as a progression beyond patient generated forces. to achieve a favorable response.
89387947|NCT06143228||Whiplash Associated Disorder without Direction Preference|Patients with WADs that do not demonstrate directional preference will be managed based on the published Clinical Practice Guidelines (2017) for management of WADs with related movement coordination deficits. Treatment and progression of care for this group will be determined by the treating therapist but will consist of education, multimodal care inclusive of therapeutic exercise, mobilization, aerobic exercise, flexibility, and postural education. In addition, if the patient symptoms are chronic in nature treatment may include exercise progression, education and reassurance, transcutaneous nerve electrical stimulation, and cognitive behavioral therapy are recommended.
89387948|NCT06143033|Experimental|DIME Beauty Luminosity Eye Serum|Participants will use the serum twice daily after their morning and evening skincare routine (i.e., after cleansing, and applying facial serums and moisturizers), but before the application of sunscreen.
89387949|NCT06141993||Men with progressive metastatic castration resistant prostate cancer (mCRPC)|Men with progressive metastatic castration resistant prostate cancer (mCRPC) and starting standard of care therapy with a second androgen receptor (AR) inhibitor (typically enzalutamide or abiraterone acetate) will have blood collected for circulating tumor cell (CTC) assessments and other research assessments at baseline, 12 weeks and upon disease progression.
89387950|NCT06140563|Experimental|Normal anticoagulation dosing|Patients are dialyzed during three consecutive hemodialysis sessions with an FX800 Cordiax dialyzer, blood flow of 300mL/min, dialysate flow of 500mL/min and ultrafiltration according to the needs of the patient. At the start of the dialysis session, the normal amount of anticoagulation is administered.
88863317|NCT05766774|Experimental|Low-added sugar, high-fat diet Arm|Patients will receive a low-added sugar, high-fat diet for 8 weeks. Study menus will be designed by registered dietitians using the Nutrient Database System for Research (NDSR) software program with a 2-wk rotation.Total kcal provided will be individually tailored to maintain body weight and adjusted throughout as needed. All foods (including snacks and drinks) for 8 wks will be delivered to participants' homes. Menus will be designed so that food will be delivered to subjects' homes every 3-4 days. It will be expected that participants consume only the foods provided by the study.
88863318|NCT05766774|Active Comparator|Typical CF diet Arm|Patients will receive a high-added sugar, high-fat CF diet for 8 weeks. Study menus will be designed by registered dietitians using the Nutrient Database System for Research (NDSR) software program with a 2-wk rotation. Total kcal provided will be individually tailored to maintain body weight and adjusted throughout as needed. All foods (including snacks and drinks) for 8 wks will be delivered to participants' homes. Menus will be designed so that food will be delivered to subjects' homes every 3-4 days. It will be expected that participants consume only the foods provided by the study.
89387951|NCT06140563|Experimental|Reduced anticoagulation dosing|Patients are dialyzed during three consecutive hemodialysis sessions with an FX800 Cordiax dialyzer, blood flow of 300mL/min, dialysate flow of 500mL/min and ultrafiltration according to the needs of the patient. At the start of the dialysis session, only one quarter of the normal amount of anticoagulation is administered.
89387952|NCT06136897|Experimental|Treatment (pertuzumab, trastuzumab)|Patients receive pertuzumab IV over 30-60 minutes and trastuzumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients also undergo radiologic evaluation throughout the trial, ECHO at screening and end of treatment, and biopsy and collection of blood samples on trial and at end of treatment.
89185199|NCT00736827||Patients with non-septic shock|Postoperative/posttraumatic surgical critically ill patients with non-septic shock with threatening acute renal failure
89185200|NCT00736827||Patients with septic shock|Postoperative/posttraumatic surgical critically ill patients with septic shock with threatening acute renal failure
89387953|NCT06134466|Experimental|Liquid Formula|Liquid Formula (Extensively hydrolyzed cow's milk protein infant formula) - 2.8 g protein/100 kcal
89387954|NCT06130371||major depressive disorder group|female MDD patients with moderate levels of depressive symptoms, mostly recruited from psychotherapist offices and the outpatient clinic of the university.
89387955|NCT06130371||premenstrual dysphoric disorder group|female participants suffering from premenstrual dysphoric disorder, as confirmed by prospective ratings of premenstrual symptoms via an app during two consecutive menstrual cycles.
89387956|NCT06130371||healthy controls|healthy controls
89387957|NCT06125912|Experimental|Test Arm|All participants will use both the test product and the active control. Participants will use the creams in the evening, applying the TBT Cream to the right side of the face, and the positive control on the left side of the face.
89387958|NCT06125730|Experimental|DIME Beauty Eyelash Boost Serum|Participants will use the eyelash serum twice daily in the morning and evening. The serum will be applied to the base of the top and bottom lashes.
89185201|NCT02202681|Experimental|OFDI Capsule Imaging|Subject will swallow the OFDI Capsule and imaging will be performed using the OFDI system.
89387959|NCT06124482|Experimental|Knee replacement|Implantation of FHK-CK prosthesis either for a complex primary arthroplasty or for revision intend
88863319|NCT05766254|Experimental|Active TMS|Participants in the active condition will receive repetitive TMS (rTMS), delivered at 110% of participants' resting motor threshold at 10 Hz continuously over the predefined prefrontal target for a total of 1000 pulses. Within each of the two TMS sessions, two targets will be stimulated.
88863320|NCT05766254|Sham Comparator|Sham TMS|Identical parameters will be applied to the SHAM group with the exception that the TMS coil will be flipped 180º to mimic auditory stimulation.
88863321|NCT05765175|Active Comparator|Repeat catheter ablation (CA)|
88863322|NCT05765175|Experimental|Varian Cardiac Radioablation (CRA)|
88863323|NCT05761561|Experimental|Exercise and medical nutrition|Over the intervention period (18 weeks on average - dependent on length of chemotherapy) women in the intervention arm will receive weekly counseling sessions, the study dietitian and exercise trainer will each conduct weekly sessions to assist the participants in achieving the diet and exercise study goals.
89185202|NCT02568813|Experimental|Scales passation|
89185203|NCT04065633|Experimental|Part A sequence 1|
89185204|NCT04065633|Experimental|Part A sequence 2|
89185205|NCT04065633|Experimental|Part B sequence 1|
89387960|NCT06123130|Experimental|Single Arm|The study is a prospective single-arm multicenter clinical trial. Adult patients will be consented and enrolled in an outpatient cardiology office or Arrhythmia Clinic.
89387961|NCT06121661|Experimental|APPRAISE cases|Trauma patients for which APPRAISE system was used
89387962|NCT06118723||Supramaximal resection|Supramaximal resection: maximal resection of the contrast-enhancing and non-contrast-enhancing part of the tumor (FLAIRectomy)
88863324|NCT05761561|No Intervention|Control|Contact limited to study assessments.
88863325|NCT05755906|Experimental|BFF MDI 160/9.6 μg BID (320/19.2μg/day)|Budesonide/ Formoterol Fumarate (BFF) metered-dose inhaler (MDI), BDI (320/19.2μg/day)
88863326|NCT05755906|Active Comparator|BD MDI 160 μg BID (320 μg/day)|Budesonide (BD) metered-dose inhaler (MDI), 160 μg BID (320 μg/day)
89185206|NCT04065633|Experimental|Part B sequence 2|
89185207|NCT00731835|No Intervention|Group I|1. Wound Care (group 1)--Best standard wound care with aggressive debridement
89185208|NCT00731835|Active Comparator|Group 2|"2. Endovascular Intervention + Wound Care (group 2)--Best standard wound care in combination with endovascular revascularization~Endovascular revascularization is the intervention"
89185209|NCT00736983|Active Comparator|1|Adalimumab
89185210|NCT00736983|Placebo Comparator|2|ciprofloxacin
89185211|NCT00713349|Other|1|Xenaderm Vehicle
89185212|NCT00713349|Placebo Comparator|2|Placebo Comparator
89387963|NCT06118723||Maximal safe resection|Maximal safe resection of the contrast-enhancing part of the tumor
89387964|NCT06114784||Severe pneumonia|Definition of severe pneumonia: New infection that meets one of the following definitions: the patient receives mechanical ventilation (invasive or non-invasive) due to acute respiratory failure, with a PEEP level of 5cm or above; The patient receives high flow oxygen therapy with a FiO2 of 50% or more and a PaO2: FiO2 ratio of less than 300; The patient receives oxygen treatment with a partial respiration mask with an air storage bag, provided that PaO2 is lower than the pre-specified indicator.
89387965|NCT06113003|Experimental|Probiotic and Prebiotic Fiber|
89185213|NCT00729261|Experimental|armA I|Patients remain intubated until the patients Glasgow coma score improves to greater than 8.
89185214|NCT00729261|Experimental|arm 2|Patients that meet standard airway and ventilatory criteria for extubation but have a Glasgow coma score of less than or equal to 8 are immediately extubated.
89387966|NCT06110780|Active Comparator|Acupuncture group|"The conductor of the study, an acupuncturist experienced in electroacupuncture, will apply electroacupuncture to the PC 6, LU7, LU2 points for 30 minutes on the day before surgery and on the day of surgery.~The placement of the needles will be applied to a depth of 1-2 cm, depending on the thickness of the local tissues, according to Traditional Chinese Medicine standards.~The EA parameter will be set to a frequency of 2 HZ/100 HZ at a current that the patients' tolerance is best within the range of 0.5 mA to 1.2 mA.~The patient will be electrically stimulated for 30 minutes until the patient feels Teh Chi - heaviness, numbness and swelling."
89387967|NCT06110780|No Intervention|Control group|Control group
88863327|NCT05746494|Experimental|Active anodal tDCS first, then Sham tDCS|Active anodal tDCS (40 minutes; divided into two 20-minutes sessions) followed by behavioral testing; Washout (about 1 week); sham stimulation (40 minutes; divided into two 20-minutes sessions) followed by behavioral testing.
88863328|NCT05746494|Sham Comparator|Sham tDCS first, then Active anodal tDCS|Sham tDCS (40 minutes; divided into two 20-minutes sessions) followed by behavioral testing; Washout (about 1 week); Active anodal tDCS (40 minutes; divided into two 20-minutes sessions) followed by behavioral testing Intervention.
88863329|NCT05745038|Experimental|Arm 1 - SONATA Intervention|
88863330|NCT05744128|Other|Single Arm|"Eligible subjects will receive up to two zirconium Zr 89 crefmirlimab berdoxam PET scans (up to 1.0 mCi ± 20% at 1.5 mg API per scan, for a total of up to 2.0 mCi ± 20% and 3.0 mg API) as an IV infusion or slow bolus injection.~PET/CT imaging is performed 24hrs ± 3hrs post administration. The two scans are performed a minimum 2 weeks apart."
88863331|NCT05743673||Validation Cohort|Older subjects (>60 years old) presenting for moderate to high-risk surgical procedure with reported subjective metabolic equivalents of >4 METS and with a score of <2 on the revised cardiac risk index (RCRI) undergoing submaximal exercise testing.
88863332|NCT05742438|Active Comparator|Lidocaine group|A loading dose of 1.5mg/kg lidocaine will be infused for 10 minutes during anesthesia induction. During the surgery and post-anaesthesia care unit (PACU) stay, 1.5 mg/kg/h of lidocaine were continuously infused until the patient was transferred to the general ward.
88863333|NCT05742438|Active Comparator|Dexmedetomidine group|A loading dose of 0.3mcg/kg dexmedetomidine will be infused for 10 minutes during anesthesia induction. During the surgery and PACU stay, 0.3 mcg/kg/h of dexmedetomidine were continuously infused until the patient was transferred to the general ward.
89185215|NCT00731913||1|Subjects with skin lesions requiring surgical excision and repair. One half of the each wound received Monocryl suture and the other half received Monosyn suture.
89185216|NCT00731913||2|Subjects with skin lesions requiring surgical excision and repair. One half of the each wound received Monocryl suture and the other half received Monosyn suture.
89185217|NCT00731991|Active Comparator|ART|ART to the levator scapulae.
89185218|NCT00731991|Active Comparator|PNF|PNF to the levator scapulae.
89387968|NCT06101641|Other|EXPERIMENTAL AND CONTROL GROUP|Participants who meet the inclusion criteria of the study will be informed about the research by the researchers and will be included in the study on a voluntary basis and their written permissions will be obtained. Firstly, the personal information of the participants will be recorded in the data collection form. The middle finger of the left hand of each participant will be the experimental group and the little finger will be the control group. After the shellac nail polish is applied to the middle finger of the left hand, SpO2 and pulse values will be measured by pulse oximetry from the left hand middle finger and little finger of the participant and recorded in the data form. At the end of the study, SpO2 and pulse values before and after the shellac nail polish application will be compared.
89387969|NCT06097481|Experimental|NICI-HF|This arm will receive the NICI-HF intervention with regular emails from a therapist for 3 months.
89387970|NCT06097481|Placebo Comparator|Attention control|This arm will receive regular emails with information about heart failure for 3 months.
89387971|NCT06088134||Non-recurrence group|
89387972|NCT06088134||Recurrence group|
89185219|NCT00731991|Placebo Comparator|Control|No treatment will be given. The participant will sit in the treatment room with the doctor for 4 minutes.
89185220|NCT00729339|Active Comparator|1|lansoprazole plus mosapride for the first month, and followed by lansoprazole plus placebo for the second month
89185221|NCT00729339|Active Comparator|2|lansoprazole plus placebo for the first month, and lansoprazole plus mosapride for the second month
88863334|NCT05742438|Active Comparator|Intrathecal Morphine group|200~300mcg of Intrathecal morphine will be injected at the anesthesia induction for colorectal surgery.
88863335|NCT05742373|Experimental|Fasted exercise|Exercise training in the fasted state
88863336|NCT05742373|Active Comparator|Fed exercise|Exercise training in the fed state
88863337|NCT05742373|No Intervention|Control|No exercise training
88863338|NCT05734391||inpatients|Individuals in inpatient wards
88863339|NCT05734196|Experimental|INZ-701|"The first 2 study participants will receive a single 0.2 mg/kg dose of INZ-701 on Day 1. On Day 8, they will commence receiving Dose Level A (0.2 mg/kg twice weekly). After the second study participant completes Day 32, the DRC will perform a cumulative review of safety and PK/PD data and will make dosing recommendations, for example, modifying the dose of the ongoing study participants and/or changing the starting dose for future participants to Dose Levels B, C, D, E, or F. Each study participant's safety and PK/PD data will also be reviewed by the DRC during its quarterly review, based upon which the participant's dose may be modified to Dose Levels B, C, D, E, or F as specified in the protocol.~Dose Level A: 0.2 mg/kg twice weekly~Dose Level B: 0.6 mg/kg twice weekly~Dose Level C: 0.2 mg/kg once weekly~Dose Level D: 0.6 mg/kg once weekly~Dose Level E: 1.8 mg/kg once weekly~Dose Level F: 3.0 mg/kg once weekly"
88863340|NCT05733923|Active Comparator|Traditional excavation|Mechanical caries Removal with low-speed Carbide Burs on a micromotor handpiece with air and water cooling.
88863341|NCT05733923|Experimental|Sodium Hypochlorite CMCR|chemomechanical caries removal using Sodium Hypochlorite Gel 2.5%.
88863342|NCT05733923|Experimental|Papacarie duo CMCR|chemomechanical caries removal using Papacarie duo.
88863343|NCT05733923|Experimental|Selecti-solve CMCR|chemomechanical caries removal using Selecti-solve Gel.
89387973|NCT06083259|Active Comparator|gelatin sponge + cyanoacrylate + suspending sutures|After administration of local anesthesia (2% articaine hydrochloride with epinephrine 1:100,000), palatal thickness will be measured by perpendicularly inserting a Michigan-O periodontal probe from the corners of the rectangular donor area. Epithelialized gingival graft will be harvested. After a rectangular-shaped initial incision, a graft with 1-1.5 mm thickness will be harvested approximately 1.5 to 3 mm away from the gingival margins of the upper teeth. The donor site will be closed with a gelatin sponge + cyanoacrylate + suspending sutures.
88863344|NCT05733923|Experimental|Brix3000 CMCR|chemomechanical caries removal using Brix3000.
89185222|NCT00737139|Active Comparator|1|Intra-articular Injection of Marcaine/Epinephrine
89185223|NCT00737139|Active Comparator|2|Intra-articular Injection of Marcaine alone
89185224|NCT00732147|Placebo Comparator|2|Type 2 diabetes patients will receive placebo with 3 meals in experimental period.
89387974|NCT06083259|Active Comparator|gelatin sponge + cyanoacrylate|After local anesthesia (2% articaine hydrochloride with epinephrine 1:100,000) administration, palatal thickness will be measured by perpendicularly inserting a Michigan-O periodontal probe from the corners of the rectangular donor area and the mean value will be recorded as palatal tissue thickness. The epithelialized gingival graft will be harvested using 15 knives. After a rectangular-shaped initial incision, a graft with 1-1.5 mm thickness will be harvested approximately 1.5 to 3 mm away from the gingival margins of the upper teeth. The donor site will be closed with a gelatin sponge and cyanoacrylate without sutures.
89387975|NCT06079476|Experimental|Phase 4: Romosozumab|Participants will be dosed with two subcutaneous (SC) injections of romosozumab once a month for 12 months.
89387976|NCT06078501|Experimental|Misoprostol 400mcg buccal|Participants will take 400mcg buccal misoprostol 2-3 hours prior to their procedure
88819021|NCT05300997||Acute Ischaemic Stroke [N=300]|Acute Ischaemic stroke subjects presenting within 24 hours from symptom onset will have serial whole blood and saliva drawn a) in the emergency department (if available) or hospital within 24 hours of the onset of symptoms; b) 18 hours +/- 6 hours from symptom onset (if available); and c) 30 hours+/- 6 hours from symptom onset (if available).
88863345|NCT05726591|Experimental|Group A|12 weeks-study intervention
88863346|NCT05726591|No Intervention|Group B|12 weeks the control first.
88863347|NCT05725161|Experimental|Acceptance and commitment therapy (ACT) group|8 weekly ACT sessions individually guided by a trained coach through Zoom videoconferencing with psychoeducation materials provided
88863348|NCT05725161|Other|Wait-list control group with psychoeducation materials provided|Care as usual with psychoeducation materials provided during the study period and ACT sessions provided after the study period ends
89185225|NCT00732147|Experimental|1|Type 2 Diabetes patient will receive Pramlintide with 3 meals in experimental period.
89387977|NCT06078501|Placebo Comparator|Placebo|Participants will take a placebo buccally 2-3 hours prior to their procedure
89387978|NCT06078397|Experimental|the Remote Programming (RP) group|After implantation of DBS and train for RP in hospital, regularly receive RP instead of in-visit SP for parameter adjustment in 1, 3, 6 month after surgery
88819022|NCT05300997||Stroke of uncertain origin [N=45]|Stroke of uncertain origin subjects presenting within 24 hours from symptom onset will have serial whole blood and saliva drawn a) in the emergency department (if available) or hospital within 24 hours of the onset of symptoms; b) 18 hours +/- 6 hours from symptom onset (if available); and c) 30 hours+/- 6 hours from symptom onset (if available).
89185226|NCT00737217||Parkinson's disease|
89185227|NCT00737217||Normal Controls|
89185228|NCT00737295|Experimental|US|There will be no experimental or control group, rather each individual will act as his/her own control.
89185229|NCT02569671|Other|Immediate Placement - Test|Straumann Bone Level Tapered Implant - Immediate Placement - Implant is placed at the time of tooth extraction to replace a single tooth.
89387979|NCT06078397|Active Comparator|the Standard Programming (SP) group|After implantation of DBS, regularly receive SP for parameter adjustment in 1, 3, 6 month after surgery
89387980|NCT06077227|Experimental|Virtual Reality (VR) Intervention|Individuals undergoing virtual reality therapy intervention
89387981|NCT06077227|Sham Comparator|Matched Control|The matched controls will receive standard care without the VR intervention
89387982|NCT06071715|Experimental|Cryoneurolysis first, then optional sham crossover treatment|"Initial treatment: Cryoneurolysis of the major nerves of the thigh in the residual limb: The cryoneurolysis device will be triggered using 1 cycle of 5.5-minute argon activation followed by a 30-60 second defrost with helium (Varian) or 2 cycles of 2-minute gas activation with an active probe separated by a 30-60 second defrost (Epimed). For active treatment, the gas will be deployed to the probe tip where a drop in temperature will result in cryoneurolysis.~Optional sham crossover treatment: Sham cryoneurolysis of the major nerves of the thigh in the residual limb: The cryoneurolysis device will be triggered using 1 cycle of 5.5-minute argon activation followed by a 30-60 second defrost period with helium (Varian) or 2 cycles of 2-minute gas activation with a sham probe separated by a 30-60 second defrost (Epimed). However, for sham treatment, the gas is NOT deployed to the probe tip and therefore there is NO drop in temperature with NO resulting cryoneurolysis."
89387983|NCT06071715|Experimental|Sham Comparator first, then optional cryoneurolysis treatment|"Initial treatment: Sham cryoneurolysis of the major nerves of the thigh in the residual limb: The cryoneurolysis device will be triggered using 1 cycle of 5.5-minute argon activation followed by a 30-60 second defrost period with helium (Varian) or 2 cycles of 2-minute gas activation with a sham probe separated by a 30-60 second defrost (Epimed). However, for sham treatment, the gas is NOT deployed to the probe tip and therefore there is NO drop in temperature with NO resulting cryoneurolysis.~Optional active crossover treatment: Cryoneurolysis of the major nerves of the thigh in the residual limb: The cryoneurolysis device will be triggered using 1 cycle of 5.5-minute argon activation followed by a 30-60 second defrost period with helium (Varian) or 2 cycles of 2-minute gas activation with an active probe separated by a 30-60 second defrost (Epimed). For active treatment, the gas will be deployed to the probe tip where a drop in temperature will result in cryoneurolysis."
89387984|NCT06071221|Experimental|Living Healthy educational program + Peer Coaching|
89387985|NCT06071221|Active Comparator|Living Healthy educational program|
89387986|NCT06068894|Experimental|"lactosamine-enriched humanized galacto-oligosaccharides (hGOS)"|The treatment will consist of 10-15 g/day of hGOS, which will be provided to participants as a powder that can be added to any non-alcoholic beverage. The intervention will last for 4 weeks since the research team has shown in adult individuals that a 4-wk period allows for the observation of changes to the gut microbiome. The study will end after the second time-point sample collection at 4 weeks.
88863349|NCT05723887|Experimental|Experimental (ABIP group)|The ABIP was created by the researchers in line with the literature and consisted of interventions that affect and increase prenatal attachment Gölbaşı et al., 2015; Güney & including perceiving /counting fetal movements, music therapy, preparation for the baby, writing notes/letters to the baby, watching images of the fetus/pregnancy. The program was completed in a total of five days, with one intervention per day. An ABIP kit, which contained the materials to be used by pregnant women during ABIP interventions, was provided to them by the researchers at the first meeting. ABIP intervention materials were included in the ABIP kit, using five different colored envelopes (Appendix 1). Pregnant women were also informed about the interventions and materials of ABIP by the researchers at the first meeting.
88863350|NCT05723887|No Intervention|control groups|No Intervention: Control group standard care group
89387987|NCT06068894|Experimental|galacto-oligosaccharides (GOS)|The treatment will consist of 10-15 g/day of GOS, which will be provided to participants as a powder that can be added to any non-alcoholic beverage. The intervention will last for 4 weeks since the research team has shown in adult individuals that a 4-wk period allows for the observation of changes to the gut microbiome. The study will end after the second time-point sample collection at 4 weeks.
89387988|NCT06068894|Placebo Comparator|Placebo|The placebo comparator treatment will consist of 10-15 g/day placebo powder, that can be added to any non-alcoholic beverage. The intervention will last for 4 weeks to mirror the treatment arms. The study will end after the second time-point sample collection at 4 weeks.
88863351|NCT05701722|No Intervention|Routine Care|Women with recurrent BV who are randomly assigned to the Routine Care (control) arm will undergo assessments at baseline, 12 weeks, and 24 weeks. They will be treated with appropriate antibiotics or antifungals in case of BV or yeast infection, respectively, but otherwise will not receive any treatment. They may engage in any vulvovaginal hygiene of their choosing except for using products made by Good Clean Love.
88863352|NCT05701722|Experimental|Flourish HEC|Women with recurrent BV who are randomly assigned to the Flourish HEC (intervention) arm will undergo assessments at baseline, 12 weeks, and 24 weeks. They will receive routine care as needed (see Routine Care arm). In addition, they will use the Flourish HEC Vaginal Care System regularly for the 24-week duration of the study. Briefly, they will use Balance intimate wash daily with regular bathing; BioNourish vaginal moisturizing gel every other day; and BiopHresh homeopathic vaginal suppository with probiotics every 3rd day. They will use no other products (except menstrual hygiene products) in the vulvovaginal area during the study.
88863353|NCT05701189|Experimental|Efgartigimod Alfa-Fcab|20mg/kg of Intravenous efgartigimod on days 1 and 5, with normal saline administered as placebo on days 2-4
88863354|NCT05701189|Active Comparator|Intravenous Immunoglobulin (IVIg)|0.4g/kg of IVIg daily for 5 days
88863355|NCT05698745||Cohort A (preclinical IBD)|asymptomatic patients with a new diagnosis of IBD during the colorectal cancer screening programme meeting all inclusion and none of the exclusion criteria (n=350).
88863356|NCT05698745||Cohort B (control)|new-onset symptomatic IBD (n=80) - patients with a symptomatic debut of IBD in the last 3 months, naïve to immunosuppressants and biologic agents.
89185230|NCT02569671|Other|Delayed Placement - Control|Straumann Bone Level Tapered Implant - Delayed Placement - Implant is placed after 16-18 weeks of healing to replace a single tooth.
89387989|NCT06068036|Experimental|Experimental group|Telehealth intervention involving the HEARTS technical package and the use of Smartwatch Mi Band 7® activity monitor. The HEARTS technical package presents the 5As brief intervention (Ask, Advise, Assess, Assist, Arrange) to promote physical activity participation. Participants will receive a physical activity monitor (as instructed in the HEARTS technical package) and will be monitored by telephone call, once a week, in order to reinforce successes and identify solutions to difficulties (as instructed in the HEARTS technical package) to practice physical activity. These individuals will undertake a 12-week intervention program. In the first week, individuals will perform the first four steps of the 5As brief intervention in person, where they will be instructed on how to use the physical activity monitor, they will receive a diary of regular physical activity practice, will be guided on how to fill it out, and will schedule the best times to receive the weekly telephone call.
89387990|NCT06068036|Active Comparator|Control group|Participants will undergo the same intervention as the experimental group, but will not receive the physical activity monitor (Smartwatch Mi Band 7®).
89387991|NCT06066619|Experimental|100% Cranberry Juice|100% Cranberry Juice will be 100% cranberry juice.
89387992|NCT06066619|Experimental|100% Cranberry Juice + 200 mg L-theanine|100% Cranberry Juice + 200 mg L-theanine will be 100% cranberry juice + L-theanine.
89185231|NCT02569515|Experimental|Epoetin Beta|Patients will be administered 3 times (X) 30 International unis per kilogram(IU/Kg body weight per week of eopetin beta subcurtaneously using the device RecoPen. The dosage could be increased every 4 weeks by 3 X20 IU/Kg.
89185232|NCT00737373|Experimental|1|FLOT
89387993|NCT06066619|Placebo Comparator|Placebo juice|Placebo juice that matches the appearance, taste, and calories of the treatment juices.
89387994|NCT06061809|Experimental|Pilot Combination Therapy|Participants will receive N-803 1 mg subcutaneously (SC), PD-L1 t-haNK (~2 × 10^9 cells/infusion) intravenously (IV), and Bevacizumab (10 mg/kg IV) combination therapy during 28-day cycles on days 1 and 15 of each cycle. Maximum treatment period is 76 weeks, 19 cycles.
88863357|NCT05698745||Cohort C (control)|healthy controls (n=20): patients with a normal screening colonoscopy, with no signs of IBD after a detailed evaluation of the ileum and colon, will be included.
88863358|NCT05696613|Experimental|Phase 3a Cohort 1|3 mg SNP-ACTH Gel sc injection 3 times per week
89387995|NCT06055855|Active Comparator|Traditional Arthrocentesis Group|
89387996|NCT06055855|Experimental|Surgery-Guided Arthrocentesis Group|
89387997|NCT06054282|Experimental|Intervention|"Patients and caregivers will use the Ready for Tonsillectomy mobile application on their mobile devices as they prepare for and recover from surgery, in addition to standard care. Individual families will receive a phone call for enrollment/verbal informed consent at least 2 weeks before the scheduled surgery, likely around the time of the clinic visit when surgery is scheduled. Participants assigned to the intervention arm will download the mobile application at this time. They will be able to access the application as often as desired in the weeks leading up to surgery and afterward."
89387998|NCT06054282|No Intervention|Control|Families will receive standard care (standard educational handouts and preoperative consults).
89387999|NCT06049589|Experimental|Coconut oil|"Participants will perform 10-minute vigorous full-mouth rinses once daily after night (2-minute brushing time) brushing. The amount of coconut oil used will be one teaspoon (5 ml). Each participant will be given a container with volume measurement markings. Patients will be provided with the same toothbrush and toothpaste for their dental hygiene 2 times a day. Participants will be asked not to use products containing xylitol, tea, coffee, systemic antibiotics, or topical fluoride during the study. Any participant who violates these rules will be excluded from the study.~Reevaluation and sampling will be done after 30 days."
88863359|NCT05696613|Experimental|Phase 3a Cohort 2|5 mg SNP-ACTH Gel sc injection 3 times per week
88863360|NCT05696613|Experimental|Phase 3b Cohort 1|Dose level to be confirmed once Phase 3a part is completed
88863361|NCT05696613|Active Comparator|Phase 3b Cohort 2|Rituximab arm: Patients randomized to the rituximab arm will receive 1 g IV infusion on T0 (after baseline measures are collected) and day 15. A second course of rituximab 1g IV infusion will be administered 6 months after the first rituximab infusion and an additional 1 g IV infusion 14 days following the first 6-month infusion.
89185233|NCT00737373|Active Comparator|2|FLO
89388000|NCT06049589|Active Comparator|Chlorhexidine|"Participants will vigorously rinse their entire mouth with Chlorhexidine 0.12% daily after morning (2 minute brushing time) and evening brushing. The amount of chlorhexidine used will be one teaspoon (5 ml). Each participant will be given a container with volume measurement markings. Patients will be provided with the same toothbrush and toothpaste for their dental hygiene 2 times a day. Participants will be asked not to use products containing xylitol, tea, coffee, systemic antibiotics, or topical fluoride during the study. Any participant who violates these rules will be excluded from the study.~Reevaluation and sampling will be done after 30 days."
89388001|NCT06049589|Placebo Comparator|Water|"Participants will vigorously rinse their entire mouth with water daily after morning (2 minute brushing time) and evening brushing. The amount of water used will be one teaspoon (5 ml). Each participant will be given a container with volume measurement markings. Patients will be provided with the same toothbrush and toothpaste for their dental hygiene 2 times a day. Participants will be asked not to use products containing xylitol, tea, coffee, systemic antibiotics, or topical fluoride during the study. Any participant who violates these rules will be excluded from the study.~Reevaluation and sampling will be done after 30 days."
89388002|NCT06047171|Experimental|Standard treatment + ALE.F02 lower dose infusions|Standard treatment + ALE.F02 lower dose infusions
89388003|NCT06047171|Experimental|Standard treatment + ALE.F02 higher dose infusions|Standard treatment + ALE.F02 higher dose infusions
89185234|NCT02569047|Active Comparator|Atraumatic Restorative Treatment|The cavity will be prepared according to the ART (Atraumatic Restorative Treatments) steps and filled with the dental material Glass Ionomer Cement without local anesthesia.
89388004|NCT06047171|Placebo Comparator|Standard treatment + placebo infusions (inactive substance)|Standard treatment + placebo infusions (inactive substance)
89388005|NCT06045572|Experimental|women diagnosed with breast cancer before cancer treatment|
89388006|NCT06043440|Active Comparator|Oxygen plus supportive care (OXT)|Nocturnal oxygen therapy plus providing patient with healthy sleep habits materials, healthy diet materials and nasal dilators.
89388007|NCT06043440|No Intervention|Supportive care (SC)|Providing patient with healthy sleep habits materials, healthy diet materials and nasal dilators.
89388008|NCT06040190|Placebo Comparator|topical placebo tablet|magnesium silicate placebo tablet three times a day for 21 days
89185235|NCT02569047|Experimental|Hall Technique|The cavity will not receive any preparation. A stainless crown will be placed and cemented with the dental material Glass Ionomer Cement without local anesthesia.
89185236|NCT00729495|Active Comparator|1|marketed celecoxib
89388009|NCT06040190|No Intervention|control|artificial saliva
89388010|NCT06040190|Experimental|topical clonazepam tablet|2.0 mg Clonazepam tablet three times a day for 21 days
89388011|NCT06040190|Experimental|oral alpha-lipoic acid capsule|300 mg alpha-lipoic acid capsule twice a day for 60 days
88863362|NCT05694546|Experimental|Community Health Worker Post-Discharge Intervention|This group will be offered a community-based visit from a community health worker following hospital discharge.
89388012|NCT06040190|Experimental|topical phytotherapic capsaicin gel|0.025 mg capsaicin gel 4 times a day for 14 days
89185237|NCT00729495|Experimental|2|overencapsulated celecoxib
89185238|NCT00737451||skin itching|
89185239|NCT00737685|Experimental|Fludarabine|
88863363|NCT05691478|Active Comparator|Efficacy Phase Arm A (MAP)|"Standard risk patients receive methotrexate IV, doxorubicin IV, and cisplatin IV for two 35-day induction cycles, followed by appropriate local control. Patients then receive consolidation with methotrexate IV, doxorubicin IV, and cisplatin IV for two 35-day cycles and methotrexate IV and doxorubicin IV for two additional 35-day cycles. Patients also undergo X-ray, CT, MRI, and PET or bone scintigraphy at diagnosis and additonal time points throughout the trial. All patients also undergo collection of blood samples during screening and on study."
88863364|NCT05691478|Experimental|Efficacy Phase Arm B (cabozantinib, MAP)|"Standard risk patients receive cabozantinib PO, methotrexate IV, doxorubicin IV, and cisplatin IV for two 35-day induction cycles, followed by appropriate local control. Patients then receive consolidation with cabozantinib PO, methotrexate IV, doxorubicin IV, and cisplatin IV for two 35-day consolidation cycles, and cabozantinib PO, methotrexate IV, and doxorubicin IV for two additional 35-day cycles. Patients then receive cabozantinib PO for six 28-day maintenance cycles. Patients also undergo X-ray, CT, MRI, and PET or bone scintigraphy at diagnosis and additonal time points throughout the trial. All patients also undergo collection of blood samples during screening and on study."
89185240|NCT00732459||1|electro-acupuncture preconditioning group
89185241|NCT00732459||2|control group
89185242|NCT00712959|Experimental|Group 1: Previous Tdap or Tdap-IPV Recipients|Participants received Tdap or Tdap-Inactivated Poliomyelitis Vaccine (IPV) in a previous study (TD9707 or TD9805)
89185243|NCT00712959|Active Comparator|Group 2: Tdap vaccine-naïve|Participants are age-balanced Tdap vaccine-naïve and will receive Tdap vaccine in the study at least 10 years after a previous tetanus, diphtheria and/or pertussis dose.
89185244|NCT00712959|No Intervention|Group 3|Past participants in Study TD9707 and TD9805 did not qualify for Tdap re-administration in this study or were unwilling to receive a second dose of Tdap. They were not included in the analysis for the study
89185245|NCT00729729|Placebo Comparator|1|Placebo
89185246|NCT00729729|Experimental|2|Slow release PCA derivative
89185247|NCT00729729|Experimental|3|Slow release PCA derivative higher dose
89185248|NCT00732537|Experimental|Inhaled Nitric Oxide|iNO started at 20 ppm for 1 hour. The gas was then weaned hourly over the next 4 hours (20 ppm to 10 to 5 to 2.5 to 1 to off).
89388013|NCT06040190|Experimental|local photobiomodulation|Photobiomodulation with wavelength of 810 nm, power of 0.6 W, power density of 1.2 W/cm², beam area of 0.5 cm², and energy of 6 J.
89388014|NCT06039410|Experimental|Treatment|ISO-101 Device
89388015|NCT06038474|Other|Descartes-08|"Drug: Descartes-08~Autologous T-cells expressing a chimeric antigen receptor directed to BCMA"
89388016|NCT06036784|Experimental|MBX 1416 (Part A)|Single ascending subcutaneous (SC) doses
89185249|NCT00732537|Placebo Comparator|Placebo|The Oxygen at high concentration (>90%), which was standard therapy for PPHN, was introduced into an oxygen hood (Oxydome ™ disposable hood from Maxtex ® Inc.) using an INOvent (Datex-Ohmeda).
89185250|NCT00712725|Experimental|1|MK3207- 2.5 mg
89388017|NCT06036784|Experimental|MBX 1416 (Part B)|Repeated ascending subcutaneous (SC) doses
89388018|NCT06036784|Placebo Comparator|Placebo|
89388019|NCT06036784|Experimental|MBX 1416 (Part C)|Single subcutaneous (SC) dose of MBX 1416, single dose of rosuvastatin and acetaminophen.
89388020|NCT06035848|Experimental|Intervention group|Components of metabolic derangement measurement every 3rd day, it was considered positive when 3 or more points were present. These patients underwent paracentesis and if it was positive (faecal aspiration, serous fluid with Gram + staining, or serohematic fluid) the decision for surgery was made.
89388021|NCT06035848|Active Comparator|Control group|Determination of surgery in a conventional manner according to Bell's criteria (absolute indication: pneumoperitoneum), with radiographic surveillance every 6 hours.
89388022|NCT06035445|Experimental|In-person adolescent-friendly service (iPAS) intervention:|Adolescents at study clinics who score low or intermediate on transition readiness during screening will be invited to enroll in the study. Adolescents attending clinics randomized to the in-person supported adolescent friendly services will attend their clinic after school hours on a designated day or on weekends dedicated for adolescent care monthly for 9 months.
89388023|NCT06035445|Experimental|mHealth (InTSHA) intervention|Adolescents at study clinics who score low or intermediate on transition readiness during screening will be invited to enroll in the study. Adolescents attending clinics randomized to the mHealth intervention will receive the InTSHA intervention based in the Got Transition elements and the SMART model for 9 months.
89388024|NCT06035445|Active Comparator|Standard of Care/Delayed Intervention|Adolescents at study clinics who score low or intermediate on transition readiness during screening will be invited to enroll in the study. Adolescents attending clinics randomized to deliver the standard of care before transitioning to adult care in their standard local adult clinic. Participants will be invited to receive the intervention the clinic is randomized to deliver when the 9 month period of administering the standard of care is complete.
88863365|NCT05691478|Active Comparator|Efficacy Phase Arm C (MAP)|"High risk patients receive methotrexate IV, doxorubicin IV, and cisplatin IV for two 35-day induction cycles, followed by appropriate local control. Patients then receive consolidation with methotrexate IV, doxorubicin IV, and cisplatin IV for two 35-day cycles and methotrexate IV and doxorubicin IV for two additional 35-day cycles. Patients also undergo X-ray, CT, MRI, and PET or bone scintigraphy at diagnosis and additonal time points throughout the trial. All patients also undergo collection of blood samples during screening and on study."
89388025|NCT06035445|No Intervention|Healthcare Providers|Healthcare providers working at one of study clinics, administering the study intervention selected for that clinic.
89388026|NCT06035445|No Intervention|Observational cohort|Adolescents at study clinics who score high on transition readiness during screening will not be invited to enroll in the study but will be asked for their consent to have their clinic records reviewed for medical records, retention data and transition readiness data. They will also complete a questionnaire at Months 9, 18, and 24.
89388027|NCT06025097|Experimental|Single Treated Arm|Single arm study, Patients with SNHL and Tinnitus all were given same Composite solution consisting of (Methyl prednisone and Platelet rich plasma) via intr-atympanic route..
89388028|NCT06019260||group 1|open surgical repair using suture button device method in acute acromioclavicular joint disruption
89388029|NCT06019260||group 2|arthroscopic assisted treatment of acute acromioclavicular joint disruption using suture button device
89388030|NCT06018402|Active Comparator|physical therapy|The physical therapy program is planned as a total of 15 sessions in the lumbar region, each session consisting of TENS (50-100 Hz stimulation frequency, 200 µs pulse duration, intensity is increased as much as the patient could tolerate, 20 minutes in total), hotpack (to be placed on the painful area, 20 minutes), US (1 mHz frequency, 10 minutes, 1.5 watt/cm2 intensity)
88863366|NCT05691478|Experimental|Efficacy Phase Arm D (cabozantinib, MAP)|"High risk patients receive cabozantinib PO, methotrexate IV, doxorubicin IV, and cisplatin IV for two 35-day induction cycles, followed by appropriate local control. Patients then receive consolidation with methotrexate IV, doxorubicin IV, and cisplatin IV for one 35-day cycle, followed by cabozantinib PO, methotrexate IV, doxorubicin IV, and cisplatin IV for one 35-day cycle and cabozantinib PO, methotrexate IV, and doxorubicin IV for two additional 35-day cycles. Patients then receive cabozantinib PO for six 28-day maintenance cycles. Patients also undergo X-ray, CT, MRI, and PET or bone scintigraphy at diagnosis and additonal time points throughout the trial. All patients also undergo collection of blood samples during screening and on study."
88863367|NCT05691478|Experimental|Feasibility phase (cabozantinib, MAP)|"Patients receive cabozantinib orally (PO), methotrexate intravenously (IV), doxorubicin IV, and cisplatin IV for two 35-day induction cycles. Patients are then considered for appropriate local control. Then they receive consolidation with methotrexate IV, doxorubicin IV, and cisplatin IV for one 35-day cycle, followed by cabozantinib PO, methotrexate IV, doxorubicin IV, and cisplatin IV for one 35-day cycle, and cabozantinib PO, methotrexate IV, and doxorubicin IV for two 35-day cycles. Patients then receive cabozantinib PO for six 28-day maintenance cycles."
88863368|NCT05691166|Experimental|Progressive resistance training|Twice weekly high-intensity progressive resistance training for 12 months
89388031|NCT06018402|Active Comparator|physical therapy + espb|"same physical therapy program, in addition Ultrasound-guided lumbar ESPB is performed using an in-line cephalic approach, and after contacting the corner of the L3 transverse process, a small dose of saline is injected into the fascial space between the L3 transverse process and the erector spinae muscles to lift off the fascia. After verification, a mixture of 20 mL of 1% lidocaine and 3 mg betamethasone is administered for unilateral injection. The procedure is performed bilaterally."
89388032|NCT06018168|Active Comparator|Group One: Skincare Routine Only|Participants will follow instructions for the skincare routine only. Participants will complete the routine twice daily.
89388033|NCT06018168|Active Comparator|Group Two: Skincare Routine + Supplement|Participants will follow instructions for the skincare routine AND will take a daily supplement.
88863369|NCT05691166|Active Comparator|Control|Referred to general practitioner
88863370|NCT05690386|Experimental|Lonapegsomatropin at 0.24 mg hGH/kg/week|Lonapegsomatropin at 0.24 mg hGH/kg/week administered once-weekly by subcutaneous injection
88863371|NCT05690386|Experimental|Lonapegsomatropin at 0.30 mg hGH/kg/week|Lonapegsomatropin at 0.30 mg hGH/kg/week administered once-weekly by subcutaneous injection
88863372|NCT05690386|Experimental|Lonapegsomatropin at 0.36 mg hGH/kg/week|Lonapegsomatropin at 0.36 mg hGH/kg/week administered once-weekly by subcutaneous injection
88863373|NCT05690386|Active Comparator|Somatropin at 0.05 mg/kg/day|Somatropin at 0.05 mg/kg/day administered once-daily by subcutaneous injection
88863374|NCT05674461|Experimental|WhatsApp Group|"In the study, training modules including general information about the postpartum period, breastfeeding counseling, postpartum nutrition, puerperal psychology, family planning and postpartum exercises, consisting of 4 sessions, will be applied to the women in the experimental group.~Trainings will be sent to the women in the WhatsApp experimental group in the form of videos via the WhatsApp application. The videos will be prepared with the researchers' own voice and image. Each training video will be sent for 15-30 minutes (in the form of short videos, if necessary, divided into parts).~Women will be supported through messages in order to increase their motivation and provide counseling regarding their possible questions and problems."
88863375|NCT05674461|Experimental|Face-to-face Group|"In the study, training modules including general information about the postpartum period, breastfeeding counseling, postpartum nutrition, puerperal psychology, family planning and postpartum exercises, consisting of 4 sessions, will be applied to the women in the experimental group.~The trainings will be given to the women in the experimental group face-to-face by the researchers in the form of 15-30 minute trainings in their own home environment.~Women will be supported through messages in order to increase their motivation and provide counseling regarding their possible questions and problems."
89388034|NCT06016634|Experimental|Alendronate group|Single-arm prospective cohort of 24 adult with SCD
89388035|NCT06011265|Experimental|Mirabegron + Isoproterenol|100mg oral + Isoproterenol IV Infusion; 3 doses, 6, 12, 24ng/ kg Fat Free Mass
89185251|NCT00712725|Experimental|2|MK3207- 5 mg
89388036|NCT06011265|Placebo Comparator|Placebo + Isoproterenol|Empty Capsule + Isoproterenol IV Infusion; 3 doses, 6, 12, 24ng/ kg Fat Free Mass
89388037|NCT06005025|Experimental|REMİNDER MESSAGE|"All participants will be given one-hour training on breast cancer, modifiable and non-modifiable risk factors for breast cancer, symptoms of breast cancer, screening programmes and breast self-examination. In addition to the presentation, breast self-examination will be applied one-to-one with a breast examination model. This group will be counselled for 6 months after the training and a reminder message will be sent via SMS on Monday every week as Check your modifiable risk factors for breast cancer and their feedback will be received."
89388038|NCT06005025|No Intervention|CONTROL GROUP|All participants will be given one-hour training on breast cancer, modifiable and non-modifiable risk factors for breast cancer, symptoms of breast cancer, screening programmes and breast self-examination. In addition to the presentation, breast self-examination will be applied one-to-one with a breast examination model. There will be no additional practice outside the training.
89388039|NCT05997693|Experimental|Ticagrelor 90 mg|
89388040|NCT05997693|Placebo Comparator|Ticagrelor placebo|
89388041|NCT05995353|Experimental|PK Cohort 1: SS1|Cohort 1 will consist of 2 age groups (6 to < 12 years and 12 to < 18 years). SS1 is a 12-week induction period where participants will receive a weight-based dose of risankizumab. All subjects who complete SS1 are eligible to enter SS2.
89388042|NCT05995353|Experimental|PK Cohort 1: SS2 Dose A|Cohort 1 will consist of 2 age groups (6 to < 12 years and 12 to < 18 years). Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive double-blind risankizumab Dose A. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3.
89388043|NCT05995353|Experimental|PK Cohort 1: SS2 Dose B|Cohort 1 will consist of 2 age groups (6 to < 12 years and 12 to < 18 years). Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive double-blind risankizumab Dose B. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3.
89388044|NCT05995353|Experimental|PK Cohort 1: SS3 Dose A|Cohort 1 will consist of 2 age groups (6 to < 12 years and 12 to < 18 years). SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2.
89388045|NCT05995353|Experimental|PK Cohort 1: SS3 Dose B|Cohort 1 will consist of 2 age groups (6 to < 12 years and 12 to < 18 years). SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2.
89388046|NCT05995353|Experimental|PK Cohort 2: SS1|Cohort 2 will enroll participants aged 2 to less than 6 years. SS1 is a 12-week induction period where participants will receive a weight-based dose of risankizumab. All subjects who complete SS1 are eligible to enter SS2.
88863376|NCT05674461|Other|Control|No intervention will be applied to the mothers in the control group.
88863377|NCT05671965|Active Comparator|Xylitol|20 volunteers receive 33.5g xylitol dissolved in 300mL tap water as an oral pre-load.
88863378|NCT05671965|Active Comparator|Sucrose|20 volunteers receive 33.5g sucrose dissolved in 300mL tap water as an oral pre-load.
89185252|NCT00712725|Experimental|3|MK3207- 10 mg
89185253|NCT00712725|Experimental|4|MK3207- 20 mg
89185254|NCT00712725|Experimental|5|MK3207- 50 mg
89185255|NCT00712725|Experimental|6|MK3207- 100 mg
89388047|NCT05995353|Experimental|PK Cohort 2: SS2 Dose A|Cohort 2 will enroll participants aged 2 to less than 6 years. Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive double-blind risankizumab Dose A. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3.
89185256|NCT00712725|Placebo Comparator|7|Placebo
89185257|NCT00737763|Experimental|A|This group will receive weekly efalizumab injections for 6 months
88863379|NCT05671965|Active Comparator|Acesulfame Potassium|20 volunteers receive 0.1675g Ace-K dissolved in 300mL tap water as an oral pre-load.
88863380|NCT05671965|Placebo Comparator|Water|20 volunteers receive 300mL tap water as an oral pre-load.
88863381|NCT05671081|Active Comparator|General anethesia +Dexmedetomidine plus Bupivacaine for Erector spinae plane block|
88863382|NCT05671081|Active Comparator|General anethesia +Magnesium sulfate plus Bupivacaine for Erector spinae plane block|
88863383|NCT05671081|Active Comparator|general anesthesia+conventional postoperative narcotic analgesia|
89185258|NCT00737763|Placebo Comparator|B|This group will receive placebo injections for 6 months
89185259|NCT00732693|Experimental|1|Treatment with standard sex steroid replacement regimen
89185260|NCT00732693|Experimental|2|Treatment with physiologic sex steroid regimen
89185261|NCT00737841|Experimental|A|Bifidobacterium breve
89185262|NCT00737841|Placebo Comparator|B|Placebo
89185263|NCT00732771|Experimental|LCI696 1mg bid|
89185264|NCT02568657|Active Comparator|Celox group|Celox placement is very simpe . During cesarean section celox is loaded in the lower uterine segment and part of it is passed through the cervix to the vagina. If PPH occurs after vaginal delivery the celox is inserted through the cervix to pack the lower uterine segment. Removal of Celox after 24 hours.
89185265|NCT02568657|Active Comparator|Bakri balloon group|Before insertion the balloon, ensure that the bladder is empty by placing a Foley catheter. Grasp the cervix with ring forceps. Insert the balloon into the cavity of the uterus under ultrasound guidance; making sure that the entire portion of the balloon passes the cervical canal above the internal cervical os. Once the correct placement is confirmed, inflate the balloon with sterile saline using the enclosed syringe.
89185266|NCT00737919|Active Comparator|1|A group of subjects consuming daily 2 grams of plant stanols 4-6 weeks before the operation
89185267|NCT00737919|Active Comparator|2|A group of patients consuming daily 2 grams of plant sterols 4-6 weeks before the operation
89185268|NCT00729885|Experimental|1 Goggle I|Optimized Goggle
89185269|NCT00729885|Sham Comparator|2 Google II|Goggle with 20 Degree error
88863384|NCT05670496||Patients|Patients at risk, suspected of having, have a history of, or currently have a diagnosed hearing, balance or communication disorder.
88863385|NCT05670080|Experimental|The Motor Imagery (MI) Group|"MI training will be prepared using the Microsoft PowerPoint program which includes written, visual and audio materials, as well as features that can be sent to participants ' phones/tablets/computers. The MI training will allow the participant to perform visual and kinesthetic imagery with visual and audible notifications and will include 6 exercises for the muscles around the shoulder, 3 exercises for strengthening, and dynamic stabilization for the muscles around the scapula. In each presentation, verbal cues will be given to explain how to imagine the movement while a visual of the motor movement is displayed on the screen. During MI exercises, participants will be called once a week and their MI practices will be followed up.~After the first four weeks of MI training, the MI group will also participate in a four-week physical therapy program."
89185270|NCT00732849|No Intervention|1|Standard Enteral Nutrition - Peptisorb, Nutricia Ltd.
89185271|NCT00732849|No Intervention|2|Standard Parenteral Nutrition: Aminomel, Lipofundin, Glucose, Cernevit, Tracutil, electrolytes
89185272|NCT00732849|Experimental|3|Immunomodulating Enteral Nutrition: Reconvan, Fresenius Kabi Poland
89185273|NCT00732849|Experimental|4|Immunomodulating Parenteral Nutrition: Aminomel, Lipofundin, Glucose, Cernevit, Tracutil, electrolytes + Omegaven (Fresenius Kabi), Dipepitven (Fresenius Kabi)
89185274|NCT00729963|Experimental|1|The first group received sibutramine 10 mg for the first 4 weeks, at which time consideration of increasing dosage to 15 mg was re-evaluated in the case of insufficient weight loss (< 1.8 kg) over the first month of treatment.
89185275|NCT00729963|Active Comparator|2|A standard reference group, which was paired according to age and BMI, received CPAP as a treatment for OSA.
89185276|NCT00737997|Placebo Comparator|1|
89185277|NCT00737997|Experimental|2|
89185278|NCT00732927|Experimental|1|parnaparin, low molecular weight heparin
89185279|NCT00732927|Active Comparator|2|aspirin
89185280|NCT00733083|Active Comparator|1|0,1 mg/kg of oxycodone
89185281|NCT00733083|Active Comparator|2|0,1 mg/kg of morphine
89185282|NCT00733083|Active Comparator|3|0,5 mg/kg dexamethasone (max 24 mg
89185283|NCT00733083|Placebo Comparator|4|NaCl 0,9%
89185284|NCT00738075||PD+FOG|Patients with Parkinson's disease prone to freezing
89185285|NCT00712335|Experimental|1|"Asthmatic smokers treated with combination therapy:~Fluticasone propionate dosage - DPI 250 mcg BID for 3 months Salmeterol dosage - DPI 50 mcg BID for 3 months"
89185286|NCT00712335|Experimental|2|"Asthmatic smoker treated with Montelukast only:~Montelukast dosage: PO 10 mg QHS for 3 months"
89388048|NCT05995353|Experimental|PK Cohort 2: SS2 Dose B|Cohort 2 will enroll participants aged 2 to less than 6 years. Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive double-blind risankizumab Dose B. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3.
89388049|NCT05995353|Experimental|PK Cohort 2: SS3 Dose A|Cohort 2 will enroll participants aged 2 to less than 6 years. SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2.
89388050|NCT05995353|Experimental|PK Cohort 2: SS3 Dose B|Cohort 2 will enroll participants aged 2 to less than 6 years. SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2.
89388051|NCT05995353|Experimental|Expansion Cohort 3: SS1|Cohort 3 will enroll participants aged 2 to less than 18 years. SS1 is a 12-week induction period where participants will receive a weight-based dose of risankizumab. All subjects who complete SS1 are eligible to enter SS2.
89388052|NCT05995353|Experimental|Expansion Cohort 3: SS2 Dose A|Cohort 3 will enroll participants aged 2 to less than 18 years. Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive either double-blind risankizumab Dose A. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3.
89388053|NCT05995353|Experimental|Expansion Cohort 3: SS2 Dose B|Cohort 3 will enroll participants aged 2 to less than 18 years. Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive either double-blind risankizumab Dose B. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3.
89388054|NCT05995353|Experimental|Expansion Cohort 3: SS3 Dose A|Cohort 3 will enroll participants aged 2 to less than 18 years. SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2.
89388055|NCT05995353|Experimental|Expansion Cohort 3: SS3 Dose B|Cohort 3 will enroll participants aged 2 to less than 18 years. SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2.
89388056|NCT05985538|Experimental|Vaping prevention text messages|Participants will receive text messages (2 daily, on average) about the harms of e-cigarette use and vaping for 28 days, with introductory messages sent on day 1 and concluding messages sent on day 28.
89388057|NCT05985538|Active Comparator|Wellness behavior text messages|Participants will receive text messages (2 daily, on average) about general wellness topics, with introductory messages sent on day 1 and concluding messages sent on day 28.
89388058|NCT05983822|Experimental|Experimental Group (GA)|The experimental group (GA) will perform specific rehabilitation for the recovery of hand function using the end-effector robot Amadeo® (Tyromotion, Austria) 3 times a week, for 4 weeks (12 total sessions), for 45 minutes of treatment in addition to conventional treatment. In particular, the technological rehabilitation performed using the robot will mostly aim at improving finger mobility and strength, and flexion-extension exercises will be proposed in passive, active assisted and active mode, exercises for improving strength and muscle tone.
89388059|NCT05983822|Active Comparator|Conventional Group (GC)|GC patients will undergo conventional rehabilitation treatment only, using the main rehabilitation methods (e.g. neurocognitive theory, progressive neuromuscular facilitation, etc.).
89388060|NCT05980442||OrthoPilot® Elite|navigated / computer assisted total knee replacement surgery
89388061|NCT05980442||MAKO|robot assisted total knee replacement surgery
89388062|NCT05978063|Active Comparator|Difelikefalin 2.0 mg tablets|Oral difelikefalin 2.0 mg tablet administered twice daily
89388063|NCT05978063|Active Comparator|Difelikefalin 1.0 mg tablets|Oral difelikefalin 1.0 mg tablet administered twice daily
89388064|NCT05978063|Active Comparator|Difelikefalin 0.25 mg tablets|Oral difelikefalin 0.25 mg tablet administered twice daily
88863386|NCT05670080|Experimental|Physical Therapy (PT) Group|"Following the preoperative evaluations, both groups will be shown remedial exercises (pumping exercises that activate the circulation), flexion, and extension wrist exercises, which they should do for four weeks.~After a 4-week immobilization period, participants in the PT Group will begin a physical therapy program that includes routine electrotherapy (TENS), cold pack therapy, joint range of motion exercises, and strengthening exercises for the muscles around the shoulder."
88863387|NCT05667142|Experimental|XEN1101 25 mg/day|XEN1101 25 mg/day
89388065|NCT05978063|Placebo Comparator|Placebo tablets|Oral placebo tablet administered twice daily
89388066|NCT05970692||Healthy Controls|Healthy individuals aged between 18-65 years old
89388067|NCT05970692||CTS Group|CTS patients aged between 18-65 years old
88863388|NCT05667142|Placebo Comparator|Placebo|Placebo
88863389|NCT05667142|Experimental|XEN1101 15 mg/day|XEN1101 15 mg/day
89185287|NCT00712335|Active Comparator|3|"Non-smoking asthmatics treated with combination therapy:~Fluticasone propionate dosage - DPI 250 mcg BID for 3 months Salmeterol dosage - DPI 50 mcg BID for 3 months"
89388068|NCT05968755|Experimental|Intervention group|
89388069|NCT05968755|Placebo Comparator|Control group|
89388070|NCT05967351|Experimental|Delandistrogene Moxeparvovec|Participant received delandistrogene moxeparvovec in a previous clinical study.
89388071|NCT05963997|Experimental|Cohort 1|Up to 6 evaluable participants will receive samuraciclib 240 mg in combination with elacestrant 300 mg in cycles of 28 days (Cycle 1 to 6), 56 days (Cycle 7 to 9) and up to 84 days (Cycles 10 onwards).
89388072|NCT05963997|Experimental|Cohort 2|Up to 6 evaluable participants will receive samuraciclib in combination with elacestrant at the SRC recommended dose (anticipated 360mg samuraciclib, 300 mg elacestrant) in cycles of 28 days (Cycle 1 to 6), 56 days (Cycle 7 to 9) and up to 84 days (Cycles 10 onward).
89388073|NCT05963997|Experimental|Cohort 3|Up to 6 evaluable participants will receive samuraciclib in combination with elacestrant at the SRC recommended dose (anticipated 360mg samuraciclib, 400 mg elacestrant) in cycles of 28 days (Cycle 1 to 6), 56 days (Cycle 7 to 9) and up to 84 days (Cycles 10 onward).
89388074|NCT05963997|Experimental|Cohort 4 Expansion|Up to 30 evaluable participants will receive samuraciclib in combination with elacestrant at the SRC recommended dose (anticipated 360mg samuraciclib, 400 mg elacestrant) in cycles of 28 days (Cycle 1 to 6), 56 days (Cycle 7 to 9) and up to 84 days (Cycles 10 onward).
89388075|NCT05963581|Experimental|Salsa Dancing|Participants will complete eight weeks of a salsa course in Oxford (of which they need to attend six classes to remain in the study), followed by a one-month follow-up time point.
89388076|NCT05963581|No Intervention|Waitlist Control|Participants will wait twelve weeks, completing the questionnaires and tasks at the same study time points as participants in the experimental condition.They will then be offered the opportunity to complete the eight-week salsa course. Should they choose to participate in the salsa course, they will additionally be offered the opportunity to complete questionnaires at two additional time points.
89388077|NCT05959434|Experimental|Integrated Cognitive Processing Therapy and Relapse Prevention (CPT+RP)|Participants will receive 12, 90-minute individual sessions of CPT+RP delivered twice-weekly. We will offer some flexibility (e.g., due to illness or scheduling conflicts) and allow up to 9 weeks to complete all 12 sessions if needed. During CPT+RP, patients receive psychoeducation pertaining to the interconnectedness of AUD and PTSD and learn techniques to identify and manage triggers for alcohol use, cope with cravings, address problem thoughts about drinking, and enhance social support. These skills address core functional outcomes relevant to addiction, including executive functioning, incentive salience, and negative emotionality. The PTSD treatment component of CPT+RP reduces PTSD symptoms via identifying and targeting maladaptive trauma-related cognitions, beliefs, and Stuck Points via cognitive restructuring exercises, such as Socratic questioning. RP skills are integrated within each session.
89388078|NCT05959434|Active Comparator|Relapse Prevention (RP)|Participants will receive 12, 90-minute individual sessions of RP delivered twice-weekly as consistent with the experimental condition. The RP manual is adapted from the NIAAA Project MATCH Cognitive-Behavioral Coping Skills Therapy Manual and has been used in prior NIH-funded trials of integrated, trauma-focused treatment. Session topics include, for example, Triggers for Alcohol Use, Coping with Cravings and Urges to Drink (e.g., avoid alcohol cues, distracting activities, talk to friends/family, urge surfing), Managing Thoughts about Alcohol and Drinking by challenging and changing thoughts, Planning for Emergencies and Coping with a Lapse, Drink Refusal Skills, Increasing Pleasant Activities and Enhancing Social Support.
89388079|NCT05957510|Experimental|Cohort 1|Patients who met the inclusion criteria, did not meet the exclusion criteria, and agreed to accept the treatment plan of this study will undertake a combination chemotherapy regimen, comprised of serplulimab (300mg), etoposide (100 mg/m2), and carboplatin (AUC 5 mg/mL/min, up to 750mg). These agents will be administered intravenously in 3-week intervals over a span of 4 to 6 cycles.
89388080|NCT05957510|Experimental|Cohort 2|Patients who met the specific inclusion criteria, did not meet the specific exclusion criteria, and agreed to accept the treatment of this study will undertake the same treatment as cohort 1 in the form of ' compassionate use '.
89388081|NCT05957510|Experimental|Cohort 3|Patients with treatment contraindications or unwillingness to accept the treatment of this study will be treated with the clinical routine treatment recommended by the investigator.
88863390|NCT05653336|Experimental|Subjects implanted with PerQseal Vascular Closure Device|Subjects implanted with bioabsorbable implant to achieve haemostasis of common femoral arteriotomies created by 12 to 22 F sheaths (up to 26 F arteriotomy) in patients undergoing percutaneous catheter-based interventional procedures.
88863391|NCT05649722|Experimental|Treprostinil Palmitil Inhalation Powder|"Participants who are not transitioning immediately from INS1009-211 and other lead-in studies, will be administered TPIP, once daily (QD), during 3-week titration period.~Participants who are transitioning immediately from a randomized blinded lead-in TPIP study and who previously received:~TPIP- will be administered placebo QD along with the maximum tolerated dose (MTS) TPIP dose from lead-in study in a blinded manner during 3-week titration period.~Placebo- will be administered TPIP QD along with the achieved placebo dose from lead-in study in a blinded manner during 3-week titration period.~The overall treatment period will be 24 months."
88863392|NCT05641519|Placebo Comparator|Enhanced Standard Intervention|Families randomized to enhanced standard intervention (ESI) will be given informational materials from the American Heart Association on cardiovascular health. ESI includes self-management which is standard care. At 12, 24, and 36 months they will be asked to return for in person follow-up to collect bio measures again and complete follow up surveys at the UCI FQHC in Santa Ana or during scheduled community data collection events. All adults will be asked to take their blood pressure with the device once a week.
88863393|NCT05641519|Experimental|SERVE OC Intervention|"In the SERVE OC intervention, participants will receive AHA informational materials, access to the app/web portal, and will be assigned a CHW to work with over the 3 years of the study. The CHW will facilitate the intervention for the family which includes 1) Conducting a family intake of risk factors through the LE8 assessment 2) Facilitate the creation of a family network-tailored action plan 3) Provide guidance to activate/reinforce action plans using the interactive part of the app/web portal. They will meet with their CHW monthly to learn about CVH, work on their goals, and action plans. Meetings with CHWs will take place in their homes, the UCI FQHC in Santa Ana, over zoom, or other locations. All adults will be asked to take their blood pressure with the device once a week."
88863394|NCT05640193|Experimental|Participants with Melanoma Brain Metastases|Participants have melanoma brain metastases who will undergo surgical excision to generate LN-144.
88863395|NCT05638854|Experimental|Part A: SAD in Healthy Volunteers|Healthy volunteers will receive a single dose of ZB002 or placebo
88863396|NCT05638854|Experimental|Part B: MAD in RA Participants|RA participants will receive ZB002 or placebo every 4 weeks (Q4W) × 3 administrations
88863397|NCT05636228|Experimental|INV-102 0.7% Three Times per Day (TID)|INV-102 ophthalmic solution administered for about 1 week
88863398|NCT05636228|Placebo Comparator|Vehicle TID|INV-102 ophthalmic solution administered for about 1 week
88863399|NCT05634499|Experimental|Giredestrant|
88863400|NCT05631366|Active Comparator|Spaced AAT|AAT-S participants will receive 4 AAT sessions totalling 1200 trails but spaced out over four weeks (one AAT session per week)
88863401|NCT05631366|Active Comparator|Massed AAT|AAT-M participants will receive 4 AAT sessions (each with 300 trials) within the space of 8 days (which totals 1200 trails).
89185288|NCT00712335|Active Comparator|4|"Non-smoking asthmatic treated with Montelukast only:~Montelukast dosage: PO 10 mg QHS for 3 months"
89388082|NCT05948618|Experimental|Embodied Conversational Agent|The ECA systems compromises 1) a smartphone based ECA patient interface; 2) clinician authoring tool, to enable new measurement systems to be rapidly configured 3) clinician and patient data visualizations; and 4) a central server with relation database, administrative user interfaces and ability to send asynchronous notifications to users' smartphones.
89388083|NCT05948618|Active Comparator|RedCap Survey|An internet-based measure will use PROMIS Profile measures which will include depression, anxiety, fatigue, pain intensity and interference, sleep disturbance, physical function and satisfaction with social role
89388084|NCT05945147|Experimental|Ketamine and Midazolam|Participants will receive intravenous infusions of ketamine and midazolam for 4 hours each day, over 5 consecutive days, in an outpatient setting.
89388085|NCT05945147|Placebo Comparator|Midazolam and Saline|Participants will receive intravenous infusions of midazolam and normal saline for 4 hours each day, over 5 consecutive days, in an outpatient setting.
89388086|NCT05944952|Experimental|high dose|High dose: Participants randomized to the high dose group will receive on day 1 in the clinic an initial dose of 2 mg of buprenorphine/naloxone, followed by a 6 mg dose an hour later, followed by an 8 mg dose an hour later, followed by an 8 mg dose an hour later. On day 2 they will receive a 12 mg dose in the clinic and a 12 mg dose as take-home medication. On days 3 through 7 they will report to the clinic and receive their 12 mg morning dose and a 12 mg dose as a take-home for evening dosing. Thereafter, dosing adjustments can be made in the first three months of the trial.
89388087|NCT05944952|Active Comparator|low dose|Low dose: Participants randomized to the low dose group will receive 0.5 mg of buprenorphine/naloxone on day 1, 0.5 mg bid on day 2, 1.0 mg bid on day 3, 2.0 mg bid on day 4, 4.0 mg bid on day 5, 4.0 mg tid on day 6, and 8 mg bid on day 7. Thereafter, dosing adjustments can be made in the first three months of the trial.
89388088|NCT05936203|Experimental|Target|Setting a higher glucose target starting from 1 hour before until the end of walk.
89388089|NCT05936203|Experimental|Snack|Consumption of 15 g of complex carbohydrates as whole grain crackers every 30 minutes, during the 4 hours of walk.
89388090|NCT05936203|Experimental|Target + Snack|Combination of both Target and Snack interventions.
89388091|NCT05933057|Experimental|Givinostat|Patients will receive concomitant corticosteroid treatment as part of the standard of care.
89388092|NCT05933057|Placebo Comparator|Placebo|Patients will receive concomitant corticosteroid treatment as part of the standard of care.
89388093|NCT05929911|Experimental|Trauma-focused psychodynamic psychotherapy|Twice-weekly psychotherapy for 24 sessions
89388094|NCT05927610|Experimental|Cohort A|Cohort A will consist of newly diagnosed patients with Glioblastoma. Eligibility for enrollment prior to pathology diagnosis will be determined by a consensus diagnosis of high grade glioma based on clinical and radiographic evidence between neuroradiologist, neurosurgeon and study PI.
89388095|NCT05927610|Experimental|Cohort B|Cohort B will consist of patients with a histologically confirmed diagnosis of IDH WT glioblastoma.
89185289|NCT00712335|No Intervention|5|Normal controls
89185290|NCT04065711|Experimental|RAP Treatment|Each treatment area will receive 30-40 minutes (30-40 individual doses) of RAP treatment.
89388096|NCT05921448|Experimental|Vaxigripetra|This arm will receive 1 dose of 0.5 mL Vaxigripetra (intra-muscular injection) and 1 dose of 0.2 mL placebo (nasal, 1 spray in each nostril).
89388097|NCT05921448|Experimental|Flumist|1 dose of 0.2 mL Flumist (nasal, 1 spray in each nostril) and 1 dose of 0.5 mL placebo (intra-muscular injection).
89388098|NCT05917938|Experimental|Participants With Normal Hepatic Function|Participants with normal hepatic function will receive a single subcutaneous dose of 30 milligram (mg) of NNC0194-0499 on Day 1.
89388099|NCT05917938|Experimental|Participants With Mild Hepatic Impairment|Participants with mild hepatic impairment (Child Pugh Grade A) will receive a single subcutaneous dose of 30 mg of NNC0194-0499 on Day 1.
89388100|NCT05917938|Experimental|Participants With Moderate Hepatic Impairment|Participants with moderate hepatic impairment (Child-Pugh Grade B) will receive a single subcutaneous dose of 30 mg of NNC0194-0499 on Day 1.
89388101|NCT05917938|Experimental|Participants With Severe Hepatic Impairment|Participants with severe hepatic impairment (Child-Pugh Grade C) will receive a single subcutaneous dose of 30 mg of NNC0194-0499 on Day 1.
89388102|NCT05914233|Experimental|Single|Stimulation of the ultrasound retinal stimulation Device
89388103|NCT05908357|Experimental|Exergaming Group (EG)|"The EG will participate in the intervention protocol with exergaming and will also receive the guidance booklet at the end of the treatment. Protocol: twice a week, with a total duration of 40-45 minutes each, conducted by a single physiotherapist. The initial 10 minutes will be for reception, accommodation/heating and anticipation of the service. The Exergaming will last 25-30 minutes, observing the children's reactions to the dosage of the game and the manual and verbal interventions of the physiotherapist. The final 5 minutes will be for cooling down (relaxing music).~The video game will be the Xbox 360 with a Kinect TM sensor , which captures body movement during the game. The game will be Kinect Adventures!, and minigames: peak of reflections and 20,000 leaks. During the game, the physiotherapist will stimulate the child's proprioception in order to promote sensory and verbal feedback. The intervention will last 12 weeks, with 2 weekly sessions, totaling 24 sessions."
89388104|NCT05908357|Active Comparator|Control Group (CG)|The CG will be formed by participants admitted to the institution and who are on the waiting list for physiotherapy care and will follow the guidelines of the physiotherapy booklet with recommendations for physical activities that encourage the child's usual mobility, such as: moments of play with the family, walks outdoors and encourage varied ludic motor experiences. This booklet will be created by the researcher and will not change the routine of the service. The CG will be telemonitored biweekly via messaging application by the researcher, through a personal telephone, with a proposal to check the progress of the application of the booklet, clarify doubts with the family and monitor the child. This telemonitoring protocol was established exclusively for the research.
89388105|NCT05906602|Experimental|Ischemic Conditioning|While seated, a rapid inflation cuff, similar to those used to measure blood pressure, will be placed around the paretic thigh to perform real ischemic conditioning. The pressure of the cuff will be increased for 5 minutes followed by no pressure for 5 minutes, repeated 5 times for a total of 50 minutes.
89388106|NCT05906602|Sham Comparator|Sham Ischemic Conditioning|While seated, a rapid inflation cuff, similar to those used to measure blood pressure, will be placed around the paretic thigh to perform sham or fake ischemic conditioning. The pressure of the cuff will be increased for 5 minutes followed by no pressure for 5 minutes, repeated 5 times for a total of 50 minutes.
89388107|NCT05906602|Active Comparator|Aerobic Exercise|Participants will perform thirty minutes of moderate intensity continuous aerobic exercise using a recumbent stepper.
89388108|NCT05897099|Experimental|Comprehensive Tele-harm Reduction|Participants will have enhanced access to a physician and clinical psychologist via remote video technology wherever the participant is located and prefers engagement (SSP, home, shelter, encampment). Participants will be in this group for 12 months.
89388109|NCT05897099|Active Comparator|Off-site Linkage to HIV prevention|Participants in this group will receive off-site linkage to HIV care by having case management/social work services through our community engagement team. Participants will be in this group for 12 months.
89388110|NCT05896800|Experimental|Low concentration group|inhaled nitric oxide (iNO) 10ppm，≥2 hours/day for 7 days
88863402|NCT05627245|Experimental|Treatment (tazemetostat, belinostat)|"Patients receive tazemetostat PO BID on days 2-21 of cycle 1 and days 1-21 of subsequent cycles, and belinostat IV over 30 minutes on days 1-5 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Patients may undergo a tumor biopsy during screening and on study (dose-expansion only). Patients undergo blood sample collection while on study and PET/CT scan throughout the study. Patients may also undergo CT scan alone throughout the study."
89388111|NCT05896800|Experimental|High concentration group|iNO 40ppm，≥2 hours/day for 7 days
89388112|NCT05896384|Experimental|Microgynon® (Reference treatment (R)) followed by BI 456906 and Microgynon® (Test treatment (T))|
88863407|NCT05619172|Experimental|Nanrilkefusp alfa and cetuximab|Participants will be first treated with 9 µg/kg of nanrilkefusp alfa and then proceed to be treated with either 12 µg/kg or 6 µg/kg of nanrilkefusp alfa in combination with cetuximab (depending on the safety evaluation of the first safety cohort). Nanrilkefusp alfa treatment will be administered on day 1 (from cycle 2 onwards, ±1 day), day 2 (±1 day), day 8 (±1 day), and day 9 (±1 day) of each 21-day cycle. Cetuximab treatment will be administered on day 1 (from cycle 2 onwards, ±1 day), day 8 (±1 day), and day 15 (±1 day) of each 21-day cycle; on day 1 and day 8, cetuximab infusion will start within 30 minutes after nanrilkefusp alfa administration.
89388113|NCT05885373|Experimental|SIM01|2 sachets daily for 3 months
89185291|NCT00738621|Active Comparator|1|Oral aprepitant 40 mg - given within 3 hours prior to induction dexamethasone (4mg intravenous) administered immediately after induction ondansetron (4mg (2ml) intravenous) administered at cessation of anesthesia
89388114|NCT05883748|Experimental|DISC-1459 Oral Dose Level 1|Oral dose, once a day
89388115|NCT05883748|Experimental|DISC-1459 Oral Dose Level 2|Oral dose, once a day
89388116|NCT05877898|No Intervention|No strategy|Individuals assigned to this arm with receive a publicly available color copy of the NIH's Healthy Blood Pressure for Healthy Hearts: Small Steps to Take Control Flyer available
88863408|NCT05617677|Experimental|Arm 1: Deucravacitinib|
88863409|NCT05617677|Placebo Comparator|Arm 2: Placebo|
88863410|NCT05615792||patients with coronavirus disease 2019 (COVID-19)|Patients diagnosed with COVID-19 in Hubei Province
88863411|NCT05611593|Experimental|FOL100|Subjects will apply FOL100 lotion topically in the defined treatment area.
89388117|NCT05877898|Experimental|Community health worker provided education|Participants will be invited to meet with the CHW to learn about eating healthier to reduce blood pressure and enhance quantity and quality of life. The CHW will register individuals for SNAP benefits and educate them on how to use their benefits locally. As other resources exist, including food pantries, food distribution events, and Fresh Access Bucks (a federal program to double SNAP if spent on local produce at eligible farmers markets), the CHW will provide information on these services. The CHW will also provide a brief motivational educational session about eating healthier to reduce BP and enhance quality and quantity of life. The CHW will meet once for up to one hour with each participant.
89388118|NCT05877898|Experimental|Community health worker provided education and Navigation|Participants will be invited to complete all the CHW education arm material and be offered a menu of optional services for personalization including: (1) transportation to the grocery store (weekly for 4 weeks), (2) culturally adapted hypertension-tailored cooking recipes, (3) a virtual cooking class with food delivered to their door led by community partner, (4) access to UF IFAS's online library of healthy food cooking videos, and (5) in-store education on food labels, grocery shopping, and food resource management skills through the Cooking Matters at the Store curricula.
89388119|NCT05867407|Experimental|Anumana Low EF AI-ECG Algorithm|Anumana Low EF AI-ECG Algorithm
89388120|NCT05867407|Other|Care-as-Usual|Care-as-Usual
89388121|NCT05862324|Experimental|TAC01-CLDN18.2|Lymphodepletion followed by TAC01-CLDN18.2 as a single IV infusion.
89388122|NCT05857969||Chemorefractory or relapsed patients|We intend to enroll chemorefractory or relapsed pediatric patients with all types of cancers where tumor tissue would be available for ex vivo drug screening and genomic profiling. The results of the drug sensitivity assay and genetic screening will be used to inform treating physician about patient-specific drug sensitivity or resistance guiding best therapy choices.
88863412|NCT05611593|Active Comparator|Propecia 1mg (oral Finasteride)|Participants will receive1 tablet of Propecia 1mg (oral Finasteride) once daily (q.d)
88863413|NCT05605496|Experimental|Stable Disease|Patients with a radiological documentation of SD according to RECIST V1.1 criteria following at least 12 weeks under standard PD-1/PD-L1 therapy. The initial evidence of SD is to be confirmed by a second assessment, no less than 4 weeks from the date of the first documented SD.
89388123|NCT05851872|Active Comparator|Fasting group|Participant will be asked to fast at least 6 hours prior to the procedure
88863414|NCT05605496|Experimental|Primary refractory|Patients with documented radiological PD according to RECIST V1.1 but with clinical benefit under PD-1/PD-L1 standard therapy.
88863415|NCT05605496|Experimental|Secondary refractory|Patients with documented radiological PD following an initial Objective Response according to RECIST V1.1, with clinical benefit under standard PD-1/PD-L1.
88863416|NCT05604508|Active Comparator|Status Quo|This condition will allow for many posters with pricing information to be displayed.
88863417|NCT05604508|Experimental|Reduced Poster|This condition will allow for a reduced number of posters with pricing information to be displayed.
88863418|NCT05604508|Experimental|No price|This condition will allow for many posters with no pricing information to be displayed.
88863419|NCT05603182|Experimental|SAD Cohorts 1-8 Experimental Arm|Subjects will receive a single intravenous or subcutaneous dose of PRA052 in a dose escalation format
88863420|NCT05603182|Placebo Comparator|SAD Cohorts 1-8 Placebo Arm|Subjects will receive a single intravenous or subcutaneous dose of placebo
88863421|NCT05603182|Experimental|MAD Cohorts 1-5 Experimental Arm|Subjects will receive three subcutaneous or intravenous doses of PRA052, one dose every 2 weeks, in a dose escalation format
88863422|NCT05603182|Placebo Comparator|MAD Cohorts 1-5 Placebo Arm|Subjects will receive three subcutaneous or intravenous doses of placebo, one dose every 2 weeks
88863423|NCT05598398|Active Comparator|Control (Wet-to-dry dressings)|Subjects randomized to the control group with receive standard of care (wet-to-dry dressings) for treatment of their pressure sore.
88863424|NCT05598398|Experimental|Treatment (NPWT with Instillation)|Subjects who are randomized into the treatment arm (NPWT with Instillation) will receive the V.A.C. VeraFlo™ Cleanse Choice Dressing Systems for treatment of their pressure sore.
89388124|NCT05851872|Experimental|Non-Fasting group|Participants will be allowed to eat and drink up to 1 hour prior to the procedure.
89388125|NCT05851573|Experimental|Psychosocial intervention|
88863425|NCT05598203|Experimental|Intervention|"The intervention group will receive four group meetings in addition to the usual care, specifically in the form of operative groups. Participants in these groups will actively participate in the sessions and will be given tasks to complete at home. There will be four sessions, which can be held weekly, fortnightly or monthly, depending on the availability of participants. Each participant will attend each meeting only once. These sessions, lasting one hour, will take place at the Hospital de Clínicas de Porto Alegre and approximately 20 participants will be invited to each group.~Topics covered in these sessions will include:~Let's go shopping = purchasing food through NOVA classification and nutritional labeling and food labels~Healthy Plate = Diabetes Plate Method.~Hunger and satiety = signs of hunger and satiety and eating mindfully~Empowering change = barriers and difficulties in the process of maintaining lifestyle changes"
88863426|NCT05598203|Active Comparator|Control (usual treatment)|"In the usual care provided, there will be a consultation with a dietitian every four months. This consultation will involve nutritional counseling, where up to five combinations of lifestyle changes will be agreed upon with the participant. The combinations will be tailored to individual needs and align with diabetes recommendations, emphasizing increased consumption of natural foods, organizing meals according to the Diabetes Plate method, and promoting a reduction in sedentary time. Subsequent visits will reassess the combinations of lifestyle changes, addressing barriers and motivations identified during the counseling process.~Patients will not be encouraged to implement caloric restrictions, but they will be motivated to adopt healthy eating patterns in accordance with the recommendations of the American Diabetes Association and the Sociedade Brasileira de Diabetes."
88863427|NCT05595434|Experimental|active stress group|20 healthy subjects will be subject to the active condition of a standardized stress protocol
88863428|NCT05595434|Placebo Comparator|placebo stress group|20 healthy subjects will be subject to the placebo condition of a standardized stress protocol.
88863429|NCT05594810|Active Comparator|TAU only: Community Reinforcement Approach (CRA) + a regular smoking cessation program|TAU only
88863430|NCT05594810|Experimental|TAU + Addiction focussed - eye movement desensitization and reprocessing (AF-EMDR) + TAU (CRA)|TAU + Addiction focussed - eye movement desensitization and reprocessing (AF-EMDR)
88863431|NCT05591144|Experimental|prednisone plus placebo group|a 10mg/d tapering 14-day course of oral prednisone intervention (the initial dose: 1mg/kg/day, max 60mg/day) in combination with ginkgo biloba agent (120mg daily)
88863432|NCT05591144|Active Comparator|control group|Patients took oral standardized Ginkgo biloba extracts (120 mg daily) three times a day.
88863433|NCT05590676|Experimental|HIE: 20 mg/kg|
88863434|NCT05590676|Experimental|HIE: 25 mg/kg|
88863435|NCT05590676|Experimental|Preterm: 15 mg/kg|
88863436|NCT05590676|Experimental|Preterm: 20 mg/kg|
88863437|NCT05585606|Placebo Comparator|Placebo|Volume Matched Placebo (normal saline)
88863438|NCT05585606|Experimental|scp776 (1.9 mg/kg)|"Cohort 1 dose regimen:~Intravenous (IV) slow injection(s) over 2 minutes~- 1.9 mg/kg"
88863439|NCT05585606|Experimental|scp776 (3.8 mg/kg)|"Cohort 2 dose regimen:~Intravenous (IV) injection(s) over 2 minutes~- 3.8 mg/kg"
88863440|NCT05581238||TRACK|External validation of TRACK prediction model with 5 variables: age, weight, sex, pre-op HCT, Type of surgery.
88863441|NCT05581238||TRACK-TCT|New model development with 6 variables. 5 From the TRACK model: age, weight, sex, pre-op HCT, Type of surgery. A sixth variable will be added i.e.: pre-operative P2Y12 drug use
88863442|NCT05576467|Active Comparator|Telephone|8 weekly classes delivered via telephone.
88863443|NCT05576467|Active Comparator|Video|8 weekly classes delivered via video.
88863444|NCT05576467|Active Comparator|Online|8 weekly online modules delivered via web portal.
88863445|NCT05567796|Experimental|Cagrisema s.c. 2.4 mg/2.4 mg|Participants will receive 2.4 mg cagrilintide and 2.4 mg semaglutide once-weekly after a dose escalation period of 16 weeks (0.25 mg of cagrilintide and 0.25 mg of semaglutide from weeks 0-4, 0.5 mg of cagrilintide and 0.5 mg of semaglutide from weeks 5-8, 1 mg of cagrilintide and 1 mg of semaglutide from weeks 9-12 and 1.7 mg of cagrilintide and 1.7 mg of semaglutide from weeks 13-16) during the maintenance period for 52 weeks in the main phase. Participants randomised to this arm will be included in the extension phase for 97 weeks.
88863446|NCT05567796|Active Comparator|Cagrilintide s.c. 2.4 mg|Participants will receive cagrilintide s.c. 2.4 mg and placebo matching to semaglutide once-weekly after a dose escalation period of 16 weeks (0.25 mg for weeks 0-4, 0.5 mg for weeks 5-8, 1 mg for weeks 9-12 and 1.7 mg for weeks 13-16) during the maintenance period for 52 weeks.
88863447|NCT05567796|Active Comparator|Semaglutide s.c. 2.4 mg|Participants will receive semaglutide s.c. 2.4 mg and placebo matched to cagrilintide once-weekly after a dose escalation period of 16 weeks (0.25 mg for weeks 0-4, 0.5 mg for weeks 5-8, 1 mg for weeks 9-12 and 1.7 mg for weeks 13-16) during the maintenance period for 52 weeks.
88863448|NCT05567796|Placebo Comparator|Placebo s.c.|Participants will receive placebo matched to cagrilintide and placebo matched to semaglutide once weekly for 68 weeks. Participants randomised to this arm will be included in the extension phase for 97 weeks.
88863449|NCT05566522||Experimental Group|Those between the ages of 20-75, Those with musculuskeletal disorders, choronic and neurological disease
88863450|NCT05566522||Control Group|Healty group
88863451|NCT05564039|Experimental|Tirzepatide|Participants will receive tirzepatide subcutaneously (SC)
88863452|NCT05564039|Active Comparator|Dulaglutide|Participants will escalate their dulaglutide dose SC.
88863453|NCT05562713|No Intervention|Control (Arm #1)|CIC will be discussed with caretakers & patients during their appointment and they will be given the instruction sheet to take home. They will not have a follow-up appointment scheduled. Research team will call them to check if the patient is able to perform CIC independently. If they can, a visit will be scheduled for them to demonstrate this in clinic.
88863454|NCT05562713|Experimental|Present Bias without Loss Aversion (Arm #2)|CIC will be discussed with caretakers & patients during their appointment and they will be given the instruction sheet to take home. Child will receive a prize (~$5-20 in value) for every CIC step completed. They will follow-up in clinic in 3 months (or earlier) to demonstrate their CIC ability. If they can demonstrate this ability, they will receive a large prize (~$30-50 in value)
89185292|NCT00738621|Placebo Comparator|A,2|Oral aprepitant 40 mg- given within 3 hours prior to induction dexamethasone (4mg intravenous) administered immediately after induction Placebo ( intravenous saline 2ml) administered at cessation of anesthesia
89388126|NCT05848687|Experimental|Treatment|"Participants who meet eligibility criteria will receive remission induction, induction intensification, consolidation I, reinduction block I, reinduction block II, consolidation II, and Maintenance.~Interventions: Dexamethasone, Mitoxantrone, PEG-asparaginase, Bortezomib, Vorinostat, Mercaptopurine, Methotrexate and Vincristine, Blinatumomab, Ziftomenib"
88863455|NCT05562713|Experimental|Present Bias with Loss Aversion (dependent on accrual) (Arm #3)|CIC will be discussed with caretakers & patients during their appointment and they will be given the instruction sheet to take home. Child will pick a prize for every CIC step completed. They will follow-up in clinic in 3 months (or earlier) to demonstrate their CIC ability. All of the prizes that the child picked will be given only if fully-independent CIC is demonstrated.
88863456|NCT05555615|Experimental|Pimavanserin|"Pimavanserin once daily. All patients will receive the pimavanserin low dose (patients aged 5 to 12 years: 10 mg/day pimavanserin; patients aged 13 to 17 years: 20 mg/day) the first 2 weeks of the study. Thereafter, the dose may be increased to the high dose (5 to 12 years: 20 mg/day; 13 to 17 years: 34 mg/day) based on the Investigator's assessment of clinical response.~After Week 2 and up to Week 20, dose adjustments are allowed at any clinic visit based on the Investigator's assessment of clinical response and tolerability. No further dose adjustments are allowed after Week 20."
88863457|NCT05554874|Experimental|Case group|participants undergoing pulsed electromagnetic fields
88863458|NCT05554874|Sham Comparator|Control group|participants undergoing sham pulsed electromagnetic fields
88863459|NCT05549297|Experimental|Arm A|Tebentafusp as single agent
88863460|NCT05549297|Experimental|Arm B|Tebentafusp in combination with Pembrolizumab
88863461|NCT05549297|Experimental|Arm C|Straight to on protocol survival follow up including investigators choice of therapy
88863462|NCT05548647|Active Comparator|Behavioral Treatment + Placebo|Behavioral treatment (lifestyle modification counseling for weight loss) plus placebo
88863463|NCT05548647|Active Comparator|Behavioral Treatment + Medication|Behavioral treatment (lifestyle modification counseling for weight loss) plus semaglutide
88863464|NCT05545306|Active Comparator|Set 1|+150% LPF +150% SOF -50% +200% LPF +200% SOF Fasting -25%
88863465|NCT05545306|Active Comparator|Set 10|+200% LPF -25% Fasting +200% SOF -50% +150% LPF +150% SOF
88863466|NCT05545306|Active Comparator|Set 2|+150% LPF +200% LPF -50% +150% SOF Fasting -25% +200% SOF
88863467|NCT05545306|Active Comparator|Set 3|+150% LPF Fasting +150% SOF -25% +200% SOF +200% LPF -50%
88863468|NCT05545306|Active Comparator|Set 4|Fasting -25% +200% LPF -50% +200% SOF +150% SOF +150% LPF
88863469|NCT05545306|Active Comparator|Set 5|-25% +150% SOF +200% LPF +150% LPF Fasting +200% SOF -50%
88863470|NCT05545306|Active Comparator|Set 6|Fasting +200% LPF +200% SOF -50% +150% LPF -25% +150% SOF
88863471|NCT05545306|Active Comparator|Set 7|-50% +200% SOF -25% +150% SOF Fasting +200% LPF +150% LPF
88863472|NCT05545306|Active Comparator|Set 8|-50% +150% SOF +200% SOF +150% LPF -25% +200% LPF Fasting
88863473|NCT05545306|Active Comparator|Set 9|+150% SOF -25% +150% LPF +200% SOF Fasting +200% LPF -50%
88863474|NCT05540171|Experimental|Education intervention (Oral health education and instructions/training for self-oral care)|The intervention arm will be given a 45 minute oral health education which will include oral hygiene instructions and motivation/training for oral self-care (dietary counselling; snacking during and not mealtimes; post-meal rinsing; flossing; brushing frequency, time, and method; tongue cleaning; toothbrush type/care; toothpaste quantity/type; dental visits). Audio-visual aids and leaflets reinforcing the oral health education will also be provided.
88863475|NCT05540171|No Intervention|No intervention (Control)|The control arm/group will receive no intervention (Oral health education) until right after the study is over.
89185293|NCT00733239|Experimental|1|Receives 2-4 of the drugs listed under Intervention
89185294|NCT00738153||A|
89388127|NCT05847166|Active Comparator|Cohort A - lymph node assessment in intermediate risk group|The patients will undergo [99mTc]Tc-PSMA-T4 semiWB- SPECT/CT as an additional modality to contrast-enhanced (CE) multiparametric MRI (according to PI-RADS 2.1 protocol) with additional chest and abdominal CE computed tomography and [99mTc]Tc-MDP bone scan in unfavorable risk prostate cancer patients
88863476|NCT05538533|Experimental|46 Gray (Gy)|46 gy of radiation therapy will be administered in 10 fractions.
88863477|NCT05538533|Experimental|40 Gray (Gy)|40 gy of radiation therapy will be administered in 7 fractions.
88863478|NCT05538533|Experimental|35 Gray (Gy)|35 gy of radiation therapy will be administered in 5 fractions.
88863479|NCT05527210|Active Comparator|Active Study Med|Participants randomized to active study medication will mix 4g of powder prebiotic with water, 3 times a day for 12 weeks.
88863480|NCT05527210|Placebo Comparator|Placebo|Participants randomized to active study medication will mix 4g of powder placebo with water, 3 times a day for 12 weeks.
88863481|NCT05524883|Experimental|Placebo-Controlled MAD Period - DYNE-251|DYNE-251 will be administered once every 4 weeks (Q4W) or once every 8 weeks (Q8W) over 24 weeks.
88863482|NCT05524883|Experimental|Placebo-Controlled MAD Period - Placebo|Placebo will be administered Q4W or Q8W over 24 weeks.
88863483|NCT05524883|Experimental|Open-Label and Long-Term Extension Period - DYNE-251|DYNE-251 will be administered Q4W or Q8W for up to 96 weeks after participants complete the Placebo-Controlled MAD Period of the study.
88863484|NCT05524220|Active Comparator|Group A: Standard care with a facemask.|
88863485|NCT05524220|Experimental|Group B: SuperNO2VA™EtCO2|
88863486|NCT05524051|Experimental|TIN816|TIN816
88863487|NCT05524051|Placebo Comparator|Placebo|Placebo
88863488|NCT05520775|Experimental|Semaglutide|Participants will receive semaglutide via subcutaneous injections at escalating doses (.25mg to 1.0mg) over 9 weeks.
88863489|NCT05520775|Sham Comparator|Sham/Placebo|Participants will receive sham subcutaneous injections over 9 weeks.
88863490|NCT05511922|Experimental|KVD900 600 mg|
88863491|NCT05509400|Experimental|Rimegepant|"Rimegepant - Double-blind (DB) Phase: One dose of rimegepant 75 mg Oral Disintegrating Tablet (ODT)~Rimegepant/Rimegepant - Open-label Extension (OLE) Phase: participants receive one dose rimegepant 75 mg ODT as needed for a qualifying acute migraine. A qualifying migraine is an attack of moderate or severe headache pain intensity. Migraine headache pain intensity will be measured on a 4-point numeric rating scale (0=none, 1=mild, 2=moderate, 3=severe)"
89185295|NCT04065165|Experimental|Experimental arm|Lanreotide 120 mg q4w Telotristat Ethyl 250 mg TID
89185296|NCT04065165|Placebo Comparator|Control arm|Lanreotide 120 mg q4w Placebo TID
89185297|NCT00577629|Experimental|Induction + Consolidation + Bexxar|Induction:Cyclophosphamide, Etoposide, and Rituxan (rituximab) followed by Consolidation: Cytarabine and Doxorubicin followed by radioimmunotherapy: Bexxar (tositumomab)
89185298|NCT00733317|Active Comparator|1-Budesonide nebulized suspension|Children will receive 0.5 mg/ml budesonide nebules every 20 minutes for 3 times and will not give after 3 doses
89185299|NCT00733317|Placebo Comparator|2- 0.9% saline|Children will receive 2 ml of saline every 20 minutes for 3 times and will not give after 3 doses
89185300|NCT00738231|Active Comparator|I|"Group I's training material consisted of a brochure with the information we wanted the public to know about heart disease. The brochure had such titles as Cardiovascular Diseases, let us protect our hearts, the importance of cholesterol in preventing heart diseases, watch out for blood pressure, quit smoking for your health, weight watching, nutrition, food to avoid in cardiovascular disease, an easy method: exercise and exercise control, and an appropriate body weight vs. height chart for adults"
89185301|NCT00738231|Active Comparator|II|The Group II training material document was a letter in the form of a prescription in which the individual was addressed by name, the risk factors established at the first stage were explained, and the suggested measures for protection from such risk factors were indicated.
89185302|NCT00733395|Experimental|1|Tart cherry juice
89185303|NCT00733395|Placebo Comparator|2|Fruit juice
89185304|NCT02568735|Experimental|Etoricoxib|Etoricoxib 60mg if body weight≤ 60kg, 90mg if body weight 61-90kg and 120mg if body weight> 90kg by mouth
89185305|NCT02568735|Active Comparator|Dexketoprofen|Dexketoprofen 0,5 mg/kg up to 50 mg intravenously
89185306|NCT00738309||Operative|Diagnosis of classical Scheuermann's Kyphosis (3 successive vertebrae wedged 5 degrees or more, +/- end plate deformities) or idiopathic structural Kyphosis (rigid structural kyphosis without classic Scheuermann's Kyphosis findings) for which surgical treatment is recommended to prevent progression of the curvature or to correct trunk deformity (unacceptable cosmesis).
89185307|NCT00738309||Non-operative|Diagnosis of classical Scheuermann's Kyphosis (3 successive vertebrae wedged 5 degrees or more, +/- end plate deformities) or idiopathic structural Kyphosis (rigid structural kyphosis without classic Scheuermann's Kyphosis findings) for which surgical treatment was not undertaken.
89185308|NCT00733473|Active Comparator|1 Budesonide|This arm consist 50 children with recurrent wheezing who are hospitalized for wheezing epizode. They received 1 mg nebulized budesonide 2 times a day upto 5 days
89185309|NCT00733473|Placebo Comparator|2 Placebo saline|This arm consist 50 children with recurrent wheezing who are hospitalized for wheezing epizode. They received 2ml of nebulized saline 2 times a day upto 5 days
89185310|NCT00733551|Experimental|Subjects receiving GSK962040 in cohort 1|Eligible subjects will receive repeat oral doses of GSK962040 given as 10 milligrams once daily tablet for 14 days.
89185311|NCT00733551|Experimental|Subjects receiving GSK962040 in cohort 2|Eligible subjects will receive repeat oral doses of GSK962040 given as 30 milligrams once daily tablet for 14 days.
89185312|NCT00733551|Experimental|Subjects receiving GSK962040 in cohort 3|Eligible subjects will receive repeat oral doses of GSK962040 given as 100 milligrams once daily tablet for 14 days.
89185313|NCT00733551|Placebo Comparator|Subjects receiving placebo in cohort 1, 2 and 3|Eligible subjects will receive repeat oral doses of placebo tablets given once daily for 14 days in cohort 1, 2 and 3.
89185314|NCT00710385|Active Comparator|Heroin|Heroin 25 mg. Administered intravenously, while participants were under 2, 8 and 24 sublingual (SL) Bup maintenance conditions.
89388128|NCT05847166|Active Comparator|Cohort B - general assessment (bone and lymph nodes) in high and very high-risk group|The patients will undergo [99mTc]TcPSMA-T4 semi-WB- SPECT/CT and CE multiparametric MRI (according to PI-RADS 2.1 protocol), and chest and abdomen CE computed tomography, and skeletal scintigraphy ([99mTc]Tc-MDP bone scan).
89185315|NCT00710385|Active Comparator|Naloxone|Naloxone (NAL) .4 mg. Administered intravenously, while participants were under 2, 8 and 24 sublingual (SL) Bup maintenance conditions.
89185316|NCT00710385|Experimental|Low Bup Dose|Combined dosing groups of (4 mg and 8mg of Buprenorphine) for participants who administered a maximum of 8 mg of Bup during the qualification phase. Administered intravenously, while participants were under 2, 8 and 24 sublingual (SL) Bup maintenance conditions.
89185317|NCT00710385|Experimental|Low Bup/Nal Dose|Combined dosing groups of (4/1 mg and 8/2mg of Buprenorphine + Naloxone) for participants who administered a maximum of 8 mg of Bup during the qualification phase. Administered intravenously, while participants were under 2, 8 and 24 sublingual (SL) Bup maintenance conditions.
89185318|NCT00710385|Experimental|High Bup Dose|Combined dosing groups of (8mg and 16mg of Bup) for participants who administered a maximum of 16 mg of Bup during the qualification phase. Administered intravenously, while participants were under 2, 8 and 24 sublingual (SL) Bup maintenance conditions.
89185319|NCT00710385|Experimental|High Bup/Nal Dose|Combined dosing groups of (8/2mg and 16/4mg of Buprenorphine + Naloxone) for participants who administered a maximum of 16 mg of Bup during the qualification phase. Administered intravenously, while participants were under 2, 8 and 24 sublingual (SL) Bup maintenance conditions.
89185320|NCT00710385|Placebo Comparator|Placebo|Intravenous placebo (PCB) administration. Administered intravenously, while participants were under 2, 8 and 24 sublingual (SL) Bup maintenance conditions.
89185321|NCT04063605|Experimental|Clinical Pilates|Participants in this group will receive twice a week, total 8 weeks of clinical pilates exercise program. Each session will take 45 minutes.
89185322|NCT04063605|Active Comparator|Classic Physiotherapy|Participants in this group will receive twice a week, total 8 weeks of classic physiotherapy exercise program. Each session will take 45 minutes.
89185323|NCT04063527|Active Comparator|Standard therapy|combination of paclitaxel and carboplatin
89185324|NCT04063527|No Intervention|Observation|Observation
89388129|NCT05847166|Active Comparator|Cohort C - recurrent disease after definitive treatment (radiotherapy or surgery)|The patients will undergo [99mTc]TcPSMA-T4 semiWB- SPECT/CT and the second confirmatory imaging modality or biopsy in the case of evidence on progressive disease (PSA persistence/recurrence or radiographic evidence of metastatic disease or clinical symptoms suggesting metastatic disease).
89388130|NCT05836012|Experimental|Experimental|HIL-214 (1 dose at 4 months of age and 1 dose at 6 months of age) and routine childhood vaccines according to schedule.
89388131|NCT05836012|Placebo Comparator|Placebo|Placebo (1 dose at 4 months of age and 1 dose at 6 months of age) and routine childhood vaccines according to schedule.
89388132|NCT05832632|Experimental|Headspace Basics Program|
89388133|NCT05832632|Experimental|Headspace Breathing Exercises|
89388134|NCT05832632|Experimental|Headspace Stress Program|
89388135|NCT05832632|Active Comparator|Active Control (Audiobook)|
89388136|NCT05832632|No Intervention|Passive Control|
88863492|NCT05509400|Placebo Comparator|Placebo|"Placebo - Double-blind (DB) Phase: One dose of matching placebo~Placebo/Rimegepant - Open-label Extension (OLE) Phase: participants receive one dose rimegepant 75 mg ODT for a qualifying migraine"
88863493|NCT05505916|Experimental|KVD900 600 mg|
88863494|NCT05505084||Collatape (Zimmer Dental)|This material is a resorbable collagen wound dressing. They are made from bovine Achilles tendons and are a source of Type I collagen. The resorbable wound dressings are sterilized after purification with ethylene oxide.
88863495|NCT05505084||Cytoplast Barrier Membranes TXT-200 Singles (Osteogenics Biomedical)|Cytoplast Barrier membranes are manufactured from high-density Polytetrafluoroethylene (PTFE) which allows them to withstand exposure to the oral environment. The textured surface increases the surface area available for cellular attachment during dental bone grafting procedures thereby aiding in stabilizing the PTFE membrane. It can be removed non-surgically after at least 21 days.
89388137|NCT05832177||Community Members who attend Cancer CientoUno (101) program|Community members who opt to participate in the online Cancer CientoUno (101) training program. They will be asked to complete a registration survey and the programs self-paced educational modules. At the start of the course, they will be asked to complete a brief survey. After every module, they will be asked to complete a brief survey. In addition, community members will be asked to complete a midterm survey and a 6-month follow up survey.
89388138|NCT05832177||Community Members who Attend Symposium|Community members who opt to attend this symposium which will offer educational presentations focused on prevention, nutrition, clinical trials, and specific cancer types addressed in breakout sessions. Participants will be asked to complete a registration form and a post-event evaluation form.
89388139|NCT05832177||Community Members who Attend Charlas (Talks)|Community members who opt to attend these charlas (talks) which will offer education on a variety of cancer-related topics. The topics are selected in response to each event, given the community interest or need for a specific cancer-related topic. Participants will be asked to complete a registration form and a post-event evaluation form.
89388140|NCT05832177||Community Members who Attend Presentations|Community members who opt to attend and researchers (including those from the PHSU-MCC U54 partnership) will participate in these presentations to generate a discussion about ongoing research and have an opportunity for community members learn and provide feedback on on-going and completed research projects. Presentations from El Puente events will occur in Spanish (in Puerto Rico and Florida) and in English (in Florida). Attendees will be asked to complete a registration form and a post-event evaluation.
89388141|NCT05832177||Community Members who Access Series of Virtual Lunch and Learn Podcasts|Community members will have access to a series of virtual Lunch and Learn podcasts, which will be 30-minute long, pre-recorded sessions in English and/or Spanish. Podcast sessions will cover updated cancer-relevant recommendations from the United States Preventive Services Task Force (USPSTF). Reach will be tracked with number of visits and/or other access metrics.
89185325|NCT00738777|Active Comparator|1|Anastrozole
88863496|NCT05505084||Ossix Plus (dantum dental)|OssixPlus is a resorbable collagen dental membrane used for Guided Bone Regeneration and Guided Tissue Regeneration. It contains a patented GLYMATRIX cross-linking technology that allows it to maintain barrier functionality for 4 to 6 months. The collagen is derived from porcine.
88863497|NCT05505084||Renovix-Plus (Salvin)|Renovix Plus is a non-cross-linked extracellular matrix containing Type I, II, and III Collagen, Fibronectin, Laminin, and Elastin. It provides architecture and barrier protection for bone regeneration and soft tissue esthetics. This membrane resorbs within six months.
89185326|NCT00738777|Experimental|2|Anastrozole + Fulvestrant
89185327|NCT00738777|Active Comparator|3|Tamoxifen
89185328|NCT00738777|Other|4|Tamoxifen (pre-menopausal and male patients)
89185329|NCT00733707|Experimental|1|Text messaging reminders
89185330|NCT00733707|No Intervention|2|No text messaging reminder
89185331|NCT00733785|Experimental|2mg tablet|2 mg tablet fasted
89185332|NCT00733785|Experimental|4 mg tablet|4 mg tablet fasted
89388142|NCT05832177||U54 Partnership Investigators|These CE workshops will be mandatory for all partnership researchers who receive U54 funding in the proposed renewal period including Full, Pilot, and Developmental projects. The CE workshops are aimed to increase researchers' knowledge about the best strategies to establish teamwork with community members to achieve mutual benefits and advance translational research in cancer.
89388143|NCT05832177||Lay Community Members|Lay community members will opt to participate in a 2-day CE workshop series. The goal is to include trained lay community members to actively participate in cancer prevention education and research. These activities will facilitate community-academic partnerships between the Partnership researchers and community members.
89388144|NCT05832177||Community Members who Join Community Advisory Panel (CAP)|The Community Advisory Panel (CAP) members will include individuals who are cancer survivors, family members/caregivers of cancer survivors, and/or representatives from healthcare, community- and faith-based organizations who are invited to join the CAP and accept the invitation. The PHSU-MCC Partnership utilizes a CAP to inform and guide overall outreach activities in PR and FL. Two CAPs, one at MCC and one at PHSU have been organized. Previous CAP members will be retained if interested and new CAP members added as needed.
89388145|NCT05832177||U54 Partnership Investigators and CAP Members|During standing CAP meetings, partnership investigators present their ongoing research to members of the CAPs. Researchers who receive U54 funding in the proposed renewal period including Full, Pilot, and Developmental projects can request CAP feedback on topics along the research continuum from concepts for new research projects, ideas for recruitment, or dissemination of fundings.
89388146|NCT05832177||Community Leaders and Stakeholders|Community leaders from disadvantaged socioeconomic areas and Stakeholders of healthcare organizations with whom the Program has established previous collaborative relationships will participate in the CBTP. The stakeholders include nurses, community health educators, clinical social workers, among other healthcare professionals.
89388147|NCT05832177||Stakeholders|Physicians, nurses, psychologists, and other stakeholders within the communities under the partnership umbrella will participate in the Cancer 101 Stakeholders program.
89388148|NCT05831579|Experimental|Cohort A: Reirradiation of Treatment Fields|Radiotherapy will consist of 20 Gy proton GRID radiotherapy x 3 fractions.
88863498|NCT05505084||BioXclude (Snoasis)|BioXclude is a minimally manipulated allograft amnion chorion tissue. It is obtained from consenting mothers who donate their placentas after elective caesarian section delivery. The tissue is processed to cleanse and maintain the tissue. Following processing and dehydration, the allografts are packaged and terminally sterilized.
88863499|NCT05504083|Experimental|D-0120 group 1|take D-0120 dose 1 orally during the treatment period.
89388149|NCT05831579|Experimental|Cohort B: De Novo Radiation Treatment Fields|Radiotherapy will consist of 20 Gy proton GRID radiotherapy x 3 fractions.
88863500|NCT05504083|Experimental|D-0120 group 2|take D-0120 dose 2 orally during the treatment period.
88863501|NCT05504083|Active Comparator|Benzbromarone|take benzbromarone orally during the treatment period.
89185333|NCT00733785|Experimental|8mg tablet|8 mg tablet fasted
89185334|NCT00733785|Experimental|2 x 4 mg tablets|2 x 4mg tablets fasting
89388150|NCT05830110|Active Comparator|Active vibrotactile coordinated reset|mechanical vibrotactile stimulation to the fingers in a defined pattern
88863502|NCT05504083|Experimental|D-0120 group 3|take D-0120 dose 3 orally during the treatment period.
88863503|NCT05503797|Experimental|Group A|Participants with unresectable, locally advanced or metastatic solid tumors or primary CNS tumors harboring BRAF fusions, will receive 900 mg of plixorafenib administered with 150 mg of cobicistat once daily (QD), continuously in 3-weeks cycles until disease progression, unacceptable toxicity, or other reason for withdrawal.
88863504|NCT05503797|Experimental|Group B|Participants with recurrent primary CNS tumors harboring BRAF V600E mutations will receive 900 mg of plixorafenib administered with 150 mg of cobicistat QD, continuously in 3-week cycles until disease progression, unacceptable toxicity, or other reason for withdrawal.
88863505|NCT05501054|Experimental|Ipilimumab, Nivolumab, and Ciforadenant|To help control advanced renal cell carcinoma.
88863506|NCT05479812|Experimental|WTX-124 monotherapy dose escalation|
88863507|NCT05479812|Experimental|WTX-124 monotherapy dose expansion in advanced or metastatic cutaneous malignant melanoma|
88863508|NCT05479812|Experimental|WTX-124 monotherapy dose expansion in advanced or metastatic RCC|
89185335|NCT00733785|Experimental|2 x 2mg tablets|2 x 2mg tablets fasting
89185336|NCT00733785|Experimental|8 mg tablet fed|8 mg tablet fed
89185337|NCT00733785|Experimental|Repeat dose|8 mg once a day for 6 days
89388151|NCT05830110|Sham Comparator|Sham vibrotactile coordinated reset|mechanical vibrotactile stimulation to the fingers in a defined pattern
88863509|NCT05479812|Experimental|WTX-124 in combination with pembrolizumab dose escalation|
88863510|NCT05479812|Experimental|WTX-124 in combo with pembro dose expansion in advanced/metastatic cutaneous malignant melanoma|
88863511|NCT05479812|Experimental|WTX-124 in combination with pembrolizumab dose expansion in advanced or metastatic RCC|
88863512|NCT05470790||athletes with anterior cruciate ligament injuries|
88863513|NCT05470790||control|
88863514|NCT05466994|Other|Group 1(Spellbound)|Participants will play the game using the iPad's standard camera, which will show you your hospital room and the decals as they appear in the real world.
88863515|NCT05466994|Other|Group 2 (Spellbound)|Participants will play the game using augmented reality
88863516|NCT05462522|Experimental|MAD Stage|Participants will be randomized in a ratio of 4:1 to receive RO7303509 or placebo, as subcutaneous (SC) injection, one time per month for 3 months. You have a 20% chance of getting placebo.
88863517|NCT05462522|Experimental|OSE Stage|Every participant in the OSE stage will receive study drug and no participant will receive placebo. Participants will receive RO7303509 as SC injection at the same dose as that administered during the MAD stage, one time per month for up to a year.
88863518|NCT05462145|Experimental|Globe Pulsed Field System|
89185338|NCT00738855|Active Comparator|1|Gastrografin group
89185339|NCT00738855|Placebo Comparator|2|Control group
89185340|NCT00738933|Active Comparator|A|A group of patients consuming 2 grams plant stanols 4-8 weeks before the operation
89185341|NCT00738933|Active Comparator|E|A group of patients consuming daily 2 grams plant sterols 4-8 weeks before the operation.
89185342|NCT00738933|Placebo Comparator|C|
89185343|NCT05741073||resected HR-cSCC|Patients with resected HR-cSCC (Cohort 1) receiving only postoperative radiotherapy or watchful waiting
89185344|NCT05741073||advanced cSCC|Patients with advanced cSCC who are not candidates for curative surgery/radiation in routine clinical practice (Cohort 2)
89185345|NCT05741073||advanced BCC|Patients with advanced BCC who are not candidates for curative surgery/radiation in routine clinical practice (Cohort 3)
89185346|NCT05740917|Experimental|Part 1: XZB-0004|
89185347|NCT00739011|Experimental|1|
89185348|NCT00739167||Y90 Group|Patients receiving treatment with radioembolization.
89185349|NCT00739167||TACE Group|Patients receiving treatment with transcatheter arterial embolization
89185350|NCT00739167||RFA Group|Patients receiving treatment with radiofrequency ablation.
89185351|NCT00701415|Experimental|Fabrazyme 0.5 mg/kg|Fabrazyme 0.5 mg/kg was administered every 2 weeks (up to 131 infusion) up to 260 weeks, the total infusion time was not less than 45 minutes. In case of significant progression of Fabry disease, the dose was increased to 1.0 mg/kg every 2 weeks.
89185352|NCT00701415|Experimental|Fabrazyme 1.0 mg/kg|Fabrazyme 1.0 mg/kg was administered every 4 weeks (up to 66 infusion) up to 260 weeks, the total infusion time was not less than 90 minutes. In case of significant progression of Fabry disease, the dose was increased to 1.0 mg/kg every 2 weeks.
89185353|NCT04063449|Experimental|Experimental:group A|endostar,210 mg,CIV 72h,d1-d3; sintilimab,200mg,IV,d1; carboplatin,5/AUC,IV,d1; Pemetrexed,500mg/m2 ,IV,d1； 3 weeks for a cycle;4-6 cycles; after the treatment for 4-6 cycles,endostar plus sintilimab for maintenance therapy until PD or intolerable toxicity ;
89185354|NCT04063449|Active Comparator|control:group B|endostar,210 mg,CIV 72h,d1-d3; carboplatin,5/AUC,IV,d1; Pemetrexed,500mg/m2 ,IV,d1； 3 weeks for a cycle;4-6 cycles; after the treatment for 4-6 cycles,endostar for maintenance therapy until PD or intolerable toxicity ;
89185355|NCT04062747|Active Comparator|I-gel LMA|After standard anesthesia i-Gel was placed into the patient.
89185356|NCT04062747|Active Comparator|Ambu Aura-i|After standard anesthesia Ambu Aura-i was placed into the patient.
89185357|NCT00700011|Active Comparator|10 mg/m2 group|Patients were treated with Clofarabine 10 mg/m2 daily x 5 days per cycle. Cycles were intended on being every 28 days but this was flexible due to the bone marrow neding to recover from each cycle before strting the next one. Neulasta was given on day 5 of each cycle. Patients were treated until disease progression, or intolerable toxicities.
89185358|NCT00700011|Active Comparator|5 mg/m2 group|Patients were treated with Clofarabine 5 mg/m2 daily x 5 days per cycle. Cycles were intended on being every 28 days but this was flexible due to the bone marrow neding to recover from each cycle before strting the next one. Neulasta was given on day 5 of each cycle. Patients were treated until disease progression, or intolerable toxicities.
89185359|NCT05740683||People with idiopathic olfactory dysfunction|
89185360|NCT05740683||People without olfactory dysfunction|
89185361|NCT04064541|Other|Virtual Visit|"At the baseline visit patients will complete an in-clinic baseline visit consisting of Medical Hx review, NYHA assessment, Questionnaires (EQ-5D-5L, KCCQ, Frailty Index for Elders & Mini Cog) and Functional Assessments (Timed Up & Go and 6MWT). Patients will also receive virtual visit training and complete an in-clinic virtual visit consisting of the previously stated functional assessments.~All follow-up visits will occur via virtual distance health visits. These f/u visits will occur at Day 7and Day 14 At the initiation of each distance health f/u visit the patient's current state of health will be assessed as well as NYHA. Patient Questionnaires(EQ-5D-5L, KCCQ & Frailty Index) and Functional Assessments(Timed Up & Go and 6MWT) will be completed."
89185362|NCT05512767|Experimental|Group I (pneumatic therapy, lymphedema management)|Patients undergo 32 minute treatments twice daily for 12 weeks using the FlexiTouch Plus System and treatment with a lymphedema therapist weekly on weeks 2-11. Patients undergo nasolaryngoscopy and videofluoroscopic swallow study at baseline.
89185363|NCT05512767|Active Comparator|Group II (standard of care, lymphedema management)|Patients undergo standard of care self-manual lymphatic drainage (technique instructions provided) twice daily for 12 weeks and treatment with a lymphedema therapist weekly on weeks 2-11. Patients undergo nasolaryngoscopy and videofluoroscopic swallow study at baseline.
89185364|NCT04063293|Experimental|PRP injection|PRP is prepared using a special device (VS-400, Genesis Comp, Korea). For each application a kit (e+ PRP, Genesis Comp, Korea) will be used. 18 cc of venous blood will be collected from the patient into the syringe with 2 cc of anticoagulant, and will be gently inverted. The sample will be slowly injected into the e+ PRP kit. The kit will be centrifuged under 1,500G for 4 minutes, which will separate the blood components into 3 different layers. The rot at the top of the kit will be pressed until the bottom of the piston will touch the red blood cell layer, and the rot will be turned clockwise to close it. The cap will be opened and the small syringe will be connected to the cap for extracting PRP. The injection will be performed in operation room under general anesthesia with either IV sedation of laryngeal mask airway (LMA) sedation. 10 cc of PRP will be directly injected in external muscles at 8 locations under the guidance of endoanal ultrasound
89185365|NCT04064385|Experimental|Intervention|FES cycle training will be performed on the RT300 FES cycle ideally 3 times per week for 6 weeks, each session lasting up to 90 minutes. Electrical stimulation will be delivered through up to 12 independent channels each delivering up to 140 mA current on the following muscles (both on the right and left leg): quadriceps, femoral biceps and gluteus, gastrocnemius and tibialis anterior. Abdominal and back extensor muscles may also be stimulated if the participant presents with neurological trunk weakness (SCI above T6). The FES unit will stimulate the muscles that extend the hip (gluteals), flex the knee (hamstrings) and extend the knee (quadriceps) in the correct order to bring about a cycling motion. The feet and lower legs of the participants will be strapped into the pedals and the wheelchair will be coupled in a rigid manner with the training device.
89185366|NCT04064385|No Intervention|Control|Participants in the control group will receive usual care, consistent with standard NHS care in this population. Usual physiotherapy care is provided, up to 2 times per day, 4 to 5 days per week, each lasting approximately 90 minutes. Physiotherapists provide one to one function-oriented physiotherapy session to improve balance, muscle strength and transfer skills.
89185367|NCT04063059|Active Comparator|Intervention|Subjects will be randomized to the program intervention which is a female-specific, culturally relevant, self-regulation based in-person group sessions and telephone counseling intervention designed for African American women who are overweight or obese.
89185368|NCT04063059|No Intervention|Control|Usual care
89185369|NCT02567955|Active Comparator|Immunogenicity two doses of Gardasil-9|Subjects will receive two doses of Gardasil-9
89388152|NCT05829174|Experimental|Cognitive Behavioral Therapy with Techniques of Starting on Time and Planning Realistically|5 session (one session a week) online group therapy including several psychoeducation and cognitive modules (what is procrastination, role of rewards, work environment, belief identification, cognitive restructuring, relapse prevention) and a behavioral module: realistic planning, timely beginning.
89388153|NCT05829174|Experimental|Cognitive Behavioral Therapy with Technique of Working Time Restriction|5 session (one session a week) online group therapy including several psychoeducation and cognitive modules (what is procrastination, role of rewards, work environment, belief identification, cognitive restructuring, relapse prevention) and a behavioral module: working time restriction.
89388154|NCT05829174|Active Comparator|Cognitive Behavioral Intervention with Time Management Technique|5 session (one session a week) online group therapy including several psychoeducation and cognitive modules (what is procrastination, role of rewards, work environment, belief identification, cognitive restructuring, relapse prevention) and a behavioral module: pomodoro technique.
89388155|NCT05829174|No Intervention|Wait-list control group|No intervention
89388156|NCT05827081|Experimental|Ribociclib + endocrine therapy|"Participants will receive ribociclib 400 mg orally once daily on days 1 to 21 of a 28-day cycle, in combination with daily endocrine therapy (ET) for 36 months (approximately 39 cycles). ET consists of:~For postmenopausal women: letrozole 2.5 mg orally once daily continuously, anastrozole 1 mg orally once daily continuously, or exemestane 25 mg once daily continuously.~For pre/perimenopausal women, and men: letrozole 2.5 mg orally once daily continuously, anastrozole 1 mg orally once daily continuously, or exemestane 25 mg once daily continuously, combined with goserelin subcutaneously (at 3.6 mg once every 4 weeks if the one-month depot formulation is used or at 10.8 mg once every 3 months if the three-month depot formulation is used) or leuprolide subcutaneously (at 3.75 mg once every 4 weeks if the one-month depot formulation is used or at 11.25 mg once every 3 months if the three-month depot formulation is used)"
89185370|NCT02567955|Experimental|Immunogenicity Cervarix and Gardasil-9|Subjects will receive a dose Cervarix and a dose Gardasil-9
88863519|NCT05452772|Active Comparator|Psilocybin|30 mg in session 1 and either 30 mg or 40 mg in session 2, with sessions 1 week apart. Dosing will be based on participants' responses to the Mystical Experiences Questionnaire (MEQ30), taken at the end of their first session. Participants with a score ≥60% of the maximum on the MEQ30 will remain at a dose of 30 mg of psilocybin for the second session. Participants with an MEQ30 score below 60% will receive a dose of 40 mg for the second session.
88863520|NCT05452772|Active Comparator|Niacin|150 mg in session 1 and either 150 mg or 200 mg in session 2, with sessions 1 week apart. Dosing will be based on participants' responses to the Mystical Experiences Questionnaire (MEQ30), taken at the end of their first session. Participants with a score ≥60% of the maximum on the MEQ30 will remain at a dose of 150 mg niacin for the second session. Participants with an MEQ30 score below 60% will receive a dose of 200 mg niacin for the second session.
89185371|NCT00739479|Active Comparator|1|Patients will be randomized to receive PHWP. Since sex and baseline weight can influence the response, randomization will be stratified according to these variables.
89388157|NCT05820711|Experimental|Mesenchymal Stem Cell (MSC) injection|
89388158|NCT05815927|Active Comparator|Arm 1 : Standard of Care|Pembrolizumab at a dose of 400mg every 6-weeks (Q6W) for a duration of 2 years (i.e 17 cycles) as per Standard of Care treatment of oligometastatic HNSCC disease. Palliative radiotherapy to oligometastatic disease is allowed if necessary as per standard of care to relieve symptomatic disease and prevent complications. Recommended dose regimens are 1x 8 Gy, 5x 4 Gy and 10x 3 Gy. Planning technique and target volume definition should be according to institutional standards.No ablative-stereotactic dose and no boost techniques are allowed with the exception of CNS-metastases treatment.
88863521|NCT05450718|Experimental|Low-dose initiation|"Participants randomized to low-dose buprenorphine initiation will start low-dose buprenorphine-naloxone (bup-nx) according to an at-home, 8-day protocol (below). Participants in the low-dose BUP initiation arm will be allowed to continue taking the full opioid agonist that they were taking at the time of enrollment until they reach a therapeutic dose of buprenorphine-naloxone.~Day 1: 0.5 mg once; Day 2: 0.5 mg every 12 hours; Day 3: 1 mg every 12 hours; Day 4: 2 mg every 12 hours; Day 5: 3mg every 12 hours; Day 6: 4 mg every 12 hours; Day 7: 6 mg every 12 hours; Day 8: 8 mg every 12 hours"
88863522|NCT05450718|Active Comparator|Treatment as usual|Participants randomized to treatment as usual will start buprenorphine-naloxone (bup-nx) following standard clinical guidelines for two-day, at-home initiation.
88863523|NCT05443880|Experimental|Exercise|The exercise intervention will undergo a exercise program 2 days / week (45 minutes per session) during a period of 8 weeks.
88863524|NCT05443880|Experimental|Exercise + mindfulness|The exercise + mindfulness intervention will carry out a an exercise intervention together with mindfulness intervention 1 day / week (2.5 hour per session).
88863525|NCT05443880|Other|Control|The control group will be provided with the usual care received in the Physical Medicine and Rehabilitation Service: stretching, breathing and motor control exercises 2 days / week (45 minutes per session) during a period of 8 weeks
89185372|NCT00739479|Placebo Comparator|2|Patients will be randomized to receive PHG. Since sex and baseline weight can influence the response, randomization will be stratified according to these variables.
88863526|NCT05434364|Experimental|Facilitated Tucking|giving facilitated tucking before, during and after the procedure
89185373|NCT04062903|Active Comparator|Immediate Appointment|Intervention group who receive the Social Prescription without delay. The effectiveness of the consultation and referral process will be assessed.
89185374|NCT04062903|Active Comparator|Delayed Appointment|Waitlist control group who receive social Prescribing after a delay of 20 working days. The effectiveness of the consultation and referral process will be assessed.
89185375|NCT00921063|Experimental|PD 0332334 250 mg|
88863527|NCT05434364|Experimental|Swaddling|giving swaddling before, during and after the procedure
89185376|NCT00921063|Experimental|PD 0332334 100 mg|
89185377|NCT00921063|Placebo Comparator|placebo|
89185378|NCT00921063|Active Comparator|Alprazolam extended release|
89185379|NCT00707031|Experimental|Lixisenatide|2-step initiation regimen of lixisenatide: 10 microgram (mcg) once daily (QD) for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment.
89388159|NCT05815927|Experimental|Arm 2 : Standard of Care + stereotattic ablative radiation (SABR)|The Experiemnt Arm consists of pembrolizumab at a dose of 400mg every 6-weeks (Q6W) for a duration of 2 years (i.e 17 cycles) as per Standard of Care treatment of oligometastatic HNSCC disease in combination with SABR. For each oligometastatic lesion treatment, specific SABR fractions and targeted dose(Gy) should be used depending on the location of the lesion. Three-fraction regimens will deliver a fraction every second day, and five-fraction regimens are delivered daily. All treatments have to be completed within 10 working days.
88863528|NCT05434364|Experimental|Prone position|giving prone position before, during and after the procedure
88863529|NCT05434364|No Intervention|control|Rutin care in the neonatal intensive care unit
88863530|NCT05428358|Experimental|Preoperative MRI|MRI before surgery.
88863531|NCT05422885|Experimental|Arm 1|Dasatinib and Quercetin
88863532|NCT05421819|Active Comparator|Calcium and vitamin D supplement|In this arm, 50 women will receive calcium and vitamin D supplement once per day.
88863533|NCT05421819|Active Comparator|Calcium, vitamin D and prebiotic supplement|In this arm, 50 women will receive calcium, vitamin D and prebiotic supplement once per day.
88863534|NCT05421819|Active Comparator|Calcium, vitamin D, prebiotic and flavonoid supplement|In this arm, 50 women will receive calcium, vitamin D, prebiotic and flavonoid supplement once per day.
88863535|NCT05418088|Experimental|Cohort A (lymphodepletion; anti-CD19/CD20/CD22 CAR-T cells)|"LYMPHODEPLETIVE REGIMEN: Patients receive cyclophosphamide IV over 60 minutes on day -6 and fludarabine IV over 30 minutes on days -5 to -3 in the absence of disease progression or unacceptable toxicity.~CAR T-CELL THERAPY: Patients receive anti-CD19/CD20/CD22 CAR-T cells IV over 5-30 minutes on day 0."
88863536|NCT05418088|Experimental|Cohort B (lymphodepletion, anti-CD19/CD20/CD22 CAR-T cells)|"LYMPHODEPLETIVE REGIMEN: Patients receive cyclophosphamide IV over 60 minutes on day -6 and fludarabine IV over 30 minutes on days -5 to -3 in the absence of disease progression or unacceptable toxicity.~CAR T-CELL THERAPY: Patients receive anti-CD19/CD20/CD22 CAR-T cells IV over 5-30 minutes on day 0 and 7."
88863537|NCT05413447|Experimental|Patients receiving digital consultations|The intervention group receive multifaceted digital consults including 1) digital data sharing (e.g. exchange of pharmacotherapy use, home measured vital signs, etc), 2) patient education via an eLearning, and 3) digital guideline recommendations to treating physicians. The consultations are performed remotely unless there is an indication to perform the consult physically.
88863538|NCT05413447|No Intervention|Standard care|If the patient is drawn into the control group the patient will receive standard care. Clinicians are free to use all standard modes of communication, and are not specifically encouraged to use remote types of communication. The clinicians are not informed about the assignment of a patient to the control group to optimally capture remote practice.
88863539|NCT05411588|Experimental|Active|PF-07275315
88863540|NCT05411588|Placebo Comparator|Placebo|Placebo
88863541|NCT05403593||Participants with Intracranial Stenosis|Patients with Intracranial Stenosis who undergo Mechanical Thrombectomy will be added to the registry given they meet the age inclusion criteria.
88863542|NCT05397782|Experimental|Pilot Group: Flourish HEC|All women in the study will use the Flourish HEC Vaginal Care System for 6 months. Flourish HEC consists of 3 products: 1) Balance, an external feminine wash; 2) BioNourish, a vaginal moisturizing gel; and 3) BiopHresh, a homeopathic vaginal suppository with probiotics. Products are pH-balanced to match healthy vaginal pH (3.5-4.5). BioNourish is formulated to be iso-osmotic with vaginal fluid. Balance and BioNourish contain lactic acid. BiopHresh contains 7 strains of lactobacilli, including Lactobacillus crispatus and other species found in healthy vaginas or shown to be effective probiotics strains.
88863545|NCT05374902|Experimental|Procedural informational animation group|Children and parents have watched procedural informational animation before venipuncture. Afterward, the children and their parents entered the blood drawn unit, and the procedure was performed as in standard care.
88863546|NCT05374902|Experimental|Buzzy group|Buzzy® was placed on the injection site and cold application and vibration were turned on 60 s before the procedure. Then, the nurse moved Buzzy® about 3-5 cm above the injection site. The procedure was performed with buzzy®. The Buzzy® intervention and phlebotomy were terminated at the same time.
88863547|NCT05374902|Experimental|Multiple interventions group|Children and parents have watched procedural informational animation before venipuncture. Afterward, the children and their parents entered the blood drawn unit. Buzzy® was placed on the injection site and cold application and vibration were turned on 60 s before the procedure. Then, the nurse moved Buzzy® about 3-5 cm above the injection site. The procedure was performed with buzzy®. The Buzzy® intervention and phlebotomy were terminated at the same time.
88863548|NCT05374902|No Intervention|Control group|Children in this group received standard care. A local anesthetic is not used, and the parents are with their children during the procedure in the standard care of the blood collection unit
88863549|NCT05370885|Other|Group A: Part 1 Active and Part 2 Placebo Treatment with Vancomycin pretreatment.|"In Part 1 of the study, patients in Group A will receive VE202 for 8 weeks.~In Part 2 of the study, patients in Group A will receive VE202 placebo for 2 weeks.~In Part 3, patients will be followed for safety for 1 year from the start of treatment."
88863550|NCT05370885|Other|Group B: Part 1 Placebo and Part 2 Active Treatment with Vancomycin pretreatment.|"In Part 1 of the study, patients in Group B will receive VE202 placebo for 8 weeks.~In Part 2 of the study, patients in Group B will receive VE202 for 2 weeks.~In Part 3, patients will be followed for safety for 1 year from the start of treatment."
88863551|NCT05360914|Experimental|Hospital at Home (HaH) treatment|The patients in this arm will receive the intervention.
88863552|NCT05360914|Active Comparator|Standard hospital admission|The patients in this arm are the control group and will receive the standard hospital treatment.
89185380|NCT00707031|Active Comparator|Exenatide|1-step initiation regimen of exenatide: 5 mcg twice daily (BID) for 4 weeks, followed by 10 mcg BID up to the end of treatment.
89185381|NCT00739635|Experimental|1|
89185382|NCT00739635|Placebo Comparator|2|
89388160|NCT05814432|Experimental|Single high dose arm|Single high dose of liposomal amphotericin B (10 mg/kg)
89388161|NCT05814432|Active Comparator|Standard dose arm|Standard treatment with 3 mg/kg of liposomal amphotericin B daily for 2 weeks
89388162|NCT05790954|Experimental|Guided imagery Group|
89388163|NCT05790954|No Intervention|Control Group|
89388164|NCT05787613|Experimental|HLX26 MTD + serplulimab 300 mg + chemotherapy intravenous infusion Q3W|In this group, HLX26 (MTD) in combination with HLX10 (300 mg) and chemotherapy will be intravenously administered every 3 weeks. About 40 subjects will be enrolled in this cohort. Patients will be treated with until disease progression, death, receiving new antitumor treatment, intolerable toxicity or withdrawal of informed consent (whichever occurs first). The efficacy of HLX26 (MTD) in combination with Serplulimab and chemotherapy will be evaluated in this group.
89388165|NCT05787613|Experimental|HLX26 MTD-1 + serplulimab 300 mg + chemotherapy intravenous infusion Q3W|In this group, HLX26 (MTD-1) in combination with HLX10 (300 mg) and chemotherapy will be intravenously administered every 3 weeks. About 40 subjects will be enrolled in this cohort. Patients will be treated with until disease progression, death, receiving new antitumor treatment, intolerable toxicity or withdrawal of informed consent (whichever occurs first). The efficacy of HLX26 (MTD-1) in combination with Serplulimab and chemotherapy will be evaluated in this group.
89388166|NCT05787613|Placebo Comparator|placebo + serplulimab 300 mg + chemotherapy intravenous infusion Q3W|In this group, placebo in combination with HLX10 (300 mg) and chemotherapy will be intravenously administered every 3 weeks. About 40 subjects will be enrolled in this cohort. Patients will be treated with until disease progression, death, receiving new antitumor treatment, intolerable toxicity or withdrawal of informed consent (whichever occurs first). The efficacy of Serplulimab and chemotherapy will be evaluated in this group.
89185383|NCT03900975||Vulvar Paget Disease|Women with vulvar paget disease
89388167|NCT05785429|Experimental|Colchicine|One tablet of colchicine 0.5 mg per day
89388168|NCT05785429|Placebo Comparator|Placebo|One tablet of microcrystalline cellulose per day
88863553|NCT05354869|Active Comparator|Usual Care|The current standard, first line treatment for MPP is a program of education, home exercises, and stretching. At enrollment, subjects will be counseled about the origins of myofascial pain in a one-on-one setting with the aid of informational handouts. They will be counseled about specific practices, such as Kegel exercises, volitional holding of urine or stool, and intensive exercise, that aggravate pelvic floor hypertonicity. They will be counseled about appropriate hydration and maintaining an adequate bowel regimen to avoid constipation. A stretching regimen aimed at abdominal and pelvic muscle release with elements of self-massage should be performed three times daily. Lastly, subjects will be prescribed 20 minutes of walking daily. Subjects will be recommended to continue this long-term, self-care program indefinitely.
89185384|NCT00739713|Experimental|SB|Sea buckthorn oil group
88863554|NCT05354869|Active Comparator|HF-TES by LVN|"In-office pulsed HF-TES will be delivered by licensed vocational nurse using the Urostym® clinic-based Pelvic Floor Rehabilitation System. An LVN will undergo didactic and practical training, which will include a detailed orientation to the device.~Sessions of electric muscle stimulation will be performed at a frequency of 200 Hz (to induce a passive pelvic floor muscle contraction) for 20 min weekly using a pulse duration of 1 ms of stimulation and an interpulse interval of 4.1 ms. Stimulation intensity (current) will be adjusted manually to palpable, but not painful, stimulation. Vaginal and surface abdominal electromyographic monitoring (EMG) will be conducted throughout the treatment session, recording the average pre- and post-treatment values for each session. In subjects whose pelvic floor EMG does not normalize to <4 millielectronvolts (mV) in a 20-minute session, the subsequent session will be increased to 30 minutes."
89185385|NCT00739713|Placebo Comparator|PL|Placebo group
89185386|NCT02568579||Breastfed|collection of blood/stool/breast milk samples and information about feeding changes and introduction of solid foods. - Cord Blood sample, stool samples monthly and blood sample at 6 month and 12 months of age
89185387|NCT02568579||Bottlefed|collection of blood/stool samples and information about feeding changes and introduction of solid foods. Coord blood sample, stool samples monthly and blood sample at 6 month and 12 month of age.
89388173|NCT05769595|Experimental|MK-2060|Participants receive MK-2060 50 mg via a single intravenous (IV) infusion over 60-minutes.
89388174|NCT05769595|Placebo Comparator|Placebo|Participants receive a single IV saline infusion over 60 minutes.
89185388|NCT05388825|Experimental|Sequence 1|N=14 subjects receive 2.5 mg TPN171H and 10 mg Placebo for Period 1; 5 mg TPN171H and 10 mg Placebo for Period 2 ; 10 mg Placebo and 5 mg Placebo for Period 3.
89388175|NCT05766306|Experimental|Probiotic|Participants will be randomized to receive the probiotic blend for 56 days.
89388176|NCT05766306|Placebo Comparator|Placebo|Participants will be randomized to receive the placebo for 56 days
89388177|NCT05757557|Active Comparator|Control group|Oxygen-air mixture without NO after intubation, during CPB, and six hours after surgery.
89388178|NCT05757557|Experimental|80-ppm NO|NO will be supplemented at 80-ppm concentration to cardiac surgery patients perioperative after trachea intubation, during CPB, and six hours after surgery.
89185389|NCT05388825|Experimental|Sequence 2|N=14 subjects receive 5 mg TPN171H and 10 mg Placebo for Period 1; 10 mg Placebo and 5 mg Placebo for Period 2 ; 2.5 mg TPN171H and 10 mg Placebo for Period 3.
89185390|NCT05388825|Experimental|Sequence 3|N=14 subjects receive 10 mg Placebo and 5 mg Placebo for Period 1; 2.5 mg TPN171H and 10 mg Placebo for Period 2; 5 mg TPN171H and 10 mg Placebo for Period 3.
89185391|NCT05388825|Experimental|Sequence 4|N=14 subjects receive 5 mg TPN171H and 10 mg Placebo for Period 1; 10 mg TPN171H and 5 mg Placebo for Period 2; 10 mg Placebo and 5 mg Placebo for Period 3.
89185392|NCT05388825|Experimental|Sequence 5|N=14 subjects receive 10 mg TPN171H and 5 mg Placebo for Period 1; 10 mg Placebo and 5 mg Placebo for Period 2; 5 mg TPN171H and 10 mg Placebo for Period 3.
89388179|NCT05756920|Experimental|ABL301|
89388180|NCT05756920|Placebo Comparator|Placebo|
89388181|NCT05747261|Experimental|Cohort 1|Subjects in Cohort 1 will receive ANB-004 at a dose 1. Depending on the DLT, the cohort may include 1 to 6 subjects in the first stage and 9 to 12 in the second stage.
89388182|NCT05747261|Experimental|Cohort 2|Subjects in Cohort 2 will receive ANB-004 at a dose 2. The dose for Cohort 2 will be determined at the IDMC meeting. Depending on the DLT, the cohort may include 1 to 6 subjects in the first stage and 9 to 12 in the second stage.
89388183|NCT05747261|Experimental|Cohort 3|Subjects of Cohort 3, if included, will receive the drug at a dose 3. The dose for Cohort 3 will be determined at the IDMC meeting. Depending on the DLT, the cohort may include 1 to 6 subjects in the first stage and 9 to 12 in the second stage.
89388184|NCT05747222|Experimental|Group Action Observation Therapy (G-AOT)|"G-AOT patients will carry out AOT therapy in addition to conventional rehabilitation therapies. In case of bilateral clinical engagement, treatment with AOT will have been conducted on the limb that on motor outcome measures appears less involved.~G-AOT patients will undergo rehabilitation treatment with AOT once a day, 5 days a week. 15 sessions will then be given, for a total duration of 3 weeks of experimental treatment with AOT."
89185393|NCT05388825|Experimental|Sequence 6|N=14 subjects receive 10 mg Placebo and 5 mg Placebo for Period 1; 5 mg TPN171H and 10 mg Placebo for Period 2; 10 mg TPN171H and 5 mg Placebo for Period 3.
89388185|NCT05747222|Active Comparator|Group Conventional (G-CONV)|G-CONV patients will only carry out rehabilitation treatments as per clinical practice.
89388186|NCT05747170|Experimental|Group natural_neutral_chemical|"The recruited subjects (DoC patients and healthy subjects) will be evaluated inside a quiet, well-ventilated room and will be subjected to olfactory stimulation using odors with different characteristics a natural type odor, e.g., mint, a chemical type odor, e.g., gasoline, and a neutral type odor, e.g., water.~Stimulation will have, for each odor the duration of 5 minutes. It will always be carried out within the same time slot (between 8:00 am and 4:00 pm) for 5 consecutive days for 2 weeks. Before and after the administration of each odor, a neutral odor (water) will be administered as a control in the same manner as described above.~The sequence of odor administration will be: natural odor (mint) for 5 minutes, neutral odor (water) for 5 minutes, chemical odor (gasoline) for 5 minutes."
89388187|NCT05747170|Experimental|Group chemical:neutral_natural|"The recruited subjects (DoC patients and healthy subjects) will be evaluated inside a quiet, well-ventilated room and will be subjected to olfactory stimulation using odors with different characteristics a natural type odor, e.g., mint, a chemical type odor, e.g., gasoline, and a neutral type odor, e.g., water.~Stimulation will have, for each odor the duration of 5 minutes. It will always be carried out within the same time slot (between 8:00 am and 4:00 pm) for 5 consecutive days for 2 weeks. Before and after the administration of each odor, a neutral odor (water) will be administered as a control in the same manner as described above.~The sequence of odor administration will be: chemical odor (gasoline) for 5 minutes, neutral odor (water) for 5 minutes, natural odor (mint) for 5 minutes."
89388188|NCT05746325|Experimental|Treatment (TTFields, digital photos)|Patients have transducer arrays applied and digital photographs taken of placement on study. Patients wear the NovoTTF-200T portable system on study. Patients also undergo MRI and may undergo LP during screening and on study.
89388189|NCT05745883|Experimental|Phase 1b Dose Escalation|Single ascending dose of DISC-0974
89388190|NCT05745883|Placebo Comparator|Placebo|
89388191|NCT05743985|Experimental|50mg CBG Capsule|50mg cannabigerol (CBG) oil capsule taken daily for 8 weeks. Study surveys and bloodwork completed for 12 weeks total, including 8 weeks of CBG treatment and subsequent 4-week washout period
89388192|NCT05739448|No Intervention|control|
88863555|NCT05354869|Active Comparator|HF-TES by Physician|"A urogynecologic specialist will deliver HF-TES in office using Urostym® pelvic floor rehabilitation system. A physician will undergo didactic and practical training, which will include a detailed orientation to the device.~Sessions of electric muscle stimulation will be performed at a frequency of 200 Hz (to induce a passive pelvic floor muscle contraction) for 20 min weekly using a pulse duration of 1 ms of stimulation and an interpulse interval of 4.1 ms. Stimulation intensity (current) will be adjusted manually to palpable, but not painful, stimulation. Vaginal and surface abdominal electromyographic monitoring (EMG) will be conducted throughout the treatment session, recording the average pre- and post-treatment values for each session. In subjects whose pelvic floor EMG does not normalize to <4 millielectronvolts (mV) in a 20-minute session, the subsequent session will be increased to 30 minutes."
89388193|NCT05739448|Experimental|fortification (FOR)|
89388194|NCT05739448|Experimental|fortification + physical activity (FAP)|
89185394|NCT00711477|Experimental|NB32|Naltrexone SR 32 mg/bupropion SR 360 mg/day
89185395|NCT00711477|Placebo Comparator|Placebo|Placebo tablets
89388195|NCT05735795|Other|Carbon Black Tattoo arm|In patients with breast cancer diagnosed with positive axillary lymph node involvement by fine needle aspiration cytology, 0.1-0.5 ml Carbon Black Tattoo dye will be applied simultaneously to the lymph node capsule and surrounding tissue, while clips are placed on the axilla before starting neoadjuvant chemotherapy. After the neoadjuvant treatment is completed, the patient who is taken into surgery will be injected with periareolar blue dye as in the standard practice, and blue stained node, clipped node and carbon stained node will be searched as sentinal lymph node. The removed lymph nodes will be evaluated histopathologically in terms of metastasis with a frozen study during the operation, and if metastasis is detected, axillary lymph node dissection will be performed
88863556|NCT05351658|Experimental|Temporary Cardiac Pacing with Active-Fixation Leads|
88863557|NCT05340621|Experimental|OKI-179 + binimetinib|
89185396|NCT00739869||1|Participants will include women who participated in the Women's Health Initiative Memory Study.
89185397|NCT05372913|Experimental|W-GenZD Mobile Application Group|Participants assigned to the W-GenZD mobile application group will be asked to download and use the W-GenZD mobile application that will provide information and tools through a chatbot (a computer program designed to communicate with users). Participants will be invited to use the mobile application as often as they like during the 4-week treatment period - we will encourage 5 to 10 minutes of daily use.
89388196|NCT05734183|Experimental|MIME Group|"Stimulation with MIME will be performed in a large ad hoc room in which video images will be projected on three walls. The patient will be positioned in the center of the room, 3 meters from the front wall, with the back of the bed tilted at a 45-degree angle, so as to obtain a truly immersive view covering the entire 220-degree field of view. Audio stimulation will be achieved through two speakers located at the sides of the room, with the low frequencies reinforced by a subwoofer. The average sound intensity recorded from the patient's position will be 81 db average (maximum 87, minimum 69).~Patients will undergo treatment with MIME once a day for five consecutive days, for a total of two weeks (10 sessions), in addition to conventional treatment."
89388197|NCT05734183|Active Comparator|MIME + tDCS Group|Simultaneously with MIME treatment, patients will undergo transcranial direct current stimulation (tDCS). Stimulation with tDCS will begin 5 minutes after the start of resting phase 1, and the electrodes will be placed as follows: the 5×4 anode (about 20 cm2) will be placed on the left dorsolateral prefrontal area; the reference electrode, 6x5 (about 30 cm2), will instead be placed on the upper arm, specifically at the level of the right deltoid muscle, contralateral to the active electrode. Current will be applied at an intensity of 2 mA, for 20 minutes a day for 2 weeks, five days a week, for a total of 10 sessions. The current density will be kept below the safe limits reported in the literature.
89388198|NCT05729165|Experimental|Experimental group (S-G)|"20 minutes of local vibration treatment with the Novafon® Pro medical device followed by 20 minutes of traditional speech therapy, for a total duration of 40 minutes. Therefore, using this instrument, local vibration therapy will be applied at the level of (i) the orbicular muscles of the upper and lower lips, (ii) the masticatory muscles (masseter, temporalis, pterygoid), and (i) local intra-oral and tongue. The Novafon® Pro medical device will be used with the following external and intraoral heads: set senses roller, ball head, disc head, ball head, arrow head, spoon head, and tongue depressor head.~Traditional speech therapy treatment will be carried out with the same tools and activities already described in the C-G."
89388199|NCT05729165|Active Comparator|Control group (C-G)|40 minutes of conventional speech treatment. Specifically, maneuvers will be performed for (i) extra-oral and intra-oral passive thermal stimulation, (ii) extra-oral and intra-oral passive tactile stimulation, and for (iii) elicitation of active bucco-lingual and laryngeal muscle movements. The following instruments will be used for this purpose: ice cubes, ice tubes, sterile gauze, tongue depressors, swabs, 10 mm laryngeal mirrors.
89388200|NCT05727969|Placebo Comparator|Control group|The control group, lactated ringer solution will be infused.
89388201|NCT05727969|Experimental|Dexmedetomidine group|In the dexmedetomidine group, dexmedetomidine will be infused.
89388202|NCT05724602|Experimental|Radiotherapy + Xevinapant|3 cycles of xevinapant (200 mg/day from Day 1 to 14, per 21-day cycle) + IMRT followed by 3 cycles of xevinapant in monotherapy (200 mg/day from Day 1 to 14, per 21-day cycle)
89388203|NCT05724602|Placebo Comparator|Radiotherapy + Placebo|3 cycles of placebo (from Day 1 to 14, per 21-day cycle) + IMRT followed by 3 cycles of placebo in monotherapy (from Day 1 to 14, per 21-day cycle).
89388204|NCT05719311|Experimental|Adrulipase|Upon study enrolment, the patient will be switched from their commercial PERT to receive adrulipase. Patients will initially receive a low dose of adrulipase. Upon the appearance of EPI symptoms, lasting at least three days, and upon discussion with the investigator, the patient will be switched to the medium dose of adrulipase. If signs and symptoms of EPI persist for three or more days, the patient will be switched to the high dose of adrulipase.
88863558|NCT05335954|Experimental|Noradrenaline|Noradrenaline diluted to 16µg/ml infused at 0.06g/kg/min by peripheral venous line from the start of peripheral venous line from the start of preoxygenation
89388205|NCT05704166|Experimental|Pirfenidone|Patients were given placebo or pirfenidone capsules orally one week before radiotherapy, 200mg/ time, 3 times a day in the first week; 300mg/ time 3 times daily for the second week and 400mg/ time 3 times daily for the third to eighth week. Take it after a meal.
89388206|NCT05704166|Placebo Comparator|Placebo|Patients were given placebo or pirfenidone capsules orally one week before radiotherapy, 200mg/ time, 3 times a day in the first week; 300mg/ time 3 times daily for the second week and 400mg/ time 3 times daily for the third to eighth week. Take it after a meal.
89388207|NCT05703373|Experimental|Multiple Micronutrient Supplement (MMS) supplied to clinic|
89388208|NCT05699863|Experimental|Metabolically unhealthy obese (Intervention group)|Obese (BMI: 30.0 - 39.9) participants with non-alcoholic fatty liver disease and metabolic syndrome.
88863559|NCT05335954|No Intervention|Standard care|standard care
88863560|NCT05326113|Experimental|Physiotherapy|"Patients will undergo physiotherapy and will be regularly examined by an assigned physician.~Initial physiotherapy will last 60minutes, other therapies will last 30minutes. Physiotherapy will aim on diaphragmatic breathing and dynamic neuromuscular stabilization exercises. In the 1st month, the patient attends physiotherapy once a week In the 2nd, 3rd and 4th month, the patient attends physiotherapy once every 14 days.~Symptomatic patients will take PPIs based on the recommendation of the treating physician who will recommend a dose of PPIs. Used PPIs will be Emanera 1x40mg (standard dose), 2x40mg (higher dose) or 1x40mg on demand.~During the follow-up period, patients may, in agreement with the attending physician, reduce the dose of PPIs (from twice a day to once a day, from once a day to an on-demand regime or discontinue them altogether).~The use of PPIs will be accurately documented."
88863561|NCT05326113|Active Comparator|Control group|"Control group will undergo standard treatment of reflux with PPIs and will be regularly examined by an assigned physician.~Symptomatic patients will take PPIs based on the recommendation of the treating physician who will recommend a dose of PPIs. Used PPIs will be Emanera 1x40mg (standard dose), 2x40mg (higher dose) or 1x40mg on demand.~All patients with esophagitis LA A/B/C will be treated with IPP-Emanera 1x40mg for at least 6 weeks at the start of the study.~During the follow-up period, patients may, in agreement with the attending physician, reduce the dose of PPIs (from twice a day to once a day, from once a day to an on-demand regime or discontinue them altogether).~The use of PPIs will be accurately documented."
89185398|NCT05372913|Active Comparator|CBT-Light Teletherapy Group|Participants assigned to the CBT-light teletherapy group will be asked to attend 1-hour teletherapy group sessions over Zoom once a week for 4 weeks. In this group, a study clinician will cover topics such as building a coping tool box, accepting your feelings, challenging negative thoughts, and problem solving.
89185399|NCT00739947||1|Standard of Care
89185400|NCT00734474|Experimental|3.0 mg LY2189265|"LY2189265 (Dulaglutide): 3.0 milligrams (mg), subcutaneous (SC) injection, once weekly for up to 104 weeks~Placebo: tablet, administered orally, once daily for up to 104 weeks~Metformin: at least 1500 milligrams per day (mg/day), administered orally for up to 104 weeks"
89185401|NCT00734474|Experimental|2.0 mg LY2189265|"LY2189265 (Dulaglutide): 2.0 milligrams (mg), subcutaneous (SC) injection, once weekly for up to 104 weeks~Placebo: tablet, administered orally, once daily for up to 104 weeks~Metformin: at least 1500 milligrams per day (mg/day), administered orally for up to 104 weeks"
88863568|NCT05318027|Experimental|Activity Monitoring and ChatBot|Patients will receive standard of care chemotherapy and radiation therapy regimens, activity monitoring and utilize a ChatBot
88863569|NCT05318027|No Intervention|Activity Monitoring without ChatBot|Patients will receive standard of care chemotherapy and radiation therapy regimens, activity monitoring alone
89185402|NCT00734474|Experimental|1.5 mg LY2189265|"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC) injection, once weekly for up to 104 weeks~Placebo: tablet, administered orally, once daily for up to 104 weeks~Metformin: at least 1500 milligrams per day (mg/day), administered orally for up to 104 weeks"
89185403|NCT00734474|Experimental|1.0 mg LY2189265|"LY2189265 (Dulaglutide): 1.0 milligrams (mg), subcutaneous (SC) injection, once weekly for up to 104 weeks~Placebo: tablet, administered orally, once daily for up to 104 weeks~Metformin: at least 1500 milligrams per day (mg/day), administered orally for up to 104 weeks"
89185404|NCT00734474|Experimental|0.75 mg LY2189265|"LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC) injection, once weekly for up to 104 weeks~Placebo: tablet, administered orally, once daily for up to 104 weeks~Metformin: at least 1500 milligrams per day (mg/day), administered orally for up to 104 weeks"
88863574|NCT05312983|Experimental|people over the age of 18 who agree to participate in the research.|They are either people who have a hearing loss about 20 years older than their age and wear a hearing aid (or come in for a hearing aid), or people over the age of 40 with normal hearing for their age.
88863577|NCT05305924|Experimental|Fulvestrant plus Abemaciclib Arm with Fulvestrant Run-In|"A 1-month (28 days) run-in of fulvestrant will precede fulvestrant plus abemaciclib treatment. Fulvestrant at a dose of 500 mg will be administered intramuscularly (IM) into the buttocks slowly (1-2 minutes per injection) as two 5-mL injections, one in each buttock, on Days 1 and 15 of the run-in period.~After the fulvestrant run-in, fulvestrant plus abemaciclib will be administered in 28-day cycles until disease progression or unacceptable toxicity. Fulvestrant (500 mg IM) will be administered on Day 1 of each 28-day cycle. Abemaciclib at a dose of 150 mg will be given p.o. BID on Days 1-28 of each cycle"
88863578|NCT05305664|Experimental|Pelacarsen (TQJ230)|
88863579|NCT05305664|Placebo Comparator|Placebo|
88863580|NCT05301478|Experimental|Diabetic with elevated plantar pressure|Diabetic with elevated plantar pressure
88863581|NCT05298423|Experimental|pembrolizumab/vibostolimab coformulation+chemotherapy+radiotherapy|For the first 3 cycles, participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) intravenously (IV) on Day 1 plus 3 cycles of investigator's choice of platinum doublet chemotherapy and concurrent standard thoracic radiotherapy (60 Gray [Gy] in 2 Gy fractions for 30 days total) during Cycles 2, 3. Participants receive pembrolizumab/vibostolimab for Cycles 4-20 or until discontinuation (up to ~14 months). Cycles 1-20 are 21-day cycles. Investigator's choice of chemotherapy: cisplatin 75 mg/m^2 and pemetrexed 500 mg/m^2 on Day 1 of Cycles 1-3 for non-squamous histology only; cisplatin 50 mg/m^2 on Days 1, 8 of Cycles 1-2 and Days 8, 15 of Cycle 3 and etoposide 50 mg/m^2 on Days 1-5 of Cycles 1-2 and Days 8-12 of Cycle 3; carboplatin area under the curve (AUC) 6 mg/ml/min on Day 1 of Cycle 1 and AUC 2 mg/ml/min on Days 1, 8, 15 of Cycles 2-3 and paclitaxel 200 mg/m^2 on Day 1 of Cycle 1 and 45 mg/m^2 on Days 1, 8, 15 of Cycles 2-3.
88863582|NCT05298423|Active Comparator|chemotherapy+radiotherapy+durvalumab|"For the first 3 cycles, participants will receive investigator's choice of platinum doublet chemotherapy and concurrent standard thoracic radiotherapy (60 Gy in 2 Gy fractions for 30 days total) during Cycles 2 and 3. Following cCRT, participants receive durvalumab 10 mg/kg every 2 weeks for up to an additional 26 cycles or until discontinuation (up to approximately 14 months). cCRT Cycles 1-3=21-day cycles; durvalumab Cycles 1-26=14-day cycles.~Investigator's choice of chemotherapy: cisplatin 75 mg/m^2 and pemetrexed 500 mg/m^2 on Day 1 of Cycles 1-3 for non-squamous histology only; cisplatin 50 mg/m^2 on Days 1, 8 of Cycles 1-2 and Days 8, 15 of Cycle 3 and etoposide 50 mg/m^2 on Days 1-5 of Cycles 1-2 and Days 8-12 of Cycle 3; carboplatin area under the curve (AUC) 6 mg/ml/min on Day 1 of Cycle 1 and AUC 2 mg/ml/min on Days 1, 8, 15 of Cycles 2-3 and paclitaxel 200 mg/m^2 on Day 1 of Cycle 1 and 45 mg/m^2 on Days 1, 8, 15 of Cycles 2-3."
88863583|NCT05295459|Experimental|LYR-210|Single administration of LYR-210 drug matrix (7500 μg)
88863584|NCT05295459|Sham Comparator|Sham procedure control|Single mock administration procedure
88863585|NCT05289856|Experimental|combination of Avelumab and Cabozantinib|800 mg Avelumab every 2 weeks and 40 mg Cabozantinib daily
88863586|NCT05285358|Experimental|Treatment (gemcitabine, cisplatin, nab-paclitaxel PIPAC)|Patients receive gemcitabine IV over 30 minutes and cisplatin IV over 60 minutes on days 1 and 8. Patients also receive nab-paclitaxel via PIPAC over 5-10 minutes on day 3 of cycles 1, 3, and 5. Treatment repeats every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity.
89388209|NCT05699863|No Intervention|Metabolically healthy obese (Comparison group 1)|Obese individuals considered metabolically healthy based on them not presenting non-alcoholic fatty liver disease or metabolic syndrome.
88863588|NCT05258084|Experimental|initiative group|1st and 2nd year nursing students who have not received education for sexual minorities before and continue their education at a university. Sexual minority awareness training will be applied to this group
88863589|NCT05258084|No Intervention|control group|1st and 2nd year nursing students who have not received education for sexual minorities before and continue their education at a university. Sexual minority awareness training will not be applied to this group
88863590|NCT05256966|Active Comparator|Sauna|Firefighters/participants based at the station with an existing sauna will be allocated to the intervention arm/sauna group. They will include a sauna session, as per study protocol, which is the intervention.
88863591|NCT05256966|No Intervention|Non Sauna|Firefighters/participants based at the stations without a sauna will be allocated to the control arm/Non sauna group. They will not sauna, as per study protocol, as to not receive the study intervention.
88863592|NCT05237336|Experimental|MBCT-IPS|Mindfulness-based Cognitive Therapy (MBCT) integrated with cultural Psychology of Soul (IPS) 2-session (IPS) + standard 8-session (MBCT)
88863593|NCT05237336|Active Comparator|Mindfulness-based Cognitive Therapy|Standard 8-session Mindfulness-based Cognitive Therapy (MBCT)
88863594|NCT05237336|Other|Counselling as usual|8-session Control group
89185405|NCT00734474|Experimental|0.5 mg LY2189265|"LY2189265 (Dulaglutide): 0.5 milligrams (mg), subcutaneous (SC) injection, once weekly for up to 104 weeks~Placebo: tablet, administered orally, once daily for up to 104 weeks~Metformin: at least 1500 milligrams per day (mg/day), administered orally for up to 104 weeks"
88863595|NCT05225961|Experimental|Tirofiban|An intravenous bolus of 500 micrograms of Tirofiban will be intravenously administered in five minutes with an infusion pump (infusion rate: 120 milliliters / hour), which is equivalent to 10 ml (500 micrograms) of Tirofiban. After five minutes, a dose reduction will be programmed to 200 micrograms / hour (infusion rate: 4 milliliters / hour for 24 hours (maximum total infused dose of 96 milliliters).
88863596|NCT05225961|Active Comparator|Acetylsalicylic acid|A single dose 500 milligrams of Acetylsalicylic acid (ASPIRINA®, 500 mg) will be intravenously administered. One vial of ASPIRINA ® in not more than 250 ml in 0.9% sodium chloride solution, 5% and 10% glucose solution, Ringer's solution or lactated Ringer's. The solution for injection should be prepared on the spot and used immediately after preparation. It is highly recommended to administer as soon as possible after femoral puncture and always before stent placement, allowing a 10-minute delay after placement of the cervical endoprosthesis. In case of exceeding this time, the patient will be withdrawn from the trial.
88863597|NCT05223816|Experimental|Safety Run-in Cohort|10 patients will be treated with IT injection of VG161 in the cohort 1 at dose level of 1.0x10E8 PFU x 3 days.
88863598|NCT05223816|Experimental|Cohort 2 (HCC)|21 patients will be treated with IT injection of VG161 in the cohort 1 at dose level of 1.0x10E8 PFU x 3 days.
88863599|NCT05223816|Experimental|Cohort 3 (ICC)|20 patients will be treated with IT injection of VG161 in the cohort 1 at dose level of 1.0x10E8 PFU x 3 days.
88863600|NCT05223816|Experimental|Cohort 4 (HCC and ICC)|Up to 12 patients will be treated with IT injection of VG161 ar dose level of 1.0x10E8 PFU x 3 days. and Nivolumab per approved label.
89185406|NCT00734474|Experimental|0.25 mg LY2189265|"LY2189265 (Dulaglutide): 0.25 milligrams (mg), subcutaneous (SC) injection, once weekly for up to 104 weeks~Placebo: tablet, administered orally, once daily for up to 104 weeks~Metformin: at least 1500 milligrams per day (mg/day), administered orally for up to 104 weeks"
89185407|NCT00734474|Active Comparator|Sitagliptin|"Sitagliptin: 100-milligrams (mg) tablet, administered orally, once daily for 104 weeks~Placebo: solution, subcutaneous (SC) injection, once weekly for 104 weeks~Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks"
89388210|NCT05699863|No Intervention|Healthy normal weight (Comparison group 2)|Normal weight individuals without non-alcoholic fatty liver disease or metabolic syndrome.
88863604|NCT05206929|Experimental|Arm 1|Arm 1 will receive instruction to use pain and discomfort as the safe limits for their upper limb use during daily activities at post operative discharge.
88863605|NCT05206929|Active Comparator|Arm 2|Arm 2 will receive the standard sternal precautions at time of post operative discharge.
89388211|NCT05695924|Experimental|BioBridge treatment group|Vascularized Lymph Node Transplant surgery (VLNT) supplemented by BioBridge Collagen Matrix implantation
88863606|NCT05206565|Experimental|Autologous with TRAM/DIEP flaps, with neurotization|Autologous with TRAM/DIEP flaps, with neurotization
88863607|NCT05206565|No Intervention|Autologous with TRAM/DIEP flaps, without neurotization|Autologous with TRAM/DIEP flaps, without neurotization
88863608|NCT05203913|Experimental|Experimental arm|This arm consists in treatment with cisplatin + nab-paclitaxel + nivolumab during radiotherapy on bladder followed by nivolumab alone after the end of radiotherapy
89388212|NCT05695924|Active Comparator|Control group|Vascularized Lymph Node Transplant surgery (VLNT) only
89388213|NCT05689164|Other|All participants|All participants enrolled in the study.
89388214|NCT05686941||Healthy Volunteers|Employees of the Host organisation in the Respiratory Team who meet the inclusion criteria
89388215|NCT05686941||Patients with suspected Inducible laryngeal Obstruction (ILO)|Patients referred to a Tertiary referral centre who are suspected of having ILO
89185408|NCT00734474|Placebo Comparator|Placebo/Sitagliptin (Baseline Through 104 Weeks)|"Placebo: solution, subcutaneous (SC) injection, once weekly for 104 weeks~Placebo: tablet, administered orally, once daily for 26 weeks~Sitagliptin: after 26 weeks, 100-milligrams (mg) tablet, administered orally, once daily for 78 weeks~Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks"
89185409|NCT00740025||QD|Women who received their meds as QD administration
88863609|NCT05197231|Experimental|IV amino acids + standardized physiotherapy with lower limb resistance exercise.|Research subjects randomized to the intervention group will receive an infusion of IV amino acids during a session of protocolized physiotherapy that includes a knee extension resistance exercise targeting the thigh muscles. The supplemental amino acid infusion will continue up until 90 minutes after the subject has returned to bed rest.
89185410|NCT00740025||BID|Women who received their gonadotropins as a BID dose
89185411|NCT00583362|Experimental|Belimumab 10 mg/kg|Belimumab 10 mg/kg IV over one hour every 28 days.
89185412|NCT00577473|Active Comparator|1|mesalamine 2.4 g/day (400 mg tablet) for 6 weeks
89185413|NCT00577473|Experimental|2|mesalamine 4.8 g/day (800 mg tablet) for 6 weeks
89185414|NCT00740103|Experimental|1|Semapimod 60 mg IV x 3 days q 6 - 8 weeks
89185415|NCT05722665||Normal chest radiographs|X-rays without alterations in the lung parenchyma
89185416|NCT05722665||COVID-19 chest radiographs|X-rays belonging to patients with a diagnosis of COVID-19 confirmed by positive Reverse Transcriptase polymerase chain reaction (RT-PCR) and/or presence of antibodies to COVID-19 and/or positive COVID-19 viral antigen.
89185417|NCT05722665||Other pneumonia chest radiographs|X-rays belonging to patients with a diagnosis of pneumonia other than COVID-19
89185418|NCT02568111|Experimental|brimonidine tartrate|Participants will apply gel to injection site erythema area after IRE development post peginterferon beta-1a injection
89185419|NCT02568111|Placebo Comparator|Vehicle Gel|Participants will apply vehicle gel placebo to injection site erythema area after IRE development post peginterferon beta-1a injection
89185420|NCT00785291|Active Comparator|Arm A (Paclitaxel)|Patients receive 90 mg/m^2 paclitaxel IV over 1 hour on days 1, 8, and 15. Patients may receive 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15.
88863610|NCT05197231|Active Comparator|IV amino acids + standardized physiotherapy.|Research subjects randomized to the control group will receive an infusion of IV amino acids during a session of protocolized physiotherapy NOT including lower limb resistance exercise. The supplemental amino acid infusion will continue up until 90 minutes after the subject has returned to bed rest.
89185421|NCT00785291|Experimental|Arm B (Nab-paclitaxel)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on days 1, 8, and 15. Patients may also receive 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15.
89185422|NCT00785291|Experimental|Arm C (Ixabepilone)|Patients receive ixabepilone IV over 60 minutes on days 1, 8, and 15. Patients may also receive 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. (closed to accrual as of 7/18/11)
89185423|NCT04063137|Active Comparator|Anthocyanin fortified bread|White bread is fortified with a 25% (w/w) black rice anthocyanin extract. Extract fortification is 4% w/w of bread flour.
89185424|NCT04063137|Placebo Comparator|White bread|
89185425|NCT00705939|Experimental|Naive 30 Units/kg|Continue taliglucerase alfa treatment from PB-06-001 (NCT00376168)
89185426|NCT00705939|Experimental|Naive 60 Units/kg|Continue taliglucerase alfa treatment from PB-06-001 (NCT00376168)
89185427|NCT00705939|Experimental|Switchover|Continue taliglucerase alfa treatment from PB-06-002 (NCT00712348)
89185428|NCT02568891|Active Comparator|Probiotic|6 g of Winclove-849 containing Bifidobacterium bifidum W23, Bifidobacterium lactis W52, Lactobacillus acidophilus W37, Lactobacillus brevis W63, Lactobacillus casei W56, Lactobacillus salivarius W24, Lactococcus lactis W19, Lactococcus lactis W58 at a concentration of 2.5 x 109 cfu/g
89388216|NCT05685849||Trial group|A total of 200 pregnant women in the first trimester (gestational age of 6-13 weeks+6 days), who had cardiovascular disease and experienced regular obstetric examinations throughout the pregnancy, were selected from the obstetric outpatients in 10 centers, with 20 cases in each center.
89388217|NCT05683262|Active Comparator|Ultrasound-guided sacrococcygeal and/or intercoccygeal joint injection|Ultrasound-guided sacrococcygeal and/or intercoccygeal joint injection is applied to patients in this group
89185429|NCT02568891|Placebo Comparator|Placebo|similar looking and tasting placebo without bacteria
89185430|NCT04079010|Placebo Comparator|Control|Participants will adhere to resistance training protocol.
89185431|NCT04079010|Active Comparator|BFR (blood flow restriction)|Participants will adhere to resistance training protocol, while also applying a blood flow restriction cuff during resistance training.
89185432|NCT04079010|Active Comparator|BFR (blood flow restriction), plus Arginine|Participants will adhere to resistance training protocol, apply a blood flow restriction cuff during resistance training, and will take the clinically safe dose of arginine prior to training sessions.
89185433|NCT02581878|Experimental|Cohort 1a|Cancer patients with relapsed or refractory non-Hodgkin's lymphoma will be randomized to receive an injection of study drug (BAY1862864) with a dosage of 1.5 MBq (2 mg antibody chelator conjugate [ACC]).
89185434|NCT02581878|Experimental|Cohort 1b|Cancer patients with relapsed or refractory non-Hodgkin's lymphoma will be randomized to receive an injection of study drug (BAY1862864) with a dosage of 1.5 MBq (10 mg ACC).
89185435|NCT02581878|Experimental|Cohort 2|Cancer patients with relapsed or refractory non-Hodgkin's lymphoma will be randomized to receive an injection of study drug (BAY1862864) with a dosage of 3.1 MBq (10 mg ACC).
89185436|NCT02581878|Experimental|Cohort 3|Cancer patients with relapsed or refractory non-Hodgkin's lymphoma will be randomized to receive an injection of study drug (BAY1862864) with a dosage of 4.6 MBq (10 mg ACC).
89185437|NCT02581878|Experimental|Cohort 4|Cancer patients with relapsed or refractory non-Hodgkin's lymphoma will be randomized to receive an injection of study drug (BAY1862864) with a dosage of 6.1 MBq (10 mg ACC).
89388218|NCT05683262|Active Comparator|Ultrasound-guided sacrococcygeal and/or intercoccygeal joint injection with coccygeal nerve block|Ultrasound-guided coccygeal nerve blockade is done before the application of ultrasound-guided sacrococcygeal and/or intercoccygeal joint injection to patients in this group
89388219|NCT05681182|Other|Single Arm|All patients who are enrolled into the study will receive the treatment. This includes the CardiaMend which should be used according to the Instructions for Use with the exception that device hydration is performed with 3 ampules of amiodarone (150mg/3ml) instead of room temperature saline. For best results, the device should be fixed in place using a continuous or interrupted stitch (approximately 1 stitch per cm) to approximate the edge of the pericardial defect. The closed defect should not put pressure on the underlying structures. A non-absorbable monofilament suture is preferred such as 5-0 or 4-0 prolene. A small edge may be left open for drain placement and a small slit for LIMA in case of CABG
89388220|NCT05668949|Experimental|Part 1 (Dose Escalation)|Participants will be assigned to a study part based on when you join this study
89388221|NCT05668949|Experimental|Part 2 (Dose Expansion)|Participants will be assigned to a study part based on when you join this study.
89388222|NCT05663567|Experimental|experimental group 1|Implementing a solution-focused approach to support breastfeeding ONE TO ONE STUDY
89388223|NCT05663567|Experimental|experimental group 2|Implementing a solution-focused approach to support breastfeeding GROUP STUDY
89388224|NCT05663567|No Intervention|No Intervention|ROUTINE MAINTENANCE WILL BE DONE SOLUTION-FOCUSED APPROACH WILL NOT BE APPLIED.
89388225|NCT05659368|Experimental|Interventional group|Tirzepatide will be injected subcutaneously once-per-week, in the abdomen, thigh or upper arm. To improve gastro-intestinal tolerability, the starting dose will be 5 mg (2.5mg for prepubertal children) and will be increased to a maximum of 15 mg (or highest tolerated dose).
89388226|NCT05649956|Experimental|Letrozole|Letrozole 2.5 mg orally
89185438|NCT04109651|Experimental|Nursing İntervention|Intervention: Other: Nursing intervention
89185439|NCT04109651|Other|No Intervention: Control Group|Receive routine nursing care
89388227|NCT05649956|No Intervention|Observation|Observation
89388228|NCT05644184|Experimental|Group 1: Young Children, nOPV1 10^5.5 CCID50|48 young children aged 1 to <5 years will receive 2 doses of nOPV1 at a dose level of 10^5.5 CCID50 on Day 1 and Day 29
89388229|NCT05644184|Experimental|Group 3: Young Children, nOPV1 10^6.0 CCID50|48 young children aged 1 to <5 years will receive 2 doses of nOPV1 at a dose level of 10^6.0 CCID50 on Day 1 and Day 29
89388230|NCT05644184|Experimental|Group 5: Young Children, nOPV1 10^6.5 CCID50|48 young children aged 1 to <5 years will receive 2 doses of nOPV1 at a dose level of 10^6.5 CCID50 on Day 1 and Day 29
89388231|NCT05644184|Active Comparator|Groups 2, 4 and 6: Young Children, mOPV1|48 young children aged 1 to <5 years will receive 2 doses of mOPV1 at a dose level of ≥ 10^6.0 CCID50 on Day 1 and Day 29
89388232|NCT05644184|Experimental|Group 7: Infants, nOPV1 10^5.5 CCID50|96 infants aged 6 weeks (+6 days) will receive 1 dose of IPV on Day 1, then 2 doses of nOPV1 at a dose level of 10^5.5 CCID50 on Day 29 and Day 57, and a challenge dose of mOPV on Day 113.
89388233|NCT05644184|Experimental|Group 9: Infants, nOPV1 10^6.0 CCID50|96 infants aged 6 weeks (+6 days) will receive 1 dose of IPV on Day 1, then 2 doses of nOPV1 at a dose level of 10^6.0 CCID50 on Day 29 and Day 57, and a challenge dose of mOPV on Day 113.
89388234|NCT05644184|Experimental|Group 11: Infants, nOPV1 10^6.5 CCID50|48 infants aged 6 weeks (+6 days) will receive 1 dose of IPV on Day 1, then 2 doses of nOPV1 at a dose level of 10^6.0 CCID50 on Day 29 and Day 57, and a challenge dose of mOPV on Day 113.
89388235|NCT05644184|Active Comparator|Groups 8, 10 and 12: Infants, mOPV1|96 infants aged 6 weeks (+6 days) will receive 1 dose of IPV on Day 1, then 2 doses of mOPV1 at a dose level of ≥ 10^6.0 CCID50 on Day 29 and Day 57, and a challenge dose of mOPV on Day 113.
89388236|NCT05644184|Experimental|Group 13: Neonates, nOPV1 10^5.5 CCID50|330 neonates (day of birth + 3 days) will receive 2 doses of nOPV1 at a dose level of 10^5.5 CCID50 on Day 1 and Day 29.
89388237|NCT05644184|Experimental|Group 15: Neonates, nOPV1 10^6.0 CCID50|330 neonates (day of birth + 3 days) will receive 2 doses of nOPV1 at a dose level of 10^6.0 CCID50 on Day 1 and Day 29.
89388238|NCT05644184|Experimental|Group 17: Neonates, nOPV1 10^6.5 CCID50|165 neonates (day of birth + 3 days) will receive 2 doses of nOPV1 at a dose level of 10^6.5 CCID50 on Day 1 and Day 29.
89388239|NCT05644184|Active Comparator|Groups 14, 16 and 18: Neonates, mOPV|330 neonates (day of birth + 3 days) will receive 2 doses of mOPV1 at a dose level of ≥ 10^6.0 CCID50 on Day 1 and Day 29
89388240|NCT05638607|Experimental|Intensified occupational therapy|Two hours occupational therapy each weekday with specific focus on basic ADL
89185440|NCT00740337||COPD|Participants in this group will be people who have COPD and plan to undergo lung resection surgery at Barnes-Jewish Hospital (BJH).
89185441|NCT00740337||Control|Participants in this group will be people who do not have COPD and plan to undergo lung resection surgery at BJH.
89185442|NCT00921141||study population|Patient with cancer requiring a long-term central venous catheter
89185443|NCT04078074|Experimental|Maxillary OSS|
89185444|NCT04078074|Experimental|Mandibular OSS|
89185445|NCT04078074|Experimental|Modified farrar splint|
89388241|NCT05638607|Active Comparator|Usual care|Occupational therapist instruct nursing staff on how to assist patients with basic ADL
89388242|NCT05636943|Experimental|Adapted Intimacy Enhancement|Participants receive intimacy enhancement sessions and read a booklet about intimacy and metastatic breast cancer
89388243|NCT05636943|Active Comparator|Intimacy Facts & Resources|Participants read a booklet about intimacy and metastatic breast cancer.
89185446|NCT00785213|Active Comparator|Rosiglitazone Alone|Baseline rosiglitazone pharmacokinetics.
89185447|NCT00785213|Experimental|Rosiglitazone with Steady State Quinine Sulfate|Rosiglitazone pharmacokinetics in the presence of steady state quinine sulfate.
89185448|NCT00577317|Experimental|Arm 1|Patients receive standard home maintenance therapy and perform self-manual lymphatic drainage once daily for 60 minutes for 24 weeks.
89185449|NCT00577317|Experimental|Arm II|Patients receive Flexitouch® home maintenance therapy once daily for 60 minutes for 24 weeks
89185450|NCT02583594|Experimental|alemtuzumab (subcutaneous injection)|Dose 1 (initial course) of alemtuzumab will be administered subcutaneously on 5 consecutive days, followed by Dose 2 (second course) on 3 consecutive days administered 12 months after initial course. Pre-medications (methylprednisolone, antihistamine [loratadine, cetirizine, dexchlorpheniramine], paracetamol, acyclovir) will be administered prior alemtuzumab administration.
89185451|NCT02583594|Experimental|alemtuzumab (intravenous infusion)|Dose 1 (initial course) of alemtuzumab will be administered intravenously on 5 consecutive days, followed by Dose 2 (second course) on 3 consecutive days administered 12 months after initial course. Pre-medications (methylprednisolone, antihistamine [loratadine, cetirizine, dexchlorpheniramine], paracetamol, acyclovir) will be administered prior alemtuzumab administration.
88863611|NCT05176470|Experimental|Treatment (pembrolizumab, lifileucel)|"Patients receive pembrolizumab IV on day -14, cyclophosphamide IV QD on days -7 to -6, fludarabine IV over 30 minutes QD on days -5 to -1, and lifileucel IV infusion on day 0. Patients also receive pembrolizumab IV on day 28 and 70, and undergo surgery on day 80.~MAINTENANCE: Patients receive pembrolizumab IV every 6 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity."
88863612|NCT05174169|Active Comparator|Cohort A - Arm 1 (ctDNA-ve)|"Oxaliplatin 85 mg/m2 IV + Leucovorin 400mg/m2 IV + 5-Fluorouracil (5-FU) 400mg/m2 bolus + 5-Fluorouracil (5-FU) 2400mg/m2 IV continuous infusion over 46-48 hours (total dose) Day1 every 2 weeks for 6-12 cycles~OR~Oxaliplatin 130 mg/m2 IV Day 1 every 3 weeks + Capecitabine 1000 mg/m2 BID by mouth days 1-14 every 3 weeks for 4 cycles"
88863613|NCT05174169|Experimental|Cohort A - Arm 2 (ctDNA-ve)|Serial ctDNA monitoring no treatment
88863614|NCT05174169|Active Comparator|Cohort B - Arm 3 (ctDNA+ve)|"Oxaliplatin 85 mg/m2 IV + Leucovorin 400mg/m2 IV + 5-Fluorouracil (5-FU) 400mg/m2 bolus + 5-Fluorouracil (5-FU) 2400mg/m2 IV continuous infusion over 46-48 hours (total dose) Day1 every 2 weeks for 12 cycles~OR~Oxaliplatin 130 mg/m2 IV Day 1 every 3 weeks + Capecitabine 1000 mg/m2 BID by mouth days 1-14 every 3 weeks for 8 cycles"
88863615|NCT05174169|Experimental|Cohort B - Arm 4 (ctDNA+ve)|Oxaliplatin 85 mg/m2 IV + Leucovorin 400mg/m2 IV + Irinotecan 150 mg/m2 IV continuous infusion (30-90 minutes) + 5-Fluorouracil (5-FU) 2400mg/m2 IV continuous infusion over 46-48 hours (total dose) Day1 every 2 weeks for 12 cycles
88863616|NCT05166590|No Intervention|Normal Sleep|Participants will sleep in the laboratory for 8 hours and then undergo the same social-rejection paradigm as the experimental group to serve as a control comparison.
88863617|NCT05166590|Experimental|Total Sleep Restriction|Participants will experience a night of total sleep restriction and then undergo a social-rejection task in the morning.
89185452|NCT05571761|Experimental|Study group|Refers to the experimental group that will receive the cognitive stimulation program intervention.
88863621|NCT05146986||Non-surgical group|Patients will receive analgesia and symptomatic management treatment
88863622|NCT05146986||Surgical group|Patients will receive surgical treatment using RibFix Blu Thoracic Fixation System
88863623|NCT05146388|No Intervention|Pre-Implementation - Usual Care|In pre-implementation phase, patient e-Rxs will be generated by the EHR in the usual fashion.
88863624|NCT05146388|Experimental|Post-Implementation - EHR-Based Approach|
88863625|NCT05129020|Experimental|Active tAN + Morphine|
88863626|NCT05129020|Sham Comparator|Sham tAN + Morphine|
88863627|NCT05126082|No Intervention|Control|Providers and patients assigned to control arm clinics will engage in the current standard of care, without access to the PedsBP clinical decision support tool.
88863628|NCT05126082|Experimental|Low-Intensity Implementation|Providers and patients in the low-intensity arm will have access to the PedsBP clinical decision support tool and will receive standard training and training resources using the health systems standard training platform.
88863629|NCT05126082|Experimental|High-Intensity Implementation|Providers and patients in the high-intensity arm will have access to the PedsBP clinical decision support tool and will receive enhanced training and training resources, and regular feedback from the project team regarding CDS use rates.
88863630|NCT05118477|Experimental|AMS group|Patients randomised to the intervention group will receive the AMS; this will be connected to the dashboard and the alerting system. Clinical staff will have access to the dashboard and alerted accordingly for the assigned patients.
88863631|NCT05118477|Active Comparator|Standard Care group|"Patients in the control group will also receive the AMS however this will not be connected to the ward dashboard and clinical staff will not be able to access these patient's continuous vital signs:~Patient will not appear on the ward dashboard~No alerting system will be given to staff"
88863632|NCT05115617||Pregnant individuals|Pregnant individuals who have previously received one-dose of COVID-19 vaccine, or who are planning to receive a COVID-19 vaccine in pregnancy.
88863633|NCT05114161|No Intervention|Standard care|All participants/caregivers will be asked for consent for point-of-care (POC) blood C-reactive protein (CRP), nasopharyngeal swab for virology/Mycoplasma testing, and urine for pneumococcal antigen (UAg) testing, but, since this testing will not affect care, these are optional (ie. refusal will not preclude enrolment). The RA will phone the caregiver at Day 2-5, Day 14-21, and Day 30 post-enrollment, for outcome ascertainment. Caregivers will be asked to fill out a daily diary (either electronically or on paper) to record the participant's symptoms, clinical progress, and possible drug adverse effects. Caregivers will also be instructed on how to take patient temperature. All participants whose symptoms do not progressively improve will be encouraged to return to the ED to be reassessed, as per standard of care.
88863634|NCT05114161|Experimental|Novel Care Pathway|Once a child is diagnosed with non-severe CAP (community-acquired pneumonia) in the ED, specific radiographic findings and point-of-care CRP testing will identify those who require antibiotic treatment immediately. The next day, results of multiplex respiratory pathogen and urine pneumococcal antigen (UAg, optional) testing will be integrated into the care plan, along with additional clinical information about the child gathered remotely, to ensure that only children at appreciable risk for bacterial infection receive antibiotics. Our care pathway uses already-available testing (NPS) in new ways, integrates newer diagnostics (point-of-care CRP, UAg), and includes properly-timed clinical follow up to change how children with non-severe CAP are managed.The research team will follow-up with the participant and caregiver the next day, 2-5 days, 7-21 days and day 30 post-enrolment to ensure clinical stability.
88863635|NCT05112601|Experimental|Arm I (nivolumab and ipilimumab)|"Patients receive nivolumab IV over 30 minutes on day 1 of each cycle and ipilimumab IV over 90 minutes on day 1 of every other cycle. Cycles repeat every three weeks. Treatment with nivolumab and ipilimumab repeats for up to 8 cycles in the absence of disease progression, unacceptable toxicity, or CR. Patients then receive nivolumab alone on day 1 of each cycle. Cycles repeat every 4 weeks in the absence of disease progression, unacceptable toxicity, or CR.~MAINTENANCE THERAPY: Patients achieving CR receive nivolumab for an additional 12 months in the absence of disease progression or unacceptable toxicity.~Patients also undergo a collection of blood and tissue samples throughout the trial and CT scan and/or MRI at screening."
88863636|NCT05112601|Active Comparator|Arm II (nivolumab)|"Patients receive nivolumab IV over 30 minutes on day 1 of each cycle. Treatment repeats every 3 weeks for up to 8 cycles, then every 4 weeks thereafter in the absence of disease progression, unacceptable toxicity, or CR.~MAINTENANCE THERAPY: Patients achieving CR receive nivolumab for an additional 12 months in the absence of disease progression or unacceptable toxicity.~Patients also undergo a collection of blood and tissue samples throughout the trial and CT scan and/or MRI at screening."
88863637|NCT05111860|Experimental|Group 1|
88863638|NCT05104892|Experimental|Rilzabrutinib|Rilzabrutinib BID or TID and ICS/LABA
88863639|NCT05104892|Placebo Comparator|Placebo|Placebo and ICS/LABA
88863640|NCT05104853|Experimental|4 mg/Kg CNP-104|200 mL intravenous infusion on Day 1 and Day 8: 4 mg/Kg CNP-104
88863641|NCT05104853|Experimental|8 mg/Kg CNP-104|200 mL intravenous infusion on Day 1 and Day 8: 8 mg/Kg CNP-104
88863642|NCT05104853|Placebo Comparator|Placebo|200 mL intravenous infusion on Day 1 and Day 8: Placebo
89185453|NCT05571761|Other|Waiting list control group|Will be the control group that remains without intervention until the study group completes the cognitive stimulation program and the subsequent neuropsychological assessment has been done. Once the intervention is completed with the study group, the same program will be applied to the control group.
89185454|NCT00740415|Experimental|ARM RiBVD|"RiBVD 6 cycles every 28 days day 1 :~Rituximab /Mabthera®, 375 mg/m2 en IV~Bendamustine, 90 mg/m2 en IVD~Bortezomib/Velcade®, 1,3 mg/m2 en IVD day 2 : - Bendamustine, 90 mg/m2 en IVD~Dexamethasone, 40 mg IV day 4 : - Bortezomib/Velcade®, 1,3 mg/m2 en IVD day 8 : - Bortezomib/Velcade®, 1,3 mg/m2 en IVD day 11 : - Bortezomib/Velcade®, 1,3 mg/m2 en IVD"
89185455|NCT02581722|Experimental|Adolescent male population|Male circumcision using the PrePex device among healthy adolescent males and contraindicated subjects due to Preputial adhesions and /or narrow foreskin/Phimosis
89185456|NCT00734162|Experimental|Tenofovir disoproxil fumarate (TDF)|
89185457|NCT00734162|Placebo Comparator|Placebo|
89185458|NCT00740493|Active Comparator|1|18 months of active warfarin therapy
89185459|NCT00740493|Placebo Comparator|2|18 months of placebo of warfarin
89185460|NCT02582580|Active Comparator|Perineal Massage|Massage is made in the perineum and vagina using your fingers to promote stretching of pelvic floor structures, making them more flexible and distensíveis, avoiding trauma during vaginal birth.
89185461|NCT02582580|Active Comparator|Vaginal Dilator|This device consists of a silicone balloon in an eight shape that, after inserted into the vagina, is inflated by manual pumping, promoting a stretching of the structures around it (hymenal edge, connective tissues and muscles perivaginal). This equipment assists the stretching of tissues around the vagina and the pelvic floor muscles, minimizing the risk of injury from the birth canal during the passage of the baby.
89185462|NCT02582580|Active Comparator|Pelvic floor muscles training|Exercises emphasizing conscious muscle relaxation, i.e., considering a resting time based on the contraction time. The resting time was double of the sustaining time of each contraction up to the 38th week of pregnancy, after remaining fixed this relaxation time up to the moment of delivery. This time was chosen because during the expulsive labor phase, there is a need for the pelvic floor muscles to consciously relax during a long period, in order to facilitate the descendants and rotational movements of the baby's head and consequently, its passage. This exercises does not aim only muscle strength but also contraction promotion, which aims body and perineal awareness, muscle tone, coordination and appropriate motor control to allow an active muscle relaxation in the second labor stage.
89185463|NCT00790751|Placebo Comparator|placebo|
89185464|NCT00790751|Experimental|avanafil 50 mg|
89185465|NCT00790751|Experimental|avanafil 100 mg|
89185466|NCT00790751|Experimental|avanafil 200 mg|
89185467|NCT00740571|Active Comparator|1|Strategy in which patient starts with amitriptyline
89185468|NCT00740571|Active Comparator|2|Strategy in which patient starts with pregabalin
89185469|NCT02582502|Experimental|Treatment|This arm will receive Hyperbaric Oxygen Therapy immediately after consent into study.
89185470|NCT02582502|Other|Wait list Treatment|This arm will receive Hyperbaric Oxygen Therapy two months after consenting into study.
89185471|NCT00740649|Experimental|1|HSD-016
89185472|NCT00740649|Other|2|placebo
89185473|NCT04107155|Experimental|Weight Management Program|Dietary Supplement: Saffron extract and Gynostemma extract with hesperidin and a handout with suggestions for healthy eating and overall health
89185474|NCT04107155|Placebo Comparator|Placebo|Placebo and handout with suggestions for healthy eating and overall health
89185475|NCT02582424|Experimental|PDL-0101|EPA +astaxanthin
89185476|NCT02582424|Placebo Comparator|placebo|olive oil
88863643|NCT05102591|Other|Standard-of-Care IV Group|Patients randomised to the standard of care IV group will receive a single, 45-minute stimulation from a sham remote electrical neuromodulation (REN) device, which will not administer the typical electrical stimulation (modulated frequency of ~ 0.083 Hz and a modulated pulse width of 40-550 µs), and will be given a single dose IV ketorolac and IV metoclopramide, at a dose of 0.5 mg/kg (for a maximum 30 mg) and 0.15 mg/kg (for a maximum 10mg), respectively. Metoclopramide will be infused over 15-30 minutes and ketorolac will be administered as a direct IV push over 1-5 minutes.
89388244|NCT05634486|Experimental|Multidisciplinary therapeutic approach|"Diagnosis of Functional Movement Disorders by one of the PI (Movement Disorders Specialist).~12 physiotherapy sessions during one month (three 60-minute sessions per week) administered by a physiotherapist with experience in functional neurological disorders.~4 cognitive-behavioral therapy sessions during one month (one 60-minute intervention per week) administered by a psychologist with experience in cognitive-behavioral therapy."
89185477|NCT05248893|Experimental|AGN-151586|Participants will receive 5 intramuscular injections in the glabellar complex on Day 1. Based on meeting the retreatment criteria, the participant may receive up to 2 additional cycles of open-label treatments.
89185478|NCT00784979|No Intervention|CMVIG followed by PP|MMF or rapamycin was given with CMVIG for 4 weeks followed by plasmapheresis
89185479|NCT02595242|Experimental|Mitoxantrone 12 mg/m2|Mitoxantrone Hydrochloride Liposome Injection 12 mg/m2 will be infused intravenously once over 1 hours in 250 ml 5％ glucose injection on the first day during a treatment phase of 3 weeks.
89185480|NCT02595242|Experimental|Mitoxantrone 16 mg/m2|Mitoxantrone Hydrochloride Liposome Injection 16 mg/m2 will be infused intravenously once over 1 hours in 250 ml 5％ glucose injection on the first day during a treatment phase of 3 weeks.
89185481|NCT02595242|Experimental|Mitoxantrone 20mg/m2|Mitoxantrone Hydrochloride Liposome Injection 20 mg/m2 will be infused intravenously once over 1 hours in 250 ml 5％ glucose injection on the first day during a treatment phase of 3 weeks.
89185482|NCT04487106|Experimental|Treatment (azacitidine, venetoclax, trametinib)|"INDUCTION (CYCLE 1): Patients receive azacitidine IV over 30-60 minutes or SC on days 1-7, venetoclax PO QD on days 1-28, and trametinib PO QD on days 1-28 in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION (CYCLES 2-24): Patients receive azacitidine IV over 30-60 minutes or SC on days 1-7, venetoclax PO QD on days 1-21, and trametinib PO QD on days 1-28. Treatment repeats every 28 days for up to 23 cycles in the absence of disease progression or unacceptable toxicity."
89185483|NCT00740883|Active Comparator|1|18 months of active warfarin therapy
89185484|NCT00740883|Placebo Comparator|2|18 months of placebo of warfarin
89185485|NCT00738920|Active Comparator|MC-CBT|Self Administered Cognitive Behavior Therapy
89185486|NCT00738920|Active Comparator|Standard-CBT|Therapist Administered Cognitive Behavior Therapy
89185487|NCT00738920|Active Comparator|Education/Support|Behavioral Patient Education/Counseling
89185488|NCT02568033|Experimental|A|"Chemotherapy:~for Non-Squamous Cell: Pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 on day 1 of 21 day cycle or Carboplatin AUC6 and Paclitaxel 75 mg/m2 on day 1 of 21 day cycle~for Squamous Cell: Cisplatin 75 mg/m2 and docetaxel 75mg m2 day 1 of 21 day cycle or Carboplatin AUC6 and paclitaxel 200 mg/m2 day 1 of 21 day cycle~Radiation- Stereotactic radiosurgery Peripheral Lung lesion: 60 Gy over 3 fractions Central Lung lesion: 50 Gy over 5 fractions Hilar and Mediastinal LNs 40-50Gy over 5 fractions~Schedule is:~2 cycles of chemotherapy, followed by SRS, followed by 2 additional cycles of chemotherapy."
89185489|NCT00582972|Experimental|Experimental|Subjects will receive omeprazole 40 mg daily for 30 days
89185490|NCT02595086|Experimental|Laparoscopic PPG|Laparoscopy assisted pylorus-preserving gastrectomy(LPPG) with D1+ lymphadenectomy is performed (exclude lymph node station No. 5) in Japanese classification. Systemic en bloc lymph node dissection is mandatory. Resection margin should be negative for malignancy with intraoperative frozen biopsy. Extra-corporeal gastro-gastrostomy should be performed
89388245|NCT05634486|Sham Comparator|Psychoeducation|"Diagnosis of Functional Movement Disorders by one of the PI (Movement Disorders Specialist).~4 psychoeducational sessions (one 60-minute intervention per week) administered by a psychologist with experience in cognitive-behavioral therapy."
89388246|NCT05615636|Experimental|Safety Run In|During the safety run-in, the study team will first test a recommended dose of mosunetuzumab, polatuzumab vedotin, tafasitamab, and lenalidomide.
89388247|NCT05615636|Experimental|Dose Expansion Cohort|Participants will receive mosunetuzumab, polatuzumab vedotin, tafasitamab, and lenalidomide at the dose level that was found tolerated in the safety run-in.
88863644|NCT05102591|Other|REN Group|Patients randomised to the REN group will receive a single 45-minutes stimulation from the REN device (modulated frequency of 100-120 Hz and a pulse width of 400 µs) and will also receive two doses of normal saline though an IV. Two doses of saline will be used to match the dosage, route of administration, and duration to ketorolac and metoclopramide, as described above in the standard-of-care IV group.
88863645|NCT05101616|Experimental|camrelizumab+chemotherapy|neoadjuvant treatment with camrelizumab+chemotherapy
88863646|NCT05101616|Active Comparator|chemotherapy|neoadjuvant treatment with chemotherapy
88863647|NCT05085028|Active Comparator|6 weekly|6 weekly pembrolizumab, 400mg intravenous
88863648|NCT05085028|Experimental|9 weekly|9 weekly pembrolizumab, 400mg intravenous
88863649|NCT05085028|Experimental|12 weekly|12 weekly pembrolizumab, 400mg intravenous
88863650|NCT05085028|Experimental|15 weekly|15 weekly pembrolizumab, 400mg intravenous
88863651|NCT05085028|Experimental|18 weekly|18 weekly pembrolizumab, 400mg intravenous
88863652|NCT05083637|Active Comparator|Intervention Arm|Children randomized to this arm will receive L- carnitine oral solution (100mg/ml) (Generic Name) with the dosage- 100 mg/kg/day, divided into 3 doses per day for 15 days.
88863653|NCT05083637|Placebo Comparator|Control Arm|Children randomized to this arm will receive placebo in same quantity, divided into 3 doses per day for 15 days.Placebo solution will be identical in appearance, smell and taste to the active preparation (L-carnitine syrup) with no therapeutic value.
89185491|NCT02595086|Active Comparator|Laparoscopic DG|"Laparoscopic distal gastrectomy(LDG) with D1+ lymphadenectomy in Japanese classification. Systemic en bloc lymph node dissection is mandatory. Resection margin should be negative for malignancy with intraoperative frozen biopsy.~Anastomosis method (extra-corporeal or intra-) and reconstruction type (Billroth I (gastroduodenostomy), Billroth II, or Roux-en Y gastrojejunostomy) are optional according to the surgeon's preference"
88863655|NCT05080790|Experimental|5 cycles (Q5W) of dinutuximab beta, interleukin-2 and zoledronic acid|5 cycles (Q5W) of dinutuximab beta, 20mg/m2/day, interleukin-2, 5.4x10^6, and zoledronic acid, 4 mg
88863656|NCT05080166|Experimental|Clinicians Interviews|Lymphoma and mental health clinicians will participate in 1x in-depth qualitative interview to provide feedback for the development of the UPLYFT program.
88863657|NCT05080166|Experimental|Lymphoma Survivors Field Test|A six person group of lymphoma survivors will participate in a six session UPLYFT program field test to provide feedback for the development of the UPLYFT program.
88863658|NCT05080166|Experimental|UPLYFT Pilot|"Lymphoma survivors will participate in the phase 1 finalized, six session UPLYFT program.~Participants will be randomized 1:1 to either UPLYFT or usual care."
88863659|NCT05068102|Experimental|Arm A|
88863660|NCT05068102|Experimental|Arm B|
88863661|NCT05061199||ECA group|TCC with extracorporeal anastomosis (ECA)
88863662|NCT05061199||ICA group|TCC with intracorporeal anastomosis (ICA).
88863663|NCT05059522|Experimental|Arm 1|Avelumab monotherapy as specified by sub-study protocol B9991001C
88863664|NCT05059522|Experimental|Arm 2|Avelumab in combination with CMP 001, Utomilumab or PF04518600 as specified by sub-study protocol B9991004C
88863665|NCT05059522|Experimental|Arm 3|Avelumab in combination with Loratanib as specified by sub-study protocol B9991005C
88863666|NCT05059522|Experimental|Arm 4|Avelumab monotherapy as specified by sub-study protocol B9991009C
88863667|NCT05059522|Experimental|Arm 5|Avelumab monotherapy or in combination with Pemetrexed as specified by sub-study protocol B9991023C
88863668|NCT05059522|Experimental|Arm 6|Avelumab in combination with Talazoparib as specified by sub-study B9991025C.
89185492|NCT05236413|Experimental|High Intensity Interval Exercise|Enrolled patients will perform supervised exercise on 3 nonconsecutive days of the week for 4 weeks.
89388248|NCT05614739|Experimental|Phase 1a: Cohort A1 LOXO-435 Monotherapy Dose Escalation|LOXO-435 administered orally to participants with FGFR3-altered advanced solid tumors.
88863669|NCT05059522|Experimental|Arm 7|Avelumab in combination with Axitinib as specified by sub-study B9991027C.
88863670|NCT05059522|Experimental|Arm 8|Avelumab in combination with Talazoparib as specified by sub-study B9991032C.
88863671|NCT05053503|Placebo Comparator|Active tAN + placebo|tAN will be delivered at a duty cycle of for 5 minutes ON and 10 seconds OFF for up to 168 hours (7 days) therapy duration. Stimulation intensity will be customized to the participants comfort level and within range of therapeutic effectiveness. Participants will receive 3 placebo pills four times per day for 7 days. The placebo will appear similar to lofexidine in size, shape, color, and smell to lofexidine.
88863672|NCT05053503|Active Comparator|Active tAN + lofexidine|tAN will be delivered at a duty cycle of for 5 minutes ON and 10 seconds OFF for up to 168 hours (7 days) therapy duration. Stimulation intensity will be customized to the participants comfort level and within range of therapeutic effectiveness. Participants will receive 3 lofexidine 0.18 mg/tablets four times per day (daily dose of 2.16 mg) for 7 days.
88863673|NCT05053503|No Intervention|Sham tAN + placebo|Participants will have the earpiece applied and the cable connected to the Patient Controller, but tAN stimulation will not be turned on. Participants will receive 3 placebo pills four times per day for 7 days. The placebo will appear similar to lofexidine in size, shape, color, and smell to lofexidine.
88863674|NCT05053503|Sham Comparator|Sham tAN + lofexidine|Participants will have the earpiece applied and the cable connected to the Patient Controller, but tAN stimulation will not be turned on. Participants will receive 3 lofexidine 0.18 mg/tablets four times per day (daily dose of 2.16 mg) for 7 days.
88863675|NCT05053503|Active Comparator|extended-release injectable naltrexone|Extended-release injectable naltrexone will be administered according to the clinical site's standard of care.
89185493|NCT05236413|Experimental|Dietary Approaches to Stop Hypertension (DASH) Diet|Enrolled patients will have all of their food prepared for them by a registered dietician for the duration of the study period. The diet will consist of a high fiber content DASH diet.
89185494|NCT05236413|Experimental|Exercise + DASH Diet|Enrolled subjects will undergo both the exercise training visits and be provided with the DASH diet.
89388249|NCT05614739|Experimental|Phase 1a: Cohort A2 LOXO-435 Monotherapy Dose Optimization|LOXO-435 administered orally to participants with FGFR3-altered advanced urothelial carcinoma. (Cohort to be implemented as needed, based on Sponsor's discretion.)
89388250|NCT05614739|Experimental|Phase 1b: Cohort B1 LOXO-435 Monotherapy Dose Expansion|LOXO-435 administered orally to participants with FGFR3-altered advanced urothelial carcinoma who were previously treated with an FGFR inhibitor.
89388251|NCT05614739|Experimental|Phase 1b: Cohort B2 LOXO-435 Monotherapy Dose Expansion|LOXO-435 administered orally to participants with FGFR3-altered advanced urothelial carcinoma who have not received a prior FGFR inhibitor.
89388252|NCT05614739|Experimental|Phase 1b: Cohort B3 LOXO-435 Plus Pembrolizumab|LOXO-435 administered orally in combination with pembrolizumab administered intravenously (IV) to participants with FGFR3-altered advanced urothelial carcinoma who have not received a prior FGFR inhibitor.
89388253|NCT05614739|Experimental|Phase 1b: Cohort C1 LOXO-435 Monotherapy Dose Expansion|LOXO-435 administered orally to participants with advanced solid tumors who have not received a prior FGFR inhibitor.
89388254|NCT05611931|Experimental|Selinexor|Participants will receive a fixed dose of selinexor 60 milligrams (mg) oral tablets once weekly (QW) on Days 1, 8, 15, and 22 of each 28-day cycle.
89388255|NCT05611931|Placebo Comparator|Placebo|Participants will receive matching placebo for selinexor oral tablets QW on Days 1, 8, 15, and 22 of each 28-day cycle.
89388256|NCT05605899|Experimental|Axicabtagene Ciloleucel|Participants will receive cyclophosphamide 500 mg/m^2/day intravenously (IV) and fludarabine 30 mg/m^2/day IV lymphodepletion chemotherapy for 3 days followed by axicabtagene ciloleucel administered as a single IV infusion at a target dose of 2 x 10^6 anti-cluster of differentiation (CD)19 chimeric antigen receptor (CAR) transduced autologous T cells/kg on Day 0.
89530409|NCT02516345|Active Comparator|Child-based Incentive (CBI)|"Children earn rewards each week (with the week beginning on Monday and ending on Sunday) that they log 10,000 daily steps on the Fitbit according to the schedule below and their matched parent logs at least 2,000 steps on ≥4 of 7 days each week (regardless of which 4 of the 7 days they wear it). Incentives are tied, in addition to child's activity, to parent's Fitbit wear so that the investigators are better able to capture parent's activity in this arm.~Step Targets for Children in CBI arm:~Months 1 - 3: ≥10,000 daily steps on ≥4 out of 7 days each week~Months 4 - 6: ≥10,000 daily steps on ≥5 out of 7 days each week~Months 7 - 12: ≥10,000 daily steps on ≥6 out of 7 days each week"
88863676|NCT05053503|Experimental|Active tAN + extended-release injectable naltrexone|"Extended-release injectable naltrexone will be administered according to the clinical site's standard of care. Participants will be provided with a Spark Sparrow Ascent Therapy System and instructed to administer therapy according to the specified frequencies:~Month 1 (Days 1 - 28): a minimum of 2 hours per day at least 5 days a week~Month 2 (Days 29 - 56): a minimum of 2 hours per day at least 3 days a week~Month 3 (Days 57 - 90: a minimum of 2 hours per day at least 1 day per week"
89185495|NCT02597972|Active Comparator|Open Reduction Internal Fixation Proximal Humerus|The patients randomized into the ORIF group will receive standard surgical treatment of their proximal humerus fracture with a proximal humeral locking plate.
88863677|NCT05051449|Experimental|Ketamine|
89185496|NCT02597972|Active Comparator|Reverse Total Shoulder Arthroplasty|The patients randomized into the RTSA group will receive standard surgical treatment of their proximal humeral fracture with a Reverse Total Shoulder Arthroplasty.
89185497|NCT05224401|Experimental|PAC treatment|
89185498|NCT05224401|Active Comparator|Standard treatment|
88863678|NCT05043051|Active Comparator|Vagal stimulation|Vagal stimulation will be given at 20 Hz for 1 hour daily with the bipolar electrode attached to the tragus for 2 months.
88863679|NCT05043051|Sham Comparator|Sham stimulation|Sham stimulation will be given at 20 Hz for 1 hour daily with the bipolar electrode attached to the earlobe for 2 months.
88863680|NCT05041699|Experimental|IPM Ring-105|Ring-105 (xx mg dapivirine + xxx mg levonorgestrel)
88863681|NCT05041699|Active Comparator|IPM Ring-106.|Ring-106 (xx mg dapivirine + xxx mg levonorgestrel)
88863682|NCT05034562|Experimental|Diagnostic (gallium Ga 68-labeled PSMA-11, PET/CT, PET/MRI)|Patients receive gallium Ga 68-labeled PSMA-11 IV. 50-100 minutes after injection, patients then undergo a PET/CT scan or PET/MRI scan over 60 minutes.
88863683|NCT05022485||Investigational group|Subjects that will be implanted with the ZNN Bactiguard tibia device.
88863684|NCT05022485||Control group|Subjects that have received an uncoated titanium-alloy tibia nail in the past (data collection is retrospective; patients will not have to undergo any study-related procedure).
88863685|NCT05022303|Placebo Comparator|Placebo|Matching placebo will be administered orally four times a day (QID) to the standard of care for MIS-C.
88863686|NCT05022303|Experimental|Larazotide Acetate|AT1001 10 μg/kg/dose up to 500 μg/dose (rounded to the nearest 50 μg) will be administered orally four times a day (QID) to the standard of care for MIS-C.
88863687|NCT05019521|Experimental|Danicopan: 100 mg|Participants will receive danicopan 100 mg bid during the masked Treatment Period. Once the optimal dose is identified, participants who have at least 52 weeks of treatment will be switched to the optimal dose for the remainder of the study.
88863688|NCT05019521|Experimental|Danicopan: 200 mg|Participants will receive danicopan 200 mg bid during the masked Treatment Period. Once the optimal dose is identified, participants who have at least 52 weeks of treatment will be switched to the optimal dose for the remainder of the study.
88863689|NCT05019521|Experimental|Danicopan: 400 mg|Participants will receive danicopan 400 mg qd during the masked Treatment Period. Once the optimal dose is identified, participants who have at least 52 weeks of treatment will be switched to the optimal dose for the remainder of the study.
88863690|NCT05019521|Placebo Comparator|Placebo|Participants will receive matching placebo and will be re-randomized to one of the active treatment groups at Week 52, or to the optimal dose, if already identified.
88863691|NCT05014841|Experimental|Electrocorticography (ECoG) recording during Speech Tasks|Participants listened to 20-minute Speech Tasks while ECoG signals for neural activity was recorded during their intraoperative procedure or inpatient hospitalization at the University of California, San Francisco (UCSF).
88863692|NCT05000697|Experimental|Arm 1 - 5FU + Oxaliplatin|1) RT (54Gy) plus daily concomitant capecitabine 825mg/m2 bid, followed by mFOLFOX6 or XELOX for 4 cycles (12 weeks), starting 1 week after radiotherapy ended;
88863693|NCT05000697|Active Comparator|Arm 2 - 5FU Only|2) RT (54Gy) plus daily concomitant capecitabine 825mg/m2 bid, followed by capecitabine 2000mg/m2/day for 14 days in a 21 days cycle for 4 cycles (12 weeks), starting 1 week after radiotherapy ended;
89535308|NCT02487953|Experimental|Nicotine ENDS + Nicotine Patch|Participants will initially receive 1 week of 21 mg nicotine skin patches while continuing to smoke their usual cigarettes ad lib. Starting with week 2, they will receive nicotine-containing ENDS devices and will be instructed to substitute ENDS for as many cigarettes as possible in this week. The target quit-smoking date will occur at the beginning of week 3. Treatments will continue until week 8 post-quit, at which time participants will be instructed to reduce ENDS use over the next 4 weeks, at which time ENDS will no longer be dispensed. Subsequently, the nicotine patch dose will be gradually reduced according to standard weaning regimen from 21 mg/24 h to 14 mg/24 h for 2 weeks, and 7 mg/ 24 h for 2 weeks. All nicotine-based treatments will end at week 16 after the quit date.
88863698|NCT04985903|Experimental|Intervention|Clinicians in the intervention arm will receive a tailored communication training on smoking cessation skills and a general lecture on smoking cessation.
88863699|NCT04985903|Active Comparator|Control|Clinicians in the control arm will be asked to attend a lecture on general information about smoking cessation for pregnant patients and smoking cessation counseling.
88863700|NCT04985682|Experimental|Hemophilia A Group|Participants with hemophilia A were treated with ADVATE according to a regimen determined by the treating physician at the study site and in accordance with the national product label under standard clinical practice for 6.7 months.
88863701|NCT04981522|Experimental|Active Treatment (AT): PM+ intervention|Active Treatment (AT) group will receive 05 sessions of indigenously adapted problem management plus (IA-PM+) intervention.
88863702|NCT04981522|No Intervention|Delayed Treatment Control (DTC): Treatment as usual|Delayed Treatment Control (DTC) group will receive routine treatment until the last follow-up.
89388257|NCT05605899|Active Comparator|Standard of Care Therapy|"Participants will receive the investigator's choice of one of the following therapies/dosing schedules:~Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for a total of 6 cycles (21-day cycle)~Rituximab 375 mg/m^2 on Day 1~Cyclophosphamide 750 mg/m^2 on Day 1~Doxorubicin 50 mg/m^2 on Day 1~Vincristine 1.4 mg/m^2 (maximum 2 mg) on Day 1~Prednisone 40 mg/m^2 on Day 1 through Day 5~Dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (DA-EPOCH-R) for a total of 6 cycles (21-day cycle)~Rituximab 375 mg/m^2 on Day 1~Etoposide 50 mg/m^2 on Days 1 to 4~Doxorubicin 10 mg/m^2 on Days 1 to 4~Vincristine 0.4 mg/m^2 on Days 1 to 4~Cyclophosphamide 750 mg/m^2 on Day 5~Prednisone 60 mg/m^2 twice daily on Days 1 to 5"
89388258|NCT05601440|Experimental|Substudy A - Monitoring|
89388259|NCT05601440|Experimental|Substudy B - RP-6306 + Gemcitabine|
89388260|NCT05601440|Experimental|Substudy C - Niraparib + Fulvestrant|
89388261|NCT05595837||COVID-19 positive donors|
89388262|NCT05595837||COVID-19 negative donors|
89388263|NCT05590923|Experimental|OLA then crossover to DEX|"OLA group: olanzapine (Zyprexa) 10 mg oral each night after chemotherapy cycle 1 on days 1-4 after HEC (or days 1-3 after MEC).~DEX group: dexamethasone (Decadron) 8 mg oral daily after chemotherapy cycle 2 on days 2-4 after HEC (or days 2-3 after MEC)"
89388264|NCT05590923|Active Comparator|DEX then crossover to OLA|"DEX group: dexamethasone (Decadron) 8 mg oral daily after chemotherapy cycle 1 on days 2-4 after HEC (or days 2-3 after MEC)~OLA group: olanzapine (Zyprexa) 10 mg oral each night after chemotherapy cycle 2 on days 1-4 after HEC (or days 1-3 after MEC)."
89388265|NCT05562466|Experimental|QMF149|QMF149 75/40μg
89388266|NCT05562466|Active Comparator|Budesonide|Budesonide 200μg o.d
89388267|NCT05561673|Active Comparator|HBs-alum Group|Participants receive three doses of GSK's Hepatitis B vaccine adjuvanted with aluminum hydroxide, one each at Day 1, Day 31 and Day 181.
89388268|NCT05561673|Experimental|HBs-AS03 Group|Participants receive two doses of GSK's HBsAg candidate vaccine adjuvanted with GSK's AS03, adjuvant system, one each at Day 1 and Day 31.
89388269|NCT05561673|Experimental|HBs-AS04 Group|Participants receive two doses of GSK's Hepatitis B vaccine adjuvanted with GSK's AS04, adjuvant system, one each at Day 1 and Day 31.
89388270|NCT05561673|Experimental|HBs-AS37_formulation 1 Group|Participants receive two doses of GSK's HBsAg vaccine adjuvanted with GSK's AS37 adjuvant system formulation 1, one each at Day 1 and Day 31.
89388271|NCT05561673|Experimental|HBs-AS37_formulation 2 Group|Participants receive two doses of GSK's HBsAg vaccine adjuvanted with GSK's AS37 adjuvant system formulation 2, one each at Day 1 and Day 31.
89388272|NCT05554458|Experimental|Control Group|Paired allocation into intervention group IG (N = 33) and control group CG (N = 33) is based on the number of risk factors identified in the family. IG and CG complete questionnaires at the baseline assessment (T0), at the post-test assessment (T1), and at the follow-up assessments after 6 months (T2) and 12 months (T3).
89388273|NCT05554458|Active Comparator|Intervention Group|IG receive the ChildTalks+ intervention within 2 months after T0 and CG after the T3 assessment.
89388274|NCT05553834|Experimental|Alirocumab and Cemiplimab|Combination of anti-PCSK9 antibody alirocumab with the anti-PD-1 antibody cemiplimab
89388275|NCT05547061|Experimental|Phase 1 Part A(Healthy/Disease group)|Subjects are administered intravenously a single dose of 2MBq/kg of Ga-68-NGUL.
89388276|NCT05547061|Experimental|Phase 1 : Part B(Low dose)|Subjects with positive lesions for Ga-68-NGUL are administered intravenously with low dose(150mCi) of Lu-177-DGUL.
89185499|NCT02598206|Experimental|Experimental 1|"All subjects will receive 2 treatments in one of the indicated sequence orders:~A - B B - A"
89388277|NCT05547061|Experimental|Phase 1 : Part B(High dose)|Subjects with positive lesions for Ga-68-NGUL are administered intravenously with high dose(200mCi) of Lu-177-DGUL.
89388278|NCT05547061|Experimental|Phase 2|Subjects with positive lesions for Ga-68-NGUL are administered intravenously with Lu-177-DGUL with the determined RP2D.
89388279|NCT05536141|Experimental|Dose Escalation Cohort 1|Participants will receive AB521 orally once daily
89388280|NCT05536141|Experimental|Dose Escalation Cohort 2|Participants will receive AB521 orally once daily
89388281|NCT05536141|Experimental|Dose Escalation Cohort 3|Participants will receive AB521 orally twice daily
89388282|NCT05536141|Experimental|Dose Escalation Cohort 4|Participants will receive AB521 orally
89388283|NCT05536141|Experimental|Dose Expansion Cohort 1|Participants will receive AB521 orally
89388284|NCT05536141|Experimental|Dose Expansion Cohort 2|Participants will receive AB521 orally
89388285|NCT05536141|Experimental|Dose Expansion Cohort 3|Participants will receive AB521 orally
89388286|NCT05534724|Other|Partial weight-bearing (10 - 15kg)|Immediate post-operative partial weight-bearing (10 - 15kg) with a VACOPASO shoe for 6 weeks, crutches and antithrombotic prophylaxis
89388287|NCT05534724|Experimental|Complete weight-bearing|Immediate post-operative complete weight-bearing with a VACOPASO shoe for 6 weeks and antithrombotic prophylaxis
89388288|NCT05529992|Experimental|Velaglucerase Alfa (VPRIV)|Participants will receive VPRIV intravenous infusion once every other week (EOW) for 60 (+10) minutes as per physician treatment plan for up to 51 weeks.
89388289|NCT05521880|Other|Historical outcomes with standard of care treatment|Historical outcomes with standard of care treatment involving IV antibiotics administered in a skilled nursing facility will be compared
89388290|NCT05519254|Experimental|Lactoferrin Arm|16-week course of lactoferrin
89388291|NCT05519254|Experimental|Lysozyme Arm|16-week course of lysozyme
89388292|NCT05519254|Experimental|Combination Arm (Lactoferrin + Lysozyme)|16-week course of lactoferrin and lysozyme
89388293|NCT05519254|Placebo Comparator|Placebo Arm|16-week course of taste/appearance-matched placebo
88863707|NCT04965675|Experimental|Eptinezumab 300 mg|Participants will receive a single IV infusion of eptinezumab 300 mg (weight adjusted).
88863708|NCT04965675|Experimental|Eptinezumab 100 mg|Participants will receive a single IV infusion of eptinezumab 100 mg (weight adjusted).
88863709|NCT04965675|Placebo Comparator|Placebo|Participants will receive a single IV infusion of placebo matching to eptinezumab.
89388294|NCT05513625|Experimental|100 mg pritelivir|Single dose 100 mg pritelivir (PTV) administered day 1
88863710|NCT04964453|Placebo Comparator|Placebo|Healthy subjects were given a single dose of placebo tablet(s) matched to the active treatment, subjects receiving placebo were equally distributed across dose groups. Tablet(s) were taken orally with 240 milliliter of water after an overnight fast of at least 10 hours.
88863711|NCT04964453|Experimental|2.5 mg BI 474121|Healthy subjects were given a single dose of 2.5 milligram (mg) of BI 474121 as a single (2.5 mg) uncoated tablet taken orally with 240 milliliter of water after an overnight fast of at least 10 hours.
88863712|NCT04964453|Experimental|5 mg BI 474121|Healthy subjects were given a single dose of 5 milligram (mg) of BI 474121 as two (2.5 mg) uncoated tablets taken orally with 240 milliliter of water after an overnight fast of at least 10 hours.
89185500|NCT00740961||Patients with cancer|Patients ≥ 65 years with new stage I-III breast or colon cancer seeking care. Patients will be matched on baseline scores, age and sex. Patients will be age and sex matched due to the known relation between inflammatory markers and demographic characteristics39,40, and will be matched on baseline VES scores to ensure similar baseline VES-13 scores between groups and which will then allow us to then assess effect of cancer treatment on outcomes.
89388295|NCT05513625|Experimental|40 mg qd ESO and 100 mg pritelivir|40 mg qd ESO Day -3 to Day1. Single dose of 100 mg PTV on Day 1
89388296|NCT05507515|Experimental|Part A: Cohort A1 ONO-2020 or Placebo - fasted|Single ascending doses of ONO-2020 orally under fasted conditions
89388297|NCT05507515|Experimental|Part A: Cohort A2 ONO-2020 or Placebo - fasted and fed|Single ascending doses of ONO-2020 orally under fasted and fed conditions
89388298|NCT05507515|Experimental|Part A: Cohort A3 ONO-2020 or Placebo - fasted|Single ascending doses of ONO-2020 orally under fasted conditions
89388299|NCT05507515|Experimental|Part A: Cohort A4 ONO-2020 or Placebo - fasted and fed|Single ascending doses of ONO-2020 orally under fasted and fed conditions
89388300|NCT05507515|Experimental|Part A: Cohort A5 ONO-2020 or Placebo - fasted|Single ascending doses of ONO-2020 orally under fasted conditions
89388301|NCT05507515|Experimental|Part A: Cohort A6 ONO-2020 or Placebo - fasted|Single ascending doses of ONO-2020 orally under fasted conditions
89388302|NCT05507515|Experimental|Part B: Cohort B1 ONO-2020 or Placebo|Multiple ascending doses of ONO-2020 orally for 14 days
88863713|NCT04964453|Experimental|10 mg BI 474121|Healthy subjects were given a single dose of 10 milligram (mg) of BI 474121 as a single (10 mg) uncoated tablet taken orally with 240 milliliter of water after an overnight fast of at least 10 hours.
88863714|NCT04964453|Experimental|20 mg BI 474121|Healthy subjects were given a single dose of 20 milligram (mg) of BI 474121 as two (10 mg) uncoated tablets taken orally with 240 milliliter of water after an overnight fast of at least 10 hours.
88863715|NCT04961567|Experimental|Litifilimab High Dose|Participants who are receiving background nonbiologic lupus SOC therapy will receive high dose of litifilimab, subcutaneously (SC), every 4 weeks (Q4W), up to Week 48 with an additional dose at Week 2.
88863716|NCT04961567|Experimental|Litifilimab Low Dose|Participants who are receiving background nonbiologic lupus SOC therapy will receive low dose of litifilimab, SC Q4W, up to Week 48 with an additional dose at Week 2.
88863717|NCT04961567|Placebo Comparator|Placebo|Participants who are receiving background nonbiologic lupus SOC therapy will receive litifilimab-matching placebo, SC Q4W, up to Week 48 with an additional dose at Week 2.
88863718|NCT04955691|Experimental|low carbohydrate diet|In this crossover study, participants will be randomized to either a low or standard carbohydrate for 2 weeks. Participants in the low carbohydrate group will limit carbohydrate intake to 15% of total daily calories.
89185501|NCT00740961||Patients without cancer|non-cancer patients, seeking care at out-patient clinics
89388303|NCT05507515|Experimental|Part B: Cohort B2 ONO-2020 or Placebo|Multiple ascending doses of ONO-2020 orally for 14 days
89388304|NCT05507515|Experimental|Part B: Cohort B3 ONO-2020 or Placebo|Multiple ascending doses of ONO-2020 orally for 14 days
89388305|NCT05507515|Experimental|Part B: Cohort B4 ONO-2020 or Placebo|Multiple ascending doses of ONO-2020 orally for 14 days
89388306|NCT05507515|Experimental|Part B: Cohort B5 ONO-2020 or Placebo|Multiple ascending doses of ONO-2020 orally for 14 days
89388307|NCT05507515|Experimental|Part C: Cohort C1 ONO-2020|Single dose of ONO-2020 orally for CSF sampling
89388308|NCT05507515|Experimental|Part C: Cohort C2 ONO-2020|Single dose of ONO-2020 orally for CSF sampling
89388309|NCT05507515|Experimental|Part D: Cohort D1 ONO-2020 or Placebo|Single dose of ONO-2020 orally in elderly healthy volunteers
89388310|NCT05507515|Experimental|Part E: Cohort E1 ONO-2020 or Placebo|Multiple ascending doses of ONO-2020 orally for 14 days in Japanese healthy volunteers
89388311|NCT05507515|Experimental|Part E: Cohort E2 ONO-2020 or Placebo|Multiple ascending doses of ONO-2020 orally for 14 days in Japanese healthy volunteers
89388312|NCT05504421|Active Comparator|Control group|Students will receive theoretical training on sustainability in nursing, given by the narrative technique, and then students will work individually on the subject and share their weekly individual study time with the researcher. When individual work is completed, a simulation application will be performed with the scenario.
89388313|NCT05504421|Experimental|Experimental group|Students will receive theoretical training on sustainability in nursing, given by the narrative technique, and then analyze the some structured cases in groups structured in line with the cooperative learning process. When the case analysis is finished, a simulation application will be performed with the scenario.
88863719|NCT04955691|Active Comparator|standard carbohydrate diet|In this crossover study, participants will be randomized to either a low or standard carbohydrate for 2 weeks. Participants in the standard carbohydrate group will follow an ad libitum diet with standard carbohydrate intake.
89388314|NCT05502237|Experimental|Zimberelimab (ZIM) +Domvanalimab (DOM) + Chemotherapy|"Participants will receive ZIM 360 mg + DOM 1200 mg (up to 35 doses) with chemotherapy every 3 weeks (Q3W) on Day 1 of each 21-day cycle.~Choice of chemotherapy is dependent on histology.~Participants with nonsquamous histology will receive cisplatin 75 mg/m^2 or carboplatin area under the concentration versus time curve (AUC)5 + pemetrexed 500 mg/m^2 Q3W for first 4 cycles. After the completion of the first 4 cycles, participants with nonsquamous histology may continue with maintenance pemetrexed 500 mg/m^2 Q3W until disease progression or intolerable toxicities.~Participants with squamous histology will receive carboplatin AUC 6 Q3W with paclitaxel 200 mg/m^2 Q3W or nab-paclitaxel 100 mg/m^2 weekly (QW) for first 4 cycles."
89388315|NCT05502237|Active Comparator|Pembrolizumab (PEMBRO) + Chemotherapy|"Participants will receive PEMBRO 200 mg (up to 35 doses) with chemotherapy Q3W on Day 1 of each 21-day cycle.~Choice of chemotherapy is dependent on histology.~Participants with nonsquamous histology will receive cisplatin 75 mg/m^2 or carboplatin AUC 5 + pemetrexed 500 mg/m^2 Q3W for first 4 cycles. After the completion of the first 4 cycles, participants with nonsquamous histology may continue with maintenance pemetrexed 500 mg/m^2 Q3W until disease progression or intolerable toxicities.~Participants with squamous histology will receive carboplatin AUC 6 Q3W with paclitaxel 200 mg/m^2 Q3W or nab-paclitaxel 100 mg/m^2 weekly (QW) for first 4 cycles."
89388316|NCT05502237|Experimental|Zimberelimab (ZIM) + Chemotherapy|"Participants will receive ZIM 360 mg (up to 35 doses) with chemotherapy Q3W on Day 1 of each 21-day cycle.~Choice of chemotherapy is dependent on histology.~Participants with nonsquamous histology will receive cisplatin 75 mg/m^2 or carboplatin AUC 5 + pemetrexed 500 mg/m^2 Q3W for first 4 cycles After the completion of the first 4 cycles, participants with nonsquamous histology may continue with maintenance pemetrexed 500 mg/m^2 Q3W until disease progression or intolerable toxicities.~Participants with squamous histology will receive carboplatin AUC 6 Q3W with paclitaxel 200 mg/m^2 Q3W or nab-paclitaxel 100 mg/m^2 weekly (QW) for first 4 cycles."
89388317|NCT05487599|Experimental|LY3884961|LY3884961 is an advanced therapy investigational medicinal product administered as a single intravenous infusion.
88863720|NCT04952753|Experimental|Safety run-in: NIS793+SOC (Investigational arm 1)|In the safety run-in part for investigational arm 1, participants will be treated with a combination of SOC anti-cancer therapy (bevacizumab with either modified FOLFOX6 or FOLFIRI) and NIS793 to confirm the RP2D of the NIS793
89388318|NCT05486416|Experimental|HSK3486 for general anesthesia induction|HSK3486 for induction of general anesthesia
89388319|NCT05486416|Active Comparator|Propofol for general anesthesia induction|Propofol for induction of general anesthesia
89388320|NCT05480800|Experimental|iNTS-TCV low dose Group|Participants 18 to 50 years of age in Stage 1 (Europe) randomized to receive 3 doses of iNTS-TCV low dose vaccine and 3 doses of saline solution, administered in different arms, at Days 1, 57, and 169.
89388321|NCT05480800|Active Comparator|iNTS-GMMA and TCV low doses Group|Participants 18 to 50 years of age in Stage 1 (Europe) randomized to receive 3 doses of iNTS-GMMA low dose vaccine and 3 doses of TCV low dose vaccine, administered in different arms, at Days 1, 57, and 169.
89388322|NCT05480800|Placebo Comparator|Placebo _Step 1 Group|Participants 18 to 50 years of age in Stage 1 (Europe) randomized to receive 3 doses of placebo and 3 doses of saline solution, administered in different arms, at Days 1, 57, and 169.
88863721|NCT04952753|Experimental|Expansion: NIS793+SOC (Investigational arm 1)|In the expansion part, participants in the investigational arm 1 will be treated with a combination of SOC anti-cancer therapy (bevacizumab with either modified FOLFOX6 or FOLFIRI) and NIS793 at the RP2D defined in the safety run-in
89388323|NCT05480800|Experimental|iNTS-TCV full dose_1 Group|Participants 18 to 50 years of age in Stage 1 (Europe) randomized to receive 3 doses of iNTS-TCV full dose vaccine and 3 doses of saline solution, administered in different arms, at Days 1, 57, and 169.
88863722|NCT04952753|Active Comparator|Expansion: SOC (control arm)|In the expansion part, participants in the control arm will be treated with a combination of SOC anti-cancer therapy (bevacizumab with either modified FOLFOX6 or FOLFIRI)
89388324|NCT05480800|Active Comparator|iNTS-GMMA and TCV full doses_1 Group|Participants 18 to 50 years of age in Stage 1 (Europe) randomized to receive 3 doses of iNTS-GMMA full dose vaccine and 3 doses of TCV full dose vaccine, administered in different arms, at Days 1, 57, and 169.
89388325|NCT05480800|Placebo Comparator|Placebo_Step 2 Group|Participants 18 to 50 years of age in Stage 1 (Europe) randomized to receive 3 doses of placebo and 3 doses of saline solution, administered in different arms, at Days 1, 57, and 169.
89388326|NCT05480800|Experimental|iNTS-TCV full dose_2 Group|Participants 18 to 50 years of age in Stage 2 (Africa) randomized to receive 3 doses of iNTS-TCV full dose vaccine and 3 doses of saline solution, administered in different arms, at Days 1, 57, and 169.
89388327|NCT05480800|Active Comparator|iNTS-GMMA and TCV full doses_2 Group|Participants 18 to 50 years of age in Stage 2 (Africa) randomized to receive 3 doses of iNTS-GMMA full dose vaccine and 3 doses of TCV full dose vaccine, administered in different arms, at Days 1, 57, and 169.
89388328|NCT05480800|Active Comparator|Control_Stage 2 Group|Participants 18 to 50 years of age in Stage 2 (Africa) randomized to receive one dose of GSK's Meningococcal A, C, Y and W-135 conjugate vaccine administered at Day 1, one dose of GSK's Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine administered at Day 57, one dose of Sanofi Pasteur's Typhoid Vi polysaccharide vaccine administered at Day 169, and 3 doses of saline solution administered at Days 1, 57 and 169.
89388329|NCT05478538||Stage IV or metastatic Non Small Cell Lung Cancer (NSCLC)|"Subjects suspected of or diagnosed with Stage IV NSCLC and meet one of the following criteria:~Subjects who are undiagnosed, have undergone imaging and are suspected to have Stage IV lung cancer.~Subjects with a Stage I, II, or III diagnosis of NSCLC, who are being re-biopsied after imaging-confirmed progression to metastatic disease~Subjects who have a confirmed diagnosis of NSCLC, and have undergone a SOC biopsy procedure and will undergo a separate procedure for the purposes of this study.~Subjects who have a previous Stage IV/metastatic NSCLC diagnosis and have already received first line treatment."
88863723|NCT04952753|Experimental|Safety run-in: NIS793+Tislelizumab+SOC (Investigational arm 2)|In the safety run-in part for investigational arm 2, participants will be treated with a combination of SOC anti-cancer therapy (bevacizumab with either modified FOLFOX6 or FOLFIRI), NIS793 and tislelizumab to confirm the RP2D of NIS793.
89185502|NCT04319718|Active Comparator|High Eudragit MK-2048 vaginal film|"Single use of 2 x 2 vaginal film containing 30 mg of MK-2048 and 68.1 mg of ammonio methacrylate copolymer type B (Eudragit®)."
88863724|NCT04952753|Experimental|Expansion: NIS793+Tislelizumab+SOC (Investigational arm 2)|In the expansion part, participants in the investigational arm 2 will be treated with a combination of SOC anti-cancer therapy (bevacizumab with either modified FLOFOX6 or FOLFIRI) with NIS793 and tislelizumab at the RP2D for NIS793 defined in the safety run-in
88863725|NCT04941768||Avelumab + Axitinib|There will not be any study-specific interventions in this study. Participants with advanced RCC receiving 800 milligrams (mg) of Avelumab intravenously every 2 weeks in combination with 5 mg of Axitinib orally twice per day in accordance with the terms of marketing authorization for the first-line therapy as per the current clinical practice will be observed for 24 months in this study.
89388330|NCT05476770|Experimental|Part 1|"Tagraxofusp~-Days 1-5~IT Therapy (may include methotrexate, cytarabine, or triple IT)~Day 1~Patients may receive additional IT therapy with their end-of-cycle disease re-evaluation at the discretion of the treating investigator"
89388331|NCT05476770|Experimental|Part 2 - Cohort A|"Tagraxofsup~-Days 4-8~Fludarabine -Days 1-5~Cytarabine~-Days 1-5~IT Therapy (may include methotrexate, cytarabine, or triple IT) CNS1 IT Therapy~Day 1~Patients may receive additional IT therapy with their end-of-cycle disease re-evaluation at the discretion of the treating investigator~CNS2/3 IT Therapy~Days 1, 8, 15, and 22~Patients may receive additional IT therapy with their end-of-cycle disease re-evaluation at the discretion of the treating investigator"
89388332|NCT05476770|Experimental|Part 2 - Cohort B|"Tagraxofsup~-Days 8-12~Dexamethasone -Days 1-5~Vincristine~-Days 1, 8, 15, and 22~IT Therapy (may include methotrexate, cytarabine, or triple IT) CNS1 IT Therapy~Day 1~Patients may receive additional IT therapy with their end-of-cycle disease re-evaluation at the discretion of the treating investigator~CNS2/3 IT Therapy~Days 1, 8, 15, and 22~Patients may receive additional IT therapy with their end-of-cycle disease re-evaluation at the discretion of the treating investigator"
88863727|NCT04924075|Experimental|Belzutifan|Belzutifan, 120 mg, oral, once daily (QD) until progressive disease or discontinuation.
88863728|NCT04913675|Active Comparator|Main Study - Sotrovimab 500 mg IV|
88863729|NCT04913675|Experimental|Main Study - Sotrovimab 500 mg IM|
89185503|NCT04319718|Active Comparator|Low Eudragit MK-2048 vaginal film|"Single use of 2 x 2 vaginal film containing 30 mg of MK-2048 and 41.5 mg of ammonio methacrylate copolymer type B (Eudragit®)."
89185504|NCT00918086|Experimental|Vitamin D pill|
88863730|NCT04913675|Experimental|Main Study - Sotrovimab 250 mg IM|
88863731|NCT04913675|Experimental|Substudy (Cohort A) - Sotrovimab 2000 mg IV|
88863732|NCT04913675|Experimental|Substudy (Optional Cohort B1) - Sotrovimab 2000 mg IV|
88863733|NCT04913675|Experimental|Substudy (Optional Cohort B2) - Sotrovimab 2000 mg IV|
88863734|NCT04913675|Experimental|Substudy (Optional Cohort C) - Sotrovimab up to 3000 mg IV|
88863735|NCT04902027|Experimental|Mitoxantrone Hydrochloride Liposome Injection|Subjects with Rrecurrent/metastatic Head and Neck Cancers will receive 20 mg/m2 Mitoxantrone Hydrochloride Liposome every 21 days (a cycle) for a maximum of 8 cycles
88863736|NCT04901039||Decompensated heart failure|Previously diagnosed heart failure presenting with decompensation to the emergency department
88863737|NCT04900766|Experimental|Mitoxantrone Hydrochloride Liposome Injection|Subjects with unresectable or metastatic bone and soft tissue sarcoma will receive 20 mg/m2 Mitoxantrone Hydrochloride Liposome injection every 21 days (a cycle) for a maximum of 6 cycles.
88863738|NCT04898894|Experimental|Treatment|"Dose Escalation Phase:~Venetoclax plus selinexor will initially be given at dose level 1 in combination with intravenous (IV) cytarabine and fludarabine. Dosing of venetoclax and selinexor will be based on tolerability.~Intrathecal (IT) chemotherapy (IT cytarabine, IT methotrexate, and IT methotrexate/hydrocortisone/cytarabine (MHA) are all acceptable) will be given.~G-CSF SC may be given.~Part 1 has been completed and RP2D has been determined to be Dose Level 2. All participants will be treated at Dose Level 2.~Dose Expansion Phase:~Two expansion cohorts will be treated at the recommended phase 2 dose (RP2D). Cohort A will include venetoclax-naïve patients, whereas Cohort B will include patients with prior exposure to venetoclax."
88863739|NCT04895241|Experimental|Litifilimab High Dose|Participants who are receiving background nonbiologic lupus SOC therapy will receive high dose of litifilimab, subcutaneously (SC) every 4 weeks (Q4W), up to Week 48 with an additional dose at Week 2.
88863740|NCT04895241|Experimental|Litifilimab Low Dose|Participants who are receiving background nonbiologic lupus SOC therapy will receive low dose of litifilimab, SC Q4W, up to Week 48 with an additional dose at Week 2.
88863741|NCT04895241|Placebo Comparator|Placebo|Participants who are receiving background nonbiologic lupus SOC therapy will receive litifilimab-matching placebo, SC Q4W, up to Week 48 with an additional dose at Week 2.
89185505|NCT00918086|Placebo Comparator|Placebo|
89185506|NCT02567487|Active Comparator|Group Levobupivacaine high volume|TAP block with levobupivacaine 0.25% of 0.5 ml/kg under general anesthesia
88863742|NCT04881643|Experimental|Blended treatment for PTSD|A trauma-focused CBT where internet-based treatment is blended with face-to-face sessions with a therapist.
88863743|NCT04876053|No Intervention|Standard Care|
88863744|NCT04876053|Experimental|Healthy Food Delivery Intervention|9000 calorie / week food box
88863745|NCT04858100|Experimental|Surgery|Each patient will receive the surgical excision of the lesion and subsequent follow-up
88863746|NCT04858100|Active Comparator|Wait and see|Each patient will receive clinical follow-up of the lesion with periodical incisional tissue biopsy.
88863750|NCT04855032|Experimental|Reactive Perturbations|
88863751|NCT04855032|Experimental|Proactive Perturbations|
88863752|NCT04847557|Experimental|Tirzepatide|Tirzepatide administered subcutaneously (SC)
88863753|NCT04847557|Placebo Comparator|Placebo|Placebo administered SC
89185507|NCT02567487|Active Comparator|Group Levobupivacaine low volume|TAP block with levobupivacaine 0.25% of 0.25 ml/kg under general anesthesia
89388333|NCT05476770|Experimental|Part 2 - Cohort C|"Tagraxofsup -Days 1-5~Azacitidine~-Days 1-5~IT Therapy (may include methotrexate, cytarabine, or triple IT) CNS1 IT Therapy~Day 1~Patients may receive additional IT therapy with their end-of-cycle disease re-evaluation at the discretion of the treating investigator~CNS2/3 IT Therapy~Days 1, 8, 15, and 22~Patients may receive additional IT therapy with their end-of-cycle disease re-evaluation at the discretion of the treating investigator"
89388334|NCT05471245|Experimental|angiographic evaluation|QCA at 9 months
89388335|NCT05464160|Experimental|G-FMV (Group Focal Muscular Vibration)|"Patients allocated in the G-FMV, in addition to conventional rehabilitation treatment, will be treated for 3 weeks with FMV, applied to the upper and/or lower limb, depending on the clinical status.~The G-FMV will perform the treatment at a frequency of 7 times per week for 3 weeks (21 total applications), using the EVM EVO medical device (Endomedica, Italy), applying an intensity of 100 Hz for a total of 23 minutes. Specifically, four different trains of stimulation lasting 5 minutes each will be performed, interspersed with 1 minute of rest (20 minutes of treatment + 3 minutes of rest). FMV will be applied on agonist (major spasticity) muscles of the lower limb and/or upper limb, either single-district or multiple-district, according to clinical evidence of intervention. Stimulation will be conducted in a stand-alone session as an adjunctive modality to the rehabilitation project of physiotherapy and occupational therapy."
89388336|NCT05464160|Active Comparator|G-CON (Group Conventional)|"Patients allocated in the G-CONwill be treated for 3 weeks by specific conventional rehabilitation based on the clinical status.~The G-CON will carry out the normal physiotherapy and occupational therapy rehabilitation treatment, as per the rehabilitation project, for an equal total treatment time to the G-FMV. Conventional treatment will focus on joint mobilization, muscle stretching, and neuromuscular facilitation activities, using the main rehabilitation methods (e.g., neurocognitive theory, Bobath Concept, Progressive Neuromuscular Facilitation, etc...)"
89388337|NCT05461131|Experimental|BPZE1|Participants will receive an intranasal dose of BPZE1 via the mucosal atomization device followed by a dose of the challenge strain (B. Pertussis strain 1917) approximately 60-120 days later. Participants will receive azythromycin for 3 days beginning 14 days after after administration of the challenge strain.
89388338|NCT05461131|Placebo Comparator|Placebo|Participants will receive an intranasal dose of placebo via the mucosal atomization device followed by a dose of the challenge strain (B. Pertussis strain 1917) approximately 60-120 days later. Participants will receive azythromycin for 3 days beginning14 days after after administration of the challenge strain.
89388339|NCT05460234||Single Cohort|data from medical records up to 3 months prior to ERC treatment start will be retrospectively collected (if available), to provide baseline data and to serve as a basis for evaluating the treatment decision. If relevant baseline data is not available within 3 months preceding treatment start, retrospective documentation can extend to up to 6 months. The observational period of ERC (both retrospective and prospective) is scheduled up to 18 months after treatment start (Protocol v2.0,06Dec2023)
89388340|NCT05449171|No Intervention|Control group|
89388341|NCT05449171|Experimental|Treatment group|
89388342|NCT05435157||Diabetic patients|Diabetic patients undergoing scheduled surgery
89388343|NCT05435157||Non-diabetic patients|Non-diabetic patients undergoing sheduled surgery
89388344|NCT05387707|Experimental|Difelikefalin 0.25 mg tablets plus TCS cream|Oral difelikefalin tablets administered twice daily. TCS cream applied by study subjects to skin lesions once a day until control is achieved, then as needed.
89388345|NCT05387707|Experimental|Difelikefalin 0.5 mg tablets plus TCS cream|Oral difelikefalin tablets administered twice daily. TCS cream applied by study subjects to skin lesions once a day until control is achieved, then as needed.
89388346|NCT05387707|Active Comparator|Placebo tablets plus TCS cream|Oral placebo tablets administered twice daily. TCS cream applied by study subjects to skin lesions once a day until control is achieved, then as needed
89388347|NCT05387707|Placebo Comparator|Placebo tablets plus Vehicle cream (Part A only)|Oral placebo tablets administered twice daily. Vehicle cream applied by study subjects to skin lesions once a day until control is achieved, then as needed
89388348|NCT05384951|Experimental|HMB + Vitamin D3 Supplement|Supplement delivery will be a tablet containing both HMB & Vitamin D3. HMB will be administered in its calcium salt form. One tablet will contain 750 mg HMB + 250 IU of Vitamin D3. The target dosage is 3 g HMB + 1000 IU of Vitamin D3 per day.
89388349|NCT05382091|Experimental|OLANI (naltrexone implant)|2 OLANI implants containing 60% naltrexone (3.6 g total NXT) administered at Day 0 with repeat dosing at Week 13 to 24
89388350|NCT05381948|Experimental|EYP-1901 2060 ug|EYP-1901 2060 ug, single dose
89388351|NCT05381948|Experimental|EYP-1901 3090 ug|EYP-1901 3090 ug, single dose
89388352|NCT05381948|Active Comparator|Aflibercept|Aflibercept 2 mg [0.05mL] every 8 weeks
89388353|NCT05373823|Experimental|Enhance MSS using multi-level stakeholder collaboration (Mo.1-15)|Enhancements of MSS to increase intervention effects - theory - based strategies (PHM), (BCT)
89388354|NCT05373823|Experimental|Involves the longitudinal RCT comparing behavioral outcomes and effectiveness (Mo.16 -60)|RCT of enhanced MSS testing effectiveness (thorough SSE, sun protection behavior Involves the longitudinal RCT comparing behavioral outcomes and effectiveness of enhanced MSS versus an educational webpage on SSE as well as new recurrences/melanomas
88863754|NCT04846322||ED delirium & dementia screening & outpatient referral|Routine ED screening for delirium and memory problems with referral for outpatient assessment of cognitive impairment.
89388355|NCT05373823|Active Comparator|Aim 3: Assess implementation outcomes, identify factors relevant for future scale-up (Mo.17-60)|Assessment of implementation outcomes and key contextual factors from the perspective of multi - level stakeholders
89388356|NCT05362409|Experimental|5-ALA with CV01|5-aminolevulinic acid [5-ALA] with CV01-delivered ultrasound
89388357|NCT05358886|Active Comparator|Study Drug|25mg BID BPN14770
89388358|NCT05358886|Placebo Comparator|Placebo|Placebo
89388359|NCT05352672|Experimental|A: fianlimab+cemiplimab dose 1|Phase 2 and Phase 3
88863755|NCT04824859|Experimental|Experimental|The eGAP consists of validated questionnaires that are used to assess health status of older adults with cancer. Based on patient responses, tailored recommendations will be provided.
89388360|NCT05352672|Experimental|A1: fianlimab+cemiplimab dose 2|Phase 2 and Phase 3 (except for PA1 patients as described in the protocol)
89388361|NCT05352672|Experimental|B: pembrolizumab+placebo|Phase 2 and Phase 3
89388362|NCT05352672|Experimental|C: cemiplimab+placebo|Phase 2 (as described in the protocol)
89388363|NCT05339438|Experimental|Epileptic patients|Epileptic patients with anterior temporal lobe epilepsy
89388364|NCT05339438|Experimental|Healthy volunteers|Healthy volunteers
89388365|NCT05337306|Experimental|GogyUp|"Participants in the GogyUp arm will have the GogyUp Reader app preloaded on a cellular-enabled tablet with the same patient education documents as the Control arm. Patients will be able to use on-demand / in-the-moment assistive-reading technologies to understand any word or phrase:~Speech-to-Text~Word-by-Word Translation~Alternative Formatting~Simplified and Contextualized Definitions~No-Fail Comprehension Questions~Personalized Training in Phonemic Awareness"
89388366|NCT05337306|No Intervention|Control|Participants in the Standard Care arm will receive the standard after-visit patient education documents the clinics current provide for type 2 diabetes education and self-management.
89388367|NCT05320822|Active Comparator|Progressive Return to Activity (Group 1)|The current practice, Progressive Return to Activity (PRA) based on Traumatic Brain Injury Center of Excellence (TBICoE) protocols, provides a framework for activity progression based on participant symptom reports and recovery. PRA TBICoE includes a graded approach for clinicians to return participants to pre-injury activities based on the severity of the participant symptoms with and without physical exertion.
88863756|NCT04817969|Other|Persona Ti-Nidium|Primary total knee arthroplasty subjects that receive the Zimmer Biomet Persona Ti-Nidium Total Knee System
88863757|NCT04806789||Children with suspected acute appendicitis|"Cohort: Children with suspected acute appendicitis. Clinical examination (including history of nausea, vomiting, temperature, information of rebound tenderness, right iliac fossa pain, duration of symptoms, gender and weight) and blood samples will be obtained at the emergency department (blood gas, C-reactive protein, neutrophiles and white blood cell count). Radiology (ultrasound and/or computed tomography) will be performed thereafter.~Outcome measures~Primary outcome measure: Plasma sodium. To investigate if plasma sodium is an independent predictor of perforation in children with acute appendicitis. In advance, five variables (Plasma sodium, C-reactive protein, symptom duration, age and temperature) will be included in the final multivariable analysis"
89388368|NCT05320822|Experimental|Active Rehab (Group 2)|"Active Rehab includes an adaptive paradigm based on personal characteristics, symptom presentation, and duty requirements that integrate with current progressive return to activity (PRA TBICoE) guidelines. Activity progressions consider the initial presentation and changes in participant status during treatment, with the goal of safely accelerating recovery. Severity and presence of symptoms will guide progression as reported by the participant.~The intervention consists of 5 phases designed to facilitate an active approach to concussion rehabilitation. Phases are symptom stabilization, impairment reduction, activity integration, recovery acceleration, and military duty specific application. Participants complete phase specific activities under direction of a clinical professional, and progress upon meeting specific requirements."
89388369|NCT05320432|Experimental|Transcutaneous electrical nerve stimulation (TENS)|Prior to the procedure, the patient will have two sets of two self-adhesive electrodes placed parallel to the spinal cord at the T10-L1 and S2-S4 levels for TENS administration. For participants randomized to the experimental group, the non-blinded study coordinator will turn on the TENS unit 5 minutes prior to the procedure and monitor stimulating frequency level (80-100 Hz and pulse duration of 400 microseconds; intensity or frequency will be monitored to be administered to a non-painful level).
89388370|NCT05320432|Sham Comparator|Sham|For the participants randomized to sham, the same placement of electrodes will occur, but the unit will not be delivering electrical stimulation.
89388371|NCT05320198|Experimental|Phase 1b: Dose Escalation|In the Phase 1b (dose-escalation) portion of the study, DISC-0974 will be administered subcutaneously every 4 weeks.
89185508|NCT02598050||older surgical patients|Patients 65 years of age and older having lower extremity joint replacement surgery.
89185509|NCT04062435|Experimental|Interventional Group|"Peschke®TE 0.25 % application in the INFERIOR FORNIX~Peschke®TE 0.25 % (Peschke Trade, Hünenberg, Switzerland) eye drops, 1 drop every 5 minutes over 60 minutes by the Principal Investigator."
89185510|NCT04062435|Active Comparator|Control Group|"Peschke®TE 0.25 % application on the CORNEA~Peschke®TE 0.25 % (Peschke Trade, Hünenberg, Switzerland) eye drops, 1 drop every 5 minutes over 60 minutes by the Principal Investigator."
89388372|NCT05320198|Experimental|Phase 2a: Expansion|In the Phase 2a (expansion) portion of the study, DISC-0974 will be administered subcutaneously every 4 weeks.
89185511|NCT02597894|Other|Prostate biopsy|Patients undergo two biopsies, the first at baseline before start of ADT and the second two months later during brachytherapy.
89388373|NCT05316935|Experimental|Non-obese EEC group (G)|20 non-obese EEC patients will be randomized to GnRHa + Letrozole group.Then every 12 weeks, an hysteroscope will be used to evaluate the endometrial condition, and the pathological findings will be recorded.
89185512|NCT04372602|Experimental|Duvelisib|-Duvelisib 25 mg twice daily for up to 10 days.
89185513|NCT04372602|Sham Comparator|Placebo|-Placebo 25 mg twice daily for up to 10 days.
89185514|NCT04078542||Chronic cough|Subject complaining cough from at least 8 weeks
89185515|NCT04366908|Active Comparator|Control - best available therapy|The subject will be treated with the best available therapy, which will include any combination of drugs included in the current protocol of the Ministry of Health and/or complementary notes issued by the Spanish Agency of Medicines and Health Products (AEMPS).
89185516|NCT04366908|Experimental|Treatment|"The subject will be treated with the best available therapy, which will include any combination of drugs included in the current protocol of the Ministry of Health and/or complementary notes issued by the Spanish Agency of Medicines and Health Products (AEMPS) plus Calcifediol caps. 266 µg. According to the pharmacokinetics of Calcifediol evaluated in an inflammatory model, the posology will be~Start: 2 capsules~Days 3, 7, 14, 21, 28: 1 capsule"
89185517|NCT00733304|Experimental|5 mg/ml TID|eligible participants received 5 mg/ml Pazopanib eye drops three times daily (TID)
89185518|NCT00733304|Experimental|2 mg/ml TID|eligible participants received 2 mg/ml Pazopanib eye drops three times daily
89185519|NCT00733304|Experimental|5 mg/ml QD|eligible participants received 5 mg/ml Pazopanib eye drops once daily (QD)
89185520|NCT00711243|Experimental|Cohort 1a|Docetaxel 25 mg/m2 + oxaliplatin 85 mg/m2 + 5-Fluorouracil 2.4 gm/m2
89185521|NCT00711243|Experimental|Cohort 2a|Docetaxel 30 mg/m2 + oxaliplatin 85 mg/m2 + 5-Fluorouracil 2.4 gm/m2
89185522|NCT00711243|Experimental|Cohort 3a|Docetaxel 40 mg/m2 + oxaliplatin 85 mg/m2 + 5-Fluorouracil 2.4 gm/m2
89185523|NCT00711243|Experimental|Cohort 4a|Docetaxel 50 mg/m2 + oxaliplatin 85 mg/m2 + 5-Fluorouracil 2.4 gm/m2
89185524|NCT00711243|Experimental|Cohort 5a|Docetaxel 60 mg/m2 + oxaliplatin 85 mg/m2 + 5-Fluorouracil 2.4 gm/m2
89185525|NCT04366518|Experimental|Aim 2: Those with psychosis/hallucinations|Participants who have a psychosis spectrum diagnosis and frequent auditory hallucinations will be given Rivastigmine capsule versus placebo capsule.
89185526|NCT04366518|Placebo Comparator|Aim 1: Healthy Controls|Healthy controls will be given scopolamine patches versus placebo patch.
89388374|NCT05316935|Experimental|Non-obese EEC group (D)|20 non-obese EEC patients will be randomized to Diane-35 + metformin group.Then every 12 weeks, an hysteroscope will be used to evaluate the endometrial condition, and the pathological findings will be recorded.
88819023|NCT05300997||Transient Ischemic Attack (TIA) [N=75]|TIA subjects presenting within 24 hours from symptom onset will have serial whole blood and saliva drawn a) in the emergency department (if available) or hospital within 24 hours of the onset of symptoms; b) 18 hours +/- 6 hours from symptom onset (if available); and c) 30 hours+/- 6 hours from symptom onset (if available).
88819024|NCT05300997||Stroke Mimics [N=30]|Stroke Mimics subjects presenting within 24 hours from symptom onset will have serial whole blood and saliva drawn a) in the emergency department (if available) or hospital within 24 hours of the onset of symptoms; b) 18 hours +/- 6 hours from symptom onset (if available); and c) 30 hours+/- 6 hours from symptom onset (if available).
89185527|NCT02803086||1|To date, around 700 patients, who were treated with Radiotherapy for Prostate Cancer, have been enrolled. 34% of them underwent radiotherapy with radical intent, whereas the others were post-prostatectomy patients (29% adjuvant, 37% salvage). Various techniques of irradiation were used (1% 3DCRT, 6% SF-IMRT, 52% VMAT, 41% Tomotherapy) in conventional (42%, 1.7-2.0 Gy/fr.) and hypofractionated (58%, 2.1-2.7 Gy/fr.) settings. EQD2(alpha/beta=3) to prescribed PTV ranged between 64 and 93 Gy. Limph nodes were treated in the 98% of cases.
89185528|NCT02568501|Experimental|Daily feedback|Participants receive daily feedback from wireless glucometers that transmit data on glucose monitoring adherence.
89185529|NCT02568501|Experimental|Daily Feedback, incentives|Participants receive daily feedback from wireless glucometers that transmit data on glucose monitoring adherence. Participants are eligible for a financial incentive if adherent.
89185530|NCT00733226|Active Comparator|1 Broncho-Vaxom|The children received one capsule per oral, OM-85 BV (3.5 mg) per day for the first 10 consecutive days of each month for 3 consecutive months.
89185531|NCT00733226|Placebo Comparator|2 (Placebo OM-85 BV)|The children received one capsule per oral, placebo per day for the first 10 consecutive days of each month for 3 consecutive months.
88819025|NCT05300997||Control Subjects [N=100]|Control group subjects, if they agree, will have serial whole blood and saliva drawn a) in the emergency department (if available) or hospital on day 1; b) 18 hours +/- 6 hours after sample 1 (if available); and c) 30 hours+/- 6 hours after sample 1 (if available).
88819026|NCT05438355||The infertility women with PCOS|Infertile women undergoing assisted reproduction were consecutively recruited at Ji Ai G-IVF institute from March 2021 to December 2021. Women aged < 38 years without endometriosis and more than 6 oocytes were retrieved . Patients were divided in PCOS according to the Rotterdam criteria for PCOS, defined by the presence of anovulation and polycystic ovaries.
89185532|NCT04076436||Fosfomycin cohort:|Cohort of patients with complicated urinary tract infection caused by Escherichia coli treated with intravenous fosfomycin
89185533|NCT04076436||Quinolones or beta-lactams cohort|Cohort of patients with complicated urinary tract infection caused by Escherichia coli treated with intravenous quinolones or beta-lactams.
89185534|NCT04364178|Experimental|Viral Specific T-Lymphocytes|Peripheral blood mononuclear cells will be collected from the donor and loaded onto our Miltenyi Biotec CliniMACS Prodigy® or CliniMACS® Plus where they will be stimulated in vitro with viral-specific antigen(s). The cells are then immunomagnetically labeled with interferon gamma via the cytokine capture system. By this method, viral specific, gamma-secreting T cells, are captured in a closed, sterile system.
89388375|NCT05316935|Experimental|Non-obese EAH group (G)|20 non-obese EAH patients will be randomized to GnRHa + Letrozole group.Then every 12 weeks, an hysteroscope will be used to evaluate the endometrial condition, and the pathological findings will be recorded.
88819027|NCT05438355||The infertility women without PCOS|Infertility women with fallopian tubal factor infertility and with normal menstrual cycles were undergoing IVF/ICSI cycles at Shanghai Ji Ai G-IVF institute from March 2021 to December 2021.Women aged < 38 years without endometriosis and more than 6 oocytes were retrieved.
88819028|NCT04133493|Placebo Comparator|Standard of Care Group|Fibracol Dressing covered with gauze and wrapped with kerlix and wrap. Change 3Xper week
89388376|NCT05316935|Experimental|Non-obese EAH group (D)|20 non-obese EAH patients will be randomized to Diane-35 + metformin group.Then every 12 weeks, an hysteroscope will be used to evaluate the endometrial condition, and the pathological findings will be recorded.
89388377|NCT05312645|Experimental|Diclofenac Gel|Nursing staff will apply 2 grams of diclofenac 1% gel topically to the posterior cervical region of the subject four times daily for 14 days. A questionnaire consisting of a Numeric Assessment Scale (NAS) and Headache Impact Test (HIT-6) will be administered at baseline (day 1), day 7, and at the study conclusion (day 14). A complete metabolic panel will obtained on day 0 and on day 14.
89388378|NCT05312645|Placebo Comparator|Control|Nursing staff will apply a petroleum gel based compound topically to the posterior cervical region of the subject four times daily for 14 days. A questionnaire consisting of a Numeric Assessment Scale (NAS) and Headache Impact Test (HIT-6) will be administered at baseline (day 1), day 7, and at the study conclusion (day 14). A complete metabolic panel will obtained on day 0 and on day 14.
89388379|NCT05306041|Experimental|Inavolisib|Inavolisib for 6 cycles (18 weeks) Neoadjuvant endocrine therapy in combination with dual anti-HER2 blockade consisting of ready-to-use fixed-dose combination of pertuzumab and trastuzumab as subcutaneous (PH-FDC SC) formulation q3w for 6 cycles (18 weeks)
89185535|NCT02567721||Study Cohort|Subjects who will receive influenza vaccination between 1 September 2015 and 30 November 2015 in the 9 GP practices from who clinical data routinely collected as part of clinical consultations in primary care will be extracted.
89185536|NCT02581800|No Intervention|Control group|The control group includes hospital consultations (usual care) on the hospital 2-3 times a week (1-2 hours) and the possibility to call the neonatal ward 24 hours a day all week until the infant gets full nutrition from the breast or bottle and gains weight. The parents register nutrition on a paper between the visits to the hospital.
89185537|NCT02581800|Experimental|App group/intervention group|The intervention group will receive the Smartphone application at inclusion time and learn to use it in the hos-pital. When the families go home they will use the application and receive planned video consultations 2-3 times a week and the possibility to call the neonatal ward 24 hours a day all week whenever needed, until the infant gets full nutrition from the breast or bottle and gains weight. Parents will borrow a baby weight to weigh the baby at home.
89185538|NCT04091724||Delirium is determined by PAED score|
89185539|NCT04091724||No delirium is determined by PAED score|
88863758|NCT04806451|Experimental|Crinecerfont|Crinecerfont solution or capsule, administered orally, twice daily for 28 weeks during the placebo-controlled treatment period, followed by active treatment with crinecerfont for at least 24 weeks.
88863759|NCT04806451|Placebo Comparator|Placebo|Placebo solution or capsule, administered orally, twice daily for 28 weeks, followed by active treatment with crinecerfont for at least 24 weeks.
88863760|NCT04798781|Experimental|telatinib + Keytruda|
89185540|NCT00741117|Active Comparator|Low Bilirubin Group|Low Bilirubin Group: subjects with a bilirubin level less than or equal to 10 mg/dl
89185541|NCT00741117|Active Comparator|Medium Bilirubin Group|Medium Bilirubin Group: subjects with a bilirubin level from 11mg/dl to 30 mg/dl
89185542|NCT00741117|Active Comparator|High Bilirubin Group|High Bilirubin Group: subjects with a bilirubin level greater than or equal to 30 mg/dl
89388380|NCT05306041|Other|without Inavolisib|Neoadjuvant endocrine therapy in combination with dual anti-HER2 blockade consisting of ready-to-use fixed-dose combination of pertuzumab and trastuzumab as subcutaneous (PH-FDC SC) formulation q3w for 6 cycles (18 weeks)
89388381|NCT05300711|Experimental|Opportunistic salpingectomy|The participating surgeons will attempt to perform bilateral salpingectomy in addition to the colorectal surgery.
89388382|NCT05300711|Active Comparator|Colorectal surgery only|Participants will receive the standard of care, that is colorectal surgery.
89185543|NCT02567565||cataract patients|cataract patients undergoing phacoemulsification
89185544|NCT00732992|Experimental|CDD|
88863761|NCT04796350|Experimental|Treated group|Subject receives standard of care to repair the index hip fracture and AGN1 LOEP treatment on the target unfractured contralateral hip
88863762|NCT04796350|No Intervention|Control group|Subject receives standard of care to repair the index hip fracture and no AGN1 LOEP treatment on the target unfractured contralateral hip
89185545|NCT00732992|Experimental|2/1|
89185546|NCT02582346|Experimental|MRI acquisition - no contrast agent|Volunteers will have an MRI with a 3T clinical system. Installation will be performed according to standard protocols. Different neurography and tractography sequences will be acquired in order to get different contrasts.
89185547|NCT00741195|Experimental|1|Docetaxel/Bevacizumab
89185548|NCT05338632|Experimental|Intravenous fentanyl year 1|continuous intravenous infusion of fentanyl to induce 40-60% respiratory depression.
89185549|NCT05338632|Experimental|Intravenous sufentanil year 1|continuous intravenous infusion of sufentanil to induce 40-60% respiratory depression.
89185550|NCT05338632|Experimental|Intravenous sufentanil year 2|continuous intravenous infusion of sufentanil to induce 40-60% respiratory depression.
88863763|NCT04795440|No Intervention|Eya-ICSI|Oocytes inseminated by ICSI technique with spermatozoa from the ejaculate (control group).
88863764|NCT04795440|Experimental|Test-ICSI|Oocytes inseminated by ICSI technique with spermatozoa from the testicle (study group).
88863765|NCT04777357|Placebo Comparator|Placebo|Participants will receive Placebo over a 6 week treatment period.
88863766|NCT04777357|Experimental|Cariprazine|Participants will receive flexible dose Cariprazine over a 6 week treatment period.
88863767|NCT04777201|Experimental|Main Study: Faricimab PTI|
88863768|NCT04777201|Experimental|Substudy: Faricimab PTI|
88863769|NCT04752813|Experimental|BPM31510, Vitamin K1, RT and TMZ|"Subjects will receive a BPM31510 96hr infusion once weekly for 8 wk. Prophylactic Vitamin K1 at a recommended dose of 10 mg will be given intramuscular (IM) to all subjects prior to the beginning of each week of therapy.~After 2 wk of treatment with BPM31510, subjects will start concurrent standard RT and TMZ 75 mg/m2 once daily (qd) × 42 days. Subjects will receive the standard TMZ treatment for additional 6 cycles post BPM31510 treatment."
88863770|NCT04747431|Experimental|Cohort 1|"Drug: PBFT02 Dose 1: 3.3 x 10^10 GC/g* Single dose of PBFT02, via intra cisterna magna~*GC/g: gene copy per gram of estimated brain weight"
88863771|NCT04747431|Experimental|Cohort 2|"Drug: PBFT02 Dose 2: 1.1 x 10^11 GC/g* Single dose of PBFT02, via intra cisterna magna~*GC/g: gene copy per gram of estimated brain weight"
88863772|NCT04747431|Experimental|Optional Cohort 3|"Drug: PBFT02 Dose 3: 2.2 x 10^11 GC/g* Single dose of PBFT02, via intra cisterna magna~*GC/g: gene copy per gram of estimated brain weight"
88863773|NCT04718402|Experimental|Mitoxantrone Hydrochloride Liposome Injection|Subjects with advanced gastric carcinoma will receive 20mg/m2Mitoxantrone Hydrochloride Liposome every 21 days (a cycle) for a maximum of 8 cycles.
88863774|NCT04718376|Experimental|Mitoxantrone Hydrochloride Liposome Injection|Subjects with Platinum-Resistant or Platinum-Refractory Relapsed Ovarian Cancer will receive 20 mg/m2 Mitoxantrone Hydrochloride Liposome every 21 days (a cycle) for a maximum of 8 cycles.
88863777|NCT04702893||Chronic fibrosing interstitial lung disease (ILD) patients with a progressive phenotype|
88863778|NCT04697316|Experimental|ADHD tDCS|
88863779|NCT04697316|Sham Comparator|ADHD Sham|
88863780|NCT04697316|Experimental|Healthy control tDCS|
88863781|NCT04697316|Sham Comparator|Healthy control Sham|
88863782|NCT04671667|Active Comparator|Arm B (cisplatin, carboplatin, IMRT, PBRT)|Patients receive cisplatin or carboplatin IV on day 1. Treatment repeats every 7 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo IMRT or PBRT QD for a total of 30 fractions in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI throughout the trial.
88863783|NCT04671667|Experimental|Arm C (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 6 weeks for 9 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI throughout the trial.
89388383|NCT05289193|Experimental|Participants with Stage III Melanoma|All participants will have cytologically or histologically confirmed stage IIIB, IIIC, IIID melanoma that can be surgically removed.
88863784|NCT04663308|Experimental|Volixibat 20mg|Participants randomized to this arm will receive volixibat 20mg twice daily.
88863785|NCT04663308|Experimental|Volixibat 80mg|Participants randomized to this arm will receive volixibat 80mg twice daily.
88863786|NCT04663308|Placebo Comparator|Placebo|Participants in this arm will receive capsules matched to the study drug minus the active volixibat substance, twice daily.
88863787|NCT04659811|Experimental|Treatment for recurrent meningioma (pembrolizumab, stereotactic radiosurgery)|Participants with recurrent grade II or III meningioma will receive stereotactic radiosurgery. in conjunction with pembrolizumab 200mg IV infusion on day 1 (to -1) of radiation and then every 3 weeks. Participants may be eligible for up to 17 additional cycles of pembrolizumab depending on disease status after completion of first course.
88863788|NCT04653064|Experimental|Placebo Cream first|"Each participant will undergo thermal pain tasks after being administered a treatment cream to one of eight body sites."
88863789|NCT04653064|Experimental|Control Cream first|"Each participant will undergo thermal pain tasks after being administered a control cream to one of eight body sites."
88863790|NCT04640974|Experimental|Cingal|Single injection of Cingal into the ankle joint of subjects diagnosed with osteoarthritis of the ankle.
88863791|NCT04640961|Experimental|Cingal|Single injection of Cingal into the shoulder joint of subjects diagnosed with osteoarthritis of the shoulder.
88863792|NCT04640298|Experimental|Cingal|Single injection of Cingal into the hip joint of subjects diagnosed with osteoarthritis of the hip.
88863793|NCT04637191|Experimental|MentalPlus®|This group performed the task in the digital game for 25 minutes and later will be evaluated with standardized and validated neuropsychological tests for the studied population.
88863794|NCT04634357|Experimental|ET140203 T Cells|ET140203 Autologous T Cells
88863795|NCT04633811|Experimental|Controlled Diet and Weight Loss Program|Subjects will consume a low oxalate diet with blood and urine collections to establish baseline levels before undergoing a weight loss program with Optifast VLCD products. After completing the weight loss program, subjects will once again consume a low oxalate diet with blood and urine collections to observe any changes that may have occurred due to the weight loss.
88863796|NCT04632992|Experimental|Arm A: Entrectinib|Participants in this treatment arm must have a positive tumor biomarker result for ROS1 gene fusion.
88863797|NCT04632992|Experimental|Arm B: Inavolisib|Participants in this treatment arm must have a positive tumor biomarker result for PI3KCA activating mutation.
88863798|NCT04632992|Experimental|Arm C: Alectinib|Participants in this treatment arm must have a positive tumor biomarker result for ALK rearrangement tumors.
88863799|NCT04632992|Experimental|Arm D: Ipatasertib|Participants in this treatment arm must have a positive tumor biomarker result for either AKT1/2/3 activating mutation or PTEN loss/loss of function.
88863800|NCT04632992|Experimental|Arm E: Atezolizumab + Investigator's Choice of Chemotherapy|Participants in this treatment arm must have a positive tumor biomarker result for either tumor mutational burden (TMB) high or microsatellite instability (MSI) high/deficient mismatch repair (dMMR).
88863801|NCT04632992|Experimental|Arm F: Trastuzumab Emtansine + Atezolizumab|Participants in this treatment arm must have a positive tumor biomarker result for ERBB2 mutations or amplification without known TMB high or MSI high/dMMR.
88863802|NCT04632992|Experimental|Arm G: PH FDC SC|Participants in this treatment arm must have a positive tumor biomarker result for ERBB2 mutation or amplification without known TMB high or MSI high/dMMR.
88863803|NCT04632992|Experimental|Arm H: PH FDC SC + Investigator's Choice of Chemotherapy|Participants in this treatment arm must have a positive tumor biomarker result for ERBB2 mutation or amplification without known TMB high or MSI high/dMMR.
88863804|NCT04632992|Experimental|Arm I: Trastuzumab Emtansine + Tucatinib|Participants in this treatment arm must have a positive tumor biomarker result for ERBB2 mutation or amplification without known TMB high or MSI high/dMMR.
88863805|NCT04632992|Experimental|Arm J: Trastuzumab Emtansine + Atezolizumab|Participants in this treatment arm must have positive tumor biomarker results for ERBB2 mutation or amplification and TMB high or MSI high/dMMR.
88863806|NCT04632992|Experimental|Arm K: Ipatasertib + Atezolizumab|Participants in this treatment arm must have a positive tumor biomarker result for PI3KCA activating mutation.
88863807|NCT04632992|Experimental|Arm L: Ipatasertib + Atezolizumab|Participants in this treatment arm must have a positive tumor biomarker result for either AKT1/2/3 activating mutation or PTEN loss/loss of function.
88863808|NCT04632992|Experimental|Arm M: Ipatasertib + Paclitaxel|Participants in this treatment arm must have a positive tumor biomarker results for PI3KCA activating mutations and either AKT1/2/3 activating mutation or PTEN loss/loss of function.
88863809|NCT04632992|Experimental|Arm N: Atezolizumab + Tiragolumab|Participants in this treatment arm must have a positive tumor biomarker result for either TMB high or MSI high/dMMR.
88863810|NCT04632992|Experimental|Arm O: Pralsetinib|Participants in this treatment arm must have a positive tumor biomarker result for RET fusion.
88863811|NCT04632719|Experimental|Covid-19 Study Group|The Study Group will be the group that was remiss for COVID-19 and has some of the mentioned comorbidities as asthma, cardiovascular disease, cancer even if controlled by drugs or treatments.
88863812|NCT04632719|Active Comparator|Covid-19 Control Group|The Control Group will be the group with remissive patients without the aforementioned comorbidities. We will assess whether comorbidities can worsen cognitive functions' impairment after the remission of the symptoms of COVID-19.
88863813|NCT04595617|Experimental|Patients with diagnosis of Glanzmann Thrombastenia (GT)|Antibodies screening will be systematically realized every six months (+/- 2 weeks) and after each last blood transfusion at 7-10 days and one month (+/- 2 weeks), during a period of 18 months
88863814|NCT04593394||Severe asthma|Gina-guidlines treatment-step 5
88863815|NCT04593394||Mild-moderate asthma|Gina-guidlines treatment-step 1-4
88863816|NCT04593394||Subjects without asthma|Matches control-group without asthma
88863817|NCT04589624|Active Comparator|Arm I ( Health Volunteer MRI)|Healthy volunteers undergo MRI over 30 minutes.
88863818|NCT04589624|Experimental|Arm II (Thyroid Cancer Patient and other malignancies of the head and neck hpMRI)|Patients with thyroid cancer and other malignancies of the head and neck undergo hpMRI over 30 minutes at baseline, and at 1 week after the initiation of treatment. During the scan, patients also receive hyperpolarized 13-C-pyruvate IV over 30 seconds and may receive a standard MRI contrast agent at the discretion of the treating physician.
88863819|NCT04587518|Experimental|Immediate Treatment|Participants in this group will receive the intervention immediately.
88863820|NCT04587518|Experimental|Waitlist/Delayed Treatment|Participants in this group will receive the intervention after an 18-week wait.
88863821|NCT04585958|Experimental|Treatment (trastuzumab deruxtecan, olaparib)|Patients receive trastuzumab deruxtecan IV over 30-90 minutes on day 1 and olaparib PO BID on days 1-21 or days 8-14 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients taking olaparib BID on days 1-21 undergo collection of blood samples at the following times: baseline, days 1, 2, 8, and 15 of cycle 1, day 1 of cycle 2, days 1, 8, and 15 of cycle 3, day 1 of cycle 4, day 1 of every fourth cycle after cycle 4 and then at treatment end. Patients taking olaparib BID on days 8-14 undergo collection of blood samples at the following times: baseline, days 1, 2, 8, 9, and 15 of cycle 1, days 1 and 8 of cycle 2, days 1, 8, and 15 of cycle 3, day 1 of cycle 4, day 1 of every fourth cycle after that, and at treatment end. Patients undergo biopsy at baseline, and then on day 3 or day 10 of cycle 1. Patients also undergo echocardiography and CT throughout the trial.
88863822|NCT04582916|Other|One Arm|All subject receive the same tests
88863823|NCT04573062||Post COVID patients|Individuals whom have previously had COVID -19 infection.
88863824|NCT04570774|Experimental|Facilitatory cerebral and cerebellar rTMS group|Patients underwent 10 consecutive daily sessions of high-frequency repetitive transcranial magnetic stimulation (rTMS) over the affected primary motor cortex of the hand and high-frequency rTMS over the ipsilateral cerebellar hemisphere.
88863825|NCT04570774|Active Comparator|Facilitatory cerebral rTMS group|Patients underwent 10 consecutive daily sessions of high-frequency repetitive transcranial magnetic stimulation (rTMS) over the affected primary motor cortex of the hand and sham high-frequency rTMS over the ipsilateral cerebellar hemisphere.
88863826|NCT04570774|Experimental|Inhibitory cerebral and cerebellar rTMS group|Patients underwent 10 consecutive daily sessions of continous theta bust stimulation (cTBS) over the unaffected primary motor cortex of the hand and high-frequency rTMS over the ipsilateral cerebellar hemisphere.
88863827|NCT04570774|Active Comparator|Inhibitory cerebral rTMS group|Patients underwent 10 consecutive daily sessions of continous theta bust stimulation (cTBS) over the unaffected primary motor cortex of the hand and sham rTMS over the ipsilateral cerebellar hemisphere.
89388384|NCT05285891|Experimental|Ocrelizumab+Placebo Arm|"All eligible participants will be initiated on Ocrelizumab (OCR) using the standard approved administration schedule of two 300 mg infusions separated by 14 days (i.e., Days 0 and 14) for a total of 600 mg, followed by 600 mg infusions at Month 6 and Month 12.~In this arm participants will then receive OCR infusions at Months 18 and 24 and then after Month 24 switch to placebo infusions every 6 months through Month 48."
89388385|NCT05285891|Experimental|Ocrelizumab Arm|"All eligible participants will be initiated on OCR using the standard approved administration schedule of two 300 mg infusions separated by 14 days (i.e., Days 0 and 14) for a total of 600 mg, followed by 600 mg infusions at Month 6 and Month 12.~In this arm participants will continue to receive OCR infusions every 6 months through Month 48."
89388386|NCT05285891|Placebo Comparator|Placebo Arm|"All eligible participants will be initiated on OCR using the standard approved administration schedule of two 300 mg infusions separated by 14 days (i.e., Days 0 and 14) for a total of 600 mg, followed by 600 mg infusions at Month 6 and Month 12.~In this arm, starting at Month 18, participants will receive placebo infusions every 6 months through Month 48."
89388387|NCT05280132|Experimental|Personalized strategy|"Personalized antibiotic treatment based on mPCR results, PCT (values and kinetics) and appearance of sputum.~A broad panel respiratory mPCR FA-PPP is performed on a respiratory tract sample collected 12 hours after inclusion.~After inclusion (D0), an algorithm of early antibiotic adaptation and discontinuation will be applied immediately and repeated every day until day 7.~This algorithm of early antibiotic adaptation and discontinuation is based on a multimodal approach, using:~The appearance of sputum (clinical approach);~PCT values and kinetics (biological approach);~Results of mPCR FA-PPP (microbiological approach)."
89388388|NCT05280132|Other|Usual strategy|"Usual antibiotic treatment~Left at the discretion of the physician as in usual practice"
89388389|NCT05279287||Minimally invasive surgical procedure|Patients undergoing any minimally invasive procedure can be included in the study. Initial focus will be on robotic prostatectomy and robotic TME (rectal cancer removal).
89388390|NCT05276297|Experimental|ASO24-TI Group|Eligible participants receive GSK3228836 (Treatment 1) study intervention for 24 weeks of Treatment 1 period, followed by GSK3528869A (Treatment 2) study intervention administered at Days 1, 57, 113 and 169 of Treatment 2 period. The interval between Treatment 1 and Treatment 2 is preferably 1 week, with the possibility to extend up to 12 weeks.
89388391|NCT05276297|Active Comparator|ASO24 Group|Eligible participants receive GSK3228836 (Treatment 1) study intervention for 24 weeks of Treatment 1 period, followed by non-active control (Treatment 2) study intervention administered at Days 1, 57, 113 and 169 of Treatment 2 period. The interval between Treatment 1 and Treatment 2 is preferably 1 week, with the possibility to extend up to 12 weeks.
89388392|NCT05276297|Experimental|ASO12-TI Group|Eligible participants receive GSK3228836 (Treatment 1) study intervention for 12 weeks of Treatment 1 period, followed by GSK3528869A (Treatment 2) study intervention administered at Days 1, 57, 113 and 169 of Treatment 2 period. The interval between Treatment 1 and Treatment 2 is preferably 1 week, with the possibility to extend up to 12 weeks.
89388393|NCT05276297|Active Comparator|ASO12 Group|Eligible participants receive GSK3228836 (Treatment 1) study intervention for 12 weeks of Treatment 1 period, followed by non-active control (Treatment 2) study intervention administered at Days 1, 57, 113 and 169 of Treatment 2 period. The interval between Treatment 1 and Treatment 2 is preferably 1 week, with the possibility to extend up to 12 weeks.
89388394|NCT05270382|Active Comparator|Cetylpyridinium chloride/pH adjuster 1|A mouthwash contains cetylpyridinium chloride and pH adjuster 1.
89388395|NCT05270382|Placebo Comparator|Placebo 1|A mouthwash without cetylpyridinium chloride and pH adjuster 1
89388396|NCT05270382|Active Comparator|Cetylpyridinium chloride/pH adjuster 2|A mouthwash contains cetylpyridinium chloride and pH adjuster 2.
88863828|NCT04569539|Experimental|Ultrasound|Ultrasound measurements of the cricothyroid membrane
88863829|NCT04565717|Experimental|Part A: ALN-HSD|Participants will be administered a single dose of ALN-HSD.
88863830|NCT04565717|Placebo Comparator|Part A: Placebo|Participants will be administered a single dose of ALN-HSD-matching placebo.
89388397|NCT05270382|Placebo Comparator|Placebo 2|A mouthwash without cetylpyridinium chloride and pH adjuster 2
89388398|NCT05269394|Experimental|E2814 plus lecanemab|"Symptomatic Population (Cohort 1)~At Week 0, participants will receive open-label lecanemab administered intravenously for the full treatment period.~At Week 24, participants randomized to E2814 will receive intravenously in a blinded fashion for the remainder of their treatment period.~Asymptomatic Population (Cohort 2)~At Week 0, participants randomized to E2814 will receive intravenously in a blinded fashion for the full treatment period.~At Week 52, all participants will initiate open-label lecanemab administered intravenously for the remainder of their treatment period."
89530410|NCT02516345|Experimental|Family-based Incentive (FBI)|"Children earn rewards each week that they log daily steps on the Fitbit according to the schedule below but only if their matched parent also logs 10,000 steps according to the schedule below. Otherwise, children earn no incentive for that week.~Step targets for children and parents in FBI arm:~Months 1 - 3: ≥10,000 daily steps on ≥4 out of 7 days each week~Months 4 - 6: ≥10,000 daily steps on ≥5 out of 7 days each week~Months 7 - 12: ≥10,000 daily steps on ≥6 out of 7 days each week"
88863831|NCT04565717|Experimental|Part B: ALN-HSD|Participants will be administered multiple doses of ALN-HSD.
88863832|NCT04565717|Placebo Comparator|Part B: Placebo|Participants will be administered multiple doses of ALN-HSD-matching placebo.
88863833|NCT04565717|Experimental|Part C: ALN-HSD|Participants will be administered multiple doses of ALN-HSD.
88863834|NCT04565691|Experimental|Bacteremia inducing arm|As mentioned the participants will be their own controls at the different time-points.
88863835|NCT04561661|Active Comparator|Conservative treatment|Fracture treated with closed reduction, custom made orthosis and early mobilization.
88863836|NCT04561661|Active Comparator|Surgery|Fractures treated with closed reduction, percutaneous pinning (k-wires) and plaster.
89185551|NCT05338632|Experimental|Intravenous fentanyl year 2|continuous intravenous infusion of fentanyl to induce 40-60% respiratory depression.
89530411|NCT03248245|Experimental|LOG-model schools|Experimental schools implement the LOG-model
88819029|NCT04133493|Active Comparator|Intervention Group|Kerecis affixed with steri-strips, cover with gauze and change one per week .
88819030|NCT02660853|Other|Severe Asthma|Patients under Steps 4/5 of Asthma Treatment - SIGN (Scottish Intercollegiate Guidelines Network) / BTS (British Thoracic Society) Guidelines
88819031|NCT02662023|Experimental|RIGHT side BOLUS and left side basal|Bilateral transversus abdominis catheters were inserted and ropivacaine 0.2% administered concurrently. For the right catheter, the ropivacaine was administered as two separate bolus doses of 24 mL each: one at time point zero and one 3 hours later. For the left catheter, the ropivacaine was administered as a continuous basal infusion (8 mL/h) from time point zero for the following 6 hours
88819032|NCT02662023|Active Comparator|RIGHT side BASAL and left side bolus|Bilateral transversus abdominis catheters were inserted and ropivacaine 0.2% administered concurrently. For the right catheter, the ropivacaine was administered as a continuous basal infusion (8 mL/h) from time point zero for the following 6 hours. For the left catheter, the ropivacaine was administered as two separate bolus doses of 24 mL each: one at time point zero and one 3 hours later
88819033|NCT00554099|Placebo Comparator|Placebo|Days 1 thru Days 10 to 14 (Visit 2): daily antibiotic therapy, dietary advice, and 6 placebo tablets (matching mesalamine) once a day. Visit 2 thru Week 12 : 1 placebo capsule (matching probiotic) and 6 placebo tablets (matching mesalamine) daily.
88819034|NCT00554099|Active Comparator|Mesalamine|Days 1 thru 10-14 (Visit 2): daily antibiotic therapy, dietary advice and 6 - 400 mg mesalamine tablets once a day. Visit 2 thru Week 12: 1 placebo capsule (matching probiotic) and 6 - 400 mg mesalamine tablets daily.
88819035|NCT00554099|Active Comparator|Mesalamine & Probiotic|Days 1 thru 10-14 (Visit 2): daily antibiotic therapy, dietary advice and 6 - 400 mg mesalamine tablets once daily. Visit 2 thru Week 12: 1- Bifidobacterium infantis 35624 capsule and 6 - 400 mg mesalamine tablets daily
88819036|NCT02664909|Experimental|Tranexamic Acid|Patients will receive 1 gram of topically applied tranexamic acid into their surgical wound at the time of wound closure during their hip hemiarthroplasty surgery. 1 gram of tranexamic acid will be mixed with normal saline to a total volume of 50 cc, half of which will be delivered intra-articularly and half of which will be delivered in the subfascial space.
88819037|NCT02664909|Placebo Comparator|Placebo|Patients will receive 50 cc of topically applied normal saline into their surgical wound at the time of wound closure during their hip hemiarthroplasty surgery. Half of this 50 cc dose of normal saline will be delivered intra-articularly and half will be delivered in the subfascial space.
88819038|NCT02664987||Patients receiving cancer pain treatment|
88819039|NCT02377362|Experimental|GLWL-01, Part A|Escalating dose in at least 2 of 3 periods, starting at 10 milligrams (mg)
88819040|NCT02377362|Placebo Comparator|Placebo, Part A|Escalating dose of placebo to match GLWL-01, in 1 period
88819041|NCT02377362|Experimental|GLWL-01, Part B|Multiple ascending daily doses of GLWL-01 at up to six dose levels, based on Part A
88819042|NCT02377362|Placebo Comparator|Placebo, Part B|Multiple daily doses of placebo to match GLWL-01
88819043|NCT02377362|Experimental|GLWL-01, Part C|Multiple daily doses of GLWL-01 at level based upon Part B
88819044|NCT02377362|Placebo Comparator|Placebo, Part C|Multiple daily doses of placebo to match GLWL-01
88819045|NCT00553631|Experimental|GA-GCB|VPRIV™ ,velaglucerase alfa
88819046|NCT00553631|Active Comparator|imiglucerase|
88819047|NCT03849573|Experimental|Mindfulness-based stress reduction + Hormone Therapy Education|
88819048|NCT03849573|Active Comparator|Hormone Therapy Education + Overall Health Education|
88819049|NCT00553319|Placebo Comparator|Placebo|Placebo
88819050|NCT00553319|Experimental|Adderall-XR 60 mg|Adderall-XR 60 mg
88819051|NCT00553319|Experimental|Adderall-XR 80 mg|Adderall-XR 80 mg
88819052|NCT05443893||Normal subjects|Gait analysis with artificial intelligence and traditional methods
88819053|NCT05443893||Subjects with abnormal gait|Gait analysis with artificial intelligence and traditional methods
88819054|NCT04768673|Experimental|Group 1|Period 1: CKD-501, D759, H053 / Period 2: CKD-393 Formulation I / Period 3: CKD-393 Formulation II
88819055|NCT04768673|Experimental|Group 2|Period 1: CKD-393 Formulation I / Period 2: CKD-393 Formulation II / Period 3: CKD-501, D759, H053
88819056|NCT04768673|Experimental|Group 3|Period 1: CKD-393 Formulation II / Period 2: CKD-501, D759, H053 / Period 3: CKD-393 Formulation I
88819057|NCT04768673|Experimental|Group 4|Period 1: CKD-501, D759, H053 / Period 2: CKD-393 Formulation II / Period 3: CKD-393 Formulation I
88819058|NCT04768673|Experimental|Group 5|Period 1: CKD-393 Formulation I / Period 2: CKD-501, D759, H053 / Period 3: CKD-393 Formulation II
88819059|NCT04768673|Experimental|Group 6|Period 1: CKD-393 Formulation II / Period 2: CKD-393 Formulation I / Period 3: CKD-501, D759, H053
88819060|NCT05197179|Other|Single-dose A|A single dose A of FB2001 or placebo will be administered by intravenous (IV) infusion
88819061|NCT05197179|Other|Single-dose B|A single dose B of FB2001 or placebo will be administered by intravenous (IV) infusion
88819062|NCT05197179|Other|Multiple-dose A|Dose A of FB2001 or placebo will be administered by intravenous (IV) infusion once daily for 5 consecutive days
88819063|NCT05197179|Other|Multiple-dose B|Dose B of FB2001 or placebo will be administered by intravenous (IV) infusion twice daily for 5.5 consecutive days
88819064|NCT05197179|Other|Single-dose C|A single dose C of FB2001 or placebo will be administered by intravenous (IV) infusion
88819065|NCT00369291|Experimental|CpG 7909|Patients treated with CpG 7909 oligodeoxynucleotides (ODNs) after autologous transplantation to enhance immune reconstitution.
88819066|NCT01868633|Active Comparator|Dexamethasone & spinal morphine|intrathecal morphine administered at time of spinal anesthesia. After cesarean delivery 8mg (2ml) of Dexamethasone given intraoperatively
88819067|NCT01868633|Placebo Comparator|Placebo injection and spinal morphine|intrathecal morphine administered at time of spinal anesthesia. After cesarean delivery 2ml of placebo (Normal saline) drawn to mimic active drug given intraoperatively
89185552|NCT02597816|Other|Three dimensional ultrasound|Infertile women with diagnosis of arcuate and septate uterus based on Hystro-salpingography were recruited. All women were examined by Three dimensional ultrasound on day 22 cycle to allow for better delineation of the uterine contour. The outer and inner fundal contours and the length of the fundal notch were examined by Three dimensional ultrasound in the mid-coronal view of the multi-planar and multi-slice display of the uterus. The final diagnosis of the anomalies was based on combined hysteroscopy/laparoscopy examination, the gold standard.
89185553|NCT04078932|Experimental|Intervention|Cohort of residents trained in the conversation script who will utilize the script at pediatric clinic visits. Will evaluate baseline feelings of comfort and self-efficacy prior to being trained in the script (pre-intervention measures). After being trained in the conversation script (the intervention), the following will be measured (post-intervention measures): frequency of facilitating conversations on safely navigating police encounters in clinical practice, feelings of comfort and self-efficacy.
88863839|NCT04557436|Other|Standard of care|"Follow-up period:~For patients achieving molecular remission by day 28, allo-HSCT will be scheduled as soon as practicable. Routine transplant care for 24 months will incorporate the disease monitoring and recording of adverse events of special interest and document elimination of PBLTT52CAR19 through the transplant conditioning period.~For patients with refractory disease at Day 56, the monitoring of adverse events of special interest, the disease outcome will be monitored monthly up to 24 months or until a palliative therapy approach is adopted.~Assessments will be carried out after the treatment period at the following time points: 1m, 2m, 3m, 6m, and 12m, 24m~Physical examination, ECOG~Laboratory tests~Vital signs (temperature, BP, HR, respiratory rate, weight)~Persistence of PBLTT52CAR19, VCN by qPCR in blood and bone marrow (if sampled)~Chimerism and MRD in blood and bone marrow (if sampled)~Adverse events~Concomitant treatments"
88863840|NCT04548700|Experimental|Dose-finding and dose-expansion|"Dose-finding stage: Patients with treatment-naïve PTCL will receive sequentially higher doses of liposomal mitoxantrone hydrochloride in combination with Cyclophosphamide, Vincristine and Prednisone for 6 cycles (planned) (28 days per cycle). The initial dose of liposomal mitoxantrone hydrochloride is 12 mg/m2.~Dose-expansion stage: Patients with treatment-naïve PTCL will receive liposomal mitoxantrone hydrochloride at RP2D in combination with Cyclophosphamide, Vincristine and Prednisone for 6 cycles (planned) (28 or 21 days per cycle)."
88863841|NCT04526782|Experimental|Cohort 1 (1st line)|Encorafenib: 450 mg (6 × 75 mg capsule) QD Binimetinib: 45 mg (3 × 15 mg tablet) BID
88863842|NCT04526782|Experimental|Cohort 2 (2nd line)|Encorafenib: 450 mg (6 × 75 mg capsule) QD Binimetinib: 45 mg (3 × 15 mg tablet) BID
88863843|NCT04525222|Experimental|Arm I (Actify, text notifications)|Participants use Actify app for smoking cessation for 8 weeks. Participants also receive motivational messages and smoking cessation information via text notifications.
88863844|NCT04525222|Active Comparator|Arm II (Current Standard Care, text notifications)|Participants use app for smoking cessation for 8 weeks. Participants also receive motivational messages and smoking cessation information via text notifications.
88863845|NCT04518930|Experimental|high fat|26 participants will be provided with (35) g of roasted, not salted peanuts as snack.
88863846|NCT04518930|Experimental|high protein|26 participants will be provided with (380) g of Plain Greek yogurt after as snack.
88863847|NCT04513587|Experimental|CBT-Based Weight Loss Model|CBT- Based weight loss model
88863848|NCT04513587|Active Comparator|Control|Usual Care
88863849|NCT04509466|Experimental|dose escalation (part 1)|"dose escalation (part 1):Patients with treatment-naïve, relapsed or refractory extranodal natural killer/T-cell lymphoma (nasal type) will receive liposomal mitoxantrone hydrochloride plus a standard dose of pegaspargase every 21 days (a cycle) for a maximum of 6 cycles. The starting dose of liposomal mitoxantrone hydrochloride is 12mg/m2.dose expansion, treatment-naïve patients (part 2):Patients with treatment-naïve extranodal natural killer/T-cell lymphoma (nasal type) will receive liposomal mitoxantrone hydrochloride at RP2D plus a standard dose of pegaspargase every 21 days (a cycle) for a maximum of 6 cycles.~dose expansion, relapsed or refractory patients (part 2):Patients with relapsed or refractor extranodal natural killer/T-cell lymphoma (nasal type) will receive liposomal mitoxantrone hydrochloride at RP2D plus a standard dose of pegaspargase every 21 days (a cycle) for a maximum of 6 cycles."
88863850|NCT04502030|Experimental|Panzyga|
88863851|NCT04502030|Placebo Comparator|Placebo|
88863852|NCT04478760||Masculinising therapy|Healthy transgender (including non-binary) adults who are on testosterone-containing hormone therapies.
88863853|NCT04478760||Feminising therapy|Healthy transgender (including non-binary) adults who are on oestrogen-containing hormone therapies.
88863854|NCT04473911|Experimental|Regimen 1: Fludarabine, Cyclophosphamide, and TBI|"-. Patients who meet eligibility criteria for the study will subsequently be enrolled for treatment. Two reduced intensity regimens will be allowed, according to the choice of the treating physician~Pre- stem cell transplant:~Fludarabine predetermined dose, intravenously, 4 times per cycle~Cyclophosphamide predetermined dose, predetermined number of times in cycle, intravenous infusion~Total body irradiation (TBI) once during treatment cycle~Post stem cell transplant:~Cyclophosphamide predetermined dose, predetermined number of times in cycle, intravenous infusion~Sirolimus: Predetermined dosage, predetermined number of time in cycle, oral.~Mycophenolate mofetil, oral or iv(predetermined dose or IV TID (based upon actual body weight), at predetermined times per cycle~RGI-2001: IV, predetermined dose, weekly to 6 total doses"
89185554|NCT04078932|No Intervention|Control|Cohort of residents at another clinical site with a similar community demographic make-up who do not receive the intervention. In the control group, we will measure frequency of facilitating conversations on safely navigating police encounters in clinical practice, feelings of comfort and self-efficacy.
89185555|NCT00732758|Experimental|Vitamin D3|Vitamin D3 1000 IU Tablet
89185556|NCT00732758|Placebo Comparator|Placebo|Placebo Tablet
89535309|NCT02487953|Active Comparator|Nicotine ENDS + Placebo Patch|Participants will initially receive 1 week of placebo skin patches while continuing to smoke their usual cigarettes ad lib. Starting with week 2, they will receive nicotine-containing ENDS devices and will be instructed to substitute ENDS for as many cigarettes as possible in this week. The target quit-smoking date will occur at the beginning of week 3. Treatments will continue until week 8 post-quit, at which time participants will be instructed to reduce ENDS use over the next 4 weeks, at which time ENDS will no longer be dispensed. Subsequently, the placebo patch size will be gradually reduced to mirror standard weaning regimen from 21 mg/24 h to 14 mg/24 h for 2 weeks, and 7 mg/ 24 h for 2 weeks. All nicotine-based treatments will end at week 16 after the quit date.
89535310|NCT02487953|Active Comparator|Placebo ENDS + Nicotine Patch|Participants will initially receive 1 week of 21 mg nicotine skin patches while continuing to smoke their usual cigarettes ad lib. Starting with week 2, they will receive placebo ENDS devices and will be instructed to substitute ENDS for as many cigarettes as possible in this week. The target quit-smoking date will occur at the beginning of week 3. Treatments will continue until week 8 post-quit, at which time participants will be instructed to reduce ENDS use over the next 4 weeks, at which time ENDS will no longer be dispensed. Subsequently, the nicotine patch dose will be gradually reduced according to standard weaning regimen from 21 mg/24 h to 14 mg/24 h for 2 weeks, and 7 mg/ 24 h for 2 weeks. All nicotine-based treatments will end at week 16 after the quit date.
89535311|NCT03207607|Experimental|Control snack|Participants received control snacks prepared by real fruits (pear, orange and mango)
89185557|NCT00741351|Experimental|IF|Sevoflurane (Inhalation)+Fentanyl
88819068|NCT04738773|Active Comparator|Patients receiving Naltrexone|
89185558|NCT00741351|Experimental|IR|Sevoflurane (Inhalation)+Remifentanyl
89185559|NCT00741351|Experimental|ER|Propofol (Endovenous)+ Remifentanyl
89185560|NCT02595164||Impulsive subjects|Subjects exhibiting impulsive symptoms Behavioral Task
88819069|NCT04738773|Placebo Comparator|Patients receiving Placebo|
88819070|NCT01868789|Experimental|Weightbearing CT (AAFD group)|Weightbearing CT scan of affected foot
88819071|NCT01868789|Active Comparator|Weightbearing CT (control group)|Weightbearing CT scan of normal foot
88819072|NCT04739397||Cataract|Patients with bilateral cataracts with Lens grade 2+ or greater, cataract classification nuclear, cortical or posterior subcapsular
88819073|NCT04739397||Non-Cataract|patients with bilateral clear lenses (no cataracts)
88819074|NCT01869647|Active Comparator|"high likelihood of stone group"|"Subjects in the high likelihood of stone group will be eligible to get either ULDCT or expectant management. The choice will be determined by the primary clinician in conjunction with the patient. If ULDCT is elected, the scan will be read diagnostically by the radiologist and the clinician will treat the patient based on these results. If the expectant management option is chosen, no CT will be done during the ED visit and they will be treated as if they have a kidney stone. Participants in this group will receive Ultra low dose CT scan."
88819075|NCT01869647|Active Comparator|"moderate likelihood of stone group"|"Subjects in the moderate likelihood of stone group will be given the option to receive either a standard dose CT or ULDCT. Again, the decision of which imaging option to choose will be made by the primary clinician in conjunction with the patient. Participants in this group will receive regular or low dose CT scan."
88819076|NCT01869647|Active Comparator|"low likelihood of stone group"|"In the low likelihood of stone group the RA will present the data from the stone score to the physician and explain that patient is unlikely to have a kidney stone and they will be advised that probability of a stone is very low and that alternate imaging choices may be warranted. If they still choose to order a CT Flank Pain Protocol they will be asked to provide reasoning and the patient will receive a regular dose CT Flank Pain Protocol. Participants in this group will not receive imaging."
88819077|NCT03833063|Placebo Comparator|placebo|injections with sodium chloride
88819078|NCT03833063|Active Comparator|botulinum toxin A|injections with botulinum toxin A
88819079|NCT02674659|Experimental|Control group|Patients after coronary bypass surgery who undergo conventional cardiac rehabilitation program (aerobic training only)
88819080|NCT02674659|Experimental|Intervention group|Patients after coronary bypass surgery who undergo conventional cardiac rehabilitation program plus resistance training (aerobic and resistance training as well)
88819081|NCT02676375|Other|Standard Monotherapy|Treatment as usual starting with one smoking cessation medication plus group therapy.
88819082|NCT02676375|Experimental|Combination Extended Treatment|Extended treatment with multiple standard medications plus group therapy.
88819083|NCT02676375|Experimental|Combination Extended Treatment + Home Visits/Calls|Extended treatment with multiple standard medications plus group therapy plus home visits.
88819084|NCT01871441|Experimental|Treatment (haploidentical allogeneic HSCT)|"Patients undergo TBI BID on days -9 to -6, undergo DLI on day -6, and receive cyclophosphamide IV over 2 hours on days -3 and -2.~TRANSPLANT: Patients undergo haploidentical allogeneic hematopoietic stem cell transplant on day 0.~GVHD PROPHYLAXIS: Patients receive tacrolimus IV beginning on day -1 with taper beginning on day 42, and mycophenolate mofetil IV BID from day -1 to day 28."
88819085|NCT02676843|Experimental|18F-AV-1451|Subjects who are microtubule associated protein tau (MAPT) family carriers and non-carriers will receive 18F-AV-1451 by injection, and undergo a Positron Emission Tomography (PET) scan, which will then be qualitatively analyzed to examine tau deposition in the brain.
88819086|NCT04338711|Experimental|Treatment A|Single oral 10 mg dose of tofacitinib MR E1 administered in the fasted state.
88819087|NCT04338711|Experimental|Treatment B|Single oral 10 mg dose of tofacitinib MR E2 administered in the fasted state.
88819088|NCT04338711|Experimental|Treatment C|Single oral 10 mg dose of tofacitinib MR E3 administered in the fasted state.
88819089|NCT04338711|Experimental|Treatment D|Single oral 10 mg dose of tofacitinib MR E1 administered in the fed state.
88819090|NCT04338711|Experimental|Treatment E|Single oral 10 mg dose of tofacitinib MR E3 administered in the fed state.
88819091|NCT04338711|Active Comparator|Treatment F|Single oral 10 mg dose of tofacitinib IR Solution (10 mL of the 1 mg/mL solution) administered in the fasted state.
88819092|NCT01874951|Placebo Comparator|Placebo|In this arm, patients will receive placebo for three weeks.
88819093|NCT01874951|Experimental|Naltrexone|In this arm, patients will receive low dose naltrexone for three weeks.
89185561|NCT02595164||Non-impulsive subjects|Subjects which do not exhibit impulsive symptoms Behavioral Task
89388399|NCT05269394|Placebo Comparator|Matching placebo (E2814) plus lecanemab|"Symptomatic Population (Cohort 1)~At Week 0, participants will receive open-label lecanemab administered intravenously for the full treatment period.~At Week 24, participants randomized to E2814 placebo will receive placebo intravenously in a blinded fashion for the remainder of their treatment period.~Asymptomatic Population (Cohort 2)~At Week 0, participants randomized to E2814 placebo will receive placebo intravenously in a blinded fashion for the full treatment period.~At Week 52, all participants will initiate open-label lecanemab administered intravenously for the remainder of their treatment period."
89388400|NCT05269121|Experimental|DAIR + Phage Treatment + Antibiotics|Phage therapy will be administered in conjunction with antibiotics.
89388401|NCT05265325|Experimental|AND017 Dose Regimen A|AND017 will be administrated orally at dose A three times a week
89388402|NCT05265325|Experimental|AND017 Dose Regimen B|AND017 will be administrated orally at dose B once a week
89388403|NCT05265325|Active Comparator|Erythropoietin stimulating agent|Investigator will select an erythropoietin stimulating agent, such as epoetin alfa, darbepoetin alfa, Mircera®, or their biosimilars, for the patient under this arm with starting doses and dose adjustment rules according to the epoetin alfa USPI or SmPC.
89388404|NCT05259735|Experimental|Intervention|Clinical guideline-based management of T2DM by Ayurvedic practitioners. The clinical guideline will cover topics like diagnostic criteria, blood glucose targets, lifestyle advice, Ayurvedic medicines, monitoring and follow-up (including screening for complications and referral to specialists for complications management). The clinical guideline will make recommendations based on the best available evidence. Ayurvedic practitioners will have at least a 5½ year undergraduate medical degree in Ayurveda. Regular training will be provided to Ayurvedic practitioners (in groups) in the use of clinical guideline which will involve roleplaying and structured and instructive feedback to improve their performance. The trainings will be recorded on the Training Attendance Log and they will be provided a Training Certificate for completing the training.
89388405|NCT05259735|Active Comparator|Comparator|"Comparator: Currently, no standard clinical guideline is used by Ayurvedic practitioners to manage T2DM in Nepal. Thus, the comparator will be the usual management of T2DM (i.e., without any clinical guideline) by Ayurvedic practitioners.~Participants will continue their medications for other systemic diseases, if any."
89388406|NCT05257629|Active Comparator|Combination Therapy Arm (Varenicline and Nicotine E-Cigarettes Plus Counseling)|Patients in the combination therapy arm will be supplied funds and instructions for the purchase of e-cigarettes and cartridges/pods upon hospital discharge and at the week 4 and 12 clinic visits. As with standard NRTs such as the gum, inhaler, and lozenge, we expect smokers will self-regulate administration according to their withdrawal symptoms. Use will be monitored via self-report for telephone follow-ups. At clinic visits, patients will be asked to bring their e-cigarettes, used and unused cartridges/pods, and purchasing receipts. Patients will be advised regarding the signs and symptoms of nicotine toxicity and of an allergic reaction.
89535312|NCT03207607|Experimental|Maltodextrin snack|Participants received maltodextrin snacks (maltodextrin + control snack)
89535313|NCT03207607|Experimental|Whey protein snack|Participants received whey protein snacks (whey protein + control snack)
89535314|NCT03207607|Experimental|Oat snack|Participants received oat snacks (oat + maltodextrin + control snack)
88863855|NCT04473911|Experimental|Regimen 2: Fludarabine, Melphalan, and TBI|"-. Patients who meet eligibility criteria for the study will subsequently be enrolled for treatment. Two reduced intensity regimens will be allowed, according to the choice of the treating physician~Pre- stem cell transplant:~Fludarabine predetermined dose, intravenously 3 times per cycle~Melphalan, infusion, determined dosage, once per cycle~Total body irradiation (TBI) once per cycle.~Post stem cell transplant~Cyclophosphamide predetermined dose, predetermined number of times in cycle, intravenous infusion~Sirolimus: Predetermined dosage, predetermined number of time in cycle, oral:~Mycophenolate mofetil, oral or iv(predetermined dose or IV TID (based upon actual body weight), at predetermined times per cycle~RGI-2001: IV, predetermined dose, weekly to 6 total doses"
88863856|NCT04468178|Experimental|Shoulder prosthesis system GLOBAL ICON from DePuy|The GLOBAL ICON stemless is a shaftless shoulder prosthesis system for anatomical reconstruction of the shoulder joint in cases of total or hemiarthroplasty in the shoulder. The base plate consists of titanium coated with hydroxyapatite, the head of cobalt-chrome.
88863857|NCT04468178|Active Comparator|SIMPLICITY shoulder prosthesis system from Wright Medical|The SIMPLICITY is a shaftless shoulder prosthesis system for anatomical reconstruction of the shoulder joint in cases of total or hemiarthroplasty in the shoulder. The base plate consists of titanium coated with hydroxyapatite, the head of cobalt-chrome.
88863858|NCT04457154||Registry Population|Pediatric subjects (age 18-21 years) who are undergoing implant of the Inspire Upper Airway Stimulation System for the treatment of moderate to severe obstructive sleep apnea (OSA)
88863859|NCT04446481|Experimental|MCI patients|Vets with mild cognitive impairment
88863860|NCT04446481|Active Comparator|NC|Normal healthy Veterans
88863861|NCT04441814||Lung cancer screening subjects|Subjects enrolled in SMILE lung cancer screening trial
89185562|NCT02582268|Experimental|TAS guided IUD insertion|the female will be asked to be full bladder. the trans-abdominal probe will be placed by an assistant on the suprapubic region. under speculum examination, the intrauterine device IUD (TCu 380A) will be placed till it reaches the fundus of the uterus and then released.
88863862|NCT04439292|Experimental|Treatment (dabrafenib, trametinib)|Patients receive dabrafenib mesylate PO BID and trametinib dimethyl sulfoxide PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88863863|NCT04439188|Experimental|Treatment (GSK2636771)|Patients receive PI3K-beta inhibitor GSK2636771 PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88863864|NCT04431388||SIPB (block)|Patients undergone nephectomy and who received SIPB as analgesia
88863865|NCT04431388||QL block|Patients undergone nephectomy and who received QL as analgesia
89185563|NCT02582268|Experimental|Traditional IUD insertion|the intrauterine device TCu 380A will be inserted in the conventional method, and checked afterwards by transvaginal ultrasound. the trans-abdominal probe will also be placed by an assistant on the suprapubic region ( the image would be on freeze mode) as it is not actually used , it is just to make the same settings for the participant females.
89185564|NCT02582190|Other|Colchicine group|Colchicine add on therapy in atrial fibrillation
89185565|NCT00699153|Experimental|Loteprednol Etabonate|Loteprednol Etabonate 0.5%
89185566|NCT00699153|Placebo Comparator|Vehicle|Vehicle of Ophthalmic Loteprednol Etabonate
89185567|NCT02582112|Active Comparator|Warming group|Active Comparator: Warming group
89185568|NCT02582112|Placebo Comparator|Control group|Control group
89185569|NCT05742243|Active Comparator|Abatacept and nasal insulin|Abatacept (CTLA4-Ig; 50 mg for participant weight <25 kg, 87.5 mg for participant weight 25-50 kg, 125 mg for participant weight >50 kg) will be injected subcutaneously once per week and nasal insulin (Humulin R®, 100 Units/mL) will be inhaled for 10 consecutive days initially and twice per week thereafter, for 48-weeks.
89185570|NCT05742243|Placebo Comparator|Abatacept and nasal placebo|Abatacept (CTLA4-Ig; 50 mg for participant weight <25 kg, 87.5 mg for participant weight 25-50 kg, 125 mg for participant weight >50 kg) will be injected subcutaneously once per week and nasal placebo (0.9% sodium chloride) will be inhaled for 10 consecutive days initially and twice per week thereafter, for 48-weeks.
89185571|NCT04077918|Active Comparator|Plant protein diet|18 g of plant protein diet added every day for 3 months , and after washout for 1 month, 18 g of animal protein diet added every day for 3 months
89185572|NCT04077918|Active Comparator|Animal protein diet|18 g of animal protein diet added every day for 3 months, and after washout for 1 month, 18 g of plant protein diet added every day for 3 months
89185573|NCT04076748|Experimental|Experimental|"* Intra Nasal Sufentanil (50 µg.ml-1): Load dose : 0.3 µg. kg-1, Followed by bolus : 5 µg / 10 minutes with 2 bolus maximum.~As soon as the venous route and ten minutes after the last administration of sufentanil:~Morphine IV: 3 mg / 5 minutes.~Objective: numeric rating scale (NRS) ≤ 3/10."
89185574|NCT04076748|Active Comparator|Control|"* EMONO : Given by respiratory administration via a face mask at a rate suitable for patient ventilation (generally at least 9l.min-1), Until a venous route is obtained and without exceeding 30 minutes.~* Morphine IV: Load dose: 0.1mg. kg-1 as soon as possible; Then bolus: 3mg / 5 minutes.~* Objective: NRS ≤ 3/10"
89185575|NCT00698997|Experimental|1 Early Start Denver Model|"Phase 1 of ESDM intervention: 12 weekly, 1 to 1.5 hr. sessions focused on teaching & coaching parents to use the ESDM in all natural caretaking routines & play periods with their child. Parents are taught & coached on 1 aspect of the ESDM each week in the clinic session, & then practice it at home daily in natural family routines & play.~Phase 2: each child in the ESDM will receive 25 hrs. a week of ESDM intervention in their homes, 50 wks. a year, for 2 years. 20 hrs. weekly will be delivered by trained interventionists (ITs); 5 hrs. weekly will be delivered by parents. (ITs) will provide ten 2 hour teaching episodes involving play activities per week in the home. Parents will continue to deliver the ESDM in natural family routines & play activities. In addition, each child will receive additional services through public services, or other therapies that the parents may choose, for several more hrs. per week."
89185576|NCT00698997|Other|2 Standard Care available in the Community|Any intervention that were available and that families accessed in their communities
89185577|NCT00711087|Placebo Comparator|ARM 2|Subjects randomized to receive placebo (saline) sham saline injections on Days 0 and 90.
89185578|NCT00711087|Active Comparator|ARM 1|Subjects randomized to receive 100 units BOTOX-A injections on Days 0 and 90.
89185579|NCT04078308|Experimental|Mesenchymal Stem Cells Transplantation|The patients with Type 1 Diabetes, who will receive Intravenous injection of autologous bone-marrow derived mesenchymal stem cells
89530412|NCT03248245|Active Comparator|Treatment as usual schools - TAU|Control schools performing interprofessional team collaboration as usual
89530413|NCT05565131|Experimental|PAtients requiring pedicle screw implantation|
88863866|NCT04431388||control|Patients undergone nephrectomy who didn´t receive regional anesthesia
88863867|NCT04421352|Experimental|low-dose radiation+CS1001|low-dose radiation+CS1001
89185580|NCT04078308|Placebo Comparator|Placebo|The patients with Type 1 Diabetes, who will receive intravenous injection of normal saline (sodium chloride 0.9%)
89185581|NCT02582034|Active Comparator|Standard dosimetry|Standard Internal Radiation Therapy : Dose of radiation delivered to the tumoral volume is fixed : 120 Gray (GY)
89185582|NCT02582034|Experimental|Optimized dosimetry|Optimized Internal Radiation Therapy : Dose of radiation absorbed by the tumor is > 205 GY, if possible 250 or 300 Gy.
88863868|NCT04419532|Experimental|Dose Escalation (DS-1055a)|Participants will be enrolled into groups with each group receiving an increased dose from the previous group as safety assessments permit in order to determine the optimal dose for safety and tolerability.
89185583|NCT02581956|Experimental|Walking Exercise|For the exercise group, subjects were asked to follow a simple walking regimen. Walk normally with stable and comfortable stride rates during their exercise. The duration and frequency was initiated at a 30-minute or more daily exercise at least five days per week and gradually increased to a maximum of 60 minutes within subject's comfort zone.
89185584|NCT02581956|Placebo Comparator|No Intervention|No exercise required
89530414|NCT02516267|No Intervention|Control Group|Patients who will discontinue inhibitor-ADP for 5 days before surgery, and must be operated on the first working day after completing the 5 days without the drug. This group will have its aggregability evaluated by platelet function testing (Multiplate ADP®) immediately before the transport to the operating room.
89535315|NCT03207607|Experimental|Coconut oil snack|Participants received coconut oil snacks (coconut oil + control snack)
88863869|NCT04410874|Experimental|Imvamune|Imvamune vaccine to be administered intratumorally at one of three doses on Days 0 and 4 of the study
88863870|NCT04394962|No Intervention|Control group|Patients who will be randomized to the control group will be waiting for the ET procedure without any intervention and without any deviation from the standard of care
88863871|NCT04394962|Experimental|Study group|Exposure to virtual reality environment exposure
88863872|NCT04380337|Experimental|Radiation/FOLFOXIRI|Treatment will comprise 6 daily fractions of radiotherapy at 5 Gy per fraction followed by 4 months of FOLFOXIRI. Patients who have performance status or conditions that may preclude use of FOLFOXIRI may be treated with FOLFOX or XELOX. Those who achieve a clinical complete response will be considered for organ preservation approach. All other patients will receive standard of care total mesorectal excision (TME).
89185585|NCT05275920|Experimental|Best Practice Alert group|Providers will receive a BPA at the time of visit for patients with HFrEF who are not on MRA (and who do not have contraindication to MRA). This alert will display the patient's current HFrEF therapies, EF, blood pressure, potassium, and glomerular filtration rate. The alert will give access to an outpatient heart failure order set, and also provide links to the most recent guidelines.
88863873|NCT04380311|Experimental|Precision Tacrolimus|Participants in this arm of the study will have their tacrolimus dose determined using a precision medicine decision support software tool. The participant's transplant physician will consider the recommended dose from the decision support tool in combination with the physician's expertise and experience to determine the proper tacrolimus dose for the participant.
88863874|NCT04356170|Active Comparator|TPF (docetaxel, cisplatine, 5-FU)|Docetaxel, cisplatine, 5-FU administered, every 3 weeks for a total of 3 cycles
88863875|NCT04356170|Experimental|TPFm (docetaxel, cisplatine, 5-FU) modifié|Docetaxel, cisplatine, 5-FU administered, every 2 weeks for a total of 6 cycles
88863876|NCT04349709|Experimental|Brief school-based DBT-A|The students of classes randomized to experimental group receive the brief school-based DBT-A..
88863877|NCT04349709|No Intervention|control group|The students of classes randomized to control group continue their school activity as routine.
88863878|NCT04322084||Participants|Participants will be enrolled during induction therapy for ALL, before the first high-risk period of treatment, and will contribute data for two 5-day periods of continuous monitoring.
88863879|NCT04308590|Experimental|Relacorilant|The dose of relacorilant will be increased sequentially from 100 mg orally once daily to a target dose of 400 mg once daily.
88863880|NCT04308590|Placebo Comparator|Placebo|Placebo matched to study drug
88863881|NCT04307004|Other|Unattended vs Attended Blood Pressure|Participants blood pressure will be measured three times attended and three times unattended using the Microlife WatchBP Office AFIB device. Whether investigators measure blood pressure attended first and then unattended or unattended first and then attended will be assigned using a random number generator. At visit 2, clinic blood pressure will be measured three times attended and three times unattended using the Microlife WatchBP Office AFIB device, as at visit 1, but in the reverse order.
88863882|NCT04307004|Other|ABPM vs HBPM|Participants will be fitted with either the Microlife WatchBP O3 ambulatory blood pressure monitoring device or instructed on how to use the Microlife WatchBP Home N home blood pressure device, depending on which they are assigned to complete first. The order in which participants undergo ambulatory or home blood pressure monitoring will be assigned through a random number generator.
88863883|NCT04305054|Experimental|Pembrolizumab + Vibostolimab|Participants will receive pembrolizumab intravenously (IV) plus vibostolimab IV at specified doses on specified days for a total treatment duration of up to approximately 2 years.
88863884|NCT04305054|Active Comparator|Pembrolizumab|Participants will receive pembrolizumab IV at a specified dose on specified days for a total treatment duration of up to approximately 2 years.
88863885|NCT04305054|Experimental|Coformulation Pembrolizumab/Quavonlimab|Participants will receive coformulation of pembrolizumab and quavonlimab (MK-1308A) IV at a specified dose on specified days for a total treatment duration of up to approximately 2 years.
89530415|NCT02516267|Active Comparator|Intervention Group|Patients will be evaluated by platelet function testing (Multiplate ADP®) daily until the value obtained> 46 AU, when they will be immediately released to CABG, to be held on the first working day after release.
88863886|NCT04305054|Experimental|Coformulation Pembrolizumab/Quavonlimab + Lenvatinib|Participants will receive coformulation of pembrolizumab and quavonlimab IV plus lenvatinib orally at specified doses on specified days for a total treatment duration of up to approximately 2 years.
89185586|NCT05275920|Experimental|In-Basket Message group|Providers will receive a monthly in-basket messages linking to a list of patients who have been seen in the past 2 months or will be seen in the upcoming month with HFrEF who are not on MRA (and who do not have contraindication to MRA). This list will display each patient's current hFrEF therapies, EF, blood pressure, potassium, glomerular filtration rate, date of last visit, and date of next visit. From the list, providers can access the patient's chart, order medications, and document communication with the patient.
88863887|NCT04305054|Experimental|Coformulation Favezelimab/Pembrolizumab|Participants will receive cofomulation of favezelimab + pembrolizumab (MK-4280A) IV at specified dose on specified days every 3 weeks (Q3W) for up to approximately 2 years
89185587|NCT05275920|No Intervention|Control group|Patients who will receive the current standard practice of care (no BPA or in-basket message)
89185588|NCT04250688|Experimental|Esko Bionics Suit + Functional Electrical Stimulation|
89185589|NCT04250688|No Intervention|Control|
89535316|NCT03207607|Experimental|Snack skipping|Participants received snack skipping
88863888|NCT04305054|Experimental|Coformulation Favezelimab/Pembrolizumab + All-trans Retinoic Acid (ATRA)|Participants will receive coformulation of favezelimab and pembrolizumab IV Q3W for up to 35 cycles, plus ATRA orally (for 3 days surrounding each infusion of MK-4280A, including Days 1, 2, and 3 of Cycle 1 and on Days -1, 1, and 2 of all subsequent cycles).
88863889|NCT04305054|Experimental|Coformulation Favezelimab/Pembrolizumab + Vibostolimab|Participants will receive coformulation of favezelimab and pembrolizumab (MK-4280A) IV and vibostolimab IV at specified doses on specified days for a total treatment duration of up to approximately 2 years.
88863890|NCT04289376|Other|Gaze tracking|No intervention. Monitor gaze as subjects watch a video
88863891|NCT04277507|Experimental|Vivaer Stylus|Intervention: Procedure: thermal treatment of submucosal tissue including cartilage in the internal nasal valve area
88863892|NCT04274530|Experimental|Intervention - CBT|Participants in this arm will receive cognitive behavioural therapy (CBT). Participants will complete a series of online modules via a mobile application in addition to standard of care for their fracture injury. Participants will be assigned a dedicated CBT therapist, and receive feedback and support from their therapist via in-app messaging. The CBT program will last approximately 6-8 weeks.
88863893|NCT04274530|No Intervention|Control|Participants in the control arm of the study will receive standard of care treatment for their fracture(s) but will not receive any Cognitive Behavioral Therapy.
88863894|NCT04259307|Experimental|Intensive nutrition group|Standard nutritional support with additional intravenous nutrition of 500 kcal per day for 3 weeks
88863895|NCT04259307|No Intervention|Control group|Standard nutritional support only per day for 3 weeks
88863896|NCT04257578|Experimental|Treatment (acalabrutinib, axicabtagene ciloleucel)|Beginning up to 3 weeks and at least 24 hours prior to leukapheresis, patients receive acalabrutinib PO every 12 hours. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients also receive axicabtagene ciloleucel IV at 36-96 hours after completion of lymphodepleting chemotherapy.
88863897|NCT04244175|Experimental|High Dose: CVL-865 25 mg|Participants will receive CVL-865 tablets orally twice daily (BID) up to the maximum dose of 25 milligrams (mg) until Day 92 during the treatment period.
88863898|NCT04244175|Experimental|Low Dose: CVL-865 7.5 mg|Participants will receive CVL-865 tablets orally BID up to the maximum dose of 7.5 mg until Day 92 during the treatment period.
88863899|NCT04244175|Placebo Comparator|Placebo|Participants will receive a placebo matched to CVL-865 tablets orally BID until Day 92 during the treatment period.
88863900|NCT04243044|Experimental|Intensity 1 (0.8x reflex threshold, continuous, 30 minute duration)|Transcutaneous spinal stimulation will be applied continuously at 0.8x reflex threshold as determined from baseline testing of posterior root muscle reflexes.
89185590|NCT00738530|Experimental|Bevacizumab + IFN-Alfa-2A|Bevacizumab infusions will be administered every 2 weeks at a dose of 10 milligram per kilogram (mg/kg) for 52 weeks or until disease progression or unacceptable toxicity. Interferon alfa-2a (IFN-Alfa-2A) will be administered 3 times per week as a subcutaneous injection at a dose of 9 million international units (MIU) for 52 weeks or until disease progression or major toxicity.
89530416|NCT03245125||HIIT subjects in HFrEF patients|heart failure patients with reduced ejection fraction (HFrEF) received at least 36 times of high-intensity interval training (HIIT)
88863901|NCT04243044|Experimental|Intensity 2 (0.8x reflex threshold, dual-site, 30 minute duration)|Transcutaneous spinal stimulation will be applied continuously at two sites at 0.8x reflex threshold as determined from baseline testing of posterior root muscle reflexes.
88863902|NCT04243044|Experimental|Intensity 3 (0.8x reflex threshold, burst, 30 minute duration)|Transcutaneous spinal stimulation will be applied in bursts at 0.8x reflex threshold as determined from baseline testing of posterior root muscle reflexes.
88863903|NCT04234113|Experimental|Experimental: Part A (SO-C101 Monotherapy)|Drug: SO-C101
88863904|NCT04234113|Experimental|Experimental: Part B (SO-C101 combined with pembrolizumab)|Drug: SO-C101 Drug: pembrolizumab
88863905|NCT04234113|Experimental|Experimental: Part A1 (SO-C101 divided dosing, Monotherapy)|Drug: SO-C101, twice a day as 2 divided doses (50%:50%)
88863906|NCT04234113|Experimental|Experimental: Part B1 (SO-C101 divided dosing, combined with pembrolizumab)|Drug: SO-C101, twice a day as 2 divided doses (50%:50%) Drug: pembrolizumab
88863907|NCT04234113|Experimental|Experimental: Part D (SO-C101 Monotherapy, dose expansion at the RP2D identified in Part A)|Drug: SO-C101 Indications: Relapsed/refractory advanced/metastatic renal cell carcinoma, relapsed/refractory advanced/metastatic skin squamous-cell carcinoma, and relapsed/refractory advanced/metastatic melanoma.
88863908|NCT04234113|Experimental|Part D1 (SO-C101 divided dosing, Monotherapy, dose expansion at RP2D identified in Part A1)|Drug: SO-C101, twice a day as 2 divided doses (50%:50%) Indications: Relapsed/refractory advanced/metastatic renal cell carcinoma, relapsed/refractory advanced/metastatic skin squamous-cell carcinoma, and relapsed/refractory advanced/metastatic melanoma.
88863909|NCT04234048|Experimental|Phase 1|"Accelerated Phase 1a + Standard Phase 1a + Phase 1b~Accelerated Phase 1a~Up to 8 patients for accelerated phase 1a (single patient cohort); dose levels of ST-001 nanoFenretinide (mg/m^2/day X 5 days every 21 days):~Dose Level 1 1.25 (1 patient) Dose Level 2 2.5 (1 patient) Dose Level 3 5.0 (1 patient) Dose Level 4 10 (1 patient) Dose Level 5 20 (1 patient) Dose Level 6 40 (1 patient) Dose Level 7 80 (1 patient) Dose Level 8 160 (1 patient)~Standard Phase 1a~Up to 18 patients for standard phase 1a (3+3 design); dose level (mg/m2/day X 5 days every 21 days):~Dose Level 9 320 (3-6 patients) Dose Level 10 448 (3-6 patients) Dose Level 11 627 (3-6 patients)~Phase 1b~20 patients for phase 1b at the maximum tolerated dose (MTD)"
88863910|NCT04225351|Experimental|MCAF+CM|Modified coronally advanced flap + collagen matrix
88863911|NCT04225351|Active Comparator|MCAT+CM|Modified coronally advanced tunnel technique + collagen matrix
88863912|NCT04214288|Experimental|AZD9833 Dose A|The patients will receive AZD9833 (Dose A).
89530417|NCT03245125||MDP subjects in HFrEF patients|heart failure patients with reduced ejection fraction (HFrEF) received only multidisciplinary disease management program (MDP) and underwent less than 36 times of high-intensity interval training (HIIT) or no exercise training
88863913|NCT04214288|Experimental|AZD9833 Dose B|The patients will receive AZD9833 (Dose B).
88863914|NCT04214288|Experimental|AZD9833 Dose C|The patients will receive AZD9833 (Dose C).
88863915|NCT04214288|Active Comparator|Fulvestrant 500 mg|The patients will receive Fulvestrant (500 mg).
88863916|NCT04210687|Active Comparator|Trapeziectomy|Standard simple trapeziectomy, no pins.
88863917|NCT04210687|Active Comparator|trapeziometacarpal limited excision|Trapeziometacarpal limited excision; Narrow pseudarthrosis of the trapeziometacarpal joint.
88863918|NCT04187612||Total body water measurement|Total body water will be measured using Bioelectrical Impedance Analysis (BIA).
88863919|NCT04181359|Experimental|Nitric Oxide|Inhaled nitric oxide, which consists of breathing medical grade air (21% O2) with 40 parts per million of nitric oxide.
88863920|NCT04181359|Placebo Comparator|Placebo|Inhaled placebo, which consists of breathing medical grade air (21% O2).
88863921|NCT04165109||Trial Ready Cohort|Non-demented adults with Down syndrome (DS)
88863922|NCT04160390||Arm I (biospecimen collection)|Patients undergo collection of blood prior to transplant, on day 0, days 3-7, day 14, and day 21. Patients also undergo collection of saliva prior to transplant and collection of stool prior to and post-transplant. Donors undergo collection of blood and saliva within 8 weeks prior to donation.
88863923|NCT04150913|Experimental|Anakinra and Axicabtagene Ciloleucel|"Patients who meet eligibility criteria for the study will subsequently be enrolled for treatment.~Screening~Enrollment/Leukapheresis period~Bridging therapy (if applicable)~Lymphodepleting chemotherapy period~Investigational Product (IP) treatment period~Anakinra~Axicabtagene Ciloleucel~Post treatment assessment period~Long term follow-up period"
88863924|NCT04144140|Experimental|Dose Escalation: Advanced Solid Tumors or Lymphomas|
88863925|NCT04144140|Experimental|Dose Expansion: Advanced Solid Tumors or Lymphomas|Dose identified from dose escalation part for E7766 will be used in dose expansion part.
88863926|NCT04139577|Experimental|Fecal Microbiota Transplant (FMT) FOR HIGH-RISK ACUTE GVHD|"The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits.~this research study for up to 6 months. You may receive up to 2 cycles of the study treatment.~- Fecal Microbiota Transplant ( FMT)- Oral Study Drug, predetermined dosage and timings, up to 2 cycles.~One cycle of treatment consists of one induction week of FMT followed by three weeks of maintenance FMT.~The maintenance weeks happen for 3 weeks after the induction week.~All doses will be administered in the clinic.~A second cycle of treatment as deemed appropriate"
88863927|NCT04130737|Experimental|TORUS Stent Graft System|The TORUS Stent Graft System (SGS) is comprised of a Stent Graft (SG) and a Stent Graft Delivery System (SGDS).
88863928|NCT04119362||Patients with pancreatic adenocarcinoma|Patients with metastatic pancreatic cancer receiving will be asked to fill in an EORTC QLQ-C30 questionnaire and additional questionnaires on worries about quality of life impairments and physical constitiution every 8 weeks, over the entire course of treatment, starting with neo-/adjuvant or 1st line therapy follow. There is no restriction on type of therapy. No further intervention.
88863929|NCT04111705|Experimental|Lorlatinib|100 mg once daily
88863930|NCT04108026|Experimental|Immunotherapy|Durvalumab 1500 mg every 4 weeks until the progression of disease, discontinuation due to toxicity or withdrawal of consent, for a maximum duration of 2 years.
88863931|NCT04107038|Active Comparator|General|Participants randomized to group A will receive general endotracheal anesthesia as their anesthetic procedure.
88863932|NCT04107038|Active Comparator|Sedation|Participants randomized to group B will receive monitored anesthesia care as their anesthetic procedure.
89535317|NCT03091569|Active Comparator|Vitamin K|
89535318|NCT03091569|Placebo Comparator|Control|
88863933|NCT04103112|No Intervention|Standard clinical care|Standard clinical care (anticoagulation) with no graduated compression stocking
88863934|NCT04103112|Experimental|Graduated compression stocking and standard clinical care|A graduated compression stocking and the standard clinical care (anticoagulation)
88863935|NCT04088890|Experimental|R/R ALL|"Relapsed/refractory ALL~Lymphodepletion prior to CD22 CAR T cell infusion (Day 0) will occur as follows:~Fludarabine 30 mg/m2 per day IV for days 5, 4, 3~Cyclophosphamide 500 mg/m2 per day IV for days 5, 4, 3~Autologous CD22 CAR T cells will be administered intravenously at Dose1: 3 x 10^5cells/kg (± 20%) 10"
88863936|NCT04088890|Experimental|R/R aggressive B-cell NHL|"Relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.~Lymphodepletion prior to CD22 CAR T cell infusion (Day 0) will occur as follows:~Fludarabine 30 mg/m2 per day IV for days 5, 4, 3~Cyclophosphamide 500 mg/m2 per day IV for days 5, 4, 3~Autologous CD22-CAR T cells will be administered in 3 escalating doses (Dose Level 1, 2, and 3) to determine MTD/RP2D.~Dose1: 1 x 10^6 cells/kg (± 20%) Dose2: 3 x 10^6 cells/kg (± 20%) Dose3: 1 x 10^7 cells/kg (± 20%)"
88863937|NCT04085523|Experimental|TransCon CNP 6 mcg|TransCon CNP 6 mcg CNP/kg delivered once weekly by subcutaneous injection.
88863938|NCT04085523|Experimental|TransCon CNP 20 mcg|TransCon CNP 20 mcg CNP/kg delivered once weekly by subcutaneous injection.
88863939|NCT04085523|Experimental|TransCon CNP 50 mcg|TransCon CNP 50 mcg CNP/kg delivered once weekly by subcutaneous injection.
88863940|NCT04085523|Experimental|TransCon CNP 100 mcg|TransCon CNP 100 mcg CNP/kg delivered once weekly by subcutaneous injection.
88863941|NCT04085523|Placebo Comparator|Placebo|Placebo mimicking 6, 20, 50, or 100 mcg CNP/kg delivered once weekly by subcutaneous injection.
88863942|NCT04085523|Experimental|Open-Label Extension Period|Subjects who complete the 52-week blinded treatment period can continue into the 104-week open-label extension period and will receive treatment with TransCon CNP.
88863943|NCT04082637|Experimental|MABT* + Medication Treatment|Mindful Awareness in Body-oriented Therapy + Medication Treatment
88863944|NCT04082637|No Intervention|Treatment as Usual|Treatment as Usual is medication for the treatment of opioid use disorder
88863945|NCT04081493|Experimental|Group 1 (BFRE)|Low-load blood flow restricted exercise 3/weekly for 8 weeks before TKR 10-min warm-up followed by unilateral leg press and unilateral knee extension
89388407|NCT05257629|Other|Varenicline Plus Counseling|All patients will begin varenicline in-hospital upon randomization. For the first 3 days, patients will take a 0.5 mg tablet once a day. They will then take a 0.5 mg tablet twice a day for the following 4 days, and one 1 mg tablet twice a day from day 8 onward for the remainder of the 12-week treatment. Use will be monitored via self-report for telephone follow-ups and return of all unused tablets at the end of the treatment period. Should a patient experience severe side effects (such as headache, nausea, vomiting, dizziness, dyspepsia, fatigue, insomnia, abnormal dreams, constipation, or flatulence) on day 8 onward, the varenicline dose should be reduced from 1 mg twice daily to 0.5 mg twice daily prior to study medication discontinuation.
89388408|NCT05241015|Active Comparator|Control Group|Patients in this group will receive standard physiotherapy program used for PD will be applied, 3 times a week for 8 weeks.
89388409|NCT05241015|Experimental|Exercises Group|In addition to standard physiotherapy programme, patients in this group will also receive sensorimotor training.
89388410|NCT05237531|Experimental|Experimental Arm|"Patients in the experimental arm will receive standardized preoperative education in the form of a brief video, interactive quiz, and written handout.~All patients will receive standardized multimodal pain management consisting of a long-acting peripheral nerve block, scheduled non-opioid pain medications, an opioid prescription to be taken only as needed, and adjunctive medicines to be taken as needed for any side effects."
89388411|NCT05237531|Active Comparator|Control Arm|"Patients in the control arm will receive education per the provider's preference (current standard of care).~All patients will receive standardized multimodal pain management consisting of a long-acting peripheral nerve block, scheduled non-opioid pain medications, an opioid prescription to be taken only as needed, and adjunctive medicines to be taken as needed for any side effects."
89388412|NCT05235282|Experimental|Usual care + IQoro|The intervention group receives usual training of swallowing function along with training 3 times each day with an IQoro oral screen
89388413|NCT05235282|Active Comparator|Usual care|The comparison group receives usual training of swallowing function
89388414|NCT05234112|Experimental|Uganda, India, Bangladesh|hrHPV self-test, followed by VIA inspection for hrHPV-positive women.
89388415|NCT05234112|Experimental|Slovakia|hrHPV self-test, followed by Pap-smear for cytology
89388416|NCT05221580||Real-world adult population of Chinese patients with T2DM|Ryzodec as per local clinical practise
89388417|NCT05218967|Experimental|In-office procedure with VR-assistance|
89388418|NCT05218967|No Intervention|In-office procedure without VR-assistance|
89185591|NCT00738530|Placebo Comparator|Placebo + IFN-Alfa-2A|Placebo matched with Bevacizumab infusions will be administered every 2 weeks for 52 weeks or until disease progression or unacceptable toxicity. IFN-Alfa-2A will be administered 3 times per week as a subcutaneous injection at a dose of 9 MIU for 52 weeks or until disease progression or major toxicity.
89185592|NCT00711009|Active Comparator|LPV/r + FTC/TDF|lopinavir/ritonavir 400/100 milligram (mg) tablet twice-daily + co-formulated emtricitabine/tenofovir disoproxil fumarate 200/300 mg once-daily
89185593|NCT00711009|Experimental|LPV/r + RAL|lopinavir/ritonavir 400/100 mg tablet twice-daily + raltegravir 400 mg twice-daily
89185594|NCT04076124|Experimental|Active rTMS-DLPFC|This active group will receive high-frequency repetitive TMS stimulation.
88863946|NCT04081493|No Intervention|Group 2 (CON)|No training before TKR
88863947|NCT04053478|Experimental|Myometrium + Ephedrine|The myometrial samples are bathed in physiological salt solution (PSS) with increasing concentrations of ephedrine
89185595|NCT04076124|Experimental|Active iTBS-DLPFC|This active group will receive intermittent theta-burst TMS stimulation.
89185596|NCT04076124|Sham Comparator|Sham TBS-DLPFC or Sham rTMS-DLPFC|Patients in the sham group will receive the same iTBS or rTMS parameter stimulation, performing by a sham coil.
89185597|NCT02592902|Active Comparator|Recurrent respiratory papillomatosis|Patients with recurrent respiratory papillomatosis (RRP) - surgical collection of histology specimen from the vocal cords and rear laryngeal commissure, performance of immunohistochemical analysis - proof of pepsin, HPV 6 and 11, herpes simplex virus (HSV) type 2, chlamydia trachomasis, and assessment of the dysplasia.
89388419|NCT05207813||Basivertebral nerve ablation treatment|Patient-reported outcomes at three (3) follow-up visits for previously treated participants from the CLBP Single-Arm study.
89388420|NCT05204329|Active Comparator|Low dose of allogenic MSC drops|Escalating doses of allogenic MSC eye drops will be assigned at the lowest dose level.
89388421|NCT05204329|Active Comparator|Medium dose of allogenic MSC drops|Escalating doses of allogenic MSC eye drops will be assigned at the medium dose level.
89388422|NCT05204329|Active Comparator|High dose of allogenic MSC drops|Escalating doses of allogenic MSC eye drops will be assigned at the high dose level.
89388423|NCT05201495|Experimental|Treatment|Jewel Patch Wearable Cardioverter Defibrillator (P-WCD)
89388424|NCT05192798|Active Comparator|Group of albumin-bound paclitaxel|Albumin-bound paclitaxel (260mg/m2, intravenous infusion, once every 3 weeks).
88863948|NCT04053478|Experimental|Myometrium + Phenylephrine|The myometrial samples are bathed in physiological salt solution (PSS) with increasing concentrations of phenylephrine
88863949|NCT04053478|Experimental|Myometrium + Norepinephrine|The myometrial samples are bathed in physiological salt solution (PSS) with increasing concentrations of norepinephrine
88863950|NCT04053478|Experimental|Myometrium + Vasopressin|The myometrial samples are bathed in physiological salt solution (PSS) with increasing concentrations of vasopressin
88863951|NCT04053478|Experimental|Umbilical artery + Ephedrine|The umbilical artery samples are bathed in physiological salt solution (PSS) with increasing concentrations of ephedrine
88863952|NCT04053478|Experimental|Umbilical artery + Phenylephrine|The umbilical artery samples are bathed in physiological salt solution (PSS) with increasing concentrations of phenylephrine
88863953|NCT04053478|Experimental|Umbilical artery + Norepinephrine|The umbilical artery samples are bathed in physiological salt solution (PSS) with increasing concentrations of norepinephrine
88863954|NCT04053478|Experimental|Umbilical artery + Vasopressin|The umbilical artery samples are bathed in physiological salt solution (PSS) with increasing concentrations of vasopressin
88863955|NCT04053478|Experimental|Umbilical vein + Ephedrine|The umbilical vein samples are bathed in physiological salt solution (PSS) with increasing concentrations of ephedrine
88863956|NCT04053478|Experimental|Umbilical vein + Phenylephrine|The umbilical vein samples are bathed in physiological salt solution (PSS) with increasing concentrations of phenylephrine
88863957|NCT04053478|Experimental|Umbilical vein + Norepinephrine|The umbilical vein samples are bathed in physiological salt solution (PSS) with increasing concentrations of norepinephrine
88863958|NCT04053478|Experimental|Umbilical vein + Vasopressin|The umbilical vein samples are bathed in physiological salt solution (PSS) with increasing concentrations of vasopressin
88863959|NCT04024254|Experimental|Folic Acid|Folic Acid supplement 1 mg by mouth daily
88863960|NCT04024254|No Intervention|No Supplementation|
88863961|NCT04022577|Experimental|experimental group|The experimental group will participate in a eight session course of Adherence Therapy
88863962|NCT04022577|Placebo Comparator|control group|The control group received routine care
88863963|NCT04000659|Experimental|Episealer Knee System|The experimental arm will comprise of subjects that will be treated with the Episealer Knee System.
88863964|NCT04000659|Placebo Comparator|Microfracture|The control arm will comprise of subjects that will receive a Microfracture surgery.
88863965|NCT03991988|Experimental|Montelukast Group|Montelukast (10, 20, or 40 mg)
88863966|NCT03991988|Placebo Comparator|Placebo Group|Matched placebo pill
88863967|NCT03986216|Experimental|Home based group|This group will involve 2-4 randomly selected participants who have already completed the lab based sessions. They will use the developed reliable and intuitive control of the paretic hand device (ReIn-Hand device) to assist them to practice 'reach-grasp-retrieve-release' movements at home, 1 hours per day (20 trials), 7 days per week for 12 weeks.
89388425|NCT05192798|Experimental|Group of albumin-bound paclitaxel combined with apatinib|Albumin-bound paclitaxel (260mg/m2, intravenous infusion, once every 3 weeks)+ apatinib mesylate tablet (500 mg, orally, once daily, every 3 weeks).
88863969|NCT03982485|Experimental|Arm I|Apatinib+Paclitaxel+Cisplatin
88863970|NCT03982485|Active Comparator|Arm II|Paclitaxel+Cisplatin
88863971|NCT03973333|Experimental|IMC-C103C - Monotherapy IV dose escalation|n= approximately 50 patients to establish the MTD/expansion dose
88863972|NCT03973333|Experimental|IMC-C103C and atezolizumab dose escalation|n=approximately 12 patients to establish the MTD/expansion dose
88863973|NCT03973333|Experimental|IMC-C103C - expansion|Patients will be enrolled n=9-24 per expansion cohort (up to 4 total): metastatic/unresectable tumors of interest patients treated at the expansion dose of IMC-C103C to assess preliminary anti-tumor efficacy
88863974|NCT03973333|Experimental|IMC-C103C monotherapy SC dose escalation|Patients will be enrolled n=9-12 to establish the MTD/expansion dose
88863975|NCT03963895|Experimental|AB002 (E-WE-thrombin) Dose 1|Participants will receive a single dose of 1.5 mcg/kg E-WE thrombin.
88863976|NCT03963895|Experimental|AB002 (E-WE-thrombin) Dose 2|Participants will receive a single dose of 3.0 mcg/kg E-WE thrombin.
88863977|NCT03963895|Placebo Comparator|Placebo|Participants will receive a single dose of placebo
88863978|NCT03945591|Experimental|Cyclophosphamide and Bortezomib|
88863979|NCT03943589|Experimental|Imlifidase|"One (1) dose of imlifidase, 0.25 mg/kg, will be administered IV over 30 minutes, Day 1.~IVIg, 0.4 g/kg, will be administered for 5 consecutive Days, starting on Day 3 at least 48 h after imlifidase administration."
88863980|NCT03937154|Experimental|Romiplostim|The study in a 2:1 randomization ratio(108 subjects to romiplostim). Amgen investigational product (romiplostim or placebo) will be administered in the clinic by a qualified healthcare provider as a subcutaneous injection.
88863981|NCT03937154|Placebo Comparator|Placebo|The study in a 2:1 randomization ratio (54 subjects to placebo) Amgen investigational product (romiplostim or placebo) will be administered in the clinic by a qualified healthcare provider as a subcutaneous injection.
88863982|NCT03915899|Experimental|WIN Intervention|WIN Intervention
89185598|NCT02592902|Active Comparator|Laryngeal cyst - control group|Patients with laryngeal cyst - surgical collection of a histology specimen from the vocal cords and rear laryngeal commissure, performance of immunohistochemical analysis - proof of pepsin and HPV 6 and 11, herpes simplex virus (HSV) type 2 and chlamydia trachomasis.
89185599|NCT04062513|Experimental|Olfactive stimulation intervention with familiarization|Participants will receive the olfactive stimulation intervention with mothers' milk odor during a previous period of nine hours and during heel prick. Sucrose will be also administered during heel prick.
88863983|NCT03915899|No Intervention|Standard of Care|No WIN intervention.
88863984|NCT03913104|Experimental|Medication Abortion Patients|Oral Mifepristone 200 mg, followed by misoprostol 800 mcg administered buccally (at 24-48 hours following mifepristone) or vaginally (as soon as 6 hours following mifepristone)
88863985|NCT03909282|Active Comparator|Surgical Excision|Surgical excision of ductal carcinoma
88863986|NCT03909282|Experimental|Neoadjuvant partial breast irradiation|Partial breast irradiation will be delivered once a day for 5 days before surgery. The planned daily dose is 6 Gy.
88863987|NCT03899792|Experimental|LOXO-292|Phase 1- Dose Escalation and determination of MTD; multiple dose levels of LOXO-292 to be evaluated; Phase 2 - The MTD/recommended dose from Phase 1
88863988|NCT03896789|No Intervention|Baseline|All sites will collect usual care data from 9 months to 21 months.
88863989|NCT03896789|Experimental|PEGASUS Program (Intervention)|This arm (half of the sites) will receive the PEGASUS program (intervention) from 21 months to 57 months.
88863990|NCT03896789|No Intervention|Usual Care (Control)|This arm (half of the sites) will maintain usual care. They will receive the opportunity for the PEGASUS program training (intervention) at the end of study data collection (57 months) period.
88863991|NCT03875716|Experimental|Low Risk|"Observation without adjuvant therapy~Pathologic T0-2, N0-1~Minimum of 15 lymph nodes retrieved on neck dissection per dissected side of the neck~Single positive lymph node up to 3cm~No extranodal extension~Clear margins"
89185600|NCT04062513|Experimental|Olfactive stimulation intervention|Participants will receive the olfactive stimulation intervention with mothers' milk odor during heel prick only. Sucrose will be also administered during heel prick.
89185601|NCT04062513|Other|Standard care|In the control arm, participants will receive the standard care for pain which is sucrose administration.
89388426|NCT05192798|Experimental|Group of albumin-bound paclitaxel combined with bevacizumab|Albumin-bound paclitaxel (260mg/m2, intravenous infusion, once every 3 weeks) + bevacizumab (7.5mg/kg, intravenous infusion, once every 3 weeks).
89388427|NCT05191706|Experimental|DEXYCU (dexamethasoneintraocular suspension) 9%|A single 0.005-mL anterior chamber injection of DEXYCU (dexamethasoneintraocular suspension) 9%, equivalent to 517mcg dexamethasone.
89388428|NCT05191706|Active Comparator|Prednisolone acetate ophthalmic suspension (USP) 1%|Active treatment control, prednisolone acetate ophthalmic suspension (USP) 1%, four times daily (QID) for 28days, followed by a treatment taper at the investigator's discretion.
89388429|NCT05183763|Experimental|STAR-MAP|Interactive health coaching sessions and medication reminder tools
89388430|NCT05183763|Active Comparator|Medication App and Reminder System Medication Adherence Program (MARS-MAP)|Medication reminder tools only
89388431|NCT05180097|Active Comparator|GDP|
89388432|NCT05180097|Active Comparator|Brentuximab vedotin + Pembrolizumab|
89388433|NCT05178043|Experimental|GT90001+Nivolumab|
89185602|NCT04075890|Active Comparator|Healthy subjects|
89388434|NCT05172999|Active Comparator|LNG-IUS|enrolled patients will receive LNG-IUS for 6 months or longer till complete response
89388435|NCT05172999|Experimental|LOX+LNG-IUS|enrolled patients will receive LNG-IUS plus polyethylene glycol loxenatide for treatment.
89388436|NCT05167903|Experimental|Time-restricted eating|Participants in the TRE group will be instructed to consume all meals between 12pm to 8pm (8 h eating window with 16 h of fasting)
89388437|NCT05167903|Experimental|Normal Diet (ND)|The ND group will consume all meals between 6 am - 10 pm (16 h eating window with 8 h of fasting, ad-libitum)
89388438|NCT05163808|Active Comparator|Study Drug|Subjects will receive 15 mg BID or 25mg BID dose of BPN14770
89388439|NCT05163808|Placebo Comparator|Placebo Arm|Subjects will receive matching Placebo
89388440|NCT05155293|Experimental|AVT06 (proposed aflibercept biosimilar)|Patients will receive 1 IVT injection of AVT06 every 4 weeks for the first 3 consecutive doses, followed by 1 IVT injection every 8 weeks through study completion.
89185603|NCT04075890|Active Comparator|OCD subjects|
89185604|NCT04087850|Experimental|Making Socially Accepting Inclusive Classrooms (MOSAIC)|
89388441|NCT05155293|Experimental|Eylea® (Aflibercept)|Patients will receive 1 IVT injection of Eylea® every 4 weeks for the first 3 consecutive doses, followed by 1 IVT injection every 8 weeks through study completion.
89388442|NCT05144555|Experimental|Group MET|Patients from this group will undergo orthodontic fixed treatment with stainless steel brackets.
89388443|NCT05144555|Active Comparator|Group CER|Patients from this group will undergo orthodontic fixed treatment with ceramic brackets.
89388444|NCT05133128|Other|PATIENTS with cancer and HEALTHY VOLUNTEERS|"Cohort 1: Patients with Non-Small Cell Lung cancer (25 patients)~Cohort 2: Patients with Colorectal cancer (25 patients)~Cohort 3: Patients with Pancreatic cancer (25 patients)~Cohort 4: Patients with Liver cancer (25 patients)~Cohort 5: Patients with Gastric cancer/cholangiocarcinoma (25 patients)~Cohort 6: Healthy volunteers (25 subjects)"
89388445|NCT05132842||Observational (survey)|Patients complete a survey about knowledge and awareness of medical cannabis, perceived risks and benefits of cannabis, mode and frequency of use (if applicable), impact on cancer-related symptoms, patient provider discussions about cannabis, and demographic characteristics including health and digital literacy.
89388446|NCT05124821||Certofix Paed|Paediatric patients in need for short-term (≤ 30 days) catheterisation of the superior vena cava using the Seldinger technique for infusion and volume therapy or parenteral nutrition, for administration of highly osmolar or very vein-irritating solutions/drugs, for continuous or intermittent monitoring of the central venous pressure, for blood sampling, or when peripheral venous puncture is not possible in state of shock, in patients with injured extremities or no detectable peripheral veins.
89388447|NCT05112198|Experimental|Noona web-based symptom tracking tool|In addition to usual care for their disease, patients interact with Noona system and system questioners to record their symptoms over a period of 6 months.
89388448|NCT05112198|No Intervention|Usual Care|Participants will receive the standard of care for their disease
89185605|NCT04087850|No Intervention|Typical Practice Control|
89185606|NCT03825510|Experimental|Treatment Arm|
89185607|NCT00921219|Experimental|Ivermectin|ivermectin
89185608|NCT04076514||patients with node negative papillary thyroid carcinoma|
89185609|NCT02567097|Active Comparator|Control|Participants read a brief statement designed to encourage them to quit smoking (we would like you to plan to quit smoking). Participants are then asked to form their plan to quit smoking.
89388449|NCT05104463|Experimental|CST-2032 (3mg)/CST-107 (3mg) to Placebo|Subjects will receive daily doses of CST-2032 (3mg) co-administered with CST-107 (3mg) for 14 days, followed by a washout period of no drug for 7 days, followed by matching placebo for CST-2032 and matching placebo for CST-107 for 14 days.
89388450|NCT05104463|Experimental|Placebo to CST-2032 (3mg)/CST-107 (3mg)|Subjects will receive matching placebo for CST-2032 and matching placebo for CST-107 for 14 days followed by a washout period of no drug for 7 days, followed by daily doses of CST-2032 (3mg) co-administered with CST-107 (3mg) for 14 days.
89388451|NCT05104463|Experimental|CST-2032 (6mg)/CST-107 (3mg) to Placebo|Subjects will receive daily doses of CST-2032 (6mg) co-administered with CST-107 (3mg) for 14 days, followed by a washout period of no drug for 7 days, followed by matching placebo for CST-2032 and matching placebo for CST-107 for 14 days.
89388452|NCT05104463|Experimental|Placebo to CST-2032 (6mg)/CST-107 (3mg)|Subjects will receive matching placebo for CST-2032 and matching placebo for CST-107 for 14 days followed by a washout period of no drug for 7 days, followed by daily doses of CST-2032 (6mg) co-administered with CST-107 (3mg) for 14 days.
89388453|NCT05102682|Experimental|Balance rehabilitation exercise|Balance rehabilitation exercise program using exoskeleton device
89388454|NCT05089656|Experimental|OAV101|OAV101 administered as a single, one-time intrathecal dose of 1.2 x 10^14 vector genomes (vg).
88863992|NCT03875716|Experimental|Intermediate Risk|"Reduced-dose radiation (46Gy)~Pathologic T0-2N0-2 and any one of the following features:~2 or more positive lymph nodes~single node >3cm~<15 lymph nodes retrieved on neck dissection for each side of the neck~Positive lymph nodes in level IB, IV, or V~-≤1mm extranodal extension~Positive lymph node(s) contralateral to the primary tumor~Close margins"
88863993|NCT03875716|Experimental|High Risk|"Postoperative radiation (60Gy) without chemotherapy~Pathologic T0-4N0-2 and any one of the following features:~->1mm extranodal extension~Microscopic positive margins"
88863994|NCT03869515||chILD|The chILD syndrome exists when a child with DLD has had the common causes of DLD excluded as the primary diagnosis and has at least three of the following four criteria: (1) respiratory symptoms (e.g., cough, rapid and/or difficult breathing, or exercise intolerance); (2) respiratory signs (e.g., resting tachypnea, adventitious sounds, retractions, digital clubbing, failure to thrive, or respiratory fail- ure); (3) hypoxemia; and (4) diffuse abnormalities on CXR or a CT scan.
89185610|NCT02567097|Active Comparator|Implementation Intention|Participants read a brief statement designed to encourage them to quit smoking (we would like you to plan to quit smoking). Participants are then asked to form a specific 'if-then' plan using an implementation intention basis.
89388455|NCT05089656|Sham Comparator|Sham control|A skin prick in the lumbar region without any medication.
89388456|NCT05089630|Experimental|Pentamer(low)/gB(low)/Adjuvant Group|Participants receive the candidate CMVsu vaccine consisting of a combination of low dose pentamer and low dose gB antigens, adjuvanted at 0, 2 and 6 months and are followed up until end of EPOCH 1 (Day 546). At the end of EPOCH 1, participants will have the option to enroll in the optional extension study (EPOCH 2-passive safety follow-up phase), and the participants that will agree to continue their enrollment will be followed up until Month 48 after end of EPOCH 1.
89388457|NCT05089630|Experimental|Pentamer (med)/gB(low)/Adjuvant Group|Participants receive the candidate CMVsu vaccine consisting of a combination of medium dose pentamer and low dose gB antigens, adjuvanted at 0, 2 and 6 months and are followed up until end of EPOCH 1 (Day 546). At the end of EPOCH 1, participants will have the option to enroll in the optional extension study (EPOCH 2-passive safety follow-up phase), and the participants that will agree to continue their enrollment will be followed up until Month 48 after end of EPOCH 1.
89388458|NCT05089630|Experimental|Pentamer (med)/gB(med)/Adjuvant Group|Participants receive the candidate CMVsu vaccine consisting of a combination of medium dose pentamer and medium dose gB antigens, adjuvanted at 0, 2 and 6 months and are followed up until end of EPOCH 1 (Day 546). At the end of EPOCH 1, participants will have the option to enroll in the optional extension study (EPOCH 2-passive safety follow-up phase), and the participants that will agree to continue their enrollment will be followed up until Month 48 after the end of EPOCH 1.
89388459|NCT05089630|Experimental|Pentamer (high)/gB(med)/Adjuvant Group|Participants receive the candidate CMVsu vaccine consisting of a combination of high dose pentamer and medium dose gB antigens, adjuvanted at 0, 2 and 6 months and are followed up until end of EPOCH 1 (Day 546). At the end of EPOCH 1, participants will have the option to enroll in the optional extension study (EPOCH 2-passive safety follow-up phase), and the participants that will agree to continue their enrollment will be followed up until Month 48 after the end of EPOCH 1.
89388460|NCT05089630|Placebo Comparator|Placebo Group|Participants receive placebo (saline) at 0,2 and 6 months and are followed up until end of EPOCH 1 (Day 546). At the end of EPOCH 1, participants will have the option to enroll in the optional extension study (EPOCH 2-passive safety follow-up phase), and the participants that will agree to continue their enrollment will be followed up until Month 48 after end of EPOCH 1.
88863995|NCT03869515||Control|Healthy subjects were recruited from participants of an ongoing prospective birth cohort study: 'The Pulmonary Function Assessment for Bronchopulmonary Dysplasia (BPD) and Recurrent Lower Respiratory Tract Infections (LRTI) in Chinese Children'. Exclusion criteria were major birth defects, upper airway pathology, cardiac or neurological diseases, failure to thrive, a history of severe respiratory disease with intensive care unit admission, previous physician-diagnosed LRTI, gestational age (GA) <37 weeks or birthweight (BW) <2.5 kg.
89388461|NCT05087329|Experimental|Virtual Mindfulness intervention|Four weekly group Zoom webinars with a 15-20 minute pre-recorded meditation
89388462|NCT05087329|No Intervention|Standard of Care|
88863996|NCT03864458|Experimental|KHK7791 A|Patients take KHK7791 low dose BID.
89388463|NCT05084508|Experimental|VNS_Low Group|Healthy children aged 12 to 15 months of age receive 1 dose of an investigational varicella vaccine (VNS) of low potency 1 dose of a measles, mumps, and rubella vaccine, 1 dose of a hepatitis A vaccine and 1 dose of a13 valent pneumococcal conjugate vaccine on Day 1. The 13 valent pneumococcal conjugate vaccine will only be administered to participants enrolled in the US and in countries where pneumococcal conjugate vaccine is recommended at 12-15 months as per national immunization schedule.
89388464|NCT05084508|Experimental|VNS_Med Group|Healthy children aged 12 to 15 months of age receive 1 dose of an investigational varicella vaccine (VNS) of medium potency, 1 dose of a measles, mumps, and rubella vaccine, 1 dose of a hepatitis A vaccine, and 1 dose of a 13-valent pneumococcal conjugate vaccine on Day 1. The 13 valent pneumococcal conjugate vaccine will only be administered to participants enrolled in the US and in countries where pneumococcal conjugate vaccine is recommended at 12-15 months as per national immunization schedule.
89388465|NCT05084508|Experimental|VNS_High Group|Healthy children aged 12 to 15 months of age receive 1 dose of an investigational varicella vaccine (VNS) of high potency 1 dose of a measles, mumps, and rubella vaccine, 1 dose of a hepatitis A vaccine, and 1 dose a 13-valent pneumococcal conjugate vaccine on Day 1. The 13 valent pneumococcal conjugate vaccine will only be administered to participants enrolled in the US and in countries where pneumococcal conjugate vaccine is recommended at 12-15 months as per national immunization schedule.
88863997|NCT03864458|Experimental|KHK7791 B|Patients take KHK7791 middle dose BID.
89388466|NCT05084508|Active Comparator|VV_Lot1 and Lot2 Pooled Group|Healthy children aged 12 to 15 months of age receive 1 dose of a marketed varicella vaccine (VV) of Lot 1 or 1 dose of a marketed varicella vaccine (VV) of Lot 2, 1 dose of a measles, mumps, and rubella vaccine, 1 dose of a hepatitis A vaccine, and a 1 dose of a 13-valent pneumococcal conjugate vaccine on Day 1. The 13 valent pneumococcal conjugate vaccine will only be administered to participants enrolled in the US and in countries where pneumococcal conjugate vaccine is recommended at 12-15 months as per national immunization schedule.
89388467|NCT05078775|Experimental|Nonessential Amino Acid Restriction (NEAAR) Medical Food|This is a single arm study in which all subjects will receive NEAAR medical food.
89388468|NCT05075603|Experimental|NT-I7 after CAR-T (Kymriah, Yescarta, or Breyanzi) infusion|CAR-T infusion administered per standard of care at Day 0 followed by NT-I7 on Day 21.
89388469|NCT05074810|Experimental|avutometinib (VS-6766)+sotorasib|To determine the recommended phase 2 dose (RP2D) for avutometinib (VS 6766) in combination with sotorasib in KRAS G12C inhibitor naïve and exposed patients
89388470|NCT05074810|Experimental|avutometinib (VS-6766)+sotorasib - KRAS G12C inhibitor naïve|To determine the efficacy of the RP2D identified from Part A in KRAS G12C inhibitor naïve patients
89388471|NCT05074810|Experimental|avutometinib (VS-6766)+sotorasib - KRAS G12C inhibitor exposed|To determine the efficacy of the RP2D identified from Part A in KRAS G12C inhibitor exposed patients
89388472|NCT05074810|Experimental|avutometinib (VS-6766)+sotorasib+defactinib|To determine the recommended phase 2 dose (RP2D) for avutometinib (VS-6766) in combination with sotorasib and defactinib in KRAS G12C inhibitor exposed patients
89388473|NCT05074810|Experimental|avutometinib (VS-6766)+sotorasib+defactinib - KRAS G12C inhibitor naive|To determine the efficacy of the RP2D identified from Part A in KRAS G12C inhibitor naïve patients
89388474|NCT05074810|Experimental|avutometinib (VS-6766)+sotorasib+defactinib - KRAS G12C inhibitor exposed|To determine the efficacy of the RP2D identified from Part A in KRAS G12C inhibitor exposed patients
88863998|NCT03864458|Experimental|KHK7791 C|Patients take KHK7791 high dose BID.
88863999|NCT03864458|Experimental|KHK7791 D|Patients start at KHK7791 high dose and can down titrate weekly ,based on a GI tolerability question.
88864000|NCT03864458|Placebo Comparator|Placebo|Patients take Placebo BID.
88864001|NCT03864445|Experimental|KHK7791|Patients take KHK7791 BID and can down titrate, based on a GI tolerability question.
88864002|NCT03864445|Placebo Comparator|Placebo|Patients take Placebo BID.
88864003|NCT03862131|Experimental|MyoStrain® unblinded treatment arm|"After consenting to the PROACT study, patients will undergo a baseline MRI to determine their risk stratification for the study. This baseline MyoStrain® MRI must demonstrate 2 or more segments measuring >-10% or 9 or more segments >-17% for entrance into the study as the Higher Risk Group~The unblinded treatment arm will enhance patient management by augmenting standard of care with serial MyoStrain® monitoring of the impact of cancer therapy on myocardial function.~Higher Risk unblinded patients will continue to undergo MyoStrain® MRI testing, regardless of study arm, at 1 month (+1 week), 3 months (+ 1 week), 6 months (+1 week), 12 months (+ 30 days), 24 months (+30 days), and 36 months (+30 days) after the baseline visit.~In addition to the MyoStrain® testing, patients will also be asked to complete a brief patient satisfaction questionnaire at each PROACT time point."
89185611|NCT02567097|Experimental|Weekly Self-Incentivising|Participants read a brief statement designed to encourage them to quit smoking (we would like you to plan to quit smoking). Participants are then asked to specify a self-incentive on which they could implement at the end of each week which they have been successful in not smoking.
89388475|NCT05073003|Placebo Comparator|ST1_Adults_Placebo_GR1 Group|Adults 18 to 50 years of age in Stage 1 (Europe) randomized to receive two doses of altSonflex Placebo, one each at Day 1 and Day 85.
89388476|NCT05073003|Experimental|ST1_Adults_Dose C_GR1 Group|Adults 18 to 50 years of age in Stage 1 (Europe) randomized to receive two doses of altSonflex1-2-3 Dose C vaccine, one each at Day 1 and Day 85.
89388477|NCT05073003|Placebo Comparator|ST1_Adults_Placebo_GR2 Group|Adults 18 to 50 years of age in Stage 1 (Europe) randomized to receive two doses of altSonflex Placebo, one each at Day 1 and Day 169.
89388478|NCT05073003|Experimental|ST1_Adults_Dose C_GR2 Group|Adults 18 to 50 years of age in Stage 1 (Europe) randomized to receive two doses of altSonflex1-2-3 Dose C vaccine, one each at Day 1 and Day 169.
89388479|NCT05073003|Active Comparator|ST2_Adults_Control C Group|Adults 18 to 50 years of age in Stage 2 (Africa) randomized to receive one dose of GSK's Meningococcal A, C, Y and W-135 conjugate vaccine at Day 1 and one dose of GSK's Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine at Day 85.
89535319|NCT03226951|Experimental|Subtherhold 532 nm laser|Applying 532nm subtherhold laser with 5% duty cycle using high density low intensity protocol at the area of non central clinical significant macular edema
89535320|NCT03323255|Active Comparator|cTBS stimulation|continuous theta-burst TMS stimulation (1200 pulses, 50Hz, separated in two sequences of 600 pulses)
89535321|NCT03323255|Sham Comparator|SHAM stimulation (placebo)|SHAM stimulation
89535322|NCT05005767|Placebo Comparator|Placebo group|ten patients with sites suffering from mild chronic periodontitis sites will be treated with scaling and root planing (SRP) only
89185612|NCT02567097|Experimental|Monthly Self-Incentivising|Participants read a brief statement designed to encourage them to quit smoking (we would like you to plan to quit smoking). Participants are then asked to specify a self-incentive on which they could implement at the end of each month which they have been successful in not smoking.
89388480|NCT05073003|Experimental|ST2_Adults_Dose C Group|Adults 18 to 50 years of age in Stage 2 (Africa) randomized to receive two doses of altSonflex1-2-3 Dose C vaccine, one each at Day 1 and Day 85.
89388481|NCT05073003|Active Comparator|ST2_Children_Control B Group|Children 24 to 59 months of age in Stage 2 (Africa) randomized to receive one dose of GSK's Meningococcal A, C, Y and W-135 conjugate vaccine at Day 1 and one dose of Sanofi Pasteur's Typhoid Vi polysaccharide vaccine at Day 85. This group is a control group for children receiving altSonflex1-2-3 Dose B vaccine.
89388482|NCT05073003|Experimental|ST2_Children_Dose B Group|Children 24 to 59 months of age in Stage 2 (Africa) randomized to receive two doses of altSonflex1-2-3 Dose B vaccine, one each at Day 1 and Day 85.
89388483|NCT05073003|Active Comparator|ST2_Children_Control C Group|Children 24 to 59 months of age in Stage 2 (Africa) randomized to receive one dose of GSK's Meningococcal A, C, Y and W-135 conjugate vaccine at Day 1 and one dose of Sanofi Pasteur's Typhoid Vi polysaccharide vaccine at Day 85. This group is a control group for children receiving altSonflex1-2-3 Dose C vaccine.
89185613|NCT02580552|Experimental|Part A, MF|Intratumoral Injection of cobomarsen
89185614|NCT02580552|Experimental|Part B, MF|Subcutaneous, intravenous or a combination of systemic and intratumoral administration of cobomarsen with or without stable background therapy
89185615|NCT02580552|Experimental|Part C, MF|Subcutaneous or intravenous administration of cobomarsen as monotherapy
89388484|NCT05073003|Experimental|ST2_Children_Dose C Group|Children 24 to 59 months of age in Stage 2 (Africa) randomized to receive two doses of altSonflex1-2-3 Dose C vaccine, one each at Day 1 and Day 85.
89388485|NCT05073003|Active Comparator|ST2_Infants_Control A_Safety Group|Infants 9 months of age in Stage 2 (Africa), part of the safety cohort, randomized to receive two doses of GSK's Meningococcal A, C, Y and W-135 conjugate vaccine, one each at Day 1 and Day 85, and one dose of GSK's Diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis (inactivated), and Haemophilus influenzae type b vaccine at Day 253. These infants also receive two doses of Serum Institute of India's Measles and rubella vaccine, one each at Day 29 and Day 281, as concomitant vaccination. This group is a control group for infants receiving altSonflex1-2-3 Dose A vaccine.
89388486|NCT05073003|Experimental|ST2_Infants_Dose A_Safety Group|Infants 9 months of age in Stage 2 (Africa), part of the safety cohort, randomized to receive three doses of altSonflex1-2-3 Dose A, one each at Day 1, Day 85 and Day 253. These infants also receive two doses of Serum Institute of India's Measles and rubella vaccine, one each at Day 29 and Day 281, as concomitant vaccination.
89388487|NCT05073003|Active Comparator|ST2_Infants_Control B_Safety Group|Infants 9 months of age in Stage 2 (Africa), part of the safety cohort, randomized to receive two doses of GSK's Meningococcal A, C, Y and W-135 conjugate vaccine, one each at Day 1 and Day 85, and one dose of GSK's Diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis (inactivated), and Haemophilus influenzae type b vaccine at Day 253. These infants also receive two doses of Serum Institute of India's Measles and rubella vaccine, one each at Day 29 and Day 281, as concomitant vaccination. This group is a control group for infants receiving altSonflex1-2-3 Dose B vaccine.
89530418|NCT03245125||HIIT subjects in HFpEF patients|heart failure patients with preserved ejection fraction (HFpEF) received at least 36 times of high-intensity interval training (HIIT)
89185616|NCT02580552|Experimental|Part D, CLL|Subcutaneous or intravenous administration of cobomarsen as monotherapy
89185617|NCT02580552|Experimental|Part E, DLBCL, activated B-cell (ABC) subtype|Subcutaneous or intravenous administration of cobomarsen as monotherapy
89185618|NCT02580552|Experimental|Part F, ATLL|Subcutaneous or intravenous administration of cobomarsen as monotherapy
89185619|NCT02567331|Experimental|Capecitabine|Participants will receive oral capecitabine 1250 milligrams per square meter (mg/m^2) twice daily for 14 days followed by 7 day rest period for 6 cycles.
89185620|NCT02580396|Other|Patients eligible for CanADVICE+® (smart phone app)|
89185621|NCT05179863||Patient population|Children, adolescents, and adults with a high suspicion, or a confirmed diagnosis of a rare disease who are treated or living in Switzerland.
89185622|NCT04077606|Active Comparator|ceramo-metallic crown|ceramo-metallic crown preparation
89185623|NCT04077606|Active Comparator|monolithic zirconia crown|monolithic zirconia crown preparation
89185624|NCT04077450|No Intervention|Modified Waitlist Control Arm|Participants will complete the following components of baseline (T1) data collection: demographics, questionnaire, heart rate variability assessment. Two weeks later, participants will be asked to complete post-intervention data collection (T2), which consists of a questionnaire and heart rate variability assessment. After the completion of data collection, participants will be offered the online heart-focused breathing intervention.
89189409|NCT05810454|Experimental|iPACES (interactive Physical and Cognitive Exercise System)|"iPACES (interactive Physical and Cognitive Exercise System) involves a pedal-to-play neuro-exergame in which physical and mental exercise are combined in an interactive way. In this condition a person will pedal to control forward motion in a tablet-based game, such as when pedaling along a virtual path and steering to different assigned errand locations."
88864004|NCT03862131|Active Comparator|MyoStrain® blinded control arm|"After consenting to the PROACT study, patients will undergo a baseline MRI to determine their risk stratification for the study. This baseline MyoStrain® MRI must demonstrate 2 or more segments measuring >-10% or 9 or more segments >-17% for entrance into the study as the Higher Risk group~The blinded control arm will provide investigators with LVEF and LVEDV/LVESV measurements, which are clinical, in conjunction with standard of care~Higher Risk blinded patients will continue to undergo MyoStrain® MRI testing, regardless of study arm, at 1 month (+1 week), 3 months (+ 1 week), 6 months (+1 week), 12 months (+ 30 days), 24 months (+30 days), and 36 months (+30 days) after the baseline visit.~In addition to the MyoStrain® testing, patients will also be asked to complete a brief patient satisfaction questionnaire at each PROACT time point."
89388488|NCT05073003|Experimental|ST2_Infants_Dose B_Safety Group|Infants 9 months of age in Stage 2 (Africa), part of the safety cohort, randomized to receive three doses of altSonflex1-2-3 Dose B vaccine, one each at Day 1, Day 85 and Day 253. These infants also receive two doses of Serum Institute of India's Measles and rubella vaccine, one each at Day 29 and Day 281, as concomitant vaccination.
89388489|NCT05073003|Active Comparator|ST2_Infants_Control C_Safety Group|Infants 9 months of age in Stage 2 (Africa), part of the safety cohort, randomized to receive two doses of GSK's Meningococcal A, C, Y and W-135 conjugate vaccine, one each at Day 1 and Day 85, and one dose of GSK's Diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis (inactivated), and Haemophilus influenzae type b vaccine at Day 253. These infants also receive two doses of Serum Institute of India's Measles and rubella vaccine, one each at Day 29 and Day 281, as concomitant vaccination. This group is a control group for infants receiving altSonflex1-2-3 Dose C vaccine.
89388490|NCT05073003|Experimental|ST2_Infants_Dose C_Safety Group|Infants 9 months of age in Stage 2 (Africa), part of the safety cohort, randomized to receive three doses of altSonflex1-2-3 Dose C vaccine, one each at Day 1, Day 85 and Day 253. These infants also receive two doses of Serum Institute of India's Measles and rubella vaccine, one each at Day 29 and Day 281, as concomitant vaccination.
89388491|NCT05073003|Active Comparator|ST2_Infants_Control_Dose find Group|"Infants 9 months of age in Stage 2 (Africa), part of the dose-finding cohort, randomized to receive two doses of GSK's Meningococcal A, C, Y and W-135 conjugate vaccine, one each at Day 1 and Day 85, and one dose of GSK's Diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis (inactivated), and Haemophilus influenzae type b vaccine at Day 253.~These infants also receive two doses of Serum Institute of India's Measles and rubella vaccine, one each at Day 1 and Day 253, as concomitant vaccination. This group is a control group for infants in dose-finding groups receiving either altSonflex1-2-3 Dose A, Dose B or Dose C vaccine."
88864005|NCT03850301|Experimental|Etifoxine then XBD173|
89388492|NCT05073003|Experimental|ST2_Infants_Dose A_Dose find Group|Infants 9 months of age in Stage 2 (Africa), part of the dose-finding cohort, randomized to receive three doses of altSonflex1-2-3 Dose A vaccine, one each at Day 1, Day 85 and Day 253. These infants also receive two doses of Serum Institute of India's Measles and rubella vaccine, one each at Day 1 and Day 253, as concomitant vaccination.
88864006|NCT03850301|Experimental|XBD173 then Etifoxine|
88864007|NCT03816397|Active Comparator|Continue adalimumab|Patients randomized to this arm will continue adalimumab at their current dose (either 20mg/0.2mL or 40mg/0.4mL) administered subcutaneously every other week.
88864008|NCT03816397|Placebo Comparator|Stop adalimumab|Patients randomized to this arm will receive a volume-matched placebo (0.8mL) administered subcutaneously every other week.
89388493|NCT05073003|Experimental|ST2_Infants_Dose B_Dose find Group|Infants 9 months of age in Stage 2 (Africa), part of the dose-finding cohort, randomized to receive three doses of altSonflex1-2-3 Dose B vaccine, one each at Day 1, Day 85 and Day 253. These infants also receive two doses of Serum Institute of India's Measles and rubella vaccine, one each at Day 1 and Day 253, as concomitant vaccination.
89388494|NCT05073003|Experimental|ST2_Infants_Dose C_Dose find Group|Infants 9 months of age in Stage 2 (Africa), part of the dose-finding cohort, randomized to receive three doses of altSonflex1-2-3 Dose C vaccine, one each at Day 1, Day 85 and Day 253. These infants also receive two doses of Serum Institute of India's Measles and rubella vaccine, one each at Day 1 and Day 253, as concomitant vaccination.
88864009|NCT03801902|Experimental|Arm I (CLOSED) (Durvalumab and ACRT)|Starting 2 weeks prior to radiation therapy, patients receive durvalumab IV over 60 minutes on day 1 of each cycle. Treatment repeats every 4 weeks for 13 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo ACRT 1 fraction per day, 5 days per week for 15 fractions. Patients also undergo brain MRI or CT scan during screening and as clinically indicated, chest CT scans on study and during follow up, and collection of blood samples during screening and on study.
89388495|NCT05071235|Placebo Comparator|CG (control group) + dressing|The group will receive placebo LLLT (low-level laser therapy) application associated with Helianthus annuus oil dressing.
89388496|NCT05071235|Active Comparator|LG1 (LLLT group 1) + dressing|The group will receive application of LLLT (low-level laser therapy) Gallium Arsenide (GaAs) 904 nm 10 J/cm² associated with Helianthus annuus oil dressing.
89388497|NCT05071235|Active Comparator|LG2 (LLLT group 2) + dressing|The group will receive application of LLLT (low-level laser therapy) Gallium Arsenide (GaAs) 904 nm 8 J/cm² associated with Helianthus annuus oil dressing.
89388498|NCT05071235|Active Comparator|LG3 (LLLT group 3) + dressing|The group will receive application of LLLT (low-level laser therapy) Gallium Arsenide (GaAs) 904 nm 4 J/cm² associated with Helianthus annuus oil dressing.
89388499|NCT05065047|Experimental|Belantamab mafodotin|belantamab mafodotin by vein over 30 minutes every 8 weeks
88864010|NCT03801902|Experimental|Arm II (CLOSED) (Durvalumab and standard RT)|Starting 2 weeks prior to radiation therapy, patients receive durvalumab IV over 60 minutes on day 1 of each cycle. Treatment repeats every 4 weeks for 13 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo conventionally fractionated radiation therapy 1 fraction per day, 5 days per week for 30 fractions. Patients also undergo brain MRI or CT scan during screening and as clinically indicated, chest CT scans on study and during follow up, and collection of blood samples during screening and on study.
89388500|NCT05053087|Experimental|Ropivacaine intermittent bolus|Subjects will have a catheter placed in the Post Anesthesia Care Unit following clinically indicated surgery with 0.2% ropivacaine dispersed in pulsed intermittent bolus.
89388501|NCT05053087|Experimental|Ropivacaine continuous|Subjects will have a catheter placed in the Post Anesthesia Care Unit following clinically indicated surgery with 0.2% ropivacaine dispersed in a continuous infusion.
89388502|NCT05053087|Placebo Comparator|Single shot adductor canal|Subjects will have a catheter placed in the Post Anesthesia Care Unit following clinically indicated surgery with saline.
89388503|NCT05049330||Derivation Cohort|The derivation cohort collected data to derive the clinical decision rule.
89388504|NCT05049330||Validation Cohort|The validation cohort collected data to validate the clinical decision rule
89388505|NCT05049057|Experimental|Active Drug|Erenumab administered once monthly via two 70-mg subcutaneous injections at 3 time points over a 12-week period.
89388506|NCT05049057|Placebo Comparator|Placebo|Placebo administered once monthly via two subcutaneous injections at 3 time points over a 12-week period.
89388507|NCT05047757|Experimental|Fava bean|The intervention consists in a test meal containing 250 g of cooked and peeled favabean, to provide 20 g protein. Fava bean are intrinsically labelled with 15N.
89388508|NCT05039281|Experimental|Treatment (atezolizumab, cabozantinib)|Patients receive atezolizumab IV over 30-60 minutes on day 1 and cabozantinib PO on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88864011|NCT03801902|Experimental|Arm III (durvalumab, monalizumab, standard RT)|Starting 2 weeks prior to radiation therapy, patients receive durvalumab IV over 60 minutes and monalizumab IV over 60 minutes on day 1 of each cycle. Treatment repeats every 4 weeks for 13 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo conventionally fractionated radiation therapy 1 fraction per day, 5 days per week for 30 fractions. Patients also undergo brain MRI or CT scan during screening and as clinically indicated, chest CT scans on study and during follow up, and collection of blood samples during screening and on study.
88864012|NCT03801902|Experimental|Arm IV (durvalumab, oleclumab, standard RT)|Starting 2 weeks prior to radiation therapy, patients receive durvalumab IV over 60 minutes on day 1 of each cycle. Patients also receive oleclumab IV over 60 minutes on days 1 and 15 of cycles 1-2, then on day 1 of cycles thereafter. Treatment repeats every 4 weeks for 13 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo conventionally fractionated radiation therapy 1 fraction per day, 5 days per week for 30 fractions. Patients also undergo brain MRI or CT scan during screening and as clinically indicated, chest CT scans on study and during follow up, and collection of blood samples during screening and on study.
88864013|NCT03793179|Experimental|Arm A (pembrolizumab, pemetrexed, carboplatin)|Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Within 6 weeks of disease progression, patients receive pemetrexed IV over 10 minutes and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then may receive pemetrexed IV over 10 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo MRI during screening, CT scan and blood sample collection throughout the study, and may undergo PET scan throughout the study.
88864014|NCT03793179|Experimental|Arm B (pembrolizumab, pemetrexed, carboplatin)|Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Within 6 weeks of disease progression, patients receive pembrolizumab IV over 30 minutes, pemetrexed IV over 10 minutes, and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive pembrolizumab IV over 30 minutes and pemetrexed IV over 10 minutes on day 1. Cycles repeat every 21 days for up to 2 years for pembrolizumab in the absence of disease progression or unacceptable toxicity and until to disease progression for pemetrexed. Patients undergo MRI during screening, CT scan and blood sample collection throughout the study, and may undergo PET scan throughout the study.
89388509|NCT05006833|Experimental|Bundled clinician training and bundled text messages|Clinicians will receive bundled approach training and parents will receive bundled text messages.
89388510|NCT05006833|Experimental|Bundled clinician training and benefits text messages|Clinicians will receive bundled approach training and parents will receive benefits text messages.
89388511|NCT05006833|Experimental|Bundled clinician training and no text messages|Clinicians will receive bundled approach training and parents will not receive any intervention text messages.
89388512|NCT05006833|Experimental|Benefits clinician training and bundled text messages|Clinicians will receive benefits approach training and parents will receive bundled text messages.
89388513|NCT05006833|Experimental|Benefits clinician training and benefits text messages|Clinicians will receive benefits approach training and parents will receive benefits text messages.
89388514|NCT05006833|Experimental|Benefits clinician training and no text messages|Clinicians will receive benefits approach training and parents will not receive any intervention text messages.
89388515|NCT05006833|Experimental|Deferred-clinician training and bundled text messages|Clinicians will receive training after the study and parents will receive bundled text messages.
89388516|NCT05006833|Experimental|Deferred-clinician training and benefits text messages|Clinicians will receive training after the study and parents will receive benefits text messages.
89388517|NCT05006833|No Intervention|Deferred-clinician training and no text messages|Clinicians will receive training after the study and parents will not receive intervention text messages.
89388518|NCT05005182|Experimental|Cohort A (luspatercept)|Patients receive luspatercept SC on day 1. Cycles repeat every 21 days for 6 months in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection, bone marrow biopsy and aspirate at baseline and on study.
89530419|NCT03245125||MDP subjects in HFpEF patients|heart failure patients with preserved ejection fraction (HFpEF) received only multidisciplinary disease management program (MDP) and underwent less than 36 times of high-intensity interval training (HIIT) or no exercise training
89388519|NCT05005182|Experimental|Cohort A (luspatercept, hydroxyurea)|Patients receive luspatercept SC on day 1 and hydroxyurea PO on days 1-21. Cycles repeat every 21 days for 6 months in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection, bone marrow biopsy and aspirate at baseline and on study.
89388520|NCT04998773|Active Comparator|Group Bilateral|32 patients, bilateral active TBS stimulation, Will receive an intensive-spaced protocol Intermittent TBS in left DLPFC and Continuous TBS in right DLPFC
88864015|NCT03793179|Active Comparator|Arm C (pembrolizumab, pembrolizumab, carboplatin)|Patients receive pembrolizumab IV over 30 minutes, pemetrexed IV over 10 minutes, and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive pembrolizumab IV over 30 minutes and pemetrexed IV over 10 minutes on day 1. Cycles repeat every 21 days for up to 2 years for pembrolizumab in the absence of disease progression or unacceptable toxicity and until to disease progression for pemetrexed. Patients undergo MRI during screening, CT scan and blood sample collection throughout the study, and may undergo PET scan throughout the study.
88864016|NCT03788811||Control subjects|Control subjects who do not have a lifetime diagnosis of SZ, BP, other psychotic disorder, recurrent mood disorder or have not met criteria for a major depression episode in the last 12 months according to DSM-V criteria.
88864017|NCT03788811||Patients with schizophrenia (SZ)|Patient with a diagnosis of schizophrenia for at least 12 months, that resulted in a diagnosis with a Structured Clinical Interview for DSM-5 (SCID-5-CT).
88864018|NCT03788811||Patients with bipolar disorder Type I (BP1)|Patient with a diagnosis of bipolar disorder Type 1 for at least 12 months, that resulted in a diagnosis with a Structured Clinical Interview for DSM-5 (SCID-5-CT).
88864019|NCT03784326|Experimental|Cohort 1-Atezolizumab combination with Oxaliplatin and 5-fluorouracil (5-FU)|The combination of Atezolizumab with Oxaliplatin and 5-Fluorouracil IV on Days 1 and 15 of each 28-day cycle for total of 6 doses followed by surgery followed by Atezolizumab on Day 1 of each 21-day cycle for total of 24 weeks
88864020|NCT03784326|Experimental|Cohort 2- Atezolizumab plus and Tiragolumab with Oxaliplatin and 5-fluorouracil (5-FU)|The combination of Atezolizumab + Tiragolumab with Oxaliplatin and 5-Flourouracil IV on Days 1 and 15 of each 28-day cycle for total of 6 doses followed by surgery followed by Atezolizumab + Tiragolumab on Day 1 of each 21-day cycle for a total of 48 weeks.
88864021|NCT03743558|Experimental|children with adenoamygdala hypertrophy|
88864022|NCT03738852|Experimental|Aim 3: Type 1 diabetes mellitus user unaware subjects 3 months|Continuous Glucose Monitor for 3 months duration
88864023|NCT03738852|Experimental|Aim 1: Impact of hypoglycemia on brain connectivity Type 1|Healthy controls, T1 aware, and T1 unawares
88864024|NCT03738852|Experimental|Aim 2: Impact of hypoglycemia on brain glucose transports in Type 1|Healthy controls, T1 aware, and T1 unawares
88864025|NCT03708302|Active Comparator|Study Group|Ultrasound guided unilateral serratus plane block and unilateral parasternal infrapectoral block with 0.5% ropivacaine.
88864026|NCT03708302|Sham Comparator|Control Group|Ultrasound guided unilateral serratus plane block and unilateral parasternal infrapectoral block with 0.9% saline.
88864027|NCT03706482|Experimental|Postnatal|"15 participants.~Administration of four postnatal doses of BOOST cells with the first dose as soon as possible after birth and the three additional doses at +4, +8 and +12 months after the first dose. Each dose is 3x10^6 MSC/kg body weight."
88864028|NCT03706482|Experimental|Prenatal|"3 participants.~Administration of one prenatal dose of BOOST cells followed by three postnatal doses at +4, +8 and +12 months after the first dose. Each dose is 3x10^6 MSC/kg body weight."
88864029|NCT03706482|No Intervention|Prospective control (untreated)|"1-30 participants.~Subjects eligible for the trial but not willing/able to participate in any of the experimental arms."
88864030|NCT03706482|No Intervention|Historic control|"18-90 participants (1-5 per included and treated subject).~Matched historical controls. Subjects will be identified in historical registries and data will be retrieved from national OI registers and the OI Variant Database (Dalgleish 2018)."
88864031|NCT03698552|Experimental|ADCT-602|Patients receive ADCT-602 by vein over 30 minutes on day 1. Courses repeat every 21 in the absence of disease progression or unacceptable toxicity. Patients who achieve CR/CRi receive ADCT-602 every 28 days.
89530420|NCT02516189|Experimental|Group A|group of elderly participants of strength training program
88864032|NCT03677102|Active Comparator|higher chloride solutions|higher chloride crystalloid (Normal saline - chloride concentration 154 mmol/L)
88864033|NCT03677102|Active Comparator|lower chloride solutions|lower chloride crystalloid (Ringer's lactate - chloride concentration 110 mmol/L)
88864034|NCT03674047|Experimental|newly-diagnosed BOS|-Participants will take ruxolitinib twice every day
88864035|NCT03674047|Experimental|Established BOS|-Participants will take ruxolitinib twice every day
88864036|NCT03616236|Active Comparator|TAU|Participants will receive a referral to buprenorphine treatment in the community.
88864037|NCT03616236|Experimental|BBT|Participants will begin buprenorphine pharmacotherapy using the MedicaSafe buprenorphine dispensing device immediately after an on-site intake at a community supervision office and continue such treatment until they are transitioned to community buprenorphine treatment
88864038|NCT03612856|Experimental|AB023 (xisomab 3G3)- Dose 1|Participants will receive a single dose of 0.25 mg/kg xisomab 3G3.
88864039|NCT03612856|Experimental|AB023 (xisomab 3G3)- Dose 2|Participants will receive a single dose of 0.5 mg/kg xisomab 3G3.
88864040|NCT03612856|Placebo Comparator|placebo|Participants will receive a single dose of placebo.
88864041|NCT03611933|No Intervention|Control group (CG)|Patients in the CG were provided with routine nursing care, as practiced in the clinic, including restricted bed rest. For this purpose, patients were given supine position in which the HOB was elevated 15° for 6-10 h; the patient's leg on the of the side of intervention was kept straight.
88864042|NCT03611933|Experimental|Experimental group (EG)|Patients in the EG were applied position changes between the first minute and sixth hour. During the initial six hours a supportive, thin pillow, 4 x 40 x 100 cm in size, was placed between the patient's shoulders and gluteals; this reduced the pressure on local tissues and muscle groups.
88864043|NCT03608319|Experimental|Single dose following overnight fast|
88864044|NCT03608319|Experimental|Single dose following high fat breakfast|
88864045|NCT03608319|Experimental|Single dose sprinkled on applesauce following overnight fast|
89003392|NCT05382338|Experimental|Treatment (chemoradiotherapy, maintenance)|"CHEMORADIOTHERAPY: Patients undergo radiation therapy on weeks 1-7 and receive vincristine IV once weekly on weeks 2-7 in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Beginning 4 weeks after chemoradiotherapy, patients receive lomustine PO on day 1 of cycles 1, 2, 4, 5, 7, and 8, cisplatin IV over 6 hours on day 1 of cycles 1, 2, 4, 5, 7, and 8, sodium thiosulfate IV over 15 minutes on day 1 of cycles 1, 2, 4, 5, 7, and 8, cyclophosphamide IV over 30-60 minutes on days 1 and 2 of cycles 3, 6, and 9, and mesna IV over 15-30 minutes TID on days 1 and 2 of cycles 3, 6, and 9. Patients also receive vincristine IV on days 1, 8, and 15 of cycles 1, 2, 4, 5, 7, and 8, and on days 1 and 8 of cycles 3, 6, and 9. Treatment repeats every 6 weeks (cycles 1, 2, 4, 5, 7 and 8) or every 4 weeks (cycles 3, 6, and 9) for up to 9 cycles in the absence of disease progression or unacceptable toxicity."
89003393|NCT05380453|Placebo Comparator|Placebo|Participants will receive placebo as subcutaneous (s.c.) injection at Baseline, Week 1,2,3,4 and then every 4 weeks thereafter.
88864048|NCT03601455|Experimental|Regimen A (radiation therapy and durvalumab)|Participants receive durvalumab IV over 60 minutes on day 1. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity. Participants also undergo EBRT for 5 fractions beginning on day 8 of course 1.
88864049|NCT03601455|Experimental|Regimen B (radiation therapy, durvalumab, tremelimumab)|Participants receive tremelimumab IV over 60 minutes on day 1 for up to 2 courses and durvalumab IV over 60 minutes on day 1. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression of unacceptable toxicity. Participants also receive undergo EBRT for 5 fractions beginning on day 8 of course 1.
88864050|NCT03594110|Experimental|Empagliflozin 10 mg|Patients with evidence of chronic kidney disease (CKD) at risk of kidney disease progression, with or without diagnosed diabetes mellitus administered orally once daily 10 milligram (mg) film-coated tablets of empagliflozin.
88864051|NCT03594110|Placebo Comparator|Placebo|Patients with evidence of chronic kidney disease (CKD) at risk of kidney disease progression, with or without diagnosed diabetes mellitus administered orally once daily film-coated tablets of placebo to match empagliflozin.
88864052|NCT03591731|Experimental|Arm A : monotherapy arm|Nivolumab administered IV
88864053|NCT03591731|Experimental|Arm B : combination arm|Nivolumab administered IV followed by ipilimumab administered IV
88864054|NCT03576417|Active Comparator|RT+ cisplatin|100 mg/m2 of cisplatin on days 1, 22,43 of RT
88864055|NCT03576417|Experimental|RT+ cisplatin + nivolumab|"240 mg of nivolumab 3 weeks before RT-Cisplatin~360 mg of nivolumab on days 1, 22,43 of -RT-cisplatin~480 mg of nivolumab for maintenance"
89003394|NCT05380453|Experimental|Secukinumab|Participants will receive secukinumab as subcutaneous (s.c.) injection at Baseline, Week 1,2,3,4 and then every 4 weeks thereafter.
89003395|NCT05350969|Experimental|CDR132L 5 mg|CDR132L 5 mg/kg body weight intravenous in single dose on Day 1, Day 29 and Day 57
89003396|NCT05350969|Experimental|CDR132L 10 mg|CDR132L 10 mg/kg body weight intravenous in single dose on Day 1, Day 29 and Day 57
89003397|NCT05350969|Placebo Comparator|Placebo|Placebo intravenous in single dose on Day 1, Day 29 and Day 57
89003398|NCT05350072|Experimental|Arm A|ianalumab
89530421|NCT02516189|No Intervention|Group B|group of seniors who did not practice strength training program
88864056|NCT03539757||Fontan patients|Pediatric and adult Fontan patients will undergo MRI (Magnetic Resonance Imaging) of the liver using novel, non-contrast MRI methods. These MR methods will be used to detect, discriminate and measure liver fibrosis and congestion. The resulting quantitative imaging measurements will be correlated with histopathologic data obtained from a clinically-indicated liver biopsy.
89535323|NCT05005767|Active Comparator|test group|Ten patients with sites suffering from mild chronic periodontitis. sites will be treated with scaling and root planing (SRP) and subgingival application of Frankincense extract gel
88864057|NCT03520114|Experimental|RP sling group|Participants assigned to the retropubic (RP) sling group will have the RP sling placement procedure.
88864058|NCT03520114|Experimental|SIS group|Participants assigned to the single-incision sling (SIS) group will have the SIS placement procedure.
88864059|NCT03515031|Experimental|High Flow Nasal Cannula Oxygenation|High Flow Nasal Cannula Oxygenation with a minimum flow ≥ 60L / min, and an FiO2 such as to maintain a SpO2 ≥ 92% for at least 48 hours until clinical stability
88864060|NCT03515031|Active Comparator|Venturi Mask Oxygenation|Venturi Mask Oxygenation, with an FiO2 such as to maintain an SpO2 ≥ 92% for at least 48 hours until clinical stability
88864061|NCT03469960|Active Comparator|Arm A : standard treatment|6 months of treatment by nivolumab + ipilimumab then nivolumab + ipilimumab then in case of progression platinum-based doublet recommended
88864062|NCT03469960|Experimental|Arm B : experimental arm|6 months of treatment by nivolumab + ipilimumab then observation the in case of progression nivolumab + ipilimumab then in case of progression platinum-based doublet recommended
88864063|NCT03464097|Experimental|Ozanimod|
88864064|NCT03464097|Placebo Comparator|Placebo|
88864065|NCT03457545|Experimental|Intervention|Eligible participants will take part in the home-based pulmonary rehabilitation using the Aidcube platform in-person assessment and training with a research coordinator (i.e. physical exercise capacity assessment, SPPB, disability survey, exercise prescription determination, exercise training, dyspnea control techniques) and complete an follow-up assessment at the 8th week.
88864066|NCT03457545|No Intervention|No Intervention|Ineligible participants will receive standard of care
88864067|NCT03427866|Experimental|Ruxolitinib Eligible pre-HSCT|"Ruxolitinib will be taken orally at a fixed dose twice every day~Dosing will be continuous, with a new cycle scheduled to start every 28 days.~There will be no break in dosing between cycles~Ruxolitinib can be administered with or without food."
88864068|NCT03427866|Experimental|Ruxolitinib Not Eligible pre-HSCT|"Ruxolitinib will be taken orally at a fixed dose twice every day after transplant~Dosing will be continuous, with a new cycle scheduled to start every 28 days.~There will be no break in dosing between cycles~Ruxolitinib can be administered with or without food."
88864069|NCT03396926|Experimental|Treatment (pembrolizumab, bevacizumab, capecitabine)|Patients receive pembrolizumab IV over 30 minutes on day 1, bevacizumab IV over 30-90 minutes on day 1, and capecitabine PO BID on days 1-14. Treatment repeats every 3 weeks for up to 35 courses in the absence of disease progression or unacceptable toxicity.
88864070|NCT03391466|Experimental|Axicabtagene Ciloleucel Treatment|Participants will receive cyclophosphamide 500 mg/m^2/day intravenously (IV) and fludarabine 30 mg/m^2/day IV conditioning chemotherapy for 3 days followed by axicabtagene ciloleucel administered as a single IV infusion at a target dose of 2 x 10^6 anti-cluster of differentiation antigen (CD) 19 CAR transduced autologous T cells/kg on Day 0.
88864071|NCT03391466|Active Comparator|Standard of Care Therapy|Participants will receive 2 or 3 21-day cycles of second-line chemotherapy regimen; R-ICE: rituximab 375 mg/m^2 before chemotherapy,ifosfamide 5 g/m^2 24hour(hr) infusion on Day 2+mesna,carboplatin area under the curve (AUC) 5 on Day 2, maximum dose 800 mg,etoposide 100 mg/ m^2/day on Days 1-3; R-ESHAP: rituximab 375 mg/m^2 Day 1,etoposide 40 mg/m^2/day IV on Days 1-4,methylprednisolone 500 mg/day IV on Days 1-4 or 5,cisplatin at 25 mg/m^2/day Days 1-4,cytarabine 2 g/m^2 on Day 5; R-GDP: rituximab 375 mg/m^2 Day 1(or Day 8),gemcitabine 1g/m^2 on Days 1 and 8,dexamethasone 40 mg on Days 1-4,cisplatin 75mg/m^2 on Day 1 or carboplatin AUC=5; or R-DHAP: Rituximab 375 mg/ m^2 before chemotherapy,dexamethasone 40 mg/day on Days 1-4,highdose cytarabine 2 g/m^2 every 12 hours for 2 doses on Day 2 following/platinum,cisplatin 100 mg/m^2 24hr infusion on Day 1 or oxaliplatin 100 mg/m^2. Participants who will respond will get high dose therapy and autologous stem cell transplant.
89003399|NCT05350072|Placebo Comparator|Arm B|placebo
89189410|NCT05810454|Active Comparator|PACE (physical and cognitive exercise)|"PACE (Physical and Cognitive Exercise) involves a pedal-while-play experience in which physical and mental exercise are combined in a simultaneous, but not fully interactive way. In this condition a person will pedal while also separately steering in a tablet-based game, such as when pedaling while automatically progressing along a virtual path to different assigned errand locations."
89535324|NCT03323177|Experimental|Nutritional supplementation gender specific formula|Patients at this arm will continue to consume the study formula until final height. The formula is a gender specific powder added to water containing about 25% of recommended Daily Recommended Intake (DRI) for calories, high protein (25% of calories) and multi vitamin and mineral (255-100%) of DRI for recommended daily allowance (RDA) or adequate intake
88864072|NCT03383575|Experimental|Arm I (enasidenib, azacitidine)|Patients who are HMA-naive receive enasidenib PO QD on days 1-28 and azacitidine IV over 30-60 minutes or SC on days 1-7. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88864073|NCT03383575|Experimental|Arm II (enasidenib)|Patients relapsed and/or refractory to HMA therapy receive enasidenib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88864074|NCT03347383|Experimental|Combination therapy DCB + stent|Patients treated with the Luminor DCB and the iVolution stent
88864075|NCT03340896|Active Comparator|TPF followed by radiotherapy|"Induction chemotherapy by Docetaxel 75 mg/m² day 1,cisplatin 75 mg/m² day 1 and 5 fluorouracil 750mg/m²(day 1 to day 5) 3 cycles day1, day 22, day 43 followed (for responders or stable disease patients) by radiotherapy~Radiotherapy ;70 gray fractionization: 2Gy/day, 5days/week, for 7 weeks."
89388521|NCT04998773|Active Comparator|Group Unilateral|32 patients, unilateral left DLPFC active TBS stimulation. Will receive an intensive-spaced protocol Intermittent TBS in left DLPFC and Sham Continuous TBS in right DLPFC
88864076|NCT03340896|Experimental|Cisplatin and radiotherapy|"Drug and radiation • Cisplatin: 100 mg / m² administered IV at J1, J22 and J43 of radiotherapy~. Radiotherapy 70 gray fractionization: 2Gy/day, 5days/week, for 7 weeks."
88864077|NCT03338621|Experimental|Drug Sensitive BPaMZ|Bedaquiline 200 mg daily for 8 weeks then 100 mg daily for 9 weeks, together with pretomanid 200 mg + moxifloxacin 400 mg + pyrazinamide 1500 mg daily for 17 weeks (Total treatment duration 4 months
88864078|NCT03338621|Active Comparator|Drug Sensitive Standard Treatment|isoniazid 75 mg + rifampicin 150 mg + pyrazinamide 400 mg + ethambutol 275 mg (HRZE) combination tablets for 8 weeks AND isoniazid 75 mg + rifampicin 150 mg (HR) combination tablets for Weeks 9 to 26
88864079|NCT03338621|Experimental|Drug Resistant BPaMZ|Bedaquiline 200 mg daily for 8 weeks then 100 mg daily for 18 weeks, together with pretomanid 200 mg + moxifloxacin 400 mg + pyrazinamide 1500 mg daily for 26 weeks (Total treatment duration 6 months)
88864080|NCT03334539|Experimental|0.10% HL036 Ophthalmic Solution|Participants self-administered HL036 0.10 percent (%) ophthalmic solution as topical ophthalmic drops, twice daily (BID) for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
88864081|NCT03334539|Experimental|0.25% HL036 Ophthalmic Solution|Participants self-administered HL036 0.25% ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
88864082|NCT03334539|Placebo Comparator|Placebo|Participants self-administered HL036 placebo (vehicle solution) as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
88864083|NCT03328130|Experimental|Cohort 1 - Low Dose|Biological: AAV2/5-hPDE6B Unilateral (one eye), subretinal, administration of the lowest dose. Dose-escalation will be performed after DSMC assessment.
88864084|NCT03328130|Experimental|Cohort 2a - Medium Dose|Biological: AAV2/5-hPDE6B Unilateral (one eye), subretinal, administration of the medium dose. Confirmatory dose will be determined after DSMC assessment.
88864085|NCT03328130|Experimental|Cohort 2b - High Dose|Biological: AAV2/5-hPDE6B Unilateral (one eye), subretinal, administration of the highest dose. Confirmatory dose will be determined after DSMC assessment.
88864086|NCT03328130|Experimental|Cohort 3 - High Dose (confirmatory cohort)|Biological: AAV2/5-hPDE6B Unilateral (one eye), subretinal, administration of the confirmatory dose.
88864087|NCT03328130|Experimental|Cohort 4 - High Dose - 13 years old or older population|Biological: AAV2/5-hPDE6B Unilateral (one eye), subretinal, administration of the confirmatory dose.
88864088|NCT03321981|Experimental|Cohort 1 doublet|zenocutuzumab + trastuzumab
88864089|NCT03321981|Experimental|Cohort 1 triplet|zenocutuzumab + trastuzumab + vinorelbine
88864090|NCT03321981|Experimental|Cohort 2|zenocutuzumab + endocrine therapy
88864091|NCT03321409||The general population|People who take the physical examination in Renji Hospital between 18 to 80 years old without any previously confirmed serious medical conditions or mental disorders.
88864092|NCT03321409||The patients with suspected CAD|Patients with suspected CAD between 18 to 80 years old without any previously confirmed serious medical conditions or mental disorders.
88864093|NCT03286530|Experimental|Ruxolitinib|Following a standard of care allogeneic stem cell transplantation, participants will be started on Ruxolitinib. Ruxolitinib is administered orally 2 times per day at a fixed dose. Each study treatment cycle lasts 28 days. Up to 24 cycles.
88864094|NCT03259204|No Intervention|Leg Immobilization|Routine care include that the lower limb will be immobilized in an orthosis or a below-knee plaster cast according to local routines.
88864095|NCT03259204|Experimental|Adjuvant IPC|Leg Immobilization with the addition of IPC. Patients will during lower limb immobilization receive bilateral calf IPC.
88864096|NCT03249831|Experimental|COH-MC-17 and immunosuppressants|"Participants receive COH-MC-17: a 21-day nonmyeloablative conditioning regimen (cyclophosphamide, pentostatin and rabbit anti-thymocyte globulin), followed by CD4+ T-cell-depleted Haploidentical Hematopoietic Transplant on Day 0.~Immunosuppressants (tacrolimus and mycophenolate mofetil) given on Day -1 onwards until discontinuation post-transplant.~The minimally manipulated transplant product is manufactured using the CliniMACS device."
89388522|NCT04998773|Placebo Comparator|Group Placebo|32 patients, bilateral sham TBS stimulation. Will receive an intensive-spaced protocol of Sham Intermittent TBS in left DLPFC and Sham Continuous TBS in right DLPFC
89388523|NCT04997499|Experimental|Teaching video|This is a single arm interventional study wherein the subjects enrolled will all participate in the study in the same way by watching the teaching video and then will be asked to self inject subcutaneous depot-medroxyprogesterone as per the protocol. All participants will then be asked to answer survey questions. All health care providers that participate in the study will likewise be asked to answer survey questions.
89388524|NCT04995575||all MINDACT patients who relapse|
88864097|NCT03246412|Experimental|Nevus doctor clinical decision support|"The GPs have access to the clinical decision support tool Nevus doctor."
88864098|NCT03246412|No Intervention|Control|"The GPs have no access to the clinical decision support tool Nevus Doctor."
88864099|NCT03207009|Experimental|LentiGlobin BB305 Drug Product|LentiGlobin BB305 Drug Product (autologous CD34+ cell-enriched population that contains cells transduced with LentiGlobin BB305 lentiviral vector encoding human βA-T87Q-globin)
88864100|NCT03201458|Experimental|Arm A (atezolizumab)|Patients receive atezolizumab IV over 30-60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI and collection of blood samples throughout the trial and undergo tumor biopsy on study.
88864101|NCT03201458|Experimental|Arm B (atezolizumab, cobimetinib)|Patients receive atezolizumab IV over 30-60 minutes on days 1 and 15 and cobimetinib PO QD on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI and collection of blood samples throughout the trial and undergo tumor biopsy on study.
88864102|NCT03179605|Experimental|DFD-06 Cream|This is a single arm, open label study and there will be no reference or control product used in this study
89388525|NCT04985942|Experimental|Lumateperone 42 mg|
89388526|NCT04985942|Placebo Comparator|Placebo|
88864103|NCT03168386|Experimental|Intensive motor rehabilitation group|
88864104|NCT03168373|Experimental|Intensive group|language rehabilitation therapy by language therapist for 1 hours on every working day for 4 weeks
88864105|NCT03168373|Active Comparator|Conventional group|language rehabilitation therapy by language therapist for 30 minutes on every working day for 4 weeks
88864106|NCT03168360|Experimental|Intensive group|cognitive rehabilitation therapy for 1 hour by cognitive therapist on every working day for 4 weeks
88864107|NCT03168360|Active Comparator|Conventional group|cognitive rehabilitation therapy for 30 minutes by cognitive therapist on every working day for 4 weeks
88864108|NCT03151499|Experimental|BI 409306 (R), then BI 409306 after pretreatment with rifampicin (T)|"Subjects were administered during Period 1 on Day 1/Visit 2 a single dose of 50 milligrams (mg) of BI 409306 film-coated tablet orally with 240 millilitre (mL) of water (reference treatment, R).~On Days -7 to -1 /Visit 3 of Period 2 participants were administered rifampicin 600 mg Eremfat® film-coated tablet orally with 240 mL of water once per day during the evenings. Afterwards on Day 1/Visit 3, participants were administered a single dose of 50 mg BI 409306 orally approximately 14 hours after the last rifampicin dose (test treatment, T).~Due to the short half-life of BI 409306, trial period 2 directly followed trial period 1 without a wash-out period."
88864109|NCT03148210|Active Comparator|Enhanced Care|Treatment strategy using evidence-based guidelines for asthma or COPD
88864110|NCT03148210|Placebo Comparator|Standard of Care|Spirometry result sent to family MD
88864111|NCT03051997|Experimental|Caregiver Contingency Management + Usual Drug Court Treatment|This group will receive a caregiver contingency management intervention plus the standard outpatient substance abuse treatment services provided at JDC.
88864112|NCT03051997|Active Comparator|Usual Drug Court Treatment|This group will receive the standard outpatient substance abuse treatment services provided at JDC.
88864113|NCT03022682||IDEO Cohort|"Adipose tissue samples are collected from all participants, including aspirational subcutaneous biopsies from nonsurgical participants and excisional biopsies, performed intra-operatively by surgical collaborators as required.~Participants also undergo anthropometric measurements, stool collection, blood sample collection for circulating blood cells, serum, and plasma.~Dual-energy x-ray absorptiometry (DXA) scan for amount and distribution of body fat as well as bone density is performed.~Study participants complete validated questionnaire inventories to measure bio-behavioral issues such as depression, stress, health locus of control, and dietary habits."
88864114|NCT02963441||DME|"Center-involved macular edema based on WRC of macular Optical Coherence Tomography images~Clinically Significant macular edema based on WRC grading of widefield stereo color fundus photographs.~Sample Size: ~45 subjects with DME"
88864115|NCT02963077|Experimental|Cohort 1 SAD - 0.1 mg A4250|Dose: 0.1 mg of A4250. Sentinel dosing was used (2 sub-cohorts dosed a minimum of 24 h apart).
88864116|NCT02963077|Experimental|Cohort 2 SAD - 0.3 mg A4250|Dose: 0.3 mg of A4250.
88864117|NCT02963077|Experimental|Cohort 3 SAD - 1 mg A4250|Dose: 1 mg A4250.
88864118|NCT02963077|Experimental|Cohort 4 SAD - 3 mg A4250|Dose: 3 mg A4250.
88864119|NCT02963077|Experimental|Cohort 5 SAD - 10 mg A4250|Dose: 10 mg A4250.
88864120|NCT02963077|Placebo Comparator|Cohort 1 SAD placebo|Dose: 0.1 mg of A4250 matching placebo. Sentinel dosing was used (2 sub-cohorts dosed a minimum of 24 h apart).
88864121|NCT02963077|Placebo Comparator|Cohort 2 SAD placebo|Dose: 0.3 mg A4250 matching placebo.
88864122|NCT02963077|Placebo Comparator|Cohort 3 SAD placebo|Dose: 1 mg A4250 matching placebo.
88864123|NCT02963077|Placebo Comparator|Cohort 4 SAD placebo|Dose: 3 mg A4250 matching placebo.
88864124|NCT02963077|Placebo Comparator|Cohort 5 SAD placebo|Dose: 10 mg A4250 matching placebo.
89189411|NCT05810441||Typical celiac disease|"symptomatic subjects (gastro-intestinal or extra-intestinal symptoms) tested positive for serum anti-ttg concentrations and with pathological intestinal biopsy;~symptomatic and asymptomatic subjects at risk of CD (first-degree relatives of CD patients or subjects with autoimmune disorders) tested positive serum CD antibodies and with atrophic intestinal mucosa"
89388527|NCT04977453|Experimental|GI-101|"Dose escalation: GI-101, multiple ascending doses~Dose expansion:"
88864125|NCT02963077|Experimental|Cohort 1 MAD - 1 mg A4250 qd|Dose: 1 mg A4250 qd for 7 days.
88864126|NCT02963077|Placebo Comparator|Cohort 1 MAD placebo|Dose: 1 mg A4250 matching placebo qd for 7 days.
88864127|NCT02963077|Experimental|Cohort 2 MAD - 3 mg A4250|Dose: 3 mg A4250 qd for 7 days
88864128|NCT02963077|Placebo Comparator|Cohort 2 MAD placebo|Dose: 3 mg A4250 matching placebo qd for 7 days.
88864129|NCT02963077|Experimental|Cohort 3 MAD - 1.5 mg A4250 b.i.d for 7 days.|Dose: 1.5 mg A4250 b.i.d. for 7 days.
88864130|NCT02963077|Placebo Comparator|Cohort 3 MAD placebo|Dose: 1.5 A4250 matching placebo b.i.d for 7 days.
88864131|NCT02963077|Experimental|Cohort 4 MAD - 3 mg A4250 qd + 1 mg Questran b.i.d|Dose: 3 mg A4250 qd + 1 mg Questran b.i.d for 7 days.
88864132|NCT02963077|Active Comparator|Cohort 4 MAD A4250 placebo + 1 mg Questran b.i.d|Dose: 3 mg A4250 matching placebo + 1 mg Questran b.i.d for 7 days.
88864133|NCT02963077|Experimental|Cohort 5 MAD - 3 mg A4250 qd + 1 g CRC b.i.d|Dose: 3 mg A4250 qd + 1 g CRC b.i.d for 7 days.
89388528|NCT04977453|Experimental|GI-101 + Pembrolizumab|"Dose escalation: GI-101, multiple ascending doses~Dose expansion:"
88864134|NCT02963077|Placebo Comparator|Cohort 5 MAD A4250 placebo + CRC placebo|Dose: 3 mg A4250 matching placebo qd + 1 g CRC placebo b.i.d for 7 days
88864135|NCT02963077|Active Comparator|Cohort 6 MAD - 1 g CRC|Dose: 1 g CRC b.i.d
89003400|NCT05346484|Experimental|CF33-hNIS IT Administration Monotherapy|
89388529|NCT04977453|Experimental|GI-101 + Lenvatinib|"Dose optimization:~Dose expansion:"
89388530|NCT04977453|Experimental|GI-101 + Local Radiotherapy|"Dose optimization:~Dose expansion:"
89388531|NCT04977453|Experimental|GI-101A|"Dose escalation: GI-101A, multiple ascending doses~Dose expansion:"
88864136|NCT02963077|Placebo Comparator|Cohort 6 MAD CRC placebo|Dose: 1 g CRC matching placebo b.i.d.
88864137|NCT02963077|Experimental|Cohort 7 MAD - 3 mg A4250 qd + 1 g CRC b.i.d|Dose: 3 mg A4250 qd + 1 g CRC b.i.d
88864138|NCT02963077|Placebo Comparator|Cohort 7 MAD A4250 placebo + CRC placebo|Dose: 3 mg A4250 matching placebo qd + 1 g CRC matching placebo b.i.d.
88864139|NCT02963025|Other|THE HIGHER PEEP LEVEL|Mechanical ventilation with VT of 5 ml/kg PBW and the level of PEEP at 10 cmH2O with lung recruitment maneuvers
88864140|NCT02963025|Other|THE LOWER PEEP LEVEL|Mechanical ventilation with VT of 5 ml/kg PBW and the level of PEEP at 5 cmH2O without lung recruitment maneuvers
88864141|NCT02945579|Experimental|Cohort A|"Neoadjuvant chemotherapy therapy~Biopsy: if no disease remaining - stay on the study and receive radiation (skip breast surgery)~H&P and Imaging every 6 months~Treatment (whole breast irradiation, EBRT) Within 12 weeks of completing neoadjuvant systemic therapy, patients undergo whole breast irradiation over 15-25 fractions on consecutive days. Patients then undergo EBRT boost over 7 fractions on consecutive days beginning the day following completion of whole breast irradiation."
88864142|NCT02945579|Experimental|Cohort B|"Neoadjuvant endocrine therapy for 6 months~Radiation if there is less than 25% tumor increase~Biopsy: if negative - additional endocrine therapy under the guidance of medical oncologist (skip breast surgery)~H&P and Imaging every 6 months~Cohort B Radiation:~Treatment (Stereotactic ablative radiotherapy -SABR) Following 3-6 months of endocrine therapy, if less than 25% tumor increase, patients undergo SABR irradiation over 10 fractions every other business day."
88864143|NCT02945579|Experimental|Cohort C|"Optional biopsy for nanomechanical biomarker assessment~Neoadjuvant chemotherapy therapy~Surgery (& optional biopsy nanomechanical biomarker assessment): if no disease remaining - stay on the study and skip radiation~H&P and Imaging every 6 months"
88864144|NCT02905370|Experimental|Progressive Multi-Component (PMC)|High intensity strength training protocol, daily protein supplementation, functionally enhanced transitions of care
88864145|NCT02905370|Active Comparator|Enhanced Usual Care (EUC)|"Low intensity rehabilitation protocol, standard education for nutrition, standard transitions of care~Name of Participant Arm updated to Enhanced Usual Care from Usual Care effective 8/16/18 to distinguish from Passive Comparator True Usual Care group."
88864146|NCT02905370|No Intervention|True Usual Care (TUC)|"Real-world home health rehabilitation, real-world education for nutrition, real-world transitions of care, non-randomized observation~Participants in the True Usual Care group will receive physical therapy following discharge from acute hospitalization. Activities and number of visits are not protocolized and are provided by real world home health care providers per physician orders.~Participant Arm added effective 8/16/18."
88864147|NCT02862379|Experimental|Elderly patients that fall|Personalized rehabilitation program for elderly patients that fall for the first time. This intervention is a home-based program combining exercises, home modifications and education on fall risk factors.
88864148|NCT02858310|Experimental|Arm 1: Phase I|Non-myeloablative, lymphocyte depleting preparative regimen, followed by E7 TCR Cells at escalating doses, followed by aldesleukin
88864149|NCT02858310|Experimental|Arm 2: Phase II|1 x 10 e11 E7 Cells that was determined in Phase I + aldesleukin
88864150|NCT02853331|Experimental|Pembrolizumab+Axitinib Combination Therapy|Participants receive pembrolizumab 200 mg intravenously every 3 weeks PLUS axitinib 5 mg orally twice daily.
88864151|NCT02853331|Active Comparator|Sunitinib Monotherapy|Participants receive sunitinib 50 mg orally once daily for 4 weeks and then are off treatment for 2 weeks.
89189412|NCT05810441||Potential celiac disease|Symptomatic subjects tested positive for both serum CD antibodies and anti-ttg-m but with normal intestinal mucosa
89388532|NCT04977453|Experimental|GI-101A + Pembrolizumab|"Dose escalation: GI-101A, multiple ascending doses~Dose expansion:"
88864152|NCT02837809|Experimental|Intervention|Low Dose CT, annual or biennial, associated with primary prevention and pulmonary function test evaluation.
88864153|NCT02837809|No Intervention|Control|Program of primary prevention with pulmonary function test evaluation
88864154|NCT02796937|Experimental|Alpha-1 MP|Alpha-1 MP 60 mg/kg/week for up to 104 weeks
88864155|NCT02785016||Stress Urinary Incontinence|Females with stress urinary incontinence, who undergo a tension free surgical sling procedure.
88864156|NCT02776098||Cystic Fibrosis without Cystic Fibrosis-related Diabetes|Subjects with a confirmed diagnosis of Cystic Fibrosis (CF) without Cystic Fibrosis-related diabetes will be followed annually for 2 years for a total of four study visits over 2 years (screening, baseline, 12 and 24 month visits).
88864157|NCT02776098||Newly Diagnosed Cystic Fibrosis-Related Diabetes|Subjects with a confirmed diagnosis of Cystic Fibrosis (CF) and new diagnosis of Cystic Fibrosis-Related Diabetes (CFRD) will be followed for a total of 3 study visits over 6 months (screening, baseline and 6 months).
88864158|NCT02776098||Healthy Controls|Age, sex, ethnicity and body mass index matched (at time of enrollment to CF without CFRD subjects) healthy controls will be followed annually for 2 years for a total of four study visits (screening, baseline, 12 and 24 month visits).
88864159|NCT02749799|Experimental|DFD-01 (betamethasone dipropionate) Spray, 0.05%|DFD-01 (betamethasone dipropionate) Spray, 0.05% to be applied twice daily on the affected areas (avoiding the face, scalp, groin, axillae and other intertriginous areas) for 28 days.
88864160|NCT02708810|Other|80 Gy Radiation & Unframed Virtual Cone|80 Gy Virtual Cone Radiosurgery unframed (face mask)
88864161|NCT02707029||Persons, with or without pain disorders|Adults and adolescents with or without pain disorders.
89388533|NCT04975152|Experimental|Neoadjuvant Cemiplimab Treatment|Participants will receive cemiplimab 350 mg IV at least 3 weeks prior to surgical resection. After surgery they will continue to receive 350 mg cemiplimab every 3 weeks for up to 8 additional doses.
89388534|NCT04968964|Experimental|Cohort 1: Scheduled to receive first line therapy|"Scheduled to receive 1st line therapy with endocrine therapy + any FDA-approved CDK 4/6 inhibitor~Serum samples (analyzed using DiviTum® TKa) at Baseline, Week 2, Week 4, Week 6, Week 8, Week 12, Week 16, Week 20, Week 24 and every 12 weeks thereafter until disease progression or 36 months. Treating physician will evaluate the patient & review any updated results of the institutional standard of care monitoring tests. Following receipt of DiviTum® TKa value, the treating physician will review the preceding locked Study Care Plan and record any changes"
89388535|NCT04968964|Experimental|Cohort 2: Currently receiving first line therapy|"1st line therapy with endocrine therapy + any FDA-approved CDK 4/6 inhibitor for ≤ 24 months with stable disease~Serum samples (analyzed using DiviTum® TKa) at Baseline, Week 2, Week 4, Week 6, Week 8, Week 12, Week 16, Week 20, Week 24 and every 12 weeks thereafter until disease progression or 36 months. Treating physician will evaluate the patient & review any updated results of the institutional standard of care monitoring tests. Following receipt of DiviTum® TKa value, the treating physician will review the preceding locked Study Care Plan and record any changes"
89003401|NCT05346484|Experimental|CF33-hNIS IV Administration Monotherapy|
89185625|NCT04077450|Experimental|Intervention Arm|Participants will complete the following components of baseline (T1) data collection: demographics, questionnaire, heart rate variability assessment. These participants will receive an online heart-focused breathing intervention. Participants will be asked to practice their breathing skills while monitoring their heart rate variability using the Welltory app on their smart device for the following two weeks. Participants will be instructed to maintain a log to record the date and time of each practice session. Research staff will make biweekly reminder calls to participants. After the two-week period, participants will complete post-intervention data collection (T2), which includes a questionnaire and HRV assessment.
89003402|NCT05346484|Experimental|CF33-hNIS IT Administration in Combination with Pembrolizumab|
89003403|NCT05346484|Experimental|CF33-hNIS IV Administration in Combination with Pembrolizumab|
89003404|NCT05344157|Experimental|XSTEM-OA|Single intra-articular injection of XSTEM-OA
88864162|NCT02667483|Experimental|DS-5141b|"DS-5141b, Subcutaneous injection~Part 1: DS-5141b will be injected subcutaneously once a week for 2 weeks at the following dose levels. Dose escalation will be performed. DS-5141b will be administered at dose levels 1 and 3 in Cohort 1 and at dose levels 2 and 4 in Cohort 2.~Level 1: 0.1 mg/kg~Level 2: 0.5 mg/kg~Level 3: 2.0 mg/kg~Level 4: 6.0 mg/kg~Part 2: Two doses of DS-5141b will be selected based on the results obtained in Part 1. Each selected dose will be administered subcutaneously once a week for 12 weeks.~Part 2-Extension-2: Two doses, 2.0 mg/kg or 6.0 mg/kg, of DS-5141b will be administered subcutaneously once a week for 48 weeks."
89003405|NCT05329922|Experimental|ALICE (experienced hearing aid/cochlear implant users)|Clients participating in this arm are asked to train their listening and communication skills using the ALICE app on their personal smart device for 8 weeks.
89003406|NCT05329922|No Intervention|Control (experienced hearing aid/cochlear implant users)|This arm will receive the standard of care given to the client. Persons with a moderate to profound hearing loss are provided with a hearing aid. Persons with a profound to severe HI are provided with a cochlear implant and concomitant rehabilitation. Most persons with a cochlear implant receive intensive rehabilitation during the first 6 months after their implantation. Afterwards, they mainly return for mapping of the device but not for listening training therapy.
89003407|NCT05329922|Experimental|ALICE (new hearing aid users)|Clients participating in this arm are asked to train their listening and communication skills using the ALICE app on their personal smart device during the hearing aid trial period (4-6 weeks on average).
89003408|NCT05329922|No Intervention|Control (new hearing aid users)|This arm will receive the standard of care given to the client during the hearing aid trial period.
89003409|NCT05327556|Active Comparator|0.5 mcg/kg Dose|Providers use 0.1 mL/kg of 5 mcg/mL epinephrine for target dose 0.5 mcg/kg
89003410|NCT05327556|Active Comparator|1.0 mcg/kg Dose|Providers use 0.1 mL/kg of 10 mcg/mL epinephrine for target dose of 1.0 mcg/kg
89003411|NCT05327023|No Intervention|Donor Arm|Donors for Recipients in Arms 1-4
89003412|NCT05327023|Experimental|Phase I Dose Escalation, Cohort 1 (matched)|DLI at escalating doses (1 x 10^6 CD3+ cells/kg, 3 x 10^6 CD3+ cells/kg, and 1 x 10^7 CD3+ cells/kg) on day +7 or +21 to assess for safety and determine Phase II dose (up to 18 evaluable patients)
89003413|NCT05327023|Experimental|Phase I Dose Escalation, Cohort 2 (haploidentical)|DLI at escalating doses (1 x 10^5 CD3+ cells/kg, 3 x 10^5 CD3+ cells/kg, and 1 x 10^6 CD3+ cells/kg) on day +7 or +21 to assess for safety and determine Phase II dose (up to 18 evaluable patients)
89003414|NCT05327023|Experimental|Phase II Efficacy, Cohort 1 (matched)|DLI at maximally tolerated, safe dose (from Phase I) to assess secondary clinical outcomes at this dosing level (up to 14 additional evaluable patients in each cohort)
88864173|NCT02630875|Active Comparator|A4250 1|Dose I
88864174|NCT02630875|Active Comparator|A4250 2|Dose 2
88864175|NCT02630875|Active Comparator|A4250 3|Dose 3
88864176|NCT02630875|Active Comparator|A4250 4|Dose 4
88864177|NCT02630875|Active Comparator|A4250 5|Dose 5
88864178|NCT02630875|Active Comparator|A4250 6|Dose 6
88864179|NCT02597998|Experimental|14C-BI 409306 - 25 mg|14C-BI 409306 oral solution
88864180|NCT02551952|Experimental|MentalPlus® PILOT-I|This preliminary group will be submitted to the digital game MentalPlus®, also be the submitted to fMRI before and after surgery. The results of standardized tests and the data of the MentalPlus® of patients undergoing surgery will be compared with the results of the same tests and the data of the MentalPlus® of healthy volunteers with similar characteristics regarding the variables age and education.
88864181|NCT02551952|Experimental|MentalPlus® PILOT-II|This preliminary group will be of healthy volunteers submitted to the digital game MentalPlus®. The results of standardized tests and the data of the MentalPlus® of volunteers will be compared with the results of tests of patients undergoing surgery and the data of the MentalPlus®.
88864182|NCT02551952|Active Comparator|Group I: MentalPlus®|Evaluated with neuropsychological tests and MentalPlus® before surgery. After surgery, from the 3rd postoperative day a tablet will be use with MentalPlus® in 7 versions for cognitive training during 7 days (7 versions with interfaces adapted for ages up to 20 years and 7 versions for ages over it).
89003415|NCT05327023|Experimental|Phase II Efficacy, Cohort 2 (haploidentical)|DLI at maximally tolerated, safe dose (from Phase I) to assess secondary clinical outcomes at this dosing level (up to 14 additional evaluable patients in each cohort)
89185626|NCT00577005|Experimental|1|Levetiracetam tablets
88864183|NCT02551952|Sham Comparator|Group II: MentalPlus®|Ratings with neuropsychological testing and evaluation with MentalPlus® before surgery will be realized. After surgery, from the 3rd postoperative day a tablet will be use for entertainment with short films (20 minutes) for use in the placebo effect of digital game MentalPlus® this group also will be submitted to fMRI before and after surgery. (With the intention to respond to the specificity of findings in relation to the control for active placebo effect)
88864184|NCT02551458|Experimental|Arm A: Systematic surgery|
88864185|NCT02551458|Experimental|Arm B: Surveillance and rescue surgery in cases of resectable|
88864186|NCT02549560|Active Comparator|tDCS GROUP|These patients will be submitted to 2 daily sessions of cerebral stimulation, starting from the first day after the surgery, for 4 consecutive days, with each session having 20 minutes, and a minimum break of 8 hours between them. Will be applied a direct current stimulus of 2 milliampere (mA) in the right anode and in the left cathode on the prefrontal right region.
89185627|NCT00577005|Placebo Comparator|2|matching placebo
89185628|NCT05162157||at-home spirometry|This group performs spirometry at home with the Nuvoair spirometer
89388536|NCT04968964|Experimental|Medical Oncologists|-Will be completing the Study Care Forms at Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24 and every 12 weeks thereafter until disease progression or 36 months.
88864187|NCT02549560|Sham Comparator|CONTROL GROUP|In these patients will be applied, with the same equipment used in tDCS, a simulated stimulus similar to the active one. They will also be submitted to some psychological test to evaluate theirs mnemonics, attentional, executive and global functions.
88864188|NCT02527421|Experimental|DFD01 Spray Group 1|DFD01 spray, twice daily, 15 days
88864189|NCT02527421|Experimental|DFD01 Spray Group 2|DFD01 spray, twice daily, 29 days
88864190|NCT02518594|Active Comparator|Progesterone|200mg micronized vaginal progesterone softgel capsule, daily from randomization to < 35 wks
88864191|NCT02518594|Placebo Comparator|Placebo|placebo softgel capsule, daily from randomization to < 35 wks
88864192|NCT02518594|Active Comparator|Arabin Pessary|placement management from randomization to < 35 wks
88864193|NCT02514278|Experimental|Chemotherapy and Radiochemotherapy|"Neoadjuvant chemotherapy Folfirinox, 4 cycles:~oxaliplatin: 85 mg/m2~irinotecan: 180 mg/m²~folinic acid: 400 mg/m2 (DL form) or 200 mg/m2 (L form)~5FU: 2400 mg/m2~Radiochemotherapy : 2 to 4 weeks after chemotherapy, 5 weeks (50 Gy, 2 Gy/session; 25 fractions) + capecitabine (1600 mg/m2 daily 5 days/7)"
88864194|NCT02514278|Active Comparator|Radiochemotherapy|Radiochemotherapy: 5 weeks (50 Gy, 2 Gy/session ; 25 fractions) + capecitabine (1600 mg/m2 daily 5 days/7, excluding weekends)
88864195|NCT02498977|Active Comparator|Arm A (weaning)|All participants satisfying clinical criteria will be weaned off immunosuppression drugs irrespective of biomarker result.
88864196|NCT02498977|Active Comparator|Arm B+ (weaning- positive biomarker)|Participants with a positive biomarker will be weaned of immunosuppression drugs.
88864197|NCT02498977|Active Comparator|Arm B- (maintenance)|Participant with negative biomarker test result will be informed of the result and will remain on baseline maintenance immunosuppression drugs.
88864198|NCT02387736|Experimental|Dialectical Behaviour Therapy-6 months|6 months of standard dialectical behaviour therapy treatment.
88864199|NCT02387736|Active Comparator|Dialectical Behaviour Therapy-12 months|12 months of standard dialectical behaviour therapy treatment
88864200|NCT02381561|Experimental|Treatment (ropidoxuridine, IMRT)|Beginning 30 minutes to 2 hours before radiation therapy, patients receive ropidoxuridine PO QD on days 1-28 in the absence of disease progression or unacceptable toxicity. Beginning on day 8, patients undergo IMRT 5 days a week for 3 weeks in the absence of disease progression or unacceptable toxicity.
88864201|NCT02379377|Experimental|Diagnostic (18F-FSPG PET)|Patients undergo an 18F-FSPG PET scan within 4 weeks of surgery or OLT. Patients may also receive a second 18F-FSPG PET scan following standard-of-care treatment.
88864202|NCT02379377|Experimental|Diagnostic (11C-Acetate PET or 18F-FDG PET)|Patients may undergo either carbon-11 (11C)-Acetate PET or 18F-FDG PET scans within 4 weeks of surgery or OLT.
88864203|NCT02332668|Experimental|Melanoma|Participants aged 6 months to <18 years with melanoma receive pembrolizumab, starting dose 2 mg/kg (maximum dose 200 mg), intravenously (IV) once every 3 weeks (Q3W). Enrollment of participants aged 6 months to <12 years with melanoma was closed with Amendment 8. Enrollment of participants aged ≥12 years to ≤18 years with melanoma continues.
88864204|NCT02332668|Experimental|Solid Tumors and Other Lymphomas|Participants aged 6 months to <18 years with solid tumors and other lymphomas receive pembrolizumab, starting dose 2 mg/kg (maximum dose 200 mg), IV Q3W. Initial enrollment limited to programmed death-ligand 1 (PD-L1)-positive participants. PD-L1-negative participants may enroll if responses are observed. Enrollment of participants with solid tumors and other lymphomas was closed with Amendment 8.
88864205|NCT02332668|Experimental|rrcHL|Participants aged 3 years to <18 years with rrcHL receive pembrolizumab, starting dose 2 mg/kg (maximum dose 200 mg), IV Q3W.
88864206|NCT02332668|Experimental|MSI-H|Participants aged 6 months to <18 years with microsatellite-instability-high (MSI-H) solid tumors receive pembrolizumab, starting dose 2 mg/kg (maximum dose 200 mg), IV Q3W.
88864207|NCT02332668|Experimental|TMB-H|Participants aged 6 months to <18 years with tumor-mutational burden-high ≥10 mutation/Mb (TMB-H) solid tumors receive pembrolizumab, starting dose 2 mg/kg (maximum dose 200 mg), IV Q3W.
88864208|NCT02332668|Experimental|Adjuvant Melanoma|Participants aged 12 years to <18 years with resected high-risk Stage IIB, IIC, III, or IV melanoma receive pembrolizumab, starting dose 2 mg/kg (maximum dose 200 mg), intravenously (IV) once every 3 weeks (Q3W).
88864209|NCT02247453|Experimental|Screening|Healthy heavy smokers aged 50-75 years
89189413|NCT05810441||Control group|Adult and pediatric subjects with inflammatory gastro-intestinal disorders (Crohn disease and ulcerative colitis in acute phase or in remission), oncologic diseases (tumors of the gastro intestinal tract) and infectious diseases (eg Helicobacter pylori gastritis) tested negative for serum anti-ttg
89189414|NCT05810389|Experimental|FFA toothbrush|
89388537|NCT04943497||ribociclib + AI/fulvestrant|Patients administered ribociclib + AI/fulvestrant by prescription AI: Aromatase inhibitor
88864210|NCT02222168|Experimental|BI 409306 fasted|Single dose 25 mg BI 409306 film-coated tablet, oral administration with 240 ml water in the morning under fasted condition.
88864211|NCT02222168|Experimental|BI 409306 fed|Single dose 25 mg BI 409306 film-coated tablet, oral administration with 240 ml water in the morning under fed condition.
88864212|NCT02222168|Experimental|BI 409306 at bed-time|Single dose 25 mg BI 409306 film-coated tablet, oral administration with 240 ml water at bed-time.
88864213|NCT02133183|Experimental|Arm I (sapanisertib before and after surgery)|Patients receive sapanisertib PO according to the results from Part I. Patients also undergo surgery on day 0. Within 45 days after surgery, patients receive sapanisertib PO according to the results from Part I. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88864214|NCT02133183|Experimental|Arm II (sapanisertib after surgery)|Patients undergo surgery on day 0. Within 45 days after surgery, patients receive sapanisertib PO according to the results from Part I. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88864215|NCT02078856|Experimental|A3384 Low dose|Administered twice daily for the duration of the study
88864216|NCT02078856|Experimental|A3384 High dose|Administered twice daily for the duration of the study
88864217|NCT02078856|Placebo Comparator|Placebo|Administered twice daily for the duration of the study
88864218|NCT02070965|Experimental|DFD01 Spray Group 1|DFD01 Spray, bid, 28 days
89185629|NCT04077060|Experimental|NIPT|Women randomized in the intervention group will be offered cfDNA screening, along with an early detailed anatomy scan, including nuchal measurement, at 11-13 weeks of gestation. cfDNA analysis will include a simultaneous microarray-based assay of non-polymorphic (chromosomes 13, 18, 21, X and Y) and polymorphic loci to estimate chromosome proportion and fetal fraction. NIPT will be performed at the time of randomization or after if gestational age at randomization < 9 6/7 weeks of gestation.
89185630|NCT04077060|Other|Combined screening|Control group includes the standard of care. In our department, first-trimester risk assessment is performed routinely at 11-13 weeks of gestation by FTCS as per standard of care. FTCS includes crown-rump length, NT measurements, and a detailed ultrasound examination based on ISUOG guidelines. All operators who perform this examination are certified by the UK Fetal Medicine Foundation (FMF). A specific risk for aneuploidy is not calculated if NT measurement is >3.5 mm or if fetal anomaly is identified. These cases are deemed to be at a very high risk for chromosomal abnormalities and are offered invasive testing.
89388538|NCT04943497||aplelicib + fulvestrant|Patients administered aplelicib + fulvestrant by prescription
89388539|NCT04943497||mono endocrine therapy|Patients administered mono endocrine therapy by prescription
89388540|NCT04943497||chemotherapy|Patients administered chemotherapy by prescription
89388541|NCT04941456|Active Comparator|Open Tracheostomy|Participants will perform the six-minute walk test each session to assess ambulation distance, alternating between the open tracheostomy (standard) versus the Passy-Muir Valve in place intervention on sequential days to compare results.
89388542|NCT04941456|Experimental|PMV in place|Participants will perform the six-minute walk test each session to assess ambulation distance, alternating between the open tracheostomy (standard) versus the Passy-Muir Valve in place intervention on sequential days to compare results.
89388543|NCT04933851|Experimental|ACT1VATE|Participants assigned to the intervention group will be offered a psychological intervention specifically designed to address diabetes-related emotional distress.
88864219|NCT02070965|Active Comparator|Comp01 Lotion|Comp01 Lotion, bid, 14 days
89388544|NCT04933851|Active Comparator|DSME/S (usual care)|Participants randomized to the usual care group will be offered standard diabetes self-management education and support (DSME/S).
89535325|NCT03323177|Other|Follow-up only|Patients who are reluctant to continue to consume the study formula will come to follow-up visits only without any intervention until final height is reached
89535326|NCT03226873|Experimental|Peer Navigation|PrEP-UP involves a Peer delivering PrEP education and counseling during street-based outreach followed by offer of a PrEP care appointment along with peer navigation (e.g., appointment accompaniment and reminders, etc.) for the first several PrEP visits.
89530422|NCT02516111|Active Comparator|Open flap debridement group|SRP with Open flap debridement (OFD) alone for treating intrabony defect
89530423|NCT02516111|Active Comparator|PRF group|SRP with Open flap debridement (OFD) with autologous Platelet rich fibrin (PRF) placement into intrabony defect
89530424|NCT02516111|Active Comparator|Alendronate group|SRP with Open flap debridement (OFD) with 1% Alendronate (ALN) placement into intrabony defect
89530425|NCT02516111|Active Comparator|Atorvastatin group|SRP with Open flap debridement (OFD) with 1.2% Atorvastatin (ATV) placement into intrabony defect
88864220|NCT02070965|Experimental|DFD01 Spray Group 2|DFD01 Spray, bid, 14 days
88864221|NCT01983241|Experimental|Alpha-1 MP 60 mg/kg|Alpha-1 MP 60 mg/kg administered weekly by IV infusion for 156 weeks
88864222|NCT01983241|Experimental|Alpha-1 MP 120 mg/kg|Alpha-1 MP 120 mg/kg administered weekly by IV infusion for 156 weeks
88864223|NCT01983241|Placebo Comparator|Placebo|0.9% Sodium Chloride for Injection, USP, administered weekly by IV infusion for 156 weeks
88864224|NCT01967069|Active Comparator|DFD01 Spray|DFD01 Spray twice daily
88864225|NCT01967069|Placebo Comparator|Vehicle Spray|Vehicle Spray twice daily
88864226|NCT01947491|Experimental|DFD01 Spray|DFD01 Spray twice daily for 28 days
88864227|NCT01947491|Placebo Comparator|Vehicle Spray|Vehicle Spray twice daily for 28 days
88864228|NCT01947491|Active Comparator|Comp01 Lotion|Comp01 Lotion twice daily for 14 days
88864229|NCT01947491|Placebo Comparator|Vehicle Lotion|Vehicle Lotion twice daily for 28 days
88864230|NCT01938222||Short Stitch|Short stitch suture technique (6:1) for abdominal all closure stitch interval < 0,5 cm and lateral 0,5-0,8 cm
88864231|NCT01861106|Active Comparator|Arm A|10/10 HLA Matched Related Donor or Unrelated Donor or 9/10 HLA with DQ mismatch Transplant
89530426|NCT03253471|Experimental|AL-611|
89388547|NCT04905407|Experimental|Part 1: Tamibarotene/Venetoclax/Azacitidine|"Participants will receive the tamibarotene/venetoclax/azacitidine triplet combination as follows: Azacitidine (intravenously or subcutaneously) at 75 milligrams (mg)/square meter (m^2) once daily, on Days 1 through 7 of each 28-day therapy cycle (per VIDAZA USPI). Alternative dosing of azacitidine (Days 1 through 5, 8, and 9) will be permitted throughout the study.~Venetoclax (orally) daily on Days 1 through 28 per standard of care. Standard of care daily dosing is 100 mg on Day 1, 200 mg on Day 2, and 400 mg on Day 3 and beyond.~Tamibarotene 6 mg twice daily (BID) orally, on Days 8 through 28 of each 28-day therapy cycle. Tamibarotene will only be administered to participants who have been confirmed as RARA-positive."
89388548|NCT04905407|Experimental|Part 2: Tamibarotene/Venetoclax/Azacitidine|Participants will receive the tamibarotene/venetoclax/azacitidine triplet combination at the dose and regimen selected in Part 1.
89388549|NCT04905407|Active Comparator|Part 2: Venetoclax/Azacitidine|Participants will receive the venetoclax/azacitidine combination at the dose and regimen selected in Part 1.
89388550|NCT04905407|Experimental|Part 3: Tamibarotene/Venetoclax/Azacitidine|Part 2 participants treated with venetoclax/azacitidine who experience progressive disease, relapse after initial CR or CRi response, or treatment failure may begin subsequent treatment in Part 3, where tamibarotene will be added to their regimen.
89388551|NCT04880863|Experimental|NAP in combination with docetaxel following obinutuzumab pretreatment|Subjects will receive obinutuzumab, 1,000 mg, administered by IV infusion on Days -13 and -12 of the first treatment cycle in order to reduce the titer of anti-drug antibodies to NAP. NAP will be administered in a daily dose of 10 μg/kg by IV bolus on Days 1 - 4 of treatment cycles 1-6, followed by docetaxel, 75 mg/m2 on Day 5. Treatment cycles with the combination NAP/docetaxel will be 21 days in duration. Starting cycle 7, NAP at a higher dose of 15 μg/kg will be administered on Day 1 and docetaxel on Day 2, in 21 days treatment cycles. Once NAP is given as monotherapy and not earlier than C7, cycles will be of 28 days of duration.
89530427|NCT03253471|Placebo Comparator|Placebo to Match AL-611|
88864232|NCT01861106|Active Comparator|Arm B|9/10 or 8/10 HLA Match Related Donor or Unrelated Donor or Haploidentical Donor Transplant
88864233|NCT01861106|Active Comparator|Arm C (combined with Arm B per Amendment N)|Haploidentical Related Donor Transplant
89530428|NCT02515955|Experimental|Cohort 1|Participants will be receiving either JNJ-54175446 at increasing dose levels using 2 oral formulation as suspension for oral dose once daily from Day 1 to Day 17 or minocycline 100 mg capsule twice daily from Day 1 to Day 17 or placebo matching with JNJ 54175446 once daily from Day 1 to Day 17.
89530429|NCT02515955|Experimental|Cohort 2|Participants will be receiving either JNJ-54175446 at increasing dose levels using 2 oral formulation as suspension for oral dose once daily from Day 1 to Day 17 or minocycline 100 mg capsule twice daily from Day 1 to Day 17 or placebo matching with JNJ 54175446 once daily from Day 1 to Day 17.
89535327|NCT03226717||Hepatitis C patients|Antiviral agents (sofosbuvir,daclatasvir,ribavirin) will be given to hepatitis C patients with arthropathy.
88864234|NCT01861106|Active Comparator|Arm D (Deleted this arm per amendment I)|Umbilical Cord Blood Transplant
88864235|NCT01861106|No Intervention|Arm E (Deleted this arm per amendment O)|Donor
88864236|NCT01856478|Experimental|afatinib|oral intake, once daily
88864237|NCT01856478|Active Comparator|methotrexate|intravenous bolus injection, once weekly
88864238|NCT01822314|Active Comparator|Paclitaxel|"Paclitaxel will be given on week 1, 2 and 3 followed by 1 week rest and will be repeated for 4 cycles.~AC or EC or FEC will then be given on day 1 every 3 weeks for 4 cycles"
88864239|NCT01822314|Experimental|Abraxane|"Abraxane will be given at the dosage of 125 mg/m2 on week 1, 2 and 3 followed by 1 week rest and will be repeated for 4 cycles.~AC or EC or FEC will then be given on day 1 every 3 weeks for 4 cycles"
88864240|NCT01753011||Stress Urinary Incontinence|Stress Urinary Incontinence
88864241|NCT01711554|Experimental|Treatment (lenalidomide, dinutuximab, isotretinoin)|Patients receive lenalidomide PO QD on days 1-21, dinutuximab IV over 10 hours on days 8-11, and isotretinoin PO BID on days 15-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
88864242|NCT01695941|Experimental|Treatment (alisertib, bortezomib, and rituximab)|"Patients receive alisertib PO BID on days 1-7; bortezomib SC on days 1, 8, and 15; and rituximab IV on day 1. Treatment repeats every 28 days* in the absence of disease progression or unacceptable toxicity.~Note: *After 8 courses, treatment with rituximab repeats once every 3 courses (12 weeks) in the absence of disease progression or unacceptable toxicity."
88864243|NCT01638533|Experimental|Treatment (romidepsin)|Patients receive romidepsin IV over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88864244|NCT01627574|Experimental|Motivational Intervention|There are two, 45-60 minute sessions of tailored Motivational Interviewing (MI). The first session occurs at the enrollment of the study, the second at 3 month follow-up.
89185631|NCT02581566|Active Comparator|Intrathecal Dexmedetomidine Group|30 patients will be given Intrathecal Dexmedetomidine plus Intrathecal Bupivacaine
88864245|NCT01627574|Active Comparator|Didactic Educational Intervention|There are two, 45-60 minute sessions of didactic educational intervention related to promoting awareness for sexual health involving contraception and STI prevention. The first session occurs at the enrollment of the study, the second at 3 month follow-up.
88864246|NCT01546545||Insulin Sensitivity in Pre-Diabetic Population|Healthy participants between the age of 18 and 70 years with fasting blood sugar that is between normal and diabetes.
88864247|NCT01475123|Active Comparator|Nicorandil|Nicorandil was administered orally (15mg/day).
88864248|NCT01475123|No Intervention|Non-nicorandil|Nicorandil was not administered.
88864249|NCT01366144|Experimental|Treatment (veliparib, paclitaxel, carboplatin)|"Patients receive veliparib* PO BID on days 1-7 and paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 3. Courses repeat every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.~NOTE: * All patients receive a single dose of veliparib PO on day -6 before course 1 (except patients with very severe renal dysfunction who receive veliparib on day -5 or -6 to coincide with a dialysis day)."
89189415|NCT05810389|Active Comparator|Varnish|
89388552|NCT04855734|Experimental|FACE-Rare Intervention|"FACE-Rare is a behavioral intervention that combines the CSNAT Pediatric Approach and the Respecting Choices® Next Steps ACP over 3 sessions.~Sessions 1&2: CSNAT is an evidence-based process of family caregiver assessment and support in specialized medical (palliative) care. The CSNAT tool is structured around 16 categories of family caregiver support. With the goal to decrease caregiver burden, this process consists of 5 stages wherein a nurse or practitioner works with the caregiver to create a shared support plan for the child.~Session 3: Respecting Choices® Next Steps- This advanced care planning (pACP) conversation engages families in a process for how to make future medical decisions consistent with their goals and values. The interview is structured in 6 stages to achieve 2 main goals: to facilitate conversations with the family about their child's medical condition, history, fears, values, beliefs, and hopes; and to set the stage for the family's future healthcare decisions."
89388553|NCT04855734|No Intervention|Treatment-as-Usual (TAU) Control|To minimize the burden to families, we have chosen a Treatment-as-Usual (TAU) comparison condition, where patients will receive their normal standard of care. Both study arms will receive palliative (specialized medical) care information at enrollment and complete questionnaires before and after the intervention or TAU period. Current practice for minors with life-limiting illnesses is to defer initial discussions of advanced care planning (pACP) until a medical crisis, so this is what the TAU control arm condition will consist of.
89388554|NCT04852328|Experimental|Schedule A: CUE-101|"In Schedule A, CUE-101 will be administered during the neoadjuvant phase as a single dose given 14 days prior to initiation of standard of care (SOC) therapy.~Standard of care therapy consists of surgery and postoperative adjuvant (cisplatin) and radiation therapy or cisplatin and radiation therapy (definitive-chemoradiation therapy)"
89388555|NCT04852328|Experimental|Schedule B: CUE-101|"In Schedule B, CUE-101 will be administered during the neoadjuvant phase as two doses: one dose given 14 days and one dose given 7 days prior to initiation of standard of care (SOC) therapy.~Standard of care therapy consists of surgery and postoperative adjuvant (cisplatin) and radiation therapy or cisplatin and radiation therapy (definitive-chemoradiation therapy)"
89388556|NCT04852328|Experimental|Schedule C: CUE-101|"In Schedule C, CUE-101 will be administered during the neoadjuvant phase as a single dose given 7 days prior to initiation of standard of care (SOC) therapy.~-Standard of care therapy consists of surgery and postoperative adjuvant (cisplatin) and radiation therapy or cisplatin and radiation therapy (definitive-chemoradiation therapy)"
89388557|NCT04848961|Experimental|Women who have had a mammogram|Participants will consist of eligible women who have had a mammogram
89388558|NCT04847466|Experimental|1/Arm 1|1-week lead in for PD-L1 CAR NK cell monotherapy followed by combination therapy of Pembrolizumab plus N-803
89185632|NCT02581566|Active Comparator|Intraarticular Dexmedetomidine Group|30 patients will be given Intraarticular Dexmedetomidine plus Intrathecal Bupivacaine
89185633|NCT02581566|Other|control Group|30 patients will be given Intrathecal Bupivacaine
88864250|NCT01317160|No Intervention|Routine care: Plaster Cast Treatment|Two weeks of postoperative conventional lower limb plaster cast immobilization in 30 degrees of plantarflexion
88864251|NCT01317160|Experimental|Intermittent pneumatic compression (IPC)|Two weeks of calf IPC by Aircast® VenaFlow® Elite System during immobilization in an orthosis Aicast® XP Walker.
88864252|NCT01314313|Experimental|PIIA - SAPIEN XT|PIIA is operable group
89185634|NCT02567019|Experimental|periodontal diseases|blood samples will be done for patients suffering of periodontal diseases
89185635|NCT02567019|Active Comparator|healthy volunteers|blood samples will be done for healthy volunteers
89185636|NCT05237076|Experimental|Diabetes Type 2|Patients with DM Type 2 using Oral Diabetes Medications only.
89185637|NCT05237076|Active Comparator|Healthy controls|Healthy controls without comorbidities.
89185638|NCT04077216|Experimental|Group A|Initially received the test meal with EVOO, then on crossover, received the meal without EVOO
89185639|NCT04077216|No Intervention|Group B|Initially received the test meal without EVOO, then on crossover, received the meal without EVOO
89185640|NCT00576927|Experimental|Group1|SHI followed by Active Drug Ramelteon
88864253|NCT01314313|Active Comparator|Control: SAVR|SAVR (surgical aortic valve replacement) is the control arm
89185641|NCT00576927|Placebo Comparator|Group 2|SHI Followed by Placebo
89189416|NCT05810389|Active Comparator|FFA gel|
89189417|NCT05810376|Experimental|Experimental Group|Experimental group will receive patient education, exercise, and digital-based physical activity intervention.
89189418|NCT05810376|Active Comparator|Control Group|Control group will receive patient education and exercise.
89189419|NCT05810337|Experimental|Splenda drink|Drink containing 4.5g Splenda dissolved on 250ml water.
89388559|NCT04845035|Experimental|BFM + Tyrosine Kinase Inhibitor|This study has 2 cohorts: participants aged 18 - 59 years and participants aged 60 or more years. Both cohorts receive the same study intervention with dosage adjusted for age. Participants receive the Berlin-Frankfurt-Münster (BFM) protocol plus dasatinib during a two-phase induction and a delayed re-induction. Participants receive the BFM protocol plus ponatinib during post-induction consolidations and maintenance.
89388560|NCT04840862|Experimental|rifabutin|Rifabutin PO [two 150mg capsules] ; Trikafta PO [one orange tablet containing ELX 100mg, TEZ 50mg, and IVA 75mg]
89388561|NCT04838626|Experimental|PET/CT imaging with [18F]CTT1057|All eligible participants will be enrolled to receive [18F]CTT1057 imaging agent on Day 1 and have PET/CT scan
89388562|NCT04823663||BSC Product Use|"Subject fulfilling one of the following conditions:~a. prospectively scheduled for a procedure involving i. use of a BSC EP Ablation product or BSC Capital Equipment product or ii. a BSC CRM product implant or b. retrospectively enrolled no more than 10 days after the index procedure and and all data necessary for appropriate reporting of all past visits is available and complete including i. the procedure where being diagnosed or treated with at least 3 separate BSC EP Ablation products/components or BSC Capital Equipment products/components or ii.the BSC CRM product implant."
89388563|NCT04821622|Experimental|Arm 1|Talazoparib plus enzalutamide
89388564|NCT04821622|Active Comparator|Arm 2|Placebo plus enzalutamide
89388565|NCT04817644|Experimental|Oral semaglutide|All participants will receive oral semaglutide once daily for a total of 10 days: 3 mg for 5 days followed by 7 mg for 5 days.
89388566|NCT04816708|Active Comparator|Arm 1: Intervention group (access to LIFT mindfulness app)|Participants randomized to the intervention arm will be provided access to LIFT app's daily mobile mindfulness therapy for 30 days.
89388567|NCT04816708|No Intervention|Arm 2: Control waitlist group (delayed access to LIFT mindfulness app)|Control participants will not receive access to the LIFT app daily mobile mindfulness therapy during study period. They may have access to LIFT app daily mobile mindfulness therapy after completion of the study period.
89388568|NCT04789291|Experimental|BI 1595043 fasted (Reference (R)) / BI 1595043 fed (Test (T))|"Two period crossover separated by a wash-out of at least 8 days:~Period 1: Healthy subjects received a single dose of 30 milligram (mg) BI 1595043 as film coated tablets (1x 5mg tablet and 1x 25mg tablet) following an overnight fast of at least 10 hours.~Period 2: Healthy subjects received a single dose of 30 milligram (mg) BI 1595043 as film coated tablets (1x 5mg tablet and 1x 25mg tablet) following an following a high fat/high calorie breakfast."
89388569|NCT04789291|Experimental|BI 1595043 fed (Test (T)) / BI 1595043 fasted (Reference (R))|"Two period crossover separated by a wash-out of at least 8 days:~Period 1: Healthy subjects received a single dose of 30 milligram (mg) BI 1595043 as film coated tablets (1x 5mg tablet and 1x 25mg tablet) following an following a high fat/high calorie breakfast.~Period 2: Healthy subjects received a single dose of 30 milligram (mg) BI 1595043 as film coated tablets (1x 5mg tablet and 1x 25mg tablet) following an overnight fast of at least 10 hours."
89388570|NCT04784715|Experimental|Arm A|Trastuzumab deruxtecan (T-DXd) plus pertuzumab-matching placebo
89388571|NCT04784715|Experimental|Arm B|Trastuzumab deruxtecan (T-DXd) plus pertuzumab
89388572|NCT04784715|Active Comparator|Arm C|Standard of care (Taxane (paclitaxel or docetaxel), trastuzumab, and pertuzumab)
89388573|NCT04781387|Experimental|CRS3123 200 milligram|"CRS3123 200 milligram dose (400 mg/day) given orally at approximately 6-hour intervals for 10 days.~Due to the difference in dosing schedules between CRS3123 (twice a day) and the standard of care vancomycin (four times a day) and appearance of study drugs used in the 3 Arms, placebo will be used to match the total number of capsules in each arm."
89388574|NCT04781387|Experimental|CRS3123 400 milligram|"CRS3123 400 milligram dose (800 mg/day) given orally at approximately 6-hour intervals for 10 days.~Due to the difference in dosing schedules between CRS3123 (twice a day) and the standard of care vancomycin (four times a day) and appearance of study drugs used in the 3 Arms, placebo will be used to match the total number of capsules in each arm."
88864254|NCT01258933|Experimental|Ofatumumab|Ofatumumab 300 mg dose 1, then 1,000 mg weekly * 7, (treatment) then 1,000 mg every 2 months beginning on week 12 for a total of 2 years of treatment or until progression (maintenance) of disease. The follow-up period will be the period after completion of maintenance.
89388575|NCT04781387|Active Comparator|Vancomycin 125 milligram|Vancomycin 125 milligram dose (500 mg/day) given orally at approximately 6-hour intervals for 10 days.
89388576|NCT04780464|Active Comparator|Standard doxorubicin|
89388577|NCT04780464|Experimental|Metronomic doxorubicin|
88864255|NCT01169259|Active Comparator|Vitamin D + fish oil|
89388578|NCT04780464|Experimental|Metronomic oral cyclophosphamide + prednisolone or prednisone|
89388579|NCT04777396|Experimental|Oral Semaglutide|Participants are given oral semaglutide once daily
89189420|NCT05810337|Placebo Comparator|Maltodextrin drink|Drink containing 4.5g maltodextrin dissolved on 250ml water.
89388580|NCT04777396|Placebo Comparator|Placebo (semagludtide)|Participants are given oral placebo once daily
89388581|NCT04772807||Healthy|
89388582|NCT04772807||Patients infected by COVID- 19 with no symptoms|
89388583|NCT04772807||Patients infected by COVID- 19 with symptoms|
89388584|NCT04772807||Patients diagnosed with atrial fibrillation|
89388585|NCT04772807||Hypertensive patients|
89388586|NCT04772807||Heart failure patients, EF < 40%|
89388587|NCT04772807||Heart failure patients, EF > 40% and < 60%|
89388588|NCT04772807||Heart failure patients, EF > 60%|
88864256|NCT01169259|Active Comparator|Vitamin D + fish oil placebo|
88864257|NCT01169259|Active Comparator|Vitamin D placebo + fish oil|
88864258|NCT01169259|Placebo Comparator|Vitamin D placebo + fish oil placebo|
88864259|NCT01069783|Experimental|A3309 low dose|
88864260|NCT01069783|Experimental|A3309 high dose|
88864261|NCT01069783|Placebo Comparator|Placebo|
88864262|NCT00492817|Experimental|Single Session Stereotactic Body Radiotherapy (SBRT)|On day 1 of radiation treatment, a CT scan using CT-on-Rails in the same treatment room, immediately before the radiation treatment will be performed.
89388589|NCT04761198|Experimental|Squamous cell carcinoma of the head and neck|Advanced and/or recurrent or metastatic squamous cell carcinoma of the head and neck
89388590|NCT04761198|Experimental|Cervical cancer on or after chemotherapy|Recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1
89388591|NCT04761198|Experimental|Gastric or gastroesophageal junction adenocarcinoma|Recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma
89388592|NCT04761198|Experimental|Endometrial carcinoma post-platinum <3L treatment|Advanced and/or metastatic endometrial carcinoma
89388593|NCT04761198|Experimental|Tumor burden high (TMB-H) and microsatellite stable (MSS) solid tumors|Advanced or metastatic tumor mutational burden-high (TMB-H)
89388594|NCT04761198|Experimental|Rare disease with high prevalence of TIGIT expression|Select rare tumors
89388595|NCT04761198|Experimental|Ovarian cancer|Recurrent high grade serous and endometrioid ovarian cancer, fallopian tube cancer or primary peritoneal cancer following front-line platinum-based therapy
89388596|NCT04761198|Experimental|Endometrial carcinoma post standard of care therapy|Advanced and/or metastatic endometrial carcinoma
89388597|NCT04759911|Experimental|Treatment (selpercatinib)|Patients receive selpercatinb PO BID on days 1-28. Treatment repeats every 28 days for up to 7 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgery.
89388598|NCT04754711|Experimental|Group with oral nutritional supplement|Group 1: receiving an oral nutritional supplement to increase calorie intake by around 20%
89388599|NCT04754711|No Intervention|Control group|"Group 2: controls receiving normal calorie intake without oral nutritional supplement"
89388600|NCT04745559|Experimental|Treatment|Pneumococcal conjugate vaccine (PCV13) .5 ml will be administered intramuscularly three times: 7 days (range 4 to 21 days) before apheresis collection and on day +30 (range +21 to +37) and day +90 (range +75 to +115) after CAR T cell infusion.
89388601|NCT04738838|Experimental|Oxytocin Nasal Spray|Single dose of intranasal oxytocin (48 IU) prior to testing protocol.
89388602|NCT04738838|Placebo Comparator|Placebo Nasal Spray|Single dose of intranasal treatment with placebo (identical to oxytocin nose spray minus the oxytocin)
89388603|NCT04732247|Experimental|Oxytocin nasal spray|4x per day (QID) intranasal treatment with oxytocin (48 IU per dose)
89388604|NCT04732247|Placebo Comparator|Placebo nasal spray|4x per day (QID) intranasal treatment with placebo (identical to oxytocin nose spray minus the oxytocin)
89388605|NCT04710940|Experimental|Intervention - Diabetes BOOST|Intervention group participants will complete a baseline survey, receive a referral to DSMT from the research team, a mailed welcome letter and self-care education sent via a series of personalized patient portal secure messages, text messages, and video call. They will be sent text messages with information about one of the American Association of Diabetes Educators 7 self-care behaviors and will receive encouragement to author their own self-management behavioral goals. Participants will also complete a telehealth training video call with research staff and review the goals that the participant replied with. The participant will then be encouraged to send a patient portal message to their DSMT CDCES that includes their personalized goals prior to their scheduled DSMT session. They will then complete a 3-month follow-up survey and qualitative interview.
89388606|NCT04710940|Active Comparator|Usual Care|Comparison Group participants will complete a baseline survey, receive a DSMT referral request from research team to their primary care provider and a mailed welcome letter. The mailed letter will welcome the participant to the study and contain general information about diabetes self-care behaviors and goal setting. They will complete a DSMT session. They will then complete a 3-month follow-up survey and qualitative interview.
89388607|NCT04706689||Unresponsive wakefulness syndrome patients (UWS)|The level of consciousness will be assessed with the Simplified Evaluation of CONsciousness Disorder (SECONDs) and the Coma Recovery Scale-Revised (CRS-R).
89388608|NCT04706689||Minimally conscious patients MINUS (MCS-)|The level of consciousness will be assessed with the Simplified Evaluation of CONsciousness Disorder (SECONDs) and the Coma Recovery Scale-Revised (CRS-R).
89388609|NCT04706689||Minimally conscious patients PLUS|The level of consciousness will be assessed with the Simplified Evaluation of CONsciousness Disorder (SECONDs) and the Coma Recovery Scale-Revised (CRS-R).
89388610|NCT04706689||Patients emerging from the minimally conscious state (EMCS)|The level of consciousness will be assessed with the Simplified Evaluation of CONsciousness Disorder (SECONDs) and the Coma Recovery Scale-Revised (CRS-R).
89388611|NCT04697719|Experimental|Aspirin 81mg, Then Aspirin 325mg|After a 3 week placebo run-in period, participants first receive Aspirin 81mg capsule daily for 3 weeks. After a placebo washout period of 3 weeks, they then receive Aspirin 325mg capsule daily for another 3 weeks.
88864263|NCT00367666|Experimental|Patients Diagnosed with Breast Cancer|
89388612|NCT04697719|Experimental|Aspirin 325mg, Then Aspirin 81mg|After a 3 week placebo run-in period, participants first receive Aspirin 325mg capsule daily for 3 weeks. After a placebo washout period of 3 weeks, they then receive Aspirin 81mg capsule daily for another 3 weeks.
89388613|NCT04682483||Cardiogenic Shock Patients|"Cardiogenic Shock patients eligible for this study are defined by at least one of the two categories below.~Patients have at least 2 of the following concurrently at any point during the index hospitalization: MAP < 60mmHg or a >30mmHg drop in MAP from baseline, SBP < 90mmHg or a >30mmHg drop in SBP from baseline, Pulse > 100, Cardiac Index < 2.2, Cardiac Power Output ≤ 0.6 or PAPI < 1.0.~Patients require the use of at least 1 vasopressor, inotrope or acute mechanical circulatory support device to maintain values above the above targets."
89388614|NCT04681066|Active Comparator|2.0 mg/kg (1.25 mL/kg)|administered intravenously over 4 hours at a constant rate of infusion. They will be administered every 24 hours (±1 hours) for three consecutive days for a total of 3 doses.
89388615|NCT04681066|Active Comparator|1.0 mg/kg (0.625 mL/kg)|administered intravenously over 4 hours at a constant rate of infusion. They will be administered every 24 hours (±1 hours) for three consecutive days for a total of 3 doses.
89388616|NCT04681066|Active Comparator|0.5 mg/kg (0.3125 mL/kg)|administered intravenously over 4 hours at a constant rate of infusion. They will be administered every 24 hours (±1 hours) for three consecutive days for a total of 3 doses.
89388617|NCT04681066|Placebo Comparator|Placebo (1.25, 0.625, or 0.3125 mL/kg)|patients randomized to placebo will receive one of three following volumes (1.25 mL/kg, 0.625 mL/kg, and 0.3125 mL/kg. although three volumes - all patients randomized to placebo will be analyzed together as one arm. administered intravenously over 4 hours at a constant rate of infusion. They will be administered every 24 hours (±1 hours) for three consecutive days for a total of 3 doses.
89388618|NCT04670822|Experimental|Breastfeeding intervention group|A multicomponent behavioral intervention to promote breastfeeding
89388619|NCT04670822|Placebo Comparator|Attention placebo control group|General infant care counseling and support
89388620|NCT04669600|Experimental|SAR445088|Participants received SAR445088 (BIVV020).
89388621|NCT04660955||Patients|Patients who had ACL reconstruction
89388622|NCT04660955||Controls|Controls who have no previous knee injury or surgery, no diagnosis of osteoarthritis
89388623|NCT04652154|Other|Control|Control group is recieving treatment as ususal
89388624|NCT04652154|Experimental|Intervention group|The intervention group getting the new assessment by a complementary professional team
89388625|NCT04648904|Experimental|Post-Mastectomy Radiotherapy|Treatment will consist of PMRT delivered using external beam RT techniques to a dose of 26 Gy in 5 fractions of 5.2 Gy delivered on consecutive weekdays with an optional chest wall boost of 5.2 Gy for 1-2 fractions or an alternate boost schedule of 2.5 Gy for 1-4 fractions at the discretion of the treating physician.
89388626|NCT04631406|Experimental|Neural Stem cells injected intracerebrally|Subject cohorts will be treated with increasing doses of Neural Stem Cells injected intracerebrally using a traditional 3+3 trial design
89388627|NCT04630496|Experimental|PRE-OPERATIVE EXERCISE TRACKING|"Participant baseline information will be collected from their electronic medical records.~After enrollment, participants will be provided a mobile device (Fitbit) to wear for tracking steps for 1 week prior to their scheduled surgery.~Participants will keep a log of daily steps for the 1 week they are wearing the device and receive one progress check-in call during the week.~The device and log will be turned in either on a pre-surgery clinic visit or on the day of surgery whichever comes first."
89388628|NCT04600466||Retrospective Non-Hispanics|Molecular testing will be done on formalin fixed paraffin-embeded (FFPE) tissue collected at the time of gastroadenocarcinoma diagnosis and subsequent biopsies. Participants who are alive will be asked to complete a survey and consent to germline testing.
89388629|NCT04600466||Retrospective Hispanic|Molecular testing will be done on formalin fixed paraffin-embeded (FFPE) tissue collected at the time of gastroadenocarcinoma diagnosis and subsequent biopsies. Participants who are alive will be asked to complete a survey and consent to germline testing.
88864264|NCT00114101|Experimental|Arm I (melphalan, autologous PBSCT, lenalidomide)|Beginning between day 100-110, patients receive lenalidomide PO once daily. Treatment continues in the absence of disease progression or unacceptable toxicity.
88864265|NCT00114101|Placebo Comparator|Arm II (melphalan, autologous PBSCT, placebo)|Beginning between day 100-110, patients receive placebo PO once daily. Treatment continues in the absence of disease progression or unacceptable toxicity.
88864266|NCT00096434|Experimental|Arm I|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89185642|NCT05742087||Patients presenting with neurological symptoms and anti-GFAP antibodies in the CSF.|"This is a non-interventional study involving biological samples. Samples are already stored in biobank repositories and collected as part of good clinical practice in the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population. Patients have already gave explicit written consent for biological specimens sampling and storage at the iological Resource Center of the Hospices Civils de Lyon (CRB-HCL) (including tissue, cells or biological fluids).~The group will be composed of patients included in the French cohort of patients with neurological syndromes and anti-GFAP antibodies in the CSF."
89189421|NCT05810324|Experimental|18F-FAPI|Experimental: Experimental: 18F-FAPI Each subject receive a single intravenous injection of 18F-FAPI, and undergo PET/CT imaging within the specificed time.
89388630|NCT04600466||Prospective Non-Hispanic|Molecular testing will be done on formalin fixed paraffin-embeded (FFPE) tissue collected at the time of gastroadenocarcinoma diagnosis and subsequent biopsies. Participants will be asked to complete a survey and consent to germline testing.
89388631|NCT04600466||Prospective Hispanic|Molecular testing will be done on formalin fixed paraffin-embeded (FFPE) tissue collected at the time of gastroadenocarcinoma diagnosis and subsequent biopsies. Participants will be asked to complete a survey and consent to germline testing.
89388632|NCT04591743|Experimental|Experimental group|
89388633|NCT04591743|Placebo Comparator|Placebo group|
89388634|NCT04564898|Experimental|trifluridine/tipiracil plus capecitabine and bevacizumab|
89388635|NCT04559334|Other|open label|All participants will receive Tetrasodium EDTA Catheter Lock Solution (KiteLock™ 4% Sterile Catheter Lock Solution)
89388636|NCT04552769|Experimental|Abemaciclib|Each cycle of therapy will be 28 days long. A completed cycle will be twice daily abemaciclib. Number of Cycles: until progression or unacceptable toxicity develops
89388637|NCT04550832|Active Comparator|Arm1(D0)|"Participants receive the following medication for the duration of 16weeks together with food.~Delpazolid : Will not administered~Bedaquiline: will be dosed as per the licensed dose: 400 mg orally once daily for the first 14 days, then 200 mg three times a week.~Delamanid: will be dosed as per the licensed dose: 200 mg orally twice daily doses of 100 mg.~Moxifloxacin: will be dosed as per the licensed dose: 400 mg orally once daily"
89388638|NCT04550832|Experimental|Arm2(D400)|"Participants receive the following medication for the duration of 16weeks together with food.~Delpazolid : Will be dosed 400 mg orally once daily~Bedaquiline: will be dosed as per the licensed dose: 400 mg orally once daily for the first 14 days, then 200 mg three times a week.~Delamanid: will be dosed as per the licensed dose: 200 mg orally twice daily doses of 100 mg.~Moxifloxacin: will be dosed as per the licensed dose: 400 mg orally once daily"
89388639|NCT04550832|Experimental|Arm3(D800-OD)|"Participants receive the following medication for the duration of 16weeks together with food.~Delpazolid : Will be dosed 800 mg orally once daily~Bedaquiline: will be dosed as per the licensed dose: 400 mg orally once daily for the first 14 days, then 200 mg three times a week.~Delamanid: will be dosed as per the licensed dose: 200 mg orally twice daily doses of 100 mg.~Moxifloxacin: will be dosed as per the licensed dose: 400 mg orally once daily"
89388640|NCT04550832|Experimental|Arm4(D1200)|"Participants receive the following medication for the duration of 16weeks together with food.~Delpazolid : Will be dosed 1200 mg orally once daily~Bedaquiline: will be dosed as per the licensed dose: 400 mg orally once daily for the first 14 days, then 200 mg three times a week.~Delamanid: will be dosed as per the licensed dose: 200 mg orally twice daily doses of 100 mg.~Moxifloxacin: will be dosed as per the licensed dose: 400 mg orally once daily"
89388641|NCT04550832|Experimental|Arm5(D800-BD)|"Participants receive the following medication for the duration of 16weeks together with food.~Delpazolid : Will be dosed 800 mg orally twice daily~Bedaquiline: will be dosed as per the licensed dose: 400 mg orally once daily for the first 14 days, then 200 mg three times a week.~Delamanid: will be dosed as per the licensed dose: 200 mg orally twice daily doses of 100 mg.~Moxifloxacin: will be dosed as per the licensed dose: 400 mg orally once daily"
89388642|NCT04515407|Other|Order 1|All participants will receive PAS in three experimental conditions, randomized to the order of condition. Experimental order will be counterbalanced across participants. Order 1 will be: Seated@Rest, Seated@Active, Walking.
89388643|NCT04515407|Other|Order 2|All participants will receive PAS in three experimental conditions, randomized to the order of condition. Experimental order will be counterbalanced across participants. Order 2 will be: Seated@Active, Walking, Seated@Rest.
89388644|NCT04515407|Other|Order 3|All participants will receive PAS in three experimental conditions, randomized to the order of condition. Experimental order will be counterbalanced across participants. Order 3 will be: Walking, Seated@Rest, Seated@Active.
89388645|NCT04515186|Other|Meglumine Antimoniate|Meglumine Antimoniate, 20 mg/kg/day for 20 days parenterally. This trial arm was discontinued after protocol amendment 7. However, patients assigned to this arm before protocol amendment 7 becomes effective will continue in the study and will receive complete treatment as initially planned.
89388646|NCT04515186|Active Comparator|Miltefosine monotherapy|Miltefosine monotherapy 2.5 mg/kg/day for 28 days orally
89388647|NCT04515186|Experimental|Thermotherapy + miltefosine|"Thermotherapy (one session, 50⁰C for 30 applications*) + miltefosine 2.5 mg/kg/day for 21 days orally."
89388648|NCT04505579||Tether|Patients who have received The Tether HUD for treatment of idiopathic scoliosis.
89388649|NCT04504435|Experimental|Participants in Cohort 1|Participants will receive a maximum of 3 ascending dose levels of GSK3494245 starting with 20 milligram (mg) and 1 placebo dose orally on Day 1 of each treatment period under fasted conditions. There will be a washout period of at least 48 hours or 5-half-lives (whichever is longer) between each dose for an individual participant.
89388650|NCT04504435|Experimental|Participants in Cohort 2|Participants will receive a maximum of 3 ascending dose levels of GSK3494245 starting with dose level (DL) 5 and 1 placebo dose orally on Day 1 of each treatment period under fasted conditions. There will be a washout period of at least 48 hours or 5-half-lives (whichever is longer) between each dose for an individual participant.
89388651|NCT04504435|Experimental|Cohort 3: Participants receiving GSK3494245 (fasted then fed)|Participants will receive the selected dose level (DLX) of GSK3494245 in the fasted state on Day 1 in Period 1 followed by a single dose of GSK3494245 in the fed state in Period 2. There will be a washout period of at least 48 hours or 5-half-lives (whichever is longer) between each dose for an individual participant.
89003416|NCT05321602|Experimental|LY03010 156 mg treatment group, deltoid|"LY03010 (paliperidone palmitate) is a pharmaceutical equivalent drug product to the listed drug (LD) product INVEGA SUSTENNA®. The chemical name is (9RS)-3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4-oxo-4H-pyrido[1,2-a]pyrimidin-9-yl hexadecanoate. Its molecular formula is C39H57FN4O4 and its molecular weight is 664.89.~LY03010 is white to off-white sterile aqueous extended-release suspension of paliperidone palmitate for IM injection. In LY03010 treatment group, all subjects will receive the first dose of 156 mg IM injection on Day 1 in the deltoid muscle."
89388652|NCT04504435|Experimental|Cohort 3: Participants receiving GSK3494245 (fed then fasted)|Participants will receive the DLX of GSK3494245 in the fed state on Day 1 in Period 1 followed by a single dose of GSK3494245 in the fasted state in Period 2. There will be a washout period of at least 48 hours or 5-half-lives (whichever is longer) between each dose for an individual participant.
89388653|NCT04499248|Experimental|Cohort 1 -Dose A|Single dose of AGN-193408 SR Dose A administered in the study eye on Day 1. One drop of Lumigan 0.01% administered in the non-study eye once daily every evening starting on Day 1.
89388654|NCT04499248|Experimental|Cohort 1 - Dose B|Single dose of AGN-193408 SR Dose B administered in the study eye on Day 1. One drop of Lumigan 0.01% administered in the non-study eye once daily every evening starting on Day 1.
89388655|NCT04499248|Experimental|Cohort 2 - Dose A|AGN-193408 SR Dose A (single dose on Day 1) + vehicle eye drops (once daily in the evening starting on Day 1) administered in the study eye. Lumigan (once daily in the evening starting on Day 1) + Sham AGN-193408 SR (single administration on Day 1) administered in the non-study eye.
89388656|NCT04499248|Experimental|Cohort 2 -Dose B|AGN-193408 SR Dose B (single dose on Day 1) + vehicle eye drops (once daily in the evening starting on Day 1) administered in the study eye. Lumigan (once daily in the evening starting on Day 1) + Sham AGN-193408 SR (single administration on Day 1) administered in the non-study eye.
89388657|NCT04499248|Experimental|Cohort 3 - Dose A|AGN-193408 SR Dose A (single dose on Day 1) + vehicle eye drops (once daily in the evening starting on Day 1) administered behind the study eye. Lumigan (once daily in the evening starting on Day 1) + Sham AGN-193408 SR (single administration on Day 1) administered in the non-study eye.
89388658|NCT04499248|Experimental|Cohort 3 -Dose B|AGN-193408 SR Dose B (single dose on Day 1) + vehicle eye drops (once daily in the evening starting on Day 1) administered behind the study eye. Lumigan (once daily in the evening starting on Day 1) + Sham AGN-193408 SR (single administration on Day 1) administered in the non-study eye.
89189422|NCT05810298|Experimental|Smokers Group|"Education about smoking~Asana practice (Only standing yoga poses with rhytmic breathing)~Pranayam (Rhytmic regulated breathing)"
89388659|NCT04481061|Other|Decision Making About Genetic Results|Adolescents between 13-21 and parent (if applicable) will make decisions about learning results using an electronic decision tool. Results that match their choices will be returned.
89388660|NCT04477330|Experimental|Priming+HIISTT|Facilitatory transcranial direct current stimulation (tDCS) and ankle motor training before high intensity interval speed based treadmill training
89388661|NCT04477330|Sham Comparator|Sham+HIISTT|Sham tDCS before high intensity interval speed based treadmill training
89530430|NCT02515955|Experimental|Cohort 3|Participants will be receiving either JNJ-54175446 at increasing dose levels using 2 oral formulation as suspension for oral dose once daily from Day 1 to Day 17 or minocycline 100 mg capsule twice daily from Day 1 to Day 17 or placebo matching with JNJ 54175446 once daily from Day 1 to Day 17.
89530431|NCT02515955|Experimental|Cohort 4|Participants will be receiving either JNJ-54175446 at increasing dose levels using 2 oral formulation as suspension for oral dose once daily from Day 1 to Day 17 or minocycline 100 mg capsule twice daily from Day 1 to Day 17 or placebo matching with JNJ 54175446 once daily from Day 1 to Day 17.
88864267|NCT00565266|Experimental|"Tio + 1xICS || LABA + 1xICS || 2xICS"|"Participants will take part in three 16-week treatment periods, which will occur in the following order:~tiotropium bromide inhalation powder 18 mcg once daily (Tio) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)~salmeterol xinafoate inhalation powder 50 mcg twice daily (LABA) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)~beclomethasone dipropionate 160 mcg twice daily (2xICS)~Each of the three 16-week treatment periods will consist of 14 weeks of treatment followed by a 2-week washout period, in which participants will receive beclomethasone dipropionate 80 mcg twice daily (1xICS)."
88864268|NCT00565266|Experimental|"TIO + 1xICS || 2xICS || LABA + 1xICS"|"Participants will take part in three 16-week treatment periods, which will occur in the following order:~tiotropium bromide inhalation powder 18 mcg once daily (Tio) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)~beclomethasone dipropionate 160 mcg twice daily (2xICS)~salmeterol xinafoate inhalation powder 50 mcg twice daily (LABA) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)~Each of the three 16-week treatment periods will consist of 14 weeks of treatment followed by a 2-week washout period, in which participants will receive beclomethasone dipropionate 80 mcg twice daily (1xICS)."
88864269|NCT00565266|Experimental|"LABA + 1xICS || Tio + 1xICS || 2xICS"|"Participants will take part in three 16-week treatment periods, which will occur in the following order:~salmeterol xinafoate inhalation powder 50 mcg twice daily (LABA) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)~tiotropium bromide inhalation powder 18 mcg once daily (Tio) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)~beclomethasone dipropionate 160 mcg twice daily (2xICS)~Each of the three 16-week treatment periods will consist of 14 weeks of treatment followed by a 2-week washout period, in which participants will receive beclomethasone dipropionate 80 mcg twice daily (1xICS)."
88864270|NCT00565266|Experimental|"LABA + 1xICS || 2xICS || Tio + 1xICS"|"Participants will take part in three 16-week treatment periods, which will occur in the following order:~salmeterol xinafoate inhalation powder 50 mcg twice daily (LABA) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)~beclomethasone dipropionate 160 mcg twice daily (2xICS)~tiotropium bromide inhalation powder 18 mcg once daily (Tio) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)~Each of the three 16-week treatment periods will consist of 14 weeks of treatment followed by a 2-week washout period, in which participants will receive beclomethasone dipropionate 80 mcg twice daily (1xICS)."
88864271|NCT00565266|Experimental|"2xICS || Tio + 1xICS| || LABA + 1xICS"|"Participants will take part in three 16-week treatment periods, which will occur in the following order:~beclomethasone dipropionate 160 mcg twice daily (2xICS)~tiotropium bromide inhalation powder 18 mcg once daily (Tio) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)~salmeterol xinafoate inhalation powder 50 mcg twice daily (LABA) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)~Each of the three 16-week treatment periods will consist of 14 weeks of treatment followed by a 2-week washout period, in which participants will receive beclomethasone dipropionate 80 mcg twice daily (1xICS)."
88864272|NCT00565266|Experimental|"2xICS || LABA + 1xICS || Tio + 1xICS"|"Participants will take part in three 16-week treatment periods, which will occur in the following order:~beclomethasone dipropionate 160 mcg twice daily (2xICS)~salmeterol xinafoate inhalation powder 50 mcg twice daily (LABA) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)~tiotropium bromide inhalation powder 18 mcg once daily (Tio) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)~Each of the three 16-week treatment periods will consist of 14 weeks of treatment followed by a 2-week washout period, in which participants will receive beclomethasone dipropionate 80 mcg twice daily (1xICS)."
88864273|NCT05609526|No Intervention|1.Group (Compression Therapy)|"The patient will be placed in the supine position. Short stretch bandages of 6, 8, 10 and 12 cm will be applied to the extremity in a multi-layered and special way. Starting with the finger bandage, the pressure will be reduced as it goes distally. The patient's gait and circulation will be checked after bandaging is finished.~will be."
88864274|NCT05609526|Experimental|2.Group (Inspiratory muscle training)|"Maximum inspiratory intraoral pressure (MIP) and expiratory intraoral pressure (MEP) will be measured before patients begin IMT. Total training time 30 minutes per day will be. On the first day, the MIP levels of the participants will be evaluated and the training workload will be determined as 30% of the MIP. For IMT, after a nose clip was inserted from the participants They will be asked to sit on the mouthpiece of the device and close their lips tightly. With the device in this position, the device for four to five breath rests after every 10 breathing cycles.~mouth, and repeat the cycle for 15 minutes."
89388662|NCT04472351|Experimental|ASCEND-I|Computerized WM training with Rehacom will be implemented in daily 30-minute sessions that are scheduled prior to the participant's occupational therapy (OT) session as an adjunct to routine rehabilitation. Tasks are tailored to the participant's current ability level and are adaptive to performance changes. During these sessions, the study staff member will use guided questioning to help the participant anticipate challenges, reflect on performance, and link computerized exercises to the Multicontext sessions. The Multicontext treatment sessions will be delivered within the participant's OT session by an OT. The Multicontext approach helps individuals to self-discover WM-related error patterns and learn to anticipate WM performance challenges through repeated practice using functionally-relevant activities. The OT conducts guided questioning pre- and post-task to help the participant anticipate challenges and self-discover WM strategies.
89388663|NCT04472351|No Intervention|Enhanced Usual Care|The control condition will account for the time spent with rehabilitation therapists and study staff and provide more general cognitive stimulation. The control group will receive usual, standard of care occupational therapy during OT by inpatient rehabilitation staff who are not trained in the Multicontext approach. The standard OT session often focuses on cognition in a non-standardized and non-targeted manner without the targeting of WM and guided self-discovery of the Multicontext approach. To control for the cognitive training element of ASCEND, individuals randomized to the control condition will meet with a study staff member for 30 minutes of general cognitive stimulation that includes word-searches, crossword puzzles, and/or jigsaw puzzles.
89388664|NCT04464668||Wave 1 Only: Clinics using CARES Intervention|Based on a stratified (rural vs urban) procedure, investigators will randomly select 7 clinics to implement the Colorectal Cancer Awareness, Research, Education & Screening (CARES) intervention.
89388665|NCT04464668||Wave 1 Only: Control Clinics|Based on a stratified (rural vs urban) procedure, investigators will randomly select 7 clinics as control (usual care) clinics.
89388666|NCT04464668||All Clinics|For Wave 2, the 7 clinics in the control group will roll out as intervention clinic, thus, all 14 clinics will be exposed to the intervention by year 2.
89388667|NCT04460586|Experimental|Omadacycline IV followed by PO|Omadacycline 100mg IV, Omadacycline 300 mg tablet
89388668|NCT04460040|Experimental|Intervention|Exercise in moderate intensity tailored individually to 20 kcal/kg/week (range 1500-2000 kcal/week) with a free choice to exercise at home/gym on a treadmill or outdoors.
89185643|NCT02580630|Active Comparator|Training and glucocorticosteroid|"Patients are instructed to carry out strengthening exercises for the diseased achilles tendon 3 times a week. Physiotherapist will instruct all patients in these heavy slow resistance exercises. First time one week after the first injection, and then every month.~All patients are informed to a reduction in running and jumping sports for the first 3 months, thereafter slowly progressing to normal sports activity.~Ultrasound guided injection with glucocorticosteroid: 1ml Lidocain 5 mg/ml and 1 ml methylprednisolone 40mg/ml in Kagers triangle underneath the thickest part of the achilles tendon. Injection is given every months until the tendon pain is markedly diminished (max 3 injections)."
89388669|NCT04453033|Active Comparator|Investigational Device|The Celeste device resembles a large tablet. It has a protective cover that folds into a stand and is magnetically attached to the back of the device. It produces a low intensity of specific bandwidths of light believed to be responsible for circadian and alerting responses in humans. The overall emission produces a pleasing soft glow of light.
89388670|NCT04453033|Sham Comparator|Control Device|The Control device is identical in appearance to Celeste. When turned on, the device emits a soft diffused light that is indistinguishable in color from the Active Device. However, this device produces a different amount of the specific wavelengths thought to be effective in the Active Device. It is impossible to tell the difference between the sham device and the active device by looking at them.
89388671|NCT04447222||Observational (survey)|Participants complete a survey online over 35-45 minutes about their experiences regarding the COVID-19 pandemic.
88864275|NCT05609526|Experimental|3.Group (Calf muscle exercise training)|A strengthening treatment program will be applied to the calf muscles. CMET will consist of static stretching exercise for the dorsiflexors and plantar flexors, isotonic resistance exercise with elastic resistance bands, heel and toe lift in both feet, followed by toe raising and lowering without heel raising. An isotonic exercise (mini squat) will be performed for ankle pumping exercise and knee flexion in sitting position. Patients will begin strength training with elastic resistance bands using red bands (lowest resistance). Green and blue bands by increasing the number of sets and repetitions will start to be used (increased resistance). (31.32)
88864276|NCT05609526|Experimental|4.Group (Inspiratory and calf muscle training)|All applications made in 3 groups will be made in this group.
88864277|NCT02124018||Post-MI patients|"Asymptomatic post-MI patients late after MI or 40 days after STEMI-NSTEMI with preserved ejection fraction and absence of active ischemia Programmed ventricular stimulation (PVS) will be performed in high-risk patients based on non-invasive evaluation.~ICD implantation will be performed in patients with induced ventricular tachycardia (VT) upon PVS"
88864278|NCT04346316|Active Comparator|SHR0302 Dose#1|
88864279|NCT04346316|Active Comparator|SHR0302 Dose#2|
88864280|NCT04346316|Active Comparator|SHR0302 Dose#3|
88864281|NCT04346316|Placebo Comparator|Placebo|
88864282|NCT00567840|Experimental|1|PA-824 200 mg/qd
88864283|NCT00567840|Experimental|2|PA-824 600 mg/qd
88864284|NCT00567840|Experimental|3|PA-824 1000 mg/qd
88864285|NCT00567840|Experimental|4|PA-824 1200 mg/qd
88864286|NCT00567840|Active Comparator|5|Rifafour e-275 mg
88864287|NCT00568386|Experimental|Systane Lubricant Eye Drops|Systane Lubricant Eye Drops 1 drop in each eye one time
88864288|NCT00568386|Active Comparator|Optive Lubricant Eye Drops|Optive Lubricant Eye Drops 1 drop each one time
88864289|NCT01798290|Experimental|Behavioral: narrative medicine: reading workshop|Students allocated to the active comparator arm will follow 5 sessions in Class-led instruction of reading patients' diaries or nurses'diaries. They will be divided into eight subgroups of 12 students. The first and fifth sessions will be presential, and 2nd 3rd and 4th sessions will be homework to do on internet.
89185644|NCT02580630|Active Comparator|Training and local anesthetic|"Patients are instructed to carry out strengthening exercises for the diseased achilles tendon 3 times a week. Physiotherapist will instruct all patients in these heavy slow resistance exercises. First time one week after the first injection, and then every month.~All patients are informed to a reduction in running and jumping sports for the first 3 months, thereafter slowly progressing to normal sports activity.~Ultrasound guided injection with local anaestethic: 1ml Lidocain 5 mg/ml and 1 ml intralipid (for blinding) in Kagers triangle underneath the thickest part of the achilles tendon. Injection is given every months until the tendon pain is markedly diminished (max 3 injections)."
89185645|NCT00698841|Experimental|Cetuximab|
88864290|NCT01798290|Active Comparator|Behavioral: critical reading|Students allocated to the active comparator arm will follow 5 sessions in Class-led instruction of reading literature. They will be divided into eight subgroups of 12 students. The first and fifth sessions will be presential, and 2nd 3rd and 4th sessions will be homework to do on internet.
88864291|NCT03830970|Experimental|1 cup of canned beans of multiple varieties|Consumption of 1 cup of canned beans of multiple varieties each day for 4 weeks
89185646|NCT00577395|Experimental|2|one 150 mg risedronate once a month, orally
89185647|NCT00577395|Placebo Comparator|1|Placebo tablet once a month, orally
89185648|NCT04062357|Active Comparator|lidocaine 5% spray|Group 1 (n₌75); was given on demand lidocaine 5% spray for 8 weeks (One to two applications (1-2 ml) of lidocaine 5% sprays; contain 5 -10 mg of lidocaine, in a metered dose aerosol-delivery system).
89185649|NCT04062357|Placebo Comparator|Placebo|Group 2 (n₌75); was given placebo in form on demand alcohol spray for 8 weeks (One to two applications (1-2 ml) of alcohol 70% sprays).
89185650|NCT05190120|Active Comparator|Femoral Block|Patients scheduled for knee arthroscopy will have a femoral nerve block done using 0.5% ropivacaine 20ml before surgery.
89185651|NCT05190120|Experimental|Adductor Canal Block|Patients scheduled for knee arthroscopy will have an adductor canal block done using 0.75% ropivacaine 13.3ml before surgery.
89185652|NCT02581332|Other|Behavioral: Mindfulness Meditation|Training will be held in groups of up to five participants. All of the participants within this group will receive up to 6 days (20m/d) of meditation training to be administered over 15 days. This is a paradigm similar to one employed in previous studies.
89185653|NCT00738374|Experimental|1|
89185654|NCT04076982|Experimental|mung bean|daily oral administration of protein supplement
89185655|NCT04076982|Placebo Comparator|biscuit|daily oral administration of control supplement
89185656|NCT04088474|Experimental|Vigiis 101-LAB|The Vigiis 101-LAB mixed lactose, crystalline cellulose, and excipient were made into capsules (Vigiis 101-LAB capsule I) containing 5 billion bacteria per capsule for the gut flora clinical trial. The Vigiis 101-LAB mixed lactose, crystalline cellulose, and excipient were also mixed into capsules (Vigiis 101- LAB capsule II) containing 5 billion bacteria per capsule for clinical trial.
89185657|NCT04088474|Placebo Comparator|placebo|Maltodextrin was used as a placebo.
89185658|NCT05016999|No Intervention|Control|Volunteers in this group will not take any products.
89185659|NCT05016999|Experimental|Intervention|Garlic concentrated extract plus onion concentrated extract plus microcrystalline cellulose (9892- Capsules®) up to 400 mg.
89185660|NCT02594930|Experimental|undirected and directed biopsy|Via an antero-lateral incision of the knee samples are taken without visual control; Afterwards an arthroscope is inserted and samples are taken from 5 defined regions of the knee (suprapatellar pouch, medial and lateral gutter, notch, Hoffa's fat pad)
89185661|NCT02581176|Experimental|Apixaban|Apixaban 10 mg two times daily for 1 week, then apixaban 5mg two times daily for 6 months, then apixaban 2.5 mg two times daily for as long as the treating physician finds it necessary.
89185662|NCT03746184||Knee osteoarthritis|Treatment course
89185663|NCT04075500|No Intervention|Arm 1|Control arm, 24-h Holter monitoring
89185664|NCT04075500|Other|Arm 2|Interventional arms, prolonged cardiac monitoring
89185665|NCT05119608|Experimental|CBT/ACT|Cognitive-behavioral therapy intervention with principal components of acceptance and commitment therapy (ACT)
89185666|NCT05119608|Active Comparator|TAU|Treatment as usual, defined by standard care, i.e. referral to relevant health care provider (typically primary care).
88864292|NCT03830970|Experimental|1/2 cup of canned beans of multiple varieties|Consumption of 1/2 cup of canned beans of multiple varieties each day for 4 weeks
88864293|NCT03830970|Other|1 cup of White rice|Consumption of 1 cup of white rice each day for 4 weeks
88864294|NCT01797978|Experimental|Intravenous methylene blue administration|2mg/kg IV bolus followed by 0.5mg/kg/hr slow infusion for 6hrs
89185667|NCT00697593|Experimental|Efalizumab|
88864295|NCT01797978|Placebo Comparator|Placebo|Normal saline administration instead of methylene blue
88864296|NCT05363202|Experimental|Fluticasone propionate inhalation aerosol USP 44 mcg (Glenmark Pharmaceuticals Ltd.)|
88864297|NCT05363202|Active Comparator|FLOVENT HFA|
89185668|NCT02566161||Trio Cohort|families were from each of 5 exposure categories: A-father exposed, mother unexposed; B-mother exposed, father unexposed; C-both parents exposed; D-neither exposed; E-high dose emergency workers).
89185669|NCT05012475|Experimental|Participants|The study involves a pre-intervention phase (4 weeks long), followed by a cause and effect training phase (1 week long), followed by an intervention phase (12 weeks long), and ending with a post-intervention phase (4-weeks long) for a total of 5-6 months from start to finish.
89185670|NCT05325021||Axial myopia|children have anisometropia due to axial myopia, axial length will be measured by optical biometry device in millimeter (mm).
89185671|NCT05325021||Refractive myopia|children have anisometropia due to refractive myopia, axial length will be measured by optical biometry device in mm.
89388672|NCT04436835|Experimental|Supportive care (ART)|Patients undergo ART over 60-90 minutes once a week for up to 5 sessions.
89388673|NCT04434092|Experimental|Arm A (Crovalimab)|Crovalimab will be administered at an initial loading dose of 1000 milligrams (mg) (for participants with body weight between 40 and 100 kg) or 1500 mg (for participants with body weight >=100kg), as intravenous (IV) injection on Day 1 of Week 1 followed by four weekly subcutaneous (SC) injections of 340 mg starting on Day 2 of Week 1 and then once weekly (QW) at Weeks 2,3 and 4. Thereafter crovalimab will be administered, as SC injection, at a maintenance dose of 680 mg (for participants with body weight between 40 and 100kg) or 1020 mg (for participants with body weight >=100kg) once every 4 weeks (Q4W) from Week 5 for a total of 24 weeks of study treatment. Participants may continue to receive crovalimab after 24 weeks of treatment up to maximum of 5 years.
89388674|NCT04434092|Active Comparator|Arm B (Eculizumab)|Participants will receive loading dose of eculizumab 600 mg on Days 1, 8, 15, and 22, followed by maintenance dose of 900 mg on Day 29 and every 2 weeks (Q2W) thereafter until 24 weeks. Participants may switch to receive crovalimab after 24 weeks of eculizumab treatment.
89388675|NCT04434092|Experimental|Arm C (Crovalimab) (Exploratory)|Paediatric participants will receive a loading series of Crovalimab comprised of an IV dose on Week 1 Day 1, followed by weekly crovalimab SC doses for 4 weeks on Week 1 (Day 2) then on Weeks 2, 3, and 4. Maintenance SC dosing will begin at Week 5 and will be administered Q4W thereafter. After 24 weeks of crovalimab treatment, participants who derive benefit from the drug may continue to receive crovalimab.
89388676|NCT04432506|Experimental|Treatment (cyclophosphamide, fludarabine, axi-cel, anakinra)|Patients receive cyclophosphamide IV over 60 minutes and fludarabine IV over 30 minutes on days -5 to -3 in the absence of disease progression or unacceptable toxicity. Patients then receive axicabtagene ciloleucel IV over 30 minutes or less on day 0 and anakinra SC on days 0-6 in the absence of disease progression or unacceptable toxicity.
89388677|NCT04388891|Experimental|Minimally supervised therapy|This group will undergo minimally supervised therapy with the robot ReHapticKnob.
89388678|NCT04384978|Active Comparator|Control Group|Control Group: Group 2 users will play solitary games (word puzzles) and activities but will have no interaction with Ryan.
89388679|NCT04384978|Experimental|Active Group|Active Group: Group 1 users will play games with and administered by Ryan, 2-3 times a week and 30-minutes per day.
89388680|NCT04372498|Experimental|Treatment|This is a pivotal trial in members of the same family carrying the V282M nutation in the Gardos channel (KCNN4) and other patients with V282 mutations with demonstrated in-vitro sensitivity to senicapoc. These mutations lead to hyperactivation of the channel and red cell dehydration. Up to 6 patients are eligible to enroll in this study, which will assess effectiveness based on individual changes of primary endpoints over individually established baselines.
89388681|NCT04369976|Experimental|SHORT ARM HUMAN CENTRIFUGE|SHORT ARM HUMAN CENTRIFUGE IN COMBINATION WITH EXERCISE INTERMITTENT CENTRIFUGATION TOTAL TIME 30 MINUTES
89388682|NCT04333745|Experimental|Controlled Dietary Study|Participants will consume the controlled diet for five days. After one day on the diet, subjects will provide three 24-hour urine collections. On the last dayof the diet, subjects will come in a fasted state to ingest a small amount of carbon-13 oxalate and sucralose, with hourly urine collections and blood samples being taken before and after the ingestion.
89388683|NCT04305873||EIAH athletes|Athletes with arterial oxyhemoglobin saturation at maximal exercise during a graded exercise test <93%
89388684|NCT04305873||Non-EIAH athletes|Athletes with arterial oxyhemoglobin saturation at maximal exercise during a graded exercise test >95%
89388685|NCT04305873||Intermediate EIAH athletes|Athletes with arterial oxyhemoglobin saturation at maximal exercise during a graded exercise test of 93-95%
89388686|NCT04284436|Experimental|High Intensity Exercise|Treadmill exercise 4x per week at 80-85% HRmax.
89388687|NCT04284436|Active Comparator|Moderate Intensity Exercise|Treadmill exercise 4x per week at 60-65% HRmax.
89388688|NCT04272619|Experimental|Liver Cancer Education|
89388689|NCT04270955|Active Comparator|Symptomatic, standard of care|Patients in this group will be offered all procedures and care deemed appropriate by the Neurosurgeon in charge of their care. This could include surgical intervention, observation, medical management.
89388690|NCT04270955|Experimental|Symptomatic, MMA embolization + standard of care|"Patients in this group will be treated with the standard of care treatment (the same care described in the arm Symptomatic, standard of care) but will also undergo MMA embolization of the affected side(s)."
89388691|NCT04270955|Active Comparator|Asymptomatic, standard of care|Patients in this group will be offered all procedures deemed appropriate by the Neurosurgeon in charge of their care. This could include surgical intervention, observation, medical management.
89185672|NCT05325021||Axial hyperopia|children have anisometropia due to axial hyperopia, axial length will be measured by optical biometry device in mm.
89185673|NCT05325021||Refractive hyperopia|children have anisometropia due to refractive hyperopia, axial length will be measured by optical biometry device in mm.
89388692|NCT04270955|Experimental|Asymptomatic, standard of care + MMA embolization|"Patients in this group will be treated with the standard of care treatment (the same care described in the arm Asymptomatic, standard of care) but will also undergo MMA embolization of the affected side(s)."
89388693|NCT04268979|Experimental|eSNAP & Caregiver Navigator|eSNAP intervention plus questionnaires
89388694|NCT04268979|No Intervention|Waitlist Control Condition|Participants randomly assigned to the waitlist control condition will only complete questionnaires during the 8-week study period. After the 8 weeks, they will then have access to the eSNAP, including completion of questionnaires and 8 weeks of Caregiver Navigator sessions as needed.
89388695|NCT04259138|Other|Symptomatic remission|Treatment target defined as achievement of corticosteroid-free symptomatic remission.
89388696|NCT04259138|Other|Symptomatic and endoscopic remission|Treatment target defined as achievement of corticosteroid-free symptomatic remission plus endoscopic remission.
89388697|NCT04259138|Other|Symptomatic, endoscopic and histological remission|Treatment target defined as achievement of corticosteroid-free symptomatic remission plus endoscopic remission plus histological remission.
89388698|NCT04258943|Experimental|Single Agent Bosutinib|Bosutinib administered orally once daily in pediatric patients with newly diagnosed chronic phase Ph+ CML (ND CML) and pediatric patients with Ph+CML who have received at least one prior TKI therapy (R/I CML). A treatment cycle is defined as 28 days
89388699|NCT04246814|Placebo Comparator|CC + dressing|The group will receive placebo LASER application associated with Helianthus annuus oil dressing.
89388700|NCT04246814|Active Comparator|LG1 + dressing|The group will receive application of LASER Gallium Arsenide (GaAs) 904 nm 10 J/cm² associated with Helianthus annuus oil dressing.
89003417|NCT05321602|Experimental|LY03010 156 mg treatment group, gluteal|"LY03010 (paliperidone palmitate) is a pharmaceutical equivalent drug product to the listed drug (LD) product INVEGA SUSTENNA®. The chemical name is (9RS)-3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4-oxo-4H-pyrido[1,2-a]pyrimidin-9-yl hexadecanoate. Its molecular formula is C39H57FN4O4 and its molecular weight is 664.89.~LY03010 is white to off-white sterile aqueous extended-release suspension of paliperidone palmitate for IM injection. In LY03010 treatment group, all subjects will receive the first dose of 156 mg IM injection on Day 1 in the gluteal muscle."
89003418|NCT05321602|Experimental|LY03010 351 mg treatment group, deltoid|"LY03010 (paliperidone palmitate) is a pharmaceutical equivalent drug product to the listed drug (LD) product INVEGA SUSTENNA®. The chemical name is (9RS)-3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4-oxo-4H-pyrido[1,2-a]pyrimidin-9-yl hexadecanoate. Its molecular formula is C39H57FN4O4 and its molecular weight is 664.89.~LY03010 is white to off-white sterile aqueous extended-release suspension of paliperidone palmitate for IM injection. In LY03010 treatment group, all subjects will receive the first dose of 351 mg IM injection on Day 1 in the deltoid muscle."
89388701|NCT04246814|Active Comparator|LG2 + dressing|The group will receive application of LASER Gallium Arsenide (GaAs) 904 nm 8 J/cm² associated with Helianthus annuus oil dressing.
89003419|NCT05321602|Experimental|LY03010 351 mg treatment group, gluteal|"LY03010 (paliperidone palmitate) is a pharmaceutical equivalent drug product to the listed drug (LD) product INVEGA SUSTENNA®. The chemical name is (9RS)-3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4-oxo-4H-pyrido[1,2-a]pyrimidin-9-yl hexadecanoate. Its molecular formula is C39H57FN4O4 and its molecular weight is 664.89.~LY03010 is white to off-white sterile aqueous extended-release suspension of paliperidone palmitate for IM injection. In LY03010 treatment group, all subjects will receive the first dose of 351 mg IM injection on Day 1 in the gluteal muscle."
89003420|NCT05319522|Active Comparator|Individuals with SCI|Male and female, Veteran and non-Veteran participants with traumatic SCI will complete the baseline blood draw, muscle biopsy and DXA/HR-pQCT bone imaging. This group will complete blood draws before and after arm ergometer high-intensity interval exercise bout.
89003421|NCT05319522|Active Comparator|Controls (No SCI)|Male and female Veterans, age and sex-matched to participants with SCI will complete the baseline blood draw, muscle biopsy and DXA/HR-pQCT bone imaging. This group will complete blood draws before and after arm ergometer high-intensity interval exercise bout.
89003422|NCT05312879|Experimental|Phase 2: VX-147|Participants will be randomized to receive different dose levels of VX-147.
89003423|NCT05312879|Placebo Comparator|Phase 2: Placebo|Participants will receive placebo matched to VX-147.
89003424|NCT05312879|Experimental|Phase 3: VX-147|Participants will receive VX-147 with the dose to be based on the outcome of Phase 2.
89003425|NCT05312879|Placebo Comparator|Phase 3: Placebo|Participants will receive placebo matched to VX-147.
89003426|NCT05289934|Experimental|Children with Epilepsy|Children (age: 4- 17 years old) will participate in this study, and they will listen to Mozart K.448 (1st movement) and instrumental age-appropriate song with 10 minutes wash out in between, each lasting up to 9 minutes in the daytime (between 1-5 pm). The music stimuli will be randomly played in 2 to 7 days during the EMU stay (average 4 days). Music will be delivered via single-use earbuds.
89003429|NCT05283616|Experimental|pegfilgrastim 3mg|Pegfilgrastim 3mg per chemotherapy cycle
89003430|NCT05283616|Active Comparator|pegfilgrastim 6mg|Pegfilgrastim 6mg per chemotherapy cycle
89003431|NCT05280470|Experimental|Ifinatamab Deruxtecan (8 mg/kg)|Participants will be randomized to receive I-DXd at 8 mg/kg.
89185674|NCT04075578||female with urinary incontinence|Female ≥ 18 years, suffers from urinary incontinence by idiopathic overactive bladder, inadequately treated by 2 anticholinergic medicines during a period of 3 months for each of them or stopped for intolerance or adverse events
89388702|NCT04246814|Active Comparator|LG3 + dressing|The group will receive application of LASER Gallium Arsenide (GaAs) 904 nm 4 J/cm² associated with Helianthus annuus oil dressing.
89388703|NCT04243538|No Intervention|Control arm|Standard of care.
89388704|NCT04243538|Experimental|I-HoME intervention|Weekly televisits with a nurse practitioner that will implement the I-HoME intervention.
89388705|NCT04221581||Patients receiving FHK ASYMETRIQUE prosthesis|
89388706|NCT04216563|Experimental|Treatment (asciminib)|Patients receive asciminib PO BID for up to 36 months while receiving standard of care dasatinib or nilotinib in the absence of disease progression or unacceptable toxicity. Patients may continue to receive asciminib after 36 months at the discretion of investigator.
89388707|NCT04212390||FISiM MDS patients|Patients receiving a diagnosis of MDS and prospectively enrolled in the FISiM registry.
89388708|NCT04208490|Other|HN-STAR|
89388709|NCT04208490|No Intervention|Usual Care|
89388710|NCT04203082|Experimental|Exposure Intervention|Participants randomized to receive the Exposure Intervention will be scheduled to come to clinic for a 1-hour session for the intervention. During this time, they will receive psychoeducation and behavioral exposure to the Cesarean section procedure.
89388711|NCT04203082|Other|Usual Care|Participants randomized to the Care as Usual condition will receive the typical standard of care that is offered in the center. This involves the anesthesiologist meeting with the patient during a delivery planning meeting to provide patients with the opportunity to review anesthetic technique and ask questions.
89189423|NCT05810298|Active Comparator|Control Group|"Asana practice (Only standing yoga poses with rhytmic breathing)~Pranayam (Rhytmic regulated breathing)"
89535328|NCT03319589|Experimental|Supplement Arm|School children (age 6 to 6.5) will receive their supplement 5 days a week in the morning before school starts. They will either receive the supplement at school or at the community health center depending on the preference of the villagers after recruitment. Young children (age 24 to 30 months) will receive the supplement 5 days a week in the morning at the community health center, distributed by community health workers.
89535329|NCT03319589|No Intervention|Control Arm|Children in the active intervention village will be compared with assessment-only controls in a separate village having comparable demographic characteristics
89535330|NCT03222193|Experimental|TRP group|Snoring subjects treated with the Tongue Right Positioner (TRP) medical device
89535331|NCT05019807|Other|WhatsApp group|The arm receives education information about diabetes and its complications, diet and physical activities through WhatsApp.
89535332|NCT05019807|Other|Control group|The arm does not received any education information.
89535333|NCT03323021|Experimental|Treatment with DHACM|Partial nephrectomy patched with DHACM
89535334|NCT03323021|Active Comparator|Control without DHACM|Partial nephrectomy without DHACM.
89535335|NCT05012553|No Intervention|no education about self and peer assesment|Stoma care skills of the group who did not receive self- and peer-assessment training will be evaluated.
89535336|NCT05012553|Experimental|education of self and peer assesment|Stoma care skills of the group who received self and peer assessment training will be evaluated.
88819122|NCT01543178|Experimental|Rifaximin open-label|"Subjects will receive open-label rifaximin 550 mg TID for 2 weeks with a 4-week treatment-free follow-up. Responders will continue into Maintenance Phase 1 (treatment free). Nonresponders will withdraw from the study.~Subjects who meet criteria for recurrence in Maintenance Phase 1 enter the double-blind period and are randomized 1:1 to receive rifaximin 550 mg or placebo."
88819123|NCT01543178|Experimental|Double-blind rifaximin (retreatment)|Subjects in this arm receive rifaximin 550 mg TID for 2 weeks with a 4-week treatment-free follow-up (first retreatment) followed by Maintenance Phase 2 (6 weeks [treatment free]) followed by a second retreatment with rifaximin 550 mg TID for 2 weeks with a 4-week treatment-free follow-up.
88819124|NCT01543178|Placebo Comparator|Double-blind placebo (retreatment)|Subjects in this arm receive placebo TID for 2 weeks with a 4-week treatment-free follow-up (first retreatment) followed by Maintenance Phase 2 (6 weeks [treatment free]) followed by a second retreatment with placebo TID for 2 weeks with a 4-week treatment-free follow-up.
88819125|NCT02677779|Experimental|CO2 laser|Ulcer debridement with laser-CO2 (DEKA SmartXide2 c80-El.En, Florence Italy)
88819126|NCT02677779|Active Comparator|Traditional surgery|Ulcer debridement with traditional surgery
88819127|NCT02679807|Active Comparator|Bifidobacterium lactis Bl-04|2*109 cfus of probiotic Bifidobacterium lactis Bl-04 (DuPont Nutrition and Health) mixed with 1g of sucrose as a carrier
88819128|NCT02679807|Placebo Comparator|Placebo|sucrose
88819129|NCT05037357||nasopharyngeal carcinoma patients|Plasma EBV DNA quantification by quantitative polymerase chain reaction (qPCR) assays in different medical centers.
88819130|NCT01649856|Experimental|A: Rituximab SC|
88819131|NCT01649856|Active Comparator|B: Rituximab IV|
88819132|NCT01543568|Other|2.0 mg intravitreal Aflibercept|open label, Subjects seen monthly & given mandatory 2.0 mg aflibercept at baseline, months 1, 2 and 4. Pro re nata (PRN) retreatment at months 3 and 5 was performed upon evidence of disease on spectral domain-optical coherence tomography (SD-OCT)
88819133|NCT05009199|Experimental|[18F]MNI-444|After a wash-out of caffeine of at least 24 hours, each participant will receive a single injection of [18F]MNI-444 followed by brain PET imaging of up to 90 minutes to establish baseline A2A receptor binding.
88819134|NCT02681757|Active Comparator|Control- triple antibiotic ointment|triple antibiotic ointment (TAO) impregnated Adaptic gauze, kling or kerlex, cast padding, gypsoma plaster, soft cast material, and coban
88819135|NCT02681757|Experimental|Variable- mepitel Ag|mepitel Ag, kling or kerlex, cast padding, gypsoma plaster, soft cast material, and coban
88819139|NCT02375724|Experimental|Aclidinium Bromide 400 μg|Aclidinium Bromide 400 μg twice daily by inhalation
88819140|NCT02375724|Placebo Comparator|Placebo|placebo twice daily by inhalation
88819141|NCT02398188|Experimental|LIPO-202|Experimental arm
88819142|NCT02398188|Placebo Comparator|Placebo|Placebo comparator
88819143|NCT02426580|Experimental|Intervention with wechat group|The wechat model will provide information of protein, calcium, phosphorus and sodium intake, which were suggested by the current KDIGO/ KDOQI guideline.
88819144|NCT02426580|No Intervention|Controlled group|Only conventional education every 3 months during routing clinical visit
88819145|NCT01651260|Other|Endotracheal (ET) tube securement device|Single arm study evaluated an experimental ET tube securement device with a bite block.
88819146|NCT03110133|Experimental|CP101|Full Spectrum Microbiota Capsule
88819147|NCT03110133|Placebo Comparator|Placebo|Matching Placebo Capsule
88819148|NCT05448066|Active Comparator|Standard diagnosis|Patients followed in the allergy clinic with indication for allergen immunotherapy using only standard diagnosis.
88819149|NCT05448066|Experimental|CRD diagnosis|Patients followed in the allergy clinic with indication for allergen immunotherapy decided with standard diagnostic tools and molecular based diagnosis.
88819150|NCT02682069|Experimental|All patients|There is one arm to this study and all patients will undergo the same procedures. The test of this technology is on a per wound basis where bacteria will fluoresce red and samples will be obtained from the discrete red locations. Microbiology results indicating the presence or absence of bacteria will be correlated to the fluorescence signal in the fluorescent images.
88819151|NCT02425098|Experimental|High-dose Tetravalent Dengue Vaccine (HD-TDV)|High-dose Tetravalent Dengue Vaccine [HD-TDV], 0.5 mL, subcutaneous injection on Day 1. TDV comprised one molecularly-characterized and cloned TDV-2 live attenuated dengue virus strain and three recombinant live attenuated dengue virus strains: TDV-1, TDV-3 and TDV-4. TDV contained 2*10^4 plaque forming units (PFU), 5*10^4 PFU, 1*10^5 PFU, and 3*10^5 PFU of TDV-1, TDV-2, TDV-3 and TDV-4 respectively.
89388712|NCT04183010|No Intervention|Control|At the end of this initial week of monitoring, participants will be randomized to a control group or an intervention group. Both groups will be followed for three months, with outcome measurements collected monthly. Both arms will continue to receive their seven day physical activity assessment using the phone's core motion sensors and HealthKit/ Google Health step count. Both groups will also be prompted to complete monthly fitness tests: the 6-minute walk test, a 12 minute run test, and the Tecumseh step test.
89388713|NCT04183010|Experimental|Physical activity coaching|"In addition to the tasks performed and feedback received by the Control arm (see above), the intervention arm will also undergo daily coaching with the goal of increasing their daily step count. Members of this arm will receive daily app notifications indicating that they have activities to complete. They will be provided with 5 exercise options:~Low intensity activity options (i.e. walking in the part, bicycling to the store, etc.).~Moderate to vigorous endurance activity, performed on their own (running, bicycling, rowing, swimming, etc)~An on demand group session video~No exercise today~Alternate physical activity -- the participants will have the option to record alternate physical activity that they performed~Participants will be asked to indicate if they completed the exercise with three options:~Yes~No~Request for a different exercise to be shown"
89388714|NCT04182334|Experimental|Slow Tempo Music|Slow-tempo 60-80 beats per minute relaxing music. The intervention includes two one-hour music listening sessions, once in the morning and once in the evening for up to seven days, delivered through noise-canceling headphones and iPad.
89388715|NCT04182334|Sham Comparator|Attention Control|One-hour sessions consisting of a silence track twice daily delivered through noise-cancelling headphones for up to 7 days.
89388716|NCT04169763|Experimental|Treatment (nelfinavir, cisplatin, EBRT)|Patients receive nelfinavir PO BID for up to 8 weeks. Starting week 2, patients also receive cisplatin IV over 60-90 minutes once weekly during weeks 2-8. Patients undergo EBRT for 5 consecutive days between weeks 2-8. Treatment continues in the absence of disease progression or unacceptable toxicity.
89388717|NCT04162015|Experimental|nivolumab with pemetrexed and cisplatin or carboplatin|Eligible patients will receive two cycles of neoadjuvant therapy with nivolumab 360 mg, pemetrexed 500 mg/m2, and cisplatin 75 mg/m2 or carboplatin AUC=5. Subsequently, they will undergo pleurectomy/decortication.
89388718|NCT04126395||Controls|"This groups consists of children now aged 6-12y:~Without a medical diagnosis possibly influencing motor development~Without motor problems (M-ABC-2 and DCD-Q)~Without social reponsiveness problems (SRS-2)"
89388719|NCT04126395||Developmental Coordination Disorder|"This groups consists of children now aged 6-12y:~With a multidisciplinary diagnosis of DCD~With motor problems (M-ABC-2 and DCD-Q)"
89388720|NCT04126395||Developmental Coordination Disorder + Autism Spectrum Disorder|"This groups consists of children now aged 6-12y:~With a multidisciplinary diagnosis of DCD~With motor problems (M-ABC-2 and DCD-Q)~With social responsiveness problems (SRS-2)"
89388721|NCT04120974|Experimental|Optimal insulin injection|Study subjects will receive personal training from the Investigator on how to optimally inject insulin to treat their Diabetes Mellitus. In addition, each subject receives instruction how to use a web-based platform with online video training modules on optimal injection technique.
89388722|NCT04115371|No Intervention|Control|Standard emergency department care
89388723|NCT04115371|Other|Intervention|Standard emergency department are plus GEDI consult
89388724|NCT04107805|Experimental|10 mg BI 1323495 bid EM|
89388725|NCT04107805|Experimental|10 mg BI 1323495 bid PM|
89388726|NCT04107805|Experimental|30 mg BI 1323495 bid EM|
88864298|NCT05363202|Placebo Comparator|Placebo of Fluticasone propionate inhalation aerosol 44 mcg|
89388727|NCT04107805|Experimental|30 mg BI 1323495 bid PM|
89388728|NCT04107805|Experimental|70 mg BI 1323495 bid + Midazolam EM|
89388729|NCT04107805|Experimental|120 mg BI 1323495 bid + Midazolam EM|
89388730|NCT04107805|Experimental|120 mg BI 1323495 qd EM|
89388731|NCT04107805|Experimental|150 mg BI 1323495 bid + Midazolam EM|
88864299|NCT05394012|Experimental|RQ3013|
88864300|NCT05394012|Active Comparator|Comirnaty|
88864301|NCT02129478|Experimental|Olanzapine|
89388732|NCT04107805|Experimental|Placebo/Placebo+ Midazolam|
89388733|NCT04085887|Experimental|Cohort 1-0.006 Panitumumab-IRDye800|Dose: 0.006 Panitumumab-IRDye800 (mg/kg)
89388734|NCT04085887|Experimental|Cohort 2-0.25 Panitumumab-IRDye800|Dose: 0.25 Panitumumab-IRDye800 (mg/kg)
89388735|NCT04085887|Experimental|Cohort 3-0.50 Panitumumab-IRDye800|Dose: 0.50 Panitumumab-IRDye800 (mg/kg)
88864302|NCT02129556|Experimental|MK-3475 with trastuzumab (single arm)|"Phase Ib: MK-3475 at dose of 2 mg/kg or 10 mg/kg (i.v.), or a fall-back dose of 1 mg/kg, together with trastuzumab 6mg/kg by (i.v.) once every 3 weeks.~Phase II: MK-3475 at a flat dose of 200mg (i.v.) together with trastuzumab 6mg/kg (i.v.) once every 3 weeks until progression, lack of tolerability, or 24 months of treatment.~A dose of 8mg/kg trastuzumab will be used in cycle 1 if prior treatment with trastuzumab was stopped more than 3 months before."
88864303|NCT05362500|Active Comparator|Group A 70% Glycolic acid|Group A: contain 27 patients which had been treated every 2 weeks for 12 weeks with 70% glycolic acid to assess chemical peeling and cold water was used for washing to stop peeling
88864304|NCT05362500|Active Comparator|Group B intradermal tranexamic acid|Group B: contain 27 patients treated with an intradermal injection of 0.05 mL of tranexamic acid solution in normal saline (4 mg/mL) into the melasma lesion at 1 cm distance using a sterile insulin syringe, weekly for 12 weeks
88864305|NCT05161806|Experimental|SOK583A1 (40 mg/mL)|participants received a single dose of 2 mg SOK583 in 0.05 mL (40 mg/mL) and completed the study
88864306|NCT05362188|Experimental|Topical Nicotinamide 2%|will receive topical nicotinamide 2%
89388736|NCT04085887|Experimental|Cohort 4-1.0 Panitumumab-IRDye800|Dose: 1.0 (with max cap dose 50 mg) Panitumumab-IRDye800 (mg/kg)
89388737|NCT04075461|Experimental|Undisplaced FNF + Arthroplasty|Arthroplasty is the typical surgery for a displaced femoral neck fracture
89388738|NCT04075461|Active Comparator|Undisplaced FNF + Internal fixation|Internal fixation is the typical surgery for an undisplaced femoral neck fracture
89530432|NCT02515955|Experimental|Cohort 5|Participants will be receiving either JNJ-54175446 at increasing dose levels using 2 oral formulation as suspension for oral dose once daily from Day 1 to Day 17 or minocycline 100 mg capsule twice daily from Day 1 to Day 17 or placebo matching with JNJ 54175446 once daily from Day 1 to Day 17.
89388739|NCT04069468||TheraSphere®|"Patients with HCC, iCC and mCRC will be treated. TheraSphere is administered in the liver through the hepatic artery. Treatment will be performed according to the Instructions for Use (IFU). Activity of administered TheraSphere is tailored in order to deliver an absorbed dose of 80 to150 gray (Gy) to the liver. Lung dose (D) will be calculated from the following formula: D=A*(1-S)*50/1. D=Planned dose absorbed by treated volume(Gy), A=Activity injected with microspheres (gigabequerel [GBq]), S=Percentage of pulmonary shunt, 1 assuming that the lung mass=1 kilograms [kg]). Number of treatments is up to Investigator's discretion while taking into account the cumulative dose to the liver and lung."
89388740|NCT04043442|Active Comparator|Active + Placebo rTMS for Custom Neural Target Group 1|Custom neural anatomical target 1 defined by neuroimaging data
89388741|NCT04043442|Active Comparator|Active + Placebo rTMS for Custom Neural Target Group 2|Custom neural anatomical target 2 defined by neuroimaging data
89388742|NCT04043442|Active Comparator|Active + Placebo rTMS for Custom Neural Target Group 3|Custom neural anatomical target 3 defined by neuroimaging data
88819152|NCT02425098|Experimental|Tetravalent Dengue Vaccine (TDV)|Tetravalent Dengue Vaccine [TDV], 0.5 mL, subcutaneous injection on Day 1. TDV comprised one molecularly-characterized and cloned TDV-2 live attenuated dengue virus strain and three recombinant live attenuated dengue virus strains: TDV-1, TDV-3 and TDV-4. TDV contained 2*10^4 plaque forming units (PFU), 5*10^3 PFU, 1*10^5 PFU, and 3*10^5 PFU of TDV-1, TDV-2, TDV-3 and TDV-4 respectively.
88819153|NCT02424630|Experimental|ISB with SSNB|During arthroscopic rotator cuff repair, ultrasound-guided ISB was performed preemptively with 7.5 mL ropivacaine immediately after general anesthesia was induced. And at the end of surgery, arthroscopy-guided SSNB was performed with 10 mL ropivacaine.
89388743|NCT04043442|Active Comparator|Active + Placebo rTMS for Left DLPFC Neural Target|"Neural anatomical target will be the Left Dorsolateral Prefrontal Cortex identified using the 5cm from the motor hot spot rule."
89388744|NCT04042025|Other|Intravenous (IV) & Intrathecal (IT) Onasemnogene Abeparvovec-xioi|Participants received treatment with IV onasemnogene abeparvovec-xioi in an onasemnogene abeparvovec-xioi or received treatment with IT onasemnogene abeparvovec-xioi in an onasemnogene.
89388745|NCT04039113|Active Comparator|Tezepelumab|Tezepelumab, SC, Q4W
89388746|NCT04039113|Placebo Comparator|Matching Placebo|Matching placebo, SC, Q4W
89388747|NCT04031508|Experimental|Omega 3|The experimental group will receive a parenteral emulsion containing soy oil, MCT, olive oil and n-3 LCPUFA in fish oil
89388748|NCT04031508|Sham Comparator|Control group|The Control group will receive a parenteral emulsion containing soy oil and MCT
89388749|NCT04018755|Experimental|treatment|anakinra 100 mg subcutaneous once daily
89388750|NCT04011579|Experimental|MSFIT|The MSFIT group will self-manage Pilates exercises at-home through a tool based on XBox Kinect for 12 weeks, performing at least 3 sessions/week for a total of 30 minutes of exercises for each session(also distributed during the day with a minimum slot of 10 minutes). No rehabilitative interventions except sphincter and speech rehabilitation and psychological support, are admitted for the 12 weeks of participation to the project and the following 6 weeks before Follow-up evaluations (a total of 18 weeks). The execution of unspecific physical activities, if not already practiced, will be suggested to the participants.
89388751|NCT04011579|No Intervention|CTRL|No rehabilitative interventions except sphincter and speech rehabilitation and psychological support, are admitted for the 12 weeks of participation to the project and the following 6 weeks before Follow-up evaluations (a total of 18 weeks). The execution of unspecific physical activities, if not already practiced, will be suggested to the participants.
89388752|NCT04011241|Experimental|Reference - BI 1323495 alone|Single oral dose of 10 milligrams (mg) of film-coated tablet of BI 1323495 was administered once on day 1 in the first treatment period (period 1, visit 2) with 240 milliliter (mL) of water after an overnight fast of at least 10 hours (h) as reference treatment R.
89388753|NCT04011241|Experimental|Test - BI 1323495 + Itraconazole|Single oral dose of 200 mg itraconazole (oral solution, 20 milliliter (mL) per day with 10 mg/mL) was administered once daily with 240 mL of water after an overnight fast of 9 hours (h) from day -3 to day 7 (total: 10 doses) in the second treatment period (period 2, visit 3) together with a single oral dose of 10 mg BI 1323495 administered 1 h after itraconazole administration with 240 mL of water after an overnight fast of 10 h on the fourth day of the itraconazole treatment (day 1, period 2, visit 3) as test treatment T.
88864307|NCT05362188|Experimental|Topical Nicotinamide 4%|will receive topical nicotinamide 4%
89185675|NCT05741931|Experimental|Intervention Group|Pregnant women and midwives will use the REST (Risk identification, Evaluation counseling, Systematic monitoring, Troubleshooting) mobile application to monitor the condition of maternal pregnancy. Mothers and midwives will implementation 3 times of pregnancy class until mothers give birth
89388754|NCT03988751|Active Comparator|Continuous Ambulation|The total distance will be 40 meters. Study team members will walk, support, and coach the subject to walk as slow as he/she wants
89388755|NCT03988751|Active Comparator|Interval Ambulation|The subject will walk a total distance of 40 meters. This distance will be divided into four intervals of 10 meters to equal the same measured distance as the continuous group. The subject will receive two minutes of rest between each interval and will be supported and coached to walk as fast as they can.
88819154|NCT02424630|Placebo Comparator|ISB alone|During arthroscopic rotator cuff repair, ultrasound-guided ISB was performed preemptively with 7.5 mL ropivacaine immediately after general anesthesia was induced. And at the end of surgery, arthroscopy-guided SSNB was performed with 10 mL normal saline.
88819155|NCT02397408|Experimental|Diagnostic 11C- and 18F-choline PET/MR imaging|Patients are given 370 megabecquerel (MBq) 11C-Choline (11C) intravenously and 3 MBq/kg 18F-Choline (18F) intravenously prior to a whole-body PET/MR imaging
88819156|NCT02397096|Experimental|Immediate Switch to Doravirine, Tenofovir, Lamivudine|Participants receiving continuous antiretroviral therapy with a ritonavir- or cobicistat-boosted protease inhibitor (atazanavir, darunavir, or lopinavir) or cobicistat-boosted elvitegravir or a non nucleoside reverse transcriptase inhibitor (NNRTI) (specifically, efavirenz, nevirapine, or rilpivirine) in combination with 2 NRTIs for >=6 months with undetectable HIV-1 RNA will switch on Day 1 to doravirine, tenofovir, lamivudine single tablet by mouth once daily for 48 weeks in the Base Study and, optionally, for up to an additional 6 years in the Study Extensions
89388756|NCT03987633||Displaying trait of interest|There are 19 disease areas under investigation. Enrolled patients are segmented into cohorts based on data collected through questionnaires and medical histories. This data-driven approach does not allow for precisely predefined cohorts for the diseases under investigation. Therefore, as a default, the two general predefined cohorts are set as either displaying or not displaying a trait that would form the basis of an investigation.
89388757|NCT03987633||Not displaying trait of interest|Please see above.
89388758|NCT03986268|Active Comparator|study group|The patients measured a total of 25 OH vitamin D3 levels, initial, 3'th month and 6'th month of neoadjuvant therapy with replacement treatment with vitamin D3 at least weekly 50000 IU for eight weeks.
89388759|NCT03986268|Other|control group|The patients had measured a total of 25 OH vitamin D3 levels, previously treated with neoadjuvant therapy without replacement treatment with vitamin D3.
88864308|NCT05362188|Placebo Comparator|Placebo|Subjects will receive only cream/gel base without API for control
88864309|NCT01798368|Experimental|PBASE system 2.0|
88864310|NCT05353374|Experimental|Sodium fusidate ointment|Electrosurgery was carried out using Ellman® Surgitron. The tissue was cleaned using sterile gauze or a cotton swab that had been moistened with 0.9% NaCl. Following electrosurgery, sodium fusidate ointment was applied to the wound according to the allocation sequence. The patient also received a wound care instruction sheet. Each subject was given two or four pots of ointment that should be applied twice daily on the wound.
89185676|NCT05741931|No Intervention|Control Group|Pregnant women and midwives will conduct pregnancy monitoring as usual. The pregnancy class will be implemented in accordance with government program standards. Mothers will take pregnancy class 3 times until the mother gives birth
89185677|NCT02580864||IBD patients|120 adult patients (Caucasian, male/female,18-65 years old) with moderate-severe active Crohns disease (220≤ CDAI ≤450; blood CRP ≥5 mg/L and/or fecal calprotectin ≥250mg/L) and with indication for anti-TNF therapy according to the normal clinical practice
89185678|NCT02580864||No-IBD patients|30 no-IBD controls with no GI disorders, as defined by medical history and standard clinical chemistry values, afferent to the out-patient clinic
89185679|NCT02580474|Experimental|Daclatasvir plus Asunaprevir|
89185680|NCT04061811||HF (heart failure)|Patients with end stage renal disease requiring dialysis with reduced or preserved ejection fraction.
89185681|NCT04061811||Control|Patients with end stage renal disease requiring dialysis without HF.
89185682|NCT02581644||Patients survey|Adult patients treated with belatacept for renal transplantation
89185683|NCT02581644||HCP survey|HCP with at least 1 patient taking belatacept
89185684|NCT02581644||Retrospective chart review study|Adult patients treated with belatacept for renal transplantation
89185685|NCT00697515|Active Comparator|Lisdexamfetamine Dimesylate (LDX, SPD489)|
89185686|NCT00697515|Placebo Comparator|Placebo|
89185687|NCT03951636|Sham Comparator|Mechanical debridement with curettes|mechanical debridement: Inflammatory tissue, excess cement or plaque deposits will be removed using hand instruments
89185688|NCT03951636|Experimental|Er:YAG laser|Er:YAG laser treatment will be provided on the implant/abutment surface.
89185689|NCT03951636|Active Comparator|Air Powder|an Air-Powder treatment will be provided on the implant/abutment surface.
89185690|NCT00738062|Active Comparator|Droxidopa|Study medication
89388760|NCT03983954|Experimental|Naptumomab estafenatox 2 µg/kg and durvalumab|NAP is to be administered on the first four days of each 21-day cycle, at daily doses of 2 µg/kg. Durvalumab (1120 mg, IV, 1- 1.5 hours after completion of the administration of NAP) will be administered on the second day of each 21-day cycle. After cycle 3, patients will continue to receive durvalumab alone at a dose of 1500 mg delivered once every 28 days, until confirmed disease progression or unacceptable toxicity for a maximum of up to 24 months.
89388761|NCT03983954|Experimental|Naptumomab estafenatox 5 µg/kg and durvalumab|NAP is to be administered on the first four days of each 21-day cycle, at daily doses of 5 µg/kg. Durvalumab (1120 mg, IV, 1- 1.5 hours after completion of the administration of NAP) will be administered on the second day of each 21-day cycle. After cycle 3, patients will continue to receive durvalumab alone at a dose of 1500 mg delivered once every 28 days, until confirmed disease progression or unacceptable toxicity for a maximum of up to 24 months.
88864311|NCT05353374|Placebo Comparator|Petrolatum|Electrosurgery was carried out using Ellman® Surgitron. The tissue was cleaned using sterile gauze or a cotton swab that had been moistened with 0.9% NaCl. Following electrosurgery, petrolatum was applied to the wound according to the allocation sequence. The patient also received a wound care instruction sheet. Each subject was given two or four pots of ointment that should be applied twice daily on the wound.
88864312|NCT05352594||Chronic Low Back Pain|The participants whose low back pain intensity score ≥2 by numeric pain rating scale at 24-week follow-up.
88864313|NCT05352594||Recovered Low Back Pain|The participants whose low back pain intensity score <1 by numeric pain rating scale at 24-week follow-up.
88864314|NCT05292300|No Intervention|Control Group|Among those who applied to the clinic, those who do not want to follow their diet will be randomized into this group.
88864315|NCT05292300|Experimental|Cornelian Cherry Group|Among those who applied to the clinic, those who do not want to follow their diet will be randomized into this group. Patients in this group will receive 20 g/day Cornelian Cherry powder.
89388762|NCT03983954|Experimental|Naptumomab estafenatox 10 µg/kg and durvalumab|NAP is to be administered on the first four days of each 21-day cycle, at daily doses of 10 µg/kg. Durvalumab (1120 mg, IV, 1- 1.5 hours after completion of the administration of NAP) will be administered on the second day of each 21-day cycle. After cycle 3, patients will continue to receive durvalumab alone at a dose of 1500 mg delivered once every 28 days, until confirmed disease progression or unacceptable toxicity for a maximum of up to 24 months.
89388763|NCT03983954|Experimental|Naptumomab estafenatox 15 µg/kg and durvalumab|NAP is to be administered on the first four days of each 21-day cycle, at daily doses of 15 µg/kg. Durvalumab (1120 mg, IV, 1- 1.5 hours after completion of the administration of NAP) will be administered on the second day of each 21-day cycle. After cycle 3, patients will continue to receive durvalumab alone at a dose of 1500 mg delivered once every 28 days, until confirmed disease progression or unacceptable toxicity for a maximum of up to 24 months.
89388764|NCT03983954|Experimental|Naptumomab estafenatox 20 µg/kg and durvalumab|NAP is to be administered on the first four days of each 21-day cycle, at daily doses of 15 µg/kg. Durvalumab (1120 mg, IV, 1- 1.5 hours after completion of the administration of NAP) will be administered on the second day of each 21-day cycle. After cycle 3, patients will continue to receive durvalumab alone at a dose of 1500 mg delivered once every 28 days, until confirmed disease progression or unacceptable toxicity for a maximum of up to 24 months.
89530433|NCT02515955|Experimental|Cohort 6|Participants will be receiving either JNJ-54175446 at increasing dose levels using 2 oral formulation as suspension for oral dose once daily from Day 1 to Day 17 or minocycline 100 mg capsule twice daily from Day 1 to Day 17 or placebo matching with JNJ 54175446 once daily from Day 1 to Day 17.
88864316|NCT05292300|Experimental|Diet Group|Among those who applied to the clinic, those who want to follow their diet will be randomized into this group. Patients in this group will be followed by a personalized diet.
88864317|NCT05292300|Experimental|Cornelian Cherry and Diet Group|Among those who applied to the clinic, those who want to follow their diet will be randomized into this group. Patients in this group will be followed by a personalized diet and will receive 20 g/day Cornelian Cherry powder for their one portion fruit a day.
88864318|NCT05214222|Experimental|group A|Penpulimab plus chemotherapy with Anlotinib
88864319|NCT05214222|Experimental|group B|Penpulimab plus chemotherapy
88864320|NCT05195268|Active Comparator|Group 1 - PVI + PWI|These patients will receive pulmonary vein isolation and posterior wall isolation.
88864321|NCT05195268|Other|Group 2 - PVI only|These patients will receive pulmonary vein isolation only.
88864322|NCT05198232|No Intervention|Control Group|This group will complete normal daily activities. The participants will complete pre-test, 10 weeks of normal daily activities, and post-test. No changes to their daily schedule will be made by the researcher, the control group will participate in normal activities as part of their community day program.
88864323|NCT05198232|Experimental|Zumba High Tempo|The Zumba high tempo group will complete a 10-week (2x a week; 60 minutes per session) virtual adapted aerobic dance intervention (adapted Zumba®). Each session will consist of: a warm-up (3-5 minutes), 5-6 songs with instruction (40 minutes), and a cool down (5 minutes) for a total of about 60 minutes including rest/water breaks and time to transition. The only difference between the two adapted Zumba® programs will be the speed at which the songs will be played and the number of times through each song. The songs for the high-tempo group will be played at full speed; the songs in the high-tempo group will be repeated to ensure an equal amount of time moving for both groups. All sessions will be video recorded and examined for fidelity. This group will complete pre-test, post-test, and a 4-week follow-up.
89003432|NCT05280470|Experimental|Ifinatamab Deruxtecan (12 mg/kg)|"Participants will be randomized to receive I-DXd at 12 mg/kg.~In Part 2, all participants will receive I-DXd 12 mg/kg."
89003433|NCT05271292|Experimental|Study arm (35 mg)|Phase 1b: Patients will be enrolled sequentially in 3 dose-escalating cohorts (Chiauranib capsules 35, 50, and 65 mg, orally)
89388765|NCT03983954|Experimental|Dose escalation, obinutuzumab pretreatment followed by NAP 10 µg/kg and durvalumab|Obinutuzumab (1000 mg/day) will be administered on days 13 and 12 prior to the first day of NAP. NAP is to be administered on the first four days of each 21-day cycle, at daily doses of 10 µg/kg. Durvalumab (1120 mg, IV, 1- 1.5 hours after completion of the administration of NAP) will be administered on the second day of each 21-day cycle. After cycle 3, patients will continue to receive durvalumab alone at a dose of 1500 mg delivered once every 28 days, until confirmed disease progression or unacceptable toxicity for a maximum of up to 24 months.
89388766|NCT03983954|Experimental|Dose escalation, obinutuzumab pretreatment followed by NAP 15 µg/kg and durvalumab|Obinutuzumab (1000 mg/day) will be administered on days 13 and 12 prior to the first day of NAP. NAP is to be administered on the first four days of each 21-day cycle, at daily doses of 15 µg/kg. Durvalumab (1120 mg, IV, 1- 1.5 hours after completion of the administration of NAP) will be administered on the second day of each 21-day cycle. After cycle 3, patients will continue to receive durvalumab alone at a dose of 1500 mg delivered once every 28 days, until confirmed disease progression or unacceptable toxicity for a maximum of up to 24 months.
89388767|NCT03983954|Experimental|MTD expansion, obinutuzumab pretreatment with NAP at MTD and durvalumab|NAP at 15mcg/kg and durvalumab (1120 mg) will be given for 6 cycles after pre-treatment of obinutuzumab (1000 mg/day) on D-13 and D-12. After cycle 6, patients will continue to receive durvalumab alone at a dose of 1500 mg delivered once every 28 days, until confirmed disease progression or unacceptable toxicity for a maximum of up to 24 months.
89388768|NCT03983954|Experimental|MTD expansion, obinutuzumab pretreatment with NAP, at the previous dose level, and durvalumab|NAP, at the previous dose level (10mcg/kg), and durvalumab (1120 mg) will be given for 6 cycles after pre-treatment of obinutuzumab (1000 mg/day) on D-13 and D-12. After cycle 6, patients will continue to receive durvalumab alone at a dose of 1500 mg delivered once every 28 days, until confirmed disease progression or unacceptable toxicity for a maximum of up to 24 months.
89388769|NCT03983954|Experimental|MTD expansion, abbreviated regimen of obinutuzumab pretreatment with NAP at MTD and durvalumab|NAP at MTD (10 mcg/kg/day) and durvalumab (1120 mg) will be given for 6 cycles after a single dose of pre-treatment of obinutuzumab (1000 mg/day) on D-7. After cycle 6, patients will continue to receive durvalumab alone at a dose of 1500 mg delivered once every 28 days, until confirmed disease progression or unacceptable toxicity for a maximum of up to 24 months.
89388770|NCT03982888|Experimental|DBS Treatment|Deep brain stimulation of both limbic and dysfunctional reward processing circuits for treatment of repetitive self injurious behaviours in children with ASD
89388771|NCT03957577||All participants|Participants with COPD or Asthma-COPD overlap syndrome (ACOS)
89388772|NCT03945552|No Intervention|Control|Care as usual
89388773|NCT03945552|Experimental|Video Interaction Project|VIP is a strengths-based, family-centered intervention that uses pediatric well-child visits to enhance parenting practices/relationships and child development by promoting positive parenting practices such as pretend play, shared reading, and daily routines.
89388774|NCT03922035|Experimental|Arm I (CBM588)|Patients receive standard peri-/post-transplant supportive care and CBM588 PO BID from day of admission to day 28 in the absence of disease progression or unacceptable toxicity.
89185691|NCT00738062|Placebo Comparator|Placebo|Placebo
89388775|NCT03922035|Active Comparator|Arm II (standard of care)|Patients receive standard peri-/post-transplant supportive care.
89388776|NCT03901573|Experimental|Checkpoint Inhibitor-Naive cSCC, MCC Pts|Anti-PD-1/PD-L1 naïve patients with cSCC and MCC
89388777|NCT03901573|Experimental|Checkpoint Inhibitor-Relapsed/Refractory cSCC MCC Melanoma Pts|Anti-PD-1/PD-L1 relapsed/refractory patients with cSCC, MCC and melanoma
89388778|NCT03886519|Active Comparator|BRAP (Bevel/rotate/advance procedure)|The BRAP procedure is a full-thickness beveled full-thickness incision
89388779|NCT03886519|Active Comparator|Trabut 3 mm|The Trabut procedure is a partial-thickness incision through the tarsal conjunctiva and tarsus parallel to the eyelid margin and 3 mm above the lash line.
89388780|NCT03864146|Experimental|Pioglitazone|Pioglitazone titrated to 45mg by mouth each day
89388781|NCT03864146|Placebo Comparator|Placebo|placebo, identical 45mg pill
89388782|NCT03842358|Experimental|Phase I - Training Set|"20 patients will be recruited to undergo US-DOT and CEM to allow for training study readers in assessing US-DOT data, intra-observer variability and to assess inter-observer variability in the assessment of US-DOT data~A hand-held hybrid probe will be used for the scans"
89388783|NCT03842358|Experimental|Phase 2: Prospective Trial|"US-DOT (US/NIR) Imaging Exam~Breast biopsy or FNA performed (standard of care)~A hand-held hybrid probe will be used for the scans"
89388784|NCT03817320|Experimental|Ixazomib Dose Level 1 (Stratum A)|Patients will be treated on ixazomib at 1.6 mg/m^2/day on Days 1, 4, 8, and 11. Vincristine IV at 1.5 mg/m^2 on Days 1, 8, 15 and 22. Pegaspargase IV/IM at 2500 IU/m^2 on Days 2 and 15, Doxorubicin at 60 mg/m^2 on Days 1, Dexamethasone IV/PO at 10 mg/m^2 continuous starting on Day 1 thru Day 14, and IT chemotherapy dependent on patient's CNS status at time of enrollment. This arm is the starting Dose Level for patients being enrolled.
89388785|NCT03817320|Experimental|Ixazomib Dose Level 2 (Stratum A)|Patients will be treated on ixazomib at 2.0 mg/m^2/day on Days 1, 4, 8, and 11. Vincristine IV at 1.5 mg/m^2 on Days 1, 8, 15 and 22. Pegaspargase IV/IM at 2500 IU/m^2 on Days 2 and 15, Doxorubicin at 60 mg/m^2 on Days 1, Dexamethasone IV/PO at 10 mg/m^2 continuous starting on Day 1 thru Day 14, and IT chemotherapy dependent on patient's CNS status at time of enrollment. Patients will be treated at this arm Dose Level once patient accrual at Dose Level 1 has been completed and dose escalation is allowed as defined by the 3+3 design.
89388786|NCT03817320|Experimental|Ixazomib Dose Level -1 (Stratum A)|Patients will be treated on ixazomib at 1.2 mg/m^2/day on Days 1, 4, 8, and 11. Vincristine IV at 1.5 mg/m^2 on Days 1, 8, 15 and 22. Pegaspargase IV/IM at 2500 IU/m^2 on Days 2 and 15, Doxorubicin at 60 mg/m^2 on Days 1, Dexamethasone IV/PO at 10 mg/m^2 continuous starting on Day 1 thru Day 14, and IT chemotherapy dependent on patient's CNS status at time of enrollment. This arm Dose Level -1 is needed only if de-escalation from Dose Level 1 is required.
88864324|NCT05198232|Experimental|Zumba Low Tempo|The Zumba low tempo group will complete a 10-week (2x a week; 60 minutes per session) virtual adapted aerobic dance intervention (adapted Zumba®). Each session will consist of: a warm-up (3-5 minutes), 5-6 songs with instruction (40 minutes), and a cool down (5 minutes) for a total of about 60 minutes including rest/water breaks and time to transition. The only difference between the two adapted Zumba® programs will be the speed at which the songs will be played and the number of times through each song. The songs for the low-tempo group will be set to three-fourths speed. All sessions will be video recorded and examined for fidelity. This group will complete pre-test, post-test, and a 4-week follow-up.
88864325|NCT05175690||Trial Population|The trial population will be enrolled from adults presenting for elective, outpatient COVID-19 testing at a single center, potentially with multiple testing locations (subject to local needs at the time of the trial). The investigational device will be provided to Participants via a cell phone preloaded with Common off-the-shelf original equipment manufacturer (COTS OEM) software and the investigational Dx SaMD. The investigational device will be evaluated during a single encounter in which an FCV-SDS will be collected. No follow-up visits or participant contacts will be involved in this trial.
88864326|NCT05048550|No Intervention|A (control)|First visit assessments at 8 weeks corrected gestational age. No glasses prescribed.
88864327|NCT05048550|Experimental|B1 (intervention)|First visit assessments at 8 weeks corrected gestational age. Full time spectacle wear prescribed.
88864328|NCT05048550|Experimental|B2 (intervention)|First visit assessments at 16 weeks corrected gestational age. Full time spectacle wear prescribed.
88864329|NCT04932018|Experimental|Interventional|The intervention group will participate in a round table educational session with a study facilitator/mentor farmer and occupational health nurse plus receive an invitation to participate in an interactive virtual community providing ongoing resources and support from community farmers and agriculture experts.
88864330|NCT04932018|Sham Comparator|Attention Control|The second group (attention control) will receive an invitation to participate in the virtual community without mentor interaction.
89003434|NCT05271292|Experimental|Study arm (50 mg)|Phase 1b: Patients will be enrolled sequentially in 3 dose-escalating cohorts (Chiauranib capsules 35, 50, and 65 mg, orally)
89003435|NCT05271292|Experimental|Study arm (65 mg)|Phase 1b: Patients will be enrolled sequentially in 3 dose-escalating cohorts (Chiauranib capsules 35, 50, and 65 mg, orally)
89388787|NCT03817320|Experimental|Ixazomib Dose Level 1 (Stratum B)|Patients will be treated on ixazomib at 1.6 mg/m^2/day on Days 1, 4, 8, and 11. Vincristine IV at 1.5 mg/m^2 on Days 1, 8, 15 and 22. Pegaspargase IV/IM at 2500 IU/m^2 on Days 2 and 15, Doxorubicin at 60 mg/m^2 on Days 1, Dexamethasone IV/PO at 10 mg/m^2 continuous starting on Day 1 thru Day 14, and IT chemotherapy dependent on patient's CNS status at time of enrollment. Leucovorin PO/IV at 5 mg/m^2/dose X 2 doses given 24 and 30 hours after IT Methotrexate or Triple IT will also be given on this arm. This arm is only for patients with Down syndrome (Stratum B).
89388788|NCT03802331|Experimental|Test Treatment|fed
89388789|NCT03802331|Experimental|Reference Treatment|fasted
89388790|NCT03799445|Experimental|Treatment (nivolumab, ipilimumab, IMRT)|Patients receive nivolumab IV over 30 minutes on days 1, 15, and 29 and ipilimumab IV over 30 minutes on day 1. Treatment repeats every for 6 weeks for 2 cycles in the absence of disease progression or unacceptable toxicity. Beginning on day 1 of cycle 2, patients also undergo IMRT 5 days a week (Monday-Friday) for 6 weeks in the absence of disease progression or unacceptable toxicity.
88864331|NCT02829528|Experimental|Little Flower Yoga For Kids|Little Flower Yoga for Kids is a New York based organization dedicated to making the tools of yoga and mindfulness available to all children and teens. Their Teacher Training Program focuses on the physical, mental emotional, and social wellbeing of students. Teachers are trained to use the five elements format (connect, breathe, move, focus, relax). Implementation of the Little Flower Yoga for Kids curriculum will be manualized prior to the start of the study with Ms. Love, and will be presented as a series of activities (e.g., poses) throughout the school year. The emphasis in these yoga and mindfulness activities is exploration not competition, which allows the child to learn and develop at her own pace with the support of Ms. Love. The children participate in the Little Flower Yoga for Kids intervention at school for 40 minutes per class, 3 to 5 times per week, for the entire academic school year (9 months).
88864332|NCT04747236|Experimental|AZA and ROMI|Oral Azacytidine (AZA) (300 mg daily on days 1-14) plus Romidepsin (ROMI) (14 mg/m2 as an intravenous infusion over 4 hours +/- 30 minutes on days 8, 15 and 22 of a 35-day cycle.
88864333|NCT04747236|Active Comparator|Investigator's Choice|Investigator's choice to include: ROMI, 14 mg/m2 IV infusion on days 1, 8, and 15 of a 28 day cycle, belinostat,1000 mg/m2 IV infusion on days 1-5 every 21 days, pralatrexate, 30 mg/m2 IV push once weekly for 6 weeks of a 7-week treatment cycle, or gemcitabine, 1000 mg/m2 IV infusion on days 1, 8, and 15 of a 28-day cycle.
88864334|NCT04742946|Experimental|TR Group|Personalized digital physiotherapy program 4 weeks. One session per day. Web and mobile application. Auto-Exercise
88864335|NCT05017194|Experimental|Emodepside 5 mg|
88864336|NCT05017194|Experimental|Emodepside 10 mg|
88864337|NCT05017194|Experimental|Emodepside 15 mg|
88864338|NCT05017194|Experimental|Emodepside 20 mg|
88864339|NCT05017194|Experimental|Emodepside 25 mg|
88864340|NCT05017194|Experimental|Emodepside 30 mg|
88864341|NCT05017194|Active Comparator|Albendazole|
88864342|NCT05017194|Placebo Comparator|Placebo|
88864343|NCT04993248|Experimental|Intervention|"The intervention will offer participants the opportunity to share feelings and needs with people who are in a similar situation to their own.~Each intervention consists of 3 dialogue circles per group. Each group is composed of 10 participants and a facilitator, in all interventions the facilitator will be the principal investigator."
88864344|NCT04993248|No Intervention|Control|Usual intervention
88864345|NCT04850820|Experimental|Novel essential amino acid supplementation (EAA+)|Arm will investigate the effect of a novel essential amino acid-based formula (essential amino acids enriched with active botanical compounds; EAA+) developed by Iovate Health Sciences International Inc. on post-exercise anabolism. The formulation was recently granted a Natural Product Number (NPN: 80087022) and approved by the Natural and Non-prescription Health Products Directorate of Health Canada.
88864346|NCT04850820|Active Comparator|Branched-chain amino acid supplementation (BCAA)|Arm will used a branched-chain amino acid supplement developed by Iovate Health Sciences International Inc. to compare with the experimental arm after exercise.
88864347|NCT04850820|Placebo Comparator|Isocaloric carbohydrate supplementation|Carbohydrate supplement that is isocaloric to the EAA+ supplement and designed to function as a placebo to the experimental arm after exercise.
88864348|NCT04850820|Other|Rested control|Carbohydrate supplement that is isocaloric to the EAA+ supplement but consumed at rest to serve as the baseline control
88864349|NCT04778748||Obstructive Sleep Apnea|Participants will be provided with a Withings sleep monitor and instructed to begin using it. Effective data collection via the Withings unit should be confirmed for at least 7 consecutive nights, and the WatchPAT device will be used during one of those same 7 nights.
88864350|NCT04520100|No Intervention|MRI without intervention|No hypnosis during MRI and care by regular MR technologist
88864351|NCT04520100|Active Comparator|MRI with clinical hypnosis and regular MR tech|Hypnosis during MRI and care by regular MR technologist
88864352|NCT04520100|Active Comparator|MRI with care by MR Tech trained in empathic communication|No hypnosis during MRI and care by MR technologist who have been trained in emphatic communication
88864353|NCT04501380|Experimental|1st regimen|15 patients will receive AEMCOLO (Rifamycin SV MMX) 194 mg two tablets to take twice daily for 14 days (56 Tablets)
88864354|NCT04501380|Experimental|2nd regimen|15 patients will receive AEMCOLO (Rifamycin SV MMX) 194 mg tablets to take two tablets three times daily for 14 days (84 Tablets).
88864355|NCT04465734|Experimental|A (treatment group)|HLX10 in combination with HLX04
88864356|NCT04465734|Sham Comparator|B (control group)|sorafenib
88864357|NCT04388358|Other|mixed Chinese herb formula|Shin-yi-san + Xiao-qing-long-tang + Xiang-sha-liu-jun-zi-tang by the weight of 9g+3g+3g/day
88864358|NCT04417296||nonlaboring term singleton pregnancies|"All patients had an uncomplicated pregnancy and to define a pregnancy uncomplicated we adopted Chappell's definition: a normotensive pregnancy, delivered at >37 weeks, ending in a live-born baby who was not small for gestational age and did not have any other notable pregnancy complications"
88864359|NCT04954872|Active Comparator|Training as usual|Standard Problem Management Plus training.
89388791|NCT03788746||Patients diagnosed with advanced urothelial carcinoma|Patients with a confirmed diagnosis of advanced urothelial carcinoma, prior to or during first line therapy, who have available tumor tissue samples collected as part of standard of care
88864360|NCT04954872|Experimental|Equip-based training|Training that uses the Equip platform to assess competencies and incorporate this information into trainers and supervisors activities.
88864361|NCT02132520|No Intervention|Control|Subjects receiving standard-of-care physical therapy only.
88864362|NCT02132520|Sham Comparator|Sham rTMS + Real BCI Training|Subjects will receive sham rTMS followed by real BCI training.
88864363|NCT02132520|Active Comparator|Real rTMS + Real BCI Training|Subjects will receive real rTMS followed by real BCI training.
88864364|NCT04020198||Parkinson's Disease|Subjects who have a PD diagnosis
88864365|NCT04020198||Multiple System Atrophy|Subjects who have an MSA diagnosis
88864366|NCT04020198||Age-matched controls|Subjects who do not have a diagnosed parkinsonian disorder
88864367|NCT04020198||Rapid Eye Movement Sleep Behavior Disorder (RBD)|Subjects who have a diagnosis of RBD
88864368|NCT04020198||Normal Pressure Hydrocephalus|Subjects who are prescribed a lumbar puncture to treat normal pressure hydrocephalus
88864369|NCT03885336||Both-Quit Group|Couples in which both individuals smoke and both individuals would like to quit smoking.
89003436|NCT05265299|Experimental|Sequence 1|"Week 1-2: aspirin 81mg~Week 5-6: aspirin 162mg~Week 9-10: aspirin 325mg"
89003437|NCT05265299|Experimental|Sequence 2|"Week 1-2: aspirin 162mg~Week 5-6: aspirin 81mg~Week 9-10: aspirin 325mg"
89388792|NCT03782376|Experimental|Group 1: Ustekinumab (IV re-induction)|Participants who experience a secondary loss of response (LoR) to 90 mg ustekinumab maintenance treatment, administered subcutaneously every 8 weeks (q8w) will receive a weight-tiered based ustekinumab IV re-induction dose of approximately 6 mg/kg and matching placebo subcutaneously at Week 0. At Weeks 8 and 16, all participants will receive SC maintenance injections of 90 mg ustekinumab. Participants will resume their standard-of-care therapy at Week 24 at the discretion of the treating physician.
89388793|NCT03782376|Active Comparator|Group 2: Ustekinumab (Continuous q8w SC maintenance)|Participants who experience a secondary LoR to 90 mg ustekinumab maintenance treatment, administered subcutaneously q8w will receive ustekinumab 90 mg subcutaneously and matching placebo intravenously at Week 0. At Weeks 8 and 16, all participants will receive SC maintenance injections of 90 mg ustekinumab. Participants will resume their standard-of-care therapy at Week 24 at the discretion of the treating physician.
88864370|NCT01798524||Kidney allograft recipients|
88864371|NCT03869814||Non-cancer|3,250 asymptomatic individuals without prior history of cancer
88864372|NCT03869814||Cancer|3,250 individuals with confirmed malignancy
88864375|NCT03821142|Experimental|Calistar S|Single arm cohort trial
88864376|NCT04256460|Experimental|Intervention arm|Behavior intervention including health education on diet, exercises and self management support through peer support, and also receive regular care and follow up in community health centers
88864377|NCT04256460|No Intervention|Control arm|Receiving regular care and follow up in Community health centers
88864378|NCT03725046|No Intervention|Usual information transmission after ED admission|The emergency department (ED) sends to the referring doctor a letter to inform him about the reason of consultations in the emergency department (mail currently realized as part of the care process).
89003438|NCT05265299|Experimental|Sequence 3|"Week 1-2: aspirin 325mg~Week 5-6: aspirin 81mg~Week 9-10: aspirin 162mg"
89003439|NCT05265299|Experimental|Sequence 4|"Week 1-2: aspirin 325mg~Week 5-6: aspirin 162mg~Week 9-10: aspirin 81mg"
89003440|NCT05265299|Experimental|Sequence 5|"Week 1-2: aspirin 162mg~Week 5-6: aspirin 325mg~Week 9-10: aspirin 81mg"
89003441|NCT05265299|Experimental|Sequence 6|"Week 1-2: aspirin 81mg~Week 5-6: aspirin 325mg~Week 9-10: aspirin 162mg"
89003442|NCT05257941|Active Comparator|IT Injection|an intrathecal (IT) injection in the back in which a small dose duramorph and bupivacaine will be placed into the spinal fluid
89003443|NCT05257941|Active Comparator|ESP Block|an erector spinae plane (ESP) block in which bupivacaine and decadron are injected near the nerves under a muscle in the back.
89003444|NCT05238675|Experimental|BI 1291583: Low dose group|
89003445|NCT05238675|Experimental|BI 1291583: Medium dose group|
89003446|NCT05238675|Experimental|BI 1291583: High dose group|
89003447|NCT05238675|Placebo Comparator|Placebo|
89388794|NCT03774082|Experimental|INC424 (ruxolitinib)|Subjects who will be administered 5mg ruxolitinib tablet or ruxolitinib oral pediatric formulation twice a day.
89530434|NCT02515955|Experimental|Cohort 7|Participants will be receiving either JNJ-54175446 at increasing dose levels using 2 oral formulation as suspension for oral dose once daily from Day 1 to Day 17 or placebo matching with JNJ 54175446 once daily from Day 1 to Day 17.
89530435|NCT02515955|Experimental|Cohort 8|Participants will be receiving either JNJ-54175446 at increasing dose levels using 2 oral formulation as suspension for oral dose once daily from Day 1 to Day 17 or placebo matching with JNJ 54175446 once daily from Day 1 to Day 17.
89388795|NCT03760523|Experimental|Minnelide Dose Escalation|A 3+3 design will be used. The first 3 patients will be treated at dose level 1. If none experience a Dose Limiting Toxicity (DLT), the next 3 patients will be treated at dose level 2. If a DLT is observed in 1 out of 3 patients at dose level 1, up to an 3 more patients will be enrolled and treated at that dose level. If 2 patients at dose level have DLTs, dosing will be lowered to dose level -1 (.5 mg daily, taken orally). If 2 or more of the up to 6 patients at any dose level have DLTs, the preceding dose will be declared the Maximum Tolerated Dose (MTD). If more than 1 DLT occurs at Dose Level -1, the investigators will consider stopping the study. Once the MTD has been established, an additional 10 patients will be enrolled at this level to better characterize safety and tolerability.
89388796|NCT03752827|Experimental|Adipose Derived Regenerative Cells|Adipose-derived regenerative cell injection into the area of the supraspinatus tendon tear
89388797|NCT03752827|Active Comparator|Corticosteroid|Subjects in the active control arm will receive a corticosteroid injection into the subacromial space using ultrasound (US) guidance.
89388798|NCT03752723|Experimental|combination with CPA, GX-I7, and pembrolizumab|"Experimental: combination~Assigned interventions: CPA, GX-I7 and pembrolizumab"
89388799|NCT03752723|Experimental|combination with GX-I7, and pembrolizumab|"Experimental: combination~Assigned interventions: GX-I7 and pembrolizumab (without CPA)"
89388800|NCT03697278|No Intervention|Control group|Using clinical routinely regime device to use and monitor postoperative controlled pain (PCA) after surgery.
89388801|NCT03697278|Experimental|Smith medical CADDsolis|This study group use a new device to use and monitor postoperative controlled pain (PCA) after surgery.
89388802|NCT03689543|Experimental|Arm 1|LY500307 at 25mg per day
89003448|NCT05237921|Experimental|Combined Exercise and Dietary Intervention|Behavioral Intervention
89388803|NCT03689543|Active Comparator|Arm 2|LY500307 at 75mg per day
89388804|NCT03689543|Placebo Comparator|Arm 3|Matched placebo
89185692|NCT04156074|Experimental|Vitamin D enriched (20 mcg/day) olive oil emulsion drink|30 mL vitamin D enriched drink consumed daily for 4 weeks
89185693|NCT04156074|Active Comparator|Vitamin D enriched (20 mcg/day) coconut oil emulsion drink|30 mL vitamin D enriched drink consumed daily for 4 weeks
89388805|NCT03683433|Experimental|Treatment (azacitidine, enasidenib mesylate)|Patients receive azacitidine SC or IV over 30 minutes on days 1-7 and enasidenib mesylate PO QD beginning on day 1. Cycles repeat every 4-6 weeks in the absence of disease progression or unacceptable toxicity.
89388806|NCT03682081|No Intervention|Usual care|Usual care groups will receive standard swallowing interventions identified by the Speech-Language Pathologist as appropriate to treat the patient's dysphagia and common in clinical practice. Such treatment would likely consist of dietary (e.g., thickened liquids or pureed foods) or postural compensatory strategies (e.g., chin down posture while swallowing). No progressive lingual strengthening approaches or regimented salivary substitute protocols are utilized.
89388807|NCT03682081|Experimental|Saliva Substitute Intervention|Each patient-caregiver dyad will be provided with a commercially available gel-based saliva substitute, Biotene® Oral Balance Gel that will be applied to the oral cavity regularly for 8 weeks.
89388808|NCT03682081|Experimental|Lingual Strengthening Intervention|Patient-caregiver dyads will be trained in the lingual strengthening protocol and patients will undergo this intervention for 8 weeks. Isometric tongue strengthening will be facilitated by the Iowa Oral Performance Instrument (IOPI) device.
89388809|NCT03682081|Experimental|Saliva Substitute and Lingual Strengthening Intervention|Each patient-caregiver dyad will be provided with a commercially available gel-based saliva substitute, Biotene® Oral Balance Gel that will be applied regularly to the oral cavity for 8 weeks. Each dyad will also be trained in the lingual strengthening protocol and will undergo this intervention for 8 weeks. Isometric tongue strengthening will be facilitated by the Iowa Oral Performance Instrument (IOPI) device.
89388810|NCT03674372|Experimental|Fetuses with Left CDH (O/E LHR < 25%)|Fetuses with Left CDH (O/E LHR < 25%) will receive Fetoscopic Endoluminal Tracheal Occlusion (FETO)
89388811|NCT03674372|Experimental|Fetuses with L- sided CDH with O/E LHR <30%.|Fetuses with Left CDH (O/E LHR < 30%) will receive Fetoscopic Endoluminal Tracheal Occlusion (FETO)
89185694|NCT04156074|Placebo Comparator|Placebo coconut oil emulsion drink|30 mL placebo drink consumed daily for 4 weeks
89003449|NCT05237921|Other|Control|Standard Care
89185695|NCT04156074|Active Comparator|Vitamin D supplement (20 mcg/day)|Vitamin D supplement consumed daily for 4 weeks
89388812|NCT03674372|Experimental|Fetuses with R- sided CDH with O/E LHR < 45%|Fetuses with Right CDH (O/E LHR < 45%) will receive Fetoscopic Endoluminal Tracheal Occlusion (FETO)
89388813|NCT03664830|Experimental|Plerixafor|Up to two subcutaneous injections of plerixafor (starting dose level: 240 µg/kg/dose)
89388814|NCT03634241|Experimental|Pembrolizumab|Participants receive pembrolizumab IV over 30 minutes on day 1. Treatment repeat every 3 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT scans and collection of blood samples throughout the trial.
89388815|NCT03588390|Experimental|Dose Group 1|Participants were orally administered single dose of BI 1323495 dose group 1 or matching placebo film-coated tablet with 240 mL of water after an overnight fast of at least 10 h.
88864379|NCT03725046|Experimental|Optimized information transmission after ED admission|Sending to the community referring physician by the emergency department an discharge report containing the reason for emergency consultations (report currently made as part of the treatment). Within 72 hours (working hours), the Emergency Clinical Pharmacist contacts the referring physician and the patient's community pharmacist to discuss how to manage the ADE. In parallel, a second report, summary of the ADE (ADE-report), is sent to them. The ADE-report, written and validated by the investigators (emergency physician and clinical pharmacist), includes the type of ADE, the suspected drug(s) and other recommendations: therapeutic modification, referral to specialized consultations (geriatrics ...).
88864380|NCT01798602|Experimental|Rosuvastatin|"Rosuvastatin 40 mg via nasogastric tube then 20 mg po or via nasogastric tube daily for 14 days or until hospital discharge Placebo is identical capsule with no active drug~Both are crushed for administration"
88864381|NCT01798602|Placebo Comparator|Placebo|Identical drug vehicle with no active agent
88864382|NCT03722082|Experimental|Enhancing cognitive reserve intervention|This intervention focuses in the improvement of academic skills, the increase of leisure activities and the improvement of neurocognitive functions with the ultimate goal of improving daily functioning. This intervention is based on ecological tasks that will be carried out in two areas, both in the hospital and at home. Most of the techniques are based on: pencil and paper tasks, with audiovisual and virtual reality support, telephone applications and group activities. The groups will be made with parents and children, adolescents and young adults separately being the content of the sessions the same but adapted to the age of the attendees.
88864383|NCT03722082|Placebo Comparator|Supportive Intervention|The participants will not receive any structured intervention focused to enhance cognitive reserve. The therapists will adopt a client-centred focus, meaning that whatever problems the patient presents will be dealt with by providing emotional support and general advise.
88864384|NCT00604890|Experimental|1|Active cream, 3% AM & PM
88864385|NCT00604890|Placebo Comparator|2|Placebo cream AM ; 3% active cream PM
88864386|NCT00604890|Placebo Comparator|3|Placebo cream AM; 1.5% active cream PM
88864387|NCT00604890|Placebo Comparator|4|Placebo AM and PM
88864388|NCT03714048||Perioperative|
88864389|NCT03714048||Cardiogenic shock minus arrest|
88864390|NCT03714048||Cardiogenic shock plus arrest|
88864391|NCT03714048||Preventive|
88864392|NCT03694704|Experimental|CI with FineHearing Strategy|cochlear implant with FineHearing strategy
88864393|NCT02783430|Experimental|Milnacipran + Ketamine|Ketamine 0,5mg/kg single intravenous perfusion during 40 minutes. Milnacipran dosage depending of glomerular filtration rate of patient, during 16 days (doses of 25 or 50 mg or 100mg per day)
88864394|NCT02783430|Active Comparator|Milnacipran + Placebo|Placebo single intravenous perfusion during 40 minutes. Milnacipran dosage depending of glomerular filtration rate of patient, during 16 days (doses of 25 or 50 mg or 100mg per day)
88864395|NCT03656328|Experimental|Lactobacillus Reuteri 4659|This Arm received standard antibiotic therapy, consisting of ciprofloxacin 400 mg twice a day and metronidazole 500 mg three times a day for seven days, with supplementation with the probiotic L. reuteri 4659 twice a day for 10 days
88864396|NCT03656328|Placebo Comparator|Placebo|This arm received the same standard antibiotic therapy and a matching placebo for the same periods.
88864397|NCT03642366|Active Comparator|Active Arm 1|
88864398|NCT03642366|Active Comparator|Active Arm 2|
89388816|NCT03588390|Experimental|Dose Group 2|Participants were orally administered single dose of BI 1323495 dose group 2 or matching placebo film-coated tablet with 240 mL of water after an overnight fast of at least 10 h.
89388817|NCT03588390|Experimental|Dose Group 3|Participants were orally administered single dose of BI 1323495 dose group 3 or matching placebo film-coated tablet with 240 mL of water after an overnight fast of at least 10 h.
89388818|NCT03588390|Experimental|Dose Group 4|Participants were orally administered single dose of BI 1323495 dose group 4 or matching placebo film-coated tablet with 240 mL of water after an overnight fast of at least 10 h.
89388819|NCT03588390|Experimental|Dose Group 5|Participants were orally administered single dose of BI 1323495 dose group 5 or matching placebo film-coated tablet with 240 mL of water after an overnight fast of at least 10 h.
88864399|NCT03642366|Sham Comparator|Sham Arm|
88864400|NCT05246436|Active Comparator|warm saline|Patients who used warm saline as a distention media in office hysteroscopy
88864401|NCT05246436|Sham Comparator|room temperature saline|Patients who used room temprature saline as a distention media in office hysteroscopy
88864402|NCT05246358|Experimental|ChroniSense Polso Respiratory Rate|Comparison of respiratory rates in normal subjects as observational with end tidal CO2. No treatment or interventions will be performed
89388820|NCT03588390|Experimental|Dose Group 6|Participants were orally administered single dose of BI 1323495 dose group 6 or matching placebo film-coated tablet with 240 mL of water after an overnight fast of at least 10 h.
89388821|NCT03588390|Experimental|Dose Group 7|Participants were orally administered single dose of BI 1323495 dose group 7 or matching placebo film-coated tablet with 240 mL of water after an overnight fast of at least 10 h.
89388822|NCT03588390|Experimental|Dose Group 8|Participants were orally administered single dose of BI 1323495 dose group 8 or matching placebo film-coated tablet with 240 mL of water after an overnight fast of at least 10 h.
88864403|NCT00604968|Experimental|Caelyx|
88864404|NCT00605202|Active Comparator|Licorice|
88864405|NCT00605202|Active Comparator|Licorice and HCTZ|
88864406|NCT00605358|Active Comparator|Open Door Intervention|Subjects who receive the Open Door Intervention will work with the study counselor to identify barriers to participation in mental health treatment, set goals, and problem-solve, in addition to receiving a referral.
88864407|NCT00605358|No Intervention|Services Referral|"Subjects who do not receive the Open Door intervention will receive:~an evaluation~referral to a local mental health provider~booklet information on depression and mental health care, and will complete an application for HEAP, a Westchester County service that provides reduced rates from oil companies on heating to seniors."
88864408|NCT05245578|Experimental|KX01 ointment and Placebo ointment|
89003450|NCT05237804|No Intervention|Control group|The randomized centres in this group will not change their practices.
89185696|NCT04076670|No Intervention|Control group|Group pf participants that received usual psychological attention.
88864409|NCT00605826|Experimental|Blinded injection of NASHA/Dx gel at randomization.|Blinded injection of NASHA/Dx (Solesta) Gel. For each treatment, a series of 4 equally spaced injections with 1 mL of Solesta into the anal canal. Subjects will be followed for 6 months during the blinded phase. During a subsequent open phase, these subjects will be followed to Month 36 (ie, for an additional 30 months).
88864410|NCT00605826|Sham Comparator|Blinded sham inject. at randomization|"Blinded sham injection (needle stick with empty syringes). For each treatment, a series of 4 equally spaced Sham injections (needle sticks) into the anal canal. Subjects will be followed for 6 months during the blinded phase.~Sham-treated subjects have the option to receive open-label injection of NASHA/Dx (Solesta) Gel at the 6-month time point following completion of the blinded phase (ie, blinded sham injection at randomization + NASHA/Dx Gel at 6 months). Following injection of NASHA/Dx gel at the start of the open phase, these subjects will be followed to Month 30 (ie, for an additional 24 months)."
88864411|NCT00605826|Other|Blinded Sham Inject. at Randomization + NASHA/Dx Gel at 6 mo.|"Blinded sham injection at randomization. Subjects will be followed for 6 months during the blinded phase.~Sham-treated subjects have the option to receive open-label injection of NASHA/Dx (Solesta) Gel at the 6-month time point following completion of the blinded phase (ie, blinded sham injection at randomization + NASHA/Dx Gel at 6 months). Following injection of NASHA/Dx gel at the start of the open phase, these subjects will be followed to Month 30 (ie, for an additional 24 months)."
88864412|NCT05216562|Experimental|Intervention group|Group participants who receive injection of EXOSOME-MSC as adjuvant
88864413|NCT05216562|Placebo Comparator|Control group|Group participants who receive injection of Placebo (NaCL) as adjuvant
88864414|NCT03381300|Other|Single cohort|
88864415|NCT02132598|Experimental|Cabozantinib (XL184)|"Patients will receive cabozantinib at 60 mg orally once daily and continue on treatment until disease progression, death or unacceptable adverse events.~Treatment cycles are 4 weeks in duration"
88864416|NCT00605904|Experimental|Acamprosate|Subjects received 3 tablets of 333mg acamprosate orally, three times daily (total dose of 999 mg) for a minimum of 2 weeks.
88864417|NCT00605904|Placebo Comparator|Placebo|Subjects received 3 tablets of placebo orally, three times daily, for a minimum of 2 weeks.
88864418|NCT02132676||Active treatment|All those scheduled for a Shared Medical Appointment (SMA), regardless of whether the Peer to Peer (P2P) program was offered.
88864419|NCT02132676||Usual Care|The randomly selected sample of those not offered participation in a Shared Medical Appointment (SMA).
88864420|NCT00607620|Experimental|Intervention|Providers receive training in alcohol screening and brief interventions from study staff in compliance with American College of Surgeons' Alcohol Screening and Brief Intervention Mandate
88864421|NCT00607620|No Intervention|Usual Care|Usual care for alcohol use problems after American College of Surgeons' Alcohol Screening and Brief Intervention Mandate
88864422|NCT05175768|Active Comparator|Nicotinamide Mononucleotide|Two sachets to be taken orally after breakfast and Two sachets after lunch with water.
88864423|NCT05175768|Active Comparator|Nicotinamide Mononucleotide with L-Leucine|Two sachets to be taken orally after breakfast and Two sachets after lunch with water.
88864424|NCT05175768|Placebo Comparator|Placebo|Two sachets to be taken orally after breakfast and Two sachets after lunch with water.
88864425|NCT05097846|Experimental|Group1: Vonoprazan Fumarate + amoxicillin + doxycycline|
88864426|NCT05097846|Experimental|Group2: Vonoprazan Fumarate + furazolidone + doxycycline|
88864427|NCT05097846|Experimental|Group3: esomeprazole + colloidal bismuth tartrate + amoxicillin + doxycycline|
88864428|NCT05097846|Experimental|Group4: esomeprazole + colloidal bismuth tartrate + furazolidone + doxycycline|
88864429|NCT04388046|Experimental|skeletal class 2 malocclusion|10 patients treated with type IV Herbst appliance. The appliance was connected directly to the mandible by a bilateral reconstruction bone plates to provide a skeletal anchorage and avoid any mandibular teeth involvement
88864430|NCT00608634|Placebo Comparator|Placebo|Patients apply a placebo cream topically to each dorsal forearm twice daily for 3 months in the absence of unacceptable toxicity.
88864431|NCT00608634|Experimental|Low Dose POH 0.30%|Patients apply perillyl alcohol (POH) cream (0.3%) topically to each dorsal forearm twice daily for 3 months in the absence of unacceptable toxicity.
88864432|NCT00608634|Experimental|High Dose POH 0.76%|Patients apply perillyl alcohol (POH) cream (0.76%) topically to each dorsal forearm twice daily for 3 months in the absence of unacceptable toxicity.
88864433|NCT03088566|Experimental|The D-Foot method|The patients are being foot screened following the routine that is programmed in the D-Foot.
88864434|NCT03088566|Active Comparator|Conventional foot screening|The patients are being foot screened according to conventional methods.
88864435|NCT02897700|Experimental|Mono-chemotherapy|"A mono-chemotherapy (a single chemotherapeutic agent out of cyclophosphamide, doxorubicin, epirubicin, fluorouracil and methotrexate (or CDEFM) was performed 30~60 days prior to surgery for patients who had no history of receiving either local or systemic cancer-associated chemotherapy.~Interventions: cyclophosphamide, doxorubicin, epirubicin, fluorouracil or methotrexate."
88864436|NCT02897700|Experimental|Combined chemotherapy|"Combined chemotherapy (random combination of two breast cancer chemotherapeutic agents including cyclophosphamide, doxorubicin, epirubicin, fluorouracil and methotrexate, or CDEFM) was performed 30~60 days prior to surgery for patients who had no history of receiving either local or systemic chemotherapy for cancer.~Interventions: cyclophosphamide, doxorubicin, epirubicin, fluorouracil or methotrexate."
88864437|NCT02897700|Placebo Comparator|Placebo treatment|No chemotherapeutic regimes using any cytotoxic agent was done for patients who have infiltrating ductal carcinoma of breast. Placebo was used instead.
88864438|NCT02889666|Experimental|Carboplatin|Carboplatin-based chemotherapy (Carboplatin 400mg) was performed 30 days before surgery for patients who had previous surgery to remove the primary non-small cell lung carcinoma but suffered from the recurrent disease. The same chemotherapy using Carboplatin was done for 3 cycles with 30 days after last surgery.
89185697|NCT04076670|Experimental|Experimental group|Group of participants that received usual psychological attention plus the structured psychological intervention prosed in the study.
89388823|NCT03581942|Experimental|Copanlisib in combination with Ibrutinib|Participants will be assigned to the following dose levels: Dose level 1: Ibrutinib 560 mg daily + Copanlisib 60 mg weekly (3w on/1w off) Dose level 2: Ibrutinib 840 mg daily + Copanlisib 60 mg weekly (3w on/1w off) Dose level -1: Ibrutinib 560 mg daily + Copanlisib 45 mg weekly (3w on/1w off). Phase II: (Simon two-stage design: 14 patients will be treated at the MTD (including 6 patients from the phaseIb portion) If at least 11 patients respond then an additional 19 patients will be accrued to the second stage. Patients in the phase II portion of the trial will receive sequential drug dosing. Patient will be treated in 28-day cycles. During one cycle, only one drug will be administered with a ibrutinib/copanlisib ratio of 1:2. Patients will receive Ibrutinib at 840 mg daily during cycle 1 (day 1 through day 28) (28-day cycles), then copanlisib 60mg weekly on day 1, 8, and 15 during cycle 2 and 3. Patients will then repeat the sequence.
89388824|NCT03573544|Experimental|OBI-888 Escalation Phase|Part A: Three cohorts of escalating dose levels of OBI-888 5, 10, and 20 mg/kg liquid form for intravenous infusion to establish maximum tolerated dose (MTD).
89388825|NCT03573544|Experimental|OBI-888 Expansion Phase|Part B: Five cohorts at dose level 20 mg/kg of liquid form OBI-888 for intravenous infusion.
89388826|NCT03543189|Experimental|Combination Therapy|Post androgen deprivation therapy (ADT), participants will receive nivolumab, HDR brachytherapy and external beam radiation therapy, followed by a 2 year follow-up period.
89388827|NCT03512249|Experimental|H56:IC31|"The H56 fusion protein is formulated with IC31 in a GMP-compliant environment in a ready to use final formulated vaccine.~H56:IC31 is administered twice with a 56 days (+/-10) interval, as 5 μg H56 adjuvanted with IC31 consisting of 500 nmol KLK and 20 nmol ODN1a, in a total volume of 0.5mL by the intramuscular route in the deltoid area using standard aseptic technique."
89388828|NCT03512249|Placebo Comparator|Placebo|Sterile saline for injection
89388829|NCT03511092|Experimental|HMB-FA|
89388830|NCT03511092|Experimental|HMB-Ca|
89388831|NCT03511092|Experimental|alfa-HICA|
89388832|NCT03511092|Placebo Comparator|Placebo|
88864439|NCT02889666|Experimental|Docetaxel|Docetaxel-based chemotherapy (Docetaxel 120mg) was performed 30 days before surgery for patients who had previous surgery to remove the primary non-small cell lung carcinoma but suffered from the recurrent disease. The same chemotherapy using Docetaxel was done for 3 cycles with 30 days after last surgery.
89185698|NCT04062045|Experimental|Group A - Local anesthetic group|Group A will receive a continuous infusion of ropivacaine 0,2% 5ml/h and intermittent boluses of the same local anesthetic 15ml/4h through the erector spinae catheter.
89185699|NCT04062045|Placebo Comparator|Group B - Placebo group|Group B will receive a continuous infusion of 0,9% saline 5ml/h and intermittent boluses of the same fluid 15ml/4h through the erector spinae catheter.
89388833|NCT03504800||Group A: Classification of Corneal Irregularities|This group will consist of participants >14 years old with various types of corneal irregularities. Their data will be compared against participants with healthy corneas. Data for this group will be gathered only once.
89388834|NCT03504800||Group B: Detection of Keratoconus Progression|Participants from Group A who are diagnosed with keratoconus will be selected for this longitudinal study to monitor keratoconus progression. They will be followed up to 4 years.
89388835|NCT03504800||Group C: OCT-and-Topography Guided PTK|Participants from Group A will be selected for this group if they have vision primarily limited by scars, dystrophy, or high astigmatism that could be treated by PTK. They will be followed up to 1 year.
89388836|NCT03494569|Experimental|Treatment (TMLI, fludarabine, melphalan)|Participants undergo TMLI BID on days -8 to -5, and receive fludarabine IV on days -4 to -2 and melphalan on day -2. Participants then undergo alloHCT on day 0.
89388837|NCT03472300||Frederiksberg Citizens|All citizen in the Frederiksberg Community aged 60-69
89388838|NCT03455985|Experimental|Discharge Order Set (DOS)|Patients in the DOS group will receive instructions for self-titration of basal insulin as part of the discharge order. The DOS contains a comprehensive checklist for basic diet, hospital follow-up, glucose targets and instructions for monitoring, insulin pens and pen needles, glucose testing supplies, and ancillary orders. Phone calls will assess adherence with instructions for self-titration. Glucose lowering medication management following discharge will otherwise be conducted by the patient's usual or designated standard of care provider.
89388839|NCT03455985|Other|Enhanced Standard Care (ESC)|Patients in the ESC group will receive hospital discharge instructions using current best practices within the overall functionality of the electronic medical record, which facilitates medication reconciliation and use of a patient care resource manager. Phone calls are information gathering only in the ESC group, and questions related to care will be referred to the usual provider.
88864440|NCT02889666|Experimental|Gemcitabine/Cisplatin|Gemcitabine/Cisplatin-based combinational chemotherapy (Gemcitabine 200mg + Cisplatin 60mg) was performed 30 days before surgery for patients who had previous surgery to remove the primary non-small cell lung carcinoma but suffered from the recurrent disease. The same chemotherapy was done for 3 cycles with 30 days after last surgery.
89388840|NCT03449537|Experimental|EHCF+LGG|extensively hydrolyzed casein formula supplemented with the probiotic Lactobacillus rhamnosus GG
89185700|NCT05007015|Experimental|Transanal Irrigation|This group will be instructed on the use of TAI to be perform daily for the three month duration of their treatment arm
89185701|NCT05007015|No Intervention|Tradition care Control arm|This group tradition care group will have no modification to the care they have received prior to commencing the study. The patients in this group will use the usual dietary modifications and medications prescribed by the treating team to manage their LARS. No changes will be made to the treatment regime prescribed by their surgeon.
89185702|NCT04064073|Experimental|1|
88864441|NCT02889666|Experimental|Cisplatin|Cisplatin-based chemotherapy (Cisplatin 60mg) was performed 30 days before surgery for patients who had previous surgery to remove the primary non-small cell lung carcinoma but suffered from the recurrent disease. The same chemotherapy using Cisplatin was done for 3 cycles with 30 days after last surgery.
89003451|NCT05237804|Experimental|Patient component|"The randomized centres in this group will be required to present patients with:~A short introductory video, viewed on a tablet during hospitalization for coronary angiography,~A paper booklet,~A website."
89185703|NCT04064073|Experimental|2|
89185704|NCT04064073|Experimental|3|
89388841|NCT03449537|Active Comparator|AAF|hypoallergenic formula based on amino acid-based formula
89388842|NCT03436992|Experimental|Women with type 1 diabetes|Women with type 1 diabetes will be randomly assigned to 1 of the 3 interventions (Antioxidant cocktail, Resveratrol, or placebo)
89388843|NCT03436992|No Intervention|Healthy control women|Healthy women who participate will receive no intervention and serve as controls.
88864442|NCT02889666|Experimental|Docetaxel/Oxaliplatin|Docetaxel/Oxaliplatin-based chemotherapy (Docetaxel 120mg + Oxaliplatin 200mg) was performed 30 days before surgery for patients who had previous surgery to remove the primary non-small cell lung carcinoma but suffered from the recurrent disease. The same chemotherapy was done for 3 cycles with 30 days after last surgery.
89388844|NCT03436992|Experimental|Men with type 1 diabetes|Men with type 1 diabetes will be randomly assigned to 1 of the 3 interventions (AOX cocktail, Resveratrol, or placebo)
89388845|NCT03357224|Experimental|Experimental: Atezolizumab|The treatment will be given for a maximum of 1-year unless confirmed disease progression or unless other criteria for treatment discontinuation are met as specified in the protocol.
89388846|NCT03336255|No Intervention|Print Health Education|Participants will receive primary care referrals and print health education material about heart disease prevention in the mail.
89388847|NCT03336255|Experimental|SAHELI Intervention|Participants will enroll in heart disease prevention group sessions focusing on physical activity, diet, weight, and stress management. Each group will have 16 to 20 participants who will attend 16 weekly, 90 minute group education sessions at Metropolitan Asian Family Services or Skokie Health Department. During each session, participants will watch videos on the day's topic followed by discussion, activities, and assistance in setting realistic goals with attention to physical activity, diet, weight, and stress management.
89388848|NCT03335267|Experimental|CPX-351 (Cytarabine:Daunorubicin) Injection|"Dosing for first induction: CPX-351~• CPX-351 at 100u/m2 will be administered on study days 1, 3 and 5~Dosing for second induction:~• CPX-351 at 100 u/m2 will be administered on days 1 and 3~Dosing for consolidation:~• CPX-351 at 65 u/m2 will be administered on days 1 and 3"
88864443|NCT02889666|Experimental|Docetaxel/Carboplatin|Docetaxel/Carboplatin-based chemotherapy (Docetaxel 120mg + Carboplatin 400mg) was performed 30 days before surgery for patients who had previous surgery to remove the primary non-small cell lung carcinoma but suffered from the recurrent disease. The same chemotherapy was done for 3 cycles with 30 days after last surgery.
88864444|NCT02889666|Experimental|Gemcitabine/Carboplatin|Gemcitabine/Carboplatin-based chemotherapy (Gemcitabine 200mg + Carboplatin 400mg) was performed 30 days before surgery for patients who had previous surgery to remove the primary non-small cell lung carcinoma but suffered from the recurrent disease. The same chemotherapy was done for 3 cycles with 30 days after last surgery.
88864445|NCT02889666|Placebo Comparator|Placebo|No Adjuvant chemotherapy using CCODG was done for patients who had previous surgery to remove the primary non-small cell lung carcinoma but subject to tumor relapse. Instead, placebo was supplied to these patients as a comparator Arm.
88864446|NCT04955340|Experimental|[14C]-resminostat|single dose of 400 mg [14C]-resminostat
88864447|NCT04815330||Patient dyspnea under veno-arterial extracorporeal circulation|"Relief of dyspnea will be carried out by the clinician in charge of the patient. He will have complete control of his behaviour. He will carry out this test according to the practices in force in the department.~If a sweep gas flow through the membrane lung increment has been decided upon to relieve dyspnea, a new recording will be made after each scan increment and the patient will be asked at each step.~In ventilated or non-ventilated patients in whom the decision to implement non-invasive ventilation has been made, an increase in PEEP in 2 cmH2O steps without exceeding a plateau pressure of 25 cmH2O and a VT of 10ml/kg of the patient's theoretical weight will be achieved."
88864448|NCT04736940||Patients|Patients followed or currently treated for a solid or haematological neoplasia
89185705|NCT04075344|Experimental|Experimental RCHEs staff|Experimental RCHEs staff will received a multimodal ICP regarding the NG tube feeding. Knowledge and skills of NG tube feeding will be measured before and after the multimodal ICP. In addition, 10 fingertips of RCHEs staff, enteral milk and NG tube hubs of residents will be taken for bacterial counts before and after the intervnetion.
89388849|NCT03333915|Experimental|Phase 1: 20 milligram (mg) pamiparib|20 mg pamiparib twice a day for 21 days
88864449|NCT04736940||Doctors|Medical oncologist or haematologist
88864450|NCT04736940||Paramedical staff|Nurses or assistant nurses
88864451|NCT04736940||Oncopsychologist|Psychologist specialised in the care of patients with cancer
89003452|NCT05237804|Experimental|Organisational component|The randomized centres in this group will be provided with a list of organisational changes to be implemented to improve patient care times.
89003453|NCT05237804|Experimental|Patient and organisational components|The randomized centres in this group will have to implement the two components.
89388850|NCT03333915|Experimental|Phase 1 : 40 mg pamiparib|40 mg pamiparib twice a day for 21 days
89388851|NCT03333915|Experimental|60 mg pamiparib|60 mg pamiparib twice a day for 21 days
89388852|NCT03333915|Experimental|60 mg pamiparib in platinum-sensitive ovarian cancer (PSOC)|60 mg pamiparib twice a day until occurrence of unacceptable toxicities, disease progression, withdrawal of consent or investigator discretion
89388853|NCT03333915|Experimental|60 mg pamiparib in platinum resistant ovarian cancer (PROC)|60 mg pamiparib twice a day until occurrence of unacceptable toxicities, disease progression, withdrawal of consent or investigator discretion
89388854|NCT03274869||Scrub typhus without cardiovascular complications|Any participants with the scrub typhus infection without cardiovascular complication will be enrolled as a positive control group during admission and clinically followed by 1 year after discharge
89388855|NCT03274869||Scrub typhus with cardiovascular complication|Any participants with the scrub typhus infection with cardiovascular complication will be enrolled as a comparison group during admission and clinically followed by 1 year after discharge
89388856|NCT03215420|Experimental|Certain or probable Meniere's disease|
89388857|NCT03208062||Patients|"The target group corresponds to the patients admitted to our Institute who are candidates for the following surgical or biopsy procedures and collection of waste materials:~patients with osteoarthritis of the hip or knee and rehabilitated in the institute~patients with primary and secondary tumors of the skeleton~patients undergoing prosthetic examination as a result of plant infection The population will include adult subjects(>18 years included). Patients will be considered eligible for enrollment in the project if they can provide informed written consent."
89388858|NCT03202706||Patients|
89388859|NCT03194607||Patients|
89388860|NCT03194607||Controls|
89388861|NCT03177291|Active Comparator|Squamous Cell Lung Cancer (SQCLC)|Arm A Combination Therapy: Pirfenidone combined with standard first-line chemotherapy. Participants will receive the combination of Pirfenidone and carboplatin plus paclitaxel in study treatment cycles that last 21 days. Phase 1 Dose Escalation; followed by Phase 1b Dose Expansion.
89388862|NCT03177291|Active Comparator|Non-Squamous Cell Lung Cancer (SQCLC)|Arm B Combination Therapy: Pirfenidone combined with standard first-line chemotherapy. Participants will receive the combination of Pirfenidone and carboplatin plus pemetrexed in study treatment cycles that last 21 days. Phase 1 Dose Escalation; followed by Phase 1b Dose Expansion.
89388863|NCT03142568|Experimental|Sildenafil cohort 1|Within cohort 1 infants will be randomized using a 3:1 scheme to receive sildenafil or placebo. Infants randomized to sildenafil will receive 0.125 mg/kg daily every 8 hours intravenously (IV), or 0.25 mg/kg daily every 8 hours enterally for 28 days.
89388864|NCT03142568|Placebo Comparator|Placebo cohort 1|Infants randomized to the placebo treatment group will receive the equivalent of dextrose 5% (sugar water) to be administered IV or enteral use.
88864452|NCT02740374|Experimental|ROTEM|"ROTEM will be performed in patients with signs of clinically relevant bleeding and in whom blood transfusion is considered (Temp above 35 Celsius degrees; pH below 7.2; Cai above 4.6 mg/dL; Hb below 9g/dL, or below 10g/dL with anticipated greater blood loss) or at a fixed range every 2 hours or at Anesthesiologist criteria based on patient's clinical situation.~There will be also be performed standard of care test for this set of patients, as described for the CONTROL arm. ROTEM results will guide transfusion strategy."
88864453|NCT02740374|Active Comparator|CONTROL/STANDARD OF CARE|"If patients are randomized to standard coagulation tests (SCT), these will be performed according to Ohio State Wexner University Medical Center standard practices and attending's criteria, or at 2 hour intervals per protocol.~Standard of care tests include but are not limited to: hemoglobin, platelet count, fibrinogen concentration, INR, aPTT, and PT. These will be performed at fixed time points (preoperatively, every 2 hours intraoperatively, procedure completion, and 24 hours after procedure completion). Arterial blood gases will be performed repetitively intraoperatively at a fixed range every 1-hour or at attending's criteria, as well as any postoperative laboratory tests. SCT will guide transfusion management."
89388865|NCT03142568|Experimental|Sildenafil cohort 2|Cohort 2 infants will receive sildenafil 0.5 mg/kg daily every 8 hours intravenously (IV) or 1 mg/kg daily every 8 hours enterally for 28 days.
89388866|NCT03142568|Placebo Comparator|Placebo cohort 2|Infants randomized to the placebo treatment group will receive the equivalent of dextrose 5% (sugar water) to be administered IV or enteral use.
89388867|NCT03142568|Experimental|Sildenafil cohort 3|Cohort 3 infants will receive sildenafil 1 mg/kg daily every 8 hours intravenously (IV) or 2 mg/kg daily every 8 hours enterally for 28 days.
89388868|NCT03142568|Placebo Comparator|Placebo cohort 3|Infants randomized to the placebo treatment group will receive the equivalent of dextrose 5% (sugar water) to be administered IV or enteral use.
89388869|NCT03142321|Experimental|Vedolizumab 300 MG Injection [Entyvio]|Vedolizumab will be initiated at 300 mg intravenous (IV) dosing at 0, 2 and 6 weeks followed by the 1st maintenance with 300 mg IV at week 14. Patients who have not achieved clinical response at week 14 will be eligible to undergo dose escalation to 4 weekly dosing of vedolizumab depending on the judgement of the treating gastroenterologist.
89388870|NCT03128866|Experimental|Arm I (tranexamic acid)|Patients receive tranexamic acid IV over 15 minutes 30 minutes prior to surgery and continuously during hemipelvectomy procedure in the absence of disease progression or unacceptable toxicity.
89388871|NCT03128866|Experimental|Arm II (no tranexamic acid)|Patients undergo standard of care hemipelvectomy in the absence of disease progression or unacceptable toxicity.
89388872|NCT03078543|Other|ANTHEM™ PS Total Knee System implant|The ANTHEM™ PS Total Knee System will demonstrate non-inferiority of 10 year implant survivorship in patients undergoing total knee arthroplasty for osteoarthritis compared to reported literature
89388873|NCT03075254||Healthy Control|normal volunteers (HC) Undergoing sensory testing, brain and spinal cord neuroimaging and Inventory assessments.
89388874|NCT03075254||Fibromyalgia Only|The diagnosis of FM will require a history of chronic widespread pain as well as the presence of at least eleven out of eighteen paired tender points. Undergoing sensory testing, brain and spinal cord neuroimaging and Inventory assessments.
89388875|NCT03075254||Chronic fatigue and Fibromyalgia Syndrome|Diagnosis of ME/CFS will require a history of chronic fatigue persisting or relapsing for more than 6 months as well as the presence of at least four out of eight designated symptoms. Undergoing sensory testing, brain and spinal cord neuroimaging and Inventory assessments.
89388876|NCT03070236|Experimental|Patient-reported Outcomes Survey|The survey will administered online, over the phone, or via mail.
89388877|NCT03063918|Experimental|Supportive Care (personalized dietary intervention)|At 6 months after standard of care treatment, patients receive 10 sessions of personalized dietary intervention over 30 minutes each over 4 months via the telephone. Patients also receive a workbook including reference materials and intervention content.
89388878|NCT03063619|Placebo Comparator|Arm A (placebo)|Patients apply placebo gel topically to each breast QD for up to 52 weeks.
89388879|NCT03063619|Experimental|Arm B (afimoxifene)|Patients apply afimoxifene gel topically to each breast QD for up to 52 weeks.
89388880|NCT03058861|Experimental|Discipline education - Play Nicely program|Parents in the intervention group will receive 1) a copy of the Play Nicely Healthy Discipline Handbook (see www.playnicely.org), 2) information about how to view the Play Nicely multimedia program online and 3) the TN ACEs Handout.
89388881|NCT03058861|No Intervention|Control Group|Routine primary care will be provided.
89388882|NCT03037385|Experimental|Phase 1 Dose Escalation|Multiple doses of pralsetinib (BLU-667) for oral administration.
89388883|NCT03037385|Experimental|Phase 2 Dose Expansion|Oral dose of pralsetinib (BLU-667) as determined during Dose Escalation.
89388884|NCT03025412|Experimental|Endoscopic surgery|Ambulatory surgery. Postoperative rehabilitation. From week 6 postoperative the patients start the same exercise regimen as the conservative treatment group.
89388885|NCT03025412|Active Comparator|Conservative treatment|Physiotherapy and exercise. First physiotherapy consultation: Information, advice, instructions. Exercise regime during 12 weeks in three phases.
89388886|NCT03013933|Experimental|Treatment (cyclosporine, verapamil, brentuximab vedotin)|Patients receive cyclosporine PO BID on days 1-5, verapamil hydrochloride PO QID on days 1-5, and brentuximab vedotin IV over 30 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89388887|NCT02996825|Experimental|Treatment (IMGN853, gemcitabine hydrochloride)|Patients receive mirvetuximab soravtansine IV on day 1 and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Cycles repeat every 3 weeks in the absence of disease progression or unexpected toxicity.
89388888|NCT02994160|Experimental|Fast electrodes|Implant temporary Fast electrodes and record the nerve signals that control delicate finger motions and play back the nerve signals that give the hand feelings of touch and movement.
89388889|NCT02993146|Experimental|Treatment (ropidoxuridine, WBRT)|Patients receive ropidoxuridine PO QD on days 1-28 and undergo WBRT daily for not more than 5 days per week beginning on day 8 for a total of 15 fractions in the absence of disease progression or unacceptable toxicity.
89388890|NCT02976337|Experimental|High-dose naloxone|Naloxone 4 mg/ml i.v. infusion, total 3.25 mg/kg, target controlled infusion with three infusion rates (0.25 mg/kg; 0.75 mg/kg; 2.25 mg/kg) each of 25 min duration)
88864454|NCT00609804|Experimental|Sorafenib+Erlotinib|Sorafenib 400 mg twice daily by mouth Erlotinib 150 mg once daily by mouth
88864455|NCT00609804|Active Comparator|Sorafenib|Sorafenib 400 mg twice daily by mouth.
88864456|NCT00610116|Other|LV lead electronically repositioning|Single arm study
88864457|NCT00610428|Placebo Comparator|Inhaled Placebo|Inhaled Staccato Placebo
88864458|NCT00610428|Experimental|Inhaled PCZ 5 mg|Inhaled Staccato Prochlorperazine 5 mg
88864459|NCT00610428|Placebo Comparator|Inhaled PCZ 10 mg|Inhaled Staccato Prochlorperazine 10 mg
88864460|NCT00610740|Experimental|Patients Treated with CerviPrep™|CerviPrep™, a novel drug delivery device, was developed specifically for applying pharmaceuticals directly on the cervix. It consists of a syringe-like tube attached to a plastic cap that covers the cervix. Drug can be delivered through the tube, directly to the cervix without spillage onto vaginal or vulvar tissues.
88864461|NCT04470180|Experimental|Virtual Teach-to-Goal (V-TTG)|They will be randomized to receive education via a virtual learning module.
89388891|NCT02976337|Placebo Comparator|Normal saline|0.9% physiological saline, i.v. infusion, total 0.81 ml/kg, target controlled infusion with three infusion rates (0.06 ml/kg; 0.19 ml/kg; 0.56 ml/kg) each of 25 min duration.
88864462|NCT04470180|Active Comparator|standardized brief intervention|Intervention that mimics usual care to deliver inhaler technique education.
88864463|NCT00611442|Active Comparator|1|split-dose PEG solution without dietary restrictions plus lubiprostone 24mcg gelcap pretreatment
89388892|NCT02967744|Experimental|NSAID treatment|8 weeks of NSAID treatment
89388893|NCT02964078|Experimental|Pembrolizumab and Interleukin-2|Outpatient Intravenous (IV) infusion of Pembrolizumab and Inpatient IV infusion of Interleukin-2.
89388894|NCT02946697|No Intervention|Enhanced care and wait-list control group|Participants in the control group will receive enhanced usual care while waiting for the JLA program. Participants will be given information booklets in Chinese developed by the American Cancer Society and cover common issues related to breast cancer, various treatments, and life after treatment. Participants will be asked to read through the booklet individually.
89530436|NCT03247933|Experimental|Telemedicine (TeleRR)|"The intervention: Telemedicine: Maintenance Respiratory Rehabilitation. Patients will receive a personal program of maintenance Respiratory Rehabilitation supported by telemedicine (TeleRR).~A personal program of Respiratory rehabilitation consists on: 20-30 minutes of static bicycle exercises + 3 series of ten repetitions from 4 different types of exercises with weights / cufflinks. 3 days a week, every week for a year.~The exercises dates must be sent after doing the training each day by the PDA . The dates will be monitoring by the physician ."
88864464|NCT00611442|Placebo Comparator|2|split-dose PEG solution without dietary restrictions plus placebo pretreatment
88864465|NCT02136420|Experimental|Tilt perception, Training, placebo|placebo
88864466|NCT02136420|Placebo Comparator|Tilt perception, No training, placebo|subject does test with no hypergravity training and placebo drug only
88864467|NCT02136420|Experimental|Tilt perception, Training, promethazine|promethazine 25 mg, one time 120 minutes prior to experiment
88864468|NCT02136420|Experimental|Tilt perception,No training,promethazine|promethazine 25 mg, one time 120 minutes prior to experiment. No hypergravity training
88864469|NCT02136420|Experimental|Manual Control, Training, placebo|placebo
88864470|NCT02136420|Placebo Comparator|Manual Control, No training, placebo|subject does test with no hyper gravity training and placebo drug only
88864471|NCT02136420|Experimental|Manual Control, Training, promethazine|promethazine 25 mg, one time 120 minutes prior to experiment
88864472|NCT02136420|Experimental|Manual Control,No training,promethazine|promethazine 25 mg, one time 120 minutes prior to experiment
88864473|NCT02136420|Experimental|Perceptual thresholds,drug then placebo|"Subjects undergo perceptual motion threshold tests to determine the smallest motion they can reliably sense for yaw rotation, interaural translation and roll tilt. Each subject is tested twice, once with promethazine then once with placebo, separated by >4 days.~This arm corresponds to results published in Diaz-Artiles et al 2017."
88864474|NCT02136420|Experimental|Perceptual thresholds,placebo then drug|"Subjects undergo perceptual motion threshold tests to determine the smallest motion they can reliably sense for yaw rotation, interaural translation and roll tilt. Each subject is tested twice, once with placebo then once with promethazine, separated by >4 days.~This arm corresponds to results published in Diaz-Artiles et al 2017."
88864475|NCT02136498|Active Comparator|mHealth self-help + varenicline|Participants in this control arm received standard cognitive-behavioral self-help materials delivered via a mobile health (mHealth) program + a standard course of varenicline.
88864476|NCT02136498|Experimental|mHealth MyMAP program + varenicline|Participants in the experimental arm received standard cognitive-behavioral self-help materials delivered via a mHealth program + additional personalized support features (automated, tailored advice managing nicotine withdrawal symptoms and medication side-effects & secure messaging with a cessation counselor; i.e., MyMAP program) + a standard course of varenicline.
88864477|NCT00612222|Experimental|ALVAC plus anti-MART-1 F5 TCR PBL + HD IL-2|"ALVAC plus anti-MART-1 F5 T cell receptor (TCR ) peripheral blood lymphocytes (PBL) + high dose (HD) interleukin 2 (IL-2): ALVAC vaccine-approximately two hours prior to cell infusion, patients will receive 0.5 mL containing a target dose of 10^7 cell culture infectious dose 50% (CCID50) (with a range of approximately 10^6,4 to 10^7,9/mL) of the MART-1 ALVAC virus subcutaneously in each extremity (total of 4 x 10^7 CCID50/2 mL). This will be repeated on day 14.~Aldesleukin - 720,000 IU/kg intravenously over 15 minutes every 8 hours (+/- 1 hour) for up to 5 days."
88864478|NCT01931436|Experimental|Qing'E pill|Administered twice a day, and each 9 g
88864479|NCT01842360|Experimental|MV130|The subjects will receive daily dose of MV130 during 12 months
88864480|NCT01842360|Placebo Comparator|Placebo|The subjects will receive daily dose of placebo during 12 months
88864481|NCT00612768|Experimental|T.R.U.E. Test allergens Fragrance Mix and Thimerosol|"Concordance (agreement) between positive patch reactions to~fragrance mix (0.43 mg/cm2) in polyvinylpyrrolidone (PVP) vs fragrance mix (0.43 mg/cm2) in hydroxypropylcellulose (HPC)~thimerosol (0.008 mg/cm2) in polyvinylpyrrolidone (PVP) vs thimerosol (0.008 mg/cm2) in hydroxypropylcellulose (HPC)~fragrance mix T.R.U.E. Test allergen vs fragrance mix reference allergen (petrolatum)~thimerosol T.R.U.E. Test allergen vs thimerosol reference allergen (petrolatum)~will be measured"
88864482|NCT01711242|Experimental|capecitabine/Oxaliplatin/radiotherapy|"sequence chemoradiotherapy following radical resection~sequence chemoradiotherapy two cycles of XELOX + concurrent chemoradiotherapy + two cycles of XELOX.~Postoperative radiotherapy regimen: Radiotherapy consisted of 4500 centigray of radiation at 180 centigray per day, five days per week for five weeks, to the tumor bed, to the margins of resection or the stoma, to the regional nodes. Protection of spinal cord, heart, liver and kidney should be considered.~Concurrent chemotherapy regimen: capecitabine 825 mg/m² twice daily Postoperative chemotherapy regimen: see arm 2"
89185706|NCT04075344|No Intervention|Control RCHEs staff|No multimodal ICP will be offered to the staff of control RCHEs.
89185707|NCT03728400||Patients in neurovascular intensive care|During the patient's hospitalization in neurovascular intensive care unit, the doctor will propose to the patient to take part in this study. If the patient agree, this search will not change the patient's usual support and will not involve any further review.
89185708|NCT02580942|Experimental|Acupoint sticking therapy group|36 patients receive acupoint sticking treatment of Chinese herbal medicine on Dazhui(GV14) and Tiantu(RN22), and magnetic stickers on Feishu(BL13), Pishu(BL20) and Shenshu(BL23) once every other day, retention for 4 hours. Patients receive verum acupoint sticking therapy once every other day with a total of 18 sessions in 6 weeks.
89185709|NCT02580942|Sham Comparator|Sham sticking therapy group|36 patients receive acupoint sticking treatment of Chinese herbal medicine on Dazhui(GV14) and Tiantu(RN22), and sham magnetic stickers on Feishu(BL13), Pishu(BL20) and Shenshu(BL23) once every other day, retention for 4 hours. Patients receive verum acupoint sticking therapy once every other day with a total of 18 sessions in 6 weeks.
88864483|NCT01711242|Active Comparator|capecitabine/Oxaliplatin|"chemotherapy alone following radical resection~Drug: chemotherapy alone following radical resection Postoperative chemotherapy regimen: The XELOX regimen was administrated: Oxaliplatin, 130mg/m2/day on day1, i.v. 2h; Capecitabine 1000mg/m²/day twice daily d1-14; every 21 days repeated, for 4 cycles."
88864484|NCT04405908|Placebo Comparator|Adult Group 1|Adult healthy subjects (18 to 54 years of age, inclusive) receive SCB-2019 3 µg.
88864485|NCT04405908|Placebo Comparator|Adult Group 2|Adult healthy subjects (18 to 54 years of age, inclusive) receive SCB-2019 3 µg with AS03 adjuvant.
89185710|NCT02565927|Experimental|Radioactive stent|Patients diagnosed as MAO treated with radioactive airway stent loaded with Iodine-125 seeds
89185711|NCT02565927|Active Comparator|Traditional airway stent|Patients diagnosed as MAO treated with traditional airway stent
89388895|NCT02946697|Experimental|Social support intervention group|The intervention is a 7-week program includes educational and peer mentoring support components. The education curriculum provides information on recognizing side effects of treatment and differentiating them from symptoms of cancer recurrence, physical therapy and alternative treatment, stress management, recognizing depression and managing emotional problems, communication with family members, and body image. The peer-support component assigns each participant with a mentor who is a breast cancer survivor. They share their own experience with participants and also make weekly phone calls to mentees during the intervention to provide support and address remaining concerns.
88864486|NCT04405908|Placebo Comparator|Adult Group 3|Adult healthy subjects (18 to 54 years of age, inclusive) receive SCB-2019 3 µg with CpG 1018 plus Alum adjuvant.
88864487|NCT04405908|Placebo Comparator|Adult Group 4|Adult healthy subjects (18 to 54 years of age, inclusive) receive SCB-2019 9 µg .
89388896|NCT02945800|Experimental|Combination Therapy|Participants will receive nab-Paclitaxel and Gemcitabine on days 1, 8, and 15 of each 28 day cycle, for up to 12 cycles.
89388897|NCT02923726|Active Comparator|ATP and Shock|Once tachycardia has been detected and duration met, this group would receive antitachycardia pacing prior to shock therapy.
89388898|NCT02923726|Experimental|Shock only|Once tachycardia has been detected and duration met, this group would receive shock therapy only.
89388899|NCT02905643||Study subjects|Patients who have or might have a brain tumor which may be a glioblastoma.
89388900|NCT02892591|Experimental|Cannabis|Medium dose THC, single administration, vaporized
88864488|NCT04405908|Placebo Comparator|Adult Group 5|Adult healthy subjects (18 to 54 years of age, inclusive) receive SCB-2019 9 µg with AS03 adjuvant.
88864489|NCT04405908|Placebo Comparator|Adult Group 6|Adult healthy subjects (18 to 54 years of age, inclusive) receive SCB-2019 9 µg with CpG 1018 plus Alum adjuvant.
88864490|NCT04405908|Placebo Comparator|Adult Group 7|Adult healthy subjects (18 to 54 years of age, inclusive) receive SCB-2019 30 µg .
88864491|NCT04405908|Placebo Comparator|Adult Group 8|Adult healthy subjects (18 to 54 years of age, inclusive) receive SCB-2019 30 µg with AS03 adjuvant.
88864492|NCT04405908|Placebo Comparator|Adult Group 9|Adult healthy subjects (18 to 54 years of age, inclusive) receive SCB-2019 30 µg with CpG 1018 plus Alum adjuvant.
88864493|NCT04405908|Placebo Comparator|Elderly Group 10|Elderly healthy subjects (55 to 75 years of age, inclusive) receive SCB-2019 3 µg with AS03 adjuvant.
88864494|NCT04405908|Placebo Comparator|Elderly Group 11|Elderly healthy subjects (55 to 75 years of age, inclusive) receive SCB-2019 3 µg with CpG 1018 plus Alum adjuvant.
88864495|NCT04405908|Placebo Comparator|Elderly Group 12|Elderly healthy subjects (55 to 75 years of age, inclusive) receive SCB-2019 9 µg with AS03 adjuvant.
88864496|NCT04405908|Placebo Comparator|Elderly Group 13|Elderly healthy subjects (55 to 75 years of age, inclusive) receive SCB-2019 9 µg with CpG 1018 plus Alum adjuvant.
88864497|NCT04405908|Placebo Comparator|Elderly Group 14|Elderly healthy subjects (55 to 75 years of age, inclusive) receive SCB-2019 30 µg with AS03 adjuvant.
88864498|NCT04405908|Placebo Comparator|Elderly Group 15|Elderly healthy subjects (55 to 75 years of age, inclusive) receive SCB-2019 30 µg with CpG 1018 plus Alum adjuvant.
88864499|NCT04405908|Placebo Comparator|SARS-CoV-2 Seropositive Group 16|SARS-CoV-2 Seropositive subjects receive SCB-2019 9 µg.
88864500|NCT04405908|Placebo Comparator|SARS-CoV-2 Seropositive Group 17|SARS-CoV-2 Seropositive subjects receive SCB-2019 9 µg with AS03 adjuvant.
88864501|NCT04405908|Placebo Comparator|SARS-CoV-2 Seropositive Group 18|SARS-CoV-2 Seropositive subjects receive SCB-2019 30 µg with CpG 1018 plus Alum adjuvant.
88864502|NCT04405908|Placebo Comparator|Adjuvant Dose Modification: Adult Group 19|Adult healthy subjects (18 to 54 years of age, inclusive) receive SCB-2019 9 µg with AS03 adjuvant.
88864503|NCT04405908|Placebo Comparator|Adjuvant Dose Modification: Adult Group 20|Adult healthy subjects (18 to 54 years of age, inclusive) receive SCB-2019 30 µg with CpG 1018 plus Alum adjuvant.
88864504|NCT04405908|Placebo Comparator|Adjuvant Dose Modification: Elderly Group 21|Elderly healthy subjects (55 to 75 years of age, inclusive) receive SCB-2019 9 µg with AS03 adjuvant.
88864505|NCT04405908|Placebo Comparator|Adjuvant Dose Modification: Elderly Group 22|Elderly healthy subjects (55 to 75 years of age, inclusive) receive SCB-2019 30 µg with CpG 1018 plus Alum adjuvant.
88864506|NCT04405908|Placebo Comparator|Alum Only Adjuvant Group 23|Subjects receive SCB-2019 9 µg with Alum adjuvant only.
89388901|NCT02892591|Active Comparator|Oxycodone|5-10 mg oxycodone hydrochloride, single administration, oral
89388902|NCT02892591|Placebo Comparator|Placebo|No active study drug
89388903|NCT02872831|Active Comparator|22G SharkCore™ needle|Covidien has recently released a novel SharkCore™ Fine Needle Biopsy (FNB) system for EUS-guided tissue acquisition of solid gastrointestinal lesions. With its unique bevel design, this needle has shown promising results to acquire histologic tissue as per oral communication with physicians around the country
89388904|NCT02872831|Active Comparator|22G BNX EUS-FNA needle|The standard 22G BNX Endoscopic Ultrasound Fine needle aspiration (Beacon Endoscopic, Newton, MA) needle is routinely used for the evaluation of solid mass lesions in the pancreas and gastrointestinal tract.
89388905|NCT02865928|Experimental|Bupivicaine HCl|Ultrasound guided serratus plane block with bupivacaine HCl.
89388906|NCT02865928|Placebo Comparator|Normal Saline|Placebo injection on operated side, same technique as experimental group.
89388907|NCT02859675||Crohn and anti-TNF treatment|Tests at 3 or 4 weeks after the beginning of anti-TNF treatment
89388908|NCT02859675||Crohn and without anti-TNF treatment|tests performed according to patient availability
89388909|NCT02859675||Control|tests performed according to patient availability
89388910|NCT02859506|Experimental|liver transplant|
89388911|NCT02859506|Active Comparator|kidney transplant|
89388912|NCT02859506|Placebo Comparator|control|
89388913|NCT02859506|Active Comparator|stable liver damage|
89388914|NCT02803905|Active Comparator|standard procedure: intrahepatic|Liver infusion: the islet mixture is delivered slowly via injection through a syringe attached to the catheter in the portal vein or portal vein tributary. Access to the portal vein is achieved by percutaneous transhepatic access under fluoroscopic, ultrasonographic, or real-time CT guidance. Alternatively access to a mesenteric or omental venous tributary of the portal vein can be obtained by mini-laparotomy under general anesthesia (transplant site preference or in the extremely rare circumstance that percutaneous access cannot be achieved). At a minimum, portal pressure will be monitored before and after infusion of the islet product. Portal pressure measurements will be documented in the medical record. Gel foam plugs and/or collagen/thrombin paste will be used to embolize the entire peripheral catheter tract immediately before the catheter is withdrawn, to reduce the chances of bleeding.
89530437|NCT03247933|No Intervention|Clinical Practice (Recommendation)|"No intervention. A recommendation from standard maintenance respiratory rehabilitation program with a minimum monitoring.~Clinical practice."
89530438|NCT03244813|Experimental|Adapted physical activity|
89388915|NCT02803905|Experimental|experimental procedure: omentum|Omentum infusion: briefly, islets are spread in the surface of the omentum, in a single omental pouch site. Transplanting in a single site will reduce risks. A single dose of at least 5000 IEQ/KG will be transplanted. The investigators should be able to achieve a meaningful metabolic improvement and prevention of severe hypoglycemia, as previously seen in experience with intraportal islet transplants. Recombinant human thrombin is added to the islets placed on the omentum to promote formation of a gel clot and facilitate adherence to the surface of the omentum. A pouch is then created by folding the omentum. The pouch is secured inn place with stitches.
89388916|NCT02793375|Placebo Comparator|Control|Patients receiving placebo preoperatively (blinded)
89388917|NCT02793375|Experimental|Study group|Patients receiving montelukast preoperatively (blinded)
89388918|NCT02770326|Experimental|Fecal Microbiota Transplantation (FMT)|Patients with recurrent or refractory CDI who meet study eligibility criteria, will consent to undergo either colonoscopy or upper endoscopy with infusion of stool admixture. Safety will be assessed by monitoring infections that occurred within 2 weeks of the FMT procedures. Additionally, 24-hours, 1 week, 2 weeks, 4 weeks, and 6 months post-FMT, a stool sample will be collected. The time window for each time point listed is +/- 48 hours, with the exception of the first, 24 hour, time point. The time window for the 24 hour time point is +48 hours post FMT.
89388919|NCT02734290|Experimental|Arm A|pembrolizumab + weekly paclitaxel
89388920|NCT02734290|Experimental|Arm B|pembrolizumab + capecitabine
89388921|NCT02721888|Experimental|Main study|
88864507|NCT04405908|Placebo Comparator|Dose Expansion Phase: Adult Group 24|Adult healthy subjects (18 to 54 years of age, inclusive) receive SCB-2019 9 µg with AS03 adjuvant.
89388922|NCT02683473||Infants|Infants aged 1-3 months
89388923|NCT02653287|Experimental|Intervention|The experimental intervention is a unique combination of four individual counseling sessions based in motivational interviewing focusing on physical activity, dietary behavior and behavioral strategies. The individual sessions will provide a tailored personalized intervention including problem-solving and goal setting for increasing physical activity, and following a healthy diet. Healthy Lifestyle Coaches (RN or MPH) will be responsible for conducting the individual for a caseload of participants. There are no drugs involved in the intervention.
89388924|NCT02653287|Active Comparator|Control|The control group intervention will receive four individual phone calls checking in with participants regarding questions about the study or from the educational sessions focusing on SLE disease management, each lasting approximately 10-15 minutes.
89388925|NCT02652260|Experimental|Immediate Switch to Doravirine, Tenofovir, Lamivudine|Participants on a baseline regimen of ATRIPLA™ for at least 12 weeks prior to screening will be switched to blinded doravirine, tenofovir, lamivudine orally, once daily for 12 weeks, followed by open-label doravirine, tenofovir, lamivudine orally, once daily for an additional 12 weeks. Participants who meet eligibility criteria can enter study extension 1 to receive open-label doravirine, tenofovir, lamivudine for an additional 96 weeks. Participants who meet eligibility criteria can enter study extension 2 to receive open-label doravirine, tenofovir, lamivudine, with a maximum total duration of treatment of 216 weeks. Participants who meet eligibility criteria can enter study extension 3 to receive open-label doravirine, tenofovir, lamivudine, with a maximum total duration of treatment of 312 weeks.
89388926|NCT02652260|Experimental|Deferred Switch to Doravirine, Tenofovir, Lamivudine|Participants will continue on their ongoing ATRIPLA™ regimen orally, once daily for 12 weeks, followed by open-label doravirine, tenofovir, lamivudine orally, once daily for 24 weeks. Participants who meet eligibility criteria can enter study extension 1 to receive open-label doravirine, tenofovir, lamivudine for an additional 96 weeks. Participants who meet eligibility criteria can enter study extension 2 to receive open-label doravirine, tenofovir, lamivudine, with a maximum total duration of treatment of 228 weeks. Participants who meet eligibility criteria can enter study extension 3 to receive open-label doravirine, tenofovir, lamivudine, with a maximum total duration of treatment of 324 weeks.
89388927|NCT02569879||Infants Group|"All infants ≤12 months of age in Bogota, reported with pertussis disease in the national databases of Bogota, between January 2005 and December 2014.~All infants ≤12 months of age in Bogota, deceased between January 2005 and December 2014 due to pertussis disease (primary diagnosis), based on death certificate information.~All infants ≤12 months of age in Bogota, with ALRTI, between January 2005 and December 2014.~All infants ≤12 months who have received primary pertussis vaccination in Bogota, between January 2005 and December 2014."
89388928|NCT02569879||Pregnant women Group|• Pregnant women will be included in the study to assess the vaccination coverage of Boostrix from March 2013 to December 2014
89530439|NCT03244813|No Intervention|Standard care|
88864508|NCT04405908|Placebo Comparator|Dose Expansion Phase: Adult Group 25|Adult healthy subjects (18 to 54 years of age, inclusive) receive SCB-2019 30 µg with CpG 1018 plus Alum adjuvant.
88864509|NCT04405908|Placebo Comparator|Dose Expansion Phase: Elderly Group 26|Elderly healthy subjects (55 to 75 years of age, inclusive) receive SCB-2019 9 µg with AS03 adjuvant.
88864510|NCT04405908|Placebo Comparator|Dose Expansion Phase: Elderly Group 27|Elderly healthy subjects (55 to 75 years of age, inclusive) receive SCB-2019 30 µg with CpG 1018 plus Alum adjuvant.
88864511|NCT04333368|Experimental|MSC|
88864512|NCT04333368|Placebo Comparator|NaCl|
89185712|NCT04137354|Placebo Comparator|Control Iron&Vitamin A Placebo|Children randomly assigned to the placebo iron & vitamin A control group will receive weekly three placebo tablets that are identical to the iron tablets (blinded) for the whole duration of the study (9 months of the school year). They will also receive placebo vitamin A at baseline and at mid-line (after 4.5 months).
88864513|NCT04331496|Experimental|Hypertonic solution|Hypertonic solution 4 ml 3% , for 8 minutes in a Philips® vibrating mesh nebulizer plus 20 minute session of Respiratory Physiotherapy based on slow expiratory flow.
89185713|NCT04137354|Experimental|Vitamin A & Placebo Iron Supplements|Children is this group will receive weekly three placebo tablets that are identical to the iron tablets (blinded) for the whole duration of the study (9 months of the school year). They will also receive a high dose vitamin A capsule (200,000IU) at baseline and after 4.5 months (at mid-line)
89388929|NCT02544022||1/Phase 1 Focus Group|Patients with NF1 who have PNs and report experiencing pNF related pain and parents of these patients. (completed)
89388930|NCT02544022||2/Phase 1 Patients|Patients with NF1 who have pNFs(completed)
89388931|NCT02544022||3/Phase 1 Parent|Parents of patients in cohort 2 (completed)
89388932|NCT02544022||4/Phase 2 Patients|Patients with NF1 who have pNFs and recent pNF-related pain
89388933|NCT02544022||5/Phase 2 Parents|Parents of patients (ages 8-17 years) enrolled in cohort 4
89388934|NCT02539992|Active Comparator|Triathlon® CR/Kinematic Alignment|Receive the Triathlon® Cruciate Retaining Total Knee System (Triathlon® CR) in a procedure using patient-specific cutting guides to reproduce the natural kinematic alignment of the knee.
89388935|NCT02539992|Active Comparator|Triathlon® CR/Neutral Overall Limb Alignment|Receive the Triathlon® CR device in a procedure using patient-specific cutting guides modified to provide neutral overall limb alignment of the knee.
89388936|NCT02539992|Active Comparator|Triathlon® CR/Conventional Limb Alignment|Receive the Triathlon® CR device in a procedure using traditional instrumentation intended to achieve a neutral overall limb alignment of the knee.
89388937|NCT02535741|Other|Triathlon CR Total Knee System|Primary total knee replacement
89388938|NCT02525627|Active Comparator|Trident cup, X3 inserts, 28 mm head|Equality of 5 year wear in the 28mm and the 40mm metal femoral head sizes. Trident cup in combination with Symax stem or Accolade TMZF stem.
89388939|NCT02525627|Active Comparator|Trident cup, X3 inserts, 40 mm head|Equality of 5 year wear in the 28mm and the 40mm metal femoral head sizes. Trident cup in combination with Symax stem or Accolade TMZF stem.
89388940|NCT02525588|Active Comparator|Conventional polyethylene inlay nitrogen/vacuum-packed (N2Vac)|Conventional UHMWPE inlay in a Triathlon Condyle Stabilizing (CS) fixed bearing total knee prosthesis
88864514|NCT04331496|Active Comparator|Physiological solution|Single-dose physiological saline serum (5 ml 0.9% NaCl), for 8 minutes in a Philips® vibrating mesh nebulizer plus 20 minute session of Respiratory Physiotherapy based on slow expiratory flow.
88864515|NCT04304274|Experimental|PTPVB-ropivacaine|Programmed intermittent bolus infusion of a thoracic paravertebral block with ropivacaine and patient-controlled analgesia with morphine
88864516|NCT04304274|Placebo Comparator|PTPVB-saline|Programmed intermittent bolus infusion of a thoracic paravertebral block with saline and patient-controlled analgesia with morphine
88864517|NCT04253496||Prospective|
89388941|NCT02525588|Active Comparator|Highly cross-linked polyethylene (X3)|X3 highly cross-linked polyethylene inlay in a Triathlon CS fixed bearing total knee prosthesis
89388942|NCT02525562|Other|Scorpio NRG Total Knee System|Patients eligible for Scorpio NRG Total Knee System with X3 insert
89388943|NCT02525562|Other|Triathlon Total Knee System|Patients eligible for Triathlon Total Knee System with X3 insert
88864518|NCT04253496||Retrospective|
88864519|NCT01285362|Active Comparator|Fish Oil Supplementation (Group A)|Group A will receive fish oil capsules, containing n3-Fatty Acids, at a dose of 4g/day. Each 1g capsule will contain 465mg of EPA and 375 mg of docosahexaenoic acid (DHA).
88864520|NCT01285362|Placebo Comparator|Placebo Supplementation (Group B)|Group B will receive corn oil in the capsules at the same dose as Group A. The corn oil capsules will appear identical in size and color to the fish oil capsules.
88864521|NCT00612924|Experimental|Anaconda|
88864522|NCT02132832|Experimental|Buspirone|Buspirone is administered orally twice per day (9:00 AM and 6:00 PM) for 3 weeks. 10 mg buspirone is administered on days 1-4, then the dose is increased by 10 mg every 3 days to a maximum of 40 mg buspirone on days 10-19.
88864523|NCT02132832|Placebo Comparator|Placebo|Placebo is administered orally twice per day (9:00 AM and 6:00 PM) for 3 weeks.
88864524|NCT00614406|Experimental|1|
88864525|NCT00614406|Placebo Comparator|2|
89003454|NCT05224518|Experimental|home-based elastic band training group|The interventional group received 12 weeks of home-based elastic band training, three days a week, with progressive, medium-intensity exercise.
89003455|NCT05224518|Active Comparator|stretching exercises group|The control group received home stretching exercises three days a week for 12 weeks.
89388944|NCT02525562|Other|Triathlon Partial Knee Resurfacing|Patients eligible for Triathlon PKR System with X3 insert
89388945|NCT02524730|Other|Scorpio NRG CR Total Knee System|Primary total knee replacement
89388946|NCT02522728|Active Comparator|Triathlon CR|Triathlon Cruciate Retaining (CR) versus Triathlon Posterior Stabilized (PS): During knee prosthesis surgery the surgeon many times need to make a judgement on if to keep a defect anatomical structure or if to replace it with knee prosthesis with a design that allows for adjustment of this defect. This study is aimed to evaluate which prosthetic choice to be made in respect of stability, long-term results and patient outcome.
89388947|NCT02522728|Active Comparator|Triathlon PS|Triathlon Cruciate Retaining (CR) versus Triathlon Posterior Stabilized (PS): During knee prosthesis surgery the surgeon many times need to make a judgement on if to keep a defect anatomical structure or if to replace it with knee prosthesis with a design that allows for adjustment of this defect. This study is aimed to evaluate which prosthetic choice to be made in respect of stability, long-term results and patient outcome.
89388948|NCT02520531|Active Comparator|Scorpio PS|Patients on the waiting list for a total knee prosthesis who fulfil the inclusion and exclusion criteria will be asked to participate in this study and are randomized to receive the Scorpio PS Total Knee Replacement.
89388949|NCT02520531|Active Comparator|Scorpio NRG PS|Patients on the waiting list for a total knee prosthesis who fulfil the inclusion and exclusion criteria will be asked to participate in this study and are randomized to receive the Scorpio NRG PS Total Knee Replacement.
89530440|NCT03345953|Experimental|BP 1.4979|15 mg tablet BID
89530441|NCT03345953|Placebo Comparator|Placebo|Matching placebo tablet
89388950|NCT02505893|Experimental|Treated|The investigational treatment will be islet transplant in the presence of induction with ATG/G-CSF and rapamycin treatment for one month. One thousand and five hundred (1,500) equivalent islet for Kg of body weight, isolated from a single brain-dead donor, will be infused into the patient's liver. ATG will be administered IV (central vein) at a total dose of 6 mg/kg up to day 6 post-transplant. Pegylated G-CSF (6 mg/dose) will be administered SC every 2 weeks for 6 doses (12 weeks) beginning after the last ATG infusion. Rapamycin will be administered orally at a starting dose of 0.2 mg/kg once a day, then targeted to blood trough level of 8-10 ng/mL and suspended one month after transplant.
89388951|NCT02505126|Experimental|Active tDCS group|Active tDCS
89388952|NCT02505126|Placebo Comparator|Placebo tDCS group|Placebo tDCS : Inactive tDCS
89388953|NCT02446236|Experimental|Dose Escalation Study|Ibrutinib 560 mg/daily rituximab 375mg/m2 IV Day 1 Lenalidomide 10-25 mg PO days 1-21
89388954|NCT02441803|Experimental|Matched Sibling Donor Group|"Salvage Chemotherapy Before Transplant: Decitabine 20 mg/m2 by vein on Days 1 - 5. Cytarabine 1 g/m2 by vein on Days 6 - 10. Idarubicin 10 mg/m2 by vein on Days 6 - 8. Clofarabine 15 mg/m2 by vein on Days 6 - 9.~Stem Cell Transplant: Test dose Busulfan 32 mg/m2 by vein on Day -8. Busulfan AUC 5,000 by vein on Days -6 to -3. Fludarabine 10 mg/m2 by vein on Days -6 to -3. Clofarabine 40 mg/m2 by vein on Days -6 to -3. Stem cell infusion performed on Day 0."
89388955|NCT02441803|Experimental|Haploidentical Donor Group|"Salvage Chemotherapy Before Transplant: Decitabine 20 mg/m2 by vein on Days 1 - 5. Cytarabine 1 g/m2 by vein on Days 6 - 10. Idarubicin 10 mg/m2 by vein on Days 6 - 8. Clofarabine 15 mg/m2 by vein on Days 6 - 9.~Stem Cell Transplant: Test dose Busulfan 32 mg/m2 given by vein on Day -8. Busulfan AUC 5,000 by vein on Days -6 to -3. Fludarabine 10 mg/m2 by vein on Days -6 to -3. Clofarabine 40 mg/m2 by vein on Days -6 to -3. Total body irradiation (TBI) delivered at 2Gy on Day -2. Stem cell infusion performed on Day 0. Cyclophosphamide 50 mg/kg by vein on Days +3 and +4. Tacrolimus 0.015 mg/kg/day by vein or mouth on Day +5. Mycophenolate mofetil 15 mg/kg/dose by vein or by mouth three times a day from Day +5 to Day+100."
89388956|NCT02441803|Experimental|Matched Unrelated Donor Group|"Salvage Chemotherapy Before Transplant: Decitabine 20 mg/m2 by vein on Days 1 - 5. Cytarabine 1 g/m2 by vein on Days 6 - 10. Idarubicin 10 mg/m2 by vein on Days 6 - 8. Clofarabine 15 mg/m2 by vein on Days 6 - 9.~Stem Cell Transplant: Test dose Busulfan 32 mg/m2 given by vein on Day -8. Busulfan AUC 5,000 by vein on Days -6 to -3. Fludarabine 10 mg/m2 by vein on Days -6 to -3. Clofarabine 40 mg/m2 by vein on Days -6 to -3. Thymoglobulin 2.0 mg/Kg by vein on Days -3 and -2. Stem cell infusion performed on Day 0."
89388957|NCT02417740||Adult with absence of Portal Hypertension|Confirmed absence of Portal Hypertension will have no findings suggestive of non cirrhotic portal hypertension on liver biopsy and on portal pressure measurements on confirmatory examination.
89388958|NCT02417740||Adult with presence of Portal Hypertension|Confirmed Presence of Noncirrhotic Portal Hypertension, through confirmatory testing, tissue diagnosis by liver biopsy and/or portal hypertension (HVPG >5mmHg).
89388959|NCT02417740||Minors likely to have the absence of Portal Hypertension|Minors identified as Confirmed Absence of Noncirrhotic Portal Hypertension will have no abnormal findings on confirmatory examination.
89388960|NCT02417740||Minors likely to have the presence of Portal Hypertension|Minors identified as Confirmed Presence of Noncirrhotic Portal Hypertension, have shown they have the disease with a tissue diagnosis by liver biopsy and/or portal hypertension (HVPG >5).
89388961|NCT02337829|Experimental|Arm A|Subjects will be randomized to receive 1 of 2 dosing regimens: 1) acalabrutinib, dose A once daily; or 2) acalabrutinib, dose B twice daily.
89388962|NCT02337829|Experimental|Arm B|Subjects will be randomized to receive 1 of 2 dosing regimens: 1) acalabrutinib, dose A once daily; or 2) acalabrutinib, dose B twice daily.
89388963|NCT02120352|Experimental|GSK744 LA 600 mg + TMC278 LA 900 mg every 8 weeks (Q8W)|In the Induction Period of 20 weeks, subjects will receive an oral regimen of GSK744 30 mg once daily plus ABC/3TC 600/300 mg once daily. In the last 4 weeks of the Induction Period subject will also receive RPV 25 mg tablet once daily. In the Maintenance Period, subject will receive following IM doses: Day 1 only - GSK744 LA 800 mg (loading dose delivered as two 400 mg IM injections) + TMC278 LA 900 mg IM. Week 4 only - GSK744 LA 600 mg IM (second loading dose, no TMC278).Week 8 - GSK744 LA 600 mg IM + TMC278 LA 900 mg IM every 8 weeks for 96 weeks.
89388964|NCT02120352|Experimental|GSK744 LA 400 mg + TMC278 LA 600 mg every 4 weeks (Q4W)|In the Induction Period of 20 weeks, subjects will receive an oral regimen of GSK744 30 mg once daily plus ABC/3TC 600/300 mg once daily. In the last 4 weeks of the Induction Period subjects will also receive RPV 25 mg tablet once daily. In the Maintenance Period, subjects will receive following IM doses: Day 1 only - GSK744 LA 800 mg (loading dose delivered as two 400 mg IM injections) + TMC278 LA 600 mg IM. Week 4 - GSK744 LA 400 mg IM + TMC278 LA 600 mg IM every 4 weeks for 96 weeks
89388965|NCT02120352|Active Comparator|Oral Control Arm|In the Induction Period of 20 weeks, subjects will receive an oral regimen of GSK744 30 mg once daily plus ABC/3TC 600/300 mg once daily. In the last 4 weeks of the Induction Period subjects will also receive RPV 25 mg tablet once daily. In the Maintenance Period, subjects will receive an oral regimen of 30 mg of GSK744 and ABC/3TC once daily for 96 weeks (or 104 weeks if going on to the Extension Period)
89388966|NCT02091141|Experimental|Trastuzumab Plus Pertuzumab|Participants will receive trastuzumab 8 milligrams per kilogram (mg/kg) intravenous (IV) infusion as loading dose, followed by 6 mg/kg IV infusion every 3 weeks; and pertuzumab 840 mg IV infusion as loading dose, followed by 420 mg IV infusion every 3 weeks.
89003456|NCT05219162|Other|EGFRm Locally Advanced or Metastatic NSCLC patients post Osimertinib 1L treatment failure|participants with advanced or metastatic non-small cell lung cancer, who have already taken osimertinib as a first treatment option, but their cancer has continued to get worse
89185714|NCT04137354|Experimental|Intermittent Iron Supplements & Placebo Vitamin A|"Children is this group will receive weekly three tablets of iron (42mg of elemental iron once a week) for 9 months (equivalent to a one school year).~They will also receive placebo vitamin A at baseline and at mid-line (after 4.5 months)."
89388967|NCT02091141|Experimental|Atezolizumab|Participants will receive atezolizumab 1200 mg IV infusion every 3 weeks.
89388968|NCT02091141|Experimental|Vemurafenib|Participants will receive vemurafenib 960 mg orally twice daily (BID) in each 28-day cycle.
89388969|NCT02091141|Experimental|Vemurafenib Plus Cobimetinib|Participants will receive vemurafenib 960 mg orally twice daily (BID) in each 28-day cycle; and cobimetinib 60 mg orally once daily for 21 days on and 7 days off in each 28-day cycle.
89388970|NCT02091141|Experimental|Vismodegib|Participants will receive vismodegib 150 mg orally once daily in each 28-day cycle.
89388971|NCT02091141|Experimental|Alectinib|Participants will receive alectinib 600 mg orally BID in each 28-day cycle.
89388972|NCT02091141|Experimental|Erlotinib|Participants will receive erlotinib 150 mg orally once daily in each 28-day cycle.
89388973|NCT02083692|Experimental|Metformin|
89388974|NCT02040857|Experimental|Palbociclib With Adjuvant Endocrine Therapy|"Palbociclib 125 mg PO qd 21 days on, 7 days off~Endocrine Therapy: Tamoxifen 20mg, Letrozole 2.5mg, Anastrozole 1mg, or Exemestane 25mg PO qd"
89388975|NCT01992146|Placebo Comparator|Placebo|Change in Pain Ratings (NRS) at the surgical site and at the mirror-site in the contralateral groin six to eight weeks after unilateral herniotomy following administration of placebo.
89388976|NCT01992146|Experimental|Target-controlled naloxone-infusion (total dose: 3.25 mg/kg)|Change in Pain Ratings (NRS) at the surgical site and at the mirror-site in the contralateral groin six to eight weeks after unilateral herniotomy following administration of naloxone.
89388977|NCT01967563||overweight and class I obese adult male volunteers|Adult Male Subjects will be recruited to determine the effects on energy expenditure of transitioning from an energy-and macronutrient-balanced standard baseline diet to a eucaloric ketogenic diet
89388978|NCT01961063|Experimental|Treatment (gene therapy)|Patients receive busulfan IV over 3 hours on day -2 followed by lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells IV on day 0.
89388979|NCT01909245|Experimental|Single Arm Study|Allogenic Human Islet Cell Transplant with immunosuppression
89388980|NCT01902407||Diagnostic MRI and CT scan of the airway|"All patients seen at CCHMC (up to 90 years of age) who are scheduled to have a clinical sleep MRI or CT scan for their OSA airway or lung disease.~Scheduled for both Sleep diagnostic tests (Sleep MRI and CT scans)."
89388981|NCT01813695||Preemptive|Patients with genotype testing entered into electronic medical record for consideration and opioid administration postoperatively.
89388982|NCT01813695||Control|Genetic sample taken but withheld from electronic medical record.
89388983|NCT01702051||1|patients with chronic pancreatitis treated with total or subtotal pancreatectomy
89388984|NCT01702051||2|patients underwent completion pancreatectomy because of anastomotic leak after partial pancreatectomy
89388985|NCT01702051||3|patients underwent pancreatoduodenectomy in which pancreatic anastomosis was made impracticable by technical difficulties and/or high risk of leakage
89003457|NCT05213598||Adults with FALD|male and female subjects =18 years of age who historically underwent Fontan procedure due to a severe CHD and thus are at risk for FALD by virtue of their altered physiology
89388986|NCT01702051||4|patients underwent extensive distal pancreatectomy for pancreatic lesions located at the neck
89388987|NCT01673334|Experimental|Fine Needle Aspiration and Core Biospsy|Patients will undergo both FNA and core biopsy during EUS evaluation of a solid pancreatic tumor.
89388988|NCT01629498|Experimental|Arm I (image-guided IMRT)|Patients undergo image-guided IMRT SIB QD 5 days a week for up to 6 weeks in the absence of disease progression or unacceptable toxicity.
89003458|NCT05211947|Experimental|Patients with cognitive impairment due to schizophrenia|
89185715|NCT04137354|Experimental|Intermittent Iron Supplements & High dose Vitamin A|Combined weekly iron supplementation (42mg of elemental iron once a week) for 9 months and high dose vitamin A (200,000IU) at baseline and after 4.5 months (mid-line).
89388989|NCT01629498|Experimental|Arm II (image-guided IMPT)|Patients undergo image-guided IMPT SIB QD 5 days a week for up to 6 weeks in the absence of disease progression or unacceptable toxicity.
89388990|NCT01485601|Experimental|MT10109|Clostridium botulinum toxin type A
89388991|NCT01485601|Active Comparator|Botox (registered trade mark)|Clostridium botulinum toxin type A
89388992|NCT01202500|Other|12 months|
89003459|NCT05206370|Placebo Comparator|Placebo + Behavioral Support|one placebo tablet orally (PO) three times daily (TID) plus behavioral support for 12 weeks
89388993|NCT01202500|Experimental|3 months|
88864526|NCT02132910|Experimental|RESTORE Intervention|"First you will receive an initial assessment of pain, physical function, and behavioral health. You will be asked to take a computer questionnaire, perform some simple physical assessments, and answer questions about yourself, your pain and your current medication use.~For the first four weeks you will receive twice-weekly, individualized, hour-long RESTORE sessions from a specially trained RESTORE instructor.~For the next four weeks, you will receive weekly, individualized, hour-long RESTORE sessions from a RESTORE instructor.~At weeks four and eight, you will repeat the assessment of pain, physical function, and behavioral health. You will be asked to take a computer questionnaire, perform some simple physical assessments, and answer questions about pain and medication use.~At three and six months, you will be contacted by telephone or email to answer questionnaires about pain, physical function, and behavioral health."
88864527|NCT02132910|No Intervention|Control Group 2|"First you will receive an initial assessment of pain, physical function, and behavioral health. You will be asked to take a computer questionnaire, perform so simple physical assessments, and answer questions about yourself, your pain and your current medication use.~You will be contacted once a week for eight weeks by phone or email to answer questions about your pain level.~At weeks four and eight, you will repeat the assessment of pain, physical function and behavioral health. You will be asked to take a computer questionnaire, perform some simple physical assessments, and answer questions about pain and medication use.~At three and six months, you will be contacted by telephone or email to answer questionnaires about pain, physical function, and behavior health."
88864528|NCT02133066|Active Comparator|US-Assisted site marking for Lumbar Punctures (LP)|Mindray M7 Ultrasound marking
88864529|NCT02133066|Placebo Comparator|Routine lumbar puncture|"These patients will receive no ultrasound-assisted site marking prior to lumbar puncture; The patients will simply have a standard-of-care spinal tap performed by the clinician"
89388994|NCT01093612|Experimental|Arm I|PART ONE: Patients are randomized to 1 of 3 dose levels. Patients undergo a PET scan 24-48 hours after injection of copper Cu 64-DOTA-trastuzumab. PART TWO: Patients undergo a PET scan 24-48 hours after injection of copper Cu 64-DOTA-trastuzumab.
88864530|NCT00614484|Experimental|Proton therapy with chemotherapy|"Induction Chemotherapy - Two cycles Taxol 200mg/m2 and Carboplatin AUC6 on day 1 and day 22. Weekly chemotherapy concurrent with radiotherapy Taxol 50mg/m2 and Carboplatin AUC 2 weekly for 5 weeks.~Proton therapy - 76 Gy in 5 weeks to lung tumor."
89388995|NCT00676715|Placebo Comparator|Placebo|Participants received two intravenous (IV) infusions of matching placebo separated by 14 days in Cycle 1, followed by two infusions of ocrelizumab 300 mg separated by 14 days in cycle 2. A single infusion of ocrelizumab 600 mg was administered on Day 1 of cycles 3 and 4. Each cycle was of 168 days.
88864531|NCT04159974|Experimental|Durvalumab|Treatment arm A will receive durvalumab IV in a dosage of 1500mg every four weeks for 12 months as mono therapy.
88864532|NCT04159974|Experimental|Durvalumab + Tremelimumab|Treatment arm B receives durvalumab in a dosage of 1500mg every 4 weeks (-3/+7 days) for 12 months post-surgery. In addition these patients receive tremelimumab IV in a fixed dose of 75mg for the first four months on day 1; 29; 57; 85 (-3/+7).
88864533|NCT04142502|Active Comparator|Propofol group|Using propofol as a sedation drug Infusion rate control Effect site concentration 0.3~1.0 mg/ml using target concentration infusion Bispectral index 60~80
88864534|NCT04142502|Active Comparator|Dexmedetomidine group|Using dexmedetomidine as a sedation drug First 10 minutes 1.0 mcg/kg loading After 10 minutes 0.3-1.0 mcg/kg/hr maintenance Bispectral index 60~80
88864535|NCT00615420|Experimental|Manuka Honey|Irradiated organic manuka honey 5ml 4 times a day held in mouth for 30 secs then swallowed
88864536|NCT00615420|Placebo Comparator|Placebo|Sugar-free placebo gel 5ml 4 times a day, swished and held in mouth for 30 secs then swallowed
88864537|NCT00568854|Active Comparator|Participants with diabetes|Persons with diagnosis of diabetes. Received biological intervention: BCG
88864538|NCT00568854|Active Comparator|Participants without diabetes|Persons with no diagnosis of diabetes and negative diabetes screening labs. Received biological intervention: BCG.
88864539|NCT00569010|Experimental|Low-Dose Ara-C + AZA-Level 0|"Group 1 = Low-Dose Ara-C + Azacitidine-Level 0~Low-Dose Ara-C: 100 mg/m^2 Daily continuous intravenous infusion (CIV) for 7 days Azacitidine (AZA): 37.5 mg/m^2 intravenous (IV) Over 20-30 minutes Daily for 7 Days"
88864540|NCT00569010|Experimental|Low-Dose Ara-C + AZA-Level 1|"Group 2 = Low-Dose Ara-C + Azacitidine-Level 1~Low-Dose Ara-C: 100 mg/m^2 Daily continuous intravenous infusion (CIV) for 7 days AZA: Level 1 = 75.0 mg/m^2 IV Over 20-30 minutes Daily for 7 days"
89388996|NCT00676715|Experimental|Ocrelizumab 600 mg|Participants two IV infusions of ocrelizumab 300 mg separated by 14 days in Cycle 1, followed by an infusion of ocrelizumab 600 mg on Day 1 and an infusion of placebo on Day 15 of Cycle 2. A single infusion of ocrelizumab 600 mg was administered on Day 1 of Cycles 3 and 4. Each cycle was of 168 days.
89388997|NCT00676715|Experimental|Ocrelizumab 1000 mg|Participants received two IV infusions of ocrelizumab 1000 mg separated by 14 days in Cycle 1, followed by an infusion of ocrelizumab 1000 mg on Day 1 and an infusion of placebo on Day 15 of Cycle 2. A single infusion of ocrelizumab 1000 mg was administered on Day 1 of Cycle 3 and a single infusion of ocrelizumab 600 mg was administered on Day 1 of Cycle 4. Each cycle was of 168 days.
88864541|NCT00569010|Experimental|High-Dose Ara-C + AZA-Level 0|Group 3 = High-Dose Ara-C + Azacitidine-Level 0 High-dose Ara-C: 1 g/m^2 Daily CIV for 4 days (age<65years) or 3 days (age>=65years) AZA: 37.5 mg/m^2 IV Over 20-30 minutes Daily for 7 Days
88864542|NCT00569010|Experimental|High-Dose Ara-C + AZA-Level 1|"Group 4 = High-Dose Ara-C + Azacitidine-Level 1~High-dose Ara-C: 1 g/m^2 Daily CIV for 4 days (age<65years) or 3 days (age>=65 years) AZA:Level 1 = 75.0 mg/m^2 IV Over 20-30 minutes Daily for 7 days"
88864543|NCT00616122|Experimental|Sunitinib, Cyclophosphamide, and Methotrexate|
88864544|NCT00616200|Experimental|A|
88864545|NCT00617058|Experimental|1|metformin, 250mg-2000 mg/day, in BID to TID doses for 26 weeks. Open, flexibly adjusted.
88864546|NCT00617058|Experimental|2|Healthy lifestyle intervention. Additional meeting at each psychiatric visit to review weight changes, level of physical activity and healthy eating behaviors
88864547|NCT00617058|No Intervention|3|Self-selected patients will be followed at major timepoints to assess weight and related measures.
88864548|NCT00618540|Experimental|Alemtuzumab|Patients administered with alemtuzumab, fludarabine phosphate, melphalan and donor stem cell transplantation in children with resistant Langerhans cell histiocytosis.
89388998|NCT00676715|Active Comparator|Avonex|Participants received weekly intramuscular injections of Avonex 30 microgram (mcg) in Cycle 1, followed by two infusions of OCR 300 mg separated by 14 days in Cycle 2. A single infusion of ocrelizumab 600 mg was administered on Day 1 of Cycles 3 and 4. Each cycle was of 168 days.
89388999|NCT00641381|Experimental|Treatment (high-dose chemotherapy, anti-HIV therapy)|Patients undergo leukapheresis to obtain PBSCs for transplantation. At least 5 days later, patients with an adequate number of collected cells proceed to high-dose chemotherapy. Patients receive carmustine IV over 4 hours on days -7 to -5, etoposide IV over 4 hours on day -4, and cyclophosphamide IV on day -2. Patients receive an autologous PBSC infusion on day 0.
88864549|NCT00570960|Experimental|1: Dextran 70|antibiotic therapy in addition to dextran 70, 1.0 g/kg on days one, two and three
88864550|NCT00570960|Active Comparator|2: Standard of Care Human Albumin|antibiotic therapy in addition to human albumin, 1.5 g/kg on day one and 1.0 g/kg on day three
88864551|NCT00571428|Experimental|15 mcg BID / 30 mcg QD|Arformoterol 15 microgram twice a day (BID) taken each morning and evening for one visit followed by Arformoterol 30 microgram once a day (QD) in the morning and placebo in the evening for the next visit.
88864552|NCT00571428|Experimental|30 mcg QD / 15 mcg BID|Arformoterol 30 microgram once a day (QD) in the morning and placebo in the evening for one visit followed by Arformoterol 15 microgram twice a day (BID) in the morning and evening for the next visit.
88864553|NCT00571974|Experimental|Phase 1 light dose escalation|"During Phase I, to determine the maximum tolerated energy density of the Pulse Dye Laser operated at 585 nm with a pulse time of 1.5 ms (PDL-585), when used in combination with 5-aminolevulinic acid (5-ALA) applied topically to the premalignant lesion.~The maximum tolerated energy density will be called the Maximum Tolerated Dose (MTD). Procedure: Fluorescence Diagnosis Imaging Interventions: Application of 5-ALA to lesion followed by activation with high power 585 nm pulsed dye laser (PDL-585, ScleroPLUS laser) at 6, 7 and 8 J/cm2."
88864554|NCT00571974|Experimental|Phase 2 - Treatment efficacy of PDT|"Procedure: Fluorescence Diagnosis Imaging~Interventions: Application of 5-ALA to lesion followed by activation with high power 585 nm pulsed dye laser (PDL-585, ScleroPLUS laser) at 8 J/cm2."
88864555|NCT00621348|Active Comparator|Isotonic fluid group|Normal saline in 5% dextrose at standard maintenance rate
88864556|NCT00621348|Active Comparator|Fluid restriction group|Reduced volume (2/3 maintenance rate) of N/5 saline in 5% dextrose
88864557|NCT00621348|Active Comparator|Hypotonic fluid group|N/5 saline in 5% dextrose at standard maintenance rate
88864558|NCT00574236|Experimental|A|
88864559|NCT00574548|Experimental|Group 1.1|Group 1.1 = 13vPnC then 13vPnC
88864560|NCT00574548|Experimental|Group 1.2|Group 1.2 = 13vPnC then 23vPS
88864561|NCT00574548|Experimental|Group 2|Group 2 = 23vPS then 13vPnC
88864562|NCT00574704|Experimental|1|
88864563|NCT00574704|Placebo Comparator|2|
89185716|NCT02566629||IBS patients in episodes phase|collect faeces from IBS patients in episodes remission phase
88864564|NCT00574704|Experimental|3|
88864565|NCT00574704|Placebo Comparator|4|
88864566|NCT01168219|Experimental|Treatment (chemotherapy and transplant)|"REDUCED-INTENSITY CONDITIONING: Patients receive fludarabine phosphate IV over 30 minutes on days -7 to -3, busulfan IV over 45 minutes on days -6 to -3, and anti-thymocyte globulin IV over 4-10 hours on days -6 to -5 (matched sibling donor [MSD]) or -6 to -4 (matched unrelated donor [MUD]).~TRANSPLANTATION: Patients undergo allogeneic hematopoietic stem cell transplantation on day 0 or on days 0-1.~GRAFT-VS-HOST DISEASE PROPHYLAXIS: Patients receive tacrolimus PO or IV on days -2 to 90 with taper on days 150-180. Patients also receive methotrexate IV on days 1, 3, 6 (MSD), and 11 (MUD).~CONSOLIDATION: Beginning on day 42, patients receive azacitidine SC or IV on days 1."
88864567|NCT01115803|Experimental|Arm A: LY2584702 + Erlotinib|Participants received 50 mg LY2584702 once daily (QD )+ 150 mg Erlotinib QD, 50 mg LY2584702 twice daily (BID) + 150 mg Erlotinib QD, 100 mg LY2584702 BID + 150 mg Erlotinib QD and 75 mg LY2584702 BID + 150 mg Erlotinib QD.
88864568|NCT01115803|Experimental|Arm B: LY2584702 + Everolimus|Participants received 50 mg LY2584702 QD + 10 mg Everolimus QD, 100 mg LY2584702 QD + 10 mg Everolimus QD and 50 mg LY2584702 BID + 10 mg Everolimus QD.
88864569|NCT01115569|Experimental|Hydrocodone Bitartrate|Open-label, all patients fulfilling the protocol Inclusion/Exclusion criteria will receive HC-CR in a flexible dosing regimen.
88864570|NCT01107886|Experimental|Saxagliptin|
88864571|NCT01107886|Placebo Comparator|Placebo|Placebo
88864572|NCT01107457|Experimental|10 mg Ixekizumab|"Part A:~10 milligrams (mg) ixekizumab given subcutaneous (SC) on weeks 0, 2, 4, 8, 12 and 16 for a total of six administrations.~Part B: (optional)~120 mg ixekizumab given SC Q4W. Subsequent to an amendment on May 2012, administration changed to 80 mg Q4W through Week 236.~Part C: (optional)~80 mg ixekizumab given SC Q4W through approximately week 344."
89185717|NCT02566629||IBS patients in remission phase|collect faeces from IBS patients in remission phase
89185718|NCT02566629||healthy controls|collect faeces from healthy controls
89389000|NCT00639301||1|Long term survivors of retinoblastoma
89389001|NCT00516373|Experimental|KU-0059436|KU-0059436 administered orally twice daily
89389002|NCT00436982|Active Comparator|Cemented Triathlon total knee system|The Triathlon total knee system is the successor of the Duracon total knee system and was observed in a prospective randomised, parallel, double-blind study.
89389003|NCT00436982|Active Comparator|Cemented Duracon total knee system|The Duracon total knee system is the predecessor of the Triathlon total knee system and was observed in a prospective randomised, parallel, double-blind study.
89389004|NCT00378105|Experimental|lenalidomide, dexamethasone, bortezomib combination|In this study each cycle will be 21 days and participants will begin the study medication in the clinic on Cycle 1 Day 1. Lenalidomide (capsules) will be taken daily for the first 2 weeks only (Day 1-14). Dexamethasone (tablets) will be taken on Day 1, 2, 4, 5, 8, 9, 11 and 12. Bortezomib will be given intravenously in the outpatient treatment clinic on Day 1, 4, 8 and 11. The third week is a rest period and no study medication will be given.
89389005|NCT02806232|Experimental|Part 1, Cohort 1: Biltricide (racemate praziquantel) 20 mg/kg|Participants received Biltricide (600 mg tablet) administered orally at a dose of 20 milligram per kilogram (mg/kg), three times a day on treatment Day 1.
89389006|NCT02806232|Experimental|Part 1, Cohort 2: Biltricide (racemate praziquantel) 40 mg/kg|Participants received Biltricide (600 mg tablet) administered orally at a dose of 40 mg/kg as a single dose on treatment Day 1.
89389007|NCT02806232|Experimental|Part 1, Cohort 3: Racemate Praziquantel 40 mg/kg|Participants received Racemate Praziquantel oral dispersible tablet (ODT) (150 mg) administered orally at a dose of 40 mg/kg as a single dose on treatment Day 1.
89389008|NCT02806232|Experimental|Part 1, Cohort 4: Racemate Praziquantel 60 mg/kg|Participants received Racemate Praziquantel ODT (150 mg) administered orally at a dose of 60 mg/kg as a single dose on treatment Day 1.
89389009|NCT02806232|Experimental|Part 1, Cohort 5: Levo Praziquantel 30 mg/kg|Participants received Levo Praziquantel ODT (150 mg tablet) administered orally at a dose of 30 mg/kg as a single dose on treatment Day 1.
89389010|NCT02806232|Experimental|Part 1, Cohort 6: Levo Praziquantel 45 mg/kg|Participants received Levo Praziquantel ODT (150 mg tablet) administered orally at a dose of 45 mg/kg as a single dose on treatment Day 1.
88864573|NCT01107457|Experimental|25 mg Ixekizumab|"Part A:~25 mg ixekizumab given SC on weeks 0, 2, 4, 8, 12 and 16 for a total of six administrations.~Part B: (optional)~120 mg ixekizumab given SC (Q4W). Subsequent to an amendment on May 2012, administration changed to 80 mg Q4W through Week 236.~Part C: (optional)~80 mg ixekizumab given SC Q4W through approximately week 344."
89389011|NCT02806232|Experimental|Part 1, Cohort 7: Levo Praziquantel 60 mg/kg|Participants received Levo Praziquantel ODT (150 mg tablet) administered orally at a dose of 60 mg/kg as a single dose on treatment Day 1.
89389012|NCT02806232|Experimental|Part 2, Cohort 8: Levo Praziquantel 50 mg/kg|Participants aged 13-24 months months received Levo Praziquantel ODT (150 mg) administered orally at a dose of 50 mg/kg as a single dose on treatment day 1.
89389013|NCT02806232|Experimental|Part 2, Cohort 9: Levo Praziquantel 50 mg/kg|Participants aged 3 to 12 months received Levo Praziquantel ODT (150 mg) administered orally at a dose of 50 mg/kg as a single dose on treatment day 1.
89389014|NCT02908087|Active Comparator|Victoza® (liraglutide)|Subjects with early diagnosis of type 1 diabetes (no symptoms, diagnosis in OGTT) aged 10-30 years, and treated with insulin are treated with Victoza®
88864574|NCT01107457|Experimental|75 mg Ixekizumab|"Part A:~75 mg ixekizumab given SC on weeks 0, 2, 4, 8, 12 and 16 for a total of six administrations.~Part B: (optional)~120 mg ixekizumab given SC Q4W. Subsequent to an amendment on May 2012, administration changed to 80 mg Q4W through Week 236.~Part C: (optional)~80 mg ixekizumab given SC Q4W through approximately week 344."
88864575|NCT01107457|Experimental|150 mg Ixekizumab|"Part A:~150 mg ixekizumab given SC on weeks 0, 2, 4, 8, 12 and 16 for a total of six administrations.~Part B: (optional)~Administered 120 mg ixekizumab SC Q4W. Subsequent to an amendment on May 2012, administration changed to 80 mg Q4W through Week 236.~Part C: (optional) 80 mg ixekizumab given SC Q4W through approximately week 344."
88864576|NCT01107457|Placebo Comparator|Placebo|"Part A:~Placebo given on weeks 0, 2, 4, 8, 12 and 16 for a total of six administrations.~Part B: (optional) 120 mg ixekizumab given SC Q4W. Subsequent to an amendment on May 2012, administration changed to 80 mg Q4W through Week 236.~Part C: (optional)~80 mg ixekizumab given SC Q4W through approximately week 344."
88864577|NCT01107457|Experimental|120 mg Ixekizumab|"Part B: (optional)~120 mg ixekizumab given SC every 4 weeks. Subsequent to an amendment on May 2012, administration changed to 80 mg every 4 weeks through Week 236.~Part C: (optional) 80 mg ixekizumab given SC every 4 weeks through approximately week 344."
88864578|NCT01107457|Experimental|80 mg Ixekizumab|"Part B: (optional)~Subsequent to an amendment on May 2012, administration changed to 80 mg ixekizumab Q4W through Week 236.~Part C: (optional) 80 mg ixekizumab given SC every 4 weeks through approximately week 344."
88864579|NCT05767008|Experimental|Static and water immersion SPF evaluation|
89389015|NCT02908087|Placebo Comparator|Placebo|Subjects with early diagnosis of type 1 diabetes (no symptoms, diagnosis in OGTT) aged 10-30, and treated with insulin are treated with placebo
89389016|NCT01357837|Placebo Comparator|Matching Placebo|Once daily oral administration of matching placebo for 4 weeks.
89389017|NCT01357837|Experimental|75 µg GRT6005|Once daily oral administration of GRT6005 for 4 weeks.
89389018|NCT01357837|Experimental|200 µg GRT6005|Once daily oral administration of GRT6005 for 4 weeks.
89389019|NCT01357837|Experimental|400 µg GRT6005|Once daily oral administration of GRT6005 for 4 weeks.
88864580|NCT05766969|Experimental|CBD/PEA|Subject will receive a 42-day supply of 10/50 mg CBD/PEA sublingual tablets to be taken 3 times a day for 42 days.
88864581|NCT05766969|Placebo Comparator|Placebo Control|A placebo sublingual tablet to be taken three times a day for 42 days.
89003460|NCT05206370|Experimental|Cytisinicline + Placebo + Behavioral Support|one cytisinicline tablet PO TID plus behavioral support for 6 weeks followed by one placebo tablet PO TID plus behavioral support for 6 weeks
89389020|NCT02053532||Positron emission tomography/magnetic resonance imaging|
89389021|NCT02053688|Active Comparator|Astigmatic Correction Lens|Nexis ACCL lenses vs commercial Toric Lenses
89389022|NCT02053688|Active Comparator|Toric Soft Contact Lenses|commercial toric soft contact lenses
89389023|NCT01349725|Experimental|ARRY-502|
89389024|NCT01349725|Placebo Comparator|Placebo|
89389025|NCT02037854|Placebo Comparator|Placebo|A nutrient formulation without the active ingredient
89389026|NCT02037854|Experimental|Nutrient formulation|Nutrient formulations with variable amounts of active ingredients.
89389027|NCT01353781|Experimental|AZD5363|Ascending doses of AZD5363 administered orally to patients to define the maximum tolerated dose (MTD)
89389028|NCT03561662|Active Comparator|Low isoflavone|Alpro soya drinks containing 10 mg isoflavones per day
89389029|NCT03561662|Active Comparator|Medium isoflavone|Alpro soya drinks containing 35 mg isoflavones per day
89389030|NCT03561662|Active Comparator|High isoflavone|Alpro soya drinks containing 60 mg isoflavones per day
89389031|NCT02051036|Experimental|Moxibustion|A series of moxibustion sessions within four weeks from the baseline with concurrent conventional medications for BPH.
89389032|NCT02051036|No Intervention|Waiting|Participants who will be allocated to waitlist will receive no moxibustion treatments throughout the 4 weeks while receiving other conventional managements for BPH. After 4 weeks, if participants choose to try the moxibustion treatment, the active acupuncture treatment will be provided for 4 weeks (2 sessions/week).
89389033|NCT02053766|Active Comparator|Sevoflurane|In the Operating Room (OR) after applying routine monitors, anesthesia will be induced with a mask using Sevoflurane up to 8%. Sevoflurane will be used for maintenance for the rest of the procedure with dosage between 1.5% and 4%. Vitals will be monitored. Fentanyl will be used as needed. Rocuronium will be used as needed for muscle relaxation. At the end of the procedure twitches will be evaluated and muscle relaxation will be reversed. Sevoflurane will be turned off at the end of procedure.
89185719|NCT02566941|Experimental|Stimulated|Patients included in the 'stimulated' group will be stimulated at the level of the quadriceps twice a day, bilaterally and simultaneously, five days per week from Monday to Friday (Stimulator: Gymna Belgium, DUO 400). The stimulation protocol (rectified alternating current; frequency, 75 Hz; intensity, 0-80 mA; pulse duration, 350 microseconds) is the one proposed by the manufacturer for atrophy prevention. The intensity of the electrical current will be gradually increased, without exceeding 80mA or the pain threshold of the patient.
89389034|NCT02053766|Active Comparator|Dexmedetomidine (Precedex®)|These subjects will receive Dexmedetomidine intravenously. In the OR routine monitors will be placed. Vitals will be monitored. A loading dose of Precedex 1mcg/ kg will be given over 10 minutes. Infusion will be started using Precedex 1mcg/ kg/ hr and can be increased or decreased as needed. Fentanyl will be used as needed. Rocuronium will be used as needed for muscle relaxation. At the end of the procedure twitches will be evaluated and muscle relaxation will be reversed. Precedex infusion will be stopped at the end of the procedure.
89389035|NCT02053766|Active Comparator|Propofol|These subjects will receive propofol for anesthesia maintenance. In the OR routine monitors will be placed. Vitals will be monitored. A loading dose of Propofol 2mg/ kg will be given over 2 minutes. Infusion will be started using Propofol 50 mcg/ kg/min and can be increased or decreased as needed (range 50-300mcg/kg/min). Fentanyl will be used as needed. Rocuronium will be used as needed for muscle relaxation. At the end of the procedure twitches will be evaluated and muscle relaxation will be reversed. Propofol infusion will be stopped at the end of the procedure.
89389036|NCT02053844|Experimental|lottery and enhanced promotion of tool|tool users in the intervention arm will be eligible to enter a monthly lottery to win one of two monthly drawings of a $500 gift card, and will receive enhanced promotion of the tool (mailed promotion, promotional message on the member web portal, and promotion through employers to employees)
89389037|NCT02053844|No Intervention|usual promotion of the tool|Routine promotion of the tool through newsletter and on health plan web site
89389038|NCT02038088||A|intravenous inhalational anesthesia
89389039|NCT02038088||B|intravenous anesthesia
89389040|NCT02053922|Active Comparator|Syntocinon|Drug is given just after delivery of the neonate during cesarean section.
89389041|NCT02053922|Active Comparator|Carbetocin|Drug is given just after delivery of the neonate during cesarean section.
89185720|NCT02566941|No Intervention|Control|
89185721|NCT05000073|Experimental|Experimental Arm|
89185722|NCT05000073|Active Comparator|Control arm|
89389042|NCT02053922|Active Comparator|Misoprostol|Drug is given just after delivery of the neonate during cesarean section.
89389043|NCT02052206|Experimental|Computer-assisted 3D planning|Realization of the fracture reconstruction according to the computer-assisted 3D preoperative plan
89389044|NCT02054000|Active Comparator|Tirofiban group|If thrombolysis in myocardial infarction flow <3 in spite of performed treatments, patients were considered as no-reflow and randomized to tirofiban or placebo group. Intracoronary tirofiban (25 µgr/kg) was administered via the guiding catheter to the infarct related artery
89185723|NCT04063917|Experimental|Sequence 1|"Participants allocated to Sequence 1 will complete the overnight sleep study with the ZENS device ON for the first half and OFF for the second half."
89389045|NCT02054000|Placebo Comparator|Placebo group|If thrombolysis in myocardial infarction flow <3 in spite of performed treatments, patients were considered as no-reflow and randomized to tirofiban or placebo group. Intracoronary serum physiologic as placebo was administered via the guiding catheter to the infarct related artery
89389046|NCT02054078|Experimental|Bevacizumab|Bevacizumab200mg by intrapleural administration
89389047|NCT02054078|Active Comparator|Pulvis talci|Pulvis talci 4g by intrapleural administration
89389048|NCT02052284|No Intervention|Control|The control group will receive standard skin care of the NICU, which does not include specific measures to modulate skin-barrier function.The current practice at GWUH NICU is that nurses clean the bodies of newborns less than 1000 grams using a piece of damp cloth with warm water. This is performed at birth and consequently every other days.
89389049|NCT02052284|Experimental|Water wash|The study group will undergo a protocol of sterile water application in addition to routine skin care of the NICU. The study group will receive more frequent and standardized applications. A commercially sterile water bottle (Enfamil® Water) will be kept inside the isolette, to be maintained at isolette temperature, and will be changed on a daily basis. Nurses use sterile gloves as a routine for care of ELBW infants. A 2 inches x 2 inches sterile gauze will be soaked in sterile water and gently applied to all skin of the baby excluding umbilical cord and IV lines sites. This procedure will be repeated every 4 hours with routine patient care for the first 1 week of life.
89003461|NCT05206370|Experimental|Cytisinicline + Behavioral Support|one cytisinicline tablet PO TID plus behavioral support for 12 weeks
89003462|NCT05203770||CBP+mOUD|Chronic Back pain participants taking opioids and classified in the opioid misuse disorder group
89003463|NCT05203770||CBP+O|Chronic Back pain participants taking opioids and without opioid misuse disorder group
89389050|NCT02807402||Paritaprevir/Ritonavir + Ombitasvir ± Dasabuvir ± Ribavirin|"Participants in this observational study received treatment with paritaprevir/ritonavir (r) and ombitasvir with or without dasabuvir ± ribavirin (RBV) for 12 or 24 weeks for the treatment of chronic hepatitis C (CHC), according to hepatitis C virus (HCV) genotype/subtype and stage of liver disease.~The prescription of treatment regimen was at the discretion of the physician in accordance with local clinical practice and label, and was made independently from this observational study and preceded the decision to offer the patient the opportunity to participate in this study."
89389051|NCT02051192|Experimental|Parent-Led Exposure Therapy (PLET)|Therapists will work with families for 10 sessions, twice weekly. The first treatment session will be a 90 minute parent only psychoeducation and treatment preparation session. Each subsequent session will last up to 60 minutes and will consist of exposure therapy using developmentally appropriate modulated behavioral approaches such as Participant modeling (PM) and Reinforced practice (RP).
89389052|NCT02051192|Active Comparator|Treatment As Usual|Patients randomized to the TAU arm will be instructed to continue receiving their prior interventions as recommended by their providers (e.g., psychotherapy, social skills training, behavioral interventions, family participation in family therapy or a parenting class, or pharmacological interventions). Treatment changes (e.g., medication increase, starting psychotherapy in the community) are not prohibited and will be monitored. Thus, treatment will continue as it would in standard practice.
89389053|NCT02052362|Experimental|Group 1 - Regimen A|8 Subjects in Group I - Regimen A: ABT-450/r/ABT-267
89389054|NCT02052362|Experimental|Group 2 - Regimen B|8 Subjects in Group II - Regimen B: ABT-450/r/ABT-267
89389055|NCT03561506|Experimental|Ferric carboxymaltose group|Ferinject®to be administered as IV drip infusion or undiluted bolus injection with a minimum administration time of 15minutes (for 1000mg single administration) for body weight ≥50 Kg or 6 minutes (for 500mg single administration) for body weight <50Kg .
89389056|NCT03561506|Active Comparator|Placebo group|Placebo will be in the form of normal saline administered over same time period as equivalent Ferinject® administration. IV drip infusion or undiluted bolus injection with a minimum administration time of 15 minutes (200mL as infusion or 20mL as bolus injection) for body weight ≥50 Kg or 6 minutes (100mL normal as infusion or 10mL as bolus injection) for body weight <50 Kg.
89389057|NCT01336439|Active Comparator|M group|A total of 25U of botulinum toxin type A was injected into each side masseter muscle in this arm.
89389058|NCT01336439|Active Comparator|MT group|A total of 25U of botulinum toxin type A was injected into each side masseter and temporal muscle in this arm.
89389059|NCT01336595|Experimental|Zirconium Femoral Component|Oxidized zirconium femoral component of Genesis II TKR system is used.
89389060|NCT01336595|Active Comparator|Cobalt Chrome|Cobalt-Chromium Femoral component of Genesis II system is used.
88864582|NCT05766826|Experimental|Treatment Arm|After enrollment over a phone call, they receive a SMS text message with an ID number to receive their coupons at the health facility. Those coupons can be used to redeem WaterGuard 150mL dilute chlorine. Participants in this group will receive a packet of coupons that ensure a monthly supply of a150ml bottle of dilute chlorine solution for at least the next 12 months. These coupons are redeemable in health facilities and other sites registered for the study.
89389061|NCT01336751|Experimental|Insulin glargine|"Lantus (insulin glargine) administered subcutaneously 15 minutes before the evening meal for 24 weeks. The initial dosage was 10 units /day for 7 days. This was followed by titration every 7 days by increasing the dosage until control was established. Insulin dosages were increased according to a subject's glucose values determined by Self-monitoring blood glucose (SMBG).~The starting dosage of metformin or sulfonylurea was the dosage the subject was taking when randomized. The dosage was to remain unchanged during the course of the study. The administration schedule was left to the discretion of the investigator."
89389062|NCT01336751|Active Comparator|Lispro mix|"Humalog Mix 75/25 (lispro mix) administered subcutaneously 15 minutes before the evening meal for 24 weeks. The initial dosage was 10 units /day for 7 days. This was followed by titration every 7 days by increasing the dosage until control was established. Insulin dosages were increased according to a subject's glucose values determined by self-monitoring blood glucose (SMBG).~The starting dosage of metformin or sulfonylurea was the dosage the subject was taking when randomized. The dosage was to remain unchanged during the course of the study. The administration schedule was left to the discretion of the investigator."
89389063|NCT01336829|Experimental|001|ETR/telaprevir Treatment A: ETR 200 mg twice a day from Day 1 to Day 10 + a single dose in the morning on Day 11. Treatment B: telaprevir 750 mg every 8 hours from Day 1 to Day 17 + 2 doses (morning and afternoon) on Day 18 and ETR 200 mg twice a day from Day 8 to Day 17 + a single dose in the morning on Day 18.
89185724|NCT04063917|Experimental|Sequence 2|"Participants allocated to Sequence 1 will complete the overnight sleep study with the ZENS device OFF for the first half and ON for the second half"
89185725|NCT04075032|Experimental|Pomegranate extract-1|Consumption of 2 daily capsules (900 mg pomegranate extract, PE) for 4 weeks
88864583|NCT05766826|Experimental|Control Arm|After enrollment over a phone call, they will not be contacted.
88864584|NCT05766696|Experimental|Atraumatic Restorative Treatment (ART)|GIC restorations placed using ART in a class room.
88864585|NCT05766696|Active Comparator|Conventional Cavity Preparation|GIC restorations placed using conventional cavity preparation in a mobile clinic.
88864586|NCT05766644|No Intervention|Control|Usual care, with no guide on app use. Surveys are administered via Short Message Services links.
88864587|NCT05766644|Experimental|Education|Enrolled in a mobile app-based education program, with guidance from a healthcare professional. All educational materials and surveys are provided via the app.
88864588|NCT05766618|Experimental|injection site|it is the arm where the patients will receive the PRF injection intraligamentally in distobuccal, and distopalatal areas of the distal surface of the canine also submucosal injection will be given buccally and palatially (0.25mm) for each side in either the right or left side of the arch.
88864589|NCT05766618|No Intervention|control site|it is the arm where the patients will not receive any injection with the same method of retraction as the intervention side.
89389064|NCT01336829|Experimental|002|telaprevir/ETR Treatment A: ETR 200 mg twice a day from Day 1 to Day 10 + a single dose in the morning on Day 11. Treatment B: telaprevir 750 mg every 8 hours from Day 1 to Day 17 + 2 doses (morning and afternoon) on Day 18 and ETR 200 mg twice a day from Day 8 to Day 17 + a single dose in the morning on Day 18.
89389065|NCT01336829|Experimental|003|TMC278/telaprevir Treatment C: TMC278 25 mg once day from Day 1 to Day 11. Treatment D: telaprevir 750 mg every 8 hours from Day 1 to Day 18 and TMC278 25 mg once daily from Day 8 to Day 18.
89389066|NCT01336829|Experimental|004|telaprevir/TMC278 Treatment C: TMC278 25 mg once day from Day 1 to Day 11. Treatment D: telaprevir 750 mg every 8 hours from Day 1 to Day 18 and TMC278 25 mg once daily from Day 8 to Day 18.
89389067|NCT01340183|Experimental|AZD5099|IV Dose
89389068|NCT01340183|Placebo Comparator|Placebo|IV Dose
89389069|NCT02960490|Experimental|E6011 400 mg/E6011 200 mg|In the Treatment Phase (24 weeks), participants will receive E6011 400 milligrams (mg) at Weeks 0, 1, and 2, and then every 2 weeks subsequently until Week 10, and will then receive E6011 200 mg every 2 weeks between Weeks 12 and 22 in a double-blind manner. Participants who complete evaluations at Week 24 of the Treatment Phase will enter the Extension Phase (conducted up to Week 104 from the start of the study treatment), in which they will receive open-label E6011 200 mg every 2 weeks until Week 102.
89389070|NCT02960490|Experimental|E6011 400 mg/E6011 400 mg|In the Treatment Phase (24 weeks), participants will receive E6011 400 mg at Weeks 0, 1, and 2, and then every 2 weeks subsequently until Week 10, and will then receive E6011 400 mg every 2 weeks between Weeks 12 and 22 in a double-blind manner. Participants who complete evaluations at Week 24 of the Treatment Phase will enter the Extension Phase (conducted up to Week 104 from the start of the study treatment), in which they will receive open-label E6011 200 mg every 2 weeks until Week 102.
88864590|NCT05766605|Experimental|the test group|The test group received postoperative conventional treatment combined with precise transarterial chemoembolization based on PDOX results. Precise transarterial chemoembolization at 1-month intervals for 2 months after surgery.
88864591|NCT05766605|Active Comparator|the control group|The control group received postoperative conventional treatment combined with Empirical transarterial chemoembolization with Doxorubicin. Empirical transarterial chemoembolization at 1-month intervals for 2 months after surgery.
88864592|NCT05766527|Experimental|KM602 monotherapy|Dose escalation and expansion
89389071|NCT02960490|Experimental|Placebo/E6011 200 mg|In the Treatment Phase (24 weeks), participants will receive placebo at Weeks 0, 1, and 2, and then every 2 weeks subsequently until Week 10, and will then receive E6011 200 mg every 2 weeks between Weeks 12 and 22 in a double-blind manner. Participants who complete evaluations at Week 24 of the Treatment Phase will enter the Extension Phase (conducted up to Week 104 from the start of the study treatment), in which they will receive open-label E6011 200 mg every 2 weeks until Week 102.
89389072|NCT02960490|Experimental|Placebo/E6011 400 mg|In the Treatment Phase (24 weeks), participants will receive placebo at Weeks 0, 1, and 2, and then every 2 weeks subsequently until Week 10, and will then receive E6011 400 mg every 2 weeks between Weeks 12 and 22 in a double-blind manner. Participants who complete evaluations at Week 24 of the Treatment Phase will enter the Extension Phase (conducted up to Week 104 from the start of the study treatment), in which they will receive open-label E6011 200 mg every 2 weeks until Week 102.
89389073|NCT02804750|Experimental|Group 1: Low-dose Group|100 mg/day for 4 weeks in Period 1, then 150 mg/day for 4 weeks in Period 2, then 200 mg/day for 4 weeks in Period 3. There was no washout between treatment periods. Period 3 was followed by a 4-week follow-up period. Per-protocol, Group 1 did not participate in treatment Period 4.
88864593|NCT05766436|Active Comparator|group D|will receive placebo ODF and nebulized dexmedetomidine (Precedex™ rxlist)
88864594|NCT05766436|Active Comparator|group M|will receive placebo nebulizer and ODF melatonin (metacyst ™ nerhadou)
88864595|NCT05766436|Placebo Comparator|group C|will receive placebo ODF and placebo 0.9% normal saline nebulizer
89185726|NCT04075032|Placebo Comparator|Placebo-1|Consumption of 2 daily capsules (900 mg microcrystalline cellulose, PLA) for 4 weeks
89389074|NCT02804750|Experimental|Group 2: High-dose Group|250 mg/day for 4 weeks in Period 1, then 300 mg/day for 4 weeks in Period 2, then 350 mg/day for 4 weeks in Period 3, then 400 mg/day for 4 weeks in Period 4. There was no washout between treatment periods. Period 4 was followed by a 4-week follow-up period.
89389075|NCT05184491|Active Comparator|Naïve patients - ACO therapy|One hundred patients naive to H. Pylori eradication therapy will receive ACO therapy for 14 days (amoxicillin 1 g with breakfast and dinner, clarithromycin 500 mg with breakfast and dinner and lansoprazole 40 mg twice daily before meals).
89185727|NCT04075032|Placebo Comparator|Placebo-2|Consumption of 2 daily capsules (900 mg microcrystalline cellulose, PLA) for 4 weeks. This arm is the previous PE-1 after crossover and one month of wash-out
89185728|NCT04075032|Experimental|Pomegranate extract-2|Consumption of 2 daily capsules (900 mg pomegranate extract, PE) for 4 weeks. This arm is the previous PLA-1 after crossover and one month of wash-out.
89185729|NCT04245345|Other|Single-arm|Subjects implanted with the Medtronic Micra AV device
88864596|NCT05766384||Normal Lung Function|Participants with FEV1 > 85% predicted and no respiratory symptoms as determined at the baseline visit for the Lung Health Cohort
88864597|NCT05766384||Low Normal Lung Function|Participants with FEV1 < 85% predicted as determined at the baseline visit for the Lung Health Cohort
88864598|NCT05766384||Respiratory Symptoms|Participants with respirator symptoms as determined at the baseline visit for the Lung Health Cohort.
88864599|NCT05766319|Experimental|Patients receiving the ICU-recover box containing home monitoring devices|"Treatment of subjects on the ICU will be state of the art, conform current practice, protocols and guidelines.~Patients discharged from the ICU will receive an ICU-Recover Box on one of the clinical wards of the LUMC filled with several devices after they have given informed consent. These devices are listed below and are described in further detail in section 6 of this protocol.~The ICU-Recover Box contains the following devices and tools:~Withings BPM Connect~Withings Body weight scale~Withings ScanWatch, from which the following features will be used:~Measurement of SpO2~Automatic recording of heart rate~Automatic recording of activity (step count)"
88864600|NCT05766293|Active Comparator|Shockwave treated group|Effect of Extracorporeal shockwaves on Fibroblast cell proliferation and cell viability
88864601|NCT05766293|Placebo Comparator|No shockwave group|Fibroblast cell lines assessed for proliferative rate and viability without shockwave exposure.
88864602|NCT05766176||Health worker|A health worker who received a second dose of booster COVID19 vaccine
88864603|NCT05766150||Patients with no oral malignant disease|
88864604|NCT05766150||Patients with oral premalignant disease|
88864605|NCT05766150||Patients with oral malignant disease|
88864606|NCT05766137|Experimental|Ridge preservation by filling the socket with autogenous partially demineralized dentin graft|2% HNO3 partial demineralization for 10 minutes
88864607|NCT05766137|Experimental|Ridge preservation by filling the socket with autogenous completely demineralized dentin graft|0.6N HCl for 30 minutes for complete demineralization
88864608|NCT05766137|Active Comparator|Ridge preservation by filling the socket with autogenous whole-tooth graft (AWTG).|After cleaning the tooth, it will be ground using bone mill and AWTG particles will be prepared by immersing tooth particles in basic ethanol for 10 min for disinfection , then washed twice in saline and dried using sterile gauze.
88864609|NCT05766098||Patients with papillary thyroid cancer|
88864610|NCT05766085||hypertension|Those patients suffering from arterial hypertension
88864611|NCT05766085||no hypertension|Those patients without arterial hypertension
88864612|NCT05766072|Active Comparator|Intervention arm|"Youth in this arm received the intervention over 10 weeks during one semester (recruiting children over 6 semesters in total), children meeting in groups of approx. seven children. The groups were led by school health nurses.~At the same time parents met for 7 group sessions, with the children participating in four of these"
88864613|NCT05766072|No Intervention|Control arm|The youth in the control condition received treatment as usual, e.g. talks with school health nurses or no intervention
88864614|NCT05766059|Experimental|[Phase 1] Stroke patients with upper-limb hemiparesis|
88864615|NCT05766059|Experimental|[Phase 2] Patients with phantom limb pain (PLP)|
88864616|NCT05766033|Experimental|Novel etchent paste|
88864617|NCT05766033|Active Comparator|Phosphoric acid 37%|
88864618|NCT05765994||ICU patients|Adult ICU patients on mechanical ventilation
88864619|NCT05765981|Experimental|Aromatic L-amino acid decarboxylase (AADC) deficiency|This early Phase trial is to prove the safety and efficacy of VGN-R09b to treat patients with AADC deficiency.
88864620|NCT05765916|Experimental|Online mindfulness and acceptance intervention|Participants of the intervention group will receive an intervention manual and videos. The duration of the intervention will be six weeks. Participants will be asked for a minimum time investment of 60 min per week. The intervention will be delivered via WeChat video call. The intervention will be conducted following the intervention manual to ensure consistency of intervention content that delivered.
88864621|NCT05765916|No Intervention|Standard of care|Participants of the control group will be received usual follow-up care including regular medical checkups, which may include a physical exam, blood tests, and imaging tests.
88864622|NCT05765877|Experimental|WX-0593|The treatment will be administrated as neoadjuvant 8 weeks before surgery. After surgical intervention the treatment will be administered up to 2 years. Treatment will be discontinued in case of unacceptable toxicity or disease progression.
88864623|NCT05765825|Experimental|LDRT concurrent cisplatin/carboplatin + etoposide + serplulimab|Participants will receive the following treatment regimens: LDRT concurrent cisplatin/carboplatin + etoposide + serplulimab. Induction treatment will be administered on a 21-day cycle for four cycles. Concurrent radiation therapy will be conducted from Day 1 - Day 5 in the first cycle. Following the induction phase, participants will continue maintenance therapy with serplulimab and thoracic radiation therapy (30Gay/10f）. Participants will be treated until loss of clinical benefit, or unaccepted toxicity, or withdrawal of consent, or death (whichever occurs first).
88864624|NCT05765799||Patient who receives a consultation before an interventional procedure|Any patient who receives a consultation before an interventional procedure will be included. Questionary will be administrated.
88864625|NCT05765773|Experimental|The study group consisted of 200 volunteers|The study group is planned to screen a maximum of 250 volunteers inclusive, of which it is planned to include 200 men and women aged 60 years and older who meet the criteria for inclusion in the study and do not have non-inclusion criteria.
88864626|NCT05765773|No Intervention|Control group|Retrospective immunogenicity data obtained in the framework of clinical study № VKI-I/II-08/20 on healthy volunteers aged 18-60 years.
88864627|NCT05765747|Experimental|Yunnan Baiyao|The Yunnan Baiyao group will be given 4 times a day, 2 capsules each time after morning, afternoon and evening meals and before going to bed. One capsule of Baoxianzi will be provided for the first time to be taken at the same time with Yunnan Baiyao Capsule, which will be given continuously for 2 weeks.
88864628|NCT05765747|Active Comparator|celecoxib|The celecoxib group will be given 1 capsule twice a day after breakfast and dinner for 2 weeks.
88864629|NCT05765708|Experimental|Motor imagery group|Motor imagery group. Only motor imagery intervention will be applied to participants.
88864630|NCT05765708|Experimental|Action Observation Group|Action Observation Group. Only action observation intervention will be applied to participants
88864631|NCT05765708|Experimental|Action Observation + Motor imagery Group|Action Observation + Motor imagery Group. Both action observation and motor imagery interventions will be applied for 5 minutes each.
88864632|NCT05765708|No Intervention|Control|
89389076|NCT05184491|Experimental|Naïve patients - LNDL therapy|One hundred patients naive to H. Pylori eradication therapy will receive LNDL therapy for 14 days (Levofloxacin 750 mg with breakfast, nitazoxanide 500 mg twice daily with meals, doxycycline 100 mg twice daily and Lansoprazole 40 mg twice daily before meals)
88864633|NCT05765695|Experimental|Treated group|
88864634|NCT05765656|Experimental|GP - pharmacist collaboration and pharmacist motivational interviewing|Once randomized, the patient will have three motivational interviews with their pharmacist. Each time, a report will be sent to the GP.
88864635|NCT05765656|No Intervention|Usual Care|The patient is handled by his GP and the pharmacist as usual (medical encounter plus medication dispensation)
88864636|NCT05765643|Experimental|Nurse parental support in symptom management using a mobile health App over 3 months|
88864637|NCT05765643|No Intervention|Wait-listed control|Parents in this group can join the usual community social or health care services as usual.
89185730|NCT02580786|Experimental|Breastfeeding peer support|Internet-based breastfeeding peer-support group in social media (Facebook). The mothers are allowed to use the group based on their individual needs from the recruitment to the first birthday of their child. Peer support is provided by three voluntary mothers. The mothers can discuss breastfeeding-related issues and ask questions. A midwife will moderate the group.
89389077|NCT05184491|Experimental|Naïve patients - MNDL therapy|One hundred patients naive to H. Pylori eradication therapy will receive MNDL therapy for 14 days ( Moxifloxacin 400 mg with breakfast, nitazoxanide 500 mg twice daily with meals, doxycycline 100 mg twice daily and Lansoprazole 40 mg twice daily before meals)
89389078|NCT05184491|Experimental|Treatment-experienced patients- LNDL therapy|One hundred patients who were unresponsive to previous eradication therapy will receive LNDL therapy for 14 days (Levofloxacin 750 mg with breakfast, nitazoxanide 500 mg twice daily with meals, doxycycline 100 mg twice daily and Lansoprazole 40 mg twice daily before meals)
88864638|NCT05765630|Active Comparator|Healthy patients|
89185731|NCT02580786|No Intervention|Routine breastfeeding support|Routine breastfeeding support provided in the hospital and in the maternal and child health clinics
89535337|NCT05012709|Experimental|intervention group|The intervention group received six 30-minute MST sessions. During MST session, participants can choose their preferred sensory stimuli such as essential oil diffuses, music and so on.
88864639|NCT05765630|Experimental|CKD patients not receiving antiplatelet agents|
88864640|NCT05765630|Experimental|CKD patients receiving antiplatelet agents|
88864641|NCT05765630|Experimental|Patients with constitutional thrombopathy with RAP1B activation defect|
88864642|NCT05765630|Experimental|Patients with ACS in the previous month treated with antiplatelet agents|
88864643|NCT05765617|Placebo Comparator|Control|Placebo 2x1 per day
88864644|NCT05765617|Experimental|Calcitriol|the treatment group received calcitriol 2x400 iu per day for 5 day
88864645|NCT05765591|Experimental|Balneotherapy group|"The patients allocated to the Balneotherapy group were subject to 3 weekly sessions of Balneotherapy together with an structured program of aquatic exercises on alternate days in groups of 8 during 4 weeks. The weekly planning was structured as following:~st day: Pool, shower, inhalation and aquatic exercises~nd day: Pool, shower, inhalation.~rd day: Pool, shower, inhalation and aquatic exercises"
88864646|NCT05765591|No Intervention|Control group|Patients from the control group were instructed to not participate in any BT-related activity during the duration of the study and to continue with usual care and activities
88864647|NCT05765565|Experimental|Octaray (intervention)|Octaray created 3D map quality
88864648|NCT05765565|Active Comparator|Pentaray (control)|Pentaray created 3D map quality
88864649|NCT05765552|Active Comparator|Control Group|Participants in control group will receive an exercise program consisted of upper and lower range of motion exercises.The exercises will be started as 8-10 repetitions and 1 set and the number of sets will be increased according to the progression of the patient. Exercises will be applied for 8 weeks, 2 days a week, each session will last for 30 minutes.
88864650|NCT05765552|Experimental|Dual-Task Training Group|Participants in the dual-task training group will receive exercises involving both motor and cognitive functions.Dual-task training sessions will begin with 10 minutes of stretching and proceed with 20 minutes of motor-cognitive dual-task exercises (counting backwards from 30 on double stance, naming the months and singing when standing on soft surfaces, finding words that starts with a given letter etc.) and sessions will end with 10 minutes of cooling.Exercises will be applied for 8 weeks 2 days a week each session will last for 30 minutes.
88864651|NCT05765539|Experimental|Pregnant women benefitting ultrasound examination|This is the unique arm of the study. This arm is made of eligible pregnant women, with a pregnancy of at least 37 weeks.
89003464|NCT05203770||CBP-O|Chronic Back pain participants not taking opioids
89003465|NCT05203770||Healthy Controls|Healthy control without pain or taking opioids.
89003466|NCT05203718|Experimental|Patients with Obesity|NYU Langone Health patients ≥18 to 80 years of age with a BMI ≥30.0 kg/m2
88864652|NCT05765474|Experimental|Training with Practice Variable|All participants will practice a motor task (the Scooping Task) for 2 consecutive days. Each day of training, participants will complete 50 trials (10 blocks of 5 trials each) with their more affected arm and 20 trials (10 blocks of 2 trials each) with their less affected arm. One trial of the task will involve using a spoon to scoop beans, one at a time, from one cup to another while seated at a table. Participants will be asked to complete as many scoops as possible from the cup closest to them to the cup farthest from them within 30 seconds in an anterior-posterior direction. One successful repetition occurs when at least one bean is transferred. The number of successful repetitions within a 30 second trial is then counted. Training for the experimental group will include the practice variable of interest.
89185732|NCT05741775|Experimental|Aerobic training|Participants in the aerobic group will undergo a training that includes walking, static bicycle, and neck exercise. The participants start the session with a warm-up for 5 minutes followed by 30 minutes of aerobic exercise and end with 5 minutes of cool-down exercise. 40 minutes/ session, 3 times per week for 6 weeks.
89185733|NCT05741775|Experimental|Biofeedback training|Participants in this group will undergo an electromyography (EMG) biofeedback training for trapezius and frontalis using rose for relaxation 3 times per week for 6 weeks. Each session will be for 30 minutes with a 5-minute resting period between each muscle session.
89185734|NCT05741775|No Intervention|Waitlist Control group|"The control group will receive the patient education sheet with the basic information about migraine in terms of symptoms, triggers, and prevention tips. This group is also called as waitlist control group who will receive intervention after the active treatment group."
89185735|NCT05741619||Anti-GABABr encephalitis|This is a non-interventional study involving clinical data. This data are information of medical follow up on patient like diagnosis, symptoms, biological results, cancer, treatments.
89185736|NCT00921297|Active Comparator|Immediate Cataract Surgery|Subjects randomly selected into the Immediate Surgery group will have their cataract surgery scheduled one month from the time their initial study visits are completed. The subjects will be followed monthly for a period of 6 months for surgical and non-surgical adverse events. At the 6-month point, subjects will receive a final comprehensive eye exam and neuropsychological testing. The research partners will complete final activities of daily living and resource utilization questionnaires.
89185737|NCT00921297|No Intervention|Delayed Cataract Surgery|Subjects selected into the Delayed Surgery group will be asked to delay their surgery for 6 months after their initial study visits. At 6 months, this group will also undergo the same testing as the Surgery Group.
89185738|NCT04902729|Active Comparator|Oxytocin 1IU|Oxytocin 1IU, administered intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby, followed by infusion 80 mU/min (40 IU in 1L given at a rate of 120 mL/h).
89185739|NCT04902729|Active Comparator|Carbetocin 80mcg|Carbetocin 80mcg, administered intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby.
89185740|NCT03674814|Experimental|Dose Level|Relacorilant will be given at a dose once daily. Enzalutamide will be given at a dose once daily.
89185741|NCT03912558|Experimental|Butterfly device implantation|"Butterfly device implantation will be performed following initial cystoscopy to evaluate prostate condition and rule out other pathologies.~Following implant size selection, the Butterfly implant will be deployed and positioned through the cystoscope over-sheath. After deployment the cystoscope (with its optics) will be re-introduced into the urethra to examine the Butterfly device position."
89185742|NCT05674032||Cases|In-patients with AP or cUTI admitted for treatment to the hospital.
89185743|NCT05674032||Control group 1|Out-patients seeking treatment for uncomplicated acute cystitis.
89185744|NCT05674032||Control group 2|In-patients admitted to the ward without signs and symptoms of a urinary tract infection and with a negative urine culture result.
89185745|NCT00698685|Experimental|Preparative Regimen|"Days - 8 through -6: pentostatin 4 mg/m2/24 hr as a continuous intravenous infusion (CIVI) (total cumulative dose, 12 mg/m2 over 3 days)~Days - 5 through - 1: alemtuzumab 20 mg per dose intravenously over 8 hours daily for 5 doses (total cumulative dose, 100 mg)~Followed by Allogeneic hematopoietic stem cell transplantation, related or unrelated donor, on day 0. Patients also receive cyclosporine intravenous (IV) continuously beginning on day -2, continuing (IV or orally) until day 100, followed by a taper."
89185746|NCT00737672|Experimental|VIABAHN Treatment Group|Use of GORE VIABAHN Endoprosthesis with PROPATEN Bioactive Surface to revise arteriovenous (AV) prosthetic grafts at the venous anastomosis in the maintenance or re-establishment of vascular access for hemodialysis as compared to Comparator Arm
89185747|NCT00737672|Active Comparator|PTA Treatment Group|Percutaneous Transluminal Angioplasty (PTA) in arteriovenous (AV) prosthetic grafts at the venous anastomosis in the maintenance or re-establishment of vascular access for hemodialysis as compared to Experimental Arm
89389079|NCT05184491|Experimental|Treatment-experienced patients- MNDL therapy|One hundred patients who were unresponsive to previous eradication therapy will receive MNDL therapy for 14 days ( Moxifloxacin 400 mg with breakfast, nitazoxanide 500 mg twice daily with meals, doxycycline 100 mg twice daily and Lansoprazole 40 mg twice daily before meals)
89003467|NCT05203172|Experimental|Binimetinib only treatment|For those participants receiving binimetinib treatment in parent studies
88864653|NCT05765474|Other|Training without Practice Variable|All participants will practice a motor task (the Scooping Task) for 2 consecutive days. Each day of training, participants will complete 50 trials (10 blocks of 5 trials each) with their more affected arm and 20 trials (10 blocks of 2 trials each) with their less affected arm. One trial of the task will involve using a spoon to scoop beans, one at a time, from one cup to another while seated at a table. Participants will be asked to complete as many scoops as possible from the cup closest to them to the cup farthest from them within 30 seconds in an anterior-posterior direction. One successful repetition occurs when at least one bean is transferred. The number of successful repetitions within a 30 second trial is then counted. Training for the control group will not include the practice variable of interest.
88864654|NCT05765422|Other|sedentary|Participant does not meet WHO's recommendations with the physical activity
88864655|NCT05765422|Other|OMS recommandations|Participant does not meet WHO's recommendations (2.5-5 hours per week of moderate physical activity OR 1.25-2.5 hours per week of vigorous physical activity);
89535338|NCT05012709|No Intervention|control group|The TAU group received usual routine care.
88864656|NCT05765422|Other|More than the OMS recommandations|Participant is practicing physical activity more than the WHO recommendations
88864657|NCT05765409|Experimental|TIMCA|The intervention will combine elements of motivational interviewing, cognitive and behavioral therapy and an attachment-based intervention. Sessions with both the adolescent and his parents are planned.
88864658|NCT05765409|Active Comparator|Treatment as Usual|"The comparator, an active control, will be Treatment As Usual (TAU) group, i.e., the therapy usually practiced in the services. Given the multiplicity of investigating centers and the different treatments offered according to the patient's problems, it seems difficult to choose a single reference treatment for the control arm. Each investigating center undertakes to adopt the treatment that seems most effective and appropriate for each patient"
88864659|NCT05765357|Experimental|Trastuzumab for injection|4mg/kg, Single dose for intravenous infusion
88864660|NCT05765357|Active Comparator|Herceptin|4mg/kg, Single dose for intravenous infusion
89389080|NCT01340339|Experimental|BILITRON BED®|Super-LED reverse phototherapy
89389081|NCT01340339|Active Comparator|BILIBERÇO®|Fluorescent Reverse Phototherapy
89389082|NCT02051270||Elders|Older people living in nursing homes will undergo a descriptive study.
89389083|NCT05187299|Experimental|Group with an observation tool|In this group (OT +), each student will complete an observer tool each time another dyad is performing
88864661|NCT05765331|Experimental|Chatbot-aid intervention|Chatbot-aid intervention group
88864662|NCT05765331|No Intervention|Control group|Written routine nursing health education guidance intervention.
88864663|NCT05765292|Active Comparator|probiotic|The multiprobiotic which contains of 14 alive probiotic strains of Lactobacillus + Lactococcus (6×1010 CFU/g), Bifidobacterium (1×1010/g), Propionibacterium (3×1010/g), Acetobacter (1×106/g) genera. Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) of probiotic per day.
88864664|NCT05765292|Placebo Comparator|placebo|Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) of gel per day
88864665|NCT05765279|Experimental|Treatment Group 1|
88864666|NCT05765279|Experimental|Treatment Group 2|
88864667|NCT05765279|Placebo Comparator|Control Group 3|
88864668|NCT05765279|Placebo Comparator|Control Group 4|
88864669|NCT05765240|Experimental|Group 1|Hyaluronic acid gel will be applied to the extraction site of the patients in group 1 immediately after the extraction.
88864670|NCT05765240|Experimental|Group 2|"Alveolar socket in group 2, will ve irradiated with an energy dose of J/cm2, 20mW/670 nm potency and 4 for 7 minutes immediately after extraction.~It will be irradiated with an energy dose of J/cm2."
88864671|NCT05765240|No Intervention|Control Group|
88864672|NCT05765188||< 25 years|42 patients younger than 25 years at the time of loop electrosurgical excision procedure
88864673|NCT05765188||> 25 years|73 patients 25 years or older at the time of loop electrosurgical excision procedure
88864674|NCT05765162||All patients form age 18 and above|All patients form age 18 and above
88864675|NCT05765149||Sleep Cohort|This is an observational study. We plan to recruit 1000 pregnant women during 10-13 weeks gestational age to build a sleep cohort. Their sleep changes during pregnancy will be recorded for identifying similar groups.
88864676|NCT05765136||Close collaboration group|Preterm infants born in hospitals where the Close Collaboration with Parents training program has been successfully implemented
88864677|NCT05765136||Single-family room group|Preterm infants born in hospitals that have implemented an architectural change to single-family room design
88864678|NCT05765136||Control group|Preterm infants born in hospitals that have not gone through any of the two aforementioned interventions (single-family room architecture or Close Collaboration with Parents training program)
89389084|NCT05187299|No Intervention|Group without observation tool|In this group (OT-), the student will not use the observer tool and will observe other students without any physical support.
89389085|NCT02054312|Experimental|Family Based Interpersonal Psychotherapy (FB-IPT)|Family Based Interpersonal Psychotherapy for Depressed Preadolescents (FB-IPT) is a promising psychosocial treatment for preadolescent depression. It is conceptually rooted in an interpersonal model of depression that focuses on how stress in interpersonal relationships is often related to the onset or maintenance of depressive symptoms. In keeping with adult and adolescent models of IPT, FB-IPT focuses on improving the interpersonal functioning of individuals as a means to improve their depressive symptoms. FB-IPT addresses two domains of interpersonal impairment in depressed preadolescents, parent-child conflict and interpersonal avoidance, and focuses on family relationships, the primary context for children's social and emotional development.
89535339|NCT03119935|Experimental|Amflow assist ambu bag ventiation|Newely developed method (Amflow assist ambu bag ventilation)
89535340|NCT03119935|Experimental|Ambu bag ventilation|Ordinary method (ambu bag ventilation
89535341|NCT03109145|Experimental|Menopause educational secure messaging|Secure messages that provide information about menopause and treatment option for menopause symptoms.
88864679|NCT05765110|Experimental|Parkinson's disease patients with DBS|All Parkinson's disease patients with bilateral deep brain stimulation (DBS) in the subthalamic nucleus
88864680|NCT05765110|Experimental|Parkinson's disease patients without DBS|All Parkinson's disease patients without bilateral deep brain stimulation (DBS) in the subthalamic nucleus
88864681|NCT05765110|No Intervention|Healthy Controls|All healthy volunteers
88864682|NCT05764902|No Intervention|Control|Patients will receive standard of care.
88864683|NCT05764902|Experimental|Intervention|The intervention group will be given an additional questionnaire assessing individual needs and preferences. CICU staff will provide patient-tailored interventions based on the expressed needs and preferences of those in the intervention group.
88864684|NCT05764850||Case|100 patients followed in pediatric diabetology at the university hospital of Geneva: a cohort
88864685|NCT05764850||Control|50 control patients
88864686|NCT05764837|Experimental|Intervention group|"Facilitation of the posterior chain was performed by foam rolling (BLACKROLL, standard hardness), where the left lower limb was rolled first, then the right lower limb and finally the spinal erectors. Rolling was performed with a sense of the highest intensity and at a high rolling speed, across the full length and width of the muscle with both cranial and caudal rolling directions. Facilitation was performed on each muscle group in the distoproximal direction, in the order of:~m. triceps surae, hamstrings, and m. gluteus maximus, with the proband attending to each muscle group for 30 s. Finally, bilateral facilitation of mm. erectores spinae in the lumbar and thoracic segments was performed, also for 30 s. The frequency of rolling was determined using a metronome at 1.5 Hz."
88864687|NCT05764837|No Intervention|Control group|The control group of probands rested in a resting sitting position for 4 minutes after pre-tests, corresponding to the intervention period.
88864688|NCT05764811|Active Comparator|Canagliflozin Treatment|Use Canagliflozin 100 mg daily, 1 month
88864689|NCT05764811|No Intervention|non-Canagliflozin Treatment|Standard treatment
88864690|NCT05764798|Experimental|Experimental group: Shugan Jieyu Capsule combined with zolpidem|Zolpidem was given orally for basic treatment, with the treatment dose of 10mg/tablet per day, one tablet per time, once a day, before sleep, for 8 consecutive weeks. Shugan Jieyu Capsule was given orally, with a therapeutic dose of 0.36g/capsule, 2 capsules each time, twice a day, and once after breakfast and dinner.
88864691|NCT05764798|Placebo Comparator|Control group: Placebo combined with zolpidem|Zolpidem was given orally for basic treatment, with the treatment dose of 10mg/tablet per day, one tablet per time, once a day, before sleep, for 8 consecutive weeks. Placebo was given orally, with a therapeutic dose of 0.36g/capsule, 2 capsules each time, twice a day, and once after breakfast and dinner.
88864692|NCT05764746|Experimental|Artemether-lumefantrine followed by artesunate amodiaquine|a standard 3-days dosage, twice a day course of Artemether-Lumefantrine (20/120mg) immediately followed by a standard 3-days, once a day course of Artesunate-Amodiaquine (40base)
88864693|NCT05764746|Experimental|Artemether-lumefantrine with Amodiaquine|a standard 3-days dosage of Artemether-Lumefantrine (20/120mg) given together with Amodiaquine hydrocloride(40 base) followed by placebo for another 3 days;
88864694|NCT05764746|Active Comparator|Artemether-Lumefantrine alone|a standard 3-days dosage of Artemether-Lumefantrine (20/120mg) followed by placebo for another 3 days
88864695|NCT05764668|Experimental|Zihua Wenfei Zhisou Granule|Patients in experimental treatment arm were given Zihua Wenfei Zhisou Granule (15 g/bag, one bag at a time, three times/day ). All treatment lasted for 14 days and no other antitussive/decongestant or bronchodilators are given to any patients.
88864696|NCT05764668|Placebo Comparator|Zihua Wenfei Zhisou Granule-matched placebo|"Patients in placebo treatment arm were given Zihua Wenfei Zhisou Granule-matched placebo (15 g/bag, one bag at a time, three times/day ). All treatment lasted for 14 days and no other antitussive/decongestant or bronchodilators are given to any patients.~Placebo does not contain active pharmaceutical ingredients, and its main ingredients are lactose, beta-cyclodextrin, stevioside, and caramel."
88864697|NCT05763602|Experimental|Nasal Povidone-Iodine Decolonization Intervention|Intranasal povidone-iodine (PDI Profend) will be applied to the patients' noses 60 minutes before surgery to repair HELEF and approximately 12 hours after the first application. If the patient will have additional HELEF repair in the 6 month followup period, intranasal PVI will be applied in a similar manner for each procedure.
88864698|NCT05763602|No Intervention|Concurrent Control|Standard of Care. This will be usual care at each participating site for subjects enrolled in the Baseline period.
88864699|NCT05762367|Experimental|Patients with IIH|Female patients with IIH between 20 and 40 years old
88864700|NCT05762367|Active Comparator|Healthy volunteers|Female healthy volunteers between 20 and 40 years old
88864701|NCT05762315|Experimental|Audio Storytelling|15 minutes transformative audio storytelling session
88864702|NCT05761145||Cases - obese with metabolic syndrome|Obese subjects with metabolic syndrome
88864703|NCT05761145||Cases - obese without metabolic syndrome|Obese subjects without metabolic syndrome
88864704|NCT05761145||Controls|Normal weight subjects
88864705|NCT05759637||T2D|patients with Type2 diabetes (T2D)
88864706|NCT05759637||obese without T2D|obese patients without Type 2 diabetes (T2D)
88864707|NCT05759117||Pleural effusion|All patients with pleural effusion who will undergo thoracentesis
88864708|NCT05746650|Experimental|1) Electrical stimulation + growth hormone|One bout of electrical stimulation with 200 eccentric contractions. This is followed by daily injections with somatropin (33.3 ug/kg in the first week, 50 ug/kg in the second week) for two weeks.
88864709|NCT05746650|Experimental|2) Electrical stimulation|One bout of electrical stimulation with 200 eccentric contractions
88864710|NCT05746650|Active Comparator|3) Growth hormone|Daily injections with somatropin (33.3 ug/kg in the first week, 50 ug/kg in the second week) for two weeks.
88864711|NCT05746650|Placebo Comparator|4) Control|No intervention
88864712|NCT05745649|Experimental|Group A|Resistive exercise
88864713|NCT05745649|Active Comparator|group B|Ankle weights
88864714|NCT05731726|Experimental|Serplulimab+CAPEOX+celecoxib|articipants will receive serplulimab 300 mg every 3 weeks (Q3W) concurrently with CAPEOX regimen: Oxaliplatin(130mg/m2) on day 1 of each cycle and Capecitabine, 1000mg/m2, PO, BID, day1-14, q3w and celecoxib, 200mg, PO, BID, day1-21, q3w. Treatment repeats every 3 weeks for 6-8 cycles followed by surgery (total mesorectal excision, TME).
89389086|NCT02054312|Active Comparator|Client Centered Therapy (CCT)|Child Centered Therapy (CCT), a supportive and nondirective treatment that closely approximates the standard of care for pediatric depression in community mental health. CCT is a manualized treatment for children between the ages of 8-14 based on a Rogerian counseling model. In that model, changes in children's mood and behavior are initiated through their experience of a therapeutic relationship marked by unconditional positive regard, empathic understanding, and therapeutic genuineness.
89389087|NCT01341509|Active Comparator|FHL tendon transferred|Surgical group in which the FHL tendon was transferred
89389088|NCT01341509|Active Comparator|FHL tendon not transferred|
89389089|NCT02051348|Placebo Comparator|Placebo|Placebo - 2 doses per day for 4 weeks
89389090|NCT02051348|Active Comparator|Pylopass|Probiotic - 2 doses per day for 4 weeks
89389091|NCT01336907||naive CNV subjects|Newly diagnosed CNV, before any treatment (naïve)
89389092|NCT01336907||previously diagnosed CNV subjects|Previously diagnosed CNV if last treatment is older than 4 months (reactivated)
89389093|NCT02052518|Experimental|Enhanced NFN Home Program|Education and Skill set training with materials to implement the behaviors recommended. Using a motivational interviewing framework, intervention participants will receive dietary and activity counseling, develop a Family Wellness Plan and will be linked to community resources.
88864715|NCT05715931|Experimental|Toripalimab plus Trastuzumab with FLOT(5-FU+leucovorin+docetaxel+oxaliplatin)|
89389094|NCT02052518|Placebo Comparator|Nurturing Family Network Home Visitation|Mothers will receive the standard of care from the Nurturing Families Network Home Visitation program
89389095|NCT01315613||Acute pancreatitis|Patients admitted in our institution for an episode of acute pancreatitis
89389096|NCT02052674|Experimental|Vented urinary drainage system|This group will be catheterized with a vented urinary drainage system. Several data sets will be evaluated to compare the two arms of the study: retained urine volume, the difference (ΔH) in meniscus heights in the dependent loops, time necessary for drainage of dependent loops, and incidence of bacteriuria.
88864716|NCT05708183||Intervention|Districts that have substituted MMS for IFA as part of routine antenatal care
88864717|NCT05708183||Comparison|Districts that continue to deliver IFA as part of routine antenatal care
88864718|NCT05699317|Experimental|Intervention|
88864719|NCT05698992||Experimental group|Patients over 18 years of age with esophageal or gastric cancer, who are living in Southern Sweden, and who are planned to undergo curative surgery treatment at Skåne University Hospital. n=100 (anticipated)
88864720|NCT05698992||Historical control group|The historical control group consists of patients, living in Southern Sweden, who underwent esophageal or gastric cancer surgery between 2013 - 2021 at Skåne University Hospital. n=100 (anticipated)
88864721|NCT05695378|Experimental|Main Study: KM-819|Subjects will receive 400 mg of KM-819 orally from Week 0 to Week 36.
88864722|NCT05695378|Placebo Comparator|Main Study: Placebo|Subjects will receive visually identical placebo pills of KM-819 orally.
88864723|NCT05695378|Experimental|Ancillary Study: KM-819|Subjects will receive 400 mg of KM-819 orally from Week 40 to Week 76.
89389097|NCT02052674|Active Comparator|Non-vented urinary drainage system|This group will be catheterized with a non-vented urinary drainage system. Several data sets will be evaluated to compare the two arms of the study: retained urine volume, the difference (ΔH) in meniscus heights in the dependent loops, time necessary for drainage of dependent loops, and incidence of bacteriuria.
89389098|NCT05163834|Experimental|Efgartigimod-1|Weekly efgartigimod infusions and the pneumovax 23 vaccine on day 22
89389099|NCT05163834|Experimental|Efgartigimod-2|Weekly efgartigimod infusions and the pneumovax 23 vaccine on day 36
89389100|NCT05163834|Placebo Comparator|Placebo|Weekly placebo infusions and the pneumovax 23 vaccine on day 22
89389101|NCT05182619|Active Comparator|ultrasoung guided stellate block|stellate ganglion will have ultrasound-guided block via bupivacaine for sympathectomy and enhancement of cerebral blood flow
88864724|NCT05686200|Experimental|Experimental group|Participants performed wrist-forearm exercise training within 2 weeks after the operation, that is, from 24 hours to 2 weeks after the operation, twice a day in the morning and evening, 3 groups each time, and each single item was repeated 5 times in each group (maintain for 5 seconds). Exercise for 40 minutes a day, use the mobile phone to install the forearm isometric exercise software program within the 3rd to 8th week, use the Bluetooth device to connect the hand-held gripper to perform the forearm isometric exercise, 2 times a day, morning and evening, and train 3 groups each time, 20 times each time , hand grip strength for 3 seconds each time, increase by 1 second per week, and rest for 90 seconds between groups.
89003468|NCT05203172|Experimental|Encorafenib only Treatment|For those participants receiving encorafenib only treatment in parent studies
89389102|NCT05182619|Active Comparator|nimodipine infusion|intravenous nimodipine will be given for enhancement of cerebral blood flow
89003469|NCT05203172|Experimental|Encorafenib & Binimetinib Treatment|For those participants receiving encorafenib & binimetinib treatment in parent studies.
89389103|NCT01065012|Experimental|Udenafil 50 mg|50 mg Udenafil
89389104|NCT01065012|Experimental|Udenafil 100 mg|100 mg Udenafil
89389105|NCT01065012|Experimental|Udenafil 150 mg|150 mg Udenafil
89389106|NCT01065012|Placebo Comparator|Placebo|Placebo Tablets matching Udenafil tablets
89389107|NCT01315691|Experimental|Arikace™|Liposomal amikacin for inhalation
89389108|NCT01315691|Placebo Comparator|Placebo|Placebo for liposomal amikacin for inhalation
89389109|NCT02038244|Experimental|Integrative Medicine|
89389110|NCT01315769||non pregnant nulliparous|Group 1
89389111|NCT01315769||primiparous women|Group 2
89389112|NCT05654090|Experimental|cefoperazone sodium and sulbactam sodium (Product name:Burotam)|Single dose Burotam
89389113|NCT05654090|Active Comparator|cefoperazone sodium and sulbactam sodium (Product name:Brosym)|Single dose Brosym
89389114|NCT01340729|Experimental|TPI 287|Starting dose TPI 287 of 125 mg/m2 intravenous (IV) for 3 weeks of 4 week schedule.
89389115|NCT02052830|Experimental|Wise Guys|A sexual health and male responsibility program for adolescent males
89389116|NCT02052830|No Intervention|Control|Business as usual sexual education in schools
89389117|NCT02959866|Experimental|Online income tool|Patients who complete the online income tool with their health provider during the study period.
89389118|NCT05183711||Nurse anesthetist|In this study, the investigator team designs to use self-evaluating form as a tool for any competencies evaluation. The Numerical Rating Scale (range from 1-10, 1= least competency, 10 =highest competency) will be used for any anesthesia skills evaluation. The participant could download the self-evaluating form (google form, no personal identity record) via QR code.
89389119|NCT02054468|Active Comparator|Single-shot-Propofol & Remifentanil|Induction group: A single-shot propofol induction dose with remifentanil infusion followed by injection of rocuronium (for doses, please see interventions). Airway: tracheal intubation
89389120|NCT02054468|Experimental|30min infusion Propofol & Remifentanil|Maintenance group: 30min of total intravenous anesthesia (TIVA) with propofol and remifentanil before rocuronium (for doses, please see interventions) is administered. Airway: tracheal intubation/laryngeal mask
89389121|NCT01340807|Experimental|Prosthetic Feet|Randomized to 4 different prosthetic feet (SACH, SAFE, TALUX, and Proprio Foot)
89389122|NCT03640650|Experimental|Dropless Therapy|Single used, pre-mixed, centrally compounded injectable that contains 15 mg/ml of triamcinolone acetonide and 1 mg/ml of moxifloxacin. This preservative-free suspension is injected at a dose of 0.2 mg into the posterior chamber, for a total drug delivery of 3 mg of triamcinolone acetonide and 0.2 mg of moxifloxacin. At the time of cataract surgery, Dropless is intended to be injected as a single administration into the anterior vitreous after the insertion of the IOL implant, with a 27 or 30-gauge cannula via a transzonular or transsceral pars plana injection, just before rinsing the viscoelastic fluid.
88864725|NCT05686200|Other|Control group|The control group began to use soft rubber balls for isometric contraction exercise from the 2nd day to the 8th week after operation. 2 times a day in the morning and evening, 3 groups of training each time, each group holds the ball for 5 minutes, and rests for 90 seconds between groups. Each grip training must be completed 20 times within 1 minute (keep 3 seconds each time in the first week) , increase by 2 seconds every week, and keep each grasping time for 10 seconds from the 5th to the 8th week.
88864726|NCT05648838|Experimental|Pivot Balloon|mornitoring with transcatheter Tricuspid Regurgitation reduction system
88864727|NCT05645744||Prior MB-102 CAR-T cell investigational product.|Patients previously treated with MB-102 CAR-T cell investigational product.
88864728|NCT05645744||Prior MB-106 CAR-T cell investigational product.|Patients previously treated with MB-106 CAR-T cell investigational product.
89189424|NCT05810207||Adult patients undergoing colorectal resection with the construction of an anastomosis|The exposure of interest in the current study regards the occurrence of anastomotic leakage in patients undergoing colorectal resection with the construction of an anastomosis. Information on the exposure of interest is gained by obtaining data from the patient files.
89389123|NCT03640650|Active Comparator|Usual Care|This therapy usually comprises an antibiotic, a steroid and in some cases a nonsteroidal anti-inflammatory drug (NSAID). Antibacterial drops are usually given at the end of surgery and are continued for one week after the surgery. Steroid drops are usually started the day of surgery and then tapered down over 3 to 4 weeks. When prescribed, NSAIDs are usually started 2 or 3 days before surgery, or started the day of surgery, and continued for 3 or 4 times a day for 3 to 4 weeks.
89389124|NCT05183555|Experimental|Patients with definite IE will be included and referred for 18F-FDG PET/CT in the study|Fourteen patients with definite IE according to the modified Duke criteria (Li) will be included and referred for 18F-FDG PET/CT in the study. A 68Ga-DOTATOC PET/CT scan will be performed specifically for research at 24 hours.
89389125|NCT03618966|Experimental|Right-real NMMS Group|It will receive a real stimulation (rNMMS) of the right arm and a sham stimulation (sNMMS) of the left arm
89389126|NCT03618966|Active Comparator|Left-real NMMS Group|It will receive a rNMMS of the left arm and a sNMMS of the right arm
89389127|NCT02052908|Experimental|Arm I (high-dose naproxen)|Patients receive high-dose naproxen PO QD for 6 months.
89389128|NCT02052908|Experimental|Arm II (low-dose naproxen, placebo)|Patients receive low-dose naproxen PO QD and placebo PO QD for 6 months.
89389129|NCT02052908|Placebo Comparator|Arm III (placebo)|Patients receive placebo PO QD for 6 months.
89389130|NCT03640572||Bone Marrow DTC|Patients with left-sided colorectal cancer and disseminated tumour cells in the bone marrow
89389131|NCT03640572||No bone marrow DTC|Patients with left-sided colorectal cancer and no disseminated tumour cells in the bone marrow
89389132|NCT03640494||Neonates with a clinical HIE diagnosis|48 neonates with a clinical diagnosis of HIE will be recruited from the patient populations of Duke University Health System and the University of Utah. All subject will have bedside optical coherence tomography (OCT) imaging performed at various time points while in the intensive care nursery.
89389133|NCT01337063|No Intervention|Pre-intervention|Usual care regarding medication reconciliation as currently practiced at each participating site.
89389134|NCT01337063|Experimental|Intervention|Improved medication reconciliation process using continuous quality improvement methods, mentored implementation, and an implementation guide.
89389135|NCT03640416|Other|Medical residents|Rambam Health Care Campus medical residents who work nights on call. Fitbit® Charge HR smart watch
89389136|NCT01337141|Experimental|Interventional telematic|80 patients will be included in this arm. They will receive 5 telematic visits (Telecare system) and 2 face to face visits.
89389137|NCT01337141|Other|Control|80 patients will be included in this arm. They will receive 7 face-to-face visits (not telematic).
89389138|NCT03640338|Experimental|Cold-therapy system|Patients will receive a cold-therapy system postoperatively (Polar Care Kodiak, Breg®) and will use the system during inpatient stay and during the first 14 days post-discharge.
89389139|NCT03640338|No Intervention|Standard care (ice-pack)|Patients will use disposable ice-pack as per standard of care
89389140|NCT05186831|Experimental|Text-based monitoring|Patients will be asked to take their BP two times daily and text their BP to the study phone number twice a day for 14 days.
89389141|NCT05186831|Active Comparator|Online patient portal|Patients will be asked to take their BP two times daily. They will be given instructions on how to upload BP readings to the online patient portal and will be asked to upload all BP readings. This represents enhanced standard of care.
88864729|NCT05640089|Experimental|Emotion network up-regulation + standard care|NF protocol targeting emotion networks (NFE) (plus standard care)
88864730|NCT05640089|No Intervention|Standard care|Continuation of treatment as usual.
88864731|NCT05635669|Experimental|Sacral acupoints group (Sacral group)|Participants will receive sacral acupoints combination treatment at bilaterally Huiyang(BL35) and Zhongliao(BL33) with prone position during the whole treatment course.
88864732|NCT05635669|Experimental|Abdominal acupoints group (Abdominal group)|Participants will receive abdominal acupoints combination treatment at unilateral Zhongji(RN3), Guanyuan(RN4) and bilaterally Dahe(KI12) with dorsal position during the whole treatment course.
88864733|NCT05635669|Experimental|Alternating acupoints group (Alternating group)|Participants will receive treatment of sacral acupoints combination and abdominal acupoints combination alternately. (For example, A for the first time, B for the second time, A for the third time, and so on. )
88864734|NCT05633680||Breast cancer group|Breast cancer is finally determined through breast puncture biopsy or excisional tissue biopsy and sent for pathological diagnosis
88864735|NCT05633680||Non-breast cancer group|By breast puncture biopsy or excisional tissue biopsy and sent to pathology for final determination of benign tumor. and healthy women
88864736|NCT05594823|Active Comparator|Fixed - dose diuretic|Pre-determined, fixed daily dose of diuretic (furosemide)
88864737|NCT05594823|Experimental|Flexible diuretic regimen|Variable daily dose of diuretic (furosemide) determined based on a pre-specified weight-based scale.
88864738|NCT05590741|Experimental|Treatment|All participants will receive a 12-session version of Emotion Regulation Therapy delivered weekly via synchronous telehealth using videoconferencing software and an asynchronous Internet-based online platform to supplement the content covered in each session.
88864739|NCT05589272|Experimental|Cognitive training + active-tDCS|Cognitive training + active-tDCS 4 times per week (20 minutes per session, each (~25cm²; current density = 0.08 mA/cm²); anode on left dorsolateral prefrontal cortex F3, cathode on right dorsolateral prefrontal cortex F4) for four weeks.
88864740|NCT05589272|Sham Comparator|Cognitive training + sham-tDCS|Cognitive training + sham-tDCS 4 times per week (20 minutes per session, each ~25cm²; current density = 0.08 mA/cm²); anode on left dorsolateral prefrontal cortex F3, cathode on right dorsolateral prefrontal cortex F4) for four weeks.
88864741|NCT05587491|Other|Gastric mucosal ablation|Participants receive submucosal injection followed by ablation of gastric mucosa using Hybrid argonplasma.
88864742|NCT05582915||Adult patients with severe Bell's palsy|Adult patients recently diagnosed with severe Bell's palsy and referred to the ENT Department by A&E or by general practitionner.
88864743|NCT05581797|Experimental|Psilocybin-assisted psychotherapy|Interpersonal Therapy integrated with psilocybin
88864744|NCT05577741|Experimental|Interventional Group|"Patients complete a measurement session at inclusion visit (Day 1). These measures include an assessment of explicit and implicit craving, a measure of mindfulness skills and a measure of the perceived richness (in stimuli) of daily environment. After inclusion visit, patients randomized in the interventional group will have 6 sessions of enriched environment (from Day 2 to Day 9).~The enriched environment includes:~the multisensory virtual reality pod offers sessions of 20 minutes of mindfulness in immersive situations. Some immersive situations are relaxing and others trigger cues in order to improve craving management;~the cognitive bike offers training sessions of 20 minutes. The patient pedals while using a touch pad with cognitive training games. This simultaneously stimulate motor skills and cognition by means of bicycle-game coupling.~A second measurement session takes place at Day 10. Alcoholic relapse is then evaluated at two weeks, one month and 3 months."
88864745|NCT05577741|Active Comparator|Control Group|"Patients complete a similar measurement session to the intervention arm, that include psychological tasks and questionnaires at inclusion visit (Day 1). After inclusion visit, patients randomized in the control group wil received the standard of care.~A second measurement session takes place at Day 10. Alcoholic relapse is then evaluated at two weeks, one month and 3 months."
88864746|NCT05573503|Experimental|Intervention|Participants complete baseline assessments and are then assigned the intervention.
88864747|NCT05565196|Experimental|Birth companion intervention arm|Women who deliver in facilities in the experimental arm will be exposed to a facility-based intervention designed to improve companionship in labor, childbirth, and postpartum periods.
88864748|NCT05565196|No Intervention|Standard of care arm|Women who deliver in facilities in the experimental arm will be exposed to the standard of care for labor, delivery, and the postpartum period.
88864749|NCT05556226|Experimental|ABBV-154 Dose A|Participants will receive subcutaneous dose of ABBV-154 Dose Formulation A.
88864750|NCT05556226|Experimental|ABBV-154 Dose B|Participants will receive subcutaneous dose of ABBV-154 Dose Formulation B.
89389142|NCT01337375|Experimental|A/B|
88864753|NCT05542758|Experimental|Total Body HIIT Program|This Total Body HIIT program (circuit and bike training) will involve 3 sessions per week (35-40 min on nonconsecutive days) progressed across the 12 weeks. All session will be lead by undergraduate exercise science students or doctor of physical therapy students and supervised by a physical therapist.
88864754|NCT05520073|Experimental|Lactobacillus and Vitamin C|Lactobacillus and Vitamin C supplements daily self-administration for 14 days
88864755|NCT05520073|Placebo Comparator|Vitamin C|Vitamin C supplements daily self-administration for 14 days
88864756|NCT05512260|Other|Women aged 23 -74 and men aged 60 - 74 invited to population based cancer screening|Women aged 23 -74 targeted for breast cancer, cervical and bowel screening and men aged 60-74 targeted for bowel screening will be invited to the project. Efforts will be made to recruit participants who normally do not participate in research and screening, such as those with various disabilities, participants who live outside society and foreign born.
89389143|NCT01337375|Experimental|C/D|
89389144|NCT03635411|Experimental|Basis|Nicotinamide riboside 500 mg and pterostilbene 100 mg given twice daily in divided doses for 90 days
89389145|NCT03635411|Placebo Comparator|Placebo|Placebo given twice daily for 90 days
89389146|NCT02748512|Experimental|FAI Insert administered using the Mk II inserter|The test article is the Fluocinolone Acetonide Intravitreal (FAI) insert, which contains 0.18 mg FA and delivers FA into the vitreous humor for 36 months, at a nominal rate of approximately 0.2 μg FA/day. The FAI insert will be administered to the study eye as an intravitreal injection through the pars plana.
89389147|NCT02748512|Active Comparator|FAI Insert administered using the Mk I inserter|The test article is the Fluocinolone Acetonide Intravitreal (FAI) insert, which contains 0.18 mg FA and delivers FA into the vitreous humor for 36 months, at a nominal rate of approximately 0.2 μg FA/day. The FAI insert will be administered to the study eye as an intravitreal injection through the pars plana.
89389148|NCT04816799|Experimental|START|START (startle adjuvant rehabilitation therapy) will be applied.
89389149|NCT04816799|No Intervention|Control|Subjects will train but without START
89389150|NCT04875455|Experimental|Experimental: POD F GF (BVI Medical), POD F (BVI Medical), Panoptix (Alcon Inc) IOL implantation|PhysIOL POD F GF: 50 (bilateral implantation) PhysIOL POD F: 50 (bilateral implantation) Alcon PanOptix: 20 (bilateral implantation) In this study, patients have already received treatment, after receiving the consent, the routinely collected pre-, intra- and postoperative data will be pseudonymized and evaluated.
88864757|NCT05510544|Experimental|Experimental arm: plerixafor, G-CSF|plerixafor in combination with granulocyte colony stimulating factor (G-CSF) for CD34+ HSC mobilization in poorly mobilized lymphoma patients
88864758|NCT05510492|Experimental|EXPERIMENTAL GROUP|EXPERIMENTAL GROUP CONSISTS OF 47 NURSES.
88864759|NCT05510492|Experimental|CONTROL GROUP|CONTROL GROUP CONSISTS OF 48 NURSES.
88864760|NCT05509699|Experimental|Surufatinib in combination with anti-PD-1/L1 therapy|Surufatinib 250 mg orally once plus anti-PD-1/L1, Q3W or Q4W, the same immune checkpoint inhibitor from patients' first-line therapy.
88864761|NCT05509699|Experimental|Anti-PD-1/L1 monotherapy|Anti-PD-1/L1 therapy, Q3W or Q4W, the same immune checkpoint inhibitor from patients' first-line therapy
88864762|NCT05506618|Other|Group A: Sample Collection|2x Nasopharyngeal Swab Sample Collection
88864763|NCT05506618|Other|Group B: Sample Collection|1x Nasopharyngeal Swab and 2x Nasal Swab Sample Collection
88864764|NCT05506618|Other|Group C: Sample Collection|1x Nasopharyngeal Swab and 2x Nasal Swab Sample Collection for sample pooling
88864765|NCT05506618|Other|Group D: Sample Collection|2x Nasal Swab Sample Collection
88864766|NCT05505903||Vaginal delivery|Newborn Infants born by vaginal delivery.
88864767|NCT05505903||Regular Cesarean section|Newborn infants born by regular Cesarean section
88864768|NCT05505903||Friendly Cesarean section|Newborn infants born by friendly Cesarean section
88864769|NCT05495126|Active Comparator|Standard Limbic Access|In this arm, participants will refer through the standard pathway of Limbic Access. During this process patients provide the minimal required information (e.g. demographic information) as well as some basic information about their experienced mental health symptoms (e.g. PHQ-9 & GAD-7). This information is attached to the referral provided to the clinician before the clinical assessment.
88864770|NCT05495126|Experimental|Limbic Access with AI|In this arm, provide all information as in the standard Limbic Access pathway. Based on this information a machine-learning model is used to predict the most likely presenting problem, based on which up to two additional anxiety specific measures are administered in order to collect more tailored information about the patients' experienced mental health symptoms. All the information is attached to the referral provided to the clinician before the clinical assessment.
88864771|NCT05488119|Experimental|Pilot Intervention|The design for this phase is a prospective pilot study. The intervention modules (co-developed with the stakeholder advisory board in Phase 1 of this aim) will be delivered weekly over a four-week period and will include pre- and post-intervention assessments of survey measurements. The investigators will also evaluate youth diabetes management and technology use. Families will be compensated in a stepwise fashion. Virtual delivery of the pilot intervention will facilitate national recruitment and allow for recruitment during the pandemic or any ensuing limitations to in-person recruitment.
88864772|NCT05444803|Other|Femoral nerve block group|Thirty minutes before the placement of spinal block, patients will be receive a femoral nerve block with Bupivacaine.
88864773|NCT05444803|Other|Peri-capsular nerve group block group|Thirty minutes before the placement of spinal block, patients will be receive a peri-capsular nerve group block with Bupivacaine.
88864774|NCT05443399|No Intervention|3D-3D|All items presented in 3D form.
88864775|NCT05443399|Experimental|3D-2D|Initial exposure to items in 3D, generalization in 2D
88864776|NCT05443399|Experimental|2D-3D|Initial exposure to items in 2D, generalization in 3D
89389151|NCT02748356|Experimental|Individuals with Spina Bifida|Lactobacillus rhamnosus GG
89389152|NCT01340963||Class I|Structurally normal heart, no bundle branch block
89389153|NCT01340963||Class II|Mild symptoms, bundle brunch block or hemi-block on resting surface electrocardiogram, normal cardiac silhouette on plain chest X-ray film, left ventricular diastolic dysfunction as relaxation deficit (type I), none or mild global left ventricular systolic dysfunction
88864777|NCT05443399|Experimental|2D-2D|Initial exposure to items in 2D, generalization in 2D
88864778|NCT05410366||Emergency department (ED) patients|Adult emergency department patients presenting with a chief complaint of 1) low back pain, 2) headache, or 3) minor head injury.
88864779|NCT05407376|Active Comparator|Intervention- High Dose|Participation will last approximately 6 months. Participants enrolled in the high-dose intervention arm will receive a weekly produce delivery directly to their home in addition to the completion of 3 questionnaires and collection of the HbA1c at the end of study.
88864780|NCT05407376|Active Comparator|Intervention-Low Dose|Participation will last approximately 6 months. Participants enrolled in the low-dose intervention arm will receive a weekly produce delivery directly to their home in addition to the completion of 3 questionnaires and collection of the HbA1c at the end of study. The amount of produce provided in this arm will be lower per month per household size than the high dose arm.
89389154|NCT01340963||Class III|Overtly symptomatic, enlarged cardiac silhouette on plain chest X-ray film, left ventricular diastolic dysfunction, global systolic dysfunction, ventricular tachycardia, atrio-ventricular block (any degree)
89389155|NCT02052986|Experimental|Vascazen|Enrolled patients will receive four capsules daily of VASCAZEN (a 3.0 gram daily dose of EPA+DHA) for a total of 12 weeks.
88864781|NCT05407376|No Intervention|Usual Care|Participation will last approximately 6 months. Participants enrolled in the Usual Care arm will complete 3 questionnaires and collection of the HbA1c at the end of study.
88864782|NCT05378386||TPVR|Transcatheter Pulmonary Valve Replacement
89185748|NCT02580084|Active Comparator|aorta femoral bypass|It is sufficient to identify only the anterior-lateral aorta surface. After heparinization the aorta is clamped above and below the anastomosis. The aorta is dissected along the anterior wall, calcium portions or mural thrombus are removed. Prosthesis is cut obliquely and anastomosis suturing starts with distal angle. Occluded at the prosthetic base jaws, aortic compressor is removed, restoring blood flow in the lower limb. Next stage is tunnel creating for jaws prosthesis conduction on hip. Ureters must remain over the prosthesis, jaw should be above the iliac arteries. After jaws prosthesis conduction on hip distal anastomosis is formed with twisting controlling. Before anastomosis completion the testing jaws and all arteries bloodletting is performed.
89185749|NCT02580084|Experimental|hybrid intervention|Iliac Arteries With Stenting and Plasty of the Common Femoral Artery
89185750|NCT05673954||Case group|Patients with primary open angle glaucoma
89185751|NCT05673954||Control group|Healthy people
89185752|NCT02594696|Experimental|Proactive Psychiatry Consultation (PPC)|"The patient is linked to a psychiatrist and case manager at cancer diagnosis who deliver team-based, patient-centered care. The psychiatrist collaborates with the oncologist to guide cancer treatment. The psychiatrist and case manager proactively monitor patient symptoms and potential barriers to care and remain in communication with the patient, oncology team, and community-based providers for the duration of the intervention.~Patients complete study assessments at baseline, 4 +/- 2 weeks after baseline, and post-intervention (12 +/-2 weeks after baseline)~Oncologists provide feedback about the usefulness of the intervention (12 +/- 2 weeks after baseline)"
89185753|NCT00737438|Experimental|1|"Initial chemo for ALL pts (ECX + BEV): Epirubicin 50 mg/m2 d1 every 21 days Cisplatin 60 mg/m2 d1 every 21 days, Capecitabine 625 mg/m2 po bid days 2-21 (held for 48 hours prior to FDG-PET/CT in week 3) Bev 15 mg/kg d1 every 21 days (cycle 1 & cycle 2 only) Salvage chemotherapy for metabolic non-responders (DI + BEV): Docetaxel 30 mg/m2 d1, d8 every 21 days, CPT-11 50 mg/m2 d1, d8 every 21 days, Bev 15 mg/kg d1, cycle 2 only 2 cycles are planned prior to resection.~Pts who aren't Cisplatin candidates (i.e. Creatinine clearance 40-60/cc, older age, marginal PS,etc.) may get oxaliplatin instead of cisplatin after discus with the PI. Oxaliplatin will be admin at 130 mg/m2 on day 1 every 21 days. Pts who aren't able to get Capecitabine (i.e. insurance restriction, unable to swallow, etc.) may get infusional fluorouracil instead of capecitabine after discus with the PI. Fluorouracil will be admin at 200 mg/m2/d x 21 days (held for 48 hours prior to FDGPET/ CT scan in week 3 of cycle 1)."
89185754|NCT00737282|Active Comparator|25 mg Proellex|Proellex 25 mg once daily
89185755|NCT00737282|Active Comparator|Proellex 50 mg|Proellex 50 mg once daily
89185756|NCT03884478|Experimental|Alcohol + Stigma Coping PNF|Participants randomized to this condition will receive gamified personalized normative feedback on their alcohol use after answering questions about alcohol use and two control topics in Round 3. Then, in the very next Round of the competition (Round 4), these participants will receive gamified personalized normative feedback on their stigma coping behaviors after answering questions about their stigma coping behaviors and two control topics.
89189425|NCT05810155||Time waiting for surgery|This group includes all patients with IBD who are waiting for elective surgery and was put on the waiting list 2017-2021 at Sahlgrenska University Hospital.
89189426|NCT05810155||Operated|This group includes patients with IBD who was operated with elective surgery 2017-2021 at Sahlgrenska University Hospital.
89389156|NCT02054624|Active Comparator|Individual|"The weight-loss treatments will include two phases. Phase 1 will last 4 months and Phase 2 will last 12 more months.~Phase 1 will be 4 months of weight loss treatment~Phase 2 will be 12 months of follow-up contact by one-on-one telephone call.~The participants will learn about nutrition, physical activity, and safe methods to lose weight during Phase 1.~During Phase 2 participants will receive two phone calls per month from their group leader for the first 6 months, and one phone call per month for the next 6 months."
88864783|NCT05338125|Experimental|Intervention arm|Patients undergoing the extra intra-operative electrophysiological measurement
88864784|NCT05335772|Experimental|VR-AOT|Experimental group, observing actions in virtual reality
88864785|NCT05335772|Other|VR-LO|Control group, observing a matched dose of videos depicting landscapes in virtual reality
88864786|NCT05315310|Experimental|REAL Training|Robotic Exosuit Augmented Locomotion (REAL) refers to gait training with soft robotic exosuits, performed under a speed-based approach where participants are asked to walk at faster speeds in treadmill and overground environments. Cues and summary feedback emphasizing walking speed and forward propulsion are provided by the physical therapist to facilitate goal-directed walking practice. Training is progressively challenging based on environmental complexity and practice variability. REAL includes 12 training sessions, administered 2-3x/week. Each session includes 30 minutes of total walking time.
88864787|NCT05294718|Active Comparator|Internal shunt|glenn with internal shunt (veno-atrial shunt) where the surgeon established a shunt between distal SVC and the right atrium, Establishing a veno-atrial shunt.
88864788|NCT05294718|Active Comparator|External shunt|Glenn with external shunt where the anesthesiologist connected the internal Jagular venous cannula which represent the SVC with the main lumen of the femoral cannula which represent the IVC through long venous extension
88864789|NCT05269953|Experimental|Active stimulation|
88864790|NCT05269953|Sham Comparator|Sham stimulation|
88864791|NCT05269953|No Intervention|Waitlist (no stimulation)|Treatment as usual
89185757|NCT03884478|Experimental|Alcohol + Control PNF|Participants randomized to this condition will receive gamified personalized normative feedback on their alcohol use after answering questions about alcohol use and control topics in Round 3. Then, in the very next Round of the competition (Round 4), these participants will receive gamified personalized normative feedback on one control topic (Relationships) after answering questions about their stigma coping behaviors and two control topics.
89185758|NCT03884478|Other|Control PNF|Participants randomized to the control arm will answer questions about the same topics as participants in the other conditions in Round 3 (Alcohol Use & Control) and Round 4 (Stigma-Coping & Control). However, in both Rounds 3 and 4 they will receive gamified PNF on control topics.
89185759|NCT03448458|Experimental|Gallium Ga 68-DOTATATE PET/CT|Patients receive gallium Ga 68-DOTATATE IV. Within 55-70 minutes, patients undergo PET (positron emission tomography)/CT (computed tomography).
89185760|NCT04075422||Prospective cohort|64 patients treated with Bezlotoxumab
89185761|NCT04075422||Retrospective Cohort (Control)|All the first episodes diagnosed in each participating sites during the previous year that meet the inclusion criteria
89185762|NCT02579538||Total Knee Arthroplasty|Patients undergoing unilateral total knee arthroplasty
89185763|NCT02579538||Thoracic/Breast Surgery|Patients undergoing mastectomy, thoracotomy, or video-assisted thoracoscopic surgery (VATS)
89185764|NCT04075968||group 1|exercise group; 6 weeks, twice a week, 30 minutes physical group exercises and 30 minutes general cognitive function exercises will be applied as groups.
89185765|NCT04075968||group 2|control group; patients will be given physical and cognitive home exercise program individually.
89185766|NCT03414372|Experimental|Tough Talks Online|Participants will use Tough Talks Online
89185767|NCT03414372|Experimental|Tough Talks Clinic|Participants will use receive Tough Talks in a clinic
89185768|NCT03414372|Placebo Comparator|Standard of Care|Participants will receive the standard of care (SOC).
89185769|NCT00582816|Experimental|1|patients will undergo a standard pre-transplant evaluation, but will also have blood drawn to evaluate their HLA class I killer immunoglobulin-like receptor (KIR) ligand typing. Parents will undergo KIR genotyping and phenotyping, and a donor will be selected based on which parent shows the greatest degree of KIR receptor-ligand mismatching. Once the donor has been selected he/she will undergo a peripheral blood stem cell (PBSC) collection utilizing G-CSF and GM-CSF for stem cell mobilization. The PBSC collection will be performed utilizing standard procedures. The PBSC will then be processed in the UW BMT Laboratory in order to deplete the graft of T cells. This will be accomplished using the CliniMACS cell separation system. T cell depletion is a standard procedure for patients receiving haploidentical stem cell grafts. The resulting stem cell product will be analyzed for T cell, stem cell and NK cell content.
89185770|NCT00737048|Experimental|Tramadol plus Acetaminophen and Placebo|Tramadol hydrochloride and acetaminophen combination tablet will be administered as single oral dosing of two tablets at a dose of 75 and 650 milligram respectively, along with two oral capsules of matching placebo, within 30 minutes after the intensity of pain associated with tooth extraction showed greater than or equal to (>=) 50.0 millimeter (mm) on the Visual Analog Scale (VAS), score ranging from 0 mm (no pain) to 100 mm (worst possible pain).
89185771|NCT00737048|Experimental|Tramadol and Placebo|Tramadol hydrochloride will be administered as single oral dosing of two capsules once at a dose of 75 milligram, along with two oral tablets of matching placebo, within 30 minutes after the intensity of pain associated with tooth extraction showed >= 50.0 mm on the VAS, score ranging from 0 mm (no pain) to 100 mm (worst possible pain).
89185772|NCT00737048|Experimental|Acetaminophen and Placebo|Acetaminophen will be administered as single oral dosing of two capsules once at a dose of 650 milligram, along with two oral tablets of matching placebo, within 30 minutes after the intensity of pain associated with tooth extraction showed >= 50.0 mm on the VAS, score ranging from 0 mm (no pain) to 100 mm (worst possible pain).
89535342|NCT03109145|No Intervention|Usual care: Control|Control group of eligible women patients between 45-60 years who do not receive the intervention at the West Palm Beach and Orlando Veterans Healthcare System. Usual care participants did not receive the educational secure messages.
89535343|NCT03207217|Experimental|Phase I Knowledge Assessment|
89535344|NCT03207217|Experimental|Phase II Efficacy|
88864792|NCT05228652||Affected Individuals|Virilised 46XX CAH individuals aged 16 years or above
88864793|NCT05228652||Parents of affected individuals|Parents of virilised 46XX CAH individuals aged 2 years and over.
89389157|NCT02054624|Active Comparator|Lifestyle intervention|"The weight-loss treatments will include two phases. Phase 1 will last 4 months and Phase 2 will last 12 more months.~Phase 1 will be 4 months of weight loss treatment~Phase 2 will be 12 months of follow-up contact by conference telephone call.~The participants will learn about nutrition, physical activity, and safe methods to lose weight during Phase 1.~During Phase 2 participants will receive two phone calls per month from their group leader for the first 6 months, and one phone call per month for the next 6 months."
89389158|NCT02054624|Active Comparator|Health Education Control|"The weight-loss treatments will include two phases. Phase 1 will last 4 months and Phase 2 will last 12 more months.~Phase 1 will be 4 months of weight loss treatment~Phase 2 will be 12 months of follow-up contact by email.~The participants will learn about nutrition, physical activity, and safe methods to lose weight during Phase 1.~During Phase 2 participants will receive a specially prepared newsletter two times per month. The newsletter will contain educational information about proper eating and physical activity. The newsletters will include low-fat and low-calorie recipes, along with tip sheets that describe strategies to help them maintain lost weight."
89389159|NCT01341041|Experimental|chlorine dioxide|2 arms
89389160|NCT01341041|Active Comparator|saline|one time wash with 50-100cc of normal saline
89389161|NCT02053064|Experimental|SAF-301|
89389162|NCT02053142|Experimental|Part 1 PK|400mg dose of acyclovir taken orally, followed by 2 ml blood plasma collection at 1,2,4,6 and 8 hours.
89185773|NCT04076358|Experimental|Tab-CBI|The Tab-CBI group receives a tablet preloaded with the Tab-CBI application and an accelerometer. During the study period, the participants have four weekly educational sessions plus one booster session by the research assistant through a videoconferencing tool. The educational modules were developed based on the principles of cognitive behavioral therapy. The key elements of the modules include activity-pacing, adjustment of goal-setting to the current physical condition, setting priorities and structured planning of a simple walking activity and time off, and cognitive restructuring of activity demands (see attached, outline of education modules).
89189427|NCT05810103|Experimental|DP303c|Eligible patients will be treated with DP303c at 3.0 mg/kg every 3 weeks.
89389163|NCT02053142|Active Comparator|Acyclovir|400 mg Acyclovir three times daily for 5 days
88864794|NCT05219916|Experimental|Adult patients infected by HIV, controlled under treatment.|Blood sample collection from HIV controlled patients during their scheduled consultation, after obtaining their non-opposition by an investigator.
88864795|NCT05219318|Experimental|Treatment pause|Treatment pause for 12 months
88864796|NCT05219318|Active Comparator|Treatment continuation|Treatment continuation regimens with PD-1/PD-L1 ICI + VEGFR-TKI until disease progression or unacceptable toxicity
88864797|NCT05214534||Experimental|Retrospective analysis of the correlation between SuPAR measurement and patient outcome after hospitalization
88864798|NCT05187533|Other|Mild dry eye disease|Osteopathic protocol of sphenopalatine ganglion stimulation
89389164|NCT02053142|Placebo Comparator|Placebo|Placebo three times daily for 5 days
89535345|NCT03207217|Experimental|Phase II Acceptability|
89535346|NCT02487719|Active Comparator|Iron sulfate|"Iron sulfate (or) is given if randomly asigned in this group and Ferritin at inclusion < 50 mcg/L.~intervention: oral iron sulfate 1 tbl daily until birth"
88864799|NCT05187533|Other|Moderate dry eye disease|Osteopathic protocol of sphenopalatine ganglion stimulation
88864800|NCT05187533|Other|Severe dry eye disease|Osteopathic protocol of sphenopalatine ganglion stimulation
88864801|NCT05177588|Experimental|Metformin|Patients in the metformin group will receive a starting dose of 1000 mg/day. The dose will be titrated as tolerated to a maximum of 2000 mg/. Patients will receive the medications for six year and will be followed up for the duration of the study. Patients will be assessed at baseline, 3 months, and 6 months.
88864802|NCT05177588|No Intervention|Standard of Care|Patients in the control arm will continue the SOC medications
88864803|NCT05174078|Experimental|Medically-Tailored Meals (MTM)|Medically-tailored meals delivered to participants' homes for 15 weeks AND one medical nutrition therapy session with a dietician + viewership of 2 to 4 nutrition education videos.
89189428|NCT05810090||TKA (Total Knee Arthroplasty)|Patients did total knee arthroplasty in our hospital.
89389165|NCT01316471|Experimental|Online Behavioral Intervention|In addition to standard medical care, children and parents in the online behavioral intervention will receive access to the full web-based program including education about chronic pain, training in behavioral and cognitive coping skills, instruction in increasing activity participation, and education about pain behaviors and parental operant strategies using an engaging, interactive format on the Internet.
89389166|NCT01316471|Active Comparator|Online Patient Education|The Online Patient Education group will serve as an attention control condition. In addition to standard medical care, children and parents will be provided with access to a modified version of the study website that will provide information from publicly available educational websites about pediatric chronic pain management.
89389167|NCT01316549||Inpatient Pediatric Bone Marrow Transplant Recipients|All patients enrolled in this study will be located on the inpatient pediatric bone marrow transplant unit at University of California, San Francisco Benioff Children's Hospital.
89389168|NCT02054780|Active Comparator|Psychosocial Counseling|"The curriculum Psychosocial Care and Counseling (PC) was developed for HIV Infected Children and Adolescents. The goal is to enable health care providers to provide safe supportive counseling and support services to HIV infected youth and their families. The course materials are designed to be adapted to different cultures and needs. The 14 modules cover child development, family systems, communicating with children, disclosure and adherence and legal/ethical issues. The course teaches basic counseling skills with children such as listening and play. It explores and challenges barriers to care such as caregivers' fear and reluctance to disclose an HIV positive diagnosis to a child, discussing adolescent sexuality, and practical issues such as inadequate legislation governing child rights. The curriculum was adapted for Zambia and endorsed by the MoH. PC is considered an enhanced model of a Psychosocial Support program for OVC."
89389169|NCT02054780|Experimental|Trauma-Focused Cognitive Behavioral Therapy|We propose using TF-CBT to address stress related problems (SRP) and reduce HIV risk behaviors. Given evidence on the link between abuse/trauma and elevated HIV risk, researchers have called for more overlap between evidence-based mental health treatments like TF-CBT and HIV prevention programs. Recent trials have provided direct evidence that CBT may be effective in HIV prevention. TF-CBT has eight components including: Psychoeducation, Relaxation, Affective Modulation, Cognitive Coping, Trauma Narrative, In-vivo Exposure (if needed), Conjoint parent-child session, and Enhancing Safety Skills. This cognitive behavioral therapy teaches skills such as how to think about situations differently in order to feel better. It also includes helping a child face the fear and anxiety of the traumatic situations, rather than avoid them. Based on earlier pilot projects, the MoH has endorsed TF-CBT in Zambia.
89389170|NCT01316627|Experimental|Crooked Mirror Externalization Therapy|"Of recent, the crooked mirror externalization therapy, developed by Dr. Eda Gorbis, has been put to use with much success (Gorbis 2004). This method involves the use of crooked or fun house mirrors made from highly reflective surfaces that can be bent in different directions, which distort and exaggerate the patient's perceived defects (Gorbis 2005). In turn, this process externalizes or reverses the patient's internalized distorted body image, and allows the patient to habituate to the reflection of the imagined defect that is even more distorted than the internalized image (Rosen et al. 1995)."
89389171|NCT01316627|Active Comparator|Mirror Retraining Method|"In treating BDD, the cognitive-behavioral technique, mirror retraining, uses ordinary and/or magnifying mirrors to amplify the supposed defect, which teaches patients to see their appearance in a more holistic way. Since BDD patients tend to only focus on their perceived flaws when looking in the mirror, and tend to think about their flaws in negative terms, in mirror retraining, patients learn how to change their negative evaluations of their appearance into more objective and nonjudgmental descriptions. Generally, this method is designed to intentionally exaggerate anxiety regarding appearance concerns through exposures with mirrors. However, using exclusively ordinary and/or magnifying mirrors does not address the internal distorted image that many patients with BDD experience (Rosen et al. 1995, Osman et al. 2004, Veale 2004)."
89389172|NCT03439657|Experimental|Co-Ad Group|Adults aged ≥50 years of age who received the first dose of GSK1437173A and one dose of Prevenar13 at Day 1 and the second dose of GSK1437173A at Month 2. Both vaccines were administered intramuscularly, GSK1437173A was administered in the deltoid muscle of the non-dominant arm, while Prevenar13 was administered in the deltoid muscle of the dominant arm
89389173|NCT03439657|Active Comparator|Control Group|Adults aged ≥50 years of age who received one dose of Prevenar13 at Day 1, the first dose of GSK1437173A at Month 2 and the second dose of GSK1437173A at Month 4. Both vaccines were administered intramuscularly, GSK1437173A was administered in the deltoid muscle of the non-dominant arm, while Prevenar13 was administered in the deltoid muscle of the dominant arm
89389174|NCT02053220|Experimental|Intra-tumoural cohort|
89003470|NCT05203172|Experimental|Treatment of Encorafenib & Binimetinib & Ribociclib|For those participants receiving treatment of encorafenib & binimetinib & ribociclib in parent studies
89389175|NCT02053220|Experimental|Intra-venous cohort|
89389176|NCT02056028||Bile leak after hepatic resection|
89389177|NCT01341743|Active Comparator|A|oral entecavir 1mg daily for 104 weeks
89389178|NCT01341743|Active Comparator|B|oral entecavir 1mg daily and adefovir 10mg daily for 104 weeks
89389179|NCT01341743|Active Comparator|C|oral entecavir 0.5mg daily and adefovir 10mg daily for 104 weeks
89535347|NCT02487719|Active Comparator|Iron polymaltose|"Iron polymaltose (or) is given if randomly asigned in this group and Ferritin at inclusion < 50 mcg/L.~intervention: oral iron polymaltose 1 tbl daily until birth"
89185774|NCT04076358|No Intervention|Usual Care|The usual care group receives Arthritis related fatigue management which are currently offered to the participants at the recruitment sites. Participant are also instructed to maintain usual activity during the study period. The control group participants also receive an accelerometer to count steps, but without a tablet.
89003471|NCT05203172|Experimental|Treatment of Encorafenib & Binimetinib & Cetuximab|For those participants receiving treatment of encorafenib & binimetinib & cetuximab in parent studies
89389180|NCT02054858|Experimental|RIPC|Preconditioning will be performed in the same manner as several previous trials. Immediately prior to having the CT scan a CE-approved blood pressure cuff will be placed around one arm of the patient. It will then be inflated to a pressure of 200mmHg for 5 minutes. For patients with a systolic blood pressure >185mmHg, the cuff will be inflated to at least 15mmHg above the patient's systolic blood pressure. The cuff will then be deflated and the arm allowed reperfuse for 5 minutes. This will be repeated so that each patient receives a total of 4 ischaemia-reperfusion cycles.
89389181|NCT02054858|No Intervention|Control|Patients randomised to this group will receive routine care associated with undergoing a CT scan.
89389182|NCT01341197||Subjects undergoing bidirectional endoscopy and fecal tests|Subjects participating in the health check-up at National Taiwan University Hospital (Health Management Center)
89389183|NCT01341197||Patients with screening detected GI tract cancers|Patients with screening detected GI tract cancer, such as throat cancer, esophageal cancer, gastric cancer and colorectal cancers, from other screening sites in Taiwan and were referred to the National Taiwan University Hospital for confirmatory diagnosis and treatment.
89389184|NCT03804632||GINA-defined clinical diagnosis of Asthma|All patients with GINA-defined clinical diagnosis of Asthma seen at respiratory clinic from October to December 2017 with age 18 and above
89389185|NCT01341275|Experimental|birth, lower dose booster|Adolescents who received their first dose of hepatitis B vaccine at or before day 7 of life who received a 10 ug dose of hepatitis B vaccine as a booster
89389186|NCT01341275|Experimental|birth, higher dose booster|Adolescents who received their first dose of hepatitis B vaccine at or before day 7 of life who received a 20 ug dose of hepatitis B vaccine as a booster
89389187|NCT01341275|Experimental|4 weeks, lower dose booster|Adolescents who received their first dose of hepatitis B vaccine at or after 4 weeks of life who received a 10 ug dose of hepatitis B vaccine as a booster
89389188|NCT01341275|Experimental|4 weeks, higher dose booster|Adolescents who received their first dose of hepatitis B vaccine at or after 4 weeks of life who received a 20 ug dose of hepatitis B vaccine as a booster
89389189|NCT02852161|Experimental|MACE|MACE procedure
89389190|NCT02852161|Active Comparator|OGD|Clinically indicated gastroscopy
88864804|NCT05174078|Experimental|Produce Box and Recipes|Weekly produce box delivered to participants' homes and access to recipes via the internet for 15 weeks AND one medical nutrition therapy session with a dietician + viewership of 2 to 4 nutrition education videos.
88864805|NCT05174078|No Intervention|Standard of Care|Matched controls from the same base population as participants in the intervention arms. Controls will identified from the electronic medical record (EMR).
88864806|NCT05171660|Experimental|Sintilimab + XELOX + Bevacizumab|Sintilimab + XELOX + Bevacizumab
88864807|NCT05171660|Active Comparator|XELOX + Bevacizumab|XELOX + Bevacizumab
89389191|NCT01353937|No Intervention|Standard of Care|All patients will be receiving the Standard of Care treatments regardless of whether or not they are receiving study drug.
89389192|NCT01353937|Active Comparator|Novel Combination Therapy|AMD3100 (Plerixafor) injection with Regranex Gel topical application
88864808|NCT05156034|Experimental|SRK-001- Dose 1|Participants will receive intravenous (IV) SRK-001 every 2 weeks (Q2W) for 4 doses.
88864809|NCT05156034|Experimental|SRK-001- Dose 2|Participants will receive IV SRK-001 every 4 weeks (Q4W) for 2 doses.
88864810|NCT05156034|Experimental|SRK-001- Dose 3|Participants will receive IV SRK-001 Q2W for 4 doses.
88864811|NCT05156034|Placebo Comparator|Placebo|Participants will receive IV placebo Q2W for 4 doses or Q4W for 2 doses.
89189429|NCT05810012|Experimental|PENG Block Group|
89189430|NCT05810012|Experimental|FICB Group|
89389193|NCT01353937|Active Comparator|Becaplermin (Regranex Gel)|Topical application
89389194|NCT04720001||Experimental: Florbetaben F18 recipients|Participants in this arm of the study will receive 8.1mCi of florbetaben F18 and then be scanned in a PET scanner for brain imaging.
89389195|NCT02878213|Experimental|D700 System|Patients referred to catheter-based Atrial-Fibrillation (AF) ablation procedure therapy comprising of Pulmonary Veins Isolation (PVI).
89389196|NCT04705883|Other|Prasterone|10 patients will be treated using prasterone during 6 months.
89389197|NCT04677491|Active Comparator|VVA-FSIAD ospemifene group|Women treated with ospemifene 60 mg/day
89389198|NCT04677491|Placebo Comparator|VVA-FSIAD placebo group|Women treated with placebo
88864812|NCT05133258||Chronic Suppurative Otitis Media group|Enrolled subjects with persistent otorrhea due to CSOM and prescribed with standard of care (prescription for antibiotic drops from a pharmacy of their choice with specific written instructions for self-administration).
88864813|NCT05059873|Experimental|Systemic corticosteroid group|Patients will receive Oral prednisone 40mg/day for five consecutive days in addition to standard treatment during emergency admission or hospitalization.
88864814|NCT05059873|Placebo Comparator|Control group|Participating patients will receive an oral placebo of 40mg/day for five consecutive days in addition to standard treatment.
89389199|NCT02053298|Experimental|Timolol & Dorzolamide|Topical preservative-free fixed combination of timolol 0.5%+dorzolamide 2% to be applied bid for 1 month
89389200|NCT02054936|Active Comparator|Rivaroxaban (Xarelto)|Rivaroxaban dosing will be 10mg once daily beginning on postoperative day 1 for a duration of 30 days.
89389201|NCT02054936|Active Comparator|Warfarin (Coumadin)|Warfarin dosing will be titrated to achieve an INR of 2-3 and dosing will begin on postoperative day 1 for a duration of 30 days.
89389202|NCT04641767||BIOTRABIS>18 - Pathologic patients|Group that includes adult patients under study. Those with mild TBI will be recruited. In order to determine the severity of the mild TBI, the doctor uses a scale called the Glasgow GCS scale and mild TBI is understood as those with GCS: 14-15.
89389203|NCT04641767||BIOTRABIS>18 - Control patients|Group that includes adult control patients. Those with very mild TBI will be recruited (GCS: 15) without symptoms
89389204|NCT04641767||BIOTRABIS<18 - Pathologic patients|Group of paediatric patients under study. This will recruit those who come to the emergency department with mild TBI (GCS 14-15) or moderate (GCS 9-13).
89389205|NCT04641767||BIOTRABIS<18 - Control patients|Group that includes paediatric control patients. Those with very mild TBI will be recruited (GCS: 15) without symptoms
88864815|NCT05055024|Experimental|NLS-2 (mazindol extended release)|NLS-2 (mazindol extended release) administered once a day.
88864816|NCT05051644|Experimental|Steps 2 Change (S2C)|Participants randomized to S2C will be scheduled for 60-minute weekly treatment sessions held over four consecutive weeks in the outpatient OAT clinic. Veterans will be expected to increase their average step counts by 10% over their prior week's average starting after Session 1. Session 1 will provide pain education including a discussion the biopsychosocial treatment model for chronic pain and benefits of activity. Session 2 and 3 will emphasize benefits of low impact physical activity and introduce activity pacing to address pain flare ups caused by cycles of over activity and subsequent sedentary behavior. Session 4 will help develop a treatment plan to continue walking and identify possible barriers to meeting goals.
88864817|NCT05051644|Active Comparator|Control|Participants randomized to control will be scheduled for 60-minute weekly treatment sessions held over four consecutive weeks focused on problems associated with MOUD, substance use, and general self-management strategies. Importantly, group will explicitly avoid talking about pain coping skills and setting goals for daily step targets.
88864818|NCT05045664|Active Comparator|Standard|Standard dose (24 Gy) involved site radiotherapy plus Rituximab
88864819|NCT05045664|Experimental|Experimental|ow-dose (4 Gy) involved site radiotherapy in combination with Obinutuzumab
88864820|NCT05037552|Active Comparator|BIPOLAR FORCEPS|The bipolar forceps allow electrocoagulation and are part of the standard laparoscopy box, delivered by the sterilization service to the gynecology operating room.
88864821|NCT05037552|Experimental|FLOSEAL|"FLOSEAL® is a hemostatic agent based on gelatin of bovine origin added to thrombin of human origin. It is a recommended medical device in surgical procedures as an adjunct to hemostasis when control of bleeding, arterial jet seepage, ligation or any other conventional method proves impractical or ineffective.~During this study, it will be used in 1st intention."
88864822|NCT05012631|Experimental|Losartan|Participants will receive oral losartan as tablets or oral solution one time daily. The dosing will depend on age and will be based on drug label and dosing used in studies on patients with SCD.
88864823|NCT04990479|Experimental|Cohort 1a|Cohort 1a: 3 patients (expandable to 9) with unresectable stage III / IV Cutaneous Melanoma.
88864824|NCT04990479|Experimental|Cohort 2a|Cohort 2a:13 patients with unresectable stage III / IV Cutaneous Melanoma.
88864825|NCT04990479|Experimental|Cohort 2b|Cohort 2b: 12 patients with stage IV NSCLC (PDL1≥ 50%).
88864826|NCT04985227|Experimental|Home weight monitoring|Weighing scales will be provided to the parents to weigh their infant and enter the weight daily during the weekdays into the patient portal.
88864827|NCT04985227|No Intervention|Control|The parents will visit their Primary Care office in the usual manner as recommended by their Pediatrician.
88864828|NCT04954196|Experimental|Amlodipine arm|Single dose per os Amlodipine 5mg administration per day
88864829|NCT04954196|Placebo Comparator|Placebo arm|Single dose per os placebo (microcrystalline cellulose) administration per day
88864830|NCT04944290|Experimental|Perrigo active|
88864831|NCT04944290|Active Comparator|Reference active|
88864832|NCT04937166|Experimental|DSP107 in combination with azacitidine or azacitidine plus venetoclax.|"DSP107 will be administered by intravenous infusion once weekly during each 28-day cycle to all patients in this study.~Azacitidine (75 mg/m2/day) will be administered subcutaneously or intravenously for the first 7 days of every cycle.~Patients enrolled in Part B only will also receive venetoclax. During Cycle 1, venetoclax will be dose escalated daily to the goal dose of 400 mg daily. Patients will receive 100 mg on Day 1, 200 mg on Day 2 and 400 mg on Day 3 and onwards."
88864833|NCT04922840|Experimental|High-intensity exercise (HIIT)|"Usual care; CVD risk assessment, lifestyle advice (heart-healthy diet, regular exercise, weight management and non-smoking) and relevant medication.~The 12-week intervention is carried out as individual or group sessions with maximal 4 patients, supervised by physiotherapists in primary health care. The HIIT group complete two weekly HIIT sessions and a third weekly session with exercise at moderate intensity. Exercise is tailored to each individual to provide the same relative exercise stress and to ensure progression. Target exercise intensity is tracked by a heart rate monitor.~Individual exercise session are recorded in a training diary. Succeeding the intervention, a questionnaire will be distributed to patients in the HIIT group. Semi-structured interviews will target physiotherapists supervising HIIT and 5-7 patients in the HIIT group."
88864834|NCT04922840|No Intervention|Usual care|Control group participants receive the same treatment as usual care; CVD risk assessment including lifestyle advice (heart-healthy diet, regular exercise, weight management and non-smoking) and relevant medication. Control group participants are invited to a physiotherapist-led theoretical and practical HIIT session following study completion.
88864835|NCT04921488|Experimental|Patients with indication for colonoscopy|The screening colonoscopy will be performed by an investigator. The automatic detection and characterization system will be activated at the time of descent of the colonoscopy (after caecal intubation), with video recording (image without CAD EYE and image with CAD EYE). The investigator performing the colonoscopy will be blinded by the results of the CAD EYE.
88864836|NCT04908176|Experimental|Participants with metastatic, unresectable GIST, non-CNS solid tumors, or CNS tumors|Participants will receive 5 mg of midazolam orally on Day 1 and Day 17. Participants will receive avapritinib 300 mg daily, orally on starting on Day 3. Participants with CNS tumors will receive avapritinib 300 mg daily orally, until Day 56.
88864837|NCT04906525|Other|Conventional physical activity guidelines|Participants are given recommendations on physical activity guidelines
88864838|NCT04906525|Experimental|Resistance training|Participants will undergo 6 weeks of supervised resistance training
88864839|NCT04882540|Experimental|brivaracetam|This is a Single-Arm study with Single- and Multiple- Dose Periods. Study participants will receive a single dose of brivaracetam (BRV) on Day 1 and will then receive multiple doses of brivaracetam from Day 5-10.
88864840|NCT04859829||Patients with autoimmune dysmotility receiving IVIG infusions|
88864841|NCT04859829||Patients with autoimmune dysmotility without IVIG infusions|
89003472|NCT05202353|Experimental|Group 1: BI 456906|PET/CT imaging for analysis of the liver
89189431|NCT05809999|Experimental|Experimental: Intervention Group|Participants will undergo standard colonoscopy as part of their routine IBD surveillance. During this colonoscopy targeted biopsies (biopsies of any pre-cancerous lesions observed by the doctor) and/or removal of any polyps will be undertaken.
89389206|NCT02802878|Experimental|Hybrid Training|"The hybrid training system combines the applications of neuromuscular electrical stimulation (NMES) with voluntary contractions (NMES-VC). Training will be performed in a seated position with feet not touching the ground, and will involve each knee flexing and extending alternately. The joint range of motion will be restricted to a 90º arc from approximately 10º to 100º of flexion. Each session will consist of 5 sets of 10 repetitions, 3-second knee flexion and extension contractions on each leg. Sets will be separated by 30-sec rest intervals.~Electrodes will be placed on the anterior thigh over the motor points of the bilateral vastus medialis and lateralis, and over the medial and lateral hamstrings on the posterior thigh. Electrical stimulation intensity will be set to approximately 40% of 1 repetition maximum (RM). A joint motion sensor will trigger stimulation of the antagonist once it senses the initiation of volitional contraction of the agonist muscle group."
88864842|NCT04851158|Experimental|ShotBlocker|ShotBlocker will be used on 35 patients. For the patient group that is applied ShotBlocker, after cleansing the skin, the protruding surface of the device is placed facing the skin surface. The injection is applied with the appropriate technique, then ShotBlocker is removed and a light pressure is applied to the area with a cotton pad for 15-20 seconds.
88864843|NCT04851158|Experimental|Local Vibration|Local Vibration will be used on 35 patients. For the patient group that was subject to local vibration, local vibration was applied to the region with a vibrator for five minutes prior to injection, following a previous study on this subject. After that, 70% alcohol was used to cleanse the skin. The injection was applied with the appropriate technique, then a light pressure was applied to the area with a cotton pad for 15-20 seconds.
88864844|NCT04851158|No Intervention|Control|For the control group (n=35), IM injection into the ventrogluteal region without using any tools is performed with the appropriate technique.
88864845|NCT04808076|Active Comparator|iNPH patients|Shunt operation
89535348|NCT02487719|No Intervention|Multimineral|"Routine supplementation of multivitamin. multimineral only. Ferritin level > 50 mcg/L at inclusion. No additional iron supplementation.~oral multivitamin- multimineral preparation 1 tbl daily until birth as done in daily clinic routine"
89535349|NCT03207295|Experimental|Intervention-Nesiritide|A standard dose of Nesiritide(0.001ug/kg/min) is administered by a continuous infusion for ≥24 hours and ≤7 admission days after cardiac intensive care unit in postoperative children
88864846|NCT04808076|No Intervention|Healthy Individuals|Healthy individuals without any neurological disease.
88864847|NCT04801680||Mpact 3d metal|Subjects, among those whose clinical condition makes them eligible for a primary total hip arthroplasty, will be invited to participate to the study during preoperative visit. The
88864848|NCT04801654||Ion released group|First 30 patients will be assessed for metalic ion released by blood sample. the patients will be monitored until 10 years follow-up for long term performance of the device
88864849|NCT04801654||Other group|The remaining 125 patients will be not assessed for metalic ion released; they will be monitored until 10 years follow-up for long term performance of the device
88864850|NCT04784260||Group A (normozoospermic): >15 mill/ml and >32% progressive mobility.|Analysis of the microbiome by extracting DNA from ejaculates, amplification of bacterial DNA with feeders aimed at the regions of the bacterial rRNA 16 S gene, sequencing, library preparation and bioinformatic analysis.
88864851|NCT04784260||Group B (normozoospérmic): <15 mill/ml and <32% progressive mobility.|Analysis of the microbiome by extracting DNA from ejaculates, amplification of bacterial DNA with feeders aimed at the regions of the bacterial rRNA 16 S gene, sequencing,library preparation and bioinformatic analysis.
88864852|NCT04778267|Active Comparator|TPVB (thoracic paravertebral block)|TPVB will be performed in the sitting position A high frequency linear ultrasound probe will be applied in the parasagittal plane approximately 2-3 cm lateral to the midline till identification of the 3rd thoracic vertebra (T3) in the same side of surgery. Then the transducer will be moved progressively more medially until transverse processes are identified.The image acquired will have the transverse process located superiorly and an image of lower rib located inferiorly on the screen.The needle tip is to be observed to enter through the superior costotransverse ligament and loss of resistance sensation will be experienced. After confirming the anterior displacement of pleura with 2-3 mL of local anesthetic (LA), 30 ml of 0.25% bupivacaine and 4 mg dexamethasone will be administered for the block.
88864853|NCT04778267|Experimental|ES-PI (erector spinae-pectointercostal block)|"ESPB In the second group (ES-PI) Using a high frequency linear ultrasound probe, it will be located in a longitudinal orientation at the level of T3 spinous process and then will be placed 3 cm laterally from the midline to the side involved in the surgery. .a 22-gauge block needle will be inserted in-plane at an angle of 30-40°. 20 mL of 0.25% bupivacaine hydrochloride and 3 mg dexamethasone will be injected in the plane deeper to the erector spinae muscle.~PIPB While the patient is in the supine position, a high frequency linear probe will be placed parallel to the long axis of the sternum at a distance 2-3 cm from the attachment of the second rib and sternum to identify the Pectoralis major muscle, external intercostal muscles and the second rib in the superficial plane. by separation of fascial layers of between the external intercostal and the pectoralis muscles, a total of 10 ml of 0.25% bupivacaine and 1 mg dexamethasone will be injected."
88864854|NCT04735471|Experimental|ADI-001 Dose Escalation|ADI-001 is administered via infusion with ascending dose levels as a single dose to determine the maximum tolerated dose (MTD) or maximum assessed dose (MAD) of ADI-001 (Part 1a).
89535350|NCT03207295|Placebo Comparator|Control-Normal saline|Normal saline(2ml/h) is administered by a continuous infusion for ≥24 hours and ≤7 admission days after cardiac intensive care unit in postoperative children
88864855|NCT04735471|Experimental|ADI-001 Dose Extension|ADI-001 is administered via infusion at MAD/MTD to evaluate the safety of multiple doses (Part 1b).
88864856|NCT04735471|Experimental|ADI-001 Dose Expansion|Dose Expansion ADI-001 is administered via infusion at the MTD/MAD to confirm recommended phase 2 dose (Part 2).
89003473|NCT05202353|Experimental|Group 2: Semaglutide|PET/CT imaging for analysis of the liver
89003474|NCT05202353|Active Comparator|Group 3: BI 456906|PET/CT imaging for analysis of the pancreas
89003475|NCT05202353|Active Comparator|Group 4: Semaglutide|PET/CT imaging for analysis of the pancreas
89003476|NCT05197556|Experimental|HSG4112 200 mg Multiple Dose|Multiple oral dosing of HSG4112 200 mg for 12 weeks
89003477|NCT05197556|Experimental|HSG4112 400 mg Multiple Dose|Multiple oral dosing of HSG4112 400 mg for 12 weeks
89389207|NCT02802878|Active Comparator|Low Intensity Exercise|40% 1-repetition maximum isokinetic training with HUMAC NORM in same repetitions/sets as experimental group.
89389208|NCT04782791|Experimental|Nivo + SOX|Nivolumab plus SOX
89389209|NCT04782791|Active Comparator|Nivo|Nivolumab
89389210|NCT04773197|Experimental|Coach-assisted C-CBT with BtB|Participants will receive coach- assisted Beating the Blues (BtB), a C- CBT program, which contains 8 weekly sessions. A coach will provide between session support throughout the 8 sessions.
89389211|NCT04773197|Active Comparator|Coach-assisted animated C-CBT with EMW|Participants will receive coach- assisted Entertain Me Well (EMW), an animated C-CBT program, which contains 8 weekly sessions. A coach will provide between session support throughout the 8 sessions.
89389212|NCT04773197|Active Comparator|Standard stand-alone C-CBT with BtB|Participants will use the stand-alone BtB for 8 weekly sessions, without coach assistance.
89389213|NCT01341353|Active Comparator|Antiarrythmic Drugs|
89389214|NCT01341353|Experimental|ablation|
89389215|NCT02056106|Active Comparator|Clinical acumen|Depression diagnosis and antidepressant treatment provided based on clinical acumen of primary care providers trained to provide depression care.
89389216|NCT02056106|Active Comparator|Protocolized Arm|Structured, algorithm-based protocol that guides depression diagnosis and antidepressant treatment
89389217|NCT05183087||Special Operations Forces (SOF) Personnel|n=30 SOF Personnel
89389218|NCT02056184|Active Comparator|Adalimumab, masked ultrasound|Adalimumab and blinded ultrasound.
89389219|NCT02056184|Experimental|Adalimumab, unmasked ultrasound|Adalimumab and open ultrasound.
89389220|NCT01341431|Experimental|bee venom|
89389221|NCT01341431|Placebo Comparator|saline|
89389222|NCT02056262||3 to 16 years of age|"Volunteers of 3 to 16 years of age, coming in to the hospital for a dental consultation. See inclusion/exclusion criteria.~Intervention: Dental cavity evaluation Intervention: Saliva sampling Intervention: Plaque sampling"
89389223|NCT02056262||17 - 45 years of age|"Volunteers of 17 to 45 years of age, coming in to the hospital for a dental consultation. See inclusion/exclusion criteria.~Intervention: Dental cavity evaluation Intervention: Saliva sampling Intervention: Plaque sampling"
89389224|NCT02801396|Active Comparator|Group Sequence A, B, C|Subjects will wear Test 1, Test 2, and Control contact lenses in order according to the randomization sequence assigned for approximately 30-60 minutes each, with a 5-minute wash-out period between lenses.
89389225|NCT02801396|Active Comparator|Group Sequence B, C, A|Subjects will wear Test 1, Test 2, and Control contact lenses in order according to the randomization sequence assigned for approximately 30-60 minutes each, with a 5-minute wash-out period between lenses.
89389226|NCT02801396|Active Comparator|Group Sequence C, A, B|Subjects will wear Test 1, Test 2, and Control contact lenses in order according to the randomization sequence assigned for approximately 30-60 minutes each, with a 5-minute wash-out period between lenses.
89389227|NCT02801396|Active Comparator|Group Sequence C, B, A|Subjects will wear Test 1, Test 2, and Control contact lenses in order according to the randomization sequence assigned for approximately 30-60 minutes each, with a 5-minute wash-out period between lenses.
89389228|NCT02801396|Active Comparator|Group Sequence A, C, B|Subjects will wear Test 1, Test 2, and Control contact lenses in order according to the randomization sequence assigned for approximately 30-60 minutes each, with a 5-minute wash-out period between lenses.
89389229|NCT02801396|Active Comparator|Group Sequence B, A, C|Subjects will wear Test 1, Test 2, and Control contact lenses in order according to the randomization sequence assigned for approximately 30-60 minutes each, with a 5-minute wash-out period between lenses.
89389230|NCT02800928|Experimental|CERC-501|Administered orally once daily, 10mg daily, 8 days
89389231|NCT02800928|Placebo Comparator|Placebo|Administered orally daily, 8 days
89389232|NCT02056418|Experimental|enteral nutrition|The patients receive treatment of enteral nutrition only.
89389233|NCT02056418|Experimental|Corticosteroid|The patients receive treatment of corticosteroid only.
89389234|NCT02056418|No Intervention|Healthy control|healthy people applied with normal diet.
89389235|NCT02056496|Experimental|Pomegranate extract|The same group will consume the two types of pomegranate extract (crossover study).
89389236|NCT02056574|Experimental|NA-1|20 amino acid peptide that consists of a 9 amino acid domain that inhibits PSD-95 and an 11 amino acid domain that enables the peptide to cross the blood-brain barrier. Single intravenous dose of 2.6 mg/kg of NA-1 administered as a 10-minute infusion.
89389237|NCT02056574|Placebo Comparator|Placebo|Single intravenous dose of 2.6 mg/kg of placebo administered as a 10-minute infusion.
89389238|NCT02058680|Experimental|PSA/IL-2/GM-CSF vaccine|"In Stage 1 (Phase 1A), patients receive intradermal injections of PSA/IL-2/GM-CSF vaccine at Weeks 1, 2, 3, 7, 11, and 15.~In Stage 2 (Phase 1B), patients will receive the same course of vaccine (induction as in Phase 1A; this will be followed in eligible patients by maintenance vaccinations alternating between IL-2 alone at Weeks 23, 31, and 39) and complete vaccine (PSA/IL-2/GM-CSF) at Weeks 27, 35, and 43."
89389239|NCT02058758||Healthy Volunteers|Device: Magnetic Resonance Imaging
89389240|NCT02058758||Breast Cancer Patients|Device: Magnetic Resonance Imaging
89389241|NCT02058914|Experimental|high fructose sweetened beverage|710 ml per day of a HF-sweetened beverage (sweetened with 50 g fructose and 15 g glucose)
89389242|NCT02058914|Active Comparator|High Glucose sweetened beverage|HG-sweetened beverage (sweetened with 50 g glucose and 15 g fructose)
89389243|NCT02055014|Active Comparator|Liraglutide alone|Liraglutide 1.8mg once daily subcutaneous injection
89389244|NCT02055014|Experimental|Endobarrier alone|Duodenal-jejunal bypass liner (Endobarrier) device implantation without additional GLP-1RA therapy
89389245|NCT02055014|Experimental|Endobarrier and Liraglutide|Duodenal-jejunal bypass liner (Endobarrier) device with combined liraglutide 1.2mg once daily subcutaneous injection
89389246|NCT02055092||YOD-FTD|Young onset dementia - frontotemporal dementia, 38 persons with their respective family members.
89389247|NCT02055092||YOD-AD|Young onset dementia - Alzheimer's disease, 50 persons with their respective family members.
89389248|NCT02055092||LOD|Late onset dementia >= 70 years of age; Control group of 100 persons with dementia (mostly AD and AD/vascular) and their respective family members. Data already collected in a previous study.
89389249|NCT03148691|Placebo Comparator|Vehicle|Vehicle Topical Solution
89185775|NCT02593448|Active Comparator|Propofol|"General anaesthesia with Propofol use. Maintenance of anaesthesia in group P will be accomplished using continuous intravenous infusion of propofol 2-4 mg kg/h.~Propofol infusion rate will be adjusted according to patient's haemodynamic parameters and the level of anaesthesia, as assessed with Bispectral Index (BIS), with a target range of 40-60.~Intervention: NIRS during VOT on several timepoints."
89389250|NCT03148691|Active Comparator|A-101 Low Dose|A-101 Low Dose Topical Solution
89389251|NCT03148691|Active Comparator|A-101 High Dose|A-101 High DoseTopical Solution
89389252|NCT02059226|Experimental|Internet-based CBT|Internet-based cognitive behavioural therapy
89389253|NCT02059226|Active Comparator|Internet-based resource page|Static webpage
89389254|NCT02059304|Other|Preterm Delivery|Preterm Delivery: Births before the completion of 37 weeks' of gestation.
89389255|NCT02059304|Other|Term Delivery|Term Delivery: Births after the completion of 37 weeks' of gestation.
89389256|NCT03148067||Patients|Patients with closed or open diaphyseal femoral and tibial fractures treated through intramedullary nailing for fracture fixation
89389257|NCT02059382|Active Comparator|Control|ChiRunning training Weekly training log Blinded accelerometer
89389258|NCT02059382|Experimental|Technology support for behavior change|ChiRunning training unblinded accelerometer tracking structured exercise using mobile app participation in online social network participation in study website
88864857|NCT04718181|Experimental|Part 1|"Cohort A+B: participants will receive, in a five-period crossover way, a single oral dose of risdiplam oral solution 5 mg in fasted state and thereafter risdiplam/F21 or F22 dispersible tablet 5 mg as tablet in fasted and fed states; tablet dispersed in water in fasted and fed states, with a 14-day wash-out period in between the single-dose administrations.~Cohort C+D: participants will receive, in a two-period fixed sequence design, a single dose of risdiplam/F21 or F22 dispersible tablet 5 mg in fasted state and omeprazole 40 mg once daily for 7 days + a single dose of risdiplam/F21 or F22 dispersible tablet 5 mg in fasted state, on the 7th day of omeprazole. There will be a 14-day wash-out between the two treatment periods.~Cohort E: participants will receive, in a two-period crossover design, a single oral dose of risdiplam oral solution 5 mg in fasted and fed states, with a 14-day wash-out period in between the single-dose administrations."
88864858|NCT04718181|Experimental|Part 2 (optional)|"Group 1: participants will receive, in four-period crossover design, a single oral dose of risdiplam oral solution 5 mg in both fed and fasted states and the selected dispersible tablet (F21) as swallowed tablet in both fed and fasted states.~Group 2: participants will receive, in four-period crossover design, a single oral dose of risdiplam oral solution 5 mg in both fed and fasted states and the selected dispersible tablet (F21) as tablet dispersed in water in both fed and fasted states."
88864859|NCT04718181|Experimental|Part 3 (optional)|"Group 1: participants will receive, in four-period crossover design, a single oral dose of risdiplam oral solution 5 mg in both fed and fasted states and the selected dispersible tablet (F22) as swallowed tablet in both fed and fasted states.~Group 2: participants will receive, in four-period crossover design, a single oral dose of risdiplam oral solution 5 mg in both fed and fasted states and the selected dispersible tablet (F22) as tablet dispersed in water in both fed and fasted states."
89003478|NCT05197556|Experimental|HSG4112 600 mg Multiple Dose|Multiple oral dosing of HSG4112 600 mg for 12 weeks
89389259|NCT02055170|Experimental|finasteride|finasteride 5mg po od from study entry to date of surgery
89389260|NCT04552925|Active Comparator|Exercise Group|Exercise group will receive ROM exercises, stretching and anterior deltoid re-education exercises described by Levy et al. Subjects will treated at the clinic three times per week for 6 weeks (18 sessions).
89389261|NCT04552925|Experimental|EMG-BF Group|EMG-BF group will receive the same exercises as with the other group, but deltoid re-education exercises were performed under the guidance of EMG-BF device. All subjects will treated at the clinic three times per week for 6 weeks (18 sessions).
89389262|NCT02055326|Experimental|Yoga|One-hour sessions of twice weekly yoga for 8 weeks.
89389263|NCT02055326|Active Comparator|Health & Wellness|8 week program of health & wellness classes, materials and handouts. Topics included healthy eating, cancer prevention and cardiovascular disease prevention.
89389264|NCT03561116|Experimental|XAN|XAN (1 sachet of 12 mg/day)
89389265|NCT03561116|Placebo Comparator|Placebo|Placebo (1 sachet with excipient)
89389266|NCT04490993|Experimental|APL-1202 treatment|
89389267|NCT04490993|Placebo Comparator|Placebo|
89389268|NCT02055482|Experimental|BAY85-3934|
89389269|NCT02055482|Active Comparator|Darbepoetin|
89389270|NCT04465565|Experimental|Intravenous fluid administration|This arm will include 20 children who received Testoviron or Estrofem prior to the the stimulation test and 40 children who did not receive preparation prior to the stimulation test. Participants in this arm will be treated with I. V of 9%NORMAL SALINE (0. 20cc /Kg) administrated over 60 minutes. The fluids treatment will be initiated 90 minutes after the stimulation test will begin
89389271|NCT04465565|No Intervention|Control Group|This arm will include 20 children who received Testoviron or Estrofem prior to the the stimulation test and 40 children who did not receive preparation prior to the stimulation test. Participants in this arm will not receive fluids intravenously during the stimulation test, unless it will be required due to safety reasons
89389272|NCT04395755||Infertile women who had the IVF treatment postponed or delayed|
89389273|NCT04743947||Patients with kidney failure receiving dialysis|Analysis of data received from clinical practice about the SARS-CoV-2 vaccination response in dialysis patients (hemodialysis or peritoneal dialysis).
89389274|NCT04743947||Kidney transplant patients|Analysis of data received from clinical practice about the SARS-CoV-2 vaccination response in kidney transplant patients.
89389275|NCT04743947||age-matched controls in non-dialysis, non-kidney transplant patients|Historical cohort of aged matched non-dialysis and non-kidney transplanted patients who received a SARS-CoV-2 vaccination.
89389276|NCT02059460|Experimental|Terlipressin group|Terlipressin group, Terlipressin (Glypressin®, Rentschler biotechnology Gmbh, Erwin, Germany) will be started by continuous infusion at a dose of 1-4 µg/kg/h till day 4 postoperatively
89389277|NCT02059460|Placebo Comparator|Control group|
89389278|NCT02055716|Placebo Comparator|alpha-cyclodextrin|A placebo comparator composed of the same acid resistant HPMC capsules filled with 300mg of alpha cyclodextrin
89389279|NCT02055716|Experimental|Sulforadex|100mg or 300mg size 00 acid resistant HPMC capsules
89389280|NCT04739735|Experimental|Computer Controlled -Intraligamentary Anaesthesia (CC-ILA)|"CC-ILA will be administered using the Wand-STA system according to the manufacturer instructions, It works with standardised 1.8 mL local anaesthetic carpules. The distalingual and mesiolingual line angles are the most effective for multi-rooted mandibular teeth.~Articaine hydrochloride 4% with 1:100,000 epinephrine will be injected for each root as shown on a special indicator.The dentist will wait 5 seconds before needle withdrawal. Same steps will be repeated at the mesiolingual line angle."
88864860|NCT04698681||Biomarker Screening|Patients with stage IV nonsquamous NSCLC not previously treated with systemic therapy for metastatic disease and who meet all of study inclusion criteria and none of the exclusion criteria.
88864861|NCT04656301|Experimental|Psilocybin|A single dose of Psilocybin 25mg p.o.
89389281|NCT04739735|Active Comparator|Conventional Injection of Inferior Alveolar Nerve Block|"In the control group, a standard technique for the Inferior Alveolar Nerve Block (IANB) will be used supplemented with long buccal infiltration for the buccal gingiva.~A 27-gauge disposable dental needle will be used to inject Articaine hydrochloride 4% with 1:100,000 epinephrine. The needle will be directed between the two primary molars on the opposite side of the arch, entering the tissues at the level of the occlusal plane or slightly lower until bony resistance is met.~Approximately 1.0 mL of LA will be delivered near the inferior alveolar nerve. Two-thirds the needle length should be inserted. The needle is withdrawn, then 0.5 ml as a long buccal infiltration distal to the second primary molar is administered."
89389282|NCT02059538|Other|Group 1|Metabolic syndrome
89389283|NCT02059538|Other|Group 2|Severly obese patients
89389284|NCT02059538|Other|Group 3|Type-2 diabetics patients
89389285|NCT02059538|Other|Group 4|Patients with first recent (< 2 weeks) acute coronary syndrome (ACS)
89389286|NCT02059538|Other|Group 5|Patients with stable chronic coronary artery disease without heart failure
89389287|NCT02059538|Other|Group 6|Patients with ischemic systolic heart failure (CHF)
89389288|NCT02059538|Other|Group 7|Patients with non-ischemic chronic heart failure
89389289|NCT02059538|Other|Group 8|Healthy volunteers
89389290|NCT01341899|Experimental|stem cell transplantation|
89389291|NCT02059616|Experimental|AML 5mg|Amlodipine 5 mg, once a day for 8 weeks
88864862|NCT04651153|Experimental|UCB7853|Part 1: Single intravenous infusion of UCB7853 Part 2: Multiple intravenous infusions of UCB7853 at pre-specified time-points
88864863|NCT04651153|Placebo Comparator|Placebo|Part 1: Single intravenous infusion of Placebo Part 2: Multiple intravenous infusions of Placebo at pre-specified time-points
88864864|NCT04644692||Case group: patients with heart failure with preserved ejection fraction|
88864865|NCT04644692||Control Group:Never diagnosed with either preserved or altered ejection fraction heart failure.|Non dyspnoeic patients with no history of Heart failure.
88864866|NCT04598711|Experimental|Remote Limb Ischemic Conditioning (RLIC)|"RLIC is achieved via blood pressure cuff inflation to at least 20 mmHg above systolic blood pressure to 200 mmHg on the more involved thigh. RLIC involves 5 cycles of 5 minutes blood pressure cuff inflation followed by alternating 5 minutes of cuff deflation and requires 45 minutes. RLIC is performed on visits 1-14.~Interventions:~Behavioral: RLIC~Behavioral: Muscle power training~Behavioral: Balance training~Behavioral: Treadmill training"
88864867|NCT04598711|Sham Comparator|Sham Conditioning|"Sham conditioning is achieved via blood pressure cuff inflation to 25 mmHg on the more involved thigh. Sham involves 5 cycles of 5 minutes blood pressure cuff inflation followed by alternating 5 minutes of cuff deflation and requires 45 minutes. Sham conditioning is performed on visits 1-14.~Interventions:~Behavioral: RLIC~Behavioral: Muscle power training~Behavioral: Balance training~Behavioral: Treadmill training"
88864868|NCT04597047|Other|All Patients:|Capillary and Venous Blood Collections
89003479|NCT05197556|Placebo Comparator|Placebo|Multiple oral dosing of placebo
89389292|NCT02059616|Experimental|AML 10mg|Amlodipine 10 mg, once a day for 8 weeks
89389293|NCT02059616|Experimental|CC 8mg|Candesartan Cilexetil 8 mg, once a day for 8 weeks
89389294|NCT02059616|Experimental|CC 16mg|Candesartan Cilexetil 16 mg, once a day for 8 weeks
89389295|NCT02059616|Experimental|AML 5mg/CC 8mg|Amlodipine 5 mg and Candesartan 8 mg, once a day for 8 weeks
89389296|NCT02059616|Experimental|AML 5mg/CC16mg|Amlodipine 5 mg and Candesartan Cilexetil 16 mg, once a day for 8 weeks
89389297|NCT02059616|Experimental|AML 10mg/CC 8mg|Amlodipine 10 mg and Candesartan Cilexetil 8 mg, once a day for 8 weeks
89389298|NCT02059616|Experimental|AML 10mg/CC 16mg|Amlodipine 10 mg and Candesartan Cilexetil 16 mg, once a day for 8 weeks
89389299|NCT04724681|Active Comparator|Monitoring arm|Patients in this arm will have their vital signs monitored with continuous wireless devices and patients in this arm will be monitored with standard Early Warning Score
89389300|NCT04724681|No Intervention|standard Early Warning Score arm|Patients in this arm will be monitored with standard Early Warning Score
89389301|NCT02055794|Active Comparator|Suturing of the perineal skin|Suturing of the perineal skin after deep vaginal and perineal tissues are closed using a continuous 3-0 Vicryl suture.
89389302|NCT02055794|Active Comparator|No suturing of the perineal skin|No suturing of the perineal skin after deep vaginal and perineal tissues are closed using a continuous 3-0 Vicryl suture.
89389303|NCT02055794|Active Comparator|Closing perineal skin with surgical glue|Closure of the perineal skin with n-Butyl 2-cyanoacrylate (Indermil®) surgical glue after deep vaginal and perineal tissues are closed using a continuous 3-0 Vicryl suture.
89389304|NCT01343849||Suspected Breast cancer subjects|
89389305|NCT02059694|Experimental|Hyaluronidase|"Dilutions (Blocks):~0.5 mL of lidocaine 2% with epinephrine 1:100,000 and 0.5 mL of marcaine 0.75% and 1 mL (150 U) of rHuPH20 for a total of 75 U/ml"
89389306|NCT02059694|Other|Comparitor|2 mL of lidocaine 2% with epinephrine 1:100,000 without rHuPH20
88864869|NCT04573504|Experimental|Antibiotic Group|The antibiotic regimen chosen is based on the Royal College of Obstetricians and Gynecologists' recommendations (Augmentin and Flagyl or Clindamycin and Flagyl if they are allergic to Penicillin). The dosage for the antibiotics are the following: Flagyl 500mg po BID (twice a day) X 5 days, Clindamycin 400 mg po TID (three times a day) X 5 days, Augmentin 875mg po BID X 5 days.
89389307|NCT03146741|Experimental|Zepatier (grazoprevir 100mg and elbasvir 50 mg)|
89389308|NCT03561038|Active Comparator|Franseen Needle|2 strokes within the mass with Franseen Needle, and then 2 strokes with the Fork-tip Needle
89389309|NCT03561038|Active Comparator|Fork-tip Needle|2 strokes within the mass with Fork-Tip needle, and then 2 strokes with the Franseen Needle
89389310|NCT04695431||Patients from the BLU-285-2101 and BLU-285-2202 studies|Patients with advanced systemic mastocytosis who received treatment with avapritinib as part of the BLU-285-2101 and BLU-285-2202 studies
89389311|NCT04695431||External Control Group|Patients with advanced systemic mastocytosis that received best available therapy
89389312|NCT02056730|Experimental|Regpara|calcium sensing receptor agonist
89389313|NCT05162573|Experimental|EBRT + 3 GBq Lu-PSMA|
89389314|NCT05162573|Experimental|EBRT + 6 GBq Lu-PSMA|
89389315|NCT05162573|Experimental|EBRT + 9 GBq Lu-PSMA|
88864870|NCT04573504|Placebo Comparator|Placebo Group|Women randomized not to receive antibiotics will be given placebo tablets postpartum, so they will all have an identical experience to the women in the experimental (antibiotic) group.
88864871|NCT04545385|Experimental|TEV-48574|Participants will receive the investigational medicinal product (IMP) loading doses on the day of randomization and the subsequent corresponding IMP maintenance doses every 2 weeks for a total of 8 doses (1 loading dose and 7 maintenance doses).
88864872|NCT04545385|Placebo Comparator|Placebo|Participants will receive placebo matching to TEV-48574 SC every 2 weeks for a total of 8 doses.
88864873|NCT04542421|Experimental|Lung ultrasound Implementation arm|Hospitalists undergo training to use lung ultrasound in their patients hospitalized with COVID
89389316|NCT02056808|Experimental|SMT C1100|Patients will be studied in 3 groups (Groups A to C), with each group consisting of 4 patients aged between 5 to 11 years. It is planned that doses for Groups A to C will be administered in an escalating manner after safety review for each dose group.
89389317|NCT02055950||Kidney perfused by pulsatile machine|
89389318|NCT02055950||Kidney stored in refrigerated solution|
89389319|NCT01337219|Other|Arm A|experimental treatment (Nebcinal/Aeroneb Idehaler pocket) - 6day-wash out period - standard treatment (Tobi/Pari LC Plus)
89389320|NCT01337219|Other|Arm B|standard treatment (Tobi/Pari LC Plus) - 6day-wash out period - experimental treatment (Nebcinal/Aeroneb Idehaler)
89389321|NCT03560804|Active Comparator|Olmesartan|ARB administration (OLMESARTAN) at a starting dose and titrating at 15 weeks according to reach blood pressure target
88864874|NCT04521335|Experimental|Treatment: all patients|disulfiram and copper gluconate in combination
88864875|NCT04515615|Experimental|Camrelizumab and chemotherapy|Participants receive camrelizumab 200 mg intravenously (IV) on the first day (q3w), then oxaliplatin 130 mg/m^2, IV on the first day (q3w), and tegafur gimeracil oteracil potassium capsule 80 mg/m^2 twice daily (BID) by continuous oral administration for 14 days, followed by a recovery period of 7 days. Three weeks as a course of treatment, a total of 8 courses.
89389322|NCT03560804|Active Comparator|Chlorthalidone|Diuretic administration (chlorthalidone) at a starting dose and titrating at 15 weeks according to reach blood pressure target
89389323|NCT02056886|Experimental|OSNA|"Intra operative sentinel lymph-node sampling. In this experimental arm, the molecular biology technique is only used through the OSNA technique (One Step Nuclear Acid analysis), and no other classical pathology's diagnosis method such as formalin fixation, then parraffin embedding before slices cutting, hematoxylin-eosin-safran staining or any other immunohistochemical stainings.~According to the results of the staging procedure, the treatment in this arm is decided in conformity with local and national guidelines in breast cancer treatments.~SLN detection +/- complementary axillary lymphadenectomy is immediately decided if a tumor invasion is detected within the sentinel LN material."
89389324|NCT02056886|Other|PATHOLOGICAL ANALYSIS|"No intra operative examination is performed in this arm, but the final pathological examination:~In this arm, the classical pathology's diagnosis method is starting with a formalin fixation of suspected invaded lymph-nodes sampling at least 24Hrs; then parraffin embedding before slices cutting; then hematoxylin-eosin-safran staining or any other immunohistochemical stainings.~According to the results of the staging procedure, the treatment in this arm is decided in conformity with local and national updated guidelines in breast cancer treatments.~SLN detection +/- complementary axillary lymphadenectomy: is decided in a second surgical step when the pathologic analysis has detected a tumor invasion"
88864876|NCT04508582||Women with Pre-eclampsia|De novo hypertension after 20 weeks gestation with evidence of end organ dysfunction.
88864877|NCT04508582||Women with Pregnancy-induced hypertension|De novo hypertension after 20 weeks gestation without evidence of end organ dysfunction.
88864878|NCT04508582||Healthy pregnant controls|Low risk women at booking as per NICE guidelines without any medical condition throughout pregnancy
89185776|NCT02593448|Experimental|Sevoflurane|"General anaesthesia with sevoflurane use. Sevoflurane concentration in exhaled gas will be adjusted according to patient's haemodynamic parameters and the level of anaesthesia, as assessed with BIS, with a target range of 40-60.~Intervention: NIRS during VOT on several timepoints."
89185777|NCT00731666|Other|Titan® IPP|Subjects implanted with Titan® IPP
89389325|NCT02056886|Other|EXTEMPORANEOUS|"Intra-operative pathological frozen sections of sentinel LN samples are coloured and examined immediately by the pathologist, allowing an immediate result at the disposal of the surgeon who can decide to complete by an axillary LN dissection or not.~Then the remaining material will be prepared similarly as in the pathological classical method (Arm B), ie formalin fixation, then parraffin embedding, then slices cutting, then HES staining or ImmunoHistochemistry for a final diagnosis.~SLN detection +/- complementary axillary lymphadenectomy: is decided immediately when the tumor invasion is detected in the sentinel LN material."
89389326|NCT03150719|Placebo Comparator|Placebo|Participants received placebo matched to TEZ/IVA fixed-dose combination tablet orally once daily in the morning followed by placebo matched to IVA tablet orally once daily in the evening for 56 days.
89389327|NCT03150719|Experimental|TEZ/IVA|Participants received TEZ 100 milligram (mg)/IVA 150 mg fixed-dose combination tablet orally once daily in the morning and IVA 150 mg tablet orally once daily in the evening for 56 days.
89185778|NCT03923400||JI-GIST|The series comprises 77 patients, of which 29 (37.7%) were located in the jejunum or ileum (JI-GIST).
88864881|NCT04454645|Experimental|Modified ABC|12-session home visiting intervention designed to increase parental sensitivity and nurturance and decrease parental frightening behavior.
88864882|NCT04454645|Active Comparator|Modified DEF|12-session home visiting intervention designed to increase parental playful interactions that stimulate infant cognitive and motor development
89185779|NCT03923400||G-GIST|The series comprises 77 patients, of which 48 (62.3%) were located in the stomach (G-GIST).
89185780|NCT05015166|Experimental|Internet delivered self-help program with therapist support|"The intervention consists of 8 therapist-supported self-help modules delivered over 8 weeks on a secure online platform. Modules consist of texts and video followed by exercises which they send to their therapist and receive feedback within a few days.~The treatment is based on principles from affect-focused psychodynamic psychotherapy."
89185781|NCT05015166|Active Comparator|Internet delivered self-help program without therapist support|The intervention consists of 8 self-help modules delivered over 8 weeks on a secure online platform. Modules consist of texts and video followed by exercises which the participants are encouraged to try. The treatment is based on principles from affect-focused psychodynamic psychotherapy.
89185782|NCT05015166|No Intervention|Waitlist|Participants will receive no intervention for 8 weeks.
89185783|NCT02592746|Experimental|Palbociclib + Exemestane + GnRH agonist|
89185784|NCT02592746|Active Comparator|Capecitabine|
88864883|NCT04438161|Active Comparator|Low Risk|"Low risk natural history study (n=250*)~*Participants will be randomized 2:1 PERCCS:Control, and the randomization will be within successive sets of three families who fall in either high risk counts (n=105) families for child maltreatment or low risk counts (n=45) families."
88864884|NCT04438161|Experimental|High Risk|"High risk families in prospective longitudinal study of newborns (n=150*).~*Participants will be randomized 2:1 PERCCS:Control, and the randomization will be within successive sets of three families who fall in either high risk counts (n=105) families for child maltreatment or low risk counts (n=45) families.~Participants in this arm will be randomized to:~PERCCS (see attached figure and table for details)~Care as Usual"
88864885|NCT04406584|Placebo Comparator|Saline|Injection of 1cc saline into olfactory cleft x4
89185785|NCT02833428|Experimental|patients with acute spinal cord injury|The study will be performed on patients with acute spinal cord injury between the cord next to the C2 vertebra and marrow next to the T12 vertebra. This is usually hospitalized patients in an emergency situation, brought by EMS (emergency medical services) and taken care of immediately in the recovery room by intensivists. Patients who accepted to participate to this study will got the installation bedside biomedical equipment for the project (Eclipse Nim, Medtronic®). The aim of this work is to analyze using an artificial intelligence engine (IA, Biomedical equipment (Eclipse Nim, Medtronic®)) the influence of the physiopathological environment (set of parametric data monitoring, imaging, biology etc.) of the traumatized spinal cord on spinal pain.
89185786|NCT00731120|Placebo Comparator|Placebo|Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks.
89185787|NCT00731120|Experimental|Vortioxetine 2.5 mg|Vortioxetine 2.5 mg encapsulated tablets, orally, once daily for up to 8 weeks.
89185788|NCT00731120|Experimental|Vortioxetine 10 mg|Vortioxetine 10 mg encapsulated tablets, orally, once daily for up to 8 weeks.
89185789|NCT02580006|Experimental|EPORON→EPREX|"EPORON PFS(PreFilled Syringe) 4000 IU/0.4 mL(Erythropoietin alfa 4000 IU) will be administered subcutaneously after 10 hours fasting on Day 1.~And wash out for 4 weeks. EPREX INJ.(Injection) 4000 IU(Erythropoietin alfa 4000 IU) will be administered subcutaneously after 10 hours fasting on Day 29."
89185790|NCT02580006|Experimental|EPREX→EPORON|"EPREX INJ. 4000 IU(Erythropoietin alfa 4000 IU) will be administered subcutaneously after 10 hours fasting on Day 1.~And wash out for 4 weeks. EPORON PFS 4000 IU/0.4 mL(Erythropoietin alfa 4000 IU) will be administered subcutaneously after 10 hours fasting on Day 29."
89185791|NCT00731042|Experimental|Avagard|3M Avagard Surgical and healthcare Personnel Hand Antiseptic with Moisturizers
89185792|NCT00731042|Active Comparator|Purell|Purell Surgical Scrub with Moisturizers
89185793|NCT02787642|Experimental|Olaparib in association with concomitant radiotherapy|Olaparib will be administered per os bi-daily, as appropriate assigned dose level, during 7.5 weeks (D1 to D52). Olaparib should be started one week before the start of radiotherapy and will be continued until the last day of radiotherapy. Beyond this period, Olaparib could be continued at the investigator's discretion and after sponsor authorization, until progression. Radiotherapy consists of fractionated focal irradiation at a dose of 1.8 Grays (Gy) per fraction given once daily five days per week (Monday through Friday) over a period of 6.5 weeks, for a total dose of 59.4 Gy. Radiotherapy starts at D8.
89389328|NCT02056964||Post-HEART Pathway Implementation|Data will be collected on patients presenting to the Emergency Department (ED) with chest pain after implementation of the HEART Pathway decision aid.
89389329|NCT02056964||Pre-HEART Pathway Implementation|Data will be collected on patients presenting to the Emergency Department (ED) with chest pain prior to Implementation of the HEART Pathway decision aid.
89389330|NCT02038400|Experimental|group A|KINETUBE medical Device
89389331|NCT02038400|Active Comparator|group B|insertion of tympanic ventilation tubes (tympanostomy)
89389332|NCT01343927|Active Comparator|Yoga|12 weeks of weekly yoga classes plus 40 weeks of either drop-in classes or home practice.
88864886|NCT04406584|Experimental|Platelet Rich Plasma|Injection of 1cc patient's own platelet rich plasma (PRP) into olfactory cleft x4
89185794|NCT02740218||Psoriasis patients|Single cohort of psoriasis patients treated with OTEZLA (apremilast)
89185795|NCT02594774|Experimental|Osteopathic treatment|Manipulative osteopathy (and standard medical treatment)
89185796|NCT02594774|No Intervention|Standard medical treatment|Standard medical treatment
89185797|NCT02580162|Active Comparator|Pro.Treatment, Not a Peer|Families receive FBT for Pediatric Weight Management by Professionals interventionists and parents are NOT Peer Interventionists
89185798|NCT02580162|Experimental|Pro.Treatment, Peer|Families receive FBT for Pediatric Weight Management by Professionals and parents ARE Peer Interventionists
89185799|NCT02580162|Experimental|Peer Treatment, Not a Peer|Families receive FBT for Pediatric Weight Management by Peers and parents are NOT Peer Interventionists
89389333|NCT01343927|Active Comparator|Physical Therapy|15 individual physical therapy treatment sessions over 12 weeks plus 40 weeks with either 5 booster sessions or home practice.
89185800|NCT02580162|Experimental|Peer Treatment, Peer|Families receive FBT for Pediatric Weight Management by Peers and parents ARE Peer Interventionists
89185801|NCT04075188|Experimental|Combined therapy|Treatment consisting in photodynamic therapy (Verteporfin, 6 mg/m2 × Body Surface Area (BSA) = Total Drug Dose; Total Drug Dose ÷ 2.0 mg/mL = Volume of Reconstituted Verteporfin; 30 mL - Volume of Reconstituted Verteporfin = Volume of 5% dextrose in water. Light dose is 50 J/cm2 administered at an intensity of 600 mW/cm2. This dose is administered over 83 seconds) and 3 intravitreal therapy of Aflibercept (2 mg/0,05 ml)monthly, the first of which performed within 7 days from photodynamic therapy.
89185802|NCT00726986|Experimental|Sorafenib, Cisplatin, and Etoposide|
89185803|NCT02594852|Experimental|Intervention (+ laser)|+ laser therapy
89185804|NCT02594852|Placebo Comparator|Non-intervention (- laser)|- laser
89185805|NCT02594540|Experimental|Feet Mechanical Stimulation|The feet mechanical stimulation will be given to all participants using GONDOLA equipment (Ecker Technologies Sagl, Switzerland). Intervention: Device: Foot Mechanical Stimulation (GONDOLA)
89185806|NCT02594540|Sham Comparator|Sham Feet Mechanical Stimulation|The sham stimulation will be given to all participants using GONDOLA equipment (Ecker Technologies Sagl, Switzerland). Intervention: Device: Foot Mechanical Stimulation (GONDOLA)
89185807|NCT02594306|Experimental|Non operation|Recording the event related potential of drug addicts when they receive the stimulus of Emotional pictures stimulation system.
89185808|NCT02594306|Experimental|Deep brain stimulation|Recording the event related potential after the deep brain stimulation operation.Recording the local field potential of drug addiction people when we conduct a test of adjacent contact stimulation in the deep brain stimulation operation. Recording the waveform of bilateral NAc/ALIC after puting the microelectrodes into bilateral nucleus accumbens and anterior limb of the internal capsule
89185809|NCT02594306|Active Comparator|Standard Control|Recording the event related potential of normal people when they receive the stimulus of emotional pictures stimulation system.
89185810|NCT03334266|Experimental|Family Spirit Nurture (FSN)|The intervention group (n=169) will receive the Family Spirit Nurture (FSN) + Optimized Standard Care (OSC). The FSN home-visiting module consists of 36, 60-minute lessons delivered by trained local Family Health Coaches (FHCs), from 28 weeks gestation to 18 months postpartum. Lessons focus on three key content domains: 1) promotion of optimal breastfeeding, complementary and responsive feeding across early childhood; 2) promotion of healthy infant/toddler diet and physical activity, as well as reduced screen time and sedentary lifestyle; and 3) promotion of maternal psychosocial well-being, optimization of healthy food/beverage availability and identification/creation of safe play spaces in the home environment.
89185811|NCT03334266|Other|Control Program|The control group will receive Injury Prevention Education (IPE) + Optimized Standard Care (OSC). The IPE home-visiting module consists of 8 30-minute lessons delivered by trained local Family Health Liaisons (FHL), from 28 weeks gestation to 18 months postpartum. The lessons will be delivered at the following assessment time points: 36 weeks gestation, 2 weeks, 2 months, 4 months, 6 months, 9 months, 12 months, and 18 months postpartum. Injury prevention lessons focus on injury prevention topics relevant to the participating communities but that will not overlap in anyway with FSN content, including: motor vehicle safety for mothers and children; preventing scald burns; fire safety; child-proofing a home; preventing falls; preventing poisonings; and preventing animal bites.
89185812|NCT00696657|Experimental|A|
89185813|NCT00696657|Experimental|B|
89185814|NCT00696657|Experimental|C|
89185815|NCT00696657|Experimental|D|
89185816|NCT00696657|Experimental|E|
89185817|NCT00696657|Experimental|F|
89185818|NCT00696657|Placebo Comparator|G1|
89185819|NCT00696657|Placebo Comparator|G2|
89185820|NCT00696657|Placebo Comparator|G3|
89185821|NCT00696657|Placebo Comparator|G4|
89185822|NCT00696657|Placebo Comparator|G5|
89185823|NCT00696657|Placebo Comparator|G6|
89185824|NCT00696657|Experimental|H|
89185825|NCT00696657|Experimental|I|
89185826|NCT00730886|Experimental|1|Non-invasive procedure for fertility enhancement (i.e., ExAblate treatment)
89185827|NCT00730886|Active Comparator|2|Invasive surgical procedure for fertility enhancement (i.e., myomectomy)
89185828|NCT01877772|Active Comparator|Bone Trephination|For the bone trephination, the wire will be advanced into the insertion site through the cortex and into the metaphyseal bone of proximal humerus.
89003480|NCT05195970|Experimental|Walnut Consumption|Following enrollment, participants will start a 7-day wash-out period where they will be asked to avoid foods and beverages high in ellagitannins. These include pomegranates, hazelnuts, pistachios, walnuts (besides the samples given by the researchers), strawberries, raspberries, blackberries, oak-aged wines and spirits; a full list of foods and beverages to avoid will be provided. Then, participants will consume 2 ounces of walnuts daily with their usual diet while continuing to avoid ellagitannins for 21 days prior to their routine colonoscopy.
89003481|NCT05194189|Experimental|Megadose vitamin C group|12 g vitamin C (48 ml) will intravenously injected by a infusion pump every 12 h for 4 days or until ICU discharge
89003482|NCT05194189|Placebo Comparator|Placebo group|5% glucose solution 48 ml every 12 h for 4 days or until ICU discharge.
89389334|NCT01343927|Active Comparator|Education|"The Back Pain Helpbook which gives exercises and tips for self-care pain management."
89185829|NCT01877772|Active Comparator|Control|The control group will undergo standard rotator cuff repair.
89185830|NCT02592590|Experimental|Group A|
89389335|NCT02057120|Active Comparator|Grupo A (Kinesio Taping)|Will be held the application of Kinesio Taping (Tex Gold) in the region of the rectus femoris dominant lower limb by a physical therapist trained in the technique (KT1 KT2 and) and with experience in this type of application to be designed without knowing in which group fits this patient. In the sequence, the athlete will be oriented to remain at rest for 30 min to get a better grip on the tape and one of the first tests and rest, only after this period will conduct a new evaluation of jump tests (single leg Hop test and Triple Hop Test) and, finally, a new test of strength in the isokinetic dinamomêtro in conjunction with the electromyographic assessment.
89185831|NCT02592590|Experimental|Group B|
89185832|NCT02592590|Experimental|Group C|
89389336|NCT02057120|Placebo Comparator|Placebo Taping|The volunteer will receive a Placebo application tape, being in this case the physical therapist will apply a strip of Kinesio Taping perpendicular to the muscle fibers of the rectus femoris of the dominant member of the individual.
89003483|NCT05186090|Experimental|24-week resistance exercise program|Participants will engage in supervised 24-week resistance exercise program with goal of maintaining 180 minutes of exercise per week.
88864889|NCT04293341|Experimental|Transdiagnostic Behavior Therapy|TBT was developed to address transdiagnostic avoidance via the use of four different types of exposure techniques (situational/in-vivo, physical/interoceptive, thought/imaginal, and [positive] emotional/behavioral activation). From the transdiagnostic avoidance perspective, the four exposure practices are matched to the type(s) of avoidance experienced by patients based upon their cluster of symptoms/disorders.
89003484|NCT05186090|No Intervention|Wait-list control group|Control group will be asked to maintain their usual lifestyle.
89003485|NCT05179421|Experimental|First infusion day low dose oxytocin, Second infusion day high dose oxytocin|On the first oxytocin study day, participants will receive a 10 minute IV infusion of saline then one hour later will receive a 10 minute infusion of oxytocin 1.3 micrograms. On the second study day they will receive a 10 minute IV infusion of oxytocin 0.3 micrograms then one hour later will receive a 10 minute infusion of oxytocin 7 micrograms.
89003486|NCT05179421|Experimental|First infusion day high dose oxytocin, Second infusion day low dose oxytocin|On the first oxytocin study day, participants will receive a 10 minute IV infusion of oxytocin 0.3 micrograms then one hour later will receive a 10 minute infusion of oxytocin 7 micrograms. On the second study day they will receive a 10 minute IV infusion of saline then one hour later will receive a 10 minute infusion of oxytocin 1.3 micrograms.
89185833|NCT02592590|Active Comparator|Group D|
89185834|NCT03301116|Experimental|Healthy Moves|Home care aides (HCAs) will be trained to deliver Healthy Moves for Aging Well (Healthy Moves), a gentle physical activity program, to their clients. On the first home care visit after the training, HCAs will introduce the program, assess their clients' readiness for the activity and have their clients set personally meaningful goals, and teach the three chair-bound moves. Home care clients will be asked to do the three moves every day. HCAs remind clients of their activity as part of their regular home care visits throughout the 4-month intervention period.
89185835|NCT03301116|Active Comparator|Active Mind|Home care aides (HCAs) will be trained to deliver Active Mind for Aging Well (Active Mind), a gentle thinking activity program, to their clients. On the first home care visit after the training, HCAs will introduce the program, assess their clients' readiness for the activity and have their clients set personally meaningful goals, and teach the activity. Home care clients will be asked to do a word search puzzle every day. HCAs remind clients of their activity as part of their regular home care visits throughout the 4-month intervention period.
89185836|NCT00726752|Experimental|Axitinib|
89185837|NCT00917930||physical training|
89185838|NCT02594462|Other|ENG-group|"Twenty-five women with homozygous sickle cell anemia (hemoglobin SS), aged between 18-40 years-old, who had at least one episode of sickle cell pain crisis in the last three months pre- enrollment; whom desire to use etonogestrel-releasing implant contraceptive without contraindications will be invited to inserted etonogestrel implant.~Etonogestrel implant is a single implant progestogen-only, with 4 cm in length and 2 mm diameter containing 68 mg etonogestrel (3- ketodesogestrel), the active metabolite of desogestrel, involved in a ethylene vinyl acetate membrane (Huber, 1998), which is released continuously in bloodstream for three years. It will be inserted subdermal, on the inner face of non-dominant arm between the first and seventh day of the menstrual cycle."
89185839|NCT02664558|Experimental|ubenimex|ubenimex capsules 150 mg three times a day (TID), administered orally for a total of 24 weeks.
89185840|NCT02664558|Placebo Comparator|placebo|placebo capsules TID, administered orally for a total of 24 weeks
89185841|NCT02566707|Experimental|PRADAII regimen|Use of PRADAII regimen during 12 weeks. This regimen consists of atazanavir 400 mg QD, dolutegravir 50 mg QD, lamivudine 300 mg QD.
89185842|NCT04063683|Experimental|Anlotinib with chemotherapy|
89003487|NCT05179395|Experimental|Brasthesis|All five participants will wear Brasthesis for 4-weeks
89389337|NCT02057354|Active Comparator|Healthy Sedentary Young Adults|Participants 18-35 years of age will be randomized to either aerobic or non-aerobic exercise training.
89389338|NCT02057354|Experimental|Healthy Sedentary Older Adults|Participants 55-85 years of age will be randomized to either aerobic or non-aerobic exercise training.
89003488|NCT05170334|Experimental|Binimetinib + Belinostat|Participants will receive binimetinib by mouth two times a day, every day during each cycle. Each cycle will last for 21 days. Participants will receive belinostat by intravenous infusion on days 1 through 5 of each cycle.
89003489|NCT05169788|Experimental|regular TOPS group|Patients are required to perform the regular TOPS program, composed of 10 core sessions and other eventual supplementary sessions. In addition, biweekly Google Meet sessions with a cognitive-behavioral psychotherapist are scheduled, with the aim to monitor patients' activities on problem-solving related to the TOPS program contents and the problem solving process in real life. The program has a specific focus on problem-solving, executive functions, behavioral strategies and social skills.
89185843|NCT02578290|Experimental|Treatment|Clinical Decision Support (CDS)
89185844|NCT02578290|No Intervention|Control|Will not receive Clinical Decision Support (CDS)
89185845|NCT02578524||Accommodating Lenses|Patients who underwent surgery with an accommodating lens implant.
89185846|NCT02578524||Multifocal Lenses|Patients who underwent surgery with an multifocal lens implant.
89185847|NCT00921531|Experimental|Thalidomide and TACE|Thalidomide is used for adjuvant therapy for TACE
89185848|NCT00921531|Active Comparator|TACE only|
89185849|NCT04072692|No Intervention|1st part: The gliding properties of the tendons|No intervention. Subjects are measured by ultrasound under 5 different postures of the hand for forty minutes.
89185850|NCT04072692|No Intervention|1st part: The gliding properties of the median nerve|No intervention. Subjects are measured by ultrasound under under 6 different postures of the wrist and hand and 5 different movement patterns of the wrist and hand for forty minutes.
89185851|NCT04072692|Experimental|2nd part: New hybrid rehabilitation strategy|"The program includes pre-test, 8 times training, post-test and follow-up test.~For pre-test, subjects perform the specific hand movement under different exerting force conditions and 4 different angles of phalangeal joints and be asked to do Phalen test, Grip strength test, Pinch test and SWMT test. It takes 40 minutes.~For post-test, the same procedure is repeated again after completing all training.~For follow-up, the same procedure is repeated again 6 months after completing all training.~After pre-test, 8 times hybrid rehabilitation training are asked. There are two times in a week, and all training will be completed in one month. Each time will take forty minutes."
89185852|NCT04072692|Experimental|2nd part: Traditional strategy|"The program includes pre-test, 8 times training, post-test and follow-up test.~For pre-test, subjects perform the specific hand movement under different exerting force conditions and 4 different angles of phalangeal joints and be asked to do Phalen test, Grip strength test, Pinch test and SWMT test. It takes 40 minutes.~For post-test, the same procedure is repeated again after completing all training.~For follow-up, the same procedure is repeated again 6 months after completing all training.~After pre-test, 8 times traditional rehabilitation training are asked. There are two times in a week, and all training will be completed in one month. Each time will take forty minutes."
89185853|NCT04072692|No Intervention|3rd part: The effect of carpal tunnel release|"No intervention. The program includes pre-test, post-test and two times follow-up tests.~For pre-test, subjects perform the mechanical properties of the flexor tendon assessment and functional assessment of both hands before carpal tunnel release surgery. It takes 40 minutes.~For post-test, subjects perform the functional assessment of both hands one week after carpal tunnel release surgery. It takes 20 minutes.~For first follow-up, subjects perform the mechanical properties of the flexor tendon assessment and functional assessment of both hands one month after carpal tunnel release surgery. It takes 40 minutes.~For second follow-up, subjects perform the mechanical properties of the flexor tendon assessment and functional assessment of both hands two month after carpal tunnel release surgery. It takes 40 minutes."
89189432|NCT05809999|No Intervention|Control Group|Participants will undergo standard colonoscopy as part of their routine IBD surveillance. During this colonoscopy both random (approximately 32 to 40) and targeted biopsies (and/or removal of any polyps) will be undertaken.
89389339|NCT04828187||Study group|8 patients aged between 18 to 75 years with Uncorrected Distance Visual Acuity ≥ 5/10
89535351|NCT03322787|No Intervention|Oxygen|The training will be performed using oxygen by the Venturi mask with the FiO2 set during the run - in session.
89185854|NCT04072692|Experimental|3rd part: Wearable anti-bowstringing orthosis (WABO)|"The program includes pre-test, post-test and two times follow-up tests.~For pre-test, subjects perform the mechanical properties of the flexor tendon assessment and functional assessment of both hands before carpal tunnel release surgery. It takes 40 minutes.~Subjects wear WABO in the morning and a splint at night within a week after carpal tunnel release surgery.~For post-test, subjects perform the functional assessment of both hands with and without wearing WABO and a splint one week after carpal tunnel release surgery. It takes 40 minutes.~From the third weeks after carpal tunnel release surgery, subjects wear WABO only in the morning.~For first follow-up, the same procedure in pre-test is repeated again one month after carpal tunnel release surgery. It takes 40 minutes.~For second follow-up, the same procedure in pre-test is repeated again two month after carpal tunnel release surgery."
89185855|NCT04094415||Semaglutide|Participants will receive semaglutide at the treating physician's discretion as part of the usual clinical practice. The prescription and use of semaglutide is completely independent of this study. Total study duration for the individual patient will be approximately 30 weeks.
89389340|NCT02057432|Experimental|Intra-operative MRI|Images will be obtained both before and after intravenous bolus injection with subsequent dynamic imaging. Dynamic contrast enhancement maps will be created for evaluation of residual tumor. Images will be reformatted into three orthogonal planes as well as into a 3D model for surgical orientation. All imaging protocols using contrast, contrast enhancement maps and reformatting, as described above, which will be applied to the intra-operative MRI performed in the AMIGO suite are consistent with the standard MRI breast imaging at Brigham and Women's Hospital.
89389341|NCT02059772|Experimental|Control Group|Standard therapy of diabetic macular edema with Lucentis (ranibizumab) according to SmPC
89389342|NCT02059772|Experimental|Treatment Group|Combination of standard therapy of Lucentis (ranibizumab) according to SmPC and micropulse diode laser treatment
89389343|NCT01344083|Experimental|T1210|
89389344|NCT01344083|Active Comparator|Olopatadine hydrochloride|
89389345|NCT04039217|Experimental|Sample collection 2, 48, and 96 hours after first dose of Biktarvy|Participants in this study arm (Arm A) will provide biological specimens 2, 48, and 96 hours after the in-clinic dose of Biktarvy. Approximately 24 mL of blood will be drawn, an oral cheek swab, 1 pre-wet penile swab and 1 dry penile swab, and a urethral swab will be collected. After previous swab collections are complete, participants will be asked to provide a urine sample (some of which will be used for gonorrhea and chlamydia testing). Participants will undergo rectal biopsy collection at one of the study visits.
89389346|NCT04039217|Experimental|Sample collection 4, 26, and 120 hours after first dose of Biktarvy|Participants in this study arm (Arm B) will provide biological specimens 4, 26, and 120 hours after the in-clinic dose of Biktarvy. Approximately 24 mL of blood will be drawn, an oral cheek swab, 1 pre-wet penile swab and 1 dry penile swab, and a urethral swab will be collected. After previous swab collections are complete, participants will be asked to provide a urine sample (some of which will be used for gonorrhea and chlamydia testing). Participants will undergo rectal biopsy collection at one of the study visits.
88864890|NCT04293341|Active Comparator|Disorder Specific Therapies|To provide an evidence-based comparison for the TBT condition, DSTs will be used that are matched to the participant's most severe diagnosis, based upon the average of the ADIS interference and distress scores. If the scores are equivalent for two or more diagnoses, participants will be asked to list which diagnosis/symptoms that they find most impairing. DSTs will be included for each of the three targeted diagnoses, including PTSD (CPT for PTSD), PD/AG (CBT for PD/AG), and MDD (CBT for MDD). Each of these DSTs have published manuals for administration and have received extensive support in the literature (Barlow, 2014).
88864891|NCT04288921|Experimental|Nasal swab|Nasal swab from subjects with signs and symptoms of influenza and/or RSV-like illness
88864892|NCT04288921|Experimental|Nasopharyngeal swab|Nasopharyngeal swab from subjects with signs and symptoms of influenza and/or RSV-like illness
88864893|NCT04263194|Experimental|Default Mode Network (DMN)|The treatment will consist in the individually tailored stimulation of a DMN node (i.e. left inferior parietal lobe).
88864894|NCT04263194|Experimental|Central Executive Network (CEN)|The treatment will consist in the individually tailored stimulation of a CEN node (i.e. left dorsolateral prefrontal cortex).
88864895|NCT04263194|Placebo Comparator|Placebo|The treatment will consist in targeting the upper part of the scalp (i.e. CZ) while using a sham rTMS coil.
88864896|NCT04247126|Experimental|Group 1: Single Agent Dose Escalation|Dose escalation phase to explore maximum tolerated dose of SY-5609 given as a single agent.
88864897|NCT04247126|Experimental|Group 2: SY-5609 + Fulvestrant|Participants with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2) negative advanced or metastatic breast cancer (BC) that has progressed following prior treatment with a cyclin-dependent kinase (CDK)4/6 inhibitor in combination with hormonal therapy will receive SY-5609 in combination with fulvestrant.
88864898|NCT04247126|Experimental|Group 3: SY-5609 + Gemcitabine|Participants with PDAC will receive SY-5609 in combination with gemcitabine in Safety Lead-in to identify a recommended combination dose for the expansion. The expansion part will assess the safety, tolerability, and preliminary clinical activity of SY-5609 in combination with gemcitabine at the recommended combination dose.
88864899|NCT04247126|Experimental|Group 4: SY-5609 + Gemcitabine + Nab-paclitaxel|Participants with PDAC will receive SY-5609 in combination with gemcitabine plus nab-paclitaxel in Safety Lead-in to identify a recommended combination dose for the expansion. The expansion part will assess the safety, tolerability, and preliminary clinical activity of SY-5609 in combination with gemcitabine plus nab-paclitaxel at the recommended combination dose.
88864900|NCT04241250|Experimental|EAW+SCES|Three months of exoskeleton training followed by 6 months of epidural stimulation.
88864901|NCT04241250|Experimental|EAW+TS|Three months of exoskeleton training followed by 6 months of transspinal stimulation.
88864902|NCT04168489|Active Comparator|active rTMS|
88864903|NCT04168489|Sham Comparator|sham rTMS|
88864904|NCT04152954|Active Comparator|Traditional cannula|Cervical Medial Branch Radiofrequency Neurotomy using a conventional cannula, the patient lying prone with a posterior approach.
88864905|NCT04152954|Experimental|Multi-tined cannula|Cervical Medial Branch Radiofrequency Neurotomy using a Multi-Tined cannula, the patient lying in lateral decubitus with a lateral approach
89389347|NCT04039217|Experimental|Sample collection 24, 28, and 72 hours after first dose of Biktarvy|Participants in this study arm (Arm C) will provide biological specimens 24, 28, and 72 hours after the in-clinic dose of Biktarvy. Approximately 24 mL of blood will be drawn, an oral cheek swab, 1 pre-wet penile swab and 1 dry penile swab, and a urethral swab will be collected. After previous swab collections are complete, participants will be asked to provide a urine sample (some of which will be used for gonorrhea and chlamydia testing). Participants will undergo rectal biopsy collection at one of the study visits.
89389348|NCT02059850|Experimental|Treatment (cyclophosphamide, NY-ESO-1 specific T cells)|Patients receive cyclophosphamide IV on days -3 and -2 and NY-ESO-1 specific T cells IV over 60 minutes on day 0. Patients may receive additional infusions at the discretion of the PI.
89389349|NCT02057744||Robotic-guided|Adult patients (21 years or older) undergoing short (4 or less consecutive vertebrae) thoracic, lumbar or lumbosacral percutaneous/minimally invasive robotic-guided spinal fixation surgery.
89185856|NCT00730028|Experimental|Limited Abscess|Limited abscess with or without cellulitis less than or equal to 5 cm in diameter will be randomized to receive a 10-day course a) TMP-SMX 160/800 mg twice daily for adults; 8-10 mg/kg of TMP, 40-50 mg/kg of SMX twice daily for children; or b) CLINDA 300 mg three times daily for adults; 25-30 mg/kg/day divided three times daily for children; or c) placebo two capsules three times daily.
88864906|NCT04151706|Experimental|fTBI/Thiotepa/fludarabine|Participants will be infused on Day 0 with donor derived CD34+ selected cells combined with CD8+CD45RA- T cells {CD Memory T Cells} following a standard myeloablative conditioning regimen that might consist of fTBI, Thiotepa, and Fludarabine or Busulfan and Cyclophosamide.
88864907|NCT04147468|Active Comparator|Virtual Reality Gaming Intervention|A newly developed VR gaming platform called Super Pop VR, a VR system that can be individualized to the movement capabilities of the child, will be used. The research team will loan the system to the family. The child will be asked to move their arms to 'pop' as many virtual objects as possible with the focus on outwards, upwards, and across midline.
89389350|NCT02057744||Freehand image-guided|Adult patients (21 years or older) undergoing short (4 or less consecutive vertebrae) thoracic, lumbar or lumbosacral percutaneous/minimally invasive image-guided freehand or navigated spinal fixation surgery.
89389351|NCT01342055|Experimental|Group 1 : Megace 800mg - Apetrol ES 650mg - Apetrol ES 675mg|
89389352|NCT01342055|Experimental|Group 2 : Apetrol ES 650mg - Apetrol ES 675mg -Megace 800mg|
89389353|NCT01342055|Experimental|Group 4: Megace 800mg - Apetrol ES 675mg - Apetrol ES 650mg|
89389354|NCT01342055|Experimental|Group 5: Apetrol ES 650mg - Megace 800mg - Apetrol ES 675mg|
89389355|NCT01342055|Experimental|Group 3: Apetrol ES 675mg - Apetrol ES 650mg - Megace 800mg|
88864908|NCT04147468|Experimental|Functional Strength Training|Children will receive repetitive progressive resistance exercise during goal-directed functional activity with the children focus on the activity being performed. Children will be offered a pamphlet containing suggested functional arm exercises which are designed to move their arms.
89389356|NCT01342055|Experimental|Group 6 : Apetrol ES 675mg - Megace 800mg - Apetrol ES 650mg|
88864909|NCT04125186||Pilot Part|After providing consent, participants with nocturia will complete web-based baseline EpiNP survey followed by 3-day bladder diary and then a qualitative interview.
89185857|NCT00730028|Experimental|Cellulitis or Larger Abscess|Subjects with cellulitis only or abscess > 5 cm in diameter, or with 2 or more sites of skin infection will be randomized to receive a 10-day course a) TMP-SMX 160/800 mg twice daily for adults; 8-10 mg/kg of TMP, 40-50 mg/kg of SMX twice daily for children; or b) CLINDA300 mg three times daily for adults; 25-30 mg/kg/day divided three times daily for children.
89389357|NCT02038478|Experimental|Transplantation Arm|"Transplantation~One day after they complete their radiation and Campath-1H treatments and have begun their Sirolimus, the donor blood stem cells described above are transfused through the central line. This process takes approximately 30 minutes to 2 hours and is normally completely without side effects."
89389358|NCT00982111|Experimental|Necitumumab + Pemetrexed + Cisplatin|Necitumumab + Pemetrexed + Cisplatin
89389359|NCT00982111|Active Comparator|Pemetrexed + Cisplatin|Pemetrexed + Cisplatin
89389360|NCT05615090|Experimental|I (Prepectoral)|Participants received the Self-help app-based CBT-E for eating disorder for 8 weeks
88864910|NCT04125186||Main Part|After providing consent, participants will complete web-based baseline EpiNP survey. All respondents who report greater than equal to (≥)2 voids/night, and a randomly selected cohort of respondents reporting 0 and 1 void/night will use the EpiNP 3-day web-based bladder diary.
88864911|NCT04119453|Experimental|Rivoceranib|Participants will receive an oral dose of rivoceranib once per day during 28-day cycles.
88864912|NCT04114734|Experimental|Park Rx|Participants will be given a park prescription as part of their treatment plan
88864913|NCT04114734|No Intervention|No Park Rx|Usual care only
89389361|NCT05615090|Other|II (Subpectoral)|Waiting list Wait-list control(participants will use the smartphone app after the intervention phase) The waitlist group will receive treatment as usual, Patients from the waitlist group will be offered access to App after a 8-weeks period.
89389362|NCT02957682|Experimental|Group 1|Praluent Regimen - Administration through subcutaneous injection
89389363|NCT02957682|Experimental|Group 2|Placebo matching Praluent - Administration through subcutaneous injection
89389364|NCT02057822||vernal keratoconjunctivitis|The main objective of our study was to compare the concentration of 40 cytokines in vernal keratoconjonctivitis and in control subjects
89389365|NCT02057822||healthy children|The main objective of our study was to compare the concentration of 40 cytokines in vernal keratoconjunctivitis and in control subjects
89389366|NCT03057951|Experimental|10 mg Empagliflozin|
89389367|NCT03057951|Placebo Comparator|Placebo|
89389368|NCT02060240|Experimental|High Activity Group|Subject randomized to High Activity group will have 36, one hour training sessions over 12 weeks.
89389369|NCT02060240|No Intervention|Standard of Care Group|The standard of care group will maintain their baseline level of activity for 12 weeks
88864914|NCT04097353|Experimental|Harvesting Hope for Kids (HH4K)|Eight weekly, 60-minute sessions at a university-based farm with booster sessions. Learning is structured around fun activities to provide information about the impact of cancer treatment on children's health, as well as the importance of nutrition and physical activity in survivorship. Each session is manualized and devoted to education, a behavioral strategy applied toward a weekly goal, a cooking demonstration/taste testing, and harvesting produce from the survivor garden. Modules are offered in a group format with families together.
88864915|NCT04097353|Sham Comparator|Surviving Strong for Kids (SS4K)|Families assigned to enhanced usual care (SS4K) group will receive education in the form of standardized guidelines for nutrition and physical activity for survivors of childhood cancer. In a one-hour session, they will learn about the impact of cancer treatment on health and the importance of nutrition and physical activity for survivors. Families will receive websites for other educational resources. They will not have access to harvesting, remote coaching, the web portal, or behavioral training to address their child's nutrition or activity.
89389370|NCT02038556|Experimental|cognitive behaviorial therapy for insomnia group program|Behavioral
89389371|NCT02057900|Experimental|Human embryonic stem cell|Patients with ischemic heart failure receiving a fibrin gel embedding human embryonic stem cell-derived CD15+ Isl-1+ progenitors in addition to coronary artery bypass grafting and/or a mitral valve procedure.
89389372|NCT02060318||Infliximab|35 Crohn patients about to start Infliximab treatment, gives as i.v. injection of 5 mg/kg at baseline, after 2 weeks, 6 weeks, and then every 8th week.
88864916|NCT04093986||Retrospective Chart Review|Medical record chart review of women seen previously for clinical care prior to June 20, 2019 at participating institutions with SCD and hydroxyurea exposure during gestation or lactation will be identified by healthcare providers.
88864917|NCT04093986||Participant Survey and Retrospective Chart Review|Participants providing their medical records without the assistance of a health care provider will be asked to complete a questionnaire through REDCap and will have the option to upload their deidentified medical records if they are available.
89389373|NCT02060318||Healthy controls|12 healthy controls without Crohn's Disease.
89389374|NCT01318837|Experimental|sofilenacin group|
89389375|NCT01318837|No Intervention|control group|age and sex matched patients without OAB symptom who will answer demographic questionaire and OABSS once
88864918|NCT04065438|Experimental|LIPOSORBER® LA-15 System|All study patients who meet the study eligibility criteria will undergo the extracorporeal treatment using LIPOSORBER® LA-15 System. The participants are to be treated with the system twice weekly for the 3weeks and then once weekly for the following 6 weeks.
88864919|NCT04006119|Experimental|Ad-RTS-hIL-12 + veledimex in combination with cemiplimab-rwlc|Intratumoral Ad-RTS-hIL-12 and oral veledimex (activator ligand, 20mg) given in combination with cemiplimab-rwlc via infusion.
88864920|NCT04004793|Experimental|Dapagliflozin plus intensive lifestyle intervention|The treatment of Dapagliflozin (Forxiga®) will be initiated and maintained at 10mg every morning until the completion of the study.
89389376|NCT03146663|Experimental|Arm A|NUC-1031 500 mg/m2 administered on Days 1, 8, and 15 of 28-day cycles
88864921|NCT04004793|Placebo Comparator|Placebo plus intensive lifestyle intervention|The treatment of placebo will be initiated and maintained at 10mg every morning until the completion of the study.
88864922|NCT04002011|Active Comparator|Group VKA|"103 patients. First intake at postoperative day 1 or later when anticoagulation is secondary indicated.~Dosage adapted to INR = [2.0-3.0], parenteral (subcoutaneous low-weight molecular or intravenous unfractionated heparin) until INR > or = 2.0.~Daily INR during hospital stay, then management by familial doctor. Duration: 3 months"
89185858|NCT05673642|Experimental|Working group|A total of 10 sessions will be applied myofascial release technique for 4 weeks, 3 times a week for the first 2 weeks, and 2 times a week for the next 2 weeks. Evaluations will be made at the beginning of the study and at the end of 4 weeks
89389377|NCT03146663|Experimental|Arm B|NUC-1031 750 mg/m2 administered on Days 1, 8, and 15 of 28-day cycles
89389378|NCT01350037|Active Comparator|remifentanil|sedative mixture for PCS consisting of propofol 10mg/ml 20 ml and remifentanil 50 mkg/ml 5 ml
89389379|NCT01350037|Active Comparator|alfentanil 0.04 mg/ml|sedative mixture for PCS consisting of propofol10 mg/ml 20 ml,alfentanil 0.5 mg/ml 2 ml, NaCL 9 mg/ml 3 ml
89389380|NCT01350037|Active Comparator|alfentanil 0.08 mg/ml|sedative mixture for PCS consisting of propofol 10 mg/ml 20 ml, alfentanil 0.5 mg/ml 4 ml,NaCl 9mg/ml 1ml
89389381|NCT02060006|Placebo Comparator|Placebo 7.5 mg daily for 8 weeks|Placebo 7.5 mg once-daily First 8 weeks of ART Only Control arm
89389382|NCT02060006|Experimental|Meloxicam 7.5 mg once-daily|Meloxicam 7.5mg once-daily for 8 weeks
89389383|NCT03621150||Cases|Patients complaining of ankle pain, swelling or dysfunction underwent ultrasound examination and then MRI as a reference to compare the diagnostic accuracy of ultrasonography in the assessment of tendino-ligamentous injuries around the ankle joint
89389384|NCT01350193|Active Comparator|Saline Nasal Irrigation|Saline Nasal Irrigation is actively being used as the standard of care. It does not contain any active ingredients.
89389385|NCT01350193|Experimental|Manuka Honey Irrigation|Manuka Honey Irrigation involves the experimental treatment of manuka honey nasal irrigation.
89389386|NCT03640182|Experimental|Management of TCM preventive medicine|The Health management model include: (1) Body constitution measurement (2) Health promotion literacy education lectures (3) Medical Ba-Duan-Jin duo-in qigong practice.
89389387|NCT03620435|Experimental|atezolizumab|Atezolizumab will be given during trimodal therapy, and every 3 weeks for 16 cycles or until disease progression or unacceptable toxicity.
89389388|NCT01357993|Experimental|001|JNS001 18 mg 27 mg and 36 mg tablets (18-72 mg/day) once daily for 48 weeks
88864923|NCT04002011|Active Comparator|Group DOAC|"103 patients - One drug among the 4 DOAC according the morbidity of each patient (preoperative DOAC, oral nutrition recovery).~First intake at hospital discharge - parenteral (subcoutaneous low-weight molecular or intravenous unfractionated heparin) during hospital stay.~Regular daily dosages according the drug, its indication (atrial fibrillation/flutter or biological mitral replacement/repair or biological tricuspid replacement versus venous thromboembolism) and the morbidity of each patient (age, weight, creatinine ou its clearance).~Validation by one referent pharmacist. No biological monitoring. Duration: 3 months"
88864924|NCT03968991|Active Comparator|Healthy volunteer group|male or female healthy volunteers
88864925|NCT03968991|Experimental|Subjects with acquired visual impairment|visual acquired disability
88864926|NCT03968991|Experimental|Subjects with congenital visual impairment|Visual congenital disability
88864927|NCT03968107||Women with a pregnancy of at least 31 weeks|All pregnant women with a pregnancy of at least 31 weeks and having to perform a fetal MRI to identify a cerebral, pulmonary or renal fetal malformation, or due to a diagnostic doubt on ultrasound on an abnormality of these structures, will be proposed inclusion in the study.
88864928|NCT03934437|Experimental|mLTCR|The mLTCR intervention consists of two smartphone applications (app), one for patients and one for patient supporters, to help facilitate communication.
88864929|NCT03934437|Active Comparator|LTC|Existing linkage to care and retention (LTCR) services which are standard-of-care
88864930|NCT03903692|Experimental|Marine polysaccharide dressing|
88864931|NCT03903692|Active Comparator|Carboxymethylcellulose dressing|
88864932|NCT03886610||Healthy controls|Individuals without spinal cord injury
88864933|NCT03886610||Subacute SCI patients|Subacute patients with spinal cord injury (duration >2 weeks)
88864934|NCT03886610||Chronic SCI patients|Patients with chronic spinal cord injury (duration ≥24 months)
88864935|NCT03878849|Experimental|2X-121|Oral administration of 2X-121 once daily as 600 mg hard gelatin capsules in a 28 days cycle.
88864936|NCT03815708||wheelchair rugby players|well-trained spinal cord injured wheelchair rugby players
88864937|NCT03815708||wheelchair basketball players|well-trained spinal cord injured wheelchair basketball players
88864938|NCT03789591|Active Comparator|Standard Arm|Participants randomized to the standard arm will receive a starting dose of hydroxyurea of 20 mg/kg/day.
88864939|NCT03789591|Experimental|Alternative Arm|Participants randomized to the alternative arm will receive a pharmacokinetic guided starting dose of hydroxyurea based on PK labs drawn at a baseline visit to target an area under the curve (AUC) of 115 mg*h/L in an attempt to approximate maximum tolerated dose (MTD). This dose will not exceed the maximum tolerated dose of 35 mg/kg/day.
88864940|NCT03783026|Experimental|Apremilast|Participants will receive apremilast 30 mg twice a day for 48 weeks.
88864941|NCT03775460|Placebo Comparator|control|Participants will receive placebo+ prednisolone. Participants will start receiving 4 dummy tablets per week, than participants weighing less than 60 kg will receive 6 dummy tablets from week 8. The placebo will be prescribe weekly. Participants weighing 60 kg or more will receive 8 dummy tablets from week 8. Participants will receive dummy tablets for 52 weeks. Along with prednisolone. The start dose of prednisolone will be 40 mg per day decreasing dosage for 20 weeks.
88864942|NCT03775460|Experimental|intervention|Participants will receive Methotrexate(MTX)+prednisolone. All participants in intervention arm will receive an initial dose of MTX 10 mg. The MTX will be increased to 15 mg the following week. Participants weighing less than 60 kg will continue to receive 15 mg of MTX weekly thereafter. Individuals weighing 60 kg or more will receive MTX 20 mg from week 8. At week 48 the MTX will be reduced to 10 mg for two weeks followed by 5 mg for two weeks and then stopped. In total participants will receive 52 weeks of MTX along side prednisolone, which will be the same as the control arm.
88864943|NCT03635112|Active Comparator|Active Treatment TD-1473 with Dose A|"1 oral Dose A daily of TD-1473 for 12 weeks in subjects with moderately to-severely active CD.~Subjects who complete Induction will continue to receive TD-1473 at Dose A in the Active Treatment Arm for up to 48 additional weeks."
88864944|NCT03635112|Active Comparator|Active Treatment TD-1473 with Dose B|"1 oral Dose B daily of TD-1473 for 12 weeks in subjects with moderately to-severely active CD.~Subjects who complete Induction will continue to receive TD-1473 at Dose B in the Active Treatment Arm for up to 48 additional weeks."
88864945|NCT03635112|Placebo Comparator|Placebo|"1 oral dose daily of placebo for 12 weeks in subjects with moderately to-severely active CD.~Subjects who complete Induction will receive TD-1473 at Dose A in the Active Treatment Arm for up to 48 additional weeks."
88864946|NCT03620409||Sepsis|Patients with and without diagnosis septic cardiomyopathy Patients with and without suspected or confirmed SARS-CoV-2 infection
89389389|NCT03618888|Active Comparator|Instructor-led training|Instructor-led training contents a supervised practical training for BLS, facilitated by a certified instructor.
88864947|NCT03620409||Cardiomyopathy without infection|Patients without operation and patients with scheduled LVAD-Implantation
89389390|NCT03618888|Experimental|Self-learning training|Self-learning training is self-directed and contents practical training for BLS
89389391|NCT05637554|Active Comparator|Laparoscopic clipping appendectomy|This group will undergo laparoscopic clipping of the base of the appendix during laparoscopic appendectomy.
89389392|NCT05637554|Active Comparator|Laparoscopic extracorporeal ligation appendectomy|This group will undergo laparoscopic extracorporeal ligation of the base of the appendix during laparoscopic appendectomy.
89389393|NCT03640104|Experimental|Intervention-Nutrition guidelines|Subjects will receive an individualized dietary plan according to their nutritional status, socioeconomic and cultural preferences. Protein intake 1-1.5g/kg body weight; 30% fat (mono and polyunsaturated fatty acids), vitamin A sources (1300 RAE). Each subject will have 7 interchangeable options for every meal time, all equivalent in macronutrient content, and every two weeks a new menu will be provided by a nutritionist.
89389394|NCT03640104|Other|Nutrition Guidelines|Participants will receive general nutritional recommendations according to international standards
88864948|NCT03620409||Healthy subjects|Healthy controls
88864949|NCT03588728|Experimental|CR + tDCS|Cognitive Remediation (CR) and Transcranial Direct Current Stimulation (tDCS)
89535352|NCT03322787|Experimental|HFO|The training will be performed using the HFO device during the run - in session at iso_FiO2 as in the Control Group (Oxygen by Venturi mask).
89389395|NCT04686773|Experimental|AZD1222 5×10^10 vp + rAd26-S (1.0±0.5) х 10^11vp|Subjects will receive 1 intramuscular (IM) injection of 5×10^10 viral particles (nominal) of AZD1222 on Day 1 followed by rAd26-S 1×10^11 viral particles (nominal) on Day 29 of the study.
89389396|NCT02058056|Experimental|Experimental: HA-PCI treatment|Irradiation HA-PCI concomitant to the second cycle of CHT and to tRT for patients with LD SCLC
89389397|NCT05162495|Experimental|Arm A|Requiring a diagnostic or screening RT-PCR test for COVID-19.
89389398|NCT05162495|Experimental|Arm B|Positive to COVID-19 in RT-PCR test performed up to 48 hours before screening.
89389399|NCT02956278|Placebo Comparator|BCRP Q141K CC|Participants that are homozygous reference for BCRP Q141K receive at least one 300 mg dose of allopurinol followed by blood/urine collection for up to 72 hours post-dose.
89389400|NCT02956278|Experimental|BCRP Q141K CA|Participants that are heterozygous for the BCRP Q141K allele receive at least one 300 mg dose of allopurinol, with blood/urine collections up to 72 hours post-dose.
89389401|NCT02956278|Experimental|BCRP Q141K AA|Participants homozygous for the BCRP Q141K allele receive at least one 300 mg dose of allopurinol with blood/urine collection for up to 72 hours post-dose.
89389402|NCT02058134|No Intervention|Control group|
89389403|NCT02058134|Experimental|Interventional group|For patients in the interventional group we use a CardioPAT cell saver intra- and postoperatively.
89389404|NCT01317173||Progressive disease|Serum creatinin level rise more than 2 times
89389405|NCT01317173||Non-progressive disease|Serum creatinin level rise less than 2 times
89389406|NCT02060396|Experimental|Acetylsalicylic acid|One tablet of Adiro 100 mg will be administered daily orally for 7 days.
89389407|NCT01358071|Experimental|Arm A: NGR-hTNF+ anthracycline|NGR-hTNF+Pegylated Liposomal Doxorubicin or Doxorubicin
88864950|NCT03588728|Sham Comparator|CR + sham tDCS|Cognitive Remediation (CR) and Sham Transcranial Direct Current Stimulation (tDCS)
89003490|NCT05169788|Active Comparator|modified TOPS group|Patients are required to perform the modified TOPS program, composed of 10 sessions focused only on health and wellness contents. Thus, this program does not include contents on problem-solving, executive functions, behavioral strategies and social skills, representing a low cognitively simulating activity. Biweekly Google Meet sessions with a cognitive-behavioral psychotherapist are scheduled, with the aim of monitoring training adherence and discuss the program's contents.
89003491|NCT05163873|No Intervention|Trans-peritoneal|Surgery technique in the formation of permanent end colostomy
89389408|NCT01358071|Active Comparator|Arm B: anthracycline|Pegylated Liposomal Doxorubicin or Doxorubicin
89389409|NCT04827719|Experimental|BST-236|Recurrent 6 days treatment courses with BST-236 (4.5 g/m2/d administered IV over 1 hour for 6 consecutive days)
89389410|NCT02058212|Placebo Comparator|no antioxidant , ROS , pregnancy outcome|no anti oxidant in the form of ascorbate 1000mg, vitamin E 400, zinc and selenium) will be given to endometriotic women undergoing IVF
89389411|NCT02058212|Active Comparator|antioxidant , ROS , pregnancy outcome|anti oxidant in the form of ascorbate 1000mg, vitamin E 400, zinc and selenium)
89389412|NCT02957136|Experimental|Rapid respiratory pathogen test arm|ED patients in this arm will receive a rapid respiratory pathogen nucleic acid amplification test plus usual care.
89389413|NCT02957136|No Intervention|Usual care control arm|ED patients in this arm will receive clinician-directed standard of care, which may include but is not limited to no testing, point-of-care influenza testing, or delayed testing for respiratory pathogens at off-site laboratory.
89389414|NCT01354093||MacTel Type 2 20 mg/day dose group|Participants will have macular telangiectasis type 2 as confirmed by the reading center. Participants will take 20 mg of zeaxanthin per day.
88864951|NCT03588728|Sham Comparator|control CR + tDCS|Control Cognitive Remediation (CR) and Transcranial Direct Current Stimulation (tDCS)
88864952|NCT03588728|No Intervention|control CR + sham tDCS|Control Cognitive Remediation (CR) and Sham Transcranial Direct Current Stimulation (tDCS)
88864954|NCT03534726||Patients|Patients with cardiomyopathy
88864955|NCT03534726||Normal subjects|No prior history of heart disease.
89389415|NCT01354093||MacTel Type 2 10 mg/day dose group|Participants will have macular telangiectasia type 2 as confirmed by the reading center. Participants will take 10 mg of zeaxanthin per day.
89389416|NCT02060474|Experimental|AHDS patients|all AHDS recruited for this study will be located in the experimental arm and will receive the investigational medicinal product Triac. The Triac dose will be individually titrated to the optimal dose level.
89389417|NCT03561272|No Intervention|Standard Patient Reported Adherence|Adherence assessment via phone call or in person
89389418|NCT03561272|Active Comparator|Smart Phone Application|Adherence assessment via phone app
89389419|NCT03561272|Experimental|POD and Smart Phone Application|"Adherence assessment via phone app partnered with an automated dispensing machine, a Pod."
89389420|NCT03640260|Experimental|experimental|The experiment arm will get educational leaflets to pursed-lip with diaphragmatic breathing training and oximetry level evaluation.
89389421|NCT03640260|No Intervention|controlled|
89389422|NCT01354171|No Intervention|TRUS guided biopsy|
89389423|NCT01354171|Experimental|MRI Assisted TRUS guided biopsy|
89389424|NCT04668443||Prospective participants in D²EFT study|HIV-positive persons who are eligible for the D²EFT study will be proposed to receive the research-related information with the set of pictures (GIC)
89389425|NCT04668443||Researchers obtaining informed consent for D²EFT study|Healthcare givers involved in the participant informed consent process of D²EFT
89389426|NCT03618810||PEGCSF first level prophylactic use|The first level prophylactic use of PEG-rhG-CSF. The Prophylactic use of PEG-rhG-CSF in all cycles of chemotherapy.
89389427|NCT03618810||PEGCSF second level prophylactic use|The second level prophylactic use of PEG-rhG-CSF. The Prophylactic use of PEG-rhG-CSF in the next cycle until FN or 4 grade neutropenia happened.
89389428|NCT01354249|Placebo Comparator|water|Patients will receive water 3h before operation in the same volume of the study group
89535353|NCT03207061|Other|3D ultrasound and MRI|All patients with confirmed endometrial cancer will recieve the gold standard pre-operative imaging (MRI) but will also be offered 3D ultrasound.
89535354|NCT04940871|Experimental|Favipiravir HU + SOC|Favipiravir HU + SOC
89535355|NCT04940871|Placebo Comparator|Placebo HU + SOC|Placebo HU + SOC
88864956|NCT03513081|Experimental|Educative Session|The experimental group receive nine educational sessions (one per week) about different vegetables and, at lunch time, they are exposed to a different vegetable. If they try it, they will receive a sticker. In each session, researcher will record their preference for the vegetable and the quantity that they consumed in a scale from one to three (1- the child tasted it; 2 - the child repeated it; 3 - the child ate all the quantity). In the end of 9 sessions, all children (experimental and control group) will receive the same salad that they had eaten at baseline and the procedure will be the same: the salad is weighted before and after the consumption of each child to verify the quantity of each one ate.
88864957|NCT03513081|No Intervention|Control|Children in the control group don´t receive an educative session. Before the study starts children are asked to eat a salad. After 9 weeks, all children in the control group will receive the same salad that they had eaten at baseline and the procedure will be the same: the salad is weighted before and after the consumption of each child to verify the quantity of each one ate.
88864958|NCT03505216||Patient population|Children referred to paediatric pulmonary outpatient clinics for respiratory symptoms such as wheeze, cough, dyspnea, exercise- and sleep-related breathing problems.
88864959|NCT03500354|Experimental|Nutrient|Nutrient drink
88864960|NCT03455582|Experimental|patient|PPMS diagnosis according to McDonald 2010 criteria (Polman et al, 2011)
88864961|NCT03455582|Active Comparator|Control|40 Healthy controls
88864962|NCT03451383||Breast Cancer Case|Women age 60+ with a newly diagnosed breast adenocarcinoma staged 0-3.
88864963|NCT03451383||Non-Cancer Controls|Women age 60+ with no diagnosis of breast cancer.
88864964|NCT03448926||DCIS|Patients must have histologically confirmed ductal carcinoma in situ (DCIS) in a single breast without evidence of invasive cancer (presence of lobular carcinoma in situ (LCIS) or other benign breast disease in addition to DCIS is acceptable)
88864965|NCT03439033|Experimental|PET/MRI|PET/MRI with Gallium-68 labeled PSMA-HBED-CC: Subjects will have one visit during which they will undergo a PET/MRI after being injected with the study drug, Gallium-68 labeled PSMA-HBED-CC.
88864966|NCT03439033|Experimental|Multiple PET/MRI|Multiple PET/MRI with Gallium-68 labeled PSMA-HBED-CC: Subjects will be invited to participate in two visits within two years, the second being an optional visit. During each visit, subjects will undergo a PET/MRI after being injected with the study drug, Gallium-68 labeled PSMA-HBED-CC. This arm will be restricted to subjects who plan to undergo focal therapy.
88864967|NCT03439033|Experimental|PET/CT|PET/CT with Gallium-68 labeled PSMA-HBED-CC: Subjects will have one visit during which they will undergo a PET/CT after being injected with the study drug, Gallium-68 labeled PSMA-HBED-CC. PET/CT occurs if a) an MRI can't be performed concurrently; or b) the participant already had an MRI of the abdomen/pelvis or pelvis only.
89185859|NCT05673642|Experimental|Exercise group|The stretching exercises that we planned to give to the exercise group were planned for the muscles to which we will apply myofascial technique. Evaluations will be made at the beginning of the study and at the end of 4 weeks
89185860|NCT05673642|Experimental|Control group|No application will be made to the control group. Evaluations will be made at the beginning of the study and at the end of 4 weeks
89535356|NCT03319511|Active Comparator|paravertebral group|ultrasound guided, in sitting position, or lateral position, at T2 and T4 levels, using 22 G spinal needle, in plane technique, traversing the costo-transverse ligament
88864970|NCT03400982|Experimental|Bone Mineral Density|Bone densitometry measurement: measurement of bone mineral densitometry with bone densitometry
88864971|NCT03380962|Experimental|Clazakizumab|All twenty patients will receive clazakizumab monthly. Patients will receive up to 6 doses pre-transplantation. If patients are transplanted during the study, they will then receive 6 doses of clazakizumab (monthly) and a 6 month protocol biopsy will be performed. Based on the biopsy results and clinical labs PI will determine if patients should continue monthly doses for up to another 6 doses and day 330 post-transplantation. Patients who received 12 post-transplant doses of clazakizumab will then undergo a 12 month protocol biopsy.
88864972|NCT03380377|Experimental|Clazakizumab (Anti-IL-6 Monoclonal)|All ten patients will be receiving clazakizumab (Anti-IL-6 Monoclonal) monthly for six months. Then patients will be scheduled for six month protocol biopsy. If biopsy and all clinical labs show benefit or stability (up to PI discretion), patients will continue receiving clazakizumab monthly for another six months. All patients completing twelve doses of clazakizumab will be scheduled for a twelve month protocol biopsy and last study visit. If at the 6 month protocol biopsy, no improvement was seen, PI will have patient come for their last study visit on month 12 post enrollment.
89185861|NCT02594228|Experimental|Whey Protein and exercise training|Six meals per day of 20 grams of protein, two of which were whey protein and 4 days per week of exercise training..
89389429|NCT01354249|Experimental|whey protein plus carbohydrate|The CHO-P group will receive 474 ml (evening drink) or 237 ml (3h prior to operation drink) of a solution containing 14% whey protein (100% lactoalbumin), 86% carbohydrates (45% hydrolyzed corn starch and 55% sucrose) and 0% lipids (Resource® Breeze - Nestlé, São Paulo, Brasil)
88864973|NCT03282799|Active Comparator|Standard Dose Etonogestrel Implant|Single 68 mg etonogestrel implant
88864974|NCT03282799|Experimental|Increased Dose Etonogestrel Implant|Two 68 mg (136 mg total) etonogestrel implants
88864975|NCT03263546|Experimental|Stepped care|Internet-delivered cognitive behavioral therapy (ICBT)
88864976|NCT03263546|Active Comparator|Gold standard treatment|Cognitive behavioral therapy (CBT)
88864977|NCT03162549||Inflammatory Bowel Disease|Pts presenting to enrolling sites across the US are invited to enroll if eligible
89185862|NCT02594228|Experimental|Food Protein and exercise training|Six meals per day of 20 grams of protein, all of which were whole food protein and 4 days per week of exercise training.
89185863|NCT03356223|Experimental|Abemaciclib|
89185864|NCT04087694|Other|Open|Open laminectomy and posterior stabilization with pedicle screws for symptomatic lumbar spine stenosis
89185865|NCT04087694|Other|Microscope|Microscopically done decompression of lumbar spine stenosis who are symptomatic
89389430|NCT01342133||Newborns|
89389431|NCT01342133||Mothers|
89389432|NCT02058446|Experimental|Study group|Amlodipine/Valsartan Single-Pill Combination
89389433|NCT02236650|Experimental|Primary Care Stepping Stones Triple P|Primary Care Stepping Stones Triple P program (PC-SS Triple P) - a parenting and family support strategy that aims to prevent and treat behavioral problems in children by enhancing parental resilience.
89389434|NCT02236650|Active Comparator|Wait List Control (WLC)|Wait List Control - Participants who will have access to treatment as usual services during the 4 weeks between baseline and 4 week assessment time points and then will have the opportunity to receive PC-SS Triple P.
89389435|NCT01354327|Experimental|Limicol|
89389436|NCT01354327|Placebo Comparator|Placebo|
89389437|NCT05160311|Other|Optimized Medical Treatment (OMT)|The patient considered non-viable by MRI and randomized to Optimized Medical Treatment (OMT) will be treated according to Optimized Medical Treatment guidelines for Coronary Artery Disease (CAD)
89389438|NCT05160311|Experimental|Angioplasty (PCI) and Optimized Medical Treatment (OMT)|The patient considered non-viable and randomized to Coronary Angioplasty will be treated with drug-eluting stent (PCI) and Optimized Medical Treatment (OMT)
89389439|NCT02058524|Experimental|fecal microbiota transplantation|
89389440|NCT02058602|Experimental|Arm 1|This is a clinical study to characterise the lung function, airway morphometry, pharyngometry and inhalation profiles in patients with mild to severe Idiopathic Pulmonary Fibrosis (IPF) over a period of up to 6 months. Approximately 30 subjects will be enrolled so that at least 20 subjects complete all critical assessments.
88864978|NCT02987543|Experimental|Olaparib|Olaparib is available as a film-coated tablet containing 150 mg or 100 mg of olaparib. Subjects will be administered study treatment orally at a dose of 300 mg twice daily (bid). The planned dose of 300 mg bid will be made up of two x 150 mg tablets twice daily, with 100 mg tablets used to manage dose reductions
89389441|NCT02031666|Active Comparator|Treatment A|15 participants will receive 240-mg dose as Softgel Capsule Formulation of JNJ-56021927.
89389442|NCT02031666|Experimental|Treatment B|15 participants will receive 240-mg dose as Tablet Formulation number 1 of JNJ-56021927.
89389443|NCT02031666|Experimental|Treatment C|15 participants will receive 240-mg dose as Tablet Formulation number 2 of JNJ-56021927.
89389444|NCT02031666|Experimental|Treatment D|15 participants will receive 240-mg dose as Tablet Formulation number 3 of JNJ-56021927.
89389445|NCT02031666|Experimental|Treatment E|15 participants will receive 240-mg dose as Tablet Formulation number 4 of JNJ-56021927.
89389446|NCT02031666|Experimental|Treatment F|15 participants will receive 240-mg dose as Tablet Formulation number 5 of JNJ-56021927.
89389447|NCT02031666|Experimental|Treatment G|15 participants will receive 240-mg dose as Tablet Formulation number 6 of JNJ-56021927.
88864979|NCT02987543|Active Comparator|Enzalutamide OR abiraterone acetate|"Enzalutamide:~Enzalutamide is available as capsules or tablets containing 40 mg of enzalutamide. Subjects will be administered study treatment orally at a dose of 160 mg once daily.~Abiraterone acetate with prednisone: Abiraterone acetate is available as tablets containing 250 mg or 500 mg of abiraterone acetate. Subjects will be administered study treatment orally at a dose of 1,000 mg once daily in combination with prednisone 5 mg administered twice daily orally. Prednisolone is permitted for use instead of prednisone if necessary."
88864980|NCT02983045|Experimental|Dose Escalation: Combination of NKTR-214 + nivolumab|NKTR 214 + nivolumab at 5 dosage levels to determine the RP2D Part 1 of RP2D in patients with advanced or metastatic melanoma, RCC, NSCLC, urothelial carcinoma, or TNBC.
89003492|NCT05163873|Experimental|Extra-peritoneal|Surgery technique in the formation of permanent end colostomy
89389448|NCT02031666|Experimental|Treatment H|15 participants will receive 240-mg dose as Tablet Formulation number 7 of JNJ-56021927.
89389449|NCT01354405||Lanreotide|
89389450|NCT03363035|Experimental|Rivaroxaban 2.5 mg|One 2.5 mg rivaroxaban tablet twice daily
89389451|NCT03363035|Experimental|Rivaroxaban 5 mg|One 5 mg rivaroxaban tablet twice daily
89389452|NCT03363035|Active Comparator|enoxaparin|Enoxaparin 1mg/kg twice daily SC twice daily
89389453|NCT02060084|Experimental|a control group|a control group : the same dose of luke warm water
89389454|NCT02060084|Experimental|treatment group|treatment group: viable Bifidobacterium 0.5 bid po
89389455|NCT05211843|No Intervention|No drink|Control; Participants will receive no drink
89389456|NCT05211843|Experimental|Drinking water|Intervention drink; Participants will receive 500 ml drinking water from the San Francisco tap (i.e. fluoridated tap water). 500 ml is the standard bottle size.
89389457|NCT05211843|Active Comparator|Apple juice|Intervention drink; Participants will receive 200 ml box of apple juice. 200 ml is the standard serving usually available to this study population in the school setting
89389458|NCT03619122|Experimental|Second Examination|Eligible patients who consent to participate undergo planned colonoscopy by endoscopists performing procedures that day per normal standard of care. The colonoscope is passed to the cecum and then withdrawn to the hepatic flexure with washing and aspirating of colonic contents as needed to optimize visualization of colonic mucosa. Then, the colonoscope is inserted to the cecum and withdrawn to the hepatic flexure again for second examination.
89389459|NCT03619122|No Intervention|Traditional Examinaiton|Eligible patients who consent to participate undergo planned colonoscopy by endoscopists performing procedures that day per normal standard of care. The colonoscope is passed to the cecum and then withdrawn to the hepatic flexure with washing and aspirating of colonic contents as needed to optimize visualization of colonic mucosa. Then, the colonoscope is withdrawn to the anus directly.
89389460|NCT01350349|Experimental|Problem Adaptation Therapy (PATH)|Problem Adaptation Therapy (PATH) focuses on the subject, the caregiver, and the subject's home-environment, to encourage problem-solving and adaptive functioning. The goal of PATH is to decrease depression and disability.
89389461|NCT01350349|Active Comparator|Supportive Therapy|Supportive Therapy assists subjects in expressing their feelings and focusing on their strengths and abilities in working through current difficulties and transitions.
89389462|NCT02060942||Coronary artery bypass grafting|Post Anaesthetic Care Unit (PACU) patients treated with coronary artery bypass grafting (CABG) are highly eligible for this study. These are patients with an indication for fast track treatment (PACU) post-cardiac surgery with a good left ventricular ejection fraction without significant co-morbidity. The final decision for PACU-classification is taken by the responsible anaesthesiologist and intensivist in close collaboration with the cardiothoracic surgeon performing the operation, as well as the cardiologist.
89389463|NCT03618732|Experimental|Bilateral movement-based computer training|"All subjects underwent 16 sessions of assigned treatment (2 times per week; for 8 weeks; 3 hours standardized rehabilitation program per visit) There was 1.5 hours standardized conventional physiotherapy training a 1.5 hours multi-disciplinary program which consisted of standardized occupational therapy, speech therapy and nursing care.~Subjects in Intervention Group will be assigned an additional 30 minutes bilateral movement-based computer games(Able-X) training program of upper limb."
89389464|NCT03618732|Other|Video-directed conventional training|All subjects underwent 16 sessions of assigned treatment (2 times per week; for 8 weeks; 3 hours standardized rehabilitation program per visit) There was 1.5 hours standardized conventional physiotherapy training a 1.5 hours multi-disciplinary program which consisted of standardized occupational therapy, speech therapy and nursing care.
89389465|NCT01318213||Intervention Arm|The intervention will consist of wearing gloves and gowns for all patient contact in the ICUs that are randomized to receive the intervention. During the intervention phases of the study, all healthcare workers (nurses, physicians, nurse extenders, respiratory therapists, social workers etc.) in the intervention group will be required to wear gloves and gowns for patient contact and when entering any patient room. In essence, healthcare workers will apply the CDC Contact Precautions guidelines for ALL patients.
88864981|NCT02983045|Experimental|Dose Expansion: Combination of NKTR-214 + nivolumab|NKTR-214+nivolumab in patients with advanced or metastatic solid tumor malignancies to assess the efficacy of the RP2D.
89389466|NCT01318213||Non-intervention - Usual Standard of Care|The non-intervention units will follow their present standard of care. For all of these units, this will consist of healthcare workers following Contact Precautions (gloves and gowns) only for patients known to have antibiotic-resistant bacteria such as VRE and MRSA based on previous admission clinical and surveillance cultures or clinical cultures from the present admission. This represents on average 20-25% of patients on Contact Precautions. For the rest of the patients standard precautions will be followed.
89389467|NCT03150485|Experimental|etafilcon A Toric Multifocal|
89389468|NCT03150485|Active Comparator|etafilcon A Multifocal|
89389469|NCT02060552|Placebo Comparator|Febuxostat|Febuxostat 40mg once a day
89389470|NCT02060552|Experimental|Febuxostat plus diacerein|Febuxostat 40mg once a day plus diacerein 50mg twice a day
88864982|NCT02983045|Experimental|Experimental: Combination of NKTR-214 + nivolumab + ipilimumab|To assess the safety and tolerability of NKTR 214 + nivolumab + ipilimumab triplet therapy and establish RP2D dosing schedules for Part 4 in patients with advanced or metastatic melanoma, RCC, NSCLC, or UCC in a first-line setting (1L).
88864983|NCT02983045|Experimental|Experimental: Dose Expansion of Part 3|To further assess the RP2D triplet combination dosing schedules from Part 3 in 1L NSCLC and 1L RCC patients.
88864984|NCT02944136|Active Comparator|Enhanced Usual Care|Referred to a therapist and/or psychiatrist in their home town depending on the type of treatment they prefer (e.g., behavioral and/or medication)
88864985|NCT02944136|Experimental|stepped collaborative care|At least biweekly contact from a care coordinator by phone and face-to- face visits occurring approximately every 2 months during the patients outpatient visits or treatment, and 24/7 access to a website that was specifically designed during the pilot study for advanced cancer patients from socioeconomically disadvantaged backgrounds.
88864986|NCT02923440|Experimental|Congenital heart defects|
88864987|NCT02894398|Experimental|Palbociclib+AI or Fulvestrant|Letrozole as first-line or later line, Anastrozole as first-line, Exemestane as first-line, Fulvestrant as first-line or later line after prior endocrine therapy.
88864988|NCT02871752|Experimental|MBSR (Mindfulness condition)|MBSR (mindfulness-based stress reduction) is a group-based, 8-week program that was developed at the University of Massachusetts Stress Reduction Clinic under the direction of Jon Kabat-Zinn. MBSR is comprised of a structured, developmentally sequenced curriculum that uses a group format to experientially instruct participants in the practice of mindfulness meditation and mindful Hatha yoga. Each session includes different forms of meditation practice, such as cultivating awareness of thoughts, feelings and bodily sensations, and learning to incorporate this awareness during stressful emotional and/or physical life situations. Lesson activities include the following: (1) mindful meditation (e.g., awareness of breathing, body scan, sitting, walking); (2) yoga; and (3) group discussion.
88864989|NCT02871752|Active Comparator|HealthPro (Control Matched Condition)|HealthPro is a health promotion program designed by Dr. David Victorson of Northwestern University Medical Social Sciences Department and his research team to function as a matched control for the MBSR intervention in this research study. The program teaches and promotes healthy behaviors, skills, and lifestyles. Major learning themes include: (1) health behavioral change readiness and self-assessment; (2) physical activity, movement, and non-sedentary lifestyles; (3) dietary and nutritional considerations for optimal health; (4) emotional wellness and coping with difficulties; (5) social engagement, relationships intimacy, and health; (6) managing bodily pain; (7) weight management and weight loss strategies; (8) health behavior maintenance over the long-term.
89185866|NCT04060875||Feasibility group|First phase group will involve piloting a novel virtual reality treatment for chronic pain to investigate feasibility and safety with a smaller number of patients
89185867|NCT00736502||Patients HIV-1 positive|
89185868|NCT04088084|Experimental|standard of care+palmitoylethanolamide|PEA was supplemented for 3 months to the standard of care (SOC, topical IOP lowering med)
89185869|NCT04088084|No Intervention|standard of care|patients were only on topical IOP lowering therapy (SOC)
89389471|NCT02060552|Experimental|Febuxostat plus Colchicine|Febuxostat 40mg once a day plus Colchicine 0.5mg twice a day
89389472|NCT01358149|Placebo Comparator|placebo|cocoa-based food 1
89389473|NCT01358149|Active Comparator|Treatment 1|cocoa-based food 2
89389474|NCT05384886||Group1: COVID-19 patients in 2020|All patients over the age of 18 diagnosed with COVID-19 in 2020
89389475|NCT05384886||Group: COVID-19 patients in 2022|All patients over the age of 18 diagnosed with COVID-19 in 2022
89185870|NCT02593370|Experimental|Suprasacral Parallel Shift guided by US/MR image fusion|Use of ultrasound/MR image fusion guided Suprasacral Parallel Shift technique to place a lumbar plexus block (20 mL 2% lidocaine with epinephrine added gadoterate meglumine).
89185871|NCT02593370|Active Comparator|Suprasacral Parallel Shift guided by US|Use of ultrasound guided Suprasacral Parallel Shift technique to place a lumbar plexus block (20 mL 2% lidocaine with epinephrine added gadoterate meglumine).
89185872|NCT04061109|Experimental|Prophylactic therapy|Subjects received Recombinant Human Coagulation FVIII for prophylactic therapy with 25 - 35 IU/kg injection once every other day or three times per week for 6 months.
89185873|NCT04087616|Experimental|CBIT|ICBIT. Intervention delivered through an internet platform called Managing children's' tics (www.cbteamathome.co.il), based on CBIT protocol (Woods et al., 2008) adapted to an online parent-guided self-help format.
89185874|NCT04087616|Placebo Comparator|Waiting List|Participants initially assigned to the wait list receive no psychosocial intervention for 9 weeks. Following post-WL assessment, all participants receive ICBIT.
89185875|NCT00918320|Experimental|Toptecan + temozolomide|
89185876|NCT02593292|Active Comparator|PROSPERO group (intervention group)|
89185877|NCT02593292|Placebo Comparator|control group|
89185878|NCT00729560|Experimental|1|Flutamide
89185879|NCT00729560|Placebo Comparator|2|control to arm 1
89185880|NCT03202017|Active Comparator|Expiratory Muscle Strength Testing (EMST)|EMST is a treatment method that has been used to improve cough function and swallowing in ALS. EMST uses a training device that has a valve set to 50% of a patient's maximum expiratory pressure (MEP). The patient exhales forcefully until the valve releases. Patients perform 5 sets of 5 repetitions a day, 5 days a week.
89185881|NCT03202017|Active Comparator|EMST + Lung Volume Recruitment (LVR)|"EMST is a treatment method that has been used to improve cough function and swallowing in ALS. EMST uses a training device that has a valve set to 50% of a patient's maximum expiratory pressure (MEP). The patient exhales forcefully until the valve releases. Patients perform 5 sets of 5 repetitions a day, 5 days a week.~LVR is a technique to increase cough function that is performed with a resuscitation bag fitted with a mouthpiece and a one-way valve. The bag is used to expand the lungs, after which the patient makes a voluntary cough."
89185882|NCT00918008||Blood sample|the blood sample only collected prior to surgery
89185883|NCT00736190|Experimental|TDF|300-mg tablet (marketed formulation) taken orally once daily
89185884|NCT04060797|Experimental|endovascular denervation|endovascular denervation
89185885|NCT02565771||Young adult survivors of childhood cancer|Adults treated for childhood cancer in Rhône-Alpes region in France between 1987 and 1992 with deregulation ANS or autonomic imbalance.
89185886|NCT00729326|Experimental|Sequence A|
89185887|NCT00729326|Experimental|Sequence B|
89185888|NCT02565303|Experimental|L2-3 intervertebral group|The initial dose of ropivacaine for subarachnoid is chosen as 12 mg in L2-3 intervertebral space group.
89185889|NCT02565303|Experimental|L3-4 intervertebral group|The initial dose of ropivacaine for subarachnoid is chosen as 15 mg in L3-4 group.
89185890|NCT02565849||Control group|Recruited volunteers aged above 18 years with no history of smoking or hospitalization in the last three months without cardiac dysfunction, orthopedic or lung.
89185891|NCT02565849||Sickle Cell Anemia normal spirometry|Recruited patients aged above 18 years with no history of smoking or hospitalization in the last three months, ability to independent ambulation and spirometry tests and plethysmography with normal medical report.
89185892|NCT02565849||Sickle Cell Anemia spirometry abnormal|Recruited patients aged above 18 years with no history of smoking or hospitalization in the last three months, ability to independent ambulation and spirometry tests and plethysmography with altered medical report.
89185893|NCT05476809|Experimental|smart-cloth|The upgraded smart-cloth assisted home nursing integrate smart-cloth monitoring system, home nursing, and family caregiver feedback app. The persons living with dementia will be asked to wear a smart cloth 24 hours a day and will be monitored on abnormal activity level, going out alone, abnormal number of getting-up at night, fall risks. In addition, monitoring for medication, abnormal life pattern, quality of hired help will also be included. The warning signals, along with weekly summary and related information will be sent to the family caregiver interactive App after the assessment of the home care nurses to provide guidance for family care.
89185894|NCT05476809|No Intervention|usual care|Routine clinical care will be provided to the participants.
89185895|NCT00696423|Experimental|Infanrix/Hib Single Injection Group|Subjects received 1 dose of Infanrix™ extemporaneously mixed with Hiberix™.
89185896|NCT00696423|Active Comparator|Infanrix + Hiberix Separate Injection Group|Subjects received two separate injections, one of Infanrix™ and one of Hiberix™.
89185897|NCT02592668|Experimental|Active stimulation|Subjects will be implanted with an epidural stimulator onto the dorsal aspect of the lumbosacral spinal cord dura mater. Patients will undergo a structured program of daily physical rehabilitation, treadmill step training, and epidural stimulation to recover motor, sensory, and autonomic function. The total estimated time for the intervention is 66 weeks.
89185898|NCT00918164|Experimental|Healthy adult volunteers|Standard Phase 1 normal healthy adult volunteers, age range 21-55 years and of either sex
89185899|NCT00576693|Experimental|intensive medical management plus stenting|intracranial angioplasty and stenting using the Gateway balloon and Wingspan self-expanding nitinol stent (or any future FDA approved iterations of the balloon, stent, or the delivery systems) plus intensive medical therapy (aspirin 325 mg / day for entire follow-up, clopidogrel 75mg per day for 90 days after enrollment unless cardiologist recommends continuing clopidogrel beyond 90 days for a cardiac indication, and aggressive risk factor management primarily targeting blood pressure < 140 / 90 mm Hg (< 130 / 80 if diabetic) and LDL < 70 mg / dl).
89389476|NCT01350427|Experimental|Leucine|
89389477|NCT01350427|Experimental|BCAA|
89389478|NCT01350427|Placebo Comparator|Placebo|
89389479|NCT05384574|Experimental|Intervention|Patients with low levels of Vitamin D on admission to ICU randomized to receive vitamin D supplementation
89389480|NCT05384574|No Intervention|Control|Patients with low levels of Vitamin D on admission to ICU not receiving vitamin D supplementation
89389481|NCT04355585|Experimental|Male|Participants in this group will be randomized to receive either a single dose of colchicine (1.8mg administered over 1 hour in the form of tablets) or placebo.
89185900|NCT00576693|Experimental|intensive medical management alone|Intensive medical therapy alone (aspirin 325 mg / day for entire follow-up, clopidogrel 75mg per day for 90 days after enrollment unless cardiologist recommends continuing clopidogrel beyond 90 days for a cardiac indication, and aggressive risk factor management primarily targeting blood pressure < 140 / 90 mm Hg (< 130 / 80 if diabetic) and LDL < 70 mg / dl)
89185901|NCT00698451|Experimental|001|doxorubicin HCL liposome; bevacizumab; carboplatin30 mg/m2 by intravenous infusion Day 1 of each 28 day cycle; 10 mg/kg by intravenous infusion Days 1 and 15 of each 28 day cycle; AUC=5 by intravenous infusion Day 1 of each 28 day cycle
89185902|NCT00921375|Experimental|Tuly, uric acid lowering drug|TULY (rasburicase) 0.20 mg/kg body weight intravenously for 4 days
89389482|NCT04355585|Experimental|Female|Participants in this group will be randomized to receive either a single dose of colchicine (1.8mg administered over 1 hour in the form of tablets) or placebo.
89389483|NCT05189743|Experimental|Dermis graft|
89389484|NCT05189743|Experimental|STSG|
89389485|NCT02061020|Experimental|Sequence 1|"THC containing cigarettes 10mg~THC containing cigarettes 30mg~Placebo"
89389486|NCT02061020|Experimental|Sequence 2|"THC containing cigarettes 30mg~Placebo~THC containing cigarettes 10mg"
89389487|NCT02061020|Experimental|Sequence 3|"Placebo~THC containing cigarettes 10mg~THC containing cigarettes 30mg"
89389488|NCT02031744|Placebo Comparator|erlotinib [Tarceva] + placebo|
89389489|NCT02031744|Experimental|erlotinib [Tarceva] + onartuzumab [MetMAb]|
89389490|NCT04653389|Experimental|Preoperative TACE+Sintilimab+/-Radiotherapy of vein tumor thrombus+postoperative Sintilimab|The first TACE and immunotherapy will be performed at the same time on the first day of treatment. Anti-PD-1 Injection will be administered every three weeks ,until the disease progresses according to mRECIST criteria or intolerable toxicity or the patients' request, or surgery.Hypofractionated radiation therapy will be adopted for Type Vp2, Vp3 PVTT or Type Vv2 HVTT about 2 weeks after the first TACE.If the imaging examination 4 weeks after the surgery confirm that there is no recurrence and no contraindications to receive immunotherapy, anti-PD-1 antibody adjuvant therapy can be started.Every 21 days is a course of treatment, and the longest medication duration lasts for 6 months.
89389491|NCT03134911||anticoagulation controlled patients|Treated with DOAC or VKA
89389492|NCT03134911||anticoagulation non controlled patients|Treated with VKA
89185903|NCT00697827|Experimental|1|In-Space
89185904|NCT00697827|Active Comparator|2|X STOP
89185905|NCT04026087||patient with kidney transplant|Blood sample will be took from subjects during this research
89185906|NCT02566551|Experimental|Prostate artery embolization|Prostatic artery embolization (PAE) To perform embolization, gelatin microspheres (300-500 microns) will be used in this arm
89185907|NCT02566551|Active Comparator|Transurethral resection of the prostate|Transurethral resection of the prostate (TURP) A bipolar electrosurgery generator will be used to perform TURP
89185908|NCT00728936|Experimental|IMO-2125 0.04 mg/kg q week|IMO-2125 given weekly at 0.04 mg/kg
89185909|NCT00728936|Experimental|IMO-2125 0.08 mg/kg q week|IMO-2125 given weekly at 0.08 mg/kg
89185910|NCT00728936|Experimental|IMO-2125 0.16 mg/kg q week|IMO-2125 given weekly at 0.16 mg/kg
89185911|NCT00728936|Experimental|IMO-2125 0.32 mg/kg q week|IMO-2125 given weekly at 0.32 mg/kg
89185912|NCT00728936|Experimental|IMO-2125 0.48 mg/kg q week|IMO-2125 given weekly at 0.48 mg/kg
89185913|NCT00728936|Placebo Comparator|Placebo|Weekly saline placebo
89185914|NCT00728936|Experimental|IMO-2125 0.16 mg/kg twice a week|IMO-2125 given twice a week at 0.16 mg/kg
89389493|NCT05182593|Experimental|Diet 1: moderate/high FODMAP diet. Diet 2: low FODMAP diet.|The subjects will follow the moderate/high FODMAP diet as the first intervention, and the low FODMAP diet as the second intervention. The subjects will follow both interventions for seven days.
89389494|NCT05182593|Experimental|Diet 1: low FODMAP diet. Diet 2: moderate/high FODMAP diet.|The subjects will follow the low FODMAP diet as the first intervention, and the moderate/high FODMAP diet as the second intervention. The subjects will follow both interventions for seven days.
89530442|NCT03244891|Experimental|Studied subjects|"Each subject will be studied during two sequential phases:~before fluid challenge~after fluid challenge~During each phase, the subjects will be studied at:~baseline - spontaneously breathing~head down position - spontaneously breathing~baseline - positive pressure ventilation~head down position - positive pressure ventilation The sequence a-b-c-d will be randomized for each subject and for each phase"
89530443|NCT03345875|Other|HPV Screening|Study eligible participants will be screened for HPV using a self collected vaginal sample using a collection device and kit. Those who test positive for HPV will be offered visual assessment of the cervix for treatment (VAT) and treatment as appropriate.
88864990|NCT02869399|Experimental|Experimental arm|The experimental arm is based on a dietary intervention in addition to standard recommendations.The diet will be based on the AICR/WCRF recommendations for cancer prevention and for the prevention of recurrences. The intervention strategy will focus on reducing inflammation and reducing glycaemia and insulinaemia while promoting nutrient-rich diet. Patients will be taught how to prepare traditional Mediterranean meals (healthy, satiating, palatable and easy to prepare).
88864991|NCT02869399|No Intervention|Control arm|Patients in the control arm will not receive specific suggestions concerning diet, but standard healthy lifestyle recommendations will be given. The recommendations, including nutritional consultation if needed by standard practice of care, will be reinforced at each clinical visit and through a leaflet according to primary cancer prevention nutritional guidelines. Patients in the control group will not receive any of the recipes or educational materials given to the intervention group and they will not have kitchen classes.
88864992|NCT02855034|Other|Blood sample|All the patients performed the same blood samples for dosage: copeptin, S-100B, GFAP, NFL and UCHL-1 proteins
88864993|NCT02678689|Experimental|BMN190 recombinant human tripeptidyl peptidase-1 (rhTPP1)|An age-appropriate dose of BMN 190 administered via intracerebroventricular (ICV) infusion every other week (qow) for a duration of 144 weeks.
88864994|NCT02678052||Cohort 1: No Chronic Disease|Pregnant women without a current diagnosis of any chronic disease with no exposure to any biological agent and at any time from first day of last menstrual period (LMP) will be observed for up to 1 year.
88864995|NCT02678052||Cohort 2: UC/CD Prospective Cohort|Pregnant women with current diagnosis of UC or CD with exposure to Entyvio or other biologic agents during pregnancy at any dose, and at any time from first day of LMP will be observed for up to 1 year.
88864996|NCT02564263|Experimental|Pembrolizumab|Participants received pembrolizumab 200 mg, intravenously (IV) on Day 1 of every 21-day (3-week) cycle for up to 35 administrations (up to approximately 25 months).
88864997|NCT02564263|Active Comparator|Chemotherapy|Participants received Investigator's choice of paclitaxel 80-100 mg/m^2 IV on Days 1, 8, and 15 of every 28-day (4-week) cycle, OR docetaxel 75 mg/m^2 IV on Day 1 of every 21-day (3-week) cycle, OR irinotecan 180 mg/m^2 IV on Day 1 of every 14-day (2-week) cycle (up to approximately 19 months).
88864998|NCT02540018|Active Comparator|Paclitaxel-coated Luminor® Balloon Catheter|The balloon dilatation procedure, including deployment to the target lesion and balloon inflation, deflation and retrieval, is performed under fluoroscopic observation. An endoluminal guidewire passage of the stenotic and occlusive femoro-popliteal lesion is mandatory. After pre-dilatation of the target lesion an angiographic assessment will be performed (DSA or XA). Randomization will be performed by envelope pull. The treatment group represents the Luminor® DEB PTA. After dilation of the target lesion, the PTA catheter is withdrawn through the introducer sheath, and a post-PTA angiography is performed (DSA or XA) to evaluate the technical result and possible procedural complications. A final run-off angiography (DSA or XA) of the BTK arteries is required.
88864999|NCT02540018|Active Comparator|Uncoated Balloon Catheter|Identical procedure also for control arm with PTA balloon (see below): After pre-dilatation, randomization will be performed by envelope pull. The control group requires an uncoated balloon catheter. After dilation of the target lesion, the PTA catheter is withdrawn and a post-PTA angiography is performed (DSA or XA) to evaluate the technical result and possible procedural complications. A final run-off angiography (DSA or XA) of the BTK arteries is required.
88865000|NCT02522247|Active Comparator|Uvulopalatoplasty|Surgery with cold steel, single sutures of palate and tonsillar pillars including palatopharyngeal muscle
88865001|NCT02522247|No Intervention|Controls|Only waiting 6 months
88865002|NCT02423265|Active Comparator|Ranolazine|500mg bd ranolazine for 1 week then uptitrated to 1000mg bd to continue for 8 weeks
88865003|NCT02423265|Placebo Comparator|Placebo|Matching placebo, with up titration after 1 week as in active treatment arm
88865004|NCT02379819|Experimental|Nucleus Hybrid L24 Implant|Adults age 18 and over who meet FDA criteria for unilateral implantation with the Nucleus Hybrid L24 Implant.
88865005|NCT02368886|Experimental|Arm A1 (lower-dose regorafenib, pre-emptive clobetasol)|Patients receive lower-dose regorafenib PO QD on days 1-21 and pre-emptive clobetasol propionate given topically BID for 12 weeks, beginning on day 1 of regorafenib.
88865006|NCT02368886|Experimental|Arm A2 (lower-dose regorafenib, reactive clobetasol)|Patients receive lower-dose regorafenib PO as in Arm A1 and reactive clobetasol propionate given topically BID beginning on day 1 per physician discretion upon occurrence of PPES grade >= 1.
88865007|NCT02368886|Experimental|Arm B1 (standard dose regorafenib, pre-emptive clobetasol)|Patients receive standard dose regorafenib PO QD on days 1-21 and pre-emptive clobetasol propionate as in Arm A1.
88865008|NCT02368886|Experimental|Arm B2 (standard dose regorafenib, reactive clobetasol)|Patients receive standard dose regorafenib PO as in Arm B1 and reactive clobetasol propionate as in Arm A2.
88865009|NCT02332369|Experimental|Device|Polymethylmethacrylate Capsular Tension Ring introduced into the posterior chamber of the eye following cataract surgery before the implantation of an intraocular lens.
88865010|NCT02262221|No Intervention|ARM A (Non intensive Follow up)|Follow up consisting of outpatient visits according to the schedule foreseen for single head and neck subsite. At each follow up visit patients will report all new symptoms and they will receive physical and fiberoptic endoscopic head and neck examination. Laboratory tests will be performed once a year. Quality of life questionnaires will be administered to patients every other visit for the first 2 years and then at each visit. A socio-economic questionnaire will be also administered at each visit. Locoregional imaging will be performed within 6 months after radiotherapy end and recommended only at the occurrence of new signs or symptoms. Patients will be contacted by a phone call between visits in order to monitor patient's reported symptoms potentially related to disease recurrence.
89003493|NCT05154201|Experimental|Dose escalation of ORIN1001 as a single agent|"Single-agent dose escalation in Chinese patients with advanced solid tumors. Nine dose groups: 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 650 mg, 900 mg, 1200 mg, and 1500 mg orally in 21-day cycles.~A total of 27-54 evaluable patients are expected to be enrolled. However, the dose in the escalation phase is not limited to these dose groups, and the number of enrolled patients is not limited to 27-54."
89530444|NCT03244735|Experimental|Modified Atkins Diet (MAD)|CCH patients that follows at least 3 months of MAD
89530445|NCT03247855|Other|Minimal invasive coronary artery bypass graft|
89530446|NCT04500743|Active Comparator|Dienogest|
89530447|NCT04500743|Active Comparator|GnRH analogue|
89185915|NCT03980925|Experimental|Nivolumab + platinum-doublet chemotherapy|"Induction Phase: Nivolumab 360 mg IV plus Carboplatin IV (AUC=5) plus Etoposide 10mg/m2/day on days 1-3D, all every 3 weeks up to 6 cycles followed by Nivolumab 480mg for 24 months or until PD, death or toxicity.~Order of administration: Nivolumab, Carboplatin, Etoposide~Maintenance Phase Nivolumab 480 mg IV will be administered every 4 weeks (±3 days) for 2 years."
89185916|NCT00693693|Active Comparator|Cream-|topical hydrocortisone 17-butyrate 0.1% Cream preparation applied twice daily to all lesions of atopic dermatitis
89185917|NCT00693693|Active Comparator|Ointment|topical hydrocortisone 17-butyrate 0.1% Ointment preparation applied twice daily to all lesions of atopic dermatitis
89185918|NCT00693693|Active Comparator|Lipocream|topical hydrocortisone 17-butyrate 0.1% Lipocream preparation applied twice daily to all lesions of atopic dermatitis
89185919|NCT02565693|Experimental|Apixaban|"Apixaban: oral, 5 mg twice daily. If two of the three following criteria are met, the dose will be reduced to 2.5 mg twice daily:~Age ≥ 80 years~Body weight ≤ 60 kg~Serum creatinine ≥ 133 μmol. Additionally, if the creatinin clearance is below 30 ml per minute, the dose will be reduced to 2.5 mg twice daily."
89185920|NCT02565693|Other|Avoiding oral anticoagulants|"The following treatment regimens are allowed in the comparator arm:~- No antithrombotic treatment~or:~Acetylsalicylic acid 80 mg once daily~Carbasalate calcium 100 mg once daily~Clopidogrel 75 mg once daily~Acetylsalicylic acid 80 mg once daily and dipyridamole 200 mg twice daily~Carbasalate calcium 100 mg once daily and dipyridamole 200 mg twice daily"
89185921|NCT04603989|Experimental|HNC042|HNC4042 for injection,freeze-dried powder,multiple ascending doses, Intravenous route
89185922|NCT04603989|Placebo Comparator|Placebo|Placebo, multiple ascending doses, Intravenous route
89185923|NCT00728468|Experimental|Treatment arm|
89185924|NCT04061655|Active Comparator|iron therapy group|Apatients (n= 40) received single dose intravenous infusions of iron isomaltoside 1000 mg over 15 min with a maximum single dose of 20 mg/kg.
89185925|NCT04061655|Placebo Comparator|placebo|Patients in the placebo group (n=40)received as a single-dose of saline (Natriumklorid 9 mg/ml; Fresenius Kabi, Copenhagen, Denmark) 100 ml infused over 15 min.
89185926|NCT04061265|Active Comparator|Lidocaine 2% group|lidocaine hydrochloride 2% and epinephrine 1:100000 (Lignospan® standard, 1.7ml, SEPTODONT Ltd)
89185927|NCT04061265|Experimental|Articaine 4%|articaine hydrochloride 4% and epinephrine 1:100000 (Septocaine® 1.7ml, SEPTODONT Ltd)
89185928|NCT02592980|Experimental|Traditional anticoagulation|For the Traditional Anticoagulation group, the physician will adjust the dose according to the current INR value based on current guidelines
89185929|NCT02592980|Experimental|Pharmacogenetic anticoagulation|For the Pharmacogenetic Anticoagulation group, the dose will be prescribed based on data from each patient applied in a pharmacogenetic algorithm. In some cases, used algorithm may provide a counter-intuitive dose, i.e., a dose that is not adequate for adjusting the current patient' INR (for example, a higher dose for a patient that already has a high INR). In these cases, the physician will adjust the dose following clinical criteria based on published guidelines
89185930|NCT00921453||Intervention 1|Participants using the prototype to receive expert system guided tailored internet information about the type of headache of a family member who provided anamnesis data for a common kind of headache.
89185931|NCT00921453||Control 1|Participants using search engines and portals to gather internet information about the type of headache of a family member who provided anamnesis data for a common kind of headache.
89185932|NCT00921453||Intervention 2|Participants using the prototype to receive expert system guided tailored internet information about the type of headache of a family member who provided anamnesis data for a less common kind of headache.
89185933|NCT00921453||Control 2|Participants using search engines and portals to gather internet information about the type of headache of a family member who provided anamnesis data for a less common kind of headache.
89185934|NCT00727844|Experimental|Delayed Start Linezolid|Subjects continued their existing regimen for 2 months after which LZD (600 mg once daily) was added. After 2 consecutive AFB negative sputum smears (not to exceed 4 months of LZD therapy), subjects were randomized to continue on 600 mg LZD once daily or to de-escalate to 300 mg once daily. Regardless of the dosage, subjects remained on LZD treatment for 18 months after sputum culture conversion or until they could no longer tolerate therapy.
89185935|NCT00727844|Experimental|Immediate Start Linezolid|Upon completion of entry criteria, subjects had LZD (600 mg once daily) added to their regimen. After 2 consecutive AFB negative sputum smears (or at 4 months) subjects were randomized to continue on 600 mg LZD once daily or to de-escalate to 300 mg once daily. Regardless of the dosage, subjects remained on LZD treatment for 18 months after sputum culture conversion or until they could no longer tolerate therapy.
89185936|NCT00735878|Experimental|ABT-751 100 mg and Carboplatin|100 mg BID ABT-751 orally for 7 days. Carboplatin AUC 4.5 once every 21 days.
89185937|NCT00735878|Experimental|ABT-751 125 mg and Carboplatin|125 mg BID ABT-751orally for 7 days. Carboplatin AUC 4.5 or 6 once every 21 days.
89185938|NCT00735878|Experimental|ABT-751 150 mg and Carboplatin|150 mg BID ABT-751orally for 7 days. Carboplatin AUC 6 once every 21 days.
89185939|NCT02594150|No Intervention|usual care|Each FIT kit will include a tube in which to deposit the stool sample, directions on how to collect and mail the sample, a letter about colorectal cancer screening, a Labcorp requisition form, and a pre-paid return envelope.
89185940|NCT02594150|Experimental|unconditional fixed incentive|This arm will receive a FIT kit as described in the mailed FIT arm and will also receive a financial incentive in the form of a gift card and a note explaining that this gift card is a token of our appreciation for completing the kit.
89185941|NCT02594150|Experimental|conditional fixed incentive|This arm will receive a FIT kit as described in the mailed FIT arm and will receive a note stating that they will receive a financial incentive in the form of a gift card if they return their completed FIT within two months of receiving the FIT kit.
89185942|NCT02594150|Experimental|conditional lottery incentive|This arm will receive a FIT kit as described in the mailed FIT arm and will receive a note stating that they will be entered in a 1/10 chance lottery to receive a financial incentive in the form of a gift card if they return their completed FIT within two months of receiving the FIT kit.
89185943|NCT02593838|Other|CTP and SPECT-MPI|Every patient enrolled will undergo CT-MPI and SPECT-MPI. The latter is clinically indicated,.
89530448|NCT03247699|Other|"Basel phenotyping cocktail capsule"|
89185944|NCT00695955|Experimental|Azilsartan Medoxomil|
89185945|NCT04547205|Experimental|AK109|
89185946|NCT00693225|Active Comparator|Omeprazole/sodium bicarbonate AM dose|8 weeks of therapy with omeprazole/sodium bicarbonate oral suspension 40 mg, once per day, taken in the morning
89185947|NCT00693225|Experimental|Omeprazole/sodium bicarbonate PM dose|8 weeks of therapy with omeprazole/sodium bicarbonate oral suspension 40 mg, once per day, taken at bedtime
89185948|NCT03890445||Adalimumab Biosimilar (Hyrimoz)|Patients with moderate-to-severe CD receiving Hyrimoz™ treatment according to the Hyrimoz™ label at the discretion of the investigator
89185949|NCT03890445||Infliximab Biosimilar (Zessly)|Patients with moderate-to-severe CD receiving Zessly™ treatment according to the Zessly™ label at the discretion of the investigator
89185950|NCT03773757|Experimental|IN-PEACE Dementia Care Coordination|In-PEACE intervention arm will have monthly contact with a dementia care coordinator (DCC) to to identify symptoms the person with memory problems is having, including: pain, sadness, or other symptoms. The Dementia Care Coordinator will consult with the project clinical team to develop a plan of care utilizing standardized protocols to reduce the burdens of disease associated symptoms and behaviors.
89185951|NCT03773757|No Intervention|Usual Care|The usual care arm will have access to education and informational materials from the local chapter of the Alzheimer's Association and other community resources and will be reminded of these resources throughout the study.
89185952|NCT00735644|Experimental|JE-CV GPO MBP (Lot 1)|Participants 12 to 18 months of age received one dose of Japanese encephalitis chimeric virus vaccine (JE-CV) from Government Pharmaceutical Organization Mérieux Biological Products (GPO-MBP) Lot 1.
89185953|NCT00735644|Experimental|JE-CV GPO MBP (Lot 2)|Participants 12 to 18 months of age received one dose of Japanese encephalitis chimeric virus vaccine (JE-CV) from Government Pharmaceutical Organization Mérieux Biological Products (GPO-MBP) Lot 2.
89185954|NCT00735644|Experimental|JE-CV GPO MBP (Lot 3)|Participants 12 to 18 months of age received one dose of Japanese encephalitis chimeric virus vaccine (JE-CV) from Government Pharmaceutical Organization Mérieux Biological Products (GPO-MBP) Lot 3.
89185955|NCT00735644|Active Comparator|JE-CV WRAIR (Group 4)|Participants 12 to 18 months of age received one dose of JE-CV from Acambis at Walter Reed Army Institute of Research (WRAIR)
89185956|NCT00735644|Sham Comparator|Hepatitis A (Group 5)|Participants 12 to 18 months of age randomized to receive Hepatitis A vaccine
89185957|NCT03718299|Other|tildrakizumab 100 mg|
89185958|NCT02591888|Active Comparator|Liposomal bupivacaine|Subjects in this arm will received the drug - liposomal bupivacaine 30 ml.
89185959|NCT02591888|Placebo Comparator|Placebo|Subjects in this arm will received the placebo - normal saline 30 mL.
89185960|NCT00724958||Remicade|Subjects with active luminal and/or fistulizing CD in the hospital or non-hospital setting.
89185961|NCT04086836||Patient suffering a late stroke after TAVR|All patients suffering a stroke after TAVR will be studied
89185962|NCT04088006|Experimental|Treated cheek and neckline area|Intra-individual study with one cheek and one side of neckline area treated
89185963|NCT04088006|No Intervention|Non-treated cheek and neckline area|Intra-individual study with one cheek and one side of neckline area non-treated
89185964|NCT02593136|Experimental|Home Fortification and Counseling|Participants aged 6 to 18 months will receive a daily supplement of vitamins and minerals in dry powder form to be taken once daily for up to nine months or up to 240 sachets. Participant caregivers will also receive improved young child feeding practices (IYCF) counseling from a front line worker.
89185965|NCT02593136|Experimental|Improved Child Feeding Practices (IYCF) Counseling|Participants ages 6 to 18 months will receive improved young child feeding practices (IYCF) counseling from a front line worker.
89185966|NCT04087928|Experimental|Group Flexors (A)|Group A was treated by applying FMV to the flexor muscles of the upper limb (brachial biceps and carpal flexors). Patients will be treated with FMV for three consecutive days: each session consisted of three sessions of 10 minutes each, interspersed with one minute of rest. A vibration frequency of 100 Hz has been applied, according to the literature.
89185967|NCT04087928|Experimental|Group Extensors (B)|Group b was treated by applying FMV to the extensors muscles of the upper limb (triceps brachial and carpus extensors). Patients will be treated with FMV for three consecutive days: each session consisted of three sessions of 10 minutes each, interspersed with one minute of rest. A vibration frequency of 100 Hz has been applied, according to the literature.
89185968|NCT00695565|Placebo Comparator|Placebo Gel|Placebo Gel is vehicle without clonidine
89185969|NCT00695565|Active Comparator|Clonidine Topical Gel (ARC-4558)|Clonidine Topical Gel contains 0.1% clonidine hydrochloride
89185970|NCT00727532|Experimental|Sorafenib|Eligible patients undergo pre-treatment DW-MRI of the abdomen and pelvis. Patient then receive Sorafenib 400mg orally twice daily on days 1-28. Following completion of 28 days of sorafenib, patients obtain a second DW-MRI.
89185971|NCT00742599|Active Comparator|N|
89185972|NCT00742599|Placebo Comparator|P|
89185973|NCT00742677|Experimental|Group 1 (early feeding)|Patients are offered a liquid diet on day 1 for 24 hours following surgery. Beginning on day 2, patients who tolerate a liquid diet are offered a light regular diet until hospital discharge.
89530449|NCT03247699|Other|"Basel phenotyping cocktail individual components"|
89185974|NCT00742677|Active Comparator|Group 2 (traditional feeding)|Patients are offered nothing by mouth on days 1 and 2 following surgery. Beginning on day 3, patients are offered a liquid diet for 24 hours. Beginning on day 4, patients who tolerate a liquid diet (absence of nausea and vomiting) are offered a semi-solid diet for 24 hours. Beginning on day 5, patients who tolerate a semi-solid diet are offered a light regular diet until hospital discharge.
89389495|NCT02061098|Experimental|Pomegranate extract|"Crossover and dose-response: Both groups A and B will consume pomegranate extract and placebo. Both groups will also consume two doses of pomegranate extract and placebo.~Group A will consume 1 daily capsule of pomegranate extract and group B will consume 1 daily capsule of placebo for 3 weeks. After a wash-out period of 3 weeks, group A will consume 1 daily capsule of placebo and group B will consume 1 daily capsule of pomegranate extract for 3 weeks. After a washout period of 3 weeks, group A will consume 4 daily capsules of pomegranate extract for 3 weeks and group B will consume 4 daily capsules of placebo for 3 weeks. After a washout period of 3 weeks, group A will consume 4 daily capsules of placebo for 3 weeks and group B will consume 4 daily capsules of pomegranate for 3 weeks."
89185975|NCT02593058|Experimental|PEPS+TAU|Eight one-hour weekly sessions of Positive Emotions Program for Schizophrenia (PEPS) + Treatment as Usual (TAU)
89389496|NCT02061098|Placebo Comparator|Placebo|"Crossover and dose-response: Both groups A and B will consume pomegranate extract and placebo. Both groups will also consume two doses of pomegranate extract and placebo.~Group A will consume 1 daily capsule of pomegranate extract and group B will consume 1 daily capsule of placebo for 3 weeks. After a wash-out period of 3 weeks, group A will consume 1 daily capsule of placebo and group B will consume 1 daily capsule of pomegranate extract for 3 weeks. After a washout period of 3 weeks, group A will consume 4 daily capsules of pomegranate extract for 3 weeks and group B will consume 4 daily capsules of placebo for 3 weeks. After a washout period of 3 weeks, group A will consume 4 daily capsules of placebo for 3 weeks and group B will consume 4 daily capsules of pomegranate for 3 weeks."
89389497|NCT01344239|Experimental|Limb RIPC|The limb RIPC protocol was applied after anesthetic induction and before the start of surgery. The limb RIPC was induced by placing a blood pressure cuff on the left upper arm of patient for three inflating-deflating cycles: 5 min inflating to 200 mmHg followed by a 5 min reperfusion with deflating the cuff.
89389498|NCT01344239|No Intervention|convention|Adult patients undergoing elective open abdominal aortic aneurysm repair received no treatment after induction of anaesthesia
89389499|NCT03618576|Experimental|Balance exercise group|During the 2-week postoperative intervention period, patients will participate in the hospital's exercise program beginning 5-7 days after HFS. All participants will follow the computer-based balance specific exercise (BSE) program.
89389500|NCT02061176|Experimental|Transanal Haemorrhoidal Dearterialization|Patients randomised to Transanal Haemorrhoidal Dearterialization.
89389501|NCT02061176|Active Comparator|Open Haemorrhoidectomy|Patients randomised to Open Haemorrhoidectomy
89389502|NCT01344317||Caffeine group|Premature infants below 30 weeks of gestation who receive Caffeine treatment
89389503|NCT01344317||Caffeine and Doxapram group|Premature infants below 30 weeks of gestation who receive Caffeine and Doxapram treatment
89389504|NCT01344317||Group with no treatment|Premature infants below 30 weeks of gestation with no stimulating treatment
88865011|NCT02262221|Other|ARM B (Intensive Follow up)|Intervention foreseen is scheduled radiologic evaluations (CT or MRI scan) and PET scan if patients ≥ 50 years old and with a smoking history ≥ 20 pack year. Follow up outpatient visits will be performed similarly to ARM A, including physical and fiberoptic endoscopic head and neck evaluation and laboratory tests and questionnaires. Locoregional imaging will be requested for all the patients 2 times/year in the first 2 years and 1 time/year in the third and fourth year; PET scan will be requested yearly in the first 3 years. In the first year after RT end, MRI or CT scan will be performed at screening and at sixth month after enrollment, while PET scan will be performed six months after enrollment only in patients ≥50 years and with a smoking history of ≥20 pack/years.
89389505|NCT01350661||Asthma control level assessment|
88865012|NCT02227238|Experimental|DTG arm|Subjects will receive one oral tablet of 50 mg DTG once daily plus two NRTIs selected by the investigator
88865013|NCT02227238|Active Comparator|LPV/RTV arm|Subjects will receive four oral tablets of200/50 mg LPV/RTV once daily or two oral tablets of 200/50 mg LPV/RTV twice daily plus two NRTIs selected by the investigator
88865014|NCT02225925|Experimental|Dynamic dosimetry brachytherapy|Cohort treated with dynamic dosimetry brachytherapy
88865015|NCT02216305|Active Comparator|Hemorrhoidectomy|Open hemorrhoidectomy may include one to three anal cushions and made according to the Milligan-Morgan technique, with resection of the anal cushion and the external hemorrhoidal epidermal component using electrocautery and ligation of the hemorrhoidal base with absorbable suture
88865016|NCT02216305|Active Comparator|HAL-RAR|Hemorrhoidal artery ligation and rectoanal repair will be performed with the AMI minimally invasive surgery device HAL/RAR, and consist in the ligation of the terminal branches of the superior rectal artery with 2-0 absorbable polyglycolic acid suture after identifying the blood flow approximately 3 cm above the dentate line by using Doppler guidance. Subsequently, a running suture was added from the suture point to 5 mm above the dentate line to lift the prolapsing hemorrhoid. Other procedures will not be associated.
89389506|NCT02061254|Experimental|3 groups of subjects|"3 groups:~group of 48 healthy volunteers (matched with venous insufficiency patients)~group of 48 patients with venous insufficiency (16 with stage 1/2, 16 with stage 3/4, 16 with stage 5/6)~group of 40 patients with unilateral lymphedema (20 on upper limb (10 early stage, 10 severe stage), and 20 on lower limb (10 early stage, 10 severe stage))~Each group have the same interventions: physical examination, measures by cutometer, high resolution ultrasonography, elastography 30 persons will have a skin biopsy (15 healthy volunteers and 15 patients with venous insufficiency) For patients with lymphedema, all measures will be performed on lymphedema limb and on controlateral healthy limb"
89389507|NCT05189665|Experimental|Extraperitoneal high sacral ligament suspension Group|We will recruit 62 POP patients ,and perform Surgery Extraperitoneal high sacral ligament suspension surgery on them.
88865017|NCT02126969|Experimental|Chemotherapy plus Radiation Therapy|Low dose fractionated radiation - 80cGy with chemotherapy
88865018|NCT02126969|Active Comparator|Chemotherapy without Radiation|Chemotherapy only
88865019|NCT02121743|Experimental|Strattice|a strattice (10 x 10) will be used during the surgery, prior to the colostomy's conception
88865020|NCT02121743|Placebo Comparator|No strattice|the colostomy is not reinforced with a mesh
88865021|NCT02099188|Experimental|Multimodality treatment|"Squamocellular Carcinoma, Sinonasal Undifferentiated Carcinoma:~Docetaxel at 75 mg/m2 as IV infusion on Day 1 q3w~Cisplatin at 80 mg/m2 as IV infusion on Day 1 q3w~5-fluorouracil at 800 mg/m2/day as IV infusion from Day 1 to Day 4 q3w~Small cell carcinoma neuroendocrine type, Pure neuroendocrine carcinoma and grade III-IV Esthesioneuroblastoma.~Cisplatin at 33 mg/m2/day as IV infusion from Day 1 to Day 3 q3w.~Etoposide at 150 mg/m2/day as IV infusion from Day 1 to Day 3 q3w . Second cycle and every other cycle~Adriamycin at 20 mg/m2/day as IV infusion from Day 1 to Day 3 q3w.~Ifosfamide at 3000 mg/m2/day as IV infusion from Day 1 to Day 3 q3w.~Intestinal Type Adenocarcinoma with functional p53.~Leucovorin* at 250 mg/m2/day as IV infusion from Day 1 to Day 5 q3w.~Cisplatin at 100 mg/m2 as IV infusion on Day 2 q3w~5-fluorouracil at 800 mg/m2/day as IV infusion from Day 2 to Day 5 q3w~Followed by radiotherapy"
88865022|NCT02099175|Experimental|Multimodality treatment|"Squamocellular Carcinoma, Sinonasal Undifferentiated Carcinoma:~Docetaxel at 75 mg/m2 as IV infusion on Day 1 q3w~Cisplatin at 80 mg/m2 as IV infusion on Day 1 q3w~5-fluorouracil at 800 mg/m2/day as IV infusion from Day 1 to Day 4 q3w~Small cell carcinoma neuroendocrine type, Pure neuroendocrine carcinoma and grade III-IV Esthesioneuroblastoma:~First Cycle and every other cycle:~Cisplatin at 33 mg/m2/day as IV infusion from Day 1 to Day 3 q3w~Etoposide at 150 mg/m2/day as IV infusion from Day 1 to Day 3 q3w~Second Cycle and every other cycle:~Adriamycin at 20 mg/m2/day as IV infusion from Day 1 to Day 3 q3w~Ifosfamide at 3000 mg/m2/day as IV infusion from Day 1 to Day 3 q3w~Intestinal Type Adenocarcinoma with functional p53:~Leucovorin* at 250 mg/m2/day as IV infusion from Day 1 to Day 5 q3w~Cisplatin at 100 mg/m2 as IV infusion on Day 2 q3w~5-fluorouracil at 800 mg/m2/day as IV infusion from Day 2 to Day 5 q3w~Followed by Radiotherapy"
88865023|NCT01840150|Experimental|Treatment (NA-NOSE breath test)|Patients undergo breath sample collection for the NA-NOSE breath test at baseline (2 pre-treatment samples), and post-treatment samples at regularly scheduled follow up visits, for 2 years in the absence of disease progression.
88865024|NCT01716026|Active Comparator|3 Month Load with 9 month p.r.n.|3 Monthly bevacizumab injections with 9 p.r.n. monthly doses if patient meets the treatment criteria for each monthly visit
88865025|NCT01716026|Experimental|Single Dose Load Phase|Single dose treatment with bevacizumab, followed by 2 sham injections if conditions are met in the months 2 and 3, and followed with bevacizumab monthly p.r.n. as per protocol
88865026|NCT01715285|Experimental|Abiraterone acetate + Prednisone + ADT|Participants will receive abiraterone acetate tablet at a total dose of 1000 milligram (mg) plus 5 mg capsule of prednisone orally once daily until disease progression, withdrawal of consent or unacceptable toxicity. Stable regimen of androgen deprivation therapy (ADT) will be administered.
88865027|NCT01715285|Placebo Comparator|Placebo + Androgen Deprivation Therapy (ADT)|Participants will receive placebo matched to abiraterone acetate plus prednisone orally once daily until disease progression, withdrawal of consent or unacceptable toxicity. Stable regimen of ADT will be administered.
88865028|NCT01705184|Experimental|BUCiL|"Sequence 1 : 3 cycles of cisplatin-pemetrexed-bevacizumab, then maintenance by bevacizumab if disease control. If progression --> Sequence 2~Sequence 2 : 3 cycles of cisplatin-pemetrexed-bevacizumab, then maintenance by bevacizumab-pemetrexed if disease control"
88865029|NCT01285817|Experimental|traetment|
88865030|NCT01250496|Experimental|Aminophylline|75 mg of intravenous aminophylline.
88865031|NCT01250496|Placebo Comparator|Placebo|Matching normal saline placebo (sterile salt water).
88865032|NCT01134757|Other|house dust mite and alternaria allergy|As the intervention patients with house dust mite or alternaria allergy will undergo a bronchial allergen challenge with mite or alternaria extract. The early asthmatic response (EAR) and the late asthmatic response (LAR) will be measured before and after one year of allergen specific immunotherapy. Except of the challenge no further interventions are planned.
88865033|NCT01105975|Experimental|30 milligram (mg) LY2484595 monotherapy|
88865034|NCT01105975|Experimental|100 mg LY2484595 monotherapy|
88865035|NCT01105975|Experimental|500 mg LY2484595 monotherapy|
88865036|NCT01105975|Placebo Comparator|Placebo|
88865037|NCT01105975|Active Comparator|20 mg Atorvastatin monotherapy|
88865038|NCT01105975|Experimental|100 mg LY2484595 + 20 mg Atorvastatin|
88865039|NCT01105975|Active Comparator|40 mg Simvastatin monotherapy|
89389508|NCT05189665|Active Comparator|Sacrospinous Ligament Suspension Group|We will recruit 62 POP patients ,and perform sacrospinous ligament suspension surgery on them.
88865040|NCT01105975|Experimental|100 mg LY2484595 + 40 mg Simvastatin|
88865041|NCT01105975|Active Comparator|10 mg Rosuvastatin monotherapy|
89389509|NCT01344395|Experimental|RK-group|
89389510|NCT01344395|Active Comparator|K-group|
88865042|NCT01105975|Experimental|100 mg LY2484595 + 10 mg Rosuvastatin|
89389511|NCT02291445|Experimental|Tempocol-ColoPulse®|Tempocol-ColoPulse® is a colon-targeted-delivery peppermint oil capsule that will deliver peppermint oil in the (ileo-) colonic region specifically.
89389512|NCT02291445|Active Comparator|Tempocol®|Tempocol® is an enteric-coated peppermint oil capsule that delivers peppermint oil in the upper small intestine.
88865043|NCT00831623|Experimental|Proton radiation therapy|Single arm
88865044|NCT00651456|Active Comparator|1|Standard Chemotherapy
89003494|NCT05154201|Experimental|Dose escalation of ORIN1001 in combination with Standard of Care|ORIN1001 will be administered daily as a tablet in combination with standard of care. This arm of the study will be carried out in 8 different cancer indications, including advanced triple-negative breast cancer received ≥ 3 lines of treatment, postmenopausal ER+/HER2-advanced breast cancer received the 1 line of treatment, advanced hepatocellular carcinoma received 1/2 line of treatment, chemotherapy-naive castrate-resistant prostatic cancer, advanced pancreatic cancer received 1/2 line of treatment, platinum-resistant/refractory advanced ovarian cancer received ≥ 2 lines of treatment, non-small cell lung cancer received ≥ 2 lines of treatment, and esophageal cancer received ≥ 2 lines of treatment.
89003495|NCT05154201|Experimental|Dose expansion of ORIN1001 as a single agent or in combination with Standard of Care|"After the recommended phase 2 dose of single-agent ORIN1001 is determined, a single-agent efficacy expansion study for advanced esophageal cancer, as well as a single-agent efficacy expansion study for advanced solid tumors with failure of standard treatments or no effective standard treatment.~After the recommended phase 2 dose of the combination treatment is determined, the efficacy expansion study of the combination treatment will be conducted in the corresponding 8 different indications."
89003496|NCT05153148|Experimental|NDI-034858 study drug - Dose 1|NDI-034858 study drug will be orally administered QD for 12 weeks
89003497|NCT05153148|Experimental|NDI-034858 study drug - Dose 2|NDI-034858 study drug will be orally administered QD for 12 weeks
89003498|NCT05153148|Experimental|NDI-034858 study drug - Dose 3|NDI-034858 study drug will be orally administered QD for 12 weeks
89003499|NCT05153148|Placebo Comparator|Placebo|Placebo will be orally administered QD for 12 weeks
89003500|NCT05151744|Experimental|Arm A: Vamikibart + Ranibizumab|Participants will receive vamikibart, 1 milligram (mg) administered as intravitreal (IVT) injection in combination with ranibizumab, 0.5 mg IVT, on Day 1 and every fourth week (Q4W) up to Week 44, for a total of 12 injections, followed by an observational period up to Week 72.
89003501|NCT05151744|Active Comparator|Arm B: Ranibizumab|Participants will receive ranibizumab, 0.5 mg IVT, from Day 1 and Q4W in combination with sham up to Week 44, for a total of 12 injections, followed by an observational period up to Week 72.
89003502|NCT05143736||Modeling cohort|The population enrolled at the intensive care unit of Zhujiang Hospital of Southern Medical University in Guangdong Province, China will be used as a modeling cohort.For the patients in this cohort, the nasal and fecal specimens and related clinical information will collected to construct the prediction model.
89003503|NCT05143736||validation cohort|The population enrolled at the intensive care unit of Dongguan People's Hospital in Guangdong Province, China will be used as a validation cohort.
89003504|NCT05132582|Experimental|Tucatinib + trastuzumab + pertuzumab|Tucatinib + trastuzumab + pertuzumab
89003505|NCT05132582|Active Comparator|Placebo + trastuzumab + pertuzumab|Placebo + trastuzumab + pertuzumab
89003507|NCT05103332|Experimental|Zilebesiran (Add-on to Olmesartan)|Following a run-in on olmesartan, eligible participants will receive zilebesiran on Day 1 of a 6-month double-blind treatment period as add-on to olmesartan. Thereafter, participants will receive zilebesiran once every 6 months during the open-label extension period.
89003508|NCT05103332|Experimental|Placebo (Add-on to Olmesartan)|Following a run-in on olmesartan, eligible participants will receive placebo on Day 1 of a 6-month double-blind treatment period as add-on to olmesartan. Thereafter, participants will receive zilebesiran once every 6 months during the open-label extension period.
89003509|NCT05103332|Experimental|Zilebesiran (Add-on to Amlodipine)|Following a run-in on amlodipine, eligible participants will receive zilebesiran on Day 1 of a 6-month double-blind treatment period as add-on to amlodipine. Thereafter, participants will receive zilebesiran once every 6 months during the open-label extension period.
89003510|NCT05103332|Placebo Comparator|Placebo (Add-on to Amlodipine)|Following a run-in on amlodipine, eligible participants will receive placebo on Day 1 of a 6-month double-blind treatment period as add-on to amlodipine. Thereafter, participants will receive zilebesiran once every 6 months during the open-label extension period.
89003511|NCT05103332|Placebo Comparator|Zilebesiran (Add-on to Indapamide)|Following a run-in on indapamide, eligible participants will receive zilebesiran on Day 1 of a 6-month double-blind treatment period as add-on to indapamide. Thereafter, participants will receive zilebesiran once every 6 months during the open-label extension period.
89003512|NCT05103332|Placebo Comparator|Placebo (Add-on to Indapamide)|Following a run-in on indapamide, eligible participants will receive placebo on Day 1 of a 6-month double-blind treatment period as add-on to indapamide. Thereafter, participants will receive zilebesiran once every 6 months during the open-label extension period.
89185976|NCT02593058|Active Comparator|Treatment As Usual (TAU)|Treatment as usual - with no attempts to standardize this treatment as TAU is tailored to the patient's specific needs
89185977|NCT02565459|Experimental|Mesenchymal Stromal Cells (MSC)|A single intravenous infusion (1-2 millions of MSCs per kilogram body weight) of ex-vivo expanded third-party (from healthy donors) MSCs will be performed in patients randomized to the MSC procedure in addition to the kidney transplantation.
89185978|NCT02565459|No Intervention|No intervention|
89185979|NCT00742755|Experimental|Prospective Intervention|Peer navigator intervention
89185980|NCT03567213|Experimental|Surgical implantation of the CortiCom system|
88865045|NCT00651456|Experimental|2|Standard Chemotherapy + bevacizumab (Avastin)
88865046|NCT00639639|Experimental|Arm I (first randomization)|Patients receive CMV-ALT IV over 45-90 minutes (course 1 only) and CMV pp65-LAMP mRNA-loaded DC (CMV-DC) vaccine intradermally and administered in equal portions to each inguinal region. Vaccination repeats every 1-3 weeks for up to 3 doses in the absence of unacceptable toxicity.
88865047|NCT00639639|Experimental|Arm II (first randomization)|Patients receive CMV-DC vaccine intradermally and administered in equal portions to each inguinal region. Vaccination repeats every 1-3 weeks for up to 3 doses in the absence of unacceptable toxicity.
88865048|NCT00639639|Experimental|Arm I (second randomization)|Within 6 to 24 hours prior to vaccination, patients undergo skin site preparation with unpulsed DCs at the vaccination site in one inguinal region. Patients then receive indium In 111-labeled CMV-DC.
89389513|NCT02062112|No Intervention|Unflavored group|The patient will mix 1 gallon of polyethylene glycol with water and drink as directed by his/her endoscopist. No flavoring will be added.
88865049|NCT00639639|Experimental|Arm II (second randomization)|Within 6 to 24 hours prior to vaccination, patients undergo vaccination skin site preparation in the opposite inguinal region with tetanus toxoid. Patients then receive 111 In-labeled CMV-DC.
88865050|NCT00591695|Active Comparator|A|positioning in emergency of a prosthetic metallic self-expanding stent followed, in case of successful colic decompression, by an elective surgical (laparoscopic or open) resection of the tumour
88865051|NCT00591695|Active Comparator|B|emergency surgery performed in these ways: Resection followed by enterostomy (Hartmann procedure), 'On table' washing and primary anastomoses, Subtotal colectomy
88865052|NCT00079417|Experimental|Treatment (chemotherapy, surgery)|Patients receive chemoreduction comprising carboplatin IV over 60 minutes followed by vincristine IV over 1-2 minutes on day 1. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. After the first course of chemoreduction, patients undergo standardized local ophthalmic therapy comprising local laser therapy, cryotherapy, and/or radioactive plaque comprising iodine I 125 or ruthenium Ru 106.
88865053|NCT04387968||agents in contact with the public|patients working with children, policemen, desk office
88865054|NCT04387968||agents with no contact with the public|administrative workers
88865055|NCT04387890||Serologic Screening|Participants will be screened for IgM and IgG SARS-CoV-2 antibodies at baseline and every 2 weeks. Participants showing symptoms compatible with COVID-19 will undergo nasopharyngeal swab for PCR testing for diagnosis. Participants recovered from COVID-19 will have to have 2 negative and consecutive nasopharyngeal swab PCR tests in order to return to work.
88865056|NCT04387578|Experimental|Group A singlestrand NiTi arch wires|in which 10 patients (5 males and 5 females) were treated with round singlestrand NiTi arch wires in a sequence of 0.012, 0.014, and 0.016 inch.
88865057|NCT04387578|Experimental|Group B Gummetal arch wires|in which 10patients (6 males and 4 females) were treated with niobium-titanium-tantalum-Zirconium arch wires (Gummetal arch wires) in a sequence of 0.014, 0.016, and 0.018 inch.
88865058|NCT04387578|Experimental|Group C multistrand NiTi arch wires|in which 10 patients (4males and 6females) were treated with multistrand NiTi arch wires in a sequence of 0.016, 0.018, and 0.020 inch.
88865059|NCT04387266||Modified reduce-volume target IMRT|Patients with newly diagnosed, non-metastatic NPC was given modified reduce-volume target IMRT
88865060|NCT04386876|Experimental|Orvical-Kaletra-Orvical-Kaletra|In first and third periods of the study, participants received Orvical 200 mg/50 mg Film Tablet manufactured by World Medicine-Turkey. In second and fourth periods, they received Kaletra 200 mg/50 mg Film CoatedTablet manufactured by AbbVie Deutschland GmbH & Co.-Germany. All periods were performed under fasting state.
88865061|NCT04386876|Experimental|Kaletra-Orvical-Kaletra-Orvical|In first and third periods of the study, participants received Kaletra 200 mg/50 mg Film Coated Tablet manufactured by AbbVie Deutschland GmbH & Co.-Germany. In second and fourth periods, they received Orvical 200 mg/50 mg Film Tablet manufactured by World Medicine-Turkey. All periods were performed under fasting state.
88865062|NCT04387032|Experimental|Experimental group|Experimental group (students with hypomobile SIJs)
88865063|NCT04387032|Sham Comparator|Control group|control group (students without hypomobile SIJs)
88865064|NCT04386486|Experimental|bathe group|The patients were divided into two equal groups randomly first group is BATHE anamnesis group.
88865065|NCT04386486|Sham Comparator|standart anamnesis group|The patients were divided into two equal groups randomly second group is standart anamnesis group.
88865066|NCT04386642|Experimental|Experiment group|Each ampule contains TXA 250 mg. TXA preparation is 2000 mg dilute in normal saline 50 ml to get the concentration of 40 mg/ml. TXA will be administered 20 mg/kg loading over 20 min before skin incision followed by a maintenance infusion of 0.025 ml/kg/h (1 mg/kg/h) until the end of operation.
88865067|NCT04386642|Placebo Comparator|Control group|Normal saline solution 50 ml is prepared in a clear 50 ml syringe similar to the experiment group.
88865068|NCT04386408|Experimental|Combination of plant extracts (BSL_EP027)|Volunteers will dissolve in water a sachet per day with the Combination of plant extracts (BSL_EP027), and maltodextrin.
88865069|NCT04386408|Placebo Comparator|Placebo|Volunteers will dissolve in water a sachet per day with maltodextrin.
88865070|NCT04386564||Mild COVID-19|Pneumonia without respiratory failure
88865071|NCT04386564||Moderate COVID-19 up to 60 years|Respiratory frequency ≥30/minute, blood oxygen saturation≤93%
89389514|NCT02062112|Active Comparator|Flavored group|The patient will mix 1 gallon of polyethylene glycol with water, add flavoring to the entire solution and drink at the time specified by his/her endoscopist.
89530450|NCT04500431|Experimental|spCART-269|spCART-269 administered by intravenous (IV) infusion
88865072|NCT04386564||Moderate COVID-19 over 60 years old and severe COVID-19|Pneumonia with respiratory distress syndrome
88865073|NCT04385628||Relatives of patients hospitalized in the intensive care unit|Demographic data of the relative of the patient (age, proximity, educational background, patient co-existence, ethnicity, marital status, number of children, history of psychological treatment and the presence of an intensive care treatment history of any family member before) will be recorded. After the 3rd, 10th, and 30th days of patient admission, and once a month, the patient satisfaction survey will be filled face to face during informing the patient's relative. These three main data (Demographic data of the patient relatives, the most recent satisfaction questionnaire and emotional reactions observed while reporting death) will be evaluated and interpreted.
88865074|NCT04385784|Experimental|Sedentary Intervention Group (SIG)|Group of sedentary older adults who perform the intervention and a home-based exercise program.
88865075|NCT04385784|Experimental|Active Intervention Group (AIG)|Group of active older adults who perform the intervention and a home-based exercise program.
88865076|NCT04385784|Active Comparator|Control Group (CG)|Group of sedentary older adults who perform a home-based exercise program.
88865077|NCT04385550|Experimental|Anlotinib hydrochloride capsule + AK105 injection|Anlotinib hydrochloride capsule 12mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21) plus AK105 200mg intravenously (IV) on Day 1 of each 21-day cycle.
88865078|NCT04385550|Active Comparator|Standard Second-line Chemotherapy|Participants receive 80 mg/m² IV paclitaxel on Days 1, 8 and 15 of each 28-day cycle, or 75mg/m² docetaxel every 3 weeks of each 21-day cycle until disease progression or unacceptable toxicity.
88865079|NCT04385316||Gastric Cancer|
88865080|NCT04385316||Colorectal Cancer|
88865081|NCT04385316||Bladder Cancer|
88865082|NCT04384926||Cohort 1|Adult patients (aged ≥18 years), planned for curative cancer surgery, that have surgery completed during the COVID-19 pandemic
88865083|NCT04384926||Cohort 2|Adult patients (aged ≥18 years), planned for curative cancer surgery, that have surgery delayed or cancelled during the COVID-19 pandemic
88865084|NCT04384614||COVID (+)|Patients COVID19(+) confirmed by PCR
88865085|NCT04384614||COVID (-)|Patients COVID19 (-) who had been in contact with COVID-19 (+) confirmed by PCR
88865086|NCT04384536|Experimental|Neural therapy group|Neural therapy group underwent local anesthetics injections by the same physician. Local injections, segmental injections and injection of trigger points of the forearm are done. The patients are evaluated at the beginning of the study and after 4 weeks of follow-up. Pre and post-treatment visual analog scale and Duruöz Hand Index scores are obtained.
88865087|NCT04384536|No Intervention|Control group|Control group used thumb spica splint and had rest
88865088|NCT04384380|Experimental|HCQ in adult Patients with COVID-19|The administration plan of HCQ is 400 mg bid on Day 1 and 200 mg bid for 6 days on Day 2-7.
88865089|NCT04384380|No Intervention|standard of care treatment (SOC)|The comparison group will receive standard of care, i.e., supportive treatment for subjects with mild COVID-19 clinical illness.
88865090|NCT04384458|Active Comparator|Hydroxychloroquine|Oral hydroxychloroquine 400 mg twice a day on day 1, one 400 mg tablet on day 2, 3, 4, and 5, followed by one 400 mg tablets every 05 days until day 50th associated with with 20 milligrams twice on day of active zinc for 45 consecutive days
88865091|NCT04384458|Active Comparator|Ivermectin|Oral ivermectin dosage guidelines based on participant body weight, once on day for 2 consecutive days. This dose schedule should be repeated every 14 days for 45 days associated with 20 milligrams twice on day of active zinc.
88865092|NCT04383990|Active Comparator|Early Glargine|To take insulin Glargine at 6-7 pm
88865093|NCT04383990|Active Comparator|Late Glargine|To take insulin Glargine at 10-12 pm
88865094|NCT04384224|Placebo Comparator|sham acupuncture + placebo tablet group|sham acupuncture point + placebo tablet
88865095|NCT04384224|Experimental|true acupuncture + placebo tablet group|true acupuncture point + placebo tablet
88865096|NCT04384224|Experimental|true acupuncture + antihistamine group|true acupuncture point + Dexchlorpheniramine (4 mg)
88865097|NCT04384224|Sham Comparator|sham acupuncture + antihistamine group|sham acupuncture point + Dexchlorpheniramine (4 mg)
88865098|NCT04384068||Chinese RA patients|Chinese RA patients who used tocilizumab in real world clinical practice
88865099|NCT04383678||COVID-19 positive patients|
89530451|NCT03253159|Experimental|Hypnosis group|The conversational hypnosis (10-15 min) is standardized and performed just before intravenous general anesthesia induction in the operative room
89530452|NCT03253159|No Intervention|Control group|No special preparation before intravenous general anesthesia induction in the operative room
88865100|NCT04383600|No Intervention|Conventional side|Canine retraction was commenced without micro-osteoperforations.
88865101|NCT04383600|Experimental|Mops side|Canine retraction was commenced with micro-osteoperforations.
88865102|NCT04383366||Patients with keratoconus|
88865103|NCT04383054|Experimental|Long PA intervention group|The long PA intervention will be a MI (motivational interview) exploring the participant's knowledge and concerns about PA. An MI involves a semi-structured discussion between an investigator and the participant. The MI initially explores the participant's knowledge of the benefits of PA and their concerns about PA. The MI will then explore the participant's confidence in increasing their PAL, help the participant come up with a plan to increase their PAL and finally the participant will be signposted to further support and local opportunities for PA. The investigator will use a Moving Medicine 'more minutes' conversation tool of a chronic health condition that the patient has to facilitate every MI. Where possible the investigator will discuss the chronic condition that most relates to the participant's current admission to hospital. For patients with no health conditions the primary prevention section will be used.
88865104|NCT04383054|Active Comparator|Short PA intervention group|The short PA intervention will involve a short (1 min) discussion between an investigator and a participant. A Moving Medicine 'one minute' intervention appropriate to the participant's health conditions will be used to guide every short intervention. The short intervention will firstly involve the investigator asking whether the participant knew that doing PA was beneficial for their health. The investigator would then explain to be more PA they could try to build more PA into their daily routine and that this was often enough to meet the current PA recommendations. The investigator will also offer the participant a patient information sheet about PA.
88865105|NCT04382742|Experimental|Exercise|
88865106|NCT04382040|Experimental|ArtemiC|Active study treatment + Standard care
88865107|NCT04382040|Placebo Comparator|PLACEBO|Placebo + Standard care
88865108|NCT04381884|Experimental|IVERMECTIN (IVER P®)|Patients in this group will receive Ivermectin (IVER P®) 600 µg / kg / once daily plus standard care.
88865109|NCT04381884|No Intervention|CONTROL|Patients in this group will receive standard care.
88865110|NCT04381962|Experimental|Azithromycin|Azithromycin 2x250mg capsules to be taken orally once daily for 14 days. The first dose will be within 4 hours of randomisation. This is in addition to standard care as per local hospital advice for those patients with suspected COVID who are not admitted: i.e. symptomatic relief with rest, as-required paracetamol (where appropriate) and advice to seek further medical attention if significant worsening of breathlessness.
89003513|NCT05094089||SYNECOR IP Device|Hernia mesh repair with GORE® SYNECOR Intraperitoneal Biomaterial
89003514|NCT05094089||SYNECOR PRE Device|Hernia mesh repair with GORE® SYNECOR Preperitoneal Biomaterial
89530453|NCT03247621|Experimental|Whatsapp|Participants will engage in Whatsapp chats on their smartphones during the taste test
89530454|NCT03247621|Placebo Comparator|Article|Participants will read a neutral article on their smartphones during the taste test
89530455|NCT03247621|Active Comparator|No Phone|Participants will not use their phones during the taste test
88865111|NCT04381962|No Intervention|Usual standard care|Standard care as per local hospital advice for those patients with suspected COVID who are not admitted: i.e. symptomatic relief with rest, as-required paracetamol (where appropriate) and advice to seek further medical attention if significant worsening of breathlessness.
88865112|NCT04382430|Experimental|US Guided Axillary venous access|Physician/ provider will perform 2 unassisted & 10 solo Ultrasound (US) guided venous access and pocket creation cardiac device implant. First 2 device implant will be done to educate physicians about ultrasound guided venous access. Subsequent subject will be randomized to 2:1 in ultrasound vs. conventional technique.
88865113|NCT04382430|Active Comparator|Conventional technique|Physician/ provider will perform 5 cardiac device implant using conventional technique for venous access and pocket creation.
88865114|NCT04381572||High fidelity simulation training|Group consisting of medical students scheduled to undergo high fidelity medical simulation as a part of standard scholastic program.
88865115|NCT04381026|Placebo Comparator|Placebo Group|Pill of 500 mg containing filler agent, two pills daily for eight weeks.
88865116|NCT04381026|Experimental|Treatment Group with botanical extracts|Pill of 500 mg containing botanicals and filler agent, two pills daily for eight weeks.
88865117|NCT04381104|Active Comparator|Paracetamol|Capsule Paracetamol 1000 mg 1 hour before the mammography procedure
88865118|NCT04381104|Placebo Comparator|Placebo|The control arm will receive 2 capsules of placebo.
88865119|NCT04380870||Chinese Herbal Medicine|Chinese Herbal Medicine for suspected COVID-19 symptoms.
88865120|NCT04380558||Prospective observational cohort|"Every patient referred to pulmonary rehabilitation program will be eligible. They will will be asked to answer two questionnaires about urinary incontinence symptoms (see outcomes) to assess the prevalence and the type of these symptoms.~They will subsequently participate in their usual pulmonary rehabilitation program consisting in 90min sessions (including endurance training, muscle strengthening and self-management), 3x/week for 8weeks (centre 1) or 2x60min sessions (including the same components), 3x/week for 8weeks (centre 2)."
88865121|NCT04380402|Experimental|Treatment|40 mg
88865122|NCT04380402|No Intervention|Control|Standard care
88865123|NCT04380246||Clinicians|"Clinicians who care for pediatric patients >50% of their time, who treat pediatric patients who are in acute pain and between 0 and 3 years of age. May include physicians, clinical pharmacists, nurse practitioners, physician assistants, and/or nurses.~This cohort will complete a qualitative interview about pain and distress in infants and young children."
88865124|NCT04380012|Experimental|Single drug group|Pyrotinib: 400 mg, po, qd, 21d for a treatment cycle
88865125|NCT04380012|Experimental|Dual-targeted drug group|Pyrotinib: 400 mg, po, qd, 21d for one treatment cycle; Trastuzumab: first dose 8 mg/kg, then 6 mg/kg, iv, q3w, 21d for one treatment cycle
88865126|NCT04380168|Active Comparator|Modified pec 11 trunk block using ketamine additive|Ultasound guided modified pec 11 trunk block using ketamie hydrochoride 1mg/kg in 2ml volume added to 30ml bupivacaine 0.25% for trunk analgesia
88865127|NCT04380168|Active Comparator|Modified pec 11trunk block using dexmedetomidine additive|Ultasound guided modified pec 11 trunk block using dexmedetomidine 1ug/kg in 2ml volume added to 30ml bupivacaine 0.25%
88865128|NCT04380168|Active Comparator|Modified pec 11trunk block without additive|Ultasound guided modified pec 11 trunk block using bupivacaine 0.25% added to 2ml saline
88865129|NCT04379934|Other|Heart failure|Ejection fraction < 45%
88865130|NCT04379934|Other|Non-heart failure|Ejection fraction > 45%
88865131|NCT04379856|Experimental|Dose 1|NM-002 will be administered at the indicated dose by subcutaneous injection on Days 1 and 15.
88865132|NCT04379856|Experimental|Dose 2|NM-002 will be administered at the indicated dose by subcutaneous injection on Days 1 and 15.
88865133|NCT04379856|Experimental|Dose 3|NM-002 will be administered at the indicated dose by subcutaneous injection on Days 1 and 15.
88865134|NCT04379388|Experimental|Web + text smoking cessation intervention|Participants will receive referral to a quit smoking hotline and 12-week web and text-based smoking cessation intervention
88865135|NCT04379388|No Intervention|Usual care control|Participants will receive referral to a quit smoking hotline
88865136|NCT04379310||covid-19 pneumonia|diagnosed with covid-19 by using PCR and computed tomography scans
88865137|NCT04378998|Experimental|Acupuncture|The intervention group received usual care plus acupuncture for three days. The acupuncture spots: Pericardium-6, Stomach-36, Liver-3 and Ying Tang were used.
88865138|NCT04378998|No Intervention|Usual care|
88865139|NCT04378686||ESKD|Patients with ESKD and on treatment with any form of dialysis
88865140|NCT04378608|Other|2 DAA (OBV/PTV/r) ± ribavirin (RBV)|Administering Ombitasvir/Paritaprevir/Ritonavir/ tablets plus RBV tablets to HCV GT4 in the treatment of Egyptian naïve patients
88865141|NCT04378218|Experimental|HIIT Intervention|
88865142|NCT04377906|Experimental|High Protein-Fiber and Exercise|give 1200 Kcal with 25% protein from fish and tempeh and 30g fiber from vegetable and fruit, 3 times/day and exercise : aerobic and resistance training for 5x/week, 45 minute each sesion
88865143|NCT04377906|Experimental|High Protein-Fiber|give 1200 Kcal with 25% protein from fish and tempeh and 30g fiber from vegetable and fruit, 3 times/day
88865144|NCT04377906|Experimental|Exercise|aerobic and resistance training for 5x/week, 45 minute each sesion
88865145|NCT04377906|No Intervention|control|regular diet
88865146|NCT04377828|Experimental|Laser intervention|1 to 2 sessions of pigment laser1
88865147|NCT04377750|Experimental|Tocilizumab treatment group|Treatment: intravenous administration of monoclonal anti body anti- IL6R. The dose is 8 mg/kg up to total dose of 800 mg.
88865148|NCT04377750|Placebo Comparator|Placebo group|Placebo. intravenous administration of 100 ml of normal saline.
89389515|NCT02062112|Active Comparator|Liberal group|The patient will mix 1 gallon of polyethylene glycol with water. Fill 2 cups with the solution. The patient will add flavoring to one cup and drink both the flavored and unflavored solutions in the cups. The patient will then determine how he/she wants to drink the rest of the bowel preparation laxatives based on their taste preference and drink at the time specified by his/her endoscopist.
88865153|NCT04377282|Experimental|Buckwheat|Cooked buckwheat
88865154|NCT04377282|Experimental|Couscous|Cooked couscous
88865155|NCT04377282|Experimental|Water|Potable water
89389516|NCT01342289|Experimental|Tacrolimus 60|Non-myeloablative bone marrow transplant with fludarabine, cyclophosphamide, total body irradiation conditioning regimen and cyclophosphamide, mycophenolate mofetil, and tacrolimus prophylaxis for graft-versus-host disease (GVHD). Tacrolimus was given for 60 days.
89389517|NCT01342289|Experimental|Tacrolimus 90|Non-myeloablative bone marrow transplant with fludarabine, cyclophosphamide, total body irradiation conditioning regimen and cyclophosphamide, mycophenolate mofetil, and tacrolimus prophylaxis for graft-versus-host disease (GVHD). Tacrolimus was given for 90 days.
89389518|NCT01342289|Experimental|Tacrolimus 120|Non-myeloablative bone marrow transplant with fludarabine, cyclophosphamide, total body irradiation conditioning regimen and cyclophosphamide, mycophenolate mofetil, and tacrolimus prophylaxis for graft-versus-host disease (GVHD). Tacrolimus was given for 120 days.
88865156|NCT04376970|Active Comparator|Fluorometholone group|This group included 38 patients treated with topical fluorometholone 0.1% (FLUCON®) 4 times a day for one month then 3 times a day for one month and 2 times a day for four months.
88865157|NCT04376970|Active Comparator|Cyclosporine A group|This group included 34 patients treated with cyclosporine A 0.5% eye drops prepared in Ricin oil by the pharmacy of Tunis Military Hospital and prescribed 4 times a day for one month then 3 times a day for one month and 2 times a day for four months.
89185981|NCT00721214|Experimental|Arm A: 5-azacytidine|5-azacytidine as pre-transplant cytoreduction prior to allogeneic stem cell transplantation for High Risk Myelodysplatic Syndromes.
88865158|NCT04377048|Experimental|Nivolumab/GS|"Part-1: GS Induction~Patients will receive GS for 1 cycle.~S-1: 60/80/100 mg per day (based on body surface area, BSA); D1-12; 3 weeks per cycle~BSA < 1.25 m2: 60 mg/day; 1.25 m2 ≤ BSA < 1.5 m2: 80 mg/day; BSA ≥ 1.5 m2: 100 mg/day~Gemcitabine: 850 mg/m2; D1, 8; 3 weeks per cycle~After GS, patients fulfilling the pre-defined CA 19-9 criteria will enter the Add-On part.~Part-2: Nivolumab Add-On~Nivolumab: 3 mg/kg every 2 weeks, 6 weeks per cycle~S-1: according to the individualized dose on D8 of cycle 1 in Part-1, 6 weeks per cycle~Gemcitabine: according to the individualized dose on D8 of cycle 1 in Part-1, 6 weeks per cycle~The treatment will be continued until disease progression, intolerance to study treatment or death."
88865159|NCT04376892||Group 1|Exercise capacity under 149 meter
88865160|NCT04376892||Group 2|Exercise capacity between 150 and 249 meter
88865161|NCT04376892||Group 3|Exercise capacity between 250 and 349 meter
89185982|NCT02564601|Experimental|A1 Piano Training|16 weekly classes will be provided to the piano training group. Each piano class session will focus upon review of materials (15-20 min), and the remaining portion of the class will focus upon learning new skills and concepts. This course includes finger dexterity exercises, basic piano technique, and basic piano repertoire.
88865162|NCT04376892||Group 4|Exercise capacity above 340
88865163|NCT04376814|Experimental|Test Group|In this group, Patients will be given a stat dose of 1600mg Favipiravir tablets for the first time, and for next time they will be given 600mg of favipiravir tablets three times per day for 7 days, plus 200mg of Hydroxychloroquine two times per day will be given to patients for 7 days.
88865164|NCT04376814|Active Comparator|Control Group|In this group, Patients will be given a stat dose of 400mg Hydroxychloroquine tablets plus 200/50 mg of Lopinavir/Ritonavirtwo times per day for seven days.
88865165|NCT04376034|Other|Mild Severity|Eligible to enroll in study and will be monitored for progression. Will not initially receive plasma.
88865166|NCT04376034|Active Comparator|Moderate Severity|"Adult patients will be treated with 1 unit (200mL) of convalescent plasma~Pediatric patients will be treated with 10mg/kg up to 1 unit of convalescent plasma."
88865167|NCT04376034|Active Comparator|Severe or Critical Severity|"Adult patients will be treated with up to 2 units of convalescent plasma~Pediatric patients will be treated with 10mg/kg up to 2 units of convalescent plasma."
88865168|NCT04376190|No Intervention|control group|12 patients treated with twin block functional appliance without low-level laser application for 9 month
88865169|NCT04376190|Experimental|laser group|12 patients treated with twin block functional appliance with low-level laser application with the following set parameters; 635 nm wavelength in continuous-wave mode, 50 mw power output, 4.5 J/cm2 energy density, 11.25 J total dose per side, 45 seconds/ point, and 8 mm fiber optic tip diameter. The laser was applied at five points located within TMJ region on both right and left sides in contact with skin as follows: lateral, superior, anterior, posterior, and posterior- inferior points. Laser application was repeated weekly for three months according to a standard protocol
88865170|NCT04375566||IT specialist|20 IT Specialist will evaluate the usability and patient-friendliness of the tool
88865171|NCT04375566||Doctors|13 doctors will evaluate the information in the tool
89185983|NCT02564601|Experimental|A2 Computer Cognitive Training|16 weekly classes will be provided to the computerized cognitive training group. Computerized cognitive training involves process-based computerized practice of adaptive perceptual exercises. Each computer cognitive training class session will focus upon practice of cognitive exercises that vary in difficulty ranging from basic auditory processing speed to application through memory and working memory exercises. Within each exercise, the stimuli (i.e., tones, speech sounds, words, sentences) become less discriminable and speed of presentation increases (making the exercises more difficult) as performance improves.
89185984|NCT02564601|No Intervention|A 3 No Treatment Controls|No classes will be provided to our control group. This is a no-treatment control group.
89389519|NCT03618342||PCOS|PCOS women
89389520|NCT03618342||Healthy controls|Healthy control women
89389521|NCT03134599|Active Comparator|etafilcon A|
89389522|NCT03134599|Active Comparator|methafilcon A - Interozzo|
89389523|NCT03134599|Active Comparator|methafilcon A - CVI|
89389524|NCT02062190|Active Comparator|resveratrol|
89389525|NCT02062190|Placebo Comparator|corn starch|"(10 patients) 100mg 2x/day~1 month"
89389526|NCT02031588||Ceftriaxone|Patients receiving a C3G (ceftriaxone) during the hospitalization.
89389527|NCT02031588||Ceftriaxone + Fluoroquinolone|ceftriaxone followed by fluoroquinolone (which is a common situation in clinical practice, Fluoroquinolone being prescribed after obtaining antibiogram).
89389528|NCT02031588||Fluoroquinolones|fluoroquinolones (levofloxacin, ofloxacin, moxifloxacin or ciprofloxacin).
89530456|NCT04501991||Patients with Type 2 Diabetes|Patients with type 2 diabetes and a scheduled visit during the lockdown for COVID-19
89185985|NCT02592512||NIV-NAVA|4 hour NIV-NAVA, followed by 4 hour NIV-PS/PC
89185986|NCT02592512||NIV-PS/PC|4 hour NIV-PS/PC, followed by 4 hour NIV-NAVA
89185987|NCT02593214|Experimental|Wondaleaf Arm|This is a single arm clinical trial, all subjects and their married couples were be recruited to the arm using investigational device Wondaleaf only.
88865172|NCT04375566||Patients|10-20 patients will evaluate the utility and the contribution of the tool in decision making proces.
88865173|NCT04375488|Experimental|Resistance Exercise Training Group|Resistance exercise training for 8 major muscle groups and 150 min per week walking suggestions were given
88865174|NCT04375488|Experimental|Inspiratory Muscle Training Group|Resistance exercise training for 8 major muscle groups and inspiratory muscle strength training and 150 min per week walking suggestions were given
88865175|NCT04375488|No Intervention|Control Group|150 min per week walking suggestions were given.
88865176|NCT04375098|Experimental|Early COVID-19 convalescent plasma|COVID-19 convalescent plasma 200 ml day 1 and 2 at admission after confirmation of eligibility
88865177|NCT04375098|Experimental|COVID-19 convalescent plasma|COVID-19 convalescent plasma 200 ml day 1 and 2 only if worsening of respiratory function or persistence of COVID symptoms for >7 days after enrolment
88865178|NCT04375176||Tested positive for SARS-CoV-2|"Patients, tested positive for SARS-CoV-2, will be recruited in E.R. of the Ospedale Di Circolo - ASST Settelaghi Teaching Hospital in Varese."
88865179|NCT04375254||Intervention group|Medical students during psychiatry clerkship who received NbN psychopharmacology training
88865180|NCT04375254||Control group|Medical students during psychiatry clerkship who received standard psychopharmacology training
88865181|NCT04375020||group1 on GABA|The first group was on insulin therapy in the form of toujeo once daily and Novorapid 3 times daily and they received GABA nutritional supplement 750mg per day.
88865182|NCT04375020||group 2 on just insulin|The second group was only on insulin injection in the form of toujeo once daily and Novorapid 3 times daily.
88865183|NCT04374942|Experimental|Study drug arm|50% of participants will be randomized to the study drug arm, and will take 400mg hydroxychloroquine orally once a day for three months (Day 1-90).
88865184|NCT04374942|Placebo Comparator|Placebo arm|50% of participants will be randomized to the placebo arm, and will take placebo orally once a day for three months (Day 1-90).
88865185|NCT04374786|Experimental|Intervention Group|"Will receive a 30-day are trial of the mobile meditation app Calm on study day 0"
88865186|NCT04374864|Experimental|Trilaglibtin 50 mg|Samples from 6 healthy, adult, male, Egyptian volunteers (age: 25-39 years, average weight: 89.8 kg, average body mass index (BMI): 34.2) were collected at 0, 0.5, 1, 1.5, 2, 2.5, 3, 8, 24, 48, 72, 96, 120, 144 and 168 hrs, transferred to heparinized centrifuge tubes and analyzed with the proposed method after single oral dose administration of one Zafatek® tablet nominally containing 50 mg trilagliptin. Blood samples (1 mL of each sample) were centrifuged at 3000 rpm for 5 min.
88865187|NCT04374396|Sham Comparator|Group 1|patients in this group will receive sham ipsilateral ultrasound-guided single shot erector spinae block at L2 after induction of anaesthesia and before the start of surgery without injection of local anesthetics
88865188|NCT04374396|Experimental|Group 2|patients in this group will receive real ipsilateral ultrasound-guided single shot erector spinae block at L2 after induction of anaesthesia and before the start of surgery with injection of 0.3 ml/kg of 0.25% of plain bupivacaine.
89185988|NCT02592200|Experimental|Lactobacillus gasseri|Lactobacillus gasseri DSM 27123 capsules, 1×109 CFU (divided in two doses)
89185989|NCT02592200|Placebo Comparator|Placebo|Placebo capsules (two doses)
89185990|NCT00720902|Active Comparator|A - Normal growth hormone secretion|Patients who have undergone transsphenoidal surgery for a pituitary adenoma and have normal growth hormone secretion: Subjects will undergo a clinical exam with vital signs and blood draws, anthropometric measurements and skin fold thickness assessments. Subjects will also undergo GH stimulation testing with growth hormone releasing hormone (GHRH) & arginine, MRI and MR spectroscopy, carotid ultrasound, and have an endothelial cell biopsy.
89185991|NCT00720902|Active Comparator|B - Growth hormone deficient|Patients who have undergone transsphenoidal surgery for pituitary adenoma who are growth hormone deficient: Subjects will undergo a clinical exam with vital signs and blood draws, anthropometric measurements and skin fold thickness assessments. Subjects will also undergo GH stimulation testing with growth hormone releasing hormone (GHRH) & arginine, MRI and MR spectroscopy, carotid ultrasound, and have an endothelial cell biopsy.
88865189|NCT04374318|Active Comparator|IT intrathecal|administration of intrathecal dexmedetomidine in addition to bupivacaine for lower limb surgeries
88865190|NCT04374318|Active Comparator|IV intravenous|administration of intravenous dexmedetomidine in addition to spinal anaesthesia for lower limb surgeries
89389529|NCT02031588||Reference|"A third reference group will consist of patients hospitalized in the same services as the case patients but did not receive antibiotics (60 patients). They will have an idea of possible changes in flora during hospitalization without any antibiotics, for example due to horizontal transfer of resistant strains. This group will be composed of 60 patients who had not received antibiotics within 3 months before and not receiving for the duration of their participation."
89389530|NCT01319071||Top-level athletes|
89389531|NCT01319071||Control group|
89389532|NCT03618498|Other|Patient accept surgery|Proliferative diabetic retinopathy suffering from MH with RD who were treated with vitrectomy combined with inverted epiretinal ILM flap,inverted ILM flaps insertion techniques, or free ILM flaps.
89389533|NCT01319149||No treatment|Patient records would be extracted from the electronic health record system of Southwest Regional Wound Care Center and placed in a separate bin.
89389534|NCT02060708|Other|Real HD-tDCS first, Sham HD-tDCS second|Real HD-tDCS will be applied in the first session Sham HD-tDCS will be applied in the second session (at least one week after the first session)
89389535|NCT02060708|Other|Sham HD-tDCS first, Real HD-tDCS second|Sham HD-tDCS will be applied in the first session Real HD-tDCS will be applied in the second session (at least one week after the first session)
89389536|NCT04194606|Active Comparator|Forearm radial access|Patients who undergo coronary angiography or intervention by forearm radial artery access
88865191|NCT04374552|Experimental|Hydroxychloroquine & Azithromycin|Hydroxychloroquine sulfate 400 mg po BID for day one and then 400 mg QD for 4 days Azithromycin 500 mg po on day one, followed by 250 mg po QD X 4 days
89389537|NCT04194606|Experimental|Distal radial access|Patients who undergo coronary angiography or intervention by accessing the distal radial artery in the area of the anatomical snuff-box
89389538|NCT01354483|Experimental|Treatment Group A|Umbilical cord blood mononuclear cell, 1.6 million
88865192|NCT04374552|Placebo Comparator|Placebo|Placebo for Hydroxychloroquine sulfate (2 pills bid day one and then 2 tablets QD for 4 days) Placebo for Azithromycin (2 pills on day one and followed by 1 pill po QD x 4 days)
88865193|NCT04374162|Placebo Comparator|Conventional PEEP|PEEP = 5 cmH2O
88865194|NCT04374162|Experimental|Driving pressure (DP) guided-PEEP|"DP is calculated as plateau pressure - PEEP. 10 min after pneumoperitoneum， PEEP is increased from 5 to 15 cm H2O incrementally. Each PEEP level is maintained for 10 respiratory cycles, with DP in the last cycle recorded. Then the PEEP level producing the lowest DP will be identified and maintained intraoperatively."
89389539|NCT01354483|Experimental|Treatment Group B|Umbilical cord blood mononuclear cell, 3.2 million
89389540|NCT01354483|Experimental|Treatment Group C|Umbilical cord blood mononuclear cell, 6.4 million
89389541|NCT01354483|Experimental|Treatment Group D|Umbilical cord blood mononuclear cell, 6.4 million; mehtylprednisolone
89389542|NCT01354483|Experimental|Treatment Group E|Umbilical cord blood mononuclear cell, 6.4 million; methylprednisolone; 6 week course of lithium carbonate tablet
89389543|NCT02061410|Experimental|Neuromuscular Electrical Stimulation (NMES)|The intervention was performed with subjects seated on a regular chair (hip and knee angles maintained at approximately 908), 3 times/week for a period of 8 weeks. NMES parameters included: rectangular biphasic symmetric current, pulse duration of 400 ms and stimulation frequency of 80 Hz.
89389544|NCT05211453|Active Comparator|Right sided atrioventricular node ablation|Right sided atrioventricular node ablation
89389545|NCT05211453|Active Comparator|Left sided atrioventricular node ablation|Left sided atrioventricular node ablation
89389546|NCT03560726|Experimental|Telehealth|Participants randomized into the telehealth arm will receive up to 7 one-hour telehealth visits with the study psychologist. The first six sessions will focus on cognitive behavioral stress management topics and the seventh session is optional, focusing on lung transplant readiness. Participants will fill out questionnaires every other week (baseline, week 2, week 4, week 6, week 8) and during a 3-month follow-up (week 20). Participants will wear an actigraphy watch to track sleep and movement for one week at a time during baseline, week 8, and week 20.
89389547|NCT03560726|No Intervention|Treatment-As-Usual (TAU)|"Participants randomized into the TAU arm will not receive any telehealth visits during the 8-week intervention phase. Participants will fill out questionnaires every other week (baseline, week 2, week 4, week 6, week 8) and during a 3-month follow-up (week 20).~Participants will wear an actigraphy watch to track sleep and movement for one week at a time during baseline, week 8, and week 20."
89389548|NCT05211375|Active Comparator|SG group|Patients undergoing sleeve gastrectomy
89389549|NCT05211375|Experimental|DJB group|Patients undergoing duodenojejunal bypass with sleeve gastrectomy
89389550|NCT03618264|Experimental|Dexamethasone plus Ropivacaine group|Participates received peri-incisional scalp infiltration of a miscible liquid of dexamethasone and ropivacaine. The local infiltration miscible liquid containing 0.33mg dexamethasone and 5mg ropivacaine per milliliter
89389551|NCT03618264|Active Comparator|Ropivacaine group|Participates received peri-incisional scalp infiltration of 5mg/mL ropivacaine.
89389552|NCT05089617|Experimental|SAD Cohort 1|5 mg YG1699 or Placebo
88865195|NCT04373850|Experimental|Home visit group|Will receive a home visit after discharge in addition to the standard discharge planning.
88865196|NCT04373850|No Intervention|Control group|Will receive only the standard discharge planning.
88865197|NCT04374006|Experimental|propolis 50|we do sonde everyday to the rat that given treatment of 50mg/kg propolis for 2, 4, and 6 weeks
89185992|NCT02592278|Experimental|Fluoride Varnish each 6 months|Fluoride Varnish application every 6 months.
88865198|NCT04374006|Experimental|propolis 100|we do sonde everyday to the rat that given treatment of 100mg/kg propolis for 2, 4, and 6 weeks
88865199|NCT04374006|Active Comparator|dienogest|we do sonde everyday to the rat that given treatment of 25mg/kg dienogest for 2, 4, and 6 weeks
89185993|NCT02592278|Experimental|Fluoride Varnish each 3 months|Fluoride Varnish application every 3 months.
89185994|NCT02592278|Active Comparator|Fluoride tooth paste|Control group. Twice a day brush with fluoride toothpaste.
89185995|NCT00695019|Experimental|500 IU qd|500 IU Interferon-alpha lozenge taken once per day plus 2 placebo lozenges per day
89185996|NCT00695019|Experimental|500 IU tid|500 IU interferon-alpha lozenge taken 3 times per day
89185997|NCT00695019|Placebo Comparator|placebo|placebo lozenges taken 3 times per day
89185998|NCT00918398|Experimental|1|AZD1981, 100 mg iv infusion
89185999|NCT00918398|Experimental|2|AZD1981, 514 mg oral solution
89186000|NCT00918398|Experimental|3|AZD1981, 500 mg oral tablet A
89389553|NCT05089617|Experimental|SAD Cohort 2|25 mg YG1699 or Placebo
89186001|NCT00918398|Experimental|4|AZD1981, 500 mg oral tablet B
89186002|NCT04086602|Experimental|Single Ascending Dose|Once daily oral IZD334 or Placebo
89186003|NCT04086602|Experimental|Multiple Ascending Dose|Once or twice daily oral IZD334 or Placebo
89186004|NCT00742833|Experimental|3|
89186005|NCT00742833|Placebo Comparator|1|
89186006|NCT04060953|Experimental|Health-Related Quality of Life Report|Participants randomized to this arm will receive the Health-Related Quality of Life Report.
89389554|NCT05089617|Experimental|Multiple Doses Cohort 1|20 mg YG1699 or Placebo
89389555|NCT03617016|Experimental|Domperidone|Participants will receive domperidone 10 milligram (mg) tablets orally thrice in a day from Day 1 to Day 14.
88865200|NCT04374006|Placebo Comparator|water|we do sonde everyday to the rat that given 0,2 ml water placebo for 2, 4, and 6 weeks
88865201|NCT04374006|Sham Comparator|sham group|after the 2nd laparotomy, we do nothing about sonde, just giving food and drink everyday
88865202|NCT04373772|Experimental|abdominal massage group|the abdominal massage group received a total of 30 minutes of massage, 15 minutes every morning and evening, until the first defecation.
88865203|NCT04373772|No Intervention|control group|Routine care for the control group
89186007|NCT04060953|No Intervention|Wait List to Receive the Report|Participants randomized to this arm will receive the Health-Related Quality of Life Report following completion of the study.
89186008|NCT03472989|Active Comparator|Radial extracorporeal shock wave|Active shock wave treatment. All patients will get standardized information and custom made foot orthosis.
89186009|NCT03472989|Sham Comparator|Sham-radial extracorporeal shock wave|Sham- shock wave treatment. All patients will get standardized information and custom made foot orthosis.
89186010|NCT03472989|Active Comparator|Standardized high-load exercise program|High-load exercise treatment. All patients will get standardized information and custom made foot orthosis.
89186011|NCT03472989|Active Comparator|Usual care|Only standardized information and custom made foot orthosis
89186012|NCT00742911|Experimental|1|
89186013|NCT00742989|Experimental|A|OLT administration
89186014|NCT00742989|Sham Comparator|B|placebo-OLT
89186015|NCT02678871|Other|All study participants|Patients meeting clinical and anatomical pre-requisites will undergo TAVI with the LOTUS or Acurate Neo heart valve system (or subsequent CE marked iterations) and LAA closure with the WATCHMAN device in the same setting. Dual antiplatelet therapy (clopidogrel and acetylsalicylic acid) will be prescribed for 6 months followed acetylsalicylic acid indefinitely. Follow-up will be performed after 1 month, 6 months and 1 year.
89186016|NCT02565069|Experimental|Treatment group|Use of CartoFinder™ device with CARTO® 3 System V5 Navigation to treat complex arrhythmias
89186017|NCT00694707|Placebo Comparator|Placebo|Participants received placebo orally once a day for 6 weeks.
89186018|NCT00694707|Experimental|Cariprazine 1.5 mg|Participants received cariprazine 1.5 mg orally once a day for 6 weeks.
89186019|NCT00694707|Experimental|Cariprazine 3.0 mg|Participants received cariprazine 3.0 mg orally once a day for 6 weeks.
89186020|NCT00694707|Experimental|Cariprazine 4.5 mg|Participants received cariprazine 4.5 mg orally once a day for 6 weeks.
88865204|NCT04373538|Experimental|Memory Support Intervention|
88865205|NCT04373304|Experimental|low FODMAP diet|
89186021|NCT00694707|Active Comparator|Risperidone 4.0 mg|Participants received risperidone 4.0 mg orally once a day for 6 weeks.
89186022|NCT00692913|Experimental|FOSAVANCE 5600|alendronate sodium (+) cholecalciferol
89186023|NCT00692913|Other|Referred-Care Model|Usual treatment for osteoporosis chosen and prescribed by patients' own physicians.
89186024|NCT00743067|Experimental|Cohort 1|Cohort 1 will include 60 milligram (mg) of GSK1363089. Dose escalation will be 100% if there is no drug-related AEs of Grade 2 or higher in previous cohort. Dose escalation will be 50% in case there is Grade 2 drug-related AEs in any previous cohort.
89186025|NCT00743067|Experimental|Cohort 2|Cohort 2 will include 120 mg of GSK1363089. Dose escalation will be 100% if there is no drug-related AEs of Grade 2 or higher in previous cohort. Dose escalation will be 50% in case there is Grade 2 drug-related AEs in any previous cohort.
89186026|NCT00743067|Experimental|Cohort 3|Cohort 3 will include 240 mg of GSK1363089. Dose escalation will be 100% if there is no drug-related AEs of Grade 2 or higher in previous cohort. Dose escalation will be 50% in case there is Grade 2 drug-related AEs in any previous cohort.
89186027|NCT00743067|Experimental|Cohort 4|Cohort 4 will include 480 mg of GSK1363089. Dose escalation will be 100% if there is no drug-related AEs of Grade 2 or higher in previous cohort. Dose escalation will be 50% in case there is Grade 2 drug-related AEs in any previous cohort.
89389556|NCT03617016|Placebo Comparator|Placebo|Participants will receive matching placebo corresponding to domperidone orally thrice in a day from Day 1 to Day 14.
89389557|NCT05210829||High Parent Anxiety|Stationary and Trait Anxiety Scale ≥ 44 points
89389558|NCT05210829||Low Parent Anxiety|Stationary and Trait Anxiety Scale < 44 points
89389559|NCT02062268||Urban area in South Jiangsu Province|health education & law enforcement
88865206|NCT04373070|Experimental|chatbot-based intervention programme (intervention)|"Participants randomised to the intervention group will receive a CAir desk and a chatbot-based intervention programme for a period of 12 weeks. The CAir desk is supplied to assess HrQoL, physical activity, and spirometry data. The first week is equal to the procedure in the control group (for details see paragraph below) and serves for baseline measurements of daily physical activity. Starting in week 2 of the study duration, participants receive feedback on their daily physical activity through the CAir chatbot application and aim to increase their daily step count by 15% from baseline. Furthermore, the CAir chatbot provides several components of the Living well with COPD programme (e.g. educational content, information on exercise training) to the patient."
88865207|NCT04373070|Other|Usual care group (control)|Participants randomised to the control group receive usual care and a CAir desk for a period of 12 weeks. The CAir desk is supplied to assess daily symptom burden, physical activity, and spirometry data. In contrast to the intervention group, participants do not receive feedback or scores of the daily reported CAT and daily physical activity.
88865208|NCT04372836|No Intervention|Control arm|During laparoscopic enucleation of unilateral endometrial cyst, no intervention is added to subjects allocated to control arm.
88865209|NCT04372836|Experimental|Study arm (with vasopressin injection)|During laparoscopic enucleation of unilateral endometrial cyst, diluted vasopressin is injected into the interface between endometrioma and ovarian parenchyma of patients allocated to study arm.
88865210|NCT04372290|Experimental|Product usage order ABECD|Subjects will use each of the 5 products sequentially (ABECD) during an evaluation period, followed by a 6 hour Test Session.
88865211|NCT04372290|Experimental|Product usage order BCADE|Subjects will use each of the 5 products sequentially (BCADE) during an evaluation period, followed by a 6 hour Test Session.
88865212|NCT04372290|Experimental|Product usage order CDBEA|Subjects will use each of the 5 products sequentially (CDBEA) during an evaluation period, followed by a 6 hour Test Session.
88865213|NCT04372290|Experimental|Product usage order DECAB|Subjects will use each of the 5 products sequentially (DECAB) during an evaluation period, followed by a 6 hour Test Session.
88865214|NCT04372290|Experimental|Product usage order EADBC|Subjects will use each of the 5 products sequentially (EADBC) during an evaluation period, followed by a 6 hour Test Session.
88865215|NCT04372290|Experimental|Product usage order DCEBA|Subjects will use each of the 5 products sequentially (DCEBA) during an evaluation period, followed by a 6 hour Test Session.
88865216|NCT04372290|Experimental|Product usage order EDACB|Subjects will use each of the 5 products sequentially (EDACB) during an evaluation period, followed by a 6 hour Test Session.
88865217|NCT04372290|Experimental|Product usage order AEBDC|Subjects will use each of the 5 products sequentially (AEBDC) during an evaluation period, followed by a 6 hour Test Session.
88865218|NCT04372290|Experimental|Product usage order BACED|Subjects will use each of the 5 products sequentially (BACED) during an evaluation period, followed by a 6 hour Test Session.
88865219|NCT04372290|Experimental|Product usage order CBDAE|Subjects will use each of the 5 products sequentially (CBDAE) during an evaluation period, followed by a 6 hour Test Session.
88865220|NCT04372212|Active Comparator|Inversion and Snaring|"Vertical trans umbilical 5-mm incision [Point A] is made and 5-mm trocar passed under vision using open technique. Pneumoperitoneum is then established with CO2 flow of 1.5-2.5 L/min.~Both SGDs were used to invert the hernia sac. Then, modified polypectomy snare (SN) was introduced via the trocar at point B and opened inside the abdomen. SGD-C passed inside the loop of SN and re-catches the hernial sac, which was then twisted around its neck several times. SN was closed tightly at the proper neck and coagulation diathermy current was applied to it leading to separation of the hernia sac. Detached sac (grasped by SGD-C) is then pushed antegradely out through the umbilical port."
88865221|NCT04372212|Active Comparator|Inversion and Ligation|"Vertical trans umbilical 5-mm incision [Point A] is made and 5-mm trocar passed under vision using open technique. Pneumoperitoneum is then established with CO2 flow of 1.5-2.5 L/min.~Both SGDs were used to invert the hernia sac. Then, modified polypectomy snare (SN) was introduced via the trocar at point B and opened inside the abdomen. SGD-C passed inside the loop of SN and re-catches the hernial sac, which was then twisted around its neck several times. SN was closed tightly at the proper neck and coagulation diathermy current was applied to it leading to separation of the hernia sac. Detached sac (grasped by SGD-C) is then pushed antegradely out through the umbilical port."
88865222|NCT04372134|Active Comparator|real rTMS group|motor incomplete traumatic SCI patients receiving real repetitive transcranial magnetic stimulation therapy
88865223|NCT04372134|Sham Comparator|sham r TMS|motor incomplete traumatic SCI patients receiving sham repetitive transcranial magnetic stimulation therapy
88865224|NCT04371978|Experimental|DPP-4 inhibition|Participants in the Dipeptidyl Peptidase-4 (DPP-4) inhibition group will receive linagliptin in addition to standard of care insulin regimen as per hospital protocol during their entire hospitalization.
88865225|NCT04371978|No Intervention|Control|Participants in the control group will receive only the standard of care insulin regimen as per hospital protocol during their entire hospitalization.
88865226|NCT04371822|Active Comparator|5 mg SnPP dose plus sunlight exposure|7 subjects with COVID-19 infection and Serum ferritin < 500 ng/ml will receive a single dose of 5 mg of Stannous Protoporphyrin and They will be exposed to sunlight one hours every day for 14 days
88865227|NCT04371822|Active Comparator|7mg SnPP dose plus sunlight exposure|7 subjects with COVID-19 infection and Serum ferritin < 500 ng/ml will receive a single dose of 7 mg of Stannous Protoporphyrin and They will be exposed to sunlight two hours every day for 14 days
88865228|NCT04371822|Active Comparator|9 mg SnPP dose plus sunlight exposure|7 subjects with COVID-19 infection and Serum ferritin < 500 ng/ml will receive a single dose of 9 mg of Stannous Protoporphyrin and They will be exposed to sunlight three hours every day for 14 days
89389560|NCT02062268||urban area in Middle Jiangsu Province|health education & law enforcement
88865229|NCT04371822|Active Comparator|5mg TPPS dose plus sunlight exposure|7 subjects with COVID-19 infection and Serum ferritin < 500 ng/ml will receive a single dose of 5 mg of sulfonatoporphyrin(TPPS), and They will be exposed to sunlight two hours every day for 14 days
88865230|NCT04371822|Placebo Comparator|placebo|No intervention
89389561|NCT02062268||urban area in North Jiangsu Province|health education & law enforcement
89389562|NCT02062268||rural area in South Jiangsu Province|health education & law enforcement
89389563|NCT02062268||rural area in North Jiangsu Province|health education & law enforcement
88865231|NCT04370886|Experimental|SMS with safty ensurance|SMS content in this group will be about what blood services will do to ensure the safety of blood donors' life saving donation during 2019-nCoV epidemic
88865232|NCT04370886|Experimental|SMS with saving life call-1|SMS content in this group will be about calling the blood donors to a life saving donation
88865233|NCT04370886|Experimental|SMS with saving life call-2|SMS content in this group will be about calling the blood donors to a life saving donation
88865234|NCT04370886|Placebo Comparator|SMS with holiday greeting|SMS content in this group will be about holiday greeting of Labour Day.
88865235|NCT04370964|Other|Family with young aged people|The family will be evaluated in two stages via the standardized situations LTP (parents and patient) and LFP (family) as well as self-assessments
88865236|NCT04370808||Mild to severe disease|Mild to severe disease (admission to isolation room)
88865237|NCT04370808||Critical patients|Critical patients (admission to ICU)
88865238|NCT04370262|Active Comparator|SOC/Famotidine|Subjects in this study arm will receive a combination of Standard of Care (SOC) treatment and intravenous famotidine. Famotidine Injection, 10mg/mL mixed with Normal Saline is given intravenously at 120mg (30% of 400 mg oral dose). The total daily dose proposed is 360mg/day famotidine IV for a maximum of 14 days, or hospital discharge, whichever comes first. SOC will be administered as per the current clinical protocol for COVID-19.
88865239|NCT04370262|Placebo Comparator|SOC/Placebo|Subjects in this arm will receive the current Standard of Care treatment for COVID-19; plus placebo infusion three times daily.
88865240|NCT04370340|No Intervention|control|
88865241|NCT04370340|Active Comparator|intervention|
88865242|NCT04369872|Experimental|Microwave Ablation|Study participants will receive percutaneous microwave ablation of their malignant lung neoplasm.
88865243|NCT04369716|Active Comparator|Whole fruit 1|Oranges
88865244|NCT04369716|Active Comparator|Whole fruit 2|Apples
88865245|NCT04369716|Experimental|Juice 1 + pomace|Orange Juice + orange pomace
88865246|NCT04369716|Experimental|Juice 2 + pomace|Apple Juice + apple pomace
88865247|NCT04369716|Active Comparator|Juice 1 alone|Orange Juice
88865248|NCT04369716|Active Comparator|Juice 2 alone|Apple Juice
88865249|NCT04369404|No Intervention|Usual care|In the usual care group, the providers do not have access to the decision aids.
88865250|NCT04369404|Experimental|Patient Decision Aid|Providers have access to patient decision aids to review and discuss during the visit.
88865251|NCT04369248||Control group|30 healthy women with BMI < 30 between 18 and 35 years old
88865252|NCT04369248||Non-obese PCOS|2003 Rotterdam ESHRE/ASRM PCOS Consensus Criteria were used to diagnose PCOS that fulfilled at least two of the followings: chronic oligo-anovulation, clinic or biochemical hyperandrogenism and presence of polycyctic ovary by ultrasound (Rotterdam). Oligo-anovulation is defined as periods lasting more than 35 days and/or amenorrhea. Clinic or biochemical hyperandrogenism is defined as the presence of acnes and/ or Ferriman-Galleway modified score >8 and/ or hyperandrogenemia defining the testosterone level > 0.6 ng/ml (2 nmol/l) and/or dehydroepiandrosterone level > 3 ng/ml (10.5 nmol/l). Polycyctic ovaries are defined as the presence of more than 12 follicules 2-9 mm in diameters or ovarian volume >10 cm3 under transvaginal or abdominal ultrasound. non-obese group are the women BMI < 30 between age of 18 and 35.
88865253|NCT04369248||Obese PCOS|Obese group are the women with BMI > 30 between age of 18 and 35.
88865254|NCT04369092|Other|without swallowing problem|patients without swallowing problem
88865255|NCT04369092|Other|mild swallowing problem|patients with mild swallowing problem
88865256|NCT04369092|Other|severe swallowing problem|patients with severe swallowing problem
88865257|NCT04369170|Other|Group A - Control Group|Control group where an intermediate abutment is placed in between the CAD-CAM dental prostheses an the dental implant.
88865258|NCT04369170|Experimental|Group B - Test Group|Test group where the CAD-CAM dental prostheses is connected directly to the dental implant
88865259|NCT04368624||Participants with PKU|"Patients with classical PKU phenotype (serum phenylalanine concentration > 10 mg/dL on a normal diet at diagnosis) # ~25~Patients with hyperphenylalaninemia (serum phenylalanine concentration < 10 mg/dL on a normal diet at diagnosis) # ~15~Patients with PKU on therapy with Kuvan # ~10"
88865260|NCT04368624||Non-PKU Control|Study Controls: Up to 50 children and adults without a known metabolic disorder.
88865261|NCT04368546||Patients|Metastatic cell carcinoma patients before sunitinib treatment, after 4 week on, after 2 week off and finally again 4 week on medication.
88865262|NCT04368546||Healthy controls|Age-matched subjects without known disease.
88865263|NCT04368312||Health care providers/hospital staff|The targeted group are doctors and nurses (hospital stuff) of a large university hospital directly confronted with patients with Cov-19
88865264|NCT04368000|Experimental|Prone Positioning|
88865265|NCT04368000|Active Comparator|Usual care|
88865266|NCT04367532|Experimental|Foam rolling|Foam rolling of cuff muscles.
88865267|NCT04367532|Experimental|Tissue flossing|Tissue flossing of cuff muscles.
88865268|NCT04367532|No Intervention|Control group|Without any intervention.
88865269|NCT04367376|Experimental|manual therapy|The control group will receive central postero-anterior grade III mobilization through the pisiform grip method at the level of pain in the lumbar spine.
88865270|NCT04367376|Experimental|instrumental manual therapy|the intervention groub rcieved central postero-anterior mobilization with a force of 20-30 N through physiotherapy instrument mobilization at the level of pain in the lumbar spine.
88865271|NCT04367454|Experimental|Personal Protective Equipment|"Wearing: Tyvek pro-tech® C gear (Bonetti, Milano, Italy), a full visor SGE 400 mask (EN 136:98 CL3) connected to an A2B2E2K2-P3 R filter (Spasciani, Milano, Italy), and well-fitting, non-sterile Mapa Ultranitril 480 gloves (Mapa SAS, Colombes, France)."
88865272|NCT04367454|No Intervention|NO-Personal Protective Equipment|only wearing well-fitting, medical examination nitrile gloves.
88865273|NCT04366986||Pregnant Women|Women who are currently pregnant
88865274|NCT04366986||Post-partum women|Women who have been pregnant in the past 6 months
89003515|NCT05091437||Retrospective|All eligible subjects with solid or subsolid (part solid, pure ground glass) lung nodule identified in the past; more preciously from March 2019 to the study initiation date. [ Fleischner Society 2017 guidelines for nodules size and definition (≥ 6 mm and < 3 cm) for subject inclusion].
89186028|NCT00743067|Experimental|Cohort 5|Cohort 5 will include 960 mg of GSK1363089. Dose escalation will be 100% if there is no drug-related AEs of Grade 2 or higher in previous cohort. Dose escalation will be 50% in case there is Grade 2 drug-related AEs in any previous cohort.
89186029|NCT00743223||1|Study-group: The volunteers were selected on a randomized form among the individuals who went to the clinic of orofacial pain and temporomandibular disorders of São Paulo Hospital.
89186030|NCT00743223||2|Control-group: The volunteers were selected on a randomized form among the individuals who went to the dental offices of the researchers.
89389564|NCT02031822|Active Comparator|US-guided Distal GON Block (Group D)|Needle placement for 2ml 0.5% bupivacaine with epinephrine 1:200,000 and Depo-Medrol 40mg will be performed under US guidance at the level of the superior nuchal line lateral to the external occipital protuberance, close to the occipital artery.
89389565|NCT02031822|Active Comparator|US-guided Proximal GON Block (Group P)|Needle placement for 2ml 0.5% bupivacaine with epinephrine 1:200,000 and Depo-Medrol 40mg will be performed under US guidance at the level of the bifid C2 spinous process laterally, between the inferior obliquus capitis and semispinalis capitis muscles.
89186031|NCT00743301|Active Comparator|Olive oil|
89389566|NCT02060786|Active Comparator|original Clopidogrel Bisulfate (Plavix®)|original Clopidogrel Bisulfate (Plavix®) 600mg loading
89389567|NCT02060786|Experimental|generic Clopidogrel Bisulfate (Plavitor®)|generic Clopidogrel Bisulfate (Plavitor®) 600mg loading
89389568|NCT03628833|Experimental|Incontinence Management system|
89389569|NCT03616938|Experimental|the two finger chest compression technique|Two finger technique (TFT): the pediatric thorax is compressed with the tips of two fingers and is recommended for lone rescuer during infant cardiopulmonary resuscitation by international resuscitation guidelines
89389570|NCT03616938|Experimental|the two thumb chest compression technique|Two thumb technique (TTHT): the two thumbs of the rescuer are placed over the lower third of the sternum, with the fingers encircling the torso and supporting the back. This technique is recommended for two rescuers during infant CPR by international CPR guidelines
88865275|NCT04366674|Active Comparator|Langerbeck's repair|Langerbeck's repair of cleft palate,without specific restoration of levator veli palatini or tensor veli palatini. Incisions along the margins of the cleft at the junction of oral and nasal mucosa. Lateral relaxing incisions were performed and the mucoperiosteal flap of hard palate were elevated on both sides except the ones with only soft palate cleft. The anterior end of the mucoperiosteal flap may be cut off for the purpose of tension relieving and would be resutured to the anterior area during closing. In the soft palate, the division was made between the oral mucous layer and the palatal musculature layer. Hamulus were broken for closing the cleft without tension. Closing was done by two seperated layers, one layer of nasal mucosa-palatal muscle, and one layer of oral mucosa.
88865276|NCT04366674|Active Comparator|restoration of levator veli palatini|The incision was made similar to Langerbeck's repair. During disection, the levator veli palatini was identified after the elevation of flap. The levator veli palatini was separate from the oral and nasal mucosa. During closing, the anterior end of levator veli palatini was rotated towards the midline and the two muscle bundle from the two sides were sutured in the midline. In this process, the tensor veli palatini was not intentionally identified or dissected.
88865277|NCT04366674|Experimental|mordified restoration of tensor veli palatini|Incision was made similar to Langerbeck's repair. During disection, the tensor veli palatini was identified after flap elevation. Its tendinous fibers was released from but still connected to the pterygoid process without breaking the hamulus or cutting off the tendinous fibers. If the tension is too strong during suturing, the tensor tendon could be partly dissected laterally meanwhile be kept continuity medially so that the tensor veli palatini could be rotated more medially. The levator veli palatini, tensor veli palatini, together with the palatine aponeurosis and the nasal mucosa from two sides were sutured in the middle line. The tensor veli palatini may not be jointed to the contralateral one directly.
88865278|NCT04366596|Experimental|DEB group|angioplasty with paclitaxel eluting balloon
88865279|NCT04366596|Placebo Comparator|POB group|Angioplasty with plain old balloon
88865280|NCT04366206||Patients exposed to the study variable|Depending on the studied variable (treatment or risk factor)
88865281|NCT04366206||Patients not exposed to the study variable|Depending on the studied variable (treatment or risk factor)
88865282|NCT04366128|Experimental|CAPA indution immunotherapy|CAPA regimen, repeat every 3 week for 4 cycles.
88865283|NCT04365972|Experimental|Home-delivered attention bias modification (ABM)|A home-delivered ABM comprised of 5 sessions using a variant of the dot-probe task in which the target probe always replaces neutral rather than threat (health-related) stimuli to induce diversion of attention away from threat.
88865284|NCT04365894|No Intervention|Control|The study was applied in 2nd grade nursing students' disability health course. The control group was taught with the traditional method.
88865285|NCT04365894|Experimental|Intervention|The intervention group with learning activities based on the transformative learning theory.
88865286|NCT04365816||Prospective cohort University Hospital, Grenoble|Semi-structured survey administered on the phone, once, one month after discharge from hospital. The interview will not be recorded.
88865287|NCT04365816||Prospective cohort University Hospital, Toulouse|Semi-structured survey administered on the phone, once, one month after discharge from hospital. The interview will not be recorded.
89186032|NCT00743301|Experimental|Palm olein|
89186033|NCT00743301|Active Comparator|Lard|
89186034|NCT00694551|Experimental|A. Level 100 mcg Peptide Vaccine|Peptide vaccine dose level 100 mcg + Poly IC-LC
89186035|NCT00694551|Experimental|B. Level 300 mcg Peptide Vaccine|Peptide vaccine dose level 300 mcg + Poly IC-LC
89186036|NCT00694551|Experimental|C. Level 1 mg Peptide Vaccine|Peptide vaccine dose level 1 mg + Poly IC-LC
89186037|NCT02564289||Healthy Chronic snus users|Healthy subjects that used snus for more than 15 years.
89186038|NCT02564289||Healthy Controls|Healthy subjects that are never-users of snus.
89389571|NCT03616938|Experimental|the new two thumb chest compression technique|'new two-thumb technique' (nTTT): this technique consists in using two thumbs directed at the angle of 90° to the chest while closing the fingers of both hands in a fist
89389572|NCT02060864|Placebo Comparator|Placebo|2 Placebo pills
89389573|NCT02060864|Experimental|AN-PEP 80.000 PPI|1 pill AN-PEP 80.000 PPI and 1 pill Placebo.
88865288|NCT04365816||Prospective cohort University Hospital, Nancy|Semi-structured survey administered on the phone, once, one month after discharge from hospital. The interview will not be recorded.
89186039|NCT00743379|Experimental|A|TH-302 in combination with Gemcitabine. 1,000 mg/m2 of Gemcitabine is administered IV over 30 minutes on Days 1, 8 and 15 of a 28-day cycle.
89186040|NCT00743379|Experimental|B|TH-302 in combination with Docetaxel. 75 mg/m2 of Docetaxel is administered IV over 60 minutes on Day 1 of a 21-day cycle.
89186041|NCT00743379|Experimental|C|TH-302 in combination with Pemetrexed. 500 mg/m2 of Pemetrexed is administered IV over 10 minutes on Day 1 of a 21-day cycle.
89186042|NCT00689871|Experimental|1|Primary augmentation
89186043|NCT00689871|Experimental|2|Primary reconstruction
89186044|NCT00689871|Experimental|3|Revision-augmentation
89186045|NCT00689871|Experimental|4|Revision-reconstruction
89186046|NCT00793793|Experimental|20mg|patient to receive 20mg solution BI201335 qd +/- PegIFN/RBV fore 28 days
89186047|NCT00793793|Experimental|48mg|patient to receive 48mg solution BI201335 qd +/- PegIFN/RBV fore 28 days
89186048|NCT00793793|Experimental|120mg|patient to receive 120mg solution BI201335 qd +/- PegIFN/RBV fore 28 days
89186049|NCT00793793|Experimental|240mg|patient to receive 240mg solution BI201335 qd +/- PegIFN/RBV fore 28 days
89186050|NCT00793793|Placebo Comparator|Placebo|
89186051|NCT00743457||VPS Patients|Children 6 months-18 years with VPS and symptoms of possible shunt failure
89186052|NCT02483637|Experimental|RejuvenAir|RejuvenAir treatment of the right lower lobe and right main stem bronchus. Each MCS will be tailored to the bronchial area undergoing treatment and the amount of liquid nitrogen delivered will vary depending on the airway diameter.
89186053|NCT02602613|Experimental|AMEND|
89186054|NCT02602379||Tetanic stimulation|Single arm study. See Study description for a through description of the intervention.
89186055|NCT02603705|Experimental|Oxycodone extended-release|Egalet abuse-deterrent, extended-release oxycodone tablet
89186056|NCT00776789|Experimental|skin to skin contact|Infants randomized to this group were placed prone over the mother's chest immediately after birth. Skin-to-skin contact was continued for the next two hours. Mothers in both the groups received support for initiating breastfeeding, if required. All mothers, regardless of the group allocation, were advised to give exclusive breastfeeding to their infants during the hospital stay. They were discouraged from giving supplemental feeds to their infants unless indicated by the duty registrar. All the mothers were counseled regarding the duration of exclusive breastfeeding at the time of discharge.
89186057|NCT00776789|Experimental|Control group|The infants who were allocated to the conventional care (control group) were kept by the mother's side and did not receive early SSC. All mothers, regardless of the group allocation, were advised to give exclusive breastfeeding to their infants during the hospital stay. They were discouraged from giving supplemental feeds to their infants unless indicated by the duty registrar. All the mothers were counseled regarding the duration of exclusive breastfeeding at the time of discharge.
89186058|NCT00776555|Experimental|Vyvanse™|50mg capsule that has been emptied and made into solution
89186059|NCT00776555|Experimental|ADDERALL XR®|20mg capsule that has been emptied, crushed, and made into solution
89186060|NCT00915785|Experimental|5 azacytidine|
89186061|NCT04104581|Placebo Comparator|Control|Volunteers will consume a diet in which all grain foods are made from refined grains.
89186062|NCT04104581|Experimental|Low Whole Grain Oat Diet|Volunteers will consume a diet with a low level of whole grain oat incorporated into some of the foods.
88865289|NCT04365816||Prospective cohort University Hospital, Rennes|Semi-structured survey administered on the phone, once, one month after discharge from hospital. The interview will not be recorded.
89186063|NCT04104581|Experimental|High Whole Grain Oat Diet|Volunteers will consume a diet with a high level of whole grain oat incorporated into some of the foods.
89186064|NCT04104581|Experimental|Low Whole Grain Wheat Diet|Volunteers will consume a diet with a low level of whole grain wheat incorporated into some of the foods.
89186065|NCT04104581|Experimental|High Whole Grain Wheat Diet|Volunteers will consume a diet with a high level of whole grain wheat incorporated into some of the foods.
89186066|NCT04104737|Experimental|Spire Medical Health Tag|Spire Medical Health Tag is worn by all subjects The study is open label
89186067|NCT00720434|Experimental|A|500 mg BID
89186068|NCT00720434|Experimental|B|300 mg BID
88865290|NCT04365816||Prospective cohort Hospices Civils de Lyon|Semi-structured survey administered on the phone, once, one month after discharge from hospital. The interview will not be recorded.
89186069|NCT00720434|Experimental|C|200 mg BID
89186070|NCT00720434|Placebo Comparator|D|Placebo
89186071|NCT00776009|Experimental|Dex-Methylphenidate hydrochloride (Focalin® XR) 30 mg|Dex-Methylphenidate hydrochloride (Focalin® XR) 30 mg dose (one 20 mg capsule and one 10 mg capsule) orally once a day for 7 days.
89186072|NCT00776009|Active Comparator|Dex-Methylphenidate hydrochloride (Focalin® XR) 20 mg|Dex-Methylphenidate hydrochloride (Focalin® XR) one 20 mg capsule orally once a day for 7 days.
89186073|NCT00776009|Placebo Comparator|Placebo|Two Capsules taken orally once a day for 7 days
89186074|NCT00694161|Experimental|Fx-1006A|
89186075|NCT00720356|Experimental|Treatment|erlotinib and bevacizumab
89186076|NCT00743535|Experimental|1|Transobturatory correction of anterior defect plus TOT
89186077|NCT00743535|Active Comparator|2|"Longitudinal vaginal incision 1 cm far from esternal urethral meatus. Bladder dissecting and identification of ischiatic spines. Bilateral transobturator insertion of anterior mesh through high and low trans-obturatory approach. Mesh anchorage.~Small incision sites at sovrapubic level. Bilateral retropubic insertion of mesh by means of mono-use needle."
89186078|NCT02564913||control group|
89389574|NCT02060864|Experimental|AN-PEP 160.000 PPI|2 pills AN-PEP 80.000 PPI
89186079|NCT02564913||pre-DM group|
89186080|NCT02564913||DM group|
89389575|NCT03560414|Experimental|simple plasma exchange group|The mode is CVVH in CRRT machine, the treatment duration is 2h-3h, the application plasma volume is 40ml/Kg, the replacement fluid flow rate is 1000ml/h, the blood flow rate is 100-140 ml/min, and the ultrafiltration volume is 0ml/h.
88865291|NCT04365816||Prospective cohort Assistance Publique Hôpitaux de Paris|Semi-structured survey administered on the phone, once, one month after discharge from hospital. The interview will not be recorded.
88865292|NCT04365816||Prospective cohort University Hospital, Rouen|Semi-structured survey administered on the phone, once, one month after discharge from hospital. The interview will not be recorded.
88865293|NCT04365738|Experimental|Pulmonary Rehabilitation|The patients who applied pulmonary rehabilitation were checked, motivated and followed-up regularly with video calls every day. Pulmonary rehabilitation program consists of patient education, breathing, in-house mobilization and range of motion exercises.
88865294|NCT04365738|Placebo Comparator|Control|As a patient education, information was given about the disease and treatment process, listening to the patient during this process and getting regular sleep, balanced nutrition and taking a break from smokers.
88865295|NCT04365582|Experimental|Azithromycin|Azithromycin
88865296|NCT04365582|Experimental|Hydroxychlororquine|Hydroxychlororquine
88865297|NCT04365582|Experimental|Lopinavir/Ritonavir|Lopinavir/Ritonavir
88865298|NCT04365582|No Intervention|standards of care|SoC
88865299|NCT04365270|Experimental|Chitosan Glass ionomer|"purified low molecular weight and viscosity chitosan will be dissolved in 0.1 mol/L acetic acid to be used to modify the stock liquid provided with the glassionomer Fuji IX to have 10% v/v chitosan.~will be placed in the prepared cavity over the last layer of caries"
88865300|NCT04365270|Experimental|Chitosan/Titanium dioxide nanoparticles Glass ionomer|"The stock liquid provided with the glassionomer Fuji IX will be modified with 10%v/v purified low molecular weight and viscosity chitosan will be dissolved in 0.1 mol/L acetic acid.~The Powder will be modified with 3% titanium dioxide nanoparticles will be placed in the prepared cavity over the last layer of caries"
88865301|NCT04365270|Active Comparator|Chlorhexidine glass ionomer|Chlorhexidine Diacetate will be added to the powder of Fuji IX with 0.5% v/v
88865302|NCT04365270|Placebo Comparator|Glass ionomer|Stock powder and liquid Fuji IX from GC japan
88865303|NCT04365504||Osteoporotic|Post menopausal females with Lumbar T score <-2.5 as determined by dual energy X ray absorbitometry
88865304|NCT04365504||Osteopenic|Post menopausal females with Lumbar T score -1 to -2.5 as determined by dual energy X ray absorbitometry
88865305|NCT04365504||Normal|Post menopausal females with T score >-1 as determined by dual energy X ray absorbitometry
88865306|NCT04365192||I-gel|
88865307|NCT04365192||Self-pressurized air-Q|
88865308|NCT04365426|Experimental|Oral contraceptive (OC)|Oral contraceptive patients will be tested to mechanical (cephalic and extracephalic) stimulus and cold pain stimulus.
88865309|NCT04365426|Experimental|No oral contraceptive (No OC)|No oral contraceptive patients will be tested to mechanical (cephalic and extracephalic) stimulus and cold pain stimulus.
88865310|NCT04364724||Study group|"All patients referred to the Hematology clinic for diagnosis and treatment of active multiple myeloma will be asked to participate in the study and undergo 3 consecutive low-dose CT scans over a period of 12 months. For non-consenting patients only minimal demographic data will be documented.~Eligible consenting patients will sign informed consent."
88865311|NCT04365036|Experimental|toripalimab with P-GemOx|Patients will receive toripalimab and induction chemotherapy with pegaspargase, gemcitabine, oxaliplatin, every 3 weeks for 4 cycles before radiation. Definitive intensity-modulated radiotherapy (IMRT) will be given. Concurrent toripalimab of 240mg will be administered every 3 weeks for 3 cycles during IMRT. Toripalimab 240mg will be given every 3 weeks for 13 cycles, started on day 1 of induction chemotherapy.
89186081|NCT00745953|Active Comparator|Valsartan|This arm will determine if blockade of the renin-angiotensin system reduces myocardial fat levels and improves insulin sensitivity. It consists of 6 visits: visit1 (baseline); visit2 (2 weeks); visit3 (1 month); visit4 (3 month); visit5 (6 month); visit6 (8 month). Visits 1 & 6 will consist of blood tests, glucose tolerance test by FSivGTT, MRS, & 24 hr ambulatory blood pressure monitoring. During visit 1, patients receive automatic blood pressure monitor, OMRON, to record blood pressure between visits. Visits 2 & 3 are needed for the adjustment of medication to the final dose level. During visits 4 & 5, Dr. Price will check subject's status as they continue the medication. In case of uncontrolled blood pressure, Dr. Price will prescribe amlodipine for the additional BP control.
88865312|NCT04365036|Active Comparator|P-GemOx|Patients will receive induction chemotherapy with pegaspargase, gemcitabine, oxaliplatin, every 3 weeks for 4 cycles before radiation. Definitive intensity-modulated radiotherapy (IMRT) will be given.
88865313|NCT04364490|Experimental|Experimental VF group|"Inpatients with a diagnosis of first-ever ischemic stroke in post acute phase, admitted for rehabilitation to S.Anna rehabilitation Institute.~The intervention consist of 2-h of rehabilitation daily sessions, five weekly over 6 weeks. During one hour of treatment, this group perform advanced gait training sessions by the computerized BWS system without visual feedback; during second hour of treatment, during the second hour of treatment patients are treated according to conventional therapy consisting of exercises for passive and active mobilization of lower limbs, trunk control, standing, deambulation."
89186082|NCT00745953|Active Comparator|Hydrochlorothiazide|This arm will determine if thiazide diuretics elevate myocardial triglyceride levels. It consists of 6 visits: visit1 (baseline); visit2 (2 weeks); visit3 (1 month); visit4 (3 month); visit5 (6 month); visit6 (8 month). Visits 1 & 6 will consist of blood tests, glucose tolerance test by FSivGTT, MRS, & 24 hr ambulatory blood pressure monitoring. During visit 1, patients receive automatic blood pressure monitor, OMRON, to record blood pressure between visits. Visits 2 & 3 are needed for the adjustment of medication to the final dose level. During visits 4 & 5, Dr. Price will check subject's status as they continue the medication. In case of uncontrolled blood pressure, Dr. Price will prescribe amlodipine for the additional BP control.
89186083|NCT00720278|Placebo Comparator|Placebo Nasal Spray|Placebo nasal spray
88865314|NCT04364490|Experimental|Experimental VF+ group|"Inpatients with a diagnosis of first-ever ischemic stroke in post acute phase, admitted for rehabilitation to S.Anna rehabilitation Institute.~The intervention consist of 2-h of rehabilitation daily sessions, five weekly over 6 weeks. During one hour of treatment, this group perform the same advanced gait training session with the addition of visual feedback ensuring a real-time interactive control of locomotor performance; during second hour of treatment, during the second hour of treatment patients are treated according to conventional therapy consisting of exercises for passive and active mobilization of lower limbs, trunk control, standing, deambulation."
88865315|NCT04364490|Active Comparator|Control group|"Inpatients with a diagnosis of first-ever ischemic stroke in post acute phase, admitted for rehabilitation to S.Anna rehabilitation Institute.~The intervention consist of 2-h of rehabilitation daily sessions, five weekly over 6 weeks. During one hour of treatment, this group perform conventional therapy consisting of exercises for passive and active mobilization of lower limbs, trunk control, standing, deambulation; during second hour of treatment, during the second hour of treatment patients are treated according to conventional therapy consisting of exercises for passive and active mobilization of lower limbs, trunk control, standing, deambulation."
88865316|NCT04364022|Active Comparator|Lopinavir/Ritonavir|
88865317|NCT04364022|No Intervention|Active surveillance|
88865318|NCT04363710|Experimental|Intervention group|Participants in this arm were advised intervention of Low Calorie Diet (800-1000 Kcal/day) for 8 weeks without any anti diabetic medication
88865319|NCT04363710|No Intervention|Control Group|Participants in this arm were kept on their standard medical treatment
88865320|NCT04363866|Experimental|Hydroxychloroquine|400 mg bid (PO) Day 1, followed by 200 mg bid (PO) Day 2 through Day 5
88865321|NCT04363866|Placebo Comparator|Placebo|Placebo pill bid (PO) Day 1 through Day 5 of the treatment period
88865322|NCT04363788||Cardiopulmonary resuscitation|The study was based on dying gloves used during resuscitation. The gloves were secured with disposable hermetically sealed pouches and described by one of the EMS team members - each time after resuscitation was completed.
88865323|NCT04363554|Other|Urine dilution test|Urine dilution test
88865324|NCT04363554|Other|Urine concentration test|Urine concentration test
88865325|NCT04363476|Experimental|Intervention|8-week exercise and education intervention. Two 60-minute physiotherapist-lead group exercise classes with education incorporated will be delivered weekly for 8 weeks (16 classes). In addition, participants will complete a 30-minute home exercise session once a week for 8-weeks (8 sessions). After the intervention, the group will enter a 16-week maintenance stage. During maintenance, a 30-minute home exercise program is completed twice a week.
88865326|NCT04363476|Other|Control|The control group will not receive an intervention during the first 8-weeks of the study. Being a step-wedge design, this group will receive the same 8-week exercise and education intervention later, after the intervention group has completed the intervention and the post-intervention testing. After the control group has completed the 8-week intervention, they will enter an 8-week maintenance stage. During maintenance, a 30-minute home exercise program is completed twice a week.
88865327|NCT04363086|Experimental|TAU|
88865328|NCT04363086|Experimental|iFD|
88865329|NCT04363086|Experimental|iFD + weekly phone calls|
88865330|NCT04363398|Experimental|Comprehensive|Coaches from schools randomized to the comprehensive follow-up receive a workshop outlining a neuromuscular training program to be used as a warm-up for 10 minutes at the beginning of each basketball practice and game. Throughout the season, a trained research team member will monitor the team weekly for injuries, participation, and adherence, and provide support to the school coaches regarding the warm-up.
88865331|NCT04363398|Active Comparator|Standard|Coaches from schools randomized to the standard follow-up receive a workshop outlining a neuromuscular training program to be used as a warm-up for 10 minutes at the beginning of each basketball practice and game. Throughout the season, a research team member will monitor the team weekly for injuries, participation, and adherence, however will not provide support to the school coaches regarding the warm-up.
88865332|NCT04362384|Experimental|Vitamin E ovules|Endoanal Vitamin E ovules will be prescriped during 14 days
88865333|NCT04362384|Active Comparator|Prednisolone ointment|Endoanal Prednisolone ointment will be prescriped during 14 days
88865334|NCT04361916|Experimental|home care with active monitoring|home care with active monitoring conducted by health workers with daily visit to patients.
88865335|NCT04361760|Experimental|Healthy younger participants (20-30y)|Within-subject design. In a visual discrimination task participants will be asked to identify specific features of visual stimuli (i.e., the gender of a face, or the motion direction of a grating). During this task, single-pulse TMS will be applied in one-third of the trials; sham stimulation will be applied in a further third of the trials; and no stimulation will be applied in the remaining third of the trials, while hd-EEG will be continuously measured. The order of these three stimulation conditions (i.e., single-pulse TMS, sham, or no stimulation, during the 1st, 2nd, or 3rd third of the trials) will be counterbalanced over participants.
88865336|NCT04361760|Experimental|Healthy older participants (65-75y)|Within-subject design. In a visual discrimination task participants will be asked to identify specific features of visual stimuli (i.e., the gender of a face, or the motion direction of a grating). During this task, single-pulse TMS will be applied in one-third of the trials; sham stimulation will be applied in a further third of the trials; and no stimulation will be applied in the remaining third of the trials, while hd-EEG will be continuously measured. The order of these three stimulation conditions (i.e., single-pulse TMS, sham, or no stimulation, during the 1st, 2nd, or 3rd third of the trials) will be counterbalanced over participants.
88865337|NCT04361526|No Intervention|Control|standard intensive care alone
88865338|NCT04361526|Experimental|Cytokine Adsorption|cytokine adsorption plus standard intensive care
88865339|NCT04361604||250 Patients co infected HIV and SRAS-CoV2|Cohort of Patient co infected HIV AND SRAS-CoV2
88865340|NCT04361604||20 patients infected HIV without COVID-19|Group of 20 comparative patients PLWHIV without COVID-19. This group will realise only the interview of the research.
88865341|NCT04361448|Other|Health Care Workers with Covid-19 symptoms|3 samples (2 nasopharyngeasl swabs, 1 oropharyngeal swab) willl be taken from each volunteer
88865342|NCT04361292|Active Comparator|Group A: one day abstinence period|Patients allocated into group A had an ejaculatory abstinence period of one day
88865343|NCT04361292|Active Comparator|Group B: three days abstinence period|Patients allocated into group B had an ejaculatory abstinence period of three days
88865344|NCT04361370|Experimental|Treatment group|BRCA mutation wild type, non-mucinous , platinum-sensitive recurrent ovarian cancer
88865345|NCT04361136|Experimental|Delgocitinib cream 1 mg/g|Single topical occlusive administration
88865346|NCT04361136|Experimental|Delgocitinib cream 3 mg/g|Single topical occlusive administration
88865347|NCT04361136|Experimental|Delgocitinib cream 8 mg/g|Single topical occlusive administration
88865348|NCT04361136|Experimental|Delgocitinib cream 20 mg/g|Single topical occlusive administration
88865349|NCT04361136|Placebo Comparator|Delgocitinib cream vehicle|Single topical occlusive administration
88865350|NCT04360902|No Intervention|Standard of Care Group|Subjects in the standard of care group will continue to receive anemia management in the same way they normally do as part of their routine dialysis care. For the purposes of this study, this means the use of the clinic's established Mircera® anemia management algorithm. Participation in this study will not affect the anemia management of subjects in the control group.
88865351|NCT04360902|Experimental|Intervention Group|"For subjects randomized into the intervention group, our erythropoiesis model will be used to identify each subject's individual values for several physiological determinants of erythropoiesis based on his/her sex, body height and history of body weights, Hgb concentrations and Mircera® administrations over the preceding 150 to 180 days.~For subjects in the intervention group, their current method of anemia management will be discontinued. From this point on, Mircera® dose recommendations will be generated by the Anemia Controller software based on our erythropoiesis model and each subject for the duration of their 26-week participation in this study. The Anemia Controller computes the Mircera® doses required to attain the target Hgb level of 10.5 g/dL. Controller-generated Mircera® recommendations will be communicated to the respective clinics' anemia managers on a standardized report."
88865352|NCT04360668|Experimental|Muscle Energy Technique combined with Trigger Point Therapy|For this group of participants, combined therapy (Muscle Energy Technique with Trigger Point Therapy) will be used
88865353|NCT04360668|Active Comparator|Muscle Energy Technique|For this group of participants, a single method (Muscle Energy Technique) will be used
88865354|NCT04360668|Active Comparator|Trigger Point Therapy|For this group of participants, a single method (Trigger Point Therapy) will be used
88865355|NCT04360512|Experimental|One session|One session of talus posteriorization
88865356|NCT04360512|Experimental|Two sessions|Two sessions of talus posteriorization
88865357|NCT04360512|Experimental|Three sessions|Three sessions of talus posteriorization
88865358|NCT04360512|Experimental|Four sessions|Four sessions of talus posteriorization
88865359|NCT04360200||Normal Aging|Normal Aging with normal cognitive function
88865360|NCT04360200||Mild cognitive impairment (MCI)|Mild cognitive impairment subjects with memory loss as predominant symptom
88865361|NCT04359966|Active Comparator|First line therapy for H pylori infection|Tripple 14 day first line therapy Esomeprazole 40 mg, Clarithromycin 500 mg, Amoxicillin 1000 mg, all BID 14 days
88865362|NCT04359966|Experimental|First line therapy for H pylori infection second arm|"Bismuth quadruple first line therapy~Bismuth subcitrat 120 mg , Amoxicillin 500 mg, Metronidazole 400 mg, all QID, Esomeprazole 40 mg BID, 14 days."
88865363|NCT04359966|Active Comparator|Second line therapy for H pylori infection|"Bismuth quadruple second line therapy for those treated with Tripple first line therapy~Bismuth subcitrat 120 mg , Amoxicillin 500 mg, Metronidazole 400 mg, all QID, Esomeprazole 40 mg BID, 14 days."
88865364|NCT04359966|Experimental|Second line therapy for H pylori infection second arm|"Tripple second line therapy~Esomeprazol 40 mg BID Amoxicillin 1000 mg BID, Levofloxacin 500 mg OID, 14 days or"
88865365|NCT04360122|Active Comparator|Levamisole|Oral Levamisole 150 mg/day for two days per week for two months
88865366|NCT04360122|Active Comparator|Isoprinosine|Oral Isoprinosine 1 g 3 times per day daily for two months
88865367|NCT04360122|Active Comparator|Levamisole and Isoprinosine|Oral Levamisole 150 mg/day for two days per week and Oral Isoprinosine 1 g 3 times per day daily for two months
88865368|NCT04360122|No Intervention|Non-interventional group|No-intervention
88865369|NCT04360356|Experimental|Ivermectin plus Nitazoxanide|Ivermectin 200 mcg/kg once orally on empty stomach plus Nitazoxanide 500 mg twice daily orally with meal for 6 days
88865370|NCT04360356|Active Comparator|Standard care|Oxygen via ventilators
88865371|NCT04359576||FET|Estrogen/progesterone substituted and natural cycles
88865372|NCT04359810|Experimental|Convalescent Plasma (anti-SARS-CoV-2 plasma)|Convalescent plasma (1 unit; ~200-250 mL) collected from a volunteer who recovered from COVID-19 disease
89389576|NCT03560414|Active Comparator|conventional PDF treatment group|The mode of conventional PDF treatment group is CVVHDF in CRRT machine, and the duration of treatment is 3 hours. the application plasma volume 1500 ml . The replacement fluid flow rate is 500 ml/h, the dialysate flow rate is 3000 ml/h, the blood flow rate is 100-140 ml/min, and the ultrafiltration volume is 0 ml/h.
88865373|NCT04359810|Active Comparator|Non-convalescent Plasma (control plasma)|Non-convalescent plasma (1 unit; ~200-250 mL) of standard plasma collected prior to December 2019
88865374|NCT04359264|Experimental|Cash transfer|
88865375|NCT04359264|No Intervention|Control|
88865376|NCT04359342|Experimental|HIIT + protein|High-intensity interval training (HIIT) combined with protein supplementation
88865377|NCT04359342|Placebo Comparator|HIIT + placebo|High-intensity interval training (HIIT) combined with placebo
88865378|NCT04359342|Experimental|HIIT and resistance training + protein|High-intensity interval training (HIIT) and resistance training combined with protein supplementation
88865379|NCT04359342|Placebo Comparator|HIIT and resistance training + placebo|High-intensity interval training (HIIT) and resistance training combined with placebo
88865380|NCT04358952||COVID + patients|Major patients hospitalized for respiratory criteria for SARS-Cov-2 infection confirmed by RT-PCR
88865381|NCT04358796|Experimental|HBOT environment|Cognitive testing in 2ATA, 100% oxygen in breathing-masks
88865382|NCT04358796|Sham Comparator|Control environment|Cognitive testing in 1ATA, air in breathing-masks
88865383|NCT04358718|Active Comparator|general anesthesia|Patients in this group will receive general anesthesia with intraoperative and postoperative intravenous opioid-based analgesia.
88865384|NCT04358718|Experimental|general analgesia combined with epidural analgesia|Patients in this group will receive combined epidural and general anesthesia with intraoperative and postoperative epidural ropivacaine-based analgesia.
88865385|NCT04358562|Experimental|Gefitinib with Anlotinib|If persistence of plasma ctDNA EGFRm after 8 weeks of gefitinib first-line treatment, Gefitinib 250mg oral daily and Anlotinib 10mg oral d1-14, every 3 weeks
88865386|NCT04358562|Experimental|Gefitinib|If clearance of plasma ctDNA EGFRm after 8 weeks of gefitinib first-line treatment, Gefitinib 250mg oral daily
88865387|NCT04358094|Experimental|Conversational hypnosis script|Patient who received conversational hypnosis script during peripherical veinous access set up
88865388|NCT04358094|Other|Standard script|Patient who received standard script during peripherical veinous access set up
88865389|NCT04358484|Experimental|Intervention Group|Participants attend The Incredible Years - ASLD parenting intervention and continue to receive usual care at their healthcare center
89186084|NCT00720278|Experimental|Astepro 0.1%|0.1% azelastine hydrochloride nasal spray
89186085|NCT00720278|Experimental|Astepro 0.15%|0.15% azelastine hydrochloride nasal spray
88865390|NCT04358484|No Intervention|Treatment As Usual (TAU) Group|Participants continue to receive usual care at their Healthcare Center
88865391|NCT04358172|Experimental|Mobile app|Participants in this group is educated using the mobile application
88865392|NCT04358172|No Intervention|Control|Participants in this group is educated using the conventional method practised in the Faculty of Dentistry, National University of Malaysia (verbal instructions accompanied by demonstrations on dental models)
88865393|NCT04357860|Experimental|Sarilumab 200 mg|Subjects treated with the best available treatment up to 14 days plus Sarilumab 200 mg single dose.
88865394|NCT04357860|Experimental|Sarilumab 400 mg|Subjects treated with the best available treatment up to 14 days plus Sarilumab 400 mg single dose.
88865395|NCT04357860|Active Comparator|Control|Subjects treated with the best available treatment up to 14 days.
88865396|NCT04358016|Experimental|terlipression|terlipression 1mg；once every 6 hours；5days
88865397|NCT04358016|Active Comparator|Control|Somatostatin，3mg， once every 12 hours; 5 days
88865398|NCT04357548||Feedback system|Once the sample was selected, a test was performed in which the professionals performed 2 minutes of CPR on the dummy without any feedback system, after 5 minutes they performed 2 minutes of CPR with feedback system through the Zoll® monitor with CPR patch -D padz training, to later compare the pretest-posttest results.
89186086|NCT00743691|No Intervention|Arm1|Make a diagnosis of Neonatal infections and refer patients according to IMNCI guideline
89186087|NCT00743691|Active Comparator|2|Health extension Workers will Make a diagnosis of Neonatal infections and treat with antibiotics when referal is not possible
89186088|NCT00746031|Active Comparator|1|GnRH analogue-Zoladex
89186089|NCT00746031|Active Comparator|2|GnRH antagonist plus GnRH analogue
88865399|NCT04358250|Experimental|direct superior approach|Direct superior approach 25 patients
88865400|NCT04358250|Active Comparator|posterolateral approach|posterolateral approach 25 patients
88865401|NCT04357626||Completed discharged hospital rehabilitation electronic record|Completed discharged hospital rehabilitation electronic record of patients who underwent inpatient rehabilitation as part of routine clinical care.
88865402|NCT04357704|Experimental|bilateral cochlear implant recipients|
88865403|NCT04357704|Active Comparator|normal hearing listners|
88865404|NCT04357470|Active Comparator|USF Group|DRF with ulnar styloid fracture
88865405|NCT04357470|Active Comparator|NON-USF Group|DRF without ulnar styloid fracture
88865406|NCT04357392|Experimental|Glucocorticoid intervention group|prednisone
88865407|NCT04357392|Placebo Comparator|Placebo control group|placebo
89186090|NCT00746031|No Intervention|3|
89186091|NCT03881241||Study Treatment|EVOS SMALL PLating System
89186092|NCT00720122|Experimental|Anorexia Nervosa Females|
89389577|NCT03560414|Active Comparator|less plasma PDF treatment group|The mode of conventional PDF treatment group is also CVVHDF in CRRT machine, and the duration of treatment is 3h. All patients are required to apply plasma 1000ml. Use plasma substitutes: 300ml NS+200ml 5% albumin. The replacement fluid flow rate is 500 ml/h, the dialysate flow rate is 3000 ml/h, the blood flow rate is 100-140 ml/min, and the ultrafiltration volume is 0 ml/h.
88865408|NCT04357002|Experimental|intravenous tranexamic acid|patients will be given a single bolus IV injection of 15 mg/kg of tranexamic acid (TXA) 20 minutes before surgical incision plus one vaginal placebo tablet 60 minutes before skin incision.
89389578|NCT02062424|Active Comparator|DIPI: Danish national dietary guidelines|The subjects will receive dietary advice according to the current national dietary guidelines
89389579|NCT02062424|Active Comparator|DIPI: Specific IHD dietary guideline|The subjects will receive dietary advice, according to the specific ischemic heart disease dietary guidelines.
89389580|NCT02062424|No Intervention|Normal dietary habits|The Subjects will be instructed to follow their normal dietary habits
88865409|NCT04357002|Active Comparator|vaginal dinoprostone|patients will be given one vaginal dinoprostone tablet (3mg) 60 minutes before skin incision and a normal saline IV bolus 20 minutes before surgical incision
88865410|NCT04357002|Placebo Comparator|placebo|patients will be given one vaginal placebo tablet 60 minutes before skin incision and a normal saline IV bolus 20 minutes before surgical incision
89389581|NCT05384418|Experimental|patients undergoing transcatheter aortic valve implantation|patients undergoing transcatheter aortic valve implantation for aortic stenosis
89389582|NCT03153137|Experimental|Macitentan|Macitentan 10 mg per day; film-coated tablet; oral use
88865411|NCT04357080||Case|Patients with urethral stricture recurrence
89389583|NCT03153137|Placebo Comparator|Placebo|film-coated tablet; oral use
89389584|NCT05654558|Experimental|Auxiliary intrusion cantilevers|"Patients received a full set of 0.022- inch slot brackets (Mini 2000, Ormco) with Roth prescription. Lower first molars received double tubed bands while 2nd molars received single bondable tubes. Leveling and alignment phase then started with 0.014 inch NiTi wires engaging all teeth and synched behind 2nd molars. Two 0.017 x 0.025 TMA (Ormco) sectional wires were attached to auxiliary tubes on 1st molars with tip back bends mesial to the molars and attached with hooks distal to lateral incisors on top of basal leveling arch wire. Amount of intrusive force was measured to range between 20 and 40 grams per side. Basal leveling arches were upgraded whenever needed. All patients were assessed after 6 months of treatment."
89389585|NCT05654558|Active Comparator|Routine leveling and alignment|Patients received a full set of 0.022- inch slot brackets (Mini 2000, Ormco) with Roth prescription, 1st and 2nd molars received tubes or bands according to each patient's further needs Lower arch was leveled and aligned with sequential wires starting with 14 NiTi and upgraded when needed. All patients were assessed after 6 months of treatment.
89389586|NCT02061566||Acute kidney injury|Acute kidney injury in ICU
89389587|NCT02061566||Non acute kidney injury|Non acute kidney injury
89389588|NCT03616626|Active Comparator|Whole Breast Irradiation|Adjuvant 3D Conformal Radiation Therapy to a dose of 50 Gy in 25 fractions over 5 weeks. Boost is given as 10 Gy in 5 fractions over one week to patients with high grade tumors or age younger than 50 years
89389589|NCT03616626|Experimental|Once Daily APBI|Adjuvant 3D Conformal Accelerated Partial Breast Irradiation to a dose of 38.5 Gy in 10 once daily fractions given over 2 weeks
89389590|NCT03616626|Experimental|Twice Daily APBI|Adjuvant 3D Conformal Accelerated Partial Breast Irradiation to a dose of 38.5 Gy in 10 twice daily fractions given over 1 week
89389591|NCT02062736||pts addicted to heroin in MMT|patients addicted to heroin who have undertaken methadone maintenance treatment
89389592|NCT03617484|Experimental|Bortezomib + Ibrutinib|"Ibrutinib will be administered orally at a dose of 560 mg daily for each 21 day cycle.~Bortezomib will be administered subcutaneously at a dose of 1.3 mg/m^2 on days 1, 4, 8, and 11 of each 21-day cycle."
88865412|NCT04357080||Control|Patients with normal, patent urethra
88865413|NCT04356846|Experimental|R/R CLL|Relapsed or Refractory Chronic Lymphocytic Leukemia Patients
88865414|NCT04356846|Experimental|R/R NHL|Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Patients, including SLL, FL, MZL, MCL, DLBCL, WM.
88865415|NCT04356378||"infection with coronavirus SARS-CoV2 group"|"SARS-CoV2 infected patients group: in-patient in the acute phase then requiring rehabilitation."
89186093|NCT00746109|Placebo Comparator|NOPACKING|The comparison group will undergo a routine incision and drainage procedure but will not have packing placed inside the abscess cavity.
89389593|NCT01344473|Experimental|Casein phosphopeptide in the form of TM|Experimental group will be given TM to use daily for 12 weeks
89389594|NCT01344473|No Intervention|No intervention|Standard oral care
88865416|NCT04356222|Experimental|Leptomeningeal Metastasis|Durvalumab + Intrathecal chemotherapy
88865417|NCT04356144||Critical infection|Patients with signs of infection with SARS-CoV-2 or already diagnosed infection with SARS-CoV-2 admitted to the ICU
88865418|NCT04356300|Experimental|The exosome of MSC arm|Exosome of MSC at a dose of 150mg will be given intravenously to Patients in the exosome of MSC arm once a day for 14 times.
89389595|NCT02063204|Experimental|HV selumetinib Stage 1|Healthy volunteer (HV)group to receive selumetinib 50mg (2x25mg) orally
89389596|NCT02063204|Experimental|ESRD selumetinib Stage 1|End stage renal disease (ESRD)patients to recieve selumetinib 50mg (2x25mg) orally
89389597|NCT02063204|Experimental|Selumetinib stage 2|If deemed necessary patients with mild and/or moderate and/or severe renal impairment will recieve selumetinib 50mg(2x25mg) orally
88865419|NCT04356300|No Intervention|The control arm|Patients in the control arm will not be given exosome of MSC.
89389598|NCT03617406|Other|Arm Volume Challenge|A standard LDDSE will be performed. The stroke volume (SV) will be recorded. The addition of VC with the passive leg raise method at peak dobutamine dose will be performed. A TEE with low dose dobutamine and a bolus of normal saline will be performed as a validation method.
89389599|NCT01344551|Active Comparator|High Flavanol|High Flavanol cocoa drink containing 495mg cocoa
89186094|NCT00746109|Experimental|PACKING|This group will receive wound packing as per usual protocol
89389600|NCT01344551|Placebo Comparator|Low Flavanol|Low Flavanol cocoa drink (23mg)
89389601|NCT03618108|Active Comparator|Active|Subjects will be given oral capsules containing the active comparators 50mg oral capsule doxycycline, 250mg oral capsule azithromycin and 150mg oral capsule rifabutin daily (days 1 to 7). From days 8 to 90 subjects will be given 50mg oral capsule doxycycline, 250mg oral capsule azithromycin and 150mg oral capsule rifabutin twice daily.
89389602|NCT03618108|Placebo Comparator|Placebo|subjects will be given sugar capsules identical in form and size to the active comparators, 1 capsule of each bottle (3 separate capsules) daily (days 1 to 7), 1 capsule of each bottle (3 separate capsules) twice daily (days 8 to 90).
89186095|NCT04087382|Active Comparator|Intervention group|it included 32 patients with acute ischemic stroke beyond the time of window (more than 6 hours) assigned to mechanical thrombectomy) plus the conventional treatment (Aspirin 150 mg and atorvastatin 40 mg).
89389603|NCT03138473||Main Group|Acute Coronary Syndrome Patients With Multi-Vessel Disease. The Residual SYNTAX score (rSS) and the SYNTAX Revascularization Index (SRI) will be calculated in this group and its relationship with patient outcomes either in hospital or in 6 months to 1 year follow-up will be evaluated.
89389604|NCT02031900||Undergoing EGD|
89389605|NCT04903704|Other|Sit to Stand testing|"Participants will undergo an ISWT in the hospital setting. This test is a standard of clinical care and it is essential to the patient assessment on their clinical visit. This test will therefore be conducted first in all cases.~They will be allowed a 30 minute rest before undertaking the 1MSTS test.~Clinical observations (heart rate, blood pressure, oxygen saturations) will be taken before and after both tests. Heart rate and oxygen saturations will be monitored during both tests.~Patient reported measures of dyspnoea and perceived exertion will be recorded on completion of both tests.~Adverse events e.g. dizziness, syncope or the participant becoming unwell be recorded.~Descriptive and inferential statistical analysis will be used to determine the safety of 1MSTS in the hospital setting and comparability between 1MSTS and ISWT for participants. We will also examine comparability between 1MSTS outcomes and other available routinely collected clinical data."
89389606|NCT01342601|Active Comparator|Ectoin products|
88865420|NCT04356456|Experimental|Lumenato Supplement|Lumenato oleoresin
88865421|NCT04356456|Placebo Comparator|Placebo|paraffin oil
89389607|NCT01342601|Placebo Comparator|Placebo products|
89389608|NCT03616548|Other|Intestinal transplantation|Magnifying endoscopy under NBI system via chimney ileostomy after intestinal transplantation using a novel VENCH scoring system
89389609|NCT04349657|Experimental|Supera Peripheral Stent System treatment group|These patients will be treated endovascularly with the Supera Peripheral Stent System (Abbott).
89389610|NCT04349657|Active Comparator|Endarterectomy treatment group|These patients will be treated surgically with endarterectomy
89389611|NCT03616392|Experimental|Part 1: Group 1(Treatment A/Treatment B)|Period 1: Treatment A (D308 1T)/day for 5days, QD, PO Period 2: Treatment B (D308 1T + CKD-501 1T)/day for 5days, QD, PO
89389612|NCT03616392|Experimental|Part 1: Group 2(Treatment B/Treatment A)|Period 1: Treatment B (D308 1T + CKD-501 1T)/day for 5days, QD, PO Period 2: Treatment A (D308 1T)/day for 5days, QD, PO
89389613|NCT03616392|Experimental|Part 2: Group 1(Treatment C/Treatment B)|Period 1: Treatment C (CKD-501 1T)/day for 5days, QD, PO Period 2: Treatment B (D308 1T + CKD-501 1T)/day for 5days, QD, PO
89389614|NCT03616392|Experimental|Part 2: Group 2(Treatment B/Treatment C)|Period 1: Treatment B (D308 1T + CKD-501 1T)/day for 5days, QD, PO Period 2: Treatment C (CKD-501 1T)/day for 5days, QD, PO
89389615|NCT03615378|Placebo Comparator|Placebo|
89389616|NCT03615378|Active Comparator|Vitamin D 1000 IU D3 daily|
89389617|NCT03615378|Active Comparator|Vitamin D 5000 IU D3 daily|
89389618|NCT03616314||stepping verticalization|in ICU they received conventional physiotherapy + stepping verticalization sessions with Erigo
89389619|NCT03616314||stepping verticalization + FES|in ICU they received conventional physiotherapy + stepping verticalization sessions with FES using ErigoPro
88865422|NCT04355988|Active Comparator|Well controlled diabetics|Nonsurgical root canal treatment
88865423|NCT04355988|Active Comparator|Poorly controlled diabetics|Nonsurgical root canal treatment
88865424|NCT04355988|Active Comparator|Healthy control group|Nonsurgical root canal treatment
88865425|NCT04356066|Other|Adult Rheumatoid Arthritis Patient with Interstitial Lung Dise|"History taking: age, sex, disease duration, history of present illness, drug intake, past and family history.~Physical examination including thorough clinical examination.~Health assessment questionnaire-disability index (HAQ-DI): It is used as a subjective measure of physical function of RA patients (Pincus et al., 1983). There are 20 items in 8 categories: dressing, rising, eating, walking, hygiene, reach, grip, and usual activities (Jessica et al., 2018)."
89389620|NCT03616314||conventional physiotherapy|in ICU they received only conventional physiotherapy
89389621|NCT02236728||Parkinson's disease patients|
89186096|NCT04087382|Other|non-intervention group|it included 25 patients with acute ischemic stroke beyond the time of window (more than 6 hours) who received medical treatment (Aspirin 150 mg and atorvastatin 40 mg).
89186097|NCT02564835|Experimental|Yoga|The Yoga Program includes two 90-minute classes every week tor a total of 12 weeks.
89186098|NCT02564835|Active Comparator|Physical Activity|The Physical Activity Program includes two 90-minutes classes every week for a total of 12 weeks.The intervention is based on the Exercise for People Living with Cancer program and will include nine resistance exercises (e.g. standing push up, squats, standing leg curl) and 8 flexibility exercises (e.g. shoulder stretch, quadriceps stretch, hamstrings and lower back stretch) targeted for the whole body as well as a brief warm up and cool down (walking).
88865426|NCT04355754|Experimental|mechanically ventilated patients|"Adult ICU patients who are mechanically ventilated and who do not require complex modes of ventilation.~A designated flow divider (Ventil) will be used to divide inspiratory gas flow from ventilator in two separate streams - one to the patient and the second to the artificial lung"
89186099|NCT02564835|No Intervention|Usual Care|Participants randomized to this arm will receive standard care only.
89186100|NCT04085666|Experimental|1st Confinement Period in Unit|Randomized to treatment with either CDX-6114 or matching Placebo
89186101|NCT04085666|Experimental|2nd Confinement Period in Unit|Randomized to treatment with either CDX-6114 or matching Placebo
89186102|NCT00746265|Active Comparator|SBT|Standard behavioral treatment based on the LEARN manual.
89186103|NCT00746265|Active Comparator|ABT|Acceptance-based group that is based on the behavioral interventions contained in LEARN manual
89186104|NCT00743769|Active Comparator|2|"Thymosin Beta 4~A single bolus injections of ascending doses of 42 mg, 140 mg, 420 mg or 1,260 QD (once a day)"
89186105|NCT00743769|Placebo Comparator|1|Placebo A single bolus injection of 0.0 mg QD of thymosin beta 4
89186106|NCT02563977||DIEP flap breast reconstruction|14 patients who have had DIEP flap breast reconstruction and preoperative CT scan of the abdomen
89186107|NCT00743847|Placebo Comparator|placebo|
89186108|NCT00743847|Active Comparator|varenicline 0.5 mg BID|
89186109|NCT00743847|Active Comparator|varenicline 1mg BID|
89186110|NCT00746343|Experimental|IRRI|"The integrated risk reduction intervention (IRRI) consists of three components:~psychiatric treatment by a study psychiatrist~assessment, referral, monitoring, and coordination by a certified registered nurse practitioner (CRNP) of medical treatment provided by the subject's own primary care physician~a healthy lifestyle behaviors program delivered by a lifestyle coach. The treating psychiatrist will work in collaboration with a CRNP and a lifestyle coach. The CRNP will assess and monitor the subject's medical needs and refer the subject to their primary care physician for care and will follow-up on adherence to the medical treatment recommendations. The CRNP will be responsible for coordinating the psychopharmacological care provided by the psychiatrist, the healthy lifestyle behaviors program that will be delivered by the lifestyle coach, and the medical care provided by the subject's PCP."
89186111|NCT00746343|Experimental|PCCM|"Psychiatric Care with Medical Monitoring (PCMM)~The psychiatric care with medical monitoring condition (PCMM) consists of two components:~psychiatric treatment by a study psychiatrist~assessment and referral by a psychiatric research nurse for medical treatment provided by the subject's own primary care physician.~The treating psychiatrist will be assisted by a psychiatric nurse clinician who will assess and monitor the subject's medical needs and refer the subject to their primary care physician for care."
89186112|NCT00717860|Experimental|Caspofungin|caspofungin acetate (MK0991)
89186113|NCT00717860|Active Comparator|Micafungin|Micafungin sodium
89186114|NCT03880617||Chronic Myeloid Leukemia (CML)|For CML, the first-line targeted drug is imatinib, and then second line as nilotinib and dasatinib. In the past, the median survival of CML is around 4 to 6 years (NCI, 2008). Fortunately, the launch of the targeted therapy, the median survival is expected to approach normal life expectancy for most patients. However, limited to the less than 20 years of advent of TKI, the exact effects on survival time is not yet determined.
89186115|NCT03880617||Gastrointestinal Stromal Tumor (GIST)|For patients with GIST, the imatinib mesylate (Glivec, Novartis Pharma, Basel, Switzerland) (Heinrich et al, 2003) is the first line drug and sunitinib as the second line drug. Sunitinib is an anti-angiogenesis agent by virtue of targeting multiple tyrosine kinases, including the vascular endothelial growth factor receptors (VEGFR). With these target drugs, the survival of advanced GIST patients is prominently prolonged (Lamba, Ambrale, Lee, Gupta, Rafiyath, & Liu D, 2012). The median overall survival (OS) of advanced GIST patients increased from 18 to 57 months with imatinib therapy (Blanke et al, 2008).
89186116|NCT02564679|Experimental|Sleeve gastrectomy|These patients are surgically treated with laparoscopic sleeve gastrectomy in association to lifestyle intervention (hypocaloric diet and physical activity)
89186117|NCT02564679|Experimental|Lifestyle Intervention|These patients are treated with lifestyle intervention (hypocaloric diet and physical activity)
89186118|NCT00746499|Experimental|1|No control group, only one active arm with subjects taking Raltegravir.
89186119|NCT02592122|Active Comparator|Atomization inhalation|First of all, investigators need to give patients to do the test, the result is more than 12% is positive group, less than 12% is negative group.Second, randomly selected into the atomization group
89186120|NCT02592122|Active Comparator|Without atomization inhalation|First of all, investigators need to give patients to do the test, the result is more than 12% is positive group, less than 12% is negative group.Secondly, the random selection is not the atomization group
89186121|NCT01497015|Experimental|memory training|memory training 10 1-hour sessions with interventionist to be delivered over 6-8 weeks
89186122|NCT01497015|Experimental|speed of processing training|Speed of processing training 10 1-hour sessions delivered over 6-8 weeks
89389622|NCT03615300||good neurologic outcome|Patients with good neurological prognosis after 6 months (CPC 1, 2). serum NGAL is collected.
88865427|NCT04355910|Experimental|Intermittent fasting mimic-diet (IFD)|Restrict 75% energy on two non-consecutive days each week.
88865428|NCT04355910|Active Comparator|Continuous calorie restriction (CCR)|A daily 25% energy-restricted Mediterranean-type diet
88865429|NCT04355910|No Intervention|Control|No advice to restrict energy
89389623|NCT03615300||poor neurologic outcome|Patients with poor neurological prognosis after 6 months (CPC 3, 4, 5). serum NGAL is collected.
89389624|NCT04254653|Experimental|Immediate Intervention|Participants receive diabetes nutrition education classes immediately.
88865430|NCT04355676|Experimental|Selinexor 40mg|Participants will receive 40 milligram (mg) of selinexor as oral tablets on Days 1 and 3 of each week for up to 2 weeks (14 days). If the participant is tolerating therapy and clinically benefitting, dosing can continue for an additional 2 weeks (28 days).
89186123|NCT01497015|Experimental|waitlist control|Breast cancer survivors will be randomized to 1 of 3 groups: memory training, speed of process training or waitlist control
89389625|NCT04254653|Experimental|Wait list intervention|Participants wait listed (control) for 3 months and then receive the diabetes nutrition education classes.
89389626|NCT03616158||Pre-RA|"Subjects with interstitial lung disease (ILD) or airways disease, no rheumatoid arthritis (RA), and positive antibodies will participate in 5 in-person study visits. Additionally, quality of life questionnaires will be mailed/emailed and completed at home every 6 months, at 4 different time points. Overall participation will take place over a 4 year time frame and an additional 6 years of survival follow-up.~In-person Study Assessments Include:~Medical History and Physical Exams~Quality of Life Questionnaires~Collection of blood~Radiology~Lung Function Test~6 Minute Walk Test~Bronchoscopy (Clinically indicated)~Sputum (Optional)~Musculoskeletal ultrasound (Optional)"
89186124|NCT02564445|Experimental|Control|"Participants choose a weight loss goal of 6-8% of baseline weight and given access to a wireless weight scale and smartphone application activity tracker to receive feedback on weight and feedback on step counts.~They will be given information on the federal and CDC guidelines for physical activity and will also be told that they should strive to achieve 10,000 steps per day to help promote weight loss."
89186125|NCT02564445|Experimental|Gamification|"Participants choose a weight loss goal of 6-8% of baseline weight and given access to a wireless weight scale and smartphone application activity tracker to receive feedback on weight and feedback on step counts.~All participants play a game with their teammate that includes points, levels and the opportunity to win a trophy, plaque or medal. They will advance or not advance based on their progress with weight loss and physical activity through 24 weeks. During the 12-week follow-up they'll be asked to maintain or make progress toward their weight loss goal."
89186126|NCT02564445|Experimental|Gamification + Share Data with PCP|"Participants choose a weight loss goal of 6-8% of baseline weight and given access to a wireless weight scale and smartphone application activity tracker to receive feedback on weight and feedback on step counts.~Participants will be asked to allow the study team to share their weight and step data with their primary care physician (PCP).~All participants play a game with their teammate that includes points, levels and the opportunity to win a trophy, plaque or medal. They will advance or not advance based on their progress with weight loss and physical activity through 24 weeks. During the 12-week follow-up they'll be asked to maintain or make progress toward their weight loss goal."
89186127|NCT02564367|Experimental|Treatment|"First Cohort 1:~(n = 30 patients) 18 cycles S-1"
89389627|NCT03616158||RA without LD|"Subjects with rheumatoid arthritis (RA), and no interstitial lung disease (ILD) or airways disease, will participate in 5 in-person study visits. Additionally, quality of life questionnaires will be mailed/emailed and completed at home every 6 months, at 4 different time points. Overall participation will take place over a 4 year time frame and an additional 6 years of survival follow-up.~In-person Study Assessments Include:~Medical History and Physical Exams~Quality of Life Questionnaires~Collection of blood~Radiology~Lung Function Test~6 Minute Walk Test~Bronchoscopy (Clinically indicated)~Sputum (Optional)~Musculoskeletal ultrasound (Optional)"
89389628|NCT03616158||RA-LD|"Subjects with rheumatoid arthritis (RA) and interstitial lung disease (ILD) or airways disease, will participate in 5 in-person study visits. Additionally, quality of life questionnaires will be mailed/emailed and completed at home every 6 months, at 4 different time points. Overall participation will take place over a 4 year time frame and an additional 6 years of survival follow-up.~In-person Study Assessments Include:~Medical History and Physical Exams~Quality of Life Questionnaires~Collection of blood~Radiology~Lung Function Test~6 Minute Walk Test~Bronchoscopy (Clinically indicated)~Sputum (Optional)~Musculoskeletal ultrasound (Optional)"
89389629|NCT03616158||LD Controls|"Subjects with interstitial lung disease (ILD) or airways disease, no rheumatoid arthritis (RA), and negative antibodies will participate in 5 in-person study visits. Additionally, quality of life questionnaires will be mailed/emailed and completed at home every 6 months, at 4 different time points. Overall participation will take place over a 4 year time frame and an additional 6 years of survival follow-up.~In-person Study Assessments Include:~Medical History and Physical Exams~Quality of Life Questionnaires~Collection of blood~Radiology~Lung Function Test~6 Minute Walk Test~Bronchoscopy (Clinically indicated)~Sputum (Optional)~Musculoskeletal ultrasound (Optional)"
89389630|NCT01344785||Patients with a intertrochanteric fracture|Patients with a intertrochanteric fracture, n=100
89389631|NCT03136861|Experimental|Secukinumab 150 mg (Group A)|Treatment Period 1: Secukinumab 150 mg (1 x 1.0 mL) s.c. administered at Baseline, Week 1, 2, 3 and 4
88865431|NCT04355676|Experimental|Selinexor 20mg|Participants will receive 20 milligram (mg) of selinexor oral tablet on Days 1, 3 and 5 of each week for up to 2 weeks (14 days). If the participant is tolerating therapy and clinically benefitting, dosing can continue for an additional 2 weeks (28 days).
88865432|NCT04355598|Experimental|Lidocaine-Prilocaine cream|2 mL of the Lidocaine-Prilocaine cream will be placed on the anterior lip of the cervix by a Q-tip applicator, followed by 2 mL will be introduced in the cervical canal 7 minutes prior to IUD insertion
88865433|NCT04355598|Active Comparator|glyceryl trinitrate cream|2 mL of the glyceryl trinitrate cream will be placed on the anterior lip of the cervix by a Q-tip applicator, followed by 2 mL will be introduced in the cervical canal 7 minutes prior to IUD insertion
88865434|NCT04355598|Placebo Comparator|placebo cream|2 mL of the placebo cream will be placed on the anterior lip of the cervix by a Q-tip applicator, followed by 2 mL will be introduced in the cervical canal 7 minutes prior to IUD insertion
88865435|NCT04355286|Experimental|Part 1, one-arm open label pilot study|Part 1 is an open label, 1-arm pilot study to evaluate the systemic absorption and effects of multiple applications of a market-image topical sunscreen formulation containing BEMT (6%) under maximum use conditions in healthy adult subjects.
89186128|NCT00717314|Experimental|MMF, 50% CNI Reduction|Participants received mycophenolate mofetil (MMF), 1.5 to 2.0 grams (g) daily, orally (PO), twice per day (BID) from baseline (BL) to Week 52. Participants also received a 50 percent (%) reduced dose of calcineurin inhibitor (CNI) from BL to Week 52.
89389632|NCT03136861|Placebo Comparator|Placebo (Group B)|Treatment Period 1: Placebo (1 x 1.0 mL) s.c. administered at Baseline and Week 1, 2, 3 and 4
89389633|NCT03136861|Active Comparator|Arm A1|Treatment Period 2: Secukinumab 150 mg (1 x 1.0 mL) plus placebo (1 x 1.0 mL) administered at Week 8, 12, 16 and 20
89186129|NCT00717314|Experimental|MMF, ≥75% CNI Reduction|Participants received MMF, 1.5 to 2.0 g daily, PO, BID from BL to Week 52. Participants also received a 75% reduced dose of CNI from BL to Week 52.
89389634|NCT03136861|Active Comparator|Arm A2|Treatment Period 2: Secukinumab 150 mg (1 x 1.0 mL) plus placebo (1 x 1.0 mL) administered at Week 8, 12, 16 and 20
89389635|NCT03136861|Active Comparator|Arm A3|Treatment Period 2: Secukinumab 300 mg (2 x 1.0 mL) administered at Week 8, 12, 16, and 20
89389636|NCT03136861|Active Comparator|Arm B1|Treatment Period 2: Secukinumab 150 mg (1 x 1.0 mL) plus placebo (1 x 1.0 mL) administered at Week 8, 12, 16 and 20
89389637|NCT03136861|Active Comparator|Arm B2|Treatment Period 2: Secukinumab 300 mg (2 x 1.0 mL) administered at Week 8, 12, 16, and 20
89389638|NCT03482856|Experimental|Modern Neuroscience Approach (MNA) plus CBT-I|MNA (i.e. modern pain neuroscience approach) combined with CBT-I (i.e. cognitive-behavioural therapy for insomnia)
89389639|NCT03482856|Active Comparator|MNA alone|The MNA (i.e. modern pain neuroscience approach) alone
89389640|NCT01342679|Experimental|dasatinib|
88865436|NCT04355520|Experimental|TQ-B3525 tablets combined with fulvestrant injection|TQ-B3525 tablets were taken orally, once daily in 28-day cycle; fulvestrant injection 500mg administered intravenously (IV) on day 1, day 15 of first cycle and on day 1 of follow-up treatment cycle. Each cycle is 28 days.
88865437|NCT04355442||contained patients|contained patients
89389641|NCT04852926||A prospective cohort of patients|Female patients treated for non-metastatic breast cancer and followed up in the Observatory of fertility at Jeanne de Flandre Hospital
89389642|NCT03616080|Experimental|experimental|children who participated in soccer play program usual activity and therapy + soccer play program (once a week for eight weeks)
88865438|NCT04355442||Comparative patients|Comparative patients
88865439|NCT04355208|Experimental|Intervention|Restoration of anterior teeth using monochromatic layering technique using body shade (filtek universal from 3m
88865440|NCT04355208|Active Comparator|comparator|Restoration of anterior teeth using polychromatic layering technique using Enamel and Dentin shades (filtek Z350 xt from 3m
89186130|NCT01090089|Experimental|Lenalidomid, PBSCT|A1 Rd until progression or max. 5 years (Rd = lenalidomide 25 mg d1-21/28d + dexamethasone 40 mg po d1, d8, d15, d22/28d)
89389643|NCT03616080|No Intervention|control|children without soccer paly program usual activity and therapy
89389644|NCT01342835|Active Comparator|drug: propofol|Drug:Propofol and sevoflurane The induction dose of propofol is 3-5 mg/kg-1 (mean induction dose: 4 mg/kg-1) follow by propofol infusion (12 mg/kg/h-1 for the first 10 min of general anesthesia, 9 mg/kg/h-1 for another 10 min, and 6 mg/kg/h-1 thereafter; mean maintenance dose: 9 mg/kg/h-1) and a 50:50 mixture of N2O and O2.
89389645|NCT01342835|Active Comparator|Sevoflurane group:sevoflurane|Drug:Sevoflurane and Propofol Mask induction is perform with sevoflurane (4-6%) follow by 1.5-2% sevoflurane in a 50:50 mixture of N2O and O2.
89389646|NCT03616002|Experimental|Hookah smoking|Healthy habitual Hookah smokers will undergo brachial artery flow mediated dilation, reactive hyperemia peripheral arterial tonometry or pulse tonometry before and after Hookah smoking.
89389647|NCT01344863|Experimental|1|
89389648|NCT01344863|Active Comparator|2|
89389649|NCT01354561|Sham Comparator|control group|Physiotherapy in the control group were also done at hospital, in dorsal decubitus position at 30-degree elevation, all receiving the same treatment given for the paediatric inpatients, except nasotracheal suction, which was not performed due to ethical reasons.
89389650|NCT01354561|Active Comparator|respiratory disease group|Respiratory disease group consisting of hospitalized children with acute viral bronchiolitis
89389651|NCT01354639||Group 1|Group 1 : conventional open thyroidectomy group (papillary thyroid carcinoma patient who underwent conventional open bilateral total thyroidectomy procedure and postoperative low dose RAI therapy)
89389652|NCT01354639||Group 2|Group 2 : robotic thyroidectomy group (papillary thyroid carcinoma patient who underwent robotic bilateral total thyroidectomy procedure and postoperative low dose RAI therapy)
89530457|NCT03247777|Active Comparator|Traditional strengthening|These subjects performed traditional strengthening exercises of targeted muscle groups (For example, bench press, lat pulldowns, dead lifts and wrist curls)
89530458|NCT03247777|Active Comparator|Functional Strengthening|These subjects performed exercises that either mimicked golf (diagonal chop) or that required balance and stability (single leg dead lift)
89530459|NCT04501601|Experimental|Experimental: weight loss program kit|weight loss program kit
88865441|NCT04355052|Active Comparator|A - HCQ + AZT|Hydroxychloroquine 400 mg BID on day 1 and than 200 mg BID on days 2-5 + Azithromycin 500 mg QD on day 1 and 250 mg QD on days 2-5
89186131|NCT01090089|Active Comparator|Lenalidomid|A2 Induction with 3 cycles Rd, tandem high dose melphalan (140 mg/m²) with autologous peripheral blood stem cell transplantation (PBSCT) followed by lenalidomide maintenance (10 mg/day) until progression or max. 5 years
89186132|NCT02591342||CPT stem|Patients treated with a polished, tapered femoral stem as a hip arthroplasty for a displaced femoral neck fracture
89186133|NCT02591342||SP2 stem|Patients treated with a anatomic femoral stem as a hip arthroplasty for a displaced femoral neck fracture
89186134|NCT00689793|Active Comparator|1|
88865442|NCT04355052|Experimental|B - HCQ + CAM|Hydroxychloroquine 400 mg BID on day 1 and than 200 mg BID on days 2-5 + Camostat mesylat 200 mg TID for 10 days
88865443|NCT04355052|No Intervention|C - NI|No Intervention
88865444|NCT04354974|Active Comparator|Eco Program (Ecological Cognitive Training for Mood Disorders)|"Duration: four months, 16 sessions~Frequency: One one-hour session and one hour of personal work per week~Modalities: Paper and pencil exercises and manipulable tools~Objective: Learning problem-solving strategies for use in daily life~Modules: Psychoeducation, Information Processing, Memory, Concept Formation, Functional Disorders"
88865445|NCT04354974|Active Comparator|ThOR Program (Remission Oriented Therapy)|"Duration: four months, 16 sessions~Frequency: One one-hour session and one hour of personal work per week~Modalities: Paper tools and verbal exchange with the patient~Objective: Improvement of the patient's quality of life~Themes: Mood, social skills, autonomy, motivation, sleep"
88865446|NCT04354662|Experimental|Toripalimab combined with FLOT|In the perioperative period, patients with resectable gastric cancer is treated with flot regimen combined with Toripalimab to observe whether the 3-year disease-free survival (DFS) rate, pathological remission rate, R0 resection rate, D2 radical resection rate, 5-year DFS rate and 5-year OS rate could be improved.
88865447|NCT04354350||Ramipril|Reference group
88865448|NCT04354350||Telmisartan|Exposure group
88865449|NCT04354740||Group A : Diabetic|group is subdivided into 2sub-groups: Group 1: Group: underwent PCI(Primary or Rescue) Group 2: underwent CABG Patients diagnosed as multivessel disease or left main coronary artery lesion will be included in the study
88865450|NCT04354740||Group B: Non diabetic|group is subdivided into 2sub-groups: Group 1: Group: underwent PCI(Primary or Rescue) Group 2: underwent CABG Patients diagnosed as multivessel disease or left main coronary artery lesion will be included in the study
88865451|NCT04354194|Experimental|Conventional Physiotherapy Group|This group will receive 15 sessions of conventional physiotherapy programme 5 times per week.
88865452|NCT04354194|Experimental|Osteopathic Manipulative Treatment Group|This group will receive 9 sessions of Osteopathic Manipulative Treatment programme 3 times per week.
89003516|NCT05091437||Prospective|All eligible subjects with solid or subsolid (part solid, pure ground glass) lung nodule identified in imaging exams in routine clinical practice, prior to 30 days of informed consent given [ Fleischner Society 2017 guidelines for nodules size and definition (≥ 6 mm and < 3 cm)) for subject inclusion]. Subjects identified from different sources (Nodules identified incidentally and in lung cancer screening programs) will be considered.
89003517|NCT05088876|Active Comparator|Paracetamol|
89186135|NCT00689793|Placebo Comparator|2|
89186136|NCT04086290|Experimental|RARP + SBRT + ADT|Radical prostatectomy + extended pelvic lymph node dissection according to EAU guidelines followed by stereotactic body radiotherapy to osseous lesions with six month of neo-adjuvant/concomitant medical castration therapy using a gonadotropin-releasing hormone antagonist or agonist.
89186137|NCT02591966||Biomarker group|"The patients who receive neoadjuvant systemic treatments:~The patients who have distant metastatic sites at first and recur from surgery:~The patients who are going to receive first-line chemotherapy:"
89186138|NCT05431491|Experimental|Ultrafiltration cohort|These patients will be recruited into the study to assess the feasibility of slow continuous ultrafiltration through either a standard central venous catheter, or peripheral intravenous cannula.
89186139|NCT00723944|Active Comparator|Osseotite Certain Prevail|Dental implant with lateralized design
89186140|NCT00723944|Placebo Comparator|Osseotite Certain|Dental implant without the lateralized design
89186141|NCT00744159||OC|Open colorectal resection
89186142|NCT00744159||LC|Laparoscopic colorectal resection
89186143|NCT04086134|Experimental|Intervention fruit products 1|Three servings of fruit products per day for 4 weeks.
89186144|NCT04086134|Experimental|Intervention fruit products 2|Three servings of fruit products per day for 4 weeks.
88865453|NCT04354116|Experimental|MARPE|Maxillary expander anchored in mini-implants (MARPE)
88865454|NCT04354116|Active Comparator|Hyrax|Tooth-born anchored maxillary expanders, without mini-implants
88865455|NCT04353882||patients with tumor recurrence|
88865456|NCT04353882||patients with-out tumor recurrence|
88865457|NCT04353336|Experimental|Chloroquine or Hydroxychloroquine|Chloroquine or Hydroxychloroquine with standard of care treatment.
88865458|NCT04353336|No Intervention|No intervention|standard of care treatment alone.
88865459|NCT04353726|Experimental|Intervention group|Eligible participants will be in an intervention group led by a registered dietitian
89003518|NCT05088876|Placebo Comparator|Placebo|
89186145|NCT04086134|Placebo Comparator|Control fruit products|Three servings of control fruit products per day for 4 weeks.
89186146|NCT04060329|No Intervention|Phase 1|Usual care
88865460|NCT04353180|Active Comparator|13 cis retinoic acid doses orally plus the standard therapy|Arm 1: infected patients will receive the standard therapy for COVID-19 (Paracetamol 500 mg /6h, Hydroxychloroquine 500 mg/ 12h, Oseltamivir 150 mg /12 h for 5 days, Azithromycin 1 gm first day then 500 mg/day for 1st line or Clarithromycin 500 mg/12 h for 7-14 days, Ascorbic acid 500 mg/12 h and Cyanocobalamin IV once daily plus Lopinavir 400mg/Ritonavir 100 mg caps 2 capsules twice daily in severe cases) and after three days of the standard therapy the infected patients will receive 13 cis retinoic acid (0.5 mg/kg/day in 2 divided doses orally for 14 days combined with the standard therapy . All subjects were encouraged to complete the full course of treatment and common side effects were explained. Side effects and compliance will be documented.
88865461|NCT04353180|Active Comparator|Aerosolized 13 cis retinoic acid plus the standard therapy|Arm 2: infected patients will receive the standard therapy for COVID-19 (Paracetamol 500 mg /6h, Hydroxychloroquine 500 mg/ 12h, Oseltamivir 150 mg /12 h for 5 days, Azithromycin 1 gm first day then 500 mg/day for 1st line or Clarithromycin 500 mg/12 h for 7-14 days, Ascorbic acid 500 mg/12 h and Cyanocobalamin IV once daily plus Lopinavir 400mg/Ritonavir 100 mg caps 2 capsules twice daily in severe cases) and after three days of the standard therapy the infected patients will receive Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days
88865462|NCT04353180|Active Comparator|13 cis retinoic acid doses orally|Infected patients will receive 13 cis retinoic acid (0.5 mg/kg/day in 2 divided doses orally for 14 days
88865463|NCT04353180|Active Comparator|Aerosolized 13 cis retinoic acid|The infected patients will receive Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days
88865464|NCT04353180|Sham Comparator|The standard therapy|Arm 3:infected patients will receive the standard therapy for COVID-19 for 14 days
88865465|NCT04352868|Active Comparator|Toric soft contact lens|Toric soft contact lens
88865466|NCT04352868|Experimental|Multifocal toric soft contact lens|A multifocal toric soft contact lens with a +2.00 D add.
88865467|NCT04352946|Experimental|Hydrocholoroquine Pre-exposure prophylaxis|HCQ will be administered as 400mg orally once for 60 days.
88865468|NCT04352946|Placebo Comparator|Placebo|Placebo will be administered as 400mg orally once for 60 days.
88865469|NCT04352712||Healthy Children|healthy children, untreated, donors of monocytes
88865470|NCT04352712||GHD children|GHD children, untreated, donors of monocytes
88865471|NCT04352634||Healthcare workers|Workers who interact with people with confirmed or suspected COVID-19 at different health services (primary care centers, emergency units, specialized care units, inpatient care units, critically ill patient units, among others). Potential participants will include any type of worker in these centers, including clinical and administrative staff, as well as supportive staff (e.g., food services)
88865472|NCT04352322|Experimental|A+HA(tm)|20 ml oral solution of hyaluronic acid mixture in combination with glucosamine and chondroitin in a bottle. Administration with 250~500 ml water under fasting condition in the morning.
88865473|NCT04352322|Placebo Comparator|Placebo|20 ml oral solution without active ingredients in a bottle. Administration with 250~500 ml water under fasting condition in the morning.
88865474|NCT04352478||Elder|elderly (≥60 years old).
88865475|NCT04352478||Young|young (<60 years old)
88865476|NCT04351932|Active Comparator|bone marrow mesenchymal stem cell|Bone marrow mesenchymal stem cells 10 cc by intra articular injection once
88865477|NCT04351932|Active Comparator|adipose mesenchymal stem cells|Stromal vascular factor from adipose mesenchymal stem cells 10 cc by intra articular injection once
88865478|NCT04351932|Active Comparator|Bone marrow and Adipose mesenchymal stem cells|Bone marrow and Stromal vascular factor from adipose mesenchymal stem cells 5 cc each one, by intra articular injection once.
88865479|NCT04352088||Allergic rhinitis patients|
88865480|NCT04352088||Allergic rhinitis and asthma patients|
88865481|NCT04352088||Healthy individuals|
88865482|NCT04351542|Experimental|Ayurveda Care Group|Individualised ayurveda treatment was given to participants based on individual constitution.
88865483|NCT04351542|Active Comparator|Usual Care Group|Participants followed the usual care.
88865484|NCT04351464|Active Comparator|Physical therapy and Reflexology group|Received reflexology implementation for 20-30 minutes on the sole along with the physical treatment involving NDT approaches. Within the scope of the implementation, all the reflex points on the sole were stimulated. The pituitary gland, which is related to sleep and control of salivation, oromotor area and areas of muscular and skeletal system were stimulated with further repetitions.
88865485|NCT04351464|Experimental|Just Physical therapy group|The group received a 45-minute physical therapy program involving NDT approaches as the control group. Within the scope of this program, the children were treated with intramuscular stretching and soft tissue mobilization, exercises that improved balance and that supported the development of postural control, position shifts, and stretching and reinforcement exercises in the necessary muscle groups.
88865486|NCT04351308|Experimental|API+apatinib|"AP = Doxorubicin (Adriamycin) 20 mg/m2/day * 2 day (total/cycle 40 mg/m²)~+ Cisplatin 100 mg/m2/course (total/cycle 120 mg/m²);~I = Ifosfamide 2000 mg/m2/day *5 day (total/cycle 10000 mg/m²);~apatinib = 500 mg QD;"
88865487|NCT04351308|Experimental|MAPI+camrelizumab|"AP = Doxorubicin (Adriamycin) 37.5 mg/m2/day * 2day (total/cycle 75 mg/m²)~+ Cisplatin 120 mg/m2/course (total/cycle 120 mg/m²);~M = Methotrexate 12000 mg/m2 (total/cycle 12000 mg/m²) with leucovorin rescue;~I = Ifosfamide 2400 mg/m2/day *5day (total/cycle 12000 mg/m²);~camralizumab = 200mg ivgtt. Q2W;"
88865488|NCT04351308|Active Comparator|MAPI|"AP = Doxorubicin (Adriamycin) 37.5 mg/m2/day * 2day (total/cycle 75 mg/m²)~+ Cisplatin 120 mg/m2/course (total/cycle 120 mg/m²);~M = Methotrexate 12000 mg/m2 (total/cycle 12000 mg/m²) with leucovorin rescue;~I = Ifosfamide 2400 mg/m2/day *5day (total/cycle 12000 mg/m²);"
88865489|NCT04351152|Experimental|Lenzilumab Arm|Participants will receive IV infusion of lenzilumab upon randomization at a pre-specified dosing interval and continued administration of standard of care
88865490|NCT04351152|Placebo Comparator|Placebo Arm|Participants will receive IV infusion of preservative-free 0.9% sodium chloride solution upon randomization matched to lenzilumab at same pre-specified dosing interval and continued administration of standard of care
88865491|NCT04351074|Active Comparator|group A , LIFT|39 patients underwnt ligation of the intersphincteric track( LIFT) for treatment of transsphincteric fistula
89186147|NCT04060329|Experimental|Phase 2|Usual care + coopeRATE Prompt intervention
89186148|NCT04060329|Other|Clinicians|After Phase 2, clinicians will be asked about their experiences with, and views about, the coopeRATE Prompt intervention.
89389653|NCT02666183|Experimental|Closer|"The full intervention (Closer) is a tested intervention that uses videoconferencing technology (WebEx) for delivery and delivers the highest dose of the intervention. This arm of the intervention will deliver personalized information to the DCG (aimed at enhancing self-efficacy) and emotional support via nurse coaching as well as the opportunity for the DCG to talk with the oncologist and patient in real time during a minimum of four patient-oncologist office visits over a 4-month period (at least once/month). For patients who have more than one oncologist-patient meeting/month, the study will use the videoconference technology to allow the DCG to join as many of the join in as many of the oncologist-patient office visits as desired."
89389654|NCT02666183|Active Comparator|Video-C Only|"This arm will involve the delivery of information solely via the use of videoconference technology during the patient-oncologist-DCG visit. There is always the possibility that the DCG will receive emotional support from the oncologist during the office visit (as would potentially occur during a face-to-face meeting) - but this will not be delivered systematically as in the Closer intervention. As with the Closer intervention, the DCG will be able to participate in the patient-oncologist visit in real time during a minimum of four office visits over the 4-month study period (total dose ~5 hours). The procedure for these meetings will be the same as outlined for Closer but will not involve having the nurse involved in the videoconference sessions with the oncologist, patient, and DCG."
89389655|NCT02666183|Active Comparator|Web-Only|"This group will be provided access to a website that will provide the following major links: a) Caregiving Resources (links to National Family Caregiver Association, etc.), b)Resources for DCGs (links to the Caregiving from a Distance, etc.), c) Cancer Information (links to National Cancer Institute, etc.). DCGs will be told that the study team will track usage of the website in order to assess which areas of the website are used most frequently. Any questions or concerns regarding use of the website can be sent online to the study's technical site, and the support staff will respond within 24 hours. As is current practice, DCGs can call an oncology nurse or oncologist to ask specific questions. Web-Only will deliver the lowest dose of the intervention."
89530460|NCT03247465|Experimental|"Group Fusion"|Trans aortic valve replacement with usual procedure with the addition of computed tomography 3D images and calcification raising to the usual fluoroscopy images.
89530461|NCT03247465|No Intervention|"Group Control"|Trans aortic valve replacement with usual procedure
88865492|NCT04351074|Active Comparator|group B fistulectomy|39 patients under went fistulectomy for treatment of transsphincteric fistula
88865493|NCT04350918|Experimental|Muscle Energy Technique (MET)|MET Group received 12 treatment sessions of MET (Nagrale et al, 2010) two times a week in addition to conventional physiotherapy. The procedures employ voluntary muscle contractions by the patient in a precisely controlled direction and intensity against a counterforce applied by the Physiotherapist. The technique requires the therapist to provide stabilization to the segment on which the distal aspect of the muscle attaches. A command for anisometric contraction of the muscle is given that causes accessory movement of the joint. Several specific muscle energy techniques are described for the subcranial region of the cervical spine.
88865494|NCT04350918|Experimental|Static stretching (SS)|"Subjects in SS Group received 12 treatment sessions of static stretching (Dutton et al, 2008) two times a week in addition to conventional physiotherapy.~Stretching involves the application of manual or mechanical force to elongate structures that have adaptively shortened and are hypo-mobile (Sullivan, 2007) Static stretching involves stretching a muscle to a point of discomfort and holding the stretch for a length of time, followed by a return to normal resting muscle length (Andrews et al, 2004). Muscles of the neck were stretched in especially in side flexion, extension, flexion and side rotation for 10 seconds and was repeated 10 times for a session."
88865495|NCT04350996||Continuous alcohol monitoring|Wearable BACtrack Skyn device
88865496|NCT04350528||Chlorpromazine|
88865497|NCT04350528||Pentobarbital|
88865498|NCT04350684|Experimental|Umifenovir|Umifenovir + Interferon-β 1a + Lopinavir / Ritonavir + Single Dose of Hydroxychloroquine + Standards of Care
88865499|NCT04350684|Active Comparator|Control|Interferon-β 1a + Lopinavir / Ritonavir + Single Dose of Hydroxychloroquine + Standards of Care
88865500|NCT04350450|Experimental|Treatment Group|Eligible participants will be offered the standard Montefiore HCQ dosing regimen of 400mg every 12 hours x 24 hours, then 400mg daily for remaining 4 days and complete a survey study
89186149|NCT04060563|Sham Comparator|Sham (fake) microcurrent therapy|Sham (fake) microcurrent therapy (placing the microcurrent pads on the patient and turning the microcurrent box on placebo mode )
89186150|NCT04060563|Experimental|Frequency specific microcurrent therapy|Frequency specific microcurrent therapy (100-300μA microccurrent amps) with Diastasis Recti Repair protocol (8),
89186151|NCT02591576||ST-elevation myocardial infarction (STEMI)|
89186152|NCT02591576||non-ST-elevation myocardial infarction (NSTEMI)|
89186153|NCT00744315|Other|1|Controlled
89186154|NCT00689481|Experimental|U0267 foam|U0267 is a vitamin D3 analog (calcipotriene) foam. It is applied twice a day for 8 weeks to psoriasis lesions on the body.
89389656|NCT03316950|Experimental|IntraGen RF|Patients will undergo treatment with radiofrequency device, using the device's standard protocol. Patients will have 3 treatments space one month apart. Each treatment will be a total of 20 minutes for internal treatment only. Prior to treatment, the Zimmern probe will be used to measure vaginal wall elasticity and a 0.33mm biopsy will be taken. At each visit, the Zimmern probe will be used. Biopsies will be taken 3 months after final treatment.
89389657|NCT03316950|Experimental|DiVA|Patients randomized into the DiVA treatment group will receive treatment per DiVA protocol. Patients will have a total of 3 treatments, space 1 month apart. Each treatment will last approximately 10 minutes. Prior to treatment, the Zimmern probe will be used to measure vaginal wall elasticity and a 0.33mm biopsy will be taken. At each visit, the Zimmern probe will be used. Biopsies will be taken 3 months after final treatment.
89186155|NCT00689481|Placebo Comparator|Vehicle foam|Vehicle foam is the same as the U0267 foam except that it does not have the active ingredient. It is applied twice a day for 8 weeks to psoriasis lesions on the body.
89186156|NCT00744393|Active Comparator|A|Active drug
89389658|NCT03316950|Sham Comparator|Placebo Arm|"Patients randomized into the Placebo arm will include participants from the DiVa PlaceboGroup and IntraGen Placebo Group combined and will receive treatment based on the DiVA Sham and IntraGen Sham protocols.~DiVa Placebo: patients will undergo a three-part placebo treatment, spaced 1 month apart (+/- 10 days) of the vulvovaginal area. The vaginal HFL handpiece will be inserted into the vaginal canal but sub-therapeutic energy will not be delivered to the tissue.~IntraGen Placebo: patients will undergo a three-part placebo treatment, space 1 month apart (+/- 10 days) of the vulvovaginal area. This will be achieved through application of the probe, but with applying sub-therapeutic energy to the tissue."
89389659|NCT03316950|Experimental|Dual Treatment|Patients previously randomized into the DiVA Sham and IntraGen Sham groups will be placed in the Dual Treatment group. Patients will have a total of 3 dual treatments, spaced 1 month apart. Each treatment will last approximately 20 minutes. Prior to dual treatments, the Zimmern probe will be used to measure vaginal wall elasticity and a 0.33mm biopsy will be taken. At each visit, the Zimmern probe will be used. Biopsies will be taken at follow up visits.
89389660|NCT03139279|Experimental|Dexmedetomidine and propofol|Intravenous dexmedetomidine 0.3 ug/kg followed by propofol. Titrated doses of propofol will be given at the discretion of the anesthesiologist based on a target BIS range between 60-70.
89389661|NCT03139279|Placebo Comparator|Saline placebo and propofol|Intravenous saline placebo followed by propofol. Titrated doses of propofol will be given at the discretion of the anesthesiologist based on a target BIS range between 60-70.
89389662|NCT02562599|Experimental|drug:raltitrexed safety and efficacy|"To receive the safety and efficacy of raltitrexed-cisplatin neoadjuvant chemotherapy followed by concurrent chemoradiotherapy with raltitrexed-cisplatin~Interventions:~Neochemotherapy (Induction Chemotherapy) Drugs: raltitrexed-cisplatin (Raltitrexed, 2.5mg/m2, IV in 15 minutes, d1; Cisplatin, 25mg/m2, IV, d1-3.Cycled every 21 days for 2 cycles).~Concurrent Chemotherapy Drugs: raltitrexed-cisplatin (Raltitrexed, 2.5mg/m2, IV in 15 minutes, d1; Cisplatin, 25mg/m2, IV, d1-3.Cycled every 21 days for 2 cycles) .~Radiation: Intensity-modulated radiotherapy (IMRT)"
88865501|NCT04350450|No Intervention|Control Group|Participants who opt not to receive the study drug will also be invited to participate in the survey study assessing COVID19 symptoms
88865502|NCT04350216|Experimental|Sarilumab therapy|Patients will be treated every two weeks with 200 mg of the anti-IL human monoclonal antibody-6Rα Sarilumab (Kevzara) with or without conventional DMARDs. Sarilumab administration will be subcutaneous (abdomen, thigh, or upper arm). The dose will be reduced to 150 mg in the event of neutropenia, thrombocytopenia, and elevated liver enzymes.
88865503|NCT04349592|Experimental|Combination therapy group|hydroxychloroquine 200mg TID for 7 days plus Azithromycin 500mg OD 1st day and 250 from day 2 to 5
89389663|NCT01358227|Experimental|PR104|
89389664|NCT03311958|Experimental|Nivolumab|
89389665|NCT01370642|Experimental|Vaniprevir 12 Week Arm|Participants on this arm receive 12 weeks of vaniprevir (300 mg twice daily) and then 12 weeks of placebo to vaniprevir along with 24 weeks of treatment with peg-IFN and RBV.
89389666|NCT01370642|Experimental|Vaniprevir 24 Week Arm|Participants on this arm receive 24 weeks of vaniprevir (300 mg twice daily) along with 24 weeks of treatment with peg-IFN and RBV.
88865504|NCT04349592|Active Comparator|Monotherapy therapy group|hydroxychloroquine 200mg TID for 7 days plus Placebo 1 tab OD 1st day and 1 tab from day 2 to 5
88865505|NCT04349592|Placebo Comparator|Control group|Placebo Cap TID for 7 days plus Placebo 1 tab OD 1st day and 1 tab from day 2 to 5
88865506|NCT04349748|Experimental|Group 1|The group is given health education, regular HIV and STDs testing prompting service in the whole study, and permission to query health status (partner notification) through app from the second observation period. HIV and STDs testing and questionnaire are given to the participants when they receive the testing service.
88865507|NCT04349748|Experimental|Group 2|The group is given health education, regular HIV and STDs testing prompting service in the whole study, and permission to query health status (partner notification) through app from the third observation period. HIV and STDs testing and questionnaire are given to the participants when they receive the testing service.
89186157|NCT00744393|Placebo Comparator|P|Placebo drug
89186158|NCT02563353|Active Comparator|controlgroup|Teriparatide, 20 microgram/day. 24 months of treatment
89186159|NCT02563353|Experimental|studygroup 1|"Teriparatide, 20 microgram/day. 24 months of treatment.~12 months of Whole-body vibration on vibration platforms."
89389667|NCT01370642|Active Comparator|Control Arm|Participants on this arm receive 24 weeks of treatment with placebo to vaniprevir along with 48 weeks of treatment with peg-IFN and RBV.
89389668|NCT02873208|Experimental|ALKS 3831|Oral tablet, daily dosing
89186160|NCT02563353|Experimental|studygroup 2|"Teriparatide, 20 microgram/day. 24 months of treatment.~24 months of Whole-body vibration on vibration platforms"
89186161|NCT00688701|Placebo Comparator|Placebo (Two-Step Titration)|2-step initiation regimen of volume matching placebo: 10 microgram (mcg) once daily (QD) for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to Week 12.
89186162|NCT00688701|Placebo Comparator|Placebo (One-Step Titration)|1-step initiation regimen of volume matching placebo: 10 mcg QD for 2 weeks, then 20 mcg QD up to Week 12.
88865508|NCT04349748|Experimental|Group 3|The group is given health education, regular HIV and STDs testing prompting service in the whole study, and permission to query health status (partner notification) through app from the fourth observation period. HIV and STDs testing and questionnaire are given to the participants when they receive the testing service.
88865509|NCT04349748|Experimental|Group 4|The group is given health education, regular HIV and STDs testing prompting service in the whole study, and permission to query health status (partner notification) through app from the fifth observation period. HIV and STDs testing and questionnaire are given to the participants when they receive the testing service.
89389669|NCT03138967|Experimental|Sugammadex|"Participants to have cystoscopy with bladder tumor resection.~Rocuronium used to induce the neuromuscular blockade and given in a rapid sequence for endotracheal intubation at a dose of 0.45 mg/kg of Ideal Body Weight. If maintenance is needed for continued relaxation then a dose of 0.15 mg/kg of Ideal Body Weight repeated as necessary.~Sugammadex administered as a single bolus, intravenous injection. The amount used is based on the patient's weight. A dose of 4 mg/kg used if recovery has reached at least 1-2 post-tetanic counts (PTC) following Rocuronium induced blockade."
89389670|NCT03138967|Active Comparator|Standard of Care - Neostigmine/Glycopyrrolate|"Participants to have cystoscopy with bladder tumor resection.~Rocuronium used to induce the neuromuscular blockade and given in a rapid sequence for endotracheal intubation at a dose of 0.45 mg/kg of Ideal Body Weight. If maintenance is needed for continued relaxation then a dose of 0.15 mg/kg of Ideal Body Weight repeated as necessary.~Neostigmine/Glycopyrrolate administered as a single bolus, intravenous injection. The amount used is based on the patient's weight. Once T1 is at 10% or greater, a dose of 70 mcg/kg of Neostigmine with 14 mcg/kg Glycopyrrolate administered simultaneously over a period of one minute up to 5 mg."
89389671|NCT01358305|Active Comparator|Whey Protein Isolate|
89389672|NCT01358305|Experimental|Protein Blend (soy, whey and casein)|
89389673|NCT01547117|Experimental|High Sodium Level|POTS and healthy controls will be randomly assigned the order of dietary sodium levels. All procedures are performed at both levels. The high sodium diet will provide 300 milliequivalents (mEq) sodium/day.
89389674|NCT01547117|Experimental|Low Sodium Dietary Level|POTS and healthy controls will be randomly assigned the order of dietary sodium levels. All procedures are performed at both levels. The low sodium diet will provide 10 mEq sodium/day.
89389675|NCT03615846||Dual Anti-Platelet Therapy (DAPT)|"Whole blood from patients who are currently receiving Dual Anti-Platelet Therapy (DAPT) Clopidogrel and aspirin (ASA) for a minimum of 4 weeks (on-drug) will be used to conduct antiplatelet reactivity tests using VerifyNow assay and LTA with AggRAM Aggregometer with and without PGE1.~There is no drug administration or therapeutic intervention in this study. The results of platelet activation testing using VerifyNow performed in this study are not used to influence patient care."
89389676|NCT03615846||One Anti Platelet Medication Only|"Whole blood from patients who are currently receiving either ASA or Clopidogrel alone for a minimum of 4 weeks (on-drug) will be used to conduct antiplatelet reactivity tests using VerifyNow assay and LTA with AggRAM Aggregometer with and without PGE1.~There is no drug administration or therapeutic intervention in this study. The results of platelet activation testing using VerifyNow performed in this study are not used to influence patient care."
88865510|NCT04349202||Beaumont employees|Beaumont employees (employees and affiliated non-employed physicians and advanced practice providers) undergoing serology testing for SARS-CoV-2 antibodies, their immediate family members, and members of other high-risk groups.
88865511|NCT04348812|Experimental|tDCS Active|Transcranial direct current stimulation with ABMT
88865512|NCT04348812|Sham Comparator|tDCS sham|Transcranial direct current sham stimulation with ABMT
89389677|NCT03615846||naive|No medication with anti-platelet effects There is no drug administration or therapeutic intervention in this study. The results of platelet activation testing using VerifyNow performed in this study are not used to influence patient care.
89389678|NCT01344941||Group 1|The first group will comprise individuals who have received a St. Jude HIV-1 vaccine and who have exhibited sustained immune responses
89389679|NCT01344941||Group 2|Groups 2 will be HIV-1-infected. The first visit of individuals in groups 2 will involve the collection of 120 ml of blood as well as a minimal blood volume required for the specified screening laboratory evaluation for each group.
89389680|NCT01344941||Group 3|Groups 3 will be HIV-1-uninfected. The first visit of individuals in groups 3 will involve the collection of 120 ml of blood as well as a minimal blood volume required for the specified screening laboratory evaluation for each group.
89389681|NCT03560336||Overall Population|Patients will be treated with commercially available liraglutide 3.0 mg according to routine clinical practice at the discretion of the treating physician
88865513|NCT04348890|Experimental|Treatment Arm|
88865514|NCT04347642|Active Comparator|Umbilical port|A Hasson port will be inserted at the level of the umbilicus,in the midline, traversing only aponeurotic layers.
88865515|NCT04347642|Experimental|Paraumbilical port|A bladeless 12mm port will be inserted lateral to the midline, traversing aponeurotic layers and rectus abdominis muscle.
88865516|NCT04347252|Experimental|Glucagon at basal glycemia|Subjects will present after an overnight fast and at time 0 an infusion of deuterated glucose will be started and continued for the remainder of the 5 hour study (4 mg/kg bolus followed by 0.04 mg/kg/min infusion). Blood will be sampled at 10 minute intervals throughout the study for measurement of substrates and hormones. At time 240 an intravenous infusion of glucagon (10-100 ng.kg.min) will be started and continued for 30 or 60 minutes.
88865517|NCT04347252|Experimental|Glucagon at hyperglycemia|Subjects will present after an overnight fast and at time 0 an infusion of deuterated glucose will be started and continued for the remainder of the 5 hour study (4 mg/kg bolus followed by 0.04 mg/kg/min infusion). Blood will be sampled at 10 minute intervals throughout the study for measurement of substrates and hormones. At time 120 an infusion of 20% glucose, labeled to 2% with deuterated glucose, will be started and adjusted to raise the blood glucose to 8.3 mM for the remainder of the study. At time 240 an intravenous infusion of glucagon (10-100 ng.kg.min) will be started and continued for 30 or 60 minutes.
89186163|NCT00688701|Experimental|Lixisenatide (Two-Step Titration)|2-step initiation regimen of lixisenatide: 10 mcg QD for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to Week 12.
89186164|NCT00688701|Experimental|Lixisenatide (One-Step Titration)|1-step initiation regimen of lixisenatide: 10 mcg QD for 2 weeks, then 20 mcg QD up to Week 12.
89389682|NCT04847388||ART-naive HIV Patients with substance abuse and without substance abuse|Group A Group B
89389683|NCT04847388||Group A and B|Group A: ART-naive HIV seropositive with H/O substance abuse Group B: ART-naive HIV seropositive without H/O substance abuse
89389684|NCT03136159|Experimental|Silver-impregnated antimicrobial dressing|All participants undergoing primary cesarean section will receive a silver impregnated antimicrobial wound dressing (Mepilex Border AG), postoperative.
89186165|NCT02563743|Experimental|Problem-solving based intervention|Problem-solving based intervention with a participative approach. During the intervention a systematic assessment of the match between the employee and the work environment is considered. The intervention applies a participatory approach where the supervisor and the employee are guided by the OHS consultant and encouraged to actively take part in problem solving concerning the work situation. The intervention consists of three meetings, one between the OHS consultant and a representative for the employer (usually the nearest supervisor), one between the consultant and the employee and then a third meeting where all three parties participate.
89186166|NCT02563743|Active Comparator|Treatment as usual|The control intervention consists of the usual interventions given at the participating OHS. These interventions are also work-directed and usually also include participation of both the employee and the supervisor. However, structured problem solving methods and the systematic consideration of the match between the employee and the job situation are not applied. The content of the control condition will vary between different occupational health service units.
89186167|NCT00999609|Experimental|AAV2-hRPE65v2,voretigene neparvovec-rzyl|voretigene neparvovec rzyl, 1.5 E11 vector genomes, per eye, administered by subretinal injection in a volume of 0.3mL, 6-18 days apart
89186168|NCT00999609|No Intervention|Control|No intervention
89389685|NCT03615768|Experimental|Adapalene-Clindamycin Combination Gel|
89186169|NCT02563119|Active Comparator|Gastric Bypass Group|Twenty morbidly obese patients undergoing gastric bypass surgery
89389686|NCT03615768|Active Comparator|Adapalene Gel|
89186170|NCT02563119|Active Comparator|Sleeve Group|Twenty morbidly obese patients undergoing sleeve gastrectomy
89186171|NCT02563119|No Intervention|Healthy controls|Thirty healthy, lean controls
89186172|NCT00744549|Experimental|A|This group of men will be on active treatment (antioxidants) for one year and placebo for the second year.
89186173|NCT00744549|Experimental|B|This group of men will be on placebo for one year and active treatment (antioxidants) for the second year.
89186174|NCT00746655|Other|SBRT / TACE|
89389687|NCT03615768|Active Comparator|Clindamycin Gel|
89186175|NCT02564133|Experimental|detection of a patent foramen ovale|
89186176|NCT00746811|Other|1|P-OM3 for the first six weeks of treatment. Placebo for the second six weeks of treatment.
89186177|NCT00746811|Other|2|Placebo for the first six weeks of treatment. P-OM3 for the second six weeks of treatment.
89186178|NCT04060173|Experimental|Treatment with ABP-671|Three sequential dose escalation cohorts of ABP-671 administered orally for 10 days.
89186179|NCT04060173|Placebo Comparator|Treatment with placebo|Three sequential dose escalation cohorts of ABP-671 matching placebo administered orally for 10 days.
89186180|NCT00741429||Ex-TI|Ex-Technosphere® Insulin Inhalation Powder (subjects previously received TI Inhalation Powder)
89186181|NCT00741429||Non Ex-TI|Non Ex-Technosphere® Insulin Inhalation Powder (subjects previously received another anti-diabetic medication)
89186182|NCT02563197|Experimental|T-326|Non Cystic fibrosis bronchiectasis patients will be enrolled for determination of peak inspiratory flow.
89186183|NCT00741507|Active Comparator|1|No alcohol drinking
89186184|NCT00741507|Active Comparator|2|Mild alcohol drinking
89186185|NCT00741507|Active Comparator|3|Moderate alcohol drinking
89186186|NCT00741507|Active Comparator|4|Severe over alcohol drinking
89389688|NCT02061644|Experimental|Spinal|Spinal anesthesia for surgical procedure will be applied to the patients. Intraocular pressures will be measured before and after the procedure.
89389689|NCT04178135|Experimental|rLH supplementation from day 1 of stimulation|rLH supplementation from day 1 of stimulation
89389690|NCT04178135|Active Comparator|rLH supplementation from day 6 of stimulation|rLH supplementation from day 6 of stimulation
89389691|NCT01318291|Placebo Comparator|Control|
89389692|NCT01318291|Experimental|CCRI Group|
89389693|NCT04158869||Cases|Patients with pMDD, enrolled in the Investigator-initiated clinical trial IICT (ClinicalTrials.gov Identifier: NCT03167307)
89389694|NCT04158869||Controls|Controls matched to cases according to age, sex and school education
89389695|NCT03614988|Active Comparator|Morning Levothyroxine Intake First|Randomized patients to receive levothyroxine in the morning and after crossover to Evening Levothyroxine Administration.
89186187|NCT00741507|Active Comparator|5|Alcohol-dependent
89186188|NCT00688623|Experimental|Everolimus|Everolimus
89389696|NCT03614988|Experimental|Evening Levothyroxine Intake First|Randomized patients to receive levothyroxine in the morning and after crossover to Morning Levothyroxine Administration.
89389697|NCT01318369|Experimental|Namisol|Namisol (dronabinol) single dose 8 mg
89389698|NCT01318369|Active Comparator|Diazepam|Diazepam single dose 5mg in subgroup non-opioid users and 10 mg in subgroup opioid users.
89530462|NCT03346577||Patients with peripheral artery disease|located in the common and external iliac artery, the common and superficial femoral artery, the popliteal artery and/or the below-the-knee (BTK) arteries (anterior tibial artery, posterior tibial artery or peroneal artery).
89530463|NCT03244657|Experimental|Q12W group|
89530464|NCT03244657|Experimental|TAE group|
89389699|NCT02061722|Experimental|PET Imaging with [18F]MNI-659|"All subjects (both HDGECs and HCs) will receive single intravenous doses of the radioligands [11C]raclopride (non-investigational medicinal product [NIMP]) and [18F]MNI-659 (investigational medicinal product [IMP]).~The radioligands [11C]raclopride and [18F]MNI-659 will be administered at doses less than 10 micrograms, i.e. within the micro dosing concept, and no pharmacological effects are expected.~The injected radioactivity of [11C]raclopride will be 300 MBq/70 kg of body weight ± 10%.~The injected radioactivity of [18F]MNI-659 will be 185 MBq/70 kg of body weight ± 10%."
89389700|NCT01345097|Experimental|Younger Group|
89389701|NCT01345097|Experimental|Elderly Group|
89186189|NCT00744705||1|Normal subjects who received routine health check-up in a comprehensive medical testing center
89186190|NCT02563821|Active Comparator|PCEA-DC|"Injection of a 2 mL initial epidural loading dose consisting of a blend (10 mL) of levobupivacaine 20 mg, sufentanil 10 µg to assure the absence of motor block and so exclude intrathecal placement of the epidural catheter.~Injection of the rest of the loading dose (8mL).~In this group the pump is programmed to deliver a continuous infusion at 10 mL /h consisting of levobupivacaine 0,573 mg/mL, sufentanil 0,37 µg/mL, clonidine 1,38 µg/ mL. Additional 5 mL patient-activated boluses will be allowed with a lockout interval of 10 minutes.~If the parturient feels she has inadequate analgesia after having activated the PCEA bolus twice in a thirty minutes period, an additional manual bolus of 6 mL of levobupivacaine 2,5 mg/mL will be administered until the Pain Visual Analog Scale (PVAS) is < 3/10."
89389702|NCT04806048||Hospitalized patients and outpatients|There may be different types of patients with differing follow-up plan but all will bie considered one group regarding on whether they receive their recommended follow-up plan
89389703|NCT01350739|Other|intraumbilical incision|an intraumbilical vertical incision is made
88865518|NCT04347252|Experimental|Glucagon at hyperglycemia with GLP-1R blockade|Subjects will present after an overnight fast and at time 0 an infusion of deuterated glucose will be started and continued for the remainder of the 5 hour study (4 mg/kg bolus followed by 0.04 mg/kg/min infusion). Blood will be sampled at 10 minute intervals throughout the study for measurement of substrates and hormones. At time 120 an infusion of 20% glucose, labeled to 2% with deuterated glucose, will be started and adjusted to raise the blood glucose to 8.3 mM for the remainder of the study; concurrently exendin-(9-39) will be infused at 750 pmol/kg/min, also for the remaining 180 minutes. At time 240 an intravenous infusion of glucagon (10-100 ng.kg.min) will be started and continued for 30 or 60 minutes.
88865519|NCT04346940|Experimental|Study Group|The group to which the exercise protocol consisting of chair-based exercises will be applied.
88865520|NCT04346940|Active Comparator|Control Group|Group to be given an exercise brochure
88865521|NCT04347096|Experimental|mHealth Intervention|The mHealth intervention group will have access to the Internet for using a newly developed Simple health web app and receive an activity tracker. The web app users are required to: (1) wear an activity tracker every day; (2) set goals of daily stand-up, physical activity, and healthy eating bi-weekly; (3) record stand-up, physical activity, and healthy eating behaviors daily; (4) set reminders to stand-up and record health behaviors; and (5) read educational and motivational tools. After completing the behavioral record, the personal advice will automatically provide to encourage, motivate and support the user. Moreover, the user will be able to look at his/her personal and team health ranking.
88865522|NCT04347096|Other|Control Intervention|The control intervention group will only receive educational tools (usual care).
88865523|NCT04346862|Experimental|Acetyl-L-carnitine hydrochloride|
88865524|NCT04346862|Placebo Comparator|Placebo|
88865525|NCT04347174|Experimental|Suspension of Mw + Standard therapy of COVID-19|"0.3 ml (0.1ml x 3 Injection) of intradermal Mw for 3 consecutive days~+ Standard therapy of COVID-19"
88865526|NCT04347174|Placebo Comparator|Standard therapy of COVID-19|0.3 ml (0.1ml x 3 Injection) of Placebo intra-dermal for 3 consecutive days
88865527|NCT04346784|Experimental|maintaining positive working memory training|Maintaining positive working memory training is based on visual positive works n-back task.In this training, positive words are presented on the pictures of happy face.According to the rules, subjects are required to identify whether the word present currently is as the same type as the word presented n before then click the keys correspondingly.Each training session contains 15 blocks which are consisted with 20+n trails.
88865528|NCT04346784|Experimental|repressing negative working memory training|Repressing negative working memory training is a dual n-back task containing visual and auditory stimulus.Both two types of stimulus are negative.In this training, subjects are required to identify whether the location of picture presented on the screen or the word appeared in the headphone is the same as the picture or the word presented n before, then react with typing correspondingly.Each training session contains 16 blocks which are consisted with 20+n trails.
88865529|NCT04346784|Experimental|Positive ABMT|In the positive attention bias, there are 54 pairs of neutral-negative words, 27 pairs of which are used in the training group and 27 pairs of which are used in the placebo group. The word pairs in each group are repeated 8 times, with a total of 216 trial.Participants received 10 sessions over 2 weeks. 90% of the targets in the training group appear in the positive word position and 10% of the targets appear in the neutral word position.
89389704|NCT01350739|Other|infraumbilical incision|incision is done in circular fashion at the inferior boarder of umbilicus
89389705|NCT03479684|Experimental|Gene-directed group|the first day given model prediction dose * 1.5 times（<6mg）；the second day given model prediction dose；adjusted dose based on INR from the third day
89389706|NCT03479684|Active Comparator|Standard care group|the first day given 4.5mg; adjusted dose based on INR from the second day
89389707|NCT01316003||Normal subjects|Thirty-seven eyes of 37 individuals without eye diseases
89389708|NCT01318447|Experimental|CyberKnife SBRT|
89389709|NCT02063282||Clostridium difficile carriers|
89389710|NCT02063282||Clostridium difficile non carriers|
89389711|NCT01986933|Experimental|Group1|Part A: nemolizumab (CIM331) Part B: nemolizumab (CIM331)
89389712|NCT01986933|Experimental|Group2|Part A: nemolizumab (CIM331) Part B: nemolizumab (CIM331)
89389713|NCT01986933|Experimental|Group3|Part A: nemolizumab (CIM331) Part B: nemolizumab (CIM331)
89389714|NCT01986933|Experimental|Group4|Part A: nemolizumab (CIM331) Part B: nemolizumab (CIM331)
89389715|NCT01986933|Experimental|Group5|Part A: Placebo Part B: nemolizumab (CIM331)
89530465|NCT03346499|Experimental|NK cells and IL-2|
89389716|NCT05251103|Experimental|time-restricted feeding trial|The participants were divided into the time-restricted feeding trial for 5 days
89389717|NCT05251103|Experimental|control trial|The participants in the control trial did not practice intermittent fasting methods
88865530|NCT04346784|Placebo Comparator|Positive placebo ABMT|In the positive attention bias, there are 54 pairs of neutral-negative words, 27 pairs of which are used in the training group and 27 pairs of which are used in the placebo group. The word pairs in each group are repeated 8 times, with a total of 216 trial.Participants received 10 sessions over 2 weeks. while 90% of the targets in the placebo group appear in the neutral word position and 10% of the targets appear in the positive word position.
89389718|NCT03614052|Experimental|tamsulosin hydrochloride|Tamsulosin hydrochloride 0,4 mg tablets by mouth per day for 5 days before ureteroscopy
89389719|NCT03614052|Placebo Comparator|Placebo oral tablet|Placebo oral tablets by mouth per day for 5 days before ureteroscopy
89389720|NCT01318525|Experimental|ALF-5755|
89389721|NCT01318525|Placebo Comparator|Saline solution (0.9% NaCl)|
89389722|NCT02062892|Experimental|Everolimus / Tacrolimus|Patients will be stable kidney transplant patients who are receiving an immunosuppressive drug regimen based on tacrolimus and sirolimus. 24 hours after the last sirolimus dose, the patients randomized to the tacrolimus/everolimus arm of the study will be switched from sirolimus to everolimus 1:1 (same sirolimus as everolimus dose). Everolimus doses will be adjusted so that trough blood concentrations are within 3-8 ng/mL. In detail: Tacrolimus (Prograf or FDA approved generic 0.5 mg, 1 mg or 5 mg capsules, twice a day) in combination with Everolimus (Zortress, 0.25, 0.5 and 0.75 tablets).
89389723|NCT02062892|Active Comparator|Sirolimus / Tacrolimus|Patients will be stable kidney transplant patients who are receiving an immunosuppressive drug regimen based on tacrolimus and sirolimus. 24 hours after the last sirolimus dose, the patients randomized to the tacrolimus/sirolimus arm of the study will remain on tacrolimus/sirolimus. In detail: Tacrolimus (Prograf or FDA approved generic 0.5 mg, 1 mg or 5 mg capsules, once a day) in combination with Sirolimus (Rapamune, 0.5, 1, and 2mg tablets).
88865531|NCT04346550|Active Comparator|Drain Group|Suction drain was placed in sub hepatic region through 5 mm lateral trocar site.
88865532|NCT04346550|No Intervention|Without Drain Group|No drain was placed
88865533|NCT04345848|Experimental|Therapeutic anticoagulation|Participants will be treated with therapeutic doses of subcutaneous low-molecular-weight heparin (enoxaparin) or intravenous unfractionated heparin, from admission until the end of hospital stay or clinical recovery.
88865534|NCT04345848|Active Comparator|Prophylactic anticoagulation|Participants will be treated with prophylactic doses of subcutaneous low-molecular-weight heparin (enoxaparin) or unfractionated heparin, from admission until the end of hospital stay or clinical recovery. If hospitalized in the intensive care unit, they will receive an augmented thromboprophylaxis regimen as standard of care.
88865535|NCT04345770|Sham Comparator|Without HIPEC|Patients will be treated with neoadjuvant chemotherapy (SOX) followed by a D2 radical gastrectomy for locally advanced gastric cancer and postoperative chemotherapy (SOX, 6 circles together with neoadjuvant chemotherapy)
88865536|NCT04345770|Experimental|With HIPEC|Patients will be treated with neoadjuvant chemotherapy (SOX) followed by a D2 radical gastrectomy for locally advanced gastric cancer and HIPEC with paclitaxel and 5-Fu and postoperative chemotherapy (SOX, 6 circles together with neoadjuvant chemotherapy)
88865537|NCT04345692|Experimental|Hydroxychloroquine|Hydroxychloroquine 400 mg 2x day by mouth on day 1, followed by 200 mg 2x day by mouth days 2-5
88865538|NCT04345692|No Intervention|Usual Care|usual care for hospitalized patients diagnosed with COVID-19
88865539|NCT04345380|Active Comparator|Acrysof Rotation|Implantation of the Acrysof SN60WF Intraocular lens to the 0 ±10, 45± 10, 90±10 or 135± axis.
88865540|NCT04345380|Active Comparator|Tecnis Rotation|Implantation of the Tecnis ZCB00 Intraocular lens to the 0 ±10, 45± 10, 90±10 or 135± axis.
88865541|NCT04345380|Active Comparator|Envista Rotation|Implantation of the Envista MX60 Intraocular lens to the 0 ±10, 45± 10, 90±10 or 135± axis.
88865542|NCT04345458|Experimental|group I|twice weekly 25 mg prefilled liquid etanercept
89389724|NCT02063360|Experimental|Cohort 1: BMS-663068+DRV/RTV|Extended release tablet BMS-663068 600mg orally twice daily on days 1-4 and 17-26. Tablet DRV 600mg / RTV 100mg orally orally twice daily on days 7-16
89389725|NCT02063360|Experimental|Cohort 2: BMS-663068+ETR|Extended release tablet BMS-663068 600mg orally twice daily on days 1-4 and 17-26. Tablet ETR 200mg orally orally twice daily on days 7-16
89389726|NCT02063360|Experimental|Cohort 3: BMS-663068+DRV/RTV+ETR|Extended release tablet BMS-663068 600mg orally twice daily on days 1-4 and 17-26. Tablet DRV 600mg / RTV 100mg and ETR 200mg orally orally twice daily on days 7-16
89389727|NCT01358461||Patients with vagal syncopes|Patients with vagal syncopes (n=120 : 60 adults & 60 children)
89389728|NCT01358461||Subjects controls without vagal syncopes|Subjects controls without vagal syncopes (n=120:60 adults & 60 children
89389729|NCT03614832|Experimental|Ticagrelor 90 mg|To observe low-dose of ticagrelor（90 mg once daily oral）on platelet aggregation in clopidogrel resistance's patients with coronary heart disease.
89389730|NCT03614832|Active Comparator|Clopidogrel 150 mg|To observe double standard-dose clopidogrel （150 mg once daily oral）on platelet aggregation in clopidogrel resistance's patients with coronary heart disease.
89389731|NCT05210595|Experimental|Control group|Clopidogrel 75 mg/day as maintenance dose
88865543|NCT04345458|Experimental|group II|once weekly 50 mg prefilled liquid etanercept
89389732|NCT05210595|Experimental|Treatment group 1|De-escalation strategy dose receive ticagrelor 60 mg twice daily
89389733|NCT05210595|Experimental|Treatment group 2|De-escalation strategy dose receive ticagrelor 45 mg twice daily
89389734|NCT01358539|Experimental|Pain education|Patients receiving pain education
89186191|NCT02563821|Active Comparator|PCEA-BIP|"Injection of a 2 mL initial epidural loading dose consisting of a blend (10 mL) of levobupivacaine 20 mg, sufentanil 10 µg to assure the absence of motor block and so exclude intrathecal placement of the epidural catheter.~Injection of the rest of the loadind dose (8 mL)~In this group the pump is programmed to deliver automated mandatory boluses of 5 mL consisting of levobupivacaine 0,573 mg/mL, sufentanil 0,37 µg/mL, clonidine 1,38 µg/mL every 30 minutes. Additional 5 mL patient-activated boluses will be allowed with a lockout interval of 10 minutes.~If the parturient feels she has inadequate analgesia after having activated the PCEA bolus twice in a thirty minutes period, an additional manual bolus of 6 mL of levobupivacaine 2,5 mg/mL will be administered until the Pain Visual Analog Scale (PVAS) is < 3/10 (0 = no pain and 10 = insufferable pain)."
89389735|NCT01358539|No Intervention|No Pain education|Control group, patients receiving no pain education
89389736|NCT03560570||Event group|CDG with antecedent of stroke-like, thrombosis or haemorrhages
89389737|NCT03560570||Non event group|CDG without antecedent of stroke-like, thrombosis or haemorrhages
89389738|NCT03560570||Control|Healthy subject
89389739|NCT03614754||Successes|Patients with reduction of symptoms >50% during the test procedure for sacral neuromodulation.
89389740|NCT03614754||Failures|Patients with reduction of symptoms <50% during the test procedure for sacral neuromodulation.
89389741|NCT02061800|Active Comparator|Full intensity with TBI|Patients will start their pre-conditioning regimen on 8 days before scheduled transplant. Fractionated total body irradiation (TBI) will be administered twice daily on the 6th, 7th, and 8th before transplant. Patients will receive Thiotepa on the 4th and 5th day before transplant, Cyclophosphamide on the 2nd and 3rd day before transplant, and Alemtuzumab on the 1st-5th day(s) before transplant. Then the stem cell infusion will be performed (allogeneic family member or ≥ 8/10 HLA matched adult unrelated donor peripheral blood stem cell transplantation with CD34 Selection using CliniMACS CD34+ Reagent System). GVHD prophylaxis will consist of tacrolimus only. Tacrolimus administration will begin on the day after transplant, and methylprednisolone will start on day -5.
88865544|NCT04345458|Active Comparator|group III|25 mg twice weekly lyophilized etanercept powder
89186192|NCT02563587|Experimental|Group LT-CT|Laughter therapy with conventional treatment
89186193|NCT02563587|Placebo Comparator|Group AW-CT|Accompaniment without causing the laughter of children more conventional treatment
89389742|NCT02061800|Experimental|Full intensity without TBI|Patients will start their pre-conditioning regimen 9 days before their scheduled transplant. Patients will receive busulfan twice daily on the 5th-8th day before transplant, and Melphalan on the 2nd-4th days before transplant and Alemtuzumab on the 1st-5th day before transplant. Subjects will then undergo with their stem cell infusion (allogeneic family member or ≥ 8/10 HLA matched adult unrelated donor peripheral blood stem cell transplantation with CD34 Selection using CliniMACS CD34+ Reagent System) and GVHD prophylaxis will consist of tacrolimus only. Tacrolimus administration will begin on the day after their transplant, and methylprednisolone will start on day -5.
89389743|NCT02061800|Experimental|Reduced intensity|Patients will begin tacrolimus 8 days pre-transplant, and then will receive alemtuzumab on the 3rd-7th day pre-transplant; busulfan twice daily on the 5th-8th day pre-transplant; and fludarabine on the 2nd-7th day pre-transplant. Methylprednisolone will start on day -7.The stem cell infusion will be performed (with CD34 Selection using CliniMACS CD34+ Reagent System). GVHD prophylaxis will consist of tacrolimus or sirolimus. For patients with a history of hepatic toxicity and/or high-risk for veno-occlusive disease or other liver toxicity post stem cell transplant, melphalan at 70 mg/m2 will be substituted for Busulfan, followed by fludarabine on the 2nd-7th day before transplant and alemtuzumab on the 3rd-7th day before transplant.
89389744|NCT01354795|Experimental|1.EUS-FNA with or without suction|During EUS FNA is performed, with or without self-retracting 10-mL syringe
89389745|NCT01354795|Experimental|2.Pushing the stylet or injecting air|EUS-FNA specimen is expelled from a needle with pushing the stylet into the needle or injecting air
88865545|NCT04345614|Experimental|Auxora|Patients will be randomized 1:1 to receive either Auxora or placebo
89389746|NCT01350817|Active Comparator|Docetaxel|
89389747|NCT01350817|Experimental|Erlotinib|
89389748|NCT02063438|Active Comparator|Pericostal Suture Technique|A #2 Vicryl suture is placed along the superior aspect of the rib above the specific thoracic interspace. This suture is then passed below the inferior rib along the superior aspect of the next rib below. These sutures are then tied to approximate the ribs leaving enough room for the tip of a finger.
88865546|NCT04345614|Placebo Comparator|Placebo|Patients will be randomized 1:1 to receive either Auxora or placebo
88865547|NCT04344912||COVID19- Population|Patients without diagnosis of COVID19, as assessed by RT-PCR and CT scan
89186194|NCT02563587|Sham Comparator|Group CT|Conventional treatment only
89389749|NCT02063438|Active Comparator|Intracostal Suture Technique|A handheld drill is used to drill holes in the rib below the specific thoracic interspace. A #2 Vicryl suture is passed through each of the holes and then passed along the superior aspect of the rib above the specific thoracic interspace. These sutures are then tied to approximate the ribs leaving enough room for the tip of a finger.
89389750|NCT01986075|Experimental|Computer-assisted CBT plus Mixed-Amphetamine Salts- Extended Release (MAS-ER)|Patients who are randomized to the computer-assisted behavior therapy plus mixed amphetamine salts (extended release) arm will have their dose titrated to 80 mg or the maximum tolerated extended release mixed amphetamine salts daily. Participants will be asked to take the medication once per day in the morning or early afternoon and will be maintained on this schedule through week 14 of the trial. Computer-assisted behavior therapy based on the Community Reinforcement Approach (CRA) to treating cocaine dependence. CRA is skills based treatment program that incorporates coping skills development and contingency management. Participants will attend the clinic 3x per week and receive counseling 2x per week.
89389751|NCT01986075|Placebo Comparator|Computer-assisted CBT plus placebo|Patients who are randomized to the Computer-assisted CBT plus placebo arm will have their medication dose titrated in a fix-flexible dose schedule matching the active medication arm. Participants will be asked to take the medication once per day in the morning or early afternoon and will be maintained on this schedule through week 14 of the trial. Computer-assisted behavior therapy based on the Community Reinforcement Approach (CRA) to treating cocaine dependence. CRA is skills based treatment program that incorporates coping skills development and contingency management. Participants will attend the clinic 3x per week and receive counseling 2x per week.
89389752|NCT04753710|Experimental|Chloroprocaine|Chloroprocaine 3% ocular gel
89389753|NCT04753710|Placebo Comparator|Placebo|Vehicle for chloroprocaine 3% ocular gel
88865548|NCT04344912||COVID19+ Population|Patients with a diagnosis of COVID19, as assessed by RT-PCR and CT scan
88865549|NCT04344990|Active Comparator|Group E- Epidural analgesia|Continuous epidural infusion (control group) with Ropivacaine 0.2% + clonidine 150μg for postoperative pain management right after the end of the procedure. The PCA pump is programmed with continuous infusion (Ropivacaine 0.2% + clonidine 150μg) 2ml/h and bolus dosage 0,5ml per 15min (max dosage 2ml/h). The epidural catheter is placed preoperatively.
88865550|NCT04344990|Active Comparator|Group F- Femoral blockade|Continuous femoral nerve blockade infusion with Ropivacaine 0.2% + clonidine 150μg for postoperative pain management right after the end of the procedure.The PCA pump is programmed with continuous infusion (Ropivacaine 0.2% + clonidine 150μg) 2ml/h and bolus dosage 0,5ml per 15min (max dosage 2ml/h). The femoral catheter is placed preoperatively.
89186195|NCT00717236|Experimental|Certolizumab pegol (CZP)|
89186196|NCT00717236|Placebo Comparator|Placebo|
89186197|NCT04085354|Placebo Comparator|Placebo|Group 1 was given placebo in form oral multivitamin tablet 1 h before intercourse.
89186198|NCT04085354|Active Comparator|Dapoxetine|Group 2 was given on-demand 30 mg dapoxetine 1-2 h before intercourse.
89186199|NCT04085354|Active Comparator|Dapoxetine and folic acid.|Group 3 was given on-demand 30 mg dapoxetine 1-2 h before intercourse and daily oral supplementation of 0.5 mg folic acid.
88865551|NCT04344990|Active Comparator|Group I- Intraarticular infusion|Continuous intraarticular infusion with Ropivacaine 0.2% + clonidine 150μg for postoperative pain management right after the end of the procedure.The PCA pump is programmed with continuous infusion (Ropivacaine 0.2% + clonidine 150μg) 2ml/h and bolus dosage 0,5ml per 15min (max dosage 2ml/h). The intraarticular catheter is placed before the closure of the incision.
88865552|NCT04344834||Health care workers|Egyptian health care workers
88865553|NCT04344834||General population|Any Egyptian personnel
88865554|NCT04344834||Recovered fromCOVID-19|Patients recovered from COVID-19
88865555|NCT04344756|Experimental|Active Coagulation|
88865556|NCT04344756|No Intervention|Standard of Care|Control patients will receive the best standard of care and a subcutaneous preventive anticoagulation for at least 14 days with enoxaparin 4000 IU/24h, tinzaparin 3500 IU/24h or dalteparin 5000 IU/24h if creatinine clearance (Cockcroft) ≥ 30mL/min or unfractionated heparin 5000 IU/12h if creatinine clearance < 30mL/min.
89186200|NCT04085354|Active Comparator|Dapoxetine and vitamin B12|Group 4 was given on-demand 30 mg dapoxetine 1-2 h before intercourse and daily oral supplementation of 0.5 mg vitamin B12
89389754|NCT02061878|Experimental|Bexarotene|The subjects will be administered three (3) capsules of Targretin™ (75 mg/capsule) on a twice daily basis (450 mg/day) for five days
89389755|NCT02061878|Placebo Comparator|Placebo|The subjects will be administered three (3) capsules of Avicel PH on a twice daily basis (450 mg/day) for five days.
89389756|NCT01358617||Biomarker analysis|Archived tissue microarray samples are analyzed for ubiquitin carboxyl-terminal hydrolase 1 (UCHL1) expression by UCHL1 monoclonal antibody and peroxidase technique.
88865557|NCT04344288|Experimental|Prednisone group|Prednisone during 10 days after randomization
88865558|NCT04344288|Other|Control group|
88865559|NCT04344522|Experimental|sequential 2 stage procedure|In this arm , the procedure will be performed in two stages ; the first stage will include performing IOL exchange together with iridoplasty ( if required) and inferior peripheral iridectomy (PI) and the second stage is performing DMEK one month later
88865560|NCT04344522|Experimental|combined single stage procedure|In this arm, both IOL exchange and DMEK will be performed in the same setting
88865561|NCT04344210|Experimental|Tele-Intervention|Participants will receive a tele-intervention by a case manager weekly to discuss topics related to diabetes management and mental well-being during the quarantine period
88865562|NCT04344210|No Intervention|Usual Care|Participants will receive the usual care
88865563|NCT04343742||chlorine dioxide 3000 ppm. Bottle x 150 cc.|"Assignment of study medication Each patient will receive, in order of admission to the study, a consecutive patient number and the corresponding study medication. The assignment of this medication was made before the start of the study, using a computer generated list. Patients will receive the 3,000 ppm chlorine dioxide base preparation with written and precise instructions on how to prepare and take the dilutions.~7.1 Dosage and route of administration. Medication: chlorine dioxide 3000 ppm. Fco x 150 cc. 10 ml of 3000 ppm chlorine dioxide are added to 1 liter of water, per day. One part is taken every hour, until the content of the bottle is finished (8 to 12 shots).~Both the original dioxide bottle and the preparation for the day should be kept refrigerated."
88865564|NCT04343508|Experimental|Fortified rice|fortified rice for daily lunch and dinner each day of the week (i.e. 14 meals/week) for six months
88865565|NCT04343196|Experimental|Group A: Low-dose DVA group|Image acquisition at a reduced X-ray dose, 0.36 µGy/frame (70% reduction) image processing by DVA
88865566|NCT04343196|Active Comparator|Group B: Normal-dose DSA group|Image acquisition at a normal dose (1.2 µGy/frame) image processing by DSA
88865567|NCT04343118||Group Removal|All patient receiving surgical removal of plate osteosynthesis
88865568|NCT04342728|Active Comparator|Ascorbic Acid|8000 mg of ascorbic acid divided into 2-3 doses/day with food.
88865569|NCT04342728|Active Comparator|Zinc Gluconate|50 mg of zinc gluconate to be taken daily at bedtime
88865570|NCT04342728|Active Comparator|Ascorbic Acid and Zinc Gluconate|8000 mg of ascorbic acid divided into 2-3 doses/day with food and 50 mg of zinc gluconate to be taken daily at bedtime.
88865571|NCT04342728|Other|Standard of Care|Standard of care medications only as prescribed by patient's physician.
88865572|NCT04342650|Active Comparator|Intervention|CQ 450mg twice daily (3 tablets of 150mg, every 12 hours) on day 1, followed by CQ 450mg once daily (3 tablets of 150mg) from D2 to D5. Oral administration.
88865573|NCT04342650|Placebo Comparator|Placebo|Placebo tables of equal characteristics and duration of treatment.
88865574|NCT04342416|Experimental|Trauma exposed women|"No Intervention: Baseline phase ('A'):~Measurements collected in a daily diary four times a day (morning, afternoon, evening and night) over one week for the primary outcome (occurrence of intrusive memories of trauma). Individual baseline phases will be used as control periods.~Experimental: Intervention phase ('B'):~A one-session intervention with a researcher including a simple cognitive task (a memory cue and 25 minutes of Tetris game-play with mental rotation) followed by instructions to engage in the task self-guided over the subsequent week. Measurements collected in a daily diary four times a day following the intervention for the primary outcome (occurrence of intrusive memories of trauma).~Intervention: Behavioral: Brief cognitive intervention"
88865575|NCT04342104||NIV|Patients on Bilevel NIV
88865576|NCT04342104||CPAP|Patients on CPAP
88865577|NCT04341714||patients enrolled|Patients with telephone consultation on neurourology department, age > 18
88865578|NCT04341402|Experimental|Experimental|miconazole 3% & diclofenac sodium 1% & urea 40% in topical gel daily for 6 months.
89389757|NCT00394355|Experimental|Group 1|MF DPI 400 mcg once a day (QD) in the evening (PM)
89389758|NCT00394355|Experimental|Group 2|MF DPI 200 mcg QD PM
89389759|NCT00394355|Active Comparator|Group 3|Fluticasone propionate (FP) metered dose inhaler (MDI) 250 mcg twice a day (BID)
89389760|NCT00394355|Active Comparator|Group 4|ML 10 mg QD PM
89389761|NCT01822743|Experimental|Osteopathic manipulative treatment|Osteopathic compression of pterygopalatine node
89389762|NCT01822743|Sham Comparator|Sham comparator|sham Osteopathic pterygopalatine node compression
89186201|NCT03947060||Nasal & Frontal sensor position|One group of participants with two modes of measurement. First mode is standard frontal placement of the SedLine® sensor. Second mode is alternative nasal placement of the SedLine® sensor.
89186202|NCT00719810|Experimental|1|
89186203|NCT00719810|Experimental|2|
89186204|NCT00719810|Active Comparator|3|
89389763|NCT02797808|Experimental|Children with OCD|Children with obsessive compulsive disorder, not currently on medication for OCD
89389764|NCT02797808|Active Comparator|Healthy Control Children|Children without obsessive compulsive disorder
89389765|NCT01800669|Experimental|Intervention|Use of the complete CHICA MLP module in routine clinical care. The MLP module screens families for medical-legal issues, alerts the physician to there presences and provides guidance and referral materials to help the physician resolve the issues.
89389766|NCT01800669|Active Comparator|Control|CHICA without the MLP module. This version includes a module that screens families for medical-legal issue but does not provide additional guidance or referrals to resolve them.
89389767|NCT05251025|Experimental|Passive sustained stretching|Passive sustained stretching along with conventional treatments
89389768|NCT05251025|Experimental|Myofascial Release|Myofascial Release Technique along with conventional treatments
89389769|NCT02796560|Experimental|Brand name travoprost|Patients will be randomized to either start in this arm for the first 3 weeks before the crossover to the other arm for the second 3 weeks or they will start in the other arm for the first 3 weeks before the crossover to this arm for the second 3 weeks.
89389770|NCT02796560|Experimental|Generic travoprost|Patients will be randomized to either start in this arm for the first 3 weeks before the crossover to the other arm for the second 3 weeks or they will start in the other arm for the first 3 weeks before the crossover to this arm for the second 3 weeks.
89389771|NCT01316081|Experimental|Antioxidant Group|500mg Vitamin C 400 I.E. Vitamin E 50 mcg Selenium
89389772|NCT01316081|Placebo Comparator|Placebo Group|identical appearing placebo supplements
89389773|NCT05735301|Other|MR/CT perfusion group|MRI group consisted of patients who underwent DWI, FLAIRE, T1, T2, and MRA sequences.After randomization, the attending physician determined surgical treatment based on the imaging results.
89389774|NCT05735301|Other|MRI group|The perfusion sequence was examined by the Control Group, and the F-stroke Stroke software (Brainseal Intelligent Technology) was used for data processing.After randomization, the attending physician determined surgical treatment based on the imaging results.
88865579|NCT04341636|Experimental|vertical bitewing|All of the bitewing radiographs will be evaluated by two experienced restorative dentists for caries. All observers will be instructed on the definition of the rating scale before the examination sessions. The observers will be using the following a 5-point confidence scale as follows: 1=caries definitely absent; 2=caries probably absent; 3=equal chance of caries being present or absent; 4=caries probably present; 5=caries definitely present. If caries was detected a second 5-point confidence scale as follows: 1=caries mostly absent (< 25%); 2=caries slightly presence( 25%-50%) ; 3=about half of the border are presence; 4=caries probably clear ( most boarders are presence); 5=caries definitely clear ( all borders are presence ).
88865580|NCT04341636|Active Comparator|horizontal bitewing|All of the bitewing radiographs will be evaluated by two experienced periodontist for bone loss measurements. The steel wire will be used to determine the magnification factor as explained by G Li et al. 8 The steel wire and cemento enamel junction (CEJ) - if not obscure by caries - will be used as reference points for bone loss measurements. Each tooth will be measured mesially and distally twice and all these measurements will be adjusted using the steel measurement.9 All the measurements will be conducted using IC measure INK software.
88865581|NCT04341480||Chemotherapy group|Routine chemotherapy every 3 weeks for 2 cycles, and follow up for 2 weeks after discharge from hospital. Total observation duration is 6 weeks.
88865582|NCT04341480||Control group|No treatment, based on patient's choice. Total observation duration is 6 weeks.
88865583|NCT04341168||Children and Adolescents with COVID-19|age range: newborn - 18 years old, subgroups will be established
88865584|NCT04341168||Adults with COVID-19|age range: from 18 years old, subgroups will be established
88865585|NCT04341168||Control group|all ages, any respiratory tract infection, subgroups will be established
88865586|NCT04341324||Active arm: Subjects received hormonal therapy|"Study subject inclusion criteria~Male patients 18 years or older~Adenocarcinoma of the prostate either histologically or cytologically confirmed~Decided to be put on ADT -bilateral orchidectomy or luteinizing hormone-releasing hormone (LHRH) agonist or LHRH antagonist, with or without additional antiandrogen~After ADT performed, serum testosterone level should reach castrated level, i.e. < 50 ng/dL after 6 weeks of treatment~Able to consent for the participate in the study"
88865587|NCT04341324||Control arm: Subjects do not plan to receive hormonal therapy|"Control subject:~Male patients 18 years or older~Adenocarcinoma of the prostate either histologically or cytologically confirmed~Able to consent for the participate in the study"
88865588|NCT04340544|Experimental|Hydroxychloroquine|Hydroxychloroquine 600mg daily for 7 days
88865589|NCT04340544|Placebo Comparator|Placebo|Equivalent number of placebo capsules
88865590|NCT04340622|Active Comparator|Reduction in opioid cravings and use|These participants will receive twice-weekly transcranial photobiomodulation with and 810 nm LED for 4 min for a delivery to the brain of 2.1 J/cm2. The treatment will last 4 weeks. We anticipate a 60% reduction in opioid cravings in this group. We anticipate a reduction of at least 1.6 days of use per week on average.
88865591|NCT04340622|Placebo Comparator|Small reduction in opioid cravings and use|Sham condition.
88865592|NCT04340934|Experimental|Use of REZUM system|Surgery of benign prostatic hyperplasia by REZUM system
89389775|NCT02062970|Experimental|septic shock patients suffering|blood sample done in a population whom suffer of septic shock
89389776|NCT03791450||pancreaticoduodenectomy|patients underwent pancreaticoduodenectomy in recent ten years.
89389777|NCT01342991|Active Comparator|Milligan-Morgan Haemorrhoidectomy|Control arm
89389778|NCT01342991|Experimental|Laser Haemorrhoidectomy|This new method of haemorrhoidectomy is being compared to the standard Milligan-Morgan Haemorrhoidectomy.
89389779|NCT02063048|No Intervention|Usual Care for Weight Loss|Patients randomized to this arm will not receive text messages or any other weight-loss support besides usual care provided at Denver Health. They will receive a weight loss educational packet and be asked to follow up with their primary care provider to further discuss their efforts at weight loss with additional follow-up as directed by their provider. They will be contacted periodically to be weighed. Providers will not be made aware that their patients are participating in the study's control arm.
89389780|NCT02063048|Experimental|Text Message Based Weight Loss Support|Patients will receive the same weight loss educational packet as those randomized to usual care. Patients will be assisted in choosing a self-management goal related to exercise and to eating behaviors. They will receive text messages at a frequency up to 1x daily; input from focus groups will guide text message frequency.
89389781|NCT05007405||Osteoarticular infections|Retrospective study on medical file of patients with osteoarticular infections diagnose (date of the positive bacteriological sample) between January 1, 2010 and December 31, 2020
89389782|NCT01343069|No Intervention|before surgical checklist|
89389783|NCT01343069|Active Comparator|after implementation surgical checklist|
89389784|NCT03560492|Experimental|Posture Plus Force|Participants are provided with the posture garment. They have to wear it 2 to 4 h per day for a 3 month period. Participants receive a logbook that should be filled every day.
88865593|NCT04340778|Experimental|vaginal dinoprostone|vaginal dinoprostone 3 mg will be given 3 hours before copper IUD insertion plus inert placebo cream will be applied on the cervix at the time of IUD insertion.
89389785|NCT03560492|Active Comparator|Exercise|A physiotherapist teaches exercises to participants (5 sessions of 20 minutes each of stretching and strengthening exercises). Exercises are focused on cervical and dorsal areas, Participants receive instructions to continue at home on a daily basis for 3 months. Participants receive a logbook that should be filled every day.
88865594|NCT04340778|Active Comparator|lidocaine prilocaine cream|Lidocaine-prilocaine Cream will be applied on the cervix at the time of copper IUD insertion plus vaginal placebo tablet 3 hours before IUD insertion
88865595|NCT04340778|Placebo Comparator|placebo|inert placebo Cream will be applied on the cervix at the time of copper IUD insertion plus vaginal placebo tablet 3 hours before IUD insertion
88865596|NCT04340466||Suspected or proven COVID-19 critically ill patients|
88865597|NCT04340466||Control|
88865598|NCT04340388|Active Comparator|Switch from a non-integrase based regimen to dolutegravir|Participants with HIV-1 infection who have had viral suppression on a non-integrase based antiretroviral regimen for greater than or equal to 3 months will be switched to a dolutegravir based regimen dosed at 50 milligrams (MG) once daily. Background regimen will remain the same.
88865599|NCT04340388|Active Comparator|Continue on non-integrase inhibitor based regimen|Participants not currently on an integrase based regimen who remain on current suppressive therapy will remain on current antiretroviral regimen.
88865600|NCT04340310||Home respiratory poligraphy|Group A: Children between 4 and 14 years-old with initial OSA suspicion there will be allocated to Home Respiratory Polygraphy (HRP)
88865601|NCT04340310||Polysomnography|Group B: Children between 4 and 14 years-old with initial OSA suspicion and concommitant diseases and false negative suspicion from HRP there will allocated to Hospital Nocturnal Polysomnography
88865602|NCT04340232|Experimental|Baricitinib Arm|This study is an Adaptive Phase 2/3 trial designed to test the safety (Phase 2) and efficacy (Phase 2 and 3) of baricitinib to treat COVID-19. Phase 2 consists of a single-arm, open-label assignment of 20 participants receiving 2 mg baricitinib once daily for 14 days. Phase 3 consists of a single-arm, open-label assignment of 60 additional participants receiving baricitinib at the same dose. In both phases, participants will be monitored daily while hospitalized for 29 days, or until discharge, whichever occurs first. Participants who are discharged will be followed up with via phone on Day 15 and Day 29.
88865603|NCT04339842||Adults in quarantine due to the virus outbreak|Individuals over the age of 18 who spend most of their time at home in social isolation because of the Coronavirus to prevent the risk of contracting the virus
88865604|NCT04339686||Suspicion of COVID 19|
88865605|NCT04338672||Pandemic Period|Patients who presented to the emergency department at our medical institute Sheba Medical Center between January 1 - March 31 in 2020.
88865606|NCT04338672||Pre Pandemic Period|Patients who presented to the emergency department at our medical institute Sheba Medical Center between January 1 - March 31 in the following years: 2017, 2018, 2019,
88865607|NCT04338906|Experimental|Camostat + Hydroxychloroquine|Subjects will receive Camostat (400 mg tid) + hydroxychloroquine (400 mg bid day1, 200 mg bid d2-d7)
88865608|NCT04338906|Active Comparator|Placebo + Hydroxychloroquine|Subjects will receive placebo (tid) + hydroxychloroquine (400 mg bid day1, 200 mg bid d2-d7)
88865609|NCT04338282|Experimental|treatment arm|anti-PD-1 antibody (toripalimab) 240mg/d, every 3 weeks, for up to one year or until disease progression.
88865610|NCT04338438|Experimental|Apatinib Mesylate tablets combined with S-1 capsules|single arm trial: apatinib 500 mg once daily, across entire cycle and S-1 60 mg twice daily, on the first 14 days of a 21-day cycle. Medication was continued until the disease progression, withdrawal requirement, or intolerable adverse events
88865611|NCT04338126|Experimental|Tranexamic Acid Treatment|Oral dosing of tranexamic acid at dose of 1300 mg p.o. three times per day x 5 days; alternative dosing intravenously with loading dose of 10 mg/kg followed by 1 mg/kg/hr infusion x 5 days
88865612|NCT04338126|Placebo Comparator|Placebo Treatment|2 tablets of placebo three times per day x 5 days; alternative dosing intravenous normal saline at volumes similar to those use for experimental arm
88865613|NCT04337736|Active Comparator|Aerobic training|12-weeks, 3-days-a week, supervised aerobic (Nordic walking or Walking) physical exercise (PhE) protocol; duration of each PhE session: 70 minutes; rate of perceived exertion (RPE): 10-11 (1st-4th week); 12-13 (5th-8th week); 13-14 (9th-12th week).
88865614|NCT04337736|Active Comparator|Resistance training|12-weeks, 2.3-days-a week (total of 28 lessons), supervised resistance physical exercise (PhE) protocol; duration of each PhE session: 50 minutes.
88865615|NCT04337658|Experimental|Trastuzumab± Pertuzumab+ Fulvestrant|"Pertuzumab(Perjeta): Participants will receive 840 milligrams (mg) loading dose of pertuzumab, followed every 3 weeks thereafter by a dose of 420 mg via intravenous (IV) infusion until disease progression, unacceptable toxicity, withdrawal of consent, or study termination. It depends on the patient's choice.~Trastuzumab(Herceptin): Participants will receive trastuzumab (8 mg/kg loading dose for Cycle 1, followed by 6 mg/kg for subsequent cycles) administered by IV infusion every 3 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.~Fulvestrant(Faslodex): 500mg intramuscular injections at day 1, 15, 28 and every 4 weeks thereafter"
89003519|NCT05087966|Experimental|Safety Planning Intervention with Navigation Services|A patient navigation (PN) intervention for SGM youth/emerging adults designed to target mechanisms (i.e., decreasing thwarted belongingness and increasing suicide-related coping skills) that theoretically underlie suicide. The proposed intervention will integrate a single-session, empirically supported, suicide prevention intervention (Safety Planning Intervention; SPI) with PN services (PN+SPI). The patient navigator will deliver the SPI and continue frequent contact for the purpose of providing motivational enhancement, problem-solving, reinforcing coping strategies, and connecting participants to social support and mental health resources (e.g., SGM-specific support groups within the community).
89003520|NCT05078866|Experimental|Part I (GAd20-209-FSPs, MVA-209-FSPs)|Patients receive GAd20-209-FSPs IM on day 1 and MVA-209-FSPs IM at week 8. Patients undergo endoscopy with biopsy during screening and follow up as well as blood sample collection on the trial.
89389786|NCT01343147|Other|Deep hyperthermia|Microwave diathermy
89389787|NCT01343147|Other|Superficial hyperthermia|Hot packs
89389788|NCT02061956||HCC received TACE|Patients with HCC in cancer center, Sun Yat-sen University received TACE between 2011.01-2011.12
88865616|NCT04337658|Active Comparator|Trastuzumab± Pertuzumab+ Capecitabine|"Pertuzumab(Perjeta): Participants will receive 840 milligrams (mg) loading dose of pertuzumab, followed every 3 weeks thereafter by a dose of 420 mg via intravenous (IV) infusion until disease progression, unacceptable toxicity, withdrawal of consent, or study termination. It depends on the patient's choice.~Trastuzumab(Herceptin): Participants will receive trastuzumab (8 mg/kg loading dose for Cycle 1, followed by 6 mg/kg for subsequent cycles) administered by IV infusion every 3 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.~Capecitabine: 1000mg/m2 orally Bid on day 1 to day 14 every 3 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or study termination."
88865617|NCT04337502||severe group|The severe group was designated when the patients had one of the following criteria during hospitalization issued by the Chinese National Health Committee (Version 3-5). 1) Respiratory distress with respiratory frequency ≥ 30/min; 2) Pulse Oximeter Oxygen Saturation ≤ 93% at rest; 3) Oxygenation index (artery partial pressure of oxygen/inspired oxygen fraction, PaO2/FiO2) ≤ 300 mmHg; 4) One of the conditions as following: a) respiratory failure occurs and requires mechanical ventilation; b) Shock occurs; c) ICU admission is required for combined organ failure.
88865618|NCT04337502||non-severe group|The non-severe group was designated when the patients did not occur in the mentioned severe criteria until discharged from the hospital.
88865619|NCT04337424||Participants with active infection test to SARS-COV2|Sampling of saliva (1 to 2 ml)
88865620|NCT04337424||Convalescent participants for SARS-COV2|Sampling of saliva (1 to 2 ml)
88865621|NCT04337424||Participants cured to SARS-COV2|Sampling of saliva (1 to 2 ml)
88865622|NCT04337424||Participants with negative test to SARS-COV2|Sampling of saliva (1 to 2 ml)
88865623|NCT04337268|Active Comparator|human glucagon-like peptide-1|"Intervention:~Drug: human glucagon-like peptide-1 Other names: GLP-1"
88865624|NCT04337268|Placebo Comparator|Placebo|"Intervention:~Drug: Placebo (saline) Other names: Placebo for human glucagon-like peptide-1"
88865625|NCT04336566|Active Comparator|Melatonin|5mg dose of melatonin manufactured by Good Neighbor Pharmacy
88865626|NCT04336566|Placebo Comparator|Placebo|Good Neighbor Pharmacy placebo tablet that looks the same without active ingredient
88865627|NCT04336254|Experimental|hDPSCs group|Routine treatment + Intravenous injection of human dental pulp stem cells
88865628|NCT04336254|Placebo Comparator|Control group|Routine treatment + Intravenous saline injection (Placebo)
88865629|NCT04336488|Experimental|Orochem (Test)|fifteen patients with lichen planus will be treated with MMPs neutralizing agent 3 times daily for 3 weeks. then pain, discomfort and disease severity will be assessed at 1 and 3 weeks periods.
88865630|NCT04336488|Active Comparator|Conventional (Control)|fifteen patients with oral lichen planus confirmed with a biopsy will be treated with topical corticosteroids, topical antifungal 3 timed daily for 3 weeks. then pain, discomfort and disease severity will be assessed at 1 and 3 weeks periods.
88865631|NCT04336176|Active Comparator|PulseFlow DF boot|PulseFlow DF boot
88865632|NCT04336176|Active Comparator|Usual Care|Measurements will be taken from patients wearing usual standard of care
88865633|NCT04336176|Sham Comparator|Sham|Sham shoe (closest to barefoot or baseline pressures)
88865634|NCT04335864|Active Comparator|Group A|39 patients with hydrosalpinx will have laparoscopic salpingectomy
88865635|NCT04335864|Active Comparator|Group B|39 patients with hydrosalpinx will have hysteroscopic proximal tubal occlusion
88865636|NCT04335786|Experimental|Active treatment arm|Valsartan at a dosage and frequency titrated to blood pressure with 80mg or 160mg tablets up to a maximum dose of 160mg b.i.d.
88865637|NCT04335786|Placebo Comparator|Placebo arm|Matching 80mg or 160mg placebo tablets at a dosage and frequency titrated to systolic blood pressure
88865638|NCT04335630||Cases|Patients admitted to the hospital with symptoms of fever, sore throat, cough, nasal congestion and/or dyspnea who were tested positive for SARS-CoV-2 by PCR.
88865639|NCT04335630||Controls|Age- and gender-matched subjects admitted to the hospital with similar symptoms but negative PCR testing for SARS-CoV-2 (one negative PCR test for patients of low clinical suspicion and two negative tests, 24 hours apart from each other, for patients of high clinical suspicion).
88865640|NCT04335474||Surgical drainage|Cases that have surgical management
88865641|NCT04335474||Percutaneous drainage|Cases that have the nonoperative management by percutaneous drainage
88865642|NCT04335396||adult patients with diabetes mellitus|Subgroup 1 - consecutive patients with diabetes mellitus with scleredema skin disorder Subgroup 2 - consecutive patients with diabetes mellitus without scleredema Subgroup 3 - patients with diabetes and scleredema - already cared in the tertiary center of the Rheumatology Department of the University of Pécs, in Hungary.
88865643|NCT04335318|Experimental|Colonoscopy with AI-assistance group|Colonoscopies were performed with AI-assistance.
88865644|NCT04335318|No Intervention|Standard Colonoscopy group|Standard clinical procedure
88865645|NCT04335162||Patients with cardiovascular complications|Patients presenting with cardiomyopathies or venous thromboembolism
88865646|NCT04335162||Patients without cardiovascular complications|Patients without cardiomyopathies or venous thromboembolism
88865647|NCT04335162||Intensive Care Unit patients|Patients admitted in intensive care unit
88865648|NCT04335162||Hospital Ward patients|Patients admitted in hospital ward
88865649|NCT04334694|Other|Atrial flow regulator|In this arm, patients who have elevated left ventricle filling pressures get (Occlutech® AFR device) and optimal therapy for Heart failure (HF).
88865650|NCT04334928|Experimental|Emtricitabine/Tenofovir|"Tenofovir Disoproxil Fumarate 245 mg/Emtricitabine 200 mg + Placebo of Hydroxychloroquine 200 mg~Strength: 200 mg/245 mg tablets~Dose: one tablet once a day (both at dinner)"
88865651|NCT04334928|Experimental|Hydroxychloroquine|"Hydroxychloroquine 200 mg + Placebo of Tenofovir Disoproxil Fumarate 245 mg/Emtricitabine 200 mg~Strength: 200 mg tablets~Dose: one tablet once a day (both at dinner)"
89389789|NCT05210127|Experimental|After Scarf Osteotomy Group|30 participants after surgery
89389790|NCT05210127|Experimental|Without Scarf Osteotomy Group|30 participants without surgery
89389791|NCT01345331|Experimental|Real Stimulation|Ear stimulation at specific points should work by stimulating a nerve called the vagus nerve. Previous research has shown that stimulating this nerve can help patients feel less pain.
88865652|NCT04334928|Experimental|Emtricitabine/Tenofovir+Hydroxychloroquine|"Tenofovir Disoproxil Fumarate 245 mg/Emtricitabine 200 mg + Hydroxychloroquine 200 mg~Strength FTC/TDF:200 mg/245 mg tablets~Strength HC: 200 mg tablets~Dose: one tablet FTC/TDF plus one tablet HC once a day (at dinner)"
88865653|NCT04334928|Placebo Comparator|Placebo|"Placebo of Tenofovir Disoproxil Fumarate 245 mg/Emtricitabine 200 mg + Placebo of Hydroxychloroquine 200 mg~Placebo tablets with similar appearance to study drugs.~Dose: one tablet once a day (both at dinner)"
88865654|NCT04334850|Experimental|Targeted antibiotic treatment according to the results of mPCR|a broad panel respiratory Mpcr FA-PPP is performed on respiratory tract sample (tracheal aspirate, BAL or sputum), collected 12 hours after inclusion. An algorithm of early antibiotic adaptation and discontinuation, based on the microbiological results, including the mPCR FA-PPP results, and the procalcitonin values and kinetics will be used. This algorithm will be applied as soon as possible after inclusion, and repeated day after day until D7.
88865655|NCT04334850|Other|Control arm|The antimicrobial therapy is left at the discretion of the physicians, as in usual practice.
88865656|NCT04334616|Active Comparator|Conventional Laryngocope|Patients in this arm will be intubated with conventional Macintosh laryngoscope
88865657|NCT04334616|Active Comparator|Video Laryngocope|Patient in this arm will be intubated with Karl Storz Video Laryngoscope
88865658|NCT04334226||Patient and Caregiver Dyad|Individuals who participated in the Stoma Boot Camp study and their caregiver will form a dyad
88865659|NCT04334382|Experimental|Hydroxychloroquine|
88865660|NCT04334382|Active Comparator|Azithromycin|
88865661|NCT04333758|Experimental|Jintronix Intervention|"2 consecutive phases of intervention for all participants using Jintronix virtual reality telerehabilitation software.~Phase 1 consisted of 9 (3/week for 3 weeks) 45-min/session clinic-based sessions conducted by study team therapist, with concurrent caregiver training.~Phase 2 consisted of 20 (5/week for 4 weeks) 45min/session home-based sessions supervised by trained caregiver, with telemonitoring by study team therapist."
88865662|NCT04333992|Active Comparator|propofol-remifentanil group|"Anesthetic induction was achieved with an initial target concentration of propofol 4 ㎍/mL and remifentanil 3-4 ng/mL.~Anesthesia was maintained with a fixed target concentration of propofol 2-4 ㎍/mL and remifentanil 2-3 ng/mL"
88865663|NCT04333992|Active Comparator|sevoflurane-remifentanil group|"Anesthetic induction was achieved with thiopental 5 mg/kg and initial target concentration of remifentanil 3-4 ng/mL.~Anesthesia was maintained with 1.5-2.5% end-tidal concentration sevoflurane in 50% oxygen with air and remifentanil 2-3 ng/mL"
88865664|NCT04333836|Experimental|Aligners group|Receiving full set of aligners ( Clear Removable Orthodontic appliance) until complete canine retraction
88865665|NCT04333836|Active Comparator|Conventional Brackets group|leveling and alignment of lower followed by complete canine retraction
88865666|NCT04332978|Experimental|Group I|"Drug names: Fluticasone Propionate - PLURAIR® brand Pharmaceutical form: Nasal spray (50mcg / dose) Administration: Topical nasal route Posology 02 jets in each nostril 1 time a day - Single daily topical nasal dose of 200 mcg / day (2 jets / nostril = 100 mcg / nostril), preferably in the morning, upon waking up and at the same time, for 4 weeks.~Manufacturer: Libbs Farmacêutica Ltda. Presentation: Deliver 1 bottle of 120 doses in original packaging"
88865667|NCT04332978|Active Comparator|Group II|"Fluticasone Propionate - FLIXONASE® brand Nasal spray (50mcg / dose) Topical nasal route 02 jets in each nostril once a day - Single daily topical nasal dose of 200 mcg / day (2 jets / nostril = 100 mcg / nostril), preferably in the morning, upon waking up and at the same time, for 4 weeks.~GlaxoSmithKline. Deliver 1 bottle of 120 doses in original packaging"
88865668|NCT04332900|No Intervention|Control condition|In this condition there will not be any application of therapeutic approach.
88865669|NCT04332900|Experimental|Intervention proximal condition|The proximal therapeutic approach will be the SERF strap (S.E.R.F. strap; DonJoy Orthopedics, Inc., vista, CA).
88865670|NCT04332900|Experimental|Intervention distal condition|The distal therapeutic approach will be a pair of foot orthoses with semi-rigid arch support and medial elevation at the forefoot and at the rearfoot by 7° each (Propulsão Produtos Biomecânicos, Minas Gerais, Brazil).
88865671|NCT04333212|Other|study arm|We projected a total of 1,100 study cases, which encompassed 100 cases of women with no intraepithelial lesion or malignancy (NILM) cytology, 300 cases of ASCUS, 300 cases of low grade squamous intraepithelial lesion (LSIL) and 400 cases high grade squamous intraepithelial lesion (HSIL) in cervical cytology.
88865672|NCT04332666|Placebo Comparator|Placebo|Standard of care treatment
88865673|NCT04332666|Experimental|Study drug|Angiotensin-(1-7) infusion (venous) of 0.2 mcg/Kg/h for 48h
88865674|NCT04332822|Active Comparator|Arm A - R-mini-CHOP|"Cycles 1-6, duration 21 days~Rituximab 375 mg/m2 i.v., day 1, cycle 1. 1400 mg s c OR 375 mg/m2 i. v. cycles 2-6~Cyclophosphamide 400 mg/m2 i.v., day 1, cycles 1-6~Doxorubicin 25 mg/m2 i.v., day 1, cycles 1-6~Vincristine 1 mg i.v. (total dose), day 1, cycles 1-6~Prednisone, 40 mg/m2 p.o, days 1-5, , cycles 1-6"
88865675|NCT04332822|Experimental|Arm B - R-pola-mini-CHP|"Cycles 1-6, duration 21 days~Rituximab 375 mg/m2 i.v., day 1, cycle 1. 1400 mg s c OR 375 mg/m2 i. v. cycles 2-6~Cyclophosphamide 400 mg/m2 i.v., day 1, cycles 1-6~Doxorubicin 25 mg/m2 i.v., day 1, cycles 1-6~Prednisone, 40 mg/m2 p.o, days 1-5, , cycles 1-6~Polatuzumab vedotin 1.8 mg/kg i.v day 1 cycles 1-6"
89389792|NCT01345331|Sham Comparator|Sham|The sham treatment will use the same equipment as the real treatment, but the participant will not receive any real stimulation to the ear.
89389793|NCT02062034|Experimental|Ubiquinone|400mg daily of oral ubiquinone for 24 weeks
89389794|NCT02062034|Experimental|Combined antioxidant therapy|(1mg copper + 20mg zinc + 180mg vitamin C + 30mg vitamin E + 1mg zeaxanthin + 4mg astaxanthin + 10mg lutein) daily of oral antioxidant combined therapy for 24 weeks
88865676|NCT04332510|Experimental|Infant milk 1|
88865677|NCT04332510|Experimental|Infant milk 2|
88865678|NCT04332510|Experimental|Infant milk 3|
88865679|NCT04332510|Experimental|Infant milk 4|
88865680|NCT04332276|Experimental|Cerebroventricular administration of A- dopamine|Cerebroventricular administration of dopamine prepared and stored in anaerobia
88865681|NCT04332276|Active Comparator|Optimized oral dopaminergic treatment|Optimized oral dopaminergic treatment with L-dopa (at least 5 doses a day) with dopaminergic agonist, monoamine B inhibitor and catechol-o-methyl inhibitor (if tolerated) (A-dopamine replaced by saline un the pump during optimized oral dopaminergic treatment)
88865682|NCT04332354||T2D diabetes obese subjects|Patients have T2D diabetes and are candidates for bariatric surgery. They will receive routine cares and follow-up and will have CGM measurement before and 2 weeks following the surgery
88865683|NCT04332042|Experimental|tofacitinib|Tofacitinib cp 5mg: 2pills twice a day for 14 days
88865684|NCT04332120|Active Comparator|Mini Laparotomic|In patients undergoing spinal anesthesia, a suprapubic 3-5 centimeter incision was entered into the abdomen. After both tubes were isolated, bilateral tube ligation was performed by Pomeroy method. After bleeding control was achieved, it was repaired in accordance with the anatomy of the abdomen.
88865685|NCT04332120|Active Comparator|Laparoscopic|In patients undergoing general anesthesia, Verres was inserted into the abdomen through the umbilicus. Pneumo peritoneum was created with carbon dioxide (CO2). Optical imaging was placed into the abdomen from the umbilicus with 10-trochar. Auxiliary trochars from 3 centimeter supero-medial of both spina iliaca anterior superior were placed in the abdomen. bilateral tubas were isolated. Bilateral tubal ligation was performed with the help of bipolar cautery. bleeding control was achieved. trochars were taken out of the abdomen. the skin was closed.
88865686|NCT04332120|Active Comparator|posterior colpotomy|The patient underwent spinal anesthesia and was placed in a high lithotomy position. cervical uteri was observed with the help of speculum. A 3 centimeter vertical incision was opened 2 centimeter below the cervix uteri. Peritoneal cavity was entered from this area. bilateral tubas were isolated. Bilateral tubal ligation was performed using the pomeroy method. bleeding control was achieved. peritoneal and posterior cervical incision line was repaired.
88865687|NCT04341870|Experimental|Sarilumab + Azithromycin + Hydroxychloroquine|Sarilumab combined with Azithromycin and Hydroxychloroquine
88865688|NCT04341870|Active Comparator|Sarilumab|Sarilumab only
88865689|NCT04331808|Experimental|TOCILIZUMAB|Tocilizumab 8mg/kg D1 and if no response (no decrease of oxygen requirement) a second injection at D3.
88865690|NCT04331808|No Intervention|Standard of care|
88865691|NCT04331574||covid-19 patients|Patients with certified diagnosis of COVID-19 recruited in Italian hospitals
88865692|NCT04331184|Experimental|RFA using combined bipolar and monopolar energy delivery|Control group: The historic cohort is used to compare the results of the conventional alternating unipolar radiofrequency energy transfer mode with RFA.
88865693|NCT04330872|Active Comparator|Enteric coated Aspirin|"EC aspirin loading dose 300mg followed by 100 mg (2 days).~The study's total duration is 3 days."
88865694|NCT04330872|Placebo Comparator|Plain Aspirin|"Dispersible Aspirin loading dose 300mg followed by 75mg tablets (2 days)~The study's total duration is 3 days."
88865695|NCT04331028|Experimental|Shockwave therapy|After dental extraction, a shockwave therapy will be applied to the area.
88865696|NCT04331028|No Intervention|Control|After dental extraction, no treatment will be applied
88865697|NCT04330794|Experimental|NMFACT|record the caries index using the NMFACT chart
88865698|NCT04330794|Active Comparator|DMF index|record the caries index using the DMF chart
88865699|NCT04331106||Population in Germany|Reasonably large and representative sample of the general population in Germany
88865700|NCT04330404|Experimental|Cognitive strategy training|The experimental group will receive the Cognitive strategy training (CST), which includes awareness enhancement, cognitive-related education, discussion of everyday cognitive difficulties, generation of cognitive strategies, cognitive strategy practice, and homework assignments.
88865701|NCT04330404|Active Comparator|group interactive game|The active control group will receive group interactive game, including table games and games using songs, balloons, newspapers and so on.
88865702|NCT04330326|Experimental|Treatment Arm|Subjects in active treatment will receive dietary supplementation with N-acetylcysteine, L-carnitine tartrate, nicotinamide riboside, and serine, administered as a mixture.
88865703|NCT04330326|Placebo Comparator|Placebo Arm|Subjects will take a mixture of placebo as powder dissolved in water by mouth.
88865704|NCT04329858|Active Comparator|conventional glass ionomer|
88865705|NCT04329858|Experimental|zinc modified glass ionomer|
88865706|NCT04329858|Experimental|silver modified glass ionomer|
89389795|NCT02062034|Placebo Comparator|Placebo|Placebo. 100mg daily oral intake for 24 weeks
89389796|NCT05209971||macular thickness and visual acuity|optical coherence tomography
89389797|NCT03620357|Experimental|Continuous Glucose Monitor (CGM) Group|
89389798|NCT03620357|Active Comparator|SMBG Group|
89389799|NCT02063594|Placebo Comparator|Saline Placebo|2 of 8 subjects in each dose cohort will receive normal saline as a single intravenous infusion
89389800|NCT02063594|Experimental|NCTX|6 of 8 subjects in each dose cohort will receive NCTX (PEGylated Liposomal Iodixanol Injection) as a single intravenous infusion
89389801|NCT00344487|Experimental|lopinavir/ritonavir (Kaletra)|lopinavir/ritonavir (Kaletra)400/100mg tablets by mouth twice a day for 48 weeks.
89389802|NCT05089643|Experimental|CA|Anlotinib 10mg Qd D1-14 Capecitabine 1G /m2 Bid D1-14 / Q21D
89389803|NCT02871492|Experimental|Pritelivir 5% w/w ointment|Topical treatment (20 applications), 5 times daily for 4 days
89389804|NCT02871492|Placebo Comparator|Pritelivir ointment matching placebo|Topical treatment (20 applications), 5 times daily for 4 days
89389805|NCT02871492|Active Comparator|Zovirax® cream|Topical treatment (20 applications), 5 times daily for 4 days
89389806|NCT01345487|Other|Low Vegetable Protein|Meal with 10 E% protein from fava beans/split peas
89389807|NCT01345487|Experimental|High Vegetable protein|Meal with 20 E% protein from fava beans/split peas
89389808|NCT01345487|Experimental|High Animal Protein|Meal with 20 E% protein from pork/beef
89389809|NCT02063126|Active Comparator|ReConnect|CFS patients who were randomized to measure the effect of oral ReConnect supplementation (NADH: 20 mg/day, Coenzyme Q10: 200 mg/day; 4 tablets/day) on the maximum HR during 8-weeks in term.
89389810|NCT02063126|Placebo Comparator|Placebo|CFS patients who were randomized to measure the effect of oral Placebo supplementation ( phosphoserine and vitamin C, 4 tablets/day) on the maximum HR during 8-weeks in term.
89389811|NCT04959435||Case|Behcet's disease patients
89389812|NCT04959435||Controls|Controls that matched two to two at case according to sex,social status and diet.
89389813|NCT02032056|Experimental|probiotic (10^9 cfu/day)|Daily intake of bifidobacterium animalis ssp. Lactis (BB12), 10^9 cfu/day, provided as powder in a sachet which can be added to food or drink.
89389814|NCT02032056|Experimental|probiotic (10^8 cfu/day)|Daily intake of bifidobacterium animalis ssp. Lactis (BB12), 10^8 cfu/day, provided as powder in a sachet which can be added to food or drink.
89389815|NCT02032056|Placebo Comparator|Placebo|provided as powder in a sachet which can be added to food or drink.
89389816|NCT05591300||Patients|Patients with acute CO poisoning needing a hyperbaric oxygen treatment
89389817|NCT05591300||Healthy controls|Healthy controls i.e., healthy phisicians than will enter the hyperbaric oxygen therapy chamber to assist the patients
89389818|NCT03615612|Other|OR Eyeglasses, then SR|Objective Refraction (OR) Eyeglasses, then Subjective Refraction (SR)
88865707|NCT04329468|Experimental|DS-MCE examination|Subjects with or without digestive symptoms will be enrolled to take DS-MCE and conventional esophagogastroduodenoscopy (EGD) within 48h successively.
88865708|NCT01628250|Active Comparator|laparoscopic complete mesocolic excision|Randomized group of patients receiving laparoscopic colectomy with the concept of complete mesocolic excision
88865709|NCT01628250|Active Comparator|D3 laparoscopic colectomy|Randomized group of patients receiving laparoscopic colectomy with D3-resection
88865710|NCT01620996|Active Comparator|1|Duffus Street Medical Centre
88865711|NCT01620996|Active Comparator|2|Sydney Family Practice
88865712|NCT01620996|No Intervention|no counseling|HRA assessment pre and post but no counselling
88865713|NCT00704106||Group 1|Persistent viremia after 48 weeks or longer.
88865714|NCT00704106||Group 2|<2 log IU/mL drop from initial HBVDNA after 12 weeks of adefovir
88865715|NCT00704106||Group 3|Patients who responded to adefovir and were switched to entecavir.
88865716|NCT00704106||Group 4|Patients with 160 copies/mL (100 IU/mL) or higher at the time of medication switch.
88865717|NCT05620680|Experimental|Treatment group|CD7 CAR-T treatment group
89186205|NCT03956342||Pediatric Clinicians - Group 1|"Pediatric clinical care clinicians who work with patients who are sedated for diagnostic or therapeutic procedures. May included, MDs, DOs, PharmDs, Nurse Practitioners, or nurses with a BSN or higher level nursing degree.~This cohort will complete a first round of interviews to assess measure content."
88865718|NCT05620602||Remedial treatment within 3 months|
88865719|NCT05620602||Remedial treatment within 3 to 6 months|
88865720|NCT05620602||Remedial treatment within 6 to 12 months|
88865721|NCT05620602||Remedial treatment after 12 months|
88865722|NCT05620446|Active Comparator|endoscopic managment of sigmoid volvulus|patients are subjected to untwist the volvulus first by endoscopy then one or two days later are subjected to sigmoid colon fixation by endoscopy using 2-shot anchor device
88865723|NCT05620446|No Intervention|surgical management of sigmoid volvulus|patients aresubjected for surgical colostomy ( hartman's procedure ) , then later on after 6 weeks , they are subjected for surgical sigmoid fixation or excision either by open or laparoscopic approach
88865724|NCT05620056||drug exposure|chemicals drugs, biological products, patent Chinese Medicines, Chinese herbs
88865725|NCT05619978||3L+ Cohort|Patients who initiated third-line treatment (3L) therapy. Treatments received in 3L were dasatinib, nilotinib, imatinib, ponatinib, bosutinib, and allo-SCT
88865726|NCT05619978||T315I cohort|Patients with chronic myeloid leukemia with T315I mutation
89186206|NCT03956342||Pediatric Clinicians - Group 2|"Pediatric clinical care clinicians who work with patients who are sedated for diagnostic or therapeutic procedures. May included, MDs, DOs, PharmDs, Nurse Practitioners, or nurses with a BSN or higher level nursing degree.~This smaller cohort will be a randomized subset of the original cohort and will complete interviews to assess changes made based on the feedback from the first cohort."
89186207|NCT02591498|Active Comparator|Auditory|Administration of 40 hours of auditory training exercises
89186208|NCT02591498|Active Comparator|Visual|Administration of 40 hours of visual training exercises
89186209|NCT02591498|Placebo Comparator|Video Games|Administration of 40 hours of commercial video games
88865727|NCT05619666|Other|Severity of COVID-19 infection|Based on the severity of Covid-19 infection patients were divided into 2 groups: First group (MMG) mild to moderate group and second group (SSG) stable severe group.
88865728|NCT05614752||Treatment group|treated with Fexuclue Tablet 40mg
88865729|NCT05578638|Experimental|aloe Vera group|10 ml of the spray will be rubbed two times per day during the skin care on the areas at risk for PIs, including the patient's sacrum area, hip areas and heels area. This action will continue for 10 days
88865730|NCT05578638|Experimental|rosemary group|10 ml of the spray will be rubbed two times per day during the skin care on the areas at risk for PIs, including the patient's sacrum area, hip areas and heels area. This action will continue for 10 days
88865731|NCT05578638|Experimental|aloe Vera rosemary compound|10 ml of the spray will be rubbed two times per day during the skin care on the areas at risk for PIs, including the patient's sacrum area, hip areas and heels area. This action will continue for 10 days
88865732|NCT05578638|No Intervention|control group|
88865733|NCT05285826|Experimental|V503|Participants will receive a single 0.5 mL intramuscular (IM) injection of V503 at Day 1, Month 2, and Month 6.
88865734|NCT05285826|Placebo Comparator|Placebo|Participants will receive a single 0.5 mL IM injection of placebo at Day 1, Month 2, and Month 6.
88865735|NCT05281536|Experimental|Postural Changes from 45° to 10° in supine decubitus|Postural changes from 45° to 10° in supine decubitus Three times of 60 minutes each step before (45°, baseline) - during (10°, intervention) - after (45°, control)
88865736|NCT05278884|Experimental|ACLS and then VAST teaching intervention|For each hospital, the intervention will be to pair a 2-day technical resuscitation skills training adapted from the ACLS/AHA and a 3-day VAST course for a multidisciplinary team of 20 participants (i.e., nurses, doctors, non-physician anesthesia providers). Participants' resuscitation skills will be tested at 4 time points: immediately before the ACLS course, immediately after the ACLS course, immediately after the VAST Course, and at 4 months post training.
88865737|NCT05136690|Experimental|Panel A: Healthy Control Participants|In Part 1, HC participants receive nicotine patch + capsule placebo, and patch placebo + capsule placebo, under a cross-over design in Periods 1 and 2. In Part 2 (Period 3), HC participants are randomly assigned to receive either MK-4334 250 mg capsule + patch placebo or capsule placebo + patch placebo.
89186210|NCT00719732|Experimental|ReSTOR Aspheric +3|Enrolled subjects receive implantation of ReSTOR +3 intraocular lenses (IOLs) for replacement of cataract in the natural lens of the eye. The patients were to be implanted bilaterally (in both eyes).
89186211|NCT02590718|Experimental|Group 1|optimized postoperative management(lying without the pillow for half an hour after lumbar puncture)
89186212|NCT02590718|No Intervention|Group 2|traditional postoperative management(lying without the pillow and fasting water and food for four hours after lumbar puncture)
89389819|NCT03615612|Other|SR Eyeglasses, then OR|Subjective Refraction (SR) Eyeglasses, then Objective Refraction (OR)
89389820|NCT02063750|Experimental|Strengthening group|This group perform muscle strengthening exercises using a Swiss ball of 65 cm diameter.
89389821|NCT02063750|Active Comparator|Stretching group|Performed stretching exercises
89389822|NCT05209113|Experimental|Study Group|The self-management module, which will be applied only to the study group, includes the clinical pharmacist informing the patient verbally and in writing about MS disease, the importance of drug compliance, and monitoring of disease symptoms. The first interview will end after the Patient Health Engagement-PHE-s, Multiple Sclerosis Self-Management Revised-MSSM-R, Patient Assessment of Chronic Illness Care-PACIC scales and self-management module are applied to the study group by the clinical pharmacist. When the patients come to the outpatient clinic examination 4 and 8 months after the first interview, second and third face-to-face interview will be held with the clinical pharmacist and all scales will be applied again. During the second and third interview, no written and/or verbal information will be given to the patient again.
89389823|NCT05209113|No Intervention|Control Group|Patient Health Engagement (PHE-s), Multiple Sclerosis Self-Management Revised (MSSM-R), Patient Assessment of Chronic Illness Care (PACIC) scales will be administered to the control group patients whose medications and demographic information were obtained in the first face-to-face interview. The same scales will be repeated at the 4th month and 8th month, the self-management module will not be applied to the control group, and within this scope, the patients will not be informed by the clinical pharmacist, and the patient's routine outpatient services will continue.
89389824|NCT03143855|Experimental|Lorcaserin|
89389825|NCT03143855|Placebo Comparator|Control Group|
89389826|NCT03615456|Active Comparator|Conventional thyroidectomy|Thyroidectomy with ligation and division of thyroid vessels
89389827|NCT03615456|Active Comparator|Harmonic scalpel thyroidectomy|Thyroidectomy with sealing of thyroid vessels using harmonic scalpel
88865738|NCT05136690|Experimental|Panel B: Participants with Mild-to-Moderate SZ|In Part 1, participants with mild-to-moderate SZ receive nicotine patch + capsule placebo, and patch placebo + capsule placebo, under a cross-over design in Periods 1 and 2. In Part 2 (Period 3), SZ participants are randomly assigned to receive either MK-4334 250 mg capsule + patch placebo or capsule placebo + patch placebo.
88865739|NCT05135754|Other|Test product - new supporting ostomy product and support service|The arm includes the newly developed ostomy support product togethter with a support service
89389828|NCT02878603|Experimental|caplacizumab|Participants who completed study ALX0681-C301 (NCT02553317) with standard of care (plasma exchange [PE], corticosteroid and other immunosuppressive agents) or caplacizumab with PE and immunosuppressive agents were enrolled in study LTS16371. Participants upon each recurrence of aTTP in LTS16371 and not meeting any criteria (namely: pregnancy, history of severe and/or serious hypersensitivity reaction to investigational medicinal product [IMP], withdrawal before receiving IMP, received more than 1 PE) were treated with caplacizumab initial 10 milligrams (mg) intravenous dose followed by a daily 10 mg subcutaneous injections during the period of PE and for 30 days after stop of PE (and eventually 28-day extension period, if needed). Participants with or without recurrence were followed up twice yearly up to maximum of 36 months in LTS16371.
89389829|NCT03613974|Experimental|lidocaine concentraion|the popliteal block will be performed (once) in all patients using 20 ml of lidoacine. The response of a patient determined the lidocaine concentration given to the next patient (a biased-coin design up-down sequential method). If a patient had a negative response (failed block), the lidocaine concentration was increased by 0.1% w/v in the next patient. If a patient had a positive response (successful block), the next patient was randomized to receive the same lidocaine concentration (with probability of 0.89), or to receive a concentration 0.1% w/v less (with probability of 0.11).
88865740|NCT05035680|Active Comparator|Arm i - Seasonal influenza vaccine|Single 0.5 mL intramuscular (IM) injection of an unadjuvanted seasonal influenza vaccine
88865741|NCT05035680|Experimental|Arm ii - SWE and unadjuvanted seasonal influenza vaccine|Single 0.8 mL IM injection of SWE mixed with unadjuvanted seasonal influenza vaccine
88865742|NCT05035680|Active Comparator|Arm iii - MF59 adjuvanted seasonal influenza vaccine|Single 0.5 mL IM injection of MF59 adjuvanted seasonal influenza vaccine
88865743|NCT04985058||Patients with breast cancer randomised in arm A of digital platform|Patients with breast cancer treated with abemaciclib in combination with endocrine treatment and randomised in Arm A of the digital platform. Patients randomised in arm A will receive a an acknowledgement and suggestion to stay in contact with their clinician.
88865744|NCT04985058||Patients with breast cancer randomised in arm B of digital platform|Patients with breast cancer treated with abemaciclib in combination with endocrine treatment and randomised in Arm B of the digital platform. Patients randomised in arm A will receive a an acknowledgement and suggestion to stay in contact with their clinician; additionally they will receive personalised support (as a few word text) for each side-effect reported.
88865745|NCT04578678||Apathy Group|Patients diagnosed with apathy
88865746|NCT04578678||Dysarthria Group|Patients diagnosed with dysarthria
88865747|NCT04578678||No Apathy and Dysarthria Group|Patients diagnosed with neither apathy nor dysarthria
88865748|NCT04578678||Apathy and Dysarthria Group|Patients diagnosed with apathy as well as dysarthria
89003521|NCT05078866|Experimental|Part II Arm A (GAd20-209-FSPs, MVA-209-FSPs)|Patients receive GAd20-209-FSPs IM at week 52 and MVA-209-FSPs IM at week 60. Patients undergo endoscopy with biopsy as well as blood sample collection on the trial.
88865749|NCT04505358|Experimental|30 mg PU AD 3:2 ratio|will be administered orally, as 30 mg active dose strength tablets qd on an empty stomach (1 hour prior to food or 2 hours after), at about the same time each day, via standard of care procedures at the site or at home. All subjects will have their first dose administered in clinic following completion of all baseline assessments
88865750|NCT04505358|Placebo Comparator|30 mg Placebo 3:2 ratio|will be administered orally, as 30 mg placebo tablets (placebo has no active ingredients) qd on an empty stomach (1 hour prior to food or 2 hours after), at about the same time each day, via standard of care procedures at the site or at home. All subjects will have their first dose administered in clinic following completion of all baseline assessments
88865751|NCT04133142|No Intervention|Medical treatment|"Patients receive the standard medical medication for herpes pain~Oral administration of Gabapentin~300 mg/d on day 1 and 2~600 mg/d on day 3 and 4 if pain persists~900 mg/d on day 5 and 6 if pain persists~Oral administration of Paracetamol up to 3 g per day prescription for 7 day and continue for 3 weeks after evaluation"
88865752|NCT04133142|Experimental|Early block Single|the patient will receive a regional anaesthesia by Inter fascial block, peripheral nerve block. Local anesthetic used will be ropivacaine 0.5% dose according to the type of block and never exceeding 3mg/kg The type of block would be the most appropriate to cover the dermatomes involved in the Herpes according to the mapping done with the higher ration benefit risks. Choice of Block by an anesthesiologist expert in regional anaesthesia techniques. After the block performance if the pain comes back patient will receive the standard medical treatment as in the group medical treatment
89003522|NCT05078866|Experimental|Part II Arm B (MVA-209-FSPs)|Patients receive MVA-209-FSPs IM at week 52. Patients undergo endoscopy with biopsy as well as blood sample collection on the trial.
89186213|NCT00723710||Intron A|Patients with malignant melanoma who are free of disease post-surgery but at high risk for systemic recurrence.
89186214|NCT04085198|Active Comparator|No-touch technique with the application of light physics rules|This procedure will be performed by the gynecologists who are familiar to the rules of the 'lights physics' and are currently 'lights physics' rules in their clinical practice. The brightness or darkness of the tissue which reflects the distance between the light source and the surrounding tissue will be used to find the correct route from the vagina introitus to the uterine cavity.
89186215|NCT04085198|Placebo Comparator|Control|Patients in this arm of the study protocol will receive standard hysteroscopy with 'no-touch' technique without the utilization of the 'lights physics' rules. The gynecologist performing this procedure will find their route from the vagina introitus to the uterine cavity by the identification of the anatomical structures on their way.
89186216|NCT02590796||Hospitalised patients with delirium|hospitalised patients with delirium in general wards.
89186217|NCT02590796||Hospitalised patients with dementia/ no delirium|Hospitalised patients with a diagnosis of dementia who do not have delirium in general wards.
89186218|NCT02590796||Hospitalised patients with no delirium or dementia|Hospitalised patients with no delirium or dementia in general wards.
89186219|NCT02590796||Outpatients with dementia|People with a diagnosis of dementia who are living in the community.
89186220|NCT02590796||Healthy volunteers|Healthy volunteers who are living in the community who do not have a cognitive impairment.
89186221|NCT02590796||ICU delirium|Patients with delirium who are hospitalised in the intensive care units.
89186222|NCT02590796||ICU no delirium|Patients who do not have delirium who are hospitalised in intensive care units.
89186223|NCT03955874||INITIAL SBT|Patients who underwent an Spontaneous Breathing Trial prior to extubation. This cohort will be further subdivided into initial patients who initially pass an SBT successes and those who initially fail an SBT.
89186224|NCT03955874||DIRECT EXTUBATION|Patients that were directly extubated without conduct of a prior SBT or tracheostomy
89186225|NCT03955874||DIRECT TRACHEOSTOMY|Patients who underwent a direct tracheostomy without conduct of a prior SBT or extubation
89186226|NCT03955874||No attempt at mechanical ventilation discontinuation|Patients who died without conduct of a prior SBT, extubation or tracheostomy
89186227|NCT03956186||Hypotension group|Parturients undergoing elective C/S under spinal anesthesia whose systolic arterial pressure drop below 80 mmHg or have symptoms of hypotension such as dizziness, nausea and vomiting during the procedure.
89186228|NCT03956186||Non-hypotension group|Parturients undergoing elective C/S under spinal anesthesia whose systolic arterial pressure does not drop below 80 mmHg or have any symptoms of hypotension during the procedure.
89186229|NCT00688545||Celecoxib|Patients treated with celecoxib as per treating physician's judgement
89186230|NCT00688545||nsNSAIDs (nonselective nonsteroidal anti-inflammatory drugs)|Patients treated with nsNSAIDs as per treating physician's judgement
89186231|NCT02563275|Other|Human fine motor skills measurements during weightlessness|
89186232|NCT04060407|Experimental|Advanced Melanoma|Patients with advanced melanoma.
89186233|NCT00741585|Active Comparator|1|Treatment with all prescribed hypertension medications on awakening
89186234|NCT00741585|Active Comparator|2|Treatment with at least one prescribed hypertension medication at bedtime
89186235|NCT00746967|Other|Arm 1|
89186236|NCT02563041|Experimental|30%TSC|After each hemodialysis (HD) session, the catheter lumens were flushed with 0.9% sodium chloride and locked with a volume of 30%TSC solution exactly equivalent to the catheter internal lumen.
89186237|NCT02563041|Active Comparator|Heparin 5000 U/mL|After each hemodialysis (HD) session, the catheter lumens were flushed with 0.9% sodium chloride and locked with a volume of unfractionated sodium heparin 5000 U/mL solution exactly equivalent to the catheter internal lumen.
89186238|NCT00741663|Active Comparator|A|
89186239|NCT00741663|Experimental|B|
89186240|NCT00745017|Experimental|1|
89186241|NCT00745017|Experimental|2|
89186242|NCT00745017|Experimental|3|
89186243|NCT00688467|Experimental|Navarixin → Placebo|Navarixin 30 mg capsule to be taken once daily in the morning for 10 days in Treatment Period 1, followed by a 2-4 week washout period, followed by matching placebo capsule to be taken once daily in the morning for 10 days in Treatment Period 2
89186244|NCT00688467|Experimental|Placebo → Navarixin|Matching placebo capsule to be taken once daily in the morning for 10 days in Treatment Period 1, followed by a 2-4 week washout period, followed by navarixin 30 mg capsule to be taken once daily in the morning for 10 days in Treatment Period 2
89186245|NCT02562807|Active Comparator|Treatment A|TAS-303 18mg single-dose and then Placebo single-dose.
89389830|NCT01343225|Active Comparator|atripla|comparator
89389831|NCT01343225|Experimental|darunavir ritonavir raltegravir|experimental
89389832|NCT02063906||Breast cancer stage I-III|who received curative surgery for stage I-III breast cancer and had available data on immunohistochemistry profiles including hormone receptor status (HR) status, human epidermal growth factor receptor 2 (HER2) status, and Ki 67 staining at Samsung Medical Center from January 2004 to September 2008.
89389833|NCT01317251|Experimental|Control diet|Diet without dairy products
89389834|NCT01317251|Experimental|Milk diet|Diet with a high content of milk
89389835|NCT01317251|Experimental|Cheese diet|Diet with a high content of cheese
89389836|NCT05078333|No Intervention|exercise|All patients in all three groups will perform 15 sessions (for 3 weeks, weekdays), cervical area isometric strengthening exercises, active ROM exercises and stretching exercises for 15 minutes a day with the same physiotherapist.
89389837|NCT05078333|Active Comparator|exercise+HILT|In addition to the exercise program, randomly selected 36 case patients + HILT (BTL brand 6000 series, United Kingdom), to the cervical area, for the a period of 3 week-weekdays, 15-minute period and 15 sessions (1.02 minutes for each 25 cm² painful area, analgesic phase, with an anergy 8.0 W, a dose 5 J / cm², a frequency of 25 Hz and total 125 joules) will be applied.
89389838|NCT05078333|Active Comparator|exercise+dry needling|In addition to the exercise program, dry needling (on 3 trigger points on the bilateral trapezius muscle) will be applied to the other 36 randomly selected patients with an acupuncture needle with a size of 0.25x0.25 by the PMR specialist for a total of 6 sessions twice a week for 3 weeks.
89186246|NCT02562807|Placebo Comparator|Treatment B|Placebo single-dose and then TAS-303 18mg single-dose.
89389839|NCT04736511|Other|Healthy volunteers|Handball players
89389840|NCT05250635||Patients underwent thoracic surgery|Patients underwent thoracic surgery and general anesthesia with usage of DLET are included. Those patients with abnormal breath sound, pulmonary disease or history of cardiothoracic surgery are excluded.
89389841|NCT01370408|Experimental|Palonosetron|"All patients will receive the following medications prior to and during their high dose chemotherapy for autologous stem cell transplantation~Prior to IV chemotherapy - ondansetron 8mg IV & Dexamethasone 10 mg IV on the last day of chemotherapy - Palonosetron .25 mg IV, dexamethasone 10mg IV Day 1-2 after IV chemotherapy - Dexamethasone 8 mg PO"
89389842|NCT04769388|Experimental|Osimertinib 80 mg QD and platinum-based chemotherapy|Osimertinib 80 mg in combination with pemetrexed (500 mg/m2) plus carboplatin (AUC5) on Day 1 of 21day cycles (every 3 weeks) for up to 6 cycles, followed by Osimertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.
88865753|NCT04133142|Experimental|Early Repeated block|the patient will receive a regional anaesthesia by Inter fascial block, peripheral nerve block. The type of block would be the most appropriate to cover the dermatomes involved in the Herpes according to the mapping done with the higher ratio benefit risks. Local anesthetic used will be ropivacaine 0.5% dose according to the type of block and never exceeding 3mg/kg The choice of the block will be done by an anesthesiologist expert in regional anaesthesia techniques. The block will be repeated every 48h until the pain will reach VAS < 3 6 h after block recovery.
88865754|NCT04133142|Experimental|Late block single|"Patients receive the standard medical medication for herpes pain~Oral administration of Gabapentin~300 mg/d on day 1 and 2~600 mg/d on day 3 and 4 if pain persists~900 mg/d on day 5 and 6 if pain persists~Oral administration of Paracetamol up to 3 g per day at day 7 if pain more than VAS 4 the patient will receive a regional anaesthesia by Inter fascial block, peripheral nerve block . Local anesthetic used will be ropivacaine 0.5% dose according to the type of block and never exceeding 3mg/kg The type of block would be the most appropriate to cover the dermatomes involved in the Herpes according to the mapping done with the higher ration benefit risks. Choice of Block by an anesthesiologist expert in regional anaesthesia techniques. After the block performance if the pain comes back patient will receive the standard medical treatment as in the group medical treatment"
88865755|NCT04133142|Experimental|late block repeated|"Patients receive the standard medical medication for herpes pain~Oral administration of Gabapentin~300 mg/d on day 1 and 2~600 mg/d on day 3 and 4 if pain persists~900 mg/d on day 5 and 6 if pain persists~Oral administration of Paracetamol up to 3 g per day prescription for 7 day and continue for 3 weeks after evaluation At day 7 if pain more than VAS 4 the patient will receive a regional anaesthesia by Inter fascial block, peripheral nerve block. The type of block would be the most appropriate to cover the dermatomes involved in the Herpes according to the mapping done with the higher ratio benefit risks. Local anesthetic used will be ropivacaine 0.5% dose according to the type of block and never exceeding 3mg/kg The choice of the block will be done by an anesthesiologist expert in regional anaesthesia techniques. The block will be repeated every 48h until the pain will reach VAS < 3 6 h after block recovery."
88865756|NCT03956082|Other|This is a prospective single arm study|"The Ultravision™ System is an FDA-cleared medical device that removes surgical smoke by means of electrostatic precipitation from the visual field during laparoscopic surgical procedures. Surgical smoke refers to the suspended particulate matter that is generated as a by-product of the combustion and other processes that are associated with the use of energy-based surgical instruments."
88865757|NCT03538314|Experimental|Experimental Treatment|UV1/GM-CSF
89186247|NCT02562807|Active Comparator|Treatment C|TAS-303 9mg single-dose and then Placebo single-dose.
89186248|NCT02562807|Placebo Comparator|Treatment D|TAS-303 Placebo single-dose and then TAS-303 9mg single-dose.
89186249|NCT00745173|Other|1|
89186250|NCT00747045|Experimental|Low tidal volume|Tidal volume of 6 mL/Kg ideal body weight
89186251|NCT00747045|Active Comparator|Usual care|Tidal volume of 10 mL/Kg ideal body weight
89186252|NCT04060095||β1-adrenergic antagonists|Patients who have been treated for more than 3 months with β1-adrenergic antagonists
89389843|NCT04769388|Active Comparator|Osimertinib 80mg QD|All patients randomized into this will only receive Osimertinib 80mg.
89389844|NCT01345565|Experimental|Hepatocyte Transplantation|See Below
89186253|NCT02562885|Experimental|Acoustic pulses|"During NREM sleep:~15 minutes without acoustic pulses~15 minutes with acoustic pulses~15 minutes without acoustic pulses~Two different protocols are applied:~(A) tone application at the Down-phase of sleep slow wave (SSW) (B) tone application at the Up-phase of SSW.~Participants with Rolandic epilepsy/BECTS or generalized spike waves: Protocol A and B alternatingly.~Participants with ESES/CSWS: only Protocol A."
89186254|NCT00745329||2|"patients~healthy volunteers"
89389845|NCT03294109|Experimental|study|liposomal bupivacain
89389846|NCT03294109|No Intervention|control|no intervention
88865758|NCT03233802|Experimental|Individualized Assess & Treatment (IATP)|Intervention: Cognitive-Behavioral IATP consists of 12 weekly visits of individual treatment. IATP employs cellphone-based experience sampling via interactive voice response (IVR) to assess drinking, plus craving, thoughts, feelings, and coping behaviors to develop near a real-time picture of patients' high-risk situations and the ways they use to deal with them. This information will be used by the therapist and client together to problem-solve and devise adaptive coping responses to these specific high-risk situations, and develop generalized solutions to deal with other situations in the future.
88865759|NCT03233802|Active Comparator|Packaged Cognitive-Behavioral (PCBT)|Intervention: Cognitive-Behavioral PCBT consists of 12 weekly visits of individual treatment. PCBT is designed to remediate deficits in skills for coping with interpersonal (e.g., social pressure, conflict with others) and intrapersonal (e.g., craving, anger) antecedents to drinking. The treatment consists of 6 mandatory modules (e.g., managing cravings) plus 6 electives from a list of 10 (e.g., receiving criticism; scheduling pleasant activities).The treatment, based on manuals developed for our previous clinical research provides a structured experience using didactic presentations, behavioral rehearsal, and homework practice exercises.
89389847|NCT01345643|Experimental|Hemoglobin level based on WCPT Score|According to WCPTS, the patient's hemoglobin level will be maintained not less than 7,8,9,or 10g/dL. Determination of whether a patient need red blood cells transfusion is based on WCPT Score.
89389848|NCT01345643|Active Comparator|Hemoglobin level 100g/L|The patient's hemoglobin level is maintained not less than 10g/dL perioperatively.
89389849|NCT03517488|Experimental|XmAb20717|XmAb20717 administered by intravenous dosing on Days 1 and 15 of each 28-day cycle for a total of two cycles
89389850|NCT04727931||Newly diagnosed epileptic patients|Newly diagnosed epileptic patients who have never be treated by antiepileptic drugs and who have no psychiatric (mental illness) and/or evolutive neurological history and for minor patients the non-opposition of the parental authority holders.
89389851|NCT04727931||Normal controls|Matched (on age, gender, socio-educationnal level and manual laterality) healthy controls who have no psychiatric (depression, mental illness) and/or neurological (stroke, traumatic brain injury, etc.) history and for minor patients the non-opposition of the parental authority holders.
89389852|NCT02065466|Experimental|Combination|nab-paclitaxel and temozolomide combined with full dose of bevacizumab
89389853|NCT01358773|Other|Lifestyle counseling|Obese adolescents are encouraged to improve their lifestyle
89389854|NCT03970811|Experimental|Immediate implants with immediate temporization|Immediate implants with simultaneous immediate placement of temporary crown and placement of the final restoration (loading) will be done 3 months postsurgical
89389855|NCT03970811|Active Comparator|Immediate implants without temporization|Immediate implants without the use of temporary crown and placement of the final restoration (loading) will be done 3 months postsurgical
88865760|NCT03233802|Active Comparator|Case Management (CaseM)|Intervention: Social and Instrumental Support CaseM is included to control for cohort and other common factors in treatment. During the 12 individual CaseM sessions the therapist and participant will identify problems in daily living that may be of concern, and consider community resources that might help in dealing with them (e.g., contacting a psychiatrist for depression, or finding a better place to live). The therapist's role is to explore the patient's concerns, help to identify goals and resources, provide verbal support, and troubleshoot difficulties that may arise in obtaining or following through with services. The support and attention to ancillary services has proven effective in reducing drinking in previous studies.
89389856|NCT01350895||Experimental Group|
88865761|NCT03063450|Experimental|Nivolumab|Nivolumab 240mg flat dose Q2W over 30 minutes IV until disease progression, to a maximum of 12 months
88865762|NCT03063450|Placebo Comparator|Placebo|Sterile 0.9% sodium chloride Q2W over 30 minutes IV until disease progression, to a maximum of 12 months
88865763|NCT02882646|Experimental|Stroke/CP survivors & healthy subjects|"Part A: Stroke and CP survivors greater than 18 years of age with hemiplegia and varying levels of impairment. The subject's stroke must have occurred at least 3 months prior to enrollment in the study. Healthy persons over the age of 18 with no upper limb impairment.~Part B: Low to mid functioning CP and stroke survivors greater than 18 years of age with hemiplegia. The subject's stroke must have occurred at least 3 months prior to enrollment in the study. All will be asked to use the Bi-ADLER system."
88865764|NCT01436292|Experimental|Albumin|Patient will receive 5% HAS daily for the first 7 days of stay in ICU according to their albumin level
88865765|NCT01326000|Experimental|KRAS WT A|
89186255|NCT00741897|Experimental|1|Fexofenadine
89186256|NCT00688155|Experimental|Physical Activity Training|The Physical Activity Training ((PAT) intervention consisted of center-based and home-based sessions comprised of aerobic, strength, flexibility, and balance training with a targeted duration of 150 mins/wk.
89389857|NCT01350895||Control Group|
89186257|NCT00688155|Experimental|Cognitive Training|The Cognitive Training (CT) intervention was developed to improve consciously-controlled memory processing or recollection of episodic memory information.
89389858|NCT02064062|Experimental|Autologous Mesenchymal Stem Cells|
89389859|NCT03963869|Experimental|Arm A: New Malaria Camp (MC) village|"Receives MC intervention in year 1 and year 2.~Each individual will be followed up 3 times (baseline and follow-ups 1, 2, and 3; 4 visits per individual) in the 2 year time frame of phase 1."
89389860|NCT03963869|Active Comparator|Arm B: No Malaria Camp (MC) village|"Receives Standard Malaria Control in Year 1 and MC intervention in Year 2.~Each individual will be followed up 3 times (baseline and follow-ups 1, 2, and 3; 4 visits per individual) in the 2 year time frame of phase 1."
89389861|NCT03963869|Active Comparator|Arm C: Old Malaria Camp (MC) village|"Villages already in receipt of MCs prior to study initiation to study longer term effects.~Each individual will be followed up 3 times (baseline and follow-ups 1, 2, and 3; 4 visits per individual)) in the 2 year time frame of phase 1."
89389862|NCT05208801|Sham Comparator|Control|a sham procedure of 2 ml of 1% lidocaine injected percutaneously using the initial 25G needle
89389863|NCT05208801|Active Comparator|Morphine|
89389864|NCT05208801|Experimental|Morphine+bupivicaine|
89389865|NCT03614598|Active Comparator|LMA-UNIQUE™|
89389866|NCT03614598|Active Comparator|LMA-SUPREME™|
89389867|NCT03614598|Active Comparator|I-GEL®|
89389868|NCT02064140|Experimental|Neuromuscular blocking agent|
89186258|NCT00688155|Experimental|Combined Intervention|"The Combined Intervention (PACT) was designed so that participants received both cognitive and physical activity training on the same day.~."
88865766|NCT01326000|Active Comparator|KRAS WT B|
88865767|NCT01326000|Experimental|KRAS mutant A|
88865768|NCT01326000|Active Comparator|KRAS mutant B|
88865769|NCT00807456|Experimental|Subjects treated with ASTRA TECH Implant System, OsseoSpeed™ Profile implant|
88865770|NCT03035526||3161 men (45-84 years old)|3161 men without known coronary artery disease
88865771|NCT03035136||Patients with colorectal lesions|Patients with a full colonoscopy that showed either a cancer or a polyp.
88865772|NCT03035136||Patients without colorectal lesions|Patients with a full colonoscopy that showed no polyps.
88865773|NCT03035214|Other|Prevention of dysplasia through steroids|Failure of lung tolerance to oxygen reduction will be defined as oxygen saturation 80 to 87% for 5 minutes, or <80% for 1 minute, then inspired oxygen will be increased back to the base line. This will be considered as an early predictor of evolving bronchopulmonary dysplasia. If there is no hypoventilation, dexamethasone will be given 0.25 mg/ kg/ d divided twice for 5 days intravenous.
89186259|NCT00688155|Active Comparator|Healthy Aging Education|The Healthy Aging Education control intervention consisted of weekly lectures based on health education.
89186260|NCT00741975|Experimental|1|Affect Management
89186261|NCT00741975|Active Comparator|2|General Health Promotion
89186262|NCT00745407|Experimental|fenofibrate 160 mg, placebo|
88865774|NCT03035370|Experimental|Viaskin PT 25 mcg|Viaskin PT 25 mcg
88865775|NCT03035370|Experimental|Viaskin PT 50 mcg|Viaskin PT 50 mcg
88865776|NCT03035370|Placebo Comparator|Viaskin PT Placebo|Viaskin PT Placebo
89186263|NCT00745485|Experimental|Zoldronic|
89186264|NCT02562729|Experimental|Nerve-Sparing Radical Hysterectomy (NSRH)|Type C1 Hysterectomy
89389869|NCT03963011|No Intervention|Arm A: AXR Only|Infants randomized to Arm A will obtain an abdominal x-ray (AXR) as per standard of care
89389870|NCT03963011|Active Comparator|Arm B: AXR + Bowel US|Infants randomized to Arm B will obtain an abdominal x-ray (AXR) as per standard of care and a bowel ultrasound (BUS) as the intervention
88865777|NCT03035058|Experimental|Vedolizumab IV 300 mg Q4W|Vedolizumab 300 mg, intravenous (IV), once at Day 1 and Week 2; followed by vedolizumab 300 mg, IV, once every 4 weeks (Q4W) starting from Week 6 to Week 102.
88865778|NCT03035058|Experimental|Vedolizumab IV 300 mg Q8W + Placebo|Vedolizumab 300 mg, IV, once at Day 1 and Week 2; followed by vedolizumab 300 mg, IV, once every 8 weeks (Q8W) starting from Week 6 to Week 102 (and placebo, IV, Q8W starting from Week 10 to Week 98.
88865779|NCT03035058|Placebo Comparator|Placebo|Vedolizumab placebo-matching, IV, at Day 1 and Week 2; followed by Vedolizumab placebo-matching, IV, Q4W starting from Week 6 to Week 102.
88865780|NCT03034824|Experimental|Scaling and root planing (SRP)-Control|Only non-surgical initial periodontal treatment (scaling and root planing)
89389871|NCT03628755|Active Comparator|Digital Manipulation|Digital manipulation of thyroid cartilage (DMT) Duration: Each child was given 15-20 minute session. Frequency: Twice in a week. Total 24 sessions were performed. The aim of DMT was to reduce the severity of stuttering and improve the fluency.
89389872|NCT03628755|Active Comparator|fluency shaping Therapy|"Fluency Shaping Therapy Duration:Each child was given 30-minute session. Fluency Shaping Therapy (FST) Frequency: Twice in a week Total 24 sessions were performed.~The aim of DMT was to reduce the severity of stuttering and improve the fluency"
89389873|NCT03628755|Experimental|combination Group|Combination Group (DMT+FST) Duration:Each subject was given 45-Minute session Frequency: Twice in a week Total 24 sessions were performed combination group was more significant option for reducing the severity of stuttering and improve fluency than practice the single DMT or FST
89389874|NCT02065544|Experimental|behavioral weight loss and exercise|weight loss and exercise lifestyle intervention over a 6 month period
89389875|NCT01355107||chronic hcv, no liver cirrhosis, no HCC|patients with chronic hepatitis c- infection: no cirrhosis of the liver (= Desmet IV), no HCC - suspected lesion in the liver
89389876|NCT01355107||chronic hcv, liver cirrhosis, no HCC|patients with hcv- associated cirrhosis of the liver, but with no HCC - suspected lesions in the liver
89389877|NCT01355107||hcv-infection, HCC|patients with hcv- associated HCC
89389878|NCT05190627|Experimental|Loratadine treatment on rapamycin|Loratadine (oral administration, daily dose 10mg) in LAM patients that are treated with rapamycin
89186265|NCT00745563|Experimental|A|
89389879|NCT05190627|Placebo Comparator|Placebo treatment on rapamycin|Placebo (oral administration, daily dose 10 mg) in LAM patients that are treated with rapamycin
89389880|NCT02064218||Hypertensive patients|Hypertensive patients naive to hypertensive treatment
89389881|NCT02064218||healthy subjects|healthy subjects
89389882|NCT01345799|Experimental|TRK-170 Low Dose|
88865781|NCT03034824|Experimental|SRP+940±15 nm diode laser|In addition to non-surgical initial periodontal treatment (scaling and root planing), individuals received 940±15 nm Diode laser
88865782|NCT03034824|Experimental|SRP+Er,Cr:YSGG laser|In addition to non-surgical initial periodontal treatment (scaling and root planing), individuals received Er,Cr:YSGG laser
89186266|NCT00742131|Experimental|Subjects receiving GSK1363089|Eligible subjects will receive GSK1363089 administered orally as a cinnamon-flavored liquid or as solid capsules with the starting dose for cohort 1 as 0.1 milligram/kilogram. Subjects in cohorts 1, 2, and 3A will receive GSK1363089 in the liquid formulation, while Cohorts 3B, 4, 5, 6, 7, and 8 will receive GSK1363089 in the solid capsule formulation.
89186267|NCT00747201|Active Comparator|2 Packaged intervention only|Patients will be seen by providers who receive the intervention package only.
89186268|NCT00747201|Experimental|1 Packaged intervention, training, and technical assistance|Patients will be seen by providers who receive the packaged intervention, along with provider training and ongoing technical assistance.
89186269|NCT00745641||1|Sixty patients with abdominal illness and scheduled abdominal X-ray computed tomography examination will be included.
89186270|NCT02563665||advanced chronic kidney disease|Subjects on dialysis with GFR (Glomerular Filtration Rate) > 30
88865783|NCT03034746|Experimental|Alzheimer's Disease (G1)|(G1) physical activity (PA)
88865784|NCT03034746|Experimental|Alzheimer's Disease (G2)|(G2) cognitive treatment (CT)
88865785|NCT03034746|No Intervention|Healthy Old Subjects (G1)|Control group old
88865786|NCT03034746|No Intervention|Healthy young Subjects (G2)|Control group young
88865787|NCT03034980||Coronary Artery Disease (CAD) patients|Patients with proven coronary artery disease, who underwent the full cardiac revalidation program at Jessa Hospital from 10-1-2013 till 12-9-2016.
88865788|NCT03034434||Patients after vaginal delivery|Patients after vaginal delivery willing to undergo 3 trans-vaginal ultrasounds within the 48 hours after delivery.
88865789|NCT03034668|Experimental|CS16-003 Full dose|350 mg capsule QD Rhodiola rosea L. & Rhaptonticum carthamoides extracts
89186271|NCT02563665||Renal replacement therapy.|Subjects who are not on dialysis with GFR (Glomerular Filtration Rate) < 15
89186272|NCT02563509|Experimental|HIV-specific CD8 cells|Transfusing HIV-specific CD8 cells 50-100mlonce a week for four times.
88865790|NCT03034668|Experimental|CS16-003 Half dose|175 mg capsule QD 50% Rhodiola rosea L. & Rhaptonticum carthamoides extracts + 50% Maltodextrin
88865791|NCT03034668|Placebo Comparator|Placebo|Maltodextrin
88865792|NCT03034278||Post surgery patients|Patients prescribed with opioid analgesic medications following surgery.
88865793|NCT03033810||Consecutive patients with FFR and iFR|Patients with stable angina pectoris with suitable for coronary angiography will be suitable for the study
88865794|NCT03033654|Experimental|Intervention|Two Consecutive Sunscreen Applications
88865795|NCT03033732|Other|Methadone|Opioid agonist treatment for opioid use disorder. Ingested in liquid oral form via strict initial daily witnessed ingestion as per local guidelines.
88865796|NCT03033732|Other|Buprenorphine/Naloxone|Opioid agonist treatment for opioid use disorder. Ingested orally via sublingual tablet form, flexible take home dosing.
89186273|NCT02563509|No Intervention|Regualar therapy|Only receiving Highly active anti-retroviral therapy(HAART).
89186274|NCT00747279|Experimental|1|Carbohydrate restrictive strategy
89186275|NCT00747279|Active Comparator|2|Intensive insulin therapy
89186276|NCT00747357|Experimental|1|Balloon first
89186277|NCT00747357|Experimental|2|Stent First
89186278|NCT00747513|Experimental|I|intervention group
89389883|NCT01345799|Experimental|TRK-170 Middle Dose|
89389884|NCT01345799|Experimental|TRK-170 High Dose|
89389885|NCT01345799|Placebo Comparator|Placebo|
89389886|NCT03614520|Experimental|Sub-study A : olive oil, wine, both, or water (placebo).|After being selected, subjects will do 4 experimental sessions (each separated by 3 days minimum) in which ones they will drink olive oil, red wine, red wine and olive oil, or water (placebo). The order of the experimental sessions will be drawn.
89389887|NCT03614520|Experimental|Sub-study B : three types of beer, and wine|The subjects will do 4 experimental sessions (each separated by 3 days minimum) in wich ones they will drink a beer (250mL) or wine (150mL). The order of the experimental sessions will be drawn.
89389888|NCT01358851|Experimental|1|Drug Las41005
89389889|NCT01358851|Other|2|Cryotherapy
89389890|NCT02065778|Experimental|Stem Cells|autologous bone marrow mononuclear cell transplantation
89389891|NCT03619941|Placebo Comparator|Placebo|
89389892|NCT03619941|Experimental|Montmorency Tart Cherry Juice|
89389893|NCT01343303|Experimental|001|JNJ-39439335 2 x 5 mg tablets once daily for 21 days
89389894|NCT01343303|Experimental|002|JNJ-39439335 2 x 25 mg tablets once daily for 21 days
89389895|NCT01343303|Other|003|Naproxen 500 mg capsule every 12 hours for 21 days
89389896|NCT01343303|Placebo Comparator|004|Placebo Placebo tablet/capsule every 12 hours for 21 days
89389897|NCT01351051||No endometriosis|
89389898|NCT01351051||Superficial endometriosis|
89186279|NCT00745719|Experimental|1|surgical total parathyroidectomy with forearm autografting
89186280|NCT00745797|Experimental|Prophylactic WBRT|Take the whole brain radiotherapy radiotherapy
89186281|NCT00745797|No Intervention|Observer Group|The first 14 days after randomization and patient follow-up after 1 month to complete the FACT-L questionnaire and the MMSE scale.
89186282|NCT00742287|Placebo Comparator|1|placebo
89186283|NCT00742287|Active Comparator|2|200 mg oligomeric proanthocyanidins (MASQUELIER'S Original OPCs)
89186284|NCT00742365||A|Participants will be given a 1-hour lab test of bright light treatment, then the bright light treatment for 6 weeks.
89389899|NCT01351051||Endometrioma|
89389900|NCT01351051||Deep infiltrating endometriosis|
89389901|NCT03614442|Experimental|slopped shoulder implant|The osteotomy site will be prepared using appropriate drill sizes with flapless approach, The implant (conventional neck implant design )will be inserted till the platform will be flushed with the crestal bone, The primary stability will be checked using torque wrench
88865797|NCT03033498|Experimental|ABBV-951 Dose 1|Participants will receive dose 1 of ABBV-951.
89389902|NCT03614442|Active Comparator|conventional implant with flat platform|inserted implant will be bone leveled implant (crestal maxi z) implant (conventional implant with platform). The primary stability will be checked using torque wrench
88865798|NCT03033498|Experimental|ABBV-951 Dose 2|Participants will receive dose 2 of ABBV-951.
88865799|NCT03033498|Experimental|ABBV-951 Dose 3|Participants will receive dose 3 of ABBV-951.
88865800|NCT03033498|Experimental|ABBV-951 Dose 4|Participants will receive dose 4 of ABBV-951.
88865801|NCT03033498|Experimental|ABBV-951 Dose 5|Participants will receive dose 5 of ABBV-951.
88865802|NCT03033498|Experimental|ABBV-951 Dose 6|Participants will receive dose 6 of ABBV-951.
88865803|NCT03033498|Experimental|ABBV-951 Dose 7|Participants will receive dose 7 of ABBV-951.
88865804|NCT03033498|Experimental|ABBV-951 Dose 8|Participants will receive dose 8 of ABBV-951.
88865805|NCT03033888|Other|Intervention Group|Intervention includes: Trained community health workers will deliver 1) 1.5-2 hour health literacy training offered in a group format at an approved community site that is most convenient to the majority of participants ; and 2) monthly phone follow-up and navigation assistance for 6 months. We will offer a Human Papilloma Virus (HPV) mobile app for participant's adolescent/young adult child (11-26 yrs), as an option rather than part of the standardized protocol. The app will be introduced at the end of the health literacy group training session for the intervention group; those who choose to download the app will be given a link with study specific password. They will be encouraged to go through the key HPV related contents with their children at home at a time that is most convenient for them.
88865806|NCT03033888|No Intervention|Control Group|
88865807|NCT03033264|Experimental|BMI>30+Dinoprostone|Women with a BMI>30 at term that will be induced for obstetrical indications with 10 mg of a Dinoprostone vaginal insert.
89186285|NCT00742365||B|Participants will be given a 1-hour treatment of the red light placebo, then the bright light treatment for 6 weeks.
89186286|NCT00690573|Experimental|Adalimumab|
89186287|NCT00742443|Other|1|Active versus Placebo within patient
89186288|NCT00742443|Other|2|Active vs. Placebo within patient
89186289|NCT00742443|Other|3|Active vs. Active within patient
89389903|NCT04418115|Experimental|Acupuncture + usual care|Participants randomized to acupuncture treatment will receive 12 acupuncture treatments during 8-12 weeks.
89389904|NCT04418115|No Intervention|Usual care|"Our control group will receive business as usual. Hence, they will continue with their usual care for their CRF. By inclusion in the study and by the end of it, the participants in the control group will fill in the requested and similar instruments as the participants in the acupuncture group. Further, we will document any medical care they have received during the study period. This includes also life styles advice, and to which point they have followed such advices."
88865808|NCT03033264|Experimental|BMI<30+Dinoprostone|Women with a BMI<30 at term that will be induced for obstetrical indications with 10 mg of a Dinoprostone vaginal insert.
88865809|NCT03033264|Experimental|BMI>30+Cervical ripening balloon|Women with a BMI>30 at term that will be induced for obstetrical indications with a double lumen cervical ripening balloon.
88865810|NCT03033264|Experimental|BMI<30+Cervical ripening balloon|Women with a BMI<30 at term that will be induced for obstetrical indications with a double lumen cervical ripening balloon.
88865811|NCT03033030||Tomosynthesis|Patients undergoing Digital Breast Tomosynthesis
89186290|NCT00719264|Experimental|bevacizumab, RAD001 (everolimus)|Participants received oral everolimus 10 mg qd plus intravenous bevacizumab 10mg/kg every 2 weeks
89186291|NCT00719264|Active Comparator|bevacizumab, interferon alfa-2a (IFN)|Participants received subcutaneous IFN dose escalated from 3 MIU (million international unit) during week 1, 6 MIU during week 2, and 9 MIU during week 3 of treatment and subsequently (if tolerated), 3 times per week plus intravenous bevacizumab 10 mg/kg every 2 weeks
89186292|NCT00749151|No Intervention|Literature|
89186293|NCT00749151|Experimental|Lit + Counseling|
89186294|NCT00687609|Experimental|Atomoxetine|0.5 milligrams per kilogram (mg/kg) daily for 1 week followed by 1.2 mg/kg daily for 11 weeks, orally, capsules.
89186295|NCT00742521|Active Comparator|1|Euglycemic glucose clamp procedure x 2 on Day 1 and hypoglycemic glucose clamp procedure on Day 2. Control study
89389905|NCT01343381|Active Comparator|Hepalean Heparin|
89389906|NCT01343381|Active Comparator|PPC Heparin|
88865812|NCT03033186||Everolimus (afinitor)|Patients using everolimus as therapy for cancer: Advanced (Hormone-Receptor [HR]-positive, HER2-negative) breast cancer (BC), advanced or unresectable neuroendocrine tumours of pancreatic (pNET), gastrointestinal or lung origin and metastatic renal cell carcinoma (mRCC)
88865813|NCT03032874||Training set|All the patients with rectal bleeding who had colonoscopy performed at Obafemi Awolowo University Teaching Hospitals Complex
88865814|NCT03032874||Validation set|All the patients with rectal bleeding who had colonoscopy performed at University College Hospital, Ibadan and University of Ilorin Teaching Hospital
88865815|NCT03032952|Experimental|"Feel Stress Free"|"Access to the Feel Stress Free mobile application intervention for 12 weeks. Instructed to use it at least once per week for 15 minutes, for the first 6 weeks, then given free access thereafter."
88865816|NCT03032952|No Intervention|Wait list control|Given access to the intervention at the end of the 12 weeks of the trial.
88865817|NCT03032796|Experimental|BBT|Body-Brain Trainer
88865818|NCT03032796|Active Comparator|Body Trainer|Participants will only perform a basic reaction task in each level/module to ensure only the most minimal cognitive challenge is present, while completing all of the physical aspects of BBT. Thus this will be a physical training protocol.
88865819|NCT03032796|Active Comparator|Brain Trainer|"The Brain Trainer group will train using the same platform as the BBT group, except while sitting down and playing with an Xbox control pad (thus removing all physical training aspects)."
88865820|NCT03032796|Placebo Comparator|Expectancy Matched Control Group|The placebo-matched control group will engage in a battery of three apps in the laboratory that we believe will have no significant impact on cognition
88865821|NCT03032562||1|Patients with neuromuscular disease
88865822|NCT03032562||2|Patients with chronic obstructive pulmonary disease
88865823|NCT03032718|Experimental|Intervention|Patients in the intervention group will receive a defined exercise program twice a week in addition to their usual treatment. Training sessions start immediately after randomization and will be supervised by trained sport students. They will take place twice a week, for twelve weeks in specific training rooms designed to meet the needs of oncological patients in the respective centers. The vibration exercises will take place on a side-alternating vibration platform (GalileoTM, Pforzheim, Germany) ®) according to the previously determined optimal (highest neuromuscular response) setting for each individual. Each session will last for about 15 to 30 minutes, leaving sufficient time for regeneration. Training will consist of four vibration exercises, chosen from a standardized pool of exercises with increasing difficulty in order to allow for individual, optimal progression. All sessions will be documented by the supervisor.
88865824|NCT03032718|No Intervention|Control|Patients in the control group will receive treatment as usual and will be given the opportunity to participate in the intervention after completion of the study.
88865825|NCT03032094|Active Comparator|1mm thick graft|connective tissue graft of 1mm thickness
88865826|NCT03032094|Active Comparator|2mm thick graft|connective tissue graft of 2mm thickness
88865827|NCT03032016||sVOD patient treated with defibrotide|Patient diagnosed with severe hepatic VOD and treated with defibrotide
88865828|NCT03031704||Endoscopic mucosectomy|
88865829|NCT03031548||ultrasound exam|Child undergoing procedure in CVL requiring ETT and CXR as standard of care - received point-of-care ultrasound exam as part of the study
88865830|NCT03031314|Active Comparator|Standard suture|standard suture used (monocryl)
88865831|NCT03031314|Active Comparator|Barbed suture|barbed suture used (Quill suture, Surgical Specialties)
88865832|NCT03031158|Experimental|SFEX+H|Participants will receive an intervention consisting of heat to the low back, manual therapy to the hip (including movement of the hip by the therapist), hip-focused strengthening exercises and a trunk muscle training program including exercises for the abdominal and low back muscles.
88865833|NCT03031158|Active Comparator|SFEX|Participants will receive an intervention consisting of heat to the low back, manual therapy to the hip (including movement of the hip by the therapist) and a trunk muscle training program including exercises for the abdominal and low back muscles.
88865834|NCT03031470|Experimental|Reparixin|Reparixin 2.772 mg/kg/hour 168 hrs continuous intravenous infusion
88865835|NCT03031470|Other|Standard Care Procedures|No treatment; standard care procedure
88865836|NCT03031080|Active Comparator|Splinted|Patients will be given Thermoplastic Hand Splint to wear overnight for 12 weeks.
89186296|NCT00742521|Active Comparator|2|Hypoglycemic glucose clamp procedure x 2 on Day 1 and hypoglycemic glucose clamp procedure on Day 2. Control study
88865837|NCT03031080|No Intervention|Un-Splinted|Patients will not wear a night splint
88865838|NCT03031002|Experimental|Exposure Treatment|Participants of this arm receive two 60-minute sessions of exposure treatment for spider fear
88865839|NCT03031002|No Intervention|No Exposure Treatment|Participants of this arm receive no exposure or other adequate treatment
88865840|NCT03030768||HIV-1 serodiscordant couples|Couples where one partner is HIV-1 infected and the other is uninfected, who will receive counseling on timed condomless sex, ART and PrEP adherence. The study intervention focuses on ART use by the HIV-1 infected partner, PrEP (Truvada) use by the HIV-1 uninfected partner, and timed condomless sex during the peri-conception period.
88865841|NCT03030846|Experimental|stabilization exercises|stabilization exercises for 6 weeks, 3 sessions per week and each session was 40 minutes for the training group.
88865842|NCT03030846|Experimental|control group|electrotherapy include of 20 minutes TENS conventional and Ultrasound pulse for 10 minutes without any exercises for the control group.
88865843|NCT03030690|Experimental|Glass Carbomer Cement|GCP Glass Fill, Glass Carbomer™Tech, Ridderkerk, Netherlands
88865844|NCT03030690|Active Comparator|Resin Modified Glass Ionomer Cement|GC Fuji II LC Capsule, GC International, Tokyo, Japan
88865845|NCT03030690|Active Comparator|Composite Resin|Filtek Z250, 3M ESPE, St Paul, MN, USA
88865846|NCT03030456|No Intervention|Control Group|Elderly women receiving a list of general health orientations through an 8 week period
88865847|NCT03030456|Experimental|Power Plate®|Power Plate®: training of elderly women
88865848|NCT03031392||Peri-implantitis|Individuals with implants ≥2mm of radiographic bone loss
88865849|NCT03031392||non-peri-implantitis patients|Individuals with implants <2mm of radiographic bone loss
89389907|NCT03620149|Experimental|Denosumab|denosumab at reduced dose
89389908|NCT02064686|No Intervention|TAE|
89186297|NCT00742521|Active Comparator|3|Euglycemic glucose clamp procedure x 2 with cortisol infusion of 2ug/kg on Day 1 and hypoglycemic glucose clamp procedure on Day 2.
89186298|NCT00742521|Active Comparator|4|Hyperinsulinemic euglycemic glucose clamp procedure x 2 with cortisol infusion at 1 ug/kg on Day 1 and hyperinsulinemic hypoglycemic glucose clamp procedure on Day 2.
89186299|NCT00751959|Active Comparator|2|Conventional therapy with intubation, initiation of mechanical ventilation and surfactant application
89186300|NCT00751959|Experimental|1|Surfactant application via a thin endotracheal catheter during spontaneous breathing with CPAP, followed by respiratory support with CPAP
89186301|NCT00723554|Experimental|Iloprost|"The study enrolled patients who were already using iloprost with PD-6 without any safety or tolerability concerns, thereby facilitating a direct comparison of the PD-15 to the PD-6.~The single-arm design allowed each patient to serve as his/her own control"
88865850|NCT03031236|Active Comparator|ECD+|Behavioral: Psychosocial stimulation, Cognitive behavioral therapy and positive parenting practice The mothers of intervention (ECD+HN) group will receive fortnightly group sessions for 12 months that will include combined messages on a) psychosocial stimulation, b) positive parenting to prevent child maltreatment and c) cognitive behavioural therapy (CBT) for positive thinking, d) health and nutrition messages and e) 15 micronutrient sprinkle supplement.(90 sachets of over 6 month-period)
88865851|NCT03031236|No Intervention|Only regular health messages|Only regular health message from government health services
88865852|NCT03030144|No Intervention|Control group|Routine nursing care
88865853|NCT03030144|Other|Intervention group|Evidence based nursing recommendations for the management of urinary incontinence will be introduced.
88865854|NCT03030300|Experimental|Novolin 30R;Pioglitazone;Metformin|Drugs: Insulin (Novolin 30R) monotherapy or combined with one or two oral drugs (metformin 0.5 mg tid and pioglitazone hydrochloride 15 mg qd).
88865855|NCT03029286|Experimental|Personalized Web Intervention Arm|Women will be assigned to view a tailored website featuring their personalized risk information for breast cancer related to breast density and other factors.
88865856|NCT03029286|Active Comparator|Usual Care Arm|Women will be assigned to view a website that will take them to the American Cancer Society website to view general risk information for breast cancer related to breast density.
88865857|NCT03027492|Active Comparator|1. NCWS retrospective patients|The clinical charts of NCWS female patients attending the outpatient centers of the Department of Internal Medicine at the University Hospital of Palermo and the Department of Internal Medicine of the Hospital of Sciacca will be reviewed with a retrospective method. They had all been diagnosed with NCWS between January 2001 and June 2011 and included in a previously published study. These charts included specific sections for associated gynaecological disorders. Incomplete clinical charts will be excluded. All the patients will be evaluated at baseline (i.e. at diagnosis) and after at least a 6-months period of gluten-free diet.
89186302|NCT00687219|Experimental|Peginterferon alfa-2b + Ribavirin|
89186303|NCT02562105||Mechanical ventilation|requiring mechanical ventilation at admission to ICU for one day or more during the study period
88865858|NCT03027492|Active Comparator|2. CD retrospective control patients|To compare the presence and characteristics of gynaecological disorders in NCWS female patients, a control group of CD female patients had been randomly chosen by a computer-generated method from female patients diagnosed during the same period (2001-2011) and age- (+2 years) matched with the NCWS female patients. Similar to NCWS patients, also this control group was asked for gynaecological disorders and the answers reported in the patients clinical charts. All the patients will be evaluated at baseline (i.e. at diagnosis) and after at least a 6-months period of gluten-free diet.
88865859|NCT03027492|Active Comparator|3. IBS retrospective control patients|To compare the presence and characteristics of gynaecological disorders in NCWS female patients, a control group of IBS female patients had been randomly chosen by a computer-generated method from female subjects diagnosed during the same period (2001-2011) and age- (+2 years) matched with the NCWS female patients. Similar to NCWS patients, also this control group was asked for gynaecological disorders and the answers reported in the patients clinical charts. All the patients will be evaluated at baseline (i.e. at diagnosis) and after at least a 6-months period of gluten-free diet.
88865860|NCT03027492|Active Comparator|4. NCWS prospective patients|The investigators prospectively will survey adult female patients with functional gastroenterological symptoms according to the Rome III criteria, and a suspected diagnosis of NCWS. The patients will be recruited between January 2017 and January 2018 at the same 2 centers. Most of the patients will be referred owing to gastrointestinal and extraintestinal symptoms, the onset of which, they reported, could be related to wheat ingestion. In addition, patients will be asked about the presence and characteristics of gynaecological disorders using an ad hoc questionnaire. All the patients will be evaluated at baseline (i.e. at diagnosis) and after at least a 6-months period of gluten-free diet.
89186304|NCT00749229|Other|1|Balloon kyphoplasty
89186305|NCT04085120|Experimental|Ropivacaine/dexamethasone group|3ml of 0.75% ropivacaine and 1ml of 4mg/l dexamethasone will be injected.
89186306|NCT04085120|Experimental|10% lignocaine injection group|4 ml of 10% lignocaine
89186307|NCT00749307|Experimental|1|
89186308|NCT00749307|Placebo Comparator|2|
89186309|NCT02562573|Experimental|PBI4050|Four 200 mg capsules (total 800 mg) administered orally, once a day.
89186310|NCT02562183|Experimental|kallikrein group|Subjects receive kallikrein treatment according to real clinical practice (suggest above 14days treatment),0.15 peptide nucleic acids(PNA), once a day.
89189433|NCT05809960|Experimental|Investigation Group|"Education was given, which was prepared in line with the Roy Adaptation Theory and considering the literature, including the problems experienced in menopausal periods and the approaches used to cope with them. The progressive relaxation exercise was explained and taught to the women and the first application was provided with the instructions. Menopause and Life booklet prepared in line with Roy Adaptation Theory was given to support the education given and to remember the information afterwards."
88865861|NCT03027492|Active Comparator|5. CD prospective control patients|To compare the presence and characteristics of gynaecological disorders in NCWS female patients, a control group of CD female patients will be randomly chosen by a computer-generated method from female subjects diagnosed during the same period (2017-2018) and age- (+2 years) matched with the NCWS female patients. Similar to NCWS patients, also this control group will be asked for gynaecological disorders and the answers reported in the patients clinical charts. All the patients will be evaluated at baseline (i.e. at diagnosis) and after at least a 6-months period of gluten-free diet.
88865862|NCT03027492|Active Comparator|6. IBS prospective control patients|To compare the presence and characteristics of gynaecological disorders in NCWS female patients, a control group of IBS female patients will be randomly chosen by a computer-generated method from female subjects diagnosed during the same period (2017-2018) and age- (+2 years) matched with the NCWS female patients. Similar to NCWS patients, also this control group will be asked for gynaecological disorders and the answers reported in the patients clinical charts. All the patients will be evaluated at baseline (i.e. at diagnosis) and after at least a 6-months period of gluten-free diet.
88865863|NCT03025620|Placebo Comparator|Sunflower arm|Participants were supplied with the usual diet of the hospital, daily enriched with 17.5g fat as follows during 42 days: 10 g of sunflower oil (with a high content in linoleic acid) were added into the dinner soup and 7.5g delivered through a 12.5g portion of margarine made with sunflower oil (60% fat) that replaced butter on the breakfast toasts.
88865864|NCT03025620|Active Comparator|Rapeseed arm|Participants were supplied with the usual diet of the hospital, daily enriched with 17.5g fat as follows during 42 days: 10 g of rapeseed oil (with a high content in alpha-linolenic acid) were added into the dinner soup and 7.5g delivered through a 12.5g portion of margarine made with rapeseed oil (60% fat) that replaced butter on the breakfast toasts.
88865865|NCT03024918||MCDA cohort|Unselected monochorionic diamniotic (MCDA) twin pregnancies, included between 11 and 14 weeks of gestation
88865866|NCT03024918||TTTS cohort|Pregnancies complicated by twin-twin transfusion syndrome (TTTS) undergoing laser treatment, included at the time of diagnosis or referral
88865867|NCT03024918||sIUGR cohort|Pregnancies complicated by selective intrauterine growth restriction (sIUGR), included at the time of diagnosis or referral. We define sIUGR as a discordance in estimated fetal weight of ≥ 20%.
88865868|NCT03024372|Active Comparator|Conventional sutures|AV fistula creation with sutures
88865869|NCT03024372|Active Comparator|Anastoclips|AV fistula creation with clips
88865870|NCT03023514|Experimental|ALA + P|Oral alpha-lipoic acid + vaginal Progesterone
88865871|NCT03023514|Active Comparator|P|vaginal Progesterone
88865872|NCT03022812|Active Comparator|Exercises at a physiotherapy clinic|Neck-specific exercise at a physiotherapy clinic, 24 times during 12 weeks (plus an additional first visit).
88865873|NCT03022812|Experimental|Exercises with Internet support|Neck-specific exercise with Internet support combined with 3 visits at a physiotherapy clinic (plus an additional first visit), exercises mainly performed outside the health care system during 12 weeks.
88865874|NCT03022266|Experimental|Intervention Arm|Participants receiving the Financial Incentive and Mobile Phone App will be given an smartphone app offering pill reminders and $50/month financial incentives for three months to upload photos of medication each day for 90 days. Medication adherence will be measured via a CleverCap(R) electronic monitoring pillbox.
88865875|NCT03022266|No Intervention|Usual Care Control Arm|Participants in the usual care control arm will receive the usual education about medications provided by hospital staff. Medication adherence will be measured via a CleverCap(R) electronic monitoring pillbox.
88865876|NCT03021252|Experimental|High intensity IEMT|Inspiratory and expiratory muscle training + standard swallow therapy.
88865877|NCT03021252|Sham Comparator|Sham IEMT|Sham inspiratory and expiratory muscle training + standard swallow therapy
88865878|NCT03020784|Placebo Comparator|Placebo|IV placebo
88865879|NCT03020784|Experimental|PF-06818883|Experimental drug
88865880|NCT03019848|Experimental|Curcumin|Each patient of this group will receive 1.67 grams of curcumin ( 7 capsules of 231 mg) divided in 3 doses daily for 6 months.
88865881|NCT03019848|Placebo Comparator|Placebo|The control group will receive 7-capsules/ day identical in color and size, containing placebo for 6 months.
88865882|NCT03019770|Experimental|PrEP Decision Aid|All participants in the study will go through the Decision Aid with a provider.
88865883|NCT03019692||enrolled babies with neonatal intracranial bleed|all babies who suffered from intra cranial or intraventricular bleed during neonatal period
89189434|NCT05809960|Active Comparator|Control Group|Routine nursing care was given to the control group. The clinical routine has not been exceeded.
89189435|NCT05809882|Experimental|the study group|
89189436|NCT05809882|Active Comparator|the control group|
89389909|NCT04369755|Other|MRI|A MRI on PTX mode will be done on healthy subjects (approx. 90 min of sequences)
89389910|NCT01343537|Experimental|Monitoring|
88865884|NCT03019614|Experimental|Group 1|"Volunteers in group 1 received the following interventions:~Chronocort® 30 mg given at night (~ 23:00h) as a combination of one 10mg capsule and one 20mg capsule (n=18).~Chronocort® 30mg given as one 20mg capsule at night (~ 23:00h) and as one 10mg capsule in the morning (~ 7:00h) following the initial night-time dose (n=18).~Hydrocortisone 30mg given at night (~ 23:00h) given as three 10mg tablets (n=18).~Each administration of IMP was separated by a washout period of at least 7 days."
89189437|NCT05809869|Experimental|Durvalumab in combination with tremelimumab and radioembolisation|"Tremelimumab 300 mg intravenous infusion on week 1 only~Durvalumab 1500mg intravenous infusion on week 1, 5, 9, 13, 17, 21 and 25, for a total of 7 cycles~Radioembolisation with yttrium-90 microspheres on week 2 only"
89189438|NCT05809843||rype 1 diabetc patients with artificial pancreas device|
89389911|NCT02064374|Experimental|Cohort 1|All subjects will be assigned to a single-sequence of three treatment periods without washout. Subjects will receive Metformin immediate release (IR) 500 mg q12h following a moderate fat meal for 5 days (Period 1), followed by Metformin IR 500 mg q12h plus DTG 50 mg q24h following a moderate fat meal for 7 days (Days 1-7 of Period 2), followed by Metformin IR 500 mg q12h following a moderate fat meal (Days 1-10 of period 3).
89389912|NCT02064374|Experimental|Cohort 2|All subjects will be assigned to a single-sequence of three treatment periods without washout. Subjects will receive Metformin IR 500 mg q12h following a moderate fat meal (Day 1-5 of Period 1), followed by Metformin IR 500 mg q12h plus DTG 50 mg q12h following a moderate fat meal for 7 days (Days 1-7 of Period 2), followed by Metformin IR 500 mg q12h following a moderate fat meal (Days 1-10 of period 3).
89389913|NCT03614208|Experimental|Home-care rehabilitation group (HCRG)|"The home-based exercise program consists of aerobic exercise on a stationary bike, muscular endurance training of the upper limb and stretching exercises for finger joint motion. The exercise on the stationary bike and muscular endurance training will be performed on alternate days, three times a week. For finger stretching the patients will be directed to perform it every day, both in the morning and in the evening.~During the rehabilitation period, the patients will report each day on a diary for each type of exercise. They received a phone call monthly, only for the first 3 months, to encourage them about the adherence and investigate any problems with the exercise program."
89389914|NCT03614208|No Intervention|Control group|Control group was encouraged to perform the generic aerobic physical activity at the baseline. Also, they received a monthly phone call, only for the first 3 months, to encourage them about the importance of doing aerobic exercise.
89186311|NCT02562027|Experimental|High-risk NSCLC participants|"Baseline assessment of demographics and comorbidities~Comorbidity scoring by interview and chart review: the Adult Comorbidity Evaluation 27, Charlson Comorbidity Index, Global Initiative for Chronic Obstructive Lung Disease, Cumulative Illness Rating Scale, and COMorbidities in Chronic Obstructive Lung Disease.~Katz Activities of Daily Living: assessment of grip strength, walk speed, and activities of daily living~HRQOL questionnaires will also be administered prior to treatment and then repeated throughout follow-up: the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) C30, EORTC QLQ-LC13, Modified Medical Research Council, EQ-5D, CES-D, and Medical Outcomes Study Social Support Survey.~All questionnaire responses will be obtained with the use of a computer assisted interview system which can be used to collect data in person or through telephone interviews"
89186312|NCT00723398|No Intervention|Group 1: Control|Control, no intervention
89186313|NCT00723398|Experimental|Group 2: Raloxifene 60 Mg Oral Tablet|Raloxifene 60 mg Orally Daily
89186314|NCT00723398|Experimental|Group 3: Raloxifene 30 Mg Oral Tablet|Raloxifene 30 mg Orally Daily
89186315|NCT00723398|Experimental|Group 4: Lovaza 4 gm oral|Lovaza 4 gm/day Orally with Meals
89186316|NCT00723398|Experimental|Group 5: Lovaza 4gm & Raloxifene 30mg|Lovaza 4 gm/day oral capsule with meals plus Raloxifene 30 mg oral tablet daily
89186317|NCT00716456|Experimental|1|In the phase I portion, patients will be enrolled in cohorts of 3-6 patients;receiving daily erlotinib 100 mg along with cetuximab given every 2 weeks beginning at 250mg/m2 IV. Following the initial dose, for dose levels 1 and 2 (250 mg/m2 and 375 mg/m2) patients will receive treatment every 2 weeks with cetuximab over 60 minutes. For dose level 3 (500 mg/m2) patients will receive treatment every 2 weeks with cetuximab over 120 minutes. The infusion rate of cetuximab should never exceed 10 mg/minute (5 mL/min). The dose may subsequently be reduced for individual patients, depending on a patient's toxicity.
89389915|NCT05188365|Active Comparator|group A|"different body acupuncture points will be selected to be manually punctured in addition to 4 acupoints on the skin of abdominal surface (the four points will be electrical stimulated during acupuncture). the session (20 minutes) will repeated thrice weekly. the total duration of the study will be 60 days.~The points that will be manually acupunctured all over the body of every patient will be: SJ(3)/SJ(5)/SJ(17)/SJ(18)/SJ(19)/SJ(20)/SJ(21)/SJ(22)/GB(2)/GB(8)/GB(20)/LI(4)/LI(11)/KI(3)/SP(6)/ST(36)/REN(4)/REN(9)/REN(12)~The acupuncture points that will be electrically stimulated on the abdomen of every patient will be: bilateral Stomach 25 in addition to gallbladder 28 acupoints."
89389916|NCT05188365|Sham Comparator|Group B|different body acupuncture points will be selected to be manually punctured in addition to 4 acupoints on the skin of abdominal surface (the four points will be electrical stimulated during acupuncture). opposite to group A, in this group, the acupuncture needles will be inserted manually and very adjacent to the real location of group-A acupoints (sham acupuncture). The electrical stimulator will connected to abdominal acupoints (bilateral Stomach 25 in addition to gallbladder 28 acupoints) but it will be turned off during the sessions. the session will repeated thrice weekly. the total duration of the study will be 60 days.
89389917|NCT05061251|Experimental|BAY 2402234|Patients will receive 1 dose (5mg) orally, per day of BAY 2402234 for the 2 days prior to standard-of-care craniotomy for tumor resection and 1 dose on the morning of surgery, for a total of 3 administered doses.
89389918|NCT01351129|Experimental|Formulation 1|
89389919|NCT01351129|Experimental|Formulation 2|
89389920|NCT01351129|Experimental|Formulation 3|
89186318|NCT00684645||Patients treated with SUTENT®|Patients with metastatic or advanced renal cell carcinoma after failure of cytokines therapy.
89186319|NCT04054869|Experimental|Bio-mechanically correct manual therapy (received first) arm|Participants will be randomized to receive manual therapy directed at the cervical spine atlanto-axial joints in the bio-mechanically correct direction followed by instruction in a home program to maintain this motion. Outcome measures will be assessed. Participants will return in 2-3 days and receive the opposite treatment and home program followed by outcomes assessment. Participants will return again in 2-3 days, outcomes will be assessed and the study will conclude. Participants will then be given the option to continue in formalized physical therapy if desired.
89389921|NCT02064452|Experimental|Triple P Online System|The Triple P Online System (TPOS) is an interactive, video-driven online parenting support website, delivered with 3 different levels of intensity, depending on severity of children's behavior problems. In this arm, pediatric clinics are randomized to receive training in child disruptive behavior disorders, Triple P principles and target parenting strategies, the Triple P Online System, effectively referring eligible families to TPOS, and supporting their use of the program. Referred parents in this condition receive access to TPOS immediately.
89389922|NCT02064452|Placebo Comparator|Enhanced Usual Community Care-Waitlist|In this arm, pediatric clinics are randomized to receive access for their parents and practitioners to a referral website designed to assist parents of children with disruptive behavior disorders in accessing appropriate community resources; on the website, community resources for treatment of child disruptive behavior disorders (mental health services, parenting services) are described and can be searched by location, cost, and acceptance of Medicare. Parents in this condition receive access to the Triple P Online System (TPOS) after completion of their 1-year follow-up assessment. Pediatricians receive free training in TPOS at the end of their waiting period.
89389923|NCT02236884|Experimental|no-scar transanal TME|no-scar transanal total mesorectal excision(TME) of rectal cancer
89389924|NCT01355263|Experimental|iron tablet, vitamin a capsule|children in Group I received a 200,000 IU vitamin A capsule just one time initially; Group II received ferrous sulfate (element Fe 1-2 mg/kg•day) once a day for 6 months;.
89389925|NCT04415177|Experimental|VR Program A|Software with active intervention
89389926|NCT04415177|Active Comparator|VR Program B|Software without active intervention
89389927|NCT02065856|Experimental|AVANZ Salsola kali|Subcutaneous immunotherapy
89389928|NCT03613428|Experimental|ruxolitinib, vincristine, prednisone|Open label dosing cohorts will evaluate oral ruxolitinib (doses ranging from 10 - 80 mg) in combination with vincristine (1.4 mg/m2) and oral prednisone (1 mg/kg, 5 days a week for 4 weeks).
89186320|NCT04054869|Experimental|Bio-mechanically incorrect manual therapy (received first) arm|Participants will be randomized to receive manual therapy directed at the cervical spine atlanto-axial joints in the bio-mechanically incorrect direction followed by instruction in a home program to maintain this motion. Outcome measures will be assessed. Participants will return in 2-3 days and receive the opposite treatment and home program followed by outcomes assessment. Participants will return again in 2-3 days, outcomes will be assessed and the study will conclude. Participants will then be given the option to continue in formalized physical therapy if desired.
89003523|NCT05078229|Experimental|FOCUS|Focusing On mindfulness for Caregivers Under Stress (FOCUS)will consist of six one-on-one, 45-60 minute sessions delivered either in-person (sessions 1-3) or via video conference (sessions 4-6). The first few sessions will primarily focus on how to direct attention to the breath or some object of attention (e.g., parts of the body). As the program progresses, participants are asked to apply these skills to thoughts and emotions. Throughout the treatment, caregivers are reminded to utilize existing coping skills, as well as how to integrate the new skills learned throughout this program for managing stress. Formal mindfulness meditations are conducted within each session, lasting from 7-20 minutes; participants will be asked to practice mindfulness exercises daily.
89003524|NCT05078229|Active Comparator|Healthy Living|Healthy Living (HL) will consist of six, 45-60 minute sessions delivered one-on-one; sessions 1-3 in-person on HCT unit and sessions 4-6 via video conference. HL will be based on the American Cancer Society's (ACS) Caregiver Resource Guide.
89003525|NCT05078229|No Intervention|Standard of Care - Enhanced Care|Participants in Enhanced Care will receive treatment consistent with what is offered to all caregivers of allogeneic HCT patients. This entails the option of attending weekly support groups and meeting with social workers as needed. At the baseline session, participants randomized to Enhanced Care will be provided with a modified version of the ACS Caregiver Resource Guide.
89003526|NCT05074303|Experimental|Beta-glucan|500 mg/day beta-glucan
89003527|NCT05074303|Placebo Comparator|Placebo|500 mg/day cellulose
89003528|NCT05070403|Experimental|Afatinib Intervention|Participants will receive afatinib 40 mg once a day. Each cycle is 4 weeks. They will have CT imaging (and/or digital photography) done at baseline and every 8 weeks while on treatment. Participants will have a baseline and on-treatment (at 4 weeks) tumor biopsy, and a biopsy at disease progression if feasible. Patients may remain on treatment as long as they are deriving clinical benefit, until disease progression or intolerable toxicity.
89003529|NCT05064423|Experimental|Clinical Trials Education|Community Health Educators (CHE) will provide Clinical Trial Education to increase knowledge of Clinical Trials and the importance of Clinical Trial participation.
89003530|NCT05064410|Experimental|Educational Intervention and Referral for Fecal Immunochemical Test (FIT) Kit or Colonoscopy|The Community Health Educator (CHE) will provide online, phone or in-person colorectal cancer (CRC) early detection, prevention, and screening education to increase knowledge of CRC and the importance of screening. These sessions will be conducted in small in-person sessions, virtually within a group, virtually via a self-paced/self-directed online learning module, or one-on-one via phone. Additionally, the CHE will provide information regarding FIT kit and colonoscopy screening and the screening process for attendees. The CHE and research assistant will be prepared to provide access to screening resources and services through participants' existing coverage. Those participants who do not have a primary care provider will be provided information on obtaining FIT kits through the mechanisms of the Federally Qualified Health Center (FQHC) and/or a colonoscopy through the cancer center on a case by case basis.
89003531|NCT05064085|Experimental|Dose Level 1|Cemiplimab 350mg + Capecitabine 800 mg/m^2
89003532|NCT05064085|Experimental|Dose Level 2|Cemiplimab 350mg + Capecitabine 1000 mg/m^2
89003533|NCT05063994|Experimental|Chronocort|Hydrocortisone modified-release capsule - Chronocort®. 25 subjects will be randomised to this group using an interactive response technology (IRT).
89003534|NCT05063994|Active Comparator|Cortef|Immediate-release hydrocortisone capsule (IRHC) - Cortef. 25 subjects will be randomised to this group using an interactive response technology (IRT).
89003535|NCT05063383||PCOS|"Oligomenorrhea/amenorrhea~Clinical androgen excess or biochemical androgen excess~Polycystic ovary showed by gynecological ultrasound"
89003536|NCT05063383||NOPCOS|not meet Rotterdam standards
89003537|NCT05061706|Experimental|Lumateperone 42 mg|
89003538|NCT05061706|Placebo Comparator|Placebo|
89003539|NCT05061550|Experimental|Arm 1: Oleclumab + Durvalumab + Platinum doublet chemotherapy (CTX)|"Participants will receive Durvalumab + Oleclumab + CTX as neoadjuvant treatment and Durvalumab + Oleclumab as adjuvant treatment.~Participants will receive one of the following chemotherapy regimens, based on the tumour histology and Investigator's discretion, as part of their treatment regimen prior to surgery:~Carboplatin/Paclitaxel Pemetrexed/Cisplatin Pemetrexed/Carboplatin"
89003540|NCT05061550|Experimental|Arm 2: Monalizumab + Durvalumab + CTX|"Participants will receive Durvalumab + Monalizumab + CTX as neoadjuvant treatment and Durvalumab + Monalizumab as adjuvant treatment.~Participants will receive one of the following chemotherapy regimens, based on the tumour histology and Investigator's discretion, as part of their treatment regimen prior to surgery:~Carboplatin/Paclitaxel Pemetrexed/Cisplatin Pemetrexed/Carboplatin"
89389929|NCT03290521|Experimental|A - Yes Washing (SL)|In this group, the washing process is continued. In particular, 1000cc of laced ringer is instilled by changing the position of the patient in Trendelenburg and Anti-Trendelenburg so that the liquid contacts not only the internal surgical wounds but the whole wall of the abdominal cavity.
89003541|NCT05061550|Experimental|Arm 3: Volrustomig (Dose Exploration) + CTX|"Participants will receive Volrustomig + CTX as neoadjuvant treatment and Volrustomig as adjuvant treatment.~Participants will receive one of the following chemotherapy regimens, based on the tumour histology and Investigator's discretion, as part of their treatment regimen prior to surgery:~Carboplatin/Paclitaxel Pemetrexed/Cisplatin Pemetrexed/Carboplatin"
89186321|NCT00752037|Other|1|open label single arm
89186322|NCT00747981|Experimental|A|Thoracic CT Scan
89189439|NCT05809843||healthy patients matched age and sex without diabetes and ocular disease|
89389930|NCT03290521|Experimental|B- No Washing (NL)|No washing was performed before the end of surgery
89389931|NCT01343615|Active Comparator|carotid stenting|
89389932|NCT01343615|Active Comparator|carotid endarterectomy|
88865885|NCT03019614|Experimental|Group 2|"Volunteers in group 2 received the following interventions:~Chronocort® 5mg given at night (~ 23:00h) as one 5mg capsule (n=12).~Chronocort® 10mg given at night (~ 23:00h) as one 10mg capsule (n=12).~Chronocort® 20mg given at night (~ 23:00h) as one 20mg capsule (n=12).~Each administration of IMP was separated by a washout period of at least 7 days."
88865886|NCT03019380|Experimental|Impacted cerumen|removing cerumen from external ears of patients with impacted cerumen, obscuring the canal and the tympanic membrane.
88865887|NCT03019302|Experimental|Arrow PICC with Chloragard Technology|Arrow Peripherally- Inserted Central Catheters with Chloragard Technology. The application of Chlorag+ard® Technology uses a proprietary process whereby chlorhexidine is chemically bonded to the intra- luminal catheter surfaces from tip to hub, and extra-luminal catheter body.
88865888|NCT03019224|Placebo Comparator|Group 1|The use of desensitizing dentifrice [Sucralose (S) Control dentifrice)] in plastic tray.
88865889|NCT03019224|Experimental|Group 2|The use of desensitizing dentifrice [Sodium fluoride (FS) with 1450ppm of fluorine (Close up triple, Unilever)] in plastic tray.
89186323|NCT05416983||Observational (discussion)|Patient and clinician discussions are observed to support refinement of a decision aid. Clinicians may use a prototype of the decision aid in discussions with their patients and may complete a questionnaire.
89186324|NCT00716144|Active Comparator|A|Talarozole 0.5 mg
89186325|NCT00716144|Active Comparator|B|Talarozole 1.0 mg
89186326|NCT00716144|Active Comparator|C|Talarozole 2.0 mg
89186327|NCT00716144|Placebo Comparator|D|Talarozole matching Placebo
89186328|NCT00752115|Active Comparator|A|Sildenafil plus carboplatin and weekly paclitaxel
89186329|NCT00752115|Placebo Comparator|P|carboplatin and weekly paclitaxel
89186330|NCT02562261||Healthy|
89186331|NCT02562261||Uncomplicated Infection|Showing signs of infection as defined by International Sepsis Definitions Conference 2003
89186332|NCT02562261||Sepsis|"Sepsis is defined as systemic inflammatory response syndrome (i.e. presence of two or more of the following~Temperature of <36 °C (96.8 °F) or >38 °C (100.4 °F)~Heart rate >90bpm~Respiratory rate >20/min or PaCO2<32 mmHg (4.3 kPa)~WBC <4x109/L (<4000/mm³), >12x109/L (>12,000/mm³), or 10% bands in response to an infectious process.."
89186333|NCT02562261||Severe Sepsis/Septic Shock|Severe sepsis is defined as sepsis with sepsis-induced organ dysfunction or tissue hypoperfusion [manifesting as hypotension, elevated lactate (serum lactate 2 times the upper limit of normal), or decreased urine output (urine output < 0.5 ml/kg/hr)] Septic shock is defined as severe sepsis plus persistently low blood pressure (< 5th percentile for age or systolic blood pressure < 2 standard deviations below normal for age) following the administration of intravenous fluids.
89186334|NCT00918476|Experimental|1. filibuvir + Oral Contraceptives|
89186335|NCT00749385|Experimental|1|PN 400
89186336|NCT00749385|Active Comparator|2|Enteric-coated naproxen tablet (500mg) plus enteric-coated esomeprazole capsule(20mg)
89186337|NCT00749385|Active Comparator|3|Enteric-coated naproxen tablet (500mg)
89186338|NCT00749385|Active Comparator|4|EC esomeprazole capsule (20mg)
89186339|NCT02592044|Experimental|Aromatherapy with lavender essential oil|The 2 drops of lavender essential oil will put on 5x5 cm gauze and the patient will inhale it for 5 minutes and during peripheral venous cannulation.
89186340|NCT02592044|Placebo Comparator|Placebo|The 2 drops water will put on 5x5 cm gauze ant the patient will inhale it for 5 minutes and during peripheral venous cannulation.
88865890|NCT03019224|Experimental|Group 3|The use of desensitizing dentifrice [Arginine, calcium carbonate (ACC) and sodium monofluorophosphate with 1450 ppm fluorine (Colgate sensitive pro-relief, Colgate-Palmolive)] in plastic tray.
88865891|NCT03019224|Experimental|Group 4|The use of desensitizing dentifrice [Sodium fluoride based dentifrice with 1450 ppm of fluorine associated with 5% potassium nitrate] in plastic tray.
88865892|NCT03019146|Experimental|High Intensity Interval Training (HIIT)|3 x 15 minute sessions per week for 6 weeks. Sessions include 5x intervals of cycling at 110% of Wmax derived from CPET, interspersed with 90s rest periods of unloaded cycling.
88865893|NCT03019146|Experimental|Isometric Handgrip (HOLD)|3x 15 minute sessions per week for 6 weeks Sessions include 4x intervals of 2minutes isometric handgrip contraction of dominant arm at 30% Maximal voluntary contraction, interspersed with 2minute rest periods
89186341|NCT00748059|Experimental|A|Patients with Orthostatic Hypotension
89186342|NCT00576381|Experimental|A|Neonates will be administered a single bolus dose of dexmedetomidine followed by a continuous infusion for up to 24 hours post cardiac surgery.
89186343|NCT00748137|Active Comparator|Fixed dose|Fixed meal size and fixed aspart insulin dose except for minor changes based on measured blood glucose. Detemir basal insulin.
89186344|NCT00748137|Experimental|ezy-BICC dose calculation card|variable meal size with variable aspart insulin dose determined with use of individualised dose calculation card. Detemir basal insulin.
89186345|NCT00749541||1normal catheter.|
89186346|NCT00749541||abnormal catheter.|
89186347|NCT02562417|Placebo Comparator|No IV dexamethasone|Patients will receive an equivalent volume of normal saline.
89186348|NCT02562417|Experimental|IV dexamethasone|Patients will receive 0.1 mg/kg of dexamethasone.
89186349|NCT00748293|No Intervention|A|PEG-ELS 2000 ml ingestion in the morning of colonoscopy
89186350|NCT00748293|Other|B|Low-reside diet on previous day (breakfast, lunch and dinner), PEG-ELS 1500 mL in the morning of colonoscopy
89186351|NCT00749619|Experimental|A|
89186352|NCT00749619|Experimental|B|
89186353|NCT00749619|No Intervention|C|
89186354|NCT00752271||1|24 adults with meniscal damage for which arthroscopy is clinically indicated
89186355|NCT00752271||2|8 adults who have already undergone meniscal resection to serve as positive controls
89186356|NCT02561403|Experimental|EVO multitask video game|
89186357|NCT02561403|Experimental|EVO words video game|
89186358|NCT02561403|No Intervention|Assessment Only|
89186359|NCT00748371|Experimental|1|ASA 40mg daily for 8 weeks followed by 3 weeks of observation
88865894|NCT03019146|Experimental|Remote Ischaemic Preconditioning (HUG)|3x 15 minute sessions per week for 6 weeks. Sessions include 3x intervals of 3 minutes of arm ischaemia (blood pressure cuff inflated to 200mmHg on dominant arm) interspersed with 3 minute rest periods.
88865895|NCT03019146|No Intervention|Control|No intervention
88865896|NCT03018990|Active Comparator|Alcoholic liver fibrosis|
88865897|NCT03018990|Active Comparator|Non-alcoholic steatohepatitis|
88865898|NCT03018990|Active Comparator|Healthy control|
88865899|NCT03018600||1|We included 15 inpatients admitted to the Immunology Department, Peking Union Medical College Hospital (PUMCH), Beijing, China from April 1, 2016 to September 1, 2016.Intervention including glucocorticoid: 1-2mg/kg/day prednisone-equivalent (intravenous/oral methylpredisolone or oral prednisone) to the patients every morning at 8am for at least five days.
88865900|NCT03018600||2|We included 10 inpatients admitted to the Immunology Department, Peking Union Medical College Hospital (PUMCH), Beijing, China from April 1, 2016 to September 1, 2016.Intervention including glucocorticoid: using less than 15mg/day prednisone-equivalent glucocorticoid maintenance for at least 3 months and now treating with 1-2mg/kg/day prednisone-equivalent (intravenous/oral methylpredisolone or oral prednisone) for the relapse of primary autoimmune disease for at least five days.
88865901|NCT03018678||Patients with HOFH|No intervention
88865902|NCT03018756|Active Comparator|Fentanyl Citrate|Single dose, nebulized 100 mcg fentanyl citrate. This is a double-blind, placebo-controlled, two-period crossover study comparing the effects of a single dose of nebulized 100 mcg fentanyl citrate to that of a placebo (0.9% saline). Treatments will be in randomized order: patients in one study arm will receive fentanyl at the first treatment visit and placebo at the second treatment visit, patients in the other arm will receive placebo first and fentanyl second.
88865903|NCT03018756|Placebo Comparator|Placebo|Single dose, nebulized 0.9% saline solution. This is a double-blind, placebo-controlled, two-period crossover study comparing the effects of a single dose of nebulized 100 mcg fentanyl citrate to that of a placebo (0.9% saline). Treatments will be in randomized order: patients in one study arm will receive fentanyl at the first treatment visit and placebo at the second treatment visit, patients in the other arm will receive placebo first and fentanyl second.
88865904|NCT03018444|Experimental|Atorvastatin|2 weeks treatment with Atorvastatin (1st week 40 mg once daily on day, 2nd week 80 mg (2x40mg) once daily)
88865905|NCT03018444|Placebo Comparator|Placebo|2 weeks treatment with placebo tablets of comparable sizes and color to the Atorvastatin tablets (1st week one tablet once daily, 2nd week two tablets once daily)
88865906|NCT03017976||Competitive swimmers|Regular and naïf competitive swimmers will be followed for a mean period of 90 days. A battery of measurements and biological samples will be collected at the baseline evaluation and 90 days after, in order to evaluate long-term changes in respiratory health biomarkers. Measurements will also be performed before and after a single regular training session in order to assess acute effects in respiratory health biomarkers.
89186360|NCT00748371|Experimental|2|ASA 1300mg daily for 8 weeks followed by 3 weeks of observation
88865907|NCT03017976||Recreational swimmers and swimming pool staff|Swimming pool physicochemical and microbiological characteristics and the association between each parameter measured as an indicator of water and air quality, contamination of surfaces will be evaluated and the association with recreational users, swimming teachers and pool attendants health parameters will be studied.
88865908|NCT03018054|Experimental|E6007 30 mg|Participants will receive E6007 30 milligrams (mg) once daily after breakfast.
88865909|NCT03018054|Experimental|E6007 60 mg|Participants will receive E6007 60 mg once daily after breakfast.
88865910|NCT03018054|Placebo Comparator|Placebo|Participants will receive matching placebo once daily after breakfast.
88865911|NCT03017664||RFG|Retrospective review of enteral feeding in pediatric ICU patients for up to 5 days
88865912|NCT03017664||PFG|Pediatric ICU population to be fed a peptide-based enteral formula with higher protein and higher calories for up to 5 days
88865913|NCT03017196|Experimental|Intervention|Sites randomized to intervention will be expected to implement the My Life, My Healthcare Discussion Aid in their practice for at least a 6-month period.
88865914|NCT03017196|No Intervention|Control|Sites randomized to control will not be expected to implement the My Life, My Healthcare Discussion Aid in practice. They will be expected to practice chronic care as usual.
88865915|NCT03017430|Experimental|Pregabalin|This group (N= 40) receives up to 600 mg a day of Pregabalin for six-seven days along with symptomatic therapy that is divided into basic treatment that is given to all patients (Doxylamin 30 mg/day) and additional medications based on patients' needs as determined by a psychiatrist using the Opioid Withdrawal Scale and included Ketorolac, Loperamide, Metoclopramide, Nefazolin and Phenazepam (benzodiazepine).
88865916|NCT03017430|Active Comparator|Clonidine|This group (N= 40) receives up to 600 micrograms of Clonidine a day for six-seven days along with symptomatic therapy that is divided into basic treatment that is given to all patients (Doxylamin 30 mg/day) and additional medications based on patients' needs as determined by a psychiatrist using the Opioid Withdrawal Scale and included Ketorolac, Loperamide, Metoclopramide, Nefazolin and Phenazepam (benzodiazepine)..
88865917|NCT03017352|Experimental|Intervention|Exenatide 10 mikrogram, thrice daily, subcutaneous injection prior to main meals, 6 months.
88865918|NCT03017352|Placebo Comparator|Placebo|Placebo, thrice daily, subcutaneous injection prior to main meals, 6 months.
88865919|NCT03016884|Experimental|RA patients|RA patients will be administered Zostavax vaccine once 2 weeks before initiation of bDMARD, and be monitored accordingly
88865920|NCT03016884|Experimental|Healthy Controls|healthy control patients will be administered Zostavax vaccine and be monitored accordingly
89186361|NCT00748371|Placebo Comparator|3|Placebo: one Avicel (cellulose) capsule by mouth twice daily
89389933|NCT03613350||Urodynamic stress incontinence|Urodynamic study incontinence Between November 2011 and January 2017, medical records of all women with ≥stage II cystocele who underwent 20-minute pad testing and urodynamic studies in a medical center were reviewed. USI included evident USI and occult USI, which were classified according to pad weight before and after prolapse reduction.
88810477|NCT06213077|Placebo Comparator|Placebo|"Upon enrollment, patients will complete the IIEF questionnaire, EHS Score questionnaire and the Quality of Life survey.~Patients will be sent home with instructions to take 2 Berkeley Life capsules once daily (in this case the placebo), in combination with their existing treatment protocol (Tadalafil) and then return on day 60, returning all unused test product.~After 60 days of taking the placebo + tadalafil, patients will repeat the IIEF questionnaire, EHS Score questionnaire and the Quality of Life survey.~After a 4 week wash out, patients will be crossed over to the active group and given the other combination.~After 60 days of each combination, placebo and active, patients will repeat the IIEF questionnaire, EHS Score questionnaire and the Quality of Life survey"
88810478|NCT06213064||Study Product, THC Only Product, Placebo|"All study participants will receive and cross-over into each group: study product, thc-only product, and placebo groups.~Study Product Ingredient List:~Active Ingredients: 10mg THCV, 5mg THC Tapioca syrup, sugar, water, pectin, citric acid, natural flavors*, coconut oil, sodium citrate, cannabis extract, soy lecithin,~Infused THC Gummy Ingredient List:~Active Ingredients: 5mg THC Tapioca syrup, sugar, water, pectin, citric acid, natural flavors*, coconut oil, sodium citrate, cannabis extract, soy lecithin, THC.~Non-infused Placebo Gummy Ingredient List:~Tapioca syrup, sugar, water, pectin, citric acid, natural flavors*, coconut oil, sodium citrate, soy lecithin."
88810479|NCT06213051||Cohort of sexually active adult females with an abnormal cervical cancer screening result|"Multi-center, prospective, paired, comparative diagnostic accuracy study To compare the performance of self-collected vaginal samples transported dry to those transported wet for detection of hrHPV DNA to screen for CIN2+ lesions~Interventions:~COPAN floq swab transported wet and dry evaluated on Roche COBAS and Cepheid Xpert HPV tests"
88810480|NCT06213025|Experimental|web-based Educational program|nurses who entered a web-based Educational program about elder abuse will demonstrate higher response and willingness to handle elderly abuse (high score in REAGERA-P scale) than those who not entered
88810481|NCT06213025|No Intervention|nurses in control group|non intervention group
88810482|NCT06212973|Experimental|Epinastine hydrochloride eye drops group|Administered Epinastine hydrochloride eye drops+Simulating Azelastine hydrochloride eye drops bilaterally, twice daily
88810483|NCT06212973|Active Comparator|Azelastine hydrochloride eye drops group|Administered Azelastine hydrochloride eye drops+Simulating Epinastine hydrochloride eye drops bilaterally, twice daily
88810484|NCT06212960|Experimental|DWP712|Patients were intramuscularly injected (IM) with a total of 20U of DWP712 in 5 places of 0.1 mL (4 U/0.1 mL) each on the glabellar line.
88810485|NCT06212960|Active Comparator|Botox®|Patients were intramuscularly injected (IM) with a total of 20U of BOTOX® in 5 places of 0.1 mL (4 U/0.1 mL) each on the glabellar line.
88810486|NCT06212947||Children with Hypochondroplasia|Children with Hypochondroplasia
88810487|NCT06212934|Experimental|"Chou's Tiaoshen acupoints group"|"AcupuncturingChou's Tiaoshen acupoints,Chou's Tiaoshen acupoints is derived from the experience of Zhou Dean, anational famous traditional Chinese medicine doctor in our department."
88810488|NCT06212934|Active Comparator|Estazolam group|Estazolam is a drug commonly used in the treatment of insomnia
88810489|NCT06212921|Other|Patient with suspicion of acute mesenteric ischaemia|Bolld samples is the only intervention. All patients with suspicion of AMI will be included and blood samples collected
88810490|NCT06212908|Other|Breast cancer|"The division was made into 2 groups: Patients with breast cancer and gingivitis (BC/G) (n=20); and control patients with gingivitis only (G) (n=20).~Clinical periodontal examinations were carried out by a single trained and calibrated examiner. Clinical periodontal, hematological and salivary flow parameters were assessed at baseline, 6 weeks, 12 and 24 weeks."
88810491|NCT06212882||Lower concentration and lower volume contrast agent group|
88810492|NCT06212882||Lower concentration and normal volume contrast agent group|
88810493|NCT06212882||Normal concentration and normal volume contrast agent group|
88810494|NCT06212856|Experimental|Group-A (Plyometric training)|
88810495|NCT06212856|Other|Group-B (Conventional)|
88810496|NCT06212843|Experimental|Group A (Plyometric training)|
88810497|NCT06212843|Other|Group B (Conventional)|
88810498|NCT06212830|Active Comparator|Gabapentin|"This group will receive a combination of drugs including:~Gabapentin, NSAIDS and Paracetamol."
88810499|NCT06212830|Active Comparator|Targin|"This group will receive a combination of drugs including:~Targin, NSAIDS and Paracetamol."
88810500|NCT06212830|Active Comparator|Control|"This group will receive a combination of drugs including:~NSAIDS and Paracetamol."
88810501|NCT06212817|Experimental|Fibre-UP tool: digital, personalized dietary advice to increase dietary fiber intake|Subjects will receive personalized dietary advice (PDA) based on their habitual food pattern (as assessed using a food frequency questionnaire) and preferences. Based on a previously developed algorithm, the PDA provides fiber-rich alternatives for currently used low-fiber products, close to subjects' current eating behavior, to help increase dietary fiber intake. This PDA will be provided using an online web-portal.
88810502|NCT06212817|Experimental|Vegetable product (dried chicory root) to increase dietary fiber intake|Subjects will consume 2 sachets with each 7.5 g of dried cubes of chicory root, which equals a total of 12.3 g of dietary fiber per day. Subjects can choose when and how they consume the vegetable product, for example sprinkle it over their meal, or include in existing recipes.
88810503|NCT06212817|No Intervention|Control|Subjects will follow their habitual diet during the preoperative period.
88810504|NCT06212804|Experimental|VIS954 Dose 1|A single VIS954 Dose 1 will be administered subcutaneously on Day 1
88810505|NCT06212804|Experimental|VIS954 Dose 2|A single VIS954 Dose 2 will be administered subcutaneously on Day 1
88810506|NCT06212804|Experimental|VIS954 Dose 3|A single VIS954 Dose 3 will be administered subcutaneously on Day 1
88810507|NCT06212804|Experimental|VIS954 Dose 4|A single VIS954 Dose 4 will be administered subcutaneously on Day 1
88810508|NCT06212804|Experimental|VIS954 Dose 5|A single VIS954 Dose 5 will be administered subcutaneously on Day 1
88810509|NCT06212804|Experimental|VIS954 Dose 6|A single VIS954 Dose 6 will be administered subcutaneously on Day 1
88810510|NCT06212804|Placebo Comparator|Placebo|A single Placebo dose will be administered subcutaneously on Day 1 for 2 participants in each cohort.
88810511|NCT06212791||Patients under going catheter ablation|Patients undergoing catheter ablation for paroxysmal AF, reduction or elimination of arrhythmia burden
89186362|NCT00749853|Experimental|1|Pituitary down-regulation will be achieved using buserelin (Suprefact®, Hoechst, Frankfurt, Germany) at a fixed daily dose of 200 mg s.c., according to a long agonist protocol, starting on day 2 of the normal menstrual cycle. Treatment with r-hFSH (Gonal-F®, Serono Austria GmbH, Vienna, Austria) will be started in women with serum E2 concentrations <200 pmol/l and no follicles >15 mm in diameter or ovarian cysts on ultrasonographic examination. The initial r-hFSH dose will be 250 IU s.c. daily for 5 days, after which the dose will be increased to a maximum of 450 IU per day using a step-up protocol with steps of 50 IU/day.
89186363|NCT00749853|Active Comparator|2|No pituitary down-regulation will be performed. Treatment with r-hFSH (Gonal-F®, Serono Austria GmbH, Vienna, Austria) will be started in women with serum E2 concentrations <200 pmol/l and no follicles >15 mm in diameter or ovarian cysts on ultrasonographic examination. The r-hFSH dose will be 150 IU s.c. daily for 11 consecutive days.
89186364|NCT00748449|Active Comparator|1|CT Colonography
89186365|NCT00748449|Active Comparator|2|Colonoscopy
89186366|NCT02561325|Experimental|NaCI group|a clinical trial protocol intended to highlight a possible differential effect in the biological effects of the same sodium intake (2.56 g / day) orally, depending on the nature salt.
89186367|NCT02561325|Placebo Comparator|placebo NaCI|a clinical trial protocol intended to highlight a possible differential effect in the biological effects of the same sodium intake (2.56 g / day) orally, depending on the nature salt.
89186368|NCT02562495|Experimental|CT scan and Ultrasonography|Up to three measurements (CT scan and Ultrasonography), will be made concurrently between the day of admission (D1) in intensive care unit and the tenth day ( D10 ) .
89186369|NCT00684567|Experimental|Single arm|It is the only arm of the study. Subjects receive a combination of radiotherapy and temozolomide, and then temozolomide monotherapy.
89186370|NCT04053621|Experimental|Experimental group|"Metformin at patient´s tolerated oral dose (maximum of 2550 mg per day) and thiamine pyrophosphate (weekly dose of 1 gram administered by IV: 25 ml of thiamine pyrophosphate + 250 ml saline solution at a 60-80 drops/minute rate).~Total duration of 12 weeks."
89186371|NCT04053621|Placebo Comparator|Placebo group|"Metformin at patient´s tolerated oral dose (maximum of 2550 mg per day) and weekly administration of 275 ml of saline solution at a 60-80 drops/minute rate).~Total duration of 12 weeks."
89186372|NCT00684411|Experimental|Imatinib mesylate|The initial starting dose of imatinib mesylate was 400 mg by mouth once daily but intra-patient dose escalation for patients who did not achieve complete response (CR) was built in upon restaging at weeks 8 and 16. At week 8, patients with partial response (PR) or stable disease (SD) were dose escalated to 600 mg. At week 16, if these patients continued in PR or SD, dose escalated to 800 mg and for patients on 400 mg dose escalated to 600 mg. Patients who experienced disease progression could be dose escalated per MD discretion. Patients were treated as long as receiving clinical benefit and no unacceptable toxicity.
89186373|NCT02561793|Active Comparator|DHEA|Women will receive DHEA 12 weeks before starting IVF/ICSI
89186374|NCT02561793|Placebo Comparator|Placebo|Women will receive a placebo 12 weeks before starting IVF/ICSI
89186375|NCT02562651|Experimental|Doxycycline|100 mg of Doxycycline bid for seven days in pts with STEMI underwent PCI (percutaneous coronary intervention) and with current medical therapy
89186376|NCT02562651|Active Comparator|Active comparator|Standard care for STEMI
89186377|NCT00748527|Active Comparator|Arm I|Patients receive carboplatin IV over 30-60 minutes on day 1.
89186378|NCT00748527|Experimental|Arm II|Patients receive decitabine IV over 6 hours on day 1 and carboplatin IV over 30-60 minutes on day 8.
89186379|NCT00686829|Experimental|VCV 30 mg|Participants take VCV 30 mg once daily.
89186380|NCT00687297|Active Comparator|Vandetanib Maintenance|Docetaxel day 1, carboplatin day 1 + vandetanib induction days 1 through 21 (daily) of a 28-day cycle for 4 cycles. If free of disease progression after 4 cycles, vandetanib maintenance daily until progression.
89186381|NCT00687297|Placebo Comparator|Placebo Maintenance|Docetaxel day 1, carboplatin day 1 + vandetanib induction days 1 through 21 (daily) of a 28-day cycle for 4 cycles. If free of disease progression after 4 cycles, placebo maintenance daily until progression.
89186382|NCT00684177|Experimental|Retapamulin Ointment, 1%|
89186383|NCT00684177|Placebo Comparator|Placebo Ointment|
89186384|NCT00684021|Active Comparator|1|Participants will receive active adult stem cell infusion 3 days after percutaneous coronary intervention (PCI).
89186385|NCT00684021|Active Comparator|2|Participants will receive active adult stem cell infusion 7 days after PCI.
89186386|NCT00684021|Placebo Comparator|3|Participants will receive placebo infusion (5% human serum albumin [HSA]) 3 days after PCI.
89186387|NCT00684021|Placebo Comparator|4|Participants will receive placebo infusion (5% HSA) 7 days after PCI.
89186388|NCT00748761|Experimental|OCD Active CBT|Children with obsessive-compulsive disorder (OCD) will be treated with cognitive behavioral therapy (CBT) from the time of enrollment.
89186389|NCT00748761|Active Comparator|OCD Waitlist|Children with OCD will receive waitlist treatment at enrollment. Nonresponders will cross over to CBT.
89186390|NCT00748761|No Intervention|Healthy Controls|Healthy control children will be given no intervention.
88865921|NCT03016962|Experimental|Cap-assisted colonoscopy|cap-assisted colonoscopy
89186391|NCT04057911|Experimental|Real NIBS|In Real NIBS arm, active Noninvasive brain stimulation (NIBS) will be given for 20 mins.
89186392|NCT04057911|Sham Comparator|Sham NIBS|In Sham NIBS arm, sham Noninvasive brain stimulation (NIBS) will be given for 20 mins.
89186393|NCT02561871|Experimental|Group 1|Two subsequent Intramuscular injections of Ad26.RSV.FA2 (5x10^10 virus particles [vp]) on Day 1 and Day 85, and one intramuscular injection of Ad35.RSV.FA2 (1x10^11 virus particles [vp]) on Day 169.
89186394|NCT02561871|Experimental|Group 2|Intramuscular injection of Ad26.RSV.FA2 (5x10^10 virus particles [vp]) on Day 1, an intramuscular injection of Ad35.RSV.FA2 (1x10^11 vp) on Day 85 and and an intramuscular injection of placebo control consisting of the vaccine formulation buffer on Day 169.
89186395|NCT02561871|Experimental|Group 3|Three intramuscular injections of placebo control on Day 1, Day 85 and Day 169.
89186396|NCT02561949|Experimental|YRI + Employment Program|Immediately following enrollment participants will complete the YRI intervention, followed by an income generating activity program.
88865922|NCT03016962|Active Comparator|Standard colonoscopy|Standard colonoscopy
88865923|NCT03017274||NCWS patients|Fifty consecutive adult patients with an IBS-like clinical presentation, according to Rome III criteria, and a definitive diagnosis of NCWS. The patients was recruited between January 2015 and November 2016 at 2 centers: the Department of Internal Medicine at the University Hospital of Palermo, Italy, and the Department of Internal Medicine of the Hospital of Sciacca, Agrigento, Italy. All subjects undergone abdominal ultrasonography at the Outpatient of Ultrasonography of the Department of Internal Medicine at the University Hospital of Palermo, Italy.
89389934|NCT03613350||USI+BO/DO|Urodynamic study incontinence + bladder oversensitivity / detrusor overactivity Between November 2011 and January 2017, medical records of all women with ≥stage II cystocele who underwent 20-minute pad testing and urodynamic studies in a medical center were reviewed. USI included evident USI and occult USI, which were classified according to pad weight before and after prolapse reduction.BO was defined as <300 mL of the volume at strong desire to void during filling cystometry. Detrusor overactivity was defined as evidence of spontaneous detrusor contractions occurring during bladder filling or an uninhibited detrusor contraction occurring at a cystometric capacity that usually results in voiding.
89389935|NCT03613350||BO/DO|Urodynamic study incontinence + bladder oversensitivity / detrusor overactivity Between November 2011 and January 2017, medical records of all women with ≥stage II cystocele who underwent 20-minute pad testing and urodynamic studies in a medical center were reviewed. BO was defined as <300 mL of the volume at strong desire to void during filling cystometry. Detrusor overactivity was defined as evidence of spontaneous detrusor contractions occurring during bladder filling or an uninhibited detrusor contraction occurring at a cystometric capacity that usually results in voiding.
89186397|NCT02561949|Experimental|Employment Program|Immediately following enrollment participants will complete an income generating activity program.
89186398|NCT02562339|Experimental|SMART-3RP for Parents or Caregivers|Participants will receive an 8-week behavioral intervention which teaches stress management and psychological resiliency-enhancing skills.
89389936|NCT03613350||No demonstrated USI+BO/DO|Urodynamic study incontinence + bladder oversensitivity / detrusor overactivity Between November 2011 and January 2017, medical records of all women with ≥stage II cystocele who underwent 20-minute pad testing and urodynamic studies in a medical center were reviewed. No urodynamic stress incontinence, no bladder oversensitivity nor detrusor overactivity was noted in this group.
89389937|NCT02064530|Active Comparator|bupivacaine|0,5% 20 ml bupivacaine added 0.9% 1 ml serum physiologic on TAP block
89389938|NCT02064530|Active Comparator|dexmedetomidine|100 mcg dexmedetomidine added to 0,5% 20 ml bupivacaine on TAP block
89389939|NCT02064530|Sham Comparator|serum phsyologic|0,9% 21 ml serum physiologic
89389940|NCT01358929|Experimental|1|
89389941|NCT01358929|Placebo Comparator|2|
89389942|NCT01345877|Other|gender|
89389943|NCT01568229|Experimental|AMG 747 - Dose 1|
89389944|NCT01568229|Experimental|AMG 747 - Dose 2|
89389945|NCT01568229|Experimental|AMG 747 - Dose 3|
89389946|NCT01568229|Placebo Comparator|Placebo Comparator|
89389947|NCT03613896|Placebo Comparator|conventional dentures|a complete denture made through conventional processing technique
89389948|NCT03613896|Active Comparator|3D printed dentures|a complete denture made through 3d printing
89389949|NCT02066012||group DIOS|group DIOS composed of subjects with dysmetabolic hepatosiderosis
89186399|NCT02562339|Experimental|SMART-3RP for Adolescent Patients|Participants will receive an 8-week behavioral intervention which teaches stress management and psychological resiliency-enhancing skills.
88865924|NCT03017274||CD control patients|To compare the abdominal ultrasonographic features of NCWS patients, a control group of CD patients was randomly chosen by a computer-generated method from subjects diagnosed during the same period and age- and sex-matched with the NCWS patients. All subjects undergone abdominal ultrasonography at the Outpatient of Ultrasonography of the Department of Internal Medicine at the University Hospital of Palermo, Italy.
89003542|NCT05061550|Experimental|Arm 4: Dato-DXd + durvalumab + single agent platinum|"Participants will receive Dato-DXd + durvalumab + single agent platinum as neoadjuvant treatment and durvalumab as adjuvant treatment.~Participants will receive one of the following chemotherapy regimens, based on physician choice of as part of their treatment regimen prior to surgery:~Carboplatin or Cisplatin"
89389950|NCT02066012||group M|group M composed of subjects with metabolic syndrom without iron overload
89186400|NCT00750009|Experimental|Arm I (PRE-ACT)|Patients receive tailored feedback and video content to address clinical trial barriers following baseline assessment.
89186401|NCT00750009|Active Comparator|Arm II (control)|Patients receive generic clinical trials educational feedback taken from NCI publications following baseline assessment.
89186402|NCT00755703|Experimental|Group 1|There will be 12 subjects in Group 1 that will receive 10e8 viral particles of the Pandemic Influenza Vaccine administered via intranasal spray on day 0 and day 28 (+/- 4d).
89186403|NCT00755703|Experimental|Group 2|There will be 12 subjects in Group 2 that will receive 10e9 viral particles of the Pandemic Influenza Vaccine administered via intranasal spray on day 0 and day 28 (+/- 4d).
89389951|NCT02066012||group T|group T composed of lean subjects
89389952|NCT05384028|Experimental|Experimental|Patients in the experimental group will receive full-course case management from a multidisciplinary team from admission to 6 months after discharge
89389953|NCT05384028|Active Comparator|Control|Patients in the control group will receive routine inpatient care and post-discharge follow-up management
89389954|NCT01355341|Experimental|HERBMED PLUS|Herbal formulation of four constituents i.e.Varuna,Yav,Aghada,Kadali as per ayurvedic literature.
89389955|NCT02066090|Experimental|Real acupuncture|manual acupuncture + electroacupuncture, twice a week, for 6 weeks
89389956|NCT02066090|Sham Comparator|Sham acupuncture|sham acupuncture + placebo acupuncture without electrical stimulation, twice a week, for 6 weeks
89389957|NCT01351207|Active Comparator|pork sausages and hash brown potatoes plus eggs|
89389958|NCT01351207|Placebo Comparator|pork sausages and hash brown potatoes plus egg-free pudding|
89389959|NCT01351207|Placebo Comparator|pork sausages and hash brown potatoes|
89389960|NCT05250557||Deferral of PCI group|Patients who undergo successful FFR pullback tracing and have a vessel determined to defer revascularization after FFR measurement will be included.
89389961|NCT05250557||PCI group|Patients who undergo successful FFR pullback tracing and have a vessel that undergo stent implantation and FFR measurement both before and after revascularization (pre-PCI FFR and post-PCI FFR) will be included.
89389962|NCT03613194|Other|Patients with metastatic colorectal cancer|"After inclusion in the study, eligible patients having hepatic metastases and/or péritonéales of a colorectal cancer considered as resecables will have biological and tissue samples.~The samples will be carried out at the time of the surgical gesture envisaged under general anaesthesia and will concern:~Tumoral material: primitive tumour (if available), hepatic metastases and/or peritoneal~Peritoneal liquid~none tumoral peritoneum~Portal blood~Peripheral blood~Cellulo-lymphatic material The necessary time to carry out the whole of these samples is estimated at 10-15 minutes maximum.~In the event of complex situations being able to complicate the surgical gesture initially envisaged or to increase by them morbidity, one or more these samples will not be carried out. This decision will be made at the discretion of the investigator."
89389963|NCT04519437|Experimental|REGN10933+REGN10987|
89389964|NCT04519437|Placebo Comparator|Placebo|
89389965|NCT02064608|Experimental|AZD2014|This is a single arm study whereby a cohort of 20 patients with early high risk prostate cancer will be treated with a 15-day course of AZD2014 (mTOR inhibitor) treatment prior to radical prostatectomy.
89389966|NCT04299997||171 mpMRIs corresponding to consecutive patients who underwent|The mpMRIs were performed on a 1.5T GE MR unit or on a 3T GE or Philips MR units. All mpMRIs included T2-weighted imaging, diffusion-weighted imaging (maximal b value: 2000 s/mm²) and dynamic contrast-enhanced imaging.
89389967|NCT03613584|Active Comparator|Group W (von Willebrand factor concentrate)|The patient receives von Willebrand factor concentrate (vWFC) as a bolus of 25 IU/kg followed by a continuous infusion of 50 IU/kg/24h until the weaning from ECMO is completed or if ECMO is needed longer than 7 days, the administration of the Investigational Medicinal Product (IMP) will be stopped on the 7th day.
89389968|NCT03613584|Placebo Comparator|Group S (standard therapy with saline solution)|The patient receives the standard therapy plus an additional volume of saline solution equivalent to the amount of von Willebrand factor concentrate (vWFC) the patient would receive in Group W to keep the blind. The volume is given according to the VWFC-solution (0.25 ml/kg BW) what would be resulting from the patient's weight followed by a continuous saline infusion (0.50 ml/kg BW) until the weaning from ECMO is completed or if ECMO is needed longer than 7 days, the Investigational Medicinal Product (IMP) administration is stopped on the 7th day.
89389969|NCT03907943|Other|Surgical treatment of carotid endarterectomy|The change in the cognitive function will be assessed in all patient undergoing carotid endarterectomy.
89186404|NCT00755703|Experimental|Group 3|There will be 12 subjects in Group 3 that will receive 10e10 viral particles of the Pandemic Influenza Vaccine administered via intranasal spray on day 0 and day 28 (+/- 4d).
89186405|NCT00755703|Placebo Comparator|Experimental: Group 4|There will be 12 subjects in Group 4 that will receive a placebo consisting of buffer administered via intranasal spray on day 0 and day 28 (+/- 4d).
89389970|NCT02066246|Sham Comparator|Olympus UHI-3|patients are treated with the Olympus UHI-3-CO2-insufflation and trocar system
89389971|NCT02066246|Active Comparator|AirSeal|patients are treated with the AirSeal-CO2-insufflator and trocar-system
88865925|NCT03016572|Experimental|Enhanced Treatment As Usual (E-TAU)|The patient will be referred for regular (Standard of Care) outpatient psychiatry/ psychology services or continue with the services that they were receiving prior to admission. They will be followed up by calling patient families at 3 months (post their initial appointment) and at 12 months. They will also have 1 research visit at 6 months (with Dr. Falcone), which they will schedule during their 3 month follow-up call; the Suicide Ideation Questionnaire (SIQ) will be administered. The patients assigned to this group will also be receiving 10 caring follow-up post cards at the following weeks and months (post-discharge from the inpatient unit): 2 weeks, 4 weeks, 6 weeks, 8 weeks, 3 months, 5 months, 7 months, 9 months, 12 months, and on the patient's birthday.
89389972|NCT01359085|Active Comparator|Pregabalin|
89389973|NCT01359085|Active Comparator|ISBPB|Interscalene brachial plexus block
89389974|NCT01351285|Experimental|Sevo group|undergoing sevoflurane-remifentanil anesthesia
89389975|NCT01351285|Active Comparator|Des group|undergoing desflurane-remifentanil anesthesia
89389976|NCT01351285|Active Comparator|Pro group|undergoing propofol-remifentanil anesthesia
89389977|NCT05189041|Other|Ruptured Cerebral Aneurysm|Quantify the aneurysmal pulsation in functional MRI on the patient with Ruptured Cerebral Aneurysm
89389978|NCT05189041|Other|Non Ruptured Cerebral Aneurysm|Quantify the aneurysmal pulsation in functional MRI on the patient with Non Ruptured Cerebral Aneurysm
89389979|NCT02032290|Active Comparator|ticagrelor|ticagrelor: loading dose of 180 mg and maintaining dose of 90 mg twice daily in NSTEMI and STEMI (Class I B) patients;
89389980|NCT02032290|Active Comparator|clopidogrel|clopidogrel: loading dose of 600 mg and maintaining dose of 75 mg daily in NSTEMI (Class I B) and STEMI (Class I C) patients.
89389981|NCT01317329|Other|Clinically prescribed CPAP therapy|Clinically prescribed CPAP therapy
89389982|NCT01351363|Experimental|Electrical pain threshold measrement patients|
89389983|NCT05384106|Experimental|Avela™ (R)-1,3-Butanediol|3 servings of Avela™, with consumption of each serving separated by 30 minutes and each serving providing 11.5 g of (R)-1,3-butanediol [total intake of 34.5 g of (R)-1,3-butanediol].
89389984|NCT03379428|Experimental|Trastuzumab plus Ibrutinib 560 mg|In Phase I, starting dose of Ibrutinib will be 560 mg orally per day. 3 patients will be enrolled first. If none of these have DLTs, 3 new patients will be enrolled at the next higher Ibrutinib dose level (840 mg orally per day). If 1 of these 3 patients have a DLT, expand this arm to 6 patients. If 2 or more of these 6 patients have a DLT, enroll 3 patients in lower dose lever (420 mg).
89389985|NCT03379428|Experimental|Trastuzumab plus Ibrutinib 840 mg|If no patients in 560 mg arm have DLTs, this arm will be opened in Phase I to see how this higher dose is tolerated.
88865926|NCT03016572|Experimental|TAU + Crisis Center (CC) Follow Up|Frontline Services will be administering (at least 9) crisis intervention phone calls to the patients; more calls will be made if they feel it is necessary for the safety and health of the patient. Follow up calls will ask the patient questions about following up in the future, whether they have had thoughts about suicide, whether they are in imminent danger of suicide by the end of the call, and whether the patient is stable. At the end of the call, the patient will be asked to rate their suicidality on a scale of 1 to 10.
89186406|NCT00576303|Experimental|RO0503821 (C.E.R.A.), 1x/4weeks|Eligible participants started RO0503821 (Continuous Erythropoietin Receptor Activator [C.E.R.A]) intravenously, at a dose of 120, 200 or 360 microgram (µg) every four weeks. The dose of C.E.R.A was based on the epoetin alfa or beta dose of<8000, 8000-16000, or >16000 international units (IU)/week, administered during the stability verification period (SVP) of 4 weeks. The SVP period was followed by dose titration period (DTP) of 16 weeks, efficacy evaluation period (EEP) of 8 weeks and long term safety period (LTSP) of 28 weeks
89186407|NCT00752739|Placebo Comparator|Arm I|Patients receive oral placebo once daily for 48 months in the absence of disease progression or unacceptable toxicity.
89186408|NCT00752739|Experimental|Arm II|Patients receive low-dose oral selenium once daily for 48 months in the absence of disease progression or unacceptable toxicity.
89186409|NCT00752739|Experimental|Arm III|Patients receive high-dose oral selenium once daily for 48 months in the absence of disease progression or unacceptable toxicity.
89186410|NCT00755781|Active Comparator|CIS|CIS in addition to standard immunosuppressive regimen.
89186411|NCT00755781|No Intervention|SOC|Standard of care (SOC) therapy for lung transplant recipients
88810512|NCT06212765|Experimental|Citrulline|The experimental product is 100% L-citrulline. Each pod will contain 10 grams of L-citrulline. Ten grams of L-citrulline provide 2.4 g of nitrogen.
88810513|NCT06212765|Active Comparator|Standard care|The active comparator is a mixture of the six non-essential amino acids. In order for the active comparator to be iso-nitrogenated compared with the experimental product, it will provide 2.4 g of nitrogen per pod. The active comparator will combine 13.2 % alanine, 19.8 % aspartate, 11.2 % glycine, 17.1 % proline, 15.6 % serine and 23.1 % histidine, for a total of 13 g of amino acids per pod.
88810514|NCT06212739|Experimental|Laser|Patients treated using fistula laser closure.
88810515|NCT06212739|Active Comparator|LIFT|Patients treated using ligation of intersphincteric fistula tract.
88810516|NCT06212726|Experimental|InjureFree Concussion Communication Tool|During the second phase of this trial, participants assigned to the experimental group (Buchholz and Gainesville High Schools) will receive the current standard of care for return to learn following SRRC with the addition of InjureFree, a wed-based injury tracking and communication tool. InjureFree will serve as a centralized area for concussion management team members to communicate and document participant progress with the return to learn program.
88810517|NCT06212726|No Intervention|Control|During the second phase of this trial, participants assigned to the control group (Newberry, Santa Fe and Eastside High Schools) Will not receive any intervention other than the current standard of care for return to learn following SRRC currently in place.
88810518|NCT06212713||Questionnaire respondents|questionnaire will be administered for validation
88810519|NCT06212700|Experimental|Virtual Multimodal Hub and usual care (Intervention Group)|The main aim of the virtual multimodal hub is to prepare participants for surgery (including the role of Enhanced Recovery after Surgery (ERAS) pathway) and support declines in physiological and psychological function associated with preoperative treatments (e.g., chemo-radiotherapy) and major surgery. The post-hospital discharge interventions will focus on the recovery of activities of daily living, occupational tasks, and recreational activities. Aided by standardised assessment tools, a comprehensive holistic baseline (first preoperative multimodal session) and post-discharge (first postoperative multimodal session) assessment of patients' physical, nutritional, psychological and overall health status, presence of co-morbidities and medical history will determine the frequency, intensity, time, type, volume, and progression of the multimodal interventions.
88810520|NCT06212700|Active Comparator|Usual care alone (Control Group)|Participants allocated to the control group will receive usual care according to their health care team, which may consist of advice on smoking cessation, reduction of alcohol intake, nutritional counselling, and medical optimisation in the preoperative anaesthetic clinic visits. Participants will be asked to maintain their normal daily activities.
88810521|NCT06212687|Experimental|Digital pre-therapy informational intervention (StartHjelp).|Patients gets access to StartHjelp, an app which gradually present treatment relevant information while the patient is on waiting list for mental health outpatient services.
88810522|NCT06212687|Active Comparator|Control group|The control group gets sent all the same information as the intervention group in written form, by mail.
88810523|NCT06212648|Experimental|SPC1001 High|SPC1001 High (Candesartan/Amlodipine/Indapamide)
88810524|NCT06212648|Experimental|SPC1001 Mid1|SPC1001 Mid1 (Candesartan/Amlodipine/Indapamide)
88810525|NCT06212648|Experimental|SPC1001 Mid2|SPC1001 Mid1 (Candesartan/Amlodipine/Indapamide)
88810526|NCT06212648|Experimental|SPC1001 Low|SPC1001 Low (Candesartan/Amlodipine/Indapamide)
88810527|NCT06212648|Active Comparator|SPC3001|SPC3001 (Candesartan 8mg)
88810528|NCT06212648|Active Comparator|SPC4001|SPC4001 (Amlodipine 5mg)
88810529|NCT06212648|Active Comparator|SPC4002|SPC4002 (Amlodipine 10mg)
88810530|NCT06212648|Placebo Comparator|Placebo|SPC1001(High, Mid1, Mid2, Low) placebo, SPC3001 placebo, SPC4001 placebo, SPC4002 placebo
88810531|NCT06212635||Non-acute decompensated liver círrhosis|Refractory ascites, low grade encephalopathy but manages to stay at home and only come in ofr check-ups.
88810532|NCT06212635||Acute decompensated liver cirrhosis|Acute event causing further decompensation and the need for in-patient care
88810533|NCT06212635||Acute on chronic liver failure|ACLF 1-3 accordic to criterias established through the Cannonic study.
88810534|NCT06212635||Controls|Healthy individuals
88810535|NCT06212596|Experimental|Selinexor cylophosphamide prednisone|Participants will receive treatment with Selinexor, Cyclophosphamide and Prednisone.
88810536|NCT06212596|Active Comparator|Cyclophosphamide predinisone|Participants will receive treatment with Cyclophosphamide and Prednisone. Participants who experience disease progression on the CP arm, may receive SCP.
88810539|NCT06212570|Experimental|KeySuite|The KeyLoop and KeyScope devices will be used to perform intra-abdominal biopsies.
88810540|NCT06212518|Experimental|GENPOP passive dehydration|In the 24 hours between the first and last face scan, reduce fluid intake by approximately 75% (equating to approximately 700 ml (women) and 800 ml (men)). Participants will be provided pre-filled water bottles and asked to only ingest fluid in bottle until second morning face scan.
88810541|NCT06212518|Experimental|GENPOP ad libitum fluid intake|No fluid restriction
89389986|NCT03379428|Experimental|Trastuzumab plus Ibrutinib 420 mg|If 2 or more patients in 560 mg arm have DLTs, this arm will be opened in Phase I to see how this lower dose is tolerated.
89389987|NCT03379428|Experimental|Phase II- Trastuzumab plus Maximum Tolerated Dose|Maximum tolerated dose from Phase I will be used here in Phase II.
89389988|NCT03132805|No Intervention|Control|Schools which receive no intervention
89389989|NCT03132805|Experimental|PATHS to PAX|Universal classroom-based preventive intervention designed to reduce aggression.
89389990|NCT03132805|Experimental|PATHS to PAX and the IncredibleYears|The combination of PATHS to PAX with the Incredible Years child and parent groups.
89186412|NCT00755859|Experimental|1|Six month steroid course plus azathioprine
89389991|NCT03628131|Experimental|Pazopanib + conventional chemotherapy|Conventional chemotherapy (Ifosfamide, carboplatin, etoposide) with Pazopanib
89389992|NCT02067884|Experimental|Diagnostic (CEUS, SWE)|Patients undergo dynamic contrast-enhanced ultrasound imaging and shear wave elastography at baseline, 2-3 weeks after initiation of chemotherapy, and before surgery.
89389993|NCT01317485|Experimental|Purulent peritonitis|"Patients with purulent peritonitis are randomised at a 2:1:1 ratio between~Laparoscopic lavage and drainage~Sigmoidectomy with primary anastomosis~Sigmoidectomy with end-colostomy"
89389994|NCT01317485|Experimental|Fecal peritonitis or overt perforation|"Patients with fecal peritonitis or an overt perforation are randomised between~Sigmoidectomy with primary anastomosis~Sigmoidectomy with end-colostomy"
89389995|NCT03612882||Western University Students|Online questionnaire
89389996|NCT03560024|Active Comparator|PACAP27|12 healthy volunteers will receive PACAP27 (10 picomole/kg/min) over 20 min
89389997|NCT03560024|Placebo Comparator|Placebo|6 healthy volunteers will receive placebo (Saline) over 20 min
89389998|NCT05102643|Experimental|Test Product|SARS-CoV-2 DNA Vaccine at 1mg and 2mg, 2 doses 3 weeks apart, intramuscular injection followed by electroporation
89389999|NCT05102643|Placebo Comparator|Reference Product|Matching placebo, 2 doses 3 weeks apart, intramuscular injection followed by electroporation
89390000|NCT01351441|Other|Age 65 years or over AND at least 5 chronic medications|
89390001|NCT02260232|Experimental|exercise intervention|Components of the program included supervised moderate to high intensity cardiorespiratory exercise, resistance training, and flexibility.
89390002|NCT02260232|No Intervention|control|
89390003|NCT01319227|Experimental|Hip Arthroplasty, ultra-short stem, conventional cup|Hip replacement with a hydroxy-apatite covered ultra-short uncemented femoral stem and a conventional uncemented acetabular cup with hydroxy-apatite covered porous coating and a moderately cross-linked polyethylene cup liner
89390004|NCT01319227|Experimental|Hip Arthroplasty, conventional stem, trabecular-titanium cup|Hip replacement with an uncemented tapered femoral stem and an uncemented acetabular cup with trabecular-Titanium backside and E-vitamin-treated polyethylene cup liner
89390005|NCT02067962|Other|Juvenile idiopathic arthritis.|Blood sample
89390006|NCT01346033||Those with Type 2 diabetes|All subjects have been diagnosed with type 2 diabetes.
89390007|NCT03613272|Experimental|Subxiphoid approach|The patients in subxiphoid group will get subxiphoid approach extended thymectomy by VATS. Whole dissection was performed through a 4 to 7cm transverse subxiphoid incision, and a single 5-mm port was inserted into the right chest cavity for the video thoracoscope and subsequently for the chest tube. The sternum was elevated with two hooks connected to the sternal frame. The lower hook was inserted through the subxiphoid incision, and the superior hook was inserted percutaneously after the mediastinal tissue including the major mediastinal vessels was dissected from the inner surface of the sternum. The thymus and fatty tissue of the anterior mediastinum and the aorta-pulmonary window was completely removed.
89390008|NCT03613272|Experimental|Intercostal approach|The patients in intercostal group will get intercostal approach extended thymectomy by VATS.
89390009|NCT05250479|No Intervention|Control group|44 pregnant women won't receive mindfulness training
89390010|NCT05250479|Experimental|"experimental group mindfulness education"|mindfulness education 44 pregnant women will receive mindfulness training
88810542|NCT06212518|Experimental|ATHLETE with fluid restriction|For 24 hours prior to the study session, encouraged to drink sufficient fluid to maintain euhydration. Asked to refrain from alcohol 24 hours prior to session. Not permitted to drink during training session.
89186413|NCT00755859|Active Comparator|2|six month steroid course
89390011|NCT01355653|Experimental|Treatment A|thermal therapy
89390012|NCT01355653|Active Comparator|Treatment B|ThermaCare Lower Back/Hip heatwrap
89390013|NCT05033223|Other|Follow-up|
89390014|NCT01346111||generation cohort|Included 5 hospitals from Buenos Aires, Argentina
89390015|NCT02032368|Experimental|TACE group|Patients in TACE group receive transarterial chemoembolization (TACE) one month after resection.
89390016|NCT02032368|No Intervention|Control group|Patients in Control group receive no management.
89390017|NCT01351519|Experimental|Aminolevulinic Acid (AL)|
89390018|NCT03612492|Active Comparator|Esmolol Group|Patients will receive esmolol during induction of anesthesia
89390019|NCT03612492|Active Comparator|Lidocaine Group|Patients will receive lidocaine during induction of anesthesia
89390020|NCT01355731||Registered Nurse|This is quality improvement study that is descriptive and is utilizing a convenience sample of direct care registered nurses employed full-time for at least one year at St. Jude Children's Research Hospital.Participants will take a onetime researcher generated therapeutic boundaries questionnaire which will describe behaviors and attitudes regarding therapeutic boundaries.
89390021|NCT04970199|Active Comparator|group 1|thirty lupus women received laser acupuncture (active) for one month (3 days week) on acupoint number 14 of GV meridian, acupoint number 4 and 11 of large intestine, acupoint number 34 of gall bladder meridian, acupoint number 3 of liver meridian, acupoint number 4, 12, and 9 of conception vessel meridian, acupoint number 40, 36, and 25 of stomach meridian, acupoint number 6 of spleen meridian, and acupoint number 5 of triple energizer meridian (laser was applied for 1 min on every acupiont).
89535357|NCT03319511|Experimental|spinal group|Ultrasound guided, In the lateral decubitus or sitting position, the puncture performed via para-median approach, at the T4-T5 or T5-T6 interspace, with a 27G spinal needle. After piercing the ligamentum flavum, the needle's stylet removed and the hub observed for free flow of CSF; injection when there is a flow of clear CSF.
89390022|NCT04970199|Sham Comparator|group 2|thirty lupus women received laser acupuncture (sham) for one month (3 days) on acupoint number 14 of GV meridian, acupoint number 4 and 11 of large intestine, acupoint number 34 of gall bladder meridian, acupoint number 3 of liver meridian, acupoint number 4, 12, and 9 of conception vessel meridian, acupoint number 40, 36, and 25 of stomach meridian, acupoint number 6 of spleen meridian, and acupoint number 5 of triple energizer meridian (laser was be applied for 1 min on every acupiont).
89390023|NCT05250401||patients with liver cirrhosis|
89390024|NCT05250401||control group|
89390025|NCT03612414|Experimental|Aqualief® tablets|400 mg mucoadhesive tablets; three times per day just
89390026|NCT03612414|Placebo Comparator|Placebo tablets|400 mg mucoadhesive placebo tablets, three times per day just
89390027|NCT01359163|Active Comparator|Femulen commercial tablets|
89186414|NCT00752817|Experimental|SC|Subjects (surgical trainees) randomised to train under a proficiency-based progression virtual reality simulation curriculum
89186415|NCT00752817|Active Comparator|CC|Subjects (surgical trainees) randomised to the current surgical training curriculum
88810543|NCT06212518|Experimental|ATHLETE ad libitum fluid intake|For 24 hours prior to the study session, encouraged to drink sufficient fluid to maintain euhydration. Asked to refrain from alcohol 24 hours prior to session. Permitted to drink during training session.
89186416|NCT00750087||1|Schizophrenia patients stabilized on Seroquel XR
88810545|NCT06212427|Other|HMO supplement|
89186417|NCT00756015|Active Comparator|Early Motion|Other: Early range of motion post-operative therapy protocol.Early range of motion group: Shoulder pendulum exercises will be allowed from the time of surgery. Immediate range of motion of the elbow, forearm, wrist and hand. At the first postoperative visit, PROM of the shoulder will be permitted under therapist direction. Patients will avoid IR and behind the back stretching. At 6 weeks, AAROM and AROM will be advanced as tolerated. Capsular stretching will be advanced until full range of motion is achieved. Strengthening activities of the rotator cuff, deltoid and scapular stabilizers will be permitted at 3 months post surgery.
89186418|NCT00756015|Other|Immobilization|Immobilization following rotator cuff repair.
89186419|NCT00686517|Experimental|PEG-IFN 24|pegylated interferon alpha-2b 1.5 ug/kg/week for 24 weeks
89186420|NCT00686517|Experimental|PEG-IFN 12|pegylated interferon alpha-2b 1.5 ug/kg/week for 12 weeks
89186421|NCT00686517|Experimental|PEG-IFN + RVB 12|pegylated interferon alpha-2b 1.5 ug/kg/week in combination with ribavirin at the dose of 10.6 mg/kg/day for 12 weeks
89186422|NCT00686205|Experimental|ABBOTT PRISM HIV O Plus assay for Specificity|All subjects will have their blood tested by the investigational HIV test.
89186423|NCT00686205|No Intervention|ABBOTT PRISM HIV O Plus Assay for Sensitivity|Samples collected from specimen vendors or from specimen collection studies were tested by the investigational HIV assay.
89186424|NCT00571701|Active Comparator|celecoxib first, then placebo|Patients randomized to start celecoxib 6 months after enrollment. Then cross over to placebo after 1 year. Celecoxib dosing will be given orally 400mg once a day for adults, 200 mg once a day for pediatric patients between 12-25kg, 100mg once a day for pediatric patients < 12kg
89390028|NCT01359163|Experimental|Femulen reformulated tablets|
89390029|NCT04952493|Experimental|anlotinib + RAI|Patients in this arm will receive anlotinib 6 cycles around RAI treatment ( 4 cycles before and 2 cycles after RAI)
89390030|NCT04952493|Other|RAI only|Patients in this arm will receive RAI treatment as scheduled.
89390031|NCT04952493|Experimental|Penpulimab + RAI|Patients in this arm will receive Penpulimab from one week prior to RAI treatment until the disease progressed or intolerable.
89390032|NCT01351597|Experimental|docetaxel/ oxaliplatin|All the patients are recurrent or metastatic breast cancer. Patients with a measurable lesion.
89390033|NCT04951245|Experimental|UC group|Ultrasound-assisted CNSs guided SLN mapping
89390034|NCT04951245|Active Comparator|GC group|CNSs plus ICG dual-tracer-guided SLN mapping
89390035|NCT01347749|Experimental|Mindfulness & Compassion Meditation-based Exposure Therapy|A 16 week group psychotherapy intervention involving PTSD psychoeducation, breathing exercises and relaxation, and Mindfulness and Self-compassion meditation exercises in session and daily at home, and Mindfulness-based in vivo exposure exercises.
89390036|NCT01347749|Active Comparator|Present Centered Therapy for PTSD|This is a more standard from of group psychotherapy (talk therapy) which focusses on current symptoms and stressors
88810546|NCT06212115||donor-mNGS-testing group|Organ donors are treated with mNGS testing before organ donation
88810547|NCT06212115||donor-non-mNGS-testing group|Organ donors are not treated with mNGS testing before organ donation
88810548|NCT06211738||People with clinical dyspnea|Any intensive care patient undergoing invasive mechanical ventilation deemed suitable for ventilatory weaning test.
88810549|NCT06211517||Adolescents|Adolescents suffering from anorexia nervosa 12 to 25 years
88810550|NCT06211517||Parents|Parents whose adolescents suffer from anorexia nervosa
88810551|NCT06211517||Healthcare professionals|Healthcare professionals in charge of adolescents suffering from anorexia nervosa
88810552|NCT06211374|Experimental|Communication Bridge™|Participants receive Communication Bridge™, a multi-component, participation-focused, dyadic intervention in which both the person with PPA and their co-enrolled communication partner are intervention recipients. Communication Bridge™ is modelled on the Living with Aphasia: Framework for Outcome Measurement (A-FROM) and the Care Pathway Model that was developed for persons living with primary progressive aphasia. Consistent with participation-focused intervention models personally salient training stimuli are incorporated into all therapy activities in the Experimental arm.
88810553|NCT06210815|Experimental|HLX42|Patients with good tolerability and well controlled disease will receive the treatment once every 3 weeks (Q3W), until progressive disease (PD) without any clinical benefit, initiation of other anti-tumor therapies, death, intolerable toxicity, or withdraw the informed consent (whichever occurs first).
88810554|NCT06210633||Endovascular thrombectomy|Patients in this group will be treated with medical management plus endovascular thrombectomy
88810555|NCT06210633||Medical management|Patients in this group will be treated with medical management alone
88810556|NCT06210555||Living kidney donors|
88810557|NCT06210555||Transplant recipients|
88810558|NCT06210555||Healthy controls|
88865927|NCT03016572|Experimental|TAU + CC Follow Up + Wraparound Services|This group will be linked with a care coordinator through Tapestry services. Wraparound is an intensive, individualized care coordination and treatment planning process that involves all of the important people in a child's life to work together to make the child successful in school, at home and in the community.
88865928|NCT03016728|Experimental|Physical Activity|Participants in the experimental arm (i.e., physical activity) will be asked to complete the 12-week home-based physical activity program and to complete all study assessments.
88865929|NCT03016728|No Intervention|Wait-List Control|Participants in the no intervention arm (i.e., wait-list control) will be asked to maintain their usual lifestyle activities and to complete all study assessments. Participants in this arm will be provided with the 12-week home-based physical activity program in the exact same way as participants in the experimental arm (i.e., physical activity) at the end of the study.
88865930|NCT03016806|Other|Full Intensity, TBI-based Conditioning|Full Intensity TBI-based Conditioning Total Body Irradiation 1200 cGy in fractions of 150 cGy days -8 or -7 to -4 Cyclophosphamide 60 mg/kg/day x 2 doses days -3 and -2 Mesna 60 mg/kg/day with 20% loading dose with first Cyclophosphamide followed by continuous infusion over 24 hours x 2 doses [to be completed 24 hours after final Cyclophosphamide dose] followed by Cord Blood Infusion Other names: TBI/Cy
88865931|NCT03016806|Other|Full Intensity, Chemo-based Conditioning|Full Intensity, Chemotherapy Conditioning Busulfan days -7 to -4 Recipients <5 years - 1 mg/kg/dose x 16 doses every 6 hours Recipients >/= 5 years - 0.8 mg/kg/dose x 16 doses every 6 hours Cyclophosphamide 60 mg/kg/day x 2 doses days -3 and -2 Mesna 60 mg/kg/day with 20% loading dose with first Cyclophosphamide followed by continuous infusion over 24 hours x 2 doses [to be completed 24 hours after final Cyclophosphamide dose] followed by Cord Blood Infusion Other names: Bu/Cy
88865932|NCT03016806|Other|Reduced Intensity Chemotherapy|Reduced Intensity Chemotherapy Fludarabine 30 mg/m2/day x 5 doses days -6 to -2 Melphalan 140 mg/m2/day x 1 dose day -2 Cord Blood Infusion Other names: Flu/Mel
88865933|NCT03016806|Other|Non-Myeloablative Conditioning|Fludarabine 40 mg/m2/day x 5 doses days -6 to -2 Cyclophosphamide 50 mg/kg/day x 1 dose day -6 Mesna 50 mg/kg/day with 20% loading dose with Cyclophosphamide dose followed by continuous infusion over 24 hours x 1 dose [to be completed 24 hours after Cyclophosphamide dose] Total Body Irradiation 200 cGy in a single fraction day -1 Cord Blood Infusion Other names: Flu/Cy/TBI
88865934|NCT03016650|Active Comparator|Paracetamol|Patients will receive 100 mL of physiologic saline with 1 g IV acetaminophen (paracetamol) 30 minutes before the end of the operation and postoperatively 6, 12 and 18 hours after percutaneous nephrolithotomy, respectively.
88865935|NCT03016650|Active Comparator|ibuprofen|Patients will receive 100 mL of physiologic saline with 800 mg IV ibuprofen 30 minutes before the end of the operation and postoperatively 6, 12 and 18 hours after percutaneous nephrolithotomy, respectively.
88865936|NCT03016494|Experimental|Test/Reference Drug|DWJ1386 Tab. followed by co-administration of DWC20155 and DWC20156 Tab.
88865937|NCT03016494|Experimental|Reference/Test Drug|co-administration of DWC20155 and DWC20156 Tab. followed by DWJ1386 Tab.
88865938|NCT03016260||Infliximab (Remicade®)|
88865939|NCT03016260||Adalimumab (Humira®)|
88865940|NCT03016260||Etanercept (Enbrel®)|
88865941|NCT03016260||Golimumab (Simponi®)|
88865942|NCT03016260||Certolizumab Pegol (Cimzia®)|
88865943|NCT03016260||Infliximab biosimilar (Remsima®/ Inflectra®)|
88865944|NCT03016260||Etanercept biosimilar (Benepali®)|
88865945|NCT03016260||Infliximab biosimilar (Flixabi®)|
88865946|NCT03016416||chronic stroke patients|Participants for the study group will be recruited from the Clalit Health Services- Ben Yair Rehabilitation Center in Jaffa Israel.
88865947|NCT03016416||control group|The control group will be with equivalent age and lifestyle as the studt group. Participants for the control group will be recruited via solicitation adds at the Ben Yair Rehabilitation Center and at near-by clinics.
88865948|NCT03016182|Active Comparator|Remote Ischemic Preconditioning(RIPC)|3 cycles of 5-min upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to a pressure 200mmHg will be given to RIPC
88865949|NCT03016182|Placebo Comparator|Control|Control group without remote ischemic preconditioning
88865950|NCT03016026|Experimental|ERAS|Preoperative education,breathing training and atomizing during the time of preoperative preparation.Shorten fasting time and carbohydrate load.The intravenous fluid therapy is restricted.Drainage and nasogastric tube are not placed (except the concerns of surgical safety).All patients undergo laparoscopic distal gastrectomy.An optimal management of acute postoperative pain is multimodal analgesia consists of surgical site infiltration, a nonsteroidal anti-inflammatory drug for postoperative three days (POD) and epidural analgesia.Early oral take and move.
88865951|NCT03015870|Experimental|Feedback|Behavioral: Vocal exercise with real-time feedback.
88865952|NCT03015870|Active Comparator|Recording|Behavioral: Vocal exercise with recording
88865953|NCT03015714|Active Comparator|MIRT|Patients in this group will undergo a 4-week Multidisciplinary Intensive Rehabilitation Treatment (MIRT).
88865954|NCT03015714|Active Comparator|MIRT-AT|Patients in this group will undergo a 4-week Multidisciplinary Intensive Rehabilitation Treatment associated with Aquatic Therapy (MIRT-AT).
89186425|NCT00571701|Placebo Comparator|Placebo first, then celecoxib|Patients randomized to start placebo 6 months after enrollment. One placebo capsule will be taken orally once a day. Placebo will match appearance of active celecoxib capsules. Cross over to 12 months of treatment with celecoxib after 1 year.
88865955|NCT03015948|Experimental|2.5mg SHR4640|10 subjects will be randomized in a 4:1 ratio to receive a single dose of either 2.5 mg SHR4640 (n=8) or placebo (n=2)
88865956|NCT03015948|Experimental|10mg SHR4640|10 subjects will be randomized in a 4:1 ratio to receive a single dose of either 10mg SHR4640 (n=8) or placebo (n=2) 10mg.
88865957|NCT03015948|Experimental|20mg SHR4640|10 subjects will be randomized in a 4:1 ratio to receive a single dose of either 20mg SHR4640 (n=8) or placebo (n=2) .
88865958|NCT03015948|Experimental|Placebo|For each dose cohort, 10 subjects will be randomized in a 4:1 ratio to receive a single dose of either SHR4640 (n=8) or placebo (n=2)
88865959|NCT03015948|Experimental|5mg SHR4640|10 subjects will be randomized in a 4:1 ratio to receive a single dose of either 5 mg SHR4640 (n=8) or placebo (n=2)
89186426|NCT00686127|Active Comparator|Lidocaine Patch|Drug: lidocaine patch 5% (Lidoderm®, Endo Pharmaceuticals Inc.), 1 patch was applied topically to the affected site(s) for 12 hours each day.
88865960|NCT03015480|Experimental|Remote counseling|This group of people will be asked to track dietary information on MyFitnessPal and receive remote dietary counseling with a dietitian.
88865961|NCT03015636|Experimental|Behavioral: Adjusted CBT-i for ADHD|Cognitive Behavioral group intervention for sleep problems in ADHD, based on Cognitive Behavioral Therapy for insomnia and behavioral treatment for Sleep Phase Disorders.
88865962|NCT03015636|Other|Treatment as Usual|Treatment as Usual. (After about ten weeks, participants in this condition are offered the experimental group treatment.)
88865963|NCT03015246|Placebo Comparator|Extended-Release Morphine + placebo stressor|Participants will be maintained on extended-release morphine (dose tailored to the individual, based on pre-experimental opioid use amount), in three divided daily doses. The placebo stressor will be administered on one day.
88865964|NCT03015246|Experimental|Buprenorphine/Naloxone low dose + placebo stressor|Participants will be maintained on Buprenorphine/Naloxone (Zubsolv™) sublingual tablet doses of 1.4/0.36 mg/day. The placebo stressor will be administered on one day.
88865965|NCT03015246|Experimental|Buprenorphine/Naloxone moderate dose + placebo stressor|Participants will be maintained on Buprenorphine/Naloxone (Zubsolv™) sublingual tablet doses of 4.2/1.08 mg/day. The placebo stressor will be administered on one day.
88865966|NCT03015246|Experimental|Buprenorphine/Naloxone high dose + placebo stressor|Participants will be maintained on Buprenorphine-Naloxone (Zubsolv™) sublingual tablet doses of 12.8/3.16 mg/day. The placebo stressor will be administered on one day.
88865967|NCT03015246|Experimental|Extended-Release Morphine + active stressor|Participants will be maintained on extended-release morphine (dose tailored to the individual, based on pre-experimental opioid use amount), in three divided daily doses. Yohimbine 60mg powder + Hydrocortisone (Cortef™) 20mg tablet administered on one day.
88865968|NCT03015246|Experimental|Buprenorphine/Naloxone low dose + active stressor|Participants will be maintained on Buprenorphine/Naloxone (Zubsolv™) sublingual tablet doses of 1.4/0.36 mg/day. The placebo stressor will be administered on one day. Yohimbine 60mg powder + Hydrocortisone (Cortef™) 20mg tablet administered on one day.
88865969|NCT03015246|Experimental|Buprenorphine/Naloxone moderate dose + active stressor|Participants will be maintained on Buprenorphine/Naloxone (Zubsolv™) sublingual tablet doses of 4.2/1.08 mg/day. Yohimbine 60mg powder + Hydrocortisone (Cortef™) 20mg tablet administered on one day.
89186427|NCT00686127|Placebo Comparator|Placebo Patch|Drug: placebo patch, 1 patch was applied topically to the affected site(s) for 12 hours each day.
89186428|NCT00718718|Experimental|Part A, Group 1|Participants will receive placebo (Week 0 to Week 10) and later CNTO 136 100 mg (Week 12 to Week 22) every 2 weeks. Stable dose of methotrexate will be maintained through Week 24.
89186429|NCT00718718|Experimental|Part A, Group 2|Participants will receive CNTO 136 100 mg (Week 0 to Week 10) and later placebo (Week 12 to Week 22) every 2 weeks. Stable dose of methotrexate will be maintained through Week 24.
88865970|NCT03015246|Experimental|Buprenorphine/Naloxone high dose + active stressor|Participants will be maintained on Buprenorphine-Naloxone (Zubsolv™) sublingual tablet doses of 12.8/3.16 mg/day. Yohimbine 60mg powder + Hydrocortisone (Cortef™) 20mg tablet administered on one day.
88865971|NCT03014934||Cases: Prior Invasive Aspergillosis|History of probable or proven Invasive Aspergillosis according to EORTC 2008 criteria
88865972|NCT03014934||Controls: No prior proven Invasive Aspergillosis|Patients really negative for Invasive Aspergillosis and those with possible Invasive Aspergillosis
88865973|NCT03014856||OB-NMR|overweight and obese children and adolescents
88865974|NCT03014856||NMR-C|normal-weight children and adolescents
88865975|NCT03015168||Observational Group|Patients with rectal cancer undergoing capecitabine and concurrent intensity modulated radiotherapy
88865976|NCT03015012|Active Comparator|Standard Nutrition Intervention (SNI)|Transplant participants will receive standard nutrition counselling from a registered dietitian focused on strategies from the Canadian Diabetes Association's patient resource 'Just the Basics.' Nutrition counselling will focus on weight management. Individuals recruited from The East Elgin Family Health Team will complete the GLB Program. Transplant participants will receive a monthly follow-up email or phone call reviewing their nutrition and physical activity plan, until 12 months after baseline data collection. Reminders of lifestyle goals will be incorporated into the GLB Program for participants at the East Elgin Family Health Team.
89003543|NCT05061550|Experimental|Arm 5: AZD0171 + durvalumab + CTX|"Participants will receive AZD0171 + durvalumab + CTX as neoadjuvant treatment and AZD0171 + durvalumab as adjuvant treatment.~Participants will receive one of the following chemotherapy regimens, based on the tumour histology and Investigator's discretion, as part of their treatment regimen prior to surgery:~Carboplatin/Paclitaxel Pemetrexed/Cisplatin Pemetrexed/Carboplatin"
89003544|NCT05058456|Experimental|Single-arm|
89186430|NCT00718718|Experimental|Part B, Group 1|Participants will receive placebo (Week 0 to Week 10) and later CNTO 136 100 mg (Week 12 to Week 24) every 2 weeks. Stable dose of methotrexate will be maintained through Week 24.
89186431|NCT00718718|Experimental|Part B, Group 2|Participants will receive CNTO 136 100 mg (Week 0 to Week 24) every 2 weeks. Stable dose of methotrexate will be maintained through Week 24.
89186432|NCT00718718|Experimental|Part B, Group 3|Participants will receive CNTO 136 100 mg (Week 0 to Week 24) every 4 weeks and placebo at interim visits (Weeks 2, 6, 10, 14, 18, and 22). Stable dose of methotrexate will be maintained through Week 24.
89186433|NCT00718718|Experimental|Part B, Group 4|Participants will receive CNTO 136 50 mg (Week 0 to Week 24) every 4 weeks and placebo at interim visits (Weeks 2, 6,10, 14, 18, and 22). Stable dose of methotrexate will be maintained through Week 24.
88865977|NCT03015012|Experimental|Personalized Nutrigenomics Testing (PNT)|Participants will receive nutrition counselling from a registered dietitian based on the results of their personalized nutrigenomics testing. Nutrition counselling will focus on weight management. Individuals recruited from The East Elgin Family Health Team will complete the GLB Program, but will be given personalized nutrition and physical activity advice based on the results of their nutrigenomics test. Transplant participants will receive a monthly follow-up email or phone call reviewing their nutrition and physical activity plan, until 12 months after baseline data collection. Reminders of lifestyle goals will be incorporated into the GLB Program for participants at the East Elgin Family Health Team.
88865978|NCT03014544||Group 1: Sequence AABB|Participants of main study with Major Depressive Disorder (MDD) will be assigned in test sequence group AABB (Group 1) to undergo sequential cognitive performance evaluations by Test A (Computer- administered test battery) on Test Day 1 (Study Day 1) and Test Day 2 (Study Day 15 to 22) followed by Test B (Examiner-administered test battery) on Test Day 3 (Study Day 29 to 43) and Test Day 4 (Study Day 43 to 64). Each separated by a memory washout period of 14 to 21 days.
88865979|NCT03014544||Group 2: Sequence BBAA|Participants of main study with MDD will be assigned in test sequence group BBAA (Group 2) to undergo sequential cognitive performance evaluations by Test B (Examiner-administered test battery) on Test Day 1 (Study Day 1) and Test Day 2 (Study Day 15 to 22) followed by Test A (Computer- administered test battery) on Test Day 3 (Study Day 29 to 43) and Test Day 4(Study Day 43 to 64). Each separated by a memory washout period of 14 to 21 days.
88865980|NCT03014778|Experimental|The Chlorhexidine gluconate arm|35 women undergoing surgery will be vaginally pre-op washed by 0.05% chlorhexidine gluconate, 50 cc for 1 minute. 3 samples will be taken for culture: before, 10 minutes and 30 minutes after the wash.
88865981|NCT03014778|Active Comparator|The Povidone iodine arm|35 women undergoing surgery will be vaginally pre-op washed by 10% Povidone iodine, 50 cc for 1 minute. 3 samples will be taken for culture: before, 10 minutes and 30 minutes after the wash.
88865982|NCT03014466|Active Comparator|Tablet|Preoperative patients will utilize a video tablet for addressing pre anesthesia anxiety
88865983|NCT03014466|Experimental|Video Projector|Preoperative patients will utilize a video projection unit for addressing pre anesthesia anxiety
88865984|NCT03014310|Experimental|Arm 1: 3.75 mcg A/H5N8 + AS03|3.75 mcg A/H5N8 + AS03 given IM on Day 1 and 22, n=30
88865985|NCT03014310|Experimental|Arm 2: 15 mcg A/H5N8 + AS03|15 mcg A/H5N8 + AS03 given IM on Day 1 and 22, n=30
88865986|NCT03014310|Active Comparator|Arm 3: 15 mcg A/H5N8 unadjuvanted|15 mcg A/H5N8 unadjuvanted given IM on Day 1 and 22, n=15
88865987|NCT03014310|Experimental|Arm 4: 3.75 mcg A/H5N8 + MF59|3.75 mcg A/H5N8 + MF59 given IM on Day 1 and 22, n=30
88865988|NCT03014310|Experimental|Arm 5: 15 mcg A/H5N8 + MF59|15 mcg A/H5N8 + MF59 given IM on Day 1 and 22, n=30
88865989|NCT03014310|Active Comparator|Arm 6: 15 mcg A/H5N8 unadjuvanted|15 mcg A/H5N8 unadjuvanted given IM on Day and 22, n=15
88865990|NCT03014154|Active Comparator|Video training Game|"Patients were submitted prior to the treadmill warming the 2kmh during 1° minutes before each session. Then held 30 minutes of aerobic interval training with video game (10 rounds of 3 minutes with 30 seconds of rest between each), followed by 5 minutes of cool-down again on the mat. The game used for training was the reflex Ridge Kinect Adventure (Xbox-360). At a higher level, it is necessary for the child to perform a greater number of jumps, squats, lateral movements and arm movements. All the activity was monitored against FC and SpO2. To determine the intensity of physical activity energy expenditure assessments were made. In which four are for the pre and post intervention evaluation and sixteen training sessions."
88865991|NCT03014154|Active Comparator|Endurance muscle training|Patients were submitted prior to the treadmill warming the 2kmh during 1° minutes before each session. Then held 30 minutes of aerobic interval training with video game (10 rounds of 3 minutes with 30 seconds of rest between each) followed by 5 minutes of cool-down again on the mat.Then the children were subjected to low intensity to endurance muscle training with 3 sets of 15 repetitions to upper limbs diagonally primitive and flexion and extension to lower lumbs. All the activity was monitored against FC and SpO2.To determine the intensity of physical activity energy expenditure assessments were made. In which four are for the pre and post intervention evaluation and sixteen training sessions.
89186434|NCT00718718|Experimental|Part B, Group 5|Participants will receive CNTO 136 25 mg (Week 0 to Week 24) every 4 weeks and placebo at interim visits (Weeks 2, 6,10, 14, 18, and 22). Stable dose of methotrexate will be maintained through Week 24.
89186435|NCT04085822|Experimental|Multiple Abdominal Injections|Ten injections per patient: 7 of SMA-001 and 3 of control device.
89186436|NCT00683787|Active Comparator|Arm I|Patients receive docetaxel IV once every 3 weeks.
89186437|NCT00683787|Experimental|Arm II|Patients receive docetaxel IV as in arm I and oral vandetanib (100 mg) once daily.
89186438|NCT00683787|Experimental|Arm III|Patients receive docetaxel IV as in arm I and oral vandetanib (300 mg) once daily.
89186439|NCT03943706||Exclusive cigarette smokers|Exclusive cigarette smokers must smoke at least 10 cigarettes per day for the past three months and have exhaled carbon monoxide (eCO) levels of at least 6 ppm at the screening visit.
89186440|NCT03943706||Dual (Electronic cigarette and cigarette smoking) users|Dual e-cigarette and cigarette users must have smoked at least 5 cigarettes per day for the last 3 months and use e-cigarettes at least 15 days per month for the last 3 months.
89186441|NCT02560935|Active Comparator|Moderate Dose Hydroxyurea|Hydroxyurea at 20 mg/kg/day (range 17.5 to 26 mg/kg/day) for primary stroke prevention.
89186442|NCT02560935|Active Comparator|Low Dose Hydroxyurea|Hydroxyurea at 10 mg/kg/day (range 7 to 15 mg/kg/day) for primary stroke prevention.
89186443|NCT00723008|Experimental|A|Upon randomization, a double blinded Alpha Stim 100 device preset to the lowest effective setting (1/6) will be applied to the earlobes of the subject for one hour per day for 5 days per week for 4 weeks; after the blinded period is completed the patient will wear a different Alpha Stim device that has not been blinded for one hour per day for 5 days per week for 4 weeks, with settings at the patient's preference (1 to 6/6). Report of pain, anxiety will be assessed before and after each daily session during the 8 week period.
89390037|NCT02793128|Experimental|UGN-101 instillations|The Mitomycin C (MMC) concentration of UGN-101 to be used in this trial will be 4 mg MMC per 1 mL of TC-3 gel, maximum dose is 15ml. 6 once weekly intravesical instillations for the ablation treatment.
89535358|NCT03226561|Active Comparator|Panoptix Group|Patients will receive bilateral phacoemulsification with diffractive trifocal lenses implantation (Phaco / Panoptix)
88865992|NCT03014232|Experimental|SLED-f with HCO dialyzer|Online sustained low-efficiency diafiltration (online SLED-f) using novel high cut-off dialyzer which had larger pore size than standard high-flux dialyzer was assigned as the new intervention to compare the efficacy of cytokine removals with the control arm.
88865993|NCT03014232|Active Comparator|SLED-f with HF dialyzer|Online sustained low-efficiency diafiltration (online SLED-f) using standard high-flux dialyzer in septic acute kidney injury patients was assigned as the control group
88865994|NCT03014388|Experimental|Autogenous bone graft (Gold Standard).|Patients with defective posterior maxillary alveolar ridges requiring implant insertion will have Autogenous bone graft (Gold standard) and to be used for bone augmentation with sinus lift.
88865995|NCT03014388|Experimental|Mineralized Plasmatic Matrix (MPM)|Patients with defective posterior maxillary alveolar ridges requiring implant insertion will receive bone graft using Mineralized plasmatic matrix.
88865996|NCT03014076|Experimental|GP2 peptide + GM-CSF + trastuzumab|HLA-A2+/A3+ subjects receive GP2 + GM-CSF vaccine and trastzumab
88865997|NCT03014076|Active Comparator|Trastuzumab|HLA-A2-/A3- subjects followed as controls receiving trastuzumab.
88865998|NCT03013842|Experimental|Administration of Fetal Oximetry Probe|Administration of Raydiant Oximetry Sensor System on 36 weeks or greater pregnant women
88865999|NCT03013686|Active Comparator|Interval Appendectomy|"The periappendicular abscess, diagnosed by a CT-scan or MRI, is initially treated conservatively with antibiotic therapy and with drainage, if necessary.~Interval appendectomy is performed at two months after the primary treatment, all patients also undergo colonoscopy prior to appendectomy."
88866000|NCT03013686|Active Comparator|Follow-up with MRI|"The periappendicular abscess, diagnosed by a CT-scan or MRI, is initially treated conservatively with antibiotic therapy and with drainage, if necessary.~The patients undergo abdominal magnetic resonance imaging at two months after the primary treatment, all patients also undergo colonoscopy right after the MRI."
88866001|NCT03013764|Placebo Comparator|normal protein intake|subjects will undergo 10 days of low physical activity while consuming a normal protein diet
88866002|NCT03013764|Experimental|high protein intake|subjects will undergo 10 days of low physical activity while consuming a high protein diet
88866003|NCT03013530||Patients with chronic disease|
88866004|NCT03013296|Placebo Comparator|Placebo|Saline
88866005|NCT03013296|Other|GIP-A|Infusion of GIP-A alone as study tool.
88866006|NCT03013296|Other|GLP-1 receptor antagonist Exendin[9-39]|Infusion of GLP-1 receptor antagonist Exendin[9-39] alone as study tool.
88866007|NCT03013296|Other|GIP-A + Exendin[9-39]|Infusion of GIP-A + GLP-1 receptor antagonist Exendin[9-39] together as study tools.
88866008|NCT03013374||Human milk fed infants|"Infants fed fortified human milk at enrollment~Any intervention is performed. Groups distinction is made according to own mother's milk availability."
88866009|NCT03013374||Preterm formula|"Infants fed preterm formula milk at enrollment.~Any intervention is performed. Groups distinction is made according to own mother's milk availability."
88866010|NCT03013452|Active Comparator|Autogenic drainage|Chest physiotherapy by autogenic drainage daily for 15 minutes each day, for 1 month. Instruction by a physiotherapist as to proper technique will be given at the beginning of the study.
88866011|NCT03013452|Active Comparator|oPEP|Chest physiotherapy with an Aerobika oPEP device daily for 15 minutes each day for 1 month. Instruction by a physiotherapist as to proper technique will be given at the beginning of the study.
88866012|NCT03013608|Experimental|relocation of nail plate|the simple relocation of the nail plate in nailbed injuries in paediatric population
88866013|NCT03013062||WITH PULMONARY HYPERTENSION|It is defined as MPAP > 25 mm Hg at rest or >30 mm Hg during exercise with PVR > 3 wood units and PCWP < 15 mm Hg.
88866014|NCT03013140|Experimental|Goal-directed preloading|"Fluid therapy: Within 30 minutes before spinal anaesthesia, repeat Ringer's Injection 3ml/kg within 3 minutes with 1-min gap until change in SV (ΔSV) <5%"
88866015|NCT03013140|Active Comparator|Preloading|"Fluid therapy: Within 30 mins before spinal anaesthesia, infuse 1000ml Ringer's injection with a pressurizer within 15 minutes."
89186444|NCT00723008|Experimental|B|Upon randomization, a double blinded Alpha Stim 100 device preset to no stimulation (0/6)will be applied to the earlobes of the subject for one hour per day for 5 days per week for 4 weeks; after the blinded period is completed the patient will wear a different Alpha Stim device that has not been blinded for one hour per day for 5 days per week for 4 weeks, with settings at the patient's preference (1 to 6/6). Report of pain, anxiety will be assessed before and after each daily session during the 8 week period.
89390038|NCT04400799|Experimental|Test Group|Enoxaparin (Clexane®) will be given at the recommended dose of 4,000 IU antiXa activity (40 mg/0.4 ml) once daily by SC injection for 14 days.
88866016|NCT03012516|Experimental|PAP-treatment by physiotherapist.|Enhanced PAP-support by physiotherapist including fitness test, individualized dialogue concerning PA, prescribed PAP and a 7 times follow-up during the one year intervention..
88866017|NCT03012516|Active Comparator|Ordinary PAP-treatment at the health care centre.|Ordinary PAP-treatment at the health care centre including individualized dialogue concerning PA, prescribed PAP and an individually adjusted follow-up.
88866018|NCT03012750|Experimental|foot perfusion|intravenous application of indocyanine green in patients receiving tibial Bypass surgery
88866019|NCT03012204|Experimental|combined rTMS at both M1|combined rTMS at both M1: sham 6 hertz(Hz) rTMS on unaffected M1 / real 1 Hz rTMS on unaffected M1 / real 6 Hz rTMS on affected M1
88866020|NCT03012204|Experimental|real primed LFrTMS at unaffected M1|real primed LFrTMS at unaffected M1: real 6 hertz(Hz) rTMS on unaffected M1 / real 1 Hz rTMS on unaffected M1 / sham 6 Hz rTMS on affected M1
88866021|NCT03012204|Active Comparator|real LFrTMS at unaffected M1|real LFrTMS at unaffected M1: sham 6 hertz(Hz) rTMS on unaffected M1 / real 1 Hz rTMS on unaffected M1 / sham 6 Hz rTMS on affected M1
89186445|NCT00750399|Experimental|Intravitreal ranibizumab|Patients will receive intravitreal ranibizumab on a monthly basis depending on response to treatment
89186446|NCT00756171|Experimental|1|Verum; colesevelam
89186447|NCT00756171|Placebo Comparator|2|placebo
89003545|NCT05056220|Active Comparator|High expected effect: Human Albumin 20% + Standard Medical Treatment|Participants stratified to a high expected effect of human albumin and randomized to active treatment with 20% Human Albumin infusions.
89003546|NCT05056220|Placebo Comparator|High expected effect: Saline (NaCl 0.9%) + Standard Medical Treatment|Participants stratified to a high expected effect of human albumin and randomized to placebo treatment with 0.9% NaCl (saline) infusions.
89003547|NCT05056220|Active Comparator|Low expected effect: Human Albumin 20% + Standard Medical Treatment|Participants stratified to a low expected effect of human albumin and randomized to active treatment with 20% Human Albumin infusions.
89003548|NCT05056220|Placebo Comparator|Low expected effect: Saline (NaCl 0.9%) + Standard Medical Treatment|Participants stratified to a low expected effect of human albumin and randomized to placebo treatment with 0.9% NaCl (saline) infusions.
89003549|NCT05053581||Patient|
89003550|NCT05044507|Sham Comparator|BQ 2.0 sham stimulation group|45 sessions over a period of 9 weeks (5 treatments per week) of sham study intervention with BQ 2.0 including a standardized, pre-defined and evidence-based physical and occupational therapy regimen concurrent with the study intervention.
89003551|NCT05044507|Active Comparator|BQ 2.0 active stimulation group|45 sessions over a period of 9 weeks (5 treatments per week) of active study intervention with BQ 2.0 including a standardized, pre-defined and evidence-based physical and occupational therapy regimen concurrent with the study intervention.
89003552|NCT05041335|Experimental|Heparin and microsieve|The needle will be prepped with 500 U heparin USP per 10 mL to coat the inside of the needle. The provider will expel the tissue onto the microsieve
89003553|NCT05041335|Experimental|Heparin and no microsieve|The needle will be prepped with 500 U heparin USP per 10 mL to coat the inside of the needle. The provider will expel the tissue into formalin
89003554|NCT05041335|Experimental|No heparin and microsieve|The needle not be prepped. The provider will expel the tissue onto the microsieve
89003555|NCT05041335|Active Comparator|No heparina nd no microsieve|The needle not be prepped. The provider will expel the tissue into formalin
89003556|NCT05040659||Anosmic patients|Anosmic patients will be recruited from Dr. Albers Smell Clinic at MGH and through past participation in research with known anosmia and permission to recontact. All consent and testing will occur on a phone/tablet app in the participant's home.
89003557|NCT05040659||Asymptomatic participants / Healthy participants|Asymptomatic participants recruited in a hospital setting (eg. healthcare workers and household members of symptomatic patients who are potentially COVID positive). No symptoms of COVID infection at the time of enrollment. Potential or definite exposure to SARS-CoV-2 virus without symptoms of upper respiratory infection (smell loss, taste loss, fever, myalgia, cough, nasal congestion, runny nose, shortness of breath). All consent and testing will occur on a phone/tablet app in the participant's home.
89003558|NCT05040659||Participants with a confirmed COVID-19 infection or related smell loss|Individuals who tested positive for SARS-CoV2 by an objective PCR or antigen test will be recruited to evaluate smell function weekly over 3 months. All consent and testing will occur on a phone/tablet app in the participant's home.
89003559|NCT05038267||Femous patients|Adults undergoing general anesthesia for an elective cardiac surgery requiring cardiopulmonary bypass
89003560|NCT05035212|Experimental|Efficacy Study: RSVpreF vaccine|RSVpreF
89003561|NCT05035212|Placebo Comparator|Efficacy Study: Placebo dose|Placebo
89003562|NCT05035212|Experimental|SSA: Vaccination of RSVpreF recipients with RSVpreF|Participants who originally received RSVpreF in the Efficacy Study and are eligible for SSA will receive RSVpreF in SSA.
89003563|NCT05035212|Placebo Comparator|SSA: Vaccination of RSVpreF recipients with Placebo|Participants who originally received RSVpreF in the Efficacy Study and are eligible for SSA will receive Placebo in SSA.
89003564|NCT05035212|Experimental|SSB: Vaccination of RSVpreF recipients with RSVpreF|Participants who originally received RSVpreF in the Efficacy Study and are eligible for SSB will receive RSVpreF in SSB.
89003565|NCT05035212|Placebo Comparator|SSB: Vaccination of RSVpreF recipients with Placebo|Participants who originally received RSVpreF in the Efficacy Study and are eligible for SSB will receive Placebo in SSB.
89003566|NCT05033366||Proov test strip users that record results with the Proov app|Participants using Proov test strips along with the Proov app who have logged at least one complete cycle will be asked to complete an online survey about fertility test results and current/previous pregnancy status. They will also be asked cycle history (irregular vs regular, cycle length), fertility testing (partners semen analysis results, AMH level, HSG results), possible fertility medications taken or prescribed, age, race, smoking status, and BMI.
89003567|NCT05028309|Experimental|Interventional Arm|Older group of adults (65-75 yrs). Everyone enrolled uses the 'intervention'/ external cuirass - mechanical unloading of thorax
89003568|NCT05027139|Experimental|Zanidatamab plus evorpacept (ALX148)|
89003569|NCT05016245|Experimental|TheraSphere™ Yttrium-90 Glass Microspheres|
89003570|NCT05016245|Active Comparator|conventional Transarterial Chemoembolization(cTACE)|
89003571|NCT05014282|Active Comparator|Standard Treatment|Participants randomized to Standard Treatment (ST) will be provided with a 10-week supply of nicotine patches and lozenges. ST participants will be connected with their state's tobacco quitline services and will complete weekly 4-item smartphone assessments electronically for 26 weeks. The weekly assessments consist of questions on smoking status, motivation, self-efficacy, and perceived stress.
89186448|NCT00750477|Experimental|NEM Treatment|NEM, 500 mg, once daily, orally for 8 weeks
89186449|NCT00750477|Placebo Comparator|Placebo|Placebo, 500 mg, once daily, orally for 8 weeks
89390039|NCT04400799|No Intervention|Control Group|No study drug
89390040|NCT01359241|Experimental|closed-loop insulin delivery|Subcutaneous insulin delivery adjusted according to computer-based algorithm advice, based on continuous glucose sensor readings
89390041|NCT01359241|Active Comparator|Usual diabetes treatment regimen|Usual non-insulin glucose-lowering medications
89390042|NCT05250323||Case|Patients with genetic confirmation of Huntington's disease, symptomatic (motor manifestations with a score greater than 4 on the Unified HD scale), who can walk with minimal support, without sensory deficits or other systemic diseases an Investigator judgment that may interfere with the execution of the study, coming from the Enroll study.
89390043|NCT05250323||Control|Age, gender-matched non-gene carriers family relatives
89390044|NCT04697238|Experimental|High load (11 % of body weight vests)|Subjects in this arm will carry heavy weight (11 percent of body weight) vests for 5 weeks.
89390045|NCT04697238|Placebo Comparator|Low load (1 % of body weight vests)|Subjects in this arm will carry heavy weight (1 percent of body weight) vests for 5 weeks.
89390046|NCT01347827||on pump|Coronary artery bypass grafting (CABG)with with cardiopulmonary bypass
89390047|NCT01347827||off pump|off-pump CABG surgery
89186450|NCT00718640|Experimental|Bortezomib and Dexamethasone|Bortezomib 1.3 milligram (mg) per meter^2 (m^2) bolus (a large amount) intravenous (into the vein) injection will be administered once daily on Days 1, 4, 8 and 11 of each 21-day cycle with addition of Dexamethasone 20 mg per day administered orally, once daily on Days 1 and 2, Days 4 and 5, Days 8 and 9 and Days 11 and 12 of each 21-day cycle as per Investigator's discretion for those participants who experience disease progression after treatment completion up to Cycle 2 or have no change from Baseline after completion of at least 4 cycles. The treatment will be given up to 8 cycles (24 weeks).
89390048|NCT05383794||Control|Evaluation of gingival crevicular fluid miRNA 7a-5p, miRNA 21-3p, miRNA 21-5p, miRNA 200b-3p, miRNA 200b-5p, miRNA 100-5p, miRNA 125-5p levels.
89390049|NCT05383794||Periodontitis|Evaluation of gingival crevicular fluid miRNA 7a-5p, miRNA 21-3p, miRNA 21-5p, miRNA 200b-3p, miRNA 200b-5p, miRNA 100-5p, miRNA 125-5p levels.
88866022|NCT03012204|Sham Comparator|all sham stimulation|all sham stimulation： sham 6 hertz(Hz) rTMS on unaffected M1 / sham 1 Hz rTMS on unaffected M1 /sham 6 Hz rTMS on affected M1
88866023|NCT03012438|Experimental|NIRF imaging in thyroid surgery|"7.5 mg ICG is administered i.v. and the system will be switched to fluorescence mode. If needed, a second dose of 7.5 mg ICG can be administered. After identification of the parathyroid glands, surgery will continue until there is a desire to visualize the parathyroid glands again, another dose of ICG can be given. After complete removal of thyroid, another 7.5 mg of ICG will be given to assess the perfusion of the parathyroid gland. Directly after the procedure the researcher will ask the surgeon whether he/she thinks the technique is feasible.~After surgery, the serum calcium levels will be determined in patients after total thyroidectomy on day 1, 2 and after two weeks. TSH will be determined after 2 weeks. The thyroid specimen will be send to pathology. In the specimen, the pathologist will search for parathyroid glands. Video recordings will be analyzed, quantifying the fluorescence signal compared to the background: measuring the TBR."
88866024|NCT03012048|Experimental|MadiDrop (ceramic tablet)|"Households receive a MadiDrop (silver-impregnated ceramic tablet) in a safe-storage water container to use for all drinking water needs in the household. MadiDrops are replaced every 6 months over the 2-year intervention study period.~In July 2017, all households in the MadiDrop arm were crossed over to the ceramic water filter arm due to inconsistent silver release from the ceramic tablets."
88866025|NCT03012048|Active Comparator|Silver-impregnated ceramic water filter|"Households receive a silver-impregnated ceramic filter in a safe-storage water container to use for all drinking water needs in the household. Filters are replaced at the end of the 2-year intervention study period.~In December 2017, all silver-impregnated ceramic water filters were replaced with the same ceramic filters without silver due to continued inconsistencies with silver release."
88866026|NCT03012048|Active Comparator|Safe-storage water container|Households receive a safe-storage water container alone to use for all drinking water needs in the household.
88866027|NCT03012048|No Intervention|No intervention|Households are encouraged to continue their usual water treatment practices.
89003572|NCT05014282|Experimental|Automated Treatment|Participants randomized to Automated Treatment (AT) will be given a 10-week supply of nicotine patches and lozenges. AT will also comprise of: 1) 12 proactive treatment videos, delivered weekly, that are tailored on smoking status, motivation, agency, and/or negative affect/stress; 2) 26 weeks of on-demand access to treatment content; 3) 26 weeks of text content
89003573|NCT05014191||Radiation therapy in frog leg position|
89003574|NCT05014191||Radiation therapy in straight leg position|
89186451|NCT00756249|Experimental|Lu AA24493 (CEPO): 0.005 mcg/kg|
89186452|NCT00756249|Experimental|Lu AA24493 (CEPO): 0.05 mcg/kg|
89186453|NCT00756249|Experimental|Lu AA24493 (CEPO): 0.5 mcg/kg|
89186454|NCT00756249|Experimental|Lu AA24493 (CEPO): 5.0 mcg/kg|
89390050|NCT05383794||Cardiovascular disease|Evaluation of gingival crevicular fluid miRNA 7a-5p, miRNA 21-3p, miRNA 21-5p, miRNA 200b-3p, miRNA 200b-5p, miRNA 100-5p, miRNA 125-5p levels.
89390051|NCT05383794||Periodontitis + cardiovascular disease|Evaluation of gingival crevicular fluid miRNA 7a-5p, miRNA 21-3p, miRNA 21-5p, miRNA 200b-3p, miRNA 200b-5p, miRNA 100-5p, miRNA 125-5p levels.
89390052|NCT02068040|Experimental|CocoaVia capsules|From baseline to 3 months, patients will consume 2 capsules containing pure epicatechin
89390053|NCT02068196|Experimental|Ipilimumab|Ipilimumab 3mg/kg
89390054|NCT03612570|Experimental|NPS Treated SH Lesion|Nano-Pulse Stimulation Device using pre-defined energy protocol
89390055|NCT03142451|Experimental|FMX103 1.5%|Participants will apply the assigned FMX103 minocycline foam 1.5% topically once daily for 12 weeks as directed.
89390056|NCT03142451|Placebo Comparator|Vehicle foam|Participants will apply the assigned vehicle foam topically once daily for 12 weeks as directed.
89390057|NCT04065789|Experimental|Carfilzomib,Daratumumab,revlimid and dexamethasone|Carfilzomib, Daratumumab, Lenalidomide, Dexamethasone
89390058|NCT02066480||women between 50 and 80 years hospitalized in CHD Vendée|
89390059|NCT03611478|Experimental|Probiotic formulation|Contains a probiotic formulation. One capsule to be taken by mouth once daily for 28 days.
88866028|NCT03012126|Experimental|Clinically Based: Healthy Weight Clinic|All families referred to the Healthy Weight Clinic intervention arm will be scheduled for a 30-45 minute orientation clinic visit to orient the child and family to the program. During this visit, the family will meet with the community health worker who will provide a schedule of clinic visits and dietitian contacts. The community health worker will assess the child's social and environmental context to allow treatment tailoring. For the first 6 months, each family will be asked to attend two clinic visits per month and complete weekly 20-30 minute contacts with the dietitian via telephone. The program aims to deliver approximately 30 contact hours in the 6-month period. This will be followed by monthly visits to the Healthy Weight Clinic and monthly calls with their dietitian.
88866029|NCT03012126|Experimental|Community Based: Healthy Weight & Your Child|All families referred to the Healthy Weight and Your Child intervention arm will be scheduled for a 60-minute family information session to orient the child and family to the program. During this visit, the family will receive information about the program and logistics such as program schedule and format and attendance. The program is delivered over 12 months, which includes 16 weekly sessions, followed by 4 sessions delivered every other week and concluding with 5 monthly sessions. Most sessions are 2 hours in length and include a group of about 8-15 children and their caregivers. The first hour is delivered in a classroom setting and the second hour in an additional area conducive for physical activity.
88866030|NCT03011970|Active Comparator|Oxytocin; 24IU, 15min|Intranasal administration, 24 international units (IU) oxytocin. Imaging starting 15min after nasal spray administration.
88866031|NCT03011970|Active Comparator|Oxytocin; 24IU, 45min|Intranasal administration, 24 IU oxytocin. Imaging starting 45min after nasal spray administration.
88866032|NCT03011970|Active Comparator|Oxytocin; 24IU, 75min|Intranasal administration, 24 IU oxytocin. Imaging starting 75min after nasal spray administration.
88866033|NCT03011970|Active Comparator|Oxytocin; 12IU, 45min|Intranasal administration, 12 IU oxytocin. Imaging starting 45min after nasal spray administration
88866034|NCT03011970|Active Comparator|Oxytocin; 48IU, 45min|Intranasal administration, 48 IU oxytocin. Imaging starting 45min after nasal spray administration
88866035|NCT03011970|Placebo Comparator|Placebo|Placebo nasal spray.
88866036|NCT03011736|Experimental|Supportive Care (parathyroidectomy)|Patients undergo standard minimally invasive parathyroidectomy without PTH testing during surgery.
88866037|NCT03011658|Placebo Comparator|GROUP A|5 ml of venous blood will be obtained from this group who do not have oral lichen planus and suffering from anxiety and/or depression. They will be administered a HADS standard questionnaire and their stress related issues calculated accordingly. This group has 30 patients totally
88866038|NCT03011658|Other|GROUP B|The group has 30 oral symptomatic lichen planus diagnosed patients also suffering with anxiety and/or depression. 5 ml of venous blood will be obtained from them for serum cortisol level analysis. HADS questionnaire will be administered for this group for evaluation of levels of anxiety and depression
88866039|NCT03011502|Experimental|Experimental arm|
88866040|NCT03011424|Experimental|Early Postoperative Extracorporal Liver Support Therapy (ELS)|Early Postoperative Extracorporal Liver Support Therapy (ELS) by using the Molecular Adsorbent Recirculating System (MARS)
88866041|NCT03011580|Experimental|Immediate supplementation arm|"Fultium-D3 (oral cholecalciferol or vitamin D3) will be given at a dose of 9,600 IU/day for 8 weeks (three capsules once daily as each Fulitium D-3 capsules contains 3,200 IU vitamin D3). Participants may also be given a Sensemedic dispenser each for real-time adherence monitoring and shown how to use it.~All participants will be given a supply of Fultium-D3 at a dose of 3,200 IU/day at the end of the study."
88866042|NCT03011580|Placebo Comparator|Delayed supplementation arm|Oral placebo will be given for 8 weeks at a dose of three capsules once daily. Fultium-D3 and placebo will be identical in appearance and taste. Participants may also be given a Sensemedic dispenser each for real-time adherence monitoring and shown how to use it. All participants will be given a supply of Fultium-D3 at a dose of 3,200 IU/day at the end of the study.
88866043|NCT03011190|Experimental|Iconic Therapy|The Iconic Therapy program consists of two parts: a) an intensive program of 10-12-week basic skills group 60-minute duration with a range of 6 to 8 face-to-face inserted sessions and b) an additional one-year program of 4 to 6 gradually less frequent face-to-face sessions. The groups are typically lead by two trainers -therapist and co-therapist- for about 8-12 outpatients. Added to these established sessions, a variable number of face-to-face individual sessions with the principal investigator will also take place. They will depend on participant´s requirements. They will consist on coaching their demands and providing human support throughout the study.
88866044|NCT03011190|Active Comparator|Support therapy|Support therapy consist of 10-12 weekly group sessions of 60-minute duration. Patients and trainers will learn and debate about different behavioral aspects of the borderline personality disorder: emotional instability and impulses control, Jacobson relaxation technique, self-image and communicational styles, mindfulness, self-esteem or social skills to name a few. The groups are typically lead by two trainers -therapist and co-therapist- for about 8-12 outpatients.Added to these established group sessions, a variable number of face-to-face individual sessions with the principal investigator will also take place. They will depend on participant´s requirements. They will consist on coaching their demands and providing human support throughout the study.
88866045|NCT03010956||Patients with uncontrolled diabetes mellitus|Patients with uncotrolled tyre 1 or type 2 diabetes mellitus
88866046|NCT03010956||Patients with controlled diabetes mellitus|Patients with controlled type 1 or type 2 diabetes mellitus
88866047|NCT03010878|Experimental|Yoga Arm|Yoga administered twice a week for 8 weeks. Self-management education sessions administered once a month through the University of Colorado Health Fort Collins Family Medicine Residency Program Pain Management Clinic (Pain Clinic). Yoga interventions were administered twice a week at the Pain Clinic.
88866048|NCT03010878|Experimental|Wait-list Control Arm|Participants received only self-management intervention, which is provided once a month through the University of Colorado Health Fort Collins Family Medicine Residency Program Pain Management Clinic.
88866049|NCT03011112||KL 1|All patients (>50 years) are classified to be Kellgrence/Lawrence grade 1 according to Kellgrence/Lawrence score.
88866050|NCT03011112||KL 2|All patients (>50 years) are classified to be Kellgrence/Lawrence grade 2 according to Kellgrence/Lawrence score.
88866051|NCT03011112||KL 3|All patients (>50 years) are classified to be Kellgrence/Lawrence grade 3 according to Kellgrence/Lawrence score.
89186455|NCT00756249|Experimental|Lu AA24493 (CEPO): 50.0 mcg/kg|
89186456|NCT00756249|Placebo Comparator|Placebo|
89186457|NCT02591810|Active Comparator|Serial Casting|Participants will receive the intervention of the placement of serial casting/splinting for the injured wrist. This is not a surgical intervention.
89390060|NCT03611478|Placebo Comparator|Placebo|Matching placebo to be taken once daily by mouth for 28 days.
89186458|NCT02591810|Active Comparator|Kirschner wires|Participants will receive the intervention of percutaneous fixation with Kirschner wires for the injured wrist. This will be performed surgically.
89186459|NCT02591810|Active Comparator|Foveal repair|Participants will receive the intervention of open anatomic foveal repair of the ligaments of the injured wrist. This is a surgical intervention.
89186460|NCT00753051|Active Comparator|1.|clozapine as the main agent and it will be adjuncted by haloperidol
89186461|NCT00753051|Active Comparator|2.|clozapine as the main agent and it will be adjuncted by electroconvulsive therapy
89390061|NCT02066558|Active Comparator|carbon monoxide|Inhalation of carbon monoxide up to a carboxyhemoglobin concentration of 12% and 22%.
89390062|NCT02066558|Placebo Comparator|placebo|Atmospheric air
89390063|NCT04933773|Experimental|Set averaging times: 2-4 seconds and 8 seconds|SpO2 is measured by two pulse oximeters on one participant's hand (on the index finger and middle finger). One pulse oximeter is set to an averaging time of 2-4 seconds, the second pulse oximeter is set to an averaging time of 8 seconds.
88810559|NCT06210126|Active Comparator|Pectointercostal Fascial Plane Block Group|In addition to routine standard perioperative and postoperative analgesia protocol patients will receive bilateral local anesthetic injections at the Pectointercostal Fascial Plane Block
88810560|NCT06210126|Other|Control|Patients will receive standard perioperative and postoperative analgesia protocol
88810561|NCT06209788|Experimental|Experimental group|The music intervention consists of two parts. The first part occurs during the surgical procedure, starting from the induction of anesthesia and continuing until the surgery over. The second part spans from the first day post-surgery to the fifth day (or until discharge), with the patient listening to music twice a day, each session lasting for 30 minutes. The planned times for the music sessions are expected to be at 11 a.m. and 8 p.m. Each day post-surgery, the music intervention must be completed, and measurements of respiratory rate, pulse rate, blood pressure, and pain score should be taken both before and after listening to the music. Other are routine post-operative care.
88810562|NCT06209788|No Intervention|Control group|Routine post-operative care.
88810563|NCT06209606|Experimental|Rux + Steroid|Subject will receive Ruxolitinib Oral Tablet [Jakafi] at 15mg BID, and Methylprednisolone at 40mg QOD until disease progression. Lenalidomide at 10mg QD will be added to the treatment (Ruxolitinib, Methylprednisolone) once disease progression was confirmed.
88810564|NCT06209606|Experimental|Rux + Steroid + Len|Ruxolitinib Oral Tablet [Jakafi] at 5mg, 10mg or 15mg BID, Lenalidomide Oral at 5mg or 10mg QD and Methylprednisolone Oral at 40mg QOD. (Dose varies during dose escalation portion of the study)
88810565|NCT06208670|Experimental|Progressive Muscle Relaxation Exercises|Progressive Relaxation Exercises (PGE) Practice: The importance and benefits of PGE exercises, situations to be avoided during the exercise, and the process of teaching by practicing and practicing the exercise will be done by the trained researcher for eight weeks, and it will be ensured that they repeat it at home. Progressive relaxation exercise instructions and a practical demonstration of the researcher will be made with the directives in the audio video with music. During the relaxation exercises, individuals will first intentionally tighten the muscle groups in the hands, arms, neck, shoulders, face, chest, abdomen, buttocks, feet, and fingers (muscle groups starting from the hands and ending with the feet) and then relax the muscles according to the commands on the CD.
88810566|NCT06208670|Experimental|Violent tendency Scale|was developed to identify aggression and violence tendencies
88810567|NCT06208020||LMS patients|The demographic characteristics will be collected, including sex, age, stroke duration, and lesion side; Penetration-aspiration (PAS) scale will be used to evaluate swallowing function. fNIRS will be used to detect changes in oxyhemoglobin (HbO) and deoxyhemoglobin (HbR) during rest and voluntary swallowing.
88810568|NCT06208020||healthy subjects|The demographic characteristics will be collected, including sex and age. fNIRS will be used to detect changes in oxyhemoglobin (HbO) and deoxyhemoglobin (HbR) during rest and voluntary swallowing.
88810569|NCT06207942|Active Comparator|Sedation, temperature device and high MAP|
88810570|NCT06207942|Active Comparator|Sedation, no temperature device and high MAP|
89390064|NCT04933773|Experimental|Set averaging times: 8 seconds and 16 seconds|SpO2 is measured by two pulse oximeters on one participant's hand (on the index finger and middle finger). One pulse oximeter is set to an averaging time of 8 seconds, the second pulse oximeter is set to an averaging time of 16 seconds.
89390065|NCT01351831|Experimental|Rehabilitation with strength training|
89390066|NCT01351831|Active Comparator|Rehabilitation without strength training|
88866052|NCT03011112||KL 4|All patients (>50 years) are classified to be Kellgrence/Lawrence grade 4 according to Kellgrence/Lawrence score.
88866053|NCT03010722||Regorafenib|"160 mg orally (po) od for 3 weeks of every 4-week cycle~All patients will be required to have pre-treatment dynamic contrast enhance computed tomography (DECT) scan pre-treatment and at 8 weeks. Suitable patients will also be required to have dynamic contrast enhanced magnetic resonance imaging (DEC-MRI) and diffusion weighted (DW)-MRI, pre-treatment and at 2 weeks. All patients will also be required to have an Ultrasound (USS) or CT-guided biopsy of suitable metastatic lesion."
89186462|NCT02591108|Experimental|Safety and Efficacy|Parallel treatment; use of standard TOF peripheral Stimulator to Novel Train of Four Device
89390067|NCT03611634||BIOLOGICAL COLLECTION FROM THE GUT MICROBIOTE|The aim of this study is just to constitute a biological collection from samples from the GUT microbiote in patients having a bone or joint infection treated by a suppressive subcutaneous antibiotherapy with betalactamine. No analysis will be done for instance.
89390068|NCT02064842|Experimental|TMC647055 150 mg or placebo + ritonavir (RTV)|Participants in Part 1 will receive a single oral dose of 150 mg of TMC647055 or placebo with 30 mg of RTV on Day 1.
89390069|NCT02064842|Experimental|TMC647055 450 mg or placebo + RTV|Participants in Part 1 will receive a single oral dose of 450 mg of TMC647055 or placebo with 30 mg of RTV on Day 1.
88810571|NCT06207942|Active Comparator|Sedation, temperature device and low MAP|
88810572|NCT06207942|Active Comparator|Sedation, no temperature device, and low MAP|
88810573|NCT06207942|Active Comparator|Minimal sedation, temperature device, and high MAP|
88810574|NCT06207942|Active Comparator|Minimal sedation, no temperature device and high MAP|
88810575|NCT06207942|Active Comparator|Minimal sedation, temperature device and low MAP|
88810576|NCT06207942|Active Comparator|Minimal sedation, no temperature device and low MAP|
88810577|NCT06206265|Experimental|Open Label Oral Psilocybin|
88810578|NCT06206265|Other|Waitlist Control|
88810579|NCT06205862|Experimental|FMT group|Participants are required to complete one colonoscopy and infuse 125ml of fecal suspension into the terminal ileum under endoscopy, performing the first fecal microbiota transplantation (FMT) on day 0. Subsequently, for 5 days continuously (day 1-5), the participants will undergo microbiota transplantation in the form of oral capsules, taking 40 FMT capsules within one day (20 capsules bid). Subsequently, participants will receive a maintenance treatment with oral FMT capsules once a month (approximately every 25 to 30 days, for a total of 6 maintenance treatments). Participants will continue maintenance treatment until 6 months after their initial FMT treatment and undergo their first follow-up colonoscopy between 6 to 12 months.
88810580|NCT06205862|No Intervention|No treatment group|Participants are required to complete one colonoscopy and during the procedure, 125ml of saline is infused into the terminal ileum on day 0. Subsequently, participants don't need any treatment. The participants will receive their first colonoscopy follow-up 6 to 12 months after enrollment.
88810581|NCT06205602|Active Comparator|Broadly neutralizing antibodies (bNAbs) infusions with antiretroviral therapy (ART)|
88810582|NCT06205602|Placebo Comparator|Placebo infusions with ART|
88810583|NCT06203639|Experimental|UR Caregiver group|Participants will be asked to use the UR Caregiver app daily (e.g., at least 15 minutes/day) for 8 weeks and complete and practice one module per week. On the eighth week, participants will be asked to review one of the past modules of their choice.
88810584|NCT06203639|Active Comparator|Active control|Participants will be asked to use the app daily (e.g., at least 15 minutes/day) for an 8-week period.
88810585|NCT06203639|No Intervention|Non-app using control|Participants in this group will not be using any apps in the study.
88810586|NCT06202014|Experimental|Concurrent Radiotherapy With Envafolimab and Capecitabine|Concurrent radiotherapy with envafolimab and capecitabine, post-adjuvant envafolimab and capecitabine for locally advanced pancreatic cancer
88810587|NCT06200194|Experimental|DIMS lens|DIMS spectacle lenses. Daily wear for 1.5 years.
88810588|NCT06200194|Experimental|0.01% Atropine|0.01% Atropine. One drop per eye, per day, for 1.5 years.
88810589|NCT06200194|No Intervention|Usual care|Usual care including promoting outdoor time
88810591|NCT06194227|Experimental|High-speed, Cognitive Challenge Yoga|Participants in this group will receive high-speed yoga training for 24 consecutive weeks for a total of 72 training sessions.
88810592|NCT06194227|Active Comparator|Traditional Yoga|Participants will perform standard Hatha yoga with slow controlled speed movements for 24 consecutive weeks for a total of 72 training sessions.
88810593|NCT06193499|Active Comparator|Platelet rich plasma (PRP)|High-concentration PRP injection PRP injection (0,6-1ml). Arthrex ACPmax system.
88810594|NCT06193499|Placebo Comparator|Placebo|intraarticular saline injection (0,6-1ml)
88810595|NCT06193174|Experimental|Recurrent Malignant Glioma|"Participants that have completed the study Trial of C134 in Patients With Recurrent GBM (C134-HSV-1)"
88810596|NCT06191198|Experimental|Communication Bridge™|Participants receive Communication Bridge™, a multi-component, participation-focused, dyadic intervention in which both the person with PPA and their co-enrolled communication partner are intervention recipients. Communication Bridge™ is modelled on the Living with Aphasia: Framework for Outcome Measurement (A-FROM) and the Care Pathway Model that was developed for persons living with primary progressive aphasia. Consistent with participation-focused intervention models personally salient training stimuli are incorporated into all therapy activities in the Experimental arm.
88810597|NCT06191198|Active Comparator|Evidence-Based Impairment Focused|The Control arm includes a non-dyadic intervention in which the person with PPA is the active intervention recipient and their communication partner is in a supporting role. In the Control arm, participants receive a speech-language intervention designed to address impairment and functional limitations, comprised of activities that address word retrieval and 'automatic' speech production using fixed, non-personalized, stimuli across participants.
88810598|NCT06191016|Experimental|nVNS Group|Experimental group will receive noninvasive vagal nerve stimulation (nVNS) in addition to prescribed medications
88810599|NCT06191016|Active Comparator|Sham Group|control will receive sham stimulation to vagal nerve along with prescribed medications.
88810600|NCT06188117|Experimental|Experimental Group|The 'Digital Game Addiction Awareness Training' program will be implemented in 2 sessions in 1 day for a total of 2 hours.
88810601|NCT06188117|No Intervention|Control Group|The digital Game Addiction Awareness Training program will not be applied to parents in the control group.
88810602|NCT06181357|Experimental|two-stage ZEPHYR® valves|
88810603|NCT06181357|Sham Comparator|one-stage ZEPHYR® valves|
88866054|NCT03010410||Influenza/respiratory virus pts <65 yrs|Patients with a primary microbiologic diagnosis of influenza (any strain) or other routinely clinically identified respiratory viruses
88866055|NCT03010410||Influenza/respiratory virus pts ≥ 65 yrs|Patients with a primary microbiologic diagnosis of influenza (any strain) or other routinely clinically identified respiratory viruses
88866056|NCT03010410||Sepsis/septic shock patients < 65 yrs|Sepsis and septic shock patients
88866057|NCT03010410||Sepsis/septic shock patients ≥ 65 yrs|sepsis and septic shock patients
89186463|NCT02591108|Active Comparator|Microstim|A peripheral nerve stimulator, also known as a train-of-four monitor, is used to assess neuromuscular transmission when neuromuscular blocking agents (NMBAs) are given to block musculoskeletal activity. By assessing the depth of neuromuscular blockade, peripheral nerve stimulation/monitoring can ensure proper medication dosing and thus decrease the incidence of side effects. Peripheral nerve stimulation is most commonly used for ongoing monitoring in the intensive care unit (ICU).
89186464|NCT00756483||M, 1|Male patients that have undergone total knee replacement
88866058|NCT03010644||Underserved school-aged children|Underserved school-aged children at risk for obesity
88866059|NCT03010098|Experimental|Dual-Loop TCI|the investigator modified the effect-site target concentrations by NI.If NI fall down to 46 and keep 46 more than 30 seconds,propofol and remifentanil were infused as feedback automatically to achieve the target NI of 26-46.Take blood sample before and after surgery to measure the levels of protein S100beta and NSE.
88866060|NCT03010098|Experimental|Open-Loop TCI|the investigator modified the effect-site target concentrations of both drugs without minimum or maximum concentration limits without using the Narcotrend monitor only depend on the experience of anesthesiologist.Take blood sample before and after surgery to measure the levels of protein S100beta and NSE.
89186465|NCT00756483||F, 1|Female patients that have undergone total knee replacement
89186466|NCT00756483||M, 2|Male patients that have undergone total hip replacement
89186467|NCT00756483||F, 2|Female patients that have undergone total hip replacement
89186468|NCT00753129|Active Comparator|1|Start with turning to prone position without head elevation, after 2 hours 30° head elevation, after 2 hours back to PP without head elevation.
89186469|NCT00753129|Active Comparator|2|Start with turning to prone position with 30° head elevation, after 2 hours PP without head elevation, after 2 hours back to 0° PP.
89186470|NCT00753207|Experimental|Lapatinib and Epirubicin|Fixed dose of lapatinib in combination with escalating dose of epirubicin.
89186471|NCT00715910|Experimental|Nimenrix 1 Group|Subjects 11-25 years of age who were previously vaccinated with 1 dose of Nimenrix vaccine at the time of vaccination
89186472|NCT00715910|Active Comparator|Menactra Group|Subjects 11-25 years of age who were previously vaccinated with 1 dose of Menactra vaccine at the time of vaccination
89390070|NCT02064842|Experimental|TMC647055 600 mg or placebo + RTV|Participants in Part 1 will receive a single oral dose of 600 mg of TMC647055 or placebo with 30 mg of RTV on Day 1.
88866061|NCT03010020|Experimental|STI-Positive: PCC|MSM diagnosed with rectal GC and/or CT infection counseled for HIV prevention using Personalized Cognitive Counseling (PCC) and treated with appropriate antibiotic therapy
88866062|NCT03010020|Placebo Comparator|STI-Positive: Traditional Counseling|MSM diagnosed with rectal GC and/or CT infection counseled for HIV prevention using traditional risk reduction counseling and treated with appropriate antibiotic therapy
88866063|NCT03010020|No Intervention|STI-Negative|MSM without rectal GC and/or CT infection
88866064|NCT03009864|Experimental|Tangshen Prescription|The prescription contains granules of five Chinese herbal medicines, every bag weighs 4.87g, take it one bag each time, two times a day.
88866065|NCT03009864|Placebo Comparator|Placebo|"Treatment with placebo corresponding to each dose of Tangshen Prescription~, every bag weighs 4.87g, take it one bag each time, two times a day."
89186473|NCT00715910|Experimental|Nimenrix 2 Group|Subjects 10<11 years of age who were previously vaccinated with 1 dose of Nimenrix vaccine at the time of vaccination
88866066|NCT03009708|Experimental|Allograft patients|Allograft patients followed at the Institut de Cancérologie Lucien Neuwirth perform blood samples during their post graft follow up in the usual practice, weekly. With the present study, two more blood tubes will be collected with the weekly blood samples.
88866067|NCT03009630|Experimental|RFA group|Patients with early-stage peripheral lung cancer will be performed RFA with the guidance of ENB. Post treatment response and follow up will be evaluated and carried out according to the standard procedure.
88866068|NCT03009474|Experimental|CJ-30060|Amlodipine 5 mg/ Valsartan 160 mg/ Rosuvastatin 10 mg
89390071|NCT02064842|Experimental|Sequence 1 (Treatment A-B-C)|Participants in Part 2 will receive Treatment ABC in the following sequence - Treatment A: TMC435 150 mg once daily on Days 1 to 7; Treatment B: TMC435 75 mg once daily + TMC647055 450 mg once daily in combination with RTV 30 mg once daily on Days 1 to 7; and Treatment C: TMC435 100 mg once daily + TMC647055 600 mg once daily in combination with RTV 30 mg once daily on Days 1 to 7 with a washout period of 7 days between consecutive treatment sessions in each individual participant.
88866069|NCT03009474|Active Comparator|Exforge tab 5/160mg, Crestor tab 10mg|Amlodipine 5 mg/ Valsartan 160 mg/ Rosuvastatin 10 mg
88866070|NCT03009318|Other|MRS imaging and 11C-MET PET/CT|Each patient underwent both MRS and MET PET before surgery.
88866071|NCT03009084|Experimental|Intervention group|Lifestyle counseling of modifiable risk factors of chronic kidney disease: telemonitoring of blood pressure, counseling for smoking cessation, losing weight and increasing the physical activity.
88866072|NCT03009084|No Intervention|Control group|Usual care.
88866073|NCT03008694|Experimental|1|PET/CT
88866074|NCT03008928|No Intervention|Control|No intervention
88866075|NCT03008928|Experimental|Alcooquizz app|Alcooquizz is a smartphone app designed to promote reductions in alcohol consumption among people who drink in a hazarzdous fashion
88866076|NCT03009006|Experimental|Calcium Hydroxide Mixed With Chlorhexidin|efficacy of calcium hydroxide and 2 % chlorhexidine gel and combination of both on the anaerobic bacteria, It was clear from the study that calcium hydroxide had limited efficacy against facultative anaerobes, but effective against obligate anaerobes while chlorhexidine only and combination group were effective against all species of anaerobic bacteria.
88866077|NCT03009006|Experimental|Calcium Hydroxide|The antimicrobial activity of calcium hydroxide Ca(OH)2 is related to the release of hydroxyl ions in an aqueous environment leading to damage in the bacterial cytoplasmic membrane, protein denaturation and DNA damage
88866078|NCT03009006|Placebo Comparator|Placebo|Mechanical preparation without intracanal medications.
88866079|NCT03008772||PCI with Commercially available DES|Patients who have undergone PCI and received a commercially available drug eluting stent
88866080|NCT03008772||Stent Types|the stent types for angina classification at follow up
88866081|NCT03008850|Active Comparator|Group M|2 ml (10 mg) of 0.5% heavy bupivacaine plus 0.5 ml (25 mg) MgSO4 will be injected intrathecally
88866082|NCT03008850|Active Comparator|Group P|2 ml (10 mg) of 0.5% heavy bupivacaine plus 0.5 ml normal saline will be injected intrathecally
88866083|NCT03008538|Experimental|Mineralized Plasmatic Matrix|MPM(Mineralized plasmatic matrix) insertion in extraction sockets for socket preservation for later implant placement and histomorphometric analysis.
88866084|NCT03008538|Active Comparator|Autogenous Bone Graft (Gold Standards).|Socket preservation using Autogenous bone graft for later implant placement and histomorphometric analysis.
88866085|NCT03008304|Experimental|High-activity natural killer|In this group, the patients will receive multiple high-activity natural killer immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
88866086|NCT03008304|No Intervention|Control group|In this group, the patients will receive no special treatment. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
88866087|NCT03008148|Active Comparator|Radiation,Temozolomide|"CCRT Phase: Radiation(60 Gy in 2 Gy/fx) + daily Temozolomide (75 mg/m²/day for 6 weeks).~Rest Phase: Rest for 4 weeks.~Chemotherapy Phase: Temozolomide 150-200 mg/m² Day 1-5 of 28-Day for a maximum of 6 cycles.~Maintenance Phase: No maintenance treatment until disease progression confirmed."
88866088|NCT03008148|Experimental|Radiation,Temozolomide,Siroquine(JP001)|"CCRT Phase: Radiation(60 Gy in 2 Gy/fx) + daily Temozolomide (75 mg/m²/day for 6 weeks) + Daily JP001 (2 tablets once a day for 6 weeks).~Rest Phase: Daily JP001(2 tablets/day) for 4 weeks.~Chemotherapy Phase: Temozolomide 150-200 mg/m² Day 1-5 of 28-Day for a maximum of 6 cycles + Daily JP001(2 tablets once a day) for 24 weeks (4 weeks for each cycle).~Maintenance Phase: JP001(2 tablets once a day) until disease progression confirmed."
88866089|NCT03007992|Experimental|Vinorelbine Oral|Test product: Navelbine® 20 mg / 30 mg soft capsules
88866090|NCT03007914||TCM cohort|Patients continue to receive the routine TCM treatments recommended by 2011 Chinese treatment guidelines of TCM for COPD.
88866091|NCT03007914||Conventional medicine cohort|Patients continue to receive the conventional medicine recommended by 2014 GOLD and Chinese treatment guidelines for COPD.
88866092|NCT03007836|Experimental|High-activity natural killer|In this group, the patients will receive multiple high-activity natural killer (HANK) immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
89535359|NCT03226561|No Intervention|Control Group|Control, age-matched presbyopic group corrected with presbyopic glasses
89535360|NCT03322709||Robotic-assisted kidney transplant|Adult patients undergoing robotic kidney transplantation. The transplant operation will be undertaken using the da Vinci systems robot in minimally invasive fashion.
88866093|NCT03007836|No Intervention|Control|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
88866094|NCT03007446|Experimental|Apatinib plus Oxaliplatin/S-1|"Apatinib :~A starting dose of apatinib was administered 500 mg daily on days 1 through 21 of each 3-week cycle.~Oxaliplatin:130 mg/m2，d1，ivgtt，in a 21 day cycle.~S-1:40mg，bid，d1-14，po，in a 21 day cycle."
88866095|NCT03007368|Experimental|Rice|Cooked white rice and tomato-based sauce
88866096|NCT03007368|Experimental|Potato|Cooked white peeled potato and tomato-based sauce
88866097|NCT03007368|Experimental|Pasta|Cooked macaroni product and tomato-based sauce
89535361|NCT03322709||Open kidney transplant|Adult patients undergoing kidney transplantation via an open approach.
88866098|NCT03007368|Experimental|Sorghum thick porridge|Sorghum thick porridge and tomato-based sauce
88866099|NCT03007368|Experimental|Millet thick porridge|Millet thick porridge and tomato-based sauce
88866100|NCT03007368|Experimental|Millet couscous|Cooked millet couscous and tomato-based sauce
88866101|NCT03007368|Experimental|Millet thin porridge|Millet thin porridge
88866102|NCT03007368|Experimental|Millet thin monikuru porridge|Millet thin porridge containing cooked millet granules (monikuru)
88866103|NCT03007602|Experimental|Treatment group: aerobic exercise|The upper extremity aerobic exercise training with an arm ergometer will be performed in the treatment group so that training intensity will be between 60% and 80% of the maximum heart rate, dyspnea perception will be 3-4 according to Modified Borg Scale and fatigue perception will be 5-6 according to Modified Borg Scale, training duration will be a 6-week.
88866104|NCT03007602|No Intervention|Control group: deep breathing exercise|Deep breathing exercises combinated with arm movements will be given as a home schedule in the control group. Training duration will be a 6-week.
88866105|NCT03007680|Experimental|Core muscle activation|Core muscle will be activated by physical fitness using plank, crunch and leg extension.
88866106|NCT03007680|No Intervention|No core muscle activation|
88866107|NCT03007524|Experimental|High dose rosuvastatin|20mg/d quaque nocte(qN), at least 6 months
88866108|NCT03007524|Active Comparator|Low dose rosuvastatin|10mg/d quaque nocte（qN）, at least 6 months
88866109|NCT03007290|Experimental|Treatment group|Group with therapeutic drug monitoring
88866110|NCT03007212|Experimental|HCC patients with Pranch portal vein thrombosis|Thirty HCC patients (24 male, 6 females) Child A cirrhotics with branch PVT. Follow up was done at 1, 3, 6 and 12 months after first TACE. All patients underwent laboratory investigations including liver function tests to assess deterioration in liver functions, triphasic spiral CT to assess radiological response according to mRECIST criteria. Survival analysis was performed using Kaplan-Meier estimations.
88866111|NCT03006900|Experimental|Pilates and massage|Pilates (twice per week for 50 minutes) and massage (once per week for one hour)
88866112|NCT03006900|Active Comparator|Massage|Massage (once per week for one hour)
88866113|NCT03006978|Experimental|TearCare|Subjects will receive a 12-minute treatment session with the TearCare System followed by manual expression of the meibomian glands.
88866114|NCT03006978|Active Comparator|Warm Compress|Subjects will apply a warm compress to the eyelids for 5 minutes daily for 4 weeks.
88866115|NCT03007056||Period 1|year 2011 nCPAP
88866116|NCT03007056||Period 2|year 2014 nCPAP and high flow nasal cannula
88866117|NCT03006822|Experimental|Application 90 minutes pressure release|Subjects will receive a pressure release technique for 90 seconds in the levator scapula muscle
89186474|NCT00715910|Experimental|Nimenrix Naive Group|Subjects 15 to <31 years of age at the time of primary vaccination with 1 dose of Nimenrix vaccine at year 5 of the current study
89390072|NCT02064842|Experimental|Sequence 2 (Treatment B-C-A)|Participants in Part 2 will receive Treatment BCA in the following sequence - Treatment B: TMC435 75 mg once daily + TMC647055 450 mg once daily in combination with RTV 30 mg once daily on Days 1 to 7; Treatment C: TMC435 100 mg once daily + TMC647055 600 mg once daily in combination with RTV 30 mg once daily on Days 1 to 7; and Treatment A: TMC435 150 mg once daily on Days 1 to 7 with a washout period of 7 days between consecutive treatment sessions in each individual participant.
89390073|NCT02064842|Experimental|Sequence 3 (Treatment C-A-B)|Participants in Part 2 will receive Treatment CAB in the following sequence - Treatment C: TMC435 100 mg once daily + TMC647055 600 mg once daily in combination with RTV 30 mg once daily on Days 1 to 7; Treatment A: TMC435 150 mg once daily on Days 1 to 7; and Treatment B: TMC435 75 mg once daily + TMC647055 450 mg once daily in combination with RTV 30 mg once daily on Days 1 to 7 with a washout period of 7 days between consecutive treatment sessions in each individual participant.
89535362|NCT03322709||Donor nephrectomy|Adult patients undergoing donor nephrectomy will have a scan of their abdominal wound to compare wound healing.
88866118|NCT03006822|Experimental|Application 60 minutes pressure release|Subjects will receive a pressure release technique for 60 seconds in the levator scapula muscle
88866119|NCT03006822|Experimental|Application 30 minutes pressure release|Subjects will receive a pressure release technique for 30 seconds in the levator scapula muscle
88866120|NCT03006744|Experimental|Phonological awareness training|Parents will be given specific training on how to improve phonological awareness using books provided by the investigator. Parents watch a video with examples of how to improve phonological awareness. Suggestions include placing emphasis on rhyme and alliteration, segmenting long words into syllables and talking about how words sound and what they mean.
88866121|NCT03006744|Placebo Comparator|Reading enjoyment training|Parents will be given general training on how to make reading fun. Parents watch a video with examples of how they can bring books to life with funny voices, actions, and so on. The training is of a similar duration to the intervention arm.
88866122|NCT03006588|Experimental|EUS-FNA for RPLN in NPC patients|Fine needle aspiration guided by EUS in retropharyngeal lymph node in suspicious recurrent naspharyngeal carcinoma.
88866123|NCT03006510|Active Comparator|Alert|If glucose <90 mg/dl and hypoglycemia prediction score >35, then alert with suggestion for intervention sent to treating team
88866124|NCT03006510|No Intervention|No alert|Routine standard care. If glucose <90 mg/dl and hypoglycemia prediction score >35, then report for investigators will be collected, but no active alert will be sent to teams.
88866125|NCT03006198||Cohort 1: Rheumatoid Arthritis|Participants with Rheumatoid arthritis as the major disease treated with REMICADE, SIMPONI or STELARA in clinical practice in the emerging regions of North Africa, the Middle East, and Western Asia will be observed for disease characteristics, treatment and outcomes.
88866126|NCT03006198||Cohort 2: Ankylosing Spondylitis|Participants with Ankylosing spondylitis as the major disease treated with REMICADE, SIMPONI or STELARA in clinical practice in the emerging regions of North Africa, the Middle East, and Western Asia will be observed for disease characteristics, treatment and outcomes.
88866127|NCT03006198||Cohort 3: Psoriatic Arthritis|Participants with Psoriatic arthritis as the major disease treated with REMICADE, SIMPONI or STELARA in clinical practice in the emerging regions of North Africa, the Middle East, and Western Asia will be observed for disease characteristics, treatment and outcomes.
88866128|NCT03006198||Cohort 4: Crohn's Disease|Participants with Crohn's disease as the major disease treated with REMICADE, SIMPONI or STELARA in clinical practice in the emerging regions of North Africa, the Middle East, and Western Asia will be observed for disease characteristics, treatment and outcomes.
89390074|NCT02064842|Experimental|Sequence 4 (Treatment A-C-B)|Participants in Part 2 will receive Treatment ACB in the following sequence - Treatment A: TMC435 150 mg once daily on Days 1 to 7; Treatment C: TMC435 100 mg once daily + TMC647055 600 mg once daily in combination with RTV 30 mg once daily on Days 1 to 7; and Treatment B: TMC435 75 mg once daily + TMC647055 450 mg once daily in combination with RTV 30 mg once daily on Days 1 to 7 with a washout period of 7 days between consecutive treatment sessions in each individual participant.
89390075|NCT02064842|Experimental|Sequence 5 (Treatment B-A-C)|Participants in Part 2 will receive Treatment BAC in the following sequence - Treatment B: TMC435 75 mg once daily + TMC647055 450 mg once daily in combination with RTV 30 mg once daily on Days 1 to 7; Treatment A: TMC435 150 mg once daily on Days 1 to 7; and Treatment C: TMC435 100 mg once daily + TMC647055 600 mg once daily in combination with RTV 30 mg once daily on Days 1 to 7 with a washout period of 7 days between consecutive treatment sessions in each individual participant.
88866129|NCT03006198||Cohort 5: Ulcerative Colitis|Participants with Ulcerative colitis as the major disease treated with REMICADE, SIMPONI or STELARA in clinical practice in the emerging regions of North Africa, the Middle East, and Western Asia will be observed for disease characteristics, treatment and outcomes.
89390076|NCT02064842|Experimental|Sequence 6 (Treatment C-B-A)|Participants in Part 2 will receive Treatment CBA in the following sequence - Treatment C: TMC435 100 mg once daily + TMC647055 600 mg once daily in combination with RTV 30 mg once daily on Days 1 to 7; Treatment B: TMC435 75 mg once daily + TMC647055 450 mg once daily in combination with RTV 30 mg once daily on Days 1 to 7; and Treatment A: TMC435 150 mg once daily on Days 1 to 7 with a washout period of 7 days between consecutive treatment sessions in each individual participant.
89390077|NCT04924881|Experimental|Active Arm|COVID Rehab Formula granules once daily for 8 weeks
89390078|NCT04924881|Placebo Comparator|Placebo Arm|Placebo granules once daily for 8 weeks
88866130|NCT03005886|Experimental|AMI+CP:|"GCF sampling,periodontal examination,phase I therapy:~Patients, who met the AMI diagnostic criteria with chronic periodontitis. Baseline periodontal examination of AMI patients and 24-48h GCF sampling was carried out in their hospital bed under sufficient illumination using artificial light. Phase I periodontal therapy including comprehensive proper plaque control program, scaling, subgingival curettage and root planning in Department of Periodontology. Mucoperiosteal flap operation was performed in cases where needed."
89390079|NCT01355809|Active Comparator|Inhalation Nitrogen/Oxygen|Nitrogen/Oxygen (65%/35%)
89390080|NCT01355809|Experimental|Inhalation Helium/Oxygen|Helium/Oxygen (65%/35%)
89390081|NCT01355809|Experimental|Inhalation gas|Medicinal oxygen 100% via NIV with FiO2 of 0.35
89390082|NCT03612102|Active Comparator|Treatment|The treatment consists of a 5-day intensive group behavioral treatment program (IGBT)
89390083|NCT03612102|No Intervention|Waitlist|The waitlist consists of a 4-week waitlist period where parents will be provided with psychoeducational materials about their child's condition (i.e., selective mutism). After the 4-week waitlist period, families will be provided with the opportunity to participate in IGBT.
89390084|NCT04013139||CKD Stage 3|CKD patients with GFR between 30-60cc/min
89390085|NCT04013139||CKD Stage 4|CKD Patients with GFR 15-30 cc/min
89535363|NCT03091335|Experimental|Music-listening group|Patients in this group will listen to music of their choosing during the entirety of the awake portion of deep brain stimulation surgery
88866131|NCT03005886|Active Comparator|Chronic Periodontitis (CP)|"GCF sampling,periodontal examination,phase I therapy:~Systemically healthy chronic periodontitis patients.Phase I periodontal therapy including comprehensive proper plaque control program, scaling, subgingival curettage and root planning in Department of Periodontology.Mucoperiosteal flap operation was performed in cases where needed."
88866132|NCT03005886|Sham Comparator|Healthy controls|clinically healthy individuals not having any periodontal and systemic diseases history.Comprehensive medical and periodontal examination to confirm that they did not have systemic and periodontal diseases
88866133|NCT03006120||Group 1|Conservative management
88866134|NCT03006120||Group 2|Angiografic stenting
88866135|NCT03006120||Group 3|Surgery
88866136|NCT03005496|Placebo Comparator|Intervention|"Nifedipin 4x10 mg oral~Dexamethasone 2x6 mg iv for 2 days~Zinc 50 mg/day~Beta-carotene 25,000 IU~Vitamin D3 50,000 IU/weekly"
89390086|NCT03787862||Hyperspectral Imaging (HSI)|Patients scheduled for foot surgery will be imaged using the HSI device. Data will be gathered from the electronic medical record for one year to determines the outcomes of the surgery, any complications, re-hosptializations, re-ulcerations or amputation.
89390087|NCT03141905|Active Comparator|Sick-Day Protocol|Sick-Day Protocol (instructions for holding and resumption of certain medicines in the event of dehydrating illness) and IVRSDRS weekly remote monitoring
89390088|NCT03141905|Placebo Comparator|Usual Care|Standard clinical care
89390089|NCT04917315|Experimental|JLP-2002|Drug: JLP-2002
89390090|NCT04917315|Placebo Comparator|Placebo|Drug: Placebo
89390091|NCT02068274||chronic pain|CO2 monitoring in chronic pain patients who treated with opioids.
89390092|NCT03612024||request for organ donation approved|
89390093|NCT03612024||request for organ donation rejected|
88866137|NCT03005496|Active Comparator|Control|"Nifedipin 4x10 mg~Dexamethasone 2x6 mg iv for 2 days"
88866138|NCT03005808|No Intervention|control group|All patients had the same protocol of anesthesia and analgesia. The control group didn´t received block.
88866139|NCT03005808|Experimental|TAP 0.25 group|The TAP 0.25 group received TAP block with ropivacaine 0.25% 0.4ml/kg. All patients had the same protocol of anesthesia and analgesia.
88866140|NCT03005808|Experimental|TAP 0.5 group|The TAP 0.5 group received TAP block with ropivacaine 0.5% 0.4ml/kg. All patients had the same protocol of anesthesia and analgesia.
88866141|NCT03005730|Experimental|Group 1|Submitted to a session of phototherapy with 39,27 Joules per point in muscle masseter and temporal bilateral.
88866142|NCT03005730|Placebo Comparator|Group 2|Submitted to a session of phototherapy placebo with 0,0 Joules per point in muscle masseter and temporal bilateral.
89390094|NCT01359319|Experimental|650 mg (single dose only)|Each patient will be sequentially assigned to a specific dose level and will receive two single-dose exposures at that same dose level (fasted and fed). The low-dose cohorts will be filled before assigning higher-dose cohorts. The patient will then be assigned to receive one repeat-dose regimen. The lower-dose repeat-dose cohorts will be filled before proceeding to higher repeat-dose levels.
89390095|NCT01359319|Experimental|1,950 mg (single and repeat dose)|Each patient will be sequentially assigned to a specific dose level and will receive two single-dose exposures at that same dose level (fasted and fed). The low-dose cohorts will be filled before assigning higher-dose cohorts. The patient will then be assigned to receive one repeat-dose regimen. The lower-dose repeat-dose cohorts will be filled before proceeding to higher repeat-dose levels.
89390096|NCT01359319|Experimental|2,925 mg (single and repeat dose)|Each patient will be sequentially assigned to a specific dose level and will receive two single-dose exposures at that same dose level (fasted and fed). The low-dose cohorts will be filled before assigning higher-dose cohorts. The patient will then be assigned to receive one repeat-dose regimen. The lower-dose repeat-dose cohorts will be filled before proceeding to higher repeat-dose levels.
89535364|NCT03091335|No Intervention|Head-phone only group|Patients in this group will receive the same noise-canceling headphones as the patients in the music-listening group. However, they will remain without music per standard of care for awake deep brain stimulation procedures
88866143|NCT03005652|Experimental|Mindfulness intervention|consists of eight weekly group-based sessions of 2 hours duration and an individual pre-class interview, in which the participants will be socialised to the treatment. The intervention will combine intensive training in mindfulness and compassion meditation and gentle yoga practices with psycho-educational components targeted at helping individuals to deal more effectively with emotional difficulties and stressors commonly encountered in old age. These will include addressing concerns about cognitive functioning and health, and will have a particular emphasis on cultivating wholesome attitudes towards self and others.
89003575|NCT05011578|Experimental|clinical and radiographic findings after surgical treatment for radiocapitellar fracture|30 patients will be included in a interventional study for an evaluation of the clinical and radiographic finding after at least 10 years after radiocapitellar surgery
89003576|NCT05006131||Patients who are at high-risk for pancreatic cancer|Patients that meet the eligibility criteria based on CAPS3 or updated national pancreatic cancer screening guidelines
89003577|NCT05003986|Experimental|Population 1: FSGS and/or MCD|Subjects with selected proteinuric glomerular diseases associated with FSGS and MCD histological patterns
88866144|NCT03005652|Active Comparator|Health education intervention|"follow the same format and structure as the mindfulness-based intervention, and will be matched to the mindfulness-based intervention in administration, dosage, and duration.~The treatment is based on a published manual, with every session of the program covering different subjects, including self-management, problem-solving, sleep, stress, exercise, managing medicines and memory, communicating with family, friends, and healthcare professionals, eating, weight management, and planning for the future. Participants will be provided with information about these subjects and engage in group exercises and discussions about these subjects. They will be given a workbook and asked to actively engage in activities described in by the workbook to improve health and well-being on 6 out of 7 days each week, matching home assignments in the mindfulness-based intervention."
88866145|NCT03005574|Experimental|TSW-HP|TSW-HP Intervention implemented by a cognitive specialist over a 6-month treatment period which includes 24 hours (1 hour per week) of facilitated cognitive exercise sessions, which will be supplemented by approximately 24 hours of home practice sessions on a tablet computer.
88866146|NCT03005574|Active Comparator|TSW-T|Participants assigned to traditional TSW will receive the usual TSW program, which includes a one hour cognitive exercise practice session per week at Brooklyn Community Services (BCS) for 6 months. This group will not receive home based cognitive practice exercises.
88866147|NCT03005028||Control|
88866148|NCT03005340|Active Comparator|Group A|Period 1: Bazedoxifene 20 mg Period 2: Cholecalciferol granule 10 mg Period 3: Bazedoxifene 20 mg+Cholecalciferol granule 10 mg
88866149|NCT03005340|Active Comparator|Group B|Period 1: Bazedoxifene 20 mg Period 2: Bazedoxifene 20 mg+Cholecalciferol granule 10 mg Period 3: Cholecalciferol granule 10 mg
88866150|NCT03005340|Active Comparator|Group C|Period 1: Cholecalciferol granule 10 mg Period 2: Bazedoxifene 20 mg Period 3: Bazedoxifene 20 mg+Cholecalciferol granule 10 mg
88866151|NCT03005340|Active Comparator|Group D|Period 1: Cholecalciferol granule 10 mg Period 2: Bazedoxifene 20 mg+Cholecalciferol granule 10 mg Period 3: Bazedoxifene 20 mg
88866152|NCT03005340|Active Comparator|Group E|Period 1: Bazedoxifene 20 mg+Cholecalciferol granule 10 mg Period 2: Cholecalciferol granule 10 mg Period 3: Bazedoxifene 20 mg
88866153|NCT03005340|Active Comparator|Group F|Period 1: Bazedoxifene 20 mg+Cholecalciferol granule 10 mg Period 2: Bazedoxifene 20 mg Period 3: Cholecalciferol granule 10 mg
88866154|NCT03005184|Experimental|S/V+Pla, S/V+I, Enal+Pla, Enal+I|Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.
88866155|NCT03005184|Experimental|S/V+Pla, Enal+I, S/V+I, Enal+Pla|Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.
88866156|NCT03005184|Experimental|S/V+Pla, Enal+Pla, Enal+I, S/V+I|Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.
88866157|NCT03005184|Experimental|S/V+I, S/V+Pla, Enal+I, Enal+P|Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.
88866158|NCT03005184|Experimental|S/V+I, Enal+Pla, S/V+Pla, Enal+I|Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.
89390097|NCT01359319|Experimental|4,875 mg (single and repeat dose)|Each patient will be sequentially assigned to a specific dose level and will receive two single-dose exposures at that same dose level (fasted and fed). The low-dose cohorts will be filled before assigning higher-dose cohorts. The patient will then be assigned to receive one repeat-dose regimen. The lower-dose repeat-dose cohorts will be filled before proceeding to higher repeat-dose levels.
89390098|NCT01359319|Experimental|6,000 mg (single and repeat dose)|Each patient will be sequentially assigned to a specific dose level and will receive two single-dose exposures at that same dose level (fasted and fed). The low-dose cohorts will be filled before assigning higher-dose cohorts. The patient will then be assigned to receive one repeat-dose regimen. The lower-dose repeat-dose cohorts will be filled before proceeding to higher repeat-dose levels.
89390099|NCT04887597|Experimental|Secukinumab Treatment|all patients receive Secukinumab as well as a biopsy before and after treatment
88866159|NCT03005184|Experimental|S/V+I, Enal+I, Enal+Pla, S/V+Pla|Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.
88866160|NCT03005184|Experimental|Enal+Pla, S/V+Pla, S/V+I, Enal+I|Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.
88866161|NCT03005184|Experimental|Enal+Pla, S/V+I, Enal+I, S/V+Pla|Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.
88866162|NCT03005184|Experimental|Enal+Pla, Enal+I, S/V+Pla, S/V+I|Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.
88866163|NCT03005184|Experimental|Enal+I, S/V+Pla, Enal+Pla, S/V+I|Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.
88866164|NCT03005184|Experimental|Enal+I, S/V+I, S/V+Pla, Enal+Pla|Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.
88866165|NCT03005184|Experimental|Enal+I, Enal+Pla, S/V+I, S/V+Pla|Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.
88866166|NCT03004560|Active Comparator|Standard Laparoscopic Approach|Minimally invasive laparoscopic procedure with 5-10 mm incisions.
88866167|NCT03004560|Active Comparator|Percutaneous Approach|Minimally invasive laparoscopic procedure with 2-3 mm incisions.
88866168|NCT03004092|Experimental|Total cohort|
89186475|NCT00715910|Experimental|Nimenrix Pooled Group|Pooled group of subjects 10-25 years of age from Nimenrix 1 and Nimenrix 2 groups in the primary study (NCT00454909) who had received 1 dose of Nimenrix vaccine in that study and will receive a booster dose in this current study.
89186476|NCT00715910|Active Comparator|Menactra Booster Group|Subjects 11-25 years of age who had received 1 dose of Menactra vaccine in primary study (NCT00454909) and will receive 1 dose of Nimenrix vaccine in this current study.
89186477|NCT04056663|Experimental|Health-Circuit mobile application|"The intervention contemplates. (i) management of unexpected events; and, (ii) empowering the patient to improve self-efficacy.~Users of the intervention arm will have the Health-Circuit mobile application, which will offer them the possibility of contacting the case managers to notify a health event at any time and that this can be resolved by their health professionals through Health -Circuit. The improvement of the patient's self-efficacy for the management of their health problems through the use of Health-Circuit is considered through the virtual visits of follow-up with the manager, the possibility of interacting with the manager and the consultation of the shared documents reminders of the action plan agreed with the patient."
89186478|NCT04056663|No Intervention|Conventional treatment|Patients assigned to this group will follow conventional treatment. Once the three months have passed, we will contact you again to ask the pertinent questions.
89186479|NCT00750711|Experimental|KT,2|There are two arms in this study: KT2 arm and KT4 arm. Patients in KT2 arm will be ablated with the 2 mm irrigated catheter and patients in KT4 mm will be ablated with the 4 mm irrigated catheter.
89186480|NCT02591732||Patient treated with Apixaban|
89186481|NCT02591732||Patient treated with Rivaroxaban|
89186482|NCT02591732||Patient treated with Dabigatran|
89186483|NCT02591732||Patient treated with vitamin K antagonists|
89186484|NCT04086914|No Intervention|Non nerve block|Receives no nerve block
89186485|NCT04086914|Experimental|Nerve block|Receives nerve block
89186486|NCT00715676|Placebo Comparator|Group 1|
89186487|NCT00715676|Experimental|Group 2|220 ng
89186488|NCT00715676|Experimental|Group 3|440 ng
89186489|NCT05163470|Experimental|On Fi.RE. framework|Men football professional players
88866169|NCT03004170|Experimental|Tele-Motivational Interviewing Plus Behavioral Skills Training|The Telephone-Administered Motivational Interviewing Plus Behavioral Skills Training (teleMI+BST) intervention comprises 5 sessions lasting approximately 45-50 minutes each. Sessions occur in weeks 3, 4, 8, and 12 post-enrollment, with a follow-up booster session in week 24. The Information-Motivation-Behavioral Skills (IMB) Model (Fisher & Fisher, 1992) provides the theoretical framework for behavior change mechanisms of teleMI+BST. The IMB posits that knowledge about condom use practices, condom use motivation, and acquisition and application of requisite condom use skills lead to engagement in condom-protected sex. The focus of this intervention is to help participants process ambivalence about engaging in condomless sex acts that risk HIV transmission.
88866170|NCT03004170|Active Comparator|Tele-Coping Effectiveness Training|The Telephone-Administered Coping Effectiveness Training (teleCET) intervention is the attention-equivalent comparator and also comprises 5 sessions lasting approximately 45-50 minutes each. The teleCET intervention is based on the Lazarus and Folkman Transactional Model of Stress and Coping (Lazarus & Folkman, 1984) and uses cognitive-behavioral principles to: (a) appraise stressor severity, (b) develop problem- and emotion-focused coping skills, (c) determine the match between coping strategies and stressor controllability, and (d) optimize coping through use of social support resources.
88866171|NCT03004014|No Intervention|Natural Sleep|OSA subjects referred for surgical treatment will evaluated endoscopically during natural sleep
88866172|NCT03004014|Other|Propofol Induced Sleep|"Sleep endoscopy during propofol induced sleep~OSA subjects referred for surgical treatment will be evaluated endoscopically during propofol induced sleep"
88866173|NCT03003702|Experimental|ETH|Overnight monitoring
88866174|NCT03003702|Other|CTH|Morning monitoring
88866175|NCT03003936|Experimental|Early Dinner Timing|Test the lack of concurrence of meal timing with endogenous melatonin concentrations
88866176|NCT03003936|Experimental|Late Dinner Timing|Test the concurrence of meal timing with elevated endogenous melatonin concentrations
88866177|NCT03003624|Experimental|Colorado microdissection needle group|In patients selected for Colorado® needle group incision was given with Colorado® needle tip ( N103 A which is 3 cm length straight, 3/32 in sleeve diameter),
88866178|NCT03003624|Experimental|Cautery group|Electrosurgery tip was used to give incisions.
88866179|NCT03003624|Active Comparator|BP Blade group|No.15 surgical blade was used to give incisions.
88866180|NCT03003234|Other|Duodenal fluid aspiration|
88866181|NCT03003156|Experimental|25 Hz magnetic seizure therapy|10 treatment sessions of 25 Hz MST, three times per week in the first two weeks, two times per in the following two weeks.
88866182|NCT03003156|Experimental|50 Hz magnetic seizure therapy|10 treatment sessions of 50 Hz MST, three times per week in the first two weeks, two times per in the following two weeks.
88866183|NCT03002844|Experimental|EGFR-TKI and Chemotherapy|gefitinib with pemetrexed/gemcitabine and carboplatin
88866184|NCT03002844|Experimental|EGFR-TK Inhibitor|Gefitinib
88866185|NCT03002922|Experimental|Healthy subjects|Subject will self-apply the test sunscreen formula to his/her face with the goal of applying 0.65 to 0.85 grams. Subject should sweat profusely.
88866186|NCT03003078|Other|OncoSil™ plus SOC Chemotherapy|OncoSil™ implanted with concurrent Standard of care Chemotherapy - either FOLFIRINOX or gemcitabine + Abraxane.
88866187|NCT03002688||Sequential Cataract Surgery with Survey|Subjects eligible for the study will fall into the sequential cataract surgery group and be administered brief surveys.
88866188|NCT03002532|Active Comparator|Whole-brain radiotherapy (WBRT) group|Conventional whole-brain radiotherapy for brain metastases from breast cancer with dose of 37.5 Gy in 15 fractions.
88866189|NCT03002532|Experimental|Hippocampal-sparing WBRT (HS-WBRT) group|Hippocampal-sparing whole brain radiotherapy is performed using modern intensity-modulated radiotherapy (IMRT) technique to avoid conformally the hippocampal neural stem-cell structure during WBRT. Prescription dose is 37.5 Gy in 15 fractions.
88866190|NCT03002220|Experimental|open-label|Patient will be treated with radium-223 at a dose of 55 kBq (after 2015 NIST implementation) per kilogram body weight, given at four-week intervals for six intravenous injections.
88866191|NCT03002298|Experimental|DMD gesture task|Experimental group that made the task using a gesture in front of a webcam
88866192|NCT03002298|Experimental|DMD button-press task|Experimental group that made the task pressing the button
89186490|NCT05163470|Active Comparator|Traditional rehabilitation|Men football professional players
89186491|NCT00718328|Experimental|I|Simvastatin Group
88866193|NCT03002298|Active Comparator|Control group gesture task|Control group that made the task using a gesture in front of a webcam
88866194|NCT03002298|Active Comparator|Control group button-press task|Control group that made the task pressing the button
88866195|NCT03002376|Experimental|REGN2810|REGN2810 treatment
88866196|NCT03002064|Experimental|DP group|Docetaxel plus cisplatin. Docetaxel: 60mg per square metre on day 1 and Cisplatin: 60mg per square metre on day 1, repeated every 3 weeks till progression or at most 6 cycles.
88866197|NCT03002064|Active Comparator|PF group|Cisplatin plus 5-fluorouracil. Cisplatin: 60mg per square metre on day 1 and 5-fluorouracil 3750mg per square metre, civ 120 hours every 3 weeks till progression or at most 6 cycles.
89186492|NCT00718328|Placebo Comparator|II|Placebo Group
88866198|NCT03001908|Active Comparator|control oscillation|control subjects with normal shoulders will undergo the glenohumeral mobilization-oscillation
88866199|NCT03001908|Active Comparator|control sustained|control subjects with normal shoulders will undergo the glenohumeral mobilization-sustained
88866200|NCT03001908|Experimental|stiff oscillation|subjects with stiff shoulders will undergo the glenohumeral mobilization-oscillation
88866201|NCT03001908|Experimental|stiff sustained|subjects with stiff shoulders will undergo the glenohumeral mobilization-sustained
88866202|NCT03002142|Experimental|Patients treated with hearing aids|Patients fitted with functional hearing aids (Phonak Audéo BR)
88866203|NCT03002142|Placebo Comparator|Patients treated with placebo device|Patients fitted with non-functional hearing aids
88866204|NCT03001752|Active Comparator|Open flap immediate implant|Open flap immediate implant insertion, without bone grafting
88866205|NCT03001752|Active Comparator|Open flap immediate implant and bone grafting|Open flap immediate implant insertion and bone grafting
89390100|NCT01347905||Obese women and men|Obese women and men undergoing restrictive bariatric surgery. Iron absorption will be estimated using stable-isotope techniques where incorporation of 57Fe and 58Fe into erythrocytes is measured 14 days after administration. This procedure will be performed at baseline (6 weeks post-surgery) and at the end of the study (6-7 months post baseline).
88866206|NCT03001752|Active Comparator|Flapless immediate implant|Immediate implant insertion without opening flap of inserting bone grafting
88866207|NCT03001596|Experimental|Neoadjuvant chemoradiotherapy|Neoadjuvant chemoradiotherapy (NCRT) is performed followed by minimally invasive esophagectomy in enrolled patients.
88866208|NCT03001596|Active Comparator|Neoadjuvant chemotherapy|Neoadjuvant chemotherapy (NCT) is performed followed by minimally invasive esophagectomy in enrolled patients.
88866209|NCT03001440||ZYBAN/WELLBUTRIN users|Subjects who currently use or who have filled a prescription for ZYBAN, WELLBUTRIN, WELLBUTRIN SR, or WELLBUTRIN XL for smoking cessation within the previous 6 months will be included in the study. Subjects will be required to complete the KAB survey either online or through a telephone interview.
89186493|NCT05346848|Experimental|Experimental Arm A: combination of radiotherapy and darolutamide|Patients with unfavorable intermediate risk prostate cancer will be treated with darolutamide for a maximum of 6 months combined with external beam radiotherapy
89390101|NCT04192266|Experimental|Prolonged Exposure (PE) therapy with estradiol|A 2.0 mg pill of estradiol (a form of estrogen) together with prolonged exposure (PE) therapy can improve this treatment outcome in women diagnosed with Post-Traumatic Stress Disorder (PTSD). Prolonged Exposure (PE) therapy is a validated treatment for PTSD. A single dose of estradiol 2mg or placebo will be taken at home by the study participant 5-6 hours before each of 5 PE treatment sessions (sessions 2 to 6)
88866210|NCT03001284||Multiple sclerosis patients|patients with confirmed multiple sclerosis, diagnosed according to the revised McDonald's criteria
88866211|NCT03001284||Control subjects|control subjects, matched for age, gender, and presence of cardiovascular risk factors
89186494|NCT05346848|Other|Standard Arm B: combination of radiotherapy and androgen deprivation therapy|Patients with unfavorable intermediate risk prostate cancer will be treated with androgen deprivation therapy (ADT) as per market authorization combined with external beam radiotherapy
89186495|NCT02591186|Experimental|Acupuncture arm|Participants receiving acupuncture during IVF process
89186496|NCT02591186|No Intervention|Control|Control arm not receiving acupuncture during IVF process
89003578|NCT05003986|Experimental|Population 2: IgAN, IgAV, or AS|Subjects with kidney biopsy-confirmed immunoglobulin A nephropathy (IgAN), immunoglobulin A vasculitis (IgAV), or Alport syndrome (AS)
89003579|NCT05003986|Experimental|Population 3: IgAN|Subjects with kidney biopsy-confirmed IgAN
89186497|NCT04087070||biosignal derived blood pressure|"Blood pressure is measured by an automated oscillometric device or arterial waveform from IntelliVue MX800 Bedside patient monitor (Philips Healthcare, Amsterdam, Netherlands).~Following parameters will be measured by non-invasive electrocardiogram (ECG), photoplethysmograph (PPG), and an accelerometer on the chest and will be used to estimate the biosignal derived blood pressure.~PAT(time between R peak of ECG and beginning of the pulse of PPG)~PEP(time between R peak of ECG and peak of accelerometer signal)~PTT(PAT-PEP)"
89186498|NCT02590874|Experimental|Duloxetine group|Active drug group
89390102|NCT04192266|Placebo Comparator|Prolonged Exposure (PE) therapy with placebo|A 2.0 mg placebo pill will be given with prolonged exposure (PE) therapy can improve this treatment outcome in women diagnosed with Post-Traumatic Stress Disorder (PTSD). Prolonged Exposure (PE) therapy is a validated treatment for PTSD.
89390103|NCT01370018|Experimental|alpha-1 proteinase inhibitor in HIV|HIV-1 infected individuals treated with Alpha-1 proteinase inhibitor
89390104|NCT01359397|Active Comparator|Herceptin -|
89390105|NCT01359397|Experimental|Herceptin +|
89390106|NCT05250245|Active Comparator|CPAP only group|Patients who are going to receive only CPAP treatment for their moderate-to-severe obstructive sleep apnea syndrome (OSAS)
89390107|NCT05250245|Active Comparator|Combined use of CPAP and tolterodine|Patients who are going to receive combined use of CPAP and tolterodine 4mg a day treatment for their OSAS
89390108|NCT02068664||Observational|prism adaptation treatment
89390109|NCT01359475|Experimental|Acetal crown|Clinical performance of acetal crowns for treatment of primary molars
88866212|NCT03001050|Other|PINPOINT system|The operative intervention will proceed as current standard protocol dictates for the described procedure. No changes in the operative technique will be undertaken apart from injection of the dye and visualization with the camera. The idea would be to place the Pinpoint probe within the subacromial space, to check the vascular status of the tendon, and then take a bite of the tendon and place the pinpoint back to check if the vascularity has decreased. The Indocyanine Green dye kit will be used along with the PINPOINT system .
89390110|NCT03611400|Experimental|Probiotic|2 capsules daily for 3 weeks, containing 3.8 x 10^9 CFU (colony forming units)/capsule of Lactobacillus rhamnosus strain R011and 0.2 x 10^9 CFU/capsule of L. helveticus strain R0052 (group is unknown, double blinded)
89390111|NCT03611400|Placebo Comparator|Placebo|2 capsules daily for 3 weeks containing the same carrier material and is similar in size, shape and taste to probiotic (group is unknown, double blinded)
89390112|NCT05249933|Placebo Comparator|Control group|All patients underwent a bowel preparation that consisted of a low-residue diet for 24 hours, fluid intake, and ingestion of two liters of polyethylene glycol-based electrolyte solution 12 hours before the examination. On the examination day, patients arrived at the hospital in the morning after an overnight fast (>8hours). Then they would be randomly assigned to the control group or pronase group randomly. 40 minutes before capsule ingestion, all patients swallowed 100ml clear water containing 50mg dimethicone. And 25 minutes before swallowing the capsule, the patient was asked to take 200ml warm water. There is still have 800-1000ml water for gastric filling 10 minutes before swallowing the capsule.
89390113|NCT05249933|Experimental|Pronase group|All patients underwent a bowel preparation that consisted of a low-residue diet for 24 hours, fluid intake, and ingestion of two liters of polyethylene glycol-based electrolyte solution 12 hours before the examination. On the examination day, patients arrived at the hospital in the morning after an overnight fast (>8hours). Then they would be randomly assigned to the control group or pronase group randomly. 40 minutes before capsule ingestion, all patients swallowed 100ml clear water containing 50mg dimethicone. And 25 minutes before swallowing the capsule, the patient was asked to take 20000 IU pronase Granules Combined with 1 g NaHCO3 dissolved in 200ml warm water to maintain the intragastric pH at 6 - 8. There is still have 800-1000ml water for gastric filling 10 minutes before swallowing the capsule.
89390114|NCT02064998|Experimental|Promillekoll|Smartphone app monitoring alcohol use with feedback on eBAC level.
89390115|NCT02064998|Experimental|PartyPlanner|Smartphone-adapted web-based app for simulating an event with alcohol consumption in advance, real time monitoring of alcohol use with eBAC feedback during the event and later possibility of comparison between the plan and the event.
89390116|NCT02064998|No Intervention|Control Study 1|Waitlist control group that is given access to the Promillekoll and PartyPlanner apps after a 12-week wait.
89390117|NCT02064998|Experimental|Crossover group 1: TeleCoach - Control|Six-week access to the TeleCoach app, with exercises and vignettes for reducing or abstaining from alcohol consumption, followed by a 6-week period with no access to the app.
89390118|NCT02064998|Experimental|Crossover group 2: Control - TeleCoach|Initially a 6 week no-app control period, followed by 6-week access to the TeleCoach app, offering exercises and vignettes for reducing or abstaining from alcohol consumption.
88866213|NCT03000972|Active Comparator|Standard Nail|Hip fracture surgery with a PFN-A Nail (Proximal Femoral Nail Augmentation).
88866214|NCT03000972|Experimental|Augmented Nail|Hip fracture surgery with a PFN-A Nail with Cement augmentation with TraumaCemV+
89390119|NCT02032602|Active Comparator|1, CG: Active MTrP|a single session of physical therapy intervention which will be consisted on Deep Dry Needling of the active MTrP most hyperalgesic to palpation of the infraspinatus muscle homolateral to painful shoulder
89390120|NCT02032602|Experimental|2, EG: Active+Latent MTrPs|The same treatment described above for the Control Group, combined with the Deep Dry Needling of the most hyperalgesic latent MTrP, both located in the infraspinatus muscle homolateral to the painful shoulder.
89390121|NCT01359553||Knee pain|Group with knee pain problems referred to an arthroscopy.
88866215|NCT03001206||ICCU patients|"The use of the Master Caution System (MCS) for continuous monitoring and detection of dysrhythmias and ischemic events :~For patient diagnosed with acute coronary syndrome (ACS) in the intensive cardiac care unit (ICCU) before and after planed catheterization procedure."
88866216|NCT03001206||Stress test subjects|"The use of the Master Caution System (MCS) for continuous monitoring and detection of dysrhythmias and ischemic events :~For patients referred to stress imaging with suspected ischemia."
88866217|NCT03001128||Cohort A: ART initiated during chronic infection|Cohort A will include 36 participants who initiated ART during chronic infection.
88866218|NCT03001128||Cohort B: ART initiated during acute or early infection|Cohort B will include 30 participants who initiated ART during acute/early HIV infection.
89186499|NCT02590874|Placebo Comparator|Placebo group|Inactive drug group
89390122|NCT01348061||Elderly Healthy Control (EHV)|No clinically significant deviation from healthy in medical history, physical examination, ECGs, MRI and clinical laboratory determinations for their respective age group.
89390123|NCT01348061||Progressive Supranuclear Palsy (PSP)|A diagnosis of possible or probable PSP according to clinical criteria of National Institute of Neurologic Diseases and Stroke - the Society for PSP plus a MRI at screening to exclude other potential causes of parkinsonism as well as a mild-to-moderate stage of disease severity according to a score of 1 to 3 in Golbe Staging System.
88866219|NCT03000894|Experimental|CBT-I plus standard care|The group CBT-I will receive both CBT-I and standard care. CBT-I covers sleep-wake cycle as well as sleep hygiene education, activity scheduling, stimulus control, sleep restriction, relaxation training, and cognitive therapy. Standard care will include those treatments provided by the psychiatrists according to their clinical needs.
88866220|NCT03000894|No Intervention|Standard care|Only standard care will be provided to this group. Medications will be prescribed and referral to community nurse, social worker and psychologist will be made by the doctors according to their need.
88866221|NCT03000738||non-hodgekin lymphoma|100 non-hodgekin lymphoma patients (age >=18y) without previous treatment would be administered, including 50 DLBCLs and 50 PTCLs.
88866222|NCT03000660|Experimental|Venetoclax and Dexamethasone|Venetoclax will be given at one of four escalating doses (100 mg/day, 200 mg/day, 400 mg/day, or 800 mg/day) by mouth on each day of the cycle. Dexamethasone will be given at 20mg by mouth on days 1, 8, 15, and 22 of each cycle.
88866223|NCT03000582|Experimental|Creatine monohydrate|5 gm creatine monohydrate, 1.5 gm dextrose
88866224|NCT03000582|Active Comparator|Creatine nitrate-1|1 gm creatine monohydrate, 0.5 gm nitrate, 5 gm dextrose
88866225|NCT03000582|Active Comparator|Creatine nitrate-2|2 gm creatine monohydrate, 1 gm nitrate, 3.5 gm dextrose
88866226|NCT03000582|Placebo Comparator|Placebo|6.5 gm dextrose
88866227|NCT03000816|Experimental|Experimental Arm|Patients in this arm will receive a treatment of SBRT for their oligometastatic lesions.
88866228|NCT03000504|Experimental|Ballooned intercostal drain|Patients will have a Rocket Medical 16F ballooned chest drain inserted as per usual clinical guidelines. No other change to treatment will be made, and the drain is inserted in exactly the same way as a standard drain, using the Seldinger technique.
88866229|NCT03000504|Active Comparator|Standard intercostal drain|Patients will have a standard 12F-16F Rocket Medical chest drain inserted as per usual clinical guidelines, using the Seldinger technique.
88866230|NCT03000270|Active Comparator|Prolonged unloading prior to PPCI|Activation of Impella CP for a 30 minute duration prior to primary percutaneous coronary intervention
88866231|NCT03000270|Active Comparator|Immediate unloading prior to PPCI|Activation of Impella CP immediately prior to primary percutaneous coronary intervention
88866232|NCT03000114|Active Comparator|Percutaneous Needle Aponeurotomy|Percutaneous Needle Aponeurotomy (PNA) involves the surgeon anaesthetizing the skin over the Dupuytren's cord, then using a small gauge needle inserted percutaneously, cutting the cord with the sharp edge of the needle using a sweeping motion. This is repeated up the length of the cord to weaken it, allowing an extension force to be applied over the finger to rupture the cord.
88866233|NCT03000114|Active Comparator|Collagenase Injection|Collagenase Injection (CI) involves the injection of collagenase clostridium histolyticum (0.58 mg), directly into the Dupuytren's cord. The patient then returns to see the surgeon within one week, has local anaesthetic is administered, and an extension force is applied to the affected digit to rupture the already weakened cord.
88866234|NCT03000192||Breast cancer|Women aged <50 years
88866235|NCT03000192||Gynaecological cancers|Includes: cervical cancer, endometrial cancer, ovarian cancer, fallopian tube cancer, primary peritoneal cancer and vulval cancer
88866236|NCT03000192||Non-Hodgkin Lymphoma|Diffuse large B cell
88866237|NCT03000036|Other|Cardiovascular Magnetic Resonance|Twenty-seven female patients were imaged in a 3T magnet after consecutively enrolled in the study if they had received a breast cancer diagnosis at the Center for Integral Attention to Women's Health (University of Campinas) and had prescribed endovenous doxorubicin as part of their chemotherapy regimen.
88866238|NCT02999802|Experimental|Exercise|Determining the effect of 12 weeks of resistance training exercise on the response of muscle amino acid sensing
88866239|NCT02999412|Active Comparator|Comprehensive medication review (I1)|
88866240|NCT02999412|Active Comparator|Comprehensive medication review with active follow-up (I2)|
88866241|NCT02999412|Other|Usual care (Control)|
88866242|NCT02998008|Other|Diabetes type 2 patients|diabetes type 2 patients whose cardiac function is tested after 4x4 high intensity interval training
88866243|NCT02998008|Other|Healthy volunteers|healthy volunteers whose cardiac function is tested after 4x4 high intensity interval training
88866244|NCT02996292|Experimental|Traditional brackets|"Fixed orthodontic appliances will be applied for aligning and leveling of teeth up to 19*25 stainless steel wires using traditional brackets; American Orthodontics Master® MBT 0.022 Brackets"
88866245|NCT02996292|Experimental|Active self-ligating brackets|"Fixed orthodontic appliances will be applied for aligning and leveling of teeth up to 19*25 stainless steel wires using active self-ligating brackets; American orthodontics active self-ligating Empower® MBT 0.022"
88866246|NCT02996292|Experimental|Passive self-ligating brackets|"Fixed orthodontic appliances will be applied for aligning and leveling of teeth up to 19*25 stainless steel wires using passive self-ligating brackets; American orthodontics passive self-ligating Empower® MBT 0.022"
88866247|NCT02995356||Doubt for ectopic pregnancy group|This group participants have doubt for ectopic pregnancy in terms of beta-HCG pregnancy follow-up results and ultrasonography results.
88866248|NCT02995356||Normal intrauterine pregnancy group|This groups participants have normal intrauterine pregnancy
88866249|NCT02991066||Patients|patients with de novo acute promyelocytic leukemia with hemorrhage.
88866250|NCT02991066||Control|healthy volunteers.
88866251|NCT02989974|Experimental|KY LEADS Survivorship Care - Survivor|The KY LEADS Survivorship Care condition involves providing a targeted and tailored psychosocial support intervention to individuals diagnosed with lung cancer (survivor).
89186500|NCT02590952|Experimental|Epitinib|Epitinib is a capsule in the form of 5mg,20 mg, and 40 mg. Route: oral (daily)
89390124|NCT01348061||Alzheimer's Disease (AD)|A diagnosis of probable AD Based on the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association and The Diagnostic and Statistical Manual of Mental Disorders as determined by a mini-mental state examination (MMSE) score of 16 to 26, inclusive.
89390125|NCT02068742|Experimental|General Anesthesia patients battery neuropsychological tests|Mini Mental State Examination, Geriatric Index of Comorbidity, Geriatric Depression Scale, Trail Making Test B-A, Digit Span, Digit Symbol Substitution Test Application of the scores will be on the day 0 (the day before the surgery), day 2 and day 4 (after the surgery).
89390126|NCT02068742|Active Comparator|Regular recovery patients|Mini Mental State Examination, Geriatric Index of Comorbidity, Geriatric Depression Scale, Trail Making Test B-A, Digit Span, Digit Symbol Substitution Test Application of the scores will be on the day 0 (the day after the hospital admission), day 2 and day 4 (days after the hospital admission).
88866252|NCT02989974|Experimental|KY LEADS Survivorship Care - Caregiver|The KY LEADS Survivorship Care condition involves providing a targeted and tailored psychosocial support intervention to caregivers of individuals diagnosed with lung cancer (caregiver)
88866253|NCT02989740||Group A|Patients with negative FFR (> 0.80) in the target lesion & decided on OCT (Optical Coherence Tomography) imaging findings with NO thin-cap fibroatheroma
89390127|NCT02032836|Experimental|I-Neb - FOX|Part 1: Subjects received single inhalation of 1.25 mcg iloprost using 10 mcg/ml iloprost solution (Ventavis 10) and then 2.5 mcg iloprost using Ventavis 10, both using the FOX nebulizer on Day 1. Part 2: On Day 2, subjects received single inhalation of 5 mcg iloprost using Ventavis 10 with the I-Neb nebulizer; followed by single inhalation of 5 mcg iloprost using 20 mcg/ml iloprost solution (Ventavis 20) with the FOX nebulizer in a cross-over fashion. A washout period of at least 2 hours was maintained between treatments in Part 1 and Part 2. Part 3: Continued on Day 2, and through until Day 30, subjects received multiple inhalations (approximately 6 to 9 inhalations per day) of 5 mcg iloprost using Ventavis 10 with the I-Neb nebulizer for 2 weeks; followed by multiple inhalations (approximately 6 to 9 inhalations per day) of 5 mcg iloprost using Ventavis 20 with the FOX nebulizer for 2 weeks in a cross-over fashion.
89390128|NCT02032836|Experimental|FOX - I-Neb|Part 1: Subjects received single inhalation of 1.25 mcg iloprost using 10 mcg/ml iloprost solution (Ventavis 10) and then 2.5 mcg iloprost using Ventavis 10, both using the FOX nebulizer on Day 1. Part 2: On Day 2, subjects received single inhalation of 5 mcg iloprost using 20 mcg/ml iloprost solution (Ventavis 20) with the FOX nebulizer; followed by single inhalation of 5 mcg iloprost using Ventavis 10 with the I-Neb nebulizer in a cross-over fashion. A wash-out period of at least 2 hours was maintained between treatments in Part 1 and Part 2. Part 3: Continued on Day 2, and through until Day 30, subjects received multiple inhalations (approximately 6 to 9 inhalations per day) of 5 mcg iloprost using Ventavis 20 with the FOX nebulizer for 2 weeks; followed by multiple inhalations (approximately 6 to 9 inhalations per day) of 5 mcg iloprost using Ventavis 10 with the I-Neb nebulizer for 2 weeks in a cross-over fashion.
88866254|NCT02989740||Group B|Patients with negative FFR (> 0.80) in the target lesion & decided on OCT (Optical Coherence Tomography) imaging findings presence of ≥ thin-cap fibroatheroma
88866255|NCT02989740||Group C|Patients hosting FFR-positive target lesions that have been treated with PCI as per standard care and have further no TCFA lesions.
88866256|NCT02989350|Active Comparator|Lactobacillus reuteri DSM 17938|2 x 10(8) CFU. Both L reuteri DSM 17938 and placebo will be taken orally, twice daily 5 drops, for consecutive 5 days.
88866257|NCT02989350|Placebo Comparator|Placebo|Placebo consists of an identical formulation, except active substance.
88866258|NCT02989428|Experimental|Early parathyroidectomy group|Parathyroidectomy (surgery), is performed as soon as possible in the experimental group after randomization.
88866259|NCT02989428|No Intervention|Late parathyroidectomy group|Parathyroidectomy (surgery), is performed three months after study inclusion.
88866260|NCT02989116|Experimental|Preterm Inhibition|"In children born very preterm:~Inhibition training, Saliva collection, Brain Magnetic Resonance Imaging, Cognitive testing"
88866261|NCT02989116|Experimental|Full-term Inhibition|"In children born full-term:~Inhibition training, Saliva collection, Brain Magnetic Resonance Imaging, Cognitive testing"
88866262|NCT02989116|Experimental|Full-term Working memory|"In children born full-term:~Working memory training, Saliva collection, Brain Magnetic Resonance Imaging, Cognitive testing"
88866263|NCT02989116|Experimental|Full-term Mindfulness|"In children born full-term:~Mindfulness training, Saliva collection, Brain Magnetic Resonance Imaging, Cognitive testing"
88866264|NCT02989116|Active Comparator|Full-term Active control|"In children born full-term:~Active control training, Saliva collection, Brain Magnetic Resonance Imaging, Cognitive testing"
88866265|NCT02989272|Placebo Comparator|saline group|Control group (30 patients), who will receive Treatment by venous infusion of saline solution
88866266|NCT02989272|Experimental|Sulfate group|magnesium group (30 patients) who will receive pre- Venous infusion of magnesium sulphate 60 mg / kg
88866267|NCT02989038|Experimental|NNC, INC, VLNC|Normal Nicotine Content (NNC), Intermediate Nicotine Content (INC), Very Low Nicotine Content (VLNC)
88866268|NCT02989038|Experimental|NNC, VLNC, INC|Normal Nicotine Content, Very Low Nicotine Content, Intermediate Nicotine Content
88866269|NCT02989038|Experimental|INC, VLNC, NNC|Intermediate Nicotine Content, Very Low Nicotine Content, Normal Nicotine Content
88866270|NCT02989038|Experimental|INC, NNC, VLNC|Intermediate Nicotine Content, Normal Nicotine Content, Very Low Nicotine Content
88866271|NCT02989038|Experimental|VLNC, NNC, INC|Very Low Nicotine Content, Normal Nicotine Content, Intermediate Nicotine Content
88866272|NCT02989038|Experimental|VLNC, INC, NNC|Very Low Nicotine Content, Intermediate Nicotine Content, Normal Nicotine Content
88866273|NCT02988804|Active Comparator|endotracheal tube|"Procedure: Endotracheal tube~Hemodynamic variables (blood pressure, HR, CO, rSO2, TCD) will be recorded at 8 moments:~baseline, in the operating room before anesthetic induction (non invasive arterial pressure)~end of surgery, before awakening (ETT group) or before ETT replacement (LMA group)~at 1, 5, 10, 15, 30 and 60 min after extubation or LMA removal (according to group assignment)."
89186501|NCT00715520|Experimental|Aim 1|Healthy adult female and male subjects will receive study drugs and TMS training to measure M1 excitability.
89390129|NCT01348217|Active Comparator|ARM A|"Conformal 3D Radiotherapy with  ENI -type prophylactic irradiation of the lymph nodes:~Radiotherapy 40 Gy, in 20 fractions / 4 weeks: PTV (1cm in every direction)~Boost 10 Gy in 5 fr: PTV = +1cm.~Chemotherapy FOLFOX 4: 6 treatments in 3 courses concomitant to the radiotherapy (D1, D15, D29)"
89390130|NCT01348217|Experimental|ARM B|"Conformal 3D Radiotherapy with  ENI -type prophylactic irradiation of the lymph nodes:~40 Gy in 20 fractions / 4 weeks, PTV (1cm in every direction)~Boost 26 Gy in 13 fr: PTV = +1cm.~Chemotherapy: FOLFOX 4: 6 treatments with 4 courses concomitant to radiotherapy (D1, D15, D29, D43)."
89390131|NCT02065076|Active Comparator|Sodium Polystyrene Sulfonate|30 g sodium polystyrene sulfonate powder, mixed with water qs ad 150 ml, taken PO once daily for seven days
89390132|NCT02065076|Placebo Comparator|Lactose with carob gum|30 g placebo powder, mixed with water qs ad 150 ml, taken PO once daily for seven days
89390133|NCT02465593|Experimental|PEP503+5-FU/capecitabine+Radiotherapy|Patients will receive PEP503 given as intratumor injection on Day 1, followed by preoperative radiation therapy.
89390134|NCT02032914||Colonoscopic examination group|The patients diagnosed with cryptogenic pyogenic liver abscess
89390135|NCT02068898|Experimental|XS003 Dose-level 1|Capsule formulation
89390136|NCT02068898|Experimental|XS003 Dose-level 2|Capsule formulation
89390137|NCT02068898|Experimental|XS003 Dose-level 3|Capsule formulation
89390138|NCT02068898|Experimental|Tasigna|Marketed capsule
88866274|NCT02988804|Active Comparator|Laryngeal mask|"Procedure: Laryngeal mask~Hemodynamic variables (blood pressure, HR, CO, rSO2, TCD) will be recorded at 8 moments:~baseline, in the operating room before anesthetic induction (non invasive arterial pressure)~end of surgery, before awakening (ETT group) or before ETT replacement (LMA group)~at 1, 5, 10, 15, 30 and 60 min after extubation or LMA removal (according to group assignment)."
89390139|NCT03611322|Experimental|DV3372 device|Participants will receive semaglutide on day 1, 8, 15, 22 and 29. The treatment period from first treatment (Day 1) to end of the treatment (Day 29) will be 4 weeks.
89390140|NCT03611322|Active Comparator|PDS290 semaglutide pen-injector|Participants will receive semaglutide on day 1, 8, 15, 22 and 29. The treatment period from first treatment (Day 1) to end of the treatment (Day 29) will be 4 weeks.
89390141|NCT02424019|Experimental|ILUVIEN 0.19 MG|All patients will receive ILUVIEN (Fluocinolone Acetonide Intravitreal Insert) 0.19 mg.
89390142|NCT01346423|Experimental|Intervention group|Treatment team with a physician, a physiotherapist, a social service worker. The main goal for the team is to make a survey of the patient's situation, in which the biomedical tradition to make a diagnosis is replaced by a disability diagnosis, with systematically identification of barriers for return to work. The patient meets at the outpatient clinic three times; at baseline, after 2 weeks and after 3 months. One year after baseline the patient has a telephone-follow-up. At baseline, the patient and the team works out a rehabilitation plan and in this process a new visual, educational tool is central.
89390143|NCT01346423|Active Comparator|Controll group|The brief intervention is a standardized intervention based on the studies by Indahl and Hagen. Therapist treatment manuals will be written for the intervention. The essential features are interview and examination by a specialist in physical medicine and rehabilitation. Patients will be given time to express their concerns and problems in daily activities. Unless symptoms and clinical findings indicate some serious disease, the patients will be informed about the good prognosis, and the importance of staying active to avoid development of muscle dysfunction.
89390144|NCT02066714||Healthy Cohort|These children will be recruited from district 8, Ho Chi Minh City where most HFMD admissions to the Hospital for Tropical Diseases occur. We wil recruit healthy children from three kindergartens and ask for volunteers from participants enrolled in an Oxford University Clinical Research Unit Dengue birth cohort study (OXTREC approval 02-09) in District 8, HCMC. This birth cohort is an observational study.
89390145|NCT02066714||Hand Foot and Mouth Disease|The Vietnamese Ministry of Health has a clinical grading system. Grade 1 disease is uncomplicated and are not admitted to hospital. Grade 2 and above are admitted to hospital with clinical features of neurological or systemic involvement. Grade 2 is split into Grade 2a and 2b depending if neurological manifestations such as myoclonus have been witnessed by the parents or by a health professional. In total, it is anticipated that 125 Grade 2a and 125 Grade 2b and 100 more severe Grade 3 and 4 will be recruited over one year. A subset who agree for brain magnetic resonance imaging (MRI) will also have a scan done during their hospital admission.
89390146|NCT03610776|Experimental|Portion control plate|Portion control plate first (50% of subjects experiment with this plate first)
89390147|NCT03610776|Active Comparator|Conventional plate|Conventional plate first (50% of subjects experiment with this plate first)
89390148|NCT03611088|Experimental|Newborns submitted to Kangaroo Position.|
89390149|NCT03611088|No Intervention|Newborns not submitted to Kangaroo Position.|
88866275|NCT02988726|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
88866276|NCT02988648|Experimental|radioiodide (I-)|The Phase I portion will follow a 3+3 design with 4 dose levels (30, 60, 120, and 200 mCi) of I- treatment. The maximum tolerated dose (from Phase I) will be used in the Phase II efficacy assessment which will follow a Simon's optimal two-stage design.
88866277|NCT02988570|Experimental|children born very preterm|A computer-evaluation of the language will be done for children born very preterm preterm in 2011 in the region of Haute-Normandie in France
88866278|NCT02988414||Staphylococcus aureus Infection|Patients with blood culture confirmed S. aureus bloodstream infections.
88866279|NCT02988414||Gram Negative Infection|Patients with blood culture confirmed Gram Negative bloodstream infecrions
88866280|NCT02988414||Endocarditis|Patients admitted for evaluation of acute endocarditis classified using the Duke Criteria.
89390150|NCT02066870|Experimental|Icotinib and arsenic trioxide|"Icotinib is administered 125 mg three times per day, until disease progression or untolerated toxicity.~Arsenic trioxide is administered by intravenous injection with an initial dose of 4mg/m2 per day for day 1 to day 14 every 21 days.~Three dose levels, 4mg/m2, 6mg/m2 and 8mg/m2 will be evaluated according to predefined dose escalation decision rules. The Maximum Administered Dose (MAD) was reached at the dose level when at least 2 patients developed a DLT. There was no further dose escalation when this dose was achieved."
89390151|NCT05030363|Experimental|Upfront ALDH enzyme supplement|Upfront ALDH enzyme supplement; After randomization, patients will receive ALDH enzyme supplement twice a day for consecutive 14 days during chemotherapy (period 1; day 1 to day 14) until unacceptable toxicity, or consent withdrawal. Patients will visit clinic on day 15, then will be followed on day 29 without ALDH enzyme administration during subsequent chemotherapy (period 2).
89390152|NCT05030363|Other|Delayed ALDH enzyme supplement|Delayed ALDH enzyme supplement; patients will not take ALDH enzyme supplement during chemotherapy after randomization on day 1 to day 14 (period 1). On day 15, Patients will visit for subsequent chemotherapy and start ALDH enzyme supplement twice a day for 14 consecutive days during chemotherapy (period 2; day 15 to day 29).
89390153|NCT03611244|Experimental|Experimental group|When loss of ambulation was observed in patients with Duchenne muscular dystrophy, portable seat device devised to maintain lumbar lordosis were applied within 1 year, and then compliance with the the device were evaluated at 6-month intervals for 5 years.
89003581|NCT04998812|Experimental|Women with CIS or MS|Women with CIS or MS (in line with the locally approved indications) receiving commercial ocrelizumab up to 6 months before the LMP or during the first trimester of pregnancy (up to gestational week 13), due to accidental exposure, or in whom a decision to treat with ocrelizumab was taken as part of routine clinical practice.
89186502|NCT00715520|Experimental|Aim 2|Healthy adult female and male subjects will receive repetitive TMS (rTMS) at different times or frequencies with respect to the training movement or sham stimulation.
89390154|NCT03611244|No Intervention|Control group|Analysis of retrospective medical records who had not been applied portable seat device devised to maintain lumbar lordosis
89390155|NCT04034355|Experimental|PledOx (5 µmol/kg)|Calmangafodipir 5 µmol/kg
89390156|NCT04034355|Placebo Comparator|Placebo|0.9% sodium chloride in 20 mL vials
89390157|NCT05210699|Experimental|Product usage order A B N C E D|Subjects will use each of the 5 products sequentially (A B N C E D) during an evaluation period, followed by a 4 hour Test Session.
89390158|NCT05210699|Experimental|Product usage order B C A D N E|Subjects will use each of the 5 products sequentially (B C A D N E) during an evaluation period, followed by a 4 hour Test Session.
89390159|NCT05210699|Experimental|Product usage order C D B E A N|Subjects will use each of the 5 products sequentially (C D B E A N) during an evaluation period, followed by a 4 hour Test Session.
89390160|NCT05210699|Experimental|Product usage order D E C N B A|Subjects will use each of the 5 products sequentially (D E C N B A) during an evaluation period, followed by a 4 hour Test Session.
89390161|NCT05210699|Experimental|Product usage order E N D A C B|Subjects will use each of the 5 products sequentially (E N D A C B) during an evaluation period, followed by a 4 hour Test Session.
89390162|NCT05210699|Experimental|Product usage order N A E B D C|Subjects will use each of the 5 products sequentially (N A E B D C) during an evaluation period, followed by a 4 hour Test Session.
89390163|NCT02066948|Active Comparator|Skew meal pattern w/ wt loss&exercise|Skew meal pattern w/ wt loss&exercise e
89390164|NCT02066948|Active Comparator|even meal pattern w/ wt loss&exercise|even meal pattern w/ wt loss&exercise
89390165|NCT01317745|Placebo Comparator|Group 5|Two doses of sanofi H5N1 antigen 7.5 mcg plus PBS diluent
89390166|NCT01317745|Placebo Comparator|Group 4|Two doses of sanofi H5N1 antigen 3.75 mcg plus Phosphate Buffered Saline (PBS) diluent
89390167|NCT01317745|Experimental|Group 3|Two doses of sanofi H5N1 antigen 15 mcg plus Novartis MF59 adjuvant
89390168|NCT01317745|Experimental|Group 2|Two doses of sanofi H5N1 antigen 7.5 mcg plus Novartis MF59 adjuvant
89390169|NCT01317745|Experimental|Group 1|Two doses of sanofi H5N1 antigen 3.75 mcg plus Novartis MF59 adjuvant
89390170|NCT01317745|Placebo Comparator|Group 6|Two doses of sanofi H5N1 antigen 15 mcg plus PBS diluent
89390171|NCT03610932|Experimental|Vitamin C|Participants will ingest 3 (500 mg) capsules of Vitamin C each day for 2 weeks.
89390172|NCT03610932|Active Comparator|Placebo|Participants will ingest a matched capsule for size and color to the Vitamin C supplement.
89390173|NCT01355965|Experimental|Cohort 1 - One dose of cells|Subjects receive one dose of 1x108 cells on day 0 followed by one dose of 1x109 autologous transfected anti-mesothelin CAR T cells on day 7.
89390174|NCT01355965|Experimental|Cohort 2 - three doses of cells|receive three doses of 1x108 cells on day 0, 2, 4 (Monday-Wednesday-Friday (MWF) of Cycle 1) followed by three doses of 1x109 T cells on day 7, 9, 11 (MWF of Cycle 2). Total target dose for Cohort 2 is 3.3x109 cells.
89390175|NCT02069054||Asthma|Patients with mild to moderate asthma diagnosed in accordance with GINA
89390176|NCT02069054||COPD|Patients with mild to moderate COPD diagnosed in accordance with GOLD
89390177|NCT02069054||Control|Healthy subjects
89390178|NCT03610620|Experimental|ARM A|Vivascope 2500 ex-vivo fluorescent confocal microscope
88866281|NCT02988492|Other|MRI perfusion imaging|MRI screening will be performed as per standard-of-care by the MRI technologist staff. Imaging will be performed with 1.5 T or 3 T systems (Magnetom Vision; Siemens, Erlangen, Germany) using a multisection, single shot, spin echo, echo planer imaging sequence. Diffusion gradients will be applied in each of the x, y and z directions with three b values (0, 500 and 1000 s/mm2). Imaging parameters include a TE of 94 ms, field of view of 23 cm, matrix of 128 and section thickness of 5.5 mm for the 1.5 T system and a TE of 83 ms, field of view of 23 cm, matrix of 128 and section thickness of 3 mm for the 3 T system. Conventional spin echo imaging also will be performed at each examination under T1 and T2 weighted conditions, with a fluid attenuated inversion recovery sequence and Time-of-flight MRA of the Circle-of-Willis.
88866282|NCT02988024|Experimental|LY03005|LY03005 80 mg
88866283|NCT02988024|Active Comparator|Pristiq|Pristiq 50 mg
88866284|NCT02988258|Experimental|Cohort 1 - 10^4 transduced cells/kg|The first 3 patients will receive a single infusion of bulk CMV-TCR transduced donor-derived T cells on first CMV reactivation post allogeneic HSCT, at a dose of 10^4 T cells/kg recipient weight
88866285|NCT02988258|Experimental|Cohort 2 - 10^5 transduced cells/kg|If no cases grade III-IV GVHD in Cohort 1 the remaining patients (N=7) each receive a single infusion of bulk CMV-TCR transduced donor-derived T cells on first CMV reactivation post allogeneic HSCT, at a dose of 10^5 T cells/kg recipient weight
88866286|NCT02988258|Experimental|Cohort 1a - 10^3 transduced cells/kg|If 1 case grade III-IV GVHD in Cohort 1, next three patients to be treated with a single infusion of bulk CMV-TCR transduced donor-derived T cells of 1 x 10^3 T cells/kg recipient weight
88866287|NCT02988180|Other|intervention group|Children in the intervention group received basic services such as family-home, food, clothing, health care, protection and education for older children. In addition, there received play-based developmental stimulation integrated into the services.
88866288|NCT02988180|Other|control group|The age-matched control children received the basic services such as family-home, food, clothing, health care, protection and education. However, they were not provided with the play-based developmental stimulation.
88866289|NCT02987790|Experimental|C-reactive Protein|In this group, the attending physicians will be instructed to follow the decision flowchart based on the CRP values. Antibiotic suspension will be encouraged when levels of this marker are <35mg/L (if peak PCR below 100mg/L); or reduce 50% of the highest value (if PCR peak > 100mg/L), with a limit of seven days, if there is clinical improvement. If a given patient has persistently elevated CRP levels (> 100 mg/l or fall less than 50% relative to the time of inclusion), the investigators will encourage attending physicians to maintain antibiotics and to perform a careful search for persistent infection. In case of doubts, if the patient is well clinically and without signs of active infection, the duration of antibiotic therapy should be the same as suggested for the Best Practice group.
88866290|NCT02987790|No Intervention|Best Practice|"Patients will be initially treated according to the current protocols used in the intensive care units. Decisions about interruption or continuation of treatment will be made according to pre-established time and also according to the clinical evolution of the patients. CRP levels will not be measured and will not be considered in the decision to discontinue antimicrobials. Any decision ultimately rests with the clinical assistants. Suggestions on the suspension of antibiotics will be provided by the researchers as follows:~7 full days for most infections~10 full days for pneumonia caused by Gram negative non-fermenting bacteria or Gram negative bacteria carbapenemase producing.~14 days of treatment for necrotizing pneumonia, confirmed by chest computed tomography."
88866291|NCT02987712|No Intervention|Survey 1|Common practice
88866292|NCT02987712|Experimental|Survey 2|Thromboelastography based protocol
88866293|NCT02987556|Active Comparator|Usual System (open-loop)|In open loop, patients will be provided with an Continuous Glucose Monitoring (CGM) and an external insulin pump programmed with its usual treatment previously prescribed by its physician.
88866294|NCT02987556|Experimental|DIABELOOP System (closed-loop)|In the closed-loop, patients will be provided with the Diabeloop system consisting of insulin pump Cellnovo or Kaleido driven by remote control augmented by Diabeloop software and connected to the CGM Prescription of insulin doses proposed by a predictive algorithm.
88866295|NCT02987400|Experimental|Treatment|Obinutuzumab is given in a 21 day cycle intravenously starting at 1000 mg on day 1, 8 and 15 in cycle 1 and on day 1 of each following cycle Venetoclax is given orally at a dose of 800mg daily from day 1 of the first cycle.
88866296|NCT02987244|Experimental|C-CHOEP|experimental arm will be treated by Chidamide combined CHOEP ( cyclophosphamide, epirubicine, vindesine, etoposide and prednisone) regimen for 6 cycles.
89186503|NCT00715520|Experimental|Aim 3|Female and male subjects who have experienced a cerebral ischemic infarction, will receive study drugs and TMS to measure M1 excitability.
89186504|NCT05306132|Experimental|ASKC202|Participants received ASKC2020 50mg~600mg orally
89390179|NCT01346657|Experimental|Nifidipine & LipoCol|The effect of LipoCol Forte® capsules on the pharmacokinetics of nifedipine after administering single-dose combination in healthy subjects
89390180|NCT01359709|Experimental|Contingency Management|
89390181|NCT01359709|Placebo Comparator|Noncontingent control|
88866297|NCT02987166|Experimental|Arm A: HDCRT administered with first dose of pembrolizumab|"Pembrolizumab (200 mg) plus HDCRT (24 Gy in 3 fractions of 8 Gy each for bone and/or soft tissue lesions; 30 Gy in 5 fractions of 6 Gy each for the prostate gland) are both administered beginning on day 1.~Pembrolizumab (200 mg) will be administered on days 1, 43, 64, 85. Subjects who have measurable disease outside of the radiation field and who have derived benefit from the 4 doses of pembrolizumab may continue to receive pembrolizumab every 3 weeks for up to 2 years.~HDCRT will be administered to the primary tumor and/or sites of metastatic disease (1 or more sites permitted) over a period of 3-5 days. The length of time for administration of the HDCRT will depend on the site of disease that is to be radiated. HDCRT will begin on day 1."
88866298|NCT02987166|Experimental|Arm B: HDCRT administered between doses 1& 2 of pembrolizumab|"Pembrolizumab (200 mg) begins on day 1. HDCRT (24 Gy in 3 fractions of 8 Gy each for bone and/or soft tissue lesions; 30 Gy in 5 fractions of 6 Gy each for the prostate gland) begins on day 22.~Pembrolizumab (200 mg) will be administered on days 1, 43, 64, 85. Subjects who have measurable disease outside of the radiation field and who have derived benefit from the 4 doses of pembrolizumab may continue to receive pembrolizumab every 3 weeks for up to 2 years.~HDCRT will be administered to the primary tumor and/or sites of metastatic disease (1 or more sites permitted) over a period of 3-5 days. The length of time for administration of the HDCRT will depend on the site of disease that is to be radiated. HDCRT will begin on day 22."
88866299|NCT02987166|Experimental|Arm C: HDCRT administered prior to first dose of pembrolizumab|"Pembrolizumab (200 mg) begins on day 1. HDCRT (24 Gy in 3 fractions of 8 Gy each for bone and/or soft tissue lesions; 30 Gy in 5 fractions of 6 Gy each for the prostate gland) begins on day 1.~Pembrolizumab will be administered on days 22, 43, 64, and 85. Subjects who have measurable disease outside of the radiation field and who have derived benefit from the four doses of pembrolizumab may continue to receive pembrolizumab every 3 weeks for up to 2 years.~HDCRT will be administered to the primary tumor and/or sites of metastatic disease (1 or more sites permitted) over a period of 3-5 days. The length of time for administration of the HDCRT will depend on the site of disease that is to be radiated. HDCRT will begin on day 1."
88866300|NCT02987322|Experimental|honey|Ziziphus honey (sider honey) orally in a dose of 1ml (1.2g)/kg/day for 3 months for the patients in the honey group.
88866301|NCT02986932|Experimental|BBB opening|ExAblate focused ultrasound under MRI-guidance delivered through the intact human skull in conjunction with timed intravenous ultrasound contrast agents (Definity®) to temporarily and focally open the BBB.
88866302|NCT02987010|Experimental|Cohort A|Neoadjuvant administration of IDH305 at 550 mg BID for 6 weeks followed by surgical resection at 6 weeks. If there is no evidence of progressive disease at 6 weeks (clinical, radiographic or histopathologic exam), the patient will continue on IDH305 at 550 mg BID post-operatively for a maximum of 11 additional 28 day cycles. Subsequent assessment of disease will occur every 2 months starting in Cycle 2.
88866303|NCT02987010|Experimental|Cohort B|Patients who have inoperable tumors but measurable 2HG pre-treatment will be treated with IDH305 at 550 mg BID x 6 weeks. If there is adequate sustained knockdown of 2HG on MRS and disease is stable or improved, then the patient will continue on treatment for a maximum of 11 additional 28 day cycles.
88866304|NCT02986776|Active Comparator|Inpatient Care + Needs Inpatient|Individuals with high alcohol involvement or low cognitive functioning receiving inpatient treatment
89186505|NCT05684978|Experimental|Single arm prospective study|"Adults patients equal or greater than 18 years~Patients in RSE that require IV anesthetic infusions. Note: RSE is defined as status epilepticus that fails to terminate after an adequate dose of benzodiazepines (1st line agents) and an AED (2nd line agent). Adequate doses have been defined in the screening (below).~Patients taking oral contraception who will be on the study long term should be informed about additional alternative methods of contraception."
89186506|NCT00756873|Placebo Comparator|1|
89186507|NCT00756873|Experimental|2|Etoricoxib 90 mg qd.
89186508|NCT00756873|Experimental|3|Etoricoxib 120 mg qd. (day 0-7) Etoricoxib 90 mg qd. (day 8-14)
89186509|NCT00790205|Experimental|Sitagliptin|Sitagliptin tablet taken orally once daily in the morning for up to approximately 5 years.
89186510|NCT00790205|Placebo Comparator|Placebo|Placebo to sitagliptin tablet taken orally once daily in the morning for up to approximately 5 years.
89186511|NCT04056039|Active Comparator|"Atorvastatin"|"-Changes of troponin I in rheumatoid arthritis with atorvastatin 40 mg orally every 24 hours for four weeks"
89186512|NCT04056039|Active Comparator|"Colchicine"|"Changes of troponin I in rheumatoid arthritis with colchicine with an initial dose of 0.25 mg every 8 hours, with titration in the first 3 days according to tolerance up to a maximum dose of 0.5 mg every 8 hours for four weeks"
89186513|NCT00750945|Experimental|A|Treadmill with Music cueing group
89186514|NCT00750945|Active Comparator|B|Treadmill group
89186515|NCT00750945|Placebo Comparator|C|Home walking group
89186516|NCT04104815|Experimental|Experimental Thickener|Powder thickener
89186517|NCT02603627||With lung cancer|Patients who have a new diagnosis of lung cancer will be invited to undergo spirometry to enable us to gather data on the prevalence of COPD in this group.
89186518|NCT02603627||Without lung cancer|Smokers who are referred to the smoking cessation clinic will be invited to undergo spirometry to ascertain the prevalence of COPD in this group.
89186519|NCT00715208|Experimental|VELCADE R-CAP|VELCADE will be administered as a 3- to 5-second intravenous bolus injection, rituximab 375 mg/m2 Intravenous on Day 1, cyclophosphamide 750 mg/m2 intravenous on Day 1, doxorubicin 50 mg/m2 intravenous on Day 1, VELCADE 1.6 mg/m2 intravenous on Days 1 and 8, prednisone 100 mg orally on Days 1 to 5 of a 21-day (3-week) cycle for 6 cycles.
89186520|NCT00715208|Experimental|VELCADE R-CP|VELCADE will be administered as a 3- to 5-second intravenous bolus injection, rituximab 375 mg/m2 intravenous on Day 1, cyclophosphamide 1000 mg/m2 intravenous on Day 1, VELCADE 1.6 mg/m2 intravenous on Days 1 and 8, prednisone 100 mg orally on Days 1 to 5 of a 21-day (3-week) cycle for 6 cycles.
89186521|NCT04104503|Experimental|Part A|
89186522|NCT04104503|Experimental|Part B group 1|"Treatment period 1: Fasted + iv;~Treatment period 2: Fasted;~Treatment period 3: High-fat meal"
89186523|NCT04104503|Experimental|Part B group 2|"Treatment period 1: High-fat meal;~Treatment period 2: Fasted + iv;~Treatment period 3: Fasted"
89186524|NCT04104503|Experimental|Part B group 3|"Treatment period 1: Fasted;~Treatment period 2: High-fat meal;~Treatment period 3: Fasted + iv"
89186525|NCT00919178|Experimental|1|Participants will receive a single immunization for Dengue virus serotype 4 (DEN4)
89186526|NCT00919178|Placebo Comparator|2|Participants will receive a single immunization in the form of placebo resembling vaccine for DEN 4
89186527|NCT05184140|Experimental|Adnexal mass with high suspicion of malignancy|An ovarian lymphatic map will be performed in patients with adnexal masses suspected of malignancy. Sentinel node exeresis and a complete staging surgery (including pelvic and para-aortic lymphadenectomy) will be performed in patients with ovarian cancer confirmation including restaging surgeries.
89186528|NCT04083872|Experimental|Group 1|"Period 1: Reference drug~Period 2: Test drug"
89186529|NCT04083872|Experimental|Group 2|"Period 1: Test drug~Period 2: Reference drug"
89186530|NCT05183672|Experimental|Intervention group|Participants will receive three tertiary stroke care consultations provided by stroke nurses via telecare in 3 months.
89186531|NCT05183672|Placebo Comparator|Control group|Participants will receive three usual face-to-face consultations provided by stroke nurses in 3 months
89186532|NCT02590250||BOTOX®|Patients who receive botulinum toxin Type A (BOTOX®) treatment for Neurogenic Detrusor Overactivity or Overactive Bladder as per local standard of care in clinical practice.
89186533|NCT05293418||ICU mechanically ventilated COVID-19 patients|Patients admitted to Milano Fiera ICU for COVID-19 requiring mechanical ventilation from October 2020 through May 2021
89186534|NCT02589782|Experimental|Regimen 1|Bedaquiline: 400 mg once daily for 2 weeks followed by 200 mg 3 times per week for 22 weeks Pretomanid: 200mg once daily for 24 weeks Moxifloxacin: 400 mg once daily for 24 weeks Linezolid: 600mg daily for 16 weeks then 300mg daily (or 600mg x3/wk) for the remaining 8 weeks or earlier when moderately tolerated
88810605|NCT06174688|Experimental|BOTOX|BOTOX will be injected on Day 1
89186535|NCT02589782|Experimental|Regimen 2|Bedaquiline: 400 mg once daily for 2 weeks followed by 200 mg 3 times per week for 22 weeks Pretomanid: 200mg once daily for 24 weeks Linezolid: 600mg daily for 16 weeks then 300mg daily (or 600mg x3/wk) for the remaining 8 weeks or earlier when moderately tolerated Clofazimine: 50 mg (less than 33 kg), 100 mg (more than 33 kg) for 24 weeks
89186536|NCT02589782|Experimental|Regimen 3|Bedaquiline: 400 mg once daily for 2 weeks followed by 200 mg 3 times per week for 22 weeks Pretomanid: 200mg once daily for 24 weeks Linezolid: 600mg daily for 16 weeks then 300mg daily (or 600mg x3/wk) for the remaining 8 weeks or earlier when moderately tolerated)
89186537|NCT02589782|Active Comparator|Control Regimen|Locally accepted standard of care which is consistent with the WHO recommendations for the treatment of M/XDR-TB.
89186538|NCT00587795|Active Comparator|StabilAir Wrist Brace|One study group will consist of patients treated with the StabilAir Wrist Brace.
89186539|NCT00587795|Placebo Comparator|Control|Study arm will consist of patients that are treated with placement of sugar tong splint or plaster cast.
89186540|NCT00587639|Experimental|rTMS Treatment|All subjects will have active rTMS treatment (10Hz, L-DLPFC - 3,000 Stimulations/treatment)
89186541|NCT00916175|Placebo Comparator|P1&P2|Food product P1&P2 is composed of: placebo1(mimic aloe vera gel) 30ml and placebo2 (mimic Cnidoscolus chayamansa infusion) 200ml;
88810606|NCT06174688|Placebo Comparator|Placebo|Placebo will be injected on Day 1
88810607|NCT06174558||Patients referred to Sleep Health Center for diagnostic PSG|Prospective obstructive sleep apnea patients referred for diagnostic overnight polysomnogram test
88810608|NCT06171893|Experimental|Control vs intervention|Each subject will take part in a four-week control period, followed by a four-week intervention period.
89186542|NCT00916175|Experimental|P1&CC|Food Product P1&CC contains: placebo1 (mimics liquified aloe vera gel) 30ml and Cnidoscolus Chayamansa infusion 200ml;
89186543|NCT00916175|Experimental|AG&P2|Food product AG&P2 contains (liquified aloe vera gel) 30ml and placebo2 (mimic CC infusion) 200ml.
89186544|NCT00916175|Experimental|AG&CC|Food product AG&CC is composed of: liquified aloe vera gel 30ml and Cnidoscolus Chayamansa infusion 200ml
89186545|NCT00916175|Experimental|TA (concentrated 5:1 aloe vera gel)|Food product TA contains concentrated 5:1 aloe vera gel by total process30 ml and purified water 200 ml.
89186546|NCT00916175|Placebo Comparator|P3|Food product Placebo 3 contains stabilizers and preservative used for TA 30 ml and purified water 200 ml.
89186547|NCT00916487|Experimental|Arm1|single arm of study in cross-over design
88810609|NCT06169735|Experimental|Parathyroid patients|patients who require parathyroid identification and preservation during parathyroid surgery maneuver
88810610|NCT06168253|Experimental|Experimental: Safety Behavior Fading|This treatment lasts a total of 28 days. Participants will be asked to identify common safety behaviors related to social anxiety. For the next 14 days, participants will receive instructions to fade out these behaviors. After 14 days, participants will be asked to re-select their target safety behaviors and continue to reduce them over the next two weeks.
88810611|NCT06168253|Active Comparator|Unhealthy Behavior Fading|This treatment lasts a total of 28 days. Participants will be asked to identify common unhealthy behaviors related to social anxiety. For the next 14 days, participants will receive instructions to fade out these behaviors. After 14 days, participants will be asked to re-select their target unhealthy behaviors and continue to reduce them over the next two weeks.
88810612|NCT06164951|Experimental|Infigratinib 0.25 mg/kg/day|Infigratinib at 2, 3.5, 5, 7, 10 mg
88810613|NCT06164951|Placebo Comparator|Placebo 0.25 mg/kg/day|Placebo Comparator at 2, 3.5, 5, 7, 10 mg
88810614|NCT06164028||Caregiver|"Participants will take part in a semi-structured qualitative interview (~1 hour).~The first set of questions will provide an opportunity for the caregiver to describe the type of conditions or injuries their child has experienced and how their child reacted to the potentially painful experiences.~Subsequently, the cognitive interview scripts will be structured to evaluate different components of the questionnaire (ObsRO measure), including the instructions, the question stems, the response options, and other key aspects of the COA.Once the participant has completed the questionnaire, the interviewer will probe on additional issues related to informing the assessment of content validity."
88819157|NCT02397096|Active Comparator|Delayed Switch to Doravirine, Tenofovir, Lamivudine|Participants receiving continuous antiretroviral therapy with a ritonavir- or cobicistat-boosted protease inhibitor (atazanavir, darunavir, or lopinavir) or cobicistat-boosted elvitegravir or a NNRTI (specifically, efavirenz, nevirapine, or rilpivirine) in combination with 2 NRTIs for >=6 months with undetectable HIV-1 RNA will continue on this therapy until Week 24, at which time they will switch to doravirine, tenofovir, lamivudine single tablet by mouth once daily for 24 weeks in the Base Study and, optionally, for up to an additional 6 years in the Study Extensions
88819158|NCT02372058|Other|BiliCare|"Three non invasive measurements of TcB:~Two measurements with the BiliCare device and one measurement with a competitive FDA approved device"
88819159|NCT02396316|Experimental|Aflibercept|Aflibercept 2 mg Intravitreal (IVT) injection group
88819160|NCT02396316|Sham Comparator|Sham Injection|Sham injection group
88819161|NCT02395536|Experimental|In office Outside walls of hospital|Reveal LINQ insertions will be performed in office setting. The in office setting was defined as a procedure or office room with controlled entry and hard floors outside the walls of the hospital and not an ambulatory surgery center.
88819162|NCT02395536|Other|Traditional Hospital Setting|Reveal LINQ insertions will be performed in a traditional setting. The traditional hospital setting includes an operating room or electrophysiology laboratory.
88819163|NCT00552929|Experimental|Sugammadex 0.5 mg/kg (Rocuronium)|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered intravenously (IV), followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of the second twitch (T2) response to Train-of-four (TOF) stimulation, a single dose of 0.5 mg/kg sugammadex was administered IV.
88819164|NCT00552929|Experimental|Sugammadex 1.0 mg/kg (Rocuronium)|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 1.0 mg/kg sugammadex was administered IV.
88819165|NCT00552929|Experimental|Sugammadex 2.0 mg/kg (Rocuronium)|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 2.0 mg/kg sugammadex was administered IV.
88819166|NCT00552929|Experimental|Sugammadex 4.0 mg/kg (Rocuronium)|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 4.0 mg/kg sugammadex was administered IV.
88819167|NCT00552929|Experimental|Sugammadex 8.0 mg/kg (Rocuronium)|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 8.0 mg/kg sugammadex was administered IV.
88819168|NCT00552929|Experimental|Sugammadex 0.5 mg/kg (Vecuronium)|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 0.5 mg/kg sugammadex was administered IV.
88866305|NCT02986776|Active Comparator|Inpatient Care + No Need for Inpatient|Individuals with low alcohol involvement or mid-high cognitive functioning receiving inpatient treatment
88866306|NCT02986776|Active Comparator|Outpatient Care + Needs Inpatient|Individuals with high alcohol involvement or low cognitive functioning receiving outpatient treatment
88866307|NCT02986776|Active Comparator|Outpatient Care + No Need for Inpatient|Individuals with low alcohol involvement and or mid-high cognitive functioning receiving outpatient treatment
88866308|NCT02986542|Active Comparator|USG with the in-plane technique|Intervention: Femoral artery catheterization under USG guidance with the in-plane technique.Patients will have their femoral arterial lines inserted under the guidance of USG. The ultrasound equipment used is LOGIQ e GE medical system(China) CO.LTD
88866309|NCT02986542|Active Comparator|USG with the out-of-plane technique|Intervention: Under USG guidance femoral artery catheterization will be done with the probe placed for the out-of-plane technique. The ultrasound equipment used is LOGIQ e GE medical system(China) CO.LTD
89186548|NCT00774995|Experimental|Engerix(4-dose)+HepatitisB(HB) Immunoglobulin (Ig)|Subjects who previously received HBV vaccine at 0, 1, 6 and 60 months (4 doses) and HBIg concomitantly at Month 0, and received a challenge dose of HBV vaccine after approximately 20 years (noted as Day 0) in the current study.
88866310|NCT02986152|Experimental|CDC Mobile App Treatment|Subjects who are randomized to the CDC mobile app treatment arm will be asked to perform the app's full suite of intervention tools such as learning about PTSD, assessment, finding support, and mind/body exercises (e.g., guided imagery, meditation, and relaxation exercises) over the entire 8-week study period.
88866311|NCT02986152|Other|CDC Mobile App Wait-List Control|Subjects who are randomized to the CDC mobile app wait-list control arm will be asked to perform only the learning about PTSD, assessment, and finding support activities for the first 4 weeks. Following completion of the Week-4 questionnaires, subjects will then be asked to additionally perform the mind/body exercises (e.g., guided imagery, meditation, and relaxation exercises) for the duration of the 8-week study period.
88866312|NCT02986464|Active Comparator|Standard pharmacological treatment|
88866313|NCT02986464|Experimental|Virtual Reality distraction|
89186549|NCT00774995|Experimental|Engerix(3-dose)+HBIg|Subjects who previously received HBV vaccine at 0, 1, 6 months (3 doses) and HBIg concomitantly at Month 0, and received a challenge dose of HBV vaccine after approximately 20 years (noted as Day 0) in the current study.
88866314|NCT02986308||Intestinal Polyps|The patients who were diagnosed with Intestinal Polyps.
88866315|NCT02986308||Normal colonoscopy|People who were diagnosed by colonoscopy without intestinal polyps.
88866316|NCT02982642|Experimental|1612 capsule|Subjects will take 1612 capsule 3 capsules per time(0.38g per capsule), 3 times per day for 52 weeks
89186550|NCT00774995|Experimental|Engerix(4-dose)|Subjects who previously received HBV vaccine at 0, 1, 6 and 60 months (4 doses) and received a challenge dose of HBV vaccine after approximately 20 years (noted as Day 0) in the current study.
89186551|NCT00774995|Experimental|Engerix(3-dose)|Subjects who previously received HBV vaccine at 0, 1, 6 months (3 doses) and received a challenge dose of HBV vaccine after approximately 20 years (noted as Day 0) in the current study.
89186552|NCT00918554|Experimental|Methotrexate|
89186553|NCT00918554|Placebo Comparator|Placebo|
89186554|NCT05684822|Experimental|The experimental group received acupuncture treatment|The experimental group received acupuncture treatment (Taichong, Shenmen, Neiguan points) twice a week, total three weeks, plus sleep hygiene guidance
89186555|NCT05684822|Sham Comparator|The control group received subcutaneous sham acupuncture|The control group received subcutaneous acupuncture (non-therapeutic acupuncture points) twice a week, total three weeks and given sleep Health guidance.
89186556|NCT04104113|Experimental|XBYRT decoction|Participants assigned to receive the modifed Xiang Bei Yang Rong Tang granules
89186557|NCT04104113|Placebo Comparator|Placebo|Participants assigned to receive placebo (contains 5% of XBYRT) granules
89186558|NCT00713648|Experimental|rFXIII|
89186559|NCT04102085||Mothers under 30|no intervention will be administered
89186560|NCT02590016|Experimental|Insulin-glucose-infusion|Insulin-glucose-infusion is administered once active labour begins and will be continued until birth.
89186561|NCT02590016|Active Comparator|Observation|Plasma glucose level is measured every 1-2 hours during active labour and insulin-glucose-infusion is started if plasma glucose level exceeds 7,5 mmol/l in two subsequent measurements.
89186562|NCT00768053|Experimental|1|
89186563|NCT00683475|Experimental|IMC-1121B (ramucirumab) + Mitoxantrone + Prednisone|
89186564|NCT00683475|Experimental|IMC-A12 + Mitoxantrone + Prednisone|
89186565|NCT02589158|Experimental|Evotaz®, washout, then Rezolsta®|All participants will be administered Evotaz®) (atazanavir 300mg + cobicistat 150mg) once daily for 10 days, undergo a ten-day wash out period and then take Rezolsta® (darunavir 800mg + cobicistat 150mg) once daily for 10 days.
89186566|NCT04083482|Experimental|Septic patients require CVVH|continuous venovenous hemofiltration. Continuous renal replacement therapy（CRRT）has become routine for patients with chronic renal failure ，AKI，fliud overload as well as oliguria in ICU .Continuous venovenous hemofiltration（CVVH）is the method of chioce for CRRT in critical ill .CVVH has significant beneficial effects on removing inflammatory cytokines ，improving oxygen index ，decreasing vasopressor requirements，increasing cardiac index and regulating immune dysfunction .
89186567|NCT04083716|Experimental|Group 1|ABI-H2158 Reference Formulation in a fasting state on Day 1 (Period 1), then ABI-H2158 Test Formulation in a fasting state on Day 8 (Period 2), then ABI-H2158 Test Formulation after a high-fat meal on Day 15 (Period 3)
89186568|NCT04083716|Experimental|Group 2|ABI-H2158 Test Formulation in a fasting state on Day 1 (Period 1), then ABI-H2158 Test Formulation after a high-fat meal on Day 8 (Period 2), then ABI-H2158 Reference Formulation in a fasting state on Day 15 (Period 3)
89390182|NCT02067026|Experimental|Aleurone supplementation|The study supplementation will be introduced in the daily diet according to the participant preference to a total of 27g of Aleurone/day. One bread bun (35 g) contains 4.8 g Aleurone; one biscuit (15 g) contains 4 g Aleurone; 36 g of RTE cereals contain 9 g Aleurone.
89390183|NCT02067026|Placebo Comparator|Hemicellulose supplementation|The study supplementation will be introduced in the daily diet according to the participant preference to a total of 27g of Hemicellulose/day. One bread bun (35 g) contains 4.8 g Hemicellulose; one biscuit (15 g) contains 4 g Hemicellulose; 36 g of RTE cereals contain 9 g Hemicellulose. Placebo products contain the same levels of cellulose in place of aleurone's dietary fiber content.
89390184|NCT04158336|Experimental|Single Agent Dose Escalation|Subjects with solid tumors with advanced or metastatic disease who are refractory or ineligible to standard therapy(ies) or for whom no standard therapy is available.
89390185|NCT04158336|Experimental|Single Agent Food Effect Cohort|Subjects with solid tumors with advanced or metastatic disease who are refractory or ineligible to standard therapy(ies) or for whom no standard therapy is available. This cohort will give subjects the option to continue treatment after PK assessments are completed.
89390186|NCT04158336|Experimental|Single Agent Dose Expansion|Subjects with histologically confirmed recurrent or persistent USC who have had treatment with at least 1 prior platinum-based chemotherapy regimen for management of advanced or metastatic USC and subjects with locally advanced or metastatic malignancy with one or more relevant biomarkers related to DNA damage pathways.
89390187|NCT01346735||ICU infections|Infections acquired during the ICU stay
89390188|NCT03940365|Experimental|Study Group|As detailed above, a single group will be used for the study to compare the output of the study device with the output of the standard device in each patient.
89390189|NCT01317823|Active Comparator|Bishop score|
88866317|NCT02982642|Placebo Comparator|Placebos|Subjects will take palcebo identified to 1612 capsule 3 capsules per time, 3 times per day for 52 weeks
88866318|NCT02982486|Experimental|Nivolumab and ipilimumab|Nivolumab 240 mg IV every 2 weeks plus Ipilimumab 1 mg/m2 IV every 6 weeks
89390190|NCT01317823|Active Comparator|transvaginal ultrasound|
88866319|NCT02982408|Experimental|Low birth weight (LBW)|25 males born at term (weeks 39-41) in 1979-1981 with LBW (BW<10th percentile)
88866320|NCT02982408|Experimental|Normal birth weight (NBW)|25 BMI- and age-matched males born at term (weeks 39-41) with normal birth weight (NBW) control individuals (BW: 50-90th percentile)
88866321|NCT02982252|Experimental|CoPILOT (6 weeks)|Experimental group participants will receive structured training in a standard powered wheelchair using the CoPILOT shared control wheelchair technology consisting of 6 hours total training time (1 hour training sessions, 3 days per week for 2 weeks).
88866322|NCT02982252|No Intervention|Standard of Care (6 weeks)|Standard of care participants will receive training according to the standard of care in rehabilitation facilities in the Vancouver area in a standard powered wheelchair consisting of 6 hours total training time (1 hour training sessions, 3 days per week for 2 weeks).
88866323|NCT02982252|Experimental|CoPILOT (12 weeks)|Experimental group participants will receive structured training in a standard powered wheelchair using the CoPILOT shared control wheelchair technology consisting of 12 hours total training time (1 hour training sessions, 4 days per week for 3 weeks).
88866324|NCT02982252|No Intervention|Standard of Care (12 weeks)|Standard of care participants will receive training according to the standard of care in rehabilitation facilities in the Vancouver area in a standard powered wheelchair consisting of 12 hours total training time (1 hour training sessions, 4 days per week for 3 weeks).
88866325|NCT02982330|Experimental|Low Carbohydrate Breakfast|Breakfast composition containing <10% carbohydrate, 75% fat, 15% protein Matched calories
89390191|NCT05539898|Other|ICD|ICD implanted
89390192|NCT02826486|Experimental|BL-8040 plus pembrolizumab (Keytruda®)|"BL-8040 monotherapy 1.25 mg/kg subcutaneous(SC) injections daily on days 1-5 of week 1 of treatment.~Combination therapy period begins following monotherapy treatment and consists of:~Pembrolizumab 200mg once every three weeks.~Beginning on Day 10, BL-8040 three times a week"
89390193|NCT02826486|Experimental|BL-8040 plus pembrolizumab (Keytruda®) plus Onivyde chemo|"BL-8040 monotherapy 1.25 mg/kg subcutaneous(SC) injections daily on days 1-5 of week 1 of treatment.~Combination therapy period begins following monotherapy treatment and consists of:~IV Onivyde® 70 mg/m2 over 90 minutes followed by IV leucovorin (LV) 400 mg/m2 over 30 minutes or according to local standard, followed by IV fluorouracil (5-FU) 2400 mg/m2 over 46 hours, every 2 weeks.~Pembrolizumab 200mg once every three weeks.~Beginning on Day 10, BL-8040 twice a week and following the chemotherapy dosing."
89390194|NCT01359787|Active Comparator|Mapracorat 0.01% Ointment|Lowest concentration
89390195|NCT01359787|Active Comparator|Mapracorat 0.03% Ointment|Middle concentration
89390196|NCT01359787|Active Comparator|Mapracorat 0.1% Ointment|Highest concentration
89390197|NCT01359787|Placebo Comparator|Vehicle without active|
89390198|NCT02067260|Active Comparator|X5 HairLaser|
89390199|NCT02067260|Sham Comparator|X5 HairLaser Sham Device|
89390200|NCT01346891||Hyponatremia Group (Cases)|Patients over 21 years old, with confirmed antecedent of thiazide-induced hyponatremia who required hospitalization with a serum sodium concentration lower than 125 meq/L.
88866326|NCT02982330|Active Comparator|Guidelines Breakfast|Breakfast composition containing 55% carbohydrate, 30% fat, 15% protein Matched calories
88866327|NCT02981784||Ponatinib (PACE trial)|"PACE trial : Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL), NCT01207440"
88866328|NCT02981784||Allogenis stem cell transplantation (EBMT registry)|EBMT : European Group for Blood and Marrow Transplantation
89390201|NCT01346891||Good Thiazide Tolerance (Controls)|Patients over 21 years old, who have consumed thiazide diuretics for more than 2 years, with a serum sodium concentration persistently over 135 meq/L.
89390202|NCT02825940|Experimental|Atezolizumab Monotherapy: PK and Extension Phases|Participants during the PK and extension phases of the study will receive atezolizumab alone at a dose of 1200 milligrams (mg) IV every 3 weeks (q3w) (in 21-day cycles) continuously until loss of clinical benefit, disease progression, unacceptable toxicity, participant or physician decision to discontinue, or death. Study treatment may continue beyond disease progression based on the investigator's discretion.
88866329|NCT02981862|Experimental|CaptHPV method|
88866330|NCT02981706|Active Comparator|Arteriovenous Fistula (AVF) Group|Patient will receive an arteriovenous fistula (connection between native artery and vein) as his/her dialysis access
88866331|NCT02981706|Active Comparator|Arteriovenous Graft (AVG) Group|Patient will receive an arteriovenous graft (synthetic connection between artery and vein) as his/her dialysis access
88866332|NCT02981394||BMAC Group|Intervention Group
88866333|NCT02981316|Active Comparator|RBX7455 Group A|4 days of 4 capsules twice daily RBX7455 for 10 subjects.
88866334|NCT02981316|Active Comparator|RBX7455 Group B|2 days of 4 capsules twice daily RBX7455 for 10 subjects.
88866335|NCT02981316|Active Comparator|RBX7455 Group C|2 days of 2 capsules twice daily RBX7455 for 10 subjects.
88866336|NCT02981316|Active Comparator|RBX7455 Group D|2 days of 1 capsule twice daily RBX7455 for 10 subjects.
88866337|NCT02981160|No Intervention|Standard Care Group|The participants assigned to this group will follow a standard weight loss program for 12-months. This patients will be instructed by the Weight loss program registered dietitian/diet tech in clinic in terms of nutrition regimen, daily intake and calories.Patients will be followed up monthly as per clinic protocol. All visits will include physical measurements including body mass index (BMI) based on height and weight, blood pressure, and body composition (fat percentage). Body composition will be assessed during clinic visits by bio-impedance. Waist circumference (cm) will be measured at the umbilicus.
88866338|NCT02981160|Experimental|Mobile Device Assistant Group|"This group will follow the same weight loss protocol, monitoring, and clinic visits as the standard weight loss group described above, but will also use the mobile health tool (Breezing) to track REE every visit. This data will be loaded onto an accompanying electronic pad using the Breezing app and will be transmitted electronically to the study investigators who will use the information to adjust dietary and physical activity recommendations and targets. The test will be performed at initial visit, 2 weeks, 1, 3, 6 and 12 months after started."
88866339|NCT02980926|Experimental|Mepivacaine Spinal Anesthetic|Mepivacaine 3 mL intrathecal injection of 2% solution
88866340|NCT02980926|Active Comparator|Bupivacaine Spinal Anesthetic|Bupivacaine 12 mg of 8.25% solution
88866341|NCT02980770||Obstructive Sleep Apnea (OSA)|Patients with OSA
88866342|NCT02980770||Obesity-Hypoventilation Syndrome (OHS)|Patients with OHS
88866343|NCT02980770||Normal Blood Gases|Normal Blood Gases
88866344|NCT02980614|Experimental|Participants to 4D flow imaging|"In addition to the standard clinical MR protocol, 2 added sequences:~4D MR sequence in cine mode 4D velocity mapping sequence"
88866345|NCT02980458|Experimental|Deferiprone 500 Lipomed film-coated tablets|Oral fasted administration of one film-coated tablet of Deferiprone 500 Lipomed film-coated tablets (Lipomed AG, Switzerland), containing 500 mg deferiprone
88866346|NCT02980458|Active Comparator|Ferriprox® film-coated tablets|Oral fasted administration of one film-coated tablet of Ferriprox® film-coated tablets (Apotex Europe B.V., Germany), containing 500 mg deferiprone
88866347|NCT02980380||Locked-in and complete locked-in state patients|Amyotrophic lateral sclerosis patients in complete locked-in state as well as in transition from locked-in to complete locked-in state who have no means of communication.
88866348|NCT02980302|Other|Patient|
88866349|NCT02980302|Other|Asymptomatic carrier|Father of the patient : asymptomatic carrier of the same mutation
88866350|NCT02980302|Other|Two control patients|
88866351|NCT02980146||"Group patients with colorectal cancer"|Major patients treated surgically for colorectal cancer at Nantes University Hospital or at the Institut de Cancerologie de l'Ouest and agreeing to participate in the study
88866352|NCT02979912|Experimental|Platelet Lysate|Autologous platelet lysate dispensed into eye droppers to be applied four times a day for a total of four weeks.
88866353|NCT02979990|Placebo Comparator|Control Video|Subjects will have access to general videos on the in vitro fertilization process. They will not have access to instructional videos related to the administration of controlled ovarian stimulation.
88866354|NCT02979990|Experimental|Experimental Video|Subjects will be asked to view instructional videos related to the administration of controlled ovarian stimulation medication during their own controlled ovarian stimulation
88866355|NCT02979834||Early perception group|The group with early perception of fetal movement (<25th percentile)
88866356|NCT02979834||Average perception group|The group with average perception of fetal movement (>25th and <75th percentile)
89186569|NCT04083716|Experimental|Group 3|ABI-H2158 Test Formulation after a high-fat meal on Day 1 (Period 1), then ABI-H2158 Reference Formulation in a fasting state on Day 8 (Period 2), then ABI-H2158 Test Formulation in a fasting state on Day 15 (Period 3)
89186570|NCT00756951|Placebo Comparator|1|Placebo
89186571|NCT00756951|Active Comparator|2|SCV-07 at a dose of 0.02 mg/kg
89186572|NCT00756951|Active Comparator|3|SCV-07 at a dose of 0.10 mg/kg
89186573|NCT00916253|Experimental|Modafinil First|Treatment by Modafinil during first condition then placebo during second condition
89186574|NCT00916253|Experimental|Placebo First|Treatment by Placebo during first condition then Modafinil during second condition
88866357|NCT02979834||Late perception group|The group which late perception of fetal movement (>75 percentile)
89186575|NCT00916253|No Intervention|H|Healthy Volunteers
89186576|NCT04087226|Active Comparator|Conventional Retraction Cord|
89186577|NCT04087226|Experimental|PTFE Retraction Cord|
89186578|NCT02561637|Experimental|Case management|Before admission the spouse-patient dyads will take part in an interview with the case manager assessing the spouses' needs during admission through an individual care plan. During admission the case manager will follow-up and assess the goals and actions of the individual care plan and coordinate with other health professionals. During the discharge meeting the case manager will provide additional information to the spouse according to needs assessed in the care plan. After discharge the case manager will conduct a follow-up telephone call for the spouse 3-4 days and 10 days after the patient's discharge consisting of information similar to that provided at the discharge meeting.
89186579|NCT02561637|Other|Control group|Spouses and patients in the control group will receive usual care and written and oral information about the fast-track program and principles in general from the nursing staff. The usual care and information is provided before admission in the out-patient facilities and during admission
89186580|NCT00757029|Other|open label|
89186581|NCT04101929|Experimental|Experimental: Apatinib + S-1+ Irinotecan|Apatinib: 250mg po qd； S-1 capsule: According to the body surface area <1.25m2 60mg/d, 1.25 ~ 1.5 m2 80 mg/d, > 1.5m2 100mg/d po bid, taking 7 days, stopping for 7 days, 28 days for 1 cycle; Irinotecan: According to the body surface area of 180 mg/m2, ivgg/90min, once every two weeks.
89186582|NCT04083638||Group 1|Control group
89186583|NCT04083638||Group 2|Feeding will not stop during the transfusion
89186584|NCT00757107|Experimental|Taperloc Microplasty|Patients with primary osteoarthritis with Taperloc microplasty non inferiority
89186585|NCT00757107|Active Comparator|Taperloc Standard|Patients with primary osteoarthritis Taperloc standard
88819169|NCT00552929|Experimental|Sugammadex 1.0 mg/kg (Vecuronium)|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 1.0 mg/kg sugammadex was administered IV.
88819170|NCT00552929|Experimental|Sugammadex 2.0 mg/kg (Vecuronium)|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 2.0 mg/kg sugammadex was administered IV.
88866358|NCT02979756|Experimental|Decentralized GDM screening and initial management|In this arm, the intervention consists of screening all pregnant women for GDM using the nationally recommended oral glucose tolerance test that will take place during antenatal care consultations in 10 randomly selected primary health care facilities. Overall, 80 women who are diagnosed with GDM and who consent to participate will receive initial nutritional counseling and will be closely followed up.
88866359|NCT02979756|No Intervention|Standard GDM screening and management practice|In this arm, screening for GDM will follow standard practice. 80 women diagnosed with GDM in 10 randomly selected primary health care facilities and who consent to participate will be followed up.
89186586|NCT00918632|Other|Sequence 1 (ABC)|"The following treatments will be administered in the following order A -> B-> C~Treatment A = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered after overnight fasting~Treatment B = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered with a high-fat, high-calorie meal.~Treatment C = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered with a moderate-fat, standard-calorie meal."
88819171|NCT00552929|Experimental|Sugammadex 4.0 mg/kg (Vecuronium)|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 4.0 mg/kg sugammadex was administered IV.
88819172|NCT00552929|Experimental|Sugammadex 8.0 mg/kg (Vecuronium)|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 8.0 mg/kg sugammadex was administered IV.
88866360|NCT02979288|Experimental|A Nugent 4 + Lactobacilli|Intermediate vaginal Flora Nugent 4 with Lactobacilli. Intervention with vaginal probiotics with 'Lactobacillus casei rhamnosus (Lcr 35 regenerans)
88819173|NCT02395302|Experimental|Dual Action Pneumatic Compression|Dual action pneumatic compression device that provides both sustained compression while ambulatory, and intermittent pneumatic compression when connected to an alternating current (AC) outlet.
88819174|NCT02682381|Experimental|0.025 mg/kg/day Teduglutide|0.025 milligrams per kilogram per day (mg/kg/day) of teduglutide for 24 weeks.
88819175|NCT02682381|Experimental|0.05 mg/kg/day Teduglutide|0.05 mg/kg/day of teduglutide for 24 weeks.
88819176|NCT02682381|Active Comparator|Standard of care|Observational cohort for the 24-week treatment period and 4 week follow-up. The subjects in the standard of care group will follow the same visit schedule as the randomized subjects.
88819177|NCT04976595|Experimental|Natesto|Participants will administer Natesto, gel, intranasally, three times daily up to Day 120. A multiple-dose dispenser will be used for gel deposition into the nasal cavity.
88819178|NCT00367965|Experimental|1|eszopiclone 3 mg
88819179|NCT00367965|Placebo Comparator|2|placebo tablet
88819180|NCT02975505|Experimental|Strict SBP Target|Target Systolic Blood Pressure <120 mm Hg
88819181|NCT02975505|No Intervention|Usual SBP Target|Target Systolic Blood Pressure 130-140 mm Hg
88819182|NCT02683083|Experimental|[131I]-SGMIB Anti-HER2 VHH1|
88819183|NCT02683161|Other|Open-label trial|All participants will attend approximately 6 study sessions pre-surgery and approximately 6 study sessions post-surgery, during which they will be provided three intervention components aimed at smoking cessation: a medication (varenicline) that has been FDA approved for smoking cessation, contingency management for biological evidence of nonsmoking, and behavioral counseling.
88819184|NCT02683707|Experimental|PCI without IV opiate|IV midazolam and Local Anesthetic, with removal of IV fentanyl from peri-procedural analgesia (which is otherwise routinely given)
88819185|NCT02683707|Active Comparator|PCI with IV opiate|IV midazolam and Local Anesthetic and IV fentanyl for peri-procedural analgesia
88819186|NCT02371980|Experimental|Open-label: Vortioxetine 10 mg|Vortioxetine 10 mg, capsules, orally, once, daily (QD) up to 8 weeks. Participants who achieved response (defined as a ≥50% reduction in Montgomery Asberg Depression Rating Scale (MADRS) total score from Baseline) continued to receive vortioxetine 10 mg, capsules, orally, QD for up to Week 16 (stabilization period) in the Open-label Period.
88819187|NCT02371980|Placebo Comparator|Double-blind: Placebo|Following Open-label Period, participants who achieved remission criteria (defined as MADRS total score ≤12 at Weeks 14 and 16) were randomized to receive vortioxetine placebo-matching capsules, orally, QD from Week 17 up to Week 44 in the Double-blind Period.
88819188|NCT02371980|Experimental|Double-blind: Vortioxetine 5 mg|Following Open-label Period, participants who achieved remission criteria (defined as MADRS total score ≤12 at Weeks 14 and 16) were randomized to receive vortioxetine 5 mg, capsules, orally, QD from Week 17 up to Week 44 in the Double-blind Period.
88819189|NCT02371980|Experimental|Double-blind: Vortioxetine 10 mg|Following Open-label Period, participants who achieved remission criteria (defined as MADRS total score ≤12 at Weeks 14 and 16) were randomized to receive vortioxetine 10 mg, capsules, orally, QD from Week 17 up to Week 44 in the Double-blind Period.
88819190|NCT02371980|Placebo Comparator|Double-blind: Vortioxetine 20 mg|Following Open-label Period, participants who achieved remission criteria (defined as MADRS total score ≤12 at Weeks 14 and 16) were randomized to receive vortioxetine 20 mg, capsules, orally, QD from Week 17 up to Week 44 in the Double-blind Period.
88819191|NCT02867865|Active Comparator|Chemotherapy arm|"Post staging laparoscopy, all patients will receive chemotherapy using Injection Gemcitabine 1000 mg/m2 delivered day 1 and 8 every 3 weeks.~In addition, Injection Cisplatin 25 mg/m2 for and 4 cycles week 1 to week 11."
88819192|NCT02867865|Experimental|Chemoradiation arm|"Post staging laparoscopy in Experimental arm The radiation dose will be 50-55 Gy/ 25 fractions to the gross disease and 45 Gy/ 25 fractions to suspected microscopic disease along with weekly gemcitabine (300 mg/ m2). Radiotherapy will be for 5 weeks which will be followed by 2 cycles of chemotherapy with Injection Gemcitabine (Gemcite,Gemzar) 1000 mg/m2 delivered day 1 and 8 every 3 weeks and cisplatin (Cisplat, Cytoplatin) 25 mg/m2from week 7 to week 11.~During week 12-13 patients will undergo repeat PETCECT scan. If the scan shows partial or good response then patients will be evaluated for surgery. Surgery if possible will be done between weeks 13-15. In case of inoperable disease patients will receive further chemotherapy"
88819193|NCT04910373|Experimental|Experimental Extensively Hydrolyzed Formula|Administered during food challenge and at home feeding period
88819194|NCT04910373|Placebo Comparator|Placebo Extensively Hydrolyzed Formula|Administered during food challenge
88866361|NCT02979288|Active Comparator|B Nugent 4 + Lactobacilli|Intermediate vaginal Flora Nugent 4 with Lactobacilli, NO Intervention
88866362|NCT02979288|Experimental|C Nugent 4 NO Lactobacilli|Intermediate vaginal Flora Nugent 4 NO Lactobacilli, Intervention with vaginal probiotics, with 'Lactobacillus casei rhamnosus (Lcr 35 regenerans)
88866363|NCT02979288|Active Comparator|D Nugent 4 NO Lactobacilli|Intermediate vaginal Flora Nugent 4 NO Lactobacilli, No Intervention
88866364|NCT02979210|Other|Artificial Fecal Insult|protease/bile acid cocktail 200 microliters (1500 µg/ml trypsin/chymotrypsin protease mixture, 6.5 mg/ml cholic acid sodium, 6.2 mg/ml deoxycholic acid sodium, and 3.1 mg/ml chenodeoxycholic acid sodium in phosphate buffered saline)
88866365|NCT02978976|Experimental|betamethasone|will receive two doses of 12mg betamethasone, then the pulsatility index (PI), resistance index (RI), systolic/diastolic ratio (SD), and the acceleration-time/ejection-time ratio (At/Et) will be determined in all cases after recruitment, just before the administration of the drug (betamethasone), 24 hours after the last dose, and on the day of elective Cs.
88866366|NCT02978976|Placebo Comparator|Saline|will receive saline injection placebo, then the pulsatility index (PI), resistance index (RI), systolic/diastolic ratio (SD), and the acceleration-time/ejection-time ratio (At/Et) will be determined in all cases after recruitment, just before the administration of the drug ( placebo), 24 hours after the last dose, and on the day of elective Cs.
88866367|NCT02979132|Active Comparator|Oral Iron Supplementation|Eisensulfat LOMAPHARM 50 mg administration for 90 days
88866368|NCT02979132|Active Comparator|Intravenous Iron Supplementation|Single-dose Ferinject(R) administration
88866369|NCT02979132|Active Comparator|Food Fortification with Iron|Consumption of iron-fortified biscuits (15 mg Fe in form of FeSO4) for 90 d
88866370|NCT02978664|Active Comparator|Air insufflation|Air insufflation will be used throughout whole procedure of colonoscopy
88866371|NCT02978664|Active Comparator|water immersion|Water will be infused during the insertion phase and removed during withdrawal phase of colonoscopy
88866372|NCT02978664|Active Comparator|water exchange|Water will be infused and removed during insertion phase of colonoscopy
88866373|NCT02978820|Experimental|SEAS exercise group|This group received SEAS exercises in addition to brace wearing for four months
88866374|NCT02978820|Experimental|CS exercise group|This group received core stabilization exercise training (CS) in addition to brace wearing for four months
88866375|NCT02978898||LN Lymph nodes|"Samples obtained from patients with :~LF: Follicular lymphoma MCL: Mantle cell lymphoma CLL/SLL: chronic lymphocytic leukemia/small lymphocytic leukemia MZL : splenic marginal zone Clt :control B-cells"
88866376|NCT02978898||PB peripheral blood|"Samples obtained from patients with :~LF: Follicular lymphoma MCL: Mantle cell lymphoma CLL/SLL: chronic lymphocytic leukemia/small lymphocytic leukemia MZL : splenic marginal zone Clt :control B-cells"
88866377|NCT02978742|Experimental|Coached Recovery Record App|Participants will complete the 8-week adaptive Recovery Record app program and will be linked with a healthcare professional who will provide standardized coaching, in the way of feedback and support to participants for the duration of the program.
88866378|NCT02978742|Active Comparator|Uncoached Recovery Record App|Participants will complete the 8-week adaptive Recovery Record app program on their own (i.e., without a coach providing feedback and support).
88866379|NCT02978586||[Ga-68]PSMA PET/MR|Up to 3 experimental PET/MRI scans will be performed to determine the level of [Ga-68]PSMA tumor uptake
88866380|NCT02978274||experimental group|MMF withdrawal by engraftment post haplo-SCT
88866381|NCT02978274||control group|MMF withdrawal by 2 month post haplo-SCT
88866382|NCT02978430|Active Comparator|Standard of care|This group (started retrospectively before the first included patient of the closed-loop goal-directed fluid therapy group) consists of patients undergoing major abdominal surgery where fluid management is carried out based only on static variables (e.g. arterial pressure, heart rate, CVP, and urine output).
88866383|NCT02978430|Active Comparator|Computer-assisted GDFT|"This group consists of patients undergoing major abdominal surgery where fluid management is carried out with a closed-loop (automated) system to deliver fluid by a goal-directed fluid therapy (GDFT) standardized protocol.~Confer: Crystalloids or Colloids for Goal-directed Fluid Therapy With Closed-loop Assistance in Major Surgery (NCT02312999)"
88866384|NCT02978352|Experimental|face-to-face|Traditional learning group (face-to-face): 4 different sessions will be conducted to suit the participants' convenience Duration of each session is 60-90 minutes Each session comprises lecture, video demonstration of CAM-ICU assessment, discussion, volunteer participation during class demonstration
88866385|NCT02978352|Experimental|E-learning|60-90 minute online course will be accessible through intranet Wi-Fi The course encompasses types, incidence, risk factors, significance and effects of delirium, diagnostic criteria and CAM-ICU application Inclusion of video demonstration of simulated patients and CAM-ICU application, common pitfalls of healthcare providers, and practice questions
88866386|NCT02977962|Experimental|Cognitive-Behavior Therapy|This consists of 16 weekly sessions up to 90 minutes each that helps the participant learn to cope with anxiety by facing fears, thinking more logically, and calming oneself.
88866387|NCT02977962|Placebo Comparator|Treatment as Usual|Participants randomized to this condition will wait for a period of 16 weeks before receiving treatment in the context of the study. During this time, youth may receive psychotherapy and/or initiate or change current psychiatric medication (if applicable).
88866388|NCT02978040|Experimental|Cangrelor|Cangrelor bolus of 30 µg/Kg followed by infusion at 4 µg/Kg/min for 2 h (or to the end of PCI).
88866389|NCT02978040|Active Comparator|Tirofiban|Tirofiban bolus of 25 µg/Kg bolus followed by infusion at 0.15 µg/Kg/min for 2 h (or to the end of PCI) (infusion rate of 0.075 µg/Kg/min for patients with creatinine clearance < 60 ml/min).
88866390|NCT02978040|Active Comparator|Prasugrel|Prasugrel oral integer or chewed at an identical loading dose of 60 mg
88866391|NCT02977416|Experimental|patients treated withTNF blockade|22 patients treated with TNF blockade
88866392|NCT02977416|Experimental|patients without TNF blockade|22 patients without TNF blockade
88866393|NCT02977416|Experimental|healthy subjects|22 matched healthy subjects by pubertal stage and sex
89390203|NCT02825940|Experimental|Atezolizumab and Chemotherapy: Extension Phase|Participants during the extension phase of the study will receive atezolizumab at a dose of 1200 mg IV on Day 1 in combination with gemcitabine at a dose of 1250 milligrams per square meter (mg/m^2) on Days 1 and 8 and cisplatin at a dose of 75 mg/m^2 on Day 1 (four or six 21-day cycles at the discretion of the investigator), followed by atezolizumab as a single agent at a dose of 1200 mg IV q3w on Day 1 of a 21-day cycle) as maintenance treatment continuously until loss of clinical benefit, disease progression, unacceptable toxicity, participant or physician decision to discontinue, or death. Study treatment may continue beyond disease progression based on the investigator's discretion.
89390204|NCT02065232||Tilmanocept|Patients will receive technetium-labeled tilmanocept, which is FDA approved for sentinel lymph node mapping in breast cancer.
89390205|NCT02065232||Sulfur Colloid|Patients will receive technetium-labeled sulfur colloid, which is FDA approved for sentinel lymph node mapping in breast cancer.
88819195|NCT05448027|Experimental|Low intensity laser therapy group|• Group (A): lt will include 26 participants suffering from primary dysmenorrhea who will receive low intensity laser therapy 3 sessions per cycle for 3 consecutive cycles (one session will be applied the day before menstruation and the other two sessions on the 1st and 2nd days of menstruation
88819196|NCT05448027|Experimental|High intensity laser therapy group|Group (B): It will include 26 participants suffering from primary dysmenorrhea who will receive high intensity laser therapy 3 sessions per cycle for 3 consecutive cycles (one session will be applied the day before menstruation and the other two sessions on the 1st and 2nd days of menstruation
88819197|NCT04338867|Active Comparator|Therapeutic arm|Patients who received WBRT and the addition 36 mg of transdermal nitroglycerin (TN) with the release of 10 mg in 24 hours, for 24 hours with a 12-hour rest interval (to avoid saturation of receptors)
88819198|NCT04338867|Active Comparator|Control arm|Patients who received whole-brain radiotherapy (WBRT) (30 Gy in 10 fractions, in 10 days of treatment)
88819199|NCT05447949|Experimental|Group 1 (ESPB + Dexmedetomidine)|Patients received Ultrasound guided ESPB with addition of dexmedetomidine 1 Mcg/kg to 30 ml levobupivacaine 0.25%, N=30 (16)
88819200|NCT05447949|Experimental|Group 2 (ESPB+ dexamethasone)|Patients received Ultrasound guided ESPB with addition of dexamethasone 10 mg to 30 ml levobupivacaine 0.25%, N=30 (16)
88819201|NCT05447949|Active Comparator|Group 3 (ESPB)|Patients received Ultrasound guided ESPB with 30 ml levobupivacaine 0.25%, N=30
88819202|NCT04850625||Pyrotinib Plus Vinorelbine|lapatinib (750-1,250 mg/day) plus capecitabine (1,500-2,000 mg/m2)
88819203|NCT04850625||Lapatinib Plus Capecitabine|pyrotinib (320-400 mg/day) plus vinorelbine (25mg/ m2 intravenously or 60 mg/m2 orally on days 1 and 8 per 21 days)
88819204|NCT02324751|Experimental|Vi-TCV|Single intramuscular injection
88819205|NCT02324751|Active Comparator|Vi-PS Vaccine|Single intramuscular injection
88819206|NCT02324751|Other|Control (Men ACWY)|Single intramuscular injection
88819207|NCT02313207|Active Comparator|FODMAP diet|FODMAP diet for 2 weeks, patients will undergo a specific FODMAP diet for a period of 2 weeks.
88819208|NCT02313207|Active Comparator|Specific bread diet|Specific bread diet eliminating wheat and yeast for 2 weeks, patients will undergo a specific FODMAP diet for a period of 2 weeks.
88819209|NCT05447871|Experimental|Ultrasound guided single injection modified 4 in 1 block technique|Patients in this group will receive ultrasound guided single injection modified 4 in 1 block with 25 ml bupivacaine 0.25%
88819210|NCT05447871|Active Comparator|Ultrasound guided adductor canal block technique|Patients in this group will receive ultrasound guided aduuctor canal block with 20 ml bupivacaine 0.25%
88819211|NCT02157129|Experimental|LipoAerosol©|LipoAerosol© inhalation, 5x/d for 30min
88819212|NCT02157129|Other|Physiologic saline inhalation|Physiologic saline inhalation, 5x/d for 30min
88819213|NCT05447793||Fitostimoline Plus|Formulation in gauzes and cream based on a particular Triticum Vulgare Extract (Rigenase®) and polyhexanide, an antiseptic which does not give any bacterial resistance.
88819214|NCT05447793||Connettivina Bio Plus|Formulation in gauzes and cream based on hyaluronic acid and silver sulphadiazine.
89003582|NCT04994132|Experimental|Arm A (VAC, VINO-CPO)|"Patients receive vincristine sulfate IV on days 1, 8 and 15 of cycles 1-4, 7, 8, 11, and 12, and day 1 of cycles 5, 6, 9, 10, 13, and 14. Patients also receive dactinomycin IV over 1-15 minutes or IVP over 1-5 minutes on day 1 of cycles 1-5, 8-10, and 11-14, and cyclophosphamide IV over 60 minutes on day 1 of each cycle. Treatment repeats every 21 days for up to 14 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo radiation therapy on weeks 13 and 40.~MAINTENANCE: Patients receive vinorelbine tartrate IV over 6-10 minutes on days 1, 8, and 15, and cyclophosphamide PO on days 1-28. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.~Patients in both arms undergo CT, MRI, PET, x-ray imaging, and/or bone scan, as well as blood sample collection throughout the trial. Patients may also undergo bone marrow aspiration and/or biopsy as clinically indicated."
89003583|NCT04994132|Experimental|Arm B (vinorelbine, VAC, VINO-CPO)|"Patients receive vinorelbine tartrate IV over 6-10 minutes on days 1 and 8, vincristine sulfate IV on day 15, dactinomycin IV over 1-15 minutes or IVP over 1-5 minutes on day 1 of cycles 1-5 and 8-14, and cyclophosphamide IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 14 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo radiation therapy on weeks 13 and 40.~MAINTENANCE: Patients receive vinorelbine tartrate IV over 6-10 minutes on days 1, 8, and 15, and cyclophosphamide PO on days 1-28. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.~Patients in both arms undergo CT, MRI, PET, x-ray imaging, and/or bone scan, as well as blood sample collection throughout the trial. Patients may also undergo bone marrow aspiration and/or biopsy as clinically indicated."
89003584|NCT04978506|Experimental|BI 1569912 MRD: treatment group 1|Multiple rising dose (MRD) part
89003585|NCT04978506|Experimental|BI 1569912 POSO treatment group|Posology part (optional)
89003586|NCT04978506|Placebo Comparator|Placebo|
89390206|NCT02304991|Experimental|Peanut (liquid peanut extract) SLIT|After the entry DBPCFC, subjects will be randomized 1:1 to active or placebo drug product. Subjects randomized to peanut SLIT therapy will dose for 36 months and undergo a second DBPCFC. The subjects will stop dosing for three months and repeat a DBPCFC at 39 months.
89390207|NCT02304991|Placebo Comparator|Placebo Glycerin SLIT|After the entry DBPCFC, subjects will be randomized 1:1 to active or placebo drug product. Subjects randomized to placebo glycerin SLIT will dose for 36 months and undergo a second DBPCFC. The subjects will stop dosing for three months and repeat a DBPCFC at 39 months.
89390208|NCT04870281||CRT-DX System|
89390209|NCT01348295||Mechanically ventilated children|All children under 16 years of age who are needing mechanical ventilation for any reason.
89390210|NCT02033070||Non-Dysplastic IM, LGD, HGD|
89390211|NCT02069132||Warfarin in elderly with comorbidity|Patients 65 years or older, candidate for therapy with warfarin for non valvular atrial fibrillation or heart valve replacement
89003587|NCT04978506|Experimental|BI 1569912 MRD: treatment group 2|Multiple rising dose (MRD) part
89003588|NCT04978506|Experimental|BI 1569912 MRD: treatment group 3|Multiple rising dose (MRD) part
89003589|NCT04978506|Experimental|BI 1569912 MRD: treatment group 4|Multiple rising dose (MRD) part
89003590|NCT04978506|Experimental|BI 1569912 MRD: treatment group 5|Multiple rising dose (MRD) part
89003591|NCT04978506|Experimental|BI 1569912 MRD: treatment group 6|Multiple rising dose (MRD) part
89003592|NCT04978506|Experimental|BI 1569912 elderly treatment group|
89003593|NCT04969783|Experimental|Ventilated Cigarette Filter|Filters with approximately 24-32% filter ventilation
89003594|NCT04969783|Experimental|Unventilated Cigarette Filter|Filters with approximately 0-5.0% filter ventilation
89003595|NCT04950985||Participants|Adults undergoing a CT scan to investigate possible NOE.
89003596|NCT04940468|Active Comparator|Arm 1: Diet Intervention|Based on participant food preferences, diet higher in fiber and lower in fat than the participant's typical diet will be provided.
89003597|NCT04940468|No Intervention|Arm 2: No Diet Intervention|No diet changes will be made for participants
89003600|NCT04931797|Experimental|Video|Video decision aid and advance care planning discussion
89003601|NCT04931797|Active Comparator|Control arm|Usual advance care planning services provided at the study site.
89003602|NCT04931342|Experimental|Ipatasertib + Paclitaxel (PIK3CA/AKT1/PTEN-altered tumors)|Participants in the Ipatasertib + Paclitaxel arm will receive treatment until unacceptable toxicity or disease progression per RECIST v1.1.
89003603|NCT04931342|Experimental|Cobimetinib (BRAF/NRAS/KRAS/NF1-altered tumors)|Participants in the Cobimetinib arm will receive treatment until unacceptable toxicity or disease progression per RECIST v1.1.
89003604|NCT04931342|Experimental|Trastuzumab Emtansine (ERBB2-amplified/mutant tumors)|Participants in the Trastuzumab Emtansine arm will receive treatment until unacceptable toxicity or disease progression per RECIST v1.1.
89390212|NCT03715985|Experimental|NeoPepVac|Group A (has not yet started standard treatment) and Group B (has begun standard treatment at least 4 months before first vaccine, and the decease development is status quo) will receive 6 vaccines in total. Firstly 3 vaccines intraperitoneal biweekly and lastly 3 vaccines intramuscular biweekly while the patients are receiving standard immune therapy.
89390213|NCT04852029|Active Comparator|Control Group|to remain on current dose of low dose hCG
89390214|NCT04852029|Experimental|Intervention Group|increased dose of low dose hCG prescribed
89390215|NCT01352065|Experimental|BOSENTAN|
89390216|NCT01352065|Experimental|AMBRISENTAN|
89390217|NCT01352065|Placebo Comparator|PLACEBO|
89390218|NCT02065310|No Intervention|Diabetes, Non-diabetes|
89390219|NCT01348373||GENOUS EPC-coated stent|Patients treated with GENOUS EPC-coated stent
89390220|NCT03610854|Experimental|Fitness tracker Arm|Patients will be wearing a commercially available fitness tracker during radiotherapy or chemotherapy and four weeks after the end of treatment.
89390221|NCT01356043|Experimental|Free combination of S-amlodipine and Telmisartan|Subjects received S-amlodipine 5mg and Telmisartan 80mg once a day for 9 days. And subjects doesn't take any medications for 19 days.
89390222|NCT01356043|Active Comparator|S-amlodipine monotherapy|Subjects received S-amlodipine 5mg once a day for 9 days. And subjects doesn't take any medications for 19 days.
88866394|NCT02977728||Mild Traumatic Brain Injury|The investigators will include patients who have been diagnosed with a mild traumatic brain injury (Glasgow Coma Scale 13 and above). The patients will be aged between 18 and 55 years old and admitted to the Hospital Visp in the 24 hours preceding the testing.
88866395|NCT02977728||Orthopaedic Injury|The investigators will include patients who have been diagnosed with a traumatic orthopedic injury to one of their limbs. The patients will be aged between 18 and 55 years old and admitted to the Hospital Visp in the 24 hours preceding the testing.
89186587|NCT00918632|Other|Sequence 2 (ACB)|"The following treatments will be administered in the following order A -> C -> B~Treatment A = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered after overnight fasting~Treatment B = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered with a high-fat, high-calorie meal.~Treatment C = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered with a moderate-fat, standard-calorie meal."
89186588|NCT00918632|Other|Sequence 3 (BCA)|"The following treatments will be administered in the following order B -> C -> A~Treatment A = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered after overnight fasting~Treatment B = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered with a high-fat, high-calorie meal.~Treatment C = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered with a moderate-fat, standard-calorie meal."
89390223|NCT02065388|Active Comparator|Standard of care dosing for warfarin|Loading dose (5mg) of warfarin for the first 3 days of treatment. Dose adjustment after initiation will using guideline modified from Tait el al. (1998).
89390224|NCT02065388|Experimental|Genotype-guided dosingTaiwan algorithm for warfarin|Initial loading dosing of warfarin for the first 3 days of treatment will be determined by the Taiwan algorithm that uses clinical and genetic information. Dose adjustment after initiation will using guideline modified from Tait el al. (1998).
89390225|NCT02065388|Experimental|Genotype-guided dosing IWPC algorithm for warfarin|Initial loading dosing of warfarin for the first 3 days of treatment will be determined by the IWPC algorithm that uses clinical and genetic information. Dose adjustment after initiation will using guideline modified from Tait el al. (1998).
89390226|NCT04835415|Active Comparator|group T|Group (T) (n=26): will receive ultrasound guided thoracic epidural analgesia: 20 ml of bupivacaine 0.25 % plus 5ug/ml adrenaline (1:200000).
89390227|NCT04835415|Active Comparator|group R|Group (R) (n=26): will receive bilateral ultrasound guided retrolaminar block analgesia: 20 ml of bupivacaine 0.25 % plus 5ug/ml adrenaline (1:200000).
89390228|NCT01317563|Active Comparator|Antioxidant arm|Two capsules twice daily (total daily dose = Vitamin A 10000 IU, Vitamin C 1200mg, Vitamin E 400 IU, Selenium 300mcg)
89390229|NCT01317563|Placebo Comparator|Placebo arm|two capsules twice daily (total daily dose = 1200mg whey protein, 800mg microcrystalline cellulose)
88866396|NCT02987634|Experimental|PeriActive mouthwash|patient is directed to rinse twice a day for 4 weeks. each rinse is 15 ml of Periactive
88866397|NCT02987634|Active Comparator|chlorhexidine 0.12% mouthwash|patient is directed to rinse twice a day for 4 weeks. each rinse is 10 ml of Periactive
88866398|NCT02977104|Other|Patients in afib or flutter|Maestro ECG
88866399|NCT02977104|Other|Patients in sinus rhythm|Maestro ECG
88866400|NCT02977182|No Intervention|Control Group|The control group will receive standard speech therapy treatments but not lymphedema treatment and will serve as the baseline for comparison for assessment of the effects of CDT.
88866401|NCT02977182|Experimental|Active Treatment Group|The active treatment group will receive standard speech therapy treatments in addition to complete decongestive therapy from a certified Speech Language Pathologist (CCC-SLP) trained in CDT.
88866402|NCT02977260|Experimental|Test Meal 1|Thin/Low Energy
88866403|NCT02977260|Experimental|Test Meal 2|Thin/High Energy
88866404|NCT02977260|Experimental|Test Meal 3|Thick/Low Energy
88866405|NCT02977260|Experimental|Test Meal 4|Thick/High Energy
88866406|NCT02976870|Experimental|Ultrasound|Single ultrasound scan of kidney on side of body where ALIF was performed. If hydronephrosis of this kidney is detected, the second kidney will also be scanned.
88866407|NCT02977026|No Intervention|Control|A questionnaire that asks individuals what components of an online intervention they might find useful.
89390230|NCT01359865|No Intervention|Lumbar plexus Block|This group will recieve pre-operative lumbar plexus block plus general anesthesia
89390231|NCT02067338|Placebo Comparator|normal saline|During posterior lumbar spinal surgery,one group of patient received normal saline soaked collagen sponge.
89390232|NCT02067338|Active Comparator|1 mg morphine soak in epidural oxidized cellulose|During posterior lumbar spinal surgery ,Another group of patients received 1 mg morphine-soaked in epidural oxidized cellulose.
89390233|NCT01336764|Experimental|Active|individual coping self-statements and stimulus guided paced breathing.
88866408|NCT02977026|Experimental|Check Your Drinking (CYD)|"Internet based program of lower intensity as compared to the Alcohol Help Centre. It was designed to provide personalized normative feedback aimed at motivating reductions in drinking"
88866409|NCT02977026|Experimental|Alcohol Help Centre (AHC)|"Internet based program of higher intensity as compared to the Check Your Drinking intervention. It was designed to assesses drinking patterns, increase self-awareness of individual triggers, and set and achieve goals regarding drinking."
88866410|NCT02976558|Experimental|Treatment Group|"Interventions:~Acupuncture, music therapy (TaKeTiNa) and Clown theatrical performance starting before allogenic stem cell transplant until three months after transplantation.~Interventions each twice a week for 4 weeks, then once a week for 4 weeks, then once every two weeks for 4 weeks"
88866411|NCT02976558|No Intervention|Control Group|control group. No interventions
88866412|NCT02976324|Experimental|external diaphragmatic pacemaker group|use the external diaphragmatic pacemakerI 9 counts per minute, with stimulate frequency 40 Hz
88866413|NCT02976324|No Intervention|control group|No inervention, just receive conventional therapy
88866414|NCT02976402|Experimental|SBRT|"Postoperative RT consisting in:~31 Gy in 5 sessions each of 6.2 Gy (adjuvant intent) delivered in one week~32.5 Gy in 5 sessions each of 6.5 Gy (salvage intent) delivered in one week"
88866415|NCT02976168|No Intervention|Horizontal|Subjects will be in horizontal supine Position for 21 hours
88866416|NCT02976168|Experimental|-12° head down tilt|Subjects will be in 12° head down supine Position for 21 hours
88866417|NCT02976246|Active Comparator|RenaKvit-vessel Active|One tablet of 360 micrograms vitamin K2 given once daily to examine the effect on vascular calcification
88866418|NCT02976246|Placebo Comparator|RenaKvit-vessel Control|One tablet of non-active drug given once daily
88866419|NCT02976246|Active Comparator|RenaKvit-bone Active|One tablet of 360 micrograms vitamin K2 given once daily to examine the effect on bone metabolism
88866420|NCT02976246|Placebo Comparator|RenaKvit-bone control|One tablet of non-active drug given once daily
88866421|NCT02976480|Active Comparator|Irrigation|The subjects randomized to this group will have their simple lacerations irrigated with a normal saline solution.
88866422|NCT02976480|Experimental|No Irrigation|The subjects randomized to this group will not have their simple lacerations directly irrigated with a normal saline solution.
88866423|NCT02975856|Experimental|Table Red Wine|250 ml Table Red Wine (12% ethanol)
88866424|NCT02975856|Experimental|Young Port Red Wine|150 ml Young Port Red Wine (20% ethanol)
88866425|NCT02976012|Active Comparator|IAI q8 week Group|"Eyes will be randomized on the day of endolaserless vitrectomy surgery or first postoperative 1-2 week visit to a group (q8 week Group) where 4 additional mandatory postoperative q4weeks IAI followed by mandatory q8 weeks IAI for 52 weeks follow-up. Starting at week 20 in the q8week group eyes may be eligible to receive additional 2mg IAI (intravitreal aflibercept) (monthly) treatment"
89390234|NCT01336764|Sham Comparator|Control|Coping self statements and breathing retraining will be replaced with undirected passive behaviors such as listening to music.
89390235|NCT04801173|Experimental|Very low calorie ketogenic diet|Dietary intervention with a very low calorie ketogenic diet, using commercial products of the Pronokal PnK® method
88866426|NCT02976012|Active Comparator|IAI q16 week Group|Eyes will be randomized on the day of endolaserless vitrectomy surgery or first postoperative 1-2 week visit to a group (q16week Group) where 2 additional mandatory postoperative q4weeks IAI will be followed by mandatory q16weeks IAI for 52 weeks follow-up. Starting at week 12 in the q16 group, eyes may be eligible to receive additional 2mg IAI (intravitreal aflibercept) (monthly) treatment.
88866427|NCT02975778|Experimental|Aged, 65 and over|
88866428|NCT02975388|Experimental|Label: RO7079901 (Mild) (Part 1)|Participants with mild renal impairment (but not undergoing hemodialysis) will be enrolled in this arm. Participants will receive the specified dose of RO7079901.
88866429|NCT02975388|Experimental|RO7079901 (Moderate) (Part 1)|Participants with moderate renal impairment (but not undergoing hemodialysis) will be enrolled in this arm. Participants will receive the specified dose of RO7079901.
88866430|NCT02975388|Experimental|RO7079901 (Severe) (Part 1)|Participants with severe renal impairment (but not undergoing hemodialysis) will be enrolled in this arm. Participants will receive the specified dose of RO7079901.
88866431|NCT02975388|Active Comparator|RO7079901 (Normal) (Part 1)|Control group of participants with normal renal function will be enrolled in this arm. Participants will receive the specified dose of RO7079901.
88866432|NCT02975388|Experimental|RO7079901 (End-stage) (Part 2)|Participants with stable end-stage renal disease undergoing hemodialysis will be enrolled in this arm. Participants will receive the specified dose of RO7079901.
88866433|NCT02975466|Experimental|AirQ Blocker supra-glottic airway device|Group of patients in which the Air-Q Blocker will be used and measured as an intubation conduit.
89390236|NCT04801173|Active Comparator|Low calorie diet|Control treatment with a low calorie standard diet
89390237|NCT01348451|Experimental|surgery|A sequential design of five groups will be utilized to reduce risk to subjects. The first group (Group A) will include six subjects and the subsequent groups will include three subjects per group. Each group represents both different inclusion criteria and location of surgery.
89390238|NCT02260310|Experimental|Weizhong and Huantiao|Patients with Ankylosing Spondylitis use the Acupuncture Protocol Involving in Weizhong (BL4) and Huantiao (GB30) Points
89390239|NCT02260310|Active Comparator|A-shi point|Patients with Ankylosing Spondylitis use the Acupuncture Protocol Involving in A-shi points, without including Weizhong (BL4) and Huantiao (GB30) Points
89390240|NCT05188651||dental professionals wearing FFP2/N95 masks|
89390241|NCT05188651||dental professionals wearing type IIR fluid resistant surgical masks|
89186589|NCT00918632|Other|Sequence 4 (BAC)|"The following treatments will be administered in the following order B -> A -> C~Treatment A = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered after overnight fasting~Treatment B = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered with a high-fat, high-calorie meal.~Treatment C = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered with a moderate-fat, standard-calorie meal."
89186590|NCT00918632|Other|Sequence 5 (CAB)|"The following treatments will be administered in the following order C -> A -> B~Treatment A = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered after overnight fasting~Treatment B = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered with a high-fat, high-calorie meal.~Treatment C = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered with a moderate-fat, standard-calorie meal."
89390242|NCT01352299|Active Comparator|Macintosh|Laryngoscopy performed with Macintosh Laryngoscope
89390243|NCT01352299|Active Comparator|McCoy|Laryngoscopy performed with MacCoy Laryngoscope
89390244|NCT01352299|Active Comparator|Miller|Laryngoscopy performed with Miller Laryngoscope
89390245|NCT01352299|Active Comparator|TrueView|Laryngoscopy performed with TrueView Laryngoscope
89390246|NCT01348529|Experimental|Internet CBT|Internet-delivered cognitive behavioral therapy with therapist support.
89390247|NCT02069210||Blood transfusion|Patients receive blood transfusion during operation
89390248|NCT05188573|Experimental|EpiDetect Arm|"Each subject can undergo to up to 3 blood draws; at the time of enrollment (T0), at 6 months (T1) and 12 months (T2) from diabetes diagnosis. After 24 months from diabetes diagnosis, a review of the electronic medical records (EMR) will be performed for all subjects with a not detected test result."
89390249|NCT05188573|Experimental|"EpiDetect not detected MRI Arm"|"A pre-specified number of cases with test results not detected will be randomly selected, gender ratio and age matched to subjects with test results detected and will undergo MRI imaging at T0 (n=226), at T1 (n=208 ) at T2 (n=208 ) and 24 months (n=208) from diabetes diagnosis."
89390250|NCT03726333|Active Comparator|Group A1 Normal hepatic function|continued daily administration of lorlatinib in patients with normal hepatic function
89390251|NCT03726333|Active Comparator|Group A2 Normal hepatic function|continued daily administration of lorlatinib in patients with normal hepatic function
89390252|NCT03726333|Experimental|Group B mild hepatic impairment|continued daily administration of lorlatinib in patients with mild hepatic imapirment
88866434|NCT02975466|Experimental|AuraGain supra-glottic airway device|Group of patients in which the AuraGain will be used and measured as an intubation conduit.
89390253|NCT03726333|Experimental|Group C moderate hepatic impairment|continued daily administration of lorlatinib in patients with moderate hepatic impairment
89390254|NCT03726333|Experimental|Group D severe hepatic impairment|continued daily administration of lorlatinib in patients with severe hepatic impairment
88866435|NCT02975466|Experimental|I-Gel supra-glottic airway device|Group of patients in which the I-Gel will be used and measured as an intubation conduit.
89390255|NCT01347125|Experimental|ImCardia|Aortic Stenosis patients candidates for Aortic Valve Replacement (AVR) implanted with the ImCardia device
89390256|NCT01347125|No Intervention|AVR control group|Aortic stenosis patients candidates for aortic valve replacement
89390257|NCT02069288|Experimental|1|Fludrocortisone
89390258|NCT02069288|Placebo Comparator|2|Placebo
88866436|NCT02975622|Active Comparator|Subclavian|Subclavian vein will be individualized and approached by longitudinal incidence, according to previous studies. Skin puncture will be made next to the transducer, lateral to the first rib, maintaining constant visualization of the needle tip.
88866437|NCT02975622|Active Comparator|Jugular|Jugular vein will be identified by transverse or longitudinal approach, and skin puncture will be made by transverse or longitudinal incidence, according to operator's preferences. Using transverse approach, the needle will be maintained in a 45 degree angle with the skin, and the insertion site will be exactly the same as the measured distance between asking and jugular vein wall.
88866438|NCT02975544|Experimental|Intervention group|Received CRECES programme during 5 weeks as part of the extracurricular plan
88866439|NCT02975544|No Intervention|Control group|Continued with their habitual school routine
88866440|NCT02975076|Experimental|Sanchitongshu & placebo of lopidogrel|sanchitongshu 1 capsule each time ,three times a day and Aspirin 75mg for 90 days ; placebo of clopidogrel 75mg daily for 21 days after randomization
89390259|NCT01356121|Active Comparator|Midazolam|Midazolam (0.5-1.0 mg) will be administered in a similar fashion with incremental dosing at intervals of approximately 1-3 min until a level of sedation will be achieved
89390260|NCT01356121|Active Comparator|Propofol|Propofol will be initiated with a 0.5-1 mg/kg i.v. bolus followed by repeated 10-20 mg doses at variable intervals (approximately 15 s, at the discretion of the endoscopist/nurse) until an appropriate level of sedation will be achieved.
89390261|NCT01356121|No Intervention|No Sedation|No sedation given in this group
89390262|NCT01336608|Experimental|Fluticasone Furoate/Vilanterol|Inhaled corticosteroid/long acting beta-agonist
88819215|NCT00369447|Experimental|1|200 mg dose
88819216|NCT00369447|Placebo Comparator|2|
88819217|NCT05447715|Other|Fruquintinib sequential BEV+FOLFIRI|
89390263|NCT01336608|Experimental|vilanterol|Inhaled long acting beta-agonist
89390264|NCT01336608|Placebo Comparator|placebo|Placebo
89390265|NCT02069444||Truview EVO2 laryngoscope|patients intubated withTruview EVO2 laryngoscope
89390266|NCT02069444||Macintosh laryngoscope|patients intubated with Macintosh laryngoscope
88819218|NCT05447715|Other|BEV+FOLFIRI sequential fruquintinib|
89390267|NCT03872999|Experimental|Attentional Control|Visuo-spatial attentional tasks with simple stimuli during functional magnetic resonance imaging (fMRI) scanning.
89390268|NCT03628521|Other|arm A|Anlotinib combined with erlotinib. Anlotinib will be given at a dose of 10mg once daily on days 1-14 of a 21-day cycle. Erlotinib will be given at a dose of 150mg once daily.
89390269|NCT03628521|Other|arm B|Anlotinib combined with chemotherapy. Anlotinib will be given at a dose of 12mg once daily on days 1-14 of a 21-day cycle. Pemetrexed (just for adenocarcinoma) will be given intravenously at a dose of 500mg per square meter of body surface area every 3 weeks; gemcitabine (just for squamous carcinoma) will be given intravenously at a dose of 1000mg per square meter of body surface area every 3 weeks; carboplatin will be given intravenously with a target area under the curve of 5 mg per milliliter per minute every 3 weeks.
89390270|NCT03628521|Other|arm C|Anlotinib combined with IBI308. Anlotinib will be given at a dose of 12mg once daily on days 1-14 of a 21-day cycle. IBI308 will be given intravenously at a dose of 200mg every 3 weeks.
89390271|NCT01347203|Experimental|Treatment A|DPOC-4088 prolonged release tablet 100 mg (Formulation A= 16 hr release formulation)
89390272|NCT01347203|Experimental|Treatment B|DPOC-4088 prolonged release tablet 200 mg (Formulation A= 16 hr release formulation)
89390273|NCT01347203|Experimental|Treatment C|DPOC-4088 prolonged release tablet 100 mg (Formulation B= 20 hr release formulation)
89390274|NCT01347203|Experimental|Treatment D|DPOC-4088 prolonged release tablet 200 mg (Formulation B= 20 hr release formulation)
88819219|NCT05447637||Individuals who meet NCCN Testing Criteria|
88819220|NCT05447637||Individuals who do not meet NCCN Testing Criteria|
88819221|NCT05447481|Experimental|Chicory inulin-type fructan - placebo|Dietary supplement: chicory inulin-type fructan Placebo: maltodextrin
88819222|NCT05447481|Experimental|Placebo - chicory inulin-type fructan|Placebo: maltodextrin Dietary Supplement: chicory inulin-type fructan
88819223|NCT04772235|Experimental|Advanced and/or metastatic EGFR mutant NSCLC|Eligible advanced and/or metastatic EGFR mutant NSCLC patients will receive the combination of osimertinib and repotrectinib.
88819224|NCT04766463|Experimental|Treatment group A|
88819225|NCT04766463|Experimental|Treatment group B|
88819226|NCT04766463|Placebo Comparator|Treatment group C|
88819227|NCT04766463|Active Comparator|Treatment group D|
88819228|NCT05452707||Patients|"Patients will be observed during their active training sessions.~Patients will be asked questions about:~fatigue~physical fatigue~pain~the difficulty of the session~motivation"
88819229|NCT05452707||Therapists|"Therapists will be asked questions about the observed training sessions of the patients. The questions will be about:~Estimation of active training time~Estimation of patient's fatigue~Estimation of the patient's perceived difficulty of the session~Estimation of the patient's perceived physical fatigue of the session~Estimation of the patient's perceived motivation for the session"
88819230|NCT04763889|Experimental|CBT workshop|Participants will be randomly allocated to either a self-help control group or a CBT workshop group. In the intervention group participants will attend a day workshop or two half day workshops focused on using CBT to manage their anxiety and stress.
88819231|NCT04763889|No Intervention|Self-help control treatment as usual group|Participants will be randomly allocated to either a self-help control group or a CBT workshop group. Participants in the treatment as usual group will receive the workshop materials after the active treatment group have completed their final follow-up at 3 months
88819232|NCT05452629|Experimental|Mindfulness Induction|A brief and single session of mindfulness practice for 30-minute.
88819233|NCT05452629|Experimental|Relaxation Induction|A brief and single session of self-directed relaxation for 30-minute.
88819234|NCT05452629|No Intervention|Control Condition|Open thinking.
88819235|NCT05452395|Experimental|Post-acute care|comprehensive geriatric assessment, and either home-based or hospital-based post-acute care
88819236|NCT05452395|No Intervention|control group|comprehensive geriatric assessment only
88819237|NCT05447169||High risk population of nasopharyngeal carcinoma|first-degree relatives of nasopharyngeal carcinoma patients, aged 30-62 male
88819238|NCT05451537||Sepsis associated encephalopathy group|Patients were diagnosed with sepsis related encephalopathy
88819239|NCT05451537||None sepsis associated encephalopathy group|Patients were not diagnosed with sepsis related encephalopathy
88819240|NCT04656561|Experimental|ANX007 Group 1|ANX007 administered every month
88819241|NCT04656561|Experimental|ANX007 Group 2|ANX007 administered every other month
88819242|NCT04656561|Sham Comparator|Sham Group 3|Sham injection administered every month
88819243|NCT04656561|Sham Comparator|Sham Group 4|Sham injection administered every other month
88819244|NCT05446701||60 case|Sixty patients diagnosed as NMOSD based on the recently revised 2015 international consensus diagnostic criteria for NMOSD (9) ,attending Neurology clinic, Asyut University hospitals, Asyut university and Kasr Al-Ainy multiple sclerosis/neuroimmunology clinic, Cairo University hospitals, Cairo University, Egypt, through one and half year from study onset
88819245|NCT05446701||60 control|Sixty healthy volunteers, without any neurological or systemic medical diseases, age and sex matched , will be enrolled as healthy controls(HCs).
89390275|NCT02067494|Experimental|Myofascial Soft Tissue Release|"Protocol: Myofascial release on thoracolumbar fascia, Myofascial release on diaphragm, Myofascial release in the psoas fascia, Indirect Myofascial release restrictions in the public area, Myofascial release in lumbo-sacral decompression, Myofascial release on sacrum, and Myofascial release on the lumbar fascia.~Myofascial release assisted the paravertebral fascia."
88866441|NCT02975076|Placebo Comparator|placebo of Sanchitongshu & lopidogrel|placebo of sanchitongshu1 capsule each time ,three times a day and Aspirin 75mg for 90 days;clopidogrel 75mg per day for 21 days after randomization
88866442|NCT02975232|Experimental|Treatment|F&V economic incentive with Cooking Matters store tour
88866443|NCT02975232|No Intervention|Control|no intervention
88866444|NCT02975154|Active Comparator|Microcurrent therapy, type A|"Microcurrent therapy: Channel A: 100 µA; 200 Hz; Channel B: 100 µA; 300 Hz. Duration of each treatment session: 30 minutes. Number of sessions: 10.~Previous treatments will be continued."
88866445|NCT02975154|Active Comparator|Microcurrent therapy, type B|Microcurrent therapy: Channel A: 25 µA; 200 Hz; Channel B: 100 µA; 300 Hz. Duration of each treatment session: 30 minutes. Number of sessions: 10. Previous treatments will be continued.
88866446|NCT02975154|Sham Comparator|Sham Microcurrent therapy|Microcurrent therapy: Channel A: 0 µA; 0 Hz; Channel B: 0 µA; 0 Hz. Duration of each treatment session: 30 minutes. Number of sessions: 10. Previous treatments will be continued.
88866447|NCT02975154|No Intervention|No Intervention|No Intervention. Previous treatments will be continued.
88866448|NCT02974920|Active Comparator|Aspirin 100 mg|100 mg of aspirin daily for 180 days
88866449|NCT02974920|Active Comparator|Rivaroxaban 10 mg|10 mg of Rivaroxaban daily for 180 days
88866450|NCT02974764||Chemotherapy Group|This cohort includes patients who will receive chemotherapy at any stage or their treatment.
88866451|NCT02974764||Radiation therapy Group|This cohort includes patients who will receive radiation therapy at any stage or their treatment.
88866452|NCT02974764||Surgical resection of the primary tumor|This cohort includes patients who will undergo resection of the primary tumor.
88866453|NCT02974452||Group I: Older adults|healthy subjects older than 68 years old whose shoulder muscle are measured by surface electromyography
88866454|NCT02974452||Group II: Adults|healthy subjects 43 to 67 years old, whose shoulder muscle are measured by surface electromyography
88866455|NCT02974452||Group III: Young adults|healthy subjects 20 to 42 years old, whose shoulder muscle are measured by surface electromyography
88866456|NCT02974530||Stroke population|Patient with stroke will be explored during their acute phase and in 6 months of diagnosis.
88866457|NCT02974530||Healthy population|Healthy subjects will be explored in Grenoble in research laboratory
88866458|NCT02974374|Experimental|PF-06835919|
88866459|NCT02974374|Placebo Comparator|Placebo|
88866460|NCT02974062|Experimental|Lumbar stabilization exercise|Lumbar stabilization exercised is a low-intensity exercise that focuses on motor control of deep abdominal and back muscles, rather than their strength or endurance. There are 3 main levels in this exercise; 1) co-contraction of deep abdominal and back muscles, 2) co-contraction with limb movement (self-perturbation), and 3) co-contraction with functional movement (i.e. walking, running, etc.)
88866461|NCT02974062|No Intervention|Healthy control|No intervention was given to this group of participants. They were asked to rest and wait for 15 minutes, then post-test was performed.
88866462|NCT02973906|Other|ADAPT Self Directed web|ADAPT Self Directed Web. In the self-directed web-only ADAPT condition, participants have access to the full ADAPT website (10 modules, online discussion forum)
88866463|NCT02973906|Other|ADAPT individualized web-facilitated|This condition comprises access to the full ADAPT web program with augmentation of individual facilitator web support (i.e. the facilitator connects via Google Hangout). Facilitators meet with families at a mutually convenient time weekly (10-14 weeks, approximately 3 sessions per month).
88866464|NCT02973906|Other|Group-based ADAPT|Groups will meet weekly for 120 minutes, at a time convenient to participants (usually early evening). Groups cover core ADAPT/PMTO topics
88866465|NCT02973672|Experimental|SGM-101|
88866466|NCT02973360|Experimental|Dose Level 1|Target dose 20 mg/kg Docosahexaenoic acid
88866467|NCT02973360|Experimental|Dose Level 2|Target dose 36 mg/kg Docosahexaenoic acid
88866468|NCT02973360|Experimental|Dose Level 3|Target dose 60 mg/kg Docosahexaenoic acid
88866469|NCT02973360|Placebo Comparator|Placebo|Soybean oil
88866470|NCT02973204||HCC sorafenib|HCC patients referred for Sorafenib treatment
88866471|NCT02973204||HCC curative treatment|HCC patient undergoing potential curative treatment, eg. radiofrequency ablation (RFA) or resection
88866472|NCT02973204||NET everolimus|Pancreatic NET patients referred for Everolimus treatment
88866473|NCT02973204||NET ssta|Small intestinal or unknown primary NET patients referred for treatment with somatostatin analogues, eg. lanreotide and octreotide
88866474|NCT02972970|Other|Aveera|This is a prospective, open label study to assess the scan, print and fit process to see if the Aveera will be able to be used with conventional CPAP therapy devices
88866475|NCT02972736||Interventional Cardiology|All procedures performed by interventional cardiologists
88866476|NCT02972736||Electrophysiology|All procedures performed by electrophysiologists
88866477|NCT02972736||Interventional Radiology|All vascular and non vascular procedures performed by interventional radiologists
88866478|NCT02972814||Thoracic pain|Patients presenting to the emergency room with thoracic pain probably due to a non-STEMI
88866479|NCT02959476|Experimental|Ropivacaine 0.2%|"Naropin® (ropivacaine HCl Injection, USP) bolus + Ropivacaine 0.2% Pre-Filled Dispenser infusion - Ropivacaine Infusion treatment arm"
88866480|NCT02959476|Placebo Comparator|Placebo|"Naropin® (ropivacaine HCl Injection, USP) bolus + placebo infusion (normal saline) - Placebo treatment arm"
88866481|NCT02959398|Active Comparator|standard mammography|standard mammography
89390276|NCT02067494|Active Comparator|Kinesio taping treatment|"Two bands in I, with anchor onset in sacrum, on paravertebral muscles. Furthermore a strip will be applies on correction space point of maximum pain."
89390277|NCT01361347|Placebo Comparator|placebo|"rice/soy/oat milkdrink, masked"
89390278|NCT01361347|Experimental|milk|cow's milk
89390279|NCT05697003|Experimental|Fluticasone propionate 100 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals|Test
88866482|NCT02959398|Experimental|standard mammography and tomosynthesis|standard mammography and tomosynthesis
88866483|NCT02959008||normal|Human without hypertension, diabetes, anemia, liver disease and kidney disease. The group will measure TOI and BP.
88866484|NCT02959008||hypertension|"Human only have hypertension, without diabetes, anemia, liver disease and kidney disease.~Hypertension group will measure TOI and BP."
88866485|NCT02958930|Experimental|TEMT Treatment|Patients in this arm will receive Transcranial Electromagnetic Treatment (TEMT) twice daily for a two-month treatment period utilizing the MemorEM 1000 head device.
88866486|NCT02958852|Active Comparator|Letrozole|Confirmed ER positive/HER2 negative metastatic breast cancer, including locally advanced stage IV disease, requiring systemic endocrine treatment, in this case letrozole, 2.5 mg daily until progression of disease. Upon progression of first line, patients will receive second line treatment using fulvestrant.
88866487|NCT02958852|Experimental|Letrozole+Atorvastatin|Confirmed ER positive/HER2 negative metastatic breast cancer, including locally advanced stage IV disease, requiring systemic endocrine treatment, in this case letrozole, 2.5 mg daily, with the addition of atorvastatin, 40 mg daily until progression of disease. Upon progression of first line, patients will receive second line treatment using fulvestrant.
89390280|NCT05697003|Active Comparator|ADVAIR DISKUS® 100/50|Reference
88866488|NCT02958852|Other|Fulvestrant|Fulvestrant will be used as second line endocrine treatment upon progression on first line with letrozole +/- atorvastatin.
88866489|NCT02958774|Experimental|Hypofractionated Radiation Therapy|Daily for 4 weeks
88866490|NCT02676804|Experimental|High-intensity aerobic exercise|Subjects will participate in a 16 week high-intensity aerobic exercise program.
88866491|NCT02641782|Active Comparator|Standard Arm|Standard IL-2 i.v. together with antibody ch14.18, GM-CSF and retinoic acid
88866492|NCT02641782|Experimental|Experimental Arm|IL-2 s.c. together with antibody ch14.18, GM-CSF and retinoic acid
88866493|NCT02641314|Experimental|metronomic therapy|Treatment consists of eight alternating 28-day-cycles of propranolol, celecoxib, cyclophosphamide, vinblastine, etoposide (PCCVE) and of propranolol, celecoxib, cyclophosphamide, vinblastine (PCCV) followed by five cycles PCCV resulting in a total of 13 cycles (364 days of treatment)
88866494|NCT01711710|Experimental|Cohesive Gel Breast Implant|Cohesive Silicone Gel-Filled Breast Implant
88866495|NCT04769622||patients affected by untreated Periodontitis|patients coming to the Unit of Periodontics at the University of Siena will be screened for the inclusion in the study. All patients eligible for the inclusion in the study will undergo non-surgical periodontal treatment and will be administered a questionnaire about lifestyles (adherence to mediterranean diet, sleep quality, physical activity, perceived stress). Patients will be then reevaluated at 3 months after the completion on non-surgical periodontal therapy.
88866496|NCT04769778|Experimental|Valsartan|Treatment with valsartan
88866497|NCT04769778|No Intervention|no treatment|no treatment received
88866498|NCT04769076|Experimental|Paclitaxel(Album-bound)|Subjects will receive neoadjuvant therapy with paclitaxel (albumin-bound) combined with cisplatin and PD-1 inhibitor (sintilimab) as well as radical concurrent radiotherapy and chemotherapy.
88866499|NCT04769232|Active Comparator|Standard Imaging|In 20 randomly assigned patients, the area of endoscopically highest activity will be biopsied as determined by standard imaging. A total of 10 biopsies will be taken in 4 sets: 1 = one single biopsy at best guess of highest activity; 2 = one single biopsy at second best guess of highest activitiy, 3 = 4 biopsies in proximal esophagus with presumed activity, 4 = 4 biopsies in distal esophagus with presumed activity. Overall qualitative (eosinophilic inflammation present vs. absent) and semi-quantitative (estimation of the number of eosinophilic neutrophils according to the following categories 1: 0, 2: 1-6, 3. 7-14, 4. 15-50, 5. :50-100, 6. > 100, together with an estimation of an absolute number of eosinophilic neutrophils) inflammatory activity will be rated for the presumed localization of maximal histologic activity and subsequently for all other 10 biopsies using this imaging modality by endoscopist.
88866500|NCT04769232|Experimental|High Magnification Imaging|In 20 randomly assigned patients, the area of endoscopically highest activity will be biopsied as determined by high magnification imaging. A total of 10 biopsies will be taken in 4 sets: 1 = one single biopsy at best guess of highest activity; 2 = one single biopsy at second best guess of highest activitiy, 3 = 4 biopsies in proximal esophagus with presumed activity, 4 = 4 biopsies in distal esophagus with presumed activity. Overall qualitative (eosinophilic inflammation present vs. absent) and semi-quantitative (see above) inflammatory activity will be rated for the presumed localization of maximal histologic activity and subsequently all other 10 biopsies using this imaging modality by endoscopist.
88866501|NCT04768998||Intersectoral Platform (SÜP) of the National Pandemic Cohort Network (NAPKON)|Streamlined sampling of biomaterials and core data elements (GErman Corona COnsensus data set GECOO), with other NAPKON study platforms (HAP, POP).
88866502|NCT04768998||Populationbased Platform (POP) of the National Pandemic Cohort Network (NAPKON)|Streamlined sampling of biomaterials and core data elements (GErman Corona COnsensus data set GECOO), with other NAPKON study platforms (HAP, SUEP).
88866503|NCT04768998||High-Resolution Platform (HAP) of the National Pandemic Cohort Network (NAPKON)|Streamlined sampling of biomaterials and core data elements (GErman Corona COnsensus data set GECOO), with other NAPKON study platforms (POP, SUEP).
88866504|NCT04768842|Experimental|LY3209590 Lyophilized Formulation|LY3209590 as lyophilized formulation administered subcutaneously (SC) in one of the two study periods.
88866505|NCT04768842|Experimental|LY3209590 Solution Formulation|LY3209590 as solution formulation administered SC in one of the two study periods.
89390281|NCT01356199|Experimental|ARTRONAT|
89390282|NCT01356199|Placebo Comparator|PLACEBO|
89390283|NCT02067572|Experimental|Salvia|Salvia mouthwash used 4 times per day for 4 days
89390284|NCT02067572|Active Comparator|Saline|Saline mouthwash used 4 times per day for 4 days.
89390285|NCT03775473|Other|progastrin|anyone who will participate in colon screening at the Princess Grace Hospital in Monaco and who has signed the informed consent document
89390286|NCT02069522|Active Comparator|Standard Milk-based Formula Containing Carotenoid|milk-based ready to feed infant formula
89390287|NCT02069522|Experimental|Investigational Milk-based Formula Containing Carotenoid|investigational milk-based ready to feed infant formula
89390288|NCT02033148|Experimental|Treatment (icotinib hydrochloride)|Patients receive icotinib hydrochloride PO BID on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
89390289|NCT01361425|Experimental|methildopa|pregnant women with stable severe pre-eclampsia will use methildopa (1,5g/day)
89390290|NCT01361425|Placebo Comparator|placebo|stable pregnant women with severe preeclampsia will use placebo
89390291|NCT02033226|Experimental|Amniotic Membrane|The test site was treated as follows; After placement and proper condensation of natural Hydroxyapatite graft in the defect, AM was cut based on defect anatomy of surgical site and then adapted over the bone graft and alveolar bone extending from base of the flap reflection to the tooth surface.
88866506|NCT04768764|Active Comparator|Group 1 Middle Adductor Canal Block|"Ultrasound Guided Middle Adductor Canal Block:~20 ml Bupivacaine 0.25% Injectable Solution will be administered for middle adductor canal block.~10 ml %0,5 Bupivacaine will be diluted with 10 ml saline solution."
88866507|NCT04768764|Active Comparator|Group 2 Femoral Nerve Block.|"Ultrasound Guided Femoral Nerve Block:~20 ml Bupivacaine 0.25% Injectable Solution will be administered for femoral nerve block.~10 ml %0,5 Bupivacaine will be diluted with 10 ml saline solution."
88866508|NCT04768530|Active Comparator|Scaling and Root Planing (SRP)|
88866509|NCT04768530|Experimental|Scaling and Root Planing with Nitazoxanide hydrogel|
88866510|NCT04768140|Experimental|Bobath group|A conventional physiotherapy program was applied to this group. Additionally, Bobath treatment approach was applied for 10 repetitions during a 30-min session in the experimental group, in addition to the conventional physiotherapy program.
88866511|NCT04768140|Active Comparator|Conventional physiotherapy group|Only conventional physiotherapy program was applied to this group.
88866512|NCT04749654|Experimental|Fixed space maintainers|band-and-loop type fixed space maintainers were applied
88866513|NCT04749654|Experimental|Removable space maintainers|All removable space maintainers were produced of an acrylic base and retention elements that were a vestibule arch, (Adam's and C clasps).
88866514|NCT04749498|Active Comparator|White Bread|White bread with a standard test breakfast
88866515|NCT04749498|Active Comparator|Whole Wheat Bread|Whole wheat bread with a standard test breakfast
88866516|NCT04749498|Experimental|Barley Bread|Barley bread with a standard test breakfast
88866517|NCT04749498|Experimental|Oat Bread|Oat bread with a standard test breakfast
88866518|NCT04749342|Experimental|Complete Decongestive Therapy|Complete decongestive therapy (CDT) is also known as complex decongestive therapy. It involves a two-stage treatment protocol. The first stage consists of skin care, manual lymph drainage, exercises and compression with multi-layered bandages. The second stage aims to optimize and conserve the volume reduction obtained in stage one. This is achieved by using a low-stretch elastic garment in combination with skin care and exercises
88866519|NCT04749342|Experimental|Compression Bandaging|External compression is the mainstay of management for all stages of lymphedema. The efficacy of compression therapy alone, or combined with MLD, has been supported by randomized clinical trials
88866520|NCT04749420||Patients group|Individuals with cervical radiculopathy
88866521|NCT04748562|Active Comparator|400 mg progesterone group|Taking 400 mg vaginal progesterone
88866522|NCT04748562|Active Comparator|200 mg progesterone group|Taking 200 mg vaginal progesterone
88866523|NCT04745286|Experimental|S-ketamine group|
88866524|NCT04745286|Placebo Comparator|saline group|
88866525|NCT04745364|Experimental|Session One|Session One participants undergo the 4-week course from 2/21/2021 to 3/15/2021
88866526|NCT04745364|Experimental|Session Two|Session Two participants undergo the 4-week course from 3/22/2021 to 4/12/2021
89186591|NCT00918632|Other|Sequence 6 (CBA)|"The following treatments will be administered in the following order C -> B -> A~Treatment A = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered after overnight fasting~Treatment B = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered with a high-fat, high-calorie meal.~Treatment C = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered with a moderate-fat, standard-calorie meal."
89390292|NCT02033226|Placebo Comparator|Control group (Hydroxyapatite only)|The control site was treated by graft placement (Hydroxyapatite) only
89390293|NCT01356355|Experimental|Herbmed plus|One capsule twice a day daily till ureteral stent in situ
89390294|NCT01356355|Placebo Comparator|Placebo|One capsule twice a day daily till ureteral stent in situ
89390295|NCT01356355|Active Comparator|Tolterodine|One capsule twice a day daily till ureteral stent in situ
89390296|NCT02069600|Active Comparator|Continuous Positive Airway Pressure|Continuous Positive Airway Pressure is a device that apply a positive pressure in the airway to avoid its collapse during sleep during three months in this study
89390297|NCT02069600|No Intervention|No intervention|No intervention. No placebo is used. Control group without CPAP treatment during three months
89390298|NCT03610542|Experimental|Cognitive Behaviour Therapy|Cognitive behaviour therapy conducted in groups of 6-8 persons.One forty-five minute session per week for 6 weeks: Triggers for anxiety, identifying and challenging negative thoughts, relaxation, overcoming avoidance, and goal setting.
89390299|NCT03610542|Experimental|Cognitive Behaviour Therapy with 2 Booster Sessions|Cognitive behaviour therapy conducted in groups of 6-8 persons.One forty-five minute session per week for 6 weeks: Triggers for anxiety, identifying and challenging negative thoughts, relaxation, overcoming avoidance, and goal setting. 2 booster sessions (forty-five minutes each) will be provided at three and nine months. Each session will recap the content of the initial 6 sessions.
89390300|NCT03610542|No Intervention|Control|This is a no intervention control arm
89390301|NCT03634969|Experimental|Normal Renal Function|
89390302|NCT03634969|Experimental|Mild Renal Impairment|
89390303|NCT03634969|Experimental|Moderate Renal Impairment|
89390304|NCT03634969|Experimental|Severe Renal Impairment|
89390305|NCT03634969|Experimental|End-Stage Renal Disease (ESRD)|ESRD participants and are on chronic hemodialysis
89390306|NCT01356433|Other|arm1, vitamin C treated first|Arm 1(50cases): intervention with oral vitamin C 200mg per day in the first 3 months, then stop oral VitC for the next 3 months.
89390307|NCT01356433|Other|Arm 2 control first|
89390308|NCT02033460|Experimental|Manual therapy, education and Exercise|"The protocol for this group is identical to the previous group with the sole difference that is added an exercise protocol :~In the fifth session we explained the patients to perform :~Five sets of isometric contraction of the deep neck flexors for 8-10 seconds.~Five sets of isometric contraction of the neck extensors for 6-8 seconds~Neural self-mobilization and stretching held for 10 - 12 seconds for the levator scapulae and the trapezius muscle.~In the sixth session the patient repeat all the exercises from the previous session and also with the help of a theraband made :~• Isotonic contraction of the head, performing 3-4 sets of 8-10 repetitions."
88866527|NCT04745442|Experimental|Best available treatment + Antithrombin|The subject will be treated with Antithrombin (50 IU/Kg/12h) for 72 hours and the best available treatment for COVID-19.
88866528|NCT04745442|Active Comparator|Best available treatment|The subject will be treated with the best available treatment for COVID-19.
89186592|NCT00751257|Experimental|1|2400mg N-acetylcysteine (1200mg b.i.d.) for 4 consecutive weeks
89390309|NCT02033460|Active Comparator|Manual Therapy and Education|"The protocol used for therapeutic education consisted of two approaches:~Manual therapy will consist on Traction oscillatory,craniocervical region, Mobilization of upper cervical region in flexion, Side glide roll, Mobilization upper cervical anteroposterior with Wedge, Sliding lateral techniques and High-velocity technique in dorsal region. And Education of the physiology of pain and Education about cognitive behavioral perspective."
89390310|NCT02033460|Active Comparator|Manual Therapy|Manual therapy will consist on Traction oscillatory, Mobilization of upper cervical region in flexion, Side glide roll, Mobilization upper cervical anteroposterior with Wedge, Sliding lateral C1- C2 ( 2 minutes) , C2 -C3, and C5 -C6 and High-velocity technique in dorsal region.
88866529|NCT04744740||PTSD+Suicidal Ideation|US Military Veterans diagnosed with PTSD and identified via the REACH VET or local high-risk list as requiring intensified surveillance by their VA's Suicide Prevention Coordinators in collaboration with their Primary Care Providers
88866530|NCT04744740||PTSD-Suicidal Ideation|US Military Veterans diagnosed with PTSD not identified as requiring intensified surveillance by their VA's Suicide Prevention Coordinators in collaboration with their Primary Care Providers
88866531|NCT04745052||Patients with acute ischemic stroke|The first is to verify the application effect of intravenous thrombolytic hemorrhage prediction models (HAT, SIT-sICH, THRIVE) in the population of acute ischemic stroke in Guangdong Province, and verify the clinical application effects of existing prediction models. Secondly, analyze the predictive value of clinical indicators, optimize HAT, SIT-sICH, and THRIVE scores, construct an improved HT prediction model, and optimize and improve the existing prediction model. The third is to apply the improved HT prediction model to the clinic, collect clinical data prospectively, evaluate the prediction effect of the model, and evaluate the clinical application effect of the improved prediction model.
88866532|NCT04744896|Experimental|cryolipolysis|3max cool shaping device is administered 3 times for each patient, one session every 6 weeks, each session is 40 minutes.
88866533|NCT04744896|Experimental|treadmill|aerobic training in form of high intensity interval training, three times per week for 3 weeks by treadmill(jkexer focus 8020A) each session is for 20 minutes.
88866534|NCT04744896|Active Comparator|treadmill+cryolipolysis|aerobic training 3 times per week and cryolipolysis once every 6 weeks
88866535|NCT04744506|Experimental|TAD ARM|
88866536|NCT04744038|Experimental|Investigational Device|Participants will then be asked to take home the investigational device to use at night while they sleep in place of their own device. The participant's therapy and comfort settings will be copied from their own device to the investigational device. Participants will use their own mask with the investigational device for the duration of this study.
88866537|NCT04743882||A|
88866538|NCT04743882||B|
88866539|NCT04743882||C|
88866540|NCT04743726||Endoscopy|Chinese volunteers who are scheduling for gastro-colonoscopy
88866541|NCT04743648|Experimental|Intervention Group|After determining the experimental and control groups, pre-tests were performed.The program was applied to students in the experimental group.The program was implemented for six weeks based on the theme of innovative thinking.The program developed a training program based on the Tyler Taba model. This model, which is often used in developing educational programs, includes all the necessary steps to teach and accept a new concept. In the ITDP training program, an interactive educational content has been created in which knowledge will be transformed into behavior.In the training, subjects were taught in units, workshops were held, seminars were given. Post-tests were applied at the end of the training.
88866542|NCT04743648|No Intervention|Control Group I|Pre-test and post-tests were applied to the non-intervention group
88866543|NCT04743648|No Intervention|Control Group II|Pre-test and post-tests were applied to the non-intervention group
89186593|NCT00751257|Placebo Comparator|2|"Identically appearing placebo pills, packaged in an N-acetylcysteine slurry so that placebo will retain smell similar to active NAC capsules"
89186594|NCT00753441|Experimental|A|Surgical bypass (choledochojejunostomy, in combination with gastroenterostomy if necessary)
89390311|NCT03691727|Experimental|tirofiban hydrochloride (AGGRASTAT®)|"tirofiban hydrochloride (AGGRASTAT®) administered continuously over the course of 7 days.~MRI Neurological Exam Vital Signs Questionnaires"
89390312|NCT03691727|Active Comparator|Standard of Care Control Arm|Standard of Care Treatment MRI Neurological Exam Vital Signs Questionnaires
88866544|NCT04743414|Experimental|CTP-543|On Day 1, participants will receive a single oral dose of CTP-543. Following a washout period on Days 2 and 3, participants will receive a single oral dose of itraconazole on Day 4 through Day 8, with a single oral dose of CTP-543 being co-administered on Day 7.
88866545|NCT04743336||Normal weight (<25 kg/m2)|
88866546|NCT04743336||overweight (25-29.9 kg/m2)|
88866547|NCT04743336||obese (≥30 kg/m2)|
88866548|NCT04743180||LUMINOR© drug eluting balloon|
88866549|NCT04743258|Experimental|EXTRACTION|treatment of class II div 1 malocclusion with bilateral maxillary premolar extraction
88866550|NCT04743258|Experimental|DISTALIZATION|treatment of class II div 1 malocclusion with distalization using zygomatic miniplates
89186595|NCT00753441|Active Comparator|B|Endoscopic biliary stenting using metal stent (completed by duodenal stent, if necessary)
89186596|NCT05685134|Experimental|Ablation|Radiofrequency catheter ablation of the abnormal - prolonged and fragmented - electrophysiologic substrate of Brugada syndrome
89390313|NCT02069834|Experimental|Arm 1 (intervention)|Dolutegravir 50 mg/d + Rilpivirine 25 mg/d qd orally (intake during a meal)
89003605|NCT04931342|Experimental|Atezolizumab + Bevacizumab (Non-matched)|Participants in the Atezolizumab + Bevacizumab arm will receive treatment until unacceptable toxicity or loss of clinical benefit as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
89003606|NCT04931342|Experimental|Giredestrant + Abemaciclib (ER+ tumors)|Participants in the Giredestrant + Abemaciclib arm will receive treatment until unacceptable toxicity or disease progression as determined by the investigator according to RECIST v1.1.
89390314|NCT02069834|Active Comparator|Arm 2 (control)|Continuation of existing HAART at the time of randomization
89390315|NCT01360177|Experimental|Radioactive Iodide and PET/CT|
89390316|NCT02071940|Experimental|PLX3397|Patients will be given PLX3397 1000mg/day as monotherapy. Patients will remain on treatment as long as they are deriving benefit. This is a single cohort study and so there is no comparator arm - all patients receive the same treatment.
89390317|NCT01346371|Placebo Comparator|Refresh Tears® eye drops|Must add drops twice a day every day during trial enrollment.
89390318|NCT01346371|Experimental|Bepreve® 1.5% solution|Must add drops twice a day every day while enrolled in trial.
89390319|NCT01348841|No Intervention|Control Arm|Usual care is care as currently delivered to clients with chronic wounds in the community.
89390320|NCT01348841|Experimental|Intervention Arm|"Systematic referral to MDWCT and comprehensive primary care:~Intervention consists of systematic referral to MDWCT in conjunction with comprehensive primary care.Systematic referral to, and follow up, by MDWCTs, co-ordinated by the CM, will occur.There will be immediate referral to the MDWCT of clients with :1/ diabetic lower extremity ulcers,2/peripheral neuropathy, charcot changes,3/wound present longer than 4 mths. ,4/ Ankle Brachial Index less than 0.6, non-diabetics, and not being seen by a vascular surgeon. Subsequent referral to MDWCT will occur if less than 30% healing by week 4."
89390321|NCT02069912|Experimental|Collaborative depression care|All enrolled patients will receive collaborative depression care management.
89390322|NCT01356511|Experimental|Prednisone group|Patients in the PDN arm received PDNorally at 1.0mg/kg body weight daily for 4 consecutive weeks.
89390323|NCT01356511|Experimental|Dexamethasone group|DXM was administered orally at 40 mg daily for 4 consecutive days and then stopped
89390324|NCT03685487||patients with failures of decolonization S. aureus|patients with failures of decolonization S. aureus in their nose
89390325|NCT02069990|Active Comparator|30000 IU cholecalcipherol once a week|30000 IU cholecalcipherol once a week oral
89390326|NCT02069990|Experimental|7000 IU cholecalcipherol once a week|7000 IU cholecalcipherol once a week oral
89390327|NCT02069990|Experimental|30000IU cholecalcipherol once a month|30000IU cholecalcipherol once a month oral
89390328|NCT02069990|Active Comparator|1000 IU cholecalciferol once a day|1000 IU cholecalciferol once a day
89390329|NCT01347281|Experimental|[18F]HX4 PET|Injection of [18F]HX4
89390330|NCT01361503||Autism Spectrum Disorder (ASD)|
89390331|NCT01361503||Controls|
89003607|NCT04931342|Experimental|Inavolisib + Palbociclib (PIK3CA-altered tumors)|Participants in the Inavolisib + Palbociclib arm will receive treatment until unacceptable toxicity or disease progression per RECIST v1.1.
89003608|NCT04931342|Experimental|Inavolisib + Palbociclib + Letrozole (ER+ and PIK3CA-altered tumors)|Participants in the Inavolisib + Palbociclib + Letrozole arm will receive treatment until unacceptable toxicity or disease progression per RECIST v1.1.
89003609|NCT04931342|Experimental|Inavolisib + Olaparib (Non-matched)|Participants in the Inavolisib + Olaparib arm will receive treatment until unacceptable toxicity or disease progression per RECIST v1.1.
89003610|NCT04931342|Experimental|Inavolisib + Giredestrant (ER+ and PIK3CA-altered tumors)|Participants in the Inavolisib + Giredestrant arm will receive treatment until unacceptable toxicity or disease progression per RECIST v1.1.
89003611|NCT04931342|Experimental|Inavolisib + Bevacizumab (PIK3CA-altered tumors)|Participants in the Inavolisib + Bevacizumab arm will receive treatment until unacceptable toxicity or disease progression per RECIST v1.1.
89003612|NCT04931342|Experimental|Atezolizumab + Bevacizumab + Cyclophosphamide (Non-matched)|Participants in the Atezolizumab + Bevacizumab + Cyclophosphamide arm will receive treatment until unacceptable toxicity or loss of clinical benefit as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
89003613|NCT04931095|Placebo Comparator|Placebo cannabis + placebo alcohol|Participants administer oral cannabis containing 0mg THC in combination with a placebo alcohol drink.
89390332|NCT02072018|Active Comparator|H-100|H-100, gel, daily, 6 months
89390333|NCT02072018|Placebo Comparator|Placebo|Placebo gel, daily, three months then switch to H-100 for three months
89390334|NCT01347359|Experimental|One-on-one peer support|The peer support intervention will take the form of a one-on-one peer mentoring program, either face-to-face or by telephone.
89390335|NCT01347359|Active Comparator|Control - Standard of care|"Standard of care is at the discretion of the treating rheumatologist."
89390336|NCT02076308|Experimental|Electroacupuncture|Electroacupuncture and physical therapy
89390337|NCT02076308|Sham Comparator|Sham-electroacupuncture|Sham-electroacupuncture and physical therapy
89390338|NCT01360255||Patients treated with TACE|Patients treated with transarterial chemoembolisation (TACE) are included in this clinical trial
89390339|NCT02070068|Experimental|Group 1|ICG administered 10 minutes prior to time of visualization
89390340|NCT02070068|Experimental|Group 2|ICG administered 45 min prior to time of visualization
89390341|NCT01347437|No Intervention|Condition|In the comparison condition, participants will receive MEMS only.
89390342|NCT01347437|Experimental|Positive STEPS|"Participants will receive one on one Positive STEPS counseling sessions (~1 hour sessions per week for 5 weeks).~Participants will receive motivational reminders to take medications sent via text message to their cell phones.~Participants will receive the Medication Event Monitoring Systems (MEMS) pill cap monitoring device to measure antiretroviral medication adherence."
89390343|NCT05076409|Experimental|All participants|
89390344|NCT02076386||Dolutegravir|Prospective, non-interventional study of the use of doluetegravir as part of an antiretroviral combination therapy in routine daily practice in Germany. No drug will be provided. No study visits or procedures are mandated per protocol.
89390345|NCT01347515|Placebo Comparator|FOO250|FOO250 ppm, the standard virgin olive oil
89390346|NCT01347515|Active Comparator|FOO500|Olive oil enriched with its own broad-spectrum phenolic compounds; FOO500 ppm
89390347|NCT01347515|Active Comparator|FOO750|Olive oil enriched with its own broad-spectra phenolic compounds; FOO750 ppm
89390348|NCT05033353|Active Comparator|Group I|Mechanical ventilation was adjusted to maintain an EtCO2 of 33-38 mm Hg in group I regional cerebral oxygen monitoring
89390349|NCT05033353|Active Comparator|Group II|Mechanical ventilation was adjusted to maintain an EtCO2 of 39-45 mm Hg in group II regional cerebral oxygen monitoring
89390350|NCT01347593|Experimental|ceftizoxime (cefizox) injection|ceftizoxime (cefizox) as single dose of 1 g at the interval of 30-60 minutes before the incision
89390351|NCT02076464|Experimental|StudentBodies - Eating Disorders|Participants will participate in the StudentBodies - Eating Disorders program
89390352|NCT02076464|No Intervention|Usual Care|Participants will be referred to treatment per protocol at students' corresponding college's mental health services center
89390353|NCT01360333|Other|Tap water, sodium chloride, carbohydrate rich fluid|
89390354|NCT02072252|Experimental|App teaching cognitive behavioral skills|"App teaching cognitive behavioral skills. This mobile phone application (app) teaches cognitive behavioral techniques to help participants manage their mood, for example by providing information, interactive tools and tips, and a mood tracker. A coach will support participants as they use the app via phone calls and email contacts."
89390355|NCT02072252|No Intervention|Wait-list with referrals|10-week wait-list control condition in which participants will be provided with and encouraged to use mental health referrals to resources in the community. After the 10-week waiting period, control group participants will have the option to receive the mobile phone application and coaching.
89390356|NCT03672227|Experimental|Mealtime Matters Training|This group of teachers will get a 3 hour nutrition training, followed by 2 one hour booster sessions.
89390357|NCT03672227|No Intervention|Family Style Dining in Head Start|This group of teachers will not get the 3 hour nutrition training until the study has concluded.
89003614|NCT04931095|Experimental|low dose cannabis with placebo alcohol|Participants administer oral cannabis containing 10mg THC in combination with a placebo alcohol drink.
89003615|NCT04931095|Experimental|high dose cannabis with placebo alcohol|Participants administer oral cannabis containing 25mg THC in combination with a placebo alcohol drink.
89003616|NCT04931095|Experimental|low dose cannabis with low dose alcohol|Participants administer oral cannabis containing 10mg THC in combination with an alcohol drink (0.05 percent BAC).
89390358|NCT01361581||ACD (acid-citrate-dextrose)|
89390359|NCT01361581||4% trisodium citrate|
89003617|NCT04931095|Experimental|high dose cannabis with low dose alcohol|Participants administer oral cannabis containing 25mg THC in combination with an alcohol drink (0.05 percent BAC).
89003618|NCT04931095|Experimental|Placebo cannabis + low dose alcohol|Participants administer oral cannabis containing 0mg THC in combination with an alcohol drink (0.05 percent BAC).
89003619|NCT04931095|Experimental|Placebo cannabis + high dose alcohol|Participants administer oral cannabis containing 0mg THC in combination with an alcohol drink (0.08 percent BAC).
89003620|NCT04920955||G1, CRC Relapse|Patients with an actual relapse of CRC, within 5 years from primary surgery. A single blood sample is collected at relapse diagnosis.
89003621|NCT04920955||G2, CRC Disease-free|Patients previously diagnosed with CRC and declared disease-free for at least 36 months but less than 5 years. A single blood sample is collected at standard monitoring visit.
89186597|NCT05685134|Sham Comparator|Control|Femoral venous punctions, catheter insertion, programmed electrical stimulation and electroanatomic mapping, with a similar duration to the ablation procedure
89390360|NCT01361581||unfractionated heparin (UFH)|
89390361|NCT01347671|Active Comparator|25 µg GRT6005|Participants allocated to this treatment arm will receive a daily dose of 25 µg GRT6005 per day
89390362|NCT01347671|Active Comparator|75 µg GRT6005|Participants allocated to this treatment arm will receive a daily dose of 75 µg GRT6005 per day
89003622|NCT04920955||G3, CRC Disease-free (longitudinal)|Patients declared disease-free for at least 3 months but less than 18 months. Longitudinal blood samples will be collected during standard monitoring visits up to relapse, or for a maximum of 4 time points.
89003623|NCT04920955||G4, Primary CRC (longitudinal)|Patients with an actual diagnosis of CRC who are eligible for a treatment with curative intent. Blood samples will be collected pre and post-surgery (~6 weeks) and, eventually, at relapse.
89003624|NCT04918745|Other|ABC|"A = Baseline stimulation, no modulation~B = Baseline stimulation, modulation stimulation~C = Reduced baseline stimulation, modulation stimulation"
89186598|NCT00757185|Experimental|1|GNRH antagonist alone
89186599|NCT00757185|Experimental|2|GnRH with Testosterone
89390363|NCT01347671|Active Comparator|200 µg GRT6005|Participants allocated to this treatment arm will receive a daily dose of 200 µg GRT6005 per day
89390364|NCT01347671|Placebo Comparator|Matching Placebo|Participants allocated to this treatment arm will receive a dose of matched placebo once a day.
89390365|NCT03671603||Iodixanol|Participants will receive Iodixanol 270 mg I/ml or Iodixanol 320 mg I/ml injection as a part of routine clinical practice at the medical discretion of the physician.
89390366|NCT02072330|Active Comparator|TAK-536CCB 20 mg/5 mg ＋Placebo (dual therapy)|TAK-536CCB 20 mg/5 mg and Hydrochlorothiazide (HCTZ) placebo for 10 weeks
89390367|NCT02072330|Experimental|TAK-536CCB 20 mg/5 mg ＋HCTZ 6.25 mg (triple therapy)|TAK-536CCB 20 mg/5 mg and Hydrochlorothiazide placebo (triple therapy) for the first 2 weeks of the treatment period and TAK-536CCB 20 mg/5 mg and HCTZ 6.25 mg for the remaining 8 weeks.
89390368|NCT02072330|Experimental|TAK-536CCB 20 mg/5 mg ＋HCTZ 12.5 mg (triple therapy)|TAK-536CCB 20 mg/5 mg and Hydrochlorothiazide placebo for the first 2 weeks of the treatment period and TAK-536CCB 20 mg/5 mg and HCTZ 12.5 mg (triple therapy) for the remaining 8 weeks.
89390369|NCT02072330|Active Comparator|Placebo ＋HCTZ 6.25 mg (HCTZ monotherapy)|TAK-536CCB placebo and Hydrochlorothiazide 6.25 mg (HCTZ monotherapy) for 10 weeks from the start of the treatment period.
89390370|NCT02072330|Active Comparator|Placebo ＋Hydrochlorothiazide 12.5 mg (HCTZ monotherapy)|TAK-536CCB placebo and Hydrochlorothiazide 12.5 mg (HCTZ monotherapy) for 10 weeks from the start of the treatment period.
89390371|NCT05128643|Experimental|Population Ⅰ|At 0,1,6 months, 3 doses of experimental vaccine were injected into the deltoid muscle of the upper arm.
89390372|NCT05128643|Experimental|Population II|At 0,1,4 months, 3 doses of experimental vaccine were injected into the deltoid muscle of the upper arm.
89390373|NCT02070224|Other|Knee osteoarthritis|
89390374|NCT03660215|No Intervention|control group|usual charge
89390375|NCT03660215|Experimental|experimental group|"Mediation:~The mediator will intervene on several levels: planning of care according to the medical prescriptions on a support adapted and comprehensible by the patient according to his level of health literacy and his linguistic capacities, coaching on the management of the chronic diseases, possible orientation towards a workshop of therapeutic education, appointments calendar, clear indication of treatment changes, provision of contact information for allied health professionals , assistance in making appointments, possible accompaniments at a professional health."
89390376|NCT02072408|Experimental|polypoidal choroidal vasculopathy without polyp|
89390377|NCT02076542|Experimental|Education - Diabetes and Sports|"Patients randomized to this arm, will participate immediately in the education module Diabetes and Sports"
88866551|NCT04742790|Experimental|Patients|The study will recruit volunteers (1) suffering from disabling post-operative pain for more than two weeks following surgery (thoracotomy, sternotomy and breast cancer surgery), (2) currently being treated for their post-operative pain with an opioid analgesic - along with possible other treatments - and (3) for which the treating physician is about to introduce an additional non-opioid drug for the treatment of their pain (e.g. an antiepileptic or an anti-depressant).
88866552|NCT04742478||Eligible subjects who underwent RA prior to PCI (with informed consent taken to join the study)|Informed consent to be obtained either prior to PCI with rotational atherectomy planned or within 48 hours after rotational atherectomy. There will be data collection of history/demographics, laboratory results, symptoms, any serious adverse events recording for this cohort as well as a telephone follow up at 12months post rotational atherectomy.
88866553|NCT04742478||Eligible subjects who underwent RA prior to PCI (without informed consent taken to join the study)|Subjects that were demised or refused to give consent will fall under this cohort. The data collection of this cohort will be done through screening of in-hospital data via available local PCI database/registry.
88866554|NCT04742244|Placebo Comparator|Placebo|0 mg LVE/capsule, 2capsule/day, 14days
88866555|NCT04742244|Experimental|Lemon Verbena extract|200 mg LVE/capsule, 2capsule/day, 14days
88866556|NCT04741854|Experimental|Investigational Device|Participants will be asked to take home the investigational device to use at night while they sleep in place of their own device. The participant's therapy and comfort settings will be copied from their own device to the investigational device.
88866557|NCT04741152||Revealed insulinoma|Cases when the tumor was revealed by the preoperative diagnostics and confirmed after the tumor elimination
88866558|NCT04741152||Hidden Insulioma|Group when the insulinoma haven't been revealed preoperative and intraoperatively and the blind resection was performed.
88866559|NCT04740840|Experimental|Levamlodipine group|Blood pressure lowering therapy with 2.5mg levamlodipine, plus metoprolol succinate
88866560|NCT04740840|Sham Comparator|Amlodipine group|To receive 5mg amlodipine to lower blood pressure, plus metoprolol succinate
88866561|NCT04740762|Experimental|Intervention group|The study group were provided with individual counseling program and followed in this study, in addition to the usual care provided by healthcare professionals.
88866562|NCT04740762|No Intervention|Control group|The control group continued to receive the routine care
88866563|NCT04740450|Experimental|study side|receive KT technique described by Gozluklu et al in 2020
88866564|NCT04740450|Placebo Comparator|Control side|tapped with wound tape following the same technique
88866565|NCT04740216|Experimental|exercise therapy plus jaw device|exercise therapy plus jaw device
88866566|NCT04740216|Placebo Comparator|exercise therapy|exercise therapy
88866567|NCT04740138|Experimental|DBT Skills + Parent Training|
88866568|NCT04739904||Preterm born|Premature born but otherwise healthy adults exposed to normoxic, normobaric hypoxic and hypobaric hypoxic interventions.
88866569|NCT04739904||Full-term control|Full-term born healthy adults exposed to normoxic, normobaric hypoxic and hypobaric hypoxic interventions.
88866570|NCT04739748||Respiratory ICU patient|patient in RICU that developed ventilator-associated pneumonia
88866571|NCT04739202|Experimental|Patients with tumors positive for EBV or microsatellite instable tumors (group 1)|Atezolizumab IV (1200 mg every 3 weeks) + Ipatasertib tablet (400 mg a day continuously).
88866572|NCT04739202|Experimental|Patients with genomically stable tumors (group 2)|Atezolizumab IV (1200 mg every 3 weeks) + Bevacizumab IV (15 mg/kg every 3 weeks).
88866573|NCT04739202|Experimental|Patients with tumors with chromosomal instability (group 3)|Atezolizumab IV (1200 mg every 3 weeks) + Bevacizumab IV (15 mg/kg every 3 weeks).
88866574|NCT04739514|Active Comparator|Mild dysphagia|
88866575|NCT04739514|Active Comparator|Moderate dysphagia|
88866576|NCT04739514|Active Comparator|Severe dysphagia|
88866577|NCT04739046|Experimental|Theragene arm|Patients who were treated with Theragene®,Ad5-yCD/mutTKSR39rep-ADP and radiation therapy
88866578|NCT04738656||Mediterranean-style diet plan|"Mediterranean-style diet plan (6 months): 22% proteins, 53% carbohydrates, and 25% of lipids.~52 participants."
88866579|NCT04738656||Open protein diet plan|"Open protein presents (6 months) 40% of proteins, 29% carbohydrate and 31% of lipids.~26 participants."
88866580|NCT04738500|Active Comparator|PENG Block|PENG Block combinate with PCA
88866581|NCT04738500|Sham Comparator|CONTROL|PCA
88866582|NCT04738188|Experimental|Drug-eluting bead transarterial chemoembolization(DEB-TACE)|
88866583|NCT04738188|Active Comparator|conventional transarterial chemoembolization(cTACE)|
88866584|NCT04737798|Experimental|oil pulling with coconut oil|patients used oil pulling therapy with coconut oil for 4 days
88866585|NCT04737798|Active Comparator|oil pulling with sesame oil|patients used oil pulling therapy with sesame oil for 4 days
88866586|NCT04737486|Experimental|Single Ascending Dose Cohort 1-4|Intervention: AV-001, 6 subjects per cohort will receive single doses of 1.4 µg/kg up to 56 µg/kg of AV-001 by intravenous bolus injection.
88866587|NCT04737486|Placebo Comparator|Single Ascending Dose Cohort 1-4, Placebo|Intervention: Placebo, 2 subjects per cohort will receive single doses of D-PBS placebo by intravenous bolus injection.
88866588|NCT04737486|Experimental|Multiple Ascending Dose Cohort 1-2|Intervention: AV-001, 6 subjects per cohort will receive multiple doses of 1.4 µg/kg/day up to 56 µg/kg/day of AV-001 daily for 7 consecutive days by intravenous bolus injection.
88866589|NCT04737486|Placebo Comparator|Multiple Ascending Dose Cohort 1-2, Placebo|Intervention: Placebo, 2 subjects per cohort will receive multiple doses of D-PBS placebo daily for 7 consecutive days by intravenous bolus injection.
88866590|NCT04737564|Experimental|ABC10 + SEEK|Participants assigned to this arm will receive the standard Attachment and Biobehavioral Catch-up intervention (ABC 10) as well as SEEK (Safe Environment for Every Kid).
88866591|NCT04737564|Experimental|ABC3 + SEEK|Participants assigned to this arm will receive an abbreviated version of the Attachment and Biobehavioral Catch-up intervention (ABC 3) as well as SEEK (Safe Environment for Every Kid).
88866592|NCT04737564|Active Comparator|SEEK Only|Participants assigned to this arm will receive SEEK (Safe Environment for Every Kid) only.
88866593|NCT04737408|Active Comparator|"Usual care"|"Usual care prevention: atorvastatin 40 mg per day for 18 months"
88866594|NCT04737408|Experimental|"Intensive care"|"Intensive care prevention: rosuvastatin 40 mg + ezetimib 10 mg per day for 18 months"
88866595|NCT04737174|Experimental|ES-481|Administered as 25 mg oral gelatin capsules
88866596|NCT04736784|Experimental|Beetroot juice|115 ml of beetroot juice per day for seven days
88866597|NCT04736784|Experimental|Leafy green vegetable juice|250 ml of green leafy vegetable juice per day for seven days
88866598|NCT04736238|Experimental|Trial group|The patients who receive arthroscopic surgery.
88866599|NCT04736238|Other|Control group|The patients who receive BrostrÖm surgery.
88866600|NCT04735848|Experimental|6mg iron-supplement|All participants will be in this arm. Everyone will take all three different doses of iron-supplement (6mg; 30mg;60mg).
88866601|NCT04735848|Experimental|30mg iron-supplement|All participants will be in this arm. Everyone will take all three different doses of iron-supplement (6mg; 30mg;60mg).
88866602|NCT04735848|Experimental|60mg iron-supplement|All participants will be in this arm. Everyone will take all three different doses of iron-supplement (6mg; 30mg;60mg).
88866603|NCT04735848|No Intervention|Baseline|Baseline measurement
88866604|NCT04735302||Sarcoidosis, Nonsarcoidosis|
88866605|NCT04735302||Malign, benign|
88866606|NCT04734912|Other|Gastroscopy in transnasal technique|All patients with indication for gastroscopy in transnasal techqiue are included.
88866607|NCT04735146|Experimental|Experimental Group|The Experimental Group will be involved in 1 weekly session of adapted physical activity lasting 1 hour for 6 weeks within the normal cycle of accompanying birth meetings provided by the University Hospital of Bologna.
88866608|NCT04735146|No Intervention|Control Group|The control group is expected to participate in 6 birth accompaniment meetings held online, 1 hour of which will be dedicated to the topic of exercise and physical activity recommendations in pregnancy.
88866609|NCT04734522|Experimental|The specified PAL design wearers|Subjects who have been already wearing any from specified design type of PAL
89390378|NCT02076542|No Intervention|Waiting-list control group|Patients in the control group will get the education with the education module after completion of the 6-month follow-up
88866610|NCT04734522|Active Comparator|The other PAL design wearers|Subjects who have been already wearing any from the other design type of PAL
88866611|NCT04734756|Experimental|Dragonfly Mitral Valve Repair System|The experimental group is allocated to use a novel mitral valve repair system for edge-to-edge repair manufactured by Hangzhou Valgen Medtech Co., Ltd.
88866612|NCT04734834|Placebo Comparator|Placebo|"Placebo will be provided orally to the Placebo Group. Placebo will be blinded and labeled either as A or B."
88866613|NCT04734834|Active Comparator|"Prodovite® VMP35"|"Prodovite® VMP35 will be provided orally to the Treatment Group. Prodovite® VMP35 will be blinded and labeled either as A or B."
88866614|NCT04734600|Experimental|aerobic training program|group a:twenty patients who will receive aerobic training program combine with traditional burger exercises for 45 mints, 3 times per week for two months as a total treatment period in addition to their medical treatment.
88866615|NCT04734600|Active Comparator|myofascial release technique|group B: twenty patients who will receive myofascial release technique combine with traditional burger exercises for 45 mints, 3 times per week for two months as a total treatment period in addition to their medical treatment.
88866616|NCT05314842|Active Comparator|control group|the group that have caries in primary molars and treat them with formocresol
88866617|NCT05314842|Experimental|experimental group|the group that have caries in primary molars and treat them with premixed bioceramic MTA
88866618|NCT05314530|Experimental|Intervention group|Will receive a rehabilitation intervention
88866619|NCT05314530|Active Comparator|Controll|Will receive conventional rehabilitation
88866620|NCT05314140||Coronary artery calcium score evaluation|Patients with diabetes and having a CT scan for evaluation of their coronary artery calcium score will be consecutively include. The indication of the scanner is at the choice of the clinician (usually cardiologist and/or diabetologist), in compliance with the recommendations
89390379|NCT03644849|Experimental|Fractional carbon dioxide laser intervention group|The intervention will only involve a single treatment with ablative fractional carbon dioxide laser therapy. The investigators will specifically be using the CO2RE® (Syneron Candela Corp, Wayland, MA).
89390380|NCT03644849|Sham Comparator|Sham laser intervention group|
89390381|NCT02070458|Experimental|Treatment (ixazomib, MEC)|Patients receive ixazomib PO on days 1, 4, 8, and 11; they receive mitoxantrone hydrochloride IV, etoposide IV over 1 hour; the receive intermediate-dose cytarabine IV over 6 hours on days 1-6.
89390382|NCT03131479|Experimental|Mild|Patients with mild renal impairment (Group 1) received LIK066 50 mg qd before breakfast for 7 days.
88866621|NCT05313984||Patients planned for the 2-staged tined-lead procedure.|"Patients with the following indications:~Overactive bladder without urgency urinary incontinence.~Overactive bladder with urgency urinary incontinence.~Non-obstructive urinary retention.~Dysfunctional voiding or Fowler Syndrome.~Fecal incontinence."
88866622|NCT05313906|Experimental|exprimental group|RC48 plus AK105 and cisplatin
88866623|NCT05313828||group 1'|patients with viral ulcers will receive antiviral medication with antibiotics
88866624|NCT05313828||group 2|patients with viral ulcers will receive antiviral medication, tear substitutes with antibiotics
88866625|NCT05313828||group 3|patients with viral ulcers will receive antiviral medication, weak steroids(at the same time) with antibiotics
88866626|NCT05313828||group 4|patients with viral ulcers will receive antiviral medication with antibiotics followed by weak steroid after epithelial healing
88866627|NCT05313750|Experimental|sitafloxacin group|Oral sitafloxacin (0.1g one time daily) for 10 days
88866628|NCT05313750|Active Comparator|levofloxacin group|Oral levofloxacin (0.4g one time daily) for 10 days
88866629|NCT05313672||IPF patients with UIP pattern requiring NIV|
88866630|NCT05313672||ARDS patients requiring NIV|
88866631|NCT05313126|Experimental|sterile male Aedes albopictus-exposed|Sterile male Aedes albopictus are released in the area.
88866632|NCT05313126|No Intervention|control|Sterile male Aedes albopictus are not released in the area.
88866633|NCT05290350||OSA Cohort|Patients With post COVID-19 condition and OSA
88866634|NCT05290350||Control Cohort|Patients With post COVID-19 condition without OSA
88866635|NCT05248464||Rheumatic diseases patients|All the rheumatic diseases outpatients from the National Institute of Medical Sciences
88866636|NCT05213910|Experimental|Patients using the product|
88866637|NCT05201196|Active Comparator|Conventional physical therapy|Conventional physical therapy Muscle strengthening and Muscle Stretching, TENS.
88866638|NCT05201196|Experimental|Task Oriented Training|Experimental group was given Task Oriented protocol including different task specific functional activities
89390383|NCT03131479|Experimental|Moderate A|Patients with moderate renal impairment grade A (Group 2) received LIK066 50 mg qd before breakfast for 7 days.
89390384|NCT03131479|Experimental|Moderate B|Patients with moderate renal impairment grade B (Group 3) received LIK066 50 mg qd before breakfast for 7 days.
89390385|NCT03131479|Experimental|Severe|Patients with severe renal impairment (Group 4) received LIK066 50 mg qd before breakfast for 7 days.
89390386|NCT03131479|Experimental|Normal|Patients with normal renal function (Group 5) received LIK066 50 mg qd before breakfast for 7 days.
89390387|NCT02076854|Experimental|Text-Message Intervention|Participants will undergo four weeks (in a randomized order) of receiving personalized motivational text-messages while receiving CBT for their eating disorder.
89390388|NCT02076854|No Intervention|No Text Message Phase|Participants will receive 4 randomized weeks of not receiving text messages while receiving CBT for their eating disorder.
89390389|NCT01348997|Active Comparator|Project Onward website + 16 person social network|
88866639|NCT05158530|Experimental|Interventional Group|Pulmonary exercises + Aerobic training, 40%-60% intensity 3 days/ week for 4 weeks
88866640|NCT05158530|Placebo Comparator|Control group|Pulmonary exercises, 3 sessions per week and 3-5 repetitions in a session for 4 weeks.
88866641|NCT05138952|Experimental|Mindfulness Meditation|30-day program of mindfulness meditation comprising weekly group meditation tuition and support sessions and daily app-based mediation practice.
88866642|NCT04662684|Experimental|Rivaroxaban|Rivaroxaban 10mg OD for 35+/- 4 days post-hospital discharge
88866643|NCT04662684|No Intervention|No intervention|control
88866644|NCT04661202|Experimental|Exercise training group|"Aerobic exercise~Resistance exercise (including pelvic floor muscle training with biofeedback)~Stretching exercise~Home exercise"
88866645|NCT04661202|No Intervention|Control group|"．Usual care~After baseline assessment, the participants will receive health and lifestyle advices related to bowel symptoms, which include maintaining moderate physical activity, healthy diet, and ideal defecation posture, and establishing a personal bowel schedule and other behavioral changes that promote regular bowel movements.~Upon request, the participants will be provided with the same intervention program as the exercise training group after 8 weeks participation."
88866646|NCT04634682|Experimental|MYODM|MYODM, three times a day, orally
88866647|NCT04634682|No Intervention|No intervention|Patients will follow the same evaluation schedule but will not receive MYODM
88866648|NCT04531410|Experimental|Linoleic|Linoleic acid 13 g and 600 mg algal docosahexaenoic acid (DHA)
88866649|NCT04531410|Active Comparator|Oleic|Oleic acid 13 g and 600 algal DHA
88866650|NCT04497246||Elderly patients|Elderly patients (over 65 years old) hospitalized for COVID-19 within the CHU Brugmann Hospital
88866651|NCT04497246||Health Care professionals|Health Care professionals working within the CHU Brugmann Hospital
89390390|NCT01348997|Active Comparator|Project Onward website + 8 person social network|
89390391|NCT03620227|Experimental|Beetroot juice|ingestion of beetroot juice before an exercise session.
89390392|NCT03620227|Placebo Comparator|Placebo|ingestion of placebo before an exercise session.
89390393|NCT02072564||Couples with indication for IVF|Couples with primary or secondary infertility with indication of IVF
89390394|NCT03784586||Positive EPS - ICD|Patients with inducible sustained ventricular tachycardia or ventricular fibrillation at EPS evaluation underwent ICD implantation
89390395|NCT03784586||Negative EPS - PMK|All non inducible patients underwent PMK implantation
89390396|NCT02076932|Active Comparator|Premenopausal women|The premenopausal women will be attending Spinning classes.
88866652|NCT04442256|Other|Dupilumab|All patients will be administered subcutaneous doses of dupilumab in a monthly fashion. Observation period will be 30 minutes after injection
88866653|NCT04175106|Experimental|a phytochemical-rich blueberry variety|Single-time consumption of 150 g phytochemical-rich blueberry per participant.
88866654|NCT04175106|Experimental|a phytochemical-poor blueberry variety|Single-time consumption of 150 g phytochemical-poor blueberry per participant.
88866655|NCT04175106|Experimental|"a minimally processed blueberry-rich protein bar"|Single-time consumption of blueberry-rich protein bar matched for 150 g blueberry phytochemicals.
88866656|NCT04175106|Placebo Comparator|a blueberry control beverage of matched-nutritive content|Single-time consumption of control beverage matched for the macronutrient content of the blueberry-rich protein bar.
88866657|NCT04044144|Experimental|Probiotic Dietary Supplement|Subjects will be asked to take 1 capsule per day of the dietary supplement for a period of 10 days
88866658|NCT04713930|Experimental|JNJ-61393215|Participants will receive one of 3 single oral doses of JNJ-61393215 on Day 1, escalated sequentially based on the safety review in Cohorts 1, 2, and 3 up to Day 5.
88866659|NCT04713930|Active Comparator|Placebo|Participants will receive a single oral dose of placebo on Day 1 in Cohorts 1, 2, and 3 up to Day 5.
88866660|NCT04714008||Active gamblers in 2019/2020|Three panels of 40 000 gamblers active in 2019 and 2020, either in France or Sweden
88866661|NCT04714008||Newly registered gamblers in 2019 or 2020 (France and Sweden)|Six panels of 10 000 gamblers who newly registered either during the period of March-May 2019 or of March-May 2020, either in France or Sweden
88866662|NCT04713696|Experimental|Functional training|Participants received functional training
88866663|NCT04713696|Active Comparator|Routine training|Participants received routine training
88866664|NCT04713306||Participants in the Swedish Neuro Register|Participants are patients with parkinsonian symptoms
88866665|NCT04713384|Experimental|Treatment|Participants will undergo 4 weeks (20 sessions) of experimental rehabilitation in their home. They will play custom therapeutic games that are intensive and adapt to their condition. Before and after the 4-week intervention participants will travel to Kessler Foundation to undergo evaluations. The therapy is designed to improve arm range, strength, endurance, as well as memory, focusing and decision making. Data will be stored on the cloud, protected and monitored by the research team.
88866666|NCT04712916|Experimental|Intervention group|Individualized education on medication use, appropriate diet and physical activity was given to the participants in intervention group.
88866667|NCT04712916|No Intervention|Control group|Participant received usual care in the clinic. No individualized education on medication use, appropriate diet and physical activity was given to the participants.
88866668|NCT04712760||Transient congenital hypothyroidism|- children with congenital hypothyroidism who are no longer treated with Levothyroxine at an age of 3 years and 6 months
88866669|NCT04712760||Permanent congenital hypothyroidism|- children with congenital hypothyroidism who are still treated with Levothyroxine at an age of 3 years and 6 months
88866670|NCT04708002|Other|First EIPCA-NH group|There are 5 nursing home in each arm (cluster), randomly selected from 3 French areas.
88866671|NCT04708002|Other|Early intermediate EIPCA-NH group|There are 5 nursing home in each arm (cluster), randomly selected from 3 French areas.
89390397|NCT02076932|Experimental|Postmenopausal Women|The postmenopausal women will be attending Spinning classes.
88866672|NCT04708002|Other|Late intermediate EIPCA-NH group|There are 5 nursing home in each arm (cluster), randomly selected from 3 French areas.
88866673|NCT04708002|Other|Last EIPCA-NH group|There are 5 nursing home in each arm (cluster), randomly selected from 3 French areas.
88866674|NCT04708080||Group E|patients who underwent thoracic epidural catheter for postoperative analgesia
88866675|NCT04708080||Group I|Patients who cannot be applied thoracic epidural catheter for postoperative analgesia
88866676|NCT04707924|Experimental|Er:YAG laser|Treatment of scars with fractional Er:YAG 2940nm laser.
88866677|NCT04707924|No Intervention|Control area|No treatment performed on control areas.
88866678|NCT04707456|No Intervention|MFM staff-level operator|
88866679|NCT04707456|Other|MFM fellowship trainee-level operator|
88866680|NCT04707378|Active Comparator|active left DLPFC navigated-rTMS|Each patient will be given 10 treatment sessions per week for 2 weeks (a total of 10 sessions). In each rTMS session, 1200 pulses of stimuli at an intensity of 100% rest motor threshold (RMT) will give over the left DLPFC. Each session is 20 minutes long and will be consisted of 10Hz stimulation trains (active) over the left DLPFC.
88866681|NCT04707378|Sham Comparator|sham left DLPFC navigated-rTMS|Each patient will be given 10 treatment sessions per week for 2 weeks (a total of 10 sessions). In each rTMS session, 1200 pulses of sham stimuli at an intensity of 100% rest motor threshold (RMT) will give over the left DLPFC. Each session is 20 minutes long and will be consisted of 10Hz stimulation trains (sham) over the left DLPFC.
88866682|NCT04706832|Other|ThorS-MagNT Treatment|Low-frequency, low-intensity repetitive magnetic stimulation bilaterally at T7-8 intravertebral space twice a day for 5 days with a total 1200 magnetic stimulations per treatment session at 1 Hz.
88866683|NCT04706286|Experimental|Group 1|"Period 1: Treatment A~Period 2: Treatment B"
88866684|NCT04706286|Experimental|Group 2|"Period 1: Treatment B~Period 2: Treatment A"
88866685|NCT04706052||Superficial Parotidectomy Patient|All the patients with pleomorphic adenoma irrespective of age and gender who underwent Superficial parotidectomy
88866686|NCT05139966|Placebo Comparator|G0 - placebo|All placebo mouthwashes were formulated with the following common ingredients: WATER (AQUA), POLYSORBATE 80, HYDROXYPROPYL GUAR,,SODIUM BENZOATE, POTASSIUM SORBATE. Finally, NO FLUORIDE WAS INCORPORATED.
88866687|NCT05139966|Experimental|G1: 100% - sodium fluoride (100% free NaF)|These mouthwashes were formulated with the following common ingredients: WATER (AQUA), POLYSORBATE 80, HYDROXYPROPYL GUAR,,SODIUM BENZOATE, POTASSIUM SORBATE. Finally, 225 ppm NaF (SODIUM FLUORIDE) WAS INCORPORATED.
88866688|NCT05139966|Experimental|G2: 50% nano fluoride (225 ppm, 50% free NaF + 50% nanoF)|These mouthwashes were formulated with the following common ingredients: WATER (AQUA), POLYSORBATE 80, HYDROXYPROPYL GUAR,,SODIUM BENZOATE, POTASSIUM SORBATE. Finally, 225 ppm (50% free NaF + 50% nanoF) WAS INCORPORATED.
89003625|NCT04918745|Other|ACB|"A = Baseline stimulation, no modulation~C = Reduced baseline stimulation, modulation stimulation~B = Baseline stimulation, modulation stimulation"
89390398|NCT01360411||Pancreatic lesions|"Any patient with a solid pancreatic lesion of unknown histology may be recruited. Cystic lesions are not included.~Elastography findings are classified and compared to cytology or histology if the standard procedures or treatment provide this. In other cases the patients are being followed up conservatively."
89390399|NCT01360411||Intramural upper GI-lesions|Patients with intramural lesions discovered by endoscopy or other imaging modalities are recruited. Elastography findings are classified and compared to cytology or histology if the standard procedures or treatment provide this. In other cases the patients are being followed up conservatively.
89390400|NCT01360411||Lymph nodes|Patients with visible mediastinal lymph nodes or retroperitoneal lymph nodes in patients with inflammatory or malignant diseases are recruited. Elastography findings are classified and compared to cytology or histology if the standard procedures or treatment provide this. In other cases the patients are being followed up conservatively.
89390401|NCT02077010|Experimental|Inhaled nebulized milrinone|Inhaled nebulized milrinone 60mg/4ml every 8 hours using a jet nebulizer
89390402|NCT01319461|Placebo Comparator|sterile normal saline injection|
89390403|NCT01319461|Experimental|Hyalgan injection|
89390404|NCT02070536||ARDS (Acute Respiratory Distress Syndrome)|
89390405|NCT03180749||Patients implanted with vendor B anchor|
89390406|NCT01361737||preeclampsia|"Control group: 86 healthy women not developing preeclampsia (PE)~Case group: 43 women developing PE"
88866689|NCT05139966|Experimental|G3: 100% nano fluoride (225 ppm)|These mouthwashes were formulated with the following common ingredients: WATER (AQUA), POLYSORBATE 80, HYDROXYPROPYL GUAR,,SODIUM BENZOATE, POTASSIUM SORBATE. Finally, 225 ppm (100% nanoF) WAS INCORPORATED.
88866690|NCT05138562|Placebo Comparator|Placebo|4 Placebo capsules
88866691|NCT05138562|Active Comparator|TU2670 High Dose|320mg, QD
88866692|NCT05138562|Active Comparator|TU2670 Medium Dose|240 mg, QD
88866693|NCT05138562|Active Comparator|TU2670 Low Dose|120 mg, QD
88866694|NCT00575016|Experimental|1|botulinum toxin Type A (50U); botulinum toxin Type A (200U)
88866695|NCT00575016|Experimental|2|botulinum toxin Type A (100U); botulinum toxin Type A (200U)
88866696|NCT00575016|Experimental|3|botulinum toxin Type A (200U)
88866697|NCT00575016|Other|4|placebo; botulinum toxin Type A (200U)
88866698|NCT00577512|Experimental|HD DTPACE|DTPACE
88866699|NCT00577590|Placebo Comparator|Metformin Alone|Participants assigned to take Metformin alone.
88866700|NCT00577590|Experimental|Metformin and Rosiglitazone|Participants assigned to take Metformin and Rosiglitazone
88866701|NCT00577590|Experimental|Metformin and Lovaza|Participants assigned to take Metformin and Lovaza
88866702|NCT00578214|Active Comparator|Randomized Midazolam|Single-dose midazolam
88866703|NCT00578214|Placebo Comparator|Placebo|
88866704|NCT00578214|Experimental|Prospective Midazolam|
88866705|NCT00580398|No Intervention|Control|Usual care included physician advice to quit smoking.
88866706|NCT00580398|Experimental|Intervention|Intervention participants were provided with a cognitive-behavioral 12-week program consisting of varenicline (1mg bid, with initial titration up over week 1) and smoking cessation counseling targeted to the issues of thoracic cancer patients. We offered 7 counseling sessions but were flexible in offering additional counseling when needed. Counseling was delivered by a certified Tobacco Treatment Counselor using Motivational Interviewing (MI) techniques.
88866707|NCT00581256|Experimental|1|Best Delivery-optimized radiotherapy technique (IMRT)
88866708|NCT00581256|Active Comparator|2|Best 3-dimensional standard PWTF technique
88866709|NCT00582660|Active Comparator|study drug BID for 7 days before surgery|400 mg Celecoxib the study drug will be given for 7 days before surgery
88866710|NCT00582660|Placebo Comparator|Placebo for 7 days before surgery|Placebo in a one to one randomization prior to surgery
88866711|NCT00582894|Other|A|Preparative regimen of 1)Busulfex 3.2 mg/kg/day for 2 days, infused over 3 hours, on Day-6 and Day-5 2)Fludarabine 30 mg/m2/day for 5 days on Day-6 to D-2 and 3) Alemtuzumab 10 mg/day IV on days - 5 to -1
89390407|NCT02077088|Experimental|Galactooligosaccharides|addition of 0,5g galactooligosaccharides to HA (hypoallergenic) starter formula
89390408|NCT02077088|No Intervention|Only HA formula|only standard HA starter formula
89390409|NCT01361815|Other|H-Coil Deep TMS Treatment|
89390410|NCT01349075||TheraSphere|
89390411|NCT02072720|No Intervention|on-treatment tumor biopsie|patients will undergo an pre-treatment and on-treatment tumor biopsy, to measure VEGF expression, and identify the time point of induction of VEGF expression.
89390412|NCT02072720|Experimental|bevacizumab|These patients will receive bevacizumab once a week during their chemoradiation, starting at the identified time point of enhanced VEGF expression. These patients will also undergo and pre-treatment tumor biopsy and 1 tumor biopsy 1 week after the start of bevacizumab treatment.
89390413|NCT05077007|Active Comparator|Percutaneous nephrolithotomy|patients suffering of pelvic renal stones underwent Percutaneous nephrolithotomy
89390414|NCT05077007|Active Comparator|Extracorporeal Shock Wave Lithotripsy|patients suffering of pelvic renal stones underwent Extracorporeal Shock Wave Lithotripsy
89390415|NCT05077007|No Intervention|control group|Healthy volunteers with negative history of renal stones or renal impairment to measure the level of urinary markers in their urine samples
89390416|NCT01356745|Experimental|premixed 50% nitrous oxide and oxygen|
89390417|NCT01356745|Placebo Comparator|medical air|
89390418|NCT02072798|Active Comparator|preoperative antibiotic|iv Cefuroxime 1,5g administered 15-60 minutes before incision
89390419|NCT02072798|Active Comparator|postoperative antibiotic|iv Cefuroxime 1,5g administered after umbilical cord clamping
89390420|NCT01361893|Other|Lifestyle Counseling|Parents who qualify for the study will be asked to participate in the survey portion of the study. informed consent will be obtained. After completing the survey each parent will be asked if they would be willing to participate in and additional interview (focus group or semi-structured in-debth interview) at a later date.
88866712|NCT00583050|Experimental|Endovascular Aneurysm Repair|Endovascular Aneurysm Repair of TAAA/AAA with Fenestrated/Branched Stent Grafts
88866713|NCT00583908|Active Comparator|Group 1: lotrafilcon B/senofilcon A/balafilcon A/omafilcon A|One intervention was worn during each study period, which consisted of lens insertion, followed by a 15 minute settling period prior to measurement. All four periods were conducted in one day. Period 1: lotrafilcon B /period 2: senofilcon A / period 3: balafilcon A / period 4: omafilcon A
88866714|NCT00583908|Active Comparator|Group 2 lotrafilcon B/omafilcon A/senofilcon A/balafilcon A|One intervention was worn during each study period, which consisted of lens insertion, followed by a 15 minute settling period prior to measurement. All four periods were conducted in one day. period 1: lotrafilcon B / period 2: omafilcon A / period 3: senofilcon A / period 4: balafilcon A
89390421|NCT03602885|Experimental|Chemotherapy education intervention arm|Patients randomized to the chemotherapy education intervention (CEI) arm will be given regimen specific written and video chemotherapy educational materials developed by the study team. The treating oncologist will identify which chemotherapy regimen(s) are being considered, in order to select the appropriate chemotherapy educational tool(s) to give the patient. The patient may be given more than one CEI tool if they are considering more than one regimen. Patients randomized to the intervention arm may receive the intervention in addition to OR in place of the standard institutionally approved chemotherapy information sheets (both are acceptable); this is at the discretion of the treating site or the treating physician.
89390422|NCT03602885|Active Comparator|Usual chemotherapy education arm|Patients randomized to the usual chemotherapy education (CE) arm will undergo the standard institutional practice of chemotherapy education. The oncologist may also choose to give the patient the institutionally approved chemotherapy information sheets according to site-specific policies and clinical practice.
89390423|NCT02070614||rs2242480 wild-type homozygote|*1/*1 Grouped by rs2242480 polymorphism genotyping
89390424|NCT02070614||rs2242480 mutant heterozygote|*1/*1G Grouped by rs2242480 polymorphism genotyping
89390425|NCT02070614||rs2242480 mutant homozygote|*1G/*1G Grouped by rs2242480 polymorphism genotyping
89390426|NCT01360567|Placebo Comparator|B formula|placebo
89390427|NCT01360567|Experimental|A formula|Green tea extract
89390428|NCT02077244|Experimental|Follow up talks|Patients with a score like or above 25 on Post traumatic stress scale-10 Intensive Care Screen after discharge from the ICU. Nurse led follow up talks at the ward and one and two months later.
89390429|NCT02077244|No Intervention|No talks|Patients with a score like or above 25 on Post traumatic stress scale-10 Intensive Care Screen after discharge from the ICU. Care as usual
89390430|NCT02077244|No Intervention|Observation group|Patients with a score below 25 on Post traumatic stress scale-10 Intensive Care Screen after discharge from the ICU. Care as usual.
88866715|NCT00583908|Active Comparator|Group 3 lotrafilcon B/balafilcon A/senofilcon A/omafilcon A|One intervention was worn during each study period, which consisted of lens insertion, followed by a 15 minute settling period prior to measurement. All four periods were conducted in one day. period 1: lotrafilcon B / period 2: balafilcon A / period 3: senofilcon A / period 4: omafilcon A
88866716|NCT00583908|Active Comparator|Group 4 senofilcon A/lotrafilcon B/omafilcon A/balafilcon A|One intervention was worn during each study period, which consisted of lens insertion, followed by a 15 minute settling period prior to measurement. All four periods were conducted in one day. period 1: senofilcon A / period 2: lotrafilcon B / period 3: omafilcon A / period 4: balafilcon A
88866717|NCT00583908|Active Comparator|Group 5 senofilcon A/omafilcon A/balafilcon A/lotrafilcon B|One intervention was worn during each study period, which consisted of lens insertion, followed by a 15 minute settling period prior to measurement. All four periods were conducted in one day. period 1: senofilcon A / period 2: omafilcon A / period 3: balafilcon A / period 4: lotrafilcon B
88866718|NCT00583908|Active Comparator|Group 6 senofilcon A/balafilcon A/lotrafilcon B/omafilcon A|One intervention was worn during each study period, which consisted of lens insertion, followed by a 15 minute settling period prior to measurement. All four periods were conducted in one day. period 1: senofilcon A / period 2: balafilcon A / period 3: lotrafilcon B / period 4: omafilcon A
88866719|NCT00583908|Active Comparator|Group 7 omafilcon B/lotrafilcon B/senofilcon A/balafilcon A|One intervention was worn during each study period, which consisted of lens insertion, followed by a 15 minute settling period prior to measurement. All four periods were conducted in one day. period 1: omafilcon A / period 2: lotrafilcon B / period 3: senofilcon A / period 4: balafilcon A
88866720|NCT00583908|Active Comparator|Group 8 balafilcon A/lotrafilcon B/senofilcon A/omafilcon A|One intervention was worn during each study period, which consisted of lens insertion, followed by a 15 minute settling period prior to measurement. All four periods were conducted in one day. period 1: balafilcon A / period 2: lotrafilcon B / period 3: senofilcon A / period 4: omafilcon A
89390431|NCT02880761|Experimental|Intervention|Patients with AVF will be followed up by a preset following-up system. Interventions would be administered according to the assessment for AVF, which including the surgery and puncture of AVF. For AVF surgery, a certain vein would be used in the operation according to the assessment results. For AVF puncture, the methods, such as 'button hole', 'rope ladder', dwelling needle, would be selected prospectively according to the assessment results.
89390432|NCT02880761|No Intervention|Control|Patients in other hemodialysis centers who are treated by routine protocal would be enrolled into control group. Their clinical data would be collected and compared with intervention group.
89390433|NCT02072876||Asymptomatic ICAD on MRI Absent|Those who test negative on QVSFS, Questionnaire to Verify Stroke Free Status, and do not have ICAD on MRI. They are clinically and biologically free of disease.
89390434|NCT02072876||Asymptomatic ICAD Present on MRI|Those who are negative for Stroke Symptoms on QVSFS, Questionnaire to Verify Stroke Free Status, yet have evidence of ICAD on MRI
89390435|NCT01356823|Experimental|30μg HPV|Participants in this arm would receive 30μg HPV vaccines which contains 20μg HPV 16 antigen and 10μg HPV 18 antigen
89390436|NCT01356823|Experimental|60μg HPV|Participants in this arm would receive 60μg HPV vaccines which contains 40μg HPV 16 antigen and 20μg HPV 18 antigen
89390437|NCT01356823|Experimental|90μg HPV|Participants in this arm would receive 90μg HPV vaccines which contains 60μg HPV 16 antigen and 30μg HPV 18 antigen
89390438|NCT01356823|Placebo Comparator|hepatitis B vaccine|Participants in this arm would receive hepatitis B vaccine.
89390439|NCT02070770|Experimental|Very low calorie diet|
89390440|NCT02070770|Active Comparator|Standard weight loss diet|
89390441|NCT01349153|Active Comparator|Facebook-based Self-help Comparison|Participants will receive a pedometer and twelve weekly messages with links to Internet resources that have educational materials related to exercise and cancer survivorship.
89390442|NCT01349153|Experimental|Facebook-based Messages/Website|Participants will receive a pedometer, twelve weekly messages, and be encouraged to participate in sixteen Facebook group discussions and use a website for exercise goal-setting and tracking activity.
88866721|NCT00583908|Active Comparator|Group 9 balafilcon A/lotrafilcon B/omafilcon A/senofilcon A|One intervention was worn during each study period, which consisted of lens insertion, followed by a 15 minute settling period prior to measurement. All four periods were conducted in one day. period 1: balafilcon A / period 2: lotrafilcon B / period 3: omafilcon A / period 4: senofilcon A
89390443|NCT03635047|Active Comparator|AL002|AL002 by intravenous (IV) infusion
89390444|NCT03635047|Placebo Comparator|Saline Solution|placebo by intravenous (IV) infusion
89390445|NCT02073032||Head -Neck cancer patients, no intervention|
89390446|NCT04943549|Active Comparator|Group (A)|History of addiction.
89390447|NCT04943549|Placebo Comparator|Group (N)|No history of addiction to any drug.
89390448|NCT01356901||Treatment naïve and pre-treated CHB patients|subanalysis with migrant and non-migrant patients
89390449|NCT02070848||Concentric vs eccentric|One arm study in which each subject will act as his own control.
89390450|NCT04790695|Experimental|Seribantumab|For the induction phase: Seribantumab 3,000 mg IV weekly for 12 weeks then Maintenance Phase: Seribantumab 3,000 mg IV infusion once every 2 weeks, initiating approximately 14 days after completion of induction phase. Dose or schedule may be adjusted at the discretion of the treating physician.
89390451|NCT02073110||≥ 18 years, solid enhancing renal mass suspected for RCC|
89390452|NCT01356979||Patients underwent medical thoracoscopy|Patients who require medical thoracoscopy for undiagnosed exudative pleural effusion by other clinical or radiological investigations.
89390453|NCT02073188|Experimental|iBGStar (Group A)|Self-Monitoring Blood Glucose will be managed with iBGStar and iBGStar Diabetes Manager Application (App) uploaded on iPhone for all duration of the study (6 months of experimental phase plus 6-months of observational phase). In the first 3 months, the patients in Group A will send their glycemic test values and notes by mail to the physician through Diabetes Manager App every 2 weeks. Afterwards until the visit V2 (six months), the patients in Group A will send their glycemic test values and notes by mail monthly. 9 reports in total.
89390454|NCT02073188|Active Comparator|Traditional Glucometer (Group B)|Self-Monitoring Blood Glucose will be managed with a traditional glucometer according to usual care for the first 6 months (experimental phase). In the 6 months post-trial follow-up (observational phase), Self-Monitoring Blood Glucose will be managed with iBGStar and iBGStar Diabetes Manager App.
89390455|NCT01319305||BREATHE I participatants|
89390456|NCT02073266|Active Comparator|SF6 vitrectomy|The first group included 31 patients who had undergone MH surgery using SF6 gas and who were advised to stay in face-down position for 7 days postoperatively (SF6 group). Patients in both groups underwent 25 G pars plana vitrectomy, ILM peeling, fluid-air exchange followed by air-gas exchange with SF6 or C3F8. The internal limiting membrane was coloured with trypan blue or indocyanine green in equal proportion in both groups.
89390457|NCT02073266|Active Comparator|C3F8 vitrectomy|The second group included 28 patients who had undergone MH surgery with C3F8 gas and who were advised to maintain a face-down position for 14 days. Patients in both groups underwent 25 G pars plana vitrectomy, ILM peeling, fluid-air exchange followed by air-gas exchange with SF6 or C3F8. The internal limiting membrane was coloured with trypan blue or indocyanine green in equal proportion in both groups.
89390458|NCT02073344|Experimental|Intevention group|A baseline polysomnography (PSG) is performed at inclusion, followed by a follow-up PSG 6 months after the beginning of a renal replacement therapy
89390459|NCT02073344|Experimental|Control group|No intervention A baseline polysomnography (PSG) is performed at inclusion, followed by a follow-up PSG at 6 months if the patient is not already on renal replacement therapy
89390460|NCT04252105|Experimental|Antioxidant rich diet|
88866722|NCT00583908|Active Comparator|Group 10 balafilcon A/senofilcon A/lotrafilcon B/omafilcon A|One intervention was worn during each study period, which consisted of lens insertion, followed by a 15 minute settling period prior to measurement. All four periods were conducted in one day. period 1: balafilcon A / period 2: senofilcon A / period 3: lotrafilcon B / period 4: omafilcon A
89390461|NCT04252105|No Intervention|Regular diet|
89390462|NCT02073422||Non-ST elevation myocardial infarction|Natural history study of non-ST elevation myocardial infarction and coronary physiology
89390463|NCT01357057||Derivation cohort|Arm 1: Derivation cohort (from 2003 to 2007)
89390464|NCT01357057||Validation cohort|Arm 2: Validation cohort (from 2008 to 2009)
88866723|NCT00583908|Active Comparator|Group 11 balafilcon A/senofilcon A/omafilcon A//lotrafilcon B|One intervention was worn during each study period, which consisted of lens insertion, followed by a 15 minute settling period prior to measurement. All four periods were conducted in one day. period 1: balafilcon A / period 2: senofilcon A / period 3: omafilcon A / period 4: lotrafilcon B
89390465|NCT02073500||Observational study|Patients diagnosed with PSM undergoing CRS with HIPEC.
89390466|NCT01360723||urothelial carcinoma|Pathological verification of UC was done by routine urological practice including endoscopic biopsy or surgical resection of urinary tract tumors followed by histopathological examination by board-certified pathologists.
89390467|NCT01360723||Healthy controls group|Age and gender matched control subjects with no evidence of UC or any other malignancy were accrued from the hospital, recruiting people receiving adult health examinations at China Medical University Hospital.
89390468|NCT02073578|Other|Treatment|Peroral Endoscopic Myotomy (POEM)
89390469|NCT02077322|Experimental|Silastic Spacer|This study arm receives the experimental treatment, a Silastic spacer.
89390470|NCT02077322|Active Comparator|Merocel Spacer|Merocel spacers are actively being used as the standard of care.
89390471|NCT02077400|No Intervention|no antibiotic|
89390472|NCT02077400|Active Comparator|Cephazolin|cefazoline
89390473|NCT01362283||Hypertension|Subject who meet eligible criteria
89390474|NCT02077478|Experimental|MCI|manually controlled infusion will be used
89390475|NCT02077478|Experimental|TCI|Target Controlled Infusion will be used
89390476|NCT02077556|Experimental|Everolimus|Everolimus/Tacrolimus/Methylprednisolone & Prednisolone
88866724|NCT00583908|Active Comparator|Group 12 balafilcon A/omafilcon A/lotrafilcon B/senofilcon A|One intervention was worn during each study period, which consisted of lens insertion, followed by a 15 minute settling period prior to measurement. All four periods were conducted in one day. period 1: balafilcon A / period 2: omafilcon A / period 3: lotrafilcon B / period 4: senofilcon A
89186600|NCT04084808|Experimental|Maple Syrup|A maple syrup solution of 6% carbohydrate per volume labeled with 13C-sucrose will first be ingested at rest (167 mL), right before starting warmup. Another dose (167 mL) will be administered after warmup. Four additional doses of 167 mL will be ingested immediately after the first four 3-minute bouts at 95% of Maximal Aerobic Power. A final dose (167 mL) will be ingested after the last effort.
89186601|NCT04084808|Experimental|Maple sap|A maple sap solution of 6% carbohydrate per volume labeled with 13C-sucrose will first be ingested at rest (167 mL), right before starting warmup. Another dose (167 mL) will be administered after warmup. Four additional doses of 167 mL will be ingested immediately after the first four 3-minute bouts at 95% of Maximal Aerobic Power. A final dose (167 mL) will be ingested after the last effort.
89186602|NCT04084808|Active Comparator|Glucose|A glucose solution of 6% carbohydrate per volume labeled with 13C-sucrose will first be ingested at rest (167 mL), right before starting warmup. Another dose (167 mL) will be administered after warmup. Four additional doses of 167 mL will be ingested immediately after the first four 3-minute bouts at 95% of Maximal Aerobic Power. A final dose (167 mL) will be ingested after the last effort.
89390477|NCT02077556|Active Comparator|Mycophenolate mofetil|Mycophenolate mofetil/Tacrolimus/ Methylprednisolone & Prednisolone
89390478|NCT02930941|Experimental|Tranexamic Acid (100 mg/mL)|TXA (100 mg/1mL) sprayed in to the affected nostril(s) via intranasal atomization device. May repeat 2 doses in each affected nostril(s).
89390479|NCT02930941|Placebo Comparator|0.9% Sodium Chloride|0.9% Sodium Chloride (1mL) in to the affected nostril(s) via intranasal atomization device. May repeat 2 doses in each affected nostril(s).
89390480|NCT02077634|Active Comparator|abiraterone acetate + prednisone + LHRH-therapy|Patients randomized to this group will continue their LHRH-therapy.
89390481|NCT02077634|Active Comparator|abiraterone acetate + prednisone|Patients randomized to this group will stop LHRH-therapy.
89390482|NCT01349309|Experimental|Swallowing Exercise Group|Swallowing Exercise Group: This arm will undergo the protocol that involves intensive swallowing exercises to begin at the start of the cancer treatment. Those patients randomized to the intensive therapy protocol will be required to participate in weekly swallowing therapy sessions either in person or over the phone and perform the learned swallowing exercises three times a day. In addition, these patients will document their swallowing practice on a daily basis.
89186603|NCT04084808|Active Comparator|Sports drink|A commercial sports drink of 6% carbohydrate per volume labeled with 13C-sucrose will first be ingested at rest (167 mL), right before starting warmup. Another dose (167 mL) will be administered after warmup. Four additional doses of 167 mL will be ingested immediately after the first four 3-minute bouts at 95% of Maximal Aerobic Power. A final dose (167 mL) will be ingested after the last effort.
89390483|NCT01349309|No Intervention|Control|Control Arm: This arm will receive the standard of care which provides swallowing evaluation and treatment once symptoms of swallowing dysfunction are experienced by the patient.
89390484|NCT01365403|Experimental|Single Arm|
89390485|NCT02070926||Perform coronary CT angiography|
89390486|NCT02070926||Do not perform coronary CT angiography|
89390487|NCT01352663|Experimental|Wockhardt's Insulin Analogue (Recomb)|Basal bolus Wockhardt's Recombinant Insulin Analogue to be injected subcutaneously.
89390488|NCT01352663|Active Comparator|Lantus®|Basal bolus Insulin analog glargine (Lantus®) to be injected subcutaneously.
89390489|NCT01362361|Experimental|Arm A|mFOLFOX6 + BIBF 1120
89390490|NCT01362361|Placebo Comparator|Arm B|mFOLFOX6+placebo
89390491|NCT02077712|Active Comparator|Dexmedetomidine 1 ug/kg|1 ug/kg of intranasal dexmedetomidine
89390492|NCT02077712|Active Comparator|Dexmedetomidine 2 ug/kg|2 ug/kg of intranasal dexmedetomidine
88866725|NCT00584220|Other|senofilcon A toric / alphafilcon A toric|senofilcon A toric contact lenses worn daily during the first period, then alphafilcon A toric contact lenses worn daily during the second period
88866726|NCT00584220|Other|alphafilcon A toric / senofilcon A toric|alphafilcon A toric contact lenses worn daily during the first period, then senofilcon A toric contact lenses worn daily during the second period
88866727|NCT00584922||AF ablation group|Patients undergoing catheter ablation of atrial fibrillation or left atrial macroreentrant tachycardia.
88866728|NCT00585780|Active Comparator|High Alcohol Withdrawal on Prazosin|High AW was determined by those scoring at or above the median on Clinical Institute of Withdrawal for Alcohol Revised (CIWA-Ar) assessment. High AW were randomized to Prazosin 16 mg/day (tid) administered for 12 weeks with fish-bowl contingency management for weekly treatment attendance and manualized 12-Step relapse prevention counseling in a double blind manner.
89390493|NCT04949789|Other|Placebo without Exercise|"2 Capsules to be taken 30 minutes before breakfast.~Whey Protein (standardized for NLT 90% AA): 48 gms of Whey protein isolate (WPI) will be taken by participants daily in two divided doses of 24 gms dissolved in 200 ml of water with their breakfast and dinner.~On testing and exercise days, WPI with IP will be taken 30 mins prior to the exercise without breakfast consumption."
89390494|NCT04949789|Other|Placebo with Exercise|"2 Capsules to be taken 30 minutes before breakfast.~Whey Protein (standardized for NLT 90% AA): 48 gms of Whey protein isolate (WPI) will be taken by participants daily in two divided doses of 24 gms dissolved in 200 ml of water with their breakfast and dinner.~On testing and exercise days, WPI with IP will be taken 30 mins prior to the exercise without breakfast consumption."
89390495|NCT04949789|Other|IP I|"2 Capsules to be taken 30 minutes before breakfast.~Whey Protein (standardized for NLT 90% AA): 48 gms of Whey protein isolate (WPI) will be taken by participants daily in two divided doses of 24 gms dissolved in 200 ml of water with their breakfast and dinner.~On testing and exercise days, WPI with IP will be taken 30 mins prior to the exercise without breakfast consumption."
89390496|NCT04949789|Other|IP II|"2 Capsules to be taken 30 minutes before breakfast.~Whey Protein (standardized for NLT 90% AA): 48 gms of Whey protein isolate (WPI) will be taken by participants daily in two divided doses of 24 gms dissolved in 200 ml of water with their breakfast and dinner.~On testing and exercise days, WPI with IP will be taken 30 mins prior to the exercise without breakfast consumption."
88866729|NCT00585780|Placebo Comparator|High Alcohol Withdrawal on PLA|High AW was determined by those scoring at or above the median on Clinical Institute of Withdrawal for Alcohol Revised (CIWA-Ar) assessment. High AW were randomized to Placebo tablets administered tid for 12 weeks with fish-bowl contingency management for weekly treatment attendance and manualized 12-Step relapse prevention counseling in a double blind manner.
89390497|NCT04949789|Other|IP III|"2 Capsules to be taken 30 minutes before breakfast.~Whey Protein (standardized for NLT 90% AA): 48 gms of Whey protein isolate (WPI) will be taken by participants daily in two divided doses of 24 gms dissolved in 200 ml of water with their breakfast and dinner.~On testing and exercise days, WPI with IP will be taken 30 mins prior to the exercise without breakfast consumption."
89390498|NCT05191771|Experimental|Investigational product|
88866730|NCT00585780|Active Comparator|Low Alcohol Withdrawal on Prazosin|Low AW was determined by those scoring below the median on Clinical Institute of Withdrawal for Alcohol Revised (CIWA-Ar) assessment. Low AW were randomized to Prazosin 16 mg/day (tid) administered for 12 weeks with fish-bowl contingency management for weekly treatment attendance and manualized 12-Step relapse prevention counseling in a double blind manner.
88866731|NCT00585780|Placebo Comparator|Low Alcohol Withdrawal on PLA|Low AW was determined by those scoring below the median on Clinical Institute of Withdrawal for Alcohol Revised (CIWA-Ar) assessment.Placebo tablets administered tid for 12 weeks with fish-bowl contingency management for weekly treatment attendance and manualized 12-Step relapse prevention counseling in a double blind manner.
88866732|NCT00586170|Experimental|EBI Bone Healing System + Surgery|Subject will be using the EBI Bone Healing System (active device) in conjunction with ORIF surgery of the nonunion site.
89390499|NCT05191771|Active Comparator|Comparator|
88866733|NCT00586170|Placebo Comparator|Placebo Device + Surgery|Subject will be using a placebo device in conjunction with ORIF surgery of the nonunion site.
88866734|NCT00586482|Active Comparator|Nicotine lozenge|"Nicotine lozenges, 2 or 4 mg, taken without restriction by mouth from 7 pm the evening before surgery until surgical admission the next day. Dosed according to time to first morning cigarette; if within 30 minutes of awakening, 4 mg lozenge used. If first cigarette smoked greater than 30 minutes of awakening, 2 mg lozenge used.~Subjects also received an abstinence advisement: a brief (approximately 2 minute) behavioral intervention advising abstinence from smoking after 7 pm the night before surgery, the potential benefits of abstinence and to use a lozenge at usual smoking times."
88866735|NCT00586482|Placebo Comparator|Placebo lozenge|"Placebo lozenges, matching in appearance the 2 and 4 mg active nicotine lozenges, taken by mouth without restriction from 7 pm the night before surgery to the time of surgical admission the next day.~Subjects also received an abstinence advisement: a brief (approximately 2 minute) behavioral intervention advising abstinence from smoking after 7 pm the night before surgery, the potential benefits of abstinence and to use a lozenge at usual smoking times."
88866736|NCT03708354|Placebo Comparator|Control|One 430 mg olive oil softgel daily for 24 weeks. Each placebo softgel of 430 mg olive oil will contain no tocotrienol or tocopherols at detectable levels.
88866737|NCT03708354|Active Comparator|Intervention|One 430 mg tocotrienol softgel daily for 24 weeks. Each tocotrienol softgel (DeltaGold® Tocotrienol 70%) contains 430 mg tocotrienol (90% δ-tocotrienol+10% γ-tocotrienol) with a 70% purity, representing 300 mg tocotrienol.
88866738|NCT01685424||Etoricoxib Prescription (Period 1)|First Etoricoxib Prescription, Apr. 1, 2002 to Feb. 17, 2005
88866739|NCT01685424||Etoricoxib Prescription (Period 2)|First Etoricoxib Prescription, Feb. 18, 2005 to Dec. 31, 2015
88866740|NCT01685424||Repeat Etoricoxib Prescription|One prescription during the Period 1 and, at least, one etoricoxib prescription during Period 2.
88866741|NCT01327638||Patients with SpA/AS and etoricoxib treatment|
88866742|NCT01327638||Patients with SpA/AS and other COX-2 inhibitor treatment|
88866743|NCT01327638||Patients with SpA/AS and nsNSAIDs treatment|
88866744|NCT00166530|Active Comparator|1|Arm 1: Active comparator
89390500|NCT02073734|Experimental|Dexamethasone|Dexamethasone
88866745|NCT00166530|Experimental|2|Arm 2: Drug
88866746|NCT00588900|Experimental|irinotecan + cediranib|"Patients receive irinotecan hydrochloride IV over 90 minutes on days 1 and 8 and oral cediranib once daily on days 1-21. Treatment repeats every 21 days for at least 2 courses in the absence of disease progression or unacceptable toxicity.~After completion of study therapy, patients are followed up every 3 months for up to 2 years from study entry."
88866747|NCT00589056|Experimental|Single arm|Nelfinavir
88866748|NCT00589836||Cardiac Pathologies|Patients with cardiomyopathy, ischemic heart disease, will have tissue Doppler echocardiograms performed
88866749|NCT00590226|Experimental|detremir + aspart insulin|Detemir insulin once daily + aspart insulin before meals three times a day at an initial total dose of 0.5 units/kg/day, subcutaneously
88866750|NCT00590226|Active Comparator|NPH + regular insulin|NPH insulin once a day + regular insulin before breakfast and dinner at an initial total dose of 0.5 units/kg/day, subcutaneously
88866751|NCT00590460|Experimental|Single Arm Study: Stem Cell Transplant|CAMPATH-1H Anti-CD45 Fludarabine Stem Cell Infusion
88866752|NCT00590772|Active Comparator|montelukast|montelukast 10 mg daily
89390501|NCT02073734|Placebo Comparator|Placebo|Sterile normal saline solution
89390502|NCT01365559|Experimental|Group A: Carfilzomib & Non-IMiD containing regimen|Bortezomib is replaced with carfilzomib in a combined regimen identical to the patient's previous regimen. Regimen cannot include thalidomide or lenalidomide.
89390503|NCT01365559|Experimental|Group B: Carfilzomib & IMiD containing regimen.|Bortezomib is replaced with carfilzomib in a regimen that includes IMiDs (lenalidomide or thalidomide). Thus, the regimen is carfilzomib in an IMiD-containing regimen.
89390504|NCT03137537|Experimental|Ivabradine|"Ivabradine will be administered for a total of 6 weeks~Ivabradine is taken orally twice daily~Dosage will be adjusted according to physician determination"
89390505|NCT03137537|Placebo Comparator|Placebo Oral Tablet|"Placebo will be administered for a total of 6 weeks~Placebo is taken orally twice daily~Dosage will be adjusted according to physician determination"
89390506|NCT02071004|Other|Aspirin|Dispersible tablet, 300mg & 75 mg, once daily for 5 days
89390507|NCT02071004|Experimental|DS-1040b|IV of 6 mg given once over 30 minutes
89390508|NCT02077790|No Intervention|Substantial Equivalence|The CASIA Cornea/Anterior Segment OCT SS-1000 was used on all subjects for this study.
89186604|NCT04084808|Placebo Comparator|Water|A solution containing stevia (sugar substitute) labeled with 13C-sucrose will first be ingested at rest (167 mL), right before starting warmup. Another dose (167 mL) will be administered after warmup. Four additional doses of 167 mL will be ingested immediately after the first four 3-minute bouts at 95% of Maximal Aerobic Power. A final dose (167 mL) will be ingested after the last effort.
89186605|NCT00751413|Experimental|1|MK0633
89390509|NCT05187559|Experimental|First Group|Neuromuscular exercise program with standard physiotherapy with no visual feedback.
89390510|NCT05187559|Experimental|Second Group|Neuromuscular exercise program with physiotherapy with visual feedback using Biodex platform
89390511|NCT03137459|Experimental|TTM|Participants enrolled at the intervention site will receive four contacts, at baseline, two, four and six months. Each of the first three contacts consists of an integrated assessment and intervention feedback report, using an expert system.
88866753|NCT00590772|Placebo Comparator|Placebo|Placebo tablet
88866754|NCT00591240||Multiplex pathogen identification.|Urine samples of patients at risk for urinary tract infections were collected. Biosensor based assays were used to detect the most common uropathogens in these samples. Analytical validity of the biosensor assays was examined by comparing biosensor results to those obtained using standard clinical microbiology laboratory methods. No interventions were performed.
88866755|NCT00591240||Antimicrobial susceptibility testing.|Urine samples of patients at risk of urinary tract infections were collected. Biosensor based antimicrobial susceptibility test, in concert with pathogen identification assay was directly performed on these samples. Analytical validity of the biosensor assays was examined by comparing biosensor results to those obtained using standard clinical microbiology laboratory methods. No interventions were performed.
88866756|NCT00591942|Active Comparator|VivaGlass dental cement|36 subjects (TOTAL) received two crowns each and another group of 11 subjects received a three-unit fixed dental bridge. Cross over design. One dental crown cemented with VivaGlass Cement/subject. Clinical visits to assess sensitivity and the integrity of the crowns/bridges occur at 6, 12, 18 and 24 months post seating of the restorations.
88866757|NCT00591942|Active Comparator|MultiLink dental cement|36 subjects (TOTAL) received two crowns each and another group of 11 subjects received a three-unit fixed dental bridge. Cross Over design. One dental crown per subject was cemented with Multilink Dental Cement. Clinical visits to assess sensitivity and the integrity of the crowns/bridges occur at 6, 12, 18 and 24 months post seating of the restorations.
88866758|NCT00592176|Experimental|Bevacizumab|Bevacizumab injection: 0.1ml, 6 monthly doses plus baseline and 1 week post baseline
88866759|NCT00592488|Other|A|Placebo for first 6 hours then Acetyl-L-Carnitine (ALC) for 12 hours
88866760|NCT00592488|Other|B|Acetyl-L-Carnitine (ALC) for first 12 hours then placebo for next 6 hours
88866761|NCT00593346|Experimental|Accelerated partial breast brachytherapy|Each patient will receive accelerated partial breast brachytherapy with multiple plane implant.
88866762|NCT00595530|Experimental|Ketamine|This group will receive ketamine
88866763|NCT00596622|Experimental|Bipolar Manic Subjects Treated|Bipolar mania picture response during fMRI before and after treatment with lithium
88866764|NCT00596622|Experimental|Bipolar Depressed Subjects Treated|Bipolar depression picture response during fMRI before and after treatment with lithium
88866765|NCT00596622|Experimental|Bipolar Euthymic Subjects Treated|Bipolar euthymia picture response before and after treatment with lithium
88866766|NCT00597246|Experimental|1|
88866767|NCT00597402|Experimental|Avastin, radiation, temozolomide, and irinotecan|
88866768|NCT00597558|Experimental|Egg white protein|Subjects, who are egg allergic, are given egg white protein for desensitization with the hypothesis they will develop tolerance.
88866769|NCT00598806|Experimental|Apaziquone|TURBT + a single intravesical dose of Apaziquone 4mg in 40ml instilled into the bladder post-TURBT
88866770|NCT00598806|Placebo Comparator|Placebo|TURBT + a single intravesical dose of placebo instilled into the bladder post-TURBT
89186606|NCT00919334|No Intervention|single vision soft contact lens|Single vision soft contact lenses with same materials of the DISC lens
89390512|NCT03137459|Active Comparator|Usual Care|Participants enrolled in control sites will receive four assessment contacts on the same schedule and in the same manner as the participants enrolled in intervention sites.
89390513|NCT02071160|No Intervention|Healthy Control|A group of healthy control without any history suggestive of perinatal asphyxia or other diseases, are enrolled to compare different laboratory measurements
89390514|NCT02071160|No Intervention|Hypothermia Group|HIE infants who will not receive melatonin and only receive routine cooling protocol.
89390515|NCT02071160|Experimental|Melatonin/ hypothermia group|HIE infants who will receive melatonin in addition to the routine cooling protocol
88866771|NCT00601146|Experimental|Low-dose Chest CT screening|Annual low-dose Chest CT screening
88866772|NCT00601926|Experimental|Bevacizumab|15 mg/kg over 90 minutes
88866773|NCT00603018|Experimental|Annorexia nervosa|Participants recovered from anorexia nervosa before and after administration of fluoxetine
88866774|NCT00603408|Experimental|Cisplatin + Radiation + Recommended Surgery|"Cisplatin 75 mg/m^2 IV Day 1 Week 1, Day 1 Week 2, Day 1 Week 7, Day 1 Week 10~Radiation = Total dose to breast or chest wall will be 50-60 Gy in 1.8-2.0 Gy daily fractions. Internal mammary nodes, supraclavicular fossa nodes and axillary nodal basins will receive 45-50 Gy over 5-6 weeks.~Surgery (recommended) mastectomy with/without axillary lymph node dissection"
88866775|NCT00603564|Active Comparator|1|CPAP delivered by a helmet
88866776|NCT00603564|No Intervention|2|O2 administration via a conventional Venturi mask
88866777|NCT00603720|Active Comparator|L-Name in Young|20 individuals age 18-35 will be getting an infusion of L-NAME (a nitric oxide inhibitor) during 3 separate PET study days, then a 10-minute infusion of L-arginine to reverse effects of L-NAME.
88866778|NCT00603720|Active Comparator|Phenylephrine|25 individuals age 18-35 will be getting an infusion of phenylephrine (primarily an alpha agonist) during 3 separate PET study days
89186607|NCT00919334|Experimental|Defocus Incorporated Soft Contact (DISC) lens|The use of DISC lens to slow down the progression of myopia
89186608|NCT00751491|Active Comparator|III|
89186609|NCT00751491|Active Comparator|A|
89186610|NCT00751491|Placebo Comparator|placebo|
89390516|NCT01362673|Experimental|Single dose|
89390517|NCT01362673|Experimental|Multiple dose|
88866779|NCT00603720|Active Comparator|L-arginine in Young|20 individuals age 18-35 will be getting an infusion of L-arginine 125 mcg/kg/min for 120 to 140 minutes during 3 separate PET study days
88866780|NCT00603720|Active Comparator|L-arginine in Old|20 individuals age 60-75 will be getting an infusion of L-arginine 125 mcg/kg/min for 120 to 140 minutes during 3 separate PET study days
88866781|NCT00603720|Experimental|L-NAME in Old|20 individuals age 60-75 will be getting an infusion of L-NAME (a nitric oxide inhibitor) during 3 separate PET study days, then a 10-minute infusion of L-arginine to reverse effects of L-NAME
88866782|NCT00622518|Active Comparator|1|homeopathic ear drops in addition to standard care for otitis media
88866783|NCT00622518|No Intervention|2|No ear drops, standard care for otitis
88866784|NCT00625404|Experimental|Truvada Arm|Daily single oral tablet of Truvada (TDF/FTC), a fixed-dose combination of emtricitabine (FTC; 200 mg) and tenofovir disoproxil fumarate (TDF; 300 mg).
88866785|NCT00625404|Placebo Comparator|Placebo Arm|Daily single oral tablet of Placebo. Tablets are identical to Truvada tablets in taste and appearance; however, they contain no active ingredients.
88866786|NCT00626340|Active Comparator|MDD diagnosis and Estrogen treatment|Menopausal women between the ages of 40-70 diagnosed with Major Depressive Disorder receiving treatment with estrogen alone.
88866787|NCT00626340|Active Comparator|MDD diagnosis and Fluoxetine treatment|Menopausal women between the ages of 40-70 diagnosed with Major Depressive Disorder receiving treatment with fluoxetine alone.
88866788|NCT00626340|Active Comparator|MDD diagnosis with both Estrogen and Fluoxetine treatment|Menopausal women between the ages of 40-70 diagnosed with Major Depressive Disorder receiving treatment with estrogen and fluoxetine combined.
88866789|NCT00626340|Active Comparator|No depression and estrogen treatment|Non-depressed menopausal women between the ages of 40-70 receiving treatment with estrogen alone.
88866790|NCT00626574|Active Comparator|A|Group A will receive Procrit® intravenous injections (40,000U) once daily for 3 days (Study Days 1, 2, and 3). The first dose of Procrit® will be given within 36 hours of the initial SAH event / symptoms and immediately before the vascular clipping procedure.
88866791|NCT00626574|Placebo Comparator|B|Group B will receive Saline intravenous injections once daily for 3 days (Study Days 1, 2, and 3).
88866792|NCT00626808||1|Children less than 24 months of age
88866793|NCT00626808||2|Children 24 to 59 months of age with a claim associated with a diagnosis of asthma
88866794|NCT00626808||3|Children 24 to 59 months of age without a claim associated with a diagnosis of asthma, but with dispensed medication for wheezing
88866795|NCT00626808||4|Children 24-59 months of age with immunosuppression
88866796|NCT00626886|Experimental|1|Two, 5x5cm bupivacaine collagen sponges implanted during surgery
88866797|NCT00626886|Placebo Comparator|2|Placebo collagen sponge implanted during surgery
88866798|NCT00627978|Experimental|Ixabepilone|Participants are treated with Ixabepilone.
88866799|NCT00627978|No Intervention|Control|
88866800|NCT00628134|Experimental|1|Subjects inhaled calfactant then isotonic saline
88866801|NCT00628134|Experimental|2|Subjects inhaled isotonic saline then calfactant
88866802|NCT00632814|Experimental|rFVIII-FS (Kogenate FS, BAY14-2222), 70 IU/kg qw|rFVIII-FS (Octocog-alfa, antihemophilic factor [recombinant]) 70 IU/kg, dosing by injection once per week [qw] (weekly on Day 7 + 1 after previous injection) for 9 months. Dose escalation was permitted due to joint bleeding (escalation to 35 IU/kg twice a week or further escalation to 25 IU/kg three times a week)
88866803|NCT00632814|Experimental|rFVIII-FS (Kogenate FS, BAY14-2222), biw (30 IU/kg + 40 IU/kg)|rFVIII-FS (Octocog-alfa, antihemophilic factor [recombinant]) 70 IU/kg, dosing by injection twice per week [biw] (30 IU/kg [day 1] + 40 IU/kg [day 4]) for 9 months. Dose escalation was permitted due to joint bleeding (escalation to 25 IU/kg three times a week)
88866804|NCT00632814|Experimental|rFVIII-FS (Kogenate FS, BAY14-2222), tiw (3 x 25 IU/kg)|rFVIII-FS (Octocog-alfa, antihemophilic factor [recombinant]) 75 IU/kg, dosing by injection three times per week [tiw] (3 x 25 IU/kg [day 1, 3, 5]) for 9 months. No escalation opportunity for participants in this group
88866805|NCT00632970|Experimental|Raltegravir plus Truvada|Raltegravir (400mg), 1 tablet, administered twice daily (BID) and Truvada (Emtricitabine/Tenofovir disoproxil fumarate) (200mg/300mg), 1 tablet administered once daily (QD)
88866806|NCT00632970|Active Comparator|Lopinavir/Ritonavir plus Truvada|Lopinavir/Ritonavir (400mg/100mg) (Kaletra), 2 tablets administered twice daily (BID) and Truvada (Emtricitabine/Tenofovir disoproxil fumarate) (200mg/300mg), 1 tablet administered once daily (QD)
88866807|NCT00635232|Active Comparator|Irbesartan 300mg|Irbesartan 300 mg once daily
88866808|NCT00635232|Placebo Comparator|Placebo|Blinded Placebo Treatment
88866809|NCT00635232|Experimental|PS433540 200mg|PS433540 200mg once daily
88866810|NCT00635232|Experimental|PS433540 400mg|PS433540 400mg once daily
88866811|NCT00635232|Experimental|PS433540 800mg|PS433540 800mg once daily
88866812|NCT00637494|Active Comparator|1|Mifepristone followed by an antidepressant
88866813|NCT00637494|Placebo Comparator|2|Placebo followed by an antidepressant
88866814|NCT00638274|Active Comparator|Air|Air 3 ml used to identify epidural space
88866815|NCT00638274|Active Comparator|Saline|Saline 3 ml used to identify epidural space
88866816|NCT00638820|Experimental|Intent-To-Treat|Patients enrolled and received study treatment.
88866817|NCT00641862|Active Comparator|Vitamin B12|Vitamin B12
88866818|NCT00641862|Placebo Comparator|Placebo|Placebo
88866819|NCT00643578|Active Comparator|2|a single dose of 24 mcg of formoterol
88866820|NCT00643578|Active Comparator|1|a single dose of 12 mcg of formoterol
88866821|NCT00644592|Active Comparator|1-Fenofibrate then Placebo|4 weeks of drug at 160 mg orally per day, 4 week washout, then 4 weeks of placebo
88866822|NCT00644592|Active Comparator|2 Placebo then Fenofibrate|4 weeks of placebo then 4 week washout then 4 weeks of Fenofibrate at 160 mg/day orally.
88866823|NCT00645450|Experimental|Propranolol|Weekly doses of short and long acting propranolol following recollection of traumatic memory
88866824|NCT00645450|Placebo Comparator|Placebo|Weekly doses of placebo following recollection of traumatic memory
88866825|NCT00645762|Active Comparator|Balloon Dilation|Balloon dilation with FinESS device
88866826|NCT00647400|Experimental|Adalimumab 40 mg every other week|
88866827|NCT00647400|Experimental|Adalimumab 80 mg every other week|
89390518|NCT02077868|Other|Control Arm A|Patients in Control Arm A receive usual maintenance Treatment according to local investigator's decsision
88866828|NCT00652080|Experimental|1|Active Cream 3%; AM & PM
88866829|NCT00652314|Experimental|1 - Thrombi-gel treatment|Thrombi-gel treatment
88866830|NCT00652314|Active Comparator|2 - Gelatin Sponge (Gelfoam)|Gelatin Sponge (Gelfoam) plus thrombin
88866831|NCT00654030|Experimental|1650-G Vaccine|Patients receive 2 injections of 1650-G Vaccine given 4 weeks apart, for a total of 52 weeks on study.
88866832|NCT00654654|Experimental|Active|
88866833|NCT00656448|Experimental|Procrit Arm|Participants receive Procrit along with blood transfusions. Procrit 40,000 units subcutaneously every week starting within two weeks (before or after) from the start of induction chemotherapy.
88866834|NCT00656448|No Intervention|No Procrit: Standard Arm|Participants do not receive Procrit before receiving blood transfusions.
88866835|NCT00659802|Placebo Comparator|placebo|Matching dose of placebo will be given orally in capsules three times per day for 56 days.
88866836|NCT00659802|Experimental|HMPL-004 low dose|A total of 1200 mg of HMPL-004 per day in three divided doses will be given orally in capsules, 200 mg each, for 56 days.
88866837|NCT00659802|Experimental|HMPL-004 high dose|A total of 1800 mg of HMPL-004 per day in three divided doses will be given orally in capsules, 200 mg each, for 56 days.
88866838|NCT00660504|Experimental|1|Amrubicin Hydrochloride-Cisplatin combined chemotherapy
88866839|NCT00660504|Active Comparator|2|Etoposide-Cisplatin combined chemotherapy
88866840|NCT00661674|Experimental|Sequence 1: Placebo, Combo, Palonosetron|"At T = 0 (minutes), healthy (non-opioid dependent, non-substance abuser) male volunteers (N=10) were pre-treated with either placebo (0.9% normal saline), palonosetron IV (0.75mg), or palonosetron IV (0.75mg) and hydroxyzine per os (PO) (100mg) in a crossover study design. This was followed at T = 30 by intravenous morphine (10mg/70kg). At T = 165, 10mg/70kg naloxone IV was given to precipitate opioid withdrawal. The objective opioid withdrawal score (OOWS) and subjective opioid withdrawal score (SOWS) were determined 5 and 15 minutes after naloxone administration (T = 170, 180, respectively). Baseline measurements were recorded at T = -30 and T = -15.~Week 1: Placebo~Week 2: Palonosetron + Hydroxyzine Combo~Week 3: Palonosetron"
89390519|NCT02077868|Experimental|Treatment Arm B|MGN1703 treatment as maintenance therapy
88866841|NCT00661674|Experimental|Sequence 2: Palonosetron, Combo, Placebo|"At T = 0 (minutes), healthy (non-opioid dependent, non-substance abuser) male volunteers (N=10) were pre-treated with either placebo (0.9% normal saline), palonosetron IV (0.75mg), or palonosetron IV (0.75mg) and hydroxyzine per os (PO) (100mg) in a crossover study design. This was followed at T = 30 by intravenous morphine (10mg/70kg). At T = 165, 10mg/70kg naloxone IV was given to precipitate opioid withdrawal. The objective opioid withdrawal score (OOWS) and subjective opioid withdrawal score (SOWS) were determined 5 and 15 minutes after naloxone administration (T = 170, 180, respectively). Baseline measurements were recorded at T = -30 and T = -15.~Week 1: Palonosetron~Week 2: Palonosetron + Hydroxyzine Combo~Week 3: Placebo"
88866842|NCT00661674|Experimental|Sequence 3: Combo, Placebo, Palonosetron|"At T = 0 (minutes), healthy (non-opioid dependent, non-substance abuser) male volunteers (N=10) were pre-treated with either placebo (0.9% normal saline), palonosetron IV (0.75mg), or palonosetron IV (0.75mg) and hydroxyzine per os (PO) (100mg) in a crossover study design. This was followed at T = 30 by intravenous morphine (10mg/70kg). At T = 165, 10mg/70kg naloxone IV was given to precipitate opioid withdrawal. The objective opioid withdrawal score (OOWS) and subjective opioid withdrawal score (SOWS) were determined 5 and 15 minutes after naloxone administration (T = 170, 180, respectively). Baseline measurements were recorded at T = -30 and T = -15.~Week 1: Palonosetron + Hydroxyzine Combo~Week 2: Placebo~Week 3: Palonosetron"
88866843|NCT00661674|Experimental|Sequence 4: Placebo, Palonosetron, Combo|"At T = 0 (minutes), healthy (non-opioid dependent, non-substance abuser) male volunteers (N=10) were pre-treated with either placebo (0.9% normal saline), palonosetron IV (0.75mg), or palonosetron IV (0.75mg) and hydroxyzine per os (PO) (100mg) in a crossover study design. This was followed at T = 30 by intravenous morphine (10mg/70kg). At T = 165, 10mg/70kg naloxone IV was given to precipitate opioid withdrawal. The objective opioid withdrawal score (OOWS) and subjective opioid withdrawal score (SOWS) were determined 5 and 15 minutes after naloxone administration (T = 170, 180, respectively). Baseline measurements were recorded at T = -30 and T = -15.~Week 1: Placebo~Week 2: Palonosetron only~Week 3: Palonosetron + Hydroxyzine Combo"
88866844|NCT00661674|Experimental|Sequence 5: Combo, Palonosetron, Placebo|"At T = 0 (minutes), healthy (non-opioid dependent, non-substance abuser) male volunteers (N=10) were pre-treated with either placebo (0.9% normal saline), palonosetron IV (0.75mg), or palonosetron IV (0.75mg) and hydroxyzine per os (PO) (100mg) in a crossover study design. This was followed at T = 30 by intravenous morphine (10mg/70kg). At T = 165, 10mg/70kg naloxone IV was given to precipitate opioid withdrawal. The objective opioid withdrawal score (OOWS) and subjective opioid withdrawal score (SOWS) were determined 5 and 15 minutes after naloxone administration (T = 170, 180, respectively). Baseline measurements were recorded at T = -30 and T = -15.~Week 1: Palonosetron + Hydroxyzine Combo~Week 2: Palonosetron only~Week 3: Placebo"
89003626|NCT04918745|Other|BAC|"B = Baseline stimulation, modulation stimulation~A = Baseline stimulation, no modulation~C = Reduced baseline stimulation, modulation stimulation"
89003627|NCT04918745|Other|BCA|"B = Baseline stimulation, modulation stimulation~C = Reduced baseline stimulation, modulation stimulation~A = Baseline stimulation, no modulation"
89390520|NCT01360957|Placebo Comparator|Water flavored placebo|to be given orally in a dosage of 30 ml trice daily for 60 days
89390521|NCT01360957|Experimental|Black cumin water extract as a traditional medicine|Black cumin water extract as a traditional medicine to be given orally in a dosage of 30 ml trice daily for 60 days
89390522|NCT04912583|Active Comparator|High tidal volume|A high tidal volume (14-16 ml/kg pbw) with positive end-expiratory pressure will be applied during mechanical ventilation.
89390523|NCT04912583|Active Comparator|Low tidal volume|A low tidal volume (8-10 ml/kg pbw) with positive end-expiratory pressure will be applied during mechanical ventilation.
89390524|NCT03131713|No Intervention|Control|The control group will receive usual perioperative care including patient education on diagnosis, treatment and prognosis of skin cancer, encouragement of food and fluid intake prior to and during the surgery as needed, and acetaminophen per patient request.
89390525|NCT03131713|Experimental|Intervention|The intervention group, in addition to usual care, will receive Acetaminophen 1000mg and commercially available carbohydrate drink (two pouches of Gatorade Prime Sports Fuel drink containing 50gm carbohydrate in approximately 250ml fluid total) at the beginning of the surgery.
88866845|NCT00661674|Experimental|Sequence 6: Palonosetron, Placebo, Combo|"At T = 0 (minutes), healthy (non-opioid dependent, non-substance abuser) male volunteers (N=10) were pre-treated with either placebo (0.9% normal saline), palonosetron IV (0.75mg), or palonosetron IV (0.75mg) and hydroxyzine per os (PO) (100mg) in a crossover study design. This was followed at T = 30 by intravenous morphine (10mg/70kg). At T = 165, 10mg/70kg naloxone IV was given to precipitate opioid withdrawal. The objective opioid withdrawal score (OOWS) and subjective opioid withdrawal score (SOWS) were determined 5 and 15 minutes after naloxone administration (T = 170, 180, respectively). Baseline measurements were recorded at T = -30 and T = -15.~Week 1: Palonosetron only~Week 2: Placebo~Week 3:Palonosetron + Hydroxyzine Combo"
88866846|NCT00662298|Experimental|Severe Asthma|
88866847|NCT00666666|Experimental|AT101 (R-(-)-gossypol acetic acid)|Patients will receive Hormone therapy with at least one LHRH agent (Leuprolide Acetate or Goserelin) for 6 weeks and include bicalutamide. Patients will begin AT101 daily at 6 weeks for 3 weeks of every 4 weeks (4 weeks - 1 cycle) and continue for 8 cycles of combined therapy (combined AT101, and LHRH agonist). After 8 cycles patients will continue hormonal therapy.
88866848|NCT00666978|Experimental|Bupropion Arm|Subjects undergo smoking cessation intervention and take bupropion.
88866849|NCT00666978|Placebo Comparator|Health Education Arm|Subjects receive counseling intervention and take placebo.
88866850|NCT00668382|Experimental|Alpha-Gal Glycosphingolipid injection|Intervention: Intratumoral injection of a single dose of Alpha-Gal Glycosphingolipid (0.1 mg,1mg, 10mg)
88866851|NCT00669552||Medtronic defibrillator|Patients undergoing a percutaneous coronary intervention (PCI) with an implanted Medtronic defibrillator with the capability of telemetry of the intracardiac signal.
88866852|NCT00670956|Active Comparator|Active Study Group|STEROID: Betamethasone; 12 mg intramuscularly x 2 doses 24 hours apart
88866853|NCT00670956|Placebo Comparator|Placebo Group|PLACEBO: IM x 2 doses 24 hours apart
88866854|NCT00671502|Experimental|Carisoprodol 700mg|tablet sustained release (SR)
89186611|NCT05685056|No Intervention|Control group|The control group will receive no intervention, and will be receiving only text reminders regarding the study, the following visits and study logistics in order to limit dropout rate.
88866855|NCT00671502|Experimental|Carisoprodol 500mg|sustained release(SR) tablet
88866856|NCT00671502|Placebo Comparator|Placebo|tablet
88866857|NCT00671970|Experimental|Bevacizumab + Erlotinib|Bevacizumab + Erlotinib
88866858|NCT00672204|Experimental|1|Allogeneic islets of Langerhans
88866859|NCT00672438|Placebo Comparator|Saline placebo infusion|Subjects will receive an intravenous infusion of normal saline.
88866860|NCT00672438|Experimental|Alfentanil infusion|Subjects will receive an intravenous infusion of alfentanil.
88866861|NCT00672594|Experimental|Sunitinib Malate|Sunitinib Malate 50mg capsule by mouth once daily for 4 weeks
88866862|NCT00673764|Experimental|Systane Ultra|Systane Ultra Lubricant Eye Drops
88866863|NCT00673764|Active Comparator|Optive|Optive Lubricant Eye Drops
88866864|NCT00674466|Experimental|1|Twice-a-week dose of 1.5 mg CJC-1134-PC
88866865|NCT00674466|Experimental|2|Twice-a-week dose of 1.5 mg CJC-1134-PC for 4 weeks, then once-a-week dose of 2.0 mg CJC-1134-PC plus mid-week dosing of placebo
88866866|NCT00674466|Placebo Comparator|3|Twice-a-week placebo for CJC-1134-PC
89390526|NCT03534011|Experimental|REBOA|Resuscitative Balloon Occlusion of the Aorta after advanced cardiac life support if return of spontaneous circulation is not achieved
88866867|NCT00674622|Experimental|Group 1-Prolotherapy|Deep injection with 15% dextrose in lidocaine
88866868|NCT00674622|Placebo Comparator|Group 2-Deep Saline/Lidocaine|Deep injection with saline/lidocaine
88866869|NCT00674622|Placebo Comparator|Group 3-Superficial Saline/lidocaine|Superficial injection with saline/lidocaine
88866870|NCT00675558||Non-Obese (NO)|Patients with a BMI < 29.9 scheduled for clinically indicated laparoscopic abdominal surgery.
88866871|NCT00675558||Morbidly Obese (MO)|Patients with a BMI > 40.0 scheduled for clinically indicated laparoscopic abdominal surgery.
88866872|NCT00675558||Super-morbidly Obese (SMO)|"Patients with a BMI > 50.0 scheduled for clinically indicated laparoscopic abdominal surgery.~10 subjects of the original 30 subjects enrolled into this group received a second bariatric procedure. The remaining 20 subjects of the original 30 subjects did not continue on to the second phase (second bariatric surgery) of the study."
88866873|NCT00675792|Experimental|Sugammadex|4 mg/kg sugammadex
88866874|NCT00675792|Active Comparator|Neostigmine|50 µg/kg neostigmine
88866875|NCT00676182||Arm 1: Telerehabilitation|telerehabilitation
88866876|NCT00676572||Severe asthma|
88866877|NCT00676572||Non-severe asthma|
88866878|NCT00676806|Experimental|Myeloablative conditioning|Umbilical cord blood for hematopoietic rescue following myeloablative conditioning
88866879|NCT00676806|Experimental|Reduced intensity conditioning|Umbilical cord blood for hematopoietic rescue following non-myeloablative conditioning
88866880|NCT00677898|Experimental|Patient-centered computerized tool|A brief computer program that provides personalized health information to patients prescribed second-generation antipsychotic medications on adherence to guidelines for screening of metabolic side effects
88866881|NCT00677898|Active Comparator|Written educational materials|Printed information on the metabolic side effects of second-generation antipsychotic medications and general recommendations for screening
88866882|NCT00678444|No Intervention|Arm 1: Non-educational video self-cath|Randomized to not watching educational video about clean intermittent self-catheterization prior to prolapse/incontinence surgery.
88866883|NCT00678444|Experimental|Arm 2: Educational Video Self-cath|Randomized to watch educational video about clean intermittent self-catheterization prior to prolapse/incontinence surgery.
88866884|NCT00678834|Active Comparator|Arm 1|To surgery patients, Tocotrienol capsules. 200mg (2 100mg capsules) to take by mouth twice daily to total 400mg daily
88866885|NCT00678834|Active Comparator|Arm 2|To surgery patients, Tocopherol capsules. 200mg (2 100mg capsules) to take by mouth twice daily to total 400mg daily
89390527|NCT01361035|No Intervention|No communication training|Physicians enrolled in the control arm do not undergo training in health literacy, cancer screening and shared decision making
89390528|NCT01361035|Other|Cancer risk ommunication skills training|Physicians enrolled in the intervention arm undergo training in health literacy, cancer screening and shared decision making
89390529|NCT04894799|Experimental|Vestibular stimulation|all participants will be given Infant Swing activity for one hour, trice a day for first 4 weeks. After that, in 5th and 6th weeks, all participants will be given Infant Swing for 30 minutes and frog swing for 30 minutes for two weeks. Next 7th and 8th weeks, Infant Swing (30 minutes) and prone on frog swing feet touching the floor (30 minutes), trice a day will be applied. In 9th week, Infant swing and normal playground swing for 30,30 minutes will be given to all participants, trice a day. In Last week of intervention i.e., 10th week, all participants will be given Infant Swing for 30 minutes and standing on platform swing (30 minutes) trice a day.
89535365|NCT03226405|Experimental|Patient Navigation Program|"The study team will identify, track, and provide navigation for all adult patients referred to Cancer Center from the CHC and community partners for cancer treatment.~The Patient Navigation Program include~Education,~Appointment reminders,~Help with insurance,~Transportation,~Navigating the Cancer Center,~Assisting in finding appropriate child care,~Interpreting,~Connecting the patient to psychosocial and/or palliative care teams,~Physically escorting the patient to appointments"
88866886|NCT00678834|Active Comparator|Arm 3|Tocotrienol to healthy subjects - 200 mg to take orally two times a day (400 mg a day).
88866887|NCT00679380|Experimental|1: budesonide-MMX® 6 mg|One budesonide-MMX® 6 mg plus three placebo Entocort EC® overencapsulated capsules daily in the morning after breakfast.
88866888|NCT00679380|Experimental|2: budesonide-MMX® 9 mg|One budesonide-MMX® 9 mg plus three placebo Entocort EC® overencapsulated capsules daily in the morning after breakfast.
88866889|NCT00679380|Active Comparator|3: Entocort EC® 3 mg|Three Entocort EC® 3 mg overencapsulated capsules plus one placebo budesonide MMX® tablet daily in the morning after breakfast.
88866890|NCT00679380|Placebo Comparator|4: Placebo|Three placebo Entocort EC® overencapsulated capsules plus one placebo Budesonide MMX® tablet daily in the morning after breakfast.
88866891|NCT00680706|Experimental|Thiamine|Receives thiamine
88866892|NCT00680706|Placebo Comparator|Control|
88866893|NCT00680862||Group 1|VA employees
88866894|NCT00682734|Active Comparator|1|Metoclopramide 10 mg+ diphenhydramine 25 mg. This medication was administered as an intravenous drip over 20 minutes
88866895|NCT00682734|Experimental|2|metoclopramide 20 mg + diphenhydramine 25 mg. Administered as an intravenous drip over 20 minutes.
88866896|NCT00682734|Experimental|3|metoclopramide 40 mg + diphenhdyramine 25mg. Administered as an intravenous drip over 20 minutes.
88866897|NCT00683046|Experimental|Drug Intervention|
88866898|NCT00683826|Experimental|L-Leucine 4grams|This will be a triple arm design where subjects will be randomized into three groups. Arm #1 will be 4g of Leucine.
88866899|NCT00683826|Experimental|L-Leucine 8 grams|Arm number two of the study will be a dose of Leucine of 8g.
88866900|NCT00683826|Placebo Comparator|L-Leucine 0 grams|The third arm of the study will be composed of a control drink with no leucine in it.
88866901|NCT00684138|Experimental|ReSTOR Aspheric +3.0D|ACRYSOF® ReSTOR® Aspheric +3.0 D Add Power Intraocular Lens
88866902|NCT00684138|Active Comparator|ReSTOR Aspheric +4.0D|ACRYSOF® ReSTOR® Aspheric +4.0 D Add Power Intraocular Lens
88866903|NCT00685932|No Intervention|Control|This arm will be randomly assigned to have conventional retractions (ie Rich retractors and similar) used in the usual fashion during the cesarean procedure.
88866904|NCT00685932|Experimental|Mobius|This arm will be randomized to have the providers who are performing the cesarean section use the Mobius retractor during the cesarean section procedure after the peritoneal cavity is opened.
88866905|NCT00687102|Experimental|Star participants assigned to Tamoxifen|Participants in the parent study, STAR assigned to Tamoxifen who were 65 or older at time of enrollment.
88866906|NCT00687102|Experimental|Star participants assigned to Raloxifene|Participants in the parent study, STAR assigned to Raloxifene who were 65 or older at time of enrollment.
88866907|NCT00688662|Active Comparator|1.ERCP with sphincterotomy|ERCP with sphincterotomy: cutting the biliary sphincter muscle (sphincterotomy)
88866908|NCT00688662|Placebo Comparator|2.ERCP without sphincterotomy|ERCP without cutting the biliary sphincter muscle (sphincterotomy)
88866909|NCT00690924|Experimental|Calcitriol|
88866910|NCT00691002|Experimental|LEO 80190|Calcipotriol 25 mcg/g plus 10 mg/g hydrocortisone ointment (LEO 80190)
88866911|NCT00691002|Placebo Comparator|LEO 80190 vehicle|Ointment Vehicle
88866912|NCT00691002|Active Comparator|Calcipotriol|Calcipotriol 25 mcg/g in the ointment vehicle
88866913|NCT00691002|Active Comparator|Hydrocortisone|Hydrocortisone 10 mg/g in the ointment vehicle
88866914|NCT00693498|Active Comparator|1|Standard leukoreduced irradiated blood cell transfusion group
88866915|NCT00693498|Experimental|2|Washed leukoreduced irradiated blood cell transfusion group
88866916|NCT00693654|Experimental|Sarna Lotion|1% pramoxine Sarna lotion
88866917|NCT00693654|Placebo Comparator|Placebo Cetaphil lotion|Placebo Cetaphil lotion
88866918|NCT00695292|Experimental|Intervention|"Patients in the study will receive the following for the duration of the study: irinotecan 60 mg/m2 intravenously on Days 1, 8, and 15 and carboplatin AUC=4 on Day 1. The study will consist of 28-day cycles, to a maximum of 6 cycles of therapy with irinotecan and carboplatin. After treatment with irinotecan and carboplatin, sunitinib will be given alone as maintenance therapy in all patients who have achieved study entry hematologic criteria and who do not have progressive disease or severe toxicity. During sunitinib maintenance therapy, patients will receive sunitinib at 25 mg orally daily. Sunitinib maintenance therapy will continue until progressive disease or irreversible toxicity occurs.~Re-staging will be performed every 2 cycles (every 8 weeks) during the study."
88866919|NCT00696618|Experimental|A|Tap water enema (hypo-osmolar) administered rectally 125 mL one time in the clinic, then self-administered on three separate occasions at home (Stage 1), Followed by Normosol-R enema (iso-osmolar) administered rectally 125 mL one time in the clinic, then self-administered on three separate occasions at home(Stage 2), Followed by Fleet enema (hyper-osmolar) administered rectally 125 mL one time in the clinic, then self-administered on three separate occasions at home (Stage 3)
89390530|NCT04894799|Active Comparator|Neck Control facilitation exercises|all participants will be given Neck Control facilitation exercises using Bobath Approach of low tone facilitation method, for one hour, trice a day for first 4 weeks. After that, in 5th and 6th weeks, all participants will be given Neck Control facilitation exercises for 30 minutes and sitting facilitation Exercises with trunk weight shifting for 30 minutes, trice a day. Next 7th and 8th weeks, Neck Control facilitation exercises (30 minutes) and sitting facilitation exercises with trunk weight shifting and kneeling weight bearing (30 minutes), trice a day will be applied. In 9th and 10th weeks, Neck Control facilitation exercises, sitting and kneeling weight bearing and standing with trunk elongation will be given to all participants for one hour, trice a day.
89390531|NCT05191693||patients with CBD stones up to 8-12mm|72 patients (mean age: 67 years, 52.8% males) were included, of whom 22 (30.5%) had multiple CBD stones, 23 (31.9%) had a history of cholecystectomy, 13 (18.1%) had a periampullary diverticulum and 22 (30.5%) had a previous EST
89390532|NCT02073812|Experimental|Multiple dose of Carbavance (RPX7009/RPX2014)|Multiple dose of Carbavance
89390533|NCT02073890||traumatic subarachnoid haemorrhage|
89390534|NCT03514121|Experimental|Phase 1a dose escalation/1b dose expansion|The study consists of Phase 1a dose escalation, Phase 1a dose exploration, Phase 1a combination safety-lead-in and Phase 1b dose expansion
89390535|NCT02930005|Experimental|Meclofenamic acid|150mg meclofenamic acid daily for 8 weeks
89390536|NCT02930005|Experimental|Pentosan polysulfate sodium|300mg of pentosan polysulfate sodium daily for 8 weeks
89390537|NCT02074046|Placebo Comparator|non-cancer stem cell vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
89390538|NCT02074046|Experimental|giving low dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
89390539|NCT02074046|Experimental|giving middle dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
89390540|NCT02074046|Experimental|giving high dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
89390541|NCT01353053||Tacrolimus, Everolimus|Immunosuppression is the same for all patients in the study until the period between the 3rd and 5th weeks, when patients will be randomized to initial regimen and remain or be converted to everolimus tacrolimus.
88866920|NCT00696618|Experimental|B|Normosol-R enema (iso-osmolar) administered rectally 125 mL one time in the clinic, then self-administered on three separate occasions at home (Stage 1), Followed by Fleet enema (hyper-osmolar) administered rectally 125 mL one time in the clinic, then self-administered on three separate occasions at home (Stage 2), Followed by Tap water enema (hypo-osmolar) administered rectally 125 mL one time in the clinic, then self-administered on three separate occasions at home (Stage 3)
88866921|NCT00696618|Experimental|C|Fleet enema (hyper-osmolar) administered rectally 125 mL one time in the clinic, then self-administered on three separate occasions at home (Stage 1), Followed by Tap water enema (hypo-osmolar) administered rectally 125 mL one time in the clinic, then self-administered on three separate occasions at home (Stage 2), Followed by Normosol-R enema(iso-osmolar) administered rectally 125 mL one time in the clinic, then self-administered on three separate occasions at home (Stage 3)
88866922|NCT00700440|Experimental|Cetuximab|400mg/m^2 intravenous infusion one week before radiotherapy, then 250mg/m^2 intravenous infusion weekly during radiotherapy
88866923|NCT00701376|Other|liver function|Subjects undergoing laparoscopic gastric surgery will be evaluated for liver function by comparing liver tissue biopsied during surgery with tissue biopsied after 60% weight loss
88866924|NCT00702780|Experimental|Escitalopram|Escitalopram 20mg tablet by mouth once a day
88866925|NCT00702780|Placebo Comparator|Placebo|Placebo 20mg tablet by mouth once a day
88866926|NCT00704028|Experimental|Ferric Carboxymaltose (FCM)|15 mg/kg up to a maximum of 750 mg at 100 mg per minute weekly to a maximum cumulative dose of 2,250 mg.
88866927|NCT00704028|Active Comparator|Iron Dextran|As determined by the investigator to a maximum cumulative dose of 2,250 mg.
88866928|NCT00704262|Experimental|Calcipotriol plus hydrocortisone (LEO 80190)|
88866929|NCT00706446|Experimental|1 - Tio/ICS in the Arg/Arg genotype|Tiotropium bromide 18 mcg qd plus inhaled steroids, either Fluticasone propionate Diskus 100 mcg 1 puff bid, Fluticasone propionate aerosol 44 mcg 2 puffs bid, Fluticasone propionate aerosol 110 mcg 2 puffs bid, Fluticasone propionate aerosol 220 mcg 2 puffs qd, Budesonide 90 mcg 2 puffs bid, or Budesonide 180 mcg 2 puffs bid, in the Arg/Arg genotype
88866930|NCT00706446|Experimental|2 - Tio/ICS in the Arg/Gly genotype|Tiotropium bromide 18 mcg QD plus inhaled steroids, either Fluticasone propionate Diskus 100 mcg 1 puff bid, Fluticasone propionate aerosol 44 mcg 2 puffs bid, Fluticasone propionate aerosol 110 mcg 2 puffs bid, Fluticasone propionate aerosol 220 mcg 2 puffs qd, Budesonide 90 mcg 2 puffs bid, or Budesonide 180 mcg 2 puffs bid, in the Arg/Gly genotype
88866931|NCT00706446|Experimental|3 - Tio/ICS in the Gly/Gly genotype|Tiotropium bromide 18 mcg QD plus inhaled steroids, either Fluticasone propionate Diskus 100 mcg 1 puff bid, Fluticasone propionate aerosol 44 mcg 2 puffs bid, Fluticasone propionate aerosol 110 mcg 2 puffs bid, Fluticasone propionate aerosol 220 mcg 2 puffs qd, Budesonide 90 mcg 2 puffs bid, or Budesonide 180 mcg 2 puffs bid, in the Gly/Gly genotype
88866932|NCT00706446|Active Comparator|4 - LABA/ICS in the Arg/Arg genotype|Salmeterol 50 mcg 1 puff BID or Formoterol 12mcg 1 puff BID plus inhaled steroid, either Fluticasone propionate Diskus 100 mcg 1 puff bid, Fluticasone propionate aerosol 44 mcg 2 puffs bid, Fluticasone propionate aerosol 110 mcg 2 puffs bid, Fluticasone propionate aerosol 220 mcg 2 puffs qd, Budesonide 90 mcg 2 puffs bid, or Budesonide 180 mcg 2 puffs bid, in the Arg/Arg genotype
89390542|NCT02071238|Experimental|Pamphlet|Patient group that will receive a written pamphlet outlining the risks of surgery as discussed in consultation.
89390543|NCT02071238|No Intervention|No pamphlet, individual|Patient group that will not receive a written pamphlet outlining the risks of surgery as discussed in consultation.
89390544|NCT02071238|Experimental|Group Consultation|Patient group that will receive informed consent discussion in a group-format.
89390545|NCT01365637|Experimental|Cohort 1 PF-05089771 or placebo|Subjects will receive multiple doses of PF-05089771 or placebo twice daily to investigate the safety/tolerability and PK of PF-05089771. The PK of alternative formulations of PF-05089771 and the effect of food on PK may also be investigated.
89535366|NCT03226405|Active Comparator|Standard of Care|"The patients will receive enhanced usual care,~This consist of personal phone call reminders about upcoming appointments at the MGH Cancer Center"
89390546|NCT01365637|Experimental|Cohort 2 PF-05089771 or placebo|Subjects will receive multiple doses of PF-05089771 or placebo twice daily to investigate the safety/tolerability and PK of PF-05089771. The PK of alternative formulations of PF-05089771 and the effect of food on PK may also be investigated.
89390547|NCT01365637|Experimental|Cohort 3 PF-05089771 or placebo|Subjects will receive multiple doses of PF-05089771 or placebo either twice or thrice daily to investigate the safety/tolerability and PK of PF-05089771. The PK of alternative formulations of PF-05089771 and the effect of food on PK may also be investigated.
89390548|NCT01365637|Experimental|Cohort 4 PF-05089771 or placebo|Subjects will receive multiple doses of PF-05089771 or placebo either twice or thrice daily to investigate the safety/tolerability and PK of PF-05089771. The PK of alternative formulations of PF-05089771 and the effect of food on PK may also be investigated.
89390549|NCT01353131||ECG Screening|1000 patients with moderate to high risk determined by stratification algorithm based on the electronic analysis of 69,088 routine 12-lead ECGs performed in a large medical institution during a 6 month period by combining previously established indices of abnormal repolarization (wide QRS-T angle) with validated measures of myocardial damage (Selvester QRS score) excluding those > 70 years of age or with LV ejection fraction ≤ 35%, or at a high risk of dying within 3 years from cancer, end stage cardiac, pulmonary, renal, immunologic or neurologic diseases excluded on clinical data obtained through medical record.
89390550|NCT01349387|Experimental|Arm1|"During their visit of consultation on the follow-up to the type 2 diabetes, les patients will be selected on the basis of active metformin treatment at a dose greater than or equal to 1400 mg/day. Patients will have to achieve a 10 ml blood sample. The blood will be processed by Ficoll gradient centrifugation to remove the red cells and isolate circulating leukocytes: this stage will be conducted in the CERITD. Analysis on circulating leukocytes and in particular the quantification of expressions of isoforms A and B of the INSR1 by quantitative RT - PCR gene will be conducted in the laboratory of the Professor Marc Peschanski (unit INSERM 861 I - STEM of Evry).~After inclusion in the study to J0, metformin treatment will be interrupted between J1 and J30, replaced by Januvia 100 mg/day dose, then resumed at J31."
89390551|NCT01365715|Experimental|Preoperative embolization|32 patients with spinal metastasis/metastases will undergo arteriography and receive transcatheter arterial embolization of spinal metastasis/metastases 0-48 hours prior to surgery.
89390552|NCT01365715|Active Comparator|Control group|32 patients with spinal metastasis/metastases will undergo arteriography of spinal metastasis/metastases without receiving transcatheter arterial embolization prior to surgery.
89390553|NCT04913441|Experimental|Routine physical therapy|"Patients in this group will get every session of 30 min 3 times per week on alternative days for 12 weeks~TENS and hot pack for 15 minutes~Ultra sound for 5 minutes~ROM exercises repeats 5 times for 10 minutes"
89390554|NCT04913441|Experimental|Manual physical therapy with routine physical therapy|"Patients in group B will get every session 30 minutes 3 times per week on alternative days~TENS and hot pack for 15 minutes~Ultra sound for 5 minutes~Mulligan technique (NAGS and SNAGS) will repeats 5 times for 10 minutes"
89390555|NCT04913441|Experimental|Stretching physical therapy with routine physical therapy|"Patients in this group will get every session 30 minutes 3 times per week on alternative days~TENS and hot pack for 15 minutes~Ultra sound for 5 minutes~Stretching exercises repeats 5 times for 10 minutes"
89390556|NCT03499613||Chronic low back pain|Patients with chronic low back pain participating to a 3 weeks Multidisciplinary rehabilitation program
89390557|NCT04905173|Experimental|Hypertrophic Cardiomyopathy|Subjects with a documented diagnosis of hypertrophic cardiomyopathy (HCM) will have an echocardiogram at rest followed by an echocardiogram with Valsalva maneuver as part of regular care. If these tests show no severe obstruction, subjects will continue with both squat-to-stand and amyl nitrite.
88866933|NCT00706446|Active Comparator|5 - LABA/ICS in the Arg/Gly genotype|Salmeterol 50 mcg 1 puff BID or Formoterol 12mcg 1 puff BID plus inhaled steroid, either Fluticasone propionate Diskus 100 mcg 1 puff bid, Fluticasone propionate aerosol 44 mcg 2 puffs bid, Fluticasone propionate aerosol 110 mcg 2 puffs bid, Fluticasone propionate aerosol 220 mcg 2 puffs qd, Budesonide 90 mcg 2 puffs bid, or Budesonide 180 mcg 2 puffs bid, in the Arg/Gly genotype
88866934|NCT00706446|Active Comparator|6 - LABA/ICS in the Gly/Gly genotype|Salmeterol 50 mcg 1 puff BID or Formoterol 12mcg 1 puff BID plus inhaled steroid, either Fluticasone propionate Diskus 100 mcg 1 puff bid, Fluticasone propionate aerosol 44 mcg 2 puffs bid, Fluticasone propionate aerosol 110 mcg 2 puffs bid, Fluticasone propionate aerosol 220 mcg 2 puffs qd, Budesonide 90 mcg 2 puffs bid, or Budesonide 180 mcg 2 puffs bid, in the Gly-Gly genotype
88866935|NCT00706836|Active Comparator|Pregabalin 50 mg|Pregabalin oral tablets (50 mg)
88866936|NCT00706836|Active Comparator|Pregabalin 200 mg|Pregabalin oral tablets (200 mg)
88866937|NCT00706836|Placebo Comparator|Placebo|Placebo
88866938|NCT00708942|Active Comparator|1|HAL suppository (single administration, HAL 100mg), laser illumination (50J/cm2)
88866939|NCT00708942|Placebo Comparator|2|Placebo suppository (single administration), laser illumination (50J/cm2)
88866940|NCT00708942|No Intervention|3|
88866941|NCT00708942|Active Comparator|4|HAL ointment (5%, 100mg, single administration), LED diode illumination (50J/cm2)
88866942|NCT00708942|Placebo Comparator|5|Placebo ointment (single administration), no illumination
88866943|NCT00709878||L|Patients treated with lapatinib who developed skin toxicities and have been biopsied for skin rash.
88866944|NCT00709878||C|Patients treated with cetuximab who developed skin toxicities and have been biopsied for skin rash.
88866945|NCT00709878||P|Patients treated with panitumumab who developed skin toxicities and have been biopsied for skin rash.
88866946|NCT00709878||E|Patients treated with erlotinib who developed skin toxicities and have been biopsied for a skin rash.
88866947|NCT00710814|Experimental|Leptin - Placebo|Leptin self-administered subcutaneously twice each day for 16 weeks, then Placebo for 16 weeks.
88866948|NCT00710814|Placebo Comparator|Placebo - Leptin|Placebo self-administered subcutaneously twice each day for 16 weeks, then Leptin for 16 weeks.
89390558|NCT01362751||Nursing home residents|In this study, patients from both the somatic and the psychogeriatric department are included. For the primary endpoint 'successful rehabilitation' only the patients from the somatic departments are included.
89390559|NCT01361269|Experimental|Fosmidomycin and clindamycin treatment|All the subject will be given fosmidomycin 30mg/kg/dose + clindamycin 10mg/kg/dose twice daily for three days (total daily dose fosmidomycin 60mg/kg, clindamycin 20mg/kg).
89390560|NCT01357187|Other|Control|
89390561|NCT01357187|Experimental|Treatment|
89390562|NCT01362829||Patients with severe sepsis|Patients who are admitted to medical ICU with severe sepsis
89390563|NCT01349543|Experimental|Viral Challenge|
89390564|NCT01353209|Experimental|Letrozole|
89390565|NCT01353209|Placebo Comparator|Placebo|
89390566|NCT03637491|Experimental|Avelumab and binimetinib|Open label
89390567|NCT03637491|Experimental|Avelumab, binimetinib and talazoparib|Open label
89390568|NCT03637491|Experimental|Binimetinib and talazoparib.|Open label.
89390569|NCT01353287||TAVI live case or video-taped transmission|
89390570|NCT01353287||TAVI without transmission|
89186612|NCT05685056|Experimental|Intervention group|Intervention will happen with weekly text messages during the study period, focusing on pregnancy nutrition and iodine rich foods. The texts will be based on the taxonomy of behavior change techniques used in interventions, the nudge theory and will be covering themes identified on our previous research.
89390571|NCT01363063|Experimental|Ketorolac tromethamine (Part A)|
89390572|NCT01363063|Experimental|Ketorolac tromethamine (Part B)|
89390573|NCT01357265|Other|1|No comparator is administered, only one IM single dose of trivalent subunit inactivated influenza vaccine is administered during the vaccination visit
88866949|NCT00711828|Experimental|Treatment (R-CYBOR-D)|Patients receive rituximab IV on day 1and cyclophosphamide PO, bortezomib IV, and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
88866950|NCT00712296|Experimental|ASHMI 4|ASHMI 4 capsules twice a day
88866951|NCT00712296|Experimental|ASHMI 12|ASHMI 12 capsules twice a day
88866952|NCT00712296|Placebo Comparator|Placebo|Placebo 6 capsules twice a day
88866953|NCT00712530|Experimental|1|"Single low-dose DermaVir immunization~0.1 mg pDNA/subject, 0.8 mL total volume of DermaVir~Administered topically with DermaPrep under two skin patches (0.4 mL/patch)"
88866954|NCT00712530|Experimental|2|"Single medium-dose DermaVir immunization~0.4 mg pDNA/subject, 3.2 mL total volume of DermaVir~Administered topically with DermaPrep under four skin patches (0.8 mL/patch)"
88866955|NCT00712530|Experimental|3|"Single high-dose DermaVir immunization~0.8 mg pDNA/subject, 6.4 mL total volume of DermaVir~Administered topically with DermaPrep under eight skin patches (0.4 mL/patch)"
88866956|NCT00714792||1|Subjects with urge incontinence due to overactive bladder
88866957|NCT00714792||2|women with no urge symptoms
89186613|NCT02561169|Experimental|Oseltamivir|75 mg oseltamivir orally twice daily for 5 days within 72 hours of symptom onset
89390574|NCT04550455|Experimental|Cladribine Tablets|All participants will receive cladribine tablets according to the current United States Federal Food and Drug Administration (FDA) package guidelines.
89390575|NCT01349621||Standard and polarized light colposcopy|Standard and polarized light colposcopy
89390576|NCT03713463||Oral Nutritional Supplement (ONS)|2 servings per day ONS
89390577|NCT01363141|Active Comparator|Regular AGE Diet|Regular AGE Diet
89390578|NCT01363141|Active Comparator|Low AGE Diet|One year reduction in dietary AGE intake
88866958|NCT00715104|Experimental|Sipuleucel-T with Booster|Subjects were to receive 3 infusions of sipuleucel-T 12 weeks prior to RP, and then an additional booster infusion 13 weeks following RP.
88866959|NCT00715104|Experimental|Sipuleucel-T without Booster|Subjects were to receive 3 infusions of sipuleucel-T 12 weeks prior to RP, with no further sipuleucel-T treatment.
88866960|NCT00715650|Experimental|Arm 1|This counseling consists of four sessions each approximately 60 minutes each. The four sessions are organized as follows: a) Orientation to Benefits Counseling: Your Benefits and Your Goals b) Work and Claims c) Financial Review: Implications of Your Work Plan and d) Your Plans After the Benefits Notice. The first session focuses on the disability application process as a non-confrontational way to explore attitudes towards work. The second session more directly addresses the claimant's attitudes about work and beliefs about whether work will prevent receipt of disability benefits. The third session addresses the same issue as the second, ambivalence about work and disability, from a financial perspective. The fourth session occurs after the disability determination has been made, and it is possible the veteran may feel differently about a benefit that has been awarded.
89390579|NCT01349699|Active Comparator|Iron loading|Subjects will receive 1.25 mg/kg iron sucrose intravenously 1 hour before endoxin administration 2ng/kg.
89390580|NCT01349699|Active Comparator|Iron chelation|Subjects will receive 30mg/kg deferasirox orally 2 hours before endotoxin administration 2ng/kg.
89390581|NCT01349699|Placebo Comparator|Placebo|Subjects will receive placebo instead of iron chelation or iron loading before endotoxin administration
89390582|NCT01370161|Experimental|TIPS treatment|Initial control of the bleeding episode will be obtained by vasoactive drugs (octreotide, somatostatin or terlipressin), endoscopic band ligation (sclerotherapy if technically difficult or not feasible) and prophylactic antibiotics.TIPS will be performed as soon as possible once the patients are enrolled in the study, always within the first 72 hours after the diagnostic endoscopy (preferably in the first 24 hours).Vasoactive drugs will be continued until the TIPS is performed and antibiotics will be continued for 5-7 days.
89390583|NCT01370161|Active Comparator|Medical treatment|Initial control of the bleeding episode will be obtained by vasoactive drugs (octreotide, somatostatin or terlipressin), endoscopic band ligation (sclerotherapy if technically difficult or not feasible) and prophylactic antibiotics.Patients will be treated with non-selective beta-blockers (propranolol)on day 5. In case of contraindications or intolerance to beta-blockers, patients will not receive pharmacological treatment (beta-blockers) and the only treatment to prevent rebleeding will be endoscopic band ligation.
89390584|NCT01370239|Experimental|Hu3S193|Single arm
89390585|NCT01801709|Experimental|AAVrh.10cuARSA|intracerebral administration of AAVrh.10cuARSA at 12 sites in the white matter of both brain hemispheres.
89390586|NCT03628443||Heart Failure without Chronic Kidney Disease|This group has patients managed with all types of heart failure without concomitant chronic kidney disease.
88866961|NCT00715650|Active Comparator|Arm 2|This will consist of four-session orientation with the sessions organized as follows: a) overview of VHA services, b) Primary Care c) Pharmacy and laboratory services and d) specialty services. After the description of each service, participants will be invited to discuss which services they plan to utilize. The counselor will provide telephone numbers and directions to the sites at which these services are provided.
88866962|NCT00715728||1: Bair Hugger|Intraoperative warming with Bair Hugger forced air system
88866963|NCT00715728||2: Hot Dog|Intraoperative warming with Hot Dog resistive heating system
88866964|NCT00715884|Experimental|1|CYPHER® ELITE™ Sirolimus-Eluting Stent System.
88866965|NCT00715884|Active Comparator|2|CYPHER® Bx VELOCITY® Sirolimus-eluting Stent System
88866966|NCT00715962|Active Comparator|Mobility Group|The Walking Intervention includes assistance to walk twice daily with or without a rolling walker. In addition, a behavioral intervention that included goal setting and discussion of how to overcome mobility barriers was used to encourage the mobility group to be more active throughout hospital stay. Participants will keep a diary of out of bed activity and will be encouraged to set goals for additional out of bed activity daily.
88866967|NCT00715962|Placebo Comparator|Control Group|The control group will receive twice daily friendly visits to counter the attention being paid to the intervention group. They will complete a diary but of visitors to their room.
88866968|NCT00716586|Experimental|Trusopt (2% dorzolamide)|Intent to treat population. All participants assigned to Trusopt (2% dorzolamide)
88866969|NCT00716742||1|bimatoprost 0.03% latanoprost 0.005% travoprost 0.004%
88866970|NCT00716820||SUNITINIB MALATE|Patients taking Sutent.
88866971|NCT00717054|Active Comparator|Aprepitant and Scopolamine group|Patients receive aprepitant and scopolamine for prevention of postoperative nausea and vomiting then were followed through the post operative period looking for nausea, vomiting, composite, and rescue medication utilization. This was compared to patients receiving aprepitant and scopolamine placebo looking for a difference in incidence of events.
88866972|NCT00717054|Placebo Comparator|Aprepitant and Scopolamine Placebo Group|Patients receiving aprepitant and placebo scopolamine for prevention of postoperative nausea and vomiting then followed through the post operative period looking for signs of nausea, vomiting, composite, and rescue medication utilization. This was compared to patients receiving aprepitant and scopolamine looking for a difference in incidence of events.
88866973|NCT00717288|Active Comparator|1|Detemir insulin dosed at 50% of calculated basal insulin infusion requirement injected once daily
88866974|NCT00717288|Active Comparator|2|Detemir insulin dosed at 65% of calculated basal insulin infusion requirement injected once daily
88866975|NCT00717288|Active Comparator|3|Detemir insulin dosed at 80% of calculated basal insulin infusion requirement injected once daily
88866976|NCT00717912|Experimental|Arm 1|Classical sugar syrup / Classical sweetener syrup / Classical sugar syrup / Experimental sweetener syrup / Experimental sweetener syrup / Experimental sweetener syrup / Classical sugar syrup
88866977|NCT00717912|Experimental|Arm 2|Experimental sweetener syrup / Experimental sweetener syrup / Classical sugar syrup / Classical sugar syrup / Classical sweetener syrup / Classical sugar syrup / Experimental sweetener syrup
88866978|NCT00717912|Experimental|Arm 3|Experimental sweetener syrup / Classical sugar syrup / Experimental sweetener syrup / Classical sweetener syrup / Classical sugar syrup / Classical sugar syrup / Experimental sweetener syrup
88866979|NCT00717912|Experimental|Arm 4|Experimental sweetener syrup / Experimental sweetener syrup / Experimental sweetener syrup / Classical sugar syrup / Classical sugar syrup / Classical sugar syrup / Classical sweetener syrup
88866980|NCT00717912|Experimental|Arm 5|Classical sugar syrup / Experimental sweetener syrup / Classical sweetener syrup / Experimental sweetener syrup / Experimental sweetener syrup / Classical sugar syrup / Classical sugar syrup
88866981|NCT00717912|Experimental|Arm 6|Experimental sweetener syrup / Experimental sweetener syrup / Experimental sweetener syrup / Classical sugar syrup / Classical sweetener syrup / Classical sugar syrup / Classical sugar syrup
88866982|NCT00718302|Experimental|Randomized treatment; antiglide plate|Randomized treatment; antiglide plate
88866983|NCT00718302|Experimental|Randomized treatment; lateral plate|Randomized treatment; lateral plate
88866984|NCT00719160|Placebo Comparator|Esomeprazole|
88866985|NCT00719160|Active Comparator|Placebo|
88866986|NCT00720330|Active Comparator|Ropivacaine|Paravertebral Group - A local anesthetic (ropivacaine) will be injected near the spine before surgery. Participants will also receive midazolam and fentanyl intravenously (through your vein) for sedation
88866987|NCT00720330|Active Comparator|Lidocaine/ketamine|Participant will receive general anesthesia through the vein before surgery. Lidocaine and ketamine will be administered intravenously throughout surgery and for 60 minutes after surgery.
88866988|NCT00720330|Placebo Comparator|Placebo|General anesthesia plus placebo. Placebo will be administered intravenously until 60 minutes after surgery
88866989|NCT00721188|Experimental|Pharmacokinetic Population|All subjects who received study drug and completed Pharmacokinetic testing through 24 hours post-dose.
88866990|NCT00721500|Experimental|narafilcon A / etafilcon A - etafilcon A - narafilcon A|First, narafilcon A and etafilcon A contact lenses worn contralaterally. Second, etafilcon A contact lenses worn in both eyes. Third, narafilcon A contact lenses worn in both eyes.
88866991|NCT00721500|Experimental|narafilcon A / etafilcon A - narafilcon A - etafilcon A|First, narafilcon A and etafilcon A contact lenses worn contralaterally. Second, narafilcon A contact lenses worn in both eyes. Third, etafilcon A contact lenses worn in both eyes.
89186614|NCT02561169|Placebo Comparator|Placebo|75mg placebo calcium carbonate pills taken twice daily for five days within 72 hours of symptom onset and will be identical in appearance to oseltamivir
89186615|NCT00753597|Experimental|1|Receiving active treatment
89186616|NCT00751569||A1|A group of 3 to 5 pregnant women as donors for umbilical cord blood
89390587|NCT03628443||Heart Failure with Chronic Kidney Disease|This group has patients managed with all types of heart failure with concomitant chronic kidney disease, without evidence of sustained hyperphosphatemia.
89390588|NCT05191069|Experimental|Moringa Oleifera Mouthwash|15ml of Moringa Oleifera mouthwash will be given to be used twice daily for 6 months.
89390589|NCT05191069|Placebo Comparator|Placebo Mouthwash|The mouthwash will have all other ingredients other than Moringa Oleifera extract. Participants will be advised to use 15ml of Placebo mouthwash twice daily for 6 months.
89390590|NCT01353443|No Intervention|Group A|Monofilament absorbable MonoPlus® suture material will be used for closing of the midline incision.
89390591|NCT01353443|Other|Group B|Abdominal wall closure with monofilament absorbable MonoPlus® suture material and onlay placement of Optilene® Mesh Elastic fixed by sutures.
89390592|NCT01353443|No Intervention|Group C|Monofilament, absorbable MonoMax suture material will be used for the closure of the abdominal cavity.
89390593|NCT03628365|Active Comparator|HMB (beta-hydroxy beta-methylbutyrate)|HMB, 1.5 g b.i.d., from day 4 to day 30 after ICU admission
89390594|NCT03628365|Placebo Comparator|Placebo|Maltodextrin, 1.5 g b.i.d., from day 4 to day 30 after ICU admission
89390595|NCT01365871|Active Comparator|basal injection|basal injection of anesthetics
89390596|NCT01365871|Active Comparator|basal + apical injection|basal + apical injection of anesthetics
89390597|NCT03040661|Experimental|Figure of 8 Suture|Hemostasis after an ablation for atrial fibrillation with a figure of 8 suture.
89390598|NCT03040661|Active Comparator|Manual Hemostasis Group|Hemostasis after an ablation for atrial fibrillation with the Manual Hemostasis Technique.
89186617|NCT00757341|Experimental|SKI-606|
88866992|NCT00721500|Experimental|narafilcon A - etafilcon A - narafilcon A / etafilcon A|First, narafilcon A contact lenses worn in both eyes. Second, etafilcon A contact lenses worn in both eyes. Third, narafilcon A and etafilcon A contact lenses worn contralaterally.
88866993|NCT00721500|Experimental|etafilcon A - narafilcon A - narafilcon A / etafilcon A|First, etafilcon A contact lenses worn in both eyes. Second, narafilcon A contact lenses worn in both eyes. Third, narafilcon A and etafilcon A contact lenses worn contralaterally.
88866994|NCT00722124|Active Comparator|SAMe 800|Each subject randomized to this arm will take a 400 mg pill of SAMe and one matching placebo pill in the AM and again in the PM
88866995|NCT00722124|Active Comparator|SAMe 1600|Each person randomized to this arm will take 2 400 mg pills of SAMe in the AM and again in the PM
88866996|NCT00722124|Placebo Comparator|Placebo|Each subject randomized to this arm will take 2 placebo pills in the AM and again in the PM
88866997|NCT00722436|Experimental|Tranexamic acid|Tranexamic acid (100 mg/kg load, 10 mg/kg/hr) intravenous
88866998|NCT00722436|Placebo Comparator|Placebo|Saline was administered intravenously
88866999|NCT00724308|Experimental|Arm 1|The telephone care coordination program involves the following steps: (1) brief counseling and referral from a mental health provider; (2) prescribing and mailing of smoking cessation medications; (3) proactive multi-call counseling from TeleQuit MH study counselors; and (4) follow-up at 2 and 6 months to check the patient's smoking status.
88867000|NCT00724308|Experimental|Arm 2|"The telephone care coordination program involves the following steps: (1) brief counseling and referral from a mental health provider; (2) prescribing and mailing of smoking cessation medications; (3) proactive multi-call counseling from the patient's state smoking cessation Quitline; and (4) follow-up at 2 and 6 months to check the patient's smoking status."
88867001|NCT00724464||Participants with Chronic Hepatitis C|Treatment-naïve participants with chronic hepatitis C, undergoing treatment with a standard treatment regimen of PegIntron and Rebetol in clinical practice at approximately 28 sites in Greece
88867002|NCT00726414|Experimental|Quinine Sulfate Capsules 2 x 324 mg Capsules - Fasting|A single dose of Quinine Sulfate (2 x 324 mg capsules) administered after an overnight fast of at least 10 hours.
89390599|NCT05683587|Experimental|experimental group|intervention
89390600|NCT01349777|Experimental|Pregrel®|clopidogrel
88867003|NCT00726414|Experimental|Quinine Sulfate Capsules 2 x 324 mg Capsules - Fed|A single dose of Quinine Sulfate (2 x 324 mg capsules) administered 30 minutes after a standardized, high fat breakfast.
88867004|NCT00727740|Experimental|1|Indomethacin liquid suspension 100 mg (25 mg/5ml) which is 20 cc of suspension instilled via a Teflon catheter (the end of which is passed through the biopsy channel of the endoscope) and situated into the duodenum. Following instillation of the suspension, the catheter is flushed with 5 cc of normal saline.
88867005|NCT00727740|Placebo Comparator|2|Placebo suspension in the same volume (20 cc) which is instilled via a Teflon catheter (the end of which is passed through the biopsy channel of the endoscope) and situated into the duodenum. The placebo suspension is also flushed with 5 cc of normal saline.
88867006|NCT00728910|Active Comparator|Atorvastatin|atorvastatin 10 mg/day by mouth for a total duration of 4 weeks
89186618|NCT00751647|Other|A1|Population receiving the CF specific outpatient PT services.
89390601|NCT01349777|Active Comparator|Plavix®|clopidogrel
89390602|NCT04240925|Experimental|Standard NIMV protocol with sigh breaths|
89390603|NCT04240925|Active Comparator|Standard NIMV protocol without sigh breaths|
89390604|NCT04700007|Experimental|Study group|
89390605|NCT01349855|Experimental|Cohort 1|Dose Level 1
89390606|NCT01349855|Experimental|Cohort 2|Dose Level 2
89390607|NCT01318655|Experimental|NKTR-118|
89390608|NCT01318655|Placebo Comparator|Placebo|
89390609|NCT04654533|Experimental|COSC|"Eight weekly manualized sessions of Circle of Security Classroom (COSC), delivered in groups, two hours per session, 5-10 childcare providers per group.~COSC is facilitated by a psychologist who is a registered COSP facilitator and who has completed the an additional COSC online training."
89390610|NCT04654533|No Intervention|Control|"Usual care control condition, i.e., standard practice in the participating childcare centers.~Teams of childcare providers are allocated to either COSC or waitlist in clusters, and baseline and follow-up measures are collected parallel in both groups. Childcare providers allocated to the waitlist will receive COSC after the follow-up data have been collected."
89390611|NCT03430869|Experimental|F-18 AV-45|F-18 AV-45 imaging
89390612|NCT03430869|Experimental|F-18-THK-5351|F-18-THK-5351 imaging
89535367|NCT02487641||Moderat Obesity|60 persons with BMI between 30-34.49 kg/m2
89535368|NCT02487641||Sever Obesity|60 persons with BMI above 34.49 kg/m2
89535369|NCT02487641||Normal weighted|60 persons with BMI between 18.5-24.49 kg/m2
89535370|NCT04433793|Experimental|Yoga group|Patients in the yoga group will receive yoga therapy, one hour every week for eight weeks.
89390613|NCT01350011|Active Comparator|Innovative System (IS)|The innovative intervention uses the treatment system to support motivational counseling treatment entrance and treatment utilization. It has two components, a Motivational Intervention component via Expert System Counseling, and a Treatment Component that incorporates both pharmacological and behavioral long-term components. An innovative aspect of the IS is the use of the pharmacist as an intervention agent, who queries participants on their readiness to quit smoking, encourages involvement in the motivational intervention and in treatment, and who, along with the counselors, is available to answer medication questions.
89390614|NCT01350011|Active Comparator|Standard Treatment Control|After a baseline interview, patients in this condition will be given a packet of brochures on quitting, including descriptions of self-quitting and help-lines. Participants in this condition will continue to have access to their primary care providers, and through that system have access to pharmacotherapy for smoking cessation, if they wish to receive it. They will receive written instructions on how to approach their primary care provider about smoking cessation medication, and a written description of the medications used in smoking cessation and a list of those that are available to them through the public health system. At each assessment, patients will be queried about their use of these resources.
89390615|NCT01357343|Active Comparator|Acupuncture|Acupuncture needling, moxa, Tui Na and cupping
88867007|NCT00728910|Active Comparator|ABT335|ABT335 135 mg/day by mouth added to atorvastatin for a total duration of at least 8
88867008|NCT00728910|Active Comparator|ER niacin|ER niacin titrated up to 2 g/day with aspirin 325 mg/day by mouth added to atorvastatin and ABT335 for 10 weeks
89390616|NCT01357343|Active Comparator|Chiropractic care|Chiropractic adjustments and active and passive physical modalities.
89390617|NCT01357343|Active Comparator|Integrated Chiropractic and Acupuncture|
89390618|NCT01353599|Experimental|Asmanex|Study participants will receive inhaled Mometasone Furoate (Asmanex) 220mcg once daily for 8 weeks.
89390619|NCT01733147|Placebo Comparator|Placebo|Subjects with known Barrett's Esophagus (no dysplasia and low-grade dysplasia) will receive a placebo which looks exactly like the study drug, but contains no active ingredient, to be taken orally for six months.
89390620|NCT01733147|Active Comparator|Omega-3 polyunsaturated fatty acids|Subjects with known Barrett's Esophagus (no dysplasia and low-grade dysplasia) will receive Omega-3 free fatty acids supplements to be taken orally for six months.
89390621|NCT04308707||Surgical specialties|
88867009|NCT00729846|Experimental|A|Patients will receive combination verteporfin with photodynamic therapy at reduced fluence [300mw/cm2] followed by intravitreal bevacizumab (1.25mg) on same day following photodynamic therapy.
88867010|NCT00729846|Experimental|B|Patients will receive combination verteporfin with photodynamic therapy at standard fluence [600mw/cm2] followed by intravitreal bevacizumab (1.25mg) on same day following photodynamic therapy.
88867011|NCT00729924|Experimental|Open label oral raltegravir|Raltegravir a single 400 mg pill taken orally every 12 hours for a total of 7 days.
88867012|NCT00731094|Experimental|Physical Activity Intervention|Expert system-based physical activity counseling: Individualized baseline counseling and guided goal setting to increase physical activity gradually to at least 150 minutes/week of moderate intensity, with a 12-month follow-up via postal mail of 14 additional counseling contacts generated by responses to a physical activity questionnaire and individually tailored computer-generated expert system feedback messages for physical activity based on stages of the motivational readiness for change model
88867013|NCT00731094|No Intervention|Attention Control|Generalized baseline healthy lifestyle education and suggestion to increase physical activity, with a 12-month follow-up via postal mail of 14 wellness newsletters focused on health issues other than physical activity
89390622|NCT04308707||Anesthesiology|
89390623|NCT01350089|Placebo Comparator|Placebo|
89390624|NCT01350089|Active Comparator|Comparator 1 (with alcohol)|
89390625|NCT01350089|Active Comparator|Comparator 2 (with alcohol and coffeine)|
89390626|NCT01350089|Experimental|Comparator 3 (with alcohol and energy drink)|
89390627|NCT01357421|Experimental|TT301|Investigational drug TT301
89390628|NCT01357421|Placebo Comparator|Placebo|Normal saline
89390629|NCT01350167|Active Comparator|Triphasic CT|Triphasic CT of the abdomen with and without contrast every 12 months with alpha-fetoprotein every 6 months.
89390630|NCT01350167|Active Comparator|Ultrasound|Ultrasound of the upper left quadrant with alpha-fetoprotein testing every 6 months.
89390631|NCT03296553|Experimental|Valganciclovir|Oral Valgancyclovir 900 mg twice in a day during 4 weeks prior to initiation of cART (combined antirretroviral therapy) until suppression of HHV-8.
88867014|NCT00731484||Volunteer Patients/Subjects|These subjects should present the general population.
89390632|NCT03296553|Active Comparator|Antiretroviral combinations|Standard treatment with cART according to current HIV Therapy Mexican guidelines.
88867015|NCT00731640|Active Comparator|Monofocal|Patients unilaterally implanted with ReSTOR lens in one eye and previously implanted with monofocal Intraocular lens (IOL) (unspecified) in other eye
88867016|NCT00731640|Active Comparator|Phakic|Patients unilaterally implanted with ReSTOR lens in one eye and phakic in the other eye with no necessary cataract removal impending
88867017|NCT00731874|Active Comparator|Arm 1 (6 to 8 ng/mL)|Target tacrolimus trough concentration of 6 to 8 ng/mL
88867018|NCT00731874|Active Comparator|Arm 2 (3 to 5 ng.mL)|Target tacrolimus trough concentration of 3 to 5 ng/mL
89186619|NCT00757419|Experimental|1|
89390633|NCT03131167|Experimental|SHP639 Ophthalmic Solution Arm (n=60)|Participants are divided into groups called cohorts. There will be approximately 12 cohorts, each consisting of 7 participants. In each cohort 5 out of 7 participants will be assigned a specified concentration of SHP639 (0.1%, 0.3%, or 0.6%) ophthalmic solution and a specific dosing schedule (the study participants will be instructed to insill the study drug one, two, three, or four times a day) in both eyes during the study.
89390634|NCT03131167|Placebo Comparator|Vehicle Ophthalmic Arm (n=24)|In each cohort 2 out of 7 participants will be assigned a placebo ophthalmic solution matched to 0.1%, 0.3%, and 0.6% SHP639 ophthalmic solution and specific dosing schedule (the study participants will be instructed to instill the study drug one, two, three, or four times a day) in both eyes during the study.
89390635|NCT01370395||Left ventricular function|According to the result of the echocardiographic exam, the patients will be divided into subgroups with (LV-EF>=55%) and without preserved ejection fraction (LV-EF<55%).
89390636|NCT01370551|Experimental|Gynoflor|This study consists only of this arm.
89390637|NCT01363375||normal foot|Subjects with normal foot structure
89390638|NCT01363375||flat foot|Subjects with flat foot structure.
89390639|NCT01363375||high arch foot|Subjects with high arch foot structure.
89390640|NCT01370707|Active Comparator|Metformin|
89390641|NCT01370707|Experimental|CJ-30001/CJ-30002|
89390642|NCT01363453||Patients with Ulcerative Colitis|
89390643|NCT04336735|Experimental|Immunization Tool Users|Users will trial a novel transplant-specific immunization tool (app)
89390644|NCT01363531|Active Comparator|Direct antibiotic treatment|The doctor gives to patient an antibiotic prescription for his respiratory infection, which he should start immediately.
89390645|NCT01363531|No Intervention|No antibiotic treatment|The doctor doesn't give to patient an antibiotic prescription for his respiratory infection.
88867019|NCT00732030|Experimental|AcrySof Toric T3|Each enrolled eye receives AcrySof Toric Model SN60T3 Intraocular Lens (IOL)
88867020|NCT00732654|Experimental|Sublingual Immunotherapy (SLIT)|"These subjects will have a dose escalation of the milk protein extract given sublingually. After dose escalation, they will continue on the sublingual daily maintenance dose for approximately one year.~Milk Protein Extract Immunotherapy : Sublingual extract daily in escalating doses to goal of 7mg/day for approximately 1 1/2 years."
88867021|NCT00732654|Experimental|SLIT/ Oral Immunotherpay (OIT) B|"These subjects will start with a dose escalation of the milk protein extract given sublingually, and then will switch to milk powder given orally and will undergo a dose escalation for a goal of 1000 mg. After dose escalation, they will continue on the oral daily maintenance dose for approximately one year.~Milk Powder Immunotherapy : Milk powder given orally in escalating doses with a goal of 1000mg/day for approximately 1 1/2 years."
88867022|NCT00732654|Experimental|SLIT/ OIT A|"These subjects will start with a dose escalation of the milk protein extract given sublingually, and then will switch to milk powder given orally and will undergo a dose escalation for a goal of 2000 mg. After dose escalation, they will continue on the oral daily maintenance dose for approximately one year.~Milk Powder Immunotherapy : Milk powder given orally in escalating doses with a goal dose of 2000mg/day given for approximately 1 1/2 years.~Milk Protein Extract Immunotherapy : Sublingual extract given daily in escalating doses with goal of 4 mg/day for approximately 20 weeks."
88867023|NCT00733278|Experimental|Copper IUD|Copper IUD
88867024|NCT00733356|Experimental|Vyvanse Treatment|All subjects were tested at baseline before medication and then titrated to best dose and retested on Vyvanse Medication.
88867025|NCT00733512||ReSTOR|AcrySof ReSTOR Aspheric +4 Intraocular Lens (IOL)
88867026|NCT00735306|Experimental|1|Avastin, Tarceva and Radiation Therapy
89390646|NCT01363531|Experimental|Delayed antibiotic prescription 1|The doctor gives to patient an antibiotic prescription for his respiratory infection with the advice to use it if needed, in case of worsening of symptoms or not improving.
89390647|NCT01363531|Experimental|Delayed antibiotic prescription 2|The doctor leaves the antibiotic prescription, for the respiratory infection of the patient, at the reception of the primary care center 3 days after the first medical visit. This prescription can be collected by patient if he needed, in case of worsening of symptoms or not improving.
89390648|NCT01366105|No Intervention|Dry Dressing|Incisions that were dressed with a sterile dry dressing at end of operation.
89390649|NCT01366105|Experimental|Negative Pressure Wound Therapy|Incisions dressed with a V.A.C. (NPWT) postoperatively.
89390650|NCT01363609|Experimental|Liraglutide|12 week treatment with liraglutide in fixed dosage
89390651|NCT01363609|Active Comparator|Insulin glargine|12 week treatment, once daily, with insulin glargine. Dosage based on fasting blood glucose measurements
89390652|NCT01363609|Other|before start of treatment period|before start of the treatment period, one day with tests will be performed. During this test a GLP-1 receptor antagonist will be administered In the group with obesity and planned gastric bypass surgery, the GLP-1 receptor agonist will be administered during 1 test before and 1 test after the surgery
89390653|NCT01363687|Experimental|Remote ischemic postconditioning group|Recipients receive remote ischemic postconditioning after declamping of renal artery during kidney transplantation
89390654|NCT01363687|No Intervention|Control group|Patients who have a deflated cuff placed on the upper limb free of arteriovenous fistula during the surgery
88867027|NCT00735462|Experimental|2.5% imiquimod cream|2.5% imiquimod cream applied daily to wart areas for up to 8 weeks
88867028|NCT00735462|Experimental|3.75% imiquimod cream|3.75% imiquimod cream applied daily to wart areas for up to 8 weeks.
89186620|NCT00757419|Placebo Comparator|2|
89390655|NCT03060447|Experimental|Vesatolimod|Participants in Period 1 will receive 10 doses of vesatolimod (4 mg to 8 mg) once every 14 days over a 20-week period along with their prescribed ART. Participants in Period 2 (ATI) will discontinue ART and vesatolimod and will be monitored for rebound in HIV-1 plasma viremia for 24 weeks. Participants who restart ART during Period 2 due to virologic rebound will complete the ART Re-Initiation Visits, and then Post-ART Re-suppression Visits monthly for 6 additional months. Participants who complete 24 Weeks of ATI without restarting ART will move onto Period 3 and have 2 options. They can remain off ART for up to an additional 24 weeks. Those who restart ART at the start of Period 3 will complete ART Re-initiation Visits and then Post-ART Re-suppression Visits monthly for 6 additional months.
89390656|NCT03060447|Experimental|Placebo|Participants in Period 1 will receive 10 doses of placebo matched to vesatolimod once every 14 days over a 20-week period along with their prescribed ART. Participants in Period 2 (ATI) will discontinue ART and placebo and will be monitored for rebound in HIV-1 plasma viremia for 24 weeks. Participants who restart ART during Period 2 due to virologic rebound will complete the ART Re-Initiation Visits, and then Post-ART Re-suppression Visits monthly for 6 additional months. Participants who complete 24 Weeks of ATI without restarting ART will move onto Period 3 and have 2 options. They can remain off ART for up to an additional 24 weeks. Those who restart ART at the start of Period 3 will complete ART Re-initiation Visits and then Post-ART Re-suppression Visits monthly for 6 additional months.
89390657|NCT04623567|Experimental|Jiangtang Tiaozhi Recipe Group|Jiangtang Tiaozhi formula granule (30g per bag), 1 bag per time, twice a day, take it with warm water after meals.
89390658|NCT04623567|Active Comparator|Metformin Group|500mg metformin tablet per time, 3 times a day, take it with meals.
89390659|NCT01712789|Experimental|Pomalidomide plus Dexamethasone|Pomalidomide 4mg by mouth (PO) daily days 1 through 21 of a 28 day cycle and dexamethasone 40mg/day PO for those ≤75 years of age or 20mg/day for those greater than 75 years of age on Days 1, 8, 15 and 22 of a 28 day cycle.
88867029|NCT00735462|Placebo Comparator|Placebo cream|Placebo cream applied daily to wart areas for up to 8 weeks.
89390660|NCT01357499||control group|A Blood pressure cuff and and the muscle stimulator pads will be applied to one lower leg but without inflating the cuff and without stimulating the muscle. Now 25 minutes will have to pass by before beginning the coronary angioplasty.
89390661|NCT01357499||intervention group 1|A Blood pressure cuff and and the muscle stimulator pads will be applied to one lower leg. The blood pressure Cuff will be inflated with 200 mmHg for 5 minutes. Next reperfusion will be allowed for 5 minutes. This cycle will be repeated for 3 times. There will be no electrical muscle stimulation in this group.
88867030|NCT00735618|Experimental|Guided Relaxation|Heart rate variability (HRV) high frequency (HF) spectral analysis, before and after a 15 minute, one-time, guided relaxation program
88867031|NCT00736242||PEG-IFN alfa-2b + RBV|Participants received a combination of PEG-IFN alfa-2b plus RBV according to routine clinical practice and locally-approved product recommendations for a minimum of 12 weeks. No investigational medicinal product was provided by the sponsor.
88867032|NCT00736632|Placebo Comparator|Placebo|Patients in the control group will receive placebo pills (instead of vitamin D) and calcium carbonate 500 mg twice daily.
88867033|NCT00736632|Active Comparator|Vitamin D|Patients in the vitamin D group will receive cholecalciferol 4000 units daily and calcium carbonate 500 mg twice daily.
88867034|NCT00737178|Active Comparator|Immediate IUD insertion|Insertion of CuT380A at the routine medication abortion follow-up visit one week after initiation of a medication abortion
88867035|NCT00737178|Active Comparator|Delayed IUD insertion|Insertion of CuT380A four to six weeks after initiation of a medication abortion
88867036|NCT00738426|Active Comparator|Erchonia ML Scanner (MLS)|Red diode low level laser light energy
88867037|NCT00738426|Sham Comparator|Sham device|non-therapeutic sham light output
89390662|NCT01357499||intervention group 2|A Blood pressure cuff and the muscle stimulator pads will be applied to one lower leg. The blood pressure Cuff will be inflated with 200 mmHg for 5 minutes. Next reperfusion will be allowed for 5 minutes. This cycle will be repeated for 3 times. In addition electrical muscle stimulation will be performed throughout the whole preconditioning cycle
89390663|NCT01353677||HSCT recipients|"Adult (≥ 18 years), or pediatric (≥ 2 years and < 18 years) allogeneic HCT recipient (related, unrelated, or CBU) at participating pilot study transplant centers.~Signed informed consent form from adult patient or parent/guardian of pediatric patient.~Patient must have a valid mailing address within the United States to receive QOL surveys.~Ability to speak and read English.~Patients with access to a telephone."
89390664|NCT01350323|Active Comparator|Type 3 NV|Wet-AMD related type 3 neovascularization
89390665|NCT01350323|Active Comparator|Type 2 NV|Wet-AMD related type 2 neovascularization
89390666|NCT01350323|Active Comparator|Type 1 NV|Wet-AMD related type 1 neovascularization
89390667|NCT01350323|Other|Controls|Aqueous sample (0.1ml) in patients undergoing cataract extraction
89390668|NCT03387449|Experimental|Bimanual Arm Training|Children in the study will all receive the same treatment, which includes 9 weeks of training on the bimanual arm trainer robotic device.
89390669|NCT01350557|No Intervention|Control group|Patients receive only usual hospital care
89390670|NCT01350557|Other|Subacute care group|Patients receive hospital usual care and subacute care. Subacute care consisted of geriatric consultation, a rehabilitation program, and early discharge planning.
88867038|NCT00739752|Experimental|Non-Framed-Offered|Non-Framed, Information Only Condition. Vaccine Offered.
88867039|NCT00739752|Experimental|Non-Framed-Recommended|Non-Framed, Information Only Condition. Vaccine Recommended.
88867040|NCT00739752|Experimental|Gain-Framed-Offered|Gain-Framed Intervention emphasizes the benefits associated with receiving HBV vaccine. Vaccine Offered.
88867041|NCT00739752|Experimental|Gain-Framed-Recommended|Gain-Framed Intervention emphasizes the benefits associated with receiving HBV vaccine. Vaccine Recommended.
88867042|NCT00739752|Experimental|Loss-Framed-Offered|Loss-Framed Intervention emphasizes the risks associated with not receiving HBV vaccine. Vaccine Offered.
88867043|NCT00739752|Experimental|Loss-Framed-Recommended|Loss-Framed Intervention emphasizes the risks associated with not receiving HBV vaccine. Vaccine Recommended.
88867044|NCT00740376|Experimental|Uniglide Mobile Bearing|Uniglide Mobile Bearing Unicondylar Knee System (MBK)
88867045|NCT00740376|Active Comparator|Uniglide Fixed Bearing|Uniglide Fixed Bearing Unicondylar Knee System (FBK)
88867046|NCT00741156|Experimental|Enalaprilat|enalaprilat 0.005-0.01 mg/kg intravenous x 1 dose
88867047|NCT00741390|Other|Arm A|In Visit 1 subjects tested BD/33G, OTM/33G, and OTM/28G devices. In Visit 2 subjects tested BD/33G and OTM/28G. See purpose for additional information.
88867048|NCT00741390|Other|Arm B|In Visit 1 subjects tested BD/33G, OTM/33G and OTU/28G devices. In Visit 2 subjects tested BD/33G and OTU/28G. See purpose for additional information.
88867049|NCT00741390|Other|Arm C|In Visit 1 subjects tested BD/33G, OTM/33G and ACC/28G devices. In Visit 2 subjects tested BD/33G and ACC/28G. See purpose for additional information.
88867050|NCT00741390|Other|Arm D|In Visit 1 subjects tested BD/33G, OTM/33G and OTM/28G devices. In Visit 2 subjects tested OTM/33G and OTM/28G. See purpose for additional information.
88867051|NCT00741468|Experimental|All subjects|Proellex 50 mg CYP1A2 probe CYP2C9 probe CYP2C19 probe CYP2D6 probe CYP3A4 probe
88867052|NCT00741858|Experimental|DuraGen (sutureless)|Duragen duraplasty - the Duragen patch is applied over the dural defect during Chiari decompression surgery. The Duragen represents sutureless technique of posterior fossa duraplasty. Rest of the treatment is as usual.
88867053|NCT00741858|Active Comparator|DuraGuard (suturable)|Duraguard duraplasty - the Duraguard patch is applied over the dural defect during Chiari decompression surgery and sutured to the dural edge. This represents suturable technique that theoretically provides better (water-tight) dural closure.
88867054|NCT00742170|Active Comparator|Active electroacupuncture|In the active electroacupuncture condition, the current is set at 2 times threshold (approximately 6-10 mA), which typically produces muscle twitching.
88867055|NCT00742170|Sham Comparator|Sham electroacupuncture|In the sham electroacupuncture condition, the current is set at 1 mA, the lowest intensity possible before the HANS device shuts off; this is undetectable stimulation.
88867056|NCT00742872|Experimental|1|Mosapride
88867057|NCT00742872|Placebo Comparator|2|Placebo
88867058|NCT00743574|Experimental|Vitamin D plus Calcium (Ca) supplementation|
88867059|NCT00743730|Active Comparator|I|Parent and Nurse Controlled Analgesics with basal
88867060|NCT00743730|Active Comparator|II|Parent and Nurse Controlled Analgesics without basal
88867061|NCT00743730|Active Comparator|III|"Intermittent opioid administered IV on an as needed basis"
88867062|NCT00745290|Active Comparator|Bupivacaine HCl|Single dose of 200 mg bupivacaine HCl administered intraoperatively via local infiltration
88867063|NCT00745290|Other|SKY0402|Single dose of 600 mg SKY0402 (study drug) administered intraoperatively via local infiltration
88867064|NCT00746694||Caelyx|Participants with metastatic breast or ovarian cancer treated with Caelyx as part of standard treatment and according to data sheet approved indications.
88867065|NCT00748410|Experimental|7 Days Repeat Dose|
88867066|NCT00748956|Experimental|Low dose NPY|Low dose, Receive 50 nmol dose of NPY
88867067|NCT00748956|Experimental|High dose NPY|High Dose, Receive 100 nmol dose of NPY
88867068|NCT00748956|Placebo Comparator|Placebo|Placebo comparator
88867069|NCT00749268|Active Comparator|A|
88867070|NCT00749268|Active Comparator|B|
88867071|NCT00750282|Experimental|Florbetaben (BAY94-9172)|
88867072|NCT00750360|Experimental|Unprimed, > 6 to < 72 Months|Subjects aged > 6 months to < 72 months who were previously not vaccinated against influenza (unprimed).
88867073|NCT00750360|Experimental|Unprimed, ≥ 72 to < 108 Months|Subjects aged ≥ 72 months to < 108 months who were previously not vaccinated against influenza (unprimed).
88867074|NCT00750360|Experimental|Primed, > 6 to < 72 Months|Subjects aged > 6 months to < 72 months who previously received a vaccination against influenza (primed).
88867075|NCT00750360|Experimental|Primed, ≥ 72 to < 108 Months|Subjects aged ≥ 72 months to < 108 months who previously received a vaccination against influenza (primed).
88867076|NCT00750360|Experimental|Primed, ≥ 108 to < 216 Months|Subjects aged ≥ 108 months to < 216 months who previously received a vaccination against influenza (primed).
88867077|NCT00750360|Experimental|Primed, ≥ 216 Months|Subjects aged ≥ 216 months who previously received a vaccination against influenza (primed).
88867078|NCT00751530||Protease Inhibitor Group|Subjects who required a protease inhibitor in their new ART regimen
88867079|NCT00751530||Non-protease Inhibitor|Subjects who did not take a protease inhibitor in their regimen
88867080|NCT00753636|Experimental|Dynacirc CR (Isradipine)|Dynacirc CR (Isradipine) will start at 5mg dose and increased in increments of 5mg every 2 weeks
88867081|NCT00753948|Experimental|Chronic Tetraplegia|Individuals with chronic tetraplegia
88867082|NCT00753948|Active Comparator|Mild Asthma|Individuals with diagnosed mild asthma
88867083|NCT00753948|Placebo Comparator|Healthy Control|Neurologically intact, otherwise healthy, age-matched control
88867084|NCT00754494|Experimental|Erlotinib Hydrochloride (25 mg)|Patients receive 25mg of erlotinib hydrochloride PO and one 100 mg of placebo and one 25 mg of placebo PO QD.
88867085|NCT00754494|Experimental|Erlotinib Hydrochloride (50 mg)|Patients receive 50 mg of erlotinib hydrochloride PO and one 100 mg of placebo PO QD.
88867086|NCT00754494|Experimental|Erlotinib Hydrochloride (100 mg)|Patients receive 100 mg of erlotinib hydrochloride PO and two 25 mg of placebo PO QD.
88867087|NCT00755040|Experimental|Ocular Cyclosporine (Restasis)|Patients receive cyclosporine ophthalmic emulsion (Restasis®) drops in each eye twice daily for up to 1 year after transplant.
88867088|NCT00755040|Placebo Comparator|Placebo|Patients receive placebo ophthalmic drops in each eye twice daily for up to 1 year after transplant.
88867089|NCT00755274|Experimental|Group 1: Primed|Have received 2 or more lifetime Flu Vaccinations Prior to Visit 1
88867090|NCT00755274|Experimental|Group 2: Naive/Inadequately Primed|Never Received or Received Only 1 Lifetime Flu Vaccination Prior to Visit 1
88867091|NCT00756600|Active Comparator|1|Regional Anesthesia
88867092|NCT00756600|Active Comparator|2|General Anesthesia
88867093|NCT00756678|Active Comparator|1|Carboxymethylcellulose and Glycerin
88867094|NCT00756678|Active Comparator|2|Polyethylene glycol 400
88867095|NCT00758550|Experimental|AcrySof Toric IOL|AcrySof Toric Intraocular Lens (IOL)
88867096|NCT00758550|Active Comparator|AcrySof Natural IOL|AcrySof Natural Intraocular Lens (IOL)
88867097|NCT00758784|Experimental|bromfenac ophthalmic solution 0.06%|bromfenac ophthalmic solution 0.06% bilaterally twice a day
88867098|NCT00758862|Experimental|1|
88867099|NCT00759330|Placebo Comparator|Placebo Tape (Arm 1)|Placebo tape remained on for 12 hours of continuous treatment per day.
88867100|NCT00759330|Experimental|Flurbiprofen Tape (Arm 2)|Flurbiprofen tape remained on for 12 hours of continuous treatment per day.
89390671|NCT01350557|Experimental|Comprehensive care group|Patients receive not only the subacute care (geriatric consultation, rehabilitation program, and discharge planning), but also health-maintenance interventions to prevent falls, consult on nutrition, and manage depression.
89390672|NCT04565379|Active Comparator|NuSepin® 0.1 mg|NuSepin® 0.1 mg/kg in 100 ml normal saline infusion
89390673|NCT04565379|Active Comparator|NuSepin® 0.2 mg|NuSepin® 0.2 mg/kg in 100 ml normal saline infusion
89390674|NCT04565379|Placebo Comparator|Placebo|100 ml normal saline infusion
89390675|NCT03074318|Experimental|Phase 1 (1.5 mg/m^2 trabectedin + avelumab)|Avelumab will be administered every 2 weeks. Trabectedin will be administered every 3 weeks for the first two doses (Week 1 and Week 4), and then every four weeks (Week 7, Week 11,…) moving forward. After Cycle 2 of trabectedin, dosing may extend to every 5 weeks at investigator discretion, for management of trabectedin-associated toxicity only. Delays of trabectedin beyond 5 weeks may be allowed but require written approval from the Sponsor-Investigator. On days where both drugs are scheduled to be administered, avelumab will be administered first. This will continue until unacceptable toxicity or confirmed disease progression.
89390676|NCT03074318|Experimental|Phase 1 (1.0 mg/m^2 trabectedin + avelumab)|Avelumab will be administered every 2 weeks. Trabectedin will be administered every 3 weeks for the first two doses (Week 1 and Week 4), and then every four weeks (Week 7, Week 11,…) moving forward. After Cycle 2 of trabectedin, dosing may extend to every 5 weeks at investigator discretion, for management of trabectedin-associated toxicity only. Delays of trabectedin beyond 5 weeks may be allowed but require written approval from the Sponsor-Investigator. On days where both drugs are scheduled to be administered, avelumab will be administered first. This will continue until unacceptable toxicity or confirmed disease progression.
89390677|NCT03074318|Experimental|Phase 1 (1.2 mg/m^2 trabectedin + avelumab)|Avelumab will be administered every 2 weeks. Trabectedin will be administered every 3 weeks for the first two doses (Week 1 and Week 4), and then every four weeks (Week 7, Week 11,…) moving forward. After Cycle 2 of trabectedin, dosing may extend to every 5 weeks at investigator discretion, for management of trabectedin-associated toxicity only. Delays of trabectedin beyond 5 weeks may be allowed but require written approval from the Sponsor-Investigator. On days where both drugs are scheduled to be administered, avelumab will be administered first. This will continue until unacceptable toxicity or confirmed disease progression.
89390678|NCT03074318|Experimental|Phase 2 (1.0 mg/m^2 trabectedin + avelumab)|Avelumab will be administered every 2 weeks. Trabectedin will be administered every 3 weeks for the first two doses (Week 1 and Week 4), and then every four weeks (Week 7, Week 11,…) moving forward. After Cycle 2 of trabectedin, dosing may extend to every 5 weeks at investigator discretion, for management of trabectedin-associated toxicity only. Delays of trabectedin beyond 5 weeks may be allowed but require written approval from the Sponsor-Investigator. On days where both drugs are scheduled to be administered, avelumab will be administered first. This will continue until unacceptable toxicity or confirmed disease progression.
88867101|NCT00759330|Placebo Comparator|Placebo Tape (Arm 3)|Placebo tape remained on for 24 hours of continuous treatment per day.
88867102|NCT00759330|Experimental|Flurbiprofen Tape (Arm 4)|Flurbiprofen tape remained on for 24 hours of continuous treatment per day.
88867103|NCT00759408|Experimental|1|BQ-123
89390679|NCT02071316|Active Comparator|Treatment group, hexacapron , esomeprazole|Treatment group - receive I.V. esomeprazole 80 mg and 8mg/h continuously with concurrent hexacapron I.V. every 6 hours until 72 hours and then continue oral treatment 6 g /day for 7 days.
89390680|NCT02071316|Placebo Comparator|Standard of care group, esomeprazole|* Standard of care group - receive I.V. esomeprazole 80 mg once then 8mg/h continuously
89390681|NCT02071472|Experimental|DP medication reconciliation|medication reconciliation by a pharmacist using an electronic pharmaceutical record associated to the anesthesiologist consultation for planned surgery patients.
89390682|NCT02071472|No Intervention|control|conventional anesthesiologist consultation for planned surgery patients
88867104|NCT00759642|Experimental|Lapatinib|lapatinib
88867105|NCT00759798|Experimental|Fludarabine, Cyclophosphamide, Rituximab|"Fludarabine 25 mg/m^2 given intravenously on Days 2-4 of Cycle 1 and Days 1-3 of Cycles 2 and beyond. Cyclophosphamide 250 mg/m2 given intravenously on Days 2-4 of Cycle 1 and Days 1-3 of Cycles 2 and beyond. Rituximab 375 mg/m2 given intravenously on Day 1 of Course 1~All subsequent Courses: 500 mg/m2 given intravenously on Day 1 (Weeks 5,9,13,17,21)"
88867106|NCT00760578|Placebo Comparator|Placebo|Microcrystaline cellulose once daily
88867107|NCT00760578|Active Comparator|Pioglitazone|Pioglitazone 45 mg once daily
88867108|NCT00760578|Experimental|MSDC-0160 90 mg|MSDC-0160 90 mg once daily
88867109|NCT00760578|Experimental|MSDC-0160 220 mg|MSDC-0160 220 mg once daily
88867110|NCT00761202|Active Comparator|1|Optive Eyedrops
88867111|NCT00761202|Active Comparator|2|Hylocomod Eyedrops
88867112|NCT00761592|Active Comparator|1|
88867113|NCT00761592|Active Comparator|2|
88867114|NCT00762216|Other|Toric|Implantation with the AcrySof® Toric intraocular lens
88867115|NCT00762450|Active Comparator|A- Positive Control|fluoride/triclosan/copolymer toothpaste
89390683|NCT02074124||Adenosine Vasodilation test|Group scanned with CT perfusion during adenosine vasodilation test.
89390684|NCT02074124||Reference group|Group scanned twice without adenosine vasodilation test for a reference. No randomization.
89390685|NCT02071550||zero PEEP|Patients undergoing laparoscopic cholecystectomy and monitorized with FORESIGHT,INVOS monitor
89390686|NCT02071550||10 CM H2O PEEP|Patients undergoing laparoscopic cholecystectomy and monitorized with FORESIGHT,INVOS monitor
89390687|NCT02074202|Experimental|FCH PET/CT scan results|PET/CT scan results with FCH intravenous injection
89390688|NCT02074202|Active Comparator|FDG PET/CT scan|PET/CT scan results with FDG intravenous injection
89390689|NCT02074280|Experimental|high dose of rifaximin|rifaximin 600 mg, bid, orally, 2 weeks and conventional treatment
89390690|NCT02074280|Experimental|low dose of rifaximin|rifaximin 400 mg bid,orally, 2 weeks
89390691|NCT02074280|No Intervention|control|conventional treatment
89390692|NCT02074592|Experimental|1|self assessment of ultrasound fetal biometry images followed by automatically generated feedback
89390693|NCT02074592|Active Comparator|2|assessment of ultrasound fetal biometry images by expert, followed by automatically generated feedback
89390694|NCT02074670|Experimental|Treadmill gait training|Five days a week, 40 sessions of Kinesiotherapy (passive and active mobilizations, muscle lengthening), Body Weight Supported Treadmill Training, bicycle, manual therapy (with and without assistance of a mechanical device) and daily life activities training.
88867116|NCT00762450|Placebo Comparator|B - Silica control|fluoride only toothpaste
88867117|NCT00762450|Experimental|C- Experimental product|fluoride/triclosan/amino acid toothpaste
88867118|NCT00762528|Active Comparator|Total Toothpaste|Triclosan/Copolymer/fluoride toothpaste
88867119|NCT00762528|Placebo Comparator|Fluoride toothpaste|sodium monofluorophosphate toothpaste
88867120|NCT00765570|Active Comparator|Treatment Group 1|Treatment Group 1-one treatment of Grid therapy followed by 15 treatments with standard radiation
88867121|NCT00765570|Active Comparator|Treatment Group-2|Treatment Group 2-15 treatments with standard radiation
88867122|NCT00765648|Active Comparator|1|nicardipine intravenous
88867123|NCT00765648|Active Comparator|2|Labetalol
88867124|NCT00766116|Experimental|Phase 1 Dose Level 1|"5-Azacitidine, Gemtuzumab ozogamicin~75 mg/m^2 5-Aza 2 days then GO at 3 mg/m^2"
89390695|NCT02074748||Bunion|Patients being treated for foot bunion with surgery.
89390696|NCT02074748||Controls (normal foot)|Participants in this group will not undergo surgery.
89390697|NCT02077946||Liraglutide / Sitagliptin|
89390698|NCT02078024|Active Comparator|Annual Ivermectin|Ivermectin 200 µg/kg body weight given orally at 0, 12 and 24 months
89390699|NCT02078024|Experimental|Biannual IVM 200 µg/kg plus ALB 800 mg|IVM 200 µg/kg plus ALB 800 mg (regardless of weight) given at 0, 6, 12, 18, and 24 months.
89390700|NCT02078024|Experimental|Annual IVM 200 µg/kg plus ALB 800 mg|IVM 200 µg/kg plus ALB 800 mg given at 0, 12 and 24 months; vitamin pills at given at 6 and 18 months.
89390701|NCT02078024|Experimental|Biannual IVM 200 µg/kg|IVM 200 µg/kg given 0, 6, 12, 18, and 24 months.
89390702|NCT02078024|Experimental|IVM 200 µg/kg plus ALB 400 mg|IVM 200 µg/kg plus ALB 400 mg given at 0, 6, 12, 18, and 24 months.
89390703|NCT02079896|Experimental|Single dose cross-over pilot|Single dose of lexaptepid pegol (NOX-H94) cross-over with single dose of placebo
89390704|NCT02079896|Placebo Comparator|Control|Twice weekly doses of placebo, 9 total
89390705|NCT02079896|Experimental|Lexaptepid pegol (NOX-H94)|Twice weekly doses of lexaptepid pegol (NOX-H94), 9 total
89390706|NCT02074826||Atrial fibrillation|"Genotyping of the AF associated variants~Measurement of the amount of left atrial fibrosis"
89390707|NCT02079974|Experimental|Pravastatin|Pravastatin sodium 20mg PO daily
89390708|NCT03559556|Experimental|Patient with AVM requiring radiotherapy|Patients on this protocol will still get treated based on target generated by interventional cerebral arteriography but also receive CT angiography.
89390709|NCT01353755|Experimental|recombinant Phleum (rPhleum) allergen cocktail|The recombinant Phleum (rPhleum) allergen cocktail is prepared by mixing equivalent volumes of each single allergen adsorbate. The recombinant Phleum (rPhleum) allergen cocktail contains Phleum pratense (Phl p) allergens: Type 1, 2, 5 and 6 at equimolar quatities. The total protein concentration in the highest strength is 200μg protein per 1mL aluminium hydroxide suspension.
89390710|NCT01353755|Placebo Comparator|Placebo|Placebo will be administered in the same way as the test product. Placebo will be identical in terms of appearance to the IMP.
89390711|NCT02080052|Experimental|Robot-assisted prostate biopsy|
89390712|NCT03135119|Active Comparator|TF-CBT|Youth will receive standard Trauma-Focused Cognitive-Behavioral Therapy
89390713|NCT03135119|Experimental|TF-CBT+AAT|Youth will received Trauma-Focused Cognitive-Behavioral Therapy with Animal-Assisted Therapy as an adjunct.
89390714|NCT02078258|Experimental|Attentional bias modification training|"Attention bias modification training (ABMT) is a a variation of attention tasks to modify attentional biases, in which a probe always appears in the location of relatively positive stimuli after the two stimuli, one neutral and one emotional, were simultaneously presented.~Participants complete 8 sessions (320 trials each with 20 minutes) over two weeks of neutral ABMT to shift attention toward neutral, in which a probe appeared in the location of neutral with 90% probability, and sadness-related with 10% probality. At a 9-week follow-up, participants completed 4 more sessions (480 trials each with 30 minutes)over two weeks of positive ABMT to shift attention toward positive words,in which a probe appeared in the location of 67% positive or 33% neutral."
89390715|NCT02078258|Active Comparator|Placebo control|The placebo ABMT was identical to the active ABMT, but shifted toward neutral (50%) or sad (50%) stimuli equally often (i.e., 50/50 training).
89390716|NCT02078336|Experimental|Midazolam|Midazolam Mylan 5 mg/ml solution for injection 15mg Oral use Single dose 45 minutes before dental treatment
89390717|NCT02078336|Active Comparator|Lorazepam / Valium+Akineton+Dehydrobenzperidol+Atropine sulfat|"Lorazepam Mylan 2,5 mg tabletten 2.5mg Oral use Single dose 45 minutes before dental treatment~OR~Valium 10 mg/2 ml solution for injection 10mg Intramuscular use Single dose 45 minutes before dental treatment~+ Akineton 5 mg/ml solution for injection 5mg Intramuscular use Single dose 45 minutes before dental treatment~+ Dehydrobenzperidol 5 mg/2 ml solution for injection 0,000125 ml/cm2 Intramuscular use Single dose 45 minutes before dental treatment~+ Atropine sulfate Sterop 0,25mg/1ml solution for injection 0,25mg Intramuscular use Single dose 45 minutes before dental treatment"
89390718|NCT01353833|Placebo Comparator|IL2-4|
89390719|NCT01353833|Experimental|IL2-2|1 millions IU of IL-2 per day
89390720|NCT01353833|Experimental|IL2-3|3 millions IU of IL-2 per day
89390721|NCT01353833|Experimental|IL2-1|0.33 millions IU of IL-2 per day
89390722|NCT02078414||Ulipristal acetate|Women choosing EllaOne as emergency contraception
89390723|NCT02078414||Copper IUD|Women choosing copper IUD as emergency contraception
89390724|NCT02080130|Experimental|Saccharomyces boulardii|FLORATIL®. Saccharomyces boulardii 200 mg sachet. One sachet orally, BID, for 5 days.
89390725|NCT02080130|Experimental|Probiotics combination|LACTIPAN®. Probiotics combination sachet. One sachet orally, BID, for 5 days. Lactobacillus acidophilus............. 1.00 x 109 cfu Lactobacillus casei........................ 1.00 x 109 cfu Lactobacillus rhamnosus............. 4.40 x 108 cfu Lactobacillus plantarum............... 1.76 x 108 cfu Bifidobacterium infantis................ 2.76 x 107 cfu Streptococcus thermophillus....... 6.66 x 105 cfu
89390726|NCT02080130|Placebo Comparator|Placebo|Placebo sachet. One sachet orally, BID, for 5 days.
89390727|NCT03559478|Active Comparator|Treatment Group 1|Sharp dissection with scalpel plus electrocautery to vessels
89390728|NCT03559478|Active Comparator|Treatment Group 2|Electrocautery for all dissection
89390729|NCT03355001||Skin Closure|Monosyn® Quick will be used for skin closure for the adaptation of soft tissue and mucous membranes, when wound support over a period of 7 days is considered adequate.
89390730|NCT03355001||Urology|Monosyn® Quick will be used in urology for the adaptation of soft tissue and mucous membranes, when wound support over a period of 7 days is considered adequate.
89186621|NCT00757575||1|
89186622|NCT00757653|Active Comparator|1|Stem with plasma sprayed porous Titanium 6Al4V alloy + Plasma sprayed HA
89186623|NCT00757653|Experimental|2|
89186624|NCT00757653|Active Comparator|3|
89186625|NCT00757731|Experimental|Minalcipran 100 mg|
89186626|NCT00757731|Experimental|Minalcipran 150 mg|
89186627|NCT00757731|Experimental|Minalcipran 200 mg|
89186628|NCT00757809|Experimental|QD|Once daily
89186629|NCT00757809|Experimental|BID|Twice daily
89186630|NCT00753831|Experimental|1|Aurosling
89186631|NCT00753909|Experimental|1|Paclitaxel/Carboplatin/Bevacizumab
89186632|NCT04015544|Experimental|Watermelon|Watermelon puree 710 mL per day for six weeks
89186633|NCT04015544|No Intervention|Control|No intervention
89390731|NCT03355001||Gynecology|Monosyn® Quick will be used in gynecology for the adaptation of soft tissue and mucous membranes, when wound support over a period of 7 days is considered adequate.
89390732|NCT01369784||refractory/relapsed LDCBG|patients with refractory/relapsed diffuse large B-cell lymphoma
89390733|NCT02078570||Breast Cancer ACR BI-RAD Category 3 or 4 result|
89390734|NCT03353675|Experimental|TG4010/Chemotherapy/Nivolumab|
89390735|NCT02075060|Experimental|IPOI|One arm with pre-operative instillation of mitomycine 1h before TURB (IPOI : Instillation pré-opératoire immédiate),
89390736|NCT02075060|Active Comparator|IPOP|One arm with early post-operative instillation of mitomycine within 24 hours (IPOP : Instillation Post Opératoire Précoce).
89390737|NCT02075138||Grass-Induced Rhinoconjunctivitis Subjects|
89390738|NCT01350713|Experimental|povidone iodine|
89390739|NCT01350713|Active Comparator|cold water|treatment by cold water after burn
89390740|NCT02075216|Experimental|Myoblasts Preparation|"Myoblast Preparation, Myoblast Transplantation & Neonatal Cystourethroscope Injection~Approximately 8 to 10 gm muscle will be obtained from the rectus abdominis. Patient muscle fibers will be isolated using the fiber explant technique described by Rosenblatt et al, with some modifications. Culture conditions will be mainly adapted from Rando and Blau.~After 22 days of culture myoblasts will be harvested by trypsinization and incubated in serum-free medium during the last 2 hours before injection. Immediately before injection the cell pellet will be resuspended in autologous serum and/ or platelet rich plasma (PRP)."
89390741|NCT01318889|Experimental|normal saline|mouth wash of normal saline ,three times a day, 10 cc each time
89186634|NCT00685035|Active Comparator|HFCWC with higher pressure/variable frequency settings|Half patients randomly assigned to perform HFCWC therapy first with a higher pressure/variable frequency protocol. This entailed performing a 30 minute session with pressure of 10 and 5 minutes each at frequencies of 8,9, and 10 Hz followed by pressure of 6 and 5 minutes each at frequencies of 18, 19, and 20 Hz. This group subsequently crossed-over to the lower-pressure/mid-frequency HFCWC protocol after a washout period of 2 days. This entailed performing a HFCWC session using a pressure of 5 and frequency of 12 Hz for the entire 30 minute session. The other half of subjects were randomly assigned to perform the lower-pressure/mid-frequency protocol first followed by the higher pressure/mixed-frequency after the 2 day washout period
89186635|NCT00685035|Active Comparator|HFCWC with lower pressure/mid-frequency settings|lower-pressure/mid-frequency protocol first followed by the higher pressure/mixed-frequency
89186636|NCT00753987|Experimental|1|
89186637|NCT00757887|Experimental|EHMI8|Previously protected volunteers, N=10
89003628|NCT04918745|Other|CAB|"C = Reduced baseline stimulation, modulation stimulation~A = Baseline stimulation, no modulation~B = Baseline stimulation, modulation stimulation"
89390742|NCT02075294||youth|"<45years~Adefovir dipivoxil or Entecavir~Participants who received 10mg ADV more than 3 years or switch to other agent due to Renal dysfunction will be recruited.~Participants who received 0.5mg ETV more than 3 years will be recruited."
89390743|NCT02075294||middle age|"≥45years and<65years~Adefovir dipivoxil or Entecavir~Participants who received 10mg ADV more than 3 years or switch to other agent due to Renal dysfunction will be recruited.~Participants who received 0.5mg ETV more than 3 years will be recruited."
89390744|NCT02075294||elderly|"≥65 years~Adefovir dipivoxil or Entecavir~Participants who received 10mg ADV more than 3 years or switch to other agent due to Renal dysfunction will be recruited.~Participants who received 0.5mg ETV more than 3 years will be recruited."
89390745|NCT01350791||Promus Element stent|Patients receiving Promus Element stents
89390746|NCT02080208|Experimental|High Flow Oxygen|Patients receiving oxygen via high flow oxygen therapy (Optiflow)
89003629|NCT04918745|Other|CBA|"C = Reduced baseline stimulation, modulation stimulation~B = Baseline stimulation, modulation stimulation~A = Baseline stimulation, no modulation"
89003630|NCT04913077|Other|Removal of submucosal gastric tumor preferably by Full Thickness Resection Device (FTRD)|FTRD (Ovesco company) in tumors up to 10 mm and predominantly intraluminal growth directly by sucking into the cap, at 10-20 mm and/or intramural/extramural growth by prior circumcision and lateral preparation, so that the lesions can be better pulled into the cap. The procedure depends on the endosonographic extent of the findings. The lesions are pulled into the cap with grippers and other instruments and, if necessary, with a snare and then resected with FTRD
89003631|NCT04908358|Sham Comparator|Sham preceded by cross-over Sham-Stimulation|Cross-over: Sham followed by experimental Respiratory-gated Auricular Vagal Afferent Nerve Stimulation (RAVANS) Wash-out period of four weeks Ten daily sessions of sham during 2 weeks
89003632|NCT04908358|Sham Comparator|Sham preceded by cross-over Stimulation-Sham|Cross-over: experimental Respiratory-gated Auricular Vagal Afferent Nerve Stimulation (RAVANS) followed by Sham Wash-out period of four weeks Ten daily sessions of sham during 2 weeks
89186638|NCT00757887|Active Comparator|control|5 malaria-naive volunteers
89186639|NCT05435079|Experimental|new type of tracheotomy high-flow oxygen therapy (NTHF)|NTHF (connect the oxygen suction tube, Venturi, Fisher & Paykel MR850 heated humidifier, RT308 breathing tube with humidification tank, airtight suction tube and tracheotomy in sequence from the output end of the automatic pressure-adjustable oxygen flow meter Catheter), adjust the MR850 to invasive automatic transmission, the temperature sensor automatically adjusts and maintains the gas temperature at the inlet of the tracheostomy catheter at 37°C according to the feedback temperature, and adjusts according to the gas outflow from the exhalation port of the patient's inspiratory phase. The gas flow rate of the oxygen therapy device is 40-60L/min. According to the monitored pulse oxygen saturation (SpO 2 ), the concentration of the venturi valve and the corresponding oxygen flow rate are adjusted to maintain the SpO 2 between 94% and 100%.
89390747|NCT02080208|No Intervention|Conventionnal|patients receiving oxygen via conventional way (low flow)
89390748|NCT01357967|Experimental|Seroquel XR adjunctive|"The quetiapine XR adjunct group will be titrated up to 300mg. Initial dosing will begin at 50mg on Day 1 and 2, increased to 150mg on Day 3 and 4. Further adjustments will be able to be made upwards or downwards within the recommended dose range of 50mg to 300mg depending upon the clinical response and tolerance of the patient. Seroquel XR will be administered daily in the evening.~The dosage of SSRIs will be maintained as low (es-citalopram 5mg, paxil CR 6.25mg, fluoxetine 10mg, and sertraline 25mg)."
89390749|NCT01357967|Active Comparator|SSRI monotherapy|active comparator
89390750|NCT02075372||Data registration of CTO-PCI patients|Patients diagnosed with the presence of one or more chronic total occlusions (CTOs) and who will receive treatment via percutaneous coronary intervention (PCI), which is standard medical practice for these types of lesions. This study will register data on the patients' demographics, CTO characteristics, procedure and outcome. This will be done in the form of a registry.
89390751|NCT02870855|Experimental|HCG group|intrauterine injection of HCG before blastocyst transfer
89390752|NCT02870855|No Intervention|Control group|blastocyst transfer
89390753|NCT02075450|No Intervention|Arm 1|Practice CPRcard lights not visible, Practice Just in Time Video - not provided to study participants, CPRcard lights not visible during study scenario
89390754|NCT02075450|Experimental|Arm 2|Practice CPRcard light- not visible, Practice CPR Just in Time Video- not provided, CPRcard light visible during study scenario.
89390755|NCT02075450|Experimental|Arm 3|Practice CPRcard light- visible, Practice Just in Time Video- watched by study participant, CPRcard light- not visible during study scenario.
89390756|NCT02075450|Experimental|Arm # 4|Practice CPRcard visible and the study participants watch the Just in Time Video,CPRcard light visible during study scenario
89390757|NCT02075528|Experimental|Paliperidone Extended Release (ER)|The participants were assigned to receive a fixed dosage of 9 mg/d of paliperidone ER for the first 2 weeks. The paliperidone ER dosage was adjusted flexibly after 2 weeks according to the clinical judgment of the physicians in charge.
89390758|NCT02075684|Other|In-office, Percutaneous Renal Biopsy|
89390759|NCT02075762|Active Comparator|Transbronchial biopsy|S-TBBx will be performed using standard biopsy forceps (Boston Scientific, Natick, MA) - 2.0mm diameter.
89390760|NCT02075762|Active Comparator|Cryoprobe biopsy|C-TBBx will be performed using the cryoprobe (ERBE, Tubingen, Germany) -1.9 mm diameter, 78cm in length. This cryoprobe is routinely used in the bronchoscopy suite for carcinoma-TBBX; therefore it is a technique already employed by the interventional pulmonologists who are familiar with its use.
89390761|NCT02075762|Active Comparator|VATS biopsy|Once the biopsies are obtained by the interventional pulmonologist, the thoracic surgeon will perform VATS biopsy. Following their procedure, subjects will be monitored in the post-anesthesia care unit as per standard of care. As part of their ongoing follow-up care, all subjects will be monitored for any adverse events that may have resulted from either the surgical or bronchoscopic procedure, specifically bleeding or pneumothorax.
89390762|NCT02078804|Experimental|Colonoscopy|20 000 subjects will be invited to an once-only colonoscopy.
89390763|NCT02078804|Experimental|FIT for occult blood|60 000 persons will be invited to take a fecal test for hemoglobin year 1 and year 3. If test-positive, they will be referred to colonoscopy.
89390764|NCT02078804|No Intervention|Controls|120 000 matched persons will be identified in the Swedish Register of the total population and will be used as controls.
89390765|NCT02080286|Active Comparator|Prism adaptation + anodal tDCS|"Participants will receive 1 milliamp (mA) anodal tDCS over the left primary motor cortex concurrent with a 20-minute session of prism adaptation.~They will undergo 5 consecutive daily sessions."
89390766|NCT02080286|Placebo Comparator|Prism Adaptation + Sham tDCS|"Participants will receive Sham tDCS over the left primary motor cortex concurrent with a 20-minute session of prism adaptation.~They will undergo 5 consecutive daily sessions."
89390767|NCT02080286|Placebo Comparator|Prism adaptation + no tDCS|"Participants will receive no tDCS at all but will undergo a 20-minute session of prism adaptation.~They will undergo 5 consecutive daily sessions."
89390768|NCT02080442||Chronic Obstructive Pulmonary Disease|
89390769|NCT03137069|Placebo Comparator|Cohort 1: Placebo|Participants received matching placebo twice daily from Day 1 to 56.
89390770|NCT03137069|Experimental|Cohort 1: GDC-0853 200mg BID|Participants received GDC-0853 200mg twice daily from Day 1 to 56.
89390771|NCT03137069|Placebo Comparator|Cohort 2: Placebo|Participants received matching placebo up to twice daily from Day 1 to 56.
88867125|NCT00766116|Experimental|Phase 1 Dose Level 2|"5-Azacitidine, Gemtuzumab ozogamicin~75mg/m^2 5-Aza for 4 days then GO at 6 mg/m^2"
88867126|NCT00766116|Experimental|Phase I Dose Level 3|"5-Azacitidine, Gemtuzumab ozogamicin~75 mg/m^2 5-Aza for 6 days then GO at 6 mg/m^2"
88867127|NCT00766116|Experimental|Phase 2 Dose Level 1|"5-Azacitidine, Gemtuzumab ozogamicin~75 mg/m^2 5-Aza for 6 days then GO at 6 mg/m^2"
88867128|NCT00767364|Experimental|Infants with bowel resection|Infants with bowel resection who will receive the oral rotavirus vaccine, RotaTeq(R).
88867129|NCT00767364|Active Comparator|Healthy Infants|Healthy infants that are gest. age and age-matched controls within 14 days will be given the oral rotavirus vaccine, RotaTeq(R).
88867130|NCT00769314|Experimental|1|Acyclovir Lauriad 50mg
88867131|NCT00769314|Placebo Comparator|2|
88867132|NCT00769392|Other|All Participants|All Participants will be randomized to receive a unique sequence of one of the 4 anesthetic agents per month, prior to a standard of care monthly intravitreal injection (1 injection per month for a total of 4 months). At the end of study participation, each patient will have received each of the 4 anesthetic agents once prior to one of the 4 intravitreal injections (ex. Randomization to sequence: Proparacaine Ophthalmic drops used prior to Injection 1; Tetracaine Ophthalmic drops used prior to Injection 2; Lidocaine 4% sponge used prior to Injection 3; Lidocaine 2% injectable solution (subconjunctival) used prior to Injection 4).
88867133|NCT00770874|Experimental|1|S-1 + Cisplatin (arm A)
89003633|NCT04908358|Experimental|Stimulation preceded by cross-over Sham-Stimulation|Cross-over: Sham followed by experimental Respiratory-gated Auricular Vagal Afferent Nerve Stimulation (RAVANS) Wash-out period of four weeks Ten daily sessions of RAVANS during 2 weeks
89390772|NCT03137069|Experimental|Cohort 2: GDC-0853 50mg QD|Participants received GDC-0853 50mg once daily from Day 1 to 56.
89390773|NCT03137069|Experimental|Cohort 2: GDC-0853 150mg QD|Participants received GDC-0853 150mg once daily from Day 1 to 56.
89390774|NCT03137069|Experimental|Cohort 2: GDC-0853 200mg BID|Participants received GDC-0853 200mg twice daily from Day 1 to 56.
89390775|NCT02080598|No Intervention|Controle|The volunteer do not smoke any cigarette during the study period
88867134|NCT00770874|Active Comparator|2|Cisplatin (arm B)
88867135|NCT00771264|Active Comparator|Urgent PC|
88867136|NCT00771264|No Intervention|Sham / Placebo|
88867137|NCT00772590|Experimental|Raltegravir, bovine colostrum|Raltegravir and hyper-immune bovine colostrum
88867138|NCT00772590|Experimental|Hyper-immune bovine colostrum|Hyper-immune bovine colostrum and Raltegravir placebo
88867139|NCT00772590|Experimental|Raltegravir|Raltegravir and Hyper-immune Bovine Colostrum Placebo
88867140|NCT00772590|Placebo Comparator|Placebo|Raltegravir placebo and hyper-immune bovine colostrum placebo
88867141|NCT00773370|Experimental|APA-Stroke|The APA-stroke exercise program designed specifically for individuals with hemiparetic gait deficits due to stroke. These progressive exercises focus on walking, balance and weight shifting and include an exercise homework component.
89390776|NCT02080598|Experimental|smoking|the volunteer smokes 2 cigarettes in 15 minutes
89390777|NCT01350869||Xience stent|Real world patients treated with XIENCE stents
89390778|NCT01358045|Active Comparator|Solaraze|
89390779|NCT01358045|Active Comparator|Solaraze + Silkis|
89390780|NCT01358045|Active Comparator|Silkis|
89390781|NCT01358045|No Intervention|No treatment|
89390782|NCT02076230|Experimental|[14C] TH-302 (Label 1)|
88867142|NCT00773370|Active Comparator|Sittercise|Sittercise is not stroke specific. This less vigorous exercise program consists of seated exercise, focusing on stretching to improve general range of motion and weight exercises to strengthen the trunk, arms, and legs. There is no assigned exercise homework associated with this group.
88867143|NCT00773604|Other|Treatment|Deep Brain Stimulation
88867144|NCT00775944|Active Comparator|Standard support|Standard 'Together Programme' telephone support for smoking cessation & advice to obtain nicotine addiction treatment
88867145|NCT00775944|Active Comparator|Proactive telephone support|Proactive support & advice to obtain nicotine addiction treatment
88867146|NCT00775944|Active Comparator|Standard support & offer NRT|Reactive telephone support (i.e. Together Programme) and offer of voucher for cost free Nicotine Replacement Therapy
88867147|NCT00775944|Active Comparator|Proactive support & offer NRT|Proactive telephone support and offer of voucher for cost free NRT
88867148|NCT00780234|Experimental|Arm 1: pioglitazone|Current or former smokers receive 6 months of treatment with pioglitazone
88867149|NCT00780234|Placebo Comparator|Arm 2: placebo|Current or former smokers receive 6 months of treatment with placebo
88867150|NCT00781950|Placebo Comparator|Placebo|Randomized, Blinded Controlled Arm of patients receiving placebo food products (ie: bagels, muffins, bars, pasta, buns, and milled seeds) containing a mixture of wheat and wheat bran to replace the flaxseed daily for one year.
88867151|NCT00781950|Experimental|Flaxseed|Randomized, Blinded group of patients that will be given food products (ie: bagels, muffins, bars, pasta, buns, and milled seeds) containing 30 g of milled flaxseed daily for one year
88867152|NCT00784524|Experimental|LMI Vaccination + IL-2|Patients receiving allogeneic large multivalent immunogen breast cancer vaccine and aldesleukin.
88867153|NCT00785772|Experimental|1: Patients with Cleatinine Clearance (CLcr) 5-14 mL/min|
88867154|NCT00785772|Experimental|2: Patients with CLcr 15-29 mL/min|
88867155|NCT00785772|Experimental|3: Patients with CLcr 30-59 mL/min|
88867156|NCT00787020||Ventriculostomy Open|Subjects are treated with near continuous cerebrospinal fluid (CSF) diversion by positioning the stopcock in the open position and the intracranial pressure (ICP) is monitored once each hour: CSF drains into an external ventricular drainage bag.
88867157|NCT00787020||Ventriculostomy Monitored|Subjects are treated with intermittent cerebrospinal fluid (CSF) diversion. Intracranial pressure (ICP) is monitored and CSF is drained only when the ICP exceeds a threshold dictated by the attending physician.
88867158|NCT00787332|Experimental|Desirudin|Patients with suspected HIT without thrombosis syndrome (HIT/TS), randomized to SC Desirudin
88867159|NCT00787332|Active Comparator|Argatroban®|Patients randomized to IV Argatroban®
88867160|NCT00787722|Experimental|Hematopoietic Stem Cell Transplantation|Hematopoietic stem cell transplantation will be performed after conditioning regimen of cyclophosphamide, G-CSF, Mesna, rATG, rituximab, and methylprednisolone.
88867161|NCT00788892|Experimental|Arm A: CPX-351|First induction: CPX-351 at 100u/m2 administered on days 1, 3 and 5 Second induction: CPX-351 at 100u/m2 administered on days 1 and 3 Consolidation: CPX-351 at 100u/m2 administered on days 1 and 3
88867162|NCT00788892|Active Comparator|Arm B: Cytarabine + Daunorubicin|First induction: Cytarabine at a dose of 100mg/m2/day on days 1-7, Daunorubicin at dose of 45 or 60mg/m2 on days 1-3 Second induction: Cytarabine at a dose of 100mg/m2/day on days 1-5, Daunorubicin at a dose of 45 or 60 mg/m2/day on days 1 and 2 Consolidation: Investigator's Choice
88867163|NCT00789438||General Anesthesia|Patients undergoing short-term surgery (30-90 min) under general anesthesia
88867164|NCT00789438||Spinal|Patients undergoing short-term surgery (30-90 min) under spinal anesthesia
88867165|NCT00789438||Spinal + Sedation|Patients undergoing short-term surgery (30-90 min) under spinal anesthesia with sedation
88867166|NCT00789672|Active Comparator|Lower Dose (3-1) levodopa/carbidopa|Oral levodopa 0.51 mg/kg tid with carbidopa 0.17 mg/kg tid (3 to 1 formulation) combined with 2 hours of daily patching, with a rapid taper of medication before a primary outcome exam 9 weeks after starting medication.
88867167|NCT00789672|Active Comparator|Higher Dose (4.5-1) levodopa/carbidopa|Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid (approximately 4.5 to 1 formulation) combined with 2 hours of daily patching, with a rapid taper of medication before a primary outcome exam 9 weeks after starting medication.
88867168|NCT00789750|Experimental|Colesevelam|Participants receive six colesevelam tablets (3.8 grams/day) in addition to pioglitazone-based therapy (30 mg or 45 mg)
88867169|NCT00789750|Placebo Comparator|Placebo|Participants receive six placebo tablets in addition to pioglitazone-based therapy (30 mg or 45 mg)
88867170|NCT00790062|Active Comparator|Oxytocin 10 units/500cc|1 dose only for prophylaxis given over 1 hour
88867171|NCT00790062|Experimental|Oxytocin 40 units/500cc|One dose only given over 1 hour. Per DSMB recommendations, this intermediate arm was stopped Jan 2010.
88867172|NCT00790062|Experimental|Oxytocin 80U/500cc|1 dose only given over 1 hour
88867173|NCT00793572|Experimental|Tandem Auto-/Nonmyeloablative Allo-HCT and Maintenance Therapy|See Detailed Description
88867174|NCT00793650|Active Comparator|Bortezomib before Melphalan|Enrolled patients were randomized to receive a single escalating dose of bortezomib (1.0, 1.3, or 1.6 mg/m2) 24 hours before melphalan.
88867175|NCT00793650|Active Comparator|Bortezomib after Melphalan|Enrolled patients were randomized to receive a single escalating dose of bortezomib (1.0, 1.3, or 1.6 mg/m2) 24 hours after melphalan.
88867176|NCT00794508|Experimental|Retroviral-mediated ADA gene transfer|Transfer of the human ADA gene to isolated CD34+ cells from the bone marrow.
88867177|NCT00795210|Experimental|GH 6mcg/kg/d|Recombinant human growth hormone 6mcg/kg SC once daily
88867178|NCT00795210|Experimental|GH 2mg daily|Recombinant human growth hormone 2mg SC once daily
88867179|NCT00795210|Experimental|Growth Hormone Releasing Hormone|Growth Hormone Releasing Hormone (Tesamorelin) 2mg daily, injected subcutaneously, x 2 weeks
88867180|NCT00795288|Experimental|Simvastatin, 80 mg/day|Simvastatin, 80 mg/day for 21 days
89390783|NCT02076230|Experimental|[14C] TH-302 (Label 2)|
89390784|NCT01353989||>60 years|
89390785|NCT01353989||< 40 years|
89390786|NCT03559712|Experimental|Telemedicine|Participants in this arm will be treated by the trained primary health care physicians in the primary health care centers, who will be having weekly supervisions with the specialists for case management.
89390787|NCT03559712|No Intervention|Control|Participants in this arm will experience treatment as usual, which means referral to a specialist.
89390788|NCT02080754|Placebo Comparator|sham arm|sham sellick maneuver
89390789|NCT02080754|Experimental|sellick arm|effective sellick maneuver
89390790|NCT01354067|Active Comparator|Control group|The control group will receive standardized patient education four times, once every two weeks, during the eight week intervention period.
89390791|NCT01354067|Experimental|High-repetitive single limb training|The experimental group will receive a high-repetitive single limb exercise regime, three times a week for two months. In addition, the exercise group will receive patient education at four occasions during the intervention period.
89390792|NCT01357811|Active Comparator|digoxin|
89390793|NCT01357811|Experimental|eliglustat with digoxin|
89390794|NCT02079116|Experimental|60 grams of fat plus water solution|"In the group with 10 volunteers with obesity, some of them are submitted first to the 60 grams of fat plus water solution (meal challenge) and in another time to only water.~Also, in the group with 10 volunteers without obesity, some of them are submitted first to the 60 grams of fat plus water solution (meal challenge) and in another time to only water."
88867181|NCT00795288|Placebo Comparator|Placebo|Placebo
88867182|NCT00795366|Active Comparator|AVP, arginine vasopressin|Vasopressin
88867183|NCT00795366|Active Comparator|Standard Catecholamine|levophed, dopamine, phenylephrine)
88867184|NCT00796302|Experimental|1|Children will receive active methylphenidate HCl and active risperidone. Parents will receive parent management training.
88867185|NCT00796302|Active Comparator|2|Children will receive methylphenidate HCl and placebo instead of the active risperidone. Parents will receive parent management training.
88867186|NCT00796926|Experimental|Systane Ultra|Used four times a day topically to each eye
88867187|NCT00796926|Active Comparator|Refresh|Used four times a day topically to each eye
88867188|NCT00798018|Placebo Comparator|Air|air was used to inflate the cuff.
88867189|NCT00798018|Placebo Comparator|Normal Saline|Normal saline was used to inflate the cuff.
88867190|NCT00798018|Active Comparator|lidocaine|2% lidocaine was used to inflate the cuff.
88867191|NCT00798018|Experimental|tetracaine|1% tetracaine was used to inflate the cuff.
88867192|NCT00798486|Other|Subjects with and without Diabetes|Subjects participating in this study included 93 who had diabetes and 17 who did not have diabetes.
88867193|NCT00798720|Experimental|Vorinostat + Bortezomib|Vorinostat 400 mg + Bortezomib 1.3 mg/m2
88867194|NCT00799578|Experimental|Cystagon-EC|
88867195|NCT00799812|Experimental|CHG Swabstick (3 @ once)|Chlorhexidine gluconate (CHG) 2% w/v CHG/isopropyl alcohol (IPA) 70% v/v - 3 swabsticks applied @ same time
88867196|NCT00799812|Experimental|CHG Swabstick sequential|Chlorhexidine gluconate (CHG) 2% w/v and isopropyl alcohol (IPA) 70% v/v - 3 swabsticks applied sequentially
88867197|NCT00799812|Active Comparator|Hibiclens|Chlorhexidine gluconate (CHG) 4% w/v in an aqueous base
88867198|NCT00799812|Placebo Comparator|Sterile water swab (3 @ once)|Sterile swabstick wetted with sterile deionized water - 3 swabsticks applied at the same time.
89390795|NCT02079116|Placebo Comparator|Pure water.|"In the same group with 10 volunteers with obesity, some of them are submitted first to only water (control) and in another time to the 60 grams of fat plus water solution (meal challenge).~Also, in the same group with 10 volunteers without obesity, some of them are submitted first to only water (control) and in another time to the 60 grams of fat plus water solution (meal challenge)."
89390796|NCT01351181|Experimental|Exercise advice|Behavioural
89390797|NCT01351181|Other|Normal Care|Normal care
89390798|NCT02080910|Experimental|Psychoeducational program|Psychoeducational program consisted of (1) two inpatient sessions of face-to-face education on stroke and its caregiving; (2) six biweekly problem-solving training via telephone contacts after the discharge of stroke survivors
89390799|NCT02080910|No Intervention|Usual care|
89390800|NCT04300985|Sham Comparator|Placebo group|Thirty patients in this group will receive infusion of 100 saline solution. After 15 min of beginning of this infusion they will start receiving general anesthesia administration.
89390801|NCT04300985|Active Comparator|Dexmedetomidine group|Thirty patients in this group will receive infusion of dexmedetomidine (0,5 mcg/kg/min). After 15 min of the beginning of this infusion they will start in the general anesthesia induction.
89390802|NCT04300985|Active Comparator|Magnesium sulfate group|Thirty patients in this group will receive infusion of magnesium sulfate (20 mg/kg/h). After 15 min of the beginning of this infusion they will start in the general anesthesia induction.
89390803|NCT02079194|Experimental|P2Y12 antagonist monotherapy|P2Y12 antagonist monotherapy after 3-month DAPT
89390804|NCT02079194|Experimental|Aspirin + P2Y12 antagonist|Aspirin + P2Y12 antagonist after 3-month DAPT
89390805|NCT01358279|Experimental|migraine|
89390806|NCT01351259|Experimental|Pneumatic device, tapered cuff|Intervention: continuous control of cuff pressure using a pneumatic device, tapered polyurethane cuff
89390807|NCT01351259|Experimental|Pneumatic device, cylindrical cuff|Continuous control of cuff pressure using a pneumatic device in patients intubated with cylindrical polyurethane cuffed tracheal tubes
89390808|NCT01351259|Active Comparator|Routine care, tapered cuff|Routine care of cuff pressure using a manometer, tapered polyurethane cuff
89390809|NCT01351259|Active Comparator|Routine care, cylindrical cuff|Routine care of cuff pressure using a manometer, cylindrical polyurethane tracheal cuff
89390810|NCT01351493|Active Comparator|Nitric oxide gel|
89390811|NCT01351493|Placebo Comparator|placebo|
89390812|NCT02829671|Other|Patients with major depressive disorders|
89390813|NCT01354379|Active Comparator|Fluzone 15 mcg HA 200 mcl IN by Pipette|
89390814|NCT01354379|Experimental|NB-1008 15 mcg HA 20% W805EC 200 mcl IN by Pipette|
89390815|NCT01354379|Active Comparator|Fluzone 15 mcg HA 200 mcl IN by Nasal Spray|
89186640|NCT05435079|Active Comparator|Respiratory Humidification Treatment（ AIRVO TM 2）|AIRVOTM 2 (Fisher & Paykel, Auckland, New Zealand), connect the special breathing circuit, tracheostomy joint and tracheostomy tube in sequence from the output end of the oxygen flow meter. The gas outflow from the mouth is the standard, adjust the output gas flow rate of the therapy device to 40-60L/min, adjust the oxygen concentration according to the monitored pulse oxygen saturation (SpO 2 ), and maintain the SpO 2 between 94% and 100%. .
89186641|NCT02560155|No Intervention|Nose-SA-carriers control|Control Group, no intervention
89186642|NCT02560155|Active Comparator|Nose-SA-carriers decolonized|"Chlorhexidine sol 4%; Mupirocin 2% nasal ointement~1 shower/day for 5 days and Nasal ointement 2x/d in each nostril for 5 days preoperatively"
88867199|NCT00799812|Placebo Comparator|Sterile water swabstick (sequential)|Sterile swabstick wetted with sterile water--3 swabsticks applied sequentially.
88867200|NCT00801138|Placebo Comparator|Group 1|Group 1 Ropivacaine: 30 ml 0.5% ropivacaine plus 2 ml 0.9% saline for interscalene block
88867201|NCT00801138|Placebo Comparator|Group 2|Group 2 Bupivacaine: 30 ml 0.5% bupivacaine plus 2 ml 0.9% saline
88867202|NCT00801138|Active Comparator|Group 3|Group 3 Ropivacaine and dexamethasone: 30 ml 0.5% ropivacaine mixed with dexamethasone 8 mg (2 ml)
88867203|NCT00801138|Active Comparator|Group 4|Group 4 Bupivacaine and steroid: 30 ml 0.5% bupivacaine mixed with dexamethasone 8 mg (2 ml).
88867204|NCT00801684|Placebo Comparator|Placebo|Represents Dose A in the Dosing Sequence assignments.
88867205|NCT00801684|Experimental|TrIP-2D (100mcg)|Represents Dose B
88867206|NCT00801684|Experimental|TrIP-2SS (100mcg)|Represents Dose C
88867207|NCT00801684|Experimental|TrIP-2D (400mcg)|Represents Dose D
88867208|NCT00801684|Experimental|TrIP-2SS (100mcg) + Foradil (12mcg)|Represents Dose E. All subjects received Dose E as their final (5th) dose, after completing their initial 4 single doses according to their sequence assignment.
88867209|NCT00803010|Active Comparator|Tacrolimus / Rapamycin (TAC/RAPA)|"Tacrolimus: beginning 3 days before transplant and given for at least 50 days.~Rapamycin: given the day before transplant and continued daily for at least one year."
88867210|NCT00803010|Active Comparator|Tacrolimus / Methotrexate (TAC/MTX)|"Tacrolimus: beginning 3 days before transplant and given for at least 50 days.~Methotrexate: given on days 1, 3, 6 and 11, after transplant."
88867211|NCT00803400|Active Comparator|Alprazolam|Patients assigned to the pharmacological plan
88867212|NCT00803400|Active Comparator|Alprazolam + Aerobic exercise|Patients assigned to mix plan
88867213|NCT00804648|Active Comparator|hemihydrate/maleate/maleate gel|Period one - Timolol hemihydrate 0.5% Period two - Timolol maleate 0.5% Period three - Timolol maleate gel forming solution 0.5%
88867214|NCT00804648|Active Comparator|maleate/maleate gel/hemihydrate|Period one - Timolol maleate 0.5% Period two - Timolol maleate gel forming solution 0.5% Period three - Timolol hemihydrate 0.5%
88867215|NCT00804648|Active Comparator|maleate gel/hemihydrate/maleate|Period one - Timolol maleate gel forming solution 0.5% Period two - Timolol hemihydrate 0.5% Period three - Timolol maleate 0.5%
88867216|NCT00804648|Active Comparator|hemihydrate/maleate gel/maleate|Period one - Timolol hemihydrate 0.5% Period two - Timolol maleate gel forming solution 0.5% Period three - Timolol maleate 0.5%
88867217|NCT00804648|Active Comparator|maleate/hemihydrate/maleate gel|Period 1 - Timolol maleate 0.5% Period 2 - Timolol hemihydrate 0.5% Period 3 - Timolol maleate gel forming solution 0.5%
88867218|NCT00804648|Active Comparator|maleate gel, maleate, hemihydrate|Period 1 - Timolol maleate gel forming solution 0.5% Period 2 - Timolol maleate 0.5% Period 3 - Timolol hemihydrate 0.5%
88867219|NCT00805038|Placebo Comparator|Control|Usual care
88867220|NCT00805038|Experimental|Intervention|Navigator will assist patients in completing steps in transplant process
88867221|NCT00806598|Experimental|Thymoglobulin + Cyclosporin|Combination of Thymoglobulin 3.5 or 2.5 mg/kg/day intravenous (IV) for 5 days + Methylprednisone 1 mg/kg/day IV for 5 days, before each dose Thymoglobulin + Cyclosporin 5 mg/kg orally for 6 months following Thymoglobulin + Granulocyte - Colony Stimulating Factor (G-CSF) 5 microgram/kg subcutaneously daily up to 3 months
88867222|NCT00806676|Other|1. Chronic Kidney Disease, NKF Stage 1-4|Gardasil vaccine series will be administered according to FDA-approved schedule, as recommended by the Centers for Disease Control and Prevention and the American Academy of Pediatrics. Geometric antibody titers among those with chronic kidney disease will be compared to titers in the general population measured during Phase III clinical studies by Merck & Co, Inc, to prove efficacy of the vaccine and obtain FDA approval.
88867223|NCT00806676|Other|2. ESRD (dialysis)|Gardasil vaccine series will be administered according to FDA-approved schedule, as recommended by the Centers for Disease Control and Prevention and the American Academy of Pediatrics. Geometric antibody titers among those with ESRD will be compared to titers in the general population measured during Phase III clinical studies by Merck & Co, Inc, to prove efficacy of the vaccine and obtain FDA approval.
89003634|NCT04908358|Experimental|Stimulation preceded by cross-over Stimulation-Sham|Cross-over: experimental Respiratory-gated Auricular Vagal Afferent Nerve Stimulation (RAVANS) followed by sham Wash-out period of four weeks Ten daily sessions of RAVANS during 2 weeks
88867224|NCT00806676|Other|3. Kidney Transplant Recipient|Gardasil vaccine series will be administered according to FDA-approved schedule, as recommended by the Centers for Disease Control and Prevention and the American Academy of Pediatrics. Geometric antibody titers among those with a kidney transplant will be compared to titers in the general population measured during Phase III clinical studies by Merck & Co, Inc, to prove efficacy of the vaccine and obtain FDA approval.
88867225|NCT00807768|Active Comparator|Arm I (pelvic radiation therapy)|Patients undergo conventional or intensity-modulated pelvic radiation therapy once daily, 5 days a week, for 5-6 weeks (total of 25-28 fractions) in the absence of disease progression or unacceptable toxicity. Patients with stage II disease or stage I disease with a confirmed diagnosis of clear cell and/or papillary serous histology may also undergo 1 or 2 intravaginal (i.e., vaginal cuff) brachytherapy boost treatments.
89003635|NCT04908358|Other|cross-over Stimulation-Sham|Cross-over: experimental Respiratory-gated Auricular Vagal Afferent Nerve Stimulation (RAVANS) followed by sham One time RAVANS versus one time Sham Two weeks wash-out
89186643|NCT02560155|No Intervention|Non-nose-SA-carriers control|Control Group, no intervention
89186644|NCT02560155|Active Comparator|Non-nose-carriers decolonized|Chlorhexidine sol 4% shower, daily for 5 days preoperatively
88867226|NCT00807768|Experimental|Arm II (brachytherapy, paclitaxel, carboplatin)|Patients undergo vaginal cuff brachytherapy comprising 3-5 high-dose rate brachytherapy treatments over approximately 2 weeks or 1 or 2 low-dose rate brachytherapy treatments over 1-2 days. Beginning within 3 weeks after initiating brachytherapy, patients receive paclitaxel IV over 3 hours and carboplatin IV over 30-60 minutes on day 1. Chemotherapy repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
88867227|NCT00808470|Experimental|Nutrients|Subjects in University of Florida music player study who are assigned to nutrient condition(beta-carotene, vitamins C and E, magnesium). Nutrient tablets are consumed for 4 days.
88867228|NCT00808470|Placebo Comparator|Placebo for nutrients|Subjects in University of Florida music player study who are assigned to control (placebo) condition. Placebo tablets are consumed for 4 days.
88867229|NCT00810498|Experimental|Trilogy|Trilogy Device
88867230|NCT00810498|Active Comparator|Standard of Care|Participants prescribed ventilator
88867231|NCT00810576|Experimental|Vorinostat + Bortezomib|Vorinostat 200 mg orally twice on Days 1-14 + Bortezomib 1.3 mg/m^2 intravenous (IV) on Days 1, 4, 8, 11.
88867232|NCT00810888|Active Comparator|Group 1-Recombinant activated factor VII|"Participants with ICH determined by CTA to be high risk for hemorrhage growth (spot sign positive for contrast leakage within the brain hematoma) randomized to receive rFVIIa at 80 mcg/kg (max dose 21.3 mL)."
88867233|NCT00810888|Placebo Comparator|Group 2 - Placebo|"Participants with ICH determined by CTA to be high risk for hemorrhage growth (spot sign positive for contrast leakage within the brain hematoma) will be randomized to receive placebo."
88867234|NCT00810888|No Intervention|Group 3 - Observation Only Arm|"Participants with ICHdetermined by CTA not to be at high risk for hemorrhage growth (CTA spot sign negative) enrolled into a prospective observational group."
88867235|NCT00811434|Active Comparator|Lactulose|3 months of Lactulose therapy based on pt. weight
88867236|NCT00811434|Placebo Comparator|placebo|1.5 ml/kg day po of sugar water placebo for three months
88867237|NCT00812604|Experimental|Ping On Ointment|Ping On Ointment
88867238|NCT00812604|Placebo Comparator|Vaseline|Vaseline with minor trace of Ping On ointment to give medicinal smell
88867239|NCT00812838|Experimental|100 units of Botulinum Toxin Type A|Injection solution will consist of 100 units of BOTOX® in 10 cc of preservative free normal saline
88867240|NCT00812838|Placebo Comparator|Normal saline|"Injection solution will consist of 10 cc preservative free normal saline~Subjects had the choice of crossing over to ARM 1 at the end of 16 weeks.~Cross-over: For subjects in Arm 2, crossover to BOTOX treatment will begin after the Week 16 Visit by repeating the study schedule as for Week 0 to Week 16."
88867241|NCT00812916||RF ablation|RF Ablation using specialized CFAE software
88867242|NCT00814788|Experimental|Bicalutamide + Everolimus|Patients receive oral bicalutamide and oral everolimus once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88867243|NCT00815490|Experimental|Desaturation|Human volunteers undergo oxygen desaturation in order to determine the accuracy of the device over a clinical range of oxygen saturations 70 - 100%.
88867244|NCT00816348|Other|Omegaven|All subjects will receive Omegaven
88867245|NCT00820872|Experimental|docetaxel + carboplatin + trastuzumab + lapatinib|"Patients receive docetaxel IV over 60 minutes and carboplatin IV over 30 minutes on day 1, trastuzumab (Herceptin®) IV over 30-90 minutes on days 1, 8, and 15, and oral lapatinib ditosylate on days 1-21 (TCHL). Treatment with TCHL repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive trastuzumab IV over 30-90 minutes on day 1 and oral lapatinib ditosylate on days 1-21 (days 1-7 of course 12 only) (LT). Treatment with LT repeats every 3 weeks for 12 courses in the absence of disease progression or unacceptable toxicity.~After completion of study treatment, patients are followed every 6 months for 2 years and then annually for up to 8 years."
88867246|NCT00821184|Active Comparator|Vesicare|Vesicare alone
88867247|NCT00821184|Active Comparator|Vesicare/behavioral modification|Vesicare plus behavioral modification
88867248|NCT05237154|Experimental|Intermittent fasting (IF)|Alternate-day intermittent fasting. Consumption of 25% of daily energy requirements on scheduled fasting days involving energy restriction for 2 non-consecutive days of the week and ad libitum feeding on the other 5 days of the week. Period: 8 weeks.
88867249|NCT05237154|Experimental|Exercise: High-Intensity Interval Training (HIIT)|High intensity circuit training. Progressive training protocol 3x/week, for 8 weeks, with at least 1 day of rest between sessions and duration of 25 minutes each session - 4 minutes of initial warm-up, 18 minutes of the main part and 3 minutes of relaxation. First and second week: 30 second run and recovery time. Third and fourth week: 35-second runtime and 25-second recovery time. Fifth and Sixth Week: 40-second runtime and 20-second recovery time. Seventh and eighth weeks: 45-second runtime and 15-second recovery time.
88867250|NCT05236686|Experimental|Hepato-celiac lymphadenectomy|This single-arm, single-center, phase II trial is to evaluate the safety and effectiveness of hepato-celiac lymphadenectomy in the treatment of ovarian cancer with hepato-celiac lymph nodes metastases, in the circumstance of primarily diagnosed advanced epithelial ovarian cancer (primary debulking surgery or interval debulking surgery) and of platinum-sensitive recurrent ovarian cancer (no more than 4 lines of therapy).
88867251|NCT05235594|Experimental|Experimental: Smart shirt|The research intervention is, for all twenty patients, to wear a smart t-shirt connected to a smart phone throughout the day (preferably 8 hours pr day) for 2 weeks.
88867252|NCT05215860|Active Comparator|Habit cessation counselling with management for OPMD|n=100; Habit cessation counselling with general and medical management for OPMD
88867253|NCT05215860|Experimental|Habit cessation counselling, management for OPMD and intraoral photographs|n=100; Habit cessation counselling with standard management for OPMD and visual exposure to personal intraoral photographs of oral lesions at baseline and review
88867254|NCT05206812|Experimental|durvalumab|The operable non-small cell lung carcinoma patients (resectable stage IIA~IIIB)
88867255|NCT05131152|Experimental|cyclosporine group|"Mild DE patients: topical usage of 0.05% cyclosporine Eye Drops BID + 0.1% Sodium Hyaluronate Eye Drops QID, both use for 16 weeks.~Moderate DE patients: topical usage of 0.05% cyclosporine Eye Drops BID +0.1% Sodium Hyaluronate Eye Drops QID, both use for 16 weeks, and 0.02% Fluoromethalone Eye Drops BID for 4 weeks."
89186645|NCT00758121||Observation|Heart failure patients with an implanted CRT-D
89390816|NCT01354379|Experimental|NB-1008 15 mcg HA 20% W805EC 200 mcl IN by Nasal Spray|
89390817|NCT01354379|Experimental|NB-1008 15 mcg HA 20% W805EC 400 mcl IN by Nasal Spray|
89390818|NCT02079272|Other|Helical tomotherapy for breast cancer|"All women included in REBECCA cohort will be treated with helical tomotherapy for theur breast cancer.~Their cardiac follow-up will be based on echocardiography, CT coronary angiogram and blood samples"
89390819|NCT03558698|Other|Group 1|"One night of good ventilation with a CO2 level of maximum 800 ppm~One night of good ventilation with high levels of CO2 (3000 ppm)~One night of poor ventilation with high concentrations of CO2 (3000 ppm) and other bio effluents (The order of the three conditions are randomized)"
89390820|NCT03558698|Other|Group 2|"One night of good ventilation with a CO2 level of maximum 800 ppm~One night of good ventilation with high levels of CO2 (3000 ppm)~One night of poor ventilation with high concentrations of CO2 (3000 ppm) and other bio effluents (The order of the three conditions are randomized)"
89390821|NCT03558698|Other|Group 3|"One night of good ventilation with High CO2 level of maximum 800 ppm~One night of good ventilation with high levels of CO2 (3000 ppm)~One night of poor ventilation with high concentrations of CO2 (3000 ppm) and other bio effluents (The order of the three conditions are randomized)"
89390822|NCT03558698|Other|Group 4|"One night of good ventilation with a CO2 level of maximum 800 ppm~One night of good ventilation with high levels of CO2 (3000 ppm)~One night of poor ventilation with high concentrations of CO2 (3000 ppm) and other bio effluents (The order of the three conditions are randomized)"
89390823|NCT03558698|Other|Group 5|"One night of good ventilation with a CO2 level of maximum 800 ppm~One night of good ventilation with high levels of CO2 (3000 ppm)~One night of poor ventilation with high concentrations of CO2 (3000 ppm) and other bio effluents (The order of the three conditions are randomized)"
89390824|NCT03558698|Other|Group 6|"One night of good ventilation with a CO2 level of maximum 800 ppm~One night of good ventilation with high levels of CO2 (3000 ppm)~One night of poor ventilation with high concentrations of CO2 (3000 ppm) and other bio effluents (The order of the three conditions are randomized)"
89390825|NCT01318187|Experimental|Paracetamol|
89390826|NCT01318187|Active Comparator|Morphine|
89390827|NCT02080988||Silent aspirators|Stroke patients with dysphagia with severe aspiration
89390828|NCT02080988||Non aspirating, no dysphagia group|Stroke patients with no dysphagia and no evidence of aspiration
89390829|NCT01358435|Experimental|Wosulin 70/30|Wosulin 70N /30R is a recombinant Human Insulin with 30 % Regular Insulin Human Neutral and 70% Isophane Insulin, 600 nmol/ml, 100 IU/ml.
89390830|NCT01358435|Active Comparator|Novolin 70/30|Novolin 70/30 is a Recombinant Human Insulin with 70% NPH, Human Insulin Isophane Suspension and 30% Regular, Human Insulin Injection
89390831|NCT03558620|Experimental|Group 1O2|A fitting mask is held by one hand -> one hand with an endoscopic bite block -> held by two hands
88867256|NCT05131152|Experimental|control group|Mild DE patients: 0.1% Sodium Hyaluronate Eye Drops QID for 16 weeks Moderate DE patients: 0.02% Fluoromethalone Eye Drops BID for 4 weeks +0.1% Sodium Hyaluronate Eye Drops QID for 16 weeks.
88867257|NCT05110872|Experimental|Menthol cigarette smokers|Adults (21 y.o. and older) who smoke ate least 10 menthol cigarettes per day will be recruited.
88867258|NCT05110872|Experimental|Non-menthol cigarette smokers|Adults (21 y.o. and older) who smoke ate least 10 non-menthol cigarettes per day will be recruited.
88867259|NCT04982718|Experimental|Oral fluid-based HCV ST|In the intervention group, participants will receive a HCV self-test (ST) kit delivered in non-identifiable packaging to their home or a preferred mailing address. The kit will include the test, instructions for use, and information about additional supporting materials, such as access to live chat and a call center for questions about testing. In order to evaluate two sampling methods for HCV self-testing, the first 250 participants in the intervention group will receive an oral fluid-based HCV ST.
89390832|NCT03558620|Experimental|Group 12O|A fitting mask is held by one hand -> held by two hands-> one hand with an endoscopic bite block
89390833|NCT03558620|Experimental|Group O12|A fitting mask is held by one hand with an endoscopic bite block->by one hand -> by two hands
89390834|NCT03558620|Experimental|Group O21|A fitting mask is held by one hand with an endoscopic bite block -> by two hands-> one hand
89390835|NCT03558620|Experimental|Group 21O|A fitting mask is held by two hands -> one hand -> one hand with an endoscopic bite block
89390836|NCT03558620|Experimental|Group 2O1|A fitting mask is held by two hands ->one hand with an endoscopic bite block-> by one hand
88867260|NCT04982718|Experimental|Blood-based HCV ST|In the intervention group, participants will receive a HCV self-test (ST) kit delivered in non-identifiable packaging to their home or a preferred mailing address. The kit will include the test, instructions for use, and information about additional supporting materials, such as access to live chat and a call center for questions about testing. In order to evaluate two sampling methods for HCV self-testing, the next 250 participants will receive a blood-based fingerstick HCV ST.
89390837|NCT01318265|Experimental|Arm1|
89390838|NCT01354457|Experimental|Epratuzumab and 90Y-Epratuzumab|Escalating dose schedule with 5 cohort. For each cohort 3 patients will receive Radio-immunotherapy (RIT ) at Day 1 and Day 8 ± 2 First cohort : 92,5 MBq/m² of 90Y-DOTA-hLL2 associated with hLL2 Second cohort : 185 MBq/m² d'90Y-DOTA-hLL2 associated with hLL2 Third cohort : 277,5 MBq/m² d'90Y-DOTA-hLL2 associated with hLL2 Fourth cohort : 370 MBq/m² d'90Y-DOTA-hLL2 associated with hLL2 Fifth cohort : 462.5 MBq/m² d'90Y-DOTA-hLL2 associated with hLL2
89390839|NCT02079350||%4 Gelofusine|patients administered %4 Gelofusine during liver transplantation
89390840|NCT02079350||%6 HES|patients administered %6 HES during liver transplantation
89390841|NCT02081066|Other|patients with cardiovascular risk factors|
89390842|NCT01351571||Cohort|
89390843|NCT01351649|Other|attention control|Sessions with school nurse to discuss health-promoting topics and after-school health-promoting workshop. Physical activity and healthy eating were not addressed.
89390844|NCT01351649|Experimental|physical activity|
89390845|NCT02079428||Systolic heart failure, Diastolic heart failure|
89390846|NCT01351727||Seniors with Seizures|Seniors aged 65 or older with newly diagnosed seizures (consistent with epilepsy) or epilepsy as of October, 2010.
89390847|NCT03062540|Experimental|TNX-102 SL Tablet, 2.8 mg|2 x TNX-102 SL, 2.8 mg Tablets taken sublingually each day at bedtime for 12 weeks.
89390848|NCT03062540|Placebo Comparator|Placebo SL Tablet|2 x Placebo Tablet taken sublingually each day at bedtime for 12 weeks.
89390849|NCT01358513||Control Patients|Patients with normal aortic valves
89390850|NCT01358513||Aortic sclerosis|To undergo PET imaging and follow up with CT and echo for 2 years
89390851|NCT01358513||Mild Aortic stenosis|To undergo PET imaging and follow up with CT and echo for 2 years
89390852|NCT01358513||Moderate Aortic stenosis|To undergo PET imaging and follow up with CT and echo for 2 years
89390853|NCT01358513||Severe aortic stenosis|To undergo PET imaging and follow up with CT and echo for 2 years
89390854|NCT01351883|No Intervention|Standard enteral nutrition supplement|regular standard enteral nutrition(SEN) was made by hospital for patient
89390855|NCT03060980|Experimental|Experimental: Group 1|ITCA 650 20/60 mcg/day
89390856|NCT03060980|Experimental|Experimental: Group 2|Empagliflozin 10 mg/day and 25 mg/day
89390857|NCT03060980|Experimental|Experimental: Group 3|Glimepiride 1-6 mg/day
89390858|NCT01358591|Sham Comparator|Control Breakfast|Normal calcium breakfast.
89390859|NCT01358591|Experimental|High calcium breakfast|High calcium breakfast.
89390860|NCT01358747|Active Comparator|Standard arm|Induction treatment: Patients will be treated by a BEACOPPesc regimen every 3 weeks for 4 cycles. A PET will be performed after 2 cycles of chemotherapy (PET2) with no decisional value, and after 4 cycles with decisional value. Consolidation treatment: depends on the reviewed PET4 result. In case of PET4 negative result, patient will received 2 additional cycles of BEACOPPesc, whatever the result of the PET2. In case of PET4 positive, the patient will be considered in treatment failure and proposed to a salvage therapy after pathologic confirmation of failure by biopsy of the hypermetabolic residual mass when possible.
89390861|NCT01358747|Experimental|Experimental arm|"Induction treatment: Patients will be treated by a BEACOPPesc regimen every 3 weeks for 2 cycles followed by a PET scan (PET2).~After PET2 central review:~In case of positive PET2, the induction treatment will be completed by 2 additional cycles of BEACOPPesc~In case of negative PET2, the induction treatment will be completed by 2 cycles of ABVD delivered every 4 weeks. The first cycle of ABVD will start at day 21 of the second cycle of BEACOPPesc.~Consolidation treatment: depends on the reviewed PET4 result In case of PET4 negative result, consolidation treatment will depends on PET2 results:~If PET2 was positive, patient will received 2 additional cycles of BEACOPPesc delivered every 3 weeks~If PET2 was negative, patient will received 2 additional cycles of ABVD delivered every 4 weeks In case of PET4 positive, the patient will be considered as treatment failure."
88867261|NCT04982718|No Intervention|Control standard of care|In the control group, participants will receive information about standard of care HCV antibody testing available at local testing sites in their community and information about additional supporting materials, such as access to live chat and a call center for questions about testing.
88867262|NCT04956276|Experimental|Cohort 1: ALXN1830/Placebo|Participants will be randomized 3:1 to receive ALXN1830 or placebo. Treatment will be received for 8 weeks followed by a follow-up period (no treatment) for 8 weeks. Once complete, participants may continue participation in the study at the participant's and investigator's discretion during the OLE period for up to 2 years inclusive of primary treatment period.
89003636|NCT04908358|Other|cross-over Sham-Stimulation|Cross-over: Sham followed by experimental Respiratory-gated Auricular Vagal Afferent Nerve Stimulation (RAVANS) One time RAVANS versus one time Sham Two weeks wash-out
89390862|NCT03124459|Experimental|Part 1 Cohort 1|ACE-083 150 mg intramuscular (IM) (tibialis anterior muscle), once every 3 weeks for up to 5 doses.
89390863|NCT03124459|Experimental|Part 1 Cohort 2|ACE-083 200 mg IM (tibialis anterior muscle), once every 3 weeks for up to 5 doses.
89390864|NCT03124459|Experimental|Part 1 Cohort 3|ACE-083 up to 250 mg IM (tibialis anterior muscle), once every 3 weeks for up to 5 doses.
89390865|NCT03124459|Experimental|Part 2 (double-blind placebo controlled)|ACE-083 up to 250 mg IM (tibialis anterior muscle) or placebo, once every 3 weeks for up to 9 doses
89390866|NCT03124459|Experimental|Part 2 (open label)|ACE-083 up to 250 mg IM (tibialis anterior muscle), once every 3 weeks for up to 8 doses
89390867|NCT02081144|No Intervention|Control Condition|Control or Standard Care condition. No intervention will be provided.
89390868|NCT02081144|Experimental|Texting + NRT Condition|Enrollment in NCI's Smokefree TXT Program 4 weeks of Nicotine Replacement Patches 4 weeks of Nicotine Replacement Gum Faxed Referral CT Smokers Quitline
89390869|NCT01351961|Other|Elderly hypertensive patients with mnemonic subjective|"Elderly hypertensive patients with mnemonic subjective without dementia. Interventions :~blood sampling brain MRI Assessment of cognitive functions brain MRI and TEP cerebral Electrocardiogram and blood pressure Pulse wave velocity Quality of life questionnaire Urine sample Vascular explorations"
89390870|NCT02083328|Active Comparator|Caffeine|Caffeine will be administrated at a dosage of 6mg/kg of body mass. It is ingested once, one hour before the exercise performance test.
89390871|NCT02083328|Placebo Comparator|Mannitol (Placebo)|Placebo capsules will be administrated one hour before the exercise performance test. The subject gets exactly the same number of capsules as for the caffeine dosage. Caffeine and placebo capsules look the same.
89390872|NCT01354535|Active Comparator|Cable plating with strut|The plate will be placed laterally with the allograft strut placed on the anterior cortex. Screw fixation will be used distal to the stem and cables and screws will be used proximal to the stem tip. Cerclage cables or wires will be used to secure the strut.
89390873|NCT01354535|Active Comparator|isolated plating|A lateral thigh incision will be used to expose the fracture site. Surgeons will attempt to minimize devascularization of the bone by meticulous dissection and indirect reduction techniques. An appropriate sized plate will be applied to the lateral aspect of the femur. Fracture reduction will be achieved with the use of intra-operative fluoroscopy and the plate will be secured with locking screws.
89390874|NCT02079506|Experimental|Treatment A|
89390875|NCT02079506|Experimental|Treatment B|
89390876|NCT01370941|Active Comparator|Drug A: Chymosin|A: 5 drops of Chymosin is added to ½ a liter of milk. This is to be consumed during breakfast.
89390877|NCT01370941|Placebo Comparator|Drug B: Placebo|B: 5 drops of placebo (water) is added to ½ a liter of milk. This is to be consumed during breakfast.
89390878|NCT02081222||patients who underwent surgery for congenital heart disease|patients who underwent surgery for congenital heart disease in 2013 at Samsung Medical Center
89390879|NCT02940548|Active Comparator|Nifedipine GITS|Nifedipine GITS 30~60mg/day
89390880|NCT02940548|Active Comparator|Amlodipine besylate|Amlodipine besylate 5~10mg/day
89390881|NCT01366183||Observational (quality of life questionnaire)|"Patients receive chemotherapy comprising carboplatin, paclitaxel, and filgrastim (regimen 1) or carboplatin alone (regimen 2) every 21 days for 4 courses according to their physicians and/or patients' choice. Patients may undergo surgery and/or further chemotherapy at the discretion of treating physician. Patients undergo blood sample collection at baseline and periodically during course 1 for pharmacokinetic studies.~Patients' quality of life is assessed by the FACT-O, the FACT-Ntx subscale, the IADL, and the Ability to Complete Social Activity questionnaires at baseline, prior to courses 1 and 3, and then 3-6 weeks after completion of course 4. Nutritional status, such as body mass index and weight loss, and comorbidity and hearing impairment are also assessed."
89390882|NCT03134183|Experimental|Vaginal Misoprostol|Intervention is misoprostol versus placebo 400mcg misoprostol formulated within cocoa butter suppository
89390883|NCT03134183|Experimental|Buccal Misoprostol|Intervention is misoprostol versus placebo 400mcg misoprostol formulated within mint flavored powder
89390884|NCT01354613|Experimental|HFpEF|25 patients with clinically diagnosed heart failure with preserved ejection fraction, confirmed by Framingham criteria, with EF > 50% and without evidence of active ischemia or known severe CAD, valvular or pericardial disease, infiltrative or hypertrophic cardiomyopathy, cor pulmonale, severe pulmonary disease, or primary renal disease. Subjects will receive amlodipine, oral administration for a period of 12 weeks.
89390885|NCT01354613|Experimental|Pulmonary Disease|20 patients with pulmonary disease and no clinical evidence of cardiovascular disease
89390886|NCT01354613|Experimental|LVH/HTN|20 subjects with known left ventricular hypertrophy and clinically diagnosed hypertension without the diagnosis of heart failure.
89003637|NCT04904614|Other|single arm|Letermovir 480 mg daily for cmv prophylaxis
88867263|NCT04956276|Experimental|Cohort 2: ALXN1830/Placebo|Participants will be randomized 3:1 to receive ALXN1830 or placebo. Treatment will be received for 8 weeks followed by a follow-up period (no treatment) for 8 weeks. Once complete, participants may continue participation in the study at the participant's and investigator's discretion during the OLE period for up to 2 years inclusive of primary treatment period.
88867264|NCT04956276|Experimental|Cohort 3: ALXN1830|If initiated, participants will receive ALXN1830. Treatment will be received for 12 weeks followed by a follow-up period (no treatment) for 8 weeks. Once complete, participants may continue participation in the study at the participant's and investigator's discretion during the OLE period for up to 2 years inclusive of primary treatment period.
88867265|NCT04905342|Experimental|NVP-1805|NVP-1805 (80/10/20.8mg)
88867266|NCT04905342|Active Comparator|NVP-1805-R1 and NVP-1805-R2|coadministration of NVP-1805-R1(80mg) and NVP-1805-R2(10/20.8mg)
88867267|NCT04900116|Active Comparator|Group 1|In this group, US guided PENG block will be performed with 20 ml 0.5% bupivacaine using a 22 gauge 10 mm block needle.
88867268|NCT04900116|Active Comparator|Group 2|In this group, US guided PENG block will be performed with 20 ml 0.25% bupivacaine using a 22 gauge 10 mm block needle.
88867269|NCT04900116|Active Comparator|Group 3|In this group, US guided PENG block will be performed with 20 ml 0.125% bupivacaine using a 22 gauge 10 mm block needle.
88867270|NCT04900116|Placebo Comparator|Group 4|In this group, US guided PENG block will be performed with 20 ml saline solution (%0.9 NaCl) using a 22 gauge 10 mm block needle.
89390887|NCT01354613|Placebo Comparator|HFpEF placebo|25 patients with clinically diagnosed heart failure with preserved ejection fraction, confirmed by Framingham criteria, with EF > 50% and without evidence of active ischemia or known severe CAD, valvular or pericardial disease, infiltrative or hypertrophic cardiomyopathy, cor pulmonale, severe pulmonary disease, or primary renal disease. Subjects will be administered a placebo for a period of 12 weeks.
89390888|NCT02808494||Affected Group|Women with a diagnosis of preeclampsia with severe features and/or fetal growth restriction.
89390889|NCT02808494||Control/Unaffected Group|Women who do not have a diagnosis of preeclampsia with severe features and/or fetal growth restriction.
89390890|NCT01317719||Distal Biceps Ruptures|
89390891|NCT05189405||INVOcell IVC|IVF using intravaginal incubation with INVOcell device for embryo development.
89390892|NCT05189405||Traditional IVF (tIVF)|Traditional IVF using laboratory equipment and incubators for embryo development
89390893|NCT02083640|Other|Treatment A (Reference)|
89390894|NCT02083640|Other|Treatment B (Test)|
89390895|NCT02083640|Other|Treatment C (Test)|
89390896|NCT01352039|Experimental|Heparin Sodium - Eurofarma|
89390897|NCT01352039|Active Comparator|Heparin Sodium - APP Pharmaceuticals|
89390898|NCT02083718|Experimental|PBSC & MSCs|PBSC will be intravenously infused at a dose of 2×10^8/kg. MSCs will be intravenously infused at a dose of 1×10^6 cells/kg once per week. The vital signs of all patients will be closely monitored during and for 24h after administration.If the NEU and PLT levels do not attain the completely response(CR)standards within 28d, a second course of the same treatment will be given.
89390899|NCT05189327||Patients with diagnosed Nonspecific Ulcerative Colitis and Crohn Disease|All patients with diagnosed Nonspecific Ulcerative Colitis and Crohn Disease in the Republic of Kazakhstan.
89390900|NCT02083796|Experimental|Shoulder impingement_TSM|For the manipulation intervention, the subjects were in a seated position and a thrust technique was performed. If no cavitation was detected with the manipulation, the thrust was repeated up to 3 times.
89390901|NCT02083796|Sham Comparator|Shoulder impingement_sham|For the sham intervention, the subjects were positioned in the same seated position with the therapist holding the patient in the same position as for the thrust manipulation. In this position, the therapist applied all the same forces as done for a thrust-manipulation and held that position for a few seconds, but a thrust was not used.
89390902|NCT02083796|Active Comparator|Asymptomatic_TSM|For the manipulation intervention, the subjects were in a seated position and a thrust technique was performed. If no cavitation was detected with the manipulation, the thrust was repeated up to 3 times
89390903|NCT02083796|Sham Comparator|Asymptomatic_sham|For the sham intervention, the subjects were positioned in the same seated position with the therapist holding the patient in the same position as for the thrust manipulation. In this position, the therapist applied all the same forces as done for a thrust-manipulation and held that position for a few seconds, but a thrust was not used.
89390904|NCT01363921|Experimental|Dialysis treatment with HCO1100|
89390905|NCT02079818|Experimental|Penumbra Ruby Coil System|
89390906|NCT01358903|Experimental|A|
89390907|NCT01358903|Experimental|B|
89390908|NCT01366261|Experimental|semirigid thoracoscopy|Semirigid instrument which we compare was autoclavable Olympus LTF-160 (Olympus Tokyo, Japan). Handle and its controls were similar to flexible fiberoptic bronchoscope, with the insertion portion composed of 22 cm long rigid part and distal 5 cm flexible tip with angulation range 1600 up / 1300 down. The external diameter of insertion portion was 7 mm with 2,8 mm inner channel diameter. The instrument was compatible with Olympus EVIS Exera 160 and 145 and EVIS 100 and 140 video processors and light sources, otherwise employed in video-bronchoscopy. Forceps, which we used was flexible FB-55CD-1 Olympus forceps with 5 mm long cusps and diameter, which fitted the diameter of inner channel of semirigid thoracoscope.
89390909|NCT01366261|Active Comparator|rigid thoracoscopy|The rigid instrument was autoclavable OP EndoEYE WA50120A (Olympus Tokyo, Japan) video thoracoscope. The length of the instrument was 29 cm with 00 direction of view and 700 field of view. The external diameter of the instrument was 10 mm with 5,2 mm inner channel diameter. The instrument was compatible with Olympus Visera OTV-S7V and EVIS Exera II CV-180 video processors. Cusps of rigid forceps had outer diameter 5 mm and length 10 mm.
88867271|NCT04690530||patients admitted in medical intensive care unit who require mechanical ventilation and sedation|The main goals of the study are to characterize cerebral hemodynamics and oxygenation as well as to study the effects of therapeutics on it in critically-ill patients. For this purpose, we plan to include all consecutive patients admitted in our medical intensive care unit who require mechanical ventilation and sedation and in whom the attending physician decides to perform one of the studied therapeutics (fluids, vasopressors or inotropes administration, blood transfusion, prone positioning, passive leg raising test, end-expiratory occlusion test) within the first 72h of ventilation onset. Cerebral hemodynamics (cerebral blood flow and cerebral autoregulation) as well as cerebral oxygenation will be non-invasively studied before and after therapeutics.
88867272|NCT04603248|Experimental|Single Arm|
88867273|NCT04481490||Home-based|Cardiac rehabilitation (including exercise training) delivered in a home-based setting, facilitated remotely by Mayo Clinic staff.
89390910|NCT02087930||Cow milk allergy children|Children affected by Immunoglobulin E medited cow milk allergy
88867274|NCT04481490||Center-based|Cardiac rehabilitation (including exercise training) delivered in a center-based setting, facilitated in person by Mayo Clinic staff.
89186646|NCT02559921|Experimental|rhRIG（20 IU/kg）only|Subjects received rhRIG（20 IU/kg） on day 0
89186647|NCT02559921|Experimental|rhRIG（40 IU/kg）only|Subjects received rhRIG（40 IU/kg） on day 0
89390911|NCT02087930||healthy control|healthy infants
89390912|NCT03136367|Experimental|Arm 1: Option Grid|Patients in this arm will receive the Option Grid for breast cancer surgery, an encounter decision aid, when they first meet with the breast surgeon to discuss their surgical options for breast cancer treatment.
89390913|NCT03136367|Experimental|Arm 2: Picture Option Grid|Patients in this arm will receive the Picture Option Grid for breast cancer surgery, an encounter decision aid, when they first meet with the breast surgeon to discuss their surgical options for breast cancer treatment.
89390914|NCT03136367|No Intervention|Arm 3: Usual Care|In the usual care arm, surgeons provided their standard information about breast cancer
89390915|NCT04419337|Experimental|Active arm|metformin+pioglitazone+an SGLT2 inhibitor
89390916|NCT04419337|Active Comparator|Control arm|metformin + DPP4 inhibitors
89390917|NCT03124381|Active Comparator|Acne Mask|Cleanser, Acne Mask
89390918|NCT03124381|Experimental|Gel-Cream + Acne Mask|Cleanser, Gel-Cream, Acne Mask
89390919|NCT01359059|Active Comparator|IV-PCA (Patient-controlled analgesia) morphine|
89390920|NCT01359059|Active Comparator|Patient controlled epidural analgesia (PCEA) fentanyl|
88867275|NCT04340700|Experimental|THC|A standard dose of THC (8 mg or 2 mg) will be placed in a Volcano Vaporizer chamber. The first THC dose is 8 mg, followed by approximately three doses of 2 mg each.
89390921|NCT01354769||Non-intubated patients|
89390922|NCT01354769||Intubated patients|
89390923|NCT01352273|Experimental|MEK162 + RAF265|
89390924|NCT01352351|Experimental|Breastfeeding promotion intervention|"Intervention:~Group breastfeeding counseling during monthly microcredit borrower group meetings~Weekly cell phone messages about breastfeeding"
89390925|NCT01352351|No Intervention|No intervention|The no intervention group will participate in their regular microcredit borrower group meetings, but will not receive breastfeeding counseling or cell phone messages.
89390926|NCT01371019||Women with preterm delivery|
89390927|NCT01371019||Women without preterm delivery|
89390928|NCT05189093|Experimental|phase I dose escalation part,Phase II efficacy exploratory part and the efficacy confirmation part|"In the phase I dose escalation part,with a standard 3+3 dose escalation design, the enrollment will proceed until the MTD has been defined or the highest dose level has been reached.~5 cohorts will be carried out in parallel in the phase II efficacy exploration part: Cohort 1: Relapsed/refractory diffuse large B-cell lymphoma; Cohort 2: Relapsed/refractory peripheral T-cell lymphoma; Cohort 3: Relapsed/refractory classic Hodgkin's lymphoma; Cohort 4: Relapsed/refractory mantle cell lymphoma; Cohort 5: Relapsed/refractory follicular lymphoma and marginal zone lymphoma; In the efficacy exploration part, each cohort will enroll 15 subjects, a total of 5 cohorts, and 75 cases are expected to be enrolled.~In the phase II efficacy confirmation part, one or two indications with better safety and efficacy among the 5 cohorts in the efficacy exploration phase will be selected."
89390929|NCT03620279|Experimental|Magic camp intervention|These children are diagnosed with cerebral palsy and we will provide motor control training.
89390930|NCT04006717|No Intervention|Control|Routine root canal treatment
89390931|NCT04006717|Placebo Comparator|Low-Level Laser Placebo|Patient informed that laser will be applied but device won't be turned on
88867276|NCT04340700|Placebo Comparator|Placebo|Placebo will also be administered through a Volcano Vaporizer via inhalation. The first placebo dose is 8 mg, followed by approximately three doses of 2 mg each to match the THC procedures.
89390932|NCT04006717|Experimental|Low-Level Laser Therapy|Low-Level Laser Therapy following root canal treatment
89390933|NCT04006717|Experimental|Intracanal Cryotherapy|Cold saline irrigation before obturation
89390934|NCT04006717|Experimental|Combination of LLLT and ICCT|Both cold saline irrigation before obturation and Low-level laser Therapy after root canal treatment
89390935|NCT01318343||Treatment Group 1|Eight (8) subjects will receive one (1) treatment with the eZ8 Large Applicator.
88867277|NCT04213248|Experimental|UMSC-exo treatment|Participants will receive artificial tears for 2 weeks to get the normalized baseline, followed by UMSC-exo intervention for 2 weeks.
88867278|NCT03878394|Experimental|Group 1|The first group will be prescribed aerobic exercise and balance exercises as home exercise. Participants in this group will perform 30 min moderate walking exercises and balance exercises. Balance exercises shall consist of feet static stops for 30 second , one leg stance for 30 second, standing at tandem position for 30 second and uplift exercises at the fingertips for 30 second. Exercises will be held once a day for 3 days per week over 6 weeks.
88867279|NCT03878394|Experimental|Group 2|The second group will be prescribed cognitive tasks combined with aerobic exercise and balance exercises as home exercises. Participants in this group will have 30 minutes of moderate intensity exercise and cognitive tasks combined with balance exercises. Participants will be asked to count backwards from 20 during the walk and then count back the days of the week back and repeat it for 30 minutes. Balance exercises shall consist of feet static stops for 30 second , one leg stance for 30 second, standing at tandem position for 30 second and uplift exercises at the fingertips for 30 second. Patients will be asked to count backwards from 20 to count the days of the week backwards during balance exercises. Exercises will be held once a day for 3 days per week over six weeks. Participants will be called by the researcher on the days of the exercise and the participant's compliance with the exercise program will be checked.
88867280|NCT03763656|Experimental|Open Label|Novel oral solution formulation of hydroxyurea
88867281|NCT03419676|No Intervention|Control|No reinforcement.
88867282|NCT03419676|Experimental|Hemopatch|Reinforcement with Hemopatch.
88867283|NCT03166722|Experimental|Study group: Invos 5100|"Supplemental oxygen support and respiratory/circulatory support is guided by cerebral regional tissue oxygenation (crSO2) measured with near-infrared spectroscopy (INVOS 5100 ), in addition to the SpO2/HR (oxygen saturation/heart rate) monitoring according to routine."
89390936|NCT01318343||Treatment Group 2|Eight (8) subjects will receive two (2) treatments two (2) months apart with the eZ8 Large Applicator.
88867284|NCT03166722|Active Comparator|Control group: Routine care|Supplemental oxygen support and respiratory/circulatory support is guided by SpO2/HR monitoring according to routine - The resuscitation team is blinded to the crSO2 monitoring.
89390937|NCT01318343||Treatment Group 3|Four (4) subjects will receive one (1) treatment, six (6) months after the previous treatment with the eZ App 8 large applicator to the abdomen. This is the same applicator that is being evaluated in this study. These subjects have been treated on-site at the Laser & Skin Surgery Center of New York by the study doctor.
89390938|NCT01371097|No Intervention|Control Group|
89390939|NCT01371097|Experimental|Treatment group|
89390940|NCT01371175|Experimental|Group A|DNA or Placebo delivered intramuscularly at Months 0 and 1 followed by MVA or Placebo at Months 5 and 8 delivered subcutaneously. Vaccine:Placebo =12/3
89390941|NCT01371175|Experimental|Group B|DNA or Placebo delivered intramuscularly at Months 0 and 1 followed by MVA or Placebo at Months 5 and 8 delivered intramuscularly. Vaccine:Placebo =12/3
89390942|NCT01371175|Experimental|Group C|DNA or Placebo delivered intramuscularly at Months 0 and 1 followed by MVA or Placebo at Months 5 and 8 delivered intradermally. Vaccine:Placebo =18/3
89390943|NCT01371175|Experimental|Group D|DNA or Placebo delivered intramuscularly at Months 0 and 1 followed by MVA or Placebo at Months 5 and 8 delivered subcutaneously. Vaccine:Placebo =12/3
89390944|NCT01371175|Experimental|Group E|DNA or Placebo delivered intramuscularly at Months 0 and 1 followed by MVA or Placebo at Months 5 and 8 delivered intramuscularly. Vaccine:Placebo =12/3
89390945|NCT01371175|Experimental|Group F|DNA or Placebo delivered intramuscularly at Months 0 and 1 followed by MVA or Placebo at Months 5 and 8 delivered subcutaneously. Vaccine:Placebo =12/3
89390946|NCT01371175|Experimental|Group G|DNA or Placebo delivered intramuscularly at Months 0 and 1 followed by MVA or Placebo at Months 5 and 8 delivered intramuscularly. Vaccine:Placebo =12/3
89390947|NCT01371175|Experimental|Groups C2/D2/E2 (Subgroups of C,D,E)|DNA or Placebo delivered intramuscularly at Months 0 and 1 followed by MVA or Placebo at Months 5 and Month 12+ (volunteers offered second MVA/placebo more than 12 months (late boost) after their enrollment into their original treatment assignment) delivered ID, SC, or IM according to original randomization. Vaccine:Placebo = blinded ratio, maximum in C2/D2/E2 = 16.
89390948|NCT01371175|Experimental|Group F2/G2 (Subgroup of F and G)|DNA or Placebo delivered intramuscularly at Months 0 and 1 followed by MVA or Placebo at Months 5 and Month 12+ (volunteers offered second MVA/placebo more than 12 months (late boost) after their enrollment into their original treatment assignment) delivered either SC or IM according to original randomization. Vaccine:Placebo = blinded ratio, maximum in F/G= 29.
89390949|NCT04208815|Experimental|MPL-rich dairy beverage|Daily consumption of 100 g of dairy powder containing 5.3 g MPL for 4 weeks
89390950|NCT04208815|Placebo Comparator|Control dairy beverage|Daily consumption of 100 g of dairy powder containing 0.3 g MPL for 4 weeks
89390951|NCT01371253|Experimental|Nintendo Wii traning|Balance training
89390952|NCT01371253|Placebo Comparator|EVA-soles|
89390953|NCT01371331|Experimental|Tacrolimus granules|oral
89390954|NCT03972865|Experimental|Participants of the race|Participants of the race are healthy triathlete volunteers who will participate in August 2019 in the Embrun (EmbrunMan) long-distance triathlon (Ironman)
89390955|NCT01366339|Experimental|Arm 1|Oral methylnaltrexone
89390956|NCT01366339|Experimental|Arm 2|Oral methylnaltrexone
88867285|NCT02682888|Experimental|high trait anxiety group|experiment 1: identified according to scores of the trait anxiety scale.
89390957|NCT01366339|Experimental|Arm 3|Oral methylnaltrexone
89390958|NCT01366339|Placebo Comparator|Arm 4|Oral placebo
89390959|NCT03133793|Placebo Comparator|Placebo Only|Participants in this group will receive placebo pills and placebo powder.
89390960|NCT03133793|Active Comparator|CoQ10 Only|Participants in this group will receive CoQ10 pills and placebo powder
89390961|NCT03133793|Active Comparator|D-ribose Only|Participants in this group will receive placebo pills and D-ribose oral powder.
88867286|NCT02682888|Experimental|low trait anxiety group|experiment 1: identified according to scores of the trait anxiety scale.
88867287|NCT02682888|Experimental|oxytocin group|experiment 2: intranasal administration of oxytocin
88867288|NCT02682888|Placebo Comparator|placebo control group|experiment 2: intranasal administration of placebo
89390962|NCT03133793|Experimental|CoQ10 + D-ribose|Participants in this group will receive CoQ10 pills and D-ribose oral powder.
88867289|NCT02641236|Active Comparator|Gut Decontamination with vancopoly|"All eligible participants will be randomized to either Arm A: Gut Decontamination or Arm B: No Gut Decontamination.~Participants assigned to this arm will receive non-absorbable, oral vancomycin-polymyxin B as per our institutional standard practice."
89390963|NCT05190601||Group 1|Enuresis nocturna with children
89390964|NCT01318421|Experimental|ELND002|ELND002 sc injection
89390965|NCT05190367||No trauma|Patients suffering from chronic pain without traumatic life events
88867290|NCT02641236|No Intervention|No Gut Decontamination|"All eligible participants will be randomized to either Arm A: Gut Decontamination or Arm B: No Gut Decontamination.~Participants assigned to this arm will not receive oral vancomycin-polymyxin B, but all other HSCT supportive care will be the same as for patients in Arm A."
88867291|NCT02402088|Active Comparator|Normal Weight|BMI18.5-24.9 (normal range)
88867292|NCT02402088|Experimental|Overweight|body mass index between 25.0 - 29.9 (overweight range)
89390966|NCT05190367||Accidental trauma|Patients suffering from chronic pain who have experienced at least one accidental trauma
89390967|NCT05190367||Interpersonal trauma|Patients suffering from chronic pain who have experienced at least one interpersonal trauma
89390968|NCT05190367||PTSD|Patients suffering from chronic pain and diagnosed with PTSD
89390969|NCT01361321||patients after GBR procedure|The study will comprise of patients who already underwent a routine Guided Bone Regeneration (GBR) procedure in order to augment a bony ridge before dental implant insertion. The patients will be followed up in order to determine bone quality and quantity formed after the usage of routinely used bone substitutes during GBR procedure.
89390970|NCT02747238|Active Comparator|Ultrasound|Woman requests epidural for pain relief Ultrasound guided CSE placed Continuous epidural infusion started
89390971|NCT02747238|Active Comparator|No ultrasound|Palpation of anatomical landmarks Woman requests epidural for pain relief CSE placed using palpation of anatomical landmarks Continuous epidural infusion started
89390972|NCT03133481|Active Comparator|Adductor Canal Nerve Block|Participants will be randomized using block randomization.
89390973|NCT03133481|Active Comparator|Femoral Nerve Block|Participants will be randomized using block randomization.
89390974|NCT01366573|Experimental|GSK1521498 &amp; alcohol|GSK1521498 20 mg and alcohol (0.5g/kg ethanol mixed with orange juice)
88867293|NCT02402088|Experimental|Obese|body mass index between 30 and 35 (obese range)
88867294|NCT00821886|Experimental|Ixabepilone/Trastuzumab/Carboplatin|Neoadjuvant treatment with Ixabepilone, Trastuzumab and Carboplatin, followed by surgery, peri-operative treatment and post-operative (adjuvant) treatment if patient deemed to be a surgical candidate
89003638|NCT04903483|Other|target-controlled infusion (propofol) with depth of anesthesia monitoring|In this group, propofol dosing is adjusted with bispectral index monitoring.
89390975|NCT01366573|Experimental|GSK1521498 & orange juice|GSK1521498 20 mg and orange juice approximately matching alcoholic beverage for volume and colour
89390976|NCT01366573|Experimental|Placebo &amp; alcohol|Placebo and alcohol (0.5g/kg ethanol mixed with orange juice)
89390977|NCT01366573|Placebo Comparator|Placebo &amp; orange juice|Placebo and orange juice approximately matching alcoholic beverage for volume and colour
89535371|NCT04433793|No Intervention|Waitlist-control group|Patients in the waitlist-control group will receive no intervention at first, but nine weeks after IG, they will get the opportunity to also receive yoga therapy for 8 weeks.
89535372|NCT03207139|Experimental|Ga-68 PSMA ligand|Diagnostic performance of [Ga68] PSMA-11
89390978|NCT01366651|Experimental|Doripenem|Doripenem Type=exact number unit=mg/kg number=10 form=solution for injection route=intravenous use every 8 hours for 2 days (total of 5 doses) for patients <12 weeks of age.Doripenem 500-mg sterile powder will be supplied for the study in single use glass vials.,Doripenem Type=exact number unit=mg/kg number=30 form=solution for injection route=intravenous use every 8 hours for 2 days (total of 5 doses) for patients 12 weeks to <1 year of age. Doripenem 500-mg sterile powder will be supplied for the study in single use glass vials.
89390979|NCT05190289||Compared Group|Patients without inferior clinical outcomes
89390980|NCT05190289||Case Group|Patients with inferior clinical outcomes
89390981|NCT05124509||Three doses of BNT162b2 vaccine|Solid organ transplant patients who received three doses of BNT162b2
89390982|NCT05124509||Two doses of Coronavac and one of BNT162b2 vaccine|Solid organ transplant patients who received two doses of CoronaVac and one dose of BNT162b2
89390983|NCT02864316|Experimental|Radiation-Induced Metastatic Sarcoma|a flat dose of Nivolumab 240 mg will be administered intravenously every 2 weeks until disease progression.
89390984|NCT02864316|Experimental|Radiation-Induced Non-Sarcoma Metastatic Solid Tumors|a flat dose of Nivolumab 240 mg will be administered intravenously every 2 weeks until disease progression.
89390985|NCT03941509|No Intervention|Control|All facilities will receive usual care during the control phase of the trial.
89390986|NCT03941509|Experimental|Antimicrobial stewardship|Implementation of the nurse-led bundled antimicrobial stewardship intervention
89390987|NCT01319201||Impaired glucose regulation|This group of subjects was diagnosed as impaired glucose regulation using oral glucose tolerance test.
89390988|NCT01319201||Type 2 diabetes|This group of subjects was diagnosed as type 2 diabetes using oral glucose tolerance test.
89390989|NCT01319201||Normal glucose regulation|This group of subjects was considered normal regarding glucose metabolism using oral glucose tolerance test.
89390990|NCT01364077|Active Comparator|Ivabradine|
89390991|NCT01364077|Placebo Comparator|Control|
88867295|NCT00821964|Experimental|Treatment (biological therapy, chemo)|Patients receive Abraxane IV over 30 minutes on days 1, 8, and 15 and apply topical imiquimod to cutaneous lesions QD on days 1-4, 8-11, 15-18, and 22-25. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
89390992|NCT05190133|Experimental|Treatment A|
88867296|NCT00822354|Experimental|1|Subjects will receive tadalafil 20mg every other day for the first month, and then placebo for the second month.
88867297|NCT00822354|Experimental|2|Subjects will receive placebo for the first month, and tadalafil 20mg orally every other day for the second month.
88867298|NCT00822510|Experimental|Telephone Interpersonal Counseling|Telephone delivered interpersonal counseling support intervention. Intervention was for 8 weeks. Participants were called on the telephone each week for about 30 minutes.
89390993|NCT05190133|Experimental|Treatment B|
89390994|NCT02862600|Experimental|Perhexiline|Perhexiline will be administered orally. Dosing will be determined based on plasma level monitoring. For the first 8 week period, the target range will be 100-300 ng/mL, for the second 8 week period, the target range will be 300-500 ng/mL.
89390995|NCT01359137|Experimental|Probation as usual|Routine supervision with no deferred jail condition.
89390996|NCT01359137|Experimental|Deferred jail|Discretionary deferred jail in response to violations of probation conditions.
89390997|NCT01359137|Experimental|Arizona's SAFE|Swift Accountable Fair Enforcement (SAFE) which uses non-discretionary brief jail sanctions for probation violations.
89390998|NCT01364155|Experimental|600 mg LIM-0705 BID for 28 days|
89390999|NCT01364155|Placebo Comparator|Placebo LIM-0705 for 28 days|
89391000|NCT01359215||Treatment|Children who received an anesthetic prior to age 2
89391001|NCT01359215||Control|Children who have never been anesthetized
89391002|NCT05189899|Active Comparator|With virtual reality|One hemodialysis session with virtual reality
89391003|NCT05189899|No Intervention|without virtual reality|One hemodialysis session without virtual reality
89391004|NCT01354847||cardiac surgery patients|cardiac surgery patients scheduled for elective complex cardiac surgery
89391005|NCT03767101|Experimental|TAU + Positive mental imagery|In all conditions the first eight sessions of treatment are focused. All sessions start with a brief, audio-tape presented positive mental imagery intervention (duration about six minutes). In this intervention patients are guided to imagine a happy, positive situation within the last seven days. Patients get the instruction to imagine from a field perspective, exploring various sensory modalities and feelings in that specific moment. Patients perform this task in the rooms of the treatment center together with their therapists. The text of the mental imagery intervention is standardized and spoken by Prof. Dr. Ulrike Willutzki. Directly before and after the imagination patients are asked on their mood with a single-item. After the short intervention patients are instructed to communicated the content of their imagination with their therapists for about one minute. After completion the regular cognitive behavioral therapy session begins.
88867299|NCT00822510|Active Comparator|Telephone delivered education only|Telephone delivered education only. Educational topics included prostate cancer health, side effects, physical activity, diet. Participants were called on the telephone each week for about 30 minutes.
88867300|NCT00822588|Experimental|1|
88867301|NCT00822588|No Intervention|2|
88867302|NCT00824070|Experimental|Besifloxacin|Besifloxacin ophthalmic suspension
88867303|NCT00824070|Active Comparator|Moxifloxacin|Vigamox (moxifloxacin ophthalmic solution, 0.5%)
88867304|NCT00824070|Active Comparator|Gatifloxacin|Zymar (gatifloxacin ophthalmic solution, 0.3%)
88867305|NCT00824460|Experimental|1.25 g PA21|
88867306|NCT00824460|Experimental|5.0 g PA21|
88867307|NCT00824460|Experimental|7.5 g PA21|
88867308|NCT00824460|Experimental|10.0 g PA21|
88867309|NCT00824460|Experimental|12.5 g PA21|
88867310|NCT00824460|Experimental|Sevelamer hydrochloride - active control|
88867311|NCT00824538|Experimental|sunitinib|Study to evaluate the effect of sunitinib (37.5 mg/day orally for 6 months) on occult tumor cells in the bone marrow of patients with high risk early stage breast cancer
88867312|NCT00825318|Experimental|Daily ultrafiltration|During the treatment phase of the study, the subject will undergo ultrafiltration 6 times a week and hemodialysis 2 times a week.
89391006|NCT03767101|Active Comparator|TAU + Neutral mental imagery|In all conditions the first eight sessions of treatment are focused. All sessions start with a brief, audio-tape presented neutral mental imagery intervention (duration about six minutes). In this intervention patients are guided to imagine a all-day, non-emotional provoking situation within the last seven days. Patients get the instruction to imagine from a field perspective, exploring various sensory modalities in that specific moment. Patients perform this task in the rooms of the treatment center together with their therapists. The text of the mental imagery intervention is standardized and spoken by Prof. Dr. Ulrike Willutzki. Directly before and after the imagination patients are asked on their mood with a single-item. After the short intervention patients are instructed to communicated the content of their imagination with their therapists for about one minute. After completion the regular cognitive behavioral therapy session begins.
89535373|NCT03319433||Group I (Perfusion Index <3.5)|Those parturient with perfusion index <3.5 when baseline monitors are attached while the patient is being prepared for surgery.
88867313|NCT00825786|Active Comparator|Group 1|combined group: ropivacaine and mepivacaine mixture: 1:1 volume mixture of 1.5% mepivacaine and 0.5% ropivacaine in 2 syringes (labeled 1 and 2) with 15 mL in each (total, 30 mL) injected in immediate sequence;
88867314|NCT00825786|Active Comparator|Group 2|sequential group: mepivacaine followed by ropivacaine: syringe 1 containing 15 mL of 1.5% mepivacaine, syringe 2 containing 15 mL of 0.5% ropivacaine (total, 30 mL); syringe 2 was injected with a 90-sec delay after injection of syringe 1.
88867315|NCT00826800|Experimental|Neoadjuvant FOLFOX Plus Bevacizumab|FOLFOX and bevacizumab will be given to colon cancer patients for 4 cycles over 8 weeks; an additional 2 cycles of FOLFOX without bevacizumab will be given for a total of 12 weeks of pre-operative chemotherapy.Restaging will be performed within 3 weeks of the 6th chemotherapy cycle. Colon surgery will be performed between weeks 3 and 6 subsequent to the 6th cycle of FOLFOX. Patients receiving preoperative chemotherapy without radiation will wait a minimum of 3 weeks from their last dose of chemotherapy, and 6 weeks from their last dose of bevacizumab, before proceeding to surgery. Specifically, it is intended that patients will undergo surgery between 3-6 weeks from completion of their neoadjuvant therapy as deemed clinically appropriate by their surgeon and medical oncologist. This permits a 7-10 week interval between the 4th bevacizumab administration and colon surgery.
88867316|NCT00830076|Experimental|Sitagliptin + placebo metformin|
88867317|NCT00830076|Experimental|Metformin + placebo sitagliptin|
88867318|NCT00830076|Experimental|Sitagliptin + metformin|Co-administration of sitagliptin and metformin
88867319|NCT00830076|Placebo Comparator|Placebo sitagliptin + placebo metformin|Co-administration of placebo to sitagliptin and placebo to metformin
88867320|NCT00830232|Active Comparator|Closed-cell stent (Xact stent)|For patients randomized to the closed-cell stent group, the Xact closed-cell stents were used. The Xact stent is a FDA approved device.
88867321|NCT00830232|Active Comparator|Open-cell stent (Acculink carotid)|For patients randomized to the open-cell stent group, the Acculink carotid stent was used. The Acculink stent is a FDA approved device.
88867322|NCT00830310|Experimental|Customized Adherence Enhancement (CAE)|"Participants will be assigned to receive one or more of the study interventions based upon the participant's responses on the Attitudes toward Mood Stabilizers Questionnaire (AMSQ) and reasons for non-adherence on the Rating of Medication Influences (ROMI).~Individuals will participate in a series of 4 60-minute sessions over a 4-week period, with the study therapist who will implement the module-based intervention. The number of modules may differ depending on the baseline adherence profile of the participant.~An intervention manual developed by the investigators will provide explicit guidelines regarding how modules may be co-administered in single or multiple sessions to minimize redundancy as well as time and effort burden on study participants. The manual for each module will specifically address how any module could be combined with the other modules."
88867323|NCT00830388|Experimental|Ketoconazole 2% Foam|Open-label study
88867324|NCT00831480|Experimental|1|All subjects will take everolimus
88867325|NCT00832338|Experimental|Docetaxel with Cytoxan|Patients will be treated with docetaxel at 75 mg/m² concomitantly with cytoxan 600 mg/m² (TC) IV D1 every 3 weeks for 6 cycles. Due to known toxicity of docetaxel, all patients require dexamethasone 4 mg twice daily (BID) PO for 3 consecutive days starting 12-24 hours prior to each dose of docetaxel to minimize hypersensitivity reactions and fluid retention.
88867326|NCT00834210|Active Comparator|1|Dapsone Gel 5% and Tazarotene Cream 0.1%
88867327|NCT00834210|Active Comparator|2|Tazarotene Cream 0.1%
88867328|NCT00834288|Experimental|1: 1x200 mg Tramadol HCl OAD tablet daily|
88867329|NCT00834288|Active Comparator|2: 1x50 mg Tramadol HCl IR (Ultram®) tablet 6-hourly|
88867330|NCT00834678|Experimental|Bendamustine and Erlotinib|Bendamustine 100 or 120 mg/m2 IV on days 1 and 2 and erlotinib 100 or 150 mg po on days 5 - 21 of each 28 day cycle.
88867331|NCT00835224|Experimental|Midodrine|A drug to treat low blood pressure.
88867332|NCT00835224|Experimental|L-Name|L-Name: A non-selective inhibitor of nitric oxide synthase and placebo. It has been used experimentally to induce hypertension.
88867333|NCT00835224|Placebo Comparator|Placebo|Placebo: A pill with an inactive substance that looks like the study drug.
88867334|NCT00835926|Experimental|Fluzone® Vaccine Group 1|Participants aged 18 to 59 years at enrollment - Fluzone® Group
88867335|NCT00835926|Experimental|Fluzone® Vaccine Group 2|Participants aged 60 years and older at enrollment - Fluzone® Group
88867336|NCT00837252|Experimental|Finasteride|
88867337|NCT00839982|Experimental|Treatment (chemotherapy)|Patients receive clofarabine PO QD on days 1-5 and low-dose cytarabine SC BID on days 1-10 or SC QD on days 1-14. Treatment repeats every 21-28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
88867338|NCT00842946|Experimental|Exposure w/ Acceptance-Based Rationale|Behavioral exposure within the context of psychological acceptance.
88867339|NCT00842946|Active Comparator|Exposure w/ Habituation-Based Rationale|Behavioral exposure within the context of habituation.
88867340|NCT00843180|Experimental|massage|
88867341|NCT00843180|No Intervention|control|usual care only as control arm
88867342|NCT00845130|Experimental|Diabetic Type II Subjects|Subjects received ascorbic acid (Vitamin C) infusion 1 g/kg (maximum 100gm
89391007|NCT03767101|Other|Treatment as usual|In all conditions the first eight sessions of treatment are focused. No additional intervention is conducted at the start of therapy sessions. Standard cognitive behavioral therapy is conducted during the whole treatment sessions.
88867343|NCT00845130|Experimental|Healthy Subjects|Subjects received ascorbic acid (Vitamin C) infusion 1 g/kg (maximum 100gm
88867344|NCT00848016|Experimental|Treatment (R-(-)-gossypol acetic acid)|Patients receive 20mg oral R-(-)-gossypol acetic acid once daily on days 1-21. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
88867345|NCT00848172|Active Comparator|Octanoic Acid|
88867346|NCT00848172|Placebo Comparator|Placebo|
88867347|NCT00849810|Experimental|Metoprolol to nebivolol|metoprolol 25-200mg at a stable daily dose for 4 weeks, then change to nebivolol at a comparable stable dose (5-20 mg) for 4 -5 weeks.
88867348|NCT00856050|Experimental|letrozole|single arm trial - all patients received letrozole 2.5mg by mouth per day
88867349|NCT00857532|Experimental|Normal cognitive performance|Subjects with age-and education-adjusted standardized Mattis Dementia Rating Scale scores of ≥9, indicating normal cognitive performance.
88867350|NCT00857532|Experimental|Mild cognitive deficits|Subjects with age-and education-adjusted standardized Mattis Dementia Rating Scale scores between 6 and 8, inclusive, indicating mild cognitive deficits.
88867351|NCT00857532|Experimental|Severe cognitive impairment|Subjects with age-and education-adjusted standardized Mattis Dementia Rating Scale scores below 5, indicating moderate to severe cognitive impairment.
88867352|NCT00858390|No Intervention|1 standard care|organ donors receiving standard care
88867353|NCT00858390|Experimental|2 Enteral Feeding|enteral feeding with Oxepa® and RESOURCE® GLUTASOLVE®
88867354|NCT00858468|Experimental|Group 1|Participants aged 6 to 12 Weeks at enrollment
88867355|NCT00858468|Experimental|Group 2|Participants aged 24 to 36 Weeks at enrollment
88867356|NCT00858858|Experimental|Arm 1|All patients are treated with DCA and UDCA perfusion of the esophagus, one year apart, followed by 8 weeks of treatment with oral ursodeoxycholic acid 10 mg/kg qd. Then a final DCA perfusion of the esophagus.
88867357|NCT00859950|Active Comparator|Sleep Apnea|Subjects found to have Obstructive Sleep Apnea (OSA) with Intermittent Hypoxemia (IH). This arm will undergo a pre-treatment blood draw, one month of Continuous Positive Airway Pressure (CPAP) to treat OSA, and a post-treatment blood draw.
88867358|NCT00859950|No Intervention|Normal Control|Subject found to have no evidence of Obstructive Sleep Apnea (OSA) after Nocturnal Polysomnography (NPSG). These subjects will only undergo a blood draw and will not have the Continuous Positive Airway Pressure (CPAP) treatment.
88867359|NCT00862446|Experimental|Treatment|All infants will receive Omegaven
88867360|NCT00864084|Experimental|Pulmonary rehabilitation|People with respiratory disease
88867361|NCT00864708|Experimental|Arm 1|radio frequency-controlled (RF) Microstimulator (RFM) Gait System
88867362|NCT00866034|Experimental|CD2|Early fixed start of a daily dose of 0.25mg Cetrotide on cycle day 2, together with the initiation of daily treatment with exogenous gonadotropins.
88867363|NCT00866034|Experimental|CD6|Late fixed start of a daily dose of 0.25mg Cetrotide on cycle day 6. As in the other arm of the study, exogenous gonadotropins will commence on cycle day 2.
88867364|NCT00868140|Experimental|1/Pioglitazone|Pioglitazone in pill form at 45mg twice per day for 6 months
88867365|NCT00868140|Placebo Comparator|2/Placebo|Placebo control to arm 1 in pill form identical to treatment form also twice per day for 6 months
88867366|NCT00868218|Active Comparator|1|30µg HA vaccine Intramuscularly administered
88867367|NCT00868218|Active Comparator|2|1.5µg HA adjuvanted with 50µg 3rd generation ISCOM™ Intramuscularly administered
88867368|NCT00868218|Active Comparator|3|7.5µg HA adjuvanted with 50µg 3rd generation ISCOM™ Intramuscularly administered
89186648|NCT02559921|Active Comparator|HRIG（20 IU/kg）only|Subjects received HRIG（20 IU/kg）on day 0
89186649|NCT02559921|Experimental|rhRIG（20 IU/kg）+ vaccine|Subjects received rhRIG（20 IU/kg）in combination with rabies vaccine for human use on day 0 and received vaccine only on days 3,7,14,28
89391008|NCT01359527||Hip Resurfacing|
89391009|NCT01359527||Total Hip Arthroplasty|
89391010|NCT01354925|Active Comparator|Insulin treatment during Ramadan|Insulin analogs will be used: Levemir and NovoMix70. .
88867369|NCT00868218|Active Comparator|4|30µg HA adjuvanted with 50µg 3rd generation ISCOM™ Intramuscularly administered
88867370|NCT00868374|Experimental|1|Quetiapine XR
88867371|NCT00868374|Placebo Comparator|2|
88867372|NCT00868452|Experimental|Lurasidone|
88867373|NCT00868452|Placebo Comparator|Placebo|
88867374|NCT00869622|Active Comparator|Risedronate|Active drug
88867375|NCT00869622|Placebo Comparator|Placebo + Calcium and Vitamin D|All patients both on placebo and active bisphosphonate to receive calcium and vitamin D
88867376|NCT00871260|Other|Open Label|Approximately 25 healthy volunteers will be recruited as controls. Scan will be done with regadenoson contrast.
88867377|NCT00874614|Experimental|Ultratrace® Iobenguane I 131 Treatment|
88867378|NCT00875550|Active Comparator|Dexmedetomidine Low Dose|
88867379|NCT00875550|Active Comparator|Dexmedetomidine High dose|
88867380|NCT00878436|Experimental|Arm A (120 mg/week)|"Each treatment cycle has 21 days:~Bicalutamide (Casodex®) 50mg P.O. daily, continuously, with the addition of:~40 mg Panobinostat 3 times per week (120 mg per week) for 2 consecutive weeks with one week rest"
88867381|NCT00878436|Experimental|Arm B (60 mg/week)-Closed to accrual|"Each treatment cycle has 21 days:~Bicalutamide (Casodex®) 50mg P.O. daily, continuously, with the addition of:~20 mg Panobinostat 3 times per week (60 mg per week) for 2 consecutive weeks with one week rest"
88867382|NCT00878826|Active Comparator|Enoxaparin 40 mg per day|
88867383|NCT00878826|Active Comparator|Enoxaparin 1 mg per kg daily|
88867384|NCT00878826|Active Comparator|Pre prescribed regimen of Enoxaparin|Current enoxaparin dose at time of first prenatal visit.
89186650|NCT02559921|Experimental|rhRIG（40 IU/kg）+ vaccine|Subjects received rhRIG（40 IU/kg）in combination with rabies vaccine for human use on day 0 and received vaccine only on days 3,7,14,28
89391011|NCT01354925|Active Comparator|Standard treatment during Ramadan|Standard of care according to physicians choice
89391012|NCT03812107|Experimental|Moderate Treatment Approach|Participants in this arm who relapse will be able to move more freely between follow up steps and are hypothesized to require fewer provider visits than those in the intensive treatment arm.
89391013|NCT03812107|Active Comparator|Intensive Treatment Approach|Participants in this arm who relapse will follow the current guidelines follow up steps of weekly, then every two weeks and finally monthly provider visits.
89391014|NCT02864082|Experimental|PAT-001 0.1%|Part 1: Bilateral comparison. Patients will have two comparable Treatment Areas: PAT-001, 0.1% (e.g., left side) and Vehicle, 0.0% (e.g., right side). This comparison lasts from Weeks 0-8 Part 2: Patients will apply only PAT-001, 0.1% to both Treatment Areas from Weeks 8-12.
89391015|NCT02864082|Experimental|PAT-001 0.2%|Part 1: Bilateral comparison. Patients will have two comparable Treatment Areas: PAT-001, 0.2% (e.g., left side) and Vehicle, 0.0% (e.g., right side). This comparison lasts from Weeks 0-8 Part 2: Patients will apply PAT-001, 0.2% to both Treatment Areas.
89391016|NCT02864082|Placebo Comparator|Vehicle for PAT-001 0.1% arm|Part 1: Bilateral comparison. Patients will have two comparable Treatment Areas: PAT-001, 0.1% (e.g., left side) and Vehicle, 0.0% (e.g., right side). The application of vehicle only lasts from Weeks 0-8.
89391017|NCT02864082|Placebo Comparator|Vehicle for PAT-001 0.2% arm|Part 1: Bilateral comparison. Patients will have two comparable Treatment Areas: PAT-001, 0.2% (e.g., left side) and Vehicle, 0.0% (e.g., right side). The application of vehicle only lasts from Weeks 0-8.
89391018|NCT01355003||All Participants|Participants who were vaccinated with GARDASIL™ by their physician
89391019|NCT05091281|Active Comparator|Group I|After induction of anesthesia intubation was done by Macintosh laryngoscope
89391020|NCT05091281|Active Comparator|Group II|After induction of anesthesia intubation was done by GlideScope®videolaryngoscope
89391021|NCT05091281|Active Comparator|Group III|After induction of anesthesia intubation was done byC-MAC®(D) videolaryngoscope
89391022|NCT03556345|Experimental|RC48-ADC|Participants will receive RC48-ADC every 2 weeks (Q2W) until investigator assessed loss of clinical benefit, unacceptable toxicity, investigator or participant decision to withdraw from therapy, or death (whichever occurs first).
89391023|NCT03610230|Experimental|Monofer|Iron Isomaltoside as a single intravenous dose 1000mg over 60 minutes
89391024|NCT03610230|Active Comparator|Venofer|Iron Sucrose 200mg weekly intravenous infusions over 2 hours for 5 weeks
89391025|NCT01359605|Experimental|varespladib methyl|
89391026|NCT01366963||Normal Controls / Healthy Volunteers|Age and gender matched individuals without postural orthostatic tachycardia syndrome
89391027|NCT01366963||Patients with Postural Tachycardia Syndrome (POTS)|Individuals with Postural Tachycardia Syndrome
89391028|NCT01355237||OCC Patients|Patients being treated for chronic low back pain at the Osher Clinical Center of Brigham and Women's Hospital
89391029|NCT01355237||Comparison|Patients being treated for chronic low back pain at Brigham and Women's Hospital, other than at Osher Clinical Center
89391030|NCT03609684|Experimental|Gymnastic and Core Stabilization|This group consist people who regularly do gymnastics and also do 30-45 minutes core stabilization exercises.
89391031|NCT03609684|Experimental|Only Gymnastic Training|People can do gymnastics twice a week during 8 weeks but can't do core stabilization exercise.
88867385|NCT00879060|Experimental|Spironolactone|Experimental group includes individuals diagnosed with HCM between the ages of 18-55 (up to 50 for men). At time of randomization subjects randomized to experimental group will be initiated on 25mg of spironolactone. If at week 4, serum potassium is <5.5 mmol/L and serum creatinine-baseline creatinine is <0.5 mg/dl, the study drug will be increased to the target dose of 50mg once daily.
89391032|NCT03609684|Active Comparator|Sedentary Group|This group consist individuals who are not interested in any sports and don't do any exercises during 8 weeks.
89391033|NCT05188859|Experimental|Treatment|"Regimen:~Sintilimab, 200mg, ivgtt d1, q3w, 21 days per cycle~Anlotinib, 12mg, po, qd, d1-14, q3w, 21 days per cycle~Pemetrexed, 500mg/m², ivgtt , d1, q3w, 21 days per cycle, 4-6 cycles.~Cisplatin, 75mg/m2 , ivgtt, d1, q3w/Carboplatin, AUC 5.0, ivgtt, d1, q3w, 21 days per cycle, 4-6 cycles."
89391034|NCT01367041|Experimental|Bone loss|Postmenopausal women with osteoporosis, whole body vibration will be applied at 40 Hz, 2mm amplitude, 30+30s
89391035|NCT01367041|Experimental|Normal|Postmenopausal women without osteoporosis, whole body vibration will be applied at 40 Hz, 2mm amplitude, 30+30s
89391036|NCT02033538|Experimental|nanoparticle albumin-bound paclitaxel|Paclitaxel protein-bound particles for injectable suspension (albumin-bound) 125 mg/m2 (IV over 30 min) (days 1 and 8) on 21 day cycle
89391037|NCT01319513|Experimental|protein feeding|Participants will complete 2 trials in a cross-over fashion in which they will consume whey protein either as a single bolus or as 10 small divided doses
89391038|NCT02792192|Experimental|Cohort 1A: Atezolizumab (BCG-unresponsive NMIBC)|Participants will receive atezolizumab 1200 mg IV infusion q3w, for a maximum of 32 doses or 96 weeks of therapy, whichever comes first.
89535374|NCT03319433||Group II (Perfusion index >3.5)|Those parturient with perfusion index >3.5 when baseline monitors are attached while the patient is being prepared for surgery.
89535375|NCT03080415|Experimental|Combined Therapy SOF and DCV|
89535376|NCT03206983|Experimental|Cana's Ring group|The device Cana's Ring was used during cataract surgery on these patients.
88867386|NCT00879060|Placebo Comparator|Placebo Control|Placebo group includes individuals diagnosed with HCM between the ages of 18-55 (up to 50 for men). At time of randomization subjects randomized to placebo group will be initiated on an inactive placebo pill.
88867387|NCT00880230|Experimental|Scuba Iliac Stent System|Device: Scuba™ iliac stent
88867388|NCT00880464|Experimental|Vaccine|"Vaccinations will be administered on days 1,8,15 and every two weeks thereafter until the supply of vaccine has been exhausted or the patient is removed from study. As indicated in 5.2.5, vaccine cell dosage will be approximately 1x10 7 , 4x10 6 ,~1x10 6 , or 1x10 5 depending on the final cell yield."
89391039|NCT02792192|Experimental|Cohort 1B: Atezolizumab + BCG (BCG-unresponsive NMIBC)|During BCG induction course (12 weeks), participants will receive atezolizumab 1200 mg IV infusion q3w for a total of four doses plus BCG at the assigned dose weekly for a total of six doses. During BCG maintenance course 1 (12 weeks), participants will receive atezolizumab 1200 mg IV infusion q3w for a total of four doses plus BCG at the assigned dose weekly for a total of three doses. Optional BCG maintenance courses 2-5 (each 24 weeks), participants will receive atezolizumab 1200 mg IV infusion q3w for a total of eight doses per course plus BCG at the assigned dose weekly for a total of three doses per course.
89391040|NCT02792192|Experimental|Cohort 2: Atezolizumab + BCG (BCG-relapsing NMIBC)|During BCG induction course (12 weeks), participants will receive atezolizumab 1200 mg IV infusion q3w for a total of four doses plus BCG at the assigned dose weekly for a total of six doses. During BCG maintenance course 1 (12 weeks), participants will receive atezolizumab 1200 mg IV infusion q3w for a total of four doses plus BCG at the assigned dose weekly for a total of three doses. During BCG maintenance courses 2-5 (each 24 weeks), participants will receive atezolizumab 1200 mg IV infusion q3w for a total of eight doses per course plus BCG at the assigned dose weekly for a total of three doses per course.
89391041|NCT02792192|Experimental|Cohort 3: Atezolizumab + BCG (BCG-naive NMIBC)|During BCG induction course (12 weeks), participants will receive atezolizumab 1200 mg IV infusion q3w for a total of four doses plus BCG at the assigned dose weekly for a total of six doses. During BCG maintenance course 1 (12 weeks), participants will receive atezolizumab 1200 mg IV infusion q3w for a total of four doses plus BCG at the assigned dose weekly for a total of three doses. During BCG maintenance courses 2-5 (each 24 weeks), participants will receive atezolizumab 1200 mg IV infusion q3w for a total of eight doses per course plus BCG at the assigned dose weekly for a total of three doses per course.
89391042|NCT01319591||CNS lymphoma patients|
89391043|NCT01359683|Other|A|This is a prospective observational study. 100 patients in one arm scheduled for cardiac surgery will be enrolled. ECG tracings will be obtained when subject is at rest, in supine position, before induction of anesthesia (within 24 hours prior to induction), after induction of general anesthesia, right before emergence from anesthesia (or before transportation to the ICU if the subject remains intubated), and within 24 hours post-operatively; additional ECG readings may be obtained during the surgery if deemed necessary.
89391044|NCT05187949||Patients|"Quantitative study: Surveys: 1,067 out of a total of 1,389,725 people of residents of the Valencian Community, Spain. Three groups with quota control: proportional to age (40-50; 50-70; > 70 years) of men aged 40 and over who have not had prostate cancer from each stratum (geographical area and population habitat).~Qualitative study: general population focus groups: 3"
89391045|NCT05187949||General Practitioners|"Quantitative study: 369 General Practitioners working in two Health Departments in the Valencian Community, Spain (Dept of Health Alicante, General Hospital 19, 255,439 habitants) and (Dept of Health Alicante, S Juan Alicante 17, 233,115 habitants).~Qualitative study: general practitioners focus groups: 2."
89391046|NCT05187949||Urologists|Quantitative study: 345 Urologists working in Valencian Community, Spain Qualitative study: urologists focus groups: 1.
89391047|NCT03609996||PDR treated with Laser|
89391048|NCT03609996||PDR treated with Lucentis|
89391049|NCT05178199|Experimental|Remote Psychological Support Group|The study will invite nurses through QR code on line, and assess their background, self-efficacy, fear of COVID-19, psychological distress, and quality of life by questionnaires first. Then four evacuation acute wards (A, B, C, and D) will be randomly allocated, and the two wards will be drawn out as experimental group ward. Each group will be followed for 2 months and their outcomes will be assessed at 3 time points: baseline (pre-RPSG) (T0), and 4 (T1), 8 (T2) weeks after-RPSG, T0-T2, respectively.
89391050|NCT05178199|Active Comparator|Mindfulness through audio and video|The study will invite nurses through QR code on line, and assess their background, self-efficacy, fear of COVID-19, psychological distress, and quality of life by questionnaires first. Then four evacuation acute wards (A, B, C, and D) will be randomly allocated, and the two wards will be drawn out as experimental group ward. Each group will be followed for 2 months and their outcomes will be assessed at 3 time points: baseline (pre-RPSG) (T0), and 4 (T1), 8 (T2) weeks after-RPSG, T0-T2, respectively.
89391051|NCT02088008|Experimental|cilnidipine/valsartan|cilnidipine/valsartan tablet
88867389|NCT00882102|Experimental|Decitabine + Gemtuzumab Ozogamicin|Decitabine 20 mg/m^2 by vein (IV) over 1-1/2 hours daily for 5 days. Gemtuzumab ozogamicin 3 mg/m^2 by vein on day 5.
88867390|NCT00884052|Experimental|levetiracetam dose escalation|6 Babies in Phase 1-Received Dose 1: 20 mg/kg; 5 mg/kg daily 12 Babies in Phase 2-Received Dose 2: 40 mg/kg; 10 mg/kg/day
88867391|NCT00884754|Experimental|rigid GlideScope Specific Stylet|
88867392|NCT00884754|Active Comparator|90º curvature, malleable stylet|
88867393|NCT00885768||A|patients with renal artery stenosis
88867394|NCT00886236|Active Comparator|1 Preoperative Gabapentin Liquid|Preoperative Gabapentin Elixir (1200 mg) AND Postoperative Placebo Elixir (300 mg x 6 doses)
88867395|NCT00886236|Experimental|2 Preoperative and Postoperative Gabapentin Liquid|Preoperative Gabapentin Elixir (1200 mg) AND Postoperative Gabapentin Elixir (300 mg x 6 doses)
88867396|NCT00886236|Placebo Comparator|3 Preoperative and Postoperative Placebo Liquid|Preoperative Placebo Liquid (1200 mg) AND Postoperative Placebo Elixir (300 mg x 6 doses)
88867397|NCT00886626|Experimental|Exenatide|Exenatide
88867398|NCT00886626|No Intervention|Control|Control - no intervention
88867399|NCT00886704|Active Comparator|Convenience drink with EPA and DHA|Daily consumption of 200 ml convenience drink, containing 0.5 g EPA and DHA (Omega-3 Fatty Acids)
88867400|NCT00886704|Placebo Comparator|Convenience drink without EPA and DHA|Daily consumption of 200 ml convenience drink, not containing 0.5 g EPA and DHA (Omega-3 Fatty Acids), but containing 1.0 g of Omega-6 Fatty Acids (e.g. corn oil)
88867401|NCT00887562|Experimental|Idebenone 900 mg/day|Idebenone 900 mg/day
88867402|NCT00887562|Experimental|Idebenone 2250 mg/day|Idebenone 2250 mg/day
88867403|NCT00887562|Placebo Comparator|placebo|Placebo
88867404|NCT00887640|Experimental|Temsirolimus 25 mg|Temsirolimus 25mg was administered by IV infusion each week (days 1, 8, 15, and 22 of each 28 day cycle). The infusion was to be administered over a period not less than 30 minutes and was to be completed within 60 minutes. Subjects were premedicated with 25 to 50 mg IV or PO diphenhydramine (or an alternative antihistamine in case of allergies) 30 minutes prior to the infusion.
89391052|NCT02088008|Active Comparator|cilnidipine+valsartan|coadministration of cilnidipine and valsartan
89391053|NCT02033772||Thoracoscopic surgery|Infants undergoing thoracoscopic surgery.
89391054|NCT01361789|Active Comparator|COXIB|"40 mg parecoxib (Dynastat, Pfizer®) one hour before surgery and 40 mg valdecoxib (prodrug of parecoxib, Bextra, Pfizer®)were given 8 hour after surgery.~After retraction of parecoxib from the market:~Etoricoxib (Arcoxia, MSD) 120 mg given one hour before surgery"
89391055|NCT01361789|Active Comparator|Dexamethasone|dexamethasone 8 mg iv
89391056|NCT01361789|Active Comparator|COXIB and dexamethasone|combination of coxib AND dexamethasone
89391057|NCT05168761||laparoscopic partial nephrectomy|The investigators included all hospitalisations for LPN using CCAM(Classification Commune des actes médicaux) code (JAFC005) after removing the 83 hospitals using RAPN in 2017. LPN complications were from hospitals using exclusively LPN.
88867405|NCT00889200|Experimental|Open-label Eszopiclone|Standard dosing of drug for 6 weeks for insomnia
88867406|NCT00889512|Active Comparator|Luveris Fixed dose|Participants in this arm will take Gonal F® and the same dose of Luveris® throughout the cycle. Their dose of Gonal F® will be adjusted throughout the cycle based on their response to the medication. The Luveris® dose will remain constant throughout.
89391058|NCT05168761||open partial nephrectomy|OPN has its own CCAM codes; they group laparotomy (JAFA019 / JAFA030) and lumbotomy (JAFA008 / JAFA024)
89391059|NCT05168761||robot assisted partial nephrectomy|At the time of this study, RAPN did not have a specific coding. The investigators had contacted the hospitals with Vinci robotic surgical procedures in 2013 and the investigators included here PN from hospitalisations from the 25 centres using exclusively RAPN for more than five years. Thus, in this study, RAPN was performed by experts in robotic surgery.
89391060|NCT02081612|Active Comparator|Nutrition Education|Educational weight management group sessions alone
88867407|NCT00889512|Experimental|Luveris increasing dose|Patients assigned to this group will gradually reduce the Gonal F® dose while increasing the Luveris® dose during the cycle, which more closely mimics the natural menstrual cycle.
88867408|NCT00889824|Experimental|prosthesis group|balance prosthesis
88867409|NCT00890682|Experimental|Sky0402|Injection of Study Drug
88867410|NCT00890682|Placebo Comparator|Placebo|Injection of study drug
88867411|NCT00890916|Experimental|Neuroprosthesis System|Receives implanted device for hand function.
88867412|NCT00892710|Experimental|Pemetrexed/Bevacizumab|"Pemetrexed 500 mg/m2 IV given over 10 minutes every 21 days~Bevacizumab 15 mg/kg IV every 21 days"
88867413|NCT00892710|Experimental|Pemetrexed/Bevacizumab/Carboplatin|"Pemetrexed 500 mg/m2 IV given over 10 minutes every 21 days~Bevacizumab 15 mg/kg IV every 21 days~Carboplatin AUC=5 IV every 21 days"
89391061|NCT02081612|Active Comparator|Nutrition Education Plus Acupuncture|Educational weight management group sessions in addition to weight loss acupuncture
89391062|NCT02964507|Experimental|GSK525762 + Fulvestrant (Phase I)|
88867414|NCT00892710|Experimental|Pemetrexed|Pemetrexed 500 mg/m2 IV given over 10 minutes every 21 days
88867415|NCT00894504|Experimental|Panitumumab/Gemcitabine/Carboplatin|Systemic therapy
89391063|NCT02964507|Experimental|GSK525762 + Fulvestrant (Phase II)|
89391064|NCT02964507|Placebo Comparator|Placebo + Fulvestrant (Phase II)|
89391065|NCT01359761|Experimental|Post Admission Cognitive Therapy (PACT)|Six (6) 60-90 Minutes Post Admission Cognitive Therapy Individual Sessions; Up to Two (2) Inpatient Booster Sessions; Up to Four (4) Telephone Booster Sessions Following Psychiatric Discharge; 12-Months Case Management
89391066|NCT01359761|No Intervention|Enhanced Usual Care (EUC)|Treatment As Usual and Study Assessment Services; 12-Months Case Management
89391067|NCT02083874|Experimental|CBD|Open label CBD
88867416|NCT00894738||antipsychotic treated|Children with psychiatric diagnoses who are currently treated with antipsychotic medications.
88867417|NCT00894738||healthy control|Age- and gender-matched children who do not have a psychiatric diagnosis, are not taking antipsychotic medications, and are otherwise healthy.
88867418|NCT00895752|Experimental|Riluzole|Six week open-label treatment with riluzole, maximum dose of 50 mg twice a day.
88867419|NCT00895830|Placebo Comparator|1|
88867420|NCT00895830|Experimental|2|0.3mg dose level
89391068|NCT01367197|No Intervention|No intervention|Observation only
89391069|NCT01367197|Experimental|Exercise training group|Group exercise training, three times weekly high-intensity
89391070|NCT05188781||Pembrolizumab combined with Anlotinib|Pembrolizumab 200 mg every 3 weeks, Anlotinib 12 mg/day, orally;2weeks treatment followed by 1week off
89391071|NCT02083952|Experimental|swaddle blanket|
89391072|NCT01367353|Experimental|ovarian cancer|
89391073|NCT01359839|Experimental|Relaxation Response Mind Body Intervention|The Relaxation Response (RR) Mind Body Intervention Arm receives the Behavioral: Relaxation Response and Cognitive Behavioral Therapy Intervention which is a RR based Mind Body Group consisting of 1½ hour group classes held weekly for 8 weeks, in a conference room at the health center.
88867421|NCT00895830|Experimental|3|1mg dose level
88867422|NCT00895830|Experimental|4|2mg dose level
88867423|NCT00895830|Experimental|5|3mg dose level
88867424|NCT00896064|Experimental|Formulation 1|
88867425|NCT00896064|Experimental|Formulation 2|
89391074|NCT02084030||Experimental: Patient with POCD|Patients who suffer from POCD after surgery. The mini-mental state examination scale decline more than 1 SD of baseline after surgery.
89391075|NCT02084030||Sham Comparator: patient without POCD|Patients who don't suffer from POCD after surgery. There is no obvious difference between pre-operation and post-operation in mini-mental state examination scale
88867428|NCT00898560|Other|Microginon®|A single oral dose of a combined oral contraceptive containing 30ug ethinyloestradiol and 150ug levonorgestrel (Microginon ®).
89391076|NCT03634735|Active Comparator|Thiamin|Oral thiamine: 600 - 1800 mg/day in 4 weeks. Dose is depending on gender and age. Tablet contains 300 mg Thiamine each.
89391077|NCT03634735|Placebo Comparator|Placebo|Placebo: same number of tablets as in the active comparator arm, in 4 weeks
89391078|NCT03634657|Active Comparator|Plain X-ray protection shield|
89391079|NCT03634657|Experimental|Protection shield & X-ray protective strips|
89391080|NCT03634657|Experimental|Protection shield & protective strips & patient cut-outs|
89391081|NCT04563195|Other|open label|open label study; all subjects will receive the same drug at the same dose
88867429|NCT00898560|Experimental|ESL and Microginon®|15-day treatment with ESL 800 mg once daily, with co administration of a single oral dose of Microginin® on Day 14 of the relevant dosing period, to assess impact of ESL on pharmacokinetics of the combined oral contraceptive.
88867430|NCT00899574|Experimental|Imiquimod|"Each treatment cycle consists of 8 weeks.~Weeks 1-8: day 1-5 of each week: 1 packet imiquimod 5% cream applied overnight, day 6-7 of each week: rest period.~Patients with responding or stable local disease (non-progressors) may continue to receive treatment following the same schedule (as outlined above for the first cycle) until complete tumor regression, unacceptable toxicity or progression of disease."
88867431|NCT00900666|Placebo Comparator|Saline injection|
89391082|NCT02084108|No Intervention|Control arm= usual care|Two clusters of patients over 60 years of age followed by a primary care physician and routinely evaluated by the home nursing service with the resident assessment instrument-home care (RAI-HC) and identified as frail by pre-defined clinical criteria.
89391083|NCT02084108|Other|Intervention arm|The intervention arm will consist of two clusters of patients over 60 years of age followed by a primary care physician and routinely evaluated by the home nursing service with the RAI-HC and identified as frail by predefined clinical criteria that will receive in addition an in-home multidimensional geriatric assessment, access 24 hours a day, 7 days a week to a call service provided by the Community Geriatrics Unit and coordinated long-term follow-up.
89391084|NCT01371409|Experimental|active cTBS|
89391085|NCT01371409|Sham Comparator|Sham cTBS|
88867432|NCT00900666|Experimental|Botulinum toxin injection|
88867433|NCT00900822|Experimental|Straumann Bone Ceramic|StraumannBone Ceramic is used as bone grafting material in sinus augmentation procedures
88867434|NCT00900822|Active Comparator|BioOss|BioOss is used as a bone grafting material in sinus augmentation procedure
88867435|NCT00902226|Experimental|Escitalopram|
88867436|NCT00903162|Experimental|Letrozole-Leuprolide|Patients will receive 2.5mg oral letrozole daily and either 7.5mg monthly of Leuprolide IM or 22.5mg every three months of Leuprolide IM. Zoledronic acid 4mg IV every 6 months x 4 will also be offered optionally.
88867437|NCT00904488|Active Comparator|Addition of PO Thiazide Diuretic|Addition of oral metolazone 5 mg daily to current intravenous bolus furosemide. All subjects will continue their current dose of intravenous bolus furosemide.
88867438|NCT00904488|Active Comparator|IV furosemide dose escalation|Current IV furosemide dose will be escalated to 2-2.5 x current dose, given as either IV bolus or continuous infusion over 24 hours.
88867439|NCT00905580|Placebo Comparator|Placebo|Patients receive oral Placebo 150 mg 1 hour prior to surgery, and 12 hours later
88867440|NCT00905580|Experimental|Pregabalin|Patients receive oral pregabalin 150 mg 1 hour prior to surgery, and 12 hours later
88867441|NCT00908388|Experimental|GORE Conformable TAG® Device Surgical Implant|
88867442|NCT00908466|Experimental|Intravitreal Injection|Will receive intravitreal injections of sirolimus 352 µg in study eye on Days 0, 60, and 120.
88867443|NCT00908466|Experimental|Subconjunctival Injection|Will receive subconjunctival injections of sirolimus 1320 µg in the study eye on Days 0, 60, and 120.
88867444|NCT00909324|Experimental|Pre-LASIK 0.3% hypromellose|
88867445|NCT00909324|Active Comparator|Post-LASIK 0.3% hypromellose|
88867446|NCT00911586|Experimental|Testosterone Undecanoate|Oral testosterone undecanoate, 200 mg testosterone (T) as TU, twice daily for 28 days.
88867447|NCT00911742|Experimental|1 Tramadol Contramid Once A Day|
88867448|NCT00911742|Active Comparator|2 Zytram (R)|
88867449|NCT00911898|Experimental|MM-111|
88867450|NCT00912990|Placebo Comparator|Normal saline|Normal saline volume calculated to be equal to the volume of cisatracurium 0.2mg/kg
88867451|NCT00912990|Active Comparator|Cisatracurium|Subjects in this arm will be given Cisatracurium 0.2mg/kg IV dose one time prior to intubation.
88867452|NCT00913068|Experimental|TAP arm|in the experimental arm, the procedure will consist of the staff urologist injecting local anesthetic into the anterior abdominal wall bilaterally from the inside of the abdomen at the end of their surgery
89391086|NCT02084186|Experimental|moxibustion group|herb-partitioned moxibustion on bilateral Tianshu (ST25) and Shangjuxu (ST37)
89391087|NCT02084186|Placebo Comparator|bran-partitioned moxibustion|bran-partitioned moxibustion on bilateral Tianshu (ST25) and Shangjuxu (ST37)
89391088|NCT02084264||Arm 1: Robotic-guided, open approach|Robotic-guided, open approach
88867453|NCT00913068|Active Comparator|standard post operative pain control|Our current post operative analgesic strategy involves a multi-modal approach, using local injectable anesthetic around the incision and systemic medications (i.e. non-steroidal anti-inflammatories, acetaminophen and break-through doses of opiates). Some of the more common adverse reactions are reparatory depression, sedation, confusion, delirium, nausea, pruritis, constipation, hypotension and bradycardia. Often it is these resulting side effects that extend the length of in hospital rehabilitation, and decrease a patient's overall satisfaction.
88867454|NCT00914862|Experimental|Children Ramelteon 4 mg|Children 6 to 11 years of age who had insomnia associated with ADHD received a single 4 mg oral dose of ramelteon.
88867455|NCT00914862|Experimental|Children Ramelteon 8 mg|Children 6 to 11 years of age who had insomnia associated with ADHD received a single oral 8 mg dose of ramelteon.
88867456|NCT00914862|Experimental|Adolescents Ramelteon 4 mg|Adolescents 12 to 17 years of age with insomnia received a single oral dose of 4 mg ramelteon.
88867457|NCT00914862|Experimental|Adolescents Ramelteon 8 mg|Adolescents 12 to 17 years of age with insomnia received a single oral dose of 8 mg ramelteon.
88867458|NCT00914862|Active Comparator|Healthy Adult Ramelteon 8 mg|Healthy adults (18 to 50 years old) received a single oral dose of 8 mg ramelteon.
88867459|NCT00915798||Smokers with ADHD|Smokers with ADHD participated in one overnight abstinence condition (withdrawal) and one smoking condition (smoking the first cigarette of the morning).
88867460|NCT00915798||Nonsmokers with ADHD|Nonsmokers with ADHD participated in one condition.
88867461|NCT00915798||Control smokers|Control smokers participated in one overnight abstinence condition (withdrawal) and one smoking condition (smoking the first cigarette of the morning).
88867462|NCT00915798||Control nonsmokers|Control nonsmokers participated in one condition.
89391089|NCT02084264||Arm 2: control arm- non-robotic, open approach|control arm- non-robotic, open approach°
89391090|NCT03170869|Experimental|DEB-TACE Procedure with Surefire Precision Infusion System|"The study duration for each patient is 24 months and includes a baseline visit, procedure visit and follow-up visits at 1 week, 1 month, 3 months, 6 months and every 3 months until liver transplant or death.~The following evaluations/activities will be performed at baseline: Informed consent, history, physical exam, data collection of CT/ MRI within 1 month of the visit date, data collection of lab values and quality of life questionnaire.~The treatment visit includes the DEB-TACE procedure with the Surefire Precision Infusion System. After the procedure, a Cone Beam CT of the liver will be performed to determine distribution and density of the beads in the tumor and adverse events monitoring.~The following evaluations / activities will be performed during the follow-up period: physical exam, data collection of contrast enhanced CT/MRI to evaluate tumor response, data collection of lab values, adverse event monitoring and quality of life questionnaire."
89391091|NCT02084342|Placebo Comparator|Group TN|"Tranexamic acid and sodium chloride injection at 10mg/kg, IV (in the vein) for 30min, before incision.Then at 1mg/kg/h, IV pump, until the surgery is over.~Normal saline (NS) 100ml IV for 20min, before incision."
89391092|NCT02084342|Experimental|Group TD|"Tranexamic acid and sodium chloride injection at 10mg/kg, IV (in the vein) for 30min,before incision.Then at 1mg/kg/h,IV pump,until the surgery is over.~Desmopressin acetate injection at 0.3μg/kg dissolved in 100ml NS, IV for 20min, before incision."
89391093|NCT03558542|Experimental|Study Group|cardiopulmonary rehabilitation plus neurorehabilitation
89391094|NCT01371487|Experimental|Treatment A|GSK1120212 Dose /Treatment 2.0 mg/Fasted
89391095|NCT01371487|Experimental|Treatment B|GSK1120212 Dose /Treatment 2.0 mg/high fat, high calorie meal
89391096|NCT02084420|Experimental|Ilaprazole or Pantoprazole placebo|Ilaprazole 10mg, Pantoprazole 40mg, Amoxicillin 1000mg, Clarithromycin 500mg 2 times/day, PO
89391097|NCT02084420|Active Comparator|Ilaprazole placebo or Pantoprazole|Pantoprazole 40mg, Ilaprazole 10mg, Amoxicillin 1000mg, Clarithromycin 500mg 2 times/day,PO
89391098|NCT01367431||20 mg|Single dose 20 mg Xanthohumol
89391099|NCT01367431||60 mg|Single dose 60 mg Xanthohumol
89391100|NCT01367431||180 mg|Single dose 180 mg Xanthohumol
89391101|NCT01367509|Experimental|Arm 1|SC Methylnaltrexone (MNTX)
89391102|NCT02084498|Active Comparator|ACC|Training in advanced carbohydrate counting
88867463|NCT00915954|Active Comparator|Active Acromegaly|Placebo, oral glucose tolerance test, and subcutaneous administration of recombinant human IGF-1 will be given at visits 2, 3, and 4 respectively. All visits will be performed within a 4 week period.
88867464|NCT00915954|Active Comparator|Type 2 Diabetes Mellitus(DM)|Placebo, oral glucose tolerance test, and subcutaneous administration of recombinant human IGF-1 will be given at visits 2, 3, and 4 respectively. All visits will be performed within a 4 week period.
89391103|NCT02084498|Experimental|ACC + ABC|Training in advanced carbohydrate counting plus the use of an automated bolus calculator.
89391104|NCT01364545|Other|Ketone ester drink Vs placebo drink|Ketone ester drink Vs placebo drink (cross over study - all patients will recieve both)
89391105|NCT02088086|Experimental|BMI screening and reporting (Group 1)|For three school years, 3rd-8th grade students will have their heights and weights measured once annually. Additionally, 5th-8th grade students will participate in five fitness assessments. Schools will send BMI reports home to parents.
88867465|NCT00915954|Active Comparator|Heathy Controls|Placebo, oral glucose tolerance test, and subcutaneous administration of recombinant human IGF-1 will be given at visits 2, 3, and 4 respectively. All visits will be performed within a 4 week period.
88867466|NCT00916032|Active Comparator|1|One infusion using a 3000 IU potency vial of Advate dissolved and administered in 5 mL diluent followed by a second infusion of two 1500 IU potency vials of Advate dissolved in 5 mL diluent each (administered in 10 mL diluent in total)
89391106|NCT02088086|Active Comparator|BMI screening only (Group 2)|For three school years, 3rd-8th grade students will have their heights and weights measured once annually. Additionally, 5th-8th grade students will participate in five fitness assessments. Schools will NOT send BMI reports home to parents.
89391107|NCT02088086|No Intervention|No BMI screening or reporting (Group 3)|For two school years, 3rd-8th grade students will NOT have their heights and weights measured at school.
89391108|NCT01364701|Active Comparator|Maximal dose sildenafil|4 tablets of sildenafil 100mg are given for on demand use
89391109|NCT01364701|Active Comparator|Tadalafil 20mg maximal dose|4 tablets of tadalafil 20mg are given for on demand use
89391110|NCT01364701|Active Comparator|Combination half dose|4 tablets of sildenafil 50mg and tadalafil 10mg are given for on demand use
89391111|NCT02088164||Healthy men|Healthy men who received PSA screening
89391112|NCT02088242|Placebo Comparator|Placebo|Subjects receiving placebo will be asked to ingest 3 capsules identical in shape, colour and size to the Astaxanthin capsules, and will contain only the inactive ingredients of the same formulation.
89391113|NCT02088242|Experimental|Astaxanthin|Subjects receiving Astaxanthin will be asked to ingest 3 capsules containing 4mg of Astaxanthin each (a daily dose of 12mg).
89391114|NCT02440464|Experimental|Ixazomib Maintenance|Allogeneic HSCT and Fludarabine/Melphalan/Bortezomib conditioning followed by Ixazomib maintenance
89391115|NCT02440464|Placebo Comparator|Placebo|Allogeneic HSCT and Fludarabine/Melphalan/Bortezomib conditioning followed by placebo maintenance.
89391116|NCT01367587|Experimental|Arm 1|
89391117|NCT02088398|Experimental|160 mg ACY-1215 CLF (20 mg/mL) fed|• Treatment A: a single dose of 160 mg ACY-1215 CLF (20 mg/mL) in the fed state
88867467|NCT00916032|Active Comparator|2|One infusion of two 1500 IU potency vials of Advate dissolved in 5 mL diluent each (administered in 10 mL diluent in total) followed by a second infusion of one 3000 IU potency vial of Advate dissolved and administered in 5 mL diluent
89391118|NCT02088398|Experimental|120 mg ACY-1215 ALF (10 mg/mL) fed|• Treatment B: a single dose of 120 mg ACY-1215 ALF (10 mg/mL) in the fed state
89391119|NCT02088398|Experimental|120 mg ACY-1215 ALF (10 mg/mL) fasted|• Treatment C: a single dose of 120 mg ACY-1215 ALF (10 mg/mL)
89391120|NCT02088476||Candidemia|Candidemia is defined as the presence of growth of any candida species in at least one blood culture obtained by either peripheral venipuncture or through an indwelling central venous catheter.
89391121|NCT02084576|Experimental|Nepafenac|One drop in the study eye 3 times daily for 30 days
89391122|NCT02084576|Active Comparator|Ketorolac|One drop in the study eye 4 times daily for 30 days
89391123|NCT03131453|Experimental|CNP520 50 mg|50 mg capsule taken orally once daily
89391124|NCT03131453|Experimental|CNP520 15 mg|15 mg capsule taken orally once daily
89391125|NCT03131453|Placebo Comparator|Placebo|Matching placebo to 15 and 50 mg CNP520 taken orally once daily
89391126|NCT02084654|Active Comparator|exenatide 5 and 10 mcg 2 times a day|Exenatide in addition to weight loss. Starting dose 5 mcg titrate to 10 mcg
89391127|NCT02084654|Placebo Comparator|placebo|placebo in addition to weight loss
89391128|NCT01367743|Active Comparator|epinephrine|
89391129|NCT01367743|Active Comparator|norepinephrine|
89391130|NCT02084732|Experimental|Sorafenib|drug
89391131|NCT02084810|Active Comparator|NovoSeven®|
89391132|NCT02084810|Experimental|Eptacog alfa A 6 mg|
89391133|NCT02780401|Experimental|Treatment (WOKVAC with sargramostim)|"Patients receive WOKVAC with sargramostim ID on day 1. Courses repeat every 28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.~Patients with ALND will have vaccine administered to the contralateral arm. Patients with bilateral ALND will have vaccine administered in the thigh. As much as possible each vaccine dose will be given within the same draining lymph node site. Patients will be monitored for a minimum of 60 minutes post vaccine administration."
89391134|NCT02533232|Placebo Comparator|placebo|Matching placebo for Minocycline
89391135|NCT02533232|Experimental|Minocycline|Minocycline 200mg once a day orally
89391136|NCT01371799|Experimental|Study drug at 4mg|GSK1034702 at 4mg
89391137|NCT01371799|Experimental|Study drug at 8mg|GSK1034702 at 8mg
89391138|NCT01371799|Placebo Comparator|Placebo|Placebo
89391139|NCT02732509||Lean|Body mass index less than 25 kg/m2
89391140|NCT02732509||Overweight/obese|Body mass index 25-45 kg/m2
89391141|NCT02686814|Experimental|MDT-2215|17mm MDT-2215 aortic valve bioprosthesis
89391142|NCT02673151|Experimental|68Ga-PSMA-11 PET/CT|Patients receive 68gallium-labeled prostate-specific membrane antigen-11 (68-Ga-PSMA-11). Participant will be injected IV with 3 to 7 millicurie (mCi) of 68Ga-PSMA-11. Beginning 50 to 100 minutes later, a low-dose computed tomography (CT) scan will be obtained from vertex to mid thighs; followed by a static positron emission tomography (PET) scan over the same .
89391143|NCT01367821||Patients with obstructive jaundice|Patients with obstructive jaundice
89391144|NCT01367821||Healthy volunteers|Healthy volunteers
89391145|NCT02082002||MS-Group|MS-Group
89391146|NCT02082002||Healthy control|Healthy control
89391147|NCT02436655|No Intervention|conventional drug treatment|conservative treatment and watchful waiting till symptom onset (then aortic valve replacement). Other indications for aortic valve replacement include reduced left ventricular systolic function
89391148|NCT02436655|Active Comparator|elective aortic valve replacement|elective aortic valve surgery (replacement) within 4 weeks after randomization
89391149|NCT02082080|Active Comparator|Obese and overweight children, education|Overweight and obese school children in grades 5 and 6
89391150|NCT02082080|No Intervention|Obese and overweight children|
89391151|NCT02084966|Experimental|OCT Imaging|OCT imaging of the kidneys prior to and following their transplant
89391152|NCT01367899||CONSERVE® Plus hip resurfacing|Recipients/C Plus (IDE)study
89391153|NCT02942277|Experimental|1a|(n=5), to receive 16 microgram Pfs25M-EPA/AS01 on D0, D28, D168
89391154|NCT02942277|Experimental|1b|(n=10), to receive 47 microgram Pfs25M-EPA/AS01 on D0, D28, D168
89391155|NCT02942277|Experimental|2a|(n=5), to receive 13 microgram Pfs230D1M-EPA/AS01 on D0, D28, D168
89391156|NCT02942277|Experimental|2b|(n=10), to receive 40 microgram Pfs230D1M-EPA/AS01 on D0, D28, D168
89391157|NCT02942277|Experimental|2c|(n=60), to receive 40 micrograms Pfs230D1M-EPA/AS01 on D0, D28, D168; all subjects will undergo antimalarial drug treatment with Coartem on D-7 (prior to vaccination #1); 4th vaccination on D476
89391158|NCT02942277|Experimental|2d|(n=60), to receive 40 micrograms Pfs230D1M-EPA/AS01 (500 (Micro)L TBV + AS01) on D0, D28, then 8 micro liters Pfs230D1M- EPA/AS01 (100 (Micro)L TBV + AS01;fractional dose) on D168; all subjects will undergo antimalarial drug treatment with Coartem on D-7 (prior to vaccination #1); 4th vaccination on D476
89391159|NCT02942277|Experimental|3a|(n=5), to receive 16 microgram Pfs25M-EPA/AS01 and 13 microgram Pfs230D1M-EPA/AS01 on D0, D28, D168
89391160|NCT02942277|Experimental|3b|(n=10), to receive 47 microgram Pfs25M-EPA/AS01 and 40 microgram Pfs230D1M-EPA/AS01 on D0, D28, D168 (Bamako)
89391161|NCT02942277|Active Comparator|4a|(n=10), to receive ENGERIX-B on D0, D28, and D168
89391162|NCT02942277|Active Comparator|4b|(n=10), to receive ENGERIX-B on DO, D28, and Dl68
89391163|NCT02942277|Active Comparator|4c|(n=120), to receive ENGERIX-B on D0, D28, and D168 (start study with Arm 2c and 2d); all subjects will undergo antimalarial drug treatment with Coartem on D-7 (prior to vaccination #1); vaccination with Menactra on D476
89391164|NCT05042947|Experimental|DLCT|After finding polyps that meet the inclusion criteria, the surgical method for resection was selected according to the operator's preferences, and the experimental group used double-loop coil clamp technology to treat the wound.
89391165|NCT05042947|Active Comparator|Traditional technology|After finding polyps that meet the inclusion criteria, the surgical method for resection was selected according to the operator's preferences.The control group used the traditional hemostatic clip technique to treat the wound
89391166|NCT01365013|Experimental|Lifestyle counseling|
89391167|NCT01365013|Active Comparator|control group|
89391168|NCT02085044|Experimental|12 months RUSF|Children between 6 to 24 months received ready-to-used supplementary food every months during the whole year.
89391169|NCT02085044|Active Comparator|4 months RUSF|children between 6 to 24 months of one zone received a ready-to-used supplement food during the 4 months of the hunger gap period (june to september)
89391170|NCT03559244|Experimental|Dynamic compression brace 8 hours|Children with pectus carinatum who will wear dynamic compression brace 8 hours a day plus exercises for three weeks
89391171|NCT03559244|Experimental|Dynamic compression brace 23 hours|Children with pectus carinatum who will wear dynamic compression brace 23 hours (except for bathing and sports activities) a day plus exercises for three weeks
88867468|NCT00919932|Active Comparator|Paper and pen homework|Treatment as usual: therapy homework is completed by paper and pen.
88867469|NCT00919932|Experimental|Text-message homework|Experimental treatment: therapy homework is completed by text messaging.
89391172|NCT03559244|Active Comparator|Only exercises|The children who are in wait in list for dynamic compression brace will receive only posture exercises, deep breathing exercises, exercises for manipulation and mobilization of ribs, and core exercises for three weeks
89391173|NCT02082236|Active Comparator|Treatment A|Sufenta® IV (50 mcg/mL) 30 mcg infused over 1 minute
89391174|NCT02082236|Experimental|Treatment B|Single dose of SSM 30 mcg
89391175|NCT02082236|Experimental|Treatment C|2 consecutive doses of SSM 15 mcg administered 20 minute apart
88867470|NCT00923598|Active Comparator|1) 0.1% Ropivicaine on Right Leg|Patients will be randomized ot 0.1% Ropivicaine infusion on the right leg and therefore 0.4% Ropivicain in fusion for the left leg for pain due to bilateral TKA. The outcome measures will be measured on both legs, starting with the right leg each time. The infusion will last for the two days following surgery, that the patient is staying in the hospital.
88867471|NCT00923598|Active Comparator|2) 0.4% Ropivicaine on Right Leg|Patients will be randomized ot 0.4% Ropivicaine infusion on the right leg and therefore 0.1% Ropivicain in fusion for the left leg for pain due to bilateral TKA. The outcome measures will be measured on both legs, starting with the right leg each time. The infusion will last for the two days following surgery, that the patient is staying in the hospital.
88867472|NCT00923910|Other|Donors|Related and unrelated donors undergo lymphapheresis to prepare cellular vaccines and to donate lymphocytes for infusion.
88867473|NCT00923910|Experimental|Recipients|Participants receive donor lymphocytes and vaccines prepared from donors.
88867474|NCT00924066|Experimental|Squamous and Nonsquamous participants|"Squamous cell carcinoma is a histologic subtype of cervical cancer. Squamous cell carcinoma of the cervix (80%) is much more common than adenocarcinoma of the cervix.~Non squamous carcinoma is a histologic subtype of cervical cancer. It is the second most common form of cervical cancer; consists of adenocarcinoma, adenosquamous and non squamous (not otherwise specified) subtypes.~All participants in both arms received ixabepilone 6 mg/m^2 x 5 days, each cycle."
88867475|NCT00924612|Experimental|Fasting (Treatment A)|Single dose of oral testosterone undecanoate (containing 300 mg T) administered orally in a fasted state
88867476|NCT00924612|Experimental|Very low fat diet (Treatment B)|Single dose of oral testosterone undecanoate (containing 300 mg T) administered, 30 minutes after the initiation of protocol-defined breakfast of ~800 calories with very low fat (6-10% fat).
88867477|NCT00924612|Experimental|Low fat diet (Treatment C)|Single dose of oral testosterone undecanoate (containing 300 mg T) administered, 30 minutes after the initiation of protocol-defined breakfast of ~800 calories with low fat (20% fat).
88867478|NCT00924612|Experimental|Normal diet (Treatment D)|Single dose of oral testosterone undecanoate (containing 300 mg T) administered, 30 minutes after the initiation of protocol-defined breakfast of ~800 calories with normal fat (30% fat).
88867479|NCT00924612|Experimental|High fat diet (Treatment E)|Single dose of oral testosterone undecanoate (containing 300 mg T) administered, 30 minutes after the initiation of protocol-defined breakfast of ~800 calories with high fat (50% fat).
88867480|NCT00925782|Other|Melphalan-Alkeran|Subjects begin with treatment Melphalan and crossover to treatment Alkeran
88867481|NCT00925782|Other|Alkeran-Melphalan|Subjects begin with treatment Alkeran and crossover to treatment Melphalan.
88867482|NCT00925938|Experimental|Misoprostol vaginal priming insert (MVPI)|One vaginal insert administered 18 - 24 hours prior to the scheduled hysteroscopy clinic visit. The initial dose is 400 mcg and dose will be adjusted between 100 - 1600 mcg after each study cohort based on safety and efficacy criteria as assessed by the Data and Safety Monitoring Board (DSMB).
88867483|NCT00925938|Placebo Comparator|MVPI Placebo|One vaginal insert of placebo administered 18 - 24 hours prior to the scheduled hysteroscopy clinic visit.
88867484|NCT00926952|Experimental|MAL-PDT 90 min incubation, no occlusion|Patients had 2-4 g of Methylaminolevulinate (MAL) spread on the entire face without occlusion and waited 90 minutes prior to photodynamic therapy (PDT) using red light.
88867485|NCT00927264|Experimental|Behavioral|"Motivational Interviewing Intervention Plus Education~Caregivers will receive a home-based motivational interviewing intervention for ETS reduction plus an educational program for ETS reduction."
89391176|NCT02082236|Experimental|Treatment D|12 consecutive doses of SSM 30 mcg administered 1 hour apart
89391177|NCT02085122|Experimental|noninvasive ventilation|
89391178|NCT02085122|No Intervention|Control Group|
88867486|NCT00927264|Active Comparator|Education Only|Caregivers will receive only educational program for ETS reduction.
89003639|NCT04903483|Other|target-controlled infusion (propofol) without depth of anesthesia monitoring|In this group, propofol dosing is adjusted without bispectral index monitoring.
89391179|NCT02085200|Other|Horizontal adduction stretch without scapular stabilization|Scapular stabilization is not provided during a manual horizontal adduction stretch of the shoulder. Each stretch is held for 25 seconds and repeated for a total of 3 times.
89391180|NCT02085200|Other|Horizontal adduction with scapular stabilization|Scapular stabilization is provided during a manual horizontal adduction stretch of the shoulder. Each stretch is held for 25 seconds and repeated for a total of 3 times.
89391181|NCT03557996|Experimental|Group 1|38% silver diamine fluoride liquid will be applied twice annually and patients will be followed up as 0,1,3,6,9 and 12 SDF is brush on liquid
89391182|NCT03557996|Active Comparator|Group 2|5% Sodium fluoride varnish will be applied four times annually and patient will be followed up at 0,1,3,6,9 and 12
89391183|NCT03559166|Experimental|cohort 1a - starting dose|Single oral dose of BLD-2660 or placebo capsule administered to healthy volunteers
89391184|NCT03559166|Placebo Comparator|cohort 1b- first SAD escalation|Single oral dose of BLD-2660 or placebo capsule(s) administered to healthy volunteers (1st dose escalation)
89391185|NCT03559166|Placebo Comparator|cohort 1c-2nd SAD escalation|Single oral dose of BLD-2660 or placebo capsule(s) administered to healthy volunteers (2nd dose escalation) in fasting state, followed by washout period and then single oral dose of BLD-2660 or placebo administered to healthy volunteers in fed state.
89391186|NCT03559166|Placebo Comparator|cohort 1d-3rd SAD escalation|Single oral dose of BLD-2660 or placebo capsules(s) administered to healthy volunteers (3rd dose escalation)
89391187|NCT03559166|Placebo Comparator|cohort 1e-4th SAD escalation|Single oral dose of BLD-2660 or placebo capsule(s) administered to healthy volunteers (final dose escalation if assessed as safe).
89391188|NCT03559166|Placebo Comparator|cohort 2a-1st MAD cohort|Multiple oral doses of BLD-2660 or placebo capsule(s) administered to healthy volunteers
89391189|NCT03559166|Placebo Comparator|cohort 2b-2nd MAD escalation|Multiple oral doses of BLD-2660 or placebo capsule(s) administered to healthy volunteers.
88867487|NCT00927576||Control subjects|Control subjects = 237. These subjects underwent extensive testing with computerized neuropsychological tests including digit span testing, spatial span testing, simple reaction time testing, choice reaction time testing, finger tapping, verbal fluency, design fluency, verbal list learning, questionnaire completion, and the trail making test.
88867488|NCT00927576||TBI patients|TBI patients N = 28. These patients underwent extensive testing with computerized neuropsychological tests including digit span testing, spatial span testing, simple reaction time testing, choice reaction time testing, finger tapping, verbal fluency, design fluency, verbal list learning, questionnaire completion, and the trail making test.
88867489|NCT00927888|Active Comparator|1 - Bupivacaine Block|3 ml of 0.25% Bupivacaine with Epi 1:100,000 (A block)
88867490|NCT00927888|Placebo Comparator|2 - Placebo|Normal saline with Epi 1:100,000 (B block)
88867491|NCT00928200|Experimental|Single Arm|All patients receive Vincristine, Dexamethasone, Doxorubicin, and Cytarabine. Dexrazoxane optional on Day 1. Erwinase is started between Days 3-5 and is given every M-W-F for a total of 10 doses. Patients with CNS 1 or 2 receive Methotrexate intrathecally on Day 15. Patients with CNS 3 receive Triple Intrathecal Therapy (Methotrexate, Cytarabine and Hydrocortisone) on Days 8, 15, and 22.
88867492|NCT00929838|Experimental|Diabetes Knowledge/Information Arm|Subjects randomized to the diabetes knowledge/information arm will complete 12 diabetes education modules over a 12-week period. The educational materials were developed based on guidelines for diabetes education by the American Diabetes Association. The content is based on the principles of the Adult Learning Theory. The information is designed to be relevant, person centered, and presented in a non-threatening manner. The modules are designed to be delivered via telephone in 10-15 minutes, so that the maximum contact time per telephone call including introduction and closing would not exceed 30 minutes.
88867493|NCT00929838|Experimental|Motivation/Behavioral Skills Arm|The motivation/behavioral skills intervention consists of patient activation (list of 5 questions to ask their provider at every visit and training on how to ask the questions), patient empowerment (diabetes responsibility contracts, personal goals, and flow charts for patients to record lab results/medications and training on how to use the empowerment tools), and behavioral skills training delivered via telephone lasting 30 minutes every week for 12 weeks. The behavioral skills training will be focused on 4 behaviors - physical activity, diet, medication adherence, and glucose self-monitoring. Guided by subjects' current problem areas and preferences, subjects will be asked to choose 1 of 4 behaviors to focus on every 3 weeks (4 behaviors over 12 weeks).
88867494|NCT00929838|Experimental|Combined Intervention Arm|The combined intervention group will receive weekly telephone-delivered diabetes knowledge/information, patient activation (list of 5 questions to ask their provider at every visit and training on how to ask the questions), patient empowerment (diabetes responsibility contracts, personal goals, and flow charts for patients to record lab results/medications and training on how to use the empowerment tools), and behavioral skills training delivered via telephone. The behavioral skills training will be focused on 4 behaviors and guided by subjects' current problem areas and preferences, subjects will be asked to choose 1 of 4 behaviors to focus on every 3 weeks. The combined intervention group telephone sessions will last for 30 minutes.
88867495|NCT00929838|Sham Comparator|Usual Care Arm|The usual care group will receive weekly telephone-delivered general health education lasting 30 minutes for 12 weeks to control for attention. Patients in the usual care group will continue to receive any usual diabetes education provided by the clinic staff; however, they will not receive targeted diabetes knowledge/information, activation, empowerment, or behavioral skills training.
89391190|NCT03559166|Placebo Comparator|cohort 2c-3rd MAD escalation|Multiple oral doses of BLD-2660 or placebo capsule(s) administered to healthy volunteers.
89391191|NCT03559166|Placebo Comparator|cohort 2d-4th MAD escalation|Multiple oral doses of BLD-2660 or placebo capsule(s) administered to healthy volunteers.
89391192|NCT03559166|Placebo Comparator|cohort 2e-5th MAD escalation|Multiple oral doses of BLD-2660 or placebo capsule(s) administered to healthy volunteers.
89391193|NCT03559166|Placebo Comparator|cohort 2F-6th MAD escalation|Multiple oral doses of BLD-2660 or placebo capsule(s) administered to healthy volunteers.
89391194|NCT02085278|Experimental|Apollo Group|Apollo Micro catheter device
89391195|NCT03559088|Experimental|Migraine Participants Using Application (App)|Participants with migraine history or a recent prescription for a common migraine medication will use a migraine app linked to their electronic health record (EHR) with results reported in their EHR.
89391196|NCT03559088|No Intervention|Controls Not Using App|Observational history on contemporaneous matched controls at similar sites without migraine app linked to their EHR.
89391197|NCT02296801|Active Comparator|A: letrozole|letrozole 2.5 mg tablet orally daily for 14 weeks
89391198|NCT02296801|Experimental|B: letrozole then letrozole + palbociclib|letrozole 2.5 mg orally daily plus beginning 2 weeks after starting letrozole, palbociclib 125 mg capsule orally daily for 1 week then 1 week off, then a 3 weeks on and 1 week off cycle for a total of 14 weeks from start of letrozole therapy
89391199|NCT02296801|Experimental|C: palbociclib then letrozole + palbociclib|palbociclib 125 mg capsule orally daily (for a 3 weeks on and 1 week off cycle for a total of 14 weeks from start of palbociclib) plus beginning 2 weeks after starting palbociclib, letrozole 2.5 mg tablet orally daily for a total of 12 weeks from start of letrozole therapy
89391200|NCT02296801|Experimental|D: letrozole + palbociclib|letrozole 2.5 mg tablet orally daily for a total of 14 weeks plus palbociclib 125 mg capsule orally daily for a 3 weeks on and 1 week off cycle, for a total of 14 weeks from start of therapy
89391201|NCT02296801|Other|Combined Groups B+D+C|Combined data
89391202|NCT02082470|Active Comparator|Arm I (standard post-treatment)|Participants receive standard post-treatment care consisting of regular cancer surveillance visits with treating oncologists.
89391203|NCT02082470|Experimental|Arm II (survivorship care planning)|Participants complete survivorship care planning in close collaboration with treating oncologists.
89391204|NCT02085434|Experimental|FITLINE practice-based referral program|
89391205|NCT02085434|No Intervention|Contemporaneous control|
89391206|NCT02859324|Experimental|CC-122 with Nivolumab|CC-122 orally 5/7 days with nivolumab Intravenously (IV) 3mg/kg every 2 weeks. Cohorts of up to 6 subjects per dose level until Recommended Phase 2 dose (RP2D).
89391207|NCT02085512|Experimental|Neurocognitive retraining|"Neurobehavioral training will be delivered through the web, with prompting for training tasks accomplished through daily emails that include a single integrated log-in system using a customized implementation with OneLogin. All training tasks have game-like features making them visually engaging, and motivating. The training tasks provide immediate feedback about performance, and are specifically designed to target circuitry critical for executive functioning (EF) and emotional reactivity."
89391208|NCT02085512|Placebo Comparator|Control, Web Based Tasks|Engaging daily, for 30 days in web-based video games or reading tasks that do not specifically engage or train neurocognitive functions.
89391209|NCT01365247|Experimental|COPE|Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure
89391210|NCT01365247|Active Comparator|RPT|Relapse Prevention Therapy
89391211|NCT01365247|Active Comparator|Active Monitoring Control Group|
89391212|NCT02085590|Active Comparator|BCG vaccine|BCG vaccine SSI, 0.75mg/ml, injection 0.1 cc intradermal
89391213|NCT02085590|Placebo Comparator|NaCl 0.9%|injection 0.1 cc intradermal
89391214|NCT02143063|Active Comparator|standard care|standard care
89391215|NCT02143063|Active Comparator|standard care plus traditional contingency managment|prize contingency management on a traditional twice weekly schedule for cocaine abstinence
89391216|NCT02143063|Experimental|standard care plus variable interval contingency management|prize contingency management on a variable interval schedule for cocaine abstinence
89391217|NCT02088866|Experimental|Transdermal Lidocaine|All patients will be in this arm. This arm will be the transdermal lidocaine group.
89391218|NCT02859246|Other|Mucinex|600 mg of Mucinex 2 times a day.
89391219|NCT02088944||exposed to IFX|
89186651|NCT02559921|Experimental|HRIG（20 IU/kg）+ vaccine|Subjects received HRIG（20 IU/kg）in combination with rabies vaccine for human use on day 0 and received vaccine only on days 3,7,14,28
89391220|NCT03609606|Experimental|Part A, Sequence1|"Period 1: Treatment of D013, D326 and D337 on Day1~Day7~Period 2: Treatment of D013 on Day22~Day28"
89391221|NCT03609606|Experimental|Part A, Sequence 2|"Period 1: Treatment of D013 on Day1~Day7~Period 2: Treatment of D013, D326 and D337 on Day22~Day28"
89186652|NCT02559921|Placebo Comparator|placebo + vaccine|Subjects received placebo in combination with rabies vaccine for human use on day 0 and received vaccine only on days 3,7,14,28
89391222|NCT03609606|Experimental|Part B, Sequence 1|"Period 1: Treatment of D013, D326 and D337 on Day1~Day7~Period 2: Treatment of D326 and D337 on Day22~Day28"
89391223|NCT03609606|Experimental|Part B, Sequence 2|"Period 1: Treatment of D326 and D337 on Day1~Day7~Period 2: Treatment of D013, D326 and D337 on Day22~Day28"
89391224|NCT02073097|Experimental|rituximab, combination chemotherapy, carfilzomib|"Participants receive (every 21 day cycle):~Rituximab IV over at least 90 minutes on day 2~Carfilzomib IV over 30 minutes on days 1, and 2~Cyclophosphamide IV over 30-60 minutes on day 3~Doxorubicin hydrochloride IV over 3-5 minutes on day 3~Vincristine sulfate IV over 1 minute on day 3~Prednisone PO on days 3-7 any time~Pegfilgrastim day 4~Acyclovir 2x per day from cycle 1, 6 months after completion of cycle 6~Courses repeat every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity."
89391225|NCT02082548|Experimental|Intervention|educational intervention arm
89391226|NCT02082548|No Intervention|control|Standard of care
89391227|NCT04523298|Experimental|Laser|
89391228|NCT04523298|Active Comparator|PFE|
89391229|NCT02089022|Experimental|Physiotherapy resources|The goal of applying ice and shortwave diathermy to the calf, ankle and sole of the foot was to verify the effect of this resources at the neuromuscular response of the lower limb and postural balance
89186653|NCT00754143|Placebo Comparator|A|Placebo
89391230|NCT03609528|Experimental|CamPROBE biopsy method|To be completed
89391231|NCT01443637||Coronary CT Angiography (CCTA)|Patients included in the CONFIRM Registry are those that have previously undergone clinically-indicated CCTA as part of their standard of care.
89391232|NCT04435470||Critical ill children|Critial ill children admited in pediatric intensive care units 1-16 years old
89391233|NCT04435470||Control|Healthy children 1-16 years old
89391234|NCT02082626|Experimental|Eribulin|All patients will receive the experimental agent eribulin. The dose will increase with subsequent cohorts of patients.
89391235|NCT03610152|No Intervention|Control|Hospitals made aware of Choosing Wisely Canada recommendations and Health Quality Ontario data.
89391236|NCT03610152|Experimental|Hospital wide policy|A hospital-wide policy will be implemented whereby medically necessary preoperative tests for patients undergoing ambulatory surgery will be ordered at the discretion of the consulting anesthesiologists based on their clinical assessment of the patient.
89391237|NCT02089100|Experimental|stereotactic body radiation therapy|The SBRT of all metastases should start in maximum 4 weeks after randomization. Beginning of systemic treatment will take place before 2 and 7 days after SBRT completion. All metastases lesions should be treated every 48h.
89391238|NCT02089100|Active Comparator|no specific treatment|no specific treatment to the oligometastatic sites except for palliation (pain, compression, hemorrhage)
89391239|NCT01083433|No Intervention|Standard Diabetes Care|Patients will attend diabetes clinic as usual, once every 3 months.
89391240|NCT01083433|Experimental|Intensive Diabetes Clinic|Patients will attend diabetes clinic on a monthly basis for 4 months in a row. Each patient will have a 30 minute visit with a physician, 30 minutes dedicated to diabetes education, and 45 minutes with a child psychologist.
89391241|NCT01083433|Experimental|Intensive Diabetes Clinic plus CGM|Patients in this group will include all procedures as listed for group 2 (intensive diabetes clinic) in addition to wearing a continuous glucose monitor for 3-5 days each month. Patients will also have an additional 30 minutes with a psychology graduate student dedicated to adherence with the CGM.
89391242|NCT02082704|Experimental|SE Game on DSME|The intervention cohort will participate in an online team-based game on diabetes self-management education (DSME) and will receive a paper documents on American history,
89391243|NCT02082704|Active Comparator|SE Game on American History|The 'attention control' cohort will participate in an online team-based game on American history and will receive a paper documents on DSME.
89391244|NCT02791490|Experimental|Sitagliptin|Participants will receive sitagliptin 100 mg once daily for 20 weeks. They will also receive immediate-release metformin (Met-IR), which will be titrated from a baseline dose of 1000 mg/day (500 mg/twice a day [b.i.d.]) up to 2000 mg/day (1000 mg/b.i.d.) by Day 15. Participants will also receive glycemic rescue therapy as needed.
89391245|NCT02791490|Placebo Comparator|Placebo|Participants will receive placebo matching sitagliptin once daily for 20 weeks. They will also receive Met-IR, which will be titrated from baseline dose of 1000 mg/day (500 mg/b.i.d.) up to 2000 mg/day (1000 mg/b.i.d.) by Day 15. Participants will also receive glycemic rescue therapy as needed.
89391246|NCT02821143|Experimental|Intervention group|Every patient identified as belonging to a palliative care after the inclusion criteria will receive intervention with a follow-up with Telemedicine consultation
88867496|NCT00931164|Experimental|Sodium oxybate|"The study is an open-label, Phase I/II trial designed to obtain additional safety and pharmacokinetic parameters for use of sodium oxybate in children and adolescents afflicted with AHC.~Given the limited number of children carrying the diagnosis of AHC, typical controls will not be available for our study. In lieu of this, the subjective recording of ictal episodes in the 6 week period prior to drug initiation will serve as reference in determining drug efficacy."
88867497|NCT00931242|Experimental|Apremilast|Apremilast is being evaluated at daily doses of 20 mg by mouth (PO) twice daily (BID) for 12 weeks of treatment (treatment phase) in subjects with recalcitrant plaque-type Atopic Dermatitis (AD) or Allergic Contact Ddermatitis (ACD).
88867498|NCT00932022|Experimental|trospium chloride XR 60 mg|Placebo capsule taken orally once daily for 2 weeks followed by trospium chloride extended release (XR) 60 mg capsule taken orally once daily for 12 weeks.
88867499|NCT00932022|Placebo Comparator|placebo|Placebo capsule taken orally once daily for 14 weeks.
88867500|NCT00934596|Experimental|Lund de-airing|Lund de-airing technique
88867501|NCT00934596|Active Comparator|Carbon-dioxide insufflation|carbon-dioxide insufflation will be provided to the open mediastinal wound in a standardized manner
88867502|NCT00935064|Active Comparator|Aliskiren|Pill, 300 mg, once daily, for 6 weeks
88867503|NCT00935064|Placebo Comparator|Placebo|
88867504|NCT00935766|Placebo Comparator|Sugar Pill|4 tabs of placebo dependent on randomization
89186654|NCT00754143|Experimental|B|FG-3019 5 mg/kg
89391247|NCT02821143|Other|Control group|Every patient identified as belonging to a palliative care after the inclusion criteria will receive Usual palliative care
89391248|NCT02660775|Experimental|schizophrenia|this project is to assess relevance of ClaCoS in schizophrenia compared to healthy controls, and to analyze links between social cognition and both neurocognition and symptoms, (2) to collect data in a large sample of healthy controls in order to establish appropriate standards for tools composing ClaCoS battery.
89391249|NCT02660775|Experimental|autism|this project is to assess relevance of ClaCoS in autism compared to healthy controls, and to analyze links between social cognition and both neurocognition and symptoms, (2) to collect data in a large sample of healthy controls in order to establish appropriate standards for tools composing ClaCoS battery.
89391250|NCT02660775|Placebo Comparator|healthy controls|this project is to assess relevance of ClaCoS in autism compared to healthy controls, and to analyze links between social cognition and both neurocognition and symptoms, (2) to collect data in a large sample of healthy controls in order to establish appropriate standards for tools composing ClaCoS battery.
89391251|NCT01365325|Experimental|handled echocardiography|home monitoring care program based on clinical and electrocardiographic evaluations and periodical handled echocardiographic examinations
89391252|NCT01365325|Active Comparator|home monitoring program|home monitoring care program based on clinical and electrocardiographic evaluations
89391253|NCT01368367|Active Comparator|Intensive exercise group|
89391254|NCT01368367|Placebo Comparator|Stretch exercise only|
89391255|NCT02833935|Experimental|Physical Activity Intervention Group|Participants will complete a baseline questionnaire (week 1) about their demographic information, self-determination theory variables, their current physical activity, and other psychological indicators. They will complete the same questionnaire at two additional time points. First, about halfway through the intervention (week 6), and then at the end (week 10). Participants in the physical activity intervention group will also receive 8 1-hour physical activity sessions over 2 months (1/week) with a trained physical activity counselor through a video-based internet platform.
89391256|NCT02833935|No Intervention|Control Group|Control Group: For participants assigned to the control group, they will be asked to continue with their regular routine for the next two months. Otherwise, the participants in this group will be asked to complete the follow-up baseline questionnaires at 6 and 10 weeks post-baseline. They will be contacted by a physical activity counsellor at the end of the 10-week period.
89391257|NCT02085824|Experimental|enoxaparin|enoxaparin 40mg 1x1 s.c. daily, once preoperatively and then daily for 28 days
89391258|NCT02085824|Experimental|rivaroxaban|rivaroxaban 10 mg 1x1 p.o. daily for 28 days after the surgery
89391259|NCT02085824|Experimental|dabigatran|dabigatran 110 mg 1x1 p.o. postoperatively and then 1x2 p.o. for 27 days after the surgery
89391260|NCT01368445|Active Comparator|MP03-36 Nasal Spray|azelastine hydrochloride 0.15%
89391261|NCT01368445|Active Comparator|MP03-36 and Placebo Nasal Spray|azelastine hydrochloride 0.15% and Placebo
89391262|NCT01368445|Active Comparator|Azelastine 0.1%, Nasal Spray|Azelastine 0.1%, Nasal Spray
89391263|NCT01368445|Placebo Comparator|Placebo Nasal Sapray|0mg, 2 sprays per nostril twice daily AM & PM)
89391264|NCT02085902|No Intervention|standard anesthesia|
89391265|NCT02085902|Experimental|standard anesthesia with ropivacaine|ropivacaine
89391266|NCT02654223|Experimental|MG56 Mannosylated 500 subcutaneous|500 mTU/mL of subcutaneous immunotherapy and sublingual placebo.
89391267|NCT02654223|Experimental|MG56 Mannosylated 1000 subcutaneous|1000 mTU/mL of subcutaneous immunotherapy and sublingual placebo.
89391268|NCT02654223|Experimental|MG56 Mannosylated 3000 subcutaneous|3000 mTU/mL of subcutaneous immunotherapy and sublingual placebo.
89391269|NCT02654223|Experimental|MG56 Mannosylated 5000 subcutaneous|5000 mTU/mL of subcutaneous immunotherapy and sublingual placebo.
89391270|NCT02654223|Experimental|MG56 Mannosylated 500 sublingual|500 mTU/mL of sublingual immunotherapy and subcutaneous placebo.
89391271|NCT02654223|Experimental|MG56 Mannosylated 1000 sublingual|1000 mTU/mL of sublingual immunotherapy and subcutaneous placebo.
89391272|NCT02654223|Experimental|MG56 Mannosylated 3000 sublingual|3000 mTU/mL of sublingual immunotherapy and subcutaneous placebo.
89391273|NCT02654223|Experimental|MG56 Mannosylated 5000 sublingual|5000 mTU/mL of sublingual immunotherapy and subcutaneous placebo.
89391274|NCT02654223|Placebo Comparator|Placebo Sublingual Placebo subcutaneous|Sublingual and subcutaneous placebo.
89391275|NCT01368523|Experimental|nilotinib|
89391276|NCT02082860|Experimental|Cohort A|rAAV2/5-PBGD vector dosage 1
89391277|NCT02082860|Experimental|Cohort B|rAAV2/5-PBGD vector dosage 2
89391278|NCT02082860|Experimental|Cohort C|rAAV2/5-PBGD vector dosage 3
89391279|NCT02082860|Experimental|Cohort D|rAAV2/5-PBGD vector dosage 4
89391280|NCT01368601|Active Comparator|CPAP (positive airway pressure)|To evaluate if continuous positive airway pressure(CPAP) on the lung undergoing lobectomy can decrease the inflammatory response PPC (postoperative pulmonary complications).
89391281|NCT01368601|No Intervention|Control without CPAP|
89391282|NCT02086136||Suspected AD|Consecutive adult patients with suspected AD presenting to Emergency Departments will be enrolled at the time of initial medical evaluation and before the establishment of a final diagnosis.
89391283|NCT01368679|Experimental|Endoprothesis Scitech|"The endoprothesis of SCITECH is a self-expandable stent mixed (laser cut and wire plotted) covered with polyester fabric. The delivery system has lower profile than the existing market and this approach allows the passage of the delivery system through the femoral artery with ease and without dissection. Fixation has proximal and distal securing lower rates of leakage and displacement.~The delivery system is done by linear drive or screw diameters greater than 30mm"
89391284|NCT02507973||Airway Pressure Release Ventilation:APRV|Each participant will serve as his/her own control using our observational crossover study comparing the effects of Airway Pressure Release Ventilation and Low Tidal Volume Ventilation on patient intracranial pressure and hemodynamic values.
89391285|NCT02507973||Low Tidal Volume Ventilation:LOTV|Each participant will serve as his/her own control using our observational crossover study comparing the effects of Airway Pressure Release Ventilation and LOTV on patient intracranial pressure and hemodynamic values.
89391286|NCT03558386||Patients between 55-64 years of age|"Patients between 55-64 years who have had a transplant at the following time points:~6 months to 1 year ago~1 year to 3 years ago~3 years ago or more"
89391287|NCT03558386||Patients 65+ years of age|"Patients 65+ years of age who have had a transplant at the following time points:~6 months to 1 year ago~1 year to 3 years ago~3 years ago or more"
89391288|NCT02086214|Experimental|Proprioceptive pressure therapy|Proprioceptive pressure therapy using a a LYCRA® compressive sleeve initially used in burn therapy : 15 to 25 mmHg.
89391289|NCT02086214|Placebo Comparator|Control|LYCRA® non-compressive sleeve initially used in burn therapy : < 5 mmHg.
89391290|NCT02082938|Experimental|Bracing|Bracing: the patients began four weeks of training the gait with the brace, under the guidance and observation of the physiotherapist belonging to the group of authors of this study.
89391291|NCT04893187|Experimental|Part 1: Single Dose Escalation SSS17|Escalating doses of SSS17, single dose administration
88867505|NCT00935766|Active Comparator|Omega 3|omega-3-acid ethyl esters and instructed to take 4 1 mg capsules daily
89391292|NCT04893187|Placebo Comparator|Part 1: Single Dose Escalation matching Placebo|Escalating doses of matching placebo, single dose administration
89391293|NCT04893187|Experimental|Part 2: Multiple Dose Escalation SSS17|Escalating doses of SSS17, multiple dose administration
89391294|NCT04893187|Placebo Comparator|Part 2: Multiple Dose Escalation matching Placebo|Escalating doses of matching placebo, multiple dose administration
89186655|NCT00754143|Experimental|C|FG-3019 10 mg/kg
89391295|NCT04893187|Experimental|Part 3: Treatment Sequence 1 (A to B)|The subjects in the first cycle received oral administration of SSS17 on an empty stomach, and subjects in the second cycle received oral administration of SSS17 after a high-fat meal
89391296|NCT04893187|Experimental|Part 3: Treatment Sequence 2 (B to A)|The subjects in the first cycle received oral administration of SSS17 after a high-fat meal, and the subjects in the second cycle received oral administration of SSS17 on an empty stomach
89391297|NCT03558308|Experimental|Brain+ with clinical support|Intervention: Computer based cognitive rehabilitation. This group will train with the programme 'Brain+' and receive continuous support from a clinician during the intervention period.
89391298|NCT03558308|Experimental|Cogmed with continuous support|Intervention: computer based cognitive rehabilitation. This group will train with the programme 'Cogmed' and receive continuous support from a clinician during the intervention period.
89391299|NCT03558308|Experimental|Brain+ without support|Intervention: computer based cognitive rehabilitation. This group will train with the programme 'Brain+' but receive no support during the intervention period.
89391300|NCT03558308|Sham Comparator|Sham-training group|Intervention: Sham computerized gaming. This group will train computerized solitaire and other computerized games which are thought to be generally cognitive stimulating but with a very limit load on executive functions. This group will receive continuous support during the intervention period.
89391301|NCT02086292|Experimental|2 milliliter lidocaine|2 ml 1% Lidocaine in one ring finger, 1 ml 2% Lidocaine in the other ring finger
89391302|NCT02086292|Experimental|1 milliliter lidocaine|1 ml 1% Lidocaine in one ring finger, 2 ml 2% Lidocaine in the other ring finger
88867506|NCT00937794||No treatment|This is a screening study designed to evaluate the behavioral, physical, and neurodevelopmental status in pediatric patients with Hunter syndrome who have early signs and symptoms of CNS involvement and who are currently receiving treatment with Elaprase.
88867507|NCT00939120|Experimental|Tolterodine ER 4mg|1:1 randomization to either Dutasteride 0.5mg orally once daily plus Tolterodine ER 4mg orally once daily or Dutasteride 0.5mg orally once daily plus placebo once daily
88867508|NCT00939120|Placebo Comparator|placebo|1:1 randomization to either Dutasteride 0.5mg orally once daily plus Tolterodine ER 4mg orally once daily or Dutasteride 0.5mg orally once daily plus placebo once daily
88867509|NCT00939198|Experimental|Na-ASP-2 Hookworm Antigen Skin Test|All participants will be skin tested with Na-ASP-2 skin test reagent applied to their arms, using both the prick-puncture and intradermal techniques.
88867510|NCT00939900|Experimental|aclasta|aclasta group
88867511|NCT00939900|No Intervention|control|control group
88867512|NCT00940290|Other|GRADE system|A clinical recommendation built and graded with the GRADE working group system
88867513|NCT00940290|Other|SIGN grading system|A clinical recommendation built and graded with the Scottish Intercollegiate Guidelines Network system
88867514|NCT00940290|Other|NICE grading system|A clinical recommendation built and graded with National Institute of Clinical Excellence grading system
88867515|NCT00940290|Other|CEBM-Oxford|A clinical recommendation built and graded with the Centre for Evidence-Based Medicine grading system
88867516|NCT00940446|Experimental|Insorb staples|Subcuticular Absorbable staples
88867517|NCT00940446|Active Comparator|Control|Metal staple wound closure
88867518|NCT00942786||No treatment|Consecutive patients undergoing emergency surgery
88867519|NCT00943098|Experimental|Diclofenac HPBCD s.c. 75mg/ml|
88867520|NCT00943098|Active Comparator|Voltarol 75mg/3ml i.m.|
88867521|NCT00943488|Experimental|Group 1: H1N1 Vaccine 15 mcg|200 subjects (100 subjects ages 18-64 and 100 subjects greater than or equal to age 65) to receive 15 mcg of H1N1 vaccine on Days 0 and 21.
88867522|NCT00943488|Experimental|Group 2: H1N1 Vaccine 30 mcg|200 subjects (100 subjects ages 18-64 and 100 subjects greater than or equal to age 65) to receive 30 mcg of H1N1 vaccine on Days 0 and 21.
88867523|NCT00943800|Experimental|Good Risks patients|For patients transplanted in remission.
88867524|NCT00943800|Experimental|High Risk Patients eligible for radiation|
88867525|NCT00943800|Experimental|High Risk Patients not eligible for radiation|
88867526|NCT00943878|Experimental|Group 3: H1N1+placebo; H1N1+TIV; placebo|200 subjects (100 ages 18-64 years and 100 aged greater than or equal to 65 years) to receive: Day 0, 15 mcg H1N1 Vaccine + placebo; Day 21, 15 mcg H1N1 Vaccine + trivalent influenza vaccine (TIV); and Day 42, placebo.
88867527|NCT00943878|Experimental|Group 1: H1N1+placebo; H1N1+placebo; TIV|200 subjects (100 ages 18-64 years and 100 aged greater than or equal to 65 years) to receive: Day 0, 15 mcg H1N1 Vaccine + placebo; Day 21, 15 mcg H1N1 Vaccine + placebo; and Day 42, trivalent influenza vaccine (TIV).
88867528|NCT00943878|Experimental|Group 2: H1N1+TIV; H1N1+placebo; placebo|200 subjects (100 ages 18-64 years and 100 aged greater than or equal to 65 years) to receive: Day 0, 15 mcg H1N1 Vaccine + trivalent influenza vaccine (TIV); Day 21, 15 mcg H1N1 Vaccine + placebo; and Day 42, placebo.
88867529|NCT00943878|Experimental|Group 4: TIV+placebo; H1N1+placebo; H1N1|200 subjects (100 ages 18-64 years and 100 aged greater than or equal to 65 years) to receive: Day 0, trivalent influenza vaccine (TIV) + placebo; Day 21, 15 mcg H1N1 Vaccine + placebo; and Day 42, 15 mcg H1N1 vaccine.
88867530|NCT00945282|Experimental|Cohort 1|In Cohort 1 subjects will receive either GSK2248761 30 mg or placebo once a day for 7 days. On Day 8 subjects will receive either Kaletra or HAART for 28 days. The doctor will choose the most appropriate medications for HAART.
88867531|NCT00945282|Experimental|Cohort 2|In Cohort 2 subjects will receive either GSK2248761 in the range of 10 mg - 20 mg or 40 mg - 90 mg or placebo once a day for 7 days. On Day 8 subjects will receive either Kaletra or HAART for 28 days. The doctor will choose the most appropriate medications for HAART. The dose for Cohort 2 will be determined following evaluation of results from Cohort 1. Cohort 2 may not be done.
88867532|NCT00945594|Experimental|Flexible cystoscopy|16F flexible cysto urethroscope (Storz, Culver city, CA)
88867533|NCT00945594|Experimental|Rigid cystoscopy|17F, 70° scope (Storz, Culver city, CA)
88867534|NCT00945750|Experimental|Sequence 1: FCT with water → CT without water → CT with water|Participants received famotidine 20 mg FCT as a single dose with 120 mL of water (Period 1), followed by a 5- to 7-day washout, followed by famotidine 20 mg CT as a single dose without water (Period 2), followed by a 5- to 7-day washout, followed by famotidine 20 mg CT as a single dose with 120 mL of water (Period 3).
88867535|NCT00945750|Experimental|Sequence 2: CT without water → CT with water → FCT with water|Participants received famotidine 20 mg CT as a single dose without water (Period 1), followed by a 5- to 7-day washout, followed by famotidine 20 mg CT as a single dose with 120 mL of water (Period 2), followed by a 5- to 7-day washout, followed by famotidine 20 mg FCT as a single dose with 120 mL of water (Period 3).
89186656|NCT02588768|Active Comparator|Active PBMT|Active PBMT was applied employing MR4 Laser Therapy Systems outfitted with LaserShower 50 4D emitters (both manufactured by Multi Radiance Medical, Solon - OH, USA). The cluster style emitter contains 12 diodes comprising of four super-pulsed laser diodes (905 nm, 0.3125 mW average power, and 12.5 W peak power for each diode), four red LED diodes (640 nm, 15 mW average power for each diode), and four infrared LEDs diodes (875 nm, 17.5 mW average power for each diode).
88867536|NCT00945750|Experimental|Sequence 3: CT with water → FCT with water → CT without water|Participants received famotidine 20 mg CT as a single dose with 120 mL of water (Period 1), followed by a 5- to 7-day washout, followed by famotidine 20 mg FCT as a single dose with 120 mL of water (Period 2), followed by a 5- to 7-day washout, followed by famotidine 20 mg CT as a single dose without water (Period 3).
88867537|NCT00945750|Experimental|Sequence 4: FCT with water → CT with water → CT without water|Participants received famotidine 20 mg FCT as a single dose with 120 mL of water (Period 1), followed by a 5- to 7-day washout, followed by famotidine 20 mg as a single dose with 120 mL of water (Period 2), followed by a 5- to 7-day washout, followed by famotidine 20 mg CT as a single dose without water (Period 3).
89186657|NCT02588768|Placebo Comparator|Placebo PBMT|Placebo PBMT was applied using the same device that emitted the same sounds and light, but with no effective irradiation.
89391303|NCT02083016|Other|Conventional Mapping|Both pre and post-ablation mapping will be performed firstly by conventional point by point mapping using a Navistar Thermocool catheter, and secondly by multielectrode contact mapping using a Pentaray catheter. In this group, ablation will be guided by conventional mapping.
89391304|NCT02083016|Other|Multielectrode mapping.|Both pre and post-ablation mapping will be performed firstly by multielectrode contact mapping using a Pentaray catheter, and secondly by conventional point by point mapping using a Navistar Thermocool catheter. In this group ablation will be guided by multielectrode contact mapping.
89391305|NCT02086370|Active Comparator|Standard PBS|the tube will be removed by coagulation and section of the tissue beginning from the very distal fimbrial and proceeding toward the uterine cornu. The resection will be performed at the level of the posterior tubal margin, sparing the mesosalpinx
89391306|NCT02086370|Experimental|Radical PBS|the tube will be removed by coagulation and section of the tissue beginning from the very distal fimbrial and proceeding toward the uterine cornu. The resection will be performed at the level of ovarian margin and the uterus-ovarian ligament, including the mesosalpinx removal
89391307|NCT02083172||Hemodynamically stable patients|Hemodynamically stable patients will be defined as patients with normal hemodynamic profile as evidenced by normal age-determined vital signs and normal perfusion.
89391308|NCT02083172||Hemodynamically unstable patients|Hemodynamically unstable patients will be defined as patients who are admitted to the Pediatric Critical Care Unit (PCCU), in whom there is a clinical diagnosis of shock as evidenced by signs and symptoms of hypoperfusion, requiring fluid resuscitation and/or inotropic support.
89391309|NCT02083172||Mechanically ventilated patients|Patients requiring mechanical ventilation
89391310|NCT02425644|Experimental|Ponesimod|Subjects to receive 20 mg ponesimod
89391311|NCT02425644|Active Comparator|Teriflunomide|Subjects to receive 14 mg teriflunomide
89391312|NCT02184741|Placebo Comparator|Placebo|Infusion of normal saline
89391313|NCT02184741|Experimental|GB-0998|Infusion of GB-0998 (Immunoglobulin)
89391314|NCT02086526|Experimental|Metformin|Metformin 500 mg. extended release (taken orally) one tablet with evening meal for one week, one tablet with morning and evening meal for one week, and one tablet at all three meals for the next three months.
89391315|NCT02086526|Other|Delayed Start Metformin|After baseline study visit, this arm will return after three months without metformin for a repeat of the baseline study visit prior to initiating metformin 500 mg. extended release (taken orally) one tablet with evening meal for one week, one tablet with morning and evening meal for one week, and one tablet at all three meals for the next three months.
89391316|NCT04180995|Experimental|Toripalimab, Axitinib|The subjects will receive Toripalimab and Axitinib combined therapy after enrollment, and receive operation 2 weeks after the last dose of Axitinib. Toripalimab will be given for a total of 4 cycles (8 weeks), whereas Axitinib will be given for a total of 8 weeks.The subjects can receive Toripalimab for up to one year after the operation.
89391317|NCT02627690||Islet transplanted|patients who underwent islet transplantation
89391318|NCT02627690||non islet transplanted|patients who refused or were non selected for islet transplantation for a non nephrologic reason
89391319|NCT04174521||Mother-Child|Mothers who have delivered at VUMC and their children who are seen by Vanderbilt-affiliated physicians.
89391320|NCT03558776|Active Comparator|Linseed oil plus defined background diet (high linolec acid)|Linseed oil (LO) plus daily menu plans (total dietary fat intake: 30 En%): 10 En% LO plus menu plan with 20 En% fat: A) 7 ± 2 En% linoleic acid (n = 37)
88867538|NCT00945750|Experimental|Sequence 5: CT without water → FCT with water → CT with water|Participants received famotidine 20 mg CT as a single dose without water (Period 1), followed by a 5- to 7-day washout, followed by famotidine 20 mg FCT as a single dose with 120 mL of water (Period 2), followed by a 5- to 7-day washout, followed by famotidine 20 mg CT as a single dose with 120 mL of water (Period 3).
88867539|NCT00945750|Experimental|Sequence 6: CT with water → CT without water → FCT with water|Participants received famotidine 20 mg CT as a single dose with 120 mL of water (Period 1), followed by a 5- to 7-day washout, followed by famotidine 20 mg CT as a single dose without water (Period 2), followed by a 5- to 7-day washout, followed by famotidine 20 mg FCT as a single dose with 120 mL of water (Period 3).
89391321|NCT03558776|Active Comparator|Linseed oil plus defined background diet (low linolec acid)|Linseed oil (LO) plus daily menu plans (total dietary fat intake: 30 En%): 10 En% LO plus menu plan with 20 En% fat: B) < 2.5 En% linoleic acid (n = 37)
89391322|NCT03558776|Active Comparator|Linseed oil plus defined background diet (high milk)|Linseed oil (LO) plus daily menu plans (total dietary fat intake: 30 En%): 10 En% LO plus menu plan with 20 En% fat: C) 15 ± 2 En% milk fat (n = 37)
89391323|NCT03558776|Placebo Comparator|Linseed oil without defined background diet|Linseed oil (LO) without defined menu plans (D) Western diet, n = 37)
89391324|NCT02089178|Experimental|intravenous|the total intravenous anesthesia group
89391325|NCT02089178|Active Comparator|inhalation|the inhalation anesthesia group
89391326|NCT02089256|Experimental|Liraglutide|Liraglutide 0.6 mg/day subcutaneously.
89391327|NCT02090816||Surgery of liver and lung|Patients carriers of both liver and right lung metastases in the same time
89391328|NCT04099329|Experimental|Pre-game Safety Huddles|Pre-game safety huddles will occur before each game and athletes and coaches will be surveyed.
88867540|NCT00947310|Experimental|A|Standard ICD Programming
88867541|NCT00947310|Experimental|B|High rate cutoff
88867542|NCT00947310|Experimental|C|Long ICD duration delay
89391329|NCT04099329|No Intervention|Control|No intervention will be delivered by athletes and coaches will be surveyed.
89391330|NCT02086760|Experimental|Ultrasonography sensibilized by oral hydratation|Ultrasonography before, 30 min and 90 min following hydratation.
89391331|NCT02861664|Experimental|Test Dentifrice: Stannous fluoride (SnF2)|Participants were instructed to apply a strip of dentifrice containing 0.454% stannous fluoride (SnF2) and 0.072% sodium fluoride (NaF) (1450 parts per million [ppm] fluoride in total) to cover the head of the toothbrush and brush their teeth for 1 timed minute, twice daily (morning and evening), following their normal routine. Participants were also permitted to rinse with tap water.
89391332|NCT02861664|Active Comparator|Negative Control Dentifrice: Sodium monofluorophosphate (SMFP)|Participants were instructed to apply a strip of dentifrice containing 1400ppm fluoride as sodium monofluorophosphate (SMFP) to cover the head of the toothbrush and brush their teeth for 1 timed minute, twice daily (morning and evening), following their normal routine. Participants were also permitted to rinse with tap water.
89391333|NCT02086838|Active Comparator|Theragran Hematinic, oral iron, 120 mg elemental iron/|pregnant women taking 60 mg elemental iron twice per day (120 mg/day) using iron tablets (Theragran Hematinic)® SmithKline Beecham, Egypt an affiliated co. to GlaxoSmithKline. Adherence to the treatment will be monitored by asking the women to bring back the empty packs and mark the consumption of tablets on calendar.
89391334|NCT02086838|Active Comparator|low molecular weight iron dextran, total dose infusion|Pregnant women taking elemental iron in the form of low molecular weight dextran complex intravenously as a total dose infusion (T.D.I) using iron dextran ampules (Cosmofer)R pharmacosmos Denmark (Inspire Pharma Egypt). Patients selected for parental iron will be admitted as day cases in the hospital in a single visit. The required dose has to be individually adapted according to the total iron deficit which is dependent on the patient's body weight and hemoglobin status. Total iron dose (mg) = weight (kg) X Hemoglobin deficit {target Hemoglobin (g/l)- Actual Hemoglobin (g/l)} X 0.24 + 500 mg.
89391335|NCT04400604||1: Patients with minimal risk of extensive fibrosis|TE < 5.8kPa; rule out cut-off value)
89391336|NCT04400604||2: Patients with intermediate risk of fibrosis|
89391337|NCT04400604||Patients with high risk of extensive fibrosis|
89391338|NCT04400604||Patients with compensated cirrhosis biopsy-proven|
89391339|NCT04400604||Patients with a first decompensation|patients with a first decompensation event of cirrhosis after exclusion of HCC.
89391340|NCT02086916||Inpatients who test positive for CDI|Observational study, hence no intervention will be administered
88867543|NCT00948090|Experimental|IV Busulfan|Pk-directed IV Busulfan (based on test dose method) for 4 days followed by Etoposide 1400mg/m2 QD for one day and Cyclophosphamide 2.5 g/m2 QD for two days followed by autologous stem cell transplant
88867544|NCT00948792|Active Comparator|Long transfusion group|This group of thrombocytopenic neonates who (as determined by the attending physician) are in need of a platelet transfusion will receive the transfusion over a period of two hours.
88867545|NCT00948792|Experimental|Short transfusion group|This group of thrombocytopenic neonates who (as determined by the attending physician) are in need of a platelet transfusion will receive the transfusion over a period of 30 minutes.
88867546|NCT00950352|Experimental|Citicoline|In a double-blind randomization design, subjects with methamphetamine dependence will be treated with citicoline or placebo for 8-9 weeks.
88867547|NCT00950352|Placebo Comparator|Placebo|In a double-blind randomization design, subjects with methamphetamine dependence will be treated with citicoline or placebo for 8-9 weeks.
88867548|NCT00953862|Experimental|Atomoxetine Treatment Arm|Patients who were identified as having adult ADHD on the ACDS were offered an open label treatment trial with atomoxetine, up to 120 mg/day over 10 weeks. Atomoxetine was titrated over a period of four weeks based upon clinical response and observed side-effects. All patients receiving atomoxetine gave written informed consent prior to participation and were assessed for ADHD symptoms via the Adult Investigator Adult ADHD Symptom Rating Scale (AISRS) every 1-2 weeks. All patients received a physical exam, review of systems and routine blood work prior to treatment. Data were analyzed for patients completing at least 2 weeks of atomoxetine therapy. Treatment response was pre-hoc defined as having a >=30% reduction in total AISRS scores from baseline.
88867549|NCT00955032|Experimental|High-Frequency Repetitive Transcranial Magentic Stimulation|High-Frequency repetitive transcranial magnetic stimulation patients randomized to this treatment will receive left prefrontal rTMS, each treatment will consist of 2000 stimuli (50 - 8-second trains of 40 stimuli at 5 Hz). We will administer rTMS trains every 30 seconds for 25 minutes. Stimulus intensity for the first and second trains will be 80 and 90% of Motor Evoked Potential (MEP) threshold, respectively.
89391341|NCT02236962|Placebo Comparator|Placebo|lactose powder in equivalent capsule
89391342|NCT02236962|Experimental|Drug treatment|sympathetic agonist and thiazolidinedione
89391343|NCT04431375|Experimental|plasma Exchange+Tenofovir+FMT|Subjects will receive Plasma exchange 2 sessions alternate day followed by FMT for 7 days and Tenofovir [antiviral] 300mg PO once a day .
89391344|NCT04431375|Active Comparator|Tenofovir|TabletTenofovir [antiviral] 300mg per oral once a day
89391345|NCT02090972||Patients with fracture|"fracture within the last 14 days~no other fractures within the last 6 month~patients >60 years"
88867550|NCT00955032|Sham Comparator|Sham Repetitive Transcranial Magentic Stimulation|Sham repetitive transcranial magnetic stimulation patients randomized to receive the sham rTMS will undergo the same procedure for identifying stimulus location used in patients receiving real rTMS. Simulated rTMS will be administered using Magstim Placebo 70 mm figure-of-8 shaped coils which produce discharge noise and vibration similar to a real 70 mm coil without stimulating the cerebral cortex. However, in addition to obvious coil discharge noise, rTMS also causes electrical stimulation of the scalp. We will simulate this experience by attaching surface electrodes underneath the sham coil and in contact with the scalp.
88867551|NCT00955266|Active Comparator|Calcium Chloride|Calcium chloride, 10mg/kg
89391346|NCT02090972||Control Patients|"patients hospitalized for an internal reason~no other fractures within the last 6 month~patients >60 years"
89391347|NCT02086994|Active Comparator|cabetocin|a single dose of carbetocin (100 μg in 1 mL ampoule, Pabal) given intravenously after delivery of anterior shoulder
89391348|NCT02086994|Active Comparator|misoprostol|misoprostol (600 μg, 3 tables) sublingually after the delivery of the anterior shoulder of the baby.
89391349|NCT01307787|Experimental|fit-program|Participants in the intervention group followed an eight week multi-disciplinary group rehabilitation program, consisting of a physical exercise part and an educational component.
89391350|NCT01307787|Other|waiting list control group|The waiting-list control group was allowed to enter the FIT program for rehabilitation after the study period.
89391351|NCT02089412|Experimental|E2006: fed conditions|E2006 10-mg will be administered as a single dose under fed treatment conditions.
89391352|NCT02089412|Experimental|E2006: fasted conditions|E2006 10-mg will be administered as a single dose under fasted treatment conditions.
89391353|NCT03557606||Alar treatment with BMC|Patients with CCJ instability that receive Alar treatment with BMC using anterior approach.
89391354|NCT02091050|Other|HDR Brachytherapy 24Gy (4 x 6Gy)|Vaginal vault brachytherapy, associated or not with external beam radiotherapy.
88867552|NCT00955266|Placebo Comparator|Placebo|Normal saline
88867553|NCT00957684|Experimental|ESL 400 mg once daily|ESL was supplied in 400-mg and 800-mg tablets
88867554|NCT00957684|Experimental|ESL 800 mg once daily|ESL was supplied in 400-mg and 800-mg tablets
88867555|NCT00957684|Experimental|ESL 1200 mg once daily|ESL was supplied in 400-mg and 800-mg tablets
89391355|NCT02087228|Experimental|Hydrothermal ablation|Uterine ablation performed with a device that circulates heated water inside the uterus
89391356|NCT02087228|Active Comparator|radiofrequency energy|ablation performed with a device that uses radiofrequency energy.
89391357|NCT02091128||Females with classic galactosemia and POI|
89391358|NCT02089490|Experimental|NEVELIA®|NEVELIA® implantation according to the intended use in the leaflet, prior to autologous skin grafting planned 3 weeks after its application.
89391359|NCT02089568|Experimental|Drug: co-amoxiclav|experimental
89391360|NCT02089568|Placebo Comparator|Control|comparator
89391361|NCT03284853|Experimental|Netarsudil/Latanoprost 0.02%/0.005%|PG324 Ophthalmic Solution (netarsudil 0.02% / latanoprost 0.005%) one drop daily to each eye for 180 days.
88867556|NCT00957684|Placebo Comparator|placebo|Placebo matching tablets
88867557|NCT00957684|Experimental|ESL - PART II|During Part II of the study all patients received Eslicarbazepine Acetate (ESL), including those who had been treated with placebo during Part I. ESL was supplied as scored 800 mg tablets; once daily administration by oral route.
88867558|NCT00958308|Placebo Comparator|Placebo|Two capsules of placebo (devoid of microorganisms) per day. Patients took their daily dose 2h after breakfast and antibiotic administration each day. Patients were then followed for an additionnal 21 days after completion of the assigned intervention.
88867559|NCT00958308|Active Comparator|BIO-K+ CL-1285|Two probiotic capsules (BIO-K+ CL-1285®) per day. Patients took their daily dose 2h after breakfast and antibiotic administration each day. Patients were then followed for an additionnal 21 days after completion of the assigned intervention.
88867560|NCT00958308|Other|BIO-K+ CL-1285® & placebo|One probiotic capsule (BIO-K+ CL-1285®) and one placebo capsule (devoid of microorganisms) per day. Patients took their daily dose 2h after breakfast and antibiotic administration each day. Patients were then followed for an additionnal 21 days after completion of the assigned intervention.
88867561|NCT00959166|Other|HIV/acute HCV coinfection|Subjects with HIV/acute HCV coinfection (aHCV cases) were required to have acute HCV, defined by a new positive plasma HCV RNA test within 12 months of a negative HCV RNA test.
88867562|NCT00959166|Other|HIV mono|HIV-infected individuals without hepatitis C co-infection
88867563|NCT00961662|Experimental|2.5 active|2.5 Active - 2.5 g D-tagatose given orally, three times daily, immediately prior to meals for 6 months.
89391362|NCT03284853|Active Comparator|GANFORT®|GANFORT® (bimatoprost 0.03%/timolol 0.5%) Ophthalmic solution one drop daily to each eye for 180 days.
89391363|NCT02091596|Placebo Comparator|PluroGel|PluroGel
89391364|NCT02091596|Experimental|PluroGel N|PluroGel N
89391365|NCT03557528||Group 1|High Ligation of Inferior mesenteric artery
89391366|NCT03557528||Group 2|Low ligation of inferior mesenteric artery with skeletonization at its origin
88867564|NCT00961662|Active Comparator|5.0 mid dose|5.0 mid dose - 5.0 g D-tagatose given orally, three times daily, immediately prior to meals for 6 months.
89391367|NCT03557450|Experimental|PET/CT scanning with sodium fluoride|Subjects will received PET/CT scanning with sodium fluoride
89391368|NCT02087384|Experimental|Gardasil|Gardasil
89391369|NCT02087384|Placebo Comparator|Placebo|Intramuscular Saline 0.9% vaccination at 0, 2 and 6 months
89391370|NCT01371955||diabetic nephropathy group|patient with diabetic nephropathy, defined as Albuminuria > 30 mg/day or urinary Albumine/ creatinine ratio > 3 mg/mmol ; or GFR estimated by MDRD less than 60 ml/min.1,73m². With no other etiology of diabetic nephropathy.
89391371|NCT01371955||diabetic retinopathy group|patient with diabetic retinopathy defined as showing at least one micro aneurysm on retinography. Without nephropathy defined as above
89391372|NCT01371955||no complication group|patient without diabetic nephropathy or retinopathy
89391373|NCT02087462|Experimental|Electroacupuncture (EA)|Use Electroacupuncture only
89391374|NCT02087462|Other|EA + Traction|Use electroacupuncture and traction together
88867565|NCT00961662|Active Comparator|7.5 high dose|7.5 high dose - 7.5 g D-tagatose given orally, three times daily, immediately prior to meals for 6 months.
88867566|NCT00962598|Placebo Comparator|Corn Oil|The dosage will correspond to the titration schedule of the Omega-3 Fatty Acid experimental treatment.
89391375|NCT02087462|Other|EA + Traction + Oral Medication|Combine electroacupuncture, traction and oral medication (Voltaren and Vitamin B1) together for treatment
89391376|NCT02087540|Experimental|Telmisartan 80mg & Rosuvastatin 20mg|PO, Once Daily, 8 weeks
89391377|NCT02087540|Experimental|Telmisartan 80mg & Rosuvastatin 10mg|PO, Once Daily, 8weeks
89391378|NCT02087540|Active Comparator|Telmisartan placebo & Rosuvastatin 20mg|PO, Once Daily, 8 weeks
89391379|NCT02087540|Active Comparator|Telmisartan Placebo & Rosuvastatin 10mg|PO, Once Daily, 8 weeks
89391380|NCT02087540|Active Comparator|Telmisartan 80mg & Rosuvastatin placebo|PO, Once Daily, 8 weeks
89391381|NCT02087540|Placebo Comparator|Telmisartan placebo & Rosuvastatin placebo|PO, Once Daily, 8 weeks
88867567|NCT00962598|Experimental|Omega-3 Fatty Acids|The initial dose will be 1.2g/d. This will be increased gradually by 0.6 per 2 weeks to a possible maximum daily dose of 3.6 g/d.
88867568|NCT00962754|No Intervention|physician insight fluid balance|physician has insight in fluid balance chart, this is standard practice
88867569|NCT00962754|Experimental|fluid balance data masked to physician|physician no insight in the fluid balance chart
89391382|NCT01372033|Experimental|CBT|Use of cognitive behavioral therapy focused on social skill development and interpersonal relationships
89391383|NCT03952923|Experimental|CD19-CAR-T cells|CD19-CAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of CAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest for 2 days before infusion.
89391384|NCT01368913||Patients treated with orally disintegrating tablet|
89391385|NCT01368913||Patients treated with tablets|
88867570|NCT00964548|Experimental|Dantrolene (low dose)|
89391386|NCT03206463|Experimental|Active 4 mg inhaled THC|Subject will have 1/3 chance of receiving 4 mg THC administered through a vaporizer, over approximately 20 minutes, followed by approximately 45 minutes of neuropsychological and physiological testing.
89391387|NCT03206463|Experimental|Active 2 mg inhaled THC|Subject will have 1/3 chance of receiving 2 mg THC administered through a vaporizer, over approximately 20 minutes, followed by approximately 45 minutes of neuropsychological and physiological testing.
89391388|NCT03206463|Placebo Comparator|Placebo|Subject will have 1/3 chance of receiving the inhaled placebo condition administered through a vaporizer, over approximately 20 minutes, followed by approximately 45 minutes of neuropsychological and physiological testing. The placebo condition will include no active cannabinoids.
89391389|NCT02091674|Experimental|Hyaluronic acid|All subjects administered hyaluronic acid
89391390|NCT02087618|Active Comparator|Kodro+|Will begin Kodro program at baseline
89391391|NCT02087618|Placebo Comparator|Kodro+D|Will begin Kodro program 12-weeks post baseline
88867571|NCT00964548|Experimental|Dantrolene (high dose)|
88867572|NCT00905268|Experimental|Group A: Idebenone|Patients under/equal 45 kg: idebenone 180 mg/day Patients over 45 kg: idebenone 360 mg/day
88867573|NCT00905268|Experimental|Group B: Idebenone|Patients under/equal 45 kg: idebenone 450 mg/day Patients over 45 kg: idebenone 900 mg/day
88867574|NCT00905268|Experimental|C: Idebenone|Patients under/equal 45 kg: idebenone 1350 mg/day Patients over 45 kg: idebenone 2250 mg/day
88867575|NCT00905268|Placebo Comparator|D: Placebo|placebo
88867576|NCT00965250|Experimental|Thymoma|Patients will receive IMC-A12 at a dose of 20 mg/kg intravenously once every three weeks. The most common tumors of the thymus are thymomas (well differentiated neoplasms and moderately differentiated neoplasms) and thymic (poorly differentiated neoplasms) carcinomas.
88867577|NCT00965250|Experimental|Thymic Carcinoma|Patients will receive IMC-A12 at a dose of 20 mg/kg intravenously once every three weeks. The most common tumors of the thymus are thymomas (well differentiated neoplasms and moderately differentiated neoplasms) and thymic (poorly differentiated neoplasms) carcinomas.
89391392|NCT04610827|Active Comparator|Ferrous sulfate daily|Subject will take 3 mg/kg oral iron in the morning
89391393|NCT04610827|Active Comparator|Ferrous sulfate twice daily|Subjects will take 1.5 mg/kg oral iron twice daily
89391394|NCT04610827|Active Comparator|Ferrous sulfate every other day|6 mg/kg oral iron every other day in the morning
89391395|NCT01218555|Experimental|Lenalidomide combination with everolimus|Non-randomized study of escalating doses of daily, orally administered lenalidomide in combination with standard doses of everolimus, an orally available mammalian target of rapamycin (mTOR) inhibitor.
89391396|NCT04503733|Experimental|Q4W GMA301 IV injections (300 mg)|"Drug: Q4W GMA301 IV injections (300 mg) Each cohort will contain 12 subjects, 9 of whom will be administered active GMA301 and 3 of whom will be administrated placebo.~Other: Q4W placebo IV injections Placebo is indistinguishable from GMA301"
89391397|NCT04503733|Experimental|Q4W GMA301 IV injections (600 mg)|"Drug: Q4W GMA301 IV injections (600 mg) Each cohort will contain 12 subjects, 9 of whom will be administered active GMA301 and 3 of whom will be administrated placebo.~Other: Q4W placebo IV injections Placebo is indistinguishable from GMA301"
89391398|NCT04503733|Experimental|Q4W GMA301 IV injections (1000 mg)|"Drug: Q4W GMA301 IV injections (1000 mg) Each cohort will contain 12 subjects, 9 of whom will be administered active GMA301 and 3 of whom will be administrated placebo.~Other: Q4W placebo IV injections Placebo is indistinguishable from GMA301"
89391399|NCT04503733|Experimental|Q4W GMA301 IV injections (1800 mg)|"Drug: Q4W GMA301 IV injections (1800 mg) Each cohort will contain 12 subjects, 9 of whom will be administered active GMA301 and 3 of whom will be administrated placebo.~Other: Q4W placebo IV injections Placebo is indistinguishable from GMA301"
89391400|NCT03557060||Subjects receiving NUCALA|Subjects with a diagnosis of EPGA, for which NUCALA is indicated will be included.
89391401|NCT02089724||vemurafenib/other BRAF inhibitors|
89391402|NCT01368991|Active Comparator|Kryptonite|Sternal closure with stainless steel and kryptonite
89391403|NCT01368991|Active Comparator|Conventional Closure|Sternal closure with stainless steel wires
88867578|NCT00966186|Active Comparator|Standard technique|Proseal laryngeal mask airway was inserted according to the manufacture's instruction manual (insertion with help of index finger insertion)
88867579|NCT00966186|Experimental|Rotational technique|The entire cuff of the PLMA was placed in the mouth without finger insertion in a midline approach and was rotated 90 degrees counterclockwise around the tongue. The PLMA was then advanced and rotated back until resistance was fel
88867580|NCT00967044|Experimental|Panobinostat + Everolimus|Panobinostat (LBH589) Plus Everolimus (RAD001)
89391404|NCT02091830||Non-surgical treatment|
88867581|NCT00968838|Experimental|Non-radiated White Blood Cell Transfusion|Four (4) non-radiated white blood cell transfusions. Each transfusion given daily and taking from 1 hour to several hours depending on toleration of the treatment.
89391405|NCT01111305|Active Comparator|Reslizumab + DEC|Reslizumab 1 mg/kg iv single dose followed by diethylcarbamazine 9 mg/kg/day po for 21 days
88867582|NCT00968838|Experimental|White Blood Cell Transfusion|Four (4) standard white blood cell transfusions (with radiation). Each transfusion given daily and taking from 1 hour to several hours depending on toleration of the treatment.
88867583|NCT00970320|No Intervention|Control group, RCT2|Participants reporting anal incontinence 6 months postpartum receiving written information only for 6 months. After 6 months they are offered the same intervention as the intervention group, i.e. PFMT for 6 months.
88867584|NCT00970320|Active Comparator|Intervention group, RCT 2|Participants reporting anal incontinence 6 months postpartum receiving pelvic floor muscle training (PFMT) for 6 months (+6 months).
88867585|NCT00970320|No Intervention|Control group, RCT3|Women with obsteric anal sphincter injury receiving written information only for 6 months. After 6 months they are offered the same intervention as the intervention group, i.e. PFMT for 6 months.
88867586|NCT00970320|Active Comparator|Intervention group, RCT 3|Women with obsteric anal sphincter injury receiving pelvic floor muscle training (PFMT) for 6 months (+6 months).
88867587|NCT00970320|No Intervention|Prevalence Study|1571 primiparae delivering at Ostfold Hospital Trust or St. Olav's Hospital during the period May 2009 to December 2010.
88867588|NCT00973752|Experimental|Experimental|All patients treated on same arm
88867589|NCT00974142|Experimental|Cyclosporine|
88867590|NCT00974142|Placebo Comparator|Placebo|
88867591|NCT00974376|Experimental|Gabapentin 1200mg/day|1200mg/day of gabapentin for 12 weeks given in conjunction with 12 weeks of manual-guided behavioral counseling.
88867592|NCT00974376|Placebo Comparator|Placebo|1200mg/day of placebo for 12 weeks given in conjunction with 12 weeks of manual-guided behavioral counseling.
88867593|NCT00976248|Experimental|RAD001|RAD001, oral, 10 mg, daily
88867594|NCT00976404|Active Comparator|Maraviroc + raltegravir intensification|ART Intensification (addition of raltegravir and maraviroc to suppressive ART for 56 weeks)
88867595|NCT00976404|Experimental|Maraviroc + raltegravir intens. plus DNA + HIV-rAd5 vaccine|ART Intensification (addition of raltegravir and maraviroc for 56 weeks) PLUS immunomodulation therapy with DNA prime vaccine (Weeks 8,12,16) + HIV-recombinant Ad5-based vaccine (Week 32)
88867596|NCT00977184|Experimental|Real rTMS|
88867597|NCT00977184|Sham Comparator|Sham rTMS|
89391406|NCT01111305|Placebo Comparator|Placebo + DEC|Placebo iv single dose followed by diethylcarbamazine 9 mg/kg/day po for 21 days
89391407|NCT05191927||female group|all are female
89391408|NCT05191927||male group|all are male
89391409|NCT02089802|Experimental|Normal plasma level patients and low plasma level patients.|"Patients with normal Pazopanib plasma trough levels; normal plasma level patients (NPLP).~Patients with low Pazopanib plasma trough levels, low plasma level patients (LPLP)."
89391410|NCT04497415|Experimental|Video-based intervention|A brief video about coping with COVID-19 stress presented to the participants
89391411|NCT04497415|No Intervention|Assessment only|Control
88867598|NCT00977808|Experimental|Closed-Loop Model Predictive Control (MPC)|Insulin dosing was performed by a model-predictive control (MPC) algorithm.
88867599|NCT00977808|Placebo Comparator|Open-Loop|Insulin dosing was performed by the patient (using their normal routine and personal insulin pump) under a physician's supervision.
89391412|NCT02087696|Other|Naive biological treatment|"Rheumatoid arthritis patients with intolerance or poor compliance or contraindication to methotrexate and who have not received previous biological treatment.~Tocilizumab dose 8mg/kg administered every 4 weeks for 24 weeks"
89391413|NCT02087696|Other|Previous Biological treatment|"Rheumatoid arthritis patients with intolerance or poor compliance or contraindication to methotrexate and who have not received more than two previous biological treatments.~Tocilizumab dose 8mg/kg administered every 4 weeks for 24 weeks"
89391414|NCT03634423|Experimental|Sweet Spot: Flexible high incentive condition|Participants will receive 500 points if they make a gym visit within a pre-specified window of time and 490 points if they make a gym visit at any other time. 7000 points convert to $25
89391415|NCT03634423|Experimental|Sweet Spot: Flexible low incentive condition|Participants will receive 300 points if they make a gym visit within a pre-specified window of time and 290 points if they make a gym visit at any other time. 7000 points convert to $25
89391416|NCT03634423|Experimental|Sweet Spot: Rigid high incentive condition|Participants will receive 500 points if they make a gym visit within a pre-specified window of time and 250 points if they make a gym visit at any other time. 7000 points convert to $25
89391417|NCT03634423|Experimental|Sweet Spot: Rigid low incentive condition|Participants will receive 300 points if they make a gym visit within a pre-specified window of time and 150 points if they make a gym visit at any other time. 7000 points convert to $25
89391418|NCT03634423|Experimental|FOTW: High incentive control condition|Participants will receive 750 points if they make a gym visit within a pre-specified window of time and 250 points if they make a gym visit at any other time. 7000 points convert to $5
89391419|NCT03634423|Experimental|FOTW: Low incentive control condition|Participants will receive 450 points if they make a gym visit within a pre-specified window of time and 150 points if they make a gym visit at any other time. 7000 points convert to $5
89391420|NCT03634423|Experimental|FOTW: High incentive treatment condition|Participants will receive 500 points if they make a gym visit within a pre-specified window of time and 250 points if they make a gym visit at any other time. Additionally, if a participant misses a scheduled gym visit, they will receive 750 points the next time they visit the gym within the pre-specified window. 7000 points convert to $5
89391421|NCT03634423|Experimental|FOTW: Low incentive treatment condition|Participants will receive 300 points if they make a gym visit within a pre-specified window of time and 150 points if they make a gym visit at any other time. Additionally, if a participant misses a scheduled gym visit, they will receive 450 points the next time they visit the gym within the pre-specified window. 7000 points convert to $5
89391422|NCT03634423|Experimental|Think Twice: Control condition|Participants get 300 points per gym visit. 7000 points convert to $5
89391423|NCT03634423|Experimental|Think Twice: Treatment condition|Participants get 300 points per gym visit and are taught about the planning fallacy. 7000 points convert to $5
89391424|NCT03634423|Experimental|WDR: Control condition|Participants get 300 points per gym visit and are allowed to vary their gym schedules in different days. 7000 points convert to $5
89391425|NCT03634423|Experimental|WDR: Treatment condition|Participants get 300 points per gym visit. Participants are required to select a single exercise time for the weekdays (Monday - Friday) and a single exercise time for the weekends (Saturday - Sunday). 7000 points convert to $5
89391426|NCT00792831|Experimental|ITF2357|ITF2357 was supplied as hard gelatine capsules for oral administration at the strength of 100 or 50 mg. Patients had to receive ITF2357 100 mg x 2/die at 12-hour intervals, in fed conditions, for three consecutive months.
89391427|NCT00496431|Experimental|ITF2357|Patients were provided with the appropriate number of 50 mg hard gelatine capsules for oral administration for 7 days treatment, i.e. at the daily dose of 100 mg, 14 capsules 50 mg each, plus 2 spare capsules suitable in case of accidental loss.
89391428|NCT03634501|Experimental|NK cells|Activated NK from peripheral blood and/or umbilical cord blood（UCB）
89391429|NCT02091908|Experimental|Arm 1: aH5N1 adult|aH5N1 healthy and non-healthy adults
89391430|NCT02091908|Experimental|Arm 2: aH5N1 elderly|aH5N1 healthy and non-healthy elderly
89391431|NCT02091908|Active Comparator|Arm 3: aTIV adult|aTIV healthy and non-healthy adults
89391432|NCT02091908|Active Comparator|Arm 4: aTIV elderly|aTIV healthy and non-healthy elderly
89391433|NCT03627897|Experimental|Regional analgesia group|ESP block at bilateral side will be performed in the lateral decubitis position and at T5 transverse process level by using 10-MHz liner ultrasound probe. The probe will be located 1 cm lateral to T5 spinous process in longitudinal parasagittal orientation. Simplex A 50mm (B.Braun, Germany) will be inserted by using out of plane technique. The ESP blocks proceed with 0,5 ml/kg of 0,25% bupivacaine
89391434|NCT03627897|Other|Control group|
89391435|NCT02248532|Active Comparator|Group A|Repetitive stem cell administration
89391436|NCT02248532|Active Comparator|Group B|Single stem cell administration
89391437|NCT05191849|Other|Small Cell Lung Cancer receiving chemotherapy|
89391438|NCT02250404||Ancillary-Correlative (molecular profile)|Previously collected tissue samples are analyzed via RNA sequencing and DNA methylation at baseline. Patients also undergo collection of tissue samples for analysis at relapse.
89391439|NCT03125941|Active Comparator|Dexamethasone 8 mg|Dexamethasone 8 mg pre-operative
89391440|NCT03125941|Active Comparator|Dexamethasone 24 mg|Dexamethasone 24 mg pre-operative
89391441|NCT02092142|Experimental|Vaccinated|The vaccine will be administered subcutaneously in the upper outer aspect of the arm (triceps area) with 0.5 mL Q fever Vaccine, Phase I, Inactivated, Dried, NDBR 105 (which equals 30 μg)
89535377|NCT03091023|Active Comparator|Natural cycle|"Endometrial biopsies and endometrial fluid obtained from healthy females throughout the menstrual cycle at each of these stages:~Early proliferative (EP; days 0-8), late proliferative (LP; days 9-14), early secretory (ES; days 15-18), mid-secretory or receptive (MS; days 19-23), and late secretory (LS; days 24-30)"
89391442|NCT02774889|Active Comparator|Stepping Online|"Stepping On graduates receive Stepping Online, a password-protected continuation website to maintain fall prevention behaviors.~Fall prevention tips~Fall prevention exercise videos noting technique and safety~Guest expert videos and communication with expert~Tools to set exercise goals, reminders and track progress~Fall prevention specialist for feedback and group activities~Discussion and messaging (1:1, small and large group)~Fall prevention resources."
89391443|NCT02774889|No Intervention|Stepping On Usual Care Control|Subjects control workshops in the condition will not have access to Stepping Online.
89391444|NCT02095886|Experimental|Cohort 1 Arm ABDC: BMS-955176 (Treatment A, B, D and C)|BMS-955176 single dose by mouth as specified
89391445|NCT02095886|Experimental|Cohort 1 Arm BCDA: BMS-955176 (Treatment B, C, D and A)|BMS-955176 single dose by mouth as specified
89391446|NCT02095886|Experimental|Cohort 1 Arm DABC: BMS-955176 (Treatment D, A, B and C)|BMS-955176 single dose by mouth as specified
89391447|NCT02095886|Experimental|Cohort 1 Arm CDAB: BMS-955176 (Treatment C, D, A and B)|BMS-955176 single dose by mouth as specified
89391448|NCT02095886|Experimental|Cohort 2 Arm EFGH: BMS-955176 (Treatment E, F, G and H)|BMS-955176 single dose by mouth as specified
89391449|NCT02095886|Experimental|Cohort 2 Arm FGHE: BMS-955176 (Treatment F, G, H and E)|BMS-955176 single dose by mouth as specified
89391450|NCT02095886|Experimental|Cohort 2 Arm HEFG: BMS-955176 (Treatment H, E, F and G)|BMS-955176 single dose by mouth as specified
89391451|NCT02095886|Experimental|Cohort 2 Arm GHEF: BMS-955176 (Treatment G, H, E and F)|BMS-955176 single dose by mouth as specified
89391452|NCT01372579|Experimental|Treatment (neoadjuvant chemotherapy)|Patients receive eribulin mesylate IV over 2-5 minutes and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
89391453|NCT02089958||Laparoscopic incisional hernia repair|Incisional hernia, LIPOM
89391454|NCT02090036|Active Comparator|artemether-lumefantrine+placebo|In the artemether-lumefantrine arm, the first dose of artemether-lumefantrine will be administered concomitantly with a single-dose placebo. A volume of normal saline will be measured based on weight bands and then will be given to patients.
89391455|NCT02090036|Experimental|artemether-lumefantrine+primaquine|All the recruited patients will be treated with a six doses, 3 days artemether-lumefantrine treatment regimen. However, patients randomized to the artemether-lumefantrine+primaquine arm will be given 0.25 mg/kg single-dose primaquine concomitantly with artemether-lumefantrine first dose.
89391456|NCT03125629|Experimental|18F-FDG PET/CT Scan|Participants will undergo a PET/CT scan with radiolabel 18F-FDG.
89391457|NCT03125629|Experimental|18F-FDG PET/MRI Scan|Participants will undergo a PET/MRI scan with radiolabel 18F-FDG.
89391458|NCT03125629|Experimental|68Ga-DOTA-TATE PET/CT Scan|Participants will undergo a PET/CT scan with radiolabel 68Ga-DOTA-TATE.
89391459|NCT03125629|Experimental|68Ga-DOTA-TATE PET/MRI Scan|Participants will undergo a PET/MRI scan with radiolabel 68Ga-DOTA-TATE.
89391460|NCT02092376|Active Comparator|Intervention|The loading dose of 300 000 IU is divided into three doses (100 000 IU) and will be given over the first months. All patients in the intervention group will receive the first loading dose of 100 000 IU at day of discharge. The second (2 weeks) and third (4 weeks postoperative) administration will be given based on the 25-hydroxy vitamin D concentration. After the last respectively third loading dose a maintenance dose of 3420 IU per day should maintain the high 25-hydroxy vitamin D concentration. It should be administered for up to 46 weeks (until follow-up visit)
88867600|NCT00981474|Active Comparator|Control|Blood pressure targets during cardiopulmonary bypass based on institutional standards of empiric management.
89391461|NCT02092376|Placebo Comparator|Placebo|The placebo loading dose (oil) is divided into three administrations and will be given over the first months. All patients in the placebo group will receive the first placebo loading dose at day of discharge. After the last placebo loading dose a maintenance dose of 3420 IU per day should maintain the 25-hydroxy vitamin D concentration. It should be administered for up to 46 weeks (until follow-up).
89391462|NCT02090192|Experimental|WBV training|"Whole-body vibration training was performed on a commercial Galileo machine (Germany). Participants were required to stand on the moveable rectangular platform and positioned their feet at an equal and standardized distance from the axis of rotation so that the vertical vibration amplitude was 1-3 mm. The frequency was set at 6-26 Hz. The vibration protocol consisted of four to five bouts (60 seconds for each bout), and three to five times a week for 12 weeks. The positions taken by the subjects differed according to their function. Participants who could stand independently were instructed to adopt a partial squat position with slight flexion at the hips, knees, and ankle joints to damp the vibrations approximately at the pelvic level."
89391463|NCT02090192|Experimental|WBV+ PRT training|
89391464|NCT02090192|Active Comparator|PRT training|
89391465|NCT02090192|Placebo Comparator|Control group|
89391466|NCT05452928|Active Comparator|Active arm|Randomisation to 7 days of active treatment with IV aciclovir 10 mg/kg q8h and possibility for oral step-down therapy with valaciclovir 1g q8h, or placebo (IV q8h and/or oral q8h).
89391467|NCT05452928|Placebo Comparator|Placebo|Randomisation to 7 days of IV and/or oral placebo.
89391468|NCT03125395|Experimental|LUM/IVA|LUM/IVA granules or tablets were administered orally every 12 hours (Participants aged 2 through 5 years received LUM 100 mg/IVA 125 mg granules or LUM 150 mg/IVA 188 mg granules based on body weight. Participants ≥6 years of age were to receive LUM 200 mg/IVA 250 mg tablets). Doses were adjusted upward for changes in weight and age.
89391469|NCT00264602|Experimental|Near Infrared Imaging|The intervention to be administered is indocyanine green dye.
89391470|NCT03557138|Experimental|Me4FDG|Intravenous injection of alpha-Methyl-4-deoxy-4-[(18)F]fluoro-D-glucopyranoside (Me4FDG) and FDG for evaluation the kidney kinetic model of FDG and Me4FDG in type 2 diabetic patients with SGLT2-inhibitor therapies.
89391471|NCT01369303|Experimental|Daily dosing|Tenofovir 1% gel will be inserted each day or evening at about the same time with the last study-sex 12 hours after the final dose
89391472|NCT01369303|Experimental|BAT24 dosing|Tenofovir 1% gel will be inserted 1 hour before and 1 hour after sex
89391473|NCT01369303|Experimental|Pericoital dosing|Tenofovir 1% gel will be inserted either 1 hour before sex OR 1 hour after sex
89391474|NCT03556436|Experimental|Group 1|YH25448 240mg single dose in korean
89391475|NCT03556436|Experimental|Group 2|YH25448 240mg single dose in caucasian
89391476|NCT02092532|Other|Intravitreal Aflibercept Injection|All patients will receive monthly IAI 2.0 mg intravitreally for 3 months (Baseline, Months 1 and 2), followed by mandatory IAI 2.0 mg every 2 months (Months 4, 6, 8 and 10) for 12 months.
89391477|NCT02092688||Study group|Study group: women between 24 and 36 6/7 weeks of gestation that present with self-reported signs, symptoms or complaints suggestive of preterm labor
89391478|NCT02092688||Control group|Control group: women between 24 and 36 6/7 weeks of gestation without signs or symptoms of PTL
89391479|NCT02095964||Cardiac Syndrome X|
89391480|NCT02095964||Control Group|
89391481|NCT02096120||All patients|
89391482|NCT02092766|Experimental|IV artesunate|Intravenous artesunate 2.4 mg/kg body weight STAT, then 2.4 mg/kg at 12, 24, 48 and 72 hours (5 doses total)
89391483|NCT02092766|Active Comparator|IV quinine|Intravenous quinine dihydrochloride 20 mg salt/kg body weight loading dose over 4 hours, then 10 mg/kg over 2 hours 8 hourly until 72 hours (9 doses total)
88867601|NCT00981474|Experimental|Intervention|Blood pressure management based on cerebral autoregulation data.
89391484|NCT02090270||Ischemic stroke|Sudden onset of focal neurologic deficit lasting more than 24 hours, with cerebral hemorrhage ruled out by brain CT, in the absence of obvious causes of embolic stroke.
89391485|NCT02090270||Control|Patients admitted to an internal medicine department for indications other than stroke or acute myocardial ischemia.
89391486|NCT02090348|Experimental|dimethyl fumarate|DMF at a dose of 120 mg twice a day (BID) for the first 7 days and 240 mg BID for the remainder of study period (up to 12 months)
89391487|NCT02721069|Experimental|NRL-1|Intranasal dose of NRL-1 will be administered at either 5 mg, 10 mg, 15 mg, or 20 mg based on the subject's body weight.
89391488|NCT02092844|Experimental|CBT for Menopausal Insomnia (CBTMI)|CBTMI is a combination of Cognitive Behavioral Therapy for Insomnia (CBTI) and Cognitive Behavioral Therapy for Hot Flashes (CBTH).
89391489|NCT02092844|Placebo Comparator|Enhanced Treatment as Usual|In the Enhanced Treatment as Usual/Information Control group, participants continue with clinical care of their choosing, but will be enhanced by the provision of 3 American Academy of Sleep Medicine (AASM) brochures.
89391490|NCT00390741|Active Comparator|1|Home-based exercise program
89391491|NCT00390741|No Intervention|2|Usual care
89391492|NCT02096198||Other CERAMAX COC 36mm Acetabular Cup|The CERAMAX COC 36mm ceramic acetabular bearing insert component is manufactured from high purity, dense alumina matrix composite ceramic. The insert is available in several inner diameter sizes, including 36mm; only 36mm inserts will be utilized in this PAS. The inserts secure to DePuy's Pinnacle acetabular shells by means of an interlocking mechanical taper.
89391493|NCT02093000||Bevacizumab|Participants who have received the induction phase of 4-6 cycles of bevacizumab plus platinum doublet chemotherapy will be treated with bevacizumab as maintenance treatment, according to approved label and local reimbursement.
89391494|NCT00261807|Other|Single ARM Study|It was a single arm study with higher dose of daptomycin used for patients with severe skin and soft tissue infections.
88867602|NCT00981630|Experimental|ChimeriVax™-JE Dose Level 1|Participants received ChimeriVax™-JE (Japanese Encephalitis) a dose of 3.0 log10 Plaque-forming units (PFU) on Day 0.
88867603|NCT00981630|Experimental|ChimeriVax™-JE Dose Level 2|Participants received ChimeriVax™-JE a dose of 4.0 log10 PFU on Day 0.
88867604|NCT00981630|Experimental|ChimeriVax™-JE Dose Level 3|Participants received ChimeriVax™-JE a dose of 5.0 log10 PFU on Day 0.
89391495|NCT05216523||Cases|Admitted Covid-19 cases who developed Barotrauma
89391496|NCT05216523||Controls|Admitted Covid-19 cases who did not develop Barotrauma, matched with Cases with respect to age and sex.
89391497|NCT02093078||CARD|"Intervention: CARD~This group will be introduced to the CARD protocol which focuses on clarification of individual roles and distribution of tasks. It relies on large identification cards specially designed for each team member's profession and role. Each card worn by a team member identifies the specific tasks associated with that individual's role. CARD enables the team leader and other team members to quickly recognize everyone's role at the code, and each team member can commence their assigned tasks without delay."
89391498|NCT02093078||Control Arm|
89391499|NCT02090504|Experimental|Sodium oxybate (SMO)|"Patients randomized to the first arm of the study will receive:~SMO (sodium oxybate 175 mg/ml suspension): 10ml at 8.00 a.m., 10ml at 12.00 p.m., 10ml at 7.00 p.m. from day 1 to day 5, 5ml at 8.00 a.m., 5ml at 12.00 p.m., 5ml at 7.00 pm, on days 6 and 7, and 2.5ml at 8.00 a.m., 2.5 ml at 12.00 p.m., 2.5ml at 7.00 p.m. from day 8 to day 10 (If patient's weight is > 75 kg the dosage will be of 12ml instead of 10 ml, 6ml instead of 5ml, 3 ml instead of 2.5ml);~placebo (tablets): 1 tablet at 8.00 a.m., 1 tablet at 12.00 p.m., 1 tablet at 7.00 p.m. from day 1 to day 10."
89391500|NCT02090504|Active Comparator|Oxazepam|"Patients randomized to the second arm of the study will receive:~OXAZEPAM (tablets): 60mg at 8.00 a.m., 60mg at 12.00 p.m., 90mg at 7.00 p.m. from day 1 to day 5, 30mg at 8.00 a.m., 30mg at 12.00 p.m., 30mg at 7.00 pm, on days 6 and 7, and 15mg at 8.00 a.m., 15mg at 12.00 p.m., 15mg at 7.00 p.m. from day 8 to day 10;~placebo (suspension): 10ml at 8.00 a.m., 10ml at 12.00 p.m., 10ml at 7.00 p.m. from day 1 to day 5, 5ml at 8.00 a.m., 5ml at 12.00 p.m., 5ml at 7.00 pm, on days 6 and 7, and 2.5ml at 8.00 a.m., 2.5 ml at 12.00 p.m., 2.5ml at 7.00 p.m. from day 8 to day 10, (If patient's weight is > 75 kg the dosage will be of 12ml instead of 10 ml, 6ml instead of 5ml, 3 ml instead of 2.5ml)."
89391501|NCT01567059|Experimental|Arm I (tosedostat and cytarabine)|Patients receive tosedostat PO QD on days 1-35 and cytarabine IV on days 1-5.
88867605|NCT00981630|Placebo Comparator|Placebo|Participants received ChimeriVax diluent, 0.5 mL on Day 0.
88867606|NCT00983346|Experimental|All patients|All participants enrolled.
89391502|NCT01567059|Experimental|Arm II (tosedostat and decitabine)|Patients receive tosedostat PO QD on days 1-35 and decitabine IV on days 1-5.
89391503|NCT02090582|Other|Structured Palliative Care|
89391504|NCT02090582|Other|Usual Care|
89391505|NCT02093156||training cohort|the training cohort was used to establish the bowel preparation score (BPS)
89391506|NCT02093156||validation cohort|the validation cohort was used to verify the BPS (bowel preparation score)
89391507|NCT03556982|Experimental|CART-123|The relapsed/refractory AML patients will receive allogenic or autologous CD123-Targeted CAR-T cells infusion after FC chemotherapy.
89391508|NCT02090660|Experimental|VATS wedge lung resection|
89391509|NCT00073671|Experimental|1= Cognitive behavioral prevention of depression program|Participants receive a group cognitive-behavioral prevention program, which involved 8 weekly sessions and 6 monthly sessions of CBT skills such as cognitive restructuring, problem-solving, assertivenss, and behavioral activation. Participants in this arm also were able to seek the same kinds of nonstudy treatments as described in the usual care arm.
88867607|NCT00985140||12 Gy TSEBT|Prospective assignment to receive 12 Gy total skin electron beam therapy (TSEBT) for mycosis fungoides
88867608|NCT00986856|Experimental|Fucidin® cream|
88867609|NCT00986856|Placebo Comparator|Fucidin® cream vehicle|
88867610|NCT00987480|Experimental|chemotherapy-based cytoreductive regimen plus a CD34+ selected|This phase II trial is designed to investigate the safety and efficacy of a chemotherapy-based cytoreductive regimen plus a CD34+ selected T-cell depleted peripheral blood stem cell (PBSC) stem cell transplant for the treatment of patients with Fanconi anemia and severe hematologic disease.
88867611|NCT00987558|Experimental|Treatment Sequence A|Simvastatin 80mg treatment period followed by Simvastatin 80 mg + eslicarbazepine acetate 800 mg treatment period
89391510|NCT00073671|Active Comparator|2 = Usual care|Participants receive usual care, which involves any type of treatment (e.g., psychotherapy, counseling, pharmacotherapy).
89391511|NCT02090738|Experimental|Arm1|Treatment group
89391512|NCT02090738|Active Comparator|Arm2|Control group
89391513|NCT02096510|Experimental|continuous subcutaneous hydrocortisone|continuous subcutaneous hydrocortisone infusion (CSHI), Solu-Cortef ® 50mg/ml infusate
89391514|NCT02096510|Active Comparator|cortef tablets|the patient regular treatment by Cortef 5 mg, produced by Nycomed Pharma two times or three times a day.
88867612|NCT00987558|Experimental|Treatment Sequence B|Simvastatin 80mg + eslicarbazepine acetate 800 mg treatment period followed by Simvastatin 80 mg treatment period
89391515|NCT02096510|Experimental|ultradian subcutaneous hydrocortisone|ultradian subcutaneous hydrocortisone infusion, Solu-Cortef ® 50mg/ml infusate
89391516|NCT03776396||Experimental cohort|"33 patient undergoing to kidney transplantation from cadaver at University Hospital G. Rodolico of Catania, in which an innovative Perioperative Goal Directed Therapy (PGDT) protocol will be used."
89186658|NCT04083248|Experimental|Feasibility group|"Intervention components:~Personalized group diabetes education.~Fitbit Charge 3 wrist activity monitor for real-time monitoring of steps, active minutes and heart rate. The Fitbit will be used by the women to set activity goals, self-assess their progress and aid in motivation to be more active.~Freestyle Libre (Abbott Labs, Alameda, CA) Personal CGM (FDA approved). The Libre CGM will be used to self-monitor glucose goals and monitor the real-time effects of activity and eating choices by the women.~Final guided interview for study acceptability and feasibility. The interviews will be audiotaped, transcribed. Thematic content analyses will be performed."
89186659|NCT05266040|Experimental|valacyclovir group|250 patients presenting with pain and a diagnosis of acute apical abscess will be recruited for the VEII preoperative pain and VEIII postoperative pain and clinical/radiographic healing phases of the clinical trial.
89391517|NCT03776396||Historical control group|"33 patients underwent to kidney transplantation from cadaver at University Hospital G. Rodolico of Catania in 2015, in which a PGDT protocol was not used, but a common hemodynamic monitoring, based on parameters such as central venous pressure and / or invasive arterial pressure, was performed."
89391518|NCT05218317||MS-Relapse|"Twenty-seven patients (MS-Relapse) for whom the administration of intravenous corticosteroids was decided due to the diagnosis of new relapse.~The diagnosis of RRMS and the new relapse was confirmed and decided by a senior neurologist (K.A) of Marmara University Department of Neurology, according to the revised McDonald criteria, based on clinical and radiological findings These subjects underwent Corneal Confocal Microscopy (IVCM)."
89391519|NCT05218317||MS-Control|"Thirty-one patients (MS-Control) who were followed up with the diagnosis of RRMS The diagnosis of RRMS and the new relapse was confirmed and decided by a senior neurologist (K.A) of Marmara University Department of Neurology, according to the revised McDonald criteria, based on clinical and radiological findings.~These subjects underwent Corneal Confocal Microscopy (IVCM)."
89391520|NCT05218317||Healthy Controls|Thirty healthy age and gender similar population These subjects underwent Corneal Confocal Microscopy (IVCM).
88867613|NCT00987948|Experimental|Maraviroc|
88867614|NCT00989586|Experimental|Phase I|Phase I portion of the study, a standard 3+3 dose escalation schema will be followed. Patients will receive veltuzumab IV weekly on day 1 for 4 doses and milatuzumab weekly on for 4 total doses during induction therapy. Induction therapy will be defined as the first 4 weeks of study therapy. During week 1 of induction therapy, patients will receive veltuzumab alone on day 1 and milatuzumab alone on day 2 to prevent overlapping infusion reactions. Starting week 2, veltuzumab will be given on day 1 and milatuzumab will be given on day 4.
88867615|NCT00989586|Experimental|Phase II|Patients will receive veltuzumab IV weekly for 4 doses and milatuzumab IV weekly on day 2 of week 1 and on day 4 of weeks 2-4 for 4 total doses during induction therapy. Patients may continue on therapy to receive extended induction therapy provided they do not experience significant toxicity or rapid disease progression during the initial 4 week induction.
88867616|NCT00990288|Experimental|Hemostatic Matrix|2 vials of Floseal applied once at the end of surgery
88867617|NCT00990288|No Intervention|Control|No intervention.
88867618|NCT00991458|Experimental|Cyclosporine 0.010% eye drops|Cyclosporine 0.010% eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.
88867619|NCT00991458|Experimental|Cyclosporine 0.005% eye drops|Cyclosporine 0.005% eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.
89391521|NCT03556280|Experimental|Treatment Group|Will use the Active GammaSense Stimulation System.
88867620|NCT00991458|Placebo Comparator|Placebo (Vehicle for Cyclosporine)|Placebo eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.
88867621|NCT00993798|Experimental|SABER-Bupivacaine Treatment 1a|double-blind
88867622|NCT00993798|Placebo Comparator|Placebo SABER-Bupivacaine Treatment 1b|double-blind
88867623|NCT00993798|Active Comparator|Bupivacaine HCl Treatment 1c|double-blind
88867624|NCT00993798|Experimental|SABER-Bupivacaine Treatment 2a|double-blind
89391522|NCT03556280|Sham Comparator|Control Group|Will use the Sham GammaSense Stimulation System.
89391523|NCT03555656|Experimental|Repeated educational intervention|Repetition every 6 months of a group educational session
89391524|NCT03555656|Active Comparator|Control group|Initial single group educational session, with no repetition
89391525|NCT02093468|Placebo Comparator|Saline|Saline administered IV for 12 hours
89391526|NCT02093468|Experimental|Lower Dose|MST-188 loading dose 100 mg/kg IV for 1 hour followed by 25 mg/kg/hr for 11 hours
89391527|NCT02093468|Experimental|Higher Dose|MST-188 loading dose 200 mg/kg IV for 1 hour followed by 75 mg/kg/hr for 11 hours
89391528|NCT02093546||Ancillary-correlative (Biospecimen collection)|Patients undergo collection of blood at screening, between days 3 and 5, 28, and 56. Patients also undergo collection of tumor biopsy at screening and day 28.
88867625|NCT00993798|Placebo Comparator|Placebo SABER-Bupivacaine Treatment 2b|double-blind
89535378|NCT03091023|Active Comparator|ERA in HRT cycle|Endometrial biopsy and endometrial fluid obtained from woman undergoing to Endometrial Receptivity Analysis (ERA) in a hormonal replacement therapy (HRT) cycle.
89391529|NCT03441555|Experimental|Venetoclax + Alvocidib|Venetoclax administered orally once daily (QD) and Alvocidib administered as an intravenous infusion on Days 1, 2, and 3 for all 28-day treatment cycles. Different combinations of dose levels for venetoclax and alvocidib may be explored.
89391530|NCT02098772|Experimental|Custodiol-N|comparison of two cardioplegic solutions, Custodiol-N versus Custodiol, in aortic valve surgery
88867626|NCT00993798|Active Comparator|Bupivacaine HCl Treatment 2c|double-blind
89391531|NCT02098772|Active Comparator|Custodiol|comparison of two cardioplegic solutions, Custodiol-N versus Custodiol, in aortic valve surgery
89391532|NCT03357081||CEUS|Adult patients over the age of 18 who have a clinical suspicion of an actively bleeding soft-tissue hematoma as determined by the treating emergency provider. Enrollment will be for one year or until a target of 20 patients is enrolled.
89391533|NCT02093780|Experimental|Alberta Anti-inflammatory Diet|Patients randomized into this group will receive a dietary menu plan that contains anti-inflammatory foods/nutrients that have been shown to be effective in the management of IBD in previous studies. The main aim of this diet will be to increase dietary intakes of prebiotics/probiotics, omega 3 fatty acids, fiber (soluble), antioxidants and decrease dietary intake of red and processed meat.
89391534|NCT02093780|Active Comparator|Canada's Food Guide Diet|"Patients that have been randomized into this group will receive simple dietary recommendations based on the Canada's Food Guide. The details of Canada's Food Guide can be available here:~http://www.hc-sc.gc.ca/fn-an/food-guide-aliment/index-eng.php"
89391535|NCT03346239|Experimental|Gaze Contingent Music Reward Therapy|Participants will receive gaze-contingent feedback according to their viewing patterns, over a course of 12 weeks.
89391536|NCT03346239|Active Comparator|Selective Serotonin Reuptake Inhibitors|Participants will receive 10-20 mg of Escitalopram over a course of 12 weeks.
89391537|NCT03346239|Placebo Comparator|Waitlist Control|Participants will wait for treatment for 12 weeks, then receive GC-MRT for 12 weeks.
89391538|NCT05216289|Active Comparator|probiac + topical fixed combination|
89391539|NCT05216289|Placebo Comparator|placebo + topical fixed combination|
89391540|NCT02098928|Active Comparator|Hand-acupuncture group|Use Hand-acupuncture directly. Four acupoints:Tianshu,Zigong,Guanyuan and Sanyinjiao. Every patient are supposed to have 24 times acupuncture treatment. 30 minutes per time.
89391541|NCT02098928|Placebo Comparator|Electric-acupuncture group|Use Electrico-acupuncture device to therapy. Four acupoints:Tianshu,Zigong,Guanyuan and Sanyinjiao. Every patient are supposed to have 24 times acupuncture treatment. 30 minutes per time.
89391542|NCT02995551|Experimental|Arthroscopy|Arthroscopic meniscal repair or resection will be conducted at the discretion of the operating surgeon (this cannot be determined before the surgeon has visual confirmation about the exact knee pathology and extend of the meniscal tear by scope).
89391543|NCT02995551|Active Comparator|Exercise and Education|Patients allocated to exercise therapy and education will participate in a 12-week (2 exercise sessions per week) supervised neuromuscular and strengthening exercise program tailored to 18-40 years old patients with a meniscal tear. Furthermore, they will participate in a patient education program developed through interviews with pilot study participants, from our experiences from the Good Life with osteoArthritis in Denmark (GLA:D) program for patients with knee and hip pain. Both the exercise and education will take place in a number of private physiotherapy clinics associated with the GLA:D program, specifically trained to supervise and lead the treatment in this study.
89391544|NCT03556124|Experimental|Active - HD tDCS|Participants randomized to this arm will receive 12 sessions of high definition tDCS (HD-tDCS) stimulation (Soterix Medical) delivered to the left dorsolateral prefrontal cortex for 20-30 minutes.
89391545|NCT03556124|Experimental|Active - Conventional tDCS|Participants randomized to this arm will receive 12 sessions of conventional tDCS (C-tDCS) stimulation (Soterix Medical) delivered to the left dorsolateral prefrontal cortex for 20-30 minutes.
88867627|NCT00995904|Experimental|Treatment A, then Treatment B, then Treatment C|Study visits were separated by 3-7 day intervals. Treatment A: 84ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 2; Treatment B: 42ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 3; Treatment C: 21ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 4
88867628|NCT00995904|Experimental|Treatment A, then Treatment C, then Treatment B|Study visits were separated by 3-7 day intervals. Treatment A: 84ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 2; Treatment C: 21ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 3; Treatment B: 42ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 4
88867629|NCT00995904|Experimental|Treatment B, then Treatment A, then Treatment C|Study visits were separated by 3-7 day intervals. Treatment B: 42ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 2; Treatment A: 84ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 3; Treatment C: 21ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 4
88867630|NCT00995904|Experimental|Treatment B, then Treatment C, then Treatment A|Study visits were separated by 3-7 day intervals. Treatment B: 42ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 2; Treatment C: 21ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 3; Treatment A: 84ug of unit dose budesonide delivered by Aeroneb® Go (MAP0020) at Visit 4
89186660|NCT05266040|Placebo Comparator|Control group|250 patients presenting with pain and a diagnosis of acute apical abscess will be recruited for the VEII preoperative pain and VEIII postoperative pain and clinical/radiographic healing phases of the clinical trial.
89391546|NCT03556124|Sham Comparator|Sham - HD tDCS|Participants randomized to this arm will receive 12 sessions of sham HD tDCS stimulation (Soterix Medical) delivered to the left dorsolateral prefrontal cortex for 20-30 minutes.
89391547|NCT03556124|Sham Comparator|Sham - Conventional tDCS|Participants randomized to this arm will receive 12 sessions of sham conventional tDCS stimulation (Soterix Medical) delivered to the left dorsolateral prefrontal cortex for 20-30 minutes.
89391548|NCT02820753|No Intervention|Enhanced Usual Care|"Patients who have not received the initial 6 weeks of text message reminders telling them to take their medicines; or did not complete at least 1 portal survey that asks them if they filled their medications, if they had any side effects or concerns; or did not receive either intervention will be considered as enhanced usual care.~Patients will only receive EHR tools (patient-friendly med-sheets about their medicines, MedList putting their medicines into the Universal Medication Schedule, and UMS sigs on their Rx bottles)."
89391549|NCT02820753|Active Comparator|Text or Portal|Participants who received EHR strategies as well as, the initial 6 weeks of SMS messaging continuously that remind them to take their medicines; or logged on to the patient portal and completed at least one survey will be considered as receiving the intervention.
89391550|NCT03556046|Experimental|89Zr-girentuximab|A single administration of 37 MBq (+/-10%) 89Zr-girentuximab, containing a mass dose of 5 mg of girentuximab
88867631|NCT00995904|Experimental|Treatment C, then Treatment A, then Treatment B|"Study visits were separated by 3-7 day intervals.~Treatment C: 21ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 2; Treatment A: 84ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 3; Treatment B: 42ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 4"
89391551|NCT02093858||olanzapine|15-25mg/day for 24 weeks
89391552|NCT05218161|Active Comparator|DA|Group DA: will be assigned to patients in whom dexmedetomidine alone will be used.
89391553|NCT05218161|Experimental|KD|Group KD: will be assigned to patients receiving ketamine plus dexmedetomidine.
89391554|NCT02861586|Experimental|Treatment Group A; MV-CHIK low|"60 subjects will receive i.m. vaccinations with MV-CHIK low dose (5xE4 (± 0.5 log) TCID50 per 0.3 mL) on study day 0 and 28, placebo on day 196.~Physical examinations, vital signs, pregnancy tests for females, inquiry of adverse events and collection of immunogenicity blood samples will be performed during all visits."
89391555|NCT02861586|Active Comparator|Treatment Group A/C; Priorix®|"20 subjects will receive i.m. vaccinations with Priorix® on study day 0 and 28, placebo on day 196.~Physical examinations, vital signs, pregnancy tests for females, inquiry of adverse events and collection of immunogenicity blood samples will be performed during all visits."
89391556|NCT02861586|Experimental|Treatment Group B; MV-CHIK low|"60 subjects will receive i.m. vaccinations with placebo on study day 0. MV-CHIK low dose (5xE4 (± 0.5 log) TCID50 per 0.3 mL) on day 28 and MV-CHIK boosting dose on day 196.~Physical examinations, vital signs, pregnancy tests for females, inquiry of adverse events and collection of immunogenicity blood samples will be performed during all visits."
89391557|NCT02861586|Active Comparator|Treatment Group B/D; Priorix®|"20 subjects will receive i.m. vaccinations with placebo on study day 0, Priorix® on day 28 and one boosting dose with Priorix® on day 196.~Physical examinations, vital signs, pregnancy tests for females, inquiry of adverse events and collection of immunogenicity blood samples will be performed during all visits."
89391558|NCT02861586|Experimental|Treatment Group C; MV-CHIK high|"60 subjects will receive i.m. vaccinations with MV-CHIK high dose (5xE5 (± 0.5 log) TCID50 per 0.3 mL) on study day 0 and 28, placebo on day 196.~Physical examinations, vital signs, pregnancy tests for females, inquiry of adverse events and collection of immunogenicity blood samples will be performed during all visits."
89391559|NCT02861586|Experimental|Treatment Group D; MV-CHIK high|"60 subjects will receive i.m. vaccinations with placebo on study day 0, MV-CHIK high dose (5xE5 (± 0.5 log) TCID50 per 0.3 mL) on study day 28 and MV-CHIK boosting dose on day 196.~Physical examinations, vital signs, pregnancy tests for females, inquiry of adverse events and collection of immunogenicity blood samples will be performed during all visits."
89391560|NCT02861586|Experimental|Measles Booster Group 1|"20 subjects will receive i.m. vaccinations with Priorix® on study day -28, MV-CHIK on day 0 and 28 and placebo on day 168 and 196.~Physical examinations, vital signs, pregnancy tests for females, inquiry of adverse events and collection of immunogenicity blood samples will be performed during all visits."
89391561|NCT02861586|Experimental|Measles Booster Group 2|"20 subjects will receive i.m. vaccinations with Priorix® on study day -28, placebo on day 0 and 28 and MV-CHIK on day 168 and 196.~Physical examinations, vital signs, pregnancy tests for females, inquiry of adverse events and collection of immunogenicity blood samples will be performed during all visits."
89391562|NCT02093936||Healthy non exposed|Healthy patients with no pulmonary symptoms that were not exposed to occupational or environmental exposure
89391563|NCT02093936||Healthy exposed|Healthy patients with no pulmonary symptoms that were exposed to occupational or environmental exposure
89391564|NCT02093936||Non-healthy exposed|Patients with pulmonary symptoms or diseases that were exposed to occupational or environmental exposure
89391565|NCT02093936||Non-healthy non-exposed|Patients with pulmonary symptoms or diseases that were not exposed to occupational or environmental exposure
89391566|NCT02096822|Active Comparator|non-nutritive sucking alone|After randomization, baby will receive heel stick procedure with non-nutritive sucking and sterile water.
89391567|NCT02096822|Experimental|Facilitated tucking + non-nutritive sucking|After randomization, baby will receive heel stick procedure with non-nutritive sucking and sterile water combined with facilited tucking.
88867632|NCT00995904|Experimental|Treatment C, then Treatment B, then Treatment A|Study visits were separated by 3-7 day intervals. Treatment C: 21ug of unit dose budesonide delivered by Aeroneb® Go (MAP0020) at Visit 2; Treatment B: 42ug of unit dose budesonide delivered by Aeroneb® Go (MAP0020) at Visit 3; Treatment A: 84ug of unit dose budesonide delivered by Aeroneb® Go (MAP0020) at Visit 4
88867633|NCT00996372|Experimental|flibanserin 100mg|flibanserin 100mg po qd
88867634|NCT00996372|Placebo Comparator|placebo|placebo one tablet po qd
88867635|NCT00997620|Placebo Comparator|Placebo|Placebo treatment given as a once daily dose intranasally.in subjects with active seasonal allergic rhinitis.
89391568|NCT05217771|Experimental|High tone power therapy group|patients in this group will receive High tone power therapy from 30 to 60 minutes, 3 session /week for 4 weeks with total sessions at least l0 sessions and self-stretch for hand and shoulder.
89391569|NCT05217771|Experimental|control group|Patients in control group will receive high tone sham therapy 3 times per week and self-stretch for hand and shoulder.
89391570|NCT02094014||Aphasic/Apraxic Participants|"The aphasic/apraxic participant group will include 30 adults who have had strokes affecting their ability to communicate verbally, broadly classified as aphasic and including individuals with and without apraxia of speech (AOS).~Participants will speak under Masked Auditory Feedback, Altered Auditory Feedback, and Normal Auditory Feedback."
89391571|NCT02094014||Neurologically Healthy Participants|"The neurologically healthy participant group will include 15 adults with no history of stroke or developmental speech or language disorder.~Participants will speak under Masked Auditory Feedback, Altered Auditory Feedback, and Normal Auditory Feedback."
89391572|NCT02099240|Active Comparator|Intravenous antibiotics|Intravenous antibiotics for the full duration of therapy
89391573|NCT02099240|Active Comparator|oral antibiotics|intravenous antibiotic therapy plus early switch to oral antibiotic therapy
89391574|NCT02384421|Experimental|Activa PC+S Neurostimulator|"Participants will be own controls and undergo both adaptive and continuous deep brain stimulation testing paradigms using Nexus D research tool~PC+S: Primary Cell+Sensing"
89391575|NCT03610074|Experimental|Mint ice cubes|"Physician applies 3 mint ice cubes in mouth of highly dehydrated patient. Patient undergoes an additional blood test at 5 min from mint ice cubes application.~Physician performs patient's questioning before mint ice cubes application and at 5 min, 1h, 2h, 4h, 12h and 24h from mint ice cubes application."
89391576|NCT02034084|Experimental|Right radial approach|Coronary diagnostic procedures performed through right radial approach
89391577|NCT02034084|Experimental|Left radial approach|Coronary diagnostic procedures performed through left radial approach
89391578|NCT05215899|Experimental|MINDFULNESS-BASED YOGA AND MEDITATION INTERVENTION|MINDFULNESS-BASED YOGA AND MEDITATION INTERVENTION
89391579|NCT05215899|Experimental|Comparison group|Patients in the comparison group will not be subjected to any intervention other than the tests specified in the method. Comparison group patients will continue their standard treatment and care. Questionnaires and scales will be applied to this group again before the application starts and after the application is finished.
89391580|NCT03609450|Active Comparator|Mindfulness Training for Primary Care|Mindfulness Training for Primary Care (MTPC) is a primary care adaptation that includes core common Mindfulness-Based Intervention (MBI) elements integrated with novel mindfulness-oriented behavior change elements into a format that is adaptable to delivery in primary care health centers.
89391581|NCT03609450|Other|Low-Dose Comparator|Comparator arm: Participants receive a 60-minute introduction to mindfulness group plus referral to a list of community mindfulness resources such as private-pay community mindfulness classes, mobile mindfulness applications, books, and online recordings. These participants are added to a 6-month wait-list for a Cambridge Health Alliance mindfulness-based intervention group, but are allowed to receive behavioral, psychiatric, and medical treatments that are consistent with treatment as usual. All participants complete an action planning protocol during Week 7.
89391582|NCT02294331||Attain Performa™ LV Leads|Patients who meet all Inclusion criteria and no Exclusion criteria and are implanted with an Attain Performa™ LV lead.
89391583|NCT02033928||Arm I: Transplant patients|
89391584|NCT02033928||Arm II: Plasma cell dyscrasia patients|
89391585|NCT05383248|Experimental|High Reward - High Variance|
89391586|NCT05383248|Active Comparator|High Reward - Low Variance|
89391587|NCT05215821||group1|subjects with evidence of insulin resistance estimated by high HOMA level
89391588|NCT05215821||group 2|subjects without insulin resistance estimated by normal HOMA level
89391589|NCT05215743|Experimental|Combined antioxidant therapy (CAT)|Intravenous administration of deferoxamine, n-acetylcysteine, and ascorbate over 90 minutes.
89391590|NCT05215743|Placebo Comparator|Placebo|Intravenous administration of NaCl 0.9% over 90 minutes
89391591|NCT02099396|Experimental|docetaxel+lobaplatin|"Pretreatment: 15 mg dexamethasone is administered orally every day since one day before administration with docetaxel for continuous three days. Dexamethasone 10 mg i.v. and promethazine 25mg im are administered 30 min before administration with docetaxel to prevent anaphylactic responses.~Intravenous infusion with docetaxel 75mg/m2 for one hour is carried out on the first day of each cycle for 21 days; intravenous infusion with lobaplatin 30 mg/m2 for two hours is carried out on the second day; q3wkb"
89391592|NCT02099396|Experimental|gemcitabine+lobaplatin|"Pretreatment: 15 mg dexamethasone is administered orally every day since one day before administration with docetaxel for continuous three days. Dexamethasone 10 mg i.v. and promethazine 25mg im are administered 30 min before administration with docetaxel to prevent anaphylactic responses.~Intravenous infusion with gemcitabine 675mg/m2 for 90 min is carried out on the first day and the eighth day of each cycle for 21 days; intravenous infusion with lobaplatin 30 mg/m2 for two hours is carried out; intravenous infusion with docetaxel 75mg/m2 for one hour is carried out on the first day; q3wkb"
89391593|NCT05215665|Experimental|group 1|Lenvatinib+Toripalimab
89391594|NCT05215665|Experimental|group 2|GEMOX+Lenvatinib+Toripalimab
89391595|NCT05215665|Experimental|group 3|Lenvatinib+Toripalimab (failure of GEMOX treatment)
89391596|NCT05215665|Experimental|group 4|GEMOX+Toripalimab
89391597|NCT02094092|Placebo Comparator|ProTectis drops|Arm A.
89391598|NCT02094092|Placebo Comparator|Placebo drops|Arm B
88867636|NCT00997620|Experimental|Fluticasone Furoate|IFluticasone Furoate 110 mcg given intranasly once daily in am as an active treatment of seasonal allergic rhinitis
88867637|NCT00997932|Other|Complete Cohort|The complete cohort of all women enrolled and stated they wanted an LNG-IUS between 48 and 72 hours of vaginal delivery.
88867638|NCT00998010|Experimental|Experimental|Patients receive bortezomib IV on days 1, 4, 8, 11, 29, 32, 36, and 39 and oral temozolomide on days 1-42.Patients undergo external-beam fractionated regional radiotherapy 5 days a week for 6 weeks in the absence of disease progression or unacceptable toxicity.2-6 weeks after radiotherapy, patients receive bortezomib IV on days 1, 4, 8, and 11 and oral temozolomide on days 1-5.Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
88867639|NCT00998868||hemiplegia|patients with hemiplegia, without other musculoskeletal disorders of the shoulder
88867640|NCT00999102|Experimental|Nebivolol, followed by Metoprolol|Participants first received Nebivolol at a dose of 5 mg daily for 4 weeks, followed by 10 mg daily for another 4 weeks (i.e., weeks 1-8 in total). The participants then received Metoprolol at a dose of 50 mg daily for 4 weeks, followed by 100 mg daily for another 4 weeks (i.e., weeks 9-16 in total).
88867641|NCT00999102|Experimental|Metoprolol, followed by Nebivolol|Participants first received Metoprolol at a dose of 50 mg daily for 4 weeks, followed by 100 mg daily for another 4 weeks (i.e., weeks 1-8 in total). The participants then received Nebivolol at a dose of 5 mg daily for 4 weeks, followed by 10 mg daily for another 4 weeks (i.e., weeks 9-16 in total)
88867642|NCT01000662|Active Comparator|ARM 1 daily boost|Radiation Therapy
88867643|NCT01000662|Active Comparator|ARM 2 weekly boost|Radiation Therapy
88867644|NCT01000818|Experimental|Period 1|MK0518
88867645|NCT01000818|Experimental|Period 2|famotidine + MK0518
88867646|NCT01000818|Experimental|Period 3|omeprazole + MK0518
88867647|NCT01001052|Experimental|Colcrys™ - young subjects (18-30 yrs)|One single dose of Colcrys™ 0.6mg taken by mouth on day 1
88867648|NCT01001052|Experimental|Colcrys™ - elderly subjects (≥60 yrs)|One single dose of Colcrys™ 0.6mg taken by mouth on day 1
88867649|NCT01001442|Experimental|BT062|BT062 was to be administered as single-dose IV infusions via a 0.22 μm in-line filter preferably in a forearm vein, according to medically accepted procedures on Days 1, 8, and 15 of each 28-day cycle. Alternatively BT062 may have been administered through a central venous line or a peripherally inserted central catheter (PICC). Other administration routes were only to be allowed after approval from Biotest. Each subject was to be monitored carefully for the effects of exposure to BT062. No subject was to have received more than 3 doses of BT062 per 28-day treatment cycle.
89391599|NCT03627663|Experimental|Intervention|Receiving treatment with Dialectic Behavior Therapy - Skills System + Treatment As Usual
89391600|NCT02099474|Experimental|Raltegravir|All women have been prescribed raltegravir before study participation.
89391601|NCT02250716|Experimental|Arm 1|Immediate treatment with Cryotherapy and 12 month cytology and histology follow-up
88867650|NCT01002456|Other|Level 1: site-specific information|provide site-specific information on nonadherence
88867651|NCT01002456|Other|Level 2: site-, patient-specific info|provide site- and patient-specific information on nonadherence
88867652|NCT01003080|Experimental|TKA with the Aquamantys for hemostasis|This arm will receive the total knee arthroplasty with the Aquamantys device used for hemostasis.
88867653|NCT01003080|Active Comparator|TKA without the Aquamantys for hemostasis|This group will receive total knee arthroplasty using the standard treatment for hemostasis.
88867654|NCT01003938|Experimental|topotecan and erlotinib|Topotecan 0.4 mg/m^2/day administered via continuous infusion for 9 days beginning on Day 1, every 21 days cycle; erlotinib 150 mg daily for 9 days every 21 days cycle. Both drugs will be given for a minimum of 2 cycles.
88867655|NCT01004718|Experimental|Fludeoxyglucose F18 (FDG) PET/CT scans|Patients undergo fludeoxyglucose F18 (FDG) positron emission tomography/computed tomography scans and 180 minutes after FDG administration.
88867656|NCT01005576|Experimental|Conditioning regimen|Hydroxyurea days -50 to -21 Alemtuzumab days -21 to -19 Fludarabine days -8 to -4 Thiotepa day -4 Melphalan day -3 Stem cell infusion day 0
88867657|NCT01005810|Active Comparator|N-Acetylcysteine|
88867658|NCT01005810|Placebo Comparator|Placebo|
88867659|NCT01005888|Experimental|C1INH-nf First, then Placebo|1,000 Units (U) of C1INH-nf administered intravenously (IV) every 3 to 4 days (approximately twice weekly) for 12 weeks, followed by matching placebo (saline) administered IV every 3 to 4 days for 12 weeks.
88867660|NCT01005888|Experimental|Placebo First, then C1INH-nf|Matching placebo (saline) administered IV every 3 to 4 days (approximately twice weekly) for 12 weeks, followed by 1,000 U of C1INH-nf administered IV every 3 to 4 days for 12 weeks.
88867661|NCT01007136|Experimental|tDCS and occupational therapy|1 mA electric current will be delivered over the lesioned motor cortex for the first 20 minutes during the one hour physical therapy.
88867662|NCT01007136|Sham Comparator|Sham and occupational therapy|Electric current will be ramped up and down over the lesioned motor cortex for the first seconds during the one hour physical therapy.
89391602|NCT02250716|No Intervention|Arm 2|12 month cytology and histology follow-up
89391603|NCT03555500|No Intervention|Fasting Group|Clear fluids up to the time of the procedure and no food for at least 2 hours before the procedure.
89391604|NCT03555500|Experimental|Non fasting group|Clear fluids and food up to the time of the procedure.
89391605|NCT05217069|Other|RAS wild-type Avelumab|"Induction therapy:~FOLFIRI 5-FU: 400 mg/m2 (i.v. bolus) Folinic acid: 400mg/m2 Irinotecan: 180 mg/m2 5-FU: 2.400 mg/m2 (i.v. 46h)~Cetuximab 400 mg/m2 i.v. 120min initial dose 250 mg/m2 i.v. 60min q 1w~Maintenance therapy:~Avelumab 10mg/kg IV (day 1 q2w)"
89391606|NCT02096978|Experimental|Osteotome preparation|Procedure/Surgery: Preparing the osteotomy to accept a standard implant device
89391607|NCT02096978|Active Comparator|Drill preparation|Preparing the osteotomy to accept a standard implant device
89391608|NCT02250170|Experimental|OPB-111077|Tablet, Oral, 300mg/500mg/700mg/900mg 4 days-on & 3 days-off (21 days=1cycle)
89391609|NCT02065635|Experimental|maintenance with sevoflurane|in patients allocated to the sevoflurane group, general anesthesia will be maintained with sevoflurane
89391610|NCT02065635|Active Comparator|maintenance with propofol|in patients allocated to the propofol group, general anesthesia will be maintained with propofol
89391611|NCT02097368||neuromuscular patient|Patients affected by neuromuscular pathology will be explored by tongue strength measurement, respiratory function measurement, swallowing tests and Magnetic resonance imaging
89391612|NCT02099552||XLHED|Those with the condition of XLHED
89391613|NCT01848561||Immunomodulatory Therapy|Patients who are being prescribed and treated with Immunomodulatory Therapy
89391614|NCT01848561||Adalimumab (Humira) Treatment|Patients who are prescribed and treated with Adalimumab
89391615|NCT03556748|No Intervention|Control group|"usual care control group receives individualized nutritional support (dietary advices: daily protein intake 1.2-1.5 g/kg bodyweight),~active exercise therapy is optionally provided (bicycle ergometers at room) during the in-Patient stay"
89391616|NCT03556748|Experimental|WB-EMS group|"physical exercise group regular WB-EMS training (2 EMS trainings per week; each session for 20 min)~+ individualized nutritional support (dietary advices: daily protein intake 1.2-1.5 g/kg bodyweight)~active exercise therapy is optionally provided (bicycle ergometers at room) during the in-Patient stay"
89391617|NCT02094248|Experimental|TPO|rhTPO（Recombinant Human Thrombopoietin，TPIAO®, Shenyang Sunshine Pharmaceutical Company Limited [SUNSHINE], Shenyang, China）， 15000U/ml, s.c injection
89391618|NCT02094248|Placebo Comparator|control|Normal saline，1ml/day, s.c injection
89391619|NCT02250248|Active Comparator|AttraX Putty|Patient will be treated with AttraX Putty intraoperatively.
89391620|NCT02250248|Active Comparator|Iliac Crest Bone Graft (ICBG)|Patients will be treated with ICBG harvested during surgery.
89391621|NCT02100020|Experimental|Direct Referral to Physical Activity|The REF group will be referred to a centre-based community exercise program in their respective community (either the MacWheelers or Revved Up) by a clinical neurologist where they will be prescribed exercise based on the PAGs for adults with MS, and according to their individual capabilities.
89391622|NCT02100020|No Intervention|Control|The CON group will be provided with a print copy of the PAGs and a link to an online resource for physical activity information.
89391623|NCT02097446|Experimental|GUARDIX-FL|Patients will be treated with 1 or 2 sheet of GUARDIX-FL after ovarian cystectomy(Operative Day).
89391624|NCT02097446|Active Comparator|Interceed|Patients will be treated with 1 or 2 sheet of interceed after ovarian cystectomy(Operative Day).
89391625|NCT02097524|Experimental|Sarilumab - dose 1|Single subcutaneous (SC) injection of Sarilumab, dose 1, plus methotrexate background treatment (dispensed and dosed according to local practice)
88867663|NCT01007526|Experimental|CCRT plus VIDL|CCRT followed by VIDL chemotherapy Concomitant chemo-radiotherapy followed by VIDL chemotherapy with risk-based application of autologous stem cell transplantation Patients who are planned to be treated with CCRT plus VIDL chemotherapy and/or autologous stem cell transplantation
89391626|NCT02097524|Experimental|Sarilumab - dose 2|Single SC injection of Sarilumab, dose 2, plus methotrexate background treatment (dispensed and dosed according to local practice)
89391627|NCT02097524|Active Comparator|Tocilizumab - dose 1|Single intravenous (IV) administration of Tocilizumab, dose 1, plus methotrexate background treatment (dispensed and dosed according to local practice)
89391628|NCT02097524|Active Comparator|Tocilizumab - dose 2|Single IV administration of Tocilizumab, dose 2, plus methotrexate background treatment (dispensed and dosed according to local practice)
89391629|NCT03628053|Experimental|Tisagenlecleucel arm|Patient to receive tisagenlecleucel after optional bridging therapy and lymphodepleting chemotherapy.
89391630|NCT03628053|Active Comparator|Control arm|blinatumomab or inotuzumab per investigator's discretion after optional bridging chemotherapy
89391631|NCT02100176||Rotigotine and MIRT|Group 1 - 20 Patients with PD (H&Y stages 1,5-2) in therapy only with Rotigotine will undergo a Multidisciplinary intensive rehabilitation treatment (MIRT).
89391632|NCT02100176||Control group, only Rotigotine|Group 2 - 20 Patients with PD (H&Y stages 1,5-2)
89391633|NCT02094404||Children at the ED<18yr|
89391634|NCT02250482|Experimental|Optivate®|Optivate® (Human Coagulation Factor VIII)
89391635|NCT01377753|Experimental|Arm 1/Magnetic Resonance (MR) Thermal Image Guided Laser Ablation|Eligible subjects will undergo MR thermal image guided laser ablation of all biopsy proven areas of prostate cancer using one or multiple laser probes during a single procedure lasting approximately two hours in duration.
89391636|NCT03556670|Experimental|Total Worker Health Intervention|
88867664|NCT01007994|Active Comparator|New Medication|A new anti-hypertensive medication (enalapril, propranolol or isradipine) will be added at 8pm.
88867665|NCT01007994|No Intervention|Control|Subjects in the control group will continue to take their medications as usual.
88867666|NCT01008462|Experimental|Treatment (autologous HCT, donor HCT)|See Detailed Description
88867667|NCT01010568|Experimental|Ofatumumab and Bendamustine|Ofatumumab and Bendamustine
88867668|NCT01011816|Experimental|BIOSTAT BIOLOGX|One injection of up to 4 mL of BIOSTAT BIOLOGX Fibrin Sealant into a single lumbar intervertebral disc
88867669|NCT01011816|Placebo Comparator|Saline|One injection of up to 4 mL of saline solution into a single lumbar intervertebral disc
89391637|NCT03556670|Active Comparator|Control|
89391638|NCT02250560|Experimental|Replenine®-VF|
89391639|NCT02094482|Other|OSAS Palatal Implant|The IMD is a resilient palatal implant which is introduced through a stab incision into the palate. Two implants are placed underneath the rostral part of the palatal bone and continue into the upper part of the soft palate .
88867670|NCT01011894|Experimental|pts getting lenalidomide|Patients with intermediate or high-risk chronic lymphocytic leukemia (≥ 65 years old) will receive lenalidomide until disease progression at the 20mg dose level (recognizing that progression at this dose requires non-protocol alternate therapy) or unacceptable toxicity.
88867671|NCT01012362|Experimental|Optimum Tolerated Dose Determination|"Patient receives assigned dose level:~Dose Level 1 = 400 milligrams (mg) of pazopanib and ixabepilone 32 mg/m2. Dose Level 2 = 400 milligrams (mg) of pazopanib and ixabepilone 40 mg/m2. Dose Level 3 = 600 milligrams (mg) of pazopanib and ixabepilone 32 mg/m2. Dose Level 4 = 800 milligrams (mg) of pazopanib and ixabepilone 32 mg/m2."
88867672|NCT01012362|Experimental|Optimum Tolerated Dose Confirmation|Dose Level 3 = 600 milligrams (mg) of pazopanib and ixabepilone 32 mg/m2.
88867673|NCT01012674|Experimental|Dotarem and TOF MRA|Each subject will undergo a Time Of Flight (TOF) Magnetic Resonance Angiography (MRA) followed by a Dotarem enhanced MRA.
88867674|NCT01013844|Active Comparator|Solo Learning|Participant learning alone (without partner).
88867675|NCT01013844|Active Comparator|Dyadic Learning|Participant and partner learning together.
88867676|NCT00986544|Sham Comparator|Absence of drain|
88867677|NCT00986544|Active Comparator|Drain|drain positioned in the subhepatic space after laparoscopic cholecystectomy
88867678|NCT01014390|Experimental|WallFlex Biliary RX FC Stent System|The WallFlex Biliary RX Fully Covered Stent System is being evaluated for treatment of benign biliary strictures.
88867679|NCT01015170|Experimental|Bupropion HCl|Up to 8 week of bupropion SR (150mg BID) + counseling.
88867680|NCT01015326||Expert Interviews|Expert cohort consists of providers with expertise in administering epidermal growth factor receptor inhibitors (EGFRI) or treating patients with EGFRI-associated skin toxicities. Experts will be asked open-ended questions about symptoms and issues as they relate to HRQL in patients with EFGRI skin toxicities. Experts will then be presented with a pool of potential items and will be asked through interview and questionnaire to relate items according to how common and how important they are when occurring in patients with this condition.
88867681|NCT01015326||Patient Interviews|Patient cohort will consist of those treated with an epidermal growth factor receptor inhibitor (EGFRI) and referred to a specialized dermatology clinic for skin rash management. Patients will be asked open-ended questions about symptoms and issues as they relate to their HRQL to elicit personal experiences about how EGFRI skin toxicities and its treatment affects patients. Patients will be asked through interview and questionnaire to rate items according to how often they are experienced and how important they are to the patient.
88867682|NCT01016106|Active Comparator|AA pts AD and IV|African American patients with a diagnosis of atopic dermatitis and ichthyosis vulgaris. During a single visit, a subject data collection form will be completed and DNA will be extracted from samples (buccal swabs) and then analyzed at IBT
88867683|NCT01016106|Active Comparator|AA patients (controls)|African American patients with no personal or family history of ichthyosis vulgaris or atopy. During a single visit, a subject data collection form will be completed and DNA will be extracted from samples (buccal swabs) and then analyzed at IBT
88867684|NCT01016652|Other|etafilcon A multifocal / etafilcon A sphere|period 1: etafilcon A multifocal worn, period 2: etafilcon A sphere worn.
88867685|NCT01016652|Other|etafilcon A sphere / etafilcon A multifocal|period 1: etafilcon A sphere worn, period 2: etafilcon A multifocal worn.
88867686|NCT01017042|Experimental|colchicine|colchicine 1.2mg by mouth initially then an additional 0.6mg orally 1 hour later (1.8mg over 2 hours)
88867687|NCT01018056|Experimental|D-serine (glutamate agonist)|24 subjects age 8-17 years with moderate to severe TS (TTS > 22) will be enrolled in this treatment arm. They will receive D-serine for 6-weeks of the study, during which time drug dose may gradually be increased as needed. At 6-weeks participants will taper off drug.
88867688|NCT01018056|Experimental|Riluzole (glutamate antagonist)|24 subjects age 8-17 years with moderate to severe TS (TTS > 22) will be enrolled in this treatment arm. They will receive riluzole for 6-weeks of the study, during which time drug dose may gradually be increased as needed. At 6-weeks participants will taper off drug.
88867689|NCT01018056|Placebo Comparator|Placebo|12 subjects age 8-17 years with moderate to severe TS (TTS > 22) will be enrolled in this treatment arm. They will receive placebo for 6-weeks of the study, during which time drug dose may gradually be increased as needed. At 6-weeks participants will taper off drug.
88867690|NCT01018134|Experimental|Desoximetasone 0.05% once daily|Desoximetasone topical spray 0.05% administered once daily to affected area
88867691|NCT01018134|Experimental|Desoximetasone 0.05% twice daily|Desoximetasone topical spray 0.05% administered twice daily to affected area
88867692|NCT01018134|Experimental|Desoximetasone 0.25% once daily|Desoximetasone topical spray 0.25% administered once daily to affected area
88867693|NCT01018134|Experimental|Desoximetasone 0.25% twice daily|Desoximetasone topical spray 0.25% administered twice daily to affected area
88867694|NCT01018134|Placebo Comparator|Vehicle once daily|Vehicle administered to affected areas once daily
88867695|NCT01018134|Placebo Comparator|Vehicle twice daily|Vehicle administered to affected areas twice daily
88867696|NCT01019928|Experimental|First AZD1386, then washout, then placebo|
88867697|NCT01019928|Experimental|First placebo, then washout, then AZD1386|
88867698|NCT01020006|Active Comparator|Gemcitabine|Subjects receive Gemcitabine 1000 mg/m2 weekly intravenous infusion.
88867699|NCT01020006|Experimental|PCI-27483 + Gemcitabine|"Part A: Subjects received PCI-27483 0.8 mg/kg BID as initial dose and may be escalated to 1.2, and 1.5 mg/kg BID. At the same time, subjects received Gemcitabine 1000 mg/m2 weekly intravenous infusion.~Part B: Subjects received the PCI-27483 at 1.2 mg/kg BID and Gemcitabine 1000 mg/m2 weekly intravenous infusion."
88867700|NCT05395962|Active Comparator|BLM|
88867701|NCT05395962|Experimental|BLM+CBP|
88867702|NCT05395728|Experimental|Group 1|Deflate the cuff at the beginning of the mechanical ventilation weaning protocol
88867703|NCT05395728|Active Comparator|Group 2|Deflate the cuff after complete weaning from mechanical ventilation
89391640|NCT05194761|Active Comparator|using nebulization|extubated neonates will be divided in two group , one will receive saline nebulization for 3 days postextubation ,
89391641|NCT05194761|No Intervention|No nebulization|the other group will only receive the standard only
89391642|NCT02094560|Experimental|Small cell lung cancer|Histologically- or cytologically-confirmed, limited and extensive SCLC disease with progression after first or second line treatment
88867704|NCT05395572|Experimental|Tape|Kinesio tape will be applied to the neck to help facilitate underactive muscles and ROM will be assessed
88867705|NCT05395572|No Intervention|Control|ROM will be assessed before tape application to determine any changes
89391643|NCT02094560|Experimental|Non small cell lung cancer|Histologically- or cytologically-confirmed diagnosis of NSCLC with Stage IIIB or IV after failure of at least two lines of therapy
89391644|NCT02094560|Experimental|biliary tract cancer|Histologically or cytologically confirmed diagnosis of biliary tract cancer progress after first line therapy
88867706|NCT05394480|Experimental|clinical treatment|"4 dentist treated 36 patient in clinical group~- For treatment in a clinic, children with positive or definitely positive (Frankl 3 and 4) behaviour according to the Frankl Scale (Behavior Evaluation Scale) 28, with the data observed in the first session, were included in the clinical treatment group. According to the clinical examination of these patients, 36 healthy children aged 5-6 years who did not require pulpal treatment and whose caries level was 1-4 according to the ICDAS (International Caries Detection And Assessment System) 29 scoring were selected. The limits of the treatment were determined as compomer filling applied to 2 primary molars after local anaesthesia, and the duration of the treatment was limited to 30 to 60 minutes."
88867707|NCT05394480|Experimental|deep sedation|"4 dentist treated 36 patient in clinical group~- Children aged 48-72 months, children with negative or absolutely negative behaviour (Frankl 1 and 2) according to the Frankl Scale, were reserved for treatment under deep sedation. In order to provide standardization among patients suitable for sedation, 36 children (n=9) whose dmft (decayed, missing, filled teeth index) were less than their age, and the duration of the procedure would be limited to between 30 and 40 minutes, were included in the study."
89391645|NCT03627975|No Intervention|Conservative treatment|Conservative treatment. The conservative treatment of hemorrhagic moyamoya disease mainly includes the control of hypertension, the prevention and treatment of secondary epilepsy, the control of intracranial hypertension(including the application of mannitol and glycerol fructose, etc.), and the corresponding symptomatic and neurotrophic treatment. Non-specific treatment is mainly deal with intracranial hematoma, including intraventricular drainage, intracranial hematoma evacuation, and ventriculoperitoneal shunt.
89391646|NCT03627975|Experimental|Indirect vascular reconstruction surgery|Indirect vascular reconstruction surgery. In addition to the pharmacotherapy used in conservative treatment, encephalo-duro-arterio-synangiosis(EDAS) is performed. The surgery is performed according to the procedures described by Matsushima.
89391647|NCT03627975|Experimental|direct vascular reconstruction surgery|Direct vascular reconstruction surgery. In addition to the pharmacotherapy used in conservative treatment, the superficial temporal artery(STA) and middle cerebral artery(MCA) bypass surgery is performed. The operation is the modified EDAS which basically similar to EDAS, but the surgical incision is as low as possible. And if necessary, the STA may not be preserved. The bone flap should be large enough to select the right recipient blood vessel.
89391648|NCT02094638||Tanreqing|Inpatient using the Tanreqing Injection
89391649|NCT05194605||Retrospective cohort|The internal cohort was retrospectively enrolled in West China Hospital, Sichuan University from June 2010 and December 2020. It is a training and internal validation cohort.
89391650|NCT05194605||Prospective cohort|The same inclusion/exclusion criteria were applied for the same center prospectively. It is an external validation cohort.
89391651|NCT02097836|Experimental|Single subject case series|Targeted training, 5-6 days a week for 6 months, minimum of 20 minutes per day
89391652|NCT03555812|Experimental|Healthy volunteers|"a medical examination~10 measurements of pelvic tilt in sitting position, 10 measurements of pelvic tilt in supine position and 10 measurements of pelvic tilt in standing position, each performed by three different operators. These measurements will be done by ultrasound."
89391653|NCT03555812|Experimental|Patients|"a consultation the day before surgery, and a consultation 2 months after surgery, each including:~a medical examination~3 pelvic tilt measurements (1 standing, 1 sitting and 1 lying down). These measurements will be done by ultrasound."
89391654|NCT05423366|Active Comparator|Large-Focused Extracorporeal Shock Wave Therapy|
89391655|NCT05423366|Active Comparator|Controlled-Unfocused (Radial) Extracorporeal Shock Wave Therapy|
89391656|NCT05423366|Sham Comparator|Sham Extracorporeal Shock Wave Therapy|
89391657|NCT02097914|No Intervention|Control|Participant receives usual care.
89391658|NCT02097914|Experimental|Intervention|Educational print materials and coaching call: Intervention group participants receive three sets of mailed educational materials about making their home smoke-free and once coaching call.
89391659|NCT05150847|Other|Prone Positioning|Patients will be ventilated in volume-controlled mode with Vt at 6 ml/kg of predicted body weight. Prone positioning will be performed over periods of 16 hours when PaO2/FiO2 was persistently lower than 150 mm Hg. Flow, volume, and airway pressure will bw measured by ventilators. Measurements of oxygenation and respiratory mechanics were performed at 5 and 15 cmH20 PEEP levels and will be repeated every season as before first period of prone positioning, before supine positioning, and again before second period of prone positioning. Total PEEP and plateau pressure will be measured by a short end-expiratory and an end-inspiratory occlusion respectively. Complete airway closure will be assessed by performing a low-flow (4 L/min) inflation( PV tool) (9). The potential for lung recruitment will be assessed by means of the R/I ratio (10).
89391660|NCT02094950|Experimental|Lung Cancer Patient with Dyspnea|
89391661|NCT04967079|Experimental|Anlotinib + Trametinib|Anlotinib given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21) plus trametinib 2 milligrams (mg) given orally, once daily.
89391662|NCT03890601||Biological APS|50 Asymptomatic patients with aPL antibodies and prolonged APTT
89391663|NCT03890601||Obstetrical APS|50 patients with Obstetrical aPL syndrome
89391664|NCT03890601||Thrombosis APS|APS with a personal history of venous or arterial thrombosis (50 patients)
89391665|NCT02100332||Chronic obstructive pulmonary disease|Patients with chronic obstructive pulmonary disease will undergo a single visit with the collection of data from his/her records.
89186661|NCT02588924||Second University of Naples|the present research project is aimed at measuring out the concentrations of copper, iron and manganese in biological fluids (blood, serum) of patients with Parkinson's disease and of subjects of the control group and assess possible correlations between changes in the content of metals and the pathology.
89391666|NCT03556592|Experimental|All subjects|"Tralokinumab - investigational medicinal product:~Week 0: subcutaneous (SC) injection of tralokinumab loading dose.~Week 2 to Week 14: SC injection of tralokinumab maintenance dose.~CYP substrates - non-investigational medicinal products:~Week -1, Week 1, and Week 15: oral administration of caffeine 100 mg, warfarin sodium 5 mg x2, omeprazole 20 mg, metoprolol tartrate 100 mg, and midazolam hydrochloride 2 mg."
89391667|NCT05070117|Experimental|Resistance/strength training|
89391668|NCT02095028|Experimental|Dietary and lifestyle intervention|Intervention group:Based on standard care,intensive dietary and lifestyle intervention was provided. Initiated from the first trimester to delivery,every 2-4 weeks follow-up
89391669|NCT02095028|No Intervention|Standard care group|Standard care group:Participants received one group session in which prenatal general dietary, nutrition guideline, physical activity and recommendation for gestational weight gain introduced by a registered dietitian in 1.5hours.Participants received their regularly scheduled visits without additional dietary and lifestyle follow-up and guidance.
89391670|NCT04964193|Experimental|Elzsa film-coated tablet|Participants received Elzsa film-coated tablet (2 mg cyproterone acetate + 0.035 mg ethinylestradiol) with 240 mL of water
89391671|NCT04964193|Active Comparator|Diane-35 Sugar-coated tablet|Participants received Diane-35 Sugar-coated tablet ( 2 mg cyproterone acetate + 0.035 mg ethinylestradiol) with 240 mL of water
89391672|NCT02098070||Knee Pain Population|Participants who have responded to the questionnaire with self-reported pain.
89391673|NCT02098070||Non-Knee Pain Population|Participants who have responded to the questionnaire, no self-reported pain.
89391674|NCT02095262|Active Comparator|STAR2|Reactive auditory training
89391675|NCT02095262|Experimental|Treasure Hunter|Interactive auditory training
89391676|NCT02095262|Experimental|Submarine|Interactive auditory training
89391677|NCT04814199||Patients using epidural management algorithm|Patients will be educated and given an algorithm to follow while in labour and after having an epidural catheter placed.
89391678|NCT02100488|Active Comparator|Open-loop insulin infusion system|Standard Open-loop intensive insulin treatment with continuous insulin infusion (CSII). Commercially available insulin infusion systems will be used.
89391679|NCT02100488|Experimental|Closed-loop insulin infusion system|Sliding Mode Reference Conditioning (SMRC) Closed-loop insulin administration. Automated insulin infusion based on subcutaneous continuous glucose monitoring (CGM). Commercially available insulin infusion systems and CGM devices will be used. However, insulin infusion will be driven by the by the software under investigation (CL4M Controls) based on blood glucose estimations from CGM.
89391680|NCT03627819|Active Comparator|Plant sterol-enriched margarine|Intake of 20 gram margarine with added plant sterol esters, providing 3 gram plant sterols per day for 1 year
89391681|NCT03627819|Active Comparator|Plant stanol-enriched margarine|Intake of 20 gram margarine with added plant stanol esters, 3 gram plant stanols per day for 1 year
89391682|NCT03627819|Placebo Comparator|Control margarine|Intake of 20 gram margarine without any addition, every day for 1 year
89391683|NCT02100566|Experimental|Behavioral Counseling|Provide an advance directive document to patients along with counseling that either focuses on care giver burden or on patient autonomy.
89391684|NCT02100566|No Intervention|Standard AD|The topic of advance directives (AD) is introduced but patient receives an AD document only upon request.
89391685|NCT02095418|Experimental|Mycophenolate mofetil, Corticosteroids|"Mycophenolate mofetil: 500-1500mg/day, bid, PO~Corticosteroids: 500mg for the first dosage. It will be tapered at least 5mg for 14days and withdrawn"
89391686|NCT02095418|Active Comparator|Corticosteroids, Mycophenolate mofetil|"Mycophenolate mofetil: 500-1000mg/day, bid, PO~Corticosteroids 500mg for the first dosage. It will be tapered at least 5mg for 3months(± 2 weeks) and withdrawn."
89391687|NCT03627585|No Intervention|Usual Care|Patients received echocardiogram but no pacemaker reprogramming or personalisation.
89391688|NCT03627585|Active Comparator|Personalised programming|Patient will have tailored pacemaker programming based on echocardiographic findings, blood results, and symptoms in an attempt to minimise right ventricular pacing and extend battery longevity.
89391689|NCT04865497|Experimental|High dose Group|S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine,10μg/dose
89391690|NCT04865497|Experimental|Low dose Group|S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine,5μg/dose
89391691|NCT04865497|Other|Adjuvant-free Group|Adjuvant-free S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine,10μg/dose
89391692|NCT04865497|Other|Control Group|Haemophilus b Conjugate Vaccine,10μg/dose
89391693|NCT02100878||Lean adolescents|
89391694|NCT02100878||Obese adolescents|
89391695|NCT05665725|Experimental|Treatment (siltuximab, biospecimen)|Patients receive siltuximab IV prior to CE19.CAR-T cell therapy and as clinically indicated on study. Patients undergo CT scan or PET scan throughout the trial. Patients also undergo blood sample collection during screening and on study.
89391696|NCT02098148|Experimental|Xenon/Placebo|Participants in this group will receive three treatments of 25% xenon followed by 3 treatments of placebo (room air).
89391697|NCT02098148|Experimental|Placebo/Xenon|Participants in this group will receive three treatments of placebo (room air) followed by three treatments of 25% xenon.
89391698|NCT01369381|Experimental|Airtraq laryngoscope|The Airtraq is an alternative indirect laryngoscope that appears to cause less cervical spine motion during intubation that conventional direct laryngoscopy (Macintosh blade)
89391699|NCT01369381|Active Comparator|Macintosh laryngoscope|This arm constitutes intubation with a conventional direct laryngoscopy with a Macintosh blade which has been shown to result in cervical spine extension, particularly in the upper cervical segments.
89391700|NCT05170321||patients undergoing knee arthroplasty in Hospital Quality Monitoring System in China|Patients who underwent knee arthroplasty and was recorded in HQMS were included in this group
89391701|NCT05170321||patients undergoing hip arthroplasty in Hospital Quality Monitoring System in China|Patients who underwent hip arthroplasty and was recorded in HQMS were included in this group
89391702|NCT05170321||patients undergoing shoulder arthroplasty in Hospital Quality Monitoring System in China|Patients who underwent shoulder arthroplasty and was recorded in HQMS were included in this group
89391703|NCT05170321||patients undergoing ankle arthroplasty in Hospital Quality Monitoring System in China|Patients who underwent ankle arthroplasty and was recorded in HQMS were included in this group
89391704|NCT05170321||patients undergoing elbow arthroplasty in Hospital Quality Monitoring System in China|Patients who underwent elbow arthroplasty and was recorded in HQMS were included in this group
88867708|NCT05394480|Experimental|general anaesthesia|"4 dentist treated 36 patient in clinical group~- Children aged 48-72 months, children with negative or definitely negative behaviour according to the Frankl Scale (Frankl 1 and 2), were reserved for treatment under general anaesthesia. In order to provide standardization among patients suitable for general anaesthesia, 36 healthy children (n=9) whose dmft was equal to, or higher than their age were allocated. In addition, patients whose treatment time would be limited to 30 to 60 minutes were included."
88867709|NCT05394090|Experimental|saliva-stimulated group|In approximately 50 randomly selected patients (group 1), from the second day of admission until the end of hospitalization, a 15-minute manual stimulation of the submandibular and sublingual bib was performed internally and externally. In addition, oral hygiene was performed in patients, taking into account the tongue and cheeks.
88867710|NCT05394090|No Intervention|the group in which the saliva was not stimulated|There was no saliva in the group of 50 patients
88867711|NCT05391048|Experimental|IMP4297 first 5*20mg then 10*10mg|Single oral dose of IMP4297 administered under fasting conditions 5*20 mg capsules in first intervention period and 10*10 mg capsules in second intervention period (after washout period: at least 7 days)
88867712|NCT05391048|Experimental|IMP4297 first 10*10mg then 5*20mg|Single oral dose of IMP4297 administered under fasting conditions 10*10 mg capsules in first intervention period and 5*20 mg capsules in second intervention period (after washout period: at least 7 days)
89391705|NCT02098382||Dilapan-S|125 Patients with / without caesarean section in their medical history
88867713|NCT05387538|Experimental|One-layer Duct-to-mucosa Pancreaticojejunostomy|pancreatic anastomosis to jejunum will be performed in one layer suturing the pancreatic duct to the mucosa of jejunum.
89391706|NCT05168527|Experimental|experimental group|This is an opened single-arm phase 2 study， the study drug includes Fruquintinib combine with Paclitaxel Injection and Gemcitabine.
89391707|NCT02095496|Experimental|Intellivent-ASV|Patients will receive Intellivent-ASV ventilation during 12 hours
89391708|NCT02095496|Active Comparator|Conventional ventilation|Patients will receive pressure support ventilation during 12 hours
89391709|NCT01372657||cataract patients|cataract patients
89391710|NCT02098460|Placebo Comparator|Probucol,Cilostazol|Atorvastatin + Probucol-placebo + Cilostazol-placebo
89391711|NCT02098460|Placebo Comparator|Cilostazol|Atorvastatin + Probucol+ Cilostazol-placebo
89391712|NCT02098460|Active Comparator|Probucol, Cilostazol|Atorvastatin + Probucol + Cilostazol
89391713|NCT05166031|Active Comparator|bOPV dose|Naïve infants to receive two doses of bOPV at 2 and 3 months of age.
89391714|NCT05166031|Active Comparator|nOPV2 dose|Naïve infants to receive two doses of nOPV2 at 2 and 3 months of age.
89391715|NCT05166031|Experimental|bOPV + nOPV2 dose|Naïve infants to receive two doses of nOPV2 and bOPV at 2 and 3 months of age.
88867714|NCT05387538|Experimental|Two-layer Duct-to-mucosa Pancreaticojejunostomy|pancreatic anastomosis to jejunum will be performed in two layer. The first layer will be suturing the pancreatic capsule to the seromuscular layer of jejunum and the 2nd layer will be suturing the pancreatic duct to the mucosa of jejunum.
88867715|NCT05017584|Experimental|Hyperbaric bupivacaine 10.5mg|
89391716|NCT02095574|Experimental|[14C]ABT-199|Subjects with relapsed or refractory Non-Hodgkin's Lymphoma
89391717|NCT03555344|Experimental|Mantra Chikitsa|Mantra chanting for 15 mins
89391718|NCT03555344|No Intervention|Wait list control|Rest for 15 Mins
89391719|NCT02095730|Active Comparator|Epi-On Continuous|Continuous beam of UV light treating cornea with surface epithelium present
89391720|NCT02095730|Active Comparator|Epi-Off Continuous|Continuous beam of UV light treating cornea without surface epithelium present
89391721|NCT02095730|Active Comparator|Epi-On Pulsed|Pulsed beam of UV light treating cornea with surface epithelium present
89186662|NCT02588924||Neuromed IRCCS|the present research project is aimed at measuring out the concentrations of copper, iron and manganese in biological fluids (blood, serum) of patients with Parkinson's disease and of subjects of the control group and assess possible correlations between changes in the content of metals and the pathology.
89186663|NCT05325710|Active Comparator|TD2 standard|Standard TD2 follow-up
89391722|NCT02095730|Active Comparator|Epi-Off Pulsed|Pulsed beam of UV light treating cornea without surface epithelium present
89391723|NCT04781283|Experimental|specular microscopy|The density measurement is a painless and very brief examination (less than a minute) during which the patient places his head on a chin rest while maintaining his forehead on a bar provided for this purpose while looking straight ahead. The measurements are then taken without contact with the patient's eye.
89391724|NCT01372189||colorectal cancer|Patients with colorectal carcinoma during conventional endoscopic imaging.
89391725|NCT01372189||colorectal adenoma|Patients with colorectal adenoma during conventional endoscopic imaging.
89391726|NCT05138731||Stable angina (SA)|Typical chronic exersive angina pectoris attacks, lasting several minutes to more than 10 minutes, 3-5 minutes in most cases, generally not more than 30 minutes. The pain disappeared after rest or taking nitrates, and the pain degree, frequency, duration, nature and inducing factors did not change in the last 1-3 months.
89391727|NCT05138731||Unstable angina (UA）|Including resting angina (attack at rest, the duration is usually >20 minutes), primary angina (usually the first symptoms within 1-2 months, very light physical activity can be induced, at least CCSIII level), worsening angina (angina gradually increases on the basis of relatively stable labor angina. More severe pain, longer or more frequent pain, at least grade I increase according to THE CCS classification, at least GRADE II CCSI). TNI was negative, routine electrocardiogram may have transient ST segment depression, T wave low flat or inverted.
89391728|NCT05138731||Acute non-ST-segment elevation myocardial infarction （NSTEMI）|Patients with elevated troponin accompanied by one or more of the following conditions: electrocardiogram showed new ST segment depression or T wave flatness or inversion; Persistent ischemic chest pain; Echocardiography showed abnormal segmental ventricular wall activity. Abnormal coronary angiography.
89391729|NCT05138731||Acute ST-segment elevation myocardial infarction （STEMI）|Troponin was elevated, and ECG showed ST segment arcuate back elevation, accompanied by one or more of the following conditions: persistent ischemic chest pain; Echocardiography showed segmental abnormal ventricular wall activity; Abnormal coronary angiography.
89391730|NCT05138731||normal coronary artery （NCA）|symptoms of chest pain and no stenosis in coronary arteries (such as myocardial bridging, reflux esophagitis, intercostals neuralgia, cervical spondylopathy, and unexplained chest pain)
89391731|NCT05138731||nonobstructive coronary atherosclerosis （NOCA）|stenosis < 50% in coronary arteries
89391732|NCT05138731||healthy volunteers|Healthy control subjects who had no significant systemic diseases (e.g. ischemic heart disease, hypertension,diabetes,cancer, pulmonary disease, or infectious diseases) were recruited from Physical Examination Center of Ningxia Medical University General Hospital
89391733|NCT05406284||double kissing nano culotte stenting|
89391734|NCT01369459|Experimental|Family Counseling with MIP Protocol|We intend for MIP to be a 5-session, family-based protocol delivered during the early portion of ASU treatment. MIP will contain three elements deemed essential for integrating pharmacological interventions into outpatient behavioral treatment for youth: (1) standardized psychiatric assessment and family-focused psychoeducation about the target problem; (2) an approved medication regimen with demonstrated efficacy for comorbid populations; (3) family-based interventions for medication acceptance and coordination of psychiatric and behavioral services. MIP will incorporate research-proven interventions from each of these core areas.
89391735|NCT01369459|No Intervention|Historical Control|
88867716|NCT05017584|Experimental|Hyperbaric bupivacaine 12mg|
88867717|NCT05017584|Experimental|Hyperbaric bupivacaine 13.5mg|
88867718|NCT05017584|Experimental|Hyperbaric bupivacaine 15mg|
88867719|NCT05010096|Experimental|Arm I (elimusertib, copanlisib)|Patients receive Patients receive elimusertib PO BID on days 1-3 and 15-17, and copanlisib IV over 1 hour on days 4 and 18. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who experience disease progression may continue to receive elimusertib PO BID and copanlisib IV at the discretion of the treating physician.
89391736|NCT02102438|Experimental|Trastuzumab and weekly chemotherapy|"Treatment schedule Weekly paclitaxel and Carboplatin at 80mg/m2 and Area under the curve (AUC) of 2, respectively. Weekly trastuzumab will be combined with chemotherapy (at a loading dose of 4mg/kg and a maintenance dose of 2mg/kg). Chemotherapy will be given at D1, D8 and D15 in a 28-day cycle, for a total of 4 treatment cycles.~After completion of four chemotherapy cycles, Trastuzumab will be given at a dose of 6mg/kg every 21 days, for a total 14 cycles."
89391737|NCT01369537||adults > 65 yrs undergoing noncardiac surgery|
88867720|NCT05010096|Experimental|Arm II (elimusertib, copanlisib)|Patients receive elimusertib PO BID on days 1-3 and 15-17, and copanlisib IV over 1 hour on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who experience disease progression may continue to receive elimusertib PO BID and copanlisib IV at the discretion of the treating physician.
89186664|NCT05325710|Experimental|TD2+ study Nurse|Specific study nurse follow-up every 4 months in addition of standard FU.
89391738|NCT04156789||Sarcoidosis group|Subjects with a definite diagnosis of sarcoidosis according to international ATS and WASOG guideline
88867721|NCT04403880||Group 1|"Persons not hospitalized for COVID-19, without clinical spectrum or outcomes specified in group 3~1A: Persons with asymptomatic infection, ages 18 through 55, inclusive~1B: Persons with asymptomatic infection, age > 55~1C: Persons with symptomatic infection (ie, COVID-19) ages 18 through 55~1D: Persons with symptomatic infection (ie, COVID-19), age > 55"
88867722|NCT04403880||Group 2|"Persons previously hospitalized for COVID-19, without clinical spectrum or outcomes specified in group 3~2A: Persons 18 through 55 years of age~2B: Persons > 55 years of age"
88867723|NCT04403880||Group 3|Persons with specific clinical spectrums or outcomes, regardless of hospitalization history (eg, persons recovered after intubation, with prolonged viral shedding, with myocarditis/pericarditis, with rapid recovery from COVID-19, with a second positive SARS-CoV-2 RT-PCR test result after a negative result)
88867724|NCT04147416|Experimental|HSK3486|HSK3486 for Sedation
88867725|NCT04147416|Active Comparator|Propofol|Propofol for Sedation
88867726|NCT04129866|Experimental|M-IBM|M-IBM is based on a slightly modified version of the word sentence association paradigm focused on words and sentences related to common concerns among those with elevated anxiety sensitivity cognitive concerns (i.e., losing control of mental processes).
88867727|NCT04129866|Placebo Comparator|Control IBM|Control-IBM is identical to M-IBM except that the sentence that follows the cue word is not related to an anxious-threat interpretation of the cue word.
88867728|NCT03984318|Experimental|patient treated with immune checkpoint targeted monoclonal AB|Blood (plasma+serum+PBMC) collection before the start of immunotherapy, at week 6 and upon grade ≥2 irAE.
88867729|NCT03899532|Experimental|Remote Ischemic Conditioning|"Remote ischemic conditioning will be performed using a standard manual blood pressure cuff. The pressure in the blood pressure cuff will be maintained at 30 mm of Hg higher than the patient's systolic blood pressure. 4 cycles of ischemic conditioning will be performed each day for a period of 7 days. Each cycle consists of 5 min of controlled upper limb ischemia (cuff up) followed by 5 min of reperfusion (cuff down). The total duration of the treatment cycle will be 40 min. The study protocol is based on our published literature in traumatic brain injury.~Blood samples will be collected at 0 hours (before randomization). Then the first 4 cycles of RIC (done consecutively) will be performed, blood samples will be taken at 6 hours post randomization and then at 24 hours post randomization. RIC cycles will then be performed on a daily basis followed by taking a blood sample once daily during the patients' length of stay up to a maximum of 7 days"
88867730|NCT03899532|Placebo Comparator|No Remote Ischemic Conditioning|Blood samples will be collected at 0 hours (before randomization). Blood samples will then be collected at 6 hours post randomization and 24 hours post randomization. These patients will not receive daily RIC therapy but will only have their blood drawn once daily during the patients' length of stay up to a maximum of 7 days.
88867731|NCT03786042|Active Comparator|E-cigarette ad exposure|Participants in the e-cigarette ad exposure condition will view e-cigarette ads on the computer screen while having their eye movements tracked
88867732|NCT03786042|Sham Comparator|non e-cigarette ad exposure|Participants in the non e-cigarette ad exposure condition will view non e-cigarette ads on the computer screen while having their eye movements tracked
88867733|NCT03767010|Experimental|Control (no PLM)|Control: Pre, post, delayed test Participants will not do the PLM, but will perform a pretest, a posttest and a delayed test at 6 months
88867734|NCT03767010|Experimental|Experimental (PLM)|Experimental: PLM group (pre, post, delayed test, PLM) Participants will do a pretest, the PLM, a posttest and a delayed test at 6 months
88867735|NCT03660072||Empliciti combination therapy|Adult patients with a confirmed diagnosis of MM who have received, are currently receiving, or will begin Empliciti combination therapy
88867736|NCT03178890|Experimental|Osseointegrated Human Machine Gateway (OHMG)|"Patients will be upgraded to the OHMG if already users of the OPRA Implant System, or implanted with the OPRA Implant System plus OHMG. Each patient will work as his/her own control before and after implantation of the OHMG.~A single surgery is required to upgrade OPRA Implant System users to the OHMG, and no additional surgeries are required if the OHMG is implanted at the same time as the OPRA Implant System."
88867737|NCT03125148|Active Comparator|Enteral stenting intraduodenal|Enteral stent (Wallflex enteral stent) will be placed in the duodenum with the entire stent lying within the duodenum bridging the obstruction.
88867738|NCT03125148|Experimental|Enteral stenting transpyloric|Enteral stent (Wallflex enteral stent) will be placed in the duodenum with the stent bridging the obstruction and the pyloric opening with proximal end of the stent lying within the stomach
88867739|NCT03029364||Male and Female Adults|Completion of Study Protocol
88867740|NCT02406222|Active Comparator|Pomalidomide and Dexamethasone|"Pomalidomide and Dexamethasone will be administered as part of a 28 day cycle. Patients will continue with their treatment until disease progression, intolerance, toxicity or withdrawal.~Dosing schedule:~Pomalidomide 4mg orally on days 1-21~Dexamethasone 40mg orally on days 1, 8, 15 and 22"
88867741|NCT02406222|Experimental|Pomalidomide Dexamethasone Cyclophosphamide|"Pomalidomide, Dexamethasone and Cyclophosphamide will be administered as part of a 28 day cycle. Patients will continue with their treatment until disease progression, intolerance, toxicity or withdrawal.~Dosing schedule:~Pomalidomide 4mg orally on days 1-21~Dexamethasone 40mg orally on days 1, 8, 15 and 22~Cyclophosphamide 500mg orally on days 1, 8 and 15"
88867742|NCT02247726|Placebo Comparator|Treatment Group A|Saline Placebo (0.5mL injection)
88867743|NCT02247726|Experimental|Treatment Group B|RSV F vaccine with adjuvant (0.5mL injection)
88867744|NCT00475488|Other|Group 1|Radial Artery versus Right Internal Thoracic Artery when used as a coronary conduit in patients undergoing multi-vessel coronary artery bypass grafting.
88867745|NCT00475488|Other|Group 2|Radial Artery versus Saphenous Vein when used as a coronary conduit in patients undergoing multi-vessel coronary artery bypass grafting.
88867746|NCT01021956|Experimental|WST11 (STAKEL)|Single doses of 2.5 mg/kg of STAKEL® in combination with transpupilar illumination of the macula at escalating doses from 12.5 to 75 Joules/cm².
88867747|NCT01022190|Experimental|Drug: Etoricoxib (Arcoxia, MSD), 90 mg.|Intervention drug: Etoricoxib (Arcoxia, MSD), 90 mg, orally, one time a day, for a 7 day period.
88867748|NCT01024296|Experimental|Gastric Bypass Surgery Patients|Surgical site closure using Port Close device
88867749|NCT01024686|Experimental|p52-p36- GAP Vaccine|"p52-/p56- GAP Vaccine: Administered by five bites from GAP-infected Anopheles mosquito.~p52-/p56- GAP Vaccine: Administered by 200 bites from GAP-infected Anopheles mosquito.~Challenge: Administered by five bites from Anopheles mosquitoes infected with wild type NF54 strain Plasmodium falciparum."
88867750|NCT01024686|No Intervention|Infectivity Control|Active Control: Administered by five bites from Anopheles mosquitoes infected with wild type NF54 strain Plasmodium falciparum
89391739|NCT04156789||Control group|Control subjects have no sarcoidosis and will be sex, age (± 3 years), height (± 20 cm), and weight (± 15 kg) matched to sarcoidosis patients.
89391740|NCT05222061|Active Comparator|provisional-stenting group|Provisional stenting will be performed according to european bifurcation club consensus. MB and SB predilatation will be at the operator's discretion. A stent is delivered in the main vessel and positioned across the bifurcation. POT is mandatotary. In case of dissection impeding the flow in the SB or acute coronary closure after MB atenting a SB stenting using a DES was allowed. Dual-stent techniques will be performed according to the recommendation of the EBC consensus.
89391741|NCT05222061|Experimental|DCB group|"Coronary guidewires should be passed to the MB and SB, respectively. Lesion preparation of the main branch should be undertaken as considered necessary. Lesion preparation of the side branch is mandatorary. If the angiographic result will be good after predilatation (residual stenosis < 30%), drug-eluting stent will implanted in the main branch of the bifurcation site (the stent diameter should be choosen based on the diameter of the distal MB). A kissing with conventional balloons should be performed in the MB and SB. Reapet kissing with drug-coated balloonin the SB and conventional balloon in MB (30 seconds at low pressure (8-10 bar) should be performed. The DCB diameter was again 0.8-1.0 of the vessel diameter.~In case of dissection impeding the flow in the SB or acute coronary closure after DCB application a SB stenting using a DES was allowed. Dual-stent techniques will be performed according to the recommendation of the EBC consensus."
89391742|NCT02098616|Experimental|Arm 1|Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day for 8 weeks
89391743|NCT02098616|Experimental|Arm 2|Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day for 6, 8 or 12 weeks
89391744|NCT02098616|Experimental|Arm 3|Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day for 4 weeks
89391745|NCT02098616|Experimental|Arm A|Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day plus weight based ribavirin orally twice a day for 8 weeks
89391746|NCT02098616|Experimental|Arm B|Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day plus weight based ribavirin orally twice a day for 6, 8 or 12 weeks
89391747|NCT02098616|Experimental|Arm C|Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day plus weight based ribavirin orally twice a day for 4 weeks
89391748|NCT05108077|Experimental|Cytokine-induced killer cells|Patients with the metastatic tumors of the urogenital area receiving standard treatment and autologous cytokine-induced killer cells
89391749|NCT05108077|Active Comparator|Control|Patients with metastatic tumors of the urogenital area receiving standard treatment
89391750|NCT04952805|Experimental|Interventional Arm _400 mg|To all the patients enrolled is admistrated with single dose of MAD0004J08 400 mg.
89391751|NCT04952805|Experimental|Interventional Arm _100 mg|To all the patients enrolled is admistrated with single dose of MAD0004J08 100 mg.
89391752|NCT04952805|Placebo Comparator|Placebo Arm|To all the patients enrolled is admistrated with single dose of placebo
89391753|NCT01372267|Experimental|CBT for pain|
89391754|NCT01372267|Active Comparator|Psychoeducational control group|This group is designed to be an active control which provides detailed information about substance us and chronic pain without providing any CBT or other specific therapy.
89391755|NCT02098694|Experimental|Physiotherapy follow-up|Consultation at Physiotherapy-led Outpatient Clinic every 4 month.
89391756|NCT02098694|No Intervention|Usual care|Consultation every 4 months, twice a year by rheumatologist as usual, once a year by nurse.
89391757|NCT04134013|Experimental|Nutrition and Chiropractic|LBP chiropractic adjustment per protocol and 4 Nutrient offerings (Vitamin Booster, Shake + 2 other offerings)
89391758|NCT04134013|Active Comparator|Chiropractic Adjustment ONLY|LBP chiropractic adjustment per protocol
89391759|NCT02102516|Experimental|SPRIX(intranasal ketorolac tromethamine)|Based on subject weight
89391760|NCT04952467|Experimental|Drug: (14C)-XEN1101|Subjects will receive oral 14C-XEN1101 under fed conditions.
88867751|NCT01024686|Experimental|p52-p36- GAP Vaccine + Infectivity Challenge|"p52-/p36- GAP Vaccine: Five doses separated by 4-weeks, each administered by 200 bites from GAP-infected Anopheles mosquito.~Challenge: Administered by five bites from Anopheles mosquitoes infected with wild type NF54 strain Plasmodium falciparum."
89391761|NCT02106182|Experimental|Silodosin|Silodosin, 8 mg, once daily, orally administered with dinner for 12 weeks
89391762|NCT01369693|Active Comparator|General Portion 1 g pouch|
89391763|NCT01369693|Active Comparator|Catch Licorice Portion 1 g pouch|
89391764|NCT01369693|Active Comparator|Catch Licorice Portion Mini 0.5 g pouch|
89391765|NCT01369693|Active Comparator|Catch Licorice Portion Dry Mini 0.3 g pouch|
89391766|NCT03554642|Experimental|Walkbot Training|This group will receive usual inpatient care that includes at least one 60-minute session of physical therapy and an additional 30-minute session of Walkbot with Augmented Reality 5-days per week during the duration of their stay (14 days).
88867752|NCT01025076|Experimental|StomaphyX Group|"Primary Roux-en-Y gastric bypass with evidence of enlarged gastric pouch volume or enlarged stoma diameter of ≥ 20 mm via endoscopy or fluoroscopy.~Patients also demonstrate a weight regain of 15% of excess body weight loss."
88867753|NCT01026402|Experimental|AZD2014|AZD2014 dose escalation phase in Part A and expansion phase in Part B.
88867754|NCT01027806|Active Comparator|Montelukast|
88867755|NCT01027806|Placebo Comparator|Placebo|
89391767|NCT03554642|Active Comparator|Physical Therapy|This group will receive usual inpatient care including at least one 60-minute session of physical therapy per day, and an additional 30-minute session of standard physical therapy focused on pre-gait and/or gait training activities 5-days per week during the duration of their stay (14 days).
88867756|NCT01029054|Experimental|carfilzomib, lenalidomide w/dexamethasone|"Phase I: carfilzomib will be taken with a combination of lenalidomide plus dexamethasone in a series of escalating dosages to determine the maximum tolerated dose level~Phase II: carfilzomib will be given at the MTD established in the Phase I portion of the study"
88867757|NCT01029912|Experimental|CCNMES|Contralaterally Controlled Neuromuscular Electrical Stimulation (CCNMES) Electrical Stimulator
88867758|NCT01029912|Active Comparator|Cyclic NMES|Cyclic Neuromuscular Electrical Stimulation (NMES) Electrical Stimulator
88867759|NCT01032330|No Intervention|Observation|Patients randomized to the observation group will receive no treatment (other than refractive correction).
88867760|NCT01032330|Active Comparator|Occlusion Therapy|Patients randomized to the occlusion treatment group will receive occlusion (patching) for 3 hours per day for at least 3 months. Choice of which eye to occlude, or whether to alternate daily, is at investigator's discretion.
88867761|NCT01032954|Active Comparator|"125 to 170 IU of 'Botulinum toxin' "|group with intervention of 125 to 170 IU of 'Botulinum toxin'
88867762|NCT01032954|Active Comparator|171 to 210 IU of 'Botulinum toxin'|Patients who have received 171 to 210 IU of 'Botulinum toxin'
88867763|NCT01032954|Active Comparator|211 to 250 IU of Botulinum toxin|Patients who have received 211 to 250 U of Botulinum toxi'
88867764|NCT01033422|Experimental|CF101 1mg|CF101 1mg orally q12 hours
88867765|NCT01033422|Placebo Comparator|Placebo|matching placebo orally q12 hours
88867766|NCT01033422|Experimental|CF101 2mg|CF101 2mg orally q12 hours
88867767|NCT05593848|Experimental|Experimental Group (Intratissue Percutaneous Electrolysis Group)|"The treatment to be performed in the Intratissue percutaneus electrolysis Group will consist of:~Palpation and localization of the myofascial trigger points in the infraspinatus muscle of the affected shoulder.~Application of the ultrasound-guided intratissue percutaneus electroysis technique (1 or 2 approaches) on the myofascial trigger points with the greatest clinical manifestations for the subject. The needle will remain at intramuscular level without movement and a galvanic current discharge will be applied in the area, through the needle, whose intensity will oscillate between 0.5 and 3 milliAmperes (mA).~Performance of an eccentric work protocol of the infraspinatus muscle to reduce post-puncture pain."
88867768|NCT05593848|Active Comparator|Active Control Group (Dry Needling Group)|"The treatment to be performed in the Dry Needling Group will consist of:~palpation and localization of myofascial trigger points in the infraspinatus muscle of the affected shoulder.~Application of the ultrasound-guided dry needling technique (1 or 2 approaches) on the myofascial trigger points with major clinical manifestations for the subject. The physiotherapist will move the needle into the muscle using Hong's rapid entry and exit technique.~Performance of an eccentric work protocol of the infraspinatus muscle to reduce post-puncture pain."
88867769|NCT05593380|Experimental|Bioelectrical impedance analysis(BIA) monitoring|Care based upon intracranial pressure and cerebral edema.
88867770|NCT05593380|Active Comparator|ICP monitoring|Care based upon intracranial pressure.
88867771|NCT05593380|Other|Usual Care|Treatment based on clinical and imaging without intracranial pressure monitoring.
88867772|NCT05593224|Experimental|Intracranial Stent (Tonbridge)|Placement of Intracranial Stent (Zhuhai Tonbridge Medical Tech. Co., Ltd. ).
88867773|NCT05593068||Dialysed patients with suspicion of hepatic iron|Patients on dialysis at Claude Galien Private Hospital who had one or more MRI scans to monitor possible hepatic iron overload between May 2012 and March 2018.
88867774|NCT05592834|Experimental|Positive deviance (PD)|This group will receive only the positive deviance intervention and not the PFT
88867775|NCT05592834|Experimental|Parent facilitator training (PFT)|This group will receive only the parent facilitator training intervention and not the PD
88867776|NCT05592834|Experimental|Parent facilitator and positive deviance(PFT/PD)|This group will receive both the PD and PFT interventions
89391768|NCT03554642|No Intervention|Usual Care Physical Therapy|Participants in this group will receive usual inpatient care including at least one 60-minute session of physical therapy per day.
89535379|NCT03206827|Active Comparator|70% animal, 30% plant proteins in diet|Dietary proteins from animal sources 70% and from plant sources 30%, representing an average Finnish diet consumed at the moment.
88867777|NCT05592834|Active Comparator|Control|This group will receive neither the PD nor the PFT interventions but care as usual.
88867778|NCT05525988|Experimental|Hemi-Hamate Graft for Proximal Pole Scaphoid Reconstruction|[All participants enrolled in this study for proximal pole scaphoid reconstruction using the Hemi-Hamate autograft]
88867779|NCT05517564|Experimental|A (GM-60106)|Drug: GM-60106 Dosage: Part A: 2.5, 5, 10, 20, 40, 60, or 100 mg, Part B: 5, 10, 20 mg, Part C: 10, 20 mg Dosage Form: Bovine-gelatin capsules Route of Administration: Oral
88867780|NCT05517564|Experimental|B (Placebo)|Dosage Form: Bovine-gelatin capsules Route of Administration: Oral Matching placebo has an identical formulation to the GM-60106 drug product, prepared without the active pharmaceutical ingredient
88867781|NCT05489328|Experimental|Candidate-1|Participants to receive a single injection of Candidate-1.
89535380|NCT03206827|Experimental|50% animal, 50% plant proteins in diet|Dietary proteins from animal sources 50% and from plant sources 50%, containing at most 500 g red meat/week (according to the current Finnish Nutrition Recommendations).
88867782|NCT05489328|Experimental|Candidate-2|Participants to receive a single injection of Candidate-2.
88867783|NCT05489328|Experimental|Candidate-3|Participants to receive a single injection of Candidate-3.
89535381|NCT03206827|Experimental|30% animal, 70% plant proteins in diet|Dietary proteins from animal sources 30% and from plant sources 70%.
89391769|NCT04663503|Experimental|Intervention arm -Exercise Program|This structured exercise program will incorporate a specially designed, low intensity, resistance based exercise regime created by our physical therapist. It consists of strengthening, endurance, stretching and relaxation exercises tailored according to age and their ability to perform activities throughout their hospitalization (Appendix 3). This exercise program will be done three times a week for 30-45 mins supervised by the same physiotherapist throughout hospitalization and will be self-administered every weekend. A home exercise program printout with the appropriate resistance exercises will be provided to the family upon discharge, with instructions on how often to complete throughout the week. Discharged children will attend one supervised exercise session per week with the physiotherapist for six weeks. The family and patient will also be provided a weekly sheet to check off the days they completed strengthening and endurance exercises.
89391770|NCT04663503|No Intervention|Control arm- No intervention|The second arm of the study involves patients following standard of care during the HSCT period in the hospital with PT evaluation and management prescribed as needed by their transplant medical team including any additional PT interventions as a result of clinical indications. No additional intervention is incorporated in this group
89391771|NCT02102594|Experimental|Bortezomib (Velcade)|
89391772|NCT03124537|Experimental|App Control Condition|The control group will just have the App with the accelerometer program to set step goals and to count and record steps for 1 month
89391773|NCT03124537|Experimental|App Experimental condition|The experimental condition will set step goals and have the schedule, map, and social components for 1 month.
89391774|NCT04946877||case group|100 ADHD patients; will be taken from outpatient clinic of child and adolescence psychiatry of Assiut university hospitals.
89391775|NCT04946877||control group|100 normal children; they will be selected from neurology clinic complaining from minor neurological complaint e.g : headache, will match with the case group for age, sex and educational level.
89391776|NCT02102672|Placebo Comparator|Sugar pill|Placebo 1 pill bid, 3 months
89391777|NCT02102672|Experimental|Trimetazidine|Trimetazidine 35 mg bid for 3 months
89391778|NCT01369771|Experimental|Tafluprost 0.0015%|Open, one arm study. Patients who have been using latanoprost 0.005% eye drops (Xalatan®) as their prior medication (at least 6 months) and who fulfil all the inclusion criteria including the specified ocular symptoms and signs, will switch from latanoprost to the assigned preservative-free tafluprost 0.0015% (Taflotan®)eye drops for twelve (12) months.
89391779|NCT03554564|Experimental|VOICE/Fitbit|VOICE enrollment with Fitbit walking activity tracking. During the VOICE phase, participants will use the digital health platform that integrates PAD-specific educational content, surveys, and Fitbit walking activity tracking for a total of five weeks (one week run-in phase plus four week study phase).
89391780|NCT03554564|Other|Daily self-reported exercise adherence|Usual care prescribed by physician (walking exercise instructions). During the Usual Care control phase, participants will conduct walking exercise based on instructions received in clinic. Walking exercise will be tracked and self-reported by participants, using a written calendar log. Participants will not have access to the VOICE platform, or use of Fitbit technology during this phase.
89391781|NCT02106260|Experimental|CLS003|
89391782|NCT02106338|Experimental|Cohort A|10 subjects (8 active, 2 placebo) receive a single oral dose of 200 mg CRS3123 or placebo every 12 hours for 10 days
89391783|NCT02106338|Experimental|Cohort B|10 subjects (8 active, 2 placebo) receive a single oral dose of 100 or 400 mg CRS3123 or placebo every 12 hours for 10 days
88867784|NCT05489328|Experimental|Candidate-4|Participants to receive a single injection of Candidate-4.
89391784|NCT02106338|Experimental|Cohort C|10 subjects (8 active, 2 placebo) receive a single oral dose of 600 mg CRS3123 or placebo every 12 hours for 10 days
89391785|NCT04806217|Experimental|¨Patients with multiple sclerosis|"Patients :~With multiple sclerosis~Aged of 18 and over~Recruited during their consultation in the adult outpatient unit or neurological unit or during a hospitalization."
89391786|NCT02101346|Experimental|Healthy, Round 1|For feeding of 5 different fatty acid meals in order to assess the monocyte response ex vivo Mixed high fat diet Low fat diet Saturated fat diet Monounsaturated fat diet Polyunsaturated fat diet
89391787|NCT02101346|Experimental|Healthy, Round 2|"For feeding of 2 different fatty meals, in order to assess the molecular monocyte response and track the fate of fats.~Saturated fat Triolein 13C"
89391788|NCT04728139|Active Comparator|patients with colorecta cancer|
89391789|NCT04728139|No Intervention|healthy individuals|
89391790|NCT05221671|No Intervention|not received information leaflet|"During the preoperative anesthesia clinic examination, demographic data will be recorded and routine information about anesthesia will be provided. However, the information leaflet will not be handed to the patient and parents.~The m-YPAS scale for pediatric patients will be evaluated and filled by the investigators before the anesthesia induction. Parents will be asked to fill out questionnaires for anxiety assessment and anesthesia knowledge level in the waiting room before the procedure."
89391791|NCT05221671|Active Comparator|received information leaflet|"During the preoperative anesthesia evaluation, the children and their parents, who are included in the group who will receive information leaflets according to randomization, will be given information leaflets and both the child and their parents will be asked to read them before the procedure day. Age-appropriate brochures will be provided for children, and parent information leaflets will be provided for parents.~The m-YPAS scale for pediatric patients will be evaluated and filled by the investigators before the anesthesia induction. Parents will be asked to fill out questionnaires for anxiety assessment and anesthesia knowledge level in the waiting room before the procedure."
89391792|NCT02101424||Overdose|
89391793|NCT05221515|Experimental|Intervention condition|Participants received both parent training and child-focussed treatment
89391794|NCT05221515|Active Comparator|Control condition|Participants received only parent training
89391795|NCT02101502|Active Comparator|Institutional Capacity|Questioner for institutional employee about Institutional Capacity
89391796|NCT02101502|Active Comparator|Educational Effectiveness|Questioner for medical and assistant staffs about Educational Effectiveness
89391797|NCT02101502|Active Comparator|Health-care|Questioner for medical, assistant staffs and patients about Quality Assurance System in Health-care
89391798|NCT02101580|Experimental|ADI-PEG 20|
89391799|NCT05648019|Experimental|Single Arm|CD19-directed CAR T-cell therapy for relapsed/refractory B-lineage leukaemia/lymphoma.
89391800|NCT02106416|Experimental|PET/MRI|Patient receives PET/MRI
89391801|NCT01372345|Experimental|Ciprofloxacin|Ciprofloxacin Extended Release Tablets of Dr. Reddy's Laboratories Limited
89391802|NCT01372345|Active Comparator|CIPRO®XR|CIPRO® XR (Bayer Health Care, Bayer Pharmaceuticals Corporation) Tablets
89391803|NCT04249323|Experimental|Part 1: SAD Cohorts A through H CORT113176|Cohorts will receive a single dose of CORT113176 lipid capsule formulation by mouth on Day 1 in a fasted or fed state. Cohort A will receive a 50-mg dose in a fasted state. Cohort B will receive a ≤3-fold increase in dose from Cohort A in a fasted state; the dose will be determined after evaluation of safety and PK data for Cohort A. Subsequent cohorts will receive a ≤3-fold increase in CORT113176 dose from the previous cohort in a fasted or fed state; the dose and prandial state will be determined after evaluation of safety and PK data from previous cohorts. Following interim review of PK data, an alternative lipidic formulation may be administered beginning with Cohort B.
89391804|NCT04249323|Placebo Comparator|Part 1: SAD Cohorts A through H Placebo|Cohorts will receive a single dose of placebo matching CORT113176 lipid capsule formulation by mouth on Day 1. The dose of placebo, prandial state, and choice of formulation will match that used for the corresponding SAD cohorts receiving CORT113176.
88867785|NCT05489328|Experimental|Candidate-5|Participants to receive a single injection of Candidate-5.
89391805|NCT04249323|Experimental|Part 2: MAD Cohorts A through D CORT113176|Cohorts will receive once- or twice-daily doses of CORT113176 lipid capsule formulation by mouth for 14 days. The anticipated exposure will not exceed the highest exposure considered safe and well-tolerated during Part 1. The dose schedule and prandial state will be determined after evaluation of safety and PK data from Part 1. The choice of formulation of CORT113176 to be used in Part 2 will depend on data review for Part 1.
89391806|NCT04249323|Placebo Comparator|Part 2: MAD Cohorts A through D Placebo|Cohorts will receive once- or twice-daily doses of placebo matching CORT113176 lipid capsule formulation by mouth for 14 days. The dose of placebo, prandial state, and choice of formulation will match that used for the corresponding MAD cohorts receiving CORT113176.
89391807|NCT04249323|Experimental|Part 3: Single Dose Pharmacodynamic Effect|In Period 1, participants will receive a single dose of prednisone 25 mg tablet by mouth on Day 1 in a fasted or fed state. After a 7-day washout, in Period 2, participants will receive a single dose of prednisone as in Period 1 plus a single dose of CORT113176 lipid capsule formulation by mouth on Day 1 in a fasted or fed state. The dose of CORT113176 and the prandial state will be determined after evaluation of safety and PK data from Part 1. The choice of formulation of CORT113176 to be used in Part 3 will depend on data review for Part 1. Part 3 will proceed only if sufficiently high plasma CORT113176 exposure is achieved in Part 1.
89391808|NCT02102750|Experimental|tafluprost|
89391809|NCT04227327|Experimental|Abemaciclib + aromatase inhibitors|Abemaciclib will be administered at 150 mg twice daily orally + Letrozole 2,5 mg daily or Anastrozole 1 mg daily
89391810|NCT02102828|Placebo Comparator|Aspirin only|Patients receive aspirin therapy
89391811|NCT02102828|Experimental|extended compression|aspirin and extended compression therapy in combination
89391812|NCT05228119|Experimental|Oncolytic Virus Injection(RT-01)|"RT-01 will be administered either intravenously or with a combination of intravenously and intratumorally on day 1.~Nivolumab will be administered intravenously every 3 weeks starting on day 5."
89391813|NCT02101658||weight data assessors|students recruited to weigh individuals in a research-based clinic
88867786|NCT05489328|Experimental|Candidate-6|Participants to receive a single injection of Candidate-6.
89391814|NCT01372423|Active Comparator|AMITIZA|Manufactured by Sucampo Pharmaceuticals (24 mcg administered for 7 days)
89391815|NCT01372423|Placebo Comparator|Placebo|Manufactured by Anchen Pharmaceuticals (24 mcg administered for 7 days)
89391816|NCT01372423|Experimental|Lubiprostone|Manufactured by Anchen Pharmaceuticals (24 mcg administered for 7 days)
88867787|NCT05489328|Active Comparator|Candidate Control|Participants to receive a single injection of Candidate Control.
89186665|NCT00773747|Experimental|Vorinostat + Bortezomib|Participants will receive vorinostat four 100 mg capsules (400 mg total) orally 0-30 minutes after a meal on Days 1-14 of a 21-day treatment cycle and bortezomib 1.3 mg/m^2 by intravenous injection on Days 1, 4, 8, and 11 of a 21-day treatment cycle.
88867788|NCT05489328|Other|13-valent pneumococcal conjugate vaccine (13vPnC)|Participants to receive a single injection of 13vPnC.
89391817|NCT02102906|Experimental|TMS treatment|Patients will receive a single session of 20 single pulses of TMS to motor cortex contralateral to affected upper limb at 120% motor threshold, with verbal encouragement throughout. Half of the patients recruited will be randomised to a 3 month delay during which they will receive treatment as normal.
88867789|NCT05489328|Other|15-valent pneumococcal conjugate vaccine (PCV15)|Participants to receive a single injection of PCV15.
88867790|NCT05412498|Experimental|Training|Participants in this arm will perform five battle rope training exercises (acute bout per exercise) at two different conditions (30 and 45 seconds).
88867791|NCT05412498|No Intervention|Control|Participants in this arm will receive no intervention.
88867792|NCT05402826|Placebo Comparator|Placebo|Patients will receive placebo pills.
88867793|NCT05402826|Active Comparator|Zinc+vitamin E supplements|Patients will receive zinc tablets plus alpha-tocopherol.
88867794|NCT05376930|Experimental|DWP16001|DWP16001 Tablets
88867795|NCT05246202|Experimental|Anxiety-alcohol personalized feedback intervention (AA-PFI 2.0)|Participants complete the brief (~20-30 minute) AA-PFI 2.0 at baseline.
88867796|NCT05246202|Active Comparator|Control personalized feedback intervention (C-PFI)|Participants complete the brief (~20-30 minute) C-PFI at baseline.
88867797|NCT05244798|Experimental|Group of sintilimab combined with neoadjuvant chemotherapy|sintilimab (D1 administration) was given in combination with chemotherapy (TP regimen: albumin-paclitaxel + carboplatin, D1 administration) for 2 cycles. Every 3 weeks, there was a dosing cycle (Q3W). Surgery was performed 6-8 weeks after completion of neoadjuvant therapy. If the patients without vital tumor cells in primary and lymph nodes after surgery, they only need regular follow-up visit. If the patients with non-pCR resected, those patients need to receive adjuvant immunotherapy. And if the patients with non-R0 resected, the regimen of those patients need to carefully decide based on multidisciplinary team discussed.
88867798|NCT05244798|Experimental|Group of sintilimab combined with neoadjuvant chemoradiotherapy|sintilimab (D1) was administered in combination with concurrent chemoradiotherapy. Chemotherapy regimen: TP regimen: albumin-paclitaxel + carboplatin, D1 administration, 2 cycles. Every 3 weeks, there was a dosing cycle (Q3W). Radiotherapy regimen: according to IMRT treatment plan, the total dose was 41.4Gy, divided into 23 times, 5 days a week. Surgery was performed 6-8 weeks after completion of neoadjuvant therapy. If the patients without vital tumor cells in primary and lymph nodes after surgery, they only need regular follow-up visit. If the patients with non-pCR resected, those patients need to receive adjuvant immunotherapy. And if the patients with non-R0 resected, the regimen of those patients need to carefully decide based on multidisciplinary team discussed.
89391818|NCT02102984|Active Comparator|covered stents|endoscopic placement of covered biliary stents
89391819|NCT02102984|Active Comparator|uncovered biliary stents|endoscopic placement of uncovered biliary stents
89391820|NCT02101814|Other|Bariatric surgery|Roux-en-Y gastric bypass procedure is being performed by surgery in all patients in this study.
89391821|NCT01375933|Active Comparator|NicVAX - Phase 3 Lot|NicVAX - Phase 3 Lot
89391822|NCT01375933|Active Comparator|NicVAX - Commercial Lot|NicVAX - Commercial Lot
89391823|NCT02106650|Experimental|Folotyn and Leucovorin|"Folotyn will be administered by IV push at a dose of 30 mg/m2 once weekly for 6 weeks in each cycle, followed by 1 week of rest (no treatment).~Leucovorin (25 mg tablets) will be taken orally tid for 2 days for a total of six doses (150 mg cumulative weekly dose), beginning 24 hours after each dose of Folotyn is administered.~Folic acid and Vitamin B12 is given prior to initiation of Folotyn."
89391824|NCT01376011|Experimental|healthy young|
89391825|NCT01376011|Experimental|healthy old|
89391826|NCT02106806|Experimental|Zinc chemotherapy|Patients in colorectal chemotherapy supplemented with zinc
89391827|NCT02106806|Placebo Comparator|Placebo chemotherapy|Patients in colorectal chemotherapy with placebo
88867799|NCT05244798|Other|Group of neoadjuvant chemoradiotherapy|The control group received neoadjuvant chemoradiotherapy and the regimen was as follows:Chemotherapy regimen: TP regimen: albumin paclitaxel + carboplatin, D1 administration, 2 cycles. Every 3 weeks, there was a dosing cycle (Q3W). Radiotherapy regimen: according to IMRT treatment plan, the total dose was 41.4Gy, divided into 23 times, 5 days a week. Surgery was performed 6-8 weeks after completion of neoadjuvant therapy. If the patients without vital tumor cells in primary and lymph nodes after surgery, they only need regular follow-up visit. If the patients with non-pCR resected, those patients need to receive adjuvant immunotherapy. And if the patients with non-R0 resected, the regimen of those patients need to carefully decide based on multidisciplinary team discussed.
88867800|NCT05193708|Active Comparator|Digital Indirect bonding|An indirect bonding tray will be fabricated from a 3D printed model
88867801|NCT05193708|Experimental|Windowed Bonding technique|3D printed guide with windows for positioning the bracket
89391828|NCT02106806|Other|Zinc Control|Healthy volunteers supplemented with zinc
89391829|NCT02106806|Other|Placebo Control|Volunteers received placebo
89391830|NCT02966119|Experimental|Start antiplatelet drug(s)|If the patient is randomized in this arm, an antiplatelet agent (aspirin or clopidogrel or dypyridamole), chosen by the patient's physician before the randomisation, will be prescribed to the patient during the study period
89391831|NCT02966119|No Intervention|Avoid antiplatelet drug(s)|If the patient is randomized in this arm, antiplatelet drugs will not be prescribed to the patient during the entire study period
89535382|NCT03091101|Experimental|Scleral lens wearing keratoconics|Newly diagnosed keratoconics with no previous rigid lens wear fitted with Sceral contact lenses
89391832|NCT05707299|Experimental|Observation group|This group will include 20 patients with MDD. Before signal collection, the subject will wear a helmet embedded with numerous near-infrared light sensors, covering the prefrontal region and both temporal lobes. The whole process will be monitored in real time by fNIRS. During needle retention, participants will be asked to keep their eyes closed and quiet throughout the intervention and to avoid physical movement as much as possible.
89391833|NCT05707299|Other|Control group|This group will include 20 healthy control participants without MDD. Before signal collection, the subject will wear a helmet embedded with numerous near-infrared light sensors, covering the prefrontal region and both temporal lobes. The whole process will be monitored in real time by fNIRS. During needle retention, participants will be asked to keep their eyes closed and quiet throughout the intervention and to avoid physical movement as much as possible.
89391834|NCT02103296|Active Comparator|Infant Blood|Control group. Admission labs to be drawn directly from the infant.
89391835|NCT02103296|Experimental|Cord Blood|Admission labs to be drawn from the infant's cord blood
89391836|NCT02956759|Experimental|Early Intervention|pan-retinal photocoagulation laser treatment applied to the study eye within 2-4 weeks.
89391837|NCT02956759|Active Comparator|Standard Care|pan-retinal photocoagulation laser treatment deferred until the onset of any PDR.
89391838|NCT02101892|Active Comparator|Amitriptyline|Amitriptyline, 25 mg per os, daily, evening, for 8 weeks; starting dose is 12.5 mg for 2 days
89391839|NCT02101892|Placebo Comparator|placebo|sugar pills
89391840|NCT03634111|Active Comparator|T group|The TAP block group was called T group. The participants were performed TAP block under guidance at the end of surgery.
89391841|NCT03634111|Placebo Comparator|C group|The controlled group was called C group. The participants has not TAP block and were treated postoperative analgesia with intravenous morphine to patients controlled analgesia
89391842|NCT02102048|Active Comparator|Atazanavir|patients that switch cART to boosted or unboosted ATV
89391843|NCT02102048|No Intervention|other Protease Inibithors|patients that continue the previous cART without changes.
89391844|NCT02102126|Experimental|Renal denervation|Subjects are treated with the renal denervation procedure after randomization and are maintained on baseline anti-hypertensive medications
89391845|NCT02102126|No Intervention|Control group|Subjects are maintained on baseline anti-hypertensive medications.
89391846|NCT03118297|Experimental|Ulipristal Acetate|15mg ulipristal acetate (capsule) daily for 7 days
89391847|NCT03118297|Placebo Comparator|Placebo|Identical placebo (capsule) daily for 7 days
88867802|NCT05179668|Experimental|Intervention arm|Hemodialysis patients receiving dapagliflozin 10 mg once daily
88867803|NCT05179668|Placebo Comparator|Placebo|Hemodialysis patients receiving placebo oral tablet once daily
89391848|NCT02250794|Active Comparator|insulin glargine and insulin lispro|insulin glargine 0.3 units per kg and insulin lispro 0.1 units per kg with each meal
89391849|NCT02250794|Experimental|metformin and sitagliptin|metformin 750 mg PO twice daily and sitagliptin 100 mg PO once daily
88867804|NCT05088564|Experimental|I (Hand-sewn group)|Doudenojejunal anastomosis by hand-swen method
88867805|NCT05088564|Active Comparator|II (Stapling group)|Doudenojejunal anastomosis by hemi-double-stapling method
88867806|NCT05048628|Active Comparator|İce Pieces İmpregnated Group|Impregnation of pieces of ice was delivered to us; one ice cube is planned after wearing and movements automatically by the throat purchase to exit use and sound program, and move with one ice cube after movement. It can be used after extubation. It is in sound class with Visual Analogue Scale (VAS) for the use of customers before and after the application. Extubation is in the last 0. hours, no small application is made, only in sound class with VAS. Evaluated by Stout's Hoarseness Scale
88867807|NCT05048628|Active Comparator|Green Tea Gargle Solution Group|To the patients included in the gargle group with green tea; four after, six after eigth after hours after extubation, the patients of the intervention group were asked to gargle 30 cc of green tea and before the application and after the patient's oral intake was requested by the physician to prevent sore throat and hoarseness afterwards, patients' sore throat is measured with Visual Analogue Scale (VAS) and hoarseness is measured with Stout's Hoarseness Scale. At the 0. th hour after extubation, no treatment is applied to the patients, only sore throat is evaluated with VAS and hoarseness is evaluated with Stout's Hoarseness Scale.0
89391850|NCT02103374|Experimental|Atrovent + Bricanyl or Atrovent + Ventolin|3 daily inhalations of Atrovent mixture to form Bricanyl or Ventolin form Atrovent 0,5mg/1ml Bricanyl 5mg/2ml Ventolin 5mg/2,5ml
89391851|NCT02103374|Placebo Comparator|Placebo|1 capsule per day lactose (in addition to the standard optimized treatment)
89186666|NCT00773747|Placebo Comparator|Placebo + Bortezomib|Participants will receive four placebo capsules orally 0-30 minutes after a meal on Days 1-14 of a 21-day treatment cycle and bortezomib 1.3 mg/m^2 by intravenous injection on Days 1, 4, 8, and 11 of a 21-day treatment cycle.
89186667|NCT04104269||Mechanical Complications|Include free wall ventricular rupture and ventricular septal rupture
89391852|NCT01374061|Active Comparator|1: Classical intubation|
89391853|NCT01374061|Experimental|2: Glidescope intubation|
89391854|NCT05658783|Experimental|Intervention Group|Participants in this study group will be asked to keep their feet in 42oC (42 Degrees Celsius) hot water for 20 minutes on the night of the day of surgery.
89391855|NCT05658783|No Intervention|Control Group|Participants in this study group will take the standard service clinical procedure and hot water foot bath will not be applied.
89391856|NCT02103452|Experimental|ovarian endometrioma|Ovarian and endometrial samples
89391857|NCT02103452|Experimental|normal ovary|Ovarian and endometrial samples
89391858|NCT03967587|Experimental|Neosense Umbilical Catheter|
89391859|NCT02250950|Experimental|MI and SDT Exercise Group|Intervention Condition: Participated in 12 weekly meetings led by MI- and SDT-trained exercise instructor.
89391860|NCT02250950|Sham Comparator|Non-MI and SDT Exercise Group|Control Condition: Participated in 12 weekly meetings led by an exercise instructor who was not trained in MI and SDT.
89391861|NCT05707221|Active Comparator|mechanical cleaning method by denture brush and Chlorhexidine toothpaste|patients will be instructed to brush both sides of the removable appliance once a day for 1 minute before bedtime using the toothbrush and the CHX toothpaste provided and water
89391862|NCT05707221|Active Comparator|chemical cleaning method with cleaning tablet|patients will be instructed to immerse the appliance in 150 ml cup with tap water and dissolve one cleansing tablet for 20 minutes according to the manufacture instructions.
89391863|NCT05707221|Active Comparator|combination of mechanical and chemical cleaning|first submitted to the mechanical method, followed by the chemical method.
89391864|NCT02103530|Experimental|FLT PET/CT|Patients who had FLT PET/CT
89391865|NCT05220969||Elite male youth footballers|Elite male youth footballers at an English championship / premier league football club
89391866|NCT02251028|Active Comparator|Group A|Group A receives value-based cognitive behavior therapy after randomization.
89391867|NCT02251028|Active Comparator|Group B|Group B receives value-based cognitive behavior therapy after 3 months.
89391868|NCT03117361|Experimental|Experimental|"Plitidepsin + bortezomib + dexamethasone~Plitidepsin will be administered as a 3-hour intravenous (i.v.) infusion on Day(D) 1 and 15 , every four weeks (q4wk)~Bortezomib will be administered as a bolus subcutaneous (s.c.) injection on D 1, 4, 8 and 11,q4wk~Dexamethasone will be taken orally on D1,8,15 and 22, q4wk"
89391869|NCT02102282||Subject study|Patients with breast cancer during pregnancy
89391870|NCT01368614|Experimental|AVAPS-AE|AVAPS-AE Mode of ventilation
89391871|NCT01368614|Active Comparator|Respironics OmniLab Advanced BiPAP S mode|OmniLab Advanced BiPAP S Mode of ventilation
89391872|NCT01368614|Active Comparator|Respironics OmniLab Advanced CPAP mode|OmniLab Advanced CPAP Mode of ventilation
89535383|NCT03226483|Experimental|Intraoperative radiotherapy|"After neurosurgical resection and proven metastasis (frozen section) a local intraoperative radiotherapy with soft energy x-rays is applied to the resection cavity.~To perform this an applicator is inserted into the situs in the tightest fit rule. The highest possible dose between 30-20 Gy is chosen depending on nearby risk structures (Optic nerve, brainstem) is prescribed. After radiotherapy the applicator is removed and the surgery will be finished in standard way."
89186668|NCT04104269||Non-Mechanical Complications|Mechanical complications were not included in patients with AMI
89391873|NCT05220891||Crystalloid group|"Group( 1)Patients will be randomly assigned to be treated with crystalloid (n=30). They will receive an intravenous infusion of saline at a constant rate utilizing a pump infusion device (170 mL of 3.5% saline solution per liter of ascites removed at 999 mL/h). The amount of liquid infused and rate of infusion was selected based on previous studies (Sola-vera et al.,2003) Group (2)Patients will be randomly assigned to be treated with colloid (n=30). Albumin will be given at a dose of 8 g/L of ascitic fluid removed and will be infused immediately during the process of paracentesis.~After paracentesis, diuretics and plasma expanders will be withheld until hospital discharge."
89391874|NCT05220891||Colloid group|"Group (2)Patients will be randomly assigned to be treated with colloid (n=30). Albumin will be given at a dose of 8 g/L of ascitic fluid removed and will be infused immediately during the process of paracentesis.~After paracentesis, diuretics and plasma expanders will be withheld until hospital discharge."
89391875|NCT05219305|Experimental|Freeze-Dried Bone Allograft|edentulous site grafted with FDBA in previous study.
89391876|NCT05219305|Experimental|Partially-demineralized tooth graft|edentulous site grafted with partially-demineralized tooth graft in the previous study.
89391877|NCT05219305|Experimental|mineralized tooth graft|edentulous site grafted with mineralized tooth graft in the previous study.
89186669|NCT04104191|Experimental|L-1000AF System|Software device on a wearable device used to detect irregular heart rhythms suggestive of Atrial Fibrillation
89186670|NCT00784277|Experimental|001|Tapentadol IR (CG5503) 50mg for 14 days
89186671|NCT00784277|Experimental|002|Tapentadol IR (CG5503) 75mg for 14 days
89186672|NCT00784277|Active Comparator|003|oxycodone IR 10mg for 14 days
89186673|NCT00784277|Placebo Comparator|004|placebo 1 capsule for 14 days
89391878|NCT05707065|Experimental|core strengthening exercises|"Participants will be positioned in supine.~first stage participants will be taught to activate abdominal wall musculature. They will be initially trained to perform abdominal bracing.~Then positioned in quadruped position and asked to lift alternate arms, gradually progressing to alternate leg lifts and alternate arm/leg raises to activate multifidus.~Then side bridges (side plank) exercise for activation of quadratus lumborum and obliques.~Then asked to perform trunk curls in crook lying, asking them to lift their upper trunk slightly (15°) from the plinth, hold the position for 5 sec.~Perform 30 repetitions of each exercise with 8-sec hold.~Maintain normal diaphragmatic breathing throughout the intervention"
89530466|NCT03244579|Experimental|Dietary intervention CHO counting|Carbohydrate counting diet will be prepared according to Kulkarni, (2005). Tailored diet plans according to patient's food preference, physical activity level and appropriate insulin: Carbohydrates ratio will be prescribed for each participants. Diets were based on each participants's recommended intakes of energy, protein (15-25%), fat (30-40%) and carbohydrate (40-50%) (Thomas and Gutierrez, 2005; Kleinwechter et al., 2014). Energy requirement will be determined in the participants' pre-pregnancy weight with adding the extra requirement (450 kcal) due to pregnancy. The carbohydrate counts will be distributed into three main meals and 3 snacks.
89186674|NCT00784277|Experimental|005|Tapentadol ER (CG5503) flexible dose tablets and capsules 2 x a day for 28 days (100-500mg/day)
89186675|NCT00784277|Active Comparator|006|oxycodone CR flexible dose tablets and capsules 2 x a day for 28 days (20-60mg/day)
89186676|NCT00784277|Placebo Comparator|007|placebo Tablets and capsules 2 x a day for 28 days
89186677|NCT05116748||LuTx recipients|Lung Transplant recipients
89186678|NCT05116748||OLT recipients|Orthotopic Liver Transplant recipients
89186679|NCT04104035||BCR-ABL-positive hematopoiesis|Patients with BCR-ABL-positive hematopoiesis (newly diagnosed CML patients, CML patients with leukocytosis, CML patients without a hematological and/or cytogenetic and/or molecular response, CML patients whose BCR-ABL status becomes negative and then positive) will be included.
89186680|NCT04104035||BCR-ABL activity inhibition under TKI|Patients with CML with BCR-ABL activity inhibition under TKI therapy (patients with MMR and/or deeper response) will be included.
89186681|NCT05254964|Experimental|Intensive cognitive rehabilitation group|Participants receive intensive cognitive rehabilitation for 20 hours for 4 weeks.
88867808|NCT05048628|Active Comparator|Arnica Montana Tea Gargle Solution Group|To the patients included in the gargle group with arnica montana tea; four after, six after eigth after hours after extubation, the patients of the intervention group were asked to gargle 30 cc of arnica montana tea and before the application and after the patient's oral intake was requested by the physician to prevent sore throat and hoarseness afterwards, patients' sore throat is measured with Visual Analogue Scale (VAS) and hoarseness is measured with Stout's Hoarseness Scale. At the 0th hour after extubation, no treatment is applied to the patients, only sore throat is evaluated with VAS and hoarseness is evaluated with Stout's Hoarseness Scale.
88867809|NCT05048628|No Intervention|Control Group|Patients in the control group; sore throat and hoarseness scores at 0 hour immediately after extubation,to collect at 4, 6 and 8 hours after extubation, sore throat (Visual Analogue Scale) VAS; Stout s Voice if hoarseness It is evaluated with the Slightness Scale.
88867810|NCT04910724|Experimental|20% Energy Deficit|Energy Deficit equal to 20% total daily energy requirements.
88867811|NCT04910724|Experimental|40% Energy Deficit|Energy Deficit equal to 40% total daily energy requirements.
88867812|NCT04910724|Experimental|60% Energy Deficit|Energy Deficit equal to 60% total daily energy requirements.
88867813|NCT04896762||Extrapulmonary presentation for COVID-19|patients with confirmed covid 19 disease who primarily presented with extrapulmonary system affection
88867814|NCT04896762||pulmonary presentation for COVID-19|patients with confirmed covid 19 disease who primarily presented with pulmonary disease
88867815|NCT04799418|Experimental|Experimental Treatment 1|Study participants will self-administer ~19-minute treatments twice daily in the home setting using a non-invasive brainstem modulation device. The device has been deemed as a nonsignificant risk for studies in Parkinson's disease by the United States Food and Drug Administration.
88867816|NCT04627038|Experimental|LY3556050 600 mg|Participants received 600 mg LY3556050 twice daily (BID) every 12 hours for up to 8 weeks.
88867817|NCT04627038|Placebo Comparator|Placebo|Participants received placebo BID every 12 hours for up to 8 weeks.
88867818|NCT04460430|Experimental|Neratinib + endocrine therapy|Neratinib plus Fulvestrant, Exemestane or Tamoxifen
88867819|NCT04316910||Postoperative delirium|The CAM-ICU (Confusion Assessment Method for Intensive Care Unit) was used for delirium assessment.
88867820|NCT04316910||Non-Postoperative delirium|The CAM-ICU (Confusion Assessment Method for Intensive Care Unit) was used for delirium assessment.
88867821|NCT04241796|Experimental|Elevated Risk and Non-Elevated Risk Groups|"Two cohorts:~Elevated risk group (approximately 70% of the total enrollment) on the basis of history of smoking, documented genetic cancer predisposition, or personal history of invasive or hematologic malignancy.~Non-elevated risk group (approximately 30% of the total enrollment) with none of the conditions listed in the Elevated Risk Group."
88867822|NCT04104594|Experimental|patients with chronic rhinosinusitis with nasal polyps|
88867823|NCT04104594|Other|Patients with an indication for septoplasty = control group|
88867824|NCT03952416|No Intervention|Standard of Care (SOC)|The control group for this study will receive rehabilitation therapy that is recommended and provided by the current healthcare structure. The SOC group will receive therapy only from four therapists who are not trained and supervised in EMR. These therapists will be monitored (videotaped or observed) but will not be not asked to do anything differently with their patients. The investigators recognize that spillover of therapist EMR training to untrained therapists is a concern. Thus, the investigators will ask therapists in the EMR group to agree not to share any of the training with non-trained therapists over the course of the study, and the investigators will provide free EMR training to the non-trained therapists once the treatment phase of the study is complete.
88867825|NCT03952416|Experimental|Enhanced Medical Rehabilitation (EMR)|Patients in the EMR group will also receive the recommended rehabilitation therapy, but they will receive therapy only from four therapists who are trained and supervised in EMR. The therapy sessions will follow EMR protocol. EMR is a set of behavioral skills that therapists can incorporate into their daily therapy sessions to increase patient engagement and achieve a high intensity of therapy, thereby improving functional and psychosocial outcomes of patients in medical rehabilitation.
88867826|NCT03446664|Experimental|Microburst Stimulation|Microburst stimulation to tolerability and effectiveness
88867827|NCT03149562||plasma transfusions|The critical ill neonates with plasma transfusions
88867828|NCT03149562||non-plasma transfusions|The critical ill neonates without plasma transfusions
88867829|NCT01842672|Experimental|Mitoxantrone/Clofarabine|Clofarabine Dose escalation starting 20 mg/m2/d days 1-5 Mitoxantrone 12 mg/m2/d days 3-6. Rituximab in patient with CD20+ disease only 375 mg/m2 day 1, 8, 15. IT Depocyt 35 or 50 mg/dose day 1 per cycle. IT ARA-C in children < 3 years age based dosing.
88867830|NCT01531374|Experimental|Extreme Risk: TAVI Iliofemoral|Extreme Risk Patients: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI); Iliofemoral Access
88867831|NCT01531374|Experimental|Extreme Risk: TAVI Non-Iliofemoral|Extreme Risk Patients: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI); Non-Iliofemoral Access
88867832|NCT01531374|Experimental|High Risk: TAVI|High Risk Surgical Patients: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)
88867833|NCT01240902|Experimental|Extreme Risk: TAVI Iliofemoral|Extreme Risk Patients: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI); Iliofemoral Access
88867834|NCT01240902|Experimental|Extreme Risk: TAVI Non-Iliofemoral|Extreme Risk Patients: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI); Non-Iliofemoral Access
88867835|NCT01240902|Experimental|High Risk: TAVI|High Risk Surgical Patients: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)
88867836|NCT01240902|Active Comparator|High Risk: SAVR|High Risk Surgical Patients: Surgical Aortic Valve Replacement (SAVR)
88867837|NCT01034592|Experimental|Lenalidomide|Subjects will initially receive lenalidomide 2.5 mg, and may escalate up to 2.5 mg/wk up to 5 mg 3x/wk, depending toxicity and response.
88867838|NCT01037790|Experimental|Arm 1 - Metastatic breast cancer|"Metastatic breast cancer~PD-0332991 Given orally, 125 mg QD on a 21-day"
88867839|NCT01037790|Experimental|Arm 2 - Metastatic colorectal cancer that harbors the Kras or BRAF mutation|"Metastatic colorectal cancer that harbors the Kras or BRAF mutation~PD-0332991 Given orally, 125 mg QD on a 21-day"
89535384|NCT03079947||Non-hodgkin Lymphoma|300 Non-hodgkin Lymphoma patients (age >=18y) without previous treatment would be administered, including DLBCLs and PTCLs.
89391879|NCT05707065|Experimental|Proprioceptive Neuromuscular Facilitation|"Rhythmic initiation (RI) Patients progressively performed voluntary relaxation, passive movements, active assisted, active resisted movements and than active movements.~Dynamic reversals (slow reversals) Isotonic contractions of first agonists and then antagonists performed against resistance was performed initially.~Stabilizing reversals Isotonic contractions of first agonists, then antagonists against resistance was performed in an alternate way.~Mixture of isotonic (agonist reversals, AR) resisted concentric, contraction of agonist muscles moving with the range was performed progressively following eccentric, lengthening contraction, moving slowing to the start position. .~Total 30 min for 3 days a week for a total duration of 4 weeks was set as a optimal time frame duration. Each technique was given for 10 min."
89391880|NCT01372891||Patients underging PCI|
89391881|NCT02102360|Experimental|Minimally invasive surgical technique (MIST)|A minimally invasive surgical technique was performed to access mandibular furcation defects in the test group, aiming to perform minimal flap reflection, minimal wound, and gentle handling of the soft and hard tissue in periodontal surgery. The use of a microsurgical approach provides magnification and optimal illumination of the surgical site improving visual acuity. Further advantages may be the reduction of flap reflection during surgery, consequently advantages in wound healing process and benefits in patient's perceptions of the procedure. A less invasive surgical procedure may lead to a less cell demand in the healing process, and a potentially reduced morbidity. The minimally invasive surgical procedures were performed using microscope.
89391882|NCT02102360|Experimental|Conventional surgical technique (CST)|A conventional surgical technique was performed to access mandibular furcation defects in the control group.
89186682|NCT05071274|Experimental|SkinPen Precision System|"After a 15-minute acclimation to ambient temperature and humidity conditions, subjects will participate in bio instrumentation to assess for erythema and will participate in standard photography.~The Investigator will treat each subject's face from hairline to jawline with the SkinPen Precision System following instructions in the SKINPEN PRECISION SYSTEM INSTRUCTIONS with the following treatment of the face at depths of up to 1.5mm. Treatment depth will be recorded for each subject at every visit. Subjects will be dispensed a study provided diary and trained on compliance."
89186683|NCT02588534|Active Comparator|Treatment A-etanercept (ENBREL®) via auto-injector device|Single dose of etanercept (ENBREL®) in a pre-filled syringe administered with an auto-injector device manufactured by Scandinavian Health Limited (SHL)
89391883|NCT03555110|Active Comparator|Controlled Group|30 morbid obese patients, 30 to 55 years old, submitted to Personality Factor Battery Test (PFB Test) during the study with the same frequency and criteria of the group of EMDR .
89391884|NCT03555110|Active Comparator|EMDR Group|"30 morbid obese patients, 30 to 55 years old, submitted to Eye Movement Desensitization and Reprocessing Therapy (EMDR) during the study with the frequency of Twelve sessions, including:~Three evaluation and preparation sessions,~Eight EMDR sessions weekly with variable length of 60 minutes and~One closing session. The total intervention time will be about 3 (three) months. After the end of the 12 sessions of EMDR therapy, the patient will be evaluated again individually to verify the existence of change in PFB test results about the 5 big factors. The instrument will also be reapplied three months, twelve months and thirty-six months after bariatric surgery."
89391885|NCT02110004|Other|Ablation procedure|Collect intra-cardiac signals
88867840|NCT01037790|Experimental|Arm 3 - Advanced or metastatic esophageal and/or gastric cancer|"Advanced or metastatic esophageal and/or gastric cancer~PD-0332991 Given orally, 125 mg QD on a 21-day"
89391886|NCT05082337|Experimental|Guidewire|The SAVVY guidewire will be used in all TAVR procedures of patients included in the study
89391887|NCT03053427|Placebo Comparator|Placebo|Placebo was administered orally once daily after the evening meal.
89391888|NCT03053427|Experimental|Gabapentin enacarbil|Gabapentin enacarbil was administered orally once daily after the evening meal. Participants with an estimated creatinine clearance of ≥ 60 mL/min to < 90 mL/min at the start of the run-in period were administrated gabapentin enacarbil 300 mg for 1 week followed by gabapentin enacarbil 600 mg for 11 weeks.
89391889|NCT02107118|Active Comparator|ARM 1: AdMSC: adipose stem cells|AdMSC: Autologous adipose tissue-derived mesenchymal stem cell. Adipose tissue will be harvested from all patients as previously described and stem cells will be cultured.
89391890|NCT02107118|Placebo Comparator|ARM 2 Placebo|Adipose tissue will be harvested from all patients as previously described and stem cells will be cultured. For those subjects in the placebo arm, the stem cells will be frozen for later use after one year when the patients cross over into the treatment arm.
89391891|NCT05081089|Active Comparator|Artemether-lumefantrine (AL)|Subjects will receive artemether-lumefantrine (AL) twice daily for 3 days.
89391892|NCT05081089|Experimental|AL with 0.25mg/kg primaquine (PQ)|Subjects will receive artemether-lumefantrine (AL) twice daily for 3 days and a single dose of 0.25mg/kg primaquine (PQ) on the first day of AL treatment.
89391893|NCT05081089|Active Comparator|Sulphadoxine-pyrimethamine with amodiaquine (SPAQ)|Subjects will receive sulphadoxine-pyrimethamine with amodiaquine (SPAQ) once daily for 3 days.
89391894|NCT05081089|Experimental|SPAQ with 1.66mg/kg tafenoquine (TQ)|Subjects will receive sulphadoxine-pyrimethamine with amodiaquine (SPAQ) once daily for 3 days and a single dose of 1.66mg/kg tafenoquine (TQ) on the first day of SPAQ treatment.
89391895|NCT03555032|Experimental|All patients|All patients will receive two pre-operative doses of T-VEC administered by intratumoural injection prior to a 3rd intratumoural dose given at the time of Isolated Limb Perfusion (ILP). No further treatment will be given.
89391896|NCT03554408|Experimental|Group 1A|HIV-uninfected individuals will be administered one 1 mL (approximately 150 mg) subcutaneous injection of 10-1074-LS or placebo (formulation buffer), in a 3:1 ratio.
89391897|NCT03554408|Experimental|Group 1B|HIV-uninfected individuals will be administered one 2 mL (approximately 300 mg) subcutaneous injection of 10-1074-LS or placebo (formulation buffer), in a 3:1 ratio.
89391898|NCT03554408|Experimental|Group 2A|HIV-uninfected individuals will be administered one intravenous infusion of 10-1074-LS dosed at 3 mg/kg.
89391899|NCT03554408|Experimental|Group 2B|HIV-uninfected individuals will be administered one intravenous infusion of 10-1074-LS dosed at 10 mg/kg.
89391900|NCT03554408|Experimental|Group 2C|HIV-uninfected individuals will be administered one intravenous infusion of 10-1074-LS dosed at 30 mg/kg.
89391901|NCT03554408|Experimental|Group 3B|HIV-infected individuals (on ART) will be administered one intravenous infusion of 10-1074-LS dosed at 10 mg/kg
89391902|NCT03554408|Experimental|Group 3C|HIV-infected individuals (on ART) will be administered one intravenous infusion of 10-1074-LS dosed at 30 mg/kg.
89391903|NCT03554408|Experimental|Group 4A|HIV-uninfected individuals will be administered one 2 mL (approximately 150 mg of each mAb) subcutaneous injection of 10-1074-LS admixed with 3BNC117-LS or placebo (formulation buffer), in a 3:1 ratio.
88867841|NCT01037790|Experimental|Arm 4 - Cisplatin-refractory, unresectable germ cell tumors|"Cisplatin-refractory, unresectable germ cell tumors~PD-0332991 Given orally, 125 mg QD on a 21-day"
89391904|NCT03554408|Experimental|Group 4B|HIV-uninfected individuals will be administered two 2 mL (approximately 300 mg of each mAb) subcutaneous injections of 10-1074-LS admixed with 3BNC117-LS or placebo (formulation buffer), in a 3:1 ratio.
89391905|NCT03554408|Experimental|Group 5|HIV-uninfected individuals will be administered one intravenous infusion of 10-1074-LS and one intravenous infusion of 3BNC117-LS, each dosed at 30 mg/kg.
89391906|NCT03554408|Experimental|Group 6|HIV-infected individuals (on ART) will be administered one intravenous infusion of 10-1074-LS and one intravenous infusion of 3BNC117-LS, each dosed at 30 mg/kg.
89391907|NCT03554408|Experimental|Group 7|HIV-uninfected individuals will be administered three subcutaneous injections of 10-1074-LS (100 mg) admixed with 3BNC117-LS (200 mg) (2 mL) at weeks 0, 12, and 24.
89391908|NCT03554408|Experimental|Group 8|HIV-infected individuals (on ART) will be administered three subcutaneous injections of 10-1074-LS (75 mg) admixed with 3BNC117-LS (225 mg) (2 mL) at weeks 0, 12, and 24.
89391909|NCT03554408|Experimental|Group 9|HIV-infected individuals (on ART) will be administered three subcutaneous injections of 10-1074-LS (60 mg) admixed with 3BNC117-LS (250 mg) (2 mL) at weeks 0, 12, and 24.
89391910|NCT05138263||Young normal controls|"age : 20 ~ 54~without dementia, MCI, or other major neurological/psychiatric illness"
88867842|NCT01037790|Experimental|Arm 5 - CCND1amplification, CDK4/6mutation, CCND2amplification, OR other functional G1/S alterations|"Any tumor type if tissue tests positive for CCND1 amplification, CDK4/6 mutation , CCND2 amplification OR any other functional alteration at the G1/S checkpoint.~PD-0332991 Given orally, 125 mg QD on a 21-day"
88867843|NCT01038336|Experimental|Multimedia HLPP|Multimedia Hearing Loss Prevention Program (HLPP)
88867844|NCT01038336|Active Comparator|Hearing Conservation Brochure|Hearing Conservation Brochure (HCB)
88867845|NCT01038336|No Intervention|Standard-of-Care|Standard-of-Care (SoC)
88867846|NCT01040052|Experimental|Study Group|
88867847|NCT01040208|Experimental|flibanserin 50 mg to 100 mg qhs|Patient to receive one tablet of flibanserin 50 mg and one tablet of flibanserin placebo qhs for 14 days then will receive 2 flibanserin tablets of 50 mg qhs
88867848|NCT01040208|Experimental|flibanserin 100 mg qhs|Patient to receive 2 flibanserin tablets of 50 mg qhs
88867849|NCT01040208|Experimental|placebo 2 tablets qhs|Patient to receive 2 placebo tablets of 50 mg qhs
89391911|NCT05138263||Elderly normal controls|"age : 55 ~ 90~without dementia, MCI, or other major neurological/psychiatric illness"
89391912|NCT05138263||MCI (Mild cognitive impairment)|"age : 55 ~ 90~without major neurological/psychiatric illness~concern regarding a change in cognition, lower performance in any cognitive domain that is greater than would be expected for the subject's age and educational background and preservation of independence in functional abilities"
89391913|NCT05138263||AD (Alzheimer's diseases)|"age: 55 ~ 90~National Institute of Aging and the Alzheimer's Association (NIA-AA) Probable AD dementia(Alzheimer's diseases)"
89391914|NCT05220579|Experimental|"Exposure to TOR device"|"Patients undergo standard therapy + exposure to the TOR device~Modes of patients' treatment with the TOR device:~The exposure is carried out for at least 5 (five) days in a row for at least 4 hours daily in the 15 + 15 mode (15 minutes exposure + 15 minutes break).~Standard therapy was prescribed in accordance with the recommended treatment regimens presented in the guidelines of the the Ministry of Health of Russia Prevention, diagnosis and treatment of coronavirus infection (COVID-19) No. 9 dated 26.10. 2020)."
88867850|NCT01043094|Experimental|Pitavastatin 4mg renal impaired|Subjects with severe renal impairment (glomerular filtration rate [GFR] of 15 to 29 mL/min/1.73 m2, inclusive) who are not being treated with hemodialysis
88867851|NCT01043094|Active Comparator|Pitavastatin 4mg healthy subjects|Healthy subjects (GFR greater than or equal to 90 mL/min/1.73 m2)
88867852|NCT01043562||Pediatric ICD pts|Inclusion criteria for study participants included: 1) weight ≤60 kg, 2) new or existing ICD system, and 3) clinically necessary assessment of the defibrillation efficacy of the ICD system. Transvenous systems utilized a high-voltage ICD coil with active-fixation lead attached to the right ventricular endocardial surface, whereas non-transvenous systems depended upon a high-voltage shocking coil placed within the pericardial, subcutaneous or pleural space. To be included in the post-shock pacing portion of the study, adequate sinus and AV node function had to be present at baseline. Exclusion criteria included 1) tenuous hemodynamic status felt to warrant abbreviation of the defibrillation efficacy testing or 2) inability to induce fibrillation during defibrillation threshold testing (DFT).
88867853|NCT01043640|Experimental|Transplant Patients|Includes patients who received allogeneic stem cell transplantation following treatment plan of Campath-1H, cyclophosphamide, cyclosporine A, mycophenolate mofetil, and busulfan.
88867854|NCT01044030|Experimental|Xylitol syrup|
88867855|NCT01044030|Placebo Comparator|Placebo|
88867856|NCT01044576||Multiple Sclerosis|Patients with relapsing-remitting or secondary progressive multiple sclerosis
88867857|NCT01044966|Experimental|ITV DepoCyt + Temozolomide|Patients will undergo an induction phase of intraventricular (ITV) DepoCyt, using the dosage determined from the Phase I portionPatients with stable disease (clinically and radiographically), not exhibiting systemic toxicity, will undergo a three month consolidation phase of ITV DepoCyt, for one month (Cycles 3-6). Patients without progression or toxicity will undergo maintenance therapy using ITV DepoCyt every four weeks (+/- 3 days) for a maximum of 8 months (cycles 7-14) or until recurrence or toxicity ensues. Oral metronomic Temozolomide dosing of 75 mg/m2 daily for 21 days followed by 7 days off will be given throughout the Induction, Consolidation, and Maintenance Phases of the ITV DepoCyt described above.
88867858|NCT01045122|Other|Propofol|Is an alkylphenol, is primarily indicated for use as a general anesthetic and has minimal analgesic properties.
88867859|NCT01045122|Other|Dexmedetomidine|Dexmedetomidine is an alpha-2 adrenoreceptor agonist that has sedative, hypnotic, and analgesic effects.
88867860|NCT01049802|Experimental|Active rTMS|Experimental subjects will receive subthreshold or suprathreshold rTMS to contralesional hemisphere for up to 20 minutes at 1 Hz followed by task oriented arm and hand therapy to affected limb.
88867861|NCT01049802|Placebo Comparator|Sham rTMS|Subject will receive sham rTMS to contralesional hemisphere for up to 20 minutes followed by task-oriented arm and hand rehabilitation to affected limb
89391915|NCT05220579|No Intervention|Control|"Patients received standard therapy~Standard therapy was prescribed in accordance with the recommended treatment regimens presented in the guidelines of the the Ministry of Health of Russia Prevention, diagnosis and treatment of coronavirus infection (COVID-19) No. 9 dated 26.10. 2020)."
89391916|NCT05220579|Placebo Comparator|"Placebo (exposure to switched off TOR device)"|"Patients undergo standard therapy + a switched off TOR device was installed in the wards~Standard therapy was prescribed in accordance with the recommended treatment regimens presented in the guidelines of the the Ministry of Health of Russia Prevention, diagnosis and treatment of coronavirus infection (COVID-19) No. 9 dated 26.10. 2020)."
89391917|NCT02103686|Active Comparator|Immediate release capsule|Immediate release capsule treatment under fasted condition
89391918|NCT02103686|Experimental|sustained release tablet|sustained release tablet treatment under fasted condition
89391919|NCT02103686|Experimental|sustained release tablet (high fat meal)|sustained release tablet under high fat meal condition.
89391920|NCT02107352||Naltrexone|50mg/day
89391921|NCT02107352||Acamprosate|1332mg/day if patient weights less than 60 kg, 1998mg/day if patient weights more than 60 kg
89391922|NCT02107352||Baclofen|30 mg/day
89391923|NCT02107352||Placebo|
89391924|NCT01372969|Experimental|Cx601|
89391925|NCT02110082|Experimental|Cohort 1: Urelumab + Cetuximab|Urelumab every 3 weeks with Cetuximab weekly through Intravenous infusion
89391926|NCT02110082|Experimental|Cohort 2: Urelumab + Cetuximab|Urelumab every 3 weeks with Cetuximab weekly through Intravenous infusion
89391927|NCT05706831|Experimental|Group 1|Group 1 will receive tEs combined with music stimulation for 2 weeks, 1 week of wash out, then sham stimulation combined with noise (placebo) for other 2 weeks.
89391928|NCT05706831|Experimental|Group 2|Group 2 will receive sham stimulation and noise (placebo) for the first 2 weeks, then 1 week wash out, and finally tEs and music stimulation for other 2 weeks.
89391929|NCT05706831|Experimental|Group 3|Group 3 will receive only music stimulation and sham stimulation for 2 weeks, 1 week of wash out, then sham stimulation and noise (placebo) for another 2 weeks.
89391930|NCT02103764|Experimental|Desogestrel|Desogestrel Dosage form : Desogestrel 150 mcg/capsule Dosage : 150 mcg/day Frequency : 1 capsule/day before bed time Duration: 10 day/month
88867862|NCT01050582|Experimental|Risperidone|Risperidone as per local prescribing practices
88867863|NCT01050582|Experimental|Other atypical antipsychotic drugs|Other atypical antipsychotic drugs as per local prescribing practices
88867864|NCT01050660|Active Comparator|3 gm/kg/day intravenous lipid emulsion|
89391931|NCT02103764|Active Comparator|Medroxyprogesterone acetate|Medroxyprogesterone acetate Dosage form : 10 mg./capsule Dosage : 10 mg./day Frequency : 1 capsule/day before bed time Duration : 10 day/month
89391932|NCT05011201|Experimental|Experimental Group|Participants will undergo a single testing session of gait retraining using two variants of the dual joint visual feedback system (DJVF). The DJVF system uses IMU sensors to measure knee and hip joint motions and calculates the users foot position, relative to their pelvis. The relative foot position is represented in real time on a screen in front of the user with feedback designed to elicit increases in anteriorly located foot positions.
88867865|NCT01050660|Experimental|Intravenous Fat Emulsion-restricted|
88867866|NCT01051440|Placebo Comparator|Placebo|Subjects will receive placebo for lisdexamfetamine.
88867867|NCT01051440|Active Comparator|Lisdexamfetamine|Subjects will start with 20 mg per day of lisdexamfetamine and may increase to a maximum of 40 mg.
88867868|NCT01051518|Experimental|CoreValve|
88867869|NCT01051596|Experimental|ABT-888 and temozolomide|Temozolomide Days 1-5 and ABT-888 Days 1-7 of each 28-day cycle
89391933|NCT02110316|Other|Bioavailability|1 arm, different dosage form
89391934|NCT02103842|Experimental|Omega-3 fatty acids|Participants will take 3.9g/day of Eicosapentaenoic acid and docosahexaenoic acid for 4 months
89391935|NCT05220267|Other|Anlotinib plus Sintilimab|Anlotinib was taken orally (10mg mg qd, d1-14, 21 days per cycle) .Sintilimab was administered intravenously (200mg once every 3weeks).
89391936|NCT02110394||bendamustine and rituximab|
89391937|NCT02373241|Active Comparator|Standard Blood Pressure Management|Participants initiated on 25mg of losartan daily and randomized to lower in-clinic BP to <95th percentile
89391938|NCT02373241|Experimental|Experimental Blood Pressure Management|Participants initiated on 25mg of losartan daily and randomized to lower in-clinic BP to <75th percentile
89391939|NCT03052959|Experimental|Immediate Intervention|
89391940|NCT03052959|Other|Wait List Intervention|
89391941|NCT02019511||High dose Steroid|"Patients scheduled for primary unilateral elective TKA Age >17 years~none of the following contraindications for Methylprednisolone:~Allergy against Methylprednisolone.~Currently in systemic treatment with glucocorticoid~Current gastric ulcer~Insulin dependent diabetes mellitus~Citizens without Danish social security number are not eligible for this study as follow-up is not possible."
89391942|NCT02019511||Historical cohort|"Patients having primary unilateral elective TKA before initiation of Methylprednisolone as standard treatment~age >17 years, Danish social security number~and none of the following at time of surgery:~systemic treatment with glucocorticoid defined as: regular prescriptions on glucocorticoid within 2 months prior to surgery.~gastric ulcer defined as: prescriptions on drugs used in triple therapy for Helicobacter Pylori infection or prescriptions on antiacids/proton pump inhibitors beginning 1 month before surgery~Insulin dependent diabetes mellitus defined as: any prescriptions on insulin within 6 months prior to surgery"
89391943|NCT02019511||Procedures without Steroid|Patients scheduled for primary unilateral elective TKA and age >17 years but who did not receive high dose Methylprednisolone regardless of reason.
89391944|NCT02107430|Experimental|DCVAC/PCa arm post radiotherapy|Dendritic Cells DCVAC/PCa Experimental therapy post radiotherapy
89391945|NCT02107430|Active Comparator|Standard radiotherapy|Standard care
88867870|NCT01053000|Experimental|Lt. Arm Tazorac/Rt. Arm No Pretreatment|Apply Tazorac 0.1% gel for 1 week to the Left arm only and then receive ALA- PDT Treatment to both arms
88867871|NCT01053000|Experimental|Rt. Arm Tazorac/Lt. Arm No Pretreatment|Apply Tazorac 0.1% gel for 1 week to the Right arm only and then receive ALA- PDT Treatment to both arms
88867872|NCT05822453|Experimental|Gemcitabine plus S1 and tislelizumab|Participants will receive gemcitabine plus S1 and tislelizumab until disease progression or unacceptable toxicity
89003640|NCT04902066|Experimental|Cognitive Behavioural Virtual Reality Therapy (CBT-VR)|The CBT-VR consists of traditional CBT with the augmentation of virtual reality exposure. The virtual reality exposure comprises four virtual social environments (a bus, café, street, and supermarket). These are daily social situations that generally elicit paranoid thinking in patients with a schizophrenia spectrum disorder. While virtually engaging in these distressing situations, the therapist will facilitate a CBT dialogue aimed at generating alternative (i.e. non-threatening) thinking, diminishing safety behaviours (e.g. social isolation), and building up new coping strategies. This is expected to alleviate distress, anxiety, and improve daily social functioning. Preliminary findings reveal this virtual reality program to be well-tolerated and highly effective in reducing paranoia and anxiety in psychosis. Patients will be offered 10 individual sessions.
89003641|NCT04902066|Active Comparator|Traditional Cognitive Behavioural Therapy|The treatment in the CBT group will follow the core principles of CBT used for psychotic disorders. The CBT treatment facilitates an individualised, problem-oriented approach, and uses key CBT techniques such as developing a problem and goal list, normalising psychotic-like experiences, evaluation of appraisals, and removing or diminishing safety behaviour. Patients will be offered 10 individual sessions.
89003642|NCT04882930|Experimental|Functional Near-Infrared Spectroscopy (fNIRS) acquisitions|The hemodynamic response in CPF will be measured using an Octomon+ system (Artinis). Eight emission and two detector probes will be arranged on the participant's forehead.
89003643|NCT04881500|Experimental|Motivational interview|"Patients followed in the primary care network participating in the study and those followed in the addictology network of northern Finistère in the context of their pathology will be offered the opportunity to participate in the study.~If the patient was randomized to the intervention group, the patient will receive 2 individual sessions (motivational interview) by telephone within 1 month of inclusion. They will then be assessed at month 1, month 3 and month 6. These assessments will be done by telephone."
89003644|NCT04881500|Active Comparator|Routine Care|"Patients followed in the primary care network participating in the study and those followed in the addictology network of northern Finistère in the context of their pathology will be offered the opportunity to participate in the study.~If the patient has been randomized to the control group, the patient will be assessed at month 1, month 3 and month 6. These assessments will be done by telephone."
89003645|NCT04876391|Experimental|Participants from parent trial (1368-0052) who were on placebo or active medication|
89003646|NCT04875416||Primary participants|Patients that have or are suspected to have ALS or a related neurodegenerative disease
89003647|NCT04875416||Secondary Participants|Family members of primary participants enrolled in the study
89003648|NCT04873661|Experimental|Hypnosis|In the hypnosis-based intervention, patients (in groups of approximately 10 participants) will participate in 8 weekly sessions (2 hours each) during which they will benefit from guided hypnosis exercises, and learn how to implement self-hypnosis. They will also receive a CD with hypnosis exercises for home practice. At-home practice is encouraged between sessions.
89003649|NCT04873661|Experimental|Cognitive trance|The cognitive trance-based intervention will consist of a two-day workshop in groups of approximately 10 participants, where they will learn how to induce the cognitive trance, with the use of different sound-loops that can induce trance in untrained people in a safe way. After two weeks of home practice, participants will redo a two-day consolidation training. At-home practice is encouraged between sessions.
89003650|NCT04873661|Experimental|Meditation|The meditation-based intervention will consist of 8 weekly sessions (2h45 each) in groups of approximately 10 participants, as well as half a day of intensive practice between the fifth and the sixth session. Participants will learn how to implement self-compassion meditation, through practical exercises proposed during the sessions. At-home practice is encouraged between sessions.
89003651|NCT04873661|No Intervention|Control group|Participants in the control group will not receive any intervention during the whole duration of the study. They will be assessed at the same times and in the same ways than the 3 experimental groups. After the study, they will have the opportunity to participe in one of the 3 interventions if they want to.
89003652|NCT04868409|Active Comparator|Rocuronium group|Rocuronium 1 mg/kg
89003653|NCT04868409|Active Comparator|Suxamethonium group|Suxamethonium 1 mg/kg
89003654|NCT04865770|Experimental|Semaglutide 1.0 mg OW|Once-weekly (OW) Semaglutide administered subcutaneously (s.c., under the skin).
89003655|NCT04865770|Placebo Comparator|Placebo (Semaglutide) 1.0 mg OW|Once-weekly (OW) placebo (Semaglutide) administered subcutaneously (s.c., under the skin).
89003656|NCT04862650|Experimental|Treatment (cemiplimab, paclitaxel, carboplatin)|Patients will be treated with a combination of cemiplimab 350 mg every three weeks, with weekly combination of paclitaxel 25 mg/m2 and carboplatin AUC 1. Treatment will continue for a total of 24 months or until disease progression or unacceptable toxicity. Weekly chemotherapy will stop after six months of treatment (24 weeks). A ten patient safety run-in phase will be initially performed.
89003657|NCT04860830|Experimental|Iclepertin treatment group|
89003658|NCT04860830|Placebo Comparator|Placebo group|
89003659|NCT04858035|Experimental|Online Speech Training|"Participants will be randomly assigned to transition from the baseline to the treatment condition at one of 7 possible points, ranging from 4 to 10 baseline sessions. All participants will receive 12 sessions of perceptual training over 4 weeks. Finally, participants will complete a 3-session maintenance phase in which perception and production are probed but not treated. Perception will be measured using the identification and category goodness judgment.~Following completion of perception training all participants will complete two weeks of production training. The production training will consists of 4, 60-minute sessions. Each session will provide instruction and practice trials."
89391946|NCT05706675|Experimental|Experimental|Periodontitis patients that will be treatyed with Non surgical Periodontal Therapy
89391947|NCT05706675|No Intervention|Control|Periodontally healthy patients
89391948|NCT03120013|Experimental|Real tDCS|10 days anodal cerebellar and cathodal spinal tDCS
89391949|NCT03120013|Sham Comparator|Sham tDCS|10 days sham cerebellar and sham spinal tDCS
89391950|NCT05656131|Experimental|fluzoparib|Fluzoparib: 150 mg twice daily (morning and evening) for 21 consecutive days as a cycle until disease progression or intolerance.
89391951|NCT05656131|Experimental|fluzoparib+Camrelizumab|"Fluzoparib: 150 mg twice daily (morning and evening) for 21 consecutive days as a cycle until disease progression or intolerance.~Camrelizumab: 200 mg IV drip over approximately 30 minutes (no less than 20 minutes and no more than 60 minutes) on Day 1 of each 3-week treatment cycle until disease progression or intolerance."
89391952|NCT02110472|Other|Presbia Flexivue Microlens Corneal Inlay|Presbia Flexivue Microlens implanted in corneal pocket in nondominant eye
89391953|NCT01373047|Experimental|Intrahepatic anti-CEA designer T cells|
89391954|NCT02103998|Experimental|T4 + KI|Continuous infusion of 4 µg/Kg/day T4 with 30 µg/Kg/day oral potassium iodide (KI) for 42 days
89391955|NCT02103998|Placebo Comparator|D5W - 5% dextrose water|Receive the same volume as study drug but as D5W placebo
89391956|NCT01941589|Active Comparator|present 5-ASA arm 1|oral 5-ASA+/-topical 5-ASA+IV corticosteroids / PO Methylprednisolone
89391957|NCT01941589|Active Comparator|5-ASA naive arm 1|oral 5-ASA+/-topical 5-ASA+IV corticosteroids / PO Methylprednisolone
88867873|NCT05822401|Experimental|Blood flow restriction (BFR)|Blood flow restricted training (BFR) integrated into the daily work tasks for 8 weeks.
88867874|NCT05822401|Active Comparator|Usual care (control)|Will continue their work as usual
88867875|NCT01028820|Experimental|Open-Label, Flexible-Dose Aripiprazole|This is a single group assignment pharmacodynamics study in which all study participants are given an open-label, flexible dose of aripiprazole for up to 8 weeks.
88867876|NCT05822349|Active Comparator|intervention group|they will receive the usual diabetes care routine plus a pictogram-enriched label.
88867877|NCT05822349|Placebo Comparator|control group|they will receive the usual diabetes care routine.
88867878|NCT05822336|Experimental|Experimental arm|In this group, the duration of IM injections was 40 seconds. The drug was the same for both groups, Clindamycin 600 mg/4 ml intramuscularly.
88867879|NCT05822336|No Intervention|Active arm|In this group, the duration of IM injections was 10 seconds. The drug was the same for both groups, Clindamycin 600 mg/4 ml intramuscularly.
88867880|NCT05822323|Experimental|Control group (FGG)|The patients in this group only underwent the FGG operation.
88867881|NCT05822323|Active Comparator|Study group (FGG+BTX)|The patients in this group received 5 U BTX-A injection into the mental muscle immediately after the FGG operation.
88867882|NCT05822310|Experimental|radiofrequency thermocoagulation to the articular branches of the femoral and obturatory nerves|radiofrequency thermocoagulation to the articular branches of the femoral and obturatory nerves applied
88867883|NCT05822310|Active Comparator|intraairticular steroid injection|intraairticular steroid injection applied
88867884|NCT05822310|Active Comparator|pericapsular nerve group (PENG) block|pericapsular nerve group (PENG) block applied
88867885|NCT05822284||Patients with stage IIIB-C driver-negative NSCLC receiving induction chemoimmunotherapy|
88867886|NCT05822271|Experimental|Orthodontic Aligner treatment|
88867887|NCT05822271|Active Comparator|Orthodontic fixed appliance treatment|
88867888|NCT05822232|Active Comparator|FreeStyle Libre 2|"Subjects randomized to Group 1: FreeStyle Libre 2 will wear two FreeStyle Libre CGM sensors for 12-14 days three times over a 12-week (3 month) period. They will have two sensors inserted under their skin:~FreeStyle Libre 2 sensor with display on, meaning they will be able to see their blood sugar values on the mobile application or a reader.~FreeStyle Libre Pro sensor is used without mobile application or reader. This sensor is place as a backup in case the information is missing from the Libre 2 sensor."
88867889|NCT05822232|Active Comparator|Point of Care (POC) Self-Monitoring of Blood Glucose (SMBG) testing|Subjects randomized to Group 2: Point of Care (POC) Self-Monitoring of Blood Glucose (SMBG) testing will wear one FreeStyle Libre Pro CGM sensor without using the mobile application or reader (blinded). These subjects will have the one sensor inserted under their skin but you will not see sugar values on the CGM. Subjects will wear the CGM for 12-14 days three times over a 12-week (3 month) period but will not use the CGM to monitor and control their blood sugar. Instead, they will monitor their sugar values by the standard method of fingerstick before each meal and at bedtime.
88867890|NCT05822206|Experimental|Treatment|Participants in the Treatment arm receive 2 therapy sessions on LifeSteps and sexual decision-making, as well at 8 sessions of Cognitive Behavioral Therapy for Trauma and Self-Care (CBT-TSC). Participants then participate in 3-, 6-, and 9-month follow-up assessments.
88867891|NCT05822206|Other|Control|Participants in the Control arm receive 2 therapy sessions on LifeSteps and sexual decision-making. Participants then participate in 3-, 6-, and 9-month follow-up assessments.
89391958|NCT01941589|Active Comparator|present 5-ASA arm 2|IV corticosteroids only / PO Methylprednisolone
89391959|NCT01941589|Active Comparator|5-ASA naive arm 2|IV corticosteroids only / PO Methylprednisolone
89391960|NCT02110550|No Intervention|IPS.emmax crown|
89391961|NCT02110550|Experimental|IPS.emmax endocrown|Patients with excessively undermined and endodontically treated molars will receive the IPS.emmax endocrown as the restoration of choice.
88867892|NCT05822193||Individuals with COVID-19 diagnosis during the SARS-CoV-2 omicron wave in Brazil|
88867893|NCT05822180|Experimental|A bras actif|The experimental arm has received the Nanos product orally with a dose of 30mL, 3 times per day and away from meals (2 hours after a meal or on an empty stomach).
88867894|NCT05822180|Placebo Comparator|B bras controle|The placebo arm has received the Nanos product orally with a dose of 30mL, 3 times per day and away from meals (2 hours after a meal or on an empty stomach).
88867895|NCT05822167|Experimental|High Protein Meal with cold temperature|
88867896|NCT05822167|Experimental|High Protein Meal with warm temperature|
88867897|NCT05822167|Experimental|High Protein Meal with Hot temperature|
88867898|NCT05822167|Experimental|High Carbohydrate Meal with cold temperature|
88867899|NCT05822167|Experimental|High Carbohydrate Meal with warm temperature|
88867900|NCT05822167|Experimental|High Carbohydrate Meal with hot temperature|
89391962|NCT02110628|Experimental|Roux-en-Y+Pouch Group|Abdominal approach D2 total gastrectomy with Roux-en-Y+Pouch anastomosis. Roux-en-Y+Pouch anastomosis: closed the stump of duodenum, cut off the jejunum from the 20cm of Treitz ligament, pouch reconstruction a J pouch with a length of 15 cm was constructed by connecting the 2 Jejunal lumina, œsophago-P type jejunum Storage bag anastomosis (duct-to-duct / duct-to-duct, before the colon/after the colon), jejunum - jejunum anastomosis (duct-to-duct / duct-to-duct), the distance between anastomotic were 40cm-60cm.
89391963|NCT02110628|Experimental|Roux-en-Y group|Abdominal approach D2 total gastrectomy with Roux-en-Y anastomosis. Roux-en-Y anastomosis : closed the stump of duodenum, cut off the jejunum from the 20cm of Treitz ligament, œsophago-jejunal anastomosis (duct-to-duct / duct-to-duct, before the colon/after the colon), jejunum - jejunum anastomosis (duct-to-duct / duct-to-duct), the distance between anastomotic were 40cm-60cm
88867901|NCT05822167|Experimental|High Fat Meal with cold temperature|
88867902|NCT05822167|Experimental|High Fat Meal with warm temperature|
88867903|NCT05822167|Experimental|High Fat Meal with hot temperature|
89391964|NCT02107664||Radiation therapy for bone cancer pain|The group includes all cancer diagnoses, and different fractions of RT planned.
89391965|NCT01845649|Active Comparator|Vehicle (3 Times/Week)|Vehicle applied to the vagina daily for 14 days followed by dosing 3 times per week for 10 weeks.
89391966|NCT01845649|Experimental|WC3011 Estradiol Vaginal Cream (3 Times/Week)|WC3011 Estradiol vaginal cream applied daily for 14 days followed by dosing 3 times per week for 10 weeks.
89391967|NCT03554252|Experimental|Frequencies|
89391968|NCT03554252|Experimental|Percentages|
89391969|NCT01345929|Experimental|CXA-201 as treatment for cUTI|CXA-201 IV infusion (1500mg q8) for 7 days
88867904|NCT05822037|Experimental|CT0594CP CAR-T Cells[BCMA-UCAR-T(CT0594) and CD9-UCAR-T(CT7590)]|CT0594CP
88867905|NCT05822024|Experimental|Intervention group|Two schools (grade 4-5) will be randomly assigned to recieve the 3PL intervention in their physical education classes during one school year.
88867906|NCT05822024|No Intervention|Control group|Two schools (grade 4-5) will be randomly assigned to the control group and will continue their normal physical education classes.
88867907|NCT05821946|Experimental|Web-Based Multi-Source Training on the Prevention of Urinary Tract İnfections|In addition to routine training, web-based multi-source training will be provided on the prevention of urinary tract infections in adult kidney transplant recipients.
88867908|NCT05821946|No Intervention|Control group|Routine training and before discharge will be directed to the organ transplant handbook on the transplant center's website.
88867909|NCT05821894||Carotid Plaque Imaging Project (CPIP)|
88867910|NCT05821803|Experimental|Experimental Group|"Insoles~Foot Core Exercises"
88867911|NCT05821803|Active Comparator|Control Group|Insoles
88867912|NCT05821790||patients treated for meningioma|Samples required for the study will be obtained from surgical waste of patients who underwent meningioma resection.
89391970|NCT01345929|Active Comparator|Levofloxacin as treatment for cUTI|Levofloxacin IV infusion (750mg qd) for 7 days
89391971|NCT02107742|Experimental|Injection speed|each participant receives 3 injections with the same amount of lidocaine subcutaneously on the abdomen, given over 15, 30 and 45 seconds
89391972|NCT01825291||sleep apnea|
89391973|NCT02250872|Active Comparator|Experimental: Gemigliptin and Cisplatin|Gemigliptin 100mg daily in two divided doses for 8 days starting from one day before cisplatin-treatment
88867913|NCT05821751|Experimental|Arm A|Pembrolizumab in monotherapy or in combination with chemotherapy (platinum + 5 FU) in standard clinical practice according to the international and local guidelines + inulin
88867914|NCT05821751|Experimental|Arm B|Nivolumab in monotherapy or in combination with chemotherapy (platinum + 5 FU) in standard clinical practice according to the international and local guidelines + inulin
88867915|NCT05821712|Experimental|0.2% zinc lactate, 0.17% amine fluoride and 0.0275% sodium fluoride Mouthwash|mouthwash
88867916|NCT05821712|Active Comparator|0.057% sodium fluoride Mouthwash|mouthwash
88867917|NCT05821673|Placebo Comparator|abutments with machine surface|abutments with machine surface characterized by circular micro-threads with a furrow of less than 2 um
88867918|NCT05821673|Placebo Comparator|abutments with rough Ultrathin Threaded Microsurface|abutments with rough Ultrathin Threaded Microsurface with a triangular contour tread with a pitch of 50 μm
88867919|NCT05821673|Experimental|argon plasma pre-treated (PT) abutments|abutments with rough Ultrathin Threaded Microsurface and abutments with machine surface were pretreated with Argon Plasma
88867920|NCT05821673|Placebo Comparator|non treated abutments|abutments with rough Ultrathin Threaded Microsurface and abutments with machine surface without Argon Plasma pretreatment.
89391974|NCT02250872|Placebo Comparator|Control arm|Placebo 100mg daily in two divided doses for 8 days starting from one day before cisplatin-treatment
89391975|NCT01374139|Experimental|Cohort 1|
89391976|NCT01374139|Experimental|Cohort 2|
89391977|NCT03817983||MRE review for axSpA|Review of MRE scan for evidence of axSpA in Crohn's disease patients
88867921|NCT05821647|No Intervention|Control group|"Objective to maintain a mean arterial blood pressure (MAP) above or equal to 65 mm Hg, as is standard care in out institution.~This is done using standard hemodynamic monitoring, which in our center consists of continuous arterial blood pressure monitoring and the pulse pressure variation parameter. The clinician will administer either fluids, inotropes, vasopressors, or a combination, or apply positional changes to maintain the set MAP threshold."
89003660|NCT04853017|Experimental|ELI-002 2P Cohort 1|ELI-002 2P Amph-CpG-7909 (0.1 mg) admixed with Amph modified KRAS peptides (Amph-G12D and Amph-G12R) administered via SC injection weekly for 4 consecutive weeks, followed by bi-weekly injections over 4 weeks, during the Immunization period; additional SC injections weekly for 4 consecutive weeks during the Booster Period (the two periods are separated by 3 months of no dosing)
88867922|NCT05821647|Experimental|Additional HPI guided treatment|"Objective to maintain a mean arterial blood pressure (MAP) above or equal to 65 mm Hg, as is standard care in out institution.~This is done using standard hemodynamic monitoring (as described for the control group) but is assisted by the Hypotension Prediction Index (HPI). This parameter is made available to the clinicians with the HemoSphere Advanced Monitoring Platform (HemoSphere) and is used to initiate treatment when the HPI values is ≥ 75.~It also provides additional advanced hemodynamic variables (e.g. cardiac output, systemic vascular resistance). The treating clinicians are trained to use these variables and are provided with a diagnostic flowchart to determine the cause (preload, contractility and afterload) of the upcoming hypotensive (MAP < 65 mmHg) event. Timing of treatment and choice of treatment is then left to the discretion of the attending clinician."
88867923|NCT05821621||Cashew nut allergy|"Inclusion criteria:~Patients under 18 years of age with a proven allergy to cashew nut and followed in the pediatric allergology unit of Nancy University Hospital.~Patients having received oral cashew immunotherapy for at least 18 months at 28/02/2023~Non-inclusion criteria:~Patients who have received oral cashew immunotherapy for less than 18 months.~Patients lost to follow-up for more than 3 years (last consultation in 2020 or earlier)"
88867924|NCT05821491||non-bedded night|geriatric patients with non-bedded night in the emergency department
88867925|NCT05821491||bedded night|geriatric patients with bedded night in the emergency department
88867926|NCT05821452|Experimental|Immumotherapy plus Chemotherapy|"Paclitaxel: 175mg/m2, intravenous infusion on the first day of each cycle, every 3 weeks for a cycle (Q3W), a total of 3 cycles.~Cisplatin: 75mg/m2, intravenous infusion on the first day of each cycle, every 3 weeks for a cycle (Q3W), a total of 3 cycles.~Camrelizumab: 200mg was administered intravenously on the first day of each cycle, every 3 weeks as a cycle (Q3W), for a total of 3 cycles."
88867927|NCT05821452|Experimental|chemoradiotherapy|"Paclitaxel: 175mg/m2, intravenous infusion on the first day of each cycle, every 3 weeks for a cycle (Q3W), a total of two cycles~Cisplatin: 75mg/m2, intravenous infusion on the first day of each cycle, every 3 weeks for a cycle (Q3W), a total of two cycles~Radiotherapy: Irradiation mode and dose: three-dimensional conformal or intensity modulated radiotherapy technology was adopted, 41.4Gy, 1.8Gy each time, 5 times a week."
88867928|NCT05821400||Healthy controls without orthostatic hypotension|
88867929|NCT05821361|Experimental|HAIC+cadonilimab+bev|
88867930|NCT05821348|Experimental|cases|acting from 2 months up to the first year of life, with age postmenstrual > 40 weeks, hospitalized, with symptoms of GER or GERD and undergoing 24-hour esophageal MII-pH. Saliva samples will be collected during the execution of the MII-pH of the esophagus 24 hours, at defined time points, at least 2 hours after the last meal, so as to study the circadian variations of their composition.
88867931|NCT05821348|No Intervention|controls|healthy infants from whom it will be taken a single saliva sample during a health assessment.
88867932|NCT05821270|Experimental|Yoga|Yoga practice: 12-week program of Ashtanga Vinyasa Yoga Supta for 1h twice a week
88867933|NCT05821270|No Intervention|Waiting list|Only mandatory pilot trainig that everyone in the academy receives
88867934|NCT05821257||Early Multiple Sclerosis|Arm swing evaluation and functional tests will be tested in this group.
89186684|NCT02588534|Other|Treatment B-etanercept (ENBREL®) via Manual injection|single dose of etanercept (ENBREL®) in a syringe given by manual injection (reference treatment)
89186685|NCT05103878|Experimental|BT051 100 mg|Participants will receive a single oral dose of 100mg BT051.
89186686|NCT05103878|Experimental|BT051 300 mg|Participants will receive a single oral dose of 300mg BT051.
89186687|NCT05103878|Experimental|BT051 700 mg|Participants will receive a single oral dose of 700mg BT051.
88867935|NCT05821257||Healthy Controls|Arm swing evaluation will be tested in this group.
88867936|NCT05821192|Experimental|R-GDP plus PD-1 monoclonal antibody|Rituximab, Gemcitabine, Cisplatin, Dexamethasone, PD-1 monoclonal antibody
88867937|NCT05821179||Group I|12 patients diagnosed with OSCC.
88867938|NCT05821179||Group II|12 patients diagnosed with OLP.
88867939|NCT05821179||Group III|12 systemically free individuals with no oral mucosal lesions.
88867940|NCT05821166|Experimental|mWBH|patients receiving moderate Whole Body Hyperthermia
89186688|NCT05103878|Experimental|BT051 1500 mg|Participants will receive a single oral dose of 1500mg BT051.
88867941|NCT05821166|No Intervention|Control group|Patients do not receive moderate Whole Body Hyperthermia
88867942|NCT05821140|Experimental|children with ECC|Children under 6 with early childhood caries receiving comprehensive dental treatment under general anesthesia
88867943|NCT05821140|Experimental|Children with orofacial dysmorphologies/malocclusion|Children with orofacial dysmorphologies/malocclusion associated or not with a general condition and in need of a functional or orthodontic treatment
88867944|NCT05821140|Experimental|Children with dental abnormalities|Children with dental abnormalities associated or not with a general condition and in need of conservative, orthodontic or prosthetic treatment
88867945|NCT05821140|Experimental|children with healthy oral state|children with healthy oral state in the course of their annual follow-up visits.
88867946|NCT05821114|Experimental|high flow oxygen|Oxygen supply (2L/kg/min.) during awakening from propofol anesthesia
88867947|NCT05821114|Active Comparator|Low flow oxygen|Oxygen supply (0.3L/kg/min.) during awakening from propofol anesthesia
88867948|NCT05821062||Group 1a|CAD patients with depression on standard ASA+CLP therapy.
89186689|NCT05103878|Experimental|BT051 3500 mg|Participants will receive a single oral dose of 3500mg BT051.
89186690|NCT05103878|Placebo Comparator|Placebo|Participants will receive a single oral dose of Placebo matching BT051 dose.
89186691|NCT00682929|Active Comparator|1) Inhaled Cannabis|Inhaled cannabis is compared to oral placebo.
89186692|NCT00682929|Active Comparator|2) Oral THC|Inhaled placebo is compared to oral THC.
89186693|NCT00682929|Placebo Comparator|3) Placebo|Inhaled placebo is compared to oral placebo.
89186694|NCT02588690||Women participating in screening|Community screening project targets women of color and/or low income women over 21 years of age in economically and ethnically diverse greater Los Angeles community. Women will be risk stratified based on ASCVD risk calculation and if labeled high risk will be referred to physician services. In 1 year, women will have their ASCVD re-risk stratify to see if seeing a physician/ health care provider reduced overall ASCVD risk scores.
89186695|NCT00758199|Active Comparator|2|Moxifloxacin
89186696|NCT00758199|Placebo Comparator|3|Prednisolone Acetate
89186697|NCT00758199|Active Comparator|1|Bromfenac
89186698|NCT00919412||Preterm delivery (< 37 weeks)|
89186699|NCT00919412||Term delivery (>=37 weeks)|
89186700|NCT00918710||1|Patients with oropharyngeal squamous cell carcinomas
89186701|NCT02559999|Other|EEG responses|The study compares electroencephalographical responses (EEG) to painful stimuli tonic to those evoked by non-painful stimuli and with or without virtual reality
89186702|NCT00919490|Experimental|Group 1|Single dose of 400 mg
89186703|NCT00919490|Experimental|Group 2|Single dose of 800 mg after safety evolution of Group I
89186704|NCT00919490|Experimental|Group 3|Single dose of 1200 mg after safety evolution of Group 2
89186705|NCT00919490|Experimental|Group 4|Single dose of 1600 mg after safety evolution of Group 3
89186706|NCT00919490|Placebo Comparator|Group 5|Single dose of placebo
89186707|NCT05434611||Kawasaki disease|All children with Kawasaki disease met the diagnostic criteria for Kawasaki disease revised by the American Heart Association in 2017.
89186708|NCT05434611||Healthy controls|Healthy control group were healthy children who underwent outpatient physical examination.
89186709|NCT05081570|Experimental|Intervention group|The participants will receive two tertiary stroke care consultations provided by stroke nurses via telecare in 2 months.
89186710|NCT02589470|Experimental|COMETE|patients will attend a specific rehabilitation programme of memory
89186711|NCT02589470|No Intervention|CONTROL|the control group where patients will benefit from a standard treatment
89186712|NCT02588378||Early dry AMD (no GA)|multi-modal cSLO imaging
89186713|NCT02588378||Late dry AMD (with GA)|multi-modal cSLO imaging
89186714|NCT02588378||Reticular Pseudodrusen (RPD)|multi-modal cSLO imaging
89186715|NCT02588378||Polypoidal Choroidal Vasculopathy (PCV)|multi-modal cSLO imaging
89186716|NCT02588378||Retinal Angiomatous Proliferaion (RAP)|multi-modal cSLO imaging
89186717|NCT02588378||Central Serous Retinopathy (CSR)|multi-modal cSLO imaging
89186718|NCT02588378||RPE Detachment (RPED)|multi-modal cSLO imaging
89186719|NCT02588378||New onset CNVM (wet AMD)|multi-modal cSLO imaging
89186720|NCT02588378||Healthy (non-AMD) controls|multi-modal cSLO imaging
89186721|NCT00680745|Experimental|1|dapagliflozin 2.5mg + Glimepiride
89186722|NCT00680745|Experimental|2|dapagliflozin 5mg + Glimepiride
89186723|NCT00680745|Experimental|3|dapagliflozin 10mg + Glimepiride
89186724|NCT00680745|Placebo Comparator|4|Placebo + Glimepiride
89186725|NCT05428293|Experimental|Group A: Ibuprofen/ Acetaminophen oral suspension in fixed dose|Pharmaceutical Form: Oral Suspension Formula: Ibuprofen 100 mg/ Acetaminophen 125 mg/ 5 mL Dosage: 5 mL Administration way: oral
88867949|NCT05821062||Group 1b|CAD Patients without depression on standard ASA+CLP therapy.
88867950|NCT05821062||Group 2a|CAD patients with depression on standard ASA+TCG/PSG therapy.
89186726|NCT05428293|Active Comparator|Group B: Ibuprofen oral suspension|Pharmaceutical Form: Oral Suspension Formula: Ibuprofen 2 g/100 mL Dosage: 5 mL (100 mg of ibuprofen) Administration way: oral
89186727|NCT05428293|Active Comparator|Group C: Acetaminophen oral suspension|Pharmaceutical Form: Oral Suspension Formula: Acetaminophen 3.2 g/100 mL Dosage: 3.9 mL (125 mg of acetaminophen) Administration way: oral
89186728|NCT05427825|Experimental|ERAS group|Patients in the experimental group receive the protocolized anesthetic care bundle including EEG spectrum-guided multimodal anesthesia and HPI-guided hemodynamic therapy.
89186729|NCT05427825|Active Comparator|Control|Patients in the control group receive standard anesthetic care including bispetral index-guided balanced anesthesia and regular hemodynamic care protocols.
89186730|NCT00680121|Placebo Comparator|Control Group|Placebo
89186731|NCT00680121|Experimental|Benfotiamine|Benfotiamine 600 mg
89186732|NCT00754533|Other|1|Continuous training
89186733|NCT00754533|Other|2|Interval training
89186734|NCT00754689|Active Comparator|Arm 1|Metformin 500mg twice daily (bid) + placebo
89186735|NCT00754689|Active Comparator|Arm 2|Metformin 1000mg bid + placebo
89186736|NCT00754689|Active Comparator|Arm 3|Rimonabant 20mg once daily (od) + placebo
89186737|NCT00754689|Experimental|Arm 4|Rimonabant 10mg bid (from week 2) in combination with metformin 500mg bid
89186738|NCT00754689|Experimental|Arm 5|Rimonabant 10mg bid (from week 2) in combination with metformin 1000mg bid
89186739|NCT05375175|Experimental|Hybrid Snack|Hybrid Snack: combination of legumes, in the highest proportion, and lean meat.
89186740|NCT05375175|Active Comparator|Meat snack|Meat snack: composed of meat from loin tape
89186741|NCT00767819|Experimental|Arm 1|Progressive or metastatic bone or soft tissue sarcomas
89186742|NCT00767819|Experimental|Arm 2|Progressive gastrointestinal stromal tumors (GIST) after failure of prior imatinib and sunitinib 1st and 2nd line
89186743|NCT00767819|Experimental|Arm 3|Progressive or metastatic alveolar soft part sarcoma (ASPS)
89186744|NCT00758277|Active Comparator|Levetiracetam|
89186745|NCT00758277|Placebo Comparator|Placebo|
88867951|NCT05821062||Group 2b|CAD patients without depression on standard ASA+TCG/PSG therapy.
88867952|NCT05821062||Group 3a|CAD patients with depression on standard ASA treatment alone at least 1 month after TCG/PSG cessation.
88867953|NCT05821062||Group 3b|CAD patients without depression on standard ASA treatment alone at least 1 month after TCG/PSG cessation.
88867954|NCT05821062||Group 1c|Subjects with depression without CAD (DS) are enrolled are enrolled as a comparison group.
88867955|NCT05821062||Group 1d|Healthy control subjects (HC), subjects without depression and without CAD are enrolled as a comparison group.
89391978|NCT02107820|Active Comparator|Percutaneous Tibial Nerve stimulation|"A needle electrode insertion site is located on the inner aspect of either leg approximately three fingerbreadths (5 cm or 2) cephalad to the medial malleolus and approximately one fingerbreadth (2 cm or ¾) posterior to the tibia. The needle electrode head is gently tapped to pierce the skin, maintaining a 60° angle, and insert to a depth of approximately 2cm. The electrode is then connected to the stimulator and the current setting needed is determined by the test mode on the stimulator. Once the current setting is known, the stimulator is started on the therapy mode which delivers the current for 30 minutes and shuts off automatically after 30 minutes. The needle is then removed and stimulator disconnected. The treatment involves twelve weekly sessions of 30 minutes each."
88867956|NCT05821036|Experimental|Intervention group|"Inclusion criteria:~Having been diagnosed with FMS by a specialist physician,~Being a woman between the ages of 18-64,~To be literate,~Having and actively using a smartphone or a computer~Exclusion criteria:~Any disease accompanying FMS, the presence of psychiatric illness and endocrine disorders,~Have previous activity management training,~Currently and up to 4 weeks on psychotropic medication,~Breastfeeding and pregnancy"
88867957|NCT05821036|No Intervention|Control group|"Inclusion criteria:~Having been diagnosed with FMS by a specialist physician,~Being a woman between the ages of 18-64,~To be literate,~Having and actively using a smartphone or a computer~Exclusion criteria:~Any disease accompanying FMS, the presence of psychiatric illness and endocrine disorders,~Have previous activity management training,~Currently and up to 4 weeks on psychotropic medication,~Breastfeeding and pregnancy"
88867958|NCT05821010|Experimental|LFMT-capsules|LFMT-capsules. 3 times bulk, and further continuous administration. This arm is also treated pre- and probiotics.
88867959|NCT05821010|Placebo Comparator|Placebo|Placebo-capsules. 3 times bulk, and further continuous administration. This arm is also treated pre- and probiotics.
88867960|NCT05820984|Experimental|SPIRIT checklist plus usual practice|After accepting to review an article, peer reviewers will receive the automated, journal specific standard email with general information as per each journal's usual practice (e.g. where to access the manuscript, date when the peer review report is due). In addition, peer-reviewers who received a manuscript which was randomised to the experimental arm will receive an additional email including a short version of the SPIRIT checklist together with a short explanation of those items.
88867961|NCT05820984|Other|Usual practice|After accepting to review an article, peer reviewers will receive the automated, journal specific standard email with general information as per each journal's usual practice.
88867962|NCT05820958|Experimental|Experimental group|The experimental group received an intervention in the form of intensified tactile contact of a mother with the newborn.
88867963|NCT05820958|No Intervention|Control group|The control group received no intervention similar to experimental intervention.
88867964|NCT05820945|Experimental|Medication review group|Pharmacist-led medication review at patient level, and change proposals at physician level.
88867965|NCT05820945|No Intervention|Control group|Usual pharmacotherapy management.
88867966|NCT05820880|Experimental|Fixed [Per/Ind/Aml]|"From inclusion to Month 2, patients receive the fixed combination of perindopril 5 mg / indapamide 1.25 mg / amlodipine 5 mg (S06593).~From Month 2 to 4, patients either stay at the same dose if the blood pressure is controlled, either are up-titrated to the next dose of the strategy if the blood pressure is not controlled (ie, perindopril 10 mg / indapamide 2.5 mg / amlodipine 5 mg).~From Month 4 to 6, patients either stay at the same dose if the blood pressure is controlled, either are up-titrated to the next dose of the strategy if the blood pressure is not controlled (ie, for patients who were up-titrated at Month 2 visit: perindopril 10 mg / indapamide 2.5 mg / amlodipine 10 mg or for patients who were not yet up-titrated: perindopril 10 mg / indapamide 2.5 mg / amlodipine 5 mg."
88867967|NCT05820880|Active Comparator|Free [Per/Ind + Aml]|"From inclusion to Month 2, patients receive the free combination of perindopril 4 mg / indapamide 1.25 mg plus amlodipine 5 mg.~From Month 2 to 4, patients either stay at the same dose if the blood pressure is controlled, either are up-titrated to the next dose of the strategy if the blood pressure is not controlled (ie, double dose of perindopril 4 mg / indapamide 1.25 mg plus amlodipine 5 mg for patients).~From Month 4 to 6, patients either stay at the same dose if the blood pressure is controlled, either are up-titrated to the next dose of the strategy if the blood pressure is not controlled (ie for patients who were up-titrated at Month 2 visit: double dose of perindopril 4 mg / indapamide 1.25 mg plus double dose of amlodipine 5 mg or for patients who were not yet up-titrated:double dose of perindopril 4 mg / indapamide 1.25 mg plus amlodipine 5 mg."
88867968|NCT05820867|Active Comparator|Single-session arm|
88867969|NCT05820867|Active Comparator|Two-session arm|
88867970|NCT05820789|Experimental|Experimental Group|When the patient comes intubated from the surgery to the cardiovascular surgery intensive care unit, when they meet the extubation criteria, the patients will be extubated by the healthcare professionals working in the intensive care unit in accordance with the service protocol.Patients in the experimental group will be provided with their relatives and support during weaning from the mechanical ventilator.
89186746|NCT00584870|Active Comparator|Naproxen|
89186747|NCT00584870|Placebo Comparator|Placebo|
89186748|NCT00584870|Experimental|RN624|
89186749|NCT00679341|Experimental|Trastuzumab emtansine|Patients received trastuzumab emtansine 3.6 mg/kg intravenously (IV) administered over 30-90 minutes every 3 weeks on Day 1 of each 21-day cycle.
89186750|NCT00679341|Active Comparator|Trastuzumab + docetaxel|Patients received a loading dose of trastuzumab 8 mg/kg IV + docetaxel 75 or 100 mg/m^2 IV on Day 1 of Cycle 1 followed by trastuzumab 6 mg/kg IV + docetaxel 75 or 100 mg/m^2 IV on Day 1 of all subsequent 21-day cycles.
89186751|NCT00679263|Experimental|MN-221|
89391979|NCT02107820|Experimental|'Bladder Training (BT) and PTNS|All patients randomised to PTNS + BT group will have BT with the nurse for 20 minutes during PTNS sessions (which last 30 minutes). Since BT is recommended by NICE for a duration of 6 weeks. BT will be discussed for the first 6 sessions of the 12 week PTNS treatment cycle.
89391980|NCT02110784|Experimental|Eurartesim tablets|Eurartesim 320 mg piperaquine / 40 mg dihydroartemisinin film coated tablets. one or more tablets according to the body weight, once a day dor three consecutive days.
89391981|NCT04988425|Experimental|TNFα monoclonal antibody group|Subcutaneous injection of 50mg of TNFα monoclonal antibody immediately after admission before surgery.
89391982|NCT04988425|Active Comparator|Methylprednisolone group|Injection of 500mg of methylprednisolone immediately after admission before surgery.
89391983|NCT04988425|Placebo Comparator|Control group|Injection of the same volume of saline immediately after admission before surgery.
89391984|NCT03553784|Experimental|Intervention Group|Group delivered Low Intensity Cognitive Behavioural Therapy (CBT).
89391985|NCT03553784|No Intervention|Control Group|No intervention.
89391986|NCT03554096|Experimental|2-HOBA|2-Hydroxybenzylamine acetate: 550mg dose
89391987|NCT02104154||symptoms of liver disease|Device: Samsung LABGEO PT10 Hepatic Panel
89391988|NCT02110862||Ulcerative colitis patients with ileal-pouch-anal anastomosis|
89391989|NCT01343901||Bevacizumab|Participants with metastatic colorectal cancer (mCRC) with exclusively liver or liver and lung metastases, who were receiving bevacizumab as part of first line treatment for potentially resectable liver metastases will be observed.
89391990|NCT02110940|Active Comparator|Conservative Physiotherapy|Subjects will be referred to the physiotherapy department to receive conventional physiotherapy treatment.
88867971|NCT05820789|No Intervention|Control Group|Patient comes intubated from the surgery to the cardiovascular surgery intensive care unit, when they meet the extubation criteria, the patients will be extubated by the healthcare professionals working in the intensive care unit in accordance with the service protocol.
89391991|NCT02110940|Experimental|Neurodynamic mobilization exercise|"The experimental group will be given three neurodynamic mobilization exercises which focus more on lower limbs and the major innervating cutaneous nerves - saphenous nerve, sciatica nerve and femoral nerve.~Subjects will be instructed to practice everyday, each action repeat for 10 times."
89391992|NCT02104232|Experimental|THPP-I|TPs in the THPP-I group receive, in addition to enhanced usual care (EUC), between 6 to 14 sessions of THPP (simple cognitive behaviour therapy) starting from their recruitment in the second/ third trimester until up to 6 months after child birth. Sessions will be delivered by peers on an individual basis at a location of convenience to the TPs.
89391993|NCT02104232|Other|Enhanced usual care (EUC)|Enhanced usual care (EUC) will comprise communicating the results of the screening to the mother through an information sheet on self-care for mental health, communicating the results to the mother's gynaecologist, providing the gynaecologist with the WHO mental health gap (mhGAP) guidelines for the treatment of depression, and providing guidance on referral of depressed mothers to mental health services.
89391994|NCT02104466|No Intervention|Treatment as Usual (TAU)|Participants randomized to this arm will receive usual care with no acupuncture.
88867972|NCT05820750|Other|standard root canal treatment|
88867973|NCT05820750|Other|photodynamic therapy|
88867974|NCT05820750|Other|instrumentation and photodynamic therapy|
88867975|NCT05818774|Experimental|RFN of CMBNn with end-on lesioning with multitIned trident cannulae|"Intervention type: RF nerve end-on lesioning at 80-850 Celsius for 90 seconds~Intervention name: End-on placement of the multitined trident cannulae~Intervention description:~Patient in lateral position, targeting joint position between the inferior C2 and superior C3 facets, the middle of the facet pillars for the third to fifth cervical levels, and the superior part of the sixth and seventh cervical facets"
88867976|NCT05818774|Active Comparator|RFN of CMBNn with parallel lesioning with sharp straight conventional cannulae (SIS's technique)|"Intervention type: RF nerve parallel lesioning at 80-850 Celsius for 90 seconds~Intervention name: Straight sharp conventional (SIS's technique)~Intervention description:~Technique as described in the SIS Practice Guidelines for parallel lesioning cannulae placement"
88867977|NCT05818189|Experimental|Personalized cueing|Personalized, step-synchronized tactile cueing, enhancing proprioceptive inputs, in the form of real-time, closed-loop tactile feedback signaling left and right stance times while walking
88867978|NCT05818189|Active Comparator|Fixed cueing|Tactile cueing at fixed intervals, enhancing proprioceptive inputs, in the form of open-loop tactile feedback (fixed rhythm) signaling left and right stance times while walking
88867979|NCT05817162|Placebo Comparator|Placebo Group: PRP|Temporomandibular joint arthrocentesis, Ringer lactate for washing, and 1ml PRP infiltration in each temporomandibular joint
89186752|NCT00679263|Placebo Comparator|PLACEBO|Placebo intravenous infusion with dosing volume equivalent to active treatment.
89391995|NCT02104466|Experimental|TAU + 12 wks of acupuncture 1x/week|Participants randomized to this arm will receive usual care with adjunctive acupuncture once per week for a period of 12 weeks.
89391996|NCT02104466|Experimental|TAU + 12 wks of acupuncture 2x/week|Participants randomized to this arm will receive usual care with adjunctive acupuncture twice per week for a period of 12 weeks.
89391997|NCT05617521|Experimental|Abdominal Binder Intervention Group|Patients randomized to the Abdominal Binder Intervention Group will have the abdominal binder (Revive 3-in-1 Postpartum Recovery Support Belt) secured firmly between the subcostal border and the anterior superior iliac spine area to the abdomen just prior the colonoscopy.
89391998|NCT05617521|Sham Comparator|Sham Group|Sham Group will have the abdominal binder (Revive 3-in-1 Postpartum Recovery Support Belt) secured firmly between the subcostal border and the anterior superior iliac spine area to the abdomen just prior the colonoscopy but it will be loosened just prior the procedure.
88867980|NCT05817162|Active Comparator|PRP + Ropivacaine|Temporomandibular joint arthrocentesis, Ringer lactate for washing, and 1ml PRP + ropivacaine infiltration in each temporomandibular joint
89003661|NCT04853017|Experimental|ELI-002 2P Cohort 2|ELI-002 2P Amph-CpG-7909 (0.5 mg) admixed with Amph modified KRAS peptides (Amph-G12D and Amph-G12R) administered via SC injection weekly for 4 consecutive weeks, followed by bi-weekly injections over 4 weeks, during the Immunization period; additional SC injections weekly for 4 consecutive weeks during the Booster Period (the two periods are separated by 3 months of no dosing)
89186753|NCT05067686||Mental Health Professionals|
89186754|NCT05067686||Non Mental Health Professionals|
89186755|NCT02588300|Experimental|Drug induced sleep endoscopy|Patients upper airway is assessed by drug induced sleep endoscopy
89186756|NCT05228210||Partners of breast cancer survivors|Convenience sample of partners/significant others/spouses of breast cancer survivors
89186757|NCT00680043|Experimental|Peginesatide 0.04 mg/kg|
89186758|NCT00680043|Experimental|Peginesatide 0.08 mg/kg|
89186759|NCT00680043|Active Comparator|Epoetin Alfa|
89186760|NCT00918944|Other|Control arm|Practices with the EHR implemented will be randomized have the asthma disease management tools available passively (the control group).
89186761|NCT00918944|Other|Intervention arm|The intervention sites will have decision support alerts and reminders activated to guide providers toward these tools in the appropriate situations.
89186762|NCT00758355||M2A magnum|Consecutive series of patients received Total Hip Resurfacing with ReCap/Magnum
89186763|NCT00758355||Recap Magnum|Consecutive series of patients received Total Hip Replacement with ReCap/Magnum
89186764|NCT02560545|Active Comparator|Cannabis oil|Cannabis oil, 20% THC 0.2 mg/kg
89186765|NCT02560545|Placebo Comparator|Placebo|Oil
89186766|NCT03877029||Study II|"Women with a screen-detected breast cancer after attending BreastScreen Norway~Women who have never attended BreastScreen Norway despite of several invitation, and who are diagnosed with symtomatic breast cancer.~Both groups of women will receive the questionnaire."
89186767|NCT03877029||Study III|"Women with a screen-detected breast cancer after attending BreastScreen Norway~Women with interval breast cancer after attending BreastScreen Norway~Women with symptomatic breast cancer, who have never been screened in BreastScreen Norway~Women free from breast cancer"
89186768|NCT03877029||Study IV|"Women with a screen-detected breast cancer after attending BreastScreen Norway~Women with interval breast cancer after attending BreastScreen Norway~Women with symptomatic breast cancer, who have never been screened in BreastScreen Norway"
89186769|NCT02560467|Experimental|Patients with HCM|This is a prospective, non-blinded single center study. Subjects with known HCM with variant will be recruited. MCE at rest and during vasodilator stress will be performed. Full echocardiography including for diastolic function and regional strain imaging will also be performed. Patient history and questionnaires will be used for evaluation of symptoms and arrhythmias.
89186770|NCT05352633|Experimental|Intensive BP Arm|Participants randomized into the Intensive treatment group will have a goal of SBP <120 mmHg. A two- or three-drug regimen should be initiated at randomization for most participants. Drug doses should be increased and/or additional antihypertensive medications should be added at each visit in the intensive treatment group, usually at monthly intervals, until the participant's goal of <120 mmHg has been reached or the local investigator decides no further antihypertensive medications may be added.
89186771|NCT05352633|Active Comparator|Standard BP Arm|Participants randomized into the Standard treatment group will have a goal of SBP <140 mmHg. It is expected to achieve a SBP of 135-139 mmHg in as many participants as possible. Medication dose titration or addition of another drug is indicated if SBP is ≥160 mmHg at a single visit or is ≥140 mmHg at two consecutive visits. Down titration should be carried out if the SBP is <130 mmHg at a single visit or <135 mmHg at two consecutive visits.
89186772|NCT05058092|Experimental|Intervention|"The Remedee Solution consists of:~a wristband designed to deliver millimeter wave~a mobile application that allows the patient to follow his treatment sessions~a personalized support to improve patient adherence to the technology and to increase compliance and effectiveness of the treatment~The use of the Remedee Solution start at the randomization day (D0)"
89186773|NCT05058092|Other|Control|"The Remedee Solution consists of:~a wristband designed to deliver millimeter wave~a mobile application that allows the patient to follow his treatment sessions~a personalized support to improve patient adherence to the technology and to increase compliance and effectiveness of the treatment~The use of the Remedee Solution start at three months (M3) after randomization day"
89186774|NCT05435937|Experimental|P4C-Swe intervention|Pupils in participating classes will receive the Partnering for change (P4C) intervention
89186775|NCT05435937|Active Comparator|Treatment as usual|Treatment as usual is provided by the Student health services that consists of a school doctor, school nurse, psychologist and counselor, and staff with special educational competence
89186776|NCT05057078|Experimental|Intervention group|A mindfulness-based stress reduction program will be done once a week for eight weeks
89186777|NCT05057078|No Intervention|Control group|During study process, no application will be made to the control group.
89391999|NCT04862858|Active Comparator|Intervention|The educational outreach intervention will entail a multi-faced strategy to provide patients resources to learn more about reducing their risk for heart disease and supporting providers in the care of their patients by sharing recent guideline-recommended treatments for these high-risk individuals.
89392000|NCT04862858|No Intervention|Control|Patients and primary care providers randomly selected and assigned to the control arm will not receive any of the educational outreach communications.
89392001|NCT02104622|Experimental|ReWalk training|
89392002|NCT05219643|Experimental|NAVA|Received NAVA.
89392003|NCT05219643|Active Comparator|PSV|Received PSV.
89186778|NCT02587754|Active Comparator|Verum acupuncture|10 sessions of verum acupuncture
89186779|NCT02587754|Placebo Comparator|Placebo acupuncture|10 sessions of placebo acupuncture via use of placebo acupuncture needles
89186780|NCT00682539|Active Comparator|Avastin|15 patients with clinical significant macular edema receive an injection of 2,5 mg Avastin every month. After three initial injections of Avastin re-injection is performed if the central retinal thickness measured with optical coherence tomography (Stratus OCT, Zeiss) stays more than 300 microns. If the Central retinal thickness decreases under 300 microns a sham injection is performed.
89392004|NCT02108132|Experimental|Cellular therapy|Cellular therapy : injection of mesenchymal stem cells subjected to hepatogenic induction
88867981|NCT05816421|Experimental|Affinity KEEP|"Affinity KEEP groups are tailored to meet a specific population's needs and are comprised of parents who all share a common interest, purpose, or key characteristic. The four types of Affinity KEEP groups for this study include:~foster/kin parents of sexual and gender minority youth~foster/kin parents of Native youth~transracial placements where the youth and one or more parents are of a different race/ethnicity~groups delivered in Spanish"
88867982|NCT05816421|Active Comparator|Non-Affinity KEEP|Parents attending a Non-Affinity KEEP group.
88867983|NCT05814809|Experimental|Sequence A|R → Washout period(7days) → T
88867984|NCT05814809|Experimental|Sequence B|T → Washout period(7days) → R
88867985|NCT05812690||Children with molar incisor hypomineralisation|Children referred to the host centres with a clear diagnosis of MIH, as given by a specialist paediatric dentist
88867986|NCT05812690||Children without molar incisor hypomineralisation|Children referred to the host centres with no evidence of MIH
88867987|NCT05810402|Experimental|BCLC B and C HCC patients|"For each participant, 30mL of blood will be collected at inclusion/before treatment initiation (baseline) and during standard of care follow-up.~The blood sample will be taken, in consultation or in outpatient clinic during a blood test for health purposes."
88867988|NCT05809180|Experimental|rituximab(100mg), orelabrutinib(50mg), pomalidomide(4mg), miniCHOP-like|"Phase I(induction therapy): Patients receive Rituximab on day 1, Pomalidomide on days 1-7 and oral administration of Orelabrutinib per day.~Phase II(stratified response therapy):~Part A: (25% or more reduction): Patients receive Pro-miniCHOP-like regimen every 21 days for 6 cycles.(Rituximab on day 1, Pomalidomide on days 1-7, Orelabrutinib per day till progression or intolerant toxicity, Cyclophosphamide on day 2, Doxorubicin/Doxorubicin Liposome on day 2, Vindesine on day 2 and Dexamethasone on days 2-6).~Part B: (reduction less than 25%): Patients receive R-miniCHOP-like regimen every 21 days for 6 cycles.(Rituximab on day 1, Cyclophosphamide on day 2, Doxorubicin/Doxorubicin Liposome on day 2, Vindesine on day 2 and Dexamethasone on days 2-6).~Phase III(maintenance and follow-up): Patients take Pomalidomide orally on days 1-7 in a cycle of 21 days for 2 years."
88867989|NCT05807854|Active Comparator|Arthroscopic surgery|The massive degenerative rotator cuff tear are treated by arthroscopy. It consists in reattaching the torn tendon with anchors and sutures.
88867990|NCT05807854|Experimental|Reverse shoulder arthroplasty|The problems induced by the massive degenerative rotator cuff tear are solved by a complete replacement of the shoulder joint with a prosthesis (reverse design).
88867991|NCT05802238|Experimental|Treatment Arm|Patients randomized to treatment arm of study will have TXA administered 10 minutes prior to surgery
88867992|NCT05802238|Placebo Comparator|Control Group|The control group will have saline administered 10 minutes prior to surgery.
89392005|NCT02108210|Experimental|Anakinra|This therapy will consist of once daily subcutaneous injections (100mg/day) during a period of 4 weeks. Patients will be monitored at week 1 and week 4 after starting medication for development of side effects. Therapy will be stopped in case of severe side effects, interfering disease or pregnancy. During the intervention period, use of co-medication is only allowed when used for ≤14 consecutive days, on the condition that there are no known interactions with anakinra. Oral contraceptives and/or paracetamol can be used without a limitation. During the follow-up period, there are no limitations regarding the use of medication. All co-medication will be registered precisely and reported afterwards.
88867993|NCT05799807|Active Comparator|Cohort 1 - Conservative|Negative weight-bearing CT (≤ 2mm between C1-M2, as opposed to the uninjured side) will be considered stable and treated conservatively with a prefabricated walker with weight-bearing as tolerated for six weeks. These patients will undergo bilateral radiographs after six weeks and combined CT and radiographs after twelve weeks to monitor the degree of stability
88867994|NCT05799807|Active Comparator|Cohort 2 - Surgical|Positive weight-bearing CT (> 2mm between C1-M2, as opposed to the uninjured side) will be operated by minimally invasive stabilization (eg, isolated homerun screw)
88867995|NCT05796570|Experimental|Cohort A: Standard Risk|"Participants with MDS, AML, AML/MDS, treatment related myeloid neoplasm (tAML/MDS) with either idiopathic disease or inherited bone marrow failure syndrome (iBMF) with standard risk for treatment related toxicities will be enrolled and will undergo study procedures as outlined:~Cycles 1: Study treatment start must occur 40 - 120 days post allogenic HCT.~Day 2 - 6 of 28-day cycle: Predetermined dose of Decitabine.~Day 1 - 6 of 28-day cycle: Predetermined dose of Filgrastim.~Cycles 2 - 6:~Day 2 - 6 of 28-day cycle: Predetermined dose of Decitabine.~Day 1 - 6 of 28-day cycle: Predetermined dose of Filgrastim.~Follow up visit every 6 months for 24 months post allogenic HCT."
88867996|NCT05796570|Experimental|Cohort B: inherited bone marrow failure (iBMF) with Increased Risk for treatment related toxicities|"Participants with MDS, AML, AML/MDS, tAML/MDS with iBMF with increased risk for treatment related toxicities will be enrolled and will undergo study procedures as outlined:~Cycles 1: Study treatment must occur 40 - 120 days post allogenic HCT.~Day 2 - 6 of 28-day cycle: Predetermined dose of Decitabine.~Day 1 - 6 of 28-day cycle: Predetermined dose of Filgrastim.~Cycles 2 - 6:~Day 2 - 6 of 28-day cycle: Predetermined dose of Decitabine.~Day 1 - 6 of 28-day cycle: Predetermined dose of Filgrastim.~Follow up visit every 6 months for 24 months post allogenic HCT."
88867997|NCT05768295|Other|Axiom BL X3|Dental implant Axiom BL X3
88867998|NCT05755945|Experimental|Custom Phone eHealth Application|Subjects diagnosed with migraine headaches and have had a positive response to prevention treatments for migraine, will wear an Apple Watch whenever possible (including during sleep) and complete application questionnaires on the eHealth application daily.
88867999|NCT05751837|Experimental|Treatment Arm|Injection of Lipopolysaccharide into one abdominal tumor
88868000|NCT05749848|Experimental|[¹⁴C]-LY3372689|Single dose of [¹⁴C]-LY3372689 administered orally.
88868001|NCT05728970||symptomatic|Self-reported symptoms by the subject and/or preliminary assessment of the subject by the Investigator/designee should be suggestive of COVID-19 and/or Influenza at the time of the study visit. The subject must present as symptomatic, exhibiting one or more of the following signs and symptoms: fever, cough, shortness of breath, difficulty breathing, muscle pain, headache, sore throat, chills, repeated shaking with chills, new loss of taste or smell congestion or runny nose, diarrhea, nausea or vomiting. The onset of these symptoms will be recorded and will be within the last twelve (12) days
88868002|NCT05714098|Experimental|Exercise|Each cohort of 5-8 participants will exercise 3 days a week for up to 12 weeks. Exercise sessions will be virtual
89392006|NCT02108210|Placebo Comparator|Placebo|"Patients in the placebo group will also receive once daily subcutaneous injection during a period of 4 weeks. Placebo injections will be identically in appearance compared to the Anakinra injections. Patients in the placebo group will have the same visits and monitoring for side effects as the patients randomized to the other treatment arm.~During the intervention period, use of co-medication is only allowed when used for ≤14 consecutive days, on the condition that there are no known interactions with anakinra. Oral contraceptives and/or paracetamol can be used without a limitation. During the follow-up period, there are no limitations regarding the use of medication. All co-medication will be registered precisely and reported afterwards."
89392007|NCT03053271|Experimental|ATR-101|During the 4-week randomized withdrawal period, eligible subjects will receive ATR-101 at the same dose level being used at the completion of the open-label dose-escalation period.
89392008|NCT03053271|Placebo Comparator|Placebo|During the 4-week randomized withdrawal period, eligible subjects will receive a placebo that matches the same ATR-101 dose level being used at the completion of the open-label dose-escalation period.
89392009|NCT02104700|Active Comparator|Rilpivirine/Emtricitabine/Tenofovir|"Immediate switch: RILPIVIRINE/ EMTRICITABINE /TENOFOVIR FDC QDAY at randomization."
89392010|NCT02104700|Active Comparator|Nevirapine/Lamivudine/ plus other NNRTI|"Delayed switch: Continue NEVIRAPINE 200MG BID + LAMIVUDINE 300MG + OTHER NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NRTI) through 24 weeks then switch to RILPIVIRINE 25MG/ EMTRICITABINE 200MG/TENOFOVIR 300MG FDC QDAY and then follow through 48 weeks."
89392011|NCT02104778|Experimental|Dexamethasone|Dexamethasone 8 mg is added to 0.5% ropivacaine 20 ml for sciatic nerve block.
89392012|NCT02104778|Placebo Comparator|Control|Normal saline 1 ml is added to 0.5% ropivacaine 20 ml for sciatic nerve block.
88868003|NCT05699031|Experimental|APP-GROUP|Patients allocated in the app-group will use the app to rehabilitate.
88868004|NCT05699031|Active Comparator|PHYSIO-GROUP|Patients allocated in the physio-group will rehabilitate according to the usual care protocol
89392013|NCT02104778|Experimental|epinephrine|Epinephrine 1:200,000 is added to 0.5% ropivacaine 20 ml for sciatic nerve block.
89392014|NCT05205681||Pandemic Group|All patients who underwent emergency appendicectomy for suspected acute appendicitis between March 2020 and February 2021
89392015|NCT05205681||Control Group|All patients who underwent emergency appendicectomy for suspected acute appendicitis between March 2019 and February 2020
88868005|NCT05689853|Experimental|AK119 in combination with AK112|AK119 and AK112, IV, every 3 weeks
88868006|NCT05686083|Active Comparator|12.5 g of C6 ketone di-ester|Low dose of C6 ketone di-ester.
88868007|NCT05686083|Active Comparator|12.5 g of novel ketone di-ester|Low dose of novel ketone di-ester.
88868008|NCT05686083|Active Comparator|25 g of novel ketone di-ester|High dose of novel ketone di-ester.
88868009|NCT06024057|Experimental|LX101|
88868010|NCT06024031|Experimental|NAC group|Low, intermediate risk AML patients were enrolled, and NAC (400mg tid) was administered orally from day1 to day 28 (D1-D28) after the end of induction chemotherapy.
88868011|NCT06024018|Experimental|first group|thirty obese males (30 males) will undergo dietary caloric restriction and will be instructed to walk 10,000 continuous steps every day using the pedometer application for 3 months. Also they will undergo high intensity electromagnetic technique (40 minutes for every session) on abdomen of males which will be 3 sessions per week for 3 months
88868012|NCT06024018|Active Comparator|second group|thirty obese males (30 males) will undergo dietary caloric restriction and will be instructed to walk 10,000 continuous steps every day using the pedometer application for 3 months.
88868013|NCT06024005|Active Comparator|Device Group|Transcutaneous device group with Urostim 2
88868014|NCT06024005|Active Comparator|Drug Group|Drug Group with Kinzy 5 mg
89392016|NCT02104856||Alair System (Bronchial Thermoplasty)|Asthma patients undergoing Bronchial Thermoplasty treatment with commercially available Alair device as per Directions For Use.
89392017|NCT02108366|Placebo Comparator|Placebo|Placebo + oseltamivir 75mg bid for 5 days
88868015|NCT06023979|Experimental|Full weight bearing|After 2 weeks after surgery the arm will begin full weight bearing
88868016|NCT06023979|Active Comparator|Partial weight bearing|The arm will perform partial weight bearing for 6 weeks after surgery
88868017|NCT06023940|Experimental|High Fiber|Subjects are provided a high-fiber diet for 2 weeks. Tests include: blood biochemistries, body composition measured via DEXA, fecal sample collection, and anthropometrics measured
88868018|NCT06023940|No Intervention|Control|Subjects are not provided any diet, instead they eat what they choose for two weeks while they participate in a series of tests including: fecal sampling, food records, questionnaires/surveys, and anthropometrics
89392018|NCT02108366|Experimental|Celecoxib|Celecoxib 200mg daily + oseltamivir 75mg bid for 5 days
89392019|NCT05602233|Experimental|Balance training:|It is planned to apply hop to stabilization exercises developed by Mckeon et al. The training will be given for 6 weeks, 3 times a week for 20 minutes. This phased balance training program is based on the participant's ability to maintain a single limb posture while performing balance activities. The program includes: 1) hop to stabilization, 2) hop to stabilization and reach, 3) hop to stabilization box drill, 4) progressive single-limb stance balance activities with eyes open, and 5) progressive single-limb stance activities with eyes closed. Participants will be followed up with a physiotherapist and will be able to proceed to the next stage of the test after completing the previous level without errors.
88868019|NCT06023914|Experimental|Isometric strength evaluation with a device of electro-stimulation|"The measurement of rotator cuff strength (medial and lateral rotation) and shoulder elevation will be performed with a Medeor® manual dynamometer. To measure the strength of the medial and lateral rotators, the subject will be positioned in dorsal decubitus, with the shoulder abducted at 45º and in 30º of horizontal adduction (scapular plane), elbow flexed at 90º and neutral rotation, with the dynamometer positioned, respectively, over the distal radio-ulnar joint on the volar or dorsal surface. In all these strength assessments, individuals will be required to perform a maximum isometric contraction for 5 seconds.~According to the order of randomization, one of the two evaluations will be carried out initially. We will call the evaluation with electrostimulation experimental here. The device to be used will be a GLOBUS® brand equipment, the equipment presents several types of pre-programmed currents, parameters have also been used in similar studies."
88868020|NCT06023914|Active Comparator|Isometric strength evaluation|"The measurement of rotator cuff strength (medial and lateral rotation) and shoulder elevation will be performed with a Medeor® manual dynamometer. To measure the strength of the medial and lateral rotators, the subject will be positioned in dorsal decubitus, with the shoulder abducted at 45º and in 30º of horizontal adduction (scapular plane), elbow flexed at 90º and neutral rotation, with the dynamometer positioned, respectively, over the distal radio-ulnar joint on the volar or dorsal surface. In all these strength assessments, individuals will be required to perform a maximum isometric contraction for 5 seconds.~We will call this intervention active comparator, as both groups of patients will undergo this evaluation, which will be performed without electrostimulation."
88868021|NCT06023901|Experimental|85 patients with only apical periodontitis (AP group)|AP group was divided into 3 subgroups. AS-PAI 1 (mild): those having at least 1 tooth with either PAI 3 or PAI 4, AS-PAI 2 (moderate): those having only 1 tooth with a PAI 5, AS-PAI 3 (severe): those having two or more teeth with a PAI 5.
88868022|NCT06023901|Experimental|50 patients with only chronic periodontitis (CP group),|In this study, the CP group was divided into 4 subgroups according to the periodontitis staging system (PSS) (Tonetti). This system classifies the periodontitis from I to IV according to the interdental clinical attachment loss (CAL), radiographic bone loss (RBL) and tooth loss. This scoring is as follows: Stage 1: CAL 1 to 2 mm, RBL is at coronal third (<15%) and no tooth loss, Stage 2: CAL 3 to 4 mm, RBL is at coronal third (15% to 33%) and no tooth loss, Stage 3: CAL > 5 mm, RBL is extending to mid-third of root and beyond and tooth loss < 4 teeth, and Stage 4: CAL > 5 mm, RBL is extending to mid-third of root and beyond and tooth loss > 5 teeth. However, Stage 1 and 2 were evaluated in the same group due to the low number of cases. As a result, the groups were designed as Stage 1-2: PSS 1-2, Stage 2: PSS 2 and Stage 3: PSS 3.
88868023|NCT06023901|No Intervention|A healthy control group of 50 volunteers|control group. A healthy control group of 50 volunteers without periodontal pathology as well as any acute/chronic disease (muscle/joint/bone diseases, inflammatory bowel disease, local or generalized infection, severe organ disease, cardiovascular disease and diabetes mellitus) were included in the study.
88868024|NCT06023888|Experimental|Periodicity-based|
88868025|NCT06023888|Other|Control|Standard ablation strategy as usual
88868026|NCT06023875|Experimental|Experimental group|Patients with locally advanced operable head and neck squamous cell carcinoma
88868027|NCT06023849|Active Comparator|PPIUD|trans cesarean IUD insertion immediately post placental
88868028|NCT06023849|Active Comparator|interval|IUD insertion 6 weeks interval post-partum
88868029|NCT06023810|Experimental|experimental|Watson's human care theory-based motivational interviewing method
89186781|NCT00682539|Active Comparator|Triamciolone|30 patients with a clinical significant diabetic macular edema receive an intraocular injection of 8mg triamcinolone at baseline under sterile conditions. 1 and 2 month after the baseline injection, patients receive a sham injection. After three month re-injection of 8mg Triamcinolone is performed if the central retinal thickness measured with optical coherence tomography (Stratus OCT, Zeiss) stays more than 300 microns. If the Central retinal thickness decreases under 300 microns patients will receive a sham injection. In between two injection of 8mg Triamcinolone must be an temporal interval of at least 3 months.
89186782|NCT00682539|Active Comparator|Lucentis|15 patients with clinical significant macular edema receive an injection of 0,5 mg Lucentis every month. After three initial injections of Lucentis re-injection is performed if the central retinal thickness measured with optical coherence tomography (Stratus OCT, Zeiss) stays more than 300 microns. If the Central retinal thickness decreases under 300 microns a sham injection is performed.
89186783|NCT02587910|Placebo Comparator|Non-invasive arm|Participants in this arm, who fit the inclusion criteria and have a GERD Q score of 3 or more, will be randomized to receive either Melanole, a herbal derived melanin, 300 mg, 2 capsules three times a day or placebo for 10 days.To assess the symptomatic improvement, GERD Q score will be calculated on day 0 (before administration of the product) and then on days 11 and 30 having taken the product for 10 days.
89186784|NCT02587910|Placebo Comparator|Invasive arm|Participants in this arm will undergo a 24-hour pH monitoring before administration of Melanole, the herbal melanin or placebo. They will then be randomized to receive either Melanole or placebo for 10 days. pH metry will be repeated between days 7 and 10 from the study product or placebo.
89186785|NCT00682461|Active Comparator|Marketed formulation|Marketed nicotine replacement therapy product
88868030|NCT06023810|No Intervention|control|
88868031|NCT06023797||MAICT|chemotherapy that included at one application of PD-1 inhibitor
88868032|NCT06023784|Experimental|left bundle branch area pacing|
88868033|NCT06023784|Active Comparator|right ventricular pacing|
88868034|NCT06023771||Acute pancreatitis requiring invasive intervention|Single-center cohort of acute pancreatitis patients requiring invasive intervention for the treatment of local complications during the whole course of disease.
89186786|NCT00682461|Experimental|prototype|Nicotine prototype
89186787|NCT02589002|Experimental|Sucralose|Ingestion of 15% of the ADI of sucralose daily during two weeks
89186788|NCT02589002|No Intervention|Control|Absence of sucralose ingestion
89186789|NCT00755001||with Plasma HA|BiHapro Hip stem with PPS Ti + Plasma HA
89186790|NCT00755001||with BoneMaster HA|BiHapro Hip stem with PPS Ti + BoneMaster HA
89186791|NCT04082546||Surgical unroofing|Refractory angina to medical treatment (beta-blockers or calcium channels blockers)
89186792|NCT04082546||Medical treatment|Responders to medical treatment for angina relief
89186793|NCT02560311||HER2+ metastatic breast cancer|
89186794|NCT02587364|Experimental|Gemcabene 50 mg|Gemcabene 50 mg
89186795|NCT02587364|Experimental|Gemcabene 150 mg|Gemcabene 150 mg
89186796|NCT02587364|Experimental|Gemcabene 450 mg|Gemcabene 450 mg
89186797|NCT02587364|Experimental|Gemcabene 750/600 mg|Gemcabene 750/600 mg
89186798|NCT02587364|Experimental|Gemcabene 900 mg|Gemcabene 900 mg
89186799|NCT02587364|Placebo Comparator|Placebo|Placebo
89186800|NCT00921765|Placebo Comparator|Placebo + Placebo|Saline single bolus dose iv + saline single bolus dose iv
89186801|NCT00921765|Active Comparator|Placebo + Ketamine|Saline single bolus dose followed by single bolus dose of ketamine 0.2 mg/kg bw
89186802|NCT00921765|Active Comparator|Naloxone + Placebo|Single bolus dose of naloxone 0.2 mg/kg bw followed by single bolus dose of saline
89392020|NCT05602233|Experimental|STARS|A combination of STARS developed by Mckeon et al. is planned for the STARS group. The training will be given for 6 weeks, 3 times a week for 5 minutes. STARS includes; joint mobilization, plantar massage and triceps surae stretching.
89392021|NCT05602233|Experimental|Combined Training|Each participant in the combined training program will receive 4 weeks of balance training after 2 weeks of STARS treatment. STARS and hop to stabilization treatment protocol will be applied in the same way.
89392022|NCT02104934|No Intervention|Local Infiltration Analgesia|The Local Infiltration Analgesia group will receive local infiltration of ropivacaine 150mg, ketorolac 30mg, morphine 10mg, adrenaline 200mcg and vancomycin 500mg in a total volume of 75mls by the surgeon.
89392023|NCT02104934|Active Comparator|Adductor Canal Block|The Adductor Canal Block group of patients will receive intravenous ketorolac 30mg intra-operatively and an adductor canal block at the end of surgery. The block will be performed under real time ultrasound guidance and 30mls of 0.5% ropivacaine (150mg) is injected with a Stimuplex A100, 21G needle.
88868035|NCT06023758|Experimental|KN026 combined with KN046|KN026 combined with KN046
88868036|NCT06023758|Experimental|KN026，KN046 and XELOX|KN026，KN046 and XELOX
88868037|NCT06023745||case|30 patients diagnosed as a clinical disease of CHB according to the diagnostic criteria of CHB based on, HBsAg, HBeAg serostatus ,HBV DNA level, biochemical liver function, and ultrasonography
88868038|NCT06023745||control|healthy volunteers with negativity for HBsAg, anti- HCV and anti-HIV and with no abnormalities based on physical examination
88868039|NCT06023693|Experimental|Guided online self-help intervention|The intervention will be a guided e-health intervention based on CBTi principles (i-Sleep & BioClock). It consists of 5 modules, to be completed in about 5 weeks, and is aimed at improving sleep in university students. The intervention will be entirely held online and will be supported by e-coaches. The topics covered will be sleep hygiene, psychoeducation on sleep and the biological clock, sleep restriction, stimulus control, worrying and relaxation, dysfunctional thoughts, and relapse prevention.
88868040|NCT06023693|Active Comparator|Online psychoeducation|The control group will receive access to the platform and to the sleep diary. Their intervention will consist of brief, unstructured online PE for insomnia based on recognized sleep hygiene advice, for example, recommendations about evening routines, and use of alcohol and caffeine. Students will be advised to monitor their sleep in the diary. In contrast to the intervention group, the control group will not receive support of an e-coach. Key differences to the CBTi group are that the online PE (1) does not provide individualized support by an e-coach; (2) includes less content, and (3) is not delivered in a step-by-step manner, but will be provided all at once.
88868041|NCT05814042|Experimental|Nutrient based intervention|Nutrition supplement used to stop diarrhea
89186803|NCT00921765|Active Comparator|Naloxone + Ketamine|Single bolus dose of ketamine 0.2 mg/kg bw followed by single bolus dose of ketamine 0.2 mg/kg bw
89392024|NCT05706207|Experimental|Arm 1|Treatment with 0.03 mg/kg HB0030 injection administered intravenously
89392025|NCT05706207|Experimental|Arm 2|Treatment with 0.3 mg/kg HB0030 injection administered intravenously
89392026|NCT05706207|Experimental|Arm 3|Treatment with 1 mg/kg HB0030 injection administered intravenously
89392027|NCT05706207|Experimental|Arm 4|Treatment with 3 mg/kg HB0030 injection administered intravenously
89392028|NCT05706207|Experimental|Arm 5|Treatment with 10 mg/kg HB0030 injection administered intravenously
89392029|NCT05706207|Experimental|Arm 6|Treatment with 20 mg/kg HB0030 injection administered intravenously
89392030|NCT05706207|Experimental|Arm 7|Treatment with 30 mg/kg HB0030 injection administered intravenously
89392031|NCT05706207|Experimental|Arm 8|Treatment with 40 mg/kg HB0030 injection administered intravenously
89392032|NCT02105090|Placebo Comparator|Sodium chloride 0.9%|Sodium chloride 0.9% flavoured lozenge 10 ml administered orally (gargled and swallowed by patient) 3 minutes before the upper GI endoscopy
89392033|NCT02105090|Experimental|Articaine hydrochloride 1%|Articaine hydrochloride 1% flavoured lozenge 10 ml administered orally (gargled and swallowed by patient) 3 minutes before the upper GI endoscopy
89392034|NCT02105090|Experimental|Articaine hydrochloride 2%|Articaine hydrochloride 2% flavoured lozenge 10 ml administered orally (gargled and swallowed by patient) 3 minutes before the upper GI endoscopy
89392035|NCT03627273|Experimental|walker|'6 minutes walking test' with a walker
89392036|NCT03627273|Active Comparator|no walker|'6 minutes walking test' without walker
89392037|NCT02108444||group with HBV reactivation|group with hepatitis B virus reactivation
89392038|NCT02108444||group without HBV reactivation|group without hepatitis B virus reactivation
89392039|NCT02111330|Experimental|Dose I - 80 mg PBF-509|one 80 mg PBF-509 capsule
89392040|NCT02111330|Placebo Comparator|Dose I - Placebo|one Placebo capsule
89392041|NCT02111330|Experimental|Dose II - 160 mg PBF-509|Two 80 mg PBF-509 capsule
89392042|NCT02111330|Placebo Comparator|Dose II - Placebo|Two Placebo capsule
89392043|NCT02111330|Experimental|Dose III - 240 mg PBF-509|three 80 mg PBF-509 capsule
89186804|NCT05435781|Active Comparator|RCT group - hydrocortisone|Patients with polymyalgia rheumatica/giant cell arteritis with glucocorticoid-induced adrenal insufficiency (Synacthen test response <420 nmol/l) that are randomised to receive hydrocortisone
89392044|NCT02111330|Placebo Comparator|Dose III - Placebo|Three Placebo capsule
89392045|NCT02105168|Experimental|Experimental arm|Blood sample Tumorous biopsy Healthy material sample
89392046|NCT03553628|Active Comparator|Chlorhexidine Once Daily|Chlorhexidine HCL 0.12% mouthwash to be used once daily for one week each month for six months
89392047|NCT03553628|Active Comparator|Chlorhexidine Twice Daily|Chlorhexidine HCL 0.12% mouthwash to be used twice daily for one week each month for six months
89392048|NCT03553628|Experimental|Propolis Once Daily|Chlorhexidine Gluconate 0.12% with Propolis 1% and Clove Oil 1% mouthwash to be used once daily for one week each month for six months
89392049|NCT03553628|Experimental|Propolis Twice Daily|Chlorhexidine Gluconate 0.12% with Propolis 1% and Clove Oil 1% mouthwash to be used twice daily for one week each month for six months
89392050|NCT02111486|Experimental|breakfast #1|breakfast food containing high viscosity fibre
89392051|NCT02111486|Experimental|breakfast #2|breakfast food containing low viscosity fibre
89392052|NCT02111486|Placebo Comparator|Control|breakfast food without viscous fibre
89392053|NCT02111720|Experimental|Maybe, Maybe Not|The intervention is an individual-level 4-session + 3 month booster series designed to assist persons with HIV in making decisions regarding the disclosure of their HIV serostatus to family members.
89392054|NCT02111720|Active Comparator|Comprehensive Risk Counseling and Services|Comprehensive Risk Counseling and Services (CRCS) will be used to provide the attention-placebo control (CDC, 2006). CRCS combines traditional case management and HIV risk-reduction in an individualized, client-centered program which focuses on the reduction of risk behavior and addresses a client's psychosocial and medical needs.
89392055|NCT02111876||AHRF follow-up|
89392056|NCT02111954||F-18-FCH & Ga-68-NODAGA-MJ9|1 PET/CT with F-18-FCH + 1 PET/CT with Ga-68-NODAGA-MJ9
89392057|NCT03769220||inpatient rehabilitation ward|"The first 20 participants will be recruited from the inpatient rehabilitation ward at Robert-Bosch-Hospital (RBK). The treating medical doctor will inform potentially eligible participants about the possibility of being involved in this study. Should participants confirm their interest a research assistant will complete a detailed information session and obtain written informed consent prior enrolment.~Participants in the study don't receive any interventions, just a baseline measurement (only health outcomes are assessed)."
89392058|NCT03769220||outpatient rehabilitation clinic|"Further 20 participants will be recruited through the outpatient rehabilitation clinic at Robert-Bosch-Hospital (RBK). The treating doctor will again inform the potential participant about the study and invite them to participate. A research assistant will complete a detailed information session and written informed consent will be obtained prior enrolment.~Participants in the study don't receive any interventions, just a baseline measurement (only health outcomes are assessed)."
89392059|NCT03769220||community dwelling older adults|"Lastly 20 community dwelling older adults will be invited to participate. Recruitment will occur through advertisement at a locally run seniors fitness group, conducted every Thursday at RBK. Older adults who are interested in being involved will be invited to receive additional information about the study and the involved procedures before providing written informed consent and being enrolled.~Participants in the study don't receive any interventions, just a baseline measurement (only health outcomes are assessed)."
89392060|NCT02112032|Experimental|Dose Level 1|MK-3475: 2 mg/kg every 3 weeks by intravenous infusion for up to 2 years Peginterferon alfa-2b: 1 µg/kg every week by subcutaneous injection for up to 2 years
89392061|NCT02112032|Experimental|Dose Level 2|MK-3475: 2 mg/kg every 3 weeks by intravenous infusion for up to 2 years Peginterferon alfa-2b: 2 µg/kg every week by subcutaneous injection for up to 2 years
89392062|NCT02112032|Experimental|Dose Level 3|MK-3475: 2 mg/kg every 3 weeks by intravenous infusion for up to 2 years Peginterferon alfa-2b: 3 µg/kg every week by subcutaneous injection for up to 2 years
89392063|NCT01343823|Active Comparator|ecallantide 10mg|Administered as one 3 mL SC injection containing 10 mg ecallantide and one 3 mL SC injection of matching placebo.
89392064|NCT01343823|Placebo Comparator|placebo|Administered as two SC 3 mL injections
89392065|NCT01343823|Active Comparator|ecallantide 60mg|Administered as two 3 mL SC injections, each containing 30 mg ecallantide
89392066|NCT01343823|Active Comparator|ecallantide 30mg|Administered as one 3 mL SC injection containing 30 mg ecallantide and one 3 mL SC injection of matching placebo.
89392067|NCT02108678|Experimental|ACT-ME|ACT-ME is designed to reduce behavioral avoidance and to enhance acceptance-based coping. It includes: 1) Behavioral Change Training involving a) teaching patients how to recognize ineffective patterns of behavior and habits, b) exploring and setting life goals and goals related to mental and physical health, and c) promoting effective and committed actions to achieve these goals despite the urge to do otherwise; 2) Acceptance and Mindfulness Training emphasizing new ways of managing troubling thoughts, feelings, and physical sensations; and 3) Migraine education whereby each of the educational topics listed below will be covered without detailed discussion of the topics.
89392068|NCT02108678|Experimental|Migraine Education Only|The MEO workshop will last six hours and involve educating participants about migraine, its natural course, its prodromal symptoms and triggers for symptom worsening, risk for migraine chronification, how to use abortive migraine medications, medication overuse headache, medical and psychological treatments of migraine, migraine comorbidity, and menstrual migraine. The group leaders will present one educational topic at a time and the participants will discuss and reflect about issues and experiences related to the topic. If necessary, the group leaders will raise specific discussion questions to facilitate group dialogue and participant involvement. However, information on coping practices will be omitted.
89392069|NCT02251184|Experimental|Aggrenox|extended release
89392070|NCT02251184|Active Comparator|dipyridamole+aspirin|immediate release
88868042|NCT05814042|Active Comparator|Standard of Care oral rehydration solution|Standard of care nutrition supplement used to stop diarrhea.
88868043|NCT05557877|Experimental|Prevention (low-dose aspirin)|"Patients undergo standard of care breast biopsy for assessment of abnormalities seen on imaging, as well as collection of blood during screening. If cancer is found, patient is taken off study and treatment options are discussed with treating physician.~Patients without a cancer finding on biopsy then receive low-dose aspirin PO daily and undergo collection of blood on study. Patients may undergo ultrasound guided breast biopsy as clinically indicated."
88868044|NCT05365061|Experimental|Periosteal electrical dry needling followed by no maintenance treatments|Periosteal electrical dry needling followed by no maintenance treatments
88868045|NCT05365061|Active Comparator|Periosteal electrical dry needling followed by maintenance treatments every other month|Periosteal electrical dry needling followed by maintenance treatments every other month
88868046|NCT05365061|Active Comparator|Periosteal electrical dry needling followed by monthly maintenance treatments|Periosteal electrical dry needling followed by monthly maintenance treatments
88868047|NCT05297396|Experimental|Slow Tapering of Chronic Opioid Therapy|Subjects who are on a stable dose of daily opioid therapy for at least 6 months will have their opioid medication doses slowly and gradually reduced every 4 weeks.
88868048|NCT05297396|No Intervention|Continued Opioid Therapy|Subjects who are on a stable dose of daily opioid therapy for at least 6 months will stay on the same dose of opioids they are currently using at the beginning of the study for the entire 12-month duration of the study.
88868049|NCT05092516|Experimental|Active tDCS|This group will receive daily active stimulation (2 mA) to the left dorsolateral prefrontal cortex for 4 weeks through a home-based tDCS device in remotely-supervised 30-min sessions.
88868050|NCT05092516|Sham Comparator|Sham tDCS|This group will receive daily sham stimulation to the left dorsolateral prefrontal cortex for 4 weeks through a home-based tDCS device in remotely-supervised 30-min sessions.
88868051|NCT05023291|Other|test group|All patients who give their consent for this study will participate in the test group and will therefore receive the injection with 18F-FDG and images (PET / CT) will be made of the resection piece.
88868052|NCT04831125||Individuals receiving conduction system pacing|
88868053|NCT04609735|Experimental|Experimental: Electric DN, Manual therapy, exercise and US|Dry needling, manual therapy, exercise and ultrasound
88868054|NCT04609735|Active Comparator|Active comparator: Manual therapy, exercise and ultrasound|Active comparator: Manual therapy, exercise and ultrasound
88868055|NCT04609709|Experimental|thrust manipulation, electric dry needling and exercise|thrust manipulation, electric dry needling and exercise
88868056|NCT04609709|Active Comparator|non-thrust Mobilization, Soft-Tissue Mobilization, Exercise and TENS|non-thrust mobilization, soft-tissue mobilization, exercise and TENS
88868057|NCT04035408||All subjects|All the enrolled subjects will be considered for the assessment of the primary and secondary outcomes.
88868058|NCT03968614|Experimental|Electrical Dry Needling and conventional PT|Electrical Dry Needling, Eccentric Exercise, Stretching and Manual Therapy
88868059|NCT03968614|Active Comparator|Conventional PT|Eccentric Exercise, Stretching and Manual Therapy
89392071|NCT05706051|Other|age-related hearing loss affected before hearing aid fitting|"patients aged 55 to 80 years old, undergoing posturography at diagnosis of ARHL and 3 months later before hearing aid fitting, within the role of control~same patients udergoing posturography at hearing aid fitting and 3 months after."
89392072|NCT02108756|Experimental|L-pantoprazole sodium|
88868060|NCT03695471|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 24 cycles or until complete response in the absence of disease progression or unacceptable toxicity.
88868061|NCT03167710|Experimental|dry needling, manipulation stretching|
88868062|NCT03167710|Active Comparator|manual therapy, exercise, ultrasound|
88868063|NCT02114138||Surgical Group|Adults undergoing major in hospital surgery; pathogenesis of perioperative acute kidney injury; urine collection
88868064|NCT02114138||Healthy Control|Healthy Adult volunteers who are willing to provide a 200 ml urine sample.
88868065|NCT01719718|Active Comparator|Closure|
88868066|NCT01719718|Sham Comparator|Non-Closure|
89186805|NCT05435781|Placebo Comparator|RCT group - placebo|Patients with polymyalgia rheumatica/giant cell arteritis with glucocorticoid-induced adrenal insufficiency (Synacthen test response <420 nmol/l) that are randomised to receive placebo
88868068|NCT00323674|Active Comparator|Light Weight Mesh|
88868069|NCT00323674|Active Comparator|Polysoft Mesh|
88868070|NCT05646628||Participants|Older adults (aged 65 years and over) enrolled in the BASIL+ trial randomized to receive the intervention (collaborative care focusing on behavioral activation) and confirmed as having chronic pain
88868071|NCT05645471|Experimental|Together After Cancer Intervention|Couples randomized into the intervention will participate in the program which is approximately 8-10 hours of web-based online content to be delivered over the course of 5-8 weeks. The online program can be done on a smartphone, tablet, or computer. In this program, partners complete the majority of the program on their own (to make it more flexible) and come together for 2-3 key conversations with their partner. In addition to the online content, couples will receive up to 100 minutes of scheduled research check-in/coaching calls from a research assistant to check-in. These coach calls will occur via a video chat via Zoom or, if not possible given a couple's technology limitations, over the phone. The coach calls serve several purposes: a) helping couples stay accountable to staying on the recommended schedule of activity completion; b) addressing any technical or program questions the couple has; and c) collecting research data as couples move through the program.
88868072|NCT05645471|No Intervention|Usual Care|"Participants randomized into UC, will consist of primary referral sources for breast cancer survivorship. At AdventHealth, Moffitt, and Sylvester Cancer centers, usual care consists of screening items assessing relationship/intimacy issues as a practical need. If these items are endorsed, referrals are provided to supportive oncology. At Sylvester, the Cancer Support Services offers caregiver support groups, mental well-being services (i.e., individual therapy), and an online support community for patients, caregivers, and survivors. At Moffitt, Support Services offers psychotherapy, support groups for patients, support groups for family/caregivers of cancer patients, and a program to help patients talk with their children about their diagnosis. At AdventHealth, patients are offered referrals to social services and psychoeducational programs like HEAL. However, none of the sites have services designed to focus on issues specific to patients' romantic relationships."
88868073|NCT05636059|Experimental|Exercise|32 sessions in total, 2 times a day, 30 min. one session. Exercise program consisted of: cycling stationary bike, isometric and isotonic exercise for knee flexion / extension, hip flexion / extension / abduction / adduction, exercise with resistance bands, weights, and gymnastic ball.
88868074|NCT05636059|Experimental|Exercise + cryotherapy|"Exercise program - 16 sessions in total, once a day, 30 min. one session. Cryotherapy - 8 sessions in total, two-three times a week, one session - 2 min. duration, temperature -60 to -140 C degrees.~Exercise program consisted of: cycling stationary bike, isometric and isotonic exercise for knee flexion / extension, hip flexion / extension / abduction / adduction, exercise with resistance bands, weights, and gymnastic ball."
89392073|NCT02108756|Active Comparator|Panmeilu|
89392074|NCT05596461|Experimental|Transcranial magnetic stimulation|
89392075|NCT05596461|Experimental|Transcranial direct-current stimulation|
89392076|NCT02108834|Active Comparator|nerve block|cervical plexus block with ropivacaine
89392077|NCT02108834|Placebo Comparator|Placebo|placebo saline
89392078|NCT05547399|Experimental|Low Dose Cohort|Zanubrutinib will be administered as a single low dose of treatment (tablet) or reference (capsule) on separate occasions across several treatment sequences
89392079|NCT05547399|Experimental|High Dose Cohort|Zanubrutinib will be administered as a single high dose of treatment (tablet) or reference (capsule) on separate occasions across several treatment sequences
89392080|NCT02109068|Active Comparator|In-Person Counseling|Participants randomized to in-person counseling will meet via in-person or via telephone (but at least 3 of the 11 sessions must be in person) weekly for month 1, then every other week for months 2, and 3, and then monthly for months 4-6 at Yale University. The meetings will last 30 minutes. Participants will turn in their diet and exercise logs and also be weighed. A lesson will then be discussed (see above for content).
88868075|NCT05636059|Experimental|Exercise + joint mobilization|"Exercise program - 16 sessions in total, once a day, 30 min. one session, two-three times a week.~Joint mobilization - 8 sessions in total, anterior - posterior tibia femoral glide, patella motion, lateral and medial movement.~Exercise program consisted of: cycling stationary bike, isometric and isotonic exercise for knee flexion / extension, hip flexion / extension / abduction / adduction, exercise with resistance bands, weights, and gymnastic ball."
88868076|NCT05620472|Experimental|[99mTc]Tc(CO)3-(HE)3-Ec1 1000 μg|At least five (5) evaluable subjects with solid tumor.
88868077|NCT05620472|Experimental|[99mTc]Tc(CO)3-(HE)3-Ec1 2000 μg|At least five (5) evaluable subjects with solid tumor.
88868078|NCT05620472|Experimental|[99mTc]Tc(CO)3-(HE)3-Ec1 3000 μg|At least five (5) evaluable subjects with solid tumor.
88868079|NCT05618951|Experimental|Group A: Lower Trapezius Strengthening Exercises|"Hot pack at neck area, upper trapezius stretching neck isometrics transverse mobilization glide and~Lower Trapezius strengthening exercise includes:~Latissimus pull down~Prone V- raise~Modified Prone Cobra and Standardized Physical Therapy treatment will be given as Hot pack at neck area, upper trapezius stretching, neck isometrics and transverse mobilization glide."
88868080|NCT05618951|No Intervention|Group B: Standardized Physical Therapy|"Hot pack at neck area, upper trapezius stretching neck isometrics transverse mobilization glide~Group B given Standardized Physical therapy management"
88868081|NCT05588583|Experimental|Supportive Care with Mepilex Up|All Subjects will use a soft, silicone, non-bordered, adhesive, foam dressing called Mepilex Up as the absorbent primary dressing.
88868082|NCT05581823|Experimental|Tavapadon Followed by Tavapadon + Carbamazepine|Participants will receive oral tavapadon tablets titrated up to a steady-state dose from Day 1 to Day 14. From Day 15, participants will receive oral carbamazepine tablets titrated up to a steady-state dose along with oral tavapadon tablets, up to Day 30.
88868083|NCT05553951|Experimental|Interventions group|will receive systematic and structured nursing supervison about their adherence
88868084|NCT05553951|Placebo Comparator|Control group|Will receive usual care
88868085|NCT05540704|Experimental|iACT Experimental Intervention|
88868086|NCT05540704|Active Comparator|Usual Care|
88868087|NCT05498116|Placebo Comparator|Placebo|One capsule daily
88868088|NCT05498116|Experimental|Montelukast|One 10mg capsule daily
88868089|NCT05489978|Experimental|Intervention Arm|"Randomization will allocate women to intervention and control arm in 1:1 ratio; with 6 wards in each group. The intervention arm will consist of 153 women who will receive Cervical Cancer Stigma Reduction Intervention."
88868090|NCT05489978|No Intervention|Control Arm|The control arm will consist of 153 women who would not be given any intervention.
88868091|NCT05483686|Experimental|Shine Intervention|Experimental group participants will have access to the mobile Shine intervention.
88868092|NCT05483686|Active Comparator|Control Videos|Control condition participants will be texted an embedded link to a series of videos developed by the Centers for Disease Control. These videos describe healthy HIV-related behaviors for trans women of any status (e.g., recommended testing frequencies, PrEP, ART, condoms), includes videos of trans women describing their experiences with HIV. All control participants will have access to Shine at the end of the research study (i.e., approximately six months after recruitment).
88868093|NCT05450484|Experimental|Durvalumab-680LT|
88868094|NCT05430373|Other|GT101 treatment group|Autologous tumor infiltrating lymphocyte injection
88868095|NCT05412446|Experimental|HER2-positive patients|"Maximum 15 evaluable subjects with HER2-positive status in primary tumour before chemo/targeted therapy have to be enrolled in the study.~Subjects withdrawn from the study for any reason will be replaced."
89186806|NCT05435781|No Intervention|Control group|Patients with polymyalgia rheumatica/giant cell arteritis with normal adrenal function (Synacthen test response ≥420 nmol/l)
89186807|NCT02560233|Experimental|Contingent|Contingent RT-fMRI-NF
88868096|NCT05412446|Experimental|HER2-negative patients|"Maximum 15 evaluable subjects with HER2-negative status in primary tumour before chemo/targeted therapy have to be enrolled in the study.~Subjects withdrawn from the study for any reason will be replaced."
88868097|NCT05408377|Experimental|MA group|Manual Acupuncture
88868098|NCT05408377|Placebo Comparator|SA group|Sham acupuncture
88868099|NCT05398484|Experimental|Participants receiving Study Drug|Advanced cancer participants will receive experimental medication, psilocybin (25mg). In addition to the pharmacologic intervention, participants will receive a manualized psychotherapy platform. The combination of interventions is referred to as psilocybin-assisted psychotherapy (PAP).
88868100|NCT05398484|Active Comparator|Participants receiving Placebo|Advanced cancer participants will receive active placebo - single dose of niacin (100mg). In addition to the placebo, participants will receive the same manualized psychotherapy platform as the experimental arm.
88868104|NCT05388786||Delphi Panel|A team of experts in open inguinal lymphadenectomy, video endoscopic inguinal lymphadenectomy (VEIL), and robotic-assisted video endoscopic inguinal lymphadenectomy (R-VEIL) in the fields of General Surgery, Gynecology Oncology, Surgical Oncology, and Urology will be invited to participate. These experts are identified according to surgical experience, research, and academic interest.
88868105|NCT05387733|Experimental|CBL-514 Group 1|Eligible participants will be enrolled and randomized into one of 2 dose groups. Group 1 with 10 mg CBL-514 per injection.
88868106|NCT05387733|Experimental|CBL-514 Group 2|Eligible participants will be enrolled and randomized to one of 2 dose groups. Group 2 with 15 mg CBL-514 per injection.
88868107|NCT05386615||Exablate|Observational study of Exablate treatment.
88868108|NCT05374655|Experimental|Preoperative blood glucose control|Under the guidance of endocrinologists, the patient's hypoglycemic strategy is formulated, follow-up guidance is guided by the patient to take the drug, the HbA1c level is reviewed after 6 weeks, the preoperative HbA1c < 7.5% is performed surgically, and if it is still above the standard, the hypoglycemic therapy is continued, during which the patient is administered according to the corresponding heart disease type.
88868109|NCT05374655|No Intervention|Preoperative blood glucose uncontrol|Patients included in this group ≥ 7.5% preoperative HbA1c and underwent surgery directly
88868110|NCT05372757|Experimental|Partial Heart Transplantation Arm|
88868111|NCT05366699|Experimental|Group A|Group A will under axillary lymphadenectomy alone
88868112|NCT05366699|Active Comparator|Group B|Group B will undergo axillary lymphadenectomy with immediate lymphatic reconstruction (LYMPHA) using reverse mapping using the SPY System.
88868113|NCT05336084|Experimental|Ultradian Sleep/Wake protocol|This study uses an ultradian sleep/wake protocol to examine circadian and homeostatic sleep systems and their contributions to reward and cognitive control function. All participants will undergo the ultradian sleep/wake protocol following a night of sleep in the lab (measured with polysomnography) for 36 hours. The ultradian sleep/wake protocol will last for 36 h, during which every 120-minutes, there will be an 80-minute period of waking, followed by a 40-minute sleep opportunity. A repeat night of sleep will occur at the end of the 36-hour ultradian sleep/wake protocol.
88868114|NCT05334979|Other|Kidney stone formers|12 stone-forming subjects will be enrolled in this arm.
88868115|NCT05334979|Other|Non-kidney stone formers|12 non-stone-forming subjects will be enrolled in this arm.
88868116|NCT05317026|Experimental|V-SBRT|Vertebroplasty followed by Stereotactic Body Radiation Therapy (SBRT)
88868117|NCT05317026|Other|SBRT|SBRT is the actual standard of care.
88868118|NCT05292755|Experimental|Carboxymethylcellulose (CMC) Artificial Tears|Refresh brand artificial tears containing 0.5% carboxymethylcellulose will be self-administered three times a day in each eye by the participants for 1 week in the experimental arm.
88868119|NCT05292755|Placebo Comparator|Preservative-free, CMC-free Artificial Tears|Systane brand artificial tears containing 0.4% polyethylene glycol 400 and 0.3% propylene glycol will be self-administered three times a day in each eye by the participants for 1 week in the control arm.
88868120|NCT05289752|Active Comparator|Group I|GroupI: The retentive caps will be picked up by the indirect method on the cast first, then by the direct method.
88868121|NCT05289752|Active Comparator|Group II|GroupII: The retentive caps will be picked up by the direct method on the cast first, then by the indirect method.
88868122|NCT05283395|Other|Netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%|
89186808|NCT02560233|Sham Comparator|Non-contingent|Sham RT-fMRI-NF
89186809|NCT05435625|Active Comparator|FCO2|Fractional Carbon dioxide laser
89186810|NCT05435625|Active Comparator|FRF|Fractional Microneedling Radiofrequency
89186811|NCT05435391||Group 1|Patients with chest pain or who are clinically suspected as acute myocardial infarction with equivalent symptoms.
89186812|NCT00755157|Experimental|1|Docetaxel(metronomic)/Bevacizumab
88868123|NCT05277532|Active Comparator|Type 1 diabetes with overweight|High intensity interval training (HIIT), a single bout, randomly performed either in the morning or in the afternoon in a cross-over design.
88868124|NCT05277532|Active Comparator|Overweight but otherwise healthy control subjects|High intensity interval training (HIIT), a single bout, randomly performed either in the morning or in the afternoon in a cross-over design.
88868125|NCT05270863|Experimental|BRIMOCHOL™ PF|A single drop in each eye at a visit.
89186813|NCT00919880|Experimental|Experimental|
89186814|NCT00919880|Active Comparator|Active Comparator|
89186815|NCT02560077|Placebo Comparator|placebo|The placebo and cashew apple fruit juice had the same color and smell
89186816|NCT02560077|Active Comparator|cashew apple juice 120 mg/day|The subjects who were assigned as the low dose treatment group received cashew apple fruit juice extract at dose of 120 mg/day
89186817|NCT02560077|Active Comparator|cashew apple juice 240 mg/day|The subjects who were assigned as the high dose treatment group received cashew apple fruit juice extract at dose of 240 mg/day
89392081|NCT02109068|Active Comparator|Telephone-based Counseling|The exact same information, content, schedule, and 30 minute sessions will be provided to telephone-based participants as offered to participants who receive in-person counseling. Participants will be taught diet, exercise and behavior change strategies via the telephone (weekly calls for month 1, every other week for months 2-3, and monthly for months 4-6). All lessons and diet and physical activity logs will be mailed to them at the beginning of the program. Participants will record their daily diet and exercise in the logs. Every four weeks, participants will return, via stamped, addressed envelopes, the logs to the study office.
89392082|NCT02109068|No Intervention|Usual Care|Immediately after randomization, participants in the Usual Care Group will be provided written information that emphasizes the importance of a healthy lifestyle. Usual care participants will be encouraged to follow the American Cancer Society (ACS) nutrition and physical activity guidelines. Upon completion of the study (at 6 months), usual care participants will be offered all the educational material, as well as an in-person or telephone counseling session.
89392083|NCT02109146|Experimental|TACE|Patients after surgery receive Transcatheter Arterial Chemoembolization (TACE)
89392084|NCT02109146|Active Comparator|Control|Patients after surgery do not receive TACE
89392085|NCT03553862|No Intervention|Control|Patients randomly assigned to the control arm will receive the usual or conventional care not interfered by the study team.
89392086|NCT03553862|Experimental|Intervention|The intervention arm will receive collaborative care from a team of healthcare professionals that consists of pharmacist, physicians, nurses and dietitians. Patients in the intervention group will also receive clinical interventions carried out by the pharmacist.
89392087|NCT01318083|Active Comparator|Alogliptin 12.5 mg QD and Glimepiride QD or BID|
89392088|NCT01318083|Active Comparator|Alogliptin 25 mg QD and Glimepiride QD or BID|
89392089|NCT01318083|Active Comparator|Glimepiride 1, 2, 3 or 4 mg QD or BID|
89392090|NCT02109224|Experimental|Treatment (ibrutinib)|Patients receive ibrutinib PO QD on days 1-28. Courses repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
89392091|NCT03554876|Active Comparator|Multi-Im Machined|Multi-Im Machined
89392092|NCT03554876|Experimental|Multi-Im® nanogolden|Multi-Im® nanogolden
89392093|NCT03554876|Experimental|Multi-Im T-Golden|Multi-Im T-Golden
88868126|NCT05270863|Active Comparator|Carbachol PF|A single drop in each eye at a visit.
88868127|NCT05270863|Active Comparator|Brimonidine tartrate|A single drop in each eye at a visit.
89392094|NCT05705895|Experimental|Intervention Group|Catheter care is provided in line with the CVC care protocol developed by the researcher.
89392095|NCT05705895|No Intervention|Control Group|No intervention will be made to the patients in the control group, and catheter care will be provided in line with the clinical routine.
89392096|NCT05192187|Experimental|LBP|This group will be asked to complete self-reported questionnaires on a single occasion (cross-sectional)
89392097|NCT02105402|Experimental|Intervention Group - PROMPT therapy|Prompts for Restructuring Oral Muscular Phonetic Targets (PROMPT)
89392098|NCT02105402|No Intervention|Waitlist or Delay Group|Participants in this group are on the waitlist for 10 weeks
89392099|NCT02112110|Experimental|BMS-791325 (oral) and [13C]-BMS-791325 (IV)|BMS-791325 single dose tablet orally and [13C]-BMS-791325 single dose solution intravenously on specific days
89392100|NCT05540067|Experimental|Acceptance-Based Behavior Therapy (ABBT)|The 2-session ABBT will be delivered remotely or in-person, depending on preference.
88868128|NCT05269511|Experimental|Treatment group|Chinese Herbal Medicine
88868129|NCT05269511|No Intervention|Control group|usual care
88868130|NCT05264857|Experimental|Thyroid nodule information|
88868131|NCT05251298|Active Comparator|Intervention group|Patients in the intervention group come from the same region (Münsterland) and will undergo therapies coordinated through the online platform.
88868132|NCT05251298|No Intervention|Control group|Patients in the control group will undergo their usual therapies as prescribed by their neurologists.
88868133|NCT05237219|Experimental|Passive heating|Patients will be randomized to receive whole-body passive heating via 38°C natural thermal mineral water baths.
88868134|NCT05237219|Active Comparator|Thermoneutral|Patients randomized to the comparator group will dip in thermoneutral natural thermal mineral water (30-32°C).
88868135|NCT05237141|Experimental|Main cohort|Insertion of etonogestrel contraceptive implant prior to LH surge
88868136|NCT05232409|Experimental|Zeaxanthin Monotherapy|Zeaxanthin administered orally on daily basis.
88868137|NCT05232409|Experimental|Zeaxanthin plus Pembrolizumab|Zeaxanthin administered orally on daily basis in addition to intravenous pembrolizumab infused every 42 days at fixed dose of 400 mg.
88868138|NCT05226078|Experimental|Four Sessions of CBT-I|
88868139|NCT05226078|Experimental|Eight Sessions of CBT-I|
88868140|NCT05226078|Experimental|Ten Sessions of CBT-I|
89392101|NCT05540067|Other|Treatment-as-Usual (TAU)|Control participants will receive the currently recommended best practices of care at the recruitment site.
89392102|NCT02112266|Other|no mail support|no mail support during follow-up
89392103|NCT02112266|Other|mail support|
89535385|NCT03119779|Experimental|TheraCal vital pulp therapy|Using rubber dam isolation we will remove the caries using large round but under copious amount of coolant and if carious exposure occur, part of the pulp chamber will be removed using sharp spoon excavator. After complete removal of the caries and control of bleeding, then direct application of incremental layers of TheraCal using the tip of the syringe container of the material and each layer should not exceed 1 mm then light curing each increment. Then Riva self-cure glass-ionomer base and composite resin final restoration. We will take immediate standardized postoperative periapical radiographs.
88868141|NCT05226078|Experimental|Twelve Sessions of CBT-I|
88868142|NCT05218369||Critically ill COVID-19 patients|Patients in ICU due to critical COVID-19 infection, who receive early (within the first 24 hours, but no later than 48 hours after intubation) IL-6 antagonist therapy at the consultant's discretion.
88868143|NCT05213741|Experimental|Magnetic-assisted colonoscopy group|Participants in this group will recieve magnetic-assisted colonoscopic examination
88868144|NCT05201989||Atrial fibrillation|Subjects with symptomatic paroxysmal atrial fibrillation scheduled for AF ablation at Örebro University hospital
88868145|NCT05201989||Control|Sex and age-matched subjects without AF
88868146|NCT05137015|Experimental|Intervention|The intervention group will use the new injury prevention program at least twice per week in their training sessions.
88868147|NCT05137015|No Intervention|Control|The control group will continue their usual training routine.
88868148|NCT05130398|Experimental|the rVSVΔG-ZEBOV-GP vaccine|Participants of the experimental arm will receive a single intramuscular dose of ≥7.8 x 107 pfu of the rVSVΔG-ZEBOV-GP vaccine. In total, 80 participants will receive the experimental vaccine: 40 participants aged 6-12 years and 40 aged 1-5 years.
89535386|NCT03119779|Active Comparator|MTA vital pulp therapy|Using rubber dam isolation we will remove the caries using large round but under copious amount of coolant and if carious exposure occur, part of the pulp chamber will be removed using sharp spoon excavator. After complete removal of the caries and control of bleeding, then direct application of freshly mixed MTA-Anglus on sterile glass slap. MTA application then gentle condensation over wet cotton till MTA thickness is about 2-3 mm thickness and removal of excess material from walls of pulp chamber. Application of wet cotton for 15 min. to achieve initial setting of MTA. Then Riva self-cure glass-ionomer base and composite resin final restoration. We will take immediate standardized postoperative periapical radiographs.
89535387|NCT03319199|Active Comparator|Primary treatment Arm|"patients with a diagnosis of NAFDL will be randomly receive trial product SLIM WATER that contains L-CARNITINE and MAGNESIUM for a duration of 16 weeks."
88868149|NCT05130398|Active Comparator|The Chikenpox or Varicella (Varilix) vaccine|The control arm consists of the chickenpox vaccine. Forty children will receive a single subcutaneous dose of Varilix, the active comparator vaccine, 20 aged 6-12 years and 20 aged 1-5 years
88868150|NCT05130398|Experimental|Fibre and equilibrate diet|Participants were assigned to receive two meals daily ( breakfast and lunch) for 21 days. About 30 children are randomly assigned to fibre and equilibrate diet.
88868151|NCT05130398|Experimental|Active detection and treatment of pathogens according to standard of care|The following pathogens: P. falciparum, Ascaris lumbricoides, Trichuris trichiura, Necator americanus, intestinal protozoa, BG+, BG- colonies and pathogens, SARS-CoV2 are actively detected and treated according to the standard of care every month. About 30 children are randomly assigned to this arm.
88868152|NCT05130398|Experimental|Diet plus Active detection and treatment of pathogens according to standard of care|Participants were assigned to receive two meals daily ( breakfast and lunch) for 21 days and concomitantly assigned to active detection of P. falciparum, Ascaris lumbricoides, Trichuris trichiura, Necator americanus, intestinal protozoa, BG+, BG- colonies and pathogens, SARS-CoV2 every month. About 30 children are assigned to receive combined interventions
88868153|NCT05130398|Placebo Comparator|No diet and no pathogen detection|About 30 children received no diet and no active detection of pathogens
88868154|NCT05107336|Experimental|Cohort 1: AZD2693|Japanese Participants will receive Dose A of AZD2693.
88868155|NCT05107336|Experimental|Cohort 2: AZD2693|Japanese Participants will receive Dose B of AZD2693.
88868156|NCT05107336|Experimental|Cohort 3: AZD2693|Japanese Participants will receive Dose C of AZD2693.
88868157|NCT05107336|Experimental|Cohort 4: AZD2693|Non-Asian Participants will receive Dose C of AZD2693
88868158|NCT05107336|Placebo Comparator|Placebo|Japanese and Non-Asian Participants will receive placebo matching Dose A, B, and C to AZD2693.
88868159|NCT05097274||BRCA mutation carriers|"Newly diagnosed with prostate cancer (any Gleason score, any stage, any PSA)~Biochemically progressing patients who were treated radically with surgery or radiotherapy (more than 6 months ago) and are currently not receiving hormonal treatment or chemotherapy~Patients on active surveillance, with a PSA doubling time of 6 months or less"
88868160|NCT05036785|Active Comparator|Suture removal at 7 days|Suture removal at 7 days post skin surgery
88868161|NCT05036785|Active Comparator|Suture removal at 10 days|Suture removal at 10 days post skin surgery
88868162|NCT05014087|Experimental|Arm A: Digoxin|In the digoxin arm, the intervention to be administered will be intravenous digoxin dosed by weight and by renal function using an adaption of the established FDA nomogram. Participants randomized to digoxin will receive an intravenous digoxin loading dose administered in 3 doses over 24 hours starting on Day 1. Digoxin levels will be monitored daily throughout the participant's hospital stay, to a maximum of 28 days. Digoxin will be discontinued at the time discharge if before 28 days.
88868163|NCT05014087|No Intervention|Arm B: No Digoxin|In the no digoxin arm, no study drug or placebo will be administered.
88868164|NCT05007093|Experimental|Anlotinib hydrochloride|12 mg, 2 weeks on/ 1 week off, 21 days per cycle; treatment interruption or reduction (to 10 mg or 8 mg) was allowed
88868165|NCT05005793|Experimental|Sodium bicarbonate|Oral sodium bicarbonate at a dose of 0.5 mEq/kg-lean body weight/day
88868166|NCT05005793|Placebo Comparator|Placebo|Oral placebo at a dose of 0.5 mEq/kg-lean body weight/day
88868167|NCT04982640|Experimental|Yoga|12-week program, 60 minutes, twice weekly group-delivered Iyengar yoga
88868168|NCT04982640|Active Comparator|Standard Exercise|12-week, 60 minutes, twice weekly group-delivered aerobic exercise (e.g., walking) program
88868169|NCT04970134||Thyroid carcinoma|"Advanced and / or metastatic thyroid carcinoma with initial histological diagnosis date before January 1, 2021 of the types:~Differentiated thyroid carcinoma (DTC) refractory to radio-iodine, including papillary carcinomas, follicular carcinomas, poorly differentiated carcinomas of the thyroid and the different corresponding variants.~Medullary thyroid carcinoma (MTC)."
88868170|NCT04966351|Experimental|Circadian misalignment (Condition A)|Participants will eat meals during the biological nighttime while remaining awake to mimic overnight work shifts.
88868171|NCT04966351|Experimental|Circadian misalignment with time-restricted feeding (Condition B)|Participants will fast during the biological nighttime while remaining awake to mimic overnight work shifts.
88868172|NCT04955678|Experimental|ZG-801|
89535388|NCT03319199|Placebo Comparator|Placebo Arm|"patients with a diagnosis of NAFDL will be randomly receive placebo for the initial 8 weeks and continue another 8 weeks with the trial product SLIM WATER."
89535389|NCT03221881|Experimental|Pegylated Liposomal Doxorubicin and docetaxel|Pegylated Liposomal Doxorubicin 30-35 mg/m (2) and docetaxel 75-80 mg/m(2) were both administered on day 1,intravenous, Cycles were repeated in 3-week intervals,for 6 cycles.
89186818|NCT00755391|Placebo Comparator|supportive psychotherapy|supportive psychotherapy: 14 sessions
89186819|NCT00755391|Active Comparator|cognitive behavior therapy|cognitive behavior therapy: 14 sessions
89392107|NCT02109380|Experimental|Bed rest|One week of bed rest.
89186820|NCT04082858|Experimental|Ketamine|Participants will receive twice-weekly infusions of ketamine at 0.05mg/kg for the duration of treatment with ECT. All infusions will be administered by a Consultant Anaesthetist.
89186821|NCT04082858|Active Comparator|Midazolam|Participants will receive twice-weekly infusions of midazolam at 0.045mg/kg for the duration of treatment with ECT. All infusions will be administered by a Consultant Anaesthetist.
89186822|NCT05198817|Experimental|Single Group|
89186823|NCT02587286|Experimental|Gather app|Use of the Gather mHealth diabetes management system
89186824|NCT02587286|No Intervention|Control|Control group participants will be recruited from the same clinics and will also fit all study inclusion and exclusion criteria. Participants will be recommended to test their BG as per usual care in India. Providers will not contact control group participants between regular visits, though they will respond to queries directed at them in typical fashion.
89392108|NCT02109536||Staff Gastroenterologists.|Staff Gastroenterologists ability to recognize loops will be assessed using an magnetic endoscopic imager.
89392109|NCT02105792||Responders|Patients with Type 2 diabetes about to commence a second- or third-line glucose-lowering treatment (Sulphonylurea, DPP-4 inhibitors, GLP-1R agonists, SGLT2 inhibitors or Glitazone or insulin).
89392110|NCT02105792||Progressors|Patients with Type 2 diabetes that progress to requiring insulin treatment ≤10 years from diagnosis or have no requirement for insulin treatment >10 years from diagnosis.
89392111|NCT02112344|Experimental|Total mucosal irradiation|
89392112|NCT02105870|Experimental|Intracoronary abciximab (Reopro)|Intracoronary abciximab (Reopro)
89392113|NCT02105870|Placebo Comparator|Control group|Intracoronary Reopro
89392114|NCT02112422|Active Comparator|Control|Patients in the intervention group will receive 0.15 mg/kg of intravenous dexamethasone (maximum dose 20mg) in 100ml normal saline 45-60 minutes prior to the OR. The control group will receive 0.15 mg/kg of intravenous dexamethasone (maximum dose 20mg) in 100ml normal saline immediately prior to skin incision.
89392115|NCT02112422|Experimental|Intervention|Patients in the intervention group will receive 0.15 mg/kg of intravenous dexamethasone (maximum dose 20mg) in 100ml normal saline 45-60 minutes prior to the OR. The control group will receive 0.15 mg/kg of intravenous dexamethasone (maximum dose 20mg) in 100ml normal saline immediately prior to skin incision.
89392116|NCT02251340|Experimental|Intervention|Families in the intervention group will receive an Eczema Care Plan
89392117|NCT02251340|No Intervention|Control|Families in the control group will not receive an Eczema Care Plan
89392118|NCT05646147|Other|Diagnostic Cohort Study|All patients will underwent full diagnostic testing.
89186825|NCT00919022||Group 1|
89186826|NCT04082156|Active Comparator|Active TENS|
89186827|NCT04082156|Sham Comparator|Sham TENS|
89186828|NCT02588222||Healthy children|Healthy children, aged 6-18 years old.
89392119|NCT02109692|Other|cohort|blood sample : doage of miRNA
89392120|NCT02106026|No Intervention|Conventional|All expectant mothers received the usual information about the advantages of maternal milk during pre-natal period. Nurses provided the information in personalized dialogue with the women during obstetric consultations.
89392121|NCT02106026|Experimental|Preventive education|It was provided by the nurses during obstetric consultation in pre-natal period and averaged 30 minutes in duration. The intervention group received education to facilitate successful breastfeeding and symptom management as nipple pain. This was supported by strategies designed to (1) prevent problems associated with breastfeeding (nipple lesions, cracks and mastitis), (2) perform breast-care procedures, (3) strengthen information about the advantages of maternal breastfeeding (nutritional support, importance as food for the baby, availability, post-partum recovery) and (4) provide asepsis and hygiene measures. The nurses encouraged participation and gave the education in personalized dialogue with the woman. The information was reinforced with an illustrated explanatory leaflet.
89392122|NCT02109770||Mother child diads or triads|Families with child affected by genetic anomaly, microdeletion, microduplication, or chromosomal anomaly
89392123|NCT05159115|Active Comparator|Low-FODMAP diet|Patients with IBS on a 4-week low-FODMAP diet.
89392124|NCT05159115|Experimental|Starch- and Sucrose Reduced Diet|Patients with IBS on a s 4-week Starch- and Sucrose Reduced Diet (SSRD).
89392125|NCT02109848||keratoconus|
89392126|NCT02109848||post-keratoplasty|
89535390|NCT03091257|Experimental|Dabrafenib|"Determine if mutation in BRAF, KRAS, NRAS~BRAF V600 mutated~Treat cohort with Dabrafenib~Analysis~Treat cohort with Dabrafenib"
88868173|NCT04955678|Placebo Comparator|Placebo|
88868174|NCT05175547|Active Comparator|Intensive blood pressure management group|Target blood pressure of 90-120mmHg (Intensive BP management group)
89186829|NCT05191953|Active Comparator|Group ESPB|A bilateral ESPB (40 ml, %0.25 bupivacaine, totally) + IV morphine-PCA
89186830|NCT05191953|Active Comparator|Group ESPB+Superficial PIPB|A bilateral ESPB (40 ml, %0.25 bupivacaine, totally) and a bilateral superficial PIPB (20 ml, %0.25 bupivacaine, totally) + IV morphine-PCA
89186831|NCT02588066|Experimental|Index test|Ligamentum teres/falciform-plasty around the gastroduodenal artery stump during pancreatoduodenectomy
89186832|NCT02588066|No Intervention|Reference test|No Ligamentum teres/falciform-plasty around the gastroduodenal artery stump during pancreatoduodenectomy
89186833|NCT05141955|Active Comparator|Group Erector Spinae Plane Block (ESPB)|
89186834|NCT05141955|Active Comparator|Group Quadratus Lumborum Block (QLB)|
89186835|NCT05141955|Other|Group (C) (Control group)|
89392127|NCT02109848||post-DSAEK|Descemet's stripping automated endothelial keratoplasty (DSAEK)
89392128|NCT02251418|Experimental|Extracorporeal shockwave therapy|6 times extracorporeal shockwave therapy in 3 weeks. This arm also receives standard care treatment.
89392129|NCT02251418|No Intervention|Control|Standard care treatment
89392130|NCT02112500|Experimental|Mesenchymal Stem Cell Infusion|Mesenchymal stem cells cultured and extracted from bone marrow of enrolled patients are infused.
89392131|NCT05644899||SMA patients|51 adults with a genetically confirmed diagnosis of SMA (13 SMA type 2, 38 SMA type 3) treated with nusinersen. The technique used was based on the anesthesiologist's preference.
89392132|NCT02106104|Experimental|Linagliptin 5 mg QD (N=24)|Linagliptin 5 mg will be taken orally, once daily for 8 weeks
89392133|NCT02106104|Active Comparator|Glimepiride 1 mg QD (N=24)|Glimepiride 1 mg will be taken orally, once daily for 8 weeks
89392134|NCT02113670|Experimental|SUI 1|Patients will perform urodynamic study before and after instillation of 50 ml of air
89392135|NCT02109926||Cases: testicular cancer patients|
89392136|NCT02109926||Group A controls|Sperm donors and husbands of women with fertility disorders All controls must have a normal spermogram
89392137|NCT02109926||Group B controls|Husbands of women with a pathological pregnancy
89392138|NCT02113748|Experimental|Downhill walking training|Exercise training including treadmill walking with a negative inclination.
89186836|NCT02559531|Experimental|Intervention group|EMS providers will evaluate computerized clinical scenarios using a mobile triage device
88868175|NCT05175547|Active Comparator|Standard blood pressure management group|Target blood pressure of 90-160mmHg (Standard BP management group)
89392139|NCT02113748|Active Comparator|Conventional walking training|Exercise training including treadmill walking without inclination. Possible to progress training intensity with positive inclinations.
89392140|NCT05703867|Experimental|Active microcurrent therapy|
89186837|NCT05122221|Experimental|CRTE7A2-01 TCR-T cell therapy|Patients will undergo lymphocytapheresis, then treatment with TCR-T cell (at escalating doses) + IL-2
89186838|NCT05119647|Other|Patient Recruited|Since this is a single-arm objective performance criteria trial, patients with acute stoke caused by artery occlusion shall not be divided into two groups.
89392141|NCT02113826|Experimental|Pazopanib|Pazopanib 800mg po qd until disease progression
89392142|NCT02118974|Experimental|Robot-assisted|Robot-assisted hysterectomy
89392143|NCT02118974|Experimental|Laparoscopic Hysterectomy|Laparoscopic Hysterectomy
89392144|NCT02112656|Experimental|ThermoDox 50 mg/m2|ThermoDox plus standardized RFA using standardized treatment dwell time for solitary HCC lesions ≥ 3.0 cm to ≤ 7.0 cm
89392145|NCT02112656|Placebo Comparator|Dummy infusion|standardized RFA alone using standardized treatment dwell time for solitary HCC lesions ≥ 3.0 cm to ≤ 7.0 cm
89392146|NCT01376323|Experimental|GSK256073 1mg bid|GSK256073 1mg capsule taken orally twice a day
89392147|NCT01376323|Experimental|GSK256073 2mg qd|GSK256073 2 x 1mg capsule taken orally once a day
89392148|NCT01376323|Experimental|GSK256073 5mg bid|GSK256073 5mg capsule taken orally twice a day
89392149|NCT01376323|Experimental|GSK256073 10mg qd|GSK256073 2 x 5mg capsule taken orally once a day
89392150|NCT01376323|Experimental|GSK256073 10mg bid|GSK256073 10mg capsule taken orally twice a day
89392151|NCT01376323|Experimental|GSK256073 20mg qd|GSK256073 2x 10mg capsule taken orally once a day
89392152|NCT01376323|Experimental|GSK256073 25mg bid|GSK256073 25mg capsule taken orally twice a day
89392153|NCT01376323|Experimental|GSK256073 50mg qd|GSK256073 2x 25mg capsule taken orally once a day
88868178|NCT04924166|Placebo Comparator|Placebo|matching capsule PO
88868179|NCT04924166|Active Comparator|HCORT|180 mg capsule PO
88868180|NCT04921787|Active Comparator|Low Intensity|MOUD training and support through the use of educational materials.
88868181|NCT04921787|Experimental|High Intensity|MOUD training and support through the use of educational materials in addition to practice facilitation.
88868182|NCT04919681|Experimental|Stretching|Static stretching of the knee flexors
89003662|NCT04853017|Experimental|ELI-002 2P Cohort 3|ELI-002 2P Amph-CpG-7909 (2.5 mg) admixed with Amph modified KRAS peptides (Amph-G12D and Amph-G12R) administered via SC injection weekly for 4 consecutive weeks, followed by bi-weekly injections over 4 weeks, during the Immunization period; additional SC injections weekly for 4 consecutive weeks during the Booster Period (the two periods are separated by 3 months of no dosing)
89392154|NCT01376323|Placebo Comparator|Placebo|Matching placebo capsules taken orally either once a day or twice a day
89392155|NCT01376323|Active Comparator|Sitagliptin 100mg qd|Commercially available Sitagliptin 100mg capsules taken once a day
89392156|NCT02113904|Experimental|Adalimumab|
89392157|NCT05703633|Experimental|uDCD arm|Patients enroled in the study will receive a kidney from a uDCD donor, after the kidney has been subjected to a reconditioning procedure, preventing ischemia/reperfusion-injury, confirming large animal data using the same protocol.
89392158|NCT02119052|Experimental|OCTEOTRIDE|octeotride 20 mg, intramuscular injection monthly for 3 years
89392159|NCT02119052|Placebo Comparator|Placebo|Placebo (saline soluction), intramuscular injection monthly for 3 years
89392160|NCT02119130|No Intervention|TST only|Tuberculin skin test for all eligible patients, to be placed and read by clinic staff. Thereafter, for 2 years, annual TST provided for patients with TST negative/unknown history. IPT to be provided to patients with a positive TST for whom active TB has been ruled out.
89392161|NCT02119130|Experimental|QGIT|QGIT for all eligible patients, to be done at routine CD4 blood draw. Thereafter, for 2 years, annual QGIT at CD4 blood draw for patients with QGIT negative/unknown history. IPT to be provided to patients with a positive QGIT for whom active TB has been ruled out.
89392162|NCT05459805|Experimental|group 1|those receive ICS/LABA plus traditional Chinese medicine
89392163|NCT05459805|Active Comparator|group 2|those receive ICS/LABA alone
89392164|NCT02119208|Experimental|Lifestyle counseling|
89392165|NCT04909957||Absence of invaded lymph node after extensive lymph node dissection|Absence of invaded lymph node after extensive lymph node dissection
89392166|NCT04909957||Presence of invaded lymph node after extensive lymph node dissection|Presence of invaded lymph node after extensive lymph node dissection
88868183|NCT04908371|Active Comparator|Selective Trunk Block (SeTB)|Patients will lie flat on their back on the examination couch with the arm in neutral position and the head turned slightly to the opposite side. Ultrasound scan will be performed sequentially starting from the base of the neck (supraclavicular fossa) to the upper part of the interscalene groove and then in the reverse direction to the supraclavicular fossa. After identifying the three trunks of the brachial plexus, ultrasound guided selective trunk block will be done using local anesthetic agents (a mixture of 2% lidocaine with 1:200,000 epinephrine and 0.5% levobupivacaine in a total of 20ml) will be injected at the superior, middle, and inferior trunks of the brachial plexus in order to anesthetize the whole upper limb.
88868184|NCT04908371|Active Comparator|Interscalene-Supraclavicular Brachial Plexus Block (IS-SC-BPB)|Patients will lie flat on their back on the examination couch with the arm in neutral position and the head turned slightly to the opposite side. Ultrasound scan will be performed sequentially starting from the base of the neck (supraclavicular fossa) to the upper part of the interscalene groove. The unique sonomorphology of the C7 transverse process will be used as the key anatomical landmark to identify the individual elements of the brachial plexus. Under ultrasound guidance, local anesthetic agents (a mixture of 2% lidocaine with 1:200,000 epinephrine and 0.5% levobupivacaine in a total of 30ml) will be injected at the interscalene groove and at the supraclavicular fossa in order to anesthetize the whole upper limb.
89392167|NCT02113982|Experimental|Relapse/Refractory Acute Myeloid Leukemia|Intervention: SL-401
89392168|NCT02113982|Experimental|Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)|Intervention: SL-401
89392169|NCT02112812|Experimental|Eradication therapy|The patients who were positive for H.pylori infection are entered into an eradication therapy protocol which includes oral esomeprazole 40mg daily, oral clarithromycin 500mg bd and oral amoxicillin 1000mg bd for 14 days.
89392170|NCT05432115|Experimental|Tid group|Tid group: Amoxicillin 1000mg bid+ Tetracycline 500mg tid+ Bismuth + Esomeprazole 40mg bid
88868185|NCT04893551|Experimental|Tilvestamab|Participants will receive tilvestamab at a low starting dose level (Cohort A) given via intravenous (IV) infusion every 2 weeks. Dose escalations to subsequent cohorts (Cohort B and Cohort C) will be decided by the Protocol Steering Committee (PSC) after review of all Cycle 1 (28 days cycle) safety and pharmacokinetics (PK) data up to Cycle 1 Day 22 for all participants in the ongoing cohort.
88868186|NCT04893512|Experimental|Orally administered CoV2-OGEN1- 2 dose schedule|50mcg,100mcg and 200mcg will be tested as single oral dose on day 1 and day 15. The dose will be in the form of oral suspension.
88868187|NCT04863313|Experimental|Group receiving the probiotic capsules|Experimental group will consume one probiotic capsule every day during 12 weeks at breakfast.
88868188|NCT04863313|Placebo Comparator|Group receiving the placebo capsules|Placebo group will consume one placebo capsule every day during 12 weeks at breakfast.
88868189|NCT04838379|Placebo Comparator|group Bupivacaine|will include 30 patients: each one will receive 2.5 mg/kg of 0.25% bupivacaine diluted in a 20 mL syringe of normal saline, 10 minutes before skin incision
88868190|NCT04838379|Active Comparator|group bupivacaine&dex|will include 30 patients: each one will receive 2.5mg/kg of 0.25% bupivacaine plus 1 µ/kg of dexmedetomidine diluted in a 20 mL syringe of normal saline, 10 minutes before skin incision
89186839|NCT02559453|Active Comparator|2 operations|Subjects in this arm will receive a maximum of two surgical debridements of their wound.
89392171|NCT05432115|Active Comparator|Qid group|Qid group: Amoxicillin 1000mg bid+ Tetracycline 500mg qid+ Bismuth + Esomeprazole 40mg bid
89392172|NCT02114528|Active Comparator|Anti-arrhythmic drug therapy|Oral and/or intravenous loading doses of Sotalol, mexiletine, procainamide or amiodarone as first line therapy. Drug chosen is preference of the treating physician. May use single or combination of AAD. Loading doses as per standard dosing guidelines for VT. Subjects on amiodarone should receive oral maintenance dose of at least 200 mg/day.
89392173|NCT02114528|Active Comparator|Catheter ablation|Ventricular tachycardia (VT) Catheter ablation, using a standardized VT ablation procedure protocol.
89392174|NCT04975321|Active Comparator|Nu Smile Zirconia crown|Anterior primary teeth which received a NuSmile zirconia crown as a final restoration
89392175|NCT04975321|Active Comparator|Nu Smile pre veneered crown|Anterior primary teeth which received a NuSmile pre veneered crown as a final restoration
89392176|NCT04975321|Active Comparator|Composite strip crown|Anterior primary teeth which received a composite strip crown as a final restoration
89392177|NCT02112890||Study Group|A random sample of subjects constituting adolescents and young adults (≥10 - ≤25 years of age) that participated in the ENSANUT 2012 in Mexico.
89392178|NCT05410587|Other|Fracture Monitor T1 (implantable device class III)|
89392179|NCT02112968|Experimental|Proscan|Ametropia Lasik treatment of virgin eyes.
89392180|NCT02112968|Experimental|Zyoptix|Wavefront based ametropia Lasik treatment of virgin eyes.
89392181|NCT02112968|Experimental|Supracor|Ametropia Lasik treatment of virgin eyes with presbyopia.
89392182|NCT01373125||Radiofrequency Ablation (RFA)|Participants in this group are greater than or equal to 12 months status post radiofrequency ablation (RFA).
89392183|NCT01373125||Radiofrequency Ablation Longitudinal (RFAL)|Participants in this group are part of a longitudinal portion of the study and are enrolled prior to their first radiofrequency ablation procedure and followed at 6 and 12 months after completion of RFA.
89392184|NCT01373125||Gastroesophageal Reflux Disease (GERD)|Participants in this group have been diagnosed with gastroesophageal reflux disease.
89392185|NCT01373125||Asymptomatic Controls (AC)|Participants in this group are asymptomatic controls and enrolled as part of the comparison group.
89392186|NCT03627117|Experimental|Verum/Placebo|This group will start with CBD and after washout will receive placebo.
89392187|NCT03627117|Experimental|Placebo/Verum|This group will start with placebo and will receive CBD after washout.
89392188|NCT02113046|Active Comparator|pancreatico-jejunal anastomosis|patients in which the finnish binding pancreatico-jejunal anastomosis is techically possible to perfom during distal pancreatic resektion
89392189|NCT02113046|Active Comparator|traditional anastomosis|pancreatic resections with traditional stump closure
89392190|NCT05074641|Experimental|Direct myofascial release treatment|Myofascial Release will be applied with Forearm and/or ulnar border of the palm. Deep Pressure will be applied and glided medially towards the base of the neck and/ or towards the upper scapular region
88816441|NCT02404350|Placebo Comparator|Placebo arm 2 (Group 4)|"Placebo to Secukinumab sc injection every week for 4 weeks followed by placebo to Secukinumab every 4 weeks until week 16. Non-responders were switched to Secukinumab either 150 or 300 mg sc injection every four weeks until week 100. Responders at week 16 continued receiving placebo until week 24, then were switched to secukinumab 150 or 300 mg sc injection every 4 weeks until week 100. PLEASE NOTE: Placebo arms 1 and 2 belong to the same placebo group (group 4)~Beginning at Week 52, for subjects whose signs and symptoms were not fully controlled, and who the investigator believed may improve further with an increase in dose, may have had the secukinumab dose increased to 300mg s.c. every 4 weeks."
88816442|NCT02508207|Placebo Comparator|Placebo|Participants received placebo matched to tezacaftor (TEZ)/ivacaftor (IVA) fixed dose combination (FDC) tablet orally once daily in the morning followed by placebo matched to IVA tablet orally once daily in the evening for 29 days.
89186840|NCT02559453|Active Comparator|3 or more operations|Subjects in this arm will receive three or more surgical debridements of their wound.
89186841|NCT03802305|Experimental|Computerized intraosseous technique (Quicksleeper™)|patients will receive the anesthetic solution with computerized intraosseous technique anesthesia near the tooth roots involved.
89186842|NCT03802305|Active Comparator|loco-regional anesthesia (IANB technique)|patients will receive the anesthetic solution with the loco-regional anesthesia technique: near the place where the nerve goes into the jaw, based on osteo muscular markers.
89186843|NCT00755469|Experimental|1|
89186844|NCT02587442|Experimental|RadProtect®|RadProtect® is not a full-closed micelle, and uses ferrous iron to provide linkage between PEG-b-PGA and amifostine. Transferrin and other related proteins can chelate with ferrous iron and break the micelle releasing amifostine into the blood stream.
89186845|NCT04084184|Experimental|Sequence 1|Period 1 : Fasted state + HGP1812, Period 2 : Fasted state + HGP1602
89186846|NCT04084184|Experimental|Sequence 2|Period 1 :Fasted state + HGP1602, Period 2 : Fasted state + HGP1812
89186847|NCT00755547|Experimental|High Intensity|70-85% of peak oxygen uptake for 30 min 3-5 days/week.
89186848|NCT00755547|Experimental|Low Intensity|40-55% of peak oxygen uptake for 60 min 3-5 days/week
89186849|NCT00755547|No Intervention|Sedentary Control|Regular activities of daily living for 6 months
89186850|NCT02587052||Tacrolimus|100 patients treated with generic tacrolimus
89186851|NCT02587052||Prograf|100 patients treated with Prograf
89186852|NCT02587130|Experimental|communicating and none-communicating patients|20 communicating patients (evaluated with the visual analogue pain scale (VAS)) and 20 none-communicating patients or patients presenting cognitive disturbance or vigilance (evaluated with the Algoplus scale)
89186853|NCT00677235|Experimental|FLAIR|FLAIR Endovascular Stent Graft
89186854|NCT00677235|Active Comparator|PTA Only|Percutaneous Transluminal Angioplasty
89186855|NCT04084418|Experimental|Control diet followed by VLCHF diet|"Phase 1 (1 to 3 weeks): Insulin dose optimization with usual diet~Phase 2 (6 weeks): Control diet (50% of energy from carbohydrates)~Phase 3 (4 weeks): Washout period~Phase 4 (6 weeks): VLCHF diet (10% of energy from carbohydrates)"
89186856|NCT04084418|Experimental|VLCHF diet followed by Control diet|"Phase 1 (1 to 3 weeks): Insulin dose optimization with usual diet~Phase 2 (6 weeks): VLCHF diet (10% of energy from carbohydrates)~Phase 3 (4 weeks): Washout period~Phase 4 (6 weeks): Control diet (50% of energy from carbohydrates)"
89186857|NCT02559141|Other|Study group (SG)|"Before induction of anaesthesia:~Arterial line~Nexfin Monitoring System~Measurement of cardiac index (CI), pulse pressure variation (PPV) and mean arterial pressure (MAP)~Baseline blood samples. Induction of anaesthesia~Study Group:~PPV ≤10%, 500 ml of crystalloids/colloids as long as CI was ≥2.5 l/min/m²~Maintenance of CI ≥2.5 l/min/m² and MAP ≥65 mmHg by using dobutamine (10 µg/kg/min) and norepinephrine (0.03 µg/kg/min)."
89186858|NCT02559141|No Intervention|Control group (CG)|"MAP ≥65 mmHg~CVP ≤12 mmHg~Haemoglobin level ≥8 g/dl.~Maintenance of MAP ≥65 mmHg by using crystalloids/colloids, bolus injection of theodrenaline/cafedrine or continuous infusion of norepinephrine (0.03 µg/kg/min) according to clinical evaluation."
89186859|NCT05679440|No Intervention|Control group|Patients in the control group are ventilated in a comfortable position according to the principles of treatment and their wishes
89186860|NCT05679440|Experimental|Intervention group|Patients are ventilated in prone position (for patients with bilateral lung lesions), left/right lateral position, semi-prone position (for patients with unilateral lung lesions or those who cannot tolerate prone ventilation, so that the diseased lung is above and the healthy lung is below), supine position (for patients who cannot tolerate prone ventilation or lateral ventilation, etc.) according to the pulmonary imaging data.
89186861|NCT04969965|Experimental|Aumolertinib|single dose oral 110mg of aumolertinib
89186862|NCT03680625|Active Comparator|Passive Distraction|The child will watch a video on an iPad® during the pin removal procedure and/or removal of sutures.
89186863|NCT03680625|Experimental|Virtual Reality Distraction|The child will visualize and interact with the virtual environment using an Oculus Quest® head-mounted device throughout the pin removal procedure and/or removal of sutures.
89535391|NCT03091257|Experimental|Dabrafenib and Trametinib|"Determine if mutation in BRAF, KRAS, NRAS~BRAF V600 mutated, BRAF/KRAS mutated, or BRAF/NRAS mutated, or BRAF non-V600 mutated~Treat cohort with Dabrafenib and Trametinib~Analysis~Treat cohort with Dabrafenib and Trametinib"
88816443|NCT02508207|Experimental|TEZ/IVA|Participants received 100 milligram (mg) TEZ/150 mg IVA FDC tablet orally once daily in the morning followed by 150 mg IVA tablet orally once daily in the evening for 29 days.
88816444|NCT04063670|Active Comparator|Control|Routine, standard-of-care treatment
88816445|NCT04063670|Experimental|Video Intervention|Routine, standard-of-care PLUS peri-operative video series
88816446|NCT02181530||OZURDEX®|Retrospective data collection study of OZURDEX® (dexamethasone intravitreal implant 0.7 mg) administered at least once in accordance with routine clinical practice. No treatment (intervention) is administered as part of this study.
88816447|NCT01193114|Experimental|Ecologically-Based Behavioral Treatment|Ecologically-Based Treatment was provided over a period of 6 months. The treatment integrated independent housing, case management services and substance abuse counseling. Specifically, the mothers were housed in an apartment of their choice and received three months of utility and rental assistance of up to $600 per month.
88816448|NCT01193114|Active Comparator|Treatment as Usual|The Mothers were offered services provided through the family shelter.
88868191|NCT04838379|Active Comparator|Group bupivacaine & dexamethasone|will include 30 patients: each one will receive 2.5 mg/kg of 0.25% bupivacaine plus dexamethasone (0.3 mg/kg) diluted in a 20 mL syringe of normal saline , 10 minutes before skin incision
88816449|NCT02509065|Active Comparator|Usual Care|Comparator week to all closed-loop control, utilizing usual diabetes care and the subject's own insulin pump.
88868192|NCT04830878|Experimental|Treatment|Methotrexate treatment
88868193|NCT04815889|No Intervention|Control group|Recruitment of the control group is done through the county parts that have not yet been included in the clinical trial of new methods. This means that children / families are not withheld from treatment they would otherwise receive.
88868194|NCT04815889|Active Comparator|PRIMUS parent training group and preschool teacher training group|The parents have undergone PRIMUS Group-based parent support program for 5 half days This parenting education for preschool children with developmental problems but without the requirement of diagnosis Hellström (2019) has been designed and tested in other parts of the country but not scientifically validated, which can be done in this study. The preschool teachers may participate for half a day in education together with the parents as a practical implementation in the child's everyday life.
88868195|NCT04815889|Other|Demand-driven intervention|"The PLUSS toddler team makes a management plan as referral to Habilitation Center, Child and Adolescent Psychiatry, Speech Therapist, or interventions eg:~Support in the child's everyday environment home / preschool~Targeted parent training group: toilet, sleep, food, everyday structure, handle behavioural problems~Web Courses Each individual intervention is evaluated afterwards with the study questionnaire."
88868196|NCT04800107|Experimental|Treatment Group|Subjects will be provided with a supply of capsules containing 500 mg of curcumin-phosphatidylcholine combined with 250 mg of boswellia-phosphatidyl. Subjects will take 1 capsule by mouth twice daily for 30 days.
88868197|NCT04800107|Placebo Comparator|Placebo Group|Subjects will be provided with a placebo compound with instructions to take 1 capsule by mouth twice daily for 30 days.
88868198|NCT04796051|Experimental|Neck orthosis - posterior cervical weight|The posterior cervical weight orthosis is made of a well-padded adjustable Velcro attached to the end with a two-kilogram weight attached with two durable straps. The device is firmly anchored around the curvature of the jaw and attached with Velcro to the apex of the skull. Neck orthosis group will use a cervical orthosis (with the posterior cervical neck weight) for 10 minutes / 3 times a day, for a total of 30 minutes a day
88868199|NCT04796051|Active Comparator|Deep cervical flexors exercise|Deep cervical flexors exercise group will do 15 repetitions x 3 sets of deep neck flexor exercises every day of the week.
88868200|NCT04786782||Three-dimensional reconstruction group|Portal hypertension is controlled with upper endoscopic screening and vPPG was detected by the noninvasive PPG-detecting software
89186864|NCT02561013|Experimental|3M™ Coban™ Custom Fit Compression System|3M™ Coban™ Custom Fit Compression System will be custom-fitted at first subject visit and will thereafter be applied and removed daily by the study subject. It will be worn throughout the day by the study subject and removed before bedtime. It will provide therapeutic compression for edema control to help in the healing of venous leg ulcers.
88868201|NCT04786782||Natural follow-up group|Portal hypertension is controlled with the most updated guideline for clinical practice, namely, cirrhotic patients with either liver stiffness measurement >15kPa or PLT<150*10^9 should be screened with upper GI endoscopy and treated according to endoscopic results
88868202|NCT04786574|Experimental|Tolvaptan (OPC-41061)|
88868203|NCT04769986|Experimental|Mobile Mindfulness-Based Relapse Prevention (mMBRP)|Participants will complete the Mindfulness Coach app program that is enhanced with additional modules containing MBRP content.
88868204|NCT04769986|Active Comparator|Active control|Participants will complete a course of an exercise/healthy eating app program that is matched in time and effort to the intervention condition app.
88868205|NCT04761159|Active Comparator|Ketofol1/1|Propofol 1 mg/kg + ketamin1 mg/kg (1/1 ratio) for group I to anesthesia induction.
88868206|NCT04761159|Active Comparator|Ketofol1/2|propofol 1,5 mg/kg + ketamin 0,75 mg/kg (2/1 ratio) for group II to anesthesia induction
89535392|NCT03091257|Experimental|Trametinib|"Determine if mutation in BRAF, KRAS, NRAS~KRAS or NRAS mutated~Treat cohort with Trametinib~Analysis~Treat cohort with Trametinib"
88816450|NCT02509065|Experimental|145 mg/dl Set Point - insulin only|Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 145 mg/dl and using only an insulin pump.
88816451|NCT02509065|Experimental|130 mg/dl Set Point - insulin only|Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 130 mg/dl and using only an insulin pump. This arm is for subjects with type 1 diabetes only. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.
88816452|NCT02509065|Experimental|130 mg/dl Set Point - bihormonal|Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 130 mg/dl using both an insulin and a glucagon pump. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.
88868207|NCT04761159|Active Comparator|Ketofol1/3|propofol 2 mg/kg +ketamin 0,66 mg/kg (3/1 ratio) for group III to anesthesia induction
88868208|NCT04761159|Active Comparator|propofol|propofol 3 mg/kg will perform for anesthesia induction
88868209|NCT04723641|Experimental|STUDY GROUP|they received progressive resistive functional strength training from plantigrade foot position conducted for one hour, 3 days/week. The therapist will replace the conventional physical therapy with the progressive resistive functional strength training, when this is consistent with the objectives of the strength training.
88868210|NCT04723641|No Intervention|control group|received a designed physical therapy program
88868211|NCT04716296|Experimental|Ketamine arm|Treatment arm consisting of patients randomized to receive a low dose of ketamine for the second stage of DBS surgery.
88868212|NCT04716296|Active Comparator|Control arm|Control arm consisting of patients randomized to receive sham control of saline during the second stage of DBS surgery.
88868213|NCT04704141||Infertile men with leukocytes in semen and eugonadal|Standard fertility evaluation and treatments
88868214|NCT04704141||Infertile men without leukocytes in semen and eugonadal|Standard fertility evaluation and treatments
88868215|NCT04704141||Infertile men with hypogonadism|Standard fertility evaluation and treatments, including hormone replacement therapy such as with clomiphene citrate
89392191|NCT05074641|Active Comparator|Bowen therapy|Thumb of the therapist will be placed on the top of the targeted muscle. The skin will be carried away gently from the spine without disturbing the muscle. The thumb was then hooked into the lateral aspect of the muscle to form a pressure on the muscle. Then the thumb will be flattened in the medial direction, when this happened the muscle would plop or respond in some way.
89392192|NCT02119364|Active Comparator|Working memory training|After baseline assessment participants will be randomized to active training or treatment as usual (waiting). The active group will start training immediately and will have 6 weeks to perform the 25 training sessions.
89392193|NCT02119364|No Intervention|Passive control group|"The control group will receive treatment as usual (special education, physiotherapy etc)."
88868216|NCT04682041|Experimental|EnteraGam + standard of care|Subjects will receive EnteraGam® (oral nutritional therapy) + standard of care for COVID-19 for 2 weeks. Total study duration (including the screening phase) will be approximately 4 weeks.
88868217|NCT04682041|Other|Control (standard of care)|Subjects will receive standard of care for COVID-19 alone for 2 weeks. Total study duration (including the screening phase) will be approximately 4 weeks.
88868218|NCT04652661|Experimental|Dexmedetomidine Group|30 children will be sedated with 2 μg/kg intranasal dexmedetomidine
89186865|NCT02561013|Active Comparator|Profore|Profore multi-layer compression bandaging system will be applied at the first subject visit and will be worn by the study subject continuously for 7 days, at which time it will be replaced with a new system, or, in the case of a product or non-product reason, replaced before 7 days. It will provide therapeutic compression for edema control to help in the healing of venous leg ulcers
89392194|NCT02119520|Active Comparator|Platelet rich fibrin + atorvastatin|In Platelet rich fibrin+ATV group PRF combined with 10 µl of 1.2% ATV was inserted into the depth of the IBD
88868219|NCT04652661|Active Comparator|Midazolam Group|30 children will be sedated with 0.3 mg/kg intranasal midazolam.
89392195|NCT02119520|Sham Comparator|Platelet rich fibrin|In Platelet rich fibrin group PRF was inserted into the depth of the IBD.
89392196|NCT02119520|Other|Open flap debridement|open flap debridement was followed by no grafting or regenerative intervention.
89392197|NCT02114762|Experimental|Balloon dilation of the Eustachian tube|Insertion and inflation of balloon into Eustachian tube for up to 1 minute
88868220|NCT04650451|Experimental|HER2-targeted dual-switch CAR-T cells|Subjects will receive one dose of BPX-603 on Day 1, followed by rimiducid IV infusion weekly (as tolerated) starting on Day 8 and continued until treatment discontinuation criteria are met.
89535393|NCT04493255|Experimental|E7090|Participants will receive 100 microcurie (μCi) of [14C]E7090 as a single 35 milligram (mg), capsule, orally on Day 1.
88868222|NCT04611542|Experimental|FIR Prototype Evaluation|30 fathers in recovery from opioid-use disorder will receive the prototype FIR online intervention.
88868223|NCT04607330|Experimental|High protein liquid|A ready to use, low calorie, low volume, ready to use, high protein liquid modular (HPLM) feed for adults.
88868224|NCT04600323|Placebo Comparator|Placebo|Placebo medication will be used at a dose of 0.5 mEq/kg-lean body weight/day
88868225|NCT04600323|Experimental|Sodium bicarbonate|Sodium bicarbonate will be used at a dose of 0.5 mEq/kg-lean body weight/day.
88868226|NCT04590781|Experimental|Part A: XmAb18087 Monotherapy|Part A, will enroll participants with previously treated advanced MCC, consists of safety-run in cohorts followed by an expansion cohort.
88868227|NCT04590781|Experimental|Part B: XmAb18087 + pembrolizumab|Part B, will enroll participants with advanced MCC not previously treated with anti-programmed cell death 1 (PD1) or anti-programmed cell death ligand 1 (PDL1) agents, consists of safety run-in cohorts followed by an expansion cohort.
89392198|NCT00263731||Group 1 (Experimental Group)|250 subjects with suspected or confirmed lung cancer undergoing surgical resection, will receive 13-C-glucose prior to surgery
89392199|NCT00263731||Group 2 (Control Group)|250 subjects with suspected or confirmed lung cancer undergoing surgical resection, will not receive 13-C-glucose prior to surgery
89392200|NCT00263731||Group 3 (Healthy Subjects)|250 healthy subjects (must be at least 30 years of age and have no prior history of diagnosed lung cancer) will provide 1 blood sample and 1 urine sample.
89392201|NCT05609877|No Intervention|Control group: LISA with analgesia combined with non-pharmacological approach as usual|The staff will perform Less Invasive Surfactant Administration using standard 0.5-1 mcg/kg fentanyl intravenously for LISA. In both groups, patients will receive the unit's standard pre- and post-procedure care including their non-pharmacological approach, use of atropine, caffeine, and naloxone at the discretion of the clinician based on local protocols and guidelines. All medications will be registered.
89186866|NCT04081844|Experimental|Fixed-Sequence|Period 1: Fasted state+HCP1306, Period 2: Fasted state+HGP0904+HGP0608, Period 3: Fasted state+HCP1306+HGP0904+HGP0608
88868228|NCT04590781|Experimental|Part C: XmAb18087 monotherapy|Part C will enroll participants with previously treated extensive-stage SCLC and consists of safety-run in cohorts followed by an expansion cohort.
88868229|NCT04573751|Sham Comparator|Standard therapy|No intracoronary epinephrine and verapamil
88868230|NCT04573751|Active Comparator|Epinephrine|Intracoronary bolus epinephrine injection requires two ampoules each of 1:1,000 epinephrine (1 μg/mL) diluted into 100 mL of normal saline solution (to 20 μg/mL epinephrine solution); therefore, a 5-mL syringe contains 100 μg of epinephrine. Intracoronary epinephrine will be administered at a dose of 100 μg and at a lower dose of 80 μg in patients with blood pressure >160 mmHg
89186867|NCT00676689|Experimental|SAPIEN THV|
89186868|NCT02589314||root planning|
89186869|NCT04978844|Active Comparator|I-WotCH|I-WotCH- Inner World of the Child- is a novel innovative therapy developed in our clinic. The therapy is based on modern concepts of early childhood developments emphasizing themes related to emotional regulation, processes of socialization, observational research on interpersonal and behavior as well as recent developments on affiliative neuroscience. More specifically, the therapist, through play, identifies themes and emotions the child is preoccupied with. The therapist then assists the child in naming these emotions, validating them, exploring their nature and consequences. The therapists discussed ways of managing and self-regulating these emotions. These methods would include behavioral techniques, the ability to enlist help from others and reframing. In addition, the therapy will address dealing with complexed emotions and enhancing symbolic play and joyfulness.
89186870|NCT04978844|Active Comparator|Dyadic therapy|"Child parent psychotherapy: CPP consists of joint parent-child sessions that focus on the child's free play and spontaneous parent-child interaction. The CPP therapist acts to translate the developmental and emotional meaning of a child's emotions and actions to the parent. The target of treatment includes the both the child's and the caregiver's adaptive conflicts, including a parent's difficulty in providing sensitive and developmentally appropriate care. CPP fosters parent-child activities that foster mutual pleasure, interpersonal trust and understanding. In the purpose of this study only mothers will be included."
89186871|NCT04978844|No Intervention|Control|Healthy control.
89186872|NCT02587988|Experimental|HCP1302+HGP0904Placebo|HCP1302+HGP0904Placebo for 12weeks
89186873|NCT02587988|Active Comparator|HCP1302Placebo+HGP0904|HCP1302Placebo+HGP0904 for 12weeks
89186874|NCT00678795|Experimental|Sativex|Each 100 ul actuation contains 27 mg delta-9-tetrahydrocannabinol (THC) and 25 mg cannabidiol (CBD). A maximum of 48 actuations (130 mg of THC and 120 mg of CBD) was permitted in any 24 hour period.
89186875|NCT00678795|Placebo Comparator|Placebo|Each 100 ul actuation contains the colorants plus excipients. A maximum of 48 actuations was permitted in any 24 hour period.
89186876|NCT00678639|Experimental|Emergency Department (ED) Observation unit|Emergency Department observation unit- Cardiac Magnetic Resonance Imaging (MRI) Protocol. Patients will be transferred to the observation unit and undergo a stress cardiac MRI evaluation.
89186877|NCT00678639|No Intervention|Usual care|This is the comparison arm. Patients are admitted to the hospital and undergo usual care.
89186878|NCT02587208|Active Comparator|conventional sleeve|In the sleeve dissection group, a double incision technique on both outer and inner layers of the foreskin is employed. Hemostasis is achieved by bipolar diathermy, and cut edges are sutured with 5/0 rapide vicryl.
89186879|NCT02587208|Active Comparator|plastibell|In the Plastibell group, the size of the device is chosen according to the lateral-lateral diameter of the glans. A dorsal slit incision is made and then the foreskin is pulled up and the Plastibell device placed between the prepuce and the glans. A non-absorbable string was tightly tied around the device and the distal prepuce is removed.
89392202|NCT05609877|Placebo Comparator|Intervention group: Non-pharmacological Approach LISA (NONA-LISA) alone|The staff will perform Less Invasive Surfactant Administration using the standard pre- and post-procedure care including non-pharmacological treatment. The patients will not receive pharmacological analgesic treatment routinely. In both groups, patients will receive the unit's standard pre- and post-procedure care including their non-pharmacological approach, use of atropine, caffeine, and naloxone at the discretion of the clinician based on local protocols and guidelines. All medications will be registered.
89392203|NCT02119754|Experimental|Plurogel PN|Plurogel PN
89392204|NCT03961789||cohorte 1|patients undergoing opioid replacement therapy
89392205|NCT02119832|Experimental|Endovascular AVF (EndoAVF)|The FLEX System will be used to endovascularly create a fistula in CKD patients who require hemodialysis vascular access
89392206|NCT01376479|Experimental|INV21 Low Dose|
88868231|NCT04573751|Active Comparator|Verapamil|Intracoronary verapamil is administered at a dose of 0.5 mg.
88868232|NCT04573751|Active Comparator|Epinephrine + verapamil|Intracoronary administration of epinephrine at a dose of 80-100 μg and verapamil at a dose of 0.5 mg.
88868233|NCT04545437||ICU|Patients treated on a general adult intensive care unit
88868234|NCT04539704|Experimental|Healthy Adults-magnet|Healthy adults with magnet and/or sham
88868235|NCT04539704|Sham Comparator|Healthy Adults-sham|Healthy adults with magnet and/or sham
88868236|NCT04536701|Experimental|Dementia/Caregiver Dyad|All dementia/caregiver dyads will have in-home acoustic monitoring to classify mood and will be provided mindfulness-based stress reduction recommendations via a smart phone.
88868237|NCT04526834|Experimental|CD30 positive NHL subtypes|"(ALCL, PTCL-NOS, ENKTCL, DLBCL-NOS, PMBCL)~Dose Level 1~Dose Level 2~Dose Level 3"
88868238|NCT04522622|Experimental|Teriparatide|Patients receive teriparatide 20 micrograms once daily for 18 months
88868239|NCT04522622|Other|Controls|Controls receive no treatment with teriparatide
88868240|NCT04511962||Fast track group|Participants randomised to the fast track group will receive the pulmonary rehabilitation intervention 14 ± 7 days after randomisation.
88868241|NCT04511962||Wait list group|Participants randomised to the wait-list group will receive the pulmonary rehabilitation intervention 56 ± 7 days after randomisation.
88868242|NCT04432207|Experimental|Dose Escalation: Monotherapy Cohort 1|10 μg/dose IMU-201 as a 0.5 mL PD1-Vaxx injection Progressed on/after ICI, TPS/TC ≥50% or IC ≥10%
88868243|NCT04432207|Experimental|Dose Escalation: Monotherapy Cohort 2|50 μg/dose IMU-201 as a 0.5 mL PD1-Vaxx injection Progressed on/after ICI, TPS/TC ≥50% or IC ≥10%
88868244|NCT04432207|Experimental|Dose Escalation: Monotherapy Cohort 3|100 μg/dose IMU-201 as a 0.5 mL PD1-Vaxx injection Progressed on/after ICI, TPS/TC ≥50% or IC ≥10%
88868245|NCT04432207|Experimental|Dose Expansion Monotherapy|mOBD (TBD) dose IMU-201 as a 0.5 mL PD1-Vaxx injection Progressed on/after ICI, TPS/TC ≥50% or IC ≥10%
89392207|NCT01376479|Experimental|INV21 High Dose|
89392208|NCT03552614||children with brain damage|Patients undergo physiotherapy + Upper limb robot-assisted rehabilitation
88868246|NCT04432207|Experimental|Dose Escalation Arm 1: Combination with atezolizumab Cohort 1|10 μg/dose IMU-201 as a 0.5 mL PD1-Vaxx injection with atezolizumab 840 mg Naïve to ICI or Progressed on/after ICI, TPS/TC ≥50% or IC ≥10%
88868247|NCT04432207|Experimental|Dose Escalation Arm 1: Combination with atezolizumab Cohort 2|50 μg/dose IMU-201 as a 0.5 mL PD1-Vaxx injection with atezolizumab 840 mg Naïve to ICI or Progressed on/after ICI, TPS/TC ≥50% or IC ≥10%
88868248|NCT04432207|Experimental|Dose Escalation Arm 1: Combination with atezolizumab Cohort 3|Cohort 3: 100 μg/dose IMU-201 as a 0.5 mL PD1-Vaxx injection with atezolizumab 840 mg Naïve to ICI or Progressed on/after ICI, TPS/TC ≥50% or IC ≥10%
88868249|NCT04432207|Experimental|Dose Escalation Arm 2: Combination with atezolizumab and chemotherapy Cohort 1|10 μg/dose IMU-201 as a 0.5 mL PD1-Vaxx injection with atezolizumab 840 mg and SOC chemotherapy Naïve to ICI, Any PD-L1 Level
88868250|NCT04432207|Experimental|Dose Escalation Arm 2: Combination with atezolizumab and chemotherapy Cohort 2|50 μg/dose IMU-201 as a 0.5 mL PD1-Vaxx injection with atezolizumab 840 mg and SOC chemotherapy Naïve to ICI, Any PD-L1 Level
88868251|NCT04432207|Experimental|Dose Escalation Arm 2: Combination with atezolizumab and chemotherapy Cohort 3|100 μg/dose IMU-201 as a 0.5 mL PD1-Vaxx injection with atezolizumab 840 mg and SOC chemotherapy Naïve to ICI, Any PD-L1 Level
89392209|NCT04854343||Case|200 patients with a suspicion of prostate cancer
88868252|NCT04432207|Experimental|Dose Expansion Arm 1: Combination with atezolizumab|cOBD (TBD) dose IMU-201 as a 0.5 mL PD1-Vaxx injection with atezolizumab 840 mg Progressed on/after ICI, TPS/TC ≥50% or IC ≥10%
88868253|NCT04432207|Experimental|Dose Expansion Arm 2: Combination with atezolizumab|cOBD (TBD) dose IMU-201 as a 0.5 mL PD1-Vaxx injection with atezolizumab 840 mg Naïve to ICI, TPS/TC ≥50% or IC ≥10%
88868254|NCT04432207|Experimental|Dose Expansion Arm 3: Combination with atezolizumab and chemotherapy|cOBD (TBD) dose IMU-201 as a 05 mL PD1-Vaxx injection with atezolizumab 840 mg and SOC chemotherapy Naïve to ICI, Any PD-L1 Level
88868255|NCT04425447|Active Comparator|Group C|30 patients will receive bilateral tumescent local anesthesia as a control group
88868256|NCT04425447|Experimental|Group TPVB|30 patients will receive bilateral US guided thoracic paravertebral block.
88868257|NCT04425447|Experimental|Group TIPB|30 patients will receive bilateral US guided thoracic interfascial plane block
88868258|NCT04422626||Critically ill COVID-19 patients, who receive CytoSorb therapy|Patients in ICU due to critical COVID-19 infection, who receive early (within the first 24 hours, but no later than 48 hours after intubation) CytoSorb therapy on consultant's discretion.
88868259|NCT04338581|Experimental|AMG 714|Participants will be administered 300 mg AMG 714 subcutaneously on Day 0 and every 2 weeks thereafter through week 10 (for a total of 6 doses).
88868260|NCT04338581|Placebo Comparator|Placebo|Participants will be administered 300 mg AMG 714 subcutaneously on Day 0 and every 2 weeks thereafter through week 10 (for a total of 6 doses).
88868261|NCT04330963||Hypersomnolence group|All patients referred to the outpatient clinic/sleep center for investigation due to complaints for excessive daytime sleepiness (EDS) and/or Hypersomnia (H) and/or suspected central disorder of hypersomnolence (CDH)
88868262|NCT04330963||Healthy controls|Healthy control subjects without complaints of EDS and /or H.
88868263|NCT04330963||SDB controls|Patients with EDS and diagnosis of severe sleep related breathing disorder (SBD) significantly improving with therapy.
89392210|NCT04854343||Control A|(a) 50 patients with benign prostate hyperplasia (BPH)
88868264|NCT04330963||Pediatric Hypersomnolence group|Pediatric group aged 10-18. Same criteria for inclusion and exclusion apply as for the adult group.
89392211|NCT04854343||Control B|(b) 30 male subjects older than 50 years with neither prostate disease nor any other neoplasia
89392212|NCT05695053|Experimental|with LLLT|
89392213|NCT05695053|Placebo Comparator|without LLLT|
89392214|NCT02119910|Experimental|Technology Supported Manual|Participants in this arm will receive behavioral intervention for a period of 5 consecutive days. A total of 3, 45-minute meals will be held at regularly scheduled times (e.g., 9:00 a.m., 10:30 a.m., and 12:00 p.m.) each day for a total of 15 meals throughout treatment.
88868265|NCT04323787||COVID19 test positive/pending or high clinical suspicion|COVID19 test positive/pending/high clinical suspicion- patient admitted to hospital
88868266|NCT04323449|Experimental|Vision-guided control|New custom control method
88868267|NCT04323449|Experimental|Default control|Default control method (joystick or switch)
89392215|NCT02119910|No Intervention|Waitlist|Participants will serve as the control condition.
88868269|NCT04272736|Experimental|Low calorie protein substitute|Single arm designed, 3 day baseline, 28 day on the lower calorie amino acid based liquid protein substitute.
89186880|NCT02559063|Experimental|Vision-based speed of processing|Vision-based speed of processing training will use the INSIGHT online program (Posit Science), which includes five games (i.e., Eye for detail, Peripheral challenge, Visual sweep, Double decision, Target tracker) that practice processing speed and attention. All games share visual components, and the tasks become increasingly more difficult and require faster reaction times. Participants respond either by identifying what object they see or where they see it on the screen. The training will automatically adjust the difficulty of each task based on the participant's performance, ensuring that the participants always operate near their optimal capacity. The training programs will automatically record the percentage of completion of each game and scores.
89392216|NCT05693337||FLIR Imaging|All patients recruited for this study will receive FLIR imaging to monitor the success of a lumbar sympathetic block for CRPS
89392217|NCT02113280|Active Comparator|Physiotherapy|Physiotherapy
88868270|NCT04261673|Experimental|Decompressive Craniectomy|After the evacuation of epidural hematoma, the bone flap should not be replaced at the end of the operation.
88868271|NCT04261673|Experimental|Craniotomy|After the evacuation of epidural hematoma, the bone flap must be replaced and fixed with an appropriate fixation system.
88868272|NCT04248868|Experimental|BEC Treatment|The Bashir™ Endovascular Catheter is a device intended for the localized infusion of therapeutic agents into the pulmonary artery.
88868273|NCT04246138|Active Comparator|kinematically alignment|
88868274|NCT04246138|Active Comparator|mechanical alignment|
88868275|NCT04217993|Experimental|Jaktinib Hydrochloride Tablets 100mg twice a day.|This is the dose group was given Jaktinib Hydrochloride Tablets 100mg （2 tablets）dose group for twice a day.
88868276|NCT04217993|Experimental|Jaktinib Hydrochloride Tablets 150mg once a day|This is the dose group was given Jaktinib Hydrochloride Tablets 150mg （3 tablets）dose group for once a day.
89392218|NCT02113280|Experimental|Arthroscopy|Arthroscopy
89392219|NCT05522127|Active Comparator|Group R (Restrictive)|Group R (Restrictive, 2ml/kg 0.9% NaCl during colonoscopy)
88816453|NCT02509065|Experimental|115 mg/dl Set Point - bihormonal|Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 115 mg/dl using both an insulin and a glucagon pump.
88816454|NCT02509065|Experimental|100 mg/dl Set Point - bihormonal|Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 100 mg/dl using both an insulin and a glucagon pump.
88816455|NCT02509065|Experimental|110 mg/dl Set Point - insulin only|Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 110 mg/dl and using only an insulin pump. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.
88868277|NCT04217993|Experimental|Jaktinib Hydrochloride Tablets 100mg once a day|This is the dose group was given Jaktinib Hydrochloride Tablets 100mg （2 tablets） dose group for once a day
89392220|NCT05522127|Active Comparator|Group L (Liberal )|Group L (Liberal 15ml/kg 0.9% NaCl during colonoscopy)
89392221|NCT02113358|Experimental|Normovolemic group (keeping SVV<10% in supine; <15% in prone)|"The anesthesiologist will infuse Voluven (Fresenius Kabi, Bad Homburg, Germany) 250 ml if stroke volume variation is over 10% during the surgery to keep the normovolemia.~If total Voluven use is over 1500ml and then the anesthesiologist will infuse Saline 250 ml instead.~The maintenance of basal fluid, criteria to use inotropes (If cardiac index is below 2.5 l/min/m2 ) are the same standards in the both groups."
89392222|NCT02113358|Active Comparator|Restricitve group (keeping SVV < 18% in supine; <23% in prone)|"The anesthesiologist will infuse Voluven (Fresenius Kabi, Bad Homburg, Germany) 250 ml if stroke volume variation is over 18% during the surgery to keep the normovolemia.~If total Voluven use is over 1500ml and then the anesthesiologist will infuse Saline 250 ml instead.~The maintenance of basal fluid, criteria to use inotropes (If cardiac index is below 2.5 l/min/m2 ) are the same standards in the both groups."
89392223|NCT04854187|Active Comparator|Intervention Arm - Indoor air purifier and N95 mask|Intervention arm will be for 4 weeks. Blood pressure and/or blood glucose will be recorded on day 0; end of week 2 and end of the intervention. Participants in the intervention group will be asked to use an indoor air purifier (Atlanta Healthcare 7-Stage 43-Watt Air Purifier) daily for 4 weeks between the hours of ¬8 PM and 8 AM. The purifier will be placed in their bedroom or in the room where participants sleep at night. When the participants are outdoors (commuting, working outdoors, running errands, etc.), they will be asked to use a N95 mask (PureMe Reusable N95 Anti-Pollution Mask). It is a reusable mask which can be washed by the participants. Every 2 weeks, the filter of the mask will be replaced, and the filter of the indoor purifier will be washed.
89392224|NCT04854187|No Intervention|Washout period - No intervention|At the end of either control or intervention arm, participants will have a washout period of 2 weeks, after which participants will be crossed over to the other group for the subsequent 4 weeks. For example, after Participant AB is in intervention arm for 4 weeks, he/she will then have a wash out period of 2 weeks in which they will return to their usual state of living. At the end of the washout period, the participant AB will be put in the control arm for 4 weeks.
89392225|NCT04854187|Sham Comparator|Controlled Arm - Indoor air purifier and N95 mask with sham filter|Control arm will be for 4 weeks. Blood pressure, blood glucose and indoor air pollution level will be recorded similarly as in the intervention group on day 0, end of week 2 and week 4. The participant will be provided an air purifier and a N-95 mask (of the same manufacturer), with the filter removed. At the end of two weeks, the health worker will make dummy adjustments to the mask and indoor air purifier, to maintain blinding of the participant.
89392226|NCT03553472||Non-immunosuppressed IBD patients|24 IBD patients on mesalamine therapy or no IBD therapy
88868278|NCT04217993|Experimental|Jaktinib Hydrochloride Tablets 200mg once a day|This is the dose group was given Jaktinib Hydrochloride Tablets 200mg （4 tablets）dose group for once a day.
89392227|NCT03553472||Thiopurine group|12 IBD patients on azathioprine at least 2.0mg/kg or 6MP 1.0mg/kg
89392228|NCT03553472||Anti-TNF therapy|12 IBD patients on maintenance therapy infliximab (at least 8 every 8 weeks), golilumab (at least monthly), adalilumab (at least every 2 weeks), or certolizumab (at least monthly)
89392229|NCT03553472||Combination therapy|12 IBD patients on anti-TNF therapy as described in group along with either 15mg of methotrexate or azathioprine at least 1.0mg/kg or 6MP 0.5mg/kg
88868279|NCT04211831|Experimental|Cohort 1: URO-902 24 mg; Placebo|Participants will receive either a single treatment of URO-902 24 milligrams (mg) or matching placebo.
88868280|NCT04211831|Experimental|Cohort 2: URO-902 48 mg; Placebo|Participants will receive either a single treatment of URO-902 48 mg or matching placebo.
88868281|NCT04205656|Experimental|Leukocyte-Poor Platelet Rich Plasma (LP-PRP)|Participants will have a knee injected with Platelet-Rich Plasma (PRP) obtained from a venous whole blood draw from the vein.
88868282|NCT04205656|Experimental|Bone Marrow Concentrate (BMC)|Participants will have a knee injected with BMC stem cells harvested from the iliac crest
88868283|NCT04205656|Placebo Comparator|Control|Patients randomized in the placebo arm will undergo their standard of care treatment and will not receive LP-PRP or BMC.
88868284|NCT04169074|Experimental|Treatment with abemaciclib|Treatment will consist of a single neoadjuvant cycle of 15-21 days (+7 days). Abemaciclib will be administered from days 1-21 in both arms. Abemaciclib may be continued for an additional 7 days, or up to 28 days, for delays in planned surgery. Abemaciclib 150 mg PO twice daily on Days 1-21 (+7 days).
88868285|NCT04148105|Placebo Comparator|Placebo|Implement standard treatment regimen of 60 mg nimodipine every 4 hours for 21 days and the standard aneurysmal subarachnoid treatment pathway.
88868286|NCT04148105|Experimental|Experimental|Administer 100 mg cilostazol, twice daily for 14 days. In addition, implement the standard treatment regimen of 60 mg nimodipine every 4 hours for 21 days, and the standard aneurysmal subarachnoid treatment pathway.
88868287|NCT04139122|Experimental|Cohort 1-4: SJP-0132|Each cohort will receive a single dose of 1 of 4 strengths of SJP-0132
88868288|NCT04139122|Placebo Comparator|Cohort 1-4: Placebo|Single dose of placebo
89186881|NCT02559063|Active Comparator|Mental leisure activities|Mental leisure activities control activities were chosen to: 1) control for computer, online experience [and amount of time]; 2) not induce acute stress (i.e., without time management, speed component, or novel cognitive stimuli); 3) simulate participants' everyday mental activities; and 4) entertain participants to keep them from dropping out. Cross-word, Sudoku, and solitaire games will be used, which were also used in previous VSOP training study as control exercises. Participants can choose to practice any combination of games. At the end of their participation, the MLA control group will be provided with free 6-week access to the VSOP training program.
89392230|NCT03553472||Healthy Control|"The control group with consist of 12 individuals who meet the following inclusion and exclusion criteria.~Individuals will be obtained from patients without an IBD diagnosis, chronic liver disease, celiac disease or other chronic health condition coming to Digestive Health Center for endoscopic procedures or clinic visits."
88868289|NCT04139122|Experimental|Cohort 5-6: SJP-0132|Cohort 5 SJP-0132 will receive the second maximum acceptable dose from Cohorts 1-4 for 4 weeks. Cohort 6 SJP-0132 will receive the maximum acceptable dose from Cohorts 1-4 for 4 weeks
88868290|NCT04139122|Placebo Comparator|Cohort 5-6: Placebo|Multiple dose placebo for 4 weeks
88868291|NCT04121676|Experimental|2-Week Monotherapy with AGEN2373|3+3 Dose escalation of AGEN2373 administered by IV.
89186882|NCT04190342|Other|control group|standard care (intervention provided after the completion of the trial)
89392231|NCT03553472||Vedolizumab therarpy|12 IBD patients on vedolizumab maintenance therapy every 4-8 weeks
89392232|NCT03553472||Prednisone and Anti-TNF therapy|12 IBD patients on Anti-TNF maintenance therapy as combination or mono therapy along with at least 10mg of prednisone
89392233|NCT02114840|Experimental|Pronator quadratus preservation|Pronator quadratus preservation
89392234|NCT02114840|Active Comparator|Pronator quadratus non repair|
89392235|NCT02114840|Active Comparator|Pronator quadratus repair after disruption|
89186883|NCT04190342|Experimental|tai chi group|Tai chi intervention + standard care
88868292|NCT04121676|Experimental|3-Week Monotherapy with AGEN2373|3+3 Dose escalation of AGEN2373 administered by IV.
88868293|NCT04121676|Experimental|4-Week Monotherapy with AGEN2373|3+3 Dose escalation of AGEN2373 administered by IV.
88868294|NCT04121676|Experimental|Combination Therapy with 3-week AGEN2373 Monotherapy Lead-In Combination with 6-week Botensilimab|3+3+3 Dose escalation of AGEN2373. AGEN2373 and botensilimab administered by IV.
88868295|NCT04121676|Experimental|Combination Therapy with 3-week AGEN2373 in combination with 6-week Botensilimab|3+3+3 Dose escalation of AGEN2373. AGEN2373 and botensilimab administered by IV.
89186884|NCT04772690|Experimental|BAL|A resource-orientered, individual and group-based intervention addressing balance in everyday life, activities and QoL among people with chronic or advanced cancer.
89392236|NCT04878055|Experimental|Reparixin|Reparixin oral tablets, 1200 mg three times daily (TID) (2 tablets 600 mg each, TID) for up to 21 days or until decision of discharge from the hospital, on top of standard supportive care
88868296|NCT04067518|Experimental|SHP674|"Part 1: Participants with ALL who were stratified into the standard risk (SR) or intermediate risk (IR) groups received total 3 doses of SHP674 in the 36-week treatment period and who were stratified into the high risk (HR) group received total 8 doses of SHP674 in the 45-week treatment period.~Part 2: Participants with ALL who were stratified into the SR or IR groups received total 3 doses of SHP674 in the 41-week treatment period and who were stratified into the HR group received total 8 doses of SHP674 in the 45-week treatment period."
89392237|NCT04878055|Placebo Comparator|Placebo|placebo, 2 tablets TID (identical to Reparixin tablets) for up to 21 days or until decision of discharge from the hospital, on top of standard supportive care.
89392238|NCT02113514||Normal Pap smear|Women with normal pap test.
89392239|NCT02113514||Abnormal Pap smear|Women with abnormal pap test.
89392240|NCT01376713|Experimental|Ofatumumab alone|Patients with melanoma unresectable stage III B (T1- 4a, N2b-c), stage III C or stage IV (AJCC 2009) will be included in this study. Ofatumumab will be administered at a dose of 1000mg iv weekly for 8 weeks and q4w for another 16 weeks. Tumor imaging is performed at wk 4 (screening for rapid disease progression), 8, 16 and 24. In case of PD, patients will have the opportunity to receive at least 3 cycles of ofatumumab q4w in combination with DTIC (1000 mg/m2) q4w (see Arm2).
89392241|NCT01376713|Experimental|Ofatumumab plus Dacarbazine|Patients will be treated with a combination of DTIC (1000 mg/m2) q4w plus ofatumumab (1000mg) qw for 8 wks, and thereafter q4w.Tumor imaging is performed at wk 8, 16 and 24.
89392242|NCT03768752||Diastolic Dysfunction|Patients with pre-existing or new diastolic dysfunction.
89392243|NCT03768752||Normal Diastolic Function|Patients with normal diastolic function.
89392244|NCT05286567|Experimental|RGRN-305|1 tablet of 250mg RGRN-305 once daily for 16 weeks
89392245|NCT05286567|Placebo Comparator|Placebo|1 tablet of placebo once daily for 16 weeks
89392246|NCT02114918|Experimental|Attention Modification Program|Active computer-based attention training treatment designed to directly but implicitly modify biased attention patterns in anxious patients in service of symptom relief. AMP is a modified version of the dot-probe paradigm similar to the original task used by MacLeod, Mathews, and Tata. This paradigm has been modified to facilitate an attention bias away from threatening material. In this case, the probe always replaces the neutral word.
89392247|NCT02114918|Placebo Comparator|Attention Control Condition|Control computer-based attention training task, which is not designed to modify biased attention patterns in anxious patients. ACC is a modified version of the dot-probe paradigm similar to the original task used by MacLeod, Mathews, and Tata. In this case, the probe randomly replaces the neutral word or the threat word.
89392248|NCT03626961||discharge|patients discharged from icu
88868297|NCT04033419|Experimental|Memantine|Subjects receive memantin
88868298|NCT04026607|Experimental|Whey Protein Supplement|Supplements will be consumed twice daily (25g per serving x 2 servings/day)
88868299|NCT04026607|Experimental|Pea Protein Supplement|Supplements will be consumed twice daily (25g per serving x 2 servings/day)
88868300|NCT04026607|Experimental|Collagen Protein Supplement|Supplements will be consumed twice daily (25g per serving x 2 servings/day)
88868301|NCT04014283|Active Comparator|BRCA(+) Selenium deficiency|Placebo: 100 Supplement: 100
88868302|NCT04014283|Active Comparator|BRCA(+) Selenium excess|Diet modification: 500 Observation: 500
88868303|NCT04014283|Active Comparator|BRCA(-) Selenium deficiency|Placebo: 900 Supplement: 900 Diet modification: 900 Observation: 900
88868304|NCT04014283|Active Comparator|BRCA(-) Selenium excess|Diet modification: 1100 Observation: 1100
89186885|NCT03417687|Active Comparator|Arm 1|Subjects will undergo hyperpolarized 129Xe MRI first, followed by 133Xe scintigraphy
88868305|NCT04014283|Active Comparator|BRCA(+) Selenium excess, age > 50|Diet modification: 200 Observation: 200
88868306|NCT03958006|Experimental|Cochlear implantation|Simultaneous cochlear implantation with tumor resection
89392249|NCT03626961||readmission|patients readmitted icu in 48 hours after icu discharge
89392250|NCT05108493|Experimental|Dry needling and home exercise|"The experimental intervention will consist of 3 sessions of dry needling of the lateral epicondyle region, once per week with disposable acupuncture needles (0.25x25mm).~Range of motion, stretching exercises, ulnar and radial deviation, forearm pronation, supination, elbow extensor, and flexor strengthening exercises will be given to all participants.~The exercise program will be performed for 10 repetitions 2 times a day. All participants will be advised to continue the exercise program for 12 weeks."
89392251|NCT05108493|Active Comparator|Home exercise|"Range of motion, stretching exercises, ulnar and radial deviation, forearm pronation, supination, elbow extensor, and flexor strengthening exercises will be given to all participants.~The exercise program will be performed for 10 repetitions 2 times a day. All participants will be advised to continue the exercise program for 12 weeks."
89392252|NCT03725293|Active Comparator|Angiodynamics BioFlo Midline Catheter|Placement of clinically indicated Angiodynamics BioFlo midline catheter.
89392253|NCT03725293|Active Comparator|Teleflex Arrowg+ard Blue Advanced Midline Catheter|Placement of clinically indicated Teleflex Arrowg+ard Blue Advanced Midline Catheter
88868307|NCT03912233|Placebo Comparator|Part 1: Placebo|Participants received placebo matched to VX-121/TEZ/VX-561 triple combination (TC) for 4 weeks in the treatment period and placebo matched to TEZ/VX-561 for 18 days in the washout period.
88868308|NCT03912233|Experimental|Part 1: VX-121/TEZ/VX-561 TC - Low Dose|Participants received VX-121 5 milligram (mg) once daily (qd)/TEZ 100 mg qd/VX-561 150 mg qd TC for 4 weeks in the treatment period and TEZ 100 mg qd/VX-561 150 mg qd for 18 days in the washout period
89186886|NCT03417687|Active Comparator|Arm 2|Subjects will undergo 133Xe scintigraphy first, followed by hyperpolarized 129Xe MRI
89186887|NCT04767698|Experimental|Belimumab + short-term Ocrelizumab|Participants will receive Belimumab and Ocrelizumab.
88868309|NCT03912233|Experimental|Part 1: VX-121/TEZ/VX-561 TC - Medium Dose|Participants received VX-121 10 mg qd/TEZ 100 mg qd/VX-561 150 mg qd TC for 4 weeks in the treatment period and TEZ 100 mg qd/VX-561 150 mg qd for 18 days in the washout period.
89186888|NCT04767698|Active Comparator|Continued Ocrelizumab|Participants will receive Ocrelizumab only.
89186889|NCT04785807|Experimental|Evaluation arm|
88868310|NCT03912233|Experimental|Part 1: VX-121/TEZ/VX-561 TC - High Dose|Participants received VX-121 20 mg qd/TEZ 100 mg qd/VX-561 150 mg qd TC for 4 weeks in the treatment period and TEZ 100 mg qd/VX-561 150 mg qd for 18 days in the washout period.
88868311|NCT03912233|Active Comparator|Part 2: TEZ/IVA|Following run-in period with TEZ 100 mg qd/IVA 150 mg every 12 hours (q12h) for 4 weeks, participants received TEZ 100 mg qd/IVA 150 mg q12h for 4 weeks in the treatment period and TEZ 100 mg/IVA 150 mg q12h for 4 weeks in the washout period.
88868312|NCT03912233|Experimental|Part 2: VX-121/TEZ/VX-561 TC - High Dose|Following run-in period with TEZ 100 mg qd/IVA 150 mg q12h for 4 weeks, participants received VX-121 20 mg qd/TEZ 100 mg qd/VX-561 150 mg qd TC for 4 weeks in the treatment period and TEZ 100 mg qd/IVA 150 mg q12h for 4 weeks in the washout period.
88868313|NCT03879668|Experimental|eIPOS|The cohort will include all participants who are cared for by the participating specialist palliative home care teams when implementing eIPOS.
88868314|NCT03879668|No Intervention|Historic control|The cohort will include all participants that were cared for by the participating specialist palliative home care teams in the last 6 months before the implementation of eIPOS.
88868315|NCT03879668|No Intervention|Prospective control|The cohort will include participants who are in the care of the participating specialist palliative home care teams at the same time as the eIPOS group, but who do not use eIPOS.
88868316|NCT03834870|Experimental|Elder adults in emergency department setting|Elder mistreatment in an Emergency Department setting.
88868317|NCT03781817|Active Comparator|Intravenous ketamine|Participants randomized to IV ketamine will be receive IV ketamine and Intranasal normal saline.
88868318|NCT03781817|Experimental|Intranasal ketamine|Participants randomized to Intranasal Ketamine group will receive Intranasal ketamine and IV normal saline.
88868319|NCT03729648|Experimental|Intervention|This arm of participants will be receiving Expressive Arts Therapy as intervention
88868320|NCT03729648|No Intervention|Control|This arm of participants will not receive any intervention and are allocated as a wait-list control group
88868321|NCT03689868|Experimental|Virtual Reality|
88868322|NCT03689868|No Intervention|Control|
88868323|NCT03636451|Experimental|40cc buffered 0.5% lidocaine with 2 units of vasopressin paracervical block|40c buffered 0.5% lidocaine with 2 units of vasopressin paracervical block with dilation and curettage under minimal sedation
88868324|NCT03636451|Active Comparator|20cc 1% lidocaine with 2 units of vasopressin paracervical block|20cc 1% lidocaine with 2 units of vasopressin paracervical block with dilation and curettage under minimal sedation
88868325|NCT03576989|Experimental|EPA+DHA Group|12 weeks of daily oral therapy with EPA+DHA (three opaque softgels to provide a total daily intake of 1.87 g of EPA + 1.0 g of DHA)
88868326|NCT03576989|Placebo Comparator|Placebo Group|12 weeks of daily oral therapy with placebo (three opaque softgels to provide a total daily intake of 2.5 mL of mineral oil)
88868327|NCT03546062||T2DM patients treated by HTx|Authors will include a population of T2DM patients with advanced heart failure and treated by heart transplant. 41 patients recluted from January 2015
88868328|NCT03546062||T2DM Metformin treated by HTx|Authors will include a population of T2DM patients with advanced heart failure and treated by heart transplant in metformin therapy. 35 patients recluted from January 2015
88868329|NCT03546062||Non-diabetic patients treated by HTx|Authors will include a population of non-diabetic patients with advanced heart failure treated by heart transplant. 82 patients recluted from January 2015
89186890|NCT04707573|Experimental|CKD, Stage 3|Participants with Stage 3 Chronic Kidney Disease (CKD) (Estimated Glomerular Filtration Rate [eGFR] 30 - 59 milliliters [mL]/minute) received a single 500 milligram (mg) oral dose of Vadadustat after fasting for at least 4 hours.
88868332|NCT03479697|Active Comparator|HIRREM|High-resolution, relational, resonance-based, electroencephalic mirroring (HIRREM) is a novel, noninvasive, closed-loop, brainwave mirroring, acoustic stimulation neurotechnology to support relaxation and auto-calibration of neural oscillations, using auditory tones to reflect brain frequencies in near real time.
88868333|NCT03479697|Other|Continued Current Care|Participants will continue their current care.
88868334|NCT03355365|Experimental|Intrathecal MSC-NP injection|Patients will receive six autologous stem cell injections through spinal taps every 2 months over a year.
88868335|NCT03355365|Placebo Comparator|Intrathecal saline injection|Patients will receive six placebo injections through spinal taps every 2 months over a year.
88868336|NCT03332550||purulent peritonitis|Hinchey 3
88868337|NCT03332550||faecal peritonitis|Hinchey 4
88868338|NCT03278691|Placebo Comparator|Placebo|Drug: Placebo Saline 1 ml IV Q6H
88868339|NCT03278691|Experimental|Intervention|Ketorolac 15 mg (15mg/ml) IV Q6H
88868340|NCT03274739||Pregnant women|Pregnant women
88868341|NCT03253991|Experimental|MRgFUS treatment|MRgFUS device treatment, thalamotomy
88868342|NCT03044158|No Intervention|Control group|Onsite ZN or LED fluorescence microscopy + hub-based GeneXpert testing per existing protocols
88868343|NCT03044158|Experimental|Intervention|Onsite molecular testing for TB with GeneXpert I + process redesign to facilitate same-day TB diagnosis and treatment + performance feedback
88868344|NCT02948569|Experimental|3-V Bioscience-2640|Subjects will take a singly daily dose of 3-V Bioscience-2640 before bedtime or 22:30, whichever comes first, for 10 days.
88868345|NCT02929108|No Intervention|Enhanced Usual Care|The family caregivers in his group will receive usual hospice care which has been enhanced as the staff have been trained in shared decision making.
88868346|NCT02929108|Experimental|Facebook|The family caregivers in this group only participates in the Facebook groups, not in the shared decision making
88868347|NCT02929108|Experimental|ACCESS|The family caregivers in this group participates in Facebook and web conferencing for shared decision making
88868348|NCT02726763|Experimental|tDCS with cognitive training|We will collect: 1) self-reported demographic information (~5 min) 2) cognitive functioning data (PAOFI) at session 1 and session 4 (~10min) [60]; 3) behavioral data and EEG data from the tDCS stimulation task for each session (downloaded by investigators); 4) patient feedback on their experience with tDCS (tDCS Patient Experience Questionnaire (tPEQ)) for each session (~5 min); 5) tDCS accrual and session completion rates at the completion of treatment and 6) Brunoni Adverse Events Questionnaire (~5 min)
88868349|NCT02708134||Pediatric Cardiac Arrests|Pediatric cardiac arrests requiring chest compressions for at least 1 minute managed at clinical centers identified as part of standard clinical operations.
88868350|NCT02705846||Mutation carriers with Prostate cancer|"Men with prostate cancer and a known pathogenic germline mutation in:~the BRCA1 or BRCA2 gene~the HOXB13 gene~The MSH2 gene~All other Lynch Syndrome genes (MLH1, MSH6, PMS2, EPCAM)~The ATM gene~Other PCa predisposition genes"
88868351|NCT02705846||Mutation non carriers|"Men with prostate cancer who have tested negative for a mutation in one of the following genes:~the BRCA1 or BRCA2 gene~the HOXB13 gene~The MSH2 gene~All other Lynch Syndrome genes (MLH1, MSH6, PMS2, EPCAM)~The ATM gene~Other PCa predisposition genes"
88868352|NCT02661295|Other|Ferric Citrate|Ferric citrate at a starting dose of 2 tablets with each meal will be given to all participants.
88868353|NCT02657265|Experimental|SpineJack® system|Spine fracture management
88868354|NCT02657265|Active Comparator|Conservative management|Surgical corset according to measurement's impression, rigid corset with sternal support
88868355|NCT02653716|Active Comparator|Case Management|CM
88868356|NCT02653716|Experimental|New Orleans Intervention Model|NIM
88868357|NCT02621489|Experimental|Bydureon 2 mg Once Weekly|Patients randomised to Bydureon will be treated with Metformin 1g BID, and only receive 10U of Humulin kwickpen QD at bedtime, with no more up-titration of insulin during the study.
88868358|NCT02621489|Active Comparator|Humulin kwickpen|Patients randomised to the comparator group will be treated with Meformin 1g BID and Humulin kwickpen to reach a fP-glucose level of 6 mmol/l. For that reason patients will be instructed to increase the bedtime Insulin dose of 2-4U every third day until this goal is reached.
88868359|NCT02596880|Experimental|Treatment|Subjects will receive sofosbuvir, daclatasvir and ribavirin
89186891|NCT04707573|Experimental|CKD, Stage 4|Participants with Stage 4 CKD (eGFR <30 mL/minute and not yet on dialysis) received a single 500 mg oral dose of Vadadustat after fasting for at least 4 hours.
89186892|NCT02589080|Experimental|Non-invasive sensory feedback|
88868360|NCT02553525|Experimental|Therapeutic Stimulation Patterns|This group will receive temporal patterns of stimulation that are designed to suppress oscillatory neural activity at theta- or beta-frequencies. These patterns are hypothesized to alleviate motor symptoms.
88868361|NCT02553525|Experimental|Symptogenic Stimulation Patterns|This group will receive symptogenic patterns of stimulation that are designed to exacerbate oscillatory neural activity at theta- or beta-frequencies. These patterns are hypothesized to exacerbate motor symptoms.
89186893|NCT04082702|Experimental|Faith-enhanced DPP|A total of six churches were randomized to this arm that included 119 participants and received 10-month DPP with faith components.
89186894|NCT04082702|Active Comparator|Standard DPP|A total of five churches were randomized to this arm that included 102 participants who received the standard DPP on the church settings.
89186895|NCT03301311|Experimental|Specific Carbohydrate Diet (First)|Participants will be following the Specific Carbohydrate Diet (SCD). Allowed foods include meat/fish/poultry, eggs, some legumes (e.g., lentils and split peas are permitted, chickpeas and soybeans are not), fully fermented yogurt, non-starchy vegetables, ripe fruit, nuts/seeds, honey and nut flours (e.g. almond flour or coconut flour). Restricted foods include all grains, milk products aside from 24-hour fermented SCD yogurt and cheeses aged greater than 30 days, starchy vegetables, processed foods with food additives and sweeteners other than honey.
89186896|NCT03301311|Experimental|Modified Specific Carbohydrate Diet (First)|Participants will be following a modified Specific Carbohydrate Diet (MSCD). In addition to the foods in the SCD, allowed foods will expand to include organic rice, oats, sweet potatoes, grade A maple syrup and cocoa. Gluten, corn products, milk products (except yogurt and hard cheeses), sweeteners (except honey), and process foods are still restricted.
89186897|NCT04082624|Active Comparator|Nutrition condition|Received nutrition information such as the comparison of nutritional information between orange juice and soda pop. Received intervention following measurements at baseline, week 4, and week 8.
89186898|NCT04082624|Experimental|Affective condition|Learned about the affective benefits (e.g., less depression) of reduced office sitting time through taking active breaks. Received intervention following measurements at baseline, week 4, and week 8.
89186899|NCT04082624|Experimental|Instrumental condition|Learned about instrumental benefits such as the relationship between sitting and cardiovascular disease and absenteeism at work. Received intervention following measurements at baseline, week 4, and week 8.
88868362|NCT02522520|Active Comparator|Pedometer intervention|"Individual progressive pedometer intervention of low to moderate intensity.~Furthermore, the patients receive individual health counseling and symptom management counseling to support behavioral change towards increased physical activity."
88868363|NCT02522520|Active Comparator|Pedometer + hospital based intervention|"Individual progressive pedometer intervention and 5 sessions supervised interval walking + followed by supervised hospital-based intervention of moderate to high-intensity~Furthermore, the patients receive individual health counseling and symptom management counseling to support behavioral change towards increased physical activity."
88868364|NCT02474368|Experimental|Cohort 1|"Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.~Cohort 1 (patients who have received prior radiation in the head and neck with gross unresectable disease)~Intensity Modulated Radiation Therapy (IMRT) : daily for 6 weeks~Cisplatin will be administered intravenously on predetermined days~Stereotactic Body Radiotherapy (SBRT)"
88868365|NCT02474368|Experimental|Cohort 2|"Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.~Cohort 2 (patients with metastatic solid tumors of any histology who have targetable lesions within the head and neck) -- Stereotactic Body Radiotherapy (SBRT)"
89003663|NCT04853017|Experimental|ELI-002 2P Cohort 4|ELI-002 2P Amph-CpG-7909 (5.0 mg) admixed with Amph modified KRAS peptides (Amph-G12D and Amph-G12R) administered via SC injection weekly for 4 consecutive weeks, followed by bi-weekly injections over 4 weeks, during the Immunization period; additional SC injections weekly for 4 consecutive weeks during the Booster Period (the two periods are separated by 3 months of no dosing)
89392254|NCT01368536|Experimental|Valturna|At double-blind randomization, all patients received 1 tablet Valturna 150/160 mg + 1 tablet Placebo Valturna+ 1 capsule placebo for 2 weeks. From Week 2, patients received 1 tablet Valturna 150/160 mg, + 1 tablet Valturna 150/160 mg + 1 capsule placebo for 6 weeks. From Week 8, patients received 1 tablet Valturna 150/160 mg + 1 tablet Valturna 150/160 mg + 1 capsule placebo for 4 weeks.
89392255|NCT01368536|Active Comparator|Valturna + Amlodipine|At double-blind randomization, all patients received 1 tablet Valturna 150/160 mg + 1 tablet Placebo Valturna+ 1 capsule placebo for 2 weeks. From Week 2, patients received 1 tablet Valturna 150/160 mg, + 1 tablet Valturna 150/160 mg + 1 capsule 5 mg amlodipine for 6 weeks. From Week 8, patients received 1 tablet Valturna 150/160 mg + 1 tablet Valturna 150/160 mg + 1 capsule 10 mg amlodipine for 4 weeks.
89392256|NCT01368536|Active Comparator|Valturna + chlorthalidone|At double-blind randomization, all patients received 1 tablet Valturna 150/160 mg + 1 tablet Placebo Valturna+ 1 capsule placebo for 2 weeks. From Week 2, patients received 1 tablet Valturna 150/160 mg, + 1 tablet Valturna 150/160 mg + 1 capsule 15 mg chlorthalidone for 6 weeks. From Week 8, patients received 1 tablet Valturna 150/160 mg + 1 tablet Valturna 150/160 mg + 1 capsule 25 mg chlorthalidonefor 4 weeks.
89392257|NCT05103735||PROPOFOL-REMIFENTANYL|"Awake craniotomy under propofol-remifentanil sedation. Propofol and remifentanyl was administered through continuous intravenous infusion, starting 30 minutes prior to surgery. The end of the infusion was at the end of the surgical procedure.~Propofol dosage: 0.2-2 mk/kg/h Remifentanyl dosage: 0.01-0.1 mcg/kg/min"
89392258|NCT05103735||DEXMEDETOMIDINE|"Awake craniotomy under dexmedetomidine sedation. Dexmedetomidine was administered through continuous intravenous infusion, starting 30 minutes prior to surgery. The end of the infusion was at the end of the surgical procedure.~Dexmedetomidine dosage: 0.2-1 mcg/kg/h In this group, remifentanyl administration was allowed."
89392259|NCT03626493||LSRH|patients who undergo laparoendoscopic single-site radical hysterectomy with pelvic lymphadenectomy
89392260|NCT03051165|Other|Hypoglossal Nerve Stimulation Treatment Withdrawal|Recipients of hypoglossal nerve stimulation (HGNS) who agree to participate in the study will have additional tests done to monitor cardiovascular responses to HGNS therapy and the temporary withdrawal of treatment.
89392261|NCT01319929|Experimental|LY2828360 then Placebo|80 milligrams (mg) of LY2828360 daily by mouth for 4 weeks: placebo daily by mouth for 4 weeks. There is a washout period of 3 weeks between treatments.
89392262|NCT01319929|Experimental|Placebo then LY2828360|Placebo daily by mouth for 4 weeks: LY2828360 daily by mouth for 4 weeks. There is a washout period of 3 weeks between treatments.
89392263|NCT03553316|Experimental|Sequence (1)|"Number of Subject: 24~Wash out Period: over 7 days (between each period)~Investigators Products(IPs) for Period1: A (Single)= PK101-002~IPs for Period2: B (Combination)= PK101-001, PK101-002"
89392264|NCT03553316|Experimental|Sequence (2)|"Number of Subject: 24~Wash out Period: over 7 days (between each period)~IPs for Period1: B (Combination)= PK101-001, PK101-002~IPs for Period2: A (Single)= PK101-002"
89392265|NCT04194099|Experimental|rTMS (Brain) + tsES (Spinal)|"First part 20 Hz rTMS (Brain) + Anode tsDCS (Spinal)~Brain:~Train pulse: 2 sec~Inter-train: 28 sec~Total time: 1200 sec~Spinal:~Continuous direct current (DC): 1200 sec~Second part iTBS rTMS(Brain) + 2.5-mA tsDCS (Spinal)~Brain:~Train pulse: 2 sec~Inter-train: 8 sec~Total time: 200 sec~Spinal:~Continuous direct current (DC): 600 sec"
89392266|NCT04194099|Experimental|rTMS (Brain) + tsES (Spinal) or sham stimulation|"First part 20 Hz rTMS (Brain) + 20 Hz current square-wave pulses (Spinal)~Brain and spinal:~Train pulse: 2 sec~Inter-train: 28 sec~Total time: 1200 sec~Second part iTBS rTMS(Brain) + sham 2.5-mA tsDCS (Spinal)~Brain:~Train pulse: 2 sec~Inter-train: 8 sec~Total time: 200 sec~Spinal:~Sham direct current (DC) stimulation"
89392267|NCT04194099|Experimental|iTBS rTMS or sham (Brain) + tsES or sham (Spinal)|"First part~Brain:~Train pulse: 2 sec~Inter-train: 8 sec~Total time: 200 sec~Spinal:~Continuous direct current (DC): 190 sec~Second part Sham iTBS rTMS (Brain) + 2.5-mA tsDCS (Spinal)~Sham iTBS rTMS Brain:~Spinal:~Continuous direct current (DC): 600 sec"
89392268|NCT04194099|Experimental|iTBS rTMS or sham (Brain) + iTBS or sham (Spinal)|"First part~Brain and spinal:~Train pulse: 2 sec~Inter-train: 8 sec~Total time: 200 sec~Second part Sham iTBS rTMS (Brain) + Sham 2.5-mA tsDCS (Spinal)~Brain:~Sham iTBS rTMS~Spinal:~Sham direct current (DC) stimulation"
89392269|NCT04194099|Sham Comparator|sham (no stimulation on brain nor spinal)|"First part Sham stimulation.~No second part"
89392270|NCT03552458|Experimental|LR group|Lactobacillus Reuteri Oral Solution [BioGaia]
89392271|NCT03552458|Placebo Comparator|Placebo group|Placebos: The control agent will not contain the active agent
89392272|NCT03633565|Active Comparator|Steroid|prednisolone 20 mg tablet by mouth taken once daily for 10 days each month for 2 years
89392273|NCT03633565|Active Comparator|Phosphodiestrase inhibitors|sildenafil 25 mg tablet by mouth once daily for 2 years
89392274|NCT03633565|Experimental|Mesenchymal stem cell transplantation|The cells can be injected intramuscular in several points in the muscle alternatively they can be injected in the motor point of the muscle. A motor point is the point at which the motor branch of the innervating nerve enters the muscle). This injection is repeated every 6 month up to 2 years.
89392275|NCT02120066|Other|Vitrectomy|
89392276|NCT02120144|Experimental|Intervention|15 young patients (<65 years old) and 15 older patients (>64 years old) are submitted to an observation phase and an imagination phase of walking at a precise rythm for 10 minutes
89392277|NCT02120144|Active Comparator|Reading|15 young patients (<65 years old) and 15 older patients (>64 years old) are submitted to a reading phase on a computer for 10 minutes.
89392278|NCT01373359|Experimental|Sublingual misoprostol|400 µg powdered misoprostol administered sublingually; IM placebo
89392279|NCT01373359|Active Comparator|Oxytocin|10 IU IM oxytocin; placebo powder
89392280|NCT02120534||Sepsis group|Forty seven patients are critically ill with evidence of sepsis during ICU stay (sepsis group). At admission, Patients data include clinical status; SOFA score; central venous pressure; laboratory analysis and arterial blood gas analysis are measured. Routine cultures will be obtained. The attending physician will evaluate the patients for sepsis, severe sepsis, or septic shock as long as their stay in ICU. A serum level of CD 14 and CD88 will be monitored.
89003664|NCT04853017|Experimental|ELI-002 2P Cohort 5|ELI-002 2P Amph-CpG-7909 (10.0 mg) admixed with Amph modified KRAS peptides (Amph-G12D and Amph-G12R) administered via SC injection weekly for 4 consecutive weeks, followed by bi-weekly injections over 4 weeks, during the Immunization period; additional SC injections weekly for 4 consecutive weeks during the Booster Period (the two periods are separated by 3 months of no dosing)
89186900|NCT04082624|Experimental|Self-regulation condition|Learned how to self-monitor their sedentary behavior and active breaks. They also learned how to create prompts/cues (e.g., sticky note reminder), problem solve to overcome barriers, action plan (i.e., specifying when, where, and how to do the behavior), and set goals in order to be less sedentary according to SMART (i.e., specific, measurable, attainable, relevant, time-oriented) principles. Received intervention following measurements at baseline, week 4, and week 8.
89186901|NCT04049253|Experimental|Acidic phosphate buffer solution|pH5.2 phosphate buffer solution
89186902|NCT04049253|Placebo Comparator|Neutral phosphate buffer solution|pH7.4 phosphate buffer solution
89186903|NCT00919958|Experimental|PLX-PAD low dose|
89186904|NCT00919958|Experimental|PLX-PAD intermediate dose|
89186905|NCT00919958|Experimental|PLX-PAD high dose|
89186906|NCT03217851||Patients Presenting P. falciparum Malaria|
89186907|NCT04082000|Experimental|BOL-DP-o-04|
89186908|NCT04082000|Placebo Comparator|Placebo|
89186909|NCT03205137||Telmisartan and hydrochlorothiazide group|
89186910|NCT03205137||Telmisartan and amlodipine group|
89186911|NCT03205137||Telmisartan+hydrochlorothiazide double-pill combination group|
89186912|NCT03205137||telmisartan+amlodipine double-pill combination group|
89186913|NCT04953650|Experimental|intervention group|two fasting days and five ad-libitum days followed by usual exercise.
89186914|NCT04953650|Sham Comparator|Control group|Usual diet and usual exercise prior to the intervention.
89186915|NCT05189522|Experimental|Innova Breeze®-based roadmap|"An Innova Breeze® bolus chase acquisition is realized prior to the revascularization to assess the lesions of the entire target limb. Guidance to the different lesions is done using a 2D roadmap based on the Innova Breeze® bolus acquisition frames if the patient position has not moved on the table.~An Innova Breeze® bolus chase acquisition is realized to assess the final result of the revascularization of the target limb. Both Innova Breeze® bolus chases are required at field of view 30-cm. Finally, the sheath is retrieved and the hemostasis at the puncture site is realized via a manual compression or using a vascular closure device.~DSAs are performed with the injector set at 7mL/s and the volume at 7mL (pressure limit 1000psi) for femoropopliteal assessment. Innova Breeze® bolus chase acquisitions are performed with the injector set at 4mL/s and the volume at 24mL (pressure limit 1000psi). An injector with iodinated contrast (50% of dilution) will be used."
89186916|NCT05189522|Other|control group|"2D roadmap guidance is used based on DSA. The treatment of the target lesion is let at the physician discretion. Treatment result of each lesion is checked by a DSA with 1 incidence.~After treatment overall limb assessment will be done through multiple staged DSA.~Finally, the sheath is retrieved and the hemostasis at the puncture site is realized via a manual compression or using a vascular closure device.~DSAs are performed with the injector set at 7mL/s and the volume at 7mL (pressure limit 1000psi) for femoropopliteal assessment. An injector with iodinated contrast (50% of dilution) will be used.~For hospitalized patients, three to five days after the procedure, a blood test is performed to assess the eGFR, as part of the usual care of patients. If the patient is no longer hospitalized, at the time of this examination, the investigating physician has given him an order before his discharge to perform this examination in an analysis laboratory."
89186917|NCT02588144|Active Comparator|[standard STN]|Device: standard stimulation on subthalamic (STN) contacts
89186918|NCT02588144|Experimental|[STN+SNr]|Device: Combined stimulation of the subthalamic nucleus (STN) and the substantia nigra pars reticulata (SNr)
89186919|NCT02586740||Pulmonary artery rehabilitation|Patients with pulmonary artery stenosis or small pulmonary arteries following surgical repair for tetralogy of Fallot with pulmonary atresia and major aortopulmonary collaterals undergoing cardiac catheterization.
89186920|NCT04951544|Experimental|Intervention Group|This arm will start the intervention using LetSync app v1.0 from T1 to T4, baseline/Month 0 to Month 14.
89186921|NCT04951544|Active Comparator|Waitlist-Control Group|This arm will wait to begin the intervention using the LetSync app v2.0 from T3 to T4, Month 8 to Month 14.
89186922|NCT02589236|Placebo Comparator|Placebo|Placebo Capsule
89186923|NCT02589236|Experimental|Cavosonstat (N91115) 200 mg|Cavosonstat (N91115) 200 mg twice daily (BID)
89186924|NCT02589236|Experimental|Cavosonstat (N91115) 400 mg|Cavosonstat (N91115) 400 mg BID
89186925|NCT00920036|Experimental|Arm 1|Eight subjects were trained to utilize a handheld biofeedback device
89186926|NCT00920036|No Intervention|Arm 2|usual care
89392281|NCT02120534||SIRS group|Forty seven patients are critically ill without evidence of infectious organism (SIRS group). At admission, Patients data include clinical status; SOFA score; central venous pressure; laboratory analysis and arterial blood gas analysis are measured. Routine cultures will be obtained. The attending physician will evaluate the patients for sepsis, severe sepsis, or septic shock as long as their stay in ICU. A serum level of CD 14 and CD88 will be monitored.
89392282|NCT02123030||Experimental|patients with pulmonary disease; and, patients with known or suspected lung or other cancers
89392283|NCT02123030||Control|healthy subjects (for example, family members of the patient or graduate students
89392284|NCT02123186||newborns testing for SMA|
88868366|NCT02412748|Active Comparator|Financial Literacy Program|"The Financial Literacy Program (FLP) attention control condition will not receive any information on fatherhood. They will participate in a nine-session financial education program, called Money Smart, which has modules that will be facilitated by a group leader that focus on banking, borrowing, checking accounts, money management, saving, establishing and repairing a credit history, using credit cards responsibly and learning about borrowing and home ownership. They will also receive a booster session 6 weeks after the final session that focuses on setting financial goals."
88868367|NCT02412748|Experimental|BBTF Intervention|"The Building Bridges to Fatherhood (BBTF) intervention employs the following key features: a collaborative model for working with parents; vignettes of father-child models engaged in situations typical of non-resident fathers with young children for stimulating discussion and problem-solving; group discussion format, which allows fathers to support one another and share ideas on using program principles to fit within the contexts of fatherhood; homework assignments that help fathers practice the new skills at home; weekly handouts summarizing the major points discussed each week, which can be shared with others and used to gain greater support from extended family; and a Leader's Manual that standardizes the program across groups and group leaders."
88868368|NCT02305095||GNB3 TT|All subjects with the GNB3 TT genotype for the polymorphism at position 825 (T/C). They will be initiated on therapy with FDC I/H, followed for 2 years and response to therapy quantified by a composite score (CS).
89392285|NCT03110185|Other|delirium|Patients in the cardiothoracic ICU diagnosed with postoperative delirium. Subjects will wear a diffuse optical tomography device in addition to the normal monitors. A non-contrast functional MRI will be performed.
89392286|NCT03110185|Other|no delirium|Patients in the cardiothoracic ICU not diagnosed with postoperative delirium. Subjects will be monitored in the same way as the delirium arm
89186927|NCT04684550|Placebo Comparator|Placebo|Health personnel who work in places of greater risk (hospitals and primary level consultation) with conventional protection elements added to the application of 2 nasal puff every 8 hours of a nasal spray containing 0.9% SSN (placebo) and gargles (SSN 0.9%).
89392287|NCT02123264|Active Comparator|Zoledronic acid|Zoledronic acid: 5 mg/year x 2 years
89392288|NCT02123264|No Intervention|No intervention|No intervention
89392289|NCT04132869|Experimental|Experimental Group|In Spring of 2020, all 6th graders in Wave 1 intervention schools (6 schools), which include 561 total 6th graders, will be invited to participate the intervention. Those in the experimental group will complete all measures according to the timeline. Those not in the experimental group will also complete the intervention, but will not participate in measurements. In Fall 2020 all 6th graders who attend the Wave 2 intervention schools (schools that were the control schools in Spring), will be invited to participate the intervention. Those in the experimental group will complete all measures on schedule. *Note these activities were delay due to schools shutting down in March 2020 because of COVID-19 In Fall 2021 all 6th graders who attend the Wave 3 intervention schools, will be invited to participate the intervention. Those in the experimental group will complete all measures on schedule.
89392290|NCT04132869|No Intervention|Control group|Wave 1 comparison schools (2 Schools) have a total of 267 6th graders. Students will be invited to join the comparison group. and will have measurements taken at baseline and 6 months. Wave 2 comparison schools (3 Schools) have a total of 363 6th graders adn will be invited to join the comparison group and will have measurements taken at baseline and 6 months. These students will continue with their normal activities as usual.*Note these activities were delay due to schools shutting down in March 2020 because of COVID-19
89392291|NCT02251964|Other|rituximab|single arm study with Zr-89-rituximab immuno PET/CT
89392292|NCT04739995|Experimental|Low-Dose-Naltrexone (LDN)|The LDN treatment will consist of one 4.5 mg naltrexone tablet (lactose-free) taken daily for 12 months before going to sleep.
88868369|NCT02305095||GNB3 C|All subjects with at least one copy of the GNB3 C allele which includes both subjects homozygous for the 825C allele (GNB3 CC genotype) and subjects who are heterozygous (GNB3 TC genotype).They will be initiated on therapy with FDC I/H, followed for 2 years and response to therapy quantified by a composite score (CS).
89392293|NCT04739995|Placebo Comparator|Placebo|The control group will take the placebo daily (a film-coated tablet, identical to the LDN, filled with a lactose-free excipient), for 12 months, following the same guidelines.
89392294|NCT02120612||Historical Control Group|Historical Control Group will be assessed for knowledge prior to the implementation of the educational program.
89392295|NCT02120612||Naloxone Education Intervention Group|Group to begin receiving the Naloxone Education Intervention on the signs of opioid overdose and appropriate use of naloxone.
89392296|NCT01374295|Experimental|video|If randomized to this arm patient watches a 3 minute video
89392297|NCT01374295|Active Comparator|standard education|If randomized to this arm patient receives standard verbal education from healthcare provider.
89392298|NCT02115152|Active Comparator|FEC|Patients will be randomized to received 4 cycles of fluorouracil, epirubicin and cyclophosphamide before surgery, and 4 cycles of docetaxel after surgery.
89392299|NCT02115152|Experimental|XEC|Patients will be randomized to received 4 cycles of capecitabine, epirubicin and cyclophosphamide before surgery, and 4 cycles of docetaxel and capecitabine after surgery.
89392300|NCT04680871||Normal, Healthy Subjects|
89392301|NCT04680871||Induced Febrile Subjects|
89392302|NCT02115230|Experimental|Renal denervation + medical therapy|Renal sympathetic denervation with an irrigated radiofrequency catheter with Celsius Thermocool (Biosense Webster, California, USA) + standard optimized medical therapy for diastolic heart failure
89392303|NCT02115230|No Intervention|Medical therapy|Standard optimized medical therapy for diastolic heart failure
89392304|NCT04657861|Experimental|Administration of APRIL CAR T-cells|Each subject receive APRIL CAR T-cells by intravenous infusion
89392305|NCT02115464|Experimental|Metformin plus Chemo-radiotherapy|Metformin orally 500 mg twice daily for the first week, 1500 mg a day in week 2 and 2000 mg a day at week 3 and then for a period of 12 months. Cisplatin-based chemotherapy with or without consolidation with standard radiotherapy of 60-63 Gy for 6 weeks.
89392306|NCT02115464|Active Comparator|Chemo-radiotherapy|Concurrent cisplatin based chemotherapy with or without consolidation and radiotherapy of 60-63 Gy for 6 weeks.
89392307|NCT02858076|Active Comparator|Intravitreous 2 mg aflibercept injections|Initial injection must be given on the day of randomization. Follow-up injections will be performed as often as every 4 weeks unless criteria for deferral are met.
89392308|NCT02858076|Active Comparator|Prompt vitrectomy plus panretinal photocoagulation|For the prompt vitrectomy + panretinal photocoagulation group, the vitrectomy must be scheduled to be performed within 2 weeks of randomization. Vitrectomy will be performed according to the investigator's usual routine, including pre-operative care, surgical procedure, and post-operative care, although anti-VEGF may not be given post-operatively unless there is recurrent hemorrhage.
89392309|NCT02115620|Experimental|Telemedicine|Patients will be followed using frequent communication of symptom status and physiologic data and remote consultations with Heart Failure specialists.
89392310|NCT01319695|Experimental|corifollitropin alfa|
89392311|NCT01319695|Active Comparator|recombinant follicle stimulating hormone (FSH)|150-300 IU of FSH for ovarian stimulation in women undergoing IVF
89392312|NCT01373437||Intubate|
89392313|NCT02123342|No Intervention|Exercise programme only|Participants randomized in this condition will not receive SMS reminders to execute the myPAtHS exercise programme.
89392314|NCT02123342|Experimental|SMS reminder|Participants in this study arm will receive SMS reminders to motivate them to execute the myPAtHS exercise programme.
89392315|NCT04594759|Experimental|Treatment Group|
88868370|NCT02272946|Other|Safety Arm|In Stage 1: all 10 subjects will receive 150 mg Canakinumab subcutaneous injection. This will be a preliminary safety study (before Stage II).
88868371|NCT02272946|Experimental|Canakinumab|In Stage II: About 67 subjects will receive 150mg Canakinumab subcutaneous injection.
88868372|NCT02272946|Placebo Comparator|Placebo|In Stage II: About 33 subjects will receive 150mg placebo subcutaneous injection
88868373|NCT02115698|Active Comparator|Heavy Resistance Training|Heavy Resistance Training of the lower extremities three times weekly in combination with two daily 20 g whey protein and 10 g carbohydrate supplementations for 52 weeks.
88868374|NCT02115698|Experimental|Light Intensity Training|Home-based Light Intensity Training of the lower extremities three-five times weekly in combination with two daily 20 g whey protein and 10 g carbohydrate supplementations for 52 weeks.
88868375|NCT02115698|Active Comparator|Protein Whey|Two daily 20 g whey protein and 10 g carbohydrate supplementations for 52 weeks.
88868376|NCT02115698|Active Comparator|Protein Collagen|Two daily 20 g collagen protein and 10 g carbohydrate supplementations for 52 weeks.
88868377|NCT02115698|Placebo Comparator|Carbohydrate|Two daily 30 g carbohydrate supplementations for 52 weeks.
89186928|NCT04684550|Experimental|Experimental|Health personnel who work in higher risk places (hospitals and primary level consultation) with conventional protection elements added to the application of 2 puffs and gargles every 8 hours of a solution with low concentrations of S-HCLO (3-5 ppm).
89186929|NCT00678561|Experimental|2% CP-690,550 QD|
89186930|NCT00678561|Experimental|0.2% CP-690,550 QD|
89186931|NCT00678561|Experimental|0.02% CP-690,550 QD|
89186932|NCT00678561|Experimental|2% CP-690,550 BID|
89186933|NCT00678561|Experimental|0.2% CP-690,550 BID|
89186934|NCT00678561|Experimental|0.02% CP-690,550 BID|
89186935|NCT00678561|Placebo Comparator|Placebo Vehicle QD|
89186936|NCT00678561|Placebo Comparator|Placebo Vehicle BID|
89186937|NCT05613296||Study group|All patients being observed during the study duration.
89186938|NCT04081532|Active Comparator|Surgical treatment|
89186939|NCT04081532|No Intervention|No surgical treatment|
89186940|NCT04731350|Experimental|Shock wave(A)|subjects will recive radial extracorporeal shock wave (2000 shock/session, 10Hz and EFD 0.178 mJ/mm²) on knee joints once per week for four weeks in addition to strengthening exercise
89186941|NCT04731350|Experimental|Iontophoresis (B)|subjects will recive dexamethasone iontophoresis on knee joints once per week for four weeks in addition to strengthening exercise
89186942|NCT04731350|Other|Control (C)|stregnthening exercise;straight leg raising exercisein which the patients were positioned in the crook lying position with the unexercised limb was the flexed one then the patients were asked to contract the quadriceps muscle and elevate the limb to 45º and hold for 6 seconds, slowly lower the limb and then relax for 6 seconds, three sets of 10 repetitions were don ,Isometric quadriceps contraction (quadriceps drill) in full knee extension maintained for 5 seconds, followed by a 5-second rest; the exercise was performed for 20 repetitions per session .treatment once per week for four weeks
89186943|NCT04081766|Active Comparator|SUGAR Handshake|"Participants assigned to the intervention group will receive an individualised, pharmacist-led patient counselling session (SUGAR Handshake package) at the inclusion visit.~Participants will also receive a pictogram with the main instructions for easy recall of the counselling contents.~They will also receive a glucometer and test strips with a demonstration on proper use, to measure their fasting blood glucose levels on a daily basis for 12 weeks.~At week 6, participants will receive a phone call to reinforce the intervention and to remind them of the study protocol. For the qualitative evaluation of the intervention, a number of participants are interviewed and asked questions through the sixth week-phone call.~Additionally, participants in this group will be provided with the usual care that is normally provided in the outpatient clinics at King Abdullah University Hospital."
89186944|NCT04081766|No Intervention|Control|"Participants within this group will receive the usual care provided by the health care professionals in the outpatient clinics at King Abdullah University Hospital.~They will also be provided with instructions on hypoglycemia diagnosis, and treatment and a demonstration on glucometer use at the inclusion visit. They will be asked to measure their fasting blood glucose level daily for 12 weeks.~Participants will receive a phone call at week 6 of the inclusion visit to remind them of measuring blood glucose levels and documenting hypoglycemic episodes on the diaries., plus a counselling session about hypoglycaemia recognition and treatment at the inclusion visit.~For the qualitative evaluation of the study, a number of participants will be interviewed and asked questions through the sixth week-phone call."
89186945|NCT02587832|Active Comparator|HHHFNC|Randomized to HHHFNC
89186946|NCT02587832|Active Comparator|NCPAP|Randomized to NCPAP
89186947|NCT00920114|Experimental|Lupus disease|
88868378|NCT02040714||Nonoperative management between ages 6-8 in early stage|The choice of non-osteotomy management without containment or surgical containment would be solely governed by the current practice of the participating surgeons (i.e. the current practice of the individual surgeon would be followed within the broad framework of the study).
88868379|NCT02040714||Operative management between age 6-8 in early stage|Operative containment treatment (femoral or pelvic osteotomy or Shelf acetabuloplasty) rendered in the early stage of the disease process
88868380|NCT02040714||Nonoperative management between age 8-11 in early stage|Patients who do not undergo some form of containment surgery because of medical, social, or other reasons will receive no surgical treatment.
89186948|NCT00920114|Active Comparator|Healthy witnesses|
89186949|NCT00920114|Active Comparator|Healthy witnesses with an other auto-immune disease|
89392316|NCT02123420|Other|Implant outcome|"This study was designed as a randomised, controlled, split-mouth trial. all enrolled patients needed single bilateral fixed implant-supported prosthesis in molar area.~A total of 18 consecutive patients were enrolled. In each eligible patient, the right molar was randomly selected to receive either Nobel Replace Tapered Groovy implant; (Nobel Biocare®, Goteborg, Sweden) with Platform Switching (PS) or Regular Platform (RP)"
89392317|NCT02123420|Other|Implant outome|"This study was designed as a randomised, controlled, split-mouth trial. all enrolled patients needed single bilateral fixed implant-supported prosthesis in molar area.~A total of 18 consecutive patients were enrolled. In each eligible patient, the left molar was randomly selected to receive either Nobel Replace Tapered Groovy implant; (Nobel Biocare®, Goteborg, Sweden) with Platform Switching (PS) or Regular Platform (RP)"
89392318|NCT02123498|Experimental|Single Arm|
89392319|NCT02237040|Experimental|treatment group|Patients are treated with the mandibular manipulation technique termly and mouth opening training
89392320|NCT02115776|No Intervention|Control|Receiving no prophylaxis
89392321|NCT02115776|Active Comparator|Amoxicillin|Receiving 2 g Amoxicillin intravenously before any dental manipulation and following endotracheal intubation
89392322|NCT02115776|Experimental|Amoxicillin-Potassium Clavulanate|Receiving 1000/200mg Amoxicillin-Potassium Clavulanate i.v. before any dental manipulation and following endotracheal intubation
89392323|NCT02115776|Active Comparator|Chlorhexidine (CHX)|Receiving a single 0.2% Chlorhexidine (CHX) mouthwash for 30 seconds before any dental manipulation and following endotracheal intubation
89392324|NCT02115776|Experimental|Amoxicillin-Potassium Clavulanate-CHX|Receiving 1000/200mg Amoxicillin-Potassium Clavulanate i.v. and a single 0.2% Chlorhexidine (CHX) mouthwash for 30 seconds before any dental manipulation and following endotracheal intubation
89392325|NCT02856282||Pirinase Hayfever Relief for Adults 0.05% Nasal Spray|Two sprays into each nostril once a day, preferably in the morning. Once symptoms are under control ,a maintenance dose of one spray may be used accordingly
89392326|NCT02115854||bacteriologically confirmed tuberculosis|
89392327|NCT02115932|Experimental|Strength & Balance Training Intervention|Subjects in this arm will undergo once weekly home-based strength and balance training for a period of 8 weeks.
89392328|NCT02115932|No Intervention|Control|Subjects in this arm will not undertake any procedures or activities related to the study. They will continue with their prescribed medication and other medical advice from their treating physician as per usual.
89392329|NCT03959319|Experimental|Movement Pattern Training|Focus will be on task-specific training to improve lower extremity movement patterns during basic daily tasks, such as sit to stand and stairs, and reported patient-specific tasks. Patient education will include instruction in abnormal movement patterns and methods to optimize movement patterns during each task. Tasks will be prioritized based on patient-report of activity limitations during the baseline examination. For example, during the first visit, the treating physical therapist will begin with the daily and patient-specific tasks that the patient reported as being most bothersome. Exercises will include repeated practice of functional tasks using optimized movement patterns. Based on the participant's performance, the difficulty of the task-specific activities will be progressed by varying the repetitions performed, increasing the load or changing the support surface. The home program will consist of repeated practice of tasks performed during the supervised sessions.
89392330|NCT03959319|Active Comparator|Manual Therapy (Joint Mobilization)|Focus will be on reducing pain and improving pain-free range of motion using manual techniques provided by the physical therapist and exercise performed in the home program. Patient education will include instruction to the benefits of manual therapy and the proposed effects on pain and joint mobility. Joint mobilizations to be used with each patient will be prioritized based on the restrictions, defined as stiffness or pain that is limiting joint range of motion, noted on the patient's baseline examination. For example, during the first visit, the treating physical therapist will begin with the two most restricted motions noted in the baseline exam and perform a standard assessment to determine treatment parameters. The home program will include joint range of motion and stretching exercises to complement techniques performed during the supervised sessions.
89392331|NCT02123654|Experimental|Arm 1: DCV 3DAA + Placebo for DCV/Placebo for ASV|DCV 3DAA tablet orally twice daily for 12 weeks + Placebo for DCV tablet orally once daily and Placebo for ASV capsule orally twice daily for 24 weeks (Double blind)
89392332|NCT02123654|Active Comparator|Arm 2: DCV/ASV + Placebo for DCV 3DAA|Daclatasvir 60 mg tablet orally once daily and Asunaprevir 100 mg capsule orally twice daily for 24 weeks + Placebo for DCV 3DAA tablet orally twice daily for 12 weeks (Double blind)
88868381|NCT02040714||Operative containment with short-term non-weightbearing in early stage|"As per the current standard practice for patients between age 8-11 in developed countries, all patients will undergo some form of containment surgery (pelvic or femoral osteotomy) in order to better contain the femoral head underneath the acetabulum. Post-operative treatment will include 6 weeks of non-weight bearing on the operated leg."
88868382|NCT02040714||Operative containment with prolonged non-weightbearing in early stage|"As per the current standard practice for patients between age 8-11, all patients will undergo some form of containment surgery (pelvic or femoral osteotomy) in order to better contain the femoral head underneath the acetabulum. Post-operative treatment will include 6 months of non-weight bearing on the operated leg."
88868383|NCT02040714||Operative containment for over 11 age group|Patients presenting over age 11 may receive multiple drilling and be non weight bearing for up to 6 months according to the treating physician's preference. Patients with application of fixator (arthrodiastasis) will be studied in this cohort arm as well, which typically involved 3-4 months followed by 8-12 weeks of non-weight bearing after fixator removal. Other surgical techniques may be included, however these are the most common for this age group.
88868384|NCT02040714||Nonoperative management in over 11 age group|Patients will be non-weight bearing and receive physical therapy according to the physician preferences.
88868385|NCT02040714||Nonoperative management in 1-6 age group|The choice of non-osteotomy management without containment or surgical containment would be solely governed by the current practice of the participating surgeons (i.e. the current practice of the individual surgeon would be followed within the broad framework of the study).
89392333|NCT02123654|Experimental|DCV 3DAA|DCV 3DAA (open label) Tablet orally twice daily for 12 weeks
89392334|NCT03609138||Study Cohort|
89392335|NCT02116010|Active Comparator|E. coli, Standard of care : Silver Sulfadiazine|Burn wounds infected by E. coli treated with Standard of care : Silver Sulfadiazine
89392336|NCT02116010|Experimental|E. coli, Phages cocktail|Burn wounds infected by E. coli treated with Pherecydes Pharma Phages cocktail
89392337|NCT02116010|Active Comparator|P. aeruginosa, Standard of care : Silver Sulfadiazine|Burn wounds infected with P. aeruginosa treated with Standard of care : Silver Sulfadiazine
89392338|NCT02116010|Experimental|P. aeruginosa, Phages cocktail|Burn wounds infected by P. aeruginosa treated treated with Pherecydes Pharma Phages cocktail
89392339|NCT03609294|Experimental|Sequence A|"Period 1(Treatment A) - Period 2(Treatment A) - Period 3(Treatment B)~There will be a washout of 35 days between the each period."
89392340|NCT03609294|Experimental|Sequence B|"Period 1(Treatment A) - Period 2(Treatment B) - Period 3(Treatment A)~There will be a washout of 35 days between the each period."
89392341|NCT03609294|Experimental|Sequency C|"Period 1(Treatment B) - Period 2(Treatment A) - Period 3(Treatment A)~There will be a washout of 35 days between the each period."
89392342|NCT05214495|Experimental|Topical oral Omega-3 hydrogel group|Patients will be given topical oral Omega-3 hydrogel
89392343|NCT05214495|Active Comparator|Conventional preventive treatment group|Patients will be given conventional preventive treatment
89392344|NCT03608904|Experimental|Music Listening|Familiar and unfamiliar music selections, listening duration of approximately 15 minutes, three times daily, 90-day listening duration.
89392345|NCT03608904|Placebo Comparator|Spoken word (language) listening|Familiar and unfamiliar spoken word (language) selections, listening duration of approximately 15 minutes, three times daily, 90-day listening duration.
89392346|NCT03551990|No Intervention|Control group; patients without a tumor disease, surgery|Control group with patients without a tumor disease but with indication for surgery in close proximity to the M. rectus abdominis
89392347|NCT03551990|No Intervention|Control group; tumor patients, surgery|Control group with patients with solid tumors; patients with pancreatic, colorectal, esophageal, gastric and liver solid tumors with indication for surgery in close proximity to the M. rectus abdominis
89392348|NCT03551990|Experimental|Intervention group; tumor patients, WB-EMS, surgery|Intervention group with patients with solid tumors who do perform an 8-week physical training in form of whole-body electromyostimulation (WB-EMS); patients with pancreatic, colorectal, esophageal, gastric and liver solid tumors with indication for surgery in close proximity to the M. rectus abdominis
89392349|NCT03907917|Active Comparator|Active tDCS|Current will be ramped in/out for 30 seconds at the begging and end of a 20-minute period and a constant current will be delivered for the 20-minutes between ramping.
89392350|NCT03907917|Sham Comparator|Sham tDCS|Current will be ramped in/out for 30 seconds at the begging and end of a 20-minute period during which no stimulation will be delivered.
89186950|NCT04691180|Experimental|Cohort 1|BRII-196 and BRII-198 dose level 1 or placebo
89186951|NCT04691180|Experimental|Cohort 2|BRII-196 and BRII-198 dose level 2 or placebo
89186952|NCT04912622|Experimental|Control|Device: Cellularis version 2.0 imaging Image acquisition of retinal pigment epithelium (RPE) cells of central retina with consecutive qualitative and quantitative description of these retinal cell layers.
89186953|NCT04912622|Experimental|Patient|Device: Cellularis version 2.0 imaging Image acquisition of retinal pigment epithelium (RPE) cells of central retina with consecutive qualitative and quantitative description of these retinal cell layers.
89186954|NCT04900376||vaccinated group|
89392351|NCT01917552|Experimental|capecitabine|capecitabine 1250 milligram (mg) / m² po bid (D1-14)
89392352|NCT01917552|No Intervention|observation|
89392353|NCT02120690|Experimental|Trigeminal nerve stimulation - active|10-day TNS interventional protocol over an 10-day follow-up
89392354|NCT02120690|Sham Comparator|Trigeminal nerve stimulation|10-day sham interventional protocol over an 10-day follow-up
89392355|NCT02120768|Experimental|Barrier resection|"Barrier resection was defined as en bloc removal of tumor with surrounding barriers. The barriers include muscular fascia, vascular adventitia, epineurium and periosteum, in some cases where there is no barrier, 3-5cm of healthy tissue is considered equivalent. Barrier resection was developed according to the above characteristics of STSs, which featured with the fact that sarcomas take the path of least resistance and initially grow within the anatomical compartment in which they arose, and the phenomenon that skip metastases are limited within the same anatomic compartment in which the primary lesion is located.Further surgery would be 1cm resection if a recurrence occurs."
89186955|NCT04900376||unvaccinated group|
89392356|NCT02120768|Active Comparator|1 cm resection|Surgical margin width is determined mainly by the distance from the tumor edge to the periphery of the specimen, different margin width of 1-5cm has been recommended for obtaining a safe margin,but the local recurrence rate remains to be 10-25%. Further surgery would be barrier resection if a recurrence occurs.
89392357|NCT02120846|Experimental|Flywheel leg-press resistance exercise|Participants from the resistance exercise group will perform a 12-wk unilateral flywheel resistance training program with the paretic limb. Four sets of seven coupled concentric and eccentric actions will be completed in the leg press device using flywheel technology twice weekly. Power in each set and repetition will be measured. During all training sessions, subjects will receive visual real-time feedback of power and force produced during each concentric-eccentric action.
89392358|NCT02120846|No Intervention|Control|Daily routines
89392359|NCT03833817|Experimental|Patient intervention arm|This intervention arm contains the patients from this single arm study in which patients and caregivers will be given the experimental intervention (TAC intervention) with assessments pre and post intervention. The intervention will consist of six 45-minute telephone-delivered sessions. Session topics will include: (a) Distress management/tolerance (Sessions 1 and 2); (b) communication skills (Sessions 3 and 4); (c) guided review of prognostic information (Session 5); and (d) Intervention review and future plan (Session 6). Sessions will be completed by the individual (Sessions 1 and 3) and dyad (Sessions 2, and 4-6).
89392360|NCT03833817|Experimental|Caregiver (of patient) intervention arm|This intervention arm contains the caregivers of patients from this single arm study in which patients and caregivers will be given the experimental intervention (TAC intervention) with assessments pre and post intervention. The intervention will consist of six 45-minute telephone-delivered sessions. Session topics will include: (a) Distress management/tolerance (Sessions 1 and 2); (b) communication skills (Sessions 3 and 4); (c) guided review of prognostic information (Session 5); and (d) Intervention review and future plan (Session 6). Sessions will be completed by the individual (Sessions 1 and 3) and dyad (Sessions 2, and 4-6).
89392361|NCT02116088|Active Comparator|Receiving Teacher Coaching|Teachers who currently take part in teacher coaching
89392362|NCT02116088|No Intervention|Waiting for Teacher Coaching|Teachers who are currently waiting for taking part in teacher coaching
89392363|NCT02116166||Young|Young (20-35 years old)
89392364|NCT02116166||Old|Older (70-99 years old)
89392365|NCT05022771|Experimental|Single Ascending Doses Cohort 1a|Subjects will receive either Dose level 1 of PMG1015 or Placebo
89392366|NCT05022771|Experimental|Single Ascending Doses Cohort 1b|Subjects will receive either Dose level 2 of PMG1015 or Placebo
88868386|NCT02040714||Operative management in 1-6 age group|The choice of osteotomy management with containment would be solely governed by the current practice of the participating surgeons (i.e. the current practice of the individual surgeon would be followed within the broad framework of the study).
89392367|NCT05022771|Experimental|Single Ascending Doses Cohort 1c|Subjects will receive either Dose level 3 of PMG1015 or Placebo
88868387|NCT02040714||Late Stage Bracing group|Patients presenting with <= 20 degrees of abduction on a maximum abduction x-ray treated with bracing who also present in the late stages of the disease (Waldenstrom Stage IIb or IIIa).The choice of management with or without containment or surgical containment would be solely governed by the current practice of the participating surgeons (i.e. the current practice of the individual surgeon would be followed within the broad framework of the study).
89186956|NCT04081376|Experimental|Treatment group|Subjects receive a single-dose treatment.Urine samples will be collected after administration (8 fractions: 0-4h, 4-8h, 8-12h, 12-24h, 24-36h, 36-48h, 48-60h, 60-72h post-administration).
89186957|NCT04890158|Experimental|Prone positioning for a total of 6 hours daily by study protocol|Patients will be positioned prone for 3 hours then placed supine for 3 hours then prone again for 3 additional hours. The change in position from prone to supine and back is to more reliably document possible changes in ventilation, oxygenation, other vital signs and respiratory support required.
89186958|NCT04890158|No Intervention|usual positioning|"Patients in the newborn intensive care unit are physically handled usually every 3-4 hours. Those study participants who are randomly assigned to usual position may rest in a variety of positions in any order based on nursing or perceived patient preference. Positions may include supine, right lateral, left lateral, and prone as well."
89186959|NCT00920192|Experimental|Foretinib|Phase I starting dose of 30 mg/day escalated to 45 mg/day, de-escalated to 30 mg/day; MTD for Phase II was 30 mg/day
89392368|NCT05022771|Experimental|Single Ascending Doses Cohort 1d|Subjects will receive either Dose level 4 of PMG1015 or Placebo
89392369|NCT05022771|Experimental|Single Ascending Doses Cohort 1e|Subjects will receive either Dose level 5 of PMG1015 or Placebo
89392370|NCT05022771|Experimental|Single Ascending Doses Cohort 1f|Subjects will receive either Dose level 6 of PMG1015 or Placebo
89392371|NCT05022771|Experimental|Single Ascending Doses Cohort 1g|Subjects will receive either Dose level 7 of PMG1015 or Placebo
89392372|NCT02116400||Suicidal|"Patients in this group have had suicidal behaviour according to the C-SSRS score.~Intervention: Interview Intervention: Neuropsychological testing Intervention: Serum concentration of lithium or sodium divalproate."
89392373|NCT02116400||Not suicidal|"Patients in this group have not had suicidal behaviour according to the C-SSRS score.~Intervention: Interview Intervention: Neuropsychological testing Intervention: Serum concentration of lithium or sodium divalproate."
89392374|NCT02732184|Experimental|AEB1102 (Co-ArgI-PEG) administered via IV weekly.|Co-ArgI-PEG modified human arginase I
89392375|NCT02121080|Experimental|Cohort 1|Dosing regimen 1
89392376|NCT02121080|Experimental|Cohort 2|Dosing regimen 2
88868388|NCT02040714||Late Stage Symptomatic treatment group|Patients presenting in the late stages of the disease (defined as Waldenstrom stage IIb or IIIa) who are treated symptomatically. The choice of management with or without containment or surgical containment would be solely governed by the current practice of the participating surgeons (i.e. the current practice of the individual surgeon would be followed within the broad framework of the study).
89392377|NCT02121080|Experimental|Cohort 3|Dosing regimen 3
89392378|NCT02121080|Experimental|Cohort 4|Dosing regimen 4
89392379|NCT02121080|Experimental|Cohort 5|Dosing regimen 5
89392380|NCT03608592|Experimental|UCMSCs group|Intravenous infusion of 1million UCMSCs per kilogram body weight suspended in 100ml normal saline, infusion duration 30-60min.
89392381|NCT03552302||Cases|Yoga exercise for 12 weeks
89392382|NCT03827265|Experimental|TMS on SFG|"Device: repetitive transcranial magnetic stimulation (real)~Transcranial magnetic stimulation (TMS) uses magnetic stimulation to change patterns of activity in your brain. This arm will target the superior frontal gyrus (SFG).~Other Name: rTMS (active stimulation)"
88868389|NCT02040714||Late Stage Surgical Containment group|Patients presenting in the late stages of the disease (defined as Waldenstrom stage IIb or IIIa) who are treated with surgical containment. The choice of management with or without containment or surgical containment would be solely governed by the current practice of the participating surgeons (i.e. the current practice of the individual surgeon would be followed within the broad framework of the study).
88868390|NCT01995344|Active Comparator|ARM A: High Dose Interleukin-2 (HD IL2)|Eligible participants will undergo surgical tumour excision from which TIL will be derived, cultured and expanded. Participants will receive preconditioning chemotherapy with cyclophosphamide (60mg/kg) day -7 and day -6, followed by fludarabine (25mg/m2) day -5 to day -1. The autologous TILs will be re-infused on day 0 and the patients will receive up to 12 doses of intravenous HD IL2
88868391|NCT01995344|Active Comparator|ARM B: Low Dose Interleukin-2 (LD IL2)|Eligible participants will undergo surgical tumour excision from which TIL will be derived, cultured and expanded. Participants will receive preconditioning chemotherapy with cyclophosphamide (60mg/kg) day -7 and day -6, followed by fludarabine (25mg/m2) day -5 to day -1. The autologous TILs will be re-infused on day 0 and the patients will receive up to 12 doses of intravenous LD-IL2
89186960|NCT02584400|Experimental|[18F]HX4 PET imaging|Injection with the hypoxia tracer [18F]HX4 and PET imaging at baseline for esophageal, rectal, prostate cancer, primary brain tumor (grade IV glioma) and brain metastases and after 2 weeks of radiotherapy for esophageal, rectal and brain metastases
89392383|NCT03827265|Experimental|TMS on PPC|"Device: repetitive transcranial magnetic stimulation (rTMS)~Transcranial magnetic stimulation (TMS) uses magnetic stimulation to change patterns of activity in your brain. This arm will target the posterior parietal cortex (PPC).~Other Name: rTMS (active stimulation)"
89392384|NCT03827265|Experimental|TMS on dlPFC|"Device: repetitive transcranial magnetic stimulation (rTMS)~Transcranial magnetic stimulation (TMS) uses magnetic stimulation to change patterns of activity in your brain. This arm will target the dorsolateral prefrontal cortex (dlPFC).~Other Name: rTMS (active stimulation)"
89392385|NCT03827265|Placebo Comparator|TMS on v5|"Device: repetitive transcranial magnetic stimulation (rTMS)~Transcranial magnetic stimulation (TMS) uses magnetic stimulation to change patterns of activity in your brain. This arm will target visual cortex (v5).~Other Name: rTMS (sham stimulation)"
89392386|NCT02720718|Experimental|Stratafix|"Patients undergoing laparoscopic RYGB (antecolic, antegastric, linear anastomosis-technique) using unidirectional barbed (knotless) sutures: Stratafix Unidirectional 2/0."
89392387|NCT02720718|Active Comparator|Vicryl|"Patients undergoing laparoscopic RYGB (antecolic, antegastric, linear anastomosis-technique) using classic sutures: Vicryl 2/0."
89392388|NCT02123732|Experimental|DbXell|Drug: DbXell three times daily for 12 weeks and then switching to Placebo of DbXell for 12 additional months Other: Lifestyle modification Each study subject will be provided with and instructed to follow a lifestyle modification (particularly regarding dietary advice and exercise) during the subject's participation in the study.
89392389|NCT02123732|Placebo Comparator|Placebo|Drug: Placebo of DbXell Placebo of DbXell three times daily for 12 weeks and then switching to DbXell for 12 additional weeks Other: Lifestyle modification Each study subject will be provided with and instructed to follow a lifestyle modification (particularly regarding dietary advice and exercise) during the subject's participation in the study.
89392390|NCT04059588|Experimental|Injection of 2141-V11|Open label study drug 2141-V11 at escalating doses until MTD is determined, and expansion utilizing the MTD.
89392391|NCT02123810|Other|Control|The investigators measure quality of chest compressions before nightshift. Control group
89392392|NCT02123810|Other|OFF|The investigators measure quality of chest compressions before nightshift. After night shift group
89186961|NCT00676143|Experimental|Bapineuzumab 0.5 mg/kg|
89186962|NCT00676143|Placebo Comparator|Placebo|
88868392|NCT01845688|Experimental|Losartan Tablets & QingReMoShen Granule|Losartan Tablets: 50mg, qd, po. QingReMoShen Granule: 12g, tid, po.
89392393|NCT03119701|Experimental|FP-1201-lyo 10 µg|"FP-12-lyo 10 µg (Interferon Beta-1a) will be administered once daily as an intravenous bolus injection for 6 days.~Investigational product is lyophilisate for solution for injection which will be reconstituted in water for injection."
89392394|NCT03119701|Placebo Comparator|FP-1201-lyo Placebo|"FP-1201-lyo Placebo will be administered once daily as an intravenous bolus injection for 6 days.~Investigational placebo is lyophilisate for solution for injection which will be reconstituted in water for injection"
89392395|NCT03717129|Active Comparator|Genvoya Oral dose|Single observed oral dose of Genvoya whole tablet
89392396|NCT03717129|Experimental|Genvoya Crushed Dose|Single observed oral dose of Genvoya crushed tablet
89392397|NCT02116478|Experimental|gastrocnemius recession|gastrocnemius recession
89392398|NCT02123888|Experimental|Cone Beam Computed Tomography|Simultaneous Cone Beam Computed Tomography acquisition during arc radiotherapy.
89392399|NCT03627039||Truven|NOTE: In the case there are not enough patients/events data will be included from other databases (e.g., Optum, Medicare)
89392400|NCT01374373|Other|Open Label|One arm open label
89392401|NCT02116556|Active Comparator|Prednisone|Prednisone PO 40mg/day for 30 days plus standard supportive care measurements
89392402|NCT02116556|Experimental|Prednisone plus Rifaximin|Prednisone PO 40mg/day for 30 days plus Rifaximin PO 1200 mg/day for 90 days plus standard supportive care measurements
88868393|NCT01845688|Placebo Comparator|Losartan Tablets & Placebo Granule|Losartan Tablets: 50mg, qd, po. Placebo Granule: 12g, tid, po.
88868394|NCT01844726|Experimental|GLYX-13|Single IV infusion of GLYX-13, 5mg/kg,
88868395|NCT01844726|Placebo Comparator|Placebo|Single IV administration of placebo
89392403|NCT02121236||Patients with benign radiolucent lesions|
89392404|NCT03634345|Experimental|PF-04965842|investigational drug
89392405|NCT02116634|Experimental|mesenchymal stem cell|intra spinal injection of 1 ×10(8) mesenchymal stem cells +10cc normal saline
88868397|NCT01679132|Experimental|BAROSTIM NEO System|Subjects implanted with the BAROSTIM NEO System.
88868398|NCT01591291|Experimental|Ondansetron|
88868399|NCT01591291|Placebo Comparator|Placebo|
89186963|NCT02586272|Experimental|Daifert|• Interventional Group: The embryo to be transferred is selected on the basis of both morphological assessment performed on Day 2 or 3 and FF G-CSF concentration. FF G-CSF concentration will be measured with the Diafert® immunoassay.
88868400|NCT01093300|Experimental|Paclitaxel-eluting balloon catheter|Paclitaxel-eluting balloon catheter use for treatment of ISR lesion
88868401|NCT01093300|Active Comparator|Everolimus-eluting stent|Everolimus-eluting stent use for treatment of ISR lesion
88868402|NCT00852124|Placebo Comparator|Placebo|Packets similar to VSL#3 will be taken 2 X daily but not containing active bacteria
88868403|NCT00852124|Active Comparator|VSL#3|Packets of VSL#3 (powder containing 8 bacteria believed to be beneficial) will be taken 2 x daily in food or a cool beverage.
88868404|NCT01053078|Experimental|Naltrexone|
88868405|NCT01053078|Placebo Comparator|Placebo|
88868406|NCT01053156|Placebo Comparator|Placebo pill|All patients will be on placebo for 3 months in this crossover study.
88868407|NCT01053156|Experimental|Minocycline|All patients will be on minocycline for 3 months in this crossover trial.
88868408|NCT01053312|Experimental|1 flutemetamol|
88868409|NCT01054404|Active Comparator|Furosemide|Furosemide 0.3 mg/kg
88868410|NCT01054404|Placebo Comparator|Placebo|Up to 5 mL saline
89186964|NCT02586272|Other|Control Group|Control Group: The embryo to be transferred is selected on the basis of morphological assessment performed on Day 2 or 3.
89186965|NCT04082390|Experimental|RELEASE Supplement|
89392406|NCT02906137|Experimental|HIV-1 infected subjects|"40 subjects will be recruited in the Department of Infectious Diseases of Toulouse University Hospital, France:~15 subjects will have an upper endoscopy (gastroscopy) with duodenal sampling~15 subjects will have a lower endoscopy (coloscopy) with colonic and ileal sampling~10 subjects will have both a gastroscopy and a coloscopy"
89392407|NCT02906137|Other|Uninfected-controls|"40 subjects will be recruited in the Department of Internal Medicine of Toulouse University Hospital, France:~10 subjects will have an upper endoscopy (gastroscopy) with duodenal sampling~10 subjects will have a lower endoscopy (coloscopy) with colonic and ileal sampling~20 subjects will have both a gastroscopy and a coloscopy"
89392408|NCT02121314|Active Comparator|Fasting-Fed|blood sampling on 3 consecutive days; by randomization, drug treatment as follows: day 1, HRZE as iv therapy; on day 2, HRZE as oral therapy in fasting condition (2 hours before meals); and on day 3 HRZE as oral therapy in fed condition (after meals).
89392409|NCT02121314|Active Comparator|Fed-Fasting|blood sampling on 3 consecutive days; by randomization, drug treatment as follows: day 1, HRZE therapy as iv therapy; day 2, HRZE as oral therapy in fed condition, and on day 3, HRZE as oral therapy in fasting condition
89392410|NCT05760859|Experimental|Chest pain|"Patient answers the initial question of history taking on why he had come to the hospital with Chest pain"
89392411|NCT05760859|Experimental|Dyspnoea|"Patient answers the initial question of history taking on why he had come to the hospital with Dyspnoea"
89392412|NCT05760859|Experimental|Chest pain AND Dyspnoea|"Patient answers the initial question of history taking on why he had come to the hospital with Chest pain, and Dyspnoea"
89392413|NCT05760859|Experimental|Chest pain AND dyspnoea, AND leg pain|"Patient answers the initial question of history taking on why he had come to the hospital with Chest pain, and Dyspnoea, and leg pain"
89392414|NCT05760859|Experimental|Chest pain AND dyspnoea, AND immobilization|"Patient answers the initial question of history taking on why he had come to the hospital with Chest pain, and Dyspnoea, and immobilization"
89392415|NCT05760859|Experimental|Chest pain AND dyspnoea, AND leg pain AND immobilization|"Patient answers the initial question of history taking on why he had come to the hospital with Chest pain, and Dyspnoea, and leg pain, and immobilization"
89392416|NCT03553238|Experimental|ETP-ALL|Chidamide at a dose of 10mg/day will be added to PDT-ETP-ALL protocol. The intervention of PDT-ETP-ALL consists of diagnostic test (bone marrow aspiration, flow immunophenotyping, Karyotyping ，FISH, NGS, Flow-MRD, PET-CT scan), induction regimen (chidamide, dexamethasone, vincristine, cyclophosphamide, idarubicin, pegaspargase), consolidation regimen (chidamide, prednisone, cytarabine, methotrexate, cyclophosphamide, etoposide, adriamycin, 6-mercaptopurine, pegaspargase), MRD assessment and maintenance regimen (chidamide, prednisone, vincristine, methotrexate, 6-mercaptopurine), intrathecal injection chemotherapy, radiation therapy (for mediastinum- and/or central nervous system-involved lymphoma/leukemia) and allogeneic hematopoietic stem cell transplantation for patients with donor.
89392417|NCT04980027|Experimental|Insuline Glargine (U300) (Gla-300)|Insulin glargine (U300) once daily for 24 weeks on top of non-insulin antidiabetic drug. Insulin dose will be adjusted according to the recommended titration algorithm
89392418|NCT01373593|Experimental|lidocaine|lidocaine block
89392419|NCT01373593|Placebo Comparator|Placebo|
89392420|NCT04611477|Placebo Comparator|Placebo|One capsule/day to be taken orally 30 minutes before breakfast
89392421|NCT04611477|Active Comparator|Synbiotic365 Ver 5|One capsule/day to be taken orally 30 minutes before breakfast
89392422|NCT04611477|Active Comparator|Synbiotic365 Ver 7|One capsule/day to be taken orally 30 minutes before breakfast
89392423|NCT02116712|Experimental|Saracatinib|"Only one arm: Intervention is Saracatinib. We plan to study three escalating doses of oral saracatinib; 50, 125 and 175 mg. Saracatinib is given orally once a day.~More regarding dose escalation is included in intervention below."
89392424|NCT02116790|Placebo Comparator|Control Group|10 participants will be given two pills: both will be placebos
89392425|NCT02116790|Active Comparator|Standard Treatment / Positive Control Group|10 participants will be given two pills: both will be Naproxen (each pill = 250mg, total dose = 500mg)
89392426|NCT02116790|Active Comparator|Experimental Group #1|10 participants will be given two pills: one will be Naproxen (250 mg) and the other will be of Sinemet (carbidopa/levodopa 12.5mg/50mg)
89392427|NCT02116790|Active Comparator|Experimental Group #2|10 participants will be given two pills: one will be Naproxen (250 mg) and the other will be of Sinemet (carbidopa/levodopa 25mg/100mg )
88868411|NCT01055184|Experimental|2009 H1N1 Vaccine|Participants will be stratified by age into two groups: those between 60 and 70 years old, and those older than 70 years of age. All participants will receive the 2009 H1N1 vaccine.
89392428|NCT04675489|Other|Vivity Toric IOL|Patients with cataract that had phacoemulsification and Vivity Toric IOL implantation.
89392429|NCT04935021|Experimental|ATTR-CM|Patients or Gene carrier
88868412|NCT01056198|Active Comparator|Santyl|2 mm Santyl applied once daily
88868413|NCT01056198|Sham Comparator|Control|Daily gauze and optional sharp debridement
88868414|NCT01058070|Experimental|Implantable Device|Subjects who meet eligibility criteria are implanted with the Magnetic Esophageal Sphincter device (MES)
88868415|NCT01060020|Experimental|Sildenafil 40mg or 80mg|A single oral dose of Sildenafil (either 40mg or 80mg) will be administered to a participant after baseline hemodynamics are measured in the catheterization lab. Each dose will be equally distributed among those with preserved (≥50%) and reduced (<50%) EF.
88868416|NCT01060098||Rheumatoid arthritis|Participants with Rheumatoid arthritis
88868417|NCT01060098||Ankylosing spondylitis|Participants with Ankylosing spondylitis
89392430|NCT02859961|Experimental|PRO 140 SC 350 mg weekly injection (Group A)|PRO 140 350 mg (175 mg/mL) SC injections per week
88868418|NCT01060098||Psoriatic arthritis|Participants with Psoriatic arthritis
88868419|NCT01064076|Experimental|S-ICD System|This is a single arm study
88868420|NCT01065480|Active Comparator|Live Teleconference Supervision|Clinicians from participating substance abuse treatment programs receive live supervision by MI trainer via teleconference while in session with client.
89392431|NCT02859961|Experimental|PRO 140 SC 525 mg weekly injections (Group B)|PRO 140 525 mg (175 mg/mL) SC injections per week
89392432|NCT02859961|Experimental|PRO 140 SC 700 mg weekly injections (Group C)|PRO 140 700 mg (175 mg/mL) SC injections per week
89392433|NCT02124200|Other|EGO/CE4, 9mg nicotine|
89392434|NCT02124278|Experimental|PUL-042 Inhalation Solution|Fixed dose combination of Pam2CSK4 acetate (Pam2) and ODN M362 (ODN) administered as an inhalation solution. Single dose administration by nebulization. Starting dose will be 2.9 micrograms Pam2: 4.25 micrograms ODN. Up to 7 doubling doses may be tested.
89392435|NCT02124278|Placebo Comparator|Sterile water for injection|Sterile water for injection administered by nebulization
88868421|NCT01065480|Active Comparator|Taped Review Supervision|Clinicians from participating substance treatment programs audio record session with client and receive supervision after the session by MI trainer.
88868422|NCT01065558|Experimental|Ecopipam 12.5 - 200 mg/day|Patients were administered ecopipam on an escalated dosing schedule over 11 days starting at 12.5 mg/day and increasing to the maximal tolerated dose or to 200 mg/day.
88868423|NCT01065714|Experimental|Hydrogel vehicle|Parallel designed study. Split body treatment
88868424|NCT01065714|Active Comparator|Eucerin Lotion|Parallel study design. Split body study.
88868425|NCT01066026|Experimental|Metallic cannula|Nasolabial Fold with metallic cannula and hyaluronic acid injected. hyaluronic acid with metallic cannula or standard needle. Hyaluronic acid injected with the new tool
88868426|NCT01066026|Active Comparator|Standard needle|Nasolabial Fold with standard needle and hyaluronic acid injected. hyaluronic acid with metallic cannula or standard needle.
88868427|NCT01072032|Experimental|Low-Reward|Low-Reward Anklebot training Group: The low reward-feedback group receives the Anklebot training with only immediate feedback on target successes, without cumulative scores and with minimal social interaction with the research team.
88868428|NCT01072032|Active Comparator|High-Reward|High-Reward Anklebot training Group: The high-reward group receives cumulative scores and abundant social interaction and are eligible for prizes during each training session and at completion of the study
88868429|NCT01072188|Active Comparator|ProClude Prophylaxis paste-A|Arginine Bicarbonate prophylaxis paste
88868430|NCT01072188|Placebo Comparator|Nupro-M Prophylaxis paste -B|Control prophylaxis paste (Fluoride free - placebo)
88868431|NCT01072656|Active Comparator|Treatment group|Active stimulation and programmed to the settings found to be optimal during the titration process.
88868432|NCT01072656|Sham Comparator|Control group|IPG is set to ON but the voltage is set to 0V.
88868433|NCT01076244|Other|Minimally invasive lumbar decompression|
88868434|NCT01082952||Asthmatic patients|
88868435|NCT01082952||Non asthmatic patients|
88868436|NCT01083654|Active Comparator|Standard Treatment Counseling|Standard Treatment (ST) will consist of 12 weeks of open-label varenicline and smoking cessation counseling consisting of four sessions: one in-person pre-quit counseling session during Study Visit 2, counseling during a phone call on the day after the quit day, and two additional in-person counseling sessions at Study Visits 3 and 4 (one week and three weeks after the quit day, respectively).
88868437|NCT01083654|Experimental|Culturally-Tailored Treatment|The Culturally-Tailored Treatment will consist of 12 weeks of open-label varenicline and culturally-tailored (for American Indians) smoking cessation counseling consisting of four sessions: one in-person pre-quit counseling session during Study Visit 2, counseling during a phone call on the day after the quit day, and two additional in-person counseling sessions at Study Visits 3 and 4 (one week and three weeks after the quit day, respectively).
88868438|NCT01083732|Experimental|dabigatran etexilate|treatment with dabigatran oral solution as a single dose
88868439|NCT01084278|Experimental|Healthy|Healthy participants with normal renal function (Creatinine Clearance [CrCl] ≥90 mL/min) received one colchicine 0.6 mg tablet on study day 1.
88868440|NCT01084278|Experimental|Mild renal impairment|Participants with mild renal impairment (estimated Glomerular Filtration Rate [eGFR] 60 to 89 mL/min) received one colchicine 0.6 mg tablet on study day 1.
88868441|NCT01084278|Experimental|Moderate renal impairment|Participants with moderate renal impairment (CrCl/eGFR 30 to 59 mL/min) received one colchicine 0.6 mg tablet on study day 1.
88868442|NCT01084278|Experimental|Severe renal impairment|Participants with severe renal impairment (eGFR 15 to 29 mL/min) received one colchicine 0.6 mg tablet on study day 1.
89392436|NCT04503993|Experimental|Hepatitis B Healthy Planet Arm|This is a single arm study where all patients eligible patients will receive a hepatitis B order set
89392437|NCT02116868|Experimental|Pupillometry guided analgesia (PP)|Analgesia is guided by pupillary reflex. The anesthesiologist in charge must adjust the peroperative remifentanil dose (Target controlled infusion) during surgery according to the algorithm proposed. Administration of antihypertensive drugs or vasopressors is also guided.
88868443|NCT01084278|Experimental|End stage renal disease (ESRD)|Participants with end stage renal disease (ESRD) received one colchicine 0.6 mg tablet on study day 1 immediately following dialysis. After a 14-day washout, participants received one colchicine 0.6 mg tablet on Day 15 prior to dialysis.
88868444|NCT01085760|Experimental|Vancomycin 125 mg orally 4 times a day|The patients will be randomized into four groups of ten patients: one group will receive low dose vancomycin, one group will receive high dose vancomycin, one group will receive low dose metronidazole and one group will receive high dose metronidazole.
88868445|NCT01085760|Experimental|Vancomycin 250 mg orally 4 times a day|
89392438|NCT02116868|No Intervention|Standard practice (ST)|Anesthesia and analgesia is left to the discretion of the anesthesiologist in charge. The anesthesiologist is blinded to the results of pupillometry.
89392439|NCT02679781|Active Comparator|oral sedation|administration of 0.5mg/kg oral midazolam. During dental treatment 50% nitrous oxide/ 50% oxygen will be administered via nasal hood.
89392440|NCT02679781|Active Comparator|nasal sedation|administration of 0.2mg/kg nasal midazolam. During dental treatment 50% nitrous oxide/ 50% oxygen will be administered via nasal hood.
89392441|NCT03551834|Active Comparator|doing scleral patch graft glaucoma implantation|
89392442|NCT03551834|Active Comparator|Using short tunnel small flap technique|
89392443|NCT03633877|Experimental|DuraporeTM on R, Hy-Tape ® on L|DuraporeTM and Hy-Tape® will be placed on patients' skin around the mouth during general anesthesia
89392444|NCT03633877|Experimental|DuraporeTM on L, Hy-Tape ® on R|DuraporeTM and Hy-Tape® will be placed on patients' skin around the mouth during general anesthesia
89392445|NCT02124356||Emergency High-risk Abdominal Surgery|
89392446|NCT02124434||Laparoscopic Sleeve Gastrectomy|Patients undergoing Laparoscopic Sleeve Gastrectomy surgery for morbid obesity
89392447|NCT04475133|Experimental|Low-frequency and high-intensity|"The intervention of ultrasound guided percutaneous neuromodulation is applied over the median nerve.~The parameters are continuous stimulation of low frequency (2 hz) and high intensity (slightly painful) during 16 minutes."
89392448|NCT04475133|Experimental|High-frequency and low-intensity|"The intervention of ultrasound guided percutaneous neuromodulation is applied over the median nerve.~The parameters are high frequency (100 hz) and low intensity trains. There are 5 trains, 5 second active current and 55 second without current per train.~The current is off on the first 11 minutes and the next 5 minutes it will be on. The total time is 16 minutes."
89392449|NCT04475133|Sham Comparator|Control group|The intervention of ultrasound guided percutaneous neuromodulation is applied over the median nerve without current during 16 minutes.
88868446|NCT01085760|Experimental|Metronidazole 250 mg orally 3 times a day|
88868447|NCT01085760|Experimental|Metronidazole 500 mg orally 3 times a day|
88868448|NCT01086228||XIENCE V / PROMUS stent|Only the patients treated with the XIENCE V / PROMUS stent during the index procedure will be analyzed.
88868449|NCT01086852|Experimental|FACTOR X|Human Coagulation Factor X
88868450|NCT01090752|Placebo Comparator|Pioglitazone|placebo-controlled, randomized, cross-over study
88868451|NCT01090752|Placebo Comparator|Metformine|placebo-controlled, randomized, cross-over study was to explore the effects of pioglitazone (45 mg q.d. for 6 weeks) on the renal, hormonal and blood pressure responses to changes in sodium intake in a population prone to insulin resistance
89392450|NCT02251730|Experimental|Refer for smoking cessation|Refer for smoking cessation
89392451|NCT02121548|Placebo Comparator|Outreach|Gets outreach materials and info on where to get screened by CHW.
89392452|NCT02121548|Active Comparator|CHW Outreach|Comprehensive CHW outreach including home visit, detailed 1:1 education, patient navigation
89392453|NCT02121548|Active Comparator|CHW Outreach and HPV Self-Sampling|Same as Arm 2 with a CHW outreach but also option of doing HPV home self-sampling
89392454|NCT02121626||Chemotheraphy Treatement|The study will be limited to NHS patients to reduce complications associated with the need for additional funding authorisations from private health care providers for algorithm-instigated investigations. It is not envisaged that participation in other studies running within the GI unit at The Royal Marsden Hospital will preclude entry into this study except in the event of those rare studies where the study is specifically measuring toxicity of treatment as the primary end point.
89392455|NCT02121704|No Intervention|Controll Group|Patients from the control group will be examined using a CF-HQ 190 EVIS Exera III Advanced Diagnostic Video Colonoscope. The Magnetic Endoscope Imaging (Scope Guide) function WILL NOT BE USED during the investigation.
89392456|NCT02121704|Active Comparator|Intervention|Patients from the control group will be examined using a CF-HQ 190 EVIS Exera III Advanced Diagnostic Video Colonoscope. The Magnetic Endoscope Imaging (Scope Guide) function WILL BE USED during the investigation.
88868452|NCT01093014|Experimental|Arm 1: High-force muscle stimulation|High-force muscle stimulation
88868453|NCT01093014|Experimental|Arm 2: Low-force muscle stimulation|Low-force muscle stimulation
88868454|NCT01093014|Experimental|Arm 3: Sequential low-force and high-force muscle stimulation|Sequential low-force and high-force muscle stimulation
88868455|NCT01093482||mechanically ventilated patients|"Patients who are admitted to the participating intensive care units and require invasive mechanical ventilation (endotracheal tube or tracheostomy) for more than 12 hours.~Patients who are admitted to the participating intensive care units and require non-invasive mechanical ventilation (Bilevel positive airway pressure (BIPAP) or continuous positive airway pressure (CPAP) with nasal or facial mask) for more than 1 hour."
88868456|NCT01093794|Experimental|1. Sit + Met500 / SitMet500 FDC / SitMet850 FDC / Sit + Met850|"Participants were administered treatment in the following sequence with a minimum 7 day washout period between treatments:~Co-administration of 50 mg sitagliptin and 500 mg metformin~sitagliptin/metformin 50 mg/500 mg FDC tablet~sitagliptin/metformin 50 mg/850 mg FDC tablet~Co-administration of 50 mg sitagliptin and 850 mg metformin"
88868457|NCT01093794|Experimental|2. SitMet500 FDC / Sit + Met850 / Sit + Met500 / SitMet850 FDC|"Participants were administered treatment in the following sequence with a minimum 7 day washout period between treatments:~sitagliptin/metformin 50 mg/500 mg FDC tablet~Co-administration of 50 mg sitagliptin and 850 mg metformin~Co-administration of 50 mg sitagliptin and 500mg metformin~sitagliptin/metformin 50 mg/850 mg FDC tablet"
88868458|NCT01093794|Experimental|3. Sit + Met850 / SitMet850 FDC / SitMet500 FDC / Sit + Met500|"Participants were administered treatment in the following sequence with a minimum 7 day washout period between treatments:~Co-administration of 50 mg sitagliptin and 850 mg metformin~sitagliptin/metformin 50 mg/850 mg FDC tablet~sitagliptin/metformin 50 mg/500 mg FDC tablet~Co-administration of 50 mg sitagliptin and 500mg metformin"
89186966|NCT04082390|Placebo Comparator|Placebo|
89392457|NCT04373031|Experimental|Control|Control Arm: (Pembro + ACT): Pembrolizumab induction (single-dose 200mg IV), followed by pembrolizumab Q3W + paclitaxel (T) weekly x 4 cycles, followed by pembrolizumab + doxorubicin + cyclophosphamide (AC) Q3W x 4 cycles as neoadjuvant therapy prior to surgery.
89186967|NCT02587676||denture liners|Evatouch Super (EVA; Neo Dental Chemical products, Washington, USA), GC RELINE (GCR; GC Dental Products Corp, Tokyo, Japan), Mucopren soft (MCP; Kettenbach GmbH & Co KG, California, USA) Soften (SFT; KAMEMIZU CHEM, Osaka, Japan), FD Soft (FDS; KAMEMIZU CHEM, Osaka, Japan), and Bio Liner (BIO; Nissin Dental Products, Kyoto, Japan).
88868459|NCT01093794|Experimental|4. SitMet850 FDC / Sit + Met500 / Sit + Met850 / SitMet500 FDC|"Participants were administered treatment in the following sequence with a minimum 7 day washout period between treatments:~sitagliptin/metformin 50 mg/850 mg FDC tablet~Co-administration of 50 mg sitagliptin and 500 mg metformin~Co-administration of 50 mg sitagliptin and 850 mg metformin~sitagliptin/metformin 50 mg/500 mg FDC tablet"
88868460|NCT01094106|Active Comparator|Ropivacaine 0,75%|Postoperative wound infusion 15 mg /h / 48h
88868461|NCT01094106|Placebo Comparator|NaCl 0,9%|Postoperative wound infusion with NaCl 0,9% 2 ml /h /48h
88868462|NCT01094574|Active Comparator|Alfentanil|Experimental inflammation, and tissue injury sites were created, an infusion of alfentanil 100ng/ml was administered over 3 hours using a programmable infusion pump, and data were collected to measure inflammation, pain response, and cytokine levels locally.
88868463|NCT01094574|Active Comparator|Propranolol|Experimental inflammation and tissue injury sites were created, an infusion of propranolol 30ng/ml was administered over 3 hours using a programmable infusion pump, and data were collected to measure inflammation, pain response, and cytokine levels locally.
89186968|NCT02586350|Experimental|Anlotinib|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent.Subjects with confirmation of disease progression by independent imaging review, while receiving blinded study drug may request to receive open label Anlotinib and enter the Optional Open Label Anlotinib Treatment Period of the Extension Phase. Subjects who request to receive open label Anlotinib(at the time of confirmed progression) will be informed whether they received placebo or Anlotinib during the period of blinded study drug administration. Subjects who received Anlotinib will not be eligible for the open-label phase.
89186969|NCT02586350|Placebo Comparator|Placebo|Placebo QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent.Subjects with confirmation of disease progression by independent imaging review, while receiving blinded study drug may request to receive open label Anlotinib and enter the Optional Open Label Anlotinib Treatment Period of the Extension Phase. Subjects who request to receive open label Anlotinib(at the time of confirmed progression) will be informed whether they received placebo or Anlotinib during the period of blinded study drug administration.
89186970|NCT04504071|Other|Dacomitinib Arm|This is a single arm study.
89186971|NCT02586194|Experimental|Control (Subjects with normal hepatic function)|Oral
89186972|NCT02586194|Experimental|Mild hepatic impairment|Oral
89186973|NCT02586194|Experimental|Moderate hepatic impairment|Oral
88868464|NCT01094574|Placebo Comparator|Placebo|Experimental inflammation and tissue injury sites were created, an infusion of normal saline was administered over 3 hours using a programmable infusion pump, and data were collected to measure inflammation, pain response, and cytokine levels locally.
88868465|NCT01095510|Experimental|500 U CINRYZE (10-25 kg body weight)|Single IV dose of 500 U CINRYZE
88868466|NCT01095510|Experimental|1000 U CINRYZE (10-25 kg body weight)|Single IV dose of 1000 U CINRYZE
88868467|NCT01095510|Experimental|1000 U CINRYZE (>25 kg body weight)|Single IV dose of 1000 U CINRYZE
88868468|NCT01095510|Experimental|1500 U CINRYZE (>25 kg body weight)|Single IV dose of 1500 U CINRYZE
88868469|NCT01096290|Experimental|Lubiprostone 24mcg BID for 30 days|Active medication
88868470|NCT01096290|Placebo Comparator|Placebo|Placebo, matched, blinded
88868471|NCT01096680|Experimental|SPD489 20 mg|
88868472|NCT01096680|Experimental|SPD489 50 mg|
88868473|NCT01096680|Experimental|SPD489 70 mg|
88868474|NCT01096680|Active Comparator|Armodafinil|
89186974|NCT04079660||Surgical patients|Diabetic patients scheduled to undergo non-cardiac surgery
88868475|NCT01096680|Placebo Comparator|Placebo|
88868476|NCT01096992|Experimental|Phase 1 20 mg/m^2|Bendamustine, Fludarabine + Rituximab
88868477|NCT01096992|Experimental|Phase 2|Bendamustine 30 mg/m^2 by vein (fixed), Days 1,2,3 + Fludarabine + Rituximab
88868478|NCT01096992|Experimental|Phase 1 30 mg/m^2|Bendamustine, Fludarabine + Rituximab
88868479|NCT01096992|Experimental|Phase 1 40 mg/m^2|Bendamustine, Fludarabine + Rituximab
88868480|NCT01096992|Experimental|Phase 1 50 mg/m^2|Bendamustine, Fludarabine + Rituximab
88868481|NCT01097304|Experimental|Treatment (ursodiol)|Patients receive ursodiol PO BID for 6 months in the absence of disease progression or unacceptable toxicity.
88868482|NCT01097460|Experimental|MM-111 + Herceptin|MM-111 will be combined with Herceptin
88868483|NCT01098006|Other|Immune tolerant patients Group|Immune tolerant patients aged between and including 18 and 65 years of age at study start, having high levels of hepatitis B viruss (HBV) replication characterized by elevated HBV DNA levels and presence of hepatitis B envelope antigen (HBeAg), but normal alanine aminotransferase (ALT) levels with normal or mild histology findings.
88868484|NCT01098006|Other|HBeAg positive Group|HBeAg positive chronic Hepatitis B patients aged between and including 18 and 65 years of age at study start, having elevated or fluctuating ALT levels, presence of HBeAg and variable HBV DNA on a high level, histology mainly with activee inflammation and varying degrees of liver fibbrosis.
88868485|NCT01098006|Other|Inactive carriers Group|Inactive carriers aged between and including 18 and 65 years of age at study start, having normal ALT levels, undetectable or low levels of serum HBV DNA; absence of HBeAg and presence of anti-HBe antibodies, histology with little or no inflammation and varying degrees of liver fibrosis.
88868486|NCT01098006|Other|HBeAg negative Group|HBeAg negative chronic Hepatitis B patients aged between and including 18 and 65 years of age at study start, having absence of HBeAg, presence of anti-HBe, elevated ALT and HBV DNA levels, histology with significant inflammatory changes, liver fibrosis and cirrhosis.
88868487|NCT01098318|Experimental|Rhodiola rosea|Herbal extract
88868488|NCT01098318|Active Comparator|Sertraline|Conventional anti-depressant
88868489|NCT01098318|Placebo Comparator|Sugar pill|Lactose monohydrate
88868490|NCT01100112|Experimental|Budesonide|Budesonide-MMX 9 mg tablet
89392458|NCT04373031|Experimental|Arm A|• Arm A: (Pembro + IRX-2 + ACT): Pembrolizumab (single-dose 200mg IV) + cyclophosphamide (single-dose 300 mg/m2 IV) + IRX-2 induction (1mL SQ x 2 daily, x 10 days), followed by pembrolizumab Q3W + paclitaxel (T) weekly x 4 cycles, followed by IRX-2 re-induction (1mL SQ x 2 daily, x 10 days), followed by pembrolizumab + doxorubicin + cyclophosphamide (AC) Q3W x 4 cycles as neoadjuvant therapy prior to surgery.
89392459|NCT02116946|Experimental|Leukocyte-rich Platelet Rish Plasma + exercise|Leukocyte-rich PRP injection and a 12 week exercise program.
89392460|NCT02116946|Experimental|Leukocyte-poor Platelet Rich Plasma + exercise|Leukocyte-poor PRP injection and a 12 week exercise program.
89392461|NCT02116946|Placebo Comparator|Saline + exercise|Saline injection and a 12 week exercise program.
89392462|NCT03553160|Other|Frequent Self-Weighing|Study examined the effectiveness of daily self-weighing to prevent age related weight gain.
89392463|NCT02121782|Experimental|Quadrivalent influenza vaccine(Part A)|Day 1: GC3110A, 0.5ml, intramuscular, a single dosing
89392464|NCT02121782|Experimental|Quadrivalent influenza vaccine(Part B)|Day 1: GC3110A, 0.5ml, intramuscular, a single dosing
89392465|NCT02121782|Active Comparator|Trivalent influenza vaccine(Part B)|Day 1: GC Flu Pre-filled Syringe Inj., 0.5ml, intramuscular, a single dosing
89392466|NCT02117102|Experimental|bladder and lumbar stimulation|Apply bladder and lumbar stimulation
89392467|NCT02117102|No Intervention|Control group|Ordinary pediatric urine collection bag
89392468|NCT03553082|Active Comparator|Total intravenous anesthsia|Patients in this group will receive Propofol 5-6 mg/kg and fentanyl 2 µg/kg for induction of anesthesia and propofol 250-300 µg/kg/min for maintenance.
89392469|NCT03553082|Active Comparator|Sevoflurane|Patients in this group will receive sevoflurane 8% and fentanyl 2 µg/kg for induction of anesthesia and sevoflurane 2% for maintenance.
89392470|NCT03318393|Active Comparator|Unfractionated heparin group|Patients randomized to this arm will undergo usual care using unfractionated heparin as the primary anticoagulant.
89392471|NCT03318393|Experimental|Bivalirudin group|Patients randomized to this arm will receive anticoagulation with bivalirudin
89392472|NCT02121938||very low birth weight infants|Very low birth weight infants weighing 1500 grams at birth or less
89392473|NCT02117180|Other|FODMAP's diet|A diet low in Fermentable Oligosaccharides, Disaccharides, Monosaccharides And Polyols (FODMAPs)
88868491|NCT01100268|Experimental|Methylphenidate ER|Subjects will start at 18mg/day; the dose will be increased in increments of 18mg per week to reach 72mg/day.
88868492|NCT01101750|Other|Liver and Kidney Transplant Patient Arm|Standard of Care Intervention: Participants on this arm receive Gardasil vaccine and have a history of liver or kidney transplant.
88868493|NCT01102218|Experimental|erythropoietin plus pentoxifylline|
89392474|NCT02117258|Experimental|Z-360 60mg+Gemcitabine|Z-360 60 mg will be taken orally, twice daily (BID) after a meal.
89392475|NCT02117258|Experimental|Z-360 120mg+Gemcitabine|Z-360 120 mg will be taken orally, twice daily (BID) after a meal.
89392476|NCT02117258|Experimental|Z-360 240mg+Gemcitabine|Z-360 240 mg will be taken orally, twice daily (BID) after a meal.
89392477|NCT02117258|Placebo Comparator|Placebo+Gemcitabine|Placebo will be taken orally, twice daily (BID) after a meal.
89392478|NCT03110029|Active Comparator|Efinaconazole 10 % and Nail Polish|Subject will have Efinaconazole 10% solution application and nail polish
89392479|NCT03110029|Placebo Comparator|Efinaconazole 10% without Nail Polish|Subject will have only Efinaconazole 10% application and no nail polish
89392480|NCT04051749||Patients submitted to VS|
88868494|NCT01102218|Active Comparator|erythropoietin alone|
88868495|NCT01102764|Experimental|Arm 1: PE via telemedicine|PE via telemedicine
89392481|NCT02122016|Experimental|SmartCare|A computer driven weaning ventilator, using closed-loop ventilation, taking into account patients lung mechanics and exhaled CO2.
89392482|NCT02122016|Active Comparator|Conventional weaning protocol|A conventional weaning protocol consisting of a daily weaning screen, which is performed by physiotherapist. All patients who are mechanically ventilated for more than 24 hours are given a spontaneous breathing trial.
88868496|NCT01102764|Active Comparator|Arm 2: PE in person|PE in person
89392483|NCT04858815|Experimental|Administration of yogic breathing program|This will be a single arm longitudinal trial designed to evaluate the feasibility and estimate the efficacy of implementing a self-administered yogic breathing program for stress reduction among anesthesiology practitioners at one academic medical center.
88868497|NCT01103934|Active Comparator|Fluticasone Propionate plus Vitamin D3|Subjects will be treated with fluticasone propionate and Vitamin D once daily for 2 weeks during allergy season
88868498|NCT01103934|Placebo Comparator|Fluticasone Propionate plus Placebo|Subjects will be treated with fluticasone propionate and placebo for Vitamin D once daily for 2 weeks during allergy season
88868499|NCT01104090|Experimental|C-MAC direct laryngoscopy, then C-MAC indirect laryngoscopy|Patients assigned to this arm will be intubated using C-MAC with direct laryngoscopy first and then using C-MAC with indirect laryngoscopy.
89392484|NCT02122094|Experimental|Sexual Health Promotion Intervention|The SHP Intervention consists of seven core and five optional modules covering topics related to sexual health. It is delivered in both community (outreach) settings and i clinic-based settings.
89392485|NCT02117336|Experimental|P1446A-05|
89392486|NCT03552146||Sedation Group 1|Patients will receive standard of care dose of Propofol, based on the provider's assessment, prior to radiologic procedure.
89392487|NCT03552146||Sedation Group 2|Patients will receive standard of care dose of dexmedetomidine, based on the provider's assessment, prior to radiologic procedure.
89392488|NCT01374763|Active Comparator|Oxycodone|Drug: prolonged-release oxycodone
89392489|NCT01374763|Active Comparator|Oxycodone/naloxone|Prolonged-release oxycodone/naloxone
89392490|NCT02117492|Experimental|Vertical Cuff|Vaginal cuff closure will be done vertically.
89392491|NCT02117492|Experimental|Horizontal Cuff|Vaginal cuff closure will be done horizontally.
88868500|NCT01104090|Experimental|C-MAC indirect laryngoscopy, then C-MAC direct laryngoscopy|Patients assigned to this arm will be intubated using C-MAC with indirect laryngoscopy first and then using C_MAC with direct laryngoscopy.
88868501|NCT01104402|No Intervention|Standard Care|Subjects will receive education about signs and symptoms indicative of worsening CF.
88868502|NCT01104402|Active Comparator|Home monitoring|Subjects will be randomized to monitor home spirometry and symptoms using a handheld device.
88868503|NCT01105650|Experimental|Arm 1: CsA|Patients receiving Cyclosporine (CsA) and Natural Killer (NK) cells infusion (created from donor lymphapheresis) after preparative regimen of Fludarabine and Cyclophosphamide. Interleukin-2 (IL-2) 6 million units 3 times a week x 6 doses given post NK cell infusion.
88868504|NCT01105650|Experimental|Arm 2: CsA plus Methylprednisolone (10mg)|Patients receiving Cyclosporine (CsA), methylprednisolone and natural killer cells (NK) infusion (created from donor lymphapheresis) after preparative regimen of Fludarabine and Cyclophosphamide. Interleukin-2 (IL-2) 6 million units 3 times a week x 6 doses given post NK cell infusion.
88868505|NCT01105650|Experimental|Arm 3: CsA plus Methylprednisolone (1 mg)|Patients receiving Cyclosporine (CsA), methylprednisolone and natural killer (NK) cells infusion (created from donor lymphapheresis) after preparative regimen of Fludarabine and Cyclophosphamide. Interleukin-2 (IL-2) 6 million units 3 times a week x 6 doses given post NK cell infusion.
88868506|NCT01105650|Experimental|Arm 4: CsA minus Methylprednisolone|Patients receiving Cyclosporine (CsA), no methylprednisolone, eliminating IL-2 doses 4-6 and receiving Natural Killer (NK) cells infusion (created from donor lymphapheresis) after preparative regimen of Fludarabine and Cyclophosphamide. Interleukin-2 (IL-2) 6 million units 3 times a week x 3 doses given post NK cell infusion.
88868507|NCT01106040|Experimental|Lymphoseek, Lymphatic mapping, Injection|
88868508|NCT01107834||Healthy Control|HIV-negative children born to healthy, HIV-negative women
88868509|NCT01107834||Exposed to HIV/HAART|HIV-negative children exposed to HIV and HAART in utero
89392492|NCT02340403|Experimental|Oxaliplatin and neuropathic pain|The objective of this study is to demonstrate a significant increase in choline concentration in the insular cortex of patients with an oxaliplatin induced neuropathy. Other objectives will assess the correlation between metabolite concentrations in the insular cortex and frequency / intensity of pain and neuropathic symptoms, cold and heat-induced pain and comorbidities (anxiety, pain, quality of life).
89392493|NCT02340403|Other|Oxaliplatin without neuropathic pain|The objective of this study is to demonstrate a significant increase in choline concentration in the insular cortex of patients with an oxaliplatin induced neuropathy. Other objectives will assess the correlation between metabolite concentrations in the insular cortex and frequency / intensity of pain and neuropathic symptoms, cold and heat-induced pain and comorbidities (anxiety, pain, quality of life).
89392494|NCT02122250|Experimental|Interactive web-based materials|Interactive web-based materials for self-management of diabetes
89392495|NCT02122250|Active Comparator|Static web-based materials|Static version of the interactive web-based materials
88868510|NCT01110252|Active Comparator|pre-procedure|emphysema patients evaluated prior to the stem cells infusion
88868511|NCT01110252|Experimental|post-procedure|emphysema patients evaluated 30 days after the stem cells infusion
89392496|NCT03608514|Active Comparator|nor-epinephrine+/- epinephrine infusion|"Intravenous infusion of Nor-epinephrine in an initial dose of 0.01µg/kg/min. which can be increased every 15-30 minutes to maximum 3µg/kg/min. ± intravenous infusion of epinephrine with an initial dose 0.05µg/kg/min. & can be titrated every 15-30 minutes up to 2µg/Kg/min.~The end point is to achieve mean arterial pressure ≥ 65 mmHg & normalized lactate ≤ 2 mmol/L or lactate clearance ≥ 10% within 6 hours.~Patients will be followed for 48 hours."
89392497|NCT03608514|Other|Terlipressin infusion|"Intravenous infusion of terlipressin by rate 1-2µg/kg/min. The end point is to achieve mean arterial pressure ≥ 65 mmHg & normalized lactate ≤ 2mmol/L or lactate clearance ≥ 10% within 6 hours.~Patients will be followed for 48 hours."
89392498|NCT03551756||Heart Failure & Coronary Artery Disease|Biomarker assessment in adults with decompensated heart failure and significant underlying coronary artery disease
89392499|NCT03551756||Healthy Adult|Biomarker assessment in 20 healthy age-matched subjects
88868512|NCT01110876|Experimental|Phase I Group 1: Vorinostat + Erlotinib + Temozolomide|"Phase I 3-Drug Combination Vorinostat with Erlotinib + Temozolomide~Starting doses Vorinostat 200 mg orally twice daily on Days 1-7 and 15-21 of every cycle; Erlotinib 200 mg orally once daily on Days 1-21; Temozolomide 125 mg/m^2 orally once daily on Days 1-7 and 15-21."
88868513|NCT01110876|Experimental|Phase I Group 2: Vorinostat + Erlotinib|"This Phase I arm to be activated only after completion of Part A of the Phase II trial of the 3-Drug combination. If part A of the Phase II trial shows lack of efficacy, trial will be terminated.~Vorinostat orally twice daily, Days 1-14; and Erlotinib orally once daily Days 1-21 of every cycle."
88868514|NCT01110876|Experimental|Phase II Part A 3-Drug Combination|"Vorinostat+Erlotinib+Temozolomide where drug dosing based on the MTD identified in the Phase I portion of the study.~Vorinostat 200 mg orally twice daily on Days 1-7 and 15-21 of every cycle; Erlotinib 200 mg orally once daily on Days 1-21; Temozolomide 100 mg/m^2 orally once daily on Days 1-7 and 15-21."
88868515|NCT01110876|Experimental|Phase II Part B 2-Drug Combination|"This Phase II Part B arm to be activated only after completion of Part A of the Phase I and II Part A trial of the 3-Drug combination. If part A of the Phase II trial shows lack of efficacy, trial will be terminated.~Vorinostat orally twice daily, Days 1-14; and Erlotinib orally once daily Days 1-21 of every cycle."
88868516|NCT01112358|Experimental|r-FSH + r-hLH|Lutropin alfa (r-hLH) will be administered at a daily dose of 150 International Units (IU) from the presence of at least one follicle greater than (>) 14 millimeter (mm) to complete ovarian stimulation. Follitropin alfa (r-FSH) will be administered at an initial dose of 225-450 IU per day (according to standard center practice); the dose will then be adjusted to ovarian response as assessed by ovarian ultrasound and/or serum estradiol. Participants will also receive analogous GnRH antagonist and natural progesterone, as per standard center practice. To complete follicular maturation and trigger ovulation, a single dose of 250 milligrams (mg) of recombinant Human Chorionic Gonadotropin (r-hCG) will be administered subcutaneously at 12 hours after the last injection of lutropin alfa and/or follitropin alfa and analogous GnRH antagonist.
89392500|NCT04207749|Experimental|LID015385|LID015385 contact lenses worn at least 5 days per week and 8 hours per day in a daily wear modality (that is, not worn while sleeping) for approximately 3 months. CLEAR CARE will be used for nightly cleaning and disinfection.
89392501|NCT04207749|Active Comparator|Biofinity|Comfilcon A contact lenses worn at least 5 days per week and 8 hours per day in a daily wear modality (that is, not worn while sleeping) for approximately 3 months. CLEAR CARE will be used for nightly cleaning and disinfection.
89392502|NCT02237274|Experimental|Patients with Fontan circulation|High altitude exposition
89392503|NCT02237274|Other|Age and gender-matched healthy volunteers|High altitude exposition
89392504|NCT02117726|Experimental|Dexmedetomidine,midazolam|Slow injection of 2mg midazolam every minute and watching patients' reaction until attaining the target level of sedation;midazolam was maintained at 0.02~0.1mg/kg/h, for 24 hours.Dexmedetomidine will be added at 0.2~1.4μg/kg/h to maintain sedation.If target sedation level (RASS score) cannot be reached in maximum dose of dexmedetomidine, continuous intravenous infusion of midazolam could be used at 0.02~0.1mg/kg/h, until the target level is reached.
89392505|NCT02117726|Active Comparator|Propofol,midazolam|Slow injection of 2mg midazolam every minute and watching patients' reaction until attaining the target level of sedation;midazolam was maintained at 0.02~0.1mg/kg/h, for 24 hours.Propofol will be added at 0.3~4mg/kg/h to maintain sedation.If target sedation level (RASS score) cannot be reached in maximum dose of propofol, continuous intravenous infusion of midazolam could be used at 0.02~0.1mg/kg/h, until the target level is reached.
89392506|NCT04125342|Experimental|Conditioned NIV in High Risk Patients|
89392507|NCT04125342|Active Comparator|HFOT in High Risk Patients|
88868517|NCT01112358|Active Comparator|r-FSH|Follitropin alfa (r-FSH) will be administered at an initial dose of 225-450 IU per day (according to standard center practice); the dose will then be adjusted to ovarian response as assessed by ovarian ultrasound and/or serum estradiol. Participants will also receive analogous GnRH antagonist and natural progesterone, as per standard center practice. To complete follicular maturation and trigger ovulation, a single dose of 250 mg of r-hCG will be administered subcutaneously at 12 hours after the last injection of follitropin alfa and analogous GnRH antagonist.
89392508|NCT04125342|Experimental|Conditioned NIV in Obese Intermediate Risk Patients|
89392509|NCT04125342|Active Comparator|HFOT in Obese Intermediate Risk Patient|
89392510|NCT03551678|Experimental|Gait retraining|Eight weeks of active-feedback gait retraining. The gait retraining device measures pressure/force under the lateral side of the foot and activates vibration if loading crosses a set threshold. The location of the vibration is customized for each subject to achieve maximal sensitivity.
89392511|NCT02733432|Experimental|Cohort 1|CD101 Vaginal Gel (3%) topically self-administered intravaginally as a single dose on days 1 and 2 and for symptomatic relief CD101 External Gel (1%)topically self-applied to external vulva up to twice per day over 72 hours.
89392512|NCT02733432|Experimental|Cohort 2|CD101 Vaginal Ointment (6%) topically self-administered intravaginally as a single dose on day 1 and for symptomatic relief CD101 External Ointment (1%) topically self-applied to external vulva up to twice per day over 72 hours.
89392513|NCT02733432|Active Comparator|Cohort 3|Oral fluconazole (150mg) administered on day 1.
89392514|NCT03634189|Experimental|HF- ACC/AHA stage A-C + CBD|Patients with HF stages A-C + Cannabidiol
88868518|NCT01112670|Experimental|ABCB1 Group 1|ABCB1 CGC/CGC genetic make-up; sitagliptin 100 mg x 1 dose; atorvastatin 40 mg x 5 doses
88868519|NCT01112670|Experimental|ABCB1 Group 2|ABCB1 CGC/TTT genetic make-up; sitagliptin 100 mg x 1 dose; atorvastatin 40 mg x 5 doses
88868520|NCT01112670|Experimental|ABCB1 Group 3|ABCB1 TTT/TTT genetic make-up; sitagliptin 100 mg x 1 dose; atorvastatin 40 mg x 5 doses
88868521|NCT01114620|Experimental|Arepanrix Group|Healthy Japanese male and female adults, 65 years of age or older, who received one dose of the study vaccine Arepanrix™, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0.
88868522|NCT01115166||Cardiac surgery|Patients subjected to open cardiac surgery with the help of extracorporal circulation.
88868523|NCT01115556|Experimental|Lucentis 2.0 mg|Lucentis 2.0 mg
89392515|NCT02117804||High ESDP Score|Patients with 10 or greater score on the Early Screen for Discharge Planning at the time of admission.
89392516|NCT02117804||Low ESDP Score|Patients with 9 or lower score on the Early Screen for Discharge Planning at the time of admission.
89392517|NCT03043365|Experimental|Arm 1: Control Fish Oil first, then Saury Oil|Subjects randomized to the control fish oil arm will take the equivalent to 3g of control /day (12 gel capsules/day) for 8 plus or less 2 weeks and crossover to the LCMUFA-rich saury oil capsule arm
89392518|NCT03043365|Experimental|Arm 2: Saury Oil first, then Control Fish Oil|Subjects randomized to the LCMUFA-rich saury oil arm will take the equivalent to 3g of control/day (12 gel capsules/day) for 8 plus or less 2 weeks and crossover to the control fish oil capsule arm
89392519|NCT03043365|No Intervention|Washout Period|8 week washout period to occur between week 8 and week 16. No study supplement taken by subject at this time.
89392520|NCT03608046|Experimental|Avelumab, Cetuximab, Irinotecan|"Avelumab : administrated at a fixed dose of 10 mg/kg once every 2- week. Cetuximab: administered at 400 mg/m2 loading dose week 1, 250 mg/m2 from week 2 followed by 500 mg/m2 from week 3.~Irinotecan: administrated every 2 weeks (180 mg/m2)."
89392521|NCT02122484|Placebo Comparator|Control group|Patients taking placebo
88868524|NCT01115556|Active Comparator|LUCENTIS 0.5 mg|
88868525|NCT01116024|Experimental|3f Enable Aortic Bioprosthesis Model 6000|Single arm study
89392522|NCT02122484|Experimental|Colchicine|Active treatment group
89392523|NCT04051515|Experimental|Intradialysis exercise guided by nursing staff|During 16 weeks subjects will exercise during the hemodialysis session, the exercise will include both aerobic and resistance training. Guidance will be provided by nursing staff
89392524|NCT04051515|Active Comparator|Home-based exercise program|During 16 weeks subjects will exercise on their own at home. A booklet will be provided, with a diary. Instructions to do resistance exercise with intervals of walking will be provided. Initial training will be provided by physiotherapy staff from the hospital.
89392525|NCT02251574|Experimental|Low Calorie Diet|Participants will take part in an experimental weight management program involving a low calorie diet (LCD), about 1200-1500 calories per day.
89186975|NCT02584166||Intervention group|38 maternity units with allocated to the intervention group: coordinating team disseminated protocols related to the management of cases, and organized mortality morbidity conferences (MMC) in each unit with staff concerned. These MMC were realized by the same outside medical binomial composed of a midwife and an obstetrician (outreach visit with a leader ship). Among the 38 maternity units, MMC were performed with the medical binomial and professionals of human science in 20 units to identify the defense mechanisms manifested by medical staff which could disturb the decision making. In the others 18 units, MMC were performed with only the outside medical binomial. Coordinating team defined with teams the area of improvement before each MMC. 3 or 4 MMC were performed according to their activity.
89392526|NCT02251574|Experimental|Very Low Calorie Diet|Participants will take part in an experimental weight management program involving a low calorie diet (LCD), about 520-800 calories per day.
89392527|NCT02251574|Active Comparator|Standard Care|Participants will receive normal care.
89392528|NCT03108157|Experimental|GROUP A: intervention group|Patients will be performed an endometrial scratch with Pipelle Cournier 3 to 4 weeks before the embryo transfer and then they will follow the conventional preparation protocol to receive embryos coming from an egg donation treatment.
89392529|NCT03108157|No Intervention|GROUP B: no intervention group|Patients will receive the conventional preparation protocol to receive embryos coming from an egg donation treatment.
89392530|NCT02237352||Control|Subjects without diabetic nephropathy
89392531|NCT02237352||Diabetic nephropathy|Subjects with diabetic nephropathy
89392532|NCT02117882||minimally invasive approach test|minimally invasive lateral approach
89392533|NCT02117882||control lateral traditional approach|standard surgical approach
89392534|NCT04051437|Experimental|Plasma exchange|The consented patients will receive standard medical management with sessions of single volume plasma exchange with fresh frozen plasma and 5% human albumin.Plasma exchange session will be done on an alternate day to a maximum of 5 procedures.
89392535|NCT04051437|Active Comparator|Standard medical treatment|The consented patients will receive standard medical treatment which includes adequate nutrition (35-45 Kcal/Kg with 1.5gm/Kg protein) diuretics, anti HE measures, appropriate antibiotics for infections, entecavir 0.5 mg once daily for hepatitis B, and steroids for autoimmune hepatitis.
89186976|NCT02584166||Control group|No intervention in 57 maternity units
89186977|NCT02559843|Experimental|pomegranate juice|200 ml pomegranate juice + lifestyle modification
89186978|NCT02559843|Active Comparator|control|lifestyle modification including dietary recommendations
89186979|NCT02586116|Active Comparator|nanOss|nanOss Cervical IBF System with nanOss BA Bone Void Filler
89392536|NCT02122874|Active Comparator|Diet|The patients follow only a 1200 Kcal diet
89392537|NCT02122874|Experimental|Diet +PENS dermatome T7|The patients undergo PENS of dermatome T7 and follow a 1200 Kcal diet
89392538|NCT03619993|Experimental|Arm A: Start with On-body injector|4 consecutive cycles of treatment in total, with 2 cycles of treatment with pegfilgrastim pre-filled syringe (PS) and 2 cycles of treatment with On-body injector (OBI) for pegfilgrastim in an alternating sequence (OBI-PS-OBI-PS)
89392539|NCT03619993|Experimental|Arm B: Start with pre-filled syringe|4 consecutive cycles of treatment in total, with 2 cycles of treatment with pegfilgrastim pre-filled syringe (PS) and 2 cycles of treatment with On-body injector (OBI) for pegfilgrastim in an alternating sequence (PS-OBI-PS-OBI)
89392540|NCT02124590|Experimental|Acute Exercise|Repeated isometric leg exercises at varying intensities and a second visit with aerobic bike exercise for 30 minutes at 50% peak VO2.
89392541|NCT02124668|Experimental|Enzalutamide|Enzalutamide
89392542|NCT02117960|Active Comparator|CVD, Omega-3|patients with Cardiovascular disease who receive 4g/d omega-3
89392543|NCT02117960|Placebo Comparator|CVD, Placebo|patients with cardiovascular disease who receive 4 cap of placebo/day
88816456|NCT02509065|Experimental|110 mg/dl Set Point - bihormonal|Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 110 mg/dl using both an insulin and a glucagon pump. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.
88816457|NCT02509065|Experimental|120 mg/dl Set Point - insulin only|Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 120 mg/dl and using only an insulin pump.
88816458|NCT01194674|Experimental|Microplasmin|
89392544|NCT03606018|Experimental|Insulin Lispro Mix 25|Single subcutaneous administration of Insulin Lispro Mix 25 in dose 0.4 IU / kg
89392545|NCT03606018|Active Comparator|Humalog® Mix 25|Single subcutaneous administration of Humalog® Mix 25 in dose 0.4 IU / kg
89392546|NCT01373749|Experimental|NOS|NO inhalation was performed in the first stage(<48h) of PPHN, NO inhalation was replaced by sildenafil in the second stage(>48h).
88816459|NCT02509767|Experimental|Self-Administration|Subjects who are randomized to self-administration will be taught self-administration of subcutaneous depot medroxyprogesterone acetate (DMPA sc) by a clinic nurse or other qualified personnel using instructions based on the packaging insert. If willing, subjects will then self-administer DMPA sc under supervision. Subjects who are able to correctly self-administer DMPA sc as assessed by the supervising nurse and who are interested in continued home self-administration will then be provided medication (3 doses of DMPA sc), a self-administration kit (includes alcohol swabs, cotton pads, bandages, mini sharps disposal container), and instructions to do so for the subsequent 3 injections indicating the appropriate dates for injection. All subjects will receive reminders when their next injection is due.
88816460|NCT02509767|Other|Clinic Administration (Standard Care)|Subjects who are randomized to clinic administration will receive subcutaneous depot medroxyprogesterone acetate (DMPA sc) injection administered by a clinic nurse or other qualified personnel and receive standard care. They will be instructed to make an appointment to return to the clinic as usual to receive subsequent injections every 12-14 weeks. All subjects will receive reminders when their next injection is due.
88816461|NCT01154192|Experimental|PCOS group|Intervention: Each subject in the PCOS group will receive 1 mg of oral dexamethasone in the evening and return in the morning for an injection of 25ug of IV recombinant human chorionic gonadotropin. Subjects will also have blood drawn at times -0.5, 0, 0.5, and 24 hours after the injection of r-hCG for measurement of steroid hormones.
88816462|NCT01154192|Experimental|Normal group|Intervention: Each subject in the Normal group will receive dexamethasone 1 mg orally in the evening and return the next morning for an injection of 25ug of IV recombinant human chorionic gonadotropin. Subjects will the have blood drawn at -0.5, 0, 0.5, and 24 hours after hCG injection for steroid hormone measurements.
89186980|NCT02586116|Active Comparator|C-Plus|C-Plus PEEK IBF Device with autograft
89186981|NCT00761163|Experimental|1|
89186982|NCT00761163|Experimental|2|
89186983|NCT00761163|Experimental|3|
89186984|NCT02584322|Experimental|ERAS patients|Enhanced recovery pathway
89186985|NCT04585022|Active Comparator|Magnum|A metal-on-metal large diameter head total hip arthroplasty
89186986|NCT04585022|Active Comparator|Recap|A metal-on-metal hip resurfacing arthroplasty
89186987|NCT02981979|Active Comparator|Leflunomide group|Use Leflunomide 20mg qd po. for 24 weeks for induced remission therapy combine with the basic prednisone therapy(start with 0.6mg/kg/d and maintained for 4 weeks, then reducing 5mg every 2 weeks until 10mg per day if the subject achieve clinical remission. If the subject has not achieve clinical remission,do not change prednisone dose）. Subjects who have achieved clinical remission, with the prednisone dose reduced to 10mg within 20 weeks and maintained to the end of 24 weeks enter the maintenance therapy.The next 32 weeks for maintenance therapy use leflunomide combine with prednisone 10mg per day.
89186988|NCT02981979|Placebo Comparator|Control Group|Use Placebo for 24 weeks for induced remission therapy(24 weeks) and use leflunomide 20mg qd po. for maintenance therapy in the next 32 weeks. Prednisone is used as basic therapy during the whole trial (start with 0.6mg/kg/d and maintained for 4 weeks, then reducing 5mg every 2 weeks until 10mg per day if the subject achieve clinical remission. Then maintain 10mg per day until the end of the study). All subjects in control group enter maintenance therapy.
89186989|NCT04081064|Experimental|Non-obese Qatar residents with type 2 diabetes|Newly diagnosed (e.g <5 years) Type 2 diabetics Qatar residents with a body mass index (BMI) of >18.5 and <30.0 kg/m2
89186990|NCT04081064|Experimental|Obese Qatar residents with type 2 diabetes|Newly diagnosed (e.g <5 years) Type 2 diabetics Qatar residents with a body mass index (BMI) of >30.0 to <40.0 kg/m2
89186991|NCT04049409|Experimental|CMAB809|
89186992|NCT04049409|Active Comparator|Trastuzumab|
89186993|NCT04568252|Experimental|Intervention|Millimetric wave emission bracelet.
89186994|NCT04568252|Sham Comparator|Control|Placebo bracelet.
89186995|NCT00920660|Experimental|Treatment Group|"Subjects will be required to attend the research unit in a fasted state (at least 10 hours without food) on six separate occasions (treatment visits) during the study. At approximately the same time every morning, subjects will consume a standard, non-high-fat meal (approximately 650 kcal with 30% of calories derived from fat). Test material (per treatment) will be administered within 15-30 minutes following the meal. There will be at least a 7-day washout period between treatment visits.~During the first five treatment visits, subjects will receive one of the following treatments in the form of 8 capsules: 0.25g SRT2104, 0.5g SRT2104, 1g SRT2104, 2g SRT2104, or placebo.~During the last treatment visit, subjects will receive 30 mg of open-label prednisolone tablets."
89186996|NCT02903355|Placebo Comparator|Placebo|Placebo contains sorbitol, orange flavor and purified water; is flavor and color matched to D-Met.
89186997|NCT02903355|Experimental|D-methionine, oral liquid suspension|D-methionine liquid suspension also contains sorbitol, orange flavor and purified water Intervention: Drug: D-methionine, oral liquid suspension.
89186998|NCT02583464|Experimental|Test-Reference|A new formulation containing a combination of emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg (T) followed by a branded formulation (R).
89186999|NCT02583464|Experimental|Reference-Test|A branded formulation containing a combination of emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg (R) followed by a new formulation (T).
89187000|NCT00675597|Experimental|1|Docetaxel (Taxotere), Vinorelbine, and Bevacizumab, as Adjuvant Chemotherapy for Patients with Resected Stage I-III Non-small Cell Lung Cancer
89187001|NCT00761397||Study Program Group|
89187002|NCT00761397||Usual Care Group|
89187003|NCT04292301|Experimental|STrategically Acquired Gradient Echo (STAGE)|STAGE Inputs are flow compensated 3D gradient echo MR images acquired at optimal parameters which are used to calculate multiple contrasts for brain imaging. All subjects within the study are imaged using both a conventional MR protocol and STAGE protocol.
89187004|NCT04255563||DCB treatment|DCB (Sequent® Please) treatment will be performed for suitable patients with CAD.
89187005|NCT04078646|Experimental|Dietary intervention|Intervention with test meal only
89187006|NCT04078646|Experimental|Dietary intervention 2|Intervention with test meal and whey protein isolate (30 g)
89187007|NCT04078646|Experimental|Dietary intervention 3|Intervention with test meal and soy protein (30 g)
89187008|NCT04049565||Procalcitonin|septic patients who will receive Procalcitonin
89187009|NCT04049565||C-Reactive Protein|septic patients who will receive C-Reactive ptotein
89187010|NCT02677545|Experimental|Ticagrelor & Aspirin|Participants will receive a loading dose of 180 mg ticagrelor 1-3 days before stenting followed by a maintenance dose of 90 mg twice daily until 28-32 days after stenting. All participants will receive 75-100 mg aspirin per day throughout the study period.
89187011|NCT02677545|Active Comparator|Clopidogrel & Aspirin|Participants will receive a loading dose of 300 mg clopidogrel 1-3 days before stenting followed by a maintenance dose of 75 mg once daily until 28-32 days after stenting. All participants will receive 75-100 mg aspirin per day throughout the study period.
89187012|NCT04479644|Experimental|Cohort 1|BRII-198 dose level 1 or placebo
89187013|NCT04479644|Experimental|Cohort 2|BRII-198 dose level 2 or placebo
89187014|NCT04479644|Experimental|Cohort 3|BRII-198 dose level 3 or placebo
89187015|NCT00921921|Experimental|Extra-fine particle steroid inhaler|
88816463|NCT01154192|Experimental|Oligomenorrhea group|Intervention: Each subject in the Oligomenorrhea group will receive dexamethasone 1 mg orally in the evening and return the next morning for an injection of 25ug of IV recombinant human chorionic gonadotropin. Subjects will the have blood drawn at -0.5, 0, 0.5, and 24 hours after hCG injection for steroid hormone measurements.
88816464|NCT02511561|Experimental|0.1 mL OTO-201|Ciprofloxacin
88816465|NCT02511561|Experimental|0.2 mL OTO-201|Ciprofloxacin
88816466|NCT02511561|Experimental|0.4 mL OTO-201|Ciprofloxacin
89187016|NCT00921921|Placebo Comparator|Placebo control|
89392547|NCT01373749|Placebo Comparator|NO|NO inhalation was performed during the whole treatment procedure of PPHN. There is no other methods given to treat PPHN during the therapy course.
89392548|NCT02118038||HELPMOM1|corresponds to the cohort of patients in whom psychological state will be studied in the immediate waning PPH then during a 6 months through appropriate questionnaires
89392549|NCT02118038||HELPMOM2|corresponds to the cohort of patients enrolled in group HELPMOM1 who experienced a cardiac abnormality in the initial management and will therefore be included in a cardiac monitoring
89392550|NCT02035254|Experimental|Intervention group|Web-based wellness program
89392551|NCT02035254|Other|Wait control group|Web-based wellness program after 3 month wait.
89392552|NCT03551600||Preterm, no PDA|"Babies </= 32 weeks gestation at birth with no symptoms of a patent ductus arteriosus (PDA) or echocardiogram confirmation of no PDA~Near-infrared spectroscopy (NIRS) monitoring x 48 hours of splanchnic and cranial regions, minimum of 8 feedings need to be recorded"
89392553|NCT03551600||Preterm, moderate to large PDA|Babies </= 32 weeks gestation at birth with confirmed moderate to large PDA on echocardiogram Near-infrared spectroscopy (NIRS) monitoring x 48 hours of splanchnic and cranial regions, minimum of 8 feedings need to be recorded
89392554|NCT03551600||>/= 34 wk infants, no CHD|"Babies >/= to 34 weeks gestation at birth with no evidence of ductal dependent congenital heart disease (CHD)~Near-infrared spectroscopy (NIRS) monitoring x 48 hours of splanchnic, renal and cranial regions, minimum of 8 feedings need to be recorded"
89392555|NCT03551600||>/= 34 week infants, CHD|"Babies >/= to 34 weeks gestation at birth with ductal dependent CHD~Near-infrared spectroscopy (NIRS) monitoring x 48 hours of splanchnic, renal and cranial regions, minimum of 8 feedings need to be recorded"
89392556|NCT04505605||Patient hospitalized without being transferred in the ICU|A blood sample on a dry tube with 5 ml separating gel in addition to the blood test made on the basis of the usual medical care, will be taken on D1 (day of the enrollment = the day of hospitalization in the healthcare institution). The total volume of blood collected as part of the research is therefore 5 ml.
89392557|NCT04505605||Patient directly hospitalized in the ICU|A blood sample on a dry tube with a 5 ml separating gel in addition to the blood test made on the basis of the usual medical care, will be taken on D1 and D3 of the admission to intensive care. The total volume of blood collected for research is therefore 10 ml.
89392558|NCT04505605||Patient transferred from an other hospital service to the ICU|A blood sample on a dry tube with 5 ml separating gel in addition to the blood test that will be taken at D1 and D3 of the patient's admission to the intensive care unit, even if it has already been included in the study during the patient's admission to the unit (D1 hospitalization). The total volume of blood collected for the research is therefore 15 ml.
89392559|NCT02118116|No Intervention|Wait-list Control|No training, wait-listed for ASIST at a later date
89392560|NCT02118116|Experimental|ASIST|Applied Suicide Intervention Skills Training is a 2-day, 14 hour intensive, interactive and practice-dominated course aimed at enabling people to recognize risk and learn how to intervene immediately to prevent suicide. The course, facilitated by 2 trained facilitators, allows for a maximum enrollment of 30 participants.
89392561|NCT02118116|Experimental|ASIST uncontrolled arm|The ASIST workshop will be offered to participants who refuse to be part of the waitlist control arm. This is due to the reality in gathering data in these communities. Many times it is not possible for participants to be waitlisted, and therefore we would still want to gather data on those that refuse to participate in the RCT design and will collect uncontrolled data on these participants only.
89392562|NCT03607968||All women in this study|All women with POP and concomitant overt or occult USI, who underwent the novel anterior TVM surgeries, were enrolled in this study. Medical records, including urodynamic studies, questionnaires and 3-day bladder diaries, were retrospectively reviewed. Linear regress analysis was used to identify factors that were responsible for the changes in pad weights from baseline [i.e., 100 * (postoperative pad weight - baseline pad weight)/baseline pad weight].
89392563|NCT05760625||Migraine|In migraineurs, venous blood samples will be collected twice: outside and during migraine attacks prior to pain medication. Analysis of BDNF performed using enzyme-linked immunosorbent assay technique.
88868526|NCT01116102|Experimental|24 ga catheter, dose flush, single-step rate scheme|Single 150 U subcutaneous (SC) dose of HYLENEX and 3 mL Lactated Ringer's solution flush administered through 24 gauge plastic catheter; followed by SC infusion of 1000 mL Lactated Ringer's solution via large-volume infusion pump at 250 mL/h for the first hour and 200 mL/hr for the remainder of the infusion.
88868527|NCT01116102|Experimental|24 ga catheter, no dose flush, single-step rate scheme|Single 150 U subcutaneous (SC) dose of HYLENEX (without a Lactated Ringer's solution flush) administered through 24 gauge plastic catheter; followed by SC infusion of 1000 mL Lactated Ringer's solution via large-volume infusion pump at 250 mL/h for the first hour and 200 mL/hr for the remainder of the infusion.
89187017|NCT02602119|Experimental|OTL38|Dosage calculated by weight of individual
89187018|NCT00761475|Placebo Comparator|1|primary closure of the midline
89392564|NCT05760625||Tension type of headache|In patients with tension-type headache (outside attack) and healthy controls, one single blood sample will take. Analysis of BDNF performed using enzyme-linked immunosorbent assay technique.
89187019|NCT00761475|Active Comparator|2|onlay mesh supported closure
89392565|NCT05760625||Cluster headache|In cluster headache patients serum samples will be collected in and outside cluster bout. Analysis of BDNF performed using enzyme-linked immunosorbent assay technique.
89392566|NCT02034786|Experimental|Test|Adipose tissue collection and Transdermal injection of the filler agent, composed of mesenchymal stem cells derived from the autologous adipose tissue, associated with hyaluronic acid.
89392567|NCT02034786|Active Comparator|Control|Transdermal injection of hyaluronic acid only.
89392568|NCT02118194||Paraplegia, spinal cord injury|An exoskeleton-assisted walking system for people with paralysis from spinal cord injury at thoracic level 1 and below (paraplegia) will be used.
89392569|NCT03605940|Experimental|Experimental group|corticosteroids + ECP
89392570|NCT03605940|Active Comparator|Contrôl group|corticosteroids alone
88868528|NCT01116102|Experimental|24 ga catheter, dose flush, up-titrated rate scheme|Single 150 U subcutaneous (SC) dose of HYLENEX and 3 mL Lactated Ringer's solution flush administered through 24 gauge plastic catheter; followed by SC infusion of 1000 mL Lactated Ringer's solution via large-volume infusion pump at 50 mL/h for the first 5 min, 100 mL/h for the next 5 min, 285 mL/h for the next 50 min and 200 mL/h for the remainder of the infusion.
88868529|NCT01116102|Experimental|24 ga catheter, no dose flush, up-titrated rate scheme|Single 150 U subcutaneous (SC) dose of HYLENEX (without a Lactated Ringer's solution flush) administered through 24 gauge plastic catheter; followed by SC infusion of 1000 mL Lactated Ringer's solution via large-volume infusion pump at 50 mL/h for the first 5 min, 100 mL/h for the next 5 min, 285 mL/h for the next 50 min and 200 mL/h for the remainder of the infusion.
88868530|NCT01116102|Experimental|25 ga needle, dose flush, single-step rate scheme|Single 150 U subcutaneous (SC) dose of HYLENEX and 3 mL Lactated Ringer's solution flush administered through 25 gauge metal butterfly needle; followed by SC infusion of 1000 mL Lactated Ringer's solution via large-volume infusion pump at 250 mL/h for the first hour and 200 mL/hr for the remainder of the infusion.
88868531|NCT01116102|Experimental|25 ga needle, no dose flush, single-step rate scheme|Single 150 U subcutaneous (SC) dose of HYLENEX (without a Lactated Ringer's solution flush) administered through 25 gauge metal butterfly needle; followed by SC infusion of 1000 mL Lactated Ringer's solution via large-volume infusion pump at 250 mL/h for the first hour and 200 mL/hr for the remainder of the infusion.
89187020|NCT00761475|Active Comparator|3|sublay mesh supported closure
89187021|NCT00675441|Experimental|Lenalidomide|Lenalidomide 10 mg (capsule) by mouth on days 1-21 of a 28-day cycle, for a total of 6 cycles.
88868532|NCT01116102|Experimental|25 ga needle, dose flush, up-titrated rate scheme|Single 150 U subcutaneous (SC) dose of HYLENEX and 3 mL Lactated Ringer's solution flush administered through 25 gauge metal butterfly needle; followed by SC infusion of 1000 mL Lactated Ringer's solution via large-volume infusion pump at 50 mL/h for the first 5 min, 100 mL/h for the next 5 min, 285 mL/h for the next 50 min and 200 mL/h for the remainder of the infusion.
89187022|NCT00761553|Experimental|1|Solid dietary supplements with exercise
89187023|NCT00761553|Experimental|2|Solid dietary supplements without exercise
89187024|NCT00761553|Experimental|3|Liquid dietary supplements with exercise
89187025|NCT00761553|Experimental|4|Liquid supplements without exercise
89187026|NCT02559297|Active Comparator|Sevoflurane|In sevoflurane arm (n=20) at the beginning after successful intubation, 2 L/min nitric oxide (N2O), 2 L/min O2 , and 2% to 2.5% sevoflurane will be given for 10 minutes then total flow will be decreased to 2 L/min. Anesthesia will be maintained using 1-1.5 minimal alveolar concentration (MAC) of sevoflurane in 50% O2 and 50% N2O.
89187027|NCT02559297|Experimental|Desflurane|In desflurane arm (n=20) at the beginning after successful intubation, 2 L/min N2O, 2 L/min O2, and 6% to 8% desflurane will be given for 10 minutes then total flow will be decreased to 2 L/min. Anesthesia will be maintained using 1-1.5 MAC of desflurane in 50% O2 and 50% N2O.
89187028|NCT01413399|Active Comparator|Intra-Arrest Therapeutic Hypothermia|
89187029|NCT01413399|Active Comparator|Post-Arrest Therapeutic Hypothermia|
89187030|NCT04049487|Active Comparator|Generalized Exercise|General wellness/exercise program designed to replicate a generic wellness program that one would find in a gym setting. Will be led by an exercise instructor.
89187031|NCT04049487|Experimental|Diastasis Specific Exercise|Diastasis specific exercise program incorporating multiple muscle groups and based on research findings of exercises that are shown to be effective for reducing size and impact of diastasis rectus.
89187032|NCT02558517|No Intervention|Prednisone maintenance|Patients will be kept under Prednisone 5 milligrams/day. Other treatments will be maintained (in particular HYDROXYCHLOROQUINE, METHOTEXATE etc..)
89187033|NCT02558517|Experimental|Prednisone discontinuation|Prednisone will be stopped and remplaced by HYDROCORTISONE for one month (20 mg/day). Other treatments will be maintained (in particular HYDROXYCHLOROQUINE, METHOTEXATE etc..)
89392571|NCT02124980|Experimental|Recovery Line plus Treatment-as-Usual (RL+TAU)|The Recovery Line is an automated computer-based IVR system that provides CBT-based modules. The RL+TAU condition will include the customized therapeutic recommendations developed in Phase 1, and the contact reminders messages and time frame that maximized system use in Phase 2. Patients will receive an orientation, 24-hour access, encouragement to use the system from clinic staff reminder, and technical assistance line for system problems. Patients will receive 12 weeks of system access.
89392572|NCT02124980|No Intervention|Treatment-as-Usual|Treatment-as Usual involves daily methadone and associated psychosocial services. Patients are required to attend 1 group session per month and are encouraged to attend open drop-in groups available daily covering a range of topics.
89392573|NCT05760547||TIME-A|Group will complete periodic surveys
89003665|NCT04847973|Experimental|12 weeks of medically-tailored meals (MTMs)|12 weeks of home-delivered medically-tailored meals (MTMs), prepared and delivered by the non-profit Community Servings. The MTM has be developed specifically for patients with heart failure, with an approximate protein intake range of 1.1-1.5 g/kg body weight/day and a maximum of 2000 mg sodium/day.
89187034|NCT00927381||Severe envenomation|Patients with a calculated severity score of 5 or 6 were included in this group.
89187035|NCT00927381||Minimal/Moderate Envenomation|Severity Score less than 5
89187036|NCT00674973|Experimental|Erlotinib|Participants with advanced pancreatic carcinoma with Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 to 2, who had failed 1 prior regimen of chemotherapy or who were considered unsuitable for chemotherapy, received erlotinib 150 mg orally once daily until disease progression, unacceptable toxicity, withdrawal, or death.
89187037|NCT00674973|Placebo Comparator|Placebo|Participants with advanced pancreatic carcinoma with ECOG PS score of 0 to 2, who had failed 1 prior regimen of chemotherapy or who were considered unsuitable for chemotherapy, received placebo matching to erlotinib 150 mg tablet orally once daily until disease progression, unacceptable toxicity, withdrawal, or death.
89187038|NCT00761787||1|Heart transplanted subjects.
89187039|NCT00673179|Experimental|Outpatient Chemotherapy|Pre-Surgery, Regimen 1: Doxorubicin intravenous (IV) 90 mg daily, Cisplatin 60 mg/m^2/day for 2 days, Methotrexate 12 gm/m^2, Leucovorin Rescue 10 mg IV, with 10 mg orally every 6 hours; Surgery; Post-Surgery, Regimen 1: Methotrexate 12 gm/m^2, Doxorubicin IV 90 mg, Cisplatin 60 mg/ m^2 twice daily, Leucovorin Rescue.
89392574|NCT03605472|Experimental|Patients|
89392575|NCT02125058|Other|Transcutaneous sutures|Transcutaneous sutures
89392576|NCT02125058|Other|Intracutaneous sutures|Intracutaneous sutures
89392577|NCT04421131|Experimental|mIVAA|Screened for cervical cancer with mIVAA in mobile units
89392578|NCT03607734|Other|Group 1 - Interventional Treatment|"A graded oral challenge test, using amoxicillin in syrup form, will be administered as follows:~50mg amoxicillin (10% total dose)~250mg amoxicillin (50% total dose)~200mg amoxicillin (remainder needed to complete a 500mg full dose) A 20 minute interval will separate each dose given, and participants will be observed throughout the test. They will be required to stay for one hour after the final dose has been administered. Fully trained staff and all equipment for emergency resuscitation will be immediately available."
89392579|NCT05296694||Coronary Care Patients|All patients admitted to coronary care unit with cardiovascular diseases.
89392580|NCT02118272|Other|Physica KR|
89392581|NCT04167345|Placebo Comparator|Parts A1, A2 and B Combined: Placebo|Participants received placebo matched to VX-814 in the treatment period for 28 days.
89392582|NCT04167345|Experimental|Part A1: VX-814 100 milligrams (mg)|Participants received VX-814 100 mg every 12 hours (q12h) in the treatment period for 28 days.
89392583|NCT04167345|Experimental|Part A1: VX-814 200 mg|Participants received VX-814 200 mg q12h in the treatment period for 28 days.
89392584|NCT04167345|Experimental|Parts A1 and A2 Combined: VX-814 400 mg|Participants received VX-814 400 mg q12h in the treatment period for 28 days.
89392585|NCT04167345|Experimental|Part B: VX-814 600 mg|Participants received VX-814 600 mg q12h in the treatment period for 28 days.
89392586|NCT01375153|Placebo Comparator|Placebo|0,9% NaCl administered as a continuous intravenous infusion during four hours.
89392587|NCT01375153|Active Comparator|BNP|3.0 pmol/kg/min human active BNP administered as a continuous intravenous infusion during four hours.
89392588|NCT02126774||focal epilepsy|observational study
89392589|NCT02035488|Experimental|Tobramycin|Patients with bronchiectasis
89392590|NCT03602430|Experimental|Drug Group|twenty-five patients will receive 200.000 IU/month native vitamin D; (Cholecalciferol) orally in addition to their standard treatment for 3 months period
89187040|NCT00673179|Experimental|Additional Risk-Adapted Outpatient Chemotherapy|Pre-Surgery, Regimen 2: Dexrazoxane 900 mg/m^2 intravenous (IV) then Doxorubicin IV 90 mg daily, Cisplatin 120 mg/m^2 (intra-arterial); Surgery; Post-Surgery, Regimen 2: Methotrexate 12 gm/m^2, Leucovorin Rescue 10 mg IV, with 10 mg orally every 6 hours; Ifosfamide 2.8 grams m^2/day and Mesna 2.8 gm/m^2/day continuous IV over 6 days; Lung-Directed Chemotherapy, Regimen 2: Gemcitabine, Sargramostim Inhaled aerosol (5 mcg/kg, maximum dose 300 mcg).
89187041|NCT00758433|Active Comparator|1|Civamide patch 0.0075%
89187042|NCT00758433|Active Comparator|2|Civamide patch 0.0150%
89392591|NCT03602430|Placebo Comparator|Placebo Group|twenty-five patients will receive a placebo ampule with their standard treatment for 3 months period.
89187043|NCT00758433|Placebo Comparator|3|Placebo patch
89392592|NCT02126852|Experimental|AMG (one-dimensionally) versus EMG|Neuromuscular monitoring in patients scheduled for surgery under general anesthesia
89392593|NCT02126852|Experimental|AMG (three-dimensionally) versus EMG|Neuromuscular monitoring in patients scheduled for surgery under general anesthesia
89392594|NCT03605238|Experimental|Corticosteroids & tanCART19/20|Twelve days of high-dose IV methylprednisolone to reduce acute inflammation, then infuse anti-CD19/20-CAR retroviral vector-transduced autologous derived T cells only once.
88816467|NCT03884270|Experimental|Hypnotherapy|7 sessions of on-line hypnotherapy treatment over the course of 12 weeks (1 new session every 2 weeks)
89187044|NCT00758511|Active Comparator|1|Orally administrated 25%sucrose before,during and after heel stick across 5 heel sticks during the first 14 days of postnatal life
89187045|NCT00758511|Active Comparator|2|facilitated tucking before, during and after heel stick across 5 heel stick during the first 14 days of postnatal life
89187046|NCT00758511|Active Comparator|3|orally administrated 25% sucrose AND facilitated tucking before, during and after heel stick across 5 heel sticks during the first 14 days of postnatal life
89187047|NCT00584012|Experimental|Dose Esclation|Determine the maximum tolerated dose (MTD) of escalating doses of lovastatin in combination with docetaxel in patients with any type of solid tumor.
89392595|NCT02252120|Active Comparator|Supreme|Supreme LMA
89392596|NCT02252120|Active Comparator|Laryngeal Tube|Laryngeal tube LTSII
89392597|NCT03633409||IBD patients and healthy volunteers|We will recruit IBD patients and healthy volunteers
89392598|NCT03605160|Active Comparator|traditional group|Perform conventional continuous curvilinear capsulorhexis. After phacoemulsification and I/A, switch to polish mode and use I/A instrument to remove the RLFs visible on the posterior capsule before injection of viscoelastic agent. IOP: 55mmHg; Aspiration: 0-10; Vacuum: 0-20. The standard for stopping polish is that the RLFs can no longer be absorbed by the side holes on the I/A instrument in this mode, or there are no discernible RLFs on the posterior capsule. If RLFs on the posterior capsular are found after IOL implantation, polish to remove them after the removal of viscoelastic agents. All operations are videotaped during the whole operation. The total polish time is recorded as the time of all polish procedures.
88816468|NCT02511717|Sham Comparator|Sham|Transcutaneous stimulation in a location and with settings not relation to the bladder nerves, 3x/week for 30 minutes for 12 weeks
88816469|NCT02511717|Active Comparator|Transcutaneous nerve stimulation|Transcutaneous stimulation of the bladder nerves, 3x/week for 30 minutes for 12 weeks
88816470|NCT02512419|Experimental|Text-Enhanced Physical Activity Intervention Arm|The Spanish-language PA intervention is based on Social Cognitive Theory (SCT) and Transtheoretical Model (TTM), and emphasizes behavioral strategies for increasing activity levels (i.e., goal-setting, self-monitoring, problem-solving barriers, increasing social support, rewarding oneself for meeting physical activity goals).
89392599|NCT03605160|Experimental|fluid-jet group|Perform conventional continuous curvilinear capsulorhexis. After phacoemulsification and I/A, inject viscoelastic agent and implant IOL without polish. Use I/A instrument to remove viscoelastic agent. A 27G irrigating syringe was used, and the RLFs on the posterior capsule were gently aligned to make a fluid-jet basically parallel to the iris. The liquid pressure of 50-120 mmHg is produced. The standard for stopping in this mode is that the RLFs can no longer be washed down from the capsule, or there are no discernible RLFs on the posterior capsule. All operations are videotaped during the whole operation. The total time of all jet procedures recorded in the videotape is the total time of jet.
89392600|NCT02260544|Experimental|Test Product - T|"doxorubicin hydrochloride liposome ( Dr. Reddy's Lab )~Use the test drug (doxorubicin hydrochloride liposome Injection 20mg/10mL i.e. 2mg/mL from Dr.Reddy's Laboratories Ltd., India) ; then use the reference drug ( doxorubicin hydrochloride liposome Injection 20mg/10mL i.e. 2mg/mL from Sun Pharma ) after at least 4-weeks."
89392601|NCT02260544|Active Comparator|Reference Product - R|"doxorubicin hydrochloride liposome ( Sun Pharma )~Use the reference drug (doxorubicin Hydrochloride Liposome Injection 20mg/10mL i.e. 2mg/mL; from Sun Pharma ) ; then use the test drug ( doxorubicin hydrochloride liposome Injection 20mg/10mL i.e. 2mg/mL from Dr.Reddy's Laboratories Ltd., India) after at least 4 weeks."
89392602|NCT05470647|Experimental|Interleukin-4 receptor responders 1|Interleukin-4 receptor was injected subcutaneously, once every two weeks.
89392603|NCT05470647|Experimental|Interleukin-4 receptor responders 2|Interleukin-4 receptor was injected subcutaneously, once a week.
89392604|NCT05470647|Placebo Comparator|Controls|Placebo was injected subcutaneously.
89392605|NCT03552848|Experimental|Mesenchymal stem cell|Patients in the MSC arm will be given MSC, i.v., 1000000 cells per kilogram of body weight.
89392606|NCT03552848|No Intervention|Control|Patients in the control arm will not be given MSC.
89392607|NCT04409665|Experimental|Ketamine sedated group|30 randomized patients will receive Ketamine 1 mg/kg , I.V. 2 minutes before LISA
89392608|NCT04409665|Active Comparator|Glucose sedated group|30 patients will receive Glucose 30% 1 mL, sublingually, 2 minutes before LISA
89392609|NCT02854800|Experimental|Weekly Opioid Tx|Participants in this group attended an outpatient opioid clinic once per week. As part of the current study, they received 12-week dosing of varenicline per label recommendations: 0.5mg once daily (Days 1-3), 0.5 mg twice daily (Days 4-7), and 1 mg twice daily (Days 8-84). Pill form/blister pack
89392610|NCT02854800|Experimental|Biweekly Opioid Tx|Participants in this group attended an outpatient opioid clinic once bi-weekly. As part of the current study, 12-week dosing of varenicline per label recommendations: 0.5mg once daily (Days 1-3), 0.5 mg twice daily (Days 4-7), and 1 mg twice daily (Days 8-84). Pill form/blister pack
89392611|NCT02854800|Experimental|Monthly Opioid Tx|Participants in this group attended an outpatient opioid clinic once per month. As part of the current study, 12-week dosing of varenicline per label recommendations: 0.5mg once daily (Days 1-3), 0.5 mg twice daily (Days 4-7), and 1 mg twice daily (Days 8-84). Pill form/blister pack
89392612|NCT03552770|Active Comparator|IVIBx1|Patients treated with a single intra-vitreous injection of bevacizumab (1.25 mg in 0.05 ml of solution) pro-re-nata repeated after monthly periodic monitoring of each patient
89392613|NCT03552770|Active Comparator|IVIBx2|Patients treated with two combined intra-vitreous injections of bevacizumab, (1.25 mg in 0.05 ml of solution) spaced 30 ± 10 days apart and pro-re-nata repeated after periodic monitoring of each patient
89392614|NCT01373827||MC1 Subjects|
89392615|NCT02118350|Experimental|Mat Pilates training|Mat Pilates training performed two times at week for 16 weeks.
89392616|NCT02118350|No Intervention|Control|
89392617|NCT02125214|Experimental|ASA 1-2|ASA 1-2 patients 20-40 yr
89392618|NCT01375231|Active Comparator|Measured Resection of patellofemoral joint|The goal is to remove an amount of bone from the patella so that when reconstructed, the composite thickness of the entire prosthetic patellofemoral joint is recreated
89392619|NCT01375231|Active Comparator|Measured resection of patella|The thickness of the anterior condyle is not considered in this measurement. The goal is to restore the composite thickness of the patella only.
89392620|NCT02035098|Experimental|The Pac-IFicO programme|The Pac-IFicO programme is a complex interventions aimed at improving the quality of pain managementi in hospitalized patients.
89392621|NCT04394923|Experimental|"Intervention group or PRINT group"|The ablation line previously drawn will be modified regarding the esophageal print position in order to avoid RF application within the red layer of the esophageal print, which is the zone where the atrioesophageal distance is shorter. The maximal distance and the area between the original line and the modified line will be noted. In cases when ablation through the red layer is unavoidable, the delivered energy can be lowered to an ablation index (AI) of 300 regardless of the local wall thickness. If the temperature rises above 39℃, ablation will be immediately stopped, and energy will be reduced.
89392622|NCT04394923|Other|Control group|The ablation line will not be modified from the original one drawn before randomization and RF applications will follow the regular path. If the temperature rises above 39℃, ablation will be immediately stopped, and energy will be reduced.
89392623|NCT02125370||Nicotine Replacement Therapy|
89392624|NCT03605082|Experimental|UCB0107|Subjects will be randomized to receive a predefined dosage of UCB0107 in order to maintain the blinding.
89392625|NCT03605082|Placebo Comparator|Placebo|Subjects will be randomized and receive a placebo in order to maintain the blinding.
89392626|NCT02126930|Active Comparator|Routine care|"The patients in this receive routine care.~Intervention: Routine care"
89392627|NCT02126930|Experimental|Pharma consult|"The patients in this arm will have a pharmaceutical consult upon hospital discharge.~Intervention: Pharma consult"
89392628|NCT03602274||orthopedic and visceral surgery patients|patient having been subjected to an intervention from the orthopedic or visceral surgery department being prescribed 4 g paracetamol / day
89392629|NCT03602274||Overdosed patients|Patent admitted to hospital with paracetamol overdoses
89392630|NCT02118506|Active Comparator|Physical practice|"Familiarization with gait cycle: Cards with pictures of an elderly person performing movements related to the adjustment of posture, gait initiation and gait phases were shown to the subjects. They should have organized them sequentially, showing that they learned gait phases.~Physical practice: is the execution of the motor action."
89392631|NCT02118506|Experimental|Mental and physical practice|"Familiarization with gait cycle: Cards with pictures of an elderly person performing movements related to the adjustment of posture, gait initiation and gait phases were shown to the subjects. They should have organized them sequentially, showing that they learned gait phases.~Mental practice: is defined as motor imagery training with the aim of improving the engine performance. Is the imagination of a motor action without its physical implementation.~Physical practice: is the execution of the motor action."
89392632|NCT05376384||Case|Patients, over 18 years old, undergoing laparoscopic cyst enucleation surgery with an occasional, unanticipated finding of cyst rupture and intraoperative spillage
89392633|NCT05376384||Control|Patients, over 18 years old, undergoing laparoscopic cystic enucleation surgery with the extraction of the intact operative specimen.
89392634|NCT02127008|Experimental|Resection of epidural fat|During surgical procedure, epidural fat was resected fully.
89392635|NCT02127008|Active Comparator|No resection of epidural fat|During surgical procedure, the epidural fat was not resected.
88868533|NCT01116102|Experimental|25 ga needle, no dose flush, up-titrated rate scheme|Single 150 U subcutaneous (SC) dose of HYLENEX (without a Lactated Ringer's solution flush) administered through 25 gauge metal butterfly needle; followed by SC infusion of 1000 mL Lactated Ringer's solution via large-volume infusion pump at 50 mL/h for the first 5 min, 100 mL/h for the next 5 min, 285 mL/h for the next 50 min and 200 mL/h for the remainder of the infusion.
88868534|NCT01118988|Experimental|Mentorship|"Subjects randomly assigned to this arm received the specified Mentorship Intervention"
88868535|NCT01118988|No Intervention|Control|Subjects randomly assigned to this control group receive treatment as usual (TAU).
88868536|NCT01118988|No Intervention|Mentors|"Subjects recruited to the Mentor arm of the study are UCLA Pediatric Pain Program patients between the ages of 14 and 18. These mentors are identified by the Principal Investigator as children who have not necessarily eliminated pain, but have learned how to cope with pain and maintain appropriate functioning in daily life. Mentors undergo an in depth training from doctoral level psychologists who are members of the research team. Mentors present pain coping information developed by the research team, provide support, and encourage mentees to attend pain management therapies. They are also monitored by doctoral level psychologists throughout the duration of the study to ensure safety and appropriate contact with mentees via telephone."
88868537|NCT01119222|Active Comparator|Gabapentin 1200mg|
88868538|NCT01119222|Active Comparator|Diphenhydramine 50 mg|
88868539|NCT01119222|Active Comparator|Morphine 10 mg|
89392636|NCT03605004||Negative|Adult patients with undiagnosed conditions who have received an uninformative negative result from exome sequence.
88868540|NCT01119222|Placebo Comparator|Placebo formulations|
88868541|NCT01119456|Experimental|IMC-RON8|A monoclonal antibody to human macrophage-stimulating 1-receptor-8 (RON8).
89187048|NCT05435846|Experimental|Phase 1: Dose Escalation|Patients receive 200 - 400 mg capmatinib orally, twice a day and 1.0 or 1.5 mg trametinib orally once a day on days 1-28 of each cycle. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.
89392637|NCT03605004||VUS|Adult patients with undiagnosed conditions who have received one or more variants ofuncertain significance from exome sequence.
88868542|NCT01120236|Experimental|Arm I (androgen deprivation and cixutumumab)|Patients receive androgen deprivation therapy comprising bicalutamide PO QD on days 1-28 and either goserelin acetate SC or leuprolide acetate IM every 1, 3, 4, 6, or 12 months. Patients also receive cixutumumab IV over 1 hour on days 1 and 15. Treatment repeats every 28 days for 7 courses in the absence of disease progression or unacceptable toxicity.
88868543|NCT01120236|Active Comparator|Arm II (androgen deprivation therapy)|Patients receive androgen deprivation therapy comprising bicalutamide and either goserelin acetate or leuprolide acetate as in arm I.
88868544|NCT01120704|Experimental|1, 26Wks, Counseling, CAM, AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, Maintenance Counseling, Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
88868545|NCT01120704|Experimental|2, 26Wks, Counseling, CAM, AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, Maintenance Counseling, Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
89392638|NCT02931539|Experimental|Maribavir Treatment|Participants will receive 400 milligrams (mg) (2x200 mg tablets) maribavir twice daily orally (doses separated by a minimum of 8 hours) for 8 weeks.
89392639|NCT02931539|Active Comparator|Investigator-Assigned Treatment|Participants will receive anti-CMV agent best suited to treat the respective participant as per the investigator's prescribed dosing regimen for 8 weeks. Agents of choice include: ganciclovir, valganciclovir, foscarnet, or cidofovir.
89392640|NCT03602196|Experimental|pregnant women|"pregnant women with one visit per trimester of pregnancy (14-18 weeks, 24-28 weeks and 34-38 weeks)~For the ancillary study: non-pregnant nulliparous women"
89392641|NCT02125448||Resectable esophageal cancer|Neoadjuvant chemoradiotherapy. MRI and PET-CT.
89392642|NCT03604926||chemo-naive patients|
89392643|NCT03604926||pre-treated patients with systemic chemotherapy +/- a targeted|
89392644|NCT02125526|Active Comparator|IABP group|After primary percutaneous coronary intervention, IABP will be implanted for 12-24 hours to alleviate persisting ischemia
89392645|NCT02125526|No Intervention|Control group|After primary percutaneous coronary intervention, this group undergoes standard treatment according to the guidelines
89392646|NCT03602118|Active Comparator|Phenobarbital Sodium Injection 20 mg|Once participants are deemed to be eligible for participation in the study and randomized to the lower dose they will be given a loading dose of phenobarbital 20 mg/kg administered intravenously over the course of 30 minutes.
89392647|NCT03602118|Active Comparator|Phenobarbital Sodium Injection 40 mg|Once participants are deemed to be eligible for participation in the study and randomized to the higher dose they will be given a loading dose of phenobarbital 20 mg/kg administered intravenously over the course of 30 minutes. ministered intravenously over the course of 30 minutes.
89392648|NCT02131142|Experimental|BioFreedom|
89392649|NCT01375309|Active Comparator|Active|Bifidobacterium bifidum
88868546|NCT01120704|Experimental|3, 26Wks, Counseling, CAM, No AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, Maintenance Counseling, Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
88868547|NCT01120704|Experimental|4, 26Wks, Counseling, CAM, No AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, Maintenance Counseling, Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
88868548|NCT01120704|Experimental|5, 26Wks, Counseling, No CAM, AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, Maintenance Counseling, No Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
88868549|NCT01120704|Experimental|6, 26Wks, Counseling, No CAM, AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, Maintenance Counseling, No Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
88868550|NCT01120704|Experimental|7, 26Wks, Counseling, No CAM, No AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, Maintenance Counseling, No Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
88868551|NCT01120704|Experimental|8, 26Wks, Counseling, No CAM, No AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, Maintenance Counseling, No Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
88868552|NCT01120704|Experimental|9, 26Wks, No Counseling, CAM, AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, No Maintenance Counseling, Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
88868553|NCT01120704|Experimental|10, 26Wks, No Counseling, CAM, AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, No Maintenance Counseling, Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
89392650|NCT01375309|Placebo Comparator|Placebo|Dextrin without Bifidobacterium bifidum
89392651|NCT03604848|Experimental|NGS-guided regimen: Regimen A|Regimen A: 9-month regimen for simple MDR-TB patients 4 months of pyrazinamide, amikacin ,moxifloxacin, prothionamide, and cycloserine , followed by 5months of pyrazinamide,moxifloxacin, prothionamide, and cycloserine
88868554|NCT01120704|Experimental|11, 26Wks, No Counseling, CAM, No AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, No Maintenance Counseling, Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
88868555|NCT01120704|Experimental|12, 26Wks, No Counseling, CAM, No AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, No Maintenance Counseling, Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
88868556|NCT01120704|Experimental|13, 26Wks, No Counseling, No CAM, AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, No Maintenance Counseling, No Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
88868557|NCT01120704|Experimental|14, 26Wks, No Counseling, No CAM, AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, No Maintenance Counseling, No Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
89392652|NCT03604848|Experimental|NGS-guided regimen: Regimen B|Regimen B: 12-month simple MDR-TB regimen for simple MDR-TB patients 6 months of pyrazinamide, amikacin ,moxifloxacin, prothionamide, and cycloserine , followed by 6 months of pyrazinamide,moxifloxacin, prothionamide, and cycloserine
89392653|NCT03604848|Experimental|NGS-guided regimen: Regimen C|"Regimen C : for complicated MDR-TB patients In regimen C, the resistant drug(s) will be replaced by the other WHO recommended drugs for MDR-TB such as linezolid, clofazimine or ethambutol based on the drug susceptibility test results. The duration of treatment in the complicated MDR-TB group is consistent with control group, with 6 months of intensive phase and 18 months of consolidation phase."
89392654|NCT03604848|Active Comparator|WHO-approved MDR-TB regimen|6 months of pyrazinamide, amikacin,moxifloxacin, prothionamide , and cycloserine , followed by 18 months of pyrazinamide, moxifloxacin, prothionamide , and cycloserine
89392655|NCT02125682|Active Comparator|low dose|patients receiving 10 mg of atorvastatin daily
89392656|NCT02125682|Active Comparator|High dose|Patients receiving 80 mg of atorvastatin daily
89392657|NCT03602040|Experimental|PISICC group|Psychoeducational intervention
89392658|NCT03551444|Active Comparator|Administration of DAA-based treatment (Arm 1)|"Arm 1 will be divided into 2 groups by randomization according to a 1:1 ratio into:~Group A: Administration of DAA-based treatment after 3 months of complete remission of HCC.~Group B: Administration of DAA-based treatment after 6 months of complete remission of HCC."
89392659|NCT03551444|Experimental|Control arm (Arm 2)|Not receiving DAAs after complete remission of HCC and to be kept on follow-up
89392660|NCT03604770||Women seeking fertility treatment|Women aged 18-45 who are seeking fertility treatment at Bethesda Fertility Center will be provided a survey and food diary to complete.
89392661|NCT02125760|Sham Comparator|Inspiratory Muscle Training (IMT)|Patients with subacute stroke in a neurorehabilitation setting.
89392662|NCT02125760|Experimental|High-intensity IMT|Patients with subacute stroke in a neurorehabilitation setting.
88868558|NCT01120704|Experimental|15, 26Wks, No Counseling, No CAM, No AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, No Maintenance Counseling, No Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
88868559|NCT01120704|Experimental|16, 26Wks, No Counseling, No CAM, No AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, No Maintenance Counseling, No Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
88868560|NCT01120704|Experimental|17, 8Wks, Counseling, CAM, AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, Maintenance Counseling, Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
88868561|NCT01120704|Experimental|18, 8Wks, Counseling, CAM, AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, Maintenance Counseling, Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
88868562|NCT01120704|Experimental|19, 8Wks, Counseling, CAM, No AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, Maintenance Counseling, Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
88868563|NCT01120704|Experimental|20, 8Wks, Counseling, CAM, No AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, Maintenance Counseling, Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
88868564|NCT01120704|Experimental|21, 8Wks, Counseling, No CAM, AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, Maintenance Counseling, No Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
89187049|NCT05435846|Experimental|Phase 1b: Dose Expansion|Patients will receive the recommended phase 2 dose (RP2D) or capmatinib in combination with trametinib determined by the safety profile of the Phase 1 group. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.
89392663|NCT05760391|Experimental|Experimental group|Patients will be treated with anti-PD-1 Immune Checkpoint Inhibitors combined with chemotherapy used as 1st line treatment for metastatic ESCC.Radiotherapy will be conducted after four cycles of IO plus chemotherapy or started simultaneously.
89392664|NCT03604614|Experimental|HIPEC and chemotherapy|Hyperthermic Intraperitoneal Chemotherapy and SOX（Tiggio+Oxaliplatin ）
89392665|NCT03604614|Sham Comparator|Without HIPEC|Without Hyperthermic Intraperitoneal Chemotherapy，Only SOX（Tiggio+Oxaliplatin ）
89392666|NCT01361945|Experimental|AUY922|Single Arm
89392667|NCT03601962|Experimental|Aqualief® tablets|oral mucoadesive tablets
89392668|NCT03601962|Placebo Comparator|Placebo tablets|oral mucoadesive tablets
89392669|NCT02127242|Experimental|air-pressure ballistic lithotripsy|In case of large, hard or impacted stones ureteroscopic air-pressure ballistic lithotripter is used for fragmentation. The probe of the lithotripter target towards the stone and then fragmented.
88868565|NCT01120704|Experimental|22, 8Wks, Counseling, No CAM, AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, Maintenance Counseling, No Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
88868566|NCT01120704|Experimental|23, 8Wks, Counseling, No CAM, No AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, Maintenance Counseling, No Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
88868567|NCT01120704|Experimental|24, 8Wks, Counseling, No CAM, No AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, Maintenance Counseling, No Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
89003666|NCT04847973|Experimental|12 weeks of protein supplementation shakes|Participants will receive 1 bottle of Ensure Max Protein shake every day (any flavor option without caffeine, daily for 12 weeks) to take in addition to their standard diet, without MTM delivery.
89003667|NCT04846881|Experimental|Iclepertin|
89187050|NCT03933878||Post-transplant recipient BAL samples|No intervention will be administered
89187051|NCT03933878||Donor BAL samples|No intervention will be administered
89392670|NCT02127242|No Intervention|hepatectomy group|Hepatic resection using an open approach is performed for all segments affected by biliary stenosis and the affected bile duct drainage area.Hepaticojejunostomy is performed in patients with common bile duct stenosis and in those considered to be at high risk for recurrence.
89392671|NCT02237430|Active Comparator|Manuel compression|Conventional manual compression
89392672|NCT02237430|Experimental|MynxGrip closure device|Closure device for femoral artery access closure
88868568|NCT01120704|Experimental|25, 8Wks, No Counseling, CAM, AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, No Maintenance Counseling, Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
88868569|NCT01120704|Experimental|26, 8Wks, No Counseling, CAM, AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, No Maintenance Counseling, Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
88868570|NCT01120704|Experimental|27, 8Wks, No Counseling, CAM, No AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, No Maintenance Counseling, Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
88868571|NCT01120704|Experimental|28, 8Wks, No Counseling, CAM, No AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, No Maintenance Counseling, Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
88868572|NCT01120704|Experimental|29, 8Wks, No Counseling, No CAM, AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, No Maintenance Counseling, No Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
88868573|NCT01120704|Experimental|30, 8Wks, No Counseling, No CAM, AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, No Maintenance Counseling, No Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
88868574|NCT01120704|Experimental|31, 8Wks, No Counseling, No CAM, No AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, No Maintenance Counseling, No Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
88868575|NCT01120704|Experimental|32, 8Wks, No Counseling, No CAM, No AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, No Maintenance Counseling, No Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
88868576|NCT01121172||obese|obese subjects according to International Obesity Task Force criteria
88868577|NCT01121172||lean|
88868578|NCT01121250|Experimental|Telephone Discussion Groups|Each telephone discussion group will meet 12 times during six months. The one-hour calls will be semi-structured conference calls with education, training in coping skills and cognitive restructuring, and support. A Participant Workbook will include comprehensive materials for all sessions and topics, other resources, and red flag resources - areas that may exacerbate problems, add a level of difficulty or distress, and/or indicate a need for referrals (e.g., unsafe behaviors, substance abuse, spouse abuse, PTSD, depression, traumatic brain injury).
88868579|NCT01121250|Active Comparator|Education sessions|Participants will have 12 sessions (delivered using slides and telephone) that cover the same education content, without skills building or support, over six months. They will also receive the Participant Workbook.
88868580|NCT01121250|No Intervention|Usual Care|Participants do not receive any services.
88868581|NCT01122030|Experimental|Cohort 1|In this cohort 9 participants received one 0.1 mg naldemedine tablet and 3 participants received matching placebo administered on Day 15 under fasted conditions.
88868582|NCT01122030|Experimental|Cohort 2|In this cohort 9 participants received a single dose of 0.3 mg naldemedine tablets and 3 participants received matching placebo tablets administered on Day 15 under fasted conditions.
88868583|NCT01122030|Experimental|Cohort 3|In this cohort 9 participants received a single dose of 1 mg naldemedine tablets and 3 participants received matching placebo tablets administered on Day 15 under fasted conditions.
88868584|NCT01122030|Experimental|Cohort 4|In this cohort 9 participants received a single dose of 3 mg naldemedine tablets and 3 participants received matching placebo tablets administered on Day 15 under fasted conditions.
88868585|NCT01122030|Experimental|Cohort 5|In this cohort 9 participants received a single dose of 0.03 mg naldemedine oral solution and 3 participants received matching placebo oral solution administered on Day 15 under fasted conditions.
88868586|NCT01122030|Experimental|Cohort 6|In this cohort 9 participants received a single dose of 0.01 mg naldemedine oral solution and 3 participants received matching placebo oral solution administered on Day 15 under fasted conditions.
88868587|NCT01122108|Active Comparator|Cholestyramine 12 grams|Cholestyramine 12 grams
89392673|NCT02546999|Experimental|botox|Botox® (onabotulinumtoxin A),injections in the calf muscles. The total maximum body dose of Botox® in this study will be 420 Units. Maximum dose per injection site will be 50 Units. The gastrocnemius muscle will receive 5-6 Units Botox® per kg, but maximum 180 Units in each leg. The soleus muscle will receive 2 Units Botox® per kg with maximum dose 60 Units in each leg. Dilution: 100 Units Botox® in 1 ml 0.9% sodium chloride, and the maximum volume per injection site will be 0,5 ml in both study groups. The route of administration is intramuscular injection.
89392674|NCT02546999|Placebo Comparator|placebo|Sterile 0,9% Sodium Chloride injection The placebo dose will be the same dose in ml as the reconstituted Botox
89392675|NCT02131220|Experimental|Prourokinase|Intracoronary bolus infusion of 20mg prourokinase using selective catheter
88868588|NCT01122108|Active Comparator|Colesevelam HCl|Colesevelam HCl, 4 grams
88868589|NCT01123512|Experimental|Kiva VCF Treatment System|
88868590|NCT01123512|Active Comparator|Balloon Kyphoplasty|
89003668|NCT04846881|Placebo Comparator|Placebo|
89187052|NCT00920270|Active Comparator|antibiotic|conventional antibiotics
89392676|NCT02131220|Active Comparator|Tirofiban|Intracoronary tirofiban bolus infusion using selective catheter (10ug/kg)
89392677|NCT02131220|Placebo Comparator|Normal saline|Intracoronary saline bolus infusion using selective catheter (20ml)
88868591|NCT01124370|Experimental|Treatment|All enrolled subjects will undergo attempted system implantation and therapeutic assessment. Subjects' baseline assessment values will serve as control parameters for the therapy evaluation.
88868592|NCT05307042||2012-cohort|
88868593|NCT05306730|Experimental|FOCUS group|"Group of patients with chest pain undergoing FOCUS ( Focused Cardiac Ultrasound ).~Patients with odd registration number."
88868594|NCT05306730|Active Comparator|Non-FOCUS group|Patients with even registration number.
88868595|NCT05306184||ECT group|110 participants with primary diagnosis of moderate to severe major depressive disorder receiving ECT as treatment
88868596|NCT05306184||TCA group|110 participants with primary diagnosis of moderate to severe major depressive disorder receiving medication (TCA) as treatment
88868597|NCT05291442|No Intervention|control group|The control group received no intervention, except for the regular care followed by the nurses in general in the rehabilitation ward.
88868598|NCT05291442|Experimental|Intervention group|"To integrate Family System Care and Theme Care Action Module to improve resilience, family function, self-efficacy, and quality of life for stroke patients and their caregivers.~First, understand the care needs of patients and caregivers, and apply The Specific Thematic Nursing Care Action Modules (STNC-AM) platform for education and training.~The Specific Thematic Nursing Care Action Modules (STNC-AM) platform that we present here is an educational program that integrates education and coaching. STNC-AM has six key aspects: stroke prevention, management of emotions, management of fatigue, physical activity, caregiver training, and integrative resources. Each scope contains detailed care guidance."
88868599|NCT05289960|Other|patients eligible for weaning by spontaneous breathing trial|
88868600|NCT05289960|Other|non invasive ventilation after weaning|
88868601|NCT05288478|Active Comparator|Group A|First 6 weeks they will use the mouthrinse 5 times a day, following 4 week washout period.
88868602|NCT05288478|Active Comparator|Group A, second period|"After the washout period, the next 6 weeks the will use the mouthrinse twice a day.~On week 0, 1, 3 and 6 of each regime patients living in the metropolitan area will be examined by the Oral Medicine specialist."
88868603|NCT05288478|Active Comparator|Group B|First 6 weeks they will use the mouthrinse twice a day, following 4 week washout period
88868604|NCT05288478|Active Comparator|Group B, second period|"After the washout period, the next 6 weeks they will use the mouthrinse 5 times a day.~On week 0, 1, 3 and 6 of each regime patients living in the metropolitan area will be examined by the Oral Medicine specialist."
88868605|NCT05115942|Experimental|Hydronidone group|Patients were given three capsules of hydronidone three times a day for 52 weeks.
88868606|NCT05115942|Placebo Comparator|The placebo group|Patients were given three capsules of placebo three times a day for 52 weeks.
88868607|NCT04974138|Active Comparator|CC with amlodipine 5mg/d|For subjects with the MTHFR CC genotype, conducting amlodipine besylate tablets (5mg/d)
88868608|NCT04974138|Experimental|CC with amlodipine folic acid 5.8mg/d|For subjects with the MTHFR CC genotype, conducting amlodipine besilate and folic acid tablets (5mg:0.8mg)
88868609|NCT04974138|Active Comparator|CT with amlodipine 5mg/d|For subjects with the MTHFR CT genotype, conducting amlodipine besylate tablets (5mg/d)
88868610|NCT04974138|Experimental|CT with amlodipine folic acid 5.8mg/d|For subjects with the MTHFR CT genotype, conducting amlodipine besilate and folic acid tablets (5mg:0.8mg)
88868611|NCT04973982|Active Comparator|ENVARSUS|ENVARSUS used as per licence
88868612|NCT04973982|Active Comparator|ADOPORT|ADOPTION used as per licence
88868613|NCT04733664|Experimental|Cohort 1|Patients will receive one dose of visible fluorescent injectate (VFI)™ and one dose of iohexol approximately 4 hours prior to undergoing dialysis followed by a second dose of VFI and iohexol approximately 1 hour after completing dialysis.
88868614|NCT04503720|Experimental|CLoWI|"CLoWI (ropivacaine) and PCA (normal saline)~The local anaesthetic infusion will be administered via 2 catheters using a ON-Q® (Halyard) delivery system that will be placed under direct vision by the surgeon at the time of wound closure. 40 mls of 0.25% ropivacaine are infiltrated in the preperitoneal plane. 0.5% ropivacaine will be infused at a rate of 4mls/hour (2mls/hour in each catheter).~The dosage 40 mls of 0.25% ropivacaine and 0.5% ropivacaine at 4mls/hr (20mg/hr) over 4 days will be less than the recommended toxic dose of 3-4 mg/kg."
88868615|NCT04503720|Active Comparator|PCA|"PCA (Morphine) and CLoWI (normal saline)~Morphine will be administered via the standard PCA protocol in accordance to the hospital's Acute Pain Service Programme:~Concentration: 1mg/ml~Bolus (Loading): 1mg~Lockout Interval: 5 minutes~Maximum hourly dose of 10mg"
88868616|NCT04487964|Active Comparator|the conventional therapy according to the MOH protocol.|Patients who are receiving conventional therapy according to the MOH protocol.
89535394|NCT03322553|Experimental|Plication group|In patients allocated to endoscopic plication, endoscopic full-thickness plication will be performed using the GERDX® system. All procedures will be performed under general anesthesia. Savary-guidewire will be placed into the stomach using a gastroscope. The GERDX® system will be introduced over the guidewire into the stomach and retroflexed. The GE junction will be visualized using another slim endoscope passed through a channel present in the GERD-X device. According to study protocol, at least 2 pretied transmural pledgeted sutures will be deployed to achieve a tight closure of GE junction around the GERD-X device
88868617|NCT04487964|Active Comparator|conventional therapy +Liquorice cap and Boswellia Serrata gum|Patients will receive Liquorice cap and Boswellia Serrata gum in addition to conventional therapy
88868618|NCT04342182|Experimental|Convalescent plasma|Standard of care plus 300mL of convalescent plasma from COVID-19 recovered donors
88868619|NCT04342182|No Intervention|Standard of care|standard of care (supportive care, oxygen, antibiotics)
89187053|NCT00920270|Experimental|colistin group|nebulized colistin
88868620|NCT04142892|Experimental|Onapristone|50 mg given orally (PO), twice a day (BID), in a continuous schedule (QD). 3 weeks of (+/-3 days) of ONA treatment
88868621|NCT04125498|Active Comparator|OMT|Osteopathic manual treatment
88868622|NCT04125498|Active Comparator|OMT plus self-massage|Patients will be submitted to OMT and then they will be invited to practice a self-massage at home.
88868623|NCT04125498|Sham Comparator|Placebo|Similar to OMT without pressure.
89187054|NCT04080674||Parkinson's disease|30 participants
89187055|NCT04080674||Essential Tremor|10 participants
88868624|NCT04125498|Active Comparator|Placebo plus self-massage|Patients will be submitted to placebo manual treatment and then they will be invited to practice a self-massage at home.
88868625|NCT04017702||Pregnant women with gestational age between 32-40 weeks.|100 patients scheduled for cesarean section under neuraxial anesthesia with 150 mcg intrathecal or 3-mg epidural morphine.
88868626|NCT04017702||Patients post anesthesia care units (PACU) and surgical floor.|100 patients scheduled to receive General Anesthesia (GA) and planned to receive opioid intravenously (boluses/patient controlled analgesia (PCA).
88868627|NCT04017702||Patients in step down/ICU.|50 patients suffered from rib fracture and 50 patients after weaning from mechanical ventilation and extubation.The Expiron will provide continuous information about the respiratory status (tidal volume, respiratory rate and minute ventilation) of non-intubated patients specifically: sleeping or awake; with the use of incentive spirometry; the response to medications and other interventions (such as paravertebral/epidural block); the need for endotracheal re-intubation.
88868628|NCT03795168|Experimental|Transcranial vibrating system effect|"Participants will be enrolled for a 4 week period and will have 2 vestibular physical therapy (PT) visits per week. During the first 2 weeks (4 visits), 20 participants will perform their PT exercises (30 minutes or less if the participant is too dizzy to finish) wearing the transcranial vibration system (TCVS) and the other 20 participants without. The following 2 consecutive weeks (4 visits), participants will perform their PT exercises wearing the TCVS if they weren't previously, or won't wear the device during their PT exercises if they were previously.~Outcomes measured:~at every visit: dizziness at the end of PT exercise (with dizziness symptom scale DSS); duration of PT exercise~at the first and last visit: force plate system assessment (balance)"
88868629|NCT03795168|Sham Comparator|Vs transcranial vibrating system sham|"40 participants will be enrolled for a 4 week period and will have 2 vestibular physical therapy (PT) visits per week. Participants will perform their PT exercises (30 minutes or less if the participant is too dizzy to finish) wearing the transcranial vibration system (TCVS) at optimal vibrating frequency or wearing the TCVS at irrelevant vibrating frequency (sham). The TCVS and TCVS sham will be labeled A or B by the sponsor. The investigators and participants will not know which TCVS is optimal or sham. The sponsor will randomly assign participants TCVS A or B.~Outcomes measured:~at every visit: dizziness at the end of PT exercise (with dizziness symptom scale DSS); duration of PT exercise~at the first and last visit: force plate system assessment (balance)"
88868630|NCT03792360|Experimental|Single Arm|
88868631|NCT03749928|Experimental|OstiSense biosensor - active|Participants will wear the biofeedback tool for 1 week with biofeedback turned off. After checking, for 3 more weeks the biofeedback will stay turned off. At 4-week recall the biofeedback mechanism will be turned on. Subjects will be instructed how to use the vibration mechanism. Participants will wear the tool with biofeedback turned on during the night/sleep for 8 more weeks. They will be asked to return for a check after the first week with biosensor turned on (5-week recall). At the end of 8 weeks, participants will be invited for a final recall visit (12-week recall). At points a questionnaire will be provided, and feedback questions will be asked. All data about bruxism episodes will be collected from the smart device.
88868632|NCT03749928|Placebo Comparator|OstiSensor biosensor - not activated|Participants in the control group will be treated, asked for feedback and receive questionnaires identical to the subjects in the active treatment group. The only difference will be that the biofeedback mechanism in the biofeedback night guard tool will always stay turned off. At the 1-week recall a check for any comfort issues will occur and accurate data recording will be confirmed. After three weeks the participant will be checked on, feedback will be requested and any wear issues will be identified, and the data recording function will be checked (4-week recall). At the end of additional 8 weeks participants will be invited for a final recall visit (12-week recall). A questionnaire will be provided, and feedback questions will be asked, data from the smart device about bruxism episodes will be collected.
89392678|NCT03601884|Experimental|OHP and Treatment as usual (TAU)|"Optimal Health Program (OHP) A self-management program that promotes patients to be actively involved in their own healthcare and overall well-being through enhancing self-efficacy.~Treatment is delivered by a trained facilitator in OHP. The OHP is delivered in groups of 8 to 10 participants It consists of 5 weekly, 1.5 hour sessions and an additional booster session post-program at 3 months a The group facilitator will contact the participants by phone at 8 weeks and 16 weeks.~Treatment-as-usual TAU is the pharmacological treatment received or prescribed by the patients' attending doctor.~To ensure standardization of treatment, attending doctors will be reminded to manage patients in accordance with the Clinical practice Guideline in Managing Diabetes Melllitus in adult patients."
89392679|NCT03601884|Other|TAU Alone|"Treatment-as-usual TAU is the pharmacological treatment received or prescribed by the patients' attending doctor.~To ensure standardization of treatment, attending doctors will be reminded to manage patients in accordance with the Clinical practice Guideline in Managing Diabetes Melllitus in adult patients."
88868633|NCT03697356|Experimental|Rituximab&Bortezomib&Lenalidomide&Dexamethasone|Rituximab&Bortezomib&Lenalidomide&Dexamethasone
88868634|NCT03616782|Experimental|Ixazomib|Ixazomib 3mg on day a, 8, 15 q 4 weeks for 24 months or until to progression
88868635|NCT03336372|Experimental|Picato topical gel|
88868636|NCT03099798||Non-Operative Management (NOM)/Observational|"Patients treated observationally for (traumatic) spleen injury."
88868637|NCT03099798||Splenic Artery Embolization|Patients treated with splenic artery embolization for (traumatic) spleen injury.
88868638|NCT03099798||Surgery|Patients treated surgically for (traumatic) spleen injury.
88868639|NCT02410512|Experimental|Dose Escalation: MOXR0916 + Atezolizumab|Cohorts of at least 3 participants each will be treated at escalating doses of MOXR0916 in combination with a fixed dose of atezolizumab to determine the MTD or maximum administered dose (MAD).
89535395|NCT03322553|Sham Comparator|Sham Group|In sham procedure, identical technique will be followed by positioning the plicator inside the stomach but sutures will not be applied.
89003669|NCT04844840|Experimental|Cohort 1: STP705 10 μg dose|STP705 at the assigned dose will be injected intradermal into the excised keloid site
89187056|NCT04080674||Dystonia|20 participants
89392680|NCT03550664|Experimental|Surgical intervention|Patients undergoing a surgical intervention within the CHU Brugmann with utilisation of rocuronium.
89392681|NCT04042077|Experimental|Delafloxacin|Delafloxacin IV, with the option to switch to delafloxacin oral
88868640|NCT02410512|Experimental|Expansion: MOXR0916 + Atezolizumab|Approximately 250-580 participants will be enrolled in the expansion stage to better characterize the safety, tolerability, pharmacokinetic variability, biomarkers of anti-tumor activity, and preliminary efficacy of MOXR0916 + atezolizumab in different cancer types.
88868641|NCT02364492|Experimental|MAG-Tn3 + AS15|"3 escalating doses of MAG-Tn3 in combination with a fixed dose of AS15 adjuvant.~For each dose patient will receive 6 injections at 3 interval weeks."
88868642|NCT00849888|Experimental|Atypical Complete DiGeorge|Thymus Transplantation with Immunosuppression
88868643|NCT00849888|Experimental|Typical Complete DiGeorge|Thymus Transplantation without Immunosuppression
88868644|NCT01125774|Experimental|Telcagepant|Telcagepant 140 mg was administered once daily at bedtime for 7 consecutive days each month, beginning at the onset of menses, for up to 6 months. Dosing could begin up to 3 days prior to menses onset if prodromal symptoms reliably predicted onset of menses.
88868645|NCT01125774|Placebo Comparator|Placebo|Placebo was administered once daily at bedtime for 7 consecutive days each month, beginning at the onset of menses, for up to 6 months. Dosing could begin up to 3 days prior to menses onset if prodromal symptoms reliably predicted onset of menses.
88868646|NCT01128192|Experimental|Pasireotide 600 µg sc bid|n=19. Pasireotide 600 µg sc bid
88868647|NCT01128192|Experimental|Pasireotide 900 µg sc bid|n=19. Pasireotide 900 µg sc bid
88868648|NCT01128192|Experimental|Pasireotide 1200 µg sc bid|n=7. Due to increased severity of gastro-intestinal side effects, this arm was discontinued. These participants were only included in the safety analysis.
88868649|NCT01128270|Experimental|1A: Chloral Hydrate and DCA: Env|Subjects consume Chloral Hydrate 1.5ug/kg by mouth for 5 nights. On the 6th day they consume DCA 2.5ug/kg by mouth and have blood samples drawn. (Period 1)
88868650|NCT01128270|Experimental|1B: Chloral Hydrate Env dose|Drug Study Subjects are admitted to the clinical research unit and receive 1.5 ug/kg (environmental dose) of Chloral Hydrate for 5 nights. Pharmacokinetics are done on days 1 and day 5. (Period 2)
88868651|NCT01128270|Experimental|2A: Chloral Hydrate and DCA therapeutic|Drug Study Subjects are admitted to the clinical research center and receive a clinical dose of Chloral Hydrate for 5 nights (25mg/kg). On day 6 they are given a clinical dose (25mg/kg)of Dichloroacetate. (Period 3)
88868652|NCT01128270|Experimental|2B: Chloral Hydrate Therapeutic|Subjects are given 25 mg/kg of Chloral Hydrate for five nights. Pharmacokinetics are done on days 1 and 5. (Period 4)
88868653|NCT01128426||1|
88868654|NCT01128972|Experimental|Test Dentifrice + Test Mouth Rinse (MR)|Test fluoride dentifrice and test fluoride MR
89187057|NCT04078724|Active Comparator|Normal subject without 5-HTP|Subjects with normal cognition will be randomly assigned to not consuming 5-HTP.
89187058|NCT04078724|Experimental|Normal subject with 5-HTP|Subjects with normal cognition will be randomly assigned to consuming 100 mg of 5-HTP.
89535396|NCT05019573|Experimental|Black tea group|Volunteers meeting inclusion/exclusion criteria will be given an appropriate number of black tea samples twice a day with main meals for the 4 weeks of the treatment.
88868655|NCT01128972|Experimental|Test Dentifrice + Sterile Water Rinse|Test fluoride dentifrice and sterile water rinse
88868656|NCT01128972|Experimental|Placebo Dentifrice + Test MR|Placebo dentifrice and test fluoride rinse
88868657|NCT01128972|Active Comparator|Reference Dentifrice + Sterile Water Rinse|Marketed fluoride dentifrice with sterile water rinse
88868658|NCT01128972|Placebo Comparator|Placebo Dentifrice + Sterile Water Rinse|Placebo dentifrice and sterile water rinse
88868659|NCT01129206|Experimental|Arm I|Patients receive pralatrexate IV over 3-5 minutes and docetaxel IV on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
88868660|NCT01129440|Active Comparator|Fluoride Varnish|Topical fluoride varnish (FV) applications every 6 months
88868661|NCT01129440|Experimental|FV + Glass Ionomer Sealants|Topical fluoride varnish (FV) applications every 6 months, and fluoride-releasing glass ionomer sealants (GIS) placed on primary molars at baseline and annually, as needed
88868662|NCT01130844|Experimental|MMX Mesalamine (30mg/kg)|
88868663|NCT01130844|Experimental|MMX Mesalamine (60 mg/kg)|
88868664|NCT01130844|Experimental|MMX Mesalamine (100 mg/kg)|
88868665|NCT01134198|Active Comparator|Mifepristone|Mifepristone 600mg
88868666|NCT01134198|Placebo Comparator|placebo|Placebo
88868667|NCT01134276|Active Comparator|PTBD|biliary drainage : PTBD procedure for obstructive jaundice in patients with periampullary cancer
88868668|NCT01134276|Active Comparator|ERBD|biliary drainage : ERBD/ENBD procedure for obstructive jaundice in patients with periampullary cancer
88868669|NCT01134900|Experimental|Dashboard|Patients appear on dashboard and are eligible for pharmacy intervention in addition to existing clinical decision support interventions.
88868670|NCT01134900|No Intervention|Control|Patients do not appear on dashboard for pharmacy intervention, but only receive existing clinical decision support interventions.
88868671|NCT01135368|Experimental|Lansoprazole|"Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks.~Depending on response, dosage could then be decreased to 15 mg, once daily, or increased to 30 mg, twice daily for up to 4 years and 10 months."
88868672|NCT01136226|Other|Eligard (TM)|Eligard (TM) administered 22.5mg
88868673|NCT01137006|Experimental|IMC-20D7S (1A-4A Cohorts)|Escalating doses up to 30 milligrams per kilogram (mg/kg) administered intravenously (i.v.) every 2 weeks; includes Cohorts 1A, 2A, 3A, and 4A.
88868674|NCT01137006|Experimental|IMC-20D7S (1B-3B Cohorts)|Escalating doses up to 30 mg/kg administered i.v. every 3 weeks; includes Cohorts 1B, 2B, and 3B.
88868675|NCT01137396|Experimental|Modafinil|
88868676|NCT01137396|Placebo Comparator|Placebo|
89003670|NCT04844840|Experimental|Cohort 2: STP705 20 μg dose|STP705 at the assigned dose will be injected intradermal into the excised keloid site
89187059|NCT02583386|Active Comparator|Free From Falls training group|Subjects randomized to this group will receive an 8 week exercise and educational program on fall prevention (Free From Falls fall prevention program). They will have mobility and quality of life assessments taken at baseline, after the training program has been completed, and 3 and 6 months later. During this time, their falls will be recorded monthly using prospective falls calendars.
89392682|NCT04042077|Active Comparator|Best Available Therapy|"Cardiothoracic / related leg SSI~Vancomycin IV~Linezolid IV, with the option to switch to linezolid oral.~In case of suspicion of Gram-negative, additional therapy shall be added as per investigator's choice~Abdominal SSI~Piperacillin/Tazobactam IV, OR~Tigecycline IV~In case of suspicion of MRSA, if the pre-selected treatment is Piperacillin/Tazobactam, additional therapy shall be added as per investigator's choice."
89392683|NCT03557359|Experimental|Nivolumab|Nivolumab 240 mg will be given every 2 weeks for 8 cycles. Beginning with Cycle 9, nivolumab 480 mg will be given every 4 weeks for a total therapy duration of 2 years, or until progressive disease, unacceptable toxicity, or withdrawal of consent. Nivolumab will be administered as a 30-minute infusion. A finite treatment duration with immune therapies in this participant population remains an area of ongoing research; therefore the treatment duration chosen was 2 years.
89392684|NCT03550586||Parturients suffering from a PDPH|Parturients suffering form a PDPH following an accidental dural puncture between the years 2007-2017 will be contacted by phone and verbal consent will be obtained for participation in the study. All participants will be requested to answer an IRB approved telephone script. Parturients will be assed for postpartum depression using the Edinburgh Postnatal Depression Scale (EPDS) translated into Hebrew . They will also be assed for PTSD using the validated PTSD questionnaire.Additionally in order to examine long term risk for chronic pain and backache parturients will be assed for persistent pain using the validated Brief Pain Inventory questionnaire ,and the validated Oswestry low back pain questionnaire
88868677|NCT01138098|Experimental|Infanrix-hexa/Engerix-B Group|Subjects aged 11-12 year old received 3 doses of Infanrix-hexa vaccine in the primary study (217744/031 (NCT01457495)) and a challenge dose of Engerix-B vaccine in this study. Engerix-B was administered as a single dose intramuscularly into the deltoid region of the non-dominant arm.
89392685|NCT03550586||Parturients not suffering from a PDPH|This group will consistent of a control group of women receiving epidural analgesia on the same day as those women who suffered an ADP. This participants will be contacted by phone and verbal consent will be obtained for participation in the study. All participants will be requested to answer an IRB approved telephone script. Parturients will be assed for postpartum depression using the Edinburgh Postnatal Depression Scale (EPDS) translated into Hebrew . They will also be assed for PTSD using the validated PTSD questionnaire.Additionally in order to examine long term risk for chronic pain and backache parturients will be assed for persistent pain using the validated Brief Pain Inventory questionnaire ,and the validated Oswestry low back pain questionnaire
89392686|NCT02035176||Autistic children ages 6-11|Autistic children ages 6-11
89392687|NCT02035176||ADHD children ages 6-11|ADHD children ages 6-11
89392688|NCT02035176||Typical children ages 6-11|Typical children ages 6-11
89392689|NCT03626025|No Intervention|Mass Learning Group|Participants underwent an eight-hour microsurgery training course in a single session under the mass-learning format.
89392690|NCT03626025|Other|Spaced Learning Group|Participants underwent two-hour microsurgery training sessions every week for a total of 4 sessions under the spaced learning format.
89392691|NCT02127320|Experimental|Sequence 1|Rosuvastatin 20mg → Ezetimibe 10mg → Rosuvastatin 20mg and Ezetimibe 10mg
89392692|NCT02127320|Experimental|Sequence 2|Rosuvastatin 20mg and Ezetimibe 10mg→ Rosuvastatin 20mg → Ezetimibe 10mg
89392693|NCT02127320|Experimental|Sequence 3|Ezetimibe 10mg → Rosuvastatin 20mg and Ezetimibe 10mg → Rosuvastatin 20mg
89392694|NCT02127320|Experimental|Sequence 4|Rosuvastatin 20mg and Ezetimibe 10mg → Ezetimibe 10mg → Rosuvastatin 20mg
89392695|NCT02127320|Experimental|Sequence 5|Ezetimibe 10mg → Rosuvastatin 20mg → Rosuvastatin 20mg and Ezetimibe 10mg
89392696|NCT02127320|Experimental|Sequence 6|Rosuvastatin 20mg → Rosuvastatin 20mg and Ezetimibe 10mg → Ezetimibe 10mg
89392697|NCT03604380|Experimental|Experimental Treatment|Computerized plasticity-based adaptive cognitive training requiring a total maximum of 36 treatment sessions, up to 7 sessions per week, 36 minutes per session.
89392698|NCT03604380|Active Comparator|Active Comparator|Commercially available computerized training requiring a total maximum of 36 treatment sessions, up to 7 sessions per week, 36 minutes per session.
89392699|NCT02125916|Experimental|COLD without long term oxygen therapy|Driving in the simulator two times, one time with and one time without oxygen therapy
89392700|NCT02125916|Experimental|COLD with long term oxygen therapy|Driving in the simulator two times, one time with and one time without oxygen therapy
89392701|NCT02125916|Experimental|ILD without long term oxygen therapy|Driving in the simulator two times, one time with and one time without oxygen therapy
89392702|NCT02125916|No Intervention|Controls|Driving in the simulator one time without oxygen therapy
89392703|NCT03522415|Experimental|HLX01+MTX|
89392704|NCT03522415|Placebo Comparator|Placebo+MTX|
89392705|NCT02125994|Active Comparator|Ropivacaine 0.5%|Ultrasound guided Intercalene nerve block with ropivacaine 0.5 %
89392706|NCT02125994|Active Comparator|Ropivacaine 0.375 %|Ultrasound guided Intercalene nerve block with ropivacaine 0.375 %
89392707|NCT04226833|Experimental|Mild|Participants with mild hepatic impairment will receive 1x100 milligram (mg) F06 (entrectinib) capsule administered orally with approximately 240 milliliter (mL) water within 30 minutes after consumption of a standardized meal.
89392708|NCT04226833|Experimental|Moderate|Participants with moderate hepatic impairment will receive 1x100 mg F06 (entrectinib) capsule administered orally with approximately 240 mL water within 30 minutes after consumption of a standardized meal.
89392709|NCT04226833|Experimental|Severe|Participants with severe hepatic impairment will receive 1x100 mg F06 (entrectinib) capsule administered orally with approximately 240 mL water within 30 minutes after consumption of a standardized meal.
89535397|NCT05019573|Placebo Comparator|Placebo group|Volunteers meeting inclusion/exclusion criteria will be given an appropriate number of placebo tea samples twice a day with main meals for the 4 weeks of the treatment.
89535398|NCT03322475|Experimental|Facial skin rejuvenation|Facial skin rejuvenation using PiQo4 laser system
88868678|NCT01138098|Active Comparator|Infanrix-IPV+Hib/Engerix-B Group|Subjects aged 11-12 year old received 3 doses of Infanrix-IPV+Hib and Engerix-B vaccines in the primary study (217744/031 (NCT01457495)) and a challenge dose of Engerix-B vaccine in this study. Engerix-B was administered as a single dose intramuscularly into the deltoid region of the non-dominant arm.
88868679|NCT01139190|Experimental|PL3100|
88868680|NCT01139190|Active Comparator|Naproxen|
88868681|NCT01139814|Experimental|Catheter Robot|device
88868682|NCT01140360|Experimental|Gleevec|Gleevec will be dosed orally with a starting dose of 100 mg twice daily for patients with a BSA > 1.8 m2 or 55 mg/m2 twice daily for patients with BSA < 1.8 m2. For patients with a BSA > 1.8 m2 the dose will increase by increments of 100 mg bid every two weeks as tolerated up to a maximum dose of 400 mg bid. For patients with a BSA < 1.8 m2 the dose will increase by increments of 55 mg/m2 bid every two weeks as tolerated up to a maximum dose of 220 mg/m2 bid.Treatment will continue for 6 months with an option to continue for 24 months if the patient is deriving a clinical benefit.
88868683|NCT01141374|No Intervention|control group without treatment|Control Group didn't receive any treatment and was evaluated at the same time and the same way of interventions group
88868684|NCT01141374|Experimental|Auriculotherapy by needles|The investigators used 3 points, Shenmen, Kidney, and Brain Stem with semi-permanent needles of 1.8 mm, 1 time per week for 8 sessions.
88868685|NCT01141374|Experimental|Auriculotherapy by seeds|The investigators used the three points Shenmen, Kidney, and Brain Stem with mustard seeds, 1 time per week for 8 sessions.
88868686|NCT01141608|Experimental|Vigorous Intensity High Dose Exercise|Usual Care Augmented with Vigorous Intensity High Dose Exercise
88868687|NCT01141608|Experimental|Health Education Intervention|Health Education Intervention
88868688|NCT01142310|Active Comparator|Lamotrigine|Dose titration: begin at Baseline at 25mg PO QD for two weeks. Increase to 50mg PO QD at Week 2 for two weeks. Increase to 100mg PO QD at Week 4. Increase to 150mg PO QD at Week 5. Increase to 200mg PO QD at Week 6. Increase to 250mg PO QD at Week 7. Increase to 300mg PO QD at Week 8. Increase to 350mg PO QD at Week 9. Increase to 400mg PO QD at Week 10. Stay at 400mg PO QD from Week 10 to Week 48.
88868689|NCT01142310|Placebo Comparator|Placebo|Placebo administered the same as the Lamotrigine just described.
88868690|NCT01143636|Sham Comparator|Active tDCS - pelvic pain patients|ACTIVE tDCS: Subjects will receive a total of 10 consecutive sessions of active tDCS over a two-week period (administered Monday - Friday). During each session, the anode electrode will be placed over the primary motor cortex of the predominantly painful side.
88868691|NCT01143636|Experimental|Sham tDCS - pelvic pain patients|SHAM tDCS: Subjects will receive a total of 10 consecutive sessions of sham tDCS over a two-week period (administered Mon-Fri). During each session, the anode will be placed over the primary motor cortex of the predominantly painful side.
88868692|NCT01143636|Experimental|Active tDCS - healthy|The healthy controls will undergo one day of treatment with active tDCS. All participants will receive both active and sham stimulation in a randomized order.
88868693|NCT01143636|Experimental|Sham tDCS - healthy|The healthy controls will undergo one day of treatment with sham tDCS. All participants will receive both active and sham stimulation in a randomized order.
88868694|NCT01143792|Experimental|CRA + HIV prevention|
88868695|NCT01143792|Active Comparator|Case Management + HIV prevention|
88868696|NCT01143792|Active Comparator|MET + HIV prevention|
88868697|NCT01143870|Other|Hemoglobin A1C|Diabetes control related to patients using standard hemoglobin A1C
88868698|NCT01143870|Experimental|Face|Face expressing emotion used to depict diabetes control
88868699|NCT01143870|Experimental|Letter grade|Letter grade used to express diabetes control
88868700|NCT01144026|Experimental|TUTI-16 (0.2mg)|Two subcutaneous injections of 0.2 mg at Day 0, and Week 5.
88868701|NCT01144026|Experimental|TUTI-16 (1.0 mg)|Two subcutaneous injections of 1.0 mg at Day 0, and Week 5.
88868702|NCT01144338|Experimental|Exenatide Once Weekly|
88868703|NCT01144338|Placebo Comparator|Placebo|
88868704|NCT01146600|Experimental|Random Group A|Subjects will be randomized to group A or group B. The order of presentation of placebo and clarithromycin will be opposite in these two groups, but investigators and subjects will remain blinded to group allocation and order of treatment presentation within the groups.
88868705|NCT01146600|Experimental|Random Group B|Subjects will be randomized to group A or group B. The order of presentation of placebo and clarithromycin will be opposite in these two groups, but investigators and subjects will remain blinded to group allocation and order of treatment presentation within the groups.
88868706|NCT01146834|Experimental|Arm A: VELCADE, CYCLOPHOSPHAMIDE, & G-CSF|VELCADE at 1.3 mg/m2 IVP on days 1, 4, 8 and 11 in combination with high-dose cyclophosphamide at 2.0 g/m2 on day 4. G-CSF is given for ten (+/- two) consecutive days starting on day 9 at a dose of 10 micrograms/kg/day. Pheresis will commence once ANC of 1.5 is reached.
88868707|NCT01146834|Experimental|Arm B: VELCADE & G-CSF|VELCADE at 1.3 mg/m2 IVP on days 1, 4, 8 and 11. G-CSF is given for ten (+/- two) consecutive days starting on day 9 at a dose of 10 micrograms/kg/day. Day 12 start pheresis collection
89187060|NCT02583386|No Intervention|Wait-list control group|Subjects in this group will participate in the same mobility and quality of life assessments and completion of the falls calendars, but will receive no training classes during this time. These subjects will have the opportunity to receive the class sessions when all assessment visits have been completed.
89392710|NCT04226833|Experimental|Normal|Participants with normal hepatic function will receive 1x100 mg F06 (entrectinib) capsule administered orally with approximately 240 mL water within 30 minutes after consumption of a standardized meal.
89392711|NCT02131298|Other|Fixed sequence|Fixed sequence study with treatment A of palbociclib alone, followed by treatment B (palbociclib with itraconazole)
89392712|NCT01375387|Experimental|Lacosamide 100 mg, Japanese|1 Lacosamide 100 mg tablet plus 3 placebo tablets
88868708|NCT01146834|Experimental|Arm C: CYCLOPHOSPHAMIDE & G-CSF|High-dose cyclophosphamide at 2.0 g/m2 on day 1. G-CSF is given for ten (+/- two) consecutive days starting on day 2 at a dose of 10 micrograms/kg/day. Pheresis will commence once ANC of 1.5 is reached.
88868709|NCT01146834|Experimental|Arm D: PLERIXAFOR & G-CSF|G-CSF is given for ten (+/- two) consecutive days starting on day 1 at a dose of 10 micrograms/kg/day. Plerixafor is given on day 4, approximately 11 hours prior to stem cell collection attempt on Day 5. Both G-CSF and plerixafor are continued daily until collection is complete. Pheresis will commence for everyone on Day 5 regardless of ANC status.
89003671|NCT04844840|Experimental|Cohort 3: STP705 30 μg dose|STP705 at the assigned dose will be injected intradermal into the excised keloid site
89392713|NCT01375387|Experimental|Lacosamide 100 mg, Chinese|1 Lacosamide 100 mg tablet plus 3 placebo tablets
89535399|NCT03322397|Experimental|Kindness to Others|Participants will complete the 'Other-Focused Acts of Kindness Intervention' by performing acts of kindness for others. They be asked to complete 3 kind acts for others throughout the week for 4 weeks. They will receive text messages three days per week (either Tuesday, Thursday, and Saturday or Wednesday, Friday, and Sunday) and will report on their kind act later that day.
88868710|NCT01146834|Experimental|Arm E: PLERIXAFOR, VELCADE, & G-CSF|"Bortezomib at 1.3 mg/m2 IVP on days 1, 4, 8 and 11. G-CSF is given for ten (+/- wo) consecutive days starting on day 9 at a dose of 10 micrograms/kg/day.~Plerixafor is given on day 12, approximately 11 hours prior to stem cell collection attempt and is continued daily until collection is complete. Pheresis will commence for everyone on Day 13 regardless of ANC status."
88868711|NCT01147302|Experimental|C1 Esterase Inhibitor (Human)|Subjects were to receive C1 esterase inhibitor intravenously at a rate of approximately 1 mL per minute as tolerated. Subjects were to receive a total of 7 doses over a 2-week period: an initial IV infusion of 5000 U (not to exceed 100 U/kg) on Day 1, followed by 2500 U (not to exceed 50 U/kg) IV on Days 3, 5, 7, 9, 11, and 13
88868712|NCT01147302|Placebo Comparator|Normal Saline|placebo infused as above
88868713|NCT01147380|Experimental|Small dose|From the donor liver perfusate, mononuclear cell will be extracted and cultured. Then, the cells will be stimulated with IL-2. The number of inoculation cells( mainly NK cells) is between 10 and 100 million cells. The cells will be given to the liver transplant recipient who had the same donor for liver and liver perfusate. Patient of this arm receive small dose of liver NK cell inoculation as described.
88868714|NCT01147380|Experimental|Large dose|From the donor liver perfusate, mononuclear cell will be extracted and cultured. Then, the cells will be stimulated with IL-2. The number of inoculation cells(mainly NK cells) is between 100 and 1000 million cells. The cells will be given to the liver transplant recipient who had the same donor for liver and liver perfusate.Patient of this arm receive large dose of liver NK cell inoculation as described.
88868715|NCT01148940||White women with Hb AA|White pregnant and postpartum women with Hb AA
88868716|NCT01148940||Black women with Hb AA|Black pregnant and postpartum women with HbAA
88868717|NCT01148940||Black women with Sickle Trait|Black pregnant and postpartum women with HbAS
89187061|NCT02583386|Active Comparator|FFF training group w/ Fall Detector|"Subjects randomized to this group will receive an 8 week exercise and educational program on fall prevention (Free From Falls fall prevention program). They will have mobility and quality of life assessments taken at baseline, after the training program has been completed, and 3 and 6 months later. During this time, their falls will be recorded monthly using prospective falls calendars.~In addition, this group will be asked to wear electronic fall detectors on their bodies for the first 10 weeks of their participation in the study."
89187062|NCT02583386|Other|Wait-list control w/ Fall Detector|"Subjects in this group will participate in the same mobility and quality of life assessments and completion of the falls calendars, but will receive no training classes during this time. These subjects will have the opportunity to receive the class sessions when all assessment visits have been completed.~In addition, this group will be asked to wear electronic fall detectors on their bodies for the first 10 weeks of their participation in the study."
89187063|NCT02585882|Experimental|Communal preschool feeding with fluoridated salt|"According to the allocation concealment, subjects of the test group were preschool children at the Kindergarten Wattenscheid in Gambia, Brikama-Kabafita, West Coast Region, The Gambia."
88868718|NCT01149876|Experimental|Nu Skin Product|
88868719|NCT01149876|Experimental|Nu Skin product with galvanic spa system|
88868720|NCT01149876|Active Comparator|Tretinoin cream 0.05|
88868721|NCT01149876|Placebo Comparator|over the counter moisturizer|
88868722|NCT01150500|Experimental|Drug Eluting Stent|Up to two lesions in two separate target vessels may be treated under this protocol. The lesions should be amenable to treatment with at least one 2.25 mm stent, a second lesion could be treated with any stent from 2.25 to 3.5 mm.
88868723|NCT01151046|Experimental|MM-121 (SAR256212) + exemestane|
88868724|NCT01151046|Placebo Comparator|Placebo + exemestane|
88868725|NCT01151436|Experimental|hyaluronic acid|
88868726|NCT01152294|No Intervention|Control|Group not receiving the decision aid (DVD and booklet)
88868727|NCT01152294|Experimental|Decision Aid|Group receiving the decision aid (DVD/booklet)
88868728|NCT01153620|Placebo Comparator|Ringer's Solution|
88868729|NCT01153620|Active Comparator|Lavasept 0.04%|
88868730|NCT01154322|Experimental|Pediatric mask|
88868731|NCT01154634|Experimental|First 5 mg, then placebo, then 16 mg, then 40 mg|period 1: AZD2516 5 mg, period 2: washout, period 3: placebo, period 4: washout, period 5: AZD2516 16 mg, period 6: washout, period 7: AZD2516 40 mg.
88868732|NCT01154634|Experimental|First 40 mg, then 16 mg, then placebo, then 5 mg|period 1: AZD2516 40 mg, period 2: washout, period 3: AZD2516 16 mg, period 4: washout, period 5: placebo, period 6: washout, period 7: AZD2516 5 mg.
88868733|NCT01154634|Experimental|First 16 mg, then 5 mg, then 40 mg, then placebo|period 1: AZD2516 16 mg, period 2: washout, period 3: AZD2516 5 mg, period 4: washout, period 5: AZD2516 40 mg, period 6: washout, period 7: placebo.
88868734|NCT01154634|Experimental|First placebo, then 40 mg, then 5 mg, then 16 mg|period 1: placebo, period 2: washout, period 3: AZD2516 40 mg, period 4: washout, period 5: AZD2516 5 mg, period 6: washout, period 7: AZD2516 16 mg
88868735|NCT01155180|Experimental|Leptin|We will start the leptin at a dose of 0.08mg/kg fat mass in men and 0.14mg/kg fat mass in women
89187064|NCT02585882|No Intervention|Communal preschool feeding with no fluoridated salt|"Subjects of the control group were preschool children at the Kindergarten Bottrop in Gambia, Brikama, West Coast Region, The Gambia."
89187065|NCT04080596|Experimental|Sequential arm|Dorzagliatin administered alone on Day 1; after wash-out, intraconazole was administered from Day 8 to Day 15, with Dorzagliatin administered together on Day 11.
89187066|NCT00920738||Cancer Survivors|Subjects who are cancer survivors must have survived childhood cancer (diagnosed < or = 18 years) for a minimum of 5 years and be in remission.
88868736|NCT01155180|Placebo Comparator|Placebo|We will start the placebo at a dose of 0.08mg/kg fat mass in men and 0.14mg/kg fat mass in women
89003672|NCT04844840|Experimental|Cohort 4: STP705 40 μg dose|STP705 at the assigned dose will be injected intradermal into the excised keloid site
88868737|NCT01155336|Experimental|Lovaza®|Lovaza® is a prescription grade EPA+DHA fish oil supplement. Four capsules (each containing 1 gram of fish oil) were taken within hours after the PCI, daily for the duration of hospitalization, and daily for 1 week until a post-discharge follow-up appointment.
88868738|NCT01155336|Placebo Comparator|Corn Oil|The placebo contained 1 gram of corn oil in each capsule. Four capsules were taken within hours after the PCI, daily for the duration of hospitalization, and daily for 1 week until a post-discharge follow-up appointment.
88868739|NCT01161420|Experimental|Inspire Therapy|Inspire Upper Airway Stimulation System, is a permanent, implantable therapy device, which consists of three implantable components: IPG, stimulation lead, and a sensing lead. In additional the patient receives a remote to activate the therapy.
88868740|NCT01163214|Experimental|Nerve Block|Preoperative femoral block with indwelling femoral catheter and a single shot sciatic block.
88868741|NCT01163214|Active Comparator|Periarticular Injection|Injection combination prior to skin closure.
88868742|NCT01163604|Experimental|Argatroban group|Patients who underwent intracranial and extracranial artery stenting were randomly chosen to receive continuous infusions of argatroban for 2 days before and 3 days after stenting, with accompanied aspirin and clopidogrel treatment.
88868743|NCT01163604|Experimental|non-argatroban treated group|Patients who underwent intracranial and extracranial artery stenting were randomly chosen to receive only aspirin and clopidogrel treatment.
88868744|NCT01163760|Other|etafilcon A / ocufilcon D|etafilcon A contact lens worn first daily disposable , ocufilcon D contact lens worn second daily disposable
88868745|NCT01163760|Other|oculfilcon D / etafilcon A|ocufilcon D contact lens worn first, etafilcon A contact lens worn second
88868746|NCT01163760|Other|ocufilcon D / ocufilcon D|ocufilcon D contact lens worn first and second
88868747|NCT01163760|Other|etafilcon A / etafilcon A|etafilcon A contact lens worn first and second
88868748|NCT01167504||Saliva Sample Collection|Saliva collection
88868749|NCT01168674|Placebo Comparator|Sugar pill|Patients are randomized to a sugar pill (placebo), added to their current medications.
88868750|NCT01168674|Active Comparator|Ziprasidone|Patients are randomized to ziprasidone, added to their current medications.
88868751|NCT01168908|Experimental|Revatio (sildenafil)|This arm will receive Revatio (sildenafil) for 12 months. During the first 6 months, the subject and investigator will be blinded to treatment. The second 6 months, will be open label treatment with Revatio.
88868752|NCT01168908|Other|Placebo|This arm will receive placebo (sugar pill) for 6 months and Revatio (sildenafil) for 6 months. During the first 6 months, the subject and investigator will be blinded to treatment. The second 6 months, will be open label treatment with Revatio.
88868753|NCT01168986|Active Comparator|Pulstar Multiple Impulse Therapy|Use of the PulStar Multiple Impulse Therapy (Sense Technology). A mechanical manual therapy device.
88868754|NCT01168986|Active Comparator|Exercise|Participants perform an exercise to strengthen the deep neck flexors
88868755|NCT01168986|No Intervention|No intervention|Participants receive/perform no intervention
88868756|NCT01169064|Active Comparator|Silver-containing surgical dressing|Self adhesive 4 x 10 dressing impregnated with nanocrystalline silver
88868757|NCT01169064|Active Comparator|Cloth adhesive dressing|Soft cloth adhesive wound dressing
88868758|NCT01170390|Other|All participants|A low dose oral contraceptive given cyclically (21 days of active pills/cycle with a 7 day hormonal-free interval) for 2 cycles (56 days).
89187067|NCT00920738||Healthy Siblings of Cancer Survivor|Healthy populations similar in age and gender distribution, derived from a frequency matched control population of 350 healthy siblings.
89187068|NCT02585648|Experimental|Patients with dry eye syndrome 1|20 patients with dry eye syndrome, they will receive intervention 1 for one week and then cross over to intervention 2
88868759|NCT01170390|Active Comparator|Aviane and Portia|A low dose oral contraceptive given cyclically (30mcg EE component, 21 days of active pills/cycle with a 7 day hormonal-free interval) for two cycles
88868760|NCT01170390|Active Comparator|Aviane & Aviane|A very-low dose oral contraceptive given continuously for 56 days (20mcg EE component, 28 days of active pills/cycle with no hormone free interval)
88868761|NCT01170546|Experimental|KLCIR|plate-loaded kneeling leg curl with internal rotation
88868762|NCT01170546|Experimental|SP (Squat Press)|plate-loaded squat press
88868763|NCT01170546|Experimental|KLC (Kneeling Leg Curl)|plate-loaded kneeling leg curl
88868764|NCT01134510|Experimental|C1 esterase inhibitor|10 subjects will receive C1 esterase inhibitor in addition to standard of care immunosuppressive therapy.
88868765|NCT01134510|Placebo Comparator|Placebo|10 subjects placebo [normal saline] in addition to standard of care immunosuppressive therapy.
88868766|NCT01171794|Active Comparator|ibuprofen|600mg ibu TID
88868767|NCT01171794|Placebo Comparator|placebo|visually identical
88868768|NCT01172184||Severe mitral regurgitation|Patients with severe mitral regurgitation are admitted for pre-operation cardiac catheterization and are willing to participate in this study.
88868769|NCT01175148|Experimental|Recipient - Atorvastatin to prevent GVHD|Atorvastatin calcium (Lipitor) will be administered at dose of 40mg orally daily starting on day -14, to permit an approximately 1-week observation period to rule out any acute atorvastatin-induced side effects before the initiation of transplant conditioning. Patients will receive atorvastatin until +180 days or development of grade 2 GVHD. This is the experimental arm for outcome measures.
88868770|NCT01175148|Other|Donor - Atorvastatin conditioning for donors|Sibling donors will start taking Atorvastatin calcium (Lipitor) orally at 40mg once daily between 14-28 days before the anticipated first day of apheresis or bone marrow harvest.
88868771|NCT01175226|Experimental|BTA798|
88868772|NCT01175226|Placebo Comparator|Placebo|
88868773|NCT01175850|Experimental|Drug-Coated Balloon (DCB)|IN.PACT Admiral: Balloon Angioplasty
88868774|NCT01175850|Active Comparator|Standard PTA|Standard Percutaneous Transluminal Angioplasty (PTA) Balloon: Balloon Angioplasty
89187069|NCT02585648|Experimental|Patients with dry eye syndrome 2|20 patients with dry eye syndrome, they will receive intervention 2 for one week and then cross over to intervention 1
88868775|NCT01177098|Experimental|bimatoprost/timolol formulation A|One drop of bimatoprost/timolol formulation A fixed combination ophthalmic solution administered in each eye every morning for 12 weeks.
88868776|NCT01177098|Active Comparator|bimatoprost/timolol fixed combination ophthalmic solution|One drop of bimatoprost 0.03%/timolol 0.5% fixed combination ophthalmic solution (Ganfort®) administered in each eye every morning for 12 weeks.
88868777|NCT01177956|Experimental|Cetuximab + Cisplatin + 5-Fluorouracil (5-FU)|
88868778|NCT01178268|Active Comparator|XIENCE V EECSS|Patients who will receive this stent.
88868779|NCT01178268|Active Comparator|CYPHER SELECT PLUS SECSS|Patients who will receive this stent.
88868780|NCT01179984|Experimental|PTA and study stent|Bard® LifeStent® Vascular Stent System
88868781|NCT01181076|Experimental|Individualized Nutrition|
88868782|NCT01181076|No Intervention|Control group|The patients in the control group will be nourished after established routine, first by the oral route, later by the PN route. Naso-jejunal tube will not be inserted and enteral nutrition will not be given.
88868783|NCT01183650|Experimental|Tadalafil|5 mg, administered orally, daily for 10 days
88868784|NCT01183728|Experimental|MSV autologous transplantation|Bone marrow collected from patient will be used for mesenchymal stem cells isolation and expansion under GMP conditions at IBGM-Valladolid (MSV). Autologous MSV implanted in knee by articular injection
88868785|NCT01184898|Experimental|Sirolimus and MEC|Sirolimus and MEC (Mitoxantrone, Etoposide, and Cytarabine)
88868786|NCT01187004||Acute Lung Injury (ALI)|patients who might develop acute lung injury (ALI) after cardiac surgery with cardiopulmonary by pass
88868787|NCT01188876|Experimental|Carboplatin/Pralatrexate|
88868788|NCT01189110|Active Comparator|Arm 1|Stimulation of auriculotherapy points on both ears with functioning Stim Flex 400A TENS unit once a week for 5 weeks.
88868789|NCT01189110|Placebo Comparator|Arm 2|Stimulation of auriculotherapy points on both ears with disabled Stim Flex 400A TENS unit once a week for 5 weeks.
88868790|NCT01192542|Other|galyfilcon A prototype lens/enfilcon A lens|galyfilcon A prototype contact lens worn daily for 6-8 days first then enfilcon A contact lens worn daily for 6-8 days second.
88868791|NCT01192542|Other|enfilcon A lens/galyfilcon A prototype lens|enfilcon A contact lens worn daily for 6-8 days first then galyfilcon A prototype contact lens worn daily for 6-8 days second.
88868792|NCT01193010|Active Comparator|Control|Surgery without computer-assisted planning.
88868793|NCT01193010|Experimental|Computer-Assisted Surgical Planning|
89187070|NCT02584010|Experimental|Kelofin Aerosol|Silicon-based Aerosol that will be applied over the postoperative scar two times a day
88868794|NCT01193868|Experimental|RO4929097|"Patients receive oral gamma-secretase inhibitor RO4929097 once daily on days 1-3, 8-10, and 15-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Blood and tumor tissue samples are collected for pharmacogenetic, pharmacodynamic, and biomarker studies by IHC, FISH, and TUNEL assay."
88868795|NCT01195116|Active Comparator|Dexmedetomidine|Dexmedetomidine is a FDA-approved medication that is a highly selective, short acting, alpha-2 adrenoreceptor agonist. To date, its safety and efficacy is well studied and established.It produces sedative, anxiolytic, and analgesic effects when used while patients undergo procedures and surgical operations.Interstitial Cystitis, as a chronic visceral pain syndrome, has the potential to have a neuropathic component for which an alpha-2 adrenergic agonist may be more effective than other classes, including opioids or NSAIDs.
88868796|NCT01195116|Placebo Comparator|Normal Saline|
88868797|NCT01195584||BMI < 25|Body Mass Index (WHO) established by WHO. BMI < 25 has been defined as 'normal weight'.
88868798|NCT01195584||25 >= BMI < 30|Body Mass Index (WHO) established by WHO. BMI >= 25 and < 30 has been defined as 'overweight'.
88868799|NCT01195584||BMI >= 30|Body Mass Index (WHO) established by WHO. BMI > 30 has been defined as 'obese'.
88868800|NCT01196442|Experimental|Arm I electric stimulation pain therapy|Patients undergo electric stimulation pain therapy comprising MC5-A Calmare therapy over 30 minutes once daily for 10 days.
88868801|NCT01197456||Exposed/chemotherapy|Breast cancer patients who will undergo chemotherapy
88868802|NCT01197456||Unexposed|Breast cancer patients who will not undergo chemotherapy
88868803|NCT01197612|Other|Single Arm; nostrils as experimental and comparator|each subject serves as their own control with one nostril being treated with pulmicort and one not
89187071|NCT02584010|Experimental|Kelofin Gel|Silicon-based Gel that will be applied over the postoperative scar two times a day
88868804|NCT01198158|Active Comparator|Arm I (everolimus)|Patients receive everolimus PO QD on days 1-28.
88868805|NCT01198158|Experimental|Arm II (everolimus with bevacizumab)|Patients receive everolimus PO QD on days 1-28 and bevacizumab IV over 30-90 minutes on days 1 and 15.
88868806|NCT01199952|No Intervention|Control|The control group will not receive a counseling phone call one month after enrollment.
88868807|NCT01199952|Experimental|Intervention|Intervention arm receives a counseling phone call 3 to 4 weeks after enrollment. The call is from a health educator intended to assist with contraception.
88868808|NCT01200030|Experimental|electrical stimulation with exercises|The TENS + TRTT group received TENS simultaneously with the TRTT at home under the instruction of a physical therapist.
88868809|NCT01200030|Placebo Comparator|placebo stimulation with exercises|The TENS + TRTT group received placebo-simultaneously with the TRTT at home under the instruction of a physical therapist.
88868810|NCT01200030|No Intervention|Control|Subjects in this group did not receive any active training. Home safety advice and health education including diet control and blood pressure monitoring were given to the subjects during the home-visit and telephone follow-up.
88868811|NCT01200498|Experimental|SB939|SB939 starting dose 60 mg by mouth every other day, three times weekly for 3 weeks.
88868812|NCT01203774|Active Comparator|Pen-administered vs syringe-admnistered Glargine|SoloSTAR pen-administered Glargine insulin then syringe-administered Glargine insulin
88868813|NCT01203774|Active Comparator|Syringe-administered vs pen-administered Glargine|Syringe-administered Glargine insulin and then pen-administered Glargine insulin
89003673|NCT04844840|Placebo Comparator|Cohort 5: Placebo control|Placebo (saline) will be injected intradermal into the excised keloid site
89187072|NCT02584010|No Intervention|Control|This group will not receive any intervention as a control group.
88868814|NCT01205568|Experimental|Patients with Resistant Pulmonary Artery Stenosis|Vessels with resistant PA stenosis were identified during catheterization and eligible vessels were randomized to Cutting Balloon or High Pressure Balloon Dilation
88868815|NCT01205646|Experimental|Zometa & PET Scans|Zoledronate therapy & PET scan ;2 scans [about 1-2 weeks apart] will be obtained over a period of 2 weeks pretherapy to confirm reproducibility, Bone scan (within 4 weeks prior to registration), bone turnover markers, and PSA will be obtained pretherapy. After that, Zometa will be administered at a dose of 4mg IV over 15 minutes. A third PET scan will be obtained within 1-2 weeks after Zometa administration.
88868816|NCT01206660|Experimental|Desoximetasone Spray 0.25%|Desoximetasone topical spray 0.25% administered to affected area twice a day for 28 days
88868817|NCT01206660|Placebo Comparator|placebo|Placebo administered to affected area twice a day for 28 days
89535400|NCT03322397|Active Comparator|Kindness to Self|Participants will complete the 'Self-Focused Acts of Kindness Intervention' by performing acts of kindness for themselves. They be asked to complete 3 kind acts for others throughout the week for 4 weeks. They will receive text messages three days per week (either Tuesday, Thursday, and Saturday or Wednesday, Friday, and Sunday) and will report on their kind act later that day.
88868818|NCT01206738|Experimental|Persuasive communication|The persuasive intervention aimed to reinforce the GP's beliefs about the positive consequences of managing sore throat without prescribing antibiotics.
88868819|NCT01206738|Experimental|Alternative intervention|This intervention was an action plan, supporting the GP to deal with two difficult prescribing situations: 1) a distressed patient (or often distressed parent of a child patient) 2) a patient demanding an antibiotic
88868820|NCT01206738|Active Comparator|General information|No additional information was provided; the general information was the information already available to GPs about antibiotic prescribing.
88868821|NCT01207752|Experimental|Systane Balance|Artificial tear emulsion
88868822|NCT01207752|Active Comparator|Optive Lubricant Eye Drops|Artificial tear
88868823|NCT01207908|Experimental|IGF-1|IGF-1 plus standard steroid treatment
88868824|NCT01207908|No Intervention|Standard steroid treatment alone|Standard daily steroid treatment for DMD
88868825|NCT01208220|Active Comparator|Negative pressure wound therapy|NPWT changed TIW
88868826|NCT01208220|Experimental|NPWT plus Collagenase Ointment|Collagenase applied TIW with NPWT
88868827|NCT01208922|Experimental|Group A|Rifamycin SV-MMX® 200 mg tablets
88868828|NCT01208922|Active Comparator|Group B|Ciprofloxacin 500 mg capsules
88868829|NCT01209702|Placebo Comparator|Part 1: Placebo|Participants received intravenous infusions of placebo once every 4 weeks until Week 12. Following the Week 12 visit, participants who completed Part 1 of the study received open-label 8 mg/kg tocilizumab through Week 208.
88868830|NCT01209702|Experimental|Part 1: Tocilizumab|Participants received intravenous infusions of 8 mg/kg tocilizumab once every 4 weeks until Week 12. Following the Week 12 visit, participants who completed Part 1 of the study received open-label 8 mg/kg tocilizumab through Week 208.
88868831|NCT01209702|Placebo Comparator|Part 2: Placebo|Participants received intravenous infusions of placebo once every 4 weeks until Week 24. Participants who did not attain an ASsessment in Ankylosing Spondylitis-20 (ASAS20) response at Week 16 were, at the investigator's discretion, eligible to receive open-label escape therapy consisting of 8 mg/kg tocilizumab. After Week 24, participants were to receive open-label treatment with 8 mg/kg tocilizumab every 4 weeks until Week 104. At the completion of Week 104, all Part 2 participants were to receive tocilizumab 8 mg/kg in the common open-label extension phase, however the study was terminated prior to any participants reaching this stage.
88868832|NCT01209702|Experimental|Part 2: Tocilizumab 4 mg/kg|Participants received intravenous infusions of 4 mg/kg tocilizumab once every 4 weeks until Week 24. Participants who did not attain an ASAS20 response at Week 16 were, at the investigator's discretion, eligible to receive open-label escape therapy consisting of 8 mg/kg tocilizumab. After Week 24, participants were to receive open-label treatment with 8 mg/kg tocilizumab every 4 weeks until Week 104. At the completion of Week 104, all Part 2 participants were to receive tocilizumab 8 mg/kg in the common open-label extension phase, however the study was terminated prior to any participants reaching this stage.
88868833|NCT01209702|Experimental|Part 2: Tocilizumab 8 mg/kg|Participants received intravenous infusions of 8 mg/kg tocilizumab once every 4 weeks until Week 24. Participants who did not attain an ASAS20 response at Week 16 were, at the investigator's discretion, eligible to receive open-label escape therapy consisting of 8 mg/kg tocilizumab. After Week 24, participants were to receive open-label treatment with 8 mg/kg tocilizumab every 4 weeks until Week 104. At the completion of Week 104, all Part 2 participants were to receive tocilizumab 8 mg/kg in the common open-label extension phase, however the study was terminated prior to any participants reaching this stage.
88868834|NCT01210170|Experimental|mometasone 400 mcg - 30 min|randomly assigned intervention
88868835|NCT01210170|Experimental|mometasone 400 mcg simultaneous|randomly assigned intervention
88868836|NCT01210170|Placebo Comparator|placebo- 30 min|randomly assigned intervention
88868837|NCT01210170|Placebo Comparator|placebo simultaneous|randomly assigned intervention
88868838|NCT01210170|Experimental|mometasone 400 mcg - 60 min|randomly assigned intervention
88868839|NCT01210170|Placebo Comparator|placebo- 60 min|randomly assigned intervention
88868840|NCT01210170|Experimental|mometasone 200 mcg - 30 min|randomly assigned intervention
88868841|NCT01210170|Experimental|mometasone 200 mcg - 60 min|randomly assigned intervention
88868842|NCT01210170|Experimental|mometasone 200 mcg simultaneous|randomly assigned intervention
88868843|NCT01210560|Experimental|20 mg MR|
88868844|NCT01210560|Experimental|40 mg MR|
88868845|NCT01210560|Experimental|60 mg MR|
88868846|NCT01210560|Experimental|120 mg MR|
88868847|NCT01210560|Experimental|120 mg IR|
88868848|NCT01210716|Experimental|AMICUS Therapeutic plasma exchange, TPE|Patients are randomized to either TPE on AMICUS or Spectra.
88868849|NCT01210716|Active Comparator|Spectra Therapeutic plasma exchange, TPE|Patients are randomized to either TPE on AMICUS or Spectra.
89003674|NCT04844840|No Intervention|Cohort 6: SOC alone|SOC (no injection)
89003675|NCT04842448|Experimental|Hyperbaric oxygen treatment|HBO2 240 kPa, 90 min, maximum 10 treatments
88868850|NCT01211106|Experimental|Arm 1: Integrated Conditions|Motivational enhancement therapy for addiction is combined with Prolonged exposure therapy for PTSD from the beginning of treatment. Both are delivered by the same provider throughout treatment.
88868851|NCT01211106|Experimental|Arm 2 Sequential therapy|Motivational enhancement therapy for addiction is delivered in the first 4 weeks and only after the addiction is addressed is the Prolonged exposure therapy for PTSD started.
88868852|NCT01211340|No Intervention|Usual Care|Usual hospice care- there is no intervention in this arm
89535401|NCT03322397|Sham Comparator|Daily Report|Participants will complete the 'Daily Reports' and be asked to report their daily activities throughout the week for 4 weeks. They will receive text messages three days per week (either Tuesday, Thursday, and Saturday or Wednesday, Friday, and Sunday) and will list activities from their day.
89535402|NCT05005377|Experimental|Socket Preservation with Platelet-Rich Fibrin|10cc of blood was drawn from each patient and centrifuged at 2700 revolutions per minute (rpm) for 12 minutes to obtain PRF. The extraction socket was filled with PRF and covered using a membrane made of PRF.
89535403|NCT05005377|Experimental|Socket Preservation with Freeze-Dried Bone Allograft|the extraction socket was filled with FDBA (CenoBone®; Tissue Regeneration Corp., Kish Island, Iran) without flap elevation. The socket was covered using a free palatal mucosal graft obtained by the pouch technique.
88868853|NCT01211340|Experimental|ACTIVE|Behavioral intervention using web conferencing
88868854|NCT01211730|Active Comparator|140 Group|Insulin treatment to target blood glucose at 140 mg/dl
88868855|NCT01211730|Active Comparator|180 Group|Insulin treatment to target blood glucose at 180 mg/dl
88868856|NCT01212900|Experimental|Imaging|Lipid targets assigned according to the severity of atherosclerotic plaque measured as wall volume in the common and internal carotid arteries by MRI
88868857|NCT01212900|Active Comparator|Standard|Standardized statin therapy based on NCEP ATP IIIR guidelines, including clinical risk factors and blood lipid levels.
88868858|NCT01215240|Experimental|Prophylactic peritoneal dialysis|Prophylactic peritoneal dialysis
88868859|NCT01215240|No Intervention|Standard care without PDC|
88868860|NCT01215318|Experimental|Modified vaginal tampons|Patients using modified vaginal tampons during FDG PET/CT
88868861|NCT01215318|Placebo Comparator|Unmodified vaginal tampons|Patients using unmodified vaginal tampons during FDG PET/CT
88868862|NCT01215786|Other|AGN-207281 ophthalmic solution|AGN-207281 0.1% ophthalmic solution on Days 1-7 and AGN-207281 0.3% ophthalmic solution on Days 8-14
88868863|NCT01215786|Active Comparator|Timolol ophthalmic solution 0.5%|timolol ophthalmic solution 0.5%
88868864|NCT01215786|Placebo Comparator|Placebo|AGN-207281 vehicle ophthalmic solution (Placebo)
88868865|NCT01216410|Active Comparator|Metoclopramide|Prophylaxis with metoclopramide and phenylephrine infusion.
88868866|NCT01216410|Placebo Comparator|Phenylephrine infusion|Prophylactic phenylephrine infusion and placebo antiemetics
88868867|NCT01216410|Active Comparator|Combination Group|Metoclopramide and Ondansetron prophylaxis with phenylephrine infusion
88868868|NCT01218048|Experimental|Neo-Adjuvant Cetuximab|"Neo-Adjuvant Cetuximab + Surgery + Post-Surgical Radiation + Cisplatin (or Carboplatin)~NOTE: Based the results of surgery if the treating physician feels patient is not a candidate for chemotherapy, radiation can be given alone or with cetuximab."
88868869|NCT01218672|Experimental|GreenLight XPS|Photoselective vaporization of the prostate using GreenLight XPS laser system.
88868870|NCT01218672|Active Comparator|Transurethral Resection of the Prostate|Monopolar and bipolar Transuretheral resection of the prostate (TURP)
88868871|NCT01218984|Experimental|Medisorb naltrexone 75 mg|
88868872|NCT01218984|Experimental|Medisorb naltrexone 150 mg|
88868873|NCT01218984|Experimental|Medisorb naltrexone 300 mg|
88868874|NCT01220466|Experimental|Refractive Error|
88868875|NCT01222260|Experimental|Treatment Arm|Subjects with AL will receive Bendamustine and Dexamethasone
88868876|NCT01222494|Placebo Comparator|Antipsychotic Treated Educational Cntrl|Antipsychotic treated participants randomized to this arm will receive diet and exercise education at monthly intervals with a study clinician or coordinator.
88868877|NCT01222494|Experimental|Antipsychotic Treated Weekly BWL|Antipsychotic treated participants randomized to this arm will engage in an evidence-based, 16 week manualized behavioral weight loss intervention that includes weekly meetings and phone check-ins with a trained study therapist.
88868878|NCT01222494|Active Comparator|Non-antipsychotic Treated Weekly BWL|Participants assigned to this arm will engage in an evidence-based, 16 week manualized behavioral weight loss intervention that includes weekly meetings and phone check-ins with a trained study therapist.
89003676|NCT04842448|Placebo Comparator|Sham treatment|Air 134-120 kPa, 90 min, maximum 10 treatments
89187073|NCT02585804|Experimental|Dapagliflozin (trade name Farxiga®)|Oral tablet, 10mg, PO, 8 weeks
89187074|NCT02585726|Active Comparator|Historical Control with Propensity Analysis|
89187075|NCT02585726|Experimental|VenaSeal Treatment Arm|
89392714|NCT01375387|Experimental|Lacosamide 200 mg, Japanese|2 Lacosamide 100 mg tablets plus 2 placebo tablets
88868879|NCT01222572|Experimental|Stereotactic Boost to Chemoradiotherapy (Dose Level 1)|"Chemotherapy: Etoposide 50 mg/m2, d1-5, 29-33 and Cisplatin 50 mg/m2, d1, 8, 29, 36; Conventional RT Dose to Primary: 54 Gy; Stereotactic Boost to Primary: 10 Gy; Total Dose to Primary: 64 Gy~- Patients were to start radiation to the primary tumor site and to the lymph nodes and chemotherapy in the same week. The treatment was identical to standard chemotherapy and radiation treatment until the 5th week. During the fifth week, patents would undergo another radiation mapping session to prepare for the stereotactic boost. After that, the radiation treatments to the lymph nodes would continue but the radiation treatment to the primary cancer site would stop until the last week (week 7). During week 7, participants would receive 2 doses of stereotactic radiotherapy to the site of the primary tumor instead of the lower doses of radiotherapy that they were treated with up to that point."
89187076|NCT04079270|Experimental|Personalized algorithm-based diet|The intervention arm will be an 'algorithm-based' arm in which patients will receive personally tailored dietary recommendations, based on their microbiome, and other clinical data such as blood tests and lifestyle features.
89187077|NCT04079270|Active Comparator|standard Mediterranean low-fat diet|The control arm will receive nutritional recommendations according to the standard Israeli dietary approach Mediterranean-style low-fat diet.
88868880|NCT01222572|Experimental|Stereotactic Boost to Chemoradiotherapy (Dose Level 2)|"Chemotherapy: Etoposide 50 mg/m2, d1-5, 29-33 and Cisplatin 50 mg/m2, d1, 8, 29, 36; Conventional RT Dose to Primary: 50 Gy; Stereotactic Boost to Primary: 15 Gy; Total Dose to Primary: 65 Gy~- Patients were to start radiation to the primary tumor site and to the lymph nodes and chemotherapy in the same week. The treatment was identical to standard chemotherapy and radiation treatment until the 5th week. During the fifth week, patents would undergo another radiation mapping session to prepare for the stereotactic boost. After that, the radiation treatments to the lymph nodes would continue but the radiation treatment to the primary cancer site would stop until the last week (week 7). During week 7, participants would receive 2 doses of stereotactic radiotherapy to the site of the primary tumor instead of the lower doses of radiotherapy that they were treated with up to that point."
89187078|NCT05674760|Active Comparator|Arterial Blood Gas (ABG) arm - Control arm|Patients in this arm will undergo arterial blood gas sampling to monitor CO2 as per the British Thoracic Society guidance which is standard practice.
88868881|NCT01222572|Experimental|Stereotactic Boost to Chemoradiotherapy (Dose Level 3)|"Chemotherapy: Etoposide 50 mg/m2, d1-5, 29-33 and Cisplatin 50 mg/m2, d1, 8, 29, 36; Conventional RT Dose to Primary: 46 Gy; Stereotactic Boost to Primary: 20 Gy; Total Dose to Primary: 66 Gy~- Patients were to start radiation to the primary tumor site and to the lymph nodes and chemotherapy in the same week. The treatment was identical to standard chemotherapy and radiation treatment until the 5th week. During the fifth week, patents would undergo another radiation mapping session to prepare for the stereotactic boost. After that, the radiation treatments to the lymph nodes would continue but the radiation treatment to the primary cancer site would stop until the last week (week 7). During week 7, participants would receive 2 doses of stereotactic radiotherapy to the site of the primary tumor instead of the lower doses of radiotherapy that they were treated with up to that point."
88868882|NCT01222884|Active Comparator|Iron isomaltoside 1000|Iron isomaltoside 1000 (Monofer)administered as 500 mg intravenous single bolus injections OR administered as 500 mg fractionated (100mg+200mg+200mg) intravenous bolus injection
88868883|NCT01222884|Active Comparator|Iron sucrose|Iron sucrose administered as 500 mg fractionated (100mg+200mg+200mg) intravenous bolus injection
89187079|NCT05674760|Experimental|transcutaneous CO2 arm|Patients in this arm will undergo transcutaneous monitoring to monitor CO2. This will be the experimental arm.
89187080|NCT04080830||Acute ischemic stroke/transient ischemic attack (TIA) with AF|patients with Acute ischemic stroke/TIA and Atrial fibrillation (observational -no intervention)
89187081|NCT02582996|Experimental|Cefalium®|Acetaminophen+Caffeine+Dihydroergotamine+Metoclopramide.
89187082|NCT02582996|Active Comparator|Tylenol®|Acetaminophen
89187083|NCT00674817|Experimental|400 microgrammes GSK961081 and salbutamol|400 microgrammes of GSK961081 single-dose (via DISKUS Metered Dry Powder Inhaler/ MDPI) followed by cumulative doses (3x 200 microgrammes at 20 min intervals, administered via spacer) of salbutamol at 1h, 12h and 24h of dosing.
89392715|NCT01375387|Experimental|Lacosamide 200 mg, Chinese|2 Lacosamide 100 mg tablets plus 2 placebo tablets
89392716|NCT01375387|Experimental|Lacosamide 400 mg, Japanese|4 Lacosamide 100 mg tablets
89392717|NCT01375387|Experimental|Lacosamide 400 mg, Chinese|4 Lacosamide 100 mg tablets
89392718|NCT01375387|Placebo Comparator|Placebo Comparator, Japanese|4 placebo tablets
89392719|NCT01375387|Placebo Comparator|Placebo Comparator, Chinese|4 placebo tablets
89392720|NCT03936699|Experimental|Treatment|The Transcutaneous Nerve Stimulator (TENS) Elira wearable patch system will be applied to varying locations on the T6/T7 dermatome for 30 minutes three times a day after meals. Subjects will be instructed to follow a 1200 calorie healthy diet and record any changes in appetite.
89392721|NCT03936699|Active Comparator|Control|Open label diet and exercise counseling only. Subjects will be instructed to follow a healthy 1200 calorie diet and record any changes in appetite.
89392722|NCT02126072|Experimental|Alcohol|The study is a randomized single blinded trial in cross over design. Subjects are randomized to drink alcohol in one session and water in another session.
89392723|NCT02126072|Active Comparator|Water|Water in the same volume as the volunteer would have to drink in wine according to the protocol.
89392724|NCT05194813|Experimental|Hydrophilic sandblasted and acid-etched dental implants|
89392725|NCT05194813|Active Comparator|Conventional hydrophobic sandblasted and acid-etched dental implant|
88868884|NCT01223352|Experimental|Bosentan 2 mg/Kg t.i.d.|2 mg/kg bosentan administered three times a day (morning, afternoon, evening) for a planned duration of 24 weeks
88868885|NCT01223352|Experimental|Bosentan 2 mg/Kg b.i.d.|2 mg/kg bosentan administered twice daily (morning and evening) for a planned duration of 24 weeks
89187084|NCT00674817|Experimental|1200 microgrammes GSK961081 and salbutamol|1200 microgrammes of GSK961081 single-dose (via DISKUS MDPI) followed by cumulative doses (3x 200 microgrammes at 20 min intervals, administered via spacer) of salbutamol at 1h, 12h and 24h of dosing.
89392726|NCT02853318|Experimental|Treatment (pembrolizumab, bevacizumab, cyclophosphamide)|Patients receive pembrolizumab IV over 30 minutes and bevacizumab IV over 30-90 minutes on day 1 and cyclophosphamide PO QD on days 1-21. Treatment repeats every 3 weeks for up to 17 courses in the absence of disease progression or unacceptable toxicity. Patients without evidence of disease progression may continue treatment in the absence of disease progression or unacceptable toxicity.
88868886|NCT01224210|Other|Ambrisentan (24 Weeks), Extension (4 Weeks)|Open Label Ambrisentan
88868887|NCT01224444||All adenomatous polyps|Standard polypectomy snare of adenomatous polyps (included serrated adenomas) from ≤5mm to ≤20mm.
88868888|NCT01224678|Placebo Comparator|Placebo|Patients receive oral placebo once daily for 12 months.
88868889|NCT01224678|Experimental|Vitamin D|Patients receive oral vitamin D (2000 IU) once daily for 12 months.
88868890|NCT01225068|Experimental|Milnacipran|milnacipran 50 mg bid; can be increased to 100 mg bid
88868891|NCT01225068|Placebo Comparator|Placebo|Placebo
88868892|NCT01225926|Experimental|Toric T3 - T9|AcrySof IQ Toric IOL surgically implanted in the capsular bag of the eye following cataract removal. Both eyes were implanted, with the second eye implanted at least 1 week after and within 1 month of the first eye.
88868893|NCT01225926|Active Comparator|IQ SN60WF|AcrySof IQ IOL surgically implanted in the capsular bag of the eye following cataract removal. Both eyes were implanted, with the second eye implanted at least 1 week after and within 1 month of the first eye.
88868894|NCT01226706|Placebo Comparator|Placebos|Placebo injected into the detrusor at Day 1,
88868895|NCT01226706|Experimental|Botulinum Toxins, Type A|Botulinum Toxins, Type A 100U injected into the detrusor at Day 1
88868896|NCT01228968||Volunteers|Volunteers will have a range of body mass index from 19 - 45 kilogram per square meter. In order to fit in the magnetic resonance scanner subjects must weigh less than 300 pounds.
89392727|NCT02127476|Experimental|KHK6640|KHK6640
88868897|NCT01231230|Experimental|fluticasone/salmeterol|participants were treated fluticasone/salmeterol,
88868898|NCT01231230|Experimental|salmeterol|participants were treated with salmeterol
88868899|NCT01231230|Experimental|fluticasone|participants were treated with fluticasone
88868900|NCT01231230|Placebo Comparator|placebo inhalation|participants were treated with placebo
88868901|NCT01232946|Experimental|Iiraglutide|Type 2 diabetic subjects will be assigned to 3 months of treatment with 1.8mg liraglutide administered once daily in addition to background metformin 2000mg/day. PET measurements of myocardial glucose uptake will take place at the end of treatment.
88868902|NCT01232946|Experimental|insulin detemir|Type 2 diabetic subjects will be assigned to 3 months of treatment with insulin detemir administered twice daily in addition to background metformin 2000mg/day. PET measurements of myocardial glucose uptake will take place at the end of treatment.
88868903|NCT01232946|Experimental|Liraglutide plus insulin detemir|Type 2 diabetic subjects will be assigned to 3 months of treatment with a combination of liraglutide and insulin detemir in addition to background metformin 2000mg/day. PET measurements of myocardial glucose uptake will take place at the end of treatment.
88868904|NCT01233726|Experimental|T-DIET PLUS DIABET IR|Patients of this group will receive T-Diet plus Diabet IR as unique nutritional support throughout the day, receiving 25 kcal / kg • day (from the first 48 hours after checking tolerance) via gastric or transpyloric
88868905|NCT01233726|Active Comparator|ISOSOURCE PROTEIN FIBRE|Patients of this group will receive ISOSOURCE PROTEIN FIBRE (Nestlé Nutrition) as unique nutritional support throughout the day receiving 25 kcal / kg • day (from the first 48 hours after checking tolerance) via gastric or transpyloric
88868906|NCT01233726|Active Comparator|GLUCERNA SELECT|Patients of this group will receive GLUCERNA SELECT (Abbott Laboratories) as unique nutritional support throughout the day, receiving 25 kcal / kg • day (from the first 48 hours after checking tolerance) via gastric or transpyloric
88868907|NCT01235910|Other|1|Aliskiren 75 mg once daily x 2 weeks, then aliskiren 150 mg once daily x 2 weeks, if blood pressure allows
88868908|NCT01236300|Experimental|Cellvizio system|
88868909|NCT01236378|Experimental|sirolimus|Subjects must be taking sirolimus (1 mg tablet formulation) with or without concomitant medications, unless specifically excluded below, for prophylaxis of renal rejection.
89392728|NCT02127476|Placebo Comparator|Placebo|Placebo
89392729|NCT03918213|Experimental|healthy subjects examined with solid-state catheter|healthy subjects - subjects without signs of functional and organic anorectal pathology
89392730|NCT03431545|Experimental|PALS and BEECH|Play and Learning Strategies (PALS) and Beginning Education: Early Childcare at Home (BEECH) include web-based parent and teacher training courses with remote coaching and in-person meetings that support the adults' developing a set of core behaviors that comprise a responsive interactive style including responses contingent to children's needs and interests with rich language input.
89392731|NCT03431545|Active Comparator|Control condition|Parents and teachers conduct business as usual in regards to care-giving in the school and at home.
89392732|NCT02127554||Electric coagulation|Patients with anterior epistaxis, treated with electric coagulation
88868910|NCT01236768|Experimental|AG200-15|Thin transdermal contraceptive delivery system (TCDS) that gives systemic exposure of levonorgestrel (LNG) and ethinyl estradiol (EE)
88868911|NCT01236768|Active Comparator|Levora|oral contraceptive containing 150mcg of LNG and 30mcg of EE
88868912|NCT01237080|Experimental|Fastrach|50 persons beeing intubated using the Fastrach.
88868913|NCT01237080|Experimental|GlideScope|50 persons beeing intubated using the GlideScope.
88868914|NCT01238640|Experimental|Code STD|"An experimental 2 mg nicotine product coded STD"
88868915|NCT01238640|Experimental|Code STE|"An experimental 2 mg nicotine product coded STE"
88868916|NCT01238640|Active Comparator|Nicorette Microtab|A comparative 2 mg marketed nicotine product called Nicorette Microtab
88868917|NCT01240122|Active Comparator|Biotrue MPS|
88868918|NCT01240122|Experimental|Investigational MPS|
88868919|NCT01241916|Experimental|Static-progressive splint|
88868920|NCT01241916|Experimental|Dynamic Splint|
88868921|NCT01243320|Experimental|10ppm Oral Silver|Oral Dose of 10ppm
88868922|NCT01243320|Experimental|32ppm Oral Silver|Oral Dose of 32ppm
88868923|NCT01245270|Experimental|Bilberry capsule first, then control cap|"Volunteers will be given a single capsule of 0.47 grams of mirtoselect (a concentrated bilberry extract) followed by a 14 day washout period then a single control placebo capsule.~First Intervention (1 day), Washout (14 days), Second Intervention (1 day)"
88868924|NCT01245270|Experimental|Control capsule first, then bilberry cap|"Volunteers will be given a single control placebo capsule followed by a 14 day washout period the a single capsule of 0.47 grams of mirtoselect (a concentrated bilberry extract)~First Intervention (1 day), Washout (14 days), Second Intervention (1 day)"
88868925|NCT01245738||Participants|Participants admitted to participating tertiary cardiac care centers who experienced a first coronary event.
88868926|NCT01245972|No Intervention|Control|No treatment administered
88868927|NCT01245972|Experimental|PDL Setting 1|PDL Setting 1: 15 J/cm2, 3ms pulse length, no dynamic cooling, 7mm spot size, 10% overlap between the pulses, 2 passes
88868928|NCT01245972|Experimental|PDL Setting 2|PDL Setting 2: 7.5 J/cm2, 3ms pulse length, no dynamic cooling, 10mm spot size, 10% overlap between the pulses, 2 stacked pulses
88868929|NCT01246050|Experimental|Arm 1: Received HF Training|Providers will receive 3 days of HF training, receive access to clinical pharmacist medication titration serviced and receive performance feedback
88868930|NCT01246050|Active Comparator|Arm 2: No HF Training|CBOC Providers in the same CBOC who did not received HF Training, access to clinical pharmacist services or performance feedback
88868931|NCT01247064|Experimental|Nebulized 3% Saline|
88868932|NCT01247064|Placebo Comparator|Nebulized 0.9% Normal Saline|
88868933|NCT01247220|Experimental|Peripheral Laser + Ranibizumab|Angiography-directed peripheral laser + ranibizumab
88868934|NCT01247220|Active Comparator|Ranibizumab|Ranibizumab
88868935|NCT01247298|Experimental|Stereotactic Body Radiation Therapy (SBRT)|Patients will receive stereotactic body radiation therapy (SBRT) which is 3 radiation treatments at 15 Gy, for a total of 45 Gy. Patients will be given Trans-Arterial Chemoembolization (TACE), prior to enrollment. (TACE is not performed as part of this clinical study, even though it is part of the inclusion criteria.)
89187085|NCT00674817|Experimental|400 microgrammes GSK961081 and ipratropium bromide|400 microgrammes of GSK961081 single-dose (via DISKUS MDPI) followed by cumulative doses (20 microgrammes, 20 microgrammes and 40 microgrammes at 20 min intervals, administered via spacer) of ipratropium bromide at 1h, 12h and 24h of dosing.
88868936|NCT01249872|Active Comparator|GROUP A : 0 mg MORPHINE-0.1% LEVOBUPIVACAINE|Group A patients receive intra-operatively (45 min before the estimated end of the surgery) a bolus dose 2 ml of normal saline. Postoperatively, patients receive PCEA of 0.1% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.
88868937|NCT01249872|Active Comparator|GROUP B : 1 mg MORPHINE- 0.1% LEVOBUPIVACAINE|Group B patients receive an epidural bolus dose of 1mg of morphine intra-operatively (45 min before the estimated end of the surgery). Postoperatively, patients receive PCEA of 0.1% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h
88868938|NCT01249872|Active Comparator|GROUP C : 2 mg MORPHINE-0.1% LEVOBUPIVACAINE|Group C patients receive an epidural bolus dose 2 mg of morphine intra-operatively (45 min before the estimated end of the surgery).Postoperatively, patients receive PCEA of 0.1% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h
88868939|NCT01249872|Active Comparator|GROUP D : 0 mg MORPHINE- 0.2% LEVOBUPIVACAINE|Group D patients receive intra-operatively (45 min before the estimated end of the surgery) a bolus dose of 2 ml of normal saline, epidurally. Postoperatively,patients receive PCEA of 0.2% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h
88868940|NCT01249872|Active Comparator|GROUP E : 1 mg MORPHINE-0.2 % LEVOBUPIVACAINE|Group E patients receive intra-operatively (45 min before the estimated end of the surgery) an epidural bolus dose of 1mg of morphine.Postoperatively, patients receive PCEA of 0.2% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h
88868941|NCT01249872|Active Comparator|GROUP F : 2 mg MORPHINE- 0.2% LEVOBUPIVACAINE|Group F patients receive intra-operatively (45 min before the estimated end of the surgery) an epidural bolus dose of 2 mg of morphine. Postoperatively, patients receive PCEA of 0.2% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h
88868942|NCT01250184|Active Comparator|Physical Therapy|Twelve sessions, 3 per week.
88868943|NCT01250184|Active Comparator|Lidocaine injection|Blocking the myofascial trigger point (MTP) with lidocaine injection, unique dose.
88868944|NCT01250184|Experimental|Lidocaine injection + physical therapy|Blocking the Myofascial trigger point (MTP) with lidocaine injection plus a standarized therapeutic exercise program, twelve sessions, 3 per week.
88868945|NCT01250730|Experimental|1.0|This study will consist of three cohorts: PF-02341066 150 mg treatment group (n = 6), PF-02341066 250 mg treatment group (n = 6) and PF-02341066 400 mg treatment group (n = 6).
88868946|NCT01251042|Experimental|Sangvia and retransfusion|
88868947|NCT01251042|Sham Comparator|Sangvia and no retransfusion|
89392733|NCT02127554||Chemical coagulation|Patients with anterior epistaxis, treated with chemical coagulation
89392734|NCT02127554||Outpatient tamponade|Patients with posterior epistaxis, treated with tamponade as an outpatient
89392735|NCT02127554||Inpatient tamponade|Patients with posterior epistaxis, treated with tamponade and kept in the hospital.
89392736|NCT02127554||Surgery|Patients with posterior epistaxis, treated with surgery as inpatients
89392737|NCT02127554||Foley balloon catheter|Patients with posterior epistaxis, treated as inpatients with Foley balloon catheter
89392738|NCT02127554||Combined treatment|Patients with posterior epistaxis, treated as inpatients with a combination of methods
89392739|NCT03626805||Migraine patients|Migraine patients attending the Danish Headache Centre
89392740|NCT03626805||Healthy Controls|Age and sex matched
89392741|NCT05194657|Experimental|Acrysof IQ Vivity|Patient will receive the enhanced depth of focus IOL during cataract surgery
89392742|NCT05194657|Experimental|Acrysof IQ|Patiet will receive the monofocal IOL during cataract surgery
89392743|NCT02126150||Ethnicity|
88868948|NCT01251588||MACI|autologous cultured chondrocytes on porcine collagen membrane implant received in previous MACI00206 study
88868949|NCT01251588||Microfracture|Microfracture treatment received in previous MACI00206 study
88868950|NCT01251978|Active Comparator|High dose Ranibizumab|6 patients will receive 3 injections of Ranibizumab (2 mg) a month apart.
88868951|NCT01251978|Active Comparator|Standard Dose Ranibizumab|6 patients will receive 0.5 mg of Ranibizumab every two weeks per 3 months.
88868952|NCT01253148|Experimental|Arterial Injection of 90-Y Microspheres|Intrahepatic Arterial Injection of 90-Y Glass Microspheres as First-Line Treatment For Cholangiocarcinoma
88868953|NCT01253460|Experimental|Cyclophosphamide, Rituximab + Sapacitabine|After Sapacitabine 350 mg orally Days 1-3, Cyclophosphamide 250 mg/m2 IV 2 hours, followed by Rituximab 375 mg/m2 IV Day 3, Course 1, and 500 mg/m2 Day 1, subsequent courses.
89187086|NCT00674817|Experimental|1200 microgrammes of GSK961081 and ipratropium bromide|1200 microgrammes of GSK961081 single-dose (via DISKUS MDPI) followed by cumulative doses (20 microgrammes, 20 microgrammes and 40 microgrammes at 20 min intervals, administered via spacer) of ipratropium bromide at 1h, 12h and 24h of dosing.
89392744|NCT02131376|Active Comparator|Cortical renorrhaphy|Cortical renorrhaphy is performed after partial nephrectomy using a running barbed suture on MH (36mm) needle. Polymer locking clips are used to maintain tension. A base layer running stitch is performed prior to the cortical renorrhaphy.
89392745|NCT02131376|Experimental|Non-renorrhaphy|The suture closure of the renal cortex after tumor removal is omitted. A base layer running stitch only is performed for hemostasis and urine leak prevention.
89392746|NCT05375370|Experimental|Patient with hepatocellular carcinoma|Circulating tumor DNA dosage will be done to patients with hepatocellular carcinoma
89392747|NCT03626727|Experimental|Sodium Oxybate Oral Solution (Xyrem®)|4.5g of oral solution Xyrem will be given as a starting dose. This will be titrated up weekly to the final treatment dose of 9.0g. Participants will be on this final dose for 8 weeks.
89392748|NCT02237742|Experimental|PF-06427878|
89392749|NCT02131454|Experimental|Education and Inhalation technique training|Training in technique of drug inhalation in asthma and COPD patients and education about the role of inhalation therapy in the course of the disease.
88868954|NCT01254396|Active Comparator|Sildenafil ODT tablet 50 mg, Fasted|Treatment A: Sildenafil ODT tablet 50 mg, administered without water under fasted conditions.
89392750|NCT02131454|No Intervention|Education|Basic education about asthma and COPD.
89392751|NCT03604224||Canagliflozin Containing Treatment Regimens|No intervention will be administered as a part of this study. Participants with type 2 diabetes mellitus (T2DM) who were initiated on canagliflozin 300 milligram (mg) treatment 12 weeks back and meeting the inclusion criteria will be observed.
89392752|NCT01373905|Active Comparator|Sustained lung inflation|recruitment was done using CPAP of 30 Cm/ H2o for 30 seconds
88868955|NCT01254396|Experimental|Sildenafil ODT tablet 50 mg, Fed|Treatment B: Sildenafil ODT tablet 50 mg, administered without water under fed conditions.
88868956|NCT01254552|Experimental|Dotarem and Xenetix 350|
88868957|NCT01256034|Active Comparator|Group A|preoperative immunonutrition
88868958|NCT01256034|No Intervention|Group B|ordinary diet
88868959|NCT01244724|Experimental|Lexapro|escitalopram 10 mg or 20 mg/d
89392753|NCT01373905|Active Comparator|Stepwise PEEP elevation|Recruitment was done using stepwise elevation of PEEP followed by determination of the alveolar collapsing pressure
89392754|NCT02131610||Obstructive slep apnea patients|Patients with OSA
89392755|NCT02131610||Control group|Subjects without OSA
89392756|NCT04159753|Other|Spinal Cord Stimulator|Burst neurostimulation
89392757|NCT02126384|Experimental|pneumovax|Single arm, open label pneumovax vaccination of healthy subjects
89392758|NCT02035410|Active Comparator|Hydrogen peroxide pretreatment group|Hydrogen peroxide pretreatment perform before cardiac devices Implantation. It disinfects the cardiac devices pocket using Hydrogen peroxide gauze.
89392759|NCT02035410|No Intervention|Control group|No intervention group
89392760|NCT02404155|Experimental|Clozapine|
89392761|NCT05760235|Experimental|Liver transplant obese candidates|Subjects with an indication to liver transplantation that are not listed because of a high BMI according to the policy of the transplant Centre (cut-off 35 kg/m2)
89392762|NCT02127788||Micafungin|Patients affected with haemopathy (or affected with solid tumor for paediatric patients) under antifungal prophylaxis with micafungin.
88868960|NCT01256424|Experimental|HAL 5% with illumination|HAL PDT 5%
88868961|NCT01256424|Experimental|HAL 1% with illumination|HAL PDT 1%
88868962|NCT01256424|Experimental|HAL 0.2% with illumination|HAL PDT 0.2%
88868963|NCT01256424|Placebo Comparator|Placebo ointment without illumination|Placebo without illumination
88868964|NCT01257750|Experimental|Pazopanib|This is a single site, open label, safety and efficacy study of pazopanib (5mg/ml) where all 20 patients with corneal neovascularization in a single arm will receive pazopanib in one eye.
88868965|NCT01258374||Single arm with dual therapy|Dual therapy RAL 400 mg bid + DRV/r 800/100 mg QD
89392763|NCT03601650|Experimental|Mindful eating|Participants will be encouraged to focus on the sensory properties of their food every time they eat. This will be achieved via an audio recording that they will listen to in the laboratory at their first appointment and that they will have access to over the three-day intervention period. They will also receive a pack of envelopes to open over the intervention period that will also contain reminders to focus on the sensory properties of their food every time they eat.
89392764|NCT03601650|Active Comparator|Eating without distractions|Participants will be encouraged to eat their food without distractions every time they eat. This will be achieved via an audio recording that they will listen to in the laboratory at their first appointment and that they will have access to over the three-day intervention period. They will also receive a pack of envelopes to open over the intervention period that will also contain reminders to eat their food without distractions every time they eat.
89392765|NCT03601650|No Intervention|No strategy control|Participants will simply complete the measures
89392766|NCT05194423|Experimental|Tricuspid Valve Replacement System via jugular vein|Subjects who received transcatheter tricuspid valve replacement with LuX-Valve and delivery system via jugular vein will be included in this arm.
89392767|NCT03626649|Experimental|DiamondTemp Cardiac Ablation System|Cardiac ablation procedure
89392768|NCT02131688|Experimental|Mitoxantrone Hydrochloride Liposome|
89392769|NCT03604146||control group|Doctors and nurses were trained to treat chronic obstructive pulmonary disease according to the GOLD guidelines.Hospital patient cohort and outpatient cohort will be setted. Subjects were interviewed and received pulmonary function tests.
89392770|NCT03604146||Intervention group|Doctors and nurses will not receive any training from research team. Hospital patient cohort and outpatient cohort will be setted. Subjects were interviewed and received pulmonary function tests.
89392771|NCT01375465|Other|Dior|One arm observational registry using the Dior paclitaxel eluting balloon for the treatment of de novo ostial bifurcated lesions.
89392772|NCT03604068|Active Comparator|Active Group|Patients in this group will be treated with the currently used standard protocol for the control of post-operative pain as well as an active RecoveryRx Pulsed Short Wave Therapy device.
89392773|NCT03604068|Sham Comparator|Control Group|Patients in this group will be treated with the currently used standard protocol for the control of post-operative pain as well as a sham RecoveryRx Pulsed Short Wave Therapy device.
89392774|NCT02126462|Experimental|30 µg Na-GST-1 + 30 µg Na-APR-1 (M74)|30 µg Na-GST-1/Alhydrogel plus 5 µg GLA-AF co-administered with 30 µg Na-APR-1 (M74)/Alhydrogel plus 5 µg GLA-AF
89392775|NCT02126462|Active Comparator|Hepatitis B vaccine|Hepatitis B vaccine co-administered with saline
89392776|NCT02126462|Experimental|100 µg Na-GST-1 plus 100 µg Na-APR-1 (M74)|100 µg Na-GST-1/Alhydrogel plus 5 µg GLA-AF co-administered with 100 µg Na-APR-1 (M74)/Alhydrogel plus 5 µg GLA-AF
89392777|NCT03113071|Experimental|Newly diagnosed AML/MDS|For Group#1 a total of 37 patients with newly diagnosed MDL or MDS will be enrolled, including the eligible patients originally enrolled in the phase Ib portion (safe dose group) of the study, with the goal of determining the clinical activity of our experimental regimen. In the phase II segment, all new patients who are enrolled will initially be randomized in a 1 to 1 fashion to receive decitabine alone or decitabine plus digoxin for one cycle before receiving decitabine plus digoxin for all subsequent cycles for a total of 6 cycles.
89392778|NCT03113071|Experimental|Refractory or relapsed AML/MDS|or Group#2 the target will be to enroll a total of 60 patients with relapsed or refractory AML/MDS, including the eligible patients enrolled in the phase Ib group. This group will have randomization and treatments similar to Group#1.
89392779|NCT02131844|Experimental|Facilitated early mobilization|Early mobilization facilitated by a dedicated health professional
89392780|NCT02131844|Active Comparator|Usual care|Instructions about early mobilization covered in a preoperative education session
89392781|NCT03050307|Experimental|TAK-438 20 mg|Helicobacter Pylori positive (HP+) participants: TAK-438 20 mg tablet, twice daily (BID) along with lansoprazole placebo-matching, capsule BID in addition to bismuth-containing quadruple antibiotic therapy for the first 2 weeks. Following 2 weeks of eradication therapy participants received TAK-438 20 mg QD along with lansoprazole matching placebo 30 mg, capsule QD for up to 6 weeks. HP negative (HP-) participants: TAK-438 20 mg tablet, (QD) along with lansoprazole matching placebo, 30 mg capsule QD for up to 8 weeks.
89392782|NCT03050307|Experimental|Lansoprazole 30 mg|HP+ participants: Lansoprazole 30 mg, capsule, orally, BID and TAK-438 placebo-matching tablet, orally, BID along with bismuth-containing quadruple antibiotic therapy for first 2 weeks. Following 2 weeks participants received Lansoprazole 30 mg, capsule, orally, QD along with TAK-438 placebo-matching tablet, orally, QD for up to 6 weeks. HP- participants: Lansoprazole 30 mg, capsule, orally, QD along with TAK-438 placebo-matching tablet, orally, QD for up to 8 weeks.
89392783|NCT03601494|Active Comparator|Intervention|peri-neural platelet rich plasma injection under ultrasound guidance in addition to medical treatment.
89392784|NCT03601494|Placebo Comparator|Control|medical treatment only
89392785|NCT05760157||Modeling cohort|The first 425(425/567,75%) patients with acute ST-segment elevation myocardial infarction were used to establish a heart failure risk prediction model.
89392786|NCT05760157||Validation cohort|The latter 142(142/567,25%) patients with acute ST-segment elevation myocardial infarction were used to further validate the validity and predictive power of the risk model
89392787|NCT02126540|Experimental|Primary Cohort|Main cohort; treatment Arm with Pantheris Atherectomy System
89392788|NCT03603990|Experimental|Vitrectomy|"Patient with standard pars plana vitrectomy~During the first 6 month :Only Panretinal photocoagulation(if high-risk PDR or rubeosis iridis) may be given.~After First Six Months : All therapies for DME may be given at the discretion of the investigator"
89392789|NCT03603990|Active Comparator|Usual care|"Patients with usual care according to the investigator choice :~During the first 6 month : All therapies for DME may be given at the discretion of the investigator during the study, except a vitrectomy.~After First Six Months : All therapies for DME may be given at the discretion of the investigator, including a vitrectomy."
89392790|NCT02127866|Experimental|CHF 5259 25 µg plus Foster 100/6 µg|
89392791|NCT02127866|Experimental|CHF 5259 50 µg plus Foster 100/6 µg|
89392792|NCT02127866|Experimental|CHF 5259 100 µg plus Foster 100/6 µg|
89392793|NCT02127866|Active Comparator|Foster 100/6 µg|
88868966|NCT01260324||NAION cases|From the study population, patients with a claim associated with an ischemic optic neuropathy diagnosis code were identified as potential NAION cases (n = 3,732). From the potential NAION cases, definite and possible NAION cases were identified using medical record review and a claims algorithm (n=1,283). Data from definite and possible NAION cases contributed to the analysis.
89392794|NCT03601416|Experimental|Transplantation of Mesenchymal Stem Cell|Mesenchymal stem cell will be given to participants with moderate and severe bronchopulmonary dysplasia.
89392795|NCT03601416|Active Comparator|No Transplantation of Mesenchymal Stem Cell|Mesenchymal stem cell will be not given to participants with moderate and severe bronchopulmonary dysplasia.
89392796|NCT00806364||1|Blood, skin, stool/rectal swabs, buccal mucosa and bone marrow aspirate samples from approximately 250 healthy volunteer donors
89392797|NCT04071379|Experimental|HepB + Penta batch 1|Recombinant Hepatitis B + DTP-HB-Hib batch 1
88868967|NCT01260324||Controls|From the study population, patients without a claim associated with an ischemic optic neuropathy diagnosis code were randomly selected as controls (n = 20,000)
88868968|NCT01262118|Experimental|CP-690,550 (tasocitinib) 10 mg twice daily (BID)|
88868969|NCT01262118|No Intervention|Healthy Volunteers|No intervention
88868970|NCT01263132|Experimental|F0434|
88868971|NCT01263132|Active Comparator|Gabapentin|
88868972|NCT01264614|Experimental|Early stage dementia|Individuals with early stage dementia who attended a Adult Day Care Program at least twice a week. Participants engaged in a strengthening exercise program three to five times per week for 10 weeks.
88868973|NCT01264614|Active Comparator|Normative older adults|Normative older adults with no known neurological condition. Participants engaged in a strengthening exercise program three to five times per week for 10 weeks.
89392798|NCT04071379|Active Comparator|Hep B + Pentabio (registered)|Recombinant Hepatitis B + Pentabio (registered)
88868974|NCT01267422|Experimental|rAAV2-ND4|injection
89187087|NCT00674817|Placebo Comparator|400 microgrammes of GSK961081 and placebo|400 microgrammes of GSK961081 single-dose (via DISKUS Metered Dry Powder Inhaler/ MDPI) followed by cumulative doses (3 doses at 20 min intervals, administered via spacer) of placebo at 1h, 12h and 24h of dosing.
89392799|NCT03869697|Experimental|SCB-313|Cohorts in SAD phase: 5 mg, 10mg, 20mg, 40mg, 80 mg. Cohort in MAD phase: biological effective dose determined from SAD phase. 1 intrapleural injection of SCB-313 on Day 1 for the SAD cohorts, and 3 intrapleural injections of SCB-313 on Days 1, 2 and 3 for the MAD cohort.
89392800|NCT03550508|Experimental|Anti-RANKL Monoclonal Antibody|Anti-RANKL Monoclonal Antibody is to be injected subcutaneously 0.5 mg/kg, 1.0 mg/kg, 2.0 mg/kg or 3.0 mg/kg.
89392801|NCT03607578|Other|Control Group - Minimal Intervention|Minimal intervention
89392802|NCT03607578|Experimental|Protection Routine 1|
88868975|NCT01267656|Experimental|Lubricating and Rewetting Drops|Lubricating and Rewetting Drops, after one week of using the first rewetting drops, the subjects will return for an exam and crossover to the second rewetting drops for one week.
88868976|NCT01267656|Active Comparator|AMO Blink Contacts Lubricant Eye Drops|AMO Blink Contacts Lubricant Eye Drops, After one week of using the first rewetting drops, the subjects will return for an exam and crossover to the second rewetting drops for one week
89392803|NCT03607578|Experimental|Protection Routine 2|
89392804|NCT03607578|Experimental|Protection Routine 1+2|
89392805|NCT05760079|Experimental|Lactoferrin Supplementation|750mg lactoferrin (three 250mg tablets) per day for 30 days
89392806|NCT02127944||FERTILE GROUP|WOMEN HAVE NO INFERTILITY PROBLEMS AND HAVE AT LEAST ONE CHILD
89392807|NCT02127944||UNEXPLAINED INFERTILE GROUP|WOMEN WITH INFERTILITY PROBLEMS,NO HISTORY OF PREGNANCY AND HAVE NO CHILDREN
89392808|NCT01375543||Enrollees|Enrolled study participants in whom genetic sequencing was done
89392809|NCT03603834|Experimental|mFOLFOXIRI|"mFOLFOXIRI consists of the following combination of drugs:~Oxaliplatin, 85 mg/m2, IV over 2 hours Leucovorin, 400 mg/m2, IV over 2 hours Irinotecan, 150 mg/m2, IV over 90 minutes 5 FU, 400 mg/m2, IV bolus 5FU, 2400 mg/m2, IV infusion over 46 hours after 5FU bolus injection~each 14 day cycle, for 6 cycles"
89392810|NCT03551132|Experimental|Group 1|"Experimental group A supervised progressive moderate-to-high RTC program designed to induce muscular hypertrophy was performed. EG followed a progressive moderate-to-high RTC program for 12-weeks. The training program incorporated resistance exercise of six major regions and consisted of 3 training sessions per week on non-consecutive days (Monday, Wednesday and Friday).~All subjects performed the sets with moderate-intensity (8 to 12 repetitions) in each exercise and 30-60 seconds rest between sets. The load was increased during the 12 weeks from 60% 1-RM to high-intensity 80% 1-RM. The training load was increased when the individual could perform more than the prescribed number of repetitions (12 repetitions) followed the OMNI-RES scale and a hard effort perception level. Rest between sets was 1-2 minutes."
89392811|NCT03551132|No Intervention|Group 2|Control group The CG not participated in the RTC program.
89392812|NCT02400723|Experimental|BREATHE|Four weeks of DVD-delivered behavioral intervention. Intervention consists of diaphragmatic breathing and progressive muscle relaxation.
89392813|NCT02400723|Placebo Comparator|Psychoeducation|Four weeks of DVD-delivered psychoeducation as an attention placebo control.
89392814|NCT03601338|Active Comparator|Bemiparin group|"Women with high resistant index of umbilical artery received the intervention Bemiparin Sodium 2,500 IU anti Xa/0.2 ml solution for injection in pre-filled syringe provided for each woman . The injections were received daily since 20 weeks gestation and up to 24 hours before delivery~Other Name: Hibor; Laboratories Rovi pharmaceuticals"
89392815|NCT03601338|Placebo Comparator|control group|Normal umbilical arty resistant index group received only multivitamins and routine antenatal follow up
89392816|NCT02128022|Experimental|GLP-1 (7-36) amide and Glibenclamide|Patients will receive 5mg Glibenclamide orally prior to PCI and infusion of GLP-1 (7-36) amide 1.2 pmol/Kg/min during PCI
88868977|NCT01269372|Other|PillCam Colon 2 and Standard Colonoscopy|All subjects received Capsule Endoscopy (CE) using the PillCam Colon 2 followed by a standard colonoscopy.
88868978|NCT01270542|Experimental|Avastin Injection Group (AIG)|Subjects in this group will get single 0.05 mL intravitreal injection of bevacizumab 1.25 mg 3-7 days prior to surgery for tractional retinal detachment secondary to Proliferative Diabetic Retinopathy.
89187088|NCT00674817|Placebo Comparator|1200 microgrammes of GSK961081 and placebo|1200 microgrammes of GSK961081 single-dose (via DISKUS Metered Dry Powder Inhaler/ MDPI) followed by cumulative doses (3 doses at 20 min intervals, administered via spacer) of placebo at 1h, 12h and 24h of dosing.
89187089|NCT04078802|Experimental|VNOTES ARM|treatment of Vaginal prolapse with VNOTES surgery and apical suspension to the uterosacral ligaments.
89187090|NCT04078802|Experimental|Vaginal hysterectomy Arm|treatment of Vaginal prolapse with classic vaginal hysterectomy surgery and apical suspension to the uterosacral ligaments.
89187091|NCT02585570|Experimental|Low dose phenylephrine|phenylephrine 0.5 mcg/kg/min
89187092|NCT02585570|Experimental|High dose phenylephrine|phenylephrine 1.0 mcg/kg/min .
89187093|NCT02585570|No Intervention|Normal saline|normal saline for 5minutes
89392817|NCT02128022|Experimental|Glibenclamide alone|Glibenclamide 5 mg orally prior to PCI
89392818|NCT02128022|Active Comparator|GLP-1 (7-36) amide|GLP-1 (7-36) amide
89392819|NCT02128022|No Intervention|Saline control|0.9% saline only (no treatment with GLP-1 (7-36) amide or glibenclamide)
89392820|NCT03256045|Experimental|Treatment-panobinostat, carfilzomib, dexamethasone,chemo assay|Patients receive panobinostat PO on days 1, 3, 5, 15, 17, and 19. Patients also receive carfilzomib IV and dexamethasone PO on days 1, 2, 8, 9, 15, and 16. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood and/or bone marrow samples for testing via in vitro chemosensitivity assay.
89392821|NCT03551054|Experimental|Healthy for Two, Healthy for You|Remotely delivered behavioral health coaching in pregnancy and postpartum
89392822|NCT03551054|Active Comparator|Pregnancy Health Education|Single health education visit with study staff member
89392823|NCT03603756|Experimental|Cohort 1|Patients with advanced or metastatic esophageal squamous cell carcinoma are to receive SHR-1210 with apatinib and irinotecan injection in cohort 1.
89392824|NCT03603756|Experimental|Cohort 2|Patients with advanced or metastatic esophageal squamous cell carcinoma are to receive SHR-1210 with apatinib and paclitaxel liposome plus nedaplatin in cohort 2.
89392825|NCT02372409|Experimental|Arm A (MRI-guided laser ablation)|"MLA is a minimally invasive laser surgery currently FDA approved for cytoreductive treatment of brain tumors, both primary and metastatic. MLA employs a small incision in the scalp and skull, through which a thin laser probe is inserted and guided by MR imaging to the core of a tumor mass where it delivers hyperthermic ablation from the core to the rim.~Participants will undergo DCE and DSC-MRI imaging at the following time points:~no more than 3 weeks prior to MLA (OPTIONAL)~within approximately 4 days after MLA~2-4 weeks after MLA~Every 12 weeks (+/- 7 days) for the first year or until disease progression"
88868979|NCT01270542|Sham Comparator|Sham Injection Group (SIG)|Subjects in this group will get a sham injection 3-7 days prior to surgery for tractional retinal detachment secondary to Proliferative Diabetic Retinopathy.
88868980|NCT01271244|Active Comparator|PTSD Depression Group|Escitalopram 10-20 mg/day
88868981|NCT01271244|Active Comparator|Major Depression Group|Escitalopram 10-20 mg/day
88868982|NCT01271868|Experimental|IB1001|
88868983|NCT01271946|Other|Diagnostic Procedure|
89392826|NCT02372409|Experimental|Arm B (MRI-guided laser ablation, doxorubicin, etoposide)|"MLA is a minimally invasive laser surgery currently FDA approved for cytoreductive treatment of brain tumors, both primary and metastatic. MLA employs a small incision in the scalp and skull, through which a thin laser probe is inserted and guided by MR imaging to the core of a tumor mass where it delivers hyperthermic ablation from the core to the rim.~Within 7 days of MLA (range 2-14 days) doxorubicin will be given intravenously on an outpatient basis weekly for 6 weeks at a dose of 25 mg/m^2 over 5-30 minutes~Following the completion of doxorubin, etoposide 50 mg/m^2/day will be given orally for 21 days of each 28-day cycle (treatment can continue up to 24 cycles)~Participants will undergo DCE and DSC-MRI imaging at the following time points:~no more than 3 weeks prior to MLA (OPTIONAL)~within approximately 4 days after MLA~2-4 weeks after MLA~every 8 weeks (+/- 7 days) until 2 years have elapsed or disease progression, whichever comes first"
89392827|NCT02126618||women with lower urinary tract symptoms|
89392828|NCT03603678|Experimental|Part A single dose BAY2253651|Single dose BAY2253651
89392829|NCT03603678|Placebo Comparator|Part A single dose Placebo|Single dose matching placebo
89392830|NCT03603678|Experimental|Part B multiple dose BAY2253651|Multiple dose BAY2253651 on 5 consecutive nights
89392831|NCT03626259|Other|losartan and amlodipine|Individuals with SAH grade 1 or 2 without triple pharmacological therapy.
89392832|NCT03626259|Active Comparator|Losartan|Individuals with SAH grade 1 or 2 without triple pharmacological therapy.
89392833|NCT03551366|No Intervention|Control|Subjects in this group will continue with their usual PE curriculum for 15 weeks.
89392834|NCT03551366|Experimental|Linear|Subjects in this group will receive a linear PE curriculum for 15 weeks. Linear Pedagogy is underpinned by neuro-computation approach to motor learning such as information processing theory and prescribes that an ideal movement pattern exists for each task and that the teacher's role is to help learners recreate that pattern. Furthermore, theorists have suggested that learning is a gradual, linear process. This linear pedagogy is supported by a teaching and learning approach that includes both prescriptive and repetitive actions, utilising technical demonstrations that provide learners with a 'visual template or criterion model' for the desired skill . As a consequence, a PE pedagogy has developed whereby the teacher's role is to make all the decisions, and the learner's role is to follow their instructions on cue - a teacher-led approach to PE.
89392835|NCT03551366|Experimental|Nonlinear|Subjects in this group will receive a nonlinear PE curriculum for 15 weeks. Nonlinear pedagogy is grounded in Ecological Dynamics theory. Ecological dynamics regards learners as complex adaptive systems which afford opportunities for action from their environment and generate movement solutions to satisfy the combination of personal, environmental and task constraints imposed upon them. According to nonlinear pedagogy, the teacher's role is to design learning experiences that create behavioural symmetry between learning and the performance environment. The teacher is a facilitator and manipulates constraints to channel the learner's physical development, while learners are left free to experiment and select the movement solutions that best answer their individual needs. This child-focused, less prescriptive approach may enhance a child's intrinsic motivation by offering freedom to choose, and an emphasis on exploration and problem solving.
89392836|NCT03601260|Other|Gout Patients|Allopurinol 100 mg-300mg/day as secondary treatment in gout patients
89392837|NCT03717597|Experimental|Intervention|Participants will complete an initial assessment within 2 weeks prior to starting the course or during the first class. The course will include 10 sessions conducted on a weekly basis. Following completion of the course, participants will again complete another assessment during the last class or within 2 weeks of course completion. Participants may be invited to complete assessments at 3- and 6-months following course completion.
89392838|NCT03603522|Experimental|BioGaia-DSM17938 then Placebo Comparator|28 days treatment with BioGaia-DSM17938, followed by 28 days washout and then crossover to 28 days placebo comparator treatment.
89392839|NCT03603522|Placebo Comparator|Placebo Comparator then BioGaia DSM17938|28 days treatment with placebo comparator treatment, followed by 28 days washout and then crossover to 28 days treatment with BioGaia DSM17938.
88868984|NCT01272882|Experimental|Adults with ARDS or ALI|Adults with PaO2/FiO2 ratio less than 300. Consented patients will be placed on EIT monitor. The only intervention is the addition of Electrical Impedance Tomography monitoring using the Chest belt with 16 electrodes connected to the EIT device. No changes to standard patient care will occur other than collecting EIT monitor data.
88868985|NCT01272960|Active Comparator|Interval Insertion|Will receive Mirena at 4-8 weeks post-partum after vaginal delivery.
88868986|NCT01272960|Experimental|Post-Placental Mirena Insertion|Will receive Mirena insertion within 10 minutes of delivery of placenta
88868987|NCT01273896|Experimental|STA-9090|This will be a monotherapy, open-label phase 2 study of STA-9090 in patients who have metastatic breast cancer.
89392840|NCT05193253||Solitary HCC <= 3 cm|Treatment-naive patients with HCC <= 3 cm
88868988|NCT01274520|Experimental|Experimental: Hypothermic Machine Perfusion Group|The Medtronic Portable Bypass System (PBS®) with Model 550 Bioconsole and the BioCal® blood temperature control module will be used for machine perfusion of liver grafts. These products are commercially available and used in clinical practice for cardiopulmonary bypass and extracorporeal membrane oxygenation. The Medtronic system utilizes an atraumatic centrifugal pump that can deliver the flow rates approximating portal venous flow in human livers, and it has modules for online membrane oxygenation, and electronic flow measurement.
88868989|NCT01274520|No Intervention|Matched control group|The proposed study is a matched cohort design. Subjects will be matched with 24 historical control patients who received similar cold stored ECD grafts. Subjects will be matched on known covariates including donor age, donation after cardiac death, steatosis, both warm and cold ischemia times, recipient age, MELD score and disease etiology. Additional analyses will be performed on historical control blood and/or tissue samples previously collected and stored in the study's sample repository.
88868990|NCT01275300|Placebo Comparator|Placebo phase I|Subjects were given 5 days of placebo. On day 5, they were given a single dose of niacin (600 mg) administered 30 minutes after the last dose of placebo. Urine was collected sequentially for analysis. The same subjects came back for cross-over study and were assigned to Aspirin group. There was a 2-week washout period between each treatment.
89392841|NCT05265182|Experimental|Semi-CAVE|The Semi-CAVE (Figure 2) will use two screens positioned at a corner of the room, each with a ceiling-mounted short throw projector in front. The user will sit in the middle of the area, giving them a viewing angle of roughly 180 degrees. The user will interact with the system through motion sensors positioned at the corners of the area. To one side of the area will be a sufficiently powerful computer running the software. The projectors will be connected to this computer via HDMI cables or similar. The Semi-CAVE may be offered as a solution for rehabilitation centers.
89392842|NCT05265182|Experimental|Head-mounted display or HMD|The HMD will be a commercially available device that uses handheld controllers in addition to the head mounted apparatus, to control movement while in the VE. This device could provide a cheaper, more practical alternative to patients with mobility issues and environmental limitations brought about by the pandemic, since this can be used at home. Any patient, with supervision from their caregivers, will be able to use the applications using only the HMD system.
89392843|NCT03601104|Active Comparator|HIET (n = 15)|High intensity eccentric training: A high intensity (80% isometric peak) eccentric training of the knee extensors in the isokinetic will be performed during 6 weeks, 3 times a week.
89392844|NCT03601104|Experimental|HIET-BFR (n= 15)|High intensity eccentric training with blood flow restriction (BFR): A high intensity eccentric (80% isometric peak) training of the knee extensors in isokinetic will be performed, associated with a pressure cuff placed in the proximal thigh (40% of absolute occlusion pressure) for 6 weeks, 3 times a week.
89392845|NCT03601104|Experimental|LIET-BFR (n = 15)|Low intensity eccentric training with blood flow restriction (BFR): A low intensity eccentric (40% isometric peak) training of the knee extensors in isokinetic will be performed associated with a pressure cuff placed in the proximal thigh (40% absolute occlusion pressure) for 6 weeks, 3 times a week.
89392846|NCT03601104|Active Comparator|LIET (n= 15)|Low intensity eccentric training: A low intensity (40% isometric peak) eccentric training of the knee extensors in the isokinetic will be performed during 6 weeks, 3 times a week.
89392847|NCT01375621||AHS cohort|population of S. aureus asymptomatic rural Iowans
89392848|NCT01375621||Non-AHS group|symptomatic S. aureus infections in rural Iowans.
88868991|NCT01275300|Active Comparator|Aspirin phase I|Subjects were given 5 days of 81 mg aspirin. On day 5, they were given a single dose of niacin (600 mg) administered 30 minutes after the last dose of aspirin or placebo. Urine was collected sequentially for analysis.
88868992|NCT01275300|Active Comparator|Aspirin phase II|In phase II study, subjects were given 5 days of 81 mg aspirin. On day 6, they were given a single dose of niacin (600 mg) administered 24 hours after the last dose of aspirin. Urine was collected sequentially for analysis
88868993|NCT01276314|Experimental|anti- TNF-a treatment|"Meet the conditions of inclusion and exclusion, seek the consent of the patient, and fill out the ICF~Fill out the case report form~Blood test and physiological assessment, and do TNF-alpha serum concentration and peripheral blood mononuclear spherical cDNA expression analysis~Etanercept administration:~The experimental group received the first dose of Etanercept (25 mg) i.v., followed by two doses per week and maintain 2 to 3 weeks"
88868994|NCT01276314|Active Comparator|control group|"Meet the conditions of inclusion and exclusion, seek the consent of the patient, and fill out the ICF~Fill out the case report form~Blood test and physiological assessment, and do TNF-alpha serum concentration and peripheral blood mononuclear spherical cDNA expression analysis~Drug administration:~The control group of drug delivery: systemic intravenous steroid therapy, the dose is equivalent to prednisolone 1-1.5 mg / kg / day, according to the treatment of 3-4 days gradually decreased dose."
88868995|NCT01276860|Other|Psychomotor Vigilance Testing|The purpose of this study is to examine the use of psychomotor vigilance testing (PVT) as a tool in the diagnosis and prediction of pediatric obstructive sleep apnea. PVT simply involves responding to a light by pressing a button on a small handheld device. It is a simple measure of reaction time.
88868996|NCT01280058|Experimental|Arm I (wild-type reovirus, carboplatin, paclitaxel)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1 and wild-type reovirus IV over 60 minutes on days 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
88868997|NCT01280058|Experimental|Arm II (carboplatin, paclitaxel)|Patients receive paclitaxel and carboplatin as in Arm I. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may crossover to Arm I.
88868998|NCT01280604|Experimental|Intervention 'Fenofibrate 54mg'|Subjects in the dose reduction group will be converted from 160mg of fenofibrate to 54mg of fenofibrate daily for 6-8 weeks.
89392849|NCT02131922|Placebo Comparator|Hygenization Treatment|Basic oral hygiene instructions Supragingival plaque removal
88868999|NCT01280604|No Intervention|Control 'Fenofibrate 160mg'|Subjects in the control group will be remain on 160mg of fenofibrate daily for the duration of the study (6-8 weeks).
89392850|NCT02131922|Experimental|Intensive Treatment|One-Stage Full-Mouth Disinfection. Scaling and root planing, four quadrants in one session. Extraction of radix relicta. Subgingival chlorhexidine (PerioKIN) (0.2%) in all pockets. Oral hygiene instructions.
89392851|NCT03551288|Experimental|Food Effect Cohort|Twelve healthy male subjects 18 to 45 years of age, inclusive, will be administered a single oral dose of SUVN-911 on Day 1 (Period 1) and Day 8 (Period 2) with and without food in a crossover manner.
89392852|NCT03551288|Experimental|Gender Effect Cohort|Eight healthy female subjects 18 to 45 years of age, inclusive, will be administered a single dose of SUVN-911.
89392853|NCT03551288|Experimental|Age Effect Cohort|Eight healthy male subjects ≥ 65 years of age will be administered a single oral dose of SUVN-911.
88869000|NCT01282086||Adults requiring anesthesia for surgery|Adult patients requiring general anesthesia for surgery
88869001|NCT01282242|Experimental|IV rt-PA|open-label
88869002|NCT01282710||Pregnant, In Labor|
88869003|NCT01283022|Experimental|MVI 200|MVI 200 mcg vaginal insert
88869004|NCT01284426||Chronic urticaria|Chronic urticaria, Natural history
88869005|NCT01285050|Other|pre post ART|HCV and HIV viral load pre and post antiretroviral therapy (ART). ART is the intervention and the comparison is the HIV and HCV viral load reductions as determined by RT-PCR after administration of interferon alfa in each instance (before and after ART)
88869006|NCT01286454|Experimental|A|4 mg fesoterodine IR beads in capsule under fasting condition
88869007|NCT01286454|Experimental|B|4 mg fesoterodine 10% coated ER beads in capsule under fasting condition
88869008|NCT01286454|Experimental|C|4 mg fesoterodine 15% coated ER beads in capsule under fasting condition.
88869009|NCT01286454|Experimental|D|4 mg fesoterodine 20% coated ER beads in capsule under fasting condition.
88869010|NCT01286454|Experimental|E|4 mg fesoterodine ER tablets under fasting condition.
88869011|NCT01286454|Experimental|F|4 mg fesoterodine TBD % coated ER beads in capsule under fed condition.
89392854|NCT02132000|Active Comparator|tamoxifen|tamoxifen,20mg/day
89392855|NCT02132000|Experimental|toremifene|toremifene,60mg/day
88869012|NCT01287078|Experimental|Inhaled Cyclosporine in Lung Transplant and HSCT Recipients|Subjects with Bronchiolitis Obliterans Syndrome (BOS) received cyclosporine inhalation solution (CIS) 150 mg, three times weekly during weeks 1-5. Dose escalated to 300 mg three times weekly from weeks 6-8. Study drug administration ended at week 19.
88869013|NCT01290978|Active Comparator|ChloraPrep|Applied ChloraPrep on the application site per manufacturer's instruction
89392856|NCT02126696||Patients on anti-retroviral therapy|The cohort consists of patients on first-line anti-retroviral therapy since at least 6 months, followed at one of the facilities involved in the study.
88869014|NCT01290978|Active Comparator|DuraPrep|Apply DuraPrep to the application site per manufacturer's instruction
88869015|NCT01291056|Active Comparator|Clomphine|Each participant will take assigned medication (clomiphene citrate 50mg or placebo) on days 3-7 of her menstrual cycle.
88869016|NCT01291056|Placebo Comparator|Placebo|Each participant will take assigned medication (clomiphene citrate 50mg or placebo) on days 3-7 of her menstrual cycle.
88869017|NCT01292304|Experimental|Tolvaptan|Tolvaptan 15 mg tablet once daily for 7 days followed by Tolvaptan 30 mg (two 15 mg tablets) once daily according to efficacy and tolerability
88869018|NCT01292538|Experimental|Erchonia GLS 532nm|532nm green laser light therapy.
88869019|NCT01292538|Sham Comparator|Placebo laser|Sham light output with no therapeutic benefit
88869020|NCT01293396|Active Comparator|Biphasic Insulin Aspart 30|35% of their usual total daily insulin dose before the standardized breakfast and 25% prior to lunch
88869021|NCT01293396|Active Comparator|Biphasic Insulin Aspart 70|35% of their usual total daily insulin dose before the standardized breakfast and 25% prior to lunch
89392857|NCT03118765|Experimental|Test Treatment T1: GSP304 Inhalation Solution|
88869022|NCT01293396|Active Comparator|Insulin Aspart|35% of their usual total daily insulin dose before the standardized breakfast and 25% prior to lunch
88869023|NCT01294098|No Intervention|PCA only|this group will only get a pain control anesthesia pump to use for post-operative pain
88869024|NCT01294098|Experimental|PCA and femoral nerve block|this group will be receiving a femoral nerve block during surgery and have a PCA post-operatively
88869025|NCT01294098|Experimental|PCA + hematoma block|patient will receive hematoma block during surgery
88869026|NCT01295112|Sham Comparator|Group 1|Active bevacizumab (Avastin®) and Sham Ozurdex®
88869027|NCT01295112|Active Comparator|Group 2|Active bevacizumab (Avastin®) and Active Ozurdex®
88869028|NCT01296360|Active Comparator|>14 months to <2 years|IXIARO 0.25 ml i.m. (milliliter, intramuscular)
88869029|NCT01296360|Active Comparator|>3 years - <18 years|IXIARO 0.5 ml i.m (milliliter, intramuscular)
88869030|NCT01298544|Other|All subjects|
89392858|NCT03118765|Experimental|Test Treatment T2: GSP304 Inhalation Solution|
88869031|NCT01299090|Experimental|Treatment Group|All subjects enrolled were in the treatment group.
88869032|NCT01301742|Active Comparator|BI 10773|Subject to receive one single dose BI 10773
88869033|NCT01301742|Experimental|BI 10773 plus gemfibrozil|Subject to receive one single dose BI 10773 plus 600 mg gemfibrozil bid for 5 days
88869034|NCT01303224|Experimental|Ibodutant low dose|Oral tablet, to be given once daily in fasting conditions.
88869035|NCT01303224|Experimental|Ibodutant intermediate dose|Oral tablet, to be given once daily in fasting conditions.
88869036|NCT01303224|Experimental|Ibodutant high dose|Oral tablet, to be given once daily in fasting conditions.
88869037|NCT01303224|Placebo Comparator|Placebo|Oral tablet, to be given once daily in fasting conditions.
88869038|NCT01304082|Placebo Comparator|normal saline|
88869039|NCT01304082|Active Comparator|lidocaine|
88869040|NCT01304082|Experimental|alkalinized lidocaine|
88869041|NCT01304238||lepirudin|lepirudin treated subjects
88869042|NCT01304238||danaparoid|danaparoid treated subjects
88869043|NCT01304238||argatroban|argatroban treated subjects
88869044|NCT01304238||fondaparinux|fondaparinux treated subjects
88869045|NCT01305252|Active Comparator|tadalafil alone|tadalafil 40mg QD(Tadalafil 20 mg QD PO increasing to 40 mg QD as tolerated).
88869046|NCT01305252|Active Comparator|tadalafil and treprostinil inhalations|Treprostinil inhalation QID starting at 3 breaths per inhalation & gradually increasing to 9 breaths.Each breath provides approximately 6 mcg of treprostinil.Tadalafil 20 mg QD PO increasing to 40 mg QD as tolerated.
89392859|NCT03118765|Experimental|Test Treatment T3: GSP304 Inhalation Solution|
89392860|NCT03118765|Placebo Comparator|Test Treatment T4: GSP304 Placebo Inhalation Solution|
89392861|NCT03118765|Active Comparator|Test Treatment T5: Spiriva® Respimat® inhalation spray|
89392862|NCT02252198||Investigational|• Participants will be asked to provide a total of three sputum samples over Days 1 and 2. The intent is for all samples to be collected before the subject starts any form of TB treatment. The first specimen (S1) should be 2 ml or greater in volume, and the second and third specimens (S2 and S3) should each be 1 ml or greater in volume. On Day 1, each participant will be asked to submit one spot sputum (S1) after enrollment and a second spot sputum after at least 2 hours (S2). Participants will be instructed to come back the following day (Day 2) and provide a third spot sputum (S3). In the event that a participant fails to return on Day 2, S3 may be collected a maximum of 7 days after enrollment, provided that no TB treatment has been initiated.
88869047|NCT01307748|Experimental|stress reducing aroma|aroma with reported stress reducing effects
89392863|NCT03603444||First study group: patients with PHPT|"Patients aged between 18-90 years old with primary hyperparathyroidism who had been diagnosed in the Unit of Endocrinology of the University of Modena and Reggio Emilia.~Exclusion criteria for both cases and controls will be: age younger than 18 or older than 90 years; severe renal and liver diseases (i.e. glomerular filtration rate (GFR) <30 ml/min); hyperparathyroidism secondary to Vitamin D deficiency; active metabolic bone disease (e.g. Paget's disease of the bone, osteomalacia, rickets, etc); any type of cancer; malnutrition; severe obesity (BMI > 40 kg/m2); a history of gastrointestinal malabsorption; sarcoidosis; hypercortisolism, diabetes insipidus, hyperthyroidism, pseudohypoparathyroidism; familial hypocalciuric hypercalcemia (FHH); treatment with steroids, active forms of vitamin D (calcitriol, ergocalciferol, etc), thiazides, phosphate binders, lithium, cinacalcet, bisphosphonates, and denosumab."
88869048|NCT01307748|Placebo Comparator|Placebo aroma 1|
88869049|NCT01307748|Placebo Comparator|Placebo aroma 2|
88869050|NCT01308060|Experimental|Botulinum Toxin type A|During part A, efficacy and safety parameters will be assessed for Azzalure vs. placebo
88869051|NCT01308060|Placebo Comparator|Placebo|During part A, efficacy and safety parameters will be assessed for Azzalure vs. placebo
88869052|NCT01308294|Experimental|2 vaccine injections in 1 limb|9 patients initially planned: patients received peptides with IMP321/LAG-3Ig and Montanide in 2 injections sites at 5 cm distance from each other 2 vaccine injections in same limb (vaccine 1 : NY-ESO-1, MAGE-3.A2, NA-17 peptides + IMP321 + Montanide) (vaccine 2 : Melan-A, MAGE-A3-DP4 peptides + IMP321 + Montanide)
88869053|NCT01308294|Experimental|2 vaccine injections in distinct limbs|Groupe2: 2 vaccine injections in different limb should include 9 patients that were initially planned: patients received the same vaccine in 2 syringes injected each in a distinct limb (vaccine 1: NY-ESO-1, MAGE-3.A2, NA-17 peptides + IMP321 + Montanide) (vaccine 2: Melan-A, MAGE-A3-DP4 peptides + IMP321 + Montanide)
88869054|NCT01308294|Experimental|"2 vaccine injections in distinct limbs"|Groupe3: 2 vaccine injections in distinct limb should include 9 patients that were initially planned; due to premature trial termination, no patients could be enrolled. Patients of this group should have received the same vaccine but without the MHC class II peptide (MAGE-A3)
88869055|NCT01308450||Single Arm, Non ADHD Control Group|Single site, single visit study. Subjects will be administered Standard Rating Scales (Defined) and the Quotient ADHD System Test (Adolescent and Adult Version). Subject's assessed to be Non-ADHD will be eligible to have their Quotient tests added to the Quotient Adolescent and Adult Normative Database.
88869056|NCT01308840|Experimental|Panitumumab|Panitumumab 6mg/kg on days 1 and 15 of every cycle (28 days); Gemcitabine 1000mg/m2 on days 1 and 15 of every cycle (28 days); Oxaliplatin 85mg/m2 on days 1 and 15 of every cycle (28 days)
88869057|NCT01308918||GlideScope DLT intubation|Patients having a thoracic surgery (non cardiac) via either thoracoscopy or thoracostomy. Patients were all 18 years old or over, and have read, understood and signed an informed consent at the preoperative evaluation or on surgery morning.
88869058|NCT01310400|Experimental|Inflexal 0.5 mL|
88869059|NCT01310400|Experimental|Inflexal 0.25 mL|
88869060|NCT01310400|Experimental|Agrippal 0.25 mL|
88869061|NCT01311102|Experimental|2% Lidocaine liquid|1.33cc of 2% liquid lidocaine infused in endo cervix and endometrium
88869062|NCT01311102|Placebo Comparator|Normal Saline|1.33cc of normal saline infused in endo cervix and endometrium
88869063|NCT01312038|Experimental|simethicone|125 mg tablet
88869064|NCT01312038|Placebo Comparator|placebo|chewable calcium tablet
88869065|NCT01312272|Placebo Comparator|Inactive nasal spray|A placebo nasal spray will be prepared to be otherwise identical to the active treatment nasal spray except lacking oxytocin. The ingredients in the inactive nasal spray are mannitol, glycerin, and preserved water.
88869066|NCT01312272|Experimental|Intranasal Oxytocin|Oxytocin nasal spray (40 units/ml) will be administered in a single intranasal dose of 40 IU. Its formula is: oxytocin 1 unit/mg mannitol trituration 0.2Gm + glycerin USP 0.1ml + preserved water 5ml.
88869067|NCT01312818|Experimental|Chemotherapy|Bortezomib IV Vorinostat PO Dexamethasone PO Intrathecal Methotrexate Imatinib Mesylate PO (for Ph+ ALL patients only)
88869068|NCT01313520|Experimental|Infliximab|3 mg/kg of Infliximab intravenous infusion
88869069|NCT01313520|Placebo Comparator|Placebo|saline via intravenous infusion
88869070|NCT01313910|Experimental|ImmunoLin®|8-week treatment course
88869071|NCT01315002|Active Comparator|Nicotine Patch|Transdermal nicotine patch
88869072|NCT01315002|Placebo Comparator|Placebo patch|Placebo patch
88869073|NCT01315158|Active Comparator|Propofol+Benzo/Opioids|"If the patient is randomized into this arm the recommended Versed and Fentanyl doses are standardized:~Recommended Versed:~a. Prior to intubation~patient is < 50 kg = 1 mg Versed~patient is 50-75 kg = 1.5 mg Versed~patient is > 75 kg = 2 mg Versed~Recommended Fentanyl~Prior to intubation = 0.5 ug/kg~Total procedural dose = 1 ug/kg"
88869074|NCT01315158|Active Comparator|Propofol Alone|"The patients randomized into the sedation with propofol alone are able to cross over if they are unable to be successfully sedated under propofol alone. The the recommended doses before considering crossover are standardized:~Induction Dose: 2-2.5 mg/kg~Maintenance Dose: 0.1-0.2 mg/kg/min"
88869075|NCT01317030||Contact Lens Wear|Senofilcon A Lenses, using Sensitive Eyes Saline Solution and/or Biotrue Multipurpose Solution
88869076|NCT01317030||Non-Contact Lens Wear|
88869077|NCT01318278|Active Comparator|Dopamine treatment|Dopamine treatment beginning at 5 mcg/kg/min and titrated by 5 mcg/kg/min to effect up to maximum of 20 mcg/kg/min
88869078|NCT01318278|Active Comparator|Vasopressin treatment|Arginine Vasopressin treatment beginning at 0.01 units/kg/hr and titrated up by 0.01 units/kg/hr to effect up to a maximum of 0.04 units/kg/hr
88869079|NCT01318278|No Intervention|Comparison Arm|Infants who did not require vasopressor support for hypotension during the first 24 hours of life
88869080|NCT01318356|Experimental|Cognitive behavioral therapy|
88869081|NCT01318356|Experimental|Doxycycline|
88869082|NCT01318356|Placebo Comparator|Placebo|
88869083|NCT01322022|Experimental|Parent Training|Behavioral Intervention
88869084|NCT01322022|Active Comparator|Parent Education|5 Sessions of individual parent education
88869085|NCT01324128|Experimental|PA21 (2.5 g tablet)|
88869086|NCT01324128|Active Comparator|Sevelamer carbonate|
88869087|NCT01324128|Other|PA21-1 (1.25 g tablet)|
88869088|NCT01324518|Experimental|Low dose of ORM-12741|
88869089|NCT01324518|Experimental|High dose of ORM-12741|
88869090|NCT01324518|Placebo Comparator|Placebo|
88869091|NCT01326780|Experimental|1.2% Facial Cream|1.2% JNJ 10229570-AAA
88869092|NCT01326780|Experimental|2.4% Facial Cream|2.4% JNJ 10229570-AAA
88869093|NCT01326780|Experimental|3.6% Facial Cream|3.6% JNJ 10229570-AAA
88869094|NCT01326780|Placebo Comparator|0% Facial Cream|Vehicle control
88869095|NCT01328184|Experimental|Reference|multiple doses of Microgynon
88869096|NCT01328184|Active Comparator|Test|multiple doses of Microgynon + BI 10773
88869097|NCT01328964||Children Ages 4-11 with asthma|Children ages 4 to 11 with a diagnosis of asthma receiving a prescription for an asthma therapy
88869098|NCT01329198|Active Comparator|Delayed Activation - Deep Brain Stimulation (DBS)|"Delayed Activation stimulation in which no electrical charge is delivered through the Neuropace RNS (responsive neurostimulation) system for the first 59 days. On Day 60, all subjects will be programmed to receive active stimulation.~There will be a one month post-operative period during which stimulation is not turned on.~One month post-implant, subjects will be randomized one to one in a blinded fashion to receive active or sham stimulation.~By Day 60, all subjects will be programmed to receive active stimulation. Physiological data will be collected for Specific Aim 2 of the study.~Both the sham and the active groups (3 subjects in each group) will undergo identical programming procedures at 30 and 60 days."
89187094|NCT02583932|Experimental|Meaning-Making intervention (MMi)|The MMi is a brief, individualized and manualized therapeutic approach based on post-trauma literature and designed to facilitate a search for meaning following a cancer diagnosis. The MMi consists of 3-4 weekly sessions of 30-90 min each with an intervener (psychologist, social worker, or nurse) who provides the necessary ingredients to foster a good therapeutic alliance (i.e., trust, warmth, empathy, neutrality, and authenticity), encourages self-exploration and systematically addresses different levels of meaning (i.e., situational, global, existential, historical).
89187095|NCT02583932|Placebo Comparator|Empathic Visitor (EV)|Empathic visitors will meet with patients over 3-4 weekly sessions of 30-90 minutes as in the experimental group. They will provide the basic ingredients for fostering a good therapeutic relationship (i.e., trust, warmth, empathy, neutrality and authenticity) without further intervention or probing. The empathic listener will be specifically instructed to avoid initiating discussions about meaning (e.g., perspective-taking, how the patient interprets his/her feelings and thoughts, understands his/her illness and meaning in life), and focus discussions on what is currently happening (rather than on the interface between past and present). If the patient initiates discussions about these topics, the visitor will simply listen without further intervening.
89187096|NCT02583932|No Intervention|Usual Care Control Group|Treatment as usual in tertiary care hospital, typically medically-focused. All participants will be free to use hospital- or community-based supports, which will be tracked in all groups throughout the study by questionnaire and through a chart review. Both recruiting centres include well established psychosocial oncology services including psychiatrists, psychologists and social workers.
89187097|NCT02583854|Active Comparator|Hemostasis achieved by TR Band|After the transradial procedure and randomization TR Band will be applied to achieve hemostasis. Patient experience and complications after the application will be measured.
89187098|NCT02583854|Experimental|Hemostasis achieved by RY Stop|After the transradial procedure and randomization, RY Stop will be applied to achieve hemostasis. Patient experience and complications after the application will be measured.
89187099|NCT02583074|Experimental|Stimulation Group|Patients in 'Neurostimulation Group' will receive subthalamic nucleus deep brain stimulation for 3 months.
89187100|NCT02583074|Sham Comparator|Sham-stimulation Group|Patients in 'Sham-stimulation Group' will receive sham stimulation of subthalamic nucleus for 3 months.
88869099|NCT01329198|Active Comparator|Immediate Activation - Deep Brain Stimulation (DBS)|"Active stimulation through the Neuropace RNS (responsive neurostimulation) system at settings to maximally reduce tic frequency & severity, while limiting potential stimulation-induced side-effects.~There will be a one month post-operative period during which stimulation is not turned on.~One month post-implant, subjects will be randomized one to one in a blinded fashion to receive active or sham stimulation.~By Day 60, all subjects will be programmed to receive active stimulation. Physiological data will be collected for Specific Aim 2 of the study.~Both the sham and the active groups (3 subjects in each group) will undergo identical programming procedures at 30 and 60 days."
89187101|NCT00764907|Experimental|Arm I|During reinduction, patients receive 1 course of protocol II.
88869100|NCT01330134|Experimental|lidocaine onto skin prior to lidocaine subcutaneous injection|1-2ml of 1% lidocaine dripped onto the surface of the skin immediately prior to subcutaneous injection of 1% lidocaine.
88869101|NCT01330134|Active Comparator|lidocaine subcutaneous injection alone|1% lidocaine subcutaneous injection alone by standard approach
88869102|NCT01330290||Neupro® Treatment|Routine treatment (2, 4, 6, 8, 10, 12, 14, 16 mg/24 hours) as per approved label in European Union (EU)/in accordance with the terms of the local marketing authorization for Neupro®
88869103|NCT01331304|Other|Li + APT|Study participants will take lithium in addition to any other medications recommended by the study physician.
88869104|NCT01331304|Other|QTP + APT|Study participants will take quetiapine in addition to any other medications recommended by the study physician.
88869105|NCT01331694||COPD|copd patients 65 years and older
88869106|NCT01333098|Experimental|mifepristone|1 week mifepristone or placebo (followed by 3 weeks open label mifepristone)
88869107|NCT01333488|No Intervention|Conventional Therapy|
88869108|NCT01333488|Experimental|Hypothermia|Subjects will have their core body temperatures lowered to 34C.
89530467|NCT03244579|Experimental|Dietary intervention CHO Counting & DASH|The recommended intakes of energy, protein (15-25%), fat (30-40%) and carbohydrate (40-50%) will be similar to that in carbohydrate counting diet which mentioned above. DASH diet food choices will be inserted in the diet of the participants assigned for the combined diet of DASH and carbohydrate counting. The emphasis will be more on the fruits and vegetables group (>8 servings/day), whole grains (at least half of the amount of the total servings of cereals; 6-8 servings/day), fat free dairy products (2-3 servings/day), lean meat and plant proteins (0-2 servings/day) and nuts (5-7 servings/week). From the fat group olive oil will represent the main type of fat (20-25% of total fat %). Adequate intake of sodium (2000mg) will be applied into participants' diet.
88869109|NCT01333488|Experimental|Hypothermia plus supplemental magnesium sulfate infusion|
88869110|NCT01335204|Experimental|Cabazitaxel plus bavituximab|Cabazitaxel (25 mg/m2) will be administered IV on Day 1 of each 21-day treatment cycle. Bavituximab (3 mg/kg) will be administered as an IV infusion on a weekly basis (Cycle 1 Day 2, all other cycles Day 1; day 8; day 15) for 8 cycles.
88869111|NCT06244979|Experimental|Intervention|Patients will undergo a PET/CT scan at t=60 min after a single intravenous injection of a fixed dose of 100 MBq +/- 10% [68Ga]Ga-DFO-B (gallium-68-deferoxamine) which contains 100 µg deferoxamine (DFO-B).
88869112|NCT06244966|Experimental|Any client attending clinic for venous blood sampling|Any client attending clinic for venous blood sampling for sexually transmitted disease diagnostics will also collect capillary blood using a finger prick
88869113|NCT06244953|Experimental|Regular screening with needs-guided palliative care treatments|The patient continues to receive clinical care from the cardiologist, as well as palliative care treatments that are based upon his/her reported distress and concerns.
88869114|NCT06244953|Other|Usual Care|Patient is referred by cardiologist to palliative care.
88869115|NCT06244940|Other|Whole Genome Sequencing (WGC) from subject samples|
88869116|NCT06244927||Only 20 patients undergo replantation following penile amputation were investigate, only 1group|Patients undergo surgery.
88869117|NCT06244901|Experimental|Exoskeleton Walking|Walking with ankle exoskeleton assistance
88869118|NCT06244901|Placebo Comparator|Normal walking|Walking under normal conditions (no exoskeleton)
88869119|NCT06244888|Experimental|System Identification|All participants who lose at least 3% of their initial body weight will be asked to participate in a system identification experiment every day for 52 weeks.
88869120|NCT06244875||Patients followed in the memory clinic|
88869121|NCT06244862|Experimental|Interventional medicinal product|
88869122|NCT06244849|Other|Patient with Crohn disease (n=150)|CD patients requiring to undergo an ileo-colonoscopy for routine investigations (assessment of disease activity or complications as stricture or screening of colorectal cancer for CD)
88869123|NCT06244849|Other|Patient without Crohn disease (n=20)|Non-IBD patients (control) requiring to undergo an ileo-colonoscopy for routine investigations (screening for colorectal cancer or diagnosis of irritable bowel syndrome for controls).
88869124|NCT06244836|No Intervention|Baseline group|Patients included in the Catalan Nosocomial Infection surveillance Program (VINCat) program, and operated on colorectal surgery before bundle implementation, from January 2011 to June 2016
88869125|NCT06244836|Experimental|Implementation of a six-measures Bundle-1 (Bundle 1 Group)|Bundle-1 period after the implementation of a six-measure bundle, from July 2016 to June 2018
88869126|NCT06244836|Experimental|Implementation of a ten-measures Bundle-2 (Bundle 2 Group)|Bundle-2 period after the implementation of a ten-measure bundle, from July 2018 to December 2022
88869127|NCT06244823|Experimental|Fremanezumab|"Patients will be treated with 225 mg of subcutaneous injections of Fremanezumab per month.~Patients will do four monthly additional hospital visits. During each visit, occurrence of any adverse event will be interrogated; clinical situation will be analyzed and Fremanezumab will be administered. Visits will be performed at weeks 0, 4 and 8. Last visit will be performed after 12 weeks, without Fremanezumab injection."
88869128|NCT06244810|Experimental|lingual retainer made of fiber made using cad cam Technique|lingual retainer made of fiber manufactured using CAD-CAM technique applied to the lingual surfaces of the mandibular incisors and evaluated every month over a period of 6 months.
88869129|NCT06244810|Experimental|lingual retainer made of metal made using cad cam Technique|lingual retainer made of metal manufactured using CAD-CAM technique applied to the lingual surfaces of the mandibular incisors and evaluated every month over a period of 6 months
88869130|NCT06244810|Experimental|Traditional lingual retainer made of braided stainless steel wire|lingual retainer made of braided stainless steel wire applied to the lingual surfaces of the mandibular incisors and evaluated every month over a period of 6 months.
88869131|NCT06244797|Placebo Comparator|CONTROL GROUP|Patient group in which no material is placed in the extraction socket after impacted tooth extraction. There will be 25 patients in this group.
88869132|NCT06244797|Active Comparator|L-PRF (leukocyte-platelet rich fibrin):|The patient group in which L-PRF will be placed in the extraction socket after impacted tooth extraction. There will be 25 patients in this group. Device information to be used: Electromag M815P centrifuge device.
88869133|NCT06244797|Active Comparator|H-PRF (horizontal-platelet rich fibrin)|The patient group in which H-PRF will be placed in the extraction socket after impacted tooth extraction. There will be 25 patients in this group. Device information to be used: Electromag M815A2 centrifuge device.
89187102|NCT00764907|Experimental|Arm II|During reinduction, patients receive 2-3 course of protocol III and interim maintenance therapy.
89392864|NCT03603444||Second study group: patients with HypoP|"Subjects with reduced serum P, but normal serum Ca, will be enrolled among HIV-infected patients on HAART treatment from the Modena cohort.~Exclusion criteria for both cases and controls will be: age younger than 18 or older than 90 years; severe renal and liver diseases (i.e. glomerular filtration rate (GFR) <30 ml/min); hyperparathyroidism secondary to Vitamin D deficiency; active metabolic bone disease (e.g. Paget's disease of the bone, osteomalacia, rickets, etc); any type of cancer; malnutrition; severe obesity (BMI > 40 kg/m2); a history of gastrointestinal malabsorption; sarcoidosis; hypercortisolism, diabetes insipidus, hyperthyroidism, pseudohypoparathyroidism; familial hypocalciuric hypercalcemia (FHH); treatment with steroids, active forms of vitamin D (calcitriol, ergocalciferol, etc), thiazides, phosphate binders, lithium, cinacalcet, bisphosphonates, and denosumab."
89392865|NCT03603444||Control group|"Patients that underwent biochemical examination by primary care physician or by endocrinologist in order to assess their calcium-phosphorus metabolism state with normal results.~Exclusion criteria for both cases and controls will be: age younger than 18 or older than 90 years; severe renal and liver diseases (i.e. glomerular filtration rate (GFR) <30 ml/min); hyperparathyroidism secondary to Vitamin D deficiency; active metabolic bone disease (e.g. Paget's disease of the bone, osteomalacia, rickets, etc); any type of cancer; malnutrition; severe obesity (BMI > 40 kg/m2); a history of gastrointestinal malabsorption; sarcoidosis; hypercortisolism, diabetes insipidus, hyperthyroidism, pseudohypoparathyroidism; familial hypocalciuric hypercalcemia (FHH); treatment with steroids, active forms of vitamin D (calcitriol, ergocalciferol, etc), thiazides, phosphate binders, lithium, cinacalcet, bisphosphonates, and denosumab."
89392866|NCT02128100|Experimental|Folririnox with SBRT|"Folfirinox~Oxaliplatin 85 mg/m² for over 2 hours,~Leucovorin 400n mg/m² for over 2 hours,~Irinotecan 180 mg/m² for over 90 minutes, along with Leucovorin infusion~Fluorouracil 400 mg/m² as a fast infusion over 15 minutes~Fluorouracil 2400 mg/m² as a slow infusion over 46 hours~SBRT 5 treatments of stereotactic body radiation therapy (SBRT) over the course of two weeks with a minimum of 36 hours in between each treatment."
89392867|NCT03603366||Primary prevention|"Patients in Italy who are eligible to use low-dose aspirin for primary prevention of CVD and CRC.~Subgroups:~Patients eligible for and using low-dose aspirin who are at 20% ten-year CVD risk for primary prevention of CVD~Patients eligible for and not using low-dose aspirin who are at 20% ten-year CVD risk for primary prevention of CVD"
89392868|NCT03603366||Secondary prevention|"Patients in Italy who are eligible to use low-dose aspirin for secondary prevention of CVD and CRC.~Subgroups:~Patients eligible for and using low-dose aspirin for secondary prevention of CVD~Patients eligible for and not using low-dose aspirin for secondary prevention of CVD"
89392869|NCT03603366||Physicians|Physicians from Italy with experience recommending low-dose aspirin for primary and/or secondary prevention of CVD and CRC.
89392870|NCT02128178|Active Comparator|ENOXAPARIN 2 HOURS BEFORE|Giving 40 mg enoxaparin SQ 2 hours before surgery and daily for 10 days thereafter
89392871|NCT02128178|Active Comparator|Enoxaparin 40 mg 12 hours before|Enoxaparin 40 mg 12 hours before surgery and once daily for 10 days thereafter
89392872|NCT03606954|Active Comparator|Combination topical corticosteroid|"The combination topical corticosteroid will be applied to specific and marked sites on the forearms (on the flexor side of the forearm- 5*5 cm with a distance of 3 cm) - two sites on both forearms of every subject (4 sites in total). The nature of this application method will enable the measurement of the level of potency of each drug, in a manner that is comparative, neutralizing thus the influence of inter-subject variability.~The drugs will be topically applied (50 microliter on each site) for 16 hours, utilizing an occlusive dressing bandage such as Tegaderm. The vasoconstriction test will be preformed both before and after drug application. The vasoconstriction in each subject will be graded on the Olsen scale"
89392873|NCT03606954|Active Comparator|Non-combination topical corticosteroid|"The non-combination topical corticosteroid will be applied to specific and marked sites on the forearms (on the flexor side of the forearm- 5*5 cm with a distance of 3 cm) - two sites on both forearms of every subject (4 sites in total). The nature of this application method will enable the measurement of the level of potency of each drug, in a manner that is comparative, neutralizing thus the influence of inter-subject variability.~The drugs will be topically applied (50 microliter on each site) for 16 hours, utilizing an occlusive dressing bandage such as Tegaderm. The vasoconstriction test will be preformed both before and after drug application. The vasoconstriction in each subject will be graded on the Olsen scale"
89392874|NCT02132078||Lung transplant recipients with uncomplicated diverticulitis|Retrospective data analysis of treatment, outcome and recurrency-rate
89392875|NCT02132078||Lung transplant recipients with complicated diverticulitis|Retrospective data analysis of treatment, outcome and recurrency-rate
89392876|NCT03600870|Experimental|Open Label|All subjects enrolled will be assigned to receive midodrine. The initial starting dose will be midodrine 5mg orally three times a day. After 7-10 days, patients will increase the dose to 10mg three times a day as tolerated if no adverse effects occur. Treatment duration will be 6 months.
89392877|NCT02128256|Experimental|Cerament G injection|Cerament G is injected to fill a bone defect after debridement of the infected bone.
89003677|NCT04840108|Experimental|Support Person Coaching Intervention|Support persons in the intervention arm will receive existing written materials on effective social support strategies for smoking cessation. Materials will be sent via postal mail. Support persons in this arm will also complete a one-session coaching intervention (15-25 minutes) delivered virtually by research staff via phone.
89003678|NCT04840108|Active Comparator|Support Person Written Materials|Support persons in the intervention arm will receive existing written materials on effective social support strategies for smoking cessation. Materials will be sent via postal mail.
89003679|NCT04829500|No Intervention|Pre-Intervention Baseline Collection Phase|All sites will start with a baseline collection phase without exposure to the intervention, consistent with the stepped wedge cluster randomized trial design. A sequential randomized crossover to the intervention (MAP-VA) will be assigned, which cannot be reversed once it has been introduced.
89187103|NCT00764907|Experimental|Arm III|During reinduction, patients are receive 2 courses of protocol II and interim maintenance therapy OR 3-block consolidation regimen and 1 course of protocol II.
89187104|NCT02585492|Active Comparator|head-of-bed elevated 15°|Mother's head-of-bead elevated 15°. Intervention: Head-of-bed elevated 15° during 2 hours after the delivery.
89187105|NCT02585492|Experimental|head-of-bed elevated 45°|Mother's head-of-bead elevated 45°. Intervention: Head-of-bed elevated 45°during 2 hours after delivery.
89392878|NCT02128334||Patients with advanced prostate carcinoma|
89392879|NCT01375699|Experimental|Sildenafil + doxorubicin|"Patients receive sildenafil citrate PO QD* beginning at least 2 days prior to scheduled first dose of doxorubicin hydrochloride and continuing until 2 weeks after last scheduled dose of doxorubicin hydrochloride. Patients also receive doxorubicin hydrochloride IV as clinically indicated and as prescribed by treating provider.~NOTE: *Patients receive sildenafil citrate PO TID on days that doxorubicin hydrochloride is also administered."
89392880|NCT01375699|Active Comparator|Doxorubicin-based chemotherapy|Patients receive doxorubicin hydrochloride IV as clinically indicated and as prescribed by treating provider.
88869134|NCT06244719|Experimental|Vibrotactile Stimulation|Participants wear vibrotactile stimulation shirts and gloves for 5 hours per day, 7 days per week, during their stay at the rehabilitation unit, which is expected to be between 2-3 weeks. Participants wear the devices after conventional therapy is done for the day.
89392881|NCT02252276|Experimental|Experimental|performed the same exercises and manual therapy during 4 weeks
89392882|NCT02252276|Active Comparator|Control|performed proprioceptive and strengthening exercises during 4 weeks
88869135|NCT06244719|No Intervention|Control|Participants undergo conventional therapy only.
88869136|NCT06244706|Other|Peristent Pain Patients|"Patients suffering from persistent pain (pain lasting for at least three months), already treated with an opioid medication (treatment A) and to whom the treating physician is about to prescribe a CNS-acting add-on drug such as an antiepileptic, an antidepressant, a benzodiazepine or an alpha2-agonist (treatment B: the combination treatment), will be included.~Evaluation of drug combination pain relief and its impact on daily life activities as therapeutic effects, and on drug-induced sedation and drug-induced cognitive dysfunction (memory and attention) as adverse effects will be evaluated through online (REDCap) patient-reported outcomes at the beginning of the study (day 0), 10 days and 3 months."
88869137|NCT06244667|Active Comparator|cervical faset median block with lidocaine|cervical faset median block with lidocaine
88869138|NCT06244667|Active Comparator|cervical faset median block with prilocaine|cervical faset median block with prilocaine
88869139|NCT06244654|Other|Standart Anesthesia management|In the non-VR group, the standard anesthesia procedure will be followed. Brachial plexus nerve block will be performed with a 50mm peripheral block needle (Vygon echoplex+ 22Gx50mm) with a mixture of 2% lidocaine and 0.5% bupivacaine (10 mL each) prepared as 20ml. After waiting for a sufficient time, the nerve block effectiveness of the patients will be measured by Modified Broomage scale and pinprick. Additional sedative agents may be applied to both groups at the discretion of the anesthesiologist and will be recorded. Anesthesia management will be applied to both groups in accordance with the standard working order of the Anesthesia clinic.
88869140|NCT06244654|Experimental|VR group|Oculus Quest 2 VR virtual reality glasses and wired over-ear headphones will be used for patients to hear the sounds of the immersive environment and to block the sounds coming from the operating room environment. Brachial plexus nerve block will be performed with a 50mm peripheral block needle (Vygon echoplex+ 22Gx50mm) with a mixture of 2% lidocaine and 0.5% bupivacaine (10 mL each) prepared as 20ml. After waiting for a sufficient time, the nerve block effectiveness of the patients will be measured by Modified Broomage scale and pinprick.Additional sedative agents may be applied to both groups at the discretion of the anesthesiologist and will be recorded. Anesthesia management will be applied to both groups in accordance with the standard working order of the Anesthesia clinic.
88869141|NCT06244641|Experimental|Intervention|
88869142|NCT06244628|Experimental|Iguratimod|Oral administration of Iguratimod, 25mg twice daily.
88869143|NCT06244615|Experimental|Verum mouth and throat rinse|Formulation containing WO 6607 for oral administration (rinse and gargle).
88869144|NCT06244615|Placebo Comparator|Placebo mouth and throat rinse|Formulation containing WO 6608 for oral administration (rinse and gargle).
88869145|NCT06244576|Experimental|Radically Open Dialectical Behaviour Therapy (RO-DBT)|RO-DBT consists of a 1 hour weekly individual session and a 2,5 hour weekly group skill training during 39 weeks in accordance with the published treatment manual and session guides for RO-DBT. For skills training, the 31 patients will be divided into four equal groups in terms on number.
88869146|NCT06244563|Experimental|Face mask with Hybrid-Hyrax and Alt-RAMEC procedure|The experimental group was comprised of 15 patients submitted to the alternate rapid maxillary expansion and constriction (alt-RAMEC) procedure for expansion protocol with a hybrid-hyrax expander as anchorage in the maxillary arch. The Face mask was used.
88869147|NCT06244563|Experimental|Face mask with Bonded RME and Alt-RAMEC procedure|The experimental group was comprised of 15 patients submitted to the alt-RAMEC procedure for expansion protocol with a bonded RME as anchorage in the maxillary arch. The Face mask was used.
89187106|NCT00672633|Experimental|A , Experimental|Lovaza, 4 grams/day orally for 6 months
89392883|NCT03606720|Experimental|group(A) low level laser therapy|composed of 30 patients who received pelvic stabilization exercises and low level laser therapy For 12 sessions over six week's period by 2 sessions per week.
89392884|NCT03606720|Active Comparator|group(B) pelvic stabilization exercises only|composed of 30 patients who pelvic stabilization exercises only For 12 sessions over six week's period by 2 sessions per week.
89392885|NCT03606720|Active Comparator|group (C) low level laser therapy only|composed of 30 patients who low level laser therapy only For 12 sessions over six week's period by 2 sessions per week.
89187107|NCT00672633|Placebo Comparator|Corn Oil Pill|Corn Oil Pill, 4 pills/day orally for 6 months
89187108|NCT00672555|Experimental|Pilonidal Sinus T. With Limberg F.|All patients treated by excision and covering of the defect by a Limberg-flap, who gave their informed consent to participate in the study, as there is only one study group.
89392886|NCT01373983|Other|ziconotide|
89392887|NCT03550430|Experimental|ADR neurofeedback|Ten ADR neurofeedback training sessions. The first five sessions comprise four training blocks. The latter five sessions consists of five training blocks each. All training blocks are seven minutes in duration. Participants take between two to three sessions each week.
88869148|NCT06244563|Experimental|Face mask with Hybrid-Hyrax and routine protocol|The experimental group was comprised of 15 patients submitted to routine palatal expansion procedure (routine) with a hybrid-hyrax expander as anchorage in the maxillary arch. The Face mask was used.
88869149|NCT06244563|Active Comparator|Face mask with Bonded RME and routine protocol|The active comparator group was comprised of 15 patients who submitted to the routine expansion procedure with a bonded RME as anchorage in the maxillary arch. The Face mask was used.
88869150|NCT06244524|No Intervention|Well-ventilated bedroom|The participants will stay and sleep for eight hours in a well-ventilated bedroom.
88869151|NCT06244524|Experimental|Non-ventilated bedroom|The participants will stay and sleep for eight hours in a closed bedroom.
88869152|NCT06244498||TXA|Tranexamic acid was administered to the participants at a dose of 1.0 g during the induction of anaesthesia and immediately after the operation.
88869153|NCT06244498||Non-TXA|Tranexamic acid were not administred to the participants .
88869154|NCT06244485|Experimental|Part 1: Dose Escalation Phase (Sub-protocol B)|Participants with previously treated, advanced, or metastatic HER2-positive gastric or gastro-esophageal junction (GEJ) adenocarcinoma will receive valemetostat in combination with T-DXd.
88869155|NCT06244485|Experimental|Part 1: Dose Escalation Phase (Sub-protocol C)|Participants with previously treated, locally advanced, unresectable, or metastatic non-squamous non-small cell lung cancer (NSCLC) with or without actionable genomic alteration(s) will receive valemetostat in combination with datopotamab deruxtecan (Dato-DXd).
88869156|NCT06244485|Experimental|Part 2: Dose Expansion (Sub-protocol B)|Participants with previously treated, advanced, or metastatic HER2-positive gastric or gastro-esophageal junction (GEJ) adenocarcinoma will receive valemetostat at the RDE in combination with T-DXd at RDE.
89535404|NCT03077997|Experimental|Space from Diabetes|Participants will be assigned the 'Space from Diabetes' intervention in a supported mode for 8 weeks. Participants are assigned a clinical supporter, who will be a psychological well-being practitioner in an NHS Mental Health Service. As the participant works through the programme content, the supporter will provide them with a review of their progress and interactions with the platform 6 times over the 8 week supported period.
89535405|NCT03319121|Experimental|Empirical therapy group|Participants will be given extended release lansoprazole (Dexlansoprazole, Takeda Pharmaceuticals, Japan) 60 mg daily for 2 weeks
88869157|NCT06244485|Experimental|Part 2: Dose Expansion (Sub-protocol C)|Participants with previously treated, locally advanced, unresectable, or metastatic non-squamous non-small cell lung cancer (NSCLC) with or without actionable genomic alteration(s) will receive valemetostat at the RDE in combination with datopotamab deruxtecan (Dato-DXd).
88869158|NCT06244472|Experimental|Healthy subjects|Healthy volunteers aged between 18 and 70 years, without neurological or psychiatric or sleep disorders
88869159|NCT06244472|Experimental|Subjects with concussion|Male athletes volunteers with concussion aged between 18 and 40 years, without neurological or psychiatric or sleep disorders other than cerebral concussion.
88869160|NCT06244446||SBRT+Atezolizumab+Bevacizumab|
88869161|NCT06244446||Atezolizumab+Bevacizumab|
88869162|NCT06244433||SUDI cases|Sudden unexpected death in infant (SUDI) cases registered within the French National Registry of SUDI
88869163|NCT06244433||Parents|Both parents of identified SUDI
88869164|NCT06244420||Patients|patients with a histological diagnosis of soft tissue or bone malignant myoepithelioma treated from 1998 to 2021.
88869165|NCT06244394||NPC patients with RTLI after IMRT|nasopharyngeal carcinoma patients with radiation-induced temporal lobe injury after intensity-modulated radiation therapy
88869166|NCT06244394||NPC patients without RTLI after IMRT|nasopharyngeal carcinoma patients without radiation-induced temporal lobe injury after intensity-modulated radiation therapy
88869167|NCT06244368|Experimental|GVM±R|Patients with relapsed or refractory aggressive NHL will undergo GVM±R therapy
89535406|NCT03319121|Experimental|Guided therapy group|Participants will be give Dexlansoprazole 30 mg daily for GERD, 60 mg daily for GERD with erosive esophagitis for 8 weeks and Theophylline SR 250 mg daily for functional chest pain for 4 weeks.
89535407|NCT02487407|Experimental|ODM-109|ODM-109 capsules for oral administration
89535408|NCT02487407|Placebo Comparator|Placebo for ODM-109|Placebo ODM-109 capsules for oral administration
89535409|NCT03078153|Experimental|Financial Incentive|Provided financial incentive at 3-month and 6-month follow-up visits
88869171|NCT06244329|Experimental|High frequency repetitive transcranial magnetic stimulation|10 Hz rTMS is applied to the left dorsolateral prefrontal cortex (DLPFC). The individual DLPFC is located using the Beam F3 method. The stimulation intensity is 100% of the resting motor threshold of the left primary motor cortex. Each session of stimulation lasts for around 9 mins. We apply 6-session rTMS, with 2-3 times per week.
88869172|NCT06244329|Experimental|Sham repetitive transcranial magnetic stimulation|Sham rTMS is applied to the left dorsolateral prefrontal cortex (DLPFC). The individual DLPFC is located using the Beam F3 method. The stimulation intensity is 20% of the resting motor threshold of the left primary motor cortex, which is deemed completely ineffective in modulating brain excitability. We apply 6-session sham rTMS, with 2-3 times per week.
88869173|NCT06244303|Active Comparator|Group I|manual Tooth Brush + Colgate Total TP (0.454% SnF, 1100 ppm F) Brush 2 x day / 2 mins Colgate Total Mouthwash (CPC+Zn) Swish 20 mL / 30 secs
88869174|NCT06244303|Placebo Comparator|Group II|Manual Toothbrush +Colgate Great Regular Flavor Toothpaste Brush w/ full ribbon, 2x day / 2mins
88869175|NCT06244290|Active Comparator|Group I|Colgate SnF Toothpaste Colgate Adult Extra Clean soft-bristle toothbrush
88869176|NCT06244290|Active Comparator|Group II|Sensodyne Extra Whitening Toothpaste Colgate Adult Extra Clean soft-bristle toothbrush
88869177|NCT06244290|Placebo Comparator|Group III|Colgate Fluoride Toothpaste (CDC) Colgate Adult Extra Clean soft-bristle toothbrush
88869178|NCT06244277|Experimental|Chinese medicine group|Participants received Suanzaoren Decoction and Huanglian Wendan Decoction orally twice daily for 4 weeks. Subjects who had previously taken Western medicine hypnotics continued to take them, and those who did not take them did not add Western medicine hypnotics.
89187109|NCT02583152||MPS patient cohort|Participants with Mucopolysaccharidosis. types I-IV, VI and VII will be recruited from the paediatric and adult ophthalmology. Participants over the age of three who are able to comply and be investigated.
89187110|NCT00764985||Syncope|
88869179|NCT06244277|Active Comparator|Western medicine group|Participants received cognitive behavioral therapy, if for various reasons can not accept cognitive behavioral therapy, or have received cognitive behavioral therapy is not effective, according to the doctor to consider drug treatment, taking Zolpidem Tartrate Tablets 0.25mg/kg, the maximum dose was 10mg / day ; according to the doctor 's clinical consideration, anxiety and depression drugs can be added. For patients under 18 years of age, under the careful consideration of the doctor for drug treatment, taking Zolpidem tablets, 10mg / day
88869180|NCT06244251|Experimental|TU-LESS for myomectomy|Patients complaint of symptoms resulting from uterine fibroids, such as abnormal vaginal bleeding, frequent micturition, lower abdominal pain, constipation, etc or patients with uterine fibroids which were identified accidentally during routine body examination who consulted at our center for surgical removal of the fibroids. In the meantime, the diagnosis of uterine fibroids should be reconfirmed by at least one radiological examination at our center. The patients in the experiment group were those who received transumbilical laparoendoscopic single site surgery (TU-LESS) for myomectomy.
88869181|NCT06244251|Active Comparator|MPLS for myomectomy|Patients complaint of symptoms resulting from uterine fibroids, such as abnormal vaginal bleeding, frequent micturition, lower abdominal pain, constipation, etc or patients with uterine fibroids which were identified accidentally during routine body examination who consulted at our center for surgical removal of the fibroids. In the meantime, the diagnosis of uterine fibroids should be reconfirmed by at least one radiological examination at our center. The patients in the experiment group were those who received multiport laparoscopic surgery (MPLS) for myomectomy.
88869182|NCT06244225|Experimental|HAIC + Sintilimab + Donafenib|HAIC combine with Sintilimab and Donafenib
88869183|NCT06244212|Active Comparator|Demonstration|Observe a live demonstration instructing how to dispense 1 fingertip unit (FTU) of medication (triamcinolone cream) per 1% body surface area
88869184|NCT06244212|Experimental|Mobile Application|Additional mobile application that provides instructions to apply the medication (triamcinolone cream)
88869185|NCT06244212|Other|Written/verbal instructions only|Standard of care written/verbal instructions only
88869186|NCT06244199|Experimental|T2CR Intervention|Participants randomized to the T2CR intervention arm will receive a transitional care program designed to supplement usual care following an acute heart event. Study personnel will follow T2CR Intervention participants for the course of the 12-month study period to assess endpoints in comparison to the Usual Care arm.
88869187|NCT06244199|Active Comparator|Usual Care|Participants randomized to the Usual Care are will receive usual care at the discretion of their clinical providers. Study personnel will follow Usual Care participants for the course of the 12-month study period to assess endpoints in comparison to the T2CR intervention arm.
88869188|NCT06244186|Experimental|Probiotics|Take one packet (6 grams) of powder orally once daily. The probiotics contain fruit juice powder (strawberry, cranberry, black currant), sucralose, anhydrous citric acid, maltodextrin, silicon dioxide, and Lactobacillus delbrueckii subsp. Bulgaricus.
88869189|NCT06244186|Placebo Comparator|Placebo|Placebo contains fruit juice powder (strawberry, cranberry, black currant), sucralose, anhydrous citric acid, maltodextrin, and silicon dioxide.
88869190|NCT06244160|Experimental|Intervention|High flow oxygen therapy delivered via nasal cannalue
88869191|NCT06244160|No Intervention|Control|Standard care with oxygen therapy as required.
88869192|NCT06244134|Active Comparator|Study group (group A) will be injected with ultrasound guidance in temporomandibular joint .|uses of ultrasound as a guiding tool for temporomandibular joint injection
89392888|NCT03550430|Active Comparator|BTR neurofeedback|Ten BTR neurofeedback training sessions. The first five sessions comprise four training blocks. The latter five sessions each consists of five training blocks. All training blocks are seven minutes in duration. Participants take between two to three sessions each week.
89392889|NCT03550430|Active Comparator|Diary Control Group|Daily diary completion for two weeks in the period between baseline and end-point assessments (total period baseline to end-point = four weeks).
89392890|NCT03603132|Active Comparator|Hetrombopag Olamine A|health subjects received 7.5 mg Hetrombopag Olamine while fasting.
89392891|NCT03603132|Active Comparator|Hetrombopag Olamine B|health subjects received a high-fat meal one hour after taking7.5 mg Hetrombopag Olamine
88869193|NCT06244134|Placebo Comparator|control group(group B) conventional non guided injection in temporomandibular joint|without ultrasound guidance only anatomical landmark will be followed during injection
89187111|NCT00758901||1 ROCC Knee prosthesis|Consecutive series of patients with ROCC Knee prosthesis.
89392892|NCT03603132|Active Comparator|Hetrombopag Olamine C|health subjects received a high-fat meal two hours after taking7.5 mg Hetrombopag Olamine
89392893|NCT03600636|Other|Control|
89392894|NCT03600636|Other|antiphospholipid syndrome patients|
89392895|NCT05812638|Experimental|Mental Imagery|For mental imagery, the calm and nice atmosphere isrequired for the patientsto focus on the details while sitting on a chair. The audiotape and headphones are given to the patients. The audiotape tape comprised of three phases. The first phase is relaxation phase. The patient has to do the first phase actively. In this phase patients have asked to do the deep breathing exercises while sitting on a chair and then contract their lower limb muscles from distal to proximal. The second phase is task-oriented phase. The patient has to imagine him performing the tasks.
89392896|NCT05812638|Active Comparator|Virtual Reality|"The virtual reality training will be given through Kinect connected with Xbox 360.~The Xbox games used are 20,000 water leaks, reflex ridge and river rush. The spacious environment will be given and walker are sometimes required for assistance. The LED and system are 3 feet away from patients. The VR training will be given to the both control and experimental groups"
89530468|NCT03244579|No Intervention|General Dietary guidlines|the general dietary advice and diet that will be prescribed by hospital for participants
89530469|NCT03244267|Active Comparator|Standard Education|Participants randomized to this arm will receive the standard education provided to patients about the importance of taking aspirin to prevent thromboembolic events after orthopedic surgery.
89530470|NCT03244267|Experimental|Medication Reminder App + Standard Education|Participants randomized to this arm will use a smartphone app with preset reminders to take aspirin to prevent thromboembolic events after orthopedic surgery in addition to usual postoperative discharge teaching.
89392897|NCT05812625|Experimental|Interventional Group A|• Group A will receive conservative baseline treatment consisted of hot pack therapy for 10 minutes and traction for 8 minutes with Myokinetic stretching technique. Subject will be in supine lying on the plinth and the head will be placed at the edge of the plinth by the therapist. Then with one hand the therapist held the neck in cervical lateral flexion to the opposite side so as to achieve the stretching of the trapezius muscle. Myofascial release by applying sustained finger pressure for 5-10 s on the involved trapezius was given. A gentle myofascial stretching force was applied to take up slack and sustained until a release occurred .The MST protocol comprised of three sets of 4 stretches with 5 seconds rest period between the stretches. Treatment will be provided twice a week for 8 weeks.
89392898|NCT05812625|Active Comparator|Interventional Group B|• Group B will be treated by conventional baseline treatment with Post-isometric Relaxation Exercises. Cervical paraspinal post isometric relaxation will be performed with the patient supine, while the therapist will slowly lift the patient's head toward the ceiling. Once a comfortable stretch will be felt, the patient is asked to push their head back (with approximately 10% of their strength), while the therapist will resist the movement; thus, creating an isometric contraction. This position is held for 8-10 seconds. The patient will be asked to inhale deeply and, upon exhalation, will be instructed to relax while the therapist will lift the patient's head a little further towards the ceiling. The protocol will be comprised of three sets of post isometric relaxation with 5 seconds rest period. Treatment will be provided twice a week for 8 weeks.
89392899|NCT05812612||COVID-19 infection in patients with autoimmune liver disease|To study the incidence of COVID-19 infection, COVID-19, disease degree and prognosis in patients with autoimmune liver disease treated with different drugs, and to explore the impact of UDCA on COVID-19 infection, disease occurrence and clinical outcome.
89392900|NCT05812599|Experimental|COVID Test Learning Module|In the experimental condition, participants will respond to survey questions (pre-exposure) before being presented with four narrative scenarios, questions, and accompanying messages about COVID testing (exposure), followed by post-test survey questions about COVID testing behaviors (post-exposure).
89392901|NCT05812599|No Intervention|Control|In the control condition, participants will respond to survey questions (pre-exposure) and post-test survey questions about COVID testing behaviors (post-exposure) only.
89392902|NCT05812586|Experimental|Group 1: SCB-2019/Clover|Cohort A: complete primary immunization, no previous booster dose: SCB-2019/Clover
89392903|NCT05812586|Experimental|Group 2: AstraZeneca/Fiocruz|Cohort A: complete primary immunization, no previous booster dose: AstraZeneca/Fiocruz
89392904|NCT05812586|Experimental|Group 3: Pfizer/Wyeth|Cohort A: complete primary immunization, no previous booster dose: Pfizer/Wyeth
89392905|NCT05812586|Experimental|Group 4: SCB-2019/Clover|Cohort B: primary immunization plus one previous booster dose:SCB-2019/Clover
89392906|NCT05812586|Experimental|Group 5: AstraZeneca/Fiocruz|Cohort B: primary immunization plus one previous booster dose: AstraZeneca/Fiocruz
89392907|NCT05812586|Experimental|Group 6: Pfizer/Wyeth|Cohort B: primary immunization plus one previous booster dose: Pfizer/Wyeth
89392908|NCT05812586|Experimental|Group 7: SCB-2019/Clover|Cohort C: primary immunization plus two previous booster doses: SCB-2019/Clover
89392909|NCT05812586|Experimental|Group 8: AstraZeneca/Fiocruz|Cohort C: primary immunization plus two previous booster doses: AstraZeneca/Fiocruz
89392910|NCT05812586|Experimental|Group 9: Pfizer/Wyeth|Cohort C: primary immunization plus two previous booster doses: Pfizer/Wyeth
89392911|NCT05812573||multiple endocrine neoplasia|patients with multiple endocrine neoplasia
89392912|NCT05812547|Experimental|The Lumen group|subjects will use the Lumen device and mobile phone application, which will guide them once a day after the night fast regarding their daily diet, sleep, and routines according to their Lumen measurements. Subjects will need Google Fit (Android) or Apple Health Kit (iOS) and will be encouraged to communicate with a study investigator via the app during the entirety of the study to resolve technical questions about the device and data collection
89392913|NCT05812547|Active Comparator|The control group|The control group will use a mobile app to keep track of their glucose levels and will be managed in accordance with the common guidelines for GDM management. Participants of both groups will measure their fasting blood glucose levels and their postprandial blood glucose levels and record it in their mobile app
89392914|NCT05812521|Experimental|Paravertebral block with methylene blue|With the patient sitting, the patient will receive paravertebral block at T4-T5 level before general anesthesia induction
89392915|NCT05812521|Active Comparator|Thoracic Epidural Anesthesia|With the patient sitting, the patient will receive thoracic epidural anesthesia at T4-T8 level before general anesthesia induction
88869194|NCT06244121|Experimental|Standard treatment with pyridoxine|This group will receive standard treatment with pyridoxine 25 mg twice daily for 8 weeks
88869195|NCT06244121|Placebo Comparator|Standard treatment with placebo|This group will receive standard treatment with placebo 25 mg twice daily for 8 weeks
88869196|NCT06244108|Experimental|OTHP Group (Intervention Group)|Children with Down syndrome will undergo an 8-week occupational therapy home program (OTHP). Evaluations will be conducted at the beginning and end of the intervention, and the results will be compared.
88869197|NCT06244108|No Intervention|None OTHP Group (Control group)|The control group (non-OTHP) will not receive occupational therapy home program, even if they have Down syndrome. Evaluations will be conducted at 8-week intervals, with the first and last evaluations being compared.
89187112|NCT00765141||No treatment|
89392916|NCT05812508||pterygium surgery with bare scleral technique|corneal topograghy before and after surgery
89392917|NCT05812508||pterygium surgery with conjunctival autograft technique|corneal topograghy before and after surgery
89392918|NCT05812495|Experimental|Esophagogastric Side to Side Anastomosis|Esophagogastric Side to Side Anastomosis
88869198|NCT06244095|Experimental|Perturbation Therapy|Perturbation Therapy will be given to this group.
88869199|NCT06244095|Active Comparator|Trunk Control Therapy|Trunk control activities will be given to this group.
89392919|NCT05812495|Experimental|Esophagogastric End to Side Anastomosis|Esophagogastric End to Side Anastomosis
89392920|NCT05812482|Experimental|Test group|The test arm will be the treated by Drug Balloon
89530471|NCT04164563|No Intervention|Control|Standard CAM boot treatment without Even-Up device.
89392921|NCT05812482|Other|Control group|The control arm will be treated by Direct vision internal urethrotomy (DVIU)
89392922|NCT05812469|Experimental|experimental group|psychoeducation and counseling provided as part of the Brain Awareness Intervention for the experimental group of 39 patients
89392923|NCT05812469|Active Comparator|control group|38 patients will receive education about Being Healthy
88869200|NCT06244082|Experimental|AOC 1044 Multiple Dose Levels|AOC 1044 will be IV infused every 6 weeks or 8 weeks for approximately 2 years.
88869201|NCT06244069||GCA patients|Patients who are going to be diagnosed with GCA and for which a fast track is available for a rapid diagnostic work-up including pre-treatment temporal artery biopsy. The main biopsy specimen will be sent for histopathology for clinical diagnosis or final validation, while the remaining specimen (at least 5 mm in length) will be digested to use for research purposes. In the fast-track, patients should rapidly receive a multi-dimensional diagnostic assessment including ultrasonography of the temporal and axillary arteries. Screening for large vessels involvement should be performed according to the local practice by a combination of ultrasonography, Position Emission Tomography (PET) and Magnetic Resonance (MR). Ideally, this assessment should be performed within five days from clinical evaluation.
89392924|NCT05812456|Active Comparator|3m Metal Brackets|"3m Unitek Gemini Roth Stainless-Steel Brackets. it is passive Stainless-Steel components used in fixed Orthodontics appliance to help in solving malocclusions by bonding it to teeth's enamel. it acts as a means to transfers forces applied by activated archwires inserted in bracket slots to try to correct and improve the patients malocclusion problems.~There are different sizes of Stainless-Steel bracket slots, There are 0.018 slot and 0.022 slot.~Brackets are made of many different materials such as Stainless-Steel, ceramics, plastic or 3d printed. The most used type is metal brackets.~Brackets come with built in prescriptions of torque and tip, there are two type of prescriptions: Roth and MBT"
89392925|NCT05812456|Active Comparator|American Orthodontics Metal Brackets|"American Orthodontics Mini Masters 0.022 Roth Stainless-Steel Brackets. it is passive Stainless-Steel components used in fixed Orthodontics appliance to help in solving malocclusions by bonding it to teeth's enamel. it acts as a means to transfers forces applied by activated archwires inserted in bracket slots to try to correct and improve the patients malocclusion problems.~There are different sizes of Stainless-Steel bracket slots, There are .18 slot and .22 slot.~Brackets are made of many different materials such as Stainless-Steel, ceramics, plastic or 3d printed. The most used type is metal brackets.~Brackets come with built in prescriptions of torque and tip, there are two type of prescriptions: Roth and MBT"
89003680|NCT04829500|Experimental|MAP-VA Intervention|Montessori approaches to person-centered care (MAP-VA) introduces practical strategies that frontline staff can use for successful engagement of residents through retained abilities such as implicit learning, procedural memory, reading abilities. Staff training provides practice with: 1) pre-developed activities and templates, 2) a simple reading assessment to inform development of external cues; and 3) identifying opportunities for increased independence and resident contribution to community routines. Staff are also introduced to concrete strategies that improve dignity, control, and independence.
89003681|NCT04824235|Experimental|Amnoitic Chorion Membrane and xenograft|extraction sockets where ridge preservation will be performed using Chorion Membrane with Xenograft
89187113|NCT02583698|Experimental|Carvedilol|Tab Carvedilol 3.125 mg twice daily followed by 6.25 mg BD and finally 12.5 mg BD if SBP > 90 mmHg and HR >55/min
89187114|NCT02583698|Placebo Comparator|placebo|
89392926|NCT05812456|Experimental|Fanta Metal Brackets|"Fanta Firmax 0.022 Roth Stainless-Steel Brackets. Fanta is a Chinese Orthodontic bracket brand that started to spread.~it is passive Stainless-Steel components used in fixed Orthodontics appliance to help in solving malocclusions by bonding it to teeth's enamel. it acts as a means to transfers forces applied by activated archwires inserted in bracket slots to try to correct and improve the patients malocclusion problems.~There are different sizes of Stainless-Steel bracket slots, There are 0.018 slot and 0.022 slot.~Brackets are made of many different materials such as Stainless-Steel, ceramics, plastic or 3d printed. The most used type is metal brackets.~Brackets come with built in prescriptions of torque and tip, there are two type of prescriptions: Roth and MBT"
89392927|NCT05812456|Experimental|Matt Orthodontics Metal Brackets|"Matt Orthodontics Pierre 0.022 Roth Metal Brackets. Matt is a Chinese Orthodontic bracket brand that started to spread.~it is passive Stainless-Steel components used in fixed Orthodontics appliance to help in solving malocclusions by bonding it to teeth's enamel. it acts as a means to transfers forces applied by activated archwires inserted in bracket slots to try to correct and improve the patients malocclusion problems.~There are different sizes of Stainless-Steel bracket slots, There are 0.018 slot and 0.022 slot.~Brackets are made of many different materials such as Stainless-Steel, ceramics, plastic or 3d printed. The most used type is metal brackets.~Brackets come with built in prescriptions of torque and tip, there are two type of prescriptions: Roth and MBT"
89392928|NCT05812430|Experimental|anlotinib+TQB2450+nab-paclitaxel+cisplatin|
89392929|NCT05812404|Experimental|Cohort 1|"Treatment A: DWC202201 40 mg qd for 7 days~Treatment B: DWP14012 40 mg qd for 7 days, followed by DWC202201 40 mg qd + DWP14012 40 mg qd for 7 days~Treatment C: DWP14012 40 mg qd for 14 days"
89392930|NCT05812404|Experimental|Cohort 2|"Treatment C: DWP14012 40 mg qd for 14 days~Treatment A: DWC202201 40 mg qd for 7 days~Treatment B: DWP14012 40 mg qd for 7 days, followed by DWC202201 40 mg qd + DWP14012 40 mg qd for 7 days"
89392931|NCT05812404|Experimental|Cohort 3|"Treatment B: DWP14012 40 mg qd for 7 days, followed by DWC202201 40 mg qd + DWP14012 40 mg qd for 7 days~Treatment C: DWP14012 40 mg qd for 14 days~Treatment A: DWC202201 40 mg qd for 7 days"
89392932|NCT05812326|Experimental|Treatment with AJMUC1--PD-1 knockout CAR-T cells|"Advanced breast cancer patients with positive MUC1 expression are the indications of this clinical study. Current conventional treatments are ineffective for these patients or there is no effective treatment plan available for them. No control group is established and a single arm design is used.~This clinical study is the first application of AJMUC1 in the clinical treatment of MUC1-positive advanced breast cancer patients. The main purpose is to assess the safety and feasibility of the product in clinical use. Therefore, according to the principle of 3+3 dose escalation design, this study explored the maximum tolerated dose of AJMUC1 for the treatment of MUC1-positive advanced breast cancer.~At the same time, the efficacy of AJMUC1 in the treatment of MUC1-positive advanced breast cancer will be observed and factors that could affect the safety and efficacy of the therapy will be exploringly evaluated."
89392933|NCT03607110||ketamine|ketamine used
89392934|NCT03607110||fentanyl|fentanyl used
89392935|NCT05812313||vocational trainees in health and care professions|
89392936|NCT05812313||vocational educators in health and care professions.|
89392937|NCT05812274|Experimental|Intervention Arm|Participants are provided with ApricityRx digital solution with pulse oximeters and 24/7 C.A.R.E. (Cancer Adverse event Rapid Evaluation) to monitor and capture ePRO, identify onset or progression of symptoms verified by nurse triage, trigger intervention by the study team.
89392938|NCT05812274|No Intervention|Control Arm|Clinicians will monitor NSCLC patients on ICIs for irAEs as a standard of care using routine practices.
89392939|NCT05812209||SGB Patients for Long COVID 19|Patients who received ultrasound guided Stellate Ganglion block for symptoms of Long COVID in our Colorado clinics.
89392940|NCT05812092||DePuy Synthes Cervical Plating System|All enrolled patients will receive CONDUIT Interbody Cervical System with supplemental fixation using a DePuy Synthes Cervical Plating System.
89392941|NCT05812066|Experimental|all ceramic single-retainer resin bonded fixed partial denture using the upper canine abutment|
89392942|NCT05812066|Active Comparator|all ceramic single-retainer resin bonded fixed partial denture using the upper central incisor|
89392943|NCT05812053|Experimental|group 1: Tea Tree Oil- Eggshell Powder|30 primary molars will be treated with Eggshell Powder freshly mixed with Tea Tree Oil till reach suitable consistency (1:1 ratio by volume) to cover pulp stumps
89392944|NCT05812053|Experimental|group II: biodentine|30 primary molars will be treated with biodentine to cover pulp stumps
89392945|NCT05812053|Active Comparator|group III: mineral tri-oxide aggregate (MTA)|30 primary molars will be treated with MTA to cover pulp stumps
89392946|NCT05811988||Direct Laryngoscopy|
88869202|NCT06244069||Healthy subjects|Healthy controls matched with GCA patients for age, sex, smoking status, previous cardiovascular events, BMI, history of cancer and cytotoxic chemo/radiotherapy.
88869203|NCT06244056|No Intervention|Narrow QRS complex Heart failure patients|Narrow QRS complex Heart failure patients with optimal medical treatment.
89003682|NCT04824235|Active Comparator|Amnoitic Chorion Membrane only|extraction sockets where ridge preservation will be performed using Chorion Membrane Alone
89187115|NCT00762099|Active Comparator|1|Pregabalin Group
89392947|NCT05811988||Video Laryngoscopy|
89392948|NCT05811975|Experimental|TCR-T cells|Drug: KSX01 injection individualization TCR-T cell injection
89392949|NCT05811962||Intrathoracic sarcoidosis cohort|Patients with intrathoracic sarcoidosis, confirmed according to European Respiratory Society/ World Association of Sarcoidosis and Other Granulomatous disease (ERS/WASOG) criteria
89392950|NCT05811962||Healthy controls|Healthy blood donors
89392951|NCT05811923|Placebo Comparator|Placebo|Maltodextrin placebo capsules
89392952|NCT05811923|Active Comparator|200 mg caffeine|200 mg caffeine capsules
89392953|NCT05811923|Experimental|100 mg paraxanthine|100 mg paraxanthine capsules
89392954|NCT05811923|Experimental|200 mg paraxanthine|200 mg paraxanthine capsules
89392955|NCT05811923|Experimental|300 mg paraxanthine|300 mg paraxanthine capsules
89392956|NCT05811923|Experimental|200 mg caffeine + 200 mg paraxanthine|200 mg caffeine + 200 mg paraxanthine capsules
89392957|NCT05811923|Experimental|200 mg 1-methylxanthine|200 mg 1-methylxanthine capsules
89392958|NCT05811884|Experimental|House rehabilitation|"The subjects will be provided of the powered exoskeleton for home use. No specific indications will be provided, but using the technology as much as possible.~Every six months, the subjects will be asked to attend a single-day session by the clinical facility (follow-up session) consisting on the assessement of a series of qualitative and quantitative measurements."
89392959|NCT05811884|Experimental|Central rehabilitation|The subjects will be asked to attend to periodic rehabilitation sessions by the clinical facility. The rehabilitation session will consist in an intense 1-week activities session every three months. Every six months, the subjects will be asked to attend a single-day session by the clinical facility (follow-up session) consisting on the assessement of a series of qualitative and quantitative measurements.
88869204|NCT06244056|Active Comparator|: Narrow QRS complex Heart failure patients|: Narrow QRS complex Heart failure patients with optimal medical treatment with stellate ganglion block.
89187116|NCT00762099|Placebo Comparator|2|Placebo group
89530472|NCT04164563|Experimental|Study|CAM boot treatment with Even-Up for contralateral extremity.
89392960|NCT05811832||Fragile elderly individuals with COPD|"Patient evaluation form and socio-demographic form of all individuals participating in the study.~properties will be questioned.To assess pulmonary functions at the assessment stage for all individuals pulmonary function test,Modified Medical Questionnaire to assess dyspnea research Council, to assess health-related quality of life, Saint George Respiratory Two Minute Walk Test to assess exercise capacity, frailty Frail fragility scale to detect fragility, Prisma-7 Vulnerability scale to assess fragility The scale is Pase to assess physical activity, Berg balance to assess balance. scale, digital hand dynamometer to evaluate quadriceps muscle strength, hand grip strength hand dynamometer to assess fatigue levels Fatigue Severity Scale will be used."
89530473|NCT03253003|Experimental|Audéo B hearing aid line extension|The line extension of the Phonak Audéo B product family will be fitted to the participants individual hearing loss.
89530474|NCT03345641||dyads|dyads with babies and their mothers
89530475|NCT03247153|Experimental|Corticosteroid Therapy Patients|Corticosteroid therapy patients will be examined by echocardiography before, during and after receiving treatment
89530476|NCT03239353|Active Comparator|1.5 mg ETV XR tablet|
88869205|NCT06244056|Active Comparator|Wide QRS complex heart failure patients|Wide QRS complex heart failure patients with optimal medical treatment who were non responders to CRT( retrospective and prospective) with stellate ganglion block.
88869206|NCT06243991||Control group|Nineteen patiens (20 eyes) received topical polyvinyl alcohol (Refresh, Allergan, Dublin, Ireland) three times daily until epithelial defect closure after CXL in control group.
88869207|NCT06243991||LMW-HA group|Twenty-two patiens (23 eyes) received topical LMW-HA (Thealose Duo®, Thea, Clermont-Ferrand, France) three times daily for 12 months.
88869208|NCT06243991||HMW-HA group|Seventeen patiens (20 eyes) received topical HMW-HA (Comfort Shield®, i.com medical GmbH, Munich, Germany) three times daily for 12 months.
88869209|NCT06243978|Experimental|liebria|"Participants allocated to the intervention group will receive access to liebria in addition to treatment as usual (TAU).~reviga is a digital health application designed for individuals with hypertension, accessible through a web browser. The application focuses on evidence-based psychological and psychotherapeutic methods combined with psychoeducation and health behavior change. Topics addressed by liebria include clarifying and strengthening motivation, training the parasympathetic nervous system, recognizing and overcoming obstacles, strengthening impulse control, development of an individualized day plan, and relapse prevention.~The program operates through interactive dialogues, which are accompanied by illustrations, audio recordings, motivating text messages, worksheets, and summaries. Users are also encouraged to regularly complete short questionnaires to monitor their complaints. Once registered, the program remains accessible for 360 days."
88869210|NCT06243978|Other|brochure on hypertension|Participants allocated to the control group will receive a brochure from the Deutsche Hochdruckliga (German Hypertension League) in addition to TAU.
88869211|NCT06243952|Experimental|All participants|All participants receive the same intervention.
88869212|NCT06243939|Experimental|Education|24-26 weeks for pregnant women diagnosed with gestational diabetes mellitus. A total of motivational interviews will be held for 4 weeks with the pregnant women. Personal Information Form, Health Management Self-Efficacy Scale and Quality of Life Scale will be administered before the motivational interview, and the Health Management Self-Efficacy Scale and Quality of Life Scale will be administered at the end of the motivational interview.
88869213|NCT06243939|No Intervention|Control|24-26 weeks for pregnant women diagnosed with gestational diabetes mellitus. Personal Information Form, Health Management Self-Efficacy Scale and Quality of Life Scale will be applied to the pregnant patient.
88869214|NCT06243926||Density gradient centrifugation (DGC)|DGC is a protocol to select sperm based on their density and isopycnic points. It is a conventional protocol commonly used in IVF laboratories.
88869215|NCT06243926||In-Situ rheotaxis handmade microfluidics (isM)|The isM is a novel protocol to select sperm for ICSI based on microfluidics and sperm guidance responses to rheotaxis and thermotaxis. The isM protocol proved its efficacy and effectivity for ICSI in previous proof of concept and non-inferiority studies, respectively.
88869216|NCT06243913||Intervention arm|Use of vitrified donor semen for Intrauterine Artificial Insemination
88869217|NCT06243874|Active Comparator|greater occipital nerve block|"Following intravenous access and monitoring, participants are placed in the prone position. The medial 1/3 of the line between the protuberance occipital externa and the mastoid process is palpated. The intervention area is cleaned with antiseptic solution. Then, 2 cc of 2% lidocaine is injected into the palpated area after confirming that it is not in the vascular area by negative aspiration. Participants are observed for 30 minutes for possible complications.~The participant will receive a block once a week for the first month and then once a month for the next 2 months."
88869218|NCT06243874|Other|transnasal sphenopalatine ganglion block|"Following intravenous access and monitoring, patients are placed in the supine position. A cotton swab impregnated with 2 cc of 2% lidocaine is advanced from the nostril along the upper edge of the middle turbinate until it reaches the posterior wall of the nasopharynx. The stick impregnated with local anesthetic is kept in the target area for 20 minutes. Participants are observed for 30 minutes for possible complications.~The participant will receive a block once a week for the first month and then once a month for the next 2 months."
89392961|NCT05811832||Non-fragile elderly individuals with COPD|"Patient evaluation form and socio-demographic form of all individuals participating in the study.~properties will be questioned.To assess pulmonary functions at the assessment stage for all individuals pulmonary function test,Modified Medical Questionnaire to assess dyspnea research Council, to assess health-related quality of life, Saint George Respiratory Two Minute Walk Test to assess exercise capacity, frailty Frail fragility scale to detect fragility, Prisma-7 Vulnerability scale to assess fragility The scale is Pase to assess physical activity, Berg balance to assess balance. scale, digital hand dynamometer to evaluate quadriceps muscle strength, hand grip strength hand dynamometer to assess fatigue levels Fatigue Severity Scale will be used."
89392962|NCT05811819|Experimental|Neurorehabilitation of the Hand|Participants will undergo a 1-hour training session 5 days per week, over 3 weeks for a total of 15 sessions. Hand function therapy will be administered using the gamified protocol to enhance rehabilitation of the hand and provide participants with greater opportunity to regain hand function over the course of the study.
89392963|NCT05811806|Experimental|Neurorehabilitation of the Hand|Participants will undergo a 1-hour training session 5 days per week, over 3 weeks for a total of 15 sessions. Hand function therapy will be administered using the gamified protocol to enhance rehabilitation of the hand and provide participants with greater opportunity to regain hand function over the course of the study.
89392964|NCT05811793|Experimental|Bevacizumab arterial infusion combined with Tislelizumab intrathecal injection|"This is a prospective, interventional, multicenter Phase 2 trial for the treatment of patients with recurrent GBM who will receive Bevacizumab arterial infusion combined with Tislelizumab intrathecal injection. The study consists of two parts: the arterial infusion part in part 1, where each subject will receive 15 mg/Kg of Bevacizumab by cerebral arterial infusion over 15 minutes at a fixed time (d0, d30, d60); the infusion of 20% mannitol 12.5 ml over 120 seconds prior to the infusion of Bevacizumab; and the intrathecal injection part in part 2, where the subject will receive a fixed dose of intrathecal PD1 therapy (Tislelizumab 20 mg, d1, Q3W) intrathecal injection every 3 weeks for 6 cycles."
89392965|NCT05811767||The Esbjerg Cohort|This is a cross-sectional study and therefore there is no intervention to describe. The study consist only of tests, questionnaires and a blood test. See the elements under outcomes measures.
89392966|NCT05811754||HZ/su-Exposed Group|Pregnant adult women diagnosed with immunocompromised (IC) conditions exposed to HZ/su vaccine during pregnancy.
89392967|NCT05811754||Comparison (Unexposed) Group|Pregnant adult women diagnosed with immunocompromised (IC) conditions who were not vaccinated with HZ/su vaccine (i.e., not receiving at least one dose of HZ/su vaccine during pregnancy).
88869219|NCT06243848|Active Comparator|Minimal Incision Surgery for median nerve decompression|Classic minimal incision surgical technique for median nerve decompression in patients diagnosed with mild, moderate, and severe carpal tunnel syndrome.
89187117|NCT00762255|Experimental|A - Phase I Dose Escalation|Dose Escalation - Irinotecan and bevacizumab are given IV on days 1 and 15 of each cycle. Vorinostat is given orally on days 1-7 and 15-21 of each cycle.
88869220|NCT06243848|Experimental|Ultrasound-guided perineural injection with 5 cc 5% Dextrose|The median nerve will be identified using ultrasound at the proximal entrance of the carpal tunnel. Using an ulnar approach with the in-plane technique, it was planned to inject 5 cc of 5% dextrose around the median nerve.
88869221|NCT06243835|Experimental|Kindolor Cohort 1|"Kindolor Tosylate~1 tablet dose 100mg NPO for 8hrs x1 AM PO ex aq"
88869222|NCT06243835|Experimental|Kindolor Cohort 2|"Kindolor Tosylate tablet~1 tablet dose 300mg NPO for 8hrs x1 AM PO ex aq"
88869223|NCT06243835|Experimental|Kindolor Cohort 3|"Kindolor Tosylate~3 tablets dose 300mg NPO for 8hrs x1 AM PO ex aq"
88869224|NCT06243835|Experimental|Kindolor Cohort 4|"Kindolor Tosylate~6 tablets dose 300mg NPO for 8hrs x1 AM PO ex aq"
88869225|NCT06243835|Placebo Comparator|Placebo Comparator|Placebo to Match tablet(s) NPO for 8hrs x1 AM PO ex aq
88869226|NCT06243822|Active Comparator|Ketamine group|
89187118|NCT00762255|Experimental|B - Treatment at Maximum Tolerated Dose (MTD)|MTD - Treatment at maximum tolerated dose
89187119|NCT04078958|Experimental|Salmon fishmeal|5 g fishmeal in capsules, single oral dose
89392968|NCT05811715|Experimental|Group A|WBS-Whole body stretching exercise group
89392969|NCT05811715|Active Comparator|Group B|control group
89392970|NCT05811689||sm tbs group|All patients will undergo densitometric examination with dual-energy x-ray absorptiometry (DXA) technique at our Facility.
89530477|NCT03239353|Active Comparator|3 mg ETV XR tablet|
89530478|NCT03239353|Active Comparator|6 mg ETV XR tablet|
88869227|NCT06243822|Active Comparator|propofol group|
89187120|NCT04078958|Active Comparator|Whey|5 g whey in capsules, single oral dose
89187121|NCT04080206|Experimental|188-0551 Spray|Investigational Topical Spray Product
89530479|NCT03239353|Placebo Comparator|Placebo-to-match 1.5 mg ETV XR tablet|
89530480|NCT03239353|Other|0.5 mg ETV IR tablet|
88869228|NCT06243783|Experimental|Stress|Montreal Imaging Stress Test during each PET/MRI measurement and in-between
88869229|NCT06243770|Experimental|Sequence 1: mRNA-0184|Participants will receive infusion duration 1 of mRNA-0184 on Day 1, followed by a washout period of approximately 21 days. They will then receive infusion duration 2 of mRNA-0184 on Day 22.
89392971|NCT05811663||DanFunD baseline|"Data from the DanFunD baseline cohort will be included. It comprises a total of 9,656 (33.7% of the invited participants) men and women aged 18-76 years born in Denmark and living in the Western part of greater Copenhagen.~Individuals with FSD are identified by means of self-reported questionnaires (n=9,656) and diagnostic research interviews (n=1,590).~Participants with FSD will be defined as follows:~FSD operationalised by the Bodily Distress Syndrome single- and multi-organ type will be defined with both self-reported questionnaires and diagnostic interviews.~Three functional somatic syndromes, i.e. irritable bowel, chronic widespread pain, and chronic fatigue will be defined with questionnaires.~Severe physical disease will be defined by means of self-report as having received at least one of the following five diagnoses: Cancer, stroke, myocardial infarction, other heart disease, and obstructive pulmonary disease."
89392972|NCT05811650|Experimental|Oral Health Intervention group|Those receiving intervention of oral health and counselling.
89392973|NCT05811650|Placebo Comparator|Control group|Those who are not receiving counseling and promotion interventions
89392974|NCT05811637|Active Comparator|Supervised Rehabilitation|The supervised rehabilitation focused mainly on strengthening the hip-knee muscles and flexibility exercises for the gastrocnemius and hamstring muscles. Hip and knee targeted strengthening and stretching exercises will be applied for 6 weeks, two sessions a week 12 sessions of all exercises, 3 sets, and 10-15 repetitions of each set.
89392975|NCT05811637|Active Comparator|Pilates Exercise|The principles of Pilates exercises will be taught to the patients in the first session, and the evaluation will be made. The exercises, including basic training exercises in the first week, will be performed for 6 weeks, each session lasting 45 minutes, two days a week, each exercise for 8-12 repetitions. The Pilates exercises, consisting of gradually increasing strengthening will be applied under the supervision of a physiotherapist.
89392976|NCT05811611|Experimental|WeChat Mini Program plus tailored online promotion videos|"Having access to a WeChat Mini Program providing HIV and STI prevention information during the project period~The WeChat Mini Program proactively asks questions assessing sexual risk behaviors at Month 0 and Month 1, and invite participants two watch online health promotion videos tailored to their sexual risk behaviors status."
89392977|NCT05811611|Active Comparator|WeChat Mini Program Only|Having access to a WeChat Mini Program providing HIV and STI prevention information during the project period
89392978|NCT05811572||With Non-Specific Low Back Pain|pelvic floor muscles measurement with perinometer
89392979|NCT05811572||Without Low Back Pain|pelvic floor muscles measurement with perinometer
89392980|NCT05811546||H. pylori Gastritis specimens|
89392981|NCT05811546||Non-H. pylori Gastritis specimens|
89392982|NCT05811546||Gastric carcinoma specimens|
89392983|NCT05811507||Cases group of patients:|It will include patients with autism spectrum disorder..
89392984|NCT05811507||control group of patients:|It will include healthy boys who don't have any manifestations of ASD according to DSM-V Criteria and CARS score, and are age and Tanner stage matched to cases.
88869230|NCT06243770|Experimental|Sequence 2: mRNA-0184|Participants will receive infusion duration 2 of mRNA-0184 on Day 1, followed by a washout period of approximately 21 days. They will then receive infusion duration 1 of mRNA-0184 on Day 22.
88869231|NCT06243757||Minimally Invasive Proximal Gastrectomy/MIPG|Participants will undergo MIPG (Trial Procedure)
88869232|NCT06243757||Minimally Invasive Total Gastrectomy/MITG|Participants will undergo MITG (Standard of Care/Control Group)
88869233|NCT06243705|Experimental|Robot-Pet Group|The robot-pet sits on the child's lap while the fissure sealant is applied. Preoperative (T1) baseline levels of dental anxiety will be measured using the Children's Fear Survey Schedule-Dental Subscale (CFSS-DS) and the Facial Image Scale (FIS), and behavior rating will be measured using the Frankl Behavior Rating Scale (FBRS). Intraoperative (T2) cooperation level will be recorded using the Modified Houpt Scale (MHS) during the surface cleaning (T2A), isolation (T2B) and washing (T2C) phases of fissure sealant application. Postoperative(T3) anxiety level and behavior rating measurements (CFSS-DS, FIS, FBRS) will be repeated. Physiological markers for dental anxiety, such as heart rate and oxygen saturation, will be measured at all time points (T1, T2A-B-C, T3). Children and parents in this group will received a questionnaire for their perception about the use of their distraction technique(T3).
89187122|NCT04080206|Active Comparator|Reference Listed Drug (RLD)|FDA Approved Topical Cream
89187123|NCT00765219|Experimental|1|CBT with ACS
89392985|NCT05811494|Experimental|End-Effector walking training|Participants in the End-effector group will receive one session per day over 4 weeks of Physical Therapy. This therapy will consist in 30 minutes of Lexo training adjusting the assistance/resistance of the device for working in 14-17 in the Borg scale and 70-85% HRmax of the patient, assessed with the Tanaka formula (208-(0,7+Age)) and with the correction of 10 beats less if the patient is taking ß-blockers.
89392986|NCT05811494|Experimental|Fixed Exoskeleton walking training|Participants in the fixed-exoskeleton group will receive one session per day over 4 weeks of Physical Therapy. This therapy will consist in 30 minutes of Lokomat training adjusting the assistance/resistance of the device for working in 14-17 in the Borg scale and 70-85% HRmax of the patient, assessed with the Tanaka formula (208-(0,7+Age)) and with the correction of 10 beats less if the patient is taking ß-blockers.
89392987|NCT05811494|Experimental|Body-Weight Support treadmill training with augmented reality|Participants in the Body-Weight Support treadmill training with augmented reality group will receive one session per day over 4 weeks of Physical Therapy. This therapy will consist in 30 minutes of C-Mill training adjusting the assistance/resistance of the device for working in 14-17 in the Borg scale and 70-85% HRmax of the patient, assessed with the Tanaka formula (208-(0,7+Age)) and with the correction of 10 beats less if the patient is taking ß-blockers.
89392988|NCT05811494|Active Comparator|Body-Weight Support treadmill training|Participants in the Body-Weight Support treadmill training group will receive one session per day over 4 weeks of Physical Therapy. This therapy will consist in 30 minutes of body-weight support treadmill training adjusting the assistance/resistance of the device for working in 14-17 in the Borg scale and 70-85% HRmax of the patient, assessed with the Tanaka formula (208-(0,7+Age)) and with the correction of 10 beats less if the patient is taking ß-blockers.
88869234|NCT06243705|Active Comparator|Virtual Reality Glasses Group|During the application of fissure sealant, the child watches a cartoon through virtual reality glasses. Preoperative (T1) baseline levels of dental anxiety will be measured using the Children's Fear Survey Schedule-Dental Subscale (CFSS-DS) and the Facial Image Scale (FIS), and behavior rating will be measured using the Frankl Behavior Rating Scale (FBRS). Intraoperative (T2) cooperation level will be recorded using the Modified Houpt Scale (MHS) during the surface cleaning (T2A), isolation (T2B) and washing (T2C) phases of fissure sealant application. Postoperative(T3) anxiety level and behavior rating measurements (CFSS-DS, FIS, FBRS) will be repeated. Physiological markers for dental anxiety, such as heart rate and oxygen saturation, will be measured at all time points (T1, T2A-B-C, T3). Children and parents in this group will received a questionnaire for their perception about the use of their distraction technique(T3).
88869235|NCT06243705|No Intervention|Control Group|Tell-Show-Do technique will be used to apply the fissure sealant. No additional distraction will be applied. Preoperative (T1) baseline levels of dental anxiety will be measured using the Children's Fear Survey Schedule-Dental Subscale (CFSS-DS) and the Facial Image Scale (FIS), and behavior rating will be measured using the Frankl Behavior Rating Scale (FBRS). Intraoperative (T2) cooperation level will be recorded using the Modified Houpt Scale (MHS) during the surface cleaning (T2A), isolation (T2B) and washing (T2C) phases of fissure sealant application. Postoperative(T3) anxiety level and behavior rating measurements (CFSS-DS, FIS, FBRS) will be repeated. Physiological markers for dental anxiety, such as heart rate and oxygen saturation, will be measured at all time points (T1, T2A-B-C, T3).
89535410|NCT03078153|Experimental|Social Media Group|Provided social media support through a facebook group for 6 months
89535411|NCT03078153|No Intervention|Control|No intervention
88869238|NCT06243679||Adjuvant immunotherapy|
88869239|NCT06243679||Observational|
88869240|NCT06243666||Vaccine group for long-term effectiveness evaluation|No intervention was implemented in this study. Participants who have participated in the immunobridging clinical trial of the bivalent HPV vaccine (Unique Protocol ID:HPV-PRO-006,Identifiers: NCT02562508) and were aged 9-17 years at the time of enrollment, and have received at least one dose of the vaccine were recruited as the vaccine group for long-term effectiveness evaluation.
88869241|NCT06243666||Control group for long-term effectiveness evaluation|No intervention was implemented in this study. Participants with no previous HPV vaccination history were recruited as the control group for long-term effectiveness evaluation.
88869242|NCT06243666||Vaccine group for immuno-persistence evaluation|No intervention was implemented in this study. Participants who have participated in the immunobridging clinical trial of the bivalent HPV vaccine (Unique Protocol ID:HPV-PRO-006,Identifiers: NCT02562508) and were aged 9-26 years at the time of enrollment, and have received at least one dose of the vaccine were recruited as the vaccine group for immuno-persistence evaluation.
88869243|NCT06243653||HFrEF|Patients with heart failure with reduced ejection fraction (HFrEF) without significant coronary artery disease (non-ischemic cardiomyopathy)
88869244|NCT06243640|Experimental|High-dose experimental group|Subjects took 120mg per day of Buagafuran capsules after breakfast and dinner for 8 weeks
88869245|NCT06243640|Experimental|Low-dose experimental group|Subjects took 60mg per day of Buagafuran capsules and Buagafuran capsules mimic after breakfast and dinner for 8 weeks
88869246|NCT06243640|Placebo Comparator|Placebo-Control group|Subjects took 0 mg per day Buagafuran capsules mimic after breakfast and dinner for 8 weeks
88869247|NCT06243627|Experimental|Arm 1: Sunscreen C Color 2.0 Sun Protection Factor (SPF) 70 and Sunscreen M Very Light SPF 50|The participants will apply topically two colored sunscreens: C color 2.0 and M very light, one on each half of the face at least twice a day for 21 days.
88869248|NCT06243627|Experimental|Arm 2: Sunscreen C Color 2.0 SPF 70 and Sunscreen M Golden Color SPF 50|The participants will apply topically two colored sunscreens: C color 2.0 and M golden color, one on each half of the face at least twice a day for 21 days.
89187124|NCT00765219|Experimental|2|CBT with Counselor
89187125|NCT00765219|Active Comparator|3|Usual Care
89392989|NCT05811481||Two treatment groups|Regorafenib + TACE
89392990|NCT05811481||Treatment ate group|Regorafinib
89535412|NCT03221569|Experimental|Intravenous ketamine|Arm will include 0.3 mg/kg intravenous piggyback ketamine over 10 minutes for 1 dose and a 1ml normal saline placebo via intravenous push
88869249|NCT06243627|Experimental|Arm 3: Sunscreen C Color 3.0 SPF 70 and Sunscreen M Very Light SPF 50|The participants will apply topically two colored sunscreens: C color 3.0 and M very light, one on each half of the face at least twice a day for 21 days.
88869250|NCT06243627|Experimental|Arm 4: Sunscreen C Color 3.0 SPF 70 and Sunscreen M Golden Color SPF 50|The participants will apply topically two colored sunscreens: C color 3.0 and M golden color, one on each half of the face at least twice a day for 21 days.
88869251|NCT06243614|Experimental|Experimental group|Participants took 60-120 mg/day Buagafuran capsules and Buspirone tablets mimic; 2 times per day, after breakfast and dinner, consecutively for 8 weeks; The dose can be adjusted according to treatment needs and tolerance in the follow-up period( at week 1, week 2 and week 4).
89187126|NCT02585180|Active Comparator|Period with endotracheal tubes not allowing SSD|During this period of the DEMETER study (NCT02515617), patients will be intubated with standard endotracheal tubes not allowing Subglottic Secretions Drainage
89535413|NCT03221569|Active Comparator|ketorolac|Arm will include 30mg ketorolac intravenous push and 50ml normal saline over 10 minutes
89535414|NCT03322319|Experimental|left Ventricular Hypertrophy|Patients with left ventricular wall thickness measuring 15mm or more, or patients with a suggestive left ventricular echogenicity. Procedure/surgery will be performed following a diagnostic tree.
89535415|NCT05012319|Experimental|treatment arm|"Nitric Oxide Nasal Spray Enovid"
89535416|NCT05012319|Placebo Comparator|Placebo|Placebo
89535417|NCT03221803|Experimental|OT Vertical attachment|The attachment consists of a male part that is in the form of a steady with a central hole. This part is attached to the abutments .the female component is a white standard retentive clip engaging the outer walls of a steady male. It is incorporated in the partial denture together with a castable balancing pin that fits into the central hole of the steady male and aids in centering the prosthesis during the final stage of insertion; thereby ensuring a longer life to the retentive clips.
89392991|NCT05811455|Experimental|Group A: aerobic exercises.|The first treatment group will be given aerobic exercises for six weeks at least three times per week. This group will include 14 participants. This study group will be assigned with basic treatment protocol with aerobic exercises along with 10 minutes of warm up period.
89392992|NCT05811455|Active Comparator|group b progressive muscle relaxation exercises.|"The intervention will be given three days per week for six weeks. Pre and post-treatment readings will be noted. Each total session will last for 45 minutes. The importance of the study will be explained, and consent will be taken from the people before the intervention will be applied.~Breathe in, and tense the first muscle group (hard but not to the point of pain or cramping) for 4 to 10 seconds.~Breathe out, and suddenly and completely relax the muscle group (do not relax it gradually) (20)"
89392993|NCT05811455|No Intervention|Group C. Control group|No intervention was given
89530481|NCT03347591||Patients with rare bleeding disorders|All patients registered in Dutch Haemophilia Treatment Centers with known disorders of the coagulation factors fibrinogen, factor II, V, V & VIII, VII, X, XI, XIII, α2-antiplasmin and plasminogen activator inhibitor type 1, aged 1 years and older.
89392994|NCT05811338|No Intervention|Project 1 - Phase 1: Development/Refinement of VR program; Usability Testing/Development of Training|The study includes one session that will last approximately 2 - 3 hours. The study involves completing some questionnaires that gather background demographic information and a structured needs assessment interview to gather information on user preferences, usability problems, implementation and training protocols.
89392995|NCT05811338|Experimental|Project 1 - Phase 2: VR Program|"Training will occur over 3 days and be conducted by research investigators in the participants' homes. Training will include training on the proper placement of the headset, the viewing lens, system headphones, and safety guidelines. The research investigator will aid in the set-up of the VR system in the home, which will be pre-loaded with applications, and will recommend an area to use the system to ensure a safe play area free of obstacles. Participants will be provided with practice tasks between training sessions. Participants will be provided with a hands-on performance assessment at the beginning of the second session and concepts/procedures that are problematic will be reviewed. Participants will be contacted one-week post training to determine if they are having any problems by study investigators. Following training, participants will use the CAST VR program and tablet at will, though encouraged to use it at least three times per week for 20 minutes."
89530482|NCT03239119|Experimental|rE-4 5 mcg|Placebo, then rE-4 5 mcg, then rE-4 5 mcg
88869252|NCT06243614|Active Comparator|Positive-control group|Participants took 10-20mg/day Buspirone tablets and Buagafuran capsules mimic; 2 times per day, after breakfast and dinner, consecutively for 8 weeks; The dose can be adjusted according to treatment needs and tolerance in the follow-up period( at week 1, week 2 and week 4).
88869253|NCT06243614|Placebo Comparator|Placebo-control group|Participants took Buagafuran capsules mimic and Buspirone tablets mimic; 2 times per day, after breakfast and dinner, consecutively for 8 weeks; The dose can be adjusted according to treatment needs and tolerance in the follow-up period( at week 1, week 2 and week 4).
88869254|NCT06243601|Experimental|Intervention Group|
88869255|NCT06243601|No Intervention|Control Group|
88869256|NCT06243588||Patients|patients treated at Rizzoli Institute from 1991 to 2021.
88869257|NCT06243536|Placebo Comparator|Type 2 diabetic patients without disordered eating behaviour|Treated with standard of care.
88869258|NCT06243536|Placebo Comparator|Type 2 diabetic patients with disordered eating behaviour A|Treated with standard of care.
88869259|NCT06243536|Experimental|Type 2 diabetic patients with disordered eating behaviour B|Receiving semaglutide for 12 weeks
88869260|NCT06243510|Active Comparator|Enoxaparin|Participants randomized to receive script for prophylactic dose of enoxaparin. Dosing will be done based on clinical providers (pharmacists) according to usual care. Participants will fill the script themselves.
88869261|NCT06243510|Experimental|Apixaban|Participants randomized to receive script for prophylactic dose of apixaban. Dosing will be done based on clinical providers (pharmacists) according to usual care. Participants will fill the script themselves.
88869262|NCT06243497||Matched eyes|Patients with glaucoma matched by sex and age.
88869263|NCT06243497||Treated eyes with UCP|The patients were definitely diagnosed as glaucoma, No age or gender limitation, IOP(intraocular pressure) ≥ 21mmHg under the maximum tolerated dose of antiglaucoma medication, or IOP < 21mmHg and glaucomatous optic nerve damage progressed. UCP treatment is required for the patients.
88869264|NCT06243484|Experimental|TOTUM-070|The experimental arm will be supplemented with TOTUM-070 twice per day
88869265|NCT06243484|Placebo Comparator|PLACEBO|The placebo comparator arm will be supplemented with a placebo twice a day
88869266|NCT06243471||Group 1|Minimally Invasive Surgery Group with Zigzag EHL Tenotomy
88869267|NCT06243471||Group 2|Minimally Invasive Surgery Group without Zig-zag EHL Tenotomy
89530483|NCT03239119|Experimental|rE-4 10 mcg|Placebo, then rE-4 5 mcg, then rE-4 10 mcg
89530484|NCT03239119|Placebo Comparator|Placebo 5 mcg|Placebo 5 mcg, then Placebo 5 mcg, then Placebo 5 mcg
89530485|NCT03239119|Placebo Comparator|Placebo 10 mcg|Placebo 5 mcg, then Placebo 5 mcg, then Placebo 10 mcg
88869268|NCT06243458|Experimental|Single-arm RVU120|
88869269|NCT06243445||Patients underwent cardiac surgery with need for a central venous catheter|Patients underwent cardiac surgery with need for a central venous catheter and indication to intraoperative trans esophageal echocardiography
88869270|NCT06243419|Experimental|vein viewer|The vein imaging device was used before the vascular access attempt
88869271|NCT06243419|Experimental|virtual reality|wearing virtual reality glasses
88869272|NCT06243419|Experimental|vein viewer and virtual reality|The vein imaging device was used before the vascular access attempt and wearing virtual reality glasses
88869273|NCT06243419|No Intervention|Control group|standard care
88869274|NCT06243393|Experimental|Sacituzumab Govitecan (SG)|Treatment with Sacituzumab Govitecan (SG) .
88869275|NCT06243393|Active Comparator|Physicians Choice (PhC).|Treatment according to oncologic guidelines.
88869276|NCT06243380||Patients with a possible allergy to beta-lactam antibiotics|Minors and adults with a possible allergy to beta-lactam antibiotics.
88869277|NCT06243367|Placebo Comparator|Fast (Control) group|Patients were instructed to be fasting for 6 hours before surgery and received only placebo drink (200 ml clear water) two hours before surgery
88869278|NCT06243367|Experimental|Carbohydrate group|Patients were given a meal of cup of yogurt (100 ml) with 2 spoonful of honey (42 gm) at midnight before surgery and 200 ml of a clear carbohydrate drink on the day of surgery, 2 h before anesthesia induction. This drink consisted of 200 ml water in which two spoonful of honey were dissolved.
88869279|NCT06243341|Experimental|MACA (MC)|Daily MACA supplementation for two weeks.
88869280|NCT06243341|Placebo Comparator|placebo|Daily placebo supplementation for two weeks.
88869281|NCT06243328|Experimental|conventional dressing|The surface of the PU will be cleaned with normal saline and packed with sterilised gauze to cover the wound. Dressing changes will be performed once or twice daily depending on the soakage of the dressing
89003683|NCT04806178|Active Comparator|BCG intradermal vaccine|Intradermal BCG Group (n=16): 0.1 ml of lyophilized, live, and attenuated BCG intradermal vaccine, containing between 2 and 8 x 1.000.000 C.F.U in a single dose.
88869282|NCT06243328|Experimental|negative pressure wound therapy|We will place a nonadherent contact layer, such as Xeroform between prepared wound bed and foam then applying a contact dressing with sealling using an adhesive drape. The dressing will be connected to the machine through tubing that was connected to the canister. Continuous pressure of 200 mm Hg will be applied. The dressing will be changed three times a week.
88869283|NCT06243302||Treatment Arm|VAAFT followed by OTSC clip inserted to close the inner opening of the anal fistula
88869284|NCT06243250||with irAE|Cancer patients who develop irAE after ICIs treatment.
88869285|NCT06243250||without irAE|Cancer patients who do not develop irAE after 3 months of ICIs treatment.
88869286|NCT06243250||healthy volunteer|Healthy volunteer.
88869287|NCT06243237|Experimental|Intervention group(acupuncture group)|After blind random allocation, investigators applied acupuncture on patient with acute intracranial hemorrhage.
88869288|NCT06243237|Placebo Comparator|Control group(sham acupuncture group (superficial acupuncture))|After blind random allocation, investigators applied superficial acupuncture on patient with acute intracranial hemorrhage.
88869289|NCT06243224|Active Comparator|High intensity interval training (HIIT)|Patients will receive high intensity interval training (HIIT).
88869290|NCT06243224|Active Comparator|Moderate intensity (MICT)|Patients will receive moderate intensity continuous training (MICT).
89535418|NCT03221803|Active Comparator|OT Cap attachment|Beveled castable bar with micro-size sphere located in first molar region, and attached to the distal surface of the waxed crowns to be cast as one piece, Nylone caps of standard retention for micro size sphere this nylon caps fit onto their spheres and located in metal housing at fitting surface on the denture and Positioning rings to maintain the space for nylon cap during construction of the partial denture metal framework.
89535419|NCT05011773|Experimental|Deep brain stimulation|"All patients have already undergone deep brain stimulation. Results compared on and off stimulation."
88869293|NCT06243185|Experimental|Dalpiciclib+letrozole|Drug: Dalpiciclib 150mg qd, d1-21, q4w Letrozole 2.5mg qd, q4w
88869294|NCT06243159|Experimental|JY231 injection for the treatment of refractory autoimmune diseases (ADs) Early exploratory clinica|Infusion of JY231 Injection by dose of 1-10×10^6 transducing units(TU)/kg、 1-5×10^7 TU/kg、5-10 ×10^7 TU/kg Administration method: intravenous infusion、Splenic artery infusion、Lymph node infusion; Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion (PI evaluation is required)
88869295|NCT06243146|Experimental|Titration|During OLV, FiO2 starts at 100%, decreases to 80% after 15 minutes of OLV, and maintains until the end of OLV.
88869296|NCT06243146|Active Comparator|Control|During OLV, FiO2 starts at 100%. Titration of inspired oxygen using blood gas analysis and SpO2 monitoring. The titration target is arterial blood gas analysis with PaO2 ≤ 200mmHg and 93% ≤ SpO2 ≤ 97%.
88869297|NCT06243133|Experimental|Dual antiplatelet therapy for 30 days|Clopidogrel 300mg on the first day, then 75mg/ day for 30 consecutive days; Aspirin 100mg/ day for 90 days
88869298|NCT06243133|Active Comparator|Dual antiplatelet therapy for 90 days|Clopidogrel 300mg on the first day, then 75mg/day for 90 consecutive days; Aspirin 100mg/day for 90 days
88869299|NCT06243120|Experimental|Study group|"The study group will receive lidocaine (2%) 1mg/ kg iv diluted by normal saline to a volume of 100 ml. The VAS will be assessed every 10 minutes for 60minutes after the treatment. A regression of more than 4 points of VAS score is considered a success and if less than 4 points, it is considered as a failure.~If intravenous lidocaine failed to manage pruritus after 30 minutes the patient will receive 20 mg intravenous propofol."
88869300|NCT06243120|Placebo Comparator|Control group|"The control group will receive 100 ml of normal saline as placebo effect and VAS will be assessed every 10 minutes for 60minutes after the treatment. A regression of more than 4 points of VAS score is considered a success and if less than 4 points, it is considered as a failure.~If intravenous lidocaine failed to manage pruritus after 30 minutes the patient will receive 20 mg intravenous propofol."
88869301|NCT06243107|Experimental|Tai-chi|Tai Chi Chuan Intervention: There are 10 styles ,Each movement is performed for 3 minutes, repeated 10 times, totaling 30 minutes per session. participants will engage Tai Chi practice six times a week for eight weeks.
88869302|NCT06243107|No Intervention|control|routine care
88869303|NCT06243081|Experimental|intervention group (Flipped Teaching Method Group)|Intervention group students will be given skill training with the Flipped Teaching method.
88869304|NCT06243081|No Intervention|Control group (Traditional Method Group)|Control group students will receive skill training with the traditional method. No intervention will be made.
88869305|NCT06243068|Experimental|Educate and Engage|Patients accrued and making treatment decisions while the clinic treating them is implementing Approach 1.
88869306|NCT06243068|Experimental|Educate and Engage Plus Kidney Supportive Care Program|Patients accrued and making treatment decisions while the clinic treating them is implementing Approach 2.
88869307|NCT06243042||Enuretic|Children complaining of monosymptomatic enuresis
88869308|NCT06243042||Non-enuretic|Healthy non enuretic children
88869309|NCT06242847||Insulin Sensitive (IS) with psoriasis|"Patients with plaque psoriasis and overweight/obese (BMI 25-35) found to have:~Hemoglobin A1c < 5.7%~Fasting plasma glucose: < 95 mg/dL~Fasting serum insulin: < 10 micro-international units per milliliter (μIU/mL)"
88869310|NCT06242847||Insulin Intermediate (II) with psoriasis|"Patients with plaque psoriasis and overweight/obese (BMI 25-35) found to have:~Hemoglobin A1c < 6.5%~Fasting plasma glucose: 80-125 mg/dL~Fasting serum insulin: 10-14 μIU/mL"
88869311|NCT06242847||Insulin Resistant (IR) with psoriasis|"Patients with plaque psoriasis and overweight/obese (BMI 25-35) found to have:~Hemoglobin A1c < 6.5%~Fasting plasma glucose: 80-125 mg/dL~Fasting serum insulin: ≥ 15 μIU/mL"
88869312|NCT06242535|Experimental|GLY-LOW supplement|This supplement is available for over-the-counter purchase. Each capsule is a combination of vitamins and natural products: Vitamin B1 (100mg); Vitamin B6 (50mg); Niacin (200mg); Alpha Lipoic Acid (150mg); and Piperine (15mg). Each participant will take this supplement daily in a pill form orally once in the morning. The test product will be two capsules a day with breakfast between 7:00 - 11:00 AM. The chosen doses were based on dose conversion from mice to humans and the prior data on safety for each of the compounds in humans.
88869313|NCT06242405|Experimental|Single-infusion group|Single peripheral venous infusion of stem cells
88869314|NCT06242405|Experimental|Double-infusion group|Repeated peripheral venous infusion of stem cells within one month
89392996|NCT05811338|Active Comparator|Project 1 - Phase 2: Tablet Control Condition|"Training will occur over 3 days and be conducted by research investigators in the participants' homes. Participants in the control condition will receive a tablet, internet support for 2 months and training (including training on cybersecurity). This will include instructions for accessing content similar to, but in 2-D, so less immersive than that included in the VR program (e.g., virtual museum tours, One click, etc.). Participants will complete all assessments and will be provided with an Android tablet that has a 10.1 display, built in modem, and a front facing camera. Research investigators are providing people with tablets for standardization. Research Assessor (RA) Training, Certification and Treatment Fidelity. At follow-up assessments, assessors and data analysts will be blinded to treatment condition."
89392997|NCT05811338|Experimental|Project 2 - Phase 2: Active Intervention Group|"Participants will receive a tablet with the adaptive program and be provided with internet service following the baseline assessment.~Participants will receive a 3-day training in their home that will include basic tablet/internet training and training on the features of the system. The training will also encompass a module on internet etiquette and security against potential spam and fraud. Participants will be provided with practice tasks in between sessions. Participants will be provided with a hands-on performance assessment at the end of the second session and concepts/procedures that are problematic will be reviewed."
88869315|NCT06242275||Postoperative delirium (POD) group|Patients who will develop postoperative delirium
89392998|NCT05811338|Active Comparator|Project 2 - Phase 2: Waitlist Control|Participants will receive a 3-day training in their home. Participants will also receive a tablet, internet support for 12 months and training. This will include instructions for accessing content pertaining to the research study.
89392999|NCT05811338|No Intervention|Project 3 - Phase 1: Problem Space Specification and Task Selection|Both the subject matter experts and older adult participants will participate in individual structured interviews for each activity category, 1.5 - 2 hours in length. This qualitative data will provide rich contextualized information regarding the specific needs of older adults for access to services, financial health management, and Medicare.gov services utilization. This data will be used to identify current barriers and facilitators to successful healthcare management that could be targeted by technology solutions and/obtain details of the challenges that are common in each activity category.
89393000|NCT05811338|No Intervention|Project 3 - Phase 2: Development of Digital Assistant Tools|The study includes one session that will last approximately 2 - 3 hours. The study involves interactions with digital assistants developed by the research team, the participants will answer structured interview questions regarding their experiences using the system. The researchers will assess the participants' comments along dimensions such as type of information requested, preference for format of information, points of confusion, and likes and dislikes of features, which will form the basis for a prioritized list of features/functions to be modified for the next prototype iteration.
89393001|NCT05811338|Experimental|Project 3 - Phase 3: DATA Condition|Participants in the DATA condition, instead of access to a generic digital assistant, will have DATA at their disposal to solve the queries and will be encouraged to use it as the primary resource. Qualitative data on how they use this tool, in isolation and in conjunction with other sources of information, will be collected. Following completion of the problems, as in Phase 2, measures of DATA usability will be collected including usefulness and comprehension associated with each tool, perceived mental workload, and usability with an efficient, two-item test based on the widely used System Usability Scale: UMUX-LITE). The investigators will then conduct an audio-recorded semi-structured exit interview about various perceptions participants had regarding the challenges associated with successfully solving the health-management problems.
89393002|NCT05811338|Active Comparator|Project 3 - Phase 3: Usual-Tool Control Condition|Participants will have access to a generic, non-adapted voice assistant available on a provided tablet. The experimenter will use a standard script that allows for guidance to participants in searching for information relevant to the problems. Participants will indicate when they are ready to move on to the next problem, which will be followed by their assessment of the confidence they have in having solved the problem, their comprehension of the information associated with the problem, their assessment of the usefulness of the available information, and the perceived mental workload they experienced in solving the problem. Investigators will track, code, and analyze participants' online interactions with any websites they use. For each of the three task activity domains, overall performance scores will be computed, as will performance scores for the simpler and more complex problems.
89393003|NCT05811325|Experimental|kinesio taping without craniosacral therapy|This group received Kinesio taping for improvement in pain,disability and quality of life.
89393004|NCT05811325|Active Comparator|kinesio taping group with craniosacral therapy|Group received kinesio Taping with craniosacral therapy for improvement in pain,disability and quality of life.
89393005|NCT05811273|Experimental|physical readiness training|Bend and Reach:5 repetitions, Rear Lunge:5 repetitions per leg, High Jumper:5 repetitions, Rower:5 repetitions, Squat Bender:5 repetitions, Windmill:5 repetitions, Forward Lunge:5 repetitions per leg, Prone Row:5 repetitions, Bent-Leg Body Twist:5 repetitions per side, Push-Up:5 repetitions.
89393006|NCT05811273|Active Comparator|control group|general routine exercises
89393007|NCT05811221|Active Comparator|single group|give esketamine 0.75 mg/kg at the time of induction
89393008|NCT05811221|Experimental|intermittent group|give esketamine 0.5mg/kg during anesthesia induction, and during the measuring ring esketamine 0.25mg/kg was given again
89393009|NCT05811208||surgical ICU patients|All surgical patients on the inpatient ward in the Department of Anesthesiology and Intensive Care
88869316|NCT06242275||No Postoperative delirium (POD) group|Patients who will not develop postoperative delirium
88869317|NCT06242262|Experimental|Deep neuromuscular block|Patients will receive deep neuromuscular block by using cis-atracurium
88869318|NCT06242262|Other|Moderate neuromuscular block|Patients will receive moderate neuromuscular block by using cis-atracurium.
88869319|NCT06242184|Experimental|Group A (Nano-fortified Adhesive)|Titanium dioxide nanoparticles incorporated in dentin adhesive
88869320|NCT06242184|Experimental|Group B (Adhesive without Nanoparticles)|Adhesive without nanoparticles
88869321|NCT06242119||J-PET group|The patient is referred for a PET/CT scan, in accordance with recognized indications for examining the brain or the entire body.
89393010|NCT05811195|Active Comparator|Intraoral photobiomodulation (PBMI)|"Intraoral application: A low-power laser (Diode Semiconductor, Duo, MMOptics Ltda, São Carlos, SP, Brazil) with a wavelength of 660 nm (red). Four anatomical areas will be irradiated perpendicularly in oral mucosa through several anatomical points with a distance of 1 cm approximately between them in order to cover the largest area per cm² in each region.~Application points:~Jugal mucosa: 4 points for each side: upper and lower internal buccal vestibule, (8 points).~Jugal mucosa for younger children 2 points internal buccal vestibule in the center - each side (4 points)~Tongue: 2 points on right and left lateral border and 1 point on right and left belly (6 points)~Oral floor: (2 points).~Upper and lower lips: 2 points on upper inner labial mucosa, 2 points on lower inner labial mucosa (4 points).~Soft palate: right and left sides (2 points)"
89393011|NCT05811195|Active Comparator|Extraoral photobiomodulation (PBME)|"A gallium-aluminum arsenide diode laser (Gemini® manufactured by Azena Medical, LLC, distributed by Ultradent Products, Inc.) with double wavelength 810 + 980 nm. The equipment will be programmed with 1 W of power.~4 points - on each side of the face (2 on the right 2 on the left);~2 points - on each side of the face: for younger children 1 point will be performed on each side of the face (1 on the right, 1 on the left)~1 point on the lip; patients with sealed lips being able to cover both the upper and lower lip;~5 points in the neck region (2 in right submandibular space and 2 in left submandibular space and submental space in the midline).~3 points in the neck region for younger children (1 in right submandibular space and 1 in left submandibular space and submental space in the midline)"
89393012|NCT05811169||Early or metastatic non-small cell lung cancer|The formalin-fixed paraffin-embedded specimen will be retrieved for next generation sequencing.
89393013|NCT05811104|Experimental|Active stimulation|Bilateral real TBS
89393014|NCT05811104|Sham Comparator|Sham stimulation|Bilateral Sham stimulation
89393015|NCT05811078|Experimental|Enterprise Group|"The contents of the research were created according to the Roy Adaptation model. Each session lasted an average of 2 hours.~Peer interactive group support sessions were administered to the adolescents in the intervention group, one week apart. There were 7 sessions in total. The sitting arrangement of the training room is designed to allow children to interact with each other . The sessions lasted an average of 90 minutes as two 45-minute sessions. Between sessions, breaks that lasted for about 15 minutes were given and refreshments prepared for individuals with Type 1 diabetes were served during the breaks. During the break, the adolescents were given the opportunity to interact with each other by chatting. Fun exercise and kitchen workshop activities were also organized as interaction sessions in the initiative group."
89393016|NCT05811078|No Intervention|Control Group|"Adolescents and their families were informed in the diabetes education room in the pediatric endocrine service of the hospital where the study was conducted, and their written consent was obtained. Within the scope of the pre-test, Diabetes Adolescent Diagnosis Form, Diabetes Information Evaluation Form, Diabetes Management Self-Efficacy Scale in Adolescents with Type 1 Diabetes and Child's Attitude towards Own Disease Scale were applied. Then, individual diabetes education was given by the diabetes education nurse as a hospital routine. Three months after the training, the adolescents were called by phone to the hospital for control, HbA1c follow-up was taken and post-test applications were made."
89393017|NCT05811052|Experimental|Suboccipital Release Group|
89393018|NCT05811052|Sham Comparator|Control Group|
89393019|NCT05811026|Experimental|Arm A: 2-week interval between treatments|The interval between the first, second, and third treatments in this arm is two weeks, and the follow-up session will take place four weeks after the third treatment.
89393020|NCT05811026|Experimental|Arm B: 4-week interval between treatments|The interval between the first, second, and third treatments in this arm is four weeks, and the follow-up session will take place four weeks after the third treatment.
89393021|NCT05811000|Active Comparator|Aricept 5 mg|Aricept 5 mg + Placebo of PM012 eight tablets, daily during 12 weeks (oral)
89393022|NCT05811000|Experimental|PM012 2,600 mg|PM012 2,600 mg + Placebo of PM012 four tablets +Placebo of Aricept one tablet, daily during 12 weeks (oral)
89393023|NCT05811000|Experimental|PM012 3,900 mg|PM012 3,900 mg + Placebo of PM012 two tablets +Placebo of Aricept one tablet, daily during 12 weeks (oral)
89393024|NCT05811000|Experimental|PM012 5,200 mg|PM012 5,200 mg + Placebo of Aricept one tablet, daily during 12 weeks (oral)
89393025|NCT05810922|Experimental|50 g arbutus berry|consumption of 50 g arbutus berry/day for 14 days
89393026|NCT05810922|Experimental|200 g arbutus berry|consumption of 200 g arbutus berry/day for 14 days
89393027|NCT05810909|Experimental|ACC group|ACC group use amorphous calcium carbonate
89393028|NCT05810909|Placebo Comparator|control group|control group use placebo
89393029|NCT05810350|Experimental|aumolertinib combined Ommaya reservoir intrathecal chemotherapy|Aumonertinib 165mg orally once daily and intrathecal chemotherapy with pemetrexed (30 mg was administered on days 1 and 8) once every 3 weeks.
89393030|NCT05801211||primary surgical tumor resection with anastomosis or only tumor resection without anastomosis|"primary surgical tumor resection with a primary colorectal anastomosis (associated or not with a diverting loop ileostomy) or without a primary anastomosis (Hartmann's procedure)"
89393031|NCT05801211||endoscopic stent positioning|staged resection after endoscopic stenting with Self-expandable Metallic Stent (SEMS)
88869322|NCT06241846|Experimental|Part 1|Patients will be treated with YL201 intravenous (IV) infusion once every 3 weeks (Q3W) as a cycle.
89393032|NCT05799391|Experimental|Active treatment (Soothing cream jel)|Soothing cream jel
89393033|NCT05799391|Placebo Comparator|Placebo|Placebo cream jel
89003684|NCT04806178|Placebo Comparator|Placebo|Placebo group (n = 16): 0.9% saline solution in the same volume as BCG vaccine in a single dose.
89393034|NCT05793489|Experimental|WBRT + Silibinin|Patients undergo WBRT concomitant to Silibinin
89393035|NCT05793489|No Intervention|WBRT|Patients undergo WBRT alone, total dose of 30 Gy in 10 fractions.
89393036|NCT05791110|Other|Pancreatic exocrine function|Strict clinical diagnosis and fecal pancreatic elastase 1 test were performed for each subject (including PEI patients (n=525) and non-PEI patients (n=528))
89393037|NCT05780060|Experimental|Intervention arm|standard stroke clinic follow, combined with remote patient blood pressure monitoring and an added patient-facing smartphone application with educational modules and adherence incentives (n=30).
89393038|NCT05780060|Active Comparator|Control arm|standard stroke clinic follow up combined with remote blood pressure monitoring
89393039|NCT05778136|No Intervention|Usual Care|Participants receive usual care
89393040|NCT05778136|Experimental|Usual Care + exercise|Participants receive usual care and one-leg resistance exercise training
89393041|NCT05773391|Experimental|Diarrhea group|Patients with diarrhea after taking pyrrolidine/naratinib，implement intervention (Yihuo 0.2g po bid+ Gold bifidum 2g po tid)
89393042|NCT05773391|No Intervention|No diarrhea group|Patients without diarrhea after taking pyrrolidine/naratinib
89393043|NCT05766982|No Intervention|Xenograft only|The Kerecis® xenograft (Kerecis® Omega3 MariGen) will be applied without the application of PRP.
89393044|NCT05766982|Experimental|Xenograft and PRP|The Kerecis® xenograft (Kerecis® Omega3 MariGen) will be applied with the application of PRP.
89393045|NCT05754853|Experimental|MRG002|MRG002 will be administrated by an IV infusion of 2.2 mg/kg on Day 1 of every 3 weeks (21-day cycle).
89393046|NCT05754853|Active Comparator|Docetaxel /Paclitaxel /Gemcitabine Hydrochloride /Pemetrexed Disodium Injection|"Docetaxel injection will be administered by an IV infusion of 75 mg/m2 on Day 1 of every 3 weeks (21-day cycle); Paclitaxel will be administrated by an IV infusion of 175 mg/m2 on Day 1 of every 3 weeks (21-day cycle).~Gemcitabine Hydrochloride will be administrated by an IV infusion of 1000 mg/m2 on Day 1 and Day 8 of every 3 weeks (21-day cycle).~Pemetrexed Disodium will be administrated by an IV infusion of 500 mg/m2 on Day 1 of every 3 weeks (21-day cycle)."
89393047|NCT05747625|Experimental|Diagnostic (89Zr panitumumab PET/CT)|Patients receive panitumumab IV, 89Zr panitumumab IV, and undergo PET/CT on study
89393048|NCT05744349|Experimental|Study group|Patients who are younger than the age of 10 years old from both genders and suffering from displaced fractures of shaft both bone of the forearm
89393049|NCT05742347|Experimental|DriGo SPT|All participants will have the DriGo skin protectant textile applied to their skin fold condition.
89393050|NCT05714267|Experimental|Active noise cancelling|Patients corresponding to the number 1 blocks in the randomization table according to the order of surgery were included in the active noise control group. Preoperative care of the patients was performed by clinical nurses. After transferring to the operating room and performing spinal anesthesia, the active noise control headset (Sony WH1000xm4) was placed on the patient's head. The active noise control feature of the headset was turned on and it was not removed until the dressing of the patient was closed at the end of the operation. In this group, the vital signs of the patients were followed up during the surgery. At the end of each surgery, the researcher disinfected the earplugs with an antiseptic solution containing 2% chlorhexidine. In addition, the battery level of the headset was checked and charged by the researcher when necessary. This ensures that the headset is ready for the next patient.
89393051|NCT05714267|Experimental|Passive noise cancelling|The patients corresponding to the number 2 blocks in the randomization table according to the order of operation were included in the passive noise control group. Preoperative care of the patients was performed by clinical nurses. After transferring to the operating room and performing spinal anesthesia, passive noise control headset (3M Peltor Optime II) was placed on the patient's head. The earphone was not removed until the dressing of the patient was closed at the end of the surgery. In this group, the vital signs of the patients were followed up during the surgery. At the end of each operation, the earplugs were disinfected by the researcher with an antiseptic solution containing 2% chlorhexidine and prepared for the next patient.
89003685|NCT04781244|Active Comparator|EndWarts® FREEZE in Soft keratin|EndWarts® FREEZE were treated to 11 patients with wart at soft keratin
89003686|NCT04781244|Active Comparator|EndWarts® FREEZE in Hard keratin|EndWarts® FREEZE were treated to 11 patients with wart at hard keratin
89003687|NCT04781244|Active Comparator|Liquid nitrogen in Soft keratin|Liquid nitrogen were treated to 11 patients with wart at soft keratin
89003688|NCT04781244|Active Comparator|Liquid nitrogen in Hard keratin|Liquid nitrogen were treated to 11 patients with wart at hard keratin
89003689|NCT04771273|Experimental|BI 456906 low dose|low dose
89003690|NCT04771273|Experimental|BI 456906 medium dose|medium dose
89003691|NCT04771273|Experimental|BI 456906 high dose|high dose
89003692|NCT04771273|Placebo Comparator|Placebo|Placebo
89003693|NCT04765332||Included patients|Fill patient questionnaires at inclusion visit, around 3 months and 12 months
89393052|NCT05714267|Experimental|Active noise cancelling with music therapy|Patients corresponding to blocks numbered 3 in the randomization table according to the order of surgery were included in the music therapy group. Preoperative care of the patients was performed by clinical nurses. After transferring to the operating room and performing spinal anesthesia, the headset (Sony WH1000xm4) was positioned on the patient's head as shown in Figure 3.7-5 (A). iPod Touch 7th Generation music player with Spotify mobile application was used for music application. The connection between the headset and the music player was provided via Bluetooth. Music chosen by the patient; Active noise control was turned on and the patient was listened to until the dressing was removed at the end of the operation. The vital signs of the patient during the operation were followed up. In addition, the battery level of the headset was checked and charged by the researcher when necessary. This ensures that the headset is ready for the next patient.
89393053|NCT05714267|No Intervention|Control group|Patients corresponding to blocks numbered 0 in the randomization table according to the order of surgery were included in the control group. The patients, whose preoperative care was performed by clinical nurses, were transferred to the operating room and spinal anesthesia was administered. No intervention was made in this group during the surgery. The vital signs of the patients were followed up during the operation.
89393054|NCT05703100|Active Comparator|Control|Maximal test on a cycle ergometer
89393055|NCT05703100|Experimental|Hyperthermia|Maximal test on a cycle ergometer at 35º-38º C room temperature
89393056|NCT05703100|Experimental|Glycogen depletion|Maximal test on a cycle ergometer after a glycogen depletion protocol
89393057|NCT05695300|Active Comparator|BLM ORGANIC GOLD+|BLM ORGANIC GOLD+ infant formula,800g/can
89393058|NCT05695300|Placebo Comparator|BLM ORGANIC|BLM ORGANIC infant formula,800g/can
89393059|NCT05695300|Other|Breast milk|Mother's breast milk
89393060|NCT05692869|Experimental|ABPM + Wearable Novel Devices + Propranolol|Participants will wear all the devices (ABPM, chest patch device, wrist device and smartwatch device) with propranolol administered orally for 5 days in one of three study periods.
89393061|NCT05692869|Experimental|ABPM + Wearable Novel Devices + Pseudoephedrine|Participants will wear all the devices (ABPM, chest patch device, wrist device and smartwatch device) with pseudoephedrine administered orally for 5 days in one of three study periods.
89393062|NCT05692869|Experimental|ABPM + Wearable Novel Devices Only|Participants will wear all the devices (ABPM, chest patch device, wrist device and smartwatch device) during one of three study periods.
89393063|NCT05691439|Experimental|"Sleep extension and advance Lark Routine"|Participants go to bed 90 minutes earlier than their typical average bedtime to extend sleep duration and advance sleep timing
89393064|NCT05691439|Active Comparator|"Regular sleep duration and timing Owl Routine"|Participants go to bed at their typical average bedtime
89393065|NCT05679284||Cases: Intravenous drug users with drug needle fragment retentions|All intravenous drug users from the service units will be asked to participate. X-ray imaging has the goal to identify patients with needle fragment retentions in subcutaneous tissue.
89393066|NCT05679284||Controls: Intravenous drug users without drug needle fragment retentions|All intravenous drug users from the service units will be asked to participate. Control group consists of those with no radiologically confirmed subcutaneous needle fragment retentions.
89393067|NCT05663476|Experimental|Control group|Periodontally and systemically healthy participants
89393068|NCT05663476|Experimental|Periodontitis without coronary artery disease|Periodontitis participants without coronary artery disease
89393069|NCT05663476|Experimental|Periodontitis with coronary artery disease|Periodontitis participants with coronary artery disease
89393070|NCT05660226|Experimental|Intervention|Home blood pressure monitoring + E-coaching
89393071|NCT05660226|Placebo Comparator|Control|Standard care in patients with hypertension
89393072|NCT05655468|Experimental|dronedarone|dronedarone 400mg twice a day for 9 months
89393073|NCT05655468|Placebo Comparator|placebo|Placebo(for dronedarone ) a day for 9 months
89393074|NCT05650242|Experimental|BA1106|"Part A (Dose-Escalation): Mixed solid tumors participants will receive ascending doses of BA1106. BA1106 will be administered by intravenous (IV) infusion. The observation period of Dose Limiting toxicity (DLT) is 28 days, then the participants will receive BA1106 every three weeks (Q3W) until confirmed progression, death, unaccepted toxicity, initiation of other antitumor therapies, or any other conditions requiring treatment discontinuation, and the maximum duration of administration was no more than 2 years.~Part B (Dose-Expansion): Participants of selected tumors will receive a fixed dose of BA1106 that selected according to the results of Part A once every 3 weeks (Q3W) or once every 2 weeks (Q2W), until confirmed progression, death, unaccepted toxicity, initiation of other antitumor therapies, or any other conditions requiring treatment discontinuation, and the maximum duration of administration was no more than 2 years."
89393075|NCT05649488|Experimental|Experimental group|184 patients were enrolled in the experimental group
89393076|NCT05649488|Other|Optical Coherence Tomography Subgroup|70 patients in the test group were enrolled in the OCT subgroup.
89393077|NCT05645627|Placebo Comparator|Group 1|Participants receive placebo through week 16,placebo participants will cross over to receive IBI112 through week 48
89393078|NCT05645627|Experimental|Group 2|Participants receive Dose 1 IBI112 through week 16 ,and then will receive Dose 2 IBI112 through week 48
89393079|NCT05645627|Experimental|Group 3|Participants receive Dose 1 IBI112 through week 16 ,and then will receive Dose 3 IBI112 through week 48
89393080|NCT05644353|Experimental|Mirikizumab Solution (Reference)|Mirikizumab administered by subcutaneous injection (SC) via a prefilled syringe (PFS) at 3 different injection sites (arm, thigh, and abdomen).
89393081|NCT05644353|Experimental|Mirikizumab Solution (Test)|Mirikizumab administered by SC via a PFS at 3 different injection sites (arm, thigh, and abdomen).
89393082|NCT05638542||Control group|Patients who are not diagnosed with colorectal adenoma or colorectal cancer
89393083|NCT05638542||Colorectal adenoma group|Patients who are diagnosed with colorectal adenoma
89393084|NCT05638542||Colorectal cancer group|Patients who are diagnosed with colorectal cancer
89393085|NCT05628155|Experimental|Oral diet including n-3 PUFA intake|Oral diet covering the nutritional requirements in macronutrients as recommended for people over 65 years of age (ANSES, 2019) and including intakes of n-3 PUFAs corresponding to the recommendations for people over 65 years of age
89393086|NCT05628155|No Intervention|Control|
89393087|NCT05620966||Patients with transient neurological symptoms and CT-negative for stroke|Patients may have transient neurological symptoms at any time point
89393088|NCT05620966||Patients with known stroke confirmed either on imaging or by stroke physician|
89393089|NCT05620966||Patients with no prior history of stroke|
89393090|NCT05617287|Experimental|Semaine Supplement|Participants are provided with a dietary supplement and are instructed to take 1 capsule per day. Participants are to take the supplement at the same time every day. If forgotten, they are to take it with the next meal. Participants will take a well-being assessment after each month (4 surveys total including the baseline.)
88869323|NCT06241846|Experimental|Part2|Patients will be treated with YL201 intravenous (IV) infusion at recommended dose of YL201 for the pivotal clinical study once every 3 weeks (Q3W) as a cycle.
88869324|NCT06241482|Experimental|Enhanced recovery after surgery|The technologies, processes and measures of enhanced recovery after surgery were applied.
88869325|NCT06241482|Active Comparator|Conventional therapy|Conventional therapy were applied.
88869326|NCT06240858|Experimental|TAPP group|The TAPP group underwent laparoscopic transperitoneal preperitoneal hernia repair.
88869327|NCT06240858|Experimental|Lichtenstein group|The Lichtenstein group underwent Lichtenstein hernia repair.
88869328|NCT06240598|Experimental|Second Look Laparoscopy (SLL)|Patients will be treated with standard of care observation or maintenance therapy as per investigator decision.The only investigational intervention performed through this study is the SLL.
88869329|NCT06240533||Historical baseline|Patients with LBP in a retrospective register based study of health care quality indicators covering historical time series data from regional health care databases in Sweden before dissemination by publication of the P3C pathway (January 2013-June 2023).
88869330|NCT06240533||Dissemination|Patients with LBP in a prospective register based study of health care quality indicators for phase 1 (January 2013-June 2023) compared to phase 2 (June 2023- February 2024) after dissemination by publication of the P3C pathway for LBP.
88869331|NCT06240533||Single-faceted implementation|Patients with LBP in a prospective register based study of health care quality indicators for phases 1+2 (January 2013-February 2024) compared to phase 3 (March 2024-February 2026) after single-faceted implementation (health care practitioner workshop) of the P3C pathway for LBP. Health care practitioner confidence in managing LBP and perspectives regarding barriers and facilitators determining implementation P3C pathway success will also be investigated via questionnaires and qualitative interviews directly after and 1 year prospectively the implementation intervention.
88869332|NCT06240533||Multi-faceted implementation|Patients with LBP in a prospective register based study of health care quality indicators for phases 1+2+3 (January 2013-February 2026) compared to phase 4 (March 2026-December 2027) after multi-faceted implementation (repeated health care practitioner workshops and follow-up) of the P3C pathway for LBP.
88869333|NCT06239675|Experimental|tDCS+CIMT|Participants will receive concurrent anodal tDCS (20 minutes, 1mA~2mA) and CIMT (2 hours) five days a week for three weeks in a row.
89393091|NCT05615480|No Intervention|Control group|The control group maintain the target blood pressure only according to the controlled hypotension guideline.
89393092|NCT05615480|Experimental|Experimental group|The experimental group adjust the controlled hypotension level under the guidance of cerebral oxygen saturation monitoring.
89393093|NCT05604924|Experimental|Participants who received virtual reality training|
88869334|NCT06239675|Sham Comparator|sham+CIMT|Participants will receive concurrent sham tDCS and CIMT (2 hours) five days a week for three weeks in a row.
88869335|NCT06239038|Experimental|scalpel group|"Proceed with following step~Using electrocautery for stop bleeding at subcutaneous tissue layer~In deep layer still use scalpel for Remove anterior cruciate ligament and posterior cruciate ligament~Soft tissue removal and synovial tissue removal~No patellar denervation"
88869336|NCT06239038|Experimental|electrocautery group|"Using an electrocautery in following step~Stop bleeding at subcutaneous tissue layer~Remove anterior cruciate ligament and posterior cruciate ligament~Bony mark for further bone cut~Patellar denervation~Soft tissue removal~Synovial tissue removal"
89393094|NCT05604924|Placebo Comparator|Participants who received similar contents in a standard PowerPoint presentation on a laptop|
89393095|NCT05600400|Experimental|Arm 1|Two weekly fractions of 13.5 Gy
88869337|NCT06238778|Experimental|HDV Lispro (HDV-L)|Subjects in this arm will use degludec as their daily basal insulin, and HDV-lispro as their bolus insulin
88869338|NCT06238778|Active Comparator|Lispro (LIS)|Subjects in this arm will use degludec as their daily basal insulin and lispro as their bolus insulin
88869339|NCT06238024|Experimental|Tocilizumab group|Intravenously for more than 1 hour.
88869340|NCT06238024|Placebo Comparator|Control group|Intravenously for more than 1 hour.
88869341|NCT06237998||Matched control group|Sex and age matched control group (5:1) from the Swedish heart failure register (1500 patients). No intervention.
89393096|NCT05600400|Active Comparator|Arm 2|Five every other day fractions of 8 Gy
89393097|NCT05576051||All TNFi initiations|
89393098|NCT05576051||TNFi initiations after 11/6/2012 for comparisons with Tofacitinib initiators|
89393099|NCT05576051||RA patient in Corrona with initiation Tofacitinib during follow-up in Corron|
89393100|NCT05575687|Other|Water|Ingestion of 500 ml of mineral water
89393101|NCT05575687|Other|Sucrose|Ingestion of 500 ml of a flavored mineral water sweetened with sucrose
89393102|NCT05575687|Other|Sucralose|Ingestion of 500 ml of a flavored mineral water sweetened with sucralose
89393103|NCT05575687|Other|Stevia|Ingestion of 500 ml of a flavored mineral water sweetened with stevia extract
89393104|NCT05575687|Other|Monk fruit|Ingestion of 500 ml of a flavored mineral water sweetened with monk fruit extract
89393105|NCT05575687|Other|Allulose + stevia|Ingestion of 500 ml of a flavored mineral water sweetened with allulose and stevia extract
89393106|NCT05568277|Experimental|Education|A minimum of 12-week training program and follow-up based on Pender's Health Promotion Model is planned until the 24th gestational week.
89393107|NCT05568277|No Intervention|Control|No intervention will be made by the researcher and they will receive routine antenatal care. After the post-test data are collected, the education booklet prepared by the researcher will be given to the pregnant women and sent to their e-mail addresses.
89393108|NCT05563389|Placebo Comparator|PLACEBO|
89393109|NCT05563389|Active Comparator|statin|
89393110|NCT05557214|Experimental|Audit and Feedback Letter|This group will receive 2 audit and feedback letters and a study closure letter.
89393111|NCT05557214|No Intervention|No Audit and Feedback Letter|This group will only receive a study closure letter.
89393112|NCT05532917||Gupta group|Cardiology consultation requested using Gupta score
89393113|NCT05532917||Non-Gupta group|Number of cardiology consultations requested without using Gupta score
89393114|NCT05530434|Experimental|Transpulmonary pressure guided positive end expiratory pressure|Patients in this group will have the positive end expiratory pressure on the ventilator set to a transpulmonary pressure of 0-2 cm H2O during ventilation and spontaneous breathing trials.
89393115|NCT05530434|Active Comparator|Standard positive end expiratory pressure|Patients in this groups will have the positive end expiratory pressure on the ventilator set by the clinician during ventilation and set to a standard positive end expiratory pressure of 5-8 cm H2O during spontaneous breathing trials.
89393116|NCT05530265|Experimental|Smart watch group|The user of the smart watch and Samsung Health app
89393117|NCT05530265|No Intervention|Usual care|No use of both the smart watch and Samsung Health app
89393118|NCT05511766|Placebo Comparator|PLACEBO|Group1: (Placebo, n=50) who will receive oral placebo tablet once daily FOR 6 MONTHS
88869342|NCT06237998||Telemonitored group|Patients with new or worsening heart failure with, assessed to be in need of follow-up in a cardiology clinic (n=300).
88869343|NCT06237270||Successful biceps recovery|Motor power more than or equal to grade 3 at 24 months after surgery
88869344|NCT06237270||Failure of biceps recovery|Motor power less than grade 3 at 24 months after surgery
88869345|NCT06236633|No Intervention|Control group|In the control group, patients will undergo standard management.
88869346|NCT06236633|Experimental|Ischemic preconditioning group|"In the experimental group, patients will undergo preoperative arteriography and ischemic preconditioning One blood sample will be taken before and two samples taken after embolization of the IMA.~These patients will receive a phone call on Day 7 post embolization. A blood sample will also be taken at the time of surgery."
88869347|NCT06235606|Active Comparator|To receive supraclavicular BPB using liposomal bupivacaine with standard bupivacaine|10ml of 0.5% plain bupivacaine and 10ml of 1.33% liposomal bupivacaine will be injected.
88869348|NCT06235606|Active Comparator|To receive supraclavicular BPB using dexmedetomidine with standard bupivacaine|19.5ml of 0.5% plain bupivacaine and 0.5ml (50mcg) of dexmedetomidine will be injected.
88869349|NCT06234553||training set and validation set|Retrospective study focusing on the diagnosis and treatment outcomes of pituitary adenomas
88869350|NCT06232434|Experimental|Experimental arm|"after diagnostic laparotomy/laparoscopy, a single intraperitoneal administration of the study drug Prospidelong, produced by UNITEHPROM BSU, Republic of Belarus, further in accordance with the protocols of the Ministry of Health of the Republic of Belarus for the treatment of patients with the corresponding pathology, systemic chemotherapy in accordance with the clinical protocol Diagnosis and treatment of malignant neoplasms&#34; (approved by Resolution of the Ministry of Health of the Republic of Belarus No. 60 of 07/06/2018)."
89393119|NCT05511766|Active Comparator|Allopurinol|Group 2:(Allopurinol n=50) who will receive oral allopurinol 300 mg daily for 6 months
89393120|NCT05511766|Active Comparator|Simvastatin|Group 3: (atorvastatin n=50) who will receive oral atorvastatin 20 mg daily for 6 months
89393121|NCT05505422|Experimental|On demand ECMO (study group)|
89393122|NCT05505422|Active Comparator|Routine ECMO (control group)|
89393123|NCT05501444|Experimental|Effect of antiperspirant|Aluminium chloride 15 percent
89393124|NCT05495711|Experimental|stem cell and collagen transplantation group|Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-UT)
89393125|NCT05495711|Active Comparator|control group|collagen transplantation
89535420|NCT03221725|Experimental|sacrospinosus fixation group|The group which sacrospinous fixation was performed
89535421|NCT03319043|Experimental|treatment group|patients are treated with Budesonide + Formoterol Fumarate dry powder (160/4.5ug bid) for inhalation and additional Chanqin granules 10g three times a day. All granules will be taken orally with 200 ml warm water.
89535422|NCT03319043|Placebo Comparator|controlled group|patients enrolled in the research are treated with Budesonide + Formoterol Fumarate dry powder (160/4.5ug bid) for inhalation and Chanqin analogous granules. All granules will be taken orally with 200 ml warm water.
89393130|NCT05479604|Experimental|SinuSonic Group|Subjects will use the SinuSonic device for 2 minutes twice daily for 8 weeks
89393131|NCT05479604|Sham Comparator|Sham Group|Subjects will use the sham device for 2 minutes twice daily for 8 weeks
89393132|NCT05468346|Experimental|[14C]-HEC585|[14C]-HEC585,solid powder，200 mg/100 µCi,single dose，oral
89393133|NCT05466734|Other|Treatment RTRT (R: Cilostazol, T: PMR)|"Treatment R: One Cilostazol Tablet 100 mg at 08:00 and another at 20:00~Treatment T: Two PMR Tablet 135 mg at 08:00~Four-period dosing following the sequence of Treatment RTRT"
89393134|NCT05466734|Other|Treatment TRTR (T: PMR, R: Cilostazol)|"Treatment R: One Cilostazol Tablet 100 mg at 08:00 and another at 20:00~Treatment T: Two PMR Tablet 135 mg at 08:00~Four-period dosing following the sequence of Treatment TRTR"
89393135|NCT05452317||Chronic active AMR group|
89393136|NCT05452317||Non-Chronic active AMR group|
89393137|NCT05439395||STEELEX|Steelex® Sternum Set for sternal closure
89393138|NCT05421988|Experimental|Individual EFT Therapy|Personal EFT instruction and practice group
89393139|NCT05421988|Experimental|Group EFT Therapy|Group EFT instruction and practice group
89393140|NCT05421988|No Intervention|Wait List|Wait list control group
89393141|NCT05420402|Active Comparator|Bolus group A|42 participants will receive 1 mg/kg intravenous bolus of propofol 3 min before the end of surgery.
89393142|NCT05420402|Active Comparator|Continuous infusion group|42 participants will receive 1 mg/kg continuous intravenous pumping of propofol 3 minutes before the end of the operation, and the pumping time was 3 minutes.
89393143|NCT05420402|Active Comparator|Bolus group B|42 participants will receive 1 mg/kg intravenous bolus of propofol at the end of surgery.
89393144|NCT05420402|No Intervention|Blank Comparator group|42 participants will not receive propofol
89393145|NCT05417087|Experimental|SF001 administered without water|test product administered without water
89393146|NCT05417087|Experimental|SF001 administered with water|test product administered with water
88869351|NCT06232434|Placebo Comparator|Comparison group|"after diagnostic laparotomy/laparoscopy, systemic chemotherapy in accordance with the clinical protocol Algorithms for the diagnosis and treatment of malignant neoplasms (approved by Resolution of the Ministry of Health of the Republic of Belarus No. 60 of 07/06/2018), namely the section regulating the treatment of patients suffering from metastatic gastric cancer with the degree of prevalence of the tumor process corresponding to sT1-4N0-3M1."
88869352|NCT06232421|Experimental|Patients with the neuropathic form. Treatment with Foscelantan|"A prospective, parallel, single-blind clinical study using stratified randomization of the effectiveness, tolerability and safety of the drug Foscelantan, medicinal plate 4.0×5.0 cm in package No. 1 produced by UNITEHPROM BSU, Republic of Belarusin adult patients with purulent-inflammatory processes of the skin and soft tissues due to the neuropathic form of diabetic foot syndrome, phase I-II wound process. All patients will receive systemic traditional therapy for the underlying and concomitant diseases."
88869353|NCT06232421|Active Comparator|Patients with the neuropathic form. Treatment with Povidone-iodine|A prospective, parallel, single-blind clinical study using stratified randomization of the effectiveness, tolerability and safety of the drug Povidone-iodine produced by BelAseptika JSC, in adult patients with purulent-inflammatory processes of the skin and soft tissues due to the neuropathic form of diabetic foot syndrome, phase I-II wound process. All patients will receive systemic traditional therapy for the underlying and concomitant diseases.
88869354|NCT06232421|Experimental|Patients with chronic venous insufficiency. Treatment with Foscelantan|"A prospective, parallel, single-blind clinical study using stratified randomization of the effectiveness, tolerability and safety of the drug Foscelantan, medicinal plate 4.0×5.0 cm in package No. 1 produced by UNITEHPROM BSU, Republic of Belarus in adult patients with purulent inflammatory processes of the skin and soft tissues due to chronic venous insufficiency, phase I-II of the wound process. All patients will receive systemic traditional therapy for the underlying and concomitant diseases."
88869355|NCT06232421|Active Comparator|Patients with chronic venous insufficiency. Treatment with Povidone-iodine|A prospective, parallel, single-blind clinical study using stratified randomization of the effectiveness, tolerability and safety of the drug Povidone-iodine produced by BelAseptika JSC, in adult patients with purulent-inflammatory processes of the skin and soft tissues due to chronic venous insufficiency&#34;, phase I-II of the wound process . All patients will receive systemic traditional therapy for the underlying and concomitant diseases.
88869356|NCT06232369|Experimental|Patient group + active stimulation intervention|Patient participants with anxiety disorders in this arm will first accept active repetitive stimulation on core brain regions and then complete the threat reversal learning paradigm.
88869357|NCT06232369|Sham Comparator|Patient group + sham stimulation intervention|Patient participants with anxiety disorders in this arm will first accept sham repetitive stimulation on core brain regions and then complete the threat reversal learning paradigm.
88869358|NCT06232369|Sham Comparator|Healthy control group + sham stimulation intervention|Healthy participants in this arm will first accept sham repetitive stimulation on core brain regions and then complete the threat reversal learning paradigm.
88869359|NCT06231368|Experimental|CNCT19 CAR T-Cell Therapy|Participants will receive CNCT19 cell infusion after preconditioning, and they need to be closely monitored for 24 hours following CAR-T cell infusion. Participants are advised to remain in the hospital for a minimum of 14 days following cell infusion. The duration of hospitalization and observation will be determined based on the researcher's comprehensive assessment of the subject's condition.
88869360|NCT06228807||HFpEF patients with metabolic abnormalities|
89393147|NCT05417087|Experimental|Trintellix|Reference product administered with water
88869361|NCT06228807||HFpEF patients without metabolic abnormalities|
88869362|NCT06225817|Experimental|Open label placebo arm|Participants who are assigned to the OLP group will be given a bottle of OLP pills. They will be asked to take one pill per day for 45 days. They will be introduced to placebo effects and the therapeutic potential of using open-label placebo for chronic pain management and sleep improvement.
88869363|NCT06225817|No Intervention|Wait-list arm|Participants in the wait-list group will not receive OLP pills until the end of the 45-day monitoring period. Therefore, the 45 days without OLP will serve as an no intervention comparators relative to the OLP group.
88869364|NCT06222957||HER2 positive group|HER2-positive (HER2+) and Estrogen receptor-positive (ER+) breast cancer patients undergoing adjuvant chemotherapy including trastuzumab.
88869365|NCT06222957||Control group|HER2-negative breast cancer patients (HER2-) and Estrogen receptor-positive (ER+) breast cancer patients undergoing adjuvant chemotherapy without trastuzumab.
88869366|NCT06222138|Experimental|Patients with newly diagnosed glioblastoma|
88869367|NCT06218472||Day hospital patient|Acceptance of the DH program (DH group): scheduling of 10 to 12 sessions over 12 weeks during a program session, followed by a reassessment at the end of the program. Outpatient follow-up thereafter.
88869368|NCT06218472||Outpatient|"Refusal or inability to participate in the DH program: multidisciplinary follow-up as usual within the service (outpatient group)."
88869369|NCT06218472||Parents|
88869370|NCT06217679|Experimental|Control Oral Glucose Tolerance Test|This visit will include a baseline OGTT to be used as a pre-exercise baseline measure for each of the arms. Participants will then consume a 75g glucose beverage (Trutol, Thermo Scientific) and blood samples will be drawn at 0, 10, 20, 30, 45, 60, 75, 90 and 120 minutes post consumption.
89393148|NCT05416957|Experimental|SF001 ODT administered under fasting condition|Investigational product administration under fasting condition
89393149|NCT05416957|Experimental|SF001 ODT administration under fed condition|Investigational product administration under fed condition
89393150|NCT05416762|Experimental|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 5 mg|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 5 mg
89393151|NCT05416762|Experimental|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 10 mg|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 10 mg
89393152|NCT05416762|Experimental|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 20 mg|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 20 mg
89393153|NCT05408949|Experimental|SEP+FR|- Single exercises program (SEP) is considered to be harmless, valid and has a valuable prescription as initial rehabilitation program. studies showed an immediate analgesic relief and increase in muscle strength after preforming single heavy-load isometric training program
89393154|NCT05408949|Active Comparator|SSMP+ETL+HSR+FR Group|"The Shoulder Symptom Modification Procedure (SSMP) consists of applying several mechanical techniques and applied when the patient moves or performs a specific activity. This procedure is designed to address the symptoms and improve range of motion by identifying mechanical changes.~Heavy slow resistance (HSR) training is an alternative from traditional exercise physiotherapy, by emphasizing on heavy weights and slow repetition. HSR training includes repetitive gradual and slow contraction of the muscle during concentric, isometric and eccentric phases against a heavy weight~Early controlled and progressive tendon loading (EPTL) in rehabilitation practice is suggested to show a high and definite impact on healing and recovery of the tendon"
89393155|NCT05404113|Experimental|sustained natural apophyseal glide|Mulligan's C1-C2 self-SNAG + Conventional PT
89393156|NCT05404113|Experimental|deep friction massage|Cyriax deep friction massage+ Conventional PT
89393157|NCT05402540|Experimental|STRAIN COUNTER STRAIN GROUP|Strain Counter Strain Technique in combination with conventional physiotherapy
89393158|NCT05402540|Experimental|ACTIVE RELEASE TECHNIQUE GROUP|Active Release Technique in combination with conventional physiotherapy
89393159|NCT05398588|Experimental|Cyriax Deep Friction Massage|Cyriax Deep Friction Massage on targeted muscles (Supraspinatus, Infraspinatus, subscapularis, Deltoid and Pectoralis) 3 minutes each muscle (15 mins in total ) x 1 set , 3 days / week
89393160|NCT05398588|Experimental|Spencer Muscle energy technique|"The Spencer technique will be applied in Abduction, External rotation and Internal rotation for targeting muscles Supraspinatus, Infraspinatus, subscapularis, Deltoid and Pectoralis.~10 repetitions x 3set , 3 days/weeK"
89393161|NCT05391607|Experimental|Albumin 20%|3mL/kg (ideal body weight) completed by a Ringer-lactate crystalloid ratio 1:1 to total amount of blood loss during removal of the bladder (i.e. the bleeding part) of cystectomy procedures.
89393162|NCT05391607|Experimental|Albumin 5%|12ml/kg (ideal body weight) completed by a Ringer-lactate crystalloid ratio 1:1 to total amount of blood loss during removal of the bladder (i.e. the bleeding part) of cystectomy procedures.
89393163|NCT05391607|Active Comparator|Ringer-lactate|Ratio 3:1 of total of blood loss during removal of the bladder (i.e. the bleeding part) of cystectomy procedures.
89393164|NCT05388097|No Intervention|Standard Of Care - No Managed Services|Subjects receive standard medical care and follow-up after hospital discharge
89393165|NCT05388097|Experimental|Managed Services After Discharge|Subjects receive in-home assessment and care coordination/connection with community resources after hospital discharge
89393166|NCT05377190|Experimental|For patients followed in a heart failure clinic (HFC), intervention HFC-IN|Use of the full Continuum solution: remote patient monitoring and digital therapeutics over a period of 12 weeks
89393167|NCT05377190|Placebo Comparator|For patients followed in a HFC, control HFC-IN|Standard of care for the follow-up, no use of remote monitoring or digital therapeutics for the first 12 weeks. After 12 weeks, option is given to the patient to use the full Continuum solution for another period of 12 weeks.
88869371|NCT06217679|Experimental|High intensity interval exercise (HIIE)|Participants performed a High intensity interval exercise (HIIE) bout which includes 10 x 1 min at 90% maximum heart rate (HRmax) with 5 min warm up and 5 min cool down at 50watts (low state steady cycling). 90mins following the exercise bout participants will undergo another oral glucose tolerance test.
89393168|NCT05377190|Experimental|For patients not followed in a HFC, intervention HFC-OUT|Use of part of the Continuum solution: the patient will use a mobile application to enter her/his data but no remote monitoring is performed. Digital therapeutics are used for the healthcare professionals.
89393169|NCT05377190|Placebo Comparator|For patients not followed in a HFC, control HFC-OUT|Standard of care for the follow-up, no use of a mobile application or digital therapeutics for the first 12 weeks. After 12 weeks, option is given to the patient to use the mobile app and digital therapeutics are activated for another period of 12 weeks.
89393170|NCT05365802|Experimental|68Ga-FAPi-46|Patients receive 68Ga-FAPi-46 IV and undergo PET/CT scan over 20-50 minutes
89393171|NCT05363826|Experimental|Photochemotherapy as an adjuvant to surgical resection of glioblastoma|3-(1-Butyloxy)ethyl-3-deacetyl-bacteriopurpurin-18-n-butylimide methyl ester (Photobac®) is injected 24 hours prior to surgical resection of a recurrent Glioblastoma or gliosarcoma. Immediately following the resection the cavity is treated with 50 joules/ square cm of 787 nm light .The drug dose is escalated using three patient cohorts until a dose limiting toxicity is reached or the upper limit of the 8 step escalation is reached.
89393172|NCT05358639|Experimental|Single|Olaparib tablet will be administered alone for 14 days at a starting dose of 200 mg twice daily (bid). Subsequently olaparib will be administered continuously over 28 days at a fixed dose and the dose of navitoclax will be escalated. Navitoclax will be administered daily. The initial dose of olaparib 200 mg has been selected after considering the single agent Phase I/II dose based and on ongoing combination studies on expected toxicity and evidence for reduced PARP inhibition
89393173|NCT05355090|Experimental|Protein Pacing|During the 8 week trial, the Protein Pacing (PP) group will consume 3 daily servings of whey protein powder mixed with water at timed intervals: morning (0600-0800), afternoon (1000-1400), and evening (2000-2200) in addition to their normal food intake.
89393174|NCT05355090|No Intervention|Standard Diet|The participants in the CON will continue with their usual habitual dietary intake over the 8-week study and receive no intervention.
89393175|NCT05347225|Experimental|Nemtabrutinib|Participants receive nemtabrutinib at specified dose orally once daily (QD) until progressive disease (PD) or discontinuation.
89393176|NCT05330871|Experimental|1. Adolescent booster sentinel group|1 dose of 0.1ml Ad5-nCoV-IH
89393177|NCT05330871|Experimental|2. Adolescent booster safety group to receive Ad5-nCoV-IH|1 dose of 0.1ml Ad5-nCoV-IH
89393178|NCT05330871|Experimental|3. Adolescent booster immuno-persistency group to receive Ad5-nCoV-IH|1 dose of 0.1ml Ad5-nCoV-IH
89393179|NCT05330871|Experimental|4. Adolescent booster cellular immunity group to receive Ad5-nCoV-IH|1 dose of 0.1ml Ad5-nCoV-IH
89393180|NCT05330871|Experimental|5. Adolescent booster safety group to receive Ad5-nCoV-IM|1 dose of 0.3ml Ad5-nCoV-IM
89393181|NCT05330871|Experimental|6. Adolescent booster immuno-persistency group to receive Ad5-nCoV-IM|1 dose of 0.3ml Ad5-nCoV-IM
89393182|NCT05330871|Experimental|7. Adolescent booster cellular immunity group to receive Ad5-nCoV-IM|1 dose of 0.3ml Ad5-nCoV-IM
89393183|NCT05330871|Active Comparator|8. Adolesent booster safety group to receive ICV|1 dose of 0.5ml ICV
89393184|NCT05330871|Active Comparator|9. Adolescent booster immunopersistency group to receive ICV|1 dose of 0.5ml ICV
89393185|NCT05330871|Active Comparator|10. Adolescent booster cellular immunity group to receive ICV|1 dose of 0.5ml ICV
89393186|NCT05330871|Experimental|11. Children booster sentinel group to receive Ad5-nCoV-IH|1 dose of 0.1ml Ad5-nCoV-IH
89393187|NCT05330871|Experimental|12. Children booster safety group to receive Ad5-nCoV-IH|1 dose of 0.1ml Ad5-nCoV-IH
89393188|NCT05330871|Experimental|13. Children booster immuno-persistency group to receive Ad5-nCoV-IH|1 dose of 0.1ml Ad5-nCoV-IH
89393189|NCT05330871|Experimental|14. Children booster cellular immunity group to receive Ad5-nCoV-IH|1 dose of 0.1ml Ad5-nCoV-IH
89393190|NCT05330871|Experimental|15. Children booster safety group to receive Ad5-nCoV-IM|1 dose of 0.3ml Ad5-nCoV-IM
89393191|NCT05330871|Experimental|16. Children booster immuno-persistency group to receive Ad5-nCoV-IM|1 dose of 0.3ml Ad5-nCoV-IM
89393192|NCT05330871|Experimental|17. Children booster cellular immunity group to receive Ad5-nCoV-IM|1 dose of 0.3ml Ad5-nCoV-IM
89393193|NCT05330871|Active Comparator|18. Children booster safety group to receive ICV|1 dose of 0.5ml ICV
89393194|NCT05330871|Active Comparator|19. Children booster immuno-persistency group to receive ICV|1 dose of 0.5ml ICV
89393195|NCT05330871|Active Comparator|20. Children booster cellular immunity group to receive ICV|1 dose of 0.5ml ICV
89393196|NCT05330871|Experimental|21. Adolescent primary sentinel group|2 doses of 0.1ml Ad5-nCoV-IH, 56 days interval
89393197|NCT05330871|Experimental|22. Adolescent primary group|2 doses of 0.1ml Ad5-nCoV-IH, 56 days interval
89393198|NCT05330871|Experimental|23. Children primary sentinel group|2 doses of 0.1ml Ad5-nCoV-IH, 56 days interval
89393199|NCT05330871|Experimental|24. Children primary group|2 doses of 0.1ml Ad5-nCoV-IH, 56 days interval
89393200|NCT05324228||Preschool children|10 preschool healthy children aged 3-5,9 years.
89393201|NCT05324228||Children of younger school age|10 children of younger school age aged 6-10,9 years.
89393202|NCT05324228||Children in puberty|10 children in puberty aged 11-14,9 years
89393203|NCT05324228||Postpubertal adolescents|10 postpubertal adolescents aged 15-18,9 years.
89393204|NCT05314153|Experimental|Open Label - Active Drug|Brexanolone (zulresso) infusion arm. All patients enrolled will receive active treatment with brexanolone.
89393205|NCT05313035|Experimental|Vaccine Candidate Formula 1|2 doses of vaccine candidate formula 1 administered with 28 days interval (0.5 mL per dose)
89393206|NCT05313035|Experimental|Vaccine Candidate Formula 2|2 doses of vaccine candidate formula 2 administered with 28 days interval (0.5 mL per dose)
89393207|NCT05313035|Placebo Comparator|Control|2 doses of placebo administered with 28 days interval (0.5 mL per dose)
89393208|NCT05308940|Experimental|Single-dose of TB001|In the SAD stage, participants will receive subcutaneous injection of TB001 once on Day 1, planning to ascend from 20 μg, 60 μg，150 μg，300 μg，600μg to 900 μg or higher dose (whether to proceed to the next higher cohort based on dose escalation criteria). Actual dose of TB001 may vary based on safety, tolerability and PK data from previous cohorts.
89187127|NCT02585180|Experimental|Period with endotracheal tubes allowing SSD|During this period of the DEMETER study (NCT02515617), patients will be intubated with specific endotracheal tubes allowing Subglottic Secretions Drainage
89187128|NCT00765297|Experimental|1|Healthy young 18-40years
89187129|NCT00765297|Experimental|2|Healthy elderly
89393209|NCT05308940|Experimental|Multiple-dose of TB001|In the MAD stage, participants will receive subcutaneous injection of TB001 once daily for 7 days, planning to ascend from 60 μg，150ug to 300 μg or higher dose (whether to proceed to the next higher cohort based on dose escalation criteria). Actual dose of TB001 may vary based on safety, tolerability and PK data from previous cohorts.
89393210|NCT05308940|Placebo Comparator|Single-dose of placebo|In the SAD stage, participants will receive subcutaneous injection of placebo once on Day 1.
89393211|NCT05308940|Placebo Comparator|Multiple-dose of placebo|In the MAD stage, participants will receive subcutaneous injection of placebo once daily for 7 days.
89393212|NCT05306626|Experimental|The BEAM program group|The BEAM Program is delivered via mobile application and weekly group telehealth sessions. BEAM includes approximately 20 minutes of weekly asynchronous video modules on parenting and mental health. Mental Health videos will provide information and emotion-regulation strategies that draw from the Unified Protocol, an evidence-based treatment for depression and anxiety disorders. Self-compassion and effective communication will also be central focuses of the mental health content. Supportive parenting videos will provide parents with emotion-focused parenting strategies and help parents understand and respond to their children's challenging emotions and behaviours. The weekly group telehealth sessions will allow participants to discuss content and ask questions, with the purpose of increasing a sense of community and social support. The online community forum will provide a space for participants to reflect on their learned skills and connect with other participants in the program.
89393213|NCT05306626|No Intervention|Treatment as usual group|The treatment as usual (TAU) control arm of the study is designed to account for the potential effects of time on depression symptoms.
89393214|NCT05302830|Experimental|Snackability app|This app allows user to search for a snack (scan barcode or type snack name), add a portion size consumed based on a portion size guide, and then provide a snack score and breakdown scores with a specific feedback message about the score.25 A score ranging from 0-10 points was designed taking into account the first ingredient, the nutrient standard by portion size, and the processing of foods (score ranging from -1 to 1 was subtracted or added depend on processed food classification). The final score ranged from -1 to 11 points. The higher the score, the more compliant it is to the guideline; therefore, the healthier the snack is. The app also provides gamification features as self-motivation (level up and achievement gained) and reporting features as goal-setting and self-monitoring (average daily score and consumed snack history).
89393215|NCT05302830|Placebo Comparator|Control group|The control group received a 1-page with information on what is a healthy snack from the USDA: https://www.fns.usda.gov/cn/tools-schools-focusing-smart-snacks. They were given access to the app after the 12-week study period.
89393216|NCT05293756|Experimental|Intervention: OPTIMA-BP Implementation|Participants randomized to OPTIMA-BP intervention for 6 months then observed for a 6 month follow up period
89393217|NCT05293756|No Intervention|Waitlist: OPTIMA-BP implementation|Participants randomized to waitlist for 6 months, then offered the OPTIMA-BP intervention for 6 months.
89393218|NCT05283408|Experimental|Dexmedetomidine infusion on recovey quality with radical mastectomy|Drug: Dexmedetomidine infusion Patients received dexmedetomidine (0.5 µg/kg over 10 min before the induction of anesthesia), and then dexmedetomidine was infused at a rate of 0.4 μg/kg/h until 20 min before the end of operation
89393219|NCT05283408|Experimental|Co-administration dexmedetomidine and low-dose esketamine on recovey quality with radical mastectomy|Drug: Dexmedetomidine and low-dose eskeamine combined infusion Patients received a bolus infusion of dexmedetomidine (0.5 µg/kg) and esketamine (0.5 mg/kg)over 10 min before the induction of anesthesia, and then dexmedetomidine were infused at a rate of 0.4 µg/kg/h and 2 µg/kg/min until 20 min before the end of operation, respectively.
89393220|NCT05283408|Experimental|Combined dexmedetomidine and high-dose esketamine on recovey quality with radical mastectomy|Drug: Dexmedetomidine and high-dose eskeamine combined infusion Patients received a bolus infusion of dexmedetomidine (0.5 µg/kg) and esketamine (0.5 mg/kg)over 10 min before the induction of anesthesia, and then dexmedetomidine were infused at a rate of 0.4 µg/kg/h and 4 µg/kg/min until 20 min before the end of operation, respectively.
89393221|NCT05265741||ArmA_Pregnant No Gestational Diabetes Mellitus|This group is composed of pregnant women divided into 3 subgroups, one of each trimester. This arm will be required to provide 2 fecal samples. One at the start of recruitment, and one at the end of a 4-week period of the trimester.
89393222|NCT05265741||ArmB_Pregnant with Gestational Diabetes Mellitus|This group is composed of pregnant women divided into 3 subgroups, one of each trimester. This arm will be required to provide 2 fecal samples. One at the start of recruitment, and one at the end of a 4-week period of the trimester.
89393223|NCT05265741||ArmC_Non- Pregnant Control|This group is composed of non-pregnant women. This arm will be required to provide 1 or more fecal samples. It will be used as a baseline for comparison of the microbiome
88869372|NCT06217679|Experimental|Moderate intensity continuous exercise (MICE)|Participants performed a Moderate intensity continuous exercise (MICE) bout which includes 30 min at 65% maximal aerobic capacity (VO2max). 90mins following the exercise bout participants will undergo another oral glucose tolerance test.
88869373|NCT06217679|Experimental|Low-load, high-repetition resistance exercise (LL-HR)|Participants performed a Low-load, high-rep resistance exercise (LL-HR) bout which includes a whole body resistance exercise bout, 3 sets at 30% maximum strength (1RM) for leg press, knee extension, hamstring curl, lat pulldown, shoulder press, chest press, 20-25 reps, last set to failure. 90mins following the exercise bout participants will undergo another oral glucose tolerance test.
88869374|NCT06217627|Experimental|Umbilical cord (UC)- mesenchymal stem cells (MSCs) secretome|19 participants received UC-MSCs secretome injections in the neck and different areas of the face including the forehead, cheeks, under eyes, chin, and nasolabial folds.
88869375|NCT06217627|Experimental|UC-explants secretome|30 participants received UC-explants secretome in the left and right hands
88869376|NCT06216275|Experimental|Intervention Arm|Participants receiving the integrated approach of Snoezelen therapy, aromatherapy, and the use of personal items.
88869377|NCT06216275|No Intervention|Control Arm|Participants receiving standard care practices for dementia and agitation without the integrated approach.
88869378|NCT06211569||Patients|Women of childbearing age, consulting for elective fertility preservation
88869379|NCT06209879|Experimental|Hyaluronic Acid/Hydroxypropyl Guar arm|Systane Hydration® MD
88869380|NCT06208501||Hypertensive patients undergoing renal denervation|
88869381|NCT06204237|Experimental|Patients|
88869382|NCT06204237|Experimental|Healthy volunteers|
88869383|NCT06203041|Experimental|Lactating women|Subjects identified as having delivered an infant and lactating will receive Vitamin D3 for 28 days.
88869384|NCT06203041|No Intervention|Breastfeeding Infants|No intervention will be administered.
88869385|NCT06202664|Experimental|Opioid Free Anesthesia Group|This will be the experimental group. Patient entering this group through computer generated random numbers will receive opioid free anesthesia in form of ultrasound guided Erector Spinae Block given bilaterally at T6 level.
88869386|NCT06202664|Active Comparator|Conventional Opioid group|Patient entering this group through computer generated random numbers will receive opioid based anesthesia.
88869387|NCT06202248|Experimental|DaRT Seeds|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds
88869388|NCT06202118|Experimental|DaRT Seeds|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds
89393224|NCT05264103|Experimental|Experimental group.|Healthy subjects and brain damaged patients with gait disorder.
88869389|NCT06199817|Experimental|Intervention Group|The intervention group was informed about the research. The intervention group consists of patients diagnosed with schizophrenic disorder. Music, sports and garden-soil activities were applied to the intervention group.
88869390|NCT06199817|No Intervention|Control Group|The control group was informed about the research.
88869391|NCT06195956|Active Comparator|Shoulder Impingement Rehabilitation|"rehabilitation program consisting of strengthening exercises (for scapular stabilizers and rotator cuff) and stretching exercises (for pectoralis major, pectoralis minor, latissimus dorsi, levator scapula).~Exercises done 3 times per weeks, 3 repetitions per exercise for 3 months"
88869392|NCT06195956|Experimental|Shoulder Impingement Rehabilitation with LL KC Exercise|"rehabilitation program consisting of strengthening exercises (for scapular stabilizers and rotator cuff) and stretching exercises (for pectoralis major, pectoralis minor, latissimus dorsi, levator scapula) in addition to lower limb kinetic chain exercise.~Exercises done 3 times per weeks, 3 repetitions per exercise for 3 months"
88869393|NCT06192979|Other|Rapid Response Group|Daratumumab, bortezomib, dexamethasone
88869394|NCT06192979|Other|Non-Rapid Response Group|Daratumumab, venetoclax, dexamethasone
88869395|NCT06192069|Experimental|Sustainable Prevention Program|"Participants will receive the 4-week Sustainable Prevention Program consisting of lectures, demonstrations, group discussions, and educational materials focused on:~Hydration strategies (proper amounts and types of fluids, reminders for intake) Rest breaks (frequency, duration, scheduling) Lightweight reflective clothing~Device: Core Temperature Sensor~Participants might be equipped with a core temperature sensor to monitor their internal body temperatures. This device will provide continuous, real-time data crucial for understanding the physiological impacts of the prevention strategies and ensuring participant safety.~Device: Heart Rate Monitor~A heart rate monitor will be used to track the cardiovascular responses of the participants to heat and physical activity. This data is essential to assess the strain on participants' bodies and the effectiveness of the prevention strategies in mitigating stress.~Portable shade covers"
88869396|NCT06192069|No Intervention|Control|Participants will receive no intervention and follow their usual workplace heat strain prevention measures such as basic hydration and voluntary rest breaks
88869397|NCT06189742|No Intervention|Non-allergic Participants|
88869398|NCT06189742|Experimental|Allergic Participants|
88869399|NCT06188624|Experimental|TQB2922 for injection|TQB2922 for injection, 28 days as a treatment cycle
88869400|NCT06183203|Experimental|Pulpotomy|Participants diagnosed with symptomatic irreversible pulpitis in vital primary molars will receive the pulpotomy treatment intervention.
88869401|NCT06183203|Active Comparator|Pulpectomy|Participants diagnosed with symptomatic irreversible pulpitis in vital primary molars will receive the pulpectomy treatment intervention.
88869402|NCT06171789|Experimental|PRO1107|PRO1107 monotherapy in escalating doses in Part A and at the two recommended phase 2 doses in Part B
88869403|NCT06170190|Experimental|Open-label：IBI133 monotherapy|
88869404|NCT06170047|Experimental|Chicago Parent Program for Foster Care|The Chicago Parent Program for Foster Care (CPP-FC) is a caregiver-directed prevention program to strengthen parenting skills and confidence in foster and kinship caregivers and prevent or reduce behavior problems in children 2-8 years old. CPP-FC was designed to specifically meet the unique needs of children ages 2-8 who are placed with foster and kinship caregivers. Participants assigned to CPP-FC will receive CPP-FC and the services typically offered from the county, Cincinnati Children's Hospital Medical Center Comprehensive Health Evaluations for Cincinnati's Kids (CHECK) clinic, and for licensed caregivers, their licensing agency.
88869405|NCT06170047|Active Comparator|Usual Care|Usual Care control will receive standard care offered from the county, Cincinnati Children's Hospital Medical Center Comprehensive Health Evaluations for Cincinnati's Kids (CHECK) clinic, and for licensed caregivers, their licensing agency.
88869406|NCT06167083||Deceased Patients|Carbapenem-resistant Gram-negative bacilli Blood Stream Infection With mortality
88869407|NCT06167083||Surviving Patients|Carbapenem-resistant Gram-negative bacilli Blood Stream Infection Without mortality
88869408|NCT06166082|Experimental|Active iTBS-DLPFC|The active group will receive active iTBS. Treat 10 times a day with 1800 pulses per day for consecutive 5 days, with 50 minutes inter-session intervals.
88869409|NCT06166082|Sham Comparator|Sham iTBS-DLPFC|The sham group will receive sham iTBS. Treat 10 times a day with 1800 pulses per day for consecutive 5 days, with 50 minutes inter-session intervals.
88869410|NCT06161831|Experimental|Text message/automated phone reminders|Text message or automated phone reminders
88869411|NCT06161831|No Intervention|Usual Care|No reminders
88869412|NCT06161519|Experimental|Phase I|Escalating and de-escalating doses of PLX038
88869413|NCT06161519|Experimental|Phase II|RP2D of PLX038
88869414|NCT06157502|Experimental|Shuxuening injection|Shuxuening Injection + Intravenous Thrombolysis
89535423|NCT05019183|Experimental|Experimental arm|Patients in the experimental arm will perform 6 indoor rower sessions (30 min each, on Day 1, 2, 3, 8, 9 and 10) during which they will be able to move freely in a virtual environment.
88869415|NCT06157502|Placebo Comparator|Placebo|Placebo + Intravenous Thrombolysis
88869416|NCT06149793|Active Comparator|empagliflozin|randomized to study medication (empagliflozin) 10 mg taken by mouth daily for 4 weeks
88869417|NCT06149793|Placebo Comparator|placebo control|randomized to placebo control taken by mouth daily for 4 weeks
88869418|NCT06146686|Experimental|Group I ( pulpectomy using single rotary file )|After opening the access cavity, a single rotary file (20 taper 4) will be adjusted on the desirable working length depending on a radiograph (1 mm shorter than the apex) and used in pulpectomy in a brushing motion at the rotational speed 300 rpm with torque set at the lowest level, irrigation with saline
89393225|NCT05255172|Experimental|Supervised exercise|The exercise intervention will include 2 supervised sessions of ergometer cycling with a warm up period of 10 minutes and 20 minutes of cycling at the aerobic intensity below the anaerobic threshold as determined from baseline results. Patients in the exercise arm will have 1 unsupervised exercise session where the participants walk or bicycle for 30 minutes at an intensity experienced as somewhat hard (Borg 13) according to the Borg Rating of Perceived Exertion Scale.
89393226|NCT05255172|No Intervention|Standard of Care|The control group will receive advise to continue to live as usual. After 4 and 8 weeks, participants in the control group will be contacted by telephone for inquiry of general wellbeing. No other interventions will be performed in the control group.
89393227|NCT05245565||PPS surgery|Patients who undergo modified PPS surgery in order to preserve anal sphincter function under the premise of radical resection of ultralow rectal cancer.
89393228|NCT05245565||Conventional|Patients who undergo conventional sphincter-preserving surgeries.
89393229|NCT05240755|No Intervention|Standard of Care|Opioid standard of care: Tramadol 50 mg PO PRN #30, Hydrocodone/Acetaminophen 5/325 PO PRN #30
89393230|NCT05240755|Experimental|Cannabidiol Oil 100 mg|CBD 100 mg PO liquid suspension QD starting 30 days prior and finishing 30 days post-op
89393231|NCT05240755|Experimental|Cannabidiol Oil 200 mg|CBD 200 mg PO liquid suspension QD starting 30 days prior and finishing 30 days post-op
89393232|NCT05229315|Experimental|PD-1 Immune Checkpoint Inhibitor Combined With Intensity Modulated Radiation Therapy|Intensity modulated radiation therapy combined with toripalimab in the treatment of nasopharyngeal carcinoma，once every 2 weeks, 10 cycles in total
88869419|NCT06146686|Active Comparator|Group II ( pulpectomy using multiple rotary files system )|After opening the access cavity, multiple rotary files system (Fanta AF baby rotary files 20 taper 4, 25 taper 4, 30 taper 4) will be adjusted on the desirable working length depending on a radiograph (1 mm shorter than the apex) and used in pulpectomy in a brushing motion at rotational speed 300 rpm with torque set at the lowest level, irrigation with saline
88869420|NCT06146270||Cohort A|A cohort in which the incidence of the primary outcomes in the study population will be assessed.
88869421|NCT06146270||Cohort B|A cohort in which risk factors for primary outcomes will be identified, and a risk calculator for their development will be developed and validated
88869422|NCT06145724|No Intervention|Hospital Stakeholders|Hospital stakeholders at the partnering hospitals who participate in 90 min focus group discussion about maternal sepsis bundle implementation.
88869423|NCT06145724|No Intervention|Patients Admitted for Delivery (Pre-implementation)|Patients admitted for delivery at one of the partnering hospitals. EHR records from Columbia, Lincoln, Harlem, and Allen hospitals will be reviewed to evaluate process and outcome measures pre-maternal sepsis bundle implementation. EHR data will be used from delivery hospitalizations from 2021-2022.
88869424|NCT06145724|Experimental|Patients Admitted for Delivery (Post-Implementation)|Patients admitted for delivery at one of the partnering hospitals. EHR records from Columbia, Lincoln, Harlem, and Allen hospitals will be reviewed to evaluate process and outcome measures post-maternal sepsis bundle implementation. EHR data will be used from delivery hospitalizations.
88869425|NCT06138795|Experimental|Cohort 1: Part A1 - AZD2389 dose 1/placebo oral administration|A total of 6 study participants will receive a single dose of AZD2389 and 2 will receive placebo.
88869426|NCT06138795|Experimental|Cohort 2: Part A1 - AZD2389 dose 2/placebo oral administration|A total of 6 study participants will receive a single dose of AZD2389 and 2 will receive placebo.
89393233|NCT05222880|Experimental|TEST Lens|Eligible subjects who are habitual soft contact lens wearers will be given the TEST Lens for the duration of the study.
89393234|NCT05216016|No Intervention|Control Group|Individuals will receive a handout with additional job related services; e.g. Job Accommodation Network.
88869427|NCT06138795|Experimental|Cohort 3: Part A1 - AZD2389 dose 3 /placebo oral administration|A total of 6 study participants will receive a single dose of AZD2389 and 2 will receive placebo.
88869428|NCT06138795|Experimental|Cohort 4: Part A1 - AZD2389 dose 4 /placebo oral administration|A total of 6 study participants will receive a single dose of AZD2389 and 2 will receive placebo.
88869429|NCT06138795|Experimental|Cohort 5: Part A1 - AZD2389 dose 5 /placebo oral administration|A total of 6 study participants will receive a single dose of AZD2389 and 2 will receive placebo.
88869430|NCT06138795|Experimental|Cohort 6: Part A2 - AZD2389 dose 6 /placebo oral administration|A total of 6 study participants will receive a single dose of AZD2389 and 2 will receive placebo.
89393235|NCT05216016|Experimental|Intervention Group|Individuals will be assigned a dedicated Minnesota RETAIN Return-to-Work Case Manager. Intervention group participants will be referred for additional career and workforce development resources when needed.
89393236|NCT05213143|Experimental|Lurasidone|Lurasidone was oral administrated with a meal or within 30 min after eating in the evening.
89393237|NCT05208931||adhesion|the group in which the adhesion of neuroepithelial detachment was observed after Anti-vascular endothelial growth factor therapy
89393238|NCT05208931||no adhesion|group in which there was no adherence of neuroepithelial detachment after Anti-vascular endothelial growth factor therapy
88869431|NCT06138795|Experimental|Cohort 7: Part A2 - AZD2389 dose 7 /placebo oral administration|A total of 6 study participants will receive a single dose of AZD2389 and 2 will receive placebo.
88869432|NCT06138795|Experimental|Cohort 8: Part A2 - AZD2389 dose 8 /placebo oral administration|A total of 6 study participants will receive a single dose of AZD2389 and 2 will receive placebo.
88869433|NCT06138795|Experimental|Cohort 9: Part A3 - AZD2389 dose 9 /placebo oral administration|A total of 6 study participants will receive a single dose of AZD2389 and 2 will receive placebo.
88869434|NCT06138795|Experimental|Cohort 10: Part B1 - AZD2389 dose 10 /placebo oral administration|A total of 6 study participants will receive multiple doses of AZD2389 and 2 will receive placebo.
88869435|NCT06138795|Experimental|Cohort 11: Part B1 - AZD2389 dose 11 /placebo oral administration|A total of 6 study participants will receive multiple doses of AZD2389 and 2 will receive placebo.
88869436|NCT06138795|Experimental|Cohort 12: Part B1 - AZD2389 dose 12 /placebo oral administration|A total of 6 study participants will receive multiple doses of AZD2389 and 2 will receive placebo.
88869437|NCT06138795|Experimental|Cohort 13: Part B2 - AZD2389 dose 13 /placebo oral administration|A total of 6 study participants will receive multiple doses of AZD2389 and 2 will receive placebo.
88869438|NCT06138249|Experimental|Calcifediol each month|Calcifediol 0,266 mg each month
88869439|NCT06138249|Experimental|Cholecalciferol 25.000 UI|Cholecalciferol 25000UI each 15 days
88869440|NCT06138249|Experimental|Calcifediol 4 drops each day|Calcifediol 4 drops each day
88869441|NCT06133179|Experimental|Cohort group|Routine care + transtemporal ultrasound examination with contract product during hospitalization
89393239|NCT05208931||разрыв|group in which neuroepithelial detachment rupture was observed after anti-vascular endothelial growth factor therapy
88869442|NCT06133075|Active Comparator|50 mg group|Ten patients will receive 50 mg mirabegron for 8 weeks.
88869443|NCT06133075|Active Comparator|25 mg group|Ten patients will receive 25 mg mirabegron for 8 weeks.
88869444|NCT06128915|Experimental|Vaccination with Prevnar.|Intramuscular vaccination with Prevnar 20
88869445|NCT06127004|Experimental|Metacognitive Training for Negative Symptoms|The original MCT intervention was adapted to negative symptoms by incorporating psychoeducation and strategies to target the cognitions suggested by the cognitive model (Beck et al., 2009) to be implicated in the development and/or maintenance of negative symptoms. Although some of the strategies have traditionally been used to target positive symptoms, it is assumed that the same reasoning styles lead to negative symptoms through the dysfunctional cognitions discussed previously (e.g., jumping to conclusions in regard to social rejection and a dysfunctional attribution style reinforcing social withdrawal). Metacognitive training for negative symptoms consists of eight sessions, delivered individually as there is evidence indicating that this approach may lead to stronger effect sizes than delivery in a group format (Liu et al., 2018). The developer of MCT (Professor Steffen Moritz) approved the modification.
88869446|NCT06127004|Active Comparator|Control group|Supportive Counselling (8 sessions) will be used as a control. Participants enrolled in this condition can then get the intervention if they request this.
88869447|NCT06126796||Arm A: CxBladder followed by cystoscopy|Arm A will undergo testing with CxBladder 3 months after randomization followed by a cystoscopy 3 months thereafter
88869448|NCT06126796||Arm B: cystoscopy followed by CxBladder|Arm B will undergo cystoscopy 3 months after randomization followed by testing with CxBladder 3 months thereafter.
88869449|NCT06124196||Case - DMD|40 male individuals with DMD
88869450|NCT06124196||Controls|40 matched controls (gender, age ± 1 year, BMI category, self-reported race/ethnicity).
88869451|NCT06123013|Experimental|Music assisted relaxation|Participants will receive a tailored music-assisted relaxation and imagery intervention
88869452|NCT06121635|Experimental|ts-DCS Group|Active ts-DCS and sham t-DCS will be applied simultaneously. 2mA intensity ts-DCS will be applied, with the active electrode being the cathode. The cathode will be placed the spinous process of T10 vertebral process, while the anode will be placed on the left deltoid. 2mA intensity t-DCS will be applied, with the active electrode being the anode. The International EEG 10/20 System will be used to electrode placement. The anode will be placed on the left M1, while the catode will be placed on the right supraorbital region. In the sham application, the placement of the electrodes will be the same as the active stimulation but It's will be stopped after 30 seconds. This sham procedure has been reported to be a good pseudostimulation method. ts-DCS and t-DCS will be administered using a stimulator (TCT Research Limited, Hong Kong). In both stimulations, 2 electrodes (35 cm2) immersed in saline solution will be used. The stimulations will be applied in 20 min sessions, 3 days/4 weeks.
88869453|NCT06121635|Experimental|t-DCS Group|Active t-DCS and sham ts-DCS will be applied simultaneously. 2mA intensity t-DCS will be applied, with the active electrode being the anode. The International EEG 10/20 System will be used to electrode placement. The anode will be placed on the left M1, while the catode will be placed on the right supraorbital region. 2mA intensity ts-DCS will be applied, with the active electrode being the cathode. The cathode will be placed the spinous process of T10 vertebral process, while the anode will be placed on the left deltoid. In the sham application, the placement of the electrodes will be the same as the active stimulation but It's will be stopped after 30 seconds. This sham procedure has been reported to be a good pseudostimulation method. ts-DCS and t-DCS will be administered using a stimulator (TCT Research Limited, Hong Kong). In both stimulations, 2 electrodes (35 cm2) immersed in saline solution will be used. The stimulations will be applied in 20 min sessions, 3 days/4 weeks.
88869454|NCT06121635|Sham Comparator|Control Group|Sham ts-DCS and sham t-DCS will be applied simultaneously. 2mA intensity ts-DCS will be applied, with the active electrode being the cathode. The cathode will be placed the spinous process of T10 vertebral process, while the anode will be placed on the left deltoid. 2mA intensity t-DCS will be applied, with the active electrode being the anode. The International EEG 10/20 System will be used to electrode placement. The anode will be placed on the left M1, while the catode will be placed on the right supraorbital region. In both stimulations, the placement of the electrodes in Sham application will be the same as in active stimulation, but it will be stopped after 30 seconds. ts-DCS and t-DCS will be administered using a stimulator (TCT Research Limited, Hong Kong). In both stimulations, 2 electrodes (35 cm2) immersed in saline solution will be used. The stimulations will be applied in 20 min sessions, 3 days/4 weeks.
88869455|NCT06120699|Experimental|360 Degree Expanded Diaphragm Exercises|Volunteers who complain of urinary incontinence in situations such as coughing, sneezing and laughing, who have been diagnosed with stress or stress-predominant mixed urinary incontinence by a Gynecology and Obstetrics physician, and who meet the inclusion criteria will be included in the study.
88869456|NCT06120699|Active Comparator|Standard Diaphragm Exercises|Volunteers who complain of urinary incontinence in situations such as coughing, sneezing and laughing, who have been diagnosed with stress or stress-predominant mixed urinary incontinence by a Gynecology and Obstetrics physician, and who meet the inclusion criteria will be included in the study.
88869457|NCT06115057|Experimental|Intervention|Fiber
88869458|NCT06112652|Active Comparator|4 session rTMS|Four sessions of active rTMS would be delivered to the left DLPFC daily, with a session of 1800 pulse.
89535424|NCT05019183|Other|Control arm|Patients in the control arm will perform 6 indoor rower sessions (30 min each, on Day 1, 2, 3, 8, 9 and 10) without being exposed to a virtual environment.
89535425|NCT02451475|Other|Amitriptyline|Amitriptyline 25 mg/day
89535426|NCT02451475|Active Comparator|Venlafaxine|Venlafaxine 75 mg/day
89535427|NCT02451475|Active Comparator|Paroxetine|Paroxetine 25 mg/day
89535428|NCT03226327|Experimental|hypertension patients|
88869459|NCT06112652|Active Comparator|6 session rTMS|Six sessions of active TMS would be delivered to the left DLPFC daily, with a session of 1800 pulse.
88869460|NCT06112652|Active Comparator|8 session rTMS|Eight sessions of active rTMS would be delivered to the left DLPFC daily, with a session of 1800 pulse.
88869461|NCT06112652|Active Comparator|10 session rTMS|Ten sessions of active rTMS would be delivered to the left DLPFC daily, with a session of 1800 pulse.
88869462|NCT06112652|Sham Comparator|sham rTMS|Subjects were randomized to receive 4 sessions or 6 sessions or 8 sessions or 10 sessions of sham rTMS to the left DLPFC daily in a 1:1:1:1 ratio.
88869463|NCT06108206|Experimental|Adaptive Radiotherapy|Subjects will receive radiotherapy per standard of care over 30 once-daily fractions in addition to 6 brain MRIs each in every week of treatment.
88869464|NCT06100575|Experimental|Website (www.mee-leven.be)|Participants in this group (all participants) are asked to complete a questionnaire and then receive access to the website during three days, after which they were asked to complete another questionnaire.
88869465|NCT06095778|Experimental|active rTMS|2 sessions with 1800 pulses per session and 50min inter-session interval of active rTMS will deliver to the assigned target
88869466|NCT06092892|Experimental|Single Arm|
88869467|NCT06092489|Active Comparator|Traditional Physiotherapy Program|Self-stretching will encapsulate the upper trapezius, pectoralis minor, posterior. Each stretch will consist of 3 repetitions of 30 seconds with a 30 second break between repetitions. Strengthening exercises will be performed using elastic resistance bands (Theraband ®) with 4 levels of resistance (red, green, blue and grey). Sets can be easily changed (without the person reporting muscle fatigue) and progressed with resistance. The therapist will ask about the level of effort required for exercise exercises and whether it would be possible to increase the resistance level. The exercise consists of three sets of 10 repetitions and is completed with 1 rest between them. Strengthening exercises will include prone extension, prone external rotation with abduction, side lying external rotation and serratus anterior strengthening . These workouts and workouts are also arranged regularly. After exercise, ice will be applied to the shoulder for 15 minutes.
88869468|NCT06092489|Experimental|Traditional Physiotherapy Program and Graded Motor Imagery Therapy|The three different treatment techniques include left/right discrimination training, explicit motor imagery exercises and mirror therapy. These techniques are delivered sequentially but require a flexible approach from the patient and clinician to move forwards, backward and sideways in the treatment process to suit the individual. With patience, persistence and often lots of hard work, GMI gives new hope for treatment outcomes.
88869469|NCT06089551|Experimental|Early supplementary|Start of study drug on postoperative day 2
88869470|NCT06089551|Active Comparator|Late supplementary|Start of study drug on postoperative day 5
88869471|NCT06088667|Experimental|Fascial mobilization group|In addition to the rehabilitation given to the control group, the fascial release group will be treated with the Graston device to the superficial and deep fascia of the neck and shoulder muscles, biceps and triceps brachii muscles and forearm compartments.
88869472|NCT06088667|Experimental|Control Group|The control group will receive heat application, electrical stimulation and shoulder exercises for 4 weeks.
88869473|NCT06082739|Experimental|Exercise group|Patients perform stretching exercises daily.
88869474|NCT06078579||Oral lichen planus patients|Assessment of salivary and serum leptin levels
88869475|NCT06078579||Healthy control group|Assessment of salivary and serum leptin levels
88869476|NCT06077565|Experimental|Intervention group|The participants will be given a Practical Resource Hub for Healthy Life leaflet containing information on various applications. the research assistant will ask about the priority the participants place on engagement in desirable health-related lifestyle practices identified in the completed behavioural risk factor survey. The participants will also be asked to choose the goal that they consider easiest to achieve. The participants will be encouraged to quit health-risk behaviours (or adopt a healthy lifestyle) sequentially, but they will also be able to choose to quit them simultaneously if they are confident in doing so. For the first 6 months of the study period, the research assistant will deliver WhatsApp/WeChat messages about once per week. Follow-up assessment of behavioural changes at 3, 6, and 12 months
89393240|NCT05208593|Placebo Comparator|Negative Event Only|Participants will be asked to think of a specific example of the most (or one of the most) negative, unpleasant event with alcohol they have experienced; the event they choose must have occurred at least a year ago. Or they will be asked to think of the most significant event that has occurred in the past year. After thinking of a specific event, they will be given three minutes to write about their experience. The writing prompt will ask that they express the event information in a few sentences. This writing prompt will help participants place themselves back into that moment and access salient emotions and cognition about it. Similar negative event prompts have been used in counterfactual thinking studies (McFarland & Alvaro, 2000; White & Lehman, 2005).
88869477|NCT06077565|Placebo Comparator|Control group|The participants will be given a Practical Resource Hub for Healthy Life leaflet containing information on various applications.The control group participants will receive a brief telephone intervention based on the AWARD model and delivered by the trained research assistant, similar to that delivered to the intervention group. However, the research assistant will simply advise the participants to change their health-risk behaviours and/or adopt a healthy lifestyle practice. The participants will also receive follow-up for outcome assessments with the same schedule as those in the intervention group.
88869478|NCT06077396|Other|To evaluate the effect of radial artery cannulation on hand perfusion|To evaluate the effect of radial artery cannulation on hand perfusion
88869479|NCT06076746|Experimental|Experimental: Intervention(s) for ineffective coping in General Anxiety|Patients with nurse diagnosis of ineffective coping will be treated using Nursing Interventions Classification (NIC) psychotherapeutic intervention(s).
88869480|NCT06076746|Active Comparator|Treatment-as-Usual for General Anxiety|Patients with nurse diagnosis of ineffective coping will receive the usual treatment for general anxiety.
88869481|NCT06076213|Experimental|Artesunate-amodiaquine|tablets of ASAQ Winthrop®
88869482|NCT06076213|Experimental|Artemether-lumefantrine|tablets of Coartem Dispersible®
88869483|NCT06074406|Experimental|Portable MRI Arm|All subjects enrolled with be assigned to Arm 1
88869484|NCT06073821|Experimental|Sonrotoclax Plus Zanubrutinib|Participants will receive from start of Cycle 1 a standard dose of zanubrutinib once or twice daily orally and in combination with sonrotoclax starting from Cycle 4 onwards at increasing doses until target dose is reached and continuing until end of Cycle 15 (each cycle is 28 days)
88869485|NCT06073821|Active Comparator|Venetoclax Plus Obinutuzumab|Participants will receive obinutuzumab 100mg intravenously on Day 1 Cycle 1, followed by 900 mg on Day 2 Cycle 1 (or alternatively receive 1000 mg intravenously on Day 1), followed by 1000 mg on Days 8 and 15 of Cycle 1 and thereafter on Day 1 of Cycles 2 through 6 (each cycle is 28 days) in combination with venetoclax at increasing doses until target dose is reached from Day 22 Cycle 1 until end of Cycle 12 (each cycles is 28 days)
88869486|NCT06070701|Experimental|SUPERFICIAL PARASTERNAL INTERCOSTAL PLANE BLOCK (SPIPB)|Following induction, ropivacaine 0.5% (1.5 mg/kg per each side) with dexamethasone 8mg/20ml is deposited under ultrasound guidance in the plane between the intercostal muscles and the pectoralis major muscles, targeting the anterior cutaneous branches of the intercostal nerves.
88869487|NCT06070701|Active Comparator|ERECTOR SPINAE PLANE BLOCK (ESPB)|Before induction, ropivacaine 0.5% (1.5 mg/kg per each side) with dexamethasone 8mg/20ml is deposited under ultrasound guidance between the transverse process of the 5th thoracic vertebra and the erector spinae muscle, targeting the dorsal and ventral rami of the spinal nerves.
88869488|NCT06066554|Active Comparator|14 early mycosis fungoids patients|Puva (psoralin and uva) Measure nlrp1 and nlrp3 and il18
88869489|NCT06066554|Active Comparator|8 mycosis fungoids patients|Puva (psoralin and uva) and methotrexate Measure nlrp1 and nlrp3 and il18
88869490|NCT06066554|Active Comparator|Eight mycosis fungoids patients|Puva (psoralin and uva)and retinoids (acetritin) Measure nlrp1 and nlrp3 and il18
88869491|NCT06066554|No Intervention|Controls|Measure nlrp1 and nlrp3 and il18
88869492|NCT06062342|Experimental|FPI Group|Participants in this group will receive the FPI intervention at any FPI coordinated outreach event (4-5 hours) during a 21 month period
88869493|NCT06056518|No Intervention|Routine Care|"Patients in the Routine Care arm are will undergo regular follow-up at the kidney transplant center."
88869494|NCT06056518|Experimental|AI-supported Care|"Patients in the AI-supported Care arm will undergo regular follow-up at the kidney transplant center. Treating physicians will be provided an AI-based risk prediction tool that predict 1-year risk of graft loss for patients in this group based on routine parameters."
88869495|NCT06055426|Experimental|bed bath|"Bed bath application stages:~Environmental elements (ambient temperature, airflow and curtain-screen) are taken under control in the clinic (Ensure that the ambient temperature is 23-24℃)."
88869496|NCT06049446||Patients receiving seed localization|Patients receiving seed localization
88869497|NCT06049082|Experimental|Cohort 1: Low dose KB408|Single dose of KB408 (low dose)
88869498|NCT06049082|Experimental|Cohort 2: Mid dose KB408|Single dose of KB408 (mid dose)
88869499|NCT06049082|Experimental|Cohort 3a/3b: High dose KB408|Single dose of KB408 (high dose)
88869500|NCT06048978|Experimental|Native Starch, then Processed Starch|Participants will first receive the Commercial Native Starch in a fasting state in one clinical visit. After a washout of >24 hours, the participants will then receive the Extrusion Processed Starch in a fasting state in one clinical visit.
88869501|NCT06048978|Experimental|Processed Starch, then Native Starch|Participants will first receive the Extrusion Processed Starch in a fasting state in one clinical visit. After a washout of >24 hours, the participants then will receive the Commercial Native Starch in a fasting state in one clinical visit.
88869502|NCT06046040|Experimental|Dose Level -1|After lymphodepleting chemotherapy subjects to receive 1x10(7) TmPSMA-02 CAR T Cells
88869503|NCT06046040|Experimental|Dose Level 1|After lymphodepleting chemotherapy subjects to receive 5 x10(7) TmPSMA-02 CAR T Cells
88869504|NCT06046040|Experimental|Dose Level 2|After lymphodepleting chemotherapy subjects to receive 1x10(8) TmPSMA-02 CAR T Cells
88869505|NCT06046040|Experimental|Dose Level 3|After lymphodepleting chemotherapy subjects to receive 3x10(8) TmPSMA-02 CAR T Cells
89535429|NCT05019417|Experimental|Glycerol phenylbutyrate treatment|"Name of the Investigational Medicinal product: Glycerol phenylbutyrate [GPB] (Ravicti oral liquid 1.1 gr/1 ml; manufacturer Horizon Pharma USA).~Dosage of GPB will follow the dosage in use for children with urea cycle disorder.~Initial dose: 5.0 gr (4.5 ml)/ meter square divided by three time a day. An escalating schedule dose of GPB will be used until normal serum T3 levels are reached.~Initial dose: 5 gr/square meter body surface area (BSA). Second visit: 10 gr/square meter BSA~The dose raising will be stopped if one of the following condition is reaches:~Clinically significant side effects~Reaching the PAA serum toxic threshold of 500 µg/ml~Reaching the maximal dose of GPB that is in use in urea cycle disorder: 12.4 gr (11.2 ml)/ meter square BSA divided by three times a day.~Duration of study: 4 months"
89535430|NCT03225937|Experimental|Cohort A|Trastuzumab and lapatinib
89535431|NCT03225937|Experimental|Cohort B|Pertuzumab and Trastuzumab-emtansine
88869506|NCT06039709|Experimental|Sonodynamic Therapy (5-ALA + LIFU)|Administration of SDT occurs 1-3 weeks prior to GBM resection
88869507|NCT06036212|Experimental|Journey II UK Partial Knee Implant with Robotic Assisted Surgery|Robotically-assisted implant of the partial (unicompartmental) knee implant (Journey II UK)
88869508|NCT06036212|Sham Comparator|Journey II UK Partial Knee Implant with Conventional, Manual Surgery|Implant of the partial (unicompartmental) knee implant (Journey II UK) with conventional, typical manual surgery
88869509|NCT06033885|Experimental|4-week control period + 4-week intervention period|Prior to the intervention a 4-week control period, where the non-instrumented standing frame is used according to current practice, will be carried out. Subsequently, a 4-week intervention period, where the standing frame is instrumented (PONDUS®) allowing continued adjustments of the force and position within and between sessions will be conducted.
88869510|NCT06031818||Patients with HCC|Patients who underwent curative liver resection for HCC in the First Affiliated Hospital of Sun Yat-Sen University in China.
88869511|NCT06022484||People with acute low back pain|No intervention.
88869512|NCT06022484||General practitioners who treat people with acute low back pain|No intervention.
88869513|NCT06022003|Experimental|Gilteritinib + Azacitidine oral (CC-486)|"Gilteritinib 120 mg/day, PO by 28 days-cycle~Azacitidine orale (CC-486) 300 mg/day, PO Day 1 to day 14, by 28 days-cycle"
88869514|NCT06018805|Active Comparator|Body Mass Index≥30 kg/m2|Pregnant women with a Body Mass Index≥30 kg/m2 will be included.
88869515|NCT06018805|Active Comparator|Body Mass Index: 18,5 - 24,9 kg/m2|Pregnant women with a Body Mass Index between 18.5 and 24.9 kg/m2 will be included.
88869516|NCT06017739|Experimental|Expiratory Flow Accelerator|Patients for 6 weeks use the Expiratory Flow Accelerator Technology
88869517|NCT06017739|Experimental|Expiratory Flow Accelerator + HIGH FLOW Technology|Patients for 6 weeks use the EFA technology and High Flow Technology
88869518|NCT06013072|Experimental|Pre-probiotic|One sachet per day during breakfast
88869519|NCT06013072|Placebo Comparator|Placebo|One sachet per day during breakfast
88869520|NCT06012487|Other|Ambulatory Blood Pressure Monitor (ABPM)|"Participants on antihypertensive pharmacotherapy in the highest decile of BPV will be offered enrollment based on inclusion/exclusion criteria. Patient's will undergo a 48 hour ABPM to determine baseline BPV. Next, each patient's primary care physician will be guided through titrations to antihypertensive medications to a low BPV regimen (Amlodipine and Indapamide, with doses titrated to reach target blood pressure). Following this, patients will undergo repeat 48h ABPM to evaluate change in BPV. All medication decisions will be at the ultimate discretion of the treating physician.~The optional sub-study will test the hypothesize that ABPM and SKNA data can be simultaneously captured and that BPV will be positively correlated with SKNA. Participants who enroll in the optional sub-study will be fitted with a single patch ECG which will capture high-fidelity ECG tracings from which SKNA can be determine in post-test analysis."
88869521|NCT06012331|Experimental|Concentrated Growth Factor (CGF)|Concentrated growth factor (CGF) is relatively a new generation of platelet concentrate product, it contains more cytokines and growth factors compared with PRP and PRF also promotes the proliferation, migration, and differentiation of stem cells
88869522|NCT06012331|Active Comparator|Blood Clot (BC)|Inducing bleeding to facilitate healing is a common surgical procedure. The blood clot formed after hemorrhage, acts as a scaffold and rich source of growth factors, and could play an important role in tissue repair in the canal. The growth factors could stimulate differentiation, growth, and maturation of fibroblasts, odontoblasts and cementoblasts, from the immature undifferentiated mesenchymal cells in the newly formed tissue matrix
89393241|NCT05208593|Active Comparator|Negative Event + Factual Thinking Task|"Participants in this group, the event plus the factual thinking task condition, will be told the following after completing the negative event writing task, After disappointing and/or negative experiences like the one you described on the previous page, people often think about the details of the situation. For example, when it happened, who was involved, and what happened right before or after the incident occurred. In the space below please provide examples of some of these details.. There will be 10 blank boxes below the instructions and participants will be asked to provide some examples of details from their traumatic event. They will be asked to only list as many as they can naturally recall without repeating any. This procedure is derived from Kray and colleague's (2010) study on counterfactual thinking and meaning in life."
89393242|NCT05208593|Experimental|Negative Event + Counterfactual Task|"Participants will be told after completing the negative event writing task, After disappointing and/or negative experiences like the one you described, people sometimes cannot help thinking what if… or if only… and imagining how things might have gone differently. That is, if only I had done something differently, the negative drinking situation could have been avoided or turned out better. In the box below please identify things that, had they been different, would have improved the outcome of the negative drinking situation you described earlier and briefly describe how the outcome would have been better. Participants will be asked to list three counterfactuals about the event. Participants will also be asked to think of situations where these strategies could be used, to list out any obstacles that might prevent them from implementing these strategies and to indicate their intention to use each strategy over the next week."
89393243|NCT05208593|Experimental|Personalized Normative Feedback|Participants in this group, the personalized normative feedback, will be asked to rate the frequency and quantity of TAMU students that use PBS when drinking.
89393244|NCT05205772|Experimental|medial prefrontal cortex - control site - dorsolateral prefrontal cortex|Participants first undergo transcranial magnetic stimulation to the medial prefrontal cortex. After a 3 week washout period, participants then undergo transcranial magnetic stimulation to the control site. After a 3 week washout period, participants undergo transcranial magnetic stimulation to the dorsolateral prefrontal cortex.
89393245|NCT05205772|Experimental|medial prefrontal cortex - dorsolateral prefrontal cortex - control site|Participants first undergo transcranial magnetic stimulation to the medial prefrontal cortex. After a 3 week washout period, participants then undergo transcranial magnetic stimulation to the dorsolateral prefrontal cortex. After a 3 week washout period, participants undergo transcranial magnetic stimulation to the control site.
89393246|NCT05205772|Experimental|dorsolateral prefrontal cortex - medial prefrontal cortex - control site|Participants first undergo transcranial magnetic stimulation to the dorsolateral prefrontal cortex. After a 3 week washout period, participants then undergo transcranial magnetic stimulation to the medial prefrontal cortex. After a 3 week washout period, participants undergo transcranial magnetic stimulation to the control site.
89393247|NCT05205772|Experimental|dorsolateral prefrontal cortex - control site - medial prefrontal cortex|Participants first undergo transcranial magnetic stimulation to the dorsolateral prefrontal cortex. After a 3 week washout period, participants then undergo transcranial magnetic stimulation to the control site. After a 3 week washout period, participants undergo transcranial magnetic stimulation to the medial prefrontal cortex.
89393248|NCT05205772|Experimental|control site - medial prefrontal cortex - dorsolateral prefrontal cortex|Participants first undergo transcranial magnetic stimulation to the control site. After a 3 week washout period, participants then undergo transcranial magnetic stimulation to the medial prefrontal cortex. After a 3 week washout period, participants undergo transcranial magnetic stimulation to the dorsolateral prefrontal cortex.
89393249|NCT05205772|Experimental|control site - dorsolateral prefrontal cortex - medial prefrontal cortex|Participants first undergo transcranial magnetic stimulation to the control site. After a 3 week washout period, participants then undergo transcranial magnetic stimulation to the dorsolateral prefrontal cortex. After a 3 week washout period, participants undergo transcranial magnetic stimulation to the medial prefrontal cortex.
89393250|NCT05191862|Other|Sequence 1|Treatment RTRT
89393251|NCT05191862|Other|Sequence 2|Treatment TRTR
89393252|NCT05189704|Experimental|NSAID group|NSAID based patient-controlled analgesia will connected to intravenous line for pain control.
89393253|NCT05189704|Active Comparator|Opioid group|Opioid based patient-controlled analgesia will connected to intravenous line for pain control.
89393254|NCT05181722|Active Comparator|Intervention group|The study participants in this group will receive support from the patient navigator as part of this study.
89393255|NCT05181722|No Intervention|Usual care group|The study participants in this group will receive the usual care per the institutional protocol.
89393256|NCT05161858||Primary Ciliary Dyskinesia (PCD) - Well State|Subjects with confirmed PCD in Well State
88816471|NCT02512419|Active Comparator|Health Education Control Arm|The health education control arm will receive the publicly available NHBLI Spanish-language booklets on heart-healthy behaviors for Latinos, which include information on PA, diet, and stress management.
88869523|NCT06012253|Experimental|Home Based Walking Program|Effect of home-based walking program on peripheral neuropathy, fatigue and quality of life
89393257|NCT05161858||Primary Ciliary Dyskinesia (PCD) - Sick State|Subjects with confirmed PCD in Sick State
88816472|NCT01155830||Infants with CHD|Infants with Congenital Diaphragmatic Hernia (CHD)
88816473|NCT01155830||Infants with sepsis|Infants who are culture positive for sepsis and require vasopressor support
88816474|NCT01155830||Infants treated with ECMO|Infants suffering cardiopulmonary failure significant enough to require heart/lung bypass treatment with extracorporeal membrane oxygenation (ECMO)
88816475|NCT02186210|Experimental|prewarming|prewarming during induction of anesthesia
88816476|NCT02186210|No Intervention|control|no prewarming during induction of anesthesia
88816477|NCT01195922|Experimental|Sirolimus|Subjects will be treated with sirolimus 21 days
88816478|NCT01197326||Group 1|Patients who triggered MET/RRT calls prior to the use of the MP5 EWS patient monitor.
88816479|NCT01197326||Group 2|Patients who triggered MET/RRT calls after the use of the MP5 EWS patient monitor.
88816480|NCT02512575|Experimental|AZD9567 oral suspension|"In Part A: up to 8 cohorts with single ascending doses (starting at 2 mg up to 155 mg).~In Part B: one cohort with a single dose"
88869524|NCT06012253|No Intervention|Control group|"The control group will be given the Ministry of Health Physical Activity Guidelines.Routine care."
89393258|NCT05137366||Known Thoracic aortic aneurysm (TAA)|"A medical confirmed TAA defined as an aneurysm measuring >3cm in the thoracic aorta e.g. aortic arch, ascending aorta or descending thoracic aorta.~Patients may also have a AAA~Patients may have had a TEVAR and will have a residual sac~A CT scan of the aorta in the last 3 years"
89393259|NCT05137366||Control group|A medically diagnosed Abdominal aortic aneurysm with a CT scan showing no TAA in the last three years. Patients who have also had their AAA repaired will also be eligible for this group.
89393260|NCT05132816|Experimental|Main arm|
89393261|NCT05123690|Experimental|Neurofeedback|24 sessions of ca 45 minutes neurofeedback using alpha-theta protocol.
89393262|NCT05123690|No Intervention|Waiting list|Those assigned to waiting list will be able to pick one of the two interventions at the end of the study.
89393263|NCT05110014|Other|Primary Care Office Visits|"The limited use dataset will contain the following data elements for each completed patient visit:~Date of clinic visit (where each date is indicated by a number relative to the clinic's Launch Date)~Clinic (designated by a unique study clinic identifier)~Type of visit completed (for example, new patient visit, return patient visit, annual exam)~Patient age~Patient gender~Patient race/ethnicity~Patient primary insurance~Nursing staff who roomed the patient (designated by a unique study identifier)~Whether patient used mPATH-CheckIn program (Y/N)~Whether nursing staff used mPATH Nursing Module to transmit mPATH data to electronic health record (Y/N)~Whether patient has a diagnosis of depression in the problem list in the EHR (Y/N)~Whether patient has an antidepressant medication listed in the active medication list ( (Y/N)~Results of depression screening items~Results of fall risk screening items~Results of safety at home screening items"
89393264|NCT05100160|Experimental|Gabapentin|used as part of a multimodal pain regimen (combination of drugs used to control pain
89393265|NCT05100160|Experimental|Placebo|designed to be compared with a study drug to learn if the study drug has any real effect
89393266|NCT05098093|Active Comparator|Standardized botanical extract|
89393267|NCT05098093|Active Comparator|Dry botanical extract|
89393268|NCT05098093|Active Comparator|Botanical powder|
89393269|NCT05097521||Veterans using practitioner delivered CIH therapies only|Veterans using practitioner-delivered (acupuncture, chiropractic care, massage) CIH therapies only
89393270|NCT05097521||Veterans using self-care CIH therapies only|Veterans using self-care (yoga, meditation, Tai Chi, Qi Gong) CIH therapies only
89393271|NCT05097521||Veterans using a combination of practitioner-delivered and self-care CIH therapies (dual-care)|Veterans using a combination of practitioner-delivered and self-care CIH therapies (dual-care)
89393272|NCT05090332|Experimental|Facial Gun|Vibrations through Facial gun along with conventional Therapy
89393273|NCT05090332|Experimental|Dry needling|Dry needling along with conventional treatment.
89393274|NCT05088525|Active Comparator|Two-tunnel meniscal root repair without a peripheral stabilization suture|Standard root repair surgery.
89393275|NCT05088525|Experimental|Meniscal root repair with an additional transtibial peripheral stabilization suture|Meniscus root repair with an added stabilization suture
89393276|NCT05082857|Active Comparator|"traditional Parents as Teachers (PAT)"|A twice-a-month home visits from trained family educators. Home visits will continue for the remainder of the study period as will the other components of the Parents as Teachers model: regular Group Connections for peer interactions and support, age-appropriate health and developmental screenings, and referrals that reflect mother and infant needs to community agencies that include the Child Development Services Agency (which provides screening for Individuals with Disabilities in Education Act (IDEA) Part C services), family services, intensive mental health services, among others. The study team will collect baseline data during the first home visit and complete monthly questionnaires during each month the mother is enrolled. An outcome assessment and participation in a focus group will be administered the last month of the study.
89393277|NCT05082857|Experimental|"hybrid PAT model"|A six-week virtual evidence-based parenting class entitled What You Do Matters, which will be delivered in partnership with the Pediatric Advocacy Program at WFBMC which combines short parent-educator discussions followed by interactive activities and peer to peer networking. Young moms will participate in Group Connections for peer interactions and support. After completing the six-week course, teens will begin receiving once a month home visits, ongoing Group Connections, age-appropriate health and developmental screenings, and referrals that reflect mother and infant needs to other community agencies and resources, as listed above. The study team will collect baseline data prior to the beginning of the virtual What You Do Matters program and will complete monthly questionnaires during each month the mother is enrolled. An outcome assessment and participation in a focus group will be administered the last month of the study.
88869525|NCT06011070|Experimental|Gambling Personalised Feedback|The intervention is a brief online intervention designed to provide personalized normative feedback aimed at motivating reductions in gambling
88869526|NCT06011070|No Intervention|Control|No intervention Control
88869527|NCT06010732|Other|Treatment Period 1|0 ppm F (placebo, negative control,1100 ppm F as sodium fluoride (positive control), 1100 ppm F as sodium fluoride Test Product
88869528|NCT06010732|Other|Treatment Period 2|0 ppm F (placebo, negative control,1100 ppm F as sodium fluoride (positive control), 1100 ppm F as sodium fluoride Test Product
88869529|NCT06010732|Other|Treatment Period 3|0 ppm F (placebo, negative control,1100 ppm F as sodium fluoride (positive control), 1100 ppm F as sodium fluoride Test Product
89393278|NCT05073276|Active Comparator|Non-weightbearing for the first six weeks after surgery|Not weightbearing after surgery
89393279|NCT05073276|Experimental|Partial weight -bearing for the first six weeks after surgery|Partial weightbearing will be defined as 40% of the patient's body weight.
88869530|NCT06010160|Experimental|Advocacy Training Intervention|7 weekly group sessions of advocacy training for cervical cancer screening
89393280|NCT05073263|Active Comparator|Partial weight -bearing for the first six weeks after surgery|Partial weightbearing will be defined as 40% of the patient's body weight.
89393281|NCT05073263|Experimental|Full weight -bearing for the first six weeks after surgery|If the patient is randomized to the full weightbearing group, the patient will be instructed about acceptable exercises and activities.
89393282|NCT05052931|Experimental|treatment group|Nab-paclitaxel combined with oxaliplatin and S-1
88869531|NCT06010160|No Intervention|Usual care control|usual care (no intervention); control participants will be offered the chance to receive the intervention at the conclusion of month 12 follow-up data collection
88869532|NCT06008912|Experimental|Calisthenic + Aerobic Exercise Group|Patients will take aerobic exercise training in 3 days per week, and 7 days per week calisthenic exercises for upper extremity, lower extremity and trunk, for 8 weeks.
88869533|NCT06008912|Active Comparator|Aerobic Exercise Group|Patients will take aerobic exercise training in 3 days per week, for 8 weeks.
88869534|NCT06008912|No Intervention|Control Group|Patients will take physical activity recommendations, and just screening after 8 weeks.
88869535|NCT06006546|Experimental|Group 1 (ATI)|"Group 1 will receive 2 doses of the vaccine at Week 0 and 12. Group 1 will transition to Schedule 2 at the Week 14 visit. The Schedule 2 ATI with Monitoring phase can last for 24 weeks OR until any antiretroviral therapy (ART) re-initiation criteria are met, OR the ATI can continue longer with the approval of the Protocol Safety Review Team (PSRT) and the participant's primary HIV healthcare provider. Group 1 will transition to Schedule 3, the Follow-up on ART restart phase that lasts until study week 64, regardless of the point where it begins."
88869536|NCT06006546|Experimental|Group 2 (No ATI) Control|"Group 2 transitions from Schedule 1 into Schedule 4, Follow-up on ART, at the Week 14 visit, and remains on Schedule 4 through study week 64."
88869537|NCT06005974|Experimental|AXIN1 Cohort|Participants will receive REC-4881 12mg PO dosed QD
88869538|NCT06005974|Experimental|APC Cohort|Participants will receive REC-4881 12mg PO dosed QD
88869539|NCT06005441|Experimental|CBL-514 Injection|Participant will receive CBL-514 administered in 2.4 mL injections, up to 120 mL per treatment session at intervals of approximately 3 weeks for up to 4 treatments.
88869540|NCT06005441|Experimental|CBL-A1 Injection|Participant will receive CBL-A1 administered in 2.4 mL injections, up to 120 mL per treatment session at intervals of approximately 3 weeks for up to 4 treatments.
88869541|NCT06005441|Experimental|CBL-A2 Injection|Participant will receive CBL-A2 administered in 2.4 mL injections, up to 120 mL per treatment session at intervals of approximately 3 weeks for up to 4 treatments.
88869542|NCT06005441|Placebo Comparator|0.9% Sodium Chloride|Participant will receive 0.9% Sodium Chloride administered in 2.4 mL injections, up to 120 mL per treatment session at intervals of approximately 3 weeks for up to 4 treatments.
88869543|NCT06001996||Pericapsular nerve group (PENG) block|"Group 1:Pericapsular nerve group (PENG) block: Using an in-plane approach with ultrasonographic imaging, the block needle reaches the fascial plane between the psoas muscle and the upper pubic ramus, and patients injected with local anesthetic solution.~After the patients were sedated with intravenous 1 mg midazolam and 50 mcg fentanyl in the preoperative preparation room, 15 ml of 0.375% bupivacaine was administered to the fractured hip side under ultrasound guidance.~After the block application, the patient will be taken to the operating room and standard spinale anaesthesia will be applied.~Each patient will receive 15 ml of 0.375% bupivacaine 0.375% on the side of the broken hip only one time approximately 15-20 minutes before the operation.~Plane block applications will be applied only once in the preoperative period~Plane block applications will be performed by anaesthesiologists with at least 5 years of experience"
89003697|NCT04757363|Experimental|Nivolumab Combined With FOLFOX and Regorafenib|Each treatment cycle consists of 28 days. Patients will initially receive induction therapy with regorafenib (80 mg on days 1-21 of the 28-day cycle) and nivolumab (240 mg on days 1 and 15 of the 28-day cycle). Starting on cycle 2, day 1, patients will also receive FOLFOX chemotherapy with oxaliplatin (85 mg/m2 IV), leucovorin (400 mg/m2 IV), 5-FU (400 mg/m2 IV bolus), and 5-FU (2400 mg/m2/day continuous IV infusion over 48 h). If the patient is not a good candidate for induction regorafenib and nivolumab (i.e. symptomatic from a large burden of disease), 5-FU and oxaliplatin can be added during cycle 1 at the treating physician's discretion. 39 Patients will continue with this regimen until disease progression, unacceptable toxicity, or development of serious intercurrent illness. Treatment will be performed on the scheduled day (±7-day treatment window).
89393283|NCT05052229|Placebo Comparator|Placebo|Inhaled medical grade normoxic gas (FiO2 = 0.21; DIN 02238755 Air Liquide Healthcare, Montreal, Quebec, Canada).
89393284|NCT05052229|Active Comparator|Nitric Oxide|Inhaled 40 ppm nitric oxide from a KINOX gas cylinder system (Air Liquid Healthcare, Montreal, Quebec, Canada; DIN 02451328).
89393285|NCT05049187||Group 1 COVISHIELD|Participants will receive one dose of COVID-19 vaccine (Covishield) at baseline and one second dose after 28 days (Window period of +3 days) intra muscularly.
89393286|NCT05049187||Group 2 COVAXIN|Participants will receive one dose of COVID-19 vaccine (Covaxin) at baseline and one second dose after 28 days (Window period of +3 days) intra muscularly.
89393287|NCT05040802||Pertussis Case Group|"Infants between 2 days to less than 2 months of age for whom a case of pertussis was reported (laboratory confirmed pertussis, epidemiological linkage to a laboratory-confirmed case and/or clinically compatible illness) and who met case inclusion criteria.~This post-hoc analysis was limited to infants born of mothers vaccinated with Adacel or who did not receive any tetanus, diphtheria, and acellular pertussis (Tdap) vaccine."
89535432|NCT03318887||Sofosbuvir/daclatasvir|Patients with hepatitis C virus (HCV) infection treated with sofosbuvir/daclatasvir combination therapy with or without ribavirin between February and September 2014
89393288|NCT05040802||Control Group|"Infants born at the same hospital as the case-infant who were less than 2 months old on the case-infant's cough onset date, and who met control inclusion criteria.~This post-hoc analysis was limited to infants born of mothers vaccinated with Adacel or who did not receive any Tdap vaccine."
89393289|NCT05020769|Experimental|SI-B001 combined with osimertinib_A|Patients with locally advanced/metastatic NSCLC progressed on 3rd generation EGFR-TKI treatment.
89393290|NCT05020769|Experimental|SI-B001 combined with osimertinib_B|Patients with locally advanced/metastatic NSCLC progressed on prior EGFR-TKI treatment and with T790M negative mutation.
89393291|NCT05020769|Experimental|SI-B001 combined with osimertinib_C|Patients with locally advanced/metastatic NSCLC and with EGFR exon20ins mutation.
89393292|NCT05008614|Experimental|Erector spinae plane block group (ESP group)|"Patients receiving continuous unilateral ESP block.~Interventions:~Procedure: Ultrasound-guided unilateral ESP block via catheter placement for continuous infusion Drug: Ropivacaine 0.75% Injectable Solution Device: 21-gauge 85 mm perineural catheter, 18-gauge 100 mm stimulator needle (Silverstim, Vygon, Ecouen, France)"
89393293|NCT05008614|Active Comparator|Thoracic epidural analgesia group (TEA group)|"Patients receiving thoracic epidural analgesia.~Interventions:~Procedure: Fluoroscopy-guided thoracic epidural analgesia Drug: Ropivacaine 0.75% Injectable Solution Device: 17-gauge Tuohy needle (FlexTip Plus®, Teleflex Medical, USA)"
89393294|NCT05002738|Experimental|Overall Cohort|Combined oral contraceptive pill containing 0.15mg desogestrel and 0.03mg ethinyl estradiol for 21 days
89393295|NCT04993443|Experimental|Active Comparator: Drug :LQ036|Experimental, Single and Multiple Oral escalating dose
89393296|NCT04993443|Placebo Comparator|Placebo Comparator: Matching Placebo for LQ036|Matching Placebo for LQ036: Matching Placebo
89393297|NCT04990284|Experimental|50 mg opicapone once-daily|
89393298|NCT04990284|Experimental|100 mg of L-DOPA|
88869544|NCT06001996||Suprainguinal fascia iliaca plane block|"Group 2: Suprainguinal fascia iliaca plane block: Patients in whom the needle entered in plane from the caudal end of the ultrasound probe passes through the musculus iliacus and fascia iliaca and local anesthetic solution has been injected immediately under the fascia.~After the patients were sedated with intravenous 1 mg midazolam and 50 mcg fentanyl in the preoperative preparation room, 15 ml of 0.375% bupivacaine was administered to the fractured hip side under ultrasound guidance. After the block application, the patient will be taken to the operating room and standard spinale anaesthesia will be applied.~Each patient will receive 15 ml of 0.375% bupivacaine 0.375% on the side of the broken hip only one time approximately 15-20 minutes before the operation.~Plane block applications will be applied only once in the preoperative period~plane block applications will be performed by anaesthesiologists with at least 5 years of experience"
88869545|NCT06000540|Experimental|Hypercapnia Group A|Healthy subjects without a history of coronary artery disease will undergo computer-controlled gas challenges.
88869546|NCT06000540|Experimental|Hypercapnia Group B|Healthy subjects without a history of coronary artery disease will undergo computer-controlled gas challenges.
88869547|NCT06000540|Experimental|Hypercapnia Group C|Healthy subjects without a history of coronary artery disease will undergo computer-controlled gas challenges.
89393299|NCT04979247|Experimental|Oliceridine|Patients receive Oliceridine for pain control.
89393300|NCT04969835|Experimental|AVA6000 Phase 1a|Patients in Phase Ia will receive escalating doses of AVA6000 following a 3+3 design, commencing with a starting dose of 80mg/m2, once every 3 weeks (Q3W) starting on Cycle 1, Day 1 (C1D1), until disease progression, unacceptable toxicities, withdrawal from treatment for other reasons, reaching maximum lifetime cumulative exposure to doxorubicin (or other anthracyclines), or death, whichever occurs first.
89393301|NCT04969835|Experimental|AVA6000 Phase 1b|Patients in Phase Ib will receive the RP2D dose of AVA6000, once every 3 weeks (Q3W) starting on Cycle 1, Day 1 (C1D1), until disease progression, unacceptable toxicities, withdrawal from treatment for other reasons, reaching maximum lifetime cumulative exposure to doxorubicin (or other anthracyclines), or death, whichever occurs first. One to three tumour types will be selected based on the assessment of Phase 1a data.
89393302|NCT04965350|Experimental|2vHPV Consistency Lot 1|
89393303|NCT04965350|Experimental|2vHPV Consistency Lot 2|
89393304|NCT04965350|Experimental|2vHPV Consistency Lot 3|
89393305|NCT04965350|Active Comparator|2vHPV Pilot Scale Lot|
88869548|NCT06000540|Experimental|Hypoxia Group|Healthy subjects without a history of coronary artery disease will undergo computer-controlled gas challenges.
88869549|NCT05999799|Experimental|GSK1070806 Dose 1|Participants will receive GSK1070806 dose 1.
88869550|NCT05999799|Experimental|GSK1070806 Dose 2|Participants will receive GSK1070806 dose 2.
89393306|NCT04955158|Experimental|Dexmedetomidine|75 µg dexmedetomidine soaked pharyngeal pack
89393307|NCT04955158|Experimental|Ketamine|50 mg ketamine soaked pharyngeal pack
89393308|NCT04955158|Experimental|Saline placebo|20 ml 0.9% saline soaked pharyngeal pack
89393309|NCT04952077|Experimental|Experimental|
89393310|NCT04938973|Experimental|NIF-Guided RAMIE using ICG Dye (Experimental Arm)|The patient will undergo NIF-guided RAMIE using ICG dye using the standard Ivor-Lewis approach. This will be a two-stage operation involving a first stage through a 5-port robotic approach through the abdomen to achieve a proximal gastrectomy and D2 nodal dissection. A feeding jejunostomy would not be inserted, as per the enhanced recovery pathway for esophagectomy. In addition, the vascularization of the conduit can be confirmed using the near-infrared camera of the robot with the ICG dye. The second stage of the operation will involve a 4-port robotic approach through the right chest to achieve thoracic nodal dissection, esophagectomy, and a hand-sewn anastomosis between the residual esophagus and the gastric conduit at the level of the azygous vein. During this second stage of the operation, NIF with ICG dye will be used to visualize the vascular supply of the gastric conduit, and assess the gastric conduit for any perfusions to potentially reduce anastomotic leaks.
89393311|NCT04938973|Active Comparator|Open Transthoracic Esophagectomy (OTE)|The patient will undergo OTE using the standard Ivor-Lewis approach. This is a two-stage operation involving a first stage through laparotomy, proximal gastrectomy, D2 nodal dissection, and insertion of feeding jejunostomy. The second stage of the operation will involve a right thoracotomy, thoracic nodal dissection, esophagectomy, and a stapled anastomosis between the residual esophagus and the gastric conduit at the level of the azygous vein.
89393312|NCT04936958||patients having had an osteomyelitis since 2017|
89393313|NCT04935554|Active Comparator|Intervention|"Baseline testing with blood samples, blood pressure and 6 minute walking test. After answering a comprehensive screening tool questionnaire and a conversation with a resource person about What is important to you, the study participant will chose one or several of the following interventions: physical activity, nutrition, motivation, health competence, psychosocial."
89393314|NCT04935554|No Intervention|Control|Baseline testing with blood samples, blood pressure, 6 minute walking test and screening tool questionnaire.
89393315|NCT04931160|Active Comparator|Sjögren patients|patients diagnosed Sjögren
89393316|NCT04931160|Other|Non-Sjögren witnesses|patients diagnosed no Sjögren
89393317|NCT04928391|Experimental|Group D|Dexmedetomidine IV at the end of surgery
89393318|NCT04928391|Experimental|Group N|Nalbuphine IV at the end of surgery
89393319|NCT04928391|Placebo Comparator|Group C|Same volume of saline placebo IV at the end of surgery
89393320|NCT04928352|Experimental|Group B1|Nebulized Bupivacaine 0.50% 0.25 mg.kg-1
89393321|NCT04928352|Experimental|Group B2|Nebulized Bupivacaine 0.50% 0.50 mg.kg-1
89393322|NCT04928352|Placebo Comparator|Group C|Same volume of nebulized saline placebo
89393323|NCT04928300|Experimental|Group D|Dexmedetomidine infusion IV for 5 days.
89393324|NCT04928300|Experimental|Group K|Ketamine infusion 2.5 µ/kg/min for 5 days.
89393325|NCT04928300|Placebo Comparator|Group C|The same dose and duration of normal saline will be given.
89393326|NCT04924140|Experimental|Aducanumab Intravenous|Participants will receive aducanumab as body weight-based dose, via IV infusion for approximately 1 hour on Day 1.
89393327|NCT04924140|Experimental|Aducanumab Subcutaneous|Participants will receive aducanumab as fixed dose, via SC injection on Day 1.
89393328|NCT04919018||Primary Ciliary Dyskinesia (PCD)|Subjects with a confirmed diagnosis of PCD
89393329|NCT04919018||Primary Immune Deficiency (PID)|Subjects with a confirmed diagnosis of PID
89393330|NCT04913948||Pregnant|Pregnant women with confirmed COVID-19 at any point during pregnancy or suspected (as identified at local hospital) of COVID-19 at time of delivery, who will be delivering at a participating hospital within Ontario
89393331|NCT04910464|Experimental|Tranexamic acid|Give 1 gram of TXA in 100 ml of 0.9% normal saline, intravenous over 10 minutes as soon as possible but no later than three hours after diagnosis, infuse a second gram of TXA IV over 8 hours in 0.9% normal saline for the first 3 days.
89393332|NCT04910464|Placebo Comparator|Saline placebo|Give the same volume (100 ml normal saline) and same duration (first three days).
89393333|NCT04905901|Experimental|Tranexamic acid 500 mg|Nebulized tranexamic acid 500 mg 15 minutes before operation
89393334|NCT04905901|Experimental|Tranexamic acid 1gm|Nebulized tranexamic acid 1 gm 15 minutes before operation
89393335|NCT04905901|Placebo Comparator|Saline placebo|Normal saline nebulization 15 minutes before operation
89393336|NCT04901988|No Intervention|Arm A|In Arm A, patients and clinicians will remain blinded to the ctDNA result and will be managed as per standard of care with regular clinical review and imaging, and treated if they develop evidence of disease recurrence.
89393337|NCT04901988|Experimental|Arm B|Patients randomised to Arm B will not be blinded to the positive ctDNA result and will be treated with the intervention.
89393338|NCT04901546|Experimental|Infants with Esophageal Atresia|Starting at 3 weeks, infants will be administered 1 mL of their own saliva via gastrostomy tube, with each feed (8x/day) for one week.
89393339|NCT04901546|No Intervention|Comparison Infants without Esophageal Atresia|Infants do not have EA and thus can swallow their own saliva.
88869551|NCT05999799|Experimental|GSK1070806 Dose 3|Participants will receive GSK1070806 dose 3.
89393340|NCT04900974|Experimental|Doravirine|100mg doravirine given by mouth once at each sampling visit.
89393341|NCT04899687|Experimental|Group A: fluoxetine then fluoxetine plus dextromethorphan|Group A participants will take fluoxetine 20mg (or prior dose) daily for 4 weeks, and will then continue fluoxetine while adding over the counter dextromethorphan, with doses increasing weekly as tolerated, for 4 weeks.
89393342|NCT04899687|Experimental|Group B: fluoxetine plus dextromethorphan then fluoxetine|Group B participants will take fluoxetine 20mg (or prior dose) daily together with over the counter dextromethorphan, with doses increasing weekly as tolerated, for 4 weeks, and then will stop dextromethorphan, continuing fluoxetine alone for 4 weeks.
89393343|NCT04866823|Experimental|Medically Tailored Meals|A series of medically tailored meals appropriate for women with gestational diabetes will be developed in partnership with chefs from a local community kitchen and catering company. Meals will create a slight caloric deficit in order to promote gradual weight loss, but with sufficient energy intake and macronutrient balance to allow breastfeeding. These meals will be roughly 40% carbohydrate, 30% protein, and 30% fat in composition. Study Team will plan up to 20 unique lunch and dinner meals for the series. Each meal will be prepared to be between 450-600 kcal and to contain 6 ounces of protein, 4 ounces of vegetable and I cup of whole grain (at a minimum). Participants will receive detailed recipe cards and nutrition information with each meal. In addition to receiving the medically tailored meals, participants will be advised to supplement their own breakfast +/- snacks to reach a total daily calorie goal determined by starting BMI category.
89393344|NCT04866823|No Intervention|Usual Care Comparison Group|Participants in this group will receive written materials on self-care, nutrition, and physical activity in the postpartum period and community resources for healthy living.
89393345|NCT04852809||Questionnaire|Observational
89393346|NCT04852809||Focus Group|Observational
89393347|NCT04844242||Group 1|Prior SARS-CoV2 infection as defined by being positive for IgG
89393348|NCT04844242||Group 2|COVID-19 disease as defined as children positive by RT-PCR
89393349|NCT04844242||Group 3|Children with MIS-C according to the WHO or CDC criteria
89393350|NCT04844242||Group 4|Control children who are negative for both RT-PCR and antibody
89393351|NCT04843124|Experimental|Intervention group|Remote hearing aid adjustment. All participants in this group are offered hearing aids possible to adjust remotely.
89393352|NCT04843124|Active Comparator|Control group|Traditional hearing aid adjustment
89393353|NCT04829877|Experimental|Web-based mind-body intervention with HRVB|Both standard usual care and the web-based mind-body intervention with HRV biofeedback (MBI-HRVB) will be provided to the participants. The web-based mind-body intervention with HRV biofeedback program consisted of 5-week training sessions and breathing training.
89393354|NCT04829877|Experimental|Web-based mind-body intervention|Both standard usual care and the web-based mind-body intervention will be provided to the participants. The web-based mind-body intervention program consisted of 5-week training sessions.
89393355|NCT04829877|No Intervention|Control|The women in the control group will receive the standard usual care provided at the fertility clinic. The standard care protocols encompass elements such as routine assessment and health education at each visit. Participants enrolled in the control group will be approached once a week by a nurse to provide health consultation about fertility treatment, medication, signs, and symptoms of discomfort for five weeks.
89393356|NCT04823845|Experimental|Plantar Wart Treatment Using Adapalene Gel 0.1%|patients treated for plantar warts with Adapalene 0.1% gel
89393357|NCT04810962|Experimental|APP13007 0.05% BID|1 drop APP13007 0.05% twice daily for 14 days to study (operated) eye
89393358|NCT04810962|Placebo Comparator|Matching Vehicle Placebo|1 drop matching vehicle placebo twice daily for 14 days to study (operated) eye
89393359|NCT04806776|Active Comparator|24hrs dressing change|The first dressing change and sampling were completed 24 hours after catheterization in the operating room or PICU Then the second dressing change and sampling were completed 7days later(if there is no clinical indication occur,such leaking,blood).
89393360|NCT04806776|Experimental|7d change dressing|Dressing change and sampling were completed 7days after catheterization in the operating room or PICU.(if there is no clinical indication occur,such leaking,blood).
89393361|NCT04806269||Thyroid dysfunction group|"Subjects with thyroid dysfunction including thyrotoxicosis and hypothyroidism Subjects who were newly diagnosed or undergoing treatment for thyroid dysfunction can be included in the study.~Subjects should use a wearable device (Fitbit Inspire 2 TM) and a mobile app (Glandy TM) during the study period."
89393362|NCT04806269||Control group|"Subjects without thyroid dysfunction including thyrotoxicosis and hypothyroidism.~Subjects should use a wearable device (Fitbit Inspire 2 TM) and a mobile app (Glandy TM) during the study period."
89393363|NCT04805983|Experimental|10 mg BMS-984923|
89393364|NCT04805983|Experimental|40 mg BMS-984923|
89393365|NCT04805983|Experimental|70 mg BMS-984923|
89393366|NCT04805983|Experimental|100 mg BMS-984923|
89393367|NCT04805983|Experimental|150 mg BMS-984923|
89393368|NCT04805983|Experimental|200 mg BMS-984923|
89393369|NCT04798378|Experimental|Treatment Arm|Participants will received a customized NuroSleeve and undergo 8 weeks of occupational therapy using the NuroSleeve (135 minutes per week for 8 weeks: this can be done as 45 minutes three times per week, 68 minute sessions twice per week, or one 135 minute once per week).
89393370|NCT04792749|Experimental|Metformin treatment|Patients who receive metformin in addition to progestin therapy
89393371|NCT04792749|No Intervention|Conventional treatment|Patients who receive progestin therapy only
89393372|NCT04789070|Active Comparator|Sirolimus|2mg capsules once daily
89393373|NCT04789070|Placebo Comparator|Placebo|2mg capsules once daily
89393374|NCT04756427|Experimental|Sodium citrate 4%|All enrolled participants will received the daily sodium citrate 4% locking solution for CLABSI prophylaxis intervention and be observed prospectively for adverse events
89393375|NCT04753359|Experimental|Med-A|"Med-A will attend a one-hour, in-person individual session with a registered dietitian (RD) during the two weeks prior to the start of the intervention. For subjects randomized to Med-A the study RD will instruct on adoption of an eating pattern consistent with a MedDiet using an individualized MedDiet exchange list and companion guide. Recommended daily exchanges are based on individual caloric needs to maintain weight. We will not ask subjects to abstain from alcohol during the trial despite its known effects on BA metabolism, but we will recommend that only 5% of calories come from alcohol taken with meals. Following the initial session, subjects will meet for 24 individual sessions (1-hour, held approximately weekly) in-person or virtually over the remaining 6 months. Additional asynchronous learning materials will be distributed weekly through a private Facebook group.~The Med-A group will be asked to maintain their usual physical activity."
89393376|NCT04753359|Experimental|WL-A|"WL-A will attend a one-hour, in-person individual session with a registered dietitian (RD) during the two weeks prior to the intervention. For WL-A, the focus will be on daily calorie restriction (-500-750 kcal/day) to achieve a 1-2 lb. per week WL and 5% WL from baseline at 6 months in the context of the subject's typical diet pattern. We will not ask subjects to abstain from alcohol during the trial despite its known effects on BA metabolism, but we will recommend that only 5% of calories come from alcohol taken with meals. Following the initial session, subjects will meet for 24 individual, virtual or in-person sessions (1-hour, held approximately weekly) over the remaining 6 months. Additional asynchronous learning materials will be distributed weekly through a private Facebook group.~The WL-A group will be prescribed an activity program. Physical activity will be monitored via FitBit."
89393377|NCT04753359|Experimental|WL-Med|"WL-Med will attend a one-hour, in-person session with a registered dietitian (RD) prior to the intervention. The RD will instruct on an eating pattern consistent with a MedDiet using an individualized exchange list. Exchanges are based on individual caloric needs to lose weight (WL-Med, calorie restriction to achieve a 1-2 lb. per week WL and 5% WL from baseline at 6 months). We will not ask subjects to abstain from alcohol despite its known effects on BA metabolism, but we will recommend that only 5% of calories come from alcohol taken with meals. Following the initial session, subjects will meet remotely or in-person for 24 individual sessions (1-hour, held approximately weekly). Additional asynchronous learning materials will be distributed weekly through a private Facebook group.~The WL-Med group will be prescribed an activity program. Some asynchronous lessons will contain information about physical activity. Physical activity will be monitored via FitBit."
89535433|NCT05011695|Active Comparator|1. Group ESWT treatment|"6000 SWT Easy device will be used for ESWT treatment. The plantar fascia of the patients will be applied once a week for 3 weeks. In each application, 2400 beats, 2.0 bar pressure and 12 frequency doses of ESWT will be applied"
89393378|NCT04753359|No Intervention|Control|The study RD will meet individually with the Control group subjects in-person for 1-hour at the start of the 6-month intervention. Control participants will be instructed to maintain current eating and activity patterns and weight over the next 6 months. No dietary recommendations are provided, and they will receive weekly health newsletters that include non-diet related health topics (e.g., flu prevention). Contact will be made again at month-3 and post-intervention (month-6) research visits and during monthly phone calls to collect data pertaining to recent diet intake. At the month-3 assessment, weight will be checked and those with >2.5% WL from baseline will receive additional instruction from the RD to maintain lifestyle patterns. All WL-Med materials are offered to the group in a self-guided format following the 6-month intervention.
89393379|NCT04733417|Experimental|SHR6390+famitinib|Participants will receive SHR6390 in combination with famitinib.
89393380|NCT04731441|Experimental|Exercise Group|Exercise Program Subjects randomized to the intervention arm should have 6 weeks of home exercise prior to surgery, with a minimum of 5 weeks and not more than 7 weeks. The program will begin with an exercise consultation appointment with a certified fitness professional. During this consultation participants will receive an exercise manual for individualized home-based exercise and a practical introduction by an exercise and cancer specialist. PowerBlock adjustable dumbbells will be used for resistance training exercises and walking or jogging will be the primary type of aerobic training. The current program design was developed and successfully used with women with breast cancer. Thus, some components may need modification for this group of patients with advanced GI cancer.
89393381|NCT04731441|Active Comparator|Education Group|Subjects randomized to the control arm will receive education and a handbook on the benefits of exercise and will be encouraged to have adequate protein in their diet and provided with the list of high protein foods and nutritional information. These subjects will undergo the same assessments as the intervention arm at all time points. Control subjects will be offered a 6-week home exercise program 3 months after CRS/HIPEC. Results and outcomes will not be recorded.
89393382|NCT04724603||patients having had avderse event after phagotherapy for bone or joint infection|
89393383|NCT04723420|Active Comparator|Steamroller Technique|Following intravitreal gas injection, patient positioned face down for 4-6 hours and subsequently patient changes the position of the head so that the bubble is then placed directly over the retina break.
89393384|NCT04723420|Active Comparator|Direct Technique|Following intravitreal gas injection, patient is immediately positioned so that the bubble is placed directly over the retina break.
89393385|NCT04722601|Experimental|Phase 1(Dose-Finding Arm): Group 1 - Dose Level 1 / Starting Dose|"Phase 1/the dose-finding arm of this study will use three dose levels (a starting dose, second dose and highest dose) of the venetoclax, CC-486 and obinutuzumab regimen. If participants in group 1 don't experience severe negative side effects to the starting dose of the regimen, then more participants will be assigned to groups 2 and 3 to take higher doses until the safest/ most tolerable dose is found.~Group 1/ Dose Level 1:~Participants in group 1 will receive a three-drug regimen of venetoclax, CC-486, and obinutuzumab at a starting dose used in previous human studies. Participants in this group will receive:~Venetoclax:~400 mg on days 1-28~CC-486:~200 mg on days 1-14~Obinutuzumab:~1000 mg on days 1, 8 and 15 of cycle 1, and on day 1 of each following cycle.~Treatment using these three study drugs (venetoclax, CC-486, and obinutuzumab) will be given in 12 consecutive cycles that run for 28 days during each cycle (336 days)."
89393386|NCT04722601|Experimental|Phase 2 (Efficacy Arm/ Expansion Cohort)|Participants in this arm will help test the efficacy of the three-drug regimen and dose established in the phase 1 of the study. Participants will take two drugs (venetoclax and CC-48) used in the same three-drug regimen during the first phase of this study. These two drugs will be paired together by themselves and given to participants in the expansion cohort before obinutuzumab (a third drug) is added during cycle 4 of treatment.
88869552|NCT05999799|Experimental|GSK1070806 Dose 4|Participants will receive GSK1070806 dose 4.
88869553|NCT05999799|Placebo Comparator|Placebo|Participants will receive placebo.
88869554|NCT05999240|Experimental|Pimavanserin tartrate|Pimavanserin 34 mg white to off-white capsules.
88869555|NCT05999240|Placebo Comparator|Placebo|Placebo to Pimavanserin tartrate
88869556|NCT05997277|Experimental|Deucravacitinib - Study Drug|Deucravacitinib group: 6 mg po bid x 16 weeks
88869557|NCT05997277|Placebo Comparator|Placebo|Placebo group: 1 tablet po bid x 16 weeks
88869558|NCT05995249|Experimental|Part 1, Treatment A + Treatment B: TAK-279 50 mg + Erythromycin 500 mg|Participants will receive single oral dose of TAK-279 50 mg, on Day 1 of Period 1. Following Period 1 participants will receive single oral dose of TAK-279 50 mg, on Day 5 and erythromycin 500 mg orally thrice daily (TID) on Day 1 through Day 10 of Period 2 in Part 1 of the study.
88869559|NCT05995249|Experimental|Part 2, Treatment C + Treatment D: TAK-279 50 mg + Phenytoin 100 mg|Participants will receive single oral dose of TAK-279 50 mg, on Day 1 of Period 1. Following Period 1 participants will receive single oral dose of TAK-279 50 mg on Day 14 and phenytoin 100 mg orally TID on Day 1 through Day 18 of Period 2 in Part 2 of the study.
88869560|NCT05995249|Experimental|Part 3, Treatment E + Treatment F: TAK-279 50 mg + Efavirenz 600 mg|Participants will receive single oral dose of TAK-279 50 mg, on Day 1 of Period 1. Following Period 1 participants will receive single oral dose of TAK-279 50 mg on Day 11 and efavirenz 600 mg orally once daily (QD) on Day 1 through Day 15 of Period 2 in Part 3 of the study.
88869561|NCT05991635|Experimental|Intervention group|Participants in this group (all participants) are asked to complete a questionnaire and then receive access to the online gatekeeper training (e-learning) during three days, after which they were asked to complete another questionnaire. After three months, a third questionnaire is sent.
88869562|NCT05988671|Placebo Comparator|Control group|received 20 ml normal saline
88869563|NCT05988671|Active Comparator|dexamethasone group|received 8mg dexamethasone
88869564|NCT05988671|Active Comparator|dexmedetomidine group|received dexmedetomidine 1mic/kg
88869565|NCT05988671|Active Comparator|combined group|received combination of both 8mg dexamethasone+ dexmedetomidine 1mic/kg
88869566|NCT05987254|Active Comparator|FICB group|received ultrasound guided suprainguinal fascia iliaca block
88869567|NCT05987254|Active Comparator|PENG group|received ultrasound guided pericapsular nerve group block
89393387|NCT04722601|Experimental|Phase 1(Dose-Finding Arm): Group 2 - Dose Level 2 /Second Dose|"Participants in group 2 will receive a three-drug regimen of venetoclax, CC-486, and obinutuzumab at the second highest dose (dose level 2) set by doctors leading the study. Participants in this group will receive:~Venetoclax:~600 mg on days 1-28~CC-486:~200 mg on days 1-14~Obinutuzumab:~1000 mg on days 1, 8 and 15 of cycle 1, and on day 1 of each following cycle.~Treatment using these three study drugs (venetoclax, CC-486, and obinutuzumab) will be given in 12 consecutive cycles that run for 28 days during each cycle (336 days)."
89393388|NCT04722601|Experimental|Phase 1 (Dose-Finding Arm) - Group 3 - Dose Level 3/ Highest Dose|"Participants in group 3 will receive a three-drug regimen of venetoclax, CC-486, and obinutuzumab at the highest dose (dose level 3) set by doctors leading the study. Participants in this group will receive:~Venetoclax:~800 mg on days 1-28~CC-486:~200 mg on days 1-14~Obinutuzumab:~1000 mg on days 1, 8 and 15 of cycle 1, and on day 1 of each following cycle.~Treatment using these three study drugs (venetoclax, CC-486, and obinutuzumab) will be given in 12 consecutive cycles that run for 28 days during each cycle (336 days)."
89393389|NCT04722601|Experimental|Phase 1 (Dose-Finding Arm) - Group 4 - Lower Dose Level 1|"Participants in this group will received a lower dose of the three-drug regimen using venetoclax, CC-486 and obinutuzumab set by doctors leading the study. Inclusion in this group is optional and based on whether the participant reports serious adverse events/side effects in response to a higher dose of the regimen. If participants are included in this group, they will receive:~Venetoclax:~400 mg on days 1-28~CC-486:~150 mg on days 1-14~Obinutuzumab:~1000 mg on days 1, 8 and 15 of cycle 1, and on day 1 of each following cycle."
89393390|NCT04722601|Experimental|Phase 1 (Dose-Finding Arm) - Group 5 - Lower Dose Level 2|"Participants in this group will received the second lowest dose of the three-drug regimen using venetoclax, CC-486 and obinutuzumab set by doctors leading the study. Inclusion in this group is optional and based on whether the participant reports serious adverse events/side effects in response to a higher dose of the regimen. If participants are included in this group, they will receive:~Venetoclax:~400 mg on days 1-10 only~CC-486:~150 mg on days 1-14~Obinutuzumab:~1000 mg on days 1, 8 and 15 of cycle 1, and on day 1 of each following cycle."
89393391|NCT04702243||Affected Participants|Subjects who have suppurative lung disease without a known genetic diagnosis
89393392|NCT04702243||Unaffected Family Members|Unaffected family members may be enrolled in the study for collection of DNA only
89393393|NCT04692844||Patients with essential tremor treated with Propranolol|Patients will be recruited from the outpatient clinic for extrapyramidal disorders. Only patients with the diagnosis of ET made according to the newest consensus statement on the classification of tremors and only patients who will receive Propranolol in the course of routine medical practice, will be included.
89393394|NCT04692844||Patients with essential tremor treated with Primidone|Patients will be recruited from the outpatient clinic for extrapyramidal disorders. Only patients with the diagnosis of ET made according to the newest consensus statement on the classification of tremors and only patients who will receive Primidone in the course of routine medical practice, will be included.
89393395|NCT04657003|Experimental|10 mg Tirzepatide|10 mg Tirzepatide administered subcutaneously (SC)
89393396|NCT04657003|Experimental|15 mg Tirzepatide|15 mg Tirzepatide administered SC
89393397|NCT04657003|Placebo Comparator|Placebo|Placebo administered SC
89393398|NCT04650607||PHA SA CO|patients having a severe infection treated by injection of phages, with or without surgery
89393399|NCT04650607||PhageRESPONSE|ancillary study : Establish a biobanking of serums, plasmas and PBMC (Peripheral Blood Mononuclear Cells) of patients who have been treated with phage therapy for a bacterial infection.
89393400|NCT04648852||Participants in the third wave of the HUNT study|General population participating in the third wave of the HUNT study
89393401|NCT04648852||Participants in the second wave of the HUNT study|General population participating in the second wave of the HUNT study
89393402|NCT04643067|Active Comparator|KPG-818 low dose|After providing informed consent, patients will be assessed for study eligibility at the Screening visit. A total of 8 to 12 patients will be randomized to receive this dose level of KPG-818 in a double-blind fashion. Patients will receive treatment for 12 weeks with a 4-week safety follow-up. Capsules of this level of dosage will be taken orally in the morning once a day. All patients will return for follow-up visits after their final dose. The total duration of study participation for each patient (from Screening through Follow-up visit) is anticipated to be approximately 20 weeks.
89393403|NCT04643067|Active Comparator|KPG-818 mid dose|After providing informed consent, patients will be assessed for study eligibility at the Screening visit. A total of 8 to 12 patients will be randomized to receive this dose level of KPG-818 in a double-blind fashion. Patients will receive treatment for 12 weeks with a 4-week safety follow-up. Capsules of this level of dosage will be taken orally in the morning once a day. All patients will return for follow-up visits after their final dose. The total duration of study participation for each patient (from Screening through Follow-up visit) is anticipated to be approximately 20 weeks.
89393404|NCT04643067|Active Comparator|KPG-818 high dose|After providing informed consent, patients will be assessed for study eligibility at the Screening visit. A total of 8 to 12 patients will be randomized to receive this dose level of KPG-818 in a double-blind fashion. Patients will receive treatment for 12 weeks with a 4-week safety follow-up. Capsules of this level of dosage will be taken orally in the morning once a day. All patients will return for follow-up visits after their final dose. The total duration of study participation for each patient (from Screening through Follow-up visit) is anticipated to be approximately 20 weeks.
89393405|NCT04643067|Placebo Comparator|Placebo arm|After providing informed consent, patients will be assessed for study eligibility at the Screening visit. A total of 8 to 12 patients will be randomized to receive this dose level of KPG-818 in a double-blind fashion. Patients will receive treatment for 12 weeks with a 4-week safety follow-up. Capsules of this level of dosage will be taken orally in the morning once a day. All patients will return for follow-up visits after their final dose. The total duration of study participation for each patient (from Screening through Follow-up visit) is anticipated to be approximately 20 weeks.
89393406|NCT04625361|Experimental|Single dose of HEC122505MsOH Tablets（pilot trial arm）|Healthy subjects receive single dose of tablets HEC122505MsOH
89393407|NCT04625361|Experimental|Single dose of HEC122505MsOH Tablets（Part 1， Cohort 1）|Healthy subjects receive single dose of HEC122505MsOH or matching placebo
89393408|NCT04625361|Experimental|Single dose of HEC122505MsOH Tablets（Part 1， Cohort 2）|Healthy subjects receive single dose of HEC122505MsOH tablets or matching placebo
89393409|NCT04625361|Experimental|Single dose of HEC122505MsOH Tablets（Part 1， Cohort 3,Fed/Fasting）|Following an overnight fast of at least 10 hours, a single dose of HEC585 will be administered on 2 separate occasions (fasting and after meal) in a randomized crossover fashion with different food restrictions.
88869568|NCT05984420|Experimental|Treatment group LimpiAD|LimpiAD 2,5% plus cream to be applied twice a day (morning and evening) for 8 weeks
89393410|NCT04625361|Experimental|Single dose of HEC122505MsOH Tablets（Part 1， Cohort 4）|Healthy subjects receive single dose of HEC122505MsOH tablets or matching placebo
89393411|NCT04625361|Experimental|Single dose of HEC122505MsOH Tablets（Part 1，Cohort 5）|Healthy subjects receive single dose of HEC122505MsOH tablets or matching placebo
89393412|NCT04625361|Experimental|Single dose of HEC122505MsOH Tablets（Part 1， Cohort 6）|Healthy subjects receive single dose of HEC122505MsOH tablets or matching placebo
89393413|NCT04625361|Experimental|Multiple doses of HEC122505MsOH Tablets（Part 2， Cohort 1）|Healthy subjects receive multiple doses of HEC122505MsOH tablets or matching placebo
89393414|NCT04625361|Experimental|Multiple doses of HEC122505MsOH Tablets（Part 2， Cohort 2）|Healthy subjects receive multiple doses of HEC122505MsOH tablets or matching placebo
89393415|NCT04625361|Experimental|Multiple doses of HEC122505MsOH Tablets（Part 2， Cohort 3）|Healthy subjects receive multiple doses of HEC122505MsOH tablets or matching placebo
89393416|NCT04624906|Experimental|Single arm intervention|"100 mg Acalabrutinib (ACP-196) oral capsules twice daily for 1 year~Bendamustine and rituximab will be given for 6 x 28-day cycles. Bendamustine will be given intravenously at 90 mg/m2 on days 1 and 2 of each cycle. Rituximab will be given on day 1 of each cycle (375 mg/m2 intravenously for the first cycle and 1400 mg subcutaneously OR 375 mg/m2 intravenously for subsequent cycles (as per institutional procedures)."
89393417|NCT04606134|Experimental|Experimental|
89393418|NCT04606134|Placebo Comparator|Control|
89393419|NCT04568759|Active Comparator|Standard care group|Observation or brace plus conventional physiotherapy exercises on video
88869569|NCT05984420|Active Comparator|Control group Vehicle of LimpiAD|Vehicle of LimpiAD 2,5% plus cream to be applied twice a day (morning and evening) for 8 weeks.
88869570|NCT05984420|Active Comparator|Control group Emollient|Emollient standard cream to be applied twice a day (morning and evening) for 8 weeks.
89393420|NCT04568759|Experimental|GPR group|GPR interventions added to standard care (observation or brace)
89393421|NCT04556188||Cases|RHD patients undergoing Cardiac surgery at Addis Abeba University Hospital
89393422|NCT04556188||RHD controls|RHD patients not offered Cardiac surgery
89393423|NCT04556188||Anticoagulation controls|Norwegian patients on anticoagulant therapy due to mechanical valve implants
89393424|NCT04550598|Experimental|HD-tCES|The experiment group will receive active HD-tCES.
89393425|NCT04550598|Sham Comparator|Sham HD-tCES|The sham control group will receive sham HD-tCES.
89393426|NCT04546399|Experimental|Arm G (dexamethasone, blinatumomab, nivolumab,MTX) DS patients|Patients receive dexamethasone PO or IV on days 1 and 8 of cycle 1 only, blinatumomab IV via continuous infusion on days 1-28, nivolumab IV over 30 minutes on days 11 and 25 of cycle 1 and days 1 and 15 of cycle 2, and MTX IT, cytarabine IT, or ITT IT on days 1,15, and 36 of cycle 1 (MTX, cytarabine, and ITT on day 1 may be omitted if intrathecal therapy was given < 7 days prior to the start this cycle 1), MTX IT, cytarabine IT, or ITT IT on days 15 and 36 of cycle 2, and leucovorin calcium IV or PO q6h for 2 doses on days 2, 16 and 37 of cycle 1 and q6h for 2 doses on days 16 and 37 of cycle 2.
89393427|NCT04546399|Experimental|Group 1, Arm A (dexamethasone, blinatumomab, MTX)|ARM A: Patients receive dexamethasone PO or IV on days 1 and 8 of cycle 1, blinatumomab via continuous IV infusion on days 1-28 of cycles 1-2, MTX IT, cytarabine IT, or ITT IT on days 1, 15, and 36 of cycle 1 (MTX, cytarabine, and ITT on day 1 may be omitted if intrathecal therapy was given < 7 days prior to the start of this cycle), and MTX IT, cytarabine IT, or ITT IT on days 15 and 36 of cycle 2. Treatment repeats every 36 days for 2 cycles in the absence of disease progression or unacceptable toxicity. NOTE: Patients with MRD < 0.01% after cycle 1 may stop study treatment or may choose to continue to cycle 2. Patients with MRD >= 0.01% after cycle 1 proceed to cycle 2.
89393428|NCT04546399|Experimental|Group 1, Arm B (dexamethasone, blinatumomab, MTX)|Patients receive dexamethasone, blinatumomab, and MTX, cytarabine, or ITT as in Arm A. Patients also receive nivolumab IV over 30 minutes on days 11 and 25 of cycle 1 and days 1 and 15 of cycle 2. Treatment repeats every 36 days for 2 cycles in the absence of disease progression or unacceptable toxicity. NOTE: Patients with MRD < 0.01% after cycle 1 may stop study treatment or may choose to continue to cycle 2. Patients with MRD >= 0.01% after cycle 1 proceed to cycle 2.
89393429|NCT04546399|Experimental|Group 2, Arm C (dexamethasone, blinatumomab, MTX)|Patients receive dexamethasone PO or IV on day 1 of cycle 1, blinatumomab via continuous IV infusion on days 1-28 of cycles 1 and 2, and methotrexate IT on days 1 and 15 of cycles 1 and 2 (day 1 may be omitted from cycle 1 if intrathecal therapy is given < 7 days prior to the start of this cycle). Treatment repeats every 36 days for 2 cycles in the absence of disease progression or unacceptable toxicity. NOTE: Patients with MRD < 0.01% after cycle 1 may stop study treatment or may choose to continue to cycle 2. Patients with MRD >= 0.01% after cycle 1 proceed to cycle 2.
89393430|NCT04546399|Experimental|Group 2, Arm D (dexamethasone, nivolumab, blinatumomab, MTX)|Patients receive dexamethasone, blinatumomab, and MTX as in Arm C. Patients also receive nivolumab IV over 30 minutes on days 11 and 25 of cycle 1 and days 1 and 15 of cycle 2. Treatment repeats every 36 days for 2 cycles in the absence of disease progression or unacceptable toxicity. NOTE: Patients with MRD < 0.01% after cycle 1 may stop study treatment or may choose to continue to cycle 2. Patients with MRD >= 0.01% after cycle 1 proceed to cycle 2.
89393431|NCT04546399|Experimental|Group 3, Arm E (dexamethasone, blinatumomab, MTX)|See Outline section
89393432|NCT04546399|Experimental|Group 3, Arm F (dexamethasone, blinatumomab, nivolumab)|See Outline section
89393433|NCT04540120|Experimental|dapansutrile capsules|Subjects will receive 4 x 250mg dapansutrile capsules BID for 14 days with an initial (first) dose of 8 x 250mg (2000 mg) administered at the study site on Day 1 (Day 1 dose may be 3000 mg).
89393434|NCT04540120|Placebo Comparator|placebo capsules|Subjects will receive 4 placebo capsules BID for 14 days with an initial (first) dose of 8 capsules administered at the study site on Day 1.
89393435|NCT04518059||Parkinsonism Group|Participants with Parkinson's disease (PD), dementia with Lewy bodies (DLB), multiple system atrophy (MSA), progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD)
89393436|NCT04518059||Control Group|Participants without parkinsonism
89393437|NCT04517383|Experimental|POS group|Patients in the POS group will undergo ET under general anesthesia. After the surgery is done, patients will keep being intubated and mechanically ventilated for 6hrs, during which period the patients will be sedated with sedatives to maintain a BIS value of 50~70 and Ramsay sedation score of 5 ~ 6. The SBP will be controlled between 120 ~ 180mmHg with vasoactive drugs. After 6hs, the patients will be recovered and extubated.
89393438|NCT04517383|Active Comparator|Con group|Patients in the Con group will undergo ET under general anesthesia and will be routinely recovered and extubated immediately after the surgery is done. The SBP will be controlled between 120 ~ 180mmHg with vasoactive drugs for at least 7hrs after the surgery.
89393439|NCT04505930|Experimental|Intervention Group with active education|The study team provides participants in the intervention group with interventional education, using interactive video watch and dynamic discussion.
89393440|NCT04505930|Active Comparator|Control Group with handouts|The study team provides the participants in the control group with education, using only handouts of vaccinations including HPV, but not using interactive video watch and dynamic discussion
89393441|NCT04489524|Experimental|individualized counselor-led MI sessions and NRT|The intervention (4 individualized counselor-led MI sessions and nicotine replacement therapy [NRT]) consisted of four 60-min in-person sessions of AMI counseling and a packet of self-help smoking cessation materials. Participants were provided NRT packs and counseled on their use.
89393442|NCT04489524|Active Comparator|general health education, self-help materials, and NRT|Participants in this condition were provided with four in-person 60-min health education sessions and packets of general health self-help information, nutrition, exercise, and the harmful effects of tobacco. Strategies for quitting smoking were also provided to participants in this group as well as a supply of NRT and counseling on its use.
89393443|NCT04480086|Experimental|Segment A: Mivebresib Dose Identification and Optimization|Participants who have been previously treated with Janus Kinase inhibitor(s) (JAKi) and stopped such therapy, will receive different dosing regimens and schedules of mivebresib to identify the safe dosing regimen and schedule.
89393444|NCT04480086|Experimental|Segment A: Mivebresib Monotherapy|Participants will receive the identified safe dosing regimen of mivebresib as monotherapy.
89393445|NCT04480086|Experimental|"Segment B: Ruxolitinib + Mivebresib Add-on Therapy"|"Participants whose disease (myelofibrosis) is inadequately controlled by ongoing ruxolitinib therapy will receive ruxolitinib and mivebresib as add-on therapy."
89393446|NCT04480086|Experimental|Segment C: Mivebresib + Navitoclax|Participants who have previously been exposed to JAKi, and stopped such therapy, will receive mivebresib and navitoclax.
89393447|NCT04480086|Experimental|Segment D: Mivebresib + Ruxolitinib|Participants who have never received JAKi will receive mivebresib and ruxolitinib.
89393448|NCT04476212|Experimental|Intervention|In the experimental arm, the surgical wound will be irrigated using an antibiotic solution (amoxicillin-clavulanate) for topical prophylaxis
89393449|NCT04476212|No Intervention|Control|In the control arm, the surgical wound will be irrigated with saline, which is our routine at present.
89393450|NCT04432688||Latuda®|Chinese schizophrenia patients who are receiving Latuda® in the real world
89393451|NCT04426825|Experimental|Atezolizumab plus Bevacizumab|Participants will receive atezolizumab plus bevacizumab intravenously on Day 1 of each cycle. Treatment will continue until progressive disease, unacceptable toxicity, or death.
89393452|NCT04424030||Multimodality imaging|Patients who have undergone echocardiography and cardiac MRI as part of their clinical management A research cardiac CT scan will be performed in eligible participants
89393453|NCT04419233||All Participants|Participants with 5q SMA and who were prescribed with nusinersen sodium injection in China according to the local marketing authorization.
89393454|NCT04418479|Active Comparator|Aspirin monotherapy arm|Patients will receive 100 mg of aspirin once daily.
89393455|NCT04418479|Experimental|Clopidogrel monotherapy arm|Patients will receive 75 mg of clopidogrel once daily.
89393456|NCT04417998|Active Comparator|Motion Correction|Aim 1 involves the prospective data collection of subjects who are already enrolled in Mayo Clinic Rochester research study 08-005553 (PI: Dr Val Lowe) and are scheduled to be scanned on the Siemens Biograph Vision 600 PET/CT system (hereafter referred to as the V600-R1) in the PET/CT Molecular Imaging Research Center on Charlton 6 of Mayo Clinic Rochester. The purpose of this arm is to evaluate the effectiveness of motion correction software.
89393457|NCT04417998|Active Comparator|Parametric Imaging|Aim 2 involves the prospective data collection of subjects undergoing brain or whole body oncologic PET/CT scans on the V600-R1. The purpose of this arm is to evaluate the data acquisition and image processing workflow.
89393458|NCT04414384|Experimental|Abdominal Binder|During this time they will wear a step counter and track their steps. This step counter will be returned at the time of their two week visit.
89393459|NCT04414384|Other|Control|This group of patients will not wear abdominal binders, but during this time they will wear a step counter and track their steps. This step counter will be returned at the time of their two week visit.
89393460|NCT04408508|Other|Amoxicillin administration|Oral amoxicillin administered to study patients
89393461|NCT04399538|Placebo Comparator|Placebo|Participants will receive medication for 6 weeks
89393462|NCT04399538|Experimental|DGAT2i (25 mg BID) + ACCi (10 mg BID)|Participants will receive medication for 6 weeks
89393463|NCT04399538|Experimental|DGAT2i (100 mg BID) + ACCi (10 mg BID)|Participants will receive medication for 6 weeks
89393464|NCT04399538|Experimental|DGAT2i (300 mg QD) + ACCi (20 mg QD)|Participants will receive medication for 6 weeks
89393465|NCT04399538|Experimental|DGAT2i (300 mg BID) + ACCi (10 mg BID)|Participants will receive medication for 6 weeks
89393466|NCT04359433|No Intervention|Standard group|The participates in this group would provide normal health education of scientific and rational diet.
89393467|NCT04359433|Experimental|Exercise intervention group|Besides normal health education of scientific and rational diet，the participates in this group would be suggested to carry out an anaerobic exercise named Tabata.
89393468|NCT04356261|Placebo Comparator|Control PNF|Personalized Normative Feedback on non-alcohol/health related topics delivered in all weekly rounds (active control)
89393469|NCT04356261|Active Comparator|Light Dose of Alcohol PNF|Personalized Normative Feedback on Alcohol Use delivered in 33% of weekly rounds
89393470|NCT04356261|Active Comparator|Heavy Dose of Alcohol PNF|Personalized Normative Feedback on Alcohol Use delivered in 67% of weekly rounds
89393471|NCT04342091|Experimental|Microneedling|Participants with fibrosing alopecia will receive microneedling with a tattoo machine.
89393472|NCT04333342|Experimental|Wearable device group|Participants use wearable device and their heart rate and activity are monitored. If their resting heart rate (rHR) increase beyond the set range or they have hyperthyroid symptoms and signs, they should come to the hospital and get tests for thyroid function. If their rHR stay within set range and they have no symptoms and signs, they come to hospital and get tests for thyroid function 6 months after discontinuing anti-thyroid drugs.
89393473|NCT04333342|No Intervention|Control group 1|articipants don't use wearable devices. If they have hyperthyroid symptoms and signs, they should come to the hospital and get tests for thyroid function. If they have no symptoms and signs, they come to hospital and get tests for thyroid function 6 months after discontinuing anti-thyroid drugs.
89393474|NCT04333342|No Intervention|Control group 2|Participants don't use wearable devices. If they have hyperthyroid symptoms and signs, they should come to the hospital and get tests for thyroid function. If they have no symptoms and signs, they come to hospital and get tests for thyroid function 3 and 6 months after discontinuing anti-thyroid drugs.
89393475|NCT04332731|Experimental|Renal angiography and Renal denervation|"Symplicity Spyral™ multi electrode renal denervation system~After renal angiography, participants in the experimental group will be immediately treated with renal denervation procedure using standard techniques. The participants will remain blinded throughout the procedure."
89393476|NCT04332731|Sham Comparator|Renal angiography|In the control group, the sham procedure will consist of only a renal angiogram. Participants will undergo diagnostic renal angiogram but will not receive any therapeutic endovascular treatment. Participants will remain on the procedure table for at least 20 min after the angiogram to prevent possible unblinding of randomization allocation.
89393477|NCT04327141|Experimental|Protein pacing and intermittent fasting|During the 8-week weight loss (WL) phase, participants assigned to the P-IF will consist of P days, whereby female participants will consume four and male participants will consume five meals/snacks total, two of which (breakfast and lunch) will include a protein powder meal replacement mixed with water (240-400 kcals per meal) along with an evening dinner meal (~500 kcals), an afternoon snack (men only), and an evening snack (250 kcals). Subjects will be calorie restricted to ~1500 and ~1800 calories per day, women and men, respectively during P days. For each IF day, subjects will be provided a variety of supplements/snacks made by Isagenix International LLC. The P-IF group will be further divided into two subgroups for weeks 1-4. One subgroup will consist of five days of P and two days of IF, and the second subgroup will consist of six days of P and one day of IF. For weeks 5-8 both subgroups will follow 6 days of a P diet and 1 day IF.
89393478|NCT04327141|Experimental|Heart Healthy|The HH group will observe the dietary guidelines in compliance with the National Cholesterol Education Program Therapeutic Lifestyle Changes (TLC) diet. This diet consists of consuming <35% of kcal as fat; 50%-60% of kcal as carbohydrates; <200 mg/dL of dietary cholesterol; and 20-30 g/day of fiber. The total calorie intake will be 1200 and 1500 calories per day, women and men, respectively during the weight loss phase (weeks 0-8).
89393479|NCT04316026|Experimental|interventional group|group receiving shock wave therapy
89393480|NCT04316026|Sham Comparator|control group|sham shock wave therapy
89393481|NCT04309864|No Intervention|Focus group-Veteran|Veterans will inform study staff regarding desired device design refinements
89393482|NCT04309864|No Intervention|Focus group-Clinicians|Clinicians will inform study staff regarding desired app design changes
89393483|NCT04309864|Other|Usability-inpatients|Clinicians will use the updated CMAP system during patient education for prevention of pressure injuries with Veterans with SCI who are completing their initial rehabilitation.
89393484|NCT04309864|Other|Usability-in-home|The Veteran will use the CMAP system at home for two weeks to use in their daily routines, along with wearing the acti-graph one week prior, two weeks during and one week after CMAP usage.
89393485|NCT04290611||Enzalutamide drug-induced toxicity|Cases reported in the World Health Organization (WHO) and the French pharmacovigilance database of patients treated by enzalutamide, with a chronology compatible with the drug toxicity
89393486|NCT04283188|Experimental|Adolescents with bipolar disorder|25 adolescents aged 14 to 21 with bipolar disorder (type I, type II, not otherwise specified/nos) will be enrolled in the dialectical behavioral therapy intervention.
89393487|NCT04279470||Adverse Events with cellular therapies|Cases reported in the World Health Organization (WHO) and the French pharmacovigilance database of patients treated by Chimeric Antigen Receptor T-cell and Cellular Therapies, with a chronology compatible with the drug toxicity
89393488|NCT04261010|Experimental|Ustekinumab|Group 1 (n=12): ustekinumab 45 mg (or 90 mg for patients > 100 kg) subcutaneously at baseline (W0), 4 weeks later (W4), and every 12 weeks until week 24 (i.e. W0, W4, and W16).
89393489|NCT04261010|Experimental|Guselkumab|Group 2 (n=12): guselkumab 100 mg subcutaneously (regardless of the weight of the patient) at weeks 0 and 4, followed by a maintenance dose every 8 weeks through week 24 (i.e. W0, W4, W12 and W20).
89393490|NCT04261010|Active Comparator|ADALIMUMAB|Group 3 (n=12): adalimumab 40 mg (regardless of the weight of the patient), subcutaneously every other week, starting from the baseline until week 24 (i.e.W0, W2, W4, W6, W8, W10, W12, W14, W16, W18, W20 and W22).
89393491|NCT04204668|Active Comparator|Targeted Muscle Reinnervation (TMR)|"In this operation, the surgeon will make a skin incision and carefully identify nerves that were likely to have been injured during the amputation surgery. These nerves are then cleaned up to be rerouted and connected to smaller nerves that control individual muscles. The connection to nerves that run into muscles is thought to be helpful in directing the nerve healing process and reducing the risk of developing pain in the future. This operation takes 2 - 4 hours and occurs in the hospital. Follow up requires six to seven clinic visits with the surgeon over the course of one year, at which time standard questionnaires will be used to assess pain."
89393492|NCT04204668|Active Comparator|Regenerative peripheral nerve interface (RPNI)|"In this operation, the surgeon will make a skin incision and carefully identify nerves that were likely to have been injured during the amputation surgery. The nerves are then cleaned up to enhance the possibility of healthy healing. Then the surgeon takes a small sample from a muscle (usually one close by to the nerves that are being operated on but sometimes through a second incision in the arm or leg, depending on the exact medical situation) and form something called a muscle graft. The muscle graft is used to wrap the cleaned ends of the nerves mentioned above. This is thought to be helpful in directing the nerve healing process and reducing the risk of developing pain in the future. This operation takes 1 - 3 hours and occurs in the hospital. Follow up requires six to seven clinic visits with the surgeon over the course of one year, at which time standard questionnaires will be used to assess pain."
89393493|NCT04204668|Active Comparator|Vascularized, denervated muscle target (VDMT )|"In this operation, the surgeon will make a skin incision and carefully identify nerves that were likely to have been injured during the amputation surgery. The nerves are then cleaned up to enhance the possibility of healthy healing. The surgeon will then identify a local muscle along with a small artery and vein that supply blood to part of the muscle. A small sample of muscle, still attached to the artery and vein, is then created. The nearby nerves are then nestled into this segment of muscle that is still connected to the artery and vein. This is thought to be helpful in directing the nerve healing process and reducing the risk of developing pain in the future. This operation takes 2 - 4 hours and occurs in the hospital. Follow up requires six to seven clinic visits with the surgeon over the course of one year, at which time standard questionnaires will be used to assess pain."
89393494|NCT04191551||Gastric intestinal metaplasia|Subjects with histologically-confirmed intestinal metaplasia found during endoscopy with protocoled biopsies.
89393495|NCT04191551||Controls|Subjects without intestinal metaplasia found during endoscopy with protocoled biopsies (age and sex matched to cases)
89393496|NCT04435340|Other|Retrospective|All patients in the retrospective cohort are contacted at least 1 year after surgery and/or 3 years after surgery via phone call or letter, informed about the study and asked to participate. In case of informed consent, they are invited to the study site. They are asked to complete the questionnaires and they undergo a Sonography of the ventral abdomen.
89393497|NCT04435340|Other|Prospective|All patients in the prospective cohort are informed about the study and asked to participate in the outpatient clinic before surgery. In case of informed consent, they are invited to the study site at least one year and three years, respectively, after surgery. They are asked to complete the questionnaires and they undergo an ultrasound of the ventral abdomen.
89393498|NCT04181515|Placebo Comparator|placebo stressor, sham rTMS|placebo stressor (lactose), sham rTMS (inactive coil)
89393499|NCT04181515|Active Comparator|placebo stressor, active rTMS|placebo stressor (lactose), active rTMS (10 Hz dlPFC in group 1; 1 Hz mPFC in group 2)
89393500|NCT04181515|Active Comparator|stressor, sham rTMS|stressor (yohimbine 54mg + hydrocortisone 20mg), sham rTMS (inactive coil)
89393501|NCT04181515|Active Comparator|stressor, active rTMS|stressor (yohimbine 54mg + hydrocortisone 20mg), active rTMS (10 Hz dlPFC in group 1; 1 Hz mPFC in group 2)
89393502|NCT04180969|Placebo Comparator|placebo stressor, sham rTMS|placebo stressor is lactose, and sham rTMS is inactive figure of 8 coil
89393503|NCT04180969|Experimental|placebo stressor, active rTMS|placebo stressor is lactose, and active rTMS is 1Hz stimulation over the medial prefrontal cortex
89393504|NCT04180969|Experimental|active stress, sham rTMS|active stressor is the combination of yohimbine 54mg + hydrocortisone 20mg, and sham rTMS is inactive figure of 8 coil
89393505|NCT04180969|Experimental|active stress, active rTMS|active stressor is the combination of yohimbine 54mg + hydrocortisone 20mg, and active rTMS is 1Hz stimulation over the medial prefrontal cortex
88869574|NCT05976022|Experimental|active rTMS|2 sessions with 1800 pulses per session and 50min inter-session interval of active rTMS will deliver to the assigned target
88869575|NCT05974800||Cancer patients|All adult patients with solid or hematological malignancies and receiving systemic therapy or having received systemic therapy within the last 3 months that are admitted to the emergency department of the Erasmus medical center for the oncology, hematological, lung- and neuro-oncology medical unit are eligible for inclusion.
88869576|NCT05973214|Experimental|CBT|
88869577|NCT05973214|Other|Waitlist|
88869578|NCT05971355|Experimental|Treatment group|LimpiAD cream 2,5% plus to be applied twice a day (morning and evening) for 4 weeks.
88869579|NCT05971355|Active Comparator|Control group|Vehicle of LimpiAD cream 2,5% plus to be applied twice a day (morning and evening) for 4 weeks.
88869580|NCT05971355|Active Comparator|Emollient group|Emollient cream to be applied twice a day (morning and evening) for 4 weeks.
88869581|NCT05968742|Experimental|Healthy Volunteers|"Study participants abstain from oral hygiene on a select set of four teeth for a period of 21 days.~The use of a custom made acrylic intraoral stent (mouthguard) will be used to protect teeth on designated test sides for each study participant during normal oral hygiene (approximately 4 minutes each day: 2 times for 2 minutes) throughout the induction phase (Day 0-21)."
89393506|NCT04172649|Experimental|Acu Arm|press tack needle acupuncture (ACU) and routine postoperative analgesic care
89393507|NCT04172649|Sham Comparator|SHAM Arm|press tack placebo acupressure (SHAM) and routine postoperative analgesic care
89393508|NCT04172649|No Intervention|CONTROL Arm|Patients in the control group will receive only routine postoperative analgesic care
89393509|NCT04131725||Cardiac Function Monitoring|Subjects will wear Cardiac Performance System (CPS) non-invasive device for brief periods during procedures including assessment by Pulmonary Artery Catheter (PAC) methods.
89393510|NCT04128969|Experimental|Carnitine supplementation (CS+)|Carnitine supplementation in liquid form, sugar free.
89393511|NCT04128969|Placebo Comparator|Placebo (CS-)|Placebo comparator liquid similar in appearance and taste to CS+.
89393512|NCT04123470|Experimental|Treatment|Delolimogene mupadenorepvec plus atezolizumab
89393513|NCT04099810|Other|Patients undergoing Cardiac MRI|Patients scheduled to undergo cardiac magnetic resonance for clinical reason will be asked if they are willing to undergo additional non invasive testing (three-dimensional echocardiography) which will take about 15-20 minutes
89393514|NCT04097314|Experimental|Zibotentan|
89393515|NCT04097314|Placebo Comparator|Placebo|
89393516|NCT04080518|Active Comparator|Experimental|Dapagliflozin, 10mg, oral dose, once every day
89187130|NCT02583542|Experimental|Dose Escalation Phase (Phase Ib)|This phase will investigate two different dosing schedules of AZD2014: a continuous daily schedule (CC-Schedule) and an intermittent schedule of 2 days on and 5 days off treatment (IC-Schedule). The dose of Selumetinib (AZD6244) will remain unchanged in both schedules. The outcome of this investigation will determine whether an additional schedule of combined intermittent Selumetinib (AZD6244) (3 days on and 4 days off treatment) with intermittent AZD2014 will be considered (II-Schedule). The II-Schedule will be initiated following the completion of the corresponding continuous regimens and will only be investigated if escalation of the AZD2014 dose in the IC-Schedule is not feasible with the corresponding continuous Selumetinib (AZD6244) regimen. Up to three individual dose levels of Selumetinib (AZD6244) might subsequently be explored within the intermittent schedule of Selumetinib (AZD6244).
89393517|NCT04080518|Placebo Comparator|Control|Matching placebo for dapagliflozin, oral dose, once every day
89393518|NCT04074811|Sham Comparator|Sham rTMS|Sham rTMS will be applied over the left dorsolateral prefrontal cortex using a sham figure of 8 coil (within-subject crossover). Sham rTMS will consist of the same auditory and tactile stimuli as the active condition, but does not induce an electromagnetic field and does not affect cortical excitability.
89393519|NCT04074811|Active Comparator|Active rTMS|Active rTMS will be applied over the left dorsolateral prefrontal cortex using an active figure of 8 coil (within-subject crossover). In the active rTMS condition, the investigators will use high-frequency (10Hz) dorsolateral prefrontal cortex (dlPFC) stimulation with intensity of 110% of resting motor threshold. rTMS will consist of 120 trains with 50 stimuli per train (i.e. 5-sec long at 10 Hz) and 10-sec intertrain interval for a total of 6000 pulses. The entire protocol will last 30 min (120 trains with 5-sec on/10-sec off).
89393520|NCT04060108||MDMA Within Subject Cross-over|Participants will be randomized to high-dose, low-dose, or placebo for each of the the three study sessions.
89393521|NCT04043936|Experimental|Cognitive Bias Modification for Help-Seeking Stigma (CBM-HS)|"CBM-HS is a 15-minute web-based intervention designed to alter maladaptive cognitions related to mental health help-seeking. In this task, individuals are presented with a series of statements regarding beliefs about using behavioral health services. Individuals then select True or False in response to each statement. Incorrect responses (i.e., demonstrating help-seeking stigma) are followed by corrective feedback. Conversely, correct responses (i.e., promoting help-seeking) are positively reinforced. Participants in this condition will complete three separate 15-minute CBM-HS sessions."
89393522|NCT04043936|Sham Comparator|Placebo Cognitive Bias Modification|Participants randomized to this condition will complete a CBM task with a neutral stimuli. The duration of the CBM-Placebo task will be comparable to the duration of the CBM-HS task (i.e., three 15-minute sessions).
89393523|NCT04043936|Active Comparator|Self-Directed Psychoeducation|Participants randomized to this condition will review psychoeducation on mental health literacy, mental illness stigma, and treatment options. Readings will be compiled from resources available in the public domain. The duration will be comparable to the duration of study tasks for individuals in the CBM-HS study condition (i.e., three 15-minute sessions).
89393524|NCT04037904||H. pylori negative group|Subjects who have not have H. pylori infection, and had not receive H. pylori eradication
89393525|NCT04037904||H. pylorieradicated group|Subjects who have had H. pylori infection currently and received successful H. pylori eradication according to appropriated indication
89393526|NCT04036123|Experimental|Urodynamic investigation|Simultaneous UDI (same session repeat filling cystometry and pressure flow study) with an air-charged and water-perfused measurement system.
89393527|NCT04023773|Experimental|Liver perfusion|"Device: Liver Machine Perfusion (MP) Device~The liver grafts will be preserved at hypothermic and normothermic temperature on the institutional-developed Liver MP Device, and have continuous perfusion with oxygen supply in the ex vivo organ preservation phase."
89393528|NCT04017598|Active Comparator|Ferrous Sulfate|Iron will be given orally in the form of tablets. A supplement of 60 mg will be taken daily for 12 weeks. World Health Organization standard dose and commonly used form of iron.
89393529|NCT04017598|Experimental|Ferrous Bisglycinate|Iron will be given orally in the form of tablets. A supplement of 18 mg will be taken daily for 12 weeks. Ferrous bisglycinate has a bioavailability 2-4x greater than ferrous sulfate.
89393530|NCT04017598|Placebo Comparator|Placebo|Placebo will be given orally in the form of tablets as a control made of microcrystalline cellulose.
89393531|NCT04014803|Active Comparator|Prasugrel plus Aspirin arm|"Patients will receive 300 mg of aspirin before PCI unless they have previously received this antiplatelet medication. A loading dose of prasugrel 60 mg will be given before or after PCI as soon as possible following randomization, unless they have previously received the assigned medication. Aspirin 100 mg plus prasugrel 10 mg once daily* will be given for one year.~* Based on previous studies including PRASFIT-ACS (PRASugrel compared with clopidogrel For Japanese patIenTs with ACS undergoing PCI) or TRILOGY ACS (The Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes), maintenance dose can be reduced to 5 mg once daily in patients with high bleeding risk or by investigator's medical judgement."
88869582|NCT05963802|No Intervention|Traditional Online tools Group|Group B will serve as the control group in this study. Participants in this group will receive instructions on how to complete the assignment using traditional online tools available on the internet, without the use of artificial intelligence. They will have a timeframe of six days to complete the assignment using these conventional tools. Similar to participants in Arm 1, they will also be required to fill out a survey on technology usability, providing feedback on their experience with the online tools.
88869583|NCT05963802|Experimental|Artificial Intelligence (ChatGPT) Group|Participants in Group A will be assigned to utilize ChatGPT as their tool to complete assignments. They will be given a period of six days to utilize artificial intelligence through ChatGPT for assignment completion. Along with the assignment instructions, participants will receive an ethical guideline and specific guidelines on how to effectively utilize ChatGPT. Once the intervention period is concluded, participants will be given a 24-hour window to complete a survey that assesses the usability of the technology. The survey aims to gather valuable feedback on the participants' experience and perception of using ChatGPT for their assignments. In addition, participants in Arm 1 will also be asked to fill out a survey regarding their perception of using artificial intelligence (AI) as an assistance tool to complete their assignments. This survey aims to gather insights into their thoughts, opinions, and attitudes towards utilizing AI in the learning process
88869584|NCT05962034|Experimental|Aspirin|one dose of aspirin
88869585|NCT05962034|Placebo Comparator|Placebo|Placebo pill
88869586|NCT05954286|Experimental|Early Treatment: Upamostat 400 mg|400 mg (2 x 200 mg) capsules administered orally once daily for 14 days
88869587|NCT05954286|Placebo Comparator|Early Treatment: Placebo Oral Capsule|The placebo arm may be pooled across more than one experimental arm if multiple investigational drug are available to be tested at the same time and administered in the same way.
88869588|NCT05954026|Other|Single arm|Prospective, open label, single-arm multicenter study
88869589|NCT05953363||All participants|Participants who require a BD NRFit™ Spinal Needles, NRFit™ Spinal Introducer Needles, and NRFit™ Syringes as part of their routine medical care.
88869590|NCT05949125|Experimental|Allo-RevCAR01-T-CD123 treatment|Following lymphodepleting therapy, R-TM123 will be administered as continuous infusion from Cycle 1 Day 1 and then will continue for 20 days. After 4 hours (±30 minutes) of R TM123 start on Day 1, a single dose of Allo-RevCAR01-T will be administered as IV infusion
88869591|NCT05945225|Experimental|Group using sonic toothbrush|Patient will be asked to use a sonic toothbrush for 3 months
88869592|NCT05945225|Experimental|Group using hydrosonic toothbrush|Patient will be asked to use a hydrosonic toothbrush for 3 months
88869593|NCT05945225|Experimental|Group using manual toothbrush with 5460 strands|Patients will be asked to use a manual toothbrush with 5460 strands for 3 months
88869594|NCT05945225|Placebo Comparator|Group using manual toothbrush|Patients will be asked to use a manual toothbrush for 3 months
88869595|NCT05943782|Experimental|additive manufacturing of onlays|additive CAD/CAM manufacturing of dental restorations by 3D printing
88869596|NCT05943782|Active Comparator|subtractive manufacturing of onlays|subtractive CAD/CAM manufacturing of dental restorations by milling
88869597|NCT05937425|Experimental|Intervention group|Effects of nurse navigation program on patients with lung cancer
88869598|NCT05937425|No Intervention|Control group|An information note will be given to the control group.
88869599|NCT05934435|Experimental|Empowered Relief treatment|Participants randomized to the ER group will complete a HIPAA compliant, password protected 2-hour Zoom ER class delivered by an ER-trained ASPMN nurse.
88869600|NCT05934435|Other|Wait-list Control|Participants randomized to the Wait-list Control group will continue their usual pain care for 2 months and complete surveys to compare with the experimental treatment group. After serving as controls, they will be invited to attend the 2-hour Zoom ER class delivered by an ER-trained ASPMN nurse.
89393532|NCT04014803|Active Comparator|Clopidogrel plus Aspirin arm|Patients will receive 300 mg of aspirin before PCI unless they have previously received this antiplatelet medication. A loading dose of clopidogrel 600 mg will be given before or after PCI as soon as possible following randomization, unless they have previously received the assigned medication. Aspirin 100 mg plus clopidogrel 75 mg once daily will be given for one year.
89393533|NCT04011371|Experimental|Cyanoacrylate closure|Subjects enrolled in the study will undergo ultrasound guided vein closure using the VenaSealTM cyanoacrylate delivery device.
89393534|NCT03994302||Immune toxicity induced by drugs and chemotherapies|Immune toxicity induced by drugs and chemotherapies Case reported in the World Health Organization (WHO) of immune toxicities(such as Antiphospholipid syndrome) of patient treated by a drug, with a chronology compatible with the drug toxicity
89393535|NCT03985189|Experimental|ME-401|ME-401 administered orally
89393536|NCT03978481||Eradicated group|Gastric cancer patients received subtotal gastrectomy, with Helicobacter pylori eradication
89393537|NCT03978481||Negative group|Gastric cancer patients received subtotal gastrectomy, without Helicobacter pylori eradication or Helicobacter pylori negative
89393538|NCT03959410|Active Comparator|HPV-positive patients|Patients who are positive for HPV DNA test
89393539|NCT03959410|Active Comparator|HPV-positive patients - Echinacea|
89393540|NCT03959410|No Intervention|HPV-positive patients - Standard|
89393541|NCT03937219|Experimental|Experimental Arm|Cabozantinib + nivolumab + ipilimumab (4 doses) followed by cabozantinib + nivolumab
89393542|NCT03937219|Active Comparator|Control Arm|Cabozantinib-matched placebo + nivolumab + ipilimumab (4 doses) followed by cabozantinib-matched placebo + nivolumab
89393543|NCT03918460|Experimental|Intervention|All patients enrolled are intended to be treated
89393544|NCT03905148|Experimental|Part A: Dose Escalation/Dose finding Dose Level Cohorts ranging in dose levels and dose regimens.|Combination doses of, Mirdametinib at once a day and lifirafenib at once a day And Mirdametinib at twice a day and lifirafenib at once a day
89393545|NCT03905148|Experimental|Part B: Expansion|Approximately 20 participants with NRAS mutated solid tumors will be enrolled
89393546|NCT03869268|Active Comparator|No Drug|"Patients will be randomised to receive no drug for the first medication period (10 days).~Patient will then be allocated to receive ticagrelor 90mg twice daily for the second medication period (10 days)"
89393547|NCT03869268|Active Comparator|Ticagrelor 180 mg|"Participants will be randomised to receive loading dose of ticagrelor 180 mg on the last day of the first medication period (10-14 days).~Participants will then be allocated to receive no aspirin but a loading dose of ticagrelor 180 mg on the last day of treatment for the second medication period (10-14 days)."
89393548|NCT03869268|Active Comparator|Aspirin 20mg|"Participants will be randomised to receive aspirin 20 mg twice daily for the first medication period (10 days).~Participants will then be allocated to receive aspirin 20 mg twice daily for the second medication period (10-14 days), plus a loading dose of ticagrelor 180 mg on the last day of the period."
89393549|NCT03869268|Active Comparator|Aspirin 20 mg & Ticagrelor 180 mg|"Participants will be randomised to receive aspirin 20 mg twice daily for the first medication period (10-14 days).~Participants will then be allocated to receive aspirin 20 mg twice daily for the second medication period (10-14 days), plus a loading dose of ticagrelor 180 mg on the last day of the period."
89393550|NCT03869268|Active Comparator|Aspirin 75 mg|"Participants will be randomised to receive aspirin 75 mg once daily for the first medication period (10-14 days).~Participants will then be allocated to receive aspirin 75 mg once daily for the second medication period (10-14 days), plus a loading dose of ticagrelor 180 mg on the last day of the period."
89393551|NCT03869268|Active Comparator|Aspirin 75 mg & Ticagrelor 180 mg|"Participants will be randomised to receive aspirin 75 mg once daily for the first medication period (10-14 days), plus a loading dose of ticagrelor 180 mg on the last day of the period.~Participants will then be allocated to receive aspirin 75 mg once daily for the second medication period (10-14 days)."
89393552|NCT03869268|Active Comparator|Aspirin 300 mg|"Participants will be randomised to receive aspirin 300 mg once daily for the first medication period (10 days).~Participants will then be allocated to receive aspirin 300 mg once daily for the second medication period (10-14 days), plus a loading dose of ticagrelor 180 mg on the last day of the period."
89393553|NCT03869268|Active Comparator|Aspirin 300 mg & Ticagrelor 180 mg|"Participants will be randomised to receive aspirin 300 mg once daily for the first medication period (10-14 days) plus a loading dose of ticagrelor 180 mg on the last day of the period.~Participants will then be allocated to receive aspirin 300 mg once daily for the second medicaion period (10-14 days)."
89393554|NCT03868397|Experimental|Liver MRI|In this study, MRI refers to phase-contrast 4D flow sequence.
89393555|NCT03845465|Active Comparator|Education|Participants in the Education group will complete a behavioral health contract and will receive an educational packet.
89393556|NCT03845465|Experimental|PA + Education|Participants in the Positive Affect + Education group will complete a behavioral health contract and receive an educational packet. In addition, they will receive intervention components aimed at inducing positive affect.
89393557|NCT03843463|Experimental|Naming Treatment + Escitalopram|10 mg escitalopram daily for three months (escalating from 5 mg per day for the first week and tapering to 5 mg per day for the last two weeks)
89393558|NCT03843463|Placebo Comparator|Naming Treatment + Placebo|10 mg placebo daily for three months
89393559|NCT03828942||Hematological toxicity induced by drugs and chemotherapies|Case reported in the World Health Organization (WHO) of hematological toxicities of patient treated by a drug, with a chronology compatible with the drug toxicity
89393560|NCT03826433|Experimental|Treatment Group|Mesenchymal Stem Cells : through peripheral intravenous slowly, every time 6*10^7 (30ml) Other medication of Treatment Group: before the30min of first time to inject stem cells, Intravenous methylprednisone 20mg. All patients require oral nucleoside drugs resistant hepatitis B virus treatment.Use stem cell therapy, by Peripheral iv, 6 * 10 ^ 7 (30 ml)
89393561|NCT03826433|No Intervention|Control Group|Control Group: Using basic contrast .
89393562|NCT03816852|Experimental|High dose group|Intravenous infusion with hucMSCs, 9*10^7 cells, 30ml
89393563|NCT03816852|Experimental|Medium dose group|Intravenous infusion with hucMSCs, 6*10^7 cells, 30ml
89393564|NCT03816852|Experimental|Low dose group|Intravenous infusion with hucMSCs, 3*10^7 cells, 30ml
89393565|NCT03808467|Experimental|CRT + TAU|Cognitive Remediation Therapy + Treatment As Usual
89393566|NCT03808467|Other|TAU only|Treatment As Usual
89393567|NCT03796104||Deficiency of delta-hemolysine|Implant infected by Staphylococcus aureus with delta-haemolysin Production Deficiency
89393568|NCT03796104||Presence of delta-hemolysine|Implant infected by Staphylococcus aureus with delta-haemolysin Production
89393569|NCT03786367||CTEPH|Clinically stable patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH) recruited from the Pulmonary Hypertension outpatient clinics at Hotel Dieu Hospital, Kingston, Ontario.
89393570|NCT03786367||Control|Age and sex-matched healthy control data collected as part of previous studies will be used as historic controls for this study.
89393571|NCT03705156|Experimental|ZL-2306|The starting dose is 300 mg or 200 mg based on patient's body weight.
89393572|NCT03705156|Placebo Comparator|Placebo|The starting dose is the matched dose of placebo (3 capsules or 2 capsules).
89393573|NCT03667339||outpatients group|Patient schedulded to undergo outpatient Direct Anterior Total Hip Arthroplasty
89393574|NCT03667339||inpatients group|Patient schedulded to undergo inpatient Direct Anterior Total Hip Arthroplasty
89393575|NCT03643796|Active Comparator|Remifentanil Group|Remifentanil infusion of 0.05 to 0.2 mcg/kg/minute started just prior to induction and stopped at emergence from anesthesia.
89393576|NCT03643796|Active Comparator|Ketamine and Dexmedetomidine group|"dexmedetomidine bolus of 0.5 mcg/kg over 10 minutes starting 5 minutes prior to induction followed by an infusion of 0.2-0.7 mcg/kg/hour that will be stopped with the start of closing the surgical wound.~Ketamine infusion of 2 mcg/kg/minute will be started at induction. It will be stopped at the beginning of the emergence from anesthesia, roughly 45 minutes from extubation."
89393577|NCT03623854|Experimental|Treatment (nivolumab and relatlimab)|Participants receive nivolumab intravenously (IV) over 60 minutes and relatlimab via infusion over 60 minutes on day 1. Courses repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
89393578|NCT03592264|Experimental|Dose escalation phase|OBI-3424 (1.0 mg/m^2 to 14.0 mg/m^2) will be administered by IV infusion on Days 1 and 8 of each 21-day cycle or Day 1 of each 21-day cycle to determine the MTD and RP2D with a classic 3+3 dose escalation design.
89393579|NCT03592264|Experimental|Cohort expansion phase|OBI-3424 (12 mg/m^2) will be administered by IV infusion on Day 1 of each 21-day cycle.
89393580|NCT03584334|Other|18FDG PET|Diagnostic performance of 18FDG PET for identification of early tumor escape to immunotherapy in patients with unresectable melanoma or Broncho-Pulmonary Carcinoma No to Advanced or Metastatic Small Cells
89393581|NCT03575884|Experimental|Screen Time Reduction Curriculum|Fit5Kids curriculum, weekly parent newsletters, in-person (or by telephone) goal setting on their child's screen time, a lending library of resources (books, games, arts/crafts, etc), and text messages on screen time parenting practices.
89393582|NCT03575884|No Intervention|Control|Students will be taught the standard preschool curriculum.
89393583|NCT03560167|Experimental|AccuCinch® Ventricular Restoration System|
89393584|NCT03531892|Experimental|AJM300 960mg/dose|Participants will orally receive AJM300 960 mg tablets, three times daily after meals for 8 weeks.
89393585|NCT03531892|Placebo Comparator|Placebo|Participants will orally receive AJM300 placebo-matching tablets, three times daily after meals for 8 weeks.
89393586|NCT03531502|Active Comparator|Standard medical therapy|Patients who have a positive NIPS study and are randomized to the medical therapy arm will either be initiated on antiarrhythmic therapy or will have their antiarrhythmic therapy intensified. All medication therapy is considered usual standard therapy.
89393587|NCT03531502|Experimental|Ventricular Tachycardia Ablation|Patients who have a positive NIPS study and are randomized to the ablation arm will undergo ventricular tachycardia ablation procedure guided by CardioInsight.
89393588|NCT03531502|Other|Negative NIPS/Non-intervention|Patients who had a negative NIPS study will not be assigned to a treatment group and will be followed according to standard of care.
89393589|NCT03530215||Adverse Events with Antineoplastic and immunomodulating agents|Cases reported in the World Health Organization (WHO) and the French pharmacovigilance database of patients treated by Antineoplastic and immunomodulating agents, with a chronology compatible with the drug toxicity
88869601|NCT05933980|Experimental|regorafenib,Toripalima and celecoxib|"Regorafenib:in dose ramping stage,the initial dose is 80mg per dose, taken orally once a day. After 3 weeks of treatment, the medication is stopped for 1 week (i.e. from day 1 to day 21 and not from day 22 to day 28), with a treatment cycle of 4 weeks.The optimal recommended dose of regofinib (80mg, 120mg, or 160mg) obtained from the phase Ib dose ramping was included in the phase II study dose extension queue.~Toripalimab:240mg, intravenous drip, administered every three weeks. celecoxib:200mg each time, taken orally twice a day."
88869602|NCT05932472|Experimental|Aspirin at bedtime|Participants randomized to aspirin administration at bedtime will be instructed to take their aspirin at approx. 8PM-12AM.
88869603|NCT05932472|Active Comparator|Aspirin in the morning|Participants randomized to aspirin administration in the morning will be instructed to take their aspirin upon awakening or with their breakfast (approx. 6-10AM).
89393590|NCT03520075|Experimental|Phase 1 Regimen 1|"Dose escalation and expansion:~Regimen 1: ASTX029 orally once a day for 21 days of each 21-day cycle."
89393591|NCT03520075|Experimental|Phase 1 Regimen 2|"Dose escalation and expansion:~Regimen 2: ASTX029 orally once a day for 14 days of each 21-day cycle."
89393592|NCT03520075|Experimental|Phase 2|ASTX029 at the RP2D of the selected dosing regimen identified in Phase 1 to subjects with tumors characterized by gene aberrations in the MAPK signal pathway that may confer sensitivity to ASTX029.
89393593|NCT03475277||Volunteers|"Participants will receive an IV infusion of ketamine (~.05mg/kg and 0.5mg/kg) or placebo.~Ketamine is an FDA-approved dissociative anesthetic. The study doses are in the subanesthetic range. During the infusion, an ACLS-certified psychiatrist or anesthesiologist will provide continuous monitoring.~Afterwards, patients will be monitored on-site by an ACLS-certified MD or highly skilled research nursing staff, and an on-call emergency response team for 4 hours (ketamine's half-life is 15 min; 4 hrs= 16 half-lives)."
88869604|NCT05928325|Experimental|Supportive Care (GA-guided intervention)|Patients complete geriatric assessments at baseline, 6 months, and 12 months later. Based on the assessments, patients may receive further intervention at survivorship visit. Patients also receive survivorship care educational materials and wear a wearable activity tracking device for 1 year on study.
89393594|NCT03472274|Active Comparator|Cisplatin-based neoadjuvant chemotherapy|"Patients allocated to the control arm will receive any of the following cisplatin based neoadjuvant treatment:~Regimen 1: Gemcitabine + Cisplatin Regimen 2: Methotrexate + Vinblastine + Doxorubicin + Cisplatin Regimen 3: Gemcitabine + Paclitaxel + Cisplatin"
89393595|NCT03472274|Experimental|Durvalumab plus Tremelimumab|Patients randomized to experimental arma will receive 28-day treatment cycle x 3 cycles of Durvalumab + Tremelimumab 75 mg every 4 weeks
89393596|NCT03456284|Experimental|Normothermic Liver perfusion|This group has the liver grafts preserved using the Normothermic Liver perfusion Device
89393597|NCT03437928|Experimental|Directional Deep Brain Stimulation|
89393598|NCT03436433|Active Comparator|Lacosamide|Enrolled subjects will be randomized to receive Lacosamide.
89393599|NCT03436433|Active Comparator|Levetiracetam|Enrolled subjects will be randomized to receive Levetiracetam.
89393600|NCT03436433|No Intervention|No anti-epileptic|Enrolled subjects will be randomized to not receive anti-epileptic drugs.
89393601|NCT03432832|Experimental|Emotion Awareness/Skills Enhancement|"EASE Therapy includes 16 weekly sessions focused on mindfulness exercise, review of prior content, practicing prior skills, outline of current session, discussion of the new skill, handouts, practice and plan for out of session practice held in Webster Hall in Pittsburgh, at the Center for the Prevention of Youth Behavior Problems in Tuscaloosa or via telehealth conferencing software. The investigators will apply a multimodal teaching approach, where individual therapy is buttressed by parent involvement and practice sessions in the youth's community. A secure website developed for this project (emotion-Coach or e-Coach) will augment the intervention by providing online supports to increase treatment intensity or dosage. There will be specific information on how to reinforce the skills at home and in the community."
89393602|NCT03432832|Active Comparator|Supportive Therapy|Supportive Therapy will involve attending 16 weekly therapy sessions held in Webster Hall in Pittsburgh, at the Center for the Prevention of Youth Behavior Problems in Tuscaloosa or via telehealth conferencing software. The intervention will not involve mindfulness or other emotion regulation strategies used in EASE. The therapy will be tailored to the individual's needs and will include aspects common in supportive therapy such as reflective listening, antecedent management, and problem-solving. This program does not have an online component.
88869605|NCT05927688||Patients whose physician used the electronic platform to access ePRO|
88869606|NCT05927688||Patients whose physician did not used the electronic platform and did not access ePRO|
88869607|NCT05925140|Active Comparator|LUSZ Control group: Corticosteroid Therapy-enhanced Standard Care (CTSC) alone.|The control group receives the standard care treatment with corticosteroid therapy.
88869608|NCT05925140|Experimental|LUSZ Antivirals Group: CTSC + Remdesivir or Lopinavir/Ritonavir.|The Antivirals group receives the standard care treatment with corticosteroid therapy in combination with antiviral (Remdesivir) or antiretroviral (Lopinavir/Ritonavir) medications.
88869609|NCT05925140|Experimental|LUSZ Immunosuppressive Group: CTSC + IL-6 receptor antagonist (Tocilizumab).|The Immunosuppressive group receives the standard care treatment with corticosteroid therapy in combination with Tocilizumab, an IL-6 receptor antagonist.
88869610|NCT05923086|Placebo Comparator|Placebo|Placebo treatment (4 tablets)
88869611|NCT05923086|Experimental|ORE001|ORE001 treatment (4 tablets)
88869612|NCT05920941|Experimental|[14C]JAB-21822|Single oral dose of 800mg 14C]JAB-2182 suspension
88869613|NCT05919940|Experimental|Intervention|High protein substitution plus NMES and EM
88869614|NCT05919940|No Intervention|Control Group|Nutrition and mobilization are carried out according to standard of care.
88869615|NCT05916092||Lateral-Oblique TransLoc 3D Screw(s)|Patients receiving the TransLoc 3D Screw(s) version will receive screw(s) placed lateral-obliquely into the intended SI joint.
89393603|NCT03425318|Experimental|Single arm|Patients with ARDS will be placed inside of a Continuous Negative Abdominal Pressure Device. Negative pressure will be applied to the abdomen as an adjunct to positive pressure ventilation
89393604|NCT03405090|Active Comparator|Fentanyl Citrate|Single dose, nebulized 100 mcg fentanyl citrate. This is a randomized, double-blind, two-treatment crossover study comparing the effects of a single dose of nebulized 100 mcg fentanyl citrate with a constant fraction of 30% inhaled oxygen to that of a nebulized bronchodilator (Combivent). Treatments will be in randomized order: patients in one study arm will receive fentanyl at the first treatment visit and combivent at the second treatment visit, patients in the other arm will receive Combivent first and fentanyl second.
89393605|NCT03405090|Active Comparator|Combivent Bronchodilator|Single dose, nebulized Combivent bronchodilator (0.5 mg ipratropium bromide + 2.5 mg salbutamol). This is a randomized, double-blind, two-treatment crossover study comparing the effects of a single dose of nebulized 100 mcg fentanyl citrate with a constant fraction of 30% inhaled oxygen to that of a nebulized bronchodilator (Combivent). Treatments will be in randomized order: patients in one study arm will receive fentanyl at the first treatment visit and combivent at the second treatment visit, patients in the other arm will receive Combivent first and fentanyl second.
89393606|NCT03383081|Experimental|Low dose mesenchymal stem cells|Low dose group: intra-articular injection with human umbilical cord mesenchymal stem cells (SCLnow 19#)
89393607|NCT03383081|Experimental|High dose mesenchymal stem cells|High dose group: intra-articular injection with human umbilical cord mesenchymal stem cells (SCLnow 19#)
89393608|NCT03383081|No Intervention|Control groups|No intervention
89393609|NCT03380052||Gastric cancer|Patients who were diagnosed with gastric cancer
88869616|NCT05916092||Lateral Oblique TransLoc 3D Screw with Posterior Device (Hybrid)|Patients receiving the TransLoc 3D Hybrid construct will receive one 3D-printed titanium screw placed lateral-obliquely and one 3D-printed titanium posterior device across the same sacroiliac joint.
88869617|NCT05913869|Experimental|Online MBSR 1|received modified online 8-week group-based MBSR intervention delivered by a UMASS trained MBSR instructor
88869618|NCT05913869|Active Comparator|Waitlist control|On a waiting list to receive the identical intervention as the treatment group after the active treatment group completes.
88869619|NCT05913193||Oral Nutritional Supplement (ONS) Group|2 servings per day as per standard of care during the study period
88869620|NCT05910203|Other|Health belief model smoking cessation scale|Describing the thoughts and behaviors of visually impaired individuals about quitting smoking
88869621|NCT05910203|Other|Nicotine addiction scale|Evaluation of individuals' smoking cessation status
88869622|NCT05910047|Experimental|Supplement|One tablet of supplement before breakfast and dinner
88869623|NCT05910047|Placebo Comparator|Placebo|One tablet of inert compound before breakfast and dinner
88869624|NCT05901545|Experimental|Diagnostic (panitumumab, 111In-panitumumab, SPECT/CT, surgery)|Patients receive loading dose of panitumumab IV over 15 minutes followed by 111In-panitumumab IV bolus on day 0. Patients then undergo SPECT/CT scan between day 1 and day of standard of care surgery (up to day 5). During standard of care surgery, patients receive local injection of optical dye per surgeon's preference and undergo intraoperative and NIR imaging. Patients additionally undergo blood sample collection during screening and ECG during screening, on day 0, and on day 15 if indicated.
88869625|NCT05897996|Experimental|creation of vascular access for hemodialysis|creation of vascular access for hemodialysis with percutaneous AVF creation
88869626|NCT05890846|Experimental|DLPFC group|Active iTBS will be delivered to the cognitive control network at left DLPFC.
88869627|NCT05890846|Sham Comparator|Sham group|Sham iTBS will be delivered to the cognitive control network at left DLPFC.
88869628|NCT05884775|Experimental|iMatter2|All the patients within a primary care provider (PCP) randomized to the intervention will receive iMatter2.
88869629|NCT05884775|No Intervention|Usual Care (UC)|All patients within PCPs randomized to UC will receive standard Type 2 diabetes (T2D) care by their PCP.
88869630|NCT05873686|Experimental|Dose Escalation|Escalating doses of NXP900 are planned with a starting dose level of 20 mg once per day.
88869631|NCT05868421|Experimental|Support Person Coaching Call and Written Materials|Support persons will receive written material resources on support strategies to stop smoking, and resources on how to stop smoking. Support person participants assigned to the intervention group will additionally receive a 1-call coaching session about 15-25 minutes in duration on how to support their Veteran smoker. The coaching session will be delivered by research staff by phone or video call. Veteran smokers will receive written smoking cessation resource and referral information for VHA and non-VHA EBCT options.
88869632|NCT05868421|Active Comparator|Written Materials Only|Support persons will receive written material resources on support strategies to stop smoking, and resources on how to stop smoking. Veteran smokers will receive written smoking cessation resource and referral information for VHA and non-VHA EBCT options.
88869633|NCT05861141|Active Comparator|Control Group|Patients will receive a selected physical therapy program only.
88869634|NCT05861141|Experimental|Study Group|Patients will receive the same selected physical therapy program as the control group in addition to aerobic exercise in the form of treadmill training.
88869635|NCT05853133|Active Comparator|Group E|ESP block will be applied bilaterally, 20 ml of %0.25 bupivacaine between the erector spinae muscle and transverse process at the 11th thoracic level.
88869636|NCT05853133|Active Comparator|Group W|Subfascial and subcutaneous wound infiltration is performed (20 ml of 0.25% bupivacaine each).
88869637|NCT05852925|Other|Human Blood Specimen Collection|Blood will be collected from each participant using two different methods: the Tasso+ device and the traditional venipuncture approach. Both collection procedures are carried out sequentially at the study site. A phlebotomist performs the traditional venipuncture and the participant collects blood using two Tasso+ devices, following provided instructions. The lab results will be analyzed to assess the correlation of biomarkers between blood samples obtained by the participant using the Tasso+ device and those collected via venipuncture.
88869638|NCT05847387||Keratoplasty group|Patients undergoing keratoplasty and their respective donor tissue
89393610|NCT03380052||Control|Healthy participants or benign disease patients such as benign gastric ulcers, duodenal ulcers, reflux esophagitis, or non-erosive reflux disease
89393611|NCT03378414|Experimental|Intravenous infusion group|Umbilical cord mesenchymal stem cells (SCLnow 19#)
89393612|NCT03378414|Experimental|Intrathecal injection group|Umbilical cord mesenchymal stem cells (SCLnow 19#)
89393613|NCT03378414|No Intervention|Control groups|No intervention
89393614|NCT03350243|Experimental|CCENT Intervention group|Participants will be assigned a dedicated key worker that will support families through the child's first year, in addition to standard medical care, which involves a primary care provider and/or neonatal follow-up at routine times.
89393615|NCT03350243|No Intervention|Control group|Participants will receive the standard medical care at their institution, which involves a primary care provider and/or neonatal follow-up at routine times.
89393616|NCT03324360|Experimental|Control Participants Part I|A MRI with injection of hyperpolarized 13C pyruvate.
89393617|NCT03324360|Experimental|Intracranial Metastasis Part II|MRI with injection of hyperpolarized 13C pyruvate prior to radiation treatment.
89393618|NCT03324360|Experimental|Intracranial Metastasis Part III|MRI with injection of hyperpolarized 13C pyruvate prior to radiation treatment. MRI with injection of hyperpolarized 13C pyruvate1-5 days following radiation treatment.
89393619|NCT03284307|Experimental|Drug Administrated|Sedatives will be administered to participants while their brain activity is measured.
89393620|NCT03279289|Experimental|Group A|INDUCTION PHASE: 6 cycles of FOLFIRI + aflibercept MAINTENANCE PHASE: 5FU/LV + aflibercept
89393621|NCT03279289|Active Comparator|Group B|FOLFIRI + aflibercept
88869639|NCT05842096|Active Comparator|Polycystic ovary syndrome (PCOS)|Women meeting the Rotterdam-ESHRE-ASRM criteria for a diagnosis of PCOS
88869640|NCT05842096|Active Comparator|Hypothalamic-Pituitary-Ovarian Axis Dysfunction (HPOD)|Women meeting the WHO criteria for a diagnosis of HPOD
88869641|NCT05841927|Experimental|ASD active|Dietary Supplement: Docosahexaenoic acid 200mg DHA once, twice a day
88869642|NCT05841927|Placebo Comparator|ASD placebo|Dietary Supplement: Placebo dietary intervention Vitamin D 400IU once, once a day
88869643|NCT05839912|Experimental|Cohort 1: Excision of cLN before systemic therapy|Excision of the clinically detected metastatic lymph node before systemic therapy.
88869644|NCT05839912|Experimental|Cohort 2: Excision of cLN after neoadjuvant systemic therapy|Excision of the clinically detected metastatic lymph node after systemic neoadjuvant therapy.
88869645|NCT05839756|Placebo Comparator|control (C) group|normal saline will be nebulized
88869646|NCT05839756|Active Comparator|Budesonide (B) group|budesonide will be nebulized
89393622|NCT03265535||Healthy Volunteers|Subjects without history of coronary artery disease
88869647|NCT05833061||Stroke Patients|Stroke patients giving written informed consent.
88869648|NCT05832255|Experimental|Psilocybin, 1.5 mg|Participants will take one capsule containing 1.5 mg psilocybin with a glass of water every other day for a period of 28 days. Dosing schedule will be same for all participants with the drug taken at days 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, and no treatment taken on alternating days. No subject shall be provided with more than five capsules (7.5mg psilocybin) at any one time to prevent diversion to the illicit market. If a dose is missed, participants are instructed to skip that dose and continue with their regularly scheduled medications. Participants are not to take >1 capsule per day.
88869649|NCT05828108|Experimental|Experimental -Bitopertin|Bitopertin, up to a maximum dose of 60 mg (5 mg, 10mg, 20mg, 40mg, 60mg)
88869651|NCT05813847|Experimental|CPL-01|Local infiltration of CPL-01
88869652|NCT05813847|Active Comparator|Ropivacaine HCl|Local infiltration of Naropin
88869653|NCT05813847|Placebo Comparator|Placebo|Local infiltration of Saline Placebo
88869654|NCT05803083|Active Comparator|Hyaluronic Acid 150 mg|Take 150 mg/day of hyaluronic acid.
88869655|NCT05803083|Active Comparator|Hyaluronic Acid 100 mg|Take 100 mg/day of hyaluronic acid.
88869656|NCT05803083|Placebo Comparator|Placebo|Take 0 mg/day of hyaluronic acid.
88869657|NCT05800275|Experimental|Tucatinib + Intrathecal Trastuzumab + Capecitabine|Intra-CSF trastuzumab: 150 mg weekly Tucatinib: 300 mg orally twice daily Capecitabine: 1000 mg/m² orally twice daily on days 1-14 of each 21-day cycle
88869658|NCT05792436|Experimental|1-min interval oscillometric method|1-min interval blood pressure monitoring using oscillometric method during induction of anesthesia
88869659|NCT05792436|Active Comparator|arterial catheterization method|Continuous blood pressure monitoring through arterial catheter during induction of anesthesia
88869660|NCT05785377|Placebo Comparator|Bupivacaine group (Group-B)|After cession section, patients Will receive ultrasound (US)-guided bilateral TAP block with 20 mL bupivacaine 0.25% plus 1 mL of normal saline (Total volume of 21mL in each side
88869661|NCT05785377|Active Comparator|Bupivacaine-Neostigmine group (Group-BN)|After cession section, patients Will receive ultrasound (US)-guided bilateral TAP block with 20 mL bupivacaine 0.25% plus 1 mL of 500 mcg neostigmine (Total volume of 21mL in each side
88869662|NCT05778942||Single Arm|Single arm with commercial study drug: Eyestil SYNFO
88869663|NCT05776563|Other|Brain Glucose Levels in Participants with Type 2 Diabetes|Intensification of diabetes management
88869664|NCT05769153|Experimental|Cohort 1 (Stage 1)|One intravitreal (IVT) injection of aflibercept 2 mg at Week -1 and one IVT insertion of AR-14034 SR lower dose at Baseline. Up to one retreatment with AR-14034 SR will be administered between Weeks 4 and 36 according to protocol-specified disease activity criteria.
88869665|NCT05769153|Experimental|Cohort 2 (Stage 1)|One IVT injection of aflibercept 2 mg at Week -1 and one IVT insertion of AR-14034 SR higher dose at Baseline. Up to one retreatment with AR-14034 SR will be administered between Weeks 4 and 36 according to protocol-specified disease activity criteria.
88869666|NCT05769153|Experimental|AR-14034 SR lower dose (Stage 2)|One IVT injection of aflibercept 2 mg at Baseline, Week 4, and Week 8, with one IVT insertion of AR-14034 SR lower dose at Week 6. Up to one retreatment of AR-14034 SR will be administered between Weeks 16 and 52 according to protocol-specified disease activity criteria. Sham procedures will be performed between Weeks 16 and 52 except when AR-14034 SR repeat treatment is administered.
88869667|NCT05769153|Experimental|AR-14034 SR higher dose (Stage 2)|One IVT injection of aflibercept 2 mg at Baseline, Week 4, and Week 8, with one IVT insertion of AR-14034 SR higher dose at Week 6. Up to one retreatment of AR-14034 SR will be administered between Weeks 16 and 52 according to protocol-specified disease activity criteria. Sham procedures will be performed between Weeks 16 and 52 except when AR-14034 SR repeat treatment is administered.
88869668|NCT05769153|Active Comparator|Aflibercept (Stage 2)|One IVT injection of aflibercept 2 mg at Baseline, Week 4, Week 8, Week 16, Week 24, Week 32, Week 40, and Week 48. Sham procedures will be performed between Weeks 16 and 52.
88869669|NCT05766124|Experimental|Low dose tPA|Patients with pleural infection and will receive a starting dose of tPA at 2.5mg
88869670|NCT05766124|Active Comparator|Standard dose tPA|Patients with pleural infection and will receive a starting dose of tPA at 10mg
89393623|NCT03265535||Subjects with coronary artery disease|Subjects with coronary artery disease and abnormal SPECT myocardial perfusion imaging within the last 12 months
88869671|NCT05760378|Experimental|A|Famitinib in Combination With Camrelizumab and TPC
88869672|NCT05760378|Active Comparator|B|Combination With Camrelizumab and TPC
88869673|NCT05759572|Experimental|Cohort 1|In this cohort, a patient would receive Dalpiciclib(CDK4/6 inhibitor) combined with Apatinib and endocrine therapy.
88869674|NCT05759572|Active Comparator|Cohort 2|In this cohort, a patient would receive Dalpiciclib(CDK4/6 inhibitor) combined with endocrine therapy.
88869675|NCT05759546|Experimental|Cohort 1|In this cohort, a patient would receive Dalpiciclib(CDK4/6 inhibitor) combined with Fluzoparib(Parp inhibitor) and endocrine therapy.
88869676|NCT05759546|Active Comparator|Cohort 2|In this cohort, a patient would receive Dalpiciclib(CDK4/6 inhibitor) combined with endocrine therapy.
88869677|NCT05753826|Experimental|Adebrelimab Combined With Fuzuloparib|
88869678|NCT05752474|Experimental|Prehabilitation|This group will receive a multicomponent prehabilitation intervention (exercise, nutritional intervention, meditation, and cognitive behavioral intervention) for 3-4 weeks prior to surgery.
88869679|NCT05751590|Active Comparator|Glidescope + Fiberoptic broncscopy|
88869680|NCT05751590|Active Comparator|Fiberoptic broncscopy|
88869681|NCT05750992|Active Comparator|surgical TAP block|twenty-five pregnant women will receive surgical TAP block performed by 40 ml of 0.25% bupivacaine (10 ml 0.5% bupivacaine bilaterally diluted with 10cc normal saline and 100 μg of fentanyl), the total volume was divided equally and administered bilaterally by the surgeon.
88869682|NCT05750992|Active Comparator|US guided TAP block|25 pregnant women will receive US guided T.A.P block performed by 40 ml of 0.25% bupivacaine (10 ml 0.5% bupivacaine bilaterally diluted with 10cc normal saline and 100 μg of fentanyl), the total volume was divided equally and administered bilaterally.
88869683|NCT05749068|Experimental|Experimental|Open label experimental arm
89393624|NCT03186456|Experimental|Group 1|Aspirin Tablet, 100mg/d; Allogeneic umbilical cord mesenchymal stem cells, 0.5-1*10^6/kg
89393625|NCT03186456|Placebo Comparator|Group 2|Aspirin Tablet, 100mg/d; Placebo
89393626|NCT03184935|Experimental|Experimental group|Basic medication: Decitabine; Allogeneic umbilical cord mesenchymal stem cells.
89393627|NCT03184935|Placebo Comparator|Control group|Basic medication: Decitabine; placebo: saline.
89393628|NCT03180463|Experimental|Group 1|Core decompression surgery; Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#).
89393629|NCT03180463|Placebo Comparator|Group 2|Core decompression surgery.
89393630|NCT03180450|Experimental|Treatment group|conventional treatment; Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#) by i.v.
89393631|NCT03180450|Placebo Comparator|Control group|Conventional treatment
89393632|NCT03176498|Experimental|Experimental group|Basic medication：Aspirin Enteric-coated Tablets & Atorvastatin Calcium； Allogeneic umbilical cord mesenchymal stem cells
89393633|NCT03176498|Placebo Comparator|Control group|Basic medication：Aspirin Enteric-coated Tablets & Atorvastatin Calcium; Placebo：saline
89393634|NCT03126591|Experimental|Olaratumab Dose Level 1 + Pembrolizumab|Olaratumab given intravenously (IV) and pembrolizumab given IV.
89393635|NCT03126591|Experimental|Olaratumab Dose Level 2 + Pembrolizumab|Olaratumab given IV and pembrolizumab given IV.
89393636|NCT03126591|Experimental|Olaratumab + Pembrolizumab Expansion|Olaratumab given IV and pembrolizumab given IV.
89393637|NCT03107000|Active Comparator|Trabeculectomy group|Patients with Open Angle Glaucoma requiring incisional surgery in whom specular microscopy can be performed without any delay in their treatment
89393638|NCT03107000|Active Comparator|Phako-trabeculectomy group|Patients with Open Angle Glaucoma and cataract requiring incisional surgery in whom specular microscopy can be performed without any delay in their treatment
89393639|NCT03094832|Experimental|Part A: Miransertib PROS/PS|During Cycles 1-3, participants with either PROS (phosphatidylinositol- 4,5-bisphosphate 3-kinase, catalytic subunit alpha [PIK3CA]-related Overgrowth Spectrum) or PS (Proteus syndrome) received miransertib 15 mg/m^2 once daily (QD) (each cycle length = 28 days). From Cycles 4-48 or until disease progression, unacceptable toxicity, or discontinuation, participants received miransertib dose titrated to 25 mg/m^2 and then titrated to 35 mg/m^2 orally QD at the investigator's discretion.
89393640|NCT03094832|Experimental|Part B: Miransertib PROS (Cohort 1)|During Cycles 1-3, participants with PROS who have a measurable lesion by volumetric magnetic resonance imaging (MRI) received miransertib 15 mg/m^2 QD (each cycle length = 28 days). From cycles 4-48 or until disease progression, unacceptable toxicity, or discontinuation, participants received miransertib dose titrated to 25 mg/m^2 orally QD at the investigator's discretion.
88816481|NCT02512575|Placebo Comparator|Placebo|Subjects randomized to placebo in the first 8 cohorts will receive the same dose volume of oral suspension as subjects on AZD9567 and subjects randomized to placebo in cohort 9(prednisolone cohort) will receive the same number of capsules as subjects on prednisolone.
88816482|NCT02512575|Experimental|Prednisolone capsules|"Within each cohort 6 subjects will be randomized to receive prednisolone 60mg oral capsules and 2 subjects randomized to receive matching placebo in a fasted state.~Sentinel dosing will not be employed for the prednisolone cohort. The SRC will not be required to evaluate the prednisolone cohort. This cohort can be performed at any time during clinical execution of the study provided the protocol amendment was approved."
88816483|NCT01199744||Influenza virus infection patients exposed to zanamivir|Safety of Influenza virus infection patients exposed to zanamivir
88816484|NCT03702374|Experimental|Combined Antioxidant Therapy group|This arm will be administered with the combined antioxidant therapy, and will consist of 30 patients with moderate non-proliferative diabetic retinopathy (NPDR), 30 subjects with severe NPDR and 30 patients with Proliferative diabetic retinopathy.
88816485|NCT03702374|Placebo Comparator|Placebo group|This arm will be administered with placebo, and will consist of 30 patients with moderate non-proliferative diabetic retinopathy (NPDR), 30 subjects with severe NPDR and 30 patients with Proliferative diabetic retinopathy.
88816486|NCT02512809|Experimental|Isoflurane Arm|Pediatric patients, aged 0-5 years, diagnosed with hydrocephalus undergoing a surgical (non-bedside) shunting procedure with general anesthesia. Pts will receive a standardized general anesthetic with isoflurane.
88816487|NCT02512809|Experimental|Dexmedetomidine/remifentanil Arm|Pediatric patients, aged 0-5 years, diagnosed with hydrocephalus undergoing a surgical (non-bedside) shunting procedure with general anesthesia. Pts will receive a standardized general anesthetic with dexmedetomidine and remifentanil infusions..
88816488|NCT02512809|No Intervention|MRI Control Arm|Otherwise healthy pediatric patients, aged 0-5 years, undergoing MRI with general anesthesia for evaluation of non-neurologic disease. Patients will receive a standardized general anesthetic with isoflurane.
88816489|NCT03527810|Experimental|Sleeve Gastrectomy With Interrogation of Hiatus|In those randomized to interrogation, the hiatus will be opened posteriorly during surgical procedure intervention with preservation of the phreno-esophageal ligament where possible, as per standard described techniques. Dissection into the mediastinum will be stopped if no hernia is seen or when appropriate intra-abdominal length of 2 cm of esophagus is created. Once opened, the Hiatal Surface Area will be measured, calculated and recorded and when possible, a photo taken of the area. Repair of the crura will then be performed around the sizing tube used to create the sleeve with enough space to allow a 5 mm instrument to be easily inserted. Permanent sutures will be placed posterior to the esophagus.
88816490|NCT03527810|Active Comparator|Sleeve Gastrectomy Without Interrogation of Hiatus|In those randomized without interrogation, the stomach is reduced to about 15% of its original size, by surgical removal of a large portion of the stomach along the greater curvature. The procedure involves a longitudinal resection of the stomach starting from the antrum at the point 5-6 cm from the pylorus and finishing at the fundus close to the cardia.[1] The remaining gastric sleeve is calibrated with a bougie. Most surgeons prefer to use a bougie between 36-40 Fr with the procedure and the ideal approximate remaining size of the stomach after the procedure is about 150 mL.
88816491|NCT01201772|Active Comparator|Prasugrel 60mg|Patients will be randomized to: 10mg, 30mg, or 60mg dose of prasugrel
88816492|NCT01201772|Active Comparator|Prasugrel 30mg|Patients will be randomized to: 10mg, 30mg, or 60mg dose of prasugrel
89393641|NCT03094832|Experimental|Part B: Miransertib PS (Cohort 2)|During Cycles 1-3, participants with PS who have a measurable lesion by standardized digital photography received miransertib 15 mg/m^2 QD (each cycle length = 28 days). From cycles 4-48 or until disease progression, unacceptable toxicity, or discontinuation, participants received miransertib dose titrated to 25 mg/m^2 orally QD at the investigator's discretion.
89393642|NCT03094832|Experimental|Part B: Miransertib PROS/PS (Cohort 3)|During Cycles 1-3, participants with PROS or PS who do not meet all the eligibility criteria for Cohorts 1 or 2 received miransertib 15 mg/m^2 QD (each cycle length = 28 days). From cycles 4-48 or until disease progression, unacceptable toxicity, or discontinuation, participants received miransertib dose titrated to 25 mg/m^2 orally QD at the investigator's discretion.
89393643|NCT03094832|Experimental|Part B: Miransertib Compassionate Use/Expanded Access (Cohort 4)|During cycles 1-48 (each cycle length = 28 days) or until disease progression, unacceptable toxicity, or discontinuation, participants previously treated with miransertib or currently receiving miransertib under Compassionate Use/Expanded Access continued to receive the current dose of miransertib (did not exceed 25 mg/m^2).
89393644|NCT03085004|Active Comparator|Control Group|Cyst will be lavaged for 3 to 5 minutes with >/=99% ethanol. Following lavage with >/=99% ethanol, the cyst will be infused with an admixture of (3mg/ml paclitaxel + 19mg/ml gemcitabine).
89393645|NCT03085004|Experimental|Study group|Cyst will be lavaged for 3 to 5 minutes with normal saline. Following lavage with normal saline, the cyst will be infused with an admixture of (3mg/ml paclitaxel + 19mg/ml gemcitabine).
88816493|NCT01201772|No Intervention|Prasugrel 10mg|Patients will be randomized to: 10mg, 30mg, or 60mg dose of prasugrel
88816494|NCT02513121|Active Comparator|Dietary modification|Low free sugar diet
88816495|NCT02513121|No Intervention|Observational Arm|Standard of care
88816496|NCT01202162|Active Comparator|Desflurane|Administration of Desflurane
88816497|NCT01202162|Active Comparator|Sevoflurane|Administration of Sevoflurane
88816498|NCT04411641|Experimental|SAR442168|Dose 1 of oral SAR442168 once daily
88816499|NCT04411641|Placebo Comparator|Placebo|Placebo tablet to match SAR442168 once daily
88816500|NCT02246972|Experimental|VRET Immediate treatment|Participants will be randomized to receive Virtual Reality Exposure Therapy (VRET) immediately
88816501|NCT02246972|Active Comparator|Waitlist|6 weeks standard of care, then Virtual Reality Exposure Therapy (VRET) treatment.
88816502|NCT01158716|Active Comparator|Remote Ischemic Preconditioning|
88816503|NCT01158716|No Intervention|Control|
88816504|NCT04405479||Patients with multiple sclerosis|MS patients will be chosen by an independent neurologist.
88816505|NCT04405479||Healthy volunteers|Healthy controls will be paired by age and sex with MS patients.
88816506|NCT01159262|Experimental|Dexmedetomidine 0.05 mcg/kg|Dexmedetomidine loading dose 0.05 mcg/kg; maintenance infusion: 0.05 mcg/kg/hr.
88816507|NCT01159262|Experimental|Dexmedetomidine 0.1 mcg/kg|Dexmedetomidine loading dose: 0.1 mcg/kg; maintenance infusion 0.1 mcg/kg/hr.
88816508|NCT01159262|Experimental|Dexmedetomidine 0.2 mcg/kg|Dexmedetomidine loading dose 0.2 mcg/kg; maintenance infusion 0.2 mcg/kg/hr.
88816509|NCT03011060|Experimental|NAC not achieving pCR|"Patients in the study group will accept neo-adjuvant chemotherapy. Among these patients, those who do not achieve pCR after neo-adjuvant chemotherapy will be treated with Capecitabine after surgery. And then they will be followed up for 5 years.~Capecitabine 1000mg/m2 tablets twice a day for 8 cycles."
88816510|NCT03011060|Experimental|NAC achieving pCR|Patients in the study group will accept neo-adjuvant chemotherapy. In these patients, those who reach to pCR after neo-adjuvant chemotherapy will be followed up for 5 years after surgery.
88816511|NCT03011060|No Intervention|Adjuvant Chemotherapy|Patients in the control group will accept surgeries and corresponding adjuvant chemotherapy.They will be followed up for 5 years after adjuvant chemotherapy.
88816512|NCT03010670|Experimental|Oxytocin (OT) spray|Syntocinon nasal spray (product code RVG 03716) will be used to intranasally administer one single dose (24 IU) of OT (3 puffs of 4 IU per nostril).
88816513|NCT03010670|Placebo Comparator|Placebo (PL) spray|Physiological water (a solution of sodium chloride (NaCl) in water) will be used to intranasally administer one single dose (24 IU) of PL (3 puffs of 4 IU per nostril).
88816514|NCT03010748||Chinese population|Chinese population of different nation from several provinces.
88816515|NCT04377711|Active Comparator|Group 1|Participants receive Alvesco 320mcg, twice daily for 30 days via pMDI
88816516|NCT04377711|Placebo Comparator|Group 2|Participants receive Placebo matching Alvesco , twice daily for 30 days via pMDI
88816517|NCT03480464|Experimental|App-technology group|"App-technology to increase physical activity Participants in the intervention group (App-technology) will use a newly developed smartphone application (app) in which the participants are able to register their daily physical activity in bouts of 10 min and their intake if supplementary vitamins. They will also be able to set personal goals every week for the level (minutes) of physical activity and get feedback every week in whether they fulfilled the goal or not. They will also get feedback on the intake of supplementary vitamin intake."
88816518|NCT03480464|No Intervention|Control group|The control group will receive standard information about the benefit of physical activity after surgery.
88816519|NCT04366713|Experimental|Neratinib|Neratinib with loperamide prophylaxis, and capecitabine for participants treated for metastatic breast cancer
88816520|NCT03413384|Experimental|Ceftriaxone|"Name: Ceftriaxone~Dosage form: crystalline powder for intramuscular injection~Dose(s): 1 g~Dosing schedule: 1 g ceftriaxone with around 2.0 ml of lidocaine solvent per day for Day 1, 3, and 5 per cycle on a 2 weekly cycle"
88816521|NCT03413384|Placebo Comparator|Placebo|same amount volume of placebo will be given on Day 1, Day 3, and Day 5 per cycle on a 2 weekly cycle
88816522|NCT05249049|Experimental|e-OPRA Implant System for Transtibial Amputees|Implantation of e-OPRA Implant System in lower limb.
88816523|NCT03012152|Active Comparator|Standard conservative group|"Group A (35 patients) have standard curative conservative breast surgery without integration of plastic techniques .~."
88816524|NCT03012152|Active Comparator|Oncoplastic group|Group B(35 patients) have curative oncoplastic surgery in which plastic techniques integrated with oncological procedures
89393646|NCT03082716|Active Comparator|blood cardioplegia group|patient will receive blood cardioplegia, delivered by microplegia delivery system by adding potassium to the blood (K= 35 ml eq/L) . The initial dose will be 35ml/ kg, and subsequent doses 20-15 ml/kg given every 20 minutes at a Temperature of 10 - 15 °C, while maintaining a perfusion pressure of 100-125 mmHg.
89393647|NCT03082716|Experimental|custodiol group|patient will receive single dose of HTK custodiol cardioplegia. at temperature of 4-8°C and will be perfused for 6-8 minutes. Dose will start from 400 up to 1000 ml according to the child's body weight. Perfusion pressure will be kept at 70 - 80 mmHg until the heart is arrested.
88869684|NCT05746455|Experimental|Motivation Skills Training (MST)|Participants will complete a baseline assessment, receive weekly MST sessions in a group format for a duration of 12 weeks, and will then repeat the assessment battery from baseline as well as a satisfaction survey.
88869685|NCT05745207|Experimental|Part A, Cohort 1: E2086 1 mg or Placebo|Participants will receive 1 milligram (mg) (2*0.5 mg) E2086 or E2086 matched placebo, tablets, orally, once on Day 1.
88869686|NCT05745207|Experimental|Part A, Cohort 2: E2086 2.5 mg or Placebo|Participants will receive 2.5 mg (5*0.5 mg) E2086 or E2086 matched placebo, tablets, orally, once on Day 1.
88869687|NCT05745207|Experimental|Part A, Cohort 3: E2086 5 mg or Placebo|Participants will receive 5 mg (1*5 mg) E2086 or E2086 matched placebo, tablets, orally, once on Day 1.
88869688|NCT05745207|Experimental|Part A, Cohort 4: E2086 10 mg or Placebo|Participants will receive 10 mg (2*5 mg) E2086 or E2086 matched placebo, tablets, orally, once on Day 1.
88869689|NCT05745207|Experimental|Part A, Cohort 5: E2086 25 mg or Placebo|Participants will receive 25 mg (1*25 mg) E2086 or E2086 matched placebo, tablets, orally, once on Day 1.
88869690|NCT05745207|Experimental|Part A, Cohort 6: E2086 50 mg or Placebo|Participants will receive 50 mg (2*25 mg) E2086 or E2086 matched placebo, tablets, orally, once on Day 1.
88869691|NCT05745207|Experimental|Part A, Cohort 7: E2086 100 mg or Placebo|Participants will receive 100 mg (4*25 mg) E2086 or E2086 matched placebo, tablets, orally, once on Day 1.
88869692|NCT05745207|Experimental|Part B, Cohort 8: E2086 25 mg or Placebo|Participants will receive 25 mg (1*25 mg) E2086 or E2086 matched placebo, tablets, orally, once on Day 1.
88869693|NCT05739149|Experimental|Microvessel Ultrasound Imaging for Chronic Ulcers|Subjects with chronic diabetic ulcers and venous ulcers will undergo wound debridement and treatment as standard of care and receive research microvessel ultrasound examination and two skin biopsies
88869694|NCT05738252||Neo-adjuvant Chemotherapy|Patients who will be receiving neo-adjuvant chemotherapy prior to surgery.
88869695|NCT05738252||No Chemotherapy|Patients who do not have planned chemotherapy.
88869696|NCT05736341|Experimental|Remimazolam|Patient group who receives remimazolam for sedation after delivery
88869697|NCT05736341|Active Comparator|Midazolam|Patient group who receives midazolam for sedation after delivery
88869698|NCT05730751||Group F|The patients will receive 2.5 ml of hyperbaric bupivacaine 0.5 % and 25 µg fentanyl [6].
88869699|NCT05730751||Group C|The patients will receive 2.5 ml of hyperbaric bupivacaine 0.5 %
88869700|NCT05730400|Active Comparator|BMAC/bovine graft|Bone marrow aspirate concentrate loaded on bovine graft (Tutogen Medical GmbH, Neunkirchen am Brand, Germany, 1- 2mm particle size) utilization for sinus floor augmentation with residual alveolar bone height less than 5 mm, 1st arm
88869701|NCT05730400|Active Comparator|Bovine graft group|bovine graft utilization for sinus floor augmentation with residual alveolar bone height less than 5 mm, 2nd arm
88869702|NCT05723692|Experimental|ALTB-268|Subcutaneous dose in healthy volunteers
88869703|NCT05723692|Placebo Comparator|Placebo|Subcutaneous dose in healthy volunteers
89393648|NCT03069287|Experimental|Patient-caregiver dyads|Dyads will include family caregivers and patients with a diagnosis of cancer who agreed to participate in a therapeutic clinical trial.
89393649|NCT03059862|Experimental|Low-tryptophan diet and L-tryptophan.|Standardized low-tryptophan diet (500-1000 mg of L-tryptophan and 1800 kcal) + L-tryptophan supplements (3 g/day).
88869704|NCT05719909|Experimental|Cognitive Training|8 sessions of web-based cognitive training
88869705|NCT05719909|Sham Comparator|Sham Training|8 sessions of web-based sham training
88869706|NCT05710224|Experimental|V181|Participants will receive a single 0.5 mL subcutaneous (SC) injection of V181 on Day 1.
88869707|NCT05710224|Experimental|Butantan-DV|Participants will receive a single 0.5 mL SC injection of Butantan-DV on Day 1.
88869708|NCT05709990|Experimental|High dose vitamin D supplementation (combined with standard urotherapy)|These patients will receive high dose vitamin D supplementation (more than 2000IU daily) and behavioral therapy for 8 weeks
89393650|NCT03059862|Placebo Comparator|Low-tryptophan diet and placebo|Standardized low-tryptophan diet (500-1000 mg of L-tryptophan and 1800 kcal) + placebo.
88869709|NCT05709990|Active Comparator|Solifenacin succinate group (combined with standard urotherapy)|These patients will receive solifenacin (5-10 mg daily) and behavioral therapy for 8 weeks
88869710|NCT05709990|Active Comparator|standard urotherapy group|These patients will receive behavioral therapy alone for 8 weeks.
88869711|NCT05706805||Coronary Artery Disease (CAD)|
88869712|NCT05703009|Experimental|Treatment|Subjects will be randomized to take active treatment, sacrosidase, 2 mL (17,000 IU) with every meal or snack, administered orally following dilution with 2 to 4 ounces (60 to 120 mL) of water or milk (either cold or at room temperature) during either Treatment Period 1 or Treatment Period 2. The study treatment period is one week.
88869713|NCT05703009|Placebo Comparator|Placebo|Subjects will be randomized to take placebo treatment, sacrosidase placebo, 2 mL (17,000 IU) with every meal or snack, administered orally following dilution with 2 to 4 ounces (60 to 120 mL) of water or milk (either cold or at room temperature) during either Treatment Period 1 or Treatment Period 2. The study treatment period is one week.
88869714|NCT05687266|Experimental|Dato-DXd + Durvalumab + Carboplatin|Participants will be randomized to receive 6.0mg/kg Dato-DXd plus 1120 mg durvalumab plus carboplatin area under the curve [AUC] 5 mg/mL/minute.
88869715|NCT05687266|Active Comparator|Histologic-specific therapy|"Non-squamous NSCLC participants will be randomized to receive 200 mg pembrolizumab plus 500 mg/m2 pemetrexed plus either AUC 5 mg/mL/minute carboplatin or 75 mg/m2 cisplatin.~Squamous NSCLC participants will be randomized to receive 200 mg of pembrolizumab plus 200 mg/m2 paclitaxel plus AUC 5 or 6 mg/mL/minute carboplatin."
88869716|NCT05683483|Experimental|Surgical WEsleep|Patients admitted into the 3 surgical departments/clusters where the WEsleep interventions are implemented.
88869717|NCT05683483|Experimental|Medical WEsleep|Patients admitted into the 3 non-surgical departments/clusters where the WEsleep interventions are implemented
88869718|NCT05683483|No Intervention|Surgical Standardcare|Patients admitted into the 3 surgical departments/clusters where the WEsleep interventions are NOT implemented, and patients are receiving standardcare
88869719|NCT05683483|No Intervention|Medical Standardcare|Patients admitted into the 3 non-surgical departments/clusters where the WEsleep interventions are NOT implemented, and patients are receiving standardcare
88869720|NCT05674955|Experimental|Circuit weight group|
88869721|NCT05674955|Experimental|Aerobic group|
88869722|NCT05674955|Experimental|Control Group|
88869723|NCT05674552|Experimental|Study group|Children receiving exogenous ketone esters + standard of care
88869724|NCT05674552|No Intervention|Control group|Children receiving only standard of care
88869725|NCT05670847|Experimental|Study group|Children receiving exogenous ketone esters + standard of care
88869726|NCT05670847|No Intervention|Control group|Children receiving only standard of care
88869727|NCT05668611|Experimental|Primary Training|4 Ministry of Health nurses will be trained by expert trainers to become certified in focused echocardiography acquisition and interpretation in order to screen patients for rheumatic heart diseases
88869728|NCT05668611|Experimental|Secondary Training|The 4 Ministry of Health nurses trained in Aim 1 will then train and certify 3 other nurses from their clinics in focused echocardiography acquisition interpretation.
88869729|NCT05660642|Experimental|Arm A|
88869730|NCT05660642|Experimental|Arm B|
88869731|NCT05658874|Experimental|Multimodal care bundle|"Components of multimodal care bundle~MD Evaluation~On site pelvic floor physical therapy~Behavioral health consult with appropriate psychiatric referrals/treatments~Central sensitization/neurogenic pain:~Amitriptyline 10-50mg Or Gabapentin (doses range from 100mg po tid to 600mg po tid)~Urinary symptoms IC/PBS:~Spasm: Overactive bladder medication chosen based on patient characteristics/insurance, dose may be increased as tolerated (Oxybutynin/Trospium/Detrol vs. Mirabegron)~Microbiome: Methenamine~Vaginal estrogen~At least once within 12 weeks of initial visit:~Operative cystoscopy~Bladder instillations x 6 weeks (lidocaine, heparin, sodium bicarb, Kenalog, gentamicin)~Pudendal/Levator and/or Obturator internus nerve block (120mg Kenalog and 0.25% Marcaine, total 23cc)"
88869732|NCT05658874|Active Comparator|Usual care|IC/PBS treatments as directed by Urogynecology specialist
88869733|NCT05656378||Single Cohort|Participants aged >0 years with no upper age limit, both healthy volunteers and those with previously known and unknown disease states
88869734|NCT05653596|Experimental|Experimental: VR restorative intervention|Individuals who are assigned to the experimental group will receive a 4-week VR-based cognitive intervention.
88869735|NCT05653596|No Intervention|Control: Usual care|Individuals who are assigned to the control group will receive the usual care and then receive the same intervention as they wish.
88869736|NCT05650632|Experimental|Arm A (Part 1): ABBV-383 Dose Escalation|B-cell maturation antigen (BCMA) naïve participants will receive different doses of ABBV-383 in 28 day cycles.
88869737|NCT05650632|Experimental|Arm A (Part 2): ABBV-383 Dose Expansion|BCMA naïve participants will receive the dose of ABBV-383 dose A in 28 day cycles.
88869738|NCT05650632|Experimental|Arm B: ABBV-383 Dose Expansion|Participants previously exposed to BCMA-targeted agents will receive ABBV-383 Dose A in 28 day cycles.
88869739|NCT05650398||Patients with exclusion|"Evaluation of the tactile sensitivity of the excluded finger using different tests: Static and dynamic two-points discrimination tests, the Semmes-Weinstein monofilament test, grating orientation task and the bar test inspired by the study of Louw et al.~Realization of the same tests on the controllateral healthy finger."
88869740|NCT05650398||Control|"Evaluation of the tactile sensitivity of the finger using different tests: Static and dynamic two-points discrimination tests, the Semmes-Weinstein monofilament test, grating orientation task and the bar test inspired by the study of Louw et al.~Realization of the same tests on the controllateral finger."
88869741|NCT05639426|Experimental|Strengthening Opportunities for Achievement and Resilience|Strengthening Opportunities for Achievement and Resilience (SOAR) is an intervention condition consisting of both Culturally-Responsive Schoolwide Positive Behavior Interventions and Supports (C-SWPBS) and Culturally Responsive Practices (CRP). It is a year-long, school-level intervention.
89535434|NCT05011695|Active Comparator|2. Group transverse friction massage|Transverse friction massage will be applied to the plantar fascia of the patients for 3 weeks, 3 days a week, on Mondays, Wednesdays, and Fridays, with a break for 1 day and 15 minutes each. Transverse friction massage, when the patient is in the supine semi-lying position, the big toe will be dorsiflexed and in this position, it will be applied in the direction that will be transverse to the plantar fascia.
89393651|NCT03037723|Other|Prone/Supine Simulation|It is institutional policy to perform CT simulation in left-sided breast cancer patients with and without the respiratory gating (this is one CT scan), in the face-up position. It is also standard of care to perform the face-down CT simulation in large breasted women. Both of these simulations are meant to reduce the exposure of the heart and lungs to radiation. In this study, all left-sided breast cancer patients that consent will receive face-up CT simulation with and without gating AND face-down CT simulation, regardless of breast size; thus, each patient is their own control.
89393652|NCT03036579|Experimental|Glazed Fired, Calibra Céram|Celtra Duo crowns will be glaze-fired in a porcelain oven and cemented with Calibra Ceram Cement
88869742|NCT05635045|Experimental|Cohort 1|"Subjects with grade 1 Tc99-PYP scans who have clinical features suggestive of ATTR-CM or have grade 1 Tc99-PYP scans but endomyocardial biopsy evidence of TTR cardiac amyloidosis will be administered single dose evuzamitide <1mCi.~Heart failure with a preserved ejection fraction (EF>40%)~Grade 1 Tc99-PYP scan performed for clinical suspicion of ATTR-CM~No evidence of monoclonal proteins by assessment of serum kappa and lambda free light chain ratio and immunofixation of serum and urine.~Left ventricular septal OR inferolateral wall thickness ≥12 mm"
88869743|NCT05635045|Experimental|Cohort 2|"Subjects with TTR variant such as Phe64Leu, late onset Val30Met, etc.) that are associated with cardiac amyloidosis but have PYP scans not diagnostic of ATTR-CM will be administered single dose evuzamitide <1mCi.~Tc99-PYP scan performed for clinical suspicion of ATTR-CM that is not diagnostic of ATTR-CM~No evidence of monoclonal proteins by assessment of serum kappa and lambda free light chain ratio and immunofixation of serum and urine.~Left ventricular septal OR inferolateral wall thickness ≥12 mm with echocardiographic features of ATTR-CM (low tissue doppler velocities, preserved apical strain, elevated E/E') or CMR features of an infiltrative cardiomyopathy (increased wall thickness with delayed enhancement or difficulty nulling of the myocardium)"
88869744|NCT05635045|Experimental|Cohort 3|"Subjects with ATTR-CM from either ATTRwt or Val122Ile variant who have biopsy proven evidence of extra-cardiac TTR amyloidosis or clinical suspicion of extracardiac disease, including but not limited to peripheral neuropathy, carpal tunnel syndrome, spinal stenosis will be administered single dose evuzamitide <1mCi..~ATTR-CM defined by the following~Amyloid deposits in cardiac or non-cardiac tissue confirmed by Congo Red (or equivalent) staining OR technetium scintigraphy with 99m Tc-pyrophosphate with Grade 2 or 3 cardiac uptake in the absence of abnormal light chains ratio,~End-diastolic interventricular septum thickness of > 12 mm on previous echocardiogram~TTR genotype shown to be either Val122Ile or wild type."
88869745|NCT05631899|Experimental|KRAS-EphA-2-CAR-DC plus anti-PD-1 antibody and anti-CTLA4 antibody|"In the priming phase, a conditioning chemotherapy regimen of Abraxane and cyclophosphamide is administered three days before vaccination, and KRAS-EphA-2-CAR-DC vaccine is infused on Day 0 and Day 7 in Week 1.~In the boost phase, KRAS-EphA-2-CAR-DC vaccine is infused one dose every 8 weeks since Week 5.~Anti-PD-1 antibody and anti-CTLA4 antibody are administered 2 days after the first dose of KRAS-EphA-2-CAR-DC vaccine in the boost phase (Day 3 in Week 5) and every 3 weeks afterwards for four doses, followed by anti-PD-1 antibody once every 3 weeks, until:~Unacceptable toxicity occurred or disease progression; or~Reactive T cells are undetected repeatedly after the last vaccine dose; or~Vaccine exhaustion."
88869746|NCT05631899|Experimental|KRAS-EphA-2-CAR-DC plus anti-PD-1 antibody|"In the priming phase, a conditioning chemotherapy regimen of Abraxane and cyclophosphamide is administered three days before vaccination, and KRAS-EphA-2-CAR-DC vaccine is infused on Day 0 and Day 7 in Week 1.~In the boost phase, KRAS-EphA-2-CAR-DC vaccine is infused one dose every 4 weeks since Week 5 for a total of 6 to 8 doses, then maintenance vaccination is given one dose every 8 weeks.~Anti-PD-1 antibody is administered 2 days after the first dose of KRAS-EphA-2-CAR-DC vaccine in the boost phase (Day 3 in Week 5) and every 4 weeks afterwards, until:~Unacceptable toxicity occurred or disease progression; or~Reactive T cells are undetected repeatedly after the last vaccine dose; or~Vaccine exhaustion."
88869747|NCT05631899|Experimental|KRAS-EphA-2-CAR-DC|"In the priming phase, a conditioning chemotherapy regimen of Abraxane and cyclophosphamide is administered three days before vaccination, and KRAS-EphA-2-CAR-DC vaccine is infused on Day 0 and Day 7 in Week 1.~In the boost phase, KRAS-EphA-2-CAR-DC vaccine is infused one dose every 4 weeks since Week 5 for a total of 6 to 8 doses, then maintenance vaccination is given one dose every 8 weeks, until:~Unacceptable toxicity occurred or disease progression; or~Reactive T cells are undetected repeatedly after the last vaccine dose; or~Vaccine exhaustion."
88869748|NCT05628805|Experimental|iTBS|Each participant will have two separate study days in the TMS lab. On one day, the participant will receive active pre-SMA iTBS. On the other day, the patricipant will receive sham pre-SMA iTBS. The order that active versus sham is given will be randomized and the participant will be blinded. After each iTBS session, blinding assessment will be performed. To avoid contamination of results, a minimum of 5 days between study days will be required.
88869749|NCT05628805|Sham Comparator|Sham iTBS|Each participant will have two separate study days in the TMS lab. On one day, the participant will receive active pre-SMA iTBS. On the other day, the patricipant will receive sham pre-SMA iTBS. The order that active versus sham is given will be randomized and the participant will be blinded. After each iTBS session, blinding assessment will be performed. To avoid contamination of results, a minimum of 5 days between study days will be required.
88869750|NCT05628350|Experimental|No UPF (Ultra-processed foods)|Participants will consume a diet containing 0% total energy from UPF for 6 weeks
88869751|NCT05628350|Active Comparator|Standard UPF|Participants will consume a diet containing 59% total energy from UPF for 6 weeks
88869752|NCT05623800|Experimental|PREM-Kit group|
88869753|NCT05623800|No Intervention|Control group|
88869754|NCT05617079||Medicine physicians|Anesthesiologists, intensive care specialists, heads of departments of anesthesiology and intensive care, deputy chief physicians for anesthesiology and intensive care (heads of centers), employees of the department of anesthesiology and intensive care, pulmonologists working in medical organizations that use nebulizer therapy.
88869755|NCT05611736|Experimental|cold saline|After standard chemo-mechanical preparation of the root canal, final irrigation will be performed using 20 milliliters of cold (at 2.5 degrees Celsius temperature) saline solution.
89393653|NCT03036579|Experimental|Hand Polished, Calibra Universal|Celtra Duo crowns will be hand-polished and cemented with Calibra Universal Cement
89393654|NCT03034811|Other|PPK subjects|Subjects that receive the Persona Partial Knee system
89393655|NCT02916862|Experimental|Soluble Corn Fiber (SCF) + Calcium|This group will receive 12 g/d of soluble corn fiber (SCF) + 600 mg/d of elemental calcium carbonate, administered twice a day
89393656|NCT02916862|Active Comparator|Soluble Corn Fiber (SCF) without calcium|This group will receive 12 g/d of soluble corn fiber (SCF) + 600 mg/d of elemental calcium carbonate, administered twice a day
89393657|NCT02916862|Placebo Comparator|Placebo|This group will receive a similar supplement without SCF or calcium, administered twice a day
89393658|NCT02916862|Placebo Comparator|Placebo + calcium|This group will receive a similar supplement without SCF + 600 mg/d of elemental calcium carbonate, administered twice a day
89393659|NCT02891447|Experimental|Treatment (mitomycin, cisplatin)|Patients undergo HIPEC comprised of mitomycin and cisplatin given intraperitoneally over 60 minutes during standard of care cytoreduction and gastrectomy.
89393660|NCT02867761|Active Comparator|Indacaterol/Glycopyrrolate|indacaterol/glycopyrrolate 27.5/15.6 mcg inhaled twice daily for 12 weeks
89393661|NCT02867761|Placebo Comparator|Placebo|Placebo 27.5/15.6 mcg inhaled twice daily for 12 weeks
89393662|NCT02858050||MEMs Cap Real-Time Monitoring|Group 1 will consist of patient taking hepatitis C medicaitons and will have Portal-724 MEMs cap place in their medication bottle and will transmit data in real-time
89393663|NCT02858050||MEMs Cap Without Real-Time Monitoring|Group 2 will consist of patient taking hepatitis C medicaitons and will have Portal-724 MEMs cap place in their medication bottle and data will be downloaded at each study visit while taking hepatitis C medications
89393664|NCT02740790|Experimental|HPV vaccine 1|300 women between 9-17 yeas of age, receiving 0,2,6 month-schedule experimental HPV vaccines
89393665|NCT02740790|Placebo Comparator|Placebo 1|300 women between 9-17 yeas of age, receiving 0,2,6 month-schedule Placebo.
89393666|NCT02740790|Experimental|HPV vaccine 2|120 women between 18-26 yeas of age, receiving 0,2,6 month-schedule experimental HPV vaccines
89393667|NCT02740790|Experimental|HPV vaccine 3|180 women between 27-45 yeas of age, receiving 0,2,6 month-schedule experimental HPV vaccines
89393668|NCT02740790|Placebo Comparator|Placebo 2|120 women between 18-26 yeas of age, receiving 0,2,6 month-schedule Placebo.
89393669|NCT02740790|Placebo Comparator|Placebo 3|180 women between 27-45 yeas of age, receiving 0,2,6 month-schedule Placebo.
89393670|NCT02740777|Experimental|2-dose adolescent|300 adolescent girl will receive a two-dose schedule (0 day, 6 months) immunization of HPV-16/18 vaccine.
89393671|NCT02740777|Experimental|3-dose adolescent|300 adolescent girl will receive a three-dose schedule (0 day, 2 months, 6 months) immunization of HPV-16/18 vaccine.
89393672|NCT02740777|Experimental|3-dose adult|300 adult women will receive a three-dose schedule (0 day, 2 months, 6 months) immunization of HPV-16/18 vaccine.
89393673|NCT02719990|Experimental|Somavaratan|Long-acting recombinant human growth hormone therapy administered subcutaneously twice-monthly in adult participants with GHD
89393674|NCT02680626|Experimental|Magnesium|Participants in this arm will receive magnesium sulfate + ropivacaine in their bilateral transversus abdominis plane blocks
89393675|NCT02680626|Active Comparator|Non-magnesium|Participants in this arm will receive saline + ropivacaine in their bilateral transversus abdominis plane blocks
88869756|NCT05611736|Active Comparator|saline|After standard chemo-mechanical preparation of the root canal, final irrigation of the root canal system will be performed using 20 milliliters of normal saline solution at room temperature.
88869757|NCT05611125|Experimental|Intervention|Individuals in the intervention group will undergo a series of two telehealth video visits and a series of survey assessments at baseline, 3, and 6 months.
88869758|NCT05611125|No Intervention|Control|Individuals in the control group will continue with their usual standard of care and undergo a series of survey assessments at baseline, 3, and 6 months.
89393676|NCT02573415|Experimental|Uterus Transplantation|Women will undergo deceased donor uterine transplantation after IVF.
89393677|NCT02494583|Experimental|Pembrolizumab Monotherapy (Pembro Mono)|Participants will receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 3-week cycle (Q3W). Eligible participants who stop pembrolizumab with Stable Disease (SD) or better but progress after discontinuation may be able to initiate a second course of pembrolizumab for up to 17 cycles (up to approximately 1 additional year) at the investigator's discretion.
89393678|NCT02494583|Experimental|Pembrolizumab + SOC Chemotherapy (Pembro Combo)|Participants will receive pembrolizumab 200 mg Q3W plus cisplatin 80 mg/m^2 Q3W plus 5-FU 800 mg/m^2/day IV infusion on Days 1-5 Q3W. Capecitabine 1000 mg/m^2 twice a day (BID) on Days 1-14 Q3W may be substituted for 5-FU per local guidelines. Eligible participants who stop pembrolizumab with Stable Disease (SD) or better but progress after discontinuation may be able to initiate a second course of pembrolizumab for up to 17 cycles (up to approximately 1 additional year) at the investigator's discretion.
89393679|NCT02494583|Placebo Comparator|Placebo + SOC Chemotherapy (SOC)|Participants receive placebo IV Q3W plus cisplatin 80 mg/m^2 Q3W plus 5-FU 800 mg/m^2/day IV infusion on Days 1-5 Q3W. Capecitabine 1000 mg/m^2 BID on Days 1-14 Q3W may be substituted for 5-FU per local guidelines.
89393680|NCT02466841||Patients undergoing cubital tunnel release surgery|Patients undergoing cubital tunnel release surgery will be enrolled. All enrolled subjects will be followed regardless of the technique used by surgeon.
89393681|NCT02371447|Experimental|VPM1002BC Induction|"Phase 1:~Induction: 6 intravesical instillations of VPM1002BC in 6-12 weeks (dose de-escalation in cohorts of 3-6 patients)~Phase 2:~Induction: VPM1002BC at RP2D established in phase I, 6 intravesical instillations in 6-12 weeks (n=39 including patients treated at RPD2 in phase I)~Maintenance: 3 instillations of VPM1002BC at months 3, 6 and 12"
89393682|NCT02359799|Experimental|Lab group|Lab-based intervention includes 18 training sessions using the IntelliStretch in the lab .
89393683|NCT02359799|Experimental|Home group|Home-based intervention includes 18 training sessions using the IntelliStretch at home.
89393684|NCT02359331|Active Comparator|14 days PBMT group|Giving the 14 days bismuth quadruple regimen as 2nd rescue therapy for eradication of persistent H. pylori infection Drug regimen Proton pump inhibitor (PPI) regular dose b.i.d., tripotassium dicitrate bismuthate 300 mg q.i.d. (three tablets at 30 min before meals and one tablet at 2 hours after dinner), metronidazole 500 mg t.i.d., and tetracycline 500 mg q.i.d
89393685|NCT02359331|Experimental|7 days tailored therapy group|According the antimicrobial susceptibility testing, the H. pylori isolates were resistant to moxifloxacin, 7 days PBMT regimen were prescribed; if the isolates were resistant to metronidazole, 7 days moxiflxacin based triple regimen (PPI regular dose b.i.d., moxifloxacin 400 mg q.d., and amoxicillin 1g b.i.d) were prescribed.
89393686|NCT02322814|Experimental|Cohort I: Cobimetinib, Paclitaxel|Participants will receive a combination of cobimetinib plus paclitaxel in 28-day cycles until disease progression, unacceptable toxicity, investigator decision, death, withdrawal of consent, or completion of study.
89393687|NCT02322814|Placebo Comparator|Cohort I: Placebo, Paclitaxel|Participants will receive a combination of cobimetinib placebo plus paclitaxel in 28-day cycles until disease progression, unacceptable toxicity, investigator decision, death, withdrawal of consent, or completion of study.
89393688|NCT02322814|Experimental|Cohort II:Cobimetinib,Paclitaxel,Atezolizumab|Participants will receive cobimetinib plus paclitaxel plus atezolizumab in 28-day cycles until disease progression, unacceptable toxicity, investigator decision, death, withdrawal of consent, or completion of study.
88869759|NCT05609539||AAA patients with a mismatched takeoff of the renal arteries candidated to standard EVAR|Patients suffering to AAA with a mismatched takeoff (>10mm) of the renal arteries
88869760|NCT05604235|Experimental|Therapeutic strength exercise group|A treatment with therapeutic strength exercises, twice a week, for two months, with a total of 10 exercises, with 20 repetitions each, aimed at improving the strength of the trapezius and sternocleidomastoid muscles mainly, as well as improving mobility in flexion, abduction and rotation of the affected upper limb. The protocol will be carried out in approximately 30 minutes.
88869761|NCT05604235|Experimental|Passive mobilization group|A treatment with passive kinesitherapy, where the physiotherapist will perform the movements of flexion, abduction and rotation of the shoulder, without the patient's intervention; active kinesitherapy, where the patient will perform specifically prescribed movements, without weight, to improve the articular and muscular balance of the scapulohumeral complex and neurodynamics, where mobilisations of the accessory spinal nerve will be performed through therapeutic exercise and manual neurodynamic therapy. This treatment will be carried out once a week for two months in 30-minute sessions.
88869762|NCT05603897|Experimental|Mann Assessment of Swallowing Ability (MASA) Group|Participants in this group will receive the MASA dysphagia screening once upon admission to inpatient rehabilitation for approximately 20 minutes.
88869763|NCT05603897|Other|Non-standardized clinical swallow evaluation Group|Participants in this group will receive standard of care treatment (dysphagia screening once upon admission to inpatient rehabilitation using a non-standardized clinical swallow evaluation for approximately 15 minutes).
88869764|NCT05602636|Active Comparator|interscalene analgesia (Group ISBPB)|"All patients will receive a supraclavicular block as their primary anesthetic. Brachial plexus blocks will be performed at the supraclavicular fossa using 20 to 30 mL of 0.5% bupivacaine under ultrasound guidance.~The C5 to C7 or C5 to C8 nerve roots between the anterior scalene and middle scalene muscles will be visualized in the absence of the subclavian artery and 10 mL 0.125% bupivacaine will be injected around the nerve roots of the brachial plexus. The needle trajectory will be adjusted to facilitate the even distribution of the local anesthetic around each nerve root."
88869765|NCT05602636|Active Comparator|The intercostobrachial nerve block ( Group ICBN)|"All patients will receive a supraclavicular block as their primary anesthetic. Brachial plexus blocks will be performed at the supraclavicular fossa using 20 to 30 mL of 0.5% bupivacaine under ultrasound guidance.~The ICBN block will be performed with 10 mL of 0.5% bupivacaine in the plane deep to the pectoralis minor and/or serratus anterior muscle over the second and third intercostal space."
88869766|NCT05602636|Active Comparator|Patient-Controlled Analgesia (Group PCA)|All patients will receive a supraclavicular block as their primary anesthetic. Brachial plexus blocks will be performed at the supraclavicular fossa using 20 to 30 mL of 0.5% bupivacaine under ultrasound guidance.
88869767|NCT05594771|Experimental|epidural needle|the loading dose for labor analgesia administrated via epidural needle before the catheter insertion.
88869768|NCT05594771|Active Comparator|epidural catheter|the loading dose for labor analgesia administrated via the epidural catheter.
88869769|NCT05594095|Experimental|SNF1 1A: PIK3CA mutation|PIK3CA inhibitors +Aromatase inhibitors(Letrozole/Anastrozole/Exemestane, po, qd, specific dose (letrozole 2.5mg/ day; Anastrozole 1mg/ day, Exemestane 25mg/ day);Or fulvestrant, 500mg ,im, qm, followed by 500mg im 2 weeks after the first dose; Premenopausal: Goserelin 3.6mg IM every 4 weeks.
88869770|NCT05594095|Experimental|SNF1 1B: AKT pathway mutation|AKT pathway inhibitors +Aromatase inhibitors(Letrozole/Anastrozole/Exemestane, po, qd, specific dose (letrozole 2.5mg/ day; Anastrozole 1mg/ day, Exemestane 25mg/ day);Or fulvestrant, 500mg ,im, qm, followed by 500mg im 2 weeks after the first dose; Premenopausal: Goserelin 3.6mg IM every 4 weeks.
88869771|NCT05594095|Experimental|SNF1 1C: without above mutation|Everolimus 10mg po qd+Aromatase inhibitors(Letrozole/Anastrozole/Exemestane, po, qd, specific dose (letrozole 2.5mg/ day; Anastrozole 1mg/ day, Exemestane 25mg/ day);Or fulvestrant, 500mg ,im, qm, followed by 500mg im 2 weeks after the first dose; Premenopausal: Goserelin 3.6mg IM every 4 weeks.
89393689|NCT02322814|Experimental|Cohort III: Cobimetinib, Nab-Paclitaxel, Atezolizumab|Participants will receive cobimetinib plus nab-paclitaxel plus atezolizumab until disease progression, unacceptable toxicity, investigator decision, death, withdrawal of consent, or completion of study.
89393690|NCT02234947||New onset of Type 1 Diabetes|The subjects with new onset of Type 1 Diabetes will have pancreatic volume assessment by ultrasonography (US), Magnetic Resonance Imaging (MRI) and biochemical testing. These test will be compared to the testing from the other groups.
89393691|NCT02234947||Antibody Positive Risk for Diabetes|The subjects with single or double antibody positive risk for Type 1 Diabetes will have pancreatic volume assessment by ultrasonography (US), Magnetic Resonance Imaging (MRI) and biochemical testing. These test will be compared to the testing from the other groups.
88869772|NCT05594095|Experimental|SNF2 2: Stratification of CD8 expression|Treatment of physician' choice+Pd-1 mab (Carrelizumab 200mg Q2W)+Famitinib 15mg po qd for 4 weeks as a cycle
88869773|NCT05594095|Experimental|SNF3 3: Stratification of BRCA/PALB2 expression|Fluzoparib SHR3162 100mg po qd+Dalpiciclib 125mg po qd for 4 weeks as a cycle
88869774|NCT05594095|Experimental|SNF4 4A: HER2 low|
89393692|NCT02234947||Antibody Negative Risk for Diabetes|The subjects with antibody negative risk for Type 1 Diabetes will have pancreatic volume assessment by ultrasonography (US), Magnetic Resonance Imaging (MRI) and biochemical testing. These test will be compared to the testing from the other groups.
89393693|NCT02234947||Healthy Control|The subjects has no family history for Type 1 Diabetes. They will have pancreatic volume assessment by ultrasonography (US), Magnetic Resonance Imaging (MRI) and biochemical testing. These test will be compared to the testing from the other groups.
89393694|NCT02170168||Orkdal region patients|cancer patients participating in a integrated palliative care program for diagnostics, treatment, care and follow-up in and between hospital care and 13 municipalities
89393695|NCT02170168||Romsdal county patients|control palliative care cancer patients in standard care, i.e. a local hospital in the county of Møre and Romsdal, Molde Hospital, and nine districts
89393696|NCT02170168||Orkdal region carers|carers of cancer patients participating in a integrated palliative care program for diagnostics, treatment, care and follow-up in and between hospital care and 13 municipalities
89393697|NCT02170168||Romsdal county carers|carers of cancer patients receiving standard care, i.e. in a local hospital in the county of Møre and Romsdal, Molde Hospital, and community care in nine districts
89393698|NCT02170168||Orkdal region health care providers|Health care providers for cancer patients participating in a integrated palliative care program for diagnostics, treatment, care and follow-up in and between hospital care and 13 municipalities
89393699|NCT02170168||Romsdal county health care providers|Health care providers for cancer patients receiving standard care, i.e. in a local hospital in the county of Møre and Romsdal, Molde Hospital, and community care in nine districts
89393700|NCT01922791|Active Comparator|Probiotic|Comparison of probiotics, fish oil and their combination to placebo
89393701|NCT01922791|Active Comparator|Fish oil|Comparison of probiotics, fish oil and their combination to placebo
88869775|NCT05594095|Experimental|SNF4 4A: HER2 zero|
88869776|NCT05594095|Active Comparator|The control arm|Treatment of Physicians' Choice (albumin-paclitaxel, capecitabine, vinorelbine, and irbribulin)
88869777|NCT05586490|Experimental|In-lab and in home feasibility testing of research device in people with Parkinson's disease (PwP)|Multifunctional rehabilitation device for PwP for human user acceptance testing for 2 lab sessions (aim 1) and 5 lab sessions (aim 2). This arm will use the experimental device in home feasibility testing (aim 3). This arm will be asked to participate in the open label extension.
88869778|NCT05586490|Active Comparator|In-home feasibility testing (alternate device)|"Multifunctional rehabilitation device for PwP for human user acceptance testing for 2 lab sessions (aim 1) and 5 lab sessions (aim 2).~This arm will use another device to compare to the experimental device for in home feasibility of using the device at home (aim 3). This arm will be asked to participate in the open label extension."
88869779|NCT05586490|Other|In-home feasibility testing (no device in at home portion)|Multifunctional rehabilitation device for PwP for human user acceptance testing for 2 lab sessions (aim 1) and 5 lab sessions (aim 2). For the at home portion, this arm will not use any device but have the same outcomes measured. (aim 3)
88869780|NCT05583773|Active Comparator|ShengXian-QuYu Decoction|"Patients will be randomized 1:1 to either ShengXian-QuYu Decoction or placebo. ShengXian-QuYu Decoction (calculated by a medicine): 30g of Astragalus membranaceus (Huangqi), 12g of Cornus officinalis (Shanzhuyu), 9g of Talinum paniculatum (Jacq.) Gaertn. (Hongshen), 12g of Rhizoma Anemarrhena (Zhimu), 8g of Rhizoma Cimicifugae (Shengma), 8g of Radix Bupleuri (Chaihu), 10g of Platycodon grandiflorum (Jiegeng), 10g of Rhizoma Sparganii (Sanleng), 9g of Rhizoma Curcumae (Ezhu), 3g of Whitmania pigra Whitman (Shuizhi)."
88869781|NCT05583773|Placebo Comparator|placebo|Placebo matching ShengXian-QuYu Decoction
88869782|NCT05583552|Experimental|Single-arm imetelstat|
88869783|NCT05582616|Experimental|Active tDCS with physiotherapy|Patients will engage in a six-week treatment protocol with 3 sessions per week (18 treatments). This was chosen to minimize discomfort and ensure the number of sessions is consistent with previous migraine literature. The primary motor cortex (M1) will be the treatment target to reduce pain sensitivity and improve motor learning. M1 will be found through measurements of the head: the point halfway between the nasion and inion and halfway between the left and right tragus will be found, we will then move down 20% of the inter-tragi distance and place the anode there. The cathode will then be placed over the super orbital region. Each electrode will be held in place with a strap and will make as much contact with the skin as possible. tDCS will be delivered via two 35cm2 surface sponge electrodes at an intensity of 2mA in the active group.
89393702|NCT01922791|Active Comparator|Probiotics and Fish oil|Comparison of probiotics, fish oil and their combination to placebo
89393703|NCT01922791|Placebo Comparator|Placebo|Comparison of probiotics, fish oil and their combination to placebo
89393704|NCT01904188||SIRS positive|Adult (> or = 18 years) patients with 3 of 4 systemic inflammatory response syndrome (SIRS) characteristics (1. tachycardia, 2. fever or hypothermia, 3. tachypnea, 4. leukocytosis), who have blood cultures drawn and urine collected for the evaluation of suspected sepsis, along with any other bodily fluid suspected to be the source of infection. May also include others without SIRS criteria but with bodily fluid production or infection of a bodily fluid
89393705|NCT01837862|Experimental|Low-grade Glioma|Patients on the low-grade arm will receive treatment with seven 10-week cycles of carboplatin, vincristine, temozolomide, and mebendazole.
89393706|NCT01837862|Experimental|High-grade Glioma/Pontine Glioma|"Patients on the high-grade glioma/pontine glioma arm will receive treatment with twelve 28-day cycles of bevacizumab, irinotecan, and mebendazole.~*High grade arm enrollment complete, no additional spots"
89393707|NCT01675219|Experimental|Group B|Blue light TUR-BT with no adjuvant instillations
89393708|NCT01675219|Active Comparator|Group A|White light TUR-BT with no adjuvant instillations
89393709|NCT01675219|Experimental|Group C|White light TUR-BT with six weekly optimized mitomycin-C instillations.
89393710|NCT01675219|Experimental|Group D|Blue light (PDD) TUR-BT with six weekly optimized mitomycin-C instillations.
89393711|NCT01333033|Experimental|Arm I (FOLFOX regimen)|Patients receive modified FOLFOX-6 therapy comprising oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1 and fluorouracil IV continuously on days 1-5. Treatment repeats every 14 days for 3 courses. Patients then undergo PET/CT scan. Patients with responsive disease (tumor metabolic activity decreased by >= 35%) receive 3 additional courses of FOLFOX-6 therapy and undergo concurrent RT (3D-conformal or intensity-modulated) once daily, 5 days a week, for approximately 6 weeks. Patients without responsive disease (tumor metabolic activity did not decrease by 35%) cross over to Arm II during RT.
89393712|NCT01333033|Experimental|Arm II (carboplatin + paclitaxel + radiation)|Patients receive carboplatin IV over 30 minutes and paclitaxel IV over 1 hour on days 1 and 8. Treatment repeats every 21 days for 2 courses. Patients then undergo PET/CT scan. Patients with responsive disease (tumor metabolic activity decreases >= 35%) continue to receive carboplatin IV over 30 minutes and paclitaxel IV over 1 hour once weekly for 5 weeks and undergo RT (3D-conformal or intensity-modulated) once a day, 5 days a week, for approximately 6 weeks. Patients without responsive disease (metabolic activity did not decrease by 35%) cross over to Arm I during RT
89187131|NCT02583542|Experimental|Dose Expansion Phase (Phase IIa)|"Following the definition of the recommended Phase 2 Dose (RP2D), three NSCLC and one TNBC dose expansion cohorts are planned to perform a preliminary assessment of the anti-tumour efficacy in different molecular settings and to further establish the safety profile of the selected RP2D. These cohorts are:~Triple-negative breast cancer (TNBC)~Squamous cell lung cancers~Non-squamous cell lung cancers with KRAS mutations~Non-squamous cell lung cancers with wild-type KRAS"
89393713|NCT01327690|No Intervention|Wait List|Wait Period corresponding in length to treatment period
89393714|NCT01327690|Experimental|EFT (Emotional Freedom Techniques)|EFT group therapy sessions.
89393715|NCT01327690|Active Comparator|CBT (Cognitive Behavior Therapy)|CBT group therapy sessions
89393716|NCT01192776|Active Comparator|33.5°C for 72 hours|Target Temp: 33.5°C Duration: 72 hrs
89393717|NCT01192776|Experimental|33.5°C for 120 hours|Target Temp: 33.5°C Duration: 120 hrs
89393718|NCT01192776|Experimental|32.0°C for 72 hours|Target Temp: 32.0°C Duration: 72 hrs
89393719|NCT01192776|Experimental|32.0°C for 120 hours|Target Temp: 32.0°C Duration:120 hrs
89393720|NCT01169831|Experimental|Sedentary Older Adults|
89393721|NCT01169831|Experimental|Older Endurance Athletes|
89393722|NCT00904241||Ancillary-Correlative (cytology specimen collection)|Patients undergo collection of blood, tissue, and bone marrow samples for analysis via RT-PCR, quantitative PCR, flow cytometry, and FISH.
89393723|NCT00807482||1|People who have been definitively diagnosed with primary ciliary dyskinesia (PCD).
88869784|NCT05582616|Sham Comparator|Sham tDCS with physiotherapy|In the sham condition, the number of sessions, placement of electrodes, and types of electrodes used will be the same, however, only a 30 second ramp up period will be administered to emulate active tDCS therapy. Patients will be able to hear the sounds of the device and will feel slight tingling for the first 30 seconds but will receive no active stimulation. Previous sham studies have demonstrated efficacy of the blinding method.
88869785|NCT05580263|Experimental|aerobic exercise(AE) preceding resistance exercise(RE)|at least moderate intensity of AE 30 minutes than RE 15 minutes, with a break of 5 minutes between two modalities of training.
88869786|NCT05580263|Experimental|RE preceding AE|RE 15 minutes than at least moderate intensity of AE 30 minutes, with a break of 5 minutes between two modalities of training.
88869787|NCT05580263|No Intervention|Control group|Participants maintain their usual life without any exercise intervention.
88869788|NCT05572138||Critically ill patients|
88869789|NCT05557981|Experimental|Trainees - treatment|"Residents and fellows paired with a faculty coach from the faculty - treatment arm to participate in up to 4 coaching meetings"
88869790|NCT05557981|No Intervention|Trainees - control|Residents and fellows randomized to the control arm. They are not paired with a faculty coach and instead continue to receive standard mentorship as part of their training program.
88869791|NCT05557981|Experimental|Faculty - treatment|"Faculty members randomized to receive coaching training and are paired with a resident/fellow from the trainees - treatment arm to conduct up to 4 coaching sessions over the course of the academic year."
88869792|NCT05557981|No Intervention|Faculty - control|Faculty members randomized to control arm. They are not paired with a trainee from this study and instead continue to provide mentorship as they typically would, as part of their role at an academic medical center
88869793|NCT05550298||Hematopoietic Cell Transplantation (HCT)|Early and accurate diagnosis of respiratory viral infections (RVIs) in children and adolescents who have undergone HCT is important for improving outcomes. The investigators are doing this study to understand more about how RVIs affect children who receive a transplant.
88869794|NCT05550298||Solid Organ Transplant (SOT)|Early and accurate diagnosis of respiratory viral infections (RVIs) in children and adolescents who have undergone SOT is important for improving outcomes. The investigators are doing this study to understand more about how RVIs affect children who receive a transplant.
88869795|NCT05545020|Active Comparator|Trivalent chromium|A dietary supplement already available in market one of its known uses is to control diabetes.
88869796|NCT05545020|Active Comparator|Immunesuppressants|Synthetic and/ or biological DMARDs
89393724|NCT00778063|Placebo Comparator|saline|intranasal saline will be given 30 minutes prior to surgery
89393725|NCT00778063|Experimental|dexmedetomidine|2 mcg/kg dexmedetomidine will be given intranasally 30 minutes prior to surgery
89393726|NCT00737399|Experimental|1|Lifestyle Counseling with Emotional Freedom Techniques (EFT)
89393727|NCT00547196|Experimental|Regimen I (FTBI, Cyclophosphamide, Fludarabine)|Patients undergo FTBI 2-3 times a day on days -9 to -6 for a total of 11 fractions. Patients also receive cyclophosphamide IV over 2 hours on days -5 and -4 and fludarabine phosphate IV on days -5 to -2. UCB transplantation: Patients receive 2 combined units of UCB IV on day 0. Patients also receive G-CSF IV or subcutaneously beginning on day 5 (or later) and continuing until blood counts recover. GVHD prophylaxis: Patients receive cyclosporine IV twice daily beginning on day -1 followed by a taper according to institutional guidelines. Patients also receive mycophenolate mofetil orally or IV beginning on day 0 and continuing until day 27 (or as clinically indicated).
89393728|NCT00547196|Experimental|Regimen II (Busulfan, Fludarabine, Melphalan)|Patients receive a test dose of busulfan on day -10 and then dose adjusted busulfan IV 3-4 times daily on days -9 to -6, melphalan IV on days -5 and -4, and fludarabine phosphate IV on days -5 to -2. UCB transplantation: Patients receive 2 combined units of UCB IV on day 0. Patients also receive G-CSF IV or subcutaneously beginning on day 5 (or later) and continuing until blood counts recover. GVHD prophylaxis: Patients receive cyclosporine IV twice daily beginning on day -1 followed by a taper according to institutional guidelines. Patients also receive mycophenolate mofetil orally or IV beginning on day 0 and continuing until day 27 (or as clinically indicated).
89393729|NCT00547196|Experimental|Regimen III (TBI, Cyclophosphamide, Fludarabine)|Patients receive fludarabine phosphate IV on days -8 to -4 and cyclophosphamide IV over 2 hours on day -3 and undergo TBI (single dose) on day -2. UCB transplantation: Patients receive 2 combined units of UCB IV on day 0. Patients also receive G-CSF IV or subcutaneously beginning on day 5 (or later) and continuing until blood counts recover. GVHD prophylaxis: Patients receive cyclosporine IV twice daily beginning on day -1 followed by a taper according to institutional guidelines. Patients also receive mycophenolate mofetil orally or IV beginning on day 0 and continuing until day 27 (or as clinically indicated).
89393730|NCT00547196|Experimental|Regimen IV (Fludarabine, Melphalan)|Patients receive fludarabine phosphate IV on days -7 to -3 and melphalan IV on day -2. UCB transplantation: Patients receive 2 combined units of UCB IV on day 0. Patients also receive G-CSF IV or subcutaneously beginning on day 5 (or later) and continuing until blood counts recover. GVHD prophylaxis: Patients receive cyclosporine IV twice daily beginning on day -1 followed by a taper according to institutional guidelines. Patients also receive mycophenolate mofetil orally or IV beginning on day 0 and continuing until day 27 (or as clinically indicated).
89393731|NCT02135978|Experimental|One-to-one training group for shoulder home exercise program|Patients will attend two sessions of one-to-one training with a physical therapist to learn the shoulder home exercise program. The sessions are 4 weeks apart. They will also review a handout on techniques to protect their shoulder during wheelchair propulsion and transfers.
89393732|NCT02135978|Active Comparator|Enhanced training group for shoulder home exercise program|Patients will attend four classes held each week for 4 consecutive weeks. The classes are led by a physical therapist and a peer mentor (with a spinal cord injury). Two to four research patients are in each class. Classes begin with an interactive education presentation on techniques and recommendations to protect the shoulder during transfers, wheelchair propulsion, raises and activities of daily living. This is followed by performance of the home exercise program. Patients will be called every 3 to 6 months by a peer mentor to receive encouragement, praise, and/or problem solve barriers to exercise.
89393733|NCT02135978|No Intervention|Historical control group|Historical control group has received no intervention. Eligibility criteria, outcome measures and study duration for historical control group is matched for the experimental group and active comparator.
89393734|NCT03603054|Active Comparator|Active neck mobilization|The subjects, who were randomly allocated to group active neurodynamic mobilization group, will receive the active sciatic nerve mobilization intervention. The subject will be instructed to do a a modification of the slump. The procedure will be performed 1 minute with each leg, two times, the subjects will rest one minute between each mobilization and between series.
89393735|NCT03603054|Experimental|Active Mobilization of the Sciatic nerve|The subjects, who were randomly allocated to group active neurodynamic mobilization group, will receive the active sciatic nerve mobilization intervention. The subject will be instructed to do a a modification of the slump. The procedure will be performed 1 minute with each leg, two times, the subjects will rest one minute between each mobilization and between series.
89393736|NCT05759923|Experimental|OATD-02|
89393737|NCT02136056|Experimental|Self-management program (SMP)|Participants in the experimental group receive six weekly group-sessions of self-management and patient education; specifically targeting self-management of the return to work process and disease symptoms.
89393738|NCT02136056|No Intervention|Treatment as usual|Participants in the control-group receive standard rehabilitation care and follow-up in the job-center.
89393739|NCT03149107|Experimental|IPPI + NAC|"IPPI (Integrated Preventive Psychological Intervention): 21 sessions, the first 20 sessions are scheduled weekly, the last session two weeks after session 20. Single blinded (statistician & rater).~N-Acetylcysteine (2000 mg/d, 1000 mg in the morning/evening, oral intake). Will be applied continously over 26 weeks parallel to the psychological intervention. Double-blinded."
88869797|NCT05544188|Experimental|individual outpatient physiotherapy|individual outpatient physiotherapy (7 times in two and a half months, approx. 90 minutes) aimed at correcting functional pathologies of the musculoskeletal system assessed by differential diagnosis (removal of trigger points, stretching of shortened muscles and mobilization of joint blockages) and changing of motor program that led to the occurrence of the functional disorder by means of Motor Programmes Activating Therapy
88869798|NCT05544188|Active Comparator|Without changing the current habits|It will not change the existing habits. At the same time, however, these are physiotherapy students who will participate in the classes. Their motor behaviour can thus be influenced in a natural way.
88869799|NCT05543785|Placebo Comparator|control|"will receive 50 ml normal saline in the intravenous regional cannula in the surgical limb with torniquet.~And receive intravenous 30 mg ketorolac diluted in 10 ml saline in the peripheral general circulation."
88869800|NCT05543785|Active Comparator|ketorolac|"will receive 15 mg ketorolac tromethamine diluted in normal saline in a total volume of 50 ml in the intravenous regional cannula in the surgical limb with torniquet.~And receive intravenous 10 ml saline in the peripheral general circulation."
88869801|NCT05541718|Experimental|Reiki|
89187132|NCT02557971||BOTOX®|Patients with idiopathic overactive bladder (OAB) treated with onabotulinumtoxinA (BOTOX®) injections into the bladder as standard of care in clinical practice. No intervention was administered in this study.
88869802|NCT05541718|Sham Comparator|Sham Reiki|
88869803|NCT05541718|Active Comparator|Mindfulness Meditation|
88869804|NCT05541718|No Intervention|Waitlist Control|
89187133|NCT02583776|Experimental|Unblinded CGM|"CGM data will be unblinded, with Hypo/hyperglycemia alarms on. Data will be recorded from CGM every three hours and intervention to adequate glucose intake will be performed to keep glycemia in normal range (72-144mg/dl) if necessary."
89187134|NCT02583776|Other|Blinded CGM|Hypo/hyper alarms are off. CGM data will be blinded. Glucose intake will be adequate according to 2-3 capillary glycemic tests per day.
89393740|NCT03149107|Experimental|PSM + NAC|"PSM (Psychological stress management): 11 sessions; the first 10 sessions will be offered biweekly, the last one 2 weeks after session 10. Single blinded (statistician & rater).~N-Acetylcysteine (2000 mg/d, 1000 mg in the morning/evening, oral intake). Will be applied continously over 26 weeks parallel to the psychological intervention. Double-blinded."
89393741|NCT03149107|Experimental|IPPI + Placebo|"IPPI (Integrated Preventive Psychological Intervention): 21 sessions, the first 20 sessions are scheduled weekly, the last session two weeks after session 20. Single blinded (statistician & rater).~Placebo will be applied continously over 26 weeks (oral intake of capsules) parallel to the psychological intervention (IPPI or PSM)."
89393742|NCT03149107|Active Comparator|PSM + Placebo|"PSM (Psychological stress management): 11 sessions; the first 10 sessions will be offered biweekly, the last one 2 weeks after session 10. Single blinded (statistician & rater).~N-Acetylcysteine (2000 mg/d, 1000 mg in the morning/evening, oral intake). Placebo will be applied continously over 26 weeks (oral intake of capsules) parallel to the psychological intervention (IPPI or PSM)."
89393743|NCT03606564||paediatric patients undergoing day care surgery|
89393744|NCT03550976|Experimental|High risk intervention group|
89393745|NCT03550976|No Intervention|High risk control group|Dietary evaluation and body composition analysis at 12 and 28 weeks of pregnancy. Receive routine obstetric examinations and routine health education which includes proper diet and exercise advice.Collect birth outcomes.
89393746|NCT03550976|No Intervention|Low risk control group|Dietary evaluation and body composition analysis at 12 and 28 weeks of pregnancy. Receive routine obstetric examinations and routine health education which includes proper diet and exercise advice.Collect birth outcomes.
89393747|NCT03135301|Experimental|letrozole plus metformin|5 mg of letrozole will be administered only for 5 days from day 3 each month of spontaneous or induced bleeding plus metformin will be started from the first day with a dose of 850 mg (1 tablet daily) and the dosage will be increased after 1 week up to 1,700 mg/day (2 tablets daily) and will be continued
89393748|NCT03135301|Active Comparator|letrozole|5 mg of letrozole will be administered only for 5 days from day 3 each month of spontaneous or induced bleeding
89393749|NCT03550274|Experimental|App-based exercise rehabilitation|Persons with Acute lateral ankle sprain (<48 hours) evaluated by a relevant health specialist in the hospital Emergency Department.
89393750|NCT03602898|Experimental|Arm 1 (ATG, tacrolimus or cyclosporine, methotrexate)|Participants receive conditioning regimen (see detailed description) and then undergo peripheral blood stem cell transplantation on day 0. Participants receive anti-thymocyte globulin IV over 4-6 hours on days -3 to -1. Beginning day -1, participants also receive tacrolimus IV or cyclosporine IV BID tapered at day 50, and methotrexate IV on days 1, 3, 6 and 11 in the absence of disease progression or unacceptable toxicity.
89393751|NCT03602898|Experimental|Arm 2 (cyclophosphamide, tacrolimus or cyclosporine)|Participants receive conditioning regimen (see detailed description) and then undergo peripheral blood stem cell transplantation on day 0. Participants receive cyclophosphamide IV over 1-2 hours on days 3 and 4. Beginning day 5, participants also receive tacrolimus IV or cyclosporine IV BID tapered at day 50 in the absence of disease progression or unacceptable toxicity.
89393752|NCT03602898|Experimental|Arm 3 (tacrolimus or cyclosporine, methotrexate)|Participants receive conditioning regimen (see detailed description) and then undergo peripheral blood stem cell transplantation on day 0. Beginning day -1, participants receive tacrolimus IV or cyclosporine IV BID tapered at day 50, and methotrexate IV on days 1, 3, 6 and 11.
89393753|NCT02983747|Experimental|PRP Treatment(P)|PRP intra-disk injection therapy combined with NSAIDs medication (Loxoprofen Sodium tablets).
89393754|NCT02983747|Active Comparator|Medication Treatment(M)|NSAIDs medication(Loxoprofen Sodium tablets) therapy only.
89393755|NCT02128412|Active Comparator|Stent oversize group|"Oversized stent deployed at low pressure:~A stent premounted on a balloon with a nominal diameter halfway between the lumen diameter and the true vessel diameter (approximated by external elastic lamina) as assessed by IVUS. This will be based on the smallest of the vessel reference diameters proximal and distal to the lesion. In addition the vessel diameter must be greater than this diameter throughout the length of the lesion. This stent will be implanted at an inflation pressure of 10 atmospheres or less for at least 15 seconds and a second IVUS will be performed to assess the end point."
89393756|NCT02128412|Active Comparator|High pressure group|"Stent deployed at high pressure:~A stent premounted on a balloon with a nominal diameter approximately equal to the vessel segment lumen reference diameter as previously assessed by IVUS will be used. This stent will be implanted at an inflation pressure of 14 atmospheres or more for at least 15 seconds and a second IVUS will be performed to assess the end point"
89393757|NCT05759845|Active Comparator|topiramate group|50 patients will take topiramate
88869805|NCT05536856|Experimental|Control group|30 patients will apply the 5-Fluorouracil plain powder on the selected patch followed by 3 milliliters of water till complete dissolution of the powder.
88869806|NCT05536856|Experimental|Study group|30 patients will apply a new effervescent mixture formula of 5-Fluorouracil prepared at faculty of pharmacy (Girls) - Al-Azhar university
88869807|NCT05525013|Experimental|Simvastatin|Simvastatin as an intracanal medication
88869808|NCT05525013|Active Comparator|Calcium hydroxide|Calcium hydroxide intracanal medication
88869809|NCT05512754|Experimental|Ibuprofen|Participants receive Ibuprofen 400 mg tablet orally every 8 hours for 10 days
88869810|NCT05512754|No Intervention|Control|Participants receive no NSAIDs
88869811|NCT05510271|Experimental|White Noise|
88869812|NCT05510271|Experimental|Yakson touch|
88869813|NCT05510271|No Intervention|Control|
88869814|NCT05501600|Experimental|Lidocaine|Subjects will receive lidocaine during the drug portion of the experiment.
88869815|NCT05498103|Active Comparator|Methazolamide 25 mg|Once a day [q.d] in the morning for 1 week, Twice a day [b.i.d.] in the morning and evening for 1 week
89187135|NCT04048785|No Intervention|control|Infant sleep monitoring (Actigraphy and sleep dairy) and parental surveys
89393758|NCT05759845|Active Comparator|amitriptyline group|50 patients will take amitriptyline
89393759|NCT05759845|Active Comparator|combination group|50 patients will take topiramate plus amitriptyline
89393760|NCT02136212|Experimental|Approach-positive AAT|Participants will receive 4 sessions over 2 weeks of a computerized AAT procedure designed to increase automatic approach responses for positive social cues.
89393761|NCT02136212|Placebo Comparator|Control AAT|Participants will receive 4 sessions over 2 weeks of a computerized AAT procedure in which there is no contingency between arm movement and positive social cues.
89393762|NCT02136290|Other|Usual Care|Weight loss counseling
89393763|NCT02136290|Experimental|Prepackaged meal|Prepackaged meals
89393764|NCT01375855|Active Comparator|Polimeric-PES|Arm receiving polimeric stent (Taxus)
89393765|NCT01375855|Active Comparator|Non-Polimeric PES|Arm receiving non-polimeric PES (axxion)
89393766|NCT00799110|Experimental|Group 2|Vaccine, GM-CSF and imiquimod,
89393767|NCT00799110|Experimental|Group 1|Vaccination plus GM-CSF
89393768|NCT05199727|Experimental|Shockwave group|This group will receive 6 sessions (2 per week) with average 6,000 shocks per session with the PiezoWave2 unit
89393769|NCT05199727|Active Comparator|Medical Treatment Group|This group will receive self-administered Tadalafil on-demand
89393770|NCT03600402|Experimental|Experimental Group|
89393771|NCT03600402|Other|Control Group|
89393772|NCT02132234|Experimental|Biological treatment|"Patients with high disease activity receiving biological treatment according to rheumatologic indication:~etanercept 50 mg s.c. every week~adalimumab 40 mg s.c. every 2 weeks~certolizumab 400 mg s.c. every 2 weeks for 4 weeks, then 200mg every 2 weeks~infliximab 3 or 5 mg/kg i.v. 2 and 6 weeks from the first admission, then every 8 weeks"
89393773|NCT02132234|Placebo Comparator|control group|Patients with high disease activity receiving other than biological treatment and receiving placebo.
89393774|NCT05415241|Experimental|FB2001Exploratory|"Stage 1 (Exploring the dose): FB2001 once daily for 5 consecutive days. If the drug is well tolerated but efficacy is inadequate, FB2001 BID for 5 consecutive days.~Stage 2 (Sample size expansion): FB2001 once daily or twice daily for 5 consecutive days depending on the result of stage 1."
89393775|NCT03602742|Other|24-hour Holter and 14-day EZYPRO®|This is an open-label study to investigate the functional features of prolonged monitoring by 14-day EZYPRO® to improve the medical care and/or diagnosis for the patient with arrhythmia. One arm included.
89393776|NCT02136368|Experimental|Multi-Modal, Mind Motor Exercise (M4)|Attend 60 minute exercise class three times per week for 24 weeks. Exercise class includes 45 minutes of multi-modal exercise and 15 minutes of mind-motor exercise.
89393777|NCT02136368|Active Comparator|Multi-Modal Exercise (M2)|Attend 60 minute exercise class three times per week for 24 weeks. Exercise class includes 45 minutes of multi-modal exercise and 15 minutes of balance and range of motion exercises.
89393778|NCT05199649|Experimental|Arm Sintilimab|Sintilimab Combined With Chemotherapy
88869816|NCT05498103|Active Comparator|Methazolamide 50 mg|Once a day [q.d] in the morning for 1 week, Twice a day [b.i.d.] in the morning and evening for 1 week
88869817|NCT05495399|Experimental|Spondylectomy with Conventional RT|Spondylectomy for involved spine level followed by conventional RT 20Gy in 5 fractions
89393779|NCT05373576|Experimental|TACHIDINO|
88869818|NCT05495399|Active Comparator|Debulking surgery with Conventional RT|Debulking surgery for involved spine level followed by conventional RT 20Gy in 5 fractions
88869819|NCT05495399|Experimental|Debulking surgery with SBRT|Debulking surgery for involved spine level followed by SBRT 24Gy in 12 fractions
88869820|NCT05492266|Experimental|Expiratory Muscle Strength Training + No Maintenance Training|These participants were initially randomized to complete 6-8 weeks of exercises with EMST-150. They had improvement in their speech score of 2 points or more and were randomized to complete 6 months of no maintenance training.
89393780|NCT05373576|No Intervention|WAITING LIST|
89393781|NCT02128568|Active Comparator|Waitlist + YRI only|Participants will complete the assessment and collection of biomarkers and be placed on a waitlist. Once the trial of the first arm has been concluded, participants complete another round of assessments and are offered the YRI sessions. The epigenetic biomarkers collected will be compared with the experimental arm.
89393782|NCT02128568|Experimental|YRI only|Immediately following assessment and collection of biomarkers, participants will be offered the YRI sessions.
89393783|NCT05199181|Experimental|Full pulpotomy|All patients were treated in one visit (with Full Pulpotomy); the previously trained General Practice Dentist performed all the clinical procedures
89393784|NCT02132390|Experimental|Arm I|Patients who didn't have CIA receive oral toremifene daily. Treatment continues for 5 years in the absence of disease progression or unacceptable toxicity
89393785|NCT02132390|Experimental|Arm II|Patients who had CIA receive toremifene as in arm I
89393786|NCT02132390|Experimental|Arm III|Patients without CIA receive oral toremifene and goserelin for ovarian function suppression
89393787|NCT02132390|Experimental|Arm IV|Patients with CIA receive oral toremifene and goserelin for ovarian function suppression.
89393788|NCT02128646|Experimental|Treatment Group 1|Treatment Group patients will receive an opioid-sparing, multimodal, postsurgical pain regimen consisting of intraoperative local wound infiltration with 266 mg EXPAREL followed by, when not contraindicated, administration of a 30 mg dose of IV ketorolac at the end of surgery. Patients scheduled in Treatment Group 1 will have an open surgery for abdominal hernia repair.
89393789|NCT02128646|Experimental|Treatment Group 2|Treatment Group patients will receive an opioid-sparing, multimodal, postsurgical pain regimen consisting of intraoperative local wound infiltration with 266 mg EXPAREL followed by, when not contraindicated, administration of a 30 mg dose of IV ketorolac at the end of surgery. Patients scheduled in Treatment Group 2 will have a laparoscopic abdominal hernia repair.
89393790|NCT02128646|Active Comparator|Control Group 1|Patients scheduled in Control Group 1 will have an open surgery for abdominal hernia repair. The Control Group patients will receive traditional treatment.
89393791|NCT02128646|Active Comparator|Control Group 2|Patients scheduled in Control Group 2 will have laparoscopic abdominal hernia repair. The Control Group patients will receive traditional treatment.
89393792|NCT02136446|Experimental|EchoGlo™ Peripheral Nerve Block Catheter|Echogenic nerve block catheter (test)
89393793|NCT02136446|Active Comparator|Pajunk® EpiLong Catheter|Non-echogenic nerve block catheter (control)
88869821|NCT05492266|No Intervention|No Exercises|These participants were initially randomized to 6-8 weeks of no exercises. They ended active study participation after the initial 6-8 weeks of no exercises. They were not eligible to be randomized to maintenance training or no maintenance training.
88869822|NCT05492266|Experimental|Expiratory Muscle Strength Training + Maintenance Training|These participants were initially randomized to complete 6-8 weeks of exercises with EMST-150. They had improvement in their speech score of 2 points or more and were randomized to complete 6 months of maintenance training.
88869823|NCT05492266|Experimental|Expiratory Muscle Strength Training|These participants were initially randomized to complete 6-8 weeks of exercises with EMST-150. They did not have improvement in their speech score of 2 points or more and ended active study participation after the initial 6-8 weeks of exercises.
88869824|NCT05491317|Experimental|Radiotherapy + GEN1042|
88869825|NCT05491317|Experimental|Radiotherapy + GEN1042 + Pembrolizumab|
88869826|NCT05490992|No Intervention|Car seat check-up traditional car seat educational method|Experiment-1a: This included 600 expectant parents who were educated by a certified child passenger safety technician with a traditional car seat educational approach. All participants were assessed at baseline, no-intervention traditional education, and follow-up, between June 1, 2015 and May 30, 2016
88869827|NCT05490992|Experimental|Behavioral Skills Training In-person Group A|Experiment-1b: This included another 600 expectant parents who were educated by a certified child passenger safety technician an in-person Behavioral Skills Training (BST) approach. All participants were assessed at baseline, BST, and follow-up, between June 1, 2016 and May 30, 2017.
88869828|NCT05490992|Experimental|Behavioral Skills Training In-person Group B|Experiment-2a: This included another 600 expectant parents who were educated by a certified child passenger safety technician an in-person Behavioral Skills Training (BST) approach. All participants were assessed at baseline, BST, and follow-up, between June 1, 2018 and June 30, 2019.
88869829|NCT05490992|Experimental|Behavioral Skills Training Telehealth|Experiment-2b: This included another 600 expectant parents who were educated by a certified child passenger safety technician a virtual telehealth version of Behavioral Skills Training (BST). All participants were assessed at baseline, BST-Telehealth, and follow-up, between April 1, 2020 and December 31, 2021.
88869830|NCT05478746|Other|Routine Care|Participants enrolled in the control arm will undergo routine care for localized provoked vulvodynia according to the doctor's usual recommendations. These may include lidocaine cream, physical therapy, a compounded cream containing a blend of lidocaine, baclofen, amitryptyline, estradiol, testosterone, and bupivacaine, radiofrequency treatment, Naropin or botulinum toxin injections.
88869831|NCT05478746|Experimental|Flourish HEC|"Participants in the Flourish HEC arm will undergo routine care as described for the control arm. Instead of lidocaine cream, they will be given a 4% lidocaine gel (called Relief, to be used up to 4x/day as needed) in an iso-osmotic, pH-balanced gel base. In addition, they will be given 3 products to use as described here, comprising the Flourish HEC kit (HEC = hydroxyethylcellulose, the principal gelling compound in the vaginal gel, to distinguish from the original Flourish kit using aloe).~Balance - external vulvar wash to be used daily in the shower.~BioNourish - vaginal moisturizing gel to be used every day before bed. Iso-osmotic and pH-adjusted with lactic acid to match healthy vaginal fluid.~BiopHresh - vaginal homeopathic suppository with 7 vaginal probiotic strains, including Lactobacillus crispatus, to be used every 3rd day before bed."
88869832|NCT05475236|Sham Comparator|Sham Stimulation|Participants will undergo 30 seconds of 2 mA electrical current to the head through saline soaked electrodes.
88869833|NCT05475236|Experimental|Transcranial Direct Current Simulation|Participants will undergo 20 minutes of 2 mA electrical stimulation to the head through saline soaked electrodes.
89393794|NCT03785665|Experimental|Participants|All study participants will be examined by the MD1 capsules, 2-5 capsules per person, one capsule at a time. Efforts will be made to maintain balanced numbers between men and women and even distribution of ages
89393795|NCT02136524|Experimental|Capsule formulation|
89393796|NCT02136524|Experimental|Tablet formulation|
89393797|NCT05199103|Experimental|Rabbit antithymocyte globulin (rATG)|
89393798|NCT02132546|Experimental|Chlorhexidine 0,2%|After surgery, the patient was given instruction following the post-operative protocol. Oral hygiene with toothbrush and dental floss was suspended only in the area that underwent periodontal surgery and the patient was given an anonymous bottle of mouthwash. According to random assignment (random generator, www.random.org), the bottle contained 0.2% CHX.
89393799|NCT02132546|Experimental|Chlorhexidine 0,2% with ADS|After surgery, the patient was given instruction following the post-operative protocol. Oral hygiene with toothbrush and dental floss was suspended only in the area that underwent periodontal surgery and the patient was given an anonymous bottle of mouthwash. According to random assignment (random generator, www.random.org), the bottle contained 0.2% CHX with ADS.
89393800|NCT02132546|Experimental|Chlorhexidine 0,12%|After surgery, the patient was given instruction following the post-operative protocol. Oral hygiene with toothbrush and dental floss was suspended only in the area that underwent periodontal surgery and the patient was given an anonymous bottle of mouthwash. According to random assignment (random generator, www.random.org), the bottle contained 0.12% CHX.
89393801|NCT05198947|Active Comparator|Group 1 Permethrin only|Standard regimen of permethrin 5% topical application to be repeated after 1 week.
89393802|NCT05198947|Active Comparator|Group 2 Permethrin and Ivermectin|A combination regimen of permethrin 5% topical application with oral ivermectin 200 mcg/kg given on the single day only
89393803|NCT05256212||firefighters|firefighters in active service
89393804|NCT05239520||People affected by FSHD|Participants with a diagnosis of FSHD. 3D movement analysis session including surface electromyography and Ultrasound.
88869834|NCT05473910|Experimental|TSC-100 Treatment Arm|HA-1 positive patients
89393805|NCT05239520||Age matched control group|Participants without a diagnosis of FSHD. 3D movement analysis session including surface electromyography and Ultrasound
88869835|NCT05473910|Experimental|TSC 101 Treatment Arm|HA-1 negative and HA-2 positive patients
88869836|NCT05473910|Active Comparator|Standard of Care or Control arm|
88869837|NCT05472038|Experimental|Cohort 1: BNT162b5 Bivalent (WT/OMI BA.2)|Participants will receive 30 µg of BNT162b5 Bivalent (WT/OMI BA.2) at Visit 1.
88869838|NCT05472038|Experimental|Cohort 1: BNT162b2 Bivalent (WT/OMI BA.1)|Participants will receive 30 µg of BNT162b2 Bivalent (WT/OMI BA.1) at Visit 1.
88869839|NCT05472038|Experimental|Cohort 2 -Group 1: 12-17 years; 30 µg|Participants 12-17 years old will receive 30 µg of BNT162b2 Bivalent (WT/OMI BA.4/BA.5) at Visit 1.
88869840|NCT05472038|Experimental|Cohort 2 - Group 2: 18-55 years; 30 µg|Participants 18-55 years old will receive 30 µg of BNT162b2 Bivalent (WT/OMI BA.4/BA.5) at Visit 1.
88869841|NCT05472038|Experimental|Cohort 2 - Group 3: 18-55 years; 60 µg|Participants 18-55 years old will receive 60 µg of BNT162b2 Bivalent (WT/OMI BA.4/BA.5) at Visit 1.
88869842|NCT05472038|Experimental|Cohort 2 - Group 4: >55 years; 30 µg|Participants over 55 years old will receive 30 µg of BNT162b2 Bivalent (WT/OMI BA.4/BA.5) at Visit 1.
88869843|NCT05472038|Experimental|Cohort 2 - Group 5: >55 years; 60 µg|Participants over 55 years old will receive 60 µg of BNT162b2 Bivalent (WT/OMI BA.4/BA.5) at Visit 1.
88869844|NCT05472038|Experimental|Cohort 3 - Group 1: 18-55 years; 30 µg|Participants will receive BNT162b2 Bivalent (WT/OMI BA.4/BA.5) 30 µg at Visit 1.
88869845|NCT05472038|Experimental|Cohort 3 - Group 2: >55 years; 30 µg|Participants will receive BNT162b2 Bivalent (WT/OMI BA.4/BA.5) 30 µg at Visit 1.
88869846|NCT05472038|Active Comparator|Cohort 4: BNT162b2 Bivalent (Original/OMI BA.4/BA.5)|Participants will receive 30 µg of BNT162b2 Bivalent (Original/OMI BA.4/BA.5) at Visit 1
88869847|NCT05472038|Experimental|Cohort 4: BNT162b5 Bivalent (Original/OMI BA.4/BA.5)|Participants will receive 30 µg of BNT162b5 Bivalent (Original/OMI BA.4/BA.5) at Visit 1
88869848|NCT05472038|Experimental|Cohort 4: BNT162b6 Bivalent (Original/OMI BA.4/BA.5)|Participants will receive 30 µg of BNT162b6 Bivalent (Original/OMI BA.4/BA.5) at Visit 1
88869849|NCT05472038|Experimental|Cohort 4: BNT162b7 Bivalent (Original/OMI BA.4/BA.5)|Participants will receive 30 µg of BNT162b7 Bivalent (Original/OMI BA.4/BA.5) at Visit 1
88869850|NCT05472038|Experimental|Cohort 4: BNT162b7 Monovalent (OMI BA.4/BA.5)|Participants will receive 30 µg of BNT162b7 Monovalent (OMI BA.4/BA.5) at Visit 1
88869851|NCT05471843|Experimental|Single Arm|Participants will receive sonrotoclax
88869852|NCT05470907||EBP|ICU COVID-19 patients treated with hemoperfusion/hemadsorption
88869853|NCT05470907||non-EBP|ICU COVID-19 patients not treated with hemoperfusion/hemadsorption
88869854|NCT05470491|Experimental|1/Recipient Arm 1|RIC+alloHCT+GVHD prophylaxis per dose levels 1, 2, and
88869855|NCT05470491|Experimental|2/Recipient Arm 2|RIC+alloHCT+GVHD prophylaxis per RP2D
88869856|NCT05470491|No Intervention|3/Donor Arm|Collection of research samples on hematopoietic donors
88869857|NCT05465330|Experimental|Desflurane Inhalational group (DR group)|
88869858|NCT05465330|Active Comparator|Desflurane propofol balanced anesthesia group (DPR group)|
88869859|NCT05462821|No Intervention|Observation Group|Participants randomized to observation alone will not be allowed to receive any other treatment for IXT, except refractive correction, for 3 months.
88869860|NCT05462821|Experimental|Full Time Patching|Participants randomized to the full-time patching group will patch full-time (all waking hours) for 3 months up until the day before the 3-month primary outcome visit. Daily alternate patching will be prescribed (right eye on even days, left eye on odd days). No other treatment for IXT will be used, except for refractive correction.
89393806|NCT05198869|Other|Spectral scan (All participants)|"Fitzpatrick skin assessment.~Fingertip scanned using the SpotLight-19 device. The scan is approximately 10-20 seconds. Participants will not feel any sensation from the device, i.e., no heat, no pain, no cold, no vibration or pressure.~Information collected from the medical record regarding participant age, COVID-19 vaccination status, presence of COVID-19 symptoms, and PCR test result."
89393807|NCT01367834|Experimental|Growth Hormone|Subjects in the somatotropin (growth hormone, GH) arm will receive GH injections from 12-24 months of life.
89393808|NCT01367834|No Intervention|Control|Subjects will receive no GH or placebo.
88869861|NCT05460039|No Intervention|Usual activities|This group will receive no intervention.
88869862|NCT05460039|Experimental|DanceMove|This group will perform dance sessions mediated by technology (a dance mat and a web platform).
88869863|NCT05455463|Experimental|Online aphasia-adapted physical activity class|Will receive the physical activity intervention.
88869864|NCT05455463|No Intervention|Usual routine control|Engage in physical activity per usual routine.
88869865|NCT05454579||- 150 HIV-positive participants, both who were diagnosed with HIV infection and new cases.|Newly diagnosed HIV-infected participants will be linked to care to start ART. Known HIV-positive participants will be linked to care if they are not in care already. All HIV-positive participants will undergo viral load and CD4 testing at screening/baseline, and be invited back every 6 months for assessment of adherence, viral load testing, STI testing, FBS and lipid profile. A CD4 count will be repeated at Month 12 and Month 24.
88869866|NCT05454579||- 150 HIV-negative participants who are already receiving PrEP or who will accept PrEP.|HIV-negative participants will be offered PrEP. Those who accept PrEP will enroll in the PrEP program in each country, undergo creatinine testing at screening/baseline and be invited back at Month 1, Month 3, and every three months thereafter for HIV testing and assessment of adherence. STI testing, FBS, creatinine and lipid profile will be repeated every 6 months.
88869867|NCT05454579||- 150 HIV-negative participants who will refuse PrEP.|HIV-negative participants who do not wish to start PrEP will be invited back at every three months for HIV-testing. STI-testing, FBS and lipid profile will be repeated every 6 months.
88869868|NCT05451771|Experimental|Phase 1: Venetoclax 200 mg|Cohort 1: Venetoclax 200 mg tablet, once daily for up to 2 cycles after achieving best response, for a maximum of 6 cycles (1 cycle = 28 days)
88869869|NCT05451771|Experimental|Phase 1: Venetoclax 400mg|Cohort 2: Venetoclax 400 mg tablet, once daily for up to 2 cycles after achieving best response, for a maximum of 6 cycles (1 cycle = 28 days)
88869870|NCT05451771|Experimental|Phase 1: Venetoclax 400mg + Dexamethasone 10 mg|Cohort 3: Venetoclax 400 mg tablet, once daily and Dexamethasone 10 mg tablet once weekly, for up to 2 cycles after achieving best response, for a maximum of 6 cycles (1 cycle = 28 days)
88869871|NCT05451771|Experimental|Phase 1: Venetoclax 400mg + Dexamethasone 20 mg|Cohort 4: Venetoclax 400 mg tablet, once daily and Dexamethasone 20 mg tablet once weekly, for up to 2 cycles after achieving best response, for a maximum of 6 cycles (1 cycle = 28 days)
88869872|NCT05451771|Experimental|Phase 2: Venetoclax MTD with Dexamethasone|Venetoclax MTD (200 mg or 400 mg) with Dexamethasone (10 mg or 20 mg) as determined by the phase I results
88869873|NCT05451771|Active Comparator|Phase 2: Control Arm (Investigator's Choice)|"Participants will receive one of the following as determined by the investigator:~Daratumumab, Pomalidomide, Bendamustine, or Ixazomib (+/- dexamethasone)"
88869874|NCT05445466|Active Comparator|Active HD-tDCS|10 tDCS; Two, twenty-minute sessions of tDCS to the OFC for 5 days (10 total sessions).
88869875|NCT05445466|Sham Comparator|Active Control (alpha, 10 Hz)|10 passive sham control; Two, twenty-minute sessions of passive sham control to the OFC for a 30 second ramped up and down at the beginning and end of the 20 min period for 5 days (10 total sessions).
88869876|NCT05445466|Experimental|Personalized Beta-Gamma tACS|10 tACS; Two, twenty-minute sessions of tACS to the OFC for 5 days (10 total sessions).
88869877|NCT05442359|Experimental|Nano-biofusion gel gingival gel (NBF)|Coverage of the free gingival graft area in the palate with stent
88869878|NCT05442359|Active Comparator|stent|Coverage of the free gingival graft area in the palate
88869879|NCT05436600|No Intervention|Control|The control group will undergo standard-of-care vascular risk factor modification. Control participants will be contacted via telephone on a weekly basis to discuss the importance of vascular risk factor management and adherence to prescribed medical management.
88869880|NCT05436600|Experimental|Exercise Intervention|The exercise intervention group will undergo 12 weeks of AeroBal exercise training (approximately 3 times/week). Each exercise session will consist of a 5-minute warm-up walk, approximately 30 minutes of aerobic exercise at a goal of 60-75% HRmax, 15 minutes of balance exercises, and a 5-minute cool-down walk.
88869881|NCT05433636|Experimental|Body Scan Practice|
88869882|NCT05433636|Experimental|Mindful Breathing Practice|
88869883|NCT05433636|Experimental|Mindfulness of Discomfort Practice|
88869884|NCT05433636|Experimental|Mindful Savoring Practice|
88869885|NCT05433636|Active Comparator|Integrative Health Recording|
88869886|NCT05425459|Experimental|Treatment|Participants randomized to the treatment arm will undergo a fluoroscopic and intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE) guided trans-septal puncture and InterAtrial Shunt Device (IASD) System II implant procedure.
88869887|NCT05425459|Sham Comparator|Control|Participants randomized to the control arm will undergo fluoroscopy and intracardiac echocardiography from the femoral vein or transesophageal echocardiography, for examination of the atrial septum and left atrial appendage.
88869888|NCT05415982|Experimental|Ketogenic Diet|Ketogenic Diet every day for 4 weeks
88869889|NCT05414851|Experimental|Whole-Food, Plant-Based Start|This group starts with the whole-food, plant-based diet, then gets the low-carbohydrate diet after the washout period.
88869890|NCT05414851|Experimental|Low-Carbohydrate Start|This group starts with the low-carbohydrate diet, then gets the whole-food, plant-based diet after the washout period.
88869891|NCT05411302|Experimental|Text4Support Arm|Patients in the intervention (Text4Support) arm of the study will receive the usual care (i.e. community care, follow-up appointments), plus daily automated supportive text messages from an online application.
88869892|NCT05411302|No Intervention|Care as usual arm|Patients in the control arm of the study will receive the usual care, which includes the freely accessible Health Authority approved low-intensity e-mental health services. They will receive a single text message informing and encouraging them to utilize current MHAP resources on the NS Health website. They will not receive automated daily supportive text messages.
88869893|NCT05400265|Experimental|Dose Cohort 1|In this cohort, the dose of HLX26 is 500mg. HLX26 will be intravenously administered every 3 weeks. HLX10 will be intravenously administered every 3 weeks with the fixed dose of 300mg. Patients will receive the treatment until they have been in therapy for 2 years, develop progressive disease (PD) without any clinical benefit, death, intolerable toxicity, or withdraw the informed consent (whichever occurs first).
89003698|NCT04754165|Experimental|Immersive Virtual Reality plus the enhanced recovery after surgery protocol|"Patients in the immersive VR group will don a VR headset connected to a software platform on a tablet, as well as noise cancelling headphones in the post anesthesia care unit (PACU) after surgery. Patients can choose their desired experience within the VR software from a selection of immersive environments and/or video content. Examples include sitting in a canoe on a river, on a peaceful meadow or in a forest. Patients also have the option to listen to guided meditation or select from a library of videos to watch on a web-based user interface.~Patients in the VR group will also be treated according to the existing enhanced recovery after surgery protocol."
89003699|NCT04754165|No Intervention|Enhanced recovery after surgery protocol|Subjects in the control group will only undergo standard enhanced recovery after surgery care.
89003700|NCT04752215|Experimental|BI 765049 single treatment group|BI 765049
89003701|NCT04752215|Experimental|BI 765049 + ezabenlimab combination treatment group|BI 765049 + ezabenlimab
89003702|NCT04751734||Vaccinations|SARS-CoV-2 vaccination
89003703|NCT04748549|Experimental|Immersive VR group|"Patients in the Immersive VR group will don a VR headset connected to a software platform on a tablet, as well as noise cancelling headphones. Patients can choose their desired experience within the VR software from a selection of immersive environments and/or video content. Examples include sitting in a canoe on a river, on a peaceful meadow or in a forest. Patients also have the option to listen to guided meditation or select from a library of videos to watch on a web-based user interface.~To reduce the influence of the anesthesia provider on the determination of sedative requirements, patients will administer their own sedation according to their needs for relaxation and comfort using a patient controlled system."
89003704|NCT04748549|Active Comparator|Music group|Patients randomized to the Music group will be equipped with VR headsets but won't view any content. They will also be equipped with noise cancelling headphones in the same fashion as the immersive VR group. A study team member will play from a library of music or other audible content (audiobook, podcast) that was preselected by the patient. Patients in the Sham VR group will also use patient controlled sedation.
89003705|NCT04748549|Sham Comparator|Sham VR + Usual Care Control Group|Subjects in the control group will wear VR headsets and headphones but will not view any content or listen to any audible content. They will undergo Monitored Anesthesia Care (MAC) according to a prespecified protocol targeting light or moderate sedation with a propofol infusion.
89003706|NCT04746677|Experimental|Complex abdominal aortic aneurysm (AAA)|Includes juxtarenal AAA, suprarenal AAA, and type IV thoracoabdominal aortic aneurysm
89003707|NCT04746677|Experimental|Thoracoabdominal aortic aneurysm (TAAA)|Includes Type I, Type II, and Type III TAAA
89003708|NCT04746677|Experimental|Type B aortic dissection|Includes all Type B dissections
89003709|NCT04746677|Experimental|Expanded Selection Arm|Includes high risk subjects who do not meet inclusion criteria for Arms !-3
89003710|NCT04735653|Experimental|Personalized Glaucoma Coaching|This is a six-month personalized glaucoma coaching program where a coach trained in motivational interviewing (MI)-based counseling uses a web-based tool that generates tailored education to help glaucoma patients identify their barriers to optimal medication adherence and explore potential solutions during three in-person coaching sessions. The coach provides between-session support through four phone calls, with two phone calls between the first and second sessions and one call after each subsequent session. Participants can elect to receive any of the following types of alarm when a dose of medication is due: visual or audible alert or automated text or phone call reminder. Glaucoma medication adherence will be monitored electronically for all participants between the baseline visit and the exit visit six months later.
89003711|NCT04735653|Active Comparator|Enhanced standard care|Participants will receive non-tailored educational materials about glaucoma from leading sources by mail every 2 months for a total of 3 mailings during the 6-month study period. Glaucoma medication adherence will be monitored electronically for all participants between the baseline visit and the exit visit six months later.
89003712|NCT04722965|Active Comparator|Fistulotomy with marsupialization|40 patients with a simple low transsphincteric anal fistula. A fistulotomy with marsupialization is performed.
89003713|NCT04722965|Active Comparator|Fistulotomy with open wound|40 patients with a simple low transsphincteric anal fistula. A fistulotomy leaving the wound open is performed.
89003714|NCT04696497|Other|Muscular Assessment|All the patients will received the muscular assessments
89003715|NCT04696055|Experimental|Regorafenib+Pembrolizumab|Participants with advanced hepatocellular carcinoma (HCC) progressed on 1L anti-PD-1/PD-L1 therapy.
89003716|NCT04695054|Experimental|Buzzy and EMLA Cream|In the experimental group children will receive the application of EMLA cream 60 minutes before the needle procedure and the use of Buzzy device during the procedure.
89003717|NCT04695054|Active Comparator|EMLA Cream|In the control group children will receive the application of EMLA cream 60 minutes before the needle procedure
89003718|NCT04692961|Experimental|Patients after free flap harvested|Patients receiving peroneal artery-based free flap harvest
89003719|NCT04687774|Experimental|single-arm study|A single-arm of 30 treated patients is appropriate to generate additional local data on Exalt D Single-use Duodenoscope, since there is existing information in the previous study of Exalt D Single-use Duodenoscope in ERCP procedures and clinical literature regarding its performance.
89003720|NCT04680832|Experimental|ILD patients|Patients diagnosed with one of the most prevalent fibrotic ILDs: IPF, CHP, CTD-ILD, iNSIP, IPAF, and unclassifiable ILD (defined as unclassifiable disease at the time of the first MDT).
89003721|NCT04676633|Experimental|Cohort 1: STP705 20 μg dose|Intratumoral injection, administered as a single agent on Day 1,8 and 15 of a 28-day cycle. If the patient is deriving clinical benefit from the agent it may be continued and will be administered on Day 1 of each successive cycle.
89003722|NCT04676633|Experimental|Cohort 2: STP705 40 μg dose|Intratumoral injection, administered as a single agent on Day 1,8 and 15 of a 28-day cycle. If the patient is deriving clinical benefit from the agent it may be continued and will be administered on Day 1 of each successive cycle.
89393809|NCT03106753|Active Comparator|Spinal anesthesia immediately for ECV.|The patient will have a spinal administered by the on call anesthesiologist using standard protocol (intrathecal bupivacaine 7.5 mg). The patient will then be administered 0.25 mg Terbutaline subcutaneously and the ECV will be attempted. Under ultrasound guidance the provider will attempt to lift the breech upward from the pelvis with one hand and guide the head with the other hand to produce a forward roll. If forward roll fails, a backward roll somersault may be attempted. ECV attempt will be abandoned if there is significant fetal bradycardia, discomfort to the patient, or if the procedure cannot be completed easily with these maneuvers. Once attempt is complete, whether successful or not, the patient will be monitored for a minimum of 30 minutes, and will be discharged once they are able to walk, void, and tolerate PO intake, only if fetal and maternal status is reassuring.
88869894|NCT05400265|Experimental|Dose Cohort 2|In this cohort, the dose of HLX26 is 800mg. HLX26 will be intravenously administered every 3 weeks. HLX10 will be intravenously administered every 3 weeks with the fixed dose of 300mg. Patients will receive the treatment until they have been in therapy for 2 years, develop progressive disease (PD) without any clinical benefit, death, intolerable toxicity, or withdraw the informed consent (whichever occurs first).
88869895|NCT05400265|Experimental|Dose Cohort 3|In this cohort, the dose of HLX26 is 1600mg. HLX26 will be intravenously administered every 3 weeks. HLX10 will be intravenously administered every 3 weeks with the fixed dose of 300mg. Patients will receive the treatment until they have been in therapy for 2 years, develop progressive disease (PD) without any clinical benefit, death, intolerable toxicity, or withdraw the informed consent (whichever occurs first).
88869896|NCT05389163|Experimental|Giomer based injectable resin composite|Beautifil Flow plus X F03, SHOFU, USA
88869897|NCT05389163|Active Comparator|Resin modified glass ionomer|Fuji II LC, GC
88869898|NCT05387525|Experimental|Tirbanibulin 10 milligram per gram (mg/g) ointment|Participants will apply tirbanibulin ointment 10 mg/g once daily to the treatment field (TF) for 5 consecutive days beginning Day 1. At subsequent visits, participants will have the option of an additional 5-day course(s) (with at least 16 weeks between starting date of treatment courses) at the discretion of the investigator if actinic keratosis (AK) lesions are present in the TF and physical treatment is not appropriate.
88869899|NCT05387525|Active Comparator|Diclofenac Sodium 3% Gel|Participants will apply diclofenac sodium 3% gel twice daily to the TF for 60 to 90 days beginning Day 1, with the option of further courses every 6 months (with at least 6 months between starting date of treatment courses) if lesions are found to be present in the TF at follow up visits and physical treatment is not appropriate.
88869900|NCT05386472|Experimental|Cohort 1|Pregnant women in their second trimester
88869901|NCT05386472|Experimental|Cohort 2|Pregnant women in their third trimester
88869902|NCT05386472|Experimental|Cohort 3|Non-pregnant women
88869903|NCT05382442|Experimental|Part 1_Chemotherapy Regimen Selection Stage Group A(AK112+AK117+XELOX)|"AK112+AK117+XELOX~AK112 and AK117 and XELOX(Oxaliplatin 130 mg/sqm iv day 1, Capecitabine via oral, the total daily dose was 2000mg/sqm, day1-14)~If no progression occurs during AK112 plus AK117 plus XELOX, patients will receive maintenance capecitabine plus AK112 plus AK117 at the same dose used at the last cycle of the induction treatment. Capecitabine plus AK112 plus AK117 will be repeated every 3 weeks until disease progression, unacceptable toxicity or patient's refusal."
88869904|NCT05382442|Experimental|Part 1_Chemotherapy Regimen Selection Stage Group B(AK112+AK117+FOLFOXIRI)|"AK112+AK117+FOLFOXIRI~AK112 and AK117 and FOLFOXIRI(Irinotecan 150-165 mg/sqm iv day 1, Oxaliplatin 85 mg/sqm iv day 1, Leucovorin(LV) 400 mg/sqm iv day 1, 5-fluorouracil(5-FU) 2400-2800 mg/sqm 48 h-continuous infusion, starting on day 1)~If no progression occurs during AK112 plus AK117 plus FOLFOXIRI, patients will receive maintenance 5-FU/LV plus AK112 plus AK117 at the same dose used at the last cycle of the induction treatment. 5-FU/LV plus AK112 plus AK117 will be repeated biweekly until disease progression, unacceptable toxicity or patient's refusal."
88869905|NCT05382442|Experimental|Part 1_Expansion Stage Group A(AK112+Chemotherapy)|"AK112+Chemotherapy(Decided by Chemotherapy Regimen Selection Stage)~AK112 and XELOX or FOLFOXIRI(the same dosage, frequency and duration with Chemotherapy Regimen Selection Stage)"
88869906|NCT05382442|Experimental|Part 1_Expansion Stage Group B(AK112+AK117+Chemotherapy)|"AK112+AK117+Chemotherapy(Decided by Chemotherapy Regimen Selection Stage)~AK112 and AK117 and XELOX or FOLFOXIRI(the same dosage, frequency and duration with Chemotherapy Regimen Selection Stage)"
88869907|NCT05382442|Experimental|Part 2 cohort 1(AK112)|"Subjects receive AK112 until disease progression or unacceptable toxicity~AK112 (until disease progression, unacceptable toxicity or patient's refusal)"
88869908|NCT05382442|Experimental|Part 2 cohort 2(AK112+AK117)|"Subjects receive AK117 and AK112 until disease progression or unacceptable toxicity~AK112 and AK117 ( until disease progression, unacceptable toxicity or patient's refusal)"
88869909|NCT05380323|Experimental|LY3541105 (Part A)|Single ascending doses of LY3541105 administered subcutaneously (SC).
88869910|NCT05380323|Experimental|LY3541105 (Part B)|Multiple ascending doses of LY3541105 administered SC.
88869911|NCT05380323|Experimental|LY3541105 (Part C)|Escalating doses of LY3541105 administered SC.
88869912|NCT05380323|Placebo Comparator|Placebo (Part A)|Placebo administered SC.
88869913|NCT05380323|Placebo Comparator|Placebo (Part B)|Placebo administered SC.
88869914|NCT05380323|Placebo Comparator|Placebo (Part C)|Placebo administered SC.
89187136|NCT04048785|Experimental|Infant behavioral sleep intervention|Interventionists collaborate with the family to design a tailored sleep intervention strategy, which involves appropriate sleep schedule and bedtime routine, putting the child to bed while still sleepy rather than when already asleep, and waiting 1 to 2 minutes before attending to the child during nocturnal awakenings. Parents are educated to implement the behavioral protocol at bedtime and subsequent night wakings.
89187137|NCT05674682|Other|Venipuncture or digital puncture for HIV test|MSM and transgender women aged 18 years or older, willing and able to sign informed consent to accept venipuncture or digital puncture for HIV testing
89393810|NCT03106753|Experimental|Spinal anesthesia if no intervention fails for ECV.|The patient will be administered terbutaline 0.25 mg subcutaneously and the version will be attempted using the same procedure as above. If successful, the patient will be monitored for 30 minutes and discharged if fetal and maternal status is reassuring. If the attempt fails, the patient will be administered spinal anesthesia as above and the same maneuvers will be attempted. Once attempt is complete, whether successful or not, the patient will be monitored for a minimum of 30 minutes, and will be discharged once they are able to walk, void, and tolerate PO intake, only if fetal and maternal status is reassuring.
89393811|NCT02132624|Experimental|CAR T cells|Autologous 3rd generation CD19-targeting CAR T cells
89393812|NCT02128880|Experimental|CARRII|CARRII: This is a highly interactive Internet intervention consisting of 6 Cores of Intervention material, including Core 1, Overview, Core 2: Your Risk for AEP, Core 3: Drinking, Core 4: Contraception, Core 5: Thoughts and Decisions, and Core 6: Commit to It.
89393813|NCT02128880|Active Comparator|Patient Education|CARRII Education: This is a static website containing educational information on the following topics: What is Alcohol Exposed Pregnancy (AEP)?, Fetal Alcohol Spectrum Disorders, Impact of AEP, Prevalence of AEP, Causes and Prevention of AEP, Treatment for AEP, and Links to related information.
89393814|NCT02136758|Experimental|Lifestyle modification|The intervention group participated in individualized therapeutic lifestyle plans to reduce cardiovascular risk. Participants were introduced to factors contributing to cardiovascular disease and met individually with a registered dietitian, exercise physiologist, stress management instructor, and psychologist to learn effective strategies for integrating healthy changes into their current lifestyle.
89393815|NCT02136758|No Intervention|Usual care controls|Control group received standard care from their primary physicians, but did not participate in any component of the lifestyle program or receive any information, advice, or counseling regarding healthy lifestyle behaviors.
89393816|NCT05385679|Active Comparator|Envelop Flap|An envelope flap designs involves a sulcular incision from the first to the second molar and a distal relieving incision to the mandibular ramus.
89393817|NCT05385679|Active Comparator|Triangular flap|Triangular flap involves incision from the mandibular ramus to the distobuccal crown edge of the second molar, followed by a perpendicular incision obliquely into the mandibular vestibulum, with a length of about 10 mm.
89393818|NCT02132702|Experimental|Ekso treatment|
89393819|NCT05198401||1|(previous covid-19 positive) n. =88
88869915|NCT05369390|Experimental|Part A: Single ascending dose (SAD)|Participants will receive a single dose of any of the six different dose levels (1, 3, 6, 12, 25 and 50 milligrams (mg)) of NNC0487-0111 A or matching placebo in a sequential manner with the dose increasing between cohorts.
88869916|NCT05369390|Experimental|Part B: Multiple ascending dose (MAD)|Participants will receive NNC0487-0111 once daily for 10 days at any of the five different dose levels (3, 6, 12, 25 and 50 milligrams (mg)) of NNC0487-0111 A or matching placebo in a sequential manner with the dose increasing between cohorts.
88869917|NCT05369390|Experimental|Part C|Participants will receive NNC0487-0111 A or matching placebo once-daily for 12 weeks: 3 or 6 mg for weeks 1-2, 6 or 12 mg for weeks 3-4, 12 or 25 mg for weeks 5-6, 25 or 50 mg for weeks 7-8, 25 or 50 mg for weeks 9-10 and 50 or 2*50 mg for weeks 11-12.
88869918|NCT05369390|Experimental|Part D|Participants will receive NNC0487-0111 B or matching placebo once-daily for 12 weeks: 3 or 6 mg for weeks 1-2, 6 or 12 mg for weeks 3-4, 12 or 25 mg for weeks 5-6, 25 or 50 mg for weeks 7-8, 25 or 50 mg for weeks 9-10 and 50 or 2*50 mg for weeks 11-12.
88869919|NCT05349318|Active Comparator|Hyperbaric Oxygen Therapy active arm|The protocol comprises of 60 consecutive hyperbaric oxygen treatment (HBOT) sessions, 5 sessions per week within a three months' period. Then there will be a maintenance period for 6 months in which the participants will receive HBOT twice a week.
89393820|NCT05198401||2|(covid-19 negative) n.=91
89393821|NCT02136836||gastric adenocarcinoma|
89393822|NCT05198323|Experimental|LT3001 Drug Product|Administered by intravenous infusion
89393823|NCT05198323|Placebo Comparator|Placebo|Administered by intravenous infusion
89393824|NCT03550898|Other|Dynamic ultrasonography|Dynamic ultrasonography was performed in all patients who underwent urodynamics, simultaneously.
89393825|NCT02133014|Experimental|surgical operation therapy|Using the method of laparoscopic-assisted percutaneous catheter drainage of SAP.After the surgery,patient's cavity are continuously douched by catheter using 0.5% 5-fluorouracil normal saline.
89393826|NCT02133014|No Intervention|conventional therapy|using the method of conventional conservative therapy without surgical management.
89393827|NCT02129114|Experimental|ReDura Onlay|The Dural Repair Patch manufactured by Guangzhou Medprin Regenerative Medical Technologies Co., Ltd.
89393828|NCT02129114|Active Comparator|DuraGen|Dural Graft Matrix manufactured by Integra LifeSciences (U.S.) Corporation.
89393829|NCT03653143|Experimental|Treatment Group|Assessment #1 Baseline Visit >> 3 month JASPER intervention (weekly) >> Assessment #2 Research Visit >> 3 month treatment as usual >> Assessment #3 Research Visit
89393830|NCT03653143|Experimental|Control/Wait-list Group|Assessment #1 Baseline Visit >> 3 month treatment as usual >> Assessment #2 Research Visit >> 3 month JASPER intervention >> Assessment #3 Research Visit
89393831|NCT03637725||Coronary Artery Disease|Suspected or known coronary artery disease
89393832|NCT02136992|Placebo Comparator|Placebo (without active ingredient)|placebo will be taken two tablets 3 times a day during the whole study process.
89393833|NCT02136992|Experimental|Pirfenidone（200mg）|Pirfenidone（200mg）tablets will be taken two tablets 3 times a day during the whole study process.
89393834|NCT03629119|Experimental|Dietary Fiber Supplement|Participants will be instructed to consume 1 tea spoon of psyllium per day for 3 months and otherwise maintain their habitual diet.
89393835|NCT02133092||Patients with respiratory syncytial virus (RSV) infection|The RSV infection is laboratory confirmed
89393836|NCT03045081|No Intervention|Usual care|Patients receive outcome tracking tool, PainTracker, but no additional web-based support for self-management
89393837|NCT03045081|Experimental|PainTracker Self-Manager|Patients are invited to complete the web-based PainTracker Self-Manager and interact with a nurse care manager who supports chronic pain self-management
89393838|NCT03621397|Experimental|Cognitive Intervention Group|Research participants in the cognitive intervention group will undergo a baseline neuropsychological evaluation. One week later, they will receive the online training program (brainHQ by Posit Science) three times a week for 45 minutes for a total of 12 weeks. This group will return one week after completing the online intervention program for their follow-up neuropsychological evaluation. They will then return again one year later for another follow-up neuropsychological evaluation.
89393839|NCT03621397|No Intervention|Control Group|Research participants in the control group will undergo a baseline neuropsychological evaluation. They will then return 13 weeks after their baseline neuropsychological evaluation for a follow-up neuropsychological evaluation and again one year later.
89393840|NCT02252978|Experimental|Arm I (ciprofloxacin)|Patients receive ciprofloxacin PO BID for 2 weeks.
89393841|NCT02252978|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID for 2 weeks.
89393842|NCT05507385|Experimental|Intervention: IMAGINE-P|"Experimental intervention: IMAGINE-POSITIVE targeting positive affect (IMAGINE-P):~The intervention will combine aspects of Memory Specificity Training (MeST), which includes information about the links between memories and emotions, with Positive Prospective Mental Imagery (PPMI)."
89393843|NCT05507385|Active Comparator|Control:|Control intervention: Non-directive supportive therapy (NDST) consists of individual sessions, with an empathetic, emotionally supportive practitioner and provides non-directive problem solving and monitoring. Using NDST will control for factors that may contribute to change, which are not active components e.g. speaking to an empathetic therapist. NDST will follow treatment guidelines.
89393844|NCT02133170|Active Comparator|Psychopharmacological + MBCT|psychopharmacological treatment plus Mindfulness Based Cognitive Therapy (MBCT)
89393845|NCT02133170|Active Comparator|psychopharmacological + psychoeducation|psychopharmacological treatment plus structured group psychoeducation;
89393846|NCT02133170|Other|Psychopharmacological treatment.|Treatment as usual (TAU), including standard psychiatric care with psychopharmacological treatment.
89393847|NCT03107377|Active Comparator|EVO100|A pH-buffering, acidity-maintaining gel (pH 3.5), containing three active compounds: lactic acid, citric acid, potassium bitartrate. 5 g intravaginally applied at least one hour prior to vaginal intercourse.
89393848|NCT03107377|Placebo Comparator|Placebo|An isotonic, non-buffering gel, pH adjusted to 4.5, containing 2.7% hydroxyethylcellulose, sorbic acid, sodium hydroxide, sodium chloride and purified water. 5 g intravaginally applied at least one hour prior to vaginal intercourse.
88869920|NCT05349318|Sham Comparator|Sham active arm|The protocol comprises of 60 consecutive Sham sessions, 5 sessions per week within a three months' period. Then there will be a maintenance period for 6 months in which the participants will receive Shan sessions twice a week.
88869921|NCT05347212|Experimental|Nivolumab+Relatlimab|nivolumab 480 mg IV plus relatlimab 480 mg IV every 4 weeks for up to 2 years
88869922|NCT05344170|Experimental|30 mg Cannabinol (CBN)|Single fixed dose administered 2 hours prior to habitual sleep onset.
88869923|NCT05344170|Experimental|300 mg Cannabinol (CBN)|Single fixed dose administered 2 hours prior to habitual sleep onset.
88869924|NCT05344170|Placebo Comparator|Placebo|Single fixed dose administered 2 hours prior to habitual sleep onset.
88869925|NCT05342220|Active Comparator|Remote Ischemic Preconditioning|Remote ischemic preconditioining
88869926|NCT05342220|Sham Comparator|Control|Sham preconditioning
88869927|NCT05335486|Experimental|RELEARN - Intervention|"Intervention group participants will be seen at the orthopedic ward and receive standard care for knee osteoarthrosis, defined by Danish clinical guidelines.~In addition, intervention group participants will be asked to attend eight sessions of RELEARN neurofeedback with an approximate duration of 45 minutes per session. Also, participants will undergo three follow-up sessions: one month, three months, and five months post-intervention"
88869928|NCT05335486|Active Comparator|Standard care control|Standard Care control. Control group participants will be seen at the orthopedic ward and receive standard care for knee osteoarthrosis, defined by Danish clinical guidelines. During standard care, the control group participants will be asked to attend eight control sessions with no RELEARN intervention with an approximate duration of 5 minutes per session. Also, participants will undergo three follow-up sessions: one month, three months, and five months post-intervention
88869929|NCT05328375|Experimental|Telehealth-enhanced Hybrid CR|Participants will receive a hybrid version of cardiac rehabilitation.
89393849|NCT02253056|Experimental|Fasting|Intermittent fasting over 8 weeks (one day per week)
89393850|NCT02253056|Active Comparator|Healthy diet|Regular healthy diet according to current German (DGE) guidelines for healthy nutrition.
89393851|NCT02129270|Active Comparator|Lidocaine HCl 2%|Lidocaine HCl 2% (200mg/10ml) 10 ml.
89393852|NCT02129270|Experimental|Lidocaine HCl 1%|Lidocaine HCl 1% (100mg/10ml) 15-20 ml.
89393853|NCT03550742|Experimental|Intervention|Daily administration of 5g of Fuco-N-Tetraose as a bolus for a period of 12 weeks.
89393854|NCT03549884|Experimental|Delayed cord clamping (DCC)|Cord clamping will be performed after 60 seconds of life
89393855|NCT03549884|Active Comparator|Early cord clamping (ECC)|Cord clamping will be performed within 10 seconds of life
89393856|NCT02133326|Experimental|Caldolor|800 mg of Caldolor® will be infused at the rate of 5-7 minutes as per the manufacturer's guidelines or
89393857|NCT02133326|Experimental|Ofirmev|1000 mg of Ofirmev® will be infused at the rate of 15 minutes as per the manufacturer's guidelines.
89393858|NCT02137304|Experimental|neuromuscular patients|Cough Assist® (JH Emerson Compagny, Cambridge, MA, USA)
89393859|NCT02133482|Experimental|BI 639667|single rising doses given as oral solution
89393860|NCT02133482|Placebo Comparator|Placebo|placebo solution
89393861|NCT05341141|Experimental|ddEC-ddT and cryotherapy combined with compression|Cryotherapy will be applied using a frozen glove and sock for 15 minutes before, during and 15 minutes after each albumin-paclitaxel infusion. Compression therapy will be applied using a surgical glove for 30 minutes before, during and 30 minutes after each albumin-paclitaxel infusion.
89393862|NCT05341141|Other|ddEC-ddT|ddEC-ddT will be administered without cryotherapy combined with compression.
89393863|NCT02137616|Active Comparator|risperidone|low dosage of antipsychotic drug
89393864|NCT02137616|Active Comparator|olanzapine|low doseage of antipsychotic
89393865|NCT02137616|Active Comparator|quetiapine|low doseage of antipsychotic
89393866|NCT02137616|Active Comparator|aripiprazole|low doseage of antipsychotic
89393867|NCT02129504|Experimental|coronal advanced technique|root coverage with the porcine collagen matrix using the coronal advanced technique (standard technique)
89393868|NCT02129504|Experimental|extended flap technique|root coverage with the porcine collagen matrix using the extended flap technique (new surgical technique)
89393869|NCT02133560|Other|Medication Administration + Education|Subjects will be asked to monitor their daily iron chelator administration by taking a video recording of preparing it and ingesting at least one sip during months 1-3 and completing the medication administration log during months 1-6. During months 1-6 subjects will meet with study staff and receive educational materials on a monthly basis. The data collected will be analyzed to describe patient adherence and comfort level with the process of daily recording of medication management.
89393870|NCT05198011|Experimental|3D mandibular ridge augmentation|
89393871|NCT05198011|Active Comparator|Conventional mandibular ridge augmentation|
89393872|NCT02133638|Active Comparator|Sevoflurane|Sevoflurane Based Volatile Induction and Maintenance of Anaesthesia
89393873|NCT02133638|Active Comparator|Propofol|Propofol Based Total Intravenous Anesthesia
88869930|NCT05328375|Active Comparator|Traditional CR|Participants will receive a standard of care version of cardiac rehabilitation.
89393874|NCT05197933|Experimental|Laparoscopic resection|laparoscopic resection for GIST at unfavorable anatomic sites of stomach
89393875|NCT02545283|Experimental|Idasanutlin plus Cytarabine|Participants will receive induction therapy idasanutlin and cytarabine for 5 Days followed by 23 days of rest in Cycle 1 (treatment cycle length=28 days). Responding participants may continue with consolidation therapy for a maximum of 2 additional cycles including idasanutlin and cytarabine for 5 days followed by 23 days of rest in each cycle (treatment cycle length=28 days). After each cycle, for participants achieving CRp or complete remission with incomplete blood count recovery (CRi), up to 28 additional days are allowed for blood count recovery, if needed.
89393876|NCT02545283|Placebo Comparator|Placebo plus Cytarabine|Participants will receive induction therapy idasanutlin matching placebo and cytarabine for 5 days followed by 23 days of rest in Cycle 1 (treatment cycle length=28 days). Responding participants may continue with consolidation therapy for a maximum of 2 additional cycles including idasanutlin matching placebo and cytarabine for 5 days followed by 23 days of rest in each cycle (treatment cycle length=28 days). After each cycle, for participants achieving CRp or CRi, up to 28 additional days are allowed for blood count recovery, if needed.
88869931|NCT05327530|Experimental|Group A: Avelumab|
88869932|NCT05327530|Experimental|Group B: Avelumab + Sacituzumab Govitecan|
88869933|NCT05327530|Experimental|Group C: Avelumab + M6223|
88869934|NCT05327530|Experimental|Group D: Avelumab + NKTR-255|
88869935|NCT05323916|Active Comparator|"Neuroproprioceptive facilitation, inhibition"|"According to the doctor's indication, a multidisciplinary team participates in the program. The practitioner from each clinical field (rehabilitation and physical medicine, physiotherapy, occupational therapy, clinical speech therapy and psychology) selects appropriate treatment methodologies for each patient (three hours). In addition, participants undergoes one hour a day of individual physiotherapy on a neurophysiological basis - neuroproprioceptive facilitation, inhibition, which, by combining appropriate stimuli in a suitable time sequence, maintains optimal motor pathway function and optimal irritability of control or regulation structures."
89003723|NCT04676633|Experimental|Cohort 3: STP705 80 μg dose|Intratumoral injection, administered as a single agent on Day 1,8 and 15 of a 28-day cycle. If the patient is deriving clinical benefit from the agent it may be continued and will be administered on Day 1 of each successive cycle.
89003724|NCT04676633|Experimental|Cohort 4: STP705 160 μg dose|Intratumoral injection, administered as a single agent on Day 1,8 and 15 of a 28-day cycle. If the patient is deriving clinical benefit from the agent it may be continued and will be administered on Day 1 of each successive cycle.
89187138|NCT02557815|Experimental|Active Repetitive Transcranial Magnetic Stimulation (rTMS)|Repetitive Transcranial Magnetic Stimulation: Active 10hz stimulation over the right dorsolateral Prefrontal Cortex (dlPFC)
89393877|NCT03363061||Antithrombotics|The patients should be on antithrombotics on the day of colonoscopy arrangement
89393878|NCT02137694|Other|PapU-APV|No drug and no placebo will be used in this study. For the study participants, only their medical history data and vaginal auto-takings ( APV) and urinary will be collected.
89393879|NCT02260700|Experimental|Sequence 1 (ABC)|Participants will receive Treatment A (single dose of JNJ-54861911 25 milligram (mg) oral suspension formulation under fasted conditions) in Period 1; followed by Treatment B (single oral dose of JNJ-54861911 25 mg solid formulation under fasted conditions) in Period 2; followed by Treatment C (single oral dose of JNJ-54861911 25 mg solid formulation under fed conditions) in Period 3. A washout period of at least 6 days will be maintained between each treatment period.
89393880|NCT02260700|Experimental|Sequence 2 (ACB)|Participants will receive Treatment A (single dose of JNJ-54861911 25 milligram (mg) oral suspension formulation under fasted conditions) in Period 1; followed by Treatment C (single oral dose of JNJ-54861911 25 mg solid formulation under fed conditions) in Period 2; followed by Treatment B (single oral dose of JNJ-54861911 25 mg solid formulation under fasted conditions) in Period 3. A washout period of at least 6 days will be maintained between each treatment period.
89393881|NCT02260700|Experimental|Sequence 3 (BAC)|Participants will receive Treatment B (single dose of JNJ-54861911 25 mg solid formulation under fasted conditions) in Period 1; followed by Treatment A (single oral dose of JNJ-54861911 25 milligram (mg) oral suspension formulation under fasted conditions) in Period 2; followed by Treatment C (single oral dose of JNJ-54861911 25 mg solid formulation under fed conditions) in Period 3. A washout period of at least 6 days will be maintained between each treatment period.
89003725|NCT04676633|Experimental|Cohort 5: STP705 320 μg dose|Intratumoral injection, administered as a single agent on Day 1,8 and 15 of a 28-day cycle. If the patient is deriving clinical benefit from the agent it may be continued and will be administered on Day 1 of each successive cycle.
89003726|NCT04665921|Experimental|SGN-STNV|SGN-STNV monotherapy
89003727|NCT04665856|Experimental|Tiragolumab + Atezolizumab + Carboplatin and Etoposide|Induction treatment with tiragolumab plus atezolizumab and CE will be administered on a 21-day cycle for 4 cycles. Following the induction phase, participants will continue maintenance therapy with tiragolumab plus atezolizumab for 21-day cycles.
89003728|NCT04665856|Placebo Comparator|Placebo + Atezolizumab + Carboplatin and Etoposide|Induction treatment with placebo plus atezolizumab and CE will be administered on a 21-day cycle for 4 cycles. Following the induction phase, participants will continue maintenance therapy with placebo plus atezolizumab for 21-day cycles
89003729|NCT04661384|Experimental|Treatment (IL13Ralpha2-CAR T cells)|Patients receive IL13Ralpha2-CAR T cells ICV over 5 minutes on day 1. Treatment repeats every 7 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
89003730|NCT04658199|Experimental|UCB0107 (bepranemab)|Subjects in this study arm will receive Intravenous UCB0107.
89003731|NCT04657991|Experimental|Triplet Arm|Encorafenib and Binimetinib in combination with Pembrolizumab
89003732|NCT04657991|Active Comparator|Control Arm|Pembrolizumab
89003733|NCT04643769|Experimental|25 mg ORIN1001 (Active)|25 mg ORIN1001
89003734|NCT04643769|Experimental|50 mg ORIN1001 (active)|50 mg ORIN1001
89003735|NCT04643769|Experimental|100 mg ORIN1001 (active)|100 mg ORIN1001
89003736|NCT04643769|Placebo Comparator|Placebo - 25 mg|Placebo comparator for ORIN1001 at 25 mg
89003737|NCT04643769|Placebo Comparator|Placebo - 50 mg|Placebo comparator for ORIN1001 at 50 mg
89003738|NCT04643769|Placebo Comparator|Placebo - 100 mg|Placebo comparator for ORIN1001 at 100 mg
89003739|NCT04641169|Other|Echocardiography|"• Echocardiography performed by the evaluator 1: 2 LVEF visual evaluations 2 LVEF automatic evaluations~• Echocardiography performed by the evaluator 2: 2 LVEF visual evaluations 2 LVEF automatic evaluations"
89003740|NCT04639830||Children with a known risk|Children between 6 months and 76 months who are at risk for developing a neurodevelopmental disorder.
89003741|NCT04639830||Children with no known risk|Children between 6 months and 76 months who don't have a risk for neurodevelopmental disorders.
89003742|NCT04639713|Experimental|Tixel 2|Tixel 2 Treatment, 4 treatment sessions, followed by 2 Follow up sessions, 1and 3 months after last treatment visit. Subject would be questioned about pain level, subjective dountime assessment and subjective response assessment. Images would be taken at baseline and in Follow-Up visits
89003743|NCT04624633|Experimental|Cohort 1-Relapsed Disease|"Participants with relapsed disease~Treatment with Acalabrutinib & Umbralisib beginning C1D1,~Ublituximab beginning C7D1~Assessment of treatment response~Treatment continues for a maximum of 24 cycles. Participants followed post treatment for a maximum of 5 years"
89003744|NCT04624633|Experimental|Cohort 2-Treatment Naive|"Participants with previously untreated disease~Treatment with Acalabrutinib & Umbralisib beginning C1D1,~Ublituximab beginning C7D1~Assessment of treatment response~Treatment continues for a maximum of 24 cycles. Participants followed post treatment for a maximum of 5 years"
89003745|NCT04624243|Experimental|MK-8189 8 mg (Acute) - MK-8189 8 mg (Extension)|Participants will be treated for a total of 12 weeks. Participants will receive MK-8189 8 mg once daily (QD) in the acute treatment period from Week 1-6 followed by MK-8189 8 mg QD in the extension treatment period from Week 7-12 and participants will simultaneously receive risperidone-matching placebo QD from Week 1-12. Enrollment of participants in the MK-8189 8 mg arm was closed with Amendment 4. Participants enrolled before Amendment 4 that have been assigned to 8 mg MK-8189 will remain on 8 mg MK-8189 per protocol.
89003746|NCT04624243|Experimental|MK-8189 16 mg (Acute) - MK-8189 16 mg (Extension)|Participants will be treated for a total of 12 weeks. Participants will receive MK-8189 16 mg QD in the acute treatment period from Week 1-6 followed by MK-8189 16 mg QD in the extension treatment period from Week 7-12 and participants will simultaneously receive risperidone-matching placebo QD from Week 1-12.
89003747|NCT04624243|Experimental|MK-8189 24 mg (Acute) - MK-8189 24 mg (Extension)|Participants will be treated for a total of 12 weeks. Participants will receive MK-8189 24 mg QD in the acute treatment period from Week 1-6 followed by MK-8189 24 mg QD in the extension treatment period from Week 7-12 and participants will simultaneously receive risperidone-matching placebo QD from Week 1-12.
89003748|NCT04624243|Active Comparator|Risperidone 6 mg (Acute) - Risperidone 6 mg (Extension)|Participants will be treated for a total of 12 weeks. Participants will receive risperidone 6 mg QD in the acute treatment period from Week 1-6 followed by risperidone 6 mg QD in the extension treatment period from Week 7-12 and participants will simultaneously receive MK-8189-matching placebo QD from Week 1-12.
89003749|NCT04624243|Experimental|Placebo to MK-8189 (Acute) - MK-8189 24 mg (Extension)|Participants will be treated for a total of 12 weeks. Participants will receive MK-8189-matching placebo QD in the acute treatment period from Week 1-6 followed by MK-8189 24 mg QD in the extension treatment period from Week 7-12 and participants will simultaneously receive risperidone-matching placebo QD from Week 1-12.
89003750|NCT04614311|Active Comparator|Intervention|Intra-articular corticosteroid injections into active joints
89003751|NCT04614311|No Intervention|Comparator|No intra-articular injections
88869936|NCT05323916|Active Comparator|Technology based physical therapy|According to the doctor's indication, a multidisciplinary team participates in the program. The practitioner from each clinical field (rehabilitation and physical medicine, physiotherapy, occupational therapy, clinical speech therapy and psychology) selects appropriate treatment methodologies for each patient (three hours). In addition, they will undergo physiotherapy for an hour a day using the implementation of modern technologies based on the principles of sensorimotor learning, i.e. repeating specific and targeted functions in different environments / conditions in order to strengthen the memory footprint and initiate structural changes in the central nervous system. According to the indication, participants will be offered one of the robotic systems using an exoskeleton (Gloreha, Erigo and Meditutor, Lokomat and Ekso) or a therapy using virtual environment.
88869937|NCT05323916|Experimental|Effectively managed rehabilitation implementing the recommendations of the World Health Organization|The concept of therapy implementing the ICF model is based on a comprehensive, so-called biopsychosocial approach to the patient and his/her disease (four hours). The key is to set individual goals of the therapy together with the rehabilitator and with the use of so-called ICF core sets, which individually take into account the given situation of the rehabilitated person. This approach includes interdisciplinary diagnosis of the current condition, i.e. not only based on the diagnosis, but also on the functional status and activities performed, it also takes into account the socio-psychological background of the patient.
88869938|NCT05323916|Placebo Comparator|Control group|Participants will undergo standard care.
88869939|NCT05319405|Active Comparator|Sana plus Treatment as Usual|Subjects will be loaned a Sana Device to use for 28 days and will also receive mental health care through the Ralph H. Johnson VA Medical Center.
88869940|NCT05319405|No Intervention|Treatment as Usual|Subjects will receive mental health care at the Ralph H. Johnson VA Medical Center or community-based outpatient clinic (CBOC).
88869941|NCT05314855||Obese individuals with normal insulin sensitivity|
88869942|NCT05314855||Obese individuals with impaired insulin sensitivity|
88869943|NCT05314855||Obese patients with type 2 diabetes|
88869944|NCT05310110|Experimental|10% lidocaine spray and cisatracurium group|The subjects received laryngeal local anesthetics (10% lidocaine spray), intravenous cisatracurium 0.12 mg/kg, and propofol before laryngeal mask airway placement. The predetermined dosage of propofol for the first subject is 1 mg/kg.
88869945|NCT05310110|Experimental|10% lidocaine spray and placebo of cisatracurium group|The subjects received laryngeal local anesthetics (10% lidocaine spray), intravenous normal saline as a substitute for cisatracurium, and propofol before laryngeal mask airway placement. The predetermined dosage of propofol for the first subject is 1.25 mg/kg.
89393882|NCT02260700|Experimental|Sequence 4 (BCA)|Participants will receive Treatment B (single dose of JNJ-54861911 25 mg solid formulation under fasted conditions) in Period 1; followed byTreatment C (single dose of JNJ-54861911 25 mg solid formulation under fed conditions) in Period 2; followed by Treatment A (single dose of JNJ-54861911 25 milligram (mg) oral suspension formulation under fasted conditions) in Period 3. A washout period of at least 6 days will be maintained between each treatment period.
88869946|NCT05310110|Experimental|Placebo of lidocaine spray and cisatracurium group|The subjects received normal saline spray as a substitute for laryngeal local anesthetics (10% lidocaine spray), intravenous cisatracurium 0.12 mg/kg, and propofol before laryngeal mask airway placement. The predetermined dosage of propofol for the first subject is 1 mg/kg.
88869947|NCT05310110|Placebo Comparator|Placebo group|The subjects received normal saline spray as a substitute for laryngeal local anesthetics (10% lidocaine spray), intravenous normal saline as a substitute for cisatracurium, and propofol before laryngeal mask airway placement. The predetermined dosage of propofol for the first subject is 2 mg/kg.
88869948|NCT05306457|Experimental|CNS10-NPC-GDNF - Group A|Unilateral, Motor Cortex, 0.25x10^6 cells in 10 µL/site, 21 sites (5.25x10^6 total cells) - Motor cortex corresponding to the non-dominant hand
88869949|NCT05306457|Experimental|CNS10-NPC-GDNF - Group B|Unilateral, Motor Cortex, 0.5x10^6 cells in 10 µL/site, 21 sites (10.5x10^6 total cells) - Motor cortex corresponding to the non-dominant hand
88869950|NCT05306457|Experimental|CNS10-NPC-GDNF - Group C|Unilateral Motor Cortex, 0.5x10^6 cells in 10 µL/site, 21 sites (10.5x10^6 total cells) - Motor cortex corresponding to the dominant hand
88869951|NCT05300464|Other|Single arm|All patients perform standard breast screening and also MammoWave exam.
88869952|NCT05296135||Main Cohort|
88869953|NCT05292287|Experimental|Home-based Watch Intervention|The home-based watch group will receive an exercise consultation with an exercise physiologist followed by check-in sessions at 1-month, 3-months, 6-months, and 12-months post-randomisation to set and review exercise and physical activity goals. They will wear a Polar Ignite wearable activity monitor which will help to monitor and guide their exercise sessions. Text-message feedback will be provided by an exercise physiologist based on information gathered from exercise sessions recorded on the watch by the participant.
88869954|NCT05292287|No Intervention|Best Practice Usual Care Control|No intervention will be administered. Best practice usual care and activity.
88869955|NCT05289063|Active Comparator|Treatment|OSA patients who adhered or did not adhere with CPAP who are randomized to receive atorvastatin 10 mg daily.
88869956|NCT05289063|Placebo Comparator|Control|OSA patients who adhered or did not adhere with CPAP who are randomized to receive placebo daily.
88869957|NCT05286866|Experimental|Low speed drilling without irrigation|The dental implants will be placed using a low-speed drilling technique without irrigation for the experimental group.
88869958|NCT05286866|Active Comparator|High speed drilling with irrigation|The dental implants will be placed using a high-speed drilling technique with irrigation for the control group.
88869959|NCT05282628|Experimental|Building Better Brains and Behavior program (B4 Preterm)|Online learning modules completed sequentially and in conjunction with live coaching sessions led by a trained therapist.
89187139|NCT02557815|Sham Comparator|Sham stimulation|Repetitive Transcranial Magnetic Stimulation: sham stimulation over the right dlPFC
89187140|NCT02583620|Other|Emmetropic volunteers|Blood sample
89393883|NCT02260700|Experimental|Sequence 5 (CAB)|Participants will receive Treatment C (single dose of JNJ-54861911 25 mg solid formulation under fed conditions) in Period 1; followed by Treatment A (single dose of JNJ-54861911 25 milligram (mg) oral suspension formulation under fasted conditions) in Period 2; followed by Treatment B (single dose of JNJ-54861911 25 mg solid formulation under fasted conditions) in Period 3. A washout period of at least 6 days will be maintained between each treatment period.
89393884|NCT02260700|Experimental|Sequence 6 (CBA)|Participants will receive Treatment C (single dose of JNJ-54861911 25 mg solid formulation under fed conditions) in Period 1; followed by Treatment B (single dose of JNJ-54861911 25 mg solid formulation under fasted conditions) in Period 2; followed by Treatment A (single dose of JNJ-54861911 25 milligram (mg) oral suspension formulation under fasted conditions) in Period 3. A washout period of at least 6 days will be maintained between each treatment period.
89393885|NCT05682391|No Intervention|Prospective experimental - no bed rest after intraoperative leak|Randomized after surgery if intraoperative CSF leakage occurs. The ratio for allocating into arm 1 vs. arm 2 is 2:1.
88869960|NCT05250908|Experimental|INTIBIA Therapeutic|Implanted with INTIBIA device and programmed to therapeutic stimulation for the duration of the study.
88869961|NCT05250908|Experimental|INTIBIA Non-Therapeutic|Implanted with INTIBIA device and programmed to non-therapeutic stimulation for the first 3 months, then to therapeutic stimulation for the duration of the study.
88869962|NCT05237739|Experimental|Test Group|Ten participants will be randomised to receive surgical periodontal treatment in the form of open flap debridement (OFD).
88869963|NCT05237739|Active Comparator|Control Group|Ten participants will be randomised to receive non-surgical periodontal treatment (NSPT). All treatment will be carried out by the same therapist, including oral hygiene.
88869964|NCT05231408|Experimental|Training Group|Training group will receive high-intensity interval aerobic exercise training on treadmill accompanied by physiotherapist for 8 weeks.
88869965|NCT05231408|Sham Comparator|Control Group|Breathing exercises will be given to control group as a home program for 8 weeks.
88869966|NCT05226663|Experimental|Treatment ([18F]FTT PET/CT)|Patients receive [18F]FTT IV over a few seconds to a minute and then undergo PET/CT scan over 20-30 minutes at baseline and another optional scan 1 week later. During the [18F]FTT PET/CT scan patients.
88869967|NCT05225272||Patients undergoing on-pump cardiac surgery|The investigators aim to conduct a bidirectional (prospective and retrospective) observational, cohort study including on-pump cardiac surgery patients.
88869968|NCT05209100||Normal Liver|Individuals will have no evidence of steatosis or fibrosis.
88869969|NCT05209100||Steatosis Only|Individuals will have at least 5.6% liver fat as assessed by magnetic resonance imaging proton density fat fraction with no evidence of fibrosis as evidenced by magnetic resonance elastography.
88869970|NCT05209100||Fibrosis without Cirrhosis|Individuals will have any level of liver fat as assessed by magnetic resonance imaging proton density fat fraction with fibrosis up to level F3 as evidenced by magnetic resonance elastography.
88869971|NCT05204459||RRMS, SPMS, PPMS, CIS or RIS|Multiple Sclerosis (relapsing-remitting, primary or secondary progressive forms), clinically isolated syndrome, or radiologically isolated syndrome
88869972|NCT05204459||NMOSD|Neuromyelitis optica spectrum disorders
88869973|NCT05204459||MOGAD|Myelin oligodendrocyte glycoprotein antibody disorders
88869974|NCT05204459||Neurological disorder other than MSRD|Neurological disorders due to neurodegenerative, vascular, or headache conditions that are not related to multiple sclerosis or related disorders.
88869975|NCT05204459||Healthy controls|Healthy controls with no known neurological conditions
88869976|NCT05202873||Short Stem (Compress)|Compress megaprosthesis
88869977|NCT05202873||Long Stem (conventional)|Conventional long stem megaprosthesis
88869978|NCT05199571|Experimental|Ofatumumab|Ofatumumab 20 mg subcutaneous injections at Week 0, 1, 2 and monthly thereafter starting at Week 4
89187141|NCT02583620|Other|High myopic volunteers|Blood sample
88869979|NCT05195918|Active Comparator|EGCG 300 mg with Nintedanib|Patients enrolled in this group will be given oral capsule EGCG 300 mg daily with doctor provided Nintedanib for 12 weeks.
88869980|NCT05195918|Active Comparator|EGCG 300 mg with Pirfenidone|Patients enrolled in this group will be given oral capsule EGCG 300 mg daily with doctor provided Pirfenidone for 12 weeks.
88869981|NCT05195918|Placebo Comparator|Placebo for EGCG 300 mg|Patients enrolled in this group will be given oral capsule Placebo daily for 12 weeks with doctor provided Nintedanib or Pirfenidone. The number of placebo capsules will be equal to that of 300 mg EGCG.
88869982|NCT05195918|Active Comparator|EGCG 600 mg with Nintedanib|Patients enrolled in this group will be given oral capsule EGCG 600 mg daily with doctor provided Nintedanib for 12 weeks.
88869983|NCT05195918|Active Comparator|EGCG 600 mg with Pirfenidone|Patients enrolled in this group will be given oral capsule EGCG 300 mg daily with doctor provided Pirfenidone for 12 weeks.
88869984|NCT05195918|Placebo Comparator|Placebo for EGCG 600 mg|Patients enrolled in this group will be given oral capsule Placebo daily for 12 weeks with doctor provided Nintedanib or Pirfenidone. The number of placebo capsules will be equal to that of 600 mg EGCG.
88869985|NCT05189028|Experimental|Locally advanced bulk cervical cancer neoadjuvant chemotherapy group(NACT)|"Radiation: Radiotherapy with IMRT/VMAT+192Ir-HDR brachytherapy Radiotherapy: 46Gy/23F to external pelvic radiotherapy and 14Gy/7F boost to imaging diagnosis of positive lymph nodes 192Ir-HDR brachytherapy:A Point dose 6Gy*4-6F~Drug: gemcitabine plus cisplatin,cisplatin Neoadjuvant chemotherapy:gemcitabine and cisplatin (GP) regimen*2 cycles Concurrent Chemotherapy: Weekly cisplatin chemotherapy ≥5 cycles"
88869986|NCT05189028|Active Comparator|Locally advanced bulk cervical cancer chemoradiotherapy group(CCRT)|"Radiation: Radiotherapy with IMRT/VMAT+192Ir-HDR brachytherapy Radiotherapy: 46Gy/23F to external pelvic radiotherapy and 14Gy/7F boost to imaging diagnosis of positive lymph nodes 192Ir-HDR brachytherapy:APoint A dose 6Gy*4-6F~Drug: cisplatin Concurrent Chemotherapy: Weekly cisplatin chemotherapy ≥5 cycles"
89393886|NCT05682391|Active Comparator|Prospective control - bed rest after intraoperative leak|Randomized after surgery if intraoperative CSF leakage occurs. The ratio for allocating into arm 1 vs. arm 2 is 2:1.
89393887|NCT05682391|No Intervention|Prospective control - no bed rest after no intraoperative leak|Enters this arm if no intraoperative CSF leakage occurs.
89393888|NCT05682391|Active Comparator|Retrospective control - bed rest after intraoperative leak|Historical control, bed rest applied after intraoperative CSF leakage.
88816525|NCT02976441|Experimental|Focal RT, Temozolomide, Stem Cell Collection/Reinfusion|"Autologous stem cell collection will be performed 1-4 days prior to initiating radiation therapy and temozolomide~Focal radiation therapy: standard of care dose daily for approximately 6 weeks~Temozolomide: standard of care dose by mouth daily for 6 weeks with radiation~2-7 days after the end of the radiation therapy and temozolomide the stem cells will be reinfused into the patient~Temozolomide: standard of care dose by mouth on days 1-5 every 28 days for 6 months following a 4-6 week rest period after the initial radiation and temozolomide"
88816526|NCT03010826||40 Demyelinating Disease patients|
88816527|NCT03010826||40 Non-patient participants|
88816528|NCT02434770|Experimental|BBIBP bOPV Lot 1|Infants received 2 drops of liquid bivalent oral polio vaccine (bOPV) manufactured by BBIBP, Lot 1, administered directly into the mouth in the first two weeks of life, and at 6, 10, and 14 weeks of age.
88816529|NCT02434770|Experimental|BBIBP bOPV Lot 2|Infants received 2 drops of liquid bivalent oral polio vaccine (bOPV) manufactured by BBIBP, Lot 2, administered directly into the mouth in the first two weeks of life, and at 6, 10, and 14 weeks of age.
88816530|NCT02434770|Active Comparator|BioFarma bOPV|Infants received 2 drops of WHO prequalified liquid bivalent oral polio vaccine manufactured by BioFarma, administered directly into the mouth in the first two weeks of life, and at 6, 10, and 14 weeks of age.
88816531|NCT05248971||Children screened for trauma and/or posttraumatic stress|Children were screened for trauma exposure and posttraumatic stress at one of the first meetings at the child and adolescent mental health clinic. For participants receiving TF-CBT, posttraumatic stress was also assessed during and after therapy.
88816532|NCT01203644|Active Comparator|Bupivacaine HCl|(e.g., Marcaine with epinephrine 1:200,000) is the reference-listed drug for bupivacaine and contains the same active, local anesthetic as SKY0402
88816533|NCT01203644|Active Comparator|SKY0402|Low dose, low-mid dose, mid-dose, and high dose
88816534|NCT00363831|Experimental|1|Oxaliplatin
88816535|NCT01220726|Active Comparator|Botox|200U onabotulinumtoxinA (botox)
88816536|NCT01220726|Placebo Comparator|Placebo|200U Saline
88816537|NCT02433834|Experimental|GP MDI 28.8 μg|GP MDI (PT001) 28.8 μg
88816538|NCT02433834|Experimental|GP MDI 14.4 μg|GP MDI (PT001) 14.4 μg
88816539|NCT02433834|Experimental|GP MDI 7.2 μg|GP MDI (PT001) 7.2 μg
88816540|NCT02433834|Experimental|GP MDI 3.6 μg per|GP MDI (PT001) 3.6 μg
88816541|NCT02433834|Experimental|GP MDI 1.9 μg|GP MDI (PT001) 1.9 μg
88816542|NCT02433834|Placebo Comparator|Placebo|Placebo
88816543|NCT02433834|Active Comparator|Serevent® Diskus® 50 μg per inhalation|Serevent® Diskus® 50 μg per inhalation
88816544|NCT01204736||Group 1|Subjects with posterior deltoid-to-triceps tendon transfers
88816545|NCT01204736||Group 2|Subjects with biceps-to-triceps tendon transfers
88816546|NCT01204736||Group 3|Subjects with cervical SCI who have not had tendon transfers
88816547|NCT01204736||Group 4|Unimpaired control subjects
88816548|NCT04346745|Experimental|Treatment group|The treatment group will receive intervention of a peer mentoring program plus usual services they could receive from community agencies.
88816549|NCT04346745|No Intervention|Control group|The control group will receive usual services they could receive from community agencies.
88816550|NCT01221194|Active Comparator|Standard therapy|Standard therapy consisting of education, regular foot care and protective shoes and insoles. The standard therapy group will use the stockings they normally wear.
88816551|NCT01221194|Active Comparator|PFC Stockings|The stocking therapy group will be given PFC shear reducing stockings to wear.
88816552|NCT02433678|Placebo Comparator|Placebo|Patients will be treated for 12 weeks with placebo once daily
88816553|NCT02433678|Active Comparator|Dapagliflozin|10 mg daily for the 12 weeks
88816554|NCT00363909|Experimental|low-dose citalopram hydrobromide|"Patients receive 1 tablet of oral citalopram once daily in weeks 2-7.~All patients complete a diary of hot flash incidence in weeks 1-7 and undergo blood collection periodically during study treatment for translational research studies."
88816555|NCT00363909|Experimental|medium-dose citalopram hydrobromide|"Patients receive 1 tablet of oral citalopram once daily in week 2 and 2 tablets once daily in weeks 3-7.~All patients complete a diary of hot flash incidence in weeks 1-7 and undergo blood collection periodically during study treatment for translational research studies."
89393889|NCT05682391|No Intervention|Retrospective control - no bed rest after no intraoperative leak|Historical control, bed rest not applied after no intraoperative CSF leakage.
89393890|NCT02133716|Experimental|expressed breast milk|"A single dose of expressed breast milk was administered through a sterile syringe in the mouth 2 minutes before venopuncture to neonates, accompanied at all times provided the technique allows it to non-nutritive sucking and containment.~The doses administered: 0.1ml in infants less than 27 weeks , 0.25 ml for infants 27-31 weeks , 0.5 ml for infants 32-37 weeks."
89393891|NCT02133716|Active Comparator|sucrose 24% oral|"A single dose of sucrose was administered through a sterile syringe in the mouth 2 minutes before venopuncture to neonates, accompanied at all times provided the technique allows it to non-nutritive sucking and containment.~The doses administered: 0.1ml in infants less than 27 weeks , 0.25 ml for infants 27-31 weeks , 0.5 ml for infants 32-37 weeks."
89393892|NCT02137928|Experimental|carboplatin periocular injection|20mg/2ml carboplatin periocular injection together with CEV chemotherapy(CEV Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first six months)
89393893|NCT02137928|Active Comparator|chemotherapy|Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first six months
89393894|NCT02138084|Experimental|Cohort 1: BMS-663068 + Rifabutin|"Regimen A: BMS-663068 tablet by mouth as specified~Regimen B: BMS-663068 tablet with Rifabutin capsule by mouth as specified"
89393895|NCT02138084|Experimental|Cohort 2: BMS-663068 + Rifabutin + Ritonavir|"Regimen A: BMS-663068 tablet by mouth as specified~Regimen C: BMS-663068 tablet, Rifabutin capsule and Ritonavir (RTV) capsule by mouth as specified"
89393896|NCT05677087|Experimental|Prepare project education|This group will receive an intensive 6-week remote nutrition education intervention
89393897|NCT01359917||autologous fat transfer|patients received fat transfer for HIV lipodystrophy
89187142|NCT00765453|Experimental|Intracoronary|Patients will be randomised in a 1:1 ratio to receive intracoronary injections of bone marrow derived stem/progenitor cells or placebo infusion through a percutaneous route
89187143|NCT00765453|Placebo Comparator|Placebo|Placebo infusion
88869987|NCT05188508|Experimental|Recurrent enhancing grade II and III IDH-mutated gliomas that have failed previous therapy|All patients will receive pembrolizumab for two cycles prior to the addition of olaparib and temozolomide. Combination olaparib and temozolomide will be added in cycle 3. Combination therapy will continue through cycle 11 (cycles 3-11 = 27 weeks or approximately 6 months). Patients will then continue on pembrolizumab maintenance for a maximum of 35 cycles (two years) or until progression of disease or unacceptable toxicity.
89003752|NCT04607421|Experimental|Safety Lead-in Cohort 1|Encorafenib 300 mg orally once daily Cetuximab 500 mg/m2 (120-minute IV infusion) every two weeks Irinotecan 180 mg/m2 (90-minute IV infusion) every two weeks Leucovorin 400 mg/m2 (120-minute IV infusion) every two weeks 5-FU 400 mg/m2 IV bolus, then 5-FU 2400 mg/m2 continuous IV infusion over 46-48 hours every two weeks
89003753|NCT04607421|Experimental|Safety Lead-in Cohort 2|Encorafenib 300 mg orally once daily Cetuximab 500 mg/m2 (120 minute IV infusion) every two weeks Oxaliplatin 85 mg/m2 (120-minute IV infusion) every two weeks Leucovorin 400 mg/m2 (120-minute IV infusion) every two weeks 5-FU 400 mg/m2 IV bolus, then 5-FU 2400 mg/m2 continuous IV infusion over 46-48 hours every two weeks
89003754|NCT04607421|Experimental|Phase 3 Arm A|Encorafenib 300 mg orally once daily Cetuximab 500 mg/m2 (120-minute IV infusion) every two weeks
89187144|NCT05332730|Experimental|BAT2506|BAT2506 injection, 50 mg, subcutaneous administration. Dose regimen: 50 mg/0.5 mL/syringe, subcutaneously injected at the lower abdomen, except for the 5 cm area around the navel. Do not inject into skin that is tender, bruised, red, scaly, or hard. Avoid areas with scars or stretch mark.
89187145|NCT05332730|Active Comparator|Simponi® (EU commercially available product)|50 mg, subcutaneous administration Dose regimen: 50 mg/0.5 mL/syringe, subcutaneously injected at the lower abdomen, except for the 5 cm area around the navel. Do not inject into skin that is tender, bruised, red, scaly, or hard. Avoid areas with scars or stretch mark.
89393898|NCT01359917||polylactic acid|treatment with polylactic acid (PLA) for HIV lipodystrophy
89393899|NCT01359917||bio-alcamid|bio-alcamid injections
89393900|NCT02129582|Experimental|Treatment (TMI, fludarabine, busulfan, allogeneic HPCT)|"CONDITIONING: Patients undergo TMI BID on days -10 to -7. Patients also receive fludarabine phosphate IV over 1 hour on days -6 to -2 and busulfan IV or PO on days -5 and -4.~TRANSPLANT: Patients undergo allogeneic hematopoietic progenitor cell transplant on day 0.~GVHD PROPHYLAXIS: Patients receive anti-thymocyte globulin IV on days -3 and -2, tacrolimus IV or PO beginning on day -1 for at least 6 months with taper beginning at 4 months, and methotrexate IV on days 1, 3, 6, and 11."
88869988|NCT05188508|Experimental|Recurrent IDH-wildtype gliomas and homologous recombination deficiency (HRD).|Five patients will receive pembrolizumab for two cycles prior to the addition of olaparib and temozolomide. Combination olaparib and temozolomide will be added in cycle 3. Combination therapy will continue through cycle 11 (cycles 3-11 = 27 weeks or approximately 6 months). Patients will then continue on pembrolizumab maintenance for a maximum of 35 cycles (two years) or until progression of disease or unacceptable toxicity. This cohort will be analyzed descriptively.
88869989|NCT05183360|Experimental|BI 706321 single dose|
88869990|NCT05183360|Experimental|BI 706321 multiple dose|
88869991|NCT05183360|Placebo Comparator|Placebo|
88869992|NCT05173844|Experimental|Treatment|Participants will be instructed to use SleepFix mobile application for 3 weeks with an optional 3 weeks of additional therapy. Participants will complete daily sleep diary entries (which take less than 1 min) which are used to calculate the sleep window titration. SleepFix incorporates sleep restriction and stimulus control which have been shown to be the most powerful components of cognitive-behavioural therapy for insomnia - CBTi. It has been shown to produce rapid, clinically-meaningful insomnia symptom reduction in a shorter period of time compared with both face-to-face and digital CBTi. SleepFix does not require the user to complete modules and multiple components such as other digital CBTi programs (e.g. Sleepio). Further, it is personalised to the individual's current sleep patterns and requires minimal engagement compared to full CBTi.
88869993|NCT05173844|No Intervention|Control|Participants randomised to the control group will gain access to the first Sleep Health Education module immediately following completion of baseline questionnaires. There are 3 modules provided bi-weekly and the information in these modules is presented as a subdomain through the study website. The participant will receive a link to this information as each module is made available. Control participants will have full access to these modules for the duration of the study.
88869994|NCT05172973|Experimental|Transcatheter Aortic Valve Replacement (TAVR) - Surgical Valve|TAVR implant in subjects with a failing aortic surgical valve.
88869995|NCT05172973|Experimental|Transcatheter Aortic Valve Replacement (TAVR) - THV|TAVR implant in subjects with a failing aortic transcatheter heart valve (THV).
88869996|NCT05169580|Experimental|FTX-6058 oral capsule(s) in Sickle Cell participants|Cohort 1 will receive 6 mg of FTX-6058 by mouth once daily. Cohort 2 will be dosed at 2 mg once daily by mouth, and cohort 3 will be dosed at 12 mg once daily by mouth. The Sponsor will reinitiate enrolment in the 3rd cohort (12 mg cohort) with the updated inclusion and exclusion criteria. Based on review of available safety and biomarker data and with the recommendation of the DMC, a subsequent 4th cohort of 20 mg and potentially a 5th cohort of 30 mg may be initiated. A total of seven cohorts may be included. Following the first cohort, doses for all subsequent cohorts will be determined following DMC review of the safety and pharmacokinetic data observed in participants from the prior and ongoing cohorts. Alternate dosing schedules may be evaluated in some of the cohorts.
88869997|NCT05168423|Experimental|Dose Level 1|Cohort 1 (N = 3-6): will receive a single fixed dose of 1x10^7 CART-EGFR-IL13Ra2 cells via intrathecal administration on Day 0.
88869998|NCT05168423|Experimental|Dose Level -1|Cohort-1 (N = 3-6): will receive a single fixed dose of 5x10^6 CART-EGFR-IL13Ra2 cells via intrathecal administration on Day 0.
88869999|NCT05168423|Experimental|Dose Level 2|Cohort 2 (N = 3-6): will receive a single fixed dose of 2.5x10^7 CART-EGFR-IL13Ra2 cells via intrathecal administration on Day 0.
88870000|NCT05168423|Experimental|Dose Level 3|Cohort 3 (N = 3-6): will receive a single fixed dose of 5x10^7 CART-EGFR-IL13Ra2 cells via intrathecal administration on Day 0.
88870001|NCT05156047|Active Comparator|Pitolisant|"Dose Optimization Period:~Week 1: 8.9 mg pitolisant administered once daily in the morning upon wakening; Week 2: 17.8 mg pitolisant administered once daily in the morning upon wakening; Weeks 3 through 6: 17.8 or 35.6 mg pitolisant administered once daily in the morning upon wakening.~Stable Dose Period:~Weeks 7 through 8: Stable dose of 17.8 or 35.6 mg pitolisant administered once daily in the morning upon wakening.~Double-Blind Randomized Withdrawal Phase:~Weeks 9 through 12: Stable dose of 17.8 or 35.6 mg pitolisant administered once daily in the morning upon wakening."
88870002|NCT05156047|Placebo Comparator|Matching Placebo|"Double-Blind Randomized Withdrawal Phase:~Weeks 9 through 12: Matching placebo tablets."
88870003|NCT05152134|Experimental|Empowered Relief On Demand|Empowered Relief On-Demand will include roughly 80 minutes of interactive and multimedia pain educational content that targets pain and stress self-regulation, pain medication misuse, a personalized plan for relief and an audio App for daily use.
88870004|NCT05152134|Placebo Comparator|"Health Education (HE; Living Better)"|"The HE arm is an interactive digital general health education intervention called Living Better that is devoid of specific content on pain, psychological skills, and has no active strategies or worksheets."
88870005|NCT05150873||Patients ttreatted for AAA|Patients affected by AAA and treated att our institution with EVAR and/or Open Repair between 2010 and 2020
88870006|NCT05129319|Active Comparator|OLD (4 U per 0.1 mL)|The total Jeuveau dose will be 20U divided into 5 injections. Each subject will receive a total of 0.5 mL of Jeuveau during the treatment.
88870007|NCT05129319|Active Comparator|COLD (4 U per 0.02 mL group)|The total Jeuveau dose will be 20U divided into 5 injections. Each injection will receive a total of 0.1 mL of Jeuveau during the treatment.
88870008|NCT05124847|Experimental|TRE-Control|
88870009|NCT05124847|Experimental|Control-TRE|
88870010|NCT05113342|Experimental|Arm 1: Dose Level 1|Minimum of 3 patients per Dose Level will be treated sequentially with once weekly infusions for 3 weeks in a 28-day cycle until the Maximum Tolerated Dose (MTD) is reached.
88870011|NCT05113342|Experimental|Arm 2: Dose Level 2|Minimum of 3 patients per Dose Level will be treated sequentially with once weekly infusions for 3 weeks in a 28-day cycle until the Maximum Tolerated Dose (MTD) is reached.
88870012|NCT05113342|Experimental|Arm 3: Dose Level 3|Minimum of 3 patients per Dose Level will be treated sequentially with once weekly infusions for 3 weeks in a 28-day cycle until the Maximum Tolerated Dose (MTD) is reached.
88870013|NCT05113342|Experimental|Arm 4: Dose Expansion|In Arm 2, the MTD established in Arm 1 will be administered for 3 28-day cycles to further evaluate the product's safety and preliminary efficacy.
88870014|NCT05111249|Experimental|Treatment Arm A|Branaplam 56 mg oral solution once weekly
88870015|NCT05111249|Experimental|Treatment Arm B|Branaplam 112 mg oral solution once weekly
88870016|NCT05111249|Experimental|Treatment Arm C or X or Y|(C) Branaplam 154 mg oral solution once weekly, OR (X) Branaplam 84 mg oral solution once weekly OR (Y) Branaplam 28 mg oral solution once weekly
88870017|NCT05111249|Placebo Comparator|Placebo|Matching placebo oral solution once weekly
88870018|NCT05109637|Experimental|Participants with SMA (PwSMA)|Participants with SMA will have their motor functions assessed using the Konectom NMD smartphone-based application up to Day 28.
88870019|NCT05109637|Experimental|Participants with ALS (PwALS)|"Participants with ALS will have their cognitive and motor functions assessed using the Konectom NMD smartphone-based application up to Day 28.~As per protocol version 4.0, enrolment of ALS participants is stopped, and the data of the already enrolled ALS participants would not be analyzed."
88870020|NCT05109637|Experimental|Healthy Participants|Healthy participants will have their cognitive and motor functions assessed using the Konectom NMD smartphone-based application for 28 days.
88870021|NCT05096481|Experimental|PEP-CMV|Participants will receive standard chemotherapy with temozolomide for five days, followed by the study vaccine, PEP-CMV, on day 21. Participants will receive a tetanus diphtheria (Td) booster vaccine and a small dose Td preconditioning vaccine to prepare their immune system to receive their first PEP-CMV vaccine. Participants will receive the first 3 PEP-CMV vaccines every 2 weeks, and after the third vaccine, the rest of the vaccines will be given monthly. The first cycle is 77 days and all subsequent cycles are 28 days. The PEP-CMV vaccine may be received for up to 24 cycles.
88870022|NCT05090787|Experimental|Investigational Device|Investigational mDCB00
88870023|NCT05090787|Active Comparator|Control Device|Control DCB00
88870024|NCT05088070|Experimental|SPH 3348 tablets|6 different dosage group of SPH 3348 will be assigned with 16mg, 40mg, 80mg, 160mg, 240mg and 320mg respectively.
88870025|NCT05085821|Experimental|Experimental 1: HEART - Placebo - HEART - Placebo|"The patient receives visual feedback in an augmented reality environment in four session, over two weeks.~Week 1: HEART, Placebo (after >24hour washout) Week 2: HEART, Placebo (after >24hour washout)"
88870026|NCT05085821|Experimental|Experimental 2: HEART - Placebo - Placebo - HEART|"The patient receives visual feedback in an augmented reality environment in four session, over two weeks.~Week 1: HEART, Placebo (after >24hour washout) Week 2: Placebo, HEART (after >24hour washout)"
88870027|NCT05085821|Experimental|Experimental 3: Placebo - HEART - Placebo - HEART|"The patient receives visual feedback in an augmented reality environment in four session, over two weeks.~Week 1: Placebo, HEART (after >24hour washout) Week 2: Placebo, HEART (after >24hour washout)"
88870028|NCT05085821|Experimental|Experimental 4: Placebo - HEART - HEART - Placebo|"The patient receives visual feedback in an augmented reality environment in four session, over two weeks.~Week 1: HEART, Placebo (after >24hour washout) Week 2: Placebo, HEART (after >24hour washout)"
88870029|NCT05085496|Experimental|Treatment (SBRT, atezolizumab)|Patients undergo SBRT on days 1, 3, 5, 7, and 9 of cycle 1. Beginning 1-2 days after SBRT, patients also receive atezolizumab IV on day 1. Treatment repeats every 3 weeks for 3 cycles in the absence of disease progression or unacceptable toxicity.
88870030|NCT05083481|Experimental|ASP1570 Monotherapy Dose Escalation (Part 1)|Participants will receive daily dose of ASP1570 in a 21-day cycle.
89187146|NCT05332730|Active Comparator|Simponi® (US commercially available product)|50 mg, subcutaneous administration Dose regimen: 50 mg/0.5 mL/syringe, subcutaneously injected at the lower abdomen, except for the 5 cm area around the navel. Do not inject into skin that is tender, bruised, red, scaly, or hard. Avoid areas with scars or stretch mark.
88870031|NCT05083481|Experimental|ASP1570 Monotherapy Tumor Specific Dose Expansion - Response-triggered Tumor (Part 2)|Participants will receive ASP1570 in a 21-day cycle in tumor-specific cohort if dose escalation cohort had partial response (PR) or complete response (CR) in same tumor type at a dose that has been cleared and deemed tolerable.
88870032|NCT05083481|Experimental|ASP1570 Monotherapy Dose Expansion - Melanoma (Part 2)|Participants who have melanoma will receive recommended Phase 2 dose (RP2D) of ASP1570 in a 21-day cycle.
88870033|NCT05083481|Experimental|ASP1570 Monotherapy Dose Expansion - Non-Small Cell Lung Carcinoma (NSCLC) (Part 2)|Participants who have NSCLC will receive RP2D of ASP1570 daily in a 21-day cycle.
88870034|NCT05083481|Experimental|ASP1570 + Pembrolizumab Combination therapy Dose Escalation (Part 1)|Participants will receive daily dose of ASP1570 in a 21-day cycle. Pembrolizumab will be administered every 6 weeks on day 1 of every other ASP1570 cycle.
89187147|NCT02581904|Experimental|High Risk - Prevena Care|The Prevena device is a product from KCI and is a sterile sponge that covers the closed incision. The device is placed sterile in the operating room and suction is then applied to the sponge for 5-7 days.
88870035|NCT05083481|Experimental|ASP1570 + Pembrolizumab Combination therapy Dose Expansion - NSCLC (Part 2)|Participants who have NSCLC will receive RP2D of ASP1570 daily in a 21-day cycle. Pembrolizumab will be administered every 6 weeks on day 1 of every other ASP1570 cycle.
88870036|NCT05083481|Experimental|ASP1570 Monotherapy Dose Expansion - Food Effect (Part 2)|Participants will receive RP2D of ASP1570 after the meal in a 21-day cycle. This cohort will be opened at the discretion of the sponsor.
89187148|NCT02581904|Active Comparator|High Risk - Dry Gauze Dressing Care|Initial dry gauze dressing will be placed sterile in the operating room and will be changed daily
89187149|NCT02581904|Active Comparator|Low Risk - Dry Gauze Dressing Care|Initial dry gauze dressing will be placed sterile in the operating room and will be changed daily
89393901|NCT03282565|Experimental|Functional Resistance Training with a Brace|Participants will receive functional resistance training via a knee brace while walking on a treadmill 2-3 times a week for about 8 weeks.
89393902|NCT03282565|Experimental|Functional Resistance Training with Elastic Band|Participants will receive functional resistance training via an elastic band attached at the ankle while walking on a treadmill 2-3 times a week for about 8 weeks.
89393903|NCT03282565|Sham Comparator|Control|Participants will while on a treadmill without an applied resistance 2-3 times a week for about 8 weeks.
89393904|NCT01355549|Experimental|Platelet-rich plasma therapy|Platelet rich plasma (PRP) describes a new technology in which platelets are isolated from a sample of a person's own blood using simple cell-separating systems such as centrifugation in order to obtain highly concentrated samples of platelets that can be re-injected into an injury site to promote healing.
89393905|NCT02129738|Experimental|LoFric|LoFric catheters
89393906|NCT01362023|No Intervention|control|Control pupils follow their usual activities
89393907|NCT01362023|Experimental|lifestyle counseling|"In 3 academic years, the intervention program consisted of three components:~Classroom practice by HPA to highlight healthy lifestyle habits~Teaching practice by HPA using books designed to include the nutritional objectives~Parental activities included with their children~In each of 12 activities (1 h/activity), the classroom practice consisted of three components:~Experimental development of activities regarding each healthy lifestyle habit~Assessment of activity performed in classroom~An activity developed for use at home"
89393908|NCT02133794|Experimental|Tomosynthesis|
89393909|NCT05188625|No Intervention|Control arm|This group will receive the standard care of face-to-face dietitian counselling sessions.
89393910|NCT05188625|Experimental|Intervention arm|This group will receive online self-paced dietary education, and followed up by telehealth video consultation with dietitian for dietary counselling.
89393911|NCT02129816|Active Comparator|Bryophyllum|50% in 350mg Lactose, 2-2-2
89393912|NCT02129816|Placebo Comparator|Placebo|Lactose 350mg, 2-2-2
89393913|NCT02129816|Experimental|Solifenacin|10mg in 350mg Lactose, 2-2-2
89393914|NCT05106205|Experimental|Sequence A|
89393915|NCT05106205|Experimental|Sequence B|
89393916|NCT01362101|Active Comparator|Traditional behavioral intervention|
89393917|NCT01362101|Active Comparator|Mindfulness behavioral intervention|
88870037|NCT05083481|Experimental|ASP1570 Monotherapy Dose Expansion - Prophylactic Steriods (Part 2)|Participants will receive RP2D of ASP1570 along with the prophylactic steroids in a 21-day cycle. This cohort will be opened at the discretion of the sponsor.
88870038|NCT05083481|Experimental|ASP1570 Monotherapy Dose Expansion - Intermittent dosing (Part 2)|Participants will receive RP2D of ASP1570 with some periodical drug holiday in a 21-day cycle. This cohort will be opened at the discretion of the sponsor.
88870039|NCT05083481|Experimental|ASP1570 Monotherapy Dose Expansion - Stepwise dosing (Part 2)|Participants will receive ASP1570 administered by intra-subject dose escalation with gradual multiple dose steps (e.g., 3 steps) and increased dose up to RP2D in a 21-day cycle. This cohort will be opened at the discretion of the sponsor.
88870040|NCT05071092|Experimental|Intervention group|The intervention will consist of personalized guidance from a dietician focussing on improving adherence to the Dutch dietary guidelines.
88870041|NCT05071092|No Intervention|Usual care group|The usual care group will not receive any special guidance regarding healthy nutrition, but will have access to their care team as usual.
89187150|NCT00765609||1|Using the information distributed with over-the-counter medication (The Patient Information Leaflet or PIL)
89187151|NCT00765609||2|Paediatric Analgesia Slide (the new device)
89393918|NCT02129894|Active Comparator|abdominal binder|Post cesarean section patients will get a abdominal binder placed
88870042|NCT05069168||LVEFrecovery|patient who shows improvement of left ventricular systolic function
88870043|NCT05069168||Non LVEF recovery|patient who don't show improvement of left ventricular systolic function
88870044|NCT05065970|Placebo Comparator|Placebo|
88870045|NCT05065970|Experimental|Felzartamab Arm #1|
88870046|NCT05065970|Experimental|Felzartamab Arm #2|
88870047|NCT05065970|Experimental|Felzartamab Arm #3|
89393919|NCT02129894|No Intervention|No Abdominal Binder|Post cesarean section patients will not have abdominal binder
89393920|NCT02129972|Experimental|video capsule endoscopy|
89393921|NCT04715243|Other|control|Face-mask NIV is the standard of care
89393922|NCT04715243|Active Comparator|intervention 1|High flow nasal cannula
89393923|NCT04715243|Active Comparator|Intervention 2|Helmet NIV
89393924|NCT02138162|Experimental|1:Single dose of enzalutamide in hepatically impaired subjects|Single dose of enzalutamide
89393925|NCT02138162|Experimental|2:Single dose of enzalutamide in healthy subjects|Single dose of enzalutamide
89393926|NCT01362179||unstimulated BM donors|Observational (non-interventional) study.
89393927|NCT01362179||filgrastim-mobilized PBSC donors|Observational (non-interventional) study.
89393928|NCT02138318|Other|chromoendoscopy|
89393929|NCT02138318|Other|High definition (HD) endoscopy|
89393930|NCT03549572||Severe Traumatic Brain Injury|We will administer Coma Recovery Scale-Revised (CRS-R) and the Coma Recovery Scale Revised For Accelerated Standardized Testing (CRSR-FAST) to patients in the intensive care unit who have impaired level of consciousness resulting from a severe traumatic brain injury.
89393931|NCT02133950|Experimental|freeze all embryos following PGD|no fresh embryo transfer; elective cryopreservation of all embryos after PGD
89393932|NCT02133950|Active Comparator|elective fresh embryo transfer|
89393933|NCT04566029||Cases|Patients who have been responding to treatment for a long time
89393934|NCT04566029||Controls|Patients who do not respond to treatment
88870048|NCT05052281|Experimental|Intervention group|"The first MB course session and technology training will take place in-person, prior to 23 weeks gestation. The Mothers and Babies course (MB) is a 12-session manualized stress-reduction intervention that will be delivered to participants, prenatally, with an integrated technology suite designed for timely detection and response to maternal stress. Sessions are delivered 1-on-1 with a trained facilitator and are based on principles of cognitive-behavioral therapy (CBT) and attachment theory. The MB course is divided into 3 sections: 1) Pleasant Activities; 2) Thoughts; 3) Contact with Others. Throughout each module, mindfulness skills training will be integrated as a strategy to help center participants. All participants will receive a Participant Manual for Families, containing worksheets that correspond to the 12 sessions."
88870049|NCT05052281|Active Comparator|Stress monitoring (control) group|This group will not receive any additional intervention but will engage in stress monitoring via biosensors and EMA text messages through the 14 week period
88870050|NCT05028790|Experimental|Single vision soft contact lens first, then multifocal soft contact lens|Participants wore the single vision soft contact lens first, then a multifocal soft contact lens
88870051|NCT05028790|Experimental|Multifocal soft contact lens first, then single vision soft contact lens|Participants wore the multifocal soft contact lens first, then the single vision soft contact lens
89187152|NCT02581826|Active Comparator|Silodosin|"Silodosin capsules of 4 mg, oral: 4 mg once daily with a meal, total dosage 12 mg for 14-21 days.~This arm received Silodosin in the first intervention period and Placebo in the second period (after washout period of 14-21 days).~The patients received 4 mg of Silodosin 1 times a day, total dosage 12 mg for 14-21 days."
89187153|NCT02581826|Placebo Comparator|Placebo|"Placebo capsules of 4 mg, oral: 4 mg once daily with a meal, total dosage 12 mg for 14-21 days.~This arm received Placebo in the first period and Silodosin in the second period (after washout period of 14-21 days).~The patients received 4 mg of Placebo 1 times a day, total dosage 12 mg for 14-21 days."
89187154|NCT00765687|No Intervention|Observation|
89187155|NCT00765921|Experimental|1.0 mg ranibizumab|1.0 mg intravitreal injection given bi-monthly for 22 months
89187156|NCT00765921|Experimental|0.5 mg ranibizumab|0.5 mg intravitreal injection given bi-monthly for 22 months
89187157|NCT02583308|Active Comparator|Period with endotracheal tubes not allowing SSD|During this period of the DEMETER study (NCT02515617), patients will be intubated with standard endotracheal tubes not allowing Subglottic Secretions
89187158|NCT02583308|Experimental|Period with endotracheal tubes allowing SSD|During this period of the DEMETER study (NCT02515617), patients will be intubated with specific endotracheal tubes allowing Subglottic Secretions Drainage
89187159|NCT02582606|Experimental|Regular|Regular meal pattern
89187160|NCT02582606|Experimental|Irregular|Irregular meal pattern
89187161|NCT02582762|Experimental|Nail gel|apply nail gel twice daily
89187162|NCT00672477|Experimental|Methylnaltrexone|Methylnaltrexone subcutaneously every other day for 14 days (ie, 7 doses). Subjects received 0.6 mL (12 mg) every other day if weight ≥ 62kg; or 0.4 mL (8 mg) every other day if weight between 38 and <62 kg. Subjects with impaired kidney function received reduced doses according to instructions in the Relistor prescribing information.
89187163|NCT00672477|Placebo Comparator|Placebo|Placebo subcutaneously every other day for 14 days (ie, 7 doses). Subjects received 0.6 mL every other day if weight ≥ 62kg; or 0.4 mL every other day if weight between 38 and < 62 kg. Subjects with impaired kidney function received reduced volumes of placebo solution to match the volumes used in the experimental group.
89187164|NCT04080362|Experimental|MitralStitch repair system|Experimental group is allocated to use novel mitral vavle repair system manufactured by Hangzhou Valgen Medtech Co., Ltd
89187165|NCT02585336|No Intervention|Observation|
89187166|NCT02585336|Experimental|Brief intervention|
89187167|NCT03925610||Morbidly obese patients with moderate-to-severe OSA|"Morbidly obese patients recovering from general anesthesia after weight loss surgery (gastric bypass and sleeve placement) surgery.~All patients will undergo preoperative and postoperative continuous transcutaneous and intermittent arterial blood PCO2 monitoring.~Sedation depth and pain assessment will be performed in the post-anesthesia care unit (PACU). Fentanyl only will be administered during surgery and in PACU to provide analgesia (verbal numerical score ≤ 3).~A total of 9, 10-mL blood samples (including a preoperative blank sample) will be obtained throughout the study period (1 preoperatively, 4 intraoperatively and 4 in the PACU) to measure fentanyl concentration in the plasma. Five 1-mL samples will be used to determine arterial PCO2."
89187168|NCT03925610||Morbidly obese patients with no or mild OSA|"Morbidly obese patients recovering from general anesthesia after weight loss surgery (gastric bypass and sleeve placement) surgery.~All patients will undergo preoperative and postoperative continuous transcutaneous and intermittent arterial blood PCO2 monitoring.~Sedation depth and pain assessment will be performed in the post-anesthesia care unit (PACU). Fentanyl only will be administered during surgery and in PACU to provide analgesia (verbal numerical score ≤ 3).~A total of 9, 10-mL blood samples (including a preoperative blank sample) will be obtained throughout the study period (1 preoperatively, 4 intraoperatively and 4 in the PACU) to measure fentanyl concentration in the plasma. Five 1-mL samples will be used to determine arterial PCO2."
88870052|NCT05028751|Experimental|Part 1: Dose Escalation|Sequential cohorts of participants will receive escalating doses of lanraplenib (LANRA) once daily (QD) + gilteritinib QD in each 28 day cycle for determination of the maximally tolerated dose (MTD) / recommended Phase 2 dose (RP2D) of LANRA in combination with gilteritinib.
88870053|NCT05028751|Experimental|Part 2: Expansion Cohort|Following identification of the maximally tolerated dose (MTD) / recommended Phase 2 dose (RP2D) of lanraplenib (LANRA) in combination with gilteritinib in Part 1, an expansion cohort will enroll. The expansion cohort will receive LANRA in combination with gilteritinib at the MTD / RP2D once daily (QD) in each 28 day cycle.
88870054|NCT05022459||Emicizumab Prophylaxis|This group will include patients on standard of care Emicizumab prophylaxis for Hemophilia A
88870055|NCT05022459||FVIII Prophylaxis|This group will include patients on standard of care FVIII prophylaxis for Hemophilia A
88870056|NCT05006716|Experimental|Part 1a (Monotherapy Dose Escalation)|Dose escalation in selected R/R B-Cell malignancies to inform safety, tolerability and MTD.
88870057|NCT05006716|Experimental|Part 1b (Monotherapy Safety Expansion)|Additional participants with selected R/R B-Cell malignancies will be enrolled at selected doses to help inform the selection of the recommended phase two dose (RP2D).
88870058|NCT05006716|Experimental|Part 1c (Additional Monotherapy Safety Expansion)|After RP2D is determined, additional safety data will be collected to confirm RP2D for participants with selected B-cell malignancies not being evaluated in Part 2
88870059|NCT05006716|Experimental|Part 2 (Monotherapy Dose Expansion)|The totality of the data from Part 1a and Part 1b will be used to further evaluate the safety and efficacy of BGB-16673 at the recommended dose(s) for Part 2 expansion in specific histologies.
88870060|NCT04999852|Experimental|Psychotherapy + SSP|All subjects enrolled in this study will receive the SSP intervention
88870061|NCT04999852|Active Comparator|Psychotherapy (treatment as usual)|Subjects who are receiving psychotherapy but not the SSP intervention
88870062|NCT04995497|Experimental|Erector Spinae Plane Block-Administration of Lidocaine|Bilateral ultrasound guided erector spinae plane catheter placement for the administration of lidocaine. Dose will be 2 mg/kg ideal body weight. Bolus will be divided equally between the two ESP catheters. This is followed by lidocaine infusion via ESP catheter at 2 mg/kg/hr for 48 hours after catheter placement.
88870063|NCT04995497|Active Comparator|Intravenous-Administration of Lidocaine|Sham block procedure (catheter will be taped to subjects skin). Subject will receive a bolus of lidocaine at 2 mg/kg ideal body weight. This is followed by lidocaine infusion via intravenous route at 2 mg/kg/hr for 48 hours after sham catheter placement.
88870064|NCT04989075|No Intervention|Control group|The control group will continue its usual oral hygiene practice.
88870065|NCT04989075|Experimental|Oral prophylactic intervention|For the study group, the oral prophylactic intervention will consist of provision of specfic package including soft-bristled manual toothbrush, toothpaste, and a kit of calibrated interdental brushes (IDBs)(Curaprox CPS; Curaden) of sizes corresponding to the diameter of their interdental spaces. The participants will be instructed to brush their teeeth twice-daily and to realise a daily interdental brushing until delivery. The instructions for the use of the toothbrush and IDBs comprised verbal instructions supported by practical demonstration. The first use of the material will be conducted under the supervision of a qualified public health professor.
88870066|NCT04983186|Experimental|Participants|Participants wear the Empatica E4 wearable sensor and use the smartphone applications developed by the research team.
88870067|NCT04980391|Experimental|RSV_MAT Group|Maternal participants randomized to the RSV_MAT Group received a single dose of the RSV MAT vaccine administered, between 24 and 36 weeks of gestation, at Day 1 in this study.
88870068|NCT04980391|Placebo Comparator|Control Group|Maternal participants randomized to the Control Group received a single dose of Placebo administered, between 24 and 36 weeks of gestation, at Day 1 in this study.
88870069|NCT04980391|No Intervention|RSV_MAT Group-Infant|This group consisted of infants born to mothers (from RSV_MAT Group-Mother) who received a single dose of RSV MAT vaccine during pregnancy.
88870070|NCT04980391|No Intervention|Control Group-Infant|This group consisted of infants born to mothers (from Control Group-Mother) who received a single dose of placebo during pregnancy.
88870071|NCT04973605|Experimental|Part 1 Dose Escalation|Dose-escalation and de-escalation to determine maximum tolerated dose (MTD)
88870072|NCT04973605|Experimental|Part 2 Cohort Expansion|There will be 5 expansion cohorts to further evaluate the safety and efficacy of BGB-11417
88870073|NCT04968236|Experimental|Deep dry needling|With the subject lying supine, we will first locate a latent myofascial trigger point in the rectus femoris muscle.Subsequently, we will apply a deep dry needling technique to the latent trigger point and make 10-12 incisions.
88870074|NCT04968236|Experimental|Superficial dry needling|With the subject lying supine, we will first locate a latent myofascial trigger point in the rectus femoris muscle.Subsequently, we will apply a superficial dry needling technique to the latent trigger point. Once the needle is placed in the subcutaneous cellular tissue, we manipulate the needle by twisting it until an unpleasant response is provoked. We keep the needle for 5 minutes
88870075|NCT04968236|Experimental|Passive muscle stretching|With the patient positioned in the supine position, the pelvis stabilized with a strap and the lower extremity where we are going to apply the rectus femoris muscle stretch placed outside the table, we perform a passive stretching technique, increasing hip extension and knee flexion until the patient feels the tension. The position is held for 60 seconds.
88870076|NCT04951479|Experimental|Gel-Bead Embolization|
88870077|NCT04943042||Full-analysis set (FAS)|The FAS includes all enrolled patients. The FAS will be used for all analyses.
88870078|NCT04939428|Experimental|Molnupiravir|Participants take molnupiravir 800 mg every 12 hours (Q12H) on Days 1 to 5.
88870079|NCT04939428|Placebo Comparator|Placebo|Participants take placebo Q12H on Days 1 to 5.
88870080|NCT04914325|Experimental|Intervention arm :copings veneered with CAD/CAM composite resin|
89393935|NCT02138396|Experimental|FSS first, then FCI|At each of two treatment visits participants fast for 10 hours before dosing, and receive naltrexone before and after dosing. Participants in this group receive a single dose of fentanyl sublingual spray (FSS) at the first visit. After a washout period of at least seven days, they receive a single intramuscular fentanyl citrate injection (FCI) at the second treatment visit.
88870081|NCT04914325|Active Comparator|Control arm : copings veneered with manual layering|
89393936|NCT02138396|Experimental|FCI first, then FSS|At each of two treatment visits participants fast for 10 hours before dosing, and receive naltrexone before and after dosing. Participants in this group receive a single intramuscular fentanyl citrate injection (FCI) at the first visit. After a washout period of at least seven days, they receive a single dose of fentanyl sublingual spray (FSS) at the second treatment visit.
89393937|NCT02138474|Experimental|Lacticum acidum homaccord|Lacticum acidum homaccord 30 mL bottle of medicated sucrose pillules take 5 pillules of the medication in the morning and in the evening for 4 weeks
89393938|NCT02138474|Placebo Comparator|Placebo|Unmedicated sucrose pillules, take 5 pillules twice daily for 4 weeks
89393939|NCT04560881|Experimental|Inactivated SARS-CoV-2 vaccine, manufactured by BIBP|Intramuscular injection
89393940|NCT04560881|Placebo Comparator|Placeboof Inactivated SARS-CoV-2 vaccine, manufactured by BIBP|Intramuscular injection
89393941|NCT02911675||Standard of Care Group|Study Group 1: Standard EVD/IVC management with therapeutic CSF drainage as appropriate and hourly EVD/IVC ICP measurements per standard of care with simultaneous IPM/Camino ICP measurements collected.
89393942|NCT02911675||Experimental Group|Study Group 2: Therapeutic CSF drainage as appropriate, with EVD/IVC closure and ICP assessment approximately every 12 hours with simultaneous IPM/Camino ICP measurements collected.
88870082|NCT04907370|Experimental|Toripalimab Combined with Induction Chemotherapy Followed by Radiotherapy Alone|All participants will receive induction chemotherapy (IC; every 3 weeks × 3 cycles; gemcitabine 1000 mg/m2 day 1, 8 + cisplatin 80 mg/m2 day 1) followed by intensity-modulated radiotherapy (IMRT; 70 Gy, 33 fractions, 5 fractions/week, 1 fraction/day) alone. PD-1 blockade toripalimab (240 mg per cycle) will start on day 1 of the first cycle IC and continue every 3 weeks for 6 cycles till the end of IMRT, involving the whole-course of IC + IMRT alone. The first and last 3 cycles of toripalimab are administrated concurrently with IC and IMRT, respectively. After 3 weeks of the completion of IMRT, adjuvant toripalimab (240 mg per cycle) will begin every 3 weeks for 11 cycles.
88870083|NCT04907370|Active Comparator|Toripalimab Combined with Induction Chemotherapy Followed by Concurrent Chemoradiotherapy|All participants will receive induction chemotherapy (IC; every 3 weeks × 3 cycles of gemcitabine 1000 mg/m2 day 1, 8 + cisplatin 80 mg/m2 day 1) followed by concurrent chemoradiotherapy (CCRT; every 3 weeks × 2 cycles of cisplatin + IMRT 70 Gy, 33 fractions, 5 fractions/week, 1 fraction/day). PD-1 blockade toripalimab (240 mg per cycle) will start on day 1 of the first cycle IC and continue every 3 weeks for 6 cycles till the end of CCRT, involving the whole-course of IC + CCRT. The first and last 3 cycles of toripalimab are administrated concurrently with IC and CCRT, respectively. After 3 weeks of the completion of CCRT, adjuvant toripalimab (240 mg per cycle) will begin every 3 weeks for 11 cycles.
88870084|NCT04905446|Other|Healthy male subjects|
89393943|NCT05223842|Experimental|Family Promoting Positive Emotions Group|Each dyad (mother and their child) will receive 8 sessions of promoting positive emotions intervention with a clinician for 8 weeks.
89393944|NCT05223842|Active Comparator|Written Information Group|Mothers will be sent written information and resources on depression for 8 weeks over email.
88870085|NCT04893109|Experimental|Arm A. T-DM1 followed by Trastuzumab SC|Randomized participants will receive intravenous T-DM1 every 3 weeks for 6 cycles (18 weeks) and then Trastuzumab SC (subcutaneous) every 3 weeks for 11 cycles
88870086|NCT04893109|Experimental|Arm B: Paclitaxel with Trastuzumab SC, followed by Trastuzumab SC alone|Randomized participants will receive weekly intravenous Paclitaxel for 12 weeks (4 cycles) and Trastuzumab SC (subcutaneous) every 3 weeks for 17 cycles. The first 4 doses Trastuzumab SC are given with Paclitaxel.
89393945|NCT02875613|Experimental|Avelumab|Avelumab 10mg/kg IV infusion on days 1 and 15 of 28-day cycle
89393946|NCT02823457|Other|VBMI intervention group|All patients will receive a 12 week VBMI intervention to promote treatment completion
89393947|NCT02130050||OSA Patient|•male patients aged 30 to 65 yr who are newly diagnosed as severe OSA (AHI >=30/hr)
89393948|NCT02130050||Control subjects:|•male control subjects are recruited from Heath Check-up Center. Subjects who are matched with OSA patients at age (+/-2 yrs), body height (+/-3cm) and body weight (<100 kg: +/-3kg, >100 kg: +/-4kg) are screened. Only subjects who are not sleepy (ESS<10) and have no OSA (AHI<5/hr PSG)
89393949|NCT01362335||patients, that are having a routine surgical procedure.|
88870087|NCT04883073|Experimental|Endo App use|use of Endo App during trial
88870088|NCT04883073|No Intervention|control|no use of Endo App during trial
88870089|NCT04881461|Placebo Comparator|Placebo|Glycerol, carbonate, sodium chloride One single-dose container (0.5 ml) once daily
88870090|NCT04881461|Experimental|5-grass mix SLIT-drops|Grass mix sublingual allergy immunotherapy drops One single-dose container (0.5 ml) once daily. 50 SRU/day for five consecutive days followed by 150 SRU/day for five additional consecutive days. Maintenance: 300 SRU/day from day 11.
88870091|NCT04871308|Placebo Comparator|Control|Placebo group using normal saline infusion
89393950|NCT02130128|Experimental|Navigation and tissue sampling|Guided bronchoscopic navigation and lung tissue sampling using the LungPoint ATV System
89393951|NCT02130206|Active Comparator|Caries Free|Gums will be examined. On some visits Saliva and plaque will be collected. Toothpaste assigned will include DenClude 1.5% Arginine.
89393952|NCT02130206|Placebo Comparator|Caries Free - Placebo|Gums will be examined. On some visits Saliva and plaque will be collected. Marketed Toothpaste will be assigned.
89393953|NCT02130206|Active Comparator|Caries Active|Gums will be examined. On some visits Saliva and plaque will be collected. Toothpaste assigned will include DenClude 1.5% Arginine.
89393954|NCT02130206|Placebo Comparator|Caries Active - Placebo|Gums will be examined. On some visits Saliva and plaque will be collected. Marketed Toothpaste will be assigned.
89393955|NCT02815267|Experimental|FMX-101, 4% minocycline foam|Subjects will apply the assigned FMX-101, 4% minocycline foam topically once daily for 12 weeks as directed
89393956|NCT02815267|Placebo Comparator|Vehicle foam|Subjects will apply the assigned vehicle foam topically once daily for 12 weeks as directed
89393957|NCT01362569||predialytic renal insufficiency|Patents without renal replacement therapy
88870092|NCT04871308|Active Comparator|Dexmedetomidine|From anesthesia induction before the initiation of cardiopulmonary bypass, dexmedetomidine is infused intravenously at a rate of 0.5 mcg/kg/hr after a loading dose infusion of 0.75 mcg/kg for 10 mins.
89393958|NCT01362569||hemodialysis/hemofiltration patients|patients undergoing regular hemodialysis/hemofiltration
89393959|NCT01362569||peritoneal dialysis patients|patients undergoing peritoneal dialysis
89393960|NCT01362569||acute renal failure|patients with acute renal failure
89393961|NCT01362569||post renal transplantation|patients after renal transplantation
89393962|NCT01362569||healthy controls|control group
89393963|NCT02130440|Active Comparator|Resveratrol nasal spray|2 sprays per nostril 3 times a day for a period of two months
89393964|NCT02130440|Placebo Comparator|Placebo|2 sprays per nostril 3 times a day for a period of two months
89393965|NCT02138552|Active Comparator|OCT 0.1% vs. Placebo|0.1 % Octenidine dihydrochloride vs. Placebo (0.9 % sodium chloride solution)
89393966|NCT02138552|Active Comparator|OCT 0.15% vs. Placebo|0.15 % Octenidine dihydrochloride vs. Placebo (0.9 % sodium chloride solution)
89393967|NCT02138552|Active Comparator|OCT 2.0% vs. Placebo|0.2 % Octenidine dihydrochloride vs. Placebo (0.9 % sodium chloride solution)
89393968|NCT02930837|Experimental|alteplase|
89393969|NCT02138708|Experimental|Shunt closed|patients with heart disease and shunt who, following hemodynamic exploration, will be selected for closure of their shunt
89393970|NCT03633175|Active Comparator|Vaginal progesterone group|Women will receive vaginal progesterone 400 mg [Prontogest® vaginal pessaries 400, Marcyrl, Cairo, Egypt], once at bed time starting from 26-28 weeks of gestation and till 36 weeks of gestation or delivery (which is closer).
89393971|NCT03633175|No Intervention|Control group|Women with gestational age from 26-28 weeks diagnosed with placenta previa who will not receive vaginal progesterone.
89393972|NCT02138864|Experimental|18F-FP-(+)-DTBZ only|PET tracer: 18F-FP-(+)-DTBZ
89393973|NCT02539693|Experimental|Clonidine 75|Patients will receive sacrococcygeal local anesthesia with 75µg/mL of clonidine. The anesthetic mixture will contain: lidocaine 2% 14 mL, bupivacaine 0.5% 5 mL, and clonidine 0.5 mL with 0.5 mL of saline (thus 75 µg/mL).
89393974|NCT02539693|Experimental|Clonidine 150|Patients will receive sacrococcygeal local anesthesia with 150µg/mL of clonidine. The anesthetic mixture will contain: lidocaine 2% 14 mL, bupivacaine 0.5% 5 mL, and clonidine 1 mL (thus 150 µg/mL).
89393975|NCT02138942|Experimental|The study population|"See inclusion/exclusion criteria.~Intervention: LIR"
89393976|NCT01362725|Experimental|Spinal cord stimulation|
88870093|NCT04867369|Experimental|Pecs II block|80 patients scheduled for open biceps tenodesis
88870094|NCT04867369|Active Comparator|Surgical infiltration|80 patients scheduled for open biceps tenodesis
88870095|NCT04862260|Experimental|Multipathway cholesterol metabolism disruption|Twelve to fifteen patients will receive a combination of daily atorvastatin 40 mg, twice daily ezetimibe 10 mg and evolocumab 420 mg subcutaneously every month. This multipathway cholesterol metabolism disruption will be combined to standard chemotherapy (FOLFIRINOX).
88870096|NCT04858568||Hodgkin lymphoma|"Diagnoses:~Hodgkin lymphoma (classical Hodgkin lymphoma)"
88870097|NCT04858568||Aggressive B-NHL|"Diagnoses:~Aggressive B-NHL (E.g. Diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma, high-grade B-cell lymphoma, Burkitt lymphoma, de novo transformed lymphoma, follicular lymphoma grade 3b)"
88870098|NCT04858568||Indolent B-NHL|"Diagnoses:~Indolent B-NHL (E.g.follicular lymphoma grades 1-3a, mantle cell lymphoma, marginal zone lymphoma, chronic lymphocytic leukaemia/small lymphocytic lymphoma, lymphoplasmacytic lymphoma, nodular lymphocyte predominant Hodgkin lymphoma)"
88870099|NCT04858568||Peripheral T/NK-cell|"Diagnoses:~Peripheral T/NK-cell lymphomas (any mature T/NK cell malignancy)"
89393977|NCT05062135|Experimental|Morphological analysis of endometrium|"PCOS: Seventeen PCOS subjects underwent two endometrial biopsies after the first P4-treated cycle, the first between days 5-9 of the cycle and the other between days 20-22 (i.e., under P4 treatment) of the cycle.~Controls: Thirteen ovulatory control women under two endometrial biopsies, performed after the first month of luteal P4 treatment, the first between days 5-9 and the second between days 20-22 of the cycle To quantify the parameters of interest, images were captured using a high-resolution camera (AxioCam-MCR, Carl Zeiss) adapted to a light microscope (Axiolab, Carl Zeiss) and adjusted with 40× objective lenses. The images were transmitted to a computer with AxioVision Rel 4.2 software (Carl Zeiss). For assessment of glandular and surface epithelial thickness, cell count, and counting newly formed blood vessels, ten images of each endometrial sample were made for each patient. For VEGF-C determination, the numerical density of blood vessels per mm2 was established"
89393978|NCT02130518|Experimental|Auriclosene (AIS)|Auriclosene Irrigation Solution, 0.2%, 8 treatments over 4 weeks
89393979|NCT02130518|Placebo Comparator|Auriclosene Vehicle Solution|Auriclosene Vehicle Solution, 8 treatments over 4 weeks
89393980|NCT01355783|Active Comparator|E7777 + CHOP Chemotherapy|
89393981|NCT01355783|Active Comparator|CHOP alone|
89393982|NCT05061667|Active Comparator|Group I|Group I will consist of randomly assigned patients scheduled for thoracic surgery. These patients will recieve paravertebral block which is already proven to be effective in postoperative pain. After applying standart monitors to the patient and proper positioning in the operating room, paravertebral block will be performed at the planned surgical side using high frequency (8-18 MHz) linear probe of GE Logiq S7 (General Electric Healthcare, Little Chalfont, United Kingdom). 20 ml of 0.25% bupivacaine will be administered into the paravertebral space at T5-T6 vertebra levels using a 50 mm 22 G block needle (BBraun, Melsungen, Germany).
89393983|NCT05061667|Experimental|Group II|Group II will consist of randomly assigned patients scheduled for thoracic surgery. These patients will recieve rhomboid block which is being experimented for its efficacy in postoperative pain. After applying standart monitors to the patient and proper positioning in the operating room, rhomboid block will be performed at the planned surgical side using high frequency (8-18 MHz) linear probe of GE Logiq S7 (General Electric Healthcare, Little Chalfont, United Kingdom). 20 ml of 0.25% bupivacaine will be administered into the plane between rhomboid muscle and intercostal muscles, medial to scapula at T5-T6 vertebra levels using a 50 mm 22 G block needle (BBraun, Melsungen, Germany).
89393984|NCT02134106|Active Comparator|Polymyxin B|Intravenous polymyxin B will be started on a standard dose of 25,000 Units (U)/kg body weight, in 2 divided doses each day, infused over 2 hours. The duration of intravenous antibiotic treatment for subjects with either bacteremia or VAP or HAP will be at least 10 days. The duration of intravenous polymyxin B can be prolonged based on clinical indication, e.g., deep-seated source of infection, etc. For patients with VAP, nebulized colistin at the dose of 2 million units (MU) 8 hourly for 5 days will be prescribed.
89393985|NCT02134106|Experimental|Polymyxin B + Doripenem|Standard dose of intravenous polymyxin B at 25,000U/kg body weight will be given in 2 divided doses each day with each dose infused over 2 hours and intravenous doripenem 500mg, with each dose infused over 4 hours. For patients with VAP, nebulized colistin at the dose of 2 MU 8 hourly for 5 days will be prescribed.
89393986|NCT01354301|Experimental|Thymoglobulin and everolimus|single dose antithymocyte globulin, reduced concentration tacrolimus, everolimus starting at day 2 posttransplant and prednisone
89393987|NCT01354301|Experimental|Basiliximabe and everolimus|basiliximab, reduced concentration tacrolimus, everolimus starting at day 2 posttransplant and prednisone
89393988|NCT01354301|Active Comparator|Basiliximabe and mycophenolate|basiliximab, reduced concentration tacrolimus, mycophenolate and prednisone.
89393989|NCT02134262|Experimental|Dose Level -1|Cyclophosphamide or Bendamustine as Pre-treatment, and in combination with CD19-CAR-T. In case when sufficient cell number of CD19-CAR-T has been manufactured, the physician judges whether the 2nd infusion of CD19-CAR-T should be performed based on the condition of the subject.
89393990|NCT02134262|Experimental|Dose Level 1|Cyclophosphamide or Bendamustine as Pre-treatment, and in combination with CD19-CAR-T. In case when sufficient cell number of CD19-CAR-T has been manufactured, the physician judges whether the 2nd infusion of CD19-CAR-T should be performed based on the condition of the subject.
89393991|NCT02134262|Experimental|Dose Level 2|Cyclophosphamide or Bendamustine as Pre-treatment, and in combination with CD19-CAR-T. In case when sufficient cell number of CD19-CAR-T has been manufactured, the physician judges whether the 2nd infusion of CD19-CAR-T should be performed based on the condition of the subject.
88870100|NCT04848584||Fully vaccinated|Prior receipt of 2 doses of BNT162b2 received with ≥7 days between receipt of the 2nd dose and the index date. This group will serve as the 'exposed' group evaluated in the primary objective.
88870101|NCT04848584||Partially vaccinated|Prior receipt of 1 dose (only) of BNT162b2 received with ≥14 days between receipt of the 1st dose and the index date.
88870102|NCT04848584||Ever vaccinated|Prior receipt ≥1 dose of BNT162b2 received with ≥14 days between index date and receipt of the 1st dose
88870103|NCT04848584||Never vaccinated|never received BNT162b2. This group will serve as the reference exposure group (i.e., 'unexposed' group) in all VE analyses
88870104|NCT04848584||Bivalent vaccinated|Receipt of the BNT162b2 BA.4/5 bivalent vaccine ≥8 weeks (≥56 days) since the most recent dose of wild-type COVID-19 mRNA vaccine (BNT162b2 or mRNA-1273) received
88870105|NCT04848584||XBB.1.5 vaccinated|Receipt of XBB.1.5-adapted monovalent vaccine with greater than or equal 14 days between receipt of vaccine and the event date.
88870106|NCT04848584||Unexposed to XBB.1.5|Unvaccinated with XBB.1.5-adapted monovalent vaccine or any other manufacturer's XBB-adapted formulation.
88870107|NCT04844541||Sub-population A Infected Cases|Symptomatic SARS-CoV-2 infected adults or adults meeting the ILI case definition (hospitalized and non-hospitalized)
88870108|NCT04844541||Sub-population B Contacts|Asymptomatic adult contacts of positive cases, defined as indoor exposure to the symptomatic case or cases within 6 feet (2 meters) for greater than or equal to 15 minutes over a 24-hour period without the use of personal protective equipment
89187169|NCT00766155|Active Comparator|Arm I|Patients receive oral capecitabine twice daily and undergo concurrent 3-dimensional conformal radiotherapy 5 days a week on days 1-33. Patients may receive additional chemoradiotherapy on days 36-38. Patients then undergo surgery. Beginning 4-8 weeks after surgery, patients receive capecitabine twice daily on day 1-15. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
88870110|NCT04824014|Experimental|4FMFES-PET imaging at 0, 6 and 18 months|Patients burdened with ER+ advanced breast cancers and recruited in the trial will undergo an experimental 4FMFES-PET imaging within a 4-week interval of a medically-prescribed FDG-PET. The 4FMFES-PET procedure will be repeated at 6 and 18 months following the initial scan.
88870111|NCT04812093||Medical Tool|Spectroscopic otoscope
88870112|NCT04810273|Experimental|early mobilization (ER) group|Participants in the EM group will undergo the progressive early mobilization protocol in the trauma ICU in a manner consistent with the our hospital practice guidelines indicated by the Modified ICU Mobility Scale for progressive mobilization during the ICU stay. EM will be started with in-bed exercises and, if no medical contraindications are present, progressed from sitting in bed with the head tilted >60° to sitting on the edge of the bed to standing (including pre-gait exercises to improve postural stability, static and dynamic balance, and marching on the spot) and, finally, to walking.
88870113|NCT04810273|Active Comparator|standard early rehabilitation (SER) group|Patients in the SER group (Progressive upright positioning protocol) will receive standard physiotherapy including passive range of motion exercises, active exercises, bed mobility, and respiratory therapy during their ICU stays. In the SER group, out-of-bed mobilization (>=Level III in the Modified Trauma ICU Mobility Scale) will be started as soon as possible after ICU discharge but at least Level III (sitting on the edge of bed) above 7 days of onset.
88870114|NCT04805671|Experimental|ADG20 IM|Participants will be dosed on Day 1 with ADG20 IM
88870115|NCT04805671|Placebo Comparator|Placebo IM|Participants will be dosed on Day 1 with placebo IM
88870116|NCT04781088|Experimental|Treatment (paclitaxel, lenvatinib, pembrolizumab)|Patients receive paclitaxel IV over 1 hour on days -15 and -8 and lenvatinib PO QD on days -15 to 0. Beginning cycle 1 day 1, patients receive lenvatinib PO QD, pembrolizumab IV over 30 minutes on day 1, and paclitaxel IV over 1 hour on days 1, 8, and 15. Cycles with pembrolizumab repeats every 3 weeks for up to 2 years, and cycles with paclitaxel and lenvatinib repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.
88870117|NCT04780971|Other|Post-PCI intra-coronary physiological and OCT measurements|After angiographically successful CTO PCI, intra-coronary physiologic assessment (RFR, FFR, CFR and IMR) of the CTO vessel will be performed directly. A staged procedure including several measurements is planned at 4 ± 2 weeks after the index procedure. These measurements consists of the same intra-coronary physiologic assessments at index procedure and OCT imaging of the stented segment in the CTO target vessel.
88870118|NCT04779489|Experimental|PULSAR|Eligible patients will receive next-generation stereotactic radiotherapy (PULSAR) 30-36 Gy in 3 fractions to the bladder and targetable, pathologically enlarged lymph nodes
88870119|NCT04778527|Experimental|Over-encapsulated DPP|A single, over-encapsulated DPP taken once daily for three 28-day cycles (Regimen A) followed by two separate tablets (oral PrEP and COC) taken once daily for three 28-day cycles (Regimen B)
88870120|NCT04778527|Experimental|Two Separate Tablets|Two separate tablets (oral PrEP and COC) taken once daily for three 28-day cycles followed by a single, over-encapsulated DPP taken once daily for three 28-day cycles
88870121|NCT04764188||Cohort 1|Participants starting alectinib treatment before (Arm A) or after (Arm B) study enrollment as first-line treatment will be followed up for up to 4 years.
88870122|NCT04764188||Cohort 2|"Participants receiving alectinib as second-line treatment after study enrollment will be followed up for up to 2 years.~NOTE: Enrollment to this cohort has been ended."
88870123|NCT04759755||Study participants|18-60 year olds who demonstrate habitual sleep onset time between 10:00 pm-3:00 am and BMI 25-39.9.
88870124|NCT04755439|Other|undergoing deep hypothermic cırculatory arrest patients|Difüsıon magnetic rezonans imaging , neuron spesific enolase enzym level , deep hypotermic cırculatory arrest
88870125|NCT04740892|Experimental|Wash and Cream Investigational Product (IP)|Parent participant will bathe the child participant with the investigational wash at least 3 times per week, but no more than once daily, for 4 weeks. Parent participant will apply the investigational cream on their child participant twice daily for 4 weeks.
88870126|NCT04739696|No Intervention|Caregiver Control|biomarker analysis; questionnaire administration; survey administration; treatment as usual
88870127|NCT04739696|Experimental|Caregiver Intervention|biomarker analysis; questionnaire administration; survey administration; PsychoEducation Paced Respiration and Relaxation (PEPRR), which includes virtual one-on-one psychoeducation and stress management intervention.
88870128|NCT04739696|Experimental|Caregiver Self-Directed|biomarker analysis; questionnaire administration; survey administration; Pep-Pal web-accessible video modules of the psychoeducation and stress management intervention.
88870129|NCT04738422|Experimental|Alkaline glycine Inhalation|Subjects inhale alkaline glycine
88870130|NCT04725032|Experimental|sevoflurane-propofol balanced anesthesia|
88870131|NCT04725032|Active Comparator|propofol-based total intravenous anesthesia|
88870132|NCT04720157|Experimental|177Lu-PSMA-617|Participant will receive 7.4 GBq (+/- 10%) 177Lu-PSMA-617, once every 6 weeks (+/- 1 week) for a planned 6 cycles, in addition to the Standard of Care (SOC); ARDT +ADT is considered as SOC and treatment will be administered per the physician's order
88870133|NCT04720157|Active Comparator|Standard of Care|For participants randomized to Standard of Care arm, ARDT +ADT is considered as SOC and treatment will be administered per the physician's order
88870134|NCT04712539|Experimental|Arm I (oseltamivir, baloxavir marboxil)|Patients receive oseltamivir PO BID for up to 10 days and baloxavir marboxil PO every 72 hours for a total of 3 doses in the absence of disease progression or unacceptable toxicity.
88870135|NCT04712539|Active Comparator|Arm II (oseltamivir)|Patients receive oseltamivir PO BID for up to 10 days in the absence of disease progression or unacceptable toxicity.
88870136|NCT04706624|Active Comparator|A - High intensity Contingency management + SMS reminders|Participants who respond to the high intensity contingency management (frontline intervention) receive the adaptive intervention of SMS reminders.
88870137|NCT04706624|Active Comparator|B - High intensity Contingency management + Matrix only|Participants who do not respond to the high intensity contingency management are randomized into the Matrix only group.
88870138|NCT04706624|Active Comparator|C - High intensity Contingency management + (Matrix + CM)|Participants who do not respond to the high intensity contingency management are randomized into the Matrix plus contingency management group.
89187170|NCT00766155|Experimental|Arm II|Patients receive oral capecitabine twice daily and undergo concurrent 3-dimensional conformal radiotherapy 5 days a week on days 1-33. Patients also receive oxaliplatin IV over 1 hour on days 1, 8, 15, 22, and 29 prior to radiotherapy followed by surgery. Patients may receive additional chemoradiotherapy on days 36-38. Beginning 4-8 weeks later, patients receive oxaliplatin IV over 2 hours on day 1, and oral capecitabine twice daily on days 1-15. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
89187171|NCT05314868||Primary cohort|Pediatrics or adults who underwent cardiac repair surgery that nessecitated the use of a PhotoFix patch.
88870139|NCT04706624|Active Comparator|D - Low intensity Contingency management + SMS reminders|Participants who respond to the low intensity contingency management (frontline intervention) receive the adaptive intervention of SMS reminders.
88870140|NCT04706624|Active Comparator|E - Low intensity Contingency management + Matrix only|Participants who do not respond to the who intensity contingency management are randomized into the Matrix only group.
88870141|NCT04706624|Active Comparator|F - Low intensity Contingency management + (Matrix+CM)|Participants who do not respond to the who intensity contingency management are randomized into the Matrix plus contingency management group.
88870142|NCT04706507|Experimental|IV Ganciclovir|5mg/kg IV twice daily for 5 days, then followed by IV ganciclovir once daily until hospital discharge
88870143|NCT04706507|Placebo Comparator|Placebo|normal saline IV twice daily for 5 days, then followed by IV normal saline once daily until hospital discharge
88870144|NCT04704999|Active Comparator|Tafenoquine standard dose (TQ-current)|"Arm 1~>10 kg to ≤20 kg 100 mg~>20 kg kg ≤35 kg 200 mg~>35 kg 300 mg~Tafenoquine will be given as 100 mg coated tablets. Tablets will be given, and dosing will be based on weight bands."
88870145|NCT04704999|Active Comparator|Tafenoquine 50% higher dose (TQ-higher)|"Arm 2~>10 kg to ≤20 kg 150 mg~>20 kg kg ≤35 kg 300 mg~>35 kg 600 mg~Tafenoquine will be given as 100 mg coated tablets. Whole tablets will be given, and dosing will be based on weight bands."
88870146|NCT04696185|Active Comparator|Dapagliflozin|Sodium-glucose cotransporter-2 (SGLT-2) inhibitor therapy with daily oral dose of dapagliflozin 10 mg
88870147|NCT04696185|No Intervention|Standard care|No SGLT-2 inhibitor therapy with dapagliflozin
89187172|NCT00766233|Active Comparator|1|Hyperthermal treatment once per week
88870148|NCT04693533|Other|treatment effect|No 2 arms and only 1 intervention
88870149|NCT04676646|Experimental|Open-label run-in phase|"Cohort 1 (4 weeks duration): Patients who are hyperkalemic at study entry will begin SZC 10 g TID for up to 48 hours followed by SZC 10 g once daily to achieve and maintain normokalemia. The SZC dose will be adjusted as needed to maintain normokalemia (dose range = 5 g every other day, to 5-15 g once daily).~Cohort 2 (up to 6 weeks duration): Patients who develop hyperkalemia during the uptitration of spironolactone will receive SZC 10 g TID for up to 48 hours followed by SZC 10 g once daily to achieve and maintain normokalemia. The SZC dose will be adjusted as needed to maintain normokalemia (dose range = 5 g every other day, to 5-15 g once daily)."
88870150|NCT04676646|Experimental|Randomized withdrawal phase (6 months)|"SZC arm and Placebo arm: Patients will continue on the SZC dose they were receiving at the end of the run-in phase.~The SZC / Placebo dose will be adjusted as needed to maintain normokalemia (dose range = 5 g every other day, to 5-15 g once daily)."
88870151|NCT04655326|Experimental|Treatment Group|Each participant receives a customized probiotic based on the results of the test of their microbiota
88870152|NCT04654858|Active Comparator|Direct composite restorations|bulk-fill composite (Filtek BulkFlow, 3M Espe) will be used after infiltration or block anaesthesia for affected molar, following by carious tissue removal. Marginal bevelling of enamel will be performed. A universal adhesive (Scotchbond Universal, 3M Espe) will be placed after selective enamel etching A bulk-fill composite will be used and covered using a nanohybrid composite, (Filtek XT, 3M Espe).
88870153|NCT04654858|Active Comparator|Performed metal crowns|PMCs (3M Espe, Seefeld, Germany) will be placed after infiltration or block anaesthesia for affected molar, followed by removal of carious dentin and enamel, Tooth preparation for fitting the crown, The correct size of crown will be chosen, and then Cemented with glass ionomer luting cement (KetacCem, 3M Espe).
88870154|NCT04637815|Experimental|Intervention|The intervention will consist of four sessions spaced two weeks apart that will last approximately 30 minutes each and consist of two parts: a network interview to capture network data about the time period since their last interview and a discussion of a resulting network visualization conducted in a motivational interviewing style. Participants will receive the intervention as part of existing case management.
88870155|NCT04637815|Active Comparator|Usual Care|As part of residency, participants receive regular case management meetings.
88870156|NCT04635358|Experimental|Intervention|Setting up hypnosis sessions, psychological and nutritional assistance.
88870157|NCT04625283|Experimental|Ketamine|Participants in this arm will receive intraoperative ketamine bolus (0.5mg/kg) followed by continuous infusion 5 mcg/kg/min and also will receive postoperative ketamine infusion (2.5 mcg/kg/min, up to 100kg max) for 48 hours.
88870158|NCT04625283|Placebo Comparator|Saline|Participants in this arm will receive an equivalent volume of intraoperative saline bolus followed by continuous saline infusion and also will receive postoperative saline infusion for 48 hours.
89003755|NCT04607421|Experimental|Phase 3 Arm B|Encorafenib 300 mg orally once daily Cetuximab 500 mg/m2 (120 minute IV infusion) every two weeks Oxaliplatin 85 mg/m2 (120-minute IV infusion) every two weeks Leucovorin 400 mg/m2 (120-minute IV infusion) every two weeks 5-FU 400 mg/m2 IV bolus, then 5-FU 2400 mg/m2 continuous IV infusion over 46-48 hours every two weeks
89393992|NCT02134262|Experimental|Dose Level 3|Cyclophosphamide or Bendamustine as Pre-treatment, and in combination with CD19-CAR-T. In case when sufficient cell number of CD19-CAR-T has been manufactured, the physician judges whether the 2nd infusion of CD19-CAR-T should be performed based on the condition of the subject.
89393993|NCT01355861|Experimental|1|Exercise group 1: Negative work exercise
89393994|NCT01355861|Other|2|Exercise group 2: Negative work exercise (delayed start for single-arm crossover trial)
89393995|NCT01343277|Experimental|Trabectedin|
89393996|NCT01343277|Active Comparator|Dacarbazine|
89393997|NCT02130596|Experimental|Acceptance-Based Behavioral Intervention|
89393998|NCT02130596|Active Comparator|Nutritional Counselling|
89393999|NCT02130674|Experimental|Dipeptiven|0.75 g/ kg/ d Dipeptiven ( L- alanine- L- glutamine; 82 mg/ ml L- alanine, 134.6 mg/ ml L- glutamine; Fresenius Kabi, Switzerland) continuous intravenous infusion
89394000|NCT04856293|Experimental|Three Period Treatment Sequence|Participants will receive a single 250 mg crizotinib dose of the formulated capsule(FC) formulation, a single 250 mg crizotinib dose of the encapsulated microsphere (eMS) formulation administered by sprinkling the contents into a dry glass vial, and a single 250 mg crizotinib dose of the encapsulated microsphere (eMS) formulation (administered as intact capsules)
89394001|NCT04856293|Experimental|Two Period Treatment Sequence|Participants will receive a single 250 mg crizotinib dose of the formulated capsule(FC) formulation, a single 250 mg crizotinib dose of the encapsulated microsphere (eMS) formulation administered by sprinkling the contents into a dry glass vial
88870159|NCT04619745|Experimental|Intervention Group|All children enrolled in the study will complete five study visits. All participants will complete all outcome measures (including surveys, questionnaires, and motor skill assessments) at or after each 1-hour assessment visit. Children will be given an omni-directional accelerometer to wear on a waist-worn belt for 7 days after each visit to assess daily physical activity. The intervention group will complete individualized, parent-led, home and play-based activity plans for 6 months, beginning as soon as the child returns to the inpatient unit. The activities in the plan will be tailored to each phase of treatment (in hospital, discharge to week 7, week 8 to 6 months), follow a standardized format and provide content individualized to each child's age and previous visit assessments.
89394002|NCT03135899|Experimental|BI 443651|
89394003|NCT03135899|Placebo Comparator|Placebo|
88870160|NCT04619745|Experimental|Wait List Control Group|All children enrolled in the study will complete five study visits. After the first visit is complete, children will be randomized to either the intervention or wait-list control study group. Control participants will follow the same schedule of assessments at each visit, but the intervention will be provided between the 12-month and 16-month assessments. All participants will complete all outcome measures (including surveys, questionnaires, and motor skill assessments) at or after each 1-hour assessment visit. Children will be given an omni-directional accelerometer to wear on a waist-worn belt for 7 days after each visit to assess daily physical activity.
88870161|NCT04606316|Experimental|Nivolumab and Ipilimumab Before and After Surgery|"One dose of nivolumab plus ipilimumab will be administered 14(±5) days before surgery.~After surgery, participants receive nivolumab in combination with ipilimumab every 3 weeks for 9 weeks and then nivolumab alone every 4 weeks."
89394004|NCT04742569||Cohort 1- Exposed/Early Symptomatic|"The population identified for this study includes subjects who request COVID-19 testing in response to a concern for recent COVID-19 exposure and/or concern of COVID-19-like related symptoms. We will recruit and enroll patients through public facing websites, clinic and pharmacy vaccination schedules and on-site vaccination marketing.~For the population with recent COVID-19 exposure and/or concern of COVID-19-like related symptoms, population identification includes subjects who visit eTrueNorth's https://www.doineedacovid19test.com/ website where subjects have access to over 7,500 testing site locations across the nation. Otherwise, individuals seeking COVID-19 testing will be directed to the ClinOne, Inc. website for information regarding the Wearable Diagnostic for Detection of COVID-19 Infection study contact information for study participation, enrollment into the study using eConsent, and will receive a BioSticker wearable kit by express mail the next day."
88870162|NCT04606316|Experimental|Nivolumab and Placebo-Ipilimumab Before Surgery, Nivolumab After Surgery|"One dose of nivolumab plus placebo-ipilimumab will be administered 14(±5) days before surgery.~After surgery, participants receive nivolumab in combination with ipilimumab every 3 weeks for 9 weeks and then nivolumab alone every 4 weeks."
88870163|NCT04606316|Experimental|Placebo-Nivolumab and Placebo-Ipilimumab Before Surgery, Nivolumab and Ipilimumab After Surgery|"One dose of placebo-nivolumab plus placebo-ipilimumab will be administered 14(±5) days before surgery.~After surgery, participants receive nivolumab in combination with ipilimumab every 3 weeks for 9 weeks and then nivolumab alone every 4 weeks"
88870164|NCT04599010|Active Comparator|FFM-indexed feeding|In FFM-indexed feeding, there will be a permissive feeding volume restriction to 150 ± 10 mL/kg (FFM)/day without increasing the milk calorie density or changing the type of formula milk for 2 weeks in the intervention group
88870165|NCT04599010|Active Comparator|Standard feeding|The standard feeding approach will include an oral feeding volume goal of 150 ± 10 mL/kg/day during the 2-week study period
88870166|NCT04578912|Active Comparator|CBIT + rTMS|Participants in this arm will receive Comprehensive Behavioral Intervention for Tics (CBIT) with 1 Hz repetitive Transcranial Magnetic Stimulation (rTMS).
88870167|NCT04578912|Active Comparator|CBIT + cTBS|Participants in this arm will receive Comprehensive Behavioral Intervention for Tics (CBIT) with continuous Theta Burst Stimulation (cTBS).
88870168|NCT04578912|Sham Comparator|CBIT + Sham|Participants in this arm will receive Comprehensive Behavioral Intervention for Tics (CBIT) with either a cTBS or rTMS sham treatment.
88870169|NCT04572906|Experimental|NTX-001|NTX-001 used during surgical repair of an upper extremity peripheral nerve injury in conjuction with standard suture neurorrhaphy.
89394005|NCT04742569||CoHort 2- Pfizer or Moderna Vaccine|Secondly, the other population identified for this study includes subjects who are scheduled for the first and second dose of the mRNA-based Pfizer/BioNTech and Moderna vaccine series. For the population seeking the mRNA-based Pfizer/BioNTech and Moderna vaccine series, we will recruit and enroll patients through public-facing websites, clinic, and pharmacy vaccination schedules, and on-site vaccination marketing
89394006|NCT02253212|Experimental|SonoCloud + carboplatin|SonoCloud : dose escalation Carboplatin : min 6 cycles - individual dose determination according to renal function and AUC
89394007|NCT01355939||Abdominal surgery after prior VHR with barrier-coated mesh|
89394008|NCT01355939||Abdominal surgery after prior VHR with nonbarrier-coated mesh|
89394009|NCT01355939||Lap adhesiolysis during abdominal surgery after prior VHR|
89394010|NCT01355939||Open adhesioloysis during abdominal surgery after prior VHR|
88870170|NCT04572906|No Intervention|Standard of Care|standard suture neurorrhaphy
88870171|NCT04563858||Cardiac patients|
88870172|NCT04548349|Experimental|Altreno Group|
88870173|NCT04548349|Experimental|BPO Group|
88870174|NCT04548349|No Intervention|Control Group|During the entire study period, the subjects in the control group will not be allowed to use any antibacterial wash, other than approved OTC cleansers.
88870175|NCT04546230|Experimental|E group|Low-Thoracic Epidural Anesthesia
88870176|NCT04546230|Active Comparator|G group|General Anesthesia
88870177|NCT04533438|Active Comparator|RhinAer Treatment|The RhinAer procedure will be performed in the study clinic using the RhinAer Stylus and Aerin Console. The RhinAer Stylus is a disposable handheld device capable of delivering bipolar radiofrequency energy to tissue when connected to the Aerin Console radiofrequency generating device. Participants will have the portion of the nasal cavity mucosa overlying the region of the posterior nasal nerve (the posterior middle meatus and posterior inferior turbinate) in both nostrils treated during a single study procedure session. Each nostril will be treated at 1, 2, 3, 4 or 5 nonoverlapping positions depending on the size of the target treatment area. Treatment settings to be used are temperature 60 °C, power 4 watts, treatment time 12 seconds, and cooling time 0 seconds
88870178|NCT04533438|Sham Comparator|Control Treatment|The control treatment will be performed in the study clinic using the RhinAer Stylus while audible sounds that accurately simulate the Aerin Console's active treatment are produced even though RF energy is not being generated or delivered. All other aspects of the procedure will be the same as used for the active treatment, including administration of anesthetic agent(s).
88870179|NCT04511234|Experimental|MagicTouch PTA sirolimus drug coated balloon (DCB)|MagicTouch PTA sirolimus drug coated balloon (DCB) in addition to standard balloon angioplasty
88870180|NCT04511234|Active Comparator|Placebo balloon angioplasty|Placebo balloon angioplasty in addition to standard balloon angioplasty (PTA)
88870181|NCT04510129||head and neck squamous cell carcinoma (HNSCC)|
88870182|NCT04510129||non-small-cell lung cancer (NSCLC)|
89187173|NCT00766233|Active Comparator|2|Hyperthermal treatment 3 times a week
89394011|NCT01356017|Experimental|Free combination of Telmisartan and S-amlodipine|Subjects received Telmisartan 80mg and S-amlodipine 5mg once a day for 9 days. And subjects doesn't take any medications for 19 days.
88870183|NCT04510129||small cell lung cancer (SCLC)|
88870184|NCT04510129||urothelial carcinoma (UCC)|
88870185|NCT04510129||gastric or gastroesophageal junction adenocarcinoma|
88870186|NCT04510129||cervical cancer|
88870187|NCT04510129||esophageal squamous cell carcinoma (ESCC)|
88870188|NCT04510129||triple-negative breast cancer (TNBC)|
88870189|NCT04510129||hepatocellular carcinoma (HCC)|
88870190|NCT04510129||renal cell carcinoma (RCC)|
88870191|NCT04510129||colorectal cancer (CRC)|
88870192|NCT04503759||Foot and Ankle Surgery using NanoBone|All patients in the study will be drawn from the individual surgeons' practice. Patients will be among those already scheduled for foot and ankle surgery after having failed conservative treatment, or will have had foot and ankle surgery using NanoBone products but have not completed their standard of care follow-up as determined by the surgeon's practice. In addition, the surgeon has determined that the use of a NanoBone product is or was clinically necessary for the patient. The choice of a NanoBone product, as well as the surgery, is or was independent of this research project. Only patients who have had NanoBone implanted and consent to participate and meet the inclusion-exclusion criteria will be included in the registry.
88870193|NCT04498078|Experimental|Creatine|Twenty grams per day b.i.d.
88870194|NCT04493736||Case|Any person receiving services from a mental health provider who is able to either consent or for whom parental consent is able to be obtained.
88870195|NCT04486716|Experimental|Ofatumumab|Investigational drug will be provided in an autoinjector for subcutaneous administration containing 20 mg ofatumumab (20 mg/0.4 ml) administered at baseline, Day 7, Day 14 and monthly thereafter
88870196|NCT04482309|Experimental|Part 1 Cohort 1|Biliary tract cancer
88870197|NCT04482309|Experimental|Part 1 Cohort 2|Bladder cancer
88870198|NCT04482309|Experimental|Part 1 Cohort 3|Cervical cancer
88870199|NCT04482309|Experimental|Part 1 Cohort 4|Endometrial cancer
88870200|NCT04482309|Experimental|Part 1 Cohort 5|Ovarian cancer
88870201|NCT04482309|Experimental|Part 1 Cohort 6|Pancreatic cancer
88870202|NCT04482309|Experimental|Part 1 Cohort 7|Rare tumors
88870203|NCT04482309|Experimental|Part 2 Cohort A|Any tumor type that is HER2 IHC 3+ (excluding breast, gastric cancer, and colorectal cancer)
88870204|NCT04482309|Experimental|Part 2 Cohort B|Any tumor type that is HER2 IHC 2+/ISH+ (excluding breast, gastric cancer, and colorectal cancer)
88870205|NCT04482309|Experimental|Part 2 Cohort C|HER2 IHC 2+ or 1+ endometrial cancer
88870206|NCT04482309|Experimental|Part 2 Cohort D|HER2 IHC 2+ or 1+ ovarian cancer
88870207|NCT04482309|Experimental|Part 2 Cohort E|HER2 IHC 2+ or 1+ cervical cancer
88870208|NCT04469465|Experimental|Danicopan + C5 Inhibitor|Participants will receive danicopan, in addition to their C5 inhibitor therapy, for 24 weeks (12 weeks in Treatment Period 1, followed by 12 weeks in Treatment Period 2).
88870209|NCT04469465|Placebo Comparator|Placebo + C5 Inhibitor|Participants will receive placebo, in addition to their C5 inhibitor therapy, for 12 weeks during Treatment Period 1. At Week 12, participants randomized to receive placebo will be switched to danicopan for an additional 12 weeks (Treatment Period 2).
88870210|NCT04461691|Other|Heart Failure|Cryoballoon pulmonary vein isolation is a common method for catheter ablation of atrial fibrillation. Cryoenergy is applied through a balloon in a single-step approach resulting in necrosis by tissue freezing.
88870211|NCT04461691|Other|Normal cardiac function|Cryoballoon pulmonary vein isolation is a common method for catheter ablation of atrial fibrillation. Cryoenergy is applied through a balloon in a single-step approach resulting in necrosis by tissue freezing.
89187174|NCT00766311|Other|1|This single-arm feasibility trial will evaluate the administration of an aggressive exercise regimen.
88870212|NCT04439032||Spine Fusion using NanoBone|All patients in the study will be drawn from the individual surgeons' practice. Patients will be candidates for spinal fusion surgery after having failed conservative treatment or will have had spinal fusion surgery but have not completed their standard of care follow-up as determined by the surgeon's practice. In addition, the surgeon has determined that the use of a NanoBone product is or was clinically necessary for the patient.
88870213|NCT04432090|Experimental|MBX-2982 first then placebo- Volunteers with Type 1 diabetes|This will be followed by a second study period in which they will be crossed over to the other treatment.
88870214|NCT04432090|Active Comparator|Healthy Volunteers|this group will not receive any medication. It will be studied to establish the norm of the measurement that will be performed to obtain the study outcomes.
88870215|NCT04432090|Experimental|Placebo first then MBX-2982- Volunteers with Type 1 diabetes|
88870216|NCT04431453|Experimental|Remdesivir (RDV), Cohort 1: Age 12 to <18 Years and Weight ≥40 kg|Participants will receive RDV 200 mg, intravenous (IV) infusion on Day 1 followed by RDV 100 mg, IV infusion, daily, up to 10 days.
88870217|NCT04431453|Experimental|RDV, Cohort 2: Age ≥ 28 Days to < 18 Years and Weight ≥ 20 kg to < 40 kg|Participants will receive RDV 5 mg/kg, IV infusion on Day 1 followed by RDV 2.5 mg/kg mg, IV infusion, daily, up to 10 days.
88870218|NCT04431453|Experimental|RDV, Cohort 3: Age ≥ 28 Days to < 18 Years and Weight ≥ 12 kg to < 20 kg|Participants will receive RDV 5 mg/kg, IV infusion on Day 1 followed by RDV 2.5 mg/kg mg, IV infusion, daily, up to 10 days.
88870219|NCT04431453|Experimental|RDV, Cohort 4: Age ≥ 28 Days to < 18 Years and Weight ≥ 3 kg to < 12 kg|Participants will receive RDV 5 mg/kg, IV infusion on Day 1 followed by RDV 2.5 mg/kg mg, IV infusion, daily, up to 10 days.
88870220|NCT04431453|Experimental|RDV, Cohort 5: Age ≥14 - <28 Days of Age, Gestational Age >37 Weeks, and Weight at Baseline ≥2.5 kg|Participants will receive RDV 5 mg/kg, IV infusion on Day 1 followed by RDV 2.5 mg/kg mg, IV infusion, daily, up to 10 days.
89187175|NCT00762489|Other|TAT vs. RT|This arm is comparing the Temporal Artery Thermometer (TAT) temperature to the Rectal Temperature (RT).
89187176|NCT00762489|Other|TAT vs. AT|This arm is comparing the Temporal Artery Thermometer (TAT) temperature to the Axillary Temperature (AT).
89187177|NCT04078100||group A|underwent mitral valve surgery through transseptal approach.
89187178|NCT04078100||group B|underwent mitral valve surgery through conventional left atrial approach.
89187179|NCT00762567|Experimental|1|phenylephrine
89187180|NCT04338620|Experimental|A: Experimental Group|Participants receive totally 3 cycles of camrelizumab combined with albumin-bound paclitaxel and Cisplatin/carboplatin/Nedaplatin treatment during preoperative period, every 3 weeks for up to 3 cycles.
89187181|NCT04338620|Active Comparator|B: Control group|Participants receive totally 3 cycles of albumin-bound paclitaxel combined with Cisplatin/carboplatin/Nedaplatin treatment during preoperative period, every 3 weeks for up to 3 cycles.
89187182|NCT00759057|Experimental|1 - Investigational|Dynesys Non-Fusion Spinal System
89187183|NCT00759057|Active Comparator|2 - Control|Silhouette Posterior Pedicle Screw System as an adjunct to Posterior Lateral Fusion with Autograft.
89187184|NCT00923234|Experimental|Azacitidine and Lenalidomide|Azacitidine 75 mg/m² SC days 1-5 every 28 days for a maximum of 8 cycles and Lenalidomide 10 - 25 mg PO days 6-19 every 28 days for a maximum of 8 cycles
89187185|NCT00766389||1|Defined glaucoma patients
89187186|NCT00766389||2|Glaucoma suspects and normal controls
89187187|NCT00759213||1|Any infant with a length of stay in the NICU of at least 7 days.
89187188|NCT00674661|Active Comparator|Corneal Collagen Cross-linking (CXL) Treatment Group|riboflavin ophthalmic solution and UVA irradiation
89187189|NCT00674661|Sham Comparator|Control Group|riboflavin opthalmic solution without UVA irradiation
89187190|NCT00766545|Experimental|cilostazol|cilostazol oral tablet 100 mg, twice daily
89187191|NCT00766545|Placebo Comparator|placebo|placebo of cilostazol, twice daily
89187192|NCT00766623|Experimental|High fat meal|A high fat milkshake containing 95g of fat
89187193|NCT00766623|Experimental|Control meal|Milkshake comparable with a normal breakfast
89187194|NCT00766623|Experimental|High fat meal 2|A high fat milkshake containing 95g of fat
89187195|NCT00766623|Experimental|High fat meal 3|A high fat milkshake containing 95g of fat
89187196|NCT00766623|Experimental|Control meal 2|Milkshake comparable with a normal breakfast
89187197|NCT00766623|Experimental|Control meal 3|Milkshake comparable with a normal breakfast
89187198|NCT04314128|Other|Patients suspected of IIH at baseline|"Intervention: TOS and TCD measurements at baseline, and at routine follow-ups.~Healthy controls will be recruited to match the patients."
89187199|NCT02558205||CT Perfusion and PET/CT|Patients undergo both a CT liver perfusion study pre Y-90 treatment and a PET/CT of liver following Y-90 treatment. For the PET/CT no additional radioactivity is required.
89187200|NCT00759369|Experimental|1|Water prescription
89187201|NCT00766779|Experimental|Transplant Arm|Hematopoietic cell transplantation after Reduced Intensity Conditioning
89187202|NCT00766779|Active Comparator|Conventional Chemotherapy|The non-transplant treatment approach for consolidation
89187203|NCT00759447||3D investigational imaging|Patients enrolled will be imaged with a 3D mammogram in one of 3 speeds of acquisition
89187204|NCT00759447||3D Imaging with commercial Mammography Device|
89187205|NCT02557737|Experimental|Ultrasonography direct-guidance|To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by Ultrasonography direct-guidance.
89187206|NCT02557737|Experimental|Electric stimulation|To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by Electric stimulation
89187207|NCT02557737|Active Comparator|Surface anatomy landmark|To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by Surface anatomy landmark.
89187208|NCT00766857|Experimental|1. Exenatide|
89187209|NCT00766857|Active Comparator|2. Insulin glargine|
89394012|NCT01356017|Active Comparator|Telmisartan monotherapy|Subjects received Telmisartan 80mg once a day for 9 days. And subjects doesn't take any medications for 19 days.
89394013|NCT02134340|Experimental|[I-124]-CPD-1028 PET/CT|"Administration of [I-124]-CPD-1028 Injection followed by a maximum of 3 PET/CT imaging sessions.~A pre-targeting dose of CPD-1061 may be given prior to injection of [I-124]-CPD-1028."
88870221|NCT04431453|Experimental|RDV, Cohort 6: Age 0 to < 14 Days of Age, Gestational Age > 37 Weeks, and Birth Weight ≥ 2.5 kg|Participants will receive RDV 2.5 mg/kg, IV infusion on Day 1 followed by RDV 1.25 mg/kg mg, IV, daily, up to 10 days.
89187210|NCT02558673|Experimental|Egg|Study meals were administered in commonly consumed serving sizes (3 hard-boiled eggs) and provided comparable amounts of TMAO dietary precursors. Each meal was served with one cup of water, administered in a single day and separated by a 1-week washout period.
89187211|NCT02558673|Experimental|Beef|Study meals were administered in commonly consumed serving sizes (6 oz beef [Philly-Gourmet Beef Patties]) and provided comparable amounts of TMAO dietary precursors. Each meal was served with one cup of water, administered in a single day and separated by a 1-week washout period.
89187212|NCT02558673|Experimental|Fish|Study meals were administered in commonly consumed serving sizes (6 oz fish [cod fillet]) and provided comparable amounts of TMAO dietary precursors. Each meal was served with one cup of water, administered in a single day and separated by a 1-week washout period.
89187213|NCT02558673|Active Comparator|Fruit|Study meals were administered in commonly consumed serving sizes (2 single-serve packages of Mott's natural applesauce) and provided comparable amounts of control (or active comparator). Each meal was served with one cup of water, administered in a single day and separated by a 1-week washout period. For the fruit control, 50 mg deuterium-labeled methyl-d9-TMAO (d9-TMAO; Cambridge Isotopes) was added to one cup of water for oral consumption to enable the tracing of the metabolic fate of TMAO, and to assess its bioavailability and clearance.
89187214|NCT02558283|Experimental|JUVÉDERM® VOLIFT® with Lidocaine - Right Side|JUVÉDERM® VOLIFT® with lidocaine injected into the right nasolabial fold on Day 1, with optional touch-up injections into the right nasolabial fold on Month 1.
89187215|NCT02558283|Active Comparator|Restylane® - Right Side|Restylane® injected into the right nasolabial fold on Day 1, with optional touch-up injections into the right nasolabial fold on Month 1.
89187216|NCT02558283|Experimental|JUVÉDERM® VOLIFT® with Lidocaine - Left Side|JUVÉDERM® VOLIFT® with lidocaine injected into the left nasolabial fold on Day 1, with optional touch-up injections into the left nasolabial fold on Month 1.
89187217|NCT02558283|Active Comparator|Restylane® - Left Side|Restylane® injected into the left nasolabial fold on Day 1, with optional touch-up injections into the left nasolabial fold on Month 1.
89187218|NCT00762879||No treatment|
89187219|NCT02585102|Other|Recommended Vegetables|Diet provided consisting of recommended vegetable intake per Dietary Guidelines for Americans amounts for 8 weeks.
89187220|NCT02585102|Other|Usual Vegetables|Diet consisting of usual vegetable intake amounts for 8 weeks.
89187221|NCT00766935||1 - lymphoedema group|Females with previously diagnosed unilateral Lymphoedema of the arm, who have had a mastectomy or breast conservation surgery with axillary sampling or dissection, with or without adjuvant therapy.
89187222|NCT00766935||2 - healthy individuals|Healthy females aged between 18-75 years chosen randomly from the population of Queensland, Australia.
89187223|NCT00767013|Experimental|AVS, CAD|DSCT
89187224|NCT00759837|Experimental|1|
89187225|NCT00767091|Active Comparator|Active treatment|A: transdermal rivastigmine at 4.6 mg per day during one month then 9.5 mg per day during 5 months.
89187226|NCT00767091|Placebo Comparator|placebo|transdermal patch of placebo
89187227|NCT00767169|Experimental|coated implant and control|
89187228|NCT00767247||1|Male or female with arterial hypertension
89187229|NCT02582528|Experimental|cognitive remediation treatment and MI|Cognitive remediation treatment consisting of a novel computerized training called My Brain Solutions (MBS) and motivational interviewing, a client-centered, directive method for enhancing intrinsic motivation to change.
89187230|NCT02582528|Active Comparator|cognitive remediation treatment|Cognitive remediation treatment consisting of a novel computerized training called My Brain Solutions (MBS)
89187231|NCT00767403|Experimental|1|
89187232|NCT00767403|Active Comparator|2|
89187233|NCT00767403|Active Comparator|3|
89187234|NCT00767481|Experimental|Travoprost/Brinzolamide PM, Vehicle AM|Travoprost/Brinzolamide PM, Vehicle AM
89187235|NCT00767481|Experimental|Travoprost/Brinzolamide AM, Vehicle PM|Travoprost/Brinzolamide AM, Vehicle PM
89187236|NCT00767481|Active Comparator|Cosopt|Cosopt BID
89187237|NCT04306874|Experimental|High Protein Supplement|60 g total protein per day, administered via twice daily ensure max protein shakes
89187238|NCT04306874|No Intervention|Control|No intervention on diet; routine dietary practice
89187239|NCT02557893|Experimental|Resistance exercise|Resistance exercise involved 12 weeks of weight lifting exercise
89187240|NCT02557893|Sham Comparator|Wait list|Wait list participants were tested on the outcomes during their pregnancy and were eligible to participate in a post-partum supervised exercise program. The wait list participants formed a no treatment control group.
88870222|NCT04431453|Experimental|RDV, Cohort 7: Age 0 to < 56 Days of Age, Gestational Age ≤ 37 Weeks, and Birth Weight ≥ 1.5 kg|Participants will receive RDV 2.5 mg/kg, IV infusion on Day 1 followed by RDV 1.25 mg/kg mg, IV, daily, up to 10 days.
88870223|NCT04431453|Experimental|RDV, Cohort 8: < 12 Years and Weight ≥ 40 kg|Participants will receive RDV 200 mg, IV infusion on Day 1 followed by RDV 100 mg, IV infusion daily up to 10 days.
89187241|NCT02557893|Placebo Comparator|Pregnancy education|Maternity nurses taught six bimonthly pregnancy education classes (~20 per class) which covered several topics including information about what to expect during normal labor and delivery, common interventions during delivery (medications, induction, Cesarean delivery), parenting skills needed for baby care, breastfeeding, baby and child cardiopulmonary resuscitation, typical child development and communicating with infants. No physical activity education was included in the curriculum. The pregnancy education participants formed an attention control group.
89187242|NCT00671931|Active Comparator|I|Dexmedetomidine low infusion, Propofol low infusion
89187243|NCT00671931|Active Comparator|II|Dexmedetomidine high infusion, Propofol low infusion
89187244|NCT00671931|Active Comparator|IV|Dexmedetomidine high infusion, Propofol high infusion
89187245|NCT00671931|Active Comparator|V|Dexmedetomidine intermediate infusion, Propofol intermediate infusion
89187246|NCT00671931|Active Comparator|III|Dexmedetomidine low infusion, Propofol high infusion
88870224|NCT04429919|Experimental|AP-325|25 mg capsule for oral use, 4 capsules (100 mg) once daily in the morning before meals
88870225|NCT04429919|Placebo Comparator|Placebo|4 capsules once daily in the morning before meals
88870226|NCT04420585|Experimental|Treatment Group|Desmopressin 0.2mg tablets, dose titrated to effect
88870228|NCT04405700||Cohort 1 (C1)|Prospective recruitment of pregnant women enrolling in antenatal clinic (ANC) at the site. All HIV+ pregnant women and a 1:1 systematic sample of HIV- pregnant women enrolling in ANC at the site will be prospectively enrolled. In addition, medical record data for the mother and infant will be collected at the time of delivery for all women who deliver at the site and as such will contribute to a subset of C2 (below). Women enrolled in C1 who do not deliver at the site will be contacted by phone and through field follow-up to ascertain their pregnancy and infant outcomes. Infants born to women enrolled in this component who are suspected of having congenital abnormalities (CAs) will be enrolled as outlined in C3 (below) if their mothers deliver at the site. If their mothers do not deliver at the site these infants will be enrolled in the field. Photos/videos of infants with CAs will also be taken for review and classification by a panel of experts (see C3 below).
88870229|NCT04405700||Cohort 2 (C2)|Cross-sectional data collection for deliveries at the site. Data will be collected retrospectively from medical records for all women who deliver at the site (including the women enrolled in C1 above), as well from the medical records of all newborn infants and stillbirths delivered at the site. Missing or incomplete information in the woman or her infant's medical record will be clarified by contacting the woman to provide this information.
88870230|NCT04405700||Cohort 3 (C3)|Photos/videos of infants with CAs. All newborn infants and stillbirths ≥ 24 weeks gestational age delivered at the site, as well as all infants born to women enrolled in C1, will be assessed by surface exam for the presence of CAs. Video and photographs will be taken of CAs identified on surface exam. These images will be reviewed and classified by panel of experts in genetics, dysmorphology and teratology. Mothers of infants with major CAs will be contacted by phone at 1, 6, and 12 months post-delivery to ascertain their infants' vital status and care engagement status.
88870231|NCT04403763|Placebo Comparator|Placebo Dose|Administered as single drop in one or both eyes
88870232|NCT04403763|Experimental|Cohort 1: AGN-241622 Dose 1 (Low Dose)|Administered as single drop in one eye
88870233|NCT04403763|Experimental|Cohort 2: AGN-241622 Dose 2 (Medium Dose)|Administered as single drop in one eye
88870234|NCT04403763|Experimental|Cohort 3: AGN-241622 Dose 3 (High Dose)|Administered as single drop in one eye
88870235|NCT04403763|Experimental|Cohort 4: AGN-241622 Dose 1 (Low Dose)|Administered as a single drop in each eye
88870236|NCT04403763|Experimental|Cohort 5: AGN-241622 Dose 2 (Medium Dose)|Administered as single drop in each eye
89394014|NCT01356095|Active Comparator|PALM-Plus control|Health centers randomized to Palm-Plus intervention in larger trial this trial is embedded in, but not receiving the adherence intervention.
89394015|NCT01356095|Experimental|Adherence intervention|Intervention arm.
88870237|NCT04403763|Experimental|Cohort 6: AGN-241622 Dose 3 (High Dose)|Administered as single drop in each eye
88870238|NCT04387227|Experimental|Treatment (carboplatin, pembrolizumab)|Patients receive carboplatin IV over 30 minutes on day -2 of cycle 1 only. Patients also receive pembrolizumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 6 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo CT or MRI throughout the trial. Patients also undergo blood sample collection on the trial.
88870239|NCT04383912|Experimental|onabotulinum toxin A group (brow)|"Product name: Onabotulinum toxin A (Botox A, Allergan), 50 unit vials Product code: 93094EC~Description: The side randomized to treatment will receive an injection of 20 units of onabotulinum toxin A as the final step of a direct brow lift surgery. The surgeon will visually divide the surgical incision in half, and divide the volume of the injection evenly between the two sides. This will be a one time administration."
88870240|NCT04383912|Placebo Comparator|placebo group (brow)|"Product name: normal saline~Description: The side randomized to placebo will receive an injection of normal saline as the final step of a direct brow lift surgery. The surgeon will visually divide the surgical incision in half, and divide the volume of the injection evenly between the two sides. This will be a one time administration."
88870241|NCT04381195||Aim 1|Item Drafting and Revising (Aim 1). Together with a stakeholder panel of autistic adults and adults with IDD and parents/caregivers, the study investigators will generate an item pool based on the conceptual model.
89394016|NCT01356095|No Intervention|Control|
88870242|NCT04381195||Aim 2|Item Calibration (Aim 2). Measures will be completed online and therefore the sample will include those with self-reported IDD or autism diagnoses and their caregivers (total n of 1000 each)
88870243|NCT04378790|Active Comparator|Sequential treatment|full-time spectacle correction first, with subsequent patching for 2 hours per day/7 days per week only if needed (no improvement (stable/worsening) and residual)
89394017|NCT02134418|Experimental|Irony CBT training|CBT of irony comprehension
89394018|NCT02134418|No Intervention|No Intervention|No Intervention
89394019|NCT04712305||Cohort A|Training cohort will be recruited in the first 24 months of the study period to generate urine metabolomic and proteomic profiles as predictive and prognostic markers.
89394020|NCT04712305||Cohort B|Validation cohort will be recruited in the next 36 months of the study period.
89394021|NCT02139098|Experimental|Amitriptyline flexible dosing|50 mg capsule amitriptyline before going to bed on 8 out of 17 nights/placebo
89394022|NCT02139098|Experimental|Zolpidem flexible dosing|5 mg capsule zolpidem before going to bed on 8 out of 17 nights/placebo
89394023|NCT02139098|Active Comparator|Amitriptyline fixed dosing|50 mg capsule amitriptyline before going to bed on 8 out of 17 nights
89394024|NCT02139098|Active Comparator|Zolpidem fixed dosing|5 mg capsule zolpidem before going to bed on 8 out of 17 nights
89394025|NCT02139098|Active Comparator|Amitriptyline continuous dosing|50 mg capsule amitriptyline before going to bed on 13 out of 17 nights
89394026|NCT02130752|Experimental|Ultrasonic scalpel surgery group|During the procedures of the abdominal approach D2 distal gastrectomy, use ultrasonic scalpel (Device) to coagulation and cut off blood vessel, separate and dissection lymph-nodes; some great vessels can ligation by nylon, silk line or Hemolock.
88870244|NCT04378790|Experimental|Simultaneous treatment|full-time spectacle correction and part-time patching for 2 hours per day/7 days per week
88870245|NCT04373473|Experimental|Patients with UC will receive FMT capsules|Patients with ulcerative colitis will receive fecal microbiota capsules from 3 healthy donors
88870246|NCT04373473|Placebo Comparator|Patients with UC will receive placebo|Patients with ulcerative colitis will receive matching placebo capsules. Placebo capsule will be identical to PRIM-DJ2727 but will not contain intestinal bacteria.
88870247|NCT04369456|Other|Covid-19 kidney transplant patients with moderate symptoms|
88870248|NCT04365205||severe asthma|"Diagnosis of severe asthma according to the American Thoracic Society / European Respiratory Society task force.~Documented post-bronchodilator reversibility of at least 12% and at least 200 mL in Forced expiratory volume forced expiratory volume at one second (FEV1) within 12 months before enrollment.~Documented blood eosinophils ≥ 300 cells per μL within 12 months or blood eosinophils ≥150 cells per μL at visit 1."
88870249|NCT04365205||non-severe asthma|• Diagnosis of non-severe asthma according to the Global Initiative for Asthma (GINA).
89394027|NCT02130752|Experimental|Monopolar electrocautery surgery group|During the procedures of the abdominal approach D2 distal gastrectomy, use monopolar electrocautery (Device) to coagulation and cut off blood vessel, separate and dissection lymph-nodes; some great vessels can ligation by nylon, silk line or Hemolock.
88870250|NCT04365205||non-asthmatic controls|"No prior history of any chronic respiratory disease including asthma.~No prior history of allergy, i.e. allergic rhinitis, allergic conjunctivitis, hay fever, eczema.~No clinically significant abnormalities as determined by medical history, measurement of vital signs, physical examination, hematologic assessments and ECG at visit 1.~Normal lung function with FEV1 > 90%."
88870251|NCT04357795|Experimental|CequaTM (Cyclosporine 0.09%) ophthalmic solution|
88870252|NCT04344665|Experimental|Virtual Care and Remote Automated Monitoring|
88870253|NCT04344665|No Intervention|Standard Care|
88870254|NCT04344262|Active Comparator|control (C) group|"Intubating dose of muscle relaxant will be atracurium 0.5 mg/kg~Maintenance doses of muscle relaxant will be given throughout the intraoperative period~to maintain the Train-of-four values continuously less than 2"
88870255|NCT04344262|Experimental|minimal dose (M) group|"Intubating dose of muscle relaxant will be 0.2 mg/kg will be injected~boluses of muscle relaxant will be given only upon complain of the surgeon and after a bolus dose of propofol 0.5 mg/kg. When required, 20% of the initial dose of muscle relaxant will be provided as a bolus to achieve this goal."
88870256|NCT04323436|Experimental|Run-in part|capmatinib in combination with spartalizumab
88870257|NCT04323436|Experimental|Randomized part - Arm 1 spartalizumab|capmatinib in combination with spartalizumab
88870258|NCT04323436|Experimental|Randomized part - Arm 2 placebo|capmatinib in combination with placebo
88870259|NCT04312022|Experimental|Berry extract intake, then Placebo|Participants received a single dose of berry extract supplement (hawthorn berry extract, tart cherry extract, and bromelain). After a washout period of 2 weeks, they then received a single dose of the placebo (flour capsule).
88870260|NCT04312022|Placebo Comparator|Placebo intake, then Berry extract intake|Participants received a single dose of placebo (flour capsule). After a washout period of 2 weeks, they then received a single dose of berry extract supplement (hawthorn berry extract, tart cherry extract, and bromelain).
88870261|NCT04298151|Experimental|zirconomer improved|zirconia reinforced glass ionomer restoration
88870262|NCT04298151|Active Comparator|ketac molar quick aplicap|conventional viscous glass ionomer restoration
88870263|NCT04284397|Experimental|Critical Environmental Limits|Subjects will perform exercise at ~200-300W with ambient temperature or humidity increasing every 5 min throughout the trial until core temperature begins to rise.
88870264|NCT04284397|Experimental|Aspirin Supplementation|After a minimum of 7 days of daily, low-dose aspirin ingestion, older subjects will repeat critical environmental limits trials. As before, subjects will perform exercise at ~200-300W with ambient temperature or humidity increasing every 5 min throughout the trial until core temperature begins to rise.
88870265|NCT04284293|Experimental|Group 1A|"Visual acuity of 20/200 or worse~Single, unilateral, subretinal injection of 300,000 CNS10-NPC (n=3)"
88870266|NCT04284293|Experimental|Group 1B|"Visual acuity of 20/200 or worse~Single, unilateral, subretinal injection of 1,000,000 CNS10-NPC (n=3)"
88870267|NCT04284293|Experimental|Group 2|"Visual acuity between 20/80 and 20/200~Single, unilateral, subretinal injection of 1,000,000 CNS10-NPC (n=10)"
89394028|NCT01360073||Cases|Cases with nonfatal MI or coronary death
89394029|NCT01360073||Controls|Age, sex, and calendar-year matched controls sampled from the original study cohort to be a round number of at least four times the number of cases
88870268|NCT04247542|Experimental|Ibezapolstat|Active investigational antibacterial agent: ibezapolstat 450 mg po Q12H x 10 days
89394030|NCT01362257|Experimental|14C-GSK573719 Oral Solution|single dose of 1000µg
89394031|NCT01362257|Experimental|14C-GSK573719 IV Solution|single dose of 65µg
88870269|NCT04247542|Active Comparator|Vancomycin|Standard of care: Vancomycin 125 mg po Q6H x 10 days
88870270|NCT04240704|Experimental|JBH492 single agent|Patients with R/R CLL or NHL
88870271|NCT04236388|Active Comparator|Dietary Ketone|Participants will consume three daily ketone drinks (one before each meal) for 2 weeks.
88870272|NCT04236388|Placebo Comparator|Placebo|Participants will consume three daily placebo drinks (one before each meal) for 2 weeks. .
88870273|NCT04231071|Active Comparator|Sutured group|Controlled group: Primary suture repair of the small umbilical hernia defect
89394032|NCT02487979|Experimental|Treatment (glembatumumab vedotin)|Patients receive glembatumumab vedotin IV over 90 minutes on day 1. Treatment repeats every 21 days for up to 18 courses in the absence of disease progression or unacceptable toxicity.
89394033|NCT02134496|No Intervention|no assessment of motorfunction in PACU|no assessment of motorfunction after spinal anesthesia in PACU
89394034|NCT02134496|Active Comparator|motorfunction assessment in PACU|Assesment of motorfunction after spinal anesthesia
89394035|NCT01356173|Experimental|A|
89394036|NCT02130830|Experimental|Topical anesthesia|Application of topical 2,5% lidocaine + 2,5% prilocaine gel to the anal canal before the procedure
89394037|NCT02130830|Placebo Comparator|Placebo|Application of placebo gel into the anal canal before the procedure
89394038|NCT02279771|Active Comparator|transanal anastomotic reinforcement|Low anterior resection with TME plus anastomotic transanal reinforcement without protective ileostomy/colostomy (transanal anastomotic reinforced arm:TAR-LAR)
89394039|NCT02279771|Active Comparator|protective ileostomy group|Standard low anterior resection with TME plus protective ileostomy/colostomy (S-LAR)
89394040|NCT02139254||Low risk|Pregnant women with a low risk for metabolic diseases
89187247|NCT00767559|Active Comparator|1|"Variable dose warfarin: 5 mg beginning the night before surgery, followed by 5mg the PM of surgery*, and then variable daily dose,until day 30 follow-up.~(target INR 2.0-2.5)"
89187248|NCT00767559|Active Comparator|2|"Fondaparinux:~2.5 mg daily starting more than 6 hours following surgery and no later than 6 AM the next day*,or 6-8 hours after epidural catheter removal, and continued until follow-up (28 days +/-2) from day of surgery."
89187249|NCT00767559|Active Comparator|3|"Fixed Low Dose warfarin~1 mg daily beginning 7 days preoperative, and continued at 1 mg daily follow-up at Day 28 (+/-2 days from surgery)."
89187250|NCT00767637|Experimental|Arm 1|
89187251|NCT00767715|Experimental|A|Patients will be given olanzapine
89187252|NCT00767715|Active Comparator|B|Patients will be given either haloperidol or zuclopentixol
89394041|NCT02139254||High risk|Pregnant women with a high risk for metabolic diseases
88870274|NCT04231071|Experimental|Onlay Mesh group|Intervention group: Primary suture repair of the small umbilical hernia defects + a small Onlay mesh on the closed defect.
88870275|NCT04227184|Experimental|Placebo/Trospium|Placebo first for 12 weeks followed by Trospium for 12 weeks.
88870276|NCT04227184|Experimental|Trospium/Placebo|Trospium first for 12 weeks followed by Placebo for 12 weeks
88870277|NCT04226053|Experimental|Intervention Group|The treatment group will consist of 160 mothers who were randomly selected to receive Room to Grow services, which include three years of social and practical support for the mother and baby through a combination of one-on-one sessions with an expert clinical social worker in-person every three months and provision of essential baby items and equipment.
88870278|NCT04226053|No Intervention|Control Group|The control group will consist of 160 mothers who will not receive Room to Grow services.
88870279|NCT04225572|No Intervention|Control Group|Patient will not receive physical therapy treatment or further instruction from the research team. The patient will receive standard care recommended by their medical provider which may or may not include physical therapy treatment.
89187253|NCT02584946|Placebo Comparator|Low-AVA oat flour cookies|
89187254|NCT02584946|Experimental|High-AVA oat flour cookies|
89187255|NCT00762957|Experimental|TAK-559 16 mg QD + Metformin QD|
89394042|NCT02139332|Active Comparator|Resource & Referral group|Individuals randomized to the control group will receive a resource & Referral service immediately after their baseline research visit.
88870280|NCT04225572|Experimental|Physical Therapy Group|
88870281|NCT04221529|Experimental|Atezolizumab|Four 21-day cycles of induction therapy with atezolizumab+carboplatin+etoposide followed by 21-day cycles of maintenance therapy with atezolizumab.
88870282|NCT04220983|Other|MR-Guided Prostate SBRT|
88870283|NCT04219085|Active Comparator|Routine Care|Monitoring of control of gestational diabetes with routine care and use of a glucometer and fingersticks 4 times a day
89394043|NCT02139332|Experimental|PFR Group|Individuals randomized to the Immediate group will receive the intervention program immediately after completing the baseline assessment.
89187256|NCT00762957|Experimental|TAK-559 32 mg QD + Metformin QD|
89187257|NCT00762957|Active Comparator|Metformin QD|
89187258|NCT04295720|Experimental|Transcranial magnetic stimulation (TMS)|We propose to test the efficacy of rTMS for the treatment of PCCI. Efficacy measures will include baseline and post-rTMS neuropsychological testing, functional MRI and biometry data using body worn sensors.
89187259|NCT00763113|Experimental|1|Vanguard PS Knee
89187260|NCT00763113|Active Comparator|2|Vanguard CR Knee
89187261|NCT05292014||Coronary Artery Disease (CAD)|
89187262|NCT02558127||50 asthma patients|50 asthma patients with bronchial mucus hypersecretion
89187263|NCT02558127||asthma patients|50 asthma patients without bronchial mucus hypersecretion
89187264|NCT00759993|Experimental|A,1|chromium piccolinate 1000mg
89187265|NCT00759993|Placebo Comparator|A,2|matching placebo
89187266|NCT00920348||Group 1|COPD moderate-severe(GOLD2-4)(post-BD FEV1/FVC<0.70 and FEV1<80% of pred.)
89187267|NCT00920348||Group 2|COPD mild (GOLD1)(post-BD FEV1/FVC<0.70 AND FEV1>=80% of pred.)
89394044|NCT01360151|Experimental|experimental|Arm 1 : combination treatment of ranibizumab(Lucentis) and verteporfin(Visudyne) injection
89394045|NCT01360151|Active Comparator|active comparator|Arm 2 : Treatment of verteporfin(Visudyne)
89394046|NCT01360151|No Intervention|normal control group|Arm 3 : normal control group
89394047|NCT02134652||Suspected Dengue|Children with an acute febrile illness, and two of the following: headache, retro-orbital pain, myalgias, arthralgia, rash, hemorrhagic manifestations, or plasma leakage (i.e. shortness of breath, abdominal distention/pain) will all receive a diagnostic bedside ultrasound.
89394048|NCT03633097|Experimental|Acupuncture + Usual care|Acupuncture with Cnoxane Injection 40mg, Esomezol Capsule, Synerjet Semi Tablet and Ocoron Tablet
89394049|NCT03633097|Active Comparator|Usual care|Cnoxane Injection 40mg, Esomezol Capsule, Synerjet Semi Tablet and Ocoron Tablet
89394050|NCT01360307||Major Depressive Disorder Patients|
89394051|NCT02139410||IGF-1 1st and 2nd quartile|Reduction of IGF-1 serum value in a cohort of patients with cognitive impairment
89187268|NCT00920348||Group 3|COPD at risk (ever smoker with post-BD FEV1/FVC>=0.70)
89187269|NCT00920348||Group 4|"Healthy control never smokers without respiratory disease (post-BD FEV1/FVC>=0.70."
89187270|NCT00673881|Experimental|Abt-335|ABT-335 (choline fenofibrate)
89187271|NCT00763347|Experimental|SYR-619 12.5 mg QD|
89187272|NCT00763347|Experimental|SYR-619 50 mg QD|
89187273|NCT00763347|Experimental|SYR-619 100 mg QD|
89187274|NCT00763347|Experimental|SYR-619 200 mg QD|
89187275|NCT00763347|Placebo Comparator|Placebo QD|
89187276|NCT00763347|Active Comparator|Alogliptin 25 mg QD|
89187277|NCT00767793|Placebo Comparator|Arm 1|One drop in each eye every 12 hours for seven days
89187278|NCT00767793|Experimental|Arm 2|One drop of Concentration #1 in one eye and one drop of placebo in contralateral eye every 12 hours for seven days
89187279|NCT00767793|Experimental|Arm 3|One drop of Concentration #2 in one eye and one drop of placebo in contralateral eye every 12 hours for seven days
89187280|NCT00767793|Experimental|Arm 4|One drop of Concentration #3 in one eye and one drop of placebo in contralateral eye every 12 hours for seven days
89187281|NCT00767871|Experimental|Escitalopram|escitalopram (10-20mg) to panic patients
89187282|NCT00760071||1CF-patients<6|Patients with diagnoses of cystic fibrosis from birth to the age of 6 years
89187283|NCT00760071||2 controls|age matched controls
89187284|NCT00760149|Placebo Comparator|1|50 patients, treated with the standard anti-TB regimen, including rifampicin (600 mg), isoniazid (300 mg), pyrazinamide (30 mg/kg), ethambutol (15 mg/kg), administered daily, orally, during the intensive phase of TB treatment. In addition they will receive 2 placebo tablets resembling rifampicin 300 mg.
88816556|NCT00363909|Experimental|high-dose citalopram hydrobromide|"Patients receive 1 tablet of oral citalopram once daily in week 2, 2 tablets once daily in week 3, and 3 tablets once daily in weeks 4-7.~All patients complete a diary of hot flash incidence in weeks 1-7 and undergo blood collection periodically during study treatment for translational research studies."
89187285|NCT00760149|Active Comparator|2|50 patients, treated with rifampicin (900 mg), and the other drugs in standard dosages (isoniazid (300 mg), pyrazinamide (30 mg/kg), ethambutol (15 mg/kg)), administered daily, orally, during the intensive phase of TB treatment. In addition they will receive 1 placebo tablet resembling rifampicin 300 mg.
89187286|NCT00760149|Active Comparator|3|50 patients, treated with rifampicin (1200 mg), and the other drugs in standard dosages (isoniazid (300 mg), pyrazinamide (30 mg/kg), ethambutol (15 mg/kg)), administered daily, orally, during the intensive phase of TB treatment.
88816557|NCT00363909|Placebo Comparator|placebo|"Patients receive 1-3 placebo tablets once daily in weeks 2-7.~All patients complete a diary of hot flash incidence in weeks 1-7 and undergo blood collection periodically during study treatment for translational research studies."
88816558|NCT01205828|Experimental|Temozolomide and ABT-888 in HCC patients|Temozolomide 150 mg/m2/day PO Days 1-5 every 28 days ABT-888 40 mg BID PO Days 1-7 every 28 days
88816559|NCT02433288|Other|Active app|The smart phone application used on the patients' smart phones will contain both the patient support tool and the questions for the clinical evaluation in the form of the Rosuvastatin Adherence questionnaire (RAQ), Beliefs about Medicine Questionnaire - General (BMQ-G), (Horne, 1999) and a Lifestyle questionnaire (LSQ) on disease understanding, lifestyle and treatment awareness. Patients in the Active group will also receive feedback on their daily rosuvastatin treatment as entered in the patient support tool.
88816560|NCT02433288|Other|Control app|a smart phone application will be used to prompt patients with the questions for the clinical evaluation (RAQ, BMQ-G and LSQ).
88816561|NCT04341597|Experimental|transperineal sonographic cervix assessment|
88816562|NCT04341597|Active Comparator|endovaginal sonographic cervix assessment|
88816563|NCT05248347|Active Comparator|Bronchoscopy training simulator|Bronchoscopy training simulator LM-092 (Koken Co., Ltd, Tokyo, Japan) was used to train the participants.
88816564|NCT05248347|Experimental|The BRONCH Mentor|Group B: The BRONCH Mentor (Simbionix, GI-Bronch Mentor, USA) was used.
88816565|NCT04333017|Experimental|treated patient|Percutaneous radiofrequency ablation of parietal endometriosis
88816566|NCT01206062|Experimental|Intensive Control of SBP|"Participants randomized into the Intensive BP arm will have a goal of SBP <120 mm Hg. 2-drug therapy initiated in most Intensive participants; age ≥75 years and SBP 130-139 mm Hg on 0-1 drug; may begin with 1 drug, but add second at 1 month if SBP ≥130 mm Hg; drugs added and/or titrated at each visit (monthly) to achieve SBP <120 mm Hg; at periodic milepost visits: addition of another drug required if not at goal."
88816567|NCT01206062|Active Comparator|Standard Control of SBP|Participants randomized into the Standard arm will have a goal of SBP <140 mm Hg. Intensify therapy if SBP ≥160 mm Hg @ 1 visit; ≥140 mm Hg @ 2 consecutive visits; Down-titration if SBP <130 mm Hg @ 1 visit; <135 mm Hg @ 2 consecutive visits
88816568|NCT02433210|Active Comparator|Solute Clearance|Solute clearance at 60 minutes for urea, creatinine, phosphate, beta 2 microglobulin, and myoglobin will be determined three times for ELISIO-15H, Revaclear and Optiflux 160NR dialyzers at the 60 minute time point.
89187287|NCT00767949|Experimental|1|iSONEP
89187288|NCT00671853|Experimental|1|Quetiapine XR
89187289|NCT00671853|Placebo Comparator|2|Placebo for quetiapine XR
89187290|NCT00760227|Other|1: HPI-C|Child Intervention Only Group
89187291|NCT00760227|Other|2: HPI-CP|Parent and Child Intervention Group
89187292|NCT00760227|No Intervention|3: SC|Standard Care Control Group- No Intervention
89187293|NCT00768105|Experimental|1|
88816569|NCT02433210|Active Comparator|Hemocompatibility|Hemocompatibility will be determined using the markers C3a, C5a, thrombin/anti-thrombin complex and complete blood count with platelets will be determined one time for each dialyzer at session 2 and at time points 0, 15, 30, 60, and 240 minutes for ELISIO-15H, Revaclear and Optiflux 160NR dialyzers ..
88816570|NCT02433210|Active Comparator|Solute removal rate|Solute (urea, creatinine, phosphate, beta 2 macroglobulin, and myoglobin) removal rate will be determined time points 0 and 240 minutes for ELISIO-15H, Revaclear and Optiflux 160NR dialyzers .
88816571|NCT03010046|Experimental|ANX005 Monotherapy|ANX005 intravenous infusion
88870284|NCT04219085|Experimental|Continuous Glucose Monitor|Monitoring of control of gestational diabetes with use of a continuous glucose monitor
89394052|NCT02139410||IGF-1 3rd and 4rd quartile|Reduction of IGF-1 serum value in a cohort of patients with cognitive impairment
89394053|NCT02139488||neoadjuvant or definitive chemoradiation|Esophageal cancer patients planned for neoadjuvant or definitive chemoradiation.
89394054|NCT01363037|Experimental|Dapivirine-Maraviroc Vaginal Ring|
89187294|NCT00768105|Placebo Comparator|2|
89394055|NCT01363037|Placebo Comparator|Placebo Vaginal Ring|
89394056|NCT01363037|Active Comparator|Maraviroc Vaginal Ring|
89394057|NCT01363037|Active Comparator|Dapivirine Vaginal Ring|
89394058|NCT02130908|Experimental|Lean fish|
89394059|NCT02130908|Experimental|Fatty fish|
89394060|NCT02130908|Experimental|Lean meat|
89394061|NCT01363115|Experimental|OJ fortified with Ca and VitD|Regular OJ fortified with Calcium (350 mg/8 fluid oz serving) and Vitamin D3 (100 IU/8 fluid oz serving): one 8 fluid oz serving three times/day (treatment) in combination with nutritional counseling
89394062|NCT01363115|Active Comparator|OJ without VitD and Ca|Regular OJ without Calcium or Vitamin D3: one 8 fluid oz serving three times/day (control)
89394063|NCT02134730|No Intervention|Wait list|Schools in waitlist condition will be offered the intervention after the 12-months follow up. Waitlist means that the schools work as usual with issues of mental health.
89394064|NCT02134730|Experimental|FRIENDS for life|The intervention is delivered for 10 consecutive weeks, 60 minutes per session.
89394065|NCT01356329|Experimental|Lovenox|Group A : Low Molecular Weight Heparin (LMWH), LovenoxTM (Enoxaparin)
89394066|NCT01356329|Experimental|Heparin|Group B:HeparinTM (Unfractionated Heparin)
89394067|NCT05579522|Experimental|injectable fat graft|Injection of fat graft from the buccal pad of fat into the interdental papilla
88816572|NCT03010046|Experimental|ANX005 and IVIg Combination Therapy|ANX005 intravenous infusion in combination with intravenous immunoglobulin (IVIg)
89394068|NCT05579522|Active Comparator|hyaluronic acid filler|injection of hyaluronic acid filler in the interdental papilla
89394069|NCT04579939|Experimental|Experimental|All 10 participants will go through the experimental arm receiving the dextrose candy oral glucose tolerance test.
88816573|NCT03010046|Placebo Comparator|Placebo|Placebo intravenous infusion
88816574|NCT02515305|Experimental|Test product|
88816575|NCT02515305|Active Comparator|Reference product|
88816576|NCT02515305|Placebo Comparator|Placebo product|
88816577|NCT01222286|Experimental|IPH2101 0.2 mg/kg|0.2 mg/Kg every 4 weeks by intravenous route over 1 hour, for 6 or up to 12 cycles
88816578|NCT01222286|Experimental|IPH2101 2 mg/kg|2 mg/Kg every 4 weeks by intravenous route over 1 hour, for 6 or up to 12 cycles
88816579|NCT01206452|Experimental|Ablation plus prednisone|Participants undergo ablation procedure and receive predinisone at protocol determined times.
88816580|NCT01206452|Placebo Comparator|Ablation plus placebo|Participants undergo ablation procedure and receive placebo at protocol determined times.
88816581|NCT01206608|Active Comparator|Low-dose SKY0402 + bupivacaine HCl|Marcaine with epinephrine 1:200,000 is the reference-listed drug for bupivacaine and contains the same active, local anesthetic as SKY0402
88816582|NCT01206608|Active Comparator|Mid-dose SKY0402 + bupivacaine HCl|Marcaine with epinephrine 1:200,000 is the reference-listed drug for bupivacaine and contains the same active, local anesthetic as SKY0402
88816583|NCT01207466|Other|Nelfilcon A invest'l / nelfilconA comm'l|Nelfilcon A investigational toric contact lenses worn first, with nelfilcon A commercial toric contact lenses worn second. Each product worn bilaterally on a daily disposable basis for one week.
88816584|NCT01207466|Other|Nelfilcon A comm'l / nelfilconA invest'l|Nelfilcon A commercial toric contact lenses worn first, with nelfilcon A investigational toric contact lenses worn second. Each product worn bilaterally on a daily disposable basis for one week.
88816585|NCT03010514||case|
88816586|NCT03010514||control|
88816587|NCT03010436|Other|Open-Label|All subjects will receive the study medication- benralizumab
88816588|NCT02432040|Experimental|Atorvastatin|Atorvastatin 40 mg once a day at night Patients asked to apply Betamethasone valerate 0.1% ointment twice a day, 3 weeks on, 1 week off, at the most
88816589|NCT02432040|Placebo Comparator|Placebo|Placebo tablets But patients are still asked to apply Betamethasone valerate 0.1% ointment twice a day, 3 weeks on, 1 week off, at the most
88816590|NCT03009968|No Intervention|Traditional backfill assisted voiding trial|Backfill the bladder with up to 300 ml as tolerated of normal saline or sterile water through an indwelling Foley catheter. The catheter is removed and the patient is given 15 minutes to void and the voided volume is measured. A post void residual (PVR) is measured after voiding (or attempt to void) using either an in and out catheter or a bladder scanner. The participant is considered to have passed the void trial if they have a PVR of less than 100 mL or less than half the voided volume if voided volume is greater than 200 mL.
88816591|NCT03009968|Experimental|Post-void residual free voiding trial|The post-void residual free voiding trial (intervention): Backfill the bladder with up to 300 ml as tolerated of normal saline or sterile water through an indwelling Foley catheter. The catheter is removed and the patient is given 15 minutes to void and the voided volume is measured. The participant is considered to have passed the void trial if they void more than 1/2 the instilled volume. A PVR will not be performed.
88816592|NCT02517021|Experimental|Pro-netupitant/Palonosetron plus Dexamethasone|Intravenous Pro-netupitant/Palonosetron (260 mg/0.25 mg) powder for solution for infusion (on Day 1) with oral dexamethasone prior to each scheduled chemotherapy cycle
88816593|NCT02517021|Active Comparator|Netupitant/Palonosetron plus Dexamethasone|Oral netupitant/palonosetron (300 mg/0.50 mg) hard capsule (on Day 1) with oral dexamethasone prior to each scheduled chemotherapy cycle
88816594|NCT02981498|Experimental|Sorafenib combined with HAIC|Sorafenib combined with Hepatic arterial infusion chemotherapy with Folfox Protocol
88816595|NCT01207934|Placebo Comparator|placebo|saline placebo for fourteen days
88816596|NCT01207934|Experimental|low-dose leptin|30mg per day of recombinant methionyl human (r-met hu) leptin for fourteen days
88816597|NCT01207934|Experimental|high-dose leptin|80mg per day of recombinant methionyl human (r-met hu) leptin for fourteen days
89187295|NCT00768183|Experimental|Regimen A|KADIAN Capsule + alcohol (under fasting conditions)
88870285|NCT04219007|Experimental|Genetic Short Stature|"Vosoritide, also known as BMN 111 or modified recombinant human C-type natriuretic peptide (CNP), is a 39-amino-acid peptide analog that includes the 37 C-terminal amino acids of the human CNP53 sequence plus the addition of 2 amino acids (Pro-Gly) on the N-terminus. This structural modification conveys resistance to neutral endopeptidase (NEP) degradation, resulting in prolonged half-life (t1/2) in comparison to endogenous CNP. This increase in t1/2 allows once daily subcutaneous (SC) administration.~Vosoritide will be administered as a single 15 μg/kg subcutaneous injection given daily for 12 months."
88870286|NCT04204291|Experimental|All|
88870287|NCT04202094|Experimental|Biopsy group|Young adult men (≥18 years) cured of childhood cancer or hematological disorders for which they received high-risk gonadotoxic treatment during childhood and who have chosen to undergo a testicular biopsy procedure at a young age as a fertility preservation strategy.
88870288|NCT04202094|Experimental|No biopsy group|Young adult men (≥18 years) cured of childhood cancer or hematological disorders for which they received high-risk gonadotoxic treatment during childhood and who have refused to undergo a testicular biopsy procedure at a young age as a fertility preservation strategy.
88870289|NCT04202094|No Intervention|Control group|Spontaneously conceived young adults whose data on reproductive health have already been published (Belva F et al., 2016/2017/2019).
88870290|NCT04195178||Anesthesia Providers|Clinically active anesthesia providers
88870291|NCT04184674|Other|Acute Respiratory Distress Syndrome|Children of more than one month of age and adults hospitalized in Intensive Care Unit for Acute Respiratory Distress Syndrome.
88870292|NCT04167969|Experimental|Prostate cancer patients|Patients will receive an intravenous (IV) injection of approximately 5 mCi (+/- 10%) of PSMAtargeting C' dot tracer up to 48 hours before surgery. Patients will then undergo serial preoperative PET/MR imaging to help characterize the safety, biodistribution/pharmacokinetics, and dosimetry of this agent. To assess total radioactivity in whole blood/plasma and urine samples, as well as radioactive metabolites, blood and urine samples will be collected at approximately 30 min post-injection as well as before each imaging session
88870293|NCT04167514|Experimental|AAT|Alpha-1 antitrypsin (AAT) is a lyophilized powder for intravenous administration
88870294|NCT04167514|Placebo Comparator|Placebo|Albumin solution administered intravenously
88870295|NCT04164966||New onset Type 1 Diabetes|
88870296|NCT04164966||Healthy Normal Volunteers (HNV)|
88870297|NCT04146051|Experimental|Phase 1b Dose-Escalation|Generalized Myasthenia Gravis
88870298|NCT04146051|Experimental|Phase IIa Expansion|Generalized Myasthenia Gravis
88870299|NCT04146051|Placebo Comparator|Phase IIb Randomized Control Trial|Generalized Myasthenia Gravis
88870300|NCT04141696|Experimental|Ketamine|Given intravenously over 40 minutes
88870301|NCT04141696|Active Comparator|Midazolam|Given intravenously over 40 minutes
88870302|NCT04139733||Prone group|"Prone position within 24 hours after VV-ECMO support.~Prone position for at least 16 hours per day for a minimum of 5 days."
88870303|NCT04139733||Supine group|1. Supine group on ECMO.
88870304|NCT04136951|Experimental|Experimental phase|The PREVENT recommendation about patient homecare priority will be shared in homecare referral communication with the homecare intake coordinators. Homecare intake coordinators will be instructed to prioritize high risk patients for care.
89394070|NCT02139566|Experimental|Hi-tech video consent|This group will be shown a professionally animated video that presents the major components of the informed consent document. Intervention is Video Consent (high-tech) PDF informed consent document.
88870305|NCT04098068|Experimental|MSI (Microsatellite Unstable) Negative with Mutator Phenotype|
88870306|NCT04090099|No Intervention|Group C|PCA (Patient controlled analgesia) and morphine consumption will be monitored in the postoperative period.
88870307|NCT04090099|Active Comparator|Group ES (Erector Spina Plane)|A high frequency (10-18 MHz) ultrasound linear probe covered with a sterile sheath will be placed 2 cm to the side of the T5 spinous process, first to the right or left. After demonstrating the T5 transverse process and the erector spinae muscle on top, the 22-gauge, 80 mm insulated Quincke-type needle will be inserted into the skin at an angle of about 30 degrees from the cranial to the caudal, using an in-plane technique. When the transverse process is touched, the needle is withdrawn and after a negative aspiration test with 0.5 mL of normal saline and after a hypo-echogenic display and hydrodissection, a local anesthetic solution will be applied to the fascia under the erector spinae muscle. A dose of 0.25% bupivacaine will be injected which is shown to spread both above and below the T5 level. The same process will be implemented on the other side.
88870308|NCT04090099|Active Comparator|Group PS (Para Sternal Block)|Before the wire is inserted into the sternum, the sternotomy and mediastinal tube regions will be infiltrated with a mixture of bupivacaine and saline.
88870309|NCT04088370||Alcoholic Hepatitis|No intervention-blood draw only
88870310|NCT04088370||Healthy Controls|No intervention- blood draw only
88870311|NCT04088370||Healthy Heavy Drinkers|No intervention- blood draw only
88870312|NCT04084314|Experimental|Erenumab|Erenumab dose could be adjusted from 70 mg to 140 mg or vice versa at the discretion of the physician at any scheduled study visit.
88870313|NCT04059484|Experimental|Amcenestrant|Daily amcenestrant dose administered orally under fed or fast condition
88870314|NCT04059484|Active Comparator|Fulvestrant/Aromatase inhibitors/Estrogen receptor modulator|"Control treatment of the choice of the physician depending on each participant's medical condition and in accordance with the approved label may include 1 of the following treatments used as monotherapy.~Fulvestrant~Aromatase inhibitors (anastrozole, letrozole, exemestane)~Selective estrogen receptor modulator (Tamoxifen)"
88870315|NCT04057677|Experimental|Exercise Recovery|Older males and females with pre-diabetes or type 2 diabetes. We are examining the effects of a recovery exercise program for older adults with pre-diabetes and type 2 diabetes. Following 10 days of bed rest and during the first 4 weeks of recovery, participants will perform a combination of aerobic and resistance exercise training.
89187296|NCT00768183|Experimental|Regimen B|KADIAN Capsule + alcohol (under fed conditions)
89187297|NCT00768183|Experimental|Regimen C|KADIAN Capsule + water (under fasting conditions)
88870316|NCT04057677|Experimental|Non-Exercise Recovery|Older males and females with pre-diabetes or type 2 diabetes. Participants in the ambulatory recovery group will not receive any exercise intervention or advice on exercise following 10 days of bed rest. Rather these participants will return to their regular daily routine that they engaged in prior to the bed rest intervention.
88870317|NCT04054778|Experimental|Avatar Therapy|Participants will be offered 9 individual and weekly sessions of 1 hour, which will be administered in an individual format by a licensed psychologist or psychiatrist experienced with psychosis patients. The therapy will consist in prompting participants to enter in a dialogue with their persecutor to better regulate their emotional responses. Over the course of the therapy, the avatar's speech and tone will gradually be changed by the therapist to echo participants' improved ability to regulate their emotions. That is, the avatar will progressively change from being abusive to becoming helpful and supportive. By doing so, the therapy will seek to reinforce participants' feeling of empowerment over their voices.
88870318|NCT04054778|Active Comparator|Cognitive Behavioral Therapy|Participants will be offered 9 individual and weekly sessions of 1 hour, which will be administered in an individual format by a licensed psychologist or psychiatrist trained in Cognitive Behavioral Therapy for psychosis (CBTp). The program is derived and adapted from current evidence-based treatments for hallucinations. The 9 CBTp sessions will consist of a succession of learning modules and suggested task assignments.
88870319|NCT04051203|Experimental|Autologous Platelet Rich Plasma Injection|PRP contains high concentrations of platelets, growth factors, and anti-inflammatory molecules.
88870320|NCT04051203|Active Comparator|Standard Treatment|Steroid and anesthetic injection: the clinical standard.
88870321|NCT04051203|Placebo Comparator|Normal Saline|Placebo injection, with no known treatment effects.
88870322|NCT04046614|Experimental|nintedanib nivolumab|nintedanib-nivolumab combination therapy
88870323|NCT04040452|Experimental|Treatment|"Description: Patients randomized for the treatment arm of the study group will receive a continuous infusion of ketorolac plus an intermittent dose of placebo (plasmalyte). To eliminate excess exposure and the associated side effects, all patients enrolled in the study will not be given any additional NSAIDs (except aspirin, which is standard of care in many post-operative cardiac surgery patients) during the study period.~Dosage and Route of Administration:~Continuous ketorolac 0.08mg/kg/hr, with a maximum of 5mg/hr for patients weighing greater than or equal to 60kg, administered intravenously by nursing staff. Study drug will infuse continuously for 48 hours.~Intermittent Plasmalyte 0.033mL/kg (max 2mL) infusion every 6 hours for 48 hours."
88870324|NCT04040452|Placebo Comparator|Standard of care|"Description: Patients randomized to the standard of care arm of the study will receive a generically marked syringe of Plasmalyte to be infused at the same rate as the treatment medication, and will only receive intermittent dosing of ketorolac (current standard of care). As in the treatment group, no additional NSAIDs (except aspirin) are to be given during the 48 hour study period.~Dosage and Route of Administration~Continuous Plasmalyte infusion to match the aforementioned ketorolac dosing~Intermittent ketorolac 0.5mg/kg IV infusion every 6 hours (max 30mg per dose)"
88870325|NCT04038359|Experimental|Duvelisib, Continuous and Intermittent Dosing|Duvelisib 25 mg BID continuously for 10 weeks, followed by 25 mg BID dosed two weeks on and two weeks off of each subsequent 4-week cycle.
88870326|NCT04038359|Experimental|Duvelisib, Intermittent Dosing|Duvelisib 25 mg BID dosed two weeks on and two weeks off.
89187298|NCT00768183|Experimental|Regimen D|Morphine sulfate IR oral solution + water (under fasting conditions)
89187299|NCT00763425|Experimental|1|
89187300|NCT00763425|Active Comparator|2|
89187301|NCT00760305|Experimental|1|Patients who received the Pro-Self psychoeducational intervention
89187302|NCT00760305|No Intervention|2|Patients who received standard care
88870327|NCT04024761|Experimental|CIML NK|"CIML NK cells will be administered intravenously on day 0.~Fludarabine will be administered as IV infusion once daily for 3 doses beginning on day -5.~Cyclophosphamide will be administered as IV infusion on days -5 and -4."
88870328|NCT04017533|Experimental|GMK Sphere|Patients receive a cementless GMK Sphere Total Knee Replacement
88870329|NCT04014335|Experimental|IONIS-FB-LRx|
89187303|NCT00768339|Experimental|1|Single agent AEG35156 as 2hr IV infusion, weekly dosing in Patients with relapsed or refractory chronic lymphocytic leukemia and indolent B-cell lymphomas
89187304|NCT00768417||Participants|Participants completed all 3-arms of this cross-over design study.
89187305|NCT00768495||One Cohort|
89187306|NCT02557581|Experimental|Terbutaline|Beta2-adrenergic stimulation with terbutaline
89187307|NCT02557581|Placebo Comparator|Placebo|Placebo
89187308|NCT02557581|Experimental|Clenbuterol|Beta2-adrenergic stimulation with clenbuterol
89187309|NCT04077944||Preterm prelabor rupture of membranes|"The diagnosis of Preterm prelabor rupture of membranes was made in the case of apparent spontaneous leakage of AF from the cervical canal during sterile speculum inspection before the onset of active labor at 37 weeks of pregnancy. The study population consisted of 55 women with a singleton pregnancy who were diagnosed with pP-ROM between 24+0 and 36+6 weeks of gestation.~The Amnisure test (AmniSure International LLC, Boston, MA) was used when there was inconclusive results to confirm the final diagnosis. The gestational age was determined by calculation from the last menstrual period and supported by the ultrasonography measurements at the first trimester of gestation."
89187310|NCT04077944||Control|The control cases were recruited from the healthy pregnant women with a gestational age-matched cohort who admitted for routine obstetric care to our outpatient clinic. Sixty healthy pregnant women who delivered at term were included in the study as the control group.
89187311|NCT02558751|Active Comparator|HIV positive PPV23|HIV-positive individuals 50-65 years of age immunized with one dose of the 23-valent pneumococcal polysaccharide vaccine, PPV23
89187312|NCT02558751|Active Comparator|HIV positive PCV13/PPV23|HIV-positive individual 50-65 years of age, Intervention: one dose of 13-valent pneumococcal conjugate vaccine,PCV13, followed 8 weeks later with one dose of 23-valent pneumococcal polysaccharide vaccine, PPV23
89187313|NCT02558751|Active Comparator|HIV negative PCV13/PPV23|HIV-negative individual 50-65 years of age, Intervention: one dose of 13-valent pneumococcal conjugate vaccine,PCV13, followed 8 weeks later with one dose of 23-valent pneumococcal polysaccharide vaccine, PPV23
89187314|NCT00768573||1. Taste test|
88870330|NCT04013542|Experimental|Treatment (nivolumab, ipilimumab, radiation therapy)|"CONCURRENT THERAPY: Patients receive nivolumab IV over 30 minutes on day 1 and ipilimumab IV over 30 minutes on day 1. Treatment with nivolumab repeats every 21 days for up to 8 cycles, and treatment with ipilimumab repeats every 42 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Within 1 day of starting nivolumab and ipilimumab, patients also undergo radiation therapy 5 days a week (Monday-Friday) over 6-7 weeks in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients then receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 28 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity."
88870331|NCT04000321|Experimental|Windmill group 30 Mins|In the Windmill Group, the Windmill technique is carried out after 30 minutes. The windmill technique of the umbilical cord for placental development is performed by a trained obstetrician or midwife with a doctor presence. In a frustrated attempt to develop placenta using the Windmill technique, a manual removal is performed according to the clinic standard.
88870332|NCT04000321|Active Comparator|Control Group|In the control group, after a total of 45 minutes of unsuccessful application of the traditional and customary measures, the Windmill technique is used. If unsuccessful, a manual placenta removal is performed according to hospital Standards.
88870333|NCT03992352||Age 60+ with planned HCT for Hematologic Malignancy|Subjects 60 years or older with a planned allogeneic transplantation for a hematologic malignancy.
88870334|NCT03984357|Experimental|PD-1 blocking antibody combined with IC+IMRT|All participants will receive induction chemotherapy (IC; every 3 weeks × 3 cycles; gemcitabine 1000 mg/m2 day 1, 8 + cisplatin 80 mg/m2 day 1) followed by intensity-modulated radiotherapy (IMRT; 70 Gy, 33 fractions, 5 fractions/week, 1 fraction/day) alone. PD-1 blocking antibody (360 mg per cycle) will start on day 1 of the first cycle IC and continue every 3 weeks for 6 cycles till the end of IMRT, involving the whole-course of IC + IMRT alone. The first and last 3 cycles of PD-1 blocking antibody are administrated concurrently with IC and IMRT, respectively. After 4 weeks of the completion of IMRT, adjuvant PD-1 blocking antibody (480 mg per cycle) will begin every 4 weeks for 6 cycles.
88870335|NCT03964389|Experimental|Intervetion group|"A sessions of Pain Neuroscience Education (PNE) joint a physical exercises programs"
88870336|NCT03964389|No Intervention|Control group|Only a therapeutic physical exercises programs
88870337|NCT03955510|Other|"Right-time eating / no alcohol"|"Right-time eating means breakfast before 8am, lunch before 1 pm and dinner before 6pm. Subjects will be asked to stick to this eating schedule for 1 week. Subjects will be asked to not drink alcohol for 1 week. Subjects will randomly be assigned to each eating pattern during the study period."
88870338|NCT03955510|Other|"Right-time eating / with alcohol"|"Right-time eating means breakfast before 8am, lunch before 1 pm and dinner before 6pm. Subjects will be asked to stick to this eating schedule for 1 week. Subjects will randomly be assigned to each eating pattern during the study period. Moderate alcohol drinking means 0.3-0.5 g/kg alcohol daily, which will be not more than 2 glasses of wine depending on subject's weight. Alcohol will always be consumed in the evening with food or after food (e.g., dinner). The timing of alcohol consumption will be consistent for each individual. Subjects will be provided with red wine for the 1 alcohol intervention week. The order of conditions will be random."
88870339|NCT03955510|Other|"Delayed-eating / no alcohol"|"Delayed-eating means eating each meal 3 hours later than the Right-time eating.Subjects will be asked to stick to this eating schedule for 1 week. Subjects will randomly be assigned to each eating pattern during the study period. Subjects will be asked to not drink alcohol for 1 week."
88870340|NCT03955510|Other|"Delayed-eating / with alcohol"|"Delayed-eating means eating each meal 3 hours later than the Right-time eating.Subjects will be asked to stick to this eating schedule for 1 week. Subjects will randomly be assigned to each eating pattern during the study period. Moderate alcohol drinking means 0.3-0.5 g/kg alcohol daily, which will be not more than 2 glasses of wine depending on subject's weight. Alcohol will always be consumed in the evening with food or after food (e.g., dinner). The timing of alcohol consumption will be consistent for each individual. Subjects will be provided with red wine for the 1 alcohol intervention week. The order of conditions will be random."
88870341|NCT03931005|Experimental|Decision-Support|An electronic copy of a collaboration decision-support guide.
88870342|NCT03931005|Active Comparator|General Support|An electronic copy of general collaboration supports (a list of collaborative implementation strategies and their definitions)
88870343|NCT03913845|Experimental|0.5% lidocaine with epinephrine|On the day of surgery, the operating room pharmacist will prepare 20 cc of either study drug (0.5% lidocaine with epinephrine 1:200,000) or normal saline with epinephrine 1:200,000) in identical appearing 20cc syringes to be injected retropubically. Our group's routine clinical practice is to inject 20cc of 0.5% lidocaine with epinephrine 1:200,000 retropubically along the path of the midurethral sling trocars. Suburethral injection of local anesthestic will be performed at surgeon discretion. Surgical teams, anesthesia teams and patients will be blinded to allocation assignment. The investigational drug pharmacist will maintain the randomization sequence.
88870344|NCT03913845|Active Comparator|Normal saline with epinephrine|On the day of surgery, the operating room pharmacist will prepare 20 cc of either study drug (0.5% lidocaine with epinephrine 1:200,000) or normal saline with epinephrine 1:200,000) in identical appearing 20cc syringes to be injected retropubically. Our group's routine clinical practice is to inject 20cc of 0.5% lidocaine with epinephrine 1:200,000 retropubically along the path of the midurethral sling trocars. Suburethral injection of local anesthestic will be performed at surgeon discretion. Surgical teams, anesthesia teams and patients will be blinded to allocation assignment. The investigational drug pharmacist will maintain the randomization sequence.
88870345|NCT03907969|Experimental|Core Module: AZD7648 Monotherapy|AZD7648 will be administered orally on an empty stomach
88870346|NCT03907969|Experimental|Combination Module 1: AZD7648 + PLD|AZD7648 will be administered in combination with Pegylated liposomal doxorubicin (PLD)
88870347|NCT03900793|Experimental|Dose Escalation and Expansion|"Part 1: This is a study escalating doses (Dose level 1-3) of losartan on a continuous daily dosing schedule and sunitinib (escalating on dose level 4) on a daily dosing with 4 weeks on, 2 weeks off. A cycle of therapy is 6 weeks (42 days).Dosing will be performed based on body surface area (BSA). This portion of the study uses a 3+3 design (i.e. cohort sizes of 3 patients for the first and second cohort at each dose level).~Part 2: Once the Maximally Tolerated Dose (MTD) has been determined, 12 patients will enroll to the expansion cohort. These patients will receive the MTD as long as less then 33% of patients experience dose-limiting toxicities."
88870348|NCT03898180|Experimental|Pembrolizumab + Lenvatinib|Participants receive pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 21-day cycle for up to 35 cycles (up to ~2 years) PLUS lenvatinib 20 mg via oral capsule once daily (QD) until progressive disease or discontinuation. With protocol amendment 3 (effective: Sep-24-2021), participants discontinue lenvatinib and participants who remain on treatment will receive open label pembrolizumab only, at the same dose and schedule (IV 200 mg on Day 1 of each 21-Day cycle for up to 35 cycles [up to ~2 years]).
88870349|NCT03898180|Active Comparator|Pembrolizumab + Placebo|Participants receive pembrolizumab 200 mg via IV infusion on Day 1 of each 21-day cycle for up to 35 cycles (up to ~2 years) PLUS placebo for lenvatinib via oral capsule QD until progressive disease or discontinuation. With protocol amendment 3 (effective: Sep-24-2021), participants discontinue placebo and participants who remain on treatment will receive open label pembrolizumab only, at the same dose and schedule (IV 200 mg on Day 1 of each 21-Day cycle for up to 35 cycles [up to ~2 years]).
88870350|NCT03892993|Experimental|Supportive care (decision aid)|Participants use decision aid and complete questionnaires.
88870351|NCT03878459|Experimental|Intervention|pioglitazone treatment
88870352|NCT03878459|Placebo Comparator|control|subjects will receive placebo
88870353|NCT03875638|Experimental|Early Alzheimer's Disease Group Low Dose|Subjects with Alzheimer's Disease will undergo a four-week treatment period consisting of low-dose levetiracetam (125 mg twice daily)
88870354|NCT03875638|Experimental|Early Alzheimer's Disease Group High Dose|Subjects with Alzheimer's Disease will undergo a four-week treatment period consisting of high-dose levetiracetam (500mg twice daily).
88870355|NCT03875638|Placebo Comparator|Early Alzheimer's Disease Group Placebo|Subjects with Alzheimer's Disease will undergo a four-week treatment period consisting of placebo twice daily.
88870356|NCT03875638|No Intervention|Healthy Control Group|A group of demographically similar subjects without Alzheimer's Disease will undergo baseline testing only, without any intervention
88870357|NCT03866837|Active Comparator|Study group A: GOS|This study group will receive daily in-home fortification for 6 months with multiple micronutrient powders with 5 mg iron (as sodium iron EDTA [2.5 mg] and ferrous fumarate [2.5 mg]) and galacto-oligosaccharides (GOS), 7.5 mg.
88870358|NCT03866837|Active Comparator|Study group B: bLF|This study group will receive daily in-home fortification for 6 months with multiple micronutrient powders with 5 mg iron (as sodium iron EDTA [2.5 mg] and ferrous fumarate [2.5 mg]), bovine lactoferrin (bLF), 1.0 g.
88870359|NCT03866837|Active Comparator|Study group C: GOS + bLF|This study group will receive daily in-home fortification for 6 months with multiple micronutrient powders with 5 mg iron (as sodium iron EDTA [2.5 mg] and ferrous fumarate [2.5 mg]), galacto-oligosaccharides (GOS), 7.5 mg, and bovine lactoferrin (bLF), 1.0 g.
88870360|NCT03866837|Placebo Comparator|Study group D|This study group will receive daily in-home fortification for 6 months with multiple micronutrient powders with 5 mg iron (as sodium iron EDTA [2.5 mg] and ferrous fumarate [2.5 mg]) alone, with no galacto-oligosaccharides (GOS), and no bovine lactoferrin (bLF).
88870361|NCT03865498|Experimental|Hispanic dementia caregivers|De-identified followers of our Hispanic dementia caregiver Twitter network will receive messages from the network (Twitter for Hispanic caregivers' intervention).
88870362|NCT03865498|Experimental|African American dementia caregivers|De-identified followers of our African American dementia caregiver Twitter network will receive messages from the network (Twitter for African American caregivers' intervention).
88870363|NCT03836079|Experimental|ADHF Patients|Treatment with preCARDIA System
88870364|NCT03809000|Active Comparator|Salvage Radiation Therapy + Standard ADT|Salvage RT will be given 66.0 - 70.2 Gy along with 24 months of a GnRH analog with or without 1-4 months of bicalutamide.
88870365|NCT03809000|Experimental|Salvage Radiation Therapy + Enhanced ADT|Salvage RT will be given 66.0 - 70.2 Gy along with 24 months of a GnRH analog + 24 months of enzalutamide.
88870366|NCT03801616|Experimental|Virtual Reality|Every participant is provided with a VR headset
88870367|NCT03778944|Active Comparator|M group|Mannitol infusion
88870368|NCT03778944|Active Comparator|D group|Dopamine infusion
88870369|NCT03778944|Active Comparator|C group|Adequate hydration
88870370|NCT03764293|Experimental|SHR-1210|SHR-1210+Apatinib
88870371|NCT03764293|Active Comparator|Control|Sorafenib
88870372|NCT03761446|Experimental|Older adults with pre-diabetes or type 2 Diabetes|Male and female older adults between the ages 60-80 with pre-diabetes or type 2 diabetes
88870373|NCT03761446|Experimental|Older adults without pre-diabetes or Type 2 Diabetes|Male and female older adults between the ages 60-80 without pre-diabetes or type 2 diabetes
89394071|NCT02139566|Experimental|Low-tech video consent|"Participants in this arm will be provided with informed consent information through viewing a talking head video produced by a non-professional presenter, with widely available and inexpensive video equipment. Intervention is video consent (low-tech), PDF informed consent document."
88870374|NCT03752307|Experimental|Corticosteroid & Isoxsuprine HCL|Corticosteroid pulse of either daily iv methylprednisolone 1000 mg/day or 600mg oral prednisone two times a day at approximately 8AM and noon for 3 to 5 consecutive days and Isoxsuprine Hydrochloride one 10 mg Capsule 3 times daily for 5 consecutive days
88870375|NCT03752307|Placebo Comparator|Corticosteroid & Placebo|Corticosteroid pulse of either daily iv methylprednisolone 1000 mg/day or 600mg oral prednisone two times a day at approximately 8AM and noon for 3 to 5 consecutive day and placebo one Capsule 3 times daily for 5 consecutive days
89394072|NCT02139566|Experimental|FAQ consent|"Participants in this arm will be provided with informed consent content through an interactive frequently asked questions format, in which the participant will click on a question and be shown text that provides an answer to that question. Major informed consent topics will have one or more question and answer pairs. Intervention is FAQ format consent, PDF informed consent document"
89394073|NCT02139566|Active Comparator|Standard consent process|Participants in this arm will be provided with informed consent content by being shown a standard informed consent document in a scrolling window within the browser window, PDF informed consent document
89394074|NCT05188079|Active Comparator|Beetroot Juice|140 ml of beetroot juice (high nitrate dietary supplement)
89394075|NCT05188079|Placebo Comparator|Placebo|Placebo drink looks and tastes like the beetroot juice but has the nitrate removed from the juice.
88870376|NCT03737734|Experimental|DaRT Seeds|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds
89394076|NCT04579549|Experimental|Repeat Testing for SARS-CoV-2|Anyone over the age of 5yrs old with consent to provide a saliva sample for SARS-CoV-2 assay will be eligible to participate. Assay takes 20 minutes.
89394077|NCT05188001||Inpatient non-cardiac surgery patients|Patients aged 45 years and older undergoing inpatient non-cardiac surgery who had MINS protocol ordered for postoperative high sensitivity troponin monitoring based on the CCS guidelines from January 2020 to June 2021.
89394078|NCT03549806||Prospective Cohort|No study intervention. Patients referred for ablation of atrial arrhythmias will be treated as per operator preference with no study intervention. Data will be collected in de-identified fashion.
89394079|NCT01356485|Experimental|MP4CO|Escalating doses of MP4CO, administered intravenously
88870377|NCT03714828|Experimental|Treatment (talimogene laherparepvec)|The subject participation period will be approximately 48 weeks. This will include a screening visit, 4 injection visits and 5 follow up visits. Total length of study/patient is 8.5 to 10.5 months. TVEC will be administered by injection with a needle directly into one or more tumors.
88870378|NCT03703908|Experimental|Sequential|All enrolled subjects will initially be treated with the active study medication CCX140-B at a dose of 5 mg twice daily. Dose will increase in a step-wise fashion up to 15 mg twice daily.
88870379|NCT03684694|Experimental|Phase 1: Dose-Escalation of ADCT-402|A standard 3+3 dose escalation design will be used. The dose-limiting toxicity (DLT) period will be the 21 days following the first dose of ibrutinib. The dose escalation cohort will receive loncastuximab tesirine for Cycle 1 and 2 (3 weeks each) with concurrent ibrutinib (concomitant therapy) daily. Participants may continue to receive ibrutinib therapy up to 1 year after Cycle 1 Day 1 (once every 4 weeks from Cycle 3 onwards). Loncastuximab tesirine will be administered intravenously (IV).
88870380|NCT03684694|Experimental|Phase 2: MTD or RP2D of ADCT-402 in Non-GCB DLBCL|Participants with non-germinal center B-cell diffuse large B-cell lymphoma (Non-GCB DLBCL) will receive the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of loncastuximab tesirine, as determined in Phase 1, once every 3 weeks for Cycle 1 and 2 and a daily dose of ibrutinib. Participants can continue treatment up to 1 year (once every 4 weeks from Cycle 3 onwards). Loncastuximab tesirine will be administered IV.
88870381|NCT03684694|Experimental|Phase 2: MTD or RP2D of ADCT-402 in GCB DLBCL|Participants with germinal center B-cell diffuse large B-cell lymphoma (GCB DLBCL) will receive the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of loncastuximab tesirine, as determined in Phase 1, once every 3 weeks for Cycle 1 and 2 and a daily dose of ibrutinib. Participants can continue treatment up to 1 year (once every 4 weeks from Cycle 3 onwards). Loncastuximab tesirine will be administered IV.
88870382|NCT03684694|Experimental|Phase 2: MTD or RP2D of ADCT-402 in MCL|Participants with mantle cell lymphoma (MCL) will receive the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of loncastuximab tesirine, as determined in Phase 1, once every 3 weeks for Cycle 1 and 2 and a daily dose of ibrutinib. Participants can continue treatment up to 1 year (once every 4 weeks from Cycle 3 onwards). Loncastuximab tesirine will be administered IV.
88870385|NCT03675620|Active Comparator|Standard Rehabilitation (Control Group)|All participants will perform traditional post-operative shoulder rehabilitation exercises. Participants randomized to this group will begin with lower extremity strengthening exercises (prior to shoulder strengthening) 2-3 times per week for for the first 6 weeks of post-operative care. Standard rehabilitation will continue until discharge.
89394080|NCT01356485|Placebo Comparator|Saline|Normal saline (0.9% sodium chloride solution)
89394081|NCT01360385||Central Retinal Vein Occlusion|CRVO-patients with planned treatment with intravitreal injections of ranibizumab, who receive three monthly injections of ranibizumab and a 3 month follow-up period, during which ranibizumab injections are provided as needed.
89394082|NCT02134808|Active Comparator|Creatine|Subjects randomized to this study arm will receive 10 grams of creatine daily for 8 weeks.
89394083|NCT02134808|Placebo Comparator|Placebo|Subjects randomized to this study arm will receive 10 grams of placebo daily for 8 weeks.
89394084|NCT01319279|Experimental|Normal Hepatic Function|Intervention Drug: Hydrocodone bitartrate extended-release tablet
89394085|NCT01319279|Experimental|Moderate Hepatic Impairment|Intervention Drug: Hydrocodone bitartrate extended-release tablet
89394086|NCT02139722|No Intervention|Provider Panel Notification (PPN) Alone|The comparison procedures consist of a panel notification given to providers and an audio-visual presentation on diet and exercise given to patients.
89394087|NCT02139722|Experimental|Video Doctor, PA + PPN|Video Doctor (VD) and Provider Alert (PA) intervention combined with Provider Panel Notification (PPN)
89187315|NCT02558361|Other|Open label, single arm|"Baseline visit:assess disease activity,synovial tissue biopsy of the knee with active synovitis [target joint] and punch skin biopsy of a target psoriatic plaque. Perform a similar punch skin biopsy on adjacent normal skin. Start apremilast (standard dosing). Perform venipuncture: blood samples will be obtained for routine studies, quantitative RT-PCR & ex vivo cytokine production assays. UA/pregnancy test.~Month 1: assess disease active , monitor for AE's; repeat punch skin biopsy of target psoriatic plaque. Blood samples will be obtained for RT-PCR and ex vivo cytokine production assays.~Month 3: same as month 1; repeat synovial tissue biopsy from target knee joint and punch skin biopsy on target psoriatic plaque. Blood samples for RT-PCR ex vivo cytokine production assays and routine studies."
89187316|NCT02558595|Experimental|Niacinamide|Participants will be asked to take niacinamide at a dose of 30 mg/kg/d orally.
89187317|NCT02558595|Placebo Comparator|Placebo|Participants will be asked to take a placebo pill at a dose of 30 mg/kg/d orally.
89187318|NCT02585024|Experimental|1.5 mg cytisine|1.5 mg cytisine given as a single dose
89187319|NCT02585024|Experimental|3 mg cytisine|3 mg cytisine given as a single dose
89187320|NCT02585024|Experimental|4.5 mg cytisine|4.5 mg cytisine given as a single dose
89187321|NCT02585024|Experimental|1.5 mg cytisine six times a day|1.5 mg (1 capsule) is given six times a day (0, 2, 4, 6, 8 and 10 hours) for 5 days
89187322|NCT02585024|Experimental|3 mg cytisine three times a day|3 mg (2 capsules) are given three times a day (0, 4 and 8 hours) for 5 days
89187323|NCT02585024|Experimental|4.5 mg cytisine two times a day|4.5 mg (3 capsules) are given two times a day (0 and 6 hours) for 5 days
89187324|NCT00760695|Active Comparator|A|the patients in this arm are receiving 2,5 mg dronabinol twice daily
89187325|NCT00760695|Placebo Comparator|B|the patients in this arm are receiving 2,5 mg placebo twice daily
89187326|NCT04048629|Experimental|Point-of-care (POC)|All facilities will receive a refresher training on Zimbabwe's 2018 Guidelines. At POC facilities, at the first antenatal visit (ANC1), all women enrolled in the intervention cohort will have a blood sample collected for VL which will be tested onsite using an existing POC device. If a woman is virally unsuppressed (VL ≥1000 cpm), she will be given adherence counseling and, if necessary, a treatment regimen switch/infant prophylaxis per national guidelines.
88810615|NCT06164028||Clinician|"Participants will take part in a semi-structured qualitative interview (~1 hour).~The first set of questions will provide an opportunity for the clinicians to describe observable indicators that a young child is in pain.~4 YouTube video links based on age groups (birth to 1 month,1 month to 6 months, 6 months to 12 months, and12 months to 24 months), will be reviewed by participants. Clinicians will be asked to rate the child's pain using the ClinRO measures while being probed for question content and understanding.~Subsequently, the cognitive interview scripts will be structured to evaluate different components of the ClinRO measures, including the instructions, the question stems, the response options, and other key aspects of the COA. Once the participant has completed the questionnaire, the interviewer will probe on additional issues related to informing the assessment of content validity."
89187327|NCT04048629|Active Comparator|Standard of care (SOC)|All facilities will receive a refresher training on Zimbabwe's 2018 Guidelines. At SOC facilities, at ANC1, all women enrolled in the intervention cohort will have a blood sample collected for VL which will be sent to centralized labs for testing. If a woman is virally unsuppressed (VL ≥1000 cpm), she will be given adherence counseling and, if necessary, a treatment regimen switch/infant prophylaxis per national guidelines.
89187328|NCT02582372|Experimental|dexmedetomidine|25 patients recieve subarachnoidal anesthesia with 12,5 mgrs of bupivacaine 0,5% plus 10 micrograms of dexmedetomidine, with needle 25 gauge
89187329|NCT02582372|Active Comparator|fentanyl|25 patients recieve subarachnoidal anesthesia with 12,5 mgrs of bupivacaine 0,5% plus 25 micrograms of fentanyl, with needle 25 gauge
89394088|NCT01363271||complicated skin and skin structure infections (cSSSI)|Identified through a pre-specified list of ICD-9 codes in study protocol.
89394089|NCT01363271||Pneumonia|Identified through a pre-specified list of ICD-9 codes in study protocol.
88810616|NCT06160193|Experimental|Brief behavioral parent training with optional care as usual|A brief, individualized, three-session parent training that exists of two (bi)weekly individually tailored training sessions of 120 minutes, and a third session of 60 minutes. Parents and children may receive care as usual as well. Care as usual may include all mental health care that is usually provided within or outside (e.g., at a child mental healthcare institution or at school) the general practitioners practice, except from pharmacological treatment for children's behavioral difficulties and/or behavioral parent training/support, up until the first posttreatment assessment (T1). Care as usual can also imply that there is no support or treatment.
89187330|NCT04048395||Follicular lymphoma arm|The analysis will involve patients diagnosed with follicular lymphoma who received induction chemotherapy and then experienced a worsening of disease within 24 months from the start date of the treatment.
88810617|NCT06160193|Active Comparator|Care as usual only|Care as usual may include all mental health care that is usually provided within or outside (e.g., at a child mental healthcare institution or at school) the general practitioners practice, except from pharmacological treatment for children's behavioral difficulties and/or behavioral parent training/support, up until the first posttreatment assessment (T1). Care as usual can also imply that there is no support or treatment.
89394090|NCT02134886|Experimental|Treatment (erlotinib hydrochloride)|Patients receive erlotinib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89394091|NCT01360463|Experimental|Behavioral and Drug Risk Counseling|Participants assigned to this arm will receive bi weekly Behavioral and Drug Risk Counseling (BDRC) counseling for six months.
89394092|NCT01360463|Active Comparator|Treatment as Usual|Participants assigned to this arm will receive methadone treatment without and alterations.
89394093|NCT02139956||stress urinary incontinence|group 1 women with stress urinary incontinence by ultrasonography
89394094|NCT02139956||continent group|group 2 women without stress urinary incontinence by ultrasonography
89394095|NCT01360541|Experimental|Radiofrequency ablation|Endoscopic radiofrequency ablation of BE
89394096|NCT01360541|Active Comparator|Surveillance|Endoscopic surveillance and PPI treatment
89394097|NCT01363427||Crohn's disease|Patients with initially diagnosed Crohn's disease
89394098|NCT02253368|Active Comparator|Sleep Arm 1|Sleep Arm 1
89394099|NCT02253368|Active Comparator|Sleep Arm 2|Sleep Arm 2
89394100|NCT03548870|Experimental|Test with TENS|Patients will perform one Constant Work-Rate Exercise Test at 80% of maximum workload with low frequency TENS
89394101|NCT03548870|Sham Comparator|Test with sham-TENS|Patients will perform one Constant Work-Rate Exercise Test at 80% of maximum workload with low frequency sham-TENS
89394102|NCT01356563|Experimental|clinical pharmacist intervention|
89394103|NCT01356563|No Intervention|usual care|Patients randomized to usual care group will receive routine review of medication by outpatient department pharmacists and nurse.
89394104|NCT05216588||EVUSHELD (tixagévimab/cilgavimab) 300 mg|"Patients who may be included in this group are patients eligible for prophylaxis treatments for COVID-19, under a cohort Temporary Authorization for Use (ATUc) of EVUSHELD 300mg. Patient are treated and monitored according to the Therapeutic Use Protocols specific for EVUSHELD defined by the ANSM.~In addition to their follow-up planned for usual care (including protocol for ATU), they are invited to participate in the research."
89394105|NCT05216588||EVUSHELD (tixagévimab/cilgavimab) 600 mg|"Patients who may be included in this group are patients eligible for prophylaxis treatments for COVID-19, under a cohort Temporary Authorization for Use (ATUc) of EVUSHELD 600mg. Patient are treated and monitored according to the Therapeutic Use Protocols specific for EVUSHELD defined by the ANSM.~In addition to their follow-up planned for usual care (including protocol for ATU), they are invited to participate in the research."
89394106|NCT01356641|Experimental|Antibiotic treatment alone|"Intravenous administration:~Amoxicillin/clavulanic acid 100/10 mg/kg 6-hourly Gentamicin 7mg/kg once daily~Oral administration of:~Amoxicillin/clavulanic acid 50/12.5 mg/kg/day (in three doses)"
89394107|NCT01356641|Active Comparator|Appendectomy|Routine appendectomy either laparoscopic or open depending on the surgeon's preference
89394108|NCT03103087|Experimental|Relugolix plus E2/NETA (Group A)|Relugolix co-administered with E2/NETA for 24 weeks.
89394109|NCT03103087|Experimental|Relugolix plus Delayed E2/NETA (Group B)|Relugolix co-administered with E2/NETA placebo for 12 weeks, followed by relugolix co-administered with E2/NETA for 12 weeks.
89394110|NCT03103087|Placebo Comparator|Placebo (Group C)|Relugolix placebo co-administered with E2/NETA placebo for 24 weeks.
89394111|NCT05579288|Experimental|Study Arm|Patients will receive inhaled N2O/O2 (70% N2O and 30% O2). A sterile bivalve speculum will be placed. Laminaria will be inserted. Inhaled N2O/O2 will be stopped after speculum removal.
89394112|NCT05579288|Placebo Comparator|Control Arm|"Patients will receive inhaled O2 (100% O2). A sterile bivalve speculum will be placed. Laminaria will be inserted. Inhaled O2 will be stopped after speculum removal.~Patients will receive inhaled O2 (100% O2) throughout the procedure until speculum removal."
89394113|NCT02081105|Other|PEEP 5|level of PEEP of 5 cm H2O randomly applied to the patient
89394114|NCT02081105|Other|PEEP 15|level of PEEP of 15 cm H2O randomly applied to the patient
89394115|NCT05579210|Experimental|Online relapse prevention therapy (eRPT)|
89394116|NCT05579210|Active Comparator|Face-to-face relapse prevention therapy (RPT)|
89394117|NCT01363505||Acute CHF patients|Acute CHF patients with BARD Intra-abdominal pressure monitors in ICU
89394118|NCT02134964|Experimental|OLT1177 Capsules|"A total of 5 patients in each cohort will receive OLT1177 Capsules:~Cohort 1 will receive a single 100 mg dose of OLT1177~Cohort 2 will receive a single 300 mg dose of OLT1177~Cohort 3 will receive two 1000 mg doses of OLT1177 (seven days apart)~Cohort 4 will receive 100 mg doses of OLT1177 QD for 8 days~Cohort 5 will receive 300 mg doses of OLT1177 QD for 8 days~Cohort 6 will receive 1000 mg doses of OLT1177 QD for 8 days"
89394119|NCT02134964|Placebo Comparator|Placebo Capsules|"A total of 1 patient in each cohort will receive Placebo Capsules:~Cohort 1 will receive a single placebo capsule~Cohort 2 will receive three placebo capsules~Cohort 3 will receive ten placebo capsules (seven days apart)~Cohort 4 will receive a single placebo capsule QD for 8 days~Cohort 5 will receive three placebo capsules QD for 8 days~Cohort 6 will receive ten placebo capsules QD for 8 days"
89394120|NCT01363583|Active Comparator|epoprostenol, Flolan®|Measurement on the effect of epoprostenol on lactate/pyruvate ratio measured by cerebral microdialysis
89394121|NCT01363583|Placebo Comparator|normal saline|Effect of saline on the lactate/pyruvate ratio measured by cerebral microdialysis
88810618|NCT06159543|Experimental|Mango added to habitual diet|Participants will be asked to consume 1.5 cups of mango per day for 12 weeks as part of their habitual diet.
88810619|NCT06159543|No Intervention|Habitual diet without mango|Participants will be asked to refrain consuming mangos for 12 weeks while continuing their habitual diet.
88810620|NCT06155071|Experimental|Group A (Plyometric training)|
88810621|NCT06155071|Other|Group B (Conventional)|
88810622|NCT06141850|Experimental|Project PEACH2 Intervention|In addition to a text-based reporting tool for reporting COVID-19 testing, participants randomized to the Project PEACH2 intervention will be sent weekly behavioral nudges via mobile phone text message to encourage adherence to COVID-19 testing and preventive behaviors.
89394122|NCT02135120|Active Comparator|Morphine group|Patients will receive a combined spinal epidural anesthesia technique with intrathecal morphine
89394123|NCT02135120|Active Comparator|Morphine-femoral group|Patients will receive a combination of combined spinal-epidural (with intrathecal morphine) and femoral nerve block
89394124|NCT02135120|Active Comparator|Morphine-femoral-sciatic group|Patients will receive a combination of combined spinal-epidural (with intrathecal morphine) and femoral nerve block as well as sciatic nerve block
89394125|NCT02135198|Experimental|2 mg AZD7325|2 mg AZD7325 in orange capsule, Size 0, single oral dose
89394126|NCT02135198|Experimental|10 mg AZD7325|10 mg AZD7325 in orange capsule, Size 0, singe oral dose
89394127|NCT02135198|Placebo Comparator|Placebo|10 mg Microcrystalline cellulose in orange capsule, Size 0, single oral dose
89394128|NCT03131999|Experimental|Imatinib Mesylate 400mg capsule|56 days of Imatinib mesylate 400 mg oral daily with or without co-administration of an mTOR inhibitor for 28 days. A dose reduction to 200 mg daily is allowed for toxicity.
89394129|NCT03131999|Placebo Comparator|Placebo Capsule|56 days of Placebo with or without co-administration of an mTOR inhibitor for 28 days. A dose reduction is allowed for toxicity.
88870386|NCT03675620|Experimental|Blood Flow Restriction (BFR)|All participants will perform traditional post-operative shoulder rehabilitation exercises. Participants randomized to the BFR group will begin combining BFR with lower extremity strengthening exercises (prior to shoulder strengthening) 2-3 times per week for the first 6 weeks post-operative care. Standard rehabilitation will continue until discharge.
88870387|NCT03665051|Other|Young adults|Obtain muscle biopsy specimens from young adults (ages 20-40) to develop a millifluidic chip for electrical stimulation of human primary muscle cell hydrogel cultures.
88870388|NCT03665051|Other|Older adults|Obtain muscle biopsy specimens from older adults (ages 60-80) to develop a millifluidic chip for electrical stimulation of human primary muscle cell hydrogel cultures.
88870389|NCT03655782|Experimental|PATH neurotraining|Subject looks at computer screen to determine whether dim gray stripes in fish-shaped window move left or right relative to stationary background stripes. The subject reports which way center stripes move by pushing left or right arrow key, receiving brief tone if incorrect. Program adaptively changes contrast of test pattern in order to keep subject at 79% correct. There are levels of difficulty introduced by making the background pattern more similar to that in fish, by increasing pattern's complexity level, and by increasing number of directions of movement from one to two directions of motion. Intervention will be trained for one training cycle, 15 minutes, 3 times each week for 16 weeks. Fifteen minutes of working memory practice, recalling the correct sequence of digits, each presented for 500 msec, from 5 digits up to 10 digits will be completed for 15 minutes following PATH training.
88870390|NCT03655782|Sham Comparator|Orientation Discrimination training|The sham intervention will be Orientation Discrimination training that is identical to PATH training except instead of low contrast sinewave gratings moving left or right, 100% contrast stationary test and background sinewave gratings are used, both red, green, and black and white gratings, see patterns in Fig. 4 below. These patterns are randomly oriented left or right, at decreasing tilt angles as the test grating's orientation is identified correctly. These patterns only activate parvocells in ventral pathways (Ungerleider & Mishkin, 1982; Kaplan & Shapley, 1986) instead of activating dorsal pathways, the key component of PATH neurotraining. Therefore, this task does not speed up the brain's visual timing, which is a function of the dorsal stream. For the Orientation Discrimination task, the subject pushes the left arrow key when the test pattern is tilted left and the right arrow key when pattern is tilted right. Otherwise the two training tasks use the same paradigm.
88870391|NCT03655782|Experimental|N-Back Working Memory Task|Participants are required to compare each item on a computer screen to the item that they saw n-items back in the sequence. The participant plays a simple game where they control the movement of an astronaut that needs to collect correct gems, avoid incorrect gems, and also obstacles, to succeed at the game. If the participants performs well then they can be advanced to the 2-back, 3-back, 4-back, etc where they make similar matches but to earlier items in the sequence. This gamified task consists of a color n-back with 6 colors (a new color every 3 seconds, requiring subjects respond to targets by tapping the screen and navigating the astronaut to the targets, and avoiding the distractors) with 30% targets, and where the n-level will change every 2 minutes depending on performance (increase if performance is >85% and decrease if <75%). Sessions consist of 10 ~2 minute blocks, each with n-level as determined by the adaptive procedure and with user paced breaks between blocks.
88870392|NCT03628209|Experimental|Dose Escalation, Resection, Dose Expansion|Participants will receive 1 cycle of neoadjuvant Nivolumab or Nivolumab + Azacitidine, followed by surgery to render them in surgical remission. Subsequently they will continue to receive Nivolumab or Nivolumab + Azacitidine for 12 additional cycles or until recurrence, whichever occurs first. Once the recommended Phase II dose (RP2D) is identified during Phase I, the Dose Expansion Phase II will be opened at this dose level. The Phase II portion of the study will consist of a maximum 33 evaluable patients (27-30 in addition to the 3-6 enrolled at RP2D on the Phase I portion).
88870393|NCT03617328|Experimental|Arm A: 6MHP/Montanide ISA-51 + polyICLC + CDX-1127|200 mcg of 6MHP plus 0.9 mg of polyICLC emulsified in Montanide ISA-51 adjuvant will be administered subcutaneously on days 1, 8, 15, and 36. 200 mcg of 6MHP in Montanide ISA-51 adjuvant (without polyICLC) will be administered subcutaneously/intradermally on day 176. CDX-1127 (3mg/kg) will be administered intravenously on days 1, 36, and 78.
88870394|NCT03617328|Experimental|Arm B: 6MHP/Montanide ISA-51 + polyICLC|200 mcg of 6MHP plus 0.9 mg of polyICLC emulsified in Montanide ISA-51 adjuvant will be administered subcutaneously on days 1, 8, 15, and 36. 200 mcg of 6MHP in Montanide ISA-51 adjuvant (without polyICLC) will be administered subcutaneously/intradermally on day 176.
88870395|NCT03617250||Active patients|50 rheumatoid patients with active disease according to Disease Activity Score-28
88870396|NCT03617250||patients with remission|50 patients with remission according to Disease Activity Score-28
88870397|NCT03617185|Active Comparator|Bariatric Surgery/HIIT|Patients who have undergone bariatric surgery will be randomized to this arm and will follow a high intensity interval training (HIIT) protocol for 24 months. Patients will complete 2 supervised HIIT sessions and 1 unsupervised HIIT session a week.
88870398|NCT03617185|Active Comparator|Bariatric Surgery/Routine Exercise|Patients who have undergone bariatric surgery will be randomized to this arm and will follow a standard routine exercise regimen for 24 months.
88870399|NCT03617185|Active Comparator|No Bariatric Surgery/HIIT|Patients who have not undergone bariatric surgery will be randomized to this arm and will follow a high intensity interval training (HIIT) protocol for 24 months. Patients will complete 2 supervised HIIT sessions and 1 unsupervised HIIT session a week.
89394130|NCT01319357|Placebo Comparator|Placebo|Placebo
89394131|NCT01319357|Active Comparator|Saxagliptin|saxagliptin 5 mg/day during 6 weeks
88870400|NCT03617185|Active Comparator|No Bariatric Surgery/Routine Exercise|Patients who have not undergone bariatric surgery will be randomized to this arm and will follow a standard routine exercise regimen for 24 months.
88870401|NCT03577522|Active Comparator|Avenir cementless hip stem|Total hip arthroplasty: Avenir vs Corail
88870402|NCT03577522|Active Comparator|Corail HA-coated hip stem|Total hip arthroplasty: Corail vs Avenir
88870403|NCT03554473|Experimental|Arm A/M7824 Monotherapy|M7824 (IV) monotherapy once every 21 days on a 21-day cycle. If patients have progressive disease on arm A, they may receive combination therapy of M7824 and Temozolomide.
88870404|NCT03554473|Experimental|Arm B/M7824 plus topotecan|M7824 (IV) on day 1 plus topotecan (IV) on days 1-5 of a 21-day cycle. At least 6 subjects to receive M7824 plus topotecan to determine safety. 4 more patients enrolled at initial or lower dose for efficacy. If efficacious, an additional 12 subjects enrolled.
88870405|NCT03554473|Experimental|Arm C/M7824 plus temozolomide|M7824 (IV) days 1 and 15 plus temozolomide (oral) on days 1-5 of a 28-day cycle. At least 6 subjects with SCLC to receive M7824 plus temozolomide to determine safety. 4 more SCLC patients enrolled at initial or lower dose for efficacy. If efficacious, an additional 12 SCLC subjects enrolled. After the 6 safety SCLC cohort, subjects with extrapulmonary small cell cancers will be enrolled.
88870406|NCT03550092|Experimental|Aphasia|Abstract Semantic Association Network Training (AbSANT) Each session will be 2 hours long and will occur twice each week for a total of 20 sessions.
88870407|NCT03494946|Experimental|Arm A|Patients that suffer from Colorectal cancer and metastasis to liver that are randomized to Group A, will undergo Liver transplantation
88870408|NCT03494946|Active Comparator|Arm B|Patients that suffer from Colorectal cancer and metastasis to liver that are randomized to Group B, will be given chemotherapy, TACE, SIRT or other available treatment options.
88870409|NCT03484507|Active Comparator|Chlorhexidine monotherapy|Topical chlorhexidine 0.04%
88870410|NCT03484507|Experimental|Chlorhexidine plus povidone iodine|Topical chlorhexidine 0.04% plus povidone iodine 2.5%
88870411|NCT03484507|Experimental|Early corticosteroids|Topical prednisolone sodium phosophate 1% for weeks 4-11
88870412|NCT03484507|Experimental|Late corticosteroids|Artificial tears for weeks 4-5, then topical prednisolone sodium phosophate 1% for weeks 6-11
88870413|NCT03484507|Placebo Comparator|Placebo|Artificial tears for weeks 4-11
88870414|NCT03474588|Active Comparator|Standard Treatment (ST)|"This is the same as the treatment normally received at this clinic. This will be tailored to participants' needs, but generally includes individual and group therapy sessions and regular urine monitoring. Sessions will generally last for 1 hour one time per week for 8 weeks and include issues such as:~Teaching about the treatment program~Teaching important ideas about recovery~Increasing knowledge about specific problems about addiction~Demonstrating new ways of coping with skills designed to fit each participant"
88870415|NCT03474588|Experimental|2. Standard treatment (ST) PLUS web-based CBT4CBT|"This is the same as the treatment normally received at this clinic. This will be tailored to participants' needs, but generally includes individual and group therapy sessions and regular urine monitoring. Sessions will generally last for 1 hour one time per week for 8 weeks and include issues such as:~Teaching about the treatment program~Teaching important ideas about recovery~Increasing knowledge about specific problems about addiction~Demonstrating new ways of coping with skills designed to fit each participant PLUS~Participants will have access the CBT4CBT website in Spanish as an add-on to treatment. In this treatment participants will work with a computerized program that teaches skills for stopping alcohol use and increasing coping skills, such as how to understand patterns of alcohol use, how to cope with cravings for alcohol, how to refuse offers of alcohol, and so on."
88870416|NCT03457142|Experimental|Treatment (abatacept, ixazomib citrate, dexamethasone)|Patients receive abatacept IV over 30 minutes on day 1 of course 1, then SC on days 2, 8, 15, and 22 of course 1, and then on days 1, 8, 15, and 22 of subsequent courses. Patients also receive ixazomib citrate PO QD on days 1, 8, and 15 and dexamethasone on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88870417|NCT03448393|Experimental|Dose escalation|CD19/CD22-CAR-transduced T cells at escalating doses
88870418|NCT03448393|Experimental|Dose expansion|CD19/CD22-CAR-transduced T cells at MTD or highest dose administered
88870419|NCT03445988|Active Comparator|Cognitive Behavioral Therapy|A trained psychologist delivers pain-CBT to individual patients or groups of patients with chronic pain. Group treatment is delivered across 8 weekly sessions that last for 2 hours each. Pain-CBT incorporates interactive discussion, practice of relaxation training, action planning, and home exercises into each session. Pain-CBT is effective for reducing pain intensity, pain catastrophizing, depression and social impacts.
88870420|NCT03445988|Active Comparator|Chronic Pain Self Management Program|The CPSMP is similar to pain-CBT in format and content but is peer-led, and is effective across pain conditions (e.g., back pain, arthritis) for improving pain and pain self-efficacy. The CPSMP consists of six weekly 2-hour group sessions in which two peer co-leaders provide patient education about pain, effective self-management, pain impacts, and other symptoms from a highly structured manual. Peers are people with chronic pain who live in the communities in which they teach. For this project, at least one peer facilitator per workshop will have had experience with prescription opioid use. Intervention fidelity is determined by having a trained observer with a checklist attend random workshop sessions. Similar to pain-CBT, CPSMP incorporates interactive discussion, practice of relaxation training, action planning, and home exercises into each session.
88870421|NCT03445988|Placebo Comparator|Taper Only (Usual Care)|Participants allocated to 'Taper Only' will engage in a physician-guided, patient-centered opioid tapering program without additional behavioral intervention.
88870422|NCT03445988|No Intervention|Observational Arm|Participants that do not wish to reduce their opioid medications but are otherwise eligible and interested in the research study will be offered participation in the observational arm. The observational arm of the study will not include interventions of any kind and will only collect survey data for the year following consent.
88870423|NCT03436368|Active Comparator|CSA group|Continuous Spinal Anesthesia
88870424|NCT03436368|Active Comparator|GA group|General Anesthesia
89394132|NCT02135354|Experimental|Azithromycin|"N = 250~From day 1 up to and including day 3: 500 mg azithromycin PO once a day~From day 4 up to and including day 90: 250 mg azithromycin PO once every 2 days"
89394133|NCT02135354|Placebo Comparator|Placebo|"N = 250~From day 1 up to and including day 3: 500 mg placebo PO once a day~From day 4 up to and including day 90: 250 mg placebo PO once every 2 days"
89394134|NCT01319435|Other|Pharmacokinetics of ciprofloxacin|Patients receiving ciprofloxacin following clinical decision by attending physician
89394135|NCT05416099||Grid laser|grid laser is one of the more conventional treatments for diabetic macular edema
89394136|NCT05416099||micropulse laser|micropulse laser is one of the more recent treatments for diabetic macular edema
89394137|NCT02140034|Experimental|Study Arm: Extensive Peritoneal Lavage|The peritoneal cavity of subject will be washed with 10 liters of warmed normal saline (1 liter per cycle for 10 cycles) . The abdomen will be closed as per standard
89394138|NCT02140034|No Intervention|Control Arm: Standard Treatment|The peritoneal cavity of subjects will be washed with 2 liters or less of warmed normal saline. The abdomen will be closed as per standard.
89394139|NCT02055053|Experimental|anesthetic intervention|After deployment of therapeutic mesh in the preperitoneal space of the abdomen wall during the procedure, the treatment group will receive infusion of 15 cc 0.5% Bupivicaine.
89394140|NCT02055053|Placebo Comparator|Saline intervention|After deployment of therapeutic mesh in the preperitoneal space of the abdomen wall during the procedure, the placebo group will receive the infusion of 15 cc 0.9% Saline.
89394141|NCT01360697|Experimental|JADE- JA|Use the JADE portal to monitor the delivery of structured care.
89394142|NCT01360697|Active Comparator|Usual care|Patients will receive usual care in between two annual comprehensive assessments.
89394143|NCT02135510|Active Comparator|metoclopramide|
89394144|NCT02135510|Active Comparator|dexamethason|
89394145|NCT02135510|Active Comparator|palonosetron|
89394146|NCT02140112|Active Comparator|Trichuris suis ova|TSO 2500 x 2 doses every 2 weeks followed by TSO 7500 x 6 doses every 2 weeks
89394147|NCT02140112|Placebo Comparator|Placebo|Placebo 8 doses every 2 weeks
89394148|NCT02263885|Experimental|ExAblate Transcranial System|Transcranial ExAblate MRgFUS
89394149|NCT05758675||≥ 60 years old population|around 2000 subjects will be screened.
89394150|NCT05758675||18~59 years old population|around 3000 subjects will be screened.
89394151|NCT05758675||< 18 years old|around 15000 subjects will be screened.
89394152|NCT02192671|Experimental|Hepatic resection|Adequate remnant liver volume was 30% for HCC patients without cirrhosis, and >50% for HCC patients with chronic hepatitis, cirrhosis, or severe fatty liver.
89394153|NCT02192671|Active Comparator|Radiofrequency ablation|RFA is performed in less than one week after clinical diagnosis.
89394154|NCT03548714|Experimental|PT150 with alcohol consumption|Study drug to be administered as a single, fixed dose over a 5-day period. An alcohol challenge (with ethanol or placebo beverage) will be completed on day 1 (pre-treatment), and day-5 (post-treatment), at predetermined times.
89394155|NCT03548714|Placebo Comparator|PT150 with placebo consumption|Study drug to be administered as a single, fixed dose over a 5-day period. An alcohol challenge (with ethanol or placebo beverage) will be completed on day 1 (pre-treatment), and day-5 (post-treatment), at predetermined times.
89394156|NCT02160691|Experimental|Anxiety Meter|The Anxiety Meter (experimental) group will receive a real-time display of physiological arousal on the Anxiety Meter during the intervention period in visit #4.
89394157|NCT02160691|No Intervention|No Anxiety Meter|The control group will have the Anxiety Meter during the intervention period, but the marker will not move.
89394158|NCT02135588|Experimental|Active Treatment|Intra-pleural deoxyribonuclease 5mg and intra-pleural Alteplase 10mg, every 12 hours over 72 hours (total of 6 treatments)
89394159|NCT03633019|Experimental|high-dose rhTPO|rhTPO (300-600U/kg/day), ih, until the platelets increased by 50 x 109/L compared to the baseline or above 100 x 109/L
89394160|NCT05755243||Biopsy performed|after 10 days of use, the sensor is removed and the biopsy performed
89394161|NCT05578508|Experimental|Treatment Arm|Submucosal endoscopic injection of 60 million allogeneic bone marrow derived mesenchymal stem cells (MSCs) into ileal pouch at baseline and possibly again after 3 months if not completely healed.
89394162|NCT03597750|Experimental|Static air support devices (Repose®)|"Alternating-pressure devices will be replaced by static air support devices (Repose®) during 14 days:~Repose® Mattress~Repose® Cushion~Repose® Wedge or Foot Protectors~The frequency of repositioning remains unchanged."
89394163|NCT03597750|No Intervention|Alternating-pressure devices|"Instead of replacing the alternating-pressure devices by static air support devices (Repose®), the residents remain on their alternating-pressure devices.~The frequency of repositioning remains unchanged."
89394164|NCT03549260|Experimental|LIB003 150 mg or matching placebo|SC LIB003 150 mg or placebo every 4 weeks
88870425|NCT03396315|Active Comparator|alendronate|Subjects will receive oral alendronate
88870426|NCT03396315|Active Comparator|zoledronic acid|Subjects will receive zoledronic acid
89394165|NCT03549260|Experimental|LIB003 300 mg or matching placebo|SC LIB003 300 mg or placebo every 4 weeks
89394166|NCT03549260|Experimental|LIB003 350 mg or matching placebo|SC LIB003 350 mg or placebo every 4 weeks
89394167|NCT01563302|Experimental|Group 1|IONIS-STAT3Rx
89394168|NCT03602664||Thoracic surgery|Patients undergoing thoracic surgery
89394169|NCT04254341||patients with OSA|Subjects that underwent regular sleep studies (PSG) and found to have moderate/severe obstructive sleep apnea
89394170|NCT04254341||subjects without OSA|Subjects that underwent regular PSG and found not to have sleep apnea
89394171|NCT02237586|Experimental|Group IA|"Adults with naturally acquired immunity and HbAA (Group IA, n=10)~As any parasitemia other than PfSPZ will interfere with results, volunteers will undergo a treatment course against P. falciparum with a five-day course of 12-hourly 5 mg/kg clindamycin (corresponds to a 300 mg tablet of clindamycin base administered twice daily). This will be completed no less than three days prior to CHMI. The initial challenge dose of 3,200 PfSPZ Challenge will be administered once intravenously. If 50% or less of volunteers become parasitemic in Groups IA or IS, 10 additional volunteers will be enrolled and challenged with 12,800 PfSPZ. Effective treatment will be initiated immediately upon development of parasitemia together with the presence of symptoms associated with malaria."
88810623|NCT06141850|Active Comparator|Control Group|Participants randomized to the control group will receive access to the text-based COVID-19 reporting tool and receive weekly texts on diabetes prevention, management or care.
89394172|NCT02237586|Experimental|Group IS|"Adults with naturally acquired immunity and HbAS (Group IS, n=10)~As any parasitemia other than PfSPZ will interfere with results, volunteers will undergo a treatment course against P. falciparum with a five-day course of 12-hourly 5 mg/kg clindamycin (corresponds to a 300 mg tablet of clindamycin base administered twice daily). This will be completed no less than three days prior to CHMI. The initial challenge dose of 3,200 PfSPZ Challenge will be administered once intravenously. If 50% or less of volunteers become parasitemic in Groups IA or IS, 10 additional volunteers will be enrolled and challenged with 12,800 PfSPZ. Effective treatment will be initiated immediately upon development of parasitemia together with the presence of symptoms associated with malaria."
89394173|NCT02237586|Experimental|Group NI|"Adults without previous exposure to malaria and HbAA (Group NI, n=5)~As any parasitemia other than PfSPZ will interfere with results, volunteers will undergo a treatment course against P. falciparum with a five-day course of 12-hourly 5 mg/kg clindamycin (corresponds to a 300 mg tablet of clindamycin base administered twice daily). This will be completed no less than three days prior to CHMI. The initial challenge dose of 3,200 PfSPZ Challenge administered once intravenously should lead to consistent infection in naïve adults (15/15 in prior studies) and thus should infect all volunteers in Group NI. Effective treatment will be initiated immediately upon development of parasitemia together with the presence of symptoms associated with malaria."
89394174|NCT02252822|Experimental|The Overcoming Bulimia Online Programme|This treatment incorporates a combination of cognitive-behavioral, motivational and education strategies. The program will be presented in 8 collaborative, multi-media, web based CBT sessions for BN.
88810624|NCT06139614|Experimental|Assistant Residents|At baseline, all participants will complete questionnaires related personal resilience, including professional fulfillment (professional fulfillment, work exhaustion, interpersonal disengagement), depression symptoms, anxiety, symptoms, self-valuation, flourishing, and psychosocial working conditions. At post-treatment (end of session 8), participants will complete the baseline questionnaires (with the exception of psychosocial working conditions), as well as a questionnaire assessing acceptability of the group experience and content. The post-treatment questionnaires will be repeated as a 3-month follow-up.
88810625|NCT06136767||Methotrexate|Participants who have received methotrexate for atopic dermatitis.
88810626|NCT06136767||Cyclosporine|Participants who have received cyclosporine for atopic dermatitis.
88810627|NCT06136767||Mycophenolate mofetil|Participants who have received mycophenolate mofetil for atopic dermatitis.
88810628|NCT06136767||Azathioprine|Participants who have received azathioprine for atopic dermatitis.
88810629|NCT06136767||Dupilumab|Participants who have received dupilumab for atopic dermatitis.
88810630|NCT06136767||Tralokinumab|Participants who have received tralokinumab for atopic dermatitis.
88810631|NCT06136767||Upadacitinib|Participants who have received upadacitinib for atopic dermatitis.
88810632|NCT06136767||Abrocitinib|Participants who have received abrocitinib for atopic dermatitis.
88810633|NCT06135701|Experimental|COPD-patients|The participants will be instructed to abstain from caffeine, nicotine, alcohol, and strenuous exercise all known to affect blood flow to the limb for 12 hours prior to the study day. After being placed on the one-leg kicking chair, baseline measurements will be performed, followed by passive leg movement for 2 minutes. Then participants will perform one-legged knee-extension exercise at submaximal intensity, first at 10% and then at 20% of the previously measured WLpeak, remaining 3.5 minutes at each level, while femoral blood flow is measured. This study day will be repeated within 2-10 days.
88810634|NCT06135701|Experimental|Matched healthy volunteers|The participants will be instructed to abstain from caffeine, nicotine, alcohol, and strenuous exercise all known to affect blood flow to the limb for 12 hours prior to the study day. After being placed on the one-leg kicking chair, baseline measurements will be performed, followed by passive leg movement for 2 minutes. Then participants will perform one-legged knee-extension exercise at submaximal intensity, first at 10% and then at 20% of the previously measured WLpeak, remaining 3.5 minutes at each level, while femoral blood flow is measured. This study day will be repeated within 2-10 days.
88810635|NCT06129825||Healthy Adult Volunteers|Healthy Adults Volunteers >/= 18yrs of age without acute or chronic illness.
88810636|NCT06128382|Experimental|OVX033 - 100µg dose level|Recombinant sarbecovirus vaccine based on the nucleocapsid of SARS-CoV-2. One single administration intramuscularly of a 100µg (0.2mL) dose on Day 1.
88810637|NCT06128382|Experimental|OVX033 - 250µg dose level|Recombinant sarbecovirus vaccine based on the nucleocapsid of SARS-CoV-2. One single administration intramuscularly of a 250µg (0.5mL) dose on Day 1.
88810638|NCT06128382|Experimental|OVX033 - 500µg dose level|Recombinant sarbecovirus vaccine based on the nucleocapsid of SARS-CoV-2. One single administration intramuscularly of a 500µg (1.0mL) dose on Day 1.
88810639|NCT06128382|Placebo Comparator|Saline solution - 0.2mL|Saline solution (NaCl 0.9%), B. Braun Ecoflac® Plus 50mL. One single administration intramuscularly of a 0.2mL dose on Day 1.
88810640|NCT06128382|Placebo Comparator|Saline solution - 0.5mL|Saline solution (NaCl 0.9%), B. Braun Ecoflac® Plus 50mL. One single administration intramuscularly of a 0.5mL dose on Day 1.
88810641|NCT06128382|Placebo Comparator|Saline solution - 1.0mL|Saline solution (NaCl 0.9%), B. Braun Ecoflac® Plus 50mL. One single administration intramuscularly of a 1.0mL dose on Day 1.
88810642|NCT06108830|Placebo Comparator|Group of patients undergoing gastroenteroscopies with normal saline|Patients undergoing gastroenteroscopies were given propofol 2-3mg/kg and 10ml 0.9% saline before the procedure began
88810643|NCT06108830|Active Comparator|Group of patients undergoing gastroenteroscopies with esketamine|Patients undergoing gastroenteroscopies were given propofol 2 to 3mg/kg and esketamine 0.2mg/kg before the procedure began
88810644|NCT06108830|Active Comparator|Group of patients undergoing gastroenteroscopies with remimazolam|Patients undergoing gastroenteroscopies were given propofol 2 to 3mg/kg and remimazolam 0.15mg/kg before the procedure began
88810645|NCT06108830|Active Comparator|Group of patients undergoing gastroenteroscopies with remimazolam and esketamine|Patients undergoing gastroenteroscopies were given propofol 2 to 3mg/kg， esketamine 0.2mg/kg and remimazolam 0.15mg/kg before the procedure began
89394175|NCT01363817|Experimental|Escalation Phase: BMS-906024|BMS-906024 escalating doses starting at 0.3 mg solution for intravenous (IV) administration once weekly continuously until disease progression or unacceptable toxicity
89394176|NCT01363817|Experimental|Expansion Phase: BMS-906024 + Dexamethasone|BMS-906024 maximum tolerated dose (To be determined) solution for IV administration once weekly and Dexamethasone 20mg/day tablet by mouth (Oral) for 3-4 days every week for 3-4 weeks per cycle continuously until disease progression or unacceptable toxicity
89394177|NCT03597048|Experimental|Curriculum|Participants received only the curriculum intervention
88870427|NCT03389347|Experimental|Device feasibility (high-throughput assay, sequencing)|Patients undergo collection of bone marrow aspirate and blood for high-throughput drug sensitivity assay and mutational analysis using next generation sequencing. Patients and their treating physicians receive the results of the tests. Treatment decisions are then made by the patients and their treating physicians.
88870428|NCT03345420|Experimental|Treatment|Within 12 weeks after breast conserving surgery, patients undergo hypofractionated radiation therapy for 9 fractions over 2 weeks.
88870429|NCT03340519||Healthy Controls|Healthy Controls will undergo MR imaging to optimize MR techniques for bowel assessment and to acquire normative data
88870430|NCT03340519||Newly Diagnosed Crohns Patients|MR imaging will be performed in newly diagnosed CD patients prior to initiation of infliximab therapy in order to obtain baseline measures in the setting of active intestinal inflammation
88870431|NCT03338205|Experimental|Ketamine Treatment|"Everyone enrolled in study presenting in status asthmaticus to pediatric emergency department at Augusta University will receive a ketamine treatment, who include:~Patients with a Clinical Asthma SCore (CAS) of greater than or equal to 10 on presentation and have received at least two (appropriately dosed based on weight) albuterol treatments prior to arrival~OR~Patients with a CAS of ≥ greater than or equal to 10 that have not received treatment prior to arrival and after receiving 1 hour of treatment per the severe asthma pathway do not have a decrease in CAS of greater than 2~OR~Patients with a CAS above > 6 but less than < 10 when as measured 1 hour after initiation of standard treatment per Augusta University's moderate asthma pathway"
88870432|NCT03337399|Experimental|Stepped PC|"Patients will receive Stepped PC~During step 1, patients will be scheduled to meet with the outpatient PC clinician within four weeks of study enrollment and after they are admitted to the hospital or have a change in their cancer treatment~Patients will complete the Functional Assessment of Cancer Therapy-Lung (FACT-L) to monitor their quality of life every six weeks and if their quality of life deteriorates substantially, they will step up to step 2 of the protocol~Patients who transition to step 2 will then meet with the PC clinician at least every four weeks for the remainder of their illness"
88870433|NCT03337399|Experimental|Early Integrated PC|"Patients will receive Early Integrated PC~Patients will meet with the PC clinician within four weeks of enrollment and at least every four weeks throughout their course of illness"
88870434|NCT03333616|Experimental|Nivolumab+Ipilimumab|"Nivolumab and Ipilimumab are administered intravenously every 3 weeks for a total of 4 maximum doses. After combination therapy, nivolumab will be administered as monotherapy every 4 weeks.~Doses are determined per protocol."
88870435|NCT03310879|Experimental|Participants with CCND1, CCND2, or CCND3|"Abemaciclib will be administered orally on a daily basis~Dosage will be determine by the PI"
88870436|NCT03310879|Experimental|Participants with CDK4 or CDK6|"Abemaciclib will be administered orally on a daily basis~Dosage will be determine by the PI"
88870437|NCT03283761|Experimental|Treatment Arm|All patients in Stage I (N=12) and Stage II (N=25) will receive FOLFOX-A on days 1 and 15 of each cycle (1 cycle = 28 days). Nab-paclitaxel will be given at a dose of 150 mg/m^2 IV over 30 minutes, followed by oxaliplatin IV 85 mg/m^2 and leucovorin IV 400 mg/m^2 over 2 hours, and 5-FU as a continuous IV infusion over Day 1 and Day 2 (for a total dose of 2400mg/m^2 over 46-48 hours.). Radiographic assessment will be performed at baseline and every other cycle (starting with Cycle 3) to evaluate response to treatment by RECIST Version 1.1 guidelines. Patients may continue to receive treatment until disease progression or unacceptable toxicity.
88870438|NCT03258723|Experimental|Intervention|Highest risk pre-diabetic patients
88870439|NCT03258723|No Intervention|Control|Control participants in existing ECHORN sites (Puerto Rico, Barbados and Trinidad) will be recruited. ECS does not have a recruitment site in New York; therefore, the New York LIME sites will need to recruit their own control participants, through random assignment of consented participants into the intervention and control groups.
88870440|NCT03230916|Experimental|IMI/REL FDC|Imipenem/Cilastatin/Relebactam (IMI/REL) administered as a single fixed 2:1 ratio of imipenem/cilastatin to relebactam, with a maximum dose of 15 mg/kg IMI and 15 mg/kg CIL (up to 500 mg IMI and 500 mg CIL) and 7.5 mg/kg REL (up to 250 mg REL).
88870441|NCT03230435||Anorexia nervosa|Treatment settings as usual.
88870442|NCT03230435||Healthy controls|No interventions.
88870443|NCT03225157||1|adult patients with head and neck squamous cell carcinoma of the upper aerodigestive tract who will undergo cisplatin chemotherapy with concurrent radiation.
88870444|NCT03211663||Interventional : MOTO Medial® UKA|Interventional : Patients who are planned to undergo a primary medial UKA using the MOTO Medial® will be enrolled.
88870445|NCT03206333||Breast cancer patients treated with radiotherapy|
88870446|NCT03203239|Experimental|Red Light treatment|This is a single arm design. All subjects will be enrolled to have peripheral blood flow measured before, during, and after red light exposure.
88870447|NCT03194789|Active Comparator|Traditional Pelvic Floor Therapy|up to six sessions, with one session every alternate week.
89394178|NCT03597048|Active Comparator|Contact|Participants received only the contact intervention
89394179|NCT03597048|Active Comparator|Materials|Participants received only the materials intervention
89394180|NCT03597048|Experimental|Curriculum and Contact|Participants received both curriculum and contact interventions
89394181|NCT03597048|Experimental|Curriculum and Materials|Participants received curriculum and materials interventions
89394182|NCT03597048|Active Comparator|Contact and Materials|Participants received contact and materials intervention
89394183|NCT03597048|Active Comparator|Curriculum, Contact and Materials|Participants received curriculum, contact and materials interventions
89394184|NCT03597048|No Intervention|No intervention|Participants received no intervention
89394185|NCT02140268|Active Comparator|Midazolam 7.5 mg|Volunteers will receive Midazolam 7.5 mg administered by mouth as a syrup
88810646|NCT06105307|Experimental|RN-SLEEP|Participants assigned to the RN-SLEEP group will access the training program via a mobile app for one month. The training app will include sleep physiology content, shift work strategies to promote sleep, cognitive behavior therapy for insomnia components, and skill-building techniques to support behavior modification.
88870448|NCT03194789|Experimental|FGBMM plus Traditional pelvic floor therapy|Treatment with FGBMM using shoes with pertupods daily at home along with traditional pelvic floor therapy sessions.
89003756|NCT04607421|Active Comparator|Phase 3 Arm C|Every two weeks: Oxaliplatin 85 mg/m2 (120-minute IV infusion) Leucovorin 400 mg/m2 (120-minute IV infusion) 5-FU 400 mg/m2 IV bolus, then 5-FU 2400 mg/m2 continuous IV infusion over 46-48 hours Bevacizumab (optional; given per prescribing instructions) -OR- Every two weeks: Irinotecan 165 mg/m2 (90-minute IV infusion) Oxaliplatin 85 mg/m2 (120-minute IV infusion) Leucovorin 400 mg/m2 (120-minute IV infusion) 5-FU 2400 or 3200 mg/m2 continuous IV infusion over 46 48 hours Bevacizumab (optional; given per prescribing instructions) -OR- Oxaliplatin 130 mg/m2 (120-minute IV infusion) every 3 weeks Capecitabine 1000 mg/m2 oral tablet twice daily on Days 1-14 Bevacizumab (optional; given per prescribing instructions)
89003757|NCT04607421|Experimental|Cohort 3 Arm D|Encorafenib 300 mg orally once daily Cetuximab 500 mg/m2 (120-minute IV infusion) every two weeks Irinotecan 180 mg/m2 (90-minute IV infusion) every two weeks Leucovorin 400 mg/m2 (120-minute IV infusion) every two weeks 5-FU 400 mg/m2 IV bolus, then 5-FU 2400 mg/m2 continuous IV infusion over 46-48 hours every two weeks
89394186|NCT02140268|Experimental|AZD1722 15 mg|Volunteers will received AZD1722 15 mg administered by mouth, as a tablet
89394187|NCT02140268|Experimental|AZD1722 15 mg and Midazolam 7.5 mg|Volunteers will receive AZD1722 15 mg tablet and Midazolam 7.5 mg syrup, by mouth
89394188|NCT05187689|Experimental|Virtual reality and mental health literacy intervention|This arm will participate in an interactive virtual reality experience to learn and practice mental health literacy and psychological first aid skills, supplemented by mhealth SMS with informational bidirectional messages.
89394189|NCT05187689|Experimental|Group Problem Management+ and VR/mental health literacy|This arm will participate in an interactive virtual reality experience to learn and practice mental health literacy and psychological first aid skills, supplemented by mhealth SMS with informational bidirectional messages. This arm will also participate in an 5-week Group Problem Management Plus intervention, a group based problem solving intervention.
89394190|NCT05187689|No Intervention|Control|This is a waitlist control. After Arms 1 and 2 are complete, the waitlist will receive the Group Problem Management Plus 5 week intervention on its own.
89394191|NCT03548636|Experimental|Single-Arm Feasibility Study|Participant determined 6-month physical activity program
89394192|NCT01360775|Experimental|nutritional counseling|Supervision and monitoring of nutritional status of patients in the home care program, after making nutritional advice
89394193|NCT01360775|No Intervention|Not nutritional counseling|
89394194|NCT00592267||1|
88870451|NCT03179176|Experimental|HFUD utilisation|
88870452|NCT03149822|Experimental|Phase 1: Pembrolizumab 200 mg plus Cabozantinib 40mg|Pembrolizumab 200 mg intravenous (IV) infusion on day 1 of each 21-day cycle in combination with cabozantinib 40 mg orally once daily until disease progression, unacceptable toxicity, or consent withdrawal.
89003758|NCT04607421|Active Comparator|Cohort 3 Arm E|Irinotecan 180 mg/m2 (90-minute IV infusion) every 2 weeks, Leucovorin 400 mg/m2 (120-minute IV infusion) every 2 weeks, 5-FU 400 mg/m2 IV bolus, then 5-FU 2400 mg/m2 continuous IV infusion over 46-48 hours every two weeks, Bevacizumab (optional; given per prescribing instructions)
89394195|NCT02252900|Experimental|cerebral MRI during follow-up of IE|All patients will undergo the diagnostic test specific to the study (Magnetic resonance imaging)
89394196|NCT01363895|Active Comparator|Percutaneous closure of LAA|Percutaneous closure of LAA
89394197|NCT01363895|Active Comparator|Catheter ablation of AF|Catheter ablation of AF
89394198|NCT02237664|Active Comparator|Patient-controlled paravertebral analgesia (PC-PVB)|Patient-controlled paravertebral analgesia
89394199|NCT02237664|Placebo Comparator|Continuous paravertebral analgesia (C-PVB)|Continuous paravertebral analgesia
89394200|NCT05750095|Experimental|Incredible Years Autism Spectrum and Language Delay Programme|Incredible Years Autism Spectrum and Language Delay Programme is a manualised group based intervention in 13 weekly 2-hour sessions. The programme targets parents of children aged 2-6 years, with autism spectrum disorder or language delay.
89394201|NCT05750095|Active Comparator|First Aid for Parents|"First Aid for Parents is a program consisting of three full day work-shops targeting communication, interaction and daily living skills for parents of children with autism spectrum disorders"
89394202|NCT05578352|Active Comparator|Oral hyppoglycemia drug group|Oral hyppoglycemia drugs, including metforemin, acarbose, dipeptidyl peptidase 4 inhibitors, or SGLT2-ihibitors, are added to reduce insulin dose.
89394203|NCT05578352|Active Comparator|GLP-1RA group|Add GLP-1 receptor agonists to reduce insulin dose.
89394204|NCT05578352|Active Comparator|long-acting insulin group|Change premix insulin to long-acting insulin plus oral hyppoglycemia drugs
89394205|NCT05578352|No Intervention|Control group|continue the present premix insulin treatment, adjust insulin dose according to the bloog glucose profile in FGM to improve glycemic control.
89394206|NCT04090229|Experimental|ASLAN004|
89394207|NCT04090229|Placebo Comparator|ASLAN004 Placebo|
89394208|NCT03602508||mirabegron|Patients on mirabegron as prescribed by a physician in routine clinical practice.
89394209|NCT03602508||antimuscarinics|Patients on one of the following antimuscarinics: solifenacin, darifenacin, imidafenacin, tolterodine, oxybutynin, trospium, fesoterodine or propiverine as prescribed by a physician in routine clinical practice.
89394210|NCT03549728|Experimental|Group A|Group A (N=44): women will receive intrauterine infusion of granulocyte colony-stimulating factor on the day of ovum-pick up during IVF cycle.
89394211|NCT03549728|Placebo Comparator|Group B|Group B (N=44): women will receive placebo intrauterine infusion of normal saline on the day of ovum-pick up during IVF cycle.
89394212|NCT01356797|Active Comparator|hyperbaric bupivacaine|
89394213|NCT01356797|Experimental|hypobaric levobupivacaine with fentanyl|
89394214|NCT05200585|Experimental|Healthy Liver/Hígado Sano program|
89394215|NCT05200585|Active Comparator|Control Group|
89394216|NCT03600012|Experimental|intervention group|"intervention group: Cycling Functional Electrical Stimulation & Physiotherapy~Children in intervention group were taken in a therapy program withRT 300 SLSA FES system for cycling functional electrical stimulation training additionly to physiotherapy program including weight shifting, knee and hip strenging and gait training for 8 weeks, 3 sessions in a week and 45 min per session."
89394217|NCT03600012|Active Comparator|control group|"control group: Physiotherapy~Children with cp in control group were taken physiotherapy program including weight shifting, knee and hip strenging and gait training for 8 weeks, 3 times in a week, 45 min per session."
89394218|NCT03764384||Hospital Monitoring Group - ALSFRS-R cohort|All patients will be first recruited to this cohort unless at their first visit the investigator deems them eligible for the Home Monitoring Device Group. At the initial screening visit, all patients recruited into the study will undergo routine assessments according to the existing MND protocol, and additionally complete the ALSFRS-R symptom-based assessment questionnaire by interview with the study researchers (with assistance from spouse, family member or carer if required). Patients will continue to complete the ALSFRS-R symptom-based questionnaire at each clinic attendance.
89394219|NCT03764384||Home Monitoring Cohort|"If eligible patients will use the N Tidal CTM, up to 3 times a day (morning, midday and evening) throughout the home monitoring period until the final outpatient clinic visit.~In addition subjects will complete a weekly diary symptom monitoring diary which asks them about their respiratory symptoms, GP attendances, respiratory infections. Patients routine standard of care assessments will also be documented according to the protocol as well as completing the ALSFRS-R at each visit."
89394220|NCT01360931||Lung Cancer group|Subject with histological confirmation of lung cancer
89394221|NCT01360931||Control group|Subjects with no diagnosis of lung cancer
88810647|NCT06105307|Active Comparator|Healthy Habit|Participants assigned to the Healthy Habit education control group will use a mobile app for one month focused on other healthy behaviors such as exercise tracking.
88810648|NCT06092996|No Intervention|Sling|Participants in the sling group will wear a sling according to current standard of care: 3 weeks postoperatively (2 weeks all the time, 3rd week at night and while in the community)
88810649|NCT06092996|Experimental|No Sling|Participants in the no sling group will only wear a sling for three days postoperatively
88810650|NCT06089577|Experimental|Cangrelor|In the Experimental group, before performing PCI, all patients will be treated with Cangrelor (Kangrexal) with an i.v. loading bolus (30mg/Kg) followed by i.v. infusion (4mg/Kg/min) for 2 hours. At the end of the infusion, as per current clinical practice, a loading dose of Clopidogrel (600mg) will be administered. A manteinance daily dose of 75mg will be associated with oral ASA (100mg).
88810651|NCT06089577|No Intervention|Control|In the Control group, either before or after PCI a loading dose of Clopidogrel will be administered and a manteinance daily dose of 75mg will be associated with oral ASA (100mg). PCI procedure will be performed as per current cinical practice, according clinical guidelines and at operator discretion.
88810652|NCT06089395|Experimental|Jiajian Guishen granules group|Jiajian Guishen granules + coenzyme Q10 simulant
88810653|NCT06089395|Active Comparator|coenzyme Q10 group|Jiajian Guishen granules simulant+ coenzyme Q10
88810654|NCT06085924||Cohort 1 - Cases of patients registered in the databases of all ages|Patients with a diagnosis of COVID-19 infection between 01 January 2021 and 31 December 2021
88810655|NCT06085924||Cohort 2 - Cases of patients registered in the databases of ≥12 years of age|Have COVID-19 diagnosis with international classification of diseases (ICD) code between 01 January 2022 and 31 December 2022
88810656|NCT06079775|Experimental|Single Dose Drug-Drug-Interaction Crossover & Multiple Dose Cohorts|"During the DDI crossover part of the study, 24 subjects will be enrolled into 3 cohorts of 8 subjects each, Cohorts 1, 2, & 3 respectively.~All subjects in Cohorts 1, 2, and 3 will receive a single dose of xeruborbactam oral prodrug on Day 1. On Day 6, they will receive a single dose of ceftibuten. On Day 9 they will receive a single combined dose of xeruborbactam oral prodrug and ceftibuten.~During the MAD part of the study, 48 subjects will be enrolled into 3 cohorts of 16 subjects each, Cohorts 4, 5, & 6 respectively.~All subjects in Cohorts 4, 5, and 6 will receive either a combined dose of xeruborbactam oral prodrug and ceftibuten, active ceftibuten, or active xeruborbactam oral prodrug.~Cohort 4 & 5 will be dosed BID on Days 1 through 9, with last and final dose on the morning of Day 10.~Cohort 6 will be dosed BID on Day 1, and then QD on Days 2 through 10 with last dose on the morning of Day 10.~All subjects will be followed for safety and PK data collection."
88810657|NCT06079775|Placebo Comparator|Placebo Comparator to maintain the blind|During the multiple-dose portion of the study, Xeruborbactam Oral Prodrug Placebo and Ceftibuten placebo will be used to maintain the blind. In Cohorts 4, 5, and 6, ten (10) subjects in each cohort will receive a combined dose of xeruborbactam oral prodrug and ceftibuten. Three (3) subjects in each cohort will receive active ceftibuten capsules with xeruborbactam oral prodrug placebo capsules. Three (3) subjects in each cohort will receive active xeruborbactam oral prodrug capsules with ceftibuten placebo capsules.
88810658|NCT06074198|Experimental|Physical Therapy Exercise|There will be no control group and only one intervention delivered
88810659|NCT06073457|Experimental|MagGJ System|"GT Metabolic Solutions Magnet System, GJ Biofragmentable (MagGJ System)"
88810660|NCT06068673|Experimental|Group A|Group I are patients who will receive clindamycin added-on therapy.
89187331|NCT00768729|Experimental|1|"Participants who have been maintained on MMF at study entry will start the study on 600 mg/m2 MMF orally daily. Participants who have been maintained on Azathioprine due to MMF intolerance will receive 1 mg/kg Azathioprine orally daily.~Participants will continue receiving sirolimus throughout the study. However, MMF or Azathioprine will be withdrawn gradually over a period of at least 6 months. Dosage will be reduced by 25% initially and by 25% every subsequent 2 months resulting in complete withdrawal by 6 months."
89187332|NCT00760773|Experimental|1|
89187333|NCT00760773|Experimental|2|
88810661|NCT06068673|Active Comparator|Group B|Group II patients will be managed with the standard regimen.
89187334|NCT00760773|Placebo Comparator|3|
89187335|NCT00768807|Sham Comparator|Sham CPAP|Patients submitted to SHAM CPAP use for 06 months
89187336|NCT00768807|Active Comparator|CPAP|OSA patients submitted to 06 months of CPAP treatment
89187337|NCT04077554||Study group|women and men with excess body mass
89187338|NCT04077554||Control group|women and men with proper body mass
89394222|NCT05747443|Experimental|Patient Video only|About 3 weeks after the index LDCT, the study Medical Assistant (MA) will deliver a link to the Patient Voices Video, an educational video about lung cancer screening.
89394223|NCT05747443|Experimental|Stepped Reminders only|"Prior to patient's next LDCT scan is due, MA begins Stepped Reminders intervention:~MA pends LDCT orders to PCP to sign. MA sends reminders to patient when order is placed and follows up by phone if patient has not scheduled LDCT."
89187339|NCT00768885|Active Comparator|PureVision 1|PureVision soft contact lens design #1.
89187340|NCT00768885|Experimental|PureVision 2|PureVision soft contact lens design #2
89187341|NCT00768963|Experimental|1|Patients will receive one injection of ranibizumab 3 days prior to surgery
89187342|NCT00768963|Experimental|2|Patients will undergo one injection of ranibizumab at the time of surgery
89394224|NCT05747443|Experimental|Patient Video and Stepped Reminders|See above. Those assigned to the Patient Video and Stepped Reminders will receive both interventions, as described above.
89394225|NCT05747443|No Intervention|Usual Care|Those assigned to the the Usual Care arm will continue to receive usual lung cancer screening care.
89394226|NCT02140346|Experimental|28 day repeat dose (low dose)|
89394227|NCT02140346|Experimental|28 day repeat dose (high dose)|
89394228|NCT02238132||Chronic Obstructive Airways Disease|
89394229|NCT05200507||High frequency precussive ventilation|After positioning a silicon belt for Electrical Impedance Tomography (EIT) and a baseline record, patients will receive the treatment of High Frequency Percussive Ventilation. Further recordings will be acquired soon after the end of the treatment, 1 and 3 hours later.
89394230|NCT02140424||youth with type 1 diabetes|
89394231|NCT02140424||healthy controls|
89394232|NCT03595722|Experimental|Early rectal cancer|Patients with early rectal cancer undergoing a treat and resect pathway - patients will be treated with high intensity focused ultrasound 7-10 days prior to the surgical resection of their rectal cancer
89394233|NCT03595722|Experimental|Late pelvic cancer|Patients with late pelvic (rectal, endometrial, cervical) cancer will undergo a treat and observe pathway - patients will be treated with high intensity focused ultrasound and their response will be observed
88810662|NCT06065280|Experimental|Diabetic/HFrEF Group|40 patients with diabetes mellitus patients will be divided into 2 subgroups one on Empagliflozin and the other one on Dapagliflozin.
88810663|NCT06065280|Experimental|Nondiabetic/HFrEF Group|40 patients non-diabetes mellitus group will be divided into 2 subgroups one on Empagliflozin and the other one on Dapagliflozin.
89187343|NCT00769041|Placebo Comparator|placebo|
89187344|NCT00769041|Active Comparator|moxifloxacin|
89187345|NCT00769041|Experimental|avanafil therapeutic|avanafil 100mg - therapeutic dose
88810664|NCT06060860|Active Comparator|Cognitive-Behavioral Therapy (CBT)|The arm receives the Unified Protocol (UP), a modular transdiagnostic CBT treatment that uses a parsimonious approach to treatment by addressing common emotion-related mechanisms underlying both anxiety and depression.
88810665|NCT06060860|Active Comparator|Mindfulness-Based Cognitive Therapy (MBCT)|Mindfulness-Based Cognitive Therapy (MBCT) is an empirically supported treatment that focuses on non-judgmental acceptance of present moment experiences and emotions. MBCT was adapted from Mindfulness-Based Stress Reduction (MBSR) to focus on improving mental health more specifically in individuals with depression and other psychiatric conditions.
88810666|NCT06050733||Solid cancer patients with disease progression|8 patients with a diagnosis of solid cancer undergoing standard of care treatment, with a PD-1 or PD-L1 inhibitor, with disease progression as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 guidelines.
88810667|NCT06050733||Solid cancer patients with stable or experience shrinkage in tumor size|8 patients with a diagnosis of solid cancer undergoing standard of care treatment, with a PD-1 or PD-L1 inhibitor, with tumor size stable or shrinkage, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 guidelines.
88810668|NCT06049342|Experimental|NCR100 injection|Cohort1:Low dose NCR100 injection; Cohort2:Mid-low dose NCR100 injection; Cohort3:Mid-high dose NCR100 injection; Cohort4:High dose NCR100 injection.
88810669|NCT06044610|Experimental|GENPOP passive dehydration|24-hour data collection using a parallel design comparison of TOI blood flow patterns vs. reference methods of hydration status in 10 PEP employees.
88810670|NCT06044610|Experimental|EXERCISE without fluid replacement|Randomized cross-over design in 15 moderately active non-employee participants. 90 minutes of standard cycling exercise trial in heat chamber. TOI signals will obtain blood flow patterns from the face to compare against reference methods of dehydration including body mass, urine specific gravity, urine color, and thirst.
88810671|NCT06044610|Other|GENPOP ad lib fluid intake|24-hour data collection using a parallel design comparison of TOI blood flow patterns vs. reference methods of hydration status in 10 PEP employees.
88810672|NCT06044610|Other|EXERCISE with fluid replacement|Randomized cross-over design in 15 moderately active non-employee participants. 90 minutes of standard cycling exercise trial in heat chamber. TOI signals will obtain blood flow patterns from the face to compare against reference methods of dehydration including body mass, urine specific gravity, urine color, and thirst.
89187346|NCT00769041|Experimental|avanafil supratherapeutic|avanafil 800mg - supratherapeutic dose
89394234|NCT05200429||Pre-Therapy Participants|All CF people with CF who do not have any known contraindications to CFTR modulator therapy and will be initiated on CFTR modulator therapy by their treating physician as part of clinical care are eligible and will be asked to participate in this study.
89394235|NCT02000219|Experimental|Oxabact OC5 capsule|"This is an open-label study so all patients will receive the active drug product, Oxalobacter formigenes, OC5. This will be administered as an enteric-coated capsules twice daily for 6 weeks of treatment.~In Germany, the protocol has been amended such that patients can receive OC5 for a further 3 year of continued treatment after the initial part of the study."
89394236|NCT02135666|Experimental|2-dose Primed Group|Adolescent subjects in this group received 2 doses of Twinrix Adult (720/20) (licensed as Ambirix in the EU) according to a 0, 6 months schedule in the primary study HAB-084 (208127/084).
88810675|NCT06017570|Experimental|Low-risk Group|Participants with DMFT score: 0 or 1.
89187347|NCT00763659|Active Comparator|1|20mg Lutein, 2mg Zeaxanthin, 510 mg Omega-3-FA; daily supplementation about one year
89394237|NCT02135666|Experimental|3-dose Primed Group|Adolescent subjects in this group received 3 doses of Twinrix Junior (360/10) according to a 0, 1, 6 months schedule in the primary study HAB-084 (208127/084).
89394238|NCT03595488|Experimental|Treatment arm|"Single-blinded, Dupilumab or matching placebo will be administered to the patients at the study visits. At each study visit, a single dose of dupilumab or placebo will be dispensed to the patients to be administered at home.~300 mg/2 ml solution in a single-dose pre-filled syringe with needle shield given once every 2 weeks in a subcutaneous injection"
89394239|NCT01356875|Experimental|HIDRA/VPA|In each cycle (30 days), Hydralazine 50mg tablets every 12 hours and Valproic 500mg tablets every 8 hours will be administrated orally to HYDRA / VPA group.Each patient will receive 6 cycles of hydralazine and valproic acid.
89394240|NCT01356875|Active Comparator|best supportive care (BSC)|The support group will be receive transfusional BSC, erythropoietin and / or G-CSF as determined by the physician.
89394241|NCT03594708|Placebo Comparator|Placebo|placebo consisting of rice starch, light olive oil, and vegetable oil
89394242|NCT03594708|Active Comparator|Supplement|active supplement consisting of a fermentable fiber, omega-3 polyunsaturated fatty acid, vitamin D3, vitamin E, and zinc
89394243|NCT05578196|Experimental|The experimental group with FMT|The gastrointestinal tube access was established, and the standard preparation of fecal bacteria solution 20ml (frozen at -80 ° C, melted at room temperature before use) was injected through the gastrointestinal tube once a day for 6 consecutive days. The other treatment measures were the same as those of the control group
89394244|NCT05578196|Other|The control group with physiological saline|The gastrointestinal tube access was established, and the standard preparation of physiological saline solution 20ml
89187348|NCT00763659|Active Comparator|2|10mg Lutein, 1mg Zeaxanthin, 255 mg Omega-3-FA; daily supplementation about one year
89394245|NCT05200273|Experimental|Intervention/treatment|Experimental
89394246|NCT01363973|Experimental|Sensory stimulation|Transcutaneous electrical stimulation at 75% of motor threshold
89394247|NCT01363973|Experimental|Motor stimulation|Transcutaneous electrical stimulation at motor threshold
89187349|NCT00763659|Placebo Comparator|3|Placebo
89187350|NCT04077476|Active Comparator|Online Yoga|Participants in both groups will follow a prescription of classes the research team (including a 200-hour yoga instructor) developed, and is safe and appropriate for this study population. The yoga prescription will be based on the prescription used in the current R34 study (see reference for description), and modified based on results (i.e., participant feedback). Participants will be given instructions about how to use the online yoga class platform (Udaya) during the intake appointment.
89187351|NCT04077476|Experimental|Online Yoga + Facebook|"In addition to what is described above, participants will be provided instructions on how to join the private Facebook group. The Facebook group will be an informal platform where participants can connect with other people in the online + SN group to share their experiences with yoga as it relates to their stillbirths. Current social media intervention research suggests careful consideration must be given to the intervention. The current intervention will be designed based on results of focus groups asking stillbirth moms who have completed an online yoga intervention what they would find helpful in a Facebook intervention. For instance, preferences included having a moderator, rules about what they can post (e.g., no rainbow babies), and discussion about both stillbirth and life in general."
89187352|NCT00760851|Experimental|1|Bb-12 supplemented strawberry yogurt drink
89187353|NCT00760851|Placebo Comparator|2|Regular strawberry yogurt drink with no Bb-12 added
88870453|NCT03149822|Experimental|Phase 1: Pembrolizumab 200 mg plus Cabozantinib 60mg|Pembrolizumab 200 mg intravenous (IV) infusion on day 1 of each 21-day cycle in combination with cabozantinib 60 mg orally once daily until disease progression, unacceptable toxicity, or consent withdrawal.
88870454|NCT03149822|Experimental|Phase 2: Pembrolizumab 200 mg plus Cabozantinib at the RP2D|Pembrolizumab 200 mg intravenous (IV) infusion on day 1 of each 21-day cycle in combination with cabozantinib at the RP2D orally once daily for up to 35 cycles, until disease progression, unacceptable toxicity, or consent withdrawal. All participants who stop pembrolizumab after 35 cycles with SD or better may be eligible for up to an additional 17 cycles (approximately 1 year) of pembrolizumab treatment if they progress after stopping pembrolizumab from the initial treatment phase.
89187354|NCT04019678|Experimental|Group 1: experimental|patients with micro metastatic sentinel lymph node and/or parasentinella lymph node (ypN1mi). Axillary dissection is not performed.
89187355|NCT04019678|Active Comparator|Group 2: standard|patients with negative sentinel lymph node (ypN0) or with ITC finding (ypN0 / YpN0 (i +)). Axillary dissection is not performed as standard treatment.
89187356|NCT00770445|Experimental|Pioglitazone 15mg BID|Insulin therapy added
89187357|NCT00770445|Experimental|Pioglitazone 15mg + Metformin 850mg BID|Insulin Therapy Added
88870455|NCT03146156|Experimental|Lifestyle Intervention|Lifestyle coaches will provide personalized instruction on physical activity, dietary data, and behavioral strategies.
88870456|NCT03146156|No Intervention|Usual Care|The usual care/control groups will be followed by their primary Obstetrical provider. All overweight/obese women will be offered nutrition counseling early in pregnancy by a registered dietician to support GWG within the IOM guidelines.
88870457|NCT03139305|Active Comparator|Glucagon Low Dose|
89187358|NCT00770445|Active Comparator|Metformin 850mg BID|Insulin therapy added
89187359|NCT04077398|Experimental|low volume High concentration group|1.Low Volume: 30 subjects randomized to Low Volume will receive bilateral Quadratus lumborum Block II. Each block of 0,75% ropivacaine x 15 mL + dexmedetomidine 0.4 mcg/kg (max dose 30 mcg for age <70, max dose 20 mcg for age >70) + dexamethasone 4 mg
89187360|NCT04077398|Experimental|high volume low concentration|2.High Volume: 30 subjects randomized to High Volume will receive bilateral Quadratus lumborum Block II. Each block of 0,375% ropivacaine x 30 mL + dexmedetomidine 0.4 mcg/kg (max dose 30 mcg for age <70, max dose 20 mcg for age >70) + dexamethasone 4 mg
89187361|NCT00763737|Experimental|FETO|prenatal FETO at 30-31+6 weeks and removal at 34-34+6 wks, followed by standardized postnatal care
88870458|NCT03139305|Active Comparator|Glucagon High Dose|
88870459|NCT03139305|Placebo Comparator|Placebo|
88870460|NCT03114319|Experimental|TNO155|TNO155 for oral administration
88870461|NCT03114319|Experimental|TNO155 in combination with EGF816 (nazartinib)|TNO155 in combination with EGF816 (nazartinib) in patients with advanced EGFR mutant NSCLC
88870462|NCT03093961|Experimental|Intervention|IASD Implantation
89003759|NCT04597944||Participants with Hereditary or Acquired Angioedema|Participants older than 18 years that are diagnosed with Hereditary or Acquired Angioedema and treated by lanadelumab.
89187362|NCT00763737|No Intervention|Expectant management|expectant management during pregnancy followed by standardized neonatal care
89187363|NCT04078256|Experimental|Experimental group|Group will carry out the proprioceptive exercise program during 8 weeks at the begining of the season
89187364|NCT04078256|Placebo Comparator|Control group|Control group will continue with their usual training routine
89187365|NCT00769197||1|Children with birth/time of neurologic insult less than 28 weeks of gestation
89187366|NCT00769197||2|Children with birth/time of neurologic insult at more than 28 weeks of gestation
89187367|NCT04079972|Experimental|personalized lifestyle intervention|to provide personalized lifestyle guidance for weight loss through SNP testing
89187368|NCT04079972|Active Comparator|general lifestyle intervention|to provide general lifestyle guidance for weight loss
89187369|NCT00769275||1|Screening at start study with Adenosine vasodilator stress Tc-99m Sestamibi SPECT imaging
89187370|NCT00769275||2|No screening
89187371|NCT05346458|Experimental|Intra coronary rapid-exchange iKOs microcatheter intervention|Patients with coronary heart disease and undergoing coronary physiology investigations (pressure wire measurements) will have additional coronary pressure and flow measurements using the iKOs rapid-exchange microcatheter and iKOr console.
89187372|NCT00769353|Experimental|Cognitive Behavioral Therapy-PASCET|Primary and Secondary Coping Enhancement Training (PASCET)
89187373|NCT00769353|Active Comparator|Supportive Non-Directive Therapy (SNDT)|Supportive Non-Directive Therapy (SNDT)
89187374|NCT00769431|No Intervention|Focus group|
89187375|NCT00763893|Placebo Comparator|A: Placebo|placebo
89187376|NCT00763893|Active Comparator|B: Losartan|Losartan
89187377|NCT04019366|Experimental|Group I|The experimental group was treated with Balance Training on Biodex Stability System along with traditional exercises.
89187378|NCT04019366|Active Comparator|Group II|The Control group was treated with Traditional exercises only for Symptomatic knee osteoarthritis.
89187379|NCT00770835|Experimental|Pioglitazone and Metformin QD|(along with lifestyle modification)
89187380|NCT00770835|Active Comparator|Glibenclamide and Metformin QD|(along with lifestyle modification)
89187381|NCT04228016|Experimental|Experimental: Device : nasal airway stent|All patients consulting for predominantly nocturnal nasal obstruction who have benefited from Nasal Respiratory Functional Exploration with detection of pathological resistance in the decubitus.
89187382|NCT00769509|Experimental|preterm formula|Assessment of energy expenditure of preterm infant during fed with preterm formula
89003760|NCT04580693||Healthy Volunteers/Control|Age and body surface area (BSA) matched volunteers who are sedentary or normally active. Normally active is defined as less than 5 hours of exercise per week. Healthy volunteer subjects must be able to exercise on an upright bicycle ergometer and be between the ages of 18-50.
89187383|NCT00769509|Active Comparator|human milk with fortifier|Assessment of energy expenditure by indirect calorimetry during fed with human milk with fortifier
89187384|NCT00769587|Experimental|Thalidomide|Use of thalidomide
89187385|NCT00769665||Systane Ultra|Systane Ultra
89187386|NCT00769665||Sensitive Eyes|Sensitive Eyes
89187387|NCT00764049|Experimental|1: Single pass albumin dialysis|Patients entered in the pilot study.
89187388|NCT04048083|Experimental|Patients-MT|3 Patients with bilateral upper limb congenital transverse deficiency that participated in kinesthetic mental training (MT) of reaching to grasp movements
89187389|NCT04048083|Experimental|Patients-CAT|3 Patients with bilateral upper limb congenital transverse deficiency that participated in computer-aided training (CAT) of reaching to grasp movements using virtual environment with visual-feedback.
89187390|NCT04048083|Experimental|Patients-CAMT|3 Patients with bilateral upper limb congenital transverse deficiency that participated in kinesthetic mental training of reaching to grasp movements supplemented by virtual environment (patients that received both types of training).
89187391|NCT04048083|Active Comparator|Healthy-controls|9 Healthy, age and gender-matched subjects, without any kind of training
89187392|NCT05674604||Participants|Adult inpatients who are referred to Victoria General Hospital for rehabilitation with the chief complaint of an acute neurological disorder such as stroke, within next 16 weeks, and suffer from shoulder and/or knee pain. All potential participants are already candidate for cryoneurolysis to mange their shoulder or knee pain.
89187393|NCT00570921|Experimental|Fulvestrant + Everolimus|"Fulvestrant + Everolimus~Fulvestrant was administered intramuscularly (in the gluteus maximus) in a loading dose schedule as follows: 500 mg in two divided doses-one on each side on day 1, then 250 mg on day 14, and then 250 mg on day 28 and every 4 weeks ± 3 days thereafter. Everolimus was administered initially at a dose of 5 mg daily in the first 5-patient cohort for the first month of treatment and then increased to 10 mg PO daily after that."
89187394|NCT04077242|Active Comparator|"Parryscope-group"|"In these patients, Fallopian tube patency is assessed using the Parryscope technique. A small amount of air is introduced into the iv tubing by inverting the drip chamber to create air bubbles. When air enters the uterine cavity, a single large air bubble or stream of air bubbles traversing the ostia is considered indicative of tubal patency. At least 10 seconds of intracavitary evaluation is typically performed before air bubble entry to allow pressure equilibration if a hydrosalpinx is present [10]. At least 30 seconds of observation per ostia is performed if patency is not observed."
89187395|NCT04077242|Active Comparator|"Tubal flow-group"|"In these patients, Fallopian tube patency is assessed using the flow technique. a positive flow is defined as the observation of saline directly traversing the ostia, endometrial structures floating toward the ostia, or air bubbles traversing the ostia."
89187396|NCT04076930||ACEI/ARB users|
89187397|NCT04076930||ACEI/ARB non-users|
89187398|NCT02557425||Maternal SP/Child 3mo DP|In this group in the PROMOTE-II study, mothers receive 3 doses of sulfadoxine-pyrimethamine (SP), and children receive every 3 month dihydroartemisinin-piperaquine (DP). No intervention is given in the observational PROTECT study.
89187399|NCT02557425||Maternal 3 dose DP/Child 3mo DP|In this group in the PROMOTE-II study, mothers receive 3 doses of DP, and children receive every 3 month DP.No intervention is given in the observational PROTECT study.
89187400|NCT02557425||Maternal 3 dose DP/Child monthly DP|In this group in the PROMOTE-II study, mothers receive 3 doses of DP, and children receive monthly DP. No intervention is given in the observational PROTECT study.
89187401|NCT02557425||Maternal monthly DP/Child 3mo DP|In this group in the PROMOTE-II study, mothers receive monthly DP, and children receive every 3 month DP. No intervention is given in the observational PROTECT study.
89187402|NCT02557425||Maternal monthly DP/child monthly DP|In this group in the PROMOTE-II study, mothers receive monthly DP, and children receive every monthly DP. No intervention is given in the observational PROTECT study.
89187403|NCT05233826|Experimental|COVI-VAC|COVI-VAC Nose Drops
89187404|NCT00769899|Experimental|1|
89187405|NCT00769899|Placebo Comparator|2|
89187406|NCT00764127||Obese Control|
89187407|NCT00764127||Normal Control|
89187408|NCT00764127||OVERWEIGHT ADOLESCENT PATIENTS UNDERGOING BARIATRIC SURGERY|
89535435|NCT05011695|Active Comparator|3. Group exercise group|Stretching the plantar fascia and gastrocsoleus muscles of the patients, towel picking exercises with the foot intrinsic muscles, heel drop exercises will be given. All stretching and exercises will be applied once a day, 5 days a week, for 3 weeks. Plantar fascia stretching exercises will be performed with a physiotherapist; While the patient is lying in the supine position, 30 seconds of stretching will be performed using the windlass (windlass) mechanism (toes are brought to dorsi flexion). This stretch will be repeated 3 times. Gastrocsoleus stretching exercises will be studied with a physiotherapist. In the supine position, the gastrocsoleus muscles will be stretched for 10 seconds and stretching will be performed with 10 repetitions. Towel collection exercises for the foot intrinsic muscles will be practiced in 3 sets, 15 repetitions per day. Heel drop exercise will be applied in 3 sets of 15 repetitions per day.
89187409|NCT00771069||1|Type II Diabetes Mellitus patients with Complication and Hypertension
89535436|NCT02487875|Experimental|COPD patients -study group|COPD inpatients GOLD2-4, in stable conditions,hospitalized to follow a pulmonary rehabilitation programme. The study group performs in addition to the standard programme, also a peripheric muscle strength training
89187410|NCT00764205||Study Group|Troponin measured prior to hospital arrival
89187411|NCT00764205||Control Group|Patients transported to hospital without troponin measurements enroute
89187412|NCT04048317|Experimental|drug eluting bead trans arterial chemo embolization|the international arm is the patients embolized with drug eluting bead trans arterial chemo embolization using Hepasphere
89187413|NCT04048317|Placebo Comparator|conventional trans arterial chemo embolization|the control arm is the patients embolized with drug eluting bead trans arterial chemo embolization using Lipiodol
89187414|NCT00764283|Experimental|1|Tegaderm dressing
89187415|NCT00764283|Active Comparator|2|Epi-Fix dressing
89187416|NCT00764283|Active Comparator|3|Lockit-Plus dressing
89187417|NCT00920504|Experimental|German PRO-SELF(c) Plus PCP|Group receives 10 weeks German PRO-SELF(c) Plus PCP intervention program
89187418|NCT00920504|Active Comparator|Standard Care|control group receives attention control and standard care
89535437|NCT02487875|Active Comparator|COPD patients -control group|COPD inpatients GOLD2-4, in stable conditions,hospitalized to follow a pulmonary rehabilitation programme
89535438|NCT03119077|Experimental|BAY1161116|Dose steps 1 to 6 of BAY1161116 (increasing dose levels)
89535439|NCT03119077|Placebo Comparator|Placebo|Placebo Dose 1 to 6 of BAY 1161116
89535440|NCT03226093|Experimental|Stromal Vascular Fraction|Isolation of SVF from fat tissue for re-administration into the same patient
89535441|NCT05011227|Experimental|Camrelizumab and chemotherapy combined with endoscopic surgery|Camrelizumab and chemotherapy combined with endoscopic surgery
89535442|NCT02487329|Active Comparator|Calcium hydroxide|Direct pulp capping with a self-hardening calcium hydroxide paste
88810676|NCT06017570|Experimental|Modarate-risk Group|Participants with DMFT score: 2, 3, 4 or 5.
88810677|NCT06017570|Experimental|High-risk Group|Participants with DMFT score above 5.
88810678|NCT06015256|Other|Severe uncontrolled asthma in exacerbation|
88810679|NCT06015256|Other|Severe uncontrolled asthma excluding exacerbation|
88810680|NCT06015256|Other|Severe controlled asthma|
88810681|NCT06015256|Other|Healthy volunteers (control group)|
88810682|NCT06014762|Experimental|P-CD19CD20-ALLO1 CAR-T Cells (Arm S)|"P-CD19CD20-ALLO1 following conditioning chemotherapy regimen S.~Rimiducid may be administered."
88810683|NCT06014762|Experimental|P-CD19CD20-ALLO1 CAR-T Cells (Arm LD 750)|"P-CD19CD20-ALLO1 following conditioning chemotherapy regimen LD 750.~Rimiducid may be administered."
88810684|NCT06014762|Experimental|P-CD19CD20-ALLO1 CAR-T Cells (Arm LD 1000)|"P-CD19CD20-ALLO1 following conditioning chemotherapy regimen LD 1000.~Rimiducid may be administered."
88810685|NCT06013748|Experimental|VR-VOICES|7-10 sessions of 45-60 minutes of individual VR assisted therapy and two booster sessions, in addition to TAU. Participants allocated to VR-VOICES create together with their therapist a VR digital representation (avatar with face, body and voice) of the voice that bothers them most. Patients have dialogues with the avatar, voiced by the therapist. As indicated in the treatment protocol, over the sessions the avatar will become less hostile and the participant will gain more power and resilience over the avatar.
88810686|NCT06013748|Other|Treatment as usual|TAU as described in the current Dutch treatment guidelines, which generally exists of pharmacological treatment, supportive counseling, and psychological interventions such as CBT and coping strategies. This will vary per individual.
88810687|NCT05990439|Experimental|Intervention|"This arm will have full access to the Baby-Feed web application. It was based on the Social Cognitive Theory and the Health Self-Empowerment Theory.~It provides automatic feedback based on the infant FFQ, showing the total amounts of each food group consumed (milk, protein foods, whole and refined grains, fruits, vegetables, juices, sugary beverages, sweets, and salty snacks) with automated feedback of which are consumed adequately or above/below the recommendations.~Recommendations: this section displays the amount recommended for each food group by age group.~Tracking: This is a short form that asks participants to evaluate if they gave the recommended amounts of each food group in the past week.~Weight gain tracker: parents are asked to input the weight and length of their baby and it shows graphically how the baby is progressing."
88810688|NCT05990439|Placebo Comparator|Control group|Participants randomized to the control arm (n=80) will have limited access to certain components of the Baby-Feed web application, such as the online infant FFQ to complete it at the same intervals (before the 4-month, 6-month, and 9-month well-child visits) and infant's weight and length as recorded in the well-child visits, but without any automatic results or feedback. The control group will have a separate user access to the Baby-Feed web application that only allows them to complete the required information without being able to see results, feedback, tracking, recommendations, or resources.
88810689|NCT05979571|Experimental|Experimental|
88810690|NCT05961592|Other|Open Label|Probiotic
88810691|NCT05961566|No Intervention|Control|Individuals with no addition of intervention (collagen matrix) after harvesting from the palate for a subepithelial connective tissue graft.
88810692|NCT05961566|Experimental|Collagen Matrix|Individuals with the addition of the intervention (collagen matrix) after harvesting form the palate for a subepithelial connective tissue graft.
89187419|NCT02584712|No Intervention|Control|This group do not participated in the intervention protocol (exercise training), and was followed throughout the entire process. Autonomic activity was assessed before and after 4 weeks.
88870463|NCT03093844|Experimental|Miltenyi CliniMACS® CD34 Reagent System|"The haploidentical donor will be mobilized by G-CSF and undergo one apheresis to collect CD34+ selected stem cell product after Miltenyi CliniMACS® CD34+ selection. The products will be cryopreserved until the time of transplantation.~Recipients will receive a standard conditioning regimen. After the conditioning regimen, the subjects will receive an allograft on day 0 containing donor CD34+ cells that have been positively selected and T-cell depleted following G-CSF mobilization combined with a single UCB unit. UCB unit will not be manipulated, and will be prepared and infused separately following standard of care procedure."
88870464|NCT03084081|Active Comparator|CO2 standard therapy|Double freeze treatment consists of three-minute freeze, five-minute thaw, three-minute freeze
88870465|NCT03084081|Experimental|CryoPen|Single freeze treatment consists of one five-minute freeze
89187420|NCT02584712|Active Comparator|Exercise Training|This group undergone exercise training intervention during 4 weeks.
89187421|NCT02582450||Patients with haemophilia|Sample of patients with haemophilia over 18 years of age that will participate in piloting of reliability and validity of the Spanish version of the Veritas-Pro questionnaire.
88870466|NCT03084081|Experimental|Thermocoagulator|Thermoablation for 60-seconds at 100 degrees Celsius
89187422|NCT02584556|Experimental|systemic chemotherapy|Pirarubicin(Brand Name:Pirarubicin - Main Luck Pharmaceutical, China) 30mg/m2 intravenously on Day 1 and Oxaliplatin(Brand Name: Eloxatin) 100 mg/m2 intravenously on Day 2 every 3 weeks within 4-6 weeks after hepatic resection(a total of 4 cycles).
89187423|NCT02584556|Active Comparator|Transcatheter Arterial Chemoembolization|Transcatheter Arterial Chemoembolization (Lipiodol 5-10ml,Pirarubicin17mg/m2 and Oxaliplatin 30mg/m2 are infused through the right and left hepatic arteries,followed by embolization using gelatin sponge particles(Gelfoam; Guangzhou)) within 4-6 weeks after hepatic resection(a total of 1 cycle).
89187424|NCT04353986|Experimental|Beta thalassemia|HCV infected Beta thalassemia major adolescents
89187425|NCT04353986|Active Comparator|Control|HCV infected, otherwise healthy, sex and age matched to the thalassemia group serving as control group
89187426|NCT04077008|Other|Bilaterally Obstructed Kidneys by benign cause|
89187427|NCT04077008|Other|Bilaterally Obstructed Kidneys by malignant cause|
89187428|NCT05325554|Experimental|Research Group|multi-mode rehabilitation
89187429|NCT05325554|No Intervention|control group|control group
89187430|NCT02581436|Experimental|kSORT assay based follow-up|Post Transplant surveillance based on the result of the kSORT assay.
89187431|NCT02581436|Active Comparator|Standard follow-up|Post Transplant surveillance based on standard of care.
89187432|NCT00670449|Experimental|Fingolimod 0.5 mg|Patients who received fingolimod 0.5 orally once daily in the core study continued on the same dose in this extension study.
89187433|NCT00670449|Experimental|Fingolimod 1.25 mg|Patients who received fingolimod 1.25 mg orally once daily in the core study continued on the same dose in this extension study.
88870467|NCT03068130|Experimental|Bardoxolone methyl 10 mg|Bardoxolone methyl will be administered orally once daily at 10 mg until it becomes commercially available. Dose de-escalation (down to 5 mg) is permitted during the study, if indicated clinically.
89187434|NCT00670449|Experimental|Placebo-fingolimod|Patients who were randomized to placebo in the core study were re-randomized to either fingolimod 0.5 or 1.25 mg (1:1) orally once daily in this extension study.
89187435|NCT00771147||Group 1|
89187436|NCT00771225|Other|prolapse surgery with fascial repair|
89187437|NCT00771225|Other|prolapse surgery with mesh repair|
89187438|NCT04155710|Experimental|Cohort 1a|CLL/SLL patients whose disease has relapsed or is relapsing post ibrutinib or acalabrutinib therapy. Patients will receive IOV-2001 + low dose IL-2.
89187439|NCT04155710|Experimental|Cohort 1b|CLL/SLL patients whose disease has relapsed or is relapsing post ibrutinib or acalabrutinib therapy. Patients will receive IOV-2001 + high dose IL-2.
89187440|NCT04155710|Experimental|Cohort 2|CLL/SLL patients with del 17p who progressed or are progressing on ibrutinib or acalabrutinib therapy. Patients will receive IOV-2001 + IL-2.
89187441|NCT04155710|Experimental|Cohort 3|CLL/SLL patients without del 17p who progressed or progressing on ibrutinib or acalabrutinib therapy. Patients will receive IOV-2001 + IL-2.
89187442|NCT00775047|Experimental|Pharmacy|Women receive their second and third depot-medroxyprogesterone acetate injections at the pharmacy by clinical pharmacists
89187443|NCT00775047|Active Comparator|Planned Parenthood clinic|Women receive their second and third depot-medroxyprogesterone acetate injections per usual care at their Planned Parenthood clinic.
89187444|NCT02557503|Experimental|Oxaliplatin by HAIC after TACE|To investigate the therapy effect and security of oxaliplatin on with or without concomitant vascular invasion and extrahepatic metastases unresectable advanced primary liver cancer
89187445|NCT02557503|No Intervention|Fluorouracil by HAIC after TACE|To investigate the therapy effect and security of fluorouracil on with or without concomitant vascular invasion and extrahepatic metastases unresectable advanced primary liver cancer
89187446|NCT00764439|Active Comparator|1|Standard NRT user direction
89187447|NCT00764439|Experimental|2|Novel NRT user direction
89187448|NCT00771303||Ct scan|Pregnant patients with suspected PE will undergo a strategy based on clinical probability assessment, D-dimer measurement, lower limb compression ultrasonography and multi-slice computed tomography.
89187449|NCT02558049|Experimental|Decision aid|Patients will receive the patient decision aid during a 15 minute consultation with a clinical pharmacist.
89187450|NCT00771381|Experimental|1|18F-FAZA + FluGlucoScan Injection
89187451|NCT00771459|Active Comparator|Ropivacaine|
89187452|NCT00771459|Placebo Comparator|Placebo|
89187453|NCT00775281||1|
89187454|NCT00775281||2|
89187455|NCT00775281||3|
89187456|NCT00775359|Experimental|1|Fenofibrate 160mg Tablets of Ranbaxy
89187457|NCT00775359|Active Comparator|2|TriCor® 160 mg Fenofibrate Tablets
89187458|NCT02557347|Experimental|Intervention|Aggressive fluid management
89535443|NCT02487329|Experimental|Er,Cr:YSGG laser + calcium hydroxide|Direct pulp capping using Er,Cr:YSGG laser combined with calcium hydroxide
89187459|NCT02582138|Experimental|Multicomponent intervention (MCI)|The multicomponent intervention will include a physical activity programme, a nutritional intervention and an information and communications intervention.
89187460|NCT02582138|Active Comparator|Healthy Aging Lifestyle Education (HALE)|The health aging lifestyle education programme will be based on workshops. Participants will receive information on a variety of topics of relevance to older persons (e.g., recommended preventive services and screenings at different ages). The programme will also include a short instructor-led programme (5-10 minutes) of upper extremity stretching exercises or some relaxation techniques that will be performed at the end of each workshop.
89187461|NCT00775515|Experimental|one|laparoscopic prostatectomy
89187462|NCT05338502|Experimental|160 milligram (mg) Selpercatinib|Participants received a single oral dose of 160 mg Selpercatinib.
89187463|NCT05338502|Experimental|150 mg Ranitidine and 160 mg Selpercatinib|Participants received 150 mg ranitidine twice a day orally for 11 days and a single oral dose of 160 mg Selpercatinib.
89187464|NCT05338502|Experimental|40 mg Omeprazole and 160 mg Selpercatinib|Participants received 40 mg omeprazole once daily for 11 days and a single oral dose of 160 mg Selpercatinib.
89187465|NCT04078334|Experimental|Group 1|PATH Tool : Prescription of exercise programs at discharge
89187466|NCT04078334|Experimental|Group 2|PATH 2.0 Tool : Prescription of exercise programs during hospitalization and discharge
89187467|NCT04078334|Experimental|Group 3|MATCH tool: Prescription of physical exercise programs during hospitalization
89187468|NCT04078334|No Intervention|Group 4|Control group: Usual care by the clinical teams
89187469|NCT03925688||without heterotopic ossification|There had not existed radiographic evidences of heterotopic ossification.
89187470|NCT03925688||with heterotopic ossification|There had existed radiographic evidences of heterotopic ossification or formatted ectopic lamellar bone.
89187471|NCT05337722|Experimental|App+fixed MI|The participants will use the SFT2.0 app and receive a fixed number of 4 counseling video sessions during pregnancy up to 1-month postpartum.
89187472|NCT05337722|Experimental|Adaptive app + as-needed MI|The participants will use the SFT2.0 app and receive as-needed prenatal and postnatal video counseling sessions (between 1 and 10 sessions) during pregnancy up to 1-month postpartum.
89394248|NCT02135822|Experimental|nanoparticle albumin-bound paclitaxel, gemcitabine|Nanoparticle albumin-bound paclitaxel is given at 125 mg/m2 intravenously on day 1 and 8, in combination with gemcitabine which is given at 1000 mg/m2, on day 1 and 8, each 21-day cycle. Number of cycle: 6 cycles.
89394249|NCT05534893|Experimental|Blueberry powder group|Participants in the blueberry powder group will receive freeze dried blueberries in form of a powder
89394250|NCT05534893|Placebo Comparator|Placebo powder group|Participants in the placebo group will receive an isocaloric placebo powder.
89394251|NCT02238210|Experimental|Atrovent® - common cold group|Treatment duration for common cold group - three time daily for 4 days
88810695|NCT05957185|Active Comparator|P3 - WHEY|OPTIZIOME® P3 HYDROLYZER® - WHEY (P3 - WHEY) is a mixture of 3 microbial protease preparations with 50,000 HUT fungal proteolytic activity units per 250 mg dose.
88810696|NCT05957185|Placebo Comparator|Placebo|Maltodextrin from waxy maize at 265 mg per dose.
88810697|NCT05947266|Experimental|Haitian immigrant iENGAGE (H-iENGAGE) intervention|"Enrollment;~Baseline assessment;~Upon baseline completion, scheduling of H-iENGAGE sessions 1 through 4~Following Session 4, conduct Process evaluation;~Post-intervention assessment;~Six-month follow up assessment*~*Six participants will complete AIM 3: Identify multi-level implementation factors contributing to intervention outcomes, using photovoice in mixed methods.~End of study participation"
88810698|NCT05942300|Experimental|CPI-0209 (150 mg) + carboplatin|CPI-0209: 150 mg (oral dosing) carboplatin administered intravenously as per institutional standards
88810699|NCT05942300|Experimental|CPI-0209 (200 mg) + carboplatin|CPI-0209: 200 mg (oral dosing) carboplatin administered intravenously as per institutional standards
88810700|NCT05942300|Experimental|CPI-0209 (250 mg) + carboplatin|CPI-0209: 250 mg (oral dosing) carboplatin administered intravenously as per institutional standards
88810701|NCT05935527|Placebo Comparator|Placebo (Normal Saline)|Subjects will be randomized 1:5 (1 Placebo subject to 5 receiving active treatment) to receive placebo (Normal Saline) with a volume of 120 microliters injection.
88810702|NCT05935527|Experimental|POLAT-001|Subjects will be randomized 1:5 (1 Placebo subject to 5 receiving active treatment) to receive POLAT-001 with a volume of 120 microliters injection, at either 1 mg/mL or 2 mg/mL
88810703|NCT05933889||Retrospective observational cohort|Retrospective patients undergoing transoral robotic surgery for early stage T1-2 oropharyngeal cancers on or before to 31/12/2021. Data will be collected from medical records.
88810704|NCT05933889||Exploratory molecular analysis|Consenting prospective patients based in the UK identified will be invited to participate in the exploratory molecular analysis by their usual care team. If agreeable, patients will consent to donation of either blood or buccal swab samples, in addition to archival tissue from their primary, and if relevant, recurrent tissue samples.
88810705|NCT05933889||Radiology/ radiomic analysis|Retrospective patients based in the UK and abroad will have their pre-operative imaging transferred to the RMH radiology department which will undergo radiomic and morphological assessment to ascertain features that put patients at high risk of local recurrence and positive margins.
88810706|NCT05931653|Experimental|Multimodal Physical Therapy|Multimodal Physical therapy/Traditional Physical therapy
88810707|NCT05931653|Experimental|Proprioceptive training along with Multimodal Physical Therapy|Proprioceptive training along with Multimodal Physical Therapy
88810708|NCT05927142|Experimental|Durvalumab and rintatolimod combination therapy|"1500mg Durvalumab administered via IV infusion once every first day of a 28 day cycle for a total of maximum 12 cycles (12 infusions in total).~200-400mg Rintatolimod administered via IV infusion twice per week for a total of 6 weeks (12 infusions in total)."
88810709|NCT05916690|Experimental|Electrochemotherapy|
88810710|NCT05912777|Experimental|Scanner Arm|A scanner must be performed by Patients
88810711|NCT05909384||Expert group|"Clinical expertise in adult sepsis management, AND~Demonstrated involvement with sepsis related research, educations, policy/protocols, professional activities"
89394252|NCT02238210|Experimental|Experimental: Atrovent® - allergy group|Treatment duration for allergy group - three time daily for 14 days
89394253|NCT02978456|Experimental|quantitative coronary angiography guided|
89394254|NCT02978456|Active Comparator|Intravascular ultrasound guided|
88870468|NCT03065062|Experimental|Combination Of Palbociclib and Gedatolisib|"Palbociclib will be administered orally once daily on Days 1-21 for each of the 4-week cycles at a pre-determined dose.~Gedatolisib will be administered intravenously once weekly on the first day for each of the four weeks during the 4-week cycles at a pre-determined dose."
88870469|NCT03036098|Experimental|Arm A: Investigational immunotherapy|
88870470|NCT03036098|Active Comparator|Arm B: Standard of care chemotherapy|
88870471|NCT03036098|Experimental|Arm C: Investigational immunotherapy|
88870472|NCT03036098|Active Comparator|Arm D: Standard of care chemotherapy|
88870473|NCT03015129|Experimental|Durvalubmab|Patients will receive intravenous infusion of durvalumab 1500mg Fixed Dose every 4 weeks until patient develops a loss of clinical benefit or experiences unacceptable toxicities.
88870474|NCT03015129|Experimental|Durvalubmab + Tremelimumab|Patients will receive 1500mg Flat Dose durvalubmab via intravenous infusion every 4 weeks for up to 4 cycles and 75mg tremelimumab via intravenous infusion every 4 weeks for up to 4 cycles, and then continue 1500mg Fixed Dose durvalumab every 4 weeks until patient develops a loss of clinical benefit or experiences unacceptable toxicities.
88870475|NCT02989948|Experimental|Main Arm - Physician-modified fenestrated endovascular graft|Use of a physician-modified fenestrated Cook Zenith Alpha Thoracic Endovascular Graft for the endovascular treatment of asymptomatic, non-ruptured thoracoabdominal aortic aneurysms of any Crawford extent (I-V) meeting traditional size criteria for open surgical repair.
88870476|NCT02989948|Experimental|Expanded Access Arm - Physician-modified fenestrated endovascular graft.|Use of a physician-modified fenestrated Cook Zenith Alpha Thoracic Endovascular Graft for the endovascular treatment of asymptomatic, non-ruptured thoracoabdominal, thoracic, or abdominal aortic aneurysms of any Crawford extent (I-V) meeting traditional size criteria for open surgical repair in an expanded use population.
88870477|NCT02965690|Active Comparator|Zimmer Biomet NexGen CR|Patients receive a Zimmer Biomet NexGen Total Knee Replacement
88870478|NCT02965690|Active Comparator|Medacta International GMK Sphere|Patients receive a Medacta International, GMK Sphere Total Knee Replacement
88870479|NCT02962557|No Intervention|Control|The control group will receive no prompts by the recorded voice.
88870480|NCT02962557|Experimental|Experimental|The experimental group will receive playback of recorded verbal prompts to breathe with an optional shoulder shake.
88870481|NCT02929810|Experimental|sleep extension|
88870482|NCT02929810|Active Comparator|sleep maintenance|
88870483|NCT02924571|Experimental|Bone Marrow Aspirate Concentrate (BMAC) + Allograft|"A total of 60, 120, or 180 mL of BMA to be aspirated. BMA is then placed into the Harvest SmartPrep® Bone Marrow Concentrate (BMAC) system and concentrated to a final volume of 10, 20, or 30 mL. The BMAC will then be combined with packed allograft cancellous bone chips using the Harvest Graft Delivery Pack. The allograft bone will be obtained routinely from the bone bank in the operating suite.~If using Harvest Graft Delivery Kit, the BMAC dosing estimate is as follows (BMAC to graft ratio will be 1:1):~1-level fusion: 10 cc of BMAC from 60 cc of BMA (roughly 10 cc of graft)~2-level fusion: 20 cc of BMAC from 120 cc of BMA~3-level fusion: 20 cc of BMAC from 120 cc of BMA~4-level fusion: 180 cc kit~5-level fusion: 240 cc kit~If not using Harvest Graft Delivery Kit:~Volume of BMAC will be slightly increased (some BMAC will not get directly into hydrating the graft as the BMAC would get lost in the hydration process and left in mixing bowls)."
88870484|NCT02924571|Active Comparator|Recombinant Human Bone Morphogenetic Protein-2 (BMP)|"12 mL BMP will be applied at the surgical site of the interbody fusion using a collagen sponge following manufacturer's directions.~The BMP kit use per level is as follows:~1 Level Fusion: Extra small kit (1.4 cc)~2 Level Fusion: Small Kit (2.8cc)~3 Level Fusion: (4.2 cc)~4 Level Fusion: Medium Kit (5.6cc)~5 Level Fusion: (7.0 cc)"
88870485|NCT02924571|Active Comparator|Autograft|As per standard of care, the control group will receive 15cc - 45 cc of allograft with autograft and bone marrow aspirate at each level. The iliac crest is the common donor site for autograft. Using the standard technique for anterior lateral fusion, the bone graft will be laid onto the desired site of fusion.
88870486|NCT02861794|Other|GMK Sphere|Patients receive a GMK Sphere Total Knee Replacement.
88870487|NCT02859337|Active Comparator|UPA-ECx1 followed by ECx2|Ulipristal acetate 30mg orally x 1 dose, washout cycle and then in the next menstrual cycle, 60mg x 1 dose. Timing of dosage depends on follicle measurements.
88870488|NCT02859337|Experimental|UPA-ECx2 followed by ECx1|Ulipristal acetate 60mg orally x 1 dose, washout cycle, and then in next menstrual cycle 30mg orally x 1 dose. Timing of dosage depends on follicle measurements.
88870489|NCT02859337|Other|UPA-ECx1 Normal BMI/weight|Ulipristal acetate 30mg orally x 1 dose. timing of dosage depends on follicle measurements. This is to obtain a normal BMI control group.
88870490|NCT02840448||Case|Subjects with WS/SVAS/WS gene region variation
88870491|NCT02840448||Controls|Healthy volunteers
89394255|NCT03598686|No Intervention|HOSENG Control|"Standard of care during a door-to-door HIV testing campaign:~For present household members: blood-based HIV testing~For absent household members or household members who refuse testing: They are encouraged to get tested by the Village Health Worker (VHW) or the nearby health facility"
89394256|NCT03598686|Experimental|HOSENG Intervention|"HOSENG Intervention during a door-to-door HIV testing campaign:~For present household members: blood-based HIV testing~a) If any absent person in the household: One of the present household members is tested and trained using the oral HIVST (OraQuick©)~For absent household members or household members who refuse testing: One oral HIVST (OraQuick©) is left behind and has to be brought back to the VHW after usage. Otherwise it will be collected by the VHW after two weeks."
89394257|NCT05736913|Active Comparator|Intradermal|One dose of 30ug (0.3mL) intradermal BNT162b2
89394258|NCT05736913|Active Comparator|Intramuscular|One dose of 30ug (0.3mL) intramuscular BNT162b2
89394259|NCT03598452|Experimental|High dose of ganciclovir group|IVG was conducted in a week interval. The initial dose was 6mg/0.1ml at the first injection and it was reduced to 4.5mg/0.1ml at the second time; 3mg/0.1ml of IVG was maintained until the CMV could not be detected in aqueous humor.
89535444|NCT02487329|Experimental|TheraCal LC|Direct pulp capping with resin based tricalcium silicate material
89394260|NCT03549182|Experimental|male TPH2-GG carriers with ATD then placebo group|male TPH2-GG carriers will first receive ATD, then will receive placebo at least 5 weeks later.
88810712|NCT05906095|Other|Intervention (each site serves as own control)|wedge-based cluster randomized, controlled trial design with each SVH acting as its own control
88810713|NCT05901168|Active Comparator|Active Video Games Intervention|"Active video games intervention will be carried out with a virtual reality system (XBOX360, Microsoft, USA) consisting of a console and sensor.~Active video games consist of Rally Ball, Rive Rush and Reflex Ridge games."
89394261|NCT03549182|Experimental|male TPH2-GG carriers with placebo then ATD group|male TPH2-GG carriers will first receive placebo, then will receive ATD at least 5 weeks later.
89394262|NCT03549182|Experimental|male TPH2-TTcarriers with ATD then placebo group|male TPH2-TT carriers will first receive ATD, then will receive placebo at least 5 weeks later.
89394263|NCT03549182|Experimental|male TPH2-TTcarriers with placebo then ATD group|male TPH2-TT carriers will first receive placebo,then will receive ATD at least 5 weeks later.
89394264|NCT03598296|Experimental|Group A:Group Tube|Patients are inserted the large size tube (28F).Patients undergo upper lobectomy are inserted one additional large size tube(28F,we named this tube upper tube).This group is planned to enroll 30 patients.
88810714|NCT05901168|Active Comparator|Traditional Exercise Intervention|Traditional Exercise Intervention consist of active exercises for the upper extremities, active exercises for the lower extremities, active exercises for the body.
88810715|NCT05900037|Experimental|GATT-Patch|Hemostatic Patch
88810716|NCT05900037|Active Comparator|SURGICEL® Original|Hemostatic Patch
88810717|NCT05899465|Experimental|Tranexamic Acid|A single dose of TXA (15 mg/kg) administered intravenously 30 min (+/-15 min) before skin incision and subsequently, TXA (1000 mg) administered orally 4 and 8 hours post-surgery and TXA (1000 mg) 3 times daily through postoperative day 4.
88810718|NCT05899465|Placebo Comparator|Placebo|A single dose of saline matching the volume of the experimental arm treatment regiment (Saline) administered intravenously 30 min (+/-15 min) before skin incision and subsequently, placebo tablets (2 tabs.) administered orally 4 and 8 hours post-surgery and (2 tabs) 3 times daily through postoperative day 4.
88810719|NCT05885074|Experimental|Empagliflozin Arm|Investigator will enroll 12 obese participants who have intentionally lost greater than or equal to 5% of body weight through a non-pharmacological structured weight loss program based on diet and exercise within the last 6 months. The participants will take empagliflozin 25mg/day orally for 12 months.
88810720|NCT05885074|Placebo Comparator|Placebo Arm|Investigator will enroll 12 obese participants who have intentionally lost greater than or equal to 5% of body weight through a non-pharmacological structured weight loss program based on diet and exercise within the last 6 months. The participants will take a placebo pill orally once a day for 12 months.
88810721|NCT05878626|Experimental|Group A|receive Anodal TDCS with spongy electrodes applied to the M1 (supplementary motor area) of the skull which corresponds to C3 and C4 on the 10/20 EEG system. The intensity of TDCS will be 2.5 mA and the duration will be 20 mints. The intervention will be applied twice a day with a time difference of 30 minutes between the two sessions.
88810722|NCT05878626|Sham Comparator|Group B|receive conventional treatment in the form of motor relearning program (MRP). And Sham application of anodal TDCS
88810723|NCT05874739||Control Cohort|Control participants who are age- and gender-matched to the PD cohort
88810724|NCT05874739||PD Cohort|PD Patients who have completed their participation in the Mobilise-D Clinical Validation Study
88810725|NCT05869591|Experimental|Cirrhotic patients with Child A or B under apixaban|"Twenty non-anticoagulated patients with Child A or B liver cirrhosis will receive a therapeutic dose of apixaban (Eliquis®) for 7 consecutive days.~Blood samples will be collected just before and after apixban intake at day 1 and 3. Another blood samples are collected at day 8 and at day 9.~In vivo thrombin generation parameters (F1+2, TAT, fibrin monomers, D-dimers), ex vivo thrombin generation parameters [ST Genesia (Drugscreen)], as well as peak and trough apixaban levels will be measured."
89394265|NCT03598296|Experimental|Group B:Group Ball|Patients are inserted the small size tube connects with a negative pressure ball(drainage ball).Patients undergo upper lobectomy are inserted one additional large size tube(28F,we named this tube upper tube).This group is planned to enroll 30 patients.
89394266|NCT05501834|No Intervention|Control Group|Both arms will receive the same Standard of Care procedures but will receive them in a different order. Patients in the control group will: 1. Go to cast room for cast removal, 2. Go to radiology for X-ray, 3. Will be seen in clinic room for pin removal. These steps are our current standard of care. An orthopedic, cast room technician bivalves and removes the top half of the patient's cast. In radiology, anteroposterior (AP) and lateral X-ray views are obtained to confirm radiographic healing. In the clinic room, a surgeon or nurse removes the pins using pin removal pliers. The order of these procedures is the current Standard of Care.
89394267|NCT05501834|Experimental|Intervention Group|Both arms will receive the same Standard of Care procedures but will receive them in a different order. Patients in the treatment group will: 1. Go to cast room for cast removal, 2. Have pins immediately pulled after cast removal, 3. Go to radiology for X-ray, 4. Will be seen in clinic room by provider.
89394268|NCT03549026|Experimental|duloxitine group|Patients will receive single oral dose of duloxetine capsule, 60 mg, 2 hours before operation and will be anesthetized with general anesthesia that includes, Induction of anesthesia will be done by intravenous fentanyl, 2 µg / kg and propofol 1 - 2 mg / kg. Endotracheal intubation will be achieved by cis-atracurium, 0.15 mg / kg. Maintenance of anesthesia will be done by isoflurane and cis-atracurium, 0.03 mg / kg on demand. Additional intraoperative analgesia will be consisted of administration of intravenous boluses of fentanyl, 50 µg according to the attending anesthesiologist's decision. At the end of surgery, muscle relaxation was reversed using neostigmine 0.05 mg / kg and atropine 0.01 mg / kg.
89394269|NCT03549026|Placebo Comparator|placebo group|Patients will receive single oral dose of placebo capsule, 2 hours before operation and will be anesthetized with general anesthesia that includes, Induction of anesthesia will be done by intravenous fentanyl, 2 µg / kg and propofol 1 - 2 mg / kg. Endotracheal intubation will be achieved by cis-atracurium, 0.15 mg / kg. Maintenance of anesthesia will be done by isoflurane and cis-atracurium, 0.03 mg / kg on demand. Additional intraoperative analgesia will be consisted of administration of intravenous boluses of fentanyl, 50 µg according to the attending anesthesiologist's decision. At the end of surgery, muscle relaxation was reversed using neostigmine 0.05 mg / kg and atropine 0.01 mg / kg.
89394270|NCT03101371|Active Comparator|Standard of care catheter insertion|Standard of care catheter insertion in which catheter is inserted right out of package/non-treated catheter.
89394271|NCT03101371|Experimental|Aseptic protocol for catheter insertion|Aseptic protocol for catheter insertion using Povidone Iodine treated catheter and maintaining plastic sleeve on catheter
89394272|NCT03588078|Experimental|combination of APR246 and azacitidine|Following completion of the Dose Finding Phase, we will conduct a dose expansion, whereby patients will be treated with APR-246 administered at the maximum tolerated dose (MTD) with azacitidine on a 28 day cycle utilizing the same dosing as in Phase 1b
89394273|NCT02140502||Men undergoing prostate biopsy|
89394274|NCT02238366||Prostate cancer patients|Patients recently diagnosed with prostate cancer requiring ADT.
89394275|NCT05494190|Experimental|Induction chemotherapy group|"Patients initially receive induction chemotherapy consisting of docetaxel, cisplatin and capecitabine (TPC), q3w, 2-3 cycles in total.~Patients with regional response of complete reaction (CR)/partial reaction (PR)≥50% after induction chemotherapy then receive concomitant chemoradiotherapy for both the primary and regional sites.~Patients with regional response of PR<50%/stable disease (SD)/progressive disease (PD) after induction chemotherapy then receive surgery for both the primary and regional sites and postoperative concomitant chemoradiotherapy."
89394276|NCT05494190|Active Comparator|Surgery group|Patients initially receive surgery for both the primary and regional sites and postoperative concomitant chemoradiotherapy.
89535445|NCT02487329|Experimental|Er,Cr:YSGG laser + TheraCal LC|Direct pulp capping using Er,Cr:YSGG laser combined with resin based tricalcium silicate material
89535446|NCT03226171|Experimental|Dose-adjusted SK-1403|
88870492|NCT02817659|Experimental|Glucagon Infusion|Glucagon infusion in escalating manner at 12.5, 25, 37.5 and 50 ng/kg/min (each step for 60 min). At 30 and 60 mins of each infusion rate, we will administer a previously established questionnaire to assess overall nausea intensity.
88870493|NCT02769845|Experimental|Longitudinal Portion|All enrolled children will undergo yearly TCD examination. The goal of serial examination is to help define the natural history of cerebrovascular disease, specifically to determine the incidence of new conditional or abnormal velocities. The goal is to obtain a total of 3 TCD examinations per enrolled patient, regardless of treatment status.
88870494|NCT02769845|Experimental|Treatment Phase|Those children with TCD velocities between 170-199 cm/sec will be eligible for protocol-directed hydroxyurea therapy. Most participants will initiate hydroxyurea treatment but those who are already on hydroxyurea and have conditional velocities will receive dose optimization. Participants will be followed until a common study termination date, defined as 3 years from the first treatment. Participants with abnormal TCD velocities ≥200 cm/sec will commence with transfusion therapy per current practice guidelines at the clinical site. Patients already on transfusion therapy identified to have conditional velocities will also be eligible for hydroxyurea and those with abnormal velocities may require re-calculation of transfusion dosing.
88870495|NCT02765256|Experimental|Fluconazole|Vancomycin 500 mg oral suspension four times daily (Day 1-14), plus neomycin 1000 mg orally three times daily (Days 1-3), plus ciprofloxacin 750 mg orally twice daily (Day 4-14), plus Polyethylene Glycol 3350 (Miralax) 238 g dissolved in 64 ounces of Gatorade or Crystal Lite on day 2, plus fluconazole 400 mg orally once daily (Day 1-14). PRN (as needed) Promethazine 12.5mg up to every four hours (Days 1-3).
88870496|NCT02765256|Placebo Comparator|Placebo|Vancomycin 500 mg oral suspension four times daily (Day 1-14), plus neomycin 1000 mg orally three times daily (Days 1-3), plus ciprofloxacin 750 mg orally twice daily (Day 4-14), plus Polyethylene Glycol 3350 (Miralax) 238 g dissolved in 64 ounces of Gatorade or Crystal Lite on day 2, plus placebo for fluconazole. PRN (as needed) Promethazine 12.5mg up to every four hours (Days 1-3).
88870497|NCT02759744|Experimental|1|ultrasound image-guided focal ablation
88870498|NCT02739087|Experimental|MRI guided cardiac catheterization|Magnetic resonance imaging will be used to guide cardiac catheterization procedures.
88870499|NCT02737579|Other|XFM guidance|X-ray fused cardiac MRI images used for guidance tool to perform cardiac catheterization procedure
89394277|NCT03582540|Active Comparator|early double-guidewire technique (DGT)|First arm: early double-guidewire technique The early arm attempts biliary cannulation using the DGT immediately once the guidewire is inserted in the pancreatic duct in cases of difficult biliary cannulation.
89394278|NCT03582540|Active Comparator|delayed double-guidewire technique (DGT)|In the delayed arm, once the guidewire is inserted in the pancreatic duct, the operator continues to attempt biliary cannulation with conventional technique (contrast- or guidewire-assisted). DGT is used only if 10 more minutes of conventional cannulation technique does not allow biliary access.
89394279|NCT05360095|Active Comparator|Usual Care|The usual care group will consist of pregnant women who receive no experimental intervention but will receive the brochure-based education about prenatal screening that is currently recommended by American College of Obstetrics and Gynecology (ACOG), delivered in an electronic format, plus any additional clinic materials or oral information provided in conversation with clinicians (n= 375 total, 125 per site). We are transferring ACOG's prenatal screening education onto the electronic platform to control for any differences in attention that may be due to technology platform and to track time interacting with the material via the web portal.
88870500|NCT02717650|Experimental|A-STEP|Study A) A-STEP Study Development of new exercise test protocol and Observational Feasibility/Safety Study (no comparator).
89394280|NCT05360095|Experimental|Game Intervention|The game intervention group will consist of pregnant women who will interact with the educational intervention also delivered on an electronic platform (n= 375 total, 125 per site). Participants will also receive whatever information is routinely provided in the clinic about prenatal screening such as the brochure and oral information by clinicians.
89394281|NCT05360095|Active Comparator|Genetic Counseling|The one-on-one genetic counseling group will receive standard of care for genetic counseling delivered by a board-certified genetic counselor for pre-test education. The counselor will be conducting pre-test education and as with the other study groups, the decision about prenatal screening will be made at the clinical visit with the provider. This group receives also the same clinical materials and oral information by clinicians as the other two groups. Both in-person and tele-health genetic counseling options are available at all sites.
89394282|NCT03548480|Placebo Comparator|Placebo|
89394283|NCT03548480|Experimental|Probiotic|
89394284|NCT03587766|Experimental|Group A|Fexinidazole (FEXI) 600 mg x 10 days in a single daily dose orally (1 fexinidazole 600 mg tablet and 1 fexinidazole matching placebo oral tablet administered in a single daily dose) (total dose: 6.0 g).
89394285|NCT03587766|Experimental|Group B|Fexinidazole (FEXI) 1200 mg x 3 days orally (2 fexinidazole 600 mg tablets administered in a single daily dose for 3 days), to be followed by matching placebo oral tablet for 7 days (2 fexinidazole matching placebo oral tablets administered once daily for 7 days) (total dose: 3.6 g).
88870501|NCT02717650|Experimental|A-STEP (New Protocol)|Study B) A-STEPmax Study Validity Study (random allocation of test order).
88870502|NCT02717650|Active Comparator|CPET cycle ergometer (Gold Standard)|Study B) A-STEPmax Study Validity Study (random allocation of test order).
88870503|NCT02657356|Placebo Comparator|Placebo capsules|Placebo capsules will be administered orally once a day for 24 weeks.
88870504|NCT02657356|Experimental|Bardoxolone methyl capsules|Each patient will receive bardoxolone methyl capsules administered orally once a day for 24 weeks. Starting dosage for each patient is 5 mg and will dose-escalate to 10 mg at Week 4, unless contraindicated clinically.
88870505|NCT02622581||NSCLC, Non-squamous cell carcinoma|"Patients with locally advanced or metastatic NSCLC at the start of palliative first-line systemic therapy or receiving best supportive care.~At least 3,250 patients with non-squamous cell carcinoma will be tested for molecular alterations. (CRISP)"
89187473|NCT05337722|Active Comparator|Control|Participants will receive low dose prenatal and postnatal MI video counseling, defined as one prenatal session and one postnatal session.
88870506|NCT02622581||NSCLC, Squamous cell carcinoma|"Patients with locally advanced or metastatic NSCLC at the start of palliative first-line systemic therapy or receiving best supportive care.~At least 1,750 patients with squamous cell carcinoma that possibly will be tested for molecular alterations. (CRISP)"
89394286|NCT03587766|Experimental|Group C|Fexinidazole (FEXI) 600 mg for 3 days, followed by 1200 mg in a single daily dose orally for 4 days (1 fexinidazole 600 mg tablet AND 1 fexinidazole matching placebo oral tablet administered in a single daily dose for 3 days, to be followed by 2 fexinidazole 600 mg tablets for 4 days), then followed by matching placebo oral tablet for 3 days (2 fexinidazole matching placebo tablets administered once daily for 3 days) (total dose: 6.6 g).
89394287|NCT03734185|Experimental|Learning and Coping|A health pedagogical strategy that builds on inductive teaching with high involvement of the participants. Characteristics of Learning and Coping are that 'experienced patients' plan, teach and evaluate, in cooperation with health professionals.
88870507|NCT02622581||NSCLC, Non-squamous cell carcinoma (not tested)|"Patients with locally advanced or metastatic NSCLC at the start of palliative first-line systemic therapy or receiving best supportive care.~Up to 5,000 patients not tested for molecular alterations (CRISP satellite untested patients stage IIIB/IIIC/IV).)."
88870508|NCT02622581||NSCLC, Stage I/II/III|Up to 1600 patients with NSCLC stage I, or stage II, or stage IIIA, or with NSCLC stage IIIB/C if they are eligible for curative surgery and/or radiochemotherapy, or are receiving best supportive care
88870509|NCT02622581||Small cell lung cancer (SCLC)|Up to 1200 patients with SCLC (limited stage (LD) or extensive stage (ED)) if they are eligible for surgery and/or radio(chemo)therapy and/or systemic therapy, or are receiving best supportive care
88870510|NCT02620826|Experimental|Indirect pulp therapy|Primary molars will be treated with indirect pulp therapy using resin-modified glass ionomer (Vitrebond Plus).
88870511|NCT02620826|Active Comparator|Pulpotomy|Primary molars treated with MTA pulpotomy.
88870512|NCT02594124|Experimental|Group 1|Participants transitioned from ISIS 396443-CS3B (NCT02193074)
88870513|NCT02594124|Experimental|Group 2|Participants transitioned from ISIS 396443-CS4 (NCT02292537)
88870514|NCT02594124|Experimental|Group 3|Participants transitioned from ISIS 396443-CS12 (NCT02052791)
88870515|NCT02594124|Experimental|Group 4|Participants transitioned from ISIS 396443-CS3A (NCT01839656)
88870516|NCT02594124|Experimental|Group 5|Participants transitioned from 232SM202 (NCT02462759)
89394288|NCT03734185|Active Comparator|Usual Cardiac Rehabilitation|The theoretical frameworks used in some of these local healthcare services are empowerment, self-efficacy and self-management
89394289|NCT05485610|Experimental|NMN intervention|3 months of NMN
89394290|NCT05485610|Placebo Comparator|Placebo|3 months of NMN-free placebo
88870517|NCT02576613|Experimental|MPP-S|at least 30 weekly sessions of modified psychodynamic psychotherapy
88870518|NCT02576613|Experimental|standard therapy (TAU)|clinical standard treatment, including supportive therapeutic contacts, pharmacotherapy, creative and occupational therapies, psychoeducation, group therapies, excluding structured individual or group psychotherapy
88870519|NCT02556762|Experimental|SMART boost|Radiotherapy with simultaneous modulated accelerated boost
88870520|NCT02556762|Active Comparator|Standard dose RT|Standard dose radiotherapy
88870521|NCT02542683||physical activity program|enrollment for 12 months in a structured physical activity program
88870522|NCT02542683||delayed physical activity program|No intervention for 12 months, then enrollment in structured physical activity program
89394291|NCT02850276|Experimental|Pyridostigmine|30mg PO three times a day
88870523|NCT02532439|Experimental|Patient group|Measure bone quality and quantity with HR-pQCT, pQCT and DEXA of patient group Patient group is patient with one of the following pathology : Osteoporosis, Bone Fragility, articular inflammatory disease or Endocrine diseases
88870524|NCT02532439|Experimental|control group|Measure bone quality and quantity with HR-pQCT, pQCT and DEXA of control group. Patient group is patient with episode of acute back pain or radicular pain
88870525|NCT02502617||Weight Improvement|Patients (n = 30) with severe AN, refered to the specialized medical nutrition section at Odense University Hospital are tested three times during nutritional rehabilitation: At admission, at discharge (or drop out) and two-four months after discharge. The first study is carried out not before the third day of hospitalization after acclimatization and water electrolyte correction.
88870526|NCT02502617||Weight-stable|To investigate the re-test effects of the the surveys, outpatients with a stable weight (less than 5%/3 months) with eating disorders (n = 15) are tested twice with 4-6 weeks interval.
88870527|NCT02500693|Experimental|Screening|
88870528|NCT02500407|Experimental|Dose Escalation|Participants will receive BTCT4465A (Mosunetuzumab) via intravenous (IV) infusion or subcutaneous (SC) injection as a single-agent or in combination with atezolizumab. Dose escalation will be guided by the observed incidence of DLTs at each dose level.
88870529|NCT02500407|Experimental|Dose Expansion|Participants will receive BTCT4465A (Mosunetuzumab) as a single-agent or in combination with atezolizumab.
89394292|NCT05418517||oromaxillofacial surgery|Patients who underwent oromaxillofacial surgery
89394293|NCT03592134||Clinical settings|Infants with the choice of the non respiratory support and settings of the non respiratory support defined by clinical practice (nocturnal gas exchange, apneas, bradycardia, oxygen desaturation)
89394294|NCT03592134||Physiological settings|Infants with the choice of the non respiratory support and settings of the non respiratory support defined by the measurement of work of breathing
89394295|NCT05577962|No Intervention|C group|The routine anesthesia group
89394296|NCT05577962|Experimental|T group|Opioid-free Anesthesia
89394297|NCT05577884||Multiple myeloma|Patients with suspicion of multiple myeloma and scheduled for CT
89394298|NCT03862170|Active Comparator|Ciprofloxacin|Patients in this arm will receive Ciprofloxacin 400mg IV 120mn (prophylactic antibiotic) before their HDR brachytherapy
89394299|NCT03862170|Experimental|Cefazolin|Patients in this arm will receive Cefazolin 2000mg IV 60mn (prophylactic antibiotic) before their HDR brachytherapy
89394300|NCT03862170|No Intervention|No prophylactic antibiotics|Patients in this arm will not receive any prophylactic antibiotics before their HDR brachytherapy
89394301|NCT02140580|Active Comparator|Minimally invasive surfactant therapy|Minimally invasive surfactant therapy - delivery of exogenous surfactant to the lung via brief catheterisation of the trachea with an instillation catheter in a preterm infant who is being supported with continuous positive airway pressure (CPAP) via nasal prongs or mask. Poractant alfa (Curosurf) at a dosage of 200 mg/kg will be administered over 15 - 30 seconds. Total duration of the procedure will be less than 5 minutes, followed by reinstitution of CPAP.
89394302|NCT02140580|Sham Comparator|Continuation on CPAP|Standard control treatment. After randomisation, infants will receive a sham treatment from a treatment team not engaged in clinical care. This will not involve removal of prongs or discontinuation of CPAP but will require setting up intubation equipment, screening the baby, testing suction unit, repositioning of the baby and changing the baby's monitoring. CPAP will thereafter continue.
89394303|NCT04955431|Placebo Comparator|Normal Sleep (with 250 ug/m^3 PM2.5)|Participants will have a normal sleep opportunity the night prior to reporting to the lab for the simulated firefighting session (250 ug/m^3 PM2.5 with moderate intensity exercise).
89394304|NCT04955431|Experimental|Restricted Sleep (with 250 ug/m^3 PM2.5)|Participants will have a restricted sleep opportunity (~4 hours) the night prior to reporting to the lab for the simulated firefighting session (250 ug/m^3 PM2.5 with moderate intensity exercise).
89394305|NCT05577806||DYG|oocyte donors undergoing controlled ovarian stimulation in a progestin-primed ovarian stimulation protocol with DYG protocol (20mg/day)
89394306|NCT05577806||Cetrorelix|oocyte donors undergoing controlled ovarian stimulation in a GnRH antagonist protocol with cetrorelix (0.25 mg/day) from Day 7 or since a leading follicle reached 14 mm
89394307|NCT03591432|Experimental|THRIVE|Using transnasal humidified rapid insufflation ventilatory exchange (THRIVE) oxygenation technique in elderly patients undergoing induction of anesthesia.
89394308|NCT03591432|Active Comparator|Facemask|Using facemask technique in elderly patients undergoing induction of anesthesia.
89394309|NCT03547388|Experimental|Single Arm|Additional application of weekly moderate whole-body hyperthermia concurrent to re-irradiation plus chemotherapy
88870530|NCT02489682|Experimental|Informed Consent Format - short written|"Intervention to be administered:~- Short-form written informed consent information, followed immediately by outcomes questionnaire"
88870531|NCT02489682|Experimental|Informed Consent Format - long written|"Intervention to be administered:~- Long-form written informed consent information, followed immediately by outcomes questionnaire"
88870532|NCT02489682|Experimental|Informed Consent Format - video|"Intervention to be administered:~- Video informed consent information, followed immediately by outcomes questionnaire"
88870533|NCT02467270|Experimental|Cohort A: Ponatinib 45 mg|Ponatinib 45 mg orally once daily in each 28-day cycle until achievement of ≤1% BCR-ABL1IS up to data cut-off: 31 May 2020. Once ≤1% BCR-ABL1IS was achieved, participants received reduced dose of ponatinib 15 mg orally once daily.
88870534|NCT02467270|Experimental|Cohort B: Ponatinib 30 mg|Ponatinib 30 mg orally once daily in each 28 day Cycle until achievement of ≤1% BCR-ABL1IS. Once ≤1% BCR-ABL1IS up to data cut-off: 31 May 2020. Once ≤1% BCR-ABL1IS was achieved, participants received reduced dose of ponatinib 15 mg orally once daily.
88870535|NCT02467270|Experimental|Cohort C: Ponatinib 15 mg|Participants received ponatinib 15 mg orally once daily up to data cut-off: 31 May 2020 in each 28 day Cycle.
89394310|NCT03591276|Experimental|Pembrolizumab and PLD|"Cohort S1: IV pembrolizumab 200 mg flat dose with IV PLD 30 mg/m2 every 3 weeks.~Reduced Dose Cohort (R1)*: IV pembrolizumab 200 mg flat dose with IV PLD 24 mg/m2 every 3 weeks.~*Subjects will be recruited into the R1 cohort only if DLT is reported in 2 or more subjects during the first 2 cycles of treatment in the first 6 patients of the S1 cohort."
89394311|NCT03582384|Experimental|Treatment|
89394312|NCT02261012||30 healthy probands|group without the condition of interest
88870536|NCT02459106||Healthy lean insulin-sensitive individuals|This group will be studied by measuring the adipose tissue miRNA release, adipose tissue-released miRNA will be profiled, and these effects will be examined.
89394313|NCT02261012||30 CRPS patients|group with condition of interest
89394314|NCT02261012||30 CTS patients|group with a different type of pain on the upper limbs
89394315|NCT03783468|Experimental|light sedation pressure support ventilation|
89394316|NCT03854526||Patients without Gougerot Sjogren disease|New patient, or patient, with no history of a dental examination in the last six months and with at least one tooth with coronal dental restoration
89394317|NCT03854526||Patients with Gougerot Sjogren disease|New patient, or patient, with no history of a dental examination in the last six months, with at least one tooth with coronal dental restoration and presenting a Gougerot Sjogren disease
89394318|NCT03763994||Control group 1|Never low back pain in the last 3 months
89394319|NCT03763994||Control group 2|occasionally (1-30days) low back pain in the last 3 months
89394320|NCT03763994||Low back pain group 3|frequently (31-60days) low back pain in the last 3 months
89394321|NCT03763994||Low back pain group 4|daily (61-90days) low back pain in the last 3 months
89394322|NCT04928287|Active Comparator|HB-adMSCs|Autologous Hope Biosciences adipose derived mesenchymal stem cells.
89394323|NCT04928287|Placebo Comparator|Placebo|Sterile Saline Solution 0.9%
88870537|NCT02459106||Obese insulin-resistant individuals|This group will be studied by measuring the effect of adipose tissue-release miRNA on skeletal muscle biology and insulin sensitivity, adipose tissue-released miRNA will be profiled, and these effects will be examined on obese insulin-resistant individuals on skeletal muscle biology and insulin sensitivity.
88870538|NCT02400944||patients with bladder cancer|
89394324|NCT03590964|Active Comparator|Open sinus lift using chin bone graft|Patients with atrophied posterior maxilla will undergo open sinus lift with chin bone graft according to standardized surgical approach.
89394325|NCT03590964|Experimental|Sinus lift using bone ring containing the implant|Patients with atrophied posterior maxilla will undergo sinus lift using bone ring containing the implant.
89394326|NCT03548948|Other|High heme iron diet|
89394327|NCT03548948|Other|Low iron diet|
89394328|NCT03548948|Other|Plant-based high non-heme iron diet|
89394329|NCT04926337||Tight fitting facemask|Preoxygenation with tight facemask, 100% oxygen.
89394330|NCT04926337||High flow nasal oxygen|Preoxygenation with high flow nasal oxygen, 100% oxygen
88870539|NCT02370199|Experimental|670 nm light|Subjects will have baseline blood flow measured in the gastrocnemius using octafluoropropane infusion and ultrasound.After baseline flow measurements are obtained, a 670 nm light emitting diode will be placed 1 cm above the gastrocnemius muscle. The diode will not be in direct contact with the skin. Subjects will be exposed to 75 mW/cm2. Contrast images will be obtained up to 5 minutes after the commencement of light.
88870540|NCT02364115|Experimental|Stereotactic Body Radiotherapy|MRI-based, cone beam CT-guided SBRT delivery of a single dose of 18 Gray (Gy) on the visible metastasis, and 8 Gy on the bony compartment containing the metastasis (e.g. the affected vertebra or pedicle).
88870541|NCT02364115|No Intervention|Conventional Radiotherapy|Delivery of a single fraction of 8 Gy using virtual simulation
88870542|NCT02290392||1|African Americans age 30-55 years with severe controlled HTN or severe resistant HTN.
88870543|NCT02274805||Adults presenting for surgery in the neck area|
88870544|NCT02215889|Experimental|Surgery|
88870545|NCT02202772|Experimental|Gem and Low Cab|Gemcitabine: Intravesical; 2000mg/100ml; 1 time a week for 6 weeks; 2 hours Cabazitaxel: Intravesical; 2.5mg/100ml; 1 time a week for 6 weeks; 2 hours
88870546|NCT02202772|Experimental|Gem and High Cab|Gemcitabine: Intravesical; 2000mg/100ml; 1 time a week for 6 weeks; 2 hours Cabazitaxel: Intravesical; 5mg/100ml; 1 time a week for 6 weeks; 2 hours
88870547|NCT02202772|Experimental|Gem, High Cab, and Low Cis|Gemcitabine: Intravesical; 2000mg/100ml; 1 time a week for 6 weeks; 2 hours Cabazitaxel: Intravesical; 5mg/100ml; 1 time a week for 6 weeks; 2 hours Cisplatin: Intravesical; 66mg/100ml; 1 time a week for 6 weeks; 2 hours
88870548|NCT02202772|Experimental|Gem, High Cab, Mod Cis|Gemcitabine: Intravesical; 2000mg/100ml; 1 time a week for 6 weeks; 2 hours Cabazitaxel: Intravesical; 5mg/100ml; 1 time a week for 6 weeks; 2 hours Cisplatin: Intravesical; 80mg/100ml; 1 time a week for 6 weeks; 2 hours
88870549|NCT02202772|Experimental|Gem, High Cab, High Cis|Gemcitabine: Intravesical; 2000mg/100ml; 1 time a week for 6 weeks; 2 hours Cabazitaxel: Intravesical; 5mg/100ml; 1 time a week for 6 weeks; 2 hours Cisplatin: Intravesical; 100mg/100ml; 1 time a week for 6 weeks; 2 hours
89394331|NCT02238444|Experimental|Warfarin with dipyridamole|From postoperative day 3, patients will receive dipyridamole 25mg tid for three months along with subcutaneous Low Molecular Weight Heparin Calcium injection for first five days and Warfarin 2.5mg qd with titration of dose to maintain a target INR of 2-3. Intially the INR will be monitored twice weekly with gradual escalation of dose to achieve target INR. After achieving the target INR, this is to be repeated every 4 weeks. The Doppler Ultra Sonography screening will be done every 3 months to assess the occurrence of portal vein thrombus, but the medications will be continue for one year irrespective of the occurrence of portal vein thrombus.
89394332|NCT02238444|Active Comparator|Aspirin with dipyridamole|From postoperative day 3, patients will receive oral dipyridamole 25mg tid for three months along with subcutaneous injection of Low Molecular Weight Heparin (4100 IU) for first five days and Aspirin Enterie Ccoated Tablets 100mg qd for one year.
89394333|NCT03638479||Parkinson's Disease|Participant's diagnosed with Parkinson's Disease
89394334|NCT03638479||Essential Tremor|Participant's diagnosed with Essential Tremor or other Movement Disorders
89394335|NCT03638479||No Parkinson's Disease and No Essential Tremor|Participant's with no diagnosis of PD, ET or other Movement Disorders
89394336|NCT02783768|Experimental|E-cigarette first|Participants will undergo the e-cigarette exposure prior to the first two MRI measures, and then they will undergo the sham exposure prior to the last two MRI measures. The two MRIs performed under both experimental exposures (e-cigarette and sham) will be enhanced by (1) gadolinium and then (2) hyperpolarized 3-helium.
88870550|NCT02179359|Experimental|Reduced Toxicity Ablative Regimen|For use in patients with a matched sibling donor or unrelated UCB donor and DBA patients who are <12 years and/or have mild/moderate iron exposure.
88870551|NCT02179359|Experimental|Reduced Intensity Preparative Regimen|For use in patients with unrelated donor bone marrow and for DBA patients who are >12 years and/or have significant iron exposure.
88870552|NCT02179359|Experimental|Myeloablative Preparative Regimen|For use in patients with a matched sibling donor, unrelated umbilical cord blood and in those with severe thalassemia.
88870553|NCT01981551|Experimental|PF-03084014 in Desmoid Tumors/Aggressive Fibromatosis|PF-03084014 will be administered orally at 150 mg twice a day in 21-day cycles
88870554|NCT01979393|Experimental|Cabozantinib|Cabozantinib maintenance 60 mg daily for 2 years or until withdrawal criterion After documented disease progression (according to RECIST 1.1), the treatment will be unblinded. Subjects receiving cabozantinib shall be further treated at the investigator discretion.
88870555|NCT01979393|Experimental|Placebo|Placebo daily for 2 years or until withdrawal criterion. After documented disease progression (according to RECIST 1.1), the treatment will be unblinded. Subjects receiving placebo shall be offered the option of receiving cabozantinib up to further progression. This is not mandatory and treatment is at the investigator decision.
88870556|NCT01911091|Experimental|Group 1 - Regular exercise|Alternate interval training and aerobic training and exercise
88870557|NCT01911091|No Intervention|Group 2 - Athlete exercise|Athletes are not given any intervention
88870558|NCT01911091|No Intervention|Group 3 - Obese No Exercise|The Obese group will not receive intervention
88870559|NCT01823562|Active Comparator|Arm I (regular diet)|Patients follow a regular diet for 4-6 weeks and then undergo prostatectomy.
88870560|NCT01823562|Active Comparator|Arm II (low polyphenol diet)|Patients follow a low polyphenol diet for 4-6 weeks and then undergo prostatectomy.
88870561|NCT01823562|Active Comparator|Arm III (low ellagitannin diet)|Patients follow a low ellagitannin diet for 4-6 weeks and then undergo prostatectomy.
88870562|NCT01823562|Experimental|Arm IV (lower-dose lyophilized black raspberry gummy)|Patients follow a low ellagitannin diet and receive lower-dose black raspberry gummy PO daily for 4-6 weeks and then undergo prostatectomy.
88870563|NCT01823562|Experimental|Arm V (higher-dose black raspberry gummy)|Patients follow a low ellagitannin diet and receive higher-dose black raspberry gummy PO daily for 4-6 weeks and then undergo prostatectomy.
88870564|NCT01823562|Experimental|Arm VI (lower-dose black raspberry confection)|Patients follow a low ellagitannin diet and receive lower-dose black raspberry confection PO daily for 4-6 weeks and then undergo prostatectomy.
88870565|NCT01823562|Experimental|Arm VII (higher-dose black raspberry confection)|Patients follow a low ellagitannin diet and receive higher-dose black raspberry confection PO daily for 4-6 weeks and then undergo prostatectomy.
88870566|NCT01796197|Experimental|Treatment Arm|"Run in: Trastuzumab IV 4 mg/kg, Pertuzumab IV 840 mg (Day 1 Week 1)~Pre-Op:~Trastuzumab IV 2 mg/kg weekly, Paclitaxel 80 mg/m2 IV weekly (beginning on Day 8 Week 2) x 16 doses.~Starting Day 21 (week 4) continue trastuzumab and paclitaxel as above, add Pertuzumab 420 mg IV x 3 weeks. After completing 16 doses of Paclitaxel, Trastuzumab (6 mg/kg IV) and Pertuzumab 420 mg IV may be continued x 3 weeks until surgery Modified Radical Mastectomy~Post-Op:~Option 1: Adriamycin 60 mg/m2 IV and Cyclophosphamide 600 mg/m2 IV x 2-3 weeks x 4 cycles. Followed by Trastuzumab 8 mg/kg and Pertuzumab 840 IV load; followed by Trastuzumab 6 mg/kg every and Pertuzumab 420 mg IV every 3 weeks to complete 12 months of HER2-directed therapy Option 2: Continue Trastuzumab 6 mg/kg and Pertuzumab 420 mg x 3 weeks to complete 12 months of HER2-directed therapy Post-mastectomy radiation to the chest wall / regional lymph nodes and endocrine therapy by standard of care."
88870567|NCT01772472|Active Comparator|Trastuzumab|
88870568|NCT01772472|Experimental|Trastuzumab emtansine|
88870569|NCT01745471||PCOS group|12 women with Polycystic Ovary Syndrome (PCOS) as defined by NIH criteria
88870570|NCT01745471||Pear shapes|12 with an android pattern as defined by a waist-to-hip greater than 0.85
88870571|NCT01745471||Apple shapes|12 will have a gynoid pattern as defined by a waist-to-hip ratio less than 0.78
88870572|NCT01703806||Conventional Treatment|Patients in the conventional treatment group will be treated according to the 2006 ACC/AHA guidelines and they will be referred for surgery if they experience any symptoms, and referred for surgery if exertional dyspnea, LV ejection fraction <0.60, LV end-systolic dimension >40 mm, Doppler estimated pulmonary artery pressure > 50 mmHg, or atrial fibrillation develops.
88870573|NCT01703806||Early Surgery|Patients in the early surgery group should undergo mitral valve surgery within 6 months of enrollment.
88870574|NCT01659606|Experimental|alemtuzumab/fludarabine conditioning|alemtuzumab/fludarabine conditioning; calcineurin-inhibitor/mycophenolate mofetil GVHD prophylaxis
88870575|NCT01643954|No Intervention|Arm A|Patients with prostate cancer who have undergone robotic radical prostatectomy at The Arthur G. James Cancer Hospital and Solove Research Institute, The Ohio State University Medical Center.
88870576|NCT01643954|Other|Arm B|Patients with prostate cancer that will undergo robotic radical prostatectomy at The Arthur G. James Cancer Hospital and Solove Research Institute, The Ohio State University Medical Center .
88870577|NCT01542437|Experimental|BIBW 2992|Patients received a daily oral 40mg dose of afatinib. Treatment was continued until docu-mented disease progression, unacceptable toxicity or withdrawal of consent. The Common Terminology Criteria for Adverse Events (CTCAE) v4.0 was used to evaluate toxicity. In patients with severe toxicity (grade ≥3) afatinib was temporary discontinued until the patient recovery to at least grade 1 toxicity and continued with a dose reduction to 30 mg/day. Dose reduction below 30mg/day was not allowed. Patients experiencing more than one grade ≥3 event, those with grade ≥2 toxicity after dose reduction, and/or those showing no recovery within 14 days discontinued treatment.
88870578|NCT01525082|Experimental|Bevacizumab + Capecitabine + Temozolomide|Cycles repeat every 28 days until disease progression, unacceptable toxicity, or withdrawal.
88870579|NCT01399411||AHS Cohort|licensed pesticide applicators and their spouses from Iowa and North Carolina already enrolled in the Agricultural Health Study (AHS)
88870580|NCT01008787|No Intervention|Focus Group|Qualitative interviews examining social support for PA conducted with African American (AA) women recruited from Wheeler Avenue Baptist Church located in Houston used to design Culturally-Appropriate Peer-based Motivational Interviewing (CAPMI) intervention.
88870581|NCT01008787|Active Comparator|Intervention Group 1|CAPMI Intervention: Training + Weekly Partner Questionnaire + Interview + PA Newsletter
88870582|NCT01008787|Active Comparator|Intervention Group 2|Interview + PA Newsletter
88870583|NCT00936936|Experimental|Cycle # 1|"First Cycle High-dose (HD) chemotherapy followed by stem-cell infusion (PBPC)~HD Cycle #1: Gemcitabine/Docetaxel/Melphalan/Carboplatin + PBPC"
88870584|NCT00936936|Experimental|Cycle #2|"Second Cycle High-dose (HD) chemotherapy followed by stem-cell infusion (PBPC)~HD Cycle #2: Ifosfamide/Carboplatin/Etoposide + PBPC"
88870585|NCT00770809|Experimental|Arm I (THL)|Patients receive trastuzumab 2 mg/kg IV over 30-90 minutes and paclitaxel 80 mg/m^2 IV over 1 hour once weekly and lapatinib ditosylate 750 mg PO once daily for 16 weeks in the absence of disease progression or unacceptable toxicity.
88870586|NCT00770809|Active Comparator|Arm II (TH)|Patients receive trastuzumab 2 mg/kg IV over 30-90 minutes and paclitaxel 80 mg/m^2 IV over 1 hour once weekly for 16 weeks in the absence of disease progression or unacceptable toxicity.
88870587|NCT00770809|Experimental|Arm III (TL)|Patients receive paclitaxel 80 mg/m^2 IV over 1 hour once weekly and lapatinib ditosylate 15000 mg PO once daily for 16 weeks in the absence of disease progression or unacceptable toxicity. (Discontinued as of 6-15-11)
88870588|NCT00392353|Experimental|Treatment (azacitidine, vorinostat)|Patients receive azacitidine SC QD on days 1-7 and vorinostat PO 2-3 times daily on days 3-5, 3-9, or 3-16. Treatment repeats every 28 days for at least 4 courses in the absence of disease progression or unacceptable toxicity.
88870589|NCT00390325|Experimental|Treatment (sorafenib tosylate)|Patients receive sorafenib tosylate PO BID in the absence of disease progression or unacceptable toxicity.
88870590|NCT00104676|Active Comparator|Arm I|Patients receive 4 courses of bleomycin, etoposide, and cisplatin (BEP).
88870591|NCT00104676|Experimental|Arm II|Patients receive 1 course of bleomycin, etoposide, and cisplatin (BEP). Patients then receive dose-dense sequential combination chemotherapy comprising cisplatin, etoposide, bleomycin, paclitaxel, oxaliplatin, and ifosfamide.
88870592|NCT01335750|Experimental|Multipurpose Solution #1|B&L Renu Fresh Multipurpose Solution
88870593|NCT01335750|Experimental|Multipurpose Solution #2|OptiFree Replenish Multipurpose Solution
88870594|NCT01335750|Experimental|Multipurpose Solution #3|Ciba ClearCare Multipurpose Solution
88870595|NCT01335750|Active Comparator|Multipurpose Solution #4|Saline Solution
88870596|NCT01336296|Active Comparator|Myfortic preload|Initiation of mycophenolic acid (Myfortic) 2 weeks prior to transplantation (with Simulect induction at time of transplant)
88870597|NCT01336296|Active Comparator|Myfortic standard|mycophenolic acid (Myfortic) at time of transplant with Thymoglobulin induction
88870598|NCT01337076|Other|cochlear implant|
88870599|NCT01337700|Experimental|Milnacipran|
89535447|NCT03322085|Experimental|paroxysmal AF with radiofrequency ablation|radiofrequency catheter ablation therapy
88870600|NCT01337700|Placebo Comparator|Placebo|
88870601|NCT01339260|Experimental|Netupitant and Palonosetron+dexamethasone-cycle 1|Oral netupitant/palonosetron (300 mg/0.50 mg) hard capsule with oral dexamethasone (12 mg), both given on Day 1, prior to each scheduled chemotherapy cycle
88870602|NCT01339260|Active Comparator|Palonosetron+dexamethasone-cycle 1|Oral palonosetron 0.50 mg (Aloxi) with oral dexamethasone (20 mg) both given on Day 1, prior to each scheduled chemotherapy cycle
88870603|NCT01339260|Experimental|Netupitant and Palonosetron+dexamethasone-multicycle extension|Oral netupitant/palonosetron (300 mg/0.50 mg) hard capsule with oral dexamethasone (12 mg), both given on Day 1, prior to each scheduled chemotherapy cycle
88870604|NCT01339260|Active Comparator|Palonosetron+dexamethasone-multicycle extension|Oral palonosetron 0.50 mg (Aloxi) with oral dexamethasone (20 mg) both given on Day 1, prior to each scheduled chemotherapy cycle
88870605|NCT01339416||HIV infected cohort|HIV infected patients in the HIV cohorts at the three participating hospitals
88870606|NCT01340586|Experimental|Group A: Apixaban|
88870607|NCT01340586|Experimental|Group B: Apixaban|
88870608|NCT01341912|Experimental|Human-cl rhFVIII|Recombinant FVIII derived from a human cell line.
88870609|NCT01342458|Experimental|Intervention Group|Daily use of the intervention Flexible footwear (Moleca®) for 6 months, for at least 42 hours/week (approximately 6 hours/day, 7 days/week). The Moleca® shoe (Calçados Beira Rio S.A., Novo Hamburgo, Rio Grande do Sul, Brazil) is a low-cost women's double canvas, flexible, flat, walking shoe without heels, with a 5-mm anti-slip rubber sole and a 3-mm flat insole of ethylene vinyl acetate that provides only protection but no correction. The mean weight of the shoe is 0.172±0.019 kg (range 0.091 to 0.182 kg), depending on size. This minimalist footwear is commonly worn by the elderly of all social classes and its average cost is US$ 6.25.
88870610|NCT01342458|No Intervention|Control Group|During the intervention period, patients from the Control Group (CG) were instructed not to wear Flexible footwear (Moleca®) or other similar minimalist footwear. During everyday activities, the CG group was only permitted to wear a standard, neutral tennis shoe. At the end of the intervention period, all CG participants also received one pair of Moleca® shoes at no cost.
88870611|NCT01342770|Experimental|Treatment (pioglitazone hydrochloride)|Patients receive pioglitazone hydrochloride PO QD for 14-42 days. Patients then undergo surgery.
88870612|NCT01343004|Placebo Comparator|Placebo|Placebo identical in appearance to BA058 study drug
88870613|NCT01343004|Experimental|BA058 80 mcg (abaloparatide)|
88870614|NCT01343004|Active Comparator|teriparatide|Blinded until after randomization, then open-label
88870615|NCT01343160|Other|GORE VIABIL® Biliary Endoprosthesis|Placement of GORE VIABIL® Biliary Endoprosthesis to establish duct patency
89394337|NCT02783768|Experimental|Sham first|Participants will undergo the sham exposure prior to the first two MRI measures, and then they will undergo the e-cigarette exposure prior to the last two MRI measures. The two MRIs performed under both experimental exposures (e-cigarette and sham) will be enhanced by (1) gadolinium and then (2) hyperpolarized 3-helium.
89394338|NCT02238522|Experimental|Dose Escalation Stage - ZEN003365|ZEN003365 will be administered orally as a single agent, enrolling LPM patients and AML patients
89394339|NCT02238522|Experimental|Dose Expansion Stage - ZEN003365|ZEN003365 will be administered orally as a single agent, enrolling LPM patients and AML patients
89394340|NCT03131687|Placebo Comparator|Placebo|Tirzepatide placebo and dulaglutide placebo administered subcutaneously (SC) once weekly.
89394341|NCT03131687|Experimental|1 mg Tirzepatide|1 milligrams (mg) tirzepatide administered SC once weekly. Dulaglutide placebo administered SC once weekly.
89394342|NCT03131687|Experimental|5 mg Tirzepatide|5 mg tirzepatide administered SC once weekly. Dulaglutide placebo administered SC once weekly.
89394343|NCT03131687|Experimental|10 mg Tirzepatide|10 mg tirzepatide administered SC once weekly. Dulaglutide placebo administered SC once weekly.
89394344|NCT03131687|Experimental|15 mg Tirzepatide|15 mg tirzepatide administered SC once weekly. Dulaglutide placebo administered SC once weekly.
89394345|NCT03131687|Active Comparator|1.5 mg Dulaglutide|1.5 mg Dulaglutide administered SC once weekly. Tirzepatide placebo administered SC once weekly.
89394346|NCT03579888|Experimental|Treatment (fludarabine, cyclophosphamide, CD19 T cell)|"CHEMOTHERAPY: Patients receive fludarabine IV over 1 hour and cyclophosphamide IV over 3 hours on days -5, -4, and -3 in the absence of disease progression or unacceptable toxicity.~T-CELL INFUSION: Patients receive autologous CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T cells IV over 15-30 minutes on day 0."
89394347|NCT05344027||ACC on mitotane|Individuals in this group were under care by the Endocrinology Team with a diagnosis of an ACC and on mitotane. These individuals were further divided into 3 groups, depending on whether they had a mitotane plasma concentration, within (14-20mg/L), above or below the therapeutic concentration range.
89394348|NCT05344027||Adrenal neoplasm without mitotane|Individuals within this category had an adrenal neoplasm and were not being treated with mitotane therapy.
89394349|NCT05344027||Pregnant group|Individuals did not have an adrenal neoplasm during this period, nor were they being treated with mitotane. These were healthy pregnant females, who were under the care at KCL during their pregnancy.
89394350|NCT05435144|Experimental|Intervention Arm|Participants will receive a 13-week supply of ElderCraft® (European black elderberry extract standardized to 15% anthocyanins). Each capsule contains 300mg of extract; participants will take a total of two capsules each day.
88870616|NCT01347060||Medicare-eligible subjects with asthma|Asthma subjects at least 65 years of age enrolled in a large Medicare managed care health plan.
88870617|NCT01351740|Experimental|Switch|switch to unboosted atazanavir 400mg daily with the same nucleoside (NRTI) backbone
88870618|NCT01351740|Active Comparator|Continuation|continue on current regimen of atazanavir/ritonavir 300mg/100mg with the same nucleoside (NRTI) backbone
89003761|NCT04580693||Hypertrophic Cardiomyopathy/HCM|HCM subjects are patients that are age and BSA-matched with the athletes who then have an established clinical diagnosis of HCM without left ventricular (LV) outflow tract obstruction. There can be no anticipated changes to baseline exercise program (if any) over the study period. HCM subjects must be able to exercise on an upright bicycle ergometer and be between the ages of 18-50.
89394351|NCT05435144|Placebo Comparator|Placebo Arm|Participants will receive a 13-week supply of inert placebo capsules matched for polysaccharide content. Participants will take a total of two capsules each day.
89394352|NCT05343247||Children with AI|
89394353|NCT05343247||Healthy controls with gender-age match|
89394354|NCT03586986||FDR with abnormal brain MRI|First degree relatives fulfilling lesions disseminated in space on MRI
89394355|NCT03586986||FDR with normal brain MRI|First degree relatives not fulfilling lesions disseminated in space on MRI
89394356|NCT03586986||Non-FDR|Age and sex-matched controls to FDRs noted above
89394357|NCT05430698|Experimental|PD-1antibody plus GEMOX|PD-1 antibody plus GEMOX was given as postoperative adjuvant therapy
89394358|NCT03585972|Experimental|Frailty Prevention Program|4 face-to-face sessions, with a licensed and registered occupational therapist over 4 months
89394359|NCT03585972|No Intervention|Educational materials|Participants receive publicly available educational materials
89394360|NCT03585894|Other|Sumatriptan|Sumatriptan 4 mg/mL I.V will be administrated over 10 min
89394361|NCT03585894|Active Comparator|Ketorolac|Ketorolac 30 mg/mL I.V will be administrated over 10 min
89394362|NCT04912921|Experimental|palmitoylethanolamide|Levagen
89394363|NCT04912921|Placebo Comparator|Placebo|microcrystalline cellulose
89394364|NCT04912921|Experimental|HydroCurc|curcumin
89394365|NCT04912921|Placebo Comparator|Control|microcrystalline cellulose
89394366|NCT03590808|Experimental|Immune checkpoint inhibitor|"Solid cancer patients who receiving immune checkpoint inhibitor patients~will be undergone Influenza vaccination using purified inactivated influenza virus antigen (Green Cross Corp.) 0.5 mL IM once"
89394367|NCT03590808|Active Comparator|Cytotoxic chemotherapy|"Solid cancer patients who receiving conventional cytotoxic chemotherapy~will be undergone Influenza vaccination using purified inactivated influenza virus antigen (Green Cross Corp.) 0.5 mL IM once"
89394368|NCT05420324|Experimental|Intervention/treatment|YH003 in combination with pebolizumab and albumin paclitaxel in first-line treatment of patients with unresectable/metastatic mucosal melanoma
89394369|NCT02238288|Active Comparator|aminocaproic acid|Crushed tablets inserted in the dental socket post-extraction
89394370|NCT02238288|Other|Routine care after dental extraction|Chompret´s manoeuver, suture, surgical wound compression with gauze for 20 minutes
89394371|NCT04901455|Experimental|COPD Frequent Exacerbators|Individuals with two or more episodes of worsening in COPD symptoms requiring treatment with antibiotics and/or steroids in the prior 12 months
88870619|NCT01352286|Experimental|Autologous Genetically modified T cells|Patients with advanced myeloma and who are candidates for autologous stem cell transplants, or syngeneic stem cell transplants (SSCT), will be eligible. Prior to full screening on this study, patients will undergo prescreening to evaluate HLA-A type and presence of NY-ESO-1c259T/LAGE antigen. Patients will undergo a steady-state mononuclear cell apheresis for T cell collection, with an optional second collection. Once mononuclear cells have been collected, patients (or donors in the case of SSCT) will then undergo hematopoietic stem cell mobilization. Patients will receive a dose >0.1-1 x 10¹º anti-CD3/anti-CD28-costimulated autologous T cells which have been genetically modified to express high affinity NY-ESO-1c259 TCRs.
89394372|NCT04901455|Experimental|COPD Infrequent Exacerbators|Individuals with less than two episodes of worsening in COPD symptoms requiring treatment with antibiotics and/or steroids in the prior 12 months
89394373|NCT04901455|Experimental|Healthy Control|Individuals with spirometry-confirmed normal lung function and no asthma history
89394374|NCT01364129|Experimental|Telemedicine|Participants in this group have digital images of their retina captured with a non-mydriatic camera and are encouraged to see an eye care provider yearly.
89394375|NCT01364129|No Intervention|Traditional Surveillance|Participants in this group are encouraged to see an eye care provider each year for a diabetic eye exam.
89394376|NCT01561040|Experimental|Omega 3, Vitamins A, D3 and E|Dry eye patients that have been screened with elevated osmolarity dispensed EZ Tears supplements containing Omega 3, Vitamins A, D3 and E to evaluate the change in dry eye conditions subjectively and objectively.
88870620|NCT01352442|Experimental|AcuFocus Corneal Inlay|The AcuFocus Corneal Inlay ACI 7000PDT, which is a small medical device, will be surgically implanted in one eye of each subject.
88870621|NCT01352598|Other|Stereotactic Body Radiotherapy|Patients will receive 30 - 40 Gy in 4 - 5 fractions. For high risk patients who also receive external beam radiotherapy, the SBRT will be given as 19 - 21 Gy in 2 - 3 fractions.
88870622|NCT01257438|Experimental|Fluency Plus Endovascular Stent Graft|Fluency Plus Endovascular Stent Graft
88870623|NCT01257438|Active Comparator|Percutaneous Transluminal Angioplasty|Percutaneous Transluminal Angioplasty only
88870624|NCT01353144|No Intervention|esomeprazole|esomeprazole (40 mg/day) for 8 weeks
88870625|NCT01353144|Active Comparator|esomeprazole plus aspirin|esomeprazole (40 mg/day) plus aspirin (100 mg/day) for 8 weeks
88870626|NCT01355484|Experimental|GTx-024|subject will receive GTx-024 treatment for the duration of the trial
88870627|NCT01355484|Placebo Comparator|Placebo|subject will receive placebo for the duration of the trial
88870628|NCT01355796|Experimental|Aerosolized Hypertonic xyltiol|Aerosolized xylitol (5 ml) twice daily for 14 days
88870629|NCT01355796|Active Comparator|Hypertonic saline|Aerosolized 7% hypertonic saline (4 ml) twice daily for 14 days
88870630|NCT01356498|Experimental|q2 RCT|Pegloticase every 2 wk arm of Randomized Controlled Trial(RCT), continued to receive pegloticase every 2 weeks (q2 wk) or every 4 weeks (q4 wk) in Open Label Extention (OLE) study
88870631|NCT01356498|Experimental|q4 RCT|Pegloticase every 4 wk arm of Randomized Controlled Trial (RCT), continued to receive pegloticase every 2 weeks (q2 wk) or every 4 weeks (q4 wk) in Open Label Extention (OLE) study
88870632|NCT01356498|Experimental|Placebo in RCT|Placebo arm in Randomized Controlled Trial (RCT), received pegloticase every 2 weeks (q2 wk) or every 4 weeks (q4 wk) in OLE
88870633|NCT01357356|Experimental|SER120 (750 ng/day)|SER120 (750 ng/day)
88870634|NCT01357356|Experimental|SER120 (1000 ng/day)|SER120 (1000 ng/day)
88870635|NCT01357356|Experimental|SER120 (1500 ng/day)|SER120 (1500 ng/day)
88870636|NCT01357356|Placebo Comparator|Placebo|Placebo
88870637|NCT01357512|Experimental|MRI done|Subjects with MRI prior prostate biopsies
89394377|NCT03590496|Active Comparator|Arm 1|31 patients will be treated with 500mg Calcium-Propionate capsules (twice a day) for 8 weeks.
89394378|NCT03590496|Placebo Comparator|Arm 2|31 patients will be treated with placebo capsules (twice a day) for 8 weeks.
89394379|NCT03914651|Active Comparator|300IU rFSH stimulation group|300IU rFSH stimulation group is defined as patients using gonadotropin-releasing hormone（GnRH）antagonist protocol with a 300IU rFSH Gonal-F® starting dose during controlled ovarian stimulation.
89394380|NCT03914651|Experimental|150IU rFSH stimulation group|150IU rFSH Gonal-F® stimulation group is defined as patients using GnRH antagonist protocol with a 150IU rFSH starting dose during controlled ovarian stimulation.
89394381|NCT03101293|Experimental|TAK-831 400 mg Fasted + TAK-831 400 mg Fed|TAK-831 400 mg, film-coated tablets, orally under fasted state, once on Day 1 of Intervention Period 1, followed by 7 days washout period, further followed by TAK-831 400 mg, film-coated tablets, orally under fed state, once on Day 1 of Intervention Period 2.
89394382|NCT03101293|Experimental|TAK-831 400 mg Fed + TAK-831 400 mg Fasted|TAK-831 400 mg, film-coated tablets, orally under fed state, once on Day 1 of Intervention Period 1, followed by 7 days washout period, further followed by TAK-831 400 mg, film-coated tablets, orally under fasted state, once on Day 1 of Intervention Period 2.
89394383|NCT01356953|Experimental|Aerobic Exercise|
89394384|NCT03590418||Intestinal stoma output|No interventions.
89394385|NCT03590418||Colonic feaces|No interventions.
89394386|NCT03590418||Healthy Control|No interventions.
89394387|NCT05577260|Experimental|Group D(dexemedetomidine group)|Patients receive 20 mL isobaric bupivacaine 0.25% + 1μg/kg Dexmedetomidine completed to 5ml with normal saline.
89394388|NCT05577260|Experimental|Group M: (magnesuim sulphate group)|Patients received 20ml isobaric bupivacaine 0.25% + 5 ml (500 mg) magnesium sulphate
89394389|NCT03590340|Experimental|Group 1a (PfSPZ Vaccine)|"Group 1a: subjects (n=21) will receive four doses of PfSPZ Vaccine (9.0 x 10^5 PfSPZ/dose) on Days 1, 3, 5, and 7 as a prime, followed by a boost of 9.0x10^5 PfSPZ Vaccine on Day 113.~Controlled human malaria infection (CHMI) with PfSPZ Challenge (NF54) will be administered 8 weeks after the last boost dose by DVI injection."
88870638|NCT01357512|No Intervention|no MRI|No MRI before prostate biopsies
88870639|NCT01362192|Other|532 nm KTP Laser Treatment|
88870640|NCT01362894|Other|nelfilcon A / etafilcon A|Nelfilcon A lenses worn first, with etafilcon A lenses worn second. Both products worn bilaterally on a daily wear, daily disposable basis for one week each.
88870641|NCT01362894|Other|etafilcon A / nelfilcon A|Etafilcon A lenses worn first, with nelfilcon A lenses worn second. Both products worn bilaterally on a daily wear, daily disposable basis for one week each.
88870642|NCT01363050|Experimental|Ketorolac tromethamine|
88870643|NCT01363128|Experimental|Treatment (hyper-CVAD, ofatumumab)|"COURSES 1, 3, 5, 7: Patients receive hyper-CVAD comprising cyclophosphamide IV over 3 hours every 12 hours on days 1-3; doxorubicin hydrochloride IV over 24 hours on day 4; vincristine sulfate IV over 15 minutes on days 4 and 11; and dexamethasone IV over 30 minutes or PO QD on days 1-4 and 11-14. Patients also receive ofatumumab IV over 4-6 hours on days 1 and 11 of courses 1 and 3.~COURSES 2, 4, 6, 8: Patients receive high-dose methotrexate IV over 2 hours and then over 22 hours on day 1 and cytarabine IV over 2 hours every 12 hours on days 2-3. Patients also receive ofatumumab IV over 4-6 hours on days 1 and 8 of courses 2 and 4.~Treatment repeats every 21-28 days for 8 courses in the absence of disease progression or unacceptable toxicity. Patients may receive maintenance therapy for an additional 30 months."
88870644|NCT01365624|Experimental|Ketorolac tromethamine|
88870645|NCT01367262|Experimental|Radiolabeled LY2886721|Single 25 milligram (mg) oral dose containing 80 microCuries of radiolabeled LY2886721
88870646|NCT01369758|Experimental|Intrauterine pathology, myomectomy|Subjects with intrauterine fibroids and/or polyps will undergo intrauterine pathology removal using the MyoSure Tissue Removal System; myomectomy procedure.
88870647|NCT01371786|Experimental|ciclesonide nasal aerosol|A radiolabeled solution of ciclesonide nasal aerosol supplied in a 37 μg/actuation canister followed by a washout period of 120 hours and a radiolabeled suspension of mometasone Aqueous (AQ) nasal spray supplied in a 50 μg/actuation bottle
88870648|NCT01371786|Active Comparator|mometasone|A radiolabeled suspension of mometasone Aqueous (AQ) nasal spray supplied in a 50 μg/actuation bottle followed by a washout period of 120 hours and a radiolabeled solution of ciclesonide nasal aerosol supplied in a 37 μg/actuation canister
88870649|NCT01373580|Experimental|Raindrop|A single-arm study to evaluate the effectiveness of a 2 mm corneal inlay (Raindrop Near Vision Inlay) for the treatment of presbyopia (age-related near vision loss). The anterior curvature of the cornea is re-shaped after implanting the Raindrop Near Vision Inlay in the non-dominant eye under a femtosecond laser flap to improve near vision.
88870650|NCT01374438|Experimental|MSDC-0160 capsules|MSDC tablets contained in #00 capsules
88870651|NCT01374438|Placebo Comparator|Placebo capsules|Placebo tablets contained in #00 capsules
89394390|NCT03590340|Experimental|Group 2a (PfSPZ Vaccine)|"Group 2a: subjects (n=21) will receive four doses of PfSPZ Vaccine (9.0 x 10^5 PfSPZ/dose) on Days 1, 3, 5, and 7 as a prime.~CHMI with PfSPZ Challenge (NF54) will be administered 8 weeks after the last prime dose by DVI injection."
89535448|NCT03322085|Experimental|persistent AF with radiofrequency ablation group|radiofrequency catheter ablation therapy
88870652|NCT01377402||Chest pain|Men and women admitted with chest pain and suspected acute coronary syndrome (ACS).
88870653|NCT01377636|Experimental|Isoproterenol, BIS, forearm test|30 consecutive patients scheduled for EP studies under general anesthesia will participate in the study. Patients with neuromuscular disease precluding the use of succinylcholine will be excluded. The only other exclusions will be patient or cardiologist refusal. No attempts will be made to alter concurrent patient medication.
89535449|NCT03322085|Experimental|paroxysmal AF with cryoballoon group|cryoballoon ablation therapy
89535450|NCT05018715||coronary heart disease|A total of 300 patients with CHD WHO were hospitalized in the First Affiliated Hospital of Xinjiang Medical University from August 2021 to February 2022 were selected, all of whom met the DIAGNOSTIC criteria of CHD formulated by the World Health Organization (WHO) and excluded diseases such as highly severe valvular disease and congenital heart disease
88870654|NCT01378416|Experimental|1|
88870655|NCT01379664|Experimental|Isoflurane|Isoflurane is to be administered to patients in this arm during surgery
88870656|NCT01379664|Experimental|Sevoflurane|Sevoflurane is to be administered to patients in this arm during surgery
88870657|NCT01380366|Other|Patients consent to rHGH study|Patients consent to be given growth hormone (rHGH) for their short bowel syndrome.
88870658|NCT01383720|Experimental|Lotus Valve System|Patients enrolled in the study to receive treatment with the Lotus Valve System for symptomatic aortic valve stenosis
88870659|NCT01386528|Experimental|Patients enrolled in trial|New patients will be included as well as transferred patients from Paradigm™ 2 or Paradigm™ 4 trial
88870660|NCT01387464|Experimental|ISV-303|
88870661|NCT01387464|Active Comparator|Bromday™|
88870662|NCT01388946|Active Comparator|Ropivacaine 0.75|Continuous infusion of ropivacaine 7.5 mg/ml, 2 ml/h for 24 hours
88870663|NCT01388946|Placebo Comparator|Normal saline|Continuous infusion of normal saline 2 ml/h for 24 hours
88870664|NCT01390818|Experimental|MSC1936369B and SAR245409 once daily|
88870665|NCT01390818|Experimental|MSC1936369B and SAR245409 twice daily|
88870666|NCT01391286|Experimental|bimatoprost solution 0.03%|One drop of bimatoprost solution 0.03% applied along each upper eyelid margin once daily in the evening for 4 months.
88870667|NCT01391286|Placebo Comparator|bimatoprost vehicle solution|One drop of bimatoprost vehicle solution applied along each upper eyelid margin once daily in the evening for 4 months.
89394391|NCT03590340|Experimental|Group 3a (PfSPZ Vaccine)|"Group 3a: subjects (n=21) will receive four doses of PfSPZ Vaccine (9.0 x 10^5 PfSPZ/dose) on Days 1, 3, 5, and 7 as a prime, followed by a boost of 9.0x10^5 PfSPZ Vaccine on Day 29.~CHMI with PfSPZ Challenge (NF54) will be administered 8 weeks after the last boost dose by DVI injection."
89394392|NCT03590340|Experimental|Group 4a (PfSPZ Vaccine)|"Group 4a: subjects (n=21) will receive two doses of PfSPZ Vaccine (9.0 x 10^5 PfSPZ/dose) on Days 1 and 8 as a prime, followed by a boost of 9.0x10^5 PfSPZ Vaccine on Day 29.~CHMI with PfSPZ Challenge (NF54) will be administered 8 weeks after the last boost dose by DVI injection."
88870668|NCT01391364|Experimental|SofLens in investigational solution|Bausch + Lomb SofLens daily disposable contact lens packaged in an investigational storage solution.
88870669|NCT01391364|Active Comparator|SofLens in currently marketed solution|SofLens daily disposable contact lens packaged in currently marketed storage solution.
88870670|NCT01393392|Experimental|Intensive, tailored intervention|Participants in the intensive intervention condition will receive eight individual counseling sessions, with a smoking cessation counselor, over three months. Each session will last approximately 45 minutes and occur in the methadone clinic. Participant treatment needs will be assessed during the first session and the intervention will be tailored to the participants' needs. Prior to quitting participants will receive nicotine replacement patches and lozenges and instructions on how to use them.
88870671|NCT01393392|Active Comparator|Control Intervention|Participants randomized to the control intervention will receive a referral to the NJ Quitline (a telephone smoking cessation counseling service). Participants will receive a brochure and information about the referral. Study staff will contact the NJ Quitline for control participants, and a counselor from the Quitline will call control participants.
88870672|NCT01393704|Active Comparator|High Volume Dilute Vasopressin|20 units Vasopressin diluted in 400 mL of Saline, inject 200 mL total of the dilute Vasopressin solution in subserosal location overlying fibroid (total 10 units Vasopressin used).
88870673|NCT01393704|Active Comparator|Low volume dilute vasopressin|20 units Vasopressin diluted in 60 mL of Normal Saline, inject 30 mL total of the dilute Vasopressin solution in subserosal location overlying fibroid (total 10 units Vasopressin used).
88870674|NCT01395966|Active Comparator|DF289|Ear drops
88870675|NCT01395966|Active Comparator|DF277|Ear drops
88870676|NCT01395966|Experimental|DF289 plus DF277|Ear drops
88870677|NCT01396044|Experimental|Electronic checklist|Electronic checklist
88870678|NCT01396044|Experimental|Verbal prompting|Verbal prompting with written checklist
88870679|NCT01399008|Experimental|Arhalofenate 400 mg|Arhalofenate 400 mg plus allopurinol 300 mg
88870680|NCT01399008|Experimental|Arhalofenate 600 mg|Arhalofenate 600 mg plus allopurinol 300 mg
88870681|NCT01399008|Active Comparator|Allopurinol|Placebo plus Allopurinol 300 mg
88870682|NCT01399866|Placebo Comparator|Placebo|50 mg capsule,single dose, twice, one week apart, by mouth
88870683|NCT01399866|Active Comparator|D-cycloserine|50 mg capsule,single dose, twice, one week apart, by mouth
88870684|NCT01400880||Pregnant|In Labor
88870685|NCT01401582|No Intervention|care as usual|care as usual, no intervention, just observation of natural change/ trajectories over time
88870686|NCT01401582|Experimental|Implementation of Dementia Care Manager|"Subjects in this arm will be provided with a specialised Dementia Care Manager to be included in a subsidiary support system"
88870687|NCT01402050|Active Comparator|FOLEY BALLOON|Comparing foley balloon to cervidil for decreased time from the start of the induction process to delivery
88870688|NCT01402050|Active Comparator|CERVIDIL|
88870689|NCT01402128|Experimental|Barley beta-glucan(3.0g)|Barley beta-glucan(3.0g/day) for 12 weeks
88870690|NCT01402128|Placebo Comparator|Placebo|Placebo for 12 weeks
88870691|NCT01403376|Experimental|Teriflunomide 7 mg|Influenza vaccine in participants treated with teriflunomide 7 mg for at least 6 months
88870692|NCT01403376|Experimental|Teriflunomide 14 mg|Influenza vaccine in participants treated with teriflunomide 14 mg for at least 6 months
88870693|NCT01403376|Active Comparator|IFN-β-1|Influenza vaccine in participants treated with a stable dose of Interferon-β-1 (IFN-β-1) for at least 6 months
88870694|NCT01404078|Active Comparator|SD Polycap without potassium|Single dose polycap without pottasium
88870695|NCT01404078|Experimental|DD Polycap plus potassium|Double Dose polycap with potassium
88870696|NCT01404936|Experimental|Interferon-2A + Chemotherapy|Interferon-2A 4 (x106 IU/m^2) subcutaneously Day 1 - 4 + ABVD Chemotherapy on Day 4 (ABVD: Adriamycin 25 mg/m2 intravenous (IV), Bleomycin 10 mg/m^2 IV, Velban 6 mg/m2 IV, and Dacarbazine 375 mg/m2 IV)
88870697|NCT01405794|Experimental|32ppm Oral Silver|14 Days Active Silver Solution
88870698|NCT01405794|Placebo Comparator|Sterile Water|No Silver Nanoparticles
88870699|NCT01408992|Experimental|FMHT|All community people will be interviewed with Thai Five Minute Hearing Test questionnaire and will be tested with an audiometry.
88870700|NCT01410084|Experimental|Vitamin D3|100,000 IU vitamin D3 once monthly
88870701|NCT01410084|Placebo Comparator|Vitamin E|400 IU vitamin E once monthly
88870702|NCT01410552|Other|ICD or CRT-D with PARAD+|only 1 arm is the study: all patients implanted with ICD or CRT-D with PARAD+ enabled, no comparator
88870703|NCT01411488|Experimental|Fecal Management System- Company 1|80 adult patients to be randomly assigned to receive a fecal management system by Bard Medical
88870704|NCT01411488|Active Comparator|Fecal Management System- Company 2|80 adult patients to be randomly assigned to receive a fecal management system by ConvaTec
88870705|NCT01413750|Experimental|Arm I (paclitaxel, carboplatin, vorinostat)|Patients receive paclitaxel IV over 3 hours, and carboplatin IV over 30 minutes on day 0. Patients also receive vorinostat PO once daily on days -2 to 2.
88870706|NCT01413750|Active Comparator|Arm II (paclitaxel, carboplatin, placebo)|Patients receive paclitaxel and carboplatin as in arm I. Patients also receive placebo PO once daily on days -2 to 2.
88870707|NCT01415232|Experimental|Ultrasound measurement|Ultrasound using the Sonosite S-Nerve® US system (SonoSite, Bothell,WA) to measure depth to epidural space in morbidly obese parturients.
89394393|NCT03590340|Placebo Comparator|Group 1b (NS)|"Group 1b: subjects (n=5) will receive normal saline (NS) placebo on Days 1, 3, 5, 7, and 113.~CHMI with PfSPZ Challenge (NF54) will be administered 8 weeks after the last immunization by DVI."
89394394|NCT03590340|Placebo Comparator|Group 2b (NS)|"Group 2b: subjects (n=5) will receive NS placebo on Days 1, 3, 5, and 7.~CHMI with PfSPZ Challenge (NF54) will be administered 8 weeks after the last immunization by DVI."
89394395|NCT03590340|Placebo Comparator|Group 3b (NS)|"Group 3b: subjects (n=5) will receive NS placebo on Days 1, 3, 5, 7, and 29.~CHMI with PfSPZ Challenge (NF54) will be administered 8 weeks after the last immunization by DVI."
89394396|NCT03590340|Placebo Comparator|Group 4b (NS)|"Group 4b: subjects (n=5) will receive NS placebo on Days 1 and 8.~CHMI with PfSPZ Challenge (NF54) will be administered 8 weeks after the last immunization by DVI."
89394397|NCT01357031|Experimental|Melatonin|Melatonin 3 mg at bedtime
89394398|NCT01357031|Placebo Comparator|Placebo|Placebo
89394399|NCT01357031|Active Comparator|Amitriptyline|Amitriptyline 25 mg
89394400|NCT05577104|Experimental|the NPWT group|For patients in the NPWT group, the wound bed preparation was facilitated by VAC device.
89394401|NCT05577104|Active Comparator|the control group|For patients in the control group, the wound bed preparation was facilitated by alginates dressing change method.
89394402|NCT01357109|Experimental|Bosentan|
89394403|NCT01357109|Placebo Comparator|Placebo|
89394404|NCT04808492|Experimental|CureWave High Intensity Laser|The participant will lie prone and the HILT will be administered in two preliminary test locations. In order to evaluate any possible adverse reactions, the initial treatment location will be delivered at a decreased intensity at two separate locations above the target treatment areas. The Power for these two locations will be at a half dose (22 W) for one minute each. The initial, half dose treatment area is indicated by the Blue circles in the image below. Upon conclusion of the initial test treatments (at half dose), the skin with be evaluated for excessive redness or any other changes in skin appearance. Also, the participant will be asked about any discomfort. Should no unanticipated changes in skin appearance occur and the participant reports no discomfort, the treatment will be administered. The process of applying the laser at half dosage will occur prior to each treatment.
89394405|NCT04808492|Placebo Comparator|Control|The participant will lie prone and the Placebo HILT will be administered is the same capacity as the treatment group however no Laser treatment will be administered. Upon conclusion of the placebo treatment, the skin with be evaluated for excessive redness or any other changes in skin appearance. Also, the participant will be asked about any discomfort.
89394406|NCT03896399|Experimental|Laparoscopic ischemic conditioning followed by esophagectomy|All included patients will receive a laparoscopic ischemic conditioning followed by an esophagectomy after an interval of 12-18 days.
89394407|NCT02850978||Spiolto|Patient with COPD to received Spiolto
89394408|NCT02253446|Experimental|Piroksikam|20 mg of piroxicam (feldene ampoule -Pfizer-France) intramuscularly (IM) was given 200 patients,
89394409|NCT02253446|Experimental|Diclofenac Sodium|Second Group: Diclofenac sodium 75mg (Miyadren drug-ampoule -Yavuz Istanbul) intramuscularly (IM) was given 200 patients.
89394410|NCT03589170||People over 60 years of age|People over 60 years of age without previous known atrial fibrillation
89394411|NCT05417893|Active Comparator|Cohort-1: MeRes 100 BRS|1248 subjects will be delivered with MeRes 100 BRS
89394412|NCT05417893|Active Comparator|Cohort- 2: Contemporary DES platforms|624 subjects will be delivered with Contemporary DES
89394413|NCT03135431|Experimental|Salpingectomy|Bilateral salpingectomy following cesarean delivery
89394414|NCT03135431|Active Comparator|Tubal Ligation|Bilateral tubal ligation following cesarean delivery via Parkland or modified Pomeroy methods.
89394415|NCT03546452||malignant NSCLC hydrothorax|cell free DNA ,which is purified from malignant NSCLC hydrothorax, tested by in vitro NGS-panel
88870708|NCT01415934|No Intervention|Continue Statins|Participant will continue on statins as per usual
88870709|NCT01415934|Experimental|Discontinue statins|Participant will stop taking their statin drugs
88870710|NCT01417026|Active Comparator|Intranasal Oxytocin|"Intranasal oxytocin (Trade name: Syntocinon)~Pharmacological class: The pharmacologic and clinical properties of Syntocinon are identical with the naturally occurring hormone oxytocin, which is released from the posterior pituitary.~Route of administration: Intranasal~Planned exposure: Each participant will receive one dose of intranasal oxytocin (24 IU) per day for 5 days.~One dose of 24 IU equals 6 spray puffs (3 puffs in each nostril).~Oxytocin will be imported from Victoria Pharmacy Zurich- Switzerland."
88870711|NCT01417026|Placebo Comparator|Intranasal Placebo|"Intranasal placebo~The placebo is identical to the oxytocin formulation with the exception of the active compound.~Route of administration: Intranasal~Planned exposure: Each participant will receive one dose of intranasal placebo per day for 5 days.~One dose equals 6 spray puffs (3 puffs in each nostril).~Placebo will be imported from Victoria Pharmacy Zurich- Switzerland."
88870712|NCT01420146|Experimental|Zr89-trastuzumab PET/CT|Zr89-trastuzumab PET/CT single arm
89394416|NCT03585348||Study cohort|The estimated cohort consists of 317.000 adult patients who are intubated for a non-cardiac surgery and extubated at the end of the case at Beth Israel Deaconess Medical Center (205.000) as well as Massachusetts General Hospital (112.000) and received treatment by anesthesia and surgical providers who have completed at least 50 anesthesias and surgeries at their respective institution, respectively.
89394417|NCT03579810|Experimental|Investigational|"An education intervention was implemented in 5 schools including 516 children, 360 parents and 240 teachers.~The Pedagogical Intervention last two and a half years. In children, the intervention included class activities (1/week) and the use of educational materials for the development of pedagogical activities (posters and educative guide).~In parents included 3 workshops/year (2 hours each) about the areas of the intervention; sending healthy notes (1/month) and celebration of healthy family day (1/year).~In teachers included 3 workshops/year (2 hours each) about the areas of the intervention; planning and realization of pedagogical activities to develop with the students (1/week) and follow-up visits to school (1/month)."
89394418|NCT03579810|Active Comparator|Control|"The control group consisted of 4 schools including 354 children, 305 parents and 110 teachers.~The activities in control group last two and a half years. Children received the standard curriculum in health and physical activity of the national Ministry of Education.~In parents and teachers included 3 workshops/year (2 hours each) about the first aid and accident prevention."
89394419|NCT03556085|Experimental|Venous sinus stenting|Subjects will have stenting of the transverse-sigmoid sinus
89394420|NCT03767634||Neonatal population (Project A)|Neonates born between 1st January 2012 and 31st December 2017 and admitted to a neonatal unit in England, Scotland and Wales).
89535451|NCT05018715||Healthy person|.A total of 300 healthy subjects from the First Affiliated Hospital of Xinjiang Medical University during the same period were selected as controls.
88870713|NCT01420848|Active Comparator|Auriculotherapy Group|"The chinese auriculotherapy is a intervention used by Chinese Traditional Medicine in order to balance the body energy and to treat several kind of diseases using semi-permanent needles in specific points of the auricular pavilion.~Two points were chosen to treat stress and anxiety (Shenmen and Brainstem)."
88870714|NCT01420848|Placebo Comparator|Placebo Group|Auriculotherapy by sham, at the fist and outer ear points. These points aren't indicated for stress and anxiety.
88870715|NCT01420848|No Intervention|Control Group|Control Group didn't receive any treatment and was evaluated at the same time and the same way of interventions group
88870716|NCT01421472|Experimental|MM-121 (SAR256212) + paclitaxel|2 week run-in of MM-121 followed by MM-121 + dosing of paclitaxel IV, followed by standard dosing of doxorubicin IV plus cyclophosphamide IV, followed by surgery.
88870717|NCT01421472|Active Comparator|Paclitaxel only|Standard dosing of paclitaxel IV, followed by standard dosing of doxorubicin IV plus cyclophosphamide IV, followed by surgery.
88870718|NCT01426230||Open Label|"Cohort by age-~- Patients >70 Yrs old"
88870719|NCT01426230||Open label|"Cohort by age-~- Patients < 70 Yrs old"
88870720|NCT01428336|Active Comparator|Patients|Subjects will undergo three ACTH stimulation test using a dose of 1 ug cotrosyn, 25 ug cortrosyn, 250ug cortrosyn and one Insulin tolerance test
88870721|NCT01428336|Active Comparator|Volunteers|Subjects will undergo three ACTH stimulation test using a dose of 1 ug cotrosyn, 25 ug cortrosyn, 250ug cortrosyn and one Insulin tolerance test
88870722|NCT01429272|Placebo Comparator|Placebo & Placebo|Placebo for minocycline & placebo for aspirin
88870723|NCT01429272|Active Comparator|minocycline & aspirin|Minocycline 100mg PO BID for 6 weeks & Aspirin 81 mg PO BID for 6 weeks
89187474|NCT00673257|Experimental|Pharmacokinetics of Daunorubicin chemotherapy patients|Patients receiving a chemotherapy regimen including daunorubicin hydrochloride administered as an infusion of any duration < 24 hours on a 1 or a 2 day schedule. Pre-study evaluations no greater than 14 days prior to daunomycin administration. If patients have had significant intercurrent illness or treatment that might affect organ function, laboratory work should be performed at an appropriately closer interval to daunomycin administration. A complete history and physical examination including height, weight and body surface area. Patients should be weighed with only light clothing; shoes must be removed before weight is measured. Patients height should be measured using a stadiometer after removing shoes. Laboratory evaluation: a) CBC with differential and platelet count. b) ALT, AST, bilirubin, creatinine, total protein, albumin, alkaline phosphatase, GGT.
89187475|NCT02582060|Other|Severe Hemophilia A Subjects|The results of the TEG/ROTEM assay (specifically the R time/CT) will be used to determine the prophylaxis treatment regimen.
89187476|NCT04344392|Other|Dysphagic hemiplegic patients|Dysphagic patients with hemiplegia as assessed by clinical examination
89187477|NCT04344392|Other|Control|Volunteers which do not have an active swallowing dysfunction.
89187478|NCT02557269|Active Comparator|Group HPMC|Hydroxyl-propyl-methyl-cellulose (HPMC) powder added immediately after other intranasal treatment options
89187479|NCT02557269|Placebo Comparator|Group Placebo|Lactose powder (placebo) added immediately after other intranasal treatment options
89187480|NCT02557269|Other|Group Immunotherapy|Immunotherapy group with grass allergens sublingually (Staloral #688) and rescue medication
89187481|NCT02581358|Experimental|Scolioscan (Ultrasound imaging system)|This diagnostic study is a single arm study with all participants receiving investigation with the Scolioscan (a diagnostic ultrasound machine) for quantitative assessment of spinal deformity
89187482|NCT00771771|Active Comparator|Day unit rehabilitation|Discharge from the hospital to the patients' homes as soon as possible, supported by an out-patient ambulatory coordinating multidisciplinary team. The patients will be offered rehabilitation in a day unit, and multidisciplinary policlinical follow-ups will be performed 3 and 6 months after inclusion.
89187483|NCT00771771|Active Comparator|Home rehabilitation|Discharge from the hospital to the patients' homes as soon as possible, supported by an out-patient ambulatory coordinating multidisciplinary team. The patients will be offered rehabilitation treatment in their homes, and multidisciplinary policlinical follow-ups will be performed 3 and 6 months after inclusion.
89187484|NCT00771771|No Intervention|Treatment as usual|Patients will receive rehabilitation treatment after today's principles and routines.
89187485|NCT00772083|Experimental|1|
89535452|NCT03206515|Other|Group 1|Patients in Group 1 undergo Mini Percutaneous Nephrolithotomy with The 18F peel-way sheath group
88870724|NCT01429350|Active Comparator|IV rtPA|IV infusion of rtPA at 0.9mg/kg to a maximum of 90mg
88870725|NCT01429350|Experimental|IV rtPA and IA Penumbra System|Dual IV rtPA therapy (0.9mg/kg to a maximum of 90mg) and IA adjunctive treatment with the Penumbra System
88870726|NCT01431300|Active Comparator|0.03 mmol/kg|FDA-approved dose for lower extremity arterial imaging
88870727|NCT01431300|Experimental|0.02 mmol/kg|
88870728|NCT01431300|Experimental|0.01 mmol/kg|
88870729|NCT01431846|No Intervention|Discharge Patient|Eight patients who were being discharged from Denver VA Medical Center for cardiac care to their primary care providers were recruited at the time of discharge and completed an interview two weeks following their discharge. Patients were asked to describe their transition to home and identify barriers and facilitators of this process, their understanding of their medical condition, new medications prescribed, timeliness of follow-up visit with their PCP and knowledge of signs/symptoms in which they should seek medical attention.
89187486|NCT00772083|Active Comparator|2|standard approach currently being used
89187487|NCT00779181|Experimental|ADX415 (high dose)|A high dose of ADX415
89187488|NCT00779181|Experimental|ADX415 (mid level dose)|A mid level dose of ADX415
89187489|NCT00779181|Experimental|ADX415 (low dose)|A low dose of ADX415
89187490|NCT00779181|Placebo Comparator|Placebo|
89187491|NCT00779337|Experimental|Single group study|Autologous AdE1- Latent Membrane Protein (LMP) Cytotoxic T Lymphocytes.
89187492|NCT02556411|Active Comparator|LNG-IUS|LNG-IUS 13,5 mg di Levonorgestrel
89187493|NCT02556411|Experimental|combined oral contraceptive plus LNG-IUS|Levonorgestrel 0,10 mg+ ethinylestradiol 0,02 mg+ LNG-IUS 13,5 mg di Levonorgestrel
89187494|NCT04085276|Experimental|JS001 Plus Nab-Paclitaxel|Patients will receive both JS001 and Nab-Paclitaxel.
89535453|NCT03206515|Other|Group 2|Patients in Group 2 undergo Mini Percutaneous Nephrolithotomy with The 18F access sheath with a suction-evacuation function group
89187495|NCT04085276|Placebo Comparator|Placebo Plus Nab-Paclitaxel|Patients will receive both placebo and Nab-Paclitaxel.
89394421|NCT03767634||No PN use (Project B)|All neonates born between 30 and 33 weeks postmenstrual age in England, Wales and Scotland and admitted to a NHS neonatal unit between 1st January 2012 and 31st December 2017 who did not receive any parenteral nutrition (for any duration, by any intravenous route) in the first seven postnatal days.
89394422|NCT03767634||PN use (Project B)|All neonates born between 30 and 33 weeks postmenstrual age in England, Wales and Scotland and admitted to a NHS neonatal unit between 1st January 2012 and 31st December 2017 who received any parenteral nutrition (for any duration, by any intravenous route) in the first seven postnatal days.
89394423|NCT01563224|Experimental|single group, crossover, 3 interventions|
89394424|NCT01361243|Experimental|NOURISH+|Participants will receive a 6-week face-to-face intervention, NOURISH+. Weekly topics teach parents skills to role model and encourage healthy lifestyle behaviors for their children.
89394425|NCT01361243|Placebo Comparator|Wellness Group|"Participants will receive an in-person Family Wellness Night followed by 6 mailings of information regarding pediatric overweight and obesity."
89394426|NCT03632629|Active Comparator|study group|3 months of individualized interactive cognitive training, 2 times per week, 15 min per session, a total of 24 sessions, in addition to traditional rehabilitation programs.
89394427|NCT03632629|No Intervention|control group|3 months of traditional rehabilitation programs, without individualized interactive cognitive training.
89394428|NCT05576870|Experimental|Plant based toddler nutrition|Plant based toddler nutrition based on almond and buckwheat drink
89394429|NCT05576870|Active Comparator|Dairy based toddler nutrition|Commercially available dairy based toddler nutrition drink
89394430|NCT01369979||Patients with chronic liver disease|"Inclusion criteria~Age between 40 and 70 years~BMI between 20 and 26~Exclusion Criteria~Diabetes mellitus~Glucose intolerance~Medical treatment of portal hypertension~People who have undergone surgery for obesity~Pregnancy"
89394431|NCT01369979||Healthy subjects|"Inclusion criteria~Age between 40 and 70 years~BMI between 20 and 26~Exclusion Criteria~Diabetes mellitus~Glucose intolerance~Medical treatment of portal hypertension~People who have undergone surgery for obesity~Pregnancy"
89394432|NCT03577860|Active Comparator|Bupivacaine 4ml|The interscalene brachial plexus block is performed with 4ml at level of C5-6 roots
89394433|NCT03577860|Active Comparator|Bupivacaine 15ml|The interscalene brachial plexus block is performed with 15ml at level of C5-6
89394434|NCT03548168||Healthy Adults|Eligible healthy young adults, aged 18-30 years, will participate in testing experiments to test-retest reliability of the muscle functional magnetic resonance imaging (mfMRI) and functional magnetic resonance imaging (fMRI) techniques that were developed in order to study the neural control of trunk muscles.
89394435|NCT03548168||Low Back Pain|Eligible young adults, aged 18-30 years, with chronic low back pain will participate in testing experiments to test-retest reliability of the muscle functional magnetic resonance imaging (mfMRI) and functional magnetic resonance imaging (fMRI) techniques that were developed in order to study the neural control of trunk muscles.
89394436|NCT03548168||Older Adults|Eligible healthy middle aged and older adults, aged 55 years and older, will participate in testing experiments to test-retest reliability of the muscle functional magnetic resonance imaging (mfMRI) and functional magnetic resonance imaging (fMRI) techniques that were developed in order to study the neural control of trunk muscles.
89394437|NCT03548168||Trunk Experts|Eligible healthy middle aged and older adults, aged 55 years and older, with high levels of trunk muscle control (ie. individuals with expertise in the Pilates Method of exercise) will participate in testing experiments to test-retest reliability of the muscle functional magnetic resonance imaging (mfMRI) and functional magnetic resonance imaging (fMRI) techniques that were developed in order to study the neural control of trunk muscles.
89394438|NCT03547661|No Intervention|Treatment as Usual|The treatment as usual (TAU) group will control for regression to the mean, spontaneous remission, natural course of disease, and the participants-provider interaction. Participants of the TAU group are allowed to continue their usual medication intake, given they are already on a stable dose (at least 30 days of intake) and the medication is not listed in the exclusion criteria.
89394439|NCT03547661|Active Comparator|Integrative Open-Label Placebo|"The intervention will encompass an integrative administration of P-Dragees rosa Lichtenstein, which are pink placebo dragées without any active ingredient. Each dragée contents the following substances: lactose monohydrate; magnesium stearate (Ph. Eur.); microcrystalline cellulose; highly dispersed silicon dioxide; white clay, macrogol glycerolhydroxy stearate (Ph. Eur.); Arabic gum; montanglycol wax; povidone (K 25); talcum; titanium dioxide (E 171); erythrosine; aluminium salt (E 127); calcium carbonate; sucrose; glucose syrup; maize starch; macrogol 6000.~All participants will be informed that the administered dragées are placebo dragées and participants will be instructed to take two dragées a day for six weeks. (Amendment regarding dosage since 08/18)"
89394440|NCT03547661|Active Comparator|Open-Label Placebo|"The intervention will encompass an administration of P-Dragees rosa Lichtenstein, which are pink placebo dragées without any active ingredient. Each dragée contents the following substances: lactose monohydrate; magnesium stearate (Ph. Eur.); microcrystalline cellulose; highly dispersed silicon dioxide; white clay, macrogol glycerolhydroxy stearate (Ph. Eur.); Arabic gum; montanglycol wax; povidone (K 25); talcum; titanium dioxide (E 171); erythrosine; aluminium salt (E 127); calcium carbonate; sucrose; glucose syrup; maize starch; macrogol 6000.~All participants will be informed that the administered dragées are placebo dragées and participants will be instructed to take two dragées a day for six weeks. (Amendment regarding dosage since 08/18)"
89535454|NCT03318731|Placebo Comparator|Sugar Pill|Maltodextrin (matches the weight of the active treatment). Taken 1-hour prior to workout on training days and each day of overreaching week. On rest days, will consume in the morning with breakfast.
89187496|NCT00775827|Experimental|1|fenofibrate 160 mg tablets of Ranbaxy Laboratories
89187497|NCT00775827|Active Comparator|2|Tricor 160 mg tablets
89187498|NCT02580032||Child Treatment Naïve group (Group A)|Pre-pubertal boy or girl, ages of 9 to 13 years with a confirmed diagnosis of GHD prior to enrolment as determined by one GH stimulation test, defined as a peak GH level of equal or below 7.0 ng/ml.
88870730|NCT01431846|No Intervention|Providers|Three providers who refer patients to the Denver VA Medical Center for cardiac care were interviewed to identify barriers and facilitators from their perspective of following-up with patients after their hospitalization at Denver VAMC. Additionally, the same information was asked of providers who participated in two focus groups in the Grand Junction VA.
88870731|NCT01431846|Experimental|Intervention|Informed by the interviews and best practices from the literature, pilot test the transitions of care intervention that targets patients and providers to evaluate the feasibility of the intervention to improve process of care measures, including: 1) PCP follow-up within 2-4 weeks of hospital discharge; 2) medications reconciled between pre and post-hospital discharge; 3) discharge summary available to PCP at time of visit; and 4) patient awareness of symptoms that require medical attention
88870732|NCT01432236|Experimental|Pregabalin|Group 1 as Pregabalin vs. Placebo (cross over study in which period one has this group)
88870733|NCT01432236|Placebo Comparator|Placebo|Group 2 as placebo vs. pregabalin (cross over study in which period two will have this group)
88870734|NCT01434030|Other|Behavioral Observer|Focus group methodology was chosen to obtain qualitative and quantitative data on participants' desire to use glucose advisory systems to manage their diabetes, their concerns about and desired features and functions of these systems, and their perceived confidence with behavioral event recording. At the outset of each interview, the personalized glucose advisory system (PGASystem) was described to participants as a system composed of a continuous glucose monitor (CGM) device and insulin pump, into which they would input daily information about their insulin, food, and physical activity. The system would then use their data to create personalized algorithms and advice about various aspects of their diabetes management, such as suggestions regarding bolus and basal rate dosing. The interview consisted of open-ended, multiple choice, and dichotomous questions.
88870735|NCT01434186|Experimental|Arm 1: Saxagliptin +Metformin XR/IR|Saxagliptin Tablet, 2.5 mg, or Saxagliptin Tablet, 5 mg, (based on subject's weight) Metformin XR/IR 1000 mg-2000 mg
88870736|NCT01434186|Placebo Comparator|Arm 2: Placebo +Metformin XR/IR|Placebo matching saxagliptin 0 mg Metformin XR/IR 1000 mg - 2000 mg
88870737|NCT01434342|Experimental|Arm I - Quitline|"Participants receive a letter from their physician advising them to quit smoking, and undergo a 15-30-minute smoking-cessation counseling session by a trained research staff.~The participants are educated and motivated about the importance of quitting smoking, and cancer-specific quitting issues. They will be called by Quitline in 2-3 days and receive a fact sheet about benefits of SC for cancer patients.~Participants receive 8 weeks of nicotine replacement patches and up to 5 proactive telephone calls over a 12-week period.~Participants also learn behavioral tips and coping skills."
88870738|NCT01434342|No Intervention|Arm II - Usual Care|"Participants receive a letter from their physician advising them to quit smoking, the importance of quitting smoking for cancer patients, and a copy of the National Cancer Institute's Clearing the Air smoking cessation booklet. Participants also receive standard of care from their oncology and other treatment providers which may or may not include nicotine replacement therapy."
88870739|NCT01435512|Experimental|Group|PTSD-Focused Cognitive Behavioral Therapy for Partner Violence
88870740|NCT01435512|No Intervention|Waitlist|Control group - no intervention
88870741|NCT01435824|Active Comparator|Water as a vehicle of amoxicillin|Amoxicillin 500 mg was dissolved in 10 ml water and orally administered in a fasting state.
88870742|NCT01435824|Experimental|Human milk as a vehicle of amoxicillin|Amoxicillin 500 mg was dissolved in 10 ml human milk and orally administered in a fasting state.
88870743|NCT01436526|Experimental|Rivaroxaban (Xarelto, BAY59-7939) first 2*5 mg, then 1*10 mg|Single oral dose of rivaroxaban administered under fasting conditions 2*5 mg tablet in first intervention period and 1*10 mg tablet in second intervention period (after washout period)
88870744|NCT01436526|Experimental|Rivaroxaban (Xarelto, BAY59-7939) first 1*10 mg, then 2*5 mg|Single oral dose of rivaroxaban administered under fasting conditions 1*10 mg tablet in first intervention period and 2*5 mg tablet in second intervention period (after washout period)
88870745|NCT01437852|Experimental|StrataGraft skin tissue|"All subjects enrolled in this study will receive StrataGraft tissue. Will randomly assign treatment regimens to the two comparable study treatment sites pre-identified as A or B. A sealed randomization envelope will be supplied to the clinical site along with the shipment of clinical tissue. Neither the surgeon nor scrubbed operating room personnel will be informed of the randomization until completion of surgical excision. The treatment sites A or B will be randomized to receive either StrataGraft skin tissue or autograft using a 1:1 ratio.~Two comparable areas of healthy skin will be pre-identified by the clinical staff as donor sites A or B. The randomization assignment will be identical as that above for the treatment sites. For example, if treatment site A is randomized to receive an autograft, donor site A will be designated the donor site for autografting"
88870746|NCT01438008|Experimental|Sucrose 24% po|"24% sucrose solution. The Children's Hospital of Eastern Ontario (CHOE) pharmacy department will provide syringes labeled NICU Pain Relief Study containing a maximum dose of 1 mL of a 24% sucrose solution"
88870747|NCT01438008|Placebo Comparator|Placebo po|"The CHEO pharmacy department will provide a syringe labeled NICU Pain Relief Study containing a maximum of 1 ml dose of water (contents almost identical in color, consistency and odor to the sucrose solution) in identical packagings"
88870748|NCT01438710|Experimental|LCP-Tacro|LCP Tacro tables for once daily oral administration
88870749|NCT01438710|Experimental|Prograf|Tacrolimus capsules for twice daily oral administration
88870750|NCT01442844|Active Comparator|Micrografting|Several small pieces of skin, each measuring 1.75 mm in diameter will be harvested from a normal pigmented area using a commercially available suction blister device. This will be attached to a sterile dressing that will be placed on the surgical wound.
88870751|NCT01442844|No Intervention|No intervention|No intervention will be performed. Subject will receive dressings that are standard of care.
88870752|NCT01443546|Active Comparator|hCG|standard dose of hCG for ovulation trigger
88870753|NCT01443546|Active Comparator|Lupron Trigger|Leuprolide acetate 2 mg ovulation trigger
88870754|NCT01443546|Experimental|Dual Trigger|Lupron and hCG combined ovulation trigger
89394441|NCT03577782|Experimental|Single group|HIV-infected subjects with no previous ART will begin ART together with Vedolizumab infusions at week 0, 4, 8, 12, 16, 20 and 24 weeks. At this time point ART and Vedolizumab treatment will be interrupted. Patients will be followed up until week 48. ART will be resumed if CD4+ T-cell levels drop below 350 CD4+/μL and/or viral load increase above 10e5 HIV-RNA copies/mL (two consecutive measurements).
88870755|NCT01444716|Experimental|Treatment (ofatumumab)|Participants receive ofatumumab IV over 4 hours once a week for 4 weeks, then monthly thereafter. Treatment continues for up to 12 months in the absence of disease progression or unacceptable toxicity.
88870756|NCT01445028|Experimental|Primary, high-risk retinal detachment|Oral isotretinoin on recurrent retinal detachment associated with Proliferative vitreoretinopathy
88870757|NCT01445028|Experimental|Recurrent RD associated with PVR|Oral isotretinoin on recurrent retinal detachment associated with Proliferative vitreoretinopathy
88870758|NCT01446666||HCC high-risk group|"Patients with liver cirrhosis with the 1-year risk of HCC of 5% or higher~; High Risk Index (>=2.33)~Risk Index = 1.65 (if the prothrombin activity is <=75%) + 1.41 (if the age is 50 years or older) + 0.92 (if the platelet count is <=100x10(3)/mm3) + 0.74 (if the presence of anti-hepatitis C virus [HCV] or hepatitis B surface antigen [HBsAg] is positive)."
88870759|NCT01447914|Experimental|ARQ 197 Treatment (Tivantinib)|Oral Tivantinib 360 mg twice daily continuously for each day (days 1-28) of every 4-week treatment cycle (taken as three tablets of 120 mg each). Courses continue every 28 days in the absence of disease progression or unacceptable toxicity.
88870760|NCT01449240||No treatment|Approximately 5 adults (equal to or not less than 18yrs old) and 5 children (equal to or not over 18yrs old)
89394442|NCT03548090|Experimental|1|Phase 1 (skateboard exercise at 50% body weight and an incline level of 0 degrees, then 5 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 50%, then 75%, then 90%), Phase 3 (control 4-week exercise intervention)
88870761|NCT01449864|Experimental|Proton RT|Subjects receive proton radiation
88870762|NCT01452126|Experimental|Ropivacaine|Sequential allocation of ropivacaine concentration depending on the success or failure of surgical anesthesia of the previous patient
88870763|NCT01456494|Experimental|Teach-to-Goal|Teach-to-goal (TTG) is a method of patient instruction that employs repeated rounds of teaching (demonstration, verbal, written instructions) and assessments (teach-back) of patient comprehension.
89394443|NCT03548090|Experimental|2|Phase 1 (skateboard exercise at 50% body weight and an incline level of 0 degrees, then 5 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 50%, then 90%, then 75%), Phase 3 (control 4-week exercise intervention)
88870764|NCT01456494|Experimental|Brief Intervention|A brief educational strategy that employs verbal and written instructions, without demonstration or repeated rounds of instruction, to teach patients how to use their inhalers.
88870765|NCT01457196|Other|Sequencing Arm|
88870766|NCT01457430|Experimental|Icatibant|Open-label study
88870767|NCT01458288|Experimental|TG-0054 (3.14 mg/kg)|TG-0054 (3.14 mg/kg)
88870768|NCT01458990|Experimental|PPI inititation|Adding 40mg omeprazole QD for 14 days
88870769|NCT01458990|Active Comparator|PPI withdrawal|The intervention here is systematically withdrawing chronic PPI for 14 days
88870770|NCT01460940|Experimental|Lenalidomide and Panobinostat|In the phase I trial, three patients will be enrolled at each dose level, starting at dose level 1 using a standard 3 + 3 dose escalation phase I design.
88870771|NCT01462812|Active Comparator|Sumatriptan|
88870772|NCT01462812|Placebo Comparator|Matching placebo|
88870773|NCT01463202|Active Comparator|DMPA postpartum|Depot medroxyprogesterone acetate postpartum
88870774|NCT01463202|Active Comparator|DMPA at 4-6 weeks after delivery|Depot medroxyprogesterone acetate at 4-6 weeks after delivery
88870775|NCT01463358|Other|DDI30|Control group based only on backup pacing with lower rate 30 ppm
88870776|NCT01463358|Active Comparator|DDD60|Treatment arm based on full pacing support (60 Lower Rate)
89394444|NCT03548090|Experimental|3|Phase 1 (skateboard exercise at 50% body weight and an incline level of 0 degrees, then 5 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 75%, then 50%, then 90%), Phase 3 (control 4-week exercise intervention)
89394445|NCT03548090|Experimental|4|Phase 1 (skateboard exercise at 50% body weight and an incline level of 0 degrees, then 5 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 75%, then 90%, then 50%), Phase 3 (control 4-week exercise intervention)
88870777|NCT01467882|Experimental|Triptorelin|Triptorelin 22.5 mg, intramuscular (IM), at Day 1 and Day 169
88870778|NCT01468350|Placebo Comparator|(PART A) AB: dalfampridine-ER 10mg then placebo|Each subject randomized to the AB arm will receive a single witnessed dose of (A) dalfampridine-ER 10 mg, and a single witnessed dose of (B) placebo, two days apart
88870779|NCT01468350|Placebo Comparator|(PART A) BA: placebo then dalfampridine-ER 10mg|Each subject randomized to the BA arm will receive a single witnessed dose of (B) placebo, and a single witnessed dose of (A) dalfampridine-ER 10 mg, two days apart
88870780|NCT01468350|Placebo Comparator|(PART B) AB: dalfampridine-ER 10mg then placebo|Each subject randomized to the AB arm will receive multiple doses of (A) dalfampridine-ER 10mg and multiple doses of (B) placebo
89003762|NCT04580693||Endurance Athletes|Official participation in a collegiate athletic varsity rowing team OR participation in competitive endurance athletics. Competitive endurance athletics is defined as greater than or equal to 10 hours of exercise training per week with the majority dedicated to endurance activities such as cycling, rowing, or running. Endurance athlete subjects must be able to exercise on an upright bicycle ergometer and be between the ages of 18-50.
89003763|NCT04578574|Experimental|BI-TDCS Stimulation Group|Participants in this group will receive the BI and TDCS interventions for 10 sessions over two weeks.
89187499|NCT02580032||Child Maintenance group (Group B)|Pre-pubertal boy or girl, ages of 9 to 13 years with a confirmed diagnosis of GHD prior to enrolment as determined by one GH stimulation test, defined as a peak GH level of equal or below 10.0 ng/ml who have been taking prescription treatment for GHD for 6 months or more.
89187500|NCT02580032||Parent Treatment Naïve group (Group C)|Parents/guardians, who live with a pre-pubertal boy or girl, age 4 to 9 years with a confirmed diagnosis of GHD prior to enrolment as determined by one GH stimulation test, defined as a peak GH level of below or equal to 7.0 ng/ml.
89187501|NCT02580032||Parent Maintenance group (Group D)|Parents/guardians, who live with a pre-pubertal boy or girl, age 4 to 9 years with a confirmed diagnosis of GHD prior to enrolment as determined by one GH stimulation test, defined as a peak GH level of below or equal to 10.0 ng/ml who have been taking prescription treatment for GHD for 6 months or more.
89187502|NCT00775905|Experimental|1|amlodipine 10 mg tablets of Ranbaxy
89187503|NCT00775905|Active Comparator|2|Norvasc® 10 mg tablets
89394446|NCT03548090|Experimental|5|Phase 1 (skateboard exercise at 50% body weight and an incline level of 0 degrees, then 5 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 90%, then 50%, then 75%), Phase 3 (control 4-week exercise intervention)
89394447|NCT03548090|Experimental|6|Phase 1 (skateboard exercise at 50% body weight and an incline level of 0 degrees, then 5 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 90%, then 75%, then 50%), Phase 3 (control 4-week exercise intervention)
89394448|NCT03548090|Experimental|7|Phase 1 (skateboard exercise at 50% body weight and an incline level of 5 degrees, then 0 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 50%, then 75%, then 90%), Phase 3 (control 4-week exercise intervention)
89394449|NCT03548090|Experimental|8|Phase 1 (skateboard exercise at 50% body weight and an incline level of 5 degrees, then 0 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 50%, then 90%, then 75%), Phase 3 (control 4-week exercise intervention)
89394450|NCT03548090|Experimental|9|Phase 1 (skateboard exercise at 50% body weight and an incline level of 5 degrees, then 0 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 75%, then 50%, then 90%), Phase 3 (control 4-week exercise intervention)
89394451|NCT03548090|Experimental|10|Phase 1 (skateboard exercise at 50% body weight and an incline level of 5 degrees, then 0 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 75%, then 90%, then 50%), Phase 3 (control 4-week exercise intervention)
89394452|NCT03548090|Experimental|11|Phase 1 (skateboard exercise at 50% body weight and an incline level of 5 degrees, then 0 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 90%, then 50%, then 75%), Phase 3 (control 4-week exercise intervention)
89394453|NCT03548090|Experimental|12|Phase 1 (skateboard exercise at 50% body weight and an incline level of 5 degrees, then 0 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 90%, then 75%, then 50%), Phase 3 (control 4-week exercise intervention)
89394454|NCT03548090|Experimental|13|Phase 1 (skateboard exercise at 50% body weight and an incline level of 0 degrees, then 5 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 50%, then 75%, then 90%), Phase 3 (experimental 4-week exercise intervention)
89394455|NCT03548090|Experimental|14|Phase 1 (skateboard exercise at 50% body weight and an incline level of 0 degrees, then 5 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 50%, then 90%, then 75%), Phase 3 (experimental 4-week exercise intervention)
89394456|NCT03548090|Experimental|15|Phase 1 (skateboard exercise at 50% body weight and an incline level of 0 degrees, then 5 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 75%, then 50%, then 90%), Phase 3 (experimental 4-week exercise intervention)
89394457|NCT03548090|Experimental|16|Phase 1 (skateboard exercise at 50% body weight and an incline level of 0 degrees, then 5 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 75%, then 90%, then 50%), Phase 3 (experimental 4-week exercise intervention)
89394458|NCT03548090|Experimental|17|Phase 1 (skateboard exercise at 50% body weight and an incline level of 0 degrees, then 5 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 90%, then 50%, then 75%), Phase 3 (experimental 4-week exercise intervention)
89394459|NCT03548090|Experimental|18|Phase 1 (skateboard exercise at 50% body weight and an incline level of 0 degrees, then 5 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 90%, then 75%, then 50%), Phase 3 (experimental 4-week exercise intervention)
89394460|NCT03548090|Experimental|19|Phase 1 (skateboard exercise at 50% body weight and an incline level of 5 degrees, then 0 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 50%, then 75%, then 90%), Phase 3 (experimental 4-week exercise intervention)
89394461|NCT03548090|Experimental|20|Phase 1 (skateboard exercise at 50% body weight and an incline level of 5 degrees, then 0 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 50%, then 90%, then 75%), Phase 3 (experimental 4-week exercise intervention)
89394462|NCT03548090|Experimental|21|Phase 1 (skateboard exercise at 50% body weight and an incline level of 5 degrees, then 0 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 75%, then 50%, then 90%), Phase 3 (experimental 4-week exercise intervention)
89394463|NCT03548090|Experimental|22|Phase 1 (skateboard exercise at 50% body weight and an incline level of 5 degrees, then 0 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 75%, then 90%, then 50%), Phase 3 (experimental 4-week exercise intervention)
89394464|NCT03548090|Experimental|23|Phase 1 (skateboard exercise at 50% body weight and an incline level of 5 degrees, then 0 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 90%, then 50%, then 75%), Phase 3 (experimental 4-week exercise intervention)
89394465|NCT03548090|Experimental|24|Phase 1 (skateboard exercise at 50% body weight and an incline level of 5 degrees, then 0 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 90%, then 75%, then 50%), Phase 3 (experimental 4-week exercise intervention)
89394466|NCT01364441|Placebo Comparator|P|
89394467|NCT01364441|Experimental|E|
89394468|NCT02238756|Experimental|CV8102|
89394469|NCT02238756|Active Comparator|Rabipur|
89394470|NCT02238756|Experimental|CV8102 + Rabipur|
89394471|NCT03577626|Experimental|Hemay005 Fast|
89394472|NCT03577626|Experimental|Hemay005 Fed|
88870781|NCT01468350|Placebo Comparator|(PART B) BA: Placebo then dalfampridine-ER 10mg|Each subject randomized to the BA arm will receive multiple doses of (B) placebo, and multiple doses of (A) dalfampridine-ER 10mg
89394473|NCT03584256||gymnasts|Female gymnasts, older than 13 years, with status of ineternational or national level,
89394474|NCT03584256||swimmers|Female swimmers, older than 12 years, with status of ineternational or national level,
88870782|NCT01468584|Experimental|MP-424|
88870783|NCT01468974|Other|ESPRIT BVS|Subjects receiving the ESPRIT BVS for the treatment of symptomatic claudication from occlusive vascular disease of the superficial femoral (SFA) or common or external iliac arteries.
88870784|NCT01471626|Experimental|telematic attended polysomnography|
88870785|NCT01472718|Active Comparator|standard primary coronary intervention|
88870786|NCT01472718|Experimental|coronary thrombectomy|
88870787|NCT01472874|Experimental|Once a day Trientine|Patients receive once a day trientine
88870788|NCT01474122|Active Comparator|Macitentan 3 mg|Oral macitentan 3 mg, once daily
88870789|NCT01474122|Active Comparator|Macitentan 10 mg|Oral macitentan 10 mg, once daily
88870790|NCT01474122|Placebo Comparator|Placebo|Oral placebo, once daily
88870791|NCT01474590|Experimental|Epiduo/Tactuo + doxycycline 200mg|
88870792|NCT01474590|Active Comparator|Isotretinoin + vehicle gel|
88870793|NCT01477320|Active Comparator|Pantoprazole 40mg IV daily and tube feed|
88870794|NCT01477320|Placebo Comparator|Placebo and tube feed.|
89187504|NCT00772161|Experimental|Sequence 1|First treatment week (day 1 to day 7) 20mg Ritalin LA; second treatment week (day 8 to day 14) 20mg Medikinet retard.
89187505|NCT00772161|Experimental|Sequence 2|First treatment week (day 1 to day 7) 20mg Medikinet retard; second treatment week (day 8 to day 14) 20mg Ritalin LA.
88870795|NCT01477710|Active Comparator|Hold Mask|The clinician will connect a SAVe ventilator to a face mask and hold the mask in place on the mannequin with two hands while maintaining the airway on the correct position for 10 minutes.
89535455|NCT03318731|Experimental|Fenugreek Extract, Low Dose|300mg Taken 1-hour prior to workout on training days and each day of overreaching week. On rest days, will consume in the morning with breakfast.
89187506|NCT04075838|Other|Recovery group|The researchers designed a recovery group suited to Taiwanese with mental illness, according to content of the PTR (Ridgway et al., 2002) and recovery-related literature (Davidson et al., 2005; Ridgway, 2001). The group gathered for a one-hour session once a week for 18 weeks.
89187507|NCT00776139|Experimental|1|Cetirizine Hydrochloride 10 mg tablet of Ohm Laboratories Inc.
89187508|NCT00776139|Experimental|2|Zyrtec® Cetirizine Hydrochloride, 10 mg tablet of Pfizer Labs
88870796|NCT01477710|Active Comparator|Strap Mask|The clinician will attach the face mask to the mannequin using the mask and mask strap included in the ventilator kit for 10 minutes
88870797|NCT01477710|Active Comparator|Airway|The clinician will blindly insert a supralaryngeal airway (the King lT) and connect the SAVe ventilator to the connector and provide ventilation for 10 minutes.
88870798|NCT01478256|Active Comparator|Besifloxocin|Use of topical besifloxocin to treat acute blepharitis
88870799|NCT01478256|Active Comparator|Erythromycin|Topical Erythromycin ointment for treatment of acute blepharitis
88870800|NCT01479270|Active Comparator|TAP Block|20mL of 0.25% Ropivacaine with Epinephrine 1:200,000 is injected into bilateral transversus abdominal planes under ultrasound guidance.
88870801|NCT01479270|No Intervention|No Block|Patients randomized to this arm have band aids applied to sites on lateral abdomen without injection.
88870802|NCT01479348|Experimental|1/Intravenous (IV) Tetrahydrouridine (THU)|[F-18]-5-fluoro-2'-deoxycytidine plus Tetrahydrouridine
88870803|NCT01479348|Experimental|2/Oral Tetrahydrouridine (THU)|[F-18]-5-fluoro-2'-deoxycytidine plus Tetrahydrouridine
88870804|NCT01479426|Experimental|EFLA400(960mg)|
88870805|NCT01479426|Placebo Comparator|Placebo(960mg)|
88870806|NCT01483560|Experimental|Metformin|Oral Metformin (as Glucophage 500mg x 2 bd) titrated from initial 500mg to target 2000mg daily
88870807|NCT01483560|Placebo Comparator|Placebo|
88870808|NCT01484340|Experimental|Counseling only|Participants in this arm will receive advice to quit smoking and self-help materials from the study interventionist in a standardized fashion (intensive anti-smoking counseling).
89187509|NCT00779415||Partial Rotator Cuff Tear|Patients who presented from 1/1/02 to 12/31/06 to Hershey Medical Center with complaint of shoulder pain and were treated by the Orthopaedic Department
89187510|NCT03810560|No Intervention|open flap debridement|surgical treatment of periodontal pocket without any intervention
89187511|NCT03810560|Active Comparator|laser device with open flap debridement|surgical intervention associated with application of Erbium chromium: YSGG laser therapy
89394475|NCT03375359||cfDNA screening|Pregnant women who are referred for FTS or for further follow-up examinations in case of a suspected anomaly or increased nuchal translucency at 11-13 weeks' gestation can be recruited for this study.
88870809|NCT01484340|Experimental|Nicotine Replacement Therapy +counseling|Participants in this arm will receive the nicotine patch in addition to the intensive anti-smoking counseling. Participants will receive instruction on proper use of the nicotine patch (i.e., placement, use of one patch a day, importance of not smoking while using the patch, and tapering of patches).
88870810|NCT01484652|Experimental|COV795|
89394476|NCT03579732||Long-term users|Adults using low-dose aspirin for > 3 years
89394477|NCT03579732||Episodic users|Adults using low-dose aspirin inconsistently, or consistently but < 3 years
89394478|NCT03579732||Former users|Subset of adult Episodic users of aspirin who discontinued the drug for at least 1 year before case/ control date
89394479|NCT03579732||Non-consumers|Adults who did not use low-dose aspirin
89394480|NCT01365533|Active Comparator|Roflumilast|
89394481|NCT01365533|Placebo Comparator|Placebo|
88870811|NCT01484652|Placebo Comparator|Placebo|
88870812|NCT01485588|Experimental|hI-con1™ 60µl|Phase 1- This is a dose escalation study (60µl, 150µl, or 300 µl) given at baseline and then the subject is followed up to week 24.
89187512|NCT00779493|Active Comparator|A|Curcumin 900mg twice daily by mouth
88870813|NCT01485588|Experimental|hI-con1™ 150µl|Phase 1- This is a dose escalation study (60µl, 150µl, or 300 µl) given at baseline and then the subject is followed up to week 24.
89187513|NCT00779493|Placebo Comparator|B|Placebo capsule to be made by Swanson Vitamins to simulate the capsule.
88870814|NCT01485588|Experimental|hI-con1™ 300µl|Phase 1- This is a dose escalation study (60µl, 150µl, or 300 µl) given at baseline and then the subject is followed up to week 24.
88870815|NCT01488318|Experimental|CETUXIMAB AND DASATINIB|"Cetuximab on a standard weekly schedule (see Section 6.2). Group 1 (subjects more than 2 weeks post last dose of Cetuximab): Loading dose of 400 mg/m2 on cycle 1, day 1 then 250 mg/m2 IV weekly.~Group 2 (subjects last Cetuximab treatment within 2 weeks): Cycle 1 will start at a dose of 250 mg/m2 Dasatinib 150 mg once daily without interruption. On the FIRST cycle (1 cycle is 3 weeks) dasatinib will start 3 days after the cetuximab loading dose (i.e. cycle 1, day 4) to avoid headache as shown on the previous phase I trial.~Treatment will continue until progression."
88870816|NCT01488708|Experimental|LY 2127399 Q2W|If participant received LY2127399 in core study: 1 subcutaneous (SC) injection of 120 mg LY2127399 and 1 SC injection of placebo at week 0, followed by 1 SC injection of 120 mg LY2127399 every 2 weeks (Q2W) for 216 weeks. If participant received placebo in core study: 2 SC injections of 120 mg LY2127399 at Week 0, followed by 1 SC injection of 120 mg LY2127399 Q2W for 216 weeks.
89003764|NCT04578574|Sham Comparator|BI-TDCS (Sham) Stimulation Group|Participants in this group will receive the BI and TDCS (Sham) interventions for 10 sessions over two weeks.
89187514|NCT00772239|Experimental|Rotem|ROTEM: Rotation thromboelastometry
89187515|NCT00772239|Active Comparator|S|Standard coagulation managment procedure
89394482|NCT03583788|Experimental|Hypnotherapy group|The intervention consisted of individual hypnotherapy of 5 hourly sessions (60 minutes) over 5 weeks, a total of five hours. The hypnotherapy treatment method was Erickson's (permissive) hypnosis (17). It began with a conversation about patient's past life events, present situation, alcohol problem and his or her thoughts about it. The hypnotherapy Group did not receive any treatment of motivational interviewing.
89394483|NCT03583788|Active Comparator|Motivational interviewing group|The comparator patient group received individual therapy as motivational interviewing (MI) for 5 hourly sessions over 5 weeks, a total of five hours. The patients in the experimental group did not receive this.
89394484|NCT03548012|Experimental|The Carer Support Needs Assessment Tool (CSNAT) intervention|('Standard' basic palliative care +) The Carer Support Needs Assessment Tool (CSNAT) intervention.
89394485|NCT03548012|No Intervention|Control|('Standard' basic palliative care). No intervention offered.
89394486|NCT05272345|Experimental|Fibromyalgia status before sexual therapy/ Fibromyalgia condition after sex therapy|"Women with sexual dysfunction (FSFI score < 26.55) in reproductive age (15-49 years) followed up with a diagnosis of fibromyalgia~Women with sexual dysfunction (FSFI score < 26.55) in reproductive age (15-49 years) followed up with a diagnosis of fibromyalgia and who were reevaluated for fibromyalgia after sexual therapy was given"
89394487|NCT05191589|Experimental|Intervention Group|In the intervention group trainees will train in an already validated laparoscopic training program with haptic devices.
89394488|NCT05191589|No Intervention|Control|In the control group trainees will complete the same validated training program in the conventional non-haptic setting.
89394489|NCT05477095|Experimental|UB-313 Cohort 1|UB-313 100mcg administered by intramuscular (IM) injection at Week 0, Week 4 and Week 12
89394490|NCT05477095|Experimental|UB-313 Cohort 2|UB-313 300mcg administered by IM injection at Week 0 and 100mcg at Week 4 and Week 12
89394491|NCT05477095|Experimental|UB-313 Cohort 3|UB-313 300mcg administered by IM injection at Week 0, Week 4 and Week 12
89394492|NCT05477095|Experimental|UB-313 Cohort 4|UB-313 600mcg administered by IM injection at Week 0 and 100mcg at Week 4 and Week 12
89394493|NCT05477095|Placebo Comparator|Placebo Comparator|Placebo (normal saline), administered by IM injection at Week 0, Week 4 and Week 12
89394494|NCT03547934|Experimental|Treatment Group|Treatment with the investigated device - High Intensity Focused ElectroMagnetic System
89394495|NCT02259816|Active Comparator|Telmisartan|
89394496|NCT02259816|Experimental|Telmisartan and amlodipine|
89394497|NCT04639505||ELISA|ELISA kit detecting the serum AMH level
89394498|NCT04639505||Chemiluminescence|CLIA method detecting the serum AMH level
89394499|NCT03547310|Experimental|MyoBeatz|The intervention consists of playing with the smartphone training program using the muscle signals picked up by surface electrodes. The study will run over a period of 5 weeks, with participants playing with the training program at home for 4 weeks.
89394500|NCT01567735|Experimental|TMC435|
89394501|NCT04631471|Active Comparator|Ibudilast|Increasing dose of Ibudilast up to 100mg/day for up to 10 weeks prior to cervical decompressive surgery and up to 24 weeks after cervical decompressive surgery
89394502|NCT04631471|Placebo Comparator|Placebo|Increasing dose of matched placebo containing mannitol instead of ibudilast up to 10 pills/day for up to 10 weeks prior to cervical decompressive surgery and up to 24 weeks after cervical decompressive surgery
89394503|NCT03577470||Group 1|Participants will not receive any intervention as a part of this study. This group will include participants in treatment with Darunavir/ Cobicistat/ Emtricitabine/ Tenofovir Alafenamide (D/C/F/TAF), who were always being treated with boosted-darunavir (DRV)-based regimen. The primary data source will be the medical records of each participant participating in this study.
89394504|NCT03577470||Group 2|Participants will not receive any intervention as a part of this study. This group will include participants who started their antiretroviral (ARV) treatment with any combination excluding DRV before starting D/C/F/TAF treatments, who were always being treated with ARV treatment with any combination excluding DRV before starting D/C/F/TAF treatments. The primary data source will be the medical records of each participant participating in this study.
89394505|NCT03577470||Group 3|Participants will not receive any intervention as a part of this study. This group will include participants started with D/C/F/TAF as naive. The primary data source will be the medical records of each participant participating in this study.
89394506|NCT03577392|Experimental|XELOX chemotherapy with recombinant human endotatin|Patients received a triweekly treatment cycle.Oxaliplatin(130mg/m2 over 2h)was intravenously administated for at least 2h on day 1. Capecitabine(1000mg/m2 twice daily)was oral administrated from the evening of day 1 to the morning of day 15.The dose of Recombinant human endostatin on day -5 was calculated according to the patients's body surface area, to provide a CIV 7 days' dose in physiological saline to 240mL volume.
89394507|NCT03577392|Active Comparator|XELOX chemotherapy without recombinant human endotatin|Patients received a triweekly treatment cycle.Oxaliplatin(130mg/m2 over 2h)was intravenously administated for at least 2h on day 1. Capecitabine(1000mg/m2 twice daily)was oral administrated from the evening of day 1 to the morning of day 15.
89394508|NCT03577314||miscarriage|Patients were aged from 18 to 35 years, 50 females who have history of at least two unexplained recurrent miscarriage below 20th week of pregnancy
89394509|NCT03577314||healthy|50 systemically healthy females with at least two normal births and no poor obstetric history such as preeclampsia and premature birth
89394510|NCT04534517|Experimental|TEST Lens|Eligible subjects who are habitual soft contact lens wearers between the ages of 40 and 70 years of age will be recruited. Alternative Spherical lenses will be used if optimization cannot be achieved with the Multifocal lenses.
89394511|NCT03577236|Experimental|Zenflow Spring System|Receives treatment with the investigational device
89394512|NCT03579654|Experimental|Arm 1 - Proscavax vaccine treatment|In this arm, during the first 4 months of induction treatment, 6 doses of the Proscavax vaccine will be administered intradermally at weeks 1, 2, 3, 7, 11, and 15, followed by maintenance booster injections once every month which will alternate between low dose IL-2 alone (at weeks 19, 27 and 35) and Proscavax vaccine (at weeks 23, 31, 39) for 6 months.
89394513|NCT03579654|No Intervention|Arm 2 - Active Surveillance|In this arm, patients will undergo active surveillance and will not receive any Proscavax vaccine treatment.
89394514|NCT04508075|Experimental|SARS-CoV-2 Vaccine|Participants receive 2 doses of SARS-CoV-2 Inactivated Vaccine with 14 days interval, intramuscularly
89394515|NCT04508075|Placebo Comparator|Placebo|Participants receive 2 doses of placebo with 14 days interval, intramuscularly
89394516|NCT05259397|Experimental|Part 1A PF-07225570 monotherapy|Intravesical (IVe) Single Agent Dose Escalation
89394517|NCT05259397|Experimental|Part 1B PF-07225570 and sasanlimab|PF-07225570 IVe and sasanlimab Subcutaneous (SQ) Combination Dose Escalation
89394518|NCT05259397|Experimental|Part 2A PF-07225570 monotherapy|IVe Single Agent Dose Expansion
89394519|NCT05259397|Experimental|Part 2B PF-07225570 and sasanlimab|PF-07225570 IVe and sasanlimab SQ Combination Dose Expansion
89394520|NCT03579576||HCV infected patients|All participants found HCV infected with or without HIV will be initiated treatment and followed up until 24 weeks ( 12 weeks after treatment)
89394521|NCT01364519|Experimental|Arm 1|
89394522|NCT01364519|Placebo Comparator|Arm 2|
89394523|NCT05142020||GDM group|Specimen collection and clinical follow-up
89394524|NCT05142020||Control group|Specimen collection and clinical follow-up
89394525|NCT03579420|Experimental|Brief lifestyle program|3-session lifestyle group intervention program focussed on physical activity and eating habits, using interactive methods and a behavioral approach
89394526|NCT03579420|Active Comparator|Traditional lifestyle longer program|6-session lifestyle group intervention program focussed on physical activity and eating habits, using traditional lessons and interactive methods
89394527|NCT01370057|Experimental|Treatment Group|Treatment with bracing
89394528|NCT01370057|No Intervention|Control Group|Watchful waiting without bracing
89394529|NCT02239146|Experimental|rFXIII|
89394530|NCT02239146|Placebo Comparator|Placebo|
89394531|NCT03225365|Other|Nivolumab|"Previous untreated patient with metastatic melanoma eligible for a Nivolumab treatment.~30 patients will be included in the arm."
89394532|NCT03225365|Other|Nivolumab + Ipilimumab|"Previous untreated patient with metastatic melanoma eligible for a Nivolumab + Ipilimumab treatment.~30 patients will be included in the arm."
89394533|NCT02831257|Experimental|AZD2014|"18 patients will be enrolled in this study in a single stage.~AZD2014 orally, 2 times a day on 2 consecutive day out of every 7 days.~One cycle will consist of 28 days (1 cycle = 28 days)."
89394534|NCT03577158|Experimental|Closed-loop controller with exercise mitigation module|"Sliding Mode Reference Conditioning (SMRC) Closed-loop insulin administration with mitigation module.~Automated insulin infusion based on subcutaneous continuous glucose monitoring (CGM). Commercially available insulin infusion systems and CGM devices will be used. However, insulin infusion will be driven by the software under investigation (SAFEAP with mitigation module) based on blood glucose estimations from CGM."
89394535|NCT03577158|Experimental|Closed-loop controller without exercise mitigation module|Sliding Mode Reference Conditioning (SMRC) Closed-loop insulin administration. Automated insulin infusion based on subcutaneous continuous glucose monitoring (CGM). Commercially available insulin infusion systems and CGM devices will be used. However, insulin infusion will be driven by the software under investigation (SAFEAP without mitigation module) based on blood glucose estimations from CGM.
89394536|NCT03577158|Active Comparator|Open-loop insulin infusion system|Standard Open-loop intensive insulin treatment with continuous subcutaneous insulin infusion (CSII). Commercially available insulin infusion systems will be used.
89394537|NCT03092609|Experimental|Attention Bias Modification|
89394538|NCT03092609|Active Comparator|Attention Control|
89394539|NCT02253914|Experimental|BILR 355 BS, solution|escalating doses
89394540|NCT02253914|Experimental|BILR 355 BS, tablet|escalating doses
88870817|NCT01488708|Experimental|LY2127399 Q4W|If participant received LY2127399 in core study: 1 subcutaneous (SC) injection of 120 mg LY2127399 and 1 SC injection of placebo at Week 0, followed by 1 SC injection of 120 mg LY2127399 every 4 weeks (Q4W) for 216 weeks. If participant received placebo in core study: 2 SC injections of 120 mg LY2127399 at week 0, followed by 1 SC injection of 120 mg LY2127399 Q4W for 216 weeks.
88870818|NCT01490892|Experimental|3D HI and SHI of UCA|Perflutren injection, suspension (IV)0.25 ml followed by 3D Harmonic imaging (HI) then (IV) 20 micro-l/kg followed by 3D subharmonic imaging (SHI)
88870819|NCT01491984|Experimental|Laryngoscopy order: 1) MAC, 2) Levitan|Levitan FPS Intubation
88870820|NCT01491984|Experimental|Laryngoscopy order: 1) Levitan, 2) MAC|Macintosh Intubation
89187516|NCT00779571|Experimental|Crispbread|Intervention: Crispbread LCD
89394541|NCT02253914|Placebo Comparator|Placebo|
89394542|NCT01364675|Experimental|Metformin+Enalapril+Simvastatin|
89394543|NCT01364675|Placebo Comparator|Placebo tablet|
89394544|NCT03577080|Active Comparator|ET+RT+ NMES|neuromuscular electrical training NMES
89394545|NCT03577080|Placebo Comparator|ET+RT|placebo neuromuscular electrical training NMES
89394546|NCT02253758|Experimental|Sedation|Volunteers will be sedated to Ramsay score 4-5 with propofol, and data will be recorded during arousal
89394547|NCT03100825|Experimental|QVM149|All eligible patients take QVM149 150/50/160 μg once daily over 52 weeks.
89394548|NCT03547232|Experimental|Indomethacin group|Indomethacin SR 50mg q12h from day1 to day 7 plus standard treatment for acute pancreatitis including adequate intravenous fluids, analgesics and early enteral nutrition support if possible.
89394549|NCT03547232|Sham Comparator|Standard group|Similar shape and size suppositories without indomethacin (Placebos) given q12h from admission day 1 to day 7, plus standard treatment for acute pancreatitis including adequate intravenous fluids, analgesics and early enteral nutrition support if possible.
89394550|NCT02250534|Experimental|0.8 mg nicotine|0.8 mg nicotine very low nicotine content cigarettes
89394551|NCT02250534|Experimental|0.12 mg nicotine|0.12 mg nicotine very low nicotine content cigarettes
89394552|NCT02250534|Experimental|0.03 mg nicotine|0.03 mg nicotine very low nicotine content cigarettes
89394553|NCT01370135|Experimental|Lucentis (Ranibizumab)|
89187517|NCT00779571|Active Comparator|Liquid meal replacement|Intervention: LMR LCD
89187518|NCT02580344|Other|Ibuprofen|
89394554|NCT05252221|No Intervention|Usual Care|"Usual Care (UC) will consist of treatment as usual, standard and systematic alcohol screening as part of the rooming process conducted by medical assistants, and brief interventions and referrals to addiction treatment delivered by PCPs. PCPs can also prescribe the same AUD medications as those in the ATC arm."
88870821|NCT01495572|Experimental|High Dose (HD) Aldesleukin|Pts receiving high dose aldesleukin: Cyclophosphamide 60 mg/kg intravenous (IV) for days -7 and -6, Fludarabine 25 mg/m^2 IV for days -5 to -1, plus melanoma antigen recognized by T cells (MART)-127-35 reactive CD8+ peripheral blood lymphocytes (PBL) up to 3x10^11 IV over 20-30 minutes on day 0, plus aldesleukin 720,000 IU/kg IV over 15 minutes, every 8 hrs for up to 5 days.
88870822|NCT01495572|Experimental|Peripheral Blood Lymphocytes (PBL)|Cyclophosphamide 60 mg/kg intravenous (IV ) for days -7 and -6, Fludarabine 25 mg/m^2 IV for days -5 to -1, plus MART-127-35 reactive CD8+ PBL up to 3x10^11 IV over 20-30 minutes on day 0
88870823|NCT01496352|Experimental|DFA-02|Progressive cohorts of 10 subjects (8 active, 2 placebo) receiving 10, 20 , 30 or 40 mL of DFA-02 or matching placebo.
88870824|NCT01496352|Placebo Comparator|DFA-02 placebo|
88870825|NCT01497756|Experimental|CAPP application|Patients in whom device is used
88870826|NCT01499862|Experimental|Tibion Arm|Arm of the study in which enrolled post-stroke subjects undergo rehabilitative therapy with the Tibion Bionic Leg.
88870827|NCT01504854|Experimental|Resveratrol|Subjects will take 500 mg by mouth once daily increasing at 13 week intervals to a maximum of 1 gram by mouth twice daily with or without food.
88870828|NCT01504854|Placebo Comparator|Placebo|Subjects will receive a matching placebo to be taken with or without food.
88870829|NCT01505166|Experimental|Vigil™|Patients will receive 1 x 10^7 cells (Group A) via intradermal injection for a minimum of 4 doses and a maximum of 12 doses (vaccine) starting post-surgery Week 4-8 (C1W1D1) and continuing C1W3D1, C2W3D1, then every 28 days.
88870830|NCT01505166|Placebo Comparator|Placebo|Patients will receive placebo (Group B) via intradermal injection for a minimum of 4 doses and a maximum of 12 doses starting post-surgery Week 4-8 (C1W1D1) and continuing C1W3D1, C2W3D1, then every 28 days.
88870831|NCT01505166|Experimental|Vigil™ Vaccine (6 patient run-in)|Six patients will be enrolled into the Part 1 of the study to receive intradermal autologous Vigil™ cancer vaccine (1.0 x 10e7 cells/injection; maximum of 12 vaccinations).
89187519|NCT00779649|Active Comparator|MoviPrep|
89187520|NCT00779649|Active Comparator|HalfLytely|
89187521|NCT04074980|Experimental|Venous only|One venous whole blood draw will be performed into two anti-coagulated collection tubes
89187522|NCT04074980|Experimental|Fingerstick and Venous|One finger-stick sample of capillary blood (~10µl/sample) from each subject, will be applied directly to a unique test strip for immediate measurement of INR on the LumiraDx Instrument. One further fingerstick sample is then obtained (~10µl/sample) from a separate finger for immediate measurement of INR on the Coaguchek PRO. From each patient, one venous whole blood draw will also be performed into two anti-coagulated collection tubes.
89187523|NCT00776217|Experimental|1|loratadine 10 mg orally disintegrating tablets
89187524|NCT00776217|Active Comparator|2|loratadine 10 mg orally disintegrating tablets
89394555|NCT05252221|Active Comparator|ATC Service (intervention)|"ATC components include in-exam-room, real-time videoconferencing or phone contact with the PCPs and their patients, asynchronous, rapid response consultation via email or phone. ATC consultants will offer a flexible service that includes:~Direct patient contact, via video or telephone, during primary care visits~Motivational Interviewing (MI) - informed facilitation of patient engagement in addiction treatment,~Advice to PCP regarding patient-specific treatment options, including pharmacotherapy, addiction treatment, and combined treatments"
89394556|NCT02238678||Deep endometriosis patients|
89394557|NCT03634787||Acute pancreatitis|First time acute pancreatitis. No later than 2 days since the clinical symptoms started.
89394558|NCT03634787||Healthy|No major systemic illness
89187525|NCT00772317|Experimental|HIFU|High Intensity Focused Ultrasound
89394559|NCT05266586|Placebo Comparator|Placebo|once-daily placebo tablet and placebo capsule
89394560|NCT05266586|Experimental|monotherapy|once-daily obicetrapib 10 mg tablet and placebo capsule
89394561|NCT05266586|Experimental|combination therapy|once-daily obicetrapib 10 mg tablet and ezetimibe 10 mg capsule
89394562|NCT01364753||Pilots|No intervention; observational study
89394563|NCT01370291|Active Comparator|active Risperidone and active rTMS|active Risperidone and active rTMS for the first-episode schizophrenia patients
89394564|NCT01370291|Experimental|active rTMS and sham Risperidone|active rTMS and sham Risperidone for the first-episode schizophrenia
89394565|NCT01370291|Sham Comparator|sham rTMS and active Risperidone|sham rTMS and active Risperidone for the first-episode schizophrenia patients
89394566|NCT05575544|Experimental|Left PVI ablation electroacupuncture group|Patient undergo right pulmonary vein isolation under general anesthesia.After successful isolation of the right pulmonary vein, use a 25-gauge stainless steel millineedle of different lengths to be ordered sequentially according to the acupuncture point prescription.Acupuncture was performed at Hegu and Neiguan points on the left side of the patient.After the manual acupuncture, the point was continuously stimulated by an electrical stimulator to analgesia,the frequency is 200 times / min, the pulse frequency is 3 ~ 4Hz. The output intensity is subject to the patient's tolerance, generally 20mA.The electroneedle stimulates until the end of the left pulmonary vein isolation.
89394567|NCT05575544|Experimental|Right PVI ablation electroacupuncture group|Patient undergo left pulmonary vein isolation under general anesthesia.After successful isolation of the left pulmonary vein, use a 25-gauge stainless steel millineedle of different lengths to be ordered sequentially according to the acupuncture point prescription.Acupuncture was performed at Hegu and Neiguan points on the left side of the patient.After the manual acupuncture, the point was continuously stimulated by an electrical stimulator to analgesia,the frequency is 200 times / min, the pulse frequency is 3 ~ 4Hz. The output intensity is subject to the patient's tolerance, generally 20mA.The electroneedle stimulates until the end of the right pulmonary vein isolation.
89394568|NCT01364909|Placebo Comparator|Control (usual practice)|
89394569|NCT01364909|Experimental|Exercise|
89394570|NCT05179772|Experimental|Olanzapine|Everyone in the study is being given Olanzapine (open label)
89394571|NCT05191199||Normal erectile response|Peak systolic velocity above 35cm/s, EDV below 5cm/s, Erectile score 4 or 3
89394572|NCT05191199||Abnormal erectile response|Peak systolic velocity below 35cm/s, EDV above 5cm/s, Erectile score 2 or 1
89394573|NCT01365767||Crohn Disease|Patients with Crohns Disease referred to referred to a Magnetic Resonance Imaging Scan.
89394574|NCT05417503|Experimental|bi-level|
89394575|NCT05417503|Placebo Comparator|placebo|
89394576|NCT05575232|Experimental|Application Group (GA)|Participants undergoing the GA will be instructed on how to download the application and how to use it. From there, all personal data must be entered into the application so that alerts, tips and incentives can be issued to each one, individually.
89394577|NCT05575232|No Intervention|Control Group (GC)|The GC, in turn, will participate in a single lecture, in the first week of the intervention, with basic guidelines related to the key points of the treatment of SAH, including the importance of medication adherence, monitoring of blood pressure values and/or capillary glucose, lifestyle modifications linked to physical activity, eating habits, smoking cessation, stress management and moderate alcohol consumption.
89394578|NCT01370681|Experimental|Group1|
89394579|NCT01370681|Experimental|Group2|
89394580|NCT02848326|Placebo Comparator|Placebo|Placebo-matching atogepant capsule orally twice daily in the morning and in the evening for 12 weeks.
89394581|NCT02848326|Experimental|Atogepant 10 mg QD|Atogepant 10 mg capsule orally once daily (QD) in the morning and one placebo-matching atogepant capsule orally once daily in the evening for 12 weeks.
89394582|NCT02848326|Experimental|Atogepant 30 mg QD|Atogepant 30 mg capsule orally once daily in the morning and one placebo-matching atogepant capsule orally once daily in the evening for 12 weeks.
89394583|NCT02848326|Experimental|Atogepant 30 mg BID|Atogepant 30 mg capsule orally twice daily (BID); 1 capsule in the morning and 1 capsule in the evening for 12 weeks.
89394584|NCT02848326|Experimental|Atogepant 60 mg QD|Atogepant 60 mg capsule orally once daily in the morning and one placebo-matching atogepant capsule orally in the evening for 12 weeks.
89394585|NCT02848326|Experimental|Atogepant 60 mg BID|Atogepant 60 mg capsule orally twice daily; 1 capsule in the morning and 1 capsule in the evening for 12 weeks.
89394586|NCT04450043|Experimental|Run In|Participants will receive a 5-session psychoeducational intervention, focused on skills to enhance post-treatment quality of life with attention to (a) managing expectations, (b) coping with uncertainty, (c) self-managing residual symptoms and (d) strengthening social support.
89394587|NCT04450043|Experimental|Intervention|Participants will receive a 5-session psychoeducational intervention, focused on skills to enhance post-treatment quality of life with attention to (a) managing expectations, (b) coping with uncertainty, (c) self-managing residual symptoms and (d) strengthening social support.
89394588|NCT04450043|Active Comparator|Control|Participants will receive a 1-session intervention, focused on reviewing goal progress for post-treatment quality of life, providing encouragement and support, identifying any current concerns, and providing tailored recommendations and resources.
89394589|NCT01567514|Active Comparator|Glass-ionomer cement lining|Presence of glass-ionomer cement lining in posterior resin composite restorations.
89394590|NCT01567514|No Intervention|No glass-ionomer cement lining|Absence of glass-ionomer cement lining in posterior resin composite restorations
88870832|NCT01507350||Obesity Surgery|Patients having gastric band, sleeve gastrectomy, and gastric bypass will have blood and urine tests, and 51 Cr-EDTA clearance to assess renal function. These are taken before and after the surgery at 6 weeks , 6 months and 12 months.
89394591|NCT01364987|Experimental|ASP015K and Mycophenolate Mofetil|
89394592|NCT01365923|Active Comparator|Remifentanil group|Remifentanil group : remifentanil effect site-TCI 2-4ng/ml
89394593|NCT01365923|Active Comparator|Dexmedetimidine group|Dexmedetomidine group: remifentanil effect site-TCI 2-4ng/ml + dexmedetomidine 0.5mcg/kg
89394594|NCT03579342|Experimental|App technology and coaching|Participants in the intervention group with app technology and coaching participate in a first meeting with the coach and will thereafter receive active support from the coach every 4 weeks for the duration of the intervention.
89394595|NCT03579342|Experimental|App technology only|Participants in the intervention group with only app technology participate in a first meeting with the coach but do not get any additional support during follow-up.
88870833|NCT01508052|Active Comparator|sequential compression device|Apply sequential compression device during the thyroidectomy
88870834|NCT01508052|Experimental|elastic stockings|Apply elastic stockings during the thyroidectomy
88870835|NCT01508832|Active Comparator|Lidocaine|Lidocaine 1% Digital Nerve Block (2 cc)
88870836|NCT01508832|Active Comparator|Bupivacaine|Bupivacaine 0.25% Digital Block (2 cc)
88870837|NCT01509612|Active Comparator|Additive homeopathy in cancer patients|Lung cancer patients receiving conventional chemo- and/or radiation therapy receive additive classical homeopathy with homeopathic globules
88870838|NCT01509612|Placebo Comparator|Additive homeopathic placebo globules|Lung cancer patients receiving conventional chemo- and/or radiation therapy receive homeopathic placebo globules
88870839|NCT01509612|No Intervention|No intervention|No intervention
88870840|NCT01510704|Placebo Comparator|Placebo|
88870841|NCT01510704|Experimental|Low dose APD421|1mg dose level
88870842|NCT01510704|Experimental|Mid Dose APD421|5mg dose level
88870843|NCT01510704|Experimental|High Dose APD421|20mg dose level
88870844|NCT01511016|Experimental|human recombinant leptin (metreleptin)|Each subject received 0.02 mg leptin / kg body weight daily by subcutaneous injection for two months, followed by 0.04 mg leptin / kg for two more months.
88870845|NCT01511016|Placebo Comparator|Placebo injection|Each subject received placebo at a dose of 0.02 mg / kg body weight daily by subcutaneous injection for two months, followed by a dose of 0.04 mg / kg for two more months.
88870846|NCT01511640|Experimental|Pregabalin 1|Dose 1
89394596|NCT03579342|No Intervention|Control group|Participants in the control group participate in baseline assessments. The control group will get access to the app and will have a meeting with a coach after 12 weeks of follow-up.
89394597|NCT03128723|Experimental|Acne Mask|The light therapy acne mask is applied to the face once in the evening for a duration of 10 minutes. The cleanser is used twice daily, once in the morning and once in the evening.
89394598|NCT03579264|No Intervention|Standard Arm|No use of My Viva Plan.
89394599|NCT03579264|Experimental|Intervention Arm|Use of My Viva Plan.
89394600|NCT01370759|Experimental|Colon-targeted cleaning capsule|
89394601|NCT05154110|Experimental|strength training group|the group will receive strength training
89394602|NCT05154110|Experimental|whole body vibration stretching group|the group will receive stretching on whole-body vibration
89394603|NCT01370915|Experimental|Pregabalin|Patients receive oral placebo 150 mg 1hour prior to septal surgery, and 12 hours later
89394604|NCT01370915|Placebo Comparator|Placebo|Patients receive oral Placebo(Vitamin complex) 150 mg 1 hour before septal surgery, and 12 hours later
88870847|NCT01511640|Placebo Comparator|Placebo 1|Placebo 1
88870848|NCT01511640|Experimental|Pregabalin 2|Dose 2
88870849|NCT01511640|Placebo Comparator|Placebo 2|Placebo 2
88870850|NCT01513122|Active Comparator|Arm 1. Lopinavir / ritonavir + 2-3N(t)RTI|LPV/r 200mg/50mg 4 tabs once daily or 2 tabs twice daily + 2-3N(t)RTI
88870851|NCT01513122|Active Comparator|Arm 2. Lopinavir /ritonavir + raltegravir|
88870852|NCT01513902|Experimental|Cohort 1|Ages 12 to less than 18
88870853|NCT01513902|Experimental|Cohort 2|Ages 6 to less than 12
88870854|NCT01513902|Experimental|Corhort 3|Ages 2 to less than 6
88870855|NCT01514292|Experimental|Real Time Continuous Glucose Monitoring System|7 day use of real time continuous glucose monitoring system
88870856|NCT01515072|No Intervention|No Remote Ischemic Preconditioning|The donors assigned to this group will receive standard of care of management of brain death donors in each organ procurement organization.
88870857|NCT01515072|Experimental|Remote Ischemic Preconditioning|The donors assigned to this group would receive two RIPC interventions. The first one would occur immediately after brain death declaration and consent for organ donation. The second one would occur immediately before commencement of organ recovery. At each occasion RIPC would be induced by 4 cycles of mid-thigh inflation of tourniquet for 5 min followed by deflation for 5 minutes.
88870858|NCT01515540|Active Comparator|lidocaine|5% lidoderm patch
88870859|NCT01515540|Placebo Comparator|control|placebo patch
88870860|NCT01515696|Active Comparator|Gastrografin|infants receive 3ml/kg Gastrografin + 6ml/kg sterile water
88870861|NCT01515696|Placebo Comparator|Sterile water|infants receive 9ml/kg sterile water
88870862|NCT01516632|Experimental|SMS USA|The 6-week smoking cessation intervention
89003765|NCT04574050|Experimental|SELF-BREATHE|Access to a self -guided, internet -based intervention for patients with chronic breathlessness known as SELF-BREATHE
89394605|NCT03577002|Active Comparator|Clinician SICP|Advance care planning between primary care clinician and the patient/family using the Serious Illness Care Program (SICP)
89394606|NCT03577002|Active Comparator|Team SICP|Advance care planning between team members and the patient/family using the Serious Illness Care Program (SICP)
89535456|NCT03318731|Experimental|Fenugreek Extract, High Dose|500mg Taken 1-hour prior to workout on training days and each day of overreaching week. On rest days, will consume in the morning with breakfast.
88870863|NCT01516632|No Intervention|Attention matched control|Messages aimed at improving one's sleep and increasing one's fitness, along with general messages about the most well known health dangers of smoking. Messages sent on the same schedule as the intervention group.
88870864|NCT01518270||Healthy Females|Healthy Females
89394607|NCT05574998|Experimental|Recombinant Human Endostatin(Endostar) in Combination With Platinum-Based Doublet Chemotherapy|"The specific treatment regimen is as follows: Non-squamous NSCLC: Endostar (210 mg, CIV for 120 h) is started on the first day of each treatment cycle and administered every three weeks. Carboplatin AUC 5-6 mg/ml/min or cisplatin 75 mg/m2 (d4) +pemetrexed 500 mg/m2 (d4) Q3W is administered in this regimen for 4 cycles followed by Endostar plus pemetrexed until disease progression or intolerable toxicity.~Squamous NSCLC: Endostar (210 mg, CIV for 120 hours) is started on the first day of each treatment cycle and administered every three weeks. Carboplatin AUC 5-6 mg/ml/min or cisplatin 75 mg/m2 (d4) + paclitaxel 175 mg/m2 (d4) Q3W.Endostar is administered after 4 cycles of this treatment regimen until disease progression or intolerable toxicity developed."
88870865|NCT01519284|Placebo Comparator|Group 1|Placebo at all the dosing times
88870866|NCT01519284|Experimental|Group 2|"Day 1 to 7:~BIA 9-1067 5 mg: 7 AM dose Placebo: 8 AM; 4 PM; 12 PM dose~Day 8:~BIA 9-1067 5 mg: 7 AM dose Placebo+ levodopa/carbidopa 100/25 mg: 8 AM dose"
88870867|NCT01519284|Experimental|Group 3|"Day 1 to 7:~BIA 9-1067 15 mg: 7 AM dose Placebo: 8 AM; 4 PM; 12 PM dose~Day 8:~BIA 9-1067 15 mg: 7 AM dose Placebo+ levodopa/carbidopa 100/25 mg: 8 AM dose"
88870868|NCT01519284|Experimental|Group 4|"Day 1 to 7:~BIA 9-1067 30 mg: 7 AM dose Placebo: 8 AM; 4 PM; 12 PM dose~Day 8:~BIA 9-1067 30 mg: 7 AM dose Placebo + levodopa/carbidopa 100/25 mg: 8 AM dose"
88870869|NCT01519284|Experimental|Group 5|"Day 1 to 7:~Placebo: 7 AM dose; Entacapone 200 mg: 8 AM; 4 PM; 12 PM dose~Day 8:~Placebo: 7 AM dose Entacapone 200 mg + levodopa/carbidopa 100/25 mg: 8 AM dose"
88870870|NCT01520454|Placebo Comparator|Placebo|IV saline with heparin, oral water
88870871|NCT01520454|Experimental|High dose fat solution|Intralipid at high dose, with heparin and PO water
88870872|NCT01520454|Experimental|Low dose fat solution|Low dose IV Intralipid with heparin and PO water
88870873|NCT01520454|Experimental|Oral fat|Oral fat load with IV saline
88870874|NCT01520532|Other|Ablation|
88870875|NCT01520688|Experimental|1 Treatment Sequence, FPQ|Period 2 Flovent Diskus Period 4 Pulmicort Flexhaler Period 6 QVAR
88870876|NCT01520688|Experimental|2 Treatment Sequence, FQP|Period 2 Flovent Diskus Period 4 QVAR Period 6 Pulmicort
88870877|NCT01520688|Experimental|3 Treatment Sequence, PFQ|Period 2 Pulmicort Period 4 Flovent Period 6 QVAR
88870878|NCT01520688|Experimental|4-Treatment Sequence, PQF|Period 2 Pulmicort Period 4 QVAR Period 6 Flovent
88870879|NCT01520688|Experimental|5 Treatment Sequence, QFP|Period 2 QVAR Period 4 Flovent Period 6 Pulmicort
88870880|NCT01520688|Experimental|6 Treatment Sequence, QPF|Period 2 QVAR Period 4 Pulmicort Period 6 Flovent
88870881|NCT01521546|Active Comparator|eplerenone|active study drug
89394608|NCT03576846|Experimental|Intervention|Stretching and Spinal Manipulative Therapy
89394609|NCT03576846|Active Comparator|Comparator|Stretching
89394610|NCT03547778|Experimental|Misoprostol group|Patients in this arm will receive vaginal misoprostol (50 mcg), the night before the procedure (concurrent office hsyteroscopy and endometrial biopsy).
88870882|NCT01521546|Placebo Comparator|sugar pill|placebo
88870883|NCT01521780|Experimental|Imaging|Magnetic resonance imaging (MRI) of HCC tumor.
88870884|NCT01521780|Experimental|Pathology|Pathology samples from surgical resection of HCC tumor and adjacent liver.
88870885|NCT01521780|Experimental|Imaging/Pathology|MRI of HCC tumor, followed by pathology samples from surgical resection of HCC tumor and adjacent liver.
88870886|NCT01523496|Active Comparator|HIV + Young Adults|All will be HIV+ and receiving randomized dose of vitamin D control dose (low dose) or supplementation dose (vitamin D medium dose or vitamin D high dose)
88870887|NCT01523496|Active Comparator|HIV - Controls|HIV negative controls will be receiving randomized Vitamin D doses: control vitamin D dose (low dose) or vitamin D supplementation dose (vitamin D medium dose or vitamin D high dose)
88870888|NCT01523808|Experimental|GRASPA 25|
88870889|NCT01523808|Experimental|GRASPA 50|
88870890|NCT01523808|Experimental|GRASPA 100|
88870891|NCT01523808|Experimental|GRASPA 150|
88870892|NCT01523964|Other|DMD subject ages 3-7 inclusive|Young DMD Testing with EIM
88870893|NCT01523964|Other|DMD subject ages 8-12 inclusive|Older DMD Testing with EIM
88870894|NCT01523964|Other|Healthy Control ages 3-7 inclusive|Young Healthy Testing with EIM
88870895|NCT01523964|Other|Healthy Control ages 8-12 inclusive|Older Healthy Testing with EIM
88870896|NCT01526538|Experimental|50 mg d-cycloserine|active drug condition
88870897|NCT01526538|Placebo Comparator|Sugar pill|Inactive placebo
88870898|NCT01527162|Experimental|SAFO worn|Child wears their prescribed SAFO for 14 days
88870899|NCT01527162|No Intervention|SAFO not worn|Child does not wear the prescribed SAFO for 14 days
88870900|NCT01528332|Experimental|Pain Relief Patch|Pain Relief Patch: Light wavelength 453 ± 7 nm, maximum 42 ± 6 mW/cm2 and average 20 ± 1 mW/cm², 30 minutes
88870901|NCT01528332|Active Comparator|Control PRP device|Control PRP device: Light wavelength 531 ± 7 nm, maximum 0.4 ± 0.1 mW/cm² and average 0.2 ± 0.05 mW/cm², light on for 5 seconds, device worn for 30 minutes
88870902|NCT01528878|Experimental|Good liver function.|Patients with good liver function as defined by no more than Child-Pugh Class A.
88870903|NCT01528878|Experimental|Compromised liver function.|Patients with compromised liver function as defined by patients with Child-Pugh Class B.
88870904|NCT01529502|Experimental|Fresh blood|
88870905|NCT01529502|Experimental|Old blood|
88870906|NCT01529502|Experimental|Old blood + inhaled Nitric Oxide|
88870907|NCT01532700|Experimental|Ofatumumab with GSK2110183|
88870908|NCT01533948|Experimental|Treatment (axitinib)|Patients receive axitinib PO BID. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
88870909|NCT01534416|Experimental|Bupivacaine|Subjects receive paracervical block with bupivacaine-epinephrine
88870910|NCT01534416|Placebo Comparator|Saline|Subjects receive paracervical injection of normal saline
88870911|NCT01535118||Adults and Children with Allergic Rhinoconjunctivitis (ARC)|Adults and children with ARC who complete the survey
88870912|NCT01535664||dalfampridine-ER 10mg|Subjects with MS taking dalfampridine-ER 10mg and considered to be responders
88870913|NCT01535976|Placebo Comparator|Placebo|.9 normal saline infusion
88870914|NCT01535976|Active Comparator|Ketamine|Infusion of ketamine
88870915|NCT01536366|Experimental|Group 1|Period 1: BIA 9-1067 + repaglinide Period 2: Repaglinide
88870916|NCT01536366|Experimental|Group 2|Period 1: Repaglinide Period 2: BIA 9-1067 + repaglinide
88870917|NCT06115291|Experimental|Group A: 4 scents|Participants will be asked to inhale 4 different scents 2 times a day.
88870918|NCT06115291|Active Comparator|Group B: 14 scents|Participants will be asked to inhale 14 different scents 2 times a day.
88870919|NCT06115265|Experimental|KDDP|KDDP - Participants enrolled in the KDDP arm will be placed on a traditional ketogenic diet (<20 grams of carbohydrate/day).
88870920|NCT06115265|Experimental|NDPP|NDPP - Participants enrolled in the NDPP arm will be placed on a low fat diet.
88870921|NCT06115252|Experimental|Motivational Interviewing (MI)|
88870922|NCT06115213|Experimental|Patient screening|Single group, no masking, receiving the intervention
89187526|NCT02556957|Experimental|HealthScouts Intervention|HealthScouts (CHWs) regularly visit residents and counsel them using a motivational interviewing approach, supported by a smartphone application.
88870923|NCT06115187||Patient group|Patients with carpal tunnel syndrome
88870924|NCT06115174|Other|People not recieving the drug|(Control group; n=22) which will receive FOLFOX (leucovorin, fluorouracil, oxaliplatin) or XELOX (oxaliplatin + capecitabine) ± target therapy (Bevacizumab).
88870925|NCT06115174|Active Comparator|People recieving the drug|(Pentoxiphylline group; n=22) which will receive the same FOLFOX (leucovorin, fluorouracil, oxaliplatin) or XELOX regimen (oxaliplatin + capecitabine) ± target therapy (Bevacizumab) in addition to Pentoxiphylline 400 mg twice daily.
88870926|NCT06115161|Experimental|Gait Analysis|Gait analysis with the instrumented orthosis as well as a reference sysmtem (Vicon Vantage 5).
88870927|NCT06115148|Experimental|Feeding|Participants will be instructed to consume study beverages to provide >1.2 grams of protein per kilogram bodyweight and >120% of total energy needs. Energy needs will be estimated by the Mifflin-St Jeor equation multiplied by an activity factor of 1.5. Study beverages will be a mix of meal replacement shakes e.g., Ensure (Abbott Laboratories, Chicago, IL, USA) products to accommodate protein and energy needs. Study beverages will be consumed every ~3 hours to induce a perpetually fed state. Feeding will occur during waking hours, typically between 7a-11p. Breath will be collected before, during and after the intervention.
88870928|NCT06115148|Experimental|Fasting|Participants will be instructed to consume only water during the duration of the Fasting Protocol. Regardless of the randomization sequence, participants will have consumed their last meal or study beverage by 11p the night prior. Breath will be collected before, during and after the intervention.
88870929|NCT06115122||Pre-eclampsia risk group|Approximately 300 women will be enrolled into a risk group according to a pre-eclampsia risk calculator.
88870930|NCT06115122||PCOS group|Women enrolled into study who fulfill ≥2 Rotterdam criteria. Women with PCOS may be included in risk- or control groups.
88870931|NCT06115122||Control group|Approximately 300 women in low risk for pre-eclampsia according to a pre-eclampsia risk calculator.
88870932|NCT06115122||Follow up group|Approximately 2100 women who are not enrolled into risk-, control- or PCOS groups.
88870933|NCT06115122||Children|Mothers and fathers will be asked for permission to follow the child's health information from national registers until the age of 15 years. Approximately 300 children will be recruited to PEPPI-offspring follow up study (including also PCOS offspring).
89003766|NCT04574050|No Intervention|Control|standard / currently available NHS care
89003767|NCT04573920|Experimental|Atrasentan 0.75 mg|Once daily oral administration of 0.75 mg atrasentan
89003768|NCT04573920|Experimental|Atrasentan 1.5 mg|Once daily oral administration 1.5 mg atrasentan (FSGS cohorts only)
89003769|NCT04571125||ADHD GROUP|Subjects with clinical diagnosis of ADHD according to the DSM-V criteria
89003770|NCT04571125||TD GROUP|Typically development controls without lifetime diagnosis with ADHD
89003771|NCT04565613|No Intervention|Standard care group|The participants will receive feeding as per standard of care (without protein or any other supplementations).
89003772|NCT04565613|Experimental|Study interventional group|The participants will receive protein supplementation to reach a final goal of 1.5 g/kg/day of protein on full feeds.
89003773|NCT04558983||Retinitis Pigmentosa|Patients with Retinitis Pigmentosa
89003774|NCT04551430|Experimental|Cohort A: Cabozantinib|Patients randomized to Cohort A will take cabozantinib at a dose of 60 mg by mouth once each day of each 28-day cycle. Treatment may continue indefinitely. At time of progression, patients will continue on cabozantinib daily but will reduce their dose to 40 mg. They will cross over into Cohort B and initiate treatment.
89003775|NCT04551430|Experimental|Cohort B: Cabozantinib + Nivolumab + Ipilimumab|-Patients randomized to Cohort B will take cabozantinib at a dose of 40 mg by mouth once each day. Nivolumab will given IV at a dose of 3 mg/kg over approximately 30 minutes every 3 weeks for 4 doses, followed by 480 mg over approximately 30 minutes every 4 weeks until treatment discontinuation. Ipilimumab will be given IV at a dose of 1 mg/kg over approximately 30 minutes every 3 weeks for 4 doses. Treatment may continue for up to 2 years.
89003776|NCT04551430|Experimental|Crossover from Cohort A to Cohort B: Cabozantinib + Nivolumab + Ipilimumab|-Participants who cross-over from Cohort A into Cohort B will initiate treatment with nivolumab at a dose of 3 mg/kg IV over approximately 30 minutes and ipilimumab at a dose of 1 mg/kg IV over approximately 30 minutes. Nivolumab and ipilimumab will be given every 3 weeks for 4 doses. Nivolumab will then be continued at a dose of 480 mg IV over approximately 30 minutes every 4 weeks, with cabozantinib to continue at 40 mg every day. Treatment may continue for up to 2 years.
89003777|NCT04546087|Experimental|Ultrasound|Ultrasound measurements of the cricothyroid membrane.
89003778|NCT04536467|Other|Goserelin arm|3.6 mg subcutaneous injection in the abdominal wall every 4 weeks (28 ± 3 days) plus standard chemotherapy at start of regimen for 3 months
89003779|NCT04536467|Other|control Arm|Standard chemotherapy
89003780|NCT04534881|Active Comparator|progesterone|subjects on active drug (progesterone)
89003781|NCT04534881|Placebo Comparator|placebo|subjects on placebo
89003782|NCT04534582|Experimental|Part I: HLX14 group|Part I: HLX14 are given subcutaneous injection at a single dose of 60 mg.
89003783|NCT04534582|Active Comparator|Part I: EU-Prolia® group|Part I: EU-Prolia® are given subcutaneous injection at a single dose of 60 mg.
89003784|NCT04534582|Experimental|Part II: HLX14 group|Part II: HLX14 are given subcutaneous injection at a single dose of 60 mg.
89003785|NCT04534582|Active Comparator|Part II: EU-Prolia® group|Part II: EU-Prolia® are given subcutaneous injection at a single dose of 60 mg.
89003786|NCT04534582|Active Comparator|Part II: US-Prolia® group|Part II: US-Prolia® are given subcutaneous injection at a single dose of 60 mg.
89003787|NCT04534582|Active Comparator|Part II: CN-Prolia® group|Part II: CN-Prolia® are given subcutaneous injection at a single dose of 60 mg.
89003788|NCT04529434|Experimental|Arm 1|Households living in novel-design houses.
89003789|NCT04529434|Other|Arm 2|Households living in traditional African houses.
89003790|NCT04528836|Experimental|Dose Escalation|Oral capsules taken in escalating levels to determine MTD/RP2D. Each treatment cycle will be 28 days in duration with BBP-398 administered, once daily (QD).
89003791|NCT04528836|Experimental|Dose Expansion|"Oral capsules administered at MTD/RP2D defined dose. Each treatment cycle will be 28 days in duration with BBP-398 administered, once daily (QD)~Cohort A: Advanced or metastatic KRAS mutant solid tumor~Cohort B: Advanced solid tumor with NF1 loss-of-function (LOF) or metastatic BRAF class II/III mutant solid tumor"
89003792|NCT04527822|Experimental|Discharge planning program|a discharge planning program. It is a modified discharge planning program depends basically on the Re-Engineered Discharge program which is a program developed by Boston Medical Center in collaboration with AHRQ , 2013. The intervention consists of several components. The program components include making appointments for follow-up care (e.g., medical appointments and post discharge tests/labs). Plan for the follow-up of results from tests or labs that are pending at discharge. Identify the correct medicines and a plan for the patient to obtain them. Teach a written discharge plan the patient can understand. Educate the patient about his or her diagnosis and medicines. Review with the patient what to do if a problem arises. Assess the degree of the patient's understanding of the discharge plan and provide a telephone reinforcement of the discharge plan
89003793|NCT04527822|Active Comparator|Standard Care|
89003794|NCT04527380|Experimental|Ixekizumab|Ixekizumab given subcutaneously (SC).
89003795|NCT04527380|Active Comparator|Adalimumab|Adalimumab given SC. Participants may have the option to switch to ixekizumab given SC during the open label extension period.
89003796|NCT04521478|Experimental|Treatment group 1|BI 1358894
89003797|NCT04521478|Placebo Comparator|Placebo group|Placebo
89003798|NCT04521478|Experimental|Treatment group 2|Quetiapine
89187527|NCT02556957|Active Comparator|Standard of Care|Referral by RCCS to HIV services. Free HIV clinic available in the community.
89187528|NCT00776451||1|Subjects diagnosed with Dry AMD
89187529|NCT02580500|Active Comparator|group 1|Pilonidal dermoid cyst surgery in Spinal anaesthesia
89187530|NCT02580500|Active Comparator|group 2|Pilonidal dermoid cyst surgery in Epidural anaesthesia
88870934|NCT06115122||Fathers|The role of fathers in the development of pregnancy complications and on the health of the offspring.
88870935|NCT06115083|Experimental|Pelvic floor muscle re-education|Intervention with pelvic floor re-education using bio-feedback and home training for 6 months, with a follow up visit after an additional period of 6 months
88870936|NCT06115083|No Intervention|Standard Care|No intervention during 6 months after inclusion. After the 6 month follow-up evaluation the study subjects are offered to participate in the interventional arm.
88870937|NCT06114979|Active Comparator|Silodosin|Patients will receive 8 mg of Silodosin tablet once daily.
88870938|NCT06114979|Placebo Comparator|Placebo|Patients will receive placebo pill once daily,
88870939|NCT06114966|Experimental|titanium framework manufactured by dry milling technique|All patients will have titanium framework manufactured by dry milling technique and occlusal material made from PMMA FPD
88870940|NCT06114966|Experimental|metal framework manufactured by dry milling/post sintering of Co-Cr soft metal blocks|All patients will have metal framework manufactured by dry milling/post sintering of Co-Cr soft metal blocks and occlusal material made from PMMA FPD
88870941|NCT06114953|Experimental|Mizoribine group|Mizoribine, glucocorticoid, tacrolimus
88870942|NCT06114953|Active Comparator|Mycophenolate group|Mycophenolate mofetil, glucocorticoid, tacrolimus
88870943|NCT06114940|Experimental|Experimental group|Subjects received Toripalimab combined with tyrosine kinase inhibitors TKI (such as Axitinib, Lenvatinib, Sunitinib,) followed by enucleation of renal tumor or partial nephrectomy or radical nephrectomy.
88870944|NCT06114901|Experimental|Intervention - SleepFix|"Participants will get access to a webpage and video which will show participants information about the dBTi SleepFix mobile application. This information will explain application download, usage concepts and frequently asked questions (FAQ). The intervention webpage will continue to be available for the participants throughout the intervention period for reference if necessary and be only accessible by this group. Participants will also be sent an email and/or text message with a direct link to iOS or Google play app stores to download the SleepFix mobile application. They will be provided a unique alphanumeric access code and instructed to enter this code to access the app program. Participants will be able to commence therapy immediately upon app onboarding."
88870945|NCT06114901|Active Comparator|Control - Sleep Health Education modules|The participant will receive a link to three Sleep Health Education modules bi-weekly. All participants in the control group will gain access to the SleepFix mobile application upon completing their control period.
88870946|NCT06114823|Active Comparator|mini incision group|Patients were subjected to a longitudinal mini-incision started just above the proximal flexor wrist crease and then extended for 1.5 - 2 cm in a proximal direction.
88870947|NCT06114823|Active Comparator|conventional group|Patients were subjected a longitudinal incision which was created between the thenar and hypothenar eminences along the longitudinal axis of the ring finger. Then, it was extended to the proximal flexor wrist crease.
88870948|NCT06114797|Active Comparator|Chamomile mouthwash interventional arm in elderly patients having end-stage renal disease.|"Chamomile was topically applied to the oral mucosa as oral rinse.~Based on this protocol, patients were had oral rinses 3 times per day.~Patients were instructed to perform chamomile rinses in the oral mucosa.~Patients were instructed not to swallow the chamomile oral rinse."
88870949|NCT06114797|Placebo Comparator|Saline mouthwash control group in elderly patients having end-stage renal disease.|"Patients in the control arm followed the same protocol with normal saline rinses. As stated before, that use of 4% hypertonic saline solution mouthwash by elderly provided better oral health by decreasing xerostomia, oral tongue plaque, halitosis, and the number of oral bacteria.~So the patients in the control group were benefited from the saline oral rinse."
88870950|NCT06114771|Active Comparator|orthognathic surgery patients / lozange|Throat lozenge (strepsilis) was given to 30 patients,30 minutes before the operation (the dissolution rate of the lozenge was proven to be 6-9 minutes).
88870951|NCT06114771|Placebo Comparator|orthognathic surgery patients / candy|Sugar dragee in the same size and shape was given to 30 patients 30 minutes before the operation. In order not to cause any complications, sugar patients were sucked and told not to chew.
88870952|NCT06114758||control group - group 1|"Patients' postoperative 1st, 2nd, and 6th-hour vital signs (pulse rate, systolic and diastolic blood pressure, temperature, oxygen saturation).~Shock indices.~Hemogram and hematocrit values at 6-24 hours postoperatively.~Duration of the surgery.~Adverse effects experienced by the patients.~Additional treatments administered.~Whether blood transfusion was performed or not."
88870953|NCT06114758||intraoperatively admistiration of tranexamic acid (1 gram intravenous) - group 2|"Patients' postoperative 1st, 2nd, and 6th-hour vital signs (pulse rate, systolic and diastolic blood pressure, temperature, oxygen saturation).~Shock indices.~Hemogram and hematocrit values at 6-24 hours postoperatively.~Duration of the surgery.~Adverse effects experienced by the patients.~Additional treatments administered.~Whether blood transfusion was performed or not."
88870954|NCT06114758||intraoperatively admistiration of prostoglandin f2 alfa (cytotec 400 microgram rectal)- group 2|"Patients' postoperative 1st, 2nd, and 6th-hour vital signs (pulse rate, systolic and diastolic blood pressure, temperature, oxygen saturation).~Shock indices.~Hemogram and hematocrit values at 6-24 hours postoperatively.~Duration of the surgery.~Adverse effects experienced by the patients.~Additional treatments administered.~Whether blood transfusion was performed or not."
89394611|NCT03547778|Placebo Comparator|Placebo group|Participants in this group will receive placebo (fatty acid), which looks similar to misoprostol and has to be inserted vaginally the night before the procedure.
89394612|NCT02238912|Experimental|Kandhaga Rasayanam- single arm|Kandhaga Rasayanam- 2grams twice a day for 45 days
89394613|NCT03547700|Experimental|Romidepsin plus Ixazomib|The phase I study includes three dose levels (DL) for romidepsin: DL4: 10 mg/m2 on Days 1, 8, 15; DL5: 14 mg/m2 Days 1, 8; DL6: 14 mg/m2 Days 1, 8, 15. Ixazomib is 4 mg PO Days 1, 8, 15. The phase II study will include treatment with ixazomib and romidepsin at the MTD established in the Phase I study. Each cycle is 28 days and patients will receive treatment until progressive disease, unacceptable toxicity, or if any other withdrawal criteria are met.
89394614|NCT02239458|Placebo Comparator|Placebo|Placebo intake during 3 months
89394615|NCT02239458|Active Comparator|Saxagliptin 5mg|Saxagliptin dose of 5mg for 3 months
89394616|NCT03546218|Experimental|Smartphone Application (SPSRS)|Participants watch motion picture using an application that displays positive-word stimuli.
89394617|NCT03546218|Active Comparator|Smartphone Application (YouTube)|Participants will watch the same motion picture as the experimental group. However, a positive-word stimulus does not appear in the motion picture.
89394618|NCT03574740||Entire population|All patients included in this retrospective study. These patients were analyzed following their tobacco smoking habits.
89394619|NCT04606550|Experimental|Vaginal Laser HR+|During our study, women will undergo treatment intravaginally and vulvar with the fractional microablative CO2 laser system (SmartXide 2 V 2 LR, MonaLisa Touch, DEKA, Florence, Italy). A treatment cycle includes three laser applications (every 40-50 days, approximately 6 weeks). The procedure will be performed in the outpatient clinic and does not require any specific preparation (e.g. analgesia/anesthesia).
89394620|NCT04606550|Active Comparator|Vaginal Estrogen HR-|The women in the vaginal estrogen group will be prescribed and asked to administer: Conjugated estrogen cream (Premarin®): 0.5 g of cream intravaginally daily (using applicator or fingertip) for two weeks (fourteen days) then 0.5 g twice weekly for 24 ± 2 additional weeks.
89394621|NCT04606550|Active Comparator|Vaginal Laser HR-|During our study, women will undergo treatment intravaginally and vulvar with the fractional microablative CO2 laser system (SmartXide 2 V 2 LR, MonaLisa Touch, DEKA, Florence, Italy). A treatment cycle includes three laser applications (every 40-50 days, approximately 6 weeks). The procedure will be performed in the outpatient clinic and does not require any specific preparation (e.g. analgesia/anesthesia).
89394622|NCT03574662|Experimental|Frailty assessment in Advanced heart failure|Subjects with advanced heart failure defined as current or recent (within the last 3 months) New York Heart Association (NYHA) class III or IV symptoms.
89394623|NCT03578952|Experimental|Pure AR|Patients with symptomatic severe aortic valve regurgitation without severe aortic stenosis requiring aortic valve replacement.
89394624|NCT03128411|Experimental|Bosutinib|Bosutinib monotherapy; All patients will receive bosutinib at a starting dose of 400 mg QD. The dose of bosutinib may be escalated (up to a maximum of 600 mg QD) for unsatisfactory response or reduced for toxicity.
89394625|NCT03578874|Experimental|SECOX|Sorafenib 400 mg twice daily from Day 1 to 14, Capecitabine 850 mg/m2 twice daily from Day 1 to 7, Oxaliplatin 85 mg/m2 on Day 1
89394626|NCT02847858|Experimental|Health-E You App Participants|
89394627|NCT02847858|No Intervention|Control Group|
89394628|NCT05168306|No Intervention|Standard of Care|No intervention will be administered. Subjects randomized to the Standard of Care Arm will continue using their Current standard of care device to monitor and manage their diabetes
89394629|NCT05168306|Active Comparator|Intervention|Subjects randomized to this Arm will use FreeStyle Libre 2 to monitor and manage their diabetes.
89394630|NCT01366001|Experimental|ALKS 33-BUP|
89394631|NCT01366001|Experimental|ALKS 33|
89394632|NCT01366001|Placebo Comparator|Placebo|
89394633|NCT03574584|Experimental|NNC0165-1562 + Semaglutide|Participants will receive NNC0165-1562 and semaglutide once weekly for 20 weeks.
88870955|NCT06114706|Active Comparator|Initial assessement by phycisians|Patients attending with an acute sore throat are initially assessed by a physician. This is one variant of current standard practice.
89394634|NCT03574584|Experimental|Placebo (NNC0165-1562) + Semaglutide|Participants will receive placebo (NNC0165-1562) and semaglutide once weekly for 20 weeks.
89394635|NCT01365065|Experimental|Vorinostat|Vorinostat 400mg ( 4 X 100mg ) orally daily for 14 days
89187531|NCT04074200||Open Inguinal Hernia Repair|These subjects will undergo an inguinal hernia repair using an open surgical approach.
89394636|NCT04564274||1|patients with rare and common diseases
89394637|NCT03576456|Active Comparator|Alprazolam|Patients receive alprazolam 0.5 mg 1 hour prior to coronary angiography.
89394638|NCT03576456|Placebo Comparator|Placebo Oral Tablet|Patients receive placebo 1 hour prior to coronary angiography.
89394639|NCT04537988|Experimental|Feasibility and usability intervention trial|Pre-post evaluation of a 3-month pilot-trial of an electronic health (eHealth) intervention
89394640|NCT04380701|Experimental|BNT162a1 (P/B) - Part A 18-55 years of age|Escalating dose levels
89394641|NCT04380701|Experimental|BNT162b1 (P/B) - Part A 18-55 years of age|Escalating dose levels
89394642|NCT04380701|Experimental|BNT162b2 (P/B) - Part A 18-55 years of age|Escalating dose levels
89394643|NCT04380701|Experimental|BNT162c2 (P/B) - Part A 18-55 years of age|Escalating dose levels
89394644|NCT04380701|Experimental|BNT162c2 (prime only) - Part A 18-55 years of age|Single dose
89394645|NCT04380701|Experimental|BNT162b1 (P/B) - Part A 56-85 years of age|Escalating dose levels
89394646|NCT04380701|Experimental|BNT162b2 (P/B) - Part A 56-85 years of age|Escalating dose levels
89394647|NCT04380701|Experimental|BNT162b2 (P/B) - Part A 18-85 years of age (Expansion cohorts 11 to 13)|Escalating dose levels
89394648|NCT04380701|Experimental|BNT162b2 (P/B) - Part A 18-85 years of age (Expansion cohort 14)|Biomarker (B cell and plasma cell immunity)
89394649|NCT05572190|Experimental|A1.1. 30 mg ETR028 Sentinel|30 mg ETR028 single oral dose (fasted)
89394650|NCT05572190|Experimental|A1.1. 30 mg ETR029 Sentinel|30 mg ETR029 single oral dose (fasted)
89394651|NCT05572190|Active Comparator|A1.1. 5 mg HCBT|5 mg hydrocodone bitartrate (HCBT) single oral dose (fasted)
89394652|NCT05572190|Active Comparator|A1.1. 10 mg HCBT|10 mg HCBT single oral dose (fasted)
88870956|NCT06114706|Active Comparator|Initial assessement by nurses|Patients attending with an acute sore throat are initially assessed by a nurse. This is one variant of current standard practice.
88870957|NCT06114706|Experimental|Initial assessement by pharmacists|Patients attending with an acute sore throat are initially assessed by a pharmacist. This is oficially not standard practice in Sweden, although it happens.
88870958|NCT06114641|Experimental|Control|Enoxaparin will be given for 3 to 8 days or until clinically stable as per its current approval for use in UA and NSTEMI. The minimum duration of therapy will be 3 days; however, catheterization and PCI can be scheduled earlier than this time as indicated. Initial 30 mg IV loading dose is administered and followed by 1 mg/kg subcutaneously every 12 hours
88870959|NCT06114641|Active Comparator|Comparator|Originitaro Enoxaparin will be given for 3 to 8 days or until clinically stable as per its current approval for use in UA and NSTEMI. Initial 30 mg IV loading dose is administered and followed by 1 mg/kg subcutaneously every 12 hours
88870960|NCT06114576|Experimental|Orange juice enriched with vitamin D3 and encapsulated probiotics|250 ml of orange juice enriched with vitamin D3 and encapsulated probiotics
88870961|NCT06114576|Active Comparator|Conventional orange juice|250 ml of conventional orange juice
88870962|NCT06114537|Experimental|Acetazolomide group|
88870963|NCT06114537|No Intervention|Control Group|
88870964|NCT06114524|Experimental|binaural music group|Binaural music therapy was applied for 15 min before the procedure.
88870965|NCT06114524|No Intervention|control|The control group was kept in a quiet room for 15 minutes before the procedure and then taken for the procedure.
88870966|NCT06114485|Experimental|Digital Mental Health Intervention (DMHI)|Participants randomized to Arm 1 will be sent an Amazon Alexa device, with a newly designed VIPA treatment program installed, and will receive a guidebook to help the older adult and their caregiver understand the device and utilize the VIPA treatment program to its fullest potential.
88870967|NCT06114485|Active Comparator|Control Treatment (CT)|Participants randomized to Arm 2 will be sent an Amazon Alexa device with guidebook to help the older adult and their caregiver understand how to use the device.
89187532|NCT04074200||Laparoscopic Inguinal Hernia Repair|These subjects will undergo an inguinal hernia repair using a laparoscopic surgical approach.
89394653|NCT05572190|Experimental|A1.2. 30 mg ETR028|30 mg ETR028 single oral dose (fasted)
89394654|NCT05572190|Experimental|A1.2. 30 mg ETR029|30 mg ETR029 single oral dose (fasted)
89394655|NCT05572190|Experimental|A2. <=60mg ETR028|<=60 mg ETR028 single oral dose (fasted)
89394656|NCT05572190|Active Comparator|A2. <= 80mg HCBT|<= 80mg HCBT single oral dose (fasted)
88870968|NCT06114459|Experimental|Chlorhexidine|Postoperative disinfection
89187533|NCT04074200||Robotic-assisted Inguinal Hernia Repair|These subjects will undergo an inguinal hernia repair using a robotic-assisted surgical approach.
88870969|NCT06114459|Experimental|Sodium Chloride|Postoperative disinfection
88870970|NCT06114420||patients with local recurrence|
89187534|NCT00667875|Placebo Comparator|1|
89394657|NCT05572190|Experimental|"B1. [ETR028 + ETR029] blend 1"|[ETR028 - dose To Be Determined (TBD) + ETR029 - <=30mg] single oral dose (fasted)
89394658|NCT05572190|Experimental|"B1. [ETR028 + ETR029] blend 2"|[ETR028 - dose TBD + ETR029 - <=30mg] single oral dose (fasted)
89394659|NCT05572190|Experimental|"B2. [ETR028 + ETR029] blend 3"|[ETR028 - dose TBD + ETR029 - <=30mg] single oral dose (fasted)
88870971|NCT06114420||patients without local recurrence|
88870972|NCT06114381|Experimental|Home Based Physical Exercise|This group composed of 30 participants who will receive full body physical exercise 6 days per week in addition to sun exposure as well as their vitamin D supplement for 6 weeks.
88870973|NCT06114381|Experimental|Diet management group|This group composed of 30 participants who will receive dietary management and sun exposure as well as their vitamin D supplement for 6 weeks.
88870974|NCT06114381|Experimental|Sun Exposure and supplements|This group composed of 30 participants who will receive only sun exposure as well as their vitamin D supplement for 6 weeks.
88870975|NCT06114381|No Intervention|Control group|This group composed of 30 participants who didn't receive any intervention
88870976|NCT06114316|No Intervention|control|The control group continued to receive routine treatment (pharmacotherapy and psychoeducation) and follow-up in the Alcohol and Substance Addiction Treatment Center, and no intervention was made.
88870977|NCT06114316|Active Comparator|experimental|"In the first step, the stimuli that led the individuals in the experimental group to drink alcohol were assessed, and the conceptual-theoretical-experimental (CTE) framework of the study was created. The personal behaviors that could be related to recurrence (physiological, self-concept, role function, and mutual commitment) and the stimuli that caused recurrence (focal and affecting) were assessed, objectives were determined, and nursing interventions were carried out in line with these objectives. The interventions planned for diagnosing ineffective coping were selected according to the patients' needs among the support coping interventions under the title of the behavioral area in the Nursing Intervention Classification (NIC). A total of 10 individual interviews were made twice a week for about 45 to 60 minutes. The interviews were evaluated by determining the area specific Nursing outcome classification (NOC) (self respect, social support, mood management, role performance)."
88870978|NCT06114303||"Mother"|Healthy women
89187535|NCT00667875|Active Comparator|2|Naltrexone
89187536|NCT00667875|Active Comparator|3|Naltrexone + Aripiprazole
89187537|NCT05056610|Experimental|Patients with IBS or FI|Food antigens are added to duodenal mucosa during CLE
89394660|NCT05572190|Experimental|"B2. [ETR028 + ETR029] blend 4"|[ETR028 - dose TBD + ETR029 - <=30mg] single oral dose (fasted)
89394661|NCT05572190|Experimental|"B3. [ETR028 + ETR029] blend 1, 2, 3, or 4 (fed)"|[ETR028 - dose TBD + ETR029 - <=30mg] single oral dose (fed)
89394662|NCT05572190|Experimental|"B3. [ETR028 + ETR029] blend 1, 2, 3, or 4 (fasted)"|"2-fold higher dose of [ETR028 + ETR029] blend 1, 2, 3, or 4 single oral dose (fasted)"
89394663|NCT05572190|Experimental|"B4. [ETR028 + ETR029] blend 1, 2, 3, or 4"|"4-fold higher dose of [ETR028 + ETR029] blend 1, 2, 3, or 4 single oral dose (fasted)"
89394664|NCT05572190|Experimental|"B5. [ETR028 + ETR029] blend 1, 2, 3, or 4"|"8-fold higher dose of [ETR028 + ETR029] blend 1, 2, 3, or 4 single oral dose (fasted)"
89394665|NCT05572190|Experimental|"B6. [ETR028 + ETR029] blend 1, 2, 3, or 4"|"8-fold higher dose of [ETR028 + ETR029] blend 1, 2, 3, or 4 single oral dose (fed)"
89394666|NCT01365143|Active Comparator|Open Radical Prostatectomy|
89394667|NCT01365143|Active Comparator|Robotic radical prostatectomy|
89394668|NCT02035722|No Intervention|Control group|AMD-related information is not given to patients randomized to the control group.
89394669|NCT02035722|Active Comparator|Video materials|Educational materials are presented in through a video (audio and visual)
89394670|NCT02035722|Active Comparator|Print materials|Educational materials are presented in the format of printed brochure (visual)
89394671|NCT01365221|Experimental|Patients who have received loading dose of clopidogrel|
89394672|NCT01365221|Active Comparator|Patients who have not received loading dose of clopidogrel|
89394673|NCT03576222|Active Comparator|patients with preventive PICO|PICO dressing is used in patients with incisional hernia intraoperatively
89394674|NCT03576222|Placebo Comparator|patients with preventive MEPORE|MEPORE dressing is used in patients with incisional hernia intraoperatively
89394675|NCT01366079|Experimental|Position change|Position change group
89394676|NCT01366079|Active Comparator|Left lateral|Left lateral position
89394677|NCT03124199|Experimental|Rifaximin|Patient with Helicobacter pylori infection with standard triple therapy prescribed by clinical practice.
89394678|NCT03546920|No Intervention|Control Phase|Usual care for patients admitted to the SNF.
89394679|NCT03546920|Experimental|ALIGN Intervention Phase|ALIGN Intervention delivered by Palliative Care Social Workers in the SNF setting. The intervention consists of aligning patient/caregiver goals of care, completing advance care planning, and connecting to community resources and services to ensure smooth transition from facility to home setting.
89394680|NCT03574428|Active Comparator|Cohort 1|GNbAC1 36 mg/kg single i.v. dose or GNbAC1 placebo
89394681|NCT03574428|Active Comparator|Cohort 2|GNbAC1 60 mg/kg single i.v. dose or GNbAC1 placebo
89394682|NCT03574428|Active Comparator|Cohort 3|GNbAC1 85 mg/kg single i.v. dose or GNbAC1 placebo
89187538|NCT05056610|Experimental|healthy controls|Food antigens are added to duodenal mucosa during CLE
89394683|NCT03574428|Active Comparator|Cohort 4|GNbAC1 110 mg/kg single i.v. dose or GNbAC1 placebo
89394684|NCT03574350|Experimental|KS in Kangaroo Position (KSKP)|KS is performed while the infant is in Kangaroo Position using a lycra band to maintain the position.
89187539|NCT02579642|Placebo Comparator|Placebo|Propofol at usual induction doses for ECT (0.75 - 1 mg/kg IV bolus) with placebo (normal saline)
89187540|NCT02579642|Experimental|Ketamine|Propofol at usual induction doses for ECT (0.75 - 1 mg/kg IV bolus) with the addition of low-dose ketamine 0.2 mg/kg (or 0.5 mg/kg - see interim analysis)
89394685|NCT03574350|Active Comparator|KS in incubator (KSI)|The infant is in the incubator, unclothed with diaper.
89394686|NCT01365377|Experimental|Booklet|Referent member of the family is designated to receive a written detailed information on Critical care.
89394687|NCT01365377|No Intervention|No booklet|daily information to the family is given as usual.
89394688|NCT03578640|Experimental|Treatment arm|Elbasvir, Grazoprevir 50-100Mg Oral Tablet
89394689|NCT02035644|Experimental|Jinlida granules|Jinlida granules, a traditional Chinese medicine, was a herbal formula which was developed under cognition of the theory in the onset of diabetes
89187541|NCT00779805|Experimental|1|Pseudoephedrine hydrochloride 120 mg ER tablets of Ranbaxy
89187542|NCT00779805|Active Comparator|2|Sudafed 120 mg ER tablets
89187543|NCT00772395|Active Comparator|Risedronate|
89187544|NCT00772395|Placebo Comparator|Placebo|
89187545|NCT03468998|Active Comparator|Ridge Preservation with Small Particle Allograft|
89394690|NCT02035644|Placebo Comparator|placebo granules|placebo prepared in indistinguishable granules
89394691|NCT03578562|Experimental|Targeted training intervention|An 8-week progressive homebased training intervention with supervised booster-sessions
89394692|NCT01371071||CIS or early relapsing-remitting MS|
89394693|NCT04465916|Experimental|Experimental Arm|Experimental Arm: EYP001a Dose A QD + NA daily (37 patients)
89394694|NCT04465916|Placebo Comparator|Control Arm|Control Arm: Placebo + NA daily (12 patients)
89394695|NCT03575988||Diabetes group|
89394696|NCT03575988||Control group|
89394697|NCT01366235|Experimental|Southeast Asians|
89394698|NCT01366235|Experimental|Korean|
89394699|NCT01366235|Experimental|Caucasians|
89394700|NCT01366235|Experimental|Africans|
89394701|NCT03578484||Volunteer female subjects|Females age 18-35 years of age. 3D breast scan will be performed and followed over 15 years. No therapeutic interventions will be performed.
89394702|NCT04871165||Oncohematological patient group|Patients with prior diagnosis of oncohematological disease vaccinated with SARS-CoV-2 vaccine.
89394703|NCT04871165||Healthy control group|Subjects without prior diagnosis of oncohematological disease vaccinated with SARS-CoV-2 vaccine.
89394704|NCT05090852|Experimental|Hi-VNI as primary or adjunct oxygenation technique|Hi-VNI used as a primary or adjunct oxygenation technique during upper airway surgery
89394705|NCT03578406|Experimental|HPV TCR-T|HPV E6-specific TCR-T cell
89394706|NCT03578406|Experimental|HPV TCR-T with anti-PD1|HPV E6-specific TCR-T cell with anti-PD1 auto-secreted element
89394707|NCT03575676|Experimental|Group A|Administration of SOM3355 100mg BID for 6 weeks, SOM3355 200mg BID for 6 weeks, SOM3355 100mg BID for 6 weeks and placebo BID for 6 weeks.
89394708|NCT03575676|Experimental|Group B|Administration of placebo BID for 6 weeks, SOM3355 100mg BID for 6 weeks, SOM3355 200mg BID for 6 weeks and SOM3355 100mg BID for 6 weeks.
89394709|NCT03574272|Experimental|Patient Transfer Monitoring System|
89394710|NCT01366313|Experimental|Paracetamol|initial doses was 1.5g g, with dose adjustment intervals of 0.5g . with maximum dose 2.5 g as an only starting dose / 24 h
89394711|NCT01366313|Experimental|Morphine|Initial doses of morphine was 5mg, with dose adjustment intervals of 1 mg .
89394712|NCT01366313|Experimental|Paracetamol-morphine|The initial doses of paracetamol and morphine were 1.5g and 3mg, respectively in the paracetamol-morphine combination group with dose adjustment intervals of 0.25g for paracetamol and 0.5mg for morphine.
89394713|NCT05190809|Experimental|Study group|Group of female patients who will undergo Goldilocks mastectomy in which they will receive an autologous fat grafting in the remaining breast flaps
89394714|NCT01371149|No Intervention|Physician led ventilator set up|Patients will be set up on non-invasive ventilation as per the current gold standard physician led approach
89394715|NCT01371149|Experimental|parasternal electromyography (EMG) set up|Ventilation parameters will be manipulated and titrated according to physiological measurements including signal from parasternal EMG and patient- ventilator asynchrony.
88870979|NCT06114303||"Daughter"|"Healthy daughter from Mother subjects"
88870980|NCT06114264|Sham Comparator|Control Group|This group will not receive any treatment during the intervention period.
88870981|NCT06114264|Experimental|Multimodal + Resistance Program|Multimodal program including exercise program 2 days / week (45 minutes per session) during a period of 8 weeks + Behaviour change program daily /24 hours via a wrist-worn activity prompting device during a period of 8 weeks + Education program 2 days / week (1.5 hour per session, except the final session lasting 2 hours) during a period of 3 weeks + Mindfulness intervention 1 day / week (2.5 hour per session) during a period of 8 weeks, and will continue with an extended exercise program (functional resistance training) additionally 3 days / week (50 minutes per session) during 8 weeks.
88870982|NCT06114251||First Affiliated Hospital, Zhejiang University School of Medicine|
88870983|NCT06114251||Shulan (Hangzhou) Hospital|
88870984|NCT06114238|Experimental|Cohort 1|Itepekimab administered via AI
88870985|NCT06114238|Active Comparator|Cohort 2|Itepekimab administered via PFS
88870986|NCT06114225|Experimental|treatment arm|The participant receive metastasectomy, immunotherapy and Stereotactic Body Radiotherapy (SBRT)
88870987|NCT06114212|Experimental|H4 dTMS|The participants will receive 18 H4 dTMS sessions over 4-6 weeks as an adjunct to evidence-based standard care for CUD (i.e., motivational interviewing and contingency management).
88870988|NCT06114173|Experimental|drug-dosing group|Cardunolizumab 6mg/kg was administered every 2 weeks, with the first evaluation at 8 weeks of treatment and subsequent evaluations every 12 weeks.
88870989|NCT06114134|Experimental|Fenugreek extract|Participants in this group will receive fenugreek extract capsules (500 mg/day, three times a day, 30 minutes before each main meal) along with common treatments
88870990|NCT06114134|Placebo Comparator|Placebo|Participants in this group will receive starch with added color (similar to the color of fenugreek extract) capsules (with the same size and color of fenugreek) (500 mg/day, three times a day, 30 minutes before each main meal) along with common treatments
88870991|NCT06114121|Experimental|erector spinae plane block|participants will be in this group for up to 9 months and receive erector spinae plane (ESP) block
88870992|NCT06114121|Experimental|standard of care|participants in this group will receive the standard of care treatment and will be in this group for up to 9 months.
88870993|NCT06114095||Disease group|Disease-specific experimental cohort of cardiovascular and neurological diseases (atrial fibrillation secondary to valvular heart disease, carotid atherosclerosis, moyamoya disease)
88870994|NCT06114095||Healthy control group|
88870995|NCT06114082|Experimental|IDA-TACE|Patients treated by conventional TACE using idarubicin chemoemulsion
88870996|NCT06114082|Active Comparator|DOX-TACE|Patients treated by conventional TACE using doxorubicin chemoemulsion
88870997|NCT06114069|Active Comparator|all on four group|4 patients received 4-implant supported fixed prosthesis
88870998|NCT06114069|Active Comparator|all on six group|4 patients received 6-implant supported fixed prosthesis
89187546|NCT03468998|Active Comparator|Ridge Preservation with Large Particle Allograft|
89187547|NCT03468998|Active Comparator|Ridge Augmentation with Small Particle Allograft|
89394716|NCT02253524|Active Comparator|Dimenhydrinate|50 mg Dimenhydrinate with 5 cc syringe in 150 ml normal saline given as a slow intravenous infusion over 15 minutes
89187548|NCT03468998|Active Comparator|Ridge Augmentation with Large Particle Allograft|
89394717|NCT02253524|Active Comparator|Metoclopramide|10 mg Metoclopramide with 5 cc syringe in 150 ml normal saline given as a slow intravenous infusion over 15 minutes
89394718|NCT01371227|Experimental|JNS002|JNS002 30 mg/m2 by intravenous infusion at a rate of = 1 mg/minute on Day 4 of each 21-day cycle.
89394719|NCT02253602|Experimental|Ferumoxytol Dose optimization|"We will assess three different dose levels of Ferumoxytol (4 mg/kg, 6 mg/kg, 8 mg/kg).~Images will be acquired at baseline (before Ferumoxytol administration), during injection of Ferumoxytol and 24, 48 and 72 hours after Ferumoxytol administration to identify the optimal moment of scanning.To assess whether USPIOs are sufficiently cleared within 12 weeks from lymph nodes, the MRI scans will be repeated in all six volunteers at 12 weeks after Ferumoxytol administration. Thus, volunteers will undergo an MRI scan for five times. Ferumoxytol is administered only once"
89394720|NCT02253602|Experimental|Before Surgery|Twenty patients will be measured directly before surgery. Patients will be measured at baseline, during injection of Ferumoxytol and 24, 48 or 72 hours after Ferumoxytol administration, depending on the results of the dose optimization study. MR parameters will be correlated with pathology data.
88870999|NCT06114030|Other|Deep margin elevation followed by crowns|Teeth restored with DME and crowns
88871000|NCT06114017|Experimental|1: Social Media Abstention|People in this arm will be encouraged to disable social media and not use social media for one week.
88871001|NCT06114017|No Intervention|2: Control|People in this group will continue their normal behavior in regard to social media use.
88871002|NCT06114004|Experimental|gemcitabine + selinexor:|"Selinexor will be given at 60 mg once per week orally days 1, 8 and 15 every 21 days~Gemcitabine will be given at the dose 1200 mg/m2 (10 mg/m2/min) days 1 and 8 every 21 days"
88871003|NCT06113991||Patients without professional exposure to beryllium|Patients without professional exposure to beryllium
88871004|NCT06113991||Patients with chronic pulmonary berylliosis|Patients with chronic pulmonary berylliosis
89187549|NCT05325398|Active Comparator|patients with NAFLD|17 patients will receive molecular hydrogen
89187550|NCT05325398|Placebo Comparator|probands in the control group|13 probands in the control group who will receive placebo.
89394721|NCT02253602|Experimental|Before Neoadjucant therapy|Ten patients will be measured before start of neoadjuvant chemoradiation. Patients will be measured at baseline, during injection of Ferumoxytol and 24, 48 or 72 hours after Ferumoxytol administration, based on the dose optimization study. MR parameters will be correlated with pathology data.
89394722|NCT05190497|Experimental|intervention group|inspiratory muscle training in addition to routine chest physiotherapy in the form of (deep breathing, coughing, and early ambulation)
89394723|NCT05190497|No Intervention|control|The Control group received only routine chest physiotherapy
89394724|NCT03575520|Experimental|Peg group|
89394725|NCT01366391|Other|Metformin|study parallel with one arm only.
89394726|NCT03761420||breast cancer postoperative|got surgery for breast cancer in St Olavs Hospital, Trondheim, during 2004-2013
89394727|NCT04589195|Experimental|Mindfulness Training (MT) Group|Participants will receive four weeks of MT.
89394728|NCT04589195|Active Comparator|Wait List MT Group|Participants will receive four weeks of MT training after a five week washout period.
89394729|NCT03546764|Experimental|Percutaneous Catheter|14-French Percutaneous catheter (pigtail or non-pigtail) placed at bedside using Seldinger technique
89394730|NCT03546764|Active Comparator|Chest tube|Placement of 28-36F chest tube placed at bedside by an open cut-down technique (traditional)
89394731|NCT04408586|Active Comparator|Phentermine - Topiramate Extended Release group|
89394732|NCT04408586|Placebo Comparator|Placebo Group|
89394733|NCT00075816|Active Comparator|Bone Marrow Transplant|Allogeneic bone marrow transplantation
89394734|NCT00075816|Active Comparator|Blood Stem Cell Transplant|Peripheral blood stem cell transplantation
89394735|NCT04479917|Experimental|TPN171H 5mg group|TPN171H 5mg tablet + Placebo 10mg 2 tablets
89394736|NCT04479917|Experimental|TPN171H 10mg group|TPN171H 10mg tablet + Placebo 5mg tablet+ Placebo 10mg tablet
88816598|NCT05859230|Experimental|The probiotic drink study group|Older adults between 60-90 years of age, diagnosed with Mild Cognitive Impairment, will participate in an 18-week long study consisting of the probiotic drink consumption for 12 weeks, followed by a 6-week follow-up period.
88816599|NCT05859230|Placebo Comparator|The placebo drink study group|The older adults between 60-90 years of age, diagnosed Mild Cognitive Impairment, participate in the total 18-week longed study consisting of the placebo milk drink consumption for 12 weeks, followed by a 6-week follow-up period.
89187551|NCT00667251|Active Comparator|Lapatinib|Plus taxane based chemotherapy
89187552|NCT00667251|Active Comparator|Trastuzumab|Plus taxane based chemotherapy.
89394737|NCT04479917|Experimental|TPN171H 20mg group|TPN171H 10mg 2 tablets + Placebo 5mg tablet
89394738|NCT04479917|Placebo Comparator|Placebo group|Placebo 5mg tablet+ Placebo 10mg 2 tablets
89394739|NCT01372553||Family history risk stratification|primary care patients who receive risk stratification and clinical decision support based upon the family health history they entered in to MeTree
89394740|NCT05159726|Experimental|Written Discharge Education + Video Education|These patients will view a 12-minute educational video on SMM warning signs, in addition to the written discharge instructions provided by nursing staff. At the completion of the video, they will complete a post-video questionnaire to assess their knowledge on the covered topics.
89394741|NCT05159726|No Intervention|Written Discharge Education|They will receive the written discharge instructions provided by nursing staff and complete the post-discharge instruction questionnaire.
89394742|NCT03578328||Cardiac arrest with targeted temperature management|
89394743|NCT05542862|Experimental|SpikoGen vaccine|Single booster dose of SpikoGen Covid-19 vaccine
89394744|NCT03575442|Other|"3 session program of art therapy"|Development of the program applied as a group, during three weeks, one session a week, each lasting approximately 90 minutes and assisted by a specialist in plastic expression. Each session was held in an occupational therapy room, including all the material deemed necessary for the execution of some of the techniques introduced by the technician. After each session, a semi-structured interview was conducted with each participant in order to analyze the meanings attributed.
89394745|NCT03578250|Experimental|Study Group|"Training of the upper extremity on a robotic device. Participants will carry out hand reaching movement for multiple directions in 3 dimensions, while grasping the robotic handle according to assignments given by the robotic device.~During training the robotic device will apply error augmentation force-field to perturbate the arm of the participant away from the straight trajectory line."
89394746|NCT03578250|Experimental|Control group|"Training of the upper extremity on a robotic device. Participants will carry out hand reaching movement for multiple directions in 3 dimensions, while grasping the robotic handle according to assignments given by the robotic device.~During training the robotic device will not apply any perturbations on the participant's arm."
89394747|NCT03575286||Pregnant female|Patient has been determined pregnant with a urine pregnancy test and, if applicable, a serum pregnancy test performed at Northwestern University.
89394748|NCT03575286||Non-pregnant female|Patient has been determined not pregnant with a urine pregnancy test and, if applicable, a serum pregnancy test performed at Northwestern University.
89394749|NCT03578016|Experimental|Circle of Security-Parenting|10 weekly, manualized group sessions at the clinic
89394750|NCT03578016|Other|Treatment as Usual (TAU)|TAU consists of clinical assessment and treatment.
89394751|NCT02239614|Experimental|Group 1: LAV (T=0), PIV (T=28)|"Tetravalent live-attenuated dengue virus vaccine formulation 17 (TDENV-LAV) reconstituted with 0.7 mL of water-for-injection; administered subcutaneously on day 0 of the study.~Tetravalent dengue purified inactivated vaccine 4 μg/serotype with alum adjuvant (TDENV-PIV 4 µg + alum adjuvant) administered intramuscularly on day 28 of the study."
89394752|NCT02239614|Experimental|Group 2: PIV (T=0), LAV (T=28)|"Tetravalent dengue purified inactivated vaccine 4 μg/serotype with alum adjuvant (TDENV-PIV 4 µg + alum adjuvant) administered intramuscularly on day 0 of the study.~Tetravalent live-attenuated dengue virus vaccine formulation 17 (TDENV-LAV) reconstituted with 0.7 mL of water-for-injection; administered subcutaneously on day 28 of the study."
89394753|NCT02239614|Experimental|Group 3: LAV (T=0), PIV (T=180)|"Tetravalent live-attenuated dengue virus vaccine formulation 17 (TDENV-LAV) reconstituted with 0.7 mL of water-for-injection; administered subcutaneously on day 0 of the study.~Tetravalent dengue purified inactivated vaccine 4 μg/serotype with alum adjuvant (TDENV-PIV 4 µg + alum adjuvant) administered intramuscularly on day 180 of the study."
88871005|NCT06113978|Active Comparator|Thoracoscopic sympathectomy for palmar hyperhidrosis in children and adolescents|Medical file records of patients of both sexes, below 18 years of age, suffering from significant bilateral palmar hyperhidrosis, managed by thoracoscopic bilateral simultaneous sympathectomy.
88871006|NCT06113978|Active Comparator|Thoracoscopic sympathotomy for palmar hyperhidrosis in children and adolescents|Medical file records of patients of both sexes, below 18 years of age, suffering from significant bilateral palmar hyperhidrosis, who underwent thoracoscopic bilateral simultaneous sympathotomy.
88871007|NCT06113978|Active Comparator|Thoracoscopic sympathetic chain clipping for palmar hyperhidrosis in children and adolescents|Medical file records of patients of both sexes, below 18 years of age, suffering from significant bilateral palmar hyperhidrosis, treated by thoracoscopic bilateral simultaneous sympathetic chain clipping.
88871008|NCT06113965|Experimental|Experimental: Post-stroke Stiff-Knee Gait Participants|Individuals with post-stroke Stiff-Knee gait
88871009|NCT06113926|No Intervention|"Exclusion by White Players"|"Excluded by White players in an online ball-tossing game (Cyberball)."
88871010|NCT06113926|No Intervention|"Inclusion by White Players"|"Included by White players in an online ball-tossing game (Cyberball)."
88871011|NCT06113926|Experimental|"Exclusion by White Players with Bystander Acknowledgment"|"Excluded by White players in an online ball-tossing game (Cyberball) with a White bystander acknowledging the exclusion."
88871012|NCT06113900|Experimental|Drug as Dapagliflozin 10 mg orally for 6 months is given|25 lupus nephritis patients will receive SGLT2is as dapagliflozin 10mg beside there usual treatment of lupus for 6 months
88871013|NCT06113900|No Intervention|On there conventional lupus nephritis treatment|25 lupus nephritis patients didn't receive SGLT2i and continue on their conventional lupus nephritis treatment
88871014|NCT06113874|Experimental|Composite with Hurriseal desensitizer|
88871015|NCT06113874|Active Comparator|Composite with Gluma Desensitizer|
88871016|NCT06113874|No Intervention|Composite without desensitizer|
88871017|NCT06113848|Active Comparator|Intra-Arterial TNK and Albumin|
88871018|NCT06113848|Active Comparator|Intra-Arterial TNK|
88871019|NCT06113848|Active Comparator|Intra-Arterial Albumin|
88871020|NCT06113848|Sham Comparator|sham|
88871021|NCT06113835||successful group|CTO PCI Technical success ,deployment of a balloon or stent with final antegrade TIMI flow grade 2 or 3, residual stenosis <30% , and no significant side branch occlusion.
88871022|NCT06113835||unsuccessful group|CTO PCI Technical unsuccess
88871023|NCT06113796||Robotic sphincter-preserving rectal resection|Patients with robotic anterior or low anterior rectal resection and primary anastomosis for rectal cancer.
88871024|NCT06113796||Robotic abdominoperineal rectal resection|Patients with robotic abdominoperineal rectal resection for rectal cancer.
88871025|NCT06113783|Experimental|Group 1- ACTIVE|Intra-articular injection at baseline of HYALUBRIX 60® plus PEP 3 times a week at home for the 12 months of observation;
88871026|NCT06113783|No Intervention|Group 2-CONTROL|Physical Exercise Program alone 3 times a week at home for the 12 months of observation.
89394754|NCT02239614|Experimental|Group 4: PIV (T=0), LAV (T=180)|"Tetravalent dengue purified inactivated vaccine 4 μg/serotype with alum adjuvant (TDENV-PIV 4 µg + alum adjuvant) administered intramuscularly on day 0 of the study.~Tetravalent live-attenuated dengue virus vaccine formulation 17 (TDENV-LAV) reconstituted with 0.7 mL of water-for-injection; administered subcutaneously on day 180 of the study."
88871027|NCT06113757|Experimental|Dr Biolyse Group Patients|When you join the Dr. Biolyse® Therapy Group, you will be given electrical signal therapy with the Dr. Biolyse® device. Before the application, the area where the electrodes will be cleaned with appropriate solutions. In addition, 500-1000 ml of isotonic serum will be supplemented according to your weight, just before the first electrical signal application during the day. The treatment protocol to be applied to DBTG patients consists of device therapy and daily fluid support therapy. No medication or different device applications are performed.
88871028|NCT06113757|Active Comparator|Control Group|In the CG patients, who constitute the Comparison Group, the same non-drug fluid support therapy applied in device therapy will be repeated (isotonic, isolated 500 ml). As both groups of patients will receive fluid support therapy, the impact of the device on the disease will be observed with monitored parameters.
89394755|NCT05031572|Other|conventional caloric restriction diet|(DCR protocol): lifestyle recommendations for a healthy Mediterranean diet under a continued daily caloric restriction diet
89394756|NCT05031572|Other|Intermitent fasting|Fasting for two days (non-consecutive) out of seven, with the fasting days separated by at least one day.
89394757|NCT02253680|No Intervention|Routine care|Wool and crepe bandage for 24 hours post-operatively
88871029|NCT06113718|Experimental|Exercise Group|Group that performed abdominal exercise for 1 week before operation.
88871030|NCT06113718|No Intervention|Control Group|Group without preoperative abdominal exercise.
88871031|NCT06113705|Experimental|Experimental Arm|Multidisciplinary and innovative approach based on plasma markers of inflammation (cytokines, circulating RNA, and extracellular microvesicles), and multimodal imaging using 18F-GE-180 positron emission tomography (PET) and advanced MRI techniques,
88871032|NCT06113692||Moderna vaccination targeting SARS-CoV-2-exposed Case Cohort|All participants with myocarditis are selected among the participants who received at least 1 dose of Moderna vaccination targeting SARS-CoV-2. Cases are those participants who develop myocarditis or pericarditis any time during the follow-up after Moderna vaccination targeting SARS-CoV-2 vaccination.
88871033|NCT06113692||Myocarditis/Pericarditis Cohort|All participants with myocarditis and/or pericarditis with or without prior Moderna vaccination targeting SARS-CoV-2 exposure will be selected from the available databases.
89394758|NCT02253680|Experimental|Compression bandage|Actico, inelastic, short-stretch compression bandage worn 24 hours post-operatively
88871034|NCT06113627|Experimental|Exercise group|The intervention group will receive a total of 24 sessions of Therapeutic Resistance Exercise, distributed in 2 weekly sessions of 50 minutes during 3 months.
88871035|NCT06113627|No Intervention|Control group|The control group will receive an educational booklet containing generalized mobility exercises such as frontal and lateral shoulder raises and rotations (hands to head, hands behind back). This is usually the usual treatment, since in most centers, patients are only referred for treatment of LACM when it is already established.
88871036|NCT06113601||Patients admitted to the ICU.|
88871037|NCT06113601||Patients who are not admitted to the ICU.|
88871038|NCT06113588||Retrospective cohort|Patients with type 1 diabetes mellitus known to Royal North Shore Hospital, who underwent transition from paediatric to adult health care from 1st January 2020-8th June 2023
89394759|NCT03572400|Experimental|Gemcitbine/Durvalumab|"Neoadjuvant CCRT with Gemcitbine/Durvalumab~+Adjuvant Gemcitabine/Durvalumab Total 6 cycles, after that, Durvalumab q4wks up to total 1 year"
89394760|NCT02253836|Experimental|TAZ/RTV - TPV/RTV - TPV/RTV+TAZ|"Days 1-9: single dose TAZ/RTV~Days 16-23: morning and evening dose TPV/RTV~Days 24-32: TPV/RTV + TAZ"
89394761|NCT03575130|Experimental|Glanatec|
89394762|NCT03575130|Placebo Comparator|Placebo|
89394763|NCT02241018|Experimental|Mesenchymal stem cells|MSCs will be given at a median dose of 1×10^6 cells/kg once weekly for 4 dose (as 1 cycle) or until CR. The response should be evaluated at 3 and 4 weeks. If symptoms of aGVHD progress at 3 weeks or the patients have NR at 4 weeks, these patients will switch to other therapy. If patients achieved PR at 4 weeks, another cycle will be given. Besides, CD25 monoclonal antibody (20mg/kg) will be administered at day 1,4,8,15, 21 and calcineurin inhibitors will also be used.
89394764|NCT02241018|Experimental|CD25 Mc Ab & calcineurin inhibitors|CD25 monoclonal antibody (20mg/kg, day 1,4,8,15,21) will be administered combined with calcineurin inhibitors. The response should be evaluated at 3 and 4 weeks. If symptoms of aGVHD progress at 3 weeks or the patients have NR at 4 weeks, these patients will switch to other therapy. If patients achieved PR at 4 weeks, another cycle will be given.
89394765|NCT04039022|Experimental|AXS-05|
89394766|NCT03570684|Experimental|tie group|During the operation, after mobilization the rectum, the disinfected Cable Tie was introduced into the pelvic cavity.then the rectum was bundled by the tie which was much easier as the tie is auto-locked. pulling the tie and the rectum would be explored clearly, and then the endoscopic linear cutter was introduced to transect the rectum.
89394767|NCT03570684|No Intervention|non-tie group|
89394768|NCT02244450|Experimental|Screened patients|SCID screening: more drops of blood are placed on a second Guthrie card when current screening (72 hours of life ) is performed after parents' information and consent. The card drawn for the protocol will follow the usual network except that the test for quantifying TRECs will be realized to determine the presence of SCID.
88871039|NCT06113588||Prospective cohort|Patients with type 1 diabetes mellitus known to Royal North Shore Hospital, undergoing transition from paediatric to adult health care, from 9th June 2023 onwards
88871040|NCT06113523||Patient cohort|Patients already tested for monogenic obesity with the 71 genes panel.
88871041|NCT06113523||Control cohort|Patients tested for other indication than monogenic obesity in the lab. The DNA samples will be sequenced for the 71 obesity genes especially for the study.
88871042|NCT06113406|Active Comparator|Classroom Training|The active control group is given traditional hazmat response training which is already part of their curriculum. For the traditional training group the session is given in the classroom for 45 minutes and the training session is ended.
88871043|NCT06113406|Experimental|Virtual Reality Training|After the traditional training has ended, the experimental group will receive the additional VR scenario, online educational content and question and answer session. For the VR training group, the participant is asked to perform the analyze, plan, implement, and evaluation steps individually. After the training is completed the session is closed.
88871044|NCT06113393|No Intervention|control group|Hold enteral feeding when GRV reaches 200 mL(current standard)
89394769|NCT02244450|No Intervention|Control group|SCID children diagnosed without screening by pediatricians local referents DIP
89394770|NCT04000178|Other|group A|patients who received polyurethane stents
89394771|NCT04000178|Experimental|group B|patients who received silicone stents
89394772|NCT03570528||Maxillary Retrusion|CT
89394773|NCT03570528||Healthy Patients|
89394774|NCT03573726|Other|Technically N/A, Crossover Design|Each participant underwent an evaluation during standard of care CIC use vs evaluations during use of the study intervention (CDIC).
88871045|NCT06113393|Experimental|study group|Hold enteral feeding when GRV reaches 300 mL(current standard)
88871046|NCT06113367||Patients with advanced/metastatic UTUC treated with second-line anti-PD-(L)1 immunotherapy|
88871047|NCT06113315||patients with sarcoma|This is an observational prospective cohort study of patients with sarcoma treated with immune checkpoint blockade (ICB; anti-PD-1, PD-L1, and/or CTLA-4) based therapy at Memorial Sloan Kettering Cancer Center (MSK)
88871048|NCT06113289|Experimental|Part 1B|"During cycle 1: Participants will take: ASTX029 tablets daily by mouth on days 1-42. ASTX727 tablets by mouth 1 time every day on Days 15-19. You should take ASTX727 and ASTX029 fasting (about 2 hours before a meal, and 2 hours after a meal).~Cycles 2 and beyond: Participants will take ASTX029 tablets by mouth every day (days 1-28) fasting, (2 hours before and 2 hours after a meal). You will also take ASTX727 tablets by mouth 1 time every day on days 1-5 of each cycle, fasting (2 hours before and 2 hours after a meal)."
88871049|NCT06113289|Experimental|Part 2|"During cycle 1: Participants will take: ASTX029 tablets daily by mouth on days 1-42. ASTX727 tablets by mouth 1 time every day on Days 15-19. You should take ASTX727 and ASTX029 fasting (about 2 hours before a meal, and 2 hours after a meal).~Cycles 2 and beyond: Participants will take ASTX029 tablets by mouth every day (days 1-28) fasting, (2 hours before and 2 hours after a meal). You will also take ASTX727 tablets by mouth 1 time every day on days 1-5 of each cycle, fasting (2 hours before and 2 hours after a meal)."
88871050|NCT06113250|Active Comparator|shortwave diathermy|
88871051|NCT06113250|Active Comparator|ultrasound waves|
89394775|NCT03573570|Experimental|Treatment|110 Fair Price Shops (FPS) in Chidambaram, Tamil Nadu, India will be assigned randomly to receive rice fortified. Rice will be fortified using Fortified Rice Kernels (FRKs) containing iron, zinc, vitamin A and vitamins B1, B3, B6, B9 and B12. All households receiving rice from the PDS will receive fortified rice instead of conventional PDS rice, and members of households sampled for baseline will have blood samples and demographic surveys taken at a baseline visit, and another visit at 12-15 months after the baseline visit. Because a given FPS only receives rice from a single upstream distributor (godown) it should be straightforward to ensure that fortified rice reaches the appropriate treatment FPS and only those FPS.
89394776|NCT03573570|No Intervention|Control|The control arm, i.e. FPS not a part of the treatment shops, will continue to receive the regular rice supplied by the Public Distribution System (PDS), and members of households sampled for baseline will have blood samples and demographic surveys taken at a baseline visit, and another visit at 12-15 months after the baseline visit. It therefore represents the status quo and serves as a control group against which any improvements observed in the treatment group will be gauged.
89394777|NCT00109772|Experimental|lenalidomide|10 mg/day lenalidomide orally for up to 12 weeks in the double-blind treatment period. Participants who completed double-blind treatment had the option of continuing on lenalidomide in the open-label extension period for as long as benefit was derived from the drug or until study closure.
89394778|NCT00109772|Placebo Comparator|Placebo|Placebo orally for up to 12 weeks in the double-blind treatment period. Participants who completed double-blind treatment had the option of crossing over to lenalidomide 10mg in the open-label extension period for as long as benefit was derived from the drug or until study closure.
89394779|NCT03573492|Active Comparator|In-Person Education by Ultrasonographer|In-person education of the DVT scanning technique by an RDMS-certified ultrasonographer
89394780|NCT03573492|Active Comparator|Online Education (EM Sono)|Online lectures of DVT scanning technique by an Emergency Ultrasound fellowship director
89394781|NCT03572010|Placebo Comparator|FeFum fortified maize test meal|
89394782|NCT03572010|Placebo Comparator|FeSO4 fortified LNS|
89394783|NCT03572010|Placebo Comparator|FeSO4 supplement|
89394784|NCT03572010|Placebo Comparator|FeSO4 fortified fruit juice|
89394785|NCT03571932||Intervention Facilities|Includes 18 health facilities
89394786|NCT03571932||Comparison facilities|Infludes 18 health facilities
89394787|NCT03545750||Regional citrate anticoagulation (RCA)|Those receiving regional citrate anticoagulation for CRRT
89394788|NCT03545750||Systemic heparin anticoagulation (SHA)|Those receiving systemic heparin anticoagulation for CRRT
89394789|NCT02245152|Experimental|PROMIS intervention|"Small group behavior change communication (BCC) on Essential Nutrition Actions (ENA), Infant and Young Child Feeding (IYCF) and Water, sanitation and hygiene (WASH) is provided during monthly well-baby visits for children 0-17 months of age~Caregivers with children 0-17 months of age that attend the well-baby visit will be provided with a monthly dose of LNS (20g/day)"
89394790|NCT02245152|Active Comparator|control|Monthly well-baby visits as prescribed by national policy This arm is the basic comparison arm. Caregivers are invited to frequent the health center once a month for well-baby visits. During these visits necessary vaccinations are administered, child growth and nutrition status is evaluated and preventive counseling on child nutrition and health is provided in large groups of caregivers.
89394791|NCT03571854|Experimental|Group PCV-VG|Pressure controlled ventilation-volume guaranteed
89394792|NCT03571854|Active Comparator|Group VCV|Volume controlled ventilation
89394793|NCT01560104|Experimental|veliparib and carboplatin and paclitaxel|Veliparib on Days 1-7 and carboplatin and paclitaxel on Day 3 of a 21 day cycle
88871052|NCT06113250|Sham Comparator|therapeutic exercises|
88871053|NCT06113224|Active Comparator|Control patients|Patients with an indication for cardiac surgery with extracorporeal circulation but without homograft
88871054|NCT06113224|Experimental|Lung homograft patients|patients requiring lung homograft implantation
89187553|NCT04063124|Experimental|Intermittent D+Q|Senolytic treatment in 5 individuals with early AD to determine levels of drug that reach the central nervous system (CNS) by collecting cerebral spinal fluid (CSF), and begin collecting initial data on target engagement of senescent cells, AD-related markers, and AD-relevant outcomes for future trials.
89394794|NCT01560104|Placebo Comparator|placebo and carboplatin and paclitaxel|Placebo on Days 1-7 and carboplatin and paclitaxel on Day 3 of a 21 day cycle
89394795|NCT03573258|Experimental|Fiber|"300 ml of orange juice plus Intervention~6 g of oat beta glucan = FIBER (study A) or~25 g inulin/FOS = FIBER (study B)"
89394796|NCT03573258|Placebo Comparator|Placebo|"300 ml of orange juice plus Placebo:~13.5 g maltodextrin = PLACEBO (study A) or~15.5 g maltodextrin = PLACEBO (study B)"
89394797|NCT00101972|Experimental|RAV12|
88871055|NCT06113198|Experimental|rMenB+OMV NZ Group|Participants received rMenB+OMV NZ on Day 1, Day 61, and any day between Day 241- Day 391.
88871056|NCT06113172|Other|Control|Patients referred for endovascular procedure (aortic or peripheral), with an indication of CTA comprising the CFA region, without significant lesions of the external iliac and common femoral arteries. In case of difference of calcifications between both CFA, the CFA with less calcifications will be chosen for analysis.
88871057|NCT06113172|Other|Stent|Patients referred for endovascular stenting of the common femoral artery with and indication of CTA before the surgery. For these patient a CTA will be performed 1 month before and 1 month after surgery
88871058|NCT06113133||Maximal oxygen uptake|Measurement of maximal oxygen uptake using < 50-millilitre and 100 millilitre oxygen as a cut-off
89394798|NCT02245854|Experimental|Colonic polyps|Exacto™
89394799|NCT00100256|Experimental|Arm 1|
89394800|NCT03571698|No Intervention|Exercise programme only|The treatment group received only exercise programme. The exercises was done by a physical therapist in clinical center. The treatment group received exercise programme with simultaneously active contraction with NMES with large electrodes.
89394801|NCT03571698|Active Comparator|Exercise with NMES standard electrodes|The treatment group received exercise programme with simultaneously active contraction with NMES with standard electrodes.The exercises was done by a physical therapist in clinical center. The treatment group received exercise programme with simultaneously active contraction with NMES with large electrodes.
89394802|NCT03571698|Active Comparator|Exercise with NMES large electrodes|The treatment group received exercise programme with simultaneously active contraction with NMES with large electrodes.The exercises was done by a physical therapist in clinical center. The treatment group received exercise programme with simultaneously active contraction with NMES with large electrodes.
89394803|NCT02245932|Experimental|Resveratrol supplementation|150 mg of resveratrol for 4 weeks (split over two doses of 75 mg/day)
89394804|NCT02245932|Placebo Comparator|Placebo supplementation|Placebo for 4 weeks (split over two doses per day)
89394805|NCT03573102|Active Comparator|control|ACE inhibitor , aspirin , statins will be given once daily
89394806|NCT03573102|Experimental|cases|SGLT2 inhibitors will be given with classic antiproteinuric drugs
89394807|NCT02246088|Experimental|MT + NE|A manual therapy (MT) intervention combined with neuroscience education (NE)
89394808|NCT02246088|Active Comparator|MT + E|Manual therapy (MT) intervention plus an educational program based on a traditional patho-anatomical or biomedical model (E)
89394809|NCT02254070|Experimental|BIBT 986 BS|
89394810|NCT04944368|Experimental|Vaccine candidate|
89394811|NCT04944368|Placebo Comparator|Saline placebo|
89394812|NCT03545672||PBC group|Patients have a definite PBC diagnosis.
89394813|NCT03545672||Control group|The healthy volunteers or patients in Renji Hospital whose medical examinations show no systemic disease, and the CMR examinations are normal.
89394814|NCT02783066|Experimental|"PulseFlow group"|Eligible subjects will try a new offloading boot for 4 weeks
88816600|NCT05859217|Experimental|Cabozantinib and Atezolizumab|Cabozantinib 40mg po daily + Atezolizumab 1200mg iv on day 1; 1 cycle = 21 days
88816601|NCT05859139|Experimental|Intervention introduced to group 1|The intervention is introduced to the first group (G1) of clusters.
89394815|NCT03546530|Experimental|Interferon|Interferon 1.5ug/kg/week, 48weeks
89394816|NCT03546530|Experimental|Interferon+resveratrol|Interferon 1.5ug/kg/week,resveratrol 1000mg/day, 48weeks
89394817|NCT03568526|Experimental|Supportive Care (sensorimotor rehabilitation program)|Patients attend 1 therapy session to receive education and training in the use of the home program. Patients then complete exercises over 90 minutes per week for 6 weeks.
89394818|NCT03545828||Good neurological outcome|CPC 1 and 2 at 6 month after ROSC
89394819|NCT03545828||Poor neurological outcome|CPC 3 to 5 at 6 month after ROSC
89394820|NCT04190420||Patients|250 patients with primary hypertension
89394821|NCT04190420||Healthy Controls|60 healthy control subjects, matched in age and gender
89394822|NCT04178252|Active Comparator|standard drug|Standard treatment of primary headache with 10 mg metoclopramide IV in 150 ml saline given over 10 minutes
89394823|NCT04178252|Active Comparator|drug mask|Standard treatment plus eye mask
89394824|NCT04178252|Active Comparator|drug headset|Standard treatment plus headset
89394825|NCT04178252|Active Comparator|drug mask headset|Standard treatment plus headset plus eye mask
89394826|NCT04872140|Experimental|Pea power with high iron bio-availability|Pea powder with low phytate levels to increase iron bio-availability (7mg iron per day)
89394827|NCT04872140|Active Comparator|Pea powder|Pea powder with normal phytate levels (7mg iron per day)
89394828|NCT04872140|Placebo Comparator|Placebo|Placebo (maltodextrin) powder (0g iron per day)
89394829|NCT04171934||Adults|Subjects 22+ years of age
89394830|NCT04171934||Pediatric|Subjects less than 22 years of age
88816602|NCT05859139|Experimental|Intervention introduced to group 2|The intervention is introduced to the second group (G2) of clusters and G1 remains in intervention conditions.
88816603|NCT05859139|Experimental|Intervention introduced to group 3|The intervention is introduced to the third group (G3) of clusters and G1 and G2 remains in intervention conditions.
88816604|NCT05859139|Experimental|Intervention introduced to group 4|The intervention is introduced to the fourth group (G4) of clusters and G1, G2 and G3 remains in intervention conditions.
88816605|NCT05859087|Experimental|Bedside Family Planning Counseling|Patient is screened for pregnancy intention and then has a bedside family planning counseling session with the investigator taking into account pregnancy intention, medical conditions, medications, and previous contraception used. At the end of the conversation, if patient is desiring contraception, the patient is offered three contraception options (as appropriate for their medical conditions and paid for as part of the study) to be initiated prior to discharge: Etonogestrel implant, medroxyprogesterone 150 mg IM injection, or a year's supply of oral contraception pills.
88816606|NCT05859087|Experimental|Flyer|Patient is given a flyer that recommends they discuss pregnancy intention and contraception with their OB/GYN or primary care physician.
88816607|NCT05859087|No Intervention|Routine care|Patients receive a deception consent so as not to influence them by the consent process. Consent states that the purpose of the project is to study patterns of birth control usage of women admitted to the hospital. Patient is not given any further intervention.
88816608|NCT05859061|Experimental|Cryoanalgesia|Intraoperative analgesic administration will be at the discretion of the anesthesia provider. Once adequate hemostasis is achieved and prior to sternal wire placement and chest closure, patients will undergo cryoablation of bilateral T2 - T6 intercostal nerves. The cryoprobe will be positioned under direct visualization and ablation of the intercostal nerve will be performed 2-4 cm lateral to the internal mammary artery near the mid-clavicular line. Each cryoablation at -50°C to -70°C will be applied for 120 seconds to sustain an ablation length of 2-3 cm at each intercostal nerve (bilateral T2 - T6).
88816609|NCT05859061|No Intervention|Standard of Care (Control)|Patients in this arm will receive standard of care pain management alone.
88871059|NCT06113055|Active Comparator|L-serine|"L-serine white or almost white crystalline powder or colourless crystal formulation which will be dissolved in water and administered orally.~The dose will be weight based: 400mg/kg/day (total daily dose)."
88871060|NCT06113055|Placebo Comparator|Dextrose|"Dextrose monohydrate powder: monohydrate form of crystalline D-glucose (dextrose) consisting of odourless, multi-granular white crystals.~The dose will be weight based: 400mg/kg/day (total daily dose)."
88871061|NCT06112977|Active Comparator|Immediate prepectoral implant-based breast reconstruction without surgical mesh.|Prepectoral implant (expander or fixed volume) breast reconstruction without mesh
88871062|NCT06112977|Active Comparator|Immediate prepectoral implant- based breast reconstruction with surgical mesh|Prepectoral implant (expander or fixed volume) breast reconstruction with mesh (biological or synthetic)
88871063|NCT06112925|Experimental|Medication Therapy Management|The patients attending hospitals assigned to interventional group received medication therapy management services in addition to usual care. The medication therapy management services was provided by the clinical pharmacists. The study participants and attending healthcare providers were blinded of participants' treatment group. The intervention was done at initial visit and repeated at 3rd and 6th month of the initial visit.
88871064|NCT06112925|No Intervention|No Medication Therapy Management|The patients attending hospitals assigned to controlled group received usual care only. The usual care is patients' discussion with the attending physician, and nurse regarding their disease, medications, and subsequent appointments which may take approximately 5 minutes. Two consecutive follow-up visits were scheduled for 3rd month and 6th of initial visit for each patients in similar to interventional group.
88871065|NCT06112912||REA Group|Students enrolled in schools receiving REA during Spring 2022 or Fall 2022
88871066|NCT06112899|Experimental|Healthy Young Men|
88871067|NCT06112886||with Hypothyroidism, without Hypothyroidism|
88871068|NCT06112873||The parents of allergic children 0 to 17 years|The parents of 200 eligible patients will complete the parent questionnaire comprising 15 questions
88871069|NCT06112873||Allergic children aged 8 to 17 years|A total of 200 eligible patients aged 8 to 17 years will complete the children's self-reported questionnaire comprising 13 questions.
88871070|NCT06112873||Adults over 18|A total of 200 adult patients will complete the adult self-reported questionnaire comprising 14 questions.
88871071|NCT06112834|Experimental|Vaccine|rBV A/B
88871072|NCT06112821||APL negative|Patients without persistent antiphospholipid antibodies (aPL) positivity
88871073|NCT06112821||APL positive|Patients with persistent antiphospholipid antibodies (aPL) positivity
88871074|NCT06112717|Experimental|Nursing Care|Seven home visit was made to adolescent in the intervention group. In the first and last visits only self-care knowledge and skills of adolescents were evaluated. In the 2.,3.,4.,5. and 6. home visits they received supportive-educational individualised nursing care based on Orem's Self Care Deficit Nursing Theory. The applied nursing interventions varied based on the individual needs and the level of assistance required by each adolescent. Each home visit lasted 30-60 minutes. Adolescents were given an educational booklet containing information about self-care in cystic fibrosis.
88871075|NCT06112717|No Intervention|Control Group|Adolescents in the control group received no intervention by the researcher.
88871076|NCT06111846|Experimental|Experimental: hBMMSC|1.0×10^6/kg hBMMSC (participant's body weight) single dose 2.0×10^6/kg hBMMSC (participant's body weight) single dose 2.0×10^6/kg hBMMSC (participant's body weight) administered twice
88871077|NCT06111144|Experimental|Polarized training Intensity distribution model without mindfulness program|"The TID of the entire training program will be zone 1 (80%), zone 2 (5%), zone 3 (15%).~The periodization of the training will be performed in a 3:1 load-recovery cycle, that is, three weeks of load for one week of recovery, this cycle will be repeated 3 times to complete the 12 weeks. The running sessions will have a volume in the load weeks as follows: The first week a volume of 5 hours, the second week 5.5 hours and the third week 6 hours. In the recovery week the volume will be 4 hours. As for the running technique and strength, these will have a weekly volume of 30 min and 1 hour respectively during all 12 weeks.~In summary:~60 running sessions 24 strength sessions 24 running technique sessions"
88871078|NCT06111144|Experimental|Pyramidal training Intensity distribution model without mindfulness program|"The TID of the entire training program will be zone 1 (80%), zone 2 (5%), zone 3 (15%).~The periodization of the training will be performed in a 3:1 load-recovery cycle, that is, three weeks of load for one week of recovery, this cycle will be repeated 3 times to complete the 12 weeks. The running sessions will have a volume in the load weeks as follows: The first week a volume of 5 hours, the second week 5.5 hours and the third week 6 hours. In the recovery week the volume will be 4 hours. As for the running technique and strength, these will have a weekly volume of 30 min and 1 hour respectively during all 12 weeks.~In summary:~60 running sessions 24 strength sessions 24 running technique sessions"
88871079|NCT06111144|Experimental|Polarized training Intensity distribution model with mindfulness program|"The TID of the entire training program will be zone 1 (80%), zone 2 (5%), zone 3 (15%).~The periodization of the training will be performed in a 3:1 load-recovery cycle, that is, three weeks of load for one week of recovery, this cycle will be repeated 3 times to complete the 12 weeks. The running sessions will have a volume in the load weeks as follows: The first week a volume of 5 hours, the second week 5.5 hours and the third week 6 hours. In the recovery week the volume will be 4 hours. As for the running technique, strength and mindfulness these will have a weekly volume of 30 min, 1 hour and 65 min respectively during all 12 weeks.~The weekly mindfulness practice will be done in 4 different types of sessions: (life-meditation, jogging-meditation, stretching-meditation, running-meditation).~In summary:~60 running sessions 60 mindfulness sessions 24 strength sessions 24 running technique sessions"
88871080|NCT06111144|Experimental|Pyramidal training Intensity distribution model with mindfulness program|"The TID of the entire training program will be zone 1 (80%), zone 2 (15%), zone 3 (5%).~The periodization of the training will be performed in a 3:1 load-recovery cycle, that is, three weeks of load for one week of recovery, this cycle will be repeated 3 times to complete the 12 weeks. The running sessions will have a volume in the load weeks as follows: The first week a volume of 5 hours, the second week 5.5 hours and the third week 6 hours. In the recovery week the volume will be 4 hours. As for the running technique, strength and mindfulness these will have a weekly volume of 30 min, 1 hour and 65 min respectively during all 12 weeks.~The weekly mindfulness practice will be done in 4 different types of sessions: (life-meditation, jogging-meditation, stretching-meditation, running-meditation).~In summary:~60 running sessions 60 mindfulness sessions 24 strength sessions 24 running technique sessions"
88871081|NCT06111105||Colorectal cancer stage III|
88871082|NCT06111105||Colorectal cancer liver metastasis|
88871083|NCT06111092|Other|Design Thinking Group|A group of randomized participants (autistic adults, parents/caregivers, OT practitioners, teachers, and cultural experts) will participate in the Design Thinking (DT) process.
88871084|NCT06111092|Other|Focus Group|A group of randomized participants (autistic adults, parents/caregivers, OT practitioners, teachers, and cultural experts) will participate in the Focus Group (FG) process.
88871085|NCT06110689||Fontan|Patients undergoing cardiac MRI for Fontan,
88871086|NCT06110689||Healthy controls|Patients undergoing thoracic MRI for chest wall deformity.
88871087|NCT06110559|Experimental|tDCS active comparator|Active transcranial Direct Current Stimulation (tDCS): Stimulation of 1.5 mA for 30 minutes.
89394831|NCT01371305|Experimental|BG00011|Participants will receive 8 consecutive weekly doses of BG00011
88871088|NCT06110559|Sham Comparator|tDCS sham comparator|Sham transcranial Direct Current Stimulation (tDCS): Effective stimulation of 1.5 mA for 30 seconds, then the current is switched off. The complete session lasts 30 minutes, with 29 minutes and 30 seconds without stimulation.
88871089|NCT06110169|Experimental|Group A (anodal tDCS)|Participants will receive 20 minutes of anodal tDCS
88871090|NCT06110169|Sham Comparator|Group B (sham tDCS)|Participants will receive 20 minutes of sham anodal tDCS
88871091|NCT06110130|Active Comparator|Placebo|Placebo 10 mg orally daily
88871092|NCT06110130|Active Comparator|Empagliflozin|Empagliflozin 10 mg orally daily
88871093|NCT06109532||DENGUE INFECTED PATIENTS. YEAR 2016|We conducted a prospective cohort study in patients with newly diagnosed dengue infection at Hospital Posadas in Argentina, between January 1, 2016, and december 31, 2016. Diagnosis was confirmed by IgM serology or PCR. Hyponatremia was defined as serum sodium concentration ≤135 mEq/L.
88871094|NCT06109532||DENGUE INFECTED PATIENTS. YEAR 2020|We conducted a prospective cohort study in patients with newly diagnosed dengue infection at Hospital Posadas in Argentina, between January 1, 2020, and december 31, 2020. Diagnosis was confirmed by IgM serology or PCR. Hyponatremia was defined as serum sodium concentration ≤135 mEq/L.
88871095|NCT06109532||DENGUE INFECTED PATIENTS. YEAR 2023|We conducted a prospective cohort study in patients with newly diagnosed dengue infection at Hospital Posadas in Argentina, between January 1, 2023, and november 1, 2023. Diagnosis was confirmed by IgM serology or PCR. Hyponatremia was defined as serum sodium concentration ≤135 mEq/L.
88871096|NCT06108895|No Intervention|Group C, control group|it will receive intrathecal 12.5 mg (2.5ml) hyperbaric bupivacaine 0.5%.
88871097|NCT06108895|Active Comparator|Group I|it will receive intrathecal 12.5 mg (2.5ml) hyperbaric bupivacaine 0.5% plus bilateral ultrasound guided IINB after surgery.
89394832|NCT01371305|Placebo Comparator|Placebo|Participants will receive 8 consecutive weekly doses of placebo.
89394833|NCT03545204|Other|Intervention Clusters|Community based Kangaroo Mother Care,KMC package in low birth weight infants of randomly selected union councils.
89394834|NCT03545204|Other|Control clusters|Essential newborn and routine standard care in low birth weight infants of randomly selected union councils.
89394835|NCT01366547|Experimental|Single Arm|Subjects will be randomized in a three-way crossover design to receive a single dose of each of two different tablet formulations of dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg or dolutegravir 50 mg plus EPZICOM (abacavir 600mg/lamivudine 300 mg). There will be a screening visit within 30 days prior to first dose and a follow-up visit 7-14 days after the last dose.
89394836|NCT01319669|Experimental|Treatment group|rhTPO(recombinant human thrombopoietin) is given on the second, 4th and 9th day of the chemotherapy cycle in a dosage of 15000U once subcutaneously.
89394837|NCT01319669|Active Comparator|Control group|15000U of rhTPO(recombinant human thrombopoietin) is given subcutaneously 6 to 24 hours within the end of chemotherapy cycle, that is, the 8th day for 3 consecutive days (d9 to d11)
89394838|NCT04032041||Group 1: Healthy Able-bodied Individuals (Completed)|Healthy able-bodied individuals with no history of lower extremity trauma.
89394839|NCT04032041||Group 2: Individuals Requiring AFO Use (Recruiting)|Individuals with unilateral, below knee functional deficits that require an AFO for daily activities (e.g. fracture, muscle and/or nerve injury, ankle arthritis, or peripheral neurologic disease).
89394840|NCT05190341|Experimental|Ibuprofen|Patients randomized to this arm will receive an identical capsule to the other patient arm, and receive 800mg ibuprofen 1 hour before HSG.
89394841|NCT05190341|Experimental|Ketorolac|Patients randomized to this arm will receive an identical capsule to the other patient arm, and receive 30mg ketorolac 1 hour before HSG.
89394842|NCT04347239|Placebo Comparator|Placebo|
89394843|NCT04347239|Experimental|700mg Leronlimab|
89394844|NCT00109928|Experimental|PEGS Treatment|VP-16 (Etoposide) 40 mg/m2 IV Days 1-4 Methyl Prednisolone 250 mg IV Days 1-4 Cisplatin 25 mg/m2 IV Days 1-4 Gemcitabine 1,000 mg/m2 IV Day 1
89394845|NCT02104310||Fluorine-18-L-dihydroxyphenylalanine|18F-DOPA PET imaging will be used to guide radiotherapy treatment volumes and patients will be followed post-treatment to analyze response and patterns of failure
89394846|NCT00109850|Experimental|Treatment|Cetuximab+Cisplatin+Irinotecan followed by radiation therapy (RT) in Cycle 3.
89394847|NCT02143232|Experimental|Remote patient monitoring (Telus RPM)|The remote monitoring device (Telus RPM) is used by every patient in the study post operatively at home.
89394848|NCT03318770||All patients|All eligible patients enrolled in the GIMEMA LAL2116 study who have completed 12 months follow-up will be included in this group.
89394849|NCT05499273|Active Comparator|scalpel-bougie tracheostomy (SBT)|SBT technique described in Interventions
89394850|NCT05499273|Active Comparator|rapid sequence tracheotomy (RST|RST technique described in Interventions
89394851|NCT01065519|Active Comparator|1|drug-eluting stent
88871098|NCT06108895|Active Comparator|Group M|it will receive intrathecal 12.5 mg hyperbaric bupivacaine 0.5% plus 200 mcg morphine in 2.5ml solution.
88871099|NCT06108817|Experimental|Information material|The intervention involved distributing an educational waiting room poster and flyers informing patients regarding the appropriate indications for prescription of an ARM for dyspepsia, which also referred to an online decision aid.
88871100|NCT06108817|Active Comparator|No information material|No intervention
88871101|NCT06106230|Experimental|Group A:Bee venom phonophoresis + Conservative care|Bee venom phonophoresis + Conservative care (32 patients)
88871102|NCT06106230|Experimental|Group B:Bee venom topical application + Conservative care|Bee venom topical application + Conservative care (32 patients)
89187554|NCT00776529|Experimental|A Sensorimotor first|In each of nine sessions: first sensorimotor exercises, then strengthening exercises
89394852|NCT01065519|Active Comparator|2|Biolimus A9-eluting Biomatrix stent
89394853|NCT01342926|Experimental|GSK933776 3 mg/kg|3 mg/kg administration of GSK933776 via intravenous infusion
89394854|NCT01342926|Experimental|GSK933776 6 mg/kg|6 mg/kg administration of GSK933776 via intravenous infusion
89394855|NCT01342926|Placebo Comparator|Placebo|Placebo via intravenous infusion
88871103|NCT06106230|Sham Comparator|Group C:Conservative care|Control group Conservative care only (32 patients) Plain gel instead of BV gel plus off ultrasound (sham ultrasound) with medical treatment
88871104|NCT06106178|Other|Simulator for Basic Ultrasound Skills|Basic course of a traditional ultrasound simulator focusing on hand-eye coordination
89394856|NCT01342926|Experimental|GSK933776 15 mg/kg|15 mg/kg administration of GSK933776 via intravenous infusion
89394857|NCT03626181|Experimental|Active TBS-DLPFC|There is only one arm. All participants will receive Theta Burst Stimulation (transcranial magnetic stimulation) of the dorsolateral prefrontal cortex.
89394858|NCT02524002|Placebo Comparator|Usual Clear Diet|This intervention consists of soup broth, variety of juices (apple, cranberry, grape), ginger ale, water, and ice.
89394859|NCT02524002|Experimental|Accel Gel|"This intervention is an enhanced clear liquid gel is Accel Gel, produced by PacificHealth Labs of Matawan, NJ. This gel has 4:1 carb to protein ratio formula, and ingredients that are not contraindicated in pregnancy (only the flavors with minimal caffeine are used).~http://www.pacifichealthlabs.com/accel-gel-all-natural-rapid-energy-gel-product.html"
89394860|NCT01810016|Experimental|Arm A|Ipilimumab (IV) followed by NY-ESO-1 recombinant protein mixed with Poly-ICLC and Montanide (SC) every 3 weeks for 4 doses.
89394861|NCT01810016|Experimental|Arm B|Ipilimumab (IV) followed by NY-ESO-1 OLP4 mixed with Poly-ICLC and Montanide (SC) every 3 weeks for 4 doses.
89394862|NCT01810016|Experimental|Arm C|Ipilimumab (IV) followed by NY-ESO-1 OLP4 mixed with Poly-ICLC (SC) every 3 weeks for 4 doses.
89394863|NCT02843178|Experimental|1: distributed, targeted vouchers|Participants receive four $5 vouchers each valid for a subsequent week of the month (i.e., one voucher valid for week 1 only, a second for week 2 only, a third for week 3 only, and a fourth for week 4 only), starting in month 1 and continuing every month through month 6. The voucher is restricted to pay for fruits and vegetables.
88871105|NCT06106178|Other|Serious Video Game|"Serious video game Underwater that focuses on hand-eye coordination training using a 3D-printed ultrasound probe for maneuvering."
89394864|NCT02843178|Active Comparator|2: lump sum, targeted vouchers|Participants receive four $5 vouchers each valid for an entire month, starting in month 1 and continuing every month through month 6. The voucher is restricted to pay for fruits and vegetables.
88871106|NCT06102083|Experimental|Experimental group 1|TDI01 dose A, once daily
88871107|NCT06102083|Experimental|Experimental group 2|TDI01 dose B, once daily
88871108|NCT06102083|Placebo Comparator|Control group|Placebo, once daily
88871109|NCT06101303||Pelvic pain|Patients with pelvic pain with and without endometriosis scheduled for an operative laparoscopic surgery for endometriosis diagnosis and/or treatment
88871110|NCT06099353|No Intervention|Arm 1: Usual Care|"General practitioners' (GPs) usual care for patients.~GPs will direct patient participants to a publicly available webpage about managing CVD risk on the Health Promotion Board website."
88871111|NCT06099353|Experimental|Arm 2: Heart Age only|"General practitioners' (GPs) usual care for patients.~GPs will direct patient participants to a publicly available webpage about managing CVD risk on the Health Promotion Board website.~GPs will also show patient participants how to access Heart Age, a risk assessment tool available online and communicate with them their respective Heart Age value."
88871112|NCT06099353|Experimental|Arm 3: Heart Age and Heart Age-HOPE-CVD app|"General practitioners' (GPs) usual care for patients.~GPs will direct patient participants to a publicly available webpage about managing CVD risk on the Health Promotion Board website.~GPs will show patient participants how to access Heart Age, a risk assessment tool available online and communicate with them their respective Heart Age value.~GPs will also direct patient participants to download the Heart Age-HOPE- CVD mobile app, an evidence-based behaviour change digital platform."
88871113|NCT06099353|Experimental|Arm 4: Heart Age, HOPE-CVD app, and genetic risk communication|"General practitioners' (GPs) usual care for patients.~GPs will direct patient participants to a publicly available webpage about managing CVD risk on the Health Promotion Board website.~GPs will show patient participants how to access Heart Age, a risk assessment tool available online and communicate with them their respective Heart Age value.~GPs will direct patient participants to download the Heart Age-HOPE- CVD mobile app, an evidence-based behaviour change digital platform.~Patient participants will undergo genetic testing from which a genetic risk score for CVD will be estimated. They will be informed which quartile of genetic risk they are at in comparison to the rest of the population. The report also contains information on what this risk means for their chances of developing cardiovascular disease in the future."
88871114|NCT06099223|Experimental|Acupuncture|Preoperative acupuncture
88871115|NCT06099223|No Intervention|Control|No acupuncture
89535457|NCT03080103||Patients submitted to appendectomy as first-line treatment|"Open or Laparoscopic Appendectomy The assignment of each patient to either the antibiotic-first management arm or the immediate surgery arm, will be non-randomized and decided independently by the Staff Specialist Surgeon on Call, upon careful assessment of AIR score, laboratory findings and imaging. The decision of the management pathway will not be influenced in any case by the participation of the patient in the study, and the assignment of the treatment will be decided by the consultant surgeon according to current good surgical practice and standard practice patterns in Italy."
88871118|NCT06090266|Experimental|OR502 monotherapy and combination therapy dose-escalation phase (Part A)|"Escalating repeated doses of OR502 by IV administration as monotherapy or in combination with cemiplimab in subjects with advanced solid tumors. OR502 will be administered once every 3 weeks (Q3W).~Cemiplimab will be administered as an IV infusion at a dose of 350 mg."
88871119|NCT06090266|Experimental|OR502 monotherapy and combination therapy dose-expansion phase (Part B)|"OR502 administered IV at 2 different dose levels identified in Part A as monotherapy or in combination with cemiplimab in subjects with platinum-resistant ovarian cancer and cutaneous squamous cell carcinoma.~Cemiplimab will be administered as an IV infusion at a dose of 350 mg."
88871120|NCT06087419|Experimental|combination drug group|
88871121|NCT06085508|Experimental|Digital patient education to reduce kinesiophobia|Intervention: Patients with MI and/or AF and kinesiophobia meet 7 times in a group education via Zoom® video meetings with a tutor (nurse, physiotherapist) for 8 weeks and learn about PA, kinesiophobia, AF and/or CAD.
88871122|NCT06083246|Experimental|Hybenix gel|Clinical application of Hybenix gel.
88871123|NCT06083246|Active Comparator|Chlosite|Clinical application of Chlosite gel.
88871124|NCT06082921|Experimental|Beef Diet|Participants will eat 3 chef prepared meals a day that contain beef as main protein source. Snacks and desserts will be provided. All aspects of the meals, except for meat type (beef/impossible beef) will be the same during each arm. The base diet will be comprised of whole foods. Meals will meet acceptable macronutrient distribution ranges of the USDA.
88871125|NCT06082921|Experimental|Impossible Beef Diet|Participants will eat 3 chef prepared meals a day that contain impossible beef as main protein source. Snacks and desserts will be provided. All aspects of the meals, except for meat type (beef/impossible beef) will be the same during each arm. The base diet will be comprised of whole foods. Meals will meet acceptable macronutrient distribution ranges of the USDA.
88871126|NCT06078150|Experimental|Experimental group: Active video game intervention for 1-6 weeks|One hour three times a week for weeks 1-6 of the intervention (consisting of a 20-minute warm-up and a 40-minute AVG game).
88871127|NCT06078150|Experimental|Experimental group: Active video game intervention for 7-12 weeks|One hour three times a week for weeks 7-12 of the intervention (consisting of a 10-minute warm-up and a 50-minute AVG game).
88871128|NCT06075290||Observation group|Intelligent jaundice instrument and Internet plus system for home monitoring and remote follow-up
88871129|NCT06075290||control group|follow-up by conventional methods ； hospital or community follow-up depending on arrangement
89187555|NCT00776529|Experimental|B Sensorimotor & strength alternated|In each of nine sessions: Strength and sensorimotor exercises alternated
89003799|NCT04505293|Experimental|InfraScanner 2000™|All patients entered onto the trial will undergo at least one cranial scanning using the InfraScanner 2000™ upon arrival to the casualty unit at MRRH following CT. Patients will be scanned using the InfraScanner 2000™ following each subsequent CT as allowed by patient or representative. Patients will know the results of the CT but not the InfraScanner 2000™. The standard for comparison will be determined as follows. A CT result that is positive for hematoma will be considered a true positive and a CT result that is negative for hematoma will be considered a true negative. In cases where the results of the CT are negative for hematoma and the results of the InfraScanner 2000™ are positive consideration of further follow-up will be given on a case-by-case basis.
89003800|NCT04502264|Experimental|Botulinum toxin, hand robot training, occupational therapy|Patient would receive Botulinum toxin (Injections of 100~400U of Botox in the upper limb muscle with a 2ml/100U dilution), robot-assisted therapy (Hand of Hope training), and standard occupational therapy.
89003801|NCT04502264|Active Comparator|Botulinum toxin, occupational therapy|Patient would receive Botulinum toxin (Injections of 100~400U of Botox in the upper limb muscle with a 2ml/100U dilution) and standard occupational therapy.
89003802|NCT04488081|Active Comparator|Control/Backbone - Remdesivir and Dexamethasone (CLOSED)|"Participants randomized to the backbone control will be given standard of care (supportive care for ARDS, including remdesivir and, if needed, lung protective ventilation). Because dexamethasone was shown to have benefit in at least one large randomized clinical trial, patients in the backbone control arm should receive dexamethasone for a total of 10 days during the hospitalization or until or hospital discharge.~Remdesivir (intravenous): 200-mg loading dose on day 1, followed by a daily maintenance dose of 100-mg on days 2 through 10.~Dexamethasone (intravenous): 6 mg intravenous or oral dexamethasone once daily up to 10 days or equivalent for alternate corticosteroid if dexamethasone unavailable."
89394865|NCT02843178|Active Comparator|3: distributed, untargeted vouchers|Participants receive four $5 vouchers each valid for a subsequent week of the month (i.e., one voucher valid for week 1 only, a second for week 2 only, a third for week 3 only, and a fourth for week 4 only), starting in month 1 and continuing every month through month 6. The voucher can pay for any food but not tobacco, alcohol or prepared foods.
89003803|NCT04488081|Experimental|Imatinib + Standard of Care (CLOSED)|Subjects will be administered standard of care + 800 mg imatinib on Day 1 orally, in divided doses of 400 mg administered twice per day. 400 mg daily will be administered orally for the following 9 days or until discharge, whichever is sooner.
89003804|NCT04488081|Experimental|Cenicriviroc + Standard of Care (CLOSED)|Subjects administered standard of care + cenicriviroc orally , loading 300 mg qAM followed by 150 mg qPM, 12 hours apart on day 1, then 150 mg BID for total of 14 to 28 days depending on date of hospital discharge.
89003805|NCT04488081|Experimental|Icatibant + Standard of Care (CLOSED)|Subjects administered standard of care + icatibant subcutaneously, a safety run-in for the first 10 subjects was conducted using a regimen of 30 mg q8h × 3 days. All subsequent subjects received drug at 30 mg q8h x 6 days.
89003806|NCT04488081|Experimental|Apremilast + Standard of Care (CLOSED)|Subjects administered standard of care + apremilast orally , 30 mg bid × 14 days.
89003807|NCT04488081|Experimental|Dornase + Standard of Care (CLOSED)|"For Non-intubated subjects: Subjects administered standard of care + dornase, 2.5 mg BID until hospital discharge, improvement to room air (or baseline oxygen use prior to illness) for 24 hours, or total of 14 days of study drug, whichever comes first.~For intubated subjects: Subjects administered standard of care + dornase, 5.0 mg BID in 10 mL normal saline until extubation or 14 days, whichever comes first. If intubated for less than 14 days, extubated subjects received 2.5 mg BID for a total Dornase treatment of 14 days, or until hospital discharge, whichever comes first."
89003808|NCT04488081|Experimental|Celecoxib/famotidine + Standard of Care (CLOSED)|"Subjects administered standard of care + celecoxib/famotidine orally .~Celecoxib, oral: 400 mg BID for 7 days.~Famotidine, oral: High dose 80 mg QID for 7 days followed by 40 mg BID for a course of 14 days."
89394866|NCT02843178|Active Comparator|4: lump sum, untargeted vouchers|Participants receive four $5 vouchers each valid for an entire month, starting in month 1 and continuing every month through month 6. The voucher can pay for any food but not tobacco, alcohol or prepared foods.
89394867|NCT03571620|Placebo Comparator|Vehicle|
89394868|NCT03571620|Experimental|1.0% Q301 Cream|
89394869|NCT03571620|Experimental|1.4% Q301 Cream|
89394870|NCT03571464|Experimental|Immediate use GGRO Mobile App|The group starts using the GGRO Mobile App immediately after the first assessment (T1) for 15 days.
89394871|NCT03571464|Active Comparator|Delayed use GGRO Mobile App|Delayed use GGRO Mobile App group started using the App 15 days after the first assessment (T2).
89394872|NCT03123185|Experimental|Placebo matching BI 705564 fasted (SRD part)|
89394873|NCT03123185|Experimental|Placebo matching BI 705564 fed (SRD part)|
89394874|NCT03123185|Experimental|1 milligram (mg) BI 705564 fasted (SRD part)|
89394875|NCT03123185|Experimental|3 mg BI 705564 fasted (SRD part)|
89394876|NCT03123185|Experimental|10 mg BI 705564 fasted (SRD part)|
89394877|NCT03123185|Experimental|20 mg BI 705564 fasted (SRD part)|
89394878|NCT03123185|Experimental|40 mg BI 705564 fasted (SRD part)|
89394879|NCT03123185|Experimental|80 mg BI 705564 fasted (SRD part)|
89394880|NCT03123185|Experimental|20 mg BI 705564 fed (SRD part)|
89394881|NCT03123185|Experimental|40 mg BI 705564 fed (SRD part)|
89394882|NCT03123185|Experimental|80 mg BI 705564 fed (SRD part)|
89394883|NCT03123185|Experimental|160 mg BI 705564 fed (SRD part)|
89394884|NCT03123185|Experimental|BI 705564 10 mg fasted/ BI 705564 10 mg fed (FE Part)|
89394885|NCT03123185|Experimental|BI 705564 10 mg fed/ BI 705564 10 mg fasted (FE Part)|
89394886|NCT03123068|Active Comparator|Active treatment group - Group A|Participants will receive a daily oral dose of 1,000 mg cocoa flavanol (CocoaVia®) for 5 days before surgery. The daily dose will consist of 8 capsules in divided doses throughout the day.
89394887|NCT03123068|Placebo Comparator|Placebo treatment group - Group B|Participants will receive a daily oral dose of a placebo for 5 days before surgery. The daily dose will consist of 8 capsules in divided doses throughout the day.
89394888|NCT01372631|Experimental|Pressure assessment|30 patients undergoing lumpectomy, mastectomy or reduction mammoplasty will be enrolled to assess the ideal pressure that should be applied when taking optical measurements.
89394889|NCT01372631|Experimental|Random and Systematic Errors|40 patients undergoing lumpectomy or mastectomy will be enrolled to assess the random and systematic errors of the miniature spectral imaging system.
89394890|NCT01372631|Experimental|Sensitivity and Specificity Assessment|150 patient undergoing lumpectomy, mastectomy or reduction mammoplasty will be enrolled in order to determine the sensitivity and specificity of the miniature spectral imaging system.
89394891|NCT02254148|Experimental|Treatment|single dose of CYP 450 substrates and a P-gp substrate + multiple doses of BI 187004
89394892|NCT01366625|Experimental|Renal Denervation|Renal Denervation and maintenance of anti-hypertensive medications and continuous positive airway pressure therapy
89394893|NCT01366625|No Intervention|Maintenance of Medications|Maintenance of anti-hypertensive medications and continuous positive airway pressure therapy
89394894|NCT02842866|Experimental|Group 1: MenACYW Conjugate Vaccine|Healthy, adult participants aged greater than or equal to (≥) 56 years received a single dose of MenACYW Conjugate Vaccine on Day 0.
89394895|NCT02842866|Active Comparator|Group 2: Menomune® Vaccine|Healthy, adult participants aged ≥56 years received a single dose of Menomune®- A/C/Y/W-135 Vaccine on Day 0.
89394896|NCT03078296||Members of the AAGL|Physicians and other providers who are members of the AAGL.
88871131|NCT06063876|Experimental|Implants with history of peri-implantitis|Implant(s) treated previously for peri-implantitis with or without exposed polished surface, no PD > 4 mm and < 50% bone loss.
88871132|NCT06054516||Ischemic heart disease|
89394897|NCT01316913|Experimental|GSK573719/GW642444 125/25|125/25 mcg once-daily
89394898|NCT01316913|Experimental|GSK573719/GW642444 62.5/25|62.5/25 mcg once-daily
89394899|NCT01316913|Experimental|GSK573719|125 mcg once-daily
89187556|NCT05673746|Active Comparator|Arm A|"Treatment for peripheral neuropathy (including neuropathic pain), according to the standard of care (e.g. Cetirizine, Gabapentin). Patient will be followed-up as per protocol for a total of 9 weeks ."
89394900|NCT01316913|Active Comparator|tiotropium bromide|18 mcg once-daily
89394901|NCT02875067|Experimental|Pembrolizumab and Lenalidomide|"An intravenous infusion of 200 mg of pembrolizumab (MK3475) once every 3 weeks for a total of 4 infusions~Lenalidomide at either 15 mg, 10 mg or 20 mg (depending on which cohort patients are enrolled in) days 1-14 every 21 days"
88871133|NCT06048107|Experimental|a prospective single-arm clinical study|
89394902|NCT03544580|Experimental|immediate implant with dentin chips|using the tooth structure presented in socket either as remaining root or as unrestorable tooth structure remove all periodontal ligaments & scraping all enamel & cementum using a stone also to cut it into slices then putting it in acid to demineralize the dentine ; then using a bone mill to transform dentine into small particles or chips to be used in jumping gap between implant & thin buccal bone
88871134|NCT06047119|Experimental|Mean arterial blood pressure above 60 mmHg during general anesthesia and 2 hours after|
88871135|NCT06047119|Experimental|Mean arterial blood pressure above 70 mmHg during general anesthesia and 2 hours after|
88871136|NCT06047119|Experimental|Mean arterial blood pressure above 80 mmHg during general anesthesia and 2 hours after|
89394903|NCT03544580|Active Comparator|immediate implant with xenograft|after surgical removal of entire badly decayed tooth we immediately put implant and in jumping gap we use xenograft
89394904|NCT02254538|Experimental|BILR 355 BS|escalating doses
89394905|NCT02254538|Placebo Comparator|Placebo|
89394906|NCT03572946|Experimental|target biopsy group|Targeted prostate biopsy
89394907|NCT03572946|Active Comparator|standard biopsy group|Standard prostate biopsy
89394908|NCT01366703||heart failure patients|stable heart failure patients, NYHA 1-2, EF > 35%, no AF, No OAC, CHADS score >2
89394909|NCT02143544|Active Comparator|Preoperative intra-aortic balloon pump.|Intervention: Preoperative placement of the intra-aortic balloon pump.
89394910|NCT02143544|No Intervention|Control|No preoperative placement of the intra-aortic balloon pump.
89394911|NCT03570294|Other|Atosiban|Total oxidant status (TOS), total antioxidant status (TAS) and oxidative stress index (OSI) values as well as 3-nitrotyrosine, carbonyl and thiol groups levels weill be measure using ELISA test in serum and plasma of 64 pregnant women before and after 48 hours of continuous administration of Atosiban.
89394912|NCT02143622|Experimental|LJM716+cetuximab|
89394913|NCT02781506|Experimental|Nivolumab and SABR|Nivolumab alone: IV, administered per standard of care according to institutional guidelines at the discretion of the treating medical oncologist, until disease progression or unacceptable toxicity. SABR, dose variable, in 1-3 fractions.
89394914|NCT03780179|Experimental|MMRvaxpro|
89394915|NCT03780179|Placebo Comparator|Placebo|
89394916|NCT03570216|Experimental|Exercise|All participants will perform 3 exercise sessions: one session to assess their cardiorespiratory fitness, one session on moderate-intensity continuous exercise and one session of high-intensity interval exercise
89394917|NCT03132753|Experimental|SUPPORT Group|Subjects enrolled in the intervention.
89394918|NCT03132753|No Intervention|Treatment as Usual|Subjects enrolled in standard services.
89394919|NCT05190185|Experimental|TAA06 injection|T cell injection targeting B7-H3 chimeric antigen receptor
89394920|NCT03571230|Experimental|Antimicrobial susceptibility testing guided therapy|"Patients in this group will receive a 10-day triple therapy for the Helicobacter pylori eradication. The regimen contains one proton pump inhibitor and two sensitive antibiotics determined by AST. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole, levofloxacin, furazolidone and tetracycline will be evaluated.~Drugs: 1.one proton pump inhibitor: lansoprazole 30mg bid for 10d 2.two sensitive antibiotics: amoxicillin 1000mg bid for 10d, clarithromycin 500mg bid for 10d, metronidazole 500mg tid for 10d, tinidazole 500mg tid for 10d, levofloxacin 500mg qd for 10d, furazolidone 100mg bid for 10d, tetracycline 750mg bid for 10d."
89394921|NCT03571230|Experimental|Empirical tailored therapy|"Patients in this group will receive a 14-day bismuth-based quadruple therapy for the H.pylori eradication. The regimen contains one PPI, Colloidal Bismuth Pectin and two antibiotics based on personal medication history. If the patient has taken clarithromycin, roxithromycin and azithromycin for less than 2 weeks before, he will be treated with amoxicillin and clarithromycin. Otherwise, he will be treated with amoxicillin and furazolidone.~Drugs: 1.one proton pump inhibitor: lansoprazole 30mg bid for 14d 2.Colloidal Bismuth Pectin 200mg bid for 14d 3.two antibiotics based on personal medication history: amoxicillin 1000mg bid and clarithromycin 500mg bid for 14d, amoxicillin 1000mg bid and furazolidone 100mg bid for 14d."
89394922|NCT03571230|Other|Salvage therapy for negative culture|"When the culture results are negative, patients will receive 14-day empirical tailored therapy based on personal medication history.~Drugs: 1.one proton pump inhibitor: lansoprazole 30mg bid for 14d 2.Colloidal Bismuth Pectin 200mg bid for 14d 3.two antibiotics based on personal medication history: amoxicillin 1000mg bid and clarithromycin 500mg bid for 14d, amoxicillin 1000mg bid and furazolidone 100mg bid for 14d."
89394923|NCT03571230|Other|Salvage therapy for failed eradication|"If patients failed with AST guided eradication therapy or empirical therapy, patients will be treated with another 14-day bismuth-based quadruple therapy.~Drugs: 1.one proton pump inhibitor: lansoprazole 30mg bid for 14d 2.Colloidal Bismuth Pectin 200mg bid for 14d 3.two antibiotics for rescue therapy: tetracycline 750mg bid and furazolidone 100mg bid for 14d."
89394924|NCT03644615|Experimental|Mindfluness and usual care|
89394925|NCT03644615|Other|Usual Care|
89394926|NCT01468454|Experimental|(18F-DOPA) PET/CT imaging|Obtain safety and efficacy data on the use of 18-labeled L-fluorodeoxyphenylalanine (18F-DOPA) PET imaging in children with HI for the clinical indication of localizing a focal lesion
88871137|NCT06047119|Experimental|Systolic blood pressure above 90% of baseline during general anesthesia and 2 hours after|
88871138|NCT06047119|Experimental|Positive end expiratory pressure 5 cm H20 during general anesthesia|
88871139|NCT06047119|Experimental|Positive end expiratory pressure 8 cm H20 during general anesthesia|
88871140|NCT06047119|Experimental|Positive end expiratory pressure 10 cm H20 during general anesthesia|
88871141|NCT06047119|Experimental|Tidal volume 5 ml/kg during general anesthesia|
89394927|NCT01366781|Experimental|Healthy males|Meal ingestion in healthy males
89394928|NCT01366781|Experimental|Healthy females|Meal ingestion in healthy females
89394929|NCT02143700||Stable and exacerbated patients|Patients diagnosed of chronic obstructive pulmonary disease in a stable or exacerbated situation. Cognitive assessment of these patients will be performed.
89394930|NCT04151225|Placebo Comparator|Participants receiving placebo|Participants will receive placebo loading dose followed by placebo for 12 weeks during Induction phase. Participants with clinical response at Week 12 will continue to receive placebo into a 40-weeks blinded maintenance period. Participants without a clinical response at Week 12 will receive a 450mg GSK2330811 SC loading dose at Week 12, followed by 150 mg SC every week from Week 13 until Week 23, followed by 150 mg SC every 2 weeks until Week 50.
88871142|NCT06047119|Experimental|Tidal volume 8 ml/kg during general anesthesia|
88871143|NCT06047119|Experimental|Tidal volume 10 ml/kg during general anesthesia|
88871144|NCT06047119|Experimental|Fraction of inspired oxygen 30% during general anesthesia and 2 hours after|
88871145|NCT06047119|Experimental|Fraction of inspired oxygen 80% during general anesthesia and 2 hours after|
88871146|NCT06041841|Experimental|POMC/PCSK1/LEPR cohort|LB54640 once daily by oral administration
88871147|NCT06038617|Experimental|Simultaneous vaccination arm|The simultaneous vaccination group will receive routine childhood vaccinations and mRNA COVID-19 vaccination at Visit 1, followed by a health education visit without vaccination at Visit 2.
88871148|NCT06038617|Experimental|Sequential vaccination arm|The sequential vaccination group will receive routine childhood vaccinations at Visit 1, followed by a health education visit with mRNA COVID-19 vaccination at Visit 2.
89394931|NCT04151225|Experimental|Participants receiving GSK2330811 450mg loading dose/150mg Q1W|Participants will receive 450mg GSK2330811 SC as loading dose followed by 150 mg GSK2330811 Q1W for 12 weeks during Induction period. Participants with clinical response at Week 12 will continue into a 40 weeks blinded maintenance period will receive 150 mg GSK2330811 SC Q2W. Participants without a clinical response will receive GSK2330811 150mg Q1W from Week 12 until Week 23, followed by GSK2330811 150mg Q2W until Week 50.
89394932|NCT04151225|Experimental|Participants receiving GSK2330811 300mg loading dose/150mg Q2W|Participants will receive 300mg GSK2330811 SC as loading dose followed by 150mg GSK2330811 SC Q2W for 12 weeks during Induction period. Participants with clinical response at Week 12 will continue into a 40 weeks blinded maintenance period will receive 150mg GSK2330811 SC Q2W. Participants without a clinical response will receive GSK2330811 150mg Q1W from Week 12 until Week 23, followed by GSK2330811 150mg Q2W until Week 50.
89394933|NCT04151225|Experimental|Participants receiving GSK2330811 300mg loading dose/150mg Q4W|Participants will receive 300mg GSK2330811 SC as loading dose followed by 150mg GSK2330811 SC Q4W for 12 weeks during Induction period. Participants with clinical response at Week 12 will continue into a 40 weeks blinded maintenance period will receive 150 mg GSK2330811 SC Q4W. Participants without a clinical response will receive GSK2330811 150mg Q1W from Week 12 until Week 23, followed by GSK2330811 150mg Q2W until Week 50.
89394934|NCT04151225|Experimental|Participants receiving GSK2330811 150mg Q8W|Participants will receive GSK2330811 SC 150 mg Q8W for 12 weeks during Induction period. Participants with clinical response at Week 12 will continue into a 40 weeks blinded maintenance period will receive 150 mg GSK2330811 SC Q8W. Participants without a clinical response will receive GSK2330811 150mg Q1W from Week 12 until Week 23, followed by GSK2330811 150mg Q2W until Week 50.
89394935|NCT03067077|Active Comparator|SMILE|SMILE surgery
88871149|NCT06035263|Experimental|FUNCTIONAL REEDUCATION AND ENVIRONMENTAL ADAPTATION PROGRAMME|prescription of reeducation in activities of daily living and the prescription of assistive devices and environmental adaptations, for one month from the first baseline assessment at the time of hospital discharge.
88871150|NCT06035263|Active Comparator|Health education programme:|"instructions and recommendations for maintaining an active and healthy life will be given as part of a health education programme. These will focus on the benefits of an active lifestyle and general guidelines to follow, as well as the importance of nutrition and hydration in a healthy lifestyle.~They will receive the dossier of instructions and recommendations of the health education programme, as in the experimental group."
89394936|NCT03067077|Active Comparator|Wavefront-guided LASIK|Wavefront-guided LASIK
89394937|NCT02143856|Experimental|100 mg GLPG1205 fasted|Single dose of 100 mg GLPG1205 as two capsules of 50 mg after an overnight fast
89394938|NCT02143856|Experimental|100 mg GLPG1205 fed|Single dose of 100 mg GLPG1205 as two capsules of 50 mg exactly 30 minutes after the start of a high-fat, high-calorie breakfast
88871151|NCT06035198||Stroke patients|Patients diagnosed with stroke at four hospitals in Korea
88871152|NCT06033859||Implants with BOP score 0|Implants with no BOP according to the modified bleeding index at baseline.
88871153|NCT06033859||Implants with BOP score 1|Implants with a bleeding dot at baseline.
88871154|NCT06033859||Implants with BOP score 2|Implants with a continuous line of blood that fills the sulcus at baseline.
88871155|NCT06033859||Implants with BOP score 3|Implants with a profuse bleeding and/or hemorrhage drip at baseline.
88871156|NCT06031662|Experimental|Treatment|
88871157|NCT06031662|Sham Comparator|Sham|
88871158|NCT06025721|Experimental|CV-Homes Intervention|Behavioral treatment by a wellness coach.
88871159|NCT05997732|Experimental|Control Condition|Normal saline will be infused through the brachial artery catheter at the same calculated rate as propranolol + phentolamine in the α+β-blockade condition to control for volumetric effects.
88871160|NCT05997732|Experimental|β-Adrenergic Blockade|β-adrenoreceptors will be blocked locally in the forearm using propranolol. Normal saline will be co-infused at the calculated rate of phentolamine in the α+β-blockade condition to control for volumetric effects.
88871161|NCT05997732|Experimental|α+β-Adrenergic Blockade|α-adrenoreceptors will be blocked locally in the forearm using phentolamine. Propranolol will be co-infused to maintain β-blockade.
88871162|NCT05979454||Rheumatoid Arthritis-associated Interstitial Lung Disease|Krebs von den Lungen-6 (KL6)
89394939|NCT03545438|Placebo Comparator|cohort 1|LIB003 dose 1 SC
89394940|NCT03545438|Placebo Comparator|cohort 2|LIB003 dose 2 SC
89394941|NCT03545438|Placebo Comparator|cohort 3|LIB003 dose 4 SC
88871163|NCT05970614|No Intervention|Control group|No application will be made to the participants. Participants will receive routine care.
89187557|NCT05673746|Experimental|Arm B|"In addition to the treatment for peripheral neuropathy and neuropathic pain, according to the standard of care (e.g. Cetirizine, Gabapentin), patient will receive acupuncture administration twice a week and for a 6-week treatment period. Patient will also be followed-up for 3 weeks after the end of treatment."
89187558|NCT00772473||1 group, usual acute triptan treatment|
88871164|NCT05970614|Other|intervention group|In addition to routine care, participants will be given eye masks and ear plugs for 3 days.
88871165|NCT05961514|Other|Traditional|The traditional/control arm consists of systematic biopsies of the prostate if PSA>4ng/ml.
88871166|NCT05961514|Experimental|Experimental|The experimental arm consists of MRI tests and targeted biopsies if PI-RADS scores ≥3 or systematic biopsies if PSA>10ng/ml.
88871167|NCT05958628|Other|Control group|Participants in this group will receive a conventional physiotherapy program 3 times a week for 5 weeks, each session lasting 1 hour.
88871168|NCT05958628|Experimental|Intervention group|Participants in this group will receive Robotic Hand Exoskeleton System for 10 minutes in addition to 50 minutes of conventional physiotherapy 3 times a week for 5 weeks.
88871169|NCT05943314|Experimental|CLL1/+CD33 CAR-T|The target dose range for subjects was set to be 1.00~2.50x10^6/kg CAR-positive T cells.
89003809|NCT04488081|Experimental|IC14 + Standard of Care (CLOSED)|Subjects administered standard of care + IC14 intravenously , 4 mg/kg on day 1, followed by 2 mg/kg on days 2, 3, 4
89394942|NCT03545438|Placebo Comparator|cohort 4|LIB003 dose 4 SC
89394943|NCT03545438|Placebo Comparator|cohort 5|LIB003 dose 5 SC
89394944|NCT03545438|Placebo Comparator|cohort 6|LIB003 dose 4 IV
89394945|NCT03545438|Placebo Comparator|cohort 7|LIB003 dose 5 IV
89394946|NCT03545438|Placebo Comparator|cohort 8|LIB003 dose 3 SC - statin treated
89394947|NCT03545438|Placebo Comparator|cohort 9|LIB003 dose 4 SC - statin treated
88871170|NCT05942326|Experimental|Sleep GOALS|Weekly 15-to-20 minute educational video each, a commercial activity tracker (e.g., Fitbit) to monitor sleep and physical activity, wireless scale to monitor weight, and a lifestyle coach who will provide personalized support.
88871171|NCT05942326|Active Comparator|Education|Brochures that provide tips for improving sleep health, diet, and physical activity
88871172|NCT05941858|Experimental|Arm I (Tai Chi)|Participants receive access to the online WaQi program to practice Tai Chi supervised and home-based over 8 weeks. Participants also receive standard cessation treatment that includes a prescription or recommendation for NRT and CO testing on study.
89394948|NCT01372709||Ovation™ or Ovation Prime™ Abdominal Stent Graft System|Adult male and female patients will be consecutively screened for the study. Eligible patients must meet all of the inclusion criteria and none of the exclusion criteria.
89394949|NCT02939612|Experimental|App for Stress management|Participants will get access to two modules per week for five weeks (total 10 modules). The app consists of stress management education, cognitive behavioral interventions and relaxation training exercises.
88871173|NCT05941858|Active Comparator|Arm II (Standard cessation)|Participants receive standard cessation treatment that includes a prescription or recommendation for NRT and undergo CO testing on study. Participants also receive an 8-week online Tai Chi self-administered teaching module subscription at the end of the study.
89394950|NCT02939612|No Intervention|Waitlist control group|Participants will get treatment as usual during the study. After the one year study follow up they will receive the stress management app.
89394951|NCT02254226|Experimental|Salmeterol MDI low|
89394952|NCT02254226|Active Comparator|Salmeterol MDI high|
88871174|NCT05935917|Active Comparator|Treatment AB - Form H (test tablet) first|"Treatment AB:~Participants assigned to Treatment AB in Period 1, will be given a single 100 mg tablet of Form H (test tablet). In Period 2, participants will be given a single 100 mg tablet of Form II (reference tablet) after a 14 day washout period."
88871175|NCT05935917|Active Comparator|Treatment BA - Form II (reference tablet) first|"Treatment BA:~Participants assigned to Treatment BA in Period 1, will be given a single 100 mg tablet of Form II (reference tablet). In Period 2, participants will be given a single 100 mg tablet of Form H (test tablet) after a 14 day washout period."
89394953|NCT02254226|Experimental|Salmeterol Diskus low|
89394954|NCT02254226|Experimental|Salmeterol Diskus high|
89394955|NCT02143934|Active Comparator|Primaquine|Primaquine, 0.5mg/kg/day, 20 days directly observed treatment Chloroquine, 25mg/kg total dose, divided over 3 days directly observed treatment Artemether-Lumefantrine, 3 days BD
89394956|NCT02143934|Placebo Comparator|Placebo|Placebo, 20 days directly observed treatment Chloroquine, mg/kg, 3 days directly observed treatment Artemether-Lumefantrine, 3 days BD
89394957|NCT01366859|Experimental|Whey Protein (Immunocal®)|The experimental study group will consist of thirty children that will be treated with Immunocal® 0.5 g/kg if less than 18 kg of body weight or 10 g/day for those children over 18 kg of body weight for three months.
89394958|NCT01366859|Placebo Comparator|Placebo: Rice Protein|The control or placebo study arm will consist of thirty children who will receive a dose of 0.5 g/kg of weight a day up to 18 kg of weight a day or a dose of 10 g/day for those over 18 kg for three months.
89394959|NCT03096847|Experimental|ribociclib + letrozole cohort A|"ribociclib + letrozole cohort A - postmenopausal women, or men; naïve.~All patients received ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o. daily."
89394960|NCT03096847|Experimental|ribociclib + letrozole cohort B1|"ribociclib + letrozole cohort B1 - premenopausal women or perimenopausal women; naïve~All patients received ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o. daily.~Premenopausal patients additionally received goserelin 3.6 mg i.m. monthly"
88871176|NCT05918302|Experimental|Experimental arm|Treatment with 6 cycles of 7.5 ± 0.7 GBq 177Lu-edotreotide. The prescribed treatment administration is as follows: a 6 (±2) weeks interval between cycles 1 and 2 followed by all remaining cycles (3-6) given 8 (± 1) weeks after the previous cycle), where possible, or until disease progression, intolerable toxicity or death, whichever occurs first.
88871177|NCT05918302|Active Comparator|Control arm|Everolimus 10 mg orally once daily (QD) until disease progression or intolerable toxicity or death, whichever occurs first.
88871178|NCT05916989||Leukocyte DNA Samples|Leukocyte DNA specimens extracted from participants enrolled in a completed NIH funded trial will be examined to determine if prior exposure to different behavioral interventions modifies DNA methylation patterns over 6 months.
88871179|NCT05895825|Experimental|Part 1: Dose Escalation|In Part 1 (dose escalation) participants with selected advanced solid tumors will receive escalating doses of EOC237 as monotherapy. Participants can receive EOC237 until disease progression, adverse event (AE), or other discontinuation criteria, whichever occurs first.
88871180|NCT05895825|Experimental|Part 2: Food influence-Group 1|"Food influence-Group 1: EOC237 was taken orally under fasted conditions, after a 3-day washout period, EOC237 was taken orally under fed conditions.~Participants can receive EOC237 until disease progression, AE, or other discontinuation criteria, whichever occurs first."
88871181|NCT05895825|Experimental|Part 2: Food influence-Group 2|"Food influence-Group 2: EOC237 was taken orally under fed conditions, after a 3-day washout period, EOC237 was taken orally under fasted conditions.~Participants can receive EOC237 until disease progression, AE, or other discontinuation criteria, whichever occurs first."
88871182|NCT05891548|Experimental|1.0 mg CLS-AX|Suprachoroidal injection of 10 mg/mL (1.0 mg in 0.1 mL) of CLS-AX
88871183|NCT05891548|Active Comparator|Aflibercept|Intravitreal injection of aflibercept (2 mg in 0.05 mL)
88871184|NCT05881161|Experimental|Adherence self-efficacy-enhancing exercise followed by internet intervention (Med-Stress Student)|
88871185|NCT05881161|Active Comparator|Internet intervention (Med-Stress Student)|
88871186|NCT05881148|Experimental|Carbon sprinting Super-spikes|Trademarked Carbon Spiked-Shoes, from one Trademark only to ensure generalization concerns, is used alternatively with standard carbon-free spiked-shoes, for 8 repetitions of 30m-sprint each, separated by 10 minutes rest each.
88871187|NCT05881148|Active Comparator|Standard sprinting carbon-free spiked-shoe|
88871188|NCT05871996||Group 1|Individuals with a diagnosis of cancer known to palliative care services. This group completes Case Report Form for Group 1.
88871189|NCT05871996||Group 2|"Individuals with a diagnosis of cancer receiving anti-cancer treatment known to oncology services.~This group completes Case Report Form for Group 2"
88871190|NCT05870670|Experimental|NNC0519-0130|Escalating multiple doses of NNC0519-0130 administered subcutaneously.
88871191|NCT05870670|Placebo Comparator|Placebo|Escalating multiple doses of NNC0519-0130 matching placebo administered subcutaneously.
88871192|NCT05869383|Placebo Comparator|Placebo|Control group get placebo 2x5 grams a day for 14 days
88871193|NCT05869383|Experimental|Ophiochepalus striatus extract|Intervention group get Ophiochepalus striatus extract 2x5 grams a day for 14 days
88871194|NCT05862792||TORS + Liposomal Bupivacaine + Postoperative Antipyretics and Opioids Group|"Per standard of care, at the conclusion of the TORS procedure, liposomal bupivacaine will be injected into the surgical bed- (bupivacaine liposome suspension 1.3% [13.3 mg/mL], intramuscular) in this group. Possible injection sites include the base of tongue and/or tonsil. Total dose injected will be 3-4 mL. Subjects will also be given a pain regimen including:~Tylenol 650 mg every 4 hours as needed for mild pain~Oxycodone 5 mg every 4 hours as needed for moderate pain~Morphine 2mg every 3 hours as needed for breakthrough pain~The treatment type (TORS +/- Liposomal Bupivacaine + Postoperative Antipyretics and Opioids) is determined by the subject's surgeon based on his standard practice."
88871195|NCT05862792||TORS + Postoperative Antipyretics and Opioids Group|"Per standard of care, subjects in this group will only be given a pain regimen including:~Tylenol 650 mg every 4 hours as needed for mild pain~Oxycodone 5 mg every 4 hours as needed for moderate pain~Morphine 2mg every 3 hours as needed for breakthrough pain~The treatment type (TORS +/- Liposomal Bupivacaine + Postoperative Antipyretics and Opioids) is determined by the subject's surgeon based on his standard practice."
88871196|NCT05855317||Patients with pulmonary embolism|The presence of pulmonary embolism is determined from a CT scan realized between Day 5 and Day 28.
88871197|NCT05855317||Patients without pulmonary embolism|The absence of pulmonary embolism is determined from a CT scan realized between Day 5 and Day 28.
88871198|NCT05849337|Experimental|Brief imagery-competing task|Access to a brief imagery-competing task for 24 weeks (with optional researcher support during the study)
88871199|NCT05849337|Experimental|Brief psychoeducation and signposting task|Access to psychoeducation and signposting regarding resources for psychological trauma in Iceland for 24 weeks (with optional researcher support during the study)
89394961|NCT03096847|Experimental|ribociclib + letrozole cohort B2|"ribociclib + letrozole cohort B2 - premenopausal women or perimenopausal women or postmenopausal women, or men; pre-treated.~All patients received ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o. daily.~Premenopausal patients additionally received goserelin 3.6 mg i.m. monthly"
89394962|NCT01365182|Experimental|BF+SUPPORT|a 60-minute session of biofeedback (BF) training in pelvic floor muscle exercises plus 6 biweekly peer support group sessions during 3 months to learn symptom self- management skills
89394963|NCT01365182|Experimental|BF+PHONE|a 60-minute session of biofeedback (BF) training in pelvic floor muscle exercises plus 6 biweekly individual telephone contact with a therapist during 3 months to learn symptom self- management skills
89394964|NCT01365182|No Intervention|Usual Care|Subjects continued receiving usual care without receiving any intervention training sessions
89394965|NCT02144090|Experimental|Fractional flow reserve|Fractional flow reserve measurement
89394966|NCT03019575|Experimental|Corifollitropin alfa (CFA)+human Chorionic Gonadotropin (hCG)|Participants received 100 μg (if body weight was ≤60 kg) or 150 μg (if body weight was >60 kg) of CFA as a subcutaneous (SC) injection once every 2 weeks for 64 Weeks (Day 1, Week 0 through Week 64) and 500-5000 IU of hCG reconstituted with 1 ml of 0.9% sodium chloride solution, as a SC injection twice a week for 52 weeks (last day of Week 12 through Week 64). The total treatment duration was 64 Weeks.
89394967|NCT03634709|Experimental|Memory Flexibility Training (MemFlex)|The MemFlex programme has been adapted from the initial format addressing depression-related memory distortions to facilitate completion with individuals experiencing posttraumatic stress. The workbook and associated materials have also been translated from English to Farsi. The programme consists of one researcher-facilitated session and eight self-guided workbook-based sessions that train memory retrieval skills and are completed over a one month period.
89394968|NCT03634709|No Intervention|Waitlist control|After randomisation, the waitlist control group will be informed that they have been placed on a waiting list for the intervention. The participants will complete the baseline assessment and receive no further contact from the researcher until the post assessment one month later, followed by the follow-up assessment three months later. After the three month assessment, wait listed participants will receive the intervention. No further assessments will be completed.
89394969|NCT02144168|Active Comparator|prebiotics-free enteral formula|Patients in this arm will be receiving standard, prebiotics-free enteral formula : Osmolite 1 cal
89394970|NCT02144168|Experimental|prebiotics containing enteral formula|Patients in this arm will be receiving prebiotics containing enteral formula:Ensure Fos for 14 days
89394971|NCT03128099|Experimental|Low dose VR social skills training|In the low dose condition, participants play the video game for one hour per session. This is a behavioral intervention study. The intervention is playing the social skills virtual reality game to exercise social skills with avatar characters.
89394972|NCT03128099|Experimental|High dose Low dose VR social skills training|In the high dose condition, participants play the same video game twice per session (it takes them two hours). This is a behavioral intervention study. The intervention is playing the social skills virtual reality game to exercise social skills with avatar characters.
89394973|NCT03128099|No Intervention|Healthy Control Participants|23 healthy control participants were recruited and consented to yield baseline comparison data. These participants did not undergo VR training. Only baseline comparison data were collected.
89394974|NCT03545516|Placebo Comparator|Placebo|Wound infiltration with a placebo
89394975|NCT03545516|Experimental|Bupivacaine|Wound Infiltration with 20 mL (150mg) of 0.75% bupivacaine diluted with 5 mL of normal saline to give a 25 mL
88816610|NCT05858983|Experimental|FT-001 Dose 1|Intraocular administration of a single low dose of range FT-001
89394976|NCT03545516|Experimental|Bupivacaine and Dexmedetomidine|Wound Infiltration with 20 mL (150mg) of 0.75% bupivacaine and 1.5 mcg/kg of dexmedetomidine will be diluted with normal saline to make 25 mL of solution .
89394977|NCT04756453|No Intervention|Standard|Standard endoscopic submucosal dissection
89394978|NCT04756453|Active Comparator|Interventional|Mandatory use of the clip-traction device
89394979|NCT04545333||ALL|patients diagnosed with acute lymphoblastic leukemia
89394980|NCT04545333||CLL|patients diagnosed with chronic lymphocytic leukemia
88816611|NCT05858983|Experimental|FT-001 Dose 2|Intraocular administration of a single Mid dose of range FT-001
88816612|NCT05858983|Experimental|FT-001 Dose 3|Intraocular administration of a single High dose of range FT-001
88816613|NCT05858944|Experimental|Intensive Home BP Control|Participants randomized into the intensive treatment arm will have a goal of home BP<125/75 mmHg.
88816614|NCT05858944|Active Comparator|Standard Home BP Control|Participants randomized into the standard treatment arm will have a goal of home BP within 125-134/75-84 mmHg.
88816615|NCT05858892||shoulder musculoskeletal group|The International Classification of Diseases, 10th revision (ICD-10) codes were selected before the study started and included the ICD-10 codes M75 (Shoulder lesions), S42 (Fracture of shoulder and upper arm), S43 (Dislocation and sprain of joints and ligaments of shoulder girdle), and S46 (Injury of muscle, fascia and tendon at shoulder and upper arm level)
88816616|NCT05858866||Smartphone-addicted group|university sdudents
88816617|NCT05858866||non-smartphone-addicted group|university sdudents
88816618|NCT05858749||Patients with mRCC|Patients with mRCC in the IMDC
88816619|NCT05858723|Experimental|Allergic participants|
88816620|NCT05858723|Experimental|Healthy participants|
88816621|NCT05858697||Declining group|Children with obesity 5-7 years of age who were invited to the intervention but declined participation.
88816622|NCT05858697||Interventions group|Children with obesity 5-7 years of age who accepted and subsequently received treatment.
89394981|NCT04545333||MM|patients diagnosed with multiple myeloma
89394982|NCT04545333||NHL|patients diagnosed with non-Hodgkin lymphoma
89394983|NCT01372787||Arm I|
88871200|NCT05849337|Other|Treatment as usual (TAU)|Routine care that participants would otherwise receive if having intrusive memories of traumatic events.
88871201|NCT05845788||Erector Spina Plan Block Group (Group E)|Patients who underwent erector spina plane block before initiation of surgery after induction of anesthesia
88871202|NCT05845788||Posterior Quadratus Lumborum Block Group ( Group Q)|Patients who underwent posterior quadratus lumborum block block before initiation of surgery after induction of anesthesia
88871203|NCT05832268||Sphincter damage|Women who suffered an injury to anal sphincter after a vaginal delivery and had a subsequent delivery after this injury
88871204|NCT05832268||Controls|Women who have had a at least two vaginal deliveries without suffering an injury to the anal sphincter
88871205|NCT05831293|Experimental|Experimental|In each session, three sections were discussed and reviewed: (1) last week's experiences, (2) training, and (3) practice. Each session usually began with mindfulness and meditation exercises, followed by group discussion, review of homework activities, and introduction to new exercises. Participants were asked to complete 15-30 minutes of daily practice each week.
88871206|NCT05831293|No Intervention|Control|No intervention will be applied to the control group.
88871207|NCT05829603|Experimental|Sequence A|Six varying doses of a fixed-combination of Dimethyltryptamin (DMT) and harmine
88871208|NCT05829603|Experimental|Sequence B|Six varying doses of a fixed-combination of Dimethyltryptamin (DMT) and harmine
89394984|NCT02886494|Active Comparator|BAC treatment|BAC, topical application on external nasal skin, scalp, and neck, 2 times daily, 30 g/day for 12 weeks
89394985|NCT02886494|Placebo Comparator|Matched vehicle|Matched vehicle, topical application on external nasal skin, scalp, and neck, 2 times daily, 30 g/day for 12 weeks
89394986|NCT04660903|Experimental|Intervention|One arm study - the intervention arm is the only actual
89394987|NCT04519749|Experimental|4D-310 Dose Level 1 - AAV Neutralizing Antibody (NAb) Group A|Single IV administration of 4D-310 Dose Level 1 - AAV NAb Titer Group A patients
88871209|NCT05804708|Experimental|GH001 Individualized Dosing Regimen|"Drug: 5-Methoxy-N,N-Dimethyltryptamine~GH001 is administered via inhalation, as an IDR (individualized dosing regimen) consisting of up to 3 increasing doses of GH001 (6 mg, 12 mg, and 18 mg), on a single day. The second and third doses are only administered if the patient did not achieve intense psychoactive effects (a peak experience [PE]) at the previously administered dose"
88871210|NCT05798975|Experimental|Aerobic Physical Exercise|Cycle ergometer exercise
88871211|NCT05798975|Experimental|Resistance Physical Exercise|Exercise with weights
88871212|NCT05798975|No Intervention|Control|No exercise. Rest
88871213|NCT05788783|Experimental|Experimental|Active intervention. 8 youth will be assigned to the active Recovery & Care Canine-Assisted Therapy intervention arm.
89394988|NCT04519749|Experimental|4D-310 Dose Level 1 - AAV NAb Titer Group B|Single IV administration of 4D-310 Dose Level 1 - AAV NAb titer Group B patients
89394989|NCT04519749|Experimental|4D-310 Dose Level 2 - AAV NAb Titer Group A and/or B|Single IV administration of 4D-310 at Dose Level 2 in AAV NAb titer Group A and/or B patients
88871214|NCT05788783|Other|Active control|Active control intervention. 8 youth will be assigned to the active Canine Education & Bonding arm.
89394990|NCT04519749|Experimental|4D-310 Dose Expansion|Dose expansion cohort of single IV administration of 4D-310 at the selected dose and selected AAV Nab titer group(s) patients
89394991|NCT00204477|Active Comparator|Soy milk|Subjects will consume two soy milk drinks from the content of 2 sachets (40 g isoflavone-free soy protein and 600 mg calcium) in place of a small meal, five days per week. Each sachet will contain 20 g soy protein and 300 mg calcium. Content of sachets will be mixed with ~1.6 liter of water for ingestion.
89394992|NCT00204477|Placebo Comparator|Cow's milk|Subjects will consume two cow's milk drinks from the content of 2 sachets (40 g cow's milk protein, casein, and 600 mg calcium) in place of a small meal, five days per week. Each sachet will contain 20 g cow's milk protein and 300 mg calcium. Content of sachets will be mixed with ~1.6 liter of water for ingestion. Casein is free of ovarian hormones.
89394993|NCT02835326|Experimental|Exercise and Dietary Weight Loss|For the first 6 months, participants will meet at a community center for 3 group-based sessions and 1 individual session each month. Sessions include a 45 minute exercise component and a 45 minute dietary weight loss component. Exercise will consist of progressive aerobic and strength training. The dietary component will focus on decreasing caloric intake, while being nutritionally safe. All diets will be monitored by a Registered Dietitian. During months 7-12, participants will meet for 1 group session and 1 individual session per month. The final 12-24 months, bimonthly phone calls are provided to the participants to aid in retention efforts.
89394994|NCT02835326|Active Comparator|Walk with Ease|The Arthritis Foundation's (AF) WWE is a self-management program for symptoms of arthritis (pain, fatigue, stiffness,etc.) through exercise. It is a 6 week program involving 3 sessions per week each lasting about 60 minutes. The WWE sessions are comprised of walking, stretching and strengthening exercises, and health education lectures. These group classes will be lead by an AF instructor. Each participant will complete 2 consecutive WWE classes for a total of 12 weeks in the program. During the final week of the program, participants will be trained and transitioin to the self-directed version of WWE for maintenance of exercise. To aid in retention efforts, phone contacts are provided to participants on a monthly basis from 4-12 months and bi-monthly from 12 to 24 months
89394995|NCT04514367|Experimental|ANX005|IV
89187559|NCT00776607|Experimental|Insulin|Insulin: NovoMix 30. Patients will be given advice on diet and exercise and life style and will be started on NovoMix 30, one dose of 6 U at the evening/main meal.
89187560|NCT00776607|Active Comparator|Tablet|Patients will progress from lifestyle modification to metformin, to metformin with Rosiglitazone and finally insulin depending on HbA1c levels.
89394996|NCT03545048|Experimental|Intervention arm|"Interventional groups will have an assessment session with the experienced staff and NRS, QST, WOMAC, MSK-HQ, 30CST, TUG, PSQI, MSK-USS, urine and blood samples will be taken at baseline. Those who consent for aspiration of synovial fluid will go through the USGA procedure.~Interventional group will shortly after that receive a link via email, which will be used to log-in to Joint Academy online portal. After log-in has been achieved, the intervention starts. It consist of a 6-week internet-based physical therapy program. Interventional group will be given actigraphy device (a device to monitor sleeping pattern) which is CE marked. Therefore, their sleeping pattern can be recorded quantitatively.~Once exercises programme is finished in six weeks, the participants will fill in the same questionnaire and perform the physical tests, to enable evaluation."
89394997|NCT03545048|No Intervention|Control arm|Control group will continue with their routine self-management which is offered in the community setup. They will be assessed on NRS, QST, WOMAC, MSK-HQ, PSQI, 30CST, TUG, isometric muscles strengthen of quadriceps, MSK-USS, muscle mass of vastus lateralis, urine and blood samples at baseline. Control group will also get the actigraphy to monitor sleeping pattern of that group. They will be re-assessed after six weeks on the primary objective measures to see if they have made any difference by following self-management strategies in the community.
89394998|NCT02846532|Experimental|Rivaroxaban|
89394999|NCT02846532|Experimental|Acetylsalicylic Acid|
89395000|NCT02809521|Other|Activity Liking|Subjects will look at images of people doing different types of activities (e.g., walking, skiing, watching television) and rate their liking of the activity.
89395001|NCT02744001|Experimental|Low Added Sugar Diet|Menu containing <10% of total daily energy intake from added sugars.
89395002|NCT01371461||Patients prescribed PAXIL|Patients with depression or depressed state prescribed PAXIL during study period
89395003|NCT02731521||3 Tesla Scanning and 7 Tesla Scanning|Scanning at 3 Tesla and 7 Tesla: Magnetic Resonance Imaging (MRI)/Magnetic Resonance Spectroscopy (MRS) of glioma and non-glioma patients.
89395004|NCT02728557|Experimental|Supportive psychotherapy|Participants will receive supportive therapy.
89395005|NCT02728557|Experimental|Supportive-expressive psychotherapy|Participants will receive supportive-expressive therapy.
88871219|NCT05782517|Experimental|I-gel|
88871220|NCT05782517|Active Comparator|Endotracheal Tube|
88871221|NCT05781958|Experimental|Cadonilimab+Gem/Cis|
89395006|NCT03571152|Experimental|Educational videos|Subjects allocated in this arms will receive the educational videos.
88871222|NCT05755152|Experimental|Cranberry PLP|Chew the treatment chewing gum made with PLP at specific time intervals for a total of 60 minutes
89395007|NCT05337527|Experimental|Beetroot supplementation|One serving 70 mL of beetroot juice (6.4 mmol of NO3-; Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) 3 h before initiating the testing session.
89395008|NCT05337527|Placebo Comparator|Placebo supplementation|One serving 70 mL of beetroot juice placebo (0.04 mmol of NO3-; Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) 3 h before initiating the testing session.
88871223|NCT05755152|Experimental|Cranberry Extract Control|Chew the control chewing gum made with Cranberry Extract at specific time intervals for a total of 60 minutes
88871224|NCT05753930|Experimental|Imlifidase|Imlifidase is administered intravenously as one infusion of 0.25 mg/kg over 15 minutes within 24 hours prior to transplantation.
88871225|NCT05737602|Experimental|3RP-VHL|"An adapted version of the 3RP (3RP-VHL) for individuals with VHL. The adapted program incorporates the three prongs of the 3RP: RR elicitation, stress awareness, and adaptive strategies. It will be delivered in weekly sessions over the course of approximately 8 weeks.~Complete pre- and post-intervention surveys."
88871226|NCT05724316|Experimental|Vitamin D Group|All participants in this group will receive cholecalciferol (VD3 25μg) tablets, one to be taken per day.
88871227|NCT05724316|No Intervention|Control Group|Will receive no vitamin D supplements.
88871228|NCT05724264|Experimental|Low-dose CT of the Chest (LDCT) + Blood sampling|
88871229|NCT05723588|Experimental|active rTMS|Participants assigned to this group will receive active repetitive transcranial magnetic stimulation (rTMS) as part of their smoking cessation treatment.
88871230|NCT05723588|Sham Comparator|sham rTMS|Participants assigned to this group will receive sham repetitive transcranial magnetic stimulation (rTMS) as part of their smoking cessation treatment.
88871231|NCT05705492|Experimental|Arm I (olanzapine, optional biospecimen collection)|Patients receive olanzapine PO for six weeks on study. Patients may also undergo an optional CT scan and blood sample collection on the study.
88871232|NCT05705492|Placebo Comparator|Arm II (placebo, olanzapine, optional biospecimen collection)|Patients receive placebo PO for six weeks and then receive olanzapine PO for 6 weeks. Patients also undergo an optional CT scan and collection of blood samples on study.
89395009|NCT05324423|Other|Cohort 1|"Colchicine 0.5 mg Oral Tablet Day-7~Day25 qd, Febuxostat 40 mg Oral Tablet Day1 and Day14 qd, XNW3009 0.5 mg Oral Tablet Day8~Day21 qd.~Interventions:~Drug: Colchicine Drug: Febuxostat Drug: XNW3009"
89395010|NCT03570138|Experimental|Flash continuous glucose monitoring system|Participants will wear the FREESTYLE LIBRE device and receive a specific therapeutic education for its use.
89395011|NCT03570138|Active Comparator|Standard self monitoring blood glucose system|Participants will use their own usual self monitoring blood glucose system and receive a C They will wear a masked FREESTYLE LIBRE Pro system.
89395012|NCT02659605|Experimental|Delayed cord clamping above the perineum|
88871237|NCT05673902|Experimental|RPH-104 80 mg|"RPH-104 80 mg SC once every 2 weeks for 24-60 weeks.~(If the patient develops a pericarditis recurrence during the safety follow-up period, at the discretion of the investigator treatment with the study drug might be re-initiated according to the following regimen: a single dose of 160 mg SC (first injection) followed by a dose of 80 mg SC 7 days and 14 days after the first injection and at doses of 80 mg SC every two weeks thereafter.)"
88871238|NCT05669911|Experimental|Teal Health Self-Collection Device Group|This group will use the Teal Health Self-Collection Device to evaluate the instructions for use, usability, and satisfaction with the self-collection device. Participants will also undergo a Pap smear performed by a clinician. Self-collected and clinician-collected research samples will undergo HPV testing and cytological analysis using tests that are FDA-approved for use for HPV and Pap cytology.
88871239|NCT05661448|Experimental|Cognitive remediation|CR was developed by Dr. Bowie (PI). Approximately 60% of CR sessions are spent on cognitive training activities, 20% on developing, monitoring, and flexibly adjusting problem-solving strategies, and 20% on transfer activities. Transfer includes discussing and role-playing how cognitive skills and strategies are applied in everyday life and teaches potential compensatory strategies for overcoming cognitive challenges. Targeted cognitive domains are processing speed, attention, memory, and executive functions, which are all commonly impaired in psychosis. The manual includes 1.5-hour sessions and uses Brain Training Pro and will be offered over an 8-week period. Zoom Health will be used for group transfer activities.
88871240|NCT05661448|Experimental|MetaCognitive Training|MCT, developed by Drs. Moritz (co-applicant) and Woodward (PI), is based in the theoretical foundations of CBT, but targets the biases underlying symptoms rather than symptoms directly. MCT includes eight modules targeting common cognitive errors and reasoning biases in schizophrenia that have, through decades of research, been shown to contribute to delusions (e.g., jumping to conclusions). MCT will be offered to groups of up to 8 participants over 12 sessions of 45-60 min each (two per week) through Zoom Health. Session aims include raising participants' awareness of distortions and prompting them to critically reflect on, expand upon, and change their current repertoire of problem-solving strategies.
88871241|NCT05641857||Low back pain and disc degeneration among elite cross-country skiers|No intervention Interview, clinical examination and MRI
88871242|NCT05641857||Low back pain and disc degeneration among healthy volunteers|No intervention Interview, clinical examination and MRI
88871243|NCT05631743|Experimental|VR-CBT|A trained psychotherapist provides CBT-VR for up to 10 sessions over 10 weeks.
88871244|NCT05631743|Active Comparator|Self-management|Participants use a commercial VR application at home for guided self-management at their own pace over 10 weeks.
88871245|NCT05623683|Active Comparator|Intermittent Walking|Intermittent walking on the treadmill
88871246|NCT05623683|Active Comparator|Continuous Walking|Continuous walking on the treadmill
88871247|NCT05614947|Experimental|tart cherry|two capsules daily for 60 days
88871248|NCT05614947|Placebo Comparator|placebo|two capsules daily for 60 days
88871249|NCT05606133|Experimental|Circulating HPV DNA|
88871250|NCT05557578|Experimental|Experimental arm|Tislelizumab combined with GEMOX (GOT) regimen
88871251|NCT05549479|Experimental|Intervention Group (AgeMatchPLUS).|
88871252|NCT05549479|Active Comparator|Control Condition (AgeMatch):|
88871253|NCT05531487||Medical students|Undergraduate medical students at one Medical University.
88871254|NCT05523778|Experimental|Stented EN|Patients are placed the pancreatic duct stent by endoscopist 1day or several hours before the enucleation surgery.
88871255|NCT05523778|Active Comparator|Direct EN|Patients will receive enucleation surgery directly following normal procedure
88871256|NCT05504915||Participants with IBD|Participants diagnosed with IBD (UC or CD) who switched from vedolizumab IV to vedolizumab SC treatment during routine clinical practice, will be observed prospectively for up to 12 months from switch.
88871257|NCT05500586|Experimental|Healthy Adults|We will study 20 subjects on one occasion using a hyperglycemic clamp with 2 doses of glucagon.
88871258|NCT05500586|Experimental|Obese Adults|We will study 20 subjects on one occasion using a hyperglycemic clamp with 2 doses of glucagon.
88871259|NCT05500586|Experimental|Adults with Type 2 Diabetes|We will study 20 subjects on one occasion using a hyperglycemic clamp with 2 doses of glucagon.
88871260|NCT05496309||Group|The group is a cohort of 4 persons.
88871261|NCT05483127|Other|P1fA, then MDT|Verofilcon A toric soft contact lenses worn first, followed by stenfilcon A toric soft contact lenses, as randomized. Each study lens type will be worn for 8 (-0/+3) days for at least 10 hours per day. Lenses will be removed nightly and disposed of after a single use.
88871262|NCT05483127|Other|MDT, then P1fA|Stenfilcon A toric soft contact lenses worn first, followed by verofilcon A toric soft contact lenses, as randomized. Each study lens type will be worn for 8 (-0/+3) days for at least 10 hours per day. Lenses will be removed nightly and disposed of after a single use.
89187561|NCT04054544|Experimental|Gluten challenge|Participants will receive a gluten 4 g powder twice daily (BID), for 13 consecutive days
89395013|NCT02659605|Active Comparator|Delayed cord clamping below the perineum|
89395014|NCT05232539|Active Comparator|Lamellar corneal transplantation type DMEK|50 operations, procedure will be randomly divided into 2 subgroups of 25 patients with and without the use of iOCT during the operation.
89395015|NCT05232539|Active Comparator|Deep sclerectomy with implantation of subchoroidal implant Esnoper Clip|50 operations, procedure will be randomly divided into 2 subgroups of 25 patients with and without the use of iOCT during the operation.
89395016|NCT05232539|Active Comparator|Pars plana vitrectomy with epiretinal membrane peeling|50 operations, procedure will be randomly divided into 2 subgroups of 25 patients with and without the use of iOCT during the operation.
89395017|NCT02242188|Experimental|Iron|"Ferric pyrophosphate (powder preparation in sachets: Actiferol, SunActive Fe, Sequoia, Poland) in a single daily dose. Three doses will be used: 7 mg for infants up to 7 kg of body weight, 10 mg for infants from 7 to 10 kg of body weight, and 15 mg for those exceeding the weight of 10 kg. Caregivers will be instructed to administer the daily dose at the same time of a day, after mixing the content of the sachet with a little amount of breastmilk or milk formula.~The intervention will last from 4 months to 9 months of age."
89395018|NCT02242188|Placebo Comparator|Placebo|"Maltodextrin prepared in sachets. Caregivers will be instructed to administer the daily dose at the same time of a day, after mixing the content of the sachet with a little amount of breastmilk or milk formula.~The intervention will last from 4 months to 9 months of age."
89395019|NCT04704843|Experimental|Module A (Without Gluten-Challenge): Guselkumab or Placebo|Participants in Module A (without gluten-challenge) will receive intravenous (IV) infusion of guselkumab or matching placebo as induction dose at every 4 weeks through Week 8 followed by subcutaneous (SC) injection of guselkumab or matching placebo at Week 12.
89395020|NCT04704843|Experimental|Module B (With Gluten-Challenge): Guselkumab or Placebo|Participants in Module B (with gluten-challenge) will receive IV infusion of guselkumab or matching placebo as induction dose at every 4 weeks through Week 8 followed by SC injection of guselkumab or matching placebo at Week 12.
89395021|NCT05189873|Experimental|HRT|HRT protocol : estradiol and progesterone
89395022|NCT05189873|Experimental|Long GnRH agonist + HRT|Long GnRH agonist + HRT protocol: Superfect and estradiol and progesterone
89395023|NCT02524080|Other|Emergency Department|Triage to optimal healthcare level
89395024|NCT02524080|Other|Healthcare Center|Triage to optimal healthcare level
89395025|NCT01367015|Experimental|Early Feeding|Early feeding group received minimal enteral feed (MEF) of 8 ml/kg of expressed human milk of the biologic mother for 48 hours after randomization followed by regular feeding with feed increments of 20ml/kg/day to reach 150 ml/kg.
89395026|NCT01367015|Active Comparator|Late feeding|Late feeding group was kept NPO for a period of 48 hours after randomization followed by minimal enteral feed (MEF) of 8 ml/kg of expressed human milk of the biologic mother for 48 hours and thereafter received regular feeding with feed increments of 20ml/kg/day till full enteral feeds of 150 ml/kg/day were achieved
88871263|NCT05482516|Experimental|Atezolizumab plus Bevacizumab|atezolizumab 1200 mg and bevacizumab 15 mg/kg given intravenously on Day 1 of each 21-day cycle (every 3 weeks [Q3W]) for a maximum of 12 months.
88816623|NCT05858697||'Non intervention' group|Children with obesity at age 5-7 years living in Aarhus, who were never invited to participate in the lifestyle interventions.
88816624|NCT05858684|Experimental|GC012F injection (CD19-BCMA CAR-T cells)|"Dose escalation phase:~DL-1：0.5±20%×10^5/kg, DL1：1±20%×10^5/kg, DL2：2±20%×10^5/kg DL3：3±20%×10^5/kg"
88816625|NCT05858645|Experimental|deucravacitinib treatment|treatment with deucravacitinib for 6 months
88816626|NCT05858619|Experimental|dupilumab treatment|Treatment with IL4RA inhibitor
88816627|NCT05858606|Experimental|200 patients with idiopathic short stature,|200 patients with apparently idiopathic short stature,
88816628|NCT05858567|Experimental|Total Neoadjuvant Therapy with Short-course Radiation followed by Envafolimab plus CAPEOX|"The enrolled patients with MSS-type advanced ultra low rectal cancer will receive a combined regimen of neoadjuvant chemoradiotherapy combined with immunotherapy and biopsy or local excision.~Radiotherapy uses a short-range mode, irradiating the primary tumor and high-risk areas with dose of 25 Gy.~After radiotherapy, PD-L1 antibody (150mg/week, subcutaneous injection × 24 weeks) immunotherapy combined with 8 courses of CAPEOX chemotherapy was performed.~Two weeks after the end of the combined treatment plan in step 2), biopsy or local excision of the lesion is performed."
88871264|NCT05476276|Experimental|EN21-01 ISA|The EN21-01 Intervention Specific Analysis is detailed in the protocol (NCT#)
88871265|NCT05476276|Placebo Comparator|Placebo Comparator|Each ISA will detail the use of the Placebo Comparator.
89395027|NCT02243904||Lead exposure|
89395028|NCT01371617|Experimental|IPI-926|Single Arm, Phase 2 trial evaluating the safety and efficacy of IPI-926 in patients with myelofibrosis
89395029|NCT04051671|Experimental|Active tDCS & PT|Dual transcranial direct current stimulation (tDCS) will be applied over the leg motor area (M1) during the first 20 mins of conventional physical therapy (about 1 hours). Anodal on affected hemisphere, Cathodal on unaffected hemisphere. Current intensity is fixed at 2 mA and current will flow continuously during 20. Physical therapist will give an intervention program exactly the same in all cases. The scope of intervention is administered to improve strength of weakened and postural lower limbs muscles such as trunk muscles, hip flexors/extensors/abductors, knee flexors/extensors.
89395030|NCT04051671|Active Comparator|Sham tDCS & PT|Dual transcranial direct current stimulation (tDCS) will be applied over the leg motor area (M1) during the first 20 mins (sham mode) of conventional physical therapy (about 1 hours). Anodal on affected hemisphere, Cathodal on unaffected hemisphere. Physical therapist will give an intervention program exactly the same in all cases. The scope of intervention is administered to improve strength of weakened and postural lower limbs muscles such as trunk muscles, hip flexors/extensors/abductors, knee flexors/extensors.
89395031|NCT01367093||ICU patients admitted for severe illness|
89395032|NCT02243982|Experimental|[F18]-FDDNP|2-(1-{6-[(2-[fluorine-18]fluoroethyl)(methyl)amino]-2-naphthyl}-ethylidene)malononitrile. Radiopharmaceutical tracer
89395033|NCT02552277|Experimental|PDA-002 Dose Level 1: 3 x 10^6 cells|3 x 10^6 PDA-002 cells administered intramuscular (IM) on study Days 1, 29, and 57.
89395034|NCT02552277|Experimental|PDA-002 Dose Level 2: 30 x 10^6 cells|30 x 10^6 PDA-002 cells administered IM on study Days 1, 29, and 57.
89395035|NCT02552277|Placebo Comparator|Placebo|Subjects will receive placebo administered IM on study days 1, 29, and 57.
89395036|NCT05185817|Experimental|vaccine|Patients who are a candidate for HSCT within the the Hematology, Oncology, and Stem Cell Transplantation Research Center of Shariaty Hospital, and agree to be vaccinated with an approved vaccine against the COVID-19 virus.
89395037|NCT03571074||Hypoxia|"Defined as a group of patients with oxygen saturation <94 % irrespective of supplemental oxygen.~If COPD, defined as oxygen saturation <88 % irrespective of supplemental oxygen."
89395038|NCT03571074||Normoxia|"Defined as a group of patients with oxygen saturation 94 % - 98 % in combination of supplemental oxygen, or oxygen saturation >94 % without supplemental oxygen.~If COPD, defined as oxygen saturation 88 % - 92 % in combination of supplemental oxygen, or oxygen saturation >88 % without supplemental oxygen."
89395039|NCT03571074||Hyperoxia|"Defined as a group of patients with oxygen saturation >98 % in combination of supplemental oxygen.~If COPD, defined as oxygen saturation >92 % in combination of supplemental oxygen."
89395040|NCT00842348|Experimental|Lanreotide (Autogel formulation)|Patients from the preceding DB study (Study 726) were treated with open label lanreotide Autogel 120 mg by deep subcutaneous injections every 28 days. Patients were included if they had been treated with lanreotide (Autogel formulation) or placebo in DB Study 726 and had stable disease at the end of the 96-week treatment period, or if they had received placebo and had disease progression at any time during Study 726. Safety data were based on the safety population patients who received lanreotide in Study 729). The main efficacy analysis was based on the ITT population (patients randomised in Study 726 regardless of whether they continued into Study 729).
89395041|NCT03095599|Experimental|Vaccine|Received one dose of IVACFLU-S vaccine intramuscularly.
89395042|NCT03095599|Placebo Comparator|Placebo|Received one dose of placebo intramuscularly.
89003810|NCT04488081|Experimental|Narsoplimab + Standard of Care (CLOSED)|Subjects administered standard of care + narsoplimab dosed at 4 mg/kg, given as a 30-minute intravenous infusion (up to a maximum of 370 mg per infusion) twice weekly for a total of four weeks (i.e. 9 doses) or until hospital discharge whichever comes first.
89003811|NCT04488081|Experimental|Aviptadil + Standard of Care (CLOSED)|Subjects administered standard of care + aviptadil (inhalation via nebulizer), 100 µg three times (TID) daily for a maximum of 14 days
89003812|NCT04488081|Experimental|Cyproheptadine + Standard of Care (CLOSED)|Subjects administered standard of care + cyproheptadine via 4 mg tablet, with dosing regimen of 8 mg every 8 hours daily for ten (10) days.
89395043|NCT03569826||Observational|There is no intervention being administered. This registry only observes patients through their regular standard of care visits.
89395044|NCT02144246|Other|Pre-intervention|Patients will act as their own controls. Will have no hormones for 3 months
89395045|NCT02144246|Experimental|Post-intervention|Ortho-cyclen (or a generic equivalent) which is Ethinyl estradiol/norgestimate, 0.035 mg/0.250 mg
89395046|NCT03569670|Experimental|Posterior Stabilized|A posterior stabilized, all-polyethylene tibial component will be used during surgery.
88871266|NCT05475873|Sham Comparator|Control group|A bolus of normal saline (2 ml) by IV was given 5 min before spinal anesthesia.
88871267|NCT05475873|Experimental|Ondansetron 4 mg|A bolus of ondansetron (2 ml; 4mg) by IV was given 5 min before spinal anesthesia.
89395047|NCT03569670|Active Comparator|Cruciate Retaining|A cruciate retaining, all-polyethylene tibial component will be used during surgery.
89187562|NCT00776685|Experimental|learning to cope with your impulsivity|Cognitive-behavioural intervention targeting impulsive personality
89395048|NCT03544502|Experimental|Music group|Music group (group M, n=35) patients applied CD player. One CDs were prepared with 5 children's songs (classic music) for the study. CD player opened during anesthesia induction and continued until postoperative 15 minute
89395049|NCT03544502|Experimental|Silence group|"silence group (group S, n=35) patients received the independent anesthesiologist applied earplugs into the patients' ears during anesthesia induction and the earplugs were removed immediately before tracheal tube extubation.~During each measurement, noise level recordings were performed using CEL-480 Sound Level Meter Sonometre."
88871268|NCT05475873|Experimental|Ondansetron 8 mg|A bolus of ondansetron (2 ml; 8mg) by IV was given 5 min before spinal anesthesia.
88871269|NCT05470595|Experimental|Atezolizumab/Platinum/Etoposide|Atezolizumab/Platinum/Etoposide Platinum will be cisplatin or carboplatin at the investigators discretion.
89395050|NCT03544502|Placebo Comparator|Noise group|"noise group (group N, n=35) patients were exposed to the ambient operating room noise.~Noise level recordings were performed using CEL-480 Sound Level Meter Sonometre.Postoperatively, Emergence delirium (ED) was assessed as a Pediatric Anesthesia Emergence Delirium (PAED) Score ≥ 10."
88871270|NCT05464186|Experimental|Whole milk|3 cups a day of whole milk for 1 year
89395051|NCT03572556||Patients|Hereditary hemorrhagic telangiectasia patients
89395052|NCT03572556||Controls|Matched for age (+/- 5 ans) and sex.
88871271|NCT05464186|Experimental|Nonfat milk|3 cups a day of nonfat milk for 1 year
89395053|NCT03095521|Experimental|Arm A|Angal, lozenges, per 1 lozenge, with an interval 2 hours or more, 6-10 lozenges per day, for a maximum 4 days or until full illness resolution, if this will happen earlier than 4th day of treatment.
89395054|NCT03095521|Active Comparator|Arm B|ANTIANGIN ® FORMULA, 1 lozenge, with an interval 2 hours or more, up to 6 lozenges per day, for a maximum 5 days or until full illness resolution, if this will happen earlier than 5th day of treatment.
89395055|NCT01372865|Experimental|Mometasone|
89395056|NCT01372865|Active Comparator|Nasonex®|
88871272|NCT05462977|Experimental|Group exercise with beat-accented synchronous music stimulation|Participants will be asked to participate in a music-based group exercise program for 24 weeks (up to 6 days/week, 30 - 45 min/day), which is designed for older adults with functional limitations to safely exercise on a chair or in a supported standing posture for the improvement of aerobic capacity, upper and lower body strength, and balance control at a gradually increasing pace based on the tempo of the beat-accented synchronous music playlists.
89395057|NCT05368116|Experimental|Video Assisted Self Management Program|It is the systematically designed Video Assisted teaching program to educate cancer patients receiving chemotherapy under the experimental group about the management of chemotherapy related side effects at home .It will be one to one teaching session of 10-20 minutes conducted by the principal researcher with the help of a video on self management of chemotherapy related side effects and the video will focus on the self management of selected side effects of chemotherapy including Nausea, vomiting, Diarrhea, Constipation, Fever, Mucositis, Skin changes, and Alopecia related distress.
89395058|NCT05368116|Active Comparator|Standard of Care|The participants were given video when they come to oncology day care and instruct the participants to watch the video at home. Knowledge, self efficacy and severity of chemotherapy related side effects were assessed after one week.
88871273|NCT05458271|Experimental|VCMX|"All patients will be treated by scaling/root planing to obtain infection control if needed. In addition, patients will receive oral hygiene instructions.~The test group will be treated with add of VCMX. Following the local anesthesia, a split thickness flap will be raised-up to uncover the implant screw. Care will be taken to preserve pre-existing KT amount. A mesio-distal and apical partial thickness dissection will be performed to release residual muscle tension and allow the passive apical displacement of the flap. The randomisation envelope will be then opened. In test group the VCMX will be gently shaped and secured under the flap with suture. Care will be applied to completely cover the xenograft."
88871274|NCT05458271|Active Comparator|CTG|The control group patients will be treated by flap surgery with add of CTG. In the control group (APF) a CTG harvested from palate will be secured under the flap with suture.
88871275|NCT05441670|Experimental|Art and Physical Therapy|45-minutes of AT immediately followed by 30 minutes of PT Monday through Friday for 2 weeks. Targeting media that offer fluidity and tactile input, two were chosen for this study: oil pastels week 1 and gouache without brush during week 2.
88871276|NCT05441670|Active Comparator|Physical Therapy|PT Monday through Friday for 2 weeks.
88871277|NCT05432193|Experimental|Dose escalation|Up to 30 patients with FAP-avid solid tumors.
88871278|NCT05412875|Experimental|Arm I (JUUL)|Beginning 1 month before surgery, patients receive a JUUL e-cigarette and a 1 month supply e-liquid pods. After completion of surgery, patients receive another 1 month supply of e-liquid pods.
88871279|NCT05412875|Active Comparator|Arm II (usual care)|Patients receive usual care.
88871280|NCT05385796|Experimental|Loop taping|Loop taping of the heel fat pad
88871281|NCT05385796|Placebo Comparator|Control taping|Control taping of the heel fat pad
88871282|NCT05342493||Drug|Ajovy syringe for SC injection 225 mg.
88871283|NCT05318469|Experimental|Treatment (ivermectin, balstilimab)|Patients receive ivermectin PO QD on days 1-3, 8-10, and 15-17. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also receive balstilimab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 35 cycles in the absence of disease progression or unacceptable toxicity.
88871284|NCT05318131|Experimental|Single Arm Prospective Study|
88871285|NCT05288283|Experimental|GWP42003-P|Participants will be initiated on a dose of GWP42003-P 2.5 milligrams per kilogram (mg/kg) twice a day (BID) (5 mg/kg/day); after 1 week, the dose will be increased to 5 mg/kg BID (10 mg/kg/day). Dose escalation up to a maximum daily dosage of 20 mg/kg/day (in increments of 5 mg/kg/day [2.5 mg/kg BID] no more rapidly than every 7 days) may occur after Day 15 based on the investigator's assessment of efficacy, safety and tolerability.
88871286|NCT05288283|Placebo Comparator|Placebo|Participants will receive the matching placebo.
88871287|NCT05259280|Experimental|Arm 1|Arm 1: Subjects will receive 24 weeks of access to the Wellinks Solution.
88871288|NCT05259280|Experimental|Arm 2|Arm 1: Subjects will receive 24 weeks of access to the Wellinks Solution. The latter 12 weeks will be entirely asynchronous.
88871289|NCT05226780|Experimental|NBI-921352|106 week treatment Period
88871290|NCT05218850|Experimental|open label intervention arm|Butyrate enemas will be administered once daily for twelve weeks.
88871291|NCT05209802|Experimental|A: Exercise|High intensity interval exercise training (4 x 4 minutes of intensity above 17 on the Borg Rating of Perceived Exertion)
88871292|NCT05209802|Active Comparator|B: Exercise|Moderate intensity exercise training
88871293|NCT05189262||Cardiac Sugery Patients Requiring Cardiopulmonary >1hour|Patients admitted for a complex cardiac surgery, heart valve replacement and/or CABG surgery requiring CPB >1hour
88871294|NCT05186363|Active Comparator|Intervention|SMC eligible kids aged 3-59 months who will receive a standard SMC intervention of 4 cycles of SPAQ over 4 months.
88871295|NCT05186363|Active Comparator|Control|SMC eligible kids aged 3-59 months who will not receive a standard SMC intervention of 4 cycles of SPAQ over 4 months.
88871296|NCT05140876|Experimental|START mHealth Intervention|Participants randomized to receive the START mHealth intervention will have access to the mHealth application for 6 months following randomization.
88871297|NCT05140876|No Intervention|Website referrals|Participants in this condition will receive no intervention and will have access to a website with resources related to substance use disorder treatment and HIV treatment.
88871298|NCT05136703|Experimental|Cognitive-Behavioral Therapy for Adherence and Depression (CBT-AD)|Participants randomized to receive CBT-AD immediately will complete up to 12 individual sessions focused on depression and one session of ART Adherence counseling during the four months following randomization.
89395059|NCT02144324|Experimental|Tandem Appliance|This group of patients will receive the new appliance which is called the Tandem Appliance
89395060|NCT02144324|No Intervention|Traditional Treatment|Patients in this group will be treated by the traditional Face Mask appliance.
89395061|NCT01372943|Experimental|synthetic stool|"synthetic stool or pure cultures of probiotic intestinal bacteria from healthy donor stool that can be used as an enema to replace the use of stool transplant, for treatment of recurrent and refractory CDI"
89395062|NCT02254382|Experimental|Adaptive servo ventilation (ASV)|This group will receive ventilation therapy (AutoSet CS, ASV device)
89395063|NCT03569592|Experimental|Overdose Prevention Intervention|The experimental group will receive a brief overdose prevention education intervention and be issues naloxone upon discharge from jail.
89395064|NCT01371773|Experimental|Left-sided double lumen tube|
89395065|NCT00475280|Other|Geriatric assessment|
89395066|NCT03570840||obese children and adolescents|
89395067|NCT03569358|Experimental|Virtual Reality and EEG Interventions|In the interventional arm, 20 subjects will receive twice daily sessions of immersive virtual reality for a maximum of 15 minutes, with EEG headband recording starting 5 minutes prior to and 5 minutes after the intervention, for a maximum of 4 consecutive days.
89395068|NCT03569358|Active Comparator|EEG Intervention group|In the control arm, 10 subjects would have EEG recorded for 25 mins twice daily, with a minimum of 4 hours intervening, for 3 consecutive days, with the EEG headband. There would be no immersive virtual reality sessions.
89395069|NCT03569358|Active Comparator|Healthy Volunteers|At the completion of the above intensive care study recruitment, demographic data of the interventional immersive virtual reality arm would analysed to recuit 10 age-matched healthy volunteers with no known cognitive disorders or visual impairment. This is to compare study data with healthy controls. A 25 minute session consisting of 15 minutes of immersive virtual reality and 5 minutes of EEG recording with the EEG headband before and after the intervention would be performed. Eye-tracking and EEG data from these groups of patients would be compared against subjects in both arms of the study performed in the intensive care unit to investigate for exploratory differences.
89395070|NCT03033875|Experimental|Tele-Savvy Group|Informal caregivers of persons living with Alzheimer's disease will be randomized to participate in the Tele-Savvy program immediately.
88871299|NCT05136703|Experimental|Wait-List Control (WLC)|Participants randomized to the WLC condition will receive one session of ART adherence counseling immediately following randomization. After six months, WLC participants will have the opportunity to receive 12 individually delivered CBT-AD sessions focused on depression.
88871300|NCT05131451|No Intervention|Usual care with educational reinforcement|Standard of care referral to Eye Care Provider (ECP) for the diabetic eye exam with educational reinforcement
88871301|NCT05131451|Experimental|Diabetic Retinopathy Exam|Point of care (POC) Diabetic Retinopathy Exam using Autonomous AI on non-mydriatic fundus camera
88871302|NCT05122897|Experimental|Pagalinor®2 (PA) test arm|All patients will wear both the test and control ring material for a within-subject comparison. Ideally, biofilm sampling can be performed in a split mouth design (randomly allocated materials within subjects) with one patient having two implants for placing the test and the control material at the same time. In addition, patients providing one implant, will receive test and control push-on rings in a randomly assigned order, so that both materials are assessed in a consecutive manner.
88871303|NCT05122897|Active Comparator|Titanium-6Aluminum- 7Niobium alloy (TAN) control arm|All patients will wear both the test and control ring material for a within-subject comparison. Ideally, biofilm sampling can be performed in a split mouth design (randomly allocated materials within subjects) with one patient having two implants for placing the test and the control material at the same time. In addition, patients providing one implant, will receive test and control push-on rings in a randomly assigned order, so that both materials are assessed in a consecutive manner.
88871304|NCT05115968||OSA case|Chinese children aged 6-11 years old with habitual snoring (≥3 nights per week) and polysomnography (PSG) confirmed OSA (obstructive apnoea hypopnoea index (OAHI) of ≥1/hour), with adenotonsillar hypertrophy and clinical indications for adenotonsillectomy will be recruited as cases.
88871305|NCT05115968||Control|Non-OSA subjects (with PSG OAHI <1/hour) who undergo adenotonsillectomy for other reasons such as recurrent tonsillitis.
89395071|NCT03033875|Other|Attention Control Group|Informal caregivers of persons living with Alzheimer's disease will be randomized to participate in the Healthy Living Education Program. Persons in this group will be able to participate in the Tele-Savvy intervention after a delay of 6 months.
89395072|NCT03033875|No Intervention|Usual Care Group|Informal caregivers of persons living with Alzheimer's disease will be randomized to continue to receive care through whatever arrangement has been in place. Persons in this group will be able to participate in the Tele-Savvy intervention after a delay of 6 months.
89395073|NCT02144402|Active Comparator|infant formula with DHASCO|standard infant formula with docosahexaenoic acid (DHA)
88871309|NCT05110456|No Intervention|Access to an online cognitive behavioural intervention without telephone support|The control group will receive a fully automated version of the virtual intervention without telephone support
89395074|NCT02144402|Experimental|infant formula with DHASCO-B|standard infant formula with DHA-B
89395075|NCT03569046|Active Comparator|group l|ear block by local anaesthetic injection 0.25% bupivacaine. general anesthetic by: midazolam 0.02 mg kg-1 , propofol 2-3 mg kg-1 and lidocaine 0.5 mg kg-1 , fentanyl 2 µg kg-1 , atracurium 0.5 mg kg-1 , isoflurane in 50% oxygen/air. hypotensives for deliberate hypotension by nitroglycerine 0.5-10 μg /kg/min and increments of 0.2 mg propranolol
89395076|NCT03569046|Placebo Comparator|Group II|ear block by Normal Saline Flush, 0.9% Injectable Solution . general anesthetic by: midazolam 0.02 mg kg-1 , propofol 2-3 mg kg-1 and lidocaine 0.5 mg kg-1 , fentanyl 2 µg kg-1 , atracurium 0.5 mg kg-1 , isoflurane in 50% oxygen/air. hypotensives for deliberate hypotension by nitroglycerine 0.5-10 μg /kg/min and increments of 0.2 mg propranolol
89395077|NCT02935595|Experimental|Ketamine|Slow infusions of ketamine will take place over a time period of 40 minutes.
89395078|NCT02140658|Active Comparator|multiple health education interventions|The first group will receive health education manuals and Digital Video Disc (DVD) during hospitalization and regular health education messages during 6 months after discharge.
89395079|NCT02140658|Placebo Comparator|conventional health education|The second group will receive conventional health education during hospitalization except health education manuals, regular health education messages and Digital Video Disc (DVD)
89395080|NCT02817347|Experimental|YH1177 (4/0.5%+0.1%)|piperacillin 4% + tazobactam 0.5% + dexamethasone 0.1%
89395081|NCT02817347|Experimental|YH1177 (8/1.0%+0.1%)|piperacillin 8% + tazobactam 1.0% + dexamethasone 0.1%
89395082|NCT02817347|Experimental|YH1177-D (2/0.25%)|piperacillin 2% + tazobactam 0.25%
89395083|NCT02817347|Experimental|YH1177-D (4/0.5%)|piperacillin 4% + tazobactam 0.5%
88871310|NCT05110456|Experimental|Cognitive-Behavioral Therapy (CBT) and interpersonal counseling with telephone support.|The experimental group will receive an online cognitive behavioural intervention with weekly telephone support
88871311|NCT05108922|Experimental|Donanemab|Donanemab is administered intravenously (IV) every 4 weeks (Q4W).
88871312|NCT05108922|Active Comparator|Aducanumab|Aducanumab administered IV per US label.
88871313|NCT05101317|Active Comparator|HMI-115 60mg|Once Every 2 weeks, subcutaneously injection
88871314|NCT05101317|Active Comparator|HMI-115 120mg|Once Every 2 weeks, subcutaneously injection
88871315|NCT05101317|Active Comparator|HMI-115 240mg|Once Every 2 weeks, subcutaneously injection
88871316|NCT05101317|Placebo Comparator|Placebo|Once Every 2 weeks, subcutaneously injection
88871317|NCT05094804|Experimental|OR2805 monotherapy and combination therapy dose-escalation phase (Part A)|"Escalating repeated doses of OR2805 by IV administration as monotherapy or in combination with cemiplimab or docetaxel in subjects with advanced solid tumors. OR2805 will be administered once every 3 weeks (Q3W) or once-weekly (QW) for 3 weeks as an IV infusion over 30 minutes.~Cemiplimab will be administered as an IV infusion at a dose of 350 mg.~Docetaxel will be administered as an IV infusion at a dose of 75 mg/m2."
88871318|NCT05094804|Experimental|OR2805 monotherapy and combination therapy dose-expansion phase (Part B)|"OR2805 administered IV at the RP2D and dosing regimen identified in Part A as monotherapy or in combination with cemiplimab or docetaxel in subjects with NSCLC and melanoma.~Cemiplimab will be administered as an IV infusion at a dose of 350 mg.~Docetaxel will be administered as an IV infusion at a dose of 75 mg/m2."
88871319|NCT05094804|Experimental|OR2805 biological effects phase (Part C)|OR2805 administered IV at the RP2D and dosing regimen identified in Part A as monotherapy to determine the mechanism of action and potential predictors of response and pharmacodynamic markers in subjects with liposarcoma, leiomyosarcoma, or SCCHN or are not otherwise eligible for Cohort B.
88871320|NCT05076032|Experimental|OXO-001 200 mg|Two tablets of 100 mg have to be taken once daily in the early morning.
88871321|NCT05076032|Experimental|OXO-001 300 mg|Two tablets of 150 mg have to be taken once daily in the early morning.
88871322|NCT05076032|Placebo Comparator|Placebo|Two tablets have to be taken once daily in the early morning.
89395084|NCT02817347|Experimental|YH1177-D (8/1.0%)|piperacillin 8% + tazobactam 1.0%
89395085|NCT02503111|Experimental|Ablative therapy|Ablative therapy involving electrocautery (EC) will occur for participants with AIN-2 and AIN-3. The Hyfrecator ® 2000 Electrosurgical System will be used for EC therapy.
89395086|NCT02503111|Active Comparator|Active Surveillance|The control arm includes active surveillance with observation alone; no treatment in AIN-2 and -3.
89395087|NCT01367327|Experimental|Exercise with music|Loaded sit-to-stand exercise with music for 6 weeks
89395088|NCT01367327|Active Comparator|Exercise without music|Loaded sit-to-stand exercise without music for 6 weeks
89395089|NCT05708820|Active Comparator|Standard care|Group in face-to-face session
89395090|NCT05708820|Experimental|Online education programme|Group in online sessions
89395091|NCT05417191|Active Comparator|Conventional fish|This arm will consume 2 portions of gilthead seabream fed with conventional diet. Each portion weighed on average 380 g (raw, quantity of edible fillet approximately 170 g). Participants were instructed to consume fish twice weekly, one portion at a time.
89395092|NCT05417191|Experimental|Enriched fish|This arm will consume 2 portions of gilthead seabream fed with olive pomace enriched diet. Each portion weighed on average 380 g (raw, quantity of edible fillet approximately 170 g). Participants were instructed to consume fish twice weekly, one portion at a time.
89395093|NCT02742311|Active Comparator|transforaminal endoscopic discectomy|
89395094|NCT02742311|Active Comparator|interlaminar endoscopic discectomy|
89395095|NCT02464553|Experimental|Group A|1x periradicular therapy in one intervertebral space, corresponding with pain radiating dermatome
89395096|NCT02464553|Experimental|Group B|2x periradicular therapy in two intervertebral spaces, the first corresponding with pain radiating dermatome the second according magnetic resonance visualization where stenosis is situated
89395097|NCT05708508|Experimental|"Immuno-guided strategy arm"|"Patients in the low risk group will be monitored between D+15 and W+28 according to a strategy preemptive.~Patients in the high risk group (anti-CMV response <130 SFC/106 cells) will be treated according to the terms of the universal prophylaxis arm from D+15 and until W+15.~At the W+15 visit:~If the patient is considered at low risk, the antiviral treatment is stopped and he will continue the follow-up according to the modalities of the universal prophylaxis arm until W+28.~If the patient is still at high risk antiviral treatment will be continued until W+28."
89395098|NCT05708508|Active Comparator|"Universal prophylaxis arm"|Patients will receive from D+15 post-transplant an antiviral treatment with valganciclovir (ROVALCYTE) for the first 3 months following the transplant. Clinico-biological monitoring during the 6 months according to the usual practices of the 2 centers and monitoring of CMV DNAemia.
89395099|NCT01373021|Placebo Comparator|F|Fentanyl+Normal saline
89395100|NCT01373021|Experimental|D|Fentanyl+Dexmedetomidine
89395101|NCT03568812|Experimental|Probiotics Rillus®|Rillus®, Chewing tablet containing viable cell 1.0 x 10^9 colony forming unit (Lactobacillus plantarum 8.55 mg, Streptococcus thermophilus 8.55 mg, Bifidobacterium bifidum 2.55 mg, fructooligosaccharide 480 mg), isomalt, xylitol, milk flavour, vanilla flavour Dosage: 1 chewing tablet Frequency: once daily every night Duration: 12 weeks
89395102|NCT03568812|Placebo Comparator|Placebo|Placebo: Chewing tablet with identical flavour, colour, smell, and size as investigational drug Dosage: 1 chewing tablet Frequency: once daily every night Duration: 12 weeks
89395103|NCT01367405|Experimental|surgical decompression|surgical decompression within 24 hours post-injury
89395104|NCT01367405|Active Comparator|Conservative treatment|Normal conservative treatment without surgical intervention
89395105|NCT03568734|Experimental|Transplant arm|Fecal transplant sample given to child at delivery
88871323|NCT05047237|No Intervention|Control|Subjects in this arm will receive standard of care treatment with no intervention. They will receive month 6 follow up.
89395106|NCT02144480|Experimental|Intensive training|intensive aerobic training in moderate intensity day5 postoperatively. 30 minutes per sessions, 2 sessions per day, 10 sessions per week. There will be 20 sessions in total.
89395107|NCT02144480|Sham Comparator|traditional training|traditional rehabilitation
88871324|NCT05047237|No Intervention|Active Decliners|Subjects who decline intervention. Standard of care treatment with month 6 follow up.
88871325|NCT05047237|Experimental|Active Intervention|Subjects are mailed Information about Type 2 Diabetes Mellitus (T2DM) Guidelines and Appointment Information (Face to face [F2F] or Telehealth). They attend up to 3 pharmacist visits, depending on if they reach target glucose levels. And they attend interviews. They also have month 6 follow up.
88871326|NCT05045872|Experimental|ferumoxytol-enhanced renal magnetic resonance imaging|Patients will receive ferumoxytol-enhanced renal magnetic resonance imaging before renal angiography. Ferumoxytol (510 mg/17mL; Chia Tai Tianqing Pharmaceutical Group Co Ltd, Nanjing, China) will be diluted at 1:4 (v/v) and intravenously infused into the antecubital vein at a dose of 3 mg/kg with an infusion speed of 0.07 mL/s.
89395108|NCT03568578|Active Comparator|Entecavir Group|Patients in this arm will be given Entecavir 0.5 mg a day for 2 years.
88871328|NCT05027464|Experimental|Intervention Arm|The VAMC Internal Facilitator will partner with the trial External Facilitators (research team and designated External Facilitators in VISNS 16 and 21) to adapt and implement the study intervention to best meet the needs and preferences of their VAMC site. In addition, each CBOC and clinic affiliated with a VAMC in the Intervention arm will need to identify a Site Champion to provide clinic-specific information to facilitate implementation of the Vaccine Acceptance Intervention at their clinic or CBOC. In addition, for clinics and CBOCs assigned to the Vaccine Acceptance Intervention, VAMC, clinic and CBOC leadership will need to agree to release PACT staff for an initial two-hour Motivational Interviewing (MI) training, and at least one 60-minute post-training consultation session over the one-year trial period. There will be additional consultation sessions offered to intervention clinics and CBOC staff, but these will be optional.
89003813|NCT04488081|Experimental|Cyclosporine + Standard of Care (CLOSED)|Subjects administered standard of care + modified cyclosporine at an oral dose of 5mg/kg per day administered in two divided doses daily for 5-days.
89395109|NCT03568578|Experimental|Entecavir and Anluohuaxian Group|Patients in this arm will be given Entecavir 0.5 mg and Anluohuaxian Pill 12 g a day for 2 years.
89395110|NCT01367483|Experimental|Arm1|MNTX active treatment
89395111|NCT02140736||Patients with chemo-induced symptomatic anemia|
89395112|NCT05417035|Experimental|Nebido|i.m 250 mg/3months 2 injectionjs
89395113|NCT05417035|Active Comparator|Testoviron Depot|i.m75mg/month 6 injections
89395114|NCT01968785|Active Comparator|Radiation dose 25 Gy|• 25 Gy: Subjects will be treated with beta radiation dosage of 25 Gy during renal denervation procedure. Subjects are to maintain baseline anti-hypertensive medications and will undergo follow-up for 24 months.
89395115|NCT01968785|Active Comparator|Radiation dose 50 Gy|• 50 Gy: Subjects will be treated with beta radiation dosage of 50 Gy during renal denervation procedure. Subjects are to maintain baseline anti-hypertensive medications and will undergo follow-up for 24 months.
89395116|NCT01373099|Experimental|Static Spacer|Patients in this group will be randomized to a static, nonarticulating, antibiotic-impregnated cement spacer.
89395117|NCT01373099|Experimental|Articulating spacer|Patients in this group will be randomized to an articulating antibiotic-impregnated cement spacer.
89395118|NCT05354388||surgery after ripretinib treatment|For subjects who achieved PR or SD, perform resection of gastrointestinal stromal tumor
89395119|NCT03095287|Experimental|Alphanate|Participants were to receive alphanate 100 International Units (IU/kg/day) for up to 33 months in Immune tolerance induction (ITI) Treatment Phase. The dose could be increased up to 200 IU/kg/day based on Investigator's discretion. Following ITI Treatment Phase, participants were to enter the Prophylactic Phase where alphanate dose was to be tapered down in a step wise manner to reach a final prophylactic dose of 50 IU/kg every other day or 3 times per week, at the investigator's discretion.
89395120|NCT01335581|Experimental|Laser treatment|Laser treatment and microdermabrasion and topical lightening agent regimen
89395121|NCT01335581|Active Comparator|Control|Microdermabrasion and topical lightening agent regimen
89395122|NCT05354310|No Intervention|Active reference group|Only baseline measurements will be done.
89395123|NCT05354310|Experimental|Metabolically compromised group|Group with metabolomic mortality scores above threshold will undergo intervention. Baseline and endline measurements.
89395124|NCT05354310|Experimental|Mobility compromised|Group with walking aids will undergo intervention. Baseline and endline measurements.
89395125|NCT05354310|Experimental|Knee replacement INT|Group with recent knee replacement surgery will undergo intervention. Baseline and endline measurements.
89395126|NCT05354310|No Intervention|Knee replacement Control|Group with recent knee replacement surgery will undergo standard care. Baseline and endline measurements.
89395127|NCT05204563|Experimental|Imipenem/Cilastatin/XNW4107|Imipenem/Cilastatin 500mg/500mg in combination with XNW4107 250mg, Q6h (0.5h Infusion)
89395128|NCT05204563|Active Comparator|Imipenem/Cilastatin/Relebactam|Imipenem/Cilastatin/Relebactam 1.25g Q6h (0.5h Infusion)
89395129|NCT02144558|Experimental|Spinal cord injured (SCI) men, para or tetraplegic|SCI men will have 4 medical visits associated to sperm retrieval (penile vibratory stimulation (PVS) or masturbation)
89395130|NCT03566940|Experimental|Group 1: Low Dose IPV Based on Sabin Strains (sIPV)|Participants will receive intramuscular (IM) injection of the low dose trivalent inactivated poliovirus vaccine (sIPV - 3 doses) at 6, 10 and 14 weeks of age. Participants will also be given a single booster vaccine of conventional Salk IPV (cIPV) at approximately 24 weeks after the third vaccination (38 weeks of age).
89395131|NCT03566940|Experimental|Group 2: Intermediate Dose sIPV|Participants will receive IM injection of the intermediate dose trivalent inactivated poliovirus vaccine (sIPV - 3 doses) at 6, 10 and 14 weeks of age. Participants will also be given a single booster vaccine of cIPV at approximately 24 weeks after the third vaccination (38 weeks of age).
89395132|NCT03566940|Experimental|Group 3: High Dose sIPV|Participants will receive IM injection of the high dose trivalent inactivated poliovirus vaccine (sIPV - 3 doses) at 6, 10 and 14 weeks of age. Participants will also be given a single booster vaccine of cIPV at approximately 24 weeks after the third vaccination (38 weeks of age).
89395133|NCT03566940|Active Comparator|Group 4: Conventional Salk IPV (cIPV)|Participants will receive IM injection of cIPV (3 doses) at 6, 10 and 14 weeks of age. Participants will also be given a single booster vaccine of cIPV at approximately 24 weeks after the third vaccination (38 weeks of age).
89395134|NCT02144636|Experimental|treament|herbalife protein shake along with exercise
89395135|NCT02144636|No Intervention|control|diet and exercise only
88871329|NCT05027464|No Intervention|Usual Care Arm|"A VAMC assigned to Usual Care will have no specific trial intervention requirements beyond their usual level of participation in national and local initiatives to improve COVID-19 vaccine acceptance. At both Intervention and Usual Care sites, the study team will perform quarterly environmental scans. The environmental scan survey will include questions about site specific barriers to COVID-19 vaccination (first dose and second dose if needed), current programs/initiatives in the clinic or local community that are improving or have had no impact on vaccination rates, and the perceived importance that the VAMC/CBOC clinic staff is placing on vaccination (Environmental Scan Survey, in preparation). At Usual Care sites, a point of contact will be chosen from each clinic and CBOC to complete the environmental scan, and at Intervention sites, the Site Champion (see below) will perform the quarterly scan."
88871330|NCT05021562||Niraparib 200-300 milligrams (mg)|Arm description: Niraparib 200 mg, capsules, orally, once daily. For adult participants weighing 77 kilograms (kg) or more and with platelet count 150,000/mcrL or higher before the first dose of this drug, niraparib 300 mg, capsules, orally, once daily.
89395136|NCT03566862||Lung cancer|Individuals with confirmed diagnosis of lung cancer including disease in the lungs and an active cough.
89395137|NCT03566862||COPD|Individuals with a confirmed diagnosis of COPD according to established criteria.
89395138|NCT03566862||Other (non-COPD) chronic lung disease|Individuals with a confirmed diagnosis of non-COPD chronic lung disease (e.g. pulmonary fibrosis, asthma).
89395139|NCT03566862||Normal smokers|Individuals who have presented with cough but who appear to have 'healthy' lungs (i.e. COPD, other chronic lung disease and lung cancer have been excluded after clinical assessment).
89395140|NCT03545360|Experimental|Treatment Group|Treated group of subjects, serves as its own control
89395141|NCT03566784||Electrocoagulation|Patients will undergo a standard procedure for inguinal hernia repair, with the use of electrocoagulation.
89395142|NCT03566784||No electrocoagulation|Patients will undergo a standard procedure for inguinal hernia repair, without the use of electrocoagulation.
89395143|NCT01209923|Experimental|Body composition testing|Body composition tested using bioelectrical impedance (BC1) and the DEXA or hydrostatic weighing methods.
89395144|NCT02140814|Experimental|Niacinamide|All subjects in this study will take niacinamide at a dose of 30 mg per kilogram of body weight by mouth daily, in two divided daily doses, for 12 months.
89395145|NCT03015090|Experimental|theophylline|
89395146|NCT02140892|Experimental|respiratory physical therapy manual technique|respiratory physical therapy manual technique- Autogenic Drainage
89395147|NCT02140892|Experimental|respiratory physical therapy technique- IPV|respiratory physical therapy technique- Intrapulmonary Percussive Ventilation
89395148|NCT02140892|No Intervention|standart medical care|standard medical care
88871331|NCT05020951||Laboratory Data|Electronic transfer of laboratory data from participating institutions' local electronic health records to the Medidata/RAVE
88871332|NCT04982926|Experimental|TAS2940 Dose Escalation|Dose escalation will assess the safety and determine the maximum tolerated dose, the recommended phase 2 dose and the recommended dosing regimen of TAS2940 administered orally.
88871333|NCT04982926|Experimental|Dose Expansion Non-small Cell Lung Cancer|Dose expansion will assess preliminary anti-tumor activity in select solid tumors characterized by HER2 or EGFR aberrations
88871334|NCT04982926|Experimental|Dose Expansion Breast Cancer|Dose expansion will assess preliminary anti-tumor activity in select solid tumors characterized by HER2 or EGFR aberrations
88871335|NCT04982926|Experimental|Dose Expansion Gliblastoma|Dose expansion will assess preliminary anti-tumor activity in select solid tumors characterized by HER2 or EGFR aberrations.
88871336|NCT04982926|Experimental|Dose Expansion Solid tumors|Dose expansion will assess preliminary anti-tumor activity in select solid tumors characterized by HER2 or EGFR aberrations.
88871337|NCT04982874|Experimental|Furosemide 40 mg tablet|volunteers received Furosemide 40 mg tablet with 240 mL of water
88871338|NCT04982874|Active Comparator|Lasix® 40 mg Tablet|volunteers received Lasix® 40 mg tablet with 240 mL of water
89395149|NCT02141048|Experimental|Positive Parenting Skills Training|Participants assigned to the intervention group will receive the Positive Parenting Skills Training.
89395150|NCT02141048|No Intervention|Wait-list control|Participants assigned to the wait-list control group will receive no intervention for the duration of this trial. Only after the one-year follow-up assessment has been completed will they receive the Positive Parenting Skills Training.
88871339|NCT04966585|Experimental|Posaconazole|Subjects administered posaconazole (Noxafil®, Merck) 300mg twice daily for 1 day followed by 300mg daily for 12 weeks
88871340|NCT04966585|Placebo Comparator|Placebo|Subjects administered three matching placebo tablets twice daily for 1 day followed by three tablets daily for 12 weeks
88871341|NCT04923880|Other|Implementation of Primary Palliative Care Intervention in CF Centers|Implement a Primary Palliative Care intervention comprising screening-and-triage workflows, best practice treatment guides for high frequency problems, patient/family and provider education, and a quality improvement (QI) toolkit in 5 CF centers.
88871342|NCT04919369|Experimental|Treatment (tretinoin, atezolizumab)|Patients receive tretinoin PO on days 1-3 of cycles 1-3. Patients also receive atezolizumab IV on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
88871343|NCT04910308|Experimental|Dose painting|Dose painting
88871344|NCT04908956|Experimental|Osimertinib & SBRT|Osimertinib 80mg once daily p.o., until progression or unacceptable toxicity & locally ablative radiotherapy (SBRT) to the primary tumour and to all metastatic sites.
89395151|NCT01367639|Experimental|intervention|Inquiry Based Stress Reduction (IBSR) program
88871345|NCT04900298|Experimental|Intervention Arm|Use of SafeHaven hand hygiene system in the operating room
88871346|NCT04900298|No Intervention|Control Arm|Standard of care hand hygiene
88871347|NCT04899024|Experimental|PARTI and CM (Contingency Management)|The PARTI intervention will be delivered in five individual sessions during a 12-week contingency management protocol for PrEP adherence
88871348|NCT04899024|Active Comparator|Attention-Control and CM (Contingency Management)|The attention-control condition will consist of five individual sessions where participants complete self-report measures and neutral writing exercises during a 12-week contingency management protocol for PrEP adherence
88871349|NCT04884594|Experimental|AAV8-hCocH Low dose: 2e12 vg/kg|Cohort 1: Participant receives one-time IV administration of low dose 2e12 vg/kg of AAV8-hCocH, with 7 week of follow-up after dose
88871350|NCT04884594|Experimental|AAV8-hCocH Medium dose: 6e12vg/kg|Cohort 2: Participant receives one-time IV administration of medium dose 6e12vg/kg of AAV8-hCocH, with 7 week of follow-up after dose
89395152|NCT02839746||Dabigatran|Patients switched from vitamin K antagonist (VKA) to dabigatran
89395153|NCT01373177|Active Comparator|BSID-II, then Bayley-III|Receive BSID-II testing 4-8 weeks before Bayley-III testing
88871351|NCT04884594|Experimental|AAV8-hCocH High dose: 2e13 vg/kg|Cohort 3: Participant receives one-time IV administration of high dose 2e13 vg/kg of AAV8-hCocH, with 7 week of follow-up after dose
88871352|NCT04883411|Experimental|Treatment|Two-Level ACDF with CEM-Plate Anterior Cervical Plating System and CEM-Cage Cervical Interbody System.
88871353|NCT04882904|Experimental|Patient with ALS|Patient with amyotrophic lateral sclerosis
88871354|NCT04880837|Experimental|Prevention (educational session, handout, survey)|Participants attend educational session about HPV-related cancers, screening, and HPV vaccination and guidelines and receive informational infographic handout on HPV vaccination. Participants also complete surveys pre and post education session over 5 minutes each to assess HPV vaccination status among children of participants, HPV knowledge, and intentions to get the HPV vaccination, and screening among participants. In addition, participants complete surveys over telephone or face-to-face at 3 and 6 months.
89395154|NCT01373177|Active Comparator|Bayley-III, then BSID-II|Receive Bayley-III testing 4-8 weeks before BSID-II testing
89395155|NCT02620748|Experimental|Tranexamic Acid|This arm will receive an injection of Tranexamic Acid
89395156|NCT02620748|Placebo Comparator|Saline|This arm will receive an injection of Saline Solution
88871355|NCT04874636|Experimental|600 Milligram (mg) LY3556050|Participants received 600 mg LY3556050 twice daily (BID) every 12 hours for up to 8 weeks.
88871356|NCT04874636|Placebo Comparator|Placebo|Participants received placebo BID every 12 hours for up to 8 weeks.
88871357|NCT04863872|Active Comparator|Proactive Care Management|
88871358|NCT04863872|Experimental|Proactive Care Management + my hypo compass education program|
88871359|NCT04851184|Active Comparator|Usual Vestibular Rehabilitation Care|Participants in this arm will perform typical PT in the clinic and home environment. They will be asked to keep a log to track their HEP.
89395157|NCT01373255|Experimental|internal iliac catheterization|Women in this arm will undergo internal iliac artery catheterization prior to the cesarean delivery
89395158|NCT01373255|No Intervention|No intervention|no intervention prior to cesarean
89395159|NCT03566706|Experimental|Unhealthy Eating|
89395160|NCT03566706|Experimental|Marijuana Use|
88871360|NCT04851184|Experimental|Home Exercises Using Virtual Reality Device|Participants in this arm will perform typical PT in the clinic, but will use the virtual reality device as part of their HEP.
88871361|NCT04851184|No Intervention|Healthy Control|Age-matched healthy control subjects will perform all balance, gait, vestibular, and patient reported outcome measure assessments, including performing 30 seconds of each level of gaze stability exercise for an active comparison to outcomes obtained to those with vestibular disorders.
89395161|NCT03566706|Experimental|Sedentary Behavior|
89395162|NCT03566628|Experimental|Warmed Saline|Patients allocated to this arm will receive a warmed (39ºC) solution of up to 500mL of isotonic saline. This solution will be administered directly to the cerebral vasculature as part of the angiography.
89395163|NCT03566628|Active Comparator|Room-Temperature Saline|Patients allocated to this arm will receive isotonic saline at room temperature. This solution will be administered directly to the cerebral vasculature as part of the angiography.
89395164|NCT02141126|Experimental|Resistance training|Usual care and resistance exercises.
89395165|NCT02141126|Other|Usual care|Usual inpatient physiotherapy
89395166|NCT03752450||ICU patients|All patients admitted to ICU >48 hours will be included. Eventually, a number of these patients will develop hypernatremia and form the cases. The patients who will not develop hypernatremia will be assigned as the controls.
89395167|NCT02144792|Active Comparator|Control group (healthy persons)|Normal controls take a [11C] -verapamil PET scan. While P-gp inhibitor (Cyclosporin A, 2.5mg/kg/hr during 2hours, intravenous) is infused, PET scans were done using [11C] -verapamil, a substrate of P-gp.
88871362|NCT04848675|Experimental|Inspiratory muscle strength training|Using a handheld device, participants will perform 30 breaths a day at 75% of maximal inspiratory pressure, six days a week, for three months.
88871363|NCT04848675|Active Comparator|Brisk walking|Participants will walk for 25 minutes a day, six days a week, for three months at a target heart rate of 40-60% heart rate reserve. Heart rate will be monitored with a heart rate monitor.
89395168|NCT02144792|Active Comparator|Patients with drug-resistant epilesy|Patients with drug-resistant epilepsy take a [11C] -verapamil PET scan. While P-gp inhibitor (Cyclosporin A, 2.5mg/kg/hr during 2hours, intravenous) is infused, PET scans were done using [11C] -verapamil, a substrate of P-gp.
89395169|NCT02144792|Active Comparator|Patients with drug-sensitive epilepsy|Patients with drug-sensitive epilepsy take a [11C] -verapamil PET scan. While P-gp inhibitor (Cyclosporin A, 2.5mg/kg/hr during 2hours, intravenous) is infused, PET scans were done using [11C] -verapamil, a substrate of P-gp.
88871364|NCT04840849|Experimental|Nirsevimab|Nirsevimab single dose IM injection
88871365|NCT04840849|Placebo Comparator|Placebo|Placebo single dose IM injection
89395170|NCT03564990|Experimental|interactive, multifaceted approach|A health education module consisting of a lecture and workshop was incorporated into a health-care course.
88871366|NCT04838639|Experimental|NO-13065, oral tablet|
88871367|NCT04838639|Placebo Comparator|Placebo matched to NO-13065, oral tablet|
88871368|NCT04796272|Active Comparator|Traditional exercise|fatigued multiple sclerosis patients with a traditional training program
88871369|NCT04796272|Experimental|Individual exercise|tired multiple sclerosis patients with an adapted and individualized training program
89395171|NCT03564990|Sham Comparator|conventional approach|conventional follow-up with oral healthy education
89395172|NCT02144870|Active Comparator|Habit Reversal Training|At first patients get informed about Tics in general. Then the individual Tics are specified and the tic-reaction is looked at further. The Tic-Symptoms are observed and the premonitory urge is specified. For all individual tics a specific reversal movement is developed. Relaxation methods are introduced.
89395173|NCT02144870|Active Comparator|Resources activation|At first patients get informed about Tics in general. Through different exercises existing resources and skills are activated and strengthened. Feeling of self-esteem and self-respect are strengthened. Also the emotional awareness is strengthened. Relaxation methods are also introduced.
89395174|NCT03566394|Experimental|Prophylactic Gabapentin|Gabapentin at a dose of 300mg three times a day for 2 days before and 5 days after each taxane infusion. Administered orally.
89395175|NCT03566394|No Intervention|Observation|
89395176|NCT03544424||Study cohort|People over 60 years of age with a Medtronic CareLink® compatible CIED in situ recruited from the Manchester University NHS Foundation Trust, England, UK
89535458|NCT03080103||Patients treated with antibiotic-first strategy|Antibiotic therapy.maging. Patients managed conservatively will receive one of the following parenteral antibiotic treatments: Piperacillin/Tazobactam (4.5 g) three intravenous administration per day; Ceftriaxone (2 g) once per day or Ciprofloxacin (500 mg) twice per day plus Metronidazole (500 mg) three times per day; Amoxicillin/Clavulanic acid (2 g) four times per day for a length depending on the clinical conditions; Ertapenem (1 g) one administration per day for three days. Patients were discharged with oral antibiotics (amoxicillin/clavulanic acid or ciprofloxacin) for at least four days.
88871370|NCT04787497|Experimental|Experimental Group|The Experimental Group will be receiving 50ml of freshly, cold-pressed, oleocanthal-rich Extra Virgin Olive Oil (EVOO) alongside their prescribed medical treatment. EVOO will be consumed on a daily basis for 12 months and all participants will undergo a neuropsychological assessment at baseline, 6 months and 12 months +/- 7 days after their first assessment or beginning of supplementation.
88871371|NCT04787497|No Intervention|Control Group|The Control Group will be continuing their standard medical treatment without additional supplementation. The neuropsychological assessment will be conducted at baseline, 6 months and 12 months +/- 7 days after their first assessment.
88871372|NCT04766892|Experimental|mavacamten (MYK-461)|
88871373|NCT04707157|Experimental|600 Milligram (mg) LY3556050|Participants received 600 mg LY3556050 twice daily (BID) every 12 hours for up to 8 weeks.
88871374|NCT04707157|Placebo Comparator|Placebo|Participants received placebo BID every 12 hours for up to 8 weeks.
88871375|NCT04700449|Experimental|Double-Blind 0.2mg CBP-307|0.2 mg CBP-307 capsules oral administration.
88871376|NCT04700449|Placebo Comparator|Double-Blind Placebo|Placebo capsules oral administration.
88871377|NCT04700449|Experimental|Open-Label CBP-307|0.2 mg CBP-307 capsules oral administration.
89395177|NCT00033293|Experimental|Arm I (chemotherapy, immunoglobulin therapy)|"Patients with intermediate-risk or high-risk neuroblastoma receive chemotherapy (including cyclophosphamide) according to the standard of care for the stage of primary neuroblastoma, beginning on day 0. Patients with low-risk neuroblastoma (and not receiving other chemotherapy) receive cyclophosphamide IV over 1 hour on day 0. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. All patients receive oral prednisone twice daily for 3 months and then every other day for 7-15 months.~Patients receive immune globulin IV on days -2 and -1, at weeks 4, 8, 12, 16, 20, and 24, and then at months 8, 10, and 12 after therapy. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients with no response after 6 months go off treatment."
89395178|NCT00033293|Active Comparator|Arm II (chemotherapy, observation)|"Patients with intermediate-risk or high-risk neuroblastoma receive chemotherapy (including cyclophosphamide) according to the standard of care for the stage of primary neuroblastoma, beginning on day 0. Patients with low-risk neuroblastoma (and not receiving other chemotherapy) receive cyclophosphamide IV over 1 hour on day 0. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. All patients receive oral prednisone twice daily for 3 months and then every other day for 7-15 months.~Patients do not receive immune globulin. Patients with unresponsive opsoclonus-myoclonus-ataxia syndrome after 2 months or progression after 6 months may cross over to arm I."
89395179|NCT03566316|Experimental|Telmisartan/Amlodipine+Rosuvastatin|Telmisartan/Amlodipine 40/5mg 2tab., Rosuvastatin 20mg1tab. and Telmisartan placebo 1tab.
89395180|NCT03566316|Active Comparator|Telmisartan/Amlodipine|Telmisartan/Amlodipine 40/5mg 2tab., Rosuvastatin placebo 1tab. and Telmisartan placebo 1tab.
89395181|NCT03566316|Active Comparator|Telmisartan +Rosuvastatin|Telmisartan/Amlodipine placebo 2tab., Rosuvastatin 80mg 1tab. and Telmisartan 20mg 1tab.
89395182|NCT02144948|Experimental|E.-coli-Nissle|10 patients will be enrolled Intervention: E.-coli-Nissle (Mutaflor), oral suspension Dose: 1 ml / day frequency: qd
89395183|NCT03566004|Other|endoscoped patients|Patients addressed for endoscopy with indication of biopsies for H. pylori detection will be enroled to provide stool specimen
89003814|NCT04488081|Experimental|Imatinib (PENDING ACTIVATION)|Subjects will be administered 800 mg on Day 1 orally, in divided doses of 400 mg administered twice per day. 400 mg daily will be administered orally for the following 9 days or until discharge, whichever is sooner.
89395184|NCT02141594||Early glaucoma|The study group consisted of consecutive unilateral glaucoma patients, categorized as early stage by Hodapp-Anderson-Parrish classification.
88871378|NCT04700449|Experimental|Double-Blind 0.1mg CBP-307|0.1 mg CBP-307 capsules oral administration.
88871379|NCT04696471|Experimental|Left ventrolateral prefrontal cortex (vlPFC)/Left SS/Left vlPFC sham|"A random number sequence will be generated for randomization of the 3 cTBS scan session order to which each participant is assigned:~left vlPFC cTBS (cTBS applied to the left ventrolateral prefrontal cortex)~left SS cTBS (cTBS applied to the left somatosensory area)~left vlPFC sham TBS (go through the motions of applying cTBS to the left ventrolateral prefrontal cortex but very low current is administered so that the participant feels like cTBS is being administered even though the current is too low to stimulate brain cells) Participants will know that one session will be a sham, but they will be blinded to which session is the sham."
88871380|NCT04696471|Experimental|Left vlPFC/Left vlPFC sham/Left SS|"A random number sequence will be generated for randomization of the 3 cTBS scan session order to which each participant is assigned:~left vlPFC cTBS (cTBS applied to the left ventrolateral prefrontal cortex)~left SS cTBS (cTBS applied to the left somatosensory area)~left vlPFC sham TBS (go through the motions of applying cTBS to the left ventrolateral prefrontal cortex but very low current is administered so that the participant feels like cTBS is being administered even though the current is too low to stimulate brain cells) Participants will know that one session will be a sham, but they will be blinded to which session is the sham."
88871381|NCT04696471|Experimental|Left SS/Left vlPFC sham/Left vlPFC|"A random number sequence will be generated for randomization of the 3 cTBS scan session order to which each participant is assigned:~left vlPFC cTBS (cTBS applied to the left ventrolateral prefrontal cortex)~left SS cTBS (cTBS applied to the left somatosensory area)~left vlPFC sham TBS (go through the motions of applying cTBS to the left ventrolateral prefrontal cortex but very low current is administered so that the participant feels like cTBS is being administered even though the current is too low to stimulate brain cells) Participants will know that one session will be a sham, but they will be blinded to which session is the sham."
88871382|NCT04696471|Experimental|Left SS/Left vlPFC/Left vlPFC sham|"A random number sequence will be generated for randomization of the 3 cTBS scan session order to which each participant is assigned:~left vlPFC cTBS (cTBS applied to the left ventrolateral prefrontal cortex)~left SS cTBS (cTBS applied to the left somatosensory area)~left vlPFC sham TBS (go through the motions of applying cTBS to the left ventrolateral prefrontal cortex but very low current is administered so that the participant feels like cTBS is being administered even though the current is too low to stimulate brain cells) Participants will know that one session will be a sham, but they will be blinded to which session is the sham."
89003815|NCT04483479|Experimental|Active Treatment|Orally Administered ENT-01 25mg Tablet Once Daily (Dose dependent on ENT-01-030 dose level stratification)
89187563|NCT00776685|Experimental|learning to cope with your sensation seeking|cognitive behavioural intervention designed to help sensation seeking youth manage their need for stimulation and excitement.
89187564|NCT00776685|Experimental|learning to cope with your anxiety sensitivity|cognitive behavioural intervention teaching anxiety sensitive youth to manager their sensitivity to threat and anxiety.
89187565|NCT00776685|Experimental|learning to manage your negative thinking|cognitive behavioural intervention targeting pessimistic and negative thinking in hopeless youth
89187566|NCT00780039|Experimental|Single Arm|Caelyx 30 mg/m2 in combination with carboplatin dosed to target AUC of 5 mg/mL.min.
89187567|NCT03436550||Patients with Chronic Liver Disease|
89187568|NCT03436550||Control Group|
89187569|NCT00669903|Experimental|1|AZD0328 low dose
89187570|NCT00669903|Experimental|2|AZD0328 Optimal dose
89187571|NCT00669903|Experimental|3|AZD0328 High dose
89187572|NCT00669903|Placebo Comparator|4|Placebo Comparator
89187573|NCT00776763|Experimental|Avastin|
89187574|NCT00772551|Active Comparator|1|
89395185|NCT02141594||Normal subjects|Normal control subjects had a normal ocular examination, Intraocular pressure (IOP) <22 mmHg, no past history of high IOP, no family history of glaucoma, normal optic disc morphology and visual field in both eyes. One eye of control subject was randomly selected.
89395186|NCT03565926|Active Comparator|Manual Therapy|"Manual Therapy Protocol~Articulation technique L4-S1~Lumbar neuromuscular technique~Fascial technique of crossed hands~Posteroanterior mobilizations of the lumbar vertebrae"
89395187|NCT03565926|Experimental|Hypopressive exercises|Protocol of 5 Hypopressive Exercises
88871383|NCT04696471|Experimental|Left vlPFC sham/Left SS/Left vlPFC|"A random number sequence will be generated for randomization of the 3 cTBS scan session order to which each participant is assigned:~left vlPFC cTBS (cTBS applied to the left ventrolateral prefrontal cortex)~left SS cTBS (cTBS applied to the left somatosensory area)~left vlPFC sham TBS (go through the motions of applying cTBS to the left ventrolateral prefrontal cortex but very low current is administered so that the participant feels like cTBS is being administered even though the current is too low to stimulate brain cells) Participants will know that one session will be a sham, but they will be blinded to which session is the sham."
88871384|NCT04696471|Experimental|Left vlPFC sham/Left vlPFC/Left SS|"A random number sequence will be generated for randomization of the 3 cTBS scan session order to which each participant is assigned:~left vlPFC cTBS (cTBS applied to the left ventrolateral prefrontal cortex)~left SS cTBS (cTBS applied to the left somatosensory area)~left vlPFC sham TBS (go through the motions of applying cTBS to the left ventrolateral prefrontal cortex but very low current is administered so that the participant feels like cTBS is being administered even though the current is too low to stimulate brain cells) Participants will know that one session will be a sham, but they will be blinded to which session is the sham."
88871385|NCT04695691|Experimental|Laser Treatment|
88871386|NCT04683718|Experimental|BIOTRONIK Prosper SCS (Spinal Cord Stimulation) System|Eligible participants will be permanently implanted with a BIOTRONIK Prospera SCS (Spinal Cord Stimulation) System with HomeStream Remote Management.
88871387|NCT04681833|Experimental|Cohort 1: BARS13 low repeat dose|Active: One dose of 10 μg rRSV G protein/10 μg CsA administered by IM injection to the deltoid region of one arm, and one dose of placebo by IM injection to the deltoid region of the other arm, given sequentially (10 μg rRSV G protein/10 μg CsA in total for each vaccination) on Day 1 and 29.
88871388|NCT04681833|Placebo Comparator|Cohort 1: BARS13 placebo low repeat dose|Placebo: One dose administered by IM injection to both arms, on Day 1 and 29.
88871389|NCT04681833|Experimental|Cohort 2: BARS13 high repeat dose|Active: One dose of 10 μg rRSV G protein/10 μg CsA administered by IM injection to the deltoid region of each arm, given sequentially (20 μg rRSV G protein/20 μg CsA in total for each vaccination) on Day 1 and 29.
88871390|NCT04681833|Placebo Comparator|Cohort 2: BARS13 placebo high repeat dose|Placebo: One dose administered by IM injection to both arms, on Day 1 and 29.
88871391|NCT04681833|Experimental|Cohort 3: BARS13 high repeat multiple dose|Active: One dose of 10 μg rRSV G protein/10 μg CsA administered by IM injection to the deltoid region of each arm, given sequentially (20 μg rRSV G protein/20 μg CsA in total for each vaccination) on Day 1, Day 29 and Day 57.
88871392|NCT04681833|Placebo Comparator|Cohort 3: BARS13 placebo high repeat multiple dose|Placebo: One dose administered by IM injection to both arms, on Day 1, Day 29 and Day 57.
88871393|NCT04667377|Experimental|0.6 mg BI 456906|
88871394|NCT04667377|Placebo Comparator|Placebo group|
88871395|NCT04667377|Experimental|2.4 mg BI456906|
88871396|NCT04667377|Experimental|3.6 mg BI 456906|
88871397|NCT04667377|Experimental|4.8 mg BI 456906|
88871398|NCT04655651||Frailty|patients with a FRAIL Scale of 3 to 5
88871399|NCT04655651||Non-frailty|patients with a FRAIL Scale of 0 to 2
89395188|NCT02145104|Experimental|Arm A|cilinidpine 10mg + valsartan 160mg
89395189|NCT02145104|Experimental|Arm B|cilnidipine 5mg + valsartan 160mg
89395190|NCT02145104|Active Comparator|Arm C|valsartan 160mg
89395191|NCT03565848||Women underwent colorectal resection for endometriosis|Women referred for colorectal resection for deep infiltrating endometriosis that underwent laparoscopic segmental colorectal resection performed with mesenteric vascular and nerve sparing surgery.
89395192|NCT02145338|Experimental|Antibiotic prophylaxis|Nitrofurantoin or Trimethoprim or Cefalexin. Daily antibiotic prophylaxis: nitrofurantoin 50 mg (or 100 mg dependent on participant weight), or trimethoprim 100 mg, or cefalexin 250 mg.
89395193|NCT02145338|Other|No prophylaxis|The control arm will be a strategy of no prophylaxis. Participants will self-monitor their symptoms as usual and report to their General Practitioner if they develop symptoms and signs suggestive of UTI requiring treatment.
89395194|NCT03565770|Experimental|standard care + coaching|minor patients with a type 1 diabetes, having therapy adjustment difficulties, receiving individual coaching and usual standard care
89395195|NCT03565770|Sham Comparator|Standard care|minor patients with a type 1 diabetes, having therapy adjustment difficulties, receiving usual standard care only.
89395196|NCT03565692||Patients treated by LUMACAFTOR-IVACAFTOR|Patients treated by LUMACAFTOR-IVACAFTOR (or other ivacaftor combinations) Patients over 6 years who are currently able to benefit from LUMACAFTOR-IVACAFTOR (or other ivacaftor combinations) according the mutation eligibility criteria and for whom conventional microbiological analysis of sputum samples and stool will be collected during their follow-up after the treatment onset.
89535459|NCT02487173|Experimental|Respirio Flu Test|"Upper respiratory tract samples from participants will be tested with:~Respirio Flu Test~Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)~Sofia® Influenza A+B Fluorescent Immunoassay (FIA)"
89535460|NCT03221413|Experimental|PD tACS|Persons with Parkinson disease who will be treated with tACS: Intervention: tACS (transcranial alternating current stimulation)
89003816|NCT04481893|Experimental|using a virtual reality headset|
88871400|NCT04647526|Experimental|[Lu-177]-PNT2002 (Arm A)|[Lu-177]-PNT2002 (6.8 GBq (±10%) every 8 weeks for 4 cycles)
88871401|NCT04647526|Active Comparator|Control Arm (Arm B)|Abiraterone (1000 mg orally qd with: 5 mg bid prednisone or 0.5 mg qd dexamethasone) or enzalutamide (160 mg orally qd).
89535461|NCT03221413|Experimental|Pain tACS|Persons with neuropathic pain who will treated with tCAS. Intervention: tACS (transcranial alternating current stimulation)
88871402|NCT04634513|Experimental|Cohort 1: Shigella Vaccine at 10^8 cfu or Placebo|3:1 randomization to one dose of vaccine or placebo (Cohort n=8)
88871403|NCT04634513|Experimental|Cohort 2: Shigella Vaccine at 10^9 cfu or Placebo|3:1 randomization to one dose of vaccine or placebo (Cohort n=8)
88871404|NCT04634513|Experimental|Cohort 3: Shigella Vaccine at 10^10 cfu or Placebo|3:1 randomization to one dose of vaccine or placebo (Cohort n=8)
88871405|NCT04634513|Experimental|Cohort 4: Shigella Vaccine or Placebo|2:2:1 randomization to receive either two doses of vaccine, 1 dose of vaccine and one dose of placebo, or two doses of placebo at Days 1 and 29 (Cohort n=30)
88871406|NCT04629729|Experimental|FT819 Single-Dose Monotherapy, B-Cell Lymphoma|FT819 single-dose monotherapy in adult subjects with r/r B-cell Lymphoma
88871407|NCT04629729|Experimental|FT819 Single-Dose in Combination with IL-2, B-Cell Lymphoma|FT819 single-dose in combination with IL-2 in adult subjects with r/r B-cell Lymphoma
88871408|NCT04629729|Experimental|FT819 Step Fractionated Monotherapy, B-Cell Lymphoma|FT819 monotherapy administered as step-fractionated dosing in adult subjects with r/r B-cell Lymphoma
88871409|NCT04629729|Experimental|FT819 Single-Dose Monotherapy, CLL|FT819 single-dose monotherapy in adult subjects with r/r CLL
88871410|NCT04629729|Experimental|FT819 Single-Dose in Combination with IL-2, CLL|FT819 single-dose in combination with IL-2 in adult subjects with r/r CLL
88871411|NCT04629729|Experimental|FT819 Step Fractionated Monotherapy, CLL|FT819 monotherapy administered as step-fractionated dosing in adult subjects with r/r CLL
88871412|NCT04629729|Experimental|FT819 Single-Dose Monotherapy, B-ALL|FT819 single-dose monotherapy in adult subjects with r/r B-ALL
88871413|NCT04629729|Experimental|FT819 Single-Dose in Combination with IL-2, B-ALL|FT819 single-dose in combination with IL-2 in adult subjects with r/r B-ALL
88871414|NCT04629729|Experimental|FT819 Step Fractionated Monotherapy, B-ALL|FT819 monotherapy administered as step-fractionated dosing in adult subjects with r/r B-ALL
88871415|NCT04629729|Experimental|FT819 Step Fractionated Monotherapy in Combination with IL-2, B-Cell Lymphoma|FT819 monotherapy administered as step-fractionated dosing in combination with IL-2 in adult subjects with r/r B-cell Lymphoma
88871416|NCT04629729|Experimental|FT819 Step Fractionated Monotherapy in Combination with IL-2, CLL|FT819 monotherapy administered as step-fractionated dosing in combination with IL-2 in adult subjects with r/r CLL
88871417|NCT04629729|Experimental|FT819 Step Fractionated Monotherapy in Combination with IL-2, B-ALL|FT819 monotherapy administered as step-fractionated dosing in combination with IL-2 in adult subjects with r/r B-ALL
88871418|NCT04609202|Experimental|Nurse led person centred care|Participants in the nurse led, person centred care arm will receive person centred follow up after hospitalization for atrial fibrillation. The person centred care and usual care routines are provided by nurses.
88871419|NCT04609202|Active Comparator|Usual care|Participants in the usual care arm will receive care as usual, ie follow up by doctors after hospitalization for atrial fibrillation.
88871420|NCT04602728|Experimental|Back2Life Program|Youth with chronic SCD pain and their parents or caregivers receiving an adaptive cognitive behavioral treatment program for pain coping skills.
88871421|NCT04599101|Other|Nasal suction devices: Nose Frida and Bulb|Nose Frida nasal suction device and bulb syringe suction device to clear nasal secretions
88871422|NCT04597099|Experimental|Flutamide|Prior to the first or second admission (randomly determined), subjects will be pretreated for 4 weeks with Flutamide (250 mg twice daily)
88871423|NCT04597099|Placebo Comparator|Placebo|Prior to the first or the second admission (randomly determined), participants will be pretreated for 2 weeks with placebo (twice daily).
88871424|NCT04584866|Active Comparator|Study Intervention|Endonasal endoscopic pituitary surgery in semi-sitting position
88871425|NCT04584866|Active Comparator|Control Intervention|Endonasal endoscopic pituitary surgery in supine position
89535462|NCT03221491|Experimental|No Background Infusion Group(Group B0)|Patients in Group B0 receive analgesic regimens using Patient-Controlled Analgesia(PCA) with background infusion 0ml/h.
89535463|NCT03221491|Experimental|Low Background Infusion Group(Group B1)|Patients in Group B1 receive analgesic regimens using Patient-Controlled Analgesia(PCA) with background infusion 1ml/h.
88871426|NCT04583839|Experimental|Navigation Group|Women who are randomized into SWEET will be assigned to a patient navigator. The navigator will meet women during hospitalization, at postpartum appointments, during primary care appointments, and as needed. At these face-to-face meetings, the navigator will perform education about the postpartum OGTT, post-GDM management plan, diabetes mellitus risks, lifestyle modification, and primary care transition. The navigator will facilitate the development of an individualized GDM Care Plan in conjunction with the patient and the medical team. The navigator will assess individual barriers to T2DM screening and prevention. At appointments, the navigator will also ensure a woman understands her diabetes-related care plan and will perform health education and barrier-reducing tasks as needed.
88871427|NCT04583839|No Intervention|Non-navigation cohort|No navigation will be provided; women will receive usual care.
88871428|NCT04582383|Experimental|Spironolactone|In this arm, participants will receive spironolactone 100mg/day for the entirety of the study. To maximize the generalizability of the study, participants will be allowed to continue their current topical regimen as long as no changes were made in the 4 weeks prior to randomization. No additions to their topical regimen may be made during the study period.
88871429|NCT04582383|Active Comparator|Doxycycline hyclate|This arm is an active-comparator arm in which participants will receive doxycycline hyclate 100mg/day for the entirety of the study. To maximize the generalizability of the study, participants will be allowed to continue their current topical regimen as long as no changes were made in the 4 weeks prior to randomization. No additions to their topical regimen may be made during the study period.
89187575|NCT00772551|Active Comparator|2|
89187576|NCT00776841|Placebo Comparator|Placebo|Placebo control single dose
89003817|NCT04481035|Experimental|N-Acetylcysteine|Participants will be dosed with 70 mg/kg/dose (max dose 900 mg) three times per day of N-Acetylcysteine (NAC) for eight (8) weeks. This is a double-blind study, neither study participant nor study team members will know whether the participant is given study drug or placebo until after all data is collected.
89003818|NCT04481035|Placebo Comparator|Placebo|Participants will be dosed three times per day with a placebo for eight (8) weeks. This is a double-blind study, neither study participant nor study team members will know whether the participant is given study drug or placebo until after all data is collected.
89003819|NCT04468607|Experimental|Dose-Escalation Stage|Participants will be assigned sequentially to escalating doses of BLYG8824A, up to the maximum tolerated dose (MTD).
89003820|NCT04468607|Experimental|Dose-Expansion Stage|Once dose escalation is completed and the MTD (or MAD) has been identified, a recommended expansion dose will be proposed for the dose-expansion stage of the trial.
89003821|NCT04449549|Experimental|1|Nilotinib will be administered at 300 mg orally BID; Paclitaxel will be administered IV at 80 mg/m2 on Days 1, 8, and 15 in 28-day cycles.
89003822|NCT04443348|Experimental|Group A (No RT Boost)|No RT boost plus pembrolizumab, followed by pembrolizumab plus paclitaxel, doxorubicin and cyclophosphamide chemotherapy.There will be up to a total of 8 cycles of pembrolizumab (4 cycle before surgery and 4 cycles after surgery at the discretion of the study doctor).
89003823|NCT04443348|Experimental|Group B (Low Dose RT Boost)|Low-dose RT boost plus pembrolizumab, followed by pembrolizumab plus paclitaxel, doxorubicin and cyclophosphamide chemotherapy. There will be up to a total of 8 cycles of pembrolizumab (4 cycle before surgery and 4 cycles after surgery at the discretion of the study doctor).
89003824|NCT04443348|Experimental|Group C (High Dose RT Boost)|High-dose RT boost plus pembrolizumab followed by pembrolizumab plus paclitaxel, doxorubicin and cyclophosphamide chemotherapy. There will be up to a total of 8 cycles of pembrolizumab (4 cycle before surgery and 4 cycles after surgery at the discretion of the study doctor).
89003825|NCT04432662|Active Comparator|Darbepoetin Alpha|Administration of Darbepoetin Alpha (10 mcg/kg) IV x2 doses following cooling therapy.
89003826|NCT04432662|No Intervention|Standard of care|Standard of care: Cooling only
89003827|NCT04420936|Experimental|Lifestyle coaching|
89003828|NCT04420936|Active Comparator|Control tracking|
89003829|NCT04412187|Other|TSPO PET imaging|All study participants will receive [18F]-GE-180, i.e. TSPO PET imaging to assess microglia activation.
89003830|NCT04401514|Experimental|Experiemntal intervention|The experimental intervention is a 20 min. long rocking chair with music therapy.
89395197|NCT02254616|Experimental|Mirror therapy with tDCS|Functional training will consist of unilateral and bilateral functional tasks in daily living, and last for 30 minutes. Some examples are mopping the table by using the affected hand or scooping beans from a bowl with one hand while the other hand stabilizes the bowl. The principles of part-task practice and whole-task practice will be applied based on the participant's performance level.Functional training will consist of unilateral and bilateral functional tasks in daily living, and last for 30 minutes. Some examples are mopping the table by using the affected hand or scooping beans from a bowl with one hand while the other hand stabilizes the bowl. The principles of part-task practice and whole-task practice will be applied based on the participant's performance level.
89395198|NCT02254616|Active Comparator|Mirror Therapy|The MT only group will receive a 60-minute MT per session followed by a 30-minute functional training. Participant will go through the same protocol as that for the MT+tDCS and MT+sham tDCS groups with no tDCS presented in setting. This group is for evaluating placebo effect of the present of tDCS application.
89535464|NCT03221491|Experimental|High Background Infusion Group(Group B2)|Patients in Group B2 receive analgesic regimens using Patient-Controlled Analgesia(PCA) with background infusion 2ml/h.
89535465|NCT03079479||Two Years Group|
89535466|NCT03079479||Five Years Group|
89535467|NCT03079479||Ten Years Group|
89003831|NCT04401514|Active Comparator|Control intervention|Control intervention is also transferred to the rocking chair, but the therapy program will not be turned on.
89003832|NCT04389632|Experimental|Part A: Dose escalation|sigvotatug vedotin monotherapy
89003833|NCT04389632|Experimental|Part B: Dose expansion|sigvotatug vedotin monotherapy
89003834|NCT04389632|Experimental|Part C: sigvotatug vedotin combination therapy in NSCLC, HNSCC, ESCC|sigvotatug vedotin + pembrolizumab +/- (carboplatin or cisplatin)
89003835|NCT04389632|Experimental|Part D: sigvotatug vedotin combination therapy in 1L NSCLC|sigvotatug vedotin + pembrolizumab +/- (carboplatin)
89003836|NCT04389632|Experimental|Part D: sigvotatug vedotin combination therapy in 1L HNSCC|sigvotatug vedotin + pembrolizumab +/- (carboplatin or cisplatin)
89003837|NCT04380831|Experimental|Treatment (TBI using IMRT, cyclophosphamide, HSCT)|Patients undergo TBI using IMRT BID on days -5 and -4 in the absence of disease progression or disease progression. Patients then receive cyclophosphamide on days -3 and -2 and undergo HSCT on day 0 in the absence of disease progression or unacceptable toxicity.
89535468|NCT03079479||Control Group|
89003838|NCT04366453|Other|Echocardiography|"• Echocardiography performed by the evaluator 1: 2 LVEF visual evaluations 2 LVEF automatic evaluations~• Echocardiography performed by the evaluator 2: 2 LVEF visual evaluations 2 LVEF automatic evaluations"
89003839|NCT04358692|Experimental|Surgical Aortic Valve Replacement|Patients with aortic stenosis
89003840|NCT04358692|Other|Reference|Coronary bypass patients without hypertrophic left ventricular remodeling or sequelae of myocardial infarction
89187577|NCT00776841|Experimental|Dose 1|Dose 30 mg
89003841|NCT04355572|Experimental|Vitamin D Supplement|Patients will take vitamin D tablet with 4,000IU daily for 6 months.
89003842|NCT04355572|Placebo Comparator|Placebo|Patients will take placebo for 6 months
89003843|NCT04336189|Active Comparator|SP + DP placebo every 4 weeks|
89003844|NCT04336189|Active Comparator|DP + SP placebo every 4 weeks|
89003845|NCT04336189|Active Comparator|SP + DP given every 4 weeks|
89003846|NCT04325568|Other|Clinician Manual|"Participants in the Clinician Manual arm will be introduced to a trained clinician and will complete one 60-minute session covering equivalent topics addressed in the PsyGist program. The manual will consist of: (1) a section exploring the youth's causal model for their high-risk state; (2) individualization per their causal model; and (3) tutorials that convey the main concepts of genetic malleability.~Clinicians will assess individual causal models via discussion with CHR youth about their at- risk state. Individualization of genetic framing will occur using youths' causal models and will fall into 1 of 3 categories (per PsyGist): 'primarily genetic', 'primarily environmental' or 'combined'."
89003847|NCT04325568|Other|AutoTutor (PsyGist)|"AutoTutor is an intelligent system that simulates talking with a human tutor. Our AutoTutor, called PsyGist, has 3 parts: (1) assessment of the youth's causal model for their high-risk state; (2) an individualized 'pre-tutorial' vignette matched to their causal model; (3) a 'tutorial' presenting the 'genetic malleability' framing.~PsyGist will guide participants through its three components."
89395199|NCT02254616|Active Comparator|Control Intervention|The CI group will receive a 60-minute conventional stroke rehabilitation training followed by a 30-minute functional training. During the 60-mimute conventional training, interventions will include passive range of movement and muscle tone normalization techniques of the affected arm, and gross motor training (e.g., shoulder ladder activity), fine motor training (e.g., grasping cones), and muscle strength training in a unilateral and bilateral manners. During the 30-minute functional training, the same principles to those in the MT groups will be applied.
89003848|NCT04307576|No Intervention|R1 - SR standard arm|Standard risk arm receiving standard treatment (Delayed Intensification including Doxorubicin).
89395200|NCT02254616|Active Comparator|Mirror Therapy with sham-tDCS|Functional training will consist of unilateral and bilateral functional tasks in daily living, and last for 30 minutes. Some examples are mopping the table by using the affected hand or scooping beans from a bowl with one hand while the other hand stabilizes the bowl. The principles of part-task practice and whole-task practice will be applied based on the participant's performance level.
89003849|NCT04307576|Experimental|R1 - SR experimental arm|Standard risk arm, receiving Delayed Intensification without Doxorubicin IV 3 x 30 mg/m2/dose.
89003850|NCT04307576|No Intervention|R2 - IR-low standard arm|Standard treatment with Delayed Intensification including Doxorubicin and Maintenance including Vincristine+Dexamethasone pulses.
89003851|NCT04307576|Experimental|R2 - IR-low experimental arm A|Standard treatment with omission of Doxorubicin IV 3 x 30 mg/m2/dose in the Delayed Intensification phase.
89003852|NCT04307576|No Intervention|R3 - IR-high standard arm|Intermediate risk high arm receiving Standard Maintenance Therapy.
89003853|NCT04307576|Experimental|R3-InO - IR-high experimental arm|Inotuzumab IV 0,5 mg/m2, given on days 253, 260, 267 and on days 274, 281, 288 before start of Standard Maintenance Therapy.
89003854|NCT04307576|Experimental|ABL-class fusions intervention|Imatinib p.o. 340 mg/m2 given daily from day 15 or 30 (depending on age) to the end of therapy (week 106) in addition to Standard IR-high chemotherapy.
89187578|NCT00776841|Experimental|Dose 2|Dose 100 mg
89187579|NCT00776841|Experimental|Dose 3|Dose 300 mg
89187580|NCT00776841|Experimental|Dose 4|Dose 900 mg
89187581|NCT00776841|Experimental|Dose 1 repeated|Dose 30 mg for 4 days
89187582|NCT00776841|Experimental|Dose 2 repeated|Dose high for 4 days
89187583|NCT00780195|Experimental|1|Single 2 hour hyperinsulinemic euglycemic clamp study at ~90 mg/dl.
89395201|NCT02254694|Experimental|high heeled shoes|see detailed description
89395202|NCT03565614|Experimental|Reablement rehabilitation|Reablement rehabilitation to maintain or increase the participants' physical, psychological and social functional abilities.
89395203|NCT03565614|Active Comparator|Traditional home care|The traditional home care and required rehabilitation efforts as by the municipality's current practice.
89395204|NCT03565536|Experimental|Nexavar neoadjuvant treatment group|"After the patient had diagnosed as anaplastic thyroid cancer, Nexavar was used for neoadjuvant treatment. At 1 month and 2 months after treatment, it was assessed whether surgery could be performed.~operation for possible surgical treatment,with complete thyroidectomy and cervical lymph node dissection are performed to completely resect thyroid tissue and metastatic lymphatic tissue.~then External radiation therapy after surgery."
89395205|NCT05128253||NASH GROUP|Recruited (n=22) patients with non-alcoholic steatohepatitis.
89395206|NCT05128253||NAFL GROUP|Recruited (n=22) patients with non-alcoholic fatty liver.
89395207|NCT05193383|Experimental|Imaginal exposure|Exposure to mental imagery including a fearful stimulus (spider) and corresponding scenes including a neutral stimulus (leaf)
88871432|NCT04569799|Other|group-1|Following treatment, patients will receive their standard CT or MRI, as routinely ordered in the post-TACE setting. This imaging will be per standard protocol, as directed by hepatology or oncology services, often 2 to 4 months after the treatment. At the same visit, patients will also receive a one-time additional contrast-enhanced ultrasound (CEUS),
88871433|NCT04546672|Experimental|Sugammadex|Sugammadex 2 mg/kg IV once at the end of surgery
88871434|NCT04546672|Active Comparator|Neostigmine|Neostigmine 0.07 mg/kg to a maximum of 5 mg (+Glycopyrrolate 0.2 mg per 1 mg of neostigmine administered) IV once at the end of surgery
88871435|NCT04738292|Experimental|Onapristone In Combination with Fulvestrant|"All participants will receive onapristone 50 mg p.o. BID (twice) daily and fulvestrant (500 mg) intramuscular injection on days 1, 15 (cycle 1), then two weeks later (cycle 2, day1), then once every 28 days thereafter. A cycle is defined as 28 days.~There will be no breaks between dosing cycles."
88871436|NCT04537923|Experimental|5 mg Tirzepatide|5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.
88871437|NCT04537923|Experimental|10 mg Tirzepatide|10 mg tirzepatide administered SC once a week.
88871438|NCT04537923|Experimental|15 mg Tirzepatide|15 mg tirzepatide administered SC once a week.
88871439|NCT04537923|Active Comparator|Insulin Lispro|Insulin lispro 100 units per milliliter (U100) administered SC three times a day.
88871440|NCT04513080|Experimental|Phase 1, Level 1: Incentive 1 + Video-chat psychotherapy|In Phase 1, participants will be randomized to one of two incentive levels. After randomization to an incentive level, participants will be randomized to either video-chat psychotherapy (VCP) or message-based psychotherapy (MBP). After six weeks of treatment, participants will move to level 2. Those who have made a 50% reduction to PHQ9 scores to their assigned treatment will continue in that same treatment for 6 more weeks.
88871441|NCT04513080|Experimental|Phase 1, Level 1: Incentive 2 + Video-chat psychotherapy (VCP)|In Phase 1, participants will be randomized to one of two incentive levels. After randomization to an incentive level, participants will be randomized to either video-chat psychotherapy (VCP) or message-based psychotherapy (MBP). After six weeks of treatment, participants will move to level 2. Those who have made a 50% reduction to PHQ9 scores to their assigned treatment will continue in that same treatment for 6 more weeks.
88871442|NCT04513080|Experimental|Phase 1, Level 2: MBP with weekly VCP|Phase 1 participants who do not show 50% reduction in PHQ9 scores will be randomized to either weekly VCP augmented with unlimited MBP (augmentation arm), monthly VCP with unlimited MBP (switch/minimal augmentation arm).
88871443|NCT04513080|Experimental|Phase 1 Level 2: MBP with monthly VCP|Phase 1 participants randomized to VCP who do not show 50% reduction in PHQ9 scores will be randomized to either weekly VCP augmented with unlimited MBP (augmentation arm) or monthly VCP with unlimited MBP (switch/minimal augmentation arm).
88871444|NCT04513080|Experimental|Phase 2 Level 1: Message-Based Psychotherapy (MBP)|Phase 2 participants who respond to MBP after 6 weeks of care will continue in this condition for another 6 weeks. Participants who do not respond by week 6 will be randomized to one of two augmentation arms, MBP plus monthly video chat (Premium Plan: PP) or MBP plus weekly video chat (Ultimate Plan: UP) for another 6 weeks of care.
88871445|NCT04513080|Experimental|Phase 2, Level 1: Video-Chat Psychotherapy (VCP)|Phase 2: Weekly psychotherapy appointments that last between 30-45 minutes. Participants who do not respond to this model will be randomized to switch (PP) or augment (UP) VCP.
88871446|NCT04513080|Experimental|Phase 2, Level 2: MBP with monthly VCP|"Phase 2: This intervention will serve as the switch arm for participants who do not respond to VCP by week 6, and one of two augmentation arms for participants who do not respond to MBP. The Premium plan allows patients unlimited texting with their therapist and once a month, 30-45 minute video chat with the same therapist."
88871447|NCT04513080|Experimental|Phase 2, Level 2: MBP with weekly VCP|Phase 2: This intervention will serve as an augmentation arm for participants who do not respond to either MBP or VCP after 6 weeks of care. Like the Premium Plan, participants will have access to both unlimited MBP, but will be able to schedule weekly, 30-45 minute video chat with the same therapist.
89395208|NCT05193383|Experimental|In vivo exposure|Exposure to video clips including a fearful stimulus (spider) and corresponding clips including a neutral stimulus (leaf)
89395209|NCT03565458|Experimental|gemigliptin|gemigliptin single dose
88871448|NCT04513080|Experimental|Phase 1, Level 1: Incentive 1 + Message-based psychotherapy|In Phase 1, participants will be randomized to one of two incentive levels. After randomization to an incentive level, participants will be randomized to either video-chat psychotherapy (VCP) or message-based psychotherapy (MBP). After six weeks of treatment, participants will move to level 2. Those who have made a 50% reduction to PHQ9 scores to their assigned treatment will continue in that same treatment for 6 more weeks.
88871449|NCT04513080|Experimental|Phase 1, Level 1: Incentive 2 + Message-based psychotherapy|In Phase 1, participants will be randomized to one of two incentive levels. After randomization to an incentive level, participants will be randomized to either video-chat psychotherapy (VCP) or message-based psychotherapy (MBP). After six weeks of treatment, participants will move to level 2. Those who have made a 50% reduction to PHQ9 scores to their assigned treatment will continue in that same treatment for 6 more weeks.
89003855|NCT04307576|Experimental|R3-TEAM - IR-high experimental arm|6-tioguanine p.o, 2,5-12,5 mg/m2, given daily in addition to Standard Maintenance Therapy.
89187584|NCT00780195|Experimental|2|Single 2 hour hyperinsulinemic hypoglycemic clamp study at ~70 mg/dl.
89395210|NCT03565458|Experimental|dapagliflozin|dapagliflozin single dose
89395211|NCT03565458|Experimental|gemigliptin and dapagliflozin|co-administration of gemigliptin and dapagliflozin
89395212|NCT03565458|Experimental|empagliflozin|empagliflozin single dose
88871450|NCT04508543||Minority (Case)|Self-identified as being a member of group traditionally underrepresented in the medical profession relative to the proportion in the general population: African-American/Black, Mexican-American, Native American (American Indians, Alaska Natives, and Native Hawaiians), and mainland Puerto Rican.
88871451|NCT04508543||Caucasian (Control)|Self-identified as Caucasian and Non-Hispanic
88871452|NCT04502732||Observational|NSSM and GEBT
88871453|NCT04496817|Experimental|Enriched Egg Group|Participants will consume 2 medium sized docosahexaenoic acid and lutein enriched eggs daily (at least 5 days per week) for 6 weeks.
88871454|NCT04496817|Placebo Comparator|Regular Egg Group|Participants will consume 2 medium sized non-enriched eggs daily (at least 5 days per week) for 6 weeks.
88871455|NCT04489017|Experimental|PEA-LUT|PEA-LUT administration at the oral dosage of 700 mg x 2/day for 24 weeks
88871456|NCT04489017|Placebo Comparator|PLACEBO|PLACEBO administration at the oral dosage of 700 mg x 2/day for 24 weeks
88871457|NCT04488666|Experimental|npSIMS|Group will receive the Aatru Medical npSIMS device
88871458|NCT04484623|Experimental|Arm A: Belantamab mafodotin plus Pomalidomide and Dexamethasone|
88871459|NCT04484623|Active Comparator|Arm B: Bortezomib plus Pomalidomide and Dexamethasone|
88871460|NCT04437485|Experimental|eIMPACT-DM intervention|eIMPACT-DM is a 6-month, modernized, collaborative, stepped care intervention consisting of (1) computerized and telephonic cognitive-behavioral therapy for depression and (2) select antidepressant medications included in an algorithm optimized for diabetes risk reduction. It is a collaborative care intervention in which a multidisciplinary team delivers established depression treatments consistent with patient preference. It uses a stepped, flexible, treat-to-target approach that modernizes the IMPACT intervention by harnessing technology to minimize staff and space requirements. Interventions are Good Days Ahead, Problem Solving Treatment in Primary Care, and select FDA-approved antidepressants. The treatment team consists of a depression clinical specialist, a supervising MD with expertise in primary care and IMPACT, and the patients' primary care providers (PCPs).
88871461|NCT04437485|Active Comparator|Active Control|Active Control (AC) consists of depression education (study staff), symptom monitoring (study staff), and primary care for depression (clinical staff).
88871462|NCT04359472|Other|Treatment Arm|Collection and reapplication of amniotic fluid.
88871463|NCT04338399|Experimental|Buparlisib & Weekly Paclitaxel|"Drug: Patients will receive 100 mg (2 x 50 mg) buparlisib hard gel capsule administered orally, once daily starting on Day 1 of Treatment Cycle 1, Drug: Paclitaxel (80 mg/m2) administered intravenously (IV) on Days 1, 8, and 15 of a 21-day treatment cycle.~Treatment will continue until disease progression, unacceptable toxicity, death or discontinuation for any other reason."
88871464|NCT04338399|Active Comparator|Weekly Paclitaxel|Patients will receive weekly paclitaxel (80 mg/m2) administered intravenously (IV) on Days 1, 8, and 15 of a 21-day treatment cycle. Treatment will continue until disease progression, unacceptable toxicity, death or discontinuation for any other reason.
88871465|NCT04306510|Other|Group 1|TEGSEDI
88871466|NCT04286425|Placebo Comparator|Placebo|"500 µl of saline solution applied in the vaginal volt twice :~one month before the IVF procedure during the ovulation period~Same month of the IVF procedure after ovum pick up"
88871467|NCT04286425|Active Comparator|seminal plasma|"500 µl of seminal plasma applied in the vaginal volt twice :~one month before the IVF procedure during the ovulation period~Same month of the IVF procedure after ovum pick up"
88871468|NCT04254198|Placebo Comparator|Control|Modified Attention Placebo Control
88871469|NCT04254198|Experimental|TERTULIAS structured dialogue peer support groups|Structured Dialogue peer support group
88871470|NCT04241029|Experimental|Intervention with probiotics|Intervention with the probiotic compound IDOFORM®Travel. The patient will receive four capsules orally every 24 hour (12*10^9 cfu/day) for eight weeks as adjuvant therapy to his/her anti-TNF treatment. The intervention arm will at the end of intervention serve as their own controls compared to baseline data (before intervention).
88871471|NCT04210024|Other|Rural-Dwelling Community Members/Residents|Rural-dwelling adults will be interviewed to map their social network structure, determine the types of social support provided by members of their social network, and identify key players within these networks. A subset of participants (~4) will be identified as Community Health Workers and will receive training with the Diabetes Empowerment Education Program (DEEP).
88871472|NCT04168320|Active Comparator|Less favorable time-position in immune cycle|"Starting two weeks prior to the initiation of radiotherapy serial, 7x blood samples will be taken every two days, excluding the weekend (for example, if starting on a Monday: Monday-Wednesday-Friday-Monday-Wednesday-Friday and Monday), but also on the day of the first radiotherapy treatment, to define the serial high-sensitivity C-reactive protein (hs-CRP) test, LDH and white cell differential count (leucocytes: neutrophils, basophils, eosinophils, lymphocytes, monocytes). Data from the assays will be assembled in a spreadsheet and analyzed for levels and cyclical fluctuations to determine each patient's idiosyncratic immune cycle's periodicity and then each patient's time-position of initiation of treatment and response to therapy.~SBRT-PATHY will be administered to this arm at an estimated less favorable time-Position in immune cycle."
88871473|NCT04168320|Experimental|Most favorable time-position in immune cycle|"Starting two weeks prior to the initiation of radiotherapy serial, 7x blood samples will be taken every two days, excluding the weekend (for example, if starting on a Monday: Monday-Wednesday-Friday-Monday-Wednesday-Friday and Monday), but also on the day of the first radiotherapy treatment, to define the serial high-sensitivity C-reactive protein (hs-CRP) test, LDH and white cell differential count (leucocytes: neutrophils, basophils, eosinophils, lymphocytes, monocytes). Data from the assays will be assembled in a spreadsheet and analyzed for levels and cyclical fluctuations to determine each patient's idiosyncratic immune cycle's periodicity and then each patient's time-position of initiation of treatment and response to therapy.~SBRT-PATHY will be administered to this arm at an estimated most favorable time-position in immune cycle."
88871474|NCT04160468|Experimental|Exebacase|
88871475|NCT04160468|Placebo Comparator|Placebo|
88871476|NCT04099121|Other|Patients with Pelvic Organ Prolapse|Patients who meet the inclusion criteria will be recruited. Ultrasound images of the pelvic floor and vaginal cavity will be analyzed to predict pessary size and type. This will be compared against the pessary size and type being used already by the patient.
89395213|NCT03565458|Experimental|gemigliptin and empagliflozin|co-administration of gemigliptin and empagliflozin
89535469|NCT03206125||Controls|Controls
89395214|NCT01367717|Active Comparator|Creatine Monohydrate|Each of the 25 subjects took Creatine Monohydrate.
89395215|NCT01367717|Active Comparator|Creatine Ethyl Ester|Each of the 25 subjects took Creatine Ethyl Ester.
89395216|NCT03565302|Placebo Comparator|Control|Subjects receive placebo treatment
89395217|NCT03565302|Experimental|Long acting beta2-agonist|Subjects are treated with long-acting beta2-agonist formoterol
89395218|NCT03565302|Experimental|Short acting beta2-agonist|Subjects are treated with short-acting beta2-agonist terbutaline
89395219|NCT03568032||the post-radiation group|patients diagnosed as non-metastatic nasopharyngeal carcinoma who received definitive IMRT more than 3 years ago
89395220|NCT03568032||the pre-radiation group|untreated patients diagnosed as non-metastatic nasopharyngeal carcinoma
89395221|NCT03567798|Experimental|A|"UPLAT® (Carica papaya leaf Extract + Tinospora cardifolia Extract~Take 4 units daily (2 in morning and 2 in evening) for 10 days"
89395222|NCT03567798|Placebo Comparator|B|"Placebo~Take 4 units daily (2 in morning and 2 in evening) for 10 days"
89395223|NCT01372007|Experimental|Lanreotide Autogel 120mg|
89395224|NCT01372007|Placebo Comparator|Placebo|
89395225|NCT03037164|Experimental|INTERCEPT (Test)|Red blood cell components treated with the INTERCEPT Blood System for Red Blood Cells ordered and administered to study patients by their treating physicians according to the local standards of care
89395226|NCT03037164|Active Comparator|Conventional (Control)|Conventional RBC components ordered and administered to study patients by their treating physicians according to the local standards of care
89395227|NCT01373411|Placebo Comparator|Placebo|Placebo twice daily. Study drug will be started within 48 hours of CABG.
89395228|NCT01373411|Active Comparator|ticagrelor 90 mg|Taken twice daily. Study drug will be started within 48 hours of CABG.
89395229|NCT03567564||Mechanically ventilated patients|Abdominal muscles ultrasound
89395230|NCT01367795||palliative tumor disease|Patients in a known palliative setting with symptoms due to tumor growth.
89395231|NCT03567408|Experimental|Selective PCI with bivalirudin|Before PCI, bivalirudin is intravenously injected with 0.75 mg/kg, 1.75 mg/(kg.h) through continuous intravenous drip to finish surgery (no more than 4 hours), if necessary, after the surgery, with a low dose of 0.2 mg/(kg.h) intravenous drip less than 20 hours.
89395232|NCT03567408|Placebo Comparator|Unfractionated heparin|Before PCI, unfractionated heparin sodium is intravenously injected with 70-100 U/kg, and if the operation time exceeded 1h, an additional 1000 U/h would be added.
89395233|NCT05354076|Experimental|liposomal doxorubicin|According to the clinical diagnosis and treatment norms, it is suitable for patients with advanced malignant tumors diagnosed by histopathology with doxorubicin hydrochloride liposome injection chemotherapy.
89395234|NCT05192993|Experimental|visual motor integration group|participants in the experimental group will receive visual motor integration program
89395235|NCT05192993|Active Comparator|Handwriting intervention group|participants in the experimental group will receive handwriting intervention program.
89395236|NCT05192993|Active Comparator|visual motor integration and Handwriting intervention group|participants in the group will receive visual motor integration program and handwriting intervention program.
89395237|NCT05065697||TAVR arm|Symptomatic severe aortic stenosis undergoing transfemoral TAVR of any devices
89395238|NCT05065697||SAVR arm|Symptomatic severe aortic stenosis undergoing isolated bioprosthetic surgical aortic valve replacement
89395239|NCT01367951|Experimental|Surgical fixation|"The fractures will be reduced and stabilized by use of plates and screws~Attempt will be made to stabilize ribs 3-7, as these are surgically accessible and most important in maintaining integrity of the chest cavity.~Goal is not to fix all the fractures, but to fix sufficient fractures to create an internal splint and allow chest wall motion to occur as a unit. In case of fibs fractured at numerous locations, as many fragments will be reduced and stabilized as necessary to ensure movement as a unit.~Chest tube(s) will be placed at the discretion of the treating surgeon in patients with pre-operative or intra-operative violation of the pleural cavity (ie pre-op pneumothorax/haemothorax, iatrogenic pleural injury). No post-operative drains will be inserted."
89395240|NCT01367951|No Intervention|non-operative|"Mechanical ventilation: Patients in respiratory distress will receive endotracheal intubation, and placed on mechanical ventilation. PEEP will be utilized as needed, at the discretion of the ICU and respiratory therapy team.~Other conservative means/Pulmonary toilet:Patients will receive aggressive pulmonary toilet (suctioning of ET tube as needed), chest physiotherapy (as per standard local protocol), and will have the head of the bed elevated to 30° unless contraindicated (ie unstable C-spine injury).~Pain control:Epidural catheters, intercostal nerve block, PCA, IV/PO pain medication"
89395241|NCT05708664|Experimental|PBCS|patients enrolled in the PBCS group underwent precision breast conserving surgery guided by wire guided localization combined with MDCT guided 3D reconstruction.
89395242|NCT05708664|No Intervention|Control|patients enrolled in the Control group underwent palpation guided breast conserving surgery
89395243|NCT05192759|Experimental|TBS Group|Participants will receive active transcranial magnetic stimulation (TMS) daily for 1 week
89395244|NCT05192681|Experimental|Tislelizumab arm|Tislelizumab: 200 mg, intravenous infusion, administered on the 1st day of each cycle, every 3 weeks Docetaxel: 60-75mg/m2 administered on the 1st day of each cycle, every 3 weeks Treatment until the disease progresses or intolerable side effects appear.
89395245|NCT01368029|Experimental|LGG|Lactobacillus rhamnosus GG (LGG) containing 1x10^10 LGG per capsule will be given to volunteers with verbal and written instructions at the baseline visit. Capsules are to be taken orally twice a day on an outpatient basis.
89395246|NCT01368029|Placebo Comparator|Placebo|Placebo capsules composed of microcrystalline cellulose are to be taken orally twice a day on an outpatient basis.
89395247|NCT03634553|Experimental|Intervention|Training with e-health product The training program follows the recommendations for training from ACSMS and SoS who states the importance that exercise programs should include muscle strengthening, cardiovascular as wells as balance exercises. Therefore, the training program includes: Strengthening exercises for the upper and lower extremities (number: 5-8 pc. with progression in three levels), daily (5-7 times / week), 30 minutes walks and balance training.
89395248|NCT03634553|Active Comparator|Control|usual care, i.e. participates in regular training regime at the physiotherapy department
89395249|NCT01368107|Placebo Comparator|Placebo Arm|the patients will receive Placebo before the 1st and during the 3rd CT cycle (N=6)
88871477|NCT04087109|Experimental|Intervention: MedSafer|In the intervention phase, the MedSafer feature will become accessible in MED e-care for the physicians, pharmacists and nurses. This feature will provide health care professionals with individualized and prioritized deprescribing opportunities: a) identifying the medication, b) explaining why that medication is potentially inappropriate and c) providing instructions on how to safely stop/taper the medication. The user will review these opportunities and appropriate candidate medications for deprescribing can then be tapered or stopped directly in the EMR. During the intervention phase, all patients will receive the educational (EMPOWER) brochures as applicable to the medications they are taking (PPI, sedative-hypnotic, antihistamine, antipsychotic, sulfonylurea, NSAID, opioid/narcotic).
88871478|NCT04087109|No Intervention|Control: Baseline (no MedSafer)|During the control phase, the MedSafer application programming interface will not be accessible to the caretakers at the aged care facilities (ACF). This serves to obtain baseline deprescribing levels for each ACF.
88871479|NCT04082442|Experimental|Evolocumab|420 mg evolocumab administered subcutaneously using an autoinjector/pen in ACS patients.
88871480|NCT04082442|Placebo Comparator|Placebo|Placebo administered subcutaneously using an autoinjector/pen in ACS patients .
89003856|NCT04307576|Experimental|ALLTogether1 DS Blinatumomab intervention|Blinatumomab IV, 5 mcg/m2/day up to 28 mcg/day (detailed dosing in protocol) continous infusion. Two 28 day courses with a two week treatment free interval in between. Blinatumomab courses replace Consolidation 1 and Consolidation 2 in the standard protocol adapted for Down syndrome patients.
88871482|NCT04054752|Experimental|1/ Arm 1|NT-I7 administered at 720 and 960g/kg to select the OBD of NT-I7
88871483|NCT04054752|Active Comparator|2/ Arm 2a|Administration of 4 vaccines according to Sequence 1 + NT-I7 administration at OBD to assess vaccine response
88871484|NCT04054752|Active Comparator|3/ Arm 2b|Administration of 4 vaccines according to Sequence 2 + NT-I7 administration at OBD to assess vaccine response
88871485|NCT04039191|Placebo Comparator|SMS survey|Subject to receive SMS survey.
88871486|NCT04039191|Active Comparator|SMS survey with education|Subject to receive SMS survey with education.
88871487|NCT04023747||Cohort 1|Participants with Monoclonal B-Cell Lymphocytosis or Asymptomatic Chronic Lymphocytic Leukaemia
88871488|NCT04023747||Cohort 2|Participants with IgM Monoclonal Gammopathy or Asymptomatic Waldenstrom's Macroglobulinaemia
88871489|NCT04023747||Cohort 3|Participants with IgA or IgG Monoclonal Gammopathy or Smouldering Myeloma
88871490|NCT04003285|Experimental|Placebo|ALLO 0 nM (placebo: loading dose, 4-hour infusion, taper)
88871491|NCT04003285|Experimental|ALLO 50 nM|ALLO 50 nM (lower dose ALLO: loading dose, 4 hour infusion, taper)
88871492|NCT04003285|Experimental|ALLO 150 nM|ALLO 150 nM (higher dose ALLO: loading dose, 4 hour infusion, taper)
88871493|NCT03989492|Experimental|Autonomic responses to stressors|Protocol 1: mental math and handgrip exercise. Protocol 2: systemic stressors and end-organ receptor stimulation. Protocol 3: local heating.
88871494|NCT03987841|Experimental|Integrated MBSR/DSME intervention|Integrated mindfulness-based stress reduction/diabetes self-management education intervention. Single-arm study, a group of participants meeting eligibility requirements will be invited to participate.
88871495|NCT03983720|Experimental|Patient with multiple sclerosis and lowly fatigued|"Patient with multiple sclerosis and lowly fatigued will be included.~They will have:~Visit 1 (day 0) = Questionnaires, blood sample, cardiopulmonary evaluation, capacity of muscular oxygen extraction, sleep assessment Visit 2 (day 15) = Neuromuscular evaluation Visit 3 (day 30) = Metabolic fatigue"
88871496|NCT03983720|Experimental|Patient with multiple sclerosis and highly fatigued|"Patient with multiple sclerosis and highly fatigued will be included. They will have:~Visit 1 (day 0) = Questionnaires, blood sample, cardiopulmonary evaluation, capacity of muscular oxygen extraction, sleep assessment Visit 2 (day 15) = Neuromuscular evaluation Visit 3 (day 30) = Metabolic fatigue"
88871497|NCT03983720|Active Comparator|Healthy subjects|"Healthy subjects will be included. They will have:~Visit 1 (day 0) = Questionnaires, blood sample, cardiopulmonary evaluation, capacity of muscular oxygen extraction, sleep assessment Visit 2 (day 15) = Neuromuscular evaluation Visit 3 (day 30) = Metabolic fatigue"
89395250|NCT01368107|Experimental|CYT107 treatment before CT|patients will receive an induction cycle of CYT107 (10µg/kg/week subcutaneously for 3 weeks) before the 1st CT cycle and the placebo during the 3rd CT cycle (N=6)
89395251|NCT01368107|Experimental|CYT107 treatment during CT|patients will receive the placebo before the 1st CT cycle and a delayed treatment with CYT107 (10µg/kg/week subcutaneously for 3 weeks) during the 3rd CT cycle (N=6)
89395252|NCT01368107|Experimental|CYT107 treatment before and during CT|patients will receive an induction cycle of CYT107 (10µg/kg/week subcutaneously for 3 weeks) before the 1st CT cycle and a maintenance cycle of IL-7 (10µg/kg/week subcutaneously for 3 weeks) during the 3rd CT cycle (N=6).
89535470|NCT03206125||ESCC Cases|ESCC Cases
89535471|NCT04493021|Experimental|Treatment with Dermal Cooling System|Dermal Cooling System will be used in all eligible subjects.
88871498|NCT03970590|Experimental|CTC|"An integrated peer narrative-based intervention (VIEW > SELECT > GET), beginning with VIEW In-person viewing of VA Stories narratives, followed by SELECT a favorite Veteran] Storyteller, and then GET favorite Storyteller narrative-aligned text messages over 6 months"
88871499|NCT03970590|Active Comparator|Control|6-month HTN management assessment text messages without narrative component
88871500|NCT03961945|Other|Screening Population|Those that have gastroesophageal reflux or other risk factors for Barrett's Esophagus will be contacted and if agreeable undergo sponge capsule procedure and fill out questionnaires.
89003857|NCT04307576|Experimental|R2 - IR-low experimental arm B|Standard treatment with omission of monthly pulses of Vincristine IV 1,5 mg/m2/dose and 5 days of Dexamethasone p.o. 6 mg/m2/day in the Maintenance Phase.
89003858|NCT04294810|Experimental|Tiragolumab + Atezolizumab|Participants will receive atezolizumab followed by tiragolumab every 3 weeks (Q3W) on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit or unacceptable toxicity.
89187585|NCT00780195|Experimental|3|Single 2 hour hyperinsulinemic hypoglycemic clamp at ~60 mg/dl.
89395253|NCT02039674|Experimental|Part 1 Cohort A2 (Pembro2mg/kg+Paclitaxel [Pa]+Carboplatin [C])|Cohort A participants receive pembrolizumab (2 mg/kg) via intravenous (IV) infusion on Day 1 of each 3-week cycle PLUS paclitaxel (200 mg/m^2) via IV infusion on Day 1 of each 3-week cycle PLUS carboplatin (Aare Under the Curve [AUC] 6 [6 mg/mL/min]) via IV infusion on Day 1 of each 3-week cycle.
89395254|NCT02039674|Experimental|Part 1 Cohort B2 (Pembro 2mg/kg+Pa+C+Bevacizumab [B])|Cohort B2 participants receive pembrolizumab (2 mg/kg) via IV infusion on Day 1 of each 3-week cycle PLUS paclitaxel (200 mg/m^2) via IV infusion on Day 1 of each 3-week cycle PLUS carboplatin (AUC 6 [6 mg/mL/min]) via IV infusion on Day 1 of each 3-week cycle PLUS bevacizumab (15 mg/kg) via IV infusion on Day 1 of each 3-week cycle.
89395255|NCT02039674|Experimental|Part 1 Cohort C2 (Pembro 2mg/kg+Pemetrexed [Pe]+C)|Cohort C2 participants receive pembrolizumab (2 mg/kg) via IV infusion on Day 1 of each 3-week cycle PLUS pemetrexed (500 mg/m^2) via IV infusion on Day 1 of each 3-week cycle PLUS carboplatin (AUC 5 [5 mg/mL/min]) via IV infusion on Day 1 of each 3-week cycle.
89395256|NCT02039674|Experimental|Part 1 Cohort D1 (Pembro 10mg/kg+Ipilimumab [I])|Cohort D1 participants receive pembrolizumab (10 mg/kg) via IV infusion on Day 1 of each 3-week cycle PLUS ipilimumab (1 mg/kg) via IV infusion on Day 1 of each 3-week cycle.
89395257|NCT02039674|Experimental|Part 1 Cohort E (Pembro 2mg/kg+Erlotinib)|Cohort E participants receive pembrolizumab (2 mg/kg) via IV infusion on Day 1 of each 3-week cycle PLUS erlotinib (150 mg) via oral tablet once a day on every day of each 3-week cycle.
89395258|NCT02039674|Experimental|Part 1 Cohort F (Pembro 2mg/kg+Gefitinib)|Cohort F participants receive pembrolizumab (2 mg/kg) via IV infusion on Day 1 of each 3-week cycle PLUS gefitinib (250 mg) via oral tablet once a day on every day of each 3-week cycle.
89395259|NCT02039674|Experimental|Part 2 Cohort G+ (Pembro 200mg+C+Pe)|Cohort G+ participants receive pembrolizumab (200 mg) via IV infusion on Day 1 of each 3-week cycle PLUS carboplatin (AUC 5 [5 mg/mL/min]) via IV infusion on Day 1 of each 3-week cycle PLUS pemetrexed (500 mg/m^2) via IV infusion on Day 1 of each 3-week cycle.
89395260|NCT02039674|Experimental|Part 2 Cohort H (Pembro+I)|Cohort H participants receive pembrolizumab (2 mg/kg) via IV infusion on Day 1 of each 3-week cycle PLUS ipilimumab (1 mg/kg) via IV infusion on Day 1 of each 3-week cycle (at the recommended Phase II dose determined in Cohort D).
89395261|NCT02039674|Experimental|Part 1 Cohort A10 (Pembro+Paclitaxel [Pa]+Carboplatin [C])|Cohort A10 participants receive pembrolizumab (10 mg/kg) via IV infusion on Day 1 of each 3-week cycle PLUS paclitaxel (200 mg/m^2) via IV infusion on Day 1 of each 3-week cycle PLUS carboplatin (AUC 6 [mg/mL/min]) via IV infusion on Day 1 of each 3-week cycle.
89395262|NCT02039674|Experimental|Part 1 Cohort B10 (Pembro+Pa+C+Bevacizumab [B])|Cohort B10 participants receive pembrolizumab (10 mg/kg) via IV infusion on Day 1 of each 3-week cycle PLUS paclitaxel (200 mg/m^2) via IV infusion on Day 1 of each 3-week cycle PLUS carboplatin (AUC 6 [6 mg/mL/min]) via IV infusion on Day 1 of each 3-week cycle PLUS bevacizumab (15 mg/kg) via IV infusion on Day 1 of each 3-week cycle.
89395263|NCT02039674|Experimental|Part 1 Cohort C10 (Pembro 10mg/kg+Pemetrexed [Pe]+C)|Cohort C10 participants receive pembrolizumab (10 mg/kg) via IV infusion on Day 1 of each 3-week cycle PLUS pemetrexed (500 mg/m^2) via IV infusion on Day 1 of each 3-week cycle PLUS carboplatin (AUC 5 [5 mg/mL/min]) via IV infusion on Day 1 of each 3-week cycle.
89395264|NCT02039674|Experimental|Part 2 Cohort G- (Placebo+C+Pe)|Cohort G- participants receive placebo (normal saline solution) via IV infusion on Day 1 of each 3-week cycle PLUS carboplatin (AUC 5 [5 mg/mL/min]) via IV infusion on Day 1 of each 3-week cycle PLUS pemetrexed (500 mg/m^2) via IV infusion on Day 1 of each 3-week cycle PLUS.
89395265|NCT02039674|Experimental|Part 1 Cohort D2 (Pembro 10mg/kg+Ipilimumab [I])|Cohort D2 participants receive pembrolizumab (10 mg/kg) via IV infusion on Day 1 of each 3-week cycle PLUS ipilimumab (3 mg/kg) via IV infusion on Day 1 of each 3-week cycle.
89395266|NCT02039674|Experimental|Part 1 Cohort D4 (Pembro 2mg/kg+Ipilimumab [I])|Cohort D1 participants receive pembrolizumab (2 mg/kg) via IV infusion on Day 1 of each 3-week cycle PLUS ipilimumab (1 mg/kg) via IV infusion on Day 1 of each 3-week cycle.
89395267|NCT03126227|Active Comparator|AR101 Powder Provided in Capsules|Study product formulated to contain peanut protein at different dosage strengths for use as defined in the protocol
89395268|NCT03126227|Placebo Comparator|Placebo powder|Placebo formulation in pull-apart capsules containing only excipients color-matched to AR101 study product.
89395269|NCT01373567|Experimental|TINEFCON|Tablets of 700 mg.
89395270|NCT01373645|Experimental|Yinyi stent|subjects with Yinyi stent implantation
89395271|NCT03099187|Experimental|Pirfenidone|Participants will receive pirfenidone 267 mg capsule three times a day from Day 1 to 7 followed by 2 capsules three times a day from Day 8 to 14 then 3 capsules three times a day from Day 15 up to Week 24.
89395272|NCT03099187|Experimental|Placebo|Participants will receive matching placebo capsule three times a day from Day 1 to 7 followed by 2 capsules three times a day from Day 8 to 14 then 3 capsules three times a day from Day 15 up to Week 24.
89395273|NCT04192474|Other|Flexible cystoscopy|50% of the patients undergo flexible diagnostic cystoscopy; 50% of the patients undergo flexible cystoscopy intervention with endoscopic accessories.
89395274|NCT03634475|Experimental|PP-001|Single intravitreal injection of 3 up to 4 doses of PP-001
89395275|NCT04544267|Experimental|QIV-HD|One injection of QIV-HD on Day 0. For participants for whom 2 doses of influenza vaccine are recommended, a second dose is administered on Day 28.
89187586|NCT00780195|Experimental|4|Single, 2 hour hyperinsulinemic hypoglycemic clamp at ~50 mg/dl.
89187587|NCT04047615|Experimental|Exercise effects on Behavior|An exercise intervention programme will be implemented 3 times a week for an 8 week period of time in a school setting. Each exercise class will last 60 minutes. The exercise classes will be fun for the students to participate in and will involve aspects of fundamental movement skills.
89395276|NCT04544267|Active Comparator|QIV-SD|One injection of QIV-SD on Day 0. For participants for whom 2 doses of influenza vaccine are recommended, a second dose is administered on Day 28.
89395277|NCT04535453|Experimental|Groups 1-6|Participants will receive a 2-dose Ad26.COV2.S vaccination regimen at Days 1 and 57 at different dose levels (Groups 1-3), or a single-dose Ad26.COV2.S vaccination regimen at different dose levels (Groups 4-5), or placebo (Group 6). At unblinded phase, participants in Group 6 initially receiving placebo will be offered 2 doses of Ad26.COV2.S vaccine at a single dose level, at a 28-day interval. Participants will also receive a single antigen presentation injection with single dose level of Ad26.COV2.S at 4 months after second vaccination (Groups 1-5) or placebo (Group 6).
88871501|NCT03961945|Other|Upper endoscopy - Barrett's Esophagus|Those that have a diagnosis of Barrett's Esophagus and are scheduled for an upper endoscopy will be approached and if agreeable undergo sponge capsule procedure as well as endoscopic biopsies and brushings of the esophagus.
88871502|NCT03961945|Other|Upper endoscopy - No Barrett's Esophagus|Those that have no known Barrett's Esophagus and are scheduled for an upper endoscopy will be approached and if agreeable undergo sponge capsule procedure as well as endoscopic biopsies and brushings of the esophagus.
88871503|NCT03957434|Experimental|Physiotherapy|12-weekly physiotherapy treatment sessions.
88871504|NCT03957434|No Intervention|Standard usual care|Participants will be asked to continue the usual care established during the regular follow-up with their medical doctor for 12 weeks.
88871505|NCT03924856|Experimental|Pembrolizumab + Gemcitabine + Cisplatin + Surgery|Participants received 4 preoperative cycles of pembrolizumab PLUS gemcitabine PLUS cisplatin, followed by surgery, followed by up to 13 cycles of postoperative pembrolizumab.
88871506|NCT03924856|Placebo Comparator|Placebo + Gemcitabine + Cisplatin + Surgery|Participants received 4 preoperative cycles of placebo to pembrolizumab PLUS gemcitabine PLUS cisplatin, followed by surgery, followed by up to 13 cycles of postoperative placebo to pembrolizumab.
88871507|NCT03919162|Experimental|600 mg|First 4 weeks 150 mg BID, week 5-8 300 mg BID, week 9-24 600 mg BID
88871508|NCT03919162|Experimental|300 mg|First 4 weeks 150 mg BID, week 5-24 300 mg BID
88871509|NCT03919162|Experimental|150 mg|24 weeks on 150 mg BID
88871510|NCT03919162|Placebo Comparator|Placebo|
88871511|NCT03847480|Experimental|Dose painting|Dose painting
88871512|NCT03844399||Patients|Cancer patients who are scheduled to undergo an ablation or biopsy of a liver or kidney tumour
88871513|NCT03843034||Study group|Infertile women with autoimmune disease
88871514|NCT03843034||Control group|Women from couples with severe male infertility
88871515|NCT03834766|Active Comparator|AMPH ER Tab|Amphetamine Extended Release Tablets 5, 10, 15 and 20 mg
88871516|NCT03834766|Placebo Comparator|Matching Placebo|Matching Placebo Tablets 5, 10, 15 and 20 mg
88871517|NCT03809026||Study group|Couples where the men have Klinefelter's syndrome, maturation stop in the spermatogenesis or failed retrieval of testicular sperm by conventional techniques with needle or TruCut, and where testicular sperm could be obtained by micro-TESE.
88871518|NCT03809026||Control group|Couples as in the study group, but where testicular sperm could not be obtained by micro-TESE. The oocytes therefore must be fertilized using donor sperm.
88871519|NCT03780309|Active Comparator|EXERCISE|Participants participated in a the exercise training program and engaged in exercise self-monitoring.
88871520|NCT03780309|Experimental|EXERCISE+PEH|Participants participated in the exercise training program and engaged in exercise self-monitoring and blood pressure self-monitoring (daily and before and after exercise).
88871521|NCT03761056|Experimental|Axicabtagene Ciloleucel|Participants will receive cyclophosphamide 500 mg/m^2/day intravenously (IV) and fludarabine 30 mg/m^2/day IV conditioning chemotherapy for 3 days followed by axicabtagene ciloleucel administered as a single IV infusion at a target dose of 2 x 10^6 anti-cluster of differentiation (CD)19 chimeric antigen receptor (CAR) transduced autologous T cells/kg on Day 0. For participants weighing ≥ 100 kg, a maximum flat dose of axicabtagene ciloleucel at 2 x 10^8 anti-CD19 CAR T cells will be administered.
88871522|NCT03747120|Active Comparator|Arm A: THP|"Arm A: Paclitaxel weekly x12 + Trastuzumab + Pertuzumab~All subjects may receive standard of care systemic therapy after surgery per their treating physician's discretion."
88871523|NCT03747120|Experimental|Arm B: THP-K|"Arm B: Paclitaxel weekly x12 + Trastuzumab + Pertuzumab + Pembrolizumab~All subjects may receive standard of care systemic therapy after surgery per their treating physician's discretion."
88871524|NCT03747120|Experimental|Arm C: TH-K|"Arm C: Paclitaxel weekly x12 + Trastuzumab + Pembrolizumab~All subjects may receive standard of care systemic therapy after surgery per their treating physician's discretion."
88871525|NCT03729557||Kidney Donors|
88871526|NCT03729557||Control group|
88871527|NCT03657732||Familial Alzheimer's disease group|Familial Alzheimer's disease with the known mutation presenilin1 (PSEN1), presenilin2 (PSEN2) and amyloid precursor protein (APP) including mutation carriers and noncarriers, presymptomatic and symptomatic.
88871528|NCT03657732||Normal control group|Normal cognitive control people
88871529|NCT03602105|Active Comparator|Intervention group|Exercise interventions for 6-12 weeks. Adherence is monitored with day journals
88871530|NCT03602105|No Intervention|Control group|Care as usual
88871531|NCT03592888|Experimental|All subjects|All subjects will receive the vaccine and be followed per the schedule of procedures.
88871532|NCT03586089|Experimental|Phenobarbital|Patients will receive a single dose of phenobarbital (7.5 mg/kg of ideal body weight, IV) in addition to usual therapy.
88871533|NCT03586089|Placebo Comparator|Placebo|Patients will receive an inactive placebo (IV).
88871534|NCT03585764|Experimental|Cohort 1: MOv19-BBz CAR T cells without chemo|Cohort 1: (n= 3 to 6 subjects): Single infusion of 1-3x107 /m2 lentivirally transduced MOv19-BBz CAR T cells on day 0 without lymphodepleting chemotherapy.
88871535|NCT03585764|Experimental|Cohort 2: MOv19-BBz CAR T cells after chemo|Cohort 2: (n= 3 to 6 subjects): Single infusion of 1-3x107 /m2 lentivirally transduced MOv19-BBz CAR T cells on day 0 beginning 3 days (+/- 1 day) after lymphodepleting chemotherapy with cyclophosphamide + fludarabine.
88871536|NCT03585764|Experimental|Cohort 3: MOv19-BBz CAR T cells after chemo|Cohort 3: (n=3 to 6 subjects): Single infusion of 1-3x108 lentivirally transduced MOv19-BBz CAR T cells on day 0 beginning 3 days (+/- 1 day) after lymphodepleting chemotherapy with cyclophosphamide + fludarabine.
89395278|NCT04535453|Experimental|Groups 7-8|Participants will receive 2-dose Ad26.COV2.S vaccination regimen at Days 1 and 29 at fixed dose level (Groups 7) or placebo (Groups 8). At unblinded phase, participants in Group 8 initially receiving placebo will be offered 2 doses of Ad26.COV2.S vaccine at a single dose level, at a 28-day interval. Participants will also receive a single antigen presentation injection with single dose level of Ad26.COV2.S at 4 months after second vaccination (Group 7) or placebo (Group 8).
88871537|NCT03585764|Experimental|Cohort-1: without chemo;only if dose de-escalation required|Cohort -1: (n= 3 to 6 subjects): Single Infusion of 1-3x106 /m2 lentivirally transduced MOv19-BBz CAR T cells on day 0 without lymphodepleting chemotherapy. Up to 6 subjects will be infused in Cohort -1 with ≤ 1 DLT/6 subjects to establish the MTD.
88871538|NCT03546686|Experimental|Treatment Arm|"Pembrolizumab + Core Biopsy/Cryoablation + Breast Surgery +Post Surgery pembrolizumab~OR~Ipilimumab and Nivolumab + Core Biopsy/Cryoablation + Breast Surgery +Post Surgery Nivolumab"
89395279|NCT04535453|Experimental|Groups 9-10|Participants will receive 2-dose Ad26.COV2.S vaccination regimen at Days 1 and 85 at fixed dose level (Group 9) or placebo (Group 10). At unblinded phase, participants in Group 10 initially receiving placebo will be offered 2 doses of Ad26.COV2.S vaccine at a single dose level, at a 28-day interval. Participants will also receive a single antigen presentation injection with single dose level of Ad26.COV2.S at 4 months after second vaccination (Group 9) or placebo (Group 10).
89395280|NCT04535453|Experimental|Groups A-C|Participants will receive a single dose Ad26.COV2.S vaccination regimen at Day 1 at fixed dose level (Groups A and B) or placebo (Group C). At approximately 6 months of study participation (unblinded phase), participants in Group C initially receiving placebo will receive Ad26.COV2.S vaccine at a single dose level, at a 56-day interval.
89395281|NCT04926220||Patients undergoing general anesthesia and benefiting from intraoperative hemodynamic optimization|Patients undergoing general anesthesia and benefiting from intraoperative hemodynamic optimization, including routine monitoring of blood pressure and measurement of cardiac output by trans-esophageal Doppler.
89535472|NCT03077763|Active Comparator|Normoxia and Nitrite (3umol/min-1)|Sodium nitrite stock solution: 100umol/10ml, prepared to concentration according to oxygen sequence. Normoxia (3umol/min-1).
88871539|NCT03508921|Experimental|Periprocedural Antibiotics Only|Patients receive a one-time dose of antibiotics at the time of injection, prior to injection.
88871540|NCT03508921|Experimental|Extended Antibiotics|Patients receive a peri-procedural dose of antibiotics and an extended (3-day) course of antibiotics to be taken post-procedurally.
88871541|NCT03494127|Experimental|Group A|DAILY COMMUNITY USE OF GEL BALL FITTED MODULAR CUSHION for 2 weeks followed by DAILY COMMUNITY USE OF SQUISHINS FITTED MODULAR CUSHION for 2 weeks
88871542|NCT03494127|Experimental|Group B|DAILY COMMUNITY USE OF SQUISHINS FITTED MODULAR CUSHION for 2 weeks followed by DAILY COMMUNITY USE OF GEL BALL FITTED MODULAR CUSHION for 2 weeks
88871543|NCT03493295||Levonogestrel IntraUterine System (LNG-IUS)|Women in childbearing age between 18 to 30 years old and who have freely chosen a LNG-IUS for contraception after being adequately counselled and informed of all contraceptive options by their physician at the routine clinical practice setting in Spain
88871544|NCT03426826|Placebo Comparator|Arm 1|Placebo Comparator placebo into the jejunum through upper endoscopy.
88871545|NCT03426826|Active Comparator|Arm 2|Active Comparator: Donor Stool Transplant Arm 2 will get FMT (Fecal Microbial Transplant) with Healthy Donor Stool into the jejunum through upper endoscopy.
88871546|NCT03401047|Experimental|Transdermal Estradiol|Subjects will undergo estradiol administration for up to 9 days. Transdermal estradiol patches will be applied each day by study staff during study days two through nine (patches deliver 0.1 mg/day for a total dose of up to 0.6 mg/day).
88871547|NCT03349450|Experimental|Single Arm-Investigational|"DPX-Survivac Priming dose of 0.5ml. DPX-Survivac Booster dose of 0.1ml.~Pembrolizumab 200mg Intravenously.~Cyclophosphamide 50mg Twice daily orally."
88871548|NCT03315026|Experimental|Siltuximab|Siltuximab 11mg/kg will be administered seven days before and 21 days after autologous stem cell infusion (+/-2 day).
88871549|NCT03307616|Experimental|Arm A (nivolumab)|Patients receive nivolumab IV over 1 hour on days 1, 15, and 29 in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgery within 2 weeks after day 43.
88871550|NCT03307616|Experimental|Arm B (nivolumab, ipilimumab)|Patients receive nivolumab as in Arm A. Patients also receive ipilimumab IV over 90 minutes on day 1 in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgery within 2 weeks after day 43.
88871551|NCT03307616|Experimental|Arm C (nivolumab, RT)|Patients receive nivolumab IV over 1 hour on days 1, 15, 29, and 43. Patients also undergo RT QD for 5 days during days 15-47 in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgery within 2 weeks after day 71.
88871552|NCT03307616|Experimental|Arm D (nivolumab, ipilimumab, RT)|Patients receive nivolumab as in Arm C, ipilimumab as in Arm B, and RT as in Arm C in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgery within 2 weeks after day 71.
88871553|NCT03289195|Experimental|MRI biopsy|All patients enrolled will have had complete MR imaging response post Neoadjuvant Chemotherapy (NAC) and will undergo percutaneous MR guided biopsy.
88871554|NCT03287453|Experimental|Screening (educational intervention)|Participants attend educational sessions comprising of an inflatable colon interactive exhibit that allows visitors to walk through a colon while seeing images, a PowerPoint presentation that contains messages that are tailored to meet the cultural and linguistic needs of Black/African Americans, Appalachians, and Hispanics/Latinos, and or flip books/flip charts. Participants also receive a copy of the study information sheet which contains the basic elements of informed consent and a pre-education session knowledge survey.
88871555|NCT03280147|Experimental|7-day course of antibiotics|Randomization of subjects will be performed at the end of 7 days of sensitive intravenous antibiotic administration, provided the subjects meet randomization criteria. Those who are randomized to the 7-day group will not receive any further antibiotics.
88871556|NCT03280147|Active Comparator|14-day course of antibiotics|Randomization of subjects will be performed at the end of 7 days of sensitive intravenous antibiotic administration, provided the subjects meet randomization criteria. Those who are randomized to the 14-day group will receive 7 more days of the same antibiotics, to make it a total of 14 days.
88871557|NCT03276572|Experimental|All Subjects|A single dose of 225Ac-J591 will be given to subjects with documented progressive metastatic CRPC.
88871558|NCT03261622|Active Comparator|Control arm|Stimulation amplitude at 90% of sensory threshold during period 1 to 3. (each period 4 weeks)
88871559|NCT03261622|Sham Comparator|Intervention arm|"Alternation of stimulation amplitude~Period - Stimulation amplitude 0.05 Volts (lowest possible)~Period - Stimulation amplitude - 50% of sensory threshold.~Period - Stimulation amplitude - 90% of sensory threshold."
88871560|NCT03240406|Active Comparator|Anti-inflammatory dietary intervention|18 month intervention of dietary counseling to adhere to the Multicultural Healthy Diet or the anti-inflammatory diet,
88871561|NCT03240406|Placebo Comparator|Usual Diet plus Self-Care|18 month intervention of usual diet plus self-care modules
88871562|NCT03240289|Other|Texting|Texting group
88871563|NCT03220893|Experimental|Observational (MRI, DBT)|Participants undergo DBT and MBI at year 0 and year 1 screening.
88871564|NCT03202069|Experimental|Even protein intake|Menu to provide 90 g of protein per day in an even distribution of 30 g at each meal.
88871565|NCT03202069|Experimental|Skewed protein intake|Menu to provide 90 g of protein per day in a skewed distribution of 10 g at breakfast, 15 g at lunch and 65 g at dinner.
88871566|NCT03200236|Experimental|Intensive Telephone Counseling|This arm provides a multi-faceted, 8-session intensive telephone counseling (ITC) protocol, tailored on lung cancer screening results, with 8-weeks of free nicotine replacement patches provided (Nicoderm patch, 21mg, 14mg, and 7mg) and primary care engagement.
88871567|NCT03200236|Active Comparator|Usual Care|This arm provides a multi-faceted, 3-session usual care telephone counseling (UC) protocol, with 2-weeks of free nicotine replacement patches provided (Nicoderm patch, 21mg, 14mg, and 7mg) and primary care engagement.
88871568|NCT03181152||ACOS group|Impulse Oscillometry Bronchial Dilation Test if needed
88871569|NCT03181152||Asthma group|Impulse Oscillometry Bronchial Dilation Test if needed
88871570|NCT03181152||COPD group|Impulse Oscillometry Bronchial Dilation Test if needed
88871571|NCT03125642|Experimental|BEAM: NHL & HL|BCNU, etoposide, Ara-C and melphalan (BEAM) for all NHL and those HL patients who are unable to receive CBV
88871572|NCT03125642|Experimental|CBV: HL|Cyclophosphamide, BCNU and VP-16 (CBV) for HL patients
88871573|NCT03125642|Experimental|CY/TBI|Cyclophosphamide/Total Body Irradiation (CY/TBI) for patients with recent history of CNS lymphoma or those with allergies/contra-indications to agents used in BEAM
88871574|NCT03105843|Experimental|Cough Variant Asthma|Individuals diagnosed with Cough variant asthma
88871575|NCT03105843|Experimental|Methacholine-induced cough|Individuals with chronic cough and negative methacholine challenge
88871576|NCT03105843|Experimental|Control|Individuals with no history of asthma or chronic cough
88871577|NCT03068910|Experimental|Spironolactone|Prior to the first or the second admission (randomly determined), participants will be pretreated for 2 weeks with spironolactone (50 mg twice daily).
88871578|NCT03068910|Placebo Comparator|Placebo|Prior to the first or the second admission (randomly determined), participants will be pretreated for 2 weeks with placebo (twice daily).
88871579|NCT03028246|Experimental|ExAblate 4000 System|MR-Guided Focused Ultrasound
88871580|NCT03005418|Experimental|Human Acellular Vessel (HAV)|Patients with life or limb threatening traumatic injury to an arterial vessel in the limb or torso, other than the heart, will be implanted with the Humacyte Human Acellular Vessel (HAV) as an interposition vessel or bypass using standard vascular surgical techniques.
88871581|NCT02984761|Experimental|Stereotactic radiotherapy|Stereotactic radiotherapy is an FDA approved treatment for lung cancer. However, for purposes of this study, it is being delivered to an operable population that is typically treated with surgical resection. Participants randomized to stereotactic radiotherapy will be treated according to the location of the tumor. Peripheral tumors will receive either 18 Gy x 3, 14 Gy x 4, or 11.5 Gy x 5 fractions, while central tumors will be treated with 10 Gy x 5. There will not be any elective coverage of local microscopic spread or regional lymph nodes.
88871582|NCT02984761|Active Comparator|Surgery|Participants randomized to surgery will undergo a standard lobectomy or limited anatomic pulmonary resection (segmentectomy) under general anesthesia. Non-anatomic (wedge) resections are not permitted. Pathological specimens must contain a separately divided pulmonary artery and bronchus, as well as sampled lymph nodes from mediastinal lymph node stations. Participants found to have incidental nodal involvement after surgery will be referred for adjuvant chemotherapy, with our without postoperative radiotherapy.
88871583|NCT02978638|Other|Finetech Vocare Bladder System|This is a pilot study of the Finetech Vocare Bladder System to improve continence and voiding in human subjects with chronic spinal cord injury. Each subject will act as their own control, comparing function with the Finetech Vocare Bladder System in use and not in use.
88871584|NCT02925195|Experimental|Active Treatment|
88871585|NCT02925195|Placebo Comparator|Placebo|Placebo
88871586|NCT02864277|No Intervention|No Intervention Conventional Strategy|Perioperative Anesthetic No Intervention Management: Conventional Strategy Group 4 pages of concise directions on how to take care of the participant.
89395282|NCT04463069|Experimental|intervention group|Participants in the intervention group participated in the APA intervention consisting of simple and fun endurance and strength-building exercise at a frequency of two sessions per week.
88871587|NCT02864277|Experimental|ERAS Group|ERAS (enhanced recovery after surgery)
88871588|NCT02840877|Other|DOT Adherence Monitoring|Daily adherence monitoring by study-employed directly observed therapy (DOT) worker on weekdays throughout the course of TB therapy
88871589|NCT02835287|Experimental|Protocol-based Integrated Care|The protocol-based integrated care, which will provide a standardized, combined, multi-component intervention according to clinical guideline treatment algorithms for diabetes and comorbidities in community clinics, will be delivered by care team (trained primary care physicians, health managers, and nurses supported by diabetes specialists) and assisted by a clinical decision support systems.
88871590|NCT02835287|Active Comparator|Enhanced Control|A usual team-based care delivered by trained primary care physicians, health managers, and nurses supported by diabetes specialists.
88871591|NCT02831985|Experimental|general practice follow-up|post-surgery follow-up by general practitioner
88871592|NCT02831985|Active Comparator|ENT specialist follow-up|post-surgery follow-up by ear-nose-throat (ENT) specialist
88871593|NCT02831556||Emergency Department Subjects|Subjects that present to the Emergency Department with complaints necessitating abdominal or pelvic imaging.
89395283|NCT04463069|No Intervention|control group|Participants in the control group received no intervention in the study time period.
89395284|NCT04397029|Experimental|Subjects without messes|Subjects who are believed to be free of masses.
89395285|NCT04397029|Experimental|Subjects with known masses|Subjects with known masses.
89395286|NCT04835272|No Intervention|control group|In the control group, the decision to decannulate was based on a 48-hour capping trial.
89395287|NCT04835272|Experimental|intervention group|In the intervention group, the decision to decannulate was based on suctioning frequency.
89395288|NCT01368341|Active Comparator|Doxycycline|Doxycycline, 100 mg, tablets, b.i.d., 14 days
88871594|NCT02831556||Non-patient volunteers|Duke employees that will voluntarily have an abdominal or pelvic ultrasound for with the sole purpose being for the study.
88871595|NCT02795533||Clinical follow-up|As part of the regular follow-up of aSAH patients at Oslo University Hospital patients with as aSAH in 2011-2012 will be invited to a clinical interview, medical examination and neuropsychological test. Patients will also be asked to answer Quality of Life Questionnaires.
88871596|NCT02694185|Experimental|Experimental Group|This group will undergo the intervention as described in the protocol
88871597|NCT02694185|No Intervention|Control Group|This group will not receive the intervention, they will receive usual care
89395289|NCT01368341|Active Comparator|Penicillin|Phenoxymethylpenicillin tablets 650 mg. 2 tablets t.i.d. 14 days
89395290|NCT01368341|Active Comparator|Amoxicillin|Amoxicillin 500 mg capsula, t.i.d., 14 days
89395291|NCT01368419|Experimental|Treatment|
89395292|NCT03139864|Experimental|type 1 diabetes|Comparison between infants with type 1 diabetes and infants without type 1 diabetes during exercise :
89395293|NCT03139864|Active Comparator|without type 1 diabetes|Comparison between infants with type 1 diabetes and infants without type 1 diabetes during exercise :
89395294|NCT01373723|Experimental|invitation letter|to participate in the screening
89395295|NCT01373723|Experimental|Invitation letter, informative leaflet and phone call reminder|to participate in the screening
88871598|NCT02684903|No Intervention|Services As Usual (SAU)|Participants receive all the usual services provided by Department of Human Services (DHS) Children's Services.
88871599|NCT02684903|Experimental|Parent Child Interaction Therapy (PCIT)|"Participants receive Parent Child Interaction Therapy (PCIT). PCIT is designed to improve child functioning by interrupting patterns of harsh, coercive interaction and enhancing parents' warm, positive parenting, autonomy support, and competent child management skills.~."
88871600|NCT02633111||Patients with aggressive B-cell Non-Hodgkin lymphoma|This is a non-therapeutic protocol aimed to assess the ability of Adaptive clonoSEQ® MRD assay to detect clinical relapse in DLBCLwhen compared to conventional approaches for detecting relapse such as patient-reported symptoms, clinical exams, and CT scans.
88871601|NCT02621424|Experimental|RTMS|repetitive transcranial magnetic stimulation
89395296|NCT01373723|Experimental|Invitation letter and informative leaflet|to participate in the screening
89395297|NCT04516564|Experimental|AK119|Single dose of AK119 is administered via intravenous infusion to healthy subjects.
89395298|NCT04516564|Experimental|Placebo|Single dose of placebo is administered via intravenous infusion to healthy subjects.
89395299|NCT05166317||Liver Cirrhosis|All the consecutive patients of cirrhosis admitted to Intensive care unit of Hepatology department of ILBS.
89395300|NCT04455100|Experimental|SHR1459|Following a 10-hour overnight fast, subjects will be administered one dose of SHR1459 orally with 240 mL of ambient temperature water on Day 1. D2-D3 was the cleaning period. Itraconazole will be administered orally 200 mg/time/day form D4 to D8 after meal. On D7 following a 10-hour overnight fast, subjects will be administered SHR1459 and itraconazole 200 mg with 240 mL of ambient temperature water.
89395301|NCT04332523|Experimental|Group 1: Participants with Mild Hepatic Impairment|Participants with mild hepatic impairment will receive a single oral dose of JNJ-53718678 suspension on Day 1.
89395302|NCT04332523|Experimental|Group 2: Participants with Moderate Hepatic Impairment|Participants with moderate hepatic impairment will receive a single oral dose of JNJ-53718678 suspension on Day 1.
89395303|NCT04332523|Experimental|Group 3: Participants with Severe Hepatic Impairment|Participants with severe hepatic impairment will receive a single oral dose of JNJ-53718678 suspension on Day 1.
89395304|NCT04332523|Experimental|Group 4: Participants with Normal Hepatic Function|Participants with normal hepatic function will receive a single oral dose of JNJ-53718678 suspension on Day 1.
89395305|NCT04439578|Experimental|Treatment|subjects receiving a single oral dose of SHR6390 tablets, then rifampicin capsules 600 mg/day orally with a single oral dose of SHR6390 tablets co-administered.
89395306|NCT03110848|Experimental|Statins|Atorvastatin 20 mg daily associated with intravenous glucocorticoids, namely 500 mg of methylprednisolone weekly for 6 weeks, followed by 250 mg weekly for another 6 weeks, for a total dose of 4.5 mg.
88871602|NCT02621424|Sham Comparator|sham|sham noise to block the sound of treatment
88871603|NCT02616185|Experimental|Dose Escalation|PF-06753512
88871604|NCT02611128||Peripubertal girls|Peripubertal girls with varying androgen concentrations will have careful phenotype/genotype assessment, primarily to assess the relationship between urinary exosomal DENND1A.V2 and serum free testosterone concentrations.
88871605|NCT02560129||ICU Survivors|ICU survivors will be seen in a MICU Recovery Clinic where Questionnaires, Physical and Cognitive Function assessments will be measured
88871606|NCT02520362||Postmenopausal Women|Postmenopausal Women
88871607|NCT02520362||Women with post menopausal osteoporosis|Women with post menopausal osteoporosis
88871608|NCT02520362||Prolia for unapproved indications|Patients who receive Prolia for unapproved indications
88871609|NCT02520362||Men with osteoporosis|Men with osteoporosis treated with denosumab
88871610|NCT02520362||Men and women who receive Prolia with Glucocorticoid exposure|Drug: denosumab subcutaneous injection
88871611|NCT02453737|Other|Catheter-based brachytherapy APBI|7 Gy x 3 fractions
88871612|NCT02453737|Other|3D-CRT APBI|7.3 Gy x 3 fractions
88871613|NCT02453737|Other|Proton APBI|7.3 Gy x 3 fractions
88871614|NCT02346747|Active Comparator|Group A|Vigil immunotherapy will be administered at a concentration of 1.0 x 10e7 cells/dose given via intradermal injection every 4 weeks for a minimum of 4 and a maximum of 6 administrations as determined by the number of doses manufactured and as long as the subject is clinically stable and recurrence free.
88871615|NCT02346747|Placebo Comparator|Group B|Placebo will be administered via intradermal injection every 4 weeks for a minimum of 4 and a maximum of 6 administrations as determined by the number of doses manufactured and as long as the subject is clinically stable and recurrence free.
88871616|NCT02324387|Experimental|Molecular Breast Imaging (MBI) + Tc99m sestamibi|Participants undergo 3 MBI scans with injections of injection of Tc99m sestamibi before each scan. First scan is 7 days before scheduled chemotherapy treatment, after 2 cycles of chemotherapy, and after completion of chemotherapy treatment.
88871617|NCT02291523|Sham Comparator|Patient Stool Transplant|Arm 1 will get FMT (Fecal Microbial Transplant) placebo and high dose 5-ASA (Pentasa). The FMT is done through colonoscopy.
88871618|NCT02291523|Active Comparator|Donor Stool Transplant|Arm 2 will get FMT (Fecal Microbial Transplant) with Healthy Donor Stool and high dose 5-ASA (Pentasa). The FMT is done through colonoscopy.
88871619|NCT02278744|Experimental|single-fraction radiosurgery|
88871620|NCT02266329|Active Comparator|prazosin|Subjects will be gradually titrated up to the maximum dose or the maximum tolerated dose based on a dosing algorithm. The maximum dose to be used in this trial is 5mg in the morning and 20 mg at bedtime.
88871621|NCT02266329|Placebo Comparator|placebo|Subjects will be gradually titrated up to the maximum dose or the maximum tolerated dose based on a dosing algorithm. The maximum dose to be used in this trial is 5mg in the morning and 20 mg at bedtime.
88871622|NCT02155933||Hyperandrogenemia|Peripubertal girls with hyperandrogenemia
88871623|NCT02155933||Controls|Peripubertal girls without hyperandrogenemia
88871624|NCT01967888|Experimental|Reparixin|Solution for intravenous (IV) infusion with active compound
88871625|NCT01967888|Placebo Comparator|Placebo|Physiologic solution
88871626|NCT01961219|Active Comparator|Adhesive Capsulitis with MUA|"Subjects with idiopathic adhesive capsulitis in the frozen or thawing phase who have failed pain management and failed improvement in range of motion after at least 3 months of supervised, regimented conservative treatment; or who after less than 3 months of conservative treatment demand a quicker return to function. Treatment closed manipulation under anesthesia."
88871627|NCT01961219|Active Comparator|Adhesive Capsulitis with Arthroscopy|"Subjects with idiopathic adhesive capsulitis in the frozen or thawing phase who have failed pain management and failed improvement in range of motion after at least 3 months of supervised, regimented conservative treatment; or who after less than 3 months of conservative treatment demand a quicker return to function. Treatment Arthroscopic Capsular Release"
88871628|NCT01910818|Experimental|Fractional CO2 laser Treatment|This is the area getting treated with CO2 laser.
88871629|NCT01910818|Experimental|No Treatment|This is the area receiving no treatment.
89395307|NCT03110848|Active Comparator|No statins|Intravenous glucocorticoids, namely 500 mg of methylprednisolone weekly for 6 weeks, followed by 250 mg weekly for another 6 weeks, for a total dose of 4.5 mg.
88871630|NCT01873131|Experimental|Topical Timolol|After verification of eligibility criteria and obtaining informed consent of parent/guardian, infants randomized to the timolol arm will receive twice daily topical application of a physician-specified amount of timolol maleate 0.5% ophthalmic solution (hereby referred to as topical timolol) for up to six months.
88871631|NCT01873131|No Intervention|Observation|After verification of eligibility criteria and obtaining informed consent of parent/guardian, infants randomized to the observation arm will be followed at study visits according to protocol.
88871632|NCT01873131|Experimental|Pulsed Dye Laser|After verification of eligibility criteria and obtaining informed consent of parent/guardian, infants randomized to the pulsed dye laser arm will receive a series of six weekly to semi-weekly laser treatments treatments for up to 6 treatments with potential for reduced number of treatments if the hemangioma completely resolves. A 595-nm pulsed-dye laser (PDL, V-beam Perfecta, Candela Corp, Wayland, MA) with a dynamic cooling device (DCD) will be utilized for all treatments. This device is cleared by the FDA for clinical treatment of vascular lesions.
88871633|NCT01508949|Experimental|NNC 90-1170|
88871634|NCT01508949|Placebo Comparator|Placebo|
88871635|NCT01507285|Experimental|NNC 90-1170|
88871636|NCT01507285|Placebo Comparator|Placebo|
88871637|NCT01486862|Experimental|BIAsp 30|
88871638|NCT01443156||Caregivers|Employees at a local medical facility, including (but not limited to): nurses, laboratory technicians, non-clinical hospital staff
88871639|NCT01428089|Experimental|Progesterone|Subjects will take 5-25 mg oral micronized P (based on body weight, to achieve mean plasma P 1-2 ng/ml)
88871640|NCT01428089|Placebo Comparator|placebo|placebo at 1100, 1500, and 1900 h.
89395308|NCT03139474|Active Comparator|agonist group|Triptorelin at a dose 1 milligram per day from the midluteal phase of the cycle preceding the treatment cycle to day 2 of the cycle then 0.5 milligram of triptorelin will be used during the period of stimulation.
89395309|NCT03139474|Active Comparator|antagonist group|•Multiple dose Gonadotrophin releasing hormone antagonist regimen will be used for ovarian stimulation 0.25 microgram per day cetrorelix will be administered from the 6th day of ovarian stimulation or from the presence of follicle 14 millimeter diameter .
89395310|NCT05166148|Experimental|eccentric cycling compared to concentric cycling|Every participant will perform the same protocol and will participated to the 3 experimental sessions (a, b and c) of the assigned intervention.
89395311|NCT01368575|Active Comparator|subgroup B1|subgroup B1 will receive CABG combined with MV repair with annuloplasty rigid ring
89395312|NCT01368575|Active Comparator|subgroup B2|B2 - CABG combined with MV repair with remodeling annuloplasty rigid ring and endoventricularplasty of subvalvular apparatus
89395313|NCT01368575|Active Comparator|subgroup A2|CABG combined with MV repair with remodeling annuloplasty rigid ring
89395314|NCT01368575|Active Comparator|subgroup A1|only CABG
88871641|NCT01425541|Experimental|estrogen, progesterone|Estrace, 0.5-1 mg once a day Micronized progesterone powder (Spectrum Chemical Manufacturing Corporation, Irving, CA), Three times a day at 0700, 1500, and 2300 hr
89395315|NCT01368575|Active Comparator|subgroup B3|patients in subgroup B3 will be performed CABG and MV replacement with preservation of subvalvular apparatus
88871642|NCT01388244|Active Comparator|Screening|Two-step screening process using FRAX risk score assessment followed by DXA scanning for high risk participants.
88871643|NCT01388244|Other|Control|Control arm - Fracture risk assessment by FRAX without any intervention
89395316|NCT01372163|Experimental|2 mg PF-05190457 or Placebo BID|
89395317|NCT01372163|Experimental|10 mg PF-05190457 or Placebo BID|
89395318|NCT01372163|Experimental|40 mg PF-05190457 or Placebo BID|Dose and dose frequency may be adjusted based on emerging safety and PK data.
89395319|NCT01372163|Experimental|150 mg PF-05190457 or Placebo BID|Dose and dose frequency may be adjusted based on emerging safety and PK data.
89395320|NCT01372163|Experimental|5 mg PF-05190457 or Placebo QD|Dose and dose frequency may be adjusted based on emerging safety and PK data.
88871644|NCT01167114|Experimental|STA-9090|All subjects receive STA-9090
88871645|NCT01156155||Participants with Rheumatoid Arthritis|Rheumatoid arthritis patients Digital xray of jaw and teeth Blood draw questionnaires Periodontal Examination Bilateral digital xray of hands
88871646|NCT01156155||Osteoarthritis|Osteoarthritis patients Digital xray of jaw and teeth Blood draw questionnaires Periodontal Examination
88871647|NCT00930228|Experimental|Flutamide|Flutamide 250 mg taken by mouth twice a day for 4 weeks. Flutamide is an androgen-receptor blocker.
88871648|NCT00930228|Placebo Comparator|Placebo|Placebo contains only inert ingredients and is not expected to exert any direct physiological effects.
88871649|NCT00918151||A|
88871650|NCT00874159||A|
88871651|NCT00849316||A|
88871652|NCT00773851|Other|A|transfacial sutures
88871653|NCT00773851|Other|B|staples
88871654|NCT00745433||A|Repaglinide add-on to metformin.
88871655|NCT00712478||A|
88871656|NCT00705172||A|
89395321|NCT01372163|Experimental|50 mg PF-05190457 or Placebo QD|Dose and dose frequency may be adjusted based on emerging safety and PK data.
89395322|NCT01372163|Experimental|xxx mg PF-05190457 or Placebo|Dose and dose frequency to be determined based on emerging safety and PK data.
89395323|NCT03141814||asthma|20 patients with ongoing ashma
89395324|NCT03141814||complete asthma remission|20 subjects with complete asthma remission
89395325|NCT03141814||clinical asthma remission|20 subjects with clinical asthma remission
89395326|NCT03141814||non-asthmatic healthy controls|20 subjects without respiratory symptoms and normal lung function and no bronchial hyperresponsiveness to methacholine and/or AMP
89395327|NCT03943966|Experimental|Myocardial Infarction|
89395328|NCT03943966|Active Comparator|Stable coronary disease with intracoronary stent insertion|
89395329|NCT03943966|Active Comparator|Deep vein thrombosis and Pulmonary embolus|
89395330|NCT03943966|Active Comparator|Surgical and Transcatheter Aortic valve replacement|
89395331|NCT03943966|Active Comparator|Transient ischaemic attack and stroke|
89395332|NCT01373801|Active Comparator|Control|
89395333|NCT01373801|Experimental|GuardaCare|
89395334|NCT01372241|Experimental|Early Intervention|This group served as the treatment group for analysis of the primary outcome.
89395335|NCT01372241|No Intervention|Delayed Intervention|This group served as a wait-list control group, eventually receiving the intervention after the treatment group completed the intervention and the primary outcomes were assessed for both groups.
89395336|NCT03140566|Experimental|Clinical assessment plus IVC diameter|Decongesting treatment guided by clinical assessment and ultrasound evaluation of the inferior vena cava diameter
89395337|NCT03140566|Sham Comparator|Clinical assessment only|Decongesting treatment guided by clinical assessment alone
89395338|NCT01319747|Active Comparator|Percutaneous therapy|
89395339|NCT01319747|Active Comparator|VATS therapy|
89395340|NCT02038972|Experimental|Autologous Stem Cells|A single dose of intravenously administered autologous hUCB will be done. The minimum acceptable dose will be 6x10 6th mononuclear cells/kilogram body weight. The hUCB reanimation, cell processing and product infusion will occur at Florida Hospital for Children and the Florida Hospital Center for Cellular Therapy.
89395341|NCT03895684|Experimental|Sp-2577|Twice-daily administration of oral SP-2577
89395342|NCT01368887|Experimental|1|DPS-102
89395343|NCT01368887|Placebo Comparator|2|Vehicle
89395344|NCT01368887|Active Comparator|3|Calcipotriol Monotherapy
89395345|NCT01368887|Active Comparator|4|Nicotinamide Monotherapy
89395346|NCT03859258||Patient having Cesarean section|Transvaginal sonography for patients having ceserean section to assess uterine Niche development and parameters
89395347|NCT03859258||Patient delivered vaginally|Transvaginal sonography for patients having vaginal delivery to confirm absence of uterine Niche development
89395348|NCT05049083|Experimental|Treatment group A|
89395349|NCT05049083|Experimental|Treatment group B|
89395350|NCT01369043|Active Comparator|Vitamin E and Vitamin C|4 weeks with Vitamin E and Vitamin C supplementation with no exercise and 4 weeks of supplementation with prescribed exercise.
89395351|NCT01369043|No Intervention|Placebo|Placebos instead of the Vitamin E and Vitamin C supplements
88871657|NCT00701155||A|
89395352|NCT04477096|Other|single arm for each part: two arms|"PART1:In the first period, HS-10234 will be administered at 25 mg QD for 7 days. In the second period, HS-10234 at 25 mg in combination with Emtricitabine at 200 mg will be administered QD for 7 days.~PART2:In the first period, Emtricitabine will be administered at 200 mg QD for 7 days. In the second period, HS-10234 at 25 mg in combination with Emtricitabine at 200 mg will be administered QD for 7 days."
89395353|NCT01369121|Experimental|Xerecept|All patients will receive hCRF (XERECEPT)
89395354|NCT03868150|Active Comparator|Inducible Atrial Fibrillation|Treatment with Amiodarone
88871658|NCT00687453|Experimental|Insulin glargine injected at bedtime|Insulin glargine injected at bedtime
88871659|NCT00687453|Active Comparator|NPH insulin injected twice-daily|NPH insulin injected twice-daily, before breakfast and at bedtime
88871660|NCT00687063||A|
88871661|NCT00653068|Experimental|Arm I (chemotherapy, autologous PBSC, 3D-CRT)|"Patients receive vincristine IV on days 1, 8, and 15; high-dose methotrexate IV on day 1; leucovorin calcium orally or IV; etoposide IV on days 4, 5, and 6; cyclophosphamide IV on days 4 and 5; cisplatin IV on day 6, and G-CSF IV or SC on day 7 until ANC recovers.~Within 2-6 weeks after induction therapy or radiation therapy, patients receive high-dose carboplatin IV and high-dose thiotepa IV on days 1 and 2 and undergo autologous PBSC rescue on approximately day 4. Patients also receive G-CSF IV or SC once daily until ANC recovers. Treatment with consolidation therapy followed by stem cell rescue repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity. After consolidation therapy, patients undergo 3D-CRT to the brain (and the spine if needed) 5 days a week for 5-6 weeks."
88871662|NCT00653068|Experimental|Arm II (chemotherapy, 3D-CRT, autologous PBSC)|"Patients receive vincristine IV on days 1, 8, and 15; high-dose methotrexate IV on day 1; leucovorin calcium orally or IV; etoposide IV on days 4, 5, and 6; cyclophosphamide IV on days 4 and 5; cisplatin IV on day 6, and G-CSF IV or SC on day 7 until ANC recovers.~Patients undergo 3D-CRT to the brain (and the spine if needed) 5 days a week for 5-6 weeks. Within 2-6 weeks after completion of radiation therapy, patients receive high-dose carboplatin IV and high-dose thiotepa IV on days 1 and 2 and undergo autologous PBSC rescue on approximately day 4. Patients also receive G-CSF IV or SC once daily until ANC recovers. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity."
89395355|NCT03868150|Other|Inducible Atrial Fibrillation - Standard Care|No initial Amiodarone Treatment unless POAF seen on post operative care unit.
89395356|NCT03868150|Other|Non-Inducible Atrial Fibrillation|Amiodarone treatment if POAF seen on post-operative care unit
89395357|NCT03606239|Experimental|isotoxic hypofractionated group|"Hypofractionated radiation:~1. Split mode: 3Gy/f. 2,Individualized prescriptions for different patients:~(1) Spinal cord: 0%>45 Gy, and ≤2 Gy each time Lung: V20≤30%, V5≤65%, MLD≤16Gy Esophagus: highest dose ≤ 69Gy 3. Maximum limit: If the limit of any A is not reached, the maximum radiation dose is 69 Gy. The lowest radiation dose: 45Gy.~Chemotherapy:~Platinum-containing two-drug regimen: docetaxel + lobaplatin: Docetaxel 60 mg/m2, d1; Lobaplatin 30 mg/m2, d1; repeated every 28 days. The first cycle of chemotherapy started on the first day of radiotherapy.~The same chemotherapy regimen is used up to 4 cycles as consolidation after the completion of radiotherapy."
89395358|NCT03551795|Experimental|treatment|The eligible patient receive the experimental infusion of iNKT cells.
89395359|NCT03141892||Diabetes Mellitus, Type 1 and Type 2|Subjects will wear the FreeStyle Libre Flash Glucose Monitoring System and will receive no treatment except for safety purposes.
89395360|NCT03842098||Musculoskeletal Disorders patients|Enroll the post operative musculoskeletal disorders patients and follow up their clinic visits and treatment regimen to analyze their utility in healthcare
89395361|NCT05084794|No Intervention|Non-fixated|Posterior malleolus fractures won't be fixated.
89395362|NCT05084794|Experimental|Fixated|Posterior malleolus fractures will be fixated with either plate or screws.
89395363|NCT03521687|Experimental|Apremilast|Patients with CCCA
89395364|NCT03141658|Experimental|TS-134 20 mg|
89395365|NCT03141658|Experimental|TS-134 60 mg|
89395366|NCT03141658|Experimental|Placebo|
89395367|NCT03139396|Active Comparator|inlay shaped inlay bridge design|The inlay shaped inlay bridge design preparation show three types of preparation, the inlay shaped, the tub shaped inlay bridge design and the proximal box shaped designs. Intracoronal preparation of the inlay retained prosthesis for the abutments (inlay shaped and tub shaped) should show the following criteria: The inlay shaped preparation should show an occlusal-proximal box preparation and to be designed with the line angles should be rounded, smooth and rounded corners, and rectangular flat floor with no beveling for the occlusal and gingival margins. The occlusal inlay preparation should have preparation depth allowed for a thickness of 2.0 mm for the material of the bridge. The occlusal reduction show 4 mm width with extension of 4 or 6 mm mesio distally for the posterior teeth.
89395368|NCT03139396|Experimental|tub shaped inlay bridge design|The tub-shaped reduction consist of an occlusal proximal inlay and prepared as the same geometry as the inlay shaped preparation, except that for the proximal box preparation which is not present in this preparation design.
89395369|NCT03498911|Active Comparator|envelope Coronally Advanced Flap (eCAF)|A mucogingival surgery where an envelope flap is coronally advanced and sutured to cover the mucosal recession
88871663|NCT00414648|Experimental|Active Agent (Sirolimus)|Participants receive sirolimus daily for 1 year and are followed with serial pulmonary function tests, 6-minute walk tests, and symptom and QOL questionnaires over a 2-year period.
88871664|NCT00414648|Placebo Comparator|Placebo Arm|Participants receive placebo daily for 1 year and followed with serial pulmonary function tests, 6-minute walk tests, and symptom and QOL questionnaires over a 2-year period.
89395370|NCT03498911|Experimental|Modified Tunnel Technique (MTT)|A mucogingival surgery where the gingiva is released without reflecting a flap (as described for tunnel techniques) and then coronally advanced and sutured to cover the mucosal recession
89395371|NCT03142048|Experimental|Schools of Health for the Elderly|"Participants receiving the community intervention (explained in the section Intervention)"
89395372|NCT03142048|No Intervention|Comparison Group|Participants in the study that do not receive the intervention
89395373|NCT03498131|Experimental|3 mg Melatonin|Subjects will receive 3 mg melatonin once a day.
89395374|NCT03498131|Experimental|5 mg Melatonin|Subjects will receive 5 mg melatonin once a day.
88871665|NCT00337155|Experimental|Radium-223 dichloride (Xofigo, BAY88-8223) Dose group 1|25 kBq/kg b.w., 3 times at 6 week intervals
88871666|NCT00337155|Experimental|Radium-223 dichloride (Xofigo, BAY88-8223) Dose group 2|50 kBq/kg b.w., 3 times at 6 week intervals
88871667|NCT00337155|Experimental|Radium-223 dichloride (Xofigo, BAY88-8223) Dose group 3|80 kBq/kg b.w., 3 times at 6 week intervals
88871668|NCT00077285|Experimental|pts with intermediate- and high-risk rhabdomyosarcoma|
89395375|NCT03141580|Experimental|Study group|Subjects with carotid stent who consented to undergo near-infrared spectroscopy and intravascular ultrasound imaging.
89395376|NCT05013827||Company representatives|
89395377|NCT03287752||BASKA MASK|Patients will be anesthetized using BASKA mask after lubrication with water soluble lubricant.
89395378|NCT03287752||Endotracheal tube|Patients will be anesthetized using appropriate sized cuffed oral endotracheal tube ETT.
89395379|NCT04566289||PiCSO treatment group|PiCSO treatment as per IFU
89395380|NCT01369277|Experimental|Japanese cohort|A total of 12 Japanese healthy subjects will be allocated to receive 3 ascending single doses (100 mg, 300 mg and 750 mg) of PF-04991532 or placebo through 3 dosing periods in a randomization ratio of 3:1.
89395381|NCT01369277|Experimental|Weterner Cohort|9 western healthy subjects will be enrolled to receive 2 single ascending doses (300 mg and 750 mg) of PF-04991532 through 2 dosing periods.
89395382|NCT02983006|Experimental|DS-8273a & Nivolumab|Patient groups (cohorts) will receive a single dose level of DS 8273a & Nivolumab; DS 8273a will be increased in subsequent cohorts.
89395383|NCT05409859||Participants|Children patients of 5 years and younger who received manual therapies by a chiropractor in private practice.
89395384|NCT04983953||Abnormal|A patient diagnosed with intracranial haemorrhage after a brain CT scan
88871669|NCT01537302|Experimental|Ocelot System|CTO crossing in femoropopliteal arteries using the Ocelot System
88871670|NCT01537926|Experimental|N-acetylcysteine (NAC)|N-acetylcysteine 600mg by mouth every 12 hours for 90 days. N-acetylcysteine 1200mg by mouth every 12 hours for 270 days
88871671|NCT01537926|Placebo Comparator|Placebo|Placebo 1 cap by mouth every 12 hours for 90 days. Placebo 2 caps by mouth every 12 hours for 270 days.
88871672|NCT01538862|Experimental|Granulocyte Colony Stimulating Factor (GCSF)|GCSF 10mcg/kg/d subcutaneously (SQ) for 7 days
88871673|NCT01540266|Experimental|first year psychology_structured|First year psychology students who watched the video where the physician gives structured information to the patient
88871674|NCT01540266|Active Comparator|First year psychology_non-structured|First year psychology students who watched the video where the physician gives non-structured information to the patient
89395385|NCT04983953||Normal|A normal person or a patient not diagnosed with intracranial haemorrhage after a brain CT scan
89395386|NCT03811756|Active Comparator|Test group|Participants will receive investigational product - Test syrup containing CoQ10 and collagen (daily dose 10 mL: fish collagen (Peptan®): 4000 mg, water soluble CoQ10 (Q10Vital®): 50 mg, vitamin C: 80 mg, vitamin A: 920 μg, biotin: 150 μg).
89395387|NCT03811756|Placebo Comparator|Placebo group|Placebo group participants will receive placebo syrup without active ingredients. (daily dose 10 mL: fish collagen: 0 mg, water soluble CoQ10 (Q10Vital®): 0 mg, vitamin C: 0 mg, vitamin A: 0 μg, biotin: 0 μg); continous administration of placebo product for 12 weeks.
89395388|NCT03125915|Active Comparator|CHTC as usual|Participants receive couples HIV testing and counseling following the CDC approved protocol.
88871675|NCT01540266|Experimental|First year medical_structured|First year medical students who watched the video where the physician gives structured information to the patient
88871676|NCT01540266|Active Comparator|First year mediclal_non-structured|First year medical students who watched the video where the physician gives non-structured information to the patient
88871677|NCT01540266|Experimental|Third year medical_structured|Third year medical students who watched the video where the physician gives structured information to the patient
88871678|NCT01540266|Active Comparator|Third year medical_non-structured|Third year medical students who watched the video where the physician gives non-structured information to the patient
88871679|NCT01541358|Experimental|Diagnostic (fluorine F 18 sodium fluoride PET/CT)|Patients undergo fluorine F 18 sodium fluoride PET/CT scan.
88871680|NCT01542372|Active Comparator|Medication augmentation|In one arm, the patients will be given a medication augmentation for SSRI/SSRN-resistant PTSD
88871681|NCT01542372|Active Comparator|CBT augmentation|In this arm, patients will receive CBT to treat SSRI/SSRN-resistant PTSD.
88871682|NCT01542684|Experimental|Azacytidine + GM-CSF|"Azacytidine administered intravenously (IV) or subcutaneously (SQ) at starting dose of 40 mg/m^2, daily for 4 days.~GM-CSF administered IV or subcutaneously at 250 mcg/m^2 one day (the next day) after completion of azacytidine treatment, for 3 consecutive days.~Each treatment cycle will last at least 4 weeks"
88871683|NCT01543074|Placebo Comparator|BSE placebo & garlic oil placebo|Two BSE placebo capsules and one garlic oil placebo capsule per day for seven days
88871684|NCT01543074|Active Comparator|garlic oil plus BSE placebo|one garlic oil capsule plus 2 BSE placebo capsules per day for seven days
88871685|NCT01543074|Active Comparator|BSE plus garlic oil placebo|two BSE capsules plus one garlic oil placebo capsule per day for seven days
88871686|NCT01543074|Active Comparator|BSE & Garlic Oil|two BSE and one garlic oil capsule per day for seven days
88871687|NCT01544088|Experimental|Arm 1: GCBT|Group Cognitive Behavioral treatment (GCBT)
88871688|NCT01544088|Active Comparator|Arm 2: Group Treatment|Present Centered Group Treatment
88871689|NCT01544166|Experimental|Overall study|
88871690|NCT01545336|Experimental|Anastrozole|1 mg tablet by mouth once daily for 3 months
88871691|NCT01545336|Placebo Comparator|Placebo|Placebo tablet by mouth once daily for 3 months
88871692|NCT01546194||Morning consent|Consent process consisting of information only provided on the morning of surgery
88871693|NCT01546194||Phone call and morning consent|Consent process consisting of information provided on the morning of surgery. In addition, a phone call on the day prior to surgery will be provided to subjects explaining that they will be approached about participation in a clinical research project
88871694|NCT01548690|Experimental|Ornithine·Phenylacetate|Ornithine Phenylacetate is administered intravenously, through a peripheral venous catheter. Each infusion should will be administered over a period of 120 hours.
88871695|NCT01549314||Subjects with CF taking ivacaftor|Subjects with CF ages 6 to 75 years old who will be or have started taking ivacaftor within the previous 6 months
88871696|NCT01549314||Subjects with CF not taking ivacaftor|Subjects with CF ages 6 to 75 years old who will not be taking ivacaftor, matched for age, race, and gender with cohort 1
88871697|NCT01549314||Healthy subjects|Healthy subjects with no medical conditions known to affect bone between the ages of 6 to 75 years old, matched for age, race, and gender with cohort 2.
88871698|NCT01551030|Experimental|Buparlisib|This is an open-label phase II study of the pan-class I selective phosphoinositide 3-kinase (PI3K) inhibitor Buparlisib in patients with metastatic urothelial carcinoma which has progressed despite treatment with prior cytotoxic chemotherapy.
88871699|NCT01551186|Experimental|Probiotic|Patients randomized to probiotic therapy will receive 1 capsule containing 1010 cells of Lactobacillus rhamnosus GG on a twice-daily basis
88871700|NCT01551186|No Intervention|Standard of Care|Patients in the control arm will receive standard care
88871701|NCT01551264|Other|4-Year Bracing Arm|This group has been randomized to 4 years of bracing after correction of clubfoot using the Ponseti Method.
88871702|NCT01551264|Other|2-Year Bracing Arm|This group has been randomized to 2 years of bracing after correction of clubfoot using the Ponseti Method.
88871703|NCT01551888|Experimental|Aclidinium/formoterol 400/12μg FDC|Aclidinium/formoterol 400/12μg fixed-dose combination (FDC), one inhalation twice daily (morning and evening) for 4 days, then one inhalation (morning) on Day 5 via the Almirall inhaler
88871704|NCT01551888|Active Comparator|Formoterol|Formoterol 12μg one inhalation twice daily (morning and evening) for 4 days, then one inhalation (morning) on Day 5 via the Foradil® Aerolizer®
88871705|NCT01553058|Active Comparator|Adalimumab (Humira)|Injection of the active drug Humira.
88871706|NCT01553058|Placebo Comparator|Placebo Injection|Injection of placebo in place of active Humira injection.
88871707|NCT01553058|Active Comparator|NB-UVB phototherapy|NB-UVB Phototherapy 3 times per week, no other intervention.
88871708|NCT01553292|Experimental|ECALMIST|Large volume 5ml/kg surfactant administered by vascular catheter while maintaining CPAP or ECALMIST; Early CPAP (continuous positive airway pressure) And Large volume Minimal Invasive Surfactant Therapy
88871709|NCT01556100|Experimental|18F-DTBZ AV-133|18F-DTBZ AV-133 imaging
88871710|NCT01556724|Active Comparator|0.2% ropivacaine nerve block (standard of care)|0.2% ropivacaine in lumbar plexus nerve catheter infusions for postoperative analgesia
88871711|NCT01556724|Experimental|0.1% ropivacaine infusion in nerve block catheter|0.1% ropivacaine in lumbar plexus nerve catheter infusions
88871712|NCT01557894|Experimental|iSOFIE|Cognitive - Behavioral: Internet-administrated CBT for Social Phobia that contains 9 self-help text modules and exercises (i.e., behavioral experiments)
88871713|NCT01557894|No Intervention|Waitlist control group|Waitlist control group
88871714|NCT01558128|Other|Amiodarone with cardioversion|If subject converts to normal sinus rhythm following amiodarone no further intervention is taken, if subject remains in atrial fibrillation following amiodarone they are cardioverted.
88871715|NCT01559064||Age group A|Subjects 30 to 40 years old
88871716|NCT01559064||Age group B|Subjects 40 to 50 years old
88871717|NCT01559064||Age group C|Subjects over 50 years old
88871718|NCT01559922|Placebo Comparator|Placebo|Normal Saline
88871719|NCT01559922|Experimental|Artefill|Dermal Filler
89395389|NCT03125915|Experimental|CHTC + communication skills videos|The couple views communication skills training videos together prior to participating in a CHTC session following the CDC approved protocol.
88871720|NCT01560624|Experimental|UT-15C|Treprostinil diolamine extended-release tablets (oral) 0.125 to 12 mg TID
88871721|NCT01560624|Placebo Comparator|Placebo|Matching placebo tablets (oral)
88871722|NCT01561716|Experimental|Crossover sequence 1|Resting/Wii Fit Free Run/Wii Fit 3 bouts/treadmill
88871723|NCT01561716|Experimental|Crossover sequence 2|Resting/Wii Fit Free Run/treadmill/Wii Fit 3 bouts
88871724|NCT01561716|Experimental|Crossover sequence 3|Resting/Wii Fit 3 bouts/Wii Fit Free Run/treadmill
88871725|NCT01561716|Experimental|Crossover sequence 4|Resting/Wii Fit 3 bouts/treadmill/Wii Fit Free Run
88871726|NCT01561716|Experimental|Crossover sequence 5|Resting/treadmill/Wii Fit Free Run/Wii Fit 3 bouts
88871727|NCT01561716|Experimental|Crossover sequence 6|Resting/treadmill/Wii Fit 3 bouts/Wii Fit Free Run
88871728|NCT01562886|Experimental|Rilpivirine and Truvada|TDF/FTC (Truvada™) one tablet once plus Rilpivirine 25 mg daily
88871729|NCT01563198|Experimental|Comfort Talk® Training|The MRI units of three clinical sites form the group. Their personnel will be trained to use Comfort Talk® to help patients who are claustrophobic, anxious, and/or cannot lie still to complete their tests
88871730|NCT01564914|Experimental|TRC105, Bevacizumab|Single arm study
88871731|NCT01565538|Experimental|Erlotinib|Erlotinib at the dose of 150 mg orally once a day continually until progression.
88871732|NCT01565538|Experimental|Pemetrexed|Pemetrexed at the dose of 500mg/m2 IV infusion every 3 weeks until progression.
88871733|NCT01565616|Experimental|Bone Marrow Transplant Recipients|Adults with sickle cell disease undergoing a bone marrow transplant from an HLA-identical sibling donor or an unrelated HLA-matched donor.
88871734|NCT01566084|Other|Normal sodium|Subjects on a 1200 mg sodium diet are given 2300 mg sodium in the form of slow sodium tablets to bring them back up to a normal salt intake. Subjects then cross-over to the low sodium condition in the second half of the study.
88871735|NCT01566084|Other|Low sodium|Subjects on a 1200 mg salt diet are given placebo pills in order to maintain them on a low salt diet. Subjects then cross-over to the normal sodium condition in the second half of the study.
88871736|NCT01566162|Experimental|Lurasidone|Lurasidone 40 - 80mg flexible dose
88871737|NCT01566630|Experimental|RLX030|"In part 1, within each cohort, two (2) patients per cohort will be treated open label with RLX030 and two (2) patients will be treated double blind with RLX030 as intravenous infusion for 72 hours. There will be 3 cohorts in part 1 with different doses of RLX030.~In part 2, there is no open label treatment on RLX030. In part 2, patients will be randomized in a double-blind fashion to this arm with the optimal dose of RLX030 as intravenous infusion for 72 hours as determined from part 1."
88871738|NCT01566630|Placebo Comparator|Placebo|"In part 1, equal number of subjects will be treated with matching placebo of RLX030 as intravenous infusion for 72 hours in 3 cohorts.~In part 2, patients will be treated with matching placebo of RLX030 as intravenous infusion for 72 hours"
88871739|NCT01567020||Control|Non-blast-exposed and non-TBI, aged younger than 50
88871740|NCT01567020||Blast|Blast-exposed with or without a TBI diagnosis
88871741|NCT01567020||Non-Blast-Exposed TBI|Non-blast-exposed with TBI diagnosis
88871742|NCT01567020||Older|Non-blast-exposed and non-TBI, aged 50 or older
88871743|NCT01569126|Experimental|5 milligrams (mg) LY110140 (SD)|5 mg administered once in the fasted state on Day 1
88871744|NCT01569126|Experimental|20 mg LY110140 (SD)|20 mg administered once in the fasted state on Day 1
88871745|NCT01569126|Experimental|40 mg LY110140 (SD)|40 mg administered once in the fasted state on Day 1
88871746|NCT01569126|Placebo Comparator|Placebo (MD)|Placebo once daily oral dosing for 28 consecutive days
88871747|NCT01569126|Experimental|20 mg LY110140 (MD)|20 mg once daily oral dosing for 28 consecutive days
88871748|NCT01569126|Experimental|40 mg LY110140 (MD)|40 mg once daily oral dosing for 28 consecutive days
88871749|NCT01569828|Experimental|Renal Impaired Subjects|once daily administration of 400 mg LCZ696 for 5 days
89395390|NCT03125915|Experimental|CHTC + substance use module|The couple completes a CHTC session which includes the substance use calendar and structured debriefing activity. This is administered following Step 5 in the standard CDC protocol, just prior to delivery of HIV test results.
89395391|NCT03125915|Experimental|CHTC + video + substance use module|The couple views communication skills training videos together prior to participating in a CHTC session which includes administration of the substance use calendar and structured debriefing activity.
89395392|NCT03141268||Healthy volunteers|Normal subjects aged 18-80 years. No chronic diseases.
88871750|NCT01569828|Experimental|Healthy Volunteers|once daily administration of 400 mg LCZ696 for 5 days
88871751|NCT01573260|Experimental|Argentinean Tango|A biweekly class of argentinean tango for a period of 3-months the intervention for this arm
88871752|NCT01573260|Placebo Comparator|A 'wait-list' control group|Intervention: Patient will receive information about exercise in PD. After 12 weeks, these patients will then start the same 12-weeks tango program.
88871753|NCT01573572|Experimental|Intravitreal Injections of Macugen|
88871754|NCT01575522|Experimental|Treatment (tivantinib)|Patients receive tivantinib 360 mg PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection at baseline and periodically during study for c-Met expression, relevant markers (HGF and VEGF), PTEN loss, and PI3K mutation analysis by FISH and IHC. Archived tumor tissue samples are also analyzed.
88871755|NCT01575756|Experimental|Octafibrin followed by Haemocomplettan® P or RiaSTAPTM|Participants received Octafibrin 70 mg/kg intravenously once followed by Haemocomplettan® P or RiaSTAPTM 70 mg/kg intravenously once 45 days later.
88871756|NCT01575756|Experimental|Haemocomplettan® P or RiaSTAPTM followed by Octafibrin|Participants received Haemocomplettan® P or RiaSTAPTM 70 mg/kg intravenously once followed by Octafibrin 70 mg/kg intravenously once 45 days later.
88871757|NCT01575912||schizophrenia SC|subjects with a diagnosis of schizophrenia (SC) according to the DSM-IV-TR, submitted to experimental pain tests
88871758|NCT01575912||major depression MD|subjects with a diagnosis of major depression (MD) according to the DSM-IV-TR, submitted to experimental pain tests
89187588|NCT03759392|Experimental|Omecamtiv Mecarbil|Omecamtiv mecarbil was administered as an oral modified-release tablet twice daily for up to 20 weeks. Participants randomized to this arm started at an omecamtiv mecarbil dose of 25 mg twice daily. The dose could be increased based on plasma concentrations at Weeks 2 and 6.
88871759|NCT01575912||controls C|subjects without any diagnosis of psychiatric disorder (C) submitted to experimental pain tests
88871760|NCT01576536||Healthy volunteers|Normal healthy volunteers
88871761|NCT01577238|Experimental|VivaGel|
88871762|NCT01577238|Placebo Comparator|HEC Placebo|
88871763|NCT01577706|Active Comparator|Alprazolam (A)|Alprazolam (Xanax), gel-capsule, 1mg, single-dose, 1-day
88871764|NCT01577706|Active Comparator|Dextroamphetamine (D)|Dextroamphetamine (Dexedrine), gel-capsule, 20mg, single-dose, 1-day
88871765|NCT01577706|Placebo Comparator|Placebo (P)|Placebo gel-capsule, single-dose, 1-day
88871766|NCT01580592|Experimental|Omalizumab 150mg|
88871767|NCT01580592|Experimental|Omalizumab 300mg|
88871768|NCT01580592|Placebo Comparator|Placebo|
88871769|NCT01580904|No Intervention|control group|Patients will not be followed by the pharmacist.
88871770|NCT01580904|Experimental|Intervention group|"Patients will be followed by the pharmacist by Pharmacotherapeutic monitoring and dosing parameters such as glucose and glycated hemoglobin.~Intervention: Pharmaceutical Care"
88871771|NCT01583868|Experimental|B&L RD2135-01 lens C|Investigational Silicone hydrogel soft contact lens
88871772|NCT01583868|Experimental|B&L RD2135-01 lens D|Investigational Silicone hydrogel soft contact lens
88871773|NCT01583868|Active Comparator|PureVision2|Bausch & Lomb High definition soft contact lenses
88871774|NCT01583868|Active Comparator|Ciba Vision Air Optix Aqua|Ciba Vision Air Optix Aqua soft contact lens
88871775|NCT01588158|Active Comparator|Vicodin 5/325 mg|Half of the patients will be randomized to Vicodin
88871776|NCT01588158|Active Comparator|Acetaminophen 325 mg|Half of the patients will be randomized to Acetaminophen
88871777|NCT01588236|Experimental|high dose KYG0395|Patients received high dose KYG0395 capsule (tid)
88871778|NCT01588236|Experimental|lower dose KYG0395|Patients received lower dose KYG0395 capsule (bid)
89395393|NCT03141268||IBS patients, lactose intolerant|Subjects 18-80 years diagnosed with IBS for more than 6 months ago; lactose intolerant. No concomitant diseases.
88871779|NCT01588236|Placebo Comparator|placebo|Patients received placebo (tid)
88871780|NCT01588470|Experimental|Pioglitazone|Only subjects with T2DM or non-diabetic subjects with coronary heart disease will receive Pioglitazone
88871781|NCT01589484|Experimental|Shockwave lithotripsy (SWL)|All patients will be submitted to a noncontrast computed tomography before to shockwave lithotripsy (SWL). Patients will be submitted to SWL under the following conditions: outpatient, general anesthesia, 3000 impulses, rate of 90/min, discharged from hospital in the same day with alpha-blocker (doxazosin) during 30 days.
88871782|NCT01590264|Other|Bimodal rTMS|"Open-label and single-arm rTMS bimodal treatment with placement of magnet over Dorsolateral Prefrontal Cortex (DLPFC) and Temporoparietal Junction (TPJ) for 2 weeks of treatment (10 days)~Stimulation Settings:~DLPFC Stimulation Frequency 10 Hz Intensity 110% of motor threshold On 5 seconds Off 15 seconds Total Trains 80 per session Total pulses session 4000/session Duration session 26.6 minutes Total pulses (study) 40000~TPJ Stimulation Frequency 1 Hz Intensity 110% of motor threshold On 900 seconds Off 60 seconds Total Trains 2 per session Total Pulses session 1800 Duration session 31 minutes Total Pulses study 18000"
88871783|NCT01591044|Active Comparator|R940343 2mg, 2 puffs bid|R343 2mg, 2 puffs bid
88871784|NCT01591044|Placebo Comparator|Placebo|
88871785|NCT01591044|Active Comparator|R940343 1mg, 1 puff bid|R343 1mg, 1 puff bid
88871786|NCT01591746|Experimental|Group A - Botulinum Toxin Type A|100 Units of Botulinum toxin A diluted in 5 mL 0.9% Sodium Chloride (NaCl) in the pectoralis major muscle in each operated breast
88871787|NCT01591746|Placebo Comparator|Group B - Placebo|5 mL 0.9% NaCl injection to the pectoralis major muscle in each operated breast
88871788|NCT01597128|Active Comparator|Flex HD|Mesh Type
88871789|NCT01597128|Active Comparator|Strattice|Use of a second mesh type
89395394|NCT03141268||IBS patients, lactose tolerant|Subjects 18-80 years diagnosed with IBS for more than 6 months ago; lactose tolerant. No concomitant diseases.
88871790|NCT05566860|Experimental|BMI <27|
89395395|NCT03122171|Experimental|Prosthesis|
89395396|NCT03138850|Experimental|Olympus standard bite block|Standard of care using standard bite block and nasal cannula
89395397|NCT03138850|Experimental|YX Mandibular advancement bite block|Mandibular advancement bite block group
88871791|NCT05566860|Experimental|BMI 27-32|
89395398|NCT03138850|Experimental|Optiflow High flow nasal cannula|High flow nasal cannula group
89395399|NCT01373879|Experimental|Group 1A|Adults (18-50 years old) vaccinated with AdCh63 ME-TRAP followed with MVA ME-TRAP
89395400|NCT01373879|Experimental|Group 1B|Adults (18-50 years old) vaccinated with AdCh63 ME-TRAP followed with MVA ME TRAP
89395401|NCT01373879|Experimental|Group 2A|Children (2-6 years old) vaccinated with AdCh63 ME-TRAP followed with MVA ME-TRAP
89395402|NCT01373879|Experimental|Group 2B|Children (2-6 years old) vaccinated with AdCh63 ME-TRAP followed with MVA ME-TRAP
89395403|NCT01373879|Active Comparator|Group 2C|Children (2-6 years old) vaccinated with human diploid cell rabies vaccine
89395404|NCT01373879|Experimental|Group 3A|Children (2-6 years old) vaccinated with AdCh63 ME-TRAP followed with MVA ME-TRAP
89395405|NCT01373879|Experimental|Group 3B|Children (2-6 years old) vaccinated with AdCh63 ME-TRAP followed with MVA ME-TRAP
89395406|NCT01373879|Active Comparator|Group 3C|Children (2-6 years old) vaccinated with human diploid cell rabies vaccine
89395407|NCT03663088|Active Comparator|GPR-A|The 6-months supervised GPR-A group will receive a 1-hour-long individual session once a week plus a home program (1 or 2 exercises, 2 times a week).
89395408|NCT03663088|Experimental|GPR-B|The 6-months supervised GPR-B group will receive a 1-hour long individual session once per two weeks alternately with a 1-hour-long class of exercises once per two weeks plus a home program (1 or 2 exercises, 2 times a week).
89395409|NCT01372319||Glaucoma Patients (OAG, Aulhorn stages II - IV)|Manifest glaucoma (OAG, Aulhorn stages II - IV) with advanced binocular visual loss, as obtained by semi-automated kinetic perimetry (SKP), no study medication
89395410|NCT01372319||Normal subjects|male+female > 18 years
89395411|NCT03634696|Experimental|Field test participants|Late-stage adult cancer patients seeking care at Ocean Road Cancer Center, consenting to participate in mPCL application field test
89395412|NCT03634696|Active Comparator|Control participants|Late-stage adult cancer patients seeking care at Ocean Road Cancer Center, consenting to serve as controls for mPCL field test
88871792|NCT05566860|Experimental|BMI >32|
88871793|NCT05566314|Experimental|Intervention|Herbal and probiotic beverage
88871794|NCT05566314|Placebo Comparator|Placebo|Similar beverage without the probiotics and botanicals
88871795|NCT05566236|Experimental|Experimental group|The participants played the board game at least once at home every week. In addition, the 60 minutes parent-child co-learning board game was played for 4 consecutive weeks.
88871796|NCT05566236|No Intervention|Control group|The control group continued to receive health education instructions at the outpatient clinic.
88871797|NCT05565924|Experimental|Group-A|"This group received moderate-intensity (50-70% heart rate reserve) aerobic exercise training on the antigravity treadmill (100% weight-bearing; n=14) 3 times/week for 12-weeks, plus oral drug therapy (Biguanide alone or Sulfonylureas plus Biguanide combination)."
88871798|NCT05565924|Experimental|Group-B|"This group received moderate-intensity (50-70% heart rate reserve) aerobic exercise training (70% weight-bearing; n=13) on the antigravity treadmill (AlterG Pro 200, AlterG Inc, California, USA) 3 times/week for 12 weeks, plus oral drug therapy (Biguanide alone or Sulfonylureas plus Biguanide combination)."
88871799|NCT05565924|Experimental|Group-C|"This group received moderate-intensity (50-70% heart rate reserve) aerobic exercise training (50% weight-bearing; n=14) on the antigravity treadmill (AlterG Pro 200, AlterG Inc, California, USA), 3 times/week for 12 weeks plus oral drug therapy (Biguanide alone or Sulfonylureas plus Biguanide combination)."
89395413|NCT03634163|Experimental|Immediate|Quality of Life Assessment plus facilitated implementation of neighbourhood exchange and personal care support
89395414|NCT03634163|Active Comparator|Delayed|Quality of Life Assessment
89395415|NCT03316781|Experimental|HLX03 group|
88871800|NCT05565924|Experimental|group-D (30% weight-bearing; n=13)|"This group received moderate-intensity aerobic exercise training (30% weight-bearing; n=13) on the antigravity treadmill (AlterG Pro 200, AlterG Inc, California, USA) 3 times/week for 12 weeks, plus oral drug therapy (Biguanide alone or Sulfonylureas plus Biguanide combination)."
88871801|NCT05565924|Sham Comparator|group-E (control group; n=14)|"Served as a control group and participated in no aerobic exercise training on the antigravity treadmill (AlterG Pro 200, AlterG Inc, California, USA) during the study, but received oral drug therapy (Biguanide alone or Sulfonylureas plus Biguanide combination)."
88871802|NCT05565300|Experimental|Cycling combined with cognitive tasks|
89395416|NCT03316781|Active Comparator|adalimumab group|
89395417|NCT03138772||Healthy Controls|No intervention. Only monitoring LCI
89395418|NCT03138772||Cystic Fibrosis Patients|No intervention. Only monitoring LCI
89395419|NCT01427725||Lipacreon|"In general, pancrelipase 600 mg/dose was orally administered immediately after a meal, 3 times a day.~Also, the dose was adjusted appropriately according to the patient's condition."
89395420|NCT05084014|Experimental|Deep Stripping|This group will receive deep stripping technique with conventional physical therapy.
89395421|NCT05084014|Experimental|Kneading|This group will receive deep kneading with conventional physical therapy.
89395422|NCT01373957||1|Patients hospitalized and diagnosed with UA, STEMI or NSTEMI
89395423|NCT03138694||Methotrexate injection|Patients with Ectopic pregnancy treated with Methotrexate injection.
88871803|NCT05565300|Active Comparator|Cycling|
88871804|NCT05564988|Experimental|Preconditionning|Ischemia will be obtained after inflating the cuff to a pressure of 200 mmHg (or a pressure at least 50 mmHg above the patient's systolic pressure). After a five-minute period, the cuff will be deflated and the arm allowed to reperfuse for five minutes. These maneuvers will be repeated until 3 cycles of ischemia- reperfusion have been completed once a day. Patients will experiment with this procedure for at least 5 days.
88871805|NCT05564988|No Intervention|Control|For subjects assigned to the control group, the pneumatic cuff is placed around the upper arm, and inflation of a blood pressure to a lower pressure (50mmHg) which will result in no impairment of antegrade flow.
88871806|NCT05564910||Coffe group|Pregnant women who referred caffeine intake.
88871807|NCT05564910||Control group|Pregnant women without caffeine intake.
88871808|NCT05564832|Experimental|Pilocarpine Therapy|The right eyes of 45 patients will be treated by Biocarpine® and Vuity® eye drops. They will be considered as the case group,
88871809|NCT05564832|No Intervention|Without Pilocarpine Therapy|The left eyes of the patients will be defined as the controls.
88871810|NCT05564676|Experimental|flaxseed oil and pomegranate extract|2g daily of flaxseed oil plus 1.2g daily pomegranate dry extract
88871811|NCT05564676|Placebo Comparator|sunflower oil and microcrystalline cellulose|2g daily of sunflower oil plus 1.2g daily microcrystalline cellulose
88871812|NCT05564442|Active Comparator|Group I: Children received 20% benzocaine gel|Comparative Evaluation of Different Pain Alleviating Methods During Intra-oral Local Anesthetic Injections
88871813|NCT05564442|Active Comparator|Group II: Children received TENS stimuli|Comparative Evaluation of Different Pain Alleviating Methods During Intra-oral Local Anesthetic Injections
88871814|NCT05564442|Active Comparator|Group III: Children received EMLA gel.|Comparative Evaluation of Different Pain Alleviating Methods During Intra-oral Local Anesthetic Injections
88871815|NCT05564442|Active Comparator|Group IV: Children received ice application at injection site|Comparative Evaluation of Different Pain Alleviating Methods During Intra-oral Local Anesthetic Injections
88871816|NCT05532774|No Intervention|Ordinary defocusing frame glasses group|wear ordinary defocusing frame glasses
88871817|NCT05532774|Experimental|AI defocusing frame glasses group|wear defocusing frame glasses with artificial intelligence
88871818|NCT05493540|Active Comparator|Medical treatment Group|40 preterm neonates will receive Ibuprofen oral suspension
88871819|NCT05493540|Placebo Comparator|Placebo Group|40 preterm neonates will receive oral placebo
88871820|NCT05214924|Experimental|Injectable platelet-rich fibrin injection|Each of the participants from iPRF injection group will receive two injections of iPRF with an interval of 30 days.
88871821|NCT05214924|Active Comparator|Platelet-rich plasma injection|Each of the participants from PRP injection group will receive two injections of PRP with an interval of 30 days.
89395424|NCT03138694||Self resolution|"Patients with Ectopic pregnancy that had signs of self resolution with our Watchful waiting protocol."
88871822|NCT05672940|Experimental|Aerobic plus resistance training group|Receive three one-hour supervised group sessions weekly for 12 weeks, in which Sections 1 and 3 were AT plus RT sessions, including 5-minute warm-up, 30-minute AT exercises on a bicycle (Comfort 408, Horizon Fitness) or a treadmill (832T, Horizon Fitness), 20-minute RT, and 5-minute cool-down; whereas Section 2 was an AT-only session, including 5-minute warm up, 50-minute aerobic exercises (bicycling or treadmill walking), and 5-minute cool-down.
88871823|NCT05672940|Experimental|Stretching plus breathing training group|Receive three one-hour sessions of weekly supervised group training combining Tongtze Gymnastics (童子體操) and breathing exercises for 12 weeks.
88871824|NCT05672706||CFR and IMR group|
88871825|NCT05672472|Experimental|Sivelestat sodium|The patients in the test group were given 0.2 mg/kg. h of sivelestat sodium (0.1 g/tube, Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd.) (the daily dose was added to 250 ml of 0.9% sodium chloride) intravenously for 24 hours and 5 consecutive days.
88871826|NCT05672472|Placebo Comparator|sodium chloride|The patients in the control group were given 250 ml 0.9% sodium chloride (250ml/bag, Jilin Dubang Pharmaceutical Co., Ltd.) by intravenous pump for 24 hours and 5 consecutive days.
88871827|NCT05672394|Experimental|Serratus anterior plane block:|
88871828|NCT05672394|Active Comparator|Thoracic Epidural|
88871829|NCT05672004|Active Comparator|Implementation as usual|Healthcare professionals will be instructed to implement ProMuscle in their practice as usual
89395425|NCT02839200|Experimental|ACT-541468 5 mg|Each subject receives one 5-mg ACT-541468 capusle (+ one placebo capsule), once daily in the evening for 4 weeks
89395426|NCT02839200|Experimental|ACT-541468 10 mg|Each subject receives one 10-mg ACT-541468 capusle (+ one placebo capsule), once daily in the evening for 4 weeks
89395427|NCT02839200|Experimental|ACT-541468 25 mg|Each subject receives one 25-mg ACT-541468 capsule (+ one placebo capsule), once daily in the evening) for 4 weeks
89395428|NCT02839200|Experimental|ACT-541468 50 mg|Each subject receives two 25-mg ACT-541468 capsules, once daily in the evening for 4 weeks
89395429|NCT02839200|Active Comparator|Zolpidem|Each subject receives one 10-mg zolpidem capsule (+ one placebo capusle), once daily in the evening for 4 weeks
89395430|NCT02839200|Placebo Comparator|Placebo|Each subject receives two placebo capsules, once daily in the evening for 4 weeks
89395431|NCT04846907||Healthcare personnel working in pediatric intensive care units during COVID-19 pandemic|Physicians, registered nurses, nurse technicians, physical therapists and other professionals; on duty, routine staff or fellow/residents working in participants PICU
89395432|NCT05083936|Experimental|[18F]FET PET|
88871830|NCT05672004|Experimental|PUMP-fit strategy: Implementation toolbox|Healthcare professionals receive a personal implementation toolbox, tailored to their contexts' barriers for implementation
88871831|NCT05671926||Training set|The whole cohort is randomly assigned to a training cohort and validation cohort.
88871832|NCT05671926||validation set|The whole cohort is randomly assigned to a training cohort and validation cohort.
89395433|NCT01375907|Experimental|Rotavin|Rotavin-M1 vaccine, 10e6.3FFU/dose, 2 doses, 1 month between doses
89395434|NCT05083858|Experimental|Classical Physiotherapy Program + Cervical Stabilization Exercises|In addition to classical physiotherapy, Cervical Stabilization Exercises will be applied to the individuals in the 1st group.
89395435|NCT05083858|Experimental|Classical Physiotherapy Program + Oculomotor Exercises|In addition to classical physiotherapy, Oculomotor Exercises will be applied to the individuals in the 2nd group.
89395436|NCT05083858|Active Comparator|Classical Physiotherapy Program|Only the classical physiotherapy program will be applied to the individuals in 3rd group.
89395437|NCT01369667|Active Comparator|vitamin D|Capsule, one taken daily
89395438|NCT01369667|Placebo Comparator|Placebo|Capsule, one taken daily
89395439|NCT05083702|Active Comparator|Fluoroscopy-guided superior hypogastric plexus block transdiscal approach|fluroscopy guided superior hypogastric plexus block transdiscal approach for chronic pain treatment in cancer bladder VAS score and morphine consumption are measured before and after 1 day , 1 month , 3 monthes
89395440|NCT05083702|Active Comparator|ultrasound-guided superior hypogastric plexus block|ultrasound guided superior hypogastric plexus block in treatment of chronic pain in cancer badder VAS score and morphine consumption are measured before and after 1 day , 1 month , 3 monthes
89395441|NCT03564912|Experimental|2 week group|
89395442|NCT03564912|Active Comparator|3 week group|
89395443|NCT05083624|Experimental|Rehabilitation group|
89395444|NCT05083624|No Intervention|control group|adhere to standardized management guidelines for anticoagulation, ventilation, sedation specific to the MICU ECMO population
89395445|NCT03565224||Cespace|The patients have been operated with Cespace Titanium Coated PEEK Cage for Degenerative Disc Disease between 2014 and 2017. All patients are invited to the Hospital for Follow-Up. Depending on the date of Initial Intervention the timeframe of follow-up for the individual Patient is 1 to 4 years.
88871833|NCT05597904||Coeliac disease patients|Adult (18 years or over) patients with previous coeliac disease or dermatitis herpetiformis diagnosis
88871834|NCT05597904||Healthy controls|500 adult (18 years or over) friends or non-related family members of coeliac disease or dermatitis herpetiformis patients participating in the study, no previous coeliac disease or dermatitis herpetiformis diagnosis. In addition 1000 controls will be included from Biobank
88871835|NCT05572242|Experimental|L-PRF preservation (test)|Using L-PRF membranes inside the socket, covering with L-PRF membranes, (test group).
88871836|NCT05572242|Active Comparator|Xenogenic bone plus collagen membrane (control)|Bio-Oss® Collagen at the bone level and application of a collagen matrix (Combi-Kit). Both materials will be used for socket preservation (control).
88871837|NCT05464992|Other|Patients with glioma or brain metastases|
88871838|NCT05392296|Experimental|Power ball|experimental group getting the power ball training with conventional treatment
88871839|NCT05392296|Active Comparator|Conventional|group will be control group getting the conventional treatment (isometric hand grip training exercises)
89395446|NCT01369901|Experimental|Group A|Functional exercise
89395447|NCT01369901|Active Comparator|Group B|Stretching exercise
89395448|NCT01567969|Experimental|IICAPS|Provision of Intensive In-home Child and Adolescent Psychiatric Service, a six to seven month family-focused in-home psychiatric intervention.
89395449|NCT01567969|Active Comparator|Home-based CTC|Provision of Home-based Child Treatment Coordination, a six to seven month child-focused case management service with monthly in-home visits with the child's parent/legal guardian.
89395450|NCT03565146|Experimental|Pigmentation|Treatment of Pigmented Lesions Using PiQo4 Laser System
89395451|NCT05353686|Placebo Comparator|Placebo|Subjects in the placebo arm will receive an oral tablet containing no active drug twice daily
89395452|NCT05353686|Active Comparator|XEN-D0501|Subjects in the XEN-D050 arm will receive an oral tablet containing 4 mg/tablet of IMP, twice daily
89395453|NCT05760053|Experimental|EP/EC+PD-1|Toripalimab 240mg D1 of each 21-day cycle IV drip; Etoposide 100mg/m2 D1-3 of each 21-day cycle IV drip; Cisplatin 25mg/m2 D1-3 of each 21-day cycle IV drip; Carboplatin AUC 5 D1 of each 21-day cycle IV drip;
89395454|NCT03509116||Patient group 1|Observations only
89395455|NCT03509116||Patient group 2|Qualitative interview, key stakeholders, documentary analysis
89395456|NCT03121157|Experimental|Intervention|The intervention group will receive two sessions of computer-delivered motivational interviewing via CIAS software programmed to target adherence to medications. The intervention group will also receive text messaged adherence reminders between sessions. Both the computer-delivered sessions and text messages will be tailored to the participant using ecological momentary assessment.
89395457|NCT03121157|No Intervention|Control|Control participants complete CIAS-delivered asthma education modules matched for length, location, and method of delivery of the intervention session. Control participants complete each module at their own pace and then complete a short quiz to assess their knowledge. Control participants also receive text messages between intervention sessions. Message content is the same for all control participants and contains general facts about asthma (not tailored). Message timing is not tailored and is sent at the same time every day (4:00 PM--time chosen to avoid AM and PM medication times but to not interfere with sleep and school activities).
89395458|NCT03505060|Experimental|Group 1: DNA CON-S env + IHV01|Participants will receive 4 mg of DNA CON-S env at Months 0 and 1. They will receive 4 mg of DNA CON-S env and 150 mcg of IHV01 at Months 3 and 6.
89395459|NCT03505060|Placebo Comparator|Group 2: Placebo|Participants will receive placebo at Months 0, 1, 3, and 6.
89395460|NCT03039647||Entry Point IR (SSPG, HOMA-IR)|All subjects will undergo baseline indirect (HOMA-IR) and direct (SSPG) measures of IR. The investigators hypothesize that a higher entry point IR will predict steeper decline in memory and executive function performance and hippocampal connectivity.
89395461|NCT03039647||Change in IR (HOMA-IR)|The investigators predict that change in IR (as measured by HOMA-IR) will predict the pattern of decline in memory and executive function performance and hippocampal connectivity.
89395462|NCT03500614|Experimental|Cohort 1|Participants (n=57) will receive either true or sham air cleaner treatment for 1 week and then alternate the treatment after a wash out interval (Air cleaner use method 1). Exposure monitoring for PM2.5 will continue throughout the treatment period and air and fine particle phase phthalates samples will be collected during the last day (24 hours) of the treatment period; and health variables will be measured and biological samples will be collected immediately after the completion of each intervention period.
88871840|NCT05194956|Experimental|Arm 1 - Alginate impressions followed by digital intraoral scan|The participant will have alginate impressions taken for orthodontic treatment records first. Followed by a digital intraoral scan a minimum of 4-6 weeks washout period. After each intervention, the participant will complete a modified visual analogue scale (VAS) questionnaire about their experience.
88871841|NCT05194956|Experimental|Arm 2 - Digital intraoral scan followed by alginate impressions|The participant will have a digital intraoral taken for orthodontic treatment records first. Followed by alginate impressions a minimum of 4-6 weeks washout period. After each intervention, the participant will complete a modified visual analogue scale (VAS) questionnaire about their experience.
88871842|NCT04997616|Experimental|25 mg/day dose of Happy Lane CBD (Lower Dose)|One 25 mg Happy Lane CBD gel capsule per day (25 mg/day total dose) for 10 consecutive days at approximately the same time of day (±1 hour) on each of these days.
88871843|NCT04997616|Experimental|50 mg/day dose of Happy Lane CBD (Larger Dose)|Two 25 mg Happy Lane CBD gel capsules per day (50 mg/day total dose) for 10 consecutive days at approximately the same time of day (±1 hour) on each of these days. Both capsules will be taken at the same time as each other.
88871844|NCT04594200|Experimental|Intervention Group: Harms Emphasis - Simple Comparator|Physicians in this group will receive a personalized antibiotic prescribing feedback letter which contains a simple comparator to represent a target or benchmark for antibiotic prescribing. For the simple comparator, we will rank the antibiotic prescribing outcomes for all Ontario family physicians and use the lowest quartile as the benchmark. The letter will also include information on both lack of benefit and potential harms caused by unnecessary use of antibiotics. Physicians will also receive a paper-copy viral prescription pad and will receive the intervention letter again 1-month post initial dissemination.
89003859|NCT04294810|Placebo Comparator|Placebo + Atezolizumab|Participants will receive atezolizumab followed by placebo Q3W on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit or unacceptable toxicity.
89003860|NCT04273893|Experimental|SBRT Additional treatment planning dose optimization|Lung SBRT 50-60Gy in 5 fractions with standard of care planning and additional treatment planning dose optimization criteria to minimize decrease in lymphocyte count beyond dosimetric criteria from RTOG 0915/0813 SBRT trials.
88871845|NCT04594200|Experimental|Intervention Group: Harms Emphasis - Complex Comparator|Physicians in this group will receive a personalized antibiotic prescribing feedback letter which contains a complex (adjusted) comparator to represent a target or benchmark for antibiotic prescribing. For the complex comparator, recipients will be compared only to top-performing 'like-peers' - the group of physicians with similar complexity and numbers of patients. We will adjust the prescribing indicators for patient sex, number of patients >85 years, rurality, continuity of care score, proportion of emergency room practice, proportion nursing home practice, neighborhood income quintile of patients, and rates of common patient comorbidities. The letter will also include information on both lack of benefit and potential harms caused by unnecessary use of antibiotics. Physicians will also receive a paper-copy viral prescription pad and will receive the intervention letter again 1-month later.
88871846|NCT04594200|Experimental|Intervention Group: No Harms Emphasis - Simple Comparator|Physicians in this group will receive a personalized antibiotic prescribing feedback letter which contains a simple comparator to represent a target or benchmark for antibiotic prescribing. For the simple comparator we will rank the antibiotic prescribing outcomes for all Ontario family physicians and use the lowest quartile as the benchmark. The letter will also include information on lack of benefit of unnecessary use of antibiotics. Physicians will also receive a paper-copy viral prescription pad and will receive the intervention letter again 1-month post initial dissemination.
88871847|NCT04594200|Experimental|Intervention Group: No Harms Emphasis - Complex Comparator|Physicians in this group will receive a personalized antibiotic prescribing feedback letter which contains a complex (adjusted) comparator to represent a target or benchmark for antibiotic prescribing. For the complex comparator, recipients will be compared only to top-performing 'like-peers' - the group of physicians with similar complexity and numbers of patients. We will adjust the prescribing indicators for patient sex, number of patients >85 years, rurality, continuity of care score, proportion of emergency room practice, proportion nursing home practice, neighborhood income quintile of patients, and rates of common patient comorbidities. The letter will also include information on lack of benefit of unnecessary use of antibiotics. Physicians will also receive a paper-copy viral prescription pad and will receive the intervention letter again 1-month later.
88871848|NCT04594200|No Intervention|Control Group|Participants in this group will not receive a personalized antibiotic prescribing feedback letter and they will not receive a viral prescription pad.
88871849|NCT04493658||Sjogrens syndrome dry eye|Patients with a previous diagnosis of dry eye made by an eye care specialist and a diagnosis of Sjogren's syndrome made according to the 2016 revised criteria
88871850|NCT04493658||Non-Sjogrens syndrome dry eye|Patients with a previous diagnosis of dry eye made by an eye care specialist and no diagnosis of Sjogren's syndrome based on 2016 revised criteria.
88871851|NCT04493658||Control|Normal individuals with no previous diagnosis of dry eye or Sjogren's syndrome
88871852|NCT03861468|No Intervention|Usual care|Patients in the usual care group will be referred to their general practitioner (GP) / primary care practitioner as usual.
88871853|NCT03861468|Active Comparator|Early care|A different care pathway will be followed by the patients randomized to this group. They will be referred to a specialist (pneumologist) for OSA diagnosis and treatment if necessary
88871854|NCT03729258|Experimental|Cefpodoxime 200 (b.i.d)|
88871855|NCT03729258|Active Comparator|Cefpodoxime 400 (q.d)|
88871856|NCT03593772|Active Comparator|Treatment arm|Treatment Arm: MR is an user-driven, dyadic, self-care management program developed with NIMH funding (R43/44) for use by Veterans and their selected partners, individually or together, to reduce pain and distress and support physical, mental, and relationship health. MR was designed for Veterans who face obstacles accessing formal mental health services. It can also be used to complement formal services. MR is a patient-centered intervention, allowing users to determine the pace at which to proceed in each program component. MR Content. The program provides video and audio instruction in a set of 11 evidence-based wellness.
88871857|NCT03593772|Placebo Comparator|Control arm|Usual Care Waitlist Control Arm: For ethical reasons, this study will use a waitlist control arm to ultimately provide all participants exposure to the MR intervention. Dyads in the control arm will participate in all assessments like those in the treatment group, however, they will be asked to agree to not access the public web site during their participation. Wait-list control participants will be instructed to seek advice about treatment from their providers. Other than this initial advice, there will be no attempt by study personnel to influence condition management unless an issue (i.e., suicidal ideation) arises. The control condition will account for potential temporal effects that occur from passage of time (brief), and expectation effects associated with anticipation of MR participation. The control group will receive access to MR after they complete data collection.
88871858|NCT03355170|Experimental|Lansoprazole/Domperidone|Patient will be administered lansoprazole/domperidone 30/30 mg capsules (brand name: Duolans) half an hour before breakfast for eight weeks according to randomisation scheme.
88871859|NCT03355170|Active Comparator|Lansoprazole|Patient will be administered lansoprazole 30 mg capsules (brand name: Lasotab) half an hour before breakfast for eight weeks according to randomisation scheme.
88871860|NCT02819778|Other|Control group|"The study protocol corresponds to a diagnostic prospective, controlled, multicenter study using a randomized stepped wedge cluster design, in which pediatric patients (aged ≤ 16 years) presenting to the pediatric emergency room for mTBI with a GCS score of 15 will benefit from usual care (conventional management arm) in the control group, and from S100B management in the interventional group"
88871861|NCT02819778|Other|interventional group|"The study protocol corresponds to a diagnostic prospective, controlled, multicenter study using a randomized stepped wedge cluster design, in which pediatric patients (aged ≤ 16 years) presenting to the pediatric emergency room for mTBI with a GCS score of 15 will benefit from usual care (conventional management arm) in the control group, and from S100B management in the interventional group"
88871862|NCT02538666|Experimental|Nivolumab monotherapy|Nivolumab intravenous fusion
88871863|NCT02538666|Experimental|Nivolumab and ipilimumab combination therapy|Nivolumab and ipilimumab intravenous fusion
88871864|NCT02538666|Placebo Comparator|Placebo|Placebo
89395463|NCT03500614|Experimental|Cohort 2|Participants (n=32) will undergo extended treatment period covering the start, peak and end phases of smog episodes in Beijing, with either true or sham air cleaner treatment and then alternate the treatment after a wash out interval (Air cleaner use method 2). Exposure monitoring for PM2.5 will continue throughout the treatment period and repeated health examinations will be conducted at time points corresponding to the start, peak and end phases of the smog episodes.
89395464|NCT03037463||Parkinson's Disease|
88871865|NCT02438358|Experimental|LUM Imaging System|No dose or a single dose of LUM015 (0.5 mg/kg or 1.0 mg/kg) will be administered by intravenous injection between 2 to 6 hours prior to surgery. The dose administered in Phase B will be determined based on results of Phase A. All subjects will have intraoperative imaging using the LUM 2.6 Imaging Device.
88871866|NCT02407236|Placebo Comparator|Induction Study - Placebo Intravenous (IV)|Participants will be randomized to receive single dose of placebo as Intravenous (IV: into the vein) infusion at Week 0. Participants with clinical response at Week 8 will be eligible to enter the Maintenance study, but will not be randomized.
88871867|NCT02407236|Experimental|Induction Study - Ustekinumab 130 milligram (mg) IV|Participants will be randomized to receive single dose of ustekinumab 130 mg as IV infusion at Week 0. Participants with clinical response at Week 8 will be eligible to enter the Maintenance study and will be randomized.
88871868|NCT02407236|Experimental|Induction Study - Ustekinumab 6 mg/kg IV|Participants will be randomized to receive ustekinumab approximating 6 mg/kg of body weight, as intravenous infusion at Week 0. Participants with clinical response at Week 8 will be eligible to enter the Maintenance study and will be randomized.
88871869|NCT02407236|Other|Induction Study- Placebo- Nonresponsders at Week 8|Participants without clinical response to placebo at Week 8 will receive a single IV infusion of ustekinumab approximating 6mg/kg along with matching subcutaneous (SC) placebo (to maintain the blind). Participants in clinical response at Week 16 will be eligible to enter Maintenance study and will be randomized.
88871870|NCT02407236|Other|Induction study-Ustekinumab Nonresponders at Week 8|Participants without clinical response to ustekinumab (130 mg or 6 mg/kg [IV]) at Week 8 will receive a single dose of ustekinumab 90 mg subcutaneously along with matching placebo intravenously (to maintain the blind). Participants in clinical response at Week 16 (that is, delayed responders) will be eligible to enter Maintenance study, but will not be randomized.
89003861|NCT04273893|Active Comparator|SBRT with standard of care planning only|Lung SBRT 50-60Gy in 5 fractions with standard of care planning (no additional dose optimization beyond SOC)
89187589|NCT03759392|Placebo Comparator|Placebo|Participants randomized this arm received placebo tablets (matching the appearance of the omecamtiv mecarbil tablets) twice daily for up to 20 weeks.
89395465|NCT03037463||Control|
89395466|NCT03495700|Experimental|L-PRF block|"For the test group the sub-sinus cavity will be filled with L-PRF block and the window will be closed with L-PRF membranes.~Eight tubes (9 ml) of venous blood will be collected from the patients. For 6 tubes (red cap) a 12 min centrifugation at 2700 rpm/408g RCF will be followed. Two tubes (white cap) will be centrifuged (IntraSpin, Intra-Lock, Florida, USA) for 3 minutes only to form the Liquid Fibrinogen.~The L-PRF clots will be removed from the tubes using surgical tweezers. The clots will be thereafter gently compressed into membranes using a sterile metal box (Xpression, Intra-Lock, Florida, USA).~To prepare the L-PRF Block, L-PRF membranes will be cut into small pieces and mixed with DBBM (Bio-Oss Small particles, Geistlich AG, Wolhusen, Switzerland). The Liquid Fibrinogen will be added to the homogeneous mix, and stirred gently for ± 10 seconds while shaping it to the L-PRF block"
89395467|NCT03495700|Active Comparator|DBBM|For the control group the sub-sinus cavity will be filled with deproteinized bovine bone mineral (DBBM). The product used will be a xenograft (Bio-Oss Small particles, Geistlich AG, Wolhusen, Switzerland). The window will be closed with a collagen membrane (Bio-Gide, Geistlich AG, Wolhusen, Switzerland).
89395468|NCT04811170|Experimental|Counselling group|Counselling sessions will be conducted at the designated centers operated by the Zubin foundation. According to the level of the DASS score, 6 to 10 sessions (based on the algorithm) of counselling service will be provided to the participants by three registered counsellors. A lead counsellor will oversee all cases and services. The counselling program consists of 6-10 60-minute sessions, and the sessions can be flexibly delivered over 1 to 2 weeks, ranging from one 60-minute session biweekly or weekly.
89395469|NCT04811170|Other|Waiting group|For participants in the waiting list control group, they will receive monitoring service over phone calls during the 8-12 weeks wait period. Counselling service will be offered after the post-treatment assessment.
89395470|NCT03118739|Experimental|Verinurad 9 mg+Febuxostat 80 mg|Capsule administered orally, once daily for 24 weeks
89395471|NCT03118739|Placebo Comparator|Placebo|Capsule administered orally, once daily for 24 weeks
89395472|NCT03181126|Experimental|Venetoclax + Navitoclax + Chemotherapy|Venetoclax weight-adjusted doses administered orally every day (QD) starting on Day 1 + navitoclax various, weight-adjusted doses administered orally QD starting on Day 3 + chemotherapy (peg-asparaginase [or any other forms of asparaginase], vincristine, dexamethasone) and tyrosine kinase inhibitor [TKI, if applicable]). This regimen and any of its components may be delayed, reduced or omitted at the discretion of the Investigator.
89395473|NCT03157492|Experimental|Aural Rehabilitation Group|The AR Group will receive six 90-minute sessions including auditory training, informational counseling, and communication strategies.
89395474|NCT03157492|Sham Comparator|Cognitive Training Group|The Cognitive Training Group will receive six 90-minute sessions including training exercises (Ken-Ken, Sudoku, Crosswords, Word Search, Spot the Difference) to improve speed and accuracy.
89395475|NCT03146338|Experimental|Magnesium-rich mineral water (Rozana)|Patients in this arm must take 1.5 Liter by day of a mineral water rich in magnesium (Rozana) during the treatment by anti-EGFR. The mineral water is provided.
89395476|NCT03146338|No Intervention|Standard|Patients will have the usual care (oral advice only according to the habits of the investigator)
89395477|NCT02995889|Experimental|FLT-PET|
89395478|NCT03141502|Experimental|Skin Stretching Device (SSD)|the wound is primarily closed by aid of the SSD after necessary surgical debridement.
89395479|NCT03141502|Active Comparator|Skin Grafting (SG)|the wound is primarily closed by the technique of skin grafting after necessary surgical debridement.
89395480|NCT04477252|Experimental|App group|Use of the Mobile App for the daily performance (Monday to Friday) of lumbopelvic stability exercises apart from the usual physiotherapy treatment for 3 months.
89395481|NCT04477252|Active Comparator|conventional physiotherapy|usual physiotherapy treatment for 3 months
89395482|NCT03094195|Experimental|EMA401 25mg BID|Ema401 25 mg was administered orally twice a day
89395483|NCT03094195|Experimental|EMA401 100mg BID|Ema401 100 mg was administered orally twice a day
89395484|NCT03094195|Placebo Comparator|Placebo BID|Matching placebo capsules administered orally twice a day
89395485|NCT03140410||Linezolid-resistant S. epidermidis|Patients affected by blood stream infections caused by meticillin-resistant S.epidermidis strains, tested resistant to linezolid
89395486|NCT03140410||Linezolid-susceptible S.epidermidis|Patients affected by blood stream infections caused by meticillin-resistant S.epidemridis strains, tested susceptible to linezolid
89395487|NCT05759975|Active Comparator|Intraoral photobiomodulation (PBMI)|"The protocol will be performed daily by a single trained professional from the first day of conditioning until D + 5 after bone marrow transplantation or while lesions are present.~PBMI protocol will use the indium-gallium-aluminium-phosphorus diode laser (InGaAlP) (DUO® - MMOptics Ltda, São Carlos, Brazil). Four anatomical areas will be irradiated perpendicularly in the buccal mucosa through several anatomical points with a distance of approximately 1 cm between them, in order to cover the largest area per cm² by region.~Application points:~Buccal mucosa: 9 points each side: bite line on cheeks and upper and lower internal buccal vestibule (18 points).~Tongue: 4 points on each side, on the lateral and ventral edge (8 points).~Floor of the mouth: 1 point on each side (2 points)~Upper and lower lips: upper and lower lips (lip redness), bottom of upper and lower sulcus and buccal commissure, right and left sides (4 points).~Soft palate: right and left side (2 points)"
89395488|NCT05759975|Active Comparator|Extraoral photobiomodulation (PBME)|"The protocol will be performed daily by a single trained professional from the first day of conditioning until D + 5 after bone marrow transplantation or while lesions are present.~A gallium-aluminum arsenide diode laser (Gemini® manufactured by Azena Medical, LLC, distributed by Ultradent Products, Inc.) with double wavelength 810 + 980 nm, previously standardized and calibrated for extraoral application by the measurement of potency (Coherent Inc, Santa Clara, CA). The equipment will be programmed with 1 W of power. The application points will be carried out perpendicularly on the face.~Application points:~4 points on each cheek (2 on the right and 2 on the left)~1 on lips; patients with sealed lips being possible to cover the upper and lower lip~5 points in the cervical region (2 in the right submandibular space and 2 in the left submandibular space and submental space in the midline)."
89395489|NCT04799548|Experimental|neoadjuvant TACE plus Tislelizumab|
89395490|NCT05083234|Experimental|Sunflower Seed Oil Group (SSO)|The skin of newborns in the sunflower seed oil group was moisturized with SSO
89395491|NCT05083234|Experimental|Liquid Vaseline Group (LV)|The skin of newborns in the liquid vaseline group was moisturized with LV.
89395492|NCT05083234|Experimental|Control Group|The skin of newborns in the control group was not moisturized.
89395493|NCT01375985|Experimental|AVI-7100|Phosphorodiamidate morpholino antisense oligomer with positive charges on selected subunits (PMOplus™)
89395494|NCT01375985|Experimental|Placebo|Vehicle
89395495|NCT01376063|Experimental|FG-4592|
89395496|NCT02893150|Active Comparator|TAU (treatment as usual)|The Treatment as Usual (TAU) will be considered as following: 1) In the cases of individuals presenting overweight (BMI of 25 kg/m ² to 29.9 kg/m ²), but without comorbidities, primary care teams propose the improvement of the life style (more physically active, and with a better eating behaviour) in order to return to the track of normal BMI (BMI of 18.5 kg/m ² to 24.9 kg/m ²). 2) For those who have comorbidities such as hypertension and diabetes, in addition to including individuals in group activities (psycho-education), it is evaluated the need for individual dietary prescription by a nutritionist.
89395497|NCT02893150|Active Comparator|TAU+MBHP|"The Mindfulness-based Health Promotion (MBHP) developed by our research group (generic protocol) will be adapted from the Mindfulness-based Stress Reduction program (MBSR), It is based on the original model developed by Jon Kabat-Zinn and colleagues (MBSR), and subsequently adapted by our research group in order to fit it better into the context and needs of Primary Care (PC) and national and local Health Systems], which has been applied by the Center Mente Aberta in Brazil (www.mindfulnessbrasil.com), and by the University of Zaragoza, in Spain (www.webmindfulness.com). One of the sessions (the sixth one) is developed in silence, with the goal of deepening the mindfulness practice."
88871871|NCT02407236|Placebo Comparator|Maintenance Study - Placebo Subcutaneous (SC)|Participants in clinical response (at Week 8 or Week 16) to Induction treatment with single IV infusion of Ustekinumab will be randomized to receive placebo subcutaneously, beginning Week 0 of Maintenance study through Week 44.
88871872|NCT02407236|Experimental|Maintenance Study - Ustekinumab 90mg SC every 12 weeks|Participants in clinical response (at Week 8 or Week 16) to Induction treatment with single IV infusion of Ustekinumab will be randomized to receive ustekinumab 90 mg subcutaneously every 12 weeks, beginning Week 0 of Maintenance study through Week 44.
88871873|NCT02407236|Experimental|Maintenance Study - Ustekinumab 90mg SC every 8 weeks (q8w)|Participants in clinical response (at Week 8 or Week 16) to Induction treatment with single IV infusion of Ustekinumab will be randomized to receive ustekinumab 90 mg subcutaneously every 8 weeks, beginning Week 0 of Maintenance study through Week 44.
88871874|NCT02407236|Other|Maintenance Study - Placebo IV - Responder - Placebo SC|Participants in clinical response to Induction treatment with IV Placebo will receive placebo subcutaneously, beginning Week 0 of Maintenance study through Week 44. Participants are not randomized.
88871875|NCT02407236|Other|Maintenance Study-Delayed Responder-Ustekinumab 90mg SC q8w|Participants without clinical response to induction treatment ustekinumab (130 mg or 6 mg/kg [IV]) at Week 8 but in clinical response at Week 16 after receiving Induction Ustekinumab at week 8 (delayed responders) will receive ustekinumab 90 mg subcutaneously every 8 weeks, beginning Week 0 of Maintenance study through Week 44. Participants are not randomized.
88871876|NCT01893138|Placebo Comparator|Placebo|Placebo control is the vehicle solution used for the study product.
88871877|NCT01893138|Experimental|Iltamiocel|AMDC is the study product (autologous muscle-derived cells). The generic name is iltamiocel. Single intraurethral injection of 150 x 10^6 cells.
88871878|NCT00221598|Experimental|hemodialysis|
88871879|NCT05120076|Active Comparator|Dexamethasone group|The patients in the dexamethasone group will receive 12mg dexamethasone (Fortecortin ®) intravenously 15-60 minutes prior to surgery while in general anasthesia as well as 12mg dexamethasone intravenously (Fortecortin®) on the first postoperative day at approx. 8.00a.m. by the investigators.
88871880|NCT05120076|Placebo Comparator|Placebo/ Control group|The patients will not receive any additional drugs preoperatively. 3ml of a 0.9% NaCl Solution (NaCl B. Braun Inf Lös 0.9 % 250ml Ecoflac plus®) will be administered at approx. 8.00 a.m. on the first postoperative day by the investigators.
88871881|NCT05079204|Active Comparator|Conventional motivation procedure|Conventional motivation procedures defined as a presentation of the modified Bass technique on a dental teaching macro model plus intra oral instruction provided in patient's mouth with a hand mirror.
88871882|NCT05079204|Experimental|Conventional motivation procedure supported by 3D representations|Conventional motivation procedures associated with 3D intra oral procedures. A 3D intra-oral modelization will added to the previously described procedure. Then, a periodontist will show the sites contaminated by dental plaque to the patient.
88871883|NCT05030844|Experimental|Intervention Group|"IMB model-based interventions were applied to the intervention group for 3 month. For the information component of the IMB model, diabetes education consisting of four sessions was given in groups of five in the first two weeks. Each patient was given a Diabetes Management Education Booklet prepared by the researchers. For the motivation component of the IMB model, total 5 sessions 30-minute motivational interview was made with individual Whatsapp calls once every two weeks starting from the third week."
88871884|NCT05030844|No Intervention|Control Group|The control group received routine nursing care in the endocrine policlinic.
88871885|NCT04946916|Experimental|Participant with psychiatric condition without cognitive impairment|In the psychiatric condition group without cognitive impairment will be included participants with schizophrenia or bipolar disorder according to DSM V criteria.
88871886|NCT04946916|Experimental|Participant with psychiatric condition with cognitive impairment|In the psychiatric condition group with cognitive impairment will be included participants with schizophrenia or bipolar disorder according to DSM V criteria. To date, there are no clinical criteria for defining the dementia evolution of psychiatric disorders. The diagnosis of psychiatric disorder with cognitive involution is often made on the basis of subjective criteria or on the appreciation of health care teams. In the present study, cognitive involution will be defined by the occurrence of cognitive deterioration objectified by disturbed neuropsychological tests and the occurrence of progressive behavioral changes contrasting with the person's previous state and reported by the care team, a member of the family or by the patient himself. Cognitive involution must be accompanied by a decrease in autonomy with respect to the person's previous abilities.
88871887|NCT04946916|Experimental|Patients with biological Alzheimer's disease|Alzheimer's disease with frontal, amnestic, language, and visual presentation with typical Alzheimer CSF according to the 2011 NIA-AA diagnostic criteria.
88871888|NCT04946916|Experimental|Patient with fronto-temporal dementia|Probable or definite Fronto-temporal dementia, mostly behavioral variant of FTD (according to the diagnostic criteria for FTDb of Rascovsky, 2011) but Semantic Disease, Primary Progressive Non-Fluent Aphasia, Progressive Supra-Nuclear Palsy-DFT will be accepted if behavioral onset.
88871889|NCT04868760|Active Comparator|Group B: ipilimumab|Ipilimumab, 0.1 and 0.3mg/kg, will be administrated intravenously in 30-60 minutes.
88871890|NCT04868760|Experimental|Group A: IBI310|IBI 310, 0.1 and 0.3mg/kg, will be administrated intravenously in 30-60 minutes.
88871891|NCT04865952|Experimental|HA application (treatment group - HA)|periodontal surgery + HA application + buccal attached gingival (G) biopsies 24 hr after surgical procedure
88871892|NCT04865952|Other|NO HA application (non treatment group - NT)|periodontal surgery + buccal attached gingival (G) biopsies 24 hr after surgical procedure
88871893|NCT04803708|Experimental|Part A- Cohort 1|8 eligible subjects with non-infected DFU will be enrolled (Cohort 1) and receive IP three times weekly (TIW) every other day for up to one week. Of these 8 enrolled subjects, 6 subjects will be randomized to TP-102 and 2 to placebo. Subjects will be followed-up for 7 days.
88871894|NCT04803708|Experimental|Part B- Cohort 2|"18 subjects with a DFU with a grade 2 or 3 infection, as per PEDIS classification, and at least one bacterial strain susceptible to bacteriophage cocktail will be included in Cohort 2. Subjects will receive IP TIW, every other day, up to four weeks and will be randomized at a 2:1 randomization rate to either:~TP-102 q.d 3x weekly up to four weeks (n=12)~Placebo q.d. 3x weekly up to four weeks (n=6)~Subjects will be followed-up for 7 days."
88871895|NCT04651452|Active Comparator|Value Affirmation|Participants in the value affirmation condition will complete six writing prompts regarding their personal values over the course of six months. For example, participants will be given a list of values and will be asked to rate them in order of importance within their own lives and write about a time when their top value was particularly important. Participants will write for about ten minutes each session. The intervention tasks will be completed on a secure, online website that each individual participant will be emailed a link to. Participants can also receive paper copies via postal mail if they prefer.
88871896|NCT04651452|Active Comparator|Reflective Journaling|Participants in the reflective journaling condition will complete six writing prompts over the course of six months. However, the reflective journaling condition will be writing about values that are not important to them and discuss why they could be important to others. In other tasks, they will write about aspects of daily life (e.g. morning routine). Participants will write for about ten minutes each session. The intervention tasks will be completed on a secure, online website that each individual participant will be emailed a link to. Participants can also receive paper copies via postal mail if they prefer.
88871897|NCT04508166|Experimental|Dexmedetomidine|Sublingual dose of dexmedetomidine
88871898|NCT04508166|Active Comparator|Gamma-hydroxybutyrate|Oral dose of gamma-hydroxybutyrate
88871899|NCT04508166|Placebo Comparator|Placebo|Oral (saline) and sublingual (orodispersible tablet) doses
88871900|NCT04420026|Experimental|Experimental Arm|Hepatocellular tumours
88871901|NCT04309500|Experimental|Amyloid Positive (Tau Positive or Negative) Participants|Participants who receive results of elevated amyloid (whether or not tau is also elevated), indicating the presence of Alzheimer's disease brain changes.
88871902|NCT04309500|Experimental|Amyloid Negative (Tau Positive or Negative) Participants|Participants who receive results of not-elevated amyloid (whether or not tau is elevated), indicating the absence of Alzheimer's disease brain changes.
88871903|NCT04309500|Experimental|Co-Participants of Amyloid Positive (Tau Positive or Negative) Participants|Study partners of participants who receive results of elevated amyloid (whether or not tau is also elevated), indicating the presence of Alzheimer's disease brain changes.
88871904|NCT04309500|Experimental|Co-Participants of Amyloid Negative (Tau Positive or Negative) Participants|Study partners of participants who receive results of not-elevated amyloid (whether or not tau is elevated), indicating the absence of Alzheimer's disease brain changes.
88871905|NCT04279236||Single-arm|In this single-arm study, the only interventions compared to routine clinical practice are the completion of two patient questionnaires (APHAB and GBI) and an additional follow-up visit after surgery.
88871906|NCT04265196|Experimental|cognitive behavioral group therapy|A Cognitive Behavioral Therapy intervention is based on a unique protocol built in the light of previous research in the field and includes a 10-week treatment focused on coping with pain and stress.
88871907|NCT04265196|Experimental|Mindfulness-based group therapy|A mindfulness-based group therapy intervention was built inspired by a mindfulness protocol that is effective in treating pain, and includes adjustments to the physical distress of fibromyalgia patients as well as an emphasis on coping with stress and pain.
88871908|NCT04265196|No Intervention|control group|A control group will wait for 3 months, during which the subjects will complete the questionnaires and only after the end of the period will they participate in the treatment so that it will serve as a control group without intervention.
88871909|NCT04175964|Experimental|Group 1|PCO patients that will receive ketogenic diet only
88871910|NCT04175964|Experimental|Group 2|PCO patients that will receive caloric diet with Metformin
88871911|NCT04175964|Experimental|Group 3|PCO patients that will receive caloric diet only
88871912|NCT03678402|Experimental|Palarum Fall Prevention System|The Study site, the OSU Wexner Center Brain and Spine Hospital, is located on three contiguous floors with each floor being made up of two units or Pods designated East and South. Following commencement of the study, and throughout its duration, Pods assigned to the Study will only utilize the Palarum Fall Prevention System and a monitored PUP™ sock, i.e., (Patient is Up) System as the standard of care intervention for fall prevention in accordance with its operating instructions and procedures.
88871913|NCT03626532|Experimental|Mindfulness-Based Stress Reduction|Participants will meet once a week for 8 weeks (2.5 hours per session), plus a 4-hour retreat day, to engage in mindfulness meditation exercises. Didactic components will include oral presentations, informational videos, and group discussion. Additionally, daily homework assignments will require participants to engage in guided practices for 30 minutes a day for 5 days a week.
88871914|NCT03626532|Active Comparator|Lifestyle Education|Participants will meet once a week for 2.5 hours for 8 weeks, plus a 4-hour retreat day, to engage in light stretching exercises and interactive discussions on health topics, such as physical activity, nutrition, sleep, stress, etc. Didactic components will include oral presentations, informational videos, and group discussion. Additionally, daily homework assignments will ask participants to engage in stretching, read or watch informational content, and answer reflection questions for 30 minutes a day for 5 days a week.
88871915|NCT03624270|Experimental|Frontline oral arsenic trioxide, ATRA and ascorbic acid (AAA)|"Induction:~Oral arsenic trioxide 10mg daily, all-trans retinoic acid (ATRA) (45mg/m2 per day in divided doses) and Ascorbic acid 1g daily for 42 days~Daunorubicin at 50mg/m2 daily for 3 days (omitted if WBC at diagnosis < 10 x 10^9/L; or age ≥ 65 years; or cardiac function impairment)~Hydroxyurea 2-4g per day if WBC > 5 x 10^9/L during the first 7 days of induction.~Consolidation (for all patients):~- Oral arsenic trioxide 10mg daily, all-trans retinoic acid (ATRA) (45mg/m2 per day in divided doses) and ascorbic acid 1g daily for 14 days every 28 days for 2 cycles~Maintenance (for all patients):~- Oral Arsenic trioxide 10mg daily, ATRA (45mg/m2 per day in divided doses) and ascorbic acid 1g daily for 2 weeks every 2 months for 24 months."
88871916|NCT03588468|Sham Comparator|healthy|will be defined as persons without pathological mutation of the TTR gene Electrophysiological biomarkers and MRI biomarkers will be performed
88871917|NCT03588468|Active Comparator|Asymptomatic carriers|"will be defined as persons with a known pathological mutation of the TTR gene but with no clinical complain, normal clinical examination, and normal renal and cardiac investigations.~Electrophysiological biomarkers and MRI biomarkers will be performed"
88871918|NCT03588468|Experimental|Symptomatic carriers|"will be defined as persons with a known pathological mutation of the TTR gene with clinical complain, abnormal clinical examination, and abnormal renal and cardiac investigations.~Electrophysiological biomarkers and MRI biomarkers will be performed"
88871919|NCT03455088|Experimental|DBT group|DBT group has 55 patients, maybe will be divided them into 6 groups. Every group has 8-10 patients. Every group receive 12 times DBT group therapy and 1 times a week for 120 minutes each time.
88871920|NCT03455088|Active Comparator|Drug therapy group|Drug therapy group has 55 patients, and the investigator may use fluoxetine as treatment drug.
88871921|NCT03455088|Experimental|DBT and drug therapy group|DBT and drug therapy group has 55 patients, maybe the investigator can divide them into 7 groups. Every group has 8-10 patients. Every group receive 12 times DBT group therapy and 1 times a week for 120 minutes each time. At the same time, the investigator use fluoxetine as treatment drug.
88871922|NCT02481336||Cancer patients receiving chemotherapy|"Stage I-IV ovarian cancer receiving chemotherapy Paclitaxel/Carboplatin~Stage II-IV endometrial cancer receiving chemotherapy Paclitaxel/Carboplatin~Stage III & high risk stage II colorectal cancer receiving chemotherapy with mFOLFOX~Questionnaires~Peripheral nervous system examination~Whole Genome Sequence"
88871923|NCT01843140||Young female cancer survivors|
88871924|NCT01597440|Experimental|N-Carbamylglutamate|Active NCG & Standard of Care
88871925|NCT01597440|Placebo Comparator|Placebo|Standard of Care therapy
88871926|NCT01598064|Experimental|GK#10|GK#10 1 pk tid for 8 weeks
88871927|NCT01598064|Placebo Comparator|Placebo|Placebo 1 pack tid for 8 weeks
88871928|NCT01600170|Active Comparator|Atorvastatin|Participants were given atorvastatin for 12 weeks at various doses based on their specific HAART treatment.
88871929|NCT01600170|Placebo Comparator|Placebo|Participants were given Placebo tablets for 12 weeks.
88871930|NCT01600482|Experimental|CELT ACD device|The CELT ACD device is a vascular closure device.
88871931|NCT01600482|No Intervention|Manual Compression|Manual Compression
88871932|NCT01600638|Experimental|Zeltiq System Treatment Group|Individuals with sharp flank curvatures were treated on one (1) flank with the Zeltiq CoolSculpting System and the CoolCurve+ applicator at protocol-defined temperatures and durations.
88871933|NCT01600950|Experimental|LY2963016|A single 0.3 units per kilogram (U/kg) dose of LY2963016 will be administered subcutaneously followed by a minimum washout period of 7 days.
88871934|NCT01600950|Active Comparator|Lantus|A single 0.3 U/kg dose of Lantus will be administered subcutaneously followed by a minimum washout period of 7 days.
88871935|NCT01603056|Experimental|PANGRAMIN SLIT HDM MIX|PANGRAMIN SLIT HDM MIX Up-dosing phase (vial 0 to vial 4) + maintenance phase (3 times per week), for 12 months.
88871936|NCT01603056|Placebo Comparator|Placebo|Placebo Up-dosing phase (vial 0 to vial 4) + maintenance phase (3 times per week), for 12 months.
88871937|NCT01604772|Experimental|Treatment (Akt inhibitor MK2206)|Patients receive Akt inhibitor MK2206 PO once weekly for 4 weeks. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88871938|NCT01605942|Experimental|Dexamethasone Drug Delivery System|Dexamethasone Drug Delivery System administered into the study eye at the conclusion of cataract surgery on Day 1.
88871939|NCT01605942|Placebo Comparator|Placebo Drug Delivery System|Placebo Drug Delivery System administered into the study eye at the conclusion of cataract surgery on Day 1.
88871940|NCT01607112|Experimental|Fluarix/Influsplit 18-60 Years Group|Subjects 18-60 years of age received 1 dose of Fluarix/Influsplit SSW 2012-2013 vaccine at Day 0. The vaccine was administered intramuscularly in the deltoid of the non-dominant arm.
88871941|NCT01607112|Experimental|Fluarix/Influsplit > 60 Years Group|Subjects above 60 years of age received 1 dose of Fluarix/Influsplit SSW 2012-2013 vaccine at Day 0. The vaccine was administered intramuscularly in the deltoid of the non-dominant arm.
88871942|NCT01607658|Placebo Comparator|Placebo|Placebo intranasal gel administered prn, 2-8 hours before a planned sexual event
88871943|NCT01607658|Experimental|Experimental 1|Low dose TBS-2 (0.6 mg) testosterone intranasal gel administered prn
88871944|NCT01607658|Experimental|Experimental 2|Medium dose TBS-2 (1.2 mg) testosterone intranasal gel administered prn
88871945|NCT01607658|Experimental|Experimental 3|High dose TBS-2 (1.8 mg) testosterone intranasal gel administered prn
88871946|NCT01608672||All participants|Botulinum toxin Type A (BOTOX®) treatment to glabellar lines as prescribed by the Investigator over at least 5 years.
88871947|NCT01610154|Experimental|Sitagliptin treatment|
88871948|NCT01611948|Active Comparator|Active Drug|125mg/d aprepitant for 8 weeks given in conjunction with 8 weeks of manual-guided behavioral counseling.
88871949|NCT01611948|Placebo Comparator|Placebo pill|Placebo pill daily for 8 weeks given in conjunction with 8 weeks of manual-guided behavioral counseling.
88871950|NCT01612494|Placebo Comparator|Normal Saline|
88871951|NCT01612494|Experimental|Hypertonic Saline|
88871952|NCT01612884|Other|TEG|Clopidogrel non-response defined as MA≥69 Clopidogrel response defined as MA<69
88871953|NCT01612884|Other|Light transmittance aggregometry|Clopidogrel non-response defined as MPA ADP >42.9% Clopidogrel response defined as MPA ADP <42.9%
88871954|NCT01614210|Experimental|All patients|All patients enrolled in the study.
88871955|NCT01616082|Active Comparator|Overwight/Obese with no drug|After screening, overweight/obese subjects (BMI >27 - ≤40.0) subjects will be started on a low calorie diet (approximately 900-1000 kcal/d) until a target weight loss is achieved.
88871956|NCT01616082|Active Comparator|Overweight/obese with Phentermine|After screening, overweight/obese (BMI >27.0 - ≤40.0) subjects will be started on a low calorie diet (approximately 900-1000 kcal/d) until a target weight loss is achieved. Individuals not on track to achieve their target weight by four weeks will receive the drug Phentermine to promote weight loss. Then, following eight weeks LCD (or four weeks LCD + four weeks LCD+Phentermine), in the event that they did not achieve the target weight loss, subjects will be given the option to continue with the LCD + Phentermine for up to an additional 12 weeks, under a doctor's supervision.
88871957|NCT01616160|Experimental|Nasal polyps subjects|24 subjects with nasal polyps. Intervention: Each subject will receive Nasonex (mometasone furoate) 2 spray per nostril twice daily for 4 weeks.
89395498|NCT02893150|Experimental|TAU+MB-EAT|The Mindfulness-based Eating Awareness (MB-EAT) protocol consists in ten weekly sessions of 2,5 hour to improve compulsive eating, and to promote conscious eating.
89395499|NCT05759897|Experimental|Group A|Subjects will receive HRS-7535 administered orally
89395500|NCT05759897|Experimental|Group B|Subjects will receive HRS-7535 administered orally
88871958|NCT01618422|Sham Comparator|Directly Observed Therapy (DOTS)|The DOTS strategy (current standard strategy) consists of the following measures: political commitment, case detection through bacteriologic evaluation, standardized treatment with supervision and patient support, an effective drug supply system, and a reporting and recording system that allows assessment of treatment. The standard regimen for treatment of new cases of pulmonary TB consists of 6 months treatment, with 4 drugs in the initial phase including isoniazid, rifampicin, pyrazinamide, and either ethambutol or streptomycin, followed by two drugs in the continuation phase including isoniazid and rifampicin. In the treatment of previously treated cases, a standard regimen consisting of 8 months treatment will be used.
88871959|NCT01618422|Active Comparator|Directly Observed Therapy (DOTS) plus|The DOTS-Plus strategy (the strategy to be tested) includes additional measures including continuous drug resistance surveillance, culture, drug susceptibility testing for TB patients, and tailoring of individual drug regimen through the use of first and second-line drugs.
88871960|NCT01619982|Active Comparator|Cefazolin 25 mg/kg body weight and vancomycin|"All infants < 1 year of age with congenital heart diseases requiring cardiac surgery with cardiopulmonary bypass or any patient who requires surgery involving the aorta or the aortic valve will receive both Cefazolin and Vancomycin as preoperative prophylaxis against Surgical Site Infections. This has been recommended in recently published guidelines but not evaluated in children.~Intervention: Cefazolin 25 mg/kg body weight and Vancomycin hydrochloride 15 mg/kg body weight"
88871961|NCT01619982|Other|Cefazolin only 30mg/kg body weight|All infants less than one year of age with congenital heart diseases requiring cardiac surgery with cardiopulmonary bypass or all patients who required surgery involving the aorta or the aortic valve received cefazolin 30 mg/kg body weight as preoperative prophylaxis against surgical site infections
88871962|NCT01620216|Experimental|Group I (dasatinib)|Patients receive dasatinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88871963|NCT01620216|Experimental|Group II (sutinib malate)|Patients receive sutinib malate PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88871964|NCT01620216|Experimental|Group III (sorafenib tosylate)|Patients receive sorafenib tosylate PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88871965|NCT01620216|Experimental|Group IV (ponatinib hydrochloride)|Patients receive ponatinib hydrochloride PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity
88871966|NCT01620216|Experimental|Group V (pacritinib)|Patients receive pacritinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88871967|NCT01620216|Experimental|Group VI (ruxolitinib)|Patients receive ruxolitinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88871968|NCT01620216|Experimental|Group VII (idelalisib)|Patients receive idelalisib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88871969|NCT01621230|Active Comparator|Epidural fentanyl|A continuous epidural infusion of fentanyl 10 mcg/cc at a basal infusion rate of 10 ml/hr with a patient-controlled epidural analgesia (PCEA) demand dose of 5 mL/hr for pain. Meperidine 25 mg intravenously every 1 hour for breakthrough pain as needed.
88871970|NCT01621230|Placebo Comparator|Epidural bupivacaine plus fentanyl|A continuous epidural infusion of bupivacaine plus fentanyl during the second stage (i.e. 10 cm dilation) of labor. Epidural infusion are 10 ml/hr basal infusion plus 5 ml/hr demand dose via patient-controlled epidural analgesia (PCEA). Meperidine 25 mg intravenously every 1 hour for breakthrough pain as needed .
88871971|NCT01621776|Active Comparator|Humalog|Subjects on this treatment arm will receive Humalog insulin for their bolus doses, with doses optimized individually to achieve glycemic targets at daily medical rounds with their cabin physicians.
88871972|NCT01621776|Active Comparator|Apidra|Subjects on this treatment arm will receive Apidra insulin for their bolus doses, with doses optimized individually to achieve glycemic targets at daily medical rounds with their cabin physicians.
88871973|NCT01621776|Active Comparator|Novolog|Subjects on this treatment arm will receive Novolog insulin for their bolus doses, with doses optimized individually to achieve glycemic targets at daily medical rounds with their cabin physicians. (NOTE: This arm was only for one year of the study which was the 2012 camp session.)
88871974|NCT01622010|Experimental|Standard care with video enhancement|"Receive standard care of an invitation to attend an Allied Health Education Class. May be referred to physiotherapy from Heart Failure Clinic at Physician request per standard clinic protocol. In addition are provided a copy of Keeping the Beat with Physiotherapy: Heart Failure edition education DVD related to heart failure, exercise and self management."
88871975|NCT01622010|Active Comparator|Standard care|Receive standard care of an invitation to attend an Allied Health Education Class. May be referred to physiotherapy from Heart Failure Clinic at Physician request per standard clinic protocol.
88871976|NCT01624740|Experimental|Low Rate Followed By High Rate|The Precision Plus spinal cord stimulation screening trial leads were temporarily implanted by the investigator. Subjects received low rate stimulation (2 Hz) for 3-4 days, followed by high rate stimulation (1200 Hz) for 3-4 days.
88871977|NCT01624740|Experimental|High Rate Followed By Low Rate|The Precision Plus spinal cord stimulation screening trial leads were temporarily implanted by the investigator. Subjects received high rate stimulation (1200 Hz) for 3-4 days, followed by low rate stimulation (2 Hz) for 3-4 days.
88871978|NCT01627002|Experimental|PA401|PA401 is a potent inhibitor of neutrophil activation and transmigration under development as a novel parenteral anti-inflammatory therapy for respiratory indications such as chronic obstructive pulmonary disease (COPD) and Cystic Fibrosis (CF). PA401 is a genetically engineered and recombinantly expressed mutant of the bioactive form of human interleukin-8.
88871979|NCT01627002|Placebo Comparator|Placebo|Placebo
89395501|NCT05759897|Experimental|Group C|Subjects will receive escalated dose of HRS-7535 administered orally
88871980|NCT01628016|Experimental|Attentional bias modification training|"Attention bias modification training (ABMT) is a modified dot probe task, in which a probe always appears in the location of neutral stimulus after the two stimuli (i.e. one is the depressive cue and the other is neutral) were simultaneously presented. In the ABMT,the probability that a probe appears in the location of neutral is 90%, and correspondingly,in the location of depressive stimuli is 10%.~ABMT intervention: Participants complete 8 sessions of attention bias modification training (ABMT) during a two-week period. Each session consists of 218 trials, and the time to complete a training session is 12 minutes (4 sessions a week, roughly one session every other day with for each session)."
88871981|NCT01628016|Placebo Comparator|Placebo training|Participants complete 8 sessions of placebo training(PT) during a two-week period. Placebo training is a classic dot probe task, in which a probe appears after either of the locations that the two stimuli (i.e. one is the depressive cue and the other is neutral) were presented, with the same frequencies. In the PT condition, each session also consists of 218 trials, and the time to complete a PT session is approximately 10 minutes as well.
88871982|NCT01628016|No Intervention|blank control|Participants only complete assessment at each point time.
88871983|NCT01628718|Active Comparator|CPT-C|Cognitive Processing Therapy, cognitive version only (CPT-C) delivered in 12 60-minute one-on-one treatment sessions.
88871984|NCT01628718|Experimental|Adaptive Disclosure (AD)|Adaptive Disclosure delivered in eight 90-minute one-on-one treatment sessions.
88871985|NCT01630200|Active Comparator|Roflumilast|Active arm including patients who receive the study drug (500µg Roflumilast once daily)
88871986|NCT01630200|Placebo Comparator|Placebo|Control arm including patients who receive the placebo tablet (once daily)
88871987|NCT01631682|Active Comparator|Propranolol|a single dose of 40mg propranolol may be given to begin visit 2, followed by 90min wait and subsequently CS reactivation
88871988|NCT01631682|Active Comparator|Reactivation with time delay|For those not receiving propranolol on visit 2, one experimental CS will be reactivated, followed by a 10 minute break and subsequently extinction
88871989|NCT01631682|Experimental|Mifepristone|a single dose of 1800mg (200mg tablets) mifepristone may be given to begin visit 2, followed by 90min wait and subsequently CS reactivation
88871990|NCT01631682|Experimental|Intranasal oxytocin|A single 32IU dose of Syntocinon (intranasal oxytocin) is given to begin visit 2, followed by a 10 minute wait and subsequent CS reactivation.
88871991|NCT01634256|Experimental|Fermented turmeric|
88871992|NCT01634256|Placebo Comparator|Placebo|
88871993|NCT01635504|Experimental|botulinum toxin A|
88871994|NCT01636206|Placebo Comparator|Placebo|Placebo
88871995|NCT01636206|Experimental|Lifitegrast|Active
88871996|NCT01636284|Experimental|JX-594 recombinant vaccina GM-CSF|JX-594 recombinant vaccina GM-CSF
88871997|NCT01638312||HIV infection patient and health people|The study does not have intervention
88871998|NCT01638468|Experimental|AngioJet Ultra PE Thrombectomy System|Patients are treated with the AngioJet Ultra PE Thrombectomy System
88871999|NCT01639872|Experimental|Clozapine|The blinded CLOZ will be titrated on a recommended standard schedule, supervised by a study physician (or other prescriber) who can make the necessary adjustments to account for symptom control and tolerability. The titration is recommended to begin at 12.5 mg and then increase while the open-label base antipsychotic is tapered with a recommended goal of decreasing the base antipsychotic by 25% each week. If clinically tolerated, the target dose of CLOZ is 400 mg/day.
88872000|NCT01639872|Active Comparator|Risperidone|The blinded RISP will also be titrated in the first weeks, using a titration schedule, with a target dose of 4 mg/day, while the open label base antipsychotic is tapered in a similar fashion.
88872001|NCT01640340|Experimental|Arm I (palonosetron hydrochloride)|Patients receive palonosetron hydrochloride IV 30 minutes prior to chemotherapy on day 1, aprepitant PO (by mouth) 60 minutes prior to chemotherapy on days 1-3, and dexamethasone PO 30 minutes prior to chemotherapy on days 1-4.
89395502|NCT05759897|Experimental|Group D|Subjects will receive escalated HRS-7535 administered orally
89395503|NCT05759897|Placebo Comparator|Group E|Subjects will receive Placebo administered orally
89395504|NCT03981497||Small Renal Tumors|Subjects with small renal tumors (SRT) ad described by current ESMO (European Society for Medical Oncology) guidelines who are candidates for MWA
89395505|NCT03981497||Primary and Secondary Liver cancer|Primary liver tumors: subjects who are candidates for MWA with nodules ≤ 3 cm Liver metastases: subjects who are candidates for MWA with nodules less than ≤ 3 cm
89395506|NCT04754074|Experimental|Behavioral Education and personalized coaching|
89395507|NCT05039047||Cohort|
88872002|NCT01640340|Experimental|Arm II (ondansetron)|Patients receive ondansetron PO 30 minutes prior to chemotherapy on day 1 and aprepitant and dexamethasone as in Arm I.
88872003|NCT01641042|Experimental|Healthy Group|The subjects in the Healthy group will be age-matched to the subjects in the At-risk group. Subjects will receive 2 doses of the investigational vaccine.
88872004|NCT01641042|Experimental|At-risk Group|This group includes subjects with medical conditions placing them at an increased risk for meningococcal disease. Subjects will receive 2 doses of the investigational vaccine.
88872005|NCT01641120|Experimental|30 gauge|Subjects used a 30 gauge needle for intramuscular injection of Avonex.
88872006|NCT01641120|Experimental|25 gauge|Subjects used a 25 gauge needle for intramuscular injection of Avonex.
88872007|NCT01641978||ICU patients|neurological level in critical patients
89395508|NCT04741594|Experimental|Versah group|
89395509|NCT02654080|Experimental|Group 1: Vaccine|Participants will receive the HIV-1 nef/tat/vif, env pDNA vaccine at Day 0 and Months 1 and 3. They will receive the rVSV HIV envC vaccine boost at Months 6 and 9.
88872008|NCT01642056|Experimental|EPI-743, then Placebo|Received EPI-743, 15mg/kg up to a maximum dose of 200 mg orally or via gastric tube three times daily with meals, then placebo three times daily orally or via gastric tube with meals. EPI-743 is structurally related to Vitamin E and can be broadly classified as an antioxidant.
88872009|NCT01642056|Placebo Comparator|Placebo, then EPI-743|Received Placebo three times daily orally or via gastric tube with meals, then EPI-743, 15mg/kg up to a maximum dose of 200 mg three times daily orally or via gastric tube with meals. EPI-743 is structurally related to Vitamin E and can be broadly classified as an antioxidant.
88872010|NCT01643382|Experimental|Tight glucose control|Patients randomized to the tight glucose control arm will be placed on an insulin infusion, or continuous low dose insulin drip.
88872011|NCT01643382|Active Comparator|Standard glucose control|Patients randomized to the standard glucose control group will be given subcutaneous doses of insulin every few hours based on their blood sugar.
88872012|NCT01643616|Active Comparator|group US|"Ultrasound guided block :~20ml Prilocaine 1% and 10ml Ropivacaine 0.75% (30ml Prilocaine 1% in outpatients)"
88872013|NCT01643616|Active Comparator|group NS|"Nerve stimulation technique:~20ml Prilocaine 1% and 10ml Ropivacaine 0.75% (30ml Prilocaine 1% in outpatients)"
88872014|NCT01644240|Experimental|TD-8954 Dose 1|
88872015|NCT01644240|Placebo Comparator|Placebo|
88872016|NCT01644240|Experimental|TD-8954 Dose 2|
88872017|NCT01644396|Other|Adalimumab|Participants received an initial adalimumab 80 mg subcutaneous dose, followed by adalimumab 40 mg subcutaneous every other week starting one week after the initial dose for up to 24 weeks.
89395510|NCT02654080|Placebo Comparator|Group 2: Placebo|Participants will receive placebo vaccine at Day 0 and Months 1, 3, 6, and 9.
89395511|NCT03140332|Other|Patient with CHC|
88872018|NCT01645098|Experimental|Dexmedetomidine 1 mcg/kg|Patients receive a loading dose of dexmedetomidine 1 mcg/kg followed by a continuous infusion of 1 mcg/kg/hr.
88872019|NCT01645098|Experimental|Dexmedetomidine 0.5 mcg/kg|Patients receive a loading dose of dexmedetomidine 0.5 mcg/kg followed by a continuous infusion of 0.5 mcg/kg/hr.
88872020|NCT01646346|Experimental|4D Conformal Image-Guided Partial Breast RT|This is a single arm trial designed to look at the results in women treated with partial breast irradiation twice daily for 5 days.
88872021|NCT01647438|Other|Print Health Education|Participants receive print health education materials
88872022|NCT01647438|Experimental|Lifestyle Intervention|Six weekly health education classes and phone counseling.
88872023|NCT01648452|Experimental|NT-501 CNTF-releasing implant|Ocular implantation of a NT-501 CNTF-releasing capsule (20 ng/day) in one eye (the study eye) at baseline
88872024|NCT01648530||Participants with Migraines|Participants who returned completed internet survey with positive screening for migraines. No intervention was administered in this study.
88872025|NCT01648920||FeNO|Participants with suspected but undiagnosed asthma will have a fractional exhaled nitric oxide (FeNO) measurement taken by NIOX MINO® Instrument (09-1100) according to the 'Perform FeNO Measurement' guidelines on page 7 of the NIOX MINO® User Manual (February 2011) during their study visit. Following that they will have a Methacholine Challenge (MCC) test performed according to the ATS guidelines and the Allergy and Asthma Specialists Procedure for conducting MCC tests
88872026|NCT01650324|Experimental|DBPR108|
88872027|NCT01650324|Placebo Comparator|matching placebo|
88872028|NCT01650402|Experimental|Intensive|Intensive anti-hypertensive therapies using standard blood pressure medications to lower blood pressure to a level less than or equal to 130 mmHg
88872029|NCT01650402|Active Comparator|Standard|Standard anti-hypertensive therapies using standard blood pressure medications to lower blood pressure to a level less than or equal to 145 mmHg
88872030|NCT01651104|Experimental|Adjuvanted Trivalent Influenza Virus Vaccine|
88872031|NCT01651806|Active Comparator|Females receiving a uniform dose of TA|Women receiving a single dose of 1 gram of TA--includes all women that will get 1 gram dose of the TA during surgery. Postop outcomes wil be measured for comparison, including hemoglobin, hematocrits and blood loss.
88872032|NCT01651806|Active Comparator|Weighted dose of TA in female patients|Female patients receiving a weighted dose of TA. Will include all women that will get a weighted dose of the TA during surgery. Postop outcomes wil be measured for comparison, including hemoglobin, hematocrits and blood loss.
88872033|NCT01651806|Active Comparator|Tranexamic acid weighted dose male|Male patients randomized to the weighted dose of TA. Postop outcomes wil be measured for comparison, including hemoglobin, hematocrits and blood loss.
88872034|NCT01651806|Active Comparator|Uniform single dose TA male patient|Male patients receiving a single dose (1gram) of TA during TKA. Includes all men that will get 1 gram dose of the TA during surgery. Postop outcomes wil be measured for comparison Postop outcomes wil be measured for comparison, including hemoglobin, hematocrits and blood loss. Patients will be randomized into one of these two groups.
88872035|NCT01651806|No Intervention|Historical Cohort|"25 patients with no TA use in their surgical history.~A control group was established from a historical cohort of primary TKAs performed by the senior author (BL), none of which received TA. The most relevant Pubmed ID would be 24997651."
88872036|NCT01652040|Experimental|RT+Tp|Resistance training using electrical stimulation and ankle weights and Testosterone patches
88872037|NCT01652040|Experimental|Tp|Applying Testosterone patches
88872038|NCT01652976|Experimental|Treatment Arm|Dasatinib and mFOLFOX6
88872039|NCT01653288|Experimental|Coping Coach|Receive access to Coping Coach online intervention at baseline for use (self-guided, with email reminders) over the next 6 weeks.
88872040|NCT01653288|Experimental|Coping Coach Waitlist Control|Treatment as usual from baseline to 12 week follow-up assessment. Then receive access to Coping Coach intervention after 12 week follow-up for use (self-guided, with email reminders) over the next 6 weeks.
88872041|NCT01654068|Experimental|Radiation Therapy to Local Spine Metastasis|Conformal High Dose Intensity Modulated Radiation Therapy to a single asymptomatic local spine metastasis.
88872042|NCT01598922|Experimental|Internet Cognitive Behavioral Therapy|Participants with major depressive disorder receive an 8-week long internet-based cognitive behavioral therapy program.
89395512|NCT05082532|Experimental|patients with critical and subcritical femoropopliteal arterial occlusions|patients presented with chronic ischemia in rest pain stage or ulcerative and gangrenous toes and by investigations long chronic total occlusion of femoropopliteal segment was documented may need stenting of the diseased segment especially if the lesion recoils after previous angioplasty. Nitinol interwoven stent has a unique design that achieves adherence to vessel wall and also malleability with the vessel and surrounding muscle motion so investigators predict more extended patency time with this interventional option and want to investigate this prediction using a scientific experimental pathway.
89395513|NCT02835690|Experimental|Pembrolizumab 2 mg/kg|Participants will receive pembrolizumab 2 mg/kg administered intravenously (IV) every 3 weeks (Q3W) for up to 35 administrations. Cycle 1 is 28 days and subsequent cycles are 21 days. Eligible participants who stop pembrolizumab with Stable Disease (SD) or better but progress after discontinuation may be able to initiate a second course of pembrolizumab for up to 17 cycles (up to approximately 1 additional year) at the investigator's discretion.
89395514|NCT02835690|Experimental|Pembrolizumab 10 mg/kg|Participants will receive pembrolizumab 10 mg/kg administered IV Q3W for up to 35 administrations. Cycle 1 is 28 days and subsequent cycles are 21 days. Eligible participants who stop pembrolizumab with Stable Disease (SD) or better but progress after discontinuation may be able to initiate a second course of pembrolizumab for up to 17 cycles (up to approximately 1 additional year) at the investigator's discretion.
89395515|NCT02835690|Experimental|Pembrolizumab 200 mg Fixed Dose|Participants will receive pembrolizumab 200 mg fixed dose administered IV Q3W for up to 35 administrations. Cycle 1 is 28 days and subsequent cycles are 21 days. Eligible participants who stop pembrolizumab with Stable Disease (SD) or better but progress after discontinuation may be able to initiate a second course of pembrolizumab for up to 17 cycles (up to approximately 1 additional year) at the investigator's discretion.
89395516|NCT04629820|Experimental|Intervention|Workers assigned to the intervention group will receive free spectacles of a design they select, based on the worker's measured refractive power and dispensed one week later at the factory by the study ophthalmic personnel.
89395517|NCT04629820|No Intervention|Control|Workers assigned to the Control group will receive similar free glasses at the end of the study assessment (3 months).
89395518|NCT02486224|Experimental|Kona Deep|Subjects will receive Kona Deep post-exercise
89395519|NCT02486224|Placebo Comparator|Spring Water|Subjects will receive commercially available Spring Water post-exercise
89395520|NCT02486224|Active Comparator|Sports Drink|Subjects will receive commercially available Sports Drink post-exercise
89395521|NCT03564834|Experimental|Laparoscopic gastrectomy|A standard laparoscopic gastrectomy with D2 lymphadenectomy will be performed by two experienced surgeons, according to the Japanese Gastric Cancer Treatment Guidelines 2014 (version 4) and the Japanese Classification of Gastric Carcinoma (3rd English edition).
88872043|NCT01598922|No Intervention|Monitored Attention Control|Participants with major depressive disorder receive no treatment but are monitored closely for 8 weeks. Participants in this arm are offered the treatment at the end of the study.
89395522|NCT03564834|Active Comparator|Open gastrectomy|A standard open gastrectomy with D2 lymphadenectomy will be performed by two experienced surgeons, according to the Japanese Gastric Cancer Treatment Guidelines 2014 (version 4) and the Japanese Classification of Gastric Carcinoma (3rd English edition).
88872044|NCT01656252|Experimental|Phase I- Cytarabine & Eltrombopag|Cycle 1= Cytarabine twice daily on Days 1, 3 and 5 and Eltrombopag (Open-Label) until platelet recovery or for 35 consecutive days, whichever occurs first. Phase I will determine the dose and schedule of Eltrombopag to be used in Phase II.
88872045|NCT01656252|Experimental|Phase II- Sequence A|Cytarabine twice daily on Days 1, 3 and 5. Eltrombopag(dose and schedule as determined in Phase I) with 1st cycle of high-dose consolidation chemotherapy and placebo with 2nd cycle. Treatment sequence will be blinded to the patient and all study/sponsor personnel.
89395523|NCT05071690||Arm 1|on breast milk 50 baby full-term and infant follow up for covid-19 symptoms and measurement of plasma DHA
89395524|NCT05071690||arm 2|50 baby depend on DHA source like infant formula milk or supplement with DHA
89395525|NCT02033980|Other|colorectal lesions|All lesions will be observed with NBI and removed endoscopically or surgically for histological diagnosis.
89395526|NCT05352906|Active Comparator|Contact goldman applanation tonometry|The standard contact tonometer
89395527|NCT05352906|Active Comparator|Handheld digital contact tonometer|A contact digital tonometer's pen.
89395528|NCT05352906|Active Comparator|Non-contact air-puff tonometer|A non-contact tonometer based on air-puff and corneal hysteresis.
89395529|NCT03564210|Active Comparator|Screen time permitted|Concussion sufferers permitted screen time for first 48 hours of recovery
89395530|NCT03564210|Active Comparator|Screen time abstain|Concussion sufferers asked to abstain from screen time for first 48 hours of recovery
89395531|NCT04496986||Cardiovascular Surgical Patients Preoperative Exam|All enrolled participants will undergo a baseline Fiberoptic Endoscopic Evaluation of Swallowing (FEES) before their surgery to determine baseline / preoperative swallowing function. Those with confirmed dysphagia will not be asked to complete the postoperative swallowing exam, given our desire to examine contributing risk factors for dysphagia development and mechanisms within cardiovascular surgical patients. In addition to the instrumental exam, systematic collection of demographic, medical, surgical, and intubation-related candidate predictor variables will be conducted over the entire perioperative period.
88872046|NCT01656252|Experimental|Phase II- Sequence B|Cytarabine twice daily on Days 1, 3 and 5. Placebo with 1st cycle of high-dose consolidation therapy and Eltrombopag(dose and schedule as determined in Phase I) with 2nd cycle. Treatment sequence will be blinded to the patient and all study/sponsor personnel.
88872047|NCT01657344||ED Patients|All patients (age 0-18 regardless of race, ethnicity, or gender and of diagnosis or chronic health condition) who are registered in the ED.
88872048|NCT01660230|Active Comparator|6 µg/kg 3K3A-APC, single-dose|Cohort 1: 6 µg/kg 3K3A-APC, diluted in 0.9% sodium chloride in water and administered as an 20 mL IV infusion over 15 minutes
89395532|NCT04496986||Cardiovascular Surgical Patients Postoperative Exam|All remaining participants without preoperative dysphagia will be seen for a postoperative exam performed within 48 hours of extubation. Simultaneous imaging using FEES and videofluoroscopy will be performed at the bedside, as well as a battery of clinical tests. Completion of these postoperative tests will indicate study completion for participants without evidence of dysphagia, while participants who demonstrate acute-phase postoperative dysphagia will continue to participate if they desire. During their standard of care one-month follow-up appointment, a third research evaluation will be offered for participants with previously identified postoperative dysphagia. During this exam, the same imaging and clinical tests from the previous research exam will be performed. Finally, participants with persisting dysphagia will be offered the opportunity to continue to be studied for a fourth and final research exam during their standard of care six-month follow up clinic visit.
89395533|NCT02837952|Active Comparator|Fixed Dose Combination(FDC) IBU/APAP 250 mg/500 mg|FDC IBU/APAP 250 mg/500 mg
89395534|NCT02837952|Placebo Comparator|Placebo|Placebo
89395535|NCT02832167|Experimental|Nivolumab|
89395536|NCT04941040|Experimental|Opioid free anesthesia|patients are going to receive intraoperative analgesics other than opioids
89395537|NCT04941040|Active Comparator|Opioid anesthesia|patients are going to receive intraoperative opioid analgesics
89395538|NCT04937374|Active Comparator|Rehmannia glutinosa leaf extract|One capsule to be taken after breakfast for 56 days
89395539|NCT04937374|Placebo Comparator|Microcrystalline Cellulose (MCC)|One capsule to be taken after breakfast for 56 days
89395540|NCT05708430|Experimental|SVF injection|Intra-articular injection of autologous cells from the stromal vascular fraction derived from adipose tissue
89395541|NCT04936516|Active Comparator|McGrath Video Laryngoscope|
89395542|NCT04936516|Active Comparator|C-MAC Video Laryngoscope|
89395543|NCT00913705|Experimental|1|The patients will be randomized to receive taxol (Paclitaxel) and carboplatin as adjuvant or as neoadjuvant regimen or to surgery alone
88872049|NCT01660230|Active Comparator|30 µg/kg 3K3A-APC, single-dose|Cohort 2: 30 µg/kg 3K3A-APC, diluted in 0.9% sodium chloride in water and administered as an 100 mL IV infusion over 15 minutes
88872050|NCT01660230|Active Comparator|90 µg/kg 3K3A-APC, single-dose|Cohort 3: 90 µg/kg 3K3A-APC, diluted in 0.9% sodium chloride in water and administered as an 100 mL IV infusion over 15 minutes
88872051|NCT01660230|Active Comparator|180 µg/kg 3K3A-APC, single-dose|Cohort 4: 180 µg/kg 3K3A-APC, diluted in 0.9% sodium chloride in water and administered as an 100 mL IV infusion over 15 minutes
88872052|NCT01660230|Active Comparator|360 µg/kg 3K3A-APC, single-dose|Cohort 5: 360 µg/kg 3K3A-APC, diluted in 0.9% sodium chloride in water and administered as an 100 mL IV infusion over 15 minutes
88872053|NCT01660230|Active Comparator|TBD µg/kg 3K3A-APC, single-dose|Cohort 6: TBD (not to exceed 720) µg/kg 3K3A-APC, diluted in 0.9% sodium chloride in water and administered as an 100 mL IV infusion over 15 minutes
89395544|NCT04934410||Patients undergoing Implantation of left ventricular assist device (Etomidate)|High-risk heart-failure patients undergoing the implantation of a left ventricular assist device (LVAD). The induction agent is etomidate.
89395545|NCT04934410||Patients undergoing Implantation of left ventricular assist device (Midazolam)|High-risk heart-failure patients undergoing the implantation of a left ventricular assist device (LVAD). The induction agent is midazolam.
89395546|NCT04934410||Patients undergoing Implantation of left ventricular assist device (Sevoflurane)|High-risk heart-failure patients undergoing the implantation of a left ventricular assist device (LVAD). The induction agent is sevoflurane.
89395547|NCT02787239|Experimental|HLX01|375mg/m2 iv q3w, 6 cycles(each cycle is 3 weeks)
88872054|NCT01660230|Active Comparator|90 µg/kg 3K3A-APC, q12h for 5 doses|Cohort 7: 90 µg/kg 3K3A-APC, diluted in 0.9% sodium chloride in water and administered as an 100 mL IV infusion over 15 minutes; given every 12 hours for 5 doses
88872055|NCT01660230|Active Comparator|180 µg/kg 3K3A-APC, q12h for 5 doses|Cohort 8: 180 µg/kg 3K3A-APC, diluted in 0.9% sodium chloride in water and administered as an 100 mL IV infusion over 15 minutes; given every 12 hours for 5 doses
88872056|NCT01660230|Active Comparator|360 µg/kg 3K3A-APC, q12h for 5 doses|Cohort 9: 360 µg/kg 3K3A-APC, diluted in 0.9% sodium chloride in water and administered as an 100 mL IV infusion over 15 minutes; given every 12 hours for 5 doses
88872057|NCT01660230|Active Comparator|TBD µg/kg 3K3A-APC, q12h for 5 doses|Cohort 10: TBD (not to exceed 720) µg/kg 3K3A-APC, diluted in 0.9% sodium chloride in water and administered as an 100 mL IV infusion over 15 minutes; given every 12 hours for 5 doses
88872058|NCT01660230|Placebo Comparator|Matching Placebo, 0.9% NaCl in water|Cohorts 1-10: 0.9% sodium chloride in water and administered as either 20 mL IV infusion over 15 minutes (Cohort 1), or 100 mL IV infusion over 15 minutes (Cohorts 2-10)
88872059|NCT01660698|Placebo Comparator|Placebo|maltodextrin powder
88872060|NCT01660698|Active Comparator|Probiotic|probiotic blended in maltodextrin
88872061|NCT01661088|Experimental|Study Treatment|"Patients will receive FOLFIRINOX x 6 followed by IMRT concurrent with fixed dose rate (FDR)-gemcitabine (1g/m^2) on days 1, 8, 22, 29.~Intensity-modulated radiotherapy (IMRT): The prescribed dose was 50.0Gy in 2.0Gy per fraction.~Patients without metastatic disease will be offered surgical exploration."
89395548|NCT02787239|Active Comparator|Rituximab|375mg/m2 iv q3w, 6 cycles(each cycle is 3 weeks)
89395549|NCT03140956|Experimental|Levodopa formulation D|Levodopa formulation D
89395550|NCT03140956|Experimental|Levodopa formulation E|Levodopa formulation E
89395551|NCT03140956|Experimental|Levodopa formulation F|Levodopa formulation F
89395552|NCT03140956|Active Comparator|Sinemet IR 100/25mg|Sinemet IR 100/25MG
89395553|NCT03140956|Active Comparator|Sinemet CR 100/25mg|Sinemet IR 100/25MG
89395554|NCT03140956|Experimental|ODM-104 100mg|ODM-104 100MG
89395555|NCT03140956|Active Comparator|Carbidopa 20mg|Carbidopa 20MG
89395556|NCT03140956|Active Comparator|Carbidopa 65mg|Carbidopa 65MG
89395557|NCT02681237|Experimental|Cediranib and Olaparib|"Cediranib will be given by mouth, at a dose of 20 mg, once a day, everyday.~Olaparib will given by mouth, at a dose of 300 mg, twice a day, every day."
89395558|NCT03141112||early CRRT initiation|Patients in ICU with severe sepsis, both gender, adult, over 18 years od age. Initiation of renal replacement therapy up to 48 hours after reaching criteria of severe sepsis.
89395559|NCT03141112||late CRRT initiation|Patients in ICU with severe sepsis, both gender, adult, over 18 years od age. Initiation of renal replacement therapy after 48 hours after reaching criteria of severe sepsis.
89395560|NCT04362007|Experimental|Phase 1 dose-escalation part|Subjects with r/r PTCL and r/r CTCL will receive ASTX660 once a day for 7 consecutive days every other week of each 28-day cycle (ie, [7 days on/ 7 days off] ×2; daily dosing on Days 1-7 and 15-21). The starting dose will be escalated stepwise in successive cohorts of 3 to 6 evaluable subjects each (standard 3+3 study design), until the RD is determined.
89395561|NCT04362007|Experimental|Phase 1 ATLL expansion part|Subjects with r/r ATLL will receive ASTX660 at RD obtained from the Phase 1 part (dose-escalation part) once a day for 7 consecutive days every other week of each 28-day cycle.
89395562|NCT04362007|Experimental|Phase 2|Subjects with r/r PTCL will receive ASTX660 at RD obtained from the Phase 1 part (dose-escalation part) once a day for 7 consecutive days every other week of each 28-day cycle.
89395563|NCT02674529|Active Comparator|Antidepressant Treatment|20mg of escitalopram will be taken over an 8-week period, starting with 10mg for the first week.
89395564|NCT02674529|Placebo Comparator|Placebo|A placebo pill will be taken over an 8-week period.
89395565|NCT05082064||MELD score group A|MELD score :group A<25
89395566|NCT05082064||MELD group B|Group B>25
89395567|NCT05082064||MELD-PACO2 Group C|Group C<25
89395568|NCT05082064||MELD -PACO2 Group D|Group D>25
89395569|NCT05082064||MELD-BICARBONATE score Group E|Group E<23
89395570|NCT05082064||MELD-BICARBONATE Group F|Group F>23
89395571|NCT05000437|Experimental|High Intensity Interval Training|single arm intervention, with high intensity interval training
89395572|NCT05250427||People / Person Living with Obesity (PLwO)|From online, general population consumer panels
89395573|NCT05250427||Health Care Professionals (HCPs)|HCPs treating people who have obesity
89395574|NCT05081908|Experimental|Multisession radiosurgery|Radiosurgery
89395575|NCT01374035|Experimental|Participating GPs|GPs working at randomly selected GP centers/offices within the region that are invited to participate and signs a written informed consent to participate. (N=30-40)
89395576|NCT01374035|No Intervention|Control group|GPs working at randomly selected GP centers/office within the region that are not invited to participate, will form the control group. (N=30-40)
88872062|NCT01661712|Active Comparator|Transcutaneous electrical stimulation|One night of transcutaneous electrical stimulation (electrical current titrated according to skin sensation)
89395577|NCT02626949|Experimental|MBSR Course|Mindfulness-Based Stress Reduction Course (MBSR) consisting of 8 weekly sessions, 2.5 hours each, and a 5 hour silent retreat during the 6th week of the program.
89395578|NCT02626949|Experimental|HEP Course|Health Enhancement Program (HEP) consisting of 8 weekly sessions, 2.5 hours each, and 1.5 hour monthly educational sessions after the 8 week intervention.
88872063|NCT01661712|Sham Comparator|Sham stimulation|One night of sham stimulation (no electrical current)
89395579|NCT03140878|Experimental|LGG|Lactobacillus rhamnosous (LGG) 450 billion CFU dissolved in water
89395580|NCT03140878|Placebo Comparator|Placebo|The placebo product is the same vegetable capsule as the experimental product, identical in composition, taste and appearance but without probiotics
89395581|NCT02921815||Patients with myeloid leukemia|All del(5q) Myelodysplastic syndrome (MDS) patients in the all-case surveillance in whom transformation to acute myeloid leukemia has not been documented at the end of the observation period of the all-case surveillance.
89395582|NCT01374113|Experimental|Group 1|Subjects with moderate renal impairment
89395583|NCT01374113|Experimental|Group 2|Subjects with severe renal impairment
89395584|NCT01374113|Experimental|Group 3|Matched subjects with normal renal function
89395585|NCT02666599|Experimental|18F-FDG PET/CT|18F-FDG radiotracer All patients will undergo a 18F-FDG PET/CT and a surgery with probe detection of β+''
89395586|NCT04459936|Experimental|Management by Rheumatologist|Treatment of modifiable risk factors for cardiovascular disease managed by the Rheumatologist according to national guideline.
89395587|NCT04459936|Active Comparator|Management by General Practitioner|Treatment of modifiable risk factors for cardiovascular disease managed by the General Practitioner according to national guideline.
89395588|NCT02616887||Vertebral metastases|Selected patients with spine metastases are treated with ablative single dose SBRT and VMAT technique in various solid tumors .
89395589|NCT03632317|Experimental|Panobinostat and Everolimus|Panobinostat daily M, W, F for 2 weeks every 28 days for the first cycle (28 days). After first cycle Panobinostat daily M, W, F for 2 weeks every 28 days combined with Everolimus daily.
89395590|NCT04394494|Experimental|Motor Imagery|Patients are instructed in a motor imagery protocol of imaging extension exercises (similar to the CG), without doing the actual extension exercises. Patients will be instructed in visualizing them moving into extension and back as well as common sensations they may experience (as if doing the actual exercise). They will repeat the visualization process 10 times while in the clinic, after which they will be instructed in a home program containing the same treatment - every 2 hours, perform 10 visualization exercises.
88872064|NCT01661946|Active Comparator|Ranibizumab|intravitreal injection of 0.5mg ranibizumab in usual fashion
88872065|NCT01661946|Active Comparator|Bevacizumab|intravitreal injection of 1.25mg bevacizumab in usual fashion
88872066|NCT01662882|Experimental|AD Subjects|
88872067|NCT01662882|Experimental|MCI|MCI (mild cognitive impairment)
88872068|NCT01662882|Experimental|Healthy Controls|
88872069|NCT01662960|Experimental|Mirror therapy|4 weeks of home-based mirror therapy. Participants practiced making movements with mirrored visual feedback of the low-functioning arm.
88872070|NCT01662960|Active Comparator|Divider therapy|4 weeks of home-based divider therapy (control therapy to mirror therapy; mirror replaced by a divider). Participants practiced making movements with no visual feedback of the low-functioning arm.
88872071|NCT01663272|Experimental|cabozantinib with gemcitabine|The Study Treatment Period will consist of continued treatment during which time patients will receive cabozantinib and gemcitabine until either disease progression or the occurrence of unacceptable drug-related toxicity
89187590|NCT02556879|Other|Liver retransplantation|"Donor specific antibodies :Additional samples for Donor specific at each visit~Serum bank : Additional samples for serum bank at each visit if possible~DNA banq : Additional sample for DNA banq at inclusion visit if possible~Liver biopsy :Liver biopsy at 12 and 24 months after retransplantation (dependind the centers : procedure performed in routine or interventional procedure)~Liver ultrasounds and Fibroscan : Liver ultrasounds and Fibroscan at 12 and 24 months after retransplantation (dependind the centers : procedure performed in routine or interventional procedure)"
89187591|NCT00777075|Active Comparator|L-arginine|
89187592|NCT00777075|Placebo Comparator|placebo|
89187593|NCT04075760|Experimental|EUS-guided combined therapy|Patients with endoscopic and EUS documented GOV II and IGV I will be included. Procedure will be performed under general anesthesia using a linear array therapeuthic echoendoscope, coils and cyanoacrylate will be injected within the feeder vessel under EUS and fluroscopic guidance.
89187594|NCT04075760|Placebo Comparator|Beta Blocker (Propranolol)|o Beta-blocker (propranolol) will be started at dose of 20 mg twice daily. The principle of incremental dosing was used to achieve the target heart rate for propranolol. The dose will be increased every alternate day to achieve a target heart rate of 55/min or to the maximal dose to 360 mg/day if the medication was well tolerated and the systolic blood pressure was > 90 mm Hg. On the occurrence of intolerable adverse effects, systolic blood pressure < 90 mm Hg or pulse rate < 55/min, the dose of the medication was decreased step-wise, and eventually stopped if these adverse events persisted. Reintroduction of the medication will be attempted if cessation of the medication did not result in improvement of the reported side-effect.
88872072|NCT01667250|Active Comparator|GammaCore Active Device|Subjects will use an Active GammaCore Device
89187595|NCT02580656|Experimental|Metacognitive Therapy|Metacognitive Therapy (MCT) is a brief psychological intervention which will be delivered over a course of six, one hour weekly sessions. Treatment will follow a manualised protocol.
89395591|NCT04394494|Active Comparator|Control|Patients are instructed in extension exercises and actually, physically doing the actual extension exercises. Patients will physically repeat the extension exercises 10 times while in the clinic, after which they will be instructed in a home program containing the same treatment - every 2 hours, perform 10 exercises.
89395592|NCT02591784|Experimental|Nimotuzumab group|Nimotuzumab+radiotherapy
89395593|NCT05203003||Adult patients who are included in the CONFIRM phase III trial|
89395594|NCT03116399|Experimental|PRISM 2.0 Condition|Exposing participants to the PRISM 2.0 interface.
88810726|NCT05869591|Experimental|Cirrrhotic patients with Child A or B under edoxaban|"Twenty non-anticoagulated patients with Child A or B liver cirrhosis will receive a therapeutic dose of edoxaban (Lixiana®) for 7 consecutive days.~Blood samples will be collected just before and after edoxaban intake at day 1 and 3. Another blood samples are collected at day 8 and at day 9.~In vivo thrombin generation parameters (F1+2, TAT, fibrin monomers, D-dimers), ex vivo thrombin generation parameters [ST Genesia (Drugscreen)], as well as peak and trough edoxaban levels will be measured."
88810727|NCT05855044|Experimental|Rosemary oil|
88810728|NCT05834738|Experimental|Sequence AB|Once daily oral administration of 0.75 mg atrasentan for 12 weeks (Period A) followed by once daily oral administration of placebo for 24 weeks (Period B)
88810729|NCT05834738|Experimental|Sequence BA|Once daily oral administration of placebo for 12 weeks (Period B) followed by once daily oral administration of 0.75 mg atrasentan for 24 weeks (Period A)
88810730|NCT05833906|Experimental|CKR-051 SAD|Participants will be administrated a single dermal dose of CKR-051 at various ascending dose levels or matching placebo for 1 day.
88810731|NCT05833906|Experimental|CKR-051 MAD|Participants will be administrated a single dermal dose of CKR-051 at various ascending dose levels or matching placebo for 21 day.
88810732|NCT05830838|Experimental|Group I (daily adaptive online replanning, SBRT)|Patients undergo daily adaptive online replanning for SBRT to the prostate fossa on study. Patients also undergo MRI and may undergo PET/CT during screening.
89395595|NCT03116399|Placebo Comparator|Tablet Condition|Exposing participants to the regular computer/tablet
88810733|NCT05830838|Experimental|Group II (daily adaptive online replanning, SBRT)|Patients undergo daily adaptive online replanning for SBRT to the prostate fossa and pelvic lymph nodes on study. Patients also undergo MRI and may undergo PET/CT during screening.
88810736|NCT05804500|Experimental|Cardiac Telerehabilitation Arm|In this prospective, single-arm study, we will look at the initiation, participation, sustained engagement, and safety of 100 adult subjects (ages 45 years or older) with recent (within the past 60 days) clinician referral to CR who are offered CTR via the RecoveryPlus platform.
88810737|NCT05787847|Other|Health Education|
88810738|NCT05787847|Experimental|Health Education plus Incentives for Abstinence|
88810739|NCT05782608|Active Comparator|group (I)|
88810740|NCT05782608|Active Comparator|group (II)|
88810741|NCT05776524|Experimental|GEM-ABR [Gemcitabine - Abraxane (nab-Paclitaxel)] with TheraBionic device|Metastatic pancreatic cancer patients will be treated with amplitude-modulated radiofrequency electromagnetic fields using TheraBionic device in combination with standard chemotherapy, gemcitabine- nab-paclitaxel. amplitude-modulated radiofrequency electromagnetic fields will be delivered by the TheraBionic device.
88810742|NCT05772234|Experimental|Aggressive hydration group|Periprocedural hydration with intravenous 20 mL/kg lactated Ringer's solution within 60 min from the start of ESWL (first shockwave delivered), directly followed by 3 mL/kg per h for 8 h.
88810743|NCT05772234|Active Comparator|Restricted hydration group|Periprocedural hydration with normal saline (maximum of 1.5mL/kg per h or 3L per 24h).
89187596|NCT03741920|Experimental|Personal KinetiGraph™ (PKG™) +|For subjects in the PKG+ Group, the study MDS will review and report on the PKG prior to the visit and use the information to guide the discussion with the subject during the clinical assessment. PKG results will be recorded in the PKG Reporting case report form (CRF). The study MDS will complete the MDS-Clinician Assessment CRF to denote patient-reported symptoms, treatable findings, and clinical management planning based on his/her routine clinical assessment procedures along with the PKG information.
89187597|NCT03741920|Active Comparator|Personal KinetiGraph™ (PKG™) -|For subjects in the PKG- Group (control group), the study Movement Disorder Specialist (MDS) will complete the MDS - Clinician Assessment CRF to denote patient-reported symptoms, treatable findings, and clinical management planning based on his/her routine clinical assessment procedures. The study Movement Disorder Specialist will be blinded to the PKG information until the second part of the 90-day follow-up visit.
88872073|NCT01667250|Sham Comparator|GammaCore Sham Device|Subjects who treat with the gammacore sham device in Phase 2 will receive the active gammacore treatment during phase 3 (active treatment) of this study.
88872074|NCT01667406|Experimental|Kisspeptin-54, 1.6 single|Participant undergoing in vitro fertilisation (IVF) treatment will receive a single trigger injection of Kisspeptin, dose of 1.6 nmol/kg
88872075|NCT01667406|Experimental|Kisspeptin-54, 3.2 single|Participant undergoing in vitro fertilisation (IVF) treatment will receive a single trigger injection of Kisspeptin, dose of 3.2 nmol/kg
88872076|NCT01667406|Experimental|Kisspeptin-54, 6.4 single|Participant undergoing in vitro fertilisation (IVF) treatment will receive a single trigger injection of Kisspeptin, dose of 6.4 nmol/kg
88872077|NCT01667406|Experimental|Kisspeptin-54, 12.8 single|Participant undergoing in vitro fertilisation (IVF) treatment will receive a single trigger injection of Kisspeptin, dose of 12.8 nmol/kg
88872078|NCT01667406|Experimental|Kisspeptin-54 OHSS, 3.2 single|Participant undergoing in vitro fertilisation (IVF) treatment and who is at high risk of ovarian hyper stimulation syndrome (OHSS) will receive a single trigger injection of Kisspeptin, dose of 3.2 nmol/kg
88872079|NCT01667406|Experimental|Kisspeptin-54 OHSS, 6.4 single|Participant undergoing in vitro fertilisation (IVF) treatment and who is at high risk of ovarian hyper stimulation syndrome (OHSS) will receive a single trigger injection of Kisspeptin, dose of 6.4 nmol/kg
88872080|NCT01667406|Experimental|Kisspeptin-54 OHSS, 9.6 single|Participant undergoing in vitro fertilisation (IVF) treatment and who is at high risk of ovarian hyper stimulation syndrome (OHSS) will receive a single trigger injection of Kisspeptin, dose of 9.6 nmol/kg
88872081|NCT01667406|Experimental|Kisspeptin-54 OHSS, 12.8 single|Participant undergoing in vitro fertilisation (IVF) treatment and who is at high risk of ovarian hyper stimulation syndrome (OHSS) will receive a single trigger injection of Kisspeptin, dose of 12.8 nmol/kg
88872082|NCT01667406|Experimental|Kisspeptin-54 OHSS, 9.6 + 9.6|Participant undergoing in vitro fertilisation (IVF) treatment and who is at high risk of ovarian hyper stimulation syndrome (OHSS) will receive a trigger injection of Kisspeptin, dose of 9.6 nmol/kg and a further injection of Kisspeptin, dose of 9.6 nmol/kg 10 hours later
88872083|NCT01667406|Experimental|Kisspeptin-54 OHSS, 9.6 + saline|Participant undergoing in vitro fertilisation (IVF) treatment and who is at high risk of ovarian hyper stimulation syndrome (OHSS) will receive a trigger injection of Kisspeptin, dose of 9.6 nmol/kg and a further injection of saline10 hours later
88872084|NCT01667796|Experimental|Vitamin D3|Both those with MS and healthy controls will be given vitamin D3 5000 IU/day by mouth for 90 days.
88872085|NCT01668030|Experimental|Bacitracin on left, Enzymatic agent on right|Subjects were randomized to receive enzymatic agent on right side of face and bacitracin on left.
88872086|NCT01668030|Experimental|Bacitractin on right, enzymatic agent on left|Subjects were randomized to receive enzymatic agent on left side of face and bacitracin on right.
88872087|NCT01669434|Experimental|ACEI continuation|Patients in this arm will be randomized to continue their chronic angiotensin converting enzyme inhibitor without interruption preoperatively
88872088|NCT01669434|Experimental|ACEI omission|Patients randomized to this arm will be told to omit their final preoperative chronic angiotensin converting enzyme inhibitor dose.
88872089|NCT01670760|Experimental|Zero-Heat-Flux|This is a single arm study. All patients will have deep tissue temperature monitored from the nasopharyngeal and lateral forehead sites simultaneously.
88872090|NCT01673022|Experimental|IC Green Arm|One arm only: Receives IC Green for testing of study objective
88872091|NCT01673256||SJM Confirm ICM Observational Group|
88872092|NCT01673568|Active Comparator|abdominal binder|"The abdominal binder is worn from immediately after the operation and continuously for 7 days, night and day. The belts are standard elastic belts (ostomy belts) from ETO garments© with standard height of 22 cm. and five different sizes in width (S, M, L, XL, XXL- depending on waist measure). A fitting will be done before the operation by waist measurement according to the recommendation from the company."
88872093|NCT01673568|No Intervention|no abdominal binder|no abdominal binder
88872094|NCT01673802|Experimental|CT imaging|Patients will undergo a standard of care Gadoxetate (Eovist) MRI for cholangiocarcinoma. Patients will then be immediately placed on the CT scanner. Patients will undergo a dual energy CT of the abdomen with no additional contrast.
88872095|NCT01675830|Experimental|Head Retention Head Wrap device|All subjects recieved the experimental intervention with the Heat Retention Head Wrap device for during the rewarming phase of cardiopulmonary bypass surgery.
88872096|NCT01676532||Students attending SBHC|Students who attend the SBHC from either Sprucecourt Public School or any other participating schools.
88872097|NCT01677312|Active Comparator|19G FNA needle|Evaluate median number of passes to diagnosis (Diagnostic accuracy) and ability to procure histological samples using a 19G FNA needle when performing pancreatic biopsy.
88872098|NCT01677312|Active Comparator|25G FNA needle|Evaluate median number of passes to diagnosis (Diagnostic accuracy) and ability to procure histological samples using a 25G FNA needle when performing pancreatic biopsy.
88872099|NCT01678794|Experimental|Candesartan|
88872100|NCT01678794|Placebo Comparator|Placebo|
88872101|NCT01679028|Placebo Comparator|Placebo Group A|150mg Placebo Single dose
89395596|NCT02653963|No Intervention|Conventional AGV|A limbus-based conjunctival peritomy was created 4mm posterior to the limbus and Tenon's capsule was dissected. The AGV Plate was secured to the sclera 8 mm posterior to the limbus. The tube was trimmed to an appropriate length and inserted into the anterior chamber through a corneoscleral track. The tube was fixed to the episclera with a 10-0 nylon mattress suture. A donor sclera was fashioned to cover the exposed part of the tube and was secured to the sclera using 10-0 nylon sutures. The conjunctiva and Tenon were closed using 10-0 nylon suture.
88810746|NCT05747794|Experimental|open label lead-in (phase 2): eftilagimod alpha 30mg + paclitaxel|eftilagimod alpha 30mg s.c. + 80mg/m^2 paclitaxel i.v. (same-day administration): The trial consists of a chemo-immunotherapy (chemo-IO) phase followed by an immunotherapy (IO)-phase. The chemo-IO phase consists of a planned 6 cycles of 4 weeks (28 days each) that may be longer or shorter depending on chemo tolerance. The IO-phase is planned to follow the chemo-IO phase. A maximum of 13 cycles (approx. 12 months) of treatment is planned.
88810747|NCT05747794|Experimental|open label lead-in (phase 2): eftilagimod alpha 90mg + paclitaxel|eftilagimod alpha 90mg s.c. + 80mg/m^2 paclitaxel i.v. (same-day administration): The trial consists of a chemo-immunotherapy (chemo-IO) phase followed by an immunotherapy (IO)-phase. The chemo-IO phase consists of a planned 6 cycles of 4 weeks (28 days each) that may be longer or shorter depending on chemo tolerance. The IO-phase is planned to follow the chemo-IO phase. A maximum of 13 cycles (approx. 12 months) of treatment is planned.
89395597|NCT02653963|Experimental|Triamcinolone adjuctival AGV|Subtenon Periplate 10 mg triamcinolone acetonide around the AGV plate after fixation of AGV Plate to the sclera
88810748|NCT05747794|Experimental|Phase 3: eftilagimod alpha + paclitaxel|eftilagimod alpha s.c. (OBD) + 80mg/m^2 paclitaxel i.v. (same-day administration): The trial consists of a chemo-immunotherapy (chemo-IO) phase followed by an immunotherapy (IO)-phase. The chemo-IO phase consists of a planned 6 cycles of 4 weeks (28 days each) that may be longer or shorter depending on chemo tolerance. The IO-phase is planned to follow the chemo-IO phase. A maximum of 13 cycles (approx. 12 months) of treatment is planned.
88810749|NCT05747794|Placebo Comparator|Phase 3: placebo + paclitaxel|placebo s.c. + 80mg/m^2 paclitaxel i.v. (same-day administration): The trial consists of a chemo-immunotherapy (chemo-IO) phase followed by an immunotherapy (IO)-phase. The chemo-IO phase consists of a planned 6 cycles of 4 weeks (28 days each) that may be longer or shorter depending on chemo tolerance. The IO-phase is planned to follow the chemo-IO phase. A maximum of 13 cycles (approx. 12 months) of treatment is planned.
88810750|NCT05747287|Experimental|Experimental group|
88810751|NCT05741476|Experimental|DBV712 250 mcg|Participants will apply DBV712 250 mcg, epicutaneous system (or patch), daily for a period of 12 months. At Month 12, a post-treatment peanut DBPCFC will be performed, with a starting dose of 3 mg peanut protein with escalation to the highest dose of 1,000 mg peanut protein according to the following schedule: 3, 10, 30, 100, 300, 600, and 1,000 mg (2,043 mg cumulative dose).
88810752|NCT05741476|Placebo Comparator|Placebo|Participants will apply DBV712 matching placebo epicutaneous system (or patch), daily for a period of 12 months. At Month 12, a post-treatment peanut DBPCFC will be performed, with a starting dose of 3 mg peanut protein with escalation to the highest dose of 1,000 mg peanut protein according to the following schedule: 3, 10, 30, 100, 300, 600, and 1,000 mg (2,043 mg cumulative dose).
88810753|NCT05738824||Healthy Volunteers|18 years old and up
88810754|NCT05738824||Patients|greater than 12 years
88810755|NCT05737693|Experimental|0.2mg/kg ketamine with psychotherapy|Two infusions of low dose Ketamine combined with trauma-focused psychotherapy. Low dose ketamine infusion will take place on day 2 and day 4, of the psychotherapy intervention. A physician will oversee and administer the ketamine infusions. A nurse will accompany the subject throughout the study sessions, from the insertion of bilateral cannula for drug infusion and blood sampling, to the recovery following ketamine infusion. Whilst subjects undergo the infusion, their heart rate and blood pressure will be constantly monitored. The participant will receive a steady state of ketamine infusion of 0.2 mg/kg for 40 minutes.
88810756|NCT05737693|Experimental|0.5mg/kg ketamine with psychotherapy|2. Two infusions of Ketamine combined with trauma-focused psychotherapy. Low dose ketamine infusion will take place on day 2 and day 4, of the psychotherapy intervention. A physician will oversee and administer the ketamine infusions. A nurse will accompany the subject throughout the study sessions, from the insertion of bilateral cannula for drug infusion and blood sampling, to the recovery following ketamine infusion. Whilst subjects undergo the infusion, their heart rate and blood pressure will be constantly monitored. The participant will receive a steady state of ketamine infusion of 0.5 mg/kg for 40 minutes.
88810757|NCT05737693|Active Comparator|Midazolam with psychotherapy|Midazolam combined with trauma-focused psychotherapy. Midazolam infusion procedure will take place on day 2 and day 4, of the psychotherapy intervention. A physician will oversee administer the Midazolam infusions. A nurse will accompany the subject throughout the study sessions, from the insertion of bilateral cannula for drug infusion and blood sampling, to the recovery following midazolam infusion. Whilst subjects undergo the infusion, their heart rate and blood pressure will be constantly monitored. The participant will receive a steady midazolam infusion at a rate 0.045 mg/kg for 40 minutes.
88816657|NCT05857995|Experimental|Kentucky LEADS Collaborative Lung Cancer Survivorship Care Program (KLCLCSC)|The Kentucky LEADS Collaborative Lung Cancer Survivorship Care Program (KLCLCSC) is a targeted and tailored lung cancer survivorship care intervention built on principles of patient-centered care, shared decision making, and motivational interviewing to build survivor engagement and improve lung cancer outcomes.
88872102|NCT01679028|Experimental|T89 Group A|150mg T89 single dose
88872103|NCT01679028|Placebo Comparator|Placebo Group B|300mg placebo single dose
89187598|NCT00667719|Experimental|Aliskiren/Amlodipine/Hydrochlorothiazide|Participants received aliskiren 300 milligrams (mg) plus hydrochlorothiazide 12.5 mg for one week, at Week 1 followed by combination of aliskiren 300 mg plus amlodipine 5 mg plus hydrochlorothiazide 12.5 mg for one week, at Week 2. Following Week 2, participants were force titrated up to aliskiren 300 mg plus amlodipine 10 mg plus hydrochlorothiazide 25 mg for 26 to 52 weeks (Weeks 28 to 54). All study medications were taken orally with water, once daily in the morning.
89187599|NCT00777387|Active Comparator|1|slow-freeze
89395598|NCT02623933|Experimental|MRI assisted HDR monotherapy|HDR monotherapy to the whole prostate gland (19Gy/1) with MRI assisted focal boost to intraprostatic nodule up to 22.5Gy
89395599|NCT05092997|No Intervention|Female SOC/Male SOC arm|Women will be provided the standard of care invitation letter for male partners for fast-track visit for HIV testing and laboratory HIV testing at enrollment and every 6 months until 6 months postpartum,
89395600|NCT05092997|Active Comparator|Female intervention/Male SOC arm|Women will be provided the standard of care invitation letter for male partners for fast-track visit for HIV testing and POC VL tests for women at enrollment, delivery, and 6 months post-partum;
89187600|NCT00777387|Active Comparator|2|vitrification
89395601|NCT05092997|Active Comparator|Female SOC/Male intervention arm|Women will be provided an invitation letter for male partners for wellness visits and laboratory-based HIV VL testing for women at enrollment, delivery, and 6 months post-partum;
89395602|NCT05092997|Active Comparator|Female intervention/male intervention arm|Women will be provided an invitation letter for male partners invitation letter for male partners for wellness visits and POC viral load testing for women at enrollment, delivery, and 6 months post-partum.
88810760|NCT05726331|Experimental|Chiropractic Care, Tai Chi, and EUC|Participants assigned to this arm will receive 10 sessions of chiropractic care over 16 weeks, administered by chiropractors at collaborating clinics in the Greater Boston area. Participants assigned to this arm will also be enrolled in a community-based TC program. Participants will also be given a neck-pain self-care book that explains common causes and management strategies for neck pain.
88810761|NCT05726331|Active Comparator|Chiropractic care and EUC|Participants assigned to the chiropractic care+EUC arm will receive 10 sessions of chiropractic care over 16 weeks administered by chiropractors at collaborating clinics in the Greater Boston area. Participants will also be given a neck-pain self-care book that explains common causes and management strategies for neck pain.
88872104|NCT01679028|Experimental|T89 Group B|300mg T89 single dose
88872105|NCT01679028|Placebo Comparator|Placebo Group C|225mg Placebo bid for 14 days
88872106|NCT01679028|Experimental|T89 Group C|225mg T89 bid for 14 days
88872107|NCT01680666|Active Comparator|landmark guided|central line placement
88872108|NCT01680666|Active Comparator|ultrasound guided|central line placement
88872109|NCT01680900|Experimental|experimental 1|vilazodone (viibryd). 20 mg or 40 mg/day for 8 weeks
88872110|NCT01680900|Placebo Comparator|placebo capsules (sugar pill)|Placebo capsules matched to the drug dose for 8 weeks
88872111|NCT01682538|Active Comparator|Orfadin capsules, fasting|Orfadin capsules, single dose, 30 mg
88872112|NCT01682538|Experimental|Orfadin suspension, fasting|Orfadin suspension 4 mg/mL, single dose 30 mg (7,5 mL)
88872113|NCT01682538|Experimental|Orfadin suspension, with food|Orfadin suspension 4mg/mL, single dose 30 mg (7,5 mL)
88872114|NCT01683630||Confirmed influenza A and B cases|Cases of influenza A and B as diagnosed by PCR, viral culture or florescence microscopy
88872115|NCT01684020|Experimental|ARTISS Human Fibrin Sealant|Prior to fixation of the external rhinoplasty skin flap, a thin layer of ARTISS human fibrin sealant will be applied over the nasal tissue and fixated to the skin flap for at least 3 minutes.
88872116|NCT01684020|No Intervention|Standard of Care|Fixation of the skin flap created during external rhinoplasty will use the standard of care
88872117|NCT01684410|Experimental|Alpha-1 HC 100 mg|100 mg of aerosolized Alpha-1 HC inhaled daily via nebulizer for 3 weeks.
88872118|NCT01684410|Experimental|Alpha-1 HC 200 mg|200 mg of aerosolized Alpha-1 HC inhaled daily via nebulizer for 3 weeks.
88872119|NCT01684410|Placebo Comparator|Placebo|Placebo inhaled daily via nebulizer for 3 weeks. Placebo (phosphate buffer saline with polysorbate).
88872120|NCT01684566|Experimental|Standard-Of-Care + episil(R)|Standard-Of-Care plus episil® administered as three consecutive pump-strokes for a total volume of 0.45 mL applied 3 times daily and additionally, as needed
88872121|NCT01684566|Other|Standard-Of-Care|Oral hygiene procedures
88872122|NCT01686750|Experimental|Integrated care centers|"Integrated care centers will provide HIV prevention and treatment services to high risk populations of IDU or MSM in an accepting and supportive environment.~HIV voluntary counseling and testing & staging~Risk reduction services including free condoms, needle and syringe exchange, opiate substitution therapy~Substance abuse counseling~Sexually transmitted infection screening and treatment~Access to free antiretroviral therapy and adherence support~Peer community outreach"
88872123|NCT01686750|No Intervention|Standard services|In Standard Services sites, HIV testing, prevention, and treatment services will be available through standard venues. Government centers typically provide most HIV testing services and are the only source for free antiretroviral therapy. Non-governmental organizations typically provide prevention and risk reduction services.
88872124|NCT01688310|Active Comparator|Open surgical circumcision|Open surgical techniques, which are commonly used for circumcision in Mozambique, require good surgical skills and minor complications are common.
88872125|NCT01688310|Experimental|Gomco clamp with tissue adhesive|Coupling removal of the foreskin with the Gomco clamp followed by wound sealing with tissue adhesive results in a procedure that can be performed by generalist doctors using the same technique in all age groups.
88872126|NCT01688856|Experimental|Arm+Hand CCFES|Uses an electrical stimulator that opens the paretic hand and extends the paretic elbow in response to and with an intensity proportional to movement of the contralateral arm and hand. The treatment dose will be approximately 2 hrs per day of self-administered stimulation-mediated exercise at home plus 70 min of functional task practice twice a week in the laboratory for 12 weeks.
89187601|NCT00780351||SLEDD-f, vanco|Surgical ICU patients who is on slow low efficiency daily hemodiafiltration (SLEDD-f) and requires vancomycin therapy
89187602|NCT00780429||1|MMF+cyclosporine
89187603|NCT00780429||2|MMF+tacrolimus
89395603|NCT03939364|Experimental|0.1% SBS-101|
88810762|NCT05726331|Active Comparator|EUC|Individuals assigned to the EUC alone group will be asked to continue their usual medical care as prescribed by their physician for 16 weeks. In addition, they will be asked to not seek chiropractic care or TC during the study. Participants will also be given a neck-pain self-care book that explains common causes and management strategies for neck pain. We will also provide this arm of participants with increased attention in the form of biweekly calls from the study research assistants.
89187604|NCT00780429||3|MMF+sirolimus
88810763|NCT05723601|Active Comparator|cream used first and then switch to tablets|participants will start with 3 months of cream and then switch to tablets
88810764|NCT05723601|Active Comparator|tablets used first and switch to cream|participants will start with 3 months of tablets and switch to cream
88810765|NCT05716893|Experimental|Adaptive Aerobic Training/AT Dosing|Participants with newly diagnosed primary breast cancer initiating chemotherapy.
88810766|NCT05716893|Active Comparator|Standard (fixed) Aerobic Training/AT dosing|Participants with newly diagnosed primary breast cancer initiating chemotherapy.
88810767|NCT05695963|Experimental|Restless Legs Syndrome|
88810768|NCT05692518|Experimental|MAGNET System, DI Bio-fragmentable|GT Metabolic Solutions DI Bio-fragmentable Magnetic Anastomosis System
88810769|NCT05689073|Experimental|Conversational AI system|
88810770|NCT05689073|Active Comparator|Educational brochure|
88810771|NCT05678959|Experimental|Ligelizumab 120 mg|120 mg
88810772|NCT05678959|Experimental|Ligelizumab 240 mg|240 mg
88810773|NCT05675774|Experimental|Dual Energy CT|Patients with acute stroke who receive intervention in the form of thrombolysis or EVT will receive dual-energy CT at the 24-hour mark in lieu of conventional single-energy CT.
88810774|NCT05674643||Cohort 1 - ultrasound and acetaminophen|Cohort 1 will include subjects who have a peripheral intravenous line placed in the pre-op area per routine care. This cohort is on average age 7 years and older. Procedures for cohort 1 will include: (a) gastric US measurement of the antral CSA and gastric volume using the Perlas US qualitative grading assessment by an expert and a novice operator to determine the inter-rater class reliability and repeat measurements by each operator to assess the intra-rater reliability (Aim 1), and (b) serial abdominal ultrasounds for gastric assessment and the acetaminophen absorption test to determine the correlation between gastric US and a gold-standard for gastric emptying (Aim 2). The acetaminophen absorption test requires administering a single weight-based enteral dose of acetaminophen with 6 oz of water and drawing of blood samples through a peripheral intravenous line.
88810775|NCT05674643||Cohort 2 - ultrasound only|Cohort 2 will include subjects for whom a peripheral intravenous line placement is not part of routine pre-operative care. Average age for cohort 2 is age less than 7 years old. Procedures for Cohort 2 will include a gastric US measurement of the antral CSA and gastric volume using Perlas US qualitative grading assessment by an expert and a novice operator to determine the inter-rater class reliability and repeat measurements by each operator for the intra-rater reliability (Aim 1). This cohort is included to examine the reliability of measurements across age groups.
88810776|NCT05673720|Experimental|preoperative active tDCS+MBI|Active tDCS with simultaneous meditation intervention will be applied.
88810777|NCT05673720|Sham Comparator|preoperative sham tDCS+MBI|Sham tDCS with simultaneous sham MBM intervention will be delivered.
88810778|NCT05671510|Experimental|Arm 1: Gotistobart 6 mg/kg with 2 loading doses of 10 mg/kg, Q3W|Gotistobart will be administrated by IV infusion in 60 minutes on day 1 of each cycle. A cycle is 21 days.
88810779|NCT05671510|Experimental|Arm 2: Gotistobart 3 mg/kg Q3W|Gotistobart will be administrated by IV infusion in 60 minutes on day 1 of each cycle. A cycle is 21 days.
88810780|NCT05671510|Active Comparator|Arm 3: Docetaxel 75 mg/m2, Q3W|Docetaxel will be administrated by IV infusion in 60 minutes on day 1 of each cycle. A cycle is 21 days.
88810781|NCT05670236|Experimental|Knee Osteoarthritis|Individuals with clinically defined unilateral symptomatic knee osteoarthritis.
88810782|NCT05670236|No Intervention|Healthy|Individuals who serve as healthy controls.
88810783|NCT05643651|Experimental|Rivaroxaban+Antiplatelet drug|Rivaroxaban as anticoagulant will be administered with antiplatelet drug for 6 months. Antiplatelet drug can choose Aspirin or Clopidogrel depending on participant medical history and physician's recommendation.
88810784|NCT05643651|Active Comparator|Standard antithrombotic care|"Warfarin as anticoagulant will be administered with antiplatelet drug for 6 months. Antiplatelet drug can choose Aspirin or Clopidogrel depending on participant medical history and physician's recommendation. International normalized ratio(INR) should be tested once a month and maintained in target range(1.5~2.5).~2.Aspirin[3 ~5mg/(kg·d), once daily] or Clopidogrel[ <2 years: 0.2~1.0mg/kg, ≥2 years: 1 mg/kg; once daily] according to experienced clinician recommendation and individual condition."
88810785|NCT05642936|Experimental|Transcendental Meditation|"The TM technique is a simple, natural, effortless mental procedure that is practiced 20 minutes twice a day while sitting comfortably with the eyes closed. During the practice, it is reported that ordinary thinking processes settle down, and a distinctive wakeful hypometabolic state characterized by neural coherence and physiological rest is gained. The TM technique was taught in a 7-step course of instruction consisting of six 1.5-2 hour individual and group meetings taught by a certified instructor."
88810786|NCT05642936|Active Comparator|Health Education|The control intervention was a cardiovascular health education program designed to match the format of the experimental intervention for instructional time, instructor attention, participant expectancy, social support, and other nonspecific factors. The classroom content was based on standard, published materials. The instructors were professional health educators.
88810787|NCT05625815|Experimental|Condition 1: prototypes from (816-v1 001) to (816-v1 050) every day|Application on the brown spots of the face and/or hands for the prototypes (816-v1001) to (816-v1 050) at D0, D1, D2, D3, D4 and D5.
88810788|NCT05625815|Experimental|Condition 2: prototypes from (816-v1 051) to (816-v1 100) every week|Application on the brown spots of the face and/or hands for the prototypes (816-v1 051) to (816-v1 100) at D0, D7, D14, D21, D28 and D35.
88810789|NCT05625815|Experimental|Conditions 3 : prototypes from (816-v1 101) to (816-v1 150) every two weeks|Application on the brown spots of the face and/or hands for the prototypes (816-v1 101) to (816-v1 150) at D0, D14, D28, D42, D56 and D70.
88816658|NCT05857995|Active Comparator|Enhanced Usual Care (EUC)|The enhanced usual care condition involves usual care plus bibliotherapy and assessment.
89395604|NCT03939364|Experimental|0.3% SBS-101|
89395605|NCT03939364|Experimental|0.2% SBS-101|
88872127|NCT01688856|Experimental|Hand CCFES|Uses an electrical stimulator that opens the paretic hand in response to and with an intensity proportional to movement of the contralateral hand. The treatment dose will be approximately 2 hrs per day of self-administered stimulation-mediated exercise at home plus 70 min of functional task practice twice a week in the laboratory for 12 weeks.
88872128|NCT01688856|Active Comparator|Arm+Hand Cyclic NMES|Uses an electrical stimulator that delivers stimulation to open the hand and extend the elbow repeatedly with preprogrammed timing and intensity. The treatment dose will be approximately 2 hrs per day of self-administered stimulation-mediated exercise at home plus 70 min of functional task practice twice a week in the laboratory for 12 weeks.
88872129|NCT01689324|Experimental|Study Group|Participants will receive a single booster dose of Tdap vaccine (ADACEL®) on Day 0.
88872130|NCT01692756|Experimental|Kenalog or Placebo|Kenalog® (40mg) or saline placebo injection 1-2 days after ACL injury and 12-14 days later.
88872131|NCT01692756|Experimental|Kenalog then placebo|Subjects will initially receive 40mg injection of Kenalog® 1-2 days after injury and saline placebo at 12-14 days post injury.
88872132|NCT01692756|Experimental|Kenalog only|Subjects will receive two consecutive (40 mg) intra-articular injections of Kenalog®
88872133|NCT01692756|Placebo Comparator|Placebo|subjects will receive two consecutive intra-articular saline placebo injections at the same time periods.
88872134|NCT01695330|Experimental|Subcutaneous bortezomib|
88872135|NCT01698528|Experimental|Intervention Group|The experimental arm will be provided with a tablet computer with a newly designed software to help manage his or her diabetes care. This arm will communicate with his or her provider through the tablet computer to initiate and titrate basal insulin dose based on the 303 protocol. The individuals in this arm will also track their glucose values and medication adherence using the tablet computer by documenting when medication was taken or insulin was injected.
88872136|NCT01698528|No Intervention|Control Group|The individuals in the control group will receive usual care from the study Clinic as they always have. These individuals will be tracking their diabetes in the same way they have been by communicating with their health care provider and his or her office via fax/phone/e-mail. These individuals will not be provided with a tablet computer.
88872137|NCT01698684|Placebo Comparator|Placebo|
88872138|NCT01698684|Experimental|Avanafil 100 mg|
88872139|NCT01698684|Experimental|Avanafil 200 mg|
89187605|NCT00780507||1|Patients are in a state of remission
89187606|NCT00780507||2|Patients are in a flare
89395606|NCT03939364|Placebo Comparator|Placebo|
88872140|NCT01699542|Active Comparator|Metal Stent|The WallFlex Biliary Fully Covered Esophageal Stent System is being evaluated for treatment of refractory anastomotic esophageal strictures.
88872141|NCT01699542|Active Comparator|Bougie Dilation|Esophageal Bougie Dilator commercially available devices used per Investigator preference are being evaluated for treatment of refractory anastomotic esophageal strictures.
88872142|NCT01699698|Experimental|Test subject|
88872143|NCT01701024|Active Comparator|ACYC|ACYC active, topically applied to the face for 12 weeks
88872144|NCT01701024|Placebo Comparator|ACYC vehicle|ACYC vehicle (placebo), topically applied to the face for 12 weeks
88872145|NCT01701102|Active Comparator|Mepivacaine 37.5 mg|
88872146|NCT01701102|Active Comparator|Mepivacaine 30 mg plus fentanyl 10 µg|
88872147|NCT01701102|Active Comparator|Mepivacaine 27 mg plus fentanyl 10 µg|
88872148|NCT01701102|Active Comparator|Mepivacaine 24 mg plus fentanyl 10 µg|
88872149|NCT01701414|Sham Comparator|Standard Care (SC)|The SC group will receive a sham injection of normal saline in order to blind both the participants and the treating physicians. A 7.5-MHz linear transducer will be placed on the side of the affected hip 1cm below the inguinal ligament. 1cm lateral to the ultrasound probe, a 27 gauge needle and syringe will be used to inject 3cc of 0.9% subcutaneously. The SC group will then be cared for by the Emergency Department physicians according to their regular clinical practice.
88872150|NCT01701414|Experimental|Femoral Nerve Block (FNB)|"Participants randomized to the second group, FNB group, will receive an Ultrasound (US) guided femoral nerve block using a Sonosite TitanTM (Sonosite, Inc., Bothell, WA) with a 7.5-MHz linear array transducer. Using this technique, 25ml of 0.5% bupivacaine will be injected along the nerve sheath. The femoral, obturator, and lateral cutaneous nerve are anesthetized with this technique (thus the name 3-in-1 femoral block is often used), providing maximum analgesia to the hip."
88872151|NCT01703598|Experimental|DBS surgery|Single arm
89187607|NCT03429296|Experimental|Autohypnosis learning|In this arm, patients are taught autohypnosis during sessions in groups of 3 to 6 with a qualified hypnotherapist. Sessions are set every two weeks, for a total of 6 sessions. Individual sessions are possible for patients who missed a session.
89395607|NCT05418829|Experimental|AT-007|Open-label AT-007 20 mg/kg once daily
89395608|NCT04288960||Chronic Stroke|Twenty chronic stroke patients (>3months post-stroke) will complete a one off session in a biomechanics lab. This session will include the Fugl Meyer Questionnaire and several walking trials along a flat, level 10m walkway. During this participants will wear a belt mounted accelerometer and small reflective markers on joints.
89395609|NCT03097861|Active Comparator|Lubiprostone Capsule|Lubiprostone 24 mcg capsule twice daily (BID) for 7 days.
89395610|NCT03097861|Experimental|Lubiprostone Sprinkle|Lubiprostone 24 mcg sprinkle BID for 7 days.
89395611|NCT03097861|Placebo Comparator|Placebo|Placebo matching to lubiprostone (sprinkle/capsule) BID for 7 days.
88872152|NCT01706952|Experimental|Cocaine|"Cocaine 4%. Three cotton neuropatties will be soaked with 4% cocaine. One neuropattie will be placed in the sphenoethmoidal recess, one in the middle meatus, and one in the anterior end of the middle turbinates on the side that the randomization has determined.~This intervention will be done before the beginning of the surgery, and will be left in the nose for 10 minutes, this will be done just once. After the 10 minutes, the neuropatties will be taken out of the nose."
88872153|NCT01706952|Active Comparator|Adrenaline|"Adrenaline 1/1.000 Three cotton neuropatties will be soaked with Adrenaline 1/1,000. One neuropattie will be placed in the sphenoethmoidal recess, one in the middle meatus, and one in the anterior end of the middle turbinates on the side that the randomization has determined.~This will be done before the beginning of the surgery, and will be left in the nose for 10 minutes, this will be done just once. After the 10 minutes, the neuropatties will be taken out of the nose."
88872154|NCT01707108|Experimental|Dental Implants|Rehabilitation of missing teeth with Dental Implant (MIS Technologies)
88872155|NCT01707420|Active Comparator|Gabapentin|gabapentin, 20 mg/kg, single dose, 60 min prior to surgery
88872156|NCT01707420|Placebo Comparator|liquid placebo|subjects randomized to the liquid placebo arm will receive a single dose elixir of 0.4 mL/kg given 60 min prior to surgery
88872157|NCT01707654|Other|nerve graft|Simultaneous repair of the infected wound and digital nerve defect in the finger using a bipedicled nerve flap including nerve graft from the dorsal branch of the digital nerve.
88872158|NCT01708122|Experimental|Fentanyl|Subjects will receive either 0.5mL or 1 mL of intranasal fentanyl (50mcg or 100mcg)
88872159|NCT01708122|Placebo Comparator|Placebo|Subjects will receive either 0.5mL or 1 mL of intranasal saline as placebo.
88872160|NCT01708278|Placebo Comparator|Sugar chew-Cohort 1|contains 350 mg of vitamin C and 10 mg niacin
88872161|NCT01708278|Active Comparator|Quercetin 1-Cohort 1|Quercetin chew containing 500 mg quercetin, 350 mg vitamin C and 10 mg niacin
88872162|NCT01708278|Active Comparator|Quercetin 2-Cohort 2|Quercetin chew containing 1000 mg quercetin, 350 mg vitamin C and 10 mg niacin
88872163|NCT01708278|Active Comparator|Quercetin 3-Cohort 3|Quercetin chew containing 2000 mg quercetin, 350 mg vitamin C and 10 mg niacin
88872164|NCT01708278|Placebo Comparator|Sugar chew-Cohort 2|contains 350 mg of vitamin C and 10 mg niacin
89187608|NCT03429296|No Intervention|Standard of care|In this arm, patients are not taught autohypnosis and are treated according to standard of care.
89187609|NCT00780585||1|Subjects who participated in previous Org 24448 trials
88872165|NCT01708278|Placebo Comparator|Sugar Chew-Cohort 3|contains 350 mg of vitamin C and 10 mg niacin
88872166|NCT01708590|Experimental|210 mg brodalumab|Administered by subcutaneous (SC) injection until week 12. At week 12, participants are rerandomized to placebo or continued treatment. Participants are retreated at return of disease.
88872167|NCT01708590|Experimental|140 mg brodalumab|Administered by subcutaneous (SC) injection until week 12. At week 12, participants are rerandomized to placebo or continued treatment. Participants are retreated at return of disease.
88872168|NCT01708590|Placebo Comparator|placebo|Administered by SC injection until week 12. At week 12 particpants are assigned to 210 mg brodalumab.
88872169|NCT05711004|Experimental|SMS group|Participants in the experimental group will receive three messages per week in the morning (9-10 am) for three months. The investigators will call them every month to ensure that the SMS is delivered.
88872170|NCT05711004|No Intervention|Control group|Patients in the control group will also receive the usual primary health care.
88872171|NCT05710458|Experimental|25 gauge 20,000 cpm Hypervit Dual Blade|New vitrectomy blade with higher cutting rate
88872172|NCT05710458|Active Comparator|25 gauge 10,000 Ultravit vitrectomy cutter|Existing vitrectomy blade with cutting rate 10,000 cut/min
88872173|NCT05710302||Patients diagnosed with acute heart failure in the emergency department|Patients with acute heart failure.
88872174|NCT05710146|Experimental|Tranexamic Acid|Patients will be injected with 15 mg/kg of tranexamic acid in 100mL of normal saline via IV access normally established for this procedure.
88872175|NCT05710146|Placebo Comparator|Placebo|Patients will be injected with 100mL of normal saline via IV access normally established for this procedure.
88872176|NCT05710068|Experimental|Conventional therapy with RF microneedle|Half face Oral tranexamic acid combined with triple combination cream with RF microneedle
88872177|NCT05710068|Active Comparator|Conventional therapy|Half face Oral tranexamic acid combined with triple combination cream
88872178|NCT05709522||Pediatric brain tumor patients|The study participants will be 5 to 21 years old children with newly diagnosed brain tumors presenting with any stage, who have not undergone any treatment
88872179|NCT05709522||Blood cancer children|The study participants will be 5 to 21 years old children with newly diagnosed blood cancer presenting with any stage, who have not undergone any treatment
88872180|NCT05706636|Active Comparator|Early localized vitiligo on topical treatment|Cases will only receive topical steroids/ calcineurin inhibitors and targeted phototherapy
89187610|NCT00780663|Experimental|Quarfloxin|Single arm study - open label.
89395612|NCT04215562|Other|patients with peripheral facial palsy|collection of data from records on the outcome of rehabilitation therapy on patients with peripheral facial palsy and types of complications associated with this therapy type
89395613|NCT01568359||Group 1 - Acromegaly, Group 2 - control|Group 1 - Acromegaly patients, Group 2 - Nonfunctioning pituitary adenoma patients (control)
89535473|NCT03077763|Active Comparator|Hypoxia and Nitrite (1umol/min-1)|This will be repeated as per the normoxia cohort, but at a reduced dose of sodium nitrite (1umol/min-1 for 30 minutes) and the volunteers will be asked to breathe 12% oxygen/88% nitrogen for 1-5 minutes before Plethysmography is performed (to get the volunteer to an oxygen saturation of 83-88% peripherally).
89395614|NCT03137914|Experimental|autologous chondrocyte transplantation|Autologous transplant of chondrocytes diluted in hyaluronic acid after orthognathic surgery. The transplantation will be performed through an intra-articular injection into the TMJ (arthrocentesis). Hyaluronic acid is used only as a soluble medium to dilute the chondrocytes, so it is not considered as another experimental group, or as part of interest in this investigation.
89395615|NCT03137758|Experimental|Level 1 (50 mg) PCUR-101|Starting Dose, 3+3 Cohort Design
89395616|NCT03137758|Experimental|Level 2 (100 mg) PCUR-101|
89395617|NCT03137758|Experimental|Level 3 (150 mg) PCUR-101|
89395618|NCT03137758|Experimental|Level 4 (200 mg) PCUR-101|
89187611|NCT02581514|Experimental|Algorithm|Eosinophilia is assessed following the diagnosis algorithm
89395619|NCT03137758|Experimental|Level 5 (250 mg) PCUR-101|
89395620|NCT03137758|Experimental|Level 6 (300 mg) PCUR-101|
89395621|NCT05087927||Focus Group|There will be 4 focus groups of up to 12 women in each focus group.
89395622|NCT05087927||Survey Group|There will be up to 200 women who complete the survey for this study.
89395623|NCT01376141||Subjects prescribed IMIGRAN|Subjects with migraine disorders prescribed IMIGRAN during study period
89395624|NCT04180852||Neurosurgical patients|"Non-elective admission to the neurosurgical ICU with one of the following acute intracranial pathologies which also serve as predefined subgroups:~Intracranial hemorrhage (subarachnoid, subdural hemorrhage or intracerebral hemorrhage)~Acute and severe head trauma with an initial Glasgow Coma Scale ≤10"
89395625|NCT04180852||Elderly patients|Age ≥ 70 years, predefined subgroups: ≥ 70 years and ≥80 years
89395626|NCT04180852||Obese patients|BMI ≥ 35 kg/m2, furthermore predefined subgroups of patients with BMI ≥ 40 kg/m2 and BMI ≥ 45 kg/m2
89395627|NCT04180852||Cardiac surgery patients|"Admission to the cardiosurgical ICU after one of the following procedures using cardiopulmonary bypass, which also serve as predefined subgroups:~Coronary revascularization (coronary artery bypass graft)~Heart valve surgery~Combined or complex heart surgery"
89395628|NCT04180852||Abdominal surgical patients|Admission to the abdominal surgery ICU after abdominal surgery
89395629|NCT03861689|Active Comparator|Tight control arm|Patients in the tight control arm will have additional FiLAC treatment within 24 months if the anatomy of the fistula is favourable. MRI pelvis will be performed at baseline and every 6 months. Biologic dosage will be adjusted according to MRI pelvis findings.
89395630|NCT03861689|No Intervention|Control arm|Patients in the control arm will have management according to physician own decision.
89395631|NCT03137680|No Intervention|Control Arm|No specific exercise regime for the control group. Usual hospital SOP will be adhered to
89395632|NCT03137680|Experimental|Exercise Arm|The exercise protocol for the intervention group will be to squeeze a soft ball 10 times for set and perform 3 sets of 10 squeezes each at an 1 minute interval. Three sets of exercises to be performed twice in the morning and twice in the evening, for a total of 6 weeks. This will be performed at least 6 weeks prior to the creation of the AV fistula
89395633|NCT03215914|Experimental|Subjects with type 1 diabetes using MiniMed 670G system|Eligible subjects with type 1 diabetes will initiate hybrid closed-loop insulin delivery based on interstitial glucose monitoring via the MiniMed 670G system according to Medtronic's labeling. This system combines subject-delivered pre-meal boluses with automatic interprandial insulin delivery that includes automated functions for both predictive and threshold suspension of insulin delivery intended to minimize exposure to glucose levels < 70 mg/dl.
88810790|NCT05625815|Experimental|Condition 4 : prototypes from (816-v1 151) to (816-v1 200) every two weeks|Application on the brown spots of the face and/or hands for the prototypes (816-v1 151) to (816-v1 200) at D0, D14, D28, D42, D56 and D70.
88810791|NCT05623319|Experimental|Pembrolizumab/Olaparib|Patients will be treated with pembrolizumab plus chemotherapy during the Induction Phase. In case of responsive or stable disease, patients will enter the Maintenance Phase and will be treated with pembrolizumab plus olaparib until progression or up to a maximum of 35 cycles.
88810792|NCT05604521|Active Comparator|Group 1a: PfSPZ Vaccine|"45 participants will receive 3 doses of 9.0x10^5 PfSPZ Vaccine on Days 1, 8, and 29 with a total dose of 2.7x10^6 PfSPZ Vaccine.~Group 1a: Approximately half (22/23) of the volunteers will undergo CHMI 3 weeks after last immunization by exposure to 3.2x10^3 PfSPZ Challenge (7G8)."
88810793|NCT05604521|Active Comparator|Group 1b: PfSPZ Vaccine|"45 participants will receive 3 doses of 9.0x10^5 PfSPZ Vaccine on Days 1, 8, and 29 with a total dose of 2.7x10^6 PfSPZ Vaccine.~Group 1b: Approximately half (22/23) of the volunteers will undergo CHMI 12 weeks after last immunization by exposure to 3.2x10^3 PfSPZ Challenge (7G8)."
88810794|NCT05604521|Placebo Comparator|Group 2a: Normal Saline Controls|"15 participants will receive 3 doses of normal saline on Days 1, 8, and 29.~Group 2a: Approximately half (7/8) of the volunteers will undergo CHMI 3 weeks after last immunization by exposure to 3.2x10^3 PfSPZ Challenge (7G8)."
88810795|NCT05604521|Placebo Comparator|Group 2b: Normal Saline Controls|"15 participants will receive 3 doses of normal saline on Days 1, 8, and 29.~Group 2b: Approximately half (7/8) of the volunteers will undergo CHMI 12 weeks after last immunization by exposure to 3.2x10^3 PfSPZ Challenge (7G8)."
88810796|NCT05578300||Patient with ischemic stroke with suspected large vessel occlusion|"The investigators shall recruit patients that meet the following inclusion criteria:~Patient who are over 18 years of age.~Patient with ischemic stroke with suspected large vessel occlusion (LVO), defined as occlusion of the internal carotid artery (ICA), M1 or M2 segment of the middle cerebral artery (MCA), or basilar artery (BA)."
88810797|NCT05576922|Active Comparator|Connective tissue graft|Autogenous connective tissue graft harvested from the palate as a free gingival graft and then de-epithelialized
88810798|NCT05576922|Experimental|Collagen matrix + rhPDGF-BB|Xenogeneic cross-linked collagen matrix + recombinant human platelet-derived growth factor-BB
88810799|NCT05564728||Intervention|All participants will receive a conversational agent app, Well Feet, to support them in learning foot care self-management.
88810800|NCT05563844|Experimental|PM 8.4 mg/m2|15 case，Take the medicine once on D1 ，D 1 through 21.
88810801|NCT05563844|Experimental|PM 11.2 mg/m2|15 case，Take the medicine once on D1 ，D 1 through 21.
88810802|NCT05560971|Active Comparator|Palmitoleic acid|The treatment arm will receive Palmitoleic acid (POA) supplement as Provinal® 420 mg capsules with at least 90% pure POA Ethyl Ester (less than 1% palmitic acid). Participants will be asked to consume 2 Provinal® 420 mg capsules twice a day for 8 weeks.
89395634|NCT03691402|Experimental|MCT-Silver|Metacognitive training for depression in later life is a cognitive-behaviorally based group therapy, which focuses on helping participants gain (metacognitive) distance from their thought patterns that contribute to depression. Over 8 modules, MCT-Silver addresses issues specific to depression in later life, such as coping with physical changes and loss, as well as adapting to new (social) roles. The program also includes modules on identifying and (re-)defining values in later life and how one may move toward acceptance of situations that cannot be prevented or changed. MCT-Silver addresses cognitive and metacognitive biases that contribute to the onset and maintenance of depression through fun and engaging exercises, as well as using examples from daily life.
89395635|NCT03691402|Active Comparator|Cognitive Remediation|mybraintraining© is a computer-based cognitive remediation program, which covers a wide range of neuropsychological exercises involving memory, reasoning, selective attention and psychomotor speed. The program is administered individually on personal computers and each session lasts approximately 45-60 min. To match the MCT-Silver group, participants will complete up to eight sessions of cognitive remediation.
89395636|NCT01816139|Experimental|Vehicle (2 Times/Week)|Vehicle applied to the vagina daily for 2 weeks followed by dosing 2 times a week for 10 weeks.
89395637|NCT01816139|Placebo Comparator|WC3011 Estradiol Vaginal Cream (2 Times/Week)|WC3011 estradiol vaginal cream applied daily for 2 weeks followed by dosing 2 times a week for 10 weeks.
89395638|NCT03443674|Experimental|SCB-313|Dose escalation cohorts--10mg, 20mg, 40mg, 80mg, 160mg. For each cohort: administered twice weekly (eg.. Monday and Thursday or Tuesday and Friday) for 2 weeks (Days 1, 4, 8, and 11) by IP bolus injection.
88872181|NCT05706636|Active Comparator|Early localized vitiligo on topical and systemic treatment|Cases will receive oral mini-pulse steroids, topical steroids/ calcineurin inhibitors and targeted phototherapy
88872182|NCT05703438|Experimental|Nutritionally balanced low-calorie diet|Experimental study with pre and post design
88872183|NCT05661942|Active Comparator|Calcium pre-treatment|Calcium gluconate 1 gram/100ml 0.9% NaCl or 100ml 0.9% NaCl
88872184|NCT05661942|Placebo Comparator|Placebo|diluent (NS) vials
88872185|NCT05647824||All Subjects|Consists of people with Diabetes and people without Diabetes
89187612|NCT04030910|Experimental|'LIFEView' intervention|"The 'LIFEView' session(s) involves the use of audiovisual software by Motitech AS (technology provided by and used with permission from Motitech AS). For its primary uses as Motiview, the audiovisual software was coupled to a mobile user-adapted cycle-trainer. Since a secondary benefit of the virtual cycle trip may include reminiscence which may in-turn facilitate conversation of past experiences, the audiovisual software is being adapted for use in reminiscence therapy for a palliative care population.~As there is an extensive library available to participants and 'LIFEView' sessions could potentially be longer than feasible for research personnel to conduct, each 'LIFEView' session will be limited to up to 3 videos per session or up to 1 hour of videos per session, whichever is a shorter duration. Additional post-study 'LIFEView' sessions can be provided upon request from participants."
89187613|NCT00669669|Experimental|Treatment (chemotherapy, autologous stem cell transplant)|See Detailed Description
89187614|NCT02579564|Experimental|chemotherapy with Oncorine and Endostar|Systemic chemotherapy with standard schemes, such as GP (Gemcitabine/Cisplatin), NP (Vinorelbine/Cisplatin), TP (Paclitaxel/Cisplatin) or PP (Pemetrexed/Cisplatin). Thoracic cavity perfusion of recombinant human adenovirus type 5 injection 1.5ml and Endostar 30mg each time, twice a week for four times.
89395639|NCT01100879|Active Comparator|Ferric carboxymaltose|Subjects will receive a total dose of 1,000 mg iron as FCM on the day of the next scheduled chemotherapy cycle after randomisation or continuous chemotherapy. In subjects with weight ≤66 kg, the first dose iron will be 500 mg; the second dose (500 mg) will be administered on the visit 3 (week 2).
88872186|NCT05641740|Experimental|Radiofrequency Therapy Group|The experimental group will receive a single-session of radiofrequency in their hands that has vasodilator action.
88872187|NCT05641740|Placebo Comparator|Placebo Comparator: Control Group|The placebo group will receive a single placebo radiofrequency session with the machine in pause mode.
88872188|NCT05639010|Active Comparator|regular hemodialysis|Routine blood purification therapy (including hemodialysis, hemofiltration) 3 times a week
88872189|NCT05639010|Experimental|hemoperfusion combined with hemodialysis|Routine blood purification therapy 3 times a week + Combination of hemodialysis and hemoperfusion treatment once a week
89395640|NCT01100879|No Intervention|Local standard of care.|Subjects will be treated according to the local institutional practice.
89395641|NCT05070689|Experimental|Single Group|A. Chohan Continuous squeezing Suture (ACCSS): An obstetrical procedure using half circle 40mm round body polyglactin 910 suture # 1 (Vicryl plus by Ethicon ®) for control of haemorrhage from the lower segment, in patients with Placenta Accreta for the prevention of hysterectomy at caesarean section
89395642|NCT00904553||Novalis Shaped Beam Surgery|Patients with limited brain metastases (mostly solitary brain metastasis) treated with Novalis Shaped Beam Surgery followed by planned craniotomy and resection of the metastases.
89395643|NCT05392660|Experimental|study arm|assumed upright position during first stage of labor
89395644|NCT05392660|No Intervention|control arm|hospital routine care
89395645|NCT01374191|Active Comparator|onabotulinum toxin type-A|1 injection of Btx-A, or up to 4 injections of Btx-A during the 1-year study period if pain recurs
89395646|NCT01374191|Placebo Comparator|placebo|saline
89395647|NCT01374191|Active Comparator|2nd phase - onabotulinum toxin type-A|2 - 3 injections of Btx-A, specific to patient pain recurrence
89395648|NCT04021810|Active Comparator|CPAP only|Obstructive sleep apnea patients with CPAP treatment only
89395649|NCT04021810|Active Comparator|Mandibular Advancement Device only|Obstructive sleep apnea patients with Mandibular Advancement Device only
89395650|NCT04021810|Experimental|CPAP + Mandibular Advancement Device|Obstructive sleep apnea patients with combined CPAP and Mandibular Advancement Device
89395651|NCT03140020||Clipping|Clipping of an aneurysm of the anterior communicating artery - A titan clip will be placed round the aneurysm neck to exclude the aneurysm from the bloodflow and prevent fatal subarachnoidal hemorrhage. Patients will undergo baseline structural MRI, task fMRI, rsfMRI, and baseline neuropsychological examinations prior as well as 2 months after microsurgical aneurysm treatment. Furthermore the patients will undergo additional neuropsychological examinations 12 months after long-term recovery from microsurgical treatment.
89395652|NCT03140020||Coiling|Coiling of an aneurysm of the anterior communicating artery - Using a catheter technique the aneurysm dome will be filled up with coils to prevent subarachnoidal hemorrhage. Patients will undergo baseline structural MRI, task fMRI, rsfMRI, and baseline neuropsychological examinations prior as well as 2 months after endovascular aneurysm treatment. Furthermore the patients will undergo additional neuropsychological examinations 12 months after long-term recovery from endovascular treatment.
89395653|NCT03140020||Healthy Controls|Healthy controls will undergo baseline structural MRI, task fMRI, rsfMRI, and baseline neuropsychological examinations prior as well as 2 months after baseline examinations. Furthermore all subjects will undergo additional neuropsychological examinations 12 months after baseline examination.
89395654|NCT03764735|Placebo Comparator|SkQ1 Vehicle|SkQ1 (Vehicle)
89395655|NCT03764735|Active Comparator|Low Dose - SkQ1|Low-dose ophthalmic solution
89395656|NCT03764735|Active Comparator|High Dose - SkQ1|High-dose ophthalmic solution
89395657|NCT03957694|Experimental|AMG531|
89395658|NCT05759507||patients|Women undergo pregnancy from 5 SA to 41 SA with no limitation of age
89395659|NCT05041673|Active Comparator|Group 1|metformin +/- insulin +/- sulfonylurea
89395660|NCT05041673|Experimental|Group 2|Metformin plus vildagliptin +/- insulin +/- sulfonylurea
89395661|NCT05041673|Experimental|Group 3|Metformin plus liraglutide +/- insulin+/- sulfonylurea
89395662|NCT05041673|Experimental|Group 4|Metformin plus empagliflozin +/- insulin +/- sulfonylurea
89395663|NCT03907540|Experimental|Part 1, Treatment A--Belumosudil 200 mg Tablet|Belumosudil 200 mg tablet
88872190|NCT05636436|Experimental|Low dose vaccine group in adults aged 18 to 49 years|Subjects aged 18 to 49 years will be vaccinated with 2 doses of low dose recombinant herpes zoster vaccine (CHO cells) on a 0, 2 month schedule, administered intramuscularly (IM).
88872191|NCT05636436|Experimental|Low dose adjuvant group in adults aged 18 to 49 years|Subjects aged 18 to 49 years will be vaccinated with 2 doses of low dose adjuvant on a 0, 2 month schedule, administered intramuscularly (IM).
89395664|NCT03907540|Experimental|Part 1, Treatment B--[14C]-KD025 IV Microdose|[14C]-KD025 at a dose of 100 μg in a 5 mL solution containing NMT 37 kBq (1000 nCi) [14C] over 15 min IV
89395665|NCT03907540|Experimental|Part 2, Treatment C--[14C]-KD025 Capsule|[14C]-KD025 200 mg capsule containing NMT 9.8 MBq (215 μCi)
89395666|NCT05759429|Active Comparator|Integrated multidisciplinary body weight reduction program (BWRP)|
89395667|NCT05759429|Active Comparator|Integrated multidisciplinary body weight reduction program (BWRP) + melatonin|
88872192|NCT05636436|Experimental|High dose vaccine group in adults aged 18 to 49 years|Subjects aged 18 to 49 years will be vaccinated with 2 doses of high dose recombinant herpes zoster vaccine (CHO cells) on a 0, 2 month schedule, administered intramuscularly (IM).
88872193|NCT05636436|Experimental|High dose adjuvant group in adults aged 18 to 49 years|Subjects aged 18 to 49 years will be vaccinated with 2 doses of high dose adjuvant on a 0, 2 month schedule, administered intramuscularly (IM).
88872194|NCT05636436|Placebo Comparator|Placebo group in adults aged 18 to 49 years|Subjects aged 18 to 49 years will be vaccinated with 2 doses of placebo on a 0, 2 month schedule, administered intramuscularly (IM).
88872195|NCT05636436|Experimental|Low dose vaccine group in adults aged 50 years and older|Subjects aged 50 years and older will be vaccinated with 2 doses of low dose recombinant herpes zoster vaccine (CHO cells) on a 0, 2 month schedule, administered intramuscularly (IM).
88872196|NCT05636436|Experimental|Low dose adjuvant group in adults aged 50 years and older|Subjects aged 50 years and older will be vaccinated with 2 doses of low dose adjuvant on a 0, 2 month schedule, administered intramuscularly (IM).
88872197|NCT05636436|Experimental|High dose vaccine group in adults aged 50 years and older|Subjects aged 50 years and older will be vaccinated with 2 doses of high dose recombinant herpes zoster vaccine (CHO cells) on a 0, 2 month schedule, administered intramuscularly (IM).
88872198|NCT05636436|Experimental|High dose adjuvant group in adults aged 50 years and older|Subjects aged 50 years and older will be vaccinated with 2 doses of high dose adjuvant on a 0, 2 month schedule, administered intramuscularly (IM).
89395668|NCT04005209|Active Comparator|Pain management without ketamine infusion|Pain management without ketamine infusion. No other restrictions on pain management or medications.
89395669|NCT04005209|Experimental|Pain management with ketamine infusion|Pain management that includes a ketamine infusion. No other restrictions on pain management or medications.
89395670|NCT05088304||The normal FFMI group|The FFMI was calculated as follows: FFMI = fat-free mass (kg)/height squared (m2). FFMI cut-off values (derived from BIA measurements, </≥15 kg/m2 for females and </≥17 kg/m2 for males). Patients with esophagogastric cancer were then divided into the normal FFMI group (FFMI ≥17 kg/m2 for male and FFMI ≥15 kg/m2 for female).
89395671|NCT05088304||The low FFMI group|The FFMI was calculated as follows: FFMI = fat-free mass (kg)/height squared (m2). FFMI cut-off values (derived from BIA measurements, </≥15 kg/m2 for females and </≥17 kg/m2 for males). Patients with esophagogastric cancer were then divided into the low FFMI group (FFMI <17 kg/m2 for male and FFMI <15 kg/m2 for female).
89395672|NCT05088226|Experimental|Ruxolitinib combined with Chidamide|Experimental: Ruxolitinib combined with Chidamide. All recipients in this arm received the modified Bu/Cy conditioning regimen intensified by Ruxolitinib and Chidamide. The conditioning regimen for allogeneic hematopoietic stem cell transplantation consist of ruxolitinib (35 mg bid [p.o.], days -15 to -10, diminishing to day -1), chidamide (30 mg/day, twice per week from days -15 to -2), cytarabine (4g/m2/day, days -10 to -9), busulfan (0.8mg/kg, Q6h, days -8 to -6), cyclophosphamide (1.8 g/m2/day, days -5 to -4), carmustine(BCNU) (250mg/m2/day, day -3)
89395673|NCT01376219||All patients|All patients entered in the study
89395674|NCT03751553|Experimental|obstetric gel group|they will have the standard care during labor and delivery with the vaginal application of the obstetrical gel.
88872199|NCT05636436|Active Comparator|Shingrix® group in adults aged 50 years and older|Subjects aged 50 years and older will be vaccinated with 2 doses of Shingrix® on a 0, 2 month schedule, administered intramuscularly (IM).
88872200|NCT05636436|Placebo Comparator|Placebo group in adults aged 50 years and older|Subjects aged 50 years and older will be vaccinated with 2 doses of placebo on a 0, 2 month schedule, administered intramuscularly (IM).
88872201|NCT05463354|Experimental|Inactivated COVID-19 vaccines cohort group 1|Participants who received 2 doses of Inactivated COVID-19 vaccines with the second dose at least 6 months (≥180 days) prior to enrolment. N=75 Intervention: Recombinant COVID-19 Vaccine (Sf9 Cell)
88872202|NCT05463354|Active Comparator|Inactivated COVID-19 vaccines cohort group 2|Participants who received 2 doses of Inactivated COVID-19 vaccines with the second dose at least 6 months (≥180 days) prior to enrolment. N=75 Intervention: COVID-19 Vaccine (Vero Cell), Inactivated
88872203|NCT05463354|Experimental|mRNA COVID-19 vaccines cohort group 1|Participants who received 2 doses of mRNA COVID-19 vaccines with the second dose at least 6 months (≥180 days) prior to enrolment. N=75 Intervention: Recombinant COVID-19 Vaccine (Sf9 Cell)
88872204|NCT05463354|Active Comparator|mRNA COVID-19 vaccines cohort group 2|Participants who received 2 doses of mRNA COVID-19 vaccines with the second dose at least 6 months (≥180 days) prior to enrolment. N=75 Intervention: COVID-19 Vaccine (Vero Cell), Inactivated
88872205|NCT05463354|Experimental|Viral Vector COVID-19 vaccines cohort group 1|Participants who received 2 doses of Viral Vector COVID-19 vaccines with the second dose at least 6 months (≥180 days) prior to enrolment. N=75 Intervention: Recombinant COVID-19 Vaccine (Sf9 Cell)
88872206|NCT05463354|Active Comparator|Viral Vector COVID-19 vaccines cohort group 2|Participants who received 2 doses of Viral Vector COVID-19 vaccines with the second dose at least 6 months (≥180 days) prior to enrolment. N=75 Intervention: COVID-19 Vaccine (Vero Cell), Inactivated
88872207|NCT05449470|Experimental|CDSS and patient portal|The intervention includes the combined use of the clinical decision support system (CDSS) that provides deprescribing advice and a personalized risk prediction and a patient portal.
88872208|NCT05449470|No Intervention|Care as usual|Care as usual
88872209|NCT05293548|Experimental|NVSI-06-09 Sequential Immunization Group|the subjects who have been vaccinated with 2 doses/3 doses of inactivated COVID-19 vaccine (Vero cell) for ≥6 months
88872210|NCT05293548|Active Comparator|Inactivated Vaccine Sequential Immunization Group|the subjects who have been vaccinated with 2 doses/3 doses of inactivated COVID-19 vaccine (Vero cell) for ≥6 months
89003862|NCT04259788|Experimental|Intervention|The intervention group will receive in-person dietary counseling from a registered dietitian to help participants consume a diet that is consistent the AHEI dietary guidelines. Participants in this arm will be asked to consume this diet for a 12-week period and discontinue any vitamin or supplement intake during this time. During the first 4 weeks 2 meals and 1 snack/day will be shipped to the participant. During the last 8 weeks of the intervention, the study will provide the participants with a 14-day meal plan (3 meals and 2 snacks) that adheres to the AHEI maximum score criteria to help facilitate adherence to the diet.
89003863|NCT04259788|No Intervention|Control|Participants in this arm will not receive the dietary intervention.
88872213|NCT05136066|Experimental|Group massaged with peppermint oil|Group of experimental
88872214|NCT04988412|Active Comparator|CoMSM LD|Participants will receive investigational product 1 containing collagen (5 g/ 25 mL), MSM (1.5 g/ 25 mL) and vitamin C (80 mg/ 25 mL).
88872215|NCT04988412|Placebo Comparator|Placebo group|Placebo group participants will receive placebo syrup without active ingredients. (daily dose 10 mL: fish collagen: 0 mg, vitamin C: 0 mg); continous administration of placebo product for 12 weeks.
88872216|NCT04988412|Active Comparator|Co HD|Participants will receive investigational product 2 containing collagen (10 g/ 25 mL) and vitamin C (80 mg/ 25 mL).
89395675|NCT03751553|No Intervention|no intervention group|they will receive the standard care during labor and delivery without the use of the obstetrical gel
89395676|NCT03904108|Experimental|Ramucirumab|Ramucirumab 10 mg/kg IV day 1, every 3 weeks for 4 cycles
88872217|NCT04988412|Active Comparator|CoMSM HD|Participants will receive investigational product 3 containing collagen (10 g/ 25 mL), MSM (1.5 g/ 25 mL) and vitamin C (80 mg/ 25 mL).
88872218|NCT04943874|Other|Technology Based Intervention 1 (Phase 1)|
88872219|NCT04943874|Other|Technology Based Intervention 1 (Phase 2)|
88872220|NCT04943874|Other|Technology Based Intervention 2 (Phase 2)|
88872221|NCT04676802|Experimental|NSAIDS|Following surgery will receive NSAID capsules following surgery. Will take online and phone surveys.
88872222|NCT04676802|Experimental|Opioids|Following surgery will receive opioid capsules following surgery. Will take online and phone surveys.
88872223|NCT04627896|Experimental|Katty focal therapy|Patients fulfilling inclusion criteria undergo focal treatment with Trinity-guided Katty device
88872224|NCT04174482|Experimental|flat foot patients|20 patients recruited consecutively and candidates for surgery to correct the adult flat foot according to the Grice technique.
88872225|NCT03979560|No Intervention|Control|"The control group will benefit from the usual support (depending on the practices of the department, prescription or not of oral nutritional supplements and physiotherapy at home, but without home intervention of adapted physical activity professionals or dieticians).~In addition to screening/inclusion visits (D0), three follow-up home visits are scheduled at D7, D45 and D90 for both study groups."
89003864|NCT04258813|Experimental|Control|40 PCP clinics; 400 patients
89003865|NCT04258813|Experimental|iGuide Intervention|40 PCP clinics; 400 patients
89003866|NCT04251416|Experimental|Sacituzumab Govitecan|Sacituzumab govitecan will be administered at 10 mg/kg weekly as an infusion for 2 consecutive weeks (2 weekly doses plus 1 week without treatment represents a single 3 week cycle). Treatment can be continued without a rest period in the absence of progression of disease or unacceptable toxicity.
89003867|NCT04248127|Experimental|Honey sweetened yogurt|1 tbsp. of honey in 0.6 cup (150g) of plain yogurt. The participants will be asked to consume 2 morning servings of the yogurt for a total of 2 tbsp. of the assigned honey per day.
89395677|NCT03636581|Experimental|Intervention|This group will receive a smart watch to track activity and diet. This group will also receive education on nutrition and exercise.
89395678|NCT03636581|No Intervention|Control|This group will receive a smart watch to track activity only with no intervention.
89395679|NCT04976309|Experimental|Placebo + saline|Placebo, 0.9% normal saline, single dose intravenous infusion over 30 minutes
89395680|NCT04976309|Experimental|Placebo + VIP and PACAP|Placebo, 0.9% normal saline, single dose intravenous infusion over 30 minutes
89395681|NCT04976309|Experimental|Lu AG09222 + VIP and PACAP|Lu AG09222, single dose intravenous infusion over 30 minutes
89395682|NCT05392348|Placebo Comparator|Normal Control group|Subjects with maltodextrin as intervention，5g/kg·bw/day.
89395683|NCT05392348|Experimental|Stachyose intervention group|Subjects with stachyose as intervention，5g/kg·bw/day.
89395684|NCT03137524|Experimental|Hand Held Fan Therapy|
89395685|NCT03137524|No Intervention|No Intervention|
89395686|NCT02833350|Experimental|Cohort 1: GDC-0853 High Dose + Adalimumab Placebo|Participants of Cohort 1 will receive GDC-0853 high dose, orally once daily along with placebo matched to adalimumab, subcutaneously every 2 weeks (Q2W) starting on Day 1 for 12 weeks. Participants will remain on a stable background therapy of MTX 15-25 milligrams per week (mg/week) (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.
89395687|NCT02833350|Experimental|Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo|Participants of Cohort 1 will receive GDC-0853 low dose, orally once daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants will remain on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.
89395688|NCT02833350|Experimental|Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo|Participants of Cohort 1 will receive GDC-0853 mid dose, orally twice daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants will remain on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.
88872226|NCT03979560|Experimental|Nutrition intervention with appropriate physical activity|"Intervention at home of professionals:~Patients in this arm will benefit from 14 home interventions~7 home nutrition support (NS) sessions in 3 months or 1 session every 10 days (+/-4 days). These sessions will be conducted by a dietician from the company Saveurs et Vie.~7 home sessions of adaptive physical activity (APA) in 3 months, one session every 10 days (+/-4 days). These sessions will be conducted by professionals from association group Siel Bleu.~In addition to screening/inclusion visits (D0), three follow-up home visits are scheduled at D7, D45 and D90 for both study groups."
89395689|NCT02833350|Active Comparator|Cohort 1: GDC-0853 Placebo + Adalimumab|Participants of Cohort 1 will receive placebo matched to GDC-0853, orally once daily along with adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants will remain on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.
89395690|NCT02833350|Placebo Comparator|Cohort 1: GDC-0853 Placebo + Adalimumab Placebo|Participants of Cohort 1 will receive placebo matched to GDC-0853, orally once daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants will remain on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.
89535474|NCT03120091||Enrolled Patients|A total of 20 patients were enrolled for the place of CGMS. Arterial blood glucose (ABG) were recorded every four hours. The duration of monitoring set was 5 days.CGMS were compared with ABG at the same time point. A total of 600 pairs of glucose level were collected
88872227|NCT03828708|Experimental|Standard iron arm|Participants randomized to this arm will consume infant formula containing 12 mg/L of iron, equivalent to the standard iron content in U.S. infant formula
88872228|NCT03828708|Experimental|Low iron arm|Participants randomized to this arm will consume infant formula containing 5 mg/L of iron, equivalent to the standard iron content in European infant formula
88872229|NCT03671304|Experimental|Just-in-time Adaptive Intervention|Participants will receive a Fitbit Versa and instructions on its use. The study design is not a traditional randomized controlled trial in which participants are randomized to either the intervention or control group. Instead the study utilizes a microrandomized design. This is a within-subjects design in which participants will receive affective framing messages and intention planning prompts on a randomized schedule, such that participants will receive each message type on 50% of days.
88872230|NCT03447990|Other|Part 1/SAD and Part 2/MAD - drug|"Part 1/SAD: Crossover, Single ascending dose of MYK-491/placebo~Part 2/MAD: Parallel, multiple ascending dose of MYK-491/placebo"
88872231|NCT03447990|Other|Part 1/SAD and Part 2/MAD - placebo|"Part 1/SAD: Crossover, Single ascending dose of MYK-491/placebo~Part 2/MAD: Parallel, multiple ascending dose of MYK-491/placebo"
88872232|NCT03032640|Active Comparator|Group 1- Healthy Lean subjects|Group 1 will receive Sodium Saccharin 200mg capsule, 2x/day, Day 1-14
88872233|NCT03032640|Active Comparator|Group 2- Healthy Lean subjects|Group 2 will receive Placebo 500mg capsule, 2x/day, Day 1-14
88872234|NCT03032640|Active Comparator|Group 3- Healthy Lean subjects|Group 3 will receive Sodium Saccharin 200mg + lactisole 335mg capsule, 2x/day, Day 1-14
88872235|NCT03032640|Active Comparator|Group 4- Healthy Lean subjects|Group 4 will receive Lactisole 335mg capsule, 2x/day, Day 1-14
89395691|NCT02833350|Experimental|Cohort 2: GDC-0853 High Dose|Participants of Cohort 2 will receive GDC-0853 high dose, orally twice daily for 12 weeks. Participants will remain on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.
89395692|NCT02833350|Placebo Comparator|Cohort 2: GDC-0853 Placebo|Participants of Cohort 2 will receive placebo matched to GDC-0853, orally twice daily for 12 weeks. Participants will remain on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.
89395693|NCT03137602|Other|ATOMIC mobile app|The proposed ATOMIC intervention consists of four primary components: (a) one-on-one chats with a PA coach, (b) informational posts, (c) PA self-monitoring through an activity tracker and (d) educational modules regarding different aspects of becoming PA delivered through our MS specific PA app.
89395694|NCT03137212|Experimental|A group|STEMI patients first are given thrombolysis and then transfer to PCI center to be treated by PCI 3-6 hours after thrombolysis if the thrombolysis is successful. if the thrombolysis is not successful, patients will be treated by PCI immediately.
89395695|NCT03137212|Experimental|B group|STEMI patients first are given thrombolysis and then transfer to PCI center to be treated by PCI 6-24 hours after thrombolysis if the thrombolysis is successful. if the thrombolysis is not successful, patients will be treated by PCI immediately.
89395696|NCT03137134|Active Comparator|Treatment A|(reference) Crizotinib cMS 300 mg in fasted state
89395697|NCT03137134|Experimental|Treatment B|(test) Crizotinib cMS 300 mg in fed state
89395698|NCT03137134|Experimental|Treatment C|(test) 5 days of esomeprazole 40 mg followed by crizotinib cMS 300 mg in fasted state
89395699|NCT03137134|Experimental|Treatment D|(test) 5 days of esomeprazole 40 mg followed by crizotinib cMS 300 mg with apple sauce.
89395700|NCT03137134|Experimental|Treatment E|(test) 5 days of esomeprazole 40 mg followed by crizotinib cMS 300 mg with orange juice
89395701|NCT03137368|Experimental|treatment group|Exemestane Tablets combined with ovarian function suppression/ablation
89395702|NCT03137368|Active Comparator|control group|Tamoxifen Tablets combined with ovarian function suppression/ablation
89395703|NCT05391958|Sham Comparator|Normal Real group|the medication group was given according to the actual weight of normal weight patients
88810803|NCT05560971|Placebo Comparator|Placebo|The placebo is a medium chain fatty acid in triglyceride form. The placebo has no shown health effects, neither beneficial or detrimental. Participants will be asked to consume 2 placebo capsules daily twice a day for 8 weeks.
88810804|NCT05551754|Active Comparator|ketone supplement|Subjects will drink single dose of ketone supplement 25g
88810805|NCT05551754|Placebo Comparator|Placebo beverage|Subjects will drink single dose of placebo beverage that will look and taste the same as ketone supplement.
88810806|NCT05548075||Fibromyalgia Cohort|*As diagnosed by an appropriate medical professional according to the American College of Rheumatology(ACR) diagnostic criteria
88810807|NCT05547178||Eurythmy Therapy (performed as part of the ENTAiER main study)|
88810808|NCT05547178||Tai Chi (performed as part of the ENTAiER main study)|
88810809|NCT05547178||Standard Care|
88810810|NCT05542550|Active Comparator|Voice Rest|48 hours of voice rest prescribed following injection
88810811|NCT05542550|Experimental|No voice rest|No voice rest required following injection
88810812|NCT05538650|Experimental|Mindfulness-based Social Work and Self-care (MBSWSC)|Participants in the experimental group will participate in the 6 session Mindfulness Based Social Work and Self Care (MBSWSC) programme. MBSWSC is facilitated by two accredited mindfulness practitioners, who are also qualified social workers. Sessions will be supported/supplemented with brief homework activities to help embed mindfulness practice.
88810813|NCT05538650|Active Comparator|Mindfulness and Self-care (MBSC)|Participants in the active comparator group will participated in the 3 session Mindfulness and Self-care (MBSC) programme. MBSC is facilitated by two accredited mindfulness practitioners, who are also qualified social workers. Sessions will be supported/supplemented with brief homework activities to help embed mindfulness practice.
88810814|NCT05536076|Active Comparator|Intervention hypercapnia arm|Intermittent hypercapnia treatment five days per week for two weeks.
88810815|NCT05536076|Experimental|SCD|Intermittent hypercapnia treatment five days per week for two weeks.
88810816|NCT05536076|Experimental|Able-Bodoed|Intermittent hypercapnia treatment five days per week for two weeks.
88810817|NCT05534243|Active Comparator|Before group|Mechanically ventilated emergency department patients receiving standard neuromuscular blockers prior to an educational initiative on the importance of ED-based targeted shorter acting neuromuscular blocker.
88810818|NCT05534243|Experimental|After group|Mechanically ventilated emergency department patients receiving neuromuscular blockers after an educational initiative aimed at improving use of shorter acting neuromuscular blocker practices in the ED.
88872236|NCT01376778|Active Comparator|CMV hyperimmune globulin - Cytogam®|Infusion of Cytogam®, Cytomegalovirus Immune Globulin Intravenous (Human) (CMV-IGIV)
88872237|NCT01376778|Placebo Comparator|Placebo|IV 5% albumin diluted 1 to 9 with 5% Dextrose in water (D5W)
88872238|NCT01309074|Experimental|Pregabalin|Pregabalin is an antiepileptic medication which has been found in double blind placebo controlled trials to be effective and safe in the treatment of primary generalized anxiety disorder. It has an indication for the treatment of this condition in Europe & Canada but not in the US.
88872239|NCT01309074|Active Comparator|Sertraline|Sertraline is an SSRI found to be an effective treatment of generalized anxiety disorder in controlled trials. It does not have an indication for this in this country.
88872240|NCT01074294|Experimental|Phase A (Single-blind Prospective Treatment Phase): Placebo + Stimulant|Participants received single-blind matching-placebo tablets along with open-label stimulant determined by the investigator, once daily for 5 weeks. Once assigned to a stimulant by the investigator, participants remained on the same stimulant for the duration of the trial. Participants who met eligibility criteria i.e., who received prior treatment for adult ADHD and treatment-naïve participants were included in this arm group. Participants with incomplete response at the end of Phase A (Week 5) entered Phase B and rest of the participants continued to Phase A+.
88872241|NCT01074294|Experimental|Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant|Participants with incomplete response (with a > 0% and < 30% reduction in ADHD Symptoms Total Score {18 items} between the baseline of Phase A and the end of prospective treatment { Week 5} as measured by the CAARS-O:SV { Conners' Adult ADHD Rating Scale-Observer: Screening Version}, and a CAARS-O:SV ADHD Symptoms Total Score {18 items} of ≥ 24 at Week 5, and a clinical global impression - improvement scale (CGI-I) score of 3 or 4 at Week 5) at the end of Phase A (Week 5), received Brexpiprazole 2 milligram (mg) tablet along with stimulant determined by the investigator, once daily for 6 weeks (up to Week 11).
88872242|NCT01074294|Placebo Comparator|Phase B (Double-blind Randomization Phase): Placebo + Stimulant|Participants with incomplete response (with a > 0% and < 30% reduction in ADHD Symptoms Total Score {18 items} between the Baseline of Phase A and the end of prospective treatment { Week 5} as measured by the CAARS-O:SV, and a CAARS-O:SV ADHD Symptoms Total Score {18 items} of ≥ 24 at Week 5, and a CGI-I score of 3 or 4 at Week 5) at the end of Phase A (Week 5), received matching-placebo tablets along with stimulant determined by the investigator, once daily for 6 weeks (up to Week 11).
88872243|NCT01074294|Experimental|Phase A+ (Single-blind Phase A Responders and Non-responders): Placebo + Stimulant|Participants with response (with a ≥ 30% reduction in ADHD Symptoms Total Score {18 items} between Baseline of Phase A and the end of prospective treatment { Week 5} as measured by the CAARS-O:SV, or a CAARS-O:SV ADHD Symptoms Total Score {18 items} of < 24 at Week 5, or a CGI-I score of < 3 at Week 5) and non-response (with deterioration or no change in ADHD symptoms at Week 5) at the end of Phase A (Week 5), received single-blind matching-placebo tablets along with open-label stimulant determined by the investigator, once daily for an additional 6 weeks (up to Week 11).
88872244|NCT01074138|Experimental|Treatment|Subjects will be enrolled into a 28-day dose-escalation study. If no DLT's are observed during the first 28 days, subjects are eligible to continue treatment in the Extension Phase and can remain on treatment until toxicity occurs or until disease progression.
88872245|NCT00951132|Experimental|2|Rosuvastatin
88872246|NCT00951132|Placebo Comparator|1|Placebo
88872247|NCT01710306|No Intervention|Outreach|To evaluate and test differences in VA mental health care engagement for those who screen positive for PTSD by randomly assigned route: existing OEF/OIF/OND outreach. VA mental health care engagement is defined as participation in any of the following: PTSD psychotherapy, cognitive processing therapy, or prolonged exposure therapy.
88872248|NCT01710306|Experimental|Nurse Care Manager (NCM)|To evaluate and test differences in VA mental health care engagement for those who screen positive for PTSD by randomly assigned route: Study concierge nurse case manager (NCM). VA mental health care engagement is defined as participation in any of the following: PTSD psychotherapy, cognitive processing therapy, or prolonged exposure therapy.
88872249|NCT01713660|Other|FS Corneal Incisions|
88872250|NCT01715064|No Intervention|Control|non-exercise control consisting of movie watching.
88872251|NCT01715064|Experimental|Exercise|1 hour of moderate intensity exercise.
88872252|NCT01716468|Other|Advanced or metastatic cancer|Patients chosen must be diagnosed with advanced or metastatic cancer of the following tumor types (colorectal, prostate, brain, breast, pancreatic, hepatobiliary, melanoma, sarcoma, non-small cell /small cell lung, genitourinary cancers).All participants will be assigned to a ketogenic diet. There are no randomization to other separate arms since this is a safety and feasibility study.
88872253|NCT01717014|Experimental|Covidien Radial Reload Stapler with Tri-Staple Technology|Covidien Radial Reload Stapler with Tri-Staple Technology in open low anterior resection or anterior proctosigmoidectomy
88872254|NCT01717872|Active Comparator|Macintosh laryngoscope blade|A photo of the larynx will be taken with the Macintosh laryngoscope blade lifting and not lifting the epiglottis. The view of the larynx will be assessed using the Percent of Glottic Opening (POGO) score by a blinded assessor.
88872255|NCT01717872|Active Comparator|Miller laryngoscope blade|A photo of the larynx will be taken with the Miller laryngoscope blade lifting and not lifting the epiglottis. The view of the larynx will be assessed using the percent of glottic opening score by a blinded assessor.
88872256|NCT01718028|Experimental|SYSTANE® BALANCE|Propylene glycol 0.6% ocular emulsion, 1 drop in each eye 4 times a day for 30 days
88872257|NCT01718028|Active Comparator|LARMABAK®|Sodium chloride 0.9% saline solution, 1 drop in each eye 4 times a day for 30 days
88872258|NCT01719900|Experimental|Pulse Fibre|The intervention group will receive a biscuit containing 5g/serving of yellow pea fibre to be eaten 3 times per day approximately 30 minutes prior to their 3 largest meals.
89395704|NCT05391958|Active Comparator|Normal Lean group|For normal weight patients, the medication group was given according to the lean body mass
88872259|NCT01719900|Placebo Comparator|Control|The placebo group will receive a biscuit an isocaloric control biscuit that is similar in taste and texture and without pulse fibre to be eaten 3 times per day approximately 30 minutes prior to their 3 largest meals.
89003868|NCT04248127|Placebo Comparator|Sugar sweetened yogurt|Sugar will be added to 0.6 cup (150g) of plain yogurt in an isocaloric amount compared to the honey. The participants will be asked to consume 2 morning servings of the yogurt per day.
88872260|NCT01721226|Sham Comparator|Control Arm|Participants in the Control Arm will receive standard discharge services according to the standards of care for that facility. In addition, participants in this arm will view an educational video on opiate overdose prevention. Study participants in the Control Arm will be followed after release/study enrollment, just like participants in the Intervention Arm, and Plasma Viral Loads will be collected from them at baseline and follow-up.
88872261|NCT01721226|Experimental|CARE tool and cell phone/text messaging|The Intervention Arm will complete the CARE tool device, a technology based HIV-counseling tool, and will receive text message reminders about HIV medical appointments and the importance of taking HIV medications. Study participants in this arm will be followed after release/study enrollment, just like participants in the Control Arm, and Plasma Viral Loads will be collected from them at baseline and follow-up.
88872262|NCT01721460|Experimental|Dexmedetomidine during MER|The study is performed in patients undergoing DBS electrode implantation to their STN for the treatment of parkinson's disease. Microelectrode recording (MER) is performed as part of STN electrode implantation surgery, to increase the precision of the stimulating electrode placement. The study includes administration of dexmedetomidine while recording electrical activity at a single location to evaluate the effects of this drug on the MER.
88872263|NCT01722318|Active Comparator|Plecanatide 0.3mg|Plecanatide 0.3mg, one tablet by mouth daily for 12 weeks
88872264|NCT01722318|Active Comparator|Plecanatide 1.0mg|Plecanatide 1.0mg one tablet by mouth daily for 12 weeks
88872265|NCT01722318|Active Comparator|Plecanatide 3.0mg|Plecanatide 3.0mg, one tablet by mouth daily for 12 weeks
88872266|NCT01722318|Active Comparator|Plecanatide 9.0mg|Plecanatide 9.0mg, one tablet by mouth daily for 12 weeks
88872267|NCT01722318|Placebo Comparator|Placebo|Placebo, one tablet by mouth daily for 12 weeks
88872268|NCT01722552|Experimental|adherence feedback|Intervention subjects will receive personalized cell phone reminder messages whenever they fail to take a dose within 30 minutes of dose time (as indicated by lack of a Wisepill opening). They will then participate in monthly interactive counseling sessions using summaries of their previous month's behavior. Patients whose mean adherence in the previous month was <95% will be required to have a counseling session, while those with higher adherence will be given the option to have a counseling session.
88872269|NCT01722552|Active Comparator|standard of care|Control subjects will use the electronic monitoring devices just like the intervention arm, but will receive standard of care. They will not receive personalized cell phone reminder messages whenever they fail to take a dose within 30 minutes of dose time, and they will not have access to the summaries of their previous month's behavior for use in interactive counseling sessions, though they will be encouraged to engage in counseling.
88872270|NCT01723722|Active Comparator|1 (Phenobarbital and Methadone)|"The following is a dosing guide for methadone:~The neonatal concentration is 1 mg/ml of methadone. It is administered orally every 12 hours.~For the first 24 hours, doses will be prescribed every 6 hours using a sliding scale in response to the last NAS score:~NAS Score Methadone dose 8-11 0.05 mg/kg/dose 12-15 0.1 mg/kg/dose~≥16 0.15 mg/kg/dose~Maximum dose of methadone will be 0.15 mg/kg/dose.~After the first 24 hours of treatment, the total methadone dose will be summed and that dose divided into two doses, given 12 hours apart. For the following 24 hours, additional doses may be given every 6 hours as needed and added to the next 24 hour's doses divided every 12 hours, until NAS scores are consistently <8 for 48 hours.~If at any pointthe maximum dose of methadone is reached and withdrawal is not controlled, then in the opinion of two neonatologists the patient can be crossed-over to the dDTO arm."
88872271|NCT01723722|Active Comparator|2 (Phenobarbital and Diluted Deodorized Tincture of Opium)|"The following is a dosing guide for dDTO:~The neonatal concentration is 1:24 dilution for a concentration of 0.4%, equivalent to 0.4 mg/ml of morphine. It is administered orally every 4 hours.~The starting dose will be determined using a sliding scale in response to the last NAS score before starting.~NAS Score Starting dDTO dose 8-11 0.4 mg/kg/day 12-15 0.6 mg/kg/day~≥16 0.8 mg/kg/day~The maximum dose of DTO will be 0.8 mg/kg/day.~After the first 24 hours of treatment, if the NAS scores are still ≥8, the dose will be increased to the next level.~If at any point the maximum dose of methadone is reached and withdrawal is not controlled, then in the opinion of two neonatologists the patient can be crossed-over to the methadone arm."
88872272|NCT01725984||AdVance|Subjects previously implanted with the AdVance Male Sling
88872273|NCT01725984||AdVance XP|Subjects previously implanted with the AdVance XP male sling
88872274|NCT01728636|Experimental|Tranexamic Acid|Tranexamic acid 10mg/kg loading dose given pre-incision and 1mg/kg/hr infusion throughout intraoperative period
88872275|NCT01728636|Placebo Comparator|Placebo|Normal saline placebo loading dose 0.5ml/kg and infusion at 0.5ml/kg/hr throughout operative course
88872276|NCT01729338|Experimental|Velcade, cyclophosphamide, Revlimid|"INDUCTION (28-day cycles for 8 cycles):~VELCADE 1.3 mg/m2 subcutaneously (SC) days 1, 8 and 15~Cyclophosphamide 300 mg/m2 orally (PO) days 1, 8 and 15~Dexamethasone 40 mg PO days 1,8 and 15~MAINTENANCE (28-day alternating cycles until stopped for toxicity, relapse or death):~Odd cycles (9, 11, 13, etc.) lenalidomide 10 mg PO days 1-21~Even cycles (10, 12, 14, etc.) VELCADE 1.3 mg/m2 SC days 1, 15"
88872277|NCT01729494|Experimental|Group A|Alemtuzumab + belatacept + mycophenolate mofetil /Enteric coated mycophenolate sodium + early cessation of steroids
88872278|NCT01729494|Experimental|Group B|Rabbit antithymocyte globulin + belatacept + mycophenolate mofetil /Enteric coated (EC) mycophenolate sodium + early cessation of steroids
88872279|NCT01729494|Active Comparator|Group C|Rabbit antithymocyte globulin + tacrolimus + mycophenolate mofetil /Enteric coated (EC) mycophenolate sodium + early cessation of steroids
88872280|NCT05317338|Experimental|Intervention group|Participants randomized to this group will be enrolled to a multicomponent training for 5-7 consecutive days and will continue to receive usual hospital care. The training program consists of strength, balance and gait exercises performed within the hospital.
89395705|NCT05391958|Sham Comparator|Obese Real group|the medication group was given according to the actual weight of obese weight patients
88872281|NCT05317338|No Intervention|Control group|Participants randomized to the control group will receive only the usual hospital care and rehabilitation, without performing multicomponent exercises.
88872282|NCT05317260||Chronic hepatitis B patients without hepatic steatosis|Patients with chronic hepatitis B will be defined as the non-steatosis group if they had histological evidence of visible lipid droplets in hepatocytes less than 5%.
88872283|NCT05317260||Chronic hepatitis B with steatosis but no steatohepatitis|Patients with chronic hepatitis B will be categorized as the steatosis but not steatohepatitis group if they had histological evidence of visible lipid droplets in hepatocytes more than 5% in the absence of steatohepatitis feature.
88872284|NCT05317260||Chronic hepatitis B patients with steatohepatitis|Patients with chronic hepatitis B will be classified as the steatohepatitis group if they had histological evidence of steatosis, hepatocyte ballooning, mixed lobular acute and chronic inflammation, and intra-acinar perisinusoidal fibrosis according to Brunt's classification.
88872285|NCT05316870|Experimental|Intervention group|The standardized anticoagulation management program of atrial fibrillation in primary medical institutions was implemented for the patients with atrial fibrillation in the intervention group.
88872286|NCT05316870|Other|Control group|The current general practitioner management mode was continued for the patients with atrial fibrillation in the control group.
88872287|NCT05316792|Active Comparator|knee osteoarthritis|In patients with knee osteoarthritis, the thickness of the femoral articular cartilage will be measured with portable USG before and immediately after walking.
88872288|NCT05316792|Active Comparator|healthy volunteers|Femoral articular cartilage thickness will be measured with portable USG before and immediately after walking in healthy volunteers.
88872289|NCT05316636|Experimental|Group A|Vibrational forces from onset of treatment, from weeks 0-6; then, no vibrational forces during the rest of the treatment
88872290|NCT05316636|Experimental|Group B|From weeks 0-6, no vibrational forces. Vibrational forces starting at 6 weeks after treatment onset and applied for 6 weeks until week 12
88872291|NCT05316636|Active Comparator|Group C|Control, no vibrational forces
88872292|NCT05316480|Experimental|Nimotuzumab|nimotuzumab 200mg/week
88872293|NCT05316402|Experimental|training on the risks associated with sun exposure|power point on the risks associated with sun exposure
88872294|NCT05316246|Experimental|CD30-positive Relapsed/Refractory NK/T-cell Lymphoma|Brentuximab vedotin will be administered as 1.8 mg/kg IV infusion on Day 1 of each 3-week cycle. PD-1 inhibitor tislelizumab will be administered as 200 mg on Day 1 of each 3-week cycle. Patients will receive maximum of 8 cycles if they do not meet the criteria for removal from the study. Patients will be assessed for overall response using the Revised Response Criteria for Malignant Lymphoma (Lugano 2014). Dedicated computed tomography (CT) scans (neck, chest, abdomen, and pelvis) will be performed at Baseline and at Cycles 2, 4 and 8, and positron emission tomography (PET) scans will be performed at Baseline and at Cycles 4 and 8.
88872295|NCT05316090|Experimental|study group|Children in study group treated using core stability exercises program in addition to traditional program
88872296|NCT05316090|Active Comparator|control group|Children in the control group treated using traditional physical therapy program.
88872297|NCT05315856||ChAdOx1 vaccine group|AstraZeneca vaccine (chimpanzee adenovirus-vectored vaccine, 0.5 mL [5 × 1010 viral particles] per dose)
88872298|NCT05315856||BNT162b2 vaccine group|Pfizer-BioNTech vaccine (mRNA vaccine; 0.3 mL [30 μg] per dose)
88872299|NCT05315778|Experimental|Anti-BCMA CAR T-cells infusion|R/R ITP patients will accept infusion of autologous anti-BCMA CAR T-cells with a total of 1.0-2.0×10e7/Kg. The patients will be follow-up for 6 months post CAR T-cell therapy.
88872300|NCT05315466|Experimental|Non-surgical treatment|Different types of non-surgical treatments
88872301|NCT05315466|Experimental|Surgical treatment|Surgical treatment for spinal stenosis
88872302|NCT05315388|No Intervention|Group 1. Regular therapy group|Group without intervention during the study period no changes will be made in their daily routine. They will receive a weekly intervention operationalized for psychosocial risk.
88872303|NCT05315388|Experimental|Group 2A: Vitamin N therapy group - metropolitan park environment|Group with periodic outings to a neighborhood or metropolitan natural park (once a week) for approximately 2 hours for a minimum period of six months.
88872304|NCT05315388|Experimental|Group 2B: Vitamin N therapy group - forest forest environment|Group with periodic outings to a forest environment (once a week) for a time of approximately 2 hours for a minimum period of six months
88872305|NCT05315154|Experimental|No axillary surgery|
88872306|NCT05315154|Active Comparator|Sentinel lymph node biopsy|
88872307|NCT05309850|Experimental|Usage of tool|Participants get access to the tool and use it regularly
88872308|NCT05309850|No Intervention|Controls on usual care|Participants who get randomized to control cannot access the tool. Development of cardiovascular disease or type 2 diabetes is followed via clinical registries.
88872309|NCT05237232||Patients|Newborns, infants and children hospitalized in pediatric intensive care unit (PICU) at Trousseau Hospital, having been treated with jugulocarotid ECMO and weaned alive off ECMO.
89395706|NCT05391958|Experimental|Obese Lean group|the medication group was given according to the lean body mass of obese weight patients
89395707|NCT05391802|Experimental|Treatment group|Patients with PMR erolled in the trail will receive transcatheter mitral valve repair using the ValveClasp system
89395708|NCT03138616|Experimental|vitamin D intervention group(NGR)|"normal glucose regulation group according to the oral glucose tolerance test (OGTT) around 42 days postpartum.~took 1600 units of vitamin D daily for nine months and meanwhile receive lifestyle intervention."
89395709|NCT03138616|No Intervention|control group(NGR)|"normal glucose regulation group according to the oral glucose tolerance test (OGTT) around 42 days postpartum.~only receive lifestyle intervention."
89395710|NCT03138616|Experimental|vitamin D intervention group(IGR)|"impaired glucose regulation group according to the oral glucose tolerance test (OGTT) around 42 days postpartum.~took 1600 units of vitamin D daily for nine months and meanwhile receive lifestyle intervention."
89395711|NCT03138616|No Intervention|control group(IGR)|"impaired glucose regulation group according to the oral glucose tolerance test (OGTT) around 42 days postpartum.~only receive lifestyle intervention."
89395712|NCT03137290|Active Comparator|Neostigmine|1 mg of Atropine (1ml) was mixed with 2.5mg of Neostigmine (1ml) and diluted into 10mls with Normal Saline 0.9% in a 10ml standard syringe.
89395713|NCT03137290|Experimental|Sugammadex sodium|100mg Sugammadex (1ml) is diluted into 10mls in a standard 10mls syringe with Normal Saline 0.9%.
88872310|NCT05237232||Controls|Newborns treated for hypoxic-ischemic encephalopathy in the PICU of Trousseau Hospital.
88872311|NCT05202366||Treatment group|Only one treatment group (CGB-400 Topical Gel) will be used for analysis
88872312|NCT05009706|Experimental|Self Care group|Patients who are randomized to the intervention Self Care group will get advice and support on physical excercise, nutrition and symptom management to perform at home for 12 weeks. Once a week, patients will come to the hospital for follow-up and to exercise with a physiotherapist.
88872313|NCT05009706|No Intervention|Control group|Patients who are randomized to the Control group will receive ordinary health care (from an outpatient clinic), but will also be encouraged to follow recommendation of 150 minutes/week of moderate physical activity (12 weeks). To compensate for the extra attention received by the intervention group by the advice/support, the patients in the control group will be dialed with a nurse at 3, 6 and 9 weeks to discuss their current activity.
88872314|NCT04894188|Experimental|Neoadjuvant RT and ADT|"Intensity modulated radiation therapy (IMRT), with 50 Gy in 25 daily fractions (2 Gy/fraction, 5 fractions weekly) for 5 weeks (week 1 - week 5).~Gosereline 3.6mg sc injection at week 1, week 5, and week 9"
88872315|NCT04894188|Active Comparator|Neoadjuvant ADT|Gosereline 3.6mg sc injection at week 1, week 5, and week 9
88872316|NCT04866420||Poststroke fatigue|Participants who are experiencing fatigue post stroke.
88872317|NCT04775628|Experimental|inferior glide|Inferior glide of the right humerus till no motion is visual on the imaging
88872318|NCT04769544|Active Comparator|Medial pivot group|Device used: medial pivot total knee arthroplasty design
88872319|NCT04769544|Active Comparator|Conventional group|Device used: conventional total knee arthroplasty design
89395714|NCT03782818|Experimental|Olaparib|After a 4-week pre-treatment phase to ensure that patients are on stable doses of PAH medication, patients will be given progressive doses of olaparib up to 300 mg BID for 24 weeks.
89395715|NCT05391724|Experimental|CMX001|single dose of CMX001 administered at 2 mg/kg of ideal body weight rounded to the closest 20 mg
88872320|NCT04767750||HCC patients|Measure lncRNA H19 and IGF-1R mRNA gene expression levels in the collected blood samples.
88872321|NCT04767750||T2DM patients|Measure lncRNA H19 and IGF-1R mRNA gene expression levels in the collected blood samples.
88872322|NCT04767750||HCC & T2DM patients|Measure lncRNA H19 and IGF-1R mRNA gene expression levels in the collected blood samples.
88872323|NCT04767750||Controls|Measure lncRNA H19 and IGF-1R mRNA gene expression levels in the collected blood samples.
88872324|NCT04724772|Experimental|Blepharoplasty patient|Patient receives LA in one eye and LA with TXA in the other eye. They are blinded. They compare eyes without knowing which one received the TXA.
88872325|NCT04717518||Lower Anchor Survey|Patients will likely rate their pain lower.
88872326|NCT04717518||Higher Anchor Survey|Patients will likely rate their pain higher.
88872327|NCT04696614|Experimental|aerobic exercise to aerobic exercise|first 8-week: aerobic exercise second 8-week: aerobic exercise
89395716|NCT03137446|No Intervention|Usual Care|Participants randomized to the usual care resuscitation strategy will receive an initial 30 ml/kg bolus and then IV fluids as needed and without limit as well as IV vasopressors to maintain a MAP>65, determined by the primary care team for the duration of the study.
89395717|NCT03137446|Experimental|Restrictive Care|Participants randomized to the restrictive fluid resuscitation strategy will be LIMITED to 60 ml/kg (up to 6000 ml) of IV fluids as initial resuscitation followed by administration of IV vasopressors to maintain a MAP>65 mm Hg for the first 72 hours of care. The intervention is defined as capping the total allowed IVF administered. After 72 hours the participants are eligible for IV fluids as determined by the primary care team.
88872328|NCT04696614|Experimental|aerobic exercise to interval training|first 8-week: aerobic exercise second 8-week: interval training
88872329|NCT04696614|Experimental|aerobic exercise to aerobic exercise +resistance exercise|first 8-week: aerobic exercise second 8-week: aerobic exercise +resistance exercise
88872330|NCT04696614|Experimental|interval training to interval training|first 8-week: interval training second 8-week: interval training
88872331|NCT04696614|Experimental|interval training to aerobic exercise|first 8-week: interval training second 8-week: aerobic exercise
88872332|NCT04696614|Experimental|interval training to aerobic exercise+resistance exercise|first 8-week: interval training second 8-week: aerobic exercise +resistance exercise
88872333|NCT04379076|Experimental|CYT107|Intra-muscular administration of CYT107 twice a week for a total of 5 administrations
88872334|NCT04379076|Placebo Comparator|Saline|Intramuscular (IM) administration of saline at the same volume and same time for a total of 5 administrations
88872335|NCT04320498|Active Comparator|control group|The control patients self-administered topical glyceryl trinitrate, in the perianal area twice a day (Anrecta, Consentis Pharmaceuticals, Istanbul, Turkey)
89395718|NCT03676738||In-patient spine surgery|Scheduled for an in-patient, elective spine surgery where subject will receive general anesthesia
89395719|NCT03676738||Non-surgical spine care|Presenting to spine clinic and undergoing conservative, non-surgical management of spine disorder
89395720|NCT03641248|Experimental|Enteric coated Devil's Claw|H. procumbens 100 mg in enteric coated capsules
89395721|NCT03641248|Active Comparator|Non-enteric coated Devil's Claw|H. procumbens 100 mg in non-enteric coated capsules
89395722|NCT05391490|Experimental|Single Arm Trial|Treatment with Lymphodepletion followed by a dose of KCAT19 T cells.
89395723|NCT03355534|Experimental|nasal dexmedetomidine|dexmedetomidine is given nasally, saline is given intravenously
89395724|NCT03355534|Experimental|intravenous dexmedetomidine|saline is given nasally, dexmedetomidine is given intravenously
89395725|NCT03355534|Placebo Comparator|normal saline|saline is given nasally and intravenously
89395726|NCT05341284||Exposed group|The subject who is receiving first or second dose of the AS04 adjuvanted HPV 16/18 vaccine at the enrollment.
89395727|NCT05341284||Non-exposed group|The subject who does not have any HPV vaccination history at the enrollment or during the study period.
89395728|NCT05385640||CPSP group|Patients who developed chronic pain 3 months after surgery
89395729|NCT05385640||UN-CPSP group|Patients who did not develop chronic pain 3 months after surgery
89395730|NCT05385562|Active Comparator|Formulated Posterior Sub Tenon Triamcinolone|
89395731|NCT05385562|Active Comparator|Posterior Sub Tenon Triamcinolone alone|
89395732|NCT01343043|Experimental|Cohort 1 treated with NY-ESO-1 T Cells|High NY-ESO-1 expression and the use of cyclophosphamide plus fludarabine as the lymphodepleting chemotherapy.
89395733|NCT01343043|Experimental|Cohort 2 treated with NY-ESO-1 T Cells|Low NY-ESO-1 expression and the use of cyclophosphamide plus fludarabine as the lymphodepleting chemotherapy.
89395734|NCT01343043|Experimental|Cohort 3 treated with NY-ESO-1 T Cells|High NYESO-1 expression and the use of cyclophosphamide only for lymphodepletion rather than fludarabine as the lymphodepleting chemotherapy.
89395735|NCT01343043|Experimental|Cohort 4 treated with NY-ESO-1 T Cells|High NY-ESO-1 expression and the use of reduced dose cyclophosphamide plus fludarabine regimen as the lymphodepleting chemotherapy.
89395736|NCT03139708|Experimental|Alphagan plus|Alphagan plus group is one drop Brimonidine then, Tropicamide and Phenylephrine ophthalmic one drop,times one.
89395737|NCT03139708|Experimental|Tropicamide and Phenylephrine plus|Tropicamide and Phenylephrine plus intervention is one drop of each then Brimonidine one drop, times one.
89395738|NCT03139708|Active Comparator|Tropicamide and Phenylephrine only|Tropicamide and Phenylephrine only arm is given one drop of each times one.
89395739|NCT03548987|Experimental|Semaglutide|"Run-in Period: Participants will receive semaglutide at an escalating doses (0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg) for 20 weeks (week 0 to week 20). The dose will be escalated to next level every 4 weeks.~Maintenance period: Participants will be randomized to receive semaglutide injection for 48 weeks (from week 20 to week 68).~The trial product will be administered as an adjunct to a reduced-calorie diet and increased physical activity during the trial period."
89395740|NCT03548987|Placebo Comparator|Placebo|"Run-in Period: Participants will receive semaglutide at an escalating doses (0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg) for 20 weeks (week 0 to week 20). The dose will be escalated to next level every 4 weeks.~Maintenance period: Participants will be randomized to receive semaglutide placebo injection for 48 weeks (from week 20 to week 68).~The trial product will be administered as an adjunct to a reduced-calorie diet and increased physical activity during the trial period."
89395741|NCT01358760|Placebo Comparator|Placebo|
89395742|NCT01358760|Experimental|0.25% DHEA|
89395743|NCT01358760|Experimental|0.5% DHEA|
89395744|NCT03139942|Experimental|Imaging using OPTIC probe|Single arm study to test the feasibility of a new device - the OPTIC imaging probe. All participants enrolled in the study may be imaged using optical spectral reflectance and autofluorescence imaging during their endoscopy procedure.
89395745|NCT05692557|Experimental|Virtual reality distraction and chest physiotherapy|"Virtual reality distraction: The Oculus Rift's Fujii - Mystical Journey was a game played by the Virtual reality distraction group on a tablet. The game is a peaceful, ethereal voyage that passes through several surreal, natural locations. The game combines elements of adventure, agriculture and revitalizing music. It alternates between outdoor exploration and inventive gardening. Players explore three different magical biomes. The life force in each biome is restored by interacting with the plants and animals there. Before beginning the chest physical therapy, the patients had 15 minutes to play this computer game"
89395746|NCT05692557|Active Comparator|Progressive relaxation exercise and chest physiotherapy|Progressive muscle relaxation: The patients of the control group performed the Progressive muscle relaxation technique, a relaxation technique used to control pain. It is believed that anxiety-inducing thoughts result in muscle tension and hence muscle relaxation can reduce anxiety. The relaxation technique consisted of tensing and relaxing different muscles, starting from the toes and finally involving muscles of the head and neck. It was recommended that this be done in a peaceful, distraction-free environment. The muscle groups were tensed for a period of 5 seconds and then relaxed for 30 seconds, the process was repeated for a period of 15 minutes
89395747|NCT03137056|Active Comparator|Hemodialysis with Theranova|This arm is represented by the period during which the patients will undergo dialysis with the Theranova membrane.
89395748|NCT03137056|Active Comparator|Hemodialysis with FX1000|This arm is represented by the period during which the patients will undergo dialysis with the FX1000 membrane.
89395749|NCT03137056|Active Comparator|Hemodiafiltration with FX1000|This arm is represented by the period during which the patients will undergo dialysis with the FX1000 membrane.
89395750|NCT04432701|Active Comparator|group A|children were extubated in a light plane of anesthesia, when they are still asleep or have swallowing reflex.
89395751|NCT04432701|No Intervention|group B|Tracheal extubation was performed when the patient regained consciousness, facial grimace, spontaneous eye opening, and purposeful arm movement.
89395752|NCT05330364|Experimental|Chidamide plus Cladribine|Chidamide 30mg/d per os (p.o.), twice per week, begins at day 1; Cladribine 5mg/m2/d, intravenous injection (i.v.), days 1-5, once per day; A cycle is during 28 days.
89535475|NCT03318653||HD - Hemodialysis|Patients with end stage renal disease treated with hemodialysis
89395753|NCT05087602|Experimental|Toripalimab plus Anlotinib capsules|Toripalimab 240 mg IV on Day 1 of each 14-day cycle plus Anlotinib capsules given 10mg orally in fasting conditions , once daily in 21-day cycles (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
89395754|NCT05087368|Experimental|Stage 1 - Formulation-finding for SCB-2019 - Group 1|"In Stage 1, immunogenicity and safety of three SCB-2019 formulations will be assessed in comparison with the ChAdOx1-S vaccine, in individuals who received two doses of ChAdOx1-S, 6 months (± 4 weeks) prior to recruitment.~Participants (N=120) will be assigned to five groups for Stage 1 and receive doses as follows:~Group 1: (N=30) Day 1: SCB-2019 (9 μg) alum;"
89395755|NCT05087368|Experimental|Stage 1 - Formulation-finding for SCB-2019 - Group 2|"In Stage 1, immunogenicity and safety of three SCB-2019 formulations will be assessed in comparison with the ChAdOx1-S vaccine, in individuals who received two doses of ChAdOx1-S, 6 months (± 4 weeks) prior to recruitment.~Participants (N=120) will be assigned to five groups for Stage 1 and receive doses as follows:~Group 2: (N=30) Day 1: SCB-2019 (9 μg) CpG 1018/alum;"
89395756|NCT05087368|Experimental|Stage 1 - Formulation-finding for SCB-2019 - Group 3|"In Stage 1, immunogenicity and safety of three SCB-2019 formulations will be assessed in comparison with the ChAdOx1-S vaccine, in individuals who received two doses of ChAdOx1-S, 6 months (± 4 weeks) prior to recruitment.~Participants (N=120) will be assigned to five groups for Stage 1 and receive doses as follows:~Group 3: (N=30) Day 1: SCB-2019 (30 μg) CpG 1018/alum;"
89395757|NCT05087368|Experimental|Stage 1 - Formulation-finding for SCB-2019 - Group 4|"In Stage 1, immunogenicity and safety of three SCB-2019 formulations will be assessed in comparison with the ChAdOx1-S vaccine, in individuals who received two doses of ChAdOx1-S, 6 months (± 4 weeks) prior to recruitment.~Participants (N=120) will be assigned to five groups for Stage 1 and receive doses as follows:~Group 4: (N=30) Day 1: ChAdOx1-S;"
89395758|NCT05087368|Experimental|Stage 2 - Homologous vs. Heterologous Booster Regimen - Group 5|"For Stage 2, immunogenicity of heterologous booster vaccination schedule (ChAdOx1-S (Group 5-7) - selected formulation of SCB-2019 or CoronaVac and CoronaVac (Group 8-10) - selected formulation of SCB-2019 or ChAdOx1) vs. a 2-dose ChAdOx1-S or CoronaVac series will be assessed.~Participants (N=400) will be randomly (2:1:1) distributed into 6 groups for Stage 2 and receive doses as follows:~Group 5: (N=100) Day 1 (boost) -SCB-2019;"
89395759|NCT05087368|Experimental|Stage 2 - Homologous vs. Heterologous Booster Regimen - Group 6|"For Stage 2, immunogenicity of heterologous booster vaccination schedule (ChAdOx1-S (Group 5-7) - selected formulation of SCB-2019 or CoronaVac and CoronaVac (Group 8-10) - selected formulation of SCB-2019 or ChAdOx1) vs. a 2-dose ChAdOx1-S or CoronaVac series will be assessed.~Participants (N=400) will be randomly (2:1:1) distributed into 6 groups for Stage 2 and receive doses as follows:~Group 6: (N=50) Day 1 (boost) -ChAdOx1-S;"
89395760|NCT05087368|Experimental|Stage 2 - Homologous vs. Heterologous Booster Regimen - Group 7|"For Stage 2, immunogenicity of heterologous booster vaccination schedule (ChAdOx1-S (Group 5-7) - selected formulation of SCB-2019 or CoronaVac and CoronaVac (Group 8-10) - selected formulation of SCB-2019 or ChAdOx1) vs. a 2-dose ChAdOx1-S or CoronaVac series will be assessed.~Participants (N=400) will be randomly (2:1:1) distributed into 6 groups for Stage 2 and receive doses as follows:~Group 7: (N=50) Day 1 (boost) -CoronaVac;"
89395761|NCT05087368|Experimental|Stage 2 - Homologous vs. Heterologous Booster Regimen - Group 8|"For Stage 2, immunogenicity of heterologous booster vaccination schedule (ChAdOx1-S (Group 5-7) - selected formulation of SCB-2019 or CoronaVac and CoronaVac (Group 8-10) - selected formulation of SCB-2019 or ChAdOx1) vs. a 2-dose ChAdOx1-S or CoronaVac series will be assessed.~Participants (N=400) will be randomly (2:1:1) distributed into 6 groups for Stage 2 and receive doses as follows:~Group 8: (N=100) Day 1 (boost) -SCB-2019;"
89395762|NCT05087368|Experimental|Stage 2 - Homologous vs. Heterologous Booster Regimen - Group 9|"For Stage 2, immunogenicity of heterologous booster vaccination schedule (ChAdOx1-S (Group 5-7) - selected formulation of SCB-2019 or CoronaVac and CoronaVac (Group 8-10) - selected formulation of SCB-2019 or ChAdOx1) vs. a 2-dose ChAdOx1-S or CoronaVac series will be assessed.~Participants (N=400) will be randomly (2:1:1) distributed into 6 groups for Stage 2 and receive doses as follows:~Group 9: (N=50) Day 1 (boost) - ChAdOx1-S;"
89395763|NCT05087368|Experimental|Stage 2 - Homologous vs. Heterologous Booster Regimen - Group 10|"For Stage 2, immunogenicity of heterologous booster vaccination schedule (ChAdOx1-S (Group 5-7) - selected formulation of SCB-2019 or CoronaVac and CoronaVac (Group 8-10) - selected formulation of SCB-2019 or ChAdOx1) vs. a 2-dose ChAdOx1-S or CoronaVac series will be assessed.~Participants (N=400) will be randomly (2:1:1) distributed into 6 groups for Stage 2 and receive doses as follows:~Group 10: (N=50) Day 1 (boost) - CoronaVac."
89395764|NCT01341990|Experimental|FID 114675A|Multi-purpose disinfecting solution used per protocol-specified instructions for cleaning, rinsing, disinfecting/storing, and reinserting study contact lenses
89395765|NCT01341990|Active Comparator|ReNu MultiPlus|Multi-purpose solution used per protocol-specified instructions for cleaning, rinsing, disinfecting/storing, and reinserting study contact lenses
89395766|NCT05087134|Experimental|11C-Choline PET/CT for Lymphangioleiomyomatosis (LAM)|The patients were injected with 11C-Choline of 5-10mCi and underwent PET/CT scan 20~40min after the injection.
89395767|NCT03487367||Early stage subjects|This cohort is defined by individuals with a total SARA score of less than or equal to 9.5
89395768|NCT03487367||Premanifest mutation carriers|This cohort is defined by the presence of positive genetic diagnosis but no signs of ataxia and total SARA score of less than or equal to 2.5
89395769|NCT03487367||50%-at-risk subjects|This cohort is defined by individuals who are at risk for SCA1 or SCA3 because they have a family member who tested positive for SCA1 or SCA3. Total SARA score is less than or equal to 2.5
89395770|NCT03487367||Previously diagnosed early stage|This cohort is defined by individuals who were included in prior CRC-SCA, EUROSCA, ESMI or SPATAX studies who had a total SARA score of less than or equal to 10 in 2009-2012
89395771|NCT03048747|Experimental|Tolvaptan|Tolvaptan tablets at 7.5, 15, 30 (one tablet each), or 60 mg (two 30 mg tablets) will be orally administered once daily after breakfast for up to 30 days.
89395772|NCT05086822|Experimental|Treatment group A|Treatment group : Irinotecan liposome
89395773|NCT05354128|Experimental|Thrombolysis Group|Patients who meet the conditions for intravenous thrombolysis are included in the intravenous thrombolysis group. Regardless of whether the thrombolysis is successful or not, CAG examination is performed afterwards to clarify the vascular condition, and PCI is performed if necessary.
89395774|NCT05354128|Other|PCI Group|Eligible patients undergoing primary PCI.
89395775|NCT03670277|Experimental|TEST arm|For subjects enrolled in the Test arm, the Test Soft Contact Lens will be bilaterally fitted to the subject's eyes. Endpoint measures will be collected over one eye only - Test Arm: OD only.
89395776|NCT03670277|Experimental|CONTROL arm|Subjects enrolled in the Control Arm will be established orthokeratology lens wearers. Endpoint measures will be collected over one eye only - Control Arm: Better OK fitted eyes based on investigator's judgement.
89395777|NCT05230186||On-Treatment Solid Tumor Responder (Tumor Biopsy)|Research tumor tissue biopsy collected at any one time point while responding to ICI therapy (radiographic regression of lesion). Tumor biopsy and companion blood sample.
89395778|NCT05230186||Pre and On-Treatment Solid Tumor Responder (Tumor Biopsy)|Tumor tissue collection prior to beginning ICI therapy (optional biopsy). If and when there is a response to ICI therapy, a second research tumor tissue biopsy is collected. Tumor biopsy and companion blood sample.
89395779|NCT05230186||On-Treatment Solid Tumor Responder (Surgical Removal Tumor)|Collection of excess tumor tissue in patients who are responding to ICI therapy and are scheduled for Surgical resection of residual disease. Excess tissue provided.
89395780|NCT05230186||Post-Treatment of patients with Melanoma who develop vitiligo|Up to 5 patients treated for melanoma that develop vitiligo - Skin Tissue Biopsy obtained at any point in time from any skin site with vitiligo (selected sites only). Tissue biopsy
89395781|NCT05230186||On-Treatment Responder (Previously Frozen Tumor Tissue)|Previously Cryopreserved Tissue obtained from a Biobank or Tissue Repository, collected from patients when they were responding to ICI Therapy (clinical data required).
88872336|NCT04320498|Experimental|PRP group|PRP was injected locally in the anal fissure area and glyceryl trinitrate was administered twice daily in the perianal region as in the control group.
88872337|NCT04270500|Active Comparator|Prehabilitation program|The preoperative period (prehabilitation) represents a more appropriate time than the postoperative period to implement an intervention. Prehabilitation is a process of enhancing an individual's functional capacity before the scheduled surgery, aimed at improving the patient's tolerance to upcoming physiologic stress, by three principal elements: exercise training, nutritional intervention, and psychological support.
88872338|NCT04270500|No Intervention|Standard of care (SOC)|Common to both groups as part of the enhanced recovery after surgery (ERAS) protocol as the standard of care in our institution.
88872339|NCT04187742|Active Comparator|LTC Physicians Receive Social Comparison Email|All LTC physicians who receive a social comparison email
88872340|NCT04187742|No Intervention|LTC Physicians Do Not Receive Social Comparison Email|All LTC physicians who do not receive a social comparison email
88872341|NCT04187742|Active Comparator|LTC Physicians Receive Maintenance Certification Email|All LTC physicians who receive a maintenance certification email
88872342|NCT04187742|No Intervention|LTC Physicians Do Not Receive Maintenance Certification Email|All LTC physicians who do not receive a maintenance certification email
88872343|NCT04187742|Active Comparator|LTC Physician Has (or has not) Opened Prior Report|LTC physicians who opened (or has not opened) at least one report receive an email informing them of their report opening status
88872344|NCT04187742|No Intervention|LTC Physician Has (or has not) Opened Prior Report (Control)|LTC physicians who opened (or has not opened) at least one report receive a standard email without report opening status
88872345|NCT04086732|Experimental|Temporomandibular disorder|
88872346|NCT04086732|Experimental|Healthy control|
88872347|NCT03878472|Experimental|Neoadjuvant immunotherapy with PD-1|
88872348|NCT03878472|Experimental|Neoadjuvant immunotherapy with PD-1+apatinib|
88872349|NCT03878472|Experimental|Neoadjuvant immunotherapy with PD-1+apatinib+S1|
89535476|NCT03318653||PD - Peritoneal dialysis|Patients with end stage renal disease treated with peritoneal dialysis
88872350|NCT03878472|Experimental|Neoadjuvant immunotherapy with PD-1+apatinib+S1+Oxaliplatin|
88872351|NCT03772626|Experimental|Heated humidified high-flow|Heated Humidified High-flow Nasal Cannula
88872352|NCT03721926|Experimental|Geriatric Oncology Collaborative Care|Patients receive three visits with a trained study nurse. At each visit, the study nurse will assess the patient's symptom burden, functional status, comorbid conditions, psychosocial issues, and medication use. The nurses can refer patients to specialists as needed. The study nurses will meet with a supervising support team, consisting of clinicians from geriatrics, palliative care, social work, and pharmacy to discuss each patient and review documentation. Following the team meetings, the nurses will document recommendations in the medical record and communicate with the primary oncology team, either in person or via phone, as appropriate. The study nurses will contact the supervising team in between meetings for any urgent issues or questions that arise.
88872353|NCT03721926|Active Comparator|Usual Care|Participants assigned to receive usual oncology care will not meet with the study nurses, though they may receive geriatric or palliative care consults at their request or at the discretion of their treating oncologist.
88872354|NCT03681912||Implementation Block 1|Competency: 12-Item Motivational Interviewing (MI) Coach Rating Scale (CRS) performed monthly but reported quarterly, starting at 3 months.
88872355|NCT03681912||Implementation Block 2|Competency: 12-Item Motivational Interviewing (MI) Coach Rating Scale (CRS) performed monthly but reported quarterly, starting at 6 months.
88872356|NCT03681912||Implementation Block 3|Competency: 12-Item Motivational Interviewing (MI) Coach Rating Scale (CRS) performed monthly but reported quarterly, starting at 9 months.
88872357|NCT03681912||Implementation Block 4|Competency: 12-Item Motivational Interviewing (MI) Coach Rating Scale (CRS) performed monthly but reported quarterly, starting at 12 months.
88872358|NCT03681912||Implementation Block 5|Competency: 12-Item Motivational Interviewing (MI) Coach Rating Scale (CRS) performed monthly but reported quarterly, starting at 15 months.
88872359|NCT03681912||Sustainment Block 1 Facilitated CoP|Randomized Guided Development of COPs with an internal facilitator after one year of implementation.
88872360|NCT03681912||Sustainment Block 2 Facilitated CoP|Randomized Guided Development of COPs with an internal facilitator after one year of implementation.
88872361|NCT03681912||Sustainment Block 3 Facilitated CoP|Randomized Guided Development of COPs with an internal facilitator after one year of implementation.
88872362|NCT03681912||Sustainment Block 4 Facilitated CoP|Randomized Guided Development of COPs with an internal facilitator after one year of implementation.
88872363|NCT03681912||Sustainment Block 5 Facilitated CoP|Randomized Guided Development of CoPs with an internal facilitator after one year of implementation.
88872364|NCT03681912||Sustainment Block 1 CoP Alone|After one year of implementation, site is randomized to receive CoP development without internal facilitation.
88872365|NCT03681912||Sustainment Block 2 CoP Alone|After one year of implementation, site is randomized to receive CoP development without internal facilitation.
88872366|NCT03681912||Sustainment Block 3 CoP Alone|After one year of implementation, site is randomized to receive CoP development without internal facilitation.
88872367|NCT03681912||Sustainment Block 4 CoP Alone|After one year of implementation, site is randomized to receive CoP development without internal facilitation.
88872368|NCT03681912||Sustainment Block 5 CoP Along|After one year of implementation, site is randomized to receive CoP development without internal facilitation.
88872369|NCT03485820|Experimental|COMPASS|COMPASS is a complex intervention that combines 2 evidence-based treatment strategies at a new point of care (transition from inpatient rehabilitation). The objective of home visits by an occupational therapy (OT) practitioner is to remediate barriers in the home and community that influence daily activities and community participation. The treatment will include a set of 1 predischarge and four 75-minute postdischarge visits. The intervention is followed by 2 booster sessions.
88872370|NCT03485820|Sham Comparator|Education program|"An OT practitioner will deliver the program in accordance with Evidence-Based Educational Guidelines for Stroke Survivors after Discharge Home. Topic order is determined by participants. Four 75-minute sessions will be provided. Topics may include stroke symptoms, risk factors and preventing stroke recurrence, nutrition, managing emotions, sleep, pain. Written materials from the National Stroke Association and the American Stroke Association are provided."
88872371|NCT03404076||GIST patients under TKI treatment|GIST patients under TKI treatment are subjected to Dual Energy CT
88872372|NCT03245580|Other|Arm 1 -modified wet suction|Intervention:Procedure Core Liver Biopsy Technique: Modified Wet Suction
88872373|NCT03245580|Other|Arm 2- Slow Pull|Intervention: Procedure Core Liver Biopsy Technique: Slow Pull
89395782|NCT04954469|Experimental|CoVAC-1 Vaccine|Peptide vaccination should be started as soon as possible after the screening visit. Or in case of two vaccinations: Peptide vaccination should be started as soon as possible after the screening visit (V1) and on day 42 (V5)
88872374|NCT03162510|Experimental|SOLAR|Albumin-Bound Paclitaxel /nab-Paclitaxel (Abraxane®) 150 mg/m2 IVD 30 min followed by Oxaliplatin 60~ 85 mg/m2 IVD 2hr at D1, plus Tegafur,oral S-1 35mg/m2 and Folinic acid/LV 30mg twice daily from D1 to D7, every 14 days as a cycle till disease progression
88872375|NCT03049644|Active Comparator|Mechanical Diagnosis and Therapy|Mechanical diagnosis refers to the classification based on examination of posture and range of motion of the spine, associated with the assessment of subjective symptomatic responses.
88872376|NCT03049644|Active Comparator|Manual Therapy|Manual therapy (MT) is a broad term encompassing many techniques which attempt to affect possible pain contributors such as joints, tendons, ligaments, and muscles, typically using the therapist's hands but may also utilize a tool or instrument in the case of some soft tissue mobilization therapies as well as low force instrument assisted spinal manipulation therapy.
88872377|NCT02996760|Experimental|Endometrium with less than 5mm|"Women receiving cycle of oocytes outside or embryos (own / others), in the treatment of substituted cycle type.~Less than 5mm despite 10 days with standard doses of estrogen"
88872378|NCT02996760|No Intervention|Endometrium with more than 5mm|"Women receiving cycle of oocytes outside or embryos (own / others), in the treatment of substituted cycle type.~More than 5mm despite 10 days with standard doses of estrogen"
88872379|NCT02987946|Active Comparator|Fraxiparine|Intervention: All patients receive Fraxiparine 2850 IE daily, starting preoperatively compatible with current practice. After randomization the patients in this arm will be subjected to fraxipareine 2850 IE daily. According to current guidelines in the LUMC the Fraxiparine dose is doubled to 5600 IE in patients with a weight above 100 kg.
88872380|NCT02987946|Experimental|IPD|Intervention: IPD Device: After randomization the patients in this arm will be subjected to fraxiparine 2850 IE daily and intermittent pressure devices for at least 48 hours or until mobilization. The intermittent pressure device is a leg pump delivered by Converis(R).
88872381|NCT02733900|Experimental|Osteonecrosis group|Patients with an aseptic osteonecrosis of the femoral head
88872382|NCT02733900|Other|Control group|Patients with coxarthrosis
88872383|NCT02718300|Experimental|Part 1: Ruxolitinib + Parsaclisib|Initial cohort dose of parsaclisib added to existing stable regimen of ruxolitinib, with subsequent cohort escalations based on protocol-specific criteria.
88872384|NCT02718300|Experimental|Part 2: Ruxolitinib + Parsaclisib|Part 2 will compare 2 doses of parsaclisib .
88872385|NCT02718300|Experimental|Part 3: Ruxolitinib + Parsaclisib|Part 3 will compare 2 different long term dosing strategies.
88872386|NCT02718300|Experimental|Part 4: Ruxolitinib + Parsaclisib|Part 4 will compare 2 different daily dosing strategies.
88872387|NCT02542644|Other|Patients with Fuchs endothelial dystrophy scheduled for DMEK|
88872388|NCT02394132|Experimental|Imiquimod|"Topical imiquimod 5% cream~application to treatment area for 5 days/week for a total of 12 weeks~dispensed at baseline visit along with patient diary"
88872389|NCT02394132|Experimental|Radiotherapy|"Radiotherapy~treatment regimen determined by treating radiation oncologist and as per standard practice at local institution~treatment to commence within 8 weeks of randomisation"
88872390|NCT02102880|Other|Healthy Subjects|
88872391|NCT01894542|Experimental|Cod protein from presscake|
88872392|NCT01894542|Experimental|Cod protein from presscake + stickwater|
88872393|NCT01894542|Placebo Comparator|Control|Control group will receive tablet containing only tablet fillers (the same as in the cod protein tablets).
88872394|NCT00700596|Active Comparator|1|Salvinorin A (SA)
88872395|NCT00700596|Placebo Comparator|2|Control or Placebo SA
89187615|NCT02579564|Active Comparator|chemotherapy with cisplatin|Systemic chemotherapy with standard schemes without cisplatin, such as Gemcitabine, Vinorelbine, Paclitaxel or Pemetrexed. Thoracic cavity perfusion of cisplatin 30mg/m2 each time, twice a week for four times.
89187616|NCT00467779|Experimental|Stage 1: Cobimetinib Dose Escalation (21/7 Schedule)|Participants will receive cobimetinib (GDC-0973/XL518) at the starting dose of 0.05 mg/kg via solution or capsule, once daily for Days 1-21 of each 28-day cycle (21 days on drug followed by 7 days off treatment [21/7 schedule]). Treatment will continue until progressive disease (PD) or unacceptable toxicity for up to 1 year at the discretion of investigator and beyond 1 year with the agreement of the sponsor.
89187617|NCT00467779|Experimental|Stage 1A: Cobimetinib Dose Escalation (14/14 Schedule)|Participants will receive cobimetinib at the starting dose of 60 mg via solution or capsule, once daily for Days 1-14 of each 28-day cycle (14 days on drug followed by 14 days off treatment [14/14 schedule]). Treatment will continue until progressive disease (PD) or unacceptable toxicity for up to 1 year at the discretion of investigator and beyond 1 year with the agreement of the sponsor.
89187618|NCT00467779|Experimental|Stage 2: Cobimetinib Expansion (21/7 Schedule)|Participants will receive cobimetinib at the maximum tolerated dose (MTD) established in Stage 1, once daily for Days 1-21 of each 28-day cycle (21 days on drug followed by 7 days off treatment [21/7 schedule]). Treatment will continue until progressive disease (PD) or unacceptable toxicity for up to 1 year at the discretion of investigator and beyond 1 year with the agreement of the sponsor.
89187619|NCT00467779|Experimental|Stage 2 A: Cobimetinib Expansion (14/14 Schedule)|Participants will receive cobimetinib at the MTD established in Stage 1A, once daily for Days 1-14 of each 28-day cycle (14 days on drug followed by 14 days off treatment [14/14 schedule]). Treatment will continue until progressive disease (PD) or unacceptable toxicity for up to 1 year at the discretion of investigator and beyond 1 year with the agreement of the sponsor.
88872396|NCT01733472|Placebo Comparator|RA-arm|RA-arm: the patients in this arm will receive intrathecal anaesthesia consisting of bupivacaine 15 mg
88872397|NCT01733472|Experimental|GA-arm, remifentanil|GA-arm: patients in this arm will receive general anaesthesia consisting of Target Controlled Infusion (TCI) of remifentanil and propofol
88872398|NCT01733628||Bevacizumab + Chemotherapy|Patients who received the addition of Bevacizumab (BV) every 2-3 weeks to Chemotherapy (CT) with either oxaliplatin or irinotecan plus fluoropyrimidines in patients with Metastatic Colorectal Cancer (MCRC), either paclitaxel or capecitabine in patients with Metastatic Breast Cancer (MBC), as first-line therapy.
88872399|NCT01736358|Experimental|Intranasal Ketoralac|A single dose of Sprix (31.5 mg) will be administered to patients 20 minutes before the end of surgery. 15.75 mg of Sprix will be sprayed in each nostril.
88872400|NCT01736358|Placebo Comparator|Placebo|A single dose of placebo will be administered 20 minutes before the end of surgery. 15.75 mg of the placebo will be sprayed in each nostril.
88872401|NCT01737684|Experimental|Participants With Moderate Hepatic Insufficiency|Participants with moderate hepatic insufficiency will receive a single oral dose of vibegron 100 mg.
88872402|NCT01737684|Experimental|Healthy Matched Control Participants|Participants who are healthy will receive a single oral dose of vibegron 100 mg.
88872403|NCT01737684|Experimental|Participants With Mild Hepatic Insufficiency|Participants with mild hepatic insufficiency will receive a single oral dose of vibegron 100 mg.
88872404|NCT01740258|Experimental|Bevaczimab, Radiation Therapy, Temozolomide|"In Part A, newly-diagnosed patients with Grade 4 malignant gliomas will receive standard radiation therapy, daily Temodar 75mg/M for 6-8 weeks. Bevacizumab will be given concurrently with radiation therapy and Temodar, 10 mg/kg every two weeks.~If they are stable at the end of Part A, they will continue to Part B. In Part B patients will receive up to 12 cycles of bevacizumab and Temodar. Bevacizumab will be given on Days 1 and 15 of a 28-day cycle. Temodar will be 200 mg/meter squared daily for 5 days (days 1-5) of each cycle.~If they have not progressed, patients will start Part C. In Part C, patients will receive bevacizumab 10mg/kg approximately every 2 weeks or 15 mg/kg approximately every 3 weeks.~If patients progress during Part B or C, they will start Part D. In Part D, patients will receive bevacizumab-based therapy containing bevacizumab in combination with a chemotherapy and/or biologic agent, as determined by the Duke treating physician."
88872405|NCT01740414|Active Comparator|MN-166 (formerly AV411) First|Participants who began 14-day maintenance on MN-166 (50 mg) first, before switching to Placebo maintenance.
88872406|NCT01740414|Placebo Comparator|Placebo First|Participants who began 14-day maintenance on Placebo first, before switching to MN-166 (50 mg) maintenance.
88872407|NCT01740726|Experimental|Behavioral Activation|
88872408|NCT01740726|Active Comparator|Fluoxetine|
88872409|NCT01741350|Experimental|CHRP Group|Patients assigned to Community-friendly Health Recovery Program (CHRP) will receive a weekly HIV risk reduction group level intervention led by two facilitators trained and supervised by the PI, a licensed clinical psychologist. The CHRP intervention is a substantially shortened version of the comprehensive Holistic Health Recovery Program (HHRP)-based interventions that have been identified as demonstrating evidence of effectiveness in two randomized clinical trials. The CHRP, which includes four 50-minute groups (1 group per week), will contain only content that relates explicitly to drug- or sex-related HIV risk reduction. Participants in both conditions will receive routine clinical services (i.e., daily methadone and case management).
88872410|NCT01741350|Active Comparator|Control Condition|The time-and-attention-matched control condition for the proposed research will be a time and contact-matched, non-contaminating support group for individuals in recovery modeled after similar groups offered in the community. There will be no overlap between the content of the comparison intervention and experimental intervention although the basic structure will be the same. Thus, each participant will be asked to attend four 50-minute weekly group sessions led by two trained facilitators. Participants in both conditions will receive routine clinical services (i.e., daily methadone and case management).
88872411|NCT01741272|Active Comparator|Group A (Usual Care)|Will be immobilized in a sling for 6 weeks. Intervention: Procedure: Sling
88872412|NCT01741272|Experimental|Group B (Early ROM)|Will use the sling for comfort only. Intervention: Procedure: No sling
88872413|NCT01742208|Experimental|Sotagliflozin 400 mg - Pioneer Group|Sotagliflozin 400 milligram (mg) (two 200 mg tablets), once daily, orally, before breakfast for 29 days; open label administration.
89395783|NCT04051827|Experimental|Part A: Midazolam + TAK-788|Midazolam 3 mg, solution, orally, once on Days 1 and 24 and midazolam 1 mg, infusion, intravenously, once on Days 2 and 25 along with TAK-788 160 mg, capsule, orally, once daily from Day 3 through 30 in Cycle 1.
89395784|NCT04051827|Experimental|Part B: TAK-788|TAK-788 160 mg, capsules, orally, once daily in a 28-day treatment cycle from Cycle 2 to Cycle 24, or until progressive disease (PD), intolerable toxicity, or another discontinuation criterion is met, whichever is sooner. Eligible participants from Part A may enter into Part B. Based on the investigator's opinion, if a participant continues to experience clinical benefit, treatment with TAK-788 may be continued after PD.
89395785|NCT05346874|Experimental|SOX-TACiE|Preoperative transcatheter arterial chemoinfusion and embolism alternated with intra-venus chemotherapy.
89395786|NCT03263195||Women with HIV only|Pregnant women with HIV infection only
89395787|NCT03263195||Women with ZIKV only|Pregnant women with ZIKV infection only
89395788|NCT03263195||Women with HIV and ZIKV|Pregnant women with HIV and ZIKV infection
89395789|NCT03263195||Women without HIV or ZIKV|Pregnant women without HIV or ZIKV infection
89395790|NCT03263195||Infants of women with HIV only|Infants of women with HIV infection during pregnancy
89395791|NCT03263195||Infants of women with ZIKV only|Infants of women with ZIKV infection during pregnancy
89395792|NCT03263195||Infants of women with HIV and ZIKV|Infants of women with HIV and ZIKV infection during pregnancy
89395793|NCT03263195||Infants of women without HIV or ZIKV|Infants of women without HIV or ZIKV infection during pregnancy
89395794|NCT03136588|Experimental|ICT based monitoring group|Intervention: In the ICT-based centralized monitoring group, both subjects and medical staff receive feedbacks regarding a missed dose, misuse, and overuse of the medication in the form of text messages and pill box alarms.
89395795|NCT03136588|No Intervention|Control group|Use standard questionnaire to gather information for drug adherence
89395796|NCT01374347||One dose, Repeat doses|First group recives one dose Second group receives several doses
89395797|NCT01374347||One dose, several doses|15 patients will take one dose of 20 mg cialis, and will have a second brain SPECT 24 hours after cialis administration. 15 other patients (age and risk factor matched) will be prescribed 5 mg of cialis once daily for 7 days, and a second SPECT study will be performed 24 hours after the last dose.
89395798|NCT02123823|Active Comparator|Everolimus 10mg + Exemestane 25mg|Phase II - Daily everolimus oral administration 10mg + daily exemestane 25 mg orally
89395799|NCT02123823|Experimental|BI836845 + Everolimus + Exemestane|Phase II - BI 836845 recommended dose will be administered intravenously once every week, in addition to daily everolimus (oral administration at recommended dose) + daily exemestane 25 mg orally
88872414|NCT01742208|Placebo Comparator|Placebo - Expansion Group|Two placebo-matching sotagliflozin tablets, once daily, orally, before breakfast for 29 days; double-blind administration.
89395800|NCT02123823|Experimental|PhI - BI836845 + Everolimus + Exemestane|Phase I - Dose escalation (24-48 patients) BI 836845 low or high dose, Everolimus 5mg, 7,5mg or 10 mg and Exemestane 25mg
89395801|NCT03380273|No Intervention|pre-intervention|The number of SSI are collected in this phase. Patients with fractures are enrolled and their standard of care treatment is observed.
89395802|NCT03380273|Other|post-intervention|Here the same observations are made as in the first arm, however this is after the hospital staff was thought the prevention measures (all by themselves approved) and enforced to be applied.
89395803|NCT05086666|Experimental|Urothelial Carcinoma with FGFR2/3 Gene Alterations|Evaluate the Efficacy of AZD4547 in Urothelial Carcinoma Patients with FGFR2/3 Gene Alterations
89395804|NCT05086588||Bio Blue 90 Plus|Patients who were underwent Macular Surgery using Bio Blue 90 Plus (Brilliant Blue G Dye; 0.25 g /l concentration in 0.5 ml BD Glass Syringe; Biotech Vision Care Pvt. Ltd., Ahmedabad, India.)
89395805|NCT05086588||ILM Blue|Patients who were underwent Macular Surgery using ILM Blue (Brilliant Blue G Dye; 0.25 g /l concentration in 0.5 ml BD Glass Syringe; D.O.R.C. Dutch Ophthalmic Research Center (International) B.V., Zuidland, The Netherlands)
88872415|NCT01742208|Experimental|Sotagliflozin 400 mg - Expansion Group|Sotagliflozin 400 mg (two 200 mg tablets), once daily, orally, before breakfast for 29 days; double-blind administration.
89395806|NCT05086042||Psoriatic arthritis patients|
89395807|NCT05086042||healthy volunteers|
89530486|NCT03239275|Experimental|Labial biocreative therapy group|"Upper six anterior teeth will be bonded (0.018-inch slot brackets), leveled and aligned until reaching 0.017*0.025 stainless steel archwire.~Right and left bracket head mini-screw (1.6*8 mm) will be inserted under local anaesthetic into the inter-radicular space between upper second premolar and first molar at the level of mucogingival junction. Crimpable hooks (10 mm) will be crimped onto the archwire between the upper lateral incisor and canine. 200 grams retraction force will be applied using NiTi coil springs from the hooks to the minscrew on both sides. Overlay reverse curve 0.016*0.022 NiTi will be inserted posteriorly into the mini-screw and ligated anteriorly to the archwire in the midline."
89395808|NCT03138304|Experimental|Adventure video game|Night Shift is an adventure video game with the transformational goal of teaching physicians key characteristics of patients with non-representative severe injuries - injuries classified by the American College of Surgeons as life-threatening or critical but that do not fit the archetype of injuries typically requiring treatment at a trauma center. Players take on the persona of Andy Jordan, a young emergency physician who moves home after the disappearance of his estranged grandfather (Robert Jordan) and takes up a job in the local Emergency Department (ED). In the preamble, players learn they have two explicit objectives. First, they must diagnose and treat patients who present to their ED. Second they must solve the mystery of Robert's disappearance: was he murdered or has he simply chosen to disappear?
88872416|NCT01742364|Experimental|Bioject Intradermal (ID) Pen|Intradermal administration of BCG vaccine via the Bioject ID Pen.
88872417|NCT01742364|Active Comparator|Needle and syringe|Intradermal administration of BCG vaccine via needle and syringe.
88872418|NCT01744860||"INCa molecular genetics laboratory in-house methods"|"BRAF V600 mutations were analysed using INCa (Institut National du Cancer [French National Cancer Institute]) molecular genetics laboratories using in-house methods"
88872419|NCT01744860||Cobas 4800 Mutation Test|BRAF V600 mutations were analysed using Cobas 4800 mutation test
88872420|NCT01745952|Experimental|figure-of-eight active rTMS coil|rTMS is administered using the figure-of-eight active coil, at 90% of the resting motor threshold over the epileptogenic region, in trains of 500 pulses with a total of 1500 pulses per day, during weekdays on two consecutive weeks.
88872421|NCT01745952|Experimental|round active rTMS coil|rTMS is administered using the round active coil, at 90% of the resting motor threshold over the epileptogenic region, in trains of 500 pulses with a total of 1500 pulses per day, during weekdays on two consecutive weeks.
88872422|NCT01745952|Sham Comparator|sham rTMS coil (figure-of-eight)|rTMS is administered using the figure-of-eight sham coil, over the epileptogenic region, in trains of 500 pulses with a total of 1500 pulses per day, during weekdays on two consecutive weeks.
88872423|NCT01746264|Experimental|Vitamin D3|Vitamin D3 supplementation at 100,000 IU once a month for 3 months
88872424|NCT01746420|Placebo Comparator|Placebo Control|Dose A - sodium acetate buffer (0 mg rhPDGF-BB)
88872425|NCT01746420|Experimental|0.45 mg rhPDGF-BB|Dose B - sodium acetate buffer + 0.45 mg rhPDGF-BB
88872426|NCT01746420|Experimental|0.75 mg rhPDGF-BB|Dose C - sodium acetate buffer + 0.75 mg rhPDGF-BB
88872427|NCT01746420|Experimental|1.5 mg rhPDGF-BB|Dose D - sodium acetate buffer + 1.5 mg rhPDGF-BB
88872428|NCT01746420|Experimental|3.0 mg rhPDGF-BB|Dose E - sodium acetate buffer + 3.0 mg rhPDGF-BB
88872429|NCT01748916|Experimental|Papaya-Carrot-Tomato|Test meals were consumed in the following order: 1. Papaya 2. Carrot 3. Tomato.
88872430|NCT01748916|Experimental|Papaya-Tomato-Carrot|Test meals were consumed in the following order: 1. Papaya 2. Tomato 3. Carrot
88872431|NCT01748916|Experimental|Tomato-Papaya-Carrot|Test meals were consumed in the following order: 1. Tomato 2. Papaya 3. Carrot
88872432|NCT01748916|Experimental|Tomato-Carrot-Papaya|Test meals were consumed in the following order: 1. Tomato 2. Carrot 3. Papaya
88872433|NCT01748916|Experimental|Carrot-Papaya-Tomato|Test meals were consumed in the following order: 1. Carrot 2. Papaya 3. Tomato
88872434|NCT01748916|Experimental|Carrot-Tomato-Papaya|Test meals were consumed in the following order: 1. Carrot 2. Tomato 3. Papaya
88872435|NCT01749930|Experimental|BOL-303259-X|BOL-303259-X ophthalmic solution QD (PM) and vehicle QD (AM) administered for 3 months (Visit 6) into the study eye(s).
88872436|NCT01749930|Active Comparator|Timolol|Timolol maleate ophthalmic solution, 0.5%, administered BID for 3 months (Visit 6) into study eye(s).
88872437|NCT01750086|Active Comparator|Denosumab 60mg subcutaneous injection|Each subject will receive one teriparatide 40-mcg subcutaneous injection at each study visit.
88872438|NCT01750086|Active Comparator|Alendronate 70mg weekly x 8 weeks|Each subject will receive one teriparatide 40-mcg subcutaneous injection at each study visit.
89530487|NCT03239275|Active Comparator|Lingual biocreative therapy group|En masse retraction of the six anterior teeth was accomplished using a lingual retractor bonded on to the lingual surface of the 6 anterior teeth, C-palatal plate fixed near the median palatal suture with 3 micro-screws, and Nickel Titanium (Ni-Ti) closing coil springs to apply a force of 200 g per side (total 400 g) directly from the C-plate to the lingual retractor.
88872439|NCT01750398|Experimental|ADT plus IV testosterone|"Men with castration-resistant prostate cancer will initiate androgen deprivation therapy (ADT) with an LHRH agonist (e.g. goserelin or leuprolide) for a total of 6 months. After this initial lead-in castration phase, patients will receive intermittent intramuscular testosterone cypionate or testosterone enanthate (T) at a dose of 400 mg while continuing on ADT."
88872440|NCT01751022|Experimental|Attain Performa LV Lead (Models 4298, 4398, 4598)|N/A: single arm study, separate analysis for each lead model (total of 3).
88872441|NCT01752426|Experimental|Heavy Water + PCI-32765|Subjects given 50ml 70% 2H2O (Heavy Water) 3 times a day for the first 5 days followed by 60 ml daily for a total of 4 weeks (labeling phase). Subjects given first dose in clinic. Subjects then given individual doses of 2H2O to consume at home; after the 5-day loading period, a 60 ml maintenance dose of 2H2O will be drunk at bedtime. At end of the 4th week, subjects stop drinking 2H2O (washout phase) and be followed from 6-12 weeks until beginning treatment with PCI-32765. PCI-32765 administered with 8 ounces (~240mL) of water at a dose of 420 mg (3 x 140mg capsules) orally once daily and continued daily. Treatment duration is 12 cycles, with each cycle consisting of 28 days.
88872442|NCT01753362|Placebo Comparator|placebo|subcutaneous daily injection
88872443|NCT01753362|Active Comparator|liraglutide|subcutaneous daily injection
88872444|NCT01754688||Jaundice infants|Bilirubin Induced Neurologic Dysfunction II score
88872445|NCT01757964|Experimental|Bacteriotherapy|Study stool recipient's will receive approximately 30 grams of processed donor stool through a tube into their stomach for the transplant.
88872446|NCT01758588|No Intervention|Observation arm|Subjects will be monitored closely for disease progression, however will receive no intervention.
88872447|NCT01758588|Experimental|Peginterferon alfa-2a|Peginterferon alfa-2a will be administered at a dose of 50 micrograms once a week for up to 3 years.
89395809|NCT03138304|Active Comparator|Educational Program|The educational module consists of two separate apps, both commercially available. myATLS includes a review of each chapter of the Advanced Trauma Life Support (ATLS) textbook, a series of videos demonstrating common trauma procedures, and clinical resources including checklists for use at the bedside. Trauma Life Support MCQ Review includes 550 multiple-choice questions with correct answers and explanations. The investigators will ask physicians to review the myATLS app and then complete questions in the Trauma Life Support MCQ Review, spending at least 1 hour on the combined tasks.
89395810|NCT03287687|Active Comparator|Air for insufflation|In this arm of patients, air which is currently used as standard of care will be used for insufflation
89395811|NCT03287687|Experimental|Carbon dioxide gas for insufflation|in this arm of patients, carbon dioxide (CO2) will be used for insufflation during endoscopy
89395812|NCT01991067|Active Comparator|HSCT patients / TBE virus vaccine|Study population: patients who had undergone an allogeneic HSCT 11 to 13 months ago Eligible patients will receive at least two TBE vaccinations (study visit 1 - day 0, study visit 2 -1month after the first vaccination) with a total of two doses of the TBE vaccine FSME-IMMUN®. Whenever possible, the patients will receive complete primary vaccination with a third dose of TBE vaccine (study visit 9 - 9 to 12 months after the first vaccination).
89395813|NCT01991067|Active Comparator|healthy volunteers / TBE virus vaccine|Clinical healthy volunteers will receive at least two TBE vaccinations (study visit 1 - day 0, study visit 2 -1month after the first vaccination) with a total of two doses of the TBE vaccine FSME IMMUN®. Whenever possible, the volunteers will receive complete primary vaccination with a third dose of TBE vaccine FSME IMMUN® (study visit 9 - 12 months after the first vaccination).
89395814|NCT03138148||Severe patient-ventilator asynchrony|Patients in whom the total percentage of time spent in asynchrony is superior to the entire cohort's 75th percentile
89395815|NCT03138148||less severe patient-ventilator asynchrony|Patients in whom the total percentage of time spent in asynchrony is inferior to the entire cohort's 75th percentile
89395816|NCT03285269||Shock Group|Patients presenting with signs and symptoms of shock will undergo the E-RUSH ultrasound protocol and bioreactance before and after a passive leg raise maneuver.
89395817|NCT05085652||hypotensive COVID19 patients|Neuraxial anesthesia-related hypotension was based on a single episode of deﬁned hypotension from the time of local anesthetic injection until 15 min after delivery of the newborn. And hypotension was deﬁned as systolic blood pressure <80% of baseline or <90 mmHg and was treated with an intravenous bolus of ephedrine 5 mg, additional bolus of Ringer Lactates and colloid infusion hydroxyethyl starch solution.
89395818|NCT05085652||non-hypotensive COVID19 patients|from the time of local anesthetic injection until 15 min after delivery of the newborn no hypotension was seen. systolic blood pressure > 80% of baseline or >90 mmHg. no medical treatment needed.
89395819|NCT01940835||Type 1 Diabetes|Subjects will have an upper endoscopy with small bowel biopsies and brushings. Blood will be collected for serum, DNA, and peripheral blood mononuclear cells (PBMC). Stool samples will be collected at baseline for future microbiome and virome studies.
89395820|NCT01940835||Healthy Control Group|Subjects will have an upper endoscopy with small bowel biopsies and brushings. Blood will be collected for serum, DNA, and peripheral blood mononuclear cells (PBMC). Stool samples will be collected at baseline for future microbiome and virome studies.
88872448|NCT01759602|Experimental|C1-esterase inhibitor (Cinryze)|This is a phase 1b open-label, interventional proof-of-concept study in patients with neuromyelitis optica (NMO) in which all subjects will receive 3 daily infusions of 2000 Units of intravenous CINRYZE at the onset of an NMO exacerbation in addition to standard of care high-dose steroids, plus an additional 2 infusions of 1000 Units of intravenous CINRYZE during a second treatment phase with plasma exchange, if necessary.
88872449|NCT01760304|Experimental|Budesonide / Formoterol|This is a crossover study, where every patient will receive in a blinded fashion either Budesonide/Formoterol (Symbicort ® ) or placebo
88872450|NCT01760304|Placebo Comparator|Placebo|This is a crossover study, where every patient will receive in a blinded fashion either Budesonide/Formoterol (Symbicort ® ) or placebo
88872451|NCT01761084|Experimental|Exercise and behaviour change strategies|The exercise program will include strength training, balance training and cardiovascular exercise that is individually tailored to the participants' abilities. The physical therapist will also implement strategies to assist with behaviour change, such as documenting progress in a log, participating in action planning and coping planning, and using techniques in the spirit of motivational interviewing.
88872452|NCT01761084|No Intervention|General health or social discussion|Participants in the control group will receive equal attention, but will not be prescribed exercise, or participate in counselling about exercise. The physical therapist will discuss topics related to general health.
88872453|NCT01762722|Experimental|Desaturation|Human volunteers undergo oxygen desaturation in order to determine the accuracy of the device over a clinical range of oxygen saturations 70 - 100%.
88872454|NCT01763346|Active Comparator|metformin|subjects receiving metformin
88872455|NCT01763346|Experimental|gastric banding|subjects receiving LAP-BAND
88872456|NCT01763970|Experimental|Hypofractionated SBRT|800 cGy delivered in 5 fractions every day to total dose of 4000 cGy
88872457|NCT01765530|Experimental|ETT cleaning manuver|Patients randomized to the treatment group will undergo an ETT cleaning maneuver with endOclear three times a day (every 8 hours) for the whole intubation period in addition to the standard of care.
88872458|NCT01765530|No Intervention|Standard of care|In the protocol no intervention is planned for the control group, which will therefore be treated with blind suctioning as per caregiver clinical decision.
88872459|NCT01766466|Experimental|Cangrelor IV + Ticagrelor 180mg at 0.5 hr|On Day 1: Open-label cangrelor IV bolus (30 µg/kg), followed by an infusion of 4 µg/kg/min for two hours. Ticagrelor (180 mg) was administered at 0.5 h after the initiation of cangrelor infusion.
88872460|NCT01766466|Experimental|Cangrelor IV + Ticagrelor 90mg (7 doses)|"On Day 1: Following completion of cangrelor and ticagrelor dosing, patients were discharged and instructed to take 90 mg ticagrelor every 12 hours for 7 doses (12, 24, 36, 48, 60, 72, and 84 h).~On Day 5: 12 h post last ticagrelor dose (90 mg), patients received another open-label cangrelor IV bolus (30 µg/kg), followed by an infusion of 4 µg/kg/min for two hours."
88872461|NCT01766466|Experimental|Cangrelor IV + Ticagrelor 180mg at 1.5 hr|On Day 1: Open-label cangrelor IV bolus (30 µg/kg), followed by an infusion of 4 µg/kg/min for two hours. Ticagrelor (180 mg) was administered at 1.5 h after the initiation of cangrelor infusion.
89395821|NCT04927715||Diseased|Females with peripartum cardiomyopathy
89395822|NCT04927715||Control|Healthy females
89395823|NCT03089398|Active Comparator|Hybrid Coronary Revascularization Group|HCR is defined, for the purposes of this trial, as a planned off-pump minimally invasive (sternal-sparing), isolated LIMA-LAD revascularization, combined with percutaneous revascularization of at least one non-LAD target.
89395824|NCT03089398|Active Comparator|Percutaneous Coronary Intervention|PCI will be performed using standard techniques at the discretion of the operator. Only Food and Drug Administration (FDA) and Health Canada approved commercially available metallic drug-eluting stents may be used in this protocol.
89395825|NCT02886845||Chinese Breast Cancers|Woman with breast cancer that have been diagnosed in clinic
89395826|NCT02886845||healthy controls|Woman without breast cancer
89395827|NCT01787643|Experimental|Standing desk|Installation of standing desk
89395828|NCT01374503|Experimental|ALX-0651|
89395829|NCT01374503|Placebo Comparator|Placebo|
89395830|NCT05085418|Experimental|Treatment of Immune Nephritis|Administration of CD19/BCMA CAR T-cells A dose levels of 1-4*10E6/kg are administrated for each subject.
89395831|NCT05759195|Other|Biomolecular tumor analysis|NGS, IHC, methylome and other molecular studies
89395832|NCT03466996|Experimental|Intervention group|The intervention group will participate in face-to-face video telemedicine visits, in addition to routine annual visits to the Spina Bifida Clinic. These 30-minute visits will occur at 2 weeks, 3 months, 6 months and 9 months from last in-person clinic appointment. The visits will consist of structured counseling using a plan-do-study-act cycle approach to incrementally adopt elements of a well-planned transition. Using qualitative notes from each session, we will identify common themes or challenges across patients and develop adjunctive education, support, and monitoring tools for patients and families in transition.
88816659|NCT05857982|Experimental|MDD group|Dexamethasone 20 mg/d, on the same day of daratumumab injection; Mitoxantrone hydrochloride liposome injection: 20 mg/m2, d1; Daratumumab: 16 mg/Kg, once a week for the first 8 weeks; then changed to once every two weeks; Each cycle is 4 weeks long and the maximum number of cycles is 6.
88816660|NCT05857956|Experimental|Proper Wild energy shot|Participants will take one bottle daily of Proper Wild Energy shot in the morning. Participants will be advised to drink one bottle in the morning, with or without a meal, depending on their preference, as a replacement for their usual first caffeinated beverage of the day.
89395833|NCT03466996|Active Comparator|Standard of care group|The control group will receive the current standard of care transition program. In addition to this, they will receive encouraging text messages and e-mails relating to their transition goals. These messages will be sent 2 weeks, 3 months, 6 months and 9 months from the last in-person clinic appointment.
88816661|NCT05857917|Experimental|VR group|Participants randomized into this group will be introduced to VR use and watch a VR video that introduces the operating room environment 1 day before surgery and play a soothing video through VR during the surgery.
89395834|NCT01709331|Experimental|Corifollitropin alfa 150 μg + hCG|During a 16-week pretreatment phase, participants will receive twice-weekly subcutaneous (SC) injections of hCG 1500 or 3000 international units (IU). Eligible participants will then be enrolled in the combined treatment phase in which they will receive a single dose of corifollitropin alfa 150 μg by SC injection once every 2 weeks for 52 weeks. In addition, eligible participants will continue to receive twice-weekly hCG injections on the same schedule as the pretreatment phase.
89395835|NCT04883099|Experimental|APIOC for Presbyopia and Presbyopia with Astigmatism|Presbyopic Spherical or Toric Contact Lens
88816662|NCT05857917|No Intervention|Standard care group|The participants randomized to this group will receive the usual standard preoperative and intraoperative management.
88816663|NCT05857904|Experimental|CT-FFR guided group|Patients randomized to the experimental group (CT-FFR guided group) will undergo coronary artery three-dimensional reconstruction and CT-FFR calculation using the coronary CT angiography (CCTA) images and RuiXin-FFR software. The researchers will interpret and analyze the clinical outcomes based on CT-FFR results. If CT-FFR is >0.8, the patient will be treated with medical therapy alone. If CT-FFR is ≤0.8, further examination with coronary angiography will be performed. During the angiography examination, the operator will determine the treatment strategy (PCI, CABG, or medical therapy alone) based on the anatomical features of the lesion and the CT-FFR results.
88816664|NCT05857904|Active Comparator|QFR guided group|Patients randomized to the control group (QFR-guided group) will undergo invasive coronary angiography (ICA) in the catheterization lab, and QFR will be calculated using the ICA images. The researchers will interpret and analyze the clinical outcomes based on QFR results. If QFR is ≤0.8 and the lesion is suitable for intervention, the patient will undergo percutaneous coronary intervention (PCI) treatment. If QFR is >0.8, the patient will be recommended for medical treatment alone.
88816665|NCT05857891|Experimental|Erythropoietin group|intravenous injection of 40000iu of rhEPO
88816666|NCT05857891|Placebo Comparator|0.9%NS|intravenous injection of the same volume of 0.9%NS as the test group
88816667|NCT05857865|Experimental|Experimental|Caregivers in this group will participate in one 90-minute session delivered by a parenting coach via Zoom. This group will be asked to complete questionnaires at baseline, immediately post-program, approximately one month after the baseline assessment, and three months after the baseline assessment.
88816668|NCT05857865|Experimental|Services as Usual (SAU)|Caregivers in this group will not participate in a single-session intervention (SSI). Rather, this group will receive services as usual on the Specialized Services for Children and Youth (SCCY) waitlist. This group will be asked to complete questionnaires at baseline, approximately one month after the baseline assessment, and three months after the baseline assessment.
89003869|NCT04235374|Experimental|FFC-AC-EIT|The stakeholder team will meet with the research nurse facilitator to review the details of the 12 month intervention and identify unit goals. The research nurse facilitator will then work with the identified champion for 10 hours weekly during months one and two and then for four hours weekly starting in month three for a total of 12 months to implement Steps 1 to 4 of FFC-AC-EIT [(1) Environment and Policy Assessments; (2) Education; (3) Establishing Patient Goals; and (4) Mentoring and Motivating of Staff, Patients and Families]. The stakeholder team will meet with the Research Nurse Facilitator monthly to review progress. In addition to monthly visits, weekly emails containing motivational Tidbits will be sent to all stakeholder team members within the cohort. The Tidbits include such things as updates about benefits of engaging patients with ADRD in physical activity while hospitalized.
89003870|NCT04235374|Placebo Comparator|Education Only|Education Only (EO) Control Intervention: Hospitals randomized to EO will be provided with an in-service for nursing staff on function focused care in patients with ADRD by an EO Research Nurse Facilitator using our developed PowerPoint presentations in 30-minute sessions as is currently done in usual practice.
89003871|NCT04227847|Experimental|Part A|SEA-CD70 dose escalation cohort in relapsed/refractory (HMA-failure) MDS
89003872|NCT04227847|Experimental|Part B|SEA-CD70 expansion cohort in relapsed/refractory (HMA-failure) MDS
89003873|NCT04227847|Experimental|Part C|SEA-CD70 expansion cohort in relapsed/refractory AML
89003874|NCT04227847|Experimental|Part D|SEA-CD70 + azacitidine dose-finding/dose optimization cohorts in relapsed/refractory MDS or AML arising from MDS, and previously untreated higher-risk MDS
89003875|NCT04227847|Experimental|Part E|SEA-CD70 + azacitidine expansion cohort in previously untreated higher-risk MDS
89003876|NCT04227847|Experimental|Part F|SEA-CD70 + azacitidine expansion cohort in relapsed/refractory MDS or AML arising from MDS
89003877|NCT04222322|Experimental|Epitomee Capsule|Epitomee Capsule combined with moderate intensity lifestyle counseling
89003878|NCT04222322|Placebo Comparator|Control-Placebo|Visually matching (to Epitomee capsule) placebo capsule combined with moderate intensity lifestyle counseling
89003879|NCT04214392|Experimental|Treatment (CAR T cell therapy) I|Arm 1 participants will undergo resection/biopsy of their tumor and placement of a Rickham catheter at the site of the resection/biopsy. Patients receive chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes NCI SYs via single delivery starting on day 0 for 3 weekly cycles over 28 days. Each treatment cycle begins with one CAR T cell infusion delivered intracranial intratumoral or intracavitary [ICT] and lasts for 1 week. Beginning 1 week after cycle 3, patients may continue with CAR T cell treatment per principal investigator and patient discretion. Treatment continues in the absence of disease progression or unacceptable toxicity.
89003880|NCT04214392|Experimental|Treatment (CAR T cell therapy) II|Arm 2 participants will undergo resection/biopsy of their tumor and placement of a Rickham catheter at the site of the resection/biopsy and the lateral ventricle. Patients receive chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes NCI SYs via dual delivery starting on day 0 for 3 weekly cycles over 28 days. Each treatment cycle begins with two CAR T cell infusions (intracranial intratumoral or intracavitary [ICT]) and also into the lateral ventricle (intracranial intraventricular [ICV]) and lasts for 1 week. Beginning 1 week after cycle 3, patients may continue with CAR T treatment per principal investigator and patient discretion. Treatment continues in the absence of disease progression or unacceptable toxicity.
89003881|NCT04205513|No Intervention|Control Group|Standard titration management strategy, consisting of regular in-office visits.
89003882|NCT04205513|Experimental|Study Group|Remote titration management strategy, consisting of telephone contacts, which will utilize data from the Medly system.
89003883|NCT04204980|Experimental|Dose escalation and full dose|"Step I: dose-escalation 3 patients treated weekly during four weeks with 4 mg/kg of daratumumab, then 3 patients treated weekly during four weeks with 8 mg/kg of daratumumab, then 3 patients treated weekly four weeks with 16 mg/kg of daratumumab~Step II: expansion cohort to 13 patients (with 10 new patients included and the last 3 patients from the step I) with eight weekly doses of 16 mg/kg daratumumab"
89003884|NCT04194944|Experimental|Selpercatinib - Treatment A (TRT A)|160 milligram (mg) Selpercatinib administered orally twice daily (BID) continuously in 21-day cycles.
89003885|NCT04194944|Active Comparator|Pemetrexed and Patinum with or without Pembrolizumab - (TRT B)|Pemetrexed 500 milligrams per meter squared (mg/m2) administered intravenously (IV) on Day 1, every 3 weeks (Q3W), plus at the investigator's choice of carboplatin area under the concentration versus time curve 5 (AUC 5 [maximum dose of 750 mg] IV), or cisplatin (75 mg/m2 cisplatin IV) on Day 1 Q3W for 4 cycles, plus investigator's choice with or without 200 mg pembrolizumab IV on Day 1 Q3W up to 35 cycles.
89395836|NCT03136510|Other|Newly diagnosed NVAF: apixaban 5 mg|blood collection for biological analyses of 30 patients new diagnosis of NVAF (VKA treatment ≤1 week) initiated with apixaban 5 mg
89395837|NCT03136510|Other|Previously diagnosed NVAF: apixaban 5 mg|blood collection for biological analyses of 30 patients previously treated by VKA for more than 3 months switched to apixaban 5 mg
89395838|NCT05693259|Experimental|EARW group|Patients in EARW group drink EARW (pH 9.5) 10 mL/kg body weight per a day using experimental device installed in the house for 6 weeks. We recommend to drink water in empty stomach three or four times a day. The water generated from device will be administered immediately, not to be stored.
89395839|NCT05693259|Sham Comparator|PW group|Patients in PW group drink PW (pH 9.5) 10 mL/kg body weight per a day using Sham device installed in the house for 6 weeks. We recommend to drink water in empty stomach three or four times a day. The water generated from device will be administered immediately, not to be stored. Sham device was built in the same shape and operation as the experimental device.
88872462|NCT01766466|Experimental|Cangrelor IV + Ticagrelor 90mg (6 doses)|"On Day 1: Following completion of cangrelor and ticagrelor dosing, patients were discharged and instructed to take 90 mg ticagrelor every 12 hours for 6 doses (12, 24, 36, 48, 60, and 72 h).~On Day 5: 24 h post last ticagrelor dose (90 mg), patients received another open-label cangrelor IV bolus (30 µg/kg), followed by an infusion of 4 µg/kg/min for two hours."
89395840|NCT03451474|Experimental|Upper extremity nerve transfer surgery|Upper extremity nerve transfer surgery is a surgical procedure where axons from an intact, functioning upper extremity peripheral nerve are moved to a target muscle that demonstrates significant weakness or paralysis as a result of spinal cord injury. After allowing time for recovery from surgery and for nerve growth to occur, the patient undergoes hand/occupational therapy in order to retrain motor skills.
89395841|NCT05693181|Experimental|Cell Therapy|Patients having acute severe contusion spinal cord injury (cervical, thoracic or upper-lumbar) and ASIA A/B neurological deficit, within 7 days post-SCI, after primary decompressive and stabilizing surgery. All participants meet inclusion and exclusion criteria. All participants obtain 4 infusions of allogenic non-related group- and rhesus-compatible mononuclear cord blood cells samples (500 +/- 50 x 10*6 cells each) with a 1-week interval. All participants are followed up for 12 months post-SCI.
88816669|NCT05857852|Experimental|Low-Intensity Focused Ultrasound (LIFU)|All subjects to receive LIFU and Sham in a randomized order.
88816670|NCT05857852|Sham Comparator|Sham LIFU|All subjects to receive LIFU and Sham in a randomized order.
89187620|NCT00467779|Experimental|Stage 3: Cobimetinib+Midazolam+Dextromethorphan|Participants will receive a single dose of midazolam (2 mg of midazolam syrup) and dextromethorphan (30 mg tablet) on Cycle 1 Day 1, in the absence of cobimetinib. After a 2-day washout period, participants will receive 21 consecutive daily doses of cobimetinib (60-mg) followed by a 7-day washout period. Participants will receive another single dose of midazolam and dextromethorphan on Cycle 1 Day 15, in the presence of steady-state cobimetinib concentrations. In Cycle 2 and beyond participants will receive cobimetinib alone, administered as a 60-mg daily dose for 21 consecutive days in 28-day cycles (21/7 schedule).
88872463|NCT01767636|Experimental|Treatment (pazopanib hydrochloride)|Patients receive pazopanib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89187621|NCT04076306|Other|iSTEP Feasibility Study Protocol|All participants will be asked to undergo the entire protocol: iSTEP exercise test, 10 metre incremental shuttle walk test, myometry, accelerometry and Haemophilia Joint Health Score.
89187622|NCT04075214|Sham Comparator|delayed-active tAN|
88872464|NCT01769274|Experimental|PF-05089771 1600 mg|
88872465|NCT01769274|Placebo Comparator|Placebo comparator: matching placebo|Single oral dose of placebo for PF-05089771 1600 mg
89187623|NCT04075214|Experimental|active tAN|
89187624|NCT00777465||KDIGO 0|Patients with no acute kidney injury after cardiac surgery
89187625|NCT00777465||KDIGO 1|Patients with acute kidney injury KDIGO stage 1 after cardiac surgery (Increase in SCr by ≥ 0.3 mg/dL (≥ 26.5 lmol/L) or 1.5 to 1.9 times baseline)
89187626|NCT00777465||KDIGO 2|Patients with acute kidney injury KDIGO stage 2 after cardiac surgery (2.0 to 2.9 times baseline SCr)
89187627|NCT00777465||KDIGO 3|Patients with acute kidney injury KDIGO stage 3 after cardiac surgery (3.0 times baseline or more; or increase in SCr to ≥ 4.0 mg/dL; or initiation of renal replacement therapy)
89187628|NCT04076774|Experimental|Wondaleaf female condom|Participants will be provided with 5 Wondaleaf condoms first at enrolment and switched to 5 FC2 condoms at the first follow up visit
89187629|NCT04076774|Active Comparator|FC2 Female condom|Participants will be provided with 5 FC2 condoms first at enrolment and switched to 5 Wondaleaf condoms at the first follow up visit
89187630|NCT01029145||1|Bipolar patients that experience a new episode of any type
89187631|NCT00570687|Experimental|1|Technosphere Insulin
89187632|NCT01021891|Experimental|Non-Diabetic Subj. w/o COPD|Single dose, 30 units
89187633|NCT01021891|Experimental|Non-Diabetic Subj. with COPD|Single dose, 30 units
89187634|NCT04075058|Experimental|Study|Patients with breast cancer post mastectomy or after breast conservative surgery to be treated with a hypofractionated radiotherapy dose of 34Gy in 10 fractions over 2 weeks.
89187635|NCT04075058|Active Comparator|Control|Patients with breast cancer post mastectomy or after breast conservative surgery to be treated with a hypofractionated radiotherapy dose of 35Gy in 15 fractions over 3 weeks
88872466|NCT01769586|Active Comparator|Diphenhydramine|Increments of 25 mcg to maximum of 3 times (total 75 mcg)
88872467|NCT01769586|Active Comparator|Midazolam|1.5 mg increments up to 3 times (maximum 4.5 mg)
88872468|NCT01770366|Placebo Comparator|Usual Care|Patients will receive usual care from the post-surgical clinic team.
89187636|NCT01029223|Experimental|ivabradine|
89187637|NCT01029223|Experimental|metoprolol|
89187638|NCT01029223|Placebo Comparator|placebo|
88872469|NCT01770366|Experimental|Intervention Condition|Intervention participants will receive the Weight and Exercise Lifestyle Support (WELS) intervention, which involves use of a wireless activity monitor and weight scale, as well as access to a patient portal website displaying data from these devices.
88872470|NCT01773954|Experimental|Intravitreal Aflibercept Injection More|Patient receives treatment at baseline and week 4 visit. The first time extension criteria are met the follow-up interval will be increased by 4 weeks. Each time the extension criteria is met the interval will be extended by 2 weeks to a maximum of 16 weeks. If a patient is being followed at an 8 week interval but fails to meet extension criteria at a particular visit, treatment will be administered as usual and the follow up interval will be reduced to 4 weeks. If patient is being followed at 10-16 week interval but fails to meet extension criteria at a particular visit, treatment will be administered but the follow-up interval will be reduced by 2 week increments.
88872471|NCT01778634|Placebo Comparator|Placebo (5% dextrose)|Placebo
89187639|NCT02556723|Experimental|Ziv-aflibercept IV|All subjects will receive intravitreal injections of ziv-aflibercept under sterile conditions at baseline, 4 weeks, 8 weeks, 12 weeks, 16 weeks, and 20 weeks.
89187640|NCT03836677|Experimental|BGF-GFF|Subject first treated with Budesonide/Glycopyrronium/Formoterol Fumarate followed by a washout period then treated with Glycopyrronium/Formoterol Fumarate
89187641|NCT03836677|Experimental|GFF-BGF|Subject first treated with Glycopyrronium/Formoterol Fumarate followed by a washout period then treated with Budesonide/Glycopyrronium/Formoterol Fumarate
89187642|NCT00777543|Other|Control|The control is the wholegrain bread enriched with bran that has not been pretreated.
89187643|NCT00777543|Experimental|Treated bran bread|This is a wholegrain bread enriched with bran that has been pretreated with food-grade enzymes and yeast fermentation
88872472|NCT01778634|Experimental|Azithromycin|Azithromycin intravenous (2 mg/ml) 20 mg/kg every 24h x 3 days
88872473|NCT01779024|Experimental|ASA/Ghrelin|Intravenous acyl-ghrelin [a loading dose (3 mcg/kg), followed by a continous infusion (16.9 ng/kg/min)] was administered on the first ASA visit; Intravenous placebo [packed in Dextrose 5% / Water USP 50mL bags and made identical to ghrelin in terms of appearance, texture, and odor] was administered on the second ASA visit.
88872474|NCT01779024|Placebo Comparator|ASA/Placebo|Intravenous placebo [packed in Dextrose 5% / Water USP 50mL bags and made identical to ghrelin in terms of appearance, texture, and odor] was administered on the first ASA visit; Intravenous acyl-ghrelin [a loading dose (3 mcg/kg), followed by a continous infusion (16.9 ng/kg/min)] was administered on the second ASA visit
89395842|NCT05693181|Placebo Comparator|Vehicle|Patients having acute severe contusion spinal cord injury (cervical, thoracic or upper-lumbar) and ASIA A/B neurological deficit, within 7 days post-SCI, after primary decompressive and stabilizing surgery. All participants meet inclusion and exclusion criteria. All participants obtain 4 infusions of vehicle (sterile saline) with a 1-week interval. All participants are followed up for 12 months post-SCI.
89187644|NCT03401840|Experimental|postoperative SBRT|SBRT consists of a total dose of 36 Gy in 6 fractions over 11-13 days
89395843|NCT03136354|Active Comparator|ESD Group|Endoscopic Submucosal Dissection
89395844|NCT03136354|Active Comparator|LAG Group|Laparoscopic Assisted Gastrectomy
89395845|NCT05692245|Active Comparator|Ondansetron|ondansetron 4 mg intravenous, given once after initiation of anesthesia
89395846|NCT05692245|Active Comparator|Dexamethasone|dexamethasone 8 mg intravenous, given once after initiation of anesthesia
89395847|NCT03136276|Active Comparator|IPS Empress CAD|Leucite Based glass Ceramics which is etchable ceramics and proved to have good success rate if used for laminate veneers
89395848|NCT03136276|Experimental|polished Celtra Duo|Zirconia reinforced lithium silicate, it is a recent material with glass ceramics enriched with 10% zirconia that offers high strength properties
89395849|NCT05693103||Urinary Incontinence|Stress Urinary Incontinence Urge incontinence
89395850|NCT05085106|Experimental|Test group|"Group Ⅰ, give the felbinac trometamol eye drops, 0.025%，1 drop，once. Group Ⅱ, give the felbinac trometamol eye drops, 0.05%，1 drop，once. Group Ⅲ, give the felbinac trometamol eye drops, 0.1%，1 drop，once. Group Ⅳ, give the felbinac trometamol eye drops, 0.2%，1 drop，once. Group Ⅴ, give the felbinac trometamol eye drops, 0.3%，1 drop，once. Multiple Group I, give the felbinac trometamol eye drops, 0.1%，1 drop per time，four times each day, for seven days totally.~Multiple Group II, give the felbinac trometamol eye drops, 0.2%，1 drop per time，four times each day, for seven days totally."
89395851|NCT05085106|Placebo Comparator|Placebo group|"Group Ⅰ, give the placebo eye drops, 0.0%，1 drop，once. Group Ⅱ, give the placebo eye drops, 0.0%，1 drop，once. Group Ⅲ, give the placebo eye drops, 0.0%，1 drop，once. Group Ⅳ, give the placebo eye drops, 0.0%，1 drop，once. Group Ⅴ, give the placebo eye drops, 0.0%，1 drop，once. Multiple Group I, give the placebo eye drops, 0.0%, 1 drop per time, four times each day, for seven days totally.~Multiple Group II, give the placebo eye drops, 0.0%, 1 drop per time, four times each day, for seven days totally."
89395852|NCT03079336|Experimental|State of the art (SOTA) check-in phase|The therapists will apply the usual SOTA check-in phase lasting between 5 and 10 minutes, as recommended in the preexisting guideline including reviewing progress in self-help and agenda setting (Zinbarg et al., 2006).
89395853|NCT03079336|Experimental|Prolonged focus on subtle changes|Based on the robust findings that over 90% of the patients will experience subtle changes, the therapists will extend the above mentioned check-in phase by systematized focus for 7 to 20 minutes capitalizing on small and subtle changes and exceptions.
88872475|NCT01779024|Experimental|fMRI/Ghrelin|Intravenous acyl-ghrelin [a loading dose (3 mcg/kg), followed by a continous infusion (16.9 ng/kg/min)] was administered on the first fMRI visit; Intravenous placebo [packed in Dextrose 5% / Water USP 50mL bags and made identical to ghrelin in terms of appearance, texture, and odor] was administered on the second fMRI visit.
88872476|NCT01779024|Placebo Comparator|fMRI/Placebo|Intravenous placebo [packed in Dextrose 5% / Water USP 50mL bags and made identical to ghrelin in terms of appearance, texture, and odor] was administered on the first fMRI visit; Intravenous acyl-ghrelin [a loading dose (3 mcg/kg), followed by a continous infusion (16.9 ng/kg/min)] was administered on the second fMRI visit
89395854|NCT05084872|Experimental|Treatment|Patients will be treated by hydroxychloroquine at a dose of 6 to 6.5mg/kg/day
88872477|NCT01780350|Experimental|ResQGARD ITD|Subjects receive a ResQGARD ITD.
88872478|NCT01781208|Experimental|Ultrasound-based Acoustic Radiation Force Imaging|The liver was scanned using ultrasound and ultrasound-based acoustic radiation force impulse imaging technique (ARFI).
88872479|NCT01783080|Experimental|Behavioral Activation for Return to Work|BA is a manualized psychotherapy with comparable efficacy to cognitive behavioral treatment and antidepressant medication for acute treatment of depression. In this study, BA's focus was shifted to target work dysfunction by activating the patient into employment-related goals. BA-W consisted of 12 50-minute weekly sessions. Conceptualizing work dysfunction as a product of avoidance patterns and low levels of positive reinforcement, the treatment addressed maladaptive coping strategies such as avoidance as maintaining work dysfunction beyond remission of symptoms. Rather than broadly activating patients, activity scheduling focused on tasks such as sending out resumes, calling for job interviews, and networking to meet potential employers.
88872480|NCT01783236|Placebo Comparator|Saline Placebo|Subjects will receive a saline placebo infusion administered over 15 minutes every 6 hours for 24 hours.
88872481|NCT01783236|Active Comparator|IV Acetaminophen|Subjects will receive an infusion of 1 g of intravenous acetaminophen administered over 15 minutes every 6 hours for 24 hours with a maximum dose of 4 grams.
89395855|NCT00159796|Experimental|Arm 1|Asenapine
89395856|NCT00159796|Active Comparator|Arm 2|Olanzapine
89395857|NCT00159796|Placebo Comparator|Arm 3|Placebo
89395858|NCT03626571||Native valve infective endocarditis|Patients with infective endocarditis of native valves of the heart with no contraindications to MRI scanning.
89395859|NCT03626571||Prosthetic endocarditis|Patients with endocarditis of prosthetic heart valves or device-related infections.
89395860|NCT03626571||Non-infective post-operative|Patients who have recently undergone valve or device implantation with no evidence of post-operative infection.
89003886|NCT04191187|Experimental|Conditioning Regimen + Transplant|All participants will receive a conditioning regimen of Fludarabine, Melphalan and Total Body Irradiation prior to transplantation of HLA-Haploidentical Related Hematopoietic Cells (Haplo-HCT)
89003887|NCT04188509|Experimental|Voxelotor|All participants will receive voxelotor once daily (QD), administered orally as tablets, dispersible tablets, or a stick pack formulation (powder blend formulation packaged as stick packs). Participants aged ≥ 12 years and/or ≥ 40 kgs will receive a voxelotor dose of 1500 mg QD. Participants aged < 12 years and < 40 kgs will receive weight based dosing of voxelotor. The participant's weight at study entry will be used to determine the starting voxelotor dose in this study. Participants may receive study drug as long they continue to receive clinical benefit that outweighs risk as determined by the investigator and/or until the participant has access to voxelotor from an alternative source.
89003888|NCT04184206|Active Comparator|attention training intervention 1|14-day smartphone-based audio-guided attention training program with heavy mindfulness influence
89003889|NCT04184206|Active Comparator|attention training intervention 2|14-day smartphone-based audio-guided attention training program with moderate mindfulness influence
89003890|NCT04184206|Active Comparator|attention training intervention 3|14-day smartphone-based audio-guided intervention without mindfulness emphasis
89003891|NCT04180475|Experimental|MedRem application|MedRem smartwatch application
89003892|NCT04148911|Experimental|Atezolizumab plus Nab-Paclitaxel|Participants will receive Atezolizumab via intravenous (IV) infusion on Days 1 and 15 of every 28-day cycle in combination with Nab-Paclitaxel on Days 1, 8, and 15 (individually selected by the investigator) until disease progression, or unacceptable toxicity, additionally until loss of clinical benefit as determined by the investigator or participant decision to discontinue treatment.
89003893|NCT04147884|Experimental|Mitral Valve Repair|All subjects will receive mitral valve repair using the Millipede System
89003894|NCT04147078|Experimental|cell_therapy|tumor neoantigen primed DC vaccines are administrated, 2-3 week interval, totally 3-5 times
89003895|NCT04136184|Experimental|Eplontersen|Eplontersen by subcutaneous injection once every 4 weeks.
89003896|NCT04136184|Active Comparator|Inotersen|Inotersen by subcutaneous injection once weekly through week 34. Participants will then convert to Eplontersen administered subcutaneously once every 4 weeks until the end of study.
89003897|NCT04135417|Experimental|HAV|The HAV is a tissue-engineered vascular conduit (6mm diameter) for hemodialysis access in patients with end-stage renal disease. HAV for this study will be manufactured using the commercial manufacturing system.It will be implanted in the forearm or upper arm using standard vascular surgical techniques. All subjects will be required to start taking daily aspirin (75 or 325 mg) on Day 1 after surgical implantation of HAV unless they are already taking another antiplatelet agent. If low molecular weight heparin (LMWH) is administered post-operatively, aspirin or other antiplatelet agents should be initiated after stopping LMWH. Subjects who are known to be aspirin-sensitive should take another antiplatelet agent at the discretion of the Principal Investigator.
89003898|NCT04083898|Experimental|Phase I Dose Level 1: Isatuximab + Bendamustine + Prednisone|-Isatuximab (10 mg/kg) on Days 1, 8, 15, and 22 during Cycle 1 and on Days 1 and 15 of subsequent cycles. Bendamustine (50 mg/m^2) will be administered on Days 1 and 2 and prednisone (60 mg) will be administered on Days 1 through 4 of each cycle.
89003899|NCT04083898|Experimental|Phase I Dose Level 2: Isatuximab + Bendamustine + Prednisone|-Isatuximab (10 mg/kg) on Days 1, 8, 15, and 22 during Cycle 1 and on Days 1 and 15 of subsequent cycles. Bendamustine (75 mg/m^2) will be administered on Days 1 and 2 and prednisone (60 mg) will be administered on Days 1 through 4 of each cycle.
89003900|NCT04083898|Experimental|Phase I Dose Level 3: Isatuximab + Bendamustine + Prednisone|-Isatuximab (10 mg/kg) on Days 1, 8, 15, and 22 during Cycle 1 and on Days 1 and 15 of subsequent cycles. Bendamustine (100 mg/m^2) will be administered on Days 1 and 2 and prednisone (60 mg) will be administered on Days 1 through 4 of each cycle.
89003901|NCT04083898|Experimental|Phase II: Isatuximab + Bendamustine + Prednisone|-Isatuximab (10 mg/kg) on Days 1, 8, 15, and 22 during Cycle 1 and on Days 1 and 15 of subsequent cycles. Bendamustine (dose determined in Phase I portion of study) will be administered on Days 1 and 2 and prednisone (60 mg) will be administered on Days 1 through 4 of each cycle.
89003902|NCT04069312|Active Comparator|Roflumilast arm|Participants will receive prescription for Roflumilast (250 mcg/day x 4 weeks, then 500 mcg/day or alternate regimen) x 6 to 72 months
89003903|NCT04069312|Active Comparator|Azithromycin arm|Participants will receive prescription for Azithromycin (250 mg/day, or 500 mg three times per week, or alternate regimen) x 6 to 72 months
89003904|NCT04049604||1|Women with prenatal testing results that suggest an incidental detection of maternal neoplasia
89003905|NCT04045080|Experimental|AMADEO Training|Twenty PD patients with hand bradykinesia will be treated with the AMADEO® system. They will undergo 15 training sessions, 5 a week for 3 weeks, each session lasting about 60 minutes. During each session, both the hands will be treated using the endeffector in its active and active-assisted modality.
89003906|NCT04045080|Active Comparator|OT training|"Twenty control subjects (PD patients) will be treated with traditional rehabilitation focused on fine hand-finger movement skills. The patients in this group will undergo the same amount of treatment.~Both the groups will be trained with conventional physiotherapy concerning postural, balance and gait."
89187645|NCT02556645|Experimental|Web-PE|Ten 60-minute psychotherapy sessions over 8 weeks, focused on gradually confronting distressing trauma-related memories and reminders. Web-PE is an internet-based version of prolonged exposure (PE) for posttraumatic stress disorder (PTSD).
89530488|NCT04130243||Congenital Heart disease|In patients with (a history of) pressure- and/or volume loaded right ventricle due to congenital heart disease extra blood will be withdrawn for a blood test; serumbiomarker
89530489|NCT04130243||Pulmonary Arterial Hypertension|In patients with (a history of) pressure- and/or volume loaded right ventricle due to pulmonary arterial hypertension extra blood will be withdrawn for a blood test; serumbiomarker
89530490|NCT04486651|Experimental|HX008 plus Irinotecan|Participants recieve HX008 200 mg intravenous (IV) every 3 weeks (Q3W) plus irinotecan 160 mg/m², IV, Q2W.
89530491|NCT04486651|Placebo Comparator|Placebo plus Irinotecan|Participants recieve placebo intravenous (IV) every 3 weeks (Q3W) plus irinotecan 160 mg/m², IV, Q2W.
88872482|NCT01783470|Experimental|beta3-adrenergic receptor agonist|single dose. Each subject was randomized to receive placebo at one visit and then the beta3-adrenergic receptor agonist on another study day.
88872483|NCT01783860|Experimental|Oral Azithromycin|Two 250 mg capsules (500 mg) of Azithromycin for the first day and 250mg/day for the next 4 days.
88872484|NCT01783860|Active Comparator|Doxycycline|Oral doxycycline 100mg capsule every 12 hours for one month
88872485|NCT04420182|Other|COVID-19 Virtual Care at Home|"VIRTUES COVID-19 Care at Home Platform~The components of the platform will include:~Vital sign monitoring, including O2 saturation with a home-based pulse oximeter, temperature and respiratory rate performed three times per day (a notification to do this will be sent from the app), with the option of doing assessments more frequently if needed. Study patients will be provided monitoring devices to collect this data.~Symptom logs will be entered by the patients.~Feedback to the patient by the local COVID-19 care team for any action:~Two-way communication between the patient and the COVID-19 care team~Ability for team members to see all prior notes in order to have continuity of care~Reports of these interactions are transmitted to the patient's health record~Current information on COVID-19 as per the Public Health Agency of Canada"
88872486|NCT01784796|Experimental|Mindfulness Based Stress Reduction|8 week Mindfulness Based Stress Reduction program
88872487|NCT01784796|Active Comparator|Health education program|8 week Health Education program
88872488|NCT01785186|Experimental|Arm 1 (R35)|Arm 1 (R35): HR35ZE isoniazid, rifampicin 35 mg/kg, pyrazinamide, ethambutol
88872489|NCT01785186|Experimental|HRZQ|Arm 2 (Q): HRZQ isoniazid, rifampicin standard, pyrazinamide, SQ109 300 mg
88872490|NCT01785186|Experimental|HR20ZQ|Arm 3 (R20Q): HR20ZQ isoniazid, rifampicin 20 mg/kg, pyrazinamide, SQ109 300 mg
88872491|NCT01785186|Experimental|HR20ZM|Arm 4 (R20M): HR20ZM isoniazid, rifampicin 20 mg/kg, pyrazinamide, moxifloxacin 400 mg
88872492|NCT01785186|Active Comparator|HRZE|HRZE: Isoniazid, rifampicin standard, pyrazinamide, ethambutol
88872493|NCT01785810|Experimental|Maraviroc|Phase II, single arm, single center trial, assessing the efficacy of the combination of tacrolimus, methotrexate and maraviroc as graft-versus-host disease (GVHD) prophylaxis after unrelated donor peripheral blood stem-cell transplantation in patients with hematologic malignancies. Patients enrolled on this trial will receive a standard conditioning regimen with fludarabine and busulfan followed by a peripheral blood stem cell infusion from an unrelated donor, standard GVHD prophylaxis and standard antiviral and antifungal prophylaxis. In addition, all patients will receive maraviroc from day -3 to d+ 90.
88872494|NCT01786902|Experimental|DA-3002 Treatment group|1.11 IU(0.37mg)/kg bodyweight of DA-3002 per week given by subcutaneous injections (six or seven times per week)
88872495|NCT01786902|No Intervention|Non-treatment control group|Height be measured with no treatment
88872496|NCT01787604|Active Comparator|Aortic Root Reimplantation Procedure|Aortic Root Reimplantation Procedure
88872497|NCT01787604|Active Comparator|Aortic Valve Reimplantation Procedure|Aortic Valve Reimplantation Procedure
88872498|NCT01787916|Experimental|Liraglutide|Liraglutide, s.c., 1.8 mg, die, 24 weeks
88872499|NCT01787916|Placebo Comparator|Placebo|Liraglutide placebo (visually identical to study drug) will be given s.c. 1.8 mg for 24 weeks
88872500|NCT01788150|Experimental|Svelte Drug-Eluting Coronary Stent|Coronary Stenting
88872501|NCT01788150|Active Comparator|Medtronic Resolute Integrity Drug-Eluting Stent|Coronary Stenting
88872502|NCT01790178|Experimental|Ultrasound Guided Biopsy|Ultrasound guided biopsy will be used in all patients.
88872503|NCT01790178|No Intervention|Non-Ultrasound Guided Group|The control group will have non-ultrasound guided biopsies performed, which is the current standard of care.
88872504|NCT01790490|Experimental|K1|Ketamine 0.41 mg/kg infused over 52 min (K1)
88872505|NCT01790490|Experimental|K2|Ketamine 0.71 mg/kg infused over 52 min (K2)
88872506|NCT01790490|Experimental|LZP|Lorazepam 2 mg infused over 52 minutes (LZP)
88872507|NCT01791972|Experimental|Albuterol Spiromax / Placebo Spiromax|Albuterol Spiromax, 180 mcg (2 inhalations of 90 mcg/inhalation), single dose on Day 1. Placebo Spiromax (2 inhalations), single dose on approximately Day 7.
88872508|NCT01791972|Experimental|Placebo Spiromax / Albuterol Spiromax|Placebo Spiromax, (2 inhalations), single dose on Day 1. Albuterol Spiromax 180 mcg (2 inhalations of 90 mcg/inhalation), single dose on approximately Day 7.
88872509|NCT01792986|Other|water-only 24-hour fasting once per week for 6 weeks|
89395861|NCT03368014|Experimental|Lyrics-writing and singing show|The one-hour lyrics-writing and singing workshop was conducted first at the beginning of the programme for the intervention group, followed by two small workshops teaching lyrics-writing skills and the lyrics-writing competition after the workshop. A lyrics writing and singing show and an award ceremony will be held at the end.
89395862|NCT03368014|No Intervention|Waitlist control|The workshops will not be provided to the control schools during the evaluation period and will be provided after the evaluation period.
89395863|NCT03361462|Experimental|Intervention group|Two joyful adventure days in the form of physical activities and competitions with adventure games and short interactive talk on SME.
89395864|NCT03361462|No Intervention|Waitlist control group|The intervention won't be provided during evaluation period and will be provided after the evaluation period
89395865|NCT03327844|Active Comparator|RET using bi-Antibiotics|Interventions: Bi-antibiotics (Ciprofloxacin and Metronidazole) placed into the root canal during first treatment stage (disinfection stage)
89395866|NCT03327844|Active Comparator|RET using non-setting Calcium Hydroxide|Interventions: non-setting calcium hydroxide placed into the root canal during first treatment stage (disinfection stage)
89395867|NCT03288766||PICC Placement with Study Device|PICC Placement with SHERLOCK 3CG™ Diamond TCS with MODUS II software
89395868|NCT03230032|Experimental|Intervention Group|Sessions will use a pacifier-activated device (PAL) system. The device sensor attaches to a routinely-used pacifier and measures timing and pressure of the sucks. If the infant reaches the preset suck pressure, he receives 10 seconds of mother's voice. The receiver/speaker box controls the volume to < 65dB on scale C. PAM will be set to the lowest settings for the first session. Using sensor measurements, the therapist will increase the threshold for number of sucks and strength once the infant produces three consecutive sucks above current level and continue per protocol.
89395869|NCT03230032|No Intervention|Control Group|Infants will receive 2 daily 15-min listening sessions of mother's voice recording, contiguous but not simultaneous with PAM NNS sessions without suck-contingent reinforcement (no voice).
89395870|NCT05691855|Experimental|89Zr-NY009|
89395871|NCT03136432||Children with cerebral palsy|Children with cerebral palsy, who can walking dependently and continuously for 6 minutes.
89395872|NCT03123640|Experimental|Intervention group|Pharmacist conducts medication reconciliation and medication review while the patient is admitted to the emergency Department. The pharmacist present results from medication reconciliation to physicians at the emergency Department before the Medical history is obtained. Further the pharmacist will discuss drug related problems obtained during the medication review with the physicians to customize and optimize the medication treatment for each patient.
89395873|NCT03123640|No Intervention|Control group|Standard treatment without pharmacist intervention in the emergency department
89395874|NCT03068416|Experimental|CAR T cells|Autologous 3rd generation CD19-targeting CAR T cells
89395875|NCT03109912|No Intervention|Control|At the baseline fitness assessment, the FitBit daily step goal is set at the manufacturer standard 10,000 steps. Throughout the study, these 30 participants will receive generic, non-personalized encouragement and recommendations (if requested by the participant) for PA at routine clinic visits, baseline and follow-up assessments at 3 and 6 month clinic visits. At the 3-month and 6-month visits, exercise is reinforced with generic encouragement, export FitBit data and review any missing data concerning for equipment failure or user error.
89395876|NCT03109912|Experimental|Exercise Intervention|The baseline fitness assessment includes an additional 30-minutes for exercise prescriptions; participant FitBit daily step goal is set based on a collaborative review between the participant and PT and participants receive individualized exercise prescriptions based on their assessment. Throughout the study, these 30 participants will receive customized encouragement and personalized fitness recommendations for PA at routine visits, baseline and follow-up assessments at 3 and 6 month clinic visits. At the 3-month and 6-month visits, study team members meet again with the participant for an additional 30-45 minutes to reinforce exercise through exercise prescriptions and individualized encouragement, export FitBit data and review any missing data concerning for equipment failure or user error and address any specific exercise concerns. FitBit daily step goals may be adjusted based on collaborative review between the participant and PT.
89395877|NCT05691621||septic AKI: S-AKI|Septic patients with AKI
89395878|NCT05691621||non-septic AKI: non-S AKI|Non-septic critically ill patients with AKI.
89187646|NCT02556645|Active Comparator|PCT|Ten 60-minute psychotherapy sessions over 8 weeks, focused on identifying and solving day-to-day problems as they are brought up by the participants. PCT is a manualized therapy that has been used as active control condition in several CBT studies.
89395879|NCT05691621||non-AKI Non-AKI|Critically ill patients without sepsis and AKI.
89395880|NCT05058820|Experimental|Post Facilitation stretch|Hot pack, TENS, Post Facilitation stretch, Deep friction massage
89395881|NCT05058820|Active Comparator|Active Isolated Stretching|Hot pack, TENS, Active Isolated Stretching, Deep friction massage
89395882|NCT05691543||study group|patients with symptomatic Stage II , III and Stage IV Apical Prolapse (diagnosed by pop Q test)
89395883|NCT04619836||segmentation type 2 diabetes patitents|Those type 2 diabetes patients, who have segmenteted for four groups to organinize cervices and self care
89395884|NCT04619836||Non-segmentation type 2 diabetes patients|Those type 2 diabetes patiets who have not segementated
89395885|NCT04619836||Segmentation substance abuse clients|Those type substance abuse clients, who have segmenteted for four groups to organinize cervices and self care
89395886|NCT04619836||Non-segmentation substance abuse clients|Those type substance abuse clients, who have not segmenteted
89395887|NCT05008510|Experimental|Sabizabulin Monotherapy|Subjects in the Sabizabulin Treated Group will receive sabizabulin 32 mg each day by mouth until disease progression confirmed by BICR is observed.
89395888|NCT05008510|Experimental|Sacituzumab govitecan-hziy/Sabizabulin Combination|Subjects in the Sacituzumab govitecan-hziy /Sabizabulin Combination Treated Group will receive sabizabulin 32 mg each day by mouth and Sacituzumab govitecan-hziy at the FDA approved dose and dosage regimen for mTNBC until disease progression confirmed by BICR is observed.
89395889|NCT05008510|Active Comparator|Sacituzumab govitecan-hziy Monotherpy|Subjects in the Control Treated Group will receive Sacituzumab govitecan-hziy intravenous infusion of 10 mg/kg in accordance with the FDA approved use and dosage regimen for mTNBC until disease progression confirmed by BICR is observed.
88872510|NCT01794702|Experimental|Clofarabine + Cytarabine + Decitabine + Idarubicin|"Phase I - Decitabine 20 mg/m2 by vein over approximately 1 hour daily for 5 days (days 1-5) Idarubicin 10 mg/m2 by vein over approximately 30 minutes daily for 3 days (days 6-8) Cytarabine 1 g/m2 by vein over approximately 2 hours daily for 5 days (days 6-10)~Phase II - Clofarabine 15 mg/m2 by vein over approximately 1 hour daily (number of days selected based on Phase I portion).~Decitabine 20 mg/m2 by vein over approximately 1 hour daily for 5 days (days 1-5) Idarubicin 10 mg/m2 by vein over approximately 30 minutes daily for 3 days (days 6-8) Cytarabine 1 g/m2 by vein over approximately 2 hours daily for 5 days (days 6-10)"
88872511|NCT01795716|Experimental|mesylate imatinib capsule|Single and multiple oral mesylate imatinib capsule 400mg qd
88872512|NCT01795716|Active Comparator|Glivec|Single and multiple oral Glivec 400mg qd
88872513|NCT01800318|Experimental|Sham NESAP with 24% oral sucrose|"Sham NESAP: Four Stim Care electrodes with gel backing will be placed on the infant's lower leg at acupuncture points. However, the Empi Select TENS unit will not be turned on. The TENS unit will be hidden from investigators so that they are blinded to the status of the unit.~Infant will receive 1 ml of 24% oral sucrose solution given along with a pacifier two minutes before the heel stick. Investigators will be blinded to the solution given."
88872514|NCT01800318|Experimental|NESAP with oral water|"NESAP: Four Stim Care electrodes with gel backing will be placed on the infant's lower leg at acupuncture points. 10 minutes before the heel stick, the Empi Select TENS unit will be turned on with settings 3.5mA, 10 Hz. The TENS unit will be hidden from investigators so that they are blinded to the status of the unit.~Infant will receive 1 ml of sterile water given via oral syringe along with a pacifier two minutes before the heel stick. Investigators will be blinded to the solution given"
88872515|NCT01800318|Experimental|NESAP with 24% oral sucrose|"NESAP: Four Stim Care electrodes with gel backing will be placed on the infant's lower leg at acupuncture points. The Empi Select TENS unit will be turned on ten minutes before the heel stick at settings 3.5 mA, 10 Hz. The TENS unit will be hidden from investigators so that they are blinded to the status of the unit.~Infant will receive 1 ml of 24% oral sucrose solution given along with a pacifier two minutes before the heel stick. Investigators will be blinded to the solution given."
88872516|NCT01800318|Placebo Comparator|Sham NESAP with oral water|"Sham NESAP: Four Stim Care electrodes with gel backing will be placed on the infant's lower leg at acupuncture points. However, the Empi Select TENS unit will not be turned on. The TENS unit will be hidden from investigators so that they are blinded to the status of the unit.~Infant will receive 1 ml of sterile water given via oral syringe along with a pacifier two minutes before the heel stick. Investigators will be blinded to the solution given."
88872517|NCT01800786|Active Comparator|OSA-CPAP group|OSA patient will use CPAP for 3 months
88872518|NCT01800786|No Intervention|OSA -no CPAP|newly diagnosed OSA patient will not wear CPAP for 3 months
88872519|NCT01803204|Experimental|Booklet - Preoperative Educational|This group received the booklet in the preoperative consult, they will monitoring during the postoperative phase
88872520|NCT01803204|No Intervention|Control|This group don't received booklet, they will be monitored during the postoperative period to control
88872521|NCT01804062||no treatment|no treatment, prospective observational
88872522|NCT01805154||CRT patients|Patients who have received any market approved St Jude Medical CRT-D or CRT-P device
88872523|NCT01809834|Active Comparator|Etafilcon A|Each participant was randomized to wear the test lens in one eye and the control lens in the other simultaneously
88872524|NCT01809834|Experimental|Stenfilcon A|Each participant was randomized to wear the test lens in one eye and the control lens in the other simultaneously
89187647|NCT01032421||GNRH|Observational (IVF is not done as part of the study)
89395890|NCT05001256||All Participants|"Individuals between the ages of 18-65 who applied to the physical therapy and rehabilitation outpatient clinic of a private hospital and voluntarily agreed to participate in the study will be included in the study. Written consent will be obtained from the participants.~Participants' information will be recorded on a pre-prepared questionnaire containing structured questions. Questionnaire questioning will be applied to individuals through face-to-face interviews. The questionnaire form consists of three parts: 1. Sociodemographic characteristics, 2. Mediterranean Diet Adherence Scale (MEDAS), 3. International Physical Activity Questionnaire (IPAQ)."
89395891|NCT03019510|Placebo Comparator|no exercise|Subjects will be studied from 6 pm to 7 am following 48 hr of no exercise
88872525|NCT01769352|Active Comparator|PredA q1h WA + Kelac qid|Prednisolone acetate (PredA) 1% ophthalmic solution every 1 hr while awake (WA) and Ketorolac (Kelac) 0.5% ophthlmic solution four times a day (qid)
88872526|NCT01769352|Active Comparator|PredA qid + Kelac qid|Prednisolone acetate (PredA) 1% ophthalmic solution four times a day (qid) and Ketorolac (Kelac) 0.5% ophthlmic solution four times a day (qid)
88872527|NCT01810692||Group 1|
88872528|NCT01810692||Group 2|
88872529|NCT01811004|Experimental|Botox®|Botox®
88872530|NCT01811004|Experimental|miraDry®|miraDry®
88872531|NCT01811004|Experimental|Nd: YAG laser|Nd: YAG laser 1440nm
88872532|NCT01811316|Active Comparator|Probiotics Lozenge (twice a day)|Subjects take their lozenge twice a day, one lozenge in the morning after brushing and one lozenge in the evening after brushing.
88872533|NCT01811316|Active Comparator|Probiotics Lozenge (once a day)|Subjects take their lozenge once a day, one lozenge at night after brushing.
89395892|NCT03019510|Active Comparator|morning exercise|Subjects will be studied from 6 pm to 7 am. Subjects will have exercised at 7 am on that day.
88872534|NCT01811316|Placebo Comparator|Placebo Lozenge (once a day)|Subjects take their lozenge once a day, one lozenge at night after brushing.
88872535|NCT01811940|Experimental|Adderall-ER and Topiramate|Adderall-ER will be taken once per day in the morning or early afternoon since it may be activating. The dose is titrated to 60 mg per day or the maximum tolerated dose over two weeks and maintained for the duration of the study. Topiramate will be taken twice per day in the morning and the evening and titrated to 200mg/day or the maximum tolerated dose over the course of 6 weeks and maintained for the duration of the study.
88872536|NCT01811940|Placebo Comparator|Placebo|Placebo will be packaged in matching gelatin capsules similar to the pills in the active arm. Placebo will be taken as frequently and for the same duration as those taken in the active arm.
88872537|NCT01813110|Placebo Comparator|Placebo|Identical olive oil capsules
88872538|NCT01813110|Experimental|Omega-3|4 g prescription omega-3 concentrate (4 g/d prescription omega-3 fatty acid concentrate taken orally for 8-12 weeks)
88872539|NCT01813734|Experimental|Ponatinib Treatment Arm|Ponatinib 30 mg PO daily
88872540|NCT01816230|Experimental|NiCord®|NiCord® is a stem/progenitor cell based product composed of ex vivo expanded allogeneic UCB cells.
88872541|NCT01816776|Experimental|Treatment Group|Subjects implanted with the remedē system device and randomized to the Treatment group will receive optimal medical therapy and have the remedē system initiated to deliver transvenous stimulation of the phrenic nerve at the Therapy Initiation Visit (1 month post device implant).
88872542|NCT01816776|Other|Control group|Subjects implanted with the remedē system device and randomized to the Control group will receive optimal medical therapy through the 6-month Post-Therapy Initiation Visit. Control group subjects will have the remedē system initiated to deliver transvenous stimulation of the phrenic nerve at the 6-month Post-Therapy Initiation Visit (7 months post device implant).
88872543|NCT01817712|Experimental|Individual Placement and Support (IPS)|The IPS intervention must achieve a rating of >66 of a possible 75 points on the Supported Employment Fidelity Scale. The fidelity ratings are conducted by the National IPS Fidelity Monitor at biannual on-site monitoring visits.
88872544|NCT01817712|Active Comparator|VA Transitional Work Program (TWP)|TWP will adhere to a lower rating (less than or equal to 55 of a possible 75 points) on the Supported Employment Fidelity Scale rated by the National Fidelity Monitor. The TWP specialist participates in face-to-face supervision with the local Compensated Work Therapy (CWT) team according to the CWT manager's schedule.
88872545|NCT01818414|Experimental|Misoprostol|Misoprostol 400 mcg buccal 3 hours prior to D&E as an adjunct to same-day Dilapan-S.
88872546|NCT01818414|Placebo Comparator|Folic Acid|Folic acid 4 mg buccally 3 hours prior to D&E as an adjunct to same-day Dilapan-S
89395893|NCT03019510|Active Comparator|evening exercise|Subjects will be studied from 6 pm to 7 am. Subjects will exercise at 8 pm following dinner on the study day.
89395894|NCT05194995|Experimental|Phase 1b Dose Escalation|Dose escalation of JAB-21822 to determine maximum tolerated dose of JAB-21822 in combination with cetuximab.
89395895|NCT05194995|Experimental|Phase 2 Dose Expansion, Cohort 1|Enrollment into the dose expansion cohort is for eligible participants with KRAS P.G12C mutant advanced colorectal cancer.
88872547|NCT06020651|Experimental|ICIs alone|Participants on ICIs alone
88872548|NCT06020651|Experimental|ICIs + VEGF inhibitors|Participants on ICIs + VEGF inhibitors
88872549|NCT06020651|Experimental|ICIs + chemotherapy|Participants on ICIs + chemotherapy
88872550|NCT06020651|Sham Comparator|Controls|Participants on other than ICIs cancer therapies
88872551|NCT06020638|Experimental|Experimental group (Positive Pressure Group)|The nasopharyngeal suction with positive pressure method was employed in the sample group. In this method, the infant's head is turned to the side, to the nostril on the other side 1-2 ml of physiological saline (PS- Mustela trademark), is injected with a 2,5-milliliter syringe (Can Medikal trademark), and then positive pressure is exerted with the help of the end of the oxygen connection hose (CGR Medikal trademark) from the same nostril, with oxygen or air supply at 5-8 lt/min (liter/minute) (if the baby requires oxygen, using an oxygen source) and the nasopharyngeal secretions are removed from the nostril into which physiological saline (PS) has been not injected. The oxygen connection hose is held one centimeter away from the infant's nostril. The researchers prepared a guideline for nasopharyngeal suction with positive pressure based on the literature.
89395896|NCT05194995|Experimental|Phase 2 Dose Expansion, Cohort 2|Enrollment into the dose expansion cohort is for eligible participants with KRAS P.G12C mutant advanced small intestinal cancer and advanced appendiceal cancer.
89395897|NCT02972944|Experimental|Cholecystectomy group|Cholecystectomy group will undergo laparoscopic cholecystectomy within 48 hrs after randomization.
89395898|NCT02972944|Active Comparator|Non-operative group|Patients of non-operative group will be treated conservatively with intravenous antibiotics (cefuroxime) at surgical ward. Elective cholecystectomy will not be arranged.
89395899|NCT03136978||Endometriosis|Patients affected by endometriosis (histologically confirmed) at different stages, who will undergo laparoscopic surgery.
89395900|NCT03136978||Ovarian functional cysts|Patients affected by ovarian functional cysts, who will undergo laparoscopic surgery.
88872552|NCT06020638|Active Comparator|Control group (Negative Pressure Group)|The nasopharyngeal suction with negative pressure method was employed in the control group in this study. In this method, the nasal secretions were softened with 1-2 ml of physiological saline (PS- Mustela trademark) like experimental group, and then negative pressure suction was performed using a pine-tipped suction set (Bıcakcılar trademark). The suction pressure was kept between 60 and 80 mmHg, and no suction lasted for more than 15 seconds
89395901|NCT04948762||Open|Patients who underwent an open approach to pelvic exenteration
89395902|NCT04948762||Laparoscopic|Patients who underwent a laparoscopic approach to pelvic exenteration
89395903|NCT04948762||Robotic|Patients who underwent a robotically-assisted pelvic exenteration
89395904|NCT04401280|Active Comparator|BiominF®|Test group
89395905|NCT04401280|Active Comparator|Novamin®|Test group
88872553|NCT06020625|Experimental|Interventional|
89395906|NCT04401280|Active Comparator|CPP-ACP|Control group
89395907|NCT02963272|Other|Conventional strategy|Conventional strategy to manage the patients with HF, following the international guidelines
88872554|NCT06020612||Presence of desmoplasia|Tumors with presence of desmoplasia according to the predefined definition.
88872555|NCT06020612||Absence of desmoplasia|Tumors in absence of desmoplasia according to the predefined definition.
88872556|NCT06020586|Experimental|hair lotion|
88872557|NCT06020560|Active Comparator|Dalteparin|
88872558|NCT06020560|Active Comparator|Tinzaparin|
88872559|NCT06020547||Adults with Cystic Fibrosis|"All patients who met the diagnostic criteria for CF, over 18 years old, with pathological sweat chloride levels (chloride >60 mEq/L) and two CFTR mutations were recruited.~Sweat chloride levels have been tested, and a panel of CFTR mutations screened. The CFTR genotype has been defined through the screening of the most frequent mutations and rearrangements."
88872560|NCT06020534||No-stenosis group|Patients who had no pre-existing aortoiliac stenosis before kidney transplantation.
88872561|NCT06020534||TASC A/B stenosis|Patients who had TASC A or B aortoiliac stenosis before kidney transplantation.
88872562|NCT06020534||TASC C/D stenosis|Patients who had TASC C or D aortoiliac stenosis before kidney transplantation.
88872563|NCT06020495|Experimental|DDAVP|"DDAVP 4µg/ml IV Additional doses may be administrated every 6h for a maximum of 48h~- Standard hyponatremia treatment : Presence of neurological symptoms : sodium chloride 3% 150ml for 20 min Absence of neurological symptoms : Hyper or isotonic fluid but never hypotonic"
89395908|NCT02963272|Other|ST2-guided strategy|Management of patients follow the international guidelines but are also guided by the ST2, to adapt the drugs indicated in patients with HF.
89395909|NCT03137836|Experimental|Intervention|Sit-to-stand desks (Ergotron LearnFit®) will replace standard desks. In addition, meeting with parents and teacher's training will be conducted in order to support behavior change.
88872564|NCT06020495|Active Comparator|Standard hyponatremia treatment|"Standard hyponatremia treatment alone :~Presence of neurological symptoms : sodium chloride 3% 150ml for 20 min Absence of neurological symptoms : Hyper or isotonic fluid but never hypotonic"
88872565|NCT06020482||A-OE|women with ovarian endometriosis (study group)
88872566|NCT06020482||A-PE|women with peitoneal endometriosis (study group)
89395910|NCT03137836|No Intervention|Control|Control classroom will maintain their routine in sitting desks.
89395911|NCT05181891|Experimental|(CM+TAU) Contingency Management + Treatment as Usual|Varenicline (VC) will be supplied in .5 mg tablets once per week during the active treatment period. During the first week of treatment (Week 3) participants will be instructed to take .5 mg once per day for days 1-3, and 0.5 mg twice per day for days 4-7. The investigators will maintain a target dose of 1mg twice per day for the remaining active treatment period. Additionally, participants will also receive Take Control counseling via video. Participants in CM+TAU will receive reinforcement for submitting urine samples that test negative for recent alcohol use.
88872567|NCT06020482||A-DE|women with deep infiltrating endometriosis (study group)
88872568|NCT06020482||B|women without endometriosis
88872569|NCT06020469||Numeric Rating Scale (NRS) score after surgery <4|
88872570|NCT06020469||Numeric Rating Scale (NRS) score after surgery ≥ 4|
88872571|NCT06020456||Variants Null|This group includes patients carrying a F8 variant with a major deleterious effect on the F8 gene (non-sense, intron 1 and 22 inversions, large deletions, small insertions/deletions leading to a frameshift and premature stop codon)
88872572|NCT06020456||Variants No Null|This group includes patients carrying a F8 variant with a mild effect on the F8 gene (missense, splice modification, small nucleotide deletion in the intron 13, and variant in the promoter)
88872573|NCT06020378||Hydroxychloroquine treatment group|The Hydroxychloroquine treatment group was defined as having exposure to Hydroxychloroquine during pregnancy.
88872574|NCT06020378||Hydroxychloroquine nontreatment group|The Hydroxychloroquine nontreatment group was defined as having no exposure to Hydroxychloroquine during pregnancy.
88872575|NCT06020365|Experimental|sequential antibiotics treatment and fecal + small intestinal microbiota transplant|
89395912|NCT05181891|Active Comparator|(NC+TAU) No Contingency + Treatment as Usual|Varenicline (VC) will be supplied in .5 mg tablets once per week during the active treatment period. During the first week of treatment (Week 3) participants will be instructed to take .5 mg once per day for days 1-3, and 0.5 mg twice per day for days 4-7. The investigators will maintain a target dose of 1mg twice per day for the remaining active treatment period. Additionally, participants will also receive Take Control counseling via video. NC+TAU will receive reinforcement for submitting any urine sample, regardless of test results.
88872576|NCT06020352|Experimental|Treatment group|KN046 combined with axitinib as a neoadjuvant treatment regimen
89395913|NCT05180487|Experimental|FCU Online + Coach|Parents in this arm will receive access to the FCU Online website and telehealth coaching/ support provided by a trained mental health provider. The FCU Online website includes a brief 5-minute assessment, feedback on parents' responses, and online tools to support parenting in areas that were identified as challenges by the assessment. These tools include animated videos, parenting tips, and interactives to help practice parenting skills. Telehealth coaching will focus on Wellness and Self-Care, Parenting and Substance Use, Positive Parenting, Proactive Parenting, and Supervision and Limit Setting.
89395914|NCT05180487|No Intervention|Waitlist Control|Parents in this arm will initially serve as the control group but will receive access to the FCU Online website and telehealth coaching after completing four waves of data collection (baseline, 3-mo, 6-mo, and 12-mo follow-up).
89395915|NCT04896970|Experimental|Concert|Participants will go to a concert in a closed hall.
89395916|NCT04896970|No Intervention|Control|Participant will stay at home.
89187648|NCT04008758|Experimental|sono group|Evaluate the participant's lung condition using ultrasound and do recruitment maneuver if it is necessary
89187649|NCT04008758|No Intervention|control group|If participants need recruitment maneuver (decreasing saturation, peak airway pressure > 35 mmHg) by clinical judgement, do recruitment maneuver not using lung ultrasound
89395917|NCT05428527||Breast cancer patients with Cancer-related fatigue treatment|Breast cancer patients who approved to use NHI to pay for Cancer-related fatigue treatment drug
89395918|NCT03136666|Experimental|Nifedipine + Candesartan cilexetil|Coadministration of single doses of nifedipine and candesartan tablets
89395919|NCT03255083|Experimental|DS-1205c with osimertinib|Participants receive DS-1205c (at planned doses given orally twice daily: 200 mg, 400 mg, 800 mg, 1200 mg) in combination with daily 80 mg oral dose of osimertinib
89395920|NCT02514148|Other|NO Intervention Control group|No therapeutic intervention are being giving to the group of patients, they only will have their Neurologist previously prescribed pharmacological treatment.
88872577|NCT06020313|Experimental|Experimental Resveratrol|Resveratrol capsules (100mg) will be used from 7am to 7pm, de 3 em 3h. That is, at 7 am, 10 am, 1 pm, 4 pm and 7 pm for 7 days.
89395921|NCT02514148|Experimental|Therapeutic exercise( TE)|The intervention giving to the patients consist on a therapeutic exercise protocol based on neck and low intensity general exercises.
89395922|NCT02514148|Experimental|Therapeutic patient education ( TPE)|The intervention giving to the patients consist on a therapeutic patient education based on pain neurophysiology protocol.
89395923|NCT02514148|Experimental|TE + TPE|The intervention giving to the patients consist on the combination of the therapeutic exercise protocol and the therapeutic patient education protocol.
89395924|NCT02514148|Experimental|TE + TPE + Manual therapy|The intervention giving to the patients consist on the combination of the therapeutic exercise protocol and the therapeutic patient education protocol plus a manual therapy techniques protocol.
89395925|NCT05234853|Experimental|"Monotherapy classic 3+3 design dose escalation and expansion"|
89187650|NCT01032499|Active Comparator|oxytetracycline|
89187651|NCT01032499|Experimental|Taro Elixir|Taken orally one tablespoon (15 mL) of Taro Elixir 3 times daily for breakfast, lunch and dinner.
89395926|NCT03240419|Experimental|Probiotics|Each probiotic capsule contains 180 mg of a standardized white to light beige fine powder consisting of freeze-dried cultures. Specifically, Bifidobacterium BB-12® and Lactobacillus rhamnosus LGG® (50%:50%). This product has a minimum potency of 6.5 billion (6.5E+9) CFU (ColonyForming Units) per capsule. Other ingredients in the powder are: microcrystalline cellulose, maltodextrin, silicon dioxide and magnesium stearate. Participants in this group will take one daily capsule orally starting at the time of recruitment (gestation week 12) and until delivery.
89395927|NCT03240419|Placebo Comparator|Placebo|Participants in this group will take one capsule containing microcrystalline cellulose, maltodextrin, silicon dioxide and magnesium stearate (all ingredients listed in the probiotic capsules except the culture) . Participants in this group will take one daily capsule orally starting at the time of recruitment (gestation week 12) and until delivery.
89395928|NCT01665118|Experimental|Treated Thigh|Trusculpt (Radio Frequency) Device
89395929|NCT01665118|No Intervention|Untreated Contra-lateral Thigh|To be used as the self control in this split body study.
89395930|NCT03735537|Active Comparator|Teriparatide and zoledronic acid|Teriparatide (TPTD) 20mcg daily using Teriparatide Pen Injector, given subcutaneously using a self-administered injection device for two years (24 months) followed by a single intravenous 5mg infusion of zoledronic acid.
89395931|NCT03735537|No Intervention|Standard Care|Continuation of existing bone modifying treatment (i.e. bisphosphonate treatment) or no active bone modifying treatment according to the clinical judgement of the local investigator.
88872578|NCT06020313|Placebo Comparator|Placebo|After 48h washout, placebo capsules (100mg) will be used from 7am to 7pm, de 3 em 3h. That is, at 7 am, 10 am, 1 pm, 4 pm and 7 pm for 7 days.
88872579|NCT06020300|Experimental|Colchicine Post ST Elevation Myocardial Infarction (STEMI)|32 patients with STEMI are assigned for oral colchicine 0.6 mg once daily upon admission for 30 days
88872580|NCT06020300|Placebo Comparator|Placebo (Pyridoxine) Post ST Elevation myocardial Infraction (STEMI)|Another 32 patients with STEMI are assigned for placebo (oral pyridoxine 10 mg) once daily upon admission for 30 days
88872581|NCT06020287||AP-RARP|the robot-assisted laparoscopic radical prostatectomy combined anterior and posterior approach
88872582|NCT06020287||RS-RARP|the robot-assisted laparoscopic radical prostatectomy with the Retzius-sparing approach
88872583|NCT06020287||anterior-RARP|he robot-assisted laparoscopic radical prostatectomy with anterior approach
89187652|NCT01022047|Experimental|Noex|The patients shall use the NOEX drug only once a day (one application in each nostril) during the 12 weeks of treatment
89187653|NCT01022047|Active Comparator|Budecort Aqua|The patients shall use the Budecort Aqua drug only once a day (one application in each nostril) during the 12 weeks of treatment.
89187654|NCT01029301|Experimental|Experimental: Endymed study group|
89187655|NCT01029379||200 patients,ASA 1|
88872584|NCT06020222|Experimental|Cryotherapy group|Both hands and feet received cryotherapy gloves and boots
88872585|NCT06020222|Placebo Comparator|Usual care group|health education leaflets
88872586|NCT06020196|Active Comparator|Rectus sheath block group|The participants will receive bilateral surgical rectus sheath block
88872587|NCT06020196|Active Comparator|Subdermal group|The participants will receive subdermal infiltration of local anaesthetics.
88872588|NCT06020131|Experimental|Thoracic Mobility Group|Thoracic Mobility Exercises Ankle Strengthening Home Exercises with resistive band
88872589|NCT06020131|Experimental|Lumbopelvic Stability Group|Lumbopelvic stabilization exercises Ankle Strengthening Home Exercises with resistive band
88872590|NCT06020092|Experimental|Injectable biphasic calcium phosphate (maxresorb inject, botiss GmbH)|This biomaterial is an alloplastic bone substitute material in the form of a paste that is placed into the defect with a plastic syringe. The material consists of an aqueous gel containing granules of biphasic calcium phosphate in the composition of 60% HA and 40% β-TCP (particle size between 15-50 nm).
88872591|NCT06020092|Active Comparator|Bovine xenograft (cerabone, botiss GmbH)|The material is completely anorganic and consists of 100% HA. For this study, the material will be used in granular form (the size of the granules is between 0.5 and 1 mm), mixed with physiological solution prior to placement into the defect.
88872592|NCT06020079|Experimental|laughter yoga group|Laughter yoga was administered to the intervention group twice a week, on Tuesdays and Fridays, for 5 weeks, in a total of 10 sessions (the duration of each session was 50 minutes). Apart from the first and last sessions, eight sessions of the laughter yoga intervention were held via an Internet program with on-line meeting option due to the COVID-19 pandemic that started in March 2019. For the feasibility of online sessions, opinions were obtained from experts who provide laughter yoga leadership training.
88872593|NCT06020079|No Intervention|Control group|no intervation
88872594|NCT06020066|Experimental|3rd generation EGFR-TKI+SRS|The experimental arm will undergo stereotactic radiotherapy targeting all residual lesions in the brain (completed in a single or multiple treatment courses within one month), while continuing EGFR-TKI therapy until disease progression or intolerable toxicity occurs.
88872595|NCT06020066|Active Comparator|3rd generation EGFR-TKI|The control group will receive 3rd generation EGFR-TKI until disease progression or intolerable toxicity occurs.
88872596|NCT06020053|No Intervention|One of the symmetrical Impacted Mandibular Third Molars, control group|Serum at room temperature (25°C) was applied to one of the mandibular impacted third molars
88872597|NCT06020053|Experimental|One of the symmetrical Impacted Mandibular Third Molars, intervention group|Serum at temperature (4°C) was applied to one of the mandibular impacted third molars
88872598|NCT06020040|Experimental|Large Bone Particles|The size of the bone particles that will be used for GBR is 1-2mm.
88872599|NCT06020040|Experimental|Small Bone Particles|The size of the bone particles that will be used for GBR is 0.25-1mm.
88872600|NCT06019936|Experimental|MT2004 Capsule|The MT2004 Capsule will be orally used twice daily after meal for 12 weeks.
88872601|NCT06019936|Placebo Comparator|MT2004 Capsule Placebo|The MT2004 Capsule Placebo will be orally used twice daily after meal for 12 weeks.
88872602|NCT06019858|Experimental|Vitamin Energy Shot|Participants will take one bottle daily of the Vitamin Energy® shot, in the morning.
88872603|NCT06019715|Experimental|Intervention Arm|This arm will receive the full intervention, including 4 months of health coaching support, 8 virtual health coaching visits, a Fitbit device, and an at home blood pressure monitor.
89395932|NCT04552587|Experimental|HEART|Patients and caregivers will complete a HEART visit virtually or in person. The visit includes a needs assessment that generates a tailored care plan with messages, referrals and educational materials for discussion with a nurse. Caregivers will receive brief training about the HEART App and then use the App for 4 weeks with bi-weekly real-time prompts and feedback.
88872604|NCT06019650|Experimental|Intervention|"C-MAP is a culturally adapted brief problem-focused therapy, based on the principles of CBT which has been adapted with permission from a self-help guide called Life after self-harm(Schmidt & Davidson, 2004). This intervention includes evaluation of the self-harm attempt, crisis skills, problem-solving and basic cognitive techniques to manage emotions, negative thinking and relapse prevention strategies."
88872605|NCT06019650|No Intervention|Standard Routine Care|Local medical, psychiatric and primary care services provide standard routine care according to their clinical judgment and available resources
88872606|NCT06019585|Active Comparator|Splint inmmobilization|Distal radius fractures fixed with volar locking plate and immobilized with an antebrachial splint for 3 weeks
88872607|NCT06019585|Active Comparator|Bandage immovilization|Distal radius fractures fixed with volar locking plate and immobilized with a compressive bandage for 3 weeks
88872608|NCT06019572||Younger cohort (<80 years)|
88872609|NCT06019572||octogenarians (≥80 years)|
88872610|NCT06019533|Experimental|LVDS|
88872611|NCT06019520|Active Comparator|Cisplatin group|This group of Patients will receive Cisplatin-base chemotherapy as per the designated schedule, alongside standard hydration protocol
88872612|NCT06019520|Experimental|N-acetylcysteine group|Patients in the NAC arm to be given N-acetylcysteine 1200 mg/day starting 12 hrs before till 6 days after Cisplatin-based chemotherapy administration. Hydration according to standard hydration protocol will be given.
88872613|NCT06019455||Observational group|Patients undergoing definitive radiochemotherapy ± immunotherapy will be assessed about the level of participation in their medical processes.
88872614|NCT06019429|Experimental|HiRO plus judo|In this condition, students receive weekly classes aimed to promote social-emotional development. In addition, they will receive 6 judo classes.
88872615|NCT06019429|Experimental|HiRO|In this condition, students receive weekly classes aimed to promote social-emotional development.
89395933|NCT04531059|Active Comparator|Tetracycline Bismuth Quadruple Therapy|Esomeprazole 20mg bid Bismuth Potassium Citrate 600mg bid Tetracycline 500mg qid Metronidazole 400mg qid
89395934|NCT04531059|Experimental|Minocycline Bismuth Quadruple Therapy|Esomeprazole 20mg bid Bismuth Potassium Citrate 600mg bid Minocycline 100mg bid Metronidazole 400mg qid
89395935|NCT03136744|Experimental|Sit Less with MS|The Sit Less with MS program is based on Social Cognitive Theory (SCT) and consists of strategies that will enable people with MS to 'sit less' by frequently interrupting sitting and 'move more' by replacing sitting with light-intensity activity during waking hours.
89395936|NCT05171127||Glioblastoma|No intervention. Observation of diffuse reflectance spectroscopy patterna are made on ex-vivo tissue samples in patients undergoing surgery for glial tumors.
89395937|NCT05090176|Experimental|povidone-soaked suture|"The patient is randomized, those with povidone-soaked suture group will be prepared for povidone-soaked suture during wound closure.~The absorbable suture will be soaked into povidone for 3 mins before the wound closure."
89395938|NCT05090176|Active Comparator|ordinary suture|the patient is randomized, those with ordinary suture group will proceed with wound closure as usual manner following the standard practice.
89395939|NCT05090020||Hypernatremia|Hypernatremia (plasma sodium value above 145 mmol/L) due to HS use in the treatment of hydatid cyst.
89395940|NCT05158335|Experimental|MBX 2109 (Part A)|Single ascending SC doses
89395941|NCT05158335|Experimental|MBX 2109 (Part B)|Repeated ascending SC doses
89395942|NCT05158335|Placebo Comparator|Placebo|
89395943|NCT04716166|Experimental|Volume-oriented incentive spirometry|Postoperative Volume oriented incentive spirometry 3 times a day
89395944|NCT04716166|Experimental|Flow-oriented incentive spirometry|Postoperative Flow oriented incentive spirometry 3 times a day
89395945|NCT04701502|Experimental|Interventional|"A total of 60 subjects will be randomized 2: 1 in this study. 40 patients will be assigned to Viusid plus Asbrip, plus standard care of the hospital.~Treatment duration: 21 days."
89395946|NCT04701502|Other|Control|"A total of 60 subjects will be randomized 2: 1 in this study. 20 control patients will be assigned to standard care of the hospital only.~Treatment duration: 21 days."
89395947|NCT01316055|Active Comparator|Healthy: Dalfampridine-ER 7.5 mg|Dalfampridine-ER 7.5 mg single and steady-state dosing in healthy volunteers
89395948|NCT01316055|Active Comparator|Mild renal: Dalfampridine-ER 7.5 mg|Dalfampridine-ER 7.5 mg single and steady-state dosing in volunteers with mild renal impairment
89003907|NCT04010357|Experimental|Abemaciclib|"Subjects will receive Abemaciclib (200 mg), orally every 12 hours on days 1 to 28 of a 28-day cycle for a total of 56 doses per cycle.~Subjects will be evaluated after 4 weeks (1st cycle) and then every 8 weeks (2 cycles) with radiographic imaging to assess response to treatment."
89395949|NCT01316055|Active Comparator|Moderate renal: Dalfampridine-ER 7.5 mg|Dalfampridine-ER 7.5 mg single and steady-state dosing in volunteers with moderate renal impairment
89395950|NCT04685668|Experimental|Women in labour|"All women in labour during the study period will be included for this pre- vs. post-study of the PartoMa intervention.~The following subgroups will be studied in-depth:~All stillbirths~All children born with low Apgar score"
89395951|NCT05349357|Active Comparator|Group A|TENS, Stretching exercises, ROM exercises Sliding neural mobilization to femoral, sciatic, tibial nerve
89003908|NCT03997162||Observational (ERAS protocol)|Participants complete standard of care early recovery after surgery protocol beginning the day before surgery to day 6 after surgery.
89003909|NCT03990896|Experimental|Talazoparib|-Talazoparib will be provided as capsules for oral administration daily
89395952|NCT05349357|Active Comparator|Group B|TENS, Stretching exercises, ROM exercises Tensioner neural mobilization to femoral, sciatic, tibial nerve
89395953|NCT04674124|Experimental|Online Mindfulness Course|Participants will be enrolled on a 9 week online mindfulness course.
89003910|NCT03989102|Experimental|Arm 1|Arm 1: (n= 100) will receive 3 doses of PfSPZ Vaccine (9 x10(5)) via direct venous inoculation (DVI) at 1, 8, 29 days.
89395954|NCT04674124|No Intervention|Delayed course materials|Participants will have access to the course materials at the closure of their involvement in the study.
89395955|NCT01340976|Experimental|LY2787106 Dose Escalation|Part A: Dose escalation starting at 0.3 milligram/kilogram (mg/kg), intravenously (IV), day one of up to three 21-day cycles.
89395956|NCT01340976|Experimental|10 mg/kg LY2787106|Part B: 10 mg/kg of LY2787106, administered IV, on day one of up to eight 7-day cycles. Participants who do not experience a stopping rule and who are felt to be benefiting during the defined treatment period may receive additional doses at the discretion of the investigator.
89395957|NCT01340976|Experimental|10 mg/kg LY2787106+Iron|Part B: 10 mg/kg of LY2787106, administered IV, on day one of up to eight 7-day cycles with daily oral iron supplementation. Participants who do not experience a stopping rule and who are felt to be benefiting during the defined treatment period may receive additional doses at the discretion of the investigator.
89395958|NCT05089240|Other|20-29 years (+0.40D extra power)|
89395959|NCT05089240|Other|30-35 years (+0.40D extra power)|
89395960|NCT05089240|Other|20-29 years (+0.40D extra power with blue cut)|
89395961|NCT05089006||robot-assisted surgery group|Patients undergoing robot-assisted surgery for small renal tumor
89395962|NCT05089006||open surgery group|Patients undergoing open surgery for small renal tumor
89395963|NCT05088915|Experimental|BREATHE Primary Care Intervention for PTSD (PCIP)|"BREATHE PCIP is a treatment for Post-Traumatic Stress Disorder (PTSD) symptoms for use with individuals who have a diagnosis of PTSD or probable PTSD. The treatment will be considered delivered when patients have learned and practiced breathing retraining and have discussed the symptoms of PTSD (Sessions 1 through 3)."
89395964|NCT05088915|Active Comparator|Treatment As Usual|Receive standard care treatment and provided information on free or low cost mental health care referrals in the Los Angeles Area.
89395965|NCT05088850||non-sepsis|
89395966|NCT05088850||sepsis|
89530492|NCT03347513|Experimental|Eradication of H-pylori|"triple attack therapy (Clarithromycin 500 mg BID for 14 days, omeprazole 20 mg BID for 14 days, metronidazole 500 mg BID for 14 days).~Followed by confirmation of eradication by repeating the H-pylori stool antigen test.~Iron therapy will be given twice daily for one month in the form ferrous(II)-glycine-sulphate complex 567.7 mg capsules (each capsule contains about 100 mg elemental iron) Ferro sanol duodenal ®Minapharm, Egypt."
89003911|NCT03989102|Experimental|Arm 2|Arm 2: (n= 100) will receive 3 doses of PfSPZ Vaccine (1.8 x10(6)) via DVI at 1, 8, 29 days.
89003912|NCT03989102|Placebo Comparator|Arm 3|Arm 3: (n=100): will receive 3 doses of normal saline (placebo) injection via DVI at 1, 8, 29 days.
89003913|NCT03987581|Experimental|CBT + mCM + incentive|Participants in this arm will receive 12 sessions of cognitive behavioral treatment, mobile contingency management for alcohol abstinence, and a monetary incentive for 30-day abstinence at the 6-month follow-up.
89003914|NCT03987581|Experimental|CBT + mCM + no incentive|Participants in this arm will receive 12 sessions of cognitive behavioral treatment and mobile contingency management for alcohol abstinence. They will not receive monetary incentive for 30-day abstinence at the 6-month follow-up.
89003915|NCT03987581|Experimental|CBT alone + incentive|Participants in this arm will receive 12 sessions of cognitive behavioral treatment and a monetary incentive for 30-day abstinence at the 6-month follow-up. They will not receive contingency management for alcohol abstinence during the treatment period.
89003916|NCT03987581|Active Comparator|CBT alone + no incentive|Participants in this arm will receive 12 sessions of cognitive behavioral treatment. They will not receive monetary incentive for 30-day abstinence at the 6-month follow-up. They will not receive contingency management for alcohol abstinence during the treatment period.
89395967|NCT05665959||Reiki Group|Patient Information Form (PIF), Visual Analog Scale (VAS), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and Holistic Well-Being Scale (HWS) were administered to the Reiki group. After the pretests of the patients were completed, the primary investigator with Reiki second degree applied Reiki therapy to the patients for 40 minutes. On the second and third days, she applied distant reiki. After 3 days and 10 days after the patients were included in the study, the post-tests were performed by calling the patients.
89395968|NCT05665959||Control Group|Patient Information Form (PIF), Visual Analog Scale (VAS), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and Holistic Well-Being Scale (HWS) were administered to the control group. After 3 days and 10 days after the patients were included in the study, the post-tests were performed by calling the patients.
89395969|NCT04592692|Experimental|Inhibitors|Patients with inhibitors to FVIII
89395970|NCT04592692|Other|Non-inhibitors|Patients without inhibitors to FVIII
89003917|NCT03983512|Experimental|PULSTA TPV|PULSTA Transcatheter Pulmonary Valve (TPV) System
89395971|NCT04558294|Experimental|100 μg LSD + Ketanserin placebo|
89395972|NCT04558294|Experimental|100 μg LSD + Ketanserin (40mg)|
89530493|NCT03347513|Active Comparator|No eradication of H-pylori|Iron therapy will be given twice daily for one month in the form ferrous(II)-glycine-sulphate complex 567.7 mg capsules (each capsule contains about 100 mg elemental iron) Ferro sanol duodenal ®Minapharm, Egypt.
89530494|NCT04088591|Experimental|Treatment arm|The study drug is ascorbic acid is 200mg/kg/day divided over 4 doses per day and delivered in 50 ml of 5% dextrose in water intravenously over a total duration of 96 hours.
89003918|NCT03955250|Experimental|Mobile After-Care Support (MACS) app|All participants download the app to their mobile phone. The app runs through a third-party software platform. It is designed to provide ecological momentary assessment and intervention.
89003919|NCT03955250|Active Comparator|Mobile app attention control|All participants download the app to their mobile phone. The app runs through a third-party software platform. It is designed to provide ecological momentary assessment and psychoeducation about illness.
89003920|NCT03955146|Experimental|Pamrevlumab|Pamrevlumab 30 mg/kg by IV infusion every 3 weeks for a total of up to 17 infusions over 48 weeks
89003921|NCT03955146|Experimental|Placebo|Placebo matching to pamrevlumab by IV infusion every 3 weeks for a total of up to 17 infusions over 48 weeks
89003922|NCT03950570|Experimental|Phase 1: Dose Escalation|"Advanced solid tumors or metastatic breast cancer: Treatment with a single oral agent, ORIN1001.~Relapsed, refractory metastatic breast cancer: Treatment with a combination of ORIN1001 and Abraxane."
89003923|NCT03950570|Experimental|Phase 2: Dose Expansion|Relapsed refractory metastatic breast cancer that are Triple negative, ER+ or HER2- and treated with a single agent (ORIN1001) or in combination with ORIN1001 and Abraxane.
89003924|NCT03948776||Healthy volunteers|Adults without HF or prior heart transplantation
89003925|NCT03948776||Participants in our existing LVAD body composition study|Currently-enrolled LVAD body composition participants, who chose to participate in this study on the same day as a DXA scan already scheduled for study #12026
89003926|NCT03948776||Patients with heart failure, an LVAD or heart transplantation|Any patients with a current diagnosis of HF, with or without an LVAD, or prior HF now status post heart transplantation
88872616|NCT06019429|Active Comparator|School as usual|In this condition, students receive any amount of classes organized by their school to promote social-emotional development.
88872617|NCT06019416|Experimental|Intervention group|As the intervention group, the participants should participate in three weekly scheduled mindfulness-positive psychological intervention sessions using virtual reality for 15 - 20 minutes per session.
88872618|NCT06019416|No Intervention|Waitlist group|As the waitlist group, no treatment was given to the participants, while the intervention group participated in the mindfulness-positive psychological intervention for three weeks. After the three-week waiting period, the participants were contacted and asked to complete the post-measurements. After completion, the participants started with the three-week mindfulness-positive psychological intervention using virtual reality for 15 - 20 minutes. No further data was obtained from these participants after the completion of the program.
88872619|NCT06019390|Experimental|experimental|
88872620|NCT06019312|Experimental|Lactobacillus plantarum 299v|15 patients will receive 2 capsules (per day - 1 capsule contains 10x10 CFU) of L. plantarum 299v for 4 weeks
88872621|NCT06019312|Experimental|Lactobacillus plantarum 299v in combination with inulin|15 patients will receive 2 capsules (per day - 1 capsule contains 10x10 CFU) of L. plantarum 299v and inulin (4 g) for 4 weeks
88872622|NCT06019312|No Intervention|Placebo in combination with inulin|15 patients will receive 2 capsules (per day) of placebo and inulin (4 g) for 4 weeks
88872623|NCT06019312|No Intervention|Placebo|15 patients will receive 2 capsules (per day) of placebo for 4 weeks
88872624|NCT06019299|Active Comparator|Positive Control|The control experimental group received training on the utilization of mindfulness-based stress reduction breathing techniques. Participants were instructed to set a timer for 5 minutes in order to engage in mindfulness breathing. Comprehensive instructions were provided during the initial laboratory time, elucidating the method by which participants were to direct their attention towards their breath. Moreover, participants were encouraged to cultivate a non-judgmental attitude when confronted with potential distractions and to subsequently redirect their focus back to their breathing. Participants were advised to integrate this technique into their daily lives as a means to alleviate anxiety and stress.
88872625|NCT06019299|Experimental|Mindfulness-Based Cognitive Therapy intervention|"The active experimental group received a mindfulness based cognitive therapy through the Sanvello smartphone application. Participants were encouraged to practice mindfulness daily through the application program Braving Anxiety, which consisted of 35 modules. The anxiety management program consists of 1) Watch, 2) Read, 3) Listen, 4) Plan, 5) Listen - Mindfulness practice."
88872626|NCT06019286||COPD cases|COPD patients for whom biological marker and dermatological score will be measured
88872627|NCT06019286||Control group|non COPD subjects for whom biological marker and dermatological score will be measured
88872628|NCT06019247|No Intervention|Usual Services.|Generally, providers of rehabilitation Usual Care for PSMI at CAISAME-EP include 2 full-time psychologists, 2 full-time social workers, a half-time occupational therapist, and a half-time psychiatrist. This team, however, also provides services to clients with other mental conditions (e.g., substance use). As a result, the Usual Care services are of lower intensity than IPS and omit most of the key ingredients of the intervention. Moreover, it does not follow a standardized manual/protocol. The Usual Care team also offers other services such as psychiatric medication, individual and group psychotherapy, and psychoeducation for clients and relatives.
88872629|NCT06019247|Experimental|Adapted IPS|The IPS program adaptation process, will be conducted with 2 teams of providers, each consisting of an employment specialist, a case manager: psychologist, social worker and a psychiatrist, who will work in coordination to provide IPS services (each specialist will have between 15 and 20 clients). The IPS team will consist of providers and will be trained by the Research Adaptation Team in consultation and supervised. Weekly case-oriented supervision with a trained IPS supervisor, biweekly telephone contact, and telephone consultations as needed will help the IPS teams maintain high fidelity IPS. Following randomization, individuals assigned to receive IPS will be assigned to an IPS treatment team and will be introduced directly to their assigned case managers. Case management and IPS staff will be in close proximity to facilitate both IPS staff attendance at case management team meetings and the ongoing interaction necessary for efficient IPS implementation.
88872630|NCT06019208||GENOMED4ALL - SCD patients|Non transplanted SCD patients aged over 1 year.
88872631|NCT06019169|Active Comparator|Workshops around storytelling|"Participate in workshops around storytelling led by the association of storytellers l'Age D'or. 4 sessions are planned (2 face-to-face and 2 remotely) per month for 3 months."
88872632|NCT06019169|Experimental|Yoga classes|Participation in YOGA classes. There are 4 sessions of 45 minutes (2 face-to-face and 2 remote) per month for 3 months.
88872633|NCT06019156|Experimental|metaverse group|
88872634|NCT06019156|Active Comparator|YouTube group|
88872635|NCT06019156|No Intervention|Control group|
88872636|NCT06019143|Experimental|Arm A|Goal Attainment Scaling (GAS) with goal inventory
88872637|NCT06019143|Active Comparator|Arm B|Goal Attainment Scaling (GAS) without goal inventory
89187656|NCT04001036|Experimental|Experimental peritoneal dialysis solution IPX15|Patients will receive treatment with the experimental solution for nocturnal (long-dwell) exchange. For daily (short-dwell) exchanges, all patients will continue the 1 to 3 bags of glucose peritoneal dialysis solution as for their pre-randomization prescription.
88872638|NCT06019130|Experimental|Patients < 26 years with non-metastatic disease with CR or PR after induction therapy|"Participants receive Nivolumab (4.5 mg/kg BW (max. 360 mg) every three weeks) during induction chemotherapy for a total of 3 doses, starting on day 1 of cycle 1 of induction standard chemotherapy with cisplatin 100 mg/m2 on day 1, plus 5-fluorouracil 1,000 mg/m2/d from day 1-5.~After induction therapy patients will undergo standard radiochemotherapy. Primary PTV1 including elective irradiated LN-levels, will be 45Gy, with a boost ad 59.4Gy in patients with PR or a reduced boost at 54Gy in patients with CR. Cisplatin will be administered at 3x20mg/m2 in the first and last week of radiotherapy, each.~Radiochemotherapy is followed by maintenance therapy with recombinant interferon-ß1a at 3x6Mio IU/week s.c. for 6 months."
88872639|NCT06019130|Experimental|Patients < 26 y with no metastases and SD or PD after induction therapy or patients with metastases|"Participants receive Nivolumab (4.5 mg/kg BW (max. 360 mg) every three weeks) during induction chemotherapy for a total of 3 doses, starting on day 1 of cycle 1 of induction standard chemotherapy with cisplatin 100 mg/m2 on day 1, plus 5-fluorouracil 1,000 mg/m2/d from day 1-5. Patients with metastases responding to induction therapy may have a fourth cycle of induction therapy, including a fourth dose of Nivolumab.~After induction therapy patients will undergo standard radiochemotherapy. Primary PTV1 including elective irradiated LN-levels, will be 45Gy, with a boost ad 59.4Gy. Cisplatin will be administered at 3x20mg/m2 in the first and last week of radiotherapy, each. Nivolumab (4.5 mg/kg BW (max. 360 mg) every three weeks) will be continued during radiochemotherapy, adding a total of 3 further doses of Nivolumab.~Radiochemotherapy is followed by maintenance therapy with recombinant interferon-ß1a at 3x6Mio IU/week s.c. for 6 months."
89395973|NCT05088538|No Intervention|Control group|When the patients are in clinic,The Patient Information Form,Turkey Health Literacy Scale-32,Patient Learning Needs Scale,Functional Assessment Form,Knee Assessment Questionnaire and Quality of Life Scale Form will be filled.The second interview will be conducted on the second or third day after the surgery, just before the patients will be discharged.The Functional Assessment Form,Knee Assessment Questionnaire,Discharge Data Collection Form, and Quality of Life Questionnaire will be applied.The third interview will be performed 15 days after the surgery when the patients come for control or by phone.The 15th Day Recovery Process Data Collection Form and Knee Assessment Questionnaire will be applied.The last interview will be carried out six weeks after the surgery,either face-to-face or by phone,and the Functional Assessment Form,Knee Assessment Questionnaire, 6th Week Post-Discharge Recovery Process Data Collection Form,and Quality of Life Questionnaire will be applied again.
89395974|NCT05088538|Experimental|Intervention group|Unlike the control group, the intervention group will be given the education plan prepared by the researchers.
88872640|NCT06019130|Experimental|Patients >25 years with non-metastatic disease with CR or PR after induction therapy|"Participants receive Nivolumab (4.5 mg/kg BW (max. 360 mg) every three weeks) during induction chemotherapy for a total of 3 doses, starting on day 1 of cycle 1 of induction standard chemotherapy with cisplatin 100 mg/m2 on day 1, plus 5-fluorouracil 1,000 mg/m2/d from day 1-5.~After induction therapy patients will undergo standard radiochemotherapy as outlined in current international guidelines (e.g. NCCN, ESMO)."
89395975|NCT01680016|Experimental|Zagreb(≥6 to ≤17 Years)|
88872641|NCT06019130|Experimental|Patients > 25 years with non-metastatic disease with SD or PD after induction therapy|"Participants receive Nivolumab (4.5 mg/kg BW (max. 360 mg) every three weeks) during induction chemotherapy for a total of 3 doses, starting on day 1 of cycle 1 of induction standard chemotherapy with cisplatin 100 mg/m2 on day 1, plus 5-fluorouracil 1,000 mg/m2/d from day 1-5.~After induction therapy patients will undergo standard radiochemotherapy as outlined in current international guidelines (e.g. NCCN, ESMO). Nivolumab (4.5 mg/kg BW (max. 360 mg) every three weeks) will be continued during radiochemotherapy, adding a total of 3 further doses of Nivolumab."
89003927|NCT03948776||Inpatients with heart failure, LVAD, heart transplantation|Patients with a current diagnosis of HF, with or without an LVAD, or prior HF now status post heart transplantation, currently admitted as inpatients at Tufts Medical Center. The 6/20/2019 protocol update includes these patients who will participate without a DXA scan (which can only be performed as an outpatient).
89395976|NCT01680016|Experimental|Zagreb(≥51 Years)|
89395977|NCT01680016|Active Comparator|Essen(≥6 to ≤17 Years)|
89395978|NCT01680016|Active Comparator|Essen(≥51 Years)|
89395979|NCT03378466|Experimental|Unfractionated Heparin (UFH)|UFH initiated at 18 IU/kg/hr
89395980|NCT03378466|Other|Venous thromboprophylaxis (VTE)|as per local standard
89395981|NCT05080270|Experimental|tolerogenic fibroblasts administered via intravenous infusion|A single dose of 100 million tolerogenic fibroblasts administered via intravenous infusion.
89395982|NCT05077540|Active Comparator|oxytocin|20 unit of oxytocin infusion in 500 ml lactated ringer's solution 125 ml/h (Syntocinon, Novartis, Switzerland)
89395983|NCT05077540|Experimental|misoprostol|800 µg sublingual misoprostol (Cytotec Pfizer, New York, USA)
89530495|NCT04088591|Placebo Comparator|Placebo arm|The placebo is 50ml of 5% dextrose in water and will be administered 4 doses per day over a total duration of 96 hours
89530496|NCT04501289|Experimental|Low dose magnesium sulphate|Experimental - participants in this arm will be pregnant women with severe preeclampsia/eclampsia who will receive low dose magnesium sulphate
89395984|NCT03619473|Experimental|intervention|"the group~assessed for proper helmet usage (type, chinstrap, standard helmet usage)~evaluated for the behavioral of helmet usage~underwent the educational session under helmet initiative program~received one standard motorcycle child safety helmet per family~assessed for proper helmet usage (type, chinstrap, standard helmet usage) 3 months after educational session and after received standard motorcycle child safety helmet~evaluated for the behavioral of helmet usage 3 months after educational session and after received standard motorcycle child safety helmet"
89395985|NCT03619473|No Intervention|control|"the group~assessed for proper helmet usage (type, chinstrap, standard helmet usage)~evaluated for the behavioral of helmet usage~assessed for proper helmet usage after 3 months 4 evaluated for the behavioral of helmet usage after 3 months~do not receive any educational session or standard motorcycle child safety helmet"
89395986|NCT05412225|Experimental|Participants with clinical T4 biopsy-proven breast cancer|Participants with clinical T4 biopsy-proven breast cancer with no evidence of distant metastases who demonstrate a complete or partial response to standard neoadjuvant chemotherapy/NAC and desire immediate autologous reconstruction/IR will be eligible to enroll.
89395987|NCT05407545|Experimental|Prosthesis|A unilateral transfemoral amputee will conduct experiments with the active prosthesis and with the current prosthesis.
88872642|NCT06019130|Experimental|Patients > 25 years with metastatic disease at diagnosis|"Participants receive Nivolumab (4.5 mg/kg BW (max. 360 mg) every three weeks) during induction chemotherapy for a total of 3 doses, starting on day 1 of cycle 1 of induction standard chemotherapy with cisplatin 80 mg/m2 on day 1, plus gemcitabine 1,000 mg/m2/d on day 1 and day 8, respectively. Patients responding to induction therapy may have a fourth cycle of induction therapy, including a fourth dose of Nivolumab.~After induction therapy patients will undergo standard radiochemotherapy as outlined in current international guidelines (e.g. NCCN, ESMO). Nivolumab (4.5 mg/kg BW (max. 360 mg) every three weeks) will be continued during radiochemotherapy, adding a total of 3 further doses of Nivolumab."
88872643|NCT06019117|Active Comparator|Arm 1 - volunteers with parkinson's disease|26 patients in this arm. in this arm will receive the probiotic K10 (2mg/kg/dia).
88872644|NCT06019117|Placebo Comparator|Arm 2 - volunteers with parkinson's disease|26 patients in this arm. In this arm will receive the controlled placebo.
88872645|NCT06019117|Active Comparator|Arm 3- volunteers with alzheimer's disease|26 patients in this arm. in this arm will receive the probiotic K10 (2mg/kg/dia).
88872646|NCT06019117|Placebo Comparator|Arm 4- volunteers with alzheimer's disease|26 patients in this arm. In this arm will receive the controlled placebo.
88872647|NCT06019104|Experimental|Task-oriented training group|Among the patients in the task-oriented training group, 12 sessions were given routinely, 3 days a week, for 4 weeks. Task-oriented training consisted of 25 different stations in total, including 9 different gaze stabilization training, 7 balance training, and 9 gait training stations. Gaze stabilization exercises included head-fixed right-left eye movements, head-fixed up-down eye movements, eye fixed right-left head movements, eye fixed up-down head movements, head and eye opposing movements (right-left/ up-down), saccadic and pursuit eye movements (right-left/ up-down). Balance and gait training included these exercises: rolling on the mat, vertical rotation, spinning on a rotary disc, standing on balance bord, jumping, playing dart, reaching, walking forward, walking with head movements (right-left/ up-down), tandem walking, '8' shape walking, walking by picking something up from the ground, walking over an obstacle, walking on treadmill, climbing and descending stairs.
88872648|NCT06019104|Active Comparator|Control group|Among the patients in the control group with peripheral vestibular disorders, 12 sessions were given routinely, 3 days a week, for 4 weeks. They were asked to perform gaze stabilization exercises for 1 min. Gaze stabilization exercises consist of head-fixed right-left eye movements, head-fixed up-down eye movements, eye fixed right-left head movements, and eye fixed up-down head movements.
88872649|NCT06019065|Experimental|Cohort A1: Single ascending dose of AJA001|AJA001 active q.d. 2.2 mL oral dose level 1
88872650|NCT06019065|Placebo Comparator|Cohort A1: Single ascending dose of placebo|AJA001 placebo q.d. 2.2 mL oral dose level 1
88872651|NCT06019065|Experimental|Cohort A2: Single ascending dose of AJA001|AJA001 active q.d. ascending oral dose level 2
88872652|NCT06019065|Placebo Comparator|Cohort A2: Single ascending dose of placebo|AJA001 placebo q.d. ascending oral dose level 2
88872653|NCT06019065|Experimental|Cohort A3: Single ascending dose of AJA001|AJA001 active q.d. ascending oral dose level 3
88872654|NCT06019065|Placebo Comparator|Cohort A3: Single ascending dose of placebo|AJA001 placebo q.d. ascending oral dose level 3
88872655|NCT06019065|Experimental|Cohort A4: Single ascending dose of AJA001|AJA001 active q.d. ascending oral dose level 4
88872656|NCT06019065|Placebo Comparator|Cohort A4: Single ascending dose of placebo|AJA001 placebo q.d. ascending oral dose level 4
88872657|NCT06019065|Experimental|Cohort B1: Multiple ascending doses of AJA001|AJA001 active b.i.d. oral dose level 1
88872658|NCT06019065|Placebo Comparator|Cohort B1: Multiple ascending doses of placebo|AJA001 placebo b.i.d. oral dose level 1
88872659|NCT06019065|Experimental|Cohort B2: Multiple ascending doses of AJA001|AJA001 active b.i.d. oral dose level 2
88872660|NCT06019065|Placebo Comparator|Cohort B2: Multiple ascending doses of placebo|AJA001 placebo b.i.d. oral dose level 2
88872661|NCT06019065|Experimental|Cohort B3: Multiple ascending doses of AJA001|AJA001 active b.i.d. oral dose level 3
89530497|NCT04501289|Experimental|Magnesium sulphate Pritchard regimen|Experimental - participants in this arm will be pregnant women with severe preeclampsia/eclampsia who will receive Pritchard regimen of magnesium sulphate
88872662|NCT06019065|Placebo Comparator|Cohort B3: Multiple ascending doses of placebo|AJA001 placebo b.i.d. oral dose level 3
88872663|NCT06019065|Experimental|Cohort B4: Multiple ascending doses of AJA001|AJA001 active b.i.d. oral dose level 4
88872664|NCT06019065|Placebo Comparator|Cohort B4: Multiple ascending doses of placebo|AJA001 placebo b.i.d. oral dose level 4
88872665|NCT06019039||Epidural Ultrasound group|After placement of the epidural catheter, parasagittal and transverse views with CFD will be obtained to identify location of the catheter within the epidural space. Two levels above and below the insertion site will be used to locate the epidural catheter.
89187657|NCT04001036|Experimental|Experimental peritoneal dialysis solution IPX07|Patients will receive 1 to 3 daily (short-dwell) exchanges with the experimental solution (the number of exchanges will be based on their pre-randomization prescription). All patients will receive icodextrin for nocturnal (long-dwell) exchange.
89395988|NCT01340898|Experimental|Nimenrix 3+1 Group|Subjects, male and female, received 4 doses of Nimenrix™ vaccine (3 doses at 2, 4 and 6 months of age followed by a booster dose at 15-18 months of age) and 4 doses of Synflorix™ and Infanrix-IPV/Hiberix™ vaccines (at 2, 4, 6 and 15-18 months of age). All vaccines were administered intramuscularly (IM) in the anterolateral region of the thigh.
89395989|NCT01340898|Experimental|Nimenrix 1+1 Group|Subjects, male and female, received 2 doses of Nimenrix™ vaccine (1 dose at 6 months of age followed by a booster dose at 15-18 months of age) and 4 doses of Synflorix™ and Infanrix-IPV/Hiberix™ vaccines (at 2, 4, 6 and 15-18 months of age). All vaccines were administered intramuscularly (IM) in the anterolateral region of the thigh.
89395990|NCT01340898|Experimental|Nimenrix Control Group|Subjects, male and female, received 1 dose of Nimenrix™ at 15-18 months of age and 4 doses of Synflorix™ and Infanrix-IPV/Hiberix™ vaccines (at 2, 4, 6 and 15-18 months of age). All vaccines were administered intramuscularly (IM) in the anterolateral region of the thigh.
89395991|NCT02426749|Active Comparator|Active Coil|Participants of this arm will receive active rTMS intervention (treatment).
89395992|NCT02426749|Sham Comparator|Sham|Participants of this arm will receive sham rTMS intervention (treatment).
89395993|NCT05328492|Experimental|iVAPS-AE|Patients with ALS and respiratory insufficiency randomised to this arm will be treated with home NIV using the Intelligent Volume-Assured Pressure Support with automatic EPAP (iVAPS-AE) mode.
89395994|NCT05328492|Active Comparator|ST-mode|Patients with ALS and respiratory insufficiency randomised to this arm will be treated with home NIV using the spontaneous timed (ST) home NIV mode.
89395995|NCT03097315|Experimental|4 mg CLS-TA Suprachoriodal Injection|Suprachoroidal injection of 40 mg/mL (4 mg in 100 μL) of CLS-TA
89395996|NCT05530707|Experimental|Microbiome|13 participants using the product for 30 days. Aims to evaluate the quantification of S. Aureus in the skin before and after usage.
89395997|NCT05530707|Experimental|Clinical Trial|36 participants using the product for 60 days. Aims to evaluate the clinical, subjective and instrumental usage.
89395998|NCT05376475||Virtual setup cohort|Participants in this cohort will use a night vision camera and level III home sleep apnea test. If the participant has a bed partner who consents to be in the study, the bed partner will also use a level III home sleep apnea test and be recorded by the night vision camera.
89395999|NCT05376475||In-person setup cohort|Participants in this cohort will use a night vision camera, a level III home sleep apnea test, a maternal-fetal transabdominal electrocardiographic heart rate monitor, and a pressure sensing mat. If the participant has a bed partner who consents to be in the study, the bed partner will also use a level III home sleep apnea test and be recorded by the night vision camera (maternal-fetal transabdominal electrocardiographic heart rate monitor and a pressure sensing mat will not be used by the bed partner).
89396000|NCT05372731|Experimental|RM after BAL|patients underwent RM after BAL
89396001|NCT05372731|No Intervention|Non-RM after BAL|patients did not undergo RM after BAL
88872666|NCT06019013|Experimental|Dose-Escalation Stage and PK-Expansion Stage|"Dose-Escalation Stage：Participants will be assigned sequentially to escalating doses of QLF3108, up to the maximum tolerated dose (MTD).~PK-Expansion Stage：1-4 recommended expansion dose will be proposed for the PK-expansion stage of the trial."
88872667|NCT06018948|Active Comparator|Dexmedetomidine 0.6 group|patients will receive a bolus dose of 1µg/kg dexmedetomidine15 minute after endotracheal intubation over 10 minutes followed by continuous infusion of 0.6 mic/kg/hour for one hour.
89396002|NCT03518671|Experimental|CBT (face to face)|"Self-limited cognitive behavioral therapy (CBT) delivered via 6 weekly sessions, face-face~Up to one year after completion of treatment, patients with body image disturbance (BID) as determined by a Body Image Scale (BIS) score > 5 will undergo time-limited CBT consisting of 6 weekly sessions. Each session will be guided by the HNC BID module that we develop but customized to each patient's specific concerns. Each session will last ~60 minutes and be conducted one-one with a psychologist. Patients will complete questionnaires prior to CBT and 1 and 3 months after CBT."
88872668|NCT06018948|Active Comparator|Dexmedetomidine 0.3group|patients will receive a bolus dose of 1µg/kg dexmedetomidine 15 minute after endotracheal intubation over 10 minutes followed by continuous infusion of 0.3 mic/kg/hour for one hour.
88872669|NCT06018948|Placebo Comparator|Control group|Patients will receive comparable volume of normal saline (0.9%) 15 minute after endotracheal intubation.
88872670|NCT06018922|Experimental|Psychological therapy for Gaming Disorder|They will be offered a module-based psychological treatment that combines Cognitive behavioral therapy (CBT) and Family therapy (FT).
88872671|NCT06018909|Experimental|Cognitive-Behavioral Interventions Package Group|Participants received CBIP. CBIP included procedural preparation and information, distraction, suggestions, parent training and positive reinforcement.
89396003|NCT03518671|Experimental|CBT (telemedicine)|"Self-limited cognitive behavioral therapy (CBT) delivered via 6 weekly sessions, via tablet-based telemedicine platform~Up to one year after completion of treatment, patients with body image disturbance (BID) as determined by a Body Image Scale (BIS) score > 5 will undergo time-limited CBT consisting of 6 weekly sessions. Each session will be guided by the HNC BID module that we develop but customized to each patient's specific concerns. Each session will last ~60 minutes and be conducted one-one with a psychologist. Patients will complete questionnaires prior to CBT and 1 and 3 months after CBT. To overcome the expected travel distance-related barrier to receipt of CBT, patients will receive the intervention via tablet-based telemedicine delivery platform"
89396004|NCT03039699|Experimental|Ergoferon|Tablet for oral use. Dose per administration - 1 tablet per intake (outside a meal/feeding). Within the first 2 hours - 1 tablet every 30 minutes, followed by 3 more tablets at time intervals equally separated throughout the rest of the day; from day 2 to day 5 - 1 tablet 3 times daily.
89530498|NCT03244345|Experimental|Epileptic patient|
89530499|NCT03247075|Experimental|Internet-delivered Cognitive Behavior Therapy|10 weeks of guided Internet-delivered Cognitive Behavior Therapy
89396005|NCT03039699|Placebo Comparator|Placebo|Tablet for oral use. Dose per administration - 1 tablet per intake (outside a meal/feeding). Within the first 2 hours - 1 tablet every 30 minutes, followed by 3 more tablets at time intervals equally separated throughout the rest of the day; from day 2 to day 5 - 1 tablet 3 times daily.
89396006|NCT02003443|Placebo Comparator|Sham Acupressure|Participants assigned to sham acupressure will receive similar instruction as those assigned to pain-relief acupressure, except that they will be taught to apply pressure to 10 acupoints that are unrelated to pain. That is, they will conduct self-administered acupressure 5 days/week for 8 weeks, as the pain-relief acupressure group does, but on 'sham' acupoints.
89396007|NCT02003443|No Intervention|Usual Care|Participants assigned to the UC group will receive no intervention.
89396008|NCT02003443|Experimental|Pain-Relief Acupressure|Participants assigned to pain-relief acupressure will be taught to apply physical pressure, using a wooden hand-held device designed for acupressure, to 10 acupoints on their body.That is, they will conduct self-administered acupressure 5 days/week for 8 weeks,on acupoints that are relevant to pain reduction.
89396009|NCT02833974|Experimental|GSK2245035 20 ng|Participants will receive 20 ng of GSK2245035 Nasal spray solution (1 spray=10 ng GSK2245035 per actuation per nostril) every week for the duration of 8 weeks administered using a metered Valois VP7 pump
89396010|NCT02833974|Placebo Comparator|Placebo|Participants will receive placebo Nasal spray solution (1 spray per nostril) every week for the duration of 8 weeks administered using a metered Valois VP7 pump
89396011|NCT03632005|Other|Sterile Dressing|Standard of care treatment - Standard wound care involves the application of an occlusive dressing in the operating room, a dressing change on Post-operative Day 3 and then dressing changes as needed until suture/staple removal on Post-operative Day 14.
89396012|NCT03632005|Active Comparator|Vacuum Assisted Closure|The Prevena™ System, a type of vacuum assisted closure, is indicated for use over clean, closed incisions that continue to drain following sutured or stapled closure. It acts by removing exudate, helping hold the edges of the incision together, protecting the surgical site from external contamination in a clean, protected postoperative wound environment.
89396013|NCT05303493|Experimental|Camu-camu (intervention) in addition to standard-of-care ICI|"Camu-camu (intervention) will be added to standard-of-care ICI in:~Cohort 1. For patients with advanced NSCLC, treatment will consist of single-agent pembrolizumab in combination with physician's choice platinum-doublet chemotherapy in combination with CC.~Cohort 2. For patients with advanced cutaneous melanoma, treatment will consist of single-agent anti-PD-1 either nivolumab or pembrolizumab at the discretion of the treating physician.~Cohort 3. For patients with advanced melanoma receiving standard-of-care ICI (either single-agent anti-PD-1 or combination anti-CTLA-4 plus anti-PD-1) who experience progressive disease (PD), their current regimen will continue unchanged and they will receive CC at 1500 mg for 3 months or until confirmed progression if progression occurs earlier."
89396014|NCT03093415|Active Comparator|Old Town Clinic, Medication Assisted Therapy group|25 People Who Inject Drugs engaged in a Medication Assisted Therapy treatment program for their substance use disorder, treated for their HCV using elbasvir-grazoprevir (50 mg/100 mg) for 12 weeks.
89396015|NCT03093415|Active Comparator|Outside In Clinic, Needle Exchange Program|25 People Who Inject Drugs engaged in a Needle Exchange Program with risk reduction education, treated for their HCV using elbasvir-grazoprevir (50 mg/100 mg) for 12 weeks.
89396016|NCT03093415|Other|OHSU Hepatology Clinic, Academic center Retrospective Cohort|50 people with substance use disorder and HCV engaged with an Academic Hepatology Clinic (Oregon Health & Sciences University, OHSU) and treated with elbasvir-grazoprevir (50 mg/100 mg) for 12 weeks.
89396017|NCT04145817|Experimental|genetic counselling|Genetic counselling (PRS for risk estimation) and questionnaires in the participating Cancer Genetic Clinics for healthy woman relative of a person first tested in the family (index case) who received a positive genetic test result or a negative non-informative test result
89396018|NCT05470257|Experimental|Elbow Flexion Cast|This cohort will be placed in a long arm flexion cast.
89396019|NCT05470257|Experimental|Elbow Extension Cast|This cohort will be placed in a long arm extension cast.
89396020|NCT01358526|Experimental|OXN|Oxycodone/Naloxone Controlled-release Tablets (OXN)
89396021|NCT01358526|Placebo Comparator|Placebo|Placebo tablets to match OXN
89396022|NCT03564054|Experimental|Photodynamic Therapy|Photodynamic therapy (PDT) uses activation of a photosensitizer by light of a specific wavelength to generate reactive oxygen species and singlet oxygen that causes direct cell damage and death, apoptosis, tumor vasculature damage and thrombosis, and inflammation leading to an immunological response.Following randomization, subjects will undergo treatment with either PDT or APC. Subjects will then have six additional study visits at 30, 45, 60, 90, and 180 days after their last PDT or APC treatment
89396023|NCT03564054|Experimental|Argon Plasma Coagulation|Argon plasma coagulation (APC) is a noncontact form of electrocautery. Following randomization, subjects will undergo treatment with either DPT or APC. Subjects will then have six additional study visits at 30, 45, 60, 90, and 180 days after their last PDT or APC treatment.
89396024|NCT02156232|Active Comparator|TIPS, SPSS Emboliaztion|The covered stents wil be used for TIPS The SPSS will be embolized during the procedure of TIPS
89396025|NCT02156232|Active Comparator|TIPS alone|The covered stents will be used for TIPS No embolization of SPSS will be performed during TIPS
89396026|NCT01310010|Experimental|Dasatinib|
89396027|NCT02830776|Experimental|Treatment group|This is a single-arm open label proof of concept pilot study evaluating use of Latisse (bimatoprost 0.03% ophthalmic solution) applied to the eyelid margin for dermatochalasis (upper eyelid drooping).
89396028|NCT03039621|Experimental|Ergoferon|Tablet for oral use, 1 tablet per intake (outside a meal/feeding). On day 1, five tablets are taken in the first 2 hours (one tablet every 30 min), followed by three more tablets regularly spaced during the rest of the day (total 8 tablets). From day 2, one tablet is taken every 8 hours. The drug is administered outside a meal (in the interval between meals or 15 minutes before meal or fluid intake). Keep the tablet in the mouth, without swallowing, until completely dissolved. For young children (aged 6 months to 3 years old), the tablet is recommended to be dissolved in a small amount (1 tablespoon) of drinking water of room temperature. The therapy lasts for 5 days.
89396029|NCT03039621|Placebo Comparator|Placebo|Placebo using Ergoferon scheme.
89396030|NCT01235130|Active Comparator|OMEGA-3|Long-Chain N-3 polyunsaturated fatty acids (OMEGA-3)
89396031|NCT01235130|Placebo Comparator|Placebo|Placebo soybean oil
88872672|NCT06018909|No Intervention|Control|The control group received the routine peripheral venous cannulation procedure.
88872673|NCT06018896|Experimental|Ascorbate|For patients with baseline serum Vitamin C concentration < 65 μmol/L, intravenous Vitamin C 10 g × 7 days, intravenous Vitamin C 4 g × 7 days, intravenous Vitamin C 2 g × 7 days, followed by continuously 900 mg/day, three times a day, orally. For patients with baseline serum Vitamin C concentration ≥ 65 μmol/L, continuously 900 mg/day, three times a day, orally.
89396032|NCT05708118||Surgical Aortic Valve Replacement (SAVR)|Patients who undergo surgical aortic valve replacement through median longitudinal sternotomy.
89396033|NCT05708118||Transcatheter Aortic Valve Replacement (TAVR)|Patients who undergo transcatheter aortic valve replacement through a transfemoral access.
89396034|NCT05708196|No Intervention|control group|ten extraction sockets left for normal healing (blood clot).
89396035|NCT05708196|Experimental|group 2|ten extraction sockets filled with Alloplast bone grafting material (EthOss, Ethoss Regeneration Ltd, Silsden, UK).
89396036|NCT05708196|Experimental|group 3|ten extraction sockets filled with Allograft bone grafting material.
89396037|NCT03563664|Experimental|Study group|38 ovulatory patients with unexplained recurrent implantation failure were recruited. Pre-treatment endometrial biopsy and immunohistochemical examination for endometrial αvβ3 integrin expression (using immunohistochemically stained endometrial biopsy) was done. After treatment with danazol (Danol® 200mg capsules, Sanofi, Guildford, UK) in daily dosage of 400 mg for 12 weeks, post-treatment endometrial biopsy and immunohistochemical examination was repeated and compared with previous results.
89396038|NCT03041181|Experimental|Arm A - Single Agent Chemotherapy + Nivolumab|"Single Agent Chemotherapy of choice plus nivolumab:~Taxotere Pemetrexed Gemcitabine"
89396039|NCT03041181|Active Comparator|Arm B - Single Agent Chemotherapy|Single Agent Chemotherapy of choice Taxotere Pemetrexed Gemcitabine
89396040|NCT02828436|Experimental|Spinal Cord Stimulation|Boston Scientific Precision Spectra System
89396041|NCT02828436|Other|Exercise Intervention|If subject cannot tolerate Spinal Cord stimulation they will be assigned this arm
89396042|NCT05278221|Other|Healthy volunteers|Each healthy volunteer during Part I of the study will receive every 2 weeks a single per os dose of Lacosamide (200 mg), Brivaracetam (50 mg) or placebo. All healthy volunteers will perform tests using the new software that combines Transcranial Magnetic Stimulation Combined With EEG/EMG,
88872674|NCT06018779|Experimental|Group A|Group A will include patients who will receive a rehabilitation treatment consisting of: cryo-ultrasound therapy and high-intensity laser therapy
88872675|NCT06018779|Placebo Comparator|Group B|Group B will include patients who will receive a rehabilitation treatment consisting of: cryo-ultrasound therapy and diathermy
88872676|NCT06018714|Experimental|Fruquintinib group|"Patients will receive Fruquintinib maintenance treatment for six months, or until tumor recurrence, metastasis, or intolerable drug toxicities occur within six months.~After achieving no evidence of disease (NED), a chest, abdomen, and pelvic CT scan with contrast or a chest CT scan with abdominal and pelvic MRI scan will be performed every 6 months within 2 years. Colonoscopy will be performed annually. CEA, CA19-9, and abdominal and pelvic ultrasound will be performed every 3 months. If abnormalities are found, further imaging studies and colonoscopy will be conducted, and if necessary, a PET/CT scan will be performed."
89396043|NCT05278221|Other|Patients with focal epilepsy|Patients during Part II, will receive the treatment according to the treating physician's discretion, regardless of the protocol, either with Lacosamide, 300 mg p.o. or Brivaracetam, 100 mg p.o. All patients will perform tests using the new software that combines Transcranial Magnetic Stimulation Combined With EEG/EMG,
89396044|NCT05369247|Experimental|1st Exercise session|Participants completed either the HIIT or MICT session.
89396045|NCT05369247|Experimental|2nd Exercise session|Participants completed the subsequent exercise protocol (i.e. HIIT or MICT)
89396046|NCT04059159|Experimental|Connected Catheter Users|
89396047|NCT05342103|Active Comparator|High flow nasal cannula (HFNC) group|All patients will have FiO2 started at 0.4 and titrated to maintain oxygen saturation (SpO2) ≥ 95%. The flow rate will be set at 60 L/min
89396048|NCT05342103|Active Comparator|Continuous positive airway pressure (CPAP) group|All patients will have FiO2 started at 0.4 and titrated to maintain oxygen saturation (SpO2) ≥ 95%. Pressure will be set to 3 cm H2O for 5 minutes, then titrated according to patient comfort and tolerance, as well as clinical observation
89396049|NCT05323071|Active Comparator|Control Group|Sucrose will be administered 2 minutes before the puncture following the current protocol of the unit. Venous or arterial puncture will be performed only in case it is required for therapeutic or care purposes.
89396050|NCT05323071|Experimental|Experimental Group|The administration of the sucrose dose is started by means of a syringe. Once 50% of the dose has been administered, puncture will be performed. The remaining 50% will be administered during the puncture. The pacifier will be left in the mouth until the end of the procedure, facilitating the non-nutritive sucking of the neonate.
88872677|NCT06018675||Group 1|Kinesiotherapy
88872678|NCT06018675||Group 2|Dry needling
88872679|NCT06018675||Group 3|Lidocain injection
88872680|NCT06018103|Experimental|Treatment|8-week online group learning course of the MBCT-vision programme
88872681|NCT06018103|No Intervention|Control|wait-list control (standard care, no research intervention)
88872682|NCT06015425|Experimental|YMS-201B+|transcranial Direct Current Stimulation (tDCS) application 5 ~7 days a week for 4 weeks (total of 20~28 applications)
89396051|NCT04770129||Time period 2010-2014|Data from Turkish participants with metastatic breast cancer diagnosed January 2010-December 2014 will be retrospectively collected.
89396052|NCT04770129||Time period 2015-2019|Data from Turkish participants with metastatic breast cancer diagnosed January 2015-December 2019 will be retrospectively collected.
89396053|NCT05263713|Experimental|Running Horizontal Mattress|Half of the wound is repaired with running horizontal mattress sutures
89396054|NCT05263713|Experimental|Running Subcuticular Suture|Half of the wound is repaired with running subcuticular sutures
89396055|NCT02828124|Experimental|Dose Escalation Monotherapy|
89396056|NCT02828124|Experimental|Dose Expansion Monotherapy|
89396057|NCT02828124|Experimental|Dose Escalation Combination Therapy|
89396058|NCT02828124|Experimental|Dose Expansion Combination Therapy|
89396059|NCT03619629|Experimental|Kinesio-taping|Kinesiotape will be applied both ankles.
88872683|NCT06014944|Experimental|Short-course radiotherapy combined with furoquintinib and PD-1 monoclonal antibody|Radiotherapy 5 * 5 Gy, once a day, 5 Gy each time, for 5 days.Two weeks after the end of radiotherapy, the patients were treated with furoquintinib combined with slurimab, furoquintinib 5 mg / time / day, d1-14, Q3 W ; combined with 300 mg of brucella, intravenous injection, d1, Q3W ; a total of 4 cycles of treatment.
88872684|NCT06014359|Placebo Comparator|Control group|Patients of this group will be Nebulized with 3 mL of 0.9% saline 15 minutes before shifting the patients to operation room with face mask 6 L/min in sitting position.
89396060|NCT03619629|Experimental|Mulligan's mobilization with movement|'Posterolateral glide mobilization with movement' will be applied both ankles.
89396061|NCT03619629|Sham Comparator|Sham Kinesio-taping|Sham kinesio-taping technique will be applied both ankles.
89396062|NCT03619629|Sham Comparator|Sham Mulligan's mobilization with movement|Sham Mulligan's mobilization with movement will be applied both ankles.
89396063|NCT02259894|Experimental|BIRT 2584|single rising doses
88872685|NCT06014359|Experimental|Study group|Patients of this group will be Nebulized with Dexmedetomidine (1 mcg/kg) in 3mL of 0.9% saline 15 minutes before shifting the patients to operation room with face mask 6 L/min in sitting position.
88872686|NCT06014229|Experimental|Cryoablation|Device: Cryoablation Single session with an argon-based device; a V-probe 17-G applicator will be used for the treatments; gas release 100%; local anesthesia or moderate sedation or general anesthesia at discretion of the anesthesiology / interventional radiology team; benign thyroid nodules (two benign cytological examinations) measuring between 5 and 65 mL of volume and less than 40% of cystic component;
89396064|NCT02259894|Placebo Comparator|Placebo|
88872687|NCT06014229|Experimental|Radiofrequency|Single session with an RF device; an antenna will be used for the treatments; local anesthesia or moderate sedation or general anesthesia at discretion of the anesthesiology / interventional radiology team; benign thyroid nodules (two benign cytological examinations) measuring between 5 and 65 mL of volume and less than 40% of cystic component;
88872688|NCT06011746|Experimental|Ketamine Group|patients will receive paravertebral block (19 mL of 0.5% levobupivacaine + 1 ml ketamine (50 mg)).
88872689|NCT06011746|Active Comparator|Control Group|patients will receive paravertebral block (19 mL of 0.5% levobupivacaine + 1 ml normal saline)
88872690|NCT06011473|Experimental|Experimental|Study subjects submitted to the General Surgery Clinic for colorectal surgery. On admission day, patients will have a CGM sensor placed on the outer part of the upper arm. Patients will undergo standard surgical procedures and perioperative care. Glycemia will be continuously monitored for 10 days. The CGM sensor will be taken off during visit in Outpatient Clinic.
88872691|NCT06010563|Experimental|TPVI|
88872692|NCT06010173|Experimental|Adult cohort|Each of 2 MRI visits will consist of gadopiclenol injection or comparator injection and MRI procedure (administered in a randomized, blinded and cross-over design). Gadopiclenol and comparator will be injected as a single intravenous (IV) bolus injection at a recommended rate of approximately 2 mL/second followed by a 0.9% saline flush via manual injection or power injector. The injection rate should be identical for both products and may vary depending on scanned organ/region and age of patients.
88872693|NCT06010173|Experimental|Pediatric cohort|Pediatric patients will undergo one MRI examination with gadopiclenol (V2). Gadopiclenol will be injected in a single intravenous (IV) bolus injection at a recommended rate of approximately 2 mL/second followed by a 0.9% saline flush via manual injection or power injector.
88872694|NCT06010173|Experimental|Pediatric PK cohort|Pediatric patients will undergo one MRI examination with gadopiclenol (V2). Gadopiclenol will be injected in a single intravenous (IV) bolus injection at a recommended rate of approximately 2 mL/second followed by a 0.9% saline flush via manual injection or power injector. In addition a total of 3 blood samples per patient will be taken post-injection for PK analysis over the period of 8 hours post-injection.
88872695|NCT06007872|Experimental|Intervention|Intracardiac Echocardiography (ICE)
88872696|NCT06005077|No Intervention|Control group|After the hospitalization procedures were completed, the pregnant women in the control group were informed and their written consents were obtained. No intervention was performed on these pregnant women other than routine hospital practices. Data collection forms were applied.
88872697|NCT06005077|Experimental|Perineal Massage|While the pregnant woman was in the lithotomy position, massage was applied with two fingers and rhythmic U-shaped movements starting from the side walls 3-4 cm inside the vagina and towards the rectum. This implementation was done for 10 minutes in three stages according to cervical dilatation. It was applied when the cervical dilatation was 3-4 cm, 5-7 cm, and 8-10 cm.
88872698|NCT06005077|Experimental|Perineal Warm Compress Application|Sterile compresses kept in hot water of 40 C were placed on the perineum. Compresses that cooled down and became dirty were changed every 5-8 minutes. This implementation was done for 30 minutes in three stages according to cervical dilatation. It was applied when the cervical dilatation was 3-4 cm, 5-7 cm, and 8-10 cm.
88872699|NCT06005077|Experimental|Perineal Massage and Perineal Warm Compress Application|When the cervical dilatation was 3-4 cm, 30 minutes of warm compress and 10 minutes of perineal massage were performed. These two methods were applied when the cervical dilatation was 5-7 cm and 8-10 cm as well.
88872700|NCT06004986|Active Comparator|Dupilumab 300 mg q2w|Dupilumab s.c. 300 mg every 2 weeks for 24 weeks.
88872701|NCT06004986|Experimental|Dupilumab 300 mg q3w|Dupilumab s.c. 300 mg every 3 weeks for 24 weeks.
88872702|NCT06004986|Experimental|Dupilumab 300 mg q4w|Dupilumab s.c. 300 mg every 4 weeks for 24 weeks.
89396065|NCT02829996|Experimental|trabodenoson 6.0% /latanoprost 0.005% QD|trabodenoson 6.0% / latanoprost 0.005% QD FDC
89396066|NCT02829996|Experimental|trabodenoson 3.0% /latanoprost 0.005% QD|trabodenoson 3.0% / latanoprost 0.005% QD FDC
89396067|NCT02829996|Experimental|trabodenoson 6.0% /latanoprost 0.0025%QD|trabodenoson 6.0% /latanoprost 0.0025% QD FDC
89396068|NCT02829996|Active Comparator|latanoprost 0.005% QD|latanoprost 0.005% ophthalmic solution QD
89396069|NCT02829996|Active Comparator|latanoprost 0.0025% QD|latanoprost 0.0025% ophthalmic solution QD
89396070|NCT02827500|Active Comparator|ivabradine|Active Comparator: ivabradine
89396071|NCT02827500|Placebo Comparator|usual care|Placebo Comparator: usual care
89396072|NCT05385549|Experimental|5 years of adjuvant imatinib treatment|
89396073|NCT03563508||CBCT of Egyptian subpopulation|Cone-beam computed tomography (CBCT) of a sample of Egyptian subpopulation containing maxillary premolars for image assessment.
89396074|NCT03563586|Active Comparator|Bowel Preparation plus antibiotics|Preoperative oral antibiotic therapy with rifaximin 400 mg plus metronidazole 500mg the day prior to surgery at 2:00, 3:00 and 10:00 pm, with mechanical bowel preparation (2 vials sodium phospate 45ml at 1:00 and 7:00 pm)
89396075|NCT03563586|Other|Bowel Preparation|Preoperative mechanical bowel preparation (2 vials sodium phospate 45ml at 1:00 and 7:00 pm)
89396076|NCT03929679||Semaglutide s.c. once-weekly|Participants will receive semaglutide at the treating physician's discretion as part of the usual clinical practice. The prescription and use of semaglutide is completely independent of this study. Total study duration for the individual patient will be approximately 30 weeks.
88872703|NCT06004167|Experimental|5-5-5 Adaptive Bridging Radiation Therapy (ABRT)|5 Gy of adaptive radiation delivered every 5 business days (1 week apart) for up to 5 weeks prior to CAR T-cell therapy infusion
89396077|NCT02826798|Experimental|VBI-1501A: 0.5µg with adjuvant|0.5µg CMV vaccine with adjuvant
89396078|NCT02826798|Experimental|VBI-1501A: 1.0µg with adjuvant|1.0µg CMV vaccine with adjuvant
89396079|NCT02826798|Experimental|VBI-1501A: 2.0 µg with adjuvant|2.0 µg CMV vaccine with adjuvant
88872704|NCT06000943||Lower Surgical Risk|Surgical risk stratification. All the following groups will be define according with STS and Euroscore II score and stratified based on antithrombotic strategy in all possible combinations (SAPT, DAPT, OAC, OAC+SAPT)
88872705|NCT06000943||Intermediate Surgical Risk|Surgical risk stratification. All the following groups will be define according with STS and Euroscore II score and stratified based on antithrombotic strategy in all possible combinations (SAPT, DAPT, OAC, OAC+SAPT)
88872706|NCT06000943||High Surgical Risk|Surgical risk stratification. All the following groups will be define according with STS and Euroscore II score and stratified based on antithrombotic strategy in all possible combinations (SAPT, DAPT, OAC, OAC+SAPT)
88872707|NCT05997134|Experimental|Group A|patients will receive ketamine parenteral infusion (0.35 mg/kg/h or maximum 24mg/h) at post anesthetic care unit(PACU) over 6 hours for 3days
88872708|NCT05997134|Experimental|Group B|patients will receive ketamine parenteral infusion (0.35 mg/kg/h or maximum 24mg/h ) at post anesthetic care unit(PACU) over 6 hours for 5 days .
89396080|NCT02826798|Experimental|VBI-1501: 1.0µg without adjuvant|1.0µg CMV vaccine without adjuvant
89396081|NCT02826798|Placebo Comparator|Placebo|Buffer/sucrose used for VBI-1501 suspension
89396082|NCT03835650||PGP|Patients in early postpartum period experiencing PGP, confirmed with dedicated functional tests
89396083|NCT03835650||no PGP|Patients in early postpartum period, with no symptoms and signs of PGP
89396084|NCT02829138|Placebo Comparator|Non-genetic Group|General Nutrition related to Omega-3 fats: Individuals in this group will be provided with only general nutrition information related to omega-3 fats and health.
89396085|NCT02829138|Experimental|Genetic Group|Genetic information and Omega-3 fat intake: Individuals in this group will be provided with general nutrition information related to omega-3 fats and health, as well as their personal genetic information for a common gene variant related to omega-3 fatty acid metabolism.
89396086|NCT03563430|Experimental|Active Recovery Group|Participants in this group will exercise for 15 minutes, for a range of 65 to 70% of the maximum heart rate.
88872709|NCT05997134|Experimental|Group C|patients will receive ketamine parenteral infusion (0.35 mg/kg/h or maximum 24mg/h ) at post anesthetic care unit(PACU) over 6 hours for 7 days
88872710|NCT05984290|Experimental|Safety and effectiveness of the Arise Orthokeratology Lens|Treatment effect of overnight orthokeratology over a 3-month period
88872711|NCT05982990|Experimental|Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals|Test
88872712|NCT05982990|Active Comparator|ADVAIR DISKUS® 250/50|Reference
89396087|NCT03563430|Experimental|Self-Massage with Foam Roller Group|This group will perform 15 minutes self-massage with foam roller following the exercise session.
89396088|NCT03563430|Experimental|Neuromuscular Electrical Stimulation|Participants of this group will be applied electrical stimulation on quadriceps femoris and hamstring muscles for 15 minutes while they are comfortable lying position.
89396089|NCT05218590|Active Comparator|Right nostril group|Nasal intubation with video rigid stylet was performed through the right nostril.
89396090|NCT05218590|Placebo Comparator|Left nostril group|Nasal intubation with video rigid stylet was performed through the left nostril.
89396091|NCT02825550|Experimental|Hepatoma treated using Taiwan ACE Beads|The use of Taiwan ACE Beads (T-ACE) microspheres embolization as a treatment for patients with hepatoma.
89396092|NCT03832140||Patients with monoclonal gammopathy|
89396093|NCT03832140||patients with a normal plasma protein electrophoresis|
89396094|NCT03563352||Observational (interview, survey)|Participants attend an interview over 15 minutes and complete surveys.
89396095|NCT05197062|Experimental|14C-aticaprant|Participants in Group A (without duodenal fluid collection) and Group B (with duodenal fluid collection) will receive a single oral dose of 14C-aticaprant on Day 1.
89396096|NCT03563196||Chest Radiograph|All the patients will undergo routine chest radiogram on day 1 after operation
89396097|NCT03563196||Lung Ultrasound|The same patient will undergo ultrasound evaluation of lungs on day 1 after operation
89396098|NCT03563118||Group OSAS|We included 56 with OSAS [13 subjects 23.2% mild, 19 subjects 33.9% moderate, 24 subjects 42.8% severe
89396099|NCT03563118||control group|simple snoring
89396100|NCT05004870|Experimental|Women with a known history of submucosal fibroids (that have not been surgically removed)|
89396101|NCT05122260|Placebo Comparator|Placebo|
89396102|NCT05122260|Experimental|Q-Griffithsin|
88872713|NCT05981105|Experimental|Adductor Canal Catheter (ACC) - Interventional|"Patients will received the an adductor canal catheter that continuously infuses numbing medication to their operative leg for 50 hours post-surgery.~Patients will also communicate with their pain doctor via the Diagnotes application while the catheter is in place."
88872714|NCT05981105|Sham Comparator|Adductor Canal Block (ACB) - Control|"Patients will received the a sham adductor canal catheter that is attached to their operative leg for 50 hours post-surgery.~Patients will also communicate with their pain doctor via the Diagnotes application while the catheter is in place."
88872715|NCT05980650|Experimental|Reiki group|Reiki will be implied to this group and this group will have routine nursing care given in the hospital during their hospitalization such as medical treatment implication and measuring vital signs
88872716|NCT05980650|No Intervention|Routine Nursing Care|This group will have just routine nursing care given in the hospital during their hospitalization such as medical treatment implication and measuring vital signs
88872717|NCT05979740|Experimental|RC48+Toripalimab+Radiotherapy|RC48: 2.0 mg/kg, Q2W, iv; Toripalimab: 3mg/kg, Q2W, iv; Radiotherapy: total dose was greater than 50Gy (about 30 times).
89187658|NCT01032577||cardiomyopathy, with implant indications|30-50 volunteers age >18, male and female with ability to give informed consent, who are expected to live more than one year, with indication for defibrillator implant and who are not pacemaker dependent.
89187659|NCT01032655|Experimental|sequential, susceptibility guided|single arm
88872718|NCT05976854|Experimental|Pain neuroscience education (PNE)|The patients in the intervention group will receive, in addition to the prenatal educational content, the 12 PNE lessons in audiovisual format. Each lesson will last between 10-15 minutes. The contents of PNE will be an adaptation, focused on the context of a pregnant woman, of the Butler & Moseley postulates. These contents have already been previously adapted according to the nature of the patients' pain, both in chronic pain and in acute pain. In summary, the participants will receive a detailed explanation about the biopsychosocial component of pain through the use of diagrams, metaphors and practical examples. In turn, the objectives of this program could be summarized as: (1) Reformulate erroneous beliefs about pain, (2) Inform about the biology and protective nature of pain and (3) Provide techniques to reduce kinesiophobia and, consequently, promote physical activity, with the beneficial effect it entails for patients with pain.
88872719|NCT05976854|Other|Prenatal education (PE)|Patients assigned to the PE group will receive different content on standard PE based on the Pregnancy and Postpartum Clinical Practice Guide, consisting of general information about pregnancy (visits and monitoring of pregnancy, diet, phases of delivery, lactation, etc.), as well as specific recommendations for lumbopelvic pain associated with pregnancy. These contents will be developed by midwives from the participating hospitals. Participants will receive 12 educational sessions, with an estimated duration of 10 minutes each.
88872720|NCT05972655|Experimental|Treatment Arm|Participants will receive 5*5Gy modified short-course radiation (radiation targeting the tumor bed without irradiating surrounding tumor-draining lymph nodes) concurrently with CAPOX and tislelizumab regimens: Oxaliplatin, 130mg/m2, intravenous infusion,d1 of each cycle; Capecitabine, 1000mg/m2, PO, BID, d1-14 and tislelizumab, 200mg intravenous infusion d1 of each cycle. CAPOX and tislelizumab repeat every 3 weeks for 3 cycles, followed by total mesorectal excision surgery.
88872721|NCT05971719|Experimental|Air Leaks|Lungs from patients undergoing lung transplantation after their removal from the recipient patient with previous informed consent signed before transplantation will be obtained. To establish a standard protocol to use our system we will use a dark box to validate that our system is able to localize the air leaks and to establish the best way to use the system. A one centimeter leak will be created on the lung with a scalpel. A laparoscope will be introduced via a trocar in the dark box and the surgeon will be asked to localize the leaks. The detection will be recorded via the laparoscope. The goal will be to perform a standardized protocol to use the system smoothly and efficiently on ex-vivo human lungs.
88872722|NCT05962502|Experimental|cetuximab plus irinotecan|Cetuximab 500 mg/m2 iv drip 90 min d1, Irinotecan 180 mg/m2 iv drip d1 (For patients with UGT*28 7/7 or UGT*6 A/A or UGT*28 6/7 plus UGT*6 A/G, irinotecan 150 mg/m2 is used) The above regimen is repeated every 2 weeks
89187660|NCT03654248|Experimental|Let's Get Organized group intervention|Group intervention with 10 weekly sessions, each lasting 1,5 hours
89187661|NCT03654248|Active Comparator|Individual Occupational Therapy|Individual intervention lasting 10 weeks
89187662|NCT02581280||On ECMO|patients who are concomitantly receiving teicoplanin or levofloxacin or piperacillin/tazobactam or meropenem or vancomycin or remifentanil or cefepime or cefpirome or sufentanil or midazolam or clopidogrel or ticagrelor or prasugrel during ECMO
89187663|NCT02581280||Off ECMO|patients who are concomitantly receiving teicoplanin or levofloxacin or piperacillin/tazobactam or meropenem or vancomycin or remifentanil or cefepime or cefpirome or sufentanil or midazolam or clopidogrel or ticagrelor or prasugrel after removing ECMO
89396103|NCT05000736||palbociclib + aromatase inhibitor|Adult patients with HR+/HER2- advanced breast cancer who received the initial endocrine therapy of palbociclib plus aromatase inhibitor at the Cancer Hospital Chinese Academy of Medical Sciences from August 1, 2018 to December 31, 2020.
89396104|NCT05000736||fulvestrant|Adult patients with HR+/HER2- advanced breast cancer who received the initial endocrine therapy of fulvestrant monotherapy at the Cancer Hospital Chinese Academy of Medical Sciences from August 1, 2018 to December 31, 2020.
89396105|NCT02744040|Other|Early ART initiation|Immediate ART initiation at the time of HIV diagnosis; daily dose of combination ART (one pill/day)
89396106|NCT02744040|Other|Deferred ART initiation|ART initiation at 24 weeks after HIV diagnosis; daily dose of combination ART (one pill/day)
89396107|NCT02743962|Active Comparator|Usual physiotherapy treatment group|This group will receive standard specialist physiotherapy intervention for bladder pain syndrome: dietary advice regarding fluid and fibre intake, advice regarding bladder retraining and 15 minutes manual intra-vaginal pelvic floor muscle myofascial release and gentle stretching each week for 6 weeks. They will be instructed to briefly contract and then fully relax their pelvic floor muscles independently (clothed, in a seated or lying position) for 5 minutes daily.
89530500|NCT03247075|Active Comparator|Internet-delivered Support and Counseling|10 weeks of guided Internet-delivered support and counseling
89187664|NCT03374072|Experimental|Siblings FORWARD|Siblings who participate in the Siblings FORWARD program will participate in telehealth sessions with a community provider. The Siblings FORWARD program includes 6-7 sessions, depending upon whether the autistic adult participates. Siblings work with a program facilitator to develop a future plan of action. They learn communication and problem-solving skills, and about adult service systems.
89396108|NCT02743962|Experimental|Therapeutic Wand group|This group will receive the standard specialist physiotherapy intervention for bladder pain syndrome for 6 weeks, but will also be provided with an intra-vaginal therapeutic wand and taught how to use it. They will then be asked to use the therapeutic wand at home twice a week to release and relax their pelvic floor muscles for 5 minutes.
89396109|NCT05314920|Experimental|transdiagnostic cognitive-behavioural therapy (TD-CBT)|Transdiagnostic cognitive-behavioral group therapy: The psychological interventions will be manualized. Patients assigned to the experimental group will receive 7 sessions (1.5 hr/session) in groups of approximately 8-10 individuals over a 12-week period.
89396110|NCT05314920|Active Comparator|relaxation therapy|The control group will receive a progressive muscle relaxation group intervention, based on the Bernstein and Borkoveck procedure. Patients will receive 7 sessions (1.5 hr/session) in groups of 8-10 individuals over a 12-week period.
89396111|NCT03563040|Experimental|Methoxsalen with the THERAKOS CELLEX Photopheresis System|Treatment will be performed according to a predefined protocol based on the consensus guidelines in patients with MF/SS. Treatment should be administered for one year unless confirmed disease progression or unless other criteria for treatment discontinuation are met as specified in the protocol.
89396112|NCT03828396||High risk (positive)|Colorectal cancer and advanced adenoma
89396113|NCT03828396||Low risk (Negative)|Healthy people and other colorectal diseases
89396114|NCT03094416|Experimental|levothyroxine sodium capsules|levothyroxine sodium capsules 88 to 250 mcg/day (depending on individual needs) for 3 months
88872723|NCT05959343|Experimental|ERAS group|The experimental group will be implemented with the ERAS Clinical Pathway (ERAS CP)
88872724|NCT05959343|No Intervention|Control group|The control group will not be implemented with the ERAS CP
89396115|NCT03106038|Experimental|Nerindocianine for Injection|One Arm: Nerindocianine for Injection (Initial dosing cohort: 0.06 mg/kg body weight); solution, intravenous, one time administration during surgery. the study has only one arm.
89396116|NCT03041025|Experimental|Cohort 1: GSK2330811 100 mg|During Cohort 1, participants will receive a single dose of GSK2330811 100 mg by SC injection via needle and syringe in to the abdomen, thigh or upper arm by the investigator or designee at every other week from D1 to D71 (total 6 doses) for 10 weeks. Participants will be followed-up up to W28 D197.
89396117|NCT03041025|Experimental|Cohort 2: GSK2330811 300 mg|During Cohort 2, participants will receive a single dose of GSK2330811 300 mg by SC injection (3 vials of 1 mL each of GSK2330811 100 mg) via needle and syringe in to the abdomen, thigh or upper arm by the investigator or designee at every other week from D1 to D71 (total 6 doses) for 10 weeks. Participants will be followed-up up to W28 D197.
89396118|NCT03041025|Placebo Comparator|Cohort 1: Placebo|During Cohort 1, participants will receive a single dose of placebo by SC injection via needle and syringe in to the abdomen, thigh or upper arm by the investigator or designee at every other week from D1 to D71 (total 6 doses) for 10 weeks. Participants will be followed-up up to W28 D197.
89396119|NCT03041025|Placebo Comparator|Cohort 2: Placebo|During Cohort 2, participants will receive a single dose of placebo by SC injection (3 vials of 1 mL each) via needle and syringe in to the abdomen, thigh or upper arm by the investigator or designee at every other week from D1 to D71 (total 6 doses) for 10 weeks. Participants will be followed-up up to W28 D197.
88872725|NCT05957757|Experimental|RC48+Tislelizumab|Approximately 20 subjects will be enrolled to evaluate the efficacy and safety of RC48 (RC48 2.0 mg/kg intravenously administered every two weeks) combined with Tislelizumab (Tislelizumab 200 mg intravenously administered every three weeks).
89396120|NCT01338870|Placebo Comparator|Placebo|Placebo for PF-04991532 and sitagliptin
89396121|NCT01338870|Experimental|25 mg PF-04991532|
89396122|NCT01338870|Experimental|75 mg PF-04991532|
89396123|NCT01338870|Experimental|150 mg PF-04991532|
89396124|NCT01338870|Experimental|300 mg PF-04991532|
89396125|NCT01338870|Active Comparator|Sitagliptin 100 mg|
88872726|NCT05954169|Experimental|Treatment group A in moderately renal insufficiency subjects|
88872727|NCT05954169|Experimental|Treatment group B in healthy subjects|
89396126|NCT02824224|Experimental|Tamoxifen|Tamoxifen 10mg tablet by mouth twice daily for 7 days
89396127|NCT02824224|Placebo Comparator|Placebo|Placebo tablet (for tamoxifen tablet) by mouth twice daily for 7 days
89396128|NCT01338792|Experimental|Treatment (chemotherapy and enzyme inhibitor)|Patients receive oxaliplatin IV over 2 hours and pemetrexed disodium IV on day 1. Courses repeat every 21 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
89396129|NCT04752072|Experimental|ESTAIR|ESTAIR (Cloitre et al., 2019) will consist of up to 25 sessions, organized in 4 modules of 6 sessions targeting symptoms of PTSD and disturbances in self-organisation (AD: affective dysregulation; NSC: negative self-concept; and DR: disturbances in relationships).
88872728|NCT05935020|Active Comparator|Usual Care|Referral to municipal rehabilitation after TKA
88872729|NCT05935020|Other|Return to Everyday Life|No referral to municipal rehabilitation after TKA
88872730|NCT05934227|Placebo Comparator|control|1) scaling and root planing (SRP) plus systemic administration of placebo (n=25)
88872731|NCT05934227|Experimental|antibiotics|2) scaling and root planing (SRP) plus systemic administration of amoxicillin and metronidazole (n=25).
88872732|NCT05933148|Active Comparator|Active Neurofeedback|Participants randomized to Active neurofeedback will receive real-time data depicting MOFC-precuneus brain activity while in the scanner.
88872733|NCT05933148|Sham Comparator|Sham Neurofeedback|Participants randomized to the Sham neurofeedback control group will receive the feedback of a prior scanned participant's active MOFC-precuneus up-regulation and not their own brain activity. This condition will still visually resemble the active conditions.
88872734|NCT05928650||Sprinters|Sprinters
88872735|NCT05928650||Long marathon runners|Long marathon runners
88872736|NCT05928650||Non-athletic Females|Non-athletic Females
88872737|NCT05917899|Experimental|Virtual Family-Centered Rounds|Parents/guardians of the hospitalized infants will be invited to join family-centered rounds virtually plus usual care (usual care is the ability to join family-centered rounds in person or not to join at all).
88872738|NCT05912790|Experimental|Treated with the eyeTube|
88872739|NCT05911880|Experimental|Subjets with rheumatoid arthritis treated with a plant-based diet for 14 days|"The present study focuses on a dietary intervention in human subjects who have been diagnosed with rheumatoid arthritis for at least one year. The intervention consists of an individualized nutritional plan, isocaloric, and modifies the percentage of plant-based proteins to 80%, for 14 days, to evaluate if a plant-based diet affects the disease activity.~The calorie intake given to each subject is calculated based on the average of 3 24-hour recalls and the basal energy expenditure using the Harris & Benedict formula. No medication modifications are made three months before and during the intervention.~Fasting blood samples of blood are collected via venipuncture before and after the intervention to analyze the blood chemistry of six elements, a complete blood count, as well as to analyze the expression of microRNAs related to the disease and pro-inflammatory cytokines.~In addition, body measurements (weight, body fat, visceral fat, and muscle) are taken using bioimpedance."
88872740|NCT05911269|Experimental|TiMBRe|an eight-week, (45 min/week), theory driven, virtually-delivered, tailored music-based relaxation (TiMBRe) intervention to decrease anxiety in AYA cancer survivors with clinically-relevant anxiety.
88872741|NCT05911269|Active Comparator|Attention-Control|Standard of care study staff calls and cancer survivorship resources
88872742|NCT05898217|Active Comparator|Dairy Milk|Participants will drink 16 oz of dairy milk daily for the duration of the study.
88872743|NCT05898217|Active Comparator|Soy Milk|Participants will drink 16 oz of soy milk daily for the duration of the study.
88872744|NCT05898217|Active Comparator|Almond Milk|Participants will drink 16 oz of almond milk daily for the duration of the study.
88872745|NCT05898217|Active Comparator|Oat Milk|Participants will drink 16 oz of oat milk daily for the duration of the study.
88872746|NCT05886296|Experimental|pre-surgical information session for people who must undergo shoulder rotator cuff surgery|implementation of an information session for people who have to undergo rotator cuff surgery of the shoulder on the post-operative evolution
88872747|NCT05886296|No Intervention|Usual care|Participants will undergo usual care
88872748|NCT05884138|Experimental|Improved skeletal muscle function due to protein supplementation and exercise|resistance exercise and protein supplementation including branched chain amino acids for 12 weeks
88872749|NCT05884138|No Intervention|control|No intervention, but the same measurements as the experimental group are conducted.
88872750|NCT05880706|Experimental|Study treatment|Participants receive BL-B01D1 in combination with Osimertinib Mesylate Tablets in the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
89187665|NCT03374072|Active Comparator|Information Only Condition|We will create an online learning module for siblings in the control condition. Siblings in the control condition will be provided with access to the same information about resources for autistic adults provided to participants in the Siblings FORWARD program.
88872752|NCT05877820|Experimental|Tislelizumab+Lenvatinib combination therapy|Participants receive tislelizumab 200 mg intravenously every 3 weeks PLUS lenvatinib 20mg orally once daily.
88872753|NCT05875077|Experimental|Propofol group|will receive propofol infusion.
88872754|NCT05875077|Experimental|Dexmedetomidine group|will receive dexmedetomidine infusion.
88872755|NCT05868902||Negative Cardiac PET|Participants without clinical significant findings for coronary ischemia on cardiac PET scan.
88872756|NCT05868902||Positive Cardiac PET|Participants with findings indicative of coronary ischemia on cardiac PET scan.
88872757|NCT05866107|Experimental|Block 1|50 patients with schizophrenia and 50 patients with bipolar disorder
88872758|NCT05866107|Experimental|Block 2|50 patients with schizophrenia and 50 patients with bipolar disorder
88872759|NCT05864612|Active Comparator|Text Message|Subjects in this arm will be asked to complete standard care screening questionnaires on anxiety and depression, delivered by Twilio text message.
88872760|NCT05864612|Active Comparator|Customized Email Prompt|Subjects in this arm will be asked to complete standard care screening questionnaires on anxiety and depression, delivered by an email with a REDCap email survey link.
88872761|NCT05864612|Active Comparator|Generic Electronic Health Record (EHR) portal email|Subjects in this arm will be prompted with customized EHR portal message after login to EHR portal.
88872762|NCT05864612|Active Comparator|EHR Portal with No Message|Subjects in this arm will not receive a reminder, but previsit questionnaires associated with a visit will be in their EHR portal.
89187666|NCT05673980|Experimental|vitamin D2|Oral dose of Vitamin D2 every two weeks
89187667|NCT05673980|Placebo Comparator|Placebo|Without any intervention
89187668|NCT02581124|Experimental|Experimental: JTZ-951 and Lapatinib|Tablets; JTZ-951, single dose on non-dialysis Days 1 and 5; Lapatinib, single dose on non-dialysis Day 5
89187669|NCT02580968|Experimental|electro-acupuncture|100hz, 2min. electro-acupoint: LI4(Large Intestine4) with LV3(Liver3).5times a week. lasting for 4 weeks.
89187670|NCT02580968|Active Comparator|routin medicine|one tablet of flunarizine hydrochloride tablet per day. lasting for 20days
88872766|NCT05852158|Experimental|Single Dose|Single pre-operative dose of 2g IV Cefazolin given prior to first incision for orthognathic surgical procedure
88872767|NCT05852158|Active Comparator|24-Hour Dosing|Single pre-operative dose of 2g IV Cefazolin given prior to first incision for orthognathic surgical procedure, as well as 2g IV Cefazolin q8h post-operatively for 24 hours (3 total doses)
88872768|NCT05846360||ORCHARDS Study Specimens|Archived ORCHARDS study specimens
88872769|NCT05844228|Experimental|Cohort 1: 8 moderate Renal Impairment (RI) participants and 8 matched healthy participants|
88872770|NCT05844228|Experimental|Cohort 2: 8 severe Renal Impairment (RI) participants and 8 matched healthy participants (optional)|
89187671|NCT03610646|Experimental|MYL-1701P|MYL-1701P
89187672|NCT03610646|Active Comparator|Eylea|Eylea
89187673|NCT04075448|Experimental|Control - 50g Walnut|Control condition followed by experimental condition.
89187674|NCT04075448|Experimental|50 g Walnut - Control|Experimental condition followed by control condition.
89396130|NCT04752072|Active Comparator|Treatment as usual (TAU)|At present, there are no recommended treatments for CPTSD. TAU will consist of a treatment package that could include elements of psychoeducation, symptom-management and trauma-focused cognitive behaviour therapy, resembling established protocols for treating PTSD.
89396131|NCT01314105|Experimental|BIBF 1120 L+ Carboplatin + PLD|BIBF 1120 (100 mg twice daily (BID)) + Carboplatin (Area Under the Curve (AUC) 5 mg/mL*min) + PLD (30 mg/m2)
89396132|NCT01314105|Experimental|BIBF 1120 M + Carboplatin + PLD|BIBF 1120 (150 mg twice daily (BID)) + Carboplatin (Area Under the Curve (AUC) 5 mg/mL*min) + PLD (30 mg/m2)
89396133|NCT01314105|Experimental|BIBF 1120 H + Carboplatin + PLD|BIBF 1120 (200 mg twice daily (BID)) + Carboplatin (Area Under the Curve (AUC) 5 mg/mL*min) + PLD (30 mg/m2)
89396134|NCT03562884|Experimental|BLI800|BLI800 given orally as a split-dose: 1st dose the evening before colonoscopy (e.g. at 6:00 p.m.- 8:00 p.m.) and 2nd dose on the morning of colonoscopy, 10 to 12 hours after the evening dose (e.g. at 5:00 a.m.-7:00 a.m.)
89396135|NCT03562884|Active Comparator|Fortrans®|Fortrans® given orally as a split dose: 1st dose the evening before colonoscopy (e.g. at 6:00 p.m - 8:00 p.m.) and 2nd dose on the morning of colonoscopy, 10 to 12 hours after the evening dose (e.g. at 5:00 a.m.-7:00 a.m.)
89396136|NCT05339724||Group 1. Total cystic fibrosis patients with pulmonary exacerbation|Platelet count (PC) and mean platelet volume (MPV) during pulmonary exacerbation.
89396137|NCT05339724||Group 2. Total cystic fibrosis patients with no pulmonary exacerbation|PC and MPV during no pulmonary exacerbation
89396138|NCT05339724||Group 3. Cystic fibrosis patients with chronic colonization in acute pulmonary exacerbation|PC and MPV during chronic colonization in acute pulmonary exacerbation
89396139|NCT05339724||Group 4. Cystic fibrosis patients with chronic colonization without pulmonary exacerbation|PC and MPV during chronic colonization without pulmonary exacerbation
89396140|NCT05339724||Group 5. Cystic fibrosis patients with chronic colonization without pulmonary exacerbation|PC and MPV during chronic colonization without pulmonary exacerbation
89396141|NCT05339724||Group 6. Cystic fibrosis patients with no chronic colonization without pulmonary exacerbation|PC and MPV during no chronic colonization without pulmonary exacerbation
89396142|NCT05297799|Experimental|Lactating women|New mothers whose infants born after 28 weeks gestational age are unable to breastfeed will exclusively breast pump their breast milk with an Ameda Pearl breast pump for a minimum of the first 14 days postpartum.
89396143|NCT05265156|Other|Plant based formula for young children|The study is designed with a single arm, so all subjects will receive the study product.
89396144|NCT03562962|Other|Functional Analytic Psychotherapy|"Within the baseline (A), Supportive Listening (SL) will be provided, which has been widely utilized in randomized control trials (Cuijpers et al., 2012), including the only Randomized Control Trial (RCT) conducted in FAP (Maitland & Gaynor, 2016), as a control condition. SL is defined as a psychological treatment in which therapists do not engage in any therapeutic strategies other than active listening and offering support, focusing on participants' problems and concerns (Cuijpers et al., 2012, p. 281). In this therapy, the therapist reflects on clients' experiences and encourage them to share emotional experiences. Therapists are prohibited from giving advice, making interpretations, and providing feedback to clients (Cuijpers et al., 2012).~FAP will be introduced at phase B, where contingent reinforcement will be administered for increasing clients' alternative behaviors (CRB2) and differential reinforcement will be utilized to reduce clients' problem behaviors (CRB1)."
89396145|NCT03040713|Experimental|FTD Subjects|Subjects diagnosed by dementia specialist with a clinical Frontotemporal Dementia (FTD) syndrome and expected tau or tar DNA binding protein (TDP)-43 pathology receiving a flortaucipir PET scan
89396146|NCT04726176||COVID-19|"Participants who were admitted to the intensive care unit due to COVID-19 or participants who exhibited mild symptoms due to COVID-19 but needed to be hospitalized."
89396147|NCT04726176||Healthy control group|Healthy matched participants who never had COVID-19.
89396148|NCT01966471|Active Comparator|Anthracycline Followed by Trastuzumab, Pertuzumab, and Taxane|Trastuzumab and pertuzumab will be administered concurrently for up to a total duration of 1 year (up to 18 cycles [1 Cycle = 21 days]) with the taxane (docetaxel or paclitaxel) component of chemotherapy following anthracycline [5 fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin and cyclophosphamide (EC) or doxorubicin and cyclophosphamide (AC)] based chemotherapy.
89396149|NCT01966471|Experimental|Anthracycline Followed by Trastuzumab Emtansine and Pertuzumab|Trastuzumab emtansine and pertuzumab will continue for up to a total duration of 1 year (up to 18 cycles [1 Cycle = 21 days]) following anthracycline [5 fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin and cyclophosphamide (EC) or doxorubicin and cyclophosphamide (AC)] based chemotherapy.
89396150|NCT01568437|Active Comparator|Conventional management|On the ward, patients will be prescribed acetaminophen 1 g every 6 hours. If additional analgesia is required, patients will take oxycodone 5-10 mg up to every 2 hours or iv morphine. Patients with contraindications to oxycodone will be prescribed oral hydromorphone 1-2 mg instead. This is the current standard of care at Toronto Western Hospital.
89396151|NCT01568437|Experimental|TAP Block+Conventional Management|The TAP block will be performed after the induction, before the surgery, by an anesthesiologist with experience of at least 10 successful TAP blocks.Also patients will be prescribed acetaminophen 1 g every 6 hours. If additional analgesia is required, patients will take oxycodone 5-10 mg(oral hydromorphone 1-2 mg) up to every 2 hours or iv morphine.
89396152|NCT04188847|Experimental|Study group|The patients would accept the regimen of apatinib combined with cisplatin and paclitaxel
89396153|NCT05255107|Sham Comparator|Standard of Care Therapy + Sham CXL + Artificial Tears|Standard-of-care treatment and Sham CXL and administration of artificial tears.
89530501|NCT03347435|Experimental|Genotype/ phenotype guided group|The patients randomized to the genotype/phenotype guided group undergo genetic tests for CYP2C19*2, CYP2C19*17 and ABCB1 3435 genetic variants immediately after diagnosis of ACS and receive one of the ADP receptor antagonists (clopidogrel/prasugrel/ticagrelor) on the basis of an algorithm that consider genetic and clinical variables.
89187675|NCT00434161|Active Comparator|Palifermin before only|Subjects received palifermin before-high dose chemotherapy (total 3 doses) and matched placebo after-high dose chemotherapy (total 3 doses)
89396154|NCT05255107|Experimental|Standard of Care Therapy + CXL + Riboflavin 0.23% L Solution|The PXL Platinum 330 Illumination System is a portable electronic medical device. The device's light emitting diode (LED) is used to deliver a metered dose of UV-A light to a targeted treatment area for illuminating the cornea during corneal collagen CXL. PESCHKE-L Solution is a riboflavin 5'-phosphate 0.23% ophthalmic solution that functions as a photosensitizer and is indicated for use with the PXL Platinum 330 Illumination System. Designed to be used when there is epithelial disruption as can occur with a corneal ulcer or wound. It does not contain benzalkonium chloride. It is intended to achieve rapid absorption.
89396155|NCT04788589|Experimental|Sedation and Ventilator Weaning Protocol|"Sedation: start midazolam 5-10 mins (max 3x). If MV 12 hrs-2d: Pain: morphine @2 hrs if needed (max 10mg/x). Sedation: midazolam @ 1-2 hrs if needed (max 10mg/x). If MV >2 d: morphine & midazolam drip (max 10mg/hr). MV weaning checklist @morning. Pass if no incr of sedation dose due to agitation, NMBAs, incr in ICP. Fail: reassessed tomorrow. Pain and SBS scores assessed @morning until extubation. Stop all sedation and analgetic for sedation. Continue analgetics for pain. Subjects monitored for 4 hrs. Assess pain and WAT-1 score. Pass (GCS of E3, tolerate sedation interruption for > 4 hrs): MV weaning protocol. Fail (Persistent anxiety/agitation, incr pain score, incr RR > 5 mins, SpO2 <88% >5 mins, acute heart dysrhythmia, >=2 signs of ARDS): sedation resumed ½ dose, up titrated.~MV weaning: CPAP 5/PS < 7. Pass: No failure criteria for 2 hrs. Fail (Incr RR > 5 mins, SpO2 <88% > 5 mins, acute decr in GCS/acute heart dysrhythmia, >=2 signs of ARDS): previous MV setting."
89396156|NCT04788589|No Intervention|Control|"Informed consent~Randomization into groups~Sedation and ventilator weaning according to attending physicians~Pain scores and SBS score is noted every 6 hours for the first 24 hours, and every day for the next 24 hours until extubation.~Attending physicians assessed that subject could be weaned: pain scores, SBS score, WAT-1 score~Extubation. Researcher did not take part in the judgement of extubation."
89396157|NCT04774081||Study group|Participants will be recruited among those whose insulin sensitivity has been previously measured by a high-dose euglycemic-hyperinsulinemic clamp at Pennington Biomedical during the last 5 years and indicated their wiliness to be re-contacted for future research
89396158|NCT05224843|Experimental|Older adults in Primary Care setting|Elder mistreatment in the Primary Care setting.
89396159|NCT05200741|Experimental|Test Product|DelNS1-2019-nCoV-RBD-OPT1 virus titre at not less than 6.3 lg CCID50/dose, 2 doses 3 weeks apart, intranasal administration
89396160|NCT05200741|Placebo Comparator|Reference Product|Matching placebo, 2 doses 3 weeks apart, intranasal administration
89396161|NCT03227471|Placebo Comparator|Part A: Pooled Placebo (Except Cohort A7)|Participants without CF who received single dose of placebo matched to VX-445 in Cohort A1 to A5.
89396162|NCT03227471|Experimental|Part A: VX-445 (Except Cohort A7)|Participants without CF who received single ascending dose of VX-445 tablet starting from 20 milligrams (mg) to 360 mg in Cohort A1 to A5.
88872771|NCT05833529|Experimental|VRCET for Cocaine Craving then MFCT|3 weeks treatment consisting of 10 meetings of Virtual Reality Cue Exposure Therapy (VRCET) for cocaine craving, followed by 5 meetings of Memory Focused Cognitive Therapy (MFCT). All meetings will last 90 minutes. VRCET meetings will take place in a 2 weeks period (weeks 1 and 2) at a daily frequency from monday to friday included. MFCT meetings will take place in the 1 week period following VRCET (week 3) at a daily frequency from monday to friday included.
88872772|NCT05833529|Active Comparator|PCET for Cocaine Craving|3 weeks treatment consisting of 15 meetings of Picture-based Cue Exposure Therapy (PCET) for cocaine craving. All meetings will last 90 minutes. PCET meetings will take place in a 3 weeks period (weeks 1 to week 3) at a daily frequency from monday to friday included.
88872773|NCT05824377|Experimental|Bolus Feeding|"Intermittent bolus feeding will be defined as delivering enteral nutrition multiple times, usually every 2-3 hours over 15 - 30 minutes by gravity or an electric pump.~It will be further stratified as per weight ( less than 1000 g, 1000-1500 g, >1500 g)."
88872774|NCT05824377|Experimental|Continuous Feeding|"Continuous feeding will be defined as delivering enteral nutrition with constant speed for 24 hours via a nutritional pump.~It will be further stratified as per weight ( less than 1000 g, 1000-1500 g, >1500 g)."
88872775|NCT05783362|Experimental|High Exposure (HE)|Participants will receive five sessions total: four sessions of the Intervention, questionnaires, quantitative sensory testing, and CPM as an outcome in the first and fifth sessions.
88872776|NCT05783362|Experimental|Low Exposure (LE)|Participants will receive only two sessions in total: questionnaires, quantitative sensory testing, and CPM as an outcome at both sessions.
88872777|NCT05783362|No Intervention|No Exposure (NE)|This group controls for natural history response, and participants will receive two sessions of questionnaires, and CPM as an outcome, and quantitative sensory testing for one session (last session).
88872778|NCT05738213|Active Comparator|Migraine|Adolescents with a migraine diagnosis
89396163|NCT03227471|Experimental|Part A: VX-445 (Cohort A7)|Participants without CF who received single dose of VX-445 100 mg tablet on Day 1 in fasted state and on Day 7 in fed state, followed by VX-445 20 mg intravenous (IV) injection on Day 13 in fed state in Cohort A7.
89396164|NCT03227471|Placebo Comparator|Part B: Pooled Placebo (Cohort B1 to B4)|Participants without CF who received multiple doses of placebo matched to VX-445 once daily (qd) for 10 days in Cohort B1 to B4.
89396165|NCT03227471|Experimental|Part B: VX-445 (Cohort B1 to B4)|Participants without CF who received VX-445 tablet qd for 10 days in Cohort B1 (60 mg), B2 (120 mg), B3 (240 mg) and B4 (340 mg).
89396166|NCT03227471|Placebo Comparator|Part C: Pooled Placebo (Cohort C1 to C3)|Participants without CF who received placebo matched to VX-445/TEZ/IVA triple combination (TC) qd in the morning and placebo matched to IVA in the evening for 14 days.
89396167|NCT03227471|Experimental|Part C: VX-445/TEZ/IVA TC (Cohort C1 to C3)|Participants without CF who received VX-445 200 mg qd/TEZ 100 mg qd/IVA 150 mg q12h in Cohort C1; VX-445 280 mg qd/TEZ 100 mg qd/IVA 150 mg q12h in Cohort C2 and VX-445 100 mg qd/TEZ 100 mg qd/IVA 150 mg q12h in Cohort C3 for 14 days.
89396168|NCT03227471|Placebo Comparator|Part D: Placebo|Participants with CF, F/MF genotype who received placebo matched to VX-445/TEZ/IVA TC qd in the morning and placebo matched to IVA qd in the evening for 4 weeks in the TC treatment period.
89396169|NCT03227471|Experimental|Part D: VX-445/TEZ/IVA TC - Low Dose|Participants with CF, F/MF genotype who received VX-445 50 mg qd/TEZ 100 mg qd/IVA 150 mg q12h for 4 weeks in the TC treatment period.
89396170|NCT03227471|Experimental|Part D: VX-445/TEZ/IVA TC - Medium Dose|Participants with CF, F/MF genotype who received VX-445 100 mg qd/TEZ 100 mg qd/IVA 150 mg q12h for 4 weeks in the TC treatment period.
89396171|NCT03227471|Experimental|Part D: VX-445/TEZ/IVA TC - High Dose|Participants with CF, F/MF genotype who received VX-445 200 mg qd/TEZ 100 mg qd/IVA 150 mg q12h for 4 weeks in the TC treatment period.
89396172|NCT03227471|Active Comparator|Part E: TEZ/IVA|Following run-in period of 4 weeks with TEZ/IVA, participants with CF, F/F genotype who received TEZ 100 mg qd/IVA 150 mg q12h and placebo matched to VX-445 for 4 weeks in the TC treatment period.
89396173|NCT03227471|Experimental|Part E: VX-445/TEZ/IVA TC|Following run-in period of 4 weeks with TEZ/IVA, participants with CF, F/F genotype who received VX-445 200 mg qd/TEZ 100 mg qd /IVA 150 mg q12h for 4 weeks in the TC treatment period.
89396174|NCT03227471|Placebo Comparator|Part F: Placebo|Participants with CF, F/MF genotype who received placebo matched to VX-445/TEZ/VX-561 for 4 weeks in the TC treatment period.
89396175|NCT03227471|Experimental|Part F: VX-445/TEZ/VX-561 TC|Participants with CF, F/MF genotype who received VX-445 200 mg qd/TEZ 100 mg qd/VX-561 150 mg qd for 4 weeks in the TC treatment period.
89396176|NCT01354314|Experimental|Fluconazole|Fluconazole 100 mg every 12 hours orally per day; placebo in place of paroxetine
89396177|NCT01354314|Experimental|Paroxetine|Paroxetine 20 mg orally once per day; placebo in place of fluconazole
89396178|NCT01354314|Experimental|Paroxetine and Fluconazole|Fluconazole 100 mg every 12 hours orally per day and paroxetine 20 mg every evening orally per day
89396179|NCT01354314|Placebo Comparator|Placebo|Placebo in place of both fluconazole and paroxetine
89396180|NCT04567836||The asymptomatic medical staff cohort|"The cohort of asymptomatic / paucisymptomatic operators will include the cohort of operators who will test positive in the serological analysis.~From the entire population of hospital workers (over 3000), three controls will be identified for each operator who tested positive for the serological test that were analyzed on the same day and were negative for the serological test."
89396181|NCT04567836||The symptomatic medical staff cohort|The cohort of symptomatic hospital workers who tested positive for the swab includes 250 operators.
89396182|NCT04561908|Active Comparator|Conventional transseptal puncture|Under the guidance of fluoroscopy and echocardiography, transseptal puncture was performed with Brockenbrough-needle.
89396183|NCT04561908|Experimental|Microguidewire-assisted transseptal puncture|"The Brockenbrough needle, with transseptal dilator and sheath, was introduced into the right atrium and engaged in the fossa ovalis, which was confirmed with angiographical and echocardiographical tenting sign. 1) the hard-end of a 0.014-inch microguidewire drilled through atrial septum through Brockenbrough-needle; 2) then the needle was advanced into left atrium over the fixed microguidewire; 3) finally the soft-end of microguidewire was introduced into left atrium/left superior pulmonary vein through Brockenbrough-needle, which was further advanced over the fixed microguidewire."
89396184|NCT04509336|Experimental|orphenadrine group|orphenadrine
89396185|NCT04509336|Active Comparator|Baclofen group|Baclofen
88872779|NCT05738213|Placebo Comparator|Healthy control|Adolescents without a migraine diagnosis
88872780|NCT05727397|Experimental|RC28-E|RC28-E 2 mg will be initially injected 3 times at 4 week intervals, then each subject will be injected every 12 weeks unless there is disease activity. If disease activity is identified, the subject will be reassigned to receive injections every 8 weeks thereafter, up to study exit.
88872781|NCT05727397|Active Comparator|Aflibercept|Aflibercept 2 mg will be injected 3 times at 4 week intervals, followed by injections every 8 weeks.
88872782|NCT05677490|Experimental|Arm I (mFOLFIRINOX, nivolumab)|Patients receive fluorouracil IV, leucovorin calcium IV, oxaliplatin IV, and irinotecan IV on study and nivolumab IV as clinically indicated. Patients undergo MRI and a CT scan throughout the trial. Patients may also undergo blood sample collection on study.
88872783|NCT05677490|Active Comparator|Arm II (mFOLFOX, nivolumab)|Patients receive fluorouracil IV, leucovorin calcium IV, and oxaliplatin IV on study and nivolumab IV as clinically indicated. Patients undergo MRI and a CT scan throughout the trial. Patients may also undergo blood sample collection on study.
88872784|NCT05676489|Experimental|Healthy Volunteers (cohort 1)|Whole Body Dosimetry for healthy volunteers
89187676|NCT00434161|Placebo Comparator|Placebo (suger pill)|Subjects received matched placebo before- and after-high dose chemotherapy
89187677|NCT00434161|Active Comparator|Palifermin before and after|Subjects received palifermin before- and after-high dose chemotherapy (total of 6 doses)
89396186|NCT03194321|Experimental|Tacrolimus Extended-Release Arm|All patients will receive tacrolimus extended-release adjusted to target trough levels, mycophenolate mofetil or mycophenolate sodium, and prednisone per CSMC practice.
89396187|NCT04684602|Experimental|Arm 1: Autoimmune Diseases|Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for autoimmune conditions. Outcomes will be compared to results in peer-reviewed literature for several conditions.
89396188|NCT04684602|Experimental|Arm 2: Cardiovascular Disorders|Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for cardiovascular disorders and conditions. Outcomes will be compared to results in peer-reviewed literature for several conditions.
89396189|NCT04684602|Experimental|Arm 3: Diabetes Complications|Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for diabetes complications. Outcomes will be compared to results in peer-reviewed literature for several conditions.
88872785|NCT05676489|Experimental|High Grade Glioma (cohort 2)|Recurrent high grade glioma after radiation therapy
88872786|NCT05676489|Experimental|Brain Metastasis (cohort 3)|Brain metastases from extra-cranial solid tumors before and after radiation therapy
88872787|NCT05676125||chronic ankle instabilty group|females with previous history of ankle sprain
89187678|NCT00441103|Experimental|Rebif® New Formulation (IFN-beta-1a, RNF)|
89187679|NCT00441103|Placebo Comparator|Placebo/RNF|
89396190|NCT04684602|Experimental|Arm 4: Integumentary Disease|Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for integumentary diseases and conditions. Outcomes will be compared to results in peer-reviewed literature for several conditions.
89396191|NCT04684602|Experimental|Arm 5: Musculoskeletal Disorders|Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for orthopedic and musculoskeletal conditions. Outcomes will be compared to results in peer-reviewed literature for several conditions.
89530502|NCT03347435|Active Comparator|phenotype only guided group|The patients randomized to the phenotype only guided group receive clopidogrel or prasugrel or ticagrelor on the basis of the standard of care on the basis of clinical algorithm alone.
89396192|NCT04684602|Experimental|Arm 6: Neurodegenerative Disorders|Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for neurologic and neurodegenerative disorders. Outcomes will be compared to results in peer-reviewed literature for several conditions.
89396193|NCT04684602|Experimental|Arm 7: Pulmonary Disorders|Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for pulmonary disorders. Outcomes will be compared to results in peer-reviewed literature for several conditions.
89396194|NCT04684602|Experimental|Arm 8: Sexual Dysfunction|Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for sexual dysfunction conditions. Outcomes will be compared to results in peer-reviewed literature for several conditions.
89396195|NCT04684602|Experimental|Arm 9: Urologic Disorders|Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for urologic conditions. Outcomes will be compared to results in peer-reviewed literature for several conditions.
89396196|NCT04684602|Experimental|Arm 10: Viral Illnesses|Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for viral illnesses. Outcomes will be compared to results in peer-reviewed literature for several conditions.
89396197|NCT04367142||positive SARS-Cov2|100 patients with a positive diagnosis of SARS-CoV-2
89396198|NCT04367142||negative SARS-Cov2|100 patients with a negative diagnosis of SARS-CoV-2 defined by the gold standard by the medical team
89396199|NCT02259972|Experimental|BI 113823 solution|single rising doses, dose group 5 twice (fed and fasted)
89396200|NCT02259972|Experimental|BI 113823 tablet|dose group 5 only
89396201|NCT02259972|Placebo Comparator|Placebo|
89396202|NCT03820752||Pediatric chronically ill patients|"Through a questionnaire parents of chronically ill patients will be asked about the vaccination status of all recommended vaccines of their child. Also questions on disease, therapy and sociodemographic factors that can influence vaccination coverage will be asked.~A blood sample to determine antibodies against measles, mumps, rubella and pertussis will be drawn from children who consent to sampling.~The following groups of patients will be questioned: diabetes, allergy, congenital heart disease, cystic fibrosis, immunodeficiency and transplant patients, cancer patients."
89396203|NCT03820752||Adult chronically ill patients|"Through a questionnaire chronically ill patients will be asked about their vaccination status of diphtheria, tetanus,pertussis, flu, pneumococcal and hepatitis B vaccine(s). Also questions on disease, therapy and sociodemographic factors that can influence vaccination coverage will be asked.~A blood sample to determine antibodies against diphtheria, tetanus and pertussis will be drawn.~The following groups of patients will be questioned: diabetes, chronic kidney disease, heart failure, COPD, immunodeficiency and transplant patients, HSCT patients."
89396204|NCT01374581|Experimental|Artemether/Lumefantrine|Tablets 20 mg/120 of Artemether/Lumefantrine will be given to 124 trial patients
89396205|NCT01374581|Experimental|Artesunate/Amodiaquine|Tablets 25mg/67,5 mg of Artesunate/Amodiaquine will be given to 124 trial patients.
89396206|NCT01374581|Active Comparator|Quinine + Clindamycin|Quinine tablet 125mg + Clindamycin syrup 75mg/5ml will be given to 60 children.
89396207|NCT02585921|No Intervention|Health & Wellness|Following enrollment, participants will learn about health and wellness.
89396208|NCT02585921|Experimental|Organ Donation Video Education|Following recruitment, participants will watch and discuss videos about organ donation.
89396209|NCT02585921|Experimental|Organ Donation Discussion Education|Following recruitment, participants will learn techniques to introduce and discuss the topic of organ donation with parents or guardians.
89396210|NCT02585921|Experimental|Both Video and Discussion Education|Following recruitment, participants will watch and discuss videos about organ donation and then learn techniques to introduce and discuss the topic of organ donation with parents and guardians.
89003928|NCT03947346||survivors of neuroblastoma treated with nephrotoxic therapy|Upon enrollment, all subjects will receive a urine collection kit by mail. Participants will bring in a first-morning urine specimen on the day of their routinely scheduled long-term follow-up visit, and will then have an additional blood and urine sample drawn with their other clinical care labs upon arrival to MSK.
89396211|NCT04501536|Experimental|High Frequency|Participants will receive therapy 4 times a week for 10 weeks for 30 minutes per session.
89396212|NCT04501536|Experimental|Low Frequency|Participants will receive therapy 1 time a week for 10 weeks for 2 hours per session.
89396213|NCT03562650|Experimental|Safety Behavior Fading|Participants are asked to pick their three most common safety behaviors from a list and then receive texts every other day for a month reminding them to fade those behaviors.
89396214|NCT03562650|Active Comparator|Present Centered|Participants receive texts every other day for a month asking them to try to focus on the present that day.
89396215|NCT01354938||Acute Exacerbation of Chronic Bronchitis (AECB)|Participants with a diagnosis of chronic bronchitis and signs and symptoms of an acute exacerbation who were prescribed Klaricid XL (500 mg of modified release clarithromycin) at a dose of one tablet once a day or two tablets once a day based on physician's decision of severity of symptoms per routine clinical care.
89396216|NCT02516969|Experimental|Stereotactic Body Radiotherapy|Subjects will receive Stereotactic Body Radiotherapy at the following levels: Treatment Volumes <25cc will receive 40Gy (5 fractions of 8Gy per fraction) or treatment Volumes ≥25cc will receive 44-50Gy (5 fractions of 8.8-10Gy per fraction). Ideally all tumors volumes ≥25cc will receive 50Gy over 5 fractions, however at the discretion of the treating radiation oncologist based on tumor bed volume, prior radiation dose, and proximity to critical organs the dose can be reduced to 44Gy over 5 fractions as outlined in prior SBRT protocols.
89396217|NCT01374659||Study patients|Study patients with histologically proven DTC were studied. All patients had previously undergone total thyroidectomy and more than one session of postoperative RI therapy. After the last RI therapy session, all patients showed increasing pathological Tg levels (Tg > 9-10 ng/ml) after TSH stimulation (TSH > 30 mU/l). However, neither tumor recurrence nor metastasis could be detected in any patient by post-therapeutic [131I] scanning, neck US, or chest radiography. Patients with obvious cervical pathology or positive fine-needle aspiration cytology (FNAC) were excluded from the study. The work was approved by our Institutional Review Board and written informed consent was obtained from each patient.
89530503|NCT02453971|Experimental|eCHUG-D|The eCHUG group is requested to conduct the German Version of eCHECKUP TO GO and to fill in their code on the last page of the program.
89187680|NCT01029613||Rheumatoid arthritis|
89396218|NCT03092791|Experimental|Adult Lead-in Cohort: sIPV High Dose|Sabin-based inactivated poliomyelitis vaccine (sIPV) containing 3, 100, and 100 D-Ag units (DU) of poliovirus types 1, 2, and 3, intramuscular injection on Day 1.
89396219|NCT03092791|Placebo Comparator|Adult Lead-in Cohort: Placebo|Placebo, intramuscular injection on Day 1.
89396220|NCT03092791|Experimental|Toddler Lead-in Cohort: sIPV High Dose|sIPV containing 3, 100, and 100 DU of poliovirus types 1, 2, and 3, intramuscular injection on Day 1.
89396221|NCT03092791|Active Comparator|Toddler Lead-in Cohort: Reference IPV|Reference IPV, intramuscular injection on Day 1.
89396222|NCT03092791|Experimental|Infant Dose Ranging Cohort: sIPV Low Dose|sIPV containing 0.75, 25, 25 DU of poliovirus types 1, 2, and 3, intramuscular injection on Days 1, 29, 57 and 365.
89396223|NCT03092791|Experimental|Infant Dose Ranging Cohort: sIPV Medium Dose|sIPV containing 1.5, 50, 50 DU of poliovirus types 1, 2, and 3, intramuscular injection on Days 1, 29 57 and 365.
89396224|NCT03092791|Experimental|Infant Dose Ranging Cohort: sIPV High Dose|sIPV containing 3, 100, 100 DU of poliovirus types 1, 2, and 3, intramuscular injection on Days 1, 29 57 and 365.
89396225|NCT03092791|Active Comparator|Infant Dose Ranging Cohort: Reference IPV|Reference IPV, intramuscular injection on Days 1, 29 57 and 365.
89396226|NCT03065556|Experimental|188-0551 Solution|188-0551 Solution applied topically twice daily
88872788|NCT05676125||control group|healthy feamles
88872789|NCT05673278||Children and young people diagnosed with inflammatory bowel disease aged 2-19 years|Diagnosis according to the modified Porto criteria All participants will undergo single ultrasound scan which will be evaluated with medical notes and results from routine care. No new samples will be taken outside of normal care.
89396227|NCT03065556|Placebo Comparator|Vehicle Solution|Vehicle Solution applied topically twice daily
89396228|NCT01374737|Other|dexmedetomidine, children|
89396229|NCT01374815|Experimental|The Online Advocate|
89396230|NCT02350595|Experimental|Lean fish|Participants eat 750g of lean fish per week for 8 weeks.
89396231|NCT02350595|Experimental|Fatty fish|Participants eat 750g of fatty fish per week for 8 weeks.
89396232|NCT02350595|No Intervention|Control|Participants eat as normal, but avoid fish and seafood for 8 weeks.
89396233|NCT02203409||Laparoscopic ALPPS group|"Patients with small future liver remnant who are operated with the Associating Liver Partition and Portal vein ligation for Staged hepatectomy approach"
89396234|NCT05172505|Active Comparator|Active prefrontal tDCS 2mA 6 weeks 5x/week|
89396235|NCT05172505|Sham Comparator|Sham prefrontal tDCS 6 weeks 5x/week|
89396236|NCT01374893|Active Comparator|Exercise|
89396237|NCT01374893|Placebo Comparator|Control group|Usual care
89396238|NCT05197283|Experimental|Glucose as reference food|Fourteen healthy, normal body weight adults (male: 6, female: 10) after 12hr fast, consumed 50g available carbohydrates from D-glucose, tested two times, in different visits as reference food; and 50g available carbohydrates from white bread, tested two times; and 50 gr available carbohydrates from spaghetti No7 types, regular, whole wheat and low carbohydrates - high fibre, tested once, in different visits, along with 300mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose and salivary insulin samples were taken at baseline, 15, 30, 45, 60, 90 and 120min after food consumption. The first glucose and salivary insulin sample was taken exactly 15min after the first bite of food or drink.
89396239|NCT05197283|Experimental|White bread|Fourteen healthy, normal body weight adults (male: 6, female: 10) after 12hr fast, consumed 50g available carbohydrates from D-glucose, tested two times, in different visits as reference food; and 50g available carbohydrates from white bread, tested two times; and 50 gr available carbohydrates from spaghetti No7 types, regular, whole wheat and low carbohydrates - high fibre, tested once, in different visits, along with 300mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose and salivary insulin samples were taken at baseline, 15, 30, 45, 60, 90 and 120min after food consumption. The first glucose and salivary insulin sample was taken exactly 15min after the first bite of food or drink.
89530504|NCT02453971|No Intervention|control|It is an assessment only condition.
88872790|NCT05656664|Placebo Comparator|Placebo|Placebo daily 12 weeks
88872791|NCT05656664|Experimental|Folic Acid|Folic acid 800 ug/day 12 weeks
88872792|NCT05654012|Other|Family History of Migraine|This group has a first degree relative diagnosed with migraine.
88872793|NCT05654012|Other|No Family History of Migraine|This group does not have a first or second degree relative diagnosed with migraine.
88872794|NCT05653089|Experimental|All patients meeting the study eligibility criteria|
88872795|NCT05644223||Exposet group|intravenous edaravone dexborneol 37.5mg twice daily
88872796|NCT05644223||Non-exposed group|standard treatment at the discretion of local clinicians
88872797|NCT05636371|Experimental|Written Communication|ICU care providers will initiate the process for providing written communication to families. Study investigators will facilitate the creation and distribution of written communication
88872798|NCT05633147|Experimental|linaprazan glurate|"Part I: Linaprazan glurate in base form, 100 mg once daily will be administered under fasting conditions at day 1 and day 10.~Part II: Linaprazan glurate hydrochloride (HCl), 75 mg twice a day for 13 days. The morning dose will be administered under fasting conditions on Day 2 and Day 14."
88872799|NCT05629728|Experimental|frail elderly-TC|Tai Chi group received 12 weeks of Tai Chi exercise program with 12 week follow-up, twice a week, 60 min per session led by a trained Tai Chi instructor
88872800|NCT05629728|No Intervention|frail elderly-WC|control group received no intervention for 12 weeks, and will be provided the chance to participate in Tai Chi program if they choose.
89003929|NCT03931564|Active Comparator|PRESERFLO Microshunt (formerly InnFocus Microshunt (IMS))|The intervention group will undergo PRESERFLO (formerly InnFocus) Microshunt implantation (IMS).
89003930|NCT03931564|Active Comparator|Trabeculectomy|The usual care/control group will undergo a standard trabeculectomy.
89396240|NCT05197283|Experimental|Regular spaghetti No 7|Fourteen healthy, normal body weight adults (male: 6, female: 10) after 12hr fast, consumed 50g available carbohydrates from D-glucose, tested two times, in different visits as reference food; and 50g available carbohydrates from white bread, tested two times; and 50 gr available carbohydrates from spaghetti No7 types, regular, whole wheat and low carbohydrates - high fibre, tested once, in different visits, along with 300mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose and salivary insulin samples were taken at baseline, 15, 30, 45, 60, 90 and 120min after food consumption. The first glucose and salivary insulin sample was taken exactly 15min after the first bite of food or drink.
89396241|NCT05197283|Experimental|Whole wheat spaghetti|Fourteen healthy, normal body weight adults (male: 6, female: 10) after 12hr fast, consumed 50g available carbohydrates from D-glucose, tested two times, in different visits as reference food; and 50g available carbohydrates from white bread, tested two times; and 50 gr available carbohydrates from spaghetti No7 types, regular, whole wheat and low carbohydrates - high fibre, tested once, in different visits, along with 300mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose and salivary insulin samples were taken at baseline, 15, 30, 45, 60, 90 and 120min after food consumption. The first glucose and salivary insulin sample was taken exactly 15min after the first bite of food or drink.
89396242|NCT05197283|Experimental|High fiber - low carbohydrate spaghetti|Fourteen healthy, normal body weight adults (male: 6, female: 10) after 12hr fast, consumed 50g available carbohydrates from D-glucose, tested two times, in different visits as reference food; and 50g available carbohydrates from white bread, tested two times; and 50 gr available carbohydrates from spaghetti No7 types, regular, whole wheat and low carbohydrates - high fibre, tested once, in different visits, along with 300mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose and salivary insulin samples were taken at baseline, 15, 30, 45, 60, 90 and 120min after food consumption. The first glucose and salivary insulin sample was taken exactly 15min after the first bite of food or drink.
89396243|NCT03631615|Experimental|Neoadjuvant therpy|neoadjuvant chemoradiation plus PD-1 antibody (SHR-1210)
89396244|NCT05197205|Experimental|sickle cell children group|A nasopharyngeal swab is taken during the consultation, with bacteriological analysis.
89396245|NCT05197205|No Intervention|control children group|healthy children control group (ACTIV network)
89396246|NCT03631537|Experimental|NST group|Nutrition support team gives the dietary supplement or other nutritional support during the period of chemotherapy
89396247|NCT03631537|No Intervention|routine group|clinicians decide whether to give and how to give the dietary supplement and other nutritional support
89396248|NCT05197127|Experimental|Device Walking Group|Twelve participants over 65 years old completed a total of twelve 30-minute gait training sessions over a period of 4-6 weeks using the GEMS-H. All gait training sessions were completed in the community spaces at a senior living community. Gait training included dynamic over-ground walking (both self-selected and fast-paced),variable conditions of multi-directional walking, and training on ramps, stairs, and obstacle negotiation.
89530505|NCT05559047|Experimental|In-House Usability Study Group|Human subjects will interact with two different CPAP interfaces including a traditional CPAP mask and the 2nd generation DreamPort-Eclipse. Subjects will be requested to put on each of the different CPAP interface options a total of three times for a total of 6 trials. The order of device tries will be randomized.
88872801|NCT05622318|Experimental|Graft-versus-host disease prophylaxis|Following reduced intensity conditioning and 8/8-matched peripheral blood transplant on Day 0, all patients will receive a GVHD prophylaxis post-transplant composed of the following: (i) cyclophosphamide administered at 25 mg/kg on Day +3 and +4, (ii) tacrolimus beginning on Day +5 and through Day +180 and administered with a trough target of 5-10 ng/ml through Day +90 and tapered thereafter; (iii) mycophenolate mofetil (MMF) administered at 15 mg/kg thrice daily beginning on Day +5 through Day +35; and (iv) ruxolitinib administered at 5 mg twice daily starting after engraftment (between Days +30 and +60) and continuing through one year post transplant.
88872802|NCT05612048|Experimental|Patients diagnosed with esophagogastric cancer|Patients have completed the intervention once completing the survey, undergoing dental imaging and future patients will also provide an optional saliva sample.
88872803|NCT05612048|Experimental|Patients diagnosed with colorectal, pancreatic, breast, head and neck, or non-small cell lung cancer|Patients undergo consenting and dental imaging during their routine visits at MSK.
88872804|NCT05612048|Experimental|Healthy volunteers who have not been diagnosed with cancer|Healthy controls will be defined as those without a known or suspected cancer history and excluding those undergoing a procedure for symptomatic reflux.
88872805|NCT05611840|Experimental|Robotic group|One-stage robotic common bile duct exploration and cholecystectomy
88872806|NCT05611840|Active Comparator|Endo-laparoscopic group|Two stage therapeutic endoscopic retrograde cholangiopancreatography (ERCP) with interval laparoscopic cholecystectomy
88872807|NCT05608083|Experimental|HEARTS NOW|Participants in the HEARTS NOW group participants will participate in a weekly six-session online HEARTS class via Zoom about relationships.
88872808|NCT05608083|Active Comparator|HEARTS LATER|Participants in the HEARTS LATER group will participate in a six-week online support group via Zoom about relationships. Participants in this arm will have the option of taking the HEARTS class after the study has ended.
88872809|NCT05597488|Experimental|EUS guided portal pressure gradient measurement|At index OGD, the presence and severity of OV, GV and portal hypertensive gastropathy would be recorded. After endoscopic treatment of varices, recruited patients would undergo 1st measurement of EUS-PPG within 10-14 days after index OGD. The patients would then be enrolled into a variceal surveillance program and be started on B-blockers if not already prescribed. The patients would then be scheduled for another follow-up OGD at 3 months with measurement of the 2nd EUS-PPG. Finally, a third follow-up OGD and EUS-PPG would be performed in 1-year after 1st EUS-PPG. Endoscopic findings attributed to chronic cirrhosis would be assessed in the 3 months and 1 year OGD and the presence and severity of OV, GV and portal hypertensive gastropathy would be recorded.
88872810|NCT05593900|Experimental|Intervention|Parents have the option to use telehealth to virtually connect with the nurse before transfer
89530506|NCT03244423|Placebo Comparator|Group 1|In control group will receive normal saline,
88872811|NCT05593900|No Intervention|Control|Standard of care
89530507|NCT03244423|Active Comparator|Group 2|Intravenous Tranexamic acid group will received Intravenous 50 mg / kg followed by infusion of 1 mg/kg/hr for six hours
89396249|NCT04275817||Individuals with prefrailty|"This is defined as a co-existing prefrailty using the Fried criteria. Frailty defined by the CHS index as proposed by Fried et al. will be identified by the presence of ≥ 3 of the following 5 components: 1) Shrinking: unintentional weight loss of ≥ 5% between two assessments, 2) Weakness: a maximal grip strength in the lowest quintile stratified by body mass index quartile; 3) Poor energy: answer of no to the question Do you feel full of energy? from the 15-item Geriatric Depression Scale; 4) Slowness: average walk speed in the lowest quintile stratified by median standing height, and 5) Low physical activity level: PASE score in the lowest quintile. Participants with none of the above components will be considered to be vigorous and those with 1 or 2 components will be considered to be in a prefrail stage."
89396250|NCT04275817||Individuals with cognitive-prefrailty|"A combination of prefrailty stage using Fried criteria and subjective cognitive impairment (SCI).~The IANA/IAGG consensus defines cognitive frailty as CDR = 0.5 and frailty by the Fried criteria.~In this study, an individual will be considered a CHI if they meet the following criteria: no history of dementia, no use of anti-dementia drugs, normal cognitive performance on cognitive tests and normal scores of ADL and IADL scales. Different participant subgroups will be identified: 1) Individuals will be classified as MCI if they meet the following criteria: Objective cognitive impairment (i.e., performance between 1.5 and 1.9 SDs below the age-appropriate mean) in one or two cognitive domains (i.e., episodic memory and/or executive function) and normal scores of ADL and IADL scales; 2) Individuals will be considered older adults with mild-stage major neurocognitive disorders"
89396251|NCT04275817||Individuals with MCR|"The diagnosis of MCR syndrome will be made following the criteria of Verghese et al. 5: a combination of subjective cognitive complaint, in particular of memory complaint, with the presence of an objective slow gait and the absence of dementia or mobility disability. MCR syndrome will be defined at baseline assessment and each year of follow-up period. Slow gait speed will be defined as gait speed that is one standard deviation (SD) or more below age-and sex-appropriate mean values established in the present cohort like in previous studies. The mean value and SD of female and male will be determined separately. Gait speed was determined from the 3-meter walking test using the best time of the two trials recorded and expressed as meters per second.~Memory complaint used to define MCR syndrome was based on standardized memory loss question on the 15-item Geriatric Depression Scale (GDS; Do you feel you have more problems with memory than most?)."
89396252|NCT04632667|Active Comparator|Comparison School Group|
89396253|NCT04632667|Experimental|Intervention School Group|
89396254|NCT01376453|Experimental|Sorafenib Dose Escalation|Pre-operative Continuous 5-FU, and Sorafenib with External Radiation Therapy. Dose level -1 will only be evaluated if dose level 1 exceeds MTD. The sorafenib and infusional 5-FU will only be given Day 1-5(Monday-Friday) with radiation only.
89396255|NCT05196893|Experimental|Immediate Student Intervention Group|Eligible students who were randomized into an immediate intervention group, and received intervention from school staff who received specialized intervention training starting in the fall semester of the academic year. Students from two clusters of schools received staggered intervention (Cluster 1 starting in year 1, and Cluster 2 starting in year 2). School staff recorded details of intervention sessions in a case management tool, and administrative records were maintained by the school district, for evaluation purposes.
89396256|NCT05196893|Experimental|Wait-list Student Intervention Group|Eligible students who were randomized into a wait-list intervention group, and received intervention from school staff who received specialized intervention training starting in the spring semester of the academic year. Students from two clusters of schools received staggered intervention (Cluster 1 starting in year 1, and Cluster 2 starting in year 2). School staff recorded details of intervention sessions in a case management tool, and administrative records were maintained by the school district, for evaluation purposes.
89396257|NCT05196893|No Intervention|Within School Student Control Group|Eligible students who were randomized into either the immediate or wait-list intervention groups, but did not receive intervention from school staff. This was used as a control group instead of an intended 3rd Cluster, which ultimately was not a comparable control based on enrollment and demographic characteristics.
89396258|NCT04569253|Experimental|All study participants|Subjects will receive treatments with the RF device on one flank. The other flank will be left untreated to serve a control.
89396259|NCT05420779|Experimental|TSL-1502 low dose group|TSL-1502 capsules 350 mg,qd,po
89396260|NCT05420779|Experimental|TSL-1502 high dose group|TSL-1502 capsules 500 mg,qd,po
89396261|NCT05420779|Active Comparator|Positive control group|Investigator selects chemotherapy regimens according to the subjects' conditions.
89396262|NCT02547311|Experimental|Team Clinic Intervention|Middle School and High School Team Clinic Intervention
89396263|NCT02547311|No Intervention|Standard Clinical Care - Control|Standard Clinical Care - Control
89396264|NCT01376531||acute renal failure|patients at intensive care unit with definition of acute renal failure and the need for continuous veno-venous hemodialysis
89396265|NCT01568125||Incretin-related drugs|
89396266|NCT02505425|Experimental|Active Intervention|"Behavioral: behavioral support~Usual HF Care + ENABLE CHF-PC"
89187681|NCT03540212|Experimental|Daclatasvir and sofosbuvir|"Daclatasvir and sofosbuvir~Single arm intervention open label trial for single tablet (Daclatasvir 90 mg and Sofosbuvir 400mg and ) Daclatasvir 90 mg for 12 weeks"
89396267|NCT02505425|Active Comparator|Usual HF Care|Usual heart failure care includes any available supportive care resources and heart failure patient medical management based on national HF guidelines.
89396268|NCT02431871||Treated for DDH in childhood|Subjects have had DDH in childhood. DDH has been diagnosed before age of 1,5 years and treated for.
89396269|NCT02431871||Control|Age an sex matched controls of DDH patients
88872812|NCT05584475|Experimental|Mindfulness Treatment|This arm consists of the mindfulness treatment that will be administered to all participants in the single-arm open trial.
89187682|NCT01022281||Normal Controls|Normal age matched controls without exfoliation
89187683|NCT01022281||Exfoliation Syndrome|Patients with exfoliation syndrome
89003931|NCT03925597|Experimental|ARM 1: Arabinoxylan, Beta-Glucan, Resistant Starch, Inulin|Participants randomized in this arm will take the 4 fiber supplements in the following order: 1- Arabinoxylan 2- Beta-Glucan 3- Resistant Starch 4- Inulin
89187684|NCT03268057|Experimental|VX15/2503 + avelumab|VX15/2503 at a concentration of 5 mg/kg, 10 mg/kg or 20 mg/kg with a fixed dose of avelumab at 10 mg/kg, administered intravenously on a bi-weekly dosing cycle.
88872813|NCT05572697|Experimental|Digital Cognitive-behavioral therapy for insomnia (dCBT-I)|"In addition to the standard rehabilitation program, participants will receive the sleep intervention delivered via a smartphone app. We will use a Norwegian a program named Assistert Selvhjelp (In English: Assisted Self-Help). The app is fully automated and requires no contact with healthcare personnel. It can also be assessed on computers, but in the present project we will use the app-delivered version. It is based on the principles from face-to-face CBT-I including several modules consisting of sleep hygiene, stimulus control sleep restriction, cognitive therapy, and relaxation training. The modules also consist of learning material (e.g., quizzes and materials explaining and educating the patients about important sleep dimensions)."
88872814|NCT05572697|Active Comparator|Usual care|Participants randomized to usual care will receive the standard inpatient rehabilitation program. This is a traditional rehabilitation program consisting of physical activity, mindfulness excises, psychoeducation and acceptance and commitment therapy. One of the educational sessions is about sleep. Although this educational session overlaps with some of the content included in the intervention (e.g., sleep hygiene, stimulus control), it does not include any of the interactive features of the app.
88872815|NCT05563779|Active Comparator|Volume Control mode|During invasive mechanical ventilation in a study location, Volume Control will be used as the mode for continuous mandatory ventilation.
88872816|NCT05563779|Active Comparator|Pressure Control mode|During invasive mechanical ventilation in a study location, Pressure Control will be used as the mode for continuous mandatory ventilation.
88872817|NCT05563779|Active Comparator|Adaptive Pressure Control mode|During invasive mechanical ventilation in a study location, Adaptive Pressure Control will be used as the mode for continuous mandatory ventilation.
88872818|NCT05535829||Patients with FH-deficient RCC|Laboratory analysis of samples
88872819|NCT05534854||Patient with heritable kidney cancer syndrome|Patients with known or suspected heritable kidney cancer syndromes, including VHL and HLRCC Disease.
88872820|NCT05534854||Family members of heritable kidney cancer syndrome|Family members (related by blood) of patients who have or are suspected of having heritable kidney cancer syndromes, including VHL and HLRCC Disease.
88872821|NCT05534854||Not proven genetic etiology|Patients and biologic family members with a heritable kidney cancer syndrome of suspected, but not proven genetic etiology.
88872822|NCT05528848|Experimental|Opioid Use Disorder and Medication Assisted Treatment (OUD+/MAT-)|"Study imaging will be performed using a whole-body PET/CT scanner.~Each participant will receive ≤ 10 mCi of [11C]carfentanil intravenously (approximate range for most studies is anticipated to be 2-10 mCi ).~Participants will undergo dynamic PET/CT imaging of the brain and body. The scan will take approximately 90 minutes for each scan session. Study imaging will be performed using a whole-body PET/CT scanner.~For the first study scan, participants will receive [11C]carfentanil radiotracer alone. For the second study scan approximately 13 mcg/kg of naloxone will be administered by IV prior to the [11C]carfentanil injection. If both scans are done the same day, then the naloxone injection will be given before the second scan session and there will be a break between the two scan sessions of approximately 3 hours."
88872823|NCT05528848|Experimental|Opioid Use Disorder Only (OUD+/MAT-)|"Study imaging will be performed using a whole-body PET/CT scanner.~Each participant will receive ≤ 10 mCi of [11C]carfentanil intravenously (approximate range for most studies is anticipated to be 2-10 mCi ).~Participants will undergo dynamic PET/CT imaging of the brain and body. The scan will take approximately 90 minutes for each scan session. Study imaging will be performed using a whole-body PET/CT scanner.~For the first study scan, participants will receive [11C]carfentanil radiotracer alone. For the second study scan approximately 13 mcg/kg of naloxone will be administered by IV prior to the [11C]carfentanil injection. If both scans are done the same day, then the naloxone injection will be given before the second scan session and there will be a break between the two scan sessions of approximately 3 hours."
88872824|NCT05528848|Experimental|Healthy Volunteers (OUD-)|"Study imaging will be performed using a whole-body PET/CT scanner.~Each participant will receive ≤ 10 mCi of [11C]carfentanil intravenously (approximate range for most studies is anticipated to be 2-10 mCi ).~Participants will undergo dynamic PET/CT imaging of the brain and body. The scan will take approximately 90 minutes for each scan session. Study imaging will be performed using a whole-body PET/CT scanner.~For the first study scan, participants will receive [11C]carfentanil radiotracer alone. For the second study scan approximately 13 mcg/kg of naloxone will be administered by IV prior to the [11C]carfentanil injection. If both scans are done the same day, then the naloxone injection will be given before the second scan session and there will be a break between the two scan sessions of approximately 3 hours."
88872825|NCT05525065||Patients with autoimmune bullous disease receiving glucocorticoids for the duration of the study|Patients with autoimmune bullous disease currently receiving glucocorticoids for their condition, as independently assessed by an appropriately qualified medical professional/dermatologist, for the duration of the study period.
88872826|NCT05525065||Patients with autoimmune bullous disease not currently receiving glucocorticoids|Patients with autoimmune bullous disease who have received glucocorticoids for their condition in the past, but are not currently on steroids.
88872827|NCT05525065||Patients with autoimmune bullous disease ceasing glucocorticoids during the study period|Patients with autoimmune bullous disease who initially had glucocorticoid treatment at the first visit, and had ceased glucocorticoid use during the study period.
88872828|NCT05519527|Experimental|Part 1 (dose escalation)|Participants of the first group will receive the lowest dose level. Participants of each new group will receive a higher dose than the group before it, if no intolerable side effects were seen. This will continue until the highest tolerable dose of STI-6129 is found.
88872829|NCT05519527|Experimental|Part 2 (dose expansion)|Participants will receive the dose of STI-6129 found in Part 1 of the study.
89003932|NCT03925597|Experimental|ARM 2: Arabinoxylan, Beta-Glucan, Inulin, Resistant Starch|Participants randomized in this arm will take the 4 fiber supplements in the following order: 1- Arabinoxylan 2- Beta-Glucan 3- Inulin 4- Resistant Starch
89003933|NCT03925597|Experimental|ARM 3: Arabinoxylan, Resistant Starch, Beta-Glucan, Inulin|Participants randomized in this arm will take the 4 fiber supplements in the following order: 1- Arabinoxylan 2- Resistant Starch 3- Beta-Glucan 4- Inulin
89003934|NCT03925597|Experimental|ARM 4: Arabinoxylan, Resistant Starch, Inulin, Beta-Glucan|Participants randomized in this arm will take the 4 fiber supplements in the following order: 1- Arabinoxylan 2- Resistant Starch 3- Inulin 4- Beta-Glucan
89396270|NCT05196425|Other|Control group|
89396271|NCT05196425|Active Comparator|MS with optic neuritis|
89396272|NCT05196425|Active Comparator|Ms without optic neuritis|
89396273|NCT03089047|Experimental|Rejuvenated RBC Transfusion|Washed and Rejuvenated autologous blood
89396274|NCT03089047|Sham Comparator|Standard RBC Transfusion|Washed autologous blood (so as to maintain equivalent unit volume and Hct)
89396275|NCT01371006|Experimental|BI201335 low dose Efavirenz|low dose Efavirenz
89396276|NCT01371006|Experimental|BI201335 high dose Efavirenz|normal dose Efavirenz
89396277|NCT05195957||rTAR|All consecutive patients undergoing bilateral robotic transversus abdominis release operation in the treatment of their ventral incisional hernia, are considered eligible for inclusion.
89396278|NCT05195957||oTAR|All consecutive patients undergoing bilateral open transversus abdominis release operation in the treatment of their ventral incisional hernia, are considered eligible for inclusion.
89396279|NCT05009173|Active Comparator|Stylet-in|Lumbar puncture performed keeping the stylet inside the needle until the practitioner reaches the appropriate location.
89396280|NCT05009173|Active Comparator|Stylet-out|The practitioner remove the stylet once he/she has passed the skin and moves the needle forward with the stylet.
89396281|NCT01375283||lung cancer surgery|
89396282|NCT04864925|Experimental|Colgate Total Clean Mint|Brush with toothpaste for a minimum of 2 minutes
89396283|NCT04864925|Active Comparator|Tom's Botanically Bright Peppermint|Brush with toothpaste for a minimum of 2 minutes
89396284|NCT04111068|Experimental|Active then Sham|Participants in this arm will be exposed to active stimulation during session 1 and sham/placebo stimulation during session 2
89396285|NCT04111068|Experimental|Sham then Active|Participants in this arm will be exposed to sham/placebo stimulation during session 1 and active stimulation during session 2
89396286|NCT03820284||Group A|Group A inflammatory bowel disease with helicobacter pylori infection
89396287|NCT03820284||Group B|Inflammatory bowel disease without helicobacter pylori infection
89396288|NCT04180098|Experimental|Context specific C-mill training|Five week C-mill training on gait adaptability.
89396289|NCT04180098|Other|Usual care|Usual care for participants with HSP. May vary per individual.
89396290|NCT02288897|Experimental|PV-10|Subjects will receive intralesional PV-10 to all Study Lesions on study Day 1. PV-10 should be re-administered at 28-day intervals until complete response, disease progression or study termination occurs.
89187685|NCT03337100|Experimental|Co-Dispensing|Early implementation of a naloxone co-dispensing pharmacy program. Pharmacies in the phase 1 (early) naloxone co-dispensing arm will be assigned to implement the pharmacy based naloxone co-dispensing program first relative to the phase 2 arm.
89396291|NCT02288897|Active Comparator|Chemotherapy or Oncolytic Viral Therapy|Subjects will receive (a) dacarbazine (intravenously at 850 m/m2) or temozolomide (orally at 200 mg/m2 daily for 5 consecutive days), administered at consecutive 28-day intervals, or (b) intralesional talimogene laherparepvec administered on an initial 21 interval followed by consecutive 14 day intervals, until complete response, disease progression or study termination occurs.
89396292|NCT01371552|Experimental|delefilcon A|Part 1: Delefilcon A contact lenses, followed by filcon II 3 contact lenses and narafilcon A contact lenses (in randomized order). Each product worn for three consecutive days, with a minimum 1-day washout between each product. At the conclusion of this wear cycle, the delefilcon A contact lenses were worn in Part 2 for one additional week. All products worn bilaterally in a daily wear, daily disposable modality.
89396293|NCT01371552|Active Comparator|filcon II 3|Part 1: Filcon II 3 contact lenses, followed by narafilcon A contact lenses and delefilcon A contact lenses (in randomized order). Each product worn for three consecutive days, with a minimum 1-day washout between each product. At the conclusion of this wear cycle, the delefilcon A contact lenses were worn in Part 2 for one additional week. All products worn bilaterally in a daily wear, daily disposable modality.
89396294|NCT01371552|Active Comparator|narafilcon A|Part 1: Narafilcon A contact lenses, followed by filcon II 3 contact lenses and delefilcon A contact lenses (in randomized order). Each product worn for three consecutive days, with a minimum 1-day washout between each product. At the conclusion of this wear cycle, the delefilcon A contact lenses were worn in Part 2 for one additional week. All products worn bilaterally in a daily wear, daily disposable modality.
89396295|NCT02207075||Subjects with SPMS|"Secondary progressive MS Subjects either untreated or on consistent treatment for six months prior to enrollment.~SPMS subjects will have two baseline [11C]PK-11195 PET scans (separated by 24 to 72 hours, test-retest) and subsequent scans at 6, 12 and 24 months. SPMS Subjects will have brain MRI's at baseline, 6, 12 and 24 months."
89396296|NCT02207075||Normal Control Subjects|Healthy Controls will have 2 baseline [C11]PK-1195 PET scans and 1 MRI.
89396297|NCT05707572|Active Comparator|steroid injection|1 injection of 1mL methylprednisolone [40mg]with 1 mL 2% lignocaine
89396298|NCT05707572|Experimental|manual manipulation|weekly manipulations to the metatarsophalangeal joints of the forefoot for 6 weeks
89396299|NCT01376687||Pain free|No pain in the cervical spine
89396300|NCT01376687||Pain|Pain of 3 or greater on a VAS scale for the cervical spine
89396301|NCT04854629|Experimental|Spinomed active orthosis|Wearing the orthosis for 16 weeks
89396302|NCT04854629|No Intervention|Control group|No intervention: non spinomed active control
89396303|NCT04068636|Experimental|Flexible endoscopy guided SNB in larynx and pharynx cancers.|Patients with larynx and pharynx cancers will undergo sentinel node biopsy via flexible endoscopy. In this procedure, a radioactive tracer will be injected at 2-4 sites edging the tumor. A SPECT scan will be performed for visualization of the sentinel node(s).
89396304|NCT02035800|Experimental|Adalimumab (humira)|As standard of care.
89396305|NCT04807361||(1) Multifocal soft contact lenses (MFCLs)|Assess accommodative function of myopic children wearing MFCLs for myopia control treatment. Accommodative stimulus-response functions and accommodative lags will be determined during one, one hour measurement session for four stimulus distances using an IR video refractometer (PowerRefractor). MFCL subjects will also be tested while wearing SVCL distance corrections for comparison.
89396306|NCT04807361||(2) orthokeratology|Assess accommodative function of myopic children wearing Orthokeratology for myopia control treatment.
89396307|NCT04807361||(3) low-dose atropine|Assess accommodative function of myopic children using low-dose atropine eye drops for myopia control treatment.
89396308|NCT04807361||(4) single vision spectacle correction (control)|Assess accommodative function of myopic children wearing single vision spectacle lenses.
89396309|NCT05195021|Experimental|Group 1 (conventional irrigation)|After finishing the mechanical instrumentation, each root canal was irrigated with 5 ml of 5.25% NaOCl using a 31-gauge needle positioned 2 mm shorter than the WL. To remove the smear layer, 5 ml of 17% ethylenediaminetetraacetic acid (EDTA) was used in each canal for 1 minute, and 5 ml of saline was then administered to neutralize all the residues.
89396310|NCT05195021|Experimental|Group 2 (EDDY)|In group 2, 1 ml of 5.25% NaOCl was agitated for 20 seconds three times with the EDDY tip positioned 2 mm shorter than the WL. The root canals were then irrigated with 2 ml of 5.25% NaOCl again. Subsequently, the EDDY tip was activated with short pumping movements, and 2 ml of 17% EDTA was activated for 30 seconds, as described above. The final irrigation followed the same procedures as in group 1.
89396311|NCT05195021|Experimental|Group 3 (conventional irrigation and laser irradiation)|In group 3, final irrigation followed the same procedures as in group 1 and group 2. During the laser therapy, both the operator and the patient wore eyewear for protection. Laser irradiation was performed using a 980-nm diode laser (Medency Primo 10 W Diode Laser; Vicenza, Italy), coupled with optical fibre (200 µm). The settings were as follows: average power of 1.2 W with a low frequency of 50 Hz and energy of 12 J (each cycle) in pulsed mode, irradiation for 10 seconds, followed by a 10 second pause, which constituted one cycle. This cycle was applied four times to each root canal. The optical fibre tip was located at the WL. The root canals were then slowly (at a speed of 2 mm/s) irradiated from the apical to the coronal portion using a continuous helicoidal movement, with optical fibre tip contacting the root canal walls in one cycle for each power.
89530508|NCT03244423|Active Comparator|Group 3|the topical Tranexamic acid group will receive 50 mg / kg poured before sternal closure.
88872830|NCT05508542|Experimental|Intervention group: Progressive relaxation exercises|"Afterwards, the researcher will first give training on progressive relaxation exercises to the patient in the patient's room. A relaxation exercise program will be installed on the patients' phones via the Whatsapp application. It is planned that the trainings will be applied to the patients one-to-one and will last an average of 40-45 minutes for each patient.~After these trainings are completed, a booklet will be given to the patients that will contribute to the correct practice of relaxation exercises on their own. Patients will be asked to practice relaxation exercises by listening to the programs downloaded to their phones at least three times a week for 4 weeks.~In the final test phase; Pittsburgh Sleep Quality Index (PUKI), Prenatal Anxiety Screening Scale and Pregnancy Stress Rating Scale will be re-administered 4 weeks after the start of exercise practices."
88872831|NCT05508542|No Intervention|No Intervention: Standard care group|Standard care group.
88872832|NCT05504044|Other|Control: Glucose|50 g glucose dissolved in 250 mL water
88872833|NCT05504044|Other|Control: Bread|91.4 g white bread
88872834|NCT05504044|Experimental|Bread and Almond paste|88.7 g white bread and 15 g almond paste
88872835|NCT05504044|Experimental|Bread, Almond paste and Inulin|88.7 g white bread, 15 g almond paste and 4 g inulin
88872836|NCT05504044|Experimental|Bread, Low dose almond paste and Inulin|89.6 g white bread, 10 g almond paste and 3.8 g inulin
88872837|NCT05492552|No Intervention|Non-COVID participants|
88872838|NCT05492552|Experimental|COVID participants in intervention|The intervention group will attend the laboratory for baseline testing and complete a week of usual daily activity. Following this week they will then be guided to increase their daily step count by 2,000 and supported through weekly telephone calls.
88872839|NCT05492552|No Intervention|COVID participants assigned to usual daily activity|
88872840|NCT05486078|Experimental|MD-Tissue Medical Device|
88872841|NCT05481320|Experimental|REACH VN Phone Intervention|A multicomponent behavioral intervention to support family caregivers of persons with dementia. The enrollment session (session 0) will be conducted face-to-face. Thereafter, participants will receive 4-6 intervention sessions by phone with either audio or video call over the course of 1-3 months. The sessions will occur every 1-2 weeks depending on the needs and availability of family caregivers.
88872842|NCT05481320|Placebo Comparator|Enhanced control|A single phone session focused on education about the nature of dementia.
88872843|NCT05476328|Experimental|OPAL Sound Processing Strategy|OPAL Sound Processing Strategy with programming being performed using a research version of Custom Sound and the investigational software: Cochlear Device Interface Tool (CDI Tool).
88872844|NCT05476328|Experimental|OPAL-EM|OPAL-Enhanced Modulation with programming being performed using a research version of Custom Sound and the investigational software: Cochlear Device Interface Tool (CDI Tool).
88872845|NCT05476328|Experimental|SPACE|Spread Precompensation Advanced Combination Encoder (SPACE) with programming being performed using a research version of Custom Sound and the investigational software: Cochlear Device Interface Tool (CDI Tool).
88872846|NCT05476328|Experimental|FAST|Fundamental Asynchronous Stimulus Timing (FAST) with programming being performed using a research version of Custom Sound and the investigational software: Cochlear Device Interface Tool (CDI Tool).
88872847|NCT05476328|Experimental|OPAL-SPACE|OPAL-SPACE (combined OPAL and SPACE strategy) with programming being performed using a research version of Custom Sound and the investigational software: Cochlear Device Interface Tool (CDI Tool).
88872848|NCT05476328|Experimental|FAST-OPAL|FAST-OPAL (combined FAST and OPAL strategy) with programming being performed using a research version of Custom Sound and the investigational software: Cochlear Device Interface Tool (CDI Tool).
88872849|NCT05465642||Drug-induced liver injury|history of taking hepatotoxic drugs, liver injury.
89396312|NCT05195021|Experimental|Group 4 (EDDY and laser irradiation)|In this group, after agitation using the EDDY (VDW) system was performed using the same procedures as in group 3, final irrigation and laser irradiation were done as in group 2.
89396313|NCT05707650|Active Comparator|Women allocated to this group will deliver by using reverse breech extraction technique.|
89396314|NCT05707650|Active Comparator|Women allocated to this group will deliver by using Push technique.|
89396315|NCT05194943||1. UOC Chirurgia Bariatrica, Policlinico San Marco, Zingonia, Italy|All patients undergoing revisional bariatric surgery in this center from 01.11.2021 through 31.04.2022 will be enrolled in a prospective, online database, registering reasons for surgery, technique, mortality, intraoperative and perioperative complications, readmission for any reason, following the same preoperative work-up protocol, indications, informed consent, and postoperative follow-up, including scheduled telephone and outpatient visits after 7, 15 and 30 postoperative days.
89396316|NCT05194943||2. UOC di Chirurgia Bariatrica e Metabolica, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy|All patients undergoing revisional bariatric surgery in this center from 01.11.2021 through 31.04.2022 will be enrolled in a prospective, online database, registering reasons for surgery, technique, mortality, intraoperative and perioperative complications, readmission for any reason, following the same preoperative work-up protocol, indications, informed consent, and postoperative follow-up, including scheduled telephone and outpatient visits after 7, 15 and 30 postoperative days.
89396317|NCT05194943||3. UOSD Week Surgery, Chirurgia Bariatrica, Azienda Ospedale-Università di Padova, Padova, Italy|All patients undergoing revisional bariatric surgery in this center from 01.11.2021 through 31.04.2022 will be enrolled in a prospective, online database, registering reasons for surgery, technique, mortality, intraoperative and perioperative complications, readmission for any reason, following the same preoperative work-up protocol, indications, informed consent, and postoperative follow-up, including scheduled telephone and outpatient visits after 7, 15 and 30 postoperative days.
89396318|NCT05194943||4. Unita di Chirurgia dell'Obesità e Metabolica, Azienda Ospedaliero-Universitaria, Bologna, Italy|All patients undergoing revisional bariatric surgery in this center from 01.11.2021 through 31.04.2022 will be enrolled in a prospective, online database, registering reasons for surgery, technique, mortality, intraoperative and perioperative complications, readmission for any reason, following the same preoperative work-up protocol, indications, informed consent, and postoperative follow-up, including scheduled telephone and outpatient visits after 7, 15 and 30 postoperative days.
89396319|NCT05194943||5. UO Chirurgia Generale, Policlinico San Marco di Zingonia, Zingonia, Italy|All patients undergoing revisional bariatric surgery in this center from 01.11.2021 through 31.04.2022 will be enrolled in a prospective, online database, registering reasons for surgery, technique, mortality, intraoperative and perioperative complications, readmission for any reason, following the same preoperative work-up protocol, indications, informed consent, and postoperative follow-up, including scheduled telephone and outpatient visits after 7, 15 and 30 postoperative days.
89396320|NCT05194943||6. UOC Chirurgia Bariatrica e Metabolica, Ospedale San Carlo di Nancy , Roma, Italy|All patients undergoing revisional bariatric surgery in this center from 01.11.2021 through 31.04.2022 will be enrolled in a prospective, online database, registering reasons for surgery, technique, mortality, intraoperative and perioperative complications, readmission for any reason, following the same preoperative work-up protocol, indications, informed consent, and postoperative follow-up, including scheduled telephone and outpatient visits after 7, 15 and 30 postoperative days.
89396321|NCT05194943||7. Dipartimento di Scienze Chirurgiche, Azienda Ospedaliera Universitaria, Torino, Italy|All patients undergoing revisional bariatric surgery in this center from 01.11.2021 through 31.04.2022 will be enrolled in a prospective, online database, registering reasons for surgery, technique, mortality, intraoperative and perioperative complications, readmission for any reason, following the same preoperative work-up protocol, indications, informed consent, and postoperative follow-up, including scheduled telephone and outpatient visits after 7, 15 and 30 postoperative days.
89396322|NCT05194943||8. UO di Chirurgia Bariatrica, Humanitas Research Hospital, Rozzano, Italy|All patients undergoing revisional bariatric surgery in this center from 01.11.2021 through 31.04.2022 will be enrolled in a prospective, online database, registering reasons for surgery, technique, mortality, intraoperative and perioperative complications, readmission for any reason, following the same preoperative work-up protocol, indications, informed consent, and postoperative follow-up, including scheduled telephone and outpatient visits after 7, 15 and 30 postoperative days.
89396323|NCT05194943||9. UOC Chirurgia Generale & Bariatric Center of Excellence IFSO-EC, Latina, Italy|All patients undergoing revisional bariatric surgery in this center from 01.11.2021 through 31.04.2022 will be enrolled in a prospective, online database, registering reasons for surgery, technique, mortality, intraoperative and perioperative complications, readmission for any reason, following the same preoperative work-up protocol, indications, informed consent, and postoperative follow-up, including scheduled telephone and outpatient visits after 7, 15 and 30 postoperative days.
89530509|NCT03239197||mother infant pair|mother infant pair, singleton infant, vaginal birth
88872850|NCT05465642||Healthy control|no liver disease or other disease
88872851|NCT05459272|Experimental|Experimental: Aquilea Sueño Forte|Patients included in this group will be administered dietary supplement with melatonin and herbal products, one tablet daily 30 min before to go to bed during 7 days (from day 7 to day 14).
88872852|NCT05459272|Placebo Comparator|Control|"The control will consist of a placebo based on excipients without active ingredients so that the tablet has the same appearance as the test product.~Patients should take one tablet daily 30 min before to go to bed during 7 days (from day 7 to day 14)."
89530510|NCT03347357|Experimental|tacrolimus|
89530511|NCT03239509||Bioprosthesis|All patients operated on of isolated AVR with a bioprosthesis implantation between 2000-2015 and age 50-65 years both inclusive.
88872853|NCT05451576|Active Comparator|Sodium selenite|200μg/d intravenous sodium selenite was dissolved in 100 ml 0.09% NaCl run 30 minutes, will be given on day 1-5, day 8-12, day 15-19, day 22-26, day 29-33, day 36-40, day 43-47 during concurrent chemoradiotherapy.
88872854|NCT05451576|Placebo Comparator|Placebo|100 ml intravenous 0.09% NaCl run 30 minutes, will be given on day 1-5, day 8-12, day 15-19, day 22-26, day 29-33, day 36-40, day 43-47 during concurrent chemoradiotherapy.
89396324|NCT05194943||10. UOC Chirurgia Generale, Ospedale Villa d'Agri, Potenza, Italy|All patients undergoing revisional bariatric surgery in this center from 01.11.2021 through 31.04.2022 will be enrolled in a prospective, online database, registering reasons for surgery, technique, mortality, intraoperative and perioperative complications, readmission for any reason, following the same preoperative work-up protocol, indications, informed consent, and postoperative follow-up, including scheduled telephone and outpatient visits after 7, 15 and 30 postoperative days.
89396325|NCT05194943||11. UOC di Chirurgia Generale e d'Urgenza, Presidio Ospedaliero ARNAS, Catania, Italy|All patients undergoing revisional bariatric surgery in this center from 01.11.2021 through 31.04.2022 will be enrolled in a prospective, online database, registering reasons for surgery, technique, mortality, intraoperative and perioperative complications, readmission for any reason, following the same preoperative work-up protocol, indications, informed consent, and postoperative follow-up, including scheduled telephone and outpatient visits after 7, 15 and 30 postoperative days.
89396326|NCT05598697|Active Comparator|Cash Transfers only|Participants allocated to this arm receive cash transfers. They are clients of a nation-wide cash transfer program.
89396327|NCT05598697|Experimental|Cash Transfers + LSB curriculum for females clients only|Participants allocated to this arm receive cash transfers and access to LSB curriculum training. Female cash transfer recipients attend 10 life-skills building sessions. Sessions are held weekly and are 90 minutes long. Two trained facilitators run the session for groups of 10 women over a ten-week period.
89396328|NCT05598697|Experimental|Cash Transfers + LSB curriculum for females clients and their husbands|Participants allocated to this arm receive cash transfers and access to LSB curriculum training in gender-segregated groups. Men and women attend 10 life-skills building sessions in parallel. Sessions are held weekly and are 90 minutes long. Two trained facilitators, whose gender matches the participants', run the session for groups of 10 women or men over a ten-week period.
89396329|NCT01568749|Active Comparator|Standard paracetamol|Marketed formulation
89396330|NCT01568749|Experimental|Formulation 1|Paracetamol formulation 1
89396331|NCT01568749|Experimental|Formulation 2|Paracetamol formulation 2
89396332|NCT01568749|Experimental|Formulation 3|Paracetamol formulation 3
89396333|NCT01568749|Experimental|Formulation 4|Paracetamol formulation 4
89396334|NCT03633851|Experimental|Toric intraocular MX60T lens|one eye will receive toric MX60T lens
89396335|NCT03633851|Other|Standard MX60 plus corneal incisions|the other eye will receive standard MX60 lens with corneal incisions
89396336|NCT04443829|Experimental|CD19CAR T-cells|Treatment with the ATIMP: CD19CAR T-cells
89396337|NCT02819310|Experimental|BLI400 Laxative|BLI400 Laxative
88872855|NCT05436756|Other|sampling and clinical data collection|"Biological sampling and collection:~whole blood: 1 dry tube for IgG and IgM anti-leptospirosis serology (volume depending on the patient's weight)~urine: 1 bottle of 30ml~Freezing of serum after centrifugation~Storage at Biological Ressources Center~Collection of clinico-biological data on a dedicated eCRF"
89187686|NCT03337100|No Intervention|Usual Care|"Usual care/Phase 2 naloxone co-dispensing:~Pharmacies in the usual care/phase 2 naloxone co-dispensing arm will provide usual pharmacy services to patients receiving chronic opioid therapy (no naloxone co-dispensing). After 10 months, they may implement the pharmacy-based naloxone co-dispensing program."
89187687|NCT01033903|Experimental|Misoprostol 800 micrograms intravaginally|
89187688|NCT01033903|No Intervention|expectant managment|
89396338|NCT03633773|Experimental|MUC-1 CART|Patients are given fludarabine and cyclophosphamide as pretreatment before MUC-1 CART immunotherapy. After treatment, specific antibodies, CART cells and serum levels of cytokines will be assessed.
89396339|NCT01375361|Experimental|Inhaled Albuterol|Patients identified to have Cardiogenic Pulmonary Edema, will receive 2.5mg of Albuterol nebulizer on enrollment in the study and again at 4 hours. Patients will be monitored on telemetry in the emergency department during and after study drug administration. Although study drug administration will cease after 4 hours, we will continue to record ongoing data during the patient's hospitalization.
89396340|NCT01375361|Placebo Comparator|Inhaled Placebo.|Patients identified to have Cardiogenic Pulmonary Edema will receive 2.5mg Normal saline inhaled (Placebo) on enrollment and at 4 hours in the emergency department. Patient will be monitor on telemetry in the emergency department during and after placebo administration.
89396341|NCT03087643|Experimental|Passive mobilization - PM|Participants will receive 2 times a day, for 5 days a week 30 minutes of passive leg movement treatment including knee flexo-extension in addition to their standard therapies.
88872856|NCT05420948|Experimental|Group 1: Participants Who Receive Pembrolizumab (Alone)|Participants in this group will receive pembrolizumab 200 mg through an intravenous (IV) needle inserted into the arm. Medications will be given on day 1 of each 21-day cycle for two cycles..
88872857|NCT05420948|Experimental|Group 2: Participants Who Receive Pembrolizumab + Chemotherapy with Carboplatin and Paclitaxel|Participants in this group will receive 200 mg of pembrolizumab through an intravenous (IV) needle inserted into the arm plus chemotherapy with carboplatin (AUC 6) on day 1 and paclitaxel (200 mg) on day 1 of each 21-day cycle for two cycles.
88872858|NCT05420623||Amputees patients|
88872859|NCT05420623||control group: non-amputees|
89396342|NCT03087643|No Intervention|Control group - ctrl|Participants will receive ther standard therapies.
89396343|NCT05194865||CMR viability study group|"Diagnostic Test: CMR Basic CMR data including LV and RV volumes, SWMA reported, EF and wall thinning will be collected.~SWMA from SSFP sequences will be reported and numbered according to the usual (1 normal, 2 hypokinetic, 3 akinetic, 4 dyskinetic, 5 aneurysmal).~Data of viability assessed with LGE imaging with scar measurement using standard deviation method with SD of 4-5 will be used.~AHA 17 segment model will be used as a reference for LV segmentation.~Viability scoring will be calculated for each segment based on the transmurality index, in a semiautomated method, with no scar given 0, 1-25% subendocardial scar given score 1, 25-50% given 2, 50-75% given 3, >75% as 4.~Wall thinning will be given 0 or 1 score for each segment, with 1 given for <6 mm thickness."
89396344|NCT05194865||direct revascularization group|Direct Coronary revascularization
89530512|NCT03239509||Mechanical prosthesis|All patients operated on of isolated AVR with a Mechanical prosthesis implantation between 2000-2015 and age 50-65 years both inclusive.
89530513|NCT03346421||diet and physical activity|
89187689|NCT03331094||surgery with graft|The procedure is to place a metal instrumentation (rods and screws) in contact with the spine to correct the deformity. Added to this is a graft between the vertebrae that will allow a bone bridge of ankylosis making the spine completely rigid.
89187690|NCT03331094||surgery without graft|Adult scoliosis surgery is performed with instrumentation without grafting: the teams use variable stiffness rods made of metal or PEEK.
89187691|NCT03329924||Pre-implementation cohort|These patients are being exposed to the current standard of care, which does include some early mobilization practices, but not a formalized program.
89396345|NCT02821962|Experimental|Sedentary prompts (VTAP)|Participants will complete supervised exercise sessions as part of cardiac rehabilitation programming on-site twice weekly for a total of 8 weeks. Participants will also be provided with a VTAP (activPAL3 VT) monitor to wear during waking hours for weeks 1 through 7 of cardiac rehabilitation. The VTAP will alert participants when they have been sedentary for 30 consecutive minutes.
89396346|NCT02821962|No Intervention|Usual care|Participants will complete supervised exercise sessions as part of cardiac rehabilitation programming on-site twice weekly for a total of 8 weeks.
89187692|NCT03329924||post-implementation cohort|These patients will have been exposed to the fully executed early mobilization program.
88872860|NCT05419999|Experimental|tDCS plus WET|Subjects will receive transcranial direct current stimulation (tDCS) plus written exposure therapy (WET)
88872861|NCT05419999|Sham Comparator|Sham plus WET|Subjects will receive sham transcranial direct current stimulation (tDCS) treatment plus written exposure therapy (WET)
88872862|NCT05418348|Experimental|Treatment A (GTX-104 IV, Test):|Nimodipine was administered by infusion over 72 hours.
88872863|NCT05418348|Experimental|Treatment B (NIMOTOP, RLD):|Nimodipine capsules (RS) administered orally with 240 mL of water at a dose level of 60 mg (two 30 mg capsules) q4h for 72 hours.
88872864|NCT05416320|Experimental|Calcipotriol Group|Subjects will use the topical formulation once daily on the scalp. The subjects will use the treatment for a total of 6 months.
88872865|NCT05416320|Sham Comparator|Control Group|Subjects will continue to use their primary physician prescribed topical formulation once daily on the scalp. The subjects will use their treatment for a total of 6 months.
88872866|NCT05403216||OLP(-)|Oral lichen planus (OLP) with negative thyroid antibody group
88872867|NCT05403216||OLP(+)|OLP with positive thyroid antibody group
88872868|NCT05399121|Active Comparator|Group A: Piano Learning then Free Improvisation|This arm (n=15) will first begin the intervention with a Piano Learning exercise followed by a Free Improvisation exercise.
88872869|NCT05399121|Active Comparator|Group B: Free Improvisation then Piano Learning|This arm (n=15) will first begin the intervention with a Free Improvisation exercise followed by a Piano Learning exercise.
88872870|NCT05393557|Active Comparator|Upfront|"Immediately after restoration of distal flow, they will receive:~i. Small dose Tirofiban (intra-coronary bolus of 25µg/Kg),[22] ii. Nitroglycerin 100-200 µg,[12] iii. Verapamil 100-200 µg (excluding patients with 2nd or 3rd degree AV block, bradycardia HR < 60, or systolic BP <100 mmHg)[5] iv. Two cycles of balloon up-balloon down (15 seconds occlusion, 15 seconds open artery; repeated two times).~v. The rest of the procedure will be completed as standard practice."
89187693|NCT00433771|Experimental|WallFlex Biliary Fully Covered stent|Single arm, biliary stenting, using WallFlex Biliary Fully Covered stent
89187694|NCT00433537|Experimental|VcR-CVAD induction followed by maintenance rituximab|"VcR-CVAD induction: Patients receive VcR-CVAD comprising bortezomib IV over 3-5 seconds on days 1 and 4; rituximab IV over 3-4 hours on day 1; doxorubicin hydrochloride IV over 48 hours on days 1 and 2; cyclophosphamide IV over 3 hours every 12 hours on days 1-3; vincristine IV over 3-5 seconds on day 3; and dexamethasone IV or orally once daily on days 1-4. Patients also receive filgrastim (G-CSF) subcutaneously (SC) or IV once daily beginning on day 5 or 6 and continuing until blood counts recover OR pegfilgrastim SC on day 5 or 6. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~Maintenance rituximab: Beginning 4-8 weeks after completion of induction therapy, patients receive rituximab IV over 3-4 hours once weekly for 4 weeks. Treatment repeats every 6 months for up to 4 courses in the absence of disease progression or unacceptable toxicity."
89396347|NCT05598541||Shoulder|Patients with shoulder problems presenting to the orthopaedic outpatient clinic of the Helsinki University Hospital
89396348|NCT05598541||Elbow|Patients with elbow problems presenting to the orthopaedic outpatient clinic of the Helsinki University Hospital
89396349|NCT01376765|Experimental|Cohort 1|Recombinant S protein severe acute respiratory syndrome (SARS) vaccine received with aluminum hydroxide adjuvant (Alhydrogel®), without adjuvant, or placebo in 2 intramuscular doses, 28 days apart, at 5 micrograms per dose; 12 subjects receive unadjuvanted vaccine (SARS vaccine alone); 12 subjects receive adjuvanted vaccine {(SARS vaccine with aluminum hydroxide adjuvant (Alhydrogel®)}; 4 subjects receive placebo.
89396350|NCT01376765|Experimental|Cohort 3|SARS vaccine with adjuvant, without adjuvant, or placebo; l in 2 intramuscular doses, 28 days apart, at 45 micrograms per dose; 12 subjects receive unadjuvanted vaccine (SARS vaccine alone); 12 subjects receive adjuvanted vaccine (SARS vaccine with adjuvant); 4 subjects receive placebo.
89396351|NCT01376765|Experimental|Cohort 2|SARS vaccine with adjuvant, without adjuvant, or placebo in 2 intramuscular doses, 28 days apart, at 15 micrograms per dose; 12 subjects receive unadjuvanted vaccine (SARS vaccine alone); 12 subjects receive adjuvanted vaccine (SARS vaccine with adjuvant) 4 subjects receive placebo.
89396352|NCT04404205||Adult patient with cochlear implant|Adult patients who had cochlear implant surgery before will be included. We will call patients from our cochlear implant list.
89396353|NCT04788563|Experimental|Heat-sensitive moxibustion group A|In this group, patients are compulsively randomized to receive heat-sensitive moxibustion. They will maintain their original antihypertensive treatment (antihypertensive drugs or no treatment).
89396354|NCT04788563|Active Comparator|Control group A|In this group, patients are compulsively randomized to not receive heat-sensitive moxibustion. They will maintain their original antihypertensive treatment (antihypertensive drugs or no treatment).
89396355|NCT04788563|Experimental|Heat-sensitive moxibustion group B|Patients who voluntarily choose to receive randomization and are randomly assigned to receive heat-sensitive moxibustion. They will maintain their original antihypertensive treatment (antihypertensive drugs or no treatment).
89396356|NCT04788563|Active Comparator|Control group B|Patients who voluntarily choose to receive randomization and are randomly assigned to not receive heat-sensitive moxibustion. They will maintain their original antihypertensive treatment (antihypertensive drugs or no treatment).
89396357|NCT04788563|Experimental|Heat-sensitive moxibustion group C|Patients who voluntarily choose to receive heat-sensitive moxibustion. They will maintain their original antihypertensive treatment (antihypertensive drugs or no treatment).
89396358|NCT04788563|Active Comparator|Control group C|Patients who voluntarily choose to not receive heat-sensitive moxibustion. They will maintain their original antihypertensive treatment (antihypertensive drugs or no treatment).
89396359|NCT05196347|Experimental|dapagliflozin + integrated CKD care program|"Subjects will be received dapagliflozin 5 mg for 4 weeks. Uptitration to 10 mg will be done between 5 to 12th weeks, if eGFR dip <20%.~In both arms, the integrated CKD care program includes CKD stage 4 and 5 education, diet counseling, bioimpedance and echocardiography measurements to control overhydration at 0-1 liter (by body composition monitor (BCM; Fresenius))"
89396360|NCT05196347|Active Comparator|integrated CKD care program|In both arms, the integrated CKD care program includes CKD stage 4 and 5 education, diet counseling, bioimpedance and echocardiography measurements to control overhydration at 0-1 liter (by body composition monitor (BCM; Fresenius))
89396361|NCT03092479|Experimental|Behavioral Intervention|4-month bi-weekly comprehensive postoperative behavioral support program addressing psychosocial changes after surgery, strategies for postoperative diet and adherence and preventing weight regain.
88872871|NCT05393557|No Intervention|Control|pPCI procedure will be performed as per standard practice.[2] Bail-out use of any pharmaceutical products will be allowed as per guidelines recommendations (such as: GPi in case of no-reflow or thrombotic complications).
88872872|NCT05387720|Active Comparator|Study Group A|Study Group A (25 patients) will receive manual diaphragmatic facilitation (PNF) technique in addition to traditional chest physiotherapy
88872873|NCT05387720|Active Comparator|Study Group B|Study Group B (25 patients) will receive trigger sensitivity adjustment on mechanical ventilator in addition to traditional chest physiotherapy.
88872874|NCT05387720|Active Comparator|Study Group C|Study Group C (25 patients) will receive a concurrent trigger sensitivity adjustment and manual diaphragmatic facilitation (PNF) technique in addition to traditional chest physiotherapy.
88872875|NCT05378672|Experimental|Dasiglucagon 0.6 mg|Participants will receive a single dose of dasiglucagon.
88872876|NCT05378087|Active Comparator|Image staging group|Standard chemoradiation (Pelvic EBRT/Extended-field EBRT + concurrent platinum-containing chemotherapy + brachytherapy).
88872877|NCT05378087|Experimental|Surgery staging group|Open/minimally invasive para-aortic lymph node dissection followed by chemoradiation (Pelvic EBRT/Extended-field EBRT + concurrent platinum-containing chemotherapy + brachytherapy).
88872878|NCT05377606|Active Comparator|Silicone oil group|Primary pars plana vitrectomy will be performed and silicone oil will be used as the tamponading agent. For these patients, optical coherence tomography (OCT) and angiography (OCTA), along with microperimetry will be done 2 months after the primary surgery. Then they will be scheduled for silicone oil removal after 3 months from the time of primary surgery. Finally, the OCT, OCTA, and microperimetry will be repeated once more after 4 months from the vitrectomy (i.e. one month after the silicone oil removal).
88872879|NCT05377606|Active Comparator|Sulfur hexafluoride (SF6) group|Primary pars plana vitrectomy will be performed and sulfur hexafluoride (SF6) will be used as the tamponading agent. For these patients, optical coherence tomography (OCT) and angiography (OCTA), along with microperimetry will be done 2 months and 4 months after the primary surgery.
88872880|NCT05374577||Patients with a suspected diagnosis of post/long-COVID-19|Patients with a suspected post-COVID-19 syndrome or a long-COVID-19 syndrome at least 3 months after severe acute respiratory syndrome coronavirus(CoV) type 2 (SARS-CoV-2) infection (symptomatic or asymptomatic)
88872881|NCT05374577||Patients without post/long-COVID-19 Syndrome|Patients at least 3 months after a SARS-CoV-2 infection (symptomatic or asymptomatic) without post/long-COVID-19.
88872882|NCT05372367|Experimental|Group 1: OATP1B1/B3 inhibitor|
88872883|NCT05372367|Experimental|Group 2: CYP3A4 inhibitor|
88872884|NCT05359562|Active Comparator|Active Comparator|Male participants will receive a brief EX/RP protocol within a 10-day window.
88872885|NCT05359562|Experimental|Experimental 1|Half of female participants will be randomized to receive a brief EX/RP protocol within the first 10 days after the start of menstruation (early follicular phase).
88872886|NCT05359562|Experimental|Experimental 2|Half of female participants will be randomized to receive a brief EX/RP protocol in days 12-22 of the menstrual cycle (late follicular, early luteal phase).
89396362|NCT03092479|No Intervention|Usual Care|Usual postoperative follow-up per the GHS Center for Nutrition and Weight Management guidelines.
89396363|NCT00732797|No Intervention|Routine Care|Participants will receive routine care.
89396364|NCT00732797|Active Comparator|Booklet|Participants will receive self-treatment booklets, but no expert telephone support.
89396365|NCT00732797|Active Comparator|Booklet &Therapist Support|Participants will receive self-treatment booklets, and up to an hour's expert telephone support.
89396366|NCT03086551|Experimental|Experimental|Application of active continuous theta burst stimulation over dorsolateral prefrontal cortex prior to upper limb motor practice.
89396367|NCT03086551|Placebo Comparator|Control|Application of sham continuous theta burst stimulation over dorsolateral prefrontal cortex prior to upper limb motor practice.
89396368|NCT01375439|Other|Active search of lower genital tract infections|"Active search of lower genital tract infections~Two groups (G1 and G2) will be part of study, each one composed of 140 pregnant women with a history of premature birth, G1 will have the active search and etiologic diagnosis of lower genital tract infections and G2 do not search of these infections, keeping for this group, the protocol of routine care of basic health units in the city of Botucatu. Workup care of pregnant women (G1) will include the completion of direct examination of vaginal contents stained by Gram's method, culture in the medium of Diamonds and polymerase chain reaction (PCR) of endocervical secretions, collected by health services in primary care the municipality in two moments: before 20th pregnancy week (M1) and in 36th pregnancy week (M2). The moment M3 will be after the birth, to evaluate the perinatal outcome."
89396369|NCT05193773|No Intervention|comparison group|The Control Group received no extra care.
89396370|NCT05193773|Experimental|Intervention Group|Intervention Group, Intervention with follow-up, will have a multifactorial interventions to reduce physical restraint.
89396371|NCT05193617|Experimental|GP combine with peramprizumab and anlotinib neoadjuvant therapy+CCRT+peramprizumab adjuvant therapy|Patients receive neoadjuvant therapy with gemcitabine(1000mg per square meter on days 1,8) , cisplatin (80mg per square meter on day 1), peramprizumab (200mg, day1), and anlotinib (10mg days 1-14) every three weeks for three cycles before radiotherapy, then followed by concurrent IMRT and cisplatin (100mg per square meter) concurrent every three weeks during radiotherapy (D1, D22, D43 of RT) ,then followed by adjuvant therapy with peramprizumab (200mg) every three weeks for a maximum of nine cycles after radiotherapy.
89396372|NCT05193617|Active Comparator|GP combine with Peramprizumab neoadjuvant therapy+CCRT+Peramprizumab adjuvant therapy|Patients receive neoadjuvant therapy with gemcitabine(1000mg per square meter on days 1,8) , cisplatin (80mg per square meter on day 1), peramprizumab (200mg, day1) every three weeks for three cycles before radiotherapy, then followed by concurrent IMRT and cisplatin (100mg per square meter) concurrent every three weeks during radiotherapy (D1, D22, D43 of RT) ,then followed by adjuvant therapy with peramprizumab (200mg) every three weeks for a maximum of nine cycles after radiotherapy.
89396373|NCT03265249|Experimental|Group 1|BRIDGE device will be placed prior to start of the surgery with standard of care pain control analgesia
89396374|NCT03265249|No Intervention|Group 2|Subjects will receive the standard of care pain control analgesia
89396375|NCT04778111||Patients with exclusion|
89187695|NCT00433537|Experimental|VcR-CVAD induction followed by ASCT|"VcR-CVAD induction: Patients receive VcR-CVAD comprising bortezomib IV over 3-5 seconds on days 1 and 4; rituximab IV over 3-4 hours on day 1; doxorubicin hydrochloride IV over 48 hours on days 1 and 2; cyclophosphamide IV over 3 hours every 12 hours on days 1-3; vincristine IV over 3-5 seconds on day 3; and dexamethasone IV or orally once daily on days 1-4. Patients also receive filgrastim (G-CSF) SC or IV once daily beginning on day 5 or 6 and continuing until blood counts recover OR pegfilgrastim SC on day 5 or 6. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~ASCT: After completion of induction therapy, patients who are eligible may have the option to receive consolidation therapy for autologous stem cell transplantation (off-study). These patients undergo stem cell harvest during courses 4, 5, or 6 of induction therapy."
89396376|NCT04778111||Control|
89187696|NCT02580110|Experimental|sucrose|14 days intervention with daily intake of a beverage (1000 ml) including 66g sucrose.
88872887|NCT05351242|Experimental|Thermotherapy/sauna bath|Must go to a sauna (min. Temperature 85℃) min. 4 times a week for 6 months. Each sauna bath must last at least 7 minutes. The intervention patients receive a subscription card for a sauna during the period. Patients will still receive pre-existing treatment
88872888|NCT05351242|No Intervention|No thermotherapy/sauna bath|"Not allowed to go to a sauna for 6 months. Patients who come to do so, by e.g. an oversight, however, remain in the study, to avoid introducing bias. It will be registered as a protocol violation, but the patient will be included in Intention To Treat analysis and modified Intention To Treat analysis. Patients will still receive pre-existing treatment."
88872889|NCT05350371|Experimental|Placebo|
88872890|NCT05350371|Experimental|Pirfenidone Treatment|
88872891|NCT05348200|Active Comparator|Monad 1 cream|Topical cream applied to the peri-anal area twice daily for seven days.
88872892|NCT05348200|Active Comparator|Monad 2 cream|Topical cream applied to the peri-anal area twice daily for seven days.
88872893|NCT05348200|Active Comparator|Monad 3 cream|Topical cream applied to the peri-anal area twice daily for seven days.
88872894|NCT05348200|Experimental|Combination-CITI-002 (low dose) cream|Topical cream applied to the peri-anal area twice daily for seven days.
88872895|NCT05348200|Experimental|Combination-CITI-002 (high dose) cream|Topical cream applied to the peri-anal area twice daily for seven days.
88872896|NCT05325502|Placebo Comparator|Placebo|7 days placebo intake.
88872897|NCT05325502|Active Comparator|Acute caffeine|6 days placebo followed by 1 day caffeine intake.
88872898|NCT05325502|Experimental|Daily caffeine|7 days caffeine intake
88872899|NCT05321108|Experimental|Group A (GA) (Aerobic exercise group):|the patient will receive aerobic exercise program: (graded treadmill machine walking and stepping exercises). The second part of the exercise program will be 10 minutes of stepping exercise at a speed of 96 beats per minute using a 20-cm-high bench, with rest after the first 5 minutes. Three sessions per week for 12 weeks.
88872900|NCT05321108|Experimental|Group B (GB) (Whole-body vibration (WBV) group)|the patient will receive whole-body vibration with frequency 30-40Hz and 2 mm of amplitude will be used for the whole-body vibration program by reciprocating vertical displacements on the left and right side of a fulcrum. The WBV group performed a training program 3 times a week with at least one day between each session for 12 weeks.
88872901|NCT05307744|Experimental|PS128|Subjects will take PS128 capsules every day (2 capsules/day, once) for 12 weeks.
88872902|NCT05307744|Placebo Comparator|Placebo|Subjects will take placebo capsules every day (2 capsules/day, once) for 12 weeks.
88872903|NCT05307744|No Intervention|Normal control|Normal control group are enrolled by invitation from the age and gender matched healthy children.
88872904|NCT05285384|Experimental|SpikoGen COVID-19 Vaccine|
88872905|NCT05265195||Semi-structured Interviews|"Interviews will be conducted with parents and clinicians regarding their experiences of periviable counselling conversations. The interviews aim to identify key priorities and topic themes for the pre-delivery conversation for both parents and the clinicians, as these are hypothesised to differ between the groups.~Thematic analysis of transcribed semi-structured interviews with 20 parents and 20 clinicians.~The recruited parents will encompass a mixture of parent experiences: those with a surviving periviable child, parents whose baby died in delivery room and parents whose baby died in the neonatal unit."
88872906|NCT05265195||National evaluation of current periviable management practices across the UK.|Review of periviable deliveries and antenatal management practices in the United Kingdom for infants where the decision is for active care at delivery.
88872907|NCT05265195||Recording and thematic analysis of periviable decision-making conversations|"Recruiting parents who have presented in periviable labour to Manchester Foundation Trust sites.~Aiming to audio record 20 conversations discussing management options and potential outcomes between healthcare professionals and parents.~Thematic analysis will be undertake to determine key topics and priorities for parents and clinicians (these may well differ), time taken to discuss each topic, order topics presented, management options offered or requested, and discussion of comfort care."
88872908|NCT05265195||Comparison of recorded and simulated periviable decision-making conversations|"Recruit 20 senior clinicians from mixture of obstetric and neonatal specialities.~Clinician will participate in a standardised simulated discussion with two parents (played by actors) who have presented in periviable labour.~Simulated conversations will be audio recorded and transcribed.~Analysis will be performed for structure and topics included in this simulated conversation. Comparison will be undertaken comparing the conversational architecture of the simulated conversations with the recorded real conversations (recorded in the above phase of this study)."
88872909|NCT05265195||Focus Groups with parents and clinicians|"Parent focus groups to consolidate and stratify key priority themes for periviable counselling and development of parent resources.~Clinician focus groups to discuss experiences with training in this area and preferences for future training methods/resources.~Parents will be recruited from parental advisory groups and local baby groups.~Aiming to run 5x focus groups with maximum 8 participants in each group."
89396377|NCT04772261|Experimental|Lot-to-Lot Variability|Participants will be administered up to six different 13C-Spirulina test meal lots
89396378|NCT04772261|Experimental|Biological Variability|Participants will be administered the same 13C-Spirulina test meal lot on two different occasions
89003935|NCT03925597|Experimental|ARM 5: Arabinoxylan, Inulin, Beta-Glucan, Resistant Starch|Participants randomized in this arm will take the 4 fiber supplements in the following order: 1- Arabinoxylan 2- Inulin 3- Beta-Glucan 4- Resistant Starch
89187697|NCT02580110|Experimental|stevia glycosides|14 days intervention with daily intake of a beverage (1000ml) including 0.220 g stevia glycosides.
89187698|NCT02580110|Experimental|saccharin|14 days intervention with daily intake of a beverage (1000ml) including 0.216g saccharin.
89187699|NCT00570765|Experimental|DB OCA 10 mg|OCA 10 mg for 3 months during the DB phase.
89003936|NCT03925597|Experimental|ARM 6: Arabinoxylan, Inulin, Resistant Starch, Beta-Glucan|Participants randomized in this arm will take the 4 fiber supplements in the following order: 1- Arabinoxylan, 2- Inulin, 3- Resistant Starch, 4- Beta-Glucan
89187700|NCT00570765|Experimental|DB OCA 50 mg|OCA 50 mg for 3 months during the DB phase.
89396379|NCT05193461|Experimental|patients with radicular pain recieved pulsed mood radiofrequency|Investigation effect of neuroplasticity of patient on outcome of pulsed mood radiofrequency
89396380|NCT04726475|Experimental|CBD-WR|"300 mg CBD-rich hemp extract oil administered within the reconsolidation window.~The timing of CBD-rich oil administration is based on preclinical studies demonstrating that CBD's disruptive effects on reconsolidation procedurally depend on timing pharmacological administration to be within the memory reconsolidation window (< 6 hrs. post-retrieval).~Thus, immediately after the 35% CO2 interoceptive memory reactivation procedure and associated measures (see measures), participants will be asked to take a single 300mg CBD-rich oral dose of a hemp-derived oil formulation."
89396381|NCT04726475|Placebo Comparator|PBO-WR|"Placebo administered within the reconsolidation window.~Immediately after the 35% CO2 interoceptive memory reactivation procedure and associated measures (see measures), participants will be asked to take a single dose of an MCT coconut oil placebo solution."
89396382|NCT04726475|Active Comparator|CBD-OR|"CBD-rich hemp extract oil administered outside of the reconsolidation window.~Participants will be asked to take a single 300mg oral dose of CBD-rich oil approximately 24 hrs after the initial 35% CO2 interoceptive memory reactivation challenge.~Thus, CBD will be administered well beyond the critical period for memory reconsolidation. The inclusion of this third arm provides a more robust test of the specific reconsolidation theory-based study hypotheses and aids in controlling for any nonspecific possible anxiolytic effects of CBD."
89396383|NCT05183945|Experimental|Localization needle insertion|Patients undergo localization needle insertion on day 1.
89396384|NCT05183945|Active Comparator|Coil insertion|Patients undergo coil insertion on day 1.
89396385|NCT05182541|Experimental|Guided self help|Introduce the knowledge about twins pregnancy, and reduce the pregnant stress, and relief the anxiety and depressor.
89396386|NCT05182541|Experimental|Face to face PST course|Problem cognition and emotional response guidance
89396387|NCT05182541|Experimental|Professional psychological intervention|Give the pregnancy woman the professional psychological intervention
89396388|NCT05760833|Active Comparator|Pulmonary vein isolation|Ablation of the pulmonary veins.
89396389|NCT05760833|Active Comparator|atrioventricular node ablation.|Ablation of the atrioventricular node.
89396390|NCT05170763|Experimental|PA9159 10 μg single dose and placebo|Ten subjects will be randomly assigned at a 4: 1 ratio to receive either single dose of 10 μg PA9159 or placebo. There will be a one week follow-up period to review all available clinical and laboratory safety data before escalating to next dosing level.
89396391|NCT05170763|Experimental|PA9159 20 μg single dose and placebo|Ten subjects will be randomly assigned at a 4: 1 ratio to receive either single dose of 20 μg PA9159 or placebo. There will be a one week follow-up period to review all available clinical and laboratory safety data before escalating to next dosing level.
89396392|NCT05170763|Experimental|PA9159 40 μg single dose and placebo|Ten subjects will be randomly assigned at a 4: 1 ratio to receive either single dose of 40 μg PA9159 or placebo. There will be a one week follow-up period to review all available clinical and laboratory safety data before escalating to next dosing level.
89396393|NCT05170763|Experimental|PA9159 80 μg single dose and placebo|Ten subjects will be randomly assigned at a 4: 1 ratio to receive either single dose of 80 μg PA9159 or placebo. There will be a one week follow-up period to review all available clinical and laboratory safety data.
89396394|NCT05170763|Experimental|PA9159 20 μg repeated doses and placebo|Ten subjects will be randomly assigned at a 4: 1 ratio to receive either 20 μg PA9159 or placebo once a day for 7 days. There will be a one week follow-up period to review all available clinical and laboratory safety data before escalating to next dosing level.
89396395|NCT05170763|Experimental|PA9159 40 μg repeated doses and placebo|Ten subjects will be randomly assigned at a 4: 1 ratio to receive either 40 μg PA9159 or placebo once a day for 7 days. There will be a one week follow-up period to review all available clinical and laboratory safety data.
89396396|NCT03093181|Placebo Comparator|No treatment and Standard cleanser|Participants randomised to the no treatment regimen will use the standard cleanser (only) twice a day (morning and night). Morning and evening applications should be separated by at least 8 hours.
89396397|NCT03093181|Experimental|Test product and Standard cleanser|Participants randomised to test product regimen will be instructed to use the standard cleanser and test product twice a day (morning and night). Morning and evening applications should be separated by at least 8 hours. Participants will be instructed to apply the test product cream immediately after cleansing.
89396398|NCT03093181|Active Comparator|Positive control and positive cleanser|Participants randomised to positive control regimen will be instructed to use the positive cleanser and positive control product twice a day (morning and night). Morning and evening applications should be separated by at least 8 hours. Participants will be instructed to apply the positive control cream immediately after cleansing.
89396399|NCT05200091|Experimental|Combined explosive strength and specific balance training group|This group will be formed with participants with incomplete spinal cord injury. This group will perform 4 weeks of combined explosive strength and specific balance training.
89396400|NCT05200091|No Intervention|Spinal cord injury control group|This group will be formed with participants with incomplete spinal cord injury. They will perform all the evaluation before and after a 4-week period of rest (no training).
89396401|NCT05200091|No Intervention|Healthy control group|Healthy participants will be recruited based on the age and sex of the participants with incomplete spinal cord injury to realize clinical and neurophysiological cortical evaluations.
89396402|NCT04666181|Experimental|Dual-task training|Dual-task training will consist of balancing on the dynamic stability platform and responding to auditory stimuli. Participants will perform 18 trials total in 3 blocks of 6 trials. Each trial will be 30 seconds (s) in duration followed by 30 s of rest (i.e. quiet standing on the platform while holding onto the rails.) Between each training block, the participant will step off the platform and rest for 2 minutes. Dual-task training will occur on consecutive visits 2-6.
89396403|NCT02922439|Experimental|Tailored Intervention|Individuals will interact with a chronic disease self-management application that provides information tailored to age, race, language (English or Spanish) and level of health literacy.
89396404|NCT02922439|Active Comparator|Control|Individuals will interact with a chronic disease self-management application that provides the same information as the experimental intervention but is not personally tailored to level of health literacy.
89396405|NCT05199623|Experimental|CHM(Chinese herbal medicine) group|Treatment with steroid, zinc, and olfactory training for one month. And then, take CHM(Chinese herbal medicine) (tailored Guizhi decoction) and perform OT(olfactory training) for 6 months
88872910|NCT05265195||Parental survey of long-term outcomes|"Survey will be distributed to all parents of surviving periviable deliveries at St Mary's Manchester over the last 2 - 10 years.~Parents will be asked to complete the survey at home giving their views on their child's strengths, difficulties, development and social interactions.~The survey also asks parents for their views on what they remember they were told before they delivered and, in light of their experiences, what would they recommend clinicians include in pre-delivery periviable conversations with future parents.~The survey will be sent to all eligible parents, which equates to 220 surviving infants. All returned surveys will be analysed."
88872911|NCT05261191|Experimental|Part 1A: Dose level 1|Single dose MGD020
88872912|NCT05261191|Experimental|Part 1A: Dose level 2|Single dose MGD020
88872913|NCT05261191|Experimental|Part 1A: Dose level 3|Single dose MGD020
88872914|NCT05261191|Experimental|Part 1A: Dose level 4|Single dose MGD020
88872915|NCT05261191|Experimental|Part 1A: Dose level 5|Single dose MGD020
88872916|NCT05261191|Experimental|Part 1A: Dose level 6|Single dose MGD020
88872917|NCT05261191|Experimental|Part 1B: MTD/MAD -1 MGD020 and MGD014|Single dose MGD020 and MGD014
88872918|NCT05261191|Experimental|Part 1B: MTD/MAD MGD020 and MGD014|Single dose MGD020 and MGD014
88872919|NCT05261191|Experimental|Part 2: MGD020 and MGD014|Multiple doses of MGD020 and MGD014
88872920|NCT05250778|Experimental|Nudge Group|Encounters in this group will be nudged
88872921|NCT05250778|No Intervention|Control Group|Encounters in this group will not receive a nudge.
88872922|NCT05249127|Experimental|64Cu-SAR-bisPSMA|Patients will receive a single administration of 200 megabecquerels (MBq) of 64Cu-SAR-bisPSMA.
88872923|NCT05235737|Active Comparator|Treatment arm 1|n=12 evaluable patients - neoadjuvant Pembrolizumab (2 doses, 200mg each) plus adjuvant Pembrolizumab (16 cycles q3w, 200mg each) on top of standard chemo-radiotherapy (Stupp protocol: radiotherapy 60Gy over 6 weeks, 2 Gy per daily fraction Mo-Fri setting plus Temozolomide 75mg/m2 of body surface area (BSA) daily during radiotherapy and six cycles post-radiotherapy of 150-200mg/m2 for 5 days in each 28-day cycle)
88872924|NCT05235737|Active Comparator|Treatment arm 2|n=12 evaluable patients - neoadjuvant Pembrolizumab (2 doses, 200mg each) on top of standard chemo-radiotherapy (Stupp protocol: radiotherapy 60Gy over 6 weeks, 2 Gy per daily fraction Mo-Fri setting plus Temozolomide 75mg/m2 BSA daily during radiotherapy and six cycles post-radiotherapy of 150-200mg/m2 for 5 days in each 28-day cycle)
88872925|NCT05235737|No Intervention|Treatment arm 3|n=12 evaluable patients - standard chemo-radiotherapy (Stupp protocol: radiotherapy 60Gy over 6 weeks, 2 Gy per daily fraction Mo-Fri setting plus Temozolomide 75mg/m2 BSA daily during radiotherapy and six cycles post-radiotherapy of 150-200mg/m2 for 5 days in each 28-day cycle)
88872926|NCT05222763|Experimental|Experimental: Interventional group|The web-supported interactive nursing program intervention will take 3 weeks. The first week of the training will begin with the patient's admission to the clinic. Shoulder and Arm Exercises, Lymphedema in the Arm and Prevention of Its Development, and qualitative study, the themes of misperception determined in this area will be emphasized. In the second week, they will be asked to continue their Shoulder and Arm Exercises training, to examine the Other Side Breast Examination Training and Adaptation Process to Life Activities, Skin Care and Post-Surgery Cancer Treatment and Breast Reconstruction. In the last week of the training, it will be requested to review the contents again. Correct perceptions that may emerge as a result of the qualitative study will be supported in the relevant parts of the training. During the study, short mobile phone messages containing reminders and motivations will be sent regularly twice a week (8 times).
88872927|NCT05222763|Active Comparator|Behavioral:|"The handbook developed within the scope of the Women's Return to Social Life After Mastectomy Project on the website of the Continuing Education, Research and Solidarity Association will be used on the website of the participants assigned to the control group."
88872928|NCT05218356|Experimental|Codivir treatment|20 mg administrated by subcutaneous (SC) injection, twice a day, for 7 days
88872929|NCT05218356|Placebo Comparator|Placebo treatment|Placebo administrated in subcutaneous (SC) injection, twice a day, for 7 days
88872930|NCT05204719|Experimental|Prophylactic Delivery Room Continuous Positive Airway Pressure|If the infant is spontaneously breathing and allocated to the experimental arm, s/he will receive 20 min of 5 cm H2O of prophylactic continuous airway pressure using either a face mask or the appropriate size of nasal prong.
88872931|NCT05204719|No Intervention|No Prophylactic Delivery Room Continuous Positive Airway Pressure|"Alternatively, spontaneously breathing infants assigned to control group will receive the standard of care with no prophylactic delivery room continuous positive airway pressure (CPAP).~In both groups, CPAP can be used to help babies with persistent labored breathing or cyanosis after the initial steps as per the participating institution's neonatal resuscitation protocol. At any time, if the patient does not present spontaneous breathing, an escalation on the resuscitation measures will be performed and the study intervention will be terminated."
88872932|NCT05176015|Experimental|Frenzel Lens with Diagnostic Algorithm|"Frenzel lens will be applied on patients' eyes during different diagnostic maneuvers to assess if a nystagmus is present and if present describe its main characteristic.~Without mentioning to patient, the emergency physician will use a diagnostic algorithm inspired from the TiTrATE approach to interpret the nystagmus and propose the need or the irrelevance for neuro-imaging"
88872933|NCT05176015|Experimental|Frenzel Lens without Diagnostic Algorithm|Frenzel lens will be applied on patients' eyes during different diagnostic maneuvers to assess if a nystagmus is present and describe its main characteristics. No diagnostic algorithm will be used to interpret nystagmus.
89187701|NCT00570765|Placebo Comparator|DB OCA Placebo|Matching placebo for 3 months during the DB phase.
89187702|NCT00570765|Experimental|LTSE OCA Total|After completion of the 3-month DB phase, all eligible participants were offered the opportunity to enter an open-label LTSE for up to 96 months beginning at 10 mg OCA. Doses up to 50 mg daily were evaluated.
88872934|NCT05176015|Experimental|No Frenzel Lens with Diagnostic Algorithm|"Nystagmus assessment in different manoeuvres is performed without the use of Frenzel lens.~Without mentioning to patient, the emergency physician will use a diagnostic algorithm inspired from the TiTrATE approach to interpret the nystagmus and propose the need or the irrelevance for neuro-imaging"
88872935|NCT05176015|No Intervention|No Frenzel Lens and No Diagnostic Algorithm|The emergency physician is performing the assessment of nystagmus and its interpretation as usual. The Frenzel lens and the diagnostic algorithm are not used.
89396406|NCT05199623|Active Comparator|OT(olfactory training) group|Treatment with steroid, zinc, and olfactory training for one month. And then, perform OT(olfactory training) only for 6 months.
89396407|NCT05413031|Active Comparator|relative motion splint|
89396408|NCT05413031|Active Comparator|static splint|
89396409|NCT03091777|Experimental|Test Drug|GDC-229 gel applied vaginally as directed.
89396410|NCT03091777|Active Comparator|Reference Drug|Metronidazole Vaginal Gel, 0.75% applied vaginally as directed.
89396411|NCT03091777|Placebo Comparator|Vehicle Placebo Gel|GDC-229 Vehicle
89396412|NCT04648085|Experimental|Pre and Post Treatment with Trigeminal Nerve Stimulation (TNS)|Individuals will receive treatment with trigeminal nerve stimulation for 20 minutes at a frequency of 100 Hertz (Hz). Ocular pain intensity will be recorded prior and after the use of therapy.
89396413|NCT03632837|Experimental|Treatment|Inclusion of an extracorporal in line adsorbing cartridge for 48h (with a cartridge exchange at 24h) post establishing ECMO in addition to standard post resuscitation intensive care
89396414|NCT03632837|No Intervention|Control|ECMO and standard post resuscitation intensive care without any additional module in extracorporal circulation
89396415|NCT04624997||Patient suspected COVID-19|"Follow-up of patients as usual in care for infection. No specific puncture. Blood sample collect at admission and every 72h during hospitalisation for hemostasis evaluation, DNA extraction, Circulating endothelial cells measuring.~Sampling can be delayed for 24h to match a planned blood collection for care or other research."
89396416|NCT05601947|Experimental|Structured Proprioception and Closed Kinetic Chain Exercises Group|In addition to electrotherapy and conventional exercise program applications, structured proprioception and closed kinetic chain exercises will be applied for 3 weeks under the supervision of a physiotherapist. A rest period of 10 seconds will be given between exercises.
89396417|NCT05601947|Experimental|Wii Based Balance Training Program Group|In addition to electrotherapy and conventional exercise program, wii-based balance training program will be applied 5 days a week for 3 weeks.
89396418|NCT05392361|Active Comparator|control group|conservative management for spinal stenosis
89396419|NCT05392361|Experimental|baclofen group|conservative management for spinal stenosis plus baclofen treatment
89396420|NCT05598983||COPD patients|Group will consist of individuals who have been diagnosed with COPD, living in their home and not recently discharged from the hospital for an exacerbation.
89396421|NCT05598983||Discharged COPD patients|Group will consist of individuals who have been diagnosed with COPD, living in their home, and are being discharged from the hospital for an exacerbation.
88872936|NCT05175430|Active Comparator|Pretreatment with paroxetine|Pretreatment with paroxetine (10 mg daily for 1 week followed by 20 mg daily for 5 weeks, per os), followed by administration of LSD (0.1 mg, per os) on the study day
88872937|NCT05175430|Placebo Comparator|Pretreatment with placebo|Pretreatment with placebo for 6 weeks (mannitol, per os), followed by administration of LSD (0.1 mg, per os) on the study day
88872938|NCT05169398|Experimental|EUS-guided hepaticogastrostomy|EUS-guided hepaticogastrostomy would be performed with the MG-biliary stent (Niti-S, Taewoong Medical, Gyeonggi-do, Korea).
89396422|NCT05760755|Experimental|Intervention group (Stick Together)|Intervention group (all participants)
88872939|NCT05168995||Asthmatic patients in treatment with BDP/FF NEXThaler® 100/6 micrograms|Not adequately controlled asthmatic patients in treatment with Beclometasone dipropionate (BDP)/formoterol fumarate (FF) 100/6 micrograms per actuation inhalation powder via NEXThaler®
89396423|NCT05335655|Active Comparator|Group A|IV bolus of dexmedetomidine, blindly administered and tittered to 0.5mcg per kilogram (real weight), diluted in 10 ml of 0.9% saline solution during 15 minutes before the spinal block. Once the anesthetic effect is confirmed, the maintenance IV infusion, based on dexmedetomidine 100 mcg diluted in 100 ml of 0.9% saline solution tittered at 0.5 mcg per kilogram per hour (real weight), begins.
89396424|NCT05335655|Placebo Comparator|Group B|IV 10 ml initial bolus of 0.9% saline solution during the 15 minutes before the spinal block. Once de anesthetic effect is confirmed, the maintenance infusion of IV 0.9% saline solution (100 ml in equivalent dosage per hour) begins.
89396425|NCT04589351|Active Comparator|Ezetimibe|One treatment period of 16 weeks with1 capsule of ezetimibe 10mg per day, as add-on to standard care.
89396426|NCT04589351|Placebo Comparator|Placebo|One treatment period of 16 weeks with 1 capsule of matching placebo per day, as add-on to standard care.
89396427|NCT04580615|Experimental|Inpatients subjects|Inpatients subjects diagnosed with a Respiratory disease/impairment or subjects with no known Respiratory disease/impairment
89396428|NCT02818998|Experimental|Aflibercept 2 mg fixed|Participants received fixed dosing of 2 mg aflibercept at injection intervals of 8 weeks
89396429|NCT02818998|Experimental|Aflibercept 2 mg flexible|Participants received flexible dosing of 2 mg aflibercept at injection intervals of ≥8 week
89396430|NCT02818998|Experimental|Aflibercept 2 mg PRN|Participants received monthly monitoring with 2 mg aflibercept injection pro re nata (PRN, as needed)
88872940|NCT05168982||Chronic liver disease (CLD) patients at stage A0 of liver inflammation|
88872941|NCT05168982||Chronic liver disease (CLD) patients at stage A1 of liver inflammation|
88872942|NCT05168982||Chronic liver disease (CLD) patients at stage A2 of liver inflammation|
88872943|NCT05168982||Chronic liver disease (CLD) patients at stage A3 of liver inflammation|
89396431|NCT05042219||COPD (ICS)|COPD before initiation of inhaled corticosteroid therapy
89396432|NCT05042219||COPD (LTOT-NIV)|COPD before initiation of long term oxygen therapy or domiciliary long-term non-invasive ventilation
88872944|NCT05168982||Chronic liver disease (CLD) patients at stage F0 of liver fibrosis|
88872945|NCT05168982||Chronic liver disease (CLD) patients at stage F1 of liver fibrosis|
88872946|NCT05168982||Chronic liver disease (CLD) patients at stage F2 of liver fibrosis|
88872947|NCT05168982||Chronic liver disease (CLD) patients at stage F3 of liver fibrosis|
88872948|NCT05168982||Chronic liver disease (CLD) patients at stage F4 of liver fibrosis|
88872949|NCT05168982||healthy subjects|
88872950|NCT05155852||Post-delivery preeclampsia patients|Women admitted to the high-risk unit(s) with elevated blood pressure and neurological symptoms, such as headache, after delivery.
89187703|NCT00777621|Active Comparator|Calorie restriction|
89187704|NCT00777621|Active Comparator|Exercise|
89396433|NCT05042219||COPD (Roflumilast )|COPD before initiation of Roflumilast therapy
89003937|NCT03925597|Experimental|ARM 7: Beta-Glucan, Arabinoxylan, Resistant Starch, Inulin|Participants randomized in this arm will take the 4 fiber supplements in the following order: 1- Beta-Glucan, 2- Arabinoxylan, 3- Resistant Starch, 4- Inulin
89003938|NCT03925597|Experimental|ARM 8: Beta-Glucan, Arabinoxylan, Inulin, Resistant Starch|Participants randomized in this arm will take the 4 fiber supplements in the following order: 1- Beta-Glucan, 2- Arabinoxylan, 3- Inulin, 4- Resistant Starch
89003939|NCT03925597|Experimental|ARM 9: Beta-Glucan, Resistant Starch, Inulin, Arabinoxylan|Participants randomized in this arm will take the 4 fiber supplements in the following order: 1- Beta-Glucan, 2- Resistant Starch, 3- Inulin, 4- Arabinoxylan
89003940|NCT03925597|Experimental|ARM 10: Beta-Glucan, Resistant Starch, Arabinoxylan, Inulin|Participants randomized in this arm will take the 4 fiber supplements in the following order: 1- Beta-Glucan, 2- Resistant Starch, 3- Arabinoxylan, 4- Inulin
89003941|NCT03925597|Experimental|ARM 11: Beta-Glucan, Inulin, Arabinoxylan, Resistant Starch|Participants randomized in this arm will take the 4 fiber supplements in the following order: 1- Beta-Glucan, 2- Inulin, 3- Arabinoxylan, 4- Resistant Starch
89003942|NCT03925597|Experimental|ARM 12: Beta-Glucan, Inulin, Resistant Starch, Arabinoxylan|Participants randomized in this arm will take the 4 fiber supplements in the following order: 1- Beta-Glucan, 2- Inulin, 3- Resistant Starch, 4- Arabinoxylan
89003943|NCT03925597|Experimental|ARM 13: Resistant Starch, Inulin, Beta-Glucan, Arabinoxylan|Participants randomized in this arm will take the 4 fiber supplements in the following order: 1- Resistant Starch 2- Inulin 3- Beta-Glucan 4- Arabinoxylan
89003944|NCT03925597|Experimental|ARM 14: Resistant Starch, Inulin, Arabinoxylan, Beta-Glucan|Participants randomized in this arm will take the 4 fiber supplements in the following order: 1- Resistant Starch, 2- Inulin, 3- Arabinoxylan, 4- Beta-Glucan
89003945|NCT03925597|Experimental|ARM 15: Resistant Starch, Arabinoxylan, Inulin, Beta-Glucan|Participants randomized in this arm will take the 4 fiber supplements in the following order: 1- Resistant Starch, 2- Arabinoxylan, 3- Inulin, 4- Beta-Glucan
89003946|NCT03925597|Experimental|ARM 16: Resistant Starch, Arabinoxylan, Beta-Glucan, Inulin|Participants randomized in this arm will take the 4 fiber supplements in the following order: 1- Resistant Starch, 2- Arabinoxylan, 3- Beta-Glucan, 4- Inulin
89003947|NCT03925597|Experimental|ARM 17: Resistant Starch, Beta-Glucan, Inulin, Arabinoxylan|Participants randomized in this arm will take the 4 fiber supplements in the following order: 1- Resistant Starch, 2- Beta-Glucan, 3- Inulin, 4- Arabinoxylan
89003948|NCT03925597|Experimental|ARM 18: Resistant Starch, Beta-Glucan, Arabinoxylan, Inulin|Participants randomized in this arm will take the 4 fiber supplements in the following order: 1- Resistant Starch, 2- Beta-Glucan, 3- Arabinoxylan, 4- Inulin
89003949|NCT03925597|Experimental|ARM 19: Inulin, Resistant Starch, Arabinoxylan, Beta-Glucan|Participants randomized in this arm will take the 4 fiber supplements in the following order: 1- Inulin, 2- Resistant Starch, 3- Arabinoxylan, 4- Beta-Glucan
89003950|NCT03925597|Experimental|ARM 20: Inulin, Resistant Starch, Beta-Glucan, Arabinoxylan|Participants randomized in this arm will take the 4 fiber supplements in the following order: 1- Inulin, 2- Resistant Starch, 3- Beta-Glucan, 4- Arabinoxylan
89003951|NCT03925597|Experimental|ARM 21: Inulin, Beta-Glucan, Resistant Starch, Arabinoxylan|Participants randomized in this arm will take the 4 fiber supplements in the following order: 1- Inulin, 2- Beta-Glucan, 3- Resistant Starch, 4- Arabinoxylan
89003952|NCT03925597|Experimental|ARM 22: Inulin, Beta-Glucan, Arabinoxylan, Resistant Starch|Participants randomized in this arm will take the 4 fiber supplements in the following order: 1- Inulin, 2- Beta-Glucan, 3- Arabinoxylan, 4- Resistant Starch
89003953|NCT03925597|Experimental|ARM 23: Inulin, Arabinoxylan, Beta-Glucan, Resistant Starch|Participants randomized in this arm will take the 4 fiber supplements in the following order: 1- Inulin, 2- Arabinoxylan, 3- Beta-Glucan, 4- Resistant Starch
89003954|NCT03925597|Experimental|ARM 24: Inulin, Arabinoxylan, Resistant Starch, Beta-Glucan|Participants randomized in this arm will take the 4 fiber supplements in the following order: 1- Inulin, 2- Arabinoxylan, 3- Resistant Starch, 4- Beta-Glucan
89187705|NCT00777621|Experimental|Calorie restriction and exercise|
89187706|NCT00777699|Experimental|1|
89187707|NCT00777777|Experimental|1|Either the Circumflex Coronary Artery or the Right Coronary Artery will receive the mesh supported vein graft and the native saphenous vein as second and control graft.
89187708|NCT00780819|Experimental|PoleStar N20 intraoperative MRI|PoleStar N20 intraoperative MRI
89187709|NCT00780897||1|POF patients; 18 years <Age> 40 years; Hormonal sampling; FMR1 analysis; FSH Receptor gene analysis; LH Receptor gene analysis; BMP15 gene analysis; GDF9 gene analysis; Connexin 37 analysis; Ovarian biopsy; Bone Mineral Density; Pelvic Ultrasonography;
89396434|NCT05042219||Bronchial asthma (antibody)|Bronchial asthma before initiation of antibody therapy
89396435|NCT05042219||Bronchial asthma (ICS)|Bronchial asthma before initiation of inhaled corticosteroid therapy
89396436|NCT05042219||Pulmonary fibrosis|Pulmonary fibrosis before initiation of antifibrotic therapy
89396437|NCT05579015|Experimental|rMDD group|Participants with remitted MDD who will receive concurrent TBS/fNIRS with iTBS and followed by cTBS after one hour. This group will also receive follow-up telephone interviews every 3 months for 2 years to monitor major depressive episode recurrence.
88816737|NCT05588778|Experimental|¡En Forma y Fuerte! @home/en casa|¡En Forma y Fuerte! @home/en casa is an exercise and health education program designed to improve arthritis-related outcomes. The classes will meet two times per week for 90 min each for 12 weeks. Each class session consists of 60 min of exercise (flexibility, aerobics and strength training) and 30 minutes of health education using group problem solving based on SCT.
88872951|NCT05148117||suspected sepsis group|We will perform a prospective observational study of patients admitted to the intensive care units (ICU) with suspected sepsis or septic shock.
89396438|NCT05579015|Other|Healthy control group|Healthy participants who will receive TBS/fNIRS with iTBS and followed by cTBS after one hour. No follow-up interviews will be conducted for this group.
89396439|NCT05575583|Experimental|Intervention group|Subjects underwent repetitive transcranial magnetic stimulation for five consecutive days from day 2 to day 6 after surgery. The stimulation target area was the posterior cingulate gyrus, and the neuronavigation system was used to accurately locate the stimulation target in this project. Continuous theta short rapid pulse mode (cTBS) was used. CTBS mode consisted of a slave stimulus delivered every 0.2 seconds (5Hz), and each slave stimulus consisted of three bursts of 50Hz. A single stimulus lasts about 40 seconds and totals 600 pulses. Stimulation sessions are from 8 to 10 a.m. daily.
89396440|NCT05575583|Sham Comparator|Control group|Subjects underwent repetitive transcranial magnetic stimulation for five consecutive days from day 2 to day 6 after surgery，but the machine does not turn on.
89396441|NCT05572307||POD group|According to the occurrence of postoperative delirium, the patients were divided into POD group and non-POD group
89396442|NCT05572307||non-POD group|According to the occurrence of postoperative delirium, the patients were divided into POD group and non-POD group
89396443|NCT05572307||CPSP group|Patients were divided into CPSP group and non-CPSP group according to the occurrence of postoperative chronic pain
89396444|NCT05572307||non-CSP group|Patients were divided into CPSP group and non-CPSP group according to the occurrence of postoperative chronic pain
88872952|NCT05148117||control group|This group will be compared to suspected sepsis or sepsis shock patients. The control group will be age matched, gender-matched, and cardiovascular risk-factor matched controls.
88872953|NCT05140343|Experimental|Mobile ECG Monitoring|Standard care with clinical follow-up plus Mobile ECG Monitoring.
88872954|NCT05140343|No Intervention|24-hour Holter monitoring|Standard care with clinical follow-up plus repeating 24-hours Holter ECG (month 1, 6, 12)
88872955|NCT05139277|Experimental|CONVIVO system|During tumor resection, study investigators trained in the use of the system will determine when the CONVIVO imaging system will be used for in vivo¬ imaging. At this point 5 mg/kg of fluorescein will be administered intravenously by an anesthesia provider over one minute.Approximately 2-5 minutes following administration of FNa in situ imaging will be performed by the participating surgeon ensuring proper technique.
88872956|NCT05139277|Other|Conventional histologic evaluation|Following image acquisition, the tissue region imaged with the CONVIVO system will then be biopsied using biopsy forceps. This will be passed immediately off the surgical field as a research specimen and provided to a member of the research team to be prepared for conventional histologic evaluation. The specimen will be labeled with the deidentified subject and sample number. This sequence will then be repeated for each successive sample.
88872957|NCT05138432|Other|Intervention Group|Monthly fruit and vegetable vouchers for 12 months, to start immediately after enrollment.
88872958|NCT05138432|Other|Delayed Intervention Group|Monthly fruit and vegetable vouchers for 12 months, to start after a 6-month waiting period.
88872959|NCT05133791|Active Comparator|0.5 mg|Annexin A5-CW800, 0.5 mg, 1 dose
88872960|NCT05133791|Active Comparator|1.0 mg|Annexin A5-CW800, 1.0 mg, 1 dose
88872961|NCT05133791|Active Comparator|2.0 mg|Annexin A5-CW800, 2.0 mg, 1 dose
88872962|NCT05127915|Experimental|Therapeutic|The therapeutic arm will include subjects with diagnosed symptomatic VTE (PE and/or DVT). Each subject will receive an Adient absorbable filter to help prevent a subsequent PE. All study subjects will return to the investigation site for the Follow-up Visits at Week 2 (±3 days), Week 10 (±1 week) and Month 9 (±2 weeks). Subjects will be interviewed and examined at each follow-up visit to perform safety and filter status evaluations.
89396445|NCT02821416|Experimental|Benralizumab|Benralizumab administered subcutaneously
89396446|NCT02821416|Placebo Comparator|Placebo|Placebo administered subcutaneously
89396447|NCT03108521|Experimental|Sitagliptin group|Patients in this group will accept Sitagliptin phosphate tablets as their intervention. Specifications: Each tablet 100mg (with sitagliptin dollars). Regimen: The recommended dose is 100mg.QD for 3 months.
89396448|NCT03108521|No Intervention|non-T2DM group|Subjects in this group are T2D free. We use their gene information to study SNP differences between T2D patients and non-T2DM people.
89187710|NCT00780897||2|Control Group No POF patients; Benign ovarian pathology; 18 years <Age> 40 years; Hormonal sampling; FMR1 analyze; FSH Receptor gene analysis; LH Receptor gene analysis; BMP15 gene analysis; GDF9 gene analysis; Connexin 37 analysis; Ovarian biopsy under specific conditions; Bone Mineral Density; Pelvic Ultrasonography
89396449|NCT03992274|No Intervention|Standard implementation|During Standard Implementation, sites will use standard Yunnan Center for Disease Control and Prevention strategies to introduce HIV prevention innovations.
89396450|NCT03992274|Experimental|Enhanced implementation|During Enhanced Implementation, sites will transition to receive enhanced Implementation Support to plan and implement PrEP.
89396451|NCT04500509|Experimental|Group A|patients will have of oral diclofenac potassium 60 minutes before the procedure plus one tablets of vaginal dinoprostone (6 mg) 6 hours prior to the procedure
89396452|NCT04500509|Placebo Comparator|Group B|patients will have of oral diclofenac potassium 60 minutes before the procedure plus one tablets of vaginal placebo 6 hours prior to the procedure
89396453|NCT03854838|Experimental|Toripalimab +Radiotherapy|Radiotherapy, intensity-modulated radiation therapy (IMRT), 60 Gy 2.2Gy per fraction ,5 fractions per week, for 6 weeks. Radiation begun the day after the first dose of Toripalimab. Toripalimab (240mg dose every 3 weeks for 7 cycles, one cycle is three weeks ) will be administered as an intravenous infusion over 60 minutes.
89396454|NCT05001191|Experimental|Gentle Human Touch Group|
89396455|NCT05001191|No Intervention|Control group|
89396456|NCT05760599|Experimental|Candonilimab Plus Bevacizumab|Candonilimab 10mg/kg, Bevacizumab 15mg/kg, every 3 week
89396457|NCT04454255|Experimental|Primo-FunSpeech|Participants will begin the study by a period using FunSpeech (45 days) followed by a control period without the game (45 days). This sequence will be repeated once.
89396458|NCT04454255|Experimental|Primo-control|Participants will begin the study by a control period without the game (45 days) followed by a period using FunSpeech (45 days). This sequence will be repeated once.
89187711|NCT00667095|Experimental|Botox and DMSO instillation|Botulinum-A Toxin (Botox) 300 units in 50 cubic centimeters of Dimethyl Sulfoxide (DMSO) 50% w/w aqueous solution
89396459|NCT04442945|Experimental|ANAVEX3-71 Oral|Up to four single ascending doses of ANAVEX3-71 administered orally
89396460|NCT04442945|Placebo Comparator|Placebo arm Oral|Placebo administered orally
89396461|NCT04441073|Experimental|Lignocaine|preoperative nebulization of lignocaine
89396462|NCT04441073|Placebo Comparator|Placebo|preoperative nebulization of normal saline (Nacl 0.9%) as a placebo
89396463|NCT03633539|Active Comparator|Conventional Laparoscopic Surgery|Patients with colorectal cancer undergo conventional laparoscopic surgery（multi-ports）.
88872963|NCT05127915|Experimental|Prophylactic - Test|The Prophylactic - Test arm will include subjects who are at transient high risk for PE and do not have diagnosed symptomatic VTE (PE and/or DVT). If randomized into this prophylactic arm, study subjects will receive an Adient absorbable filter to help prevent PE in addition to being administered current best practice PE prevention, namely sequential compression machines, compression stockings, and anticoagulants when indicated. All study subjects will return to the investigation site for the Follow-up Visits at Week 2 (±3 days), Week 10 (±1 week) and Month 9 (±2 weeks). Subjects will be interviewed and examined at each follow-up visit to perform safety and filter status evaluations.
88872964|NCT05127915|Active Comparator|Prophylactic - Control|The Prophylactic - Control arm will include subjects who are at transient high risk for PE and do not have diagnosed symptomatic VTE (PE and/or DVT). If randomized into this prophylactic arm, study subjects will receive current best practice PE prevention, namely sequential compression machines, compression stockings, and anticoagulants when indicated. All study subjects will return to the investigation site for the Follow-up Visits at Week 2 (±3 days), Week 10 (±1 week) and Month 9 (±2 weeks). Subjects will be interviewed and examined at each follow-up visit.
88872965|NCT05125822|Experimental|Meal Replacement and Lifestyle Therapy|Participants in this study will have an 8-week meal replacement therapy period in which they are asked to reduce their BMI by 5% by following a prescribed eating regimen consisting of meal replacement shakes and/or frozen meals for breakfast and lunch. For dinner they will consume a pre-packaged frozen entree to be consumed with two servings of fruit and three servings of vegetables per day. Participants will also have lifestyle/behavioral modification counseling every 2 weeks throughout the entire study.
88872966|NCT05115513|Experimental|Placebo Marijuana|Placebo Marijuana will be administered.
88872967|NCT05115513|Experimental|Medium THC Marijuana|Medium THC marijuana will be administered.
88872968|NCT05099991|Placebo Comparator|Dilapan-S|A number of Dilapan-S will be inserted for cervical preparation. The number will be determined by a standard protocol that is based on gestational age. The dilators will stay in until the next day prior to their procedure, or earlier if they fall out on their own.
88872969|NCT05099991|Experimental|Foley balloon|A Foley balloon will be inserted for cervical preparation and filled to 30mL of water or saline. The balloon will stay in until the next day prior to their procedure, or earlier if it falls out on its own.
88872970|NCT05089760||Infants with bacteria sepsis|Infants diagnosed with culture-proven sepsis
88872971|NCT05080075|Experimental|Participants receiving a platelet rich plasma injection|All patients in the study will be receiving a platelet rich plasma injection, and we will be following their clinical outcomes
88872972|NCT05071170||Degree of food processing and food texture|"Processed vs unprocessed foods based on NOVA classification~Soft and hard foods manipulated by cooking method"
88872973|NCT05067244|Experimental|MDMA assisted psychotherapy|Participants will undergo a 2-month course of CPT psychotherapy for PTSD with two sessions that integrate MDMA-assisted psychotherapy. MDMA will be administered ini two separate sessions and integrated into the psychotherapy protocol. The two doses of MDMA during this study will be used as an adjunct to psychotherapy.
88872974|NCT05063487||Recent HIV Infection|Persons ≥15 years of age who are newly-diagnosed with HIV, consent to participate in case-based surveillance and recency testing and test recent on the rapid test for recent infection (RTRI).
88872975|NCT05063487||Long-Term HIV Infection|Persons ≥15 years of age who are newly-diagnosed with HIV, consent to participate in case-based surveillance and recency testing and test long-term on the rapid test for recent infection (RTRI).
88872976|NCT05062057||Palpitations|n=20 peri- and postmenopausal women with self-reported palpitations within 2 weeks prior to enrollment
88872977|NCT05062057||No palpitations|n=20 peri- and postmenopausal women with no self-reported palpitations within 6 months prior to enrollment
88872978|NCT05060887|Experimental|OVX836 - 180µg dose level|Adjuvant-free recombinant influenza candidate vaccine based on the Nucleoprotein (NP) of the influenza virus. One single administration intramuscularly of a 180μg dose on Day 1.
88872979|NCT05060887|Experimental|OVX836 - 300µg dose level|Adjuvant-free recombinant influenza candidate vaccine based on the Nucleoprotein (NP) of the influenza virus. One single administration intramuscularly of a 300μg dose on Day 1.
88872980|NCT05060887|Experimental|OVX836 - 480µg dose level|Adjuvant-free recombinant influenza candidate vaccine based on the Nucleoprotein (NP) of the influenza virus. One single administration intramuscularly of a 480μg dose on Day 1.
89187712|NCT00667095|Placebo Comparator|DMSO instillation|Dimethyl Sulfoxide (DMSO) 50% w/w aqueous solution, 50 cubic centimeters
89187713|NCT00777933|Active Comparator|cyclosporine|
89187714|NCT00777933|Experimental|Tacrolimus|
89187715|NCT00773331|Experimental|1|
89396464|NCT03633539|Experimental|Single-incision Laparoscopic Surgery|Patients with colorectal cancer undergo single-incision laparoscopic surgery.
89396465|NCT02036034|Active Comparator|drape with forced air warmer|forced air warmer placed under the chin before draping, inflated after draping completed.
89396466|NCT02036034|Placebo Comparator|drape with warming blanket|warming blanket placed on torso of patient under the drape.
89396467|NCT04343989|Experimental|Clazakizumab 25 mg|
89396468|NCT04343989|Experimental|Clazakizumab 12.5 mg|
89396469|NCT04343989|Placebo Comparator|Placebo|
89396470|NCT05598073|Experimental|1-hour vinyasa yoga session|Participants will complete a 1-hour vinyasa yoga DVD.
89396471|NCT04089787|Experimental|Intervention group|Shortened antibiotic treatment of 5 days
89396472|NCT04089787|Active Comparator|Control group|Antibiotic treatment of 7 days or longer at the discretion of the treating physician
89396473|NCT02817828|Experimental|15 mg E4/3 mg DRSP|15 mg E4/3 mg DRSP tablet
89396474|NCT03632681|Active Comparator|Insulin|In this arm a single-dose of (160 IU/1.6ml) intranasal insulin will be administrated
89396475|NCT03632681|Placebo Comparator|Placebo|In this arm a single-dose intranasal placebo will be administrated
89396476|NCT05483387|Experimental|HBS 2 Resorb Mg|Study arm treated with the HBS 2 Resorb Mg.
89396477|NCT05597995|Experimental|Treatment with 1.5% sodium tetradecyl sulfate foam|each subject will have cyst contents aspirated through an 18g needle followed by an injection of 1.5% STS solution foamed 1:4 with air until foam is flowing out of the injection site.
89396478|NCT04880057|Active Comparator|Resistance+Aerobic training group|Resistance+Aerobic training group (RAeT) RAeT includes resistance training (RT) program and aerobic training (AeT) program.
89396479|NCT04880057|Experimental|Agility training group|Agility training
89396480|NCT02817906|Experimental|ITI-007|9 mg ITI-007 administered as a solid oral dose formulation once daily for 4 weeks.
89396481|NCT02817906|Placebo Comparator|Placebo|Placebo administered as a visually-matched solid oral dose formulation once daily for 4 weeks
89396482|NCT04338971|Experimental|IpsiHand Device|All participants will receive treatment with the IpsiHand Device.
89396483|NCT03796650|Experimental|Fecal microbiota transplantation|Fecal microbiota from healthy, screened stool donors at the University Hospital of North Norway. Patients will receive one FMT enema immediately after enrolment.
89396484|NCT03796650|Active Comparator|Antibiotic treatment|Patients randomized to the control group will receive a ten-day course of oral vancomycin four times a day. This is according to international guidelines for primary C. difficile treatment.
89396485|NCT05597527|Experimental|Fluzopari and Apatinib group|Fluzopari and Apatinib were used in patients with newly diagnosed ovarian cancer before any treatment. The daily dose should be strictly controlled according to the experimental design.
89396486|NCT04234295|Active Comparator|Lean, Healthy Controls|Subjects with a body mass index (BMI) of 25 or less will have a fat tissue biopsy collected
89396487|NCT04234295|Experimental|Obese, Non-Diabetic|Subject with a BMI between 30 and 50 kg/m2 will have fat tissue biopsy collected
89396488|NCT02912143||newly diagnosed children with hemophilia|no intervention
89396489|NCT05198999|Experimental|Aqua-PLYO group|Participants in this group received the Aqua-PLYO training program
89396490|NCT05198999|Active Comparator|Control group|Participants in this group received the standard physical rehabilitation program
89396491|NCT02036112|Experimental|Individual ELAPE|Patients will receive Individual ELAPE technique
89396492|NCT02036112|Experimental|Conventional ELAPE|Patients with advanced lower rectal cancer will receive conventional EALPE technique
89396493|NCT05707416|Active Comparator|Experimental group|Will includes 9 patients who will receive intrusive arche after leveling and alignment assisted with laser with wavelength 635 nm, 6.5J/cm2,The laser will be applied to 4 points of application for each tooth two labial and two palatal started immediately after first intrusive wire then at days 3,7,14 and then every 15 day until achievement of the study objectives
89396494|NCT05707416|Active Comparator|Control group|Will includes 9 patients who will receive intrusive arches after leveling and alignment without laser application
89396495|NCT02036268|Active Comparator|Standard|Subjects will receive standard ostomy education.
89396496|NCT02036268|Experimental|Pre-Operative Education|In addition to standard ostomy education, subjects will receive additional education pre-operatively.
89396497|NCT02036268|Experimental|Two-week Post Operative Education|In addition to standard ostomy education, subjects will receive additional education two weeks following surgery.
89396498|NCT04749251|Experimental|Individual blood pressure management arm|During the EVT procedure(in general anesthesia), mean arterial blood pressure (MABP) during is targeted to remain within +/- 10 % of a reference value using vasoactive drugs and/or fluids
89396499|NCT04749251|Active Comparator|Standard blood pressure management arm|During the EVT procedure(in general anesthesia), mean arterial blood pressure (MABP) during is targeted to remain within a fixed range of 70-90 mmHg
89396500|NCT04215185|Experimental|Blood pressure monitor|The CS6BP device will be placed on non-anesthetized subjects in the ICU (Intensive Care Unit) with arterial line placement in the radial artery. The first measurement will be for up to 24h; subsequent measures will be up to 5h.
89396501|NCT02817594||Paritaprevir/Ritonavir + Ombitasvir ± Dasabuvir ± Ribavirin|"Participants in this observational study received treatment with paritaprevir/ritonavir (r) and ombitasvir with or without dasabuvir ± ribavirin (RBV) for 12 or 24 weeks for the treatment of chronic hepatitis C (CHC), according to hepatitis C virus (HCV) genotype/subtype and stage of liver disease.~The prescription of treatment regimen was at the discretion of the physician in accordance with local clinical practice and label, was made independently from this observational study and preceded the decision to offer the patient the opportunity to participate in this study."
89396502|NCT04187495|Experimental|MAX-40279-01|
89396503|NCT03633383||Transfemoral Approach|
89396504|NCT03633383||Transapical Approach|
89396505|NCT05198141|Active Comparator|Control group I (GI)|Patients who were undergoing surgical treatment
89396506|NCT05198141|Experimental|low dose letrozole group II (GII)|patients who were medically treated with 5 mg of letrozole
89396507|NCT05198141|Experimental|High dose letrozole group (GIII)|patients who were medically treated with 10 mg of letrozole using
89396508|NCT02813694|Experimental|lefamulin|oral lefamulin, 600mg
89396509|NCT02813694|Active Comparator|Moxifloxacin|oral moxifloxacin, 400mg
89396510|NCT03632161|Active Comparator|Dexmedetomidine|Dexmedetomidine is added to bupivacaine the paravertebral block
89396511|NCT03632161|Other|Bupivacaine|Bupivacaine only in the paravertebral block
89396512|NCT03631459||Kanglaite Injection/Capsules|Kanglaite injection 200ml, iv. gtt qd×7d or more, followed by Kanglaite capsule 0.45g×6 tablets qid po×14d as one cycle for at least 4 cycles
89396513|NCT03103919|Active Comparator|Rotigotine + Standard Care|Subjects will use the Kinesia-ONE™ wearable device in-clinic at Visit 1 and Visit 2 for recording of specific motor symptoms. The optimal dose of Neupro for any given subject will be determined by standard clinical practice.
89396514|NCT03103919|Experimental|Rotigotine + Standard Care + Kinesia-360™ wearable device|Subjects will use the Kinesia-ONE™ wearable device in-clinic at Visit 1 and Visit 2 for recording of specific motor symptoms, and additionally subjects will use the Kinesia-360™ wearable device at home while awake for continuous measurement of motor symptoms. The Investigator will use these symptom data to provide feedback to subjects on their motor symptoms and to supplement standard of care to titrate the optimal dose of Neupro for any given subject.
89396515|NCT01568203|Experimental|AMG 579|
89396516|NCT01568203|Placebo Comparator|Placebo|
89396517|NCT02036892|Experimental|Lifestyle counseling with smartphones|Lifestyle counseling assisted by smartphones
89396518|NCT02036892|Active Comparator|Lifestyle counseling|Lifestyle counseling
89396519|NCT04173325|Experimental|Nivolumab and Irinotecan|Drug: Nivolumab 360mg IV Day 1 of each 21 day cycle until disease progression or unacceptable toxicity + Drug: Irinotecan 500mg IV Day of each 21 day cycle for 2 cycles Followed by maintenance nivolumab (without irinotecan)
89396520|NCT05597449|Experimental|Video group|Access to YouTube videos and written postoperative instructions
88872981|NCT05060887|Placebo Comparator|Saline solution (B. Braun Ecoflac® Plus)|Saline solution (NaCl 0.9%), B. Braun Ecoflac® Plus 50mL. One single administration intramuscularly of a 0.8mL dose on Day 1.
89396521|NCT05597449|No Intervention|Control group|Access to written instructions only
89396522|NCT02810964|Experimental|Sulforaphane Nutraceutical|The sulforaphane nutraceutical contains inactive glucoraphanin, a glucosinolate from broccoli seeds, and myrosinase from broccoli sprouts. The ingestion of this compound leads to the hydrolysis of glucoraphanin, the generation of sulforaphane within the gastrointestinal (GI) tract, and the subsequent systemic absorption of the sulforaphane. The dose per tablet is 16 mg of glucoraphanin or 37 µmol; 6 tablets per day should yield about 100 µmol of sulforaphane. The tablets, which will be swallowed, are provided as .375 punch size, round concave tablets. In this arm, the participant will take 6 tablets of the sulforaphane nutraceutical daily for 16 weeks after a 2-week placebo run-in.
89396523|NCT02810964|Placebo Comparator|Identical-appearing Placebo|The inert compound placebo looks identical to the sulforaphane nutraceutical. In this arm, the participant will take 6 tablets of the placebo daily for 16 weeks after a 2-week placebo run-in.
88872982|NCT05032703|Experimental|Arm ergometer|Children in group I will receive strength-endurance protocol of arm ergometer for 30 minutes in addition to the conventional physical therapy program for 30 minutes, per session, three times a week, for three consecutive months.
89187716|NCT00773331|Active Comparator|2|
89396524|NCT05596123|Experimental|therapeutic Chinese foot massage (TCFM)|A one-to-one ratio will be used to randomly assign participants to the TCFM group or the placebo massage group.
89396525|NCT05596123|Placebo Comparator|The Placebo Massage Group|Six weekly 25-minute TCFM sessions will be delivered to participants in the TCFM group.
89396526|NCT05591131|Experimental|Study Time and Events Table|"Study Procedures are as followed:~On Day 1 Surgery/biopsy will be performed to obtain ovarian and endometrial samples. Day 14 will include Informed consent, demographics collection and Blood samples will be obtained. Subjects will complete a survey about knowledge of, attitudes towards, and awareness of genetic testing use over 30 minutes on Day 14. Days 14-21 Tumor/blood DNA preparation. On Day 42 Genetic test results will be released and uploaded in the EMR. If the genetic testing is positive, genetic counseling will be scheduled."
89187717|NCT00778011|Active Comparator|1|
89187718|NCT00778011|Active Comparator|2|
89187719|NCT00778011|Active Comparator|3|
89187720|NCT02556021|Experimental|CJ-12420 50mg|CJ-12420 50 mg, tablet, once daily, oral administration for up to 4 weeks
89396527|NCT02036346|Experimental|Oral rehydration solution|Patients who have undergone colorectal resection surgery resulting in an ileostomy creation
89396528|NCT02036346|Experimental|No intervention|Patients who have undergone colorectal resection surgery resulting in an ileostomy creation
89396529|NCT02036346|Active Comparator|Colorectal resection without an ileostomy|Patients who have undergone colorectal resection surgery without an ileostomy creation
88872983|NCT05032703|Experimental|Trunk stabilization exercise|Children in group II will receive trunk stabilization exercises for 30 minutes in addition to the conventional physical therapy program for 30 minutes, per session, three times a week, for three consecutive months.
88872984|NCT05031468||Group 1: Individuals vaccinated during pregnancy|Individuals who receive a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) vaccine during pregnancy (up to 200 individuals per vaccine type)
88872985|NCT05031468||Group 2: Individuals vaccinated postpartum|Individuals who receive a SARS-CoV-2 vaccine postpartum (up to 65 individuals per vaccine type)
88872986|NCT05031468||Group 3: Infants of individuals vaccinated during pregnancy|Infants of individuals who receive a SARS-CoV-2 vaccine during pregnancy (approximately 200 infants per vaccine type)
88872987|NCT05031468||Group 4: Infants of individuals vaccinated postpartum|Infants of individuals who receive a SARS-CoV-2 vaccine postpartum (approximately 65 infants per vaccine type)
88872988|NCT05031468||Group 5: Individuals receiving additional vaccines during pregnancy|Individuals who receive additional SARS-CoV-2 vaccine(s), beyond the primary series, during pregnancy (up to 200 individuals).
88872989|NCT05031468||Group 6: Infants of individuals receiving additional vaccines during pregnancy|Infants of individuals who received additional SARS-CoV-2 vaccine(s), beyond the primary series, during pregnancy (approximately 200 infants).
88872990|NCT05031117|Experimental|Conventional Epidural Technique|
88872991|NCT05031117|Active Comparator|Dural Puncture Epidural technique using pencil-point 25G Whitacre needle|
88872992|NCT05006157|Experimental|ViaOne device|ViaOne device will be used for percutaneous subxiphoid pericardial access utilizing a proprietary mechanism of entry into the pericardial sac
88872993|NCT04999059||Participants with Fabry Disease|This is a long-term follow-up study of participants who previously received AVR-RD-01 (single dose administration) in the AVRO-RD-01-201 treatment study. No investigational product will be administered in this study.
88872994|NCT04987541|Experimental|Active|"Participants received the real intervention of TBS (iTBS 600) over the left dorsolateral prefrontal cortex for 4 weeks (5 days/week).~*iTBS = intermittent theta burst stimulation"
88872995|NCT04987541|Sham Comparator|Sham|Participants received the sham intervention of TBS (sham-coil) over the left dorsolateral prefrontal cortex for 4 weeks (5 days/week).
89396530|NCT02810652|Experimental|Perioperative Geriatrics Intervention|Evaluation with a board-certified geriatric clinician, both pre- and post-operatively.
89396531|NCT02810652|Active Comparator|Standard Care|Usual care participants will not meet with a geriatric clinician perioperatively, but may receive a geriatric consult upon request or at the discretion of their treating clinician(s).
89396532|NCT05197985|Experimental|Integrated Early Childhood Development Intervention|Integrated Early Childhood Development Intervention is one intervention package. Inclusion criteria are adults (age 18+) who are primary caregiver of one or more children under the age of 5 years; and pregnant women (age 18+).
89396533|NCT05197985|No Intervention|Control Arm|This is the control arm that receives no intervention. Inclusion criteria are adults (age 18+) who are primary caregiver of one or more children under the age of 5 years; and pregnant women (age 18+).
89396534|NCT02742883|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for up to 104 days. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dosage is reached, but not exceeding 12.0 g/kg/d Atengenal or 0.4 mg/kg/d Astugenal.
89396535|NCT05760131||Patients wiht Hyporthyroidism|Patients diagnosed with hypothyroidism.
89396536|NCT04167943|Experimental|indirect pulp capping|TheraCAL PT will be applied to affected dentin covering the pup.
89396537|NCT04167943|Experimental|Direct pulp Capping|TheraCAL PT will be applied to pinpoint pulp exposures surrounded by sound dentin.
89396538|NCT04167943|Experimental|Partial Pulpotomy|Pulp exposure will be enlarged to a depth of 1-3 mm by a sterile round diamond bur, and then TheraCAL PT will applied after hemostasis.
88872996|NCT04986943||ABTHERA Advance without Wittmann patch|Patients with necrotizing pancreatitis that require an open abdomen after their initial operation will be treated with ABTHERA ADVANCE only, without the use of Wittmann patch.
88872997|NCT04978805|Experimental|Progressive Relaxation Exercise|A total of 56 sessions of progressive relaxation were performed, 7 days a week for 8 weeks. Each session is set as fifty minutes
88872998|NCT04978805|No Intervention|Control group|Routine maintenance will be applied
88872999|NCT04978298|Experimental|Rasagiline group|Participants will receive rasagiline once daily (QD) for 14 days from Days 59 to 72.
88873000|NCT04978298|Experimental|Phenelzine group|Participants will receive phenelzine twice daily (BID) for 14 days from Days 59 to 72.
88873001|NCT04978298|Experimental|Ozanimod Therapeutic group|Participants will receive ozanimod QD for 65 days (including the initial 7-day dose escalation) from Days 8 to 72.
88873002|NCT04978298|Experimental|Ozanimod Supra-therapeutic group|Participants will receive ozanimod QD for 65 days (including the initial 10-day dose escalation) from Days 8 to 72.
88873003|NCT04978298|Placebo Comparator|Placebo|Participants will receive matched appropriate placebos from Days 8 to 72.
88873004|NCT04941222|Experimental|"With robotic seal PARO"|The robot will be made available to the patient by the caregiver in charge of the patient for 5 minutes before a toilet and for the duration of the treatment (about 10 minutes), twice a week for 16 weeks.
88873005|NCT04941222|No Intervention|"Without robotic seal PARO"|The care of the patient during the toilet will be carried out according to the modalities currently in use in the facility.
88873006|NCT04939727|Experimental|OUD-CDS + Suicide Risk Model associated CDS (Intervention arm)|Providers that practice in the clinics in this intervention arm will receive access to the OUD-CDS + Suicide Risk Model associated CDS, for all eligible encounters.
88873007|NCT04939727|No Intervention|Control|"Providers that practice in the clinics in this control arm will not receive any access to the OUD-CDS + Suicide Risk Model associated CDS, however these clinical decision-support tools will run silently in the background, collecting data on eligible encounters."
88873008|NCT04935619|Other|Non-Contingency Reinforcement Group|Subjects assigned to the NCR group with self-reported abstinence verified by urinary THC-COOH level <20 ng/ml will not receive contingency monetary reinforcement at Day 28 of the study.
88873009|NCT04935619|Experimental|Contingency Reinforcement Group|Subjects assigned to the CR group with self-reported abstinence verified by urinary THC-COOH level <20 ng/ml will receive contingency monetary reinforcement at Day 28 of the study.
88873010|NCT04930341|Experimental|Self-Acupressure|Each application to the acupressure points (H17, L14, ST36, SP6) will be done in 2 minutes and right and left)
88873011|NCT04930341|No Intervention|Control group|Routine maintenance will be applied
89396539|NCT04167943|Experimental|pulpotomy|complete removal of coronal pulp tissue will be attempted if bleeding persisted after attempting Partial pulpotomy for exposures that are not eligible for DPC. TheraCAL PT will be applied thereafter, after achieving hemostasis.
88873012|NCT04921527|Experimental|Chiauranib plus weekly paclitaxel|Patients receive the combined treatment of chiauranib plus paclitaxel, 21 days for a cycle, 6 cycles at most,Chiauranib is given orally, 50mg once daily. Paclitaxel is given in intravenous infusion on Day 1, 8 and 15. After 6 cycles combined treatment, patients enter the single agent therapy of chiauranib.
88873013|NCT04921527|Placebo Comparator|placebo plus weekly paclitaxel|Patients receive the combined treatment of placebo plus paclitaxel, 21 days for a cycle, 6 cycles at most,placebo is given orally, 50mg once daily. Paclitaxel is given in intravenous infusion on Day 1, 8 and 15. After 6 cycles combined treatment, patients enter the single agent therapy of placebo.
88873014|NCT04902378|Experimental|Tandem t:slim X2 insulin pump with Control IQ technology plus CGM|Participants randomized to the intervention group will be fitted with the Tandem t:slim X2 insulin pump with Control IQ technology and Dexcom G6 Continuous Glucose Monitor.
89396540|NCT04073147|Experimental|Dosing group 1|Venetoclax 600mg + Obinutuzumab 1000mg
89396541|NCT04073147|Experimental|Dosing group 2|Venetoclax 800mg + Obinutuzumab 1000mg
89396542|NCT04073147|Experimental|Dosing group 3|Venetoclax 1000mg + Obinutuzumab 1000mg
88873015|NCT04902378|No Intervention|Standard insulin delivery (multiple daily injections (MDI) or pump) and CGM|Participants randomized to the control group will be fitted with the Dexcom G6 Continuous Glucose Monitor. They will continue to use standard insulin delivery (MDI or pump) and CGM.
89396543|NCT02707159|Experimental|Nab paclitaxel / gemcitabine|Patients will receive 125 mg per m2 nab-paclitaxel and 1000 mg per m2 on days 1, 8 and 15 followed by one week of rest before new treatment cycle.
89396544|NCT05197907|Experimental|Diaphragm fascial release group.|Ten minutes lasting fascial release techinques performed on diaphragm.
88873016|NCT04898504|No Intervention|Next line chemotherapy only|Next line chemotherapy is the current standard treatment for patients with CRLM and progression on chemotherapy. We will include 18 patients in this treatment arm.
88873017|NCT04898504|Active Comparator|Liver transplant|Liver transplant (LTX) has emerged as a possible solution for some patients with unresectable CRLM who otherwise have good prognosis based on available scorings systems. We will include 9 patients in this treatment arm. They will be given next line chemotherapy followed by Liver-Tx.
88873018|NCT04898504|Active Comparator|Hepatic artery infusion (HAI) chemotherapy|The biological rationale for intra-arterial chemotherapy is that the hepatic artery rather than the portal vein is responsible for most of the blood supply to liver tumors. We will include 18 patients in this arm
88873019|NCT04896021|Experimental|Intervention|On referral to Tasmanian pathology services for blood cholesterol, intervention participants will have their blood pressure measured and collated with other cardiovascular disease risk factors. An absolute cardiovascular disease risk score is calculated, interpreted according to guideline recommendations and reported to referring doctors via the established pathology system. High risk is highlighted in red as per usual practice for pathology tests outside of normal range, and advice provided regarding appropriate action according to National Vascular Disease Prevention Alliance guidelines.
88873020|NCT04896021|Active Comparator|Control|On referral to Tasmanian pathology services for blood cholesterol, control participants will have their blood pressure measured and collated with other cardiovascular disease risk factors as per the intervention arm. However, only the results relating to blood cholesterol are reported to the referring doctor, as per usual practice.
89396545|NCT05197907|Placebo Comparator|Classic massage group|Ten minutes lasting classic massage performed on abdomen.
89396546|NCT04113187|Experimental|Propranolol arm|
89396547|NCT04113187|Placebo Comparator|Placebo arm|
89396548|NCT03103763||Aged 90 and older|Subjects 90 years and older with atrial fibrillation, taking warfarin, followed by the Penobscot Bay Medical Center Anticoagulation Services.
88873021|NCT04883606||All Participants|Retrospective data will be collected from participants who followed up at least 6 months before teduglutide initiation or intestinal failure associated with SBS-IF diagnosis and at least 6 months of follow-up after teduglutide treatment initiation.
89396549|NCT03103763||Aged 80-89|Subjects aged 80-89 with atrial fibrillation, taking warfarin, followed by the Penobscot Bay Medical Center Anticoagulation Services.
88873022|NCT04876079|Active Comparator|16g of carbohydrates - Plasma glucose < 4.0 mmol/L|16g of carbohydrates will be given when glucose levels are below 4.0 mmol/L (management per guidelines)
88873023|NCT04876079|Active Comparator|16g of carbohydrates - Plasma glucose ≤ 4.5 mmol/L|16g of carbohydrates will be given when glucose levels are equal or below 4.5 mmol/L.
89396550|NCT03103763||Aged 70-79|Subjects aged 70-79 with atrial fibrillation, taking warfarin, followed by the Penobscot Bay Medical Center Anticoagulation Services.
88873024|NCT04876079|Active Comparator|16g of carbohydrates - Plasma glucose ≤ 5.0 mmol/L|16g of carbohydrates will be given when glucose levels are equal or below 5.0 mmol/L.
88873025|NCT04865523|Experimental|Manual Lymphatic Drainage|
88873026|NCT04865523|No Intervention|No intervention|
88873027|NCT04852211|Active Comparator|Open major hepatectomy|Resection of the tumor together with 3 or more liver segments using open standard techniques of hepatectomy
88873028|NCT04852211|Active Comparator|Laparoscopic major hepatectomy|Resection of the tumor together with 3 or more liver segments using minimally invasive techniques of hepatectomy
88873029|NCT04832113|Experimental|Patient Therapeutics Education (PTE)|Educational diagnosis prior radiotherapy and participation to Patient Therapeutics Education (PTE) in Adapted Physical Activity (APA) and dietetic sessions. In addition to conventional support (dietary and hydration advice).
89187721|NCT02556021|Experimental|CJ-12420 100mg|CJ-12420 100 mg, tablet, once daily, oral administration for up to 4 weeks
89187722|NCT02556021|Placebo Comparator|Placebo|Placebo, tablet, once daily, oral administration for up to 4 weeks
89396551|NCT04092127||premature infants (<32 weeks of Gestation Age)|premature babies (<32 weeks of Gestation Age) to be screened with RetCam for retinopathy of prematurity and who will be filmed during the screening procedure to evaluate pain with the PIPP score (Premature Infant Pain Profile)
88873030|NCT04832113|Other|Conventional support|Dietary and hydration advices
88873031|NCT04818385||Participants Receiving Risankizumab|Participants will receive risankizumab as prescribed by their physician.
88873032|NCT04818385||Participants Receiving All Other Biologics|Participants will receive all other biologics as prescribed by their physician.
88873033|NCT04811573|Experimental|EU-Otezla fasted(A)/ Japan-Otezla fasted(E)/ US-Otezla fasted(B)/ US-Otezla fed(D)/ EU-Otezla fed(C)|Treatment sequence AEBDC is applied. The 5 treatments were separated by a washout period of at least 5 days.
88873034|NCT04811573|Experimental|US-Otezla fasted(B)/ EU-Otezla fasted(A)/ EU-Otezla fed(C)/ Japan-Otezla fasted(E)/ US-Otezla fed(D)|Treatment sequence BACED is applied. The 5 treatments were separated by a washout period of at least 5 days.
88873035|NCT04811573|Experimental|EU-Otezla fed(C)/US-Otezla fasted(B)/US-Otezla fasted(D)/EU-Otezla fasted(A)/ Japan-Otezla fasted(E)|Treatment sequence CBDAE is applied. The 5 treatments were separated by a washout period of at least 5 days.
88873036|NCT04811573|Experimental|US-Otezla fed(D)/ EU-Otezla fed(C)/ Japan-Otezla fasted(E)/ US-Otezla fasted(B)/ EU-Otezla fasted(A)|Treatment sequence DCEAB is applied. The 5 treatments were separated by a washout period of at least 5 days.
88873037|NCT04811573|Experimental|Japan-Otezla fasted(E)/ US-Otezla fed(D)/ EU-Otezla fasted(A)/EU-Otezla fed(C)/ US-Otezla fasted(B)|Treatment sequence EDACB is applied. The 5 treatments were separated by a washout period of at least 5 days.
88873038|NCT04811573|Experimental|EU-Otezla fasted(A)/ US-Otezla fasted(B)/ Japan-Otezla fasted(E)/ EU-Otezla fed(C)/ US-Otezla fed(D)|Treatment sequence ABECD is applied. The 5 treatments were separated by a washout period of at least 5 days.
89187723|NCT00778089|Other|Open Label Single Arm|All enrolled subjects will have a skin test composed of Bovine Collagen and Lidocaine.
89396552|NCT05197517|Experimental|Rosuvastatin 10 mg film coated tablets|Single oral dose of 1 tablet (10 mg)
89396553|NCT05197517|Active Comparator|Crestor® 10 mg film coated tablets|Single oral dose of 1 tablet (10 mg)
89396554|NCT05499559||Joint Academy|The participants receive the digital treatment of Joint Academy.
89396555|NCT04011475||Subjects with Tiotropium and Olodaterol|
89396556|NCT04011475||Subjects treated with other LABA/LAMA therapy|
89396557|NCT04011475||Subjects treated with LAMA therapy|
89396558|NCT05063903||Fontan Group|"Fontan Group Inclusion Criteria~be between the ages of 8-50 Having undergone Fontan operation in our hospital or another center Clinical stability of the patients (preserved ventricular function), No change in ongoing drug therapy that adversely affects clinical stability, At least 1 year after the operation and to be followed in the Pediatric Cardiology Polyclinic of our hospital~Fontan Group Exclusion Criteria:~Inability to access the patient's medical data Neurological and/or genetic musculoskeletal disease Having orthopedic and cognitive problems that prevent testing The patient's and/or family's unwillingness to participate in the study"
89396559|NCT05063903||Control Group|"Control Group Inclusion Criteria:~Not have cardiovascular, neurological and/or genetic musculoskeletal disease Not having orthopedic and cognitive problems that prevent testing The patient's and/or family's willingness to participate in the study"
89396560|NCT04212221|Experimental|MGD013|MGD013 monotherapy dose escalation and expansion
89396561|NCT04212221|Experimental|MGD013+Brivanib Alaninate|MGD013+Brivanib Alaninate dose escalation and expansion
89396562|NCT03663335|Experimental|Arm 1/Cohort 1|CFZ533 dose A+ MMF + Corticosteroids
89396563|NCT03663335|Experimental|Arm 2/Cohort 1|CFZ533 dose B + MMF + Corticosteroids
89396564|NCT03663335|Active Comparator|Arm 3/Cohort 1|Control/Standard of Care: TAC + MMF + Corticosteroids
89396565|NCT03663335|Experimental|Arm 1/Cohort 2|CFZ533 dose C + MMF ± Corticosteroids
89396566|NCT03663335|Active Comparator|Arm 2/Cohort 2|Tac + MMF ± Corticosteroids
88873039|NCT04811573|Experimental|US-Otezla fasted(B)/ EU-Otezla fed(C)/ EU-Otezla fasted(A)/ US-Otezla fed(D)/ Japan-Otezla fasted(E)|Treatment sequence BCADE is applied. The 5 treatments were separated by a washout period of at least 5 days.
88873040|NCT04811573|Experimental|EU-Otezla fed(C)/ US-Otezla fed(D)/ US-Otezla fasted(B)/ Japan-Otezla fasted(E)/ EU-Otezla fasted(A)|Treatment sequence CDBEA is applied. The 5 treatments were separated by a washout period of at least 5 days.
88873041|NCT04811573|Experimental|US-Otezla fed(D)/ Japan-Otezla fasted(E)/ EU-Otezla fed(C)/ EU-Otezla fasted(A)/ US-Otezla fasted(B)|Treatment sequence DECAB is applied. The 5 treatments were separated by a washout period of at least 5 days.
88873042|NCT04811573|Experimental|Japan-Otezla fasted(E)/ EU-Otezla fasted(A)/ US-Otezla fed(D)/ US-Otezla fasted(B)/ EU-Otezla fed(C)|Treatment sequence EADBC is applied. The 5 treatments were separated by a washout period of at least 5 days.
88873043|NCT04801316|Other|Part 1: Video training|"Participants will undergo the following procedures:~Community instructors (involved in the training itself):~Attend a video-facilitated training~Be assessed for competency level of class execution before and after the video-facilitated training~Might need to conduct or observe 2 video-facilitated SF exercise classes (about 1 hour each time) over the course of 2 weeks (1 class per week)~Might need to participate in one interview/discussion which will last up to 2 hours~Community-dwelling older adult or community providers (individuals involved in the programme implementation but not the training itself):~Attend or observe 2 video-facilitated SF exercise classes (about 1 hour each time) over the course of 2 weeks (1 class per week)~Participate in one interview/discussion which will last up to 2 hours"
88873044|NCT04801316|Experimental|Part 2: Exercise Intervention|"Participants will participate in 6 months of exercises, and be provided with education and advice on how to reduce their risk of falls.~The exercises are divided into 2 phases:~The Steady Feet (SF) exercise programme phase. A twice-weekly tailored structured group exercise class will be conducted for 3 months with community instructors and exercise video.~A 3 months maintenance exercise phase. A once-weekly structured community group exercise class."
88873045|NCT04801316|No Intervention|Part 2: Control|Participants will be provided with the usual education and advice on how to reduce their risk of falls.
89396567|NCT03632915||No study intervention|No study intervention
88873046|NCT04795362||patients with Delayed cerebral ischemia|50 adult patients hospitalized in neurological intensive care unit for subarachnoid hemorrhage, in whom the onset of delayed cerebral ischemia is suspected will be included.
88873047|NCT04789694|No Intervention|A|Patients will be provided with a basic information and standard of care support.
89396568|NCT03651245||Participants with suspicion for Alpha-Mannosidosis|Participants with suspicion for Alpha-Mannosidosis based on their clinical symptoms aged from 2 months to 18 years
89396569|NCT04836845|Active Comparator|Focus extracorporeal shock wave therapy|
89396570|NCT04836845|Active Comparator|Radial extracorporeal shock wave therapy|
89396571|NCT04836845|Sham Comparator|Sham extracorporeal shock wave therapy|
89396572|NCT03538535|Experimental|Go/No-Go Active Learning (GOAL)|Adaptation of Behavioral Activation, focused on reinforcement learning strategies.
89396573|NCT04769375||Group 1: Pregnant women diagnosed with GDM (first pregnancy)|This group will consist of women with gestational diabetes mellitus according to routine control tests in their first pregnancy.
89396574|NCT04769375||Group 2:Pregnant women diagnosed with GDM (2nd or 3rd pregnancy)|This group will consist of women with gestational diabetes mellitus according to routine control tests in their second or third pregnancy.
89396575|NCT04769375||Group 3: Healthy pregnant women (first pregnancy)|This group will consist of women who do not have gestational diabetes mellitus according to routine control tests in their first pregnancy.
89396576|NCT04769375||Group 4:Healthy pregnant women (2nd or 3rd pregnancy)|This group will consist of women who do not have gestational diabetes mellitus according to routine control tests in their second or third pregnancy.
89396577|NCT03524729|Active Comparator|Ankle osteoarthritis patients|Ambulatory adult patients (18+) with ankle osteoarthritis.
89396578|NCT03524729|Other|Healthy control subjects|Ambulatory adults (18+) with no known ankle osteoarthritis.
89396579|NCT04717505||Healthy Control Group|Demographic information ( age, gender, occupation, weight, height) of all participants in the study will be recorded first. The cognitive functions of all participants within the scope of the study will be evaluated in the Standardized Mini Mental Test; The 10 Meter Walk Test for dual task assessments will be applied in 3 different ways, with a portable gait device with wearable sensors: 1-single task conditions, 2-dual task conditions (motor + cognitive), 3-dual task conditions (motor + motor).
89396580|NCT04717505||Rheumatological Condition Group|Demographic information (diagnosis, age, gender, occupation, weight, height) of all participants in the study will be recorded first. The cognitive functions of all participants within the scope of the study will be evaluated in the Standardized Mini Mental Test; The 10 Meter Walk Test for dual task assessments will be applied in 3 different ways, with a portable gait device with wearable sensors: 1-single task conditions, 2-dual task conditions (motor + cognitive), 3-dual task conditions (motor + motor). In addition, in order to evaluate their health status, only the case group will be applied Arthritis Impact Measurement Scales 2 (questionnaire) and Visual Analogue Scale for pain assessment.
89396581|NCT05649605|Active Comparator|Active comparator arm|Active treatment
89396582|NCT05649605|Placebo Comparator|Placebo comparator arm|Placebo treatment
89396583|NCT05321927|Sham Comparator|Control group|Sham stimulation will be applied over rectus femoris, tibialis anterior, the median nerve and the thenar eminence on both sides for 10 min to each limb, one at a time. Stimulation is delivered for 10 min to each limb, one at a time in three 10 minute sessions per week, for 4 weeks.
89396584|NCT05321927|Active Comparator|Strength-training group|Three training sessions for 10 minutes per muscle per week, for 4 weeks during which sham stimulation will be applied.
89396585|NCT05321927|Active Comparator|Trancutaneous Electrical Nerve Stimulation (TENS)|Trancutaneous Electrical Nerve Stimulation (TENS) stimulation applied over rectus femoris, tibialis anterior, the median nerve and the thenar eminence on both sides for 10 min to each limb, one at a time. Stimulation is delivered for 10 min to each limb, one at a time in three 10 minute sessions per week, for 4 weeks.
89396586|NCT05321927|Experimental|TENS with strength training|Three training sessions for 10 minutes per muscle per week, for 4 weeks during which Trancutaneous Electrical Nerve Stimulation (TENS) stimulation is applied over rectus femoris, tibialis anterior, the median nerve and the thenar eminence on both sides for 10 min to each limb, one at a time.
89396587|NCT04712123||relapse due to S. aureus|patients having had an initial infection due to S. aureus and who present a relapse with persistence of S. aureus
89396588|NCT05312021|Experimental|IMR-687|Participants randomly assigned to this arm will take IMR-687 orally with food BID for 16 weeks. IMR-687 dosing will be 300 mg BID for participants weighing less than 100 kg and 400 mg BID for participants weighing 100 kg or more.
89396589|NCT05312021|Placebo Comparator|Placebo|Participants randomly assigned to this arm will take placebo orally with food BID for 16 weeks.
89396590|NCT05640479|Active Comparator|pregabalin group|patients will receive pregabalin capsules (75 mg) will be given 2 h prior to induction of anesthesia and every 12 h for 24h postoperatively by nasogastric tube or orally. Patients will receive IV saline as placebo with the same rate of dexmedetomidine.
89396591|NCT05640479|Active Comparator|dexmedetomidine group|patients in the dexmedetomidine group will receive after induction of GA a bolus dose of 0.4 μg/kg dexmedetomidine (over a period of 10 to 20 min) followed by an infusion of 0.2 to 0.7 μg/kg/h. Patients will receive placebo 2 h prior to induction of anesthesia and every 12 h for 24h postoperatively by nasogastric tube or orally. If patients are hemodynamically unstable, the bolus dose will be omitted. The infusion of dexmedetomidine will be continued for a maximum period of 24 h. Dexmedetomidine infusion will be not discontinued before extubation.
89187724|NCT00433381|Experimental|Arm I (bevacizumab and temozolomide)|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15 and oral temozolomide once daily on days 1-21.
89187725|NCT00433381|Experimental|Arm II (bevacizumab & irinotecan hydrochloride)|Patients receive bevacizumab IV as in Arm I followed by irinotecan hydrochloride IV over 90 minutes on days 1 and 15.
89187726|NCT00781053|Experimental|P144 cream|P144 cream 0.03% will be used once a day during the whole extension period of 6 months.
89187727|NCT00773565|Other|Optifast|Patients included take part at a weight reduction program over one year.
89396592|NCT05309525|Active Comparator|Cohort A|"Per treatment area, subjects will be injected with up to 0.84 mg of QWO as 12 subcutaneous injections (0.3-mL injection administered as three 0.1-mL aliquots per injection), dependent on the amount of dimples (0.3 ml per dimple). A treatment area is defined as a left or right buttock, so patients may receive up to 1.84 mg, or 24 injections total (2 areas per treatment visit). The minimum dosage of QWO will be 0.92 mg, or 6 injections per treatment area (2 areas per treatment visit.~Cohort A subjects will be given 1300 mg tranexamic acid PO TID prior to the day of the first CCH injections, the day of the first CCH injections, and the 3 days following the first CCH injections."
89396593|NCT05309525|Active Comparator|Cohort B|"Per treatment area, subjects will be injected with up to 0.84 mg of QWO as 12 subcutaneous injections (0.3-mL injection administered as three 0.1-mL aliquots per injection), dependent on the amount of dimples (0.3 ml per dimple). A treatment area is defined as a left or right buttock, so patients may receive up to 1.84 mg, or 24 injections total (2 areas per treatment visit). The minimum dosage of QWO will be 0.92 mg, or 6 injections per treatment area (2 areas per treatment visit.~Cohort B subjects will be given 1300 mg tranexamic acid PO TID prior to the day of the first and second CCH injections, the day of the first and second CCH injection, and the 3 days following the first and second CCH injections."
89396594|NCT05309525|Active Comparator|Cohort C|"Per treatment area, subjects will be injected with up to 0.84 mg of QWO as 12 subcutaneous injections (0.3-mL injection administered as three 0.1-mL aliquots per injection), dependent on the amount of dimples (0.3 ml per dimple). A treatment area is defined as a left or right buttock, so patients may receive up to 1.84 mg, or 24 injections total (2 areas per treatment visit). The minimum dosage of QWO will be 0.92 mg, or 6 injections per treatment area (2 areas per treatment visit.~Cohort C subjects will be given 1300 mg tranexamic acid PO TID prior to the day of the first, second, and third CCH injections, the day of the first, second, and third CCH injection, and the 3 days following the first, second, and third CCH injections."
89396595|NCT03101267|Experimental|ASP4070 4 mg|Participants received ASP4070 4 mg 8 times by intradermal vaccination at 14-day intervals.
89396596|NCT03101267|Experimental|ASP4070 1 mg|Participants received ASP4070 1 mg 8 times by intradermal vaccination at 14-day intervals.
89396597|NCT03101267|Placebo Comparator|Placebo|Participants received Placebo 8 times by intradermal vaccination at 14-day intervals.
89396598|NCT04922801||Neuroendocrine Toumours|"Patients will undergo 177LU-Dotatate Neoruendocrine Tumours MRT in accordance with existing protocols at GSTTFT. In addition, all MRT patients will be asked to undertake the following non-invasive procedures.~Post-treatment gamma camera (Planar Whole Body & SPECT/CT) imaging to estimate disease/ target tissue and whole-body dose for Neuroendocrine and thyroid cancer MRT.~Post-treatment gamma camera planar Whole Body imaging for hyperthyroidism MRT.~Post-treatment patient-led self-monitoring.~Complete a feedback questionnaire relating to the use of self radiation monitoring."
89396599|NCT04922801||Thyroid Cancer|"Patients will undergo 131I-Thyroid cancer MRT in accordance with existing protocols at GSTTFT. In addition, all MRT patients will be asked to undertake the following non-invasive procedures.~Post-treatment gamma camera (Planar Whole Body & SPECT/CT) imaging to estimate disease/ target tissue and whole-body dose for Neuroendocrine and thyroid cancer MRT.~Post-treatment gamma camera planar Whole Body imaging for hyperthyroidism MRT.~Post-treatment patient-led self-monitoring.~Complete a feedback questionnaire relating to the use of self radiation monitoring."
89396600|NCT04922801||Hyperthyrodism|"Patients will undergo 131I-Hyperthyroidism MRT in accordance with existing protocols at GSTTFT. Patients will have one whole-body scan at 24 hr post MRT which will not involve any additional radiation. In addition, all MRT patients will be asked to undertake the following non-invasive procedures.~Post-treatment gamma camera (Planar Whole Body & SPECT/CT) imaging to estimate disease/ target tissue and whole-body dose for Neuroendocrine and thyroid cancer MRT.~Post-treatment gamma camera planar Whole Body imaging for hyperthyroidism MRT.~Post-treatment patient-led self-monitoring.~Complete a feedback questionnaire relating to the use of self radiation monitoring."
89396601|NCT04911101|Experimental|7G needle|7G needle dimension used
89396602|NCT04911101|Experimental|10G needle|10G needle dimension used
89396603|NCT05296187|Active Comparator|GROUP TEAS|Patients will receive TEAS bilaterally at two acupoints: Hegu (L14) and Neiguan (PC6).
89396604|NCT05296187|Placebo Comparator|Control Sham Group|Patients in the sham group will be undergoing electrode attachment on the target acupoints without electronic stimulation.
89396605|NCT04886219||Healthy individual|Healthy individual
89396606|NCT02810418|Experimental|Arm A1, Dose Level 1 (Phase 1, short infusion) 100µg/kg LMB-100|"Arm A1, Dose Level 1, Phase I Short Infusion 100µg/kg LMB-100 +125mg/m^2 nab-paclitaxel~Dose level 1 (DL1) Maximum tolerated dose (MTD) determination in patients with pancreatic cancer receiving short infusion LMB-100+nabpaclitaxel"
89396607|NCT02810418|Experimental|Arm A1, Dose Level-1 (Phase 1, short infusion) 65µg/kg LMB-100|Arm A1, DL-1, Ph I Short Infusion 65µg/kg LMB-100 +125mg/m^2 nab-paclitaxel
89396608|NCT02810418|Experimental|Arm A2 (Phase 2, short infusion) 65µg/kg LMB-100|"Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100 +125mg/m^2 nab-paclitaxel~Efficacy determination in patients with pancreatic cancer receiving short infusion LMB-100 + nabpaclitaxel"
89396609|NCT02810418|Experimental|Arm B1, Dose Level 2 Phase I (Continuous infusion single agent lead-in)|Arm B1, DL2, 48-hr Continuous Infusion Single Agent Lead-in 100µg/kg/day LMB-100 Maximum tolerated dose (MTD) determination in patients with pancreatic cancer receiving continuous infusion LMB-100 as single agent
89396610|NCT02810418|Experimental|Arm B1, Dose Level 1 Phase I (Continuous infusion single agent lead-in)|Arm B1, DL1, 48-hr Continuous Infusion Single Agent Lead-in 65µg/kg/day LMB-100
89396611|NCT02810418|Experimental|Arm B1, Dose Level 3R Phase I (Continuous infusion single agent lead-in)|Arm B1, DL3R, 24-hr Continuous Infusion Single Agent Lead-in 100µg/kg LMB-100
89396612|NCT02810418|Experimental|Arm B2 Phase I (continuous infusion combination therapy)|Subjects with pancreatic cancer receiving continuous infusion LMB-100 combination therapy
88873048|NCT04789694|Experimental|B|Active prehabilitation will be provided, composed of i) three physical activity-related interventions provided by a physical and rehabilitation medicine (PRM) specialist; iii) three 30 min consultations regarding nutritional status with physician or nutrition specialist; ii) three sessions with psychologist.
88873049|NCT04783207|Active Comparator|Supplement containing Mitopure|
89396613|NCT05417945|Experimental|JensClip transcatheter valve repair system|Using the JensClip transcatheter valve repair system for the treatment of patients with moderate-severe or severe degenerative mitral regurgitation who are at high surgical risk.
89396614|NCT02959541|Other|Calciumfolinat 60 mg/m²|Intravenous infusion of Calciumfolinat 60 mg/m²given to patients with colon cancer at the time for the operation of the colon cancer.
89396615|NCT02959541|Other|Calciumfolinat 200 mg/m²|Intravenous infusion of Calciumfolinat 200 mg/m² given to patients with colon cancer at the time for the operation of the colon cancer.
88873050|NCT04783207|Placebo Comparator|Placebo Supplement|
88873051|NCT04774094|Experimental|CAZ-AVI|
89396616|NCT02959541|Other|Calciumfolinat 500 mg/ m²|Intravenous infusion of Calciumfolinat 500 mg/ m² given to patients with colon cancer at the time for the operation of the colon cancer.
89396617|NCT02736305|Experimental|Regorafenib|Patients will receive Regorafenib 120mg once daily, with consideration for dose escalation to 160mg if there are no toxicities
89396618|NCT05417633|Active Comparator|Group 1|monovision 0.25 - 0.74 D
89396619|NCT05417633|Active Comparator|Group 2|monovision 0.75 -1.24 D
89396620|NCT05417633|Active Comparator|Group 3|monovision 1.24 - 1.75
89396621|NCT02810340|Experimental|MCV-5 with adjuvant|Received a single intramuscular injection of Adjuvanted MCV-5.
89396622|NCT02810340|Experimental|MCV-5 without adjuvant|Received a single intramuscular injection of Non-Adjuvanted MCV-5.
89396623|NCT02810340|Active Comparator|Menactra®|Received a single intramuscular injection of Menactra.
89396624|NCT05695014|Experimental|Teach Back Metod|"The patients in the intervention group, on the other hand, will be trained with the teach-back method after completing the Personal Data Collection Form, Knowledge Test, and the Ready to Discharge Scale. In these trainings, Discharge Training Booklet, which will be prepared by the researcher, will be used as training material. This booklet will include information about discharge after Lumbar Disc Herniation Surgery."
89396625|NCT05695014|No Intervention|Control|The discharge training of the patients in the control group will be given by the health professionals responsible for their care and treatment according to their clinical routines.
89396626|NCT02036658|Active Comparator|Cognitive Behavioral Group Therapy|Cognitive behavioral group therapy (CBGT) will be delivered by two Ph.D. clinical psychologists trained by Dr. Richard Heimberg to implement his CBGT for SAD (Heimberg & Becker, 2002). Groups of six individuals will meet for 12 sessions of 2.5 hours each. The participants will also use selected portions of the client workbook developed by (Hope, Heimberg, & Turk, 2010) to supplement relevant portions of the protocol. The treatment will be comprised of four major components: (1) psychoeducation and orientation to CBGT; (2) cognitive restructuring skills; (3) graduated exposure to feared social situations, within session and as homework; and (4) relapse prevention and termination. Further details of the treatment are available elsewhere (Heimberg & Becker, 2002).
88873052|NCT04770545|Experimental|Pegcetacoplan, 15 mg/100 μL, monthly for up to 36 months|Participants from Study APL2-103 (NCT03777332) or those who completed the treatment at Month 24 from either Study APL2-303 (Derby, NCT03525613) or Study APL2-304 (Oaks, NCT03525600) and were administered monthly intravitreal (IVT) pegcetacoplan (15 mg/100 μL) or monthly sham will receive IVT pegcetacoplan (15 mg/100 μL) monthly for up to approximately 36 months.
88873053|NCT04770545|Experimental|Pegcetacoplan, 15 mg/100 μL, every other month (EOM) for up to 36 months|Participants from Study APL2-103 (NCT03777332) or those who completed the treatment at Month 24 from either Study APL2-303 (Derby, NCT03525613) or Study APL2-304 (Oaks, NCT03525600) and were administered every other month (EOM) intravitreal (IVT) pegcetacoplan (15 mg/100 μL) or EOM sham will receive IVT pegcetacoplan (15 mg/100 μL) EOM for up to approximately 36 months.
89530514|NCT02325349|Experimental|radiopharmaceutical|PET/CT after intravenous administration of 2-4MBq/kg of body weight of Flotegatide (18F) or RGD (68Ga) performed prior and after 2 cycles of chemotherapy including an agent with antiangiogenic effect (two examinations in each patient)
89530515|NCT02515877|Experimental|Radiotherapy + Vistide + Chemoterapy|
88873054|NCT04753437|Experimental|Clarithromycin + Amoxicillin + Bismuth + Vonoprazan|Clarithromycin 500 milligram (mg), tablets, orally, BID, along with amoxicillin 1000 mg, capsules, orally, BID, bismuth potassium citrate 600 mg, capsules, orally, BID, and vonoprazan 20 mg, tablets, orally, BID on Days 1 to 14.
88873055|NCT04753437|Active Comparator|Clarithromycin + Amoxicillin + Bismuth + Esomeprazole|Clarithromycin 500 mg, tablets, orally, BID, along with amoxicillin 1000 mg, capsules, orally, BID, bismuth potassium citrate 600 mg, capsules, orally, BID, and esomeprazole 20 mg, tablets, orally, BID on Days 1 to 14.
88873056|NCT04743310|Experimental|Tozuleristide with Canvas imaging system|
88873057|NCT04722237|Experimental|Immediate Acceptance and Commitment Therapy|Receiving 6-to-12 weekly sessions of Acceptance and Commitment Therapy immediately after allocation. Each session will be up to one hour in length.
88873058|NCT04722237|No Intervention|Waitlist Control|Receiving no intervention during a 12-week wait, though no restrictions will be placed on the use of other services. After the wait participants will receive 6-to-12 weekly sessions of Acceptance and Commitment Therapy. Each session will be up to one hour in length.
88873059|NCT04653220|Other|Control 1|Glucose 25g
88873060|NCT04653220|Other|Control 2|Glucose 25g
88873061|NCT04653220|Experimental|Standard Crokao|Commercially available snack bar
88873062|NCT04653220|Experimental|Low sugar variant 1|Low sugar snack bar with sticky rice
88873063|NCT04653220|Experimental|Low sugar variant 2|Low sugar snack bar with promitor
88873064|NCT04653220|Experimental|Low sugar variant 3|Low sugar snack bar with inulin
88873065|NCT04653220|Experimental|Low sugar variant 4|Low sugar snack bar with yellow soy
88873066|NCT04653220|Experimental|Low sugar variant 5|Low sugar snack bar with rice syrup
88873067|NCT04647630||CAP|community acquired pneumonia
88873068|NCT04619017|Experimental|Segmental allergen challenge|Allergic individuals with and without asthma will be enrolled.
88873069|NCT04613557|Experimental|CYAD-211|Infusion post preconditioning non-myeloablative chemotherapy
88873070|NCT04605094|Experimental|Benralizumab|
88873071|NCT04605094|Experimental|Placebo / Benralizumab|
88873072|NCT04605081|Experimental|Naltrexone+Bupropion Medication|
88873073|NCT04605081|Placebo Comparator|Placebo|
88873074|NCT04599504|Experimental|Lisdexamfetamine dimesylate|
88873075|NCT04599504|Placebo Comparator|Placebo|
88873076|NCT04599478|Experimental|Behavioral Weight Loss (BWL) + Naltrexone and Bupropion (NB) medication|Participants randomly assigned to this arm will receive 16 weeks of BWL counseling and NB medication. The naltrexone and bupropion will be taken daily in pill form.
88873077|NCT04599478|Experimental|BWL + Placebo|Participants randomly assigned to this arm will receive 16 weeks of BWL counseling and placebo. Placebo will be inactive and taken daily in pill form.
88873078|NCT04599478|Experimental|NB medication|Participants randomly assigned to this arm will receive 16 weeks of NB medication taken daily in pill form.
88873079|NCT04599478|Placebo Comparator|Placebo|Participants randomly assigned to this arm will receive 16 weeks of placebo. Placebo will be inactive and taken daily in pill form.
88873080|NCT04599439||High arrhythmia risk|Patients with a cardiac magnetic resonance-derived border zone channel (BZC) mass > 5.15 g will be considered at highest risk for developing ventricular arrhythmias (VA) or sudden cardiac death (SCD).
88873081|NCT04599439||Low arrhythmia risk|Patients with a cardiac magnetic resonance-derived border zone channel (BZC) mass < 5.15 g will be considered at lowest risk for developing ventricular arrhythmias (VA) or sudden cardiac death (SCD).
88873082|NCT04578639|Experimental|Rituximab|Rituximab will be given as infusion at week 0, week 26, week 52, week 78, and week 104 unless there is a reason for schedule modifications (see Section 6.3). Each infusion is given over approximately 4 hours and follow local guidelines for infusion. Initial dose; 1000 mg Subsequent doses; 500 mg
88873083|NCT04578639|Active Comparator|Ocrelizumab|Ocrelizumab will be given as infusion at week 0, week 26, week 52, week 78, and week 104 unless there is a reason for schedule modifications (see Section 6.3). Each infusion is given over approximately 4 hours and follow local guidelines for infusion. Initial and subsequent doses; 600 mg
88873084|NCT04573296|Experimental|Participants using Vitadio|Participants in the intervention arm undergo a 6-month digitally administered behavioral change program Vitadio focused on lifestyle change and self-management. The program aims for strengthening patients autonomy with the goal to promote weight loss and improve metabolic health. The program includes personalized education, adaptive daily tasks and weekly goals, automated motivational and educational messaging, monitoring tools, recipes, peer-support group and one-on-one remote coaching. In addition, they undergo regular face-to-face medical assessment.
88873085|NCT04573296|Active Comparator|Participants assigned to conventional high-intensity lifestyle intervention program|Participants in the control group undergo a 6-month high-intensity lifestyle intervention program consisting of of 5 face-to-face nutrition/lifestyle education sessions. Participants can use an online diary tool for recording meals with an option to receive remote feedback on their diet from the educator. In addition, they undergo regular face-to-face medical assessment.
88873086|NCT04555265|Other|Thermal ablation group|Patients with hepatocellular carcinoma treated by thermal ablation
88873087|NCT04534296|Experimental|Early Mobilization Group (EM group)|Early mobilization will be performed in this arm. Critically ill children will be assessed for appropriate activity within 24 hours of intubation. When the safe criteria is met, early mobilization goals will be set according to the children's clinical conditions, developmental maturity, strength and endurance. The detailed mobilization activities include bed repositioning，passive or active range of motion and stretching exercises, passive or active respiratory muscle strengthening, sitting in bed, transfer from lying to sitting at edge of bed. Progressive mobilization goals will be individualized for each subject daily.
88873088|NCT04534296|Active Comparator|Routine Care Group (RC group)|Routine care strategy without early mobilization will be performed in this arm. It includes the clinical status management, spontaneous breathing trials, choice of sedation and analgesia and routine nursing care including repositioning every 2 hours and bed head elevation.
88873089|NCT04526639|Experimental|Virtual Reality games for training executive functions|Virtual Reality games for training three core executive functions
88873090|NCT04526639|Placebo Comparator|Control VR Game on Playground|A relaxing virtual reality game for control group to play in VR playground without training their executive functions
88873091|NCT04526210|Experimental|Treatment A|Participants will receive bupropion.
88873092|NCT04526210|Experimental|Treatment B|Participants will receive bupropion with ALXN1840.
88873093|NCT04504968|Experimental|Intervention group|Multimodal intervention:
89187728|NCT00667017|Experimental|IMTOX25 at 2mg/m²/dose|Patients will receive IMTOX25 at 2mg/m²/dose, by IV administration, every other day for a total of 3 doses. A total of 6 cycles of treatment will be allowed. A cycle is equal to 6 weeks, with IMTOX25 infusion on Day 1, 3 and 5, followed by a 5 week rest period.
89187729|NCT00781131|Placebo Comparator|1|
88873094|NCT04504968|Placebo Comparator|Usual care group|Usual care group
88873095|NCT04478201|Experimental|Back lying sleep position|sleep on the back
88873096|NCT04478201|Experimental|Side lying sleep position|sleep on the side
88873097|NCT04473222|Experimental|Sleep Well! Intervention|Participants in this condition will begin the Sleep Well! intervention after initiating baseline, daily diary, and actigraph procedures. Sleep Well! will be provided over approximately 6-8 weeks and will include 3 sessions. Intervention sessions will typically last about an hour, but session length may vary.
88873098|NCT04473222|Other|Enhanced Usual Care|The enhanced usual care condition will occur between 6 and 8 weeks. At randomization to this condition, participants will be provided with an evidence-based sleep guidelines for young children from the CHOP Parent Family Education manual. Participants in this condition will also be able to consult with their primary care physician for management of child sleep. Consistent with usual care in the CHOP system, the primary care physician may manage the sleep concern or choose to make a referral to the CHOP sleep center or to other behavioral health services internal or external to the CHOP system. Of note, the CHOP Parent Family Education handouts provide contact information for the CHOP Sleep Center and direct readers to follow-up with their primary care provider for further guidance.
88873099|NCT04451213|Experimental|experimental|
89187730|NCT00781131|Experimental|2|Pregabalin 75 mg
89396627|NCT02036658|Active Comparator|Mindfulness-Based Stress Reduction|MBSR will follow the standard curriculum outline compiled in 1993 by Jon Kabat-Zinn except that the one-day meditation retreat will be converted to four additional weekly group sessions between the standard class 6 and 7 so that there will be 12 weekly 2.5 hour sessions. This will be done to match the CBGT protocol in duration and time. The MBSR intervention will be delivered by a University of Massachusetts Center for Mindfulness certified MBSR instructor with more than 30 years of teaching experience. To support the practice, each participant will be given A Mindfulness-Based Stress Reduction Workbook (Stahl & Goldstein, 2010), which includes descriptions of mindfulness exercises together with pre-recorded audio files to support ongoing practice.
89396628|NCT02036658|No Intervention|Waitlist Control|This will be a delayed treatment arm. Participants randomized to the waitlist control group will be re-randomized after completing the no treatment period of 12 weeks to CBGT or MBSR with equal probability.
89396629|NCT05705700|Experimental|1245c positive (1245c+) patients with dutasteride|Continue on abiraterone 1000 mg PO daily with dutasteride 3.5 mg PO daily as an add-on therapy until radiographic progression is documented
89396630|NCT05705700|Experimental|1245c positive (1245c+) patients|Continue on abiraterone 1000 mg PO daily (the standard of care for PSA only progression) until radiographic progression is documented
89396631|NCT05705700|Experimental|1245c negative (1245c-) patients|abiraterone 1000 mg PO daily (the standard of care for PSA only progression) until radiographic progression is documented
89396632|NCT05227547|Other|Thoracic resection surgery|Smokers (active or ex-smokers) and non-smokers with COPD and without COPD undergoing thoracic resection surgery
89396633|NCT04796909|Experimental|Parent coaching|The parent-coaching intervention consists of up to 8 weekly/fortnightly sessions, and each session will last up to one hour.
89396634|NCT04796909|Active Comparator|Parent consultation|The parent consultations are given for up to 8 weekly/fortnightly sessions, and each session may last up to one hour.
89396635|NCT05416619|Experimental|sEMG-biofeedback Group|Receive 1 hour of sEMG-biofeedback hand training provided by wearable REMO® and 1 hour of daily conventional rehabilitation therapy.
89396636|NCT02817516|Experimental|Part 1: TAK-828 15 milligram (mg)|TAK-828 15 mg, solution (0.2 milligram per milliliter [mg/mL] or 5 mg/mL), orally, twice daily on Days 1-13, and once on the morning of Day 14 in healthy non-Japanese participants.
89396637|NCT02817516|Experimental|Part 1: TAK-828 45 mg|TAK-828 45 mg, solution (0.2 mg/mL or 5 mg/mL), orally, twice daily on Days 1-13, and once on the morning of Day 14 in healthy non-Japanese participants.
89396638|NCT02817516|Experimental|Part 1: TAK-828 75 mg|TAK-828 75 mg, solution (0.2 mg/mL or 5 mg/mL), orally, twice daily on Days 1-13, and once on the morning of Day 14 in healthy non-Japanese participants.
89396639|NCT02817516|Experimental|Part 1: TAK-828 100 mg|TAK-828 100 mg, solution (0.2 mg/mL or 5 mg/mL), orally, twice daily on Days 1-13, and once on the morning of Day 14 in healthy non-Japanese participants.
89396640|NCT02817516|Experimental|Part 2: TAK-828 45 mg|TAK-828 45 mg, solution (0.2 mg/mL or 5 mg/mL), orally, twice daily on Days 1-13, and once on the morning of Day 14 in healthy Japanese participants.
89396641|NCT02817516|Experimental|Part 2: TAK-828 100 mg|TAK-828 100 mg, solution (0.2 mg/mL or 5 mg/mL), orally, twice daily on Days 1-13, and once on the morning of Day 14 in healthy Japanese participants.
89396642|NCT02817516|Placebo Comparator|Part 1: Placebo|TAK-828 placebo-matching solution, orally, twice daily on Days 1-13, and once on the morning of Day 14 in healthy non-Japanese participants.
89396643|NCT02817516|Placebo Comparator|Part 2: Placebo|TAK-828 placebo-matching solution, orally, twice daily on Days 1-14 in healthy Japanese participants.
89396644|NCT05416463|Sham Comparator|Control|The control group will receive primary elective THA as per standard of care surgical protocols for this type of surgery
89396645|NCT05416463|Experimental|Treatment|The intervention group will receive primary elective THA with the use of Intellijoint HIP 3D mini-optical navigation tool.
89396646|NCT02036190||Control group|Former or current smokers without emphysema
89396647|NCT02036190||Emphysema|Current or former smokers with emphysema
89396648|NCT02498951|Experimental|Arm I (obinutuzumab)|Patients receive obinutuzumab IV on days 1 and 2 for the first cycle, and on day 1 for the subsequent cycles, and on day 1 for the subsequent cycles. Cycles repeat every 60 days for 2 years in the absence of disease progression or unacceptable toxicity
88816738|NCT05588713|Other|Brief assessment protocol|"The brief protocol will contain a minimum according to guidelines for assessing ADHD:~review of medical records, a validated diagnostic interview (MINI-KID), a structured medical history, a pedagogical statement including suspicion of intellectual disability, and rating scales for symptoms such as ADHD, oppositional defiant disorder, autism, anxiety, and depression directed to children (≥ 13 years), parents, and teachers."
89187731|NCT00781131|Experimental|3|Pregabalin 150 mg
89396649|NCT02498951|Active Comparator|Arm II (observation)|Patients undergo observation for a total of 2 years.
89396650|NCT05687214|Experimental|Experimental group|Each participant in the experimental group will receive eight weekly osteopathic manipulative treatments within eight weeks. Each treatment session will include several specific manipulations.
89396651|NCT05687214|No Intervention|Control Group|Participants in the control group will not receive any treatment.
89187732|NCT00778245|Experimental|1|cefprozil 500mg tablets of Ranbaxy
89187733|NCT00778245|Active Comparator|2|CEFZIL ® 500 mg tablets of Bristol-Myers Squibb Company, USA
89187734|NCT00778323|Experimental|A,2, II|
89187735|NCT00778401|Experimental|1|Gabapentin tablets 800 mg by Ranbaxy Laboratories Limited
89396652|NCT02260050|Experimental|WAL 801 CL new formulation|
89396653|NCT02260050|Active Comparator|WAL 801 CL conventional formulation|
89396654|NCT05415995|Experimental|101 Patients with Below The Knee Artery stenosis or occlusion in Experimental Group|Patients in this group use Drug eluting Balloon (Zylox-tonbridge), this is the product to be test in this clinical trail. The drug we coated is paclitaxel.
89396655|NCT05415995|Active Comparator|101 Patients with Below The Knee Artery stenosis or occlusion in Controlled Group|Patients in this group use Drug eluting Balloon(Acotec), this is a product that has got approved by NMPA in 2016.
89396656|NCT02047656|Placebo Comparator|Placebo to LFF269 (Part 1)|Placebo to LFF269 twice daily (b.i.d) for 10 days in healthy volunteers
89396657|NCT02047656|Experimental|LFF269 (Part 1)|LFF269 twice daily (b.i.d) for 10 days in healthy volunteers
89396658|NCT02047656|Experimental|LFF269 (Part 2)|LFF269 twice daily (b.i.d) for 5 days in patients with hypertension
89396659|NCT02047812||High volume hospitals|The hospitals in the upper tertile for procedural volume
89396660|NCT02047812||Medium volume hospitals|The hospitals in the middle tertile for procedural volume
89396661|NCT02047812||Low volume hospitals|The hospitals in the lowest tertile for procedural volume.
89396662|NCT02047890|Experimental|BAY1000394|Approximately 12 subjects will be included: 3 to 6 evaluable subjects for each cohort. The cycle length will be 3 weeks (21 days).
89396663|NCT02047968|Experimental|wake therapy, light therapy and sleep time stabilisation|Wake therapy/sleep deprivation: Patients are awake for 36 hours three times in one week with a normal night of sleep between. Light therapy for 30 minutes daily in the entire study period. Sleep time stabilisation which involves psychoeducation regarding sleep hygiene and keeping the day-night cycle constant.
89396664|NCT02047968|No Intervention|treatment as usual|
89396665|NCT02048046||ECMO|
89396666|NCT02048124|Active Comparator|25g standard needle|"EUS-FNA passes will be performed without stylet. One needle pass is defined as 5 strokes in 4 different areas of the lesion. The material from the needle passes will be expressed into formalin to look for core samples. Material from the next needle passes will be expressed onto slides for cytological analysis. Ease of puncture will be scored qualitatively as poor (scored 1), good (scored 2) or excellent (scored 3)."
89396667|NCT02048124|Experimental|25d ProCor needle|"EUS-FNA passes will be performed without stylet. One needle pass is defined as 5 strokes in 4 different areas of the lesion. The material from the needle passes will be expressed into formalin to look for core samples. Material from the next needle passes will be expressed onto slides for cytological analysis. Ease of puncture will be scored qualitatively as poor (scored 1), good (scored 2) or excellent (scored 3)."
89396668|NCT03729102|Active Comparator|Control group|Persons who had received primary immunization
89396669|NCT03729102|Experimental|Study group|Persons who had received primary immunization and later received booster vaccination for at least 3 times
89396670|NCT02036736|Experimental|Propofol|Intraoperative anesthetic strategy by Propofol versus Desflurane
89396671|NCT02036736|Experimental|Desflurane|Intraoperative anesthetic strategy by Desflurane versus Propofol
89396672|NCT05415839|Active Comparator|Pulsed dye laser|Laser device
89396673|NCT05415839|Active Comparator|Fractional CO2|Laser Device
89396674|NCT05693688|Experimental|atosiban|Atosiban: bolus injection of 6.75 mg/0.9 ml atosiban in one minute followed by a continuous infusion of 18 mg/hour (=24ml/hour) for 3 hours followed by a continuous infusion of 6 mg/hour (=8 ml/hour) for the remaining 45 hours.
89396675|NCT05693688|Placebo Comparator|placebo|Placebo: injection of 0.9 ml saline in one minute followed by a saline infusion for 3 hours (24 ml/hour) followed by a continuous infusion (8 ml/hour) for the remaining 45 hours.
89396676|NCT03671850|Experimental|VT-EBV-N|Epstein-barr virus human cytotoxic T lymphocytes (EBV-CTL)
89396677|NCT03671850|Placebo Comparator|Placebo|Peripheral blood mononuclear cell, PBMC
89396678|NCT02036814|Experimental|Group A who underwent to an inter-relational strategy|Group A who underwent to a health educational orientation program (inter-relational strategy)
89396679|NCT02036814|Experimental|Group B who underwent group orientation by the nurse|
89396680|NCT02048202||premature neonate|premature neonate
89396681|NCT02048280|Experimental|Intubated|NAVA level from 0.1 to 3
89396682|NCT03562260|Experimental|children who had bipolar release|children who had bipolar release are included
89396683|NCT02047422|Experimental|Add furosemide/no spironolactone|
89396684|NCT02047422|Experimental|Add metolazone/no spironolactone|
89396685|NCT02047422|Experimental|Add furosemid/spironolactone|
89396686|NCT02047422|Experimental|Add metolazone/spironolactone|
89396687|NCT02048358|Experimental|2B3-201 150mg|2B3-201 150mg, once, IV infusion in 1000ml 5% dextrose/ Methylprednisolone hemisuccinate 1000mg, once, IV infusion in 1000ml 5% dextrose/ Placebo, once, IV infusion 1000ml 5% dextrose
89396688|NCT02048358|Experimental|2B3-201 300mg|2B3-201 300mg, once, IV infusion in 1500ml 5% dextrose/ Methylprednisolone hemisuccinate 300mg, once, IV infusion in 1500ml 5% dextrose/ Placebo, once, IV infusion 1500ml 5% dextrose
88873100|NCT04443608|Active Comparator|Veltassa|3 packets of study drug powder will be mixed with a liquid (water, apple or cranberry juice) and given to patient to drink while in the emergency department
88873101|NCT04443608|Placebo Comparator|Placebo|3 packets of study drug powder will be mixed with a liquid (water, apple or cranberry juice) and given to patient to drink while in the emergency department
88873102|NCT04435444|Experimental|Masterful supportive care|This intervention uses teachings, discussions, and exercises about personal experiences that focus on specific topics related to meaning and cancer. For example, we may discuss what is meaningful in your life, how you identify yourself before and after cancer, and your hopes for the future. The Masterful intervention is available in both English and Arabic, and it will be delivered by a trained bilingual member of the study team. It includes 3 weekly (or at participant's preference) 1-hour sessions with a member of the study team. The sessions for either the treatment or the control arm will take place in-person in a private room at MSKCC or via teleconference, depending on the patients preference. Meeting one-on-one with an interventionist was feasible in our pilot study and will enhance relationship-building between interventionist and patient. Participants will have the option to meet with the interventionist via teleconference in order to reduce in-person contact burden.
88873103|NCT04435444|Active Comparator|Attention control supportive care|This intervention uses the American Cancer Society's patient education materials. These sessions will include discussions about managing a self-identified current problem in your life. The attention control supportive care intervention is available in both English and Arabic, and it will be delivered by a trained bilingual member of the study team. It includes 3 weekly (or at participant's preference) 1-hour sessions with a member of the study team. The sessions for either the treatment or the control arm will take place in-person in a private room at MSKCC or via teleconference, depending on the patients preference. Meeting one-on-one with an interventionist was feasible in our pilot study and will enhance relationship-building between interventionist and patient. Participants will have the option to meet with the interventionist via teleconference in order to reduce in-person contact burden.
88873104|NCT04422652|Active Comparator|Strategy 1|Strategy 1: Single-blind Behavioral Activation Therapy plus placebo for 8 weeks (Phase 1), augmented in non-remitters at 8 weeks with single-blind bupropion (Phase 2) for another 8 weeks.
89187736|NCT00778401|Active Comparator|2|Neurontin ® 800 mg tablets of Parke Davis Pharmaceuticals Ltd.
89396689|NCT02048358|Experimental|2B3-201 450mg|2B3-201 450mg, once, IV infusion in 2500ml 5% dextrose/ Methylprednisolone hemisuccinate 1000mg, once, IV infusion in 2500ml 5% dextrose/ Placebo, once, IV infusion 2500ml 5% dextrose
89396690|NCT02048358|Experimental|450mg 2B3-201|2B3-201 450mg, once, IV infusion in 2500ml 5% dextrose
89396691|NCT02048358|Experimental|300mg 2B3-201|2B3-201 300mg, once, IV infusion in 1500ml 5% dextrose
89396692|NCT02048358|Experimental|2B3-201 450mg male volunteers|2B3-201 450mg, once, IV infusion in 1500ml 5% dextrose
89396693|NCT02048358|Experimental|2B3-201 300mg or 450mg female volunteers|2B3-201 300mg or 450mg, once, IV infusion in 1500 or 2500ml 5% dextrose/ Methylprednisolone hemisuccinate 1000mg, once, IV infusion in 1500 or 2500ml 5% dextrose
89396694|NCT02048358|Experimental|Relapsing MS patients; 2B3-201 450 mg|2B3-201 450mg, once, IV infusion in 2500ml 5% dextrose
89396695|NCT02048358|Experimental|Relapsing MS patients; 2B3-201 dose tbd|2B3-201 (dose to be determined), once, IV infusion in 5% dextrose
89396696|NCT02048436||male female 18-45 years range of body types|18 male female subject mix that are 18-45 years of age and selected to represent a range of body types of varying physiques and body mass indexes
89396697|NCT03562338|Experimental|Manual Therapy and Exercise|
89396698|NCT03562338|Active Comparator|Usual Care|
89396699|NCT02051478|Experimental|Thoracic manipulation|A high-velocity, end range, anterior-posterior thrust applied through the elbows to the mid-thoracic spine will be applied.
89396700|NCT02051478|Active Comparator|Thoracic mobilization|Patients will receive 20 seconds bouts of grade III-IV of central posterior-anterior (PA) non-thrust mobilization from T3 to T6 spinous process as described by Maitland et al for an overall intervention time of approximately 2 minutes
89396701|NCT02048514|Experimental|Nellix Aneurysm Sealing|The Nellix® EndoVascular Aneurysm Sealing System
89396702|NCT02928029|Experimental|Phase1, arm1: 33 kBq/kg Radium-223 dichloride+SOC|Phase 1: Radium-223 dichloride; 33 kiloBecquerel (kBq)/kg body weight every 6 weeks for a total of 6 radium-223 dichloride doses plus SOC (standard of care) bortezomib/ dexamethasone.
89396703|NCT02928029|Experimental|Phase1, arm2: 55 kBq/kg Radium-223 dichloride+SOC|Phase 1: Radium-223 dichloride; 55 kBq/kg body weight every 6 weeks for a total of 6 radium-223 dichloride doses plus SOC bortezomib/ dexamethasone.
89396704|NCT02928029|Placebo Comparator|Phase2, arm1: Placebo+SOC|Phase 2: Matching placebo (isotonic saline) every 6 weeks for a total of 6 doses plus SOC bortezomib/dexamethasone.
89396705|NCT02928029|Experimental|Phase2, arm2: Radium-223 dichloride+SOC|Phase 2: Phase 1b-selected dose of radium-223 dichloride every 6 weeks for 6 doses plus SOC bortezomib/dexamethasone
89396706|NCT03562182||Women Receiving Antenatal Steroids|Group 2: Determine how (and if) serum hLPCAT1 mRNA changes with administration of a course of steroids by measuring its plasma levels before, 24hrs after the first dose and 24hrs after the second dose of bethamethasone as well as one and two week after the first dose. This is accomplished through a simple blood draw. We seek to understand the effects of the 2nd dose of steroids and determine if, once the hLPCAT1 expression begins, does it continue or does it turn off again after some time from steroid administration.
89396707|NCT03562182||Normal Pregnancy Controls|1) Group 1: Determine the plasma levels of hLPCAT1 mRNA in pregnant women from 32- 36+6/7 weeks gestation. This is accomplished through a simple blood draw. More specifically, we seek to find out, at what moment in gestation, expression spontaneously begins.
89396708|NCT02048592|Active Comparator|Impact-Nutridrink|The first arm will be given immunonutrition -Impact- for 8 weeks, afterwards the patients will return to their previous nutrition support for another 8 weeks. We expect the improvement of oxidative stress parameters after 8 weeks of immunonutriton and return to baseline values when immunonutrition is stopped
89396709|NCT02048592|Active Comparator|Nutridrink-Impact|The second group will be given their previous nutrition support (Nutridrink) for 8 weeks, afterwards the patients will be switched to immunonutrition- Impact- for another 8 weeks. In this group of patients we do not expect any change of oxidative stress parameters after the first 8 weeks. The improvement is expected at the end of the second half of study.
89396710|NCT02049996||Robotic-assisted prolapse repair|Subjects already scheduled for robotic-assisted prolapse repair in conjunction with vaginal hysterectomy
89396711|NCT02049996||Vaginal prolapse repair|Subjects already scheduled for vaginal prolapse repair in conjunction with vaginal hysterectomy.
89396712|NCT02050074|Experimental|Colesevelam|
89396713|NCT02050074|Experimental|Metformin|
89396714|NCT02050074|Experimental|Placebo|
89396715|NCT02050074|Experimental|Colesevelam + exendin (9-39)|
89396716|NCT02050074|Experimental|Metformin + exendin (9-39)|
89396717|NCT02050074|Experimental|Placebo + + exendin (9-39)|
89396718|NCT02050152|Placebo Comparator|0% nitrous oxide|Explicit and implicit memory will be tested in 0% nitrous oxide
89396719|NCT02050152|Active Comparator|30% nitrous oxide|Explicit and Implicit memory in 30% nitrous oxide
89396720|NCT02050152|Active Comparator|60% nitrous oxide|Explicit and Implicit memory with 60% nitrous oxide
89396721|NCT02050230|Active Comparator|Fresh blood transfusion|One unit of blood stored for less than 14 days
89396722|NCT02050230|Experimental|Standard issue blood transfusion|One unit of blood stored under standard conditions
89396723|NCT02806986|Experimental|IGSC 20%|13 doses of IGSC 20% in Treatment Stage 1 and 39 doses of IGSC 20% in Treatment Stage 2 for a total of 52 doses if IGSC 20%
89396724|NCT02050386||Cold pressor stimulation|Immersion of the foot in 0-2 degrees C water for 50 seconds.
89396725|NCT02050386||Sham Stimulation|Immersion of the foot in room temperature water for 50 seconds.
89396726|NCT03562104|Experimental|Minimally consciousness Patient|Wessex Head Injury Matrix scale and Videofluoroscopy for characterization of swallowing disorders in Minimally consciousness Patient
89396727|NCT02037360|Active Comparator|Active Comparator App/Training|This is a standard smoking cessation smartphone app using the latest evidence-based smoking cessation methods and behavior change theory. Subjects will be encouraged to set a quit date of 3 weeks, to allow comparison to experimental arm quit date.
89396728|NCT02037360|Experimental|Experimental App/Training|This is a 3-week smartphone-based training program that trains mindfulness for smoking cessation by helping smokers self-monitor their smoking habits, recognize when and how often they smoke, identify triggers for smoking, and learn methods to become more mindful of triggers, to quit smoking with a target quit date of 3 weeks.
89396729|NCT02050464||Healthy controls|Healthy controls
89396730|NCT02050464||Alzheimer's disease|Patients with mild Alzheimer's disease
89396731|NCT02050464||Vascular dementia|Patients with vascular dementia
89396732|NCT02050464||Fronto-temporal dementia|Patients with fronto-temporal dementia
89396733|NCT02050464||Mild cognitive impairment|Patients with mild cognitive impairment
89396734|NCT02037750|Experimental|LINKS|Foster parent and child participate in 16-week intervention
89396735|NCT02037750|No Intervention|Services as Usual|Foster parent and child receive standard services through child welfare system
88816739|NCT05588713|Other|Comprehensive assessment protocol|The comprehensive protocol will extend the brief protocol by adding an approximately three-hour long battery of neuropsychological tests (WISC-V and CPT 3) and biomarkers (heart-rate variability, pupil dilation and the pupillary light reflex) assessed during the CPT 3.
88816740|NCT05584007|Placebo Comparator|Intervention|Flucloxacillin 500mg four times a day (QDS) for 5 days (unblinded NHS prescription) followed by blinded placebo QDS for 2 days (5 days of antibiotic)
88816741|NCT05584007|Active Comparator|Control|Flucloxacillin 500mg QDS for 5 days (unblinded NHS prescription) followed by flucloxacillin 500mg QDS (blinded) for 2 days (7 days of antibiotic)
88816742|NCT05643976|Active Comparator|Standard-of-care cardiac rehabilitation (SOC CR)|
89396736|NCT02050542|Other|Targeted biopsies guided by a fusion of MRI and ultrasound|After the 12 systematic biopsies, the same patients will have to undergo 3 additional targeted biopsies on the suspicious image detected by IRM, guided by a fusion of MRI and ultrasound- images with the Koelis ® system
89396737|NCT02050542|Other|Systematic biopsies|The patients will have to undergo 12 systematic transrectal ultrasound-guided biopsies of the prostate
89396738|NCT02048748|Experimental|Telemonitoring|Device: Weight and blood pressure device Device: Home telemonitoring device
89396739|NCT02048748|No Intervention|Control|Usual care
89396740|NCT02048982|Experimental|Guideline and Cost|The Choosing Wisely guideline and the cost of the test at our institution: $60.35 for a basic metabolic panel.
89396741|NCT02048982|Placebo Comparator|Guideline|"The Choosing Wisely guideline: Don't perform blood chemistry panels in asymptomatic, healthy adults."
89396742|NCT02048982|Active Comparator|Guideline and Victim|The Choosing Wisely Guideline and a clinical scenario with a patient as an identifiable victim who suffered harm from having an unnecessary test done
89396743|NCT02048982|Experimental|Guideline, Cost, and Victim|The Choosing Wisely guideline and a clinical scenario with a physician as an identifiable victim who suffered harm when he ordered an unnecessary test.
89396744|NCT02051556|Experimental|Best Side Improvement|Physical Therapy BSI (Best Side Improvement), aimed to potentiate the less affected body side.
89396745|NCT02051556|Experimental|Worse side improvement|Physical Therapy WSI (Worst Side Improvement), aimed to potentiate the most affected body side.
89396746|NCT02051556|Active Comparator|Standard treatment|Physical Therapy ST (Standard Treatment), aimed to potentiate both sides equally.
89396747|NCT02049060|Experimental|Tivantinib+carboplatino+pemetrexed|"•- 1 level: Tivantinib 120 mg p.o. BID + Carboplatin AUC 5 i.v. day 1 every 3 weeks + Pemetrexed 500 mg/mq i.v. day 1 every 3 weeks~•0 level: Tivantinib 240 mg p.o. BID + Carboplatin AUC 5 i.v. day 1 every 3 weeks + Pemetrexed 500 mg/mq i.v. day 1 every 3 weeks~•+ 1 level: Tivantinib 360 mg p.o. BID + Carboplatin AUC 5 i.v. day 1 every 3 weeks + Pemetrexed 500 mg/mq i.v. day 1 every 3 weeks"
89396748|NCT02049216|Sham Comparator|Sham tape|"Fixomull tape only~Single piece of 10cm wide, 32cm long applied from inferior to tibial tuberosity, over patella and onto quadriceps muscle. Corners rounded. Tape to be applied with the knee in 90 degrees flexion.~Participants in both groups will also be prescribed an individualised home exercise program by a physiotherapist."
89187737|NCT00773643|Experimental|Tissue Sample|A biopsy of the patient's temporalis muscle, subcutaneous adipose, and bone tissue is the experimental procedure. The procedure will not involve any extra incisions or dissection, as these tissues will be exposed during the reconstructive procedure. A very small fragment of each tissue type, 2mm X 2mm X 3mm biopsy, will be removed.
89187738|NCT00773721|Experimental|1|Volunteers who are currently using CPAP treatment will trial a new mask system for up to five weeks
89187739|NCT00778479|Experimental|Sepraspray|Receive Sepraspray
89187740|NCT00778479|No Intervention|Control|no treatment
89187741|NCT00666705|Experimental|Maraviroc alone|
89187742|NCT00666705|Experimental|Maraviroc + Raltegravir|
89187743|NCT00666705|Experimental|Raltegravir alone|
89187744|NCT00433147|Experimental|Afegostat tartrate 25 milligrams (mg) once per day|Afegostat tartrate was administered orally during the 4-week treatment period.
89187745|NCT00433147|Experimental|Afegostat tartrate 150 mg once per day|Afegostat tartrate was administered orally once per day during the 4-week treatment period.
89187746|NCT00433147|Experimental|Afegostat tartrate 150 mg once every four days|Afegostat tartrate was administered orally once every 4 days during the 4-week treatment period.
89187747|NCT00433147|Experimental|Afegostat tartrate 150 mg once every seven days|Afegostat tartrate was administered orally once every 7 days during the 4-week treatment period.
89187748|NCT00773799||rehabilitation center's hospitalized patients|
89187749|NCT04047849|Experimental|Antibiotics|This will include those subjects randomized into the treatment arm, receiving the outpatient antibiotic course of azithromycin and amoxicillin prior to re-admission at viability (23 0/7 weeks gestation). They will receive a single, 500mg dose of Azithromycin given prior to discharge to home, followed by 250mg daily for 4 more days, and Amoxicillin 500mg orally TID for 7 days (first dose also being given prior to discharge home).
89187750|NCT04047849|No Intervention|No antibiotics|This will include those subjects randomized into the control arm and will not receive outpatient antibiotics prior to re-admission at viability (23 0/7 weeks gestation).
89187751|NCT00773877||1|Primary open angle glaucoma
89187752|NCT00773877||2|Normal Controls
89187753|NCT04047381||Atrial Fibrillation|Turkish patients diagnosed with atrial fibrillation
89187754|NCT04047927|Experimental|EpiFinder|Eligible subjects will be included to this group to receive an epidural injection of steroids to treat their chronic back pain. The investigational device will be used in conjugation to the standard practice of epidural injections, to assist the investigator to identify the epidural space.
89187755|NCT00778557|Experimental|1|CEFPROZIL FOR ORAL SUSPENSION USP 250 mg/ 5 mL (Ranbaxy Laboratories Limited, India)
89187756|NCT00778557|Active Comparator|2|Cefzil TM (CEFPROZIL) for oral suspension equivalent to 250mg/5mL anhydrous, cefprozil (Bristol-Myers Squibb Company, New Jersey USA)
89187757|NCT00778557|Active Comparator|3|Cefzil TM (CEFPROZIL) for oral suspension equivalent to 250mg/5mL anhydrous, cefprozil (Bristol-Myers Squibb Company, New Jersey USA)
89187758|NCT00774033|Experimental|1|Treatment of acute burn in adults and children by epidermal cell spray
89187759|NCT00774033|Active Comparator|2|Treatment of acute burn in adults and children by classic skin grafts
89187760|NCT00778713|Experimental|1|Fosinopril sodium and hydrochlorothiazide 20-12.5 mg tablets of Ranbaxy laboratories Limited
89187761|NCT00778713|Active Comparator|2|Monopril ® - HCT 20-12.5 mg tablets by Bristol Meyers Squibb following a single oral dose (1 x 20/12.5 mg tablet)
89187762|NCT00781209|Experimental|Exp|Posterior Fossa Irradiation 37.5 Gy in 2.5 Gy fractions+Radiosurgical boost; Follow up:Contrast enhanced MRI & Mini Mental Status Examination
89187763|NCT00781287|Experimental|Raltegravir + 3-drug anti-HIV therapy|
89187764|NCT00781287|Active Comparator|3-drug anti-HIV therapy|
89187765|NCT00774111|Experimental|Sequence 1|
89187766|NCT02557191||Group 1|Preterm infants <32 weeks gestational age
89187767|NCT00778791|Experimental|1|metformin HC1 750 mg extended-release tablets
89187768|NCT00778791|Experimental|2|Glucophage® XR 750 mg tablets
89187769|NCT00774189|Experimental|1|clarithromycin 250 mg tablets of Ranbaxy Laboratories
89187770|NCT00774189|Active Comparator|2|Biaxin 250 mg tablets
89187771|NCT00774423|Placebo Comparator|Placebo|MAIN EXCIPIENT OF THE RILUTEK
89187772|NCT00774423|Active Comparator|Riluzole|RILUTEK
89187773|NCT00781521|Experimental|1|Floxin otic solution twice a day for 7 days
89187774|NCT02557113|Active Comparator|Vertebroplasty|This Group Underwent the Vertebroplasty Procedure (Injection of Bone Cement into the Fractured Osteoporotic Vertebral Body)
89187775|NCT02557113|Experimental|Cavuplasty|This Group Underwent the Cavuplasty Procedure (Small Cavity was Created in the Vertebral Body Prior to Injection of Bone Cement)
89187776|NCT00778947|Active Comparator|1|
89187777|NCT00778947|Active Comparator|2|
89187778|NCT00774501|Experimental|treatment of metastatic liver disease|The intervention is the use of image guidance with general anesthesia and suspended ventilation during treatment delivery. This will allow precise localization and delivery of dose to the tumor.
89187779|NCT04047147||Enrollment in the Million Hearts CVD Risk Reduction Model|Eligible Medicare fee-for-service (FFS) beneficiaries enrolled in provider organizations that were randomly assigned to participate in the Million Hearts CVD Risk Reduction Model intervention.
88816743|NCT05643976|Experimental|Cardiac Rehabilitation + KardioPAC (CR+KardioPAC)|
88816744|NCT05570292|Active Comparator|Domperidone|
88816745|NCT05570292|Placebo Comparator|Folic acid|
89187780|NCT04047147||Enrollment in control provider organizations|Eligible Medicare fee-for-service (FFS) beneficiaries enrolled in provider organizations that were randomly assigned to the control group.
89187781|NCT00784407|Active Comparator|FOCUS (group A)|Patients submitted to total thyroidectomy with the use of the FOCUS harmonic scalpel device
89187782|NCT00784407|Active Comparator|HARMONIC ACE (group B)|Patients submitted to total thyroidectomy with the use of the HARMONIC ACE harmonic scalpel device
89187783|NCT00784485|Experimental|Xolair injections|All subjects receive active drug (Xolair-see 'interventions').
89187784|NCT00781677||MDD|
89187785|NCT00781755|Experimental|1|VAR-MI: This group will receive 1mg/day varenicline (titrated from .5mg/day) and two sessions of a motivational interviewing platform CBT treatment over the course of two weeks.
89396749|NCT02049216|Experimental|Flexible tape|"Flexible tape (rocktape brand) applied as follows:~First piece of tape 10 cm wide and 32cm long (length of a standard goniometer). Split down centre 18cm from 1 end. Second piece of tape 5cm wide and 14cm long.~Tape applied in 90 degrees knee flexion Applied with no tension in proximal and distal ends. 30% tension to un-split portion placed over quads. 50% tension to split portion placed either side of patella and crossing over at tibial tuberosity Additional piece of 5cm wide flexible tape applied with 80% tension over patella tendon, with no tension in 3cm from ends All tape corners rounded~Participants in both groups will also be prescribed an individualised home exercise program by a physiotherapist."
89396750|NCT03095651|Experimental|T1DM MK-5160 16 nmol/kg|Participants with T1DM received MK-5160, 16 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.
89396751|NCT03095651|Experimental|T1DM MK-5160 32 nmol/kg|Participants with T1DM received MK-5160, 32 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.
89396752|NCT03095651|Experimental|T1DM MK-5160 64 nmol/kg|Participants with T1DM received MK-5160 64 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.
89396753|NCT03095651|Active Comparator|T1DM Glargine 0.4 U/kg|Participants with T1DM received Glargine 0.4 U/kg and placebo to MK-5160 daily for 12 days. Dextrose was administered as needed to maintain blood sugar.
89396754|NCT03095651|Experimental|T2DM MK-5160 16 nmol/kg|Participants with T2DM received MK-5160 16 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.
89396755|NCT03095651|Experimental|T2DM MK-5160 32 nmol/kg|Participants with T2DM received MK-5160 32 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.
89396756|NCT03095651|Experimental|T2DM MK-5160 64 nmol/kg|Participants with T2DM received MK-5160 64 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.
89396757|NCT03095651|Active Comparator|T2DM Glargine 0.6 U/kg|Participants with T2DM received Glargine 0.6 U/kg and placebo to MK-5160 daily for 12 days. Dextrose was administered as needed to maintain blood sugar.
89396758|NCT02808312|Experimental|Cohort 1: Mild Hepatic Impairment|Participants with mild hepatic impairment will receive a single oral dose of cilofexor 30 mg (3 x 10 mg tablets).
89396759|NCT02808312|Experimental|Cohort 1: Normal Hepatic Function|Matched normal hepatic function participants to mild hepatic impairment participants will receive a single oral dose of cilofexor 30 mg (3 x 10 mg tablets).
89396760|NCT02808312|Experimental|Cohort 2: Moderate Hepatic Impairment|Participants with moderate hepatic impairment will receive a single oral dose of cilofexor 30 mg (3 x 10 mg tablets).
89396761|NCT02808312|Experimental|Cohort 2: Normal Hepatic Function|Matched normal hepatic function participants to moderate hepatic impairment participants will receive a single oral dose of cilofexor 30 mg (3 x 10 mg tablets).
89396762|NCT02808312|Experimental|Cohort 3: Severe Hepatic Impairment|Participants with severe hepatic impairment will receive a single oral dose of cilofexor 10 mg (1 x 10 mg tablet).
89396763|NCT02808312|Experimental|Cohort 3: Normal Hepatic Function|Matched normal hepatic function participants to severe hepatic impairment participants will receive a single oral dose of cilofexor 10 mg (1 x 10 mg tablet).
89396764|NCT03561948|Experimental|Experimental group|Surgery and Intraperitoneal Chemotherapy
89187786|NCT00781755|Placebo Comparator|2|PLA-MI: VAR-MI: This group will receive a daily placebo pill and two sessions of a motivational interviewing platform CBT treatment over the course of two weeks.
89187787|NCT00781833|Experimental|Treatment|Intramuscular Electrical Stimulation
89187788|NCT00774735|Experimental|Sequence 1|
89187789|NCT00774735|Experimental|Sequence 2|
89187790|NCT00666237|Experimental|Tube shunt surgery group|Participants in this group will receive a tube shunt surgery (Baerveldt Glaucoma implant).
89187791|NCT00666237|Experimental|Trabeculectomy with Mitomycin C|Participants in this group will receive a Trabeculectomy surgery with Mitomycin C
89187792|NCT00774813|Active Comparator|A|Nexalin 1.3mA device + placebo antidepressant
89187793|NCT00774813|Active Comparator|B|Nexalin 15mA device + placebo antidepressant
89187794|NCT00774813|Placebo Comparator|C|Placebo device + SSRI (Citalopram or similar)
89396765|NCT03561948|Placebo Comparator|Control group|only surgery
89396766|NCT02050698|Active Comparator|short leg walking cast|After 1 weeks of immobilization in a short leg posterior splint, patient is allowed protected weightbearing in a short leg walking cast
89396767|NCT02050698|Experimental|hard-soled shoe|After 1 weeks of immobilization in a short leg posterior splint, patient is allowed tolerable weightbearing in a hard-soled shoe
89396768|NCT02050776|Experimental|Stem Cells|autologous bone marrow mononuclear cell transplantation
89396769|NCT02051634|Active Comparator|Fermented Papaya Preparation (FPP)|A total of 9 grams of FPP per day (divided into three 3 gram doses) will be consumed for 8 weeks. Participants will consume three 3g sachets containing FPP per day - once 30-40 min before breakfast, once 30-40 min before lunch, and once 30-40 min before dinner. Participants will open the sachet, empty contents into their mouth, and let it dissolve before swallowing.
89396770|NCT02051634|Placebo Comparator|Sugar Pill|A total of 9 grams of placebo (sugar) per day (divided into three 3 gram doses) will be consumed for 8 weeks. Participants will consume three 3g sachets containing placebo per day - once 30-40 min before breakfast, once 30-40 min before lunch, and once 30-40 min before dinner. Participants will open the sachet, empty contents into their mouth, and let it dissolve before swallowing.
89396771|NCT02037828||Stable COPD in STEP1|no intervention
89396772|NCT02037828||Control in STEP 1|no intervention
89396773|NCT02037828||Case group in STEP 2|no intervention
89396774|NCT02037828||Control group in STEP2|no intervention
89396775|NCT05212025|Experimental|Adavosertib and Gemcitabine|"Participants will receive:~Adavosertib 1x per day on days 2, 3, 9, 10, 16, and 17 of every 28 day study cycle.~Gemcitabineon on days 1,8, and 15 of every 28-day cycle"
89396776|NCT02051868|Active Comparator|Arm A|Cisplatin and 5-Fluorouracil
89396777|NCT02051868|Experimental|Arm B|Carboplatin plus Paclitaxel
89396778|NCT04696757|Experimental|Cape|Capecitabine without surgery
89396779|NCT02049294|Active Comparator|Omalizumab (Xolair)|Dosage/frequency is dependent on body weight (kg) and baseline blood IgE level.
89396780|NCT02049294|Placebo Comparator|Placebo (Normal Saline)|0.9% normal saline equivalent to the dosage/frequency/duration of Omalizumab
89396781|NCT05155943|Experimental|KALPA X|The KALPA™ and KALPA X™ systems will be used during the performance of the LAAC procedure that is performed using customary and conventional tools and imaging technologies as currently performed in the participating center.
89396782|NCT02051946|Active Comparator|Retroject device only|The first 5 patients enrolled will serve as controls and will have the device alone placed on the eye (without an injection of ethacrynic acid).
89396783|NCT02051946|Experimental|Retroject injection with ethacrynic acid injection|The next 3 patients, after the first 5 controls, will have the device placed on the eye with a subsequent injection of ethacrynic acid into the episcleral vein.
89396784|NCT02051946|Experimental|randomization to ethacrynic acid or balanced salt solution|The last 12 patients will all have the device placed on their eye. They will then be randomized in a 2:1 ratio to receive either an injection of ethacrynic acid or balanced salt solution.
89396785|NCT02049528|Experimental|3 mg CC-122 reference capsule formulation|3 mg CC-122 reference capsule given by mouth with 240 mL of room temp tap water
89396786|NCT02049528|Experimental|3 mg CC-122 test capsule formulation|3 mg CC-122 test capsule give by mouth with 240 mL of room temp tap water
89396787|NCT02049528|Experimental|3 mg CC-122 test capsule + high fat meal|3 mg CC-122 test capsule given by mouth with 240 mL of room temp tap water approximately 5 minutes after eating a high-fat meal
89396788|NCT02049606|Experimental|LAYLA|Drug : LAYLA tablet/bid
89396789|NCT02049606|Active Comparator|CENATONE|Drug : CENATONE tablet/qd
89396790|NCT02049684||Surgery|
89396791|NCT02049684||Physiotherapy|
89396792|NCT02037516|Active Comparator|Control Group|qualitative monitoring of neuromuscular paralysis, standard treatment at this facility
89396793|NCT02037516|Active Comparator|Study Group|quantitative monitoring of neuromuscular paralysis as described in (Brull Murphy Anesth Analg 2010;111:129-40) Acceleromyography
89396794|NCT01568099|Experimental|A: AFFITOPE® PD01A + Adjuvant|4 injections of 15µg AFFITOPE® PD01A/ adjuvanted, once every 4 weeks
89396795|NCT01568099|Experimental|B: AFFITOPE® PD01A + Adjuvant|4 injections of 75µg AFFITOPE® PD01A/ adjuvanted, once every 4 weeks
89396796|NCT01568099|Other|Control|Untreated control group
89396797|NCT02050854||Observation|Subjects with Bipolar 1 Disorder or Schizophrenia who have a history of suboptimal adherence and are currently on treatment with oral aripiprazole
89396798|NCT02050932|Experimental|Iron absorption assessement|"60 mg Fe as FeSO4 with stable isotopic labels participants will receive at different times of the day (total of three dosages) and follow a standardized diet scheme.~Subjects will act as their own controls during the study"
89187795|NCT00784797|Active Comparator|pitocin|high dose pitocin drip 48 hours after mifepristone preparation.
89396799|NCT02051010||Metastatic Breast Cancer|
89396800|NCT03561792|No Intervention|traditional RSBI|the decision to continue SBT depends on the traditional RSBI (RSBI < 105 predicts successful weaning)
89396801|NCT03561792|Experimental|Diaphragmatic RSBI|diaphragm ultrasound was done to measure diaphragmatic displacement which is used to calculate DRSBI and The investigator takes the decision about SBT continuation based on the result of DRSBI (DRSBI < 1.3 predicts successful weaning)
89396802|NCT02052024|Active Comparator|Botox|Treatment group will receive 100 units of BOTOX and will receive 1-3 injections per muscle at each visit.
89396803|NCT02052024|Active Comparator|MYOBLOC|Treatment group will receive 5,000 units of MYOBLOC and will receive 1-3 injections per muscle at each visit.
89396804|NCT02037672|Active Comparator|metformin|In the metformin group metformin was initiated at a dose of 500 mg once per day and increased by 500 mg every 3 days up to 1000 mg BID per os.
89396805|NCT02037672|Active Comparator|metformin and roflumilast|In the metformin group metformin was initiated at a dose of 500 mg once per day and increased by 500 mg every 3 days up to 1000 mg BID per os. At the same time roflumilast was initiated at a dose of 500 mg BID per os.
89396806|NCT02049762|Active Comparator|P2Y12 inhibitors and aspirin|ACS patients on novel P2Y12 inhibitors and aspirin
89396807|NCT02049762|Placebo Comparator|P2Y12 inhibitors and placebo|ACS patients on novel P2Y12 inhibitors and placebo
89396808|NCT02049840|Experimental|Altis Single Incision Sling System|Altis Single Incision Sling System
89396809|NCT02037594|Experimental|Counseling + SOC Adherence|Sexual Health Counseling followed by Standard of Care Adherence Support
89396810|NCT02037594|Experimental|Counseling + Enhanced Adherence|Sexual Health Counseling followed by Enhanced Adherence Intervention
89396811|NCT02037594|Experimental|Information + SOC Adherence|PrEP Information followed by Standard of Care Adherence Support
89396812|NCT02037594|Experimental|Information + Enhanced Adherence|PrEP Information followed by Enhanced Adherence Intervention
89396813|NCT02052102|Active Comparator|No prior therapy, DIBH irradiation|Cohort 1 - No prior anthracycline-based chemotherapy or herceptin, deep inspiration breath hold breast radiation therapy
89396814|NCT02052102|Active Comparator|No prior therapy, FB technique|Cohort II - no prior Anthracycline based chemotherapy or Herceptin and (ii) to receive FB RT (not able to hold breath for at least 20 seconds or does not have a minimum of 1.0 cm of heart on at least 3 slices (3mm slices) on the FB scan)
89396815|NCT02052102|Active Comparator|Prior therapy, DIBH irradiation|Cohort III - Prior Anthracycline-based chemotherapy or Herceptin, and (ii) eligible to receive DIBH RT. (Patient has a minimum of 1.0 cm of heart on at least 3 slices (3mm slices) on the FB scan)
89396816|NCT03561558|Experimental|Ibuprofen D, oral suspension|Ibuprofen oral suspension, 200 mg/ 5 ml is the test product. In period 1 and period 2, 15 of 30 subjects will be given single oral dose (5 ml containing 200 mg of ibuprofen) of suspension.
89396817|NCT03561558|Active Comparator|Nurofen® for Children, oral suspension|Nurofen® for Children oral suspension, 100 mg/ 5 ml is the reference product. In period 1 and period 2, 15 of 30 subjects will be given single oral dose (10 ml containing 200 mg of ibuprofen) of suspension.
88873105|NCT04422652|Active Comparator|Strategy 2|Strategy 2: Double-blind bupropion plus single-blind Clinical Management (CM) attention control for 8 weeks (Phase 1), augmented in non-remitters at 8 weeks with single-blind BAT (Phase 2) for another 8 weeks.
89396818|NCT02037906|Experimental|Escalating Energy SWL|50 Patients
88873106|NCT04422652|Placebo Comparator|Control|Control: Clinical management attention control plus placebo for 16 weeks
88873107|NCT04402541|Experimental|CB-5339|Orally administered CB-5339
88873108|NCT04377451|No Intervention|Control arm|The control group will be formed of 60 overweight or obese dengue patients receiving standard of care
88873109|NCT04377451|Experimental|Intervention arm|Two cohorts receive a 5-day course of metformin treatment. In the initial phase (cohort 1), 5 young adults and 5 children (age <16) will receive a low dose of metformin. In the second phase (cohort 2), 25 adult and 25 paediatric patients will receive a weight-based dose of metformin.
88873110|NCT04363307||Adult participants|Adult participants ages 18 and older with AF
88873111|NCT04351776|Other|VR-Biofeedback|
88873112|NCT04351776|Other|VR-Distraction|
88873113|NCT04351776|Other|360 Video|
88873114|NCT04335942|Other|AFNOR 3.6 alerts|"Alert called AFNOR 3.6 in connection with the dispersion index described by Drummond et al 1985 and validated by Sprigle et al 2003. This alert corresponds to the quantification of the percentage of weight on the slick distributed over a small area (55% on one to three zones totalling 30cm2),"
88873115|NCT04335942|Other|AFNOR 3.6 alerts and Guidelines|"AFNOR 3.6 alerts and Guidelines alerts. By alertes Guidelines we mean the clinical recommendations of the Spinal Cord medicine association, i.e. weight relief every 15 to 30 minutes (Bergstrom et al., 1992; Nixon, 1985; Ho and Bogie, 2007) over a period of 1 minute 51 (Coggrave and Rose 2003) for spinal cord injuries. For patients who do not push up, a tilt of at least 25° of seat and 120° of backrest or a minimum of 45° in one block (Dicianno et al. 2009)."
88873116|NCT04329325|Experimental|Blinatumomab & Concurrent Oral Tyrosine Kinase Inhibitor (TKI)|Patients may receive steroids and hydroxyurea pre-study entry and receive a 7-day steroid prephase before starting TKI therapy. Planned initial TKI is dasatinib 140 mg daily; dasatinib dose may be reduced or TKI may be changed to a different agent under certain conditions. Induction consists of continuous TKI + 24 days of dexamethasone, followed by taper of dexamethasone, with bone marrow aspirate/biopsy (BMA) and CNS prophylaxis at days 22 and 43. Patients achieving morphologic complete response post-induction proceed to consolidation with up to 3 cycles of blinatumomab (28-day cycles, 14 days between cycles) + TKI, with BMA and CNS prophylaxis between cycles. Patients achieving complete molecular response may proceed to maintenance with up to 4 more cycles of blinatumomab (28-day cycles with 28 days between cycles) + TKI, with CNS prophylaxis between cycles and BMA after cycles 5 and 7. Patients can come off study to undergo allogeneic hematopoietic cell transplantation at any time.
88873117|NCT04317781|Experimental|Treatment (tagraxofusp-erzs)|Within day 45 and 180 after stem cell transplant, patients receive tagraxofusp-erzs IV over 15 minutes on days 1-3 of cycles 1-4 and days 1-2 of subsequent cycles. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
88873118|NCT04283175||Neuromuscular disease (MNM) subjects (Charcot Marie Tooth disease, CMT)|
88873119|NCT04283175||Hemiparetic subjects|
88873120|NCT04283175||Healthy subjects|
88873121|NCT04281485|Other|Cohort 1|Approximately two thirds of participants will be randomized to Cohort 1.
88873122|NCT04281485|Other|Cohort 2|Approximately one third of participants will be randomized to Cohort 2.
88873123|NCT04273347||patient with brain trauma|all patient with brain trauma in intensive care unit
88873124|NCT04273347||patient with spinal cord injury|all patient with spinal cord injury in intensive care unit
88873126|NCT04216719|Experimental|OCM-RISE|Opioid court team provided external facilitation to generate action plans to develop and roll out or improve practice of the county opioid court.
88873127|NCT04216667|Active Comparator|PVI|Pulmonary vein isolation alone will be performed using radiofrequency energy
88873128|NCT04216667|Experimental|PVI + PWI|Pulmonary vein isolation plus posterior wall isolation will be performed using radiofrequency energy
88873129|NCT04216667|Experimental|PVI + PWI + LAAEI|Pulmonary vein isolation plus posterior wall isolation plus left atrial appendage electrical isolation will be performed using radiofrequency energy
88873130|NCT04216667|Experimental|PVI + PWI + LAAEI + CSI|Pulmonary vein isolation plus posterior wall isolation plus left atrial appendage electrical isolation plus coronary sinus isolation will be performed using radiofrequency energy
89187796|NCT00784797|Active Comparator|misopristol|vaginal and oral misopristol 48 hours after mifepristone preparation.
89187797|NCT00774969|Experimental|All|6 patients with Perianal Crohn's Disease and 10 healthy Volunteers
89396819|NCT02037906|Experimental|Constant Energy SWL|50 Patients
89396820|NCT02037906|Experimental|Reduction Energy SWL|50 Patients
89396821|NCT03099161|Experimental|Preladenant 25 mg Twice a Day (BID)|During an initial dose evaluation phase, participants received 25 mg of preladenant orally twice a day (BID) on Days 1 through 21 of each 21-day cycle (for a maximum of 35 cycles) until the RP2D could be established. The RP2D was to be established based on the number of dose limiting toxicities (DLTs) at each dose level administered. Participants continued receiving 25 mg of preladenant BID on Days 1 through 21 of each infusion cycle until discontinuation or receiving a maximum of 35 cycles.
89396822|NCT03099161|Experimental|Preladenant 50 mg BID|During an initial dose evaluation phase, participants received 50 mg of preladenant orally BID on Days 1 through 21 of each 21-day cycle (for a maximum of 35 cycles) until the RP2D could be established. The RP2D was established based on the number of DLTs at each dose level administered. Participants continued receiving 50 mg of preladenant BID on Days 1 through 21 of each infusion cycle until discontinuation or receiving a maximum of 35 cycles.
89396823|NCT03099161|Experimental|Preladenant + Pembrolizumab|During an initial dose evaluation phase, participants received 25 mg of preladenant administered orally BID on Days 1 through 21 in combination with 200 mg pembrolizumab administered as an intravenous (IV) infusion on Day 1 of each 21-day cycle (for a maximum of 35 cycles). Participants continued receiving preladenant 25 mg BID in combination with 200 mg pembrolizumab for each infusion cycle until discontinuation or receiving a maximum of 35 cycles.
89396824|NCT04855487|Experimental|Intervention group|Adolescents/young adults with cancer will participate in a 5-week online expressive storytelling intervention. They will independently create digital stories about themselves while their target audiences are their primary nurses. They will then participate in weekly online meetings with nursing research staff, during which they introduce their stories and discuss their reflections. In the final session, they will create a one-page or five-slide story to share with their primary nurses, if they want.
89396825|NCT03095027|Other|FID122819, then stenfilcon A|FID122819 contact lenses worn first, followed by stenfilcon A contact lenses, as randomized. Each product worn in both eyes in a daily disposable mode for at least 8 hours per day, 5 days per week, for 1 week
89396826|NCT03095027|Other|Stenfilcon A, then FID122819|Stenfilcon A contact lenses worn first, followed by FID122819 contact lenses, as randomized. Each product worn in both eyes in a daily disposable mode for at least 8 hours per day, 5 days per week, for 1 week
89396827|NCT04639115|Experimental|Ozanimod in subjects with mild hepatic impairment|Participants will receive ozanimod 0.23 mg once daily (QD) on Days 1 to 4, 0.46 mg QD on Days 5 to 7, and 0.92 mg QD on Day 8 in subjects with mild hepatic impairment
89396828|NCT04639115|Experimental|Ozanimod in subjects with moderate hepatic impairment|Participants will receive ozanimod 0.23 mg once daily (QD) on Days 1 to 4, 0.46 mg QD on Days 5 to 7, and 0.92 mg QD on Day 8 in subjects with moderate hepatic impairment
89396829|NCT04639115|Experimental|Ozanimod in healthy subjects|Participants will receive ozanimod 0.23 mg once daily (QD) on Days 1 to 4, 0.46 mg QD on Days 5 to 7, and 0.92 mg QD on Day 8 in healthy subjects
89396830|NCT04260659|Active Comparator|Opioid liberal group|
89396831|NCT04260659|Experimental|Opioid free group|
89396832|NCT04340609|Experimental|Intravenous Group|Dosage of intravenous route is 2 million MSCs/kg for each subject.
89396833|NCT04340609|Experimental|Intracoronary Group|Dosage of intracoronary route is ±50 million MSCs for each subject.
89396834|NCT04340609|No Intervention|Control Group|Standard treatment of acute myocardia infarction
89396835|NCT04148495|Experimental|Treatment group|Morphine IV and the placebo of acetaminophen IV.
89396836|NCT04148495|Active Comparator|Control group|Morphine IV and acetaminophen IV
89396837|NCT04227197|Experimental|Intervention Group|The participants randomized to the intervention group completed the DSC2U questionnaire, and received online access to a personalized Caregiver Checklist and PCP plan. Caregivers were encouraged to share and discuss the PCP plan at their next wellness visit with the PCPs.
88873131|NCT04209946|Active Comparator|Less Invasive Surfactant Administration (LISA)|Infants that are spontaneously breathing with a normal heart rate will be randomized to receive prophylactic surfactant (Curosurf 2.5 mL/kg, based on estimated fetal weight) by the LISA procedure in the first 2 hours of life, using a conventional or video laryngoscope and a small flexible 16 gauge angiocatheter. Any repeat dosing for surfactant will be based on clinical indication at the physician discretion by the conventional endotracheal approach.
88873132|NCT04209946|Active Comparator|Continuous Positive Airway Pressure (CPAP)|Infants that are spontaneously breathing with a normal heart rate will be randomized to early Continuous Positive Airway Pressure (CPAP).
88873133|NCT04190056|Experimental|Arm A (pembrolizumab, vorinostat, tamoxifen)|Patients receive pembrolizumab IV over 30 minutes on day 1, vorinostat PO QD for 4 days weekly, and tamoxifen PO QD on days 1-21. Cycles repeat every 21 days in the absence of disease progression of unacceptable toxicity.
88873134|NCT04190056|Experimental|Arm B (pembrolizumab, tamoxifen)|Patients receive pembrolizumab IV over 30 minutes on day 1 and tamoxifen PO QD on days 1-21. Cycles repeat every 21 days in the absence of disease progression of unacceptable toxicity.
88873135|NCT04189757|Experimental|Treatment (acalabrutinib)|Patients receive acalabrutinib PO BID on days 1-28. Treatment repeats every 28 days for up to 36 cycles in the absence of disease progression or unacceptable toxicity.
88873136|NCT04179539|Experimental|Intervention|"Patients with suspected acute PE undergo CTPA and V/Q PET/CT imaging within 24 hours. V/Q PET/CT images are not used for patients management.~After completion of inclusion, central readings will be independently conducted:~CTPA will be interpreted by two radiologists, blinded to the results of any clinical information or imaging test results. The results of this interpretation will be used as a reference standard.~V/Q PET/CT will be interpreted by two independant nuclear medicine physicians, blinded to the results of any clinical information or imaging test results (including the reference standard)."
88873137|NCT04162171|Experimental|Imaging & SBRT Treatment for Ventricular Tachycardia|
88873138|NCT04149964|Active Comparator|Standard of Care arm|Standard of Care Post-operative pain medication, Acetaminophen 325 mg every 6 hours as needed for pain plus acetaminophen/hydrocodone 7.5 mg/325 mg 1 tab every 4 hours as needed for pain.
88873139|NCT04149964|Experimental|Study Arm|Acetaminophen 650 mg 1 tab every 6 hours round the clock plus Oxycodone 5 mg 1 tab every 6 hours as needed for breakthrough pain,.
88873140|NCT04146649|Experimental|Primary Osteoarthritis|Patients with native knees and effusions will participate in this arm.
88873141|NCT04146649|Experimental|Primary TKA|Patients with total knee replacements will participate in this arm.
88873142|NCT04115657|Experimental|Starch 1|Tapioca starch
88873143|NCT04115657|Experimental|Starch 2|High amylose
88873144|NCT04115657|Experimental|Starch 3|Kithul flour
88873145|NCT04115657|Experimental|Starch 4|Sago flour
89396838|NCT04227197|No Intervention|Control Group|The participants randomized to the control group, received usual care for 7 months, after their scheduled PCP appointment. They did not receive DSC2U during these 7 months, but did receive the online, personalized health assessment tool (DSC2U) at the end of the 7 months, after the primary and secondary outcomes were measured.
89396839|NCT03632447|Experimental|Leva Arm|Subjects will undergo pelvic floor muscle training using the leva device (a vaginal probe) which provides immediate visual feedback via smartphone regarding the motion of pelvic floor muscles. Subjects will perform exercises 2 1/2 minutes twice daily for 8 weeks. At the beginning of the study, four weeks later, and eight weeks later subjects will undergo pelvic floor muscle testing using the PFDx device and surveys to document response to training. After eight weeks, subjects may pursue any additional treatments they wish, but may continue to use the device. They will be further randomized to receive reminder text messages or no messages over 10 months. Subjects will be asked to complete follow up surveys at 6- and 12-months.
89396840|NCT03632447|Active Comparator|Kegel Arm|Subjects in this arm will perform pelvic floor muscle exercises (Kegels) for the treatment of stress or mixed urinary incontinence. Subjects will be asked to perform exercises three times daily for 8 weeks. At the beginning of the study, four weeks later, and eight weeks later, subjects will undergo pelvic floor muscle testing (using the PFDx device) and surveys to document response to training. After eight weeks, subjects may pursue any additional treatments they wish, but may continue to use the device.
89396841|NCT05051189|Active Comparator|Patients with sleep apnea having oxygen Saturation >85%|Children with OSA having procedures requiring endotracheal intubation and an who will receive opioids for evaluation of respiratory changes
89396842|NCT05051189|Active Comparator|Patients with sleep apnea having oxygen Saturation <85%|Children without OSA having procedures requiring endotracheal intubation and an who will receive opioids for evaluation of respiratory changes
89396843|NCT04540289|Active Comparator|Optimal Medical Therapy without ICD device therapy|Patients will be treated according to Optimal Medical Therapy defined by ESC Guidelines for treatment of patients with heart failure / chronic coronary syndromes and will not receive an ICD device
89396844|NCT04540289|Experimental|Optimal Medical Therapy with ICD device therapy|Patients will be treated according to Optimal Medical Therapy defined by ESC Guidelines for treatment of patients with heart failure / chronic coronary syndromes and will receive an ICD device
89396845|NCT05027165||Observational group|"In this cohort, 40 NSCLC patients with indication for chemoradiotherapy followed by durvalumab maintenance treatment (standard of care) will be consecutively recruited.~Comprehensive characterization of all patients includes immunophenotyping of peripheral blood mono-nuclear cells, ctDNA as well as gut/saliva microbiome analyses and will be performed before, after 15 fractions of radiotherapy, at the end of concurrent chemoradiotherapy as well as 3-, 6- and 12 months after start of durvalumab.~18F-FDG-PET/CT will be performed 5-10 d before start of radiotherapy, 6 weeks, 6 months,12 and 24 months after the end of radiochemotherapy. Lung function will be asssed before start of radiotherapy, at the end and 6 weeks after chemoradiotherapy as well as 3-, 6- and 12, 18, 24months after start of durvalumab."
89396846|NCT04097873|Experimental|Diaphragm biofeedback reeducation plus inspiratory training|
89396847|NCT04097873|Active Comparator|Isolated high-intensity inspiratory muscle training|
89396848|NCT04087655|Experimental|Exercise training|Eight weeks of interval exercise training
89396849|NCT04015427|Active Comparator|screw-retained|Patients in group A will receive a screw-retained implant crown. Following this first period of 16 weeks, the screw-retained implant crown will be replaced by a new intraorally cemented implant crown. Cement removal will be preformed according to best clinical procedure. These implant crowns will again be left for another period of 16 weeks and followed up for the harvesting of microbiological samples every 8 weeks. After the second 16-week the implant crowns will be removed to evaluate any excess cement. All patients will be fitted with the original screw-retained implant crown. Clinical parameters for inflammation and probing depths will be obtained after each 16 week-period.
89396850|NCT04015427|Active Comparator|cement-retained|In group B the implant crowns will be incorporated in a reverse pattern. During the first 16 weeks a cemented implant crown will be inserted and any possible cement residues will be removed according to best clinical procedure, while for the second period of 16 weeks patients will be fitted with a screw-retained single implant crown. Again, microbiological and clinical parameters will be obtained at the same intervals as in Group A.
89396851|NCT00446225|Experimental|A|"Erlotinib (Tarceva)150 mg /day~Patients will receive treatment until disease progression or unacceptable toxicity.~For all practical effects a treatment cycle will be defined as three weeks of continuous treatment with erlotinib"
89396852|NCT00446225|Active Comparator|B|"4 cycles of Chemotherapy:~Cisplatin / Gemcitabine; Cisplatin /Docetaxel; Carboplatin / Gemcitabine; Carboplatin / Docetaxel.~- Cisplatin plus docetaxel: cisplatin 75 mg/m2 i.v. day 1 and docetaxel 75 mg/m2 i.v.~day 1. Repeat cycles every 3 weeks.~- Cisplatin plus gemcitabine: Cisplatin 75 mg/m2 i.v. on day 1 and gemcitabine 1250 mg/m2 on days 1 and 8. Repeat cycles every 3 weeks.~In the case of patients not eligible for treatment with cisplatin, cisplatin can be replaced by carboplatin. The schedules will be the following:~Docetaxel 75 mg/m2 day 1 and carboplatin AUC = 6 day 1, every 21 days.~Gemcitabine 1000 mg/m2 days 1 and 8 and carboplatin AUC = 5 day 1, every 21 days.~Patients in the chemotherapy arm will receive the treatment until disease progression or unacceptable toxicity occurs, or until a maximum of 4 treatment cycles are given."
89396853|NCT03080935|Experimental|Evolocumab|Single arm study administering Evolocumab.
89396854|NCT04031105|Experimental|Condition 1|Priming sham TBS, followed by iTBS after an inter-stimulation-interval (ISI) of 0 minutes
89396855|NCT04031105|Experimental|Condition 2|Priming cTBS, followed by iTBS after an ISI of 0 minutes
88873146|NCT04115657|Experimental|Sugar 1|Pure palatinose
88873147|NCT04115657|Experimental|Sugar 2|Blend of sucrose and palatinose
88873148|NCT04114981|Active Comparator|Arm I (SSRS)|Patients undergo SSRS over 1 session.
88873149|NCT04114981|Experimental|Arm II (FSRS)|Patients undergo FSRS over 3 or 5 daily sessions.
88873150|NCT04088669|Experimental|Intervention group|A home-based pulmonary rehabilitation program for 8 weeks, with a minimum of 3 days per week and one session of this is under the supervision of a physiotherapist.
88873151|NCT04088669|Active Comparator|Control group|A training session about the disease and the correct inhaler use, booklets that include breathing exercises and aerobic exercises (walking) and physical activity recommendations for a minimum of 2-3 days per week for 8 weeks.
89396856|NCT04031105|Experimental|Condition 3|Priming cTBS, followed by iTBS after an ISI of 10 minutes
89396857|NCT04031105|Experimental|Condition 4|Priming cTBS, followed by iTBS after an ISI of 20 minutes
89396858|NCT03976115|Experimental|1. healthy volunteers|3x single dose of DDO-3055 and placebo
89396859|NCT03976115|Experimental|2. Patients with chronic kidney disease|3x single dose of DDO-3055 and placebo
89396860|NCT03973255|Placebo Comparator|Home based vestibular rehabilitation program|Home-based vestibular rehabilitation program including vestibular adaptation exercises, oculomotor exercises, static and dynamic balance exercises was given to each group in the form of a booklet. All exercises were demonstrated and performed first time at hospital under supervision. Booklet with descriptions and pictures of each exercise were given to patients in order to enable them to perform exercises at home. Vestibular rehabilitation exercises were prescribed as once daily with 10 repetitions at home for one month and wanted to mark a chart if the exercises were performed daily. A diary was used to monitor adherence with the program.
89396861|NCT03973255|Active Comparator|Biofeedback training|"Biofeedback training was performed five days a week during a month for 20 minutes for a total of 20 sessions with Tetrax ® (Sunlight Medical Ltd) static posture analysis device. Biofeedback training including catch, speedball, sky ball, gotcha exercises which requires following a visual target during weight transfer movements, capturing fast-moving objects by changing the center of gravity or quickly escaping from incoming objects, were applied to the patients in biofeedback training. There is a 30 seconds pause between each exercise."
89396862|NCT03973255|Active Comparator|Whole body vibration|Whole body vibration training was also performed five days a week during a month for 20 minutes for a total of 20 sessions with Power Plate Pro 5 (MDD CE 0086). In whole body vibration, single leg, squat and deep squat positions were applied respectively with 35 Hz frequency, including rest periods of 30 seconds between each application.
89396863|NCT04479449|Experimental|SP-8203|SP-8203 80 mg (40 mg/dose twice a day for three days)
89396864|NCT04479449|Placebo Comparator|Placebo|Placebo group: twice a day for three days
89396865|NCT05303207|Other|Your Super Detox|Dietary supplement
89396866|NCT04434131|Experimental|Convalescent Plasma|The investigational product is anti-SARS-CoV-2 convalescent plasma obtained from former patients identified as having recovered from COVID-19 and obtained by Vitalant from local and national donors following national blood donation guidelines. All subjects receive the convalescent plasma.
89396867|NCT01383811|Active Comparator|Moderate Intensity Aerobic Exercise|
89396868|NCT01383811|Other|Wait List/Usual Care|The subjects in this group will continue to receive the usual treatment that they were on at the time of enrollment through the wait list period of 12 weeks. Subsequently they will receive the 12 weeks of aerobic exercise program intervention
89396869|NCT05418959|Experimental|DermTech PLA noninvasive adhesive biopsy|Prior to surgical biopsy, a DermTech PLA noninvasive adhesive will be pressed over the lesion to collect superficial skin cells.
89396870|NCT03787901|Experimental|Morula Vitrification Arm|
89396871|NCT03787901|Active Comparator|Blastocyst Vitrification Arm|
89396872|NCT03503435|Other|Art therapy intervention|Participants will then take part in six-weeks of group art therapy with a goal of increasing self-awareness and expression. During the intervention sessions, participants will have access to a wide range of materials conventionally used in art therapy excluding materials that may be abrasive or powdery and unsuitable around people wearing a stoma.
89396873|NCT05291273|Experimental|Intervention|All subjects will perform the same tests.
89396874|NCT05418881|Other|postoperative Spot Measurements|Measurement of vital signs via 4 different tracking devices in the setting of post-anaesthesia care unit. Simultaneous collection of vital signs measured by the gold standard of clinical monitoring (ecg, blood-gas-analysis, invasive blood pressure, transmissive photoplethysmography).
88873152|NCT04076579|Experimental|Olaparib + Trabectedin|"There are 2 cohorts. Both cohorts receive the same treatment:~Cohort 1: Leiomyosarcoma and liposarcoma~Cohort 2: Other bone or soft tissue sarcoma histologies~Treatment consists of 21-day cycles for a maximum of 18 months."
89187798|NCT00784953||1|Asthma patients who were partly controlled or uncontrolled, need to step up, or adjust dose of the controller medications to ICS/LABA
89187799|NCT00785031|Active Comparator|internet based intervention|
88873155|NCT04049110|Experimental|Dapagliflozin first, placebo second|Dapagliflozin followed by placebo
89396875|NCT05418881|Other|Longitudinal postoperative Measurements|Continuous measurement of vital signs and activity level with tracking devices for the postoperative period in the patient ward up until 21 days postoperative.
89396876|NCT03845335|Experimental|HA-coated hybrid implant|Patient allocated to this group will receive an iMAX® Hyaluronic Acid-coated hybrid dental implant for their dental implant-supported restoration.
89396877|NCT03845335|Active Comparator|Moderately rough implant|Patient allocated in this group will receive an iMAX® non-coated moderately rough dental implant with a machined neck their dental implant-supported restoration.
89396878|NCT02868541||Haaj pilgrim|Patient that are showing at the traveler hospital health center requiring the mandatory Meningococcal vaccine ACYW135
89396879|NCT01568983|Placebo Comparator|Control|"12 weeks intake of 0.5 liter/day placebo juice containing sugar, aromas and salt corresponding to the berry juices in the other groups.~Blood pressure will be taken at time point 0,6 and 12 weeks. Blood and urine samples will be collected and weight and bioelectric impedance will be monitored at time point 0 and 12 weeks."
89396880|NCT01568983|Active Comparator|Mana-juice|"12 weeks intake of 0.5 liter/day of a commercially available berry juice (Mana blue) rich in polyphenols (grape, cherries, bilberries and aronia).~Blood pressure will be taken at time point 0,6 and 12 weeks. Blood and urine samples will be collected and weight and bioelectric impedance will be monitored at time point 0 and 12 weeks."
88873156|NCT04049110|Experimental|Placebo first, Dapagliflozin second|Placebo followed by dapagliflozin
88873157|NCT04016415|Experimental|Mindfulness Based Stress Reduction|
88873158|NCT04016415|Active Comparator|Stress Management Education|
89187800|NCT00785031|No Intervention|usual care|Patients receive their usual care from their specialist or general practitioner.
89187801|NCT00781989||Rheumatoid Arthritis patients|Patients with seropositive Rheumatoid Arthritis with symptom onset of less than three years
89187802|NCT00789789||1|
89396881|NCT01568983|Active Comparator|Optijuice|"12 weeks intake of 0.5 liter/day of berry juice rich in polyphenols (grape, cherries, blueberry and aronia) and added extract from press cake of black currant.~Blood pressure will be taken at time point 0,6 and 12 weeks. Blood and urine samples will be collected and weight and bioelectric impedance will be monitored at time point 0 and 12 weeks."
89396882|NCT04453267||Patient Arm.|"Consecutive patients undergoing elective percutaneous coronary intervention (PCI) or isolated coronary artery bypass grafting (CABG) for symptomatic stable angina (SA) despite optimal medical therapy at the University Hospital Southampton NHS Foundation Trust will be prospectively enrolled (n=86).~No interventions administered. 40ml of whole blood in EDTA vials to be taken for cellular separation and analysis."
89396883|NCT04453267||Age and gender matched controls|"Age and gender-matched patients being investigated for chest pain with unobstructed coronary arteries, defined as coronary stenosis ≤ 30% in any major epicardial vessel on CT or invasive coronary angiography, will also be recruited as controls (n=86).~40ml of whole blood in EDTA vials to be taken for cellular separation and analysis."
89396884|NCT01383733|Experimental|Single Arm|
89396885|NCT01383655|Experimental|Magnesium|i.v. magnesium infusion 40mg/kg in 20 min
89396886|NCT01383655|Placebo Comparator|Placebo|i.v. 0.9 % NaCl
89396887|NCT01623193|Active Comparator|Control|Patients receive standard 4:1 cardioplegia for myocardial protection during cardiac surgery
89396888|NCT01623193|Experimental|Treatment|Patients receive all-blood cardiolpegia for myocardial protection during surgery
89396889|NCT01615159|No Intervention|Self directed control|
89396890|NCT01615159|Active Comparator|Behavior and lifestyle counseling|
89396891|NCT02136355|Experimental|Stereotactic Body Radiation Therapy plus Surgery|Stereotactic body radiation therapy followed by surgical resection
88873159|NCT03995758|Active Comparator|Standard laser lithotripsy|standard of care for stone fragmentation in ureteroscopy
88873160|NCT03995758|Active Comparator|MOSES laser lithotripsy|MOSES technology used for stone fragmentation in ureteroscopy
88873161|NCT03974932|Experimental|Cohort 1|HTX-011 + MMA
88873162|NCT03974932|Experimental|Cohort 2|HTX-011 + MMA
88873163|NCT03974932|Experimental|Cohort 3|HTX-011 + MMA
88873164|NCT03974932|Experimental|Cohort 4|HTX-011 + MMA
88873165|NCT03967522|Experimental|Cabozantinib treatment|All participants will be treated by 60 mg of cabozantinib once daily.
88873166|NCT03930316|Other|observation|validation of observational arm
88873167|NCT03900403|No Intervention|Habitual Intake|This will be the comparative arm, of 6 weeks before and after the study participant is on their habitual diet
88873168|NCT03900403|Experimental|Walnut Intake|Experimental Arm of 12 weeks of Walnut Intake, with study visits at baseline (prior to walnut intake) and after 6 and 12 weeks of 40g of Walnut Intake.
89187803|NCT00785109|Experimental|1|100 patients daily additional intake of 2mg vitamin k1
89187804|NCT00785109|Placebo Comparator|2|100 patients no additional intake of vitamin K
89187805|NCT00662025|Experimental|1|
89187806|NCT00789945|Placebo Comparator|Study Arm A|Study Arm A will be the primary control arm.
89187807|NCT00789945|Experimental|Study Arm B|Study Arm B will serve as the intervention arm.
89187808|NCT00785265|Experimental|Group Based|60-minute group session involving other study patients who have been assigned to this condition and their guests.
89187809|NCT00785265|Active Comparator|Home-Based|60-minute educational intervention in their home, which will be delivered by an African American health educator.
89396892|NCT01568281|Experimental|1|2 way crossover
89396893|NCT01568281|Experimental|2|2 way crossover
89396894|NCT01568281|Experimental|3|2 way crossover
89396895|NCT01568281|Experimental|4|2 way crossover
89396896|NCT01013935|Active Comparator|Full CARE+ Spanish computer-counseling group|
89396897|NCT01013935|Active Comparator|Brief risk assessment study group only (control)|
89396898|NCT01383577|Experimental|Single hemorrhoidal ligation|Effective ligation of one hemorrhoidal group and sham ligation of the two other major hemorrhoidal groups is performed in each session of treatment.
89396899|NCT01383577|Experimental|Triple hemorrhoidal ligation|The three major hemorrhoidal groups are ligated in the first session of ligation. The three following monthly appointments of patients of this arm are for sham hemorrhoidal ligations and final revision.
89396900|NCT02921789|Active Comparator|Standard of Care (SOC) Regimen|Participants received SOC regimen (basiliximab induction, MMF, Tacrolimus, Methylprednisone, Prednisolone). Basiliximab 20 milligrams (mg) administered by intravenous injection prior to transplantation or intra- operatively before revascularisation as induction therapy and 20mg on day 3 or 4 or 5 post-transplant. MMF 1 gram (g) administered orally or intravenously twice daily until 12 months post transplant. Tacrolimus 0.1 milligram per kilogram per day (mg/kg/day) (two equally divided doses at 0.05 mg/kg/day every 12 hours with a target trough level of 4 - 11 nanogram per milliliter (ng/mL) administered orally within 48 hours post-transplant until 12 months post transplant. Methylprednisone 500, 250, 125 and 60mg administered orally or intravenously on days 0, 1, 2 and 3 respectively and continue through 12 months post transplant. Prednisolone administered orally by tapered doses of 20-30 mg on days 4-14, 10-20mg on days 15-28, 5-10mg on days 29 through 12 months post transplant.
89396901|NCT02921789|Experimental|Bleselumab Regimen|Participants received bleselumab regimen (basiliximab induction, bleselumab, Tacrolimus, Methylprednisone, Prednisolone). Basiliximab 20mg administered by intravenous injection prior to transplantation or intra - operatively before revascularisation as induction therapy and 20mg on day 3 or 4 or 5 post-transplant. Bleselumab 200mg administered by intravenous infusion on day 0, 7, 14, 28, 42, 56, 70, 90 and once per month until month 12. Tacrolimus 0.1 mg/kg/day (two equally divided doses at 0.05 mg/kg/day every 12 hours with a target trough level of 4 - 11 ng/mL) administered orally within 48 hours post transplant until 12 months post transplant. Methylprednisone 500, 250, 125 and 60mg administered orally or intravenously on days 0, 1, 2 and 3 respectively and continue through 12 months post transplant. Prednisolone administered orally by tapered doses of 20-30 mg on days 4-14, 10-20mg on days 15-28, 5-10mg on days 29 through 12 months post transplant.
89396902|NCT05420155||Surgical group|Patients operated on liver hydatidic cyst
89396903|NCT05419843|Experimental|HSCT arm group|"Conditioning regimen~Stem cell source Only Bone Marrow With a minimal target dose of 4x108 nucleated cells/kg recipient ideal body weight. If the graft is less rich than the minimum target dose, it can be administered at the discretion to the physician.~GVHD Prophylaxis~Prevention of EBV reactivation : Rituximab 150mg/m2 IV at Day+5 post HSCT."
89396904|NCT01568333|Experimental|Decitabine|Decitabine 3.5mg/m2，ivdrip，qd x 3d, every four weeks for one cycle. It will be given three cycles.
89396905|NCT03437005|Experimental|Desonide 0.05%|Low potency steroid topical medication applied to specific locations on the face and extremities, twice daily for two weeks
89396906|NCT03437005|Experimental|Ketoconazole 2%|Antifungal topical medication applied to specific locations on the face and extremities, twice daily for two weeks
89396907|NCT03943823|Active Comparator|Estrogen vaginal cream|
89396908|NCT03943823|Active Comparator|Trimo-San vaginal gel|
89396909|NCT03097289|Experimental|Platelets stored in InterSol|Platelets collected on the Trima Accel system and stored in 65% InterSol/35% plasma
89396910|NCT02419742|Experimental|Trastuzumab|Participants will receive trastuzumab as a part of either AC-TH or TCH treatment regimen. The choice of the regimen will be based on investigator's discretion referring the local prescribing document of trastuzumab. AC-TH consists of doxorubicin and cyclophosphamide followed by either paclitaxel or docetaxel. TCH consists of docetaxel and carboplatin. Trastuzumab will be common in both treatment regimens and could be administered weekly or every 3 weeks, as per investigator discretion. Each cycle will be of 3 weeks.
89396911|NCT02409290|Active Comparator|Regimen A|Regimen A locally-used WHO-approved MDR-TB regimen in accordance with 2011 WHO MDR-TB treatment guidelines.
89396912|NCT02409290|Active Comparator|Regimen B|"Regimen B is based on the regimen described by Van Deun 2010. With Version 8.0 of the protocol Regimen B (Regimen Bmox) is modified by replacement of moxifloxacin with levofloxacin (Regimen Blev). Regimen B without specification of which fluoroquinolone is in the regimen refers to either (Bmox or Blev).~Product and dose for [<33 kg, 33-50kg, >50 kg] respectively:~Moxifloxacin [400mg, 600mg, 800mg] OR Levofloxacin [750mg, 750mg,1000mg]; Clofazimine [50mg,100mg,100mg]; Ethambutol [800mg,800mg,1200mg]; Pyrazinamide [1000mg,1500mg, 2000mg]; Isoniazid 300mg, 400mg, 600mg]; Prothionamide [250mg,500mg,750mg]; Kanamycin [15mg per kilogram body weight (maximum 1g)]."
89396913|NCT02409290|Experimental|Regimen C|"Regimen C is a 40-week all-oral regimen consisting of bedaquiline, clofazimine, ethambutol, levofloxacin, and pyrazinamide given for 40 weeks supplemented by isoniazid and prothionamide for the first 16 weeks (intensive phase).~Product and dose for [<33kg, 33-50kg, >50 kg] respectively:~Bedaquiline 400mg once daily for first 14 days/200 mg thrice weekly thereafter; Levofloxacin [750mg, 750mg,1000mg]; Clofazimine [50mg, 100mg, 100mg]; Ethambutol [800mg, 800mg, 1200mg]; Pyrazinamide [1000mg,1500mg, 2000mg]; Isoniazid [300mg, 400mg, 600mg]; Prothionamide [250mg, 500mg,750mg]."
88873169|NCT03842969|Experimental|RO7234292 (RG6042) Q8W|Participants who received open-label RO7234292 Q4W in a preceding study or who received RO7234292 Q4W in this study may be randomly allocated to receive RO7234292 Q8W. Participants who previously received open-label of RO7234292 Q8W in a preceding study or are currently receiving RO7234292 Q8W in this study will receive RO7234292 Q8W. Participants who previously received placebo, or did not previously receive treatment with RO7234292 or received short-term treatment with a treatment-free follow-up period may be randomly allocated to receive RO7234292 Q8W. Participants who previously received blinded placebo Q8W may receive RO7234292 Q8W. Participants who received blinded RO7234292 Q8W will receive open-label RO7234929 Q8W. Participants who received blinded placebo Q8W may receive RO7234292 Q8W. Participants who received blinded RO7234292 Q4W or blinded placebo Q4W may be randomly allocated to receive open-label of RO7234292 Q8W.
89396914|NCT02409290|Experimental|Regimen D|"Regimen D is a 28-week regimen consisting of bedaquiline, clofazimine, levofloxacin, and pyrazinamide given for 28 weeks supplemented by isoniazid and kanamycin for the first 8 weeks (intensive phase).~Product and dose for [<33kg, 33 to<40kg, 40-50kg, >50-60 kg, >60 kg] respectively:~Bedaquiline 400mg once daily for first 14 days/200mg thrice weekly thereafter; Levofloxacin [750mg, 750mg, 750mg, 1000mg, 1000mg]; Clofazimine [50mg, 100mg, 100mg, 100mg, 100mg]; Pyrazinamide [1000mg,1500mg, 1500mg, 2000mg, 2000mg]; Isoniazid [400mg, 500mg, 600mg, 800mg, 900mg]; Kanamycin [15 mg per kilogram body weight (maximum 1g)]."
89396915|NCT02351414||Primary Total Knee Arthroplasty|Single study group previously implanted with the EVOLUTION® TKA System with cruciate sacrificing (CS) inserts
89396916|NCT02145494|Experimental|Treatment|Radiotherapy
89530516|NCT03244501|Experimental|Left Frontal|An active magnet (active tSMS) will be placed over the left frontal cortex, while a sham magnet (sham tSMS, a nonmagnetic metal cylinder made of brass) will be placed over the right frontal cortex.
89187810|NCT00785265|No Intervention|Standard Care|60-minute individual session with an African American health educator.
89396917|NCT02147756|Active Comparator|CO2RE|Fractional CO2 laser system that utilizes a sealed off, all metal carbon dioxide gas tube that is Radio Frequency (RF) excited and air cooled, emitting light at a wavelength of 10.6 μm with programmable pulse duration and frequency. The system has a programmable 2 axis scanning laser beam device that allows the physician to select the skin area coverage from a selection of predetermined patterns in different sizes based on the skin area to be treated. The versatility of the fractional CO2RE system enables precise, effective and simultaneous treatment of the skin's surface in the middle, and deep dermal levels.
89187811|NCT05013645|Experimental|Sterilized probiotic (LfQi601)|Sterilized probiotic topically administered.
89187812|NCT05013645|Placebo Comparator|Gel control product|Inactive placebo.
89187813|NCT00782145|Experimental|Arm I|"Each dyad receives institution-specific care for 6 months, which typically includes psychosocial support for the HSCT recipient and individualized or group education and support for the accompanying parent during the peri-transplant period. They also receive the Web-based Hematopoietic Stem Cell Transplantation (HSCT-) Comprehensive Health Enhancement Support System (HSCT-CHESS) intervention for 6 months. Accompanying parents also identify a companion to receive access to the HSCT-CHESS Web Site.~The HSCT-CHESS Web site provides ready access to accurate information and resources about pediatric HSCT, practical tips, organizational tools, and other supporting services for use during the transplant process. In addition to collecting data for later analysis, the Web site tracking system allows for further tailoring of information and support for the user, principally by time post transplant."
89187814|NCT00782145|Active Comparator|Arm II|Each dyad receives institution-specific usual care for 6 months as described in arm I. Accompanying parents also receive a book from the Blood and Marrow Transplant Information Network (BMT Infonet).
89187815|NCT00782223||1|Hip X-rays DDH
89187816|NCT00782223||2|Hip X-rays, CP
89187817|NCT00782223||3|Long standing lower Limb X-rays
89187818|NCT00782223||4|Scoliosis, AP X-rays
89187819|NCT00782223||5|Scoliosis Lateral X-rays
89187820|NCT00790101|Experimental|1|Risedronate 35mg once a week
89187821|NCT00790101|Active Comparator|2|Raloxifene 60mg daily
89187822|NCT00790101|Placebo Comparator|3|
89187823|NCT02555085|Experimental|IV Dose 1|Single ascending IV dose or matching placebo based on body weight recorded on Day 1
89187824|NCT02555085|Experimental|IV Dose 2|Single ascending IV dose or matching placebo based on body weight recorded on Day 1
89187825|NCT02555085|Experimental|IV Dose 3|Single ascending IV dose or matching placebo based on body weight recorded on Day 1
89187826|NCT02555085|Experimental|IV Dose 4|Single ascending IV dose or matching placebo based on body weight recorded on Day 1
89187827|NCT02555085|Experimental|IV Dose 5|Single ascending IV dose or matching placebo based on body weight recorded on Day 1
89187828|NCT02555085|Experimental|IV Dose 6|Single ascending IV dose or matching placebo based on body weight recorded on Day 1
89187829|NCT02555085|Experimental|IV Dose 7|Single ascending IV dose or matching placebo based on body weight recorded on Day 1
89187830|NCT02555085|Experimental|SC Dose|Single SC dose or matching placebo
89187831|NCT00782301|Active Comparator|Maraviroc|
89187832|NCT00782301|Active Comparator|Etravirine|
89187833|NCT00785343|Active Comparator|Conventional Treatment|
89187834|NCT00785343|Experimental|Robotic and Conventional Therapy|
89187835|NCT00785421|Experimental|A|"Patients with KPS > 80% and normal kidney function receive GFFC + LMWH (gemcitabine 1 g/m2 (30 min), cisplatin 30 mg/m2 (90 min), 5-fluorouracil 750 mg/m2 (24 h), folinic acid 200 mg/m2 (30 min), d1, 8; q3w +/- Enoxaparin 1mg/kg daily s.c.).~Pts with KPS < 80 % and increased creatinin plasma levels (>1.3 mg/dl) receive the current standard therapy (gemcitabine 1 g/m2 (30 min), d1, 8, 15; q4w) + Enoxaparin 1mg/kg daily s.c.~After 12 weeks of initial chemotherapy all patients who have not progressed received the standard therapy (gemcitabine mono) + Enoxaparin 40mg/d s.c."
89187836|NCT00785421|Active Comparator|B|"Patients with KPS > 80% and normal kidney function receive GFFC - LMWH (gemcitabine 1 g/m2 (30 min), cisplatin 30 mg/m2 (90 min), 5-fluorouracil 750 mg/m2 (24 h), folinic acid 200 mg/m2 (30 min), d1, 8; q3w - Enoxaparin 1mg/kg daily s.c.).~Pts with KPS < 80 % and increased creatinin plasma levels (>1.3 mg/dl) receive the current standard therapy (gemcitabine 1 g/m2 (30 min), d1, 8, 15; q4w) - Enoxaparin 1mg/kg daily s.c.~After 12 weeks of initial chemotherapy all patients who have not progressed received the standard therapy (gemcitabine mono) - Enoxaparin 40mg/d s.c."
89187837|NCT00790179|Active Comparator|PCA;active comparator|Patients with intravenous PCA hydromorphone alone
89187838|NCT00790179|Active Comparator|CFB|Patients with a continuous femoral block (CFB) + PCA hydromorphone
89187839|NCT00790179|Active Comparator|CLPB|Patients with a continuous lumbar plexus block + PCA hydromorphone
89187840|NCT00790257|Experimental|Monolayer Cellular Device|Encapsulated human islets allotransplantation transplanted in subcutaneous tissue in Type 1 diabetes patient
89187841|NCT00785499|Experimental|skim milk|skim milk
89187842|NCT00785499|Experimental|whey|Whey milk drink
89187843|NCT00785499|Experimental|casein|casein milk drink
89187844|NCT00785499|Active Comparator|water|Danish mineral water
89187845|NCT00782457|Active Comparator|OPEN SURGERY|
89187846|NCT00782457|Experimental|LAPAROSCOPIC SURGERY|
89187847|NCT00790413|Experimental|High-dose MIBG with haploidentical stem cell transplantation|High-dose MIBG followed by Fludarabine, Thiotepa and Melfalan as conditioning Before haploidentical transplantation of T-cell depleted graft
89187848|NCT00785655|Experimental|1|Dermacyd PH_DETINLYN (Lactic Acid)
89187849|NCT00790491|Experimental|Lifestyle counseling|
89187850|NCT00790725|Other|PAV|Proportional Assist Ventilation will be used as a mechanical ventilation method for randomized patients in RACU
89187851|NCT00790725|Other|PS|Pressure Support Ventilation will be used as a mechanical ventilation method for randomized patients in RACU
89187852|NCT00785733||1|Moderate and severe asthma patients stabilized on Symbicort SMART
89187853|NCT00785811|Experimental|1|L-arginine aspartate (Targifor)
89396918|NCT02147756|Active Comparator|RePair|Fractional CO2 system that comprises an infrared laser controlled by an embedded processor and a handpiece that directs the laser treatment. The device laser has a wavelength of 10.6μm and its tissue chromophore is water. It delivers multiple low energy pulses in microscopic spots as the handpiece glides over the skin surface. The selected energy determines the depth and width for each microscopic treatment zone (MTZs).
89396919|NCT05435755|Experimental|hAESCs treatment|A total of 6 times hAESCs transplants will be performed. 50 million (in 2ml) hAESCs will be transplanted into the ventricle of participants through the Ommaya sac (set as day 0 at the beginning of the trial). Subsequently, hAESCs ventricle transplants will be performed at 1 month ±5 days, 2 months ±5 days, 3 months ±5 days, 6 months ±5 days, and 9 months ±5 days after the first cell transplantation, with a volume of 50 million cells (in 2 ml) each time.
89396920|NCT05435755|Placebo Comparator|Control group|Four times hAESCs transplants and two times placebo (cell preservation solution) injections will be performed by Ommaya sac. 50 million (in 2ml) hAESCs will be transplanted into the ventricle of participants (set as day 0 at the beginning of the trial). Subsequently, hAESCs will be transplanted into the ventricle for 3 times, respectively, at 1 month ±5 days , 2 months±5 days , and 3 months ±5 days after the first cell transplantation, with a volume of 50 million cells (in 2 ml) each time. Ventricle injection of 2 ml placebo (cell preservation solution) will be performed at 6 months ±5 days and 9 months ±5 days after the first cell transplantation.
89396921|NCT02147912|Active Comparator|Aerobic exercise|A six week aerobic exercise intervention in COPD depressed population.
89396922|NCT02147912|No Intervention|Control sample|"Only participants randomized in the arm named Aerobic exercise will receive a six weeks aerobic exercise intervention."
89396923|NCT02898077|Experimental|8 milligram/kilogram (mg/kg) Ramucirumab + 80 mg/square meter (mg/m²) Paclitaxel|"8 mg/kg ramucirumab was administered as an intravenous infusion (IV) on days 1 and 15, in combination with 80 mg/m² paclitaxel administered by IV on days 1, 8, and 15 of every 28-day cycle.~Participants may continue on treatment until discontinuation criteria were met."
89396924|NCT02898077|Experimental|Placebo + 80 mg/m² Paclitaxel|"Placebo was administered at a volume equivalent to a dose of 8 mg/kg by IV on Days 1 and 15, in combination with 80 mg/m² paclitaxel administered by IV on Days 1, 8, and 15 of a 28-day cycle.~Participants may continue on treatment until discontinuation criteria were met."
89396925|NCT02145572||Obese adolescents with type 2 diabetes|No intervention
89396926|NCT02145572||Obese adolescents without diabetes|No intervention
89396927|NCT02145572||Healthy non-obese adolescents|No intervention
89396928|NCT03544346||Retired professional rugby players|"Rugby Players will Provide detailed demographic information Provide detailed overall health information Questionnaires Provide information on athlete's playing career; age of debut, career duration, number of seasons participated in. Provide information on concussion history. Be given a general health screen including- heart rate, blood pressure, body composition and height weight ratio.~Perform a battery of neuropsychological tests (Sound-induced flash illusion and CANTAB, NART) Provide a sample of blood."
89396929|NCT03544346||Retired professional rowers|"Rowers will Provide detailed demographic information Provide detailed overall health information Questionnaires Provide information on athlete's playing career; age of debut, career duration, number of seasons participated in. Provide information on concussion history. Be given a general health screen including- heart rate, blood pressure, body composition and height weight ratio.~Perform a battery of neuropsychological tests (Sound-induced flash illusion and CANTAB, NART) Provide a sample of blood."
89396930|NCT03544892|Experimental|Experimental: Low carbohydrate diet|
88873170|NCT03842969|Experimental|RO7234292 (RG6042) Q16W|Participants who previously received open-label RO7234292 Q4W in a preceding study or who received RO7234292 Q4W in this study may be randomly allocated to receive RO7234292 Q16W. Participants who previously received placebo in a preceding study or did not previously receive treatment with RO7234292 or received short-term treatment with a treatment-free follow-up period may be randomly allocated to receive RO7234292 Q16W. Participants who previously received blinded placebo Q8W will receive RO7234292 Q8W. Participants who previously received blinded RO7234292 Q16W will receive open-label RO7234292 Q16W. Participants who received blinded RO7234292 Q4W or blinded placebo Q4W may be randomly allocated to receive open-label of RO7234292 Q16W. Participants who previously received open-label RO7234292 Q16W will receive open-label RO7234292 Q16W.
88873171|NCT03835312|Experimental|Interventional|Sequential transplantation of umbilical cord blood stem cells and islet cells
89396931|NCT03544892|Active Comparator|Experimental: Standard of care diet|
89396932|NCT03692975|Experimental|CIS patients|Clinically isolated neurological syndrome (CIS) compatible with a demyelinating inflammatory episode within the central nervous system, potentially suggestive of multiple sclerosis (MS) whatever the mode of presentation
89396933|NCT03692975|Active Comparator|Control|50 Healthy controls
89396934|NCT02145650||All Participants|Patients with a diagnosis of CP, MS, Stroke, SCI, or TBI will be evaluated for spasticity by their healthcare provider. Patients diagnosed with spasticity requiring treatment will be enrolled in the study. There is no intervention administered in this study.
89530517|NCT03244501|Experimental|Right Frontal|An active magnet (active tSMS) will be placed over the right frontal cortex, while a sham magnet (sham tSMS, a nonmagnetic metal cylinder made of brass) will be placed over the left frontal cortex.
89530518|NCT03244501|Sham Comparator|Sham Frontal|Sham magnets (sham tSMS, a nonmagnetic metal cylinder made of brass) will be placed over the left and right frontal cortex.
89396935|NCT02145728|Experimental|Individual Cognitive Functional Therapy|The intervention being tested has four main components: (1) a cognitive component, for each patient, their vicious cycle of pain will outlined in a diagram based on their findings from the examination and the Orebro Musculoskeletal Pain Screening Questionnaire; (2) specific movement exercises designed to normalize maladaptive movement behaviours; (3) targeted functional integration of activities in their daily life previously, reported to be avoided or provocative by the patient; and (4) a physical activity and lifestyle programme.
89396936|NCT02145728|Active Comparator|Group Exercise Classes|6 classes will take place in total. The class has 3 components each week. First, a 30 minute talk and discussion on chronic pain, and some tips for participants. Second, a 40 minute exercise circuit, involving aerobic exercise, and gentle stretching and strengthening exercises. Finally, a 5 minute relaxation/mindfulness session will take place at the end. The total time involved is approximately 1 hour and 15 minutes.
89396937|NCT03544034|No Intervention|Pre-intervention|Routine/ standard care and retrospective chart review for identifying preventable and ameliorable Adverse drug events as baseline
89396938|NCT03544034|Experimental|Post-intervention|Hometeam toolkit interventions (including improved discharge education, proactive medication safety assessment in daily rounds and handoffs, safety briefings) applied in all hospitalist services.
89396939|NCT03543956||Systemic Sclerosis patient|patients affected by SSc according to EULAR 2013 criteria
89396940|NCT02145884|Experimental|timolol maleate 0.5% gel|timolol gel 1 to 2 drops twice a day to lesions for 4 months
89396941|NCT02145962|Active Comparator|Forearm tissue exposure with ELF-MF|This study arm should include subjects with diabetic foot ulcers recruited at the medical services site of the Autonomous University of Nuevo Leon, Monterrey, Mexico. These study patients should receive treatment in the forearm region.
89396942|NCT02145962|Active Comparator|Thorax tissue exposure with ELF-MF|This study arm should include subjects with diabetic foot ulcers recruited at the IMSS Regional General Hospital N. 1 and Servicios de Salud de Morelos, Cuernavaca, Mexico. These study patients received treatment in the thorax region.
89396943|NCT02148068||Bariatric Surgery - Gastric Bypass|This population will undergo a laparoscopic roux-en-y gastric bypass
89396944|NCT02148068||Bariatric Surgery - Sleeve Gastrectomy|This group will undergo a laparoscopic sleeve gastrectomy
89396945|NCT03544814|Experimental|Concurrent therapy group|Icotinib combined with pemetrexed plus cisplatin.
89396946|NCT03544814|Experimental|Sequential therapy group|First icotinib and then pemetrexed plus cisplatin.
89396947|NCT03097133|Experimental|Esketamine + Standard of care|Participants will receive intranasal esketamine 84 milligram (mg) on Day 1, 4, 8, 11, 15, 18, 22, and 25 along with standard of care antidepressant treatment.
89396948|NCT03097133|Placebo Comparator|Placebo + Standard of care|Participants will receive intranasal placebo on Day 1, 4, 8, 11, 15, 18, 22, and 25 along with standard of care antidepressant treatment.
88873172|NCT03823690|Active Comparator|EUS-guided gastrojejunostomy|"The procedures would be performed under conscious sedation or monitored anesthesia by a therapeutic gastroscope. The endoscope would be used to reach the site of obstruction. The stricture would be cannulated with a 0.025 or 0.035 guide-wire. The double balloon occluder would then be inserted on guidewire beyond the duodenal-jejunal flexure and the two balloons of the occluder would be inflated.~A segment of duodenum/jejunum would then be occluded and saline would be injected. A linear echoendoscope would then be inserted into the stomach to guide insertion of the gastrojejunostomy stent."
88873173|NCT03823690|Active Comparator|Pyloro-duodenal stent|The uncovered DS used in this study is Wallflex (Boston, Natick, MA, USA), made of nitinol wire, with a diameter of 22mm and length of 6, 9, 12cm. This stent is a braided stent with high axial force, good flexibility and conformability.
88873174|NCT03819387|Experimental|NBF-006|
88873175|NCT03777813|Experimental|Arm A|"Concomitant administration of durvalumab (dose: 1500 mg):~Every 4 weeks during concurrent FOLFOX and after FOLFOX completion (total of 12 months of treatment)~Definitive modulated-intensity radiotherapy will be delivered according to boost integrated technique 5 days a week for 5 weeks at a dose of:~50 Gy delivered in 25 fractions to the macroscopic disease (endoscopic, TDM and fused FDG PET)~45 Gy to the adjacent peri tumoral mucosis and prophylactic lymph node~FOLFOX 4 simplified protocol, 1 infusion every 2 weeks during 3 months starting with radiotherapy (+/- 1 day):~IV oxaliplatin 85 mg/m² in 2 h on D1~IV Leucovorin 200 mg/m² in 2 h on D1, followed by~IV 5-FU 400 mg/m² in 10 minutes on D1 followed by~IV continuous infusion 5-FU 2400 mg/m² in 46 h"
89187854|NCT00785811|Placebo Comparator|2|Placebo
89396949|NCT02142062||Venography and IVUS imaging guiding treatment|
89396950|NCT02148224||healthy without diabetes|
89396951|NCT02148380|Experimental|chemotherapy group(B)|pemetrexed plus carboplatin pemetrexed (500 mg/m(2) on day 1) plus carboplatin (AUC 5 on day 1) every 4 weeks for up to six cycles, then continued to receive pemetrexed(500 mg/m(2) on day 1) alone every 4 weeks
89396952|NCT02148380|Experimental|combination therapy group(A)|pemetrexed (500 mg/m(2) on day 1) plus carboplatin (AUC 5 on day 1) combined with gefitinib (250 mg/day on days 5-21) and repeated every 4 weeks for up to six cycles,then continued to receive pemetrexed combined with gefitinib every 4 weeks.
89396953|NCT02148380|Experimental|gefitinib group (group C)|received gefitinib( 250 mg/day)alone. All therapies of 3 groups were continued until progression or unacceptable toxicity or death
89396954|NCT02146118|Experimental|Erlotinib and Silibin|
89396955|NCT02146196|Experimental|Heart failure, robotic assisted training|4 weeks robotic assisted training with the Lokomat®
89396956|NCT02146196|Experimental|Post cardiac surgery|One week robotic assisted gait training with the Lokomat®
89396957|NCT05418569|Active Comparator|Intervention Arm - Use of the new smartphone application for T1DM|"The use of the locally designed smartphone application for T1DM for 6 months, which contained the following domains:~Type 1 DM self-management information and decision-making algorithm~Carbohydrate counting information on local food in Hong Kong~DM day-to-day troubleshooting psychosocial scenarios~Game-based interactive tools for DM knowledge enhancement~Usage tracking for each domain of the smartphone application~Individual participant identification and access code (known to research assistant)"
89396958|NCT05418569|Placebo Comparator|Control Arm - Standard diabetic education|Received standard diabetic care (diabetic nurse education and regular follow-ups) with optional use of an existing smartphone application for general diabetic information for both adult and pediatric population (that encompasses both information for type 1 and type 2 DM)
89396959|NCT02142140|Experimental|Medication Monitoring & Case Management|All children entered into this study will be prescribed medication for their ADHD symptoms (usually a long-acting stimulant). Based on the individual needs of the child and family, they could receive the following interventions - Academic and organization skills, social skills training and parent training. Participants randomized to this group will meet with the study clinicians 4 times a year for medication monitoring and adjustment. This group will also receive a monthly call from a case manager who will explore the child's academic, social and emotional functioning. Depending on the needs of the child and family, the case manager may offer 1 to 5 intervention sessions with the child (e.g. social skills, anger management), the family (e.g. family counselling), and the school (e.g. consultation with the teacher).
89396960|NCT02142140|Active Comparator|Community Follow-up Group|All children entered into this study will be prescribed medication for their ADHD symptoms (usually a long-acting stimulant). Based on the individual needs of the child and family, they could receive the following interventions - Academic and organization skills, social skills training and parent training. Families randomized to this group will be referred to their pediatricians or family physicians for medication follow-up and their local Community Health Clinic (CLSC) for other psychosocial interventions that may be required and available.
89396961|NCT02148458|Other|Control group|Western diet for 8 weeks, followed by 8 weeks of Western diet with intermittent fasting.
89396962|NCT02148458|Experimental|Mediterranean diet|Mediterranean diet for 8 weeks, followed by 8 weeks of Mediterranean diet with intermittent fasting.
89396963|NCT02148536||HPS-TIPS group|
89396964|NCT03543800|Experimental|ABP|(test treatment)
89396965|NCT03543800|Active Comparator|PRP|(active control)
89396966|NCT02142296|Other|Eylea|The intravitreal dose of Eylea will be 2mg (50ul) per injection. The medication will be supplied in single use vials. Given monthly for 3 months and then every 8 weeks until week 52. This is an open-label study.
89396967|NCT02148614|Placebo Comparator|Placebo|Subjects will be randomly assigned to treatment with placebo or LibramedR with a double blind clinical trial.
89396968|NCT02148614|Active Comparator|Libramed|Subjects will be randomly assigned to treatment with placebo or LibramedR with a double blind clinical trial.
89396969|NCT03889639|Experimental|Cohort 1: SAR442168 5 mg Then Placebo|Participants received SAR442168 5 milligrams (mg), orally once daily for first 12 weeks then crossed over to matching placebo orally once daily for 4 weeks during the 16 weeks treatment period. To maintain the blinding, each participant was given a total of 4 tablets daily, either of SAR442168 or SAR442168 and placebo, to achieve the specified daily dose of SAR442168.
89396970|NCT03889639|Experimental|Cohort 1: SAR442168 15 mg Then Placebo|Participants received SAR442168 15 mg, orally once daily for first 12 weeks then crossed over to matching placebo orally once daily for 4 weeks during the 16 weeks treatment period. To maintain the blinding, each participant was given a total of 4 tablets daily, either of SAR442168 or SAR442168 and placebo, to achieve the specified daily dose of SAR442168.
89396971|NCT03889639|Experimental|Cohort 1: SAR442168 30 mg Then Placebo|Participants received SAR442168 30 mg, orally once daily for first 12 weeks then crossed over to matching placebo orally once daily for 4 weeks during the 16 weeks treatment period. To maintain the blinding, each participant was given a total of 4 tablets daily, either of SAR442168 or SAR442168 and placebo, to achieve the specified daily dose of SAR442168.
89396972|NCT03889639|Experimental|Cohort 1: SAR442168 60 mg Then Placebo|Participants received SAR442168 60 mg, orally once daily for first 12 weeks then crossed over to matching placebo orally once daily for 4 weeks during the 16 weeks treatment period. To maintain the blinding, each participant was given a total of 4 tablets daily, either of SAR442168 or SAR442168 and placebo, to achieve the specified daily dose of SAR442168.
89530519|NCT05555537||Drug resistant epilepsy|failure to achieve sustained seizure freedom after adequate and well tolerated trials of two antiseizure medications
89530520|NCT05555537||Medically controled epilepsy|seizure freedom for at least the last 6months) matched in sex and age.
89396973|NCT03889639|Experimental|Cohort 2: Placebo Then SAR442168 5 mg|Participants received placebo matching to SAR442168 tablets, orally once daily for first 4 weeks then crossed over to SAR442168 5 mg orally once daily for 12 weeks during the 16 weeks treatment period. To maintain the blinding, each participant was given a total of 4 tablets daily, either of SAR442168 or SAR442168 and placebo, to achieve the specified daily dose of SAR442168.
89396974|NCT03889639|Experimental|Cohort 2: Placebo Then SAR442168 15 mg|Participants received placebo matching to SAR442168 tablets, orally once daily for first 4 weeks then crossed over to SAR442168 15 mg orally once daily for 12 weeks during the 16 weeks treatment period. To maintain the blinding, each participant was given a total of 4 tablets daily, either of SAR442168 or SAR442168 and placebo, to achieve the specified daily dose of SAR442168.
89396975|NCT03889639|Experimental|Cohort 2: Placebo Then SAR442168 30 mg|Participants received placebo matching to SAR442168 tablets, orally once daily for first 4 weeks then crossed over to SAR442168 30 mg orally once daily for 12 weeks during the 16 weeks treatment period. To maintain the blinding, each participant was given a total of 4 tablets daily, either of SAR442168 or SAR442168 and placebo, to achieve the specified daily dose of SAR442168.
89396976|NCT03889639|Experimental|Cohort 2: Placebo Then SAR442168 60 mg|Participants received placebo matching to SAR442168 tablets, orally once daily for first 4 weeks then crossed over to SAR442168 60 mg orally once daily for 12 weeks during the 16 weeks treatment period. To maintain the blinding, each participant was given a total of 4 tablets daily, either of SAR442168 or SAR442168 and placebo, to achieve the specified daily dose of SAR442168.
89396977|NCT02148692|Experimental|Higher PEEP|PEEP of 12 cmH2O or higher and lung recruitment maneuvers
89396978|NCT02148692|Active Comparator|Lower PEEP|PEEP of 4 cmH2O without lung recruitment maneuvers
89396979|NCT02142452|Experimental|mobile health intervention|Behavioral intervention. Women with excessive weight gain in pregnancy will be recruited in their 3rd trimester. They will begin with a 5 week group session on weight management. After they deliver the baby, they will begin receiving text messages supporting behavior change they learned in their 3rd trimester. They will follow up at 6 weeks postpartum and 4 months postpartum.
89396980|NCT02142452|Placebo Comparator|Control Group|Women will receive usual prenatal care from their OB. Postpartum, they will receive a monthly newsletter relevant to the new mother on her nutrition and physical activity. They will be followed at 6 weeks postpartum and 4 months postpartum.
89396981|NCT05418985|Experimental|Intervention group|Women in this group were given training on breast self-examination (BSE). In the three-month period following the training, a reminder text message was sent to mobile phones by the researcher to perform BSE. The text message was sent to women with regular and regular menstrual cycles on the seventh day after the bleeding ceased, and on the first day of the month to menopausal women with irregular menstrual cycles.
88873176|NCT03777813|Active Comparator|Arm B|"Definitive modulated-intensity radiotherapy will be delivered according to boost integrated technique 5 days a week for 5 weeks at a dose of:~50 Gy delivered in 25 fractions to the macroscopic disease (endoscopic, TDM and fused FDG PET)~45 Gy to the adjacent peri tumoral mucosis and prophylactic lymph node~FOLFOX 4 simplified protocol, 1 infusion every 2 weeks during 3 months starting with radiotherapy (+/- 1 day):~IV oxaliplatin 85 mg/m² in 2 h on D1~IV Leucovorin 200 mg/m² in 2 h on D1, followed by~IV 5-FU 400 mg/m² in 10 minutes on D1 followed by~IV continuous infusion 5-FU 2400 mg/m² in 46 h"
88873177|NCT03754933|Experimental|Ad/PNP + fludarabine phosphate, 5 cycles|
88873178|NCT03722654|Experimental|MTFS|MTFS-I Installation
88873179|NCT03722654|No Intervention|Control|
88873180|NCT03721120|Experimental|Liquid biopsy|Liquid biopsy will be performed at the first visit using InVisionFirst®. Treatment will be determined by (i) genomic characterization in plasma for patients with druggable alteration in first-line, (ii) after pathology results (including assessment of PD-L1 level of expression by immunohistochemistry) for patients with an informative molecular characterization on plasma and no druggable alteration in first-line and (iii) after pathology results and tissue molecular characterization for the remaining patients.
88873181|NCT03721120|No Intervention|Cytological or histological sampling|During the first visit, cytological or histological sampling will be planned and treatment will be initiated according to European Society of Medical Oncology (ESMO) recommendations; in case of a tissue sample inadequate for genomic characterization, physicians may resort to liquid biopsy according to their usual practice and available technology.
88873182|NCT03694262|Experimental|Treatment|Cycle length = 21 days Atezolizumab 1,200mg IV on day 1 Bevacizumab 15mg/kg IV on day 1 Rucaparib 600mg orally twice daily by continuous dosing
88873183|NCT03685539|Experimental|Diagnostic (DECT)|Within 7 days before the standard Gamma Knife MRI, patients undergo DECT scan over 6 seconds at 1.5, 5, 10, and 20 minutes after receiving the contrast agent.
88873184|NCT03653702|Experimental|Contrast Enhanced Ultrasound|Participants will undergo a contrast enhanced ultrasound (CEUS) using Lumason
88873185|NCT03646812|Other|Glucose Reference 1|50g of glucose dissolved in 250ml of water to be consumed.
88873186|NCT03646812|Other|Glucose Reference 2|50g of glucose dissolved in 250ml of water to be consumed.
88873187|NCT03646812|Other|Glucose Reference 3|50g of glucose dissolved in 250ml of water to be consumed.
88873188|NCT03646812|Experimental|Semolina Penne|70g of semolina penne boiled in 1 Litre of water for 11 minutes. Drained and consume immediately.
88873189|NCT03646812|Experimental|Wholegrain Penne|76g of wholegrain penne boiled in 1 Litre of water for 9 minutes. Drained and consume immediately.
88873190|NCT03646812|Experimental|Semolina Spaghetti|71g of semolina spaghetti boiled in 1 Litre of water for 8 minutes. Drained and consume immediately.
88873191|NCT03646812|Experimental|Wholegrain Spaghetti|76g of wholegrain spaghetti boiled in 1 Litre of water for 8 minutes. Drained and consume immediately.
89396982|NCT05418985|No Intervention|Control droup|Women in this group were given training on breast self-examination (BSE). No intervention was made afterwards.
89530521|NCT03246919|Placebo Comparator|Control (Group A)|One bag of 500 ml 0.9% NaCl (normal saline) will be hung by Anesthesia when the fetal anterior shoulder delivers. After the placenta is delivered, then one bag of 500 ml 0.9% NaCl with 30 units of Oxytocin (Oxytocin solution) will be hung by Anesthesia. This amount of fluid is part of standard of care.
89396983|NCT02142530|Experimental|Carfilzomib/ Belinostat|"Carfilzomib and Belinostat will be administered on a 28-day schedule.~Carfilzomib will be given on days 1-2, 8-9, and 15-16 of each cycle, beginning at a dose of 20 mg/m2 (dose level 0).~Belinostat will be given on days 1-5 beginning at a dose of 600 mg/m2.~Belinostat dosing will precede carfilzomib dosing on days when both drugs are administered. In dose level 1 and beyond, carfilzomib will be given at a dose of 20mg/m2 with cycle 1, and then escalated with cycle 2~A maximum of four dose levels are planned with carfilzomib escalated no higher than 20/36 mg/m2 and belinostat escalated no higher than 900 mg/m2."
89396984|NCT05418439|Experimental|Poppi ACV prebiotic soda|Each day in the morning, for lunch, or in the afternoon, participants will drink one 12 fl oz. can of Poppi ACV prebiotic soda.
89396985|NCT01383343|Experimental|Treatment (FOLFIRI and bevacizumab)|Patients receive irinotecan hydrochloride IV over 90 minutes on day 1, leucovorin calcium IV over 2 hours on day 1, fluorouracil IV continuously over 46 hours on days 1-2, bevacizumab IV over 30-90 minutes on day 1, and sorafenib tosylate PO QD or BID on days 3-6 and 10-13*. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
89396986|NCT02254850|Experimental|Mesoglycan|"The Patients firstly underwent to intramuscular administration of 1 vial only, containing: Mesoglycan 30mg/ml and inactive ingredients: sodium chloride, chlorocresol, water for injections.~Nextly the patients underwent to oral treatment with 1 capsule, administered bis in die for a period of 90 days, containing: Mesoglycan 50 mg and Inactive ingredients: lactose monohydrate, corn starch, croscarmellose sodium, magnesium stearate, gelatin, titanium dioxide, erythrosine.~Patients also performed Flow Mediated Dilation (FMD)."
89396987|NCT02254850|Placebo Comparator|Placebo|"The Patients firstly underwent to intramuscular administration only of 1 vial containing inactive ingredients: sodium chloride, chlorocresol, water for injections.~Nextly the patients underwent to oral treatment with 1 capsule, administered bis in die for a period of 90 days, containing inactive ingredients: lactose monohydrate, corn starch, croscarmellose sodium, magnesium stearate, gelatin, titanium dioxide, erythrosine.~Patients also performed Flow Mediated Dilation (FMD)."
89396988|NCT02142686|Active Comparator|Filling pressure 80|After the hysteroscope is introduced into the uterine cavity, the filling pressure will remain at 80mm.
89396989|NCT02142686|Active Comparator|Filling pressure 50.|After the hysteroscope is introduced into the uterine cavity, the filling pressure will be reduced to 50mm Hg in this group
89396990|NCT02142686|Active Comparator|illing pressure 30|After the hysteroscope is introduced into the uterine cavity, the filling pressure will be reduced to 30mm Hg.
89396991|NCT05416645|Active Comparator|Patients in group I (G1) had GERD|Patients developed GERD after LSG
89396992|NCT05416645|Active Comparator|Patients in group I (G2) had no GERD|Patients not developed GERD after LSG
89396993|NCT02148770|Experimental|Neurofeedback|Neurofeedback training: Up-regulation of DLPFC.
89396994|NCT02148770|Sham Comparator|Neurofeedback SHAM|Neurofeedback training: Sham-regulation of DLPFC.
89396995|NCT03631147|Experimental|Rifaximin treatment group|Rifaximin 400mg bid for 8 weeks
89396996|NCT03631147|No Intervention|The control group|
89396997|NCT02148848|Active Comparator|Early bisphosphonate use|"Give risedronate (actonel) at 2 weeks after hemiarthroplasty for an osteoporotic femoral neck fracture. In addition, calcium and vitamin D supplementation will be given to all patients.~Risedronate (35 mg) 1 tablet orally once a week"
89396998|NCT02148848|No Intervention|Late bisphosphonate use|"Give only calcium and vitamin D supplementation during the first 3 months after the surgery.~Bisphosphonate, risedronate (Actonel), will be given at 3 months after surgery for an osteoporotic femoral neck fracture."
89396999|NCT03265145|Experimental|Stiolto Respimat|
89397000|NCT03265145|Active Comparator|ICS plus LABA plus LAMA (triple therapy)|ICS (Inhaled Corticosteroid) plus LABA (Long-Acting Beta Agonist) plus (Long-Acting Muscarinic Antagonist)
89397001|NCT03786679|Active Comparator|Orthosis group|An orthosis with the broken arm in neutral position fixed for four weeks. After these four weeks the patient is instructed to start rehabilitation.
89397002|NCT03786679|Active Comparator|Early rehabilitation group|The patient is instructed to start early rehabilitation about one week after the trauma.
89397003|NCT02146586||Dystrophinopathies|
89397004|NCT02146586||Gold Standard Clinical Evaluators (GS-CEs)|
89397005|NCT02146586||Sites Clinical Evaluators (CEs)|
89397006|NCT02146664|Experimental|DLBS1033|DLBS1033 enteric-coated tablet is administered at the dose of 490 mg, one tablet three times daily, everyday for eight weeks of study period
89397007|NCT02146664|Placebo Comparator|Placebo|Placebo is administered one tablet three times daily, everyday for eight weeks of study period
89397008|NCT05402059||Cohort A|Study Cohort A will include patients with unresectable and/or metastatic melanoma, regardless of BRAF mutation in the tumor, who were started on any of the drug regimens in accordance with current clinical guidelines, except for patients assigned to the vemurafenib + cobimetinib + atezolizumab, which should be included in the A1 cohort. The initiation of therapy on the regimen that will be used at the time of signing the informed consent will be considered an index event.
89535477|NCT04955223|Experimental|Yinhu Qingwen Granule|For mild and common patients, take 1 bag 2 times a day. For severe patients, take 1 bag 3 times a day. All treatment should be used for 10 days unless all the symtopms of patient with the viral pneumonia are relieved.
89397009|NCT05402059||Cohort A1|Study Cohort A1 will include patients with unresectable and/or metastatic melanoma and an activating BRAF mutation in the tumor who were treated with vemurafenib + cobimetinib + atezolizumab, either newly diagnosed or progressing during previous lines of therapy. Initiation of vemurafenib + cobimetinib + atezolizumab would be considered an index event.
89397010|NCT05402059||Cohort B|Study Cohort B will include patients with stage III equivalent skin melanoma (i.e., regional lymph node involvement), regardless of tumor BRAF mutation, who have undergone surgery (lymphadenectomy, SLNB, or metastasectomy) and/or initiated or planned treatment according to any of the drug therapy regimens or only dynamic observation, in accordance with current clinical guidelines. Surgery for stage III melanoma will be considered an index event.
89397011|NCT05402059||Cohort C|Study cohort C will include patients with stage 0-II equivalent skin melanoma (i.e., no regional lymph node involvement), regardless of BRAF mutation in the tumor, who have undergone surgery (excision of the primary tumor +/- SLNB) and/ or initiated or planned treatment for any of the drug regimens or only dynamic observation, in accordance with current clinical guidelines. Surgical treatment (operation) for stage 0-II melanoma will be considered an index event.
89397012|NCT05402059||Cohort D|Study cohort D will include patients with stage 0-IV non-cutaneous melanoma, regardless of the BRAF mutation in the tumor, who underwent morphological verification of the diagnosis, surgery (any volume) and / or treatment initiated or planned for any of the drug therapy regimens or only dynamic observation, in accordance with current clinical guidelines. Initiation of therapy according to the regimen that will be used at the time of signing of informed consent or surgical treatment will be considered an index event.
89397013|NCT02142764|Experimental|Multiple Sclerosis|Human Leukocyte Antigen (HLA)-A2 patients whose Multiple Sclerosis has just been diagnosed
89397014|NCT02142764|Other|Control|HLA-A2 patients hospitalized in the neurology department who are not affected with a neuroimmunological disorder
89397015|NCT02142764|Experimental|Multiple Sclerosis patients treated|HLA-A2 Multiple Sclerosis patients treated by Natalizumab therapy
88873192|NCT03646812|Experimental|Jasmine rice|63g of rice cook with 150g of water. Served and consume immediately.
88873193|NCT03646812|Experimental|Asian Noodles|92.4g of Asian Noodles cook in boiling water for 45 seconds. Drained and consume immediately
88873194|NCT03639935|Experimental|Rucaparib and Nivolumab|Rucaparib 600 mg PO BID days 1-28 Nivolumab 240 mg IV days 1 and 15
88873195|NCT03624231|Experimental|Arm 1 - stopped after interims analyses|"Patients in arm 1 will receive a single dose of durvalumab of 1500 mg administered on day 1, 14 days prior to initiation of the radiotherapy.~Radiotherapy with 35 fractions over 7 weeks (administered as daily fractions of 2 Gy given 5 days every week for 7 weeks) will start on day 14. On week 5, 9, 13 and 17 patients will receive durvalumab (1500 mg) and tremelimumab (75 mg) for up to 4 doses/cycles and then continue 1500 mg durvalumab q4w starting on week 21 to complete a total of 12 months of therapy (overall 9 single doses durvalumab including the initial dose on day 1)."
88873196|NCT03624231|Experimental|Arm 2|"Patients in arm 2 will receive durvalumab (1500 mg) q4w starting on day 1. Radiotherapy with 35 fractions over 7 weeks (administered as daily fractions of 2 Gy given 5 days every week for 7 weeks) will start on day 14.~Overall patients will receive treatment with durvalumab mono up to a total of 12 months (up to 13 doses in total)."
88873197|NCT03603405|Experimental|Experimental: ADV/HSV-tk (gene therapy)|"Experimental: ADV/HSV-tk (gene therapy)~The gene therapy investigational product, HSV-tk will be injected during the surgery. Within 24 hours valacyclovir will be given for 14 days. Radiotherapy will be administered over 30 sessions (over 6 weeks) starting within 9 days of surgery. Standard of care/routine chemotherapy will be started concurrent with the radiotherapy dependent on patient status based on best clinical judgment following the Stupp protocol.~Patient can receive second treatment of HSV-tk after 6 months."
88873198|NCT03596086|Experimental|ADV/HSV-tk (gene therapy)|"The gene therapy investigational product, HSV-tk will be injected during the surgery. Within 24 hours valacyclovir will be given for 14 days. Radiotherapy will be administered over 10 sessions (over 2 weeks) starting within 9 days of surgery. Standard of care/routine chemotherapy will be started concurrent or after completion of the radiotherapy dependent on patient status based on best clinical judgment.~Patient can receive second treatment of HSV-tk after 6 months"
88873199|NCT03564509|Experimental|FE 999302 (1 μg) and follitropin delta|
88873200|NCT03564509|Experimental|FE 999302 (2 μg) and follitropin delta|
88873201|NCT03564509|Experimental|FE 999302 (4 μg) and follitropin delta|
88873202|NCT03564509|Experimental|FE 999302 (8 μg) and follitropin delta|
88873203|NCT03564509|Experimental|FE 999302 (12 μg) and follitropin delta|
88873204|NCT03564509|Placebo Comparator|Placebo and follitropin delta|
89397016|NCT03631069||Dementia|People with hospital episode statistics labels of dementia
89397017|NCT03631069||Normal|
89397018|NCT02146742|Experimental|1. ASP1707 lowest dose|
89397019|NCT02146742|Experimental|2 ASP1707 higher dose|
89187855|NCT00782613|Active Comparator|1|Two psoriatic plaques of similar surface area and severity will be identified for each subject. ALT-2074 will be applied topically twice daily to 1 of the 2 target plaques, and the placebo control to the other plaque for a period of 28 days in amounts sufficient to cover the entire surface area of the target plaque, extending to 1 cm outside of the plaque border.
89187856|NCT00782613|Placebo Comparator|2|Placebo
89397020|NCT02146742|Experimental|3. ASP1707 Highest dose|
89397021|NCT05344495|Active Comparator|hyalse group|ultrasonographic median nerve hydrodissection by hyalase and bupivacaine 0.5%
89397022|NCT05344495|Active Comparator|midazolam group|ultrasonographic median nerve hydrodissection by midazolam and bupivacaine 0.5%
89397023|NCT05079386|Experimental|New Voice Prosthesis|Patients will use the New Voice Prosthesis for two weeks to investigate short term feasibility and explore limitations and advantages. If the patient wishes to leave the New Voice Prosthesis in situ, this will be allowed under the condition that the subject agrees to remain in the study and report (adverse) events on an ongoing basis, until the device is removed after a maximum of 12 months.
89397024|NCT01590355|Active Comparator|Radiotherapy plus or minus Chemotherapy|Radiotherapy plus or minus chemotherapy with surgical treatment for salvage of persistent disease
89397025|NCT01590355|Experimental|Transoral Robotic Surgery + Neck Dissection|Transoral robotic excision will be carried out using the da Vinci surgical robot. The spatula cautery will be used to remove the tumours with 1 cm margins. At the time of surgery circumferential margins will be taken and sent for frozen section analysis. The resection will proceed until negative margins are obtained if feasible.
89397026|NCT05960565|Experimental|Glucagon|Micro dose of glucagon is aded at the insulin injection site
89397027|NCT05960565|No Intervention|Control|Insulin injected without any glucagon
89397028|NCT05960539||robotic procedures|surgical residents and experts; differentiation due to organ systems
89397029|NCT05960526|Active Comparator|nasal irrigation with Saline group|The patient uses nasal irrigation with saline only and then mixed with 300 ml of water. The treatment was done by tilting the head 45 degrees, then spraying 150 ml of liquid on one side and repeating it on the other. The treatment was done twice daily (morning and evening) for 14 days.
89397030|NCT05960526|Experimental|nasal irrigation with Saline combination with binahong extract|The patient uses nasal irrigation with saline and combination with Binahong Extract 2,5% and then mixed with 300 ml of water. The treatment was done by tilting the head 45 degrees, then spraying 150 ml of liquid on one side and repeating it on the other. The treatment was done twice daily (morning and evening) for 14 days.
89397031|NCT05960487||The patients with a significant decrease in pain severity|Evaluation will be done separately in the 3rd week and 3rd month follow-up periods of the cervical epidural steroid injection. Numerical rating scale (NRS) will be used to evaluate pain severity. A reduction of at least 50 percent in the NRS score will be considered significant.
89397032|NCT05960487||Patients without significant decrease in pain severity|Evaluation will be done separately in the 3rd week and 3rd month follow-up periods of the cervical epidural steroid injection. Numerical rating scale (NRS) will be used to evaluate pain severity. A reduction of at least 50 percent in the NRS score will be considered significant.
89397033|NCT05960435|Experimental|PNF group|Patients in the PNF group will deliver PNF stretching, active-assistive ROM exercises, PNF scapular patterns mobilization, posterior capsule stretching, and isometric strengthening for 3 weeks. Between 3-6 weeks PNF stretching and scapular mobilization exercises will progress and PNF strengthening and active ROM exercises will add to the program.
89397034|NCT05960435|Active Comparator|Control group|Patients in the conservative group will deliver shoulder muscle static stretching, active-assistive ROM exercises, scapular mobilization, posterior capsule stretching, and isometric strengthening for 3 weeks. Between 3-6 weeks these exercises will progress and shoulder muscles strengthening via NMES and active ROM exercises will add to the program.
89397035|NCT05960409||blunt chest trauma patients|patients with chest injuries due to a blunt trauma
89397036|NCT05960409||penetrating chest trauma patients|patients with chest injuries due to penetrating trauma
89397037|NCT05960409||polytraumatized patients|patients with multible traumas beside the chest injury
89397038|NCT05960409||chest trauma only patients|patients with only chest injuries
89397039|NCT05960396|Experimental|balanced diet|Carbohydrates 50% -65%, fats 20% -30%, and proteins 10% -15%.
89397040|NCT05960396|Experimental|Low-carbohydrate diet|Carbohydrates 20% -40%, fats 30% -45%, and proteins 30% -40%.
89397041|NCT05960383||Lung transplant patients|53 patients who receive lung transplant and undergo microbiologic assessment with BioFire Pneumonia Panel Plus and conventional culture
89397042|NCT05960370||"exposed or compaction group"|103 women with a decrease of ≥ 5% in endometrial thickness between the estrogenic phase (ovulation induction day) and the day of embryo transfer (7 days after ovulation induction).
89397043|NCT05960370||"non-exposed non-compaction group"|103 women with similar or greater endometrial thickness between the estrogenic phase (ovulation induction day) and the day of embryo transfer (7 days after ovulation induction).
89397044|NCT05960357|Experimental|Informed group during Ultrasound Examination|Before starting the detailed USG examination for the experimental group, Personal Information Form and State-Anxiety Inventory will be filled. While informing about the fetus during the USG examination, the pregnant woman will be informed by using the physical images of the fetus (hand, arm, face, heartbeat, information about the internal organs, etc.) using the USG screen. After the USG is completed, the State-Anxiety Inventory will be filled again as a final test.
89397045|NCT05960357|No Intervention|Control group|In the control group, the Personal Information Form and the State-Anxiety Inventory will be filled before the USG procedure, and only the State-Anxiety Inventory after the USG procedure. After the data collection process is completed, the pregnant woman will be informed about the USG results.
89397046|NCT05960331|Experimental|Self-control group|Participants will be able to choose over feedback schedule when practicing finger-pressing trajectory matching task.
89397047|NCT05960331|Active Comparator|Yoked group|Participants will receive feedback, which was determined by their counterpart in self-control group, with no-choice when practicing finger-pressing trajectory matching task.
89397048|NCT05960279||Training group|The head CT findings from this patient group will be used to teach the MD100 how to interpret its scan of the patients.
89397049|NCT05960279||Testing group|Once sufficient training data has been obtained, subsequent head CT findings from patients enrolled into the study will be used to test the accuracy of the MD100
89397050|NCT05960266|Active Comparator|Subcutaneous immunotherapy|"Subcutaneous injection of grass-rye pollen allergen extract and micro-crystalline tyrosine.~Single dose of 2000 U allergen in 0.5 ml. Dosage form: aqueous suspension."
89397051|NCT05960266|Experimental|Intralymphatic immunotherapy|"Subcutaneous injection of grass-rye pollen allergen extract and micro-crystalline tyrosine.~Single dose of 400 U allergen in 0.1 ml. Dosage form: aqueous suspension."
89397052|NCT05960227|Experimental|Iron dextran IV|In patients with acute renal damage, they will be aleatorized to receive the administration of intravenous iron dextran 1200mg in 1 single exhibition compared to placebo.
89397053|NCT05960227|Placebo Comparator|Placebo|In patients with acute renal damage, they will be aleatorized to receive the administration of placebo.
89397054|NCT05960214||13 pts with BC+TM|Patients diagnosed with breast cancer and thalassemia minor
89397055|NCT05960214||13 pts with BC|Patients diagnosed with breast cancer for comparison.
89397056|NCT05960201|Experimental|invasive lobular breast cancer|images for 90 minutes after F-18 FES injection
89397057|NCT05960149|Experimental|Group using Indocyanine Green|Performing nerve-sparing robot-assisted laparoscopic radical prostatectomy by IV injecting of Indocyanine Green
89397058|NCT05960149|Experimental|The Indocyanine Green -unused group|Nerve-sparing robot-assisted laparoscopic radical prostatectomy without the use of Indocyanine Green
89397059|NCT05960123|Active Comparator|Group with Spongioplasty|patients underwent TIPU with spongioplasty-Dartosoraphy reinforcement
89397060|NCT05960123|Active Comparator|Group without Spongioplasty|patients underwent TIPU with dorsal dartos flap interposition without spongioplasty
89397061|NCT05960110|Experimental|Test Group|Fluoride toothpaste and fluoride varnish
89397062|NCT05960110|Sham Comparator|Control Group|Fluoride toothpaste
89397063|NCT05960071|Active Comparator|Group S|patients received protective lung strategy with recruitment manoeuvre (RM) every 30 minutes and steady PEEP (10) cm H2O in between RM till end of surgery.
89397064|NCT05960071|Active Comparator|Group D|patients received protective lung strategy with recruitment manoeuvre (RM) every 30 minutes and decreasing PEEP (15, 10, and 5) cm H20 (10 minutes for each level) in between RM till end of surgery.
89397065|NCT05960058||Cases (Autologous Haematopoietic Stem Cell Transplantation (AHSCT))|Systemic Sclerosis (SSc) patients treated by AHSCT and actively followed at Saint Louis on January 1st, 2021
89397066|NCT05960058||Controls (without Autologous Haematopoietic Stem Cell Transplantation)|Systemic Sclerosis (SSc) patients treated by AHSCT and actively followed at Saint Louis on January 1st, 2021
89397067|NCT05960045|Active Comparator|Patients receiving direct milk antigen (Group A)|Patients with cow milk protein allergy after 6 month of elimination diet will receive direct milk antigen and will be followed up for 2 months for the development of any symptoms of milk intolerance
89397068|NCT05960045|Active Comparator|Patients subjected to gradual reintroduction of milk through a milk ladder (Group B)|Patient with cow milk protein allergy after 6 month of elimination diet will be offered indirect milk antigen through a ladder starting by baked milk products and will be followed up for also for 2 months to detect any symptoms of intolerance.
89397069|NCT05960006||Ceftriaxone|Patiënts with liver cirrhosis receiving ceftriaxone treatment.
89397070|NCT05959967|Experimental|Vestibular Rehabilitation Exercises (VRE)|The VRE arm will be engaged in vestibular exercises including gaze stabilization, balance, and gait training.
89397071|NCT05959967|Active Comparator|General Fitness Training (GFT)|The GFT arm will participate in general fitness exercises including cardiovascular, strength, and flexibility training.
89397072|NCT05959954||Carpal Tunnel Syndrome (CTS) Patients|Adults with clinical and electrodiagnostic evidence of carpal tunnel syndrome.
89397073|NCT05959889|Placebo Comparator|Placebo Group|group (A) will recieved placebo tablet.
89397074|NCT05959889|Active Comparator|Motelukast Group|Patients will receive motelukast 10 mg for 4 cycles of AC.
89397075|NCT05959863||Primary Aldosteronism Group|Patients diagnosed with primary aldosteronism
89397076|NCT05959863||Essential Hypertension Group|Patients diagnosed with essential hypertension
89397077|NCT05959824|Experimental|Group 1|Treatment with OR-AT0222
89397078|NCT05959824|Placebo Comparator|Group 2|Treatment with Placebo
89397079|NCT05959798||High power short duration ablation|
89397080|NCT05959798||Moderate power long duration ablation|
89397081|NCT05959785|Experimental|intervention group|Assignment to the intervention group will be done by simple randomization of the sample. A random sequence of numbers will be generated using the statistical program SPSS v.28. Patients will be included in the intervention group of each subcategory if their subject number matches one of the random numbers generated.The intervention groups will receive an explanatory video where a study collaborator performs a series of abdominal or diaphragmatic breathing exercises, which are intended to assess their effectiveness in this clinical trial.
89397082|NCT05959785|Placebo Comparator|control groups|The patients belonging to the control groups of each subcategory will also receive an explanatory video with basic and light cervical mobilization exercises (Annex 12). This group of exercises will be made up of a series of cervical mobilization exercises that are performed without pain, smooth, controlled by the patients, and without forcing the angulations. They are performed seated, with the arms extended along the body and forearms and hands resting on the legs. The chair must be firm and comfortable. Head movements to the right and left, right and left lateral flexion of the cervical region, cervical flexion and extension will be performed. This exercise will be performed for 5 minutes 3 times a day and beginning in the first 24 postoperative hours.
89397083|NCT05959772|Experimental|Photobiomodulation ON|Photobiomodulation therapy Group PBM Application of Photobiomodulation exposure time between 4 and 9 minutes, application of PBM with treatment time of 5 weeks
89397084|NCT05959772|Placebo Comparator|Photobiomodulation Off|Photobiomodulation Placebo Group Appication of Photobiomodulatio off, time between 4 and 9 minutes, to 5 weeks
89397085|NCT05959759|Experimental|Dimethyl fumarate|dimethyl fumarate enteric capsule (the initial dose is 120 mg twice a day, and after 7 days, the dose will be increased to the maintenance dose of 240 mg twice a day, for 6 months)
89397086|NCT05959759|Placebo Comparator|Placebo|placebo with the same appearance (color, taste, size, shape)
89397087|NCT05959681|Experimental|Study Cohort|A cohort of 60 biological females who volunteered to be part of the 6 months study.
89397088|NCT05959668||Children, adolescents and young adults with cystinosis and their parents|"Depending on the patient's age, different HrQoL aspects are more relevant in cystinosis patients and their families. Therefore, a division based on age groups is needed to measure and interpret HrQoL measures successfully:~Age group stratification will include young patients aged 8-12, 13-17 and 18-26 for a self-reported version and children and adolescents aged 0-4, 5-7, 8-12, 13-17, 18-26 for a parent-reported version."
89397089|NCT05959616|Experimental|Group 1 Shigella sonnei 53G 1500CFU (N=10)|"Dose finding group~Group 1 will receive lyophilised S. sonnei 53G strain at a dose of 1500CFU.~Group 1 will receive curative treatment of Ciprofloxacin."
89397090|NCT05959616|Experimental|Group 2 Shigella sonnei 53G 2000CFU (N=10)|"Dose finding group~Group 2 will receive lyophilised S. sonnei 53G strain at a dose of 2000CFU.~Group 2 will receive curative treatment of Ciprofloxacin."
89535478|NCT03206281||Clinical fetal weight estimation|The fetal weight estimation will be taken by professional obstetrician durin her 39 week
88873205|NCT03556384|Experimental|TMZ 85 mg/m2 mg orally|"TMZ 85 mg/m2 mg orally once for 21 days followed by 7 days without treatment in 28 day cycles.~Treatment will continue for 6 months (with option to continue if benefiting treatment) or until disease progression or unacceptable toxicity (whichever occurs first). All patients will have regular evaluations for assessment of safety parameters. Temozolomide dose may be held and/or modified for the management of adverse treatment effects according to pre-specified criteria. Patients will have radiographic imaging (CT or MRI) every 8 weeks to assess tumor resection.~An end of treatment visit for clinical evaluations and safety assessments will be performed approximately 28 days after the last dose of study drug. Patients discontinuing study treatment will be followed every 3-6 months for disease recurrence and survival."
88873206|NCT03507894||m-health stroke rehabilitation|8-week multimodal exercise rehabilitation program (MERP) based on aerobic exercise, task oriented activities, balance and stretching exercises complemented with a mobile app technology
88873207|NCT03483597||rheumatologists|Inclusion criteria: Registered rheumatoid specialist physicians subordinated to the 12 designated hospitals The Treatment Satisfaction Questionnaire for Medication (TSQM-II) will be used in rheumatologists.
89187857|NCT00440947|Other|Simplification|Atazanavir (ATV) 400 mg QD + abacavir (ABC) 600 mg/lamivudine (3TC) 300 mg fixed dose combination (FDC) QD for 48 weeks followed by optional treatment extension for 60 weeks on the same regimen.
89187858|NCT00440947|Other|Continuation|Atazanavir (ATV) 300 mg QD + ritonavir (/r) 100 mg QD + abacavir (ABC) 600mg/lamivuidine (3TC )300 mg FDC QD for 48 weeks followed by optional treatment extension for 60 weeks on the same regimen.
89187859|NCT00790881|Other|Antiretroviral-naive|Antiretroviral-naive included as control group
89187860|NCT00790881|Active Comparator|Nevirapine-based antiretroviral therapy|Nevirapine-based antiretroviral therapy
89187861|NCT00782691||Head-and-neck cancer patients.|Head-and-neck cancer patients eligible for therapeutic lymph node dissection of cervical nodes.
89187862|NCT01029769|Active Comparator|initial olanzapin|
89187863|NCT01029769|Active Comparator|initial amisulpride|
89187864|NCT01029769|Active Comparator|early responders|
89187865|NCT01029769|Active Comparator|early non-responders switched|
89187866|NCT01029769|Active Comparator|ealy non-responders non-switched|
89187867|NCT02557945|Experimental|Gabapentin|Gabapentin 3600mg PO daily
89187868|NCT02557945|Placebo Comparator|Placebo|Matching placebo PO daily
89187869|NCT03268070|Experimental|Repetitive TMS over contralateral premotor cortex|Location of repetitive Transcranial Magnetic Stimulation (rTMS): contralateral premotor cortex.
89187870|NCT03268070|Experimental|Repetitive TMS over ipsilateral premotor cortex|Location of repetitive Transcranial Magnetic Stimulation (rTMS): ipsilateral premotor cortex.
89187871|NCT03268070|Experimental|Repetitive TMS over contralateral primary motor cortex|Location of repetitive Transcranial Magnetic Stimulation (rTMS): contralateral primary motor cortex.
89187872|NCT03268070|Sham Comparator|Sham repetitive TMS over contralateral premotor cortex|Location of Sham repetitive Transcranial Magnetic Stimulation (rTMS): contralateral premotor cortex.
89187873|NCT03268070|Experimental|Single TMS over extensor carpi ulnaris spot of motor cortex|Location of single-pulse Transcranial Magnetic Stimulation (sTMS): extensor carpi ulnaris (ECU) hotspot of primary motor cortex (M1).
89187874|NCT00664521|Experimental|Rituximab Plus Atacicept|Rituximab will be administered as an intravenous infusion at a dose of 1000 mg at Weeks 1 and 3, followed by atacicept 150 mg subcutaneously once a week from Week 7 to 32.
89187875|NCT00664521|Placebo Comparator|Rituximab Plus Placebo|Rituximab will be administered as an intravenous infusion at a dose of 1000 mg at Weeks 1 and 3, followed by placebo matched to atacicept subcutaneously once a week from Week 7 to 32.
89187876|NCT02581046|Experimental|3 month surgical group|Phacoemulsification pediatric cataract surgery is performed at the age of 3 month of patients without IOL implantation.
89187877|NCT02581046|Experimental|6 month surgical group|Phacoemulsification pediatric cataract surgery is performed at the age of 3 month of patients without IOL implantation..
89187878|NCT02580890|Experimental|tDCS active|"Stimulation will be performed with the anode placed over the right DLPFC, and the cathode placed on the left DLPFC. The applied electric current will be 2mA and is going to be applied for 20 minutes. The electrodes have a size of 35cm ² each and will be covered by sponges soaked with saline. The stimulator to be used will be the Chattanooga Ionto ISO 13485. Stimulation will be performed for 5 days, one time per day."
89187879|NCT02580890|Sham Comparator|tDCS sham|For the sham tDCS, the same setting will be used. However, the current is going to be applied for only 30 seconds, not being able to induce effects on neuronal excitability.
89187880|NCT00664209|Other|Active-placebo|These subject receive treatment with active triple therapy followed by treatment with placebo therapy.
89187881|NCT00664209|Other|Placebo-active|These subject receive treatment with placebo therapy followed by treatment with active triple therapy.
89187882|NCT05254977||B.V. HOSPITAL|Local population in surrounding premises of site
89187883|NCT05254977||Baldia Hall Yazman|Local population in surrounding premises of site
89187884|NCT05254977||CIVIL HOSPITAL Bahahwalpur|Local population in surrounding premises of site
89187885|NCT05254977||DDHO KPT|Local population in surrounding premises of site
89187886|NCT05254977||Govt Girls Elementry School|Local population in surrounding premises of site
89187887|NCT05254977||Govt Higher Secondary School|Local population in surrounding premises of site
89187888|NCT05254977||Govt Sadiq Higher Secondary School|Local population in surrounding premises of site
89187889|NCT05254977||Govt TibIA College Bahawalpur|Local population in surrounding premises of site
89187890|NCT05254977||CEO Office DHA BWP|Local population in surrounding premises of site
89187891|NCT05254977||Papulation Welfare office APE|Local population in surrounding premises of site
89187892|NCT05254977||RHC Ballah Jhulan|Local population in surrounding premises of site
89187893|NCT05254977||RHC Channi Goth|Local population in surrounding premises of site
89187894|NCT05254977||RHC Choona wala|Local population in surrounding premises of site
89187895|NCT05254977||RHC Dera Bakha|Local population in surrounding premises of site
89187896|NCT05254977||RHC Headrajkan|Local population in surrounding premises of site
89187897|NCT05254977||RHC Khanqah sharif|Local population in surrounding premises of site
89187898|NCT05254977||RHC Khutri Banglow|Local population in surrounding premises of site
89187899|NCT05254977||RHC Kud Wala|Local population in surrounding premises of site
89187900|NCT05254977||RHC Lal Sohanra|Local population in surrounding premises of site
89187901|NCT05254977||RHC Mubarkpur|Local population in surrounding premises of site
89187902|NCT05254977||RHC Qaimpur|Local population in surrounding premises of site
89187903|NCT05254977||RHC Uch Sharif|Local population in surrounding premises of site
89187904|NCT05254977||Special Education Degree Colage|Local population in surrounding premises of site
89187905|NCT05254977||THQ HOSPITAL, AHMADPUR|Local population in surrounding premises of site
89187906|NCT05254977||THQ HOSPITAL, HASILPUR.|Local population in surrounding premises of site
89187907|NCT05254977||THQ KHAIR PUR TAMEWALI|Local population in surrounding premises of site
89187908|NCT05254977||THQ YAZMAN|Local population in surrounding premises of site
89187909|NCT05254977||TMA Office Hasilpur (NEW)|Local population in surrounding premises of site
89187910|NCT04074434||All Participants|
89187911|NCT03192332|Experimental|Direct mechanical thrombectomy|Treatment with direct mechanical thrombectomy with a commercially available stent-retriever revascularization device of the Solitaire™ type.
89187912|NCT03192332|Active Comparator|Combined intravenous thrombolysis and mechanical thrombectomy|Treatment with intravenous thrombolysis with recombinant tissue-type plasminogen activator (IV t-PA) followed by mechanical thrombectomy with a commercially available stent-retriever revascularization device of the Solitaire™ type.
89187913|NCT02555943|Active Comparator|Prophylactic/Early anti-HBV treatment|"HCV/HBV co-infection patients in this arm will receive nucleos(t)ides analog (Entecavir or Tenofovir disoproxil fumarate) for the treatment of hepatitis B infection before or at the commencement of direct anti-HCV treatment using DAAs (Ledipasvir/Sofosbuvir; or Sofosbuvir and Daclatasvir, or Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir; or Sofosbuvir+Ribavirin).~."
89187914|NCT02555943|Experimental|Deferred anti-HBV treatment|HCV/HBV co-infection patients in this arm will receive nucleos(t)ides analog (Entecavir or Tenofovir disoproxil fumarate) for the treatment of hepatitis B infection when HBV viral breakthrough occurred during anti-HCV treatment using DAAs (Ledipasvir/Sofosbuvir; or Sofosbuvir and Daclatasvir, or Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir; or Sofosbuvir+Ribavirin).
89187915|NCT00790959|Experimental|SASA!|
89187916|NCT00790959|Active Comparator|Control|
89187917|NCT02580812|Experimental|MONALISA 5-years old children|Clinical and neuropsychological evaluation procedure 90 children
89187918|NCT02580812|Active Comparator|EPIPAGE 5 -years old children|Cohort of prematurely borne children and their controls Clinical and neuropsychological evaluation procedure 270 children
89187919|NCT04047459||Patient undergoing prosthetic surgery|Patients undergoing surgery for the insertion of a hip prosthesis or a cruciate ligament reconstruction will be included. On those patients tissue samples collection and cells isolation will be performed
89187920|NCT00782847|Active Comparator|with DiaNe program|study subjects which participated in the DiaNe consultation and support program
89187921|NCT00782847|No Intervention|without DiaNe program|study subjects which received standard care by diabetologist and/or nephrologist
89187922|NCT00785967|Experimental|1|raltegravir 400mg bid + Truvada 1 tab qd
89187923|NCT00785967|Active Comparator|2|efavirenz 600mg qhs + Truvada 1 tab qd (or Atripla 1 tab qhs)
89187924|NCT03923504|Active Comparator|Physical Activity Intervention (PAI)|Tailored multi-level physical activity intervention (PAI) on exercise capacity, cardiovascular and cognitive function, health-related quality of life (QOL), strength and fatigue among lymphoma and breast cancer patients undergoing active treatment with anthracycline based chemotherapy (anthra-bC).
89187925|NCT03923504|Active Comparator|Healthy Living Control Group|Healthy living intervention (HLI) on exercise capacity, cardiovascular and cognitive function, health-related quality of life (QOL), strength and fatigue among lymphoma and breast cancer patients undergoing active treatment with anthracycline based chemotherapy (anthra-bC).
89187926|NCT02555553|No Intervention|Treatment as Usual|"The control group for the RCT will be a usual care condition in which participants are free to seek any assistance for their ED during the study period."
89187927|NCT02555553|Experimental|CBT-GSH with Noom Monitor|Participation will include 12 weeks of guided cognitive-behavioral therapy- guided self help (CBT-GSH) with an MA-level health coach or nutritionist from the KPNW health plan. Patients will use a self-help book, Overcoming Binge Eating (2013) by Christopher Fairburn. The first session will last 60 minutes, and each subsequent session lasts 20-25 minutes. The first four sessions are weekly, with the subsequent four twice monthly. Self-monitoring will be conducted through Noom Monitor and individuals will receive a specialized set of instructions on how to use the monitor. Therapists will also be asked to check feedback report on clients before each session.
89187928|NCT00786045|Experimental|Home Cycling Program|Participants will be given a time and intensity graded program at an intensity that is comfortable and tolerable for the individual. The individual will be encouraged to augment, gradually, either the time of cycling per day or the work of cycling, always keeping within the limits of comfort and tolerability. Participants will also be given a target heart rate threshold to try and meet but not to exceed. This will be based their response to the stress test and will most likely be between 50% and 70% of maximum age-predicted heart rate. The aim is to build up to one-half hour of cycling per day. All bicycles will be equipped with electronic monitoring of speed, distance, and heart rate.
89187929|NCT00786045|No Intervention|Control|The investigators have devised a series of mobility-related tasks that can be easily and safely carried out at home without ongoing professional supervision
89187930|NCT02631044|Experimental|JCAR017 1-dose schedule|Each cycle of JCAR017 (lisocabtagene maraleucel) will be administered as 1 intravenous (IV) injection
89187931|NCT02631044|Experimental|JCAR017 2-dose schedule (no longer accruing)|Each cycle of JCAR017 (lisocabtagene maraleucel) will be administered as 2 intravenous (IV) injections
89187932|NCT02580578||All Participants|Female patients who are diagnosed and treated for symptoms associated with their uterine fibroids per routine clinical practice. No intervention is administered in this study.
89187933|NCT02557412|Placebo Comparator|Conventional treatment|Hygiene and diet recommendations on sleep.
89397091|NCT05959616|Experimental|Group 3 Shigella sonnei 53G 2500CFU (N=10)|"Dose finding group~Group 3 will receive lyophilised S. sonnei 53G strain at a dose of 2500CFU.~Group 3 will receive curative treatment of Ciprofloxacin."
89397092|NCT05959616|Experimental|Group 4 Shigella sonnei 53G 3000CFU (N=10)|"Dose finding group~Group 4 will receive lyophilised S. sonnei 53G strain at a dose of 3000CFU.~Group 4 will receive curative treatment of Ciprofloxacin."
89397093|NCT05959616|Experimental|Group 5 Shigella sonnei 53G TBDCFU (N=15)|"Dose verification group~Group 5 will receive lyophilised S. sonnei 53G strain at a dose TBD.~Group 5 will receive curative treatment of Ciprofloxacin."
89397094|NCT05959616|Experimental|Group 6 Shigella sonnei 53G TBDCFU (N=15)|"Dose verification group~Group 6 will receive lyophilised S. sonnei 53G strain at a dose TBD.~Group 6 will receive curative treatment of Ciprofloxacin."
89397095|NCT05959603|No Intervention|Standard of care|2 g of IV cefazolin will be administered within 60 minutes before surgical incision (3 g for pts weighing ≥120 kg), repeated dose in the operating room every four hours (allergic patients will receive 900 mg of clindamycin within 60 minutes which will be repeated every six hours or 15 mg/kg of vancomycin once within two hours before incision).
89397096|NCT05959603|Experimental|Intervention group: 500 mg vancomycin|Patients will receive 500 mg of powdered vancomycin to the surgical site in addition to standard of care IV prophylaxis
89397097|NCT05959603|Experimental|Intervention group: 1 g vancomycin|Patients will receive one gram of powdered vancomycin to the surgical site in addition to standard of care IV prophylaxis
89397098|NCT05959590|Experimental|study group|Patients will receive Ferumoxides 11.2Mg Solution for Injection.
89397099|NCT05959577|Experimental|Ferguson hemorrhoidectomy|The patients who meet the inclusion and exclusion criteria in this group will undergo Ferguson hemorrhoidectomy
89397100|NCT05959577|Active Comparator|Stapled hemorrhoidopexy with anoplasty|The patients who meet the inclusion and exclusion criteria in this group will undergo Stapled hemorrhoidopexy with anoplasty
89397101|NCT05959551|Experimental|left DLPFC stimulation|HD-tDCS will be used to deliver direct current to the target via rubber electrodes and HD-tDCS gels. The 9 electrodes (8 channels + 1 ground) positions and current intensity will be determined based on computer simulation using HDTargets software (Soterix Inc.) that results in maximum focal current on the left dorsolateral prefrontal cortex (DLPFC; x=-44, y=10, z=30) with inward field orientation. The peak current will not exceed 2 mA. A constant current will be delivered for 20 minutes.
89397102|NCT05959551|Experimental|right DLPFC stimulation|HD-tDCS will be used to deliver direct current to the target via rubber electrodes and HD-tDCS gels. The 9 electrodes (8 channels + 1 ground) positions and current intensity will be determined based on computer simulation using HDTargets software (Soterix Inc.) that results in maximum focal current on the right dorsolateral prefrontal cortex (DLPFC; x=+42, y=+14, z=+30) with inward field orientation. The peak current will not exceed 2 mA. A constant current will be delivered for 20 minutes.
89397103|NCT05959551|Experimental|left IPL stimulation|HD-tDCS will be used to deliver direct current to the target via rubber electrodes and HD-tDCS gels. The 9 electrodes (8 channels + 1 ground) positions and current intensity will be determined based on computer simulation using HDTargets software (Soterix Inc.) that results in maximum focal current on the left intraparietal lobe (IPL; x=-50, y=-36, z=+42) with inward field orientation. The peak current will not exceed 2 mA. A constant current will be delivered for 20 minutes.
89397104|NCT05959551|Experimental|VLPFC-PCC stimulation|HD-tDCS will be used to deliver direct current to the target via rubber electrodes and HD-tDCS gels. The 9 electrodes (8 channels + 1 ground) positions and current intensity will be determined based on computer simulation using HDTargets software (Soterix Inc.) that results in maximum focal current on the left ventrolateral prefrontal cortex (VLPFC; x=-50, y=+26, z=+8) and posterior cingulate cortex (PCC; x=1, y=-61, z=38) with inward field orientation. The peak current will not exceed 2 mA. A constant current will be delivered for 20 minutes.
89397105|NCT05959551|Sham Comparator|Sham stimulation|One of the above three targets will be randomly selected. The current will be applied for 30 seconds ramp-up followed by 30 seconds ramp-down.
89397106|NCT05959525||Ovoid dental arch|
89397107|NCT05959525||Square dental arch|
89397108|NCT05959525||Tapered dental arch|
89397109|NCT05959460||1|This is an observation study to determine exclusive breastfeeding practice. Mother-child pairs were enrolled at 3 months ± 7d and were followed-up at 6 months ± 7d. Questionnaire was administered. Then, baseline saliva samples were collected and deuterium oxide dose was administered. Then, post-dose saliva samples were collected.
89397110|NCT05959408|Experimental|men who have sex with men|
89397111|NCT05959382|No Intervention|with no magnification aid treatment|Dental caries treatment with no magnification aid
89397112|NCT05959382|Active Comparator|with x2 dental loupe|Dental caries treatment with x2 dental loupe
88816746|NCT05545891|Placebo Comparator|Placebo|5mg once daily of placebo for three weeks, then 10mg once daily for the remaining three weeks.
89397113|NCT05959382|Active Comparator|with x5 dental loupe|Dental caries treatment with x5 dental loupe
89397114|NCT05959382|Active Comparator|with dental operation microscope|Dental caries treatment with dental operation microscope
89397115|NCT05959369|Experimental|elite kickboxer|athletes who have completed the age of 18 professionally, participating in fighting competitions and actively training
89397116|NCT05959304||brolucizumab 6 mg|brolucizumab 6 mg intravitreal injection
89530522|NCT03246919|Active Comparator|Intervention (Group B)|One bag of 500 ml 0.9% NaCl with 30 units of Oxytocin (Oxytocin solution) will be hung by Anesthesia when the fetal anterior shoulder delivers. After the placenta is delivered, then one bag of 500 ml 0.9% NaCl (normal saline) will be hung by Anesthesia. This amount of fluid is part of standard of care.
89530523|NCT04502537||Roxadustat|treatment with roxadustat
88816747|NCT05545891|Experimental|Aripiprazole|5mg once daily of aripiprazole for three weeks, then 10mg once daily for the remaining three weeks.
88816748|NCT05545007|Experimental|HSRS pre-operative|"Patients undergo HSRS (hypofractionated Radiosurgery) on day 1, consisting in 27 Gray (gy) administered in 3 daily fractions.~Within 1 weeks, patients undergo surgical resection."
88816749|NCT05545007|Active Comparator|HSRS post-operative|Patients undergo surgical resection on day 1. Within 4-6 weeks, patients undergo HSRS (hypofractionated Radiosurgery), consisting in 27 Gray (gy) administered in 3 daily fractions.
89397117|NCT05959265|Experimental|Arm1|Patients in the treatment group will undergo a 12-week intervention consisting of three 30-minute walking exercises per week during their standard cancer treatment. A personalized walking plan using fitness trackers will be provided to record each patient's daily average heart rate, step count, and additional steps and heart rate during the three 30-minute walking exercises per week to assess their activity levels. Weekly collaborations between the principal investigator and each participant will be conducted to assess step-related parameters.
89397118|NCT05959265|No Intervention|Arm2|Patients in the control group will receive standard cancer treatment and will not be instructed to avoid exercise. They will also be provided with fitness trackers to record their daily average heart rate and step count to evaluate their daily activity level. Furthermore, participants will be retrospectively asked about their physical activity during the intervention period at the end of the intervention phase.
89397119|NCT05959226|Experimental|Exercise and Enteral Nutrition Intervention|A comprehensive postoperative management combined physical exercise intervention with oral nutritional support
89397120|NCT05959226|Active Comparator|Enteral Nutrition Intervention|The control group will not receive exercise intervention, but will receive postoperative nutritional support treatment with the same standards as the experimental group.
89397121|NCT05959187|Experimental|Pharmacogenomic testing group|In the pharmacogenomic testing group, patients underwent collection of oral mucosal epithelial cells for common psychiatric drug gene testing, the clinical doctors were required to combine the patients' symptom characteristics with their own clinical experience and refer to the results of pharmacogenomic testing to guide drug treatment.
88816750|NCT05528458|Experimental|Osimertinib|Subjects should continue on study treatment until objective disease progression, or for three years since osimertinib administration. If progression of remaining GGN on serial CT scan, patients will receive proper treatment for progressed GGN.
89003955|NCT03924440||PDG Test strip Users|"Participants were asked to predict ovulation by monitoring changes in cervical mucus and/or tracking luteinizing hormone (LH) via home test kits. Participants were asked to self-report their peak fertility day, which was defined as the first LH surge day and/or day of peak cervical mucus (stretchy and eggwhite in consistence).~Participants collected first morning urine as various times during their cycle, including, prior to, during, and after peak fertility signs were observed. Participants were provided PDG rapid response test strips and self-administered their tests and recorded their results. Test results were reported back researchers via a log sheet. Log sheets recorded testing date, day of cycle, date of peak fertility (if known), personal assessment of results (positive result vs negative result) and a place to tape the completed test strip."
89397122|NCT05959187|No Intervention|Control|In the control group, patients did not undergo pharmacogenomic testing, and the clinical doctors were required to provide drug treatment based on their own diagnostic and therapeutic experience and the patients' symptom characteristics.
89397123|NCT05959174|Active Comparator|3d printed appliance|
89397124|NCT05959174|Active Comparator|side chair appliance|
89397125|NCT05959161||improvement and no improvement|We observed whether the symptoms of patients improved after DBS surgery and divided them into groups.
89397126|NCT05959161||imp+ and imp-|
89397127|NCT05959148|Experimental|MIRE group|Participants in this group underwent MIRE application in addition to the traditional physical therapy program
89003956|NCT03921528|Experimental|Cohort 1|Ambulatory Type 3 SMA
89003957|NCT03921528|Experimental|Cohort 2|Type 2 SMA / Non-Ambulatory Type 3 SMA
89003958|NCT03921528|Experimental|Cohort 3|Type 2 SMA
89003959|NCT03912987||Affected|Affected with ALS or a related disorder, including ALS-FTD, FTD, PLS, and PMA.
89003960|NCT03912987||Healthy Controls|Those never diagnosed with and not at particular risk for developing ALS or a related disorder.
89003961|NCT03911128||Participants with newly diagnosed ALL|
89003962|NCT03909893|Experimental|Adaptive Radiation Therapy|
89003963|NCT03908463||The patients who undergo percutaneous coronary intervention|The patients who undergo percutaneous coronary intervention will be enrolled.
89397128|NCT05959148|Active Comparator|Control|Participants in this group received the traditional physical therapy program only.
89397129|NCT05959122||group A|group (A) thirty-six non-anemic children
89397130|NCT05959122||group B|group (B) twenty five children with mild IDA
89397131|NCT05959122||Group C|group (C) 26 children with moderate
89397132|NCT05958992|Experimental|E-Liquid 1|Participants will self-administer an assigned e-liquid.
89397133|NCT05958992|Experimental|E-Liquid 2|Participants will self-administer an assigned e-liquid.
89397134|NCT05958992|Experimental|E-liquid 3|Participants will self-administer an assigned e-liquid.
89397135|NCT05958992|Experimental|E-liquid 4|Participants will self-administer an assigned e-liquid.
89397136|NCT05958992|No Intervention|No e-liquid|Participants will not receive an e-liquid to self-administer.
89397137|NCT05958979|Experimental|E-cigarette e-liquid 1|
89397138|NCT05958979|Experimental|E-cigarette e-liquid 2|
89397139|NCT05958979|Experimental|E-cigarette e-liquid 3|
89397140|NCT05958979|Experimental|E-cigarette e-liquid 4|
89397141|NCT05958979|Experimental|E-cigarette e-liquid 5|
89003964|NCT03889743|Experimental|Dexamethasone|
89003965|NCT03889743|Placebo Comparator|controls|
89003966|NCT03888105|Experimental|FL|Follicular lymphoma grade 1-3a cohort
89003967|NCT03888105|Experimental|DLBCL|Diffuse large B-cell lymphoma cohort
89003968|NCT03888105|Experimental|MCL|Mantle Cell Lymphoma cohort
89003969|NCT03888105|Experimental|MZL|Marginal Zone Lymphoma cohort
89003970|NCT03888105|Experimental|Other B-NHL|Other B-cell non-Hodgkin lymphoma cohort (excluding FL Grade 1-3a, DLBCL, MCL, MZL, Waldenström macroglobulinemia [WM]); Patients with a current diagnosis of mixed histology of B-NHL with an aggressive component (such as concurrent FL and DLBCL) will be allowed
89003971|NCT03847649|Active Comparator|Cohort 1: High Risk|
89003972|NCT03847649|Active Comparator|Cohort 2: Standard Risk - Arm A|
89003973|NCT03847649|Active Comparator|Cohort 2: Standard Risk - Arm B|
89397142|NCT05958979|Experimental|E-cigarette e-liquid 6|
89397143|NCT05958979|Experimental|E-cigarette e-liquid 7|
89397144|NCT05958979|Experimental|E-cigarette e-liquid 8|
89397145|NCT05958979|Experimental|E-cigarette e-liquid 9|
88816751|NCT05528458|No Intervention|Obsevation|Subjects with confirmation of pathologic stage IA NSCLC after surgery will be allocated to the control group.
89003974|NCT03840668|Experimental|Dry eye|Participants who will be using the USB-powered eye mask.
89187934|NCT02557412|Active Comparator|Intensive lifestyle intervention|Lifestyle intervention will consist of a structured intervention in a specific alimentary plan (carbohydrates: 40-45%; fats: 25-35% [saturated fats <7% monounsaturated fats up to 20% and polyunsaturated fats <10% ] and proteins: 15-20%), which will be repeated in each review. Also, be recommended to increase daily physical activity, setting a target walking 10,000 steps a day. To do this, to patients assigned to this treatment arm, will be provided with a pedometer and will asked to fill out a form with the steps that they walked each day. At each visit, the distance walked will be reviewed and the target set will be remarked.
89187935|NCT02557412|Active Comparator|Continuous positive airway pressure|Treatment with nasal continuous positive airway pressure (CPAP). Treatment begins with an empirical pressure of 8 centimetres of water (cmH2O) and in a period of three weeks, the pressure is adjusted by titration with an automatic positive airway pressure device (AutoSet II, ResMed).
89187936|NCT02542202|Experimental|Stereotactic body radiation therapy|Patients undergo stereotactic body radiation therapy on day 1 over 3 times a week for 28 days in the absence of disease progression or unacceptable toxicity.
89187937|NCT02487134|Placebo Comparator|Conventional abdominal wall closure|The aponeurosis is closed with continuous PDS 2/0 sutures, with self-locking anchor knots. The stitches are placed 5-8 mm from the wound edge, 4-5 mm apart.
89187938|NCT02487134|Active Comparator|Reinforcement with resorbable mesh|After closing the aponeurosis with PDS 2/0, a 7 cm wide TIGR Matrix Surgical Mesh is applied on the aponeurosis. The mesh is sutured to the aponeurosis with continuous PDS 2/0, with a wound to suture ratio of 1:4.
89187939|NCT00440557|Experimental|TIW: Epoetin alfa 3 injections Weekly/Once Weekly|Participants will be administered with epoetin alfa 3 times weekly for 22 weeks (initial subcutaneous (SC) dose 50 IU/kg), then once weekly, for 22 weeks (initial SC dose 10,000 IU)
89187940|NCT00440557|Experimental|QW: Epoetin alfa once weekly|Participants will be administered with epoetin alfa once weekly for 44 weeks (initial subcutaneous dose 10,000 IU).
89187941|NCT00440557|Experimental|Q2W: Epoetin alfa once every two weeks|Participants will be administered with epoetin alfa once every 2 weeks for 44 weeks (initial subcutaneous dose 20,000 IU).
89187942|NCT02528227|Experimental|Language Curriculum|The Language Intervention group will receive some of the known methods for early language development. Six lessons will include: Knowing your Baby, Reading Aloud, Sing-A-Long, Mimicking First Sounds, Language Game and Narrating Your Day. Parents will receive feedback every 2 weeks from a Language Environment Analysis digital language processor (LENA).
89187943|NCT02528227|Placebo Comparator|Health and Safety Curriculum|Parents will receive six lessons on important infant safety topics including, feeding safety, care seat safety, bath safety, back to sleep/SIDS prevention, taking a temperature and signs of infection, infection control methods and vaccine information. Parents will receive LENA feedback at discharge from NICU.
89187944|NCT01029847|Placebo Comparator|Placebo|
89187945|NCT01029847|Active Comparator|Adalimumab|TNF-alpha inhibitor
89187946|NCT02452268|Experimental|NIZ985|"Single treatment arm, dose escalation administered subcutaneously (SC) on MWF for 2 consecutive weeks.~Cycle length 28 days.~Occurrence of a dose-limiting toxicity (DLT) leads to the expansion to 6 subjects.~MTD is the dose prior to the dose level where ≥ 2/6 subjects have a DLT.~Following identification of the MTD / RDE, dose expansion will follow."
89187947|NCT02452268|Experimental|NIZ985 + PDR001|"The phase Ib dose escalation portion of the study will consist of a fixed dose (400 mg, IV infusion, Q4W) of PDR001 and escalating doses of NIZ985 (hetIL-15) to evaluate safety, tolerability and determine the MTD and/or RDE of the combination to be used in expansion cohorts.~On days when PDR001 and NIZ985 are administered on the same day, PDR001 will be administered first. NIZ985 will be administered after the PDR001 infusion has been completed.~Information on the preparation and administration of PDR001 is found in the PDR001 pharmacy manual."
89187948|NCT03872492|Experimental|Patients with Major Depressive Disorder|"Patients will be followed for 12 weeks. Hospital visits will be made at week 2 and week 6 (Phase1) as well as week 8 and week 12 (Phase 2).~At the end of phase 1 if the patient is considered as an responder he will make one more visit at week 12.~If the patient is considered as non-responder, he will make 2 other visits: at week 8 and week 12.~Between each visit, the patient will perform REDRESS application assessments every day for My daily survey and every 3 days for the other assessments."
89187949|NCT02524249|Active Comparator|Early caffeine group|55 newborns will be randomized to receive caffeine within 24 hours of life. They will receive 20mg/kg IV bolus followed by IV or PO 5mg/kg daily for the next 14 days. The clinical team may decide to give PO caffeine if the newborn tolerates >75% of fluid goals by feeds.
89187950|NCT02524249|Placebo Comparator|Late caffeine group|55 newborns will be randomized to receive a placebo (dextrose) in the first 24 hours of life. They will receive a 20mg/kg IV bolus followed by IV or PO 5mg/kg daily for the next 14 days. The clinical team may decide to give the placebo orally is the newborn tolerates >75% of fluid goals by feeds.
89187951|NCT01033981||Central America and Caribbean|Dominican Republic, Guatemala, Panama, Costa Rica, Honduras, Trinidad & Tobago
89397146|NCT05958979|Experimental|E-cigarette e-liquid 10|
89397147|NCT05958979|Experimental|E-cigarette e-liquid 11|
89397148|NCT05958979|Experimental|E-cigarette e-liquid 12|
89397149|NCT05958979|Experimental|E-cigarette e-liquid 13|
89397150|NCT05958979|Experimental|E-cigarette e-liquid 14|
89397151|NCT05958979|Experimental|E-cigarette e-liquid 15|
89397152|NCT05958979|Experimental|E-cigarette e-liquid 16|
89397153|NCT05958979|Experimental|E-cigarette e-liquid 17|
89397154|NCT05958979|Experimental|E-cigarette e-liquid 18|
89397155|NCT05958979|Experimental|E-cigarette e-liquid 19|
88873208|NCT03483597||patients|Inclusion criteria: Aged over 18, confirming RA for more than 6 months Exclusion criteria. Patients with Chinese reading comprehension barriers (unable to complete the questionnaire independently), without any RA treatment The Treatment Satisfaction Questionnaire for Medication (TSQM-II) will be used in patients.
89397156|NCT05958979|Experimental|E-cigarette e-liquid 20|
89397157|NCT05958966|Experimental|E-cigarette e-liquid 1|Participants will self-administer an e-cigarette e-liquid.
89397158|NCT05958966|Experimental|E-cigarette e-liquid 2|Participants will self-administer an e-cigarette e-liquid.
89397159|NCT05958966|Experimental|E-cigarette e-liquid 3|Participants will self-administer an e-cigarette e-liquid.
89397160|NCT05958966|Experimental|E-cigarette e-liquid 4|Participants will self-administer an e-cigarette e-liquid.
89397161|NCT05958966|No Intervention|No e-liquid|Participants do not receive an e-cigarette e-liquid to self-administer.
89397162|NCT05958953|Experimental|active management|early IOL within 8 hours of rupture of membranes. Center-specific IOL protocols will be used.
89397163|NCT05958953|No Intervention|Expectant management|monitoring until 24 hours from rupture of membranes, with subsequent induction of labor (IOL).
89397164|NCT05958940|Active Comparator|Light@Home|Standard Care - BLT in the home environment
89397165|NCT05958940|Experimental|LightCafé|BLT will be administered in a specialized cafe, under the supervision of clinical staff, promoting lifestyle changes and social interaction.
89397166|NCT05958940|Experimental|LightCafé+|Treatment will be identical to the second arm but now complemented with the use of blue-light blocking glasses in the evening and the adoption of personalized BLT timing based on sleep-wake patterns
89397167|NCT05958914|Experimental|Arm 1|"women with regular ovarian cycle. Patients, as per normal clinical practice, will undergo three blood draws in the follicular, ovulatory and luteal phases.~Biological samples will be analyzed for the concentration of neuropeptides (enkephalins, CGRP, SP and VIP)"
89397168|NCT05958914|Experimental|Arm 2|"non-PCOS women undergoing ovarian stimulation and ICSI treatment. Patients will undergo ovarian stimulation treatment with gonadotropins and egg retrieval. As part of this process, as per clinical practice, blood and follicular fluid sampling will be performed.~Biological samples will be analyzed for the concentration of neuropeptides (enkephalins, CGRP, SP and VIP)"
89530524|NCT04502537||erythropoietin|treatment with erythropoietin
89530525|NCT03246997|Other|Autumn Group|Intervention Group
88816752|NCT05519566|Experimental|Pulsed Fluoroscopy Retrograde Urethrogram|
88816753|NCT05519566|Active Comparator|Traditional Retrograde Urethrogram|
88816754|NCT05490706|Experimental|Bodyweight interval exercise|Performing 15 minutes of bodyweight interval exercise after dinner
88816755|NCT05490706|Experimental|Walking|Performing a 30 minute walk after dinner
88816756|NCT05490706|No Intervention|Non exercise control|Performing no exercise after dinner
88816757|NCT05489744|Experimental|125 mg [14C]Afuresertib|125 mg/150 µCi [14C]Afuresertib (125 mg of Afuresertib containing 150 µCi of [14C]Afuresertib)
88816758|NCT05467761|Experimental|Oral and IV psilocybin|Psilocybin with psychological support: Psilocybin will be administered in the form of capsules, taken orally with water, at one visit. Psilocybin will be administered through IV at the other visit.
88816759|NCT05454254|Active Comparator|Adults with Fontan circulation|Individualised muscle strengthening exercise training protocol.
88816760|NCT05454254|Active Comparator|Healthy controls|Individualised muscle strengthening exercise training protocol.
88816761|NCT05448014|Experimental|CFT group intervention|Compassion Focused Therapy in Group on the internet
88816762|NCT05448014|No Intervention|Control group|Waiting list
88816763|NCT05443919|Experimental|treatment group|The arm contains patients with acute pulmonary embolism who undergoing interventional therapy with transcatheter pulmonary embolectomy system which named 'TwiFlow-Thrombectomy Catheter System'
88816764|NCT05418361||ACEIs group|Patients suffer from cardiovascular diseases)controlled hypertension or heart failure ) taking ACE inhibitors
88816765|NCT05418361||ARBs group|Patients suffer from cardiovascular diseases)controlled hypertension or heart failure ) taking Angiotensin receptor blockers
88816766|NCT05418361||healthy|matched healthy controls
88816767|NCT05410548|Other|Standard-of-Care|Patient participants will receive routine standardized prosthetic follow-up care by a certified prosthetist, including evaluation of prosthesis use, prosthesis-enabled mobility, socket comfort and sock ply usage, falls, body anthropometrics, and functional mobility.
89187952|NCT01032811||Study Participants|St. Jude Children's Research Hospital patients from Leukemia, Neuro-Oncology, Radiation Oncology, and After Completion of Therapy (ACT) clinics.
89187953|NCT02430194|Experimental|lonafarnib/ritonavir - I|lonafarnib 100 mg BID + ritonavir 100 mg QD
89003975|NCT03837899|Experimental|Durvalumab / Tremelimumab Combination Therapy|"Part 1 (dose finding) Durvalumab + tremelimumab Combination Treatment. Durvalumab and tremelimumab are initially administered at dose level 1 and dose escalated based on results from PK modeling and tolerance to determine the RP2D. Both drugs are administered every 4 weeks as intravenous infusions. Tremelimumab is only administered with durvavalumab for 4 doses, from cycles 2-5. (sarcoma, NB and NHL)~Part 2 (dose expansion phase) Durvalumab + tremelimumab Combination Treatment. Durvalumab and tremelimumab are administered at the RP2D, every 4 weeks as intravenous infusions. Tremelimumab is only administered with durvalumab for 4 doses, from cycles 1-4. Tremelimumab may be added for 4 doses at time of progressive disease. Cohorts: solid tumors, sarcomas, NHL restricted to PMBCL and ALCL subtypes)"
89003976|NCT03834883|Experimental|Postmenopausal women: Progesterone|Subjects will receive treatment with oral progesterone 400 mg once daily (two x 200 mg capsules) every evening for 7 days
89003977|NCT03834883|Placebo Comparator|Postmenopausal women: Placebo|Subjects will receive oral placebo, two capsules once daily every evening for 7 days
89003978|NCT03834883|Experimental|Premenopausal women: Progesterone|Subjects will receive treatment with oral progesterone 400 mg once daily (two x 200 mg capsules) every evening for 7 days
89003979|NCT03834883|Placebo Comparator|Premenopausal women: Placebo|Subjects will receive oral placebo, two capsules once daily every evening for 7 days
89003980|NCT03789318|Active Comparator|CA-008 5 mg (0.05 mg/mL) Cohort 1|Cohort 1 (CA-008 5 mg): the surgery for each subject is to be performed under general anesthesia supplemented by a transverse abdominis plane (TAP) block and local surgical site infiltration. Prior to the surgery, perform the TAP block as a single injection of 0.25% bupivacaine hydrochloride (HCl) 60 mL (150 mg).
89187954|NCT02430194|Experimental|lonafarnib/ritonavir - II|lonafarnib 100 mg BID + ritonavir 50 mg BID
89187955|NCT02430194|Experimental|lonafarnib/ritonavir - III|lonafarnib 100 mg QD + ritonavir 100 mg QD
89187956|NCT02430194|Experimental|lonafarnib/ritonavir - IV|lonafarnib 150 mg QD + ritonavir 100 mg QD
89187957|NCT02430194|Experimental|lonafarnib/ritonavir/PEG IFN-a - V|lonafarnib 75 mg BID + ritonavir 100 mg BID (+ PEG IFN-a 180 ug QW on Week 12)
89187958|NCT02430194|Experimental|lonafarnib/ritonavir - VI|lonafarnib 25 mg BID + ritonavir 100 mg BID
89187959|NCT02430194|Experimental|lonafarnib/ritonavir - VII|lonafarnib 50 mg BID + ritonavir 100 mg BID
89187960|NCT02430194|Experimental|lonafarnib/ritonavir/PEG IFN-a - VIII|lonafarnib 50 mg BID + ritonavir 100 mg BID (+ PEG IFN-a 180 ug QW on Week 12)
89187961|NCT02430194|Experimental|lonafarnib/ritonavir/PEG IFN-a - IX|lonafarnib 25 mg BID + ritonavir 100 mg BID + PEG IFN-a 180 ug QW
89187962|NCT02430194|Experimental|lonafarnib/ritonavir/PEG IFN-a - X|lonafarnib 50 mg BID + ritonavir 100 mg BID + PEG IFN-a 180 ug QW
89187963|NCT00582608|Experimental|131I-8H9 and 8H9|This is an open-label single arm study of 131 I-8H9. injected intravenously at 10mCi/1.73m^2 dose [intended specific activity of '20mCi/mg protein] preceded by administration of 50mg/1.73m2 of unlabeled -8H9.
89187964|NCT02579798|Experimental|PEEP 10 cmH20|In this group, a PEEP of 10 cmH20 is applied for the duration of the intervention and a recruitment maneuver is applied each time the SpO2 (oxygen pulsated saturation) drops below 95%.
89187965|NCT02579798|Active Comparator|optimal PEEP|"In this group, 10 cmH20 PEEP is applied immediately. Then the optimal PEEP is sought at three key moments. It is determined by the best value of lung compliance found in the patient. It is sought by increasing or decreasing the value of the PEEP by increments or decrements of 2 cmH20. If after 6 respiratory cycles, the value of the compliance is increased, the investigator continues to increase the value of the PEEP. On the other hand, if the value of compliance is reduced, the investigator reduces the value of PEEP. The value of the PEEP selected shall in no event exceed the set pressure range (maximum pressure plate of 30 cmH20 and maximum inspiratory peak pressure 40cmH20). A recruitment maneuver is applied each time the SpO2 drops below 95%, as in the PEEP 10cmH2O group."
89187966|NCT02579330|Experimental|Coloshield Group|In the Intervention group the Coloshield Device (double balloon system) will be introduced at the beginning of surgery followed by a washout of the rectum with 500ml of saline solution. The grade of macroscopic contamination will be assessed.
89187967|NCT02579330|Sham Comparator|Control Group|In the control Group the grade of macroscopic contamination will be assessed after rectal washout with 500ml of saline solution.
89187968|NCT03087656|Active Comparator|Antibiotic arm|The drugs ceftriaxone and levofloxacin will be administered to patients in the antibiotic arm.
89187969|NCT03087656|No Intervention|No Antibiotic arm|No prophylactic antibiotics will be administered.
89187970|NCT03870776|Placebo Comparator|Placebo|Patients will receive the placebo during 42 days.
89187971|NCT03870776|Experimental|MAP4343 group B|Patients will receive daily dose 1 during 42 days.
89187972|NCT03870776|Experimental|MAP4343 group C|Patients will receive daily dose 2 during 42 days.
89187973|NCT03014570|Active Comparator|Education-Only Control|This arm includes the education provided to all sites (this is Step 2 of the EIT-4-BPSD intervention). The sites are given the opportunity to decide how they want the education around management of behavioral symptoms to occur-face-to-face by a research staff member, via a powerpoint they can use on their own or via a webinar.
89187974|NCT03014570|Experimental|EIT-4-BPSD|This arm includes the four step intervention: 1. Assessment of the environment and policies; 2. Education of staff; 3. Establishing person-centered care plans; and 4. Mentoring and motivating staff. We provide the sites with a research nurse who works with an identified stakeholder group and champion within the facility and visits the settings monthly, connects by email weekly to complete the four intervention steps. The implementation process is guided by the Evidence Integration Triangle (EIT) framework. The EIT brings together evidence and key stakeholders from the facility to influence care practices. EIT includes: participatory implementation processes, provision of practical evidence-based interventions, and pragmatic measures of progress toward goals.
89187975|NCT03925298||group 1|participants with elevated serum troponin level (≥0.01μg/L)
89187976|NCT03925298||group 2|those with normal serum troponin level (<0.01μg/L)
89530526|NCT03246997|Other|Spring Group|Delayed Intervention
89003981|NCT03789318|Placebo Comparator|Placebo for Cohort 1|"Cohort 1:~Placebo comparator is identical in appearance to the investigational product, containing the same excipients as the active comparator.~The surgery for each subject is to be performed under general anesthesia supplemented by a transverse abdominis plane (TAP) block and local surgical site infiltration. Prior to the surgery, perform the TAP block as a single injection of 0.25% bupivacaine hydrochloride (HCl) 60 mL (150 mg)."
89187977|NCT04073654|Active Comparator|SA Implants|Dental implant with sandblasted and Acid-etched (SA) surface
89187978|NCT04073654|Experimental|SOI Implants|Same dental implant with sandblasted and Acid-etched surface modified with pH buffering agent
89187979|NCT04076228||Pembrolizumab|Chinese lung cancer patients who will receive pembrolizumab will be enrolled in this study. Clinically, the treatment course of pembrolizumab is depended on the efficacy, but average cycle is about 3-4 weeks and patient will receive 6 treatment courses.
89187980|NCT02579252|Experimental|AADvac1|"AADvac1 is a suspension for subcutaneous injection. AADvac1 is provided in single-use vials. Dosage: 40 µg Axon peptide 108 (coupled to keyhole limpet haemocyanin (KLH)) using aluminium hydroxide (containing 0.5 mg Al3+) as adjuvant, in a phosphate buffer.~Patients receive 6 doses in 4-week intervals, and then 5 individual booster doses in 3-month intervals, for a total of 11 doses."
89187981|NCT02579252|Placebo Comparator|Placebo|Placebo is a suspension for subcutaneous injection. Placebo is provided in single-use vials. Dosage: aluminium hydroxide (containing 0.5 mg Al3+), in a phosphate buffer. Patients receive 6 doses in 4-week intervals, and then 5 individual booster doses in 3-month intervals, for a total of 11 doses.
89187982|NCT02580734|Placebo Comparator|placebo|tablet without melatonin
89187983|NCT02580734|Experimental|melatonin|tablet with melatonin
89187984|NCT05673434|Experimental|Experimental: TM4SF1 positive CAR-T cells for digestive tumors|"The present study is proposed to study advanced malignant digestive tumors in adults, and the four escalating doses, namely, 0.5~1.0.,1.0~2.0,2.0~3.0 and 3.0~10.0 (×10 ^6/kg), will be given.~Intervention: Biological: TM4SF1-positive chimeric antigen receptor T-cell therapy"
89187985|NCT04073576|Experimental|AHCL|Advanced Hybrid Closed Loop
89187986|NCT04073576|Active Comparator|SAP+PLGM|Sensor Augmented Pump with Predictive Low Glucose Monitoring
89187987|NCT02924870|Active Comparator|Control group|Conventional management. Treatment and follow-up according to conventional clinical practice (GesEPOC guidelines), including recommendations on healthy habits and lifestyle.
89187988|NCT02924870|Experimental|Intervention group|Conventional management plus health education program. In addition to conventional treatment and follow-up, the patients will be referred to a nursing consultation for perform two health education sessions, at 15 and 30 days after hospital discharge.
89187989|NCT00427999|Experimental|STI571+ pioglitazone+ etoricoxib + dexamethasone + treosulfane|STI571 (imatinib) 400mg po daily + pioglitazone 60mg po daily + etoricoxib 60mg po daily + dexamethasone 1mg po daily + treosulfane 500mg po daily for 24 weeks
89187990|NCT01032967|Active Comparator|Surgery, esophagectomy|The patients randomized to receive either standard esophagectomy will have the operation performed in an open manner with two-field lymphadenectomy
89187991|NCT01032967|Active Comparator|Definitive chemoradiation|3-weekly cycles of cisplatin and 5-fluorouracil chemotherapy and radical radiotherapy delivered in a three-dimensional conformal mode (total of 50-60 Gy given in 25-30 fractions) will be given over a period 5-6 weeks.
89187992|NCT02218892||Juvenil Idiopathic Arthritis|The group consists of children age 7-14 with an diagnosis of active Juvenile Idiopathic Arthritis.
89187993|NCT02579018|Experimental|Anorexia Nervosa (AN)|Diagnosis of anorexia spectrum disorder and stable use of all medications ≥ three months.
89187994|NCT02579018|Experimental|Matched Controls|No diagnosis of anorexia spectrum disorder. Stable use of all medications ≥ three months. Also age (+/- 2 years) and gender matched to AN study participant and exercise regularly.
89187995|NCT02579018|Experimental|Healthy Controls|No diagnosis of anorexia spectrum disorder. Stable use of all medications ≥ three months. Do not exercise regularly.
89187996|NCT00661713|Experimental|rMenB06|Subjects received one injection of rMenB+OMV NZ vaccine (month 0) and two injections of placebo (at month 1, month 2). A second injection of rMenB+OMV NZ vaccine was given later (month 6).
89187997|NCT00661713|Experimental|rMenB0|Subjects received one injection of rMenB+OMV NZ vaccine (month 0) and three injections of placebo (month 1, month 2 and month 6).
89187998|NCT00661713|Experimental|rMenB016|Subjects received two injections of rMenB+OMV NZ vaccine (at month 0 and month 1) and one injection of placebo (at month 2). A third injection of rMenB+OMV NZ vaccine was given later (at month 6).
89187999|NCT00661713|Experimental|rMenB01|Subjects received two injections of rMenB+OMV NZ vaccine (at month 0 and month 1) and two injection of placebo (at month 2 and month 6).
89188000|NCT00661713|Experimental|rMenB026|Subjects received two injections of rMenB+OMV NZ vaccine (at month 0 and month 2) and one injection of placebo (at month 2). A third injection of rMenB+OMV NZ vaccine was given later (at month 6).
89535479|NCT03206281||Sonographic fetal weight estimation|The fetal weight estimation will be taken by professional Sonographic obstetrician durin her 39 week
89003982|NCT03789318|Active Comparator|CA-008 10 mg (0.1 mg/mL)|Cohort 2 (CA-008 10 mg): the surgery is to be performed under general anesthesia supplemented by a transverse abdominis plane (TAP) block and local surgical site infiltration. Prior to the surgery, perform the TAP block as a single injection of 0.25% bupivacaine hydrochloride (HCl) 60 mL (150 mg).
89003983|NCT03789318|Active Comparator|CA-008 15 mg (0.15 mg/mL)|Cohort 3 (CA-008 15 mg): the surgery is to be performed under general anesthesia supplemented by a transverse abdominis plane (TAP) block and local surgical site infiltration. Prior to the surgery, perform the TAP block as a single injection of 0.25% bupivacaine hydrochloride (HCl) 60 mL (150 mg).
89003984|NCT03789318|Placebo Comparator|Placebo for Cohorts 2 and 3|"Cohorts 2 & 3:~Placebo comparator in each cohort is identical in appearance to the investigational product, containing the same excipients as the active comparator.~The surgery for each subject is to be performed under general anesthesia supplemented by a transverse abdominis plane (TAP) block and local surgical site infiltration. Prior to the surgery, perform the TAP block as a single injection of 0.25% bupivacaine hydrochloride (HCl) 60 mL (150 mg)."
89003985|NCT03783546|Experimental|Immediate Acupuncture|"Will receive a standardized acupuncture protocol for a 10-week period~20 sessions: twice a week for 10 weeks~After the completion of the 10 weeks main study period, participants will cross over to the usual care as a follow-up without acupuncture for additional 10 weeks."
89003986|NCT03783546|Active Comparator|Delayed acupuncture|"Will receive standard usual care without acupuncture for 10 weeks~Participants will cross over to receive the same acupuncture protocol for 10 weeks --10 sessions: once a week for 10 weeks before exiting the study"
89003987|NCT03768063|Experimental|Atezolizumab Monotherapy|Participants will receive atezolizumab by intravenous infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
89003988|NCT03768063|Experimental|Combined Agents with Atezolizumab|Participants will receive treatment of atezolizumab with combined agent(s) as directed per the parent study. Participants will receive agent(s) in combination with atezolizumab at the same dose and schedule, and with the same administration guidelines that were in effect at the time of participant discontinuation from the parent study.
89003989|NCT03768063|Active Comparator|Comparator Treatment|Participants will receive comparator treatment administration as directed per the parent study. Participants will receive comparator treatment at the same dose and schedule, and with the same administration guidelines that were in effect at the time of participant discontinuation from the parent study.
89003990|NCT03765073|Experimental|Stage 1 - Highest dose formulation a|Multivalent group B streptococcus vaccine - Stage 1 Nonpregnant women
89003991|NCT03765073|Experimental|Stage 1 - Highest dose formulation b|Multivalent group B streptococcus vaccine - Stage 1 Nonpregnant women
89003992|NCT03765073|Experimental|Stage 2 - Lowest dose formulation a|Multivalent group B streptococcus vaccine - Stage 2 Pregnant women
89003993|NCT03765073|Experimental|Stage 2 - Lowest dose formulation b|Multivalent group B streptococcus vaccine - Stage 2 Pregnant women
89003994|NCT03765073|Experimental|Stage 2 - Middle dose formulation a|Multivalent group B streptococcus vaccine - Stage 2 Pregnant women
89003995|NCT03765073|Experimental|Stage 2 - Middle dose formulation b|Multivalent group B streptococcus vaccine - Stage 2 Pregnant women
89003996|NCT03765073|Experimental|Stage 2 - Highest dose formulation a|Multivalent group B streptococcus vaccine - Stage 2 Pregnant women
89003997|NCT03765073|Experimental|Stage 2 - Highest dose formulation b|Multivalent group B streptococcus vaccine - Stage 2 Pregnant women
89003998|NCT03765073|Experimental|Stage 3 - Selected dose and formulation|Multivalent group B streptococcus vaccine - Stage 3 Pregnant women
89003999|NCT03765073|Placebo Comparator|Stage 1 Placebo|Saline control
89004000|NCT03765073|Placebo Comparator|Stage 2 Placebo|Saline control
89004001|NCT03765073|Placebo Comparator|Stage 3 Placebo|Saline control
89004002|NCT03759873|Experimental|Incentives|Patient earns incentives for completing cardiac rehabilitation sessions.
89004003|NCT03759873|Experimental|Case Management|Patient is assigned a case manager while in hospital.
89004004|NCT03759873|Experimental|Incentives and Case Management|Patient receives both the Incentives and Case Management interventions.
89004005|NCT03759873|No Intervention|Usual care|This control condition does not receive either intervention.
89004006|NCT03749447|Experimental|Bardoxolone methyl|"Adult participants received bardoxolone methyl capsules, once daily (QD) at a starting dose of 5 milligrams (mg), followed by dose- escalation to 10 mg at Week 2 (Day 14 ± 3), and to 20 mg at Week 4 (Day 28 ± 3). Based on the eligibility UACR >300 milligrams per gram (mg/g), the dose was increased to 30 mg starting from Week 6 (Day 42 ± 3) until the end of the study.~Participants under 18 years of age received bardoxolone methyl capsules at a starting dose of 5 mg every other day during the first week and QD during the second week of the study, followed by dose-escalation to 10 mg at Week 2 and to 20 mg at Week 4. Based on the eligibility UACR >300 mg/g, the dose was increased to 30 mg starting from Week 6 until the end of the study."
89004007|NCT03737032|Experimental|Intermittent, Continuous, Sham Order|3 sessions of theta burst stimulation administered in the following order: 1) Intermittent theta burst stimulation, 2) Continuous theta burst stimulation, 3) Sham theta burst stimulation.
89004008|NCT03737032|Experimental|Intermittent, Sham, Continuous Order|3 sessions of theta burst stimulation administered in the following order: 1) Intermittent theta burst stimulation, 2) Sham theta burst stimulation, 3) Continuous theta burst stimulation.
89397169|NCT05958914|Experimental|Arm 3|"PCOS women undergoing ovarian stimulation and ICSI treatment. Patients will undergo ovarian stimulation treatment with gonadotropins and egg retrieval. As part of this process, as per clinical practice, blood and follicular fluid sampling will be performed.~Biological samples will be analyzed for the concentration of neuropeptides (enkephalins, CGRP, SP and VIP)"
88873209|NCT03430648||Cognitively and metabolically normal|This group has been defined as being cognitively and metabolically normal.
88873210|NCT03430648||Cognitively normal with prediabetes|This group has been defined as being cognitively normal but showing signs of prediabetes.
88873211|NCT03430648||Persons with Mild Cognitive Impairment|This group has been defined as being mildly cognitively impaired.
88873212|NCT03430648||Persons with early Alzheimer's disase|This group has been defined as having early Alzheimer's disease.
88873213|NCT03426579||Reliability of NeuroSENSE ®in children|Children scheduled for direct laryngoscopy with surgical intervention the reliability of NeuroSENSE ®monitoring will be evaluated
88873214|NCT03400137|Active Comparator|Healthy Volunteers|No family history (first degree relative) of glaucoma.
88873215|NCT03400137|Active Comparator|Glaucoma suspects|oEither IOP between 25 to 30 mmHg with central corneal thickness < 550µm, or a difference ≥ 0.2 in cup to disc ratio between eyes.
88873216|NCT03400137|Active Comparator|Glaucoma|Rim thinning, notching, undermining (excavation) or diffuse or localized RNFL defects that are characteristic of glaucoma.
88873217|NCT03366012|Other|Cytosponge Test|This arm will include individuals without formal diagnosis of Barrett's esophagus.
88873218|NCT03327532|Experimental|Patients hospitalized for acute heart failure|"One arm study.~Patients hospitalized for acute heart failure will undergo the following evaluations:~Clinical examination centered on congestion~Cardiopulmonary and peritoneal ultrasound~Blood sample retrieved for biological assessment and biobanking~Telephone interview"
88873219|NCT03240016|Experimental|Pembrolizumab and Abraxane|Pembrolizumab 200mg IV D1 Abraxane 100mg/m^2 IV D1 and D8 21 Day Cycles
88873220|NCT03229499|Experimental|Anastrozole|1mg (1 tablet)taken by mouth once a day for one year
88873221|NCT03229499|Placebo Comparator|Placebo|1 tablet taken by mouth once a day for one year
88873222|NCT03223025|Experimental|CinnaTropin®, Then Nordilet®|CinnaTropin® was administered with 0.03 mg/kg daily subcutaneous injections for three months. After that, the participants received 0.03 mg/kg daily subcutaneous injections of Nordilet® for three months.
88873223|NCT03223025|Active Comparator|Nordilet®, Then CinnaTropin®|Nordilet® was administered with 0.03 mg/kg daily subcutaneous injections for three months. After that, the participants received 0.03 mg/kg daily subcutaneous injections of CinnaTropin® for three months.
88873224|NCT03190889|No Intervention|STAN|Patients in the STAN group will participate in twelve sessions of supervised physical therapy over a six week period. Patients will participate in agility and plyometric drills, and continue strength exercises from the previous treatment phase. The clinic program will be performed in conjunction with a home running program. Patients in this group will not receive feedback from the therapist regarding movement quality during activities.
88873225|NCT03190889|Other|HOME|HOME Program is distinguished by patients participating in a home only intervention that consists of running and strengthening exercises performed twice a week for six weeks. No plyometric or agility drills are performed in this study arm. This represents the minimal intervention to prepare for a return to sports. No neuromuscular training or movement training beyond the sagittal plane will be performed.
88873226|NCT03190889|Experimental|TNMT|Patients who are enrolled in the TNMT group will participate in 12 sessions of supervised outpatient physical therapy over a six week period. The TNMT protocol is distinguished by performance of exercises designed to enhance core and hip strength, performance of neuromuscular training exercise that are designed to correct movement flaws associated with second ACL injury25, providing verbal and visual feedback and performance of single leg drills on both legs.
88873227|NCT03118037||Sonata|Women who undergo transcervical radiofrequency(RF) ablation with the Sonata System for treatment of their fibroids
88873228|NCT02976389|Experimental|$40/month|Financial incentives: Participants will be randomized to receive $40/month in incentive dollars for the purchase of SNAP eligible fruits and vegetables. Purchasing behaviors will be tracked.
88873229|NCT02976389|Active Comparator|$20/month|Financial Incentives: Participants will be randomized to receive $20/month in incentive dollars for the purchase of SNAP eligible fruits and vegetables. Purchasing behaviors will be tracked.
88873230|NCT02976389|Active Comparator|$10/month|Financial Incentives: Participants will be randomized to receive $10/month in incentive dollars for the purchase of SNAP eligible fruits and vegetables. Purchasing behaviors will be tracked.
88873231|NCT02972580||Cohort A|DMD/BMD Female Carriers who have/had an affected child (n=150)
88873232|NCT02972580||Cohort B|DMD/BMD Female non-carriers controls who have/had an affected child (n=50)
88873233|NCT02972580||Cohort C|Healthy Age-Matched Controls (n=50)
88873234|NCT02972580||Cohort D|DMD/BMD Female Carriers with no affected children (n=25)
88873235|NCT02947633|Experimental|Continuous sciatic PNB|If a CPI catheter is placed, the CPI catheter will be placed under ultra-sound guidance, with the tip of the catheter being placed immediately adjacent to the sciatic nerve, after the local anesthesia has been deposited. CPI catheters will only remain in-situ for 48 hours.
88873236|NCT02947633|Active Comparator|Single-injection sciatic PNB|Under ultrasound-guidance, the sciatic nerve can readily be identified in the posterior thigh. The nerve appears hyperechoic and can be traced distally to the popliteal fossa, where it divides into the tibial and common peroneal nerves. Local anesthesia is injected under real-time visualization following a negative aspiration. If a single-injection block is done, local anesthesia is deposited adjacent to the sciatic nerve within the fascial plane, but not within the epineurium. As such, single-injection sciatic PNB, which can last up to 24 hours, should provide adequate analgesia precluding the need for oral narcotic or nonsteroidal anti-inflammatory medications following ACL reconstruction with a hamstring autograft.
88873237|NCT02830360|Active Comparator|VT catheter ablation|Catheter ablation of ventricular tachycardia
88873238|NCT02830360|Active Comparator|Antiarrhythmic Drug Therapy|Patients will be prescribed either oral amiodarone or sotalol daily (dosage and frequency to be determined based on patient's clinical presentation at the time of the qualifying arrhythmia).
88873239|NCT02768766|Experimental|Dose Level 1: Selumetinib|Subjects will receive selumetinib (hyd-sulfate AZD6244) orally twice a day for three days followed by four days off in four week cycles at a dose of 100mg.
89397170|NCT05958901||pulmonary hypertension|
89397171|NCT05958901||healthy|
89397172|NCT05958849|Experimental|Prospective Research|"Soventinib in combination with solutumab and tegeo dosing regimen:~Soventinib: 200 mg orally, within 1 hour of breakfast, administered once daily as a continuous dose, d1-d21, every 3 weeks in treatment cycles~Slulizumab: 300 mg administered intravenously, d1, every 3 weeks for one treatment cycle.~Tegeo: 40-60 mg/dose administered twice daily, d1-d14, continuously (dosing based on body surface area (BSA): 40 mg/dose for BSA ≤ 1.25 m2; 50 mg/dose for 1.25 ≤ BSA < 1.5 m2 and 60 mg/dose for BSA ≥ 1.5 m2), every 3 weeks for one treatment cycle. Dose adjustments, including suspension, dose reduction, or permanent discontinuation, were allowed as required by the protocol."
89397173|NCT05958836||Micra TPS group|
89397174|NCT05958836||Traditional PM group|
89397175|NCT05958823|Experimental|Group S (Serratus anterior plane block)|The patient who underwent open heart surgery will be taken to the cardiovascular surgery intensive care unit after the surgical procedure. Necessary preparations will be made to perform serratus anterior plane block (SAP). After ensuring the hygiene of the anterior chest wall, it is advanced with an 8 cm long peripheral block needle under ultrasound guidance. SAP block is a local anesthetic injection procedure applied superficially or deeply to the serratus anterior muscle and specifically targeting the lateral cutaneous and muscular branches of the intercostal nerves. The long thoracic nerve and the thoracodorsal nerve are located in the fascial plane on the surface of the serratus anterior muscle and can be blocked. The serratus anterior block can be performed anywhere between the anterior and posterior axillary lines and the 2nd and 7th ribs.
89397176|NCT05958823|Experimental|Group P ( PECS I-II)|The patient who underwent open heart surgery will be taken to the postoperative intensive care unit. Preparation for the PECS block will be made, and after the anterior chest wall hygiene is ensured, an 8 cm long peripheral block needle will be advanced under ultrasound guidance. PECS II block is a combination of PECS I and subpectoral local anesthetic injection targeting the lateral cutaneous branches of the intercostal nerves, long thoracic and thoracodorsal nerves. To perform the PECS I block, the ultrasound probe is placed in the midclavicular line and in the parasagittal plane, and the pectoralis major-minor, axillary vessels and pleura are visualized. After identifying the second and third ribs by sliding the ultrasound probe caudally, the lower end will be rotated towards the axilla to make the probe parallel to the deltapectoral groove.
89397177|NCT05958810||Patients detected with Plasmodium falciparum (Artemether-lumefantrine)|Patients with mono-infection of Plasmodium falciparum with 1,000-100,000 asexual forms per µl
89397178|NCT05958797||Patients detected with Plasmodium vivax (Chloroquine)|Patients with mono-infection of Plasmodium falciparum with ≥ 250 per µl
89397179|NCT05958784|Experimental|Genetic Carriers and Non-Carriers of PKU|
88873240|NCT02768766|Experimental|Dose Level 2: Selumetinib|Subjects will receive selumetinib (hyd-sulfate AZD6244) orally twice a day for three days followed by four days off in four week cycles at a dose of 125mg.
88873241|NCT02768766|Experimental|Dose Level 3: Selumetinib|Subjects will receive selumetinib (hyd-sulfate AZD6244) orally twice a day for three days followed by four days off in four week cycles at a dose of 150mg.
88873242|NCT02768766|Experimental|Dose Level 4: Selumetinib|Subjects will receive selumetinib (hyd-sulfate AZD6244) orally twice a day for three days followed by four days off in four week cycles at a dose of 175mg.
88873243|NCT02768766|Experimental|Dose Level 5: Selumetinib|Subjects will receive selumetinib (hyd-sulfate AZD6244) orally twice a day for three days followed by four days off in four week cycles at a dose of 200mg.
88873244|NCT02768766|Experimental|Dose Level 6: Selumetinib|Subjects will receive selumetinib (hyd-sulfate AZD6244) orally twice a day for three days followed by four days off in four week cycles at a dose of 225mg.
88873245|NCT02750826|Other|Arm 1: Health Education Program|Patients will receive a standardized intervention focusing on healthy living. This will include mailings at study entry and one year later describing healthy lifestyle behaviors. All participants will also receive a 2-year subscription to a health magazine. In addition, all study participants will be invited to join twice-yearly Webinars/teleconferences that focus on breast cancer and other health topics, such as treatment updates in breast cancer, management of menopausal side effects, general cancer screening, etc. Finally, the study will also provide birthday and holiday greeting cards and a twice-yearly study newsletter with study updates and other general breast cancer news.
88873246|NCT02750826|Other|Arm 2: Health Education Program + Weight Loss Intervention|Patients will receive a standardized intervention focusing on healthy living as described in the Arm 1 (Health Education Program). In addition, patients will utilize a standardized, 2-year, telephone-based weight loss intervention. The intervention will include individual weight loss, caloric restriction, and physical activity goals for each participant. It will be administered through semi-structured phone calls delivered by trained coaches at the BWEL call center and supplemented through print and on-line materials. The intervention will utilize a toolbox approach that will allow for tailoring for the individual participant.
89397180|NCT05958771|Active Comparator|Children who receive the IP|"The Test Article/placebo will be co-administered with the childhood vaccines that are scheduled at the regular National Program of Immunization vaccination visits around 2 months, 4 months and 6 months of age.~Test article: ROTAVAC 5D, 3 doses. Each dose of 0.5 mL. Administered orally."
88873247|NCT02745184|Experimental|lung stem cells|Patients will receive 0.5-5x10^6 (0.5-5 million)/Kg/person cells of clinical grade lung stem cells (LSCs)injected via fiberoptic bronchoscopy after fully lavage of the localized lesions.
89397181|NCT05958771|Placebo Comparator|Children who receive placebo|"The Test Article/placebo will be co-administered with the childhood vaccines that are scheduled at the regular National Program of Immunization vaccination visits around 2 months, 4 months and 6 months of age.~Placebo: 3 doses. Each dose of 0.5 mL. Administered orally."
89397182|NCT05958758|Experimental|Single arm|Group administered Psilocybin-assisted therapy
89397183|NCT05958745|Experimental|Aerobic Exercise|12 week aerobic exercise
89397184|NCT05958745|Active Comparator|Aerobic + Resistance Exercise|12 week aerobic + resistance exercise
89397185|NCT05958745|No Intervention|Control|control
89397186|NCT05958732|Experimental|Experimental Group|The experimental group will receive body awareness therapy for 20 minutes.The following steps will be conducted, (1) Put your left hand on your right toe. (2) Put your right hand on your left toe. (3) Touch your heels. (4) Put your feet together. (5) Put your knees together. (6) Touch your right knee with your left hand. (7) Touch your left knee with your right hand. (8) Touch one knee and one foot. (9) Put your right hand on your left knee. (10) Put your left hand on your right knee. (11) Put your feet apart. (12) Touch your toes with your arms crossed. (13) Touch your thumbs to your toes. (14) Bend your knees. (15) Stamp your feet. Duration is 5 days a week for two weeks. Along with conventional therapy.
89397187|NCT05958732|Other|Control group|conventional training plan: (1) 5 minute warm up then, (2) static balance exercises, such as, Two leg stance, One Leg stance, and (3) dynamic balance exercises such as, sideway walking with crossover, Forward walking or running in a zigzag line, Backward walking or running in a zigzag line, Jogging end to end, (4) Coordination exercises such as, Tandem stepping, Finger to nose, Finger to finger, Sitting with Shifting weight in all directions, Rebound Phenomenon and cool down for 5 minutes.
89397188|NCT05958719|Experimental|interim evaluation of CR group|Untreated patients with TFH-derived peripheral T-cell lymphoma will be treated with chidamide combined with azacitidine for four cycles. For patients with interim-PET evaluation of CR, consolidation therapy with ASCT or another eight cycles with chidamide combined with azacitidine can be obtained. Subsequently, cidarbenamide monotherapy was given as maintenance therapy for 12 months. Patients with interim evaluation of SD or PD withdrew from this study.
89004009|NCT03737032|Experimental|Continuous, Intermittent, Sham Order|3 sessions of theta burst stimulation administered in the following order: 1) Continuous theta burst stimulation, 2) Intermittent theta burst stimulation, 3) Sham theta burst stimulation.
89004010|NCT03737032|Experimental|Continuous, Sham, Intermittent Order|3 sessions of theta burst stimulation administered in the following order: 1) Continuous theta burst stimulation, 2) Sham theta burst stimulation, 3) Intermittent theta burst stimulation.
89004011|NCT03737032|Experimental|Sham, Intermittent, Continuous Order|3 sessions of theta burst stimulation administered in the following order: 1) Sham theta burst stimulation, 2) Intermittent theta burst stimulation, 3) Continuous theta burst stimulation.
89397189|NCT05958719|Experimental|interim evaluation of PR group|Untreated patients with TFH-derived peripheral T-cell lymphoma will be treated with chidamide combined with azacitidine for four cycles. For patients with interim-PET evaluation of PR, another two cycles of chidamide combined with azacitidine will be continued, followed by the second PET-CT efficacy evaluation, and those who achieve CR receive consolidation therapy with ASCT or another six cycles of chidamide combined with azacitidine. Subsequently, cidarbenamide monotherapy was given as maintenance therapy for 12 months. Patients with second efficacy evaluation of PR or SD or PD withdrew from this study.
89397190|NCT05958706||patients with manifest heart failure|patients with manifest heart failure and T2DM or patients with manifest heart failure without T2DM
89397191|NCT05958706||patients with terminal heart failure|patients with terminal heart failure and T2DM or patients with terminal heart failure without T2DM
89397192|NCT05958706||patients after heart transplantation|patients after heart transplantation and T2DM or patients after heart transplantation without T2DM
89397193|NCT05958290|Experimental|Discontinuation of antibiotics|
89397194|NCT05958290|No Intervention|Standard treatment|
89397195|NCT05958251||Cicaben|Umbilical cord stump of the newborns was medicated by Cicaben ® (Orsana S.r.l.), a natural topical dermo-protective powder
88873248|NCT02734797||Pediatric patients|This is an observational study. Validated measures of nutritional status, dietary intake, body composition, functional status and psychosocial factors will be used to measure outcomes in study patients at 4 time-points: (1) pre-HCT (Baseline), (2) 30-days post-HCT, (3) 100-days post-HCT and (4) one year post-HCT.
88873249|NCT02595060|Experimental|150 mcg inhaled molgramostim|once daily inhaled molgramostim (rhGM-CSF) for 3 days
89188001|NCT00661713|Experimental|rMenB02|Subjects received two injections of rMenB+OMV NZ vaccine (at month 0 and month 2) and two injections of placebo (at month 1 and month 6).
89188002|NCT00661713|Experimental|rMenB012|Subjects received three injections of rMenB+OMV NZ vaccine (at month 0, month 1 and month 2) and one injection of placebo later (at month 6).
89188003|NCT00661713|Experimental|rMenB6|Subjects received three injections of placebo(at month 0, month 1 and month 2) and one injection of rMenB+OMV NZ vaccine(at month 6).
89188004|NCT02578472|Experimental|Group 1 (Sequence ABC)|Participants will receive Treatment A (2 capsules of 20 milligram [mg] JNJ-42847922) in Period 1, Treatment B (10 mg zolpidem and 1 placebo capsule) in Period 2 and Treatment C (2 placebo capsules) in Period 3 with a washout interval of at least 3 days between treatment periods. Participants randomized to this group will be assessed for pharmacodynamic testing at 2 and 6 hours after dosing.
89188005|NCT02578472|Experimental|Group 2 (Sequence BCA)|Participants will receive Treatment B in Period 1, Treatment C in Period 2 and Treatment A in Period 3 with a washout interval of at least 3 days between treatment periods. Participants randomized to this group will be assessed for pharmacodynamic testing at 2 and 6 hours after dosing.
89188006|NCT02578472|Experimental|Group 3 (Sequence CAB)|Participants will receive Treatment C in Period 1, Treatment A in Period 2 and Treatment B in Period 3 with a washout interval of at least 3 days between treatment periods. Participants randomized to this group will be assessed for pharmacodynamic testing at 2 and 6 hours after dosing.
89188007|NCT02578472|Experimental|Group 4 (Sequence ABC)|Participants will receive Treatment A in Period 1, Treatment B in Period 2 and Treatment C in Period 3 with a washout interval of at least 3 days between treatment periods. Participants randomized to this group will be assessed for pharmacodynamic testing at 4 and 8 hours after dosing.
89188008|NCT02578472|Experimental|Group 5 (Sequence BCA)|Participants will receive Treatment B in Period 1, Treatment C in Period 2 and Treatment A in Period 3 with a washout interval of at least 3 days between treatment periods. Participants randomized to this group will be assessed for pharmacodynamic testing at 4 and 8 hours after dosing.
89188009|NCT02578472|Experimental|Group 6 (Sequence CAB)|Participants will receive Treatment C in Period 1, Treatment A in Period 2 and Treatment B in Period 3 with a washout interval of at least 3 days between treatment periods. Participants randomized to this group will be assessed for pharmacodynamic testing at 4 and 8 hours after dosing.
89397196|NCT05958251||Standard dry care|Umbilical cord stump of the newborns was medicated by standard dry care
88873250|NCT02595060|Experimental|450 mcg inhaled molgramostim|once daily inhaled molgramostim (rhGM-CSF) for 3 days
89188010|NCT00786123|Experimental|VSL#3|Patients taking probiotics (VSL#3)
89188011|NCT00786123|Placebo Comparator|Placebo|Identical looking preparation of placebo taken at the same dose regimen as the active comparator
89188012|NCT04047225|Experimental|Analgesia Nociceptive Index (ANI)|Using ANI for guiding intraoperative opioid administration.
89188013|NCT04047225|No Intervention|No Analgesia Nociceptive Index (ANI)|Do not use ANI
89188014|NCT00782925|Experimental|1|"Study intervention:~A face/profile X-ray of their entire spine at baseline~Educational program~Exercise program~Self-led exercises~A follow-up at 12 and 24 months with their occupational therapist.~A follow-up at 18 months with a physical therapist.~Workers received also at the end of the educational program written standardized information about back pain (the back book, an information booklet) 1.~Coudeyre E., Tubach F., Rannou F. & all, Effect of simple information booklet on pain persistance after an acute episode of low back pain: a non- randomised trial in a primary care setting. PLoS ONE. 2007 ; 2 : e706"
89188015|NCT00782925|No Intervention|2|"Control intervention :~No intervention~A face/profile X-ray of their entire spine at baseline~A follow-up at 12 and 24 months with their occupational therapist,~A follow-up at 18 months with a physical therapist."
89188016|NCT04073888|Other|Single arm|Men with Fabry Disease
89397197|NCT05958043|Experimental|3D-printed group|The patients randomized to the 3D-printed group will receive a 3D-printed full arch implant-supported provisional restoration.
89397198|NCT05958043|Other|CAD/CAM- milled group|The patients randomized to the CAD/CAM-milled group will receive a PMMA-milled full-arch implant-supported provisional restoration.
88873251|NCT02595060|Placebo Comparator|inhaled placebo|once daily inhaled placebo for 3 days
88873252|NCT02587065|Experimental|peginterferon beta-1a|125 μg administered subcutaneously (SC) every 2 weeks
88873253|NCT02572856|Experimental|CGM patients|Apply continuous glucose monitor, calibrate and make glucose measurements. Measurements are blinded to the care provider
88873254|NCT02544503|Experimental|Stroke Patients|Subjects will undergo single pulse transcranial magnetic stimulation (TMS), paired pulse transcranial stimulation (ppTMS), and low frequency repetitive transcranial magnetic stimulation (rTMS) at one month and six months post stroke.
88873255|NCT02544503|Active Comparator|Healthy Controls|Subjects will undergo single pulse transcranial magnetic stimulation (TMS), paired pulse transcranial stimulation (ppTMS), and low frequency repetitive transcranial magnetic stimulation (rTMS) at one month and six months.
88873256|NCT02492867|Experimental|Response-driven Adaptive RT|Patients will receive treatment 5 days per week, in once daily fractions, for 30 treatments with dose per fraction individually adapted over the final 9 treatments. Patients may also receive concurrent chemotherapy with Carboplatin and Paclitaxel. Patients may receive consolidation chemotherapy (carboplatin and paclitaxel) or immunotherapy (durvalumab) at the discretion of the medical oncologist.
88873257|NCT02375204|Other|Arm A: TIP|"Patients will receive treatment for 4 cycles administered every 21 days.~Cycles 1-4 (1 cycle = 21 days)~paclitaxel 250 mg/m^2 IV over 24 hours on Day 1 including premedication as defined in the protocol (eg, dexamethasone, diphenhydramine and H2 blocker)~ifosfamide 1500 mg/m^2 IV daily on Days 2-5 with mesna protection as defined in the protocol~cisplatin 25 mg/m^2 IV daily on Days 2-5~pegylated G-CSF 6 mg subcutaneous on Day 6 or 7 or G-CSF as defined in the protocol on Days 6-18~Patients may commence with each Arm A cycle provided they meet the criteria as defined in the protocol."
89397199|NCT05956938|Experimental|Action Video game Group|A one-hour training session will be held, divided into 2 30-minute sessions over 2 days. Each session will take into account an increase in the difficulty of the task gradually based on the nature of the video game. The video game selected will be ContraIII: Alien Wars, from the Nintendo Mini Classic console.
89397200|NCT05956938|Experimental|Stroboscopic Glasses Group|A one-hour training session will be held, divided into 2 30-minute sessions over 2 days. Each session will take into account a gradual increase in the difficulty of the task, divided into three visuomotor and anticipation components (ball size, type of trajectory and distance from the stimulus). The training sessions will consist of 2 series, and will be based on passing a ball between two people. Every 60 passes the flicker level of the glasses will increase, starting with level 1 (6hz) and ending at level 6 (1.75hz).
89397201|NCT05956938|No Intervention|Control Group|Participants in the control group will watch 1 video clip/series/film of 1 hour duration on a television located at least 1.5 meters away.
89397202|NCT05956314|Experimental|KM-001 cream 1%|KM-001 will be applied twice a day.
88873258|NCT02375204|Other|Arm B: TI-CE|"Patients will receive treatment for a total of 5 cycles.~Cycles 1-2 (1 cycle = 14 days)~paclitaxel 200 mg/m^2 IV over 3 hours on Day 1 including premedication as defined in the protocol (eg, dexamethasone, diphenhydramine and H2 blocker)~ifosfamide 2000 mg/m^2 IV daily on Days 1-3 with mesna protection as defined in the protocol~G-CSF 10 µg/kg subcutaneously on Days 3-15 (cycle 1) and Days 3-14 (cycle 2) or pegylated G-CSF 6 mg subcutaneous on Day 4 or 6 (cycle 1) and Day 4 or 5 (cycle 2)~leukapheresis every 14 days, if there is an inadequate number of CD34+ cells/kg collected in cycle 1~Cycles 3-5 (1 cycle = 21 days)~carboplatin daily on Days 1-3~etoposide 400 mg/m^2 daily on Days 1-3~stem cell reinfusion on day 5~pegylated G-CSF 6 mg subcutaneously or G-CSF at approximately 5 µg/kg daily on Days 5-15~Patients may commence with each Arm B cycle provided they meet the criteria as defined in the protocol."
88873259|NCT02365792|Active Comparator|CDSS1|The CDSS1 will provide decision support according to existing protocols for clinical procedures and medical treatment, mainly starting from specific symptoms or diagnostic related patients groups. The symptom oriented approach is categorised in a specific list of predetermined conditions.
88873260|NCT02365792|Active Comparator|CDSS2|The CDSS2 will provide decision support according to existing protocols for clinical procedures and medical treatment, mainly starting from specific symptoms or diagnostic related patients groups. The symptom oriented approach is categorised in a specific list of predetermined conditions.
88873261|NCT02365792|Placebo Comparator|Booklet|The control group will provide prehospital patient care with usual decision support: a pocket-size booklet, backed by a mobile phone through which the PIT can get in contact with an Emergency Physician.
88873262|NCT02339168|Experimental|enzalutamide and metformin hydrochloride|Patients receive enzalutamide PO QD and metformin hydrochloride PO BID. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88873263|NCT02295891|Experimental|MiraDry ® treatment|"MiraDry ® is the trademarked name of a non-invasive thermolytic technology which utilizes a microwave energy-based mechanism targeted for eccrine gland reduction at the dermal-fat interface.~Each participant will be scheduled two MiraDry ® treatment appointments approximately three months apart."
88873264|NCT02269319|Experimental|MRX-I|MRX-I tablets 800 mg given twice a day for 10 days
88873265|NCT02269319|Active Comparator|Linezolid|Linezolid 600 mg given twice a day for 10 days
88873266|NCT02120404|No Intervention|Control group (GC)|Control group: no esmolol administration
88873267|NCT02120404|Experimental|Group 10 (G10)|Esmolol titrated in order to reduce heart rate by 10% as compared to baseline heart rate
88873268|NCT02120404|Experimental|Group 20 (G20)|Esmolol titrated in order to reduce heart rate by 20% as compared to baseline heart rate
88873269|NCT02103491|Active Comparator|Salt administration|Participants were provided with 3 plastic bags each one containing 4 white capsules (e.g., a total of 12 capsules). In the salt group, the capsules were filled with a commercially available product that contains buffered electrolyte salts (Saltstick caps, Saltstick, California US). The total amount of electrolytes provided in the salt group was: 2580 mg of sodium (113 mmol), 3979 mg of chloride (112 mmol), 756 mg of potassium (19.3 mmol) and 132 mg of magnesium (5.4 mmol).
88873270|NCT02103491|Placebo Comparator|Placebo administration|In the control group, participants received the same number of capsules with the exact same appearance but filled with an isocaloric placebo (cellulose).
88873271|NCT02055456|Experimental|Nandrolone Decanoate|Nandrolone Decanoate intramuscularly administered, every two weeks, 5 mg/kg/dose
88873272|NCT02031250|Active Comparator|Control Arm|Standard chemotherapy (Cisplatin or Carboplatin) and IMRT (Intensity-Modulated Radiation Therapy)
88873273|NCT02031250|Experimental|Boost Arm|Boost radiation to hypoperfused/low-diffusion volumes in addition to standard chemotherapy (Cisplatin or Carboplatin) and IMRT (Intensity-Modulated Radiation Therapy)
88873274|NCT01995669|Experimental|Treatment (lenalidomide, obinutuzumab)|Patients receive lenalidomide PO QD on days on days 2-22 and obinutuzumab IV over 4-5 hours on days 1, 2, 8, 15, and 22 of cycle 1 and on day 1 of each subsequent cycle. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients not experiencing progression and who in the opinion of treating physician are deriving benefit from combination treatment may continue lenalidomide for an additional 6 cycles (up to cycle 12) and obinutuzumab on day 1 every 2 months for up to 2 years in the absence of disease progression or unacceptable toxicity.
88873275|NCT01880567|Experimental|Treatment (ibrutinib, rituximab)|Patients receive ibrutinib PO daily on days 1-28 and rituximab IV over 4-8 hours on days 1, 8, 15, and 22 of course 1; on day 1 of courses 3-8; and on day 1 of every other course for all subsequent courses. Treatment with rituximab repeats every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Courses with ibrutinib repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88873276|NCT01750567|Experimental|Metformin (Glucophage)|The starting dose of metformin will be 500 mg po daily for one week. The dose can be escalated to 500 mg twice a day after one week, and further escalated to the final dose of 1000 mg twice a day in week 3 if the medication is tolerated without adverse side effects (refer to holding parameters described in section 9.3.3). All doses should be administered with food to decrease gastrointestinal upset.
88873277|NCT01740557|Experimental|Treatment (genetically modified T-cells, high-dose aldesleukin|Patients receive cyclophosphamide IV over 2 hours on days -7 and -6, fludarabine phosphate IV daily over 15-30 minutes on days -5 to -1, and CXCR2-transduced autologous TIL and NGFR-transduced autologous TIL IV over up to 4 hours on day 0. Patients then receive high-dose aldesleukin IV over 15 minutes every 8-16 hours on days 1-5 (up to 15 doses) and 22-26 (up to 15 doses).
88873278|NCT01705977|Placebo Comparator|Placebo plus standard therapy|Placebo IV plus standard therapy; placebo administered on Days 0, 14, 28, and every 28 days thereafter through Week 48, with a final evaluation at Week 52 in the double-blind period.
88873279|NCT01705977|Experimental|Belimumab 10 mg/kg plus standard therapy|Belimumab 10 mg/kg IV plus standard therapy; belimumab administered on Days 0, 14, 28, and then every 28 days thereafter through Week 48, with a final evaluation at Week 52 in the double-blind period.
88873280|NCT01686711|Experimental|SYR-322 25 mg , AD-4833 15 mg|
89397203|NCT05956015|Experimental|Patients with liver disease|"patients with chronic liver disease will receive a oral dose of a stable isotope labeled amino acid, 2H5-Phenylalanine, (45 mg/kg body weight 50% MPE).~Blood samples will be taken over 12 weeks."
89397204|NCT05956015|Experimental|Healthy volunteers with no signs of liver disease|"Healthy volunteers with no signs of liver disease will receive a oral dose of a stable isotope labeled amino acid, 2H5-Phenylalanine, (45 mg/kg body weight 50% MPE).~Blood samples will be taken over 12 weeks."
89397205|NCT05955976||Patients suffering of knee ostheoarthritis undergoing a surgery for a total knee prosthesis.|
88873281|NCT01686711|Experimental|SYR-322 25 mg , AD-4833 30 mg|
89004012|NCT03737032|Experimental|Sham, Continuous, Intermittent Order|3 sessions of theta burst stimulation administered in the following order: 1) Sham theta burst stimulation, 2) Continuous theta burst stimulation, 3) Intermittent theta burst stimulation.
88873282|NCT01686711|Placebo Comparator|SYR-322 25 mg , AD-4833 placebo|
89397206|NCT05955885|Experimental|Flurbiprofen Oral Lozenge|30 participants will be asked to suck one (1) flurbiprofen 8.75 mg honey and lemon lozenge (tradename: Strepfen) until dissolved.
89397207|NCT05955885|Placebo Comparator|Placebo lozenge|30 participants will be asked to suck one (1) non-medicated Difflam Soothing Drops + Immune Support Honey & Lemon flavour lozenge until dissolved.
89397208|NCT05955885|Experimental|Flurbiprofen 8.75 MG|30 participants will be asked to perform three (3) oral actuations (2.91 mg per actuation) of flurbiprofen 8.75mg spray.
89397209|NCT05955885|Other|Low dose flurbiprofen spray|30 participants will be asked to perform one (1) oral actuation of flurbiprofen 8.75 mg spray, equivalent to a 2.91mg dosage. This will serve a a low dose control as there is no placebo spray available.
89397210|NCT05952752|Placebo Comparator|Dexamethsone|4 mg will be given for this group IV
89397211|NCT05952752|Experimental|Dexemedetomidine|12 ug will be given IV infusion for this group
89397212|NCT05950789|Experimental|Virtual reality application group|During the preparation stage of the port catheter injection attempt, the intervention group was given a calming video and music concert using virtual reality glasses.
89397213|NCT05950789|No Intervention|Control|In the control group, no intervention was made other than the routine application.
89397214|NCT05950568|Active Comparator|Quadratus lumborum block type II|A 22 gauge needle was positioned between the erector spinae muscle in the thoracolumbar fascia's middle layer
89397215|NCT05950568|Active Comparator|Quadratus lumborum block type III|A 22 gauge needle was positioned between the psoas and quadratus lumborum muscles at the anterior fascia lumbosacral
89397216|NCT05950568|Active Comparator|Transversus abdominis plane block|A 22 gauge needle was positioned between the internal oblique and transversus abdominis muscles
89397217|NCT05933681|Experimental|Determination of DLPFC neurophysiology biomarkers of DBS associated cognitive impairment|Neurophysiology recordings will be performed from dorsolateral prefrontal cortex (DLPFC) during deep brain stimulation surgery, with and without STN or GPI stimulation, at rest and during a working memory task.
88873283|NCT01664234|Experimental|laryngoscopy with simultaneous insufflation of oxygen|Patients will be randomly assigned to laryngoscopy with or without simultaneous insufflation of oxygen at 4 L/minute. Oxygen will be provided by a flowmeter connected via rigid tubing to the track-mounted endotracheal tube on the AirTraq.
88873284|NCT01664234|Placebo Comparator|laryngoscopy without simultaneous oxygen insufflation|Patients will be randomly assigned to laryngoscopy with or without simultaneous insufflation of oxygen at 4 L/minute. Oxygen will be provided by a flowmeter connected via rigid tubing to the track-mounted endotracheal tube on the AirTraq.
89188017|NCT04072796||Case group|Case group reported urinary complaints
89188018|NCT04072796||Control group|Control group did not have any urinary complaints.
89188019|NCT03835975|Active Comparator|13vPnC|Pneumococcal conjugate vaccine
89188020|NCT03835975|Active Comparator|PPSV23|Pneumococcal polysaccharide vaccine
89188021|NCT03835975|Experimental|20vPnC|Pneumococcal conjugate vaccine
89004013|NCT03723460||Households|Household here means a family unit comprising of at least both parents (mother and father) and a child under 5 years of age or an adolescent child.
89004014|NCT03698149|Experimental|Electrocorticography-based brain computer interface|
89004015|NCT03688100|Active Comparator|Patients: Medication Management (MEDS)|The medication management group will meet with the patient in a one 50 minute in person introductory antidepressant medication treatment session to educate the patient about depression and medication options. Patients will get prescribed a standard of care anti-depressant medication by treating physician, followed by 12 weekly follow up telephone visits, then on a monthly basis for 3 months, and then as needed thereafter.
89188022|NCT04072718|Other|Single arm|
89188023|NCT04038086|Experimental|oral glucose tolerance test|
89188024|NCT04038086|Other|circadian rhythm|
89188025|NCT04038086|Experimental|effect of insulin on peptide transport|
89188026|NCT03177577|Placebo Comparator|Splint Only|Subjects with carpometacarpal (CMC) osteoarthritis treated by splinting of their thumb.
89188027|NCT03177577|Active Comparator|Splint with first dorsal interosseous (FDI) strengthening|Subjects with carpometacarpal (CMC) osteoarthritis treated by splinting of their thumb combined with first dorsal interosseous (FDI) strengthening stabilization exercises.
89397218|NCT05933681|Experimental|Neurophysiology biomarkers of DBS mediated cognitive impairment following chronic stimulation|Neurophysiology recordings will be performed from subthalamic nucleus (STN) or globus pallidus internus (GPI) with stimulation on and off, at rest and during a working memory task, in patients who have previously been implanted with DBS and have implantable pulse generators capable of recording local field potentials.
89397219|NCT05922566|Experimental|fMRI scanning while Mukbang watching|"The fMRI scanning will be divided into 3 parts, includes structural image scans, resting state scans, and task state scans. For the task state function image scanning, participants will be asked to watch the specific video program which includes the food images and eating sound of Mukbang and General short videos without food cues.~Healthy kids and children with cancer hospitalized for radiotherapy and chemotherapy will both accept this intervention."
89397220|NCT05921279||Anthracycline based chemotehrapy low and moderate risk|"Patients recieving anthracycline based chemotherapy who fall into the low and moderate risk category following HFA - ICOS cardiac risk assessment as per the European Society of Cardiology Guidelines.~These patients are monitored taking biobank bloods, bloods, ecg and cardiac echo as per the European Society of Cardiology guidelines whilst receiving chemotherapy."
89397221|NCT05921279||Anthracycline based chemotherapy - high and very high risk|"Patients who recieving anthracycline who fall into the high and very high risk category following HFA - ICOS cardiac risk assessment as per the European Society of Cardiology Guidelines.~These patients are monitored taking biobank bloods, bloods, ecg and cardiac echo as per the European Society of Cardiology guidelines whilst receiving chemotherapy."
89397222|NCT05921279||Herceptin targeted therapy - low and moderate risk|Patients who are recieving herceptin that fall into the low and moderate risk category following HFA-ICOS cardiac risk assessment as per the European Society of Cardiology Guidelines. These patients are monitored taking biobank bloods, bloods, ecg and cardiac echo as per the European Society of Cardiology Guidelines.
89397223|NCT05921279||Herceptin targeted therapy - high and very high risk|Patients who are recieving herceptin that fall into the high and very high risk category following HFA-ICOS cardiac risk assessment as per the European Society of Cardiology Guidelines. These patients are monitored taking biobank bloods, bloods, ecg and cardiac echo as per the European Society of Cardiology Guidelines.
89397224|NCT05920733|Experimental|HealthyLifetime Group|This project is designed to prepare and equip the participant for improved self-care capacity, motivational insight, health-related problem solving and decision-making.
89397225|NCT05919810|Experimental|Probiotic|Daily consumption of probiotic
89397226|NCT05919810|Experimental|Oral herbal supplement|Daily consumption of oral herbal supplement powder
89397227|NCT05916222|Active Comparator|Indirect Training (DTTC + Home Practice)|Children in the Indirect Training Arm will receive DTTC treatment 2x/week administered by an SLP for 8 weeks. Parent/caregivers in this Arm will complete an online, self-paced educational module on CAS prior to the start of treatment, observe all treatment sessions, and review home practice guidelines with the clinician at the end of each therapy session. Parent/caregivers will engage their children in home practice during the treatment phase and follow-up phase. Home practice will consist of 30-minute practice sessions 3x/week during the 8-week treatment phase and 6x/week during the 4-week follow-up phase.
89397228|NCT05916222|Experimental|Direct Training (DTTC + Coaching + Home Practice)|Children in the Direct Training Arm will receive DTTC treatment 2x/week for 8 weeks with half of each session administered only by the SLP. In the other half of the session, DTTC will be administered by the parent/caregiver with online coaching by the SLP. During the coaching portion of treatment sessions, the SLP will provide direct training to guide the parent/caregiver in the administration of DTTC to support home practice sessions. Parent/caregivers in this Arm will also complete an online, self-paced educational module on CAS prior to the start of treatment and review home practice guidelines with the clinician at the end of each therapy session. Parent/caregivers will engage their children in home practice during the treatment phase and follow-up phase. Home practice will consist of 30-minute practice sessions 3x/week during the 8-week treatment phase and 6x/week during the 4-week follow-up phase.
89397229|NCT05914857|Experimental|Intervention group|Patients in the intervention group will be administered Dapagliflozin 10 mg/day in addition to lifestyle intervention.
89397230|NCT05914857|Placebo Comparator|Control group|Patients in the control group will be given lifestyle intervention only.
89397231|NCT05909696|Experimental|Age range of 18 to 44 years olds|Age range of 18 to 44 years olds The initial dose of rocuronium for pre-injection was set at 0.04mg/kg according to previous literature and preliminary test results. The dose of rocuronium was according to the patients' myofibrillation level. If there is no myofibrillation (negative reaction), the dose of rocuronium in the next patient will be reduced until the patient has myofibrillation. If there is myofibrillation (positive reaction), the dose of rocuronium will be increased in the next patient until the patient is no fibrillation.
89397232|NCT05909696|Experimental|Age range of 45 to 59 years olds|Age range of 18 to 44 years olds The initial dose of rocuronium for pre-injection was set at 0.04mg/kg according to previous literature and preliminary test results. The dose of rocuronium was according to the patients' myofibrillation level. If there is no myofibrillation (negative reaction), the dose of rocuronium in the next patient will be reduced until the patient has myofibrillation. If there is myofibrillation (positive reaction), the dose of rocuronium will be increased in the next patient until the patient is no fibrillation.
89397233|NCT05909696|Experimental|Age range of 60 to 80 years olds|Age range of 18 to 44 years olds The initial dose of rocuronium for pre-injection was set at 0.04mg/kg according to previous literature and preliminary test results. The dose of rocuronium was according to the patients' myofibrillation level. If there is no myofibrillation (negative reaction), the dose of rocuronium in the next patient will be reduced until the patient has myofibrillation. If there is myofibrillation (positive reaction), the dose of rocuronium will be increased in the next patient until the patient is no fibrillation.
89397234|NCT05909527|Experimental|Treatment group|"Dose escalation: After enrollment ,Participants complete the PBMC apheresis, then complete the Lymphocyte clearance, and then receive the dose climming test: 0.50E6/kg±20%, 1.00E6/kg±20%、2.00E6/kg±20%.~Dose Expansion: During or after the dose increase process, if a certain dose group is determined to have preliminary anti-tumor effects and controllable safety, it can be extended at this dose level to further evaluate the tolerance and safety of CD7 CAR-T injection, and to preliminarily evaluate its effectiveness."
89397235|NCT05907811|Sham Comparator|Group general anesthesia (GA)|Anesthesia induction was applied to all patients with 1mg/kg lidocaine, 1μcg/kg fentanyl, 2mg/kg propofol, 0.6mg/kg rocuronium. When the TOF value was 0, the patients were intubated with an endotracheal tube. In the maintenance, desflurane at 8% concentration was used in a mixture of 50% O2 + 50% air. The time to reach 25% of the TOF value was noted in both groups. 0.1mg/kg rocuronium will be added to patients who reach 0.25.It was planned to administer 0.05mg/kg morphine 30 minutes before the end of the operation to the GA group.
89397236|NCT05907811|Experimental|Group General anesthesia and Thoracal epidural (GAE)|Electrodes were placed for TOF monitoring after thoracic epidural catheterization in the GAE group. Anesthesia induction was applied to all patients with 1mg/kg lidocaine, 1μcg/kg fentanyl, 2mg/kg propofol, 0.6mg/kg rocuronium. When the TOF value was 0, the patients were intubated with an endotracheal tube. In the maintenance, desflurane at 8% concentration was used in a mixture of 50% O2 + 50% air. The time to reach 25% of the TOF value was noted in both groups. 0.1mg/kg rocuronium will be added to patients who reach 0.25.The number of additional muscle relaxant requirements made will be recorded. In the GAE group, 5 ml of epidural medication will be given per hour. When the TOF value reached 70%, inhaler anesthetics were discontinued and the patients with a TOF value of 90% were extubated.
89397237|NCT05903300||Professional orchestra musicians|The study group consists of adult, professionally active people (women and men) who are professional orchestra musicians. The mother tongue of the respondents must be Polish.
89397238|NCT05901350|No Intervention|Levodopa Reduction Group After STN-DBS|Patients in this group started to reduce levodopa dose 1 months after STN-DBS
89397239|NCT05901350|Experimental|Levodopa non-Reduction Group After SNT-DBS|Patients in this group did not reduce levodopa dose until 12 months after STN-DBS
89397240|NCT05894967|Experimental|C1 - Standard Perceptual Learning (SPL)|Participants will complete SPL training during the first phase of training. In the cross-over they will then complete either SPL, LT, SS, MD, NT, TWF, or NCC.
89397241|NCT05894967|Experimental|C2 - Long Training (LT)|Participants will complete LT training during the first phase of training. In the cross-over they will then complete either LT, SPL, or NCC.
89397242|NCT05894967|Experimental|C3 - Short Staircases (SS)|Participants will complete SS training during the first phase of training. In the cross-over they will then complete either SS, SPL, or NCC.
89397243|NCT05894967|Experimental|C4 - Mixed Difficulty (MD)|Participants will complete MD training during the first phase of training. In the cross-over they will then complete either MD, SPL, or NCC.
89397244|NCT05894967|Experimental|C5 - Noise Training (NT)|Participants will complete NT training during the first phase of training. In the cross-over they will then complete either NT, SPL, or NCC.
89397245|NCT05894967|Experimental|C6 - Training with Flankers (TWF|Participants will complete TWF training during the first phase of training. In the cross-over they will then complete eitherTWF, SPL, or NCC.
89397246|NCT05894967|Experimental|C7 - Parafoveal Training (PT)|Participants will complete PT training during the first phase of training. In the cross-over they will then complete either PT, SV, CF, ExAT, EnAT, MF, or NCC.
89397247|NCT05894967|Experimental|C8 - Stimulus Variety (SV)|Participants will complete SV training during the first phase of training. In the cross-over they will then complete either SV, PT, or NCC.
89397248|NCT05894967|Experimental|C8a - Complex Features (CF)|Participants will complete CF training during the first phase of training. In the cross-over they will then complete either CF, PT, NCC.
89397249|NCT05894967|Experimental|C9 - Exogenous Attention Training (ExAT)|Participants will complete ExAT training during the first phase of training. In the cross-over they will then complete either ExAT, PT, NCC.
89004016|NCT03688100|Active Comparator|Patients: Behavioral Activation Therapy (BA)|BA is an evidence-based psychotherapy with more than 25 randomized trials showing effectiveness in depression. The therapy group will consist of an introductory in person 50-minute treatment session, followed by 12 weekly telephone 50-minute outpatient treatment sessions, then 3 monthly telephone 50-minute outpatient maintenance sessions. A typical BA session will last 50 minutes and include a review of the previous session and completed daily monitoring record forms, an in-depth discussion of life areas and value, and verbal reinforcement of activity engagement.
89188028|NCT04072640|Experimental|voriconazole treatment|induction treatment with Voriconazole 200mg bid (IV) + 5FC (100mg/kg/d) for 14 days, consolidation treatment wiht fluconazole 400mg/d for two months, then maintenance treatment with fluconazole 200mg/d
88873285|NCT01568177|Other|abnormal CRT|"40 subjects with microvascular coronary dysfunction (MCD) defined as abnormal CRT.~Visits 1, 2, and 3"
88873286|NCT01568177|Other|Cardiac Syndrome X|20 subjects with symptoms and normal stress tests, no MCD. Visits 1 and 2
88873287|NCT01568177|Other|normal reference controls|40 normal reference controls subjects Visits 1 and 2
88873288|NCT01536990||Stroke|Medically stable patients receiving inpatient or outpatient physical therapy care for lower extremity dysfunction secondary to stroke.
88873289|NCT01503632|Experimental|Arm I (intervention program and mercaptopurine)|See detailed description.
88873290|NCT01503632|Active Comparator|Arm II (standard of care and mercaptopurine)|Patients receive the usual standard of care and the mercaptopurine from the MEMS® medication bottle with TrackCap™ as patients in arm I. Patients and caregivers also view an interactive multimedia educational program on day 29.
88873291|NCT01474889|Experimental|Hypoglycemia Unaware T1 Diabetes RT-CGM|"This arm is the intervention group. It consists of participants with type 1 diabetes complicated by hypoglycemia unawareness. Patients wore an RT-CGM for 18 months. We studied glucose production and symptom generation during insulin-induced hypoglycemia (metabolic testing) by subjecting this intervention group to a pair of metabolic clamps (hypoglycemic and euglycemic) at baseline, at 6 months and at 18 months to determine if hypoglycemia avoidance can reverse unawareness.~Please note: Arms are not assigned to the two control groups (non-diabetics and T1Ds with intact awareness) in ct.gov as they are only used as a baseline for clinical significance. Neither group wore a CGM nor are they analyzed at 6-month and 18-month time-points."
88873292|NCT01407081|Experimental|Training|telerehabilitation cognitive strategy training
88873293|NCT01231906|Experimental|Arm A (combination chemotherapy)|"INDUCTION THERAPY: Patients receive vincristine sulfate IV on day 1 in weeks 1, 2, 5, 6, 9, and 10; doxorubicin hydrochloride IV over 1-15 minutes (or as per institutional policies up to 60-minutes) on days 1 and 2 and cyclophosphamide IV over 30-60 minutes on day 1 in weeks 1, 5, and 9; and ifosfamide IV over 1 hour and etoposide IV over 1-2 hours on days 1-5 in weeks 3, 7, and 11.~CONSOLIDATION THERAPY: Patients receive vincristine sulfate IV on day 1 in weeks 1, 2, 7, 8, 9, 10, 13, 14, 17, 18, 21, and 22; doxorubicin hydrochloride IV on days 1 and 2 in weeks 1 and 9; cyclophosphamide IV over 30-60 minutes on day 1 in weeks 1, 7, 9, 13, 17, and 21; and ifosfamide IV over 1 hour and etoposide IV over 1-2 hours on days 1-5 in weeks 3, 5, 11, 15, and 19. Patients received Dexrazoxane with doxorubicin hydrochloride in weeks 1 and 9."
88873294|NCT01231906|Experimental|Arm B (combination chemotherapy, topotecan hydrochloride)|"INDUCTION THERAPY: Patients receive vincristine sulfate IV on day 1 in weeks 1, 2, 5, 6, 9, 10, 11 and 12; topotecan hydrochloride IV over 30 minutes on days 1-5 in weeks 1 and 9; cyclophosphamide IV over 15-30 minutes on days 1-5 in weeks 1 and 9, and over 30-60 minutes on day 1 of weeks 5 and 11; ifosfamide and etoposide as in arm A; and doxorubicin hydrochloride IV on days 1 and 2 in weeks 5 and 11.~CONSOLIDATION THERAPY: Patients receive vincristine sulfate IV on day 1 in weeks 1, 2, 7-10, 13-16, 19, and 20; topotecan hydrochloride IV over 30 minutes on days 1-5 in weeks 1, 7, and 15; cyclophosphamide IV over 15-60 minutes on days 1-5 in weeks 1, 7, and 15, and over 30-60 minutes on day 1 in weeks 9, 13, and 19; ifosfamide IV over 1 hour and etoposide IV over 1- 2 hours on days 1-5 in weeks 3, 5, 11, 17, and 21; and doxorubicin hydrochloride IV on days 1 and 2 in weeks 9,13, and 19. Patients received Dexrazoxane with doxorubicin hydrochloride in weeks 13 and 19."
88873295|NCT01154257|Experimental|Cleaning teeth with toothbrush|Following randomisation one side of the mouth (split mouth study) will be assigned to cleaning teeth with a toothbrush
88873296|NCT01154257|Experimental|Cleaning teeth with foam swab|Following randomisation one side of the mouth (split mouth study) will be assigned to cleaning teeth with a faom swab
88873297|NCT01143961|Experimental|NBL with one-way valve|NBL performed with one-way valve in ventilator circuit during procedure
88873298|NCT01143961|No Intervention|Standard NBL|Performance of standard NBL with recording of changes in regional ventilation by electrical impedance tomography
89397250|NCT05894967|Experimental|C10 - Endogenous Attention Training (EnAT)|Participants will complete EnAT training during the first phase of training. In the cross-over they will then complete either EnAT, PT, NCC.
88873299|NCT00899223||Group 1|Previously untreated patients on a CALGB treatment protocol for leukemia (acute or chronic) or myelodysplasia are eligible. Patients must be registered to CALGB 9665 prior to receiving any therapy for their disease.
88873300|NCT00788164|Experimental|Groups 1-3|Patients receive pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine intramuscularly (IM) on days 1 and 29 and TA-HPV vaccine IM on day 57.
88873301|NCT00788164|Experimental|Group 4|Patients receive topical imiquimod on days 1, 29, and 57.
88873302|NCT00788164|Experimental|Group 5|Patients receive pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine and TA-HPV vaccine as in groups 1-3, and imiquimod as in group 4.
88873303|NCT00724048|Placebo Comparator|Placebo|Participants will receive a placebo capsule once daily for the first 4 weeks. After 4 weeks (Weeks 5 to 12), placebo capsule will be taken twice daily (BID) as 2 separate doses.
88873304|NCT00724048|Experimental|ACR16 10 mg BID|Participants will receive ACR16 10 milligrams (mg) capsule orally once daily for the first 4 weeks. After 4 weeks (Weeks 5 to 12), ACR16 10 mg capsule will be taken twice daily (BID) as 2 separate doses (total dose: 20 mg).
88873305|NCT00724048|Experimental|ACR16 22.5 mg BID|Participants will receive ACR16 22.5 mg capsule orally once daily for the first 4 weeks. After 4 weeks (Weeks 5 to 12), ACR16 22.5 mg capsule will be taken twice daily (BID) as 2 separate doses (total dose: 45 mg).
88873306|NCT00724048|Experimental|ACR16 45 mg BID|Participants will receive ACR16 45 mg capsule once daily for the first 4 weeks. After 4 weeks (Weeks 5 to 12), ACR16 45 mg capsule will be taken twice daily (BID) as 2 separate doses (total dose: 90 mg).
88873307|NCT00579605|Experimental|1 Motivational Interviewing|1 intervention group 1 attention intervention group Behavioral: Motivational Interviewing Client-centered strategy that may decrease ambivalence in behavior performance
88873308|NCT00572416|Experimental|1 Individual Sleep Promotion Plan|Four component behavioral sleep intervention comprised of activity-rest, sleep-wake, psychological distress and symptom management. Four components of the Individual Sleep Promotion Plan are: stimulus control, sleep restruction, relaxation, and sleep hygiene.
88873309|NCT00572416|Placebo Comparator|2 Healthy Eating Control|Equal time and attention, information about healthy eating and general conversation
88873310|NCT00354393|Experimental|Induction Combination Chemotherapy|"Induction chemotherapy: Patients get MVP chemo. Treatment repeats every 28 days for 2 courses.~Patients w/ unresectable disease may get up to 2 add'l courses of induction chemo. Patients requiring palliative radiotherapy or have PD are removed from study. Patients w/ resectable disease or sarcomatoid histology & T1-3, N1-2 disease w/ a CR or PR to induction chemo go to surgery.~Surgery: Patients w/ extensive disease get palliative debulking pleurectomy and decortication & are taken off study. Other patients undergo a thoracotomy w/ extrapleural pneumonectomy & proceed to chemoradiotherapy.~Chemoradiotherapy: At 6-10 weeks post-op, patients get 3-dimensional conformal or intensity-modulated radiotherapy once daily, 5 days a week, for 6 weeks. Patients receive cisplatin IV over 30-60 minutes days 1 & 22. Patients w/ responding disease proceed to adjuvant chemotherapy.~Adjuvant chemotherapy: Patients get 2 more courses of MVP chemotherapy"
88873311|NCT00160680|Experimental|Continuous Treatment|5 mg of Levocetirizine (LCTZ) was taken orally once a day.
88873312|NCT00160680|Experimental|On Demand Treatment|5 mg of Levocetirizine (LCTZ) was taken whenever needed.
88873313|NCT01818804|Active Comparator|n-3PUFA|n-3 polyunsaturated fattyacids from fish oil
88873314|NCT01818804|Placebo Comparator|olive oil|Olive oil
88873315|NCT01820754|Experimental|Ipilimumab|Neoadjuvant (Pre-Surgery): Cycles 2 and 3: Ipilimumab 10 mg/kg IV over 90 minutes Adjuvant (Post-Surgery): Ipilimumab 10 mg/kg IV every 3 weeks times 2 doses beginning 4 weeks postoperative ( up to 10 weeks if needed for recovery) Maintenance: Ipilimumab 10 mg/kg/IV every 12 weeks times 2 doses
88873316|NCT01821300||Down syndrome|No intervention occurred as this was a cross sectional observational study.
89397251|NCT05894967|Experimental|C11 - Multisensory Facilitation (MF)|Participants will complete MF training during the first phase of training. In the cross-over they will then complete either MF, PT, NCC.
88873317|NCT01821300||Control|No intervention occurred as this was a cross sectional observational study.
88873318|NCT01821378|Experimental|Lurasidone 20 mg|Lurasidone 20 mg once daily
88873319|NCT01821378|Experimental|Lurasidone 80 mg|Lurasidone 80 mg once daily initially rerandomized either to 80 mg or 160 mg at week 2
88873320|NCT01821378|Placebo Comparator|Placebo|Placebo Comparator 20 or 80 mg once daily
88873321|NCT01821534||All Participants|Healthy volunteers. No treatment (intervention) was administered.
88873322|NCT01822548|Experimental|Vildagliptin & metformin|Vildagliptin 100 mg tablet and metformin (max dose=2500 mg) tablet daily oral administration
89397252|NCT05894967|Other|No Contact Control|Participants will complete NCC training during the first phase of training. In the cross-over they will then complete either SPL, LT, SS, MD, NT, TWF, PT, SV, CF, ExAT, EnAT, MF, NCC.
89397253|NCT05894018|Experimental|Fluzoparib+radioactive particle implantation|Fluzoparib 150 mg bid was given orally after meals for 2 months (60 days) in a continuous cycle 48h after radioactive particle implantation.
88873323|NCT01822548|Active Comparator|Glibenclamide & metformin|Glibenclamide maximum dose of 10 mg tablet and metformin (max dose=2500 mg) tablet daily oral administration
88873324|NCT01825122|Placebo Comparator|Placebo|placebo
88873325|NCT01825122|Experimental|Active, nadolol|Active
88873326|NCT01825512|Experimental|Deferiprone|75-100 mg/kg/day seven days per week
88873327|NCT01825512|Active Comparator|Deferasirox|20 to 40 mg/kg/day seven days per week
89004017|NCT03688100|No Intervention|Caregivers: Medication Management (MEDS)|Caregivers of patients receiving the the above described Medication Management (MEDS) intervention were monitored for caregiver burden at 3, 6, and 12 months.
89397254|NCT05893407||Patients with acute brain injuries when a contrast ultrasound imaging is requested by the physician|Contrast-enhanced ultrasound perfusion imaging (PerCEUS)
89397255|NCT05892497|Experimental|Tecartherpay Group|A single 25-minute tecartherapy procedure will be performed in both legs with the T-Plus Wintecare® machine. The configuration of the tecartherapy programme will be in 40 watts resistive mode for each muscle.
89397256|NCT05892497|Sham Comparator|Sham group|The same procedure of the intervention group will be performed but with the tecartherapy machine without power (sham). The machine will be on but no power will be supplied.
89397257|NCT05888675|Other|Clinical Study of Weifuchun Treatment on Gastric Cancer|72 patients with gastric cancer were randomly divided into a treatment group of 36 cases and a control group of 36 cases. The treatment group received combination chemotherapy with Weifuchun tablets, while the control group received monotherapy chemotherapy.
88873328|NCT01827462|Experimental|18-30 year olds at enrollment|"Licensed seasonal Fluzone (inactivated influenza vaccine):~Trivalent, inactivated influenza vaccine (TIV) was given through the 2013-2014 season.~Beginning with 2014-2015 season, Quadrivalent, inactivated influenza vaccine (IIV4) was given."
89397258|NCT05882084|Experimental|Astaxanthin|6 mg daily
89397259|NCT05882084|Placebo Comparator|Placebo|
89397260|NCT05870462|Experimental|Semaglutide|Participants will receive once-weekly semaglutide subcutaneous injection [Ozempic] at escalating doses from 0.25 mg/week, 0.5 mg/week, to 1.0 mg/week.
89397261|NCT05870462|No Intervention|Usual care|Participants will continue to receive other usual medications, rehabilitation, procedures, and interventions as recommended by their healthcare providers.
89397262|NCT05861102|Experimental|Jaktinib 100mg BID (twice daily)|
89397263|NCT05861102|Placebo Comparator|Placebo|
89397264|NCT05830500|Experimental|Anlotinib capsules|Anlotinib: 12 mg once daily for 2 weeks, followed by a discontinuance of 1 week (21-daya as a cycle)
88873329|NCT01827462|Experimental|60-80 year olds at enrollment|"Licensed seasonal Fluzone (inactivated influenza vaccine):~Trivalent, inactivated influenza vaccine (TIV) was given through the 2013-2014 season.~Beginning with 2014-2015 season, High-Dose trivalent, inactivated influenza vaccine (TIV High-Dose) was given."
88873330|NCT01827462|Experimental|80-100 year olds at enrollment|"Licensed seasonal Fluzone (inactivated influenza vaccine):~Trivalent, inactivated influenza vaccine (TIV) was given through the 2013-2014 season.~Beginning with 2014-2015 season, High-Dose trivalent, inactivated influenza vaccine (TIV High-Dose) was given."
89397265|NCT05830500|No Intervention|Observation|Observational group: prospectively and retrospectively collect data for patients who did not receive anlotinib hydrochloride capsules or similar small-molecule antivascular inhibitors (including Rearranged during transfection (RET) inhibitors, etc.).
89397266|NCT05830292|Experimental|DRS in-vivo|Participants (patients undergoing GI cancer surgery) will have a DRS probe used on the in-vivo tissue for 5-10 minutes during a single operation
89397267|NCT05829421|Experimental|Impairment-specific occupational therapy (OT) intervention|Patients receive an impairment-specific OT intervention targetting problems in managing activities of daily living (ADL) due to mild-to-moderate poststroke cognitive impairments. The intervention is initiated in the stroke unit as soon as patients' medical condition allows it, and it is delivered 3 times per week until 3 months poststroke. After hospital discharge, the intervention continues in community settings.
89397268|NCT05822440|Experimental|Period 1|The treatment arm includes a single dose of PF-07817883 (Period 1 Day 1)
89397269|NCT05822440|Experimental|Period 2|This treatment arm includes 7-day dosing of itraconazole with a single dose of PF-07817883 Co-administered on Day 4 (Period 2 Day 4)
89397270|NCT05819203|Experimental|Healsea Babykids|Healsea® Babykids, nasal spray indistinguishable from the comparator. Subjects have to spray 2 puffs in each nostril 2 times per day with a minimum of 7-day-treatment period (14 intakes ) up to 10 days (20 intakes ).
89397271|NCT05819203|Placebo Comparator|Placebo|"The comparator is a saline isotonic nasal spray considered as inert Placebo i.e., neutral for the nasal mucosa.~Subjects have to spray 2 puffs in each nostril 2 times per day with a minimum of 7-day-treatment period (14 intakes ) up to 10 days (20 intakes )."
89397272|NCT05819190|Experimental|Healsea Rescue* group|Subjects will receive Healsea Rescue* according to its intended use.
89397273|NCT05819190|Placebo Comparator|Placebo group|Subjects will receive Placebo according to identical posology, instructions for use, contraindication, precaution of use and labelling to those of Healsea Rescue.
89397274|NCT05814341|Experimental|High iCa target|Post-filter iCa between 0,35-0.45 mmol/L
89397275|NCT05814341|Active Comparator|Low iCa target|Post-filter iCa between 0.25-0.35 mmol/L
89397276|NCT05805839|Experimental|Healthy Control Group|Subjects without inflammatory-demyelinating diseases of the central nervous system
89397277|NCT05805839|Experimental|Multiple Sclerosis Group|Subjects with current diagnosis of Multiple Sclerosis or an InflammatoryDemyelinating Disease of the Central Nervous System will have a PET/CT scan with radiotracer drug C-11 PIB & C-11 ER176
89397278|NCT05795114|No Intervention|Enhanced treatment as usual|Those randomized to enhanced treatment as usual will receive brief psychoeducation about perinatal depression and the associations between ACEs and perinatal depression. Information about the collaborative care program will be provided. Individuals will be followed with monthly self-reported screens for depression, without any prevention programming for perinatal depression. Those identified to have incident depression symptoms will receive recommendations for treatment within the collaborative care model.
88873331|NCT01827930|Experimental|Imatinib 600 (Randomized trial)|Randomized Cohort: Adapted strategy of dosage of Imatinib Mesylate : 600mg/d po
88873332|NCT01827930|Active Comparator|Imatinib 400 (Randomized trial)|Randomized Cohort: Standard strategy of dosage of Imatinib Mesylate : 400mg/d po
88873333|NCT01827930|Other|Imatinib400 (Cohort)|Parallel Cohort: Standard strategy of dosage of Imatinib Mesylate : 400mg/d po
88873334|NCT01828164|Experimental|Treatment Arm|20 minutes per day of ultrasound treatment on the active side of the device. The device consists of a mouth guard type device with transducers embedded in the mouth guard. In the split mouth design, the treatment arm consist of the side of the mouth with the transducers activated.
88873335|NCT01828164|Sham Comparator|Control Arm|The transducers are not activated on the control side of the device.The subjects wear the device for 20 minutes per day for the duration of the study. The device consists of a mouth guard type device with transducers embedded in the mouth guard. In the split mouth design, the control arm consist of the side of the mouth with the transducers deactivated.
88873336|NCT01828476|Experimental|ARM A|Abiraterone with ABT-263
88873337|NCT01828476|Experimental|ARM B|Abiraterone with both ABT-263 and Hydroxychloroquine
88873338|NCT01828554|Experimental|Xeloda (Capecitabine)|"Cycle 1: Days 1-7 (21 day cycle): 1250 mg/m2 Xeloda orally twice a day using Ideal Body Weight to calculate dosage. Cycle 1, Day 8-No drug.~Cycle 1: Days 9-15 (21 day cycle): 1250 mg/m2 Xeloda orally twice a day using Actual Body Weight to calculate dosage. Days 16-21-No drug.~Cycle 2 and greater: Days 1-14 (21 day cycle): 1250 mg/m2 Xeloda orally twice a day using Actual Body Weight to calculate dosage."
88873339|NCT01832610||HeartWare® VAS|Ventricular Assist Device (HeartWare® VAS)
88873340|NCT01833078|Other|7 day ghrelin dosing - all participants|All participants will receive an injection of ghrelin (7.5mcg/kg) dose subcutaneously once daily on Days 1, 2 and 7 in the research center and will self-administer the subcutaneous injection before breakfast on Days 2-6 at home.
88873341|NCT01833936|Active Comparator|Group 1- Compex® muscle stimulator|Group 1 will receive an active muscle stimulator, which will be placed immediately following surgery. Eight electrodes will be placed on the lower leg: four electrodes on the gastrocnemius (calf muscle), and two electrodes each on the lateral gastrocnemius (side) and anterior tibialis muscle (front). Subjects will use the stimulator for three 20 minute sessions per day.
88873342|NCT01833936|Sham Comparator|Group 2 -(inactive) muscle stimulator|Group 2 will receive a placebo (inactive) muscle stimulator, which will be placed immediately following surgery. Eight electrodes will be placed on the lower leg: four electrodes on the gastrocnemius (calf muscle), and two electrodes each on the lateral gastrocnemius (side) and anterior tibialis muscle (front). Subjects will be instructed to use the stimulator for three 20 minute sessions per day.
88873343|NCT01834326|Active Comparator|Palatal Oral Mucosa (POM) Graft|Standard of care palatal oral mucosa (POM) graft will be taken from the palate and then surgically placed onto the defect area
88873344|NCT01834326|Experimental|Ex vivo Produced Oral Mucosa Equivalent|Palatal biopsy will be harvested for fabrication of autogenous ex vivo produced oral mucosa equivalent (EVPOME) and then surgically placed onto the defect area
88873345|NCT01834404|Experimental|Phentermine-Topiramate ER|Qualifying participants were assigned to the Phentermine-Topiramate ER for a minimum of 5 days. The dosing of the study drug was phentermine 3.75 mg / topiramate 23 mg days 1-5. The dosing of the study drug was increased to phentermine 7.5 mg / topiramate 46 mg days 6-14.
88873346|NCT01834404|Placebo Comparator|Placebo|Qualifying participants were assigned to placebo for a minimum of 5 days. Placebo pills matched the study drug in appearance for the 2 dose levels.
88873347|NCT01834716|Experimental|Aerobics exercise|Participants in this group will be randomized to aerobics exercise (the equivalent of walking briskly for 50 minutes three times per week).
88873348|NCT01834716|Experimental|Non-Aerobics Exercise|Participants in this group will be randomized to a non-aerobics (attending classes of toning and stretching a minimum of three times per week) exercise group.
88873349|NCT01835262|Active Comparator|Morphine|Morphine Group -- Receiving morphine at 0.1 mg /kg given as IVP
88873350|NCT01835262|Experimental|Ketamine Group|Ketamine Group - - Receiving ketamine at 0.3 mg/given as IVP
89397279|NCT05795114|Experimental|ROSE intervention|"Those randomized to the intervention will be offered 4 group-based prenatal sessions and one individual postpartum booster session guided by the Reach Out, Stand Strong, Essentials for New Mothers (ROSE) program embedded within the collaborative care model. Participants will be followed with monthly self-reported screens for depression, and those identified to have incident depression symptoms will receive treatment within the collaborative care model."
88873351|NCT01835496|No Intervention|Ferriprox|single 1500 mg dose of Ferriprox
88873352|NCT01836042||Randomized iStent|Implantation of one iStent in conjunction with cataract surgery, patients randomized to group
88873353|NCT01836042||Randomized cataract surgery|Cataract surgery alone, patients randomized to group
88873354|NCT01836042||Non-randomized iStent|Implantation of one iStent in conjunction with cataract surgery, patients not randomized to group
88873355|NCT01766076|Experimental|atorvastatin, Lipitor®|"Intervention is be atorvastatin, Lipitor® (40mg) 2 tablets daily (as adjuvant to HAART) for 12 weeks.~Peripheral blood mononuclear cells (PBMC) will be collected for immune activation assays using flowcytometry"
88873356|NCT01766076|Placebo Comparator|Placebo|Intervention for the placebo comparator arm is Placebo 2 tablets daily for 12 weeks PBMC will be collected for immune activation assays using flowcytometry
88873357|NCT01767792|Experimental|Bevacizumab|Follow participant for 2 years and assess hearing response rates
88873358|NCT01794312|Experimental|T4020|One drop every 2 days
88873359|NCT01794312|Placebo Comparator|Vehicle|One drop every 2 days
88873360|NCT01797822|Experimental|Artificial tears first, then Dexamethasone|Artificial tears four times a day both eyes for two weeks, then Dexamethasone 0.01% four times a day both eyes for two weeks
88873361|NCT01809054|Active Comparator|Arixtra Arm|Arixtra (2.5 mg SQ/QD) subcutaneous injection daily for 2 weeks followed by aspirin 325 mg for 5 weeks
88873362|NCT01809054|Active Comparator|Pneumatic compression stockings arm|Pneumatic compression stockings (MCS, Active Care, medical compression systems Inc., Israel) for 2 weeks with concomitant Aspirin 325 mg daily for 5 weeks.
89188029|NCT04072640|Active Comparator|amphotericin treatment (0.7-1.0mg/kg/d)|Induction treatment with amphotericin B 0.7-1.0mg/kg/d + 5FC (100mg/kg/d) for 14 days,consolidation treatment wiht fluconazole 400mg/d for two months, then maintenance treatment with fluconazole 200mg/d
89188030|NCT04072640|Experimental|amphotericin B treatment (0.4-0.5mg/kg/d)|Induction treatment with amphotericin B 0.4-0.5mg/kg/d + 5FC (100mg/kg/d) for 28 days, consolidation treatment with fluconazole 400mg/d for two months, then maintenance treatment with fluconazole 200mg/d
89188031|NCT01566487|Experimental|Quetiapine fumarate tablets 300 mg|Quetiapine fumarate film-coated tablets 300 mg of Dr. Reddy's Laboratories Limited
89188032|NCT01566487|Active Comparator|Seroquel|Seroquel film-coated tablets 300 mg of Astrazeneca Pharmaceuticals, USA
89188033|NCT04819646|Experimental|Inflammation|Marine Lipid Oil concentrate softgel and dietary supplement capsule
89188034|NCT04073264|Experimental|monofilament|monofilament absorbable suture
89188035|NCT04073264|Active Comparator|polifilament|synthetic absorbable braided (polifilament) suture
89188036|NCT04019210|Experimental|MODIFIED TRABECULECTOMY|"Recta-angular scleral flap (one half the scleral thickness) is dissected,reaching 2 mm into the cornea. The dissection through the cornea is carried out with great care, leaving only thin corneal stroma over Descement's membrane.~Application of direct heat cautery using a prob Imm in size (the prob was heated for 45 seconds) the cautery was applied at 4 points two of them just in front of blue corneal line and the other two at 2 mm anterior to the blue line, the diameter of each point is 1 - 1.5 mm."
89188037|NCT02576288|Experimental|Sitagliptin|100mg will be administered by mouth daily for 28days
89188038|NCT02576288|Placebo Comparator|Matching Placebo|One placebo will be administered by mouth daily for 28days
89188039|NCT00427921|Experimental|1|Open Label
89188040|NCT04794374|Experimental|Discharged COVID-19 survivors|"Telerehabilitation will be provided by physiotherapists including audio, video visits.~A brochure designed by physiotherapists for COVID-19 survivors will be used. Physiotherapists will call patients weekly and guide, design, modify the exercises accordingly to the patients."
89188041|NCT00432991|Placebo Comparator|Saline Placebo|Drug: Saline Placebo 0.5 mL, IM (in the muscle), one time
89188042|NCT00432991|Experimental|IM Ephedrine|Drug: Ephedrine [Synonyms: Ephedra, Ephedrinum] 25 mg, IM (in the muscle), one time
89188043|NCT00432835|Active Comparator|Gastric Stimulation Days1-4/Sham5-8|The sequence followed for patients in Group 1 was: enrollment and acquisition of baseline data, then placement of electrode, then determination of mucosal EGG, then randomization to Group 1, then active stimulation for 72 consecutive hours, then a 1 day wash out, then the cross over, which entailed the device remaining inactive for the final 3 study days
89188044|NCT00432835|Active Comparator|Sham1-4/Gastric Stimulation Days5-8|The sequence followed for patients in Group 2 was: enrollment and acquisition of baseline data, then placement of electrode, then determination of mucosal EGG, then randomization to Group 2, then no stimulation whatsoever until Day 5, then the cross over,then active stimulation with the Gastric Electrical Stimulator for 72 consecutive hours.
89397280|NCT05790772|Experimental|Vigorous Exercise|50 Minutes of running on a treadmill
89397281|NCT05790252|Experimental|Bridge Induction Arm|
89397282|NCT05790252|Placebo Comparator|Standard Arm|
89397283|NCT05784480|Other|Evaluation of reversible causes using digital checklist and diagnostic support|
88873363|NCT01827306|Active Comparator|Biofreeze|Apply 5 minutes before therapy by applying a small coin sized amount to the painful area. Subjects will then complete a standard shoulder therapy program.
88873364|NCT01827306|No Intervention|Control|Subjects in this arm will complete a standard shoulder therapy program as normal, with no intervention.
88873365|NCT01833546|Experimental|Evofosfamide 240 mg|
88873366|NCT01833546|Experimental|Evofosfamide 340 mg|
88873367|NCT01833546|Experimental|Evofosfamide 480 mg|
88873368|NCT01833546|Experimental|Evofosfamide 340 mg + Gemcitabine|
88873369|NCT01837524|Experimental|Grocery-Store-Based Visit Arm|25 participants will be randomized to this arm. They will receive a baseline 30-minute phone call with the study dietitian to determine their current health problems, dietary patterns, shopping and cooking habits and health goals. They will then have 3 in-person visits with the dietitian conducted during grocery shopping trips at a local supermarket. These in-person visits will be conducted monthly over a 3 month period. The information delivered in the visits will be similar in content to that delivered in an in-office visit, including how to pick the best types of foods or ingredients for a given health condition, how to read and understand food labels, healthy recipes, how to track food and drink intake, and basic nutritional knowledge.
89397284|NCT05782985||Myeloproliferative neoplasms Cases|The myeloproliferative neoplasms Cases will be tested for expression of heterogeneous nuclear ribonucleoprotein H1 (HNRNPH1) and K (HNRNPK) genes
89397285|NCT05782985||Controls|Healthy controls will be tested for expression of heterogeneous nuclear ribonucleoprotein H1 (HNRNPH1) and K (HNRNPK) genes
89397286|NCT05781555|Experimental|DaRT seeds|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds
89397287|NCT05780593|Experimental|Intervention Group A|Manual mobilization of lumbosacral spine along with passive stretching of the hip abductors and 01 minute of inclined board standing for 03 times a day.
89397288|NCT05780593|Experimental|Intervention Group B|Routine medications(if any) along with 01 minute of inclined board standing for 03 times a day.
89397289|NCT05779397|Experimental|Test Subject|All subjects who are enrolled into the test group and participate in data collection receive the noninvasive Masimo RAD-GT
89397290|NCT05779280|Experimental|THDA + Acetyl Zingerone|Product will be used twice daily- once in the morning and once in the evening for 8 weeks. Each application will consist of 1-2 pumps (size of quarter) onto the face and neck, until fully absorbed.
88873370|NCT01837524|Active Comparator|Office-Based Visit Arm|25 participants will be randomized to this arm. They will receive a baseline 30-minute phone call with the study dietitian to determine their current health problems, dietary patterns, shopping and cooking habits and health goals. They will then have 3 in-person visits with the dietitian conducted in an office at one of our medical office buildings. These in-person visits will be conducted monthly over a 3 month period. The information delivered in the visits will include how to pick the best types of foods or ingredients for a given health condition, how to read and understand food labels, healthy recipes, how to track food and drink intake, and basic nutritional knowledge.
88873371|NCT01838226|Experimental|Group Prevention Clinics|A group problem-solving intervention, with interval phone calls delivered to check in on goal progress and reinforce group learning. Groups will meet monthly for 6 months, and each patient will be called once between each group session. Each group will consist of 10 patients. Problem-solving teaches patients to overcome internal barriers to healthful behaviors. Problem solving will be combined, at all group sessions, with self-efficacy training, so that patients will be taught simultaneously to overcome both internal and external barriers. Participants will be asked to develop personal goals related to cardiovascular disease (CVD)-related behaviors (e.g., smoking and weight reduction).
89397291|NCT05779280|Active Comparator|THDA only|Product will be used twice daily- once in the morning and once in the evening for 8 weeks. Each application will consist of 1-2 pumps (size of quarter) onto the face and neck, until fully absorbed.
89397292|NCT05771805|Experimental|Vagus nerve stimulation with task oriented training|Vagus nerve stimulation with task oriented training
89397293|NCT05771805|Active Comparator|Task oriented training|Task oriented training alone
89397294|NCT05766280|Experimental|Treatment|Soft Skills Training Intervention via telehealth
89397295|NCT05766280|No Intervention|Control|Treatment as Usual (TAU)
89397296|NCT05762237||Group|In the open source database (VitalDB, https://vitaldb.net), the patients who underwent general anesthesia with non-invasive monitoring including blood pressure, electrocardiography, pulse oximetry, bispectral index, capnography, and minimal alveolar concentration of inhalation agent.
89397297|NCT05757999|Active Comparator|MgSo4|A magnesium sulphate infusion (60 mg kg-1, total volume 100 ml, infusion rate 10 ml min-1) 10 min. will be administered before induction of anesthesia
89397298|NCT05757999|Placebo Comparator|Saline Placebo|an intravenous 0.9% saline infusion (total volume 100 ml, infusion rate 10 ml min-1) 10 min. will be administered before induction of anesthesia.
89397299|NCT05755958|Sham Comparator|HIFU SHAM|"The patient placed in the right lateral decubitus position under general anesthesia or spinal anesthesia on the operating table. An endorectal probe is inserted in the patient's rectum. The probe includes an imaging transducer to visualize the endometriosis lesions and locate areas to be treated and an ultrasound therapy transducer to administer the HIFU treatment. After identification of the treatment area, HIFU shots will not be delivered on the lesion to be treated in a blinded manner.~Patients randomized to this arm will received exactly the same procedure as patients in the HIFU group with the exception of the HIFU shots."
89397300|NCT05755958|Active Comparator|HIFU TREATMENT|The patient placed in the right lateral decubitus position under general anesthesia or spinal anesthesia on the operating table. An endorectal probe is inserted in the patient's rectum. The probe includes an imaging transducer to visualize the endometriosis lesions and locate areas to be treated and an ultrasound therapy transducer to administer the HIFU treatment. After identification of the treatment area, HIFU shots will be delivered on the lesion to be treated in a blinded maner.
89397301|NCT05751122|Experimental|Dynamic flex cast with neurodevelopmental Group|Dynamic flex cast with neurodevelopmental treatment
89397302|NCT05751122|Active Comparator|Rigid Ankle foot Orthosis with neurodevelopmental Group|Rigid Ankle foot Orthosis with neurodevelopmental treatment
89397303|NCT05748782||BASKA GROUP|the BASKA mask will be inserted, and its size will be chosen according to the manufacturer's weight-based recommendations.
89397304|NCT05748782||ETT GROUP|Patients in this group will be anesthetized using an endotracheal tube of appropriate size.
89397305|NCT05739747||Women undergoing cesarean section|This study is designed with a single cohort of women who will undergo a scheduled cesarean section
89397306|NCT05734300|Experimental|CELS|The Combined Endoscopic Laparoscopic Surgery (CELS) is a hybrid procedure that enables large local excisions of the colon without segmental resection while under general anaesthesia. In our study, CELS refers only to endoscopic assisted laparoscopic resection.
89397307|NCT05734300|Active Comparator|Standard Surgery|Standard surgical resection of colonic cancer following standard oncologic principles while under general anaesthesia.
89397308|NCT05731921|Experimental|Experimental group|The exercise program with the 'Empathy Dress'
89397309|NCT05731921|No Intervention|Control group|No intervention
88873372|NCT01838226|No Intervention|Treatment as usual control|Usual VA care
89530527|NCT03347201|Experimental|Intervention Group|"Initial heparin bolus before CPB to be calculated using HMS Plus.~Following commencement of CPB further heparin requirements will be determined using the HMS Plus. ACT's will also be checked whilst on CPB and if falls below 480 seconds, additional heparin will also be given.~Following cessation of CPB the dose of protamine required to reverse residual heparin will be calculated using the HMS Plus."
88873373|NCT01838304|Active Comparator|Monitoring|Standard of care sedation by CRNA using proposal with manual recording of drug dosing
88873374|NCT01838304|Experimental|Probability ramp control|Propofol titrated to deep sedation using PRC software.
88873375|NCT01839318|Experimental|DAILIES AquaComfort Plus|Nelfilcon A contact lenses worn first, followed by etafilcon A and omafilcon A in randomized order. Each product worn for 1 day, 12 hours.
88873376|NCT01839318|Active Comparator|1-DAY ACUVUE MOIST|Etafilcon A contact lenses worn first, followed by nelfilcon A and omafilcon A in randomized order. Each product worn for 1 day, 12 hours.
88873377|NCT01839318|Active Comparator|Proclear 1 day|Omafilcon A contact lenses worn first, followed by etafilcon A and nelfilcon A in randomized order. Each product worn for 1 day, 12 hours.
88873378|NCT01839708|Experimental|Lifestyle Counseling|Intervention group: in addition to usual WIC care, watch the DVDs at home, complete action plan worksheets, call in to moderated (MI) group discussions.
88873379|NCT01839708|No Intervention|No Lifestyle Counseling|Comparison group: usual WIC care; read printed materials at home
88873380|NCT01840722|No Intervention|NIDA Standard HIV Education|NIDA Standard HIV Education Participants in this condition will be given HIV education using NIDA standard pre and post-test counseling, HIV and HCV rapid testing, and an information packet on existing community drug abuse and HIV/HCV resources
88873381|NCT01840722|Experimental|MI-based HIV Risk Reduction|MI-based HIV Risk Reduction -- In addition to what is received in the HIV-Ed group, participants in this condition will also receive a CDC evidence-based brief intervention for high-risk women focused on an individualized plan for enhancing motivation to reduce risk behaviors and to use health and behavioral health services in the community.
88873382|NCT01842594|Experimental|Sirolimus and hydroxychloroquine|Both hydroxychloroquine 200 mg/tab and sirolimus 1 mg/tab are pills each are taken 2 tablet orally once daily(QD) for 2 cycles . Each treatment cycle is 28 days.
88873383|NCT01842906|Experimental|Theravent|A singe use, disposable, positive end expiratory pressure device worn over the nostrils while sleeping.
88873384|NCT01842906|Sham Comparator|Control|A visibly identical sham device that does not provide positive end expiratory pressure.
88873385|NCT01843920|Active Comparator|Post surgery without glaucoma drops|This will be for the group that had gas duration surgery using SF6 (Sulfur Hexafluoride) or C3F8 (perfluoropropane gas tamponade) and only uses the standard post-operative topical drops.
88873386|NCT01843920|Experimental|Post surgery with glaucoma drops|This will be for the group that had gas duration surgery (using SF6 or C3F8). In addition to the standard post-operative topical drops, glaucoma drops, Timolol-dorzolamide (timolol 0.5%-dorzolamide 2%) will be given.
88873387|NCT01844388|Experimental|Carboxymethylcellulose Based Eye Drop Formula|1-2 drops of carboxymethylcellulose based eye drop formula in each eye, a minimum of 4 times a day for 90 days. One of the 4 times a day may be to prepare the contact lens for insertion.
88873388|NCT01844388|Active Comparator|REFRESH CONTACTS®|1-2 drops carboxymethylcellulose sodium based eye drop solution (REFRESH CONTACTS®) in each eye, a minimum of 4 times a day for 90 days. One of the 4 times a day may be to prepare the contact lens for insertion.
88873389|NCT01845636|Experimental|Donepezil Treatment & Atropine Challenge|Atropine nasal spray is administered at baseline for the atropine challenge which involves administration of the 40-item University of Pennsylvania Smell Identification Test (UPSIT) immediately before and 45 minutes after atropine administration. Immediately after the atropine challenge, donepezil treatment is started and continues for 52 weeks.
88873390|NCT01845792|Experimental|Cabazitaxel with Abiraterone Acetate|Cabazitaxel administered as a single intravenous dose every 3 weeks, in combination with abiraterone acetate and prednisone taken daily.
88873391|NCT01845792|Active Comparator|Cabazitaxel Alone|Cabazitaxel administered as a single intravenous dose every 3 weeks
88873392|NCT01846494||Hepatitis C Virus (HCV) patients exposed to BMS-986094|Hepatitis C infected patients with previous exposure to BMS-986094
88873393|NCT01846494||HCV patients not exposed to BMS-986094|Hepatitis C patients without exposure to BMS-986094
88873394|NCT01846728|Experimental|Estrogen suppression|Estrogen production will be suppressed using Lupron, a drug that blocks normal production of ovarian hormones
88873395|NCT01847196|Experimental|Angel® Catheter|All eligible subjects will receive an Angel® Catheter.
88873396|NCT01847430|Experimental|HBV Group|Subjects received a single dose of Engerix™-B Kinder vaccine (HBV). The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
88873397|NCT01848054|Experimental|BNX Sublingual Tablets Induction|"Day 1-2 (Blinded Induction): BNX sublingual tablets~Day 3-28 (Open-label Maintenance): BNX sublingual tablets"
88873398|NCT01848054|Active Comparator|Buprenorphine Induction|"Day 1-2 (Blinded Induction): Generic buprenorphine sublingual tablets~Day 3-28 (Open-label Maintenance): BNX sublingual tablets"
88873399|NCT01848366|Experimental|Biowave Treatment|Twelve weekly treatments
88873400|NCT01849068|Experimental|Ezetimibe|
88873401|NCT01849068|Placebo Comparator|Placebo|
88873402|NCT01849692|Experimental|ESBA1008 1.2 mg/10 μL|Cohort 1: One intravitreal injection on Day 0, followed by one intravitreal (IVT) injection of ESBA1008 6 mg/50 μL on Day 28
88873403|NCT01849692|Experimental|ESBA1008 1 mg/8.3 μL|Cohort 2: One intravitreal infusion on Day 0, followed by one intravitreal injection of ESBA1008 6 mg/50 μL on Day 28
88873404|NCT01849692|Experimental|ESBA1008 0.6 mg/10 μL|Cohort 3: One intravitreal injection on Day 0, followed by one intravitreal injection of ESBA1008 6 mg/50 μL on Day 28
88873405|NCT01849692|Experimental|ESBA1008 0.5 mg/8.3 μL|Cohort 4: One intravitreal infusion on Day 0, followed by one intravitreal injection of ESBA1008 6 mg/50 μL on Day 28
88873406|NCT01849692|Active Comparator|Ranibizumab 0.5 mg in 50 μL|Cohorts 1-4: One intravitreal injection on Day 0, followed by another intravitreal injection on Day 28
88873407|NCT01849770|Active Comparator|Mexiletine, 300 milligrams|Mexiletine, 300 milligrams by mouth per day for 12 weeks.
88873408|NCT01849770|Active Comparator|Mexiletine, 900 milligrams|Mexiletine, 900 milligrams by mouth per day for 12 weeks.
88873409|NCT01849770|Placebo Comparator|Placebo|Placebo, by mouth per day for 12 weeks.
88873410|NCT01850394|Placebo Comparator|Control group|physiologic saline 25 ml
88873411|NCT01850394|Active Comparator|TXA-250 group|A total of 25-ml solution with 250-mg tranexamic acid
88873412|NCT01850394|Active Comparator|TXA-500 group|A total of 25-ml solution with 500-mg tranexamic acid
89397310|NCT05729646|Experimental|Arm A (Chemotherapy+Toripalimab)|"Toripalimab, 240 mg IV infusion on Day 1 of each 21 day cycle for 3 cycles prior to surgery and 3 cycles after surgery.~Chemotherapy: SOX(S-1+Oxaliplatin) Oxaliplatin, administered as a 2-hour intravenous infusion (130 mg/m2) S-1, orally twice daily for 2 weeks followed by a 7-day rest period. The dose of S-1 was 80 mg/day for body surface area less than 1.25 m2, 100 mg/day for body surface area greater than or equal to 1.25 to less than 1.5 m2, and 120 mg/day for body surface area greater than or equal to 1.5 m2 Chemotherapy will be repeated each 21 day for 3 cycles prior to surgery and 3 cycles after surgery."
89397311|NCT05729646|Experimental|Arm B (Toripalimab monotherapy)|Toripalimab, 240 mg IV infusion on Day 1 of each 21 day cycle for 3 cycles prior to surgery and 3 cycles after surgery.
89397312|NCT05729646|Active Comparator|Arm C (Chemotherapy)|Chemotherapy: SOX(S-1+Oxaliplatin) Oxaliplatin, administered as a 2-hour intravenous infusion (130 mg/m2) S-1, orally twice daily for 2 weeks followed by a 7-day rest period. The dose of S-1 was 80 mg/day for body surface area less than 1.25 m2, 100 mg/day for body surface area greater than or equal to 1.25 to less than 1.5 m2, and 120 mg/day for body surface area greater than or equal to 1.5 m2 Chemotherapy will be repeated each 21 day for 3 cycles prior to surgery and 3 cycles after surgery.
89397313|NCT05726240|Experimental|Ghrelin treatment|Treatment in the intervention group will consist of intravenous acylated ghrelin, 600micrg dissolved in 50cc normal saline, by bolus (short term) infusion in 30 minutes, twice daily, for five days. This treatment will be additional to standard treatment, including intravenous thrombolysis, if indicated.
89397314|NCT05726240|No Intervention|Standard care|Treatment in the standard group consists of local practices for the treatment of stroke, including intravenous thrombolysis, if indicated.
89397315|NCT05698485|Experimental|3 Step Skin Care Regimen|3 different skin care products will be applied to the face
89397316|NCT05688527|Experimental|5 Step Skin Care Regimen|The subject uses 5 facial products in the regimen; a cleansing balm, a toner, a serum, a moisturizer and an eye cream.
89397317|NCT05687890|Experimental|SC0062 low dose group|Subjects will take two capsules daily for 24 weeks during the treatment period
89397318|NCT05687890|Experimental|SC0062 medium dose group|Subjects will take two capsules daily for 24 weeks during the treatment period
89397319|NCT05687890|Experimental|SC0062 high dose group|Subjects will take two capsules daily for 24 weeks during the treatment period
89397320|NCT05687890|Placebo Comparator|Placebo of SC0062 group|Subjects will take two capsules daily for 24 weeks during the treatment period
89397321|NCT05674344|Experimental|Masimo noninvasive temperature device|All subjects who qualify for the trial and participate in data collection will have temperature taken using the Masimo noninvasive temperature device and the reference temperature device.
89397322|NCT05661409|Active Comparator|Sugammadex 2 mg/kg|"The study team will identify patients who are scheduled to undergo an elective surgery under general anesthesia, received rocuronium for NMB and neostigmine for NMB reversal.~Patients will be randomized using the Emory University REDCap (Research Electronic Data Capture) software to six groups: 2 mg/kg (the lowest dose approved by the FDA), 1 mg/kg, 0.5 mg/kg, 0.25 mg/kg, 0.125 mg/kg of sugammadex and placebo. Doses would be based on actual body weight. The time taken to reach a TOF ratio of 0.9 thereafter would be measured. If the patient fails to achieve this goal by 10 minutes, sugammadex would be given in 2 mg/kg increments until the patient reaches this threshold and can be safely extubated. The TOF ratio would be measured again at 30 minutes after arrival at the PACU to exclude delayed residual NMB with the plan to give further 2 mg/kg doses of sugammadex if detected."
89397323|NCT05661409|Experimental|Sugammadex 1 mg/kg|"The study team will identify patients who are scheduled to undergo an elective surgery under general anesthesia, received rocuronium for NMB and neostigmine for NMB reversal.~Patients will be randomized using the Emory University REDCap (Research Electronic Data Capture) software to six groups: 2 mg/kg (the lowest dose approved by the FDA), 1 mg/kg, 0.5 mg/kg, 0.25 mg/kg, 0.125 mg/kg of sugammadex and placebo. Doses would be based on actual body weight. The time taken to reach a TOF ratio of 0.9 thereafter would be measured. If the patient fails to achieve this goal by 10 minutes, sugammadex would be given in 2 mg/kg increments until the patient reaches this threshold and can be safely extubated. The TOF ratio would be measured again at 30 minutes after arrival at the PACU to exclude delayed residual NMB with the plan to give further 2 mg/kg doses of sugammadex if detected."
88873413|NCT01850550|No Intervention|Control|"Participants in the control condition will be given written information at the baseline visit from the NIH website Aim for a Healthy Weight to provide a basic understanding of weight loss and access to basic online resources, but will not participate in group weight loss sessions with peer leaders."
88873414|NCT01850550|Experimental|Weight Loss Groups|Participants in this arm will receive peer-led facilitation within groups using an adaptation of the Diabetes Prevention Program.
88873415|NCT01851876|Experimental|Endometrial injury|The patients in this group will be subjected to endometrial injury procedure in preceding IVF cycle.
88873416|NCT01851876|No Intervention|No endometrial injury|The patients in this group will not be subjected to endometrial injury procedure in presiding IVF cycle. The patients will be stimulated with standard IVF protocol.
88873417|NCT01852032|Experimental|Breast cancer Patients|Tomosynthesis Breast Scanning is done and breast CT Scanning is done.
88873418|NCT01852344|Other|Placebo Easy|Healthy participant to be given 20 mgs of a placebo one hour before task performance and will perform an easy task.
88873419|NCT01852344|Other|Placebo Hard|Healthy participants are given 20 mgs of placebo one hour before task performance and will perform a hard task.
89397324|NCT05661409|Experimental|Sugammadex 0.5 mg/kg|"The study team will identify patients who are scheduled to undergo an elective surgery under general anesthesia, received rocuronium for NMB and neostigmine for NMB reversal.~Patients will be randomized using the Emory University REDCap (Research Electronic Data Capture) software to six groups: 2 mg/kg (the lowest dose approved by the FDA), 1 mg/kg, 0.5 mg/kg, 0.25 mg/kg, 0.125 mg/kg of sugammadex and placebo. Doses would be based on actual body weight. The time taken to reach a TOF ratio of 0.9 thereafter would be measured. If the patient fails to achieve this goal by 10 minutes, sugammadex would be given in 2 mg/kg increments until the patient reaches this threshold and can be safely extubated. The TOF ratio would be measured again at 30 minutes after arrival at the PACU to exclude delayed residual NMB with the plan to give further 2 mg/kg doses of sugammadex if detected."
89397325|NCT05661409|Experimental|Sugammadex 0.25 mg/kg|"The study team will identify patients who are scheduled to undergo an elective surgery under general anesthesia, received rocuronium for NMB and neostigmine for NMB reversal.~Patients will be randomized using the Emory University REDCap (Research Electronic Data Capture) software to six groups: 2 mg/kg (the lowest dose approved by the FDA), 1 mg/kg, 0.5 mg/kg, 0.25 mg/kg, 0.125 mg/kg of sugammadex and placebo. Doses would be based on actual body weight. The time taken to reach a TOF ratio of 0.9 thereafter would be measured. If the patient fails to achieve this goal by 10 minutes, sugammadex would be given in 2 mg/kg increments until the patient reaches this threshold and can be safely extubated. The TOF ratio would be measured again at 30 minutes after arrival at the PACU to exclude delayed residual NMB with the plan to give further 2 mg/kg doses of sugammadex if detected."
89397326|NCT05661409|Experimental|Sugammadex 0.125 mg/kg|"The study team will identify patients who are scheduled to undergo an elective surgery under general anesthesia, received rocuronium for NMB and neostigmine for NMB reversal.~Patients will be randomized using the Emory University REDCap (Research Electronic Data Capture) software to six groups: 2 mg/kg (the lowest dose approved by the FDA), 1 mg/kg, 0.5 mg/kg, 0.25 mg/kg, 0.125 mg/kg of sugammadex and placebo. Doses would be based on actual body weight. The time taken to reach a TOF ratio of 0.9 thereafter would be measured. If the patient fails to achieve this goal by 10 minutes, sugammadex would be given in 2 mg/kg increments until the patient reaches this threshold and can be safely extubated. The TOF ratio would be measured again at 30 minutes after arrival at the PACU to exclude delayed residual NMB with the plan to give further 2 mg/kg doses of sugammadex if detected."
89397327|NCT05661409|Placebo Comparator|Placebo|The inclusion of a placebo group would allow the study team to examine if patients may recover spontaneously over that time without needing any sugammadex at all, and what parameters may predict that subset of patients. It will also improve the dose response modelling, in that randomization has been weighted so that patients who are least likely to need sugammadex (i.e. if they achieved a TOF count of 4 twitches without fade) are more likely to be in the placebo group or at the lowest dose of sugammadex that is being tested.
89397328|NCT05652803|Experimental|bibliotherapy-based psychoeducation program|In the bibliotherapy-based psychoeducation program sessions, techniques such as information and discussion based on the bibliotherapy method were included. Brief information will be given for 5-10 minutes in each session. At the end of the sessions, exercises will be given to reinforce the knowledge and skills acquired by the group members in the sessions and to transfer them to daily life, and the sessions will be concluded.
89397329|NCT05652803|Experimental|Psychoeducation Program|The General Purpose of the Psychoeducation Program for Reducing Depression and Hopelessness: To help the participants gain awareness, skills and attitudes in order to help them reduce their depression and hopelessness levels.
89397330|NCT05645887|Experimental|Human Albumim (20%, 300mL, 60gr) in 180 min IV|Further doses of albumin (60g/l) will be administered daily from day 0 to day 7 in patients with serum albumin concentrations <35 g/L.
89397331|NCT05645887|Placebo Comparator|Saline solution 0,9% (500mL) in 180 min IV|Saline solution will be given from day 0 to day 7.
89397332|NCT05634291|Experimental|Standard of Care followed by AR digital treatment|Standard of care period without active intervention followed by Digital treatment with active intervention
89397333|NCT05627531|No Intervention|Blank composition book with encouragement to write|The comparison group will receive a blank composition book with encouragement to write.
88873420|NCT01852344|Other|Methylphenidate Easy|Healthy participants are given 20 mgs of methylphenidate one hour before task performance and will perform an easy task.
88873421|NCT01852344|Other|Methylphenidate Hard|Healthy participants are given 20 mgs of methylphenidate one hour before task performance and will perform a hard task.
88873422|NCT01854138|No Intervention|Control|Retrospectively reviewed patients who underwent Total Knee or Hip Arthroplasty and received traditional gauze dressing to cover their clean surgical wound.
88873423|NCT01854138|Experimental|Prevena Knee/Hip|Prospectively enrolled patients undergoing Total Knee Arthroplasty or Total Hip Arthroplasty and receiving Prevena Incision Management System on the clean surgical wound.
88873424|NCT01856712|Active Comparator|oral naltrexone|an initial 50 mg oral dose of naltrexone prior to hospital discharge plus a 30-day prescription for oral naltrexone
88873425|NCT01856712|Experimental|injectable naltrexone|a single 380 mg intramuscular injection of naltrexone (duration of action = 30 days)prior to hospital discharge followed by a second injection one month later.
88873426|NCT01857258|Experimental|Green Tea|Participants will be provided a confection containing green tea concentrate
88873427|NCT01857258|Active Comparator|Control|Participants will be provided a confection devoid of green tea concentrate
88873428|NCT01857882|Experimental|Decision Support Workshop|The decision support workshop will be 2 hours in duration on the morning of the consultation and will be facilitated by a dedicated social worker from psycho-oncology.
88873429|NCT01857882|No Intervention|Standard Care|Routine pre-consultation education
88873430|NCT01858428|Active Comparator|Bare PTA|The control device is a commercially available PTA balloon catheter (EverCross™ 0.035 PTA Balloon Catheter, Covidien, Plymouth, MN 55441, USA).
88873431|NCT01858428|Experimental|Drug-Coated PTA|The CVI Paclitaxel-coated PTA Catheter is a commercially available PTA balloon catheter (EverCross™ 0.035 PTA Balloon Catheter, Covidien, Plymouth, MN 55441, USA) coated with paclitaxel using a proprietary carrier.
89397334|NCT05627531|Experimental|Narrative Medicine|The intervention group will receive a blank composition book with daily writing prompts developed during at least one in-person session with the Narrative Medicine Coordinator to discuss their writing and their writing process.
89397335|NCT05626738|Experimental|Colonoscopy with Endorail|In case of long-lasting colonoscopy, the Endorail Balloon Guide can be inserted inside the endoscope tool channel. It is connected at its proximal (user) end to the syringe containing the Ferromagnetic Fluid. The anchored balloon guide allows to straighten the scope and thus the colon itself. As it is kept in tension, its rigidity increases and works as a rail supporting the movements of the colonoscope. The guided colonoscope can thus be easily moved back and forward to allow better colonoscope positioning and colonoscopy completion. After the Endorail is removed, the straightened colonoscope can be easily pushed forward to achieve colonoscopy completion as foreseen in standard endoscopic technique.
89397336|NCT05621239||COMIRNATY|COVID-19 mRNA vaccine
89397337|NCT05586217|Experimental|Incentive Spirometry|12 weeks, 1 session per week; each session took about 1 hour.
89397338|NCT05586217|Active Comparator|Active Cycle of Breathing|Breathing Control Deep Breathing Exercises or Thoracic Expansion Exercises Huffing or Forced Expiratory Technique (FET)
89397339|NCT05563636|Other|control (group S)|patients will be given standard PRF treatment: temperature 42 ℃, frequency 2 Hz, pulse width 20 ms, voltage 37-41 V, time 120 s.
89397340|NCT05563636|Experimental|group H|patients will be given high-voltage long-term PRF treatment: temperature 42 ℃, frequency 2 Hz, pulse width 20 ms, the voltage range of 50-90 V, At the beginning, the patient will feel a severe burning sensation in the original pain area, and slowly after the patient tolerates it. Increase the voltage and gradually increase to the maximum voltage that the patient can tolerate (up to 70-90 V) until the end of 900 s.
89397341|NCT05561881|Other|IPACK group|visualization of the popliteal artery and posterior surface of the distal femur then the image of the femoral condyles and popliteal artery will be obtained. A needle with a tip length of 100 mm will be inserted in a medial to a lateral plane parallel to the femur in the middle area between the popliteal artery and femur,20 ml local anesthetic solution will be given into this space with adequate and equal distribution of anesthetic agent
89397342|NCT05561881|Experimental|genicular group|US transducer placed parallel to the femur shaft and the epicondyle will be identified, the superomedial superolateral and inferomedial genicular arteries, which follow a similar route with each genicular nerve will be visualized close to the periosteal areas, and A 20G needle with a tip length of 50mm will be directed in the plane of the US probe in the long axis view. After confirming the placing of the needle next to each genicular artery a total amount of 20 ml of local anesthetic in equal increments at multiple sites
89397343|NCT05558735||case group|The case group is composed of Adult male with a positive biopsy (Gleason score greater than or equal to 7)
88873432|NCT01861002|Experimental|AML Arm|"Participants with Acute Myeloid Leukemia (AML)~Intervention:~Azacytidine (Dose Level 1 @ 75 mg/m2/day)~Fludarabine 30 mg/m2/dose~Cytarabine 2000 mg/m2/dose~Intrathecal (IT) Cytarabine"
88873433|NCT01861002|Experimental|ALL Arm|"Patients with Acute Lymphocytic Leukemia~Intervention:~Azacytidine (Dose Level 1 @ 75 mg/m2/day)~Fludarabine 30 mg/m2/dose~Cytarabine 2000 mg/m2/dose~Intrathecal Methotrexate (IT MTX)"
88873434|NCT01861704|Active Comparator|Lyric|Silver Lyric device
88873435|NCT01861704|Active Comparator|Lyric2|Lyric2 (Barracuda) device
88873436|NCT01863030||Phasix mesh|Mesh being used for approved use. Mesh for ventral and incisional hernias.
88873437|NCT01863498|Active Comparator|PCA pain control|Patients will have PCA for pain control
88873438|NCT01863498|Active Comparator|Epidural pain control|Patients will have an epidural for pain control
88873439|NCT01864434||Patients with a Stryker Triathlon CR TKA|Patients implanted with a Stryker Triathlon Posterior Cruciate Retaining Total Knee Arthroplasty.
88873440|NCT01864434||Patients with a Zimmer PCR TKA|Patients implanted with a Zimmer NexGen Posterior Cruciate Retaining Total Knee Arthroplasty.
88873441|NCT01866150||Cohort|
89188045|NCT00580970|Experimental|Lovastatin for 1 yr|Lovastatin (20-80 mg/d) was started on day 1 of radiation and continued for 12 months. Patients were followed for an additional 12 months. Lovastatin once per day for 1 year. After the implant, they are asked to return for checkups (study visits 4-13) 4 weeks, 8 weeks, 4 months, 6 months, 9 months, 12 months, 15 months, 18 months, 21 months and 24 months after the procedure. At 8 weeks, 4 months, 6 months, 9 months and 12 months, will also have a blood test to check their liver.
89188046|NCT01030081|Experimental|Amlodipine (Norvasc®)|
89188047|NCT01030081|Active Comparator|Nifedipine GITS (Adalat® XL 30)|
89188048|NCT00665925|Experimental|1|R788, 100 mg tablet, orally, twice-a-day
89188049|NCT00665925|Experimental|2|R788, 150 mg tablet, orally, once a day
89188050|NCT00665925|Placebo Comparator|3|Placebo, orally, either once a day, or twice a day
89188051|NCT02578004||100 patients suffering from pressure ulcer|100 subjects were having at least one wound of pressure ulcer (74 men and 26 women) middle-aged (55.5±20 years) and were recruited from many services of three University Regional hospitals of Tunisia.
89397344|NCT05558735||control group|The control group is made up of adult men performing a biopsy whose Gleason score is less than or equal to 6.
89397345|NCT05557136|Experimental|Multistranded stainless steel fixed retainer|Multistranded stainless steel fixed retainer is used for lower anterior teeth (canine to canine) to maintain the stability of teeth after completion of orthodontic treatment
89397346|NCT05557136|Experimental|Polyether-Ether-Ketone (PEEK) fixed retainer|Polyether-Ether-Ketone (PEEK) fixed retainer is used for lower anterior teeth (canine to canine) to maintain the stability of teeth after completion of orthodontic treatment
88873442|NCT01866306|Experimental|Healthy 10 TCID50 (Part 1)|Healthy participants were treated with 10 Tissue Culture Infective Dose 50 (TCID50) administered by spraying an atomized viral suspension of RV16UB into a single nostril.
88873443|NCT01866306|Experimental|Healthy 100 TCID50 (Part 1)|Healthy participants were treated with 100 TCID50 administered by spraying an atomized viral suspension of RV16UB into a single nostril.
88873444|NCT01866306|Experimental|Healthy 1000 TCID50 (Part 1)|Healthy participants were treated with 1000 TCID50 administered by spraying an atomized viral suspension of RV16UB into a single nostril.
88873445|NCT01866306|Experimental|Asthmatic non-LABA 10 TCID50 (Part 1)|Participants with mild to moderate asthma, not concomitantly treated with LABA, were treated with 10 TCID50 administered by spraying an atomized viral suspension of RV16UB into a single nostril.
88873446|NCT01866306|Experimental|Asthmatic non-LABA 100 TCID50 (Part 1)|Participants with mild to moderate asthma, not concomitantly treated with LABA, were treated with 100 TCID50 administered by spraying an atomized viral suspension of RV16UB into a single nostril.
88873447|NCT01866306|Experimental|Asthmatic LABA 100 TCID50 (Part 1)|Participants with mild to moderate asthma, concomitantly treated with LABA, were treated with 100 TCID50 administered by spraying an atomized viral suspension of RV16UB into a single nostril.
88873448|NCT01866306|Experimental|Asthmatic non-LABA 100 TCID50 (Part 2)|Participants with mild to moderate asthma, not concomitantly treated with LABA, were treated with 100 TCID50 administered by spraying an atomized viral suspension of RV16UB into a single nostril.
88873449|NCT01867164|Experimental|Gynoclin V|One ovule containing 80 milligram (mg) terconazole, 100 mg clindamycin and 0.5 mg fluocinolone acetonide will be administered vaginally, every 24 hours at night, for 3 days.
88873450|NCT01867164|Experimental|Vagitrol V|One ovule containing 500 mg metronidazole, 0.5 mg fluocinolone acetonide and 100,000.00 microgram/milliliter nystatin will be administered vaginally, every 24 hours at night, for 10 days.
88873451|NCT01867632||Prospective group|Prospective cohort where all patients routinely received ADM during cleft palate surgery. A tailored piece of Acellular Dermal Matrix will be placed between the oral and nasal layers at the time of a Furlow Palatoplasty for repair of a Cleft Palate.
88873452|NCT01867632||Retrospective group|Retrospective cohort of cleft palate patients treated at the same institution and by the same surgeon. These patients received ADM selectively for certain cases (tenuous nasal layer closure, tight oral closure, wide cleft).
88873453|NCT01868334|Experimental|Intervention with the Toolkit|"Pillar 1: Convenient Vaccination Services Pillar 2: Patient notification Pillar 3: Enhanced Office Systems Pillar 4: Motivation~13 clinical practices (intervention sites) will receive the Toolkit in Year 1 to increase their adult influenza, PPSV, Tdap/Td vaccination rates. In Year 2, those who choose to continue will maintain use of the Toolkit and online resources available but will receive no active intervention from study staff."
88873454|NCT01868334|No Intervention|12 clinical practices (control sites)|12 diverse clinical practices will receive no additional assistance in Year 1 to increase their adult influenza, PPSV, Tdap/Td vaccination rates, they will follow guidelines for usual care. In Year 2 however they will become intervention sites and receive the 4 Pillars Toolkit for use in increasing vaccination rates
88873455|NCT01870596|Experimental|Arm A (cytarabine, Chk1 inhibitor SCH 900776)|Patients receive cytarabine IV continuously over 72 hours on days 1-3 and 10-12 and Chk1 inhibitor SCH 900776 IV over 30 minutes on days 2, 3, 11, and 12.
89188052|NCT02578004||213 healthy subjects|213 healthy subjects (125 men and 88 women) middle-aged (51.5±17 years). Although, healthy individuals, were included as controls, followed in the outpatient services of the University Hospital Farhat Hached and they considered clinically free of pressure ulcer and tissue necrosis.
88873456|NCT01870596|Active Comparator|Arm B (cytarabine)|Patients receive cytarabine as in Arm A.
88873457|NCT01874262|Experimental|Active group|The software application used on the patients' smart phones in the active group, will contain both the e-diary and the mobile-phone based patient support. Patients will receive feedback by the mobile-phone based support not only on the data they enter into the mobile-phone based patient support but also on their reported daily ticagrelor use.
89397347|NCT05553509||ANGIOPLASTY GROUP|All patients undergoing PTA are going to be classified according to GLASS staging system
88873458|NCT01874262|Placebo Comparator|The control group|In this group the patients will have access to the e-diary only, in which they will report their daily use of ticagrelor. The patients in the control group will not receive any feed-back.
88873459|NCT01875510|Active Comparator|Fish-oil emulsions|Fish-oil emulsions:Preterm infants will receive a fish-oil emulsion administered from the first day of life 1gr/kg, second day 2gr/kg and third day and after 3 gr/kg.
88873460|NCT01875510|Placebo Comparator|soybean-oil emulsion|Preterm infants will receive a soybean-oil emulsion administered from the first day of life 1gr/kg, second day 2gr/kg and the third day and after 3gr/kg
88873461|NCT01875978|Active Comparator|Phytosterols & placebo|Group A:daily 1.8g phytosterols powder for 4 weeks first;group B:placebo for 4 weeks first
88873462|NCT01876212|Experimental|Vaccine + dasatinib|"Patients will start vaccine on cycle 1, day 1 and dasatinib on cycle 2, day 1 (week 5).~All patients will receive dasatinib at a starting dose of 70 mg twice daily by mouth in the outpatient setting. Dasatinib will be supplied as 50 mg and 20 mg tablets. Patients will take 1 of the 50 mg tablets and 1 of the 20 mg tablets twice daily, approximately every 12 hours, at the same time each day.~The DC vaccine will be administered by a single intradermal injection of approximately 10e7 cells, with all the DCs being administered on days 1 and 15 of each cycle. The intradermal administration will be in the vicinity of the four nodal drainage groups of the four extremities."
89004018|NCT03688100|No Intervention|Caregivers: Behavioral Activation Psychotherapy (BA)|Caregivers of patients receiving the the above described Behavioral Activation Psychotherapy (BA) intervention were monitored for caregiver burden at 3, 6, and 12 months.
89188053|NCT02578160|Experimental|Tell-Show-Do Behavior Technique|This technique will involve verbal explanations related to the inferior alveolar and lingual nerve block procedure in phrases appropriate to the developmental level of the patient (tell);demonstrations for the patient of the visual, auditory, olfactory, and tactile aspects of the procedure in a carefully defined, nonthreatening setting (show); and then, without deviating from the explanation and demonstration, completion of the procedure (do).
89188054|NCT02578160|Active Comparator|"Conventional Technique"|The operator will explain how he/she will do the inferior alveolar and lingual nerve block procedure in phrases appropriates to the child. Then quietly cover the child's field of view by hand during the inferior alveolar and lingual nerve block.
89188055|NCT02578784|Placebo Comparator|POBA-after-Cutting Balloon|After cutting balloon angioplasty, subsequent angioplasty is performed using a standard, non-coated balloon (plain old balloon, POBA).
89188056|NCT02578784|Active Comparator|DCB-after-Cutting Balloon|After cutting balloon angioplasty, subsequent angioplasty is performed using a drug-coated balloon (DCB)
89188057|NCT00426751|Active Comparator|Abciximab|Intravenous bolus of 0.25 mg/kg followed by continuous intravenous infusion of 0.125 mcg/kg/min (max. 10 mcg/min) for 12 h after PCI.
89188058|NCT00426751|Experimental|Eptifibatide|Intravenous bolus of 180 mcg/kg followed immediately by a continuous infusion of 2.0 mcg/kg/ min for 20-24 h after end of PCI, and a second bolus of 180 mcg/kg administered 10 min after the first bolus.
89188059|NCT02576366|Experimental|Voriconazole|Four hundred mg of voriconazole (2 tablets of 200 mg Vfend; Pfizer, Karlsruhe, Germany) will be administered twice daily on day 2. Two hundred mg of voriconazole (1 tablet of 200 mg Vfend) will be administered twice daily on days 3, 4, 5 and 6.
89188060|NCT02576366|Experimental|Rifampin|Six hundred mg of rifampicin (2 tablets of 300mg Rifadine; Sanofi, Belgium) will be administered once daily on days 7 through 13.
89188061|NCT01030159||001|
89188062|NCT01030237|Experimental|FID 114657|FID 114657
89188063|NCT01030237|Active Comparator|Soothe XP Lubricant Eye Drops|Soothe XP Lubricant Eye Drops
89188064|NCT04046679|Experimental|Bleomycin|Bleomycin Infusion By Tattoo Machine
89188065|NCT04046679|Placebo Comparator|Saline Solution|Saline Infusion by Tattoo Machine
89188066|NCT01323439||Axium™ MicroFX™ PGLA Treated Subjects|This observational evaluation will evaluate early experience using the Axium™ MicroFX™ PGLA COILS as compared to published literature of coils with electrolytic, thermal or hydraulic detachment process or the Axium™ Bare Detachable Coils arm obtained from previous evaluation conducted following the same protocol
89188067|NCT00786279|Placebo Comparator|1|150 cc daily of flavored, calorie-free beverage without alcohol
89188068|NCT00786279|Experimental|2|150 cc flavored, calorie-free beverage with 15 gm ethanol daily
89188069|NCT01030315|Experimental|Cohort 1|The lowest dose level of HM10760A
89188070|NCT01030315|Experimental|Cohort 2|Second dose level of HM10760A
89188071|NCT01030315|Experimental|Cohort 3|Third dose level of HM10760A
89188072|NCT01030315|Experimental|Cohort 4|Fourth dose level of HM10760A
89188073|NCT01030315|Experimental|Cohort 5|The highest dose level of HM10760A
89188074|NCT00791271|Experimental|Decitabine + Peginterferon Alfa-2b|Decitabine starting dose of 10mg/m^2 given daily via intravenous infusion on days 1-5 of 28 day cycle. Peginterferon Alfa-2b starting dose of 3 µg/kg injection under the skin once a week on days 1, 8, 15, and 21 of 28 day cycle.
89397348|NCT05553509||DEBRIDEMENT GROUP|The most commonly used technique for diabetic foot ulcers is sharp or surgical debridement using a scalpel, tissue forceps or similar instruments. It should be sufficiently extensive to remove all infected and necrotic tissue;
89397349|NCT05551273|Experimental|Arm A|Selgantolimod 3 mg once weekly for 24 weeks
89397350|NCT05551273|Placebo Comparator|Arm B|Matching Placebo for Selgantolimod once weekly for 24 weeks
89397351|NCT05543551|Experimental|Diaphragmatic breathing with Resistance Training|"Diaphragmatic breathing with Resistance Training:~Wall press-up: Attempt 3 sets of 5 to 10 repetitions. Dumbbell biceps curls: Attempt 3 sets of 5 to 10 repetitions. Back squats: 1 set of 10 repetitions Leg press:1 set of 10 repetitions"
89188075|NCT02555163|Experimental|HoLERBT|Holmium (Ho: YAG) Laser En Bloc Resection Of Bladder Tumor
89397352|NCT05543551|Active Comparator|Diaphragmatic breathing exercises without Resistance Training|"Diaphragmatic Breathing:~Lie on your back on a flat surface (or in bed) with your knees bent. You can use a pillow under your head and your knees for support if that's more comfortable.~Place one hand on your upper chest and the other on your belly, just below your rib cage.~Breathe in slowly through your nose, letting the air in deeply, towards your lower belly. The hand on your chest should remain still, while the one on your belly should rise.~Tighten your abdominal muscles and let them fall inward as you exhale through pursed lips. The hand on your belly should move down to its original position. You can also practice this sitting in a chair, with your knees bent and your shoulders, head, and neck relaxed"
89188076|NCT02555163|Active Comparator|cTURBT|Conventional Transurethral Resection Of Bladder Tumors
89188077|NCT00786357|Experimental|Intervention|
89188078|NCT00440401|Active Comparator|TachoSil®|
89188079|NCT00440401|Active Comparator|Standard Treatment|Standard Treatment of haemorrhage in cardiovascular surgery
89188080|NCT00783003|Experimental|Long acting muscarinic receptor antagonist (LAMA)|Inhaled Long acting muscarinic receptor antagonist (LAMA which is in development as a treatment for Chronic Obstructive Pulmonary Disease.
89188081|NCT00783003|Experimental|Long acting Beta 2 agonist (LABA)|Inhaled Long Acting Beta 2 agonist (LABA) which is in development as a treatment for Chronic Obstructive Pulmonary Disease.
89188082|NCT00783003|Experimental|LAMA with LABA|Inhaled Long Acting Muscarinic receptor Antagonist (LAMA) and a inhaled Long Acting Beta 2 Agonist (LABA), both in development for treatment of Chronic Obstructive Pulmonary Disease and taken in combination.
89188083|NCT00783003|Placebo Comparator|Placebo|Matching placebo, no intervention.
89188084|NCT01034215|Active Comparator|Imagery Practice, live trainer|Patients attend a five week training program, with the instructor in the room with them, and actively practice imagery techniques, both in the classroom, and daily, outside of the classroom. Classes are four hours a week for five weeks. Patients practice what they learn for a full 17 weeks, beginning with the first week of class.
89188085|NCT01034215|Active Comparator|"Envision the Rhythms of Life /video"|Patients learn to practice passive, active and targeted imagery for the purpose of improving mood state, modifying physiology (HRV, Body temperature, pain reduction) and also to mitigate the effects of their treatments, as defined by the IOM: chemo brain, fatigue, sleep deprivation, stress, anxiety, depression, and/or PTSD.
89188086|NCT01034215|No Intervention|Waitlist Control Group|No treatment delivery during the 17 weeks of testing live delivery (trainer in the room with patients) vs. distance delivery (trainer delivers program via telemedicine/videoconferencing equipment)
89188087|NCT00791427||AMD Patients|
88873463|NCT01876212|Experimental|Vaccine + dasatinib from cycle 1|"Patients will start vaccine on cycle 1, day 1 and dasatinib on cycle 1, day 1.~All patients will receive dasatinib at a starting dose of 70 mg twice daily by mouth in the outpatient setting. Dasatinib will be supplied as 50 mg and 20 mg tablets. Patients will take 1 of the 50 mg tablets and 1 of the 20 mg tablets twice daily, approximately every 12 hours, at the same time each day.~The DC vaccine will be administered by a single intradermal injection of approximately 10e7 cells, with all the DCs being administered on days 1 and 15 of each cycle. The intradermal administration will be in the vicinity of the four nodal drainage groups of the four extremities."
88873464|NCT01876992|Experimental|Metformin|"Doses will be increased incrementally. Decisions to escalate the metformin dose will be made based upon tolerability of side effects as described in the schedule of evaluations to follow. All subjects will be monitored for safety while receiving metformin. Any participant with blood glucose of <60mg/dl at any time while receiving metformin will have therapy stopped and will be withdrawn from the study.~For children <50kg:~Baseline:250mg po qd, Week 2:250mg po bid, Week 4:500mg po am/250mg po pm, Week 8:500mg po bid.~For children ≥50kg:~Baseline:500mg po qd, Week 2:500mg po bid, Week 4:1000mg po am/500mg po pm, Week 8:1000mg po bid.~For adults:~Baseline:500mg po qd,Week2:500mg po bid,Week 4:1000mg po am/500mg po pm,Week 8:1000mg po bid."
88873465|NCT01876992|No Intervention|Obese Controls|"Three obese but otherwise healthy adult participants will be recruited into the study as controls. These will be individuals who are not currently (or previously) on any diabetic medication including metformin.~There will be a single study visit and no medication will be administered. They will be administered a meal and pre and post-prandial blood samples will be drawn."
88873466|NCT01877148|Experimental|Physiotherapy + anodal tDCS|The patients will be submit to anodal tDCS applied in the motor cortex and after the patient will be submit to a 30 minutes of physiotherapy protocol.
88873467|NCT01877148|Sham Comparator|Physiotherapy + sham tDCS|The patients will be submit to sham tDCS and after the patient will be submit to a 30 minutes of physiotherapy protocol.
88873468|NCT01877538||[11C]donepezil PET|[11C]donepezil is a radiopharmaceutical. It is evaluated whether the binding of [11C]donepezil in various peripheral tissues is in accordance with known distribution of the parasympathetic nervous system.
88873469|NCT01878006|Experimental|Morphine|Morphine injection 10 mg/70kg
88873470|NCT01878006|Placebo Comparator|Placebo|Saline injection
88873471|NCT01879176|Experimental|CytoSorb|For the intervention group, the CytoSorb filter will be installed on the CPB machine in a parallel circuit to the body circulation. The flow through the filter will be driven by a roller pump with 200ml.min-1 .
88873472|NCT01879176|No Intervention|Control|No filter will be installed on the CPB machine.
88873473|NCT01879332|Placebo Comparator|Placebo|Matching placebo tablets for oral administration
88873474|NCT01879332|Experimental|BIA 2-093 3000 mg once daily|Subjects in Cohort 2 received a dose of 3000 mg once daily (5 x 600 mg eslicarbazepine acetate tablets)
88873475|NCT01879332|Experimental|BIA 2-093 3600 mg once daily|Subjects in Cohort 1 received a dose of 3600 mg once daily (6 x 600 mg eslicarbazepine acetate tablets)
88873476|NCT05329272|Experimental|The VR group: the Virtual Reality Cognitive Training Intervention (VRCTI)|The VRCTI was developed to improve cognitive function. The intervention was designed that simulated schema of underwater world fish swimming. Each 1-hour session was typically divided into three parts: easy, medium and difficult, each with 4 different tasks, so there are 12 tasks/session in total. In some tasks, the VRCTI also distinguished between the real lure (e.g. a red triangle fish with a half-moon pattern) as well as unrelated lure items (i.e., blue square fish with polka dot pattern and other irrelevant items). The use of hardware elements for this study included visual (head-mounted display [HMD] in delivering the VR intervention), audio, and motor equipment.
88873477|NCT05329272|No Intervention|The control group|The control group received usual care.
88873478|NCT05328882||ERAF after PFA|Patients with an early recurrence after pulsed field ablation of paroxysmal atrial fibrillation.
88873479|NCT05328882||no ERAF after PFA|Patients without an early recurrence after pulsed field ablation of paroxysmal atrial fibrillation.
88873480|NCT05327478||Non ECD|50-60 years old AND non ECD
88873481|NCT05327478||ECD|>60 years old or ECD
89188088|NCT00786435||1|Those with a cervical spinal cord injury
89188089|NCT00786435||2|Those with a thoracic spinal cord injury
89188090|NCT00786435||3|Healthy, control group
89188091|NCT00786513|Active Comparator|Control Arm|
89397353|NCT05541653|Experimental|Intervention|"At the individual level, participants in the intervention arm receive place-based and financial well-being interventions.~These include, at the individual level:~Tax preparation~Access to public benefits~Financial counseling and microgrants~At the neighborhood level:~Abandoned house remediation~Trash cleanup~Vacant lot greening~Tree planting"
89397354|NCT05541653|No Intervention|Control|Participants in the control arm will not receive any of the listed interventions.
89397355|NCT05523206||Cohort 1|Participants with MPS IIIA
89397356|NCT05509218|Experimental|Personalized feedback plus incentive|Following each daily survey on which a participant indicates prior day drinking, personalized feedback will be provided. Participants in this group will receive $1 per day for submitting their daily survey.
89397357|NCT05509218|Experimental|Personalized feedback without incentive|Following each daily survey on which a participant indicates prior day drinking, personalized feedback will be provided. Participants in this group will NOT receive $1 per day for submitting their daily survey.
89397358|NCT05509218|No Intervention|Control|Participants in this arm will only complete baseline and follow-up surveys.
89397359|NCT05508698|No Intervention|Passive Control|No change to the standard of care for flu vaccines
89397360|NCT05508698|Experimental|Pre-visit Questionnaire|One-item questionnaire in online patient portal and additional information in the flu shot alert
89397361|NCT05507931|Experimental|1 Serving of broccoli sprouts|113 grams
89397362|NCT05507931|Experimental|3 Servings of broccoli sprouts|339 grams
89397363|NCT05502081|Experimental|casirivimab and imdevimab|casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes.
89397364|NCT05502081|Experimental|Remdesivir|Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes
89397365|NCT05502081|Experimental|Favipravir|Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours
89397366|NCT05500560||COVID-19|Patients admitted to our hospital due to COVID-19
89397367|NCT05500560||Controls|Healthy volunteers matched for age, sex and cardiovascular risk factors.
88873482|NCT05327088|Active Comparator|Group A (Dexmedetomidine group)|a bolus dose of 11ml of 0.25% bupivacaine + 0.5μg/ml preservative free dexmedetomidine (1ml volume) will be injected via the epidural catheter. For top up 5 ml of 0.25% bupivacaine + 0.5μg/ml dexmedetomidine (1ml volume) will be given when VAS score becomes 4 or more.
89397368|NCT05494385|Placebo Comparator|Preoperative Gabapentin/Postoperative Placebo|
89397369|NCT05494385|Active Comparator|Preoperative Gabapentin/Postoperative Gabapentin|
89397370|NCT05494073|Experimental|Hybrid Remnant Repair|Patients in this arm will have an ACL reconstruction with preservation and incorporation of the the ACL remnant.
89397371|NCT05494073|Active Comparator|Control|Patients in this arm will have a ACL reconstruction where the ACL remnant is not incorporated into the graft.
89397372|NCT05486286|Experimental|video assisted NG placement|This is a single-arm study. A live-video system (NCKU-NG system) was developed to assist in the placement of enteral feeding tubes.
89397373|NCT05483712|Experimental|Post-Mastectomy Radiation Therapy Patients|Any patient who is going through radiation to their chest wall following mastectomy using a rotational delivery technique and 6 MV, and uses Superflab bolus for some but not all fractions of radiotherapy
89397374|NCT05482997|No Intervention|Control Group: Subjects with no protien intake|20 subjects will receive no intervention for 10 weeks but complete performance tests and assessments during weeks 0, 4, 6, and 10.
89397375|NCT05482997|Experimental|Whey Protein, Then Plant-based Protein|"Performance tests/assessments will be conducted as baseline testing without whey protein, followed by four weeks of whey protein intervention consisting of one 70cc (32g) scoop of supplement provided within an hour after athletic practice, five days a week. For athletes with more than one practice a day, the supplement will be provided after the strength training session. The powder will be shaken with 8-12oz water. Performance measured at the end of 4 weeks.~After a two-week washout period, they will undergo another performance evaluation and begin the same protein supplement regimen, but with a 70cc (32g) scoop of the plant-based protein supplement."
89397376|NCT05482997|Experimental|Plant-based Protein, Then Whey Protein|"Performance tests/assessments will be conducted as baseline testing without plant-based protein, followed by four weeks of plant-based protein intervention consisting of one 70cc (32g) scoop of supplement provided within an hour after athletic practice, five days a week, for four weeks. For athletes with more than one practice a day, the supplement will be provided after the strength training session. The powder will be shaken with 8-12oz water. Performance measured at the end of 4 weeks.~After a two-week washout period, they will undergo another performance evaluation and begin the same protein supplement regimen, but with a 70cc (32g) scoop of the whey protein supplement."
88873483|NCT05327088|Active Comparator|Group B (Nalbuphine group)|a bolus dose of 11ml of 0.25% bupivacaine + 10mg preservative free nalbuphine (1ml volume) will be injected via the epidural catheter. For top up 5 ml of 0.25% bupivacaine + 2mg nalbuphine (1ml volume) will be given when VAS score becomes 4 or more.
88873484|NCT05310474|No Intervention|Group C|Upon consent, patients will be randomized to receive standard of care, and not be given the active range of motion monitor (the knee glider) two weeks prior to surgery. All patients enrolled in the study will have access to Force Therapeutics, patient engagement and outcome collection system utilized by OSI Orthopedic & Sports Medicine.
88873485|NCT05310474|Experimental|Group B|Upon consent, patients will be randomized to receive the active range of motion monitor (the knee glider) close to surgery to use postoperatively (through week 4). All patients enrolled in the study will have access to Force Therapeutics, patient engagement and outcome collection system utilized by OSI Orthopedic & Sports Medicine.
89535480|NCT04493099|Experimental|Treatment (decitabine, alvocidib hydrochloride, venetoclax)|"INDUCTION: Patients receive decitabine IV over 1 hour on days 1-10, alvocidib hydrochloride IV over 1 hour on days 1-3, 1-5, 1-7, 1-10, or 1-14, and venetoclax PO QD on days 1-14 in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Patients receive decitabine IV over 1 hour on days 1-5, alvocidib hydrochloride IV over 1 hour on days 1-3, 1-5, 1-7, 1-10 or 1-14, and venetoclax PO QD on days 1-10. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity."
89535481|NCT05004909|Active Comparator|1 Fingertip Unit 0.05% Tretinoin|Subjects were randomized to receive the instructions to use 1 fingertip unit of 0.05% tretinoin cream for 2 weeks before the first chemical peeling. After that, this therapy is instructed to be used for 4 weeks after the chemical peeling procedure with 30% trichloroacetic acid until the scheduled evaluation.
89397379|NCT05468398|No Intervention|Control|The control group will receive a genicular RFA with local anesthetic as per the standard-of-care
89397380|NCT05468398|Experimental|VR Intervention|The VR Intervention group will receive a genicular RFA with local anesthetic as per the standard-of-care and the use of the Soothe VR device.
89397381|NCT05459519|Experimental|Intervention group A|Dengzhanxixin Capsules plus Placebo Capsules
89397382|NCT05459519|Experimental|Intervention group B|Dengzhanxixin Capsules plus Placebo Capsules
89397383|NCT05459519|Placebo Comparator|Control group|Placebo Capsules
89397384|NCT05455294|Experimental|Dose Level 0: Decitabine + Venetoclax + Navitoclax [AML and Non-AML]|"Dose Level 0 [AML and Non-AML]~Decitabine [intravenously (IV) preferred]~Venetoclax Cycle 1: ramp-up days 1-2 and days 3-14 absence of strong/moderate CYP3A inhibitor and reduced doses dependent on presence of moderate or strong CYP3A inhibitor Cycle 2+: dosing days 1-14~Navitoclax Cycle 1: dosing days 3-14; Cycle 2+: dosing on days 1-14~Cycle length=28 days Participants are treated indefinitely until disease progression, unacceptable toxicity or withdrawal for other reasons."
89397385|NCT05455294|Experimental|Dose Level 1: Venetoclax + Decitabine + Navitoclax [AML and Non-AML]|"Dose Level 1 [AML and Non-AML]~Decitabine [intravenously (IV) preferred] Cycle 1+: dosing on days 1-5~Venetoclax [orally] Cycle 1: ramp-up starting on day 1-2 then days 3-14 continued dosing in absence of strong/moderate CYP3A inhibitor and reduced doses dependent on presence of moderate or strong CYP3A inhibitor Cycle 2+: dosing days 1-14~Navitoclax [orally] Cycle 1: Dosing days 3-14 Cycle 2+: dosing on days 1-14~Cycle length=28 days Participants are treated indefinitely until disease progression, unacceptable toxicity or withdrawal for other reasons."
89397386|NCT05455294|Experimental|Dose Level 2: Venetoclax + Decitabine + Navitoclax [AML]|"Dose Level 2 [AML]~Decitabine [intravenously (IV) preferred] Cycle 1+: dosing on days 1-5~Venetoclax [orally] Cycle 1: ramp-up on day 1-2, days 3-21 continued dosing in absence of strong/moderate CYP3A inhibitor and reduced doses dependent on presence of moderate or strong CYP3A inhibitor Cycle 2+: dosing on days 1-21~Navitoclax [orally] Cycle 1: dosing on days 3-14 Cycle 2+: dosing on days 1-14~Cycle length=28 days Participants are treated indefinitely until disease progression, unacceptable toxicity or withdrawal for other reasons."
89397387|NCT05455294|Experimental|Dose Level -1: Venetoclax + Decitabine + Navitoclax [Non-AML]|"Dose Level -1 [Non-AML]~Decitabine [intravenously (IV) preferred] Cycle 1+:dosing [intravenously (IV) preferred] on days 1-3~Venetoclax [orally] Cycle 1: ramp-up of starting day 1-2 then days 3-7 continued dosing in absence of strong/moderate CYP3A inhibitor and reduced doses dependent on presence of moderate or strong CYP3A inhibitor Cycle 2+: dosing on days 1-7~Navitoclax [orally] Cycle 1: Dosing days 3-14 Cycle 2+: continued dosing on days 1-14~Cycle length=28 days Participants are treated indefinitely until disease progression, unacceptable toxicity or withdrawal for other reasons."
89397388|NCT05455294|Experimental|Recommended Phase 2 Dose Level: Venetoclax + Decitabine + Navitoclax [AML and Non-AML]|"RP2D [AML and Non-AML]~Decitabine [intravenously (IV) preferred] To be determined based on dose escalation design.~Venetoclax [orally] To be determined based on dose escalation design.~Navitoclax [orally] To be determined based on dose escalation design.~Cycle length=28 days Participants are treated indefinitely until disease progression, unacceptable toxicity or withdrawal for other reasons."
89397389|NCT05442346|Experimental|γ-globin reactivated autologous hematopoietic stem cells|each subject will accept one dose of γ-globin reactivated autologous hematopoietic stem cells
89397390|NCT05437796|Active Comparator|Hypnotic virtual reality support|Hypnotic virtual reality support using hypnosis software Hypno-VR® (Strasbourg, France) paired with VR headsets Oculus VR® (Menlo Park, CA, USA)
89397391|NCT05437796|Sham Comparator|Without hypnotic virtual reality support|
89397392|NCT05399095|Experimental|5 days supine positioning|Supine positioning for 5 days after DMEK with upright positioning for only 10 min every hour.
89397393|NCT05399095|Active Comparator|1 day supine positioning followed by usual physical activity for 4 days|Supine positioning for 1 days after DMEK with upright positioning for only 10 min every hour.
89397394|NCT05392868|Experimental|SDF|38% silver diamine fluoride solution
89397395|NCT05392868|Active Comparator|KNO3|5% potassium nitrate solution
89397396|NCT05390788|Experimental|Experimental Group|Joint Position Sense is measured in 6 different moments. 1st Moment: Measurement with no intervention; 2nd Moment: 5 days later, imediately before intervention (kinesiotaping/neuromuscular bands); 3rd Moment: Imediately after intervention; 4th Moment: 5 days after the previous measurement, with kinesiotape still applied; 5th Moment: Measurement imediately after removing kinesiotape; 6th Moment: 5 days after the previous measurement, with no intervention (follow-up)
89397397|NCT05390788|No Intervention|Control Group|4 Measurements with no intervention, with a 5 day interval between
89397398|NCT05381779|Experimental|Inspiratory Muscle Training Group|Patients in the training group will be performed inspiratory muscle training with the PowerBreathe® (inspiratory muscle training device) device at 50% of the maximal inspiratory pressure.
89397399|NCT05381779|Experimental|High Intensity Interval Training Group|Training group will receive high-intensity interval aerobic exercise training on treadmill accompanied by physiotherapist for 8 weeks.
89397400|NCT05381779|Sham Comparator|Control Group|Breathing exercises will be given to control group as a home program for 8 weeks.
89397401|NCT05381727||Patients with Post COVID-19|"That group consists from patients who had diagnosed with COVID-19 by doctors.~Oxygen consumption using cardiopulmonary exercise test, physical activity level using multi-sensor activity monitor, pulmonary function using spirometer, functional exercise capacity with six minute walk test, respiratory muscle strength using mouth pressure device, peripheral muscle strength with hand held dynamometer, inspiratory muscle endurance using incremental threshold loading test, dyspnea with 'Turkish version of London Chest Daily Living Activity Scale', fatigue with 'Turkish version of Fatigue Severity Scale' and quality of life with 'Turkish version of Saint George Respiratory Questionnaire' will be evaluated in patient with post COVID-19. Chronotropic response will be assessed according to results of maximal exercise test. Besides, functional statu of patients will be evaluated with Turkish version of 'Post COVID-19 Functional Status Scale'."
89397402|NCT05381727||Healthy Group|"That group consists from people who do not have any diagnosed disease.~Oxygen consumption using cardiopulmonary exercise test, physical activity level using multi-sensor activity monitor, pulmonary function using spirometer, functional exercise capacity with six minute walk test, respiratory muscle strength using mouth pressure device, peripheral muscle strength with hand held dynamometer, inspiratory muscle endurance using incremental threshold loading test, dyspnea with 'Turkish version of London Chest Daily Living Activity Scale', fatigue with 'Turkish version of Fatigue Severity Scale' and quality of life with 'Turkish version of Saint George Respiratory Questionnaire' will be evaluated in healthy controls."
89397403|NCT05367882||critically ill COVID-19 patients in ICU|critically ill COVID-19 patients who are recommended to receive IL-6R antagonist as tocilizumab at the dosage of 8 mg/kg with a second dose 12 hours after the first dosage, or sarilumab at the dosage of 200 mg subcutaneously or 200 to 800 mg intravenously.
89188092|NCT00786513|Experimental|Intervention Arm|
89188093|NCT00791505|Active Comparator|Ciprofloxacin|750 mg a day during 10 days
89188094|NCT00791505|Active Comparator|trimethoprim-sulfamethoxazole|2000 mg a day for 10 days
89188095|NCT00786591||Acute Pancreatitis Patients|Patients presenting with clinical features compatible with acute pancreatitis
89188096|NCT00786591||Control|Preoperative patients going for elective cholecystectomy
89188097|NCT02598960|Experimental|BMS-986156: Dose Escalation|
89397404|NCT05357560|Experimental|Group 1 - Infants R21 delayed 3rd dose|11 volunteers (infant 5-17 months) given 50 µg of Matrix-M in combination with 5µg R21 at months 0, 1 and 6 via intramuscular (IM) injection in the anterolateral thigh
89397405|NCT05357560|Experimental|Group 2 - Infants R21 standard regimen|11 volunteers (infant 5-17 months) given 50 µg of Matrix-M in combination with 5µg R21 at months 0, 1 and 2 via intramuscular (IM) injection in the anterolateral thigh
89188098|NCT02598960|Experimental|BMS-986156 + nivolumab (nivo): Dose Escalation|
89188099|NCT02598960|Experimental|BMS-986156: Dose Expansion|
89188100|NCT02598960|Experimental|BMS-986156 + nivolumab (nivo): Dose Expansion|
89188101|NCT02598960|Experimental|BMS986156 + Nivo: Cohort Expansion|
89188102|NCT00426361|Experimental|Cervarix Group|Subjects who received GSK Biologicals' HPV-16/18 L1 AS04 vaccine (Cervarix TM) at Month 0, 1 and 6.
89188103|NCT00426361|Experimental|Boostrix Polio → Cervarix Group|Subjects who received Boostrix™ Polio at Month 0 and GSK Biologicals' HPV-16/18 L1 AS04 vaccine (Cervarix TM) at Month 1, 2 and 7.
89188104|NCT00426361|Experimental|Cervarix + Boostrix Polio Group|Subjects who received GSK Biologicals' HPV-16/18 L1 AS04 vaccine (Cervarix TM) at Month 0, 1 and 6 with co-administration of Boostrix™ Polio at Month 0.
89188105|NCT00665847|Experimental|Etravirine (TMC125)|
89188106|NCT01030393|Experimental|intrauterine hCG|"Experimental arm : intrauterine injection of 100 iu(group1)or 200 iu (group2) of hCG before embryo transfer.~Intrauterine injection of 500 iu hCG before embryo transfer"
89188107|NCT00783081|Experimental|low dose K-134|
89188108|NCT00783081|Experimental|mid dose K-134|
89397406|NCT05357560|Experimental|Group 3 - Adults RH5.2 low dose, standard regimen|10 volunteers (adult 18-45 years) given 50 µg of Matrix-M in combination with 10µg RH5.2 VLP at months 0, 1 and 2 via intramuscular (IM) injection in the deltoid region of the non-dominant arm
89397407|NCT05357560|Experimental|Group 4 - Adults RH5.2 high dose, standard regimen|10 volunteers (adult 18-45 years) given 50 µg of Matrix-M in combination with 50µg RH5.2 VLP at months 0, 1 and 2 via intramuscular (IM) injection in the deltoid region of the non-dominant arm
89397408|NCT05357560|Experimental|Group 5 - Adults RH5.2 and R21 low dose, standard regimen|10 volunteers (adult 18-45 years) given 50 µg of Matrix-M in combination with 10µg RH5.2 VLP and 10µg R21 at months 0, 1 and 2 via intramuscular (IM) injection in the deltoid region of the non-dominant arm
89397409|NCT05357560|Experimental|Group 6 - Infants RH5.2 standard regimen|11 volunteers (infant 5-17 months) given 50µg of Matrix-M in combination with 5µg RH5.2 VLP at months 0, 1 and 2 via intramuscular (IM) injection in the anterolateral thigh
89188109|NCT00783081|Experimental|high dose K-134|
89188110|NCT00783081|Active Comparator|Comparator|
89188111|NCT00783081|Placebo Comparator|Placebo|
89188112|NCT00426127|Experimental|Docetaxel and Liposomal Doxorubicin Combined with Enoxaparin|Docetaxel 75 mg/m^2 + Doxil 30 mg/m^2 + Enoxaparin 1.5 mg/kg
89188113|NCT02578212|Placebo Comparator|Control|"All participants will also be introduced to the control cream: This cream is a control cream."
89188114|NCT02578212|Sham Comparator|Placebo|"All participants will then be introduced to an analgesia expectation: This cream is a powerful pain killer, while receiving an inert cream. In this study participants will be told that they will receive a potent painkiller as well as a control cream. Making use of placebo cream is an established method to induce placebo expectations . Moreover, to increase the analgesic effect, heat pain stimuli intensity will be surreptitiously lowered for the placebo trials to a temperature corresponding to 30% of the VAS intensity and to 60% for the control trials. As the occurrence of a placebo response is highly dependent on expectations, the deceptive procedure described above is used in order to maximally enhance expectations and therefore placebo response. Participants will be debriefed after the completion of study participation."
89188115|NCT02578056|Experimental|Mid-urethral sling|Patients randomized to anti-incontinence surgery will undergo TVT sling placement as the standard technique at the same time of genital prolapse surgery.
89188116|NCT02578056|Sham Comparator|POP|Patients randomized to the sham group will be submitted to genital prolapse surgery and sham incisions as if they had undergone the TVT procedure (two small incisions of 0.5 cm in the suprapubic region in a similar way to that used for the insertion of the sling). These incisions intended to keep the raters blind to the achievement or otherwise of the sling during the postoperative evaluation.
89188117|NCT00783159|Experimental|A|Training I
89188118|NCT00783159|Experimental|B|Training II
89188119|NCT00783159|Active Comparator|C|Control
89188120|NCT02555709|Placebo Comparator|Placebo 1|healthy volunteers
89188121|NCT02555709|Experimental|VTP-43742 Dose 1|healthy volunteers
89188122|NCT02555709|Experimental|VTP-43742 Dose 2|healthy volunteers
89188123|NCT02555709|Experimental|VTP-43742 Dose 3|healthy volunteers
89188124|NCT02555709|Experimental|VTP-43742 Dose 4|healthy volunteers
89188125|NCT02555709|Experimental|VTP-43742 Dose 5|healthy volunteers
89188126|NCT02555709|Experimental|VTP-43742 Dose 6|healthy volunteers
89188127|NCT02555709|Experimental|VTP-43742 Dose 7|healthy volunteers
89188128|NCT02555709|Placebo Comparator|Placebo 2|psoriatic patients
89188129|NCT02555709|Experimental|VTP-43742 Dose 8|psoriatic patients
89188130|NCT02555709|Experimental|VTP-43742 Dose 9|psoriatic patients
89188131|NCT02555709|Experimental|VTP-43742 Dose 10|psoriatic patients
89188132|NCT02555709|Experimental|VTP-43742 Dose 11|psoriatic patients
89188133|NCT04047069|Other|Control|Awareness Training
89188134|NCT04047069|Experimental|Intervention group|"Awareness Training~Person-Centered Occupational Therapy Intervention"
89397410|NCT05357560|Experimental|Group 7 - Infants RH5.2, delayed 3rd dose|11 volunteers (infant 5-17 months) given 50µg of Matrix-M in combination with 5µg RH5.2 VLP at months 0, 1 and 6 via intramuscular (IM) injection in the anterolateral thigh
89397411|NCT05357560|Experimental|Group 8 - Infants RH5.2 and R21, standard regimen|11 volunteers (infant 5-17 months) given 50µg of Matrix-M in combination with 5µg RH5.2 VLP and 5µg R21 at months 0, 1 and 2 via intramuscular (IM) injection in the anterolateral thigh
89397412|NCT05357560|Experimental|Group 9 - Infants RH5.2 and R21, delayed 3rd dose|11 volunteers (infant 5-17 months) given 50µg of Matrix-M in combination with 5µg RH5.2 VLP and 5µg R21 at months 0, 1 and 6 via intramuscular (IM) injection in the anterolateral thigh
89397413|NCT05345769|Experimental|Phase I- All|Subjects with neovascular AMD
89397414|NCT05345158|Experimental|Robotic Retroperitoneal Lymph Node Dissection|Robotic retroperitoneal lymph node dissection performed using the DaVinci robotic surgical system.
89188135|NCT00786669|Experimental|Bevacizumab+TEM/VCR/IRN/CEF|"Bevacizumab(IV) 15 mg/Kg on day 1 every 3 weeks for up to 6 cycles~Temozolomide (TEM) 100 mg/m2/day po on Days 1-5 every 3 weeks for up to 6 cycles. For patients under 0.5 m2 BSA, TEM = 3.3 mg/kg/day po on Days 1-5.~Vincristine (VCR) 1.5 mg/m2 on Day 1 (max dose 2 mg) administered as an IV bolus every 3 weeks for up to 6 cycles. For patients <0.5 m2 BSA, VCR dose = 0.05 mg/kg (maximum dose 2 mg).~Irinotecan (IRN) 90 mg/m2/day po on Days 1-5 every 3 weeks for up to 6 cycles~Cefexime (CEF) 8 mg/kg/day (max. daily dose 400 mg) of cefixime or 5 mg/kg/dose bid (max. daily dose 400 mg) of cefpodoxime starting Day -1 BEFORE chemotherapy and continuing EVERY DAY while on study, or for 2 days after last dose of chemotherapy if treatment stopped early for disease progression or toxicity"
89397415|NCT05304689|Other|test system for the determination of interleukins|test system for the determination of interleukins
89397416|NCT05298891|Experimental|Acromegalic adult in therapy with somatostatin analogues|Patients will continue the usual medical outpatient visits cadency and will keep the same pharmacological therapy throughout the whole duration of the study. Drugs have to include somatostatin analogues. At the same time, patients will be trained by an expert dietician in the habit of an isocaloric and hypoproteic diet and will come back at 2,4,6 and 8 weeks after T0 for all the necessary study assessments and compliance checking.
89397417|NCT05269888||Study group - Ocrelizumab|30 patients with multiple sclerosis on Ocrelizumab (standard of care)
89397418|NCT05269888||Study group - Natalizumab|30 patients with multiple sclerosis on Natalizumab (standard of care)
89397419|NCT05269888||Study group - Alemtuzumab|30 patients with multiple sclerosis on Alemtuzumab (standard of care)
89397420|NCT05269888||Study group - Tecfidera|30 patients with multiple sclerosis on Tecfidera (standard of care)
89397421|NCT05269888||Study group - Fingolimod|30 patients with multiple sclerosis on Fingolimod (standard of care)
89397422|NCT05269888||Study group - Interferon|30 patients with multiple sclerosis on Interferon (standard of care)
89397423|NCT05269888||Study group - off DMT|30 patients with multiple sclerosis off disease modification treatment (DMT) (standard of care)
89397424|NCT05269888||Control group|30 healthy volunteers
89397425|NCT05263557|Experimental|DHEA|Adult females with polycystic ovary syndrome (PCOS) and evidence of clinical or biochemical androgen excess will be recruited and randomised.
89188136|NCT01030471|Experimental|Lifestyle counseling|
89188137|NCT01030471|No Intervention|Wait list control group|
89397426|NCT05263557|Experimental|11KA4|Adult females with polycystic ovary syndrome (PCOS) and evidence of clinical or biochemical androgen excess will be recruited and randomised.
89397427|NCT05219110|Experimental|Hyperhydration|"In this study arm, all eligible children are admitted for the administration of intravenous fluids.~The following specifics will form the basis of the fluid management protocol:~Reversal of dehydration: Initial ED rehydration strategies should focus on rapidly reversing dehydration.~Infusion of 200% of maintenance fluids x 24 hours~If hematocrit reduction < 20% from initial value, repeat step #2 [infusion of 200% maintenance fluids x 24 hours].~Oral fluids permitted ad lib.~Once the target hematocrit reduction is achieved (20% decrement in initial HCT) AND a 10% weight gain, adjust total IV fluid volume to maintain targeted weight gain: insensible plus output (i.e., urine plus stool)."
89530197|NCT03122015|Experimental|Therapeutic clown distraction|The child will interact with the therapeutic clown throughout the painful procedure. The types of distraction interventions will be determined by the clown according to the child's age, culture and behavior. The clown can use different distraction activities such as magic, humor, visualization and play. According to various writings, the presence of the clown before the procedure varied between two to 20 minutes. In our study, the presence of the clown with parents and children will be about 10 minutes before the procedure and while the nurse performs the procedure until the child leaves the room. The distraction performed by a therapeutic clown is used in St. Justine' Hospital. Indeed, a team of therapeutic clowns is present in the hospital four times a week to distract the children. However, this procedure is not applied routinely in painful procedures and no study has evaluated its usefulness or effect.
88873486|NCT05310474|Experimental|Group A|Upon consent, patients will be randomized to receive the active range of motion monitor (the knee glider) Receives Knee Glider 2 weeks prior to surgery to utilize through postoperative week 4. All patients enrolled in the study will have access to Force Therapeutics, patient engagement and outcome collection system utilized by OSI Orthopedic & Sports Medicine.
88873487|NCT05290194|Experimental|Oligometastatic nasopharyngeal carcinoma|Patients included are going to receive radiotherapy, chemotherapy and immunotherapy. Radiotherapy includes IMRT and SBRT. IMRT is applied for primary sites and cervical lymph nodes，and SBRT following is applied for oligometastatic sites. PD-1 inhibitors: during the whole trial, intravenous, Q3W; Capecitabine: 650mg, po, bid, following the radiotherapy for a year.
88873488|NCT05279196|Experimental|Muscular response to the training|Epigenetic signature associated with different levels of muscle response induced by 6-month training
88873489|NCT04810338||All patients received conventional dialysis treatment|All patients received conventional dialysis treatment during an observational period of 3 years
88873490|NCT04774068|Experimental|Treatment (romidepsin, parsaclisib)|"PRE-PHASE: Patients receive romidepsin IV over 4 hours on days 1, 8, and 15. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.~INDUCTION PHASE: Patients receive romidepsin IV over 4 hours on days 1,8, and 15 and parsaclisib PO QD on days 1-28. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE PHASE: Patients receive romidepsin IV over 4 hours on days 1, 8, and 15 and parsaclisib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
88873491|NCT04304742||Suspicion of hip fracture|Suspicion of hip fracture
89397428|NCT05219110|Active Comparator|Conservative Fluid Management|The conservative fluid management arm has been designed to align and integrate into existing local practice patterns. Implementation of this approach will allow institutions and their practitioners to choose their management of protocol eligible children. All children will undergo a protocolized baseline evaluation that includes reversal of dehydration (if present) and follow-up plan (see Pre-Pathway care). The fluid management decision in the ED (i.e., to treat dehydration) will be at the discretion of the clinical care team. In the absence of evidence of microangiopathy (i.e., normal urinalysis, LDH, hemoglobin and platelet counts, and creatinine concentrations), the decision to admit the child to hospital or discharge the child to home will be at the discretion of the clinical care team. If microangiopathy is present (i.e., abnormal urinalysis, LDH, hemoglobin or platelet counts, or creatinine concentrations) admission for monitoring will be required.
88873492|NCT04260672|Experimental|Child-Centred Health Dialogue (CCHD)|The intervention CCHD consists of two parts 1) a universal Child Centred Health Dialog by the CHS-nurse directed in the first place to all 4-year-olds and their families (10 minutes) and 2) a targeted Family Guidance by the CHS-nurse to families where a child is identified with overweight at the age of 4 (60 minutes). All children invites to their regular 5-yrs health visit.
88873493|NCT04260672|No Intervention|usual care|Usual care for preschool children identified with overweight and obesity Usual care is performed according to national guidelines that invites all 4-year-olds to a '4-years health visit' including a health conversation. A survey on usual care in the case of identified overweight initial to this study among almost all nurses working at the participating CHCs showed that two thirds of questioned CHS-nurses used to invite families in which the child is identified with overweight for 1 or 2 extra visits outside the usual program. The majority o referred children to a dietician, or to another caregiver. All children invites to their regular 5-yrs health visit.
88873494|NCT04233138|Experimental|Intervention|The intervention group will have immediate access to the SUPPORT platform.
89397429|NCT05212948|Experimental|S-268019-b, Then Placebo|Participants will first receive a dose of S-268019-b via intramuscular (IM) injection on Day 1 and Day 29 during the initial vaccination period. After the initial vaccination period, participants will then receive a placebo IM injection (matching S-268019-b) on Day 225 and Day 253.
88873495|NCT04132206||ScS patients|Patients will provide two stool samples: one collected the day of inclusion and a second, six months later
88873496|NCT04132206||Healthy subjects|Healthy subjects will provide one stool sample at inclusion.
88873497|NCT03916614|Experimental|START treatment|Participants randomized into the treatment arm will receive the START intervention as described above alongside usual care from the VPOP staff
89397430|NCT05212948|Experimental|Placebo, Then S-268019-b|Participants will first receive a dose of placebo IM injection (matching S-268019-b) on Day 1 and Day 29 during the initial vaccination period. After the initial vaccination period, participants will then receive S-268019-b IM injection on Day 225 and Day 253.
89397431|NCT05212155|Other|Participating families|Parent/child dyads enrolled in the open-label program
89397432|NCT05201300|Experimental|Remimazolam 6|Remimazolam starts at 6 mg/kg/hr until loss of consciousness
89397433|NCT05201300|Experimental|Remimazolam 12|Remimazolam starts at 12 mg/kg/hr until loss of consciousness
89397434|NCT05201300|Active Comparator|Propofol|Propofol starts at a target controlled infusion 4 µg/ml until loss of consciousness.
89397435|NCT05176106|Experimental|Intervention-Randomized Parishes|Parishes will be randomized in Masindi District to receive the intervention (i.e., an incentives package). VHTs who are active in that parish will thereby receive the incentives intervention.
89397436|NCT05176106|No Intervention|Control-Randomized Parishes|Non-intervention randomized parishes will be the control parishes. Active VHTs in the control parishes will not receive the incentives intervention.
89397437|NCT05175495||Normal young|Aged less than 45 years old,no underlying heart disease
89397438|NCT05175495||Young people diagnosed with coronary heart disease|Aged less than 45 years old,Diagnosed coronary heart disease;Confirmed by coronary angiography;Diagnosed myocardial infarction;Typical symptom of ischemic chest pain with positive stress test;
89397439|NCT05175495||Coronary heart disease|Older than 65 years, diagnosed with coronary heart disease
89397440|NCT05163275||Patients|
89397441|NCT05155280|Experimental|Anorexia Nervosa patients|"30 patients with anorexia nervosa = 15 with moderate to high anxiety (STAI YB anxiety (STAI YB > 51) and 15 with low anxiety (STAI YB<51).~A TOBII eye tracker will be realised at Day 1. PET and MRI scans will be acquired at Day 2."
89397442|NCT05155280|Placebo Comparator|Controls|15 healthy volunteers (control group) and a low level of anxiety trait (< 51) A TOBII eye tracker will be realised at Day 1. PET and MRI scans will be acquired at Day 2.
89397443|NCT05152771|Other|Ketogenic Diet|This will be a prospective cohort study. All families with children who have been newly diagnosed with confirmed SSPE (based on Dyken's Criteria) will be approached to start the low glycemic index diet (liberalized kind of KD). A thorough dietary history will be taken from the parents/caregivers, and they will be counseled by a trained dietitian on the diet, all pros and cons, and the format. After the verbal agreement, formal consent will be taken from the parent/ caregiver for initiation of the diet.
89397444|NCT05139589||Infective endocarditis, surgical arm|Patients with infective endocardits requiring valve surgery
89397445|NCT05139589||Infective endocarditis, conservative arm|Patients with infective endocardits, not requiring valve surgery
89397446|NCT05139589||Valve disease, heart, surgically repaired|Patients requiring valve surgery
89397447|NCT05139433|Experimental|Intervention Group|Participants in this arm will receive 5 internet-delivered cognitive-behavioral intervention and will have access to 15 educational videos
89397448|NCT05139433|Active Comparator|Active Control Group|Participants in this arm will have access to 15 educational videos.
89397449|NCT05119439|No Intervention|71-77 days of gestational age|Pregnant people whose pregnancies are estimated to have a gestational age of 71-77 days. (Participants in this arm receive the standard of care for medical termination of pregnancy in the stated gestational age range).
89397450|NCT05119439|Experimental|78-84 days of gestational age|Pregnant people whose pregnancies are estimated to have a gestational age of 78-84 days.
89397451|NCT05065346|Experimental|DaRT seeds|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds
89397452|NCT05040503|Active Comparator|Patients without sepsis|patient without sepsis admitted to the Intensive Care Unit or the Anesthesia and Intensive Care Unit of the Dijon University Hospital
89397453|NCT05040503|Experimental|Patients with sepsis|Patients with sepsis admitted to the Intensive Care Unit or the Anesthesia and Intensive Care Unit of the Dijon University Hospital
89397454|NCT05040503|Experimental|Patients with septic shock|Patients with septic shock admitted to the Intensive Care Unit or the Anesthesia and Intensive Care Unit of the Dijon University Hospital
89397455|NCT05040503|Active Comparator|Healthy volunteers|
89397456|NCT05036512|Placebo Comparator|Placebo|Placebo as a tablet or capsule with dose based off of preceding cohort's data.
89397457|NCT05036512|Experimental|GBT021601|GBT021601 as a tablet or capsule with dose based off of preceding cohort's data.
89397458|NCT05020392|Experimental|Effective of CAR-T-CD19 cells with concurrent BTK inhibitor|After enrollment, all subjects will receive oral BTK inhibitor immediately and BTK inhibitor treatment will continue for up to 90 days (or longer for who are benefiting from BTK inhibitor) after CAR-T-CD19 infusion. Eligible patients will undergo leukapheresis to obtain peripheral blood mononuclear cells (PBMCs) for CAR T-cell production. Upon successful generation CAR-T-CD19 product, participants will receive fludarabine-based lymphodepletion chemotherapy, followed by infusion of CAR-T-CD19 cells (2*10^6 cells/kg) on day 0 and day 1 respectively.
89397459|NCT05020392|Active Comparator|Effective of CAR-T-CD19 cells monotherapy|Eligible patients will undergo leukapheresis to obtain peripheral blood mononuclear cells (PBMCs) for CAR T-cell production. Upon successful generation CAR-T-CD19 product, participants will receive fludarabine-based lymphodepletion chemotherapy, followed by infusion of CAR-T-CD19 cells (2*10^6 cells/kg) on day 0 and day 1 respectively.
89397460|NCT05006430|Active Comparator|Intervention Arm|"Subjects will receive Standard of Care (SOC), based on AASLD/EASL guidelines and one dose of PRIM-DJ2727 (30 grams of stool/dose ~ 3 capsules) every day for a week followed by once weekly for 3 weeks, amounting to total 10 doses.~PRIM-DJ2727 (microbiota suspension) is an intestinal microbial suspension prepared form stool obtained from carefully and thoroughly screened healthy human donors. It will be provided by University of Texas School of Public Health."
89397461|NCT05006430|Placebo Comparator|Placebo Arm|"Subjects will receive Standard of Care (SOC), based on AASLD/EASL guidelines and one dose of Placebo every day for a week followed by once weekly for 3 weeks, amounting to total 10 doses.~Placebo will be identical to the investigational product but will not contain active PRIM-DJ2727."
88873498|NCT03916614|Active Comparator|standard of care|Those randomized to the control arm will receive the usual screening for PTSD and referral for outpatient services if warranted as well as usual care from VPOP staff.
88873499|NCT03820596|Experimental|Sintilimab+Chidamide|"Sintilimab：200mg(fixed dosage), ivd, qd, q21d~Chidamide:~Phase I: 20mg-30mg,biw,continued oral，to evaluate RP2D. Phase II：RP2D，continued oral"
88873500|NCT03776760||Fingerstick Point of Care GeneXpert HCV Test|Participants will have HCV testing using the finger-stick point of care GeneXpert quantitative HCV RNA assay.
88873501|NCT03776760||Treat - SOF/VEL|Participants with active HCV infection will be offered treatment with one of two pan-genoptyic regimens available in Australia - sofosbuvir/velpatesvir
88873502|NCT03776760||Treat - G/P|Participants with active HCV infection will be offered treatment with one of two pan-genoptyic regimens available in Australia - glecaprevir/pibrentasvir
88873503|NCT03423888|Experimental|High-flow nasal oxygen|
88873504|NCT03393390||Healthy Controls|Subjects in this group will be defined as healthy controls after meeting with a clinician and determining that they do not meet the diagnostic criteria for any externalizing disorders or other psychiatric disorders.
88873505|NCT03393390||Externalizing|Subjects in this group will be defined as externalizing if the clinician determines that they meet the diagnostic criteria for one or more externalizing disorders, such as ADHD, ODD, or CD.
88873506|NCT03252834||Patients with endometrial or ovarian cancer|
88873507|NCT03252834||Patients with colorectal cancer|
88873508|NCT03191526|Experimental|KW-0761 0.3 mg/kg IV|Intravenous injection every 12 weeks. Duration of double-blind treatment is going to be for 24 weeks and be followed by transitional period, which is for maximal 4 weeks. After that, duration of open label treatment is going to be conducted for 24 weeks. And an extension treatment will be continued until the approval or termination.
88873509|NCT03191526|Placebo Comparator|Placebo (saline)|Intravenous injection every 12 weeks. Duration of double-blind treatment is going to be for 24 weeks and be followed by transitional period, which is for maximal 4 weeks. After that, duration of open label treatment is going to be conducted for 24 weeks. And an extension treatment will be continued until the approval or termination.
88873510|NCT02885220|Active Comparator|Conventional Program|The aim of our study is to determine if a goal directed program improves weight loss outcomes after sleeve gastrectomy. In the conventional weight loss program, patients will only be given their ideal weight to strive toward after surgery. Routine dietary and physiotherapy/exercise counseling are provided and patients would be educated on their ideal weights based on a BMI of 23. The target weight loss over a 12 month period would be 100% excess weight loss.
88873511|NCT02885220|Experimental|Goal Directed Program|For the goal directed program, patients would be given an additional sheet to show expected weight loss goals to strive towards at each consultation after surgery (3, 6, 9 and 12 months post operation). Bariatric patients in this modified program will be counselled prior to laparoscopic sleeve gastrectomy (LSG) and EWL (excess weight loss) targets will be set for patients to achieve at fixed intervals post LSG. These targets are charted in a graph, with the patient's actual weight charted on the graph at each clinic consultation, providing a strong visual aid counselling and motivation.
88873512|NCT02232282|Sham Comparator|Minimal Acupuncture|"Fifteen (15) will be allocated in the control sham/minimal acupuncture + standard medical treatments of IC. The sham intervention (also described as minimal intervention) will use superficial needle insertion at body locations not recognized as true acupoints. Patients will be explained that various acupuncture treatment protocols will be tested including minimal acupuncture, therefore, the control group will not be aware of receiving sham acupuncture."
88873513|NCT02232282|Active Comparator|Standard acupuncture treatment|Fifteen (15) will be allocated in the standard acupuncture treatment + medical management of IC. Standard acupuncture treatment protocol will include 4 gates plus GV 20 to reduce anxiety and help with relaxation and to assess acupuncture naïve patient's response to needles during their first acupuncture encounter. Subsequent visits would include administration of curious meridian Chong Mo paired with Yang Ming. 4 Hz low level electrical stimulation will be applied.
88873514|NCT01643460|Experimental|98% Ethanol with Paclitaxel injection|
88873515|NCT01879800|No Intervention|Treatment As Usual/Waitlist|Treatment As Usual/Waitlist
88873516|NCT01879800|Experimental|Acceptance and Commitment Therapy plus Illness Management|Acceptance and Commitment Training plus Illness Management (ACT-IM) Patients in the ACT-IM group will attend a 1-day group workshop. Three broad areas will be covered: 1) Illness Management will cover the importance of physical and psychological self-care for the management of co-morbid depression/anxiety and vascular problems 2) Behavioral Change Training will involve i) teaching patients how to recognize ineffective patterns of behavior and habits, ii) exploring and setting life goals and those related to mental and physical health, and iii) promoting effective and committed actions to achieve these goals despite the urge to do otherwise; 3) Mindfulness and Acceptance Training will emphasize new ways of managing troubling thoughts, feelings, and physical sensations .
88873517|NCT05748132|Experimental|trigeminal Radiofrequency|Combined conventional and pulsed radiofrequency (CCPRF) achieved comparable pain relief to PRF treatment alone in patients with chronic pain, the combination of PRF and CRF would increase the effect of CRF and reduce the need for long-duration CRF (LCRF) and its attendant side effects.
89530198|NCT03122015|No Intervention|Standard care|
89530199|NCT03249649||Phoenix Cohort|Somali Refugee women ages 15 and older
89530200|NCT03249649||Tucson Cohort|Somali Refugee women ages 15 and older
88873518|NCT05747898|Active Comparator|Cannula arm|the cannula's 18 gauge tip was pointed upward and approximately parallel to the skin's surface when it was put into the superficial dermis, 1-2 millimeters away from the targeted scar. In order to completely remove fibrous tissue from the superficial dermis, a lancing motion (linear inserting-withdrawing needle action) was utilized first.
89397462|NCT05004883|Experimental|Regulation of Cues Enhanced Treatment|The ROC program provides psychoeducation, coping skills, self-monitoring and experiential learning, and it will be combined with aspects of BWL to capitalize on the strengths of both treatments.
89397463|NCT05004883|Active Comparator|Behavioral Weight Loss|The BWL program will include dietary recommendations, physical activity recommendations, and behavioral change recommendations.
89397464|NCT05004883|Active Comparator|Nutrition, Stress Management, and Social Support|Nutrition Education, Stress Management and Social Support will be covered. Mindfulness will be practiced in every session.
89397465|NCT04992468|Experimental|GnRH-a+rhCG|Ovulation triggering with GnRH-a+rhCG
89397466|NCT04992468|Active Comparator|GnRH-a|Ovulation triggering with GnRH-a
89397467|NCT04990674|Experimental|REMOTION + TAU|
89397468|NCT04990674|Active Comparator|TAU|
89397469|NCT04984343|Experimental|5 radiation treatments - ARM 1|Patients randomized to ARM 1 will receive 37.5 in 5 radiotherapy treatments.
89397470|NCT04984343|Active Comparator|2 radiation treatments - ARM 2|Patients randomized to ARM 2 will receive 25 Gy in 2 radiotherapy treatments.
89397471|NCT04981548||raised intracranial pressure|more than 200 mmH2O
89397472|NCT04981548||the normal intracranial pressure group|more than 80 mmH2O and no more than 200 mmH2O
89397473|NCT04975100|Experimental|Test|Patients in the test group will get Sarcosine 500 mg capsules once daily as an add-on to ongoing SSRI treatment.
89397474|NCT04975100|Active Comparator|Control|Patients in the control group will get identical-looking capsules containing placebo in addition to SSRI at an once daily dose
89397475|NCT04970342|Experimental|"Sober or Double Placebo"|Subject receives alprazolam capsule containing placebo (lactose). Subject receives placebo cannabis (0% THC / 0% CBD).
89397476|NCT04970342|Experimental|Active Alprazolam (Xanax), Placebo Cannabis|Subject receives active 0.75 mg alprazolam capsule. Subject receives placebo cannabis (0% THC / 0% CBD).
89397477|NCT04970342|Experimental|Placebo Alprazolam (Xanax), Active Cannabis|Subject receives alprazolam capsule containing placebo (lactose). Subject receives active cannabis (6.18% THC / <0.025% CBD).
89397478|NCT04959981|Experimental|Dose Escalation (Part 1): ERAS-007 plus osimertinib|ERAS-007 will be orally administered in combination with osimertinib to study participants with EGFRm NSCLC in sequential ascending doses until unacceptable toxicity, disease progression, or withdrawal of consent.
89397479|NCT04959981|Experimental|Dose Escalation (Part 2): ERAS-007 plus sotorasib|ERAS-007 will be orally administered in combination with sotorasib to study participants with KRAS G12Cm NSCLC in sequential ascending doses until unacceptable toxicity, disease progression, or withdrawal of consent.
89397480|NCT04959981|Experimental|Dose Escalation (Part 3): ERAS-601 plus sotorasib|ERAS-601 will be orally administered in combination with sotorasib to study participants with KRAS G12Cm NSCLC in sequential ascending doses until unacceptable toxicity, disease progression, or withdrawal of consent.
89397481|NCT04959981|Experimental|Dose Expansion (Part 4): ERAS-007 plus osimertinib|ERAS-007 will be orally administered at the recommended dose (as determined from Part 1) in combination with osimertinib to study participants with EGFRm NSCLC.
89397482|NCT04959981|Experimental|Dose Expansion (Part 5): ERAS-007 plus sotorasib|ERAS-007 will be orally administered at the recommended dose (as determined from Part 2) in combination with sotorasib to study participants with KRAS G12Cm NSCLC.
89397483|NCT04959981|Experimental|Dose Expansion (Part 6): ERAS-601 plus sotorasib|ERAS-601 will be orally administered at the recommended dose (as determined from Part 3) in combination with sotorasib to study participants with KRAS G12Cm NSCLC.
88873519|NCT05747898|Active Comparator|Needle arm|The needle's 27 gauge tip was pointed upward and approximately parallel to the skin's surface when it was put into the superficial dermis, 1-2 millimeters away from the targeted scar. In order to completely remove fibrous tissue from the superficial dermis, a lancing motion (linear inserting-withdrawing needle action) was utilized first.
88873520|NCT05747664|Experimental|DWP16001 to normal haptic function|Normal hepatic function
89397484|NCT04951193|Experimental|Goal2QuitVaping|Participants in the Goal2QuitVaping group will be asked to download the Goal2QuitVaping app to their smartphone. Goal2QuitVaping focuses on mood management as well as on quitting vaping nicotine. Participants will be asked to use Goal2QuitVaping regularly, at least once per day, for the study duration. Participants will also be asked to complete questionnaires weekly for 4 weeks.
89397485|NCT04951193|Other|Treatment as Usual|Participants in the treatment as usual group will be provided with educational material about quitting vaping nicotine and it will be suggested that they discuss any questions about mood management and about quitting vaping with their primary care provider. The educational material is from the National Cancer Institute's SmokeFree Teen website and includes information on recognizing reasons for quitting vaping, avoiding dual use of e-cigarettes and other tobacco products, setting a quit date, understanding triggers, and accessing social support.
89397486|NCT04933162|Experimental|High Protein and Low Fiber Group|Subjects will consume a high protein and low fiber diet for 8 weeks
89397487|NCT04933162|Experimental|Low Protein and High Fiber Group|Subjects will consume a low protein and high fiber diet for 8 weeks
88873521|NCT05747664|Experimental|DWP16001 to Child-Pugh Class A|Child-Pugh Class A
88873522|NCT05747664|Experimental|DWP16001 to Child-Pugh Class B|Child-Pugh Class B
88873523|NCT05747508|Active Comparator|Inhaled Nitric Oxide (iNO)|Pulsed inhaled iNO30, 45 and 75 mcg/kg Ideal Body Weight (IBW)/hour (hr)
88873524|NCT05747508|Placebo Comparator|Placebo|Pulsed inhaled N2, 99.999% gas
88873525|NCT05747508|Active Comparator|Long Term Follow Up|Pulsed inhaled iNO30, 45 or 75 mcg/kg IBW/hr
89397488|NCT04901377||Combined oral contraception: Estradiol valerate / Dienogest|Young women (18-35 years of age) using estradiol valerate / dienogest in real clinical practice.
88873526|NCT05747040|Other|48-h monitoring|"The intervention consists of 48-h monitoring by using two types of monitoring: an objective monitoring, through a class IIa wearable medical device recording four physiological signals, and a subjective monitoring through a questionnaire developed with Microsoft Forms that can be compiled with a smartphone. The monitoring will be conducted during a motor neurorehabilitation treatment, 24 hours before and 24 hours after the treatment at the participant's home. Besides this monitoring, stratification questionnaires will be administered to each participant to be stratified in one of the three categories (absence of pain, nociceptive pain, or neuropathic pain) based on the following timeline:~t0: baseline~t1: pre-treatment~t2: post-treatment~t3: follow-up"
88873527|NCT05746728|Experimental|surufatinib + tislelizumab|"Safety Lead-in Phase: Six patients with metastatic triple-negative breast cancer will be recruited to receive surufatinib in combination with tislelizumab, and DLT will be evaluated over a 28-day DLT observation period.~Dose expansion phase: Surufatinib was administered according to the dose determined in the safety run-in phase and tislelizumab is same as Safety Lead-in Phase."
88873528|NCT05743686|Experimental|Application|
88873529|NCT05727540||Noninfectious uveitis|
88873530|NCT05727540||Infectious uveitis|
88873531|NCT05714670|No Intervention|standard of care|patients will receive oral MMF initial dose of 1200 mg/m2/day, no more than 2000 mg/day, increased to 1800 mg/m2/day, no more than 3000 mg/day, if response is not good + corticosteroid protocols are: intravenous pulse of methylprednisolone (30 mg/kg/dose for three consecutive days, no more than de 1000 mg/dose), followed by oral prednisolone/prednisone (0.5-1.0 mg/kg/day); or high dosage oral prednisone/prednisolone (1-2 mg/kg/day, no more than 60 mg/day) + hydroxychloroquine 4.0-5.5 mg/kg/day second regimen: low-dose intravenous cyclophosphamide (CY) (total dose 3 g over 3 months) -monthly pulses 0.5-1 g/m2- in combination with glucocorticoids
88873532|NCT05714670|Experimental|Curcumin Oral Capsule group|"patients will receive oral 1000 mg of curcumin capsules daily in addition to their standard treatment for three months.~Standard treatment includes: oral MMF initial dose of 1200 mg/m2/day, no more than 2000 m g/day, increased to 1800 mg/m2/day, no more than 3000 mg/day, if response is not good + corticosteroid protocols are: intravenous pulse of methylprednisolone (30 mg/kg/dose for three consecutive days, no more than de 1000 mg/dose), followed by oral prednisolone/prednisone (0.5-1.0 mg/kg/day); or high dosage oral prednisone/prednisolone (1-2 mg/kg/day, no more than 60 mg/day) + hydroxychloroquine 4.0-5.5 mg/kg/day~second regimen: low-dose intravenous cyclophosphamide (CY) (total dose 3 g over 3 months) -monthly pulses 0.5-1 g/m2- in combination with glucocorticoids"
88873533|NCT05670132|Experimental|Neurocardiac rehabilitation program|"The home-based neuro-cardiac rehabilitation program will consist of weekly sessions of neuro-cardiac training during 12 weeks at home.~The physical activity training consists of two 1-hour sessions of adapted physical activities per week supervised by an APA educator or equal. One weekly session is held in person, at home, and the second one in videoconference. All training sessions follow the same scheme with 30 minutes of bicycle training, adapted from high-intensity training (30-33), and 30 minutes of free adapted physical activities~The neuropsychological component will consist of 2 home-based weekly 25-minute sessions of computerized cognitive training via the new platform of CogMed (standard format) for the patient and 1 weekly 30/45-min teleconsultation session of neuropsychological feedback on every-day life emotional regulation and executive functioning applied to school and family life for either the parent (for ages 17 and younger) or young adults with CHD."
88873534|NCT05670132|Active Comparator|Standard of care|The control group will follow European recommendations for cardiology care (standard of care) without introducing any additional interventions for research purposes at the exception of primary (HRQoL questionnaires) and secondary outcomes
88873535|NCT05606718|Experimental|dapagliflozin group|GDMT and dapagliflozin 10mg once daily
88873536|NCT05606718|Active Comparator|control group|GDMT only
88873537|NCT05592522|Experimental|EOI group|Ultrasound-guided bilateral external oblique intercostal (EOI) using 30 ml of 0.25% bupivacaine hydrochloride and oblique subcostal transverse abdominis plane (OSTAP) block using Placebo (NSS 0.9%) 30 ml combined with bilateral posterior rectus sheath block with 15 ml bupivacaine 0.25%.
88873538|NCT05592522|Experimental|OSTAP group|Ultrasound-guided bilateral oblique subcostal transverse abdominis plane (OSTAP) block using 30 ml of 0.25% bupivacaine hydrochloride and external oblique intercostal (EOI) using Placebo (NSS 0.9%) 30 ml combined with bilateral posterior rectus sheath block with 15 ml bupivacaine 0.25%.
88873539|NCT05584566|Experimental|OSSIX Breeze|
88873540|NCT05584566|Active Comparator|Jason membrane|
88873541|NCT05548374|Experimental|Acupucnture|Treatment will start 2 weeks before the onset of menstruation in 3 consecutive menstrual cycles, three sessions per week (ideally every other day) in the first two menstrual cycles and two sessions per week in the last menstrual cycle, 16 sessions in total.
88873542|NCT05548374|Sham Comparator|Sham Acupuncture|Treatment will start 2 weeks before the onset of menstruation in 3 consecutive menstrual cycles, three sessions per week (ideally every other day) in the first two menstrual cycles and two sessions per week in the last menstrual cycle, 16 sessions in total.
88873543|NCT05472948|Experimental|Surufatinib and Sintilimab in Combination With Capecitabine|"Patients were given solventinib (a 3+3 design was adopted in the dose exploration phase, with two dose levels of 200mg and 250mg for dose exploration; after the recommended dose was determined in the dose exploration phase, the dose amplification phase was entered), once a day (QD) for continuous administration~sindilizumab, 200mg, iv every 3 weeks (Q3W)~Capecitabine, 1000mg/m2, twice a day (BID, once in the morning and once in the evening), orally after meals, stopped for 1 week after 2 weeks of treatment;~The three-drug combination therapy was continued every 3 weeks in a cycle until patients developed disease progression or met other criteria for termination of study treatment specified in the protocol."
88873544|NCT05460624|Experimental|Intervention group|Participants randomized to the intervention group will receive six premade egg-containing breakfast meals per week in the form of a 3-day rotating menu. Each meal contains 2 eggs to provide 12 eggs per week for a duration of 12 weeks.
88873545|NCT05460624|Other|Control group|Participants randomized to the control group will receive breakfast meals in the form of a 3-day rotating menu including typical foods found in American diets excluding eggs, e.g., corn flakes, milk, sausage, granola bars, fruit. Control recipes are matched to the intervention foods on total energy and saturated fat and to the 'What We Eat in America' on percent energy from macronutrients.
88873546|NCT05368896||Elderly patients with postoperative complications after major surger|Patients >80 years that will undergo major visceral or orthopedic surgery
89397489|NCT04881357|Experimental|Experimental Group|The experimental group will use three times daily a provided manual toothbrush with a sodium fluoride dentifrice, followed by the use of the test mouth rinse (Lacer Oros Acción Integral - new formula, Barcelona, Spain).
89397490|NCT04881357|Placebo Comparator|Control Group|The control group will use three times daily a provided manual toothbrush with a sodium fluoride dentifrice, followed by the use of the control mouth rinse (Lacer Oros Acción Integral - new formula, without active ingredients, Barcelona, Spain).
89397491|NCT04871737|Experimental|Low Dose, IM-IM|Group 1. Dose: 10 7.0-7.49 EID 50/dose. Both first and second administration by the intramuscular route, separated by 21 days.
89397492|NCT04871737|Experimental|Intermediate dose, IM-IM|Group 2. Dose: 10 7.5-7.99 EID 50/dose. Both first and second administration by the intramuscular route, separated by 21 days
89397493|NCT04871737|Experimental|High dose, IM-IM|Group 3. Dose: 10 8.0-8.49 EID 50/dose. Both first and second administration by the intramuscular route, separated by 21 days.
89397494|NCT04871737|Experimental|Low dose, IN-IN|Group 4. Dose: 10 7.0-7.49 EID 50/dose. Both first and second administration by the intranasal route, separated by 21 days
89397495|NCT04871737|Experimental|Intermediate dose, IN-IN|Group 5. Dose: 10 7.5-7.99 EID 50/dose. Both first and second administration by the intranasal route, separated by 21 days
89397496|NCT04871737|Experimental|High dose, IN-IN|Group 6. Dose: 10 8.0-8.49 EID 50/dose. Both first and second administration by the intranasal route, separated by 21 days
89397497|NCT04871737|Experimental|Low dose, IN-IM|Group 7. Dose: 10 7.0-7.49 EID 50/dose. First administration by the intranasal route and second administration by the intramuscular route, separated by 21 days
89397498|NCT04871737|Experimental|Intermediate dose, IN-IM|Group 8. Dose: 10 7.5-7.99 EID 50/dose. First administration by the intranasal route and second administration by the intramuscular route, separated by 21 days
89397499|NCT04871737|Experimental|High dose, IN-IM|Group 9. Dose: 10 8.0-8.49 EID 50/dose. First administration by the intranasal route and second administration by the intramuscular route, separated by 21 days
89397500|NCT04871737|Experimental|High dose, IM|Group 10. Dose: 10 8.0-8.49 EID 50/dose. 3rd administration by the intramuscular route to all the volunteers who agree to participate
88873547|NCT05294796|Active Comparator|Short course of antibiotherapy|Patients enrolled in this arm, will receive 8 weeks of antibiotherapy in case of early infection (< 2 week), and 12 weeks of antibiotherapy in case of delayed infection (2-10 weeks)
88873548|NCT05294796|Active Comparator|Long course of antibiotherapy|Patients enrolled in this arm, will receive 12 weeks of antibiotherapy in case of early infection (< 2 week), and until fracture healing of antibiotherapy in case of delayed infection
88873549|NCT05215470|Experimental|Nivolumab+Ipilimumab|Nivolumab IV 3mg/kg 3/3w + Ipilimumab 1mg/kg 3/3w 4 doses, followed by Nivolumab IV 480mg 4/4w until progression, toxicity, or up to 2 years of use.
88873550|NCT05166720|Experimental|NIDCAP care|The training core group was formed by the project team. After a one-month clinical unified training on the best evidence of NIDCAP for the VLBW nursing professional group, the best evidence of NIDCAP was applied to the intervention group.
88873551|NCT05166720|No Intervention|routine nursing care|routine nursingPerform routine care for NICU infants according to the nursing routine of each hospital
89188138|NCT00786747|Experimental|Personally tailored computer program|The experimental computer program provides the user with information about colorectal cancer screening that is tailored to their self-efficacy, readiness, and perceived barriers to undergoing screening, in their preferred language (English or Spanish).
89397501|NCT04865367||DEG n1: euploid medium|culture media derived from euploid embryos
89397502|NCT04865367||DEG n2: aneuploid medium|culture media derived from aneuploid embryos
89397503|NCT04865367||DEG n3: medium arrested embryos|culture media derived from arrested embryos
89397504|NCT04865367||DEG n4: control culture medium|pure culture media without contact to embryos
89397505|NCT04795245||patients treated with afatinib|
89397506|NCT04749901|Other|Patients with epilepsy|
89397507|NCT04749901|Other|Patients with PTSD|
89397508|NCT04749901|Other|Patients with type 1 diabetes|
89397509|NCT04749901|Other|Patients with a heart rhythm disorder|
89397510|NCT04725409||Epilepsy patients|All participants will be patients with medically refractory epilepsy undergoing depth electrode placement for seizure localization. For this study participants will complete psychiatric questionnaires measuring depression, anxiety, obsessive compulsive disorder, and impulsivity, and EEG recordings will be collected from the depth electrodes while subjects rest quietly. Some subjects will also participate in neuro cognitive tasks while neural recordings/stimulation are performed.
89397511|NCT04715984|Experimental|Neural recordings and stimulation|
89397512|NCT04707937|Experimental|Online education|Participants will gain access to the online education modules in addition to receiving current standard of care education (pamphlets and one on one teaching with health care provider)
88873552|NCT05151588|Experimental|Induction therapy followed by surgery and postoperative therapy|Induction chemotherapy with docetaxel 75mg/m2 on day 1, cisplatin 75mg/m2 on day 1, 5-FU 750mg from day 1 to day 5, given every 3 weeks for 3 cycles and tazemetostat 800mg twice daily orally for 3 cycles, followed by radical surgery or radical chemoradiation, and maintenance tazemetostat 800mg twice daily orally for 6 months
88873553|NCT05117892|Experimental|Trained vendors|"The intervention consists of a Training, Certification and Marketing scheme for dairy vendors operating in the informal sector. This scheme includes a 12hr training offered at the beginning of the study, followed by 2 quarterly visits where milk will be tested for microbiological quality and results will be discussed with participants.~The training will include three main components: (i) milk hygiene and quality; (ii) business skills; (iii) milk marketing.~Trainings will be offered free of charge. The trainings will be given by business development service (BDS) providers, who will be trained through a training of trainers ahead of the intervention. Quarterly visits will involve the collection of a milk sample from each participant in the experimental arm in an unannounced visit and results on the microbiological quality of the milk reported back individually and explained to each vendor"
88873554|NCT05117892|No Intervention|Untrained vendors|Participants in the no-intervention arm will receive the same unannounced quarterly visits, where milk will be sampled and tested for microbiological quality, but results will not be shared with the participants. The participants in this arm will only receive the training upon completion of the endline survey (i.e. when the study is finished)
88873555|NCT04929834|Experimental|Experimental group|All patients will receive the experimental emollients during 3 weeks.
88873556|NCT04921332|Experimental|Bright Light Therapy (BLT)|The intervention will consist of daily BLT sessions lasting 30 minutes at approximately 10AM (since many CF and COPD patients may not awaken until this time) starting on the day of admission through discharge for a goal of seven consecutive days. The intervention will use a 10,000-lux light box placed approximately 16-24 inches from the patient's face.
88873557|NCT04894734|Experimental|EES on|Patients will undergo epidural electrical stimulation (EES) and be randomized in a 1:1 allocation to EES on. Both the patient and the provider will be formally blinded to treatment assignment. Only the biostatistician and programming team will be unblinded to treatment assignments.
88873558|NCT04894734|Placebo Comparator|EES off|Patients will undergo epidural electrical stimulation (EES) and be randomized in a 1:1 allocation to EES off. Both the patient and the provider will be formally blinded to treatment assignment. Only the biostatistician and programming team will be unblinded to treatment assignments.ES off. Those in the EES off category will have their EES turned on at the 9-month timepoint.
88873559|NCT04576182|Experimental|Supportive-Expressive|Participants will receive supportive-expressive treatment for 16 weeks.
88873560|NCT04576182|Experimental|Emotion-Focused|Participants will receive Emotion-Focused treatment for 16 weeks.
88873561|NCT04470804|Experimental|Sirolimus on newly diagnosed primary acquired PRCA|A prospective research of the sirolimus efficiency on newly diagnosed primary acquired PRCA patients. Sirolimus dosage: 2mg QD with plasma concentration 4-15ng/mL. Medication time should last at least 6 months
88873562|NCT04470804|Active Comparator|Cyclosporine A on newly diagnosed primary acquired PRCA|Cyclosporine A (CsA) efficiency on newly diagnosed primary acquired PRCA patients. CsA dosage: 4mg/kg QD. Medication time should last at least 6 months
88873563|NCT04418466|Experimental|DLP-114 alpha-4 (6-months)|2 360mg Risperidone Implants
88873564|NCT04418466|Experimental|DLP-114 alpha-7 (12-months)|2 435mg Risperidone Implants
88873565|NCT04360044|Experimental|THC ~5%|4 puffs of cannabis flower containing THC ~5% administered by vaporizer using Foltin Uniform Puff Procedure for treatment of a moderate-severe migraine attack. The flower is from the United States National Institute on Drug Abuse (NIDA).
88873566|NCT04360044|Experimental|THC ~5%/CBD ~12%|4 puffs of cannabis flower containing THC ~5% and CBD ~12% administered by vaporizer using Foltin Uniform Puff Procedure for treatment of a moderate-severe migraine attack. The flower is from the United States National Institute on Drug Abuse (NIDA).
88873567|NCT04360044|Experimental|CBD ~12%|4 puffs of cannabis flower containing CBD ~12% administered by vaporizer using Foltin Uniform Puff Procedure for treatment of a moderate-severe migraine attack. The flower is from the United States National Institute on Drug Abuse (NIDA).
89188139|NCT00786747|Active Comparator|Non-tailored control computer program|This program provides non-tailored, generic information about colorectal cancer screening, in the user's preferred language (English or Spanish).
89188140|NCT03919734||AI ACS/possible ACS|Patients with adrenal incidentalomas and cortisol following overnight 1-mg dexamethasone suppression equal to or above 50 nmol/l. The patients should not have clinical signs of Cushing Syndrome, such as catabolic skin and muscle changes.
89188141|NCT03919734||AI non-ACS|Patients with adrenal incidentalomas and cortisol following overnight 1-mg dexamethasone suppression below 50 nmol/l.
89188142|NCT03919734||Treatment with Inhalation Steroids|Patients treated with inhalation steroids with and without ACS/possible ACS but not operated with adrenalectomy.
89188143|NCT03919734||Adrenalectomy|Patients with unilateral AI operated with adrenalectomy
89188144|NCT03919734||Controls|"A Group of Controls matched for sex and age, achieved by the government agency Statistics Sweden (SCB)."
89188145|NCT00791739|Experimental|one arm study|
89188146|NCT00425269|Experimental|Intervention|The intervention group was divided into nine subgroups of ten to twelve women who were offered six educational sessions, each lasting 2 h, during a 7 +- 1-month period. The main focus was on the physiological importance of blood glucose and its regulation by diet and physical activity, and on knowledge about the Pakistani lifestyle in Pakistan and Norway
89188147|NCT00425269|No Intervention|Control|One lesson recieved after post-test
89397513|NCT04707937|Active Comparator|Regular standard of care education|Participants only receive current standard of care education (pamphlets and one on one teaching with health care provider)
89397514|NCT04706728|Experimental|Playlists with Expert-Curated Music - four weeks|Patients can choose from two expert-curated playlists with music, matching the trajectory of the ECT treatment (immediately before-, during and after the procedure). Playlists are available to the patients for four weeks (the first eight ECT procedures).
89397515|NCT04706728|Active Comparator|Playlists with Expert-Curated Music - two weeks|Patients can choose from two expert-curated playlists with music, matching the trajectory of the ECT treatment (immediately before-, during and after the procedure). Playlists are available to the patients for two weeks (the first four ECT procedures).
89397516|NCT04706728|Placebo Comparator|Playlists with Nature Sounds|Patients can choose from two expert-curated playlists with recorded sounds from nature (Rain, Waves) during ECT treatment (immediately before-, during and after the procedure). Playlists are available to the patients for four weeks (the first eight ECT procedures).
89397517|NCT04705025|Experimental|Supportive care (BNT001 app, CBSM, interview)|Prior to participating in the study patients complete an online baseline questionnaire to assess anxiety and depression and general quality of life, as well as some specific questions related to their coping. They are also interviewed by a clinician who rates their level of anxiety and depression. After this, patients use the BNT001 app and undergo 10 sessions of CBSM over 45-60 minutes each consisting of cancer-specific educational videos, guided relaxation training, interactive exercises, and discussion modules. Following completion of the 5th session, patients undergo a telephone check-in assessment to see how things are going, update their treatments and medications, and schedule a phone call to assess for adverse events. At the end of the 10th session, patients complete a post-treatment online questionnaire and a phone debriefing interview to discuss their experience with the intervention.
89397518|NCT04693013|Experimental|Interventional|use of virtual reality (VR)
89397519|NCT04693013|No Intervention|Control|no use of VR
89397520|NCT04688749||Healthy Control|Individuals without skin damage (melanoma, BCC, SCC, etc)
89397521|NCT04688749||Skin lesion|Individuals diagnosed with confirmed skin damage by Dermatologists
88873568|NCT04360044|Sham Comparator|Sham Cannabis|4 puffs of cannabis flower from which the THC and CBD have been extracted administered by vaporizer using Foltin Uniform Puff Procedure for treatment of a moderate-severe migraine attack. The flower is from the United States National Institute on Drug Abuse (NIDA).
88873569|NCT04337814|Experimental|COTA Arm|Patients getting combined (C) oral (O) and topical (T) analgesics (A)
88873570|NCT04337814|Experimental|OA Arm|Patients getting oral (O) analgesics (A) and topical placebo
88873571|NCT04337814|Placebo Comparator|Placebo Arm|Patients getting oral placebo and topical placebo
88873572|NCT04336332|Experimental|Arm 1: Hydroxychloroquine Sulfate + Azithromycin|"Hydroxychloroquine sulfate 200 mg taken by mouth three (3) times a day for 10 days~Azithromycin 500 mg taken by mouth on Day 1, followed by~Azithromycin 250 mg taken by mouth once (1) time a day for four (4) days."
88873573|NCT04336332|Experimental|Arm 2: Hydroxychloroquine Sulfate alone|• Hydroxychloroquine sulfate 200 mg taken by mouth three (3) times a day for 10 days
88873574|NCT04336332|No Intervention|Arm 3: Placebo|"Placebo pills Days 1-6.~If you still have COVID-19 symptoms you will receive Hydroxychloroquine sulfate 200 mg by mouth three (3) times a day for 10 days"
88873575|NCT03953508|Other|Menthol|Participants will smoke and rate several puffs of a menthol Camel Crush cigarette
88873576|NCT03953508|Other|Non-menthol|Participants will smoke and rate several puffs of a non-menthol Camel Crush cigarette
88873577|NCT03882840|Experimental|itNK cell therapy group|Patient-originated and induced T-to-natural killer (ITNK) cells, will be administrated to kill tumor cells.
88873578|NCT03671148|Experimental|Risankizumab|Participants randomized to receive 150 mg risankizumab administered by subcutaneous injection at Week 0, Week 4, and Week 16 in Period 1. At Week 24 participants will receive blinded placebo followed by open-label 150 mg risankizumab at Week 28, and every 12 weeks thereafter in Period 2 until the final dosing time point at Week 316.
88873579|NCT03671148|Placebo Comparator|Placebo|Participants randomized to receive double-blind placebo at Week 0, Week 4, and Week 16 in Period 1. At Week 24 participants will receive 150 mg risankizumab followed by open-label 150 mg risankizumab at Week 28, and every 12 weeks thereafter in Period 2 until the final dosing time point at Week 316.
88873580|NCT03465852|Experimental|Intervention arm|"Persons randomized to this arm will have completed the study consent process (including being tested with the INSTI rapid HIV test to verify their self-reported HIV negative status and their eligibility to participate in the study) and the baseline survey, and will receive the Spanish language ChiCAS intervention shortly after being randomized and will complete a follow-up assessment 6 months after completing the intervention.~."
88873581|NCT03465852|Other|Wait list comparison (control) arm|Persons randomized to this arm will have completed the study consent process (including being tested with the INSTI rapid HIV test to verify their self-reported HIV negative status and their eligibility to participate in the study) and the baseline survey, but will not receive the Spanish language ChiCAS intervention until they complete a follow-up assessment 6 months after completing the baseline assessment.
88873582|NCT03295344||Patients|
88873583|NCT03295344||Healthy volunteers|
88873584|NCT03198546|Other|CAR-T cell therapy group|Appropriate patients who could benefit from the GPC3 and TGFβ targeting CAR-T cell therapy against HCC are chosen to be the CAR-T cell therapy group.
89397522|NCT04665557|Experimental|Dove Confident Me Indonesia - Single Session|Dove Confident Me Indonesia Single Session is school-based, body image curriculum.
89397523|NCT04665557|No Intervention|Lessons As Usual Control|School lessons as usual.
89397524|NCT04654507|Active Comparator|Adjuvant dexamethasone|Drug: Dexamethasone
89397525|NCT04654507|Placebo Comparator|Placebo|Drug: Placebo
88873585|NCT01430442|Experimental|Treatment A: Rimegepant, 10 mg|Participants received a single dose (one capsule) of rimegepant 10 milligram (mg) orally and three rimegepant placebo-matching capsules, orally, anytime within 45 days of randomization, once they experienced a migraine headache of moderate to severe intensity.
88873586|NCT01430442|Experimental|Treatment B: Rimegepant, 25 mg|Participants received a single dose (one capsule) of rimegepant 25 mg orally; and three rimegepant placebo-matching capsules, orally, anytime within 45 days of randomization, once they experienced a migraine headache of moderate to severe intensity.
89397526|NCT04654039||Treatment of Infertility|Non intervention
88873587|NCT01430442|Experimental|Treatment C: Rimegepant, 75 mg|Participants received a single dose (one capsule) of rimegepant 75 mg orally; and three rimegepant placebo-matching capsules, orally, anytime within 45 days of randomization, once they experienced a migraine headache of moderate to severe intensity.
89397527|NCT04646655|Active Comparator|Enoxaparin at prophylactic dose|Enoxaparin at prophylactic dose: standard 4.000 IU QD via subcutaneous injection (6000 IU if body weight>100 kg)
89397528|NCT04646655|Experimental|Enoxaparin at therapeutic dose|"Enoxaparin at therapeutic dose : 70 U/Kg b.i.d. (every 12 h)~In order to easily calculate the correct therapeutic dose of enoxaparin for each patient, a simplified categorization will be applied, as follows:~weight < 65 Kg: 4.000 IU b.i.d. (every 12 h)~weight ≥ 65 Kg: 6.000 IU b.i.d. (every 12 h)~weight ≥ 100 Kg: 8.000 IU b.i.d. (every 12 h) The most appropriate dose will be evaluated in patients with creatinine clearance between 30 and 50 ml/min"
89397529|NCT04629443|Experimental|S64315 (also referred as MIK665) with azacitidine|
89397530|NCT04627922|Experimental|N-acetyl cysteine (NAC) & cognitive behavioral therapy|N-acetyl cysteine (NAC) & cognitive behavioral therapy experimental arm consists of 30 regular cigarette smokers and cannabis users with current TUD, who will be randomized to receive N-acetyl cysteine 3600 mg per day over 8 weeks to experimental arm. Participants will also receive weekly cognitive behavioral therapy for substance use disorders targeting TUD and cannabis use.
89397531|NCT04627922|Placebo Comparator|Placebo Comparator: Placebo & cognitive behavioral therapy|Placebo comparator & cognitive behavioral therapy arm consists of 30 regular cigarette smokers and cannabis users with current TUD, who will be randomized to receive placebo over 8 weeks. Participants will also receive weekly cognitive behavioral therapy for substance use disorders targeting TUD and cannabis use.
89397532|NCT04608110|Experimental|Azacitidine + Cedazuridine|"Drug: Azacitidine~Tablets or capsules for oral administration and powder for reconstitution to aqueous suspension for subcutaneous administration~Drug: Cedazuridine~Tablets for oral administration"
89397533|NCT04581226||Lung ultrasound|Sonographic assessments including the lung consolidation score, B-line score and Lung aeration score will be recorded 1min. after intubation, at end of surgery and 2h postoperatively.
89397534|NCT04577716||Endoleak Group|Participants with a previous Endovascular Aneurysm Repair (EVAR) who have developed an endoleak
89397535|NCT04577716||No Endoleak Group|Participants with a previous Endovascular Aneurysm Repair (EVAR) who have not developed an endoleak
88873588|NCT01430442|Experimental|Treatment D: Rimegepant, 150 mg|Participants received a single dose (one capsule) of rimegepant 150 mg orally; and three rimegepant placebo-matching capsules, orally, anytime within 45 days of randomization, once they experienced a migraine headache of moderate to severe intensity.
88873589|NCT01430442|Experimental|Treatment E: Rimegepant, 300 mg|Participants received a single dose (two 150 mg capsules) of rimegepant 300 mg orally; and two rimegepant placebo-matching capsules, orally, anytime within 45 days of randomization, once they experienced a migraine headache of moderate to severe intensity.
88873590|NCT01430442|Experimental|Treatment F: Rimegepant, 600 mg|Participants received a single dose (four capsules of 150 mg each) of rimegepant 600 mg orally; anytime within 45 days of randomization, once they experienced a migraine headache of moderate to severe intensity.
89397536|NCT04577716||Pre-EVAR Group|Participants who have an abdominal aortic aneurysm and who are undergoing an Endovascular Aneurysm Repair as standard of care
89397537|NCT04576416|Experimental|Intervention|During the three months the intervention group will receive access to the AI augmented digital educational platform and its two modules (Training Module and Clinical Feedback Module). They will receive continuous clinical feedback on their registered lesions.
88873591|NCT01430442|Placebo Comparator|Treatment P: Rimegepant Placebo-Matching Capsules|Participants received a single dose (4 capsules) of rimegepant placebo-matching capsules orally, anytime within 45 days of randomization once they experienced a migraine headache of moderate to severe intensity.
89397538|NCT04576416|No Intervention|Control|The control group continues its standard clinical practice without access to the E-app, but does register skin lesions throughout the full 3 month period.
89397539|NCT04572269||Subjects with OSA|Female and male subjects with Obstructive Sleep Apnea (OSA) (AHI >5)
89397540|NCT04569487|Active Comparator|Sarcopenic population|"Diagnosed sarcopenia following definition of the EWGSOP2:~Muscle strength assessed by the handgrip test <27 kg~Skeletal muscle mass index (Appendicular lean muscle mass) assessed by DXA <7.0 kg/m2"
89397541|NCT04569487|Active Comparator|Non sarcopenic population|"Non-sarcopenic population adapted from the EWGSOP2:~Muscle strength assessed by the handgrip test ≥ 27 kg~Skeletal muscle mass index (Appendicular lean muscle mass) assessed by DXA ≥ 7.0 kg/m2"
89530201|NCT02517827|Active Comparator|Endovascular procedure|Common femoral artery (target lesion) to be treated with directional atherectomy and paclitaxel-coated balloon angioplasty. Optional: stentimplantation.
89397542|NCT04562883|Experimental|Single Culture|"Transfer the COCs cultured individually in Capacitation medium to the individual washing droplets from the washing dish containing Maturation Medium and wash them thoroughly. Then transfer COCs one by one to the Culture dish with Maturation Medium."
89397543|NCT04562883|Experimental|Group Culture|"Transfer half of the COCs (5-10 at a time) from the Capacitation culture dish to the washing dish containing Maturation Medium (Group Culture) by using an Eppendorf micropipette and wash them thoroughly (load pipette tips with 5µl, max. 10µl). Then transfer COCs to the IVM dish with Maturation Medium (Group Culture)."
89397544|NCT04540588|Experimental|DaRT Seeds|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds
89397545|NCT04534127|Experimental|DaRT Seeds|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds
89397546|NCT04532242|Experimental|fMRI Participants|Participants will be scanned in an fMRI session lasting approximately 45-50 minutes and will be shown negative images for which they will have to take on a cognitive reappraisal tactic. All participants will be taken through the scanner with the same reappraisal protocol for each participant.
89397547|NCT04521413|Experimental|A1: Monotherapy Escalation|Dose escalation arm with CFI-402411. CFI-402411 is administered orally once daily.
89397548|NCT04521413|Experimental|A2: Monotherapy Biomarker|Dose escalation biomarker arm with CFI-402411. CFI-402411 is administered orally once daily.
89397549|NCT04521413|Experimental|A3: Monotherapy Expansion|Dose expansion arm with CFI-402411 at its recommended phase 2 dose.
89397550|NCT04521413|Experimental|B1: Combination Escalation|Dose escalation arm with CFI-402411 in combination with pembrolizumab (at its labeled dose and schedule).
89397551|NCT04521413|Experimental|B2: Combination Expansion|Dose expansion arm with the recommended phase 2 dose of CFI-402411 in combination with pembrolizumab (at its labeled dose and schedule).
89397552|NCT04516057|Experimental|Nabilone Arm|Participants randomized to the nabilone arm will be titrated up to a maximum dose of 2 mg/day.
88873592|NCT01430442|Active Comparator|Treatment G: Sumatriptan 100 mg|Participants received a single dose (one capsule) of rimegepant-matching sumatriptan 100 mg orally and three rimegepant matching placebo capsules orally, anytime within 45 days of randomization once they experienced a migraine headache of moderate to severe intensity.
89004019|NCT03684980|Experimental|Arm A - Rituximab + MTX + Glucarpidase|Patients will receive rituximab Day 1 (+/- 7 days) and MTX Day 2 (+/- 7 days) as per standard of care. Voraxaze will be administered each cycle 24 hours (+/- 2 h) after start of MTX infusion. Dose of Voraxaze will be 2000 units during cycles 1-4, and 1000 units during cycles 5-8. Patients will be treated with rituximab 500 mg/m^2. (Cohort A) will receive MTX 3 g/m2. Patients will also receive standard of care leucovorin rescue starting at least 24 hours after MTX and 2 hours after Voraxaze. Cycles will be 14 days long.
89397553|NCT04516057|Placebo Comparator|Placebo Arm|Participants randomized to the placebo arm will receive placebo capsules.
89397554|NCT04507464|Experimental|Ecological Momentary Intervention|Participants will receive real time physical activity notifications via a wearable activity tracker and smartphone application.
89397555|NCT04507464|No Intervention|Physical Activity Guidelines|Participants will be sent general guidelines for disruption of sedentary time.
89397556|NCT04484571|Experimental|Robotic treatment|Patients receive 4 weeks of elbow rehabilitation treatment provided by the NEEM robotic elbow exoskeleton
89397557|NCT04484571|Active Comparator|Conventional treatment|Patients receive 4 weeks of elbow conventional rehabilitation treatment matched in time
89397558|NCT04483245||controls|persons free of hemorrhage or haemostasis disorder
89397559|NCT04483245||Haemorrhagic|Acute hemorrhagic patient
89397560|NCT04483245||ECMO|ECMO surgery patient with hemorrhagic complication
89397561|NCT04483245||polytrauma|
89397562|NCT04483245||Platelet disorder|Patient with an identified platelet disorder or treated with antiplatelet agents
89397563|NCT04451278||Resting-state functional MRI (r-fMRI)|"The MRI examination will be performed on a 3T multi-parametric MRI. Compared to the standard protocol, patients will benefit from an additional fMRI-r sequence, called resting state, and performed before injection of gadoline contrast.~A neuropsychological evaluation is performed as part of the 6 months prior to the procedure. These data will be used as a basis for the evaluation of language visual and language recovery."
89397564|NCT04441892|Experimental|QTc Meter|Infants/Children (Day 0-Age 5) will participate in this study as minimal risk. Patients will record 30 seconds of data that is collected on the QTc Screening device
89397565|NCT04441892|Experimental|QTc Meter - Healthy Controls|Infants/Children (Day 0-Age 5) will participate in this study as minimal risk. Patients will record 30 seconds of data that is collected on the QTc Screening device.
89397566|NCT04436497|Experimental|Zilucoplan|"Drug: Zilucoplan Administration: Subcutaneous injection~Dosage: 0.3mg/kg administered daily"
89397567|NCT04436497|Placebo Comparator|Matching Placebo|"Administration: Subcutaneous injection~Dosage: Daily subcutaneous injection"
89397568|NCT04434755||health care professionals in palliative care|health care professionals in palliative care
89397569|NCT04434755||health care professionals in neurorehabiliation|health care professionals in neurorehabiliation
89397570|NCT04424641|Experimental|GEN1044|
89397571|NCT04421846|Other|Group 1 : Status epilepticus|
89397572|NCT04421846|Other|Group 2 : Dysimmune encephalitis|
89397573|NCT04421846|Other|Group 3 : Control patients|
89397574|NCT04414345|Experimental|CNM-Au8|"Drug: CNM-Au8~Administration: Oral~Dosage: 30 mg or 60 mg daily"
89397575|NCT04414345|Placebo Comparator|Matching Placebo|"Administration: Oral~Dosage: 2 bottles daily"
89397576|NCT04393103|Other|Follow up|Follow Up of 30 patients after administration of atropine.
89397577|NCT04393103|Experimental|intralipid 20% adjuvant|30 patients will receive atropine and intralipid AS AN ADJUVANT Three boluses of IFE 15 mg/kg were given over 3 minutes, 20 minutes apart.
89397578|NCT04368195|No Intervention|Control group|This group will not receive any regional block
89397579|NCT04368195|Experimental|Erector spinae block group|This group will receive erector spinae block
89397580|NCT04335370||Patients with CF lung disease receiving Polymyxin B (PMB)|Participants receiving polymyxcin B as part of standard of care treatment for CF exacerbation will have blood drawn measure blood concentrations of PMB
89397581|NCT04334629|No Intervention|Standard of care|
89397582|NCT04334629|Experimental|Standard of care plus lipid ibuprofen|
89397583|NCT04296890|Experimental|Treatment|All patients will receive single-agent mirvetuximab soravtansine (MIRV) at 6 mg/kg adjusted ideal body weight (AIBW) administered on Day 1 of every 3-week cycle (Q3W).
89397584|NCT04276090|Experimental|Colorectal liver metastases|Patients with unresectable colorectal liver metastases will undergo hepatic artery infusion pump placement using the Synchromed II pump and the Codman tapered arterial catheter. Patients will then receive hepatic artery infusion floxuridine as well as disease-appropriate systemic chemotherapy (FOLFOX, FOLRIRI, or oxaliplatin/irinotecan, or panitumumab if KRAS/NRAS wild type)
89397585|NCT04276090|Experimental|Intrahepatic cholangiocarcinoma|Patients with unresectable intrahepatic cholangiocarcinoma will undergo hepatic artery infusion pump placement using the Synchromed II pump and the Codman tapered arterial catheter. Patients will then receive hepatic artery infusion floxuridine as well as disease-appropriate systemic chemotherapy (gemcitabine/oxaliplatin or gemcitabine alone)
89397586|NCT04273139|Experimental|Ibrutinib and Venetoclax (3 dose ramp up)|"The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits.~First 12 participants~Ibrutinib will be administered at a predetermined dose, once daily for 28 days~TLS Prophylaxis (Treatment to reduce risk of tumor lysis syndrome) prior to first dose of venetoclax (and for at least the first 2 weeks of treatment)~Venetoclax Cycle 2-24. PO daily, predetermined dosage ramp up during cycle 2."
88873593|NCT01420926|Experimental|Arm A (decitabine)|"REMISSION INDUCTION THERAPY: Patients receive 20 mg/m^2 decitabine IV over 1 hour QD on days 1-10. Treatment repeats every 28 days for 2-4 courses in the absence of disease progression or unacceptable toxicity. Patients not achieving CR CRi proceed to continuation therapy. Patients achieving CR or CRi proceed to maintenance therapy.~CONTINUATION THERAPY: Patients receive 20 mg/m^2 decitabine IV over 1 hour QD on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive 20 mg/m^2 decitabine IV over 1 hour QD on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
89397587|NCT04273139|Experimental|Ibrutinib and Venetoclax (2 dose ramp up)|"The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits.~Ibrutinib will be administered at a predetermined dose, once daily for 28 days~TLS Prophylaxis (Treatment to reduce risk of tumor lysis syndrome) prior to first dose of venetoclax (and for at least the first 2 weeks of treatment)~Venetoclax Cycle 2-24. PO daily, predetermined dosage ramp up schedule during cycle 2."
89397588|NCT04248023|Experimental|Intervention Practices|Intervention practices will work with a practice facilitator to make practice specific changes to address unhealthy alcohol use.
89397589|NCT04248023|No Intervention|Control Practices|Control practices will continue to screening and address unhealthy alcohol use based on their existing practice patterns.
89397590|NCT04244370|Experimental|Caterpillar™ Arterial Embolization Device|Placement of the Caterpillar™ Arterial Embolization Device via percutaneous transcatheter embolization (PTE).
89397591|NCT04207437|Experimental|Vibration Therapy|Patients will hold a hand held vibrating device for 3 minutes on each hand daily for 4 weeks.
89397592|NCT04207359|Experimental|Creatine Supplement Group|Participants will engage in three center-based exercise sessions each week for 12 weeks; each session lasting roughly 1-hour. Participants will be given a fitbit (electronic watch that measures steps or heart rate) as well to track heart rate and monitor activity throughout the study.
89397593|NCT04207359|No Intervention|Exercise Only Control Group|Participants will not participate in the creatine intervention (creatine supplementation). Participants will engage in three center-based exercise sessions each week for 12 weeks; each session lasting roughly 1-hour. Exercise sessions will be held by trained study staff held at the Medical Arts and Research Center Physical Therapy clinic (address listed above).
89004020|NCT03684980|Experimental|Arm B - Rituximab + MTX + Glucarpidase|Patients will receive up to 8 cycles of treatment consisting of rituximab Day 1 (+/- 7 days) and MTX Day 2 (+/- 7 days) as per standard of care. Voraxaze will be administered each cycle 24 hours (+/- 2 h) after start of MTX infusion. Dose of Voraxaze will be 2000 units during cycles 1-4, and 1000 units during cycles 5-8. Patients will be treated with rituximab 500 mg/m^2. (Cohort B) will receive MTX 8 g/m2. Patients will also receive standard of care leucovorin rescue starting at least 24 hours after MTX and 2 hours after Voraxaze. Cycles will be 14 days long.
89397594|NCT04195503|Other|liver transplantation|Surgical Intervention - Liver transplantation
89397595|NCT04193475||Chest pain|Individuals presenting with chest pain requiring a stress echocardiogram.
89397596|NCT04159168|Experimental|Arm 1: R61 FAST|Individuals in this Arm will receive the FAST intervention, as described in the Intervention section of the Clinical Trials form below, with a focus on demonstrating target (facial affect sensitivity) engagement.
89397597|NCT04159168|No Intervention|Arm 2: R61 No-Treatment Control|Individuals in this Arm will not receive any intervention.
89397598|NCT04159168|Experimental|Arm 3: R33 FAST|Individuals randomized this Arm of the R33 phase will receive the FAST intervention, with the aim of replicating FAST target engagement (as demonstrated in the R61 phase) with a new high-CU sample, and to evaluate the FAST intervention in comparison to an active control condition (Arm 4, implicit eye gaze training).
89397599|NCT04159168|Active Comparator|Arm 4: R33 Active Control|Individuals in this Arm will receive the active control component, which is an implicit gaze training intervention.
89397600|NCT04134689|Active Comparator|DOT Selfie Intervention Arm|"The DOT Selfie Intervention will comprise a smart phone, the VDOT App, a prepaid weekly internet bundle and text message medication reminders.~Patients in this arm will receive detailed training (in English or Luganda) on VDOT use prior to starting treatment. Each patient will be required to record and submit daily videos as they self-administer their medication. Patients who successfully submit their videos for seven consecutive days will receive a weekly incentive in the form of social bundles of airtime minutes. A prepaid internet bundle will also be uploaded to each mobile phone weekly to allow for daily video uploads. Additionally, patients will receive text message medication reminders to encourage treatment compliance."
89530202|NCT02517827|Active Comparator|Surgery|Common femoral artery (target lesion) to be treated with open, surgical endarterectomy
89530203|NCT02456311|Other|Harmonic Ace+7|Pulmonary ARtery sealing with Harmonic Ace+7 in open lobectomy
89530204|NCT05584865|Experimental|Group I|
89530205|NCT05584865|Active Comparator|Group II|
88873594|NCT01420926|Experimental|Arm B (decitabine and bortezomib)|"REMISSION INDUCTION THERAPY: Patients receive 20 mg/m^2 decitabine IV over 1 hour QD on days 2-11 and 1.3 mg/m^2 bortezomib SC on days 1, 4, 8, and 11. Treatment repeats every 28 days for 2-4 courses in the absence of disease progression or unacceptable toxicity. Patients not achieving CR or CRi proceed to continuation therapy. Patients achieving CR or CRi proceed to maintenance therapy.~CONTINUATION THERAPY: Patients receive 1.3 mg/m^2 bortezomib SC on day 1 and 20 mg/m^2 decitabine IV over 1 hour QD on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive 1.3 mg/m^2 bortezomib SC on day 1 and 20 mg/m^2 decitabine IV over 1 hour QD on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
88873595|NCT00941538|Experimental|intervention|"Residents aged 30-69 years in eight screening towns in the intervention group are invited to screening marker tests - IgA antibodies to EBV VCA/IgA and EBV nuclear antigen-1 (EBNA1/IgA) by ELISA.~The trial will use two minimally acceptable false-positive rates (i.e., 10% and 3%) as the cutoffs to define medium-risk (seropositive, 0.65 ≤ score < 0.98) and high-risk participants (seropositive, score ≥ 0.98). After a blood test, participants whose EBV-based risk exceeds the predefined high-risk threshold (score ≥ 0.98) will be referred to endoscopy for clinical evaluation. Participants who are defined as medium-risk or high-risk (score ≥ 0.65) will be followed annually through blood testing and linkage to registers. The remaining participants (seronegative, score < 0.65) will be asked to return for a follow-up visit after five years."
88873596|NCT00941538|No Intervention|Control|The individuals aged 30-69 in the other eight towns will be included as controls, which is a comparable population that will not be screened for NPC.
88873597|NCT01881828|Experimental|Metformin|Metformin 2000 mg per day
88873598|NCT01881828|Placebo Comparator|Oral Placebo|"A central pharmacy will compound a placebo to match the metformin tablets.~The placebo product will contain the following components:~Micosolle™, silica based excipient~Silicified Micro Crystalline Cellulose, National Formulary~Safflower Oil, United States Pharmacopeia~K-30 Povidone Powder~Magnesium Stearate, National Formulary (Vegetable source)~Fumed Silica, National Formulary"
88873599|NCT01882062|Experimental|Triheptanoin 1g/kg/day|All patients received Triheptanoin oil at 1g/kg/day during 1 month
88873600|NCT01882764|Experimental|HMPL-004 1800 mg/day|"Subjects qualifying for entry into the Maintenance Phase of the study were randomized to take an oral dose of HMPL-004 (600 mg TID; total dose 1800 mg/day) daily, for 52 weeks.~Those subjects who demonstrated clinical remission or response after completing the HMPL-004-03 Induction Study, or after completing the Open Label Phase of this study, were eligible for enrollment in the Maintenance Phase of this study."
88873601|NCT01882764|Placebo Comparator|Placebo|"Subjects qualifying for entry into the Maintenance Phase of the study were randomized to take an oral dose of Placebo tablets TID, daily, for 52 weeks.~Those subjects who demonstrated clinical remission or response after completing the HMPL-004-03 Induction Study, or after completing the Open Label Phase of this study, were eligible for enrollment in the Maintenance Phase of this study."
88873602|NCT01883856|Active Comparator|Silicone Plate Ahmed Glaucoma Valve|Silicone plate Ahmed Glaucoma Valve
88873603|NCT01883856|Experimental|Porous Plate Ahmed Glaucoma Valve|Porous Plate Ahmed Glaucoma Valve
88873604|NCT01887132|Experimental|Open-Label Donepezil|
88873605|NCT01887132|Experimental|Donepezil - Blinded|
88873606|NCT01887132|Placebo Comparator|Placebo|
88873607|NCT01887990|Active Comparator|Suicidal, Depression with Ketamine|suicidal ideation and depression (no substance use disorder) 0.2 mg/kg IV ketamine administered as a one time dose
88873608|NCT01887990|Placebo Comparator|Suicidal, Depression with Saline|Suicidal ideation and depression (no substance use disorder) comparable amount of placebo (saline)
89188148|NCT02555475|No Intervention|Group 1, tertiary hospital based care|Group 1: (n=190) Following their initial screen, these participants will be referred to a tertiary hospital for hepatitis C care, transient elastography and DAA treatment (traditional / standard model of care).
89188149|NCT02555475|Experimental|Group 2, community based care|Group 2: (n=190) Following their initial screen, these participants will be offered community based hepatitis C care and treatment. Hepatitis C care, transient elastography and DAA treatment will be delivered at the primary healthcare centre only.
89188150|NCT00791895|Experimental|A|
89188151|NCT00786981|Other|Epidural steroid injection and physical therapy|
88873609|NCT01887990|Active Comparator|Suicidal, opioid use with ketamine|suicidal ideation,depression, opioid use disorder 0.2 mg/kg IV ketamine one time dose
88873610|NCT01887990|Placebo Comparator|Suicidal, opioid use with Saline|Patients with suicidal ideation and depression with opioid use disorder who are given comparable amount of placebo (saline) as would have been used with the Ketamine arm
88873611|NCT01890642|Sham Comparator|J tip Noise|This group will have a J tip deployed without medication to create the noise that the device makes. They will also receive Pain Ease spray if > age 1 yr or sucrose if < 1 yr
88873612|NCT01890642|Other|Pain Ease|This group will receive Pain Ease Spray only if > 1 yr or sucrose only if child < 1 yr
88873613|NCT01890642|Experimental|J tip|This group will receive 1% buffered lidocaine via Jet Injection. They will receive placebo cooling spray (normal saline spray) to maintain blinding if > 1 yr and will receive sucrose is < 1 yr
89188152|NCT00786981|Other|Epidural steroid injection|
89188153|NCT00430573|Experimental|DCS-augmented CBT-IC|D-cycloserine-augmented CBT-IC
89188154|NCT00430573|Placebo Comparator|Placebo-augmented CBT-IC|Placebo-augmented CBT-IC
89188155|NCT00783315|Active Comparator|1|Self-Directed Weight Loss Program (Control Group)
89188156|NCT00783315|Experimental|2|Call-Center Directed (CCD) Weight Loss Program
89188157|NCT00783315|Experimental|3|In-Person Directed (IPD) Weight Loss Program
89188158|NCT04073940|Experimental|Targeted Ballet Program|A 16-week (32 sessions of 1 hour each) ballet-based intervention targeted to improve motor function in persons with multiple sclerosis.
89188159|NCT00783393|Experimental|Single arm|"The study consists of two steps:~Step 1, the therapeutic study phase, comprising six cycles of treatment with temozolomide, and~Step 2, the long-term treatment phase, where subjects with at least disease stabilization at the end of Step 1 may continue temozolomide treatment until unacceptable toxicity or disease progression occur, up to a maximum of 2 years from the start of treatment in Cycle 1."
89188160|NCT00783471|Experimental|1|Erlotinib followed by Docetaxel
89188161|NCT00783471|Experimental|2|Docetaxel followed by Erlotinib
89188162|NCT00792051|Active Comparator|1|Influenza vaccine
89188163|NCT00792051|Placebo Comparator|2|
89188164|NCT00787215||no treatment|observational: no treatment involved
89188165|NCT00792129||Control|Posterior unilateral interbody fusion using an open approach midline incision (TLIF)
89188166|NCT00792129||Experimental|MiLIF procedure with specialized Atavi instrumentation and minimally invasive visualization capabilities
89188167|NCT00792207|Experimental|Intervention|"Intervention Group:~The intervention being tested, the Virtual Coach, is an automated empathic computer agent which will run on patient's home computer and engage the patient in dialogues to deliver personalized feedback, education and coaching based on physiological data recorded by an activity monitor."
89188168|NCT00792207|Active Comparator|Control|The control group will use an activity monitor and will have access to a website to monitor activity, but will not receive the Virtual Coach program.
89397601|NCT04134689|Active Comparator|In-person DOT Control Arm.|Patients in this arm will be managed according to the usual clinical practice in Uganda i.e. community- or home-based directly observed treatment .Patients in this arm will make prior arrangements with a study nurse to determine a convenient meeting place (e.g. at the patient's work, home etc.) The study nurse will then meet the patient at this location. At each daily meeting, the patient will self-administer the TB drugs as the study nurse directly observes and documents (date, time, drug dosing etc.) At the end of each meeting, the patient and nurse will agree on a convenient meeting place for the next day's dosing. These daily meetings will continue until treatment completion. The study nurse will record patient's medication intake, as well as the time taken to reach the patient, amount of money spent on round-trip transportation, and total amount of time spent during each patient encounter.
89397602|NCT04105842|Experimental|Delfilcon A|All study participants will be refit with Delfilcon A (Dailies Total 1) lenses which they will wear for 1 month.
89397603|NCT04092803|No Intervention|GA for LP|Patients who decline to undergo an LP with VR will be asked if they would be willing to participate by answering questionnaires specific to their pre procedure anxiety. This will include questionnaires 2 and 3 from above. The investigators will also plan to collect vital sign data if they agree to participate in that capacity.
89397604|NCT04092803|Experimental|VR for LP|"The patients in this study will be presented the opportunity to use VR instead of undergo GA for a LP. Patients who agree to undergo an LP with VR will be assessed by a certified child life specialist (CCLS) to determine whether the patient is an appropriate candidate for using VR.The system includes a VR headset with VR software already loaded in to it. The VR software to be used is either a game called Pebbles the Penguin or SpacePups (Weightless Studios)."
89397605|NCT04088734|Experimental|ABO-102|Dose of 3x10^13 vg/kg
89397606|NCT04081688|Experimental|Treatment (varlilumab, atezolizumab, SBRT)|Patients receive varlilumab IV over 90 minutes and atezolizumab IV over 30-60 minutes every cycle. Cycles repeat every 21 days for up to 1 year (18 cycles) in the absence of disease progression or unacceptable toxicity. Between cycle 1 and 2, patients also receive SBRT.
89397607|NCT04068155|Experimental|DaRT Seeds Intratumoral Diffusing alpha-emitters|An intratumoral insertion of securely fixed seeds loaded with Radium-224. The seeds release by recoil short-lived alpha-emitting atoms into the tumor.
89188169|NCT00787293|Experimental|1|Patient is screened for study and given baseline assessments. Pending fulfillment of study eligibility criteria, patient is implanted with PTMA system.
89188170|NCT02460900|Active Comparator|Varenicline and Standard of Care|Participants will receive varenicline and standard of care
89188171|NCT02460900|Placebo Comparator|Placebo and Standard of Care|Participants will receive placebo and standard of care
89397608|NCT04064814|Active Comparator|Flunarizine|flunarizine will be prescribed at a dose of 5mg once daily , orally for 12 weeks
89397609|NCT04064814|Experimental|Alpha Lipoic Acid|Alpha Lipoic Acid will be prescribed at a dose of 300mg once daily,orally for 12 weeks
89397610|NCT04060966||Cohort 1: Stress Task|Participants in Cohort 1 randomized to the stress task will complete the Cold-Pressor Task (CPT), which requires the continuous submersion of the forearm in ice-water (0-4°C) for 3 minutes in the presence of an experimenter. After the CPT, participants will complete a decision-making task. During the decision-making task, participants will do one of the following: evaluate different features of foods/monetary prizes in 'rating trials', choose between pairs or bundles of snack foods in 'choice trials', bid for the chance to win foods/monetary prizes or bid to remove certain foods from their choice menu in 'auction trials', or choose between pairs of monetary lotteries in 'lottery trials'.
89397611|NCT04060966||Cohort 1: Control|Participants in Cohort 1 randomized to the Control group will complete a matching control task to the CPT, which involves continuous submersion of the forearm in warm water, ~30°C, for 3 minutes. After the control CPT, participants will complete a decision-making task. During the decision-making task, participants will do one of the following: evaluate different features of foods/monetary prizes in 'rating trials', choose between pairs or bundles of snack foods in 'choice trials', bid for the chance to win foods/monetary prizes or bid to remove certain foods from their choice menu in 'auction trials', or choose between pairs of monetary lotteries in 'lottery trials'.
89397612|NCT04060966||Cohort 2: Stress Task + fMRI|Participants in Cohort 2 randomized to the Stress task will complete the CPT, which requires the continuous submersion of the forearm in ice-water (0-4°C) for 3 minutes in the presence of an experimenter. After the CPT, participants will complete decision-making tasks while being scanned via functional MRI (fMRI). The tasks will involve attending to auditory and/or visual stimuli on a computer. On each trial, different food items and different amounts of time (1-60 minutes) will be presented and participants will be asked to indicate how much they would pay from their $10 study endowment to avoid spending the trial's stated amount of time with the snack food.
89397613|NCT04060966||Cohort 2: Control + fMRI|Participants in Cohort 2 randomized to the Control group will complete a matching control task to the CPT, which involves continuous submersion of the forearm in warm water, ~30°C, for 3 minutes. After the control CPT, participants will complete decision-making tasks while being scanned via functional MRI (fMRI). The tasks will involve attending to auditory and/or visual stimuli on a computer. On each trial, different food items and different amounts of time (1-60 minutes) will be presented and participants will be asked to indicate how much they would pay from their $10 study endowment to avoid spending the trial's stated amount of time with the snack food.
89397614|NCT04060966||Cohort 3: M-Turk Survey|Participants in Cohort 3 will access the Amazon Mechanical Turk (M-Turk) platform, where they can search for available surveys ('HITs') to complete for payment on the M-Turk website. After completing the surveys, participants will complete the Stress and Adversity Inventory (STRAIN) questionnaire.
89397615|NCT04041609|Experimental|LYR-210 (Low Dose)|In-office bilateral placement of the LYR-210 drug depot (mometasone furoate low dose) in the middle meatus
89397616|NCT04041609|Experimental|LYR-210 (High Dose)|In-office bilateral placement of the LYR-210 drug depot (mometasone furoate high dose) in the middle meatus
89397617|NCT04041609|Sham Comparator|Sham Procedure|In-office bilateral sham procedure
89397618|NCT04001478||Control group|Patients who are attending hospital for a gastroscopy as part of their routine clinical care as a 2 week wait rule referral and those on Barrett's surveillance , will be asked to give a sample of their breath prior to the procedure.
89397619|NCT04001478||Early oesophageal cancer (T1)/ Barrett's high grade dysplasia|Patients who have known pre-diagnosed T1 oesophageal adenocarcinoma or HGD attending hospital as part of their clinical care will be asked to give a breath sample prior to their endoscopy resection/ cancer operation. Patients will be sampled upon return for follow up endoscopy to assess breath profile changes and correlation with endoscopy findings.
89397620|NCT04001478||Advanced Oesophageal cancer (T2/3/4)|Patients who have been diagnosed with oesophageal adenocarcinoma attending hospital as part of their clinical care will be asked to give a breath sample prior to their endoscopy resection/ cancer operation.
89397621|NCT03995082|Experimental|Experimental Group|Patients will receive the results from the PROM survey in graphical form each time they complete a survey.
89397622|NCT03995082|No Intervention|Normative Control|These patients will complete the PROM surveys, but will not be presented with the results of the survey.
89397623|NCT03967626|Experimental|Cerebral temperature target|CCT performed by the external cooling device with cerebral temperature target, measured by a intracranial sensor (coupled to the intracranial pressure device)
89397624|NCT03967626|Active Comparator|Systemic temperature target|CCT performed by the external cooling device with systemic temperature target, measured by a bladder sensor (coupled to the vesal probe, according to the standard service protocol).
89397625|NCT03940963|Active Comparator|AxoGuard® Nerve Cap|"Porcine derived extracellular matrix (ECM) based Nerve Termination Device~Implantation of appropriate diameter of AxoGuard® Nerve Cap at the time of surgery"
89397626|NCT03940963|Active Comparator|Standard Neurectomy|Standard surgical treatment for symptomatic neuroma entailing neuroma excision.
89397627|NCT03938987|Experimental|CAR T cells|Patients with relapsed/refractory B-cell ALL or NHL.
89397628|NCT03924414|Active Comparator|Zoledronic acid (ZA)|A single intravenous infusion of Zoledronic acid (5 mg) infused over 45 minutes
89397629|NCT03924414|Placebo Comparator|Placebo|A single intravenous infusion of placebo infused over 45 minutes
89397630|NCT03914703||EZ Pass Suture Passer|Patients who have surgery using the EZ Pass Suture Passer Instrument either in rotator cuff or soft tissue repair
89397631|NCT03914703||Precision Flexible Reamer|Patients who have surgery using the Precision Flexible Reamer Instrument in ACL repair
89397632|NCT03904927|Experimental|Experimental Arm|The arm will be treated with combined systemic therapy and local therapy such as radiation, surgery or radiofrequency ablation.
89397633|NCT03904927|Active Comparator|Control Arm|The arm will be treated with systemic therapy alone.
89397634|NCT03891563||Sport specialists, MVPA|"AOSSM Criteria:~Participation in intensive training and/or competition in organized sports greater than 8 months per year (essentially year round)~Participation in 1 sport to the exclusion of participation in other sports (limited free play overall)~Involving prepubertal (seventh grade or roughly age 12 years) children.~AND~Activity Tracker Criteria:~Greater than 180 accumulated minutes of moderate-to-vigorous physical activity (MVPA) during participation in one sport type across one week of activity tracking~- Meets these criteria within either one or both years of follow-up"
89397635|NCT03891563||Non-sport specialist, any activity level|"AOSSM Criteria:~Participation in more than 1 sport at any physical activity level OR~Participation in none or low training and/or competition in organized sports for any period of time.~Involving prepubertal children.~AND~Activity Tracker Criteria:~Greater than or less than 180 accumulated minutes of MVPA across one week of activity tracking~- Meets these criteria during both years of follow-up"
89188172|NCT02460900|Active Comparator|Positively Smoke Free and Placebo|Participant will receive Positively Smoke Free (a tailored behavioral intervention) and Placebo
89188173|NCT02460900|Active Comparator|Positively Smoke Free and Varenicline|Participant will receive Positively Smoke Free (a tailored behavioral intervention) and Varenicline
89188174|NCT00787371|Experimental|0.25 Dose Group|PegIntron 0.25 mcg/kg SC QW for 12 weeks
89188175|NCT00787371|Experimental|0.5 Dose Group|PegIntron 0.5 mcg/kg SC QW for 12 weeks
89397636|NCT03886181|Experimental|DaRT Seeds|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds
88873614|NCT01891734|Experimental|Problem Solving Therapy plus Moving Forward (PST-MF)|All Veterans will receive a standard 6-session administration of Problem Solving Therapy (Nezu & D'Zurilla, 1999). Session 1 will take place in-person during a scheduled appointment and will last for 1 hour. Subsequent sessions will take place over the telephone and will last for approximately 30 minutes. Participants in this arm will also receive the Moving Forward app for SmartPhones, which was adapted from Problem Solving Therapy to be used either as a standalone treatment or as an adjunct to other related therapies such as in-person Problem Solving Therapy or the Moving Forward website. The phone content matches Problem Solving Therapy. Benefits of the app include 24-hours accessibility of psychoeducational materials and worksheets.
88873615|NCT01891734|Active Comparator|Problem Solving Therapy|All Veterans will receive a standard 6-session administration of Problem Solving Therapy (Nezu & D'Zurilla, 1999). Session 1 will take place in-person during a scheduled appointment and will last for 1 hour. Subsequent sessions will take place over the telephone and will last for approximately 30 minutes.
88873616|NCT01891968|Experimental|Bortezomib|Bortezomib administered via subcutaneous route at a dose of 1.3 mg/m2 on days 1, 4, 8 and 11 of a 21 day cycle. A course of treatment will be 21 days.
88873617|NCT01893372|Experimental|Eltrombopag|Eltrombopag 200 mg by mouth daily in a 28 day cycle.
88873618|NCT01893372|Experimental|Eltrombopag + Hypomethylating Agent (HMA)|"Eltrombopag in combination with continuation of hypomethylating agent in 28-day cycles. Eltrombopag 200 mg by mouth daily in a 28 day cycle.~The choice of HMA agent (e.g. azacitidine or decitabine) will be the HMA the patient has received prior to enrollment on study. Eltrombopag should be initiated at the start of the next HMA cycle whenever possible so the start date of both agents is consistent."
88873619|NCT01895088|Experimental|Patients prev. impl. with ACI 7000 PDT|AcuFocus Corneal Inlay ACI 7000 PDT
88873620|NCT01895634|Experimental|Treatment|Intervention Device: Rev-01
88873621|NCT01895946|Experimental|Part A: Formulation Switch|AZD5363 tablet twice daily followed by AZD5363 capsule twice daily on an intermittent regimen (4 days on, 3 days off).
89188176|NCT00787371|Experimental|1.0 Dose Group|PegIntron 1.0 mcg/kg SC QW for 12 weeks
89188177|NCT00787371|No Intervention|No-treatment Control|No treatment (no placebo)
89188178|NCT00783549|Experimental|Cohort 1|6 active 2 placebo
89188179|NCT00783549|Experimental|Cohort 2|9 active 3 placebo
89188180|NCT00783549|Experimental|Cohort 3|Optional cohort
89188181|NCT00783549|Experimental|Cohort 4|12 active
89188182|NCT00783549|Experimental|Cohort 5|12 active
89188183|NCT00783627||1|Patient with sickle cell disease
89188184|NCT00783627||2|Healthy volunteers
89188185|NCT00430495|Experimental|Atacicept 25 mg|
89188186|NCT00430495|Experimental|Atacicept 75 mg|
89188187|NCT00430495|Experimental|Atacicept 150 mg|
89188188|NCT00430495|Placebo Comparator|Placebo|
89188189|NCT02554695|Placebo Comparator|placebo|single subcutaneous injection of placebo (normal saline)
89188190|NCT02554695|Active Comparator|Denosumab|single subcutaneous injection of denosumab 60 mg
89188191|NCT02554695|No Intervention|young normal premenopausal women|no intervention
89188192|NCT00792285|Experimental|Automated Telephone Outreach|Automated Telephone Outreach with Speech Recognition
89188193|NCT00792285|No Intervention|Usual Care|Usual Care
89188194|NCT00787683|Experimental|Home-monitoring|Patients receive an additional home-monitoring (remote-monitoring) device (CardioMessengerII) following Biotronik Lumax ICD implantation. The device enables regular transmission and examination of ICD information via home-monitoring. Follow-up appointments in outpatient clinic are changed compared to standard care. While follow-up 1, 12, and 24 months after ICD implantation consist of outpatient clinic appointments, follow-up 3, 6, and 18 months after ICD implantation are conducted remotely.
89188195|NCT00787683|No Intervention|Standard care|Patients randomised to the standard care group receive no home-monitoring device (CardioMessengerII) following Lumax ICD implantation. Patients have scheduled follow-up appointments at the ICD outpatient clinics at 1, 3, 6, 12, 18, and 24 months after ICD implantation.
89188196|NCT00425113|Experimental|Metronidazole|Metronidazole added to background TB treatment regimen during initial 2 months
89188197|NCT00425113|Placebo Comparator|Placebo|Placebo added to background TB treatment regimen during initial 2 months
89397637|NCT03868787|Experimental|Active TENS|The active TENS unit consists of the active unit and electrode pads connected to the unit via direct wires. The program that will be used is a high frequency (80Hz) program that runs for an hour in duration. It will be initiated 5 minutes prior to speculum placement. Participants will be instructed to increase the amplitude of the current as needed to provide analgesia but avoiding discomfort from the TENS stimulation
89397638|NCT03868787|Sham Comparator|Sham TENS|The sham TENS will be the same unit without the true TENS electrical connections. The sham group will be given the active unit and have electrode pads placed but without wire connections. These participants will be told the device is a wireless device. They will also be told they may or may not feel sensation from the TENS. This will allow the device to be powered on and run in the same manner as the active group, but will not allow for electrical transmission between the unit and electrodes
89397639|NCT03856320|No Intervention|Usual Care|Patient attends a MOVE! visit (weight management visit).
89397640|NCT03856320|Experimental|Intervention|Patient attends a MOVE! visit (weight management visit) and watches an educational video describing obesity treatment options available in the VA.
89397641|NCT03846388|Other|Patients with unexplained infertility|
89397642|NCT03846388|Other|patients with tubal, male factor or polycystic ovary syndrome|
89397643|NCT03804671|Experimental|All Subjects|Test treatment T followed by Reference treatment R
89397644|NCT03804255||Observational (survey)|Participants complete a self-administered web-based Biomarker Survey and may also complete an Outcome Validation Survey.
89397645|NCT03675815|Active Comparator|Standard of care|darunavir 800 mg oral tablet + ritonavir 100 mg oral tablet + (N(t)RTIs) po qd
89397646|NCT03675815|Experimental|Dolutegravir + tenofovir (TDF) + either lamivudine (3TC) or emtricitabine (FTC)|dolutegravir 50 mg oral tablet + TDF 300 mg oral tablet + either 3TC 300 mg oral tablet or FTC 200 mg oral capsule po qd
89397647|NCT03675815|Experimental|Dolutegravir + darunavir|dolutegravir 50 mg oral tablet + darunavir 800 mg oral tablet + ritonavir 100 mg oral tablet po qd
89397648|NCT03669133|Active Comparator|Group A|Vitamin E 800 IU/daily for 24 weeks
89397649|NCT03669133|Placebo Comparator|Group B|Matching placebo for 24 weeks
89188198|NCT00792441|No Intervention|intervention group|Patients with mechanical ventilated who met the criteria for weaning from medical doctor in Srinagarind hospital, Khon Kaen University
89397650|NCT03647969|Experimental|mFOLFOX/Nivolumab/Ipilimumab A/A1|"Nivolumab 240mg Flatdose i.v. d1 over 30 min every 2 weeks followed by Ipilimumab 1mg/kg i.v. d1 over 30 min every 6 weeks followed by FOLFOX Oxaliplatin 85 mg/m² iv 2hrs (day 1), Leucovorin 400 mg/m2 iv 2hrs (day 1), Fluorouracil 400 mg/m² iv bolus (day 1), and Fluorouracil 2400 mg/m² iv continuous infusion over 44 hours (day 1+2) every 2 weeks until disease progression or inacceptable toxicity or end of study treatment."
89397651|NCT03647969|Experimental|mFOLFOX/Nivolumab/Ipilimumab sequential A2|"3 cycles of induction chemotherapy with FOLFOX: FOLFOX Oxaliplatin 85 mg/m² iv 2hrs (day 1), Leucovorin 400 mg/m2 iv 2hrs (day 1), Fluorouracil 400 mg/m² iv bolus (day 1), and Fluorouracil 2400 mg/m² iv continuous infusion over 44 hours (day 1+2) every 2 weeks followed by immunotherapy consisting of: 4 administrations of Nivolumab 240mg Flatdose i.v. d1 over 30 minutes every 2 weeks and 2 administrations of Ipilimumab 1mg/kg i.v. d1 over 30 minutes every 6 weeks~Sequence as described may be repeated starting two weeks after last administration of immunotherapy once, or, if medically reasonable, for an unlimited number of repetitions upon investigator decision. After discontinuation of chemotherapy, immunotherapy will be continued consisting of:~Nivolumab at 240mg Flatdose i.v. d1 every 2 weeks and Ipilimumab at 1mg/kg i.v. d1 every 6 weeks until disease progression or inacceptable toxicity or end of study treatment."
89397652|NCT03647969|Active Comparator|mFOLFOX B|FOLFOX Oxaliplatin 85 mg/m² iv 2hrs (day 1), Leucovorin 400 mg/m2 iv 2hrs (day 1), Fluorouracil 400 mg/m² iv bolus (day 1), and Fluorouracil 2400 mg/m² iv continuous infusion over 44 hours (day 1+2) every 2 weeks until disease progression or inacceptable toxicity or end of study treatment.
89397653|NCT03647969|Experimental|FLOT/Nivolumab C|"Nivolumab 240mg Flatdose i.v. d1 every 2 weeks followed by FLOT: Docetaxel 50mg/², Oxaliplatin 85 mg/m², leucovorin 200 mg/m² on day 1 and fluorouracil 2600 mg/m² IV continuous infusion over 24 hours every 2 weeks until disease progression or inacceptable toxicity or end of study treatment. After completion or discontinuation of chemotherapy, immunotherapy may be continued consisting of: Nivolumab at 240mg Flatdose i.v. d1 every 2 weeks Chemotherapy can also be administered per local standard."
89188199|NCT01034293|Experimental|low feeding frequency (3x)|
89397654|NCT03644186|Active Comparator|Paclitaxel plus trastuzumab and pertuzumab|Receiving paclitaxel 80mg/m2 i.v. on day 1, 8, 15 every 28 days for 4 cycles, trastuzumab 600mg s.c. every 3 weeks for a total of 5 doses and pertuzumab 840 mg i.v. loading dose followed by 420 mg i.v. every 3 weeks for a total of 5 doses.
89397655|NCT03644186|Experimental|Palbociclib plus letrozole plus trastuzumab and pertuzumab|Receiving palbociclib 125 mg/day orally for 21 days followed by 7 day's rest, for four 28 day cycles, letrozole 2.5 mg/day orally for 16 weeks and trastuzumab 600 mg s.c. every 3 weeks for a total of 5 doses and pertuzumab 840 mg i.v. loading dose followed by 420 mg i.v. every 3 weeks for 5 doses.
89188200|NCT01034293|Experimental|High feeding frequency (14x)|
89188201|NCT00792519|Experimental|CBT|group cognitive behavioral treatment
89188202|NCT00792519|Active Comparator|HIV support group|group support
89188203|NCT03994783|Active Comparator|Standard of Care (SOC)|Intravenous Methylprednisolone (500 mg (600 mg/m2 for paediatric participants), n=3) Plasma Exchange (PEX) (60 ml/kg max 4 l (1 - 1.5 plasma volumes for paediatric participants), n=7) Intravenous Immunoglobulin (high dose: 2 g/kg total, or low dose: 100 mg/kg n=7 after each PEX, no dose adjustment for paediatric participants)
89188204|NCT03994783|Experimental|Standard of Care plus Rituximab (SOCR)|Intravenous Methylprednisolone (500 mg (600 mg/m2 for paediatric participants), n=3) Plasma Exchange (PEX) (60 ml/kg max 4 l (1 - 1.5 plasma volumes for paediatric participants), n=7) Intravenous Immunoglobulin (high dose: 2 g/kg total, or low dose: 100 mg/kg n=7 after each PEX, no dose adjustment for paediatric participants) Rituximab (375 mg/m2 max 1 g (no dose adjustment for paediatric participants), n=2 14 days +/- 2 days apart)
88873622|NCT01895946|Experimental|Part B: Food effect|AZD5363 tablet twice daily on an intermittent regimen (4 days on, 3 days off) with/without food on one occasion
89188205|NCT04072536|Experimental|Electric wheelchair with activated assistance module|This condition will be achieved in 3 standardized test circuits of increasing difficulty, one week apart. At each session, the patient will perform the circuit 6 times, including 3 with activated assistance, in a random order established upstream.
89188206|NCT04072536|Other|Electric wheelchair with assistance module not activated|This condition will be achieved in 3 standardized test circuits of increasing difficulty, one week apart. At each session, the patient will perform the circuit 6 times, including 3 without activated assistance, in a random order established upstream.
89188207|NCT00792597||spine or hip surgery|
89188208|NCT00787995||MPS IVA|Subjects with mucopolysaccharidosis IVA (Morquio Syndrome)
89188209|NCT00783783||Poor metabolizers|Patients with CYP2D6 genotypes predictive of poor metabolizer phenotype
89188210|NCT00783783||Non poor metabolizers|Patients with CYP2D6 genotypes predictive of intermediate, extensive, or ultra-rapid metabolizer phenotypes
89188211|NCT00440011|Experimental|1|
89188212|NCT00440011|Active Comparator|2|
89188213|NCT03105102|Placebo Comparator|Double-blind Placebo for Risankizumab (Sub-Study 1)|Participants randomized to receive double-blind placebo for risankizumab for 52 weeks.
89188214|NCT03105102|Experimental|Double-blind Risankizumab Dose 1 (Sub-Study 1)|Participants randomized to receive double-blind risankizumab dose 1 for 52 weeks.
89188215|NCT03105102|Experimental|Double-blind Risankizumab Dose 2 (Sub-Study 1)|Participants randomized to receive double-blind risankizumab dose 2 for 52 weeks.
89188216|NCT03105102|Experimental|Maintenance Risankizumab Dose 1 (Sub-Study 2)|Participants will receive double-blind subcutaneous (SC)risankizumab dose 1 and intravenous placebo at Week 0 followed by open-label SC risankizumab dose 1 from Week 8 through Week 52.
89188217|NCT03105102|Experimental|Maintenance Risankizumab Dose 2 (Sub-Study 2)|Participants will receive double-blind subcutaneous placebo and intravenous risankizumab dose 3 at Week 0 followed by open-label SC risankizumab dose 1 from Week 8 through Week 52.
89188218|NCT03105102|Experimental|Open-label Risankizumab (Sub-Study 3)|Participants who completed Sub-study 1 or Sub-study 2 or other AbbVie risankizumab Crohn's disease study or M16-006 or M15-991 without endoscopy will receive open-label risankizumab dose 1 or dose 2 depending on their preceding study beginning at Week 56.
89188219|NCT03105102|Experimental|Risankizumab On-Body Injector and Open Label (Sub-Study 4)|Participants in Sub-study 3 who meet eligible criteria for Sub-study 4 will receive risankizumab dose 1 or dose 2 via on-body injectors on Weeks 0,8 and 16. Beginning Week 24, participants will receive risankizumab dose 1 or dose 2 via pre-filled syringes Q8W.
89188220|NCT03105102|Experimental|CTE: Open Label Continuous Treatment Extension|Participants who tolerate and derive benefit from receiving risankizumab and complete Sub-study 3 or Sub-study 4 will receive risankizumab dose 1 or dose 2 Q8W.
89188221|NCT00877448|Experimental|Multimeric-001 250 Mcg|Multimeric-001 250 Mcg in PBS
89188222|NCT00877448|Experimental|Adjuvanted Multimeric-001 250 Mcg|250 Mcg in montanide
89188223|NCT00877448|Placebo Comparator|Phosphate Buffered saline|Non-adjuvanted placebo
89188224|NCT00877448|Placebo Comparator|Adjuvanted PBS|Adjuvant was montanide
89188225|NCT00877448|Experimental|Multimeric-001 500 Mcg|Multimeric-001 in PBS
89188226|NCT00877448|Experimental|Adjuvanted Multimeric-001 500 Mcg|Adjuvant was montanide
89188227|NCT00877448|Experimental|Multimeric-001 125 Mcg|Multimeric-001 in PBS
88873623|NCT01898754|Experimental|Pre-ART Oligonucleotide Assay (OLA)|Pre-ART OLA will be tested for resistance at 5 pol codons conferring high-level resistance to NNRTI and 3TC (K103N, V106M, Y181C, G190A and M184V)
88873624|NCT01898754|No Intervention|No OLA (Standard of Care [SOC])|The participants will receive standard of care as per Kenya guidelines but will be offered OLA resistance testing after 12 months
89188228|NCT00783861|Experimental|1|Lactic Acid (Dermacyd Femina)
89188229|NCT01034371|Experimental|One-stop hybrid revasularization|
89188230|NCT01034371|Active Comparator|Off-pump coronary artery bypass|
89188231|NCT04971213|Active Comparator|Non Invasive Ventilation|Bilevel non-invasive ventilation. Support pressure will be set to obtain a 6-8 mL/kg of predicted body weight PEEP will be set within 5-10 cmH2O and FiO2 for a SpO2 equal or over 94% target. (92% in patients with chronic respiratory failure) All settings will be adjusted according tolerance of the patient.
89188232|NCT04971213|Experimental|High-flow nasal cannula heated and humidified oxygen|"Flow will be set at 60 L/min and ajusted according the tolerance of the patient.~FiO2 will be set according a SpO2 equal or over 94% target. (92% in patients with chronic respiratory failure)"
89188233|NCT00783939|Experimental|1|Lactic Acid (Dermacyd PH_DETINBACK Tangerine Mix)
89188234|NCT04739930|Experimental|Bone Marrow Aspiration Group|A bone marrow aspiration will be performed from the iliac crest. The bone marrow aspirate will be processed using a bone marrow aspirate concentrate (BMAC) harvesting system. The osteochondral allograft plug will then be soaked in the BMAC for a minimum 2 minutes prior to implantation. The remaining BMAC will be placed in the defect site prior to plug implantation.
89188235|NCT04739930|Sham Comparator|Control|The control group will receive a 0.5cm sham incision over the iliac crest, but bone marrow aspiration will not be performed. The osteochondral allograft plug will not be soaked in BMAC prior to implantation.
89188236|NCT00788229|Experimental|1. Study Drugs|
89188237|NCT00788229|Experimental|2. Study Drug|
89188238|NCT00788229|Experimental|3. Study Drug|
89188239|NCT00788229|Placebo Comparator|4. Placebo|
89188240|NCT00663117|Placebo Comparator|Placebo, Sugar pill|placebo for 3 months blinded then followed by an open-labelled study and all are treated with naltrexone 4.5 mg for 3 additional months
89188241|NCT00663117|Active Comparator|Naltrexone-HCl|Subjects are treated in a blinded fashion for 3 months with naltrexone 4.5 mg po for active Crohn's disease followed an open-labelled study where naltrexone is given an additional 3 months at 4.5 mg po; hence the total treatment interval in this arm is 6 months. The response to the intervention administered is measured in the activity index and mucosal healing by colonoscopy.
89188242|NCT02578628|Active Comparator|Active|These subjects will continue to receive Patient Engagement services.
89188243|NCT02578628|No Intervention|Control|These patients will have all Patient Engagement services discontinued.
88873625|NCT01899300|Experimental|Metal Stent|The WallFlex™ Esophageal Fully Covered Metal Stent (FCMS)is being evaluated for the treatment of refractory benign esophageal strictures caused by caustic ingestion.
88873626|NCT01900392|No Intervention|Control Arm|No other financial incentive other than for the 3-, 6-, 9-, & 12-month weigh-ins and surveys. Participants will receive daily feedback for months 1-6 and will be observed without intervention in Phase II (months 7-12). Two weigh-ins will be required during Phase II, one at 9 months and the other at 12 months.
88873627|NCT01900392|Experimental|Direct payment|"In addition to the incentives for the 3-, 6-, 9-, & 12-month weigh-ins, participants who meet their daily goal will be eligible to receive an incentive for each day their goal is met during the first 6 months of the study. All daily incentive earnings will be paid out after verifying participants' weights during an in person weigh in at a Weight Watchers location at months 3 and 6. Winnings will be proportional to weight loss. For example, if a participant's goal was to lose 6 pounds by month 3, but he/she only lost 3 pounds, that participant would only receive 50% of their total eligible winnings.~Similar to the control arm, participants will receive daily feedback for months 1-6 and will be observed without intervention in Phase II (months 7-12). The weigh-ins at 9- and 12-months will also be required."
89188244|NCT04072328|Experimental|Propofol alone|Participants who receive propofol alone during sedative endoscopy.
89188245|NCT04072328|Active Comparator|Midazolam with propofol|Participants who receive midazolam + propofol during sedative endoscopy.
89188246|NCT00792753|Experimental|1. DESyne DES|Test arm: Intervention with DESyne Novolimus-Eluting Coronary Stent DESyne Novolimus Stent System
89188247|NCT00792753|Active Comparator|2. Medtronic Endeavor DES|Control arm: Intervention with Medtronic Endeavor Zotarolimus-Eluting Coronary Stent Medtronic Endeavor Coronary Stent System
89188248|NCT00792753|Experimental|3. DESyne BD DES|Test arm: Intervention with DESyne BD Novolimus-Eluting Coronary Stent DESyne BD Novolimus Stent System
89188249|NCT00495716|Active Comparator|Episodic Treatment Arm|800 mg acyclovir orally 3 times daily for 2 days at the start of a genital herpes recurrence
89188250|NCT00495716|Active Comparator|Suppressive Therapy Arm|400 mg acyclovir orally twice daily for 1 year
89188251|NCT00793065||1|Physicians that are using paper-based medical charts and who are not receiving Medical Home redesign incentives.
89188252|NCT00793065||2|Physicians that are using Electronic Health Records (EHRs) and who are not undergoing Medical Home redesign.
89188253|NCT00793065||3|Physicians that are using Electronic Health Records (EHRs) and undergoing Medical Home redesign.
89188254|NCT00784017|Active Comparator|asparaginase medac|
89188255|NCT00784017|Experimental|recombinant asparaginase|
89188256|NCT04074122||Symptomatic LQTS patients|Pharmacological (adenosine, epinephrine, isoprenaline) provocation, ECG-imaging and tissue-phase mapping using magnetic resonance imaging (TPM-MRI).
89188257|NCT04074122||Asymptomatic LQTS patients|Pharmacological (adenosine, epinephrine, isoprenaline) provocation, ECG-imaging and tissue-phase mapping using magnetic resonance imaging (TPM-MRI).
89188258|NCT04074122||Healthy controls|Pharmacological (adenosine, epinephrine, isoprenaline) provocation, ECG-imaging and tissue-phase mapping using magnetic resonance imaging (TPM-MRI).
89188259|NCT04073342||Surgical Necrotizing enterocolitis|Cases of preterm infants with necrotizing enterocolitis need surgical intervention
89188260|NCT04073342||Non Necrotizing enterocolitis|babies with intestinal operations for non necrotizing enterocolitis pathologies like congenital intestinal obstruction.
89188261|NCT00570141|Active Comparator|OASIS Wound Matrix (Oasis)|This is a single arm study with only the test article Oasis used on all subjects
89188262|NCT00793143||Sleeve|
89188263|NCT00793143||Bypass|
89188264|NCT02578550|Experimental|Treatment Sequence (AB)|Participant will receive a single oral tablet of darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg (D/C/F/TAF fixed dose combination [FDC]) (Treatment A) in period 1, then 1 tablet of DRV 800 mg + 1 tablet of COBI 150 mg + 1 tablet of FTC/TAF 200/10 mg FDC (Treatment B) in period 2
89188265|NCT02578550|Experimental|Treatment Sequence (BA)|Participant will receive 1 tablet of DRV 800 mg + 1 tablet of COBI 150 mg + 1 tablet of FTC/TAF 200/10 mg FDC (Treatment B) in period 1, then a single oral tablet of D/C/F/TAF (800/150/200/10 mg) FDC (Treatment A) in period 2
89188266|NCT03916224||Intubated critically ill patients|Critically ill patients older than 18 years old, intubated in an Intensive Care Unit.
89397656|NCT03622814|Experimental|Treatment - Partners at Meals (PAM)|People with dementia (PWD) often lose weight and suffer subsequent health issues: the goal of this intervention is to improve or maintain weight of a PWD, and to improve or maintain food intake. A train-the-trainer intervention is used with volunteers in Respite Care Centers who partner with family caregivers of PWD. Designed to be personalized to the PWD and focusing on his/her existing strengths and compensating for his/her deficits in mealtime management, sessions occur initially (1 hr) and every month (~30 mins) to reinforce key areas of behavioral or environmental change. Samsung tablets are used initially and then monthly (x5) to record mealtimes in the home, and are reviewed by the volunteer with the family member at the monthly session to discuss areas where changes could be made.
89188267|NCT00788463|Experimental|Aerosol|
89188268|NCT00788463|Active Comparator|Spray|
89188269|NCT02574806||Healthy newborn|Healthy newborn at term of healthy mother.
89188270|NCT02574806||Preeclamptic newborn|Newborn at term of mother with pre-eclampsia with severity features.
89188271|NCT00793221|Other|Sirolimus-eluting stent|Implantation of sirolimus-eluting coronary stent
89188272|NCT00793221|Active Comparator|Everolimus-eluting stent|Implantation of everolimus-eluting coronary stent
89188273|NCT02578134|Experimental|US-guided percutaneous electrolysis|Patients will receive one weekly session for 5 weeks for 5 weeks of US-guided percutaneous electrolysis. This intervention consists of the application of a galvanic electrical current with an acupuncture needle in the soft tissue, in this case the plantar fascia insertion. In addition, patients will be asked for conducting a best-evidence low-load exercise programs for the intrinsic foot musculature. The exercise program will be asked to be performed on an individual basis twice every day.
89535482|NCT05004909|Experimental|2 Fingertip Units 0.05% Tretinoin|Subjects were randomized to receive the instructions to use 2 fingertip units of 0.05% tretinoin cream for 2 weeks before the first chemical peeling. After that, this therapy is instructed to be used for 4 weeks after the chemical peeling procedure with 30% trichloroacetic acid until the scheduled evaluation.
89535483|NCT03119545|Experimental|Beardslee family centered intervention|This Group will have the family centered program.
88873628|NCT01900392|Experimental|Lottery|"In addition to the incentives for the 3-, 6-, 9-, & 12-month weigh-ins, participants who meet their daily goal will be eligible for the daily lottery during the first 6 months of the study. The expected daily winning for the lottery is the same as for the direct payment arm. All daily incentive earnings will be paid out after verifying participants' weights during an in person weigh in at a Weight Watchers location at months 3 and 6. Winnings will be proportional to weight loss. For example, if a participant's goal was to lose 6 pounds by month 3, but he/she only lost 3 pounds, that participant would only receive 50% of their total eligible winnings.~Similar to the control arm, participants will receive daily feedback for months 1-6 and will be observed without intervention in Phase II (months 7-12). The weigh-ins at 9- and 12-months will also be required."
89535484|NCT03119545|No Intervention|Comparison group|This Group will have standard care
88873629|NCT01900704|Experimental|SER120 750 ng|SER120 750 ng
88873630|NCT01900704|Experimental|SER120 1500 ng|SER120 1500 ng
89188274|NCT02578134|Sham Comparator|Sham US-guided percutaneous electrolysis|Patients will receive one weekly session for 5 weeks for 5 weeks of sham US-guided percutaneous electrolysis. In this case, the acupuncture needle will be inserted in the soft tissue, in this case the plantar fascia insertion without the application of the galvanic electrical current. In addition, patients will be asked for conducting a best-evidence low-load exercise programs for the intrinsic foot musculature. The exercise program will be asked to be performed on an individual basis twice every day.
89188275|NCT04072562|Experimental|AZD7594 0.7 mg|The study subjects will receive AZD7594 via nebulizer, during 8 minutes: 0.7 mg, delivered dose 1 inhalation
89530206|NCT03255499|Experimental|Exercise and cognitive training|This intervention includes a combination of high-intensity exercise (10min/day) and computerized cognitive training (20min/day). The software for the latter has been developed by our group, and includes 8 mini-games targeting different cognitive abilities. Both are developed for the MovinCog intervention. The intervention is personalized, based on individual performance.
88873631|NCT01900704|Placebo Comparator|Placebo|Placebo
89188276|NCT04072562|Experimental|AZD7594 1.6 mg|The study subjects will receive AZD7594 via nebulizer, during 8 minutes: 1.6 mg, delivered dose 1 inhalation
89188277|NCT04072562|Active Comparator|AZD7594 720 μg|The study subjects will receive AZD7594 via DPI: 0.72 mg, delivered dose (792 µg nominal dose) 1 inhalation
88873632|NCT01901250|Experimental|Xylitol GB|Xylitol gummy bears 7.8g/day throughout the 9 month kindergarten year, oral health education, fluoride varnish, and dental sealant
88873633|NCT01901250|Placebo Comparator|Fiber GB|Sugar free fiber gummy bears 20g/day throughout the 9 month kindergarten year, oral health education, fluoride varnish, and dental sealant
88873634|NCT01904448|Experimental|Auditory Brainstem Implant|single-arm study of auditory brainstem implantation in children
88873635|NCT01904526|Experimental|Guanfacine|Guanfacine 3 mg/day immediate release followed by Guanfacine 4mg/day extended release followed by Guanfacine 6 mg/day extended release
88873636|NCT01906866|Active Comparator|Circadin 2/5/10 mg|
88873637|NCT01906866|Placebo Comparator|Placebo|Placebo arm
88873638|NCT01907334|Active Comparator|Advair Diskus100/50 µg and Advair Diskus 100/50 µg|The Advair Diskus 100/50 µg and Advair Diskus 100/50 µg will be administered in a blinded fashion. One hour after receiving the dose of Advair a methacholine challenge will be performed to determine the PC40R5. After the PC40R5 has been reached or a negative result after the highest methacholine concentration, 64 mg/mL, subjects will inhale albuterol through a valved holding chamber to reverse bronchoconstriction and their lung function will be monitored until it has returned to within 20% of that day's baseline R5.
88873639|NCT01907334|Active Comparator|Advair Diskus 100/50 µg and Flovent Diskus 100 µg|The Advair Diskus 100/50 µg and Flovent Diskus 100 µg will be administered in a blinded fashion. One hour after receiving the dose of Advair and Flovent a methacholine challenge will be performed to determine the PC40R5. After the PC40R5 has been reached or a negative result after the highest methacholine concentration, 64 mg/mL, subjects will inhale albuterol through a valved holding chamber to reverse bronchoconstriction and their lung function will be monitored until it has returned to within 20% of that day's baseline R5.
88873640|NCT01907490|Experimental|1|Ha44 Gel 0.74%, topical solution, maximum feasible amount applied for 10 minutes
88873641|NCT01908972|Active Comparator|Prednisolone|Patients who will receive prednisolone medication (2 mg/kg/day ) for 16 weeks
88873642|NCT01908972|Experimental|Propranolol|Patients who will receive propranolol medication 2 mg/kg/day for 16 weeks
88873643|NCT01910064|Experimental|GK530G|GK530G is the fixed-dose combination gel of Adapalene and Benzoyl Peroxide, BPO
88873644|NCT01910688|Experimental|RFA treatment (Radiofrequency ablation)|If eligible for enrollment, patients receive initial RFA treatment at 0 month. Patients return to the study site at 3.5 months to review weight data since initial RFA. If the patient has not reached ideal body weight, the patient is scheduled for endoscopy with RFA at 4 months. All patients are seen at 7.5months and if the patient has not reached ideal body weight, the patient is scheduled for endoscopy with RFA at 8 months. All patients are seen at the study site at 12 months for final clinic weight.
88873645|NCT01911390|Placebo Comparator|Control Arm|No bean or rice bran additive in smoothie or muffin.
88873646|NCT01911390|Active Comparator|Bean powder|1/4 cup beans (17.5 grams powder)/day in smoothie or muffin.
88873647|NCT01911390|Active Comparator|Rice bran|15 grams rice bran/day in smoothie or muffin.
88873648|NCT01911390|Active Comparator|Bean powder and rice bran|9 grams bean powder/day and 8 grams rice bran /day in smoothie or muffin.
88873649|NCT01912716|Experimental|high-dose indomethacin|200mg rectal indomethacin
88873650|NCT01912716|Active Comparator|standard dose indomethacin|100mg rectal indomethacin
88873651|NCT01914510|Experimental|ENMD-2076|ENMD-2067 will be taken orally at a dose of 275 mg, once a day, everyday. Patients with a body surface area of less than 1.65 m2 will receive a starting dose of 250 mg, once a day, everyday.
88873652|NCT01916928||Non-viable pregnancy|Women presenting with stillbirth, defined as fetal death occurring after 20 weeks gestation or with miscarriage, defined as fetal death prior to 20 weeks gestation.
88873653|NCT01918800|Experimental|Fatigue: Take Control|Fatigue: Take Control, is the first formal education program modeled on the MS-related fatigue guideline
88873654|NCT01918800|Active Comparator|MS: Take Control|MS: Take Control includes topics of interest to people with MS other than fatigue.
88873655|NCT01920282|Active Comparator|Nebivolol|Subjects will be provided with daily 5 mg of nebivolol for the first 2 weeks. Subjects receive additional daily doses of 10 mg nebivolol for the remainder of the study period. The dose remains at 5 mg per day, however, if BP falls below 110/70 during the first 2 weeks. Subjects will continue taking the drug during the 2-week follow-up period.
89530207|NCT03255499|Experimental|Exercise|High-intensity training regimen, 10min/day. Developed for the MovinCog intervention.
89188278|NCT00784329|Experimental|Optical Frequency Domain Imaging|Optical Frequency Domain Imaging System used during Lung and Bronchial biopsies to detect cancerous tissue. Tissue imaging results will be compared to tissue biopsy results.
88873656|NCT01920282|Active Comparator|Lifestyle Modification|Subjects will receive weekly lifestyle counseling by a registered dietitian to ensure adequate progress and compliance. Sample menus, 14-days of meal plans, and grocery shopping lists are provided to each individual. Individuals were instructed to reduce their daily caloric intake by 500-1000 calories and to perform a minimum of 150 minutes per week of moderate-intensity physical activity or 3000 steps/day above baseline levels. The diet plan conformed to the Dietary Approach to Stop Hypertension dietary guidelines emphasizing low fat dairy products, fruits and vegetable and contained 55% calories as carbohydrates, 30% calories as fat, and 15% calories as protein. Sodium consumption was set at 2,400 mg/day for all subjects.
89188279|NCT04072484|No Intervention|Room Air|The reduced oxygen breathing device will be set to deliver room air. (i.e., no oxygen is removed from the gas mixture. The subject will perform CPR while breathing through mask and tubing that is connected to the device.
89188280|NCT04072484|Experimental|Hypoxia|The reduced oxygen breathing device will be set to deliver a gas mixture with15% oxygen. (Equivalent to the partial pressure of oxygen at 2,438 meters.) The subject will perform CPR while breathing through mask and tubing that is connected to the device.
89188281|NCT00793299|Experimental|Video Illness Narrative|single arm pilot study
89188282|NCT04072406|Active Comparator|Arm I: Usual Care|"Participants assigned to usual care will receive a packet of instructions with information about how to complete weekly surveys via a link that will be emailed to them~Participants in both arms will be asked to complete a total of five surveys: baseline, at the end of each of three weeks, and a final survey one month later"
89188283|NCT04072406|Experimental|Arm II: Mindfulness Meditation|"Participants will listen to mindfulness meditations daily over the course of three weeks.~Participants in both arms will be asked to complete a total of five surveys: baseline, at the end of each of three weeks, and a final survey one month later"
89188284|NCT00788619|Active Comparator|Day 3 transfer|Subjects in this arm will have two embryos transferred three days after fertilization. Embryos will be selected based on the concentration of nitric oxide metabolites in the culture medium.
89188285|NCT00788619|Active Comparator|Day 5 transfer|Subjects will have two embryos transferred on day 5 after fertilization with selection of embryos based on morphologic criteria.
89188286|NCT00661089|Experimental|Intramuscular OnabotulinumtoxinA|Injection of Botulinum Toxin type A - onabotulinumtoxinA into specified shoulder muscles at second visit
89188287|NCT00661089|Active Comparator|Intramuscular Placebo (Saline)|Injection of saline into specified shoulder muscles at Visit 2. Blind broken and subjects were offered study drug if initially in the placebo group, at week 12
89188288|NCT03098082|Other|Actim Pancreatitis Dipstick Test|All enrolled subjects who meet inclusion/exclusion criteria will have the Urine Trypsinogen 2 Dipstick test done.
89188289|NCT01773278|Experimental|antioxidant effects on retinal function|Patients with SLOS will be treated with both cholesterol supplementation and antioxidants. Retinal function will be followed by serial electroretinogram (ERG) testing and pigmentary retinopathy will be followed by Serial Ophthalmologic exams under anesthesia
89188290|NCT01773278|Experimental|antioxidant effects on hearing|Patients with SLOS will be treated with cholesterol and antioxidant medication and their hearing will be followed by serial brainstem audiometry (ABR)
89188291|NCT01773278|Experimental|Antioxidant effect on Oxysterols|Patients with SLOS will be treated with antioxidants and cholesterol. Blood oxysterol levels will be measured. Future focus will be on being able to use oxysterol levels to regulate antioxidant doses, and to determine which particular antioxidants might have the most benefit in lowering oxysterols
89188292|NCT00788853||A|
89188293|NCT04071002|Active Comparator|surgical group|distal radius fractures that treated volar plate
89188294|NCT04071002|Active Comparator|conservative group|distal radius fractures that treated plaster of paris
89188295|NCT00788931|Experimental|IV LBH589 + trastuzumab + paclitaxel|i.v. panobinostat
89188296|NCT00788931|Experimental|Oral LBH589 + trastuzumab + paclitaxel|oral panobinostat
89188297|NCT00709514|Experimental|DCB-WH1 ointment|DCB-WH1 ointment 1.25%, topical use, two times daily for 12 weeks or until ulcer closes completely or discontinuation due to treatment failure, whichever comes first.
89188298|NCT00709514|Placebo Comparator|Placebo|Placebo, topical use, two times daily for 12 weeks or until ulcer closes completely or discontinuation due to treatment failure, whichever comes first.
89188299|NCT00709670|Experimental|whole population who receive both tests|this arm includes the whole study population who will receive both tests: MSCT and stress echocardiography
89188300|NCT00709748|Active Comparator|1|Subjects in this study arm will receive treatment (fully active) Empi Select TENS devices.
89188301|NCT00709748|Placebo Comparator|2|Subjects in this study arm will receive control (not fully active) Empi Select TENS devices.
89397657|NCT03622814|Placebo Comparator|Enhanced Usual Condition (EUC)|In the non-treatment respite care centers, an Enhanced Usual Condition will be delivered to caregivers of People with Dementia (PWD). This program consists of enhanced training in caregiving using components from a module of the evidence-based Savvy Caregiver program (K. Hepburn) given in a group setting with opportunity for a question and answer period; the program is given for new enrollees and every 6 months. The PI (EJA), the nutritionist (KM) or the Program Manager (MCP) will lead these groups. Weight of the PWD is measured initially and monthly (x5); amount of food consumed will be measured using the Samsung tablets, also initially and monthly (x5).
89188302|NCT02574650|Experimental|Open Label|Non-randomized, open label clinical study that intends to treat up to 30 subjects with the Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS) using standard of care techniques and services that are typically used for structural heart procedures.
89188303|NCT04072094|Experimental|Minimally Invasive Locking Plate Fixation|Patients randomized to the Minimally Invasive Locking Plate Fixation arm will be treated with plate fixation. The plate may be applied in a percutaneous fashion. Any combination of locked and/or non-locked screws may be used.
89188304|NCT04072094|Active Comparator|Intramedullary Nail Fixation|Patients randomized to the Intramedullary Nail Fixation arm will be receive a standard locked intramedullary nail fixation. The nail must use at least one static interlock proximal to and one static interlock distal to the fracture site. The nail may be placed with a reamed technique.
89397658|NCT03616470|Experimental|Uproleselan (GMI-1271)|Uproleselan in combination with mitoxantrone, etoposide and cytarabine (MEC) or fludarabine, cytarabine and idarubicin (FAI)
88873657|NCT01920282|Experimental|Nebivolol plus Lifestyle Modification|Subjects begin with 5 mg/day of nebivolol and increase to 10 mg/day if brachial blood pressure is greater than 120/80 mmHg during the first 2 weeks of therapy. Subjects also receive weekly lifestyle counseling by a registered dietitian to ensure adequate progress and compliance. Sample menus, 14-days of meal plans, and grocery shopping lists are provided to each individual. Individuals will be instructed to reduce their daily caloric intake by 500-1000 calories and to perform a minimum of 150 min/wk of moderate-intensity physical activity or 3000 steps/day above baseline levels. The diet plan conforms to the Dietary Approaches to Stop Hypertension dietary guidelines emphasizing low fat dairy products, fruits and vegetable and contains 55% calories as carbohydrates, 30% calories as fat, and 15% calories as protein with sodium consumption set at 2,400 mg/day for all subjects.
88873658|NCT01921296|Experimental|Cyclobenzaprine|Cyclobenzaprine (Flexeril) 5 milligrams orally 2 hours before bed, for a total of 24 weeks.
88873659|NCT01921452|Experimental|POC TSH Kits + Third Generation TSH Kit|
88873660|NCT01929642|Experimental|Sirolimus or Everolimus|Oral solution or tablet,titrated to therapeutic serum trough range (sirolimus); Oral tablet, titrated to therapeutic serum trough range (everolimus)
88873661|NCT01932060|Experimental|Oxytocin Infusion 1|Oxytocin Infusion 15 U/hr to begin after the delivery of the fetus and to terminate at the time of patient discharge from the post-anesthesia care unit.
88873662|NCT01932060|Active Comparator|Oxytocin Infusion 2|Oxytocin infusion 2.5 U/hr to begin after the delivery of the fetus and to terminate at the time of discharge from the post-anesthesia care unit.
88873663|NCT01932606|Experimental|Nitrite|Study drug (NaNO_2 50 mcg/kg/min) will be infused for 5 minutes during the cardiac catheterization procedure.
88873664|NCT01932606|Placebo Comparator|Saline|Saline Placebo for Nitrite will be infused for 5 minutes during the cardiac catheterization procedure.
88873665|NCT01933230|Other|Excel Cryo Cooling System Collar|An Excel Cryo Cooling System collar will be placed around the neck for a 2 hour neck cooling period. This will cool the blood in the neck that goes to the brain causing the brain to become cool. The collar is a standard neck collar used for patients after neck surgery with a modification that allows for the placement of a cooling pack in the collar. The cooling pack is similar to the cooling packs used for sports injuries. The cooling packs will be changed every 20 minutes for the two-hour duration. During the study and for two hours after, we will collect data concerning the brain temperature, body temperature, brain oxygen level and pressure both in the head and in the blood.
88873666|NCT01933464|Experimental|Cromolyn|Subjects in this arm will be asked to apply their assigned medication twice daily to their entire face. The medication they will be receiving is cromolyn sodium ophthalmic solution, 4%.
88873667|NCT01933464|Placebo Comparator|Vehicle|Participants in this group will be assigned a solution consisting of only the inactive ingredients in cromolyn sodium ophthalmic solution to apply to their entire face twice daily.
88873668|NCT01933776|Experimental|Group 1: Adults|Participants 18 through 64 years of age will receive a single booster dose of Tdap vaccine (ADACEL).
88873669|NCT01933776|Experimental|Group 2: Children|Participants 4 through 8 years of age will receive a single booster dose of Tdap vaccine (ADACEL)
88873670|NCT01935180|No Intervention|Standard colonoscopy|
88873671|NCT01935180|Active Comparator|Cap assisted colonoscopy|A transparent cap will be affixed to tip of the high-definition wide angle colonoscope.
88873672|NCT01936662|Experimental|Largyngeal Mask Airway for EGD procedure|Patients randomized to LMA to maintain airway through EGD procedure
88873673|NCT01936662|Active Comparator|Endotracheal Tube for EGD procedure|Patients were randomized to ETT to maintain airway for EGD procedure. This is the standard of care at this hospital
89188305|NCT02577848|Experimental|GLP-1 group|liraglutide (Novo Nordisk, Bagsværd, Denmark); the frequency: Subcutaneous liraglutide were taken daily; duration: 7 days. After admission, the patients were treated with 0.6 mg liraglutide once daily for 2 day, then 1.2 mg liraglutide for another 2 day, and then 1.8 mg liraglutide for 3 days.
89397659|NCT03616470|Placebo Comparator|Placebo (Saline, 0.9% Sodium Chloride)|Placebo in combination with mitoxantrone, etoposide and cytarabine (MEC) or fludarabine, cytarabine and idarubicin (FAI)
88873674|NCT01936896|Experimental|Alpha-1 anti-trypsin (AAT)|We will use plasma derived AAT 60 mg/Kg, single infusion, within 12 hours of hospital admission for ST-segment elevation myocardial infarction (STEMI)
88873675|NCT01937520|Experimental|acupuncture|acupuncture will be administered after induction for a period of 30 minutes, followed by a 30 minute rest period and then resumption of acupuncture for 30 minutes.
88873676|NCT01937520|Placebo Comparator|device|no acupuncture will be done on this group of subjects
88873677|NCT01937598|Experimental|Sitagliptin, then Placebo|
88873678|NCT01937598|Experimental|Placebo, then Sitagliptin|
88873679|NCT01938066|Active Comparator|Negative Pressure with Procellera|Arm 2 is Negative Pressure Therapy and Procellera Dressing under the sponge dressing of the Negative Pressure Therapy. The dressing will be changed at the end of 5 days. This is the intervention arm of the study.
89397660|NCT03593759|Active Comparator|Prednisone (or Prednisolone)|"[Dose everywhere except Japan] Prednisone 0.5 mg kg/day for 6 months (max dose 30 mg)~[Dose in Japan] Prednisone or prednisolone 0.5 mg/kg po (max 30mg) for one month then reduce by 5 mg per month for five months"
88873680|NCT01938066|Sham Comparator|Negative Pressure Therapy only|Arm 1 is Negative Pressure Therapy only with no Procellera Dressing and the dressing is changed every other day per standard of care when you use Negative Pressure Therapy with no dressing underneath the sponge.
88873681|NCT01938378|Other|Pediatric patients undergoing TPE|octaplas™
88873682|NCT01939938|Experimental|All Subjects-Nasal and Oronasal PAP Mask|Each subject will be imaged in a dynamic MRI with both a oronasal and nasal mask at pressures of 5, 10, and 15 cm of H2O.
88873683|NCT01942668|Experimental|Treatment 1|Combined Estradiol 1 mg / Progesterone 100 mg softgel capsule formulation and placebo taken orally once a day for twelve months.
88873684|NCT01942668|Experimental|Treatment 2|Combined Estradiol 0.5 mg / Progesterone 100 mg softgel capsule formulation and placebo taken orally once a day for twelve months.
88873685|NCT01942668|Experimental|Treatment 3|Combined Estradiol 0.5 mg / Progesterone 50 mg softgel capsule formulation and placebo, taken orally once a day for twelve months.
89397661|NCT03593759|Experimental|Methotrexate|"[Dose everywhere except Japan] Methotrexate 15-20 mg orally, sc, or IM once a week for 6 months + Prednisone 20 mg po daily for one month then 10 mg po daily for one month then 5 mg po daily for one month and then stop. Also Folic Acid 2 mg po daily for 6 months.~[Dose in Japan] Methotrexate 5-20mg mg orally, sc, or IM once a week for 6 months+ Prednisone or Prednisolone 20mg OD for 1 month then 10mg OD for 1 month then 5 mg OD one month. Also Folic Acid 2 mg po daily for 6 months."
89397662|NCT03557905|Active Comparator|Group I|Patients will receive recruitment maneuver (RM) followed by decremental PEEP titration 1min. after establishment of mechanical ventilation and after documented lung re-collapse at an FiO2 of 0.5. .
89397663|NCT03557905|Active Comparator|Group II|Patients will receive recruitment maneuver (RM) followed by decremental PEEP titration 1min. after establishment of mechanical ventilation and after documented lung re-collapse at an FiO2 of 0.3.
89397664|NCT03548155|Experimental|berberine group|
89397665|NCT03548155|Placebo Comparator|control group|
88873686|NCT01942668|Experimental|Treatment 4|Combined Estradiol 0.25 mg / Progesterone 50 mg softgel capsule formulation and placebo, taken orally once a day for twelve months.
89397666|NCT03516708|Experimental|Dose Escalation Cohort (Phase I): Epacadostat + SCRT + Chemotherapy + Surgery|"Epacadostat at the designated dose level starting the day of radiation therapy, throughout chemotherapy, and until the day of surgery~Epacadostat is taken by mouth twice per day every day of each 21 day cycle~Standard of care preoperative therapy will consist of a total of approximately 20-24 weeks' preoperative therapy followed by surgery. Breakdown of the 20-24 weeks of preoperative therapy are as follows:~Week 1: Short-course pelvic radiation therapy, 5 fractions over 1 week~Weeks 2-4: Treatment break for 2 to 4 weeks; for patients enrolled at Washington University only, tumor biopsy will be obtained on or after the last radiation day (D5-8) and before the start of chemotherapy (D21-28)~6 cycles of CAPOX for a total of 18 weeks~surgery will follow approximately 4 to 6 weeks after completion of chemotherapy~CAPOX is typically capecitabine at 1000 mg/m2 PO BID and oxaliplatin 130 mg/m2 IV Q3W. The second cycle of epacadostat will begin when CAPOX starts"
89397667|NCT03516708|Experimental|Phase II Treatment Cohort: Epacadostat + SCRT + Chemotherapy + Surgery|"Epacadostat 400 mg BID starting the day of radiation therapy, throughout chemotherapy, and until the day of surgery~Epacadostat is taken by mouth twice per day every day of each 21 day cycle~Standard of care preoperative therapy will consist of a total of approximately 20-24 weeks' chemoradiation followed by surgery. Breakdown of the preoperative therapy are as follows:~Cycle 1 Days 1-7 (Week 1): Short-course pelvic radiation therapy, typically 5 fractions over 1 week~Cycle 0 Days 8-21 or 28 (Weeks2-4): Treatment break for 2-3 weeks; tumor biopsy will be obtained between the end of RT and prior to chemotherapy (for patients enrolled at Washington University and Dana Farber Cancer Institute only)~Cycles 1-6: 6 21 day cycles of CAPOX for a total of 18 weeks: CAPOX is typically capecitabine at 1000 mg/m^2 PO BID (days 1-14 of each 3-week cycle) and oxaliplatin 130 mg/m^2 IV Q3W.~Surgery will follow approximately 4 to 6 weeks after completion of chemotherapy"
89397668|NCT03516708|Active Comparator|Phase II Biomarker Cohort: SCRT + Chemotherapy + Surgery|"-Patients enrolled to the biomarker cohort will not receive epacadostat but will only receive standard of care preoperative therapy consisting of a total of approximately 20 to 24 weeks of chemoradiation as follows:~Cycle 0 Days 1-7 (Week 1): Short-course pelvic radiation therapy, typically 5 Gy x 5 fractions over 1 week~Cycle 0 Days 8-21 or 28 (Weeks 2-4): treatment break for 2 to 3 weeks; for patients enrolled at Washington University and Dana Farber Cancer Institute ONLY, tumor biopsy will be obtained between the end of RT and prior to initiation of chemotherapy via proctoscopy or sigmoidoscopy (if safe, feasible, and evidence of necessary) (target Days 5-28)~Cycles 1-6: 6 21-day cycles of CAPOX for a total of 18 weeks; CAPOX is typically capecitabine at 1000 mg/m*2 PO BID (Days 1-14 of each 3-week cycle) and oxaliplatin 130 mg/m^2 IV Q3W.~Surgery will follow approximately 4 to 6 weeks after completion of CAPOX, although surgery may occur outside this timeframe."
89397669|NCT03512899|Active Comparator|Internal jugular vein access|Internal jugular vein access preferably right, assisted by ultrasound and radioscopy. Catheter: districath®, 8.5 French.
89397670|NCT03512899|Active Comparator|Axillary vein access|Axillary vein access with single incision, assisted by ultrasound and radioscopy. Catheter: districath®, 8.5 French.
89397671|NCT03501173||Metastatic Castrate-Sensitive Prostate Cancer (mCSPC)|Participants will be defined as having mCSPC if there is a new mCSPC diagnosis in the past 6 months, documented metastatic prostate cancer, no more than 12 months of androgen deprivation therapy (ADT) in any setting and no more than 6 months of systemic treatment for mCSPC (example, next generation androgen receptor targeted therapy or chemotherapy).
89530208|NCT03255499|Experimental|Cognitive training|Computerized cognitive training, 20min/day. Developed for the MovinCog intervention.
88873687|NCT01942668|Placebo Comparator|Placebo|Two Placebo softgel capsules taken orally once a day for twelve months.
88873688|NCT01944930|Experimental|Narrow Band Imaging Laparoscopy First|Study has single cohort assessed in crossover design. In this arm NBI laparoscopy will be performed first, followed by standard white-light laparoscopy.
88873689|NCT01944930|Experimental|Standard White-Light Laparoscopy First|Study has single cohort assessed in crossover design. In this arm standard white-light laparoscopy will be performed first, followed by NBI laparoscopy.
88873690|NCT01947816||Humira|Humira 40 mg (marketed product) eow for subcutaneous injection after initial dosage of 160 mg and 2nd dosage of 80 mg in two weeks after the initial administration, for up to 52 weeks.
88873691|NCT01948518|Experimental|Oral sildenafil 20 mg|oral sildenafil, single dose at baseline
88873692|NCT01948986|Experimental|Ertugliflozin 15 mg (T2DM with Normal Renal Function)|Ertugliflozin (15 mg), oral, administered in participants with T2DM and with normal renal function
88873693|NCT01948986|Experimental|Ertugliflozin 15 mg (T2DM with Mild Renal Impairment)|Ertugliflozin (15 mg), oral, administered in participants with T2DM and with mild renal impairment
88873694|NCT01948986|Experimental|Ertugliflozin 15 mg (T2DM with Moderate Renal Impairment)|Ertugliflozin (15 mg), oral, administered in participants with T2DM and with moderate renal impairment
88873695|NCT01948986|Experimental|Ertugliflozin 15 mg (T2DM with Severe Renal Impairment)|Ertugliflozin (15 mg), oral, administered in participants with T2DM and with severe renal impairment
88873696|NCT01948986|Experimental|Ertugliflozin, 15 mg (Healthy Part. with Normal Renal Funct.)|Ertugliflozin (15 mg), oral, administered in participants with healthy participants and with normal renal function
88873697|NCT01949844|Other|Suspected coronary artery disease (CAD)|"This pilot study has a single arm/group of subjects with suspected CAD based on the following inclusion criteria:~Prior nuclear myocardial perfusion scan (PET/SPECT) with a visual interpretation of definitely abnormal, or prior myocardial infarction; or,~Clinically stable individuals with suspected coronary artery disease on the basis of coronary angiography.~The study protocol involved only a myocardial perfusion MRI procedure for detection of ischemia (perfusion deficits) using an improved protocol with the administration of a vasodilator drug (Regadenoson/Lexiscan®) and gadolinium-based MRI contrast agent (Optimark®; dose: 0.2 mmol/kg). Lexiscan® was used off-label as a vasodilator drug during the MRI scan (0.4 mg/5mL) supplied by the manufacturer, Astellas Pharma U.S."
88873698|NCT01950078||surgical patients|grouped by receiving surgery
88873699|NCT01950078||Healthy volunteers group|grouped by healthy college students
88873700|NCT01950780|Experimental|Ruxolitinib|A fixed dose of ruxolitinib (20mg) will be self-administered orally twice daily for 12 to 24 weeks. Dosing may be decreased or held if needed due to adverse effects.
88873701|NCT01951326|Active Comparator|RHB-104|5 RHB-104 capsules administered orally BID
88873702|NCT01951326|Placebo Comparator|Placebo|5 placebo capsules administered orally BID
89188306|NCT02577848|Placebo Comparator|placebo|placebo (Novo Nordisk, Bagsværd, Denmark); the frequency: Placebo were taken daily; duration: After admission, the patients were treated with 0.6 mg placebo once daily for 2 day, then 1.2 mg placebo for another 2 day, and then 1.8 mg placebo for 3 days.
89397672|NCT03501173||Metastatic Castrate-Resistant Prostate Cancer (mCRPC)|Participants will be defined as having mCRPC if there is mCRPC diagnosis at any time, documented metastatic prostate cancer, documented castration resistance per Prostate Cancer Working Group 2 criteria (elevated prostate specific antigen [PSA] despite testosterone less than [<]50 nanogram per deciliter [ng/dL] [<1.7 nano moles per liter{nmol/L}]), the first treatment for mCRPC was started in the past 6 months or is scheduled to begin.
88873703|NCT01951950|Active Comparator|Nicardipine|"Subjects will receive a 15 mcg/kg bolus of nicardipine as needed followed by an infusion initiated at 5 mg/hr. Nicardipine may be titrated every 5 minutes, increasing 5 mg/hr and administering 15 mcg/kg bolus every minute to a maximum dose of 15 mg/hr. If systolic blood pressure (SBP) is not maintained < 140 mmHg 5 minutes after achieving the maximum dose of nicardipine, medication failure will be declared and rescue drug (medication to be determined per anesthesiologist discretion) will be administered. Infusions may be titrated down if SBP decreases below 90 mmHg."
88873704|NCT01951950|Active Comparator|Esmolol|"Subjects will receive a 0.5 mg/kg bolus of esmolol as needed followed by an infusion initiated at 50 mcg/kg/min. Esmolol may be titrated every 5 minutes, increasing 50 mcg/kg/min and administering 0.5 mg/kg bolus every minute to a maximum dose of 200 mcg/kg/min. If SBP is not maintained < 140 mmHg 5 minutes after achieving the maximum dose of esmolol, medication failure will be declared and rescue drug (medication to be determined per anesthesiologist discretion) will be administered. Infusions may be titrated down if SBP decreases below 90 mmHg."
88873705|NCT01952418|No Intervention|"Standard monitor (24)"|"Endoscopists in this arm will perform colonoscopy using the standard size video monitor (24)."
88873706|NCT01952418|Active Comparator|"Large monitor (32)"|"Subjects randomized to this group will perform colonoscopy while viewing a large video monitor (32)."
88873707|NCT01953432|Experimental|Doxazosin|Doxazosin is a long-acting and selective alpha 1-NE blocker, which inhibits the binding of norepinephrine to alpha receptors in the autonomic nervous system.
88873708|NCT01953432|Placebo Comparator|Placebo|Matched placebo daily dosing.
88873709|NCT01955382|Experimental|AS + oAC|All children will receive Artesunate (AS) 2.4 mg/kg IV at 0 and 12 h, 24 h, and 48 h. Children in the AS+oAC group will be given weight-based doses of oAC (Actidose Aqua) (Table 1) at 0, 6, 12, and 18 h. All children will then receive amodiaquine.
88873710|NCT01955382|Placebo Comparator|AS only (water)|Children in the AS only group will receive a weight-based volume of clean water (Bottled Water) to drink rather than the oAC.
88873711|NCT01957410|Experimental|Ketamine Intravenous (IV)|Patients will receive a single IV dose of ketamine given as a continuous infusion.
88873712|NCT01957410|Placebo Comparator|Placebo Intravenous (IV)|Patients will receive a single IV dose of placebo given as a continuous infusion.
88873713|NCT01958112|Experimental|GSK1120212 (trametinib) and GSK2141795|GSK1120212 (trametinib) 1.5 mg QD + GSK2141795 50 mg QD in 28 day cycles
88873714|NCT01958346|Sham Comparator|Fiberoptic Intubation Alone|Intubation with fiberoptic scope assistance
88873715|NCT01958346|Experimental|Fiberoptic Intubation with lingual traction|Intubation with fiberoptic scope assistance and lingual traction maneuver provided by a second anesthesiologist
88873716|NCT05739864|Experimental|Donor FMT (D-FMT)|Patients enrolled in this arm will receive donor FMT
88873717|NCT05739864|Placebo Comparator|Placebo FMT (P - FMT)|Patients enrolled in this arm will receive placebo FMT
88873718|NCT05739786|Active Comparator|Group A liquid nitrogen|liquid nitrogen In Group A patients were subjected to liquid nitrogen cryotherapy (-196 0C) for 3 sessions at every 3 weeks interval. Effectiveness in was ascertained in terms of > 50% reduction in wart size by an expert dermatologist on physical examination at the end of third session. Patients were followed for further 6 weeks after last session to look for any sort of recurrence and remission.
88873719|NCT05739786|Active Comparator|Group B intralesional Vit D3|intralesional Vit D3 Group B were subjected to vitamin D3 (5mg/ml) for 3 sessions at every 3 weeks interval. Effectiveness was ascertained in terms of > 50% reduction in wart size by an expert dermatologist on physical examination at the end of third session. Patients were followed for further 6 weeks after last session to look for any sort of recurrence and remission.
88873720|NCT05739630|Experimental|M+PTCy group|For the M-PTCy group, Mitoxantrone liposomes with 36mg/m2 and Bu 3.2mg/kg -5 to -4, Flu 30mg/m2 -12 to -9, Ara-C 1.5g/m2 -12 to -9，CTX 15mg/kg/d -3 to -2, was used as conditioning regimen, Post Transplant Cyclophosphamide 50 mg/kg IV daily on days +3 and +4.
88873721|NCT05739630|Active Comparator|BuCy group|For the BUCY group, the conditioning regimen involved Ara-C 2g/m2 q12h -8, BU 3.2 mg/kg -7 to -5,CTX 1.8 g/m2 -4 to -3, to prevent GVHD, MTX 15mg/m2 +1d, 10mg/m2 +3,+6,+11,CsA 3mg/kg/d from -8d,MMF 1g q12h from -8d， ATG 2.5mg/kg/d -5 to -2.
88873722|NCT05739318|Experimental|The cuff of endotracheal and endobronchial is collapsed|The diameter of double-lumen tube at the cuff of endotracheal and endobronchial during the cuff is collapsed
88873723|NCT05739318|Experimental|The cuff of endotracheal and endobronchial is inflated|The diameter of double-lumen tube at the cuff of endotracheal and endobronchial during the cuff is inflated
88873724|NCT05739084||Retrospective cohort|A total sample size of 200 patients is expected in the retrospective thanks to the NETSARC/ CONTICABASE databases (French sarcoma reference network)
88873725|NCT05739084||Prospective cohort|"To ensure an external validation, patients from NETsarc centers experiencing preoperative RT will be prospectively accrued and transcriptomic signature will be tested.~Up to 100 patients will be enrolled in this prospective cohort."
88873726|NCT05738772||hcc group|The study group will include 45 patients with HCC on top of liver cirrhosis. All virus-related liver cirrhosis and all BCLC stages of HCC will be accepted. Verified presence of HCC, will be assessed by computed tomography (CT) and/or magnetic resonance imaging (MRI) or based on histological validation. In patients with presence of liver cirrhosis, non-invasive diagnosis of HCC is standard, when dynamic imaging shows typical diagnostic patterns as the combination of hypervascularity in late arterial phase and washout on portal venous and/or delayed phases
89188307|NCT00582426|Experimental|Octreotide Long Acting Release|Prevention of Chemotherapy Induced Diarrhea (CID)
89188308|NCT00582426|Other|Standard Treatment|Physician treatment of choice for chemotherapy induced diarrhea other than Octreotide LAR.
89188309|NCT02574572|Experimental|Single group|Patients with spinal cord injury that will undergo laminectomy and autologous mesenchymal cells intralesional injection
88873727|NCT05738772||LC group|Will include 45 patients diagnosed with liver cirrhosis on top of HCV or HBV with an absence of focal lesions on ultrasound screening as a control group. Cirrhosis will be determined according to clinical, serological, and radiological findings
88873728|NCT05738616|Experimental|lenvatinib combined with TACE and camrelizumab|
88873729|NCT05738616|Active Comparator|lenvatinib alone|
88873730|NCT05738460||Reproductive tract GBS colonization group of mothers during pregnancy|Reproductive tract GBS colonization group of mothers during pregnancy，Use of antibiotics
88873731|NCT05738460||No reproductive tract GBS colonization group in mothers during pregnancy|No reproductive tract GBS colonization group in mothers during pregnancy
88873732|NCT05738382|Experimental|BG2109 75mg|oral, once a day
88873733|NCT05738382|Experimental|BG2109 150mg|oral, once a day
88873734|NCT05738382|Experimental|BG2109 200mg|oral, once a day
88873735|NCT05738382|Active Comparator|Cetrorelix|0.25mg, Subcutaneous injection, once a day
88873736|NCT05738226|Experimental|EpiCare@Home|Patients with a history or suspicion of focal onset epilepsy admitted to the EMU for routine observation will be able to opt-in to using EpiCare@Home during their admission. Optionally, they will be able to continue using the device at home after EMU discharge.
88873737|NCT05737680|Active Comparator|Hydroxychloroquine arm|Hydroxychloroquine 400mg daily
88873738|NCT05737680|Active Comparator|Colchicine arm|Colchicine continued
88873739|NCT05737290|Active Comparator|Group A|
88873740|NCT05737290|Active Comparator|Group B|
88873741|NCT05736510|Experimental|Binaural|Exposed to binaural sound (40 Hz) from the end of pneumoperitoneum until the eyes are open
88873742|NCT05736510|Active Comparator|Control|Applied silent files from the end of pneumoperitoneum until the eyes are open
88873743|NCT05735964|Experimental|ICG|Patients in this single arm will receive ICG during their surgery
88873744|NCT05735418|Experimental|GI Biome #7|The intervention consists of daily administration of probiotics GI Biome #7 for four weeks.
88873745|NCT05735418|Placebo Comparator|Placebo|The placebo consists of daily administration of the placebo pills made up of 100% maltodextrin for four weeks.
88873746|NCT05735028|Experimental|CM group|CM+PD-1/PD-L1 inhibitor
88873747|NCT05735028|Active Comparator|Control group|PD-1/PD-L1 inhibitor
88873748|NCT05734872|Experimental|Experimental group|
88873749|NCT05734872|Other|Control group|
88873750|NCT05734482|Experimental|Biosimilar Product|CMAB015 150 mg Subcutaneous injection in upper arm
88873751|NCT05734482|Active Comparator|Reference Product|Cosentyx（Secukinumab ） 150 mg Subcutaneous injection in upper arm
88873752|NCT05725200|Experimental|Individualized treatment in patients with metastatic colorectal cancer|"Interventions with anti-cancer drugs having marketing authorisation in Norway will be used in this study.~The intervention will be study drugs as monotherapy or treatment with approved combinations.~This trial will facilitate access to potentially effective interventions to which they would otherwise not have access."
88873753|NCT05724966||Registration of side effects|patients are to registrer side effects prior to treatment with Bortezomib through an app.
88873754|NCT05714592|Experimental|Optical genome mapping|
88873755|NCT05712252||Fallers without a fracture|Individuals who obtain no fracture.
89188310|NCT02575898|Other|One|"Creative writing and questionnaires interventions:~First Session, Second Session, Third through Sixth Sessions"
89530209|NCT03255499|Active Comparator|Games|The active control is composed of a blend of board games, computer games, and trivia quizzes. Specific content is personalized based on individual preferences, so as to reflect the flexibility of the experimental arms.
89530210|NCT05082779|Experimental|Cohort A1: 0.2 mg|Participants in fasted state will receive CS0159 0.2 mg or placebo once on Day 1.
88873756|NCT05712252||Fallers with a fracture|Individuals who obtain one or several fractures through fall. This group can be further subgrouped according to type of fracture.
88873757|NCT05606484|Experimental|Intervention Group (IG)|They will perform an intradialysis physical exercise program with non-immersive virtual reality during the first two hours of hemodialysis treatment (n = 40).
88873758|NCT05606484|Active Comparator|Control Group (CG)|They will exercise with a static pedal during the first two hour of hemodialysis treatment (n = 40).
88873759|NCT05599698|Experimental|chemotherapy|chemotherapy
88873760|NCT05574894|Experimental|GH group|Growth Hormone supplement, GnRH antagonist protocol for ovarian stimulation
88873761|NCT05574894|Active Comparator|Control group|No Growth Hormone supplement, GnRH antagonist protocol for ovarian stimulation
88873762|NCT05530278|Experimental|ABBV-576 with Galicaftor + Navocaftor|Participants will receive ABBV-576 for 14 consecutive days, with navocaftor + galicaftor for the latter 7 consecutive days.
88873763|NCT05530278|Experimental|Navocaftor + Galicaftor with ABBV 576|Participants will receive Navocaftor + galicaftor for 14 consecutive days, with ABBV 576 for the latter 7 consecutive days.
88873764|NCT05530278|Experimental|Optional: Navocaftor with ABBV 576|Participants will receive Navocaftor for 14 consecutive days with ABBV 576 for the latter 7 consecutive days.
88873765|NCT05530278|Experimental|Optional: Galicaftor with ABBV 576|Participants will receive Galicaftor for 14 consecutive days, with ABBV 576 for the latter 7 consecutive days.
88873766|NCT05530278|Experimental|Optional: Midazolam with ABBV-576 + Navocaftor|Participants will receive Midazolam alone and in combination with multiple doses of ABBV-576 + navocaftor.
88873767|NCT05438628||Patients scheduled for total knee arthroplasty surgery|
88873768|NCT05436288|Experimental|Single arm active|KIO-201, a Crosslinked Thiolated Carboxymethyl Hyaluronic Acid 0.75% (CMHA-S), up to 6 times a day for 4 weeks.
88873769|NCT05434962|Experimental|Cardiac resynchronization therapy (CRT) obtained by stimulating the left branch area|"The CRT-P/CRT-D device and leads should be implanted according to the physician's standard practice. Only locally approved Medtronic CRT-P/CRT-D generators will be used during the study. It is strongly encouraged the designation of a single and experienced implanting physician at each center for the LBBAP implant procedures.~During the implant procedure lead impedances, pacing and sensing parameters will be measured using a pacing system analyzer (PSA).~For LBBAP, the Medtronic 3830 lead will be used. Acceptable LBBAP threshold should be <2,5V@0,5ms."
88873770|NCT05434962|Active Comparator|Cardiac resynchronization therapy (CRT) obtained by biventricular pacing|"The CRT-P/CRT-D device and leads should be implanted according to the physician's manual provided with the devices. Only locally approved Medtronic CRT-P/CRT-D generators will be used during the study.~Investigators may use any market approved right atrial (RA) pace/sense lead, right ventricular (RV) pacing/defibrillator lead with pace/sense capabilities and any market approved unipolar/bipolar/quadripolar LV pacing lead.~During the implant procedure lead impedances, pacing and sensing parameters will be measured using a pacing system analyzer (PSA).~The LV lead should be implanted at a lateral or posterolateral CS branch in a basal or mid ventricular position confirmed by ortogonal fluoroscopic views (RAO and LAO 40º).~Acceptable LV pacing threshold should be <3V@0,5ms and phrenic nerve stimulation (PNS) margin should be >1V with respect to the pacing threshold"
88873771|NCT05378568|Experimental|the selection scheme of peripheral venous access devices|To implement the selection scheme of peripheral venous access devices, based on the Clinical Practice Guideline on Infusion Therapy in Children. Then observe the appropriateness of peripheral venous access devices selection.
88873772|NCT05378568|Active Comparator|the existing nursing routine|Follow the existing nursing routine of intravenous infusion and the selection of peripheral venous access devices.
88873773|NCT05245734|Experimental|Main group|"Patients receive two prophylactic doses of the Human Anti-D (rh) immunoglobulin at a dose of 300 mcg - at 28 weeks of gestation and within 72 hours after delivery. Patients receive the second dose only in the case of the birth of an Rh-positive child.~Before and after each injection of the drug, blood will be taken to control the level of anti-Rh0 (D) antibodies. after the last injection of the drug, blood samples are taken after 3 and 6 months to assess sensitization to the Rh antigen.~15 participants from the Main group are formed the Pharmacokinetics subgroup for additional blood samples taking, to determine the pharmacokinetic parameters"
88873774|NCT05242692|Experimental|S-ketamine|S-ketamine (50 mg, 2 ml) is diluted to 50 ml (1 mg/ml) with 48 ml normal saline;
88873775|NCT05242692|Active Comparator|Dexmedetomidine|Dexmedetomidine (200 ug, 2 ml) is diluted to 100 ml (2 ug/ml) with 98 ml normal saline;
88873776|NCT05242692|Placebo Comparator|Normal saline|Control group only contains 50 ml normal saline in light of blindness
88873777|NCT05131620|Experimental|Venture in the Virtual Reality Group|Informed consent form will be signed by the patients who will be included in this group as a result of randomization, and a personal information form and STAI will be filled. After CAG, 10 minutes before the catheter extraction, the patients will be selected from videos such as park and nature walks, beach and seaside walks, underwater, museum tour, and virtual reality glasses will be put on and will be worn during the procedure. In the literature, VR glasses were put on 5-10 minutes before the procedure, continued throughout the procedure, and used for a total of 30-60 minutes. Catheter extraction takes approximately 15-20 minutes and it is planned to continue the virtual reality glasses viewing period for 30 minutes. VAS will be applied during the catheter extraction process, and VAS, SAI and PCS will be applied to all patients after catheter extraction. Vital signs of patients will be recorded before, during and after catheter extraction.
88873778|NCT05131620|Experimental|Venture in the Acupressure Group|Initiative in the Acupressure Group Informed consent form will be signed by the patients who will be included in this group as a result of randomization, and a personal information form and STAI will be filled. Acupressure will be applied 10 minutes before catheter extraction after CAG. Catheter extraction takes approximately 15-20 minutes. VAS will be applied during the catheter extraction process, and then VAS, SAI and PCS will be applied to all patients. Vital signs of patients will be recorded before, during and after catheter extraction.
89397673|NCT03501173||NonMetastatic Castrate-Resistant Prostate Cancer (nmCRPC)|Participants will be defined as having nmCRPC if there is nmCRPC diagnosis at any time, documented non-metastatic prostate cancer, documented castration resistance per Prostate Cancer Working Group 3 criteria (elevated PSA despite testosterone <50 ng/dL [<1.7 nmol/L]). nmCRPC, defined as a prostate specific antigen doubling time (PSADT) of less than or equal to 12 months, or beginning next generation ARAT for nmCRPC.
88873779|NCT05131620|No Intervention|Control Group|Informed consent form will be signed by the patients who will be included in this group as a result of randomization, and a personal information form and STAI will be filled. Routine application will be made. VAS will be applied during the catheter extraction process, and then VAS, SAI and PCS will be applied to all patients. Vital signs of patients will be recorded before, during and after catheter extraction.
88873780|NCT05110404|Active Comparator|Group (A): The high-volume HIIT|Exercise group A (n=30): It will include patients that will perform high-volume high-intensity interval training (HIIT), and will receive medical intervention.
88873781|NCT05110404|Active Comparator|Group (B): The low-volume HIIT|Exercise group B (n=30): will receive medical intervention. that will perform the low-volume high-intensity interval training, and will receive medical intervention.
88873782|NCT05110404|No Intervention|Group C|patients will receive medical intervention only.
89397674|NCT03501173||mCRPC (Treatment-experienced in the nmCRPC or mCSPC Setting)|Participants will be defined as having mCRPC (treatment-experienced in the nmCRPC or mCSPC setting) if there is nmCRPC diagnosis at any time, documented non-metastatic prostate cancer, documented metastatic prostate cancer, documented castration resistance per Prostate Cancer Working Group 2 criteria (elevated PSA despite testosterone <50 ng/dL [<1.7nmol/L]), the first treatment for mCRPC clinical state was started in the past 6months or is scheduled to begin, disease progression occurred while receiving active treatment (ARAT or chemotherapy) in the prior nmCRPC or mCSPC clinical state.
89397675|NCT03494556||No Intervention|Paramedic will use data collected during routine care to complete four risk stratification tools.
89397676|NCT03403231|Active Comparator|Arm 1: Stock messages only|Participants will only receive the stock messages that encourage following recommended behaviors for reducing the risk for developing diabetes.
89397677|NCT03403231|Experimental|Arm 2: Urgency frame message strategy|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with the urgency frame message strategy.
89188311|NCT04019184|Experimental|Glutamine group|Intravenous infusion of 0.5 g/kg body weight (2.5 ml/kg body weight) L-alanyl-Lglutamine over 12 h after randomization
89188312|NCT04019184|Placebo Comparator|Control group|Intravenous infusion of 2.5 ml/kg body weight sodium chloride 0.9 % over 12 h after randomization
89530211|NCT05082779|Experimental|Cohort A2: 0.6 mg|Participants in fasted state will receive CS0159 0.6 mg or placebo once on Day 1.
88873783|NCT05087940||Resistant hypertension|The adult patients with resistant hypertension which is defined as casual blood pressure during clinical examination of more than 140/90 mmHg despite treatment with optimal or best-tolerated doses of three or more drugs, which should include a diuretic, typically an angiotensin converting enzyme (ACE) inhibitor or an angiotensin receptor blocker (ARB), and a calcium channel blocker (CCB). All reference blood pressures will be taken as a mean of the 2nd and 3rd measurements in physician's office during a single examination, measured at least 3 min apart. The following add-on therapy is available in Serbia, where the study is conducted: an aldosterone receptor blocker (e.g. spironolactone), a loop diuretic (e.g. furosemide), a thiazide in large daily dose, an alpha 1 selective blocker and a beta 1 selective blocker.
88873784|NCT05077566|Active Comparator|Exercise at 60% vo2|This arm will receive 15 minutes of exercise at 60% VO2 max.
89397678|NCT03403231|Experimental|Arm 3: Social norm message strategy|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with the social norm messaging strategy.
88873785|NCT05077566|Experimental|Exercise at 90% vo2|This arm will receive 15 minutes of exercise at 90% VO2 max.
89188313|NCT02387970|Active Comparator|Immediate provisionalization|Individuals will receive temporary dental crowns supported by NobelParallel CC implant at the same day as implant surgery
89188314|NCT02387970|Active Comparator|Delayed provisionalization|Individuals will receive temporary dental crowns supported by NobelParallel CC implant 3 months after implant surgery
89188315|NCT00710060|Experimental|1|Participating communities will receive the Community Popular Opinion Leader intervention and HIV/STD educational materials.
89188316|NCT00710060|Active Comparator|2|Participating communities will receive HIV/STD educational materials only.
89188317|NCT04070690|Other|Intervention-Control group|"In this group, the participants will receive intervention for 2 months first, followed by a wash-out period of 1 month and control for 2 months.~In the intervention period, the investigators will provide the participants with lower dialysate HCO3 concentrations. (dialysate HCO3 to 28 mmol/L for half of the HD session and 30 to the second half of their HD session.) Besides, the investigators will give the participants with pre-HD HCO3<22 mEq/L oral Na-bicarbonate 650 mg 1#-2# three times a day as supplements.~In the control period, the investigators will provide the participants with dialysate HCO3 concentration of 38-40 mEq/L (as we usually provide to patients)."
89188318|NCT04070690|Other|Control-Intervention group|"In this group, the participants will receive control for 2 months first, followed by a wash-out period of 1 month and intervention for 2 months.~In the control period, the investigators will provide the participants with dialysate HCO3 concentration of 38-40 mEq/L (as we usually provide to patients).~In the intervention period, the investigators will provide the participants with lower dialysate HCO3 concentrations. (dialysate HCO3 to 28 mmol/L for half of the HD session and 30 to the second half of their HD session.) Besides, the investigators will give the participants with pre-HD HCO3<22 mEq/L oral Na-bicarbonate 650 mg 1#-2# three times a day as supplements."
89188319|NCT03086850|Experimental|Pedometer|Standard recommendations on healthy habits and lifestyle plus daily recording of steeps with a pedometer
89188320|NCT03086850|Active Comparator|Conventional management|Treatment and follow-up according to conventional clinical practice (SEPAR guidelines), including standard recommendations on healthy habits and lifestyle.
89188321|NCT00710138|Active Comparator|1|400 µg hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma) given as a single intramuscular injection. The syringe is covered so it is impossible to see whether or not it contains any substance.
89188322|NCT00710138|Sham Comparator|2|"The controls receive an intramuscular injection, however, it is only an introduction of the needle into the muscle, but no injections are given. The syringe is covered so it is impossible to see whether or not it contains any substance."
89188323|NCT04072172|Experimental|Female with leg spider veins|Females at the age of 20 to 45 not known diabetics or hypertensive complaining of leg spider veins.
89188324|NCT00580034|Experimental|Campath Purged Non-myeloablative ASCT|Campath Purged Non-myeloablative Allo Stem Cell Transplant (ASCT) in lymphoma, myeloma, or marrow failure: leukemia or myelodysplasia; and solid tumors
89188325|NCT00580034|Other|Donor Apheresis|"Donor must be a sibling, half sibling, parent, child or first cousin familial relationship and 3-5/6 Human Leukocyte Antigen matched related to subject. They must not have any medical condition which would make apheresis and G-CSF administration more than a minimal risk, and should have the following:~Adequate cardiac function by history and physical examination~bilirubin and hepatic transaminases < 2.5 x upper limit of normal~normal hematologic parameters Females should have a negative serum pregnancy test."
89188326|NCT00710216|Active Comparator|A|
89188327|NCT00710216|Experimental|B|
89188328|NCT02575820||RBC_old|shelf life of red blood cells of 15 or higher days
89188329|NCT02575820||RBC_new|shelf life of red blood cells 14 or lower days
89188330|NCT02577692|Experimental|Oxygen|Day 1: breathing of 100% oxygen; Day 2: ambient air breathing
89188331|NCT02577692|Experimental|Ambient|Day 1: breathing of 100% oxygen; Day 2: ambient air breathing
89397679|NCT03403231|Experimental|Arm 4: Urgency frame and social norm strategies|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with both the urgency frame and social norm messaging strategies.
88873786|NCT05077566|No Intervention|No intervention|No intervention
89188332|NCT00710372|Experimental|1|CYT006-AngQb
89188333|NCT00710372|Placebo Comparator|2|
89188334|NCT00710450||1|Allergic Asthma
89188335|NCT00710450||2|Allergic Rhinitis
89188336|NCT00773513|Active Comparator|Erythropoiesis Stimulating Agents|Participants will receive reference ESA according to approved label. The approved reference ESA compounds in the study will be darbepoetin alfa, epoetin alfa and epoetin beta.
89397680|NCT03403231|Experimental|Arm 5: Implementation Intentions and Urgency Frame|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with both the implementation intentions and urgency frame messaging strategies.
89397681|NCT03403231|Experimental|Arm 6: Implementation Intentions and Social Norm|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with both the implementation intentions and social norm messaging strategies.
89397682|NCT03403231|Experimental|Arm 7: Implementation Intentions, Urgency Frame & Social Norm|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with the implementation intentions, urgency frame, and social norm messaging strategies.
88873787|NCT04993326|Other|Intervention|"emPOWERed to Change~Online Courses:~4 Critical Step to Manage Diabetes modules~Step 1 Learn about diabetes~Step 2 Know your diabetes ABCs~Step 3 Learn how to live with diabetes~Step 4 Get routine care to stay healthy Diabetes + COVID-19 Protection and Prevention modules~Introduction to understanding COVID-19 and the risks specific to T2DM~Learn preventive and protective measures to avoid COVID-19~COVID-19 Vaccine education and Discussion guide~Community resource guide to access COVID-19 testing and vaccination Stress Management modules~Understanding of the relationship between diabetes and stress~Learn stress management techniques for diabetes Ongoing Program Support: Motivation for participation, medication adherence, accountability and peer-to-peer interaction and support (bi-weekly text messages & private and closed Facebook community support group with peers and professionals)"
88873788|NCT04993326|No Intervention|Control|Usual Standard of Care as deemed by participants provider(s)
88873789|NCT04930770|Experimental|Renal/renopancreatic transplant's patients with a verified seronegativity|
88873790|NCT04922658|Experimental|Surufatinib|
88873791|NCT04922658|Experimental|Surufatinib plus Vinorelbine|
88873792|NCT04915404|Experimental|pK Assessment of Berubicin and its active metabolite|The first 18 patients will undergo a pK assessment of Berubicin and it's active metabolite Berubicinol during the dosing days of the first two cycles. After 18 patients are done n intern analysis will new performed.
88873793|NCT04879602|Experimental|Bronchoscopy group|patients receive suction before extubation by bronchoscopy in PACU
88873794|NCT04879602|No Intervention|Control group|patients receive routine ordinary suction in PACU
88873795|NCT04794660|Active Comparator|Arm 1|In this arm, HPV-positive women will undergo a Visual Inspection with Acetic Acid (VIA) triage test followed by biopsies. Treatment by thermal ablation (or cryotherapy in South Africa) will be applied to VIA positive women eligible for ablative treatment. Non eligible women will be referred to colposcopy.
88873796|NCT04794660|Active Comparator|Arm 2|In this arm, HPV positive women will get biopsies and receive an ablative treatment by thermal ablation (or cryotherapy in South Africa) if they are eligible to ablative treatment. Non eligible women will be referred to colposcopy
88873797|NCT04660968|Experimental|Dyadic Health Behaviour Change Intervention|The dyadic health behaviour change intervention is a 10 sessions program provided over 16 weeks. It includes nutritional, physical activity and sedentary related information, as well as couples-based adaptation of motivational interviewing, self-monitoring, goals setting, stimulus control, problem-solving, and relapse prevention as well as specific strategies to support their partner's autonomy and intrinsic motivation.
88873798|NCT04660968|Active Comparator|Dyadic nutrition counselling intervention|The couples-based nutrition counselling intervention is a 10 sessions program provided over 16 weeks. Topics are based on Dietitians of Canada's Practice-based Evidence in Nutrition discussions. Participants are also encouraged to meet the current physical activity recommendations. Both members of the couples are seen at the same, but no intervention target specifically the behaviour change process or the romantic relationship.
88873799|NCT04438902|Experimental|osimertinib combined with anlotinib|
88873800|NCT04329390||anticoagulant|Subjects of both sexes, aged 18 years or older, requiring the prescription of, or already on oral anticoagulant treatment, will be eligible for the study, irrespective of the index event, of the intended treatment duration, and the type of drug used.
88873801|NCT04326036|Experimental|Lipoaspiration|Closed sterile, disposable microcannula of small volume adipose tissue, including the stromal vascular fraction (SVF) (cells and stromal tissue
89188337|NCT00773513|Experimental|Methoxy Polyethylene Glycol-Epoetin Beta|Participants not currently being treated with an ESA will receive methoxy polyethylene glycol-epoetin beta iv or sc once every 2 weeks for correction of renal anemia (target Hb 10-12 g/dL). Once corrected and in participants currently being treated with an ESA, methoxy polyethylene glycol-epoetin beta will be administered once monthly.
89397683|NCT03403231|Experimental|Arm 8: Implementation Intentions|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with the implementation intentions messaging strategy.
89397684|NCT03403231|Experimental|Arm 9: Preference Checklists and Urgency Frame|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with both the preference checklists and urgency frame messaging strategies.
88873802|NCT04326036|Experimental|Isolation & Concentration of cSVF|Isolation & Concentration of cellular stromal vascular fraction (cSVF) using Healeon Centricyte 1000 Centrifuge, incubator and shaker plate with sterile Liberase enzyme (Roche Medical) per manufacturer protocols
88873803|NCT04326036|Experimental|Delivery cSVF via Intravenous|cSVF from Arm 2 is suspended in a 250 cc of sterile Normal Saline IV solution and deployed though 150 micron in-line filtration and intravenous route over 30-60 minute timeframe
89397685|NCT03403231|Experimental|Arm 10: Preference Checklists and Social Norms|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with both the preference checklists and social norm messaging strategies.
89397686|NCT03403231|Experimental|Arm 11: Preference Checklists, Urgency Frame & Social Norm|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with the preference checklists, urgency frame, and social norm messaging strategies.
89188338|NCT00710528|Experimental|one arm|
89397687|NCT03403231|Experimental|Arm 12: Preference Checklists|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with the preference checklists messaging strategy.
88873804|NCT04326036|Other|Liberase TM|Use of sterile Liberase TM enzyme to allow cSVF separation and isolation
89188339|NCT04070612||children with autoimmune haemolytic anemia|A blood sample of 2 times 2 to 5 ml additional maximum
89188340|NCT04070612||Children with Evans syndrome|A blood sample of 2 times 2 to 5 ml additional maximum
89397688|NCT03403231|Experimental|Arm 13: Tailored Aspirations and Urgency Frame|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with both the tailored aspirations and urgency frame messaging strategies.
89397689|NCT03403231|Experimental|Arm 14: Tailored Aspirations and Social Norm|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with both the tailored aspirations and social norm messaging strategies.
89397690|NCT03403231|Experimental|Arm 15: Tailored Aspirations, Urgency Frame & Social Norm|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with the tailored aspirations, urgency frame, and social norm messaging strategies.
89397691|NCT03403231|Experimental|Arm 16: Tailored Aspirations|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with the tailored aspirations messaging strategy.
89397692|NCT03347292|Experimental|Dose escalation|The regorafenib starting dose will be 120 mg q.d.(once daily) 3 weeks on / 1 week off in combination with the recommended dose of pembrolizumab (200 mg Q3W). Pembrolizumab dose will not be escalated or de-escalated.
89397693|NCT03347292|Experimental|Dose expansion|Dose expansion cohorts will continue to be expanded until the sample size of 30-35 patients per cohort is reached.
89397694|NCT03269526|Experimental|EGFR BATs after standard of care chemo|Subjects will undergo apheresis to collect peripheral blood mononuclear cells. Cells will be cultured for up to 2 weeks before activated T-cells will be harvested, armed with EGFR Biarmed activated T-cells, washed to remove unbound EGFRBi, and cryopreserved. Subjects will then receive one dose of standard of care chemotherapy prior to receiving EGFR BATs.
89397695|NCT03182426|Experimental|Treated arm|"For participants assigned to the treated arm, they will follow study regime below: Intervention treatment will last from Day 0 up to Month 24.~Day 0: Subjects will receive alemtuzumab (30mg iv single dose); anakinra (100 mg sc.); etanercept (50 mg sc.) and liraglutide (0.6 mg sc.).~Day 1: Subjects will receive plerixafor (0.24 mg/kg/day) sc. to mobilize CD34+ stem cells to peripheral blood.~Day 1: Continuing with anakinra 100mg sc. daily for 12 month; etanercept 50mg sc. twice weekly for first 3 months, and 50mg sc. weekly for another 9 months; liraglutide 0.6 mg sc. daily for 7 days, then 1.2 mg sc. daily (or up to 1.8mg daily) as tolerated for 24 months."
89397696|NCT03182426|Experimental|Control arm|"For participant assigned to the control arm, they will be monitored and tested for the first 12 months, and receive intervention treatment from Month 12 up to Month 24.~Month 12: Subjects will receive alemtuzumab (30mg iv single dose); anakinra (100 mg sc.); etanercept (50 mg sc.) and liraglutide (0.6 mg sc.).~Month 12 + 1 day: Subjects will receive plerixafor (0.24 mg/kg/day) sc.. Month 12 + 1 day: Continuing with anakinra 100mg sc. daily for 12 month; etanercept 50mg sc. twice weekly for first 3 months, and 50mg sc. weekly for another 9 months; liraglutide 0.6 mg sc. daily for 7 days, then 1.2 mg sc. daily (or up to 1.8mg daily) as tolerated for 12 months."
89397697|NCT03102593|Experimental|ARGX-113 Dose A + SoC|Patients will be randomized in a 1:1:1 ratio to ARGX-113 (Dose A or Dose B) or placebo
89397698|NCT03102593|Experimental|ARGX-113 Dose B +SoC|Patients will be randomized in a 1:1:1 ratio to ARGX-113 (Dose A or Dose B) or placebo
89397699|NCT03102593|Placebo Comparator|Placebo + SoC|Patients will be randomized in a 1:1:1 ratio to ARGX-113 (Dose A or Dose B) or placebo
89397700|NCT03078946|Active Comparator|Dexmedetomidine Group (N=30)|
89397701|NCT03078946|Active Comparator|Morphine with Midazolam (N=30)|
89397702|NCT02915601|Experimental|Sodium Bicarbonate|Participants assigned to oral sodium bicarbonate will receive 0.5 mEq/kg-lean body weight (LBW)/day for the entire 12 months. Participants will take ½ the daily dose in the morning and the other ½ in the evening. The number of capsules will be rounded to the nearest whole capsule. To reduce pill burden and increase compliance the maximum number of pills per day will be six.
89397703|NCT02915601|Placebo Comparator|Placebo|Subjects randomly assigned to placebo will take the same number of capsules as if they were assigned to receive 0.5 mEq/kg-LBW/day of sodium bicarbonate. Participants will take ½ the daily dose in the morning and the other ½ in the evening. The number of capsules will be rounded to the nearest whole capsule. To reduce pill burden and increase compliance the maximum number of pills per day will be six.
89397704|NCT02878473|Experimental|Liver transplantation|The intervention will consist of liver transplantation
89397705|NCT02760238||Patients with a diagnosis of MPN|"Patients with a myeloproliferative neoplasm (MPN) diagnosis:~Atypical chronic myeloid leukemia (aCML), chronic eosinophilic leukemia-not otherwise specified (CEL NOS), chronic myelomonocytic leukemia (CMML), chronic neutrophilic leukemia (CNL), polycythemia vera (PV), essential thrombocythemia (ET), JMML, mastocytosis, MPN unclassifiable, myeloproliferative neoplasm/myelodysplastic syndrome unclassifiable (MPN/MDS unclassifiable), primary myelofibrosis (PMF), post-ET MF, post-PV MF, or (refractory anemia with ringed sideroblasts associated with marked thrombocytosis) RARS-T"
89397706|NCT02743741|Experimental|Lutetium-177 Octreotate|Lutetium-177 Octreotate 200 mCi (7.4 GBq) by IV for 18-30 weeks
89397707|NCT02694978|Experimental|Ferumoxytol|Participants received an IV infusion of ferumoxytol 510 milligram (mg) diluted (17 milliliter [mL]) in 233 mL 0.9% sodium chloride injection, United States Pharmacopeia (USP) (normal saline) (final volume 250 mL) over at least 15 minutes with a second dose 7-8 days after the first dose, for a total cumulative dose of 1.020 g.
89397708|NCT02694978|Active Comparator|FCM|Participants received an IV infusion of FCM 750 mg diluted (15 mL) in 235 mL 0.9% sodium chloride injection, USP (normal saline) (final volume 250 mL) over at least 15 minutes with a second dose 7-8 days after the first dose, for a total cumulative dose of 1.500 g.
89397709|NCT02663518|Experimental|PF-07901800 (TTI-621) Escalation Phase - R/R Lymphoma|The Escalation Phase will include multiple doses of PF-07901800 (TTI-621)
89397710|NCT02663518|Experimental|Indolent B-Cell Lymphoma|Monotherapy expansion cohort with PF-07901800 (TTI-621)
89397711|NCT02663518|Experimental|Aggressive B-Cell Lymphoma|Monotherapy expansion cohort with PF-07901800 (TTI-621)
89397712|NCT02663518|Experimental|T-Cell Lymphoma|Monotherapy expansion cohort with PF-07901800 (TTI-621)
89397713|NCT02663518|Experimental|Hodgkin Lymphoma|Monotherapy expansion cohort with PF-07901800 (TTI-621)
88873805|NCT04326036|Other|Sterile Normal Saline|250 cc of sterile Normal Saline for Intravenous with sterile 150 micron in-line filtration for suspension of the concentrated cSVF and deployment IV
89397714|NCT02663518|Experimental|Chronic Lymphocytic Leukemia|Monotherapy expansion cohort with PF-07901800 (TTI-621)
89397715|NCT02663518|Experimental|Multiple Myeloma|Monotherapy expansion cohort with PF-07901800 (TTI-621)
89397716|NCT02663518|Experimental|Acute Myeloid Leukemia|Monotherapy expansion cohort with PF-07901800 (TTI-621)
88873806|NCT04303572|Experimental|Eloctate ITI plus Emicizumab|Arm A: Eloctate 100 IU/kg every other day by intravenous infusion plus Emicizumab 1.5 mg/kg subcutaneously (following 3 mg/kg/wk x 4 induction) in children and adults with severe hemophilia A and anti-FVIII inhibitor, continued up to 48 weeks.
88873807|NCT04303572|Active Comparator|Eloctate ITI|Arm B: Eloctate 100 IU/kg every other day by intravenous infusion in children and adults with severe hemophilia A and anti-FVIII inhibitor, continued up to 48 weeks.
88873808|NCT04177602|Experimental|Trifluridine/tipiracil based radiotherapy|Trifluridine/tipiracil based chemoradiotherapy (CRT)
88873809|NCT04177602|Active Comparator|standard calibration arm (internal control)|capecitabine based chemoradiotherapy
88873810|NCT04135482||CD|patients with severe crohn's disease
88873811|NCT03849066||Cross-Sectional PRSA|This will be a cross-sectional analysis of children with neurological impairment and polypharmacy.
88873812|NCT03816618|Experimental|CONTROL|CONTROL GROUP
88873813|NCT03816618|Experimental|TREATMENT1|TREATMENT GROUP 1
88873814|NCT03816618|Experimental|TREATMENT2|TREATMENT GROUP 2
88873815|NCT03816618|Experimental|TREATMENT3|TREATMENT GROUP 3
88873816|NCT03770598|Active Comparator|Distressed|Study participants who do indicate distress or who do meet criteria for depression or anxiety will be randomized to receive either treatment as usual (referral to Psychiatry or Psychology for evaluation and further treatment) or team based care model.
88873817|NCT03770598|Active Comparator|Non-Distressed|Study participants who do not indicate distress or who do not meet criteria for depression or anxiety will be randomize to monitoring only or to receive psycho-education regarding subjects that when used can promote wellness.
88873818|NCT03692208|Experimental|Intervention|Patients that are enrolled in the intervention arm will receive an email message via MyChart (University of Chicago patient portal) to complete an initial questionnaire. Completion of the questionnaire will be required prior to initiating risk factor tracking and opening the portal to requests for care management support. A study team member (diabetes nurse educator) will contact the patient, if requested via the survey, to initiate telephonic care management or links to additional support services. Upon completion the study, all patients will receive a post-survey via MyChart.
88873819|NCT03692208|Active Comparator|Delayed Intervention/Control|Patients enrolled in the delayed intervention arm will receive usual care for the first 6 months, and then will receive the survey and intervention as stated above.
88873820|NCT03662646||IBD patients|
88873821|NCT03662646||Healthy controls|
88873822|NCT03590574|Experimental|AUTO4|Relapsed or refractory T cell non-Hodgkin Lymphoma patients
88873823|NCT03551730|Experimental|Module 3 (210 mg bolus) original|210 mg PRT064445 given as a single IV bolus
88873824|NCT03551730|Experimental|Module 3 (420 mg bolus) original|420 mg PRT064445 given as a single IV bolus
88873825|NCT03551730|Experimental|Module 3 (210 mg) lyophilized|210 mg PRT064445 (lyophilized formulation) given as a single IV bolus
88873826|NCT03551730|Placebo Comparator|Module 3 Placebo|Placebo administered intravenously (IV) as a bolus.
88873827|NCT03491592|Experimental|Enhanced Physical Activity Intervention|A data driven enhanced Pasos Hacia La Salud intervention based on results and participant feedback from the motivationally-tailored, Spanish Language, Internet-based Physical Activity intervention in the parent study.
89397717|NCT02663518|Experimental|Myelodysplastic Syndrome|Monotherapy expansion cohort with PF-07901800 (TTI-621)
88873828|NCT03491592|Active Comparator|Original Physical Activity Intervention|The original Internet-based program is a computer expert system-driven, individually tailored Spanish language intervention, guided by Social Cognitive Theory (SCT) and the Transtheoretical Model (TTM).
88873829|NCT03366480|Experimental|Endometrial cancer|ABTL0812 (starting 1,300 mg tid orally) in combination with paclitaxel and carboplatin will be given to patients with advanced endometrial cancer, up to 12 months from initiation.
88873830|NCT03366480|Experimental|Squamous non-small cell lung cancer|ABTL0812 (starting 1,300 mg tid orally) in combination with paclitaxel and carboplatin will be given to patients with squamous NSCLC, up to 12 months from initiation.
88873831|NCT03267108|Active Comparator|Inhaled Nitric Oxide (iNO)|Pulsed inhaled iNO 45 mcg/kg Ideal Body Weight (IBW)/hour (hr)
88873832|NCT03267108|Placebo Comparator|Placebo|Pulsed inhaled N2, 99.999% gas
88873833|NCT03267108|Other|Open Label Extension|Pulsed inhaled iNO 45 mcg/kg IBW/hr
88873834|NCT03239808|Experimental|Experimental group|76 patients who start RRT with the incremental HD regimen.
88873835|NCT03239808|Active Comparator|Control group|76 patients who start RRT with the conventional HD (3 sessions per week)
88873836|NCT02923362||Laparoscopic Fundoplication Group|This group of patients are surgical candidates based on preoperative testing results for laparoscopic fundoplication antireflux procedure and possible hiatal hernia repair.
88873837|NCT02923362||LINX Antireflux Device Group|This group of patients are surgical candidates based on preoperative testing results for the laparoscopic LINX antireflux device placement and possible hiatal hernia repair.
88873838|NCT02890758|Experimental|Cytokine Arm|Two infusions of Natural Killer (NK) cells and ALT803
88873839|NCT02890758|Active Comparator|No Cytokine Arm|Two infusions of Natural Killer (NK) Cells
88873840|NCT02683200|Experimental|Treatment (MRI-guided Tri-60Co teletherapy SBRT)|Patients undergo MRI-guided Tri-60Co teletherapy SBRT 3-5 fractions over 1-2 weeks.
88873841|NCT02534844|Experimental|Parts A/B: Sham Control|Participants receive no study drug
88873842|NCT02534844|Other|Parts A/B: Adrabetadex|Participants receive adrabetadex
88873843|NCT02534376|Experimental|Treatment|Vytorin (ezetimibe 10mg-simvastatin 40mg)
88873844|NCT02103348||Mild-to-Moderate Asthma|Those with mild-to-moderate persistent asthma as defined by the NAEPP EPR-3 guidelines.
89188341|NCT04070612||Children with Immune thrombocytopenic purpura|A blood sample of 2 times 2 to 5 ml additional maximum
89188342|NCT00711074|Experimental|1|
89397718|NCT02663518|Experimental|Myeloproliferative Neoplasms|Monotherapy expansion cohort with PF-07901800 (TTI-621)
89397719|NCT02663518|Experimental|Small Cell Lung Cancer|Monotherapy expansion cohort with PF-07901800 (TTI-621)
89397720|NCT02663518|Experimental|Rituximab Combination|Combination therapy expansion cohort with PF-07901800 (TTI-621) plus Rituximab for CD20 positive malignancies
88873845|NCT02103348||Severe Asthma|"Major Criteria: (1 required)~Treatment with oral corticosteroids for at least 6 of the previous 12 months~Treatment with high-dose inhaled corticosteroids for at least 10 of the previous 12 months~Minor Criteria: (2 required)~Daily treatment with an asthma controller medication in addition to inhaled, or~Asthma symptoms requiring short-acting bronchodilator use on a daily or near daily basis (defined as at least 5 of 7 days), or~Persistent airway obstruction with baseline FEV1 <80% predicted, or~≥ 1 urgent visits for asthma in the previous 12 months, or~≥ 3 systemic corticosteroid bursts in the previous 12 months, or~Prompt deterioration with a reduction in oral or inhaled corticosteroid dose, or~A near-fatal asthma event (i.e., intubation) in the past."
88873846|NCT02103348||Healthy Controls|Those without asthma or other chronic lung disease.
88873847|NCT02065596|Experimental|Immunomodulation with Fludarabine prior to HSCT|Fludarabine given beginning at 25mgm/m2 three times per day. Patients may be escalated up to 25mgm/m2 five times per day depending on dose-limiting toxicity
88873848|NCT01818492|Experimental|NI-0501|NI-0501 administered by IV infusion at a starting dose of 1 mg/kg.
88873849|NCT01239030|Active Comparator|10 mg|Biphentin Methylphenidate Hydrochloride Extended Release Capsules 10 mg
88873850|NCT01239030|Active Comparator|15 mg|Biphentin Methylphenidate Hydrochloride Extended Release Capsules 15 mg
88873851|NCT01239030|Active Comparator|20 mg|Biphentin Methylphenidate Hydrochloride Extended Release Capsules 20 mg
88873852|NCT01239030|Active Comparator|40 mg|Biphentin Methylphenidate Hydrochloride Extended Release Capsules 40 mg
88873853|NCT01239030|Placebo Comparator|Placebo|Placebo capsules
88873854|NCT01239030|Experimental|Methylphenidate HCl ER Capsules (10, 15, 20, 40, 50 or 60 mg)|Biphentin Methylphenidate Hydrochloride Extended Release Capsules (10, 15, 20, 40, 50 or 60 mg) - Open Label Phase
88873855|NCT01129050|Experimental|Low-dose Flaxseed Oil|2.2 g ALA (alpha-linolenic acid) per day
88873856|NCT01129050|Experimental|High-dose Flaxseed Oil|6.6 g ALA (alpha-linolenic acid) per day
88873857|NCT01129050|Experimental|Low-dose Fish Oil|1.2 g EPA+DHA (700 mg EPA and 500 mg DHA) per day
88873858|NCT01129050|Experimental|High-dose Fish Oil|3.6 g EPA+DHA (2.1 g EPA and 1.5 g DHA) per day
88873859|NCT01129050|Placebo Comparator|Placebo|4 g or 6 g soybean oil per day
88873860|NCT01086540|Experimental|Rituximab+PAH SOC|"Rituximab (1000 mg) will be administered as 2 intravenous infusions given 2 weeks apart.~Concurrent stable-dose Pulmonary Arterial Hypertension (PAH) medical therapy will be continued/managed as per standard of care (PAH SOC)."
88873861|NCT01086540|Placebo Comparator|Placebo + PAH SOC|"Placebo will be administered as 2 intravenous infusions given 2 weeks apart.~Concurrent stable-dose Pulmonary Arterial Hypertension (PAH) medical therapy will be continued/managed as per standard of care (PAH SOC)."
88873862|NCT00594750||Asthma|People who have been diagnosed with Asthma
88873863|NCT01959048|Experimental|fecal microbiota transplant|fecal microbiota transplantation
88873864|NCT01962558|Experimental|VNS Treatment|Vagus nerve stimulation and tones are used 2.5 hours per day for a 6-week period.
88873865|NCT01962558|Sham Comparator|VNS Control|Vagus nerve stimulation and tones are given daily over a 2.5 hour period, but not in the same way as the experimental group, and in such a way that it is believed to be ineffective but still provide both VNS and tones so that blinding is maintained.
88873866|NCT01962714|Experimental|Loving-Kindness Meditation|A 12-week duration, 90-minute per session Loving-Kindness Meditation (LKM) course, taught in groups of 10 participants.
88873867|NCT01962714|Active Comparator|Cognitive Processing Therapy - Cognitive Only|A 12-week duration, 90-minute per session Cognitive Processing Therapy (CPT) course, taught in groups of 10 participants.
88873868|NCT01962870|Placebo Comparator|Placebo|Placebo Nasal Spray
88873869|NCT01962870|Active Comparator|Vasopressin|Vasopressin Nasal Spray
88873870|NCT01965288|Experimental|comfilcon A|Each subject randomized to wear the test lens (comfilcon A) or the control lens (lotrafilcon B) for one month of daily wear before repeating the schedule for the second pair without a washout period.
88873871|NCT01965288|Active Comparator|lotrafilcon B|Each subject randomized to wear the test lens (comfilcon A) or the control lens (lotrafilcon B) for one month of daily wear before repeating the schedule for the second pair without a washout period.
88873872|NCT01965366|Active Comparator|Dexamethasone + VRE|0.5 mg DEX + virtual reality exposure therapy
88873873|NCT01965366|Placebo Comparator|Placebo + VRE|Placebo + virtual reality exposure therapy
88873874|NCT01965756|Experimental|Metformin, Then Placebo|Participants first received metformin for 8 weeks, according to the following dosing schedule: 500 mg by mouth daily for 1 week, then daily dose (in divided doses) increased by 500 mg per week until a maximum of 2000 mg/d (1000mg twice daily) was reached. After 8 weeks, subjects were switched to matching placebo for an additional 8 weeks.
88873875|NCT01965756|Experimental|Placebo, Then Metformin|Participants first received placebo for 8 weeks. After 8 weeks, subjects were switched to metformin, according to the following dosing schedule: 500 mg by mouth daily for 1 week, then daily dose (in divided doses) increased by 500 mg per week until a maximum of 2000 mg/d (1000mg twice daily) was reached.
88873876|NCT01966380|Experimental|Device, dressing|Intervention: Device, Leia dressing
88873877|NCT01966380|Active Comparator|Dressing , device|Intervention: Device: Hydroactive surgical dressing
88873878|NCT01966458|Experimental|HeartWare® VAS (HVAD)|Implant of HeartWare® Ventricular Assist System
88873879|NCT01966458|Active Comparator|Control LVAD|Implant of FDA-approved LVAD approved for destination therapy
88873880|NCT01966770|Active Comparator|Pair 1 (ocufilcon D / ocufilcon D)|Randomized to contra lateral lens pair 1 (ocufilcon D hydrogel / ocufilcon D hydrogel)
88873881|NCT01966770|Active Comparator|Pair 2 (ocufilcon D / enfilcon A)|Randomized to contra lateral lens pair 2 (ocufilcon D hydrogel / enfilcon A silicone)
88873882|NCT01966770|Active Comparator|Pair 3 (ocufilcon D / comfilcon A)|Randomized to contra lateral lens pair 3 (ocufilcon D hydrogel / comfilcon A silicone)
88873883|NCT01966770|Active Comparator|Pair 4 (methafilcon A / methafilcon A)|Randomized to contra lateral lens pair 4 (methafilcon A hydrogel sphere / methafilcon A hydrogel asphere)
89397721|NCT02663518|Experimental|Nivolumab Combination|Combination therapy expansion cohort with PF-07901800 (TTI-621) plus Nivolumab for Hodgkin Lymphoma
89397722|NCT02663518|Experimental|Cutaneous T-Cell Lymphoma (CTCL)|Monotherapy expansion cohort with PF-07901800 (TTI-621)
88873884|NCT01966770|Active Comparator|Pair 5 (methafilcon A / comfilcon A)|Randomized to contra lateral lens pair 5 (methafilcon A hydrogel / comfilcon A silicone)
88873885|NCT01966770|Active Comparator|Pair 6 (omafilcon A / comfilcon A)|Randomized to contra lateral lens pair 6 (omafilcon A hydrogel / comfilcon A silicone)
88873886|NCT01966926|Experimental|Daily Weight Tracking|weighing frequency instructions and tips
88873887|NCT01966926|Experimental|Weekly Weight Tracking|weighing frequency instructions and tips
88873888|NCT01967784|Experimental|Study Group|Participants age 9 to 17 years will receive a dose of Quadrivalent Influenza Vaccine
88873889|NCT01967862|Experimental|Diagnostic (CT, bone scan, WB/axial MRI, F18 NaF PET/CT)|Patients first undergo CT scan and bone scan. Patients with negative results from the CT and bone scans then undergo WB MRI scan using diffusion-weighted MRI, axial MRI scan using 3-Tesla MRI, and fluorine F 18 sodium fluoride PET/CT scan.
88873890|NCT01974102|Active Comparator|lifestyle|Attentional control group will receive weekly meeting to view relaxing video and facilitate discussion along with counseling on nutrition and physical activity for 8 weeks.
88873891|NCT01974102|Experimental|therapy|Active group will receive weekly mindfulness based parenting stress reduction (PMH) plus nutrition and physical activity counseling for 8 weeks.
88873892|NCT01975974||Ultrasound|Ultrasound guided peripheral vascular access
88873893|NCT01976988|Active Comparator|Post-op Heparin|Postoperative venous thromboprophylaxis (Control Arm/current standard practice: subcutaneous Heparin 5000 units started 23 hours after the end of surgery and continued every 8 hours for the remainder of the patients hospital course
88873894|NCT01976988|Experimental|Pre-op Heparin|Treatment arm: subcutaneous Heparin 5000 Units given in the preoperative area one hour prior to surgery and continued every 8 hours for the remainder of the patients hospital course
88873895|NCT01978314|Experimental|Cohort 1|eGFR renal function ≥60 mL/min for normal function 75 mg / 6mL VFI™ and 5mL of Iohexol
88873896|NCT01978314|Experimental|Cohort 2|eGFR renal function 30-59 mL/min for stage 3, moderate CKD 75 mg / 6mL VFI™ and 5mL of Iohexol
88873897|NCT01978314|Experimental|Cohort 3|eGFR renal function 15-29 mL/min for stage 4, severe CKD 75 mg / 6mL VFI™ and 5mL of Iohexol
88873898|NCT01978314|Experimental|Cohort 4|a diagnosis of either RIFLE stage I or Acute Kidney Injury Network (AKIN) stage 2 AKI 75 mg / 6mL VFI™ and 5mL of Iohexol
88873899|NCT01978314|Experimental|Cohort 5|eGFR renal function ≥60 mL/min for normal function 75 mg / 6mL VFI™ and 5mL of Iohexol
88873900|NCT01980654|Experimental|Main Study Arm 1|Subjects enrolled into this arm will receive ibrutinib continuously until disease progression or unacceptable toxicity. In addition, subjects will receive rituximab once weekly for four doses for the first four weeks of study treatment.
88873901|NCT01980654|Experimental|Exploratory Study Arm 2|Subjects enrolled into this arm will receive ibrutinib continuously as a single agent for the first eight weeks, then ibrutinib concurrently with rituximab once weekly for four doses. After the rituximab treatment, subjects will receive ibrutinib continuously until disease progression or unacceptable toxicity.
88873902|NCT01981590|Experimental|All enrolled patients|All enrolled patients that underwent a scheduled cardiac catheterization involving an atrial fibrillation (AF) ablation procedure as per clinical practice
89397723|NCT02663518|Experimental|Peripheral T-Cell Lymphoma (PTCL)|Monotherapy expansion cohort with PF-07901800 (TTI-621)
88873903|NCT01983228|No Intervention|Arm 1: Usual Care|Participants randomized to the usual care control condition will receive pedometers and an informational brochure.
88873904|NCT01983228|Experimental|Arm 2: Intervention Group|Participants assigned to the intervention group will receive personalized recruitment materials, including a letter and brochure describing the program and the benefits of walking for pain. They will also receive pedometers. Participants will complete 6 sessions of telephone coaching over a 10-12 week period, using a patient workbook with visual aids (e.g., diagram of the pain/inactivity cycle) and worksheets that they will complete during the counseling sessions. Participants are expected to receive approximately 180 minutes of total therapist time during the study.
88873905|NCT01984398|Experimental|12.5 mg Androxal (formulations A and B)|12.5 mg Androxal formulation A and 12.5 mg Androxal formulation B, a single dose of each formulation
88873906|NCT01984398|Experimental|25 mg Androxal (formulations A and B)|25 mg Androxal formulation A and 12.5 mg Androxal formulation B, a single dose of each formulation
88873907|NCT01985958|Experimental|Single arm|In this trial, we will deliver low-dose (8Gy in a single fraction) radiotherapy (SBRT or any other acceptable delivery method as determined by the treating physician) for palliation of symptoms in patients in whom it is clinically indicated. This dose is far lower than what has been used in the definitive settings described above. This is a safe dose, and is entirely consistent with the dose range used for routine palliation. Therefore, this trial does not involve an experimental intervention; the research aspect of this protocol is the evaluation of the immune response to clinically indicated palliative radiotherapy.
89397724|NCT02663518|Experimental|Part 4: Cutaneous T-Cell Lymphoma (CTCL)|Monotherapy expansion Part 4 (Dose Optimization) cohort with PF-07901800 (TTI-621)
88873908|NCT01987752||Combigan® Ophthalmic Solution|Patients treated with Combigan® Ophthalmic Solution as per local standard of care in clinical practice.
88873909|NCT01988376|Experimental|Women with cervical cancer receive Surepath for screening|Women will receive Surepath as a tool for screening the recurrence of cervical cancer.
89397725|NCT02563002|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 21-day cycle (Q3W) for up to 35 treatments (approximately 2 years). Participants that have stopped the initial course of pembrolizumab and have stable disease but progress after discontinuation can initiate a second course of pembrolizumab for up to 17 cycles (approximately 1 year additional).
89188343|NCT00711152|Experimental|JADE with CHW|Patients will be enrolled into JADE program and will undergo annual comprehensive assessment (CA) with personalized JADE report with additional support by the CHW.
88873910|NCT01988376|Active Comparator|Women receive conventional Pap smear for screening|Women who will receive conventional Pap smear for screening
89188344|NCT00711152|Active Comparator|JADE only|Patients will be enrolled into JADE program and undergo annual comprehensive assessment (CA) with personalized JADE report without additional support by the CHW.
89535485|NCT03077529|Experimental|Galacto-oligosaccharide|During this period subjects will receive 5.65 grams of Vivinal GOS supplements three times daily for four weeks
88873911|NCT01988922|Experimental|Ketamine arm- *1/*1|1.*1/*1- oral racemic ketamine 0.4 mg/kg
88873912|NCT01988922|Experimental|Ketamine arm - *1/*6|2. *1/*6- oral racemic ketamine 0.4 mg/kg
88873913|NCT01988922|Experimental|Ketamine arm - *6/*6|3. *6/*6- oral racemic ketamine 0.4 mg/kg
88873914|NCT01990794||Study Volunteers|"Volunteers (males and females) were instructed to take the cobalt dietary supplement in the morning according to the manufacturer's label, which suggested a serving of 1 mg cobalt (~2 mL) daily in water or juice as maintenance. Dietary supplementation lasted for approximately three months."
88873915|NCT01991808|Experimental|DCE-MRI|
88873916|NCT01992354|Experimental|Single Arm|Evaluation of PET MR device for image assessment and device performance
88873917|NCT01994538|Active Comparator|Longer (14 day) duration antimicrobial treatment|14 days of ciprofloxacin or trimethoprim/sulfamethoxazole
88873918|NCT01994538|Placebo Comparator|Shorter (7 day) duration antimicrobial treatment|7 days of ciprofloxacin or trimethoprim/sulfamethoxazole, followed by 7 days of placebo
88873919|NCT01996644|Experimental|Setraline|250 mg DCS (setraline) versus placebo plus exposure
88873920|NCT01996644|Placebo Comparator|placebo|Placebo group plus exposure
88873921|NCT01998360|Experimental|Unicirc with tissue adhesive|Excision of foreskin with Unicirc device and sealing wound with tissue adhesive
88873922|NCT01998360|Active Comparator|Surgical control|Surgical circumcision using forceps guided, dorsal slit, or sleeve method
88873923|NCT01998438|Experimental|small dose|10mg/kg tranexamic acid add in priming fluid, 10mg/kg single shot slowly when incision, followed by 2mg/(kg·h) infusion until the end of surgery
88873924|NCT01998438|Experimental|medium dose|20mg/kg tranexamic acid add in priming fluid, 20mg/kg single shot slowly when incision, followed by 4mg/(kg·h) infusion until the end of surgery
88873925|NCT01998438|Experimental|large dose|30mg/kg tranexamic acid add in priming fluid, 30mg/kg single shot slowly when incision, followed by 6mg/(kg·h) infusion until the end of surgery
88873926|NCT01999530|Experimental|Prazosin Hydrochloride|Gradual upward titration to 15mg/day (or highest dose tolerated) for approximately three weeks.
88873927|NCT01999920|Experimental|Vilazodone|Vilazodone treatment. Dosage will begin at 10mg/day and will be increased to 20mg/day after 1 week, and 40mg/day after two weeks (optional). Dosage can be held steady or lowered at any time during the study as clinically indicated in the event of adverse effects. Twelve weeks of treatment, total.
88873928|NCT01999920|Placebo Comparator|Placebo|Pill placebo.
88873929|NCT02000154|Experimental|SyB L-1101|
88873930|NCT02001714|Experimental|Group Behavioral Treatment|Participants will attend a group behavioral treatment class and follow-up visits.
88873931|NCT02001714|No Intervention|No Treatment|Subjects will not attend group behavioral treatment class.
88873932|NCT02002494||volunteers in different positions|"The following will be compared in the same volunteer:~Bilateral internal jugular venous flow in supine and prone position~Bilateral internal jugular venous flow in supine and park bench position~Bilateral internal jugular venous flow in prone and park bench"
88873933|NCT02002650|Experimental|Pre-ERCP group|Pre-ERCP rectal Indomethacin in all patients.
88873934|NCT02002650|Active Comparator|Post-ERCP group|Post-ERCP rectal Indomethacin in high-risk patients.
88873935|NCT02003352|Experimental|Functional Neurological Rehabilitation|Functional Neurological and physical/vestibular rehabilitation strategies
88873936|NCT02003508||Pre-school based vaccination program (not vaccine eligible)|Young (17-19 years) men who were not eligible for school based vaccination due to their age at the time of the programs roll out.
88873937|NCT02003508||Post-school based vaccination program (vaccine eligible)|Young men (17-19 years) who were eligible for school based vaccination due to their age at the time of the programs roll out.
88873938|NCT02004132|Experimental|Axiron|Axiron administered topically via metered dose pump to each underarm on Day 1
88873939|NCT02004288|Experimental|Lactobacillus reuteri Protectis DSM17938|One chewable tablet twice per day with L reuteri Protectis DSM 17938, 1x108 CFU/tablet (colony forming unit)
88873940|NCT02004288|Placebo Comparator|Placebo|One chewable tablet twice per day with placebo per day
88873941|NCT02004366|Experimental|Linagliptin In-hospital|Linagliptin once daily+ correction doses of aspart or lispro if needed
88873942|NCT02004366|Active Comparator|Basal Bolus In-hospital|Glargine once daily and rapid-acting insulin before meals + correction doses of aspart or lispro if needed
88873943|NCT02004366|Experimental|Linagliptin on discharge|Patients with admission A1C < 7% will be discharged on same pharmacologic regimen (oral agents, insulin therapy) or linagliptin 5 mg/day. If contraindication to oral anti-diabetics (OAD), discharge patient on linagliptin once daily.
88873944|NCT02004366|Experimental|Linagliptin+50%Glargine dose on d/c|Patients with admission HbA1c between 7% and 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 50% of daily hospital dose. Patient who did not receive glargine in the hospital, discharge on previous OAD + linagliptin once daily, and consider starting glargine at 0.15 unit/kg/day.
88873945|NCT02004366|Experimental|Linagliptin+80%Glargine dose on d/c|Patients with admission HbA1c ≥ 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 80% of daily hospital dose. Patient who did not receive glargine in the hospital, discharge on previous OAD + linagliptin once daily, and consider starting glargine at 0.15 unit/kg/day.
88873946|NCT02004990|Experimental|Single cleansing procedure of 10% povidone iodine cleansing|10% povidone iodine cleansing
88873947|NCT02005536|Experimental|Study Group|Participants will receive one booster dose of SP059 (IMOVAX POLIO®)
88873948|NCT02006160|Active Comparator|treatment|dalfampridine
89397726|NCT02563002|Active Comparator|Standard of Care (SOC)|Participants receive 1 of 6 possible standard chemotherapy regimens: mFOLFOX6, or mFOLFOX6+bevacizumab 5 mg/kg IV on Day 1 of each 2-week cycle, or mFOLFOX6+cetuximab 400 mg/m^2 IV over 2 hours then 250 mg/m^2 over 1 hour weekly in each 2-week cycle, or FOLFIRI, or FOLFIRI+bevacizumab 5 mg/kg IV on Day 1 of each 2-week cycle, or FOLFIRI+cetuximab 400 mg/m^2 IV over 2 hours then 250 mg/m^2 over 1 hour weekly in each 2-week cycle. Participants with documented disease progression following chemotherapy can crossover to receive pembrolizumab for up to 35 cycles (approximately 2 years). Participants that have stopped pembrolizumab and have stable disease but progress after discontinuation can initiate a second course of pembrolizumab for up to 17 cycles (approximately 1 year additional).
89397727|NCT02454933|Experimental|MEDI4736 & AZD9291 Combination|10mg/kg q2w (IV) infusion & once daily tablet 80 mg
89397728|NCT02454933|Experimental|AZD9291 Monotherapy|Once daily tablet 80 mg
89397729|NCT02430480|Experimental|1/Arm 1- Enzalutamide and Goserelin|Patients will have an multi-parametric magnetic resonance imaging (mpMRI) guided biopsy, then receive enzalutamide and goserelin subcutaneous (SC) treatment for 6 months followed by a second mpMRI examination.
89397730|NCT02422875||Healthy Controls|Subjects are healthy persons without any autoimmune conditions or infectious diseases
89397731|NCT02422875||Autoimmune Disease|Subjects diagnosed with autoimmune disease including but not limited to: Systemic Lupus Erythematosus (SLE), Sjögren's Syndrome (SS), Scleroderma, Myositis, Juvenile Idiopathic Arthritis (JIA), Rheumatoid Arthritis (RA), inflammatory arthritis, undifferentiated connective tissue disease, idiopathic thrombocytopenic purpura (ITP), Graft vs Host Disease (GVHD), Autoimmune Lymphoproliferative Syndrome (ALPS) and IgG4-related disease
89397732|NCT02422875||Infectious Disease|Subjects diagnosed with an infectious disease including but not limited to: Hepatitis C, Epstein Barr Virus (infectious mononucleosis - EBV), Sepsis, Guillain-Barre syndrome (GBS), Mycoplasma pneumoniae or Human Immunodeficiency Virus (HIV)
89397733|NCT02422875||Autoimmune - Family|Subjects have a brother, sister, mother, father, or child with an autoimmune disease
89397734|NCT02422875||Vaccination|Subjects have received or will receive a vaccination as part of regular standard of care from their healthcare provider or other outside source
89397735|NCT02263274|Experimental|Direct Cortical Measurement|Consented subjects will also have transcranial electrodes applied at four extracranial sites, below the sterile dressing and distant from the surgical skull defect. The four electrodes will be placed in uniform positions based on the standard 10-10 electrode system, at the temples bilaterally (positions F9 and F10) and at the occiput bilaterally (positions PO9 and PO10). Subjects will be stimulated according to a predetermined set of parameters which fall well within empirically and computationally determined safety thresholds, as discussed above. The entire stimulation protocol is described in detail in section 5, and is anticipated to last no longer than 30 minutes.
89397736|NCT02207439|Experimental|Single Arm Phase 2|Single Arm, Phase II study of Nelfinavir Lead-In (Period 1) Followed by Concurrent Chemoradiation with Nelfinavir (Period 2)
89397737|NCT01689766|Other|Technetium Tc 99m EC20|
89397738|NCT01582087||acute or chronic hepatic failure|All patients presenting at University of Texas Medical Branch (UTMB) with acute and chronic hepatic failure and who are developing coma
88873949|NCT02006160|Placebo Comparator|control|placebo
88873950|NCT02010216|Experimental|tocilizumab [RoActemra/Actemra]|Participants received tocilizumab 8 mg/kg by intravenous infusion every 4 weeks for 12 weeks (3 cycles).
88873951|NCT02010996|Experimental|Vacuum assisted closure|Vacuum assisted closure (also called vacuum therapy, vacuum sealing or topical negative pressure therapy) is a sophisticated development of a standard surgical procedure, the use of vacuum assisted drainage to remove blood or serous fluid from a wound or operation site.
88873952|NCT02010996|Active Comparator|Axillary dissection|Axillary dissection is a surgical procedure that incises (opens) the armpit (axilla or axillary) to identify, examine, or remove lymph nodes (small glands, part of the lymphatic system, which filters cellular fluids).
88873953|NCT02011464|Experimental|Exparel infiltration|Exparel infiltrated into the posterior compartment of the knee
88873954|NCT02011464|Placebo Comparator|Control|Saline infiltrated into posterior compartment
88873955|NCT02013180||prostate cancer|prostate adenocarcinoma in pathologic evaluation
88873956|NCT02013180||control|benign prostatic diseases in pathologic evaluation
88873957|NCT02058420|No Intervention|Placebo group|No active dose of tocotrienols
88873958|NCT02058420|Active Comparator|Low tocotrienols group|Low dose of tocotrienols
89188345|NCT00711230|Experimental|1: Low dose DermaVir|"Dosage: 0.2 mg DNA~Dosage form: 1.6 mL DNA/PEIm nanomedicine~Administration with 2 DermaPrep patches~Frequency: every six weeks~Duration: 18 weeks (4 DermaVir treatments)"
88873959|NCT02058420|Active Comparator|High tocotrienols group|High dose of tocotrienol
88873960|NCT02015442|Experimental|High sucrose diet|High sucrose diet for 7 days
88873961|NCT02015442|Experimental|Low sucrose diet|Low sucrose diet for 7 days
88873962|NCT02016612|Active Comparator|Reduction, Mastopexy No Implant, No Seri|Patients undergoing reduction or mastopexy but no implant is used and no Seri Surgical Scaffold support is used
88873963|NCT02016612|Active Comparator|Mastopexy, Implant no Seri Scaffold|Mastopexy with implant, No Seri Surgical Scaffold support is used
88873964|NCT02016612|Active Comparator|Breast Reduction with Seri Support|Patients undergoing breast reduction with the use of Seri Surgical scaffold support
88873965|NCT02016612|Active Comparator|Augmentation Mastopexy, Implant and Seri|Augmentation Mastopexy patients where Seri Surgical scaffold is used
89397739|NCT01466582||HIV-negative controls|A group of HIV-negative controls, aged 45 years and above, that is recruited at the STD-clinic of the Public Health Service Amsterdam or at the existing Amsterdam Cohort Studies.
89397740|NCT01466582||HIV-positive patients|A group of HIV-1-infected patients, aged 45 years and above, that is recruited at the HIV outpatient clinic of the Academic Medical Center.
89397741|NCT01465542||Oral NAC|Patients receiving oral NAC treatment after an acute acetaminophen ingestion.
89397742|NCT01465542||IV NAC|Patients receiving IV NAC after an acute Acetaminophen ingestion.
89397743|NCT01205048|Experimental|Emervel Classic Lidocaine|NLFs (Nasolabial Folds) were injected with Emervel Classic Lidocaine (20 mg/mL with 0.3% lidocaine).
89397744|NCT01205048|Active Comparator|Juvederm® Ultra|NLFs were injected with Juvéderm Ultra (24 mg/mL).
89397745|NCT01052779|Experimental|Ferumoxytol|Participants received an IV injection of ferumoxytol (510 milligrams [mg], 17 milliliters [mL]) on Day 1 (Baseline). This was followed by a second injection of ferumoxytol (510 mg, 17 mL) 5±3 days later for a total cumulative dose of 1.02 grams (g).
89397746|NCT01052779|Active Comparator|Iron Sucrose|"Participants received iron sucrose based on hemodialysis status. Participants on hemodialysis received either slow IV injection or IV drip infusion of 100 mg of iron sucrose on Day 1 (Baseline) and at the following 9 consecutive hemodialysis sessions for a total cumulative dose of 1.0 g.~Participants not on dialysis received either slow IV injection or IV drip infusion of 200 mg of iron sucrose on Day 1 (Baseline) and at 4 subsequent visits on nonconsecutive days over a 14-day period for a total cumulative dose of 1.0 g."
89397747|NCT00743262|Experimental|Provox voice prosthesis|
89397748|NCT00591370|Experimental|1 - Temozolomide (TMZ)|
89397749|NCT03064763|Experimental|Talimogene laherparepvec|"Participants will receive talimogene laherparepvec administered by intralesional injection only into injectable cutaneous, subcutaneous, and nodal tumors, with or without image ultrasound guidance.~On Day 1 (Week 0), the initial dose of talimogene laherparepvec will be up to 4.0 mL of 10^6 Plaque forming units per millilitre (PFU/mL). Subsequent doses of talimogene laherparepvec will be up to 4.0 mL of 10^8 or 10^7 PFU/mL. The second dose is to be administered 3 weeks (+ 5 days) after the initial dose, and subsequent doses were to be given every 2 weeks (+ 3 days)."
89397750|NCT02782676|Experimental|Investigational Healon5 OVD|Subjects to receive investigational Healon5 OVD in one eye and control Healon5 in the fellow eye.
89397751|NCT02782676|Active Comparator|Approved Healon5 OVD|Subjects to receive investigational Healon5 OVD in one eye and control Healon5 in the fellow eye.
89397752|NCT03033095|Experimental|etanercept|"The etanercept is not the experimental study drug. Etanercept is a treatment justifying the inclusion of patients and is used in accordance with its marketing authorization.~Modality of administration :~Etanercept : 50 mg / week subcutaneously, every 7 days The clinical response will be evaluated after 6 months of etanercept treatment, at the M6 visit."
89397753|NCT02471339|Experimental|1/Acceptance and Commitment Therapy (ACT) Group|2 Acceptance and Commitment Therapy (ACT) Training Sessions followed by weekly emails and video chats.
89397754|NCT02471339|Active Comparator|2/Waitlist (WL) Group|Waitlist group - no intervention for first 8 weeks (then will receive Acceptance and Commitment Therapy (ACT) intervention as Arm 1)
89397755|NCT02142842|Experimental|Treatment|Autologous stromal vascular fraction (SVF) and platelet rich plasma (PRP) will be injected into joints of 16 patients with grade 2, 3 radiographic OA severity with 16 patients as control.
89397756|NCT02149004||Site Bonn|
89397757|NCT02149004||Site Heidelberg|
89397758|NCT02149004||Site Munich|
89397759|NCT02149004||Site Hamburg|
89397760|NCT02149004||Site Hannover|
89397761|NCT02149004||Site Cologne|
89397762|NCT02149004||Site Freiburg|
89397763|NCT02149004||Site Frankfurt|
89397764|NCT02149004||Site Essen|
89397765|NCT03632057|Active Comparator|Fixed Tilt (65%)|This is the control group, so device programming for shock energy is the default setting
89397766|NCT03632057|Active Comparator|Fixed Pulse Width|This is the Study group.
89397767|NCT05075720|Experimental|Dietary Supplement: Meat with added nitrate|"The intervention comprises 50 g salami and 35 g ham on white bread sandwich at breakfast and lunch.~This intervention will allow us to determine both endogenous formation of N-nitrosamines as well as N-nitrosamines present in the commercially prepared meat."
89397768|NCT05075720|Experimental|Dietary Supplement: Meat without added nitrate|"The intervention comprises 65 g Pork mince on white bread sandwich at breakfast and lunch. Nitrate is not an allowed additive in pork mince.~This intervention will allow us to determine if there is endogenous formation of N-nitrosamines as well as N-nitrosamines present in the prepared meat due to the natural content of nitrate in meat."
89397769|NCT05075720|Sham Comparator|Dietary Supplement: Control|The control comprises low nitrate vegetable protein burger on white bread. Protein content matched to interventions 1 and 2.
89397770|NCT02931851|Placebo Comparator|Placebo|Standard Information
89397771|NCT02931851|Active Comparator|Intervention|Professionally developed website for relatives of ICU patients
89397772|NCT02146820|Experimental|Picosecond Laser System|
89397773|NCT02142920|Experimental|[14C] PF 05212384|Receive PF-05212384 89 mg Dose
89397774|NCT03544112||ED and OUD treatment providers and staff|"ED patients will be recruited to participate in interviews or focus groups.~ED patients who are eligible for and willing to receive ED-initiated BUP will be recruited to participate in two research visits.~Administrative and health record data will be examined to assess rates of screening, assessment, eligibility determination, etc."
89397775|NCT03544112||Community Stakeholders|"Community treatment providers/OTP leadership and program staff: Providers, leadership and staff involved in the provision of office-based BUP, community treatment, and/or at opioid treatment programs (OTPs) will be recruited to participate in the formative evaluation and the Implementation Facilitation.~Other Stakeholders: Other community leaders and members (e.g., EMS, fire department, police, local government leadership, community advocacy groups, etc.) may be recruited to participate in qualitative interviews or focus groups."
89397776|NCT03544112||Patients|ED patients will be recruited to participate in interviews or focus groups.
89397777|NCT02142998|Active Comparator|GERD Symptoms|
89397778|NCT02142998|Active Comparator|No GERD Symptoms|
89397779|NCT01383785|Active Comparator|GROUP A|Intracoronary full bolus dose of abciximab proximal to thrombus occlusion
89397780|NCT01383785|Experimental|GROUP B|Half bolus of intracoronary abciximab proximal to thrombus occlusion and the other half distal by aspiration catheter
89397781|NCT01383785|Experimental|GROUP C|Distal injection to thrombus occlusion of total bolus dose of abciximab by aspiration catheter
89397782|NCT02146898|Active Comparator|Lateral|patient placed in the lateral postion for spinal anesthesia
88873966|NCT02019888||Normal hearing adults|Adults between 20 and 79 years old with hearing at all audiometric frequencies between 250 and 8000 Hz at less than or equal to 25 dB HL
88873967|NCT02019888||Adults with sensory neural hearing loss|Adults between 20 and 79 years old with sensory neural hearing at one or more audiometric frequencies between 250 and 8000 Hz.
89397783|NCT02146898|Active Comparator|Sitting|patient placed in the sitting position for spinal anestheisa, then supine
89397784|NCT02146898|Active Comparator|Recline|patient placed in the sitting position for spinal anesthesia administration. After spinal placed, the patient turned to a 30-degree upperbody tilt, followed by a slow recline to supine over 5 minutes
89397785|NCT02146976|Experimental|Propofol|introvenious infusion of propofol
89397786|NCT02146976|Experimental|Inhaled anaesthetic (Sevoflurane)|sevoflurane (1.0-1.3% Minimum Alveolar Concentration)
89397787|NCT03746990||observational|Total of 2015 Libyan school children aged 7 to 16 years, from urban (Tobruk) and rural (Kufra) areas were included in the main study. The children were of almost equal number of both sexes from each age group (table-I) .The total of 1935 children were examined for enamel fluorosis
89397788|NCT02365883||Prostate Cancer Group|
89397789|NCT02147054|Active Comparator|Rocuronium with >95% inhibition|"IV Rocuronium to be given:~Bolus dose of Rocuronium 0.3 mg/kg to achieve >95% inhibition as indicated by Train of Four monitoring~Continuous infusion of 1.5 mg/kg/hr to maintain level of inhibition~To continue until two rises in butyrylcholinesterase seen or for a maximum of 5 days"
89397790|NCT02147054|Active Comparator|Rocuronium with 50% inhibition|"IV Rocuronium to be given:~Bolus dose of Rocuronium 0.3 mg/kg to achieve 50% inhibition as indicated by Train of Four monitoring~Continuous infusion of 1.5 mg/kg/hr to maintain level of inhibition~To continue until two rises in butyrylcholinesterase seen or for a maximum of 5 days"
89397791|NCT02147054|No Intervention|No Rocuronium|No Rocuronium will be given
89397792|NCT02149082||Infrascanner exam|Infrascanner Model 2000 exams may be conducted either before or after an associated head CT for pediatric patients presenting to the emergency department (ED) or pediatric intensive care unit (PICU) with a known or suspected traumatic head injury undergoing a head CT scan to evaluate for the presence or absence of an intracranial hematoma. The time between the head CT scan and the Infrascanner exam will be within 6 hours. The exam involves placing a sensor on the designated areas of the head with the most common locations for traumatic hematoma. Readings from the monitor evaluating each region will be evaluated and recorded. The 8-point exam can be accomplished within 5 minutes or less.
89397793|NCT02149160|Experimental|FRM-0334; Arm 1|low dose, Capsule, Once Daily, Day 1 through Day 28
88873968|NCT02019888||Adults with middle ear disorders|Adults between 20 and 89 years old with middle ear disorders: tympanic membrane perforation, serous otitis media, cholesteatoma, otosclerosis, and unspecified middle ear disorders.
88873969|NCT02020278|Experimental|Tolvaptan|"Participants enrolled in this trial were eligible to receive open-label tolvaptan if they had a clinical need as determined by the investigator and met the eligibility criteria for optional tolvaptan treatment.~Daily dose levels would have included 3.75 milligrams (mg), 7.5 mg, 15 mg, 30 mg, and 60 mg."
88873970|NCT02020590|Experimental|ALLOB® Implantation|One arm: ALLOB® Implantation
88873971|NCT02023944|Other|Intervention|12-week course on memory and aging, consists of psychoeducation and skills training
88873972|NCT02023944|No Intervention|Control, No Intervention|"No Intervention, considered treatment as usual"
88873973|NCT02024646|Experimental|210 mg brodalumab|Administered via subcutaneous injections.
88873974|NCT02024646|Experimental|140 mg brodalumab|Administered via subcutaneous injection.
89397794|NCT02149160|Experimental|FRM-0334; Arm 2|high dose, Capsule, Once Daily, Day 1 through Day 28
89397795|NCT02149160|Placebo Comparator|Placebo Comparator; Arm 3|Placebo, Capsule, Once Daily, Day 1 through Day 28
89397796|NCT02149238|Active Comparator|flavanol rich drink intervention|flavanol rich drink
89397797|NCT02149238|Active Comparator|methylxanthine rich drink intervention|methylxanthine rich drink
89397798|NCT02149238|Active Comparator|flavanol + methylxanthine rich drink intervention|flavanol + methylxanthine rich drink
89397799|NCT02149316|Experimental|RIPC+RIPostC|
89397800|NCT02149316|Sham Comparator|control|
88873975|NCT02024646|Placebo Comparator|Placebo|Administered via subcutaneous injection until week 24.
88873976|NCT02024724|Active Comparator|Dexamethasone|4 mg of Dexamethasone and 4 mL of 0.25% bupivacaine
88873977|NCT02024724|Active Comparator|Triamcinolone|40 mg of Triamcinolone and 4 mL of 0.25% bupivacaine
89397801|NCT02149394|Experimental|Ice|The concealment of allocation was performed through the use of individual opaque envelopes numbered externally in sequence, containing information of the group randomly defined. This step was carried out by a researcher who did not take part in data collection.Thirst intensity was measured within the range from 1 to 10 according to the numeric visual analogue scale.The experimental group received an ice popsicle made of 10 mL mineral water.The ice popsicles were made according to the predetermined volumes and packed in the freezer of the anesthetic recovery room at the institution researched. The block of ice was supported by a stick, allowing the patients to control the intensity of cold conferred by the ice for their comfort.
89397802|NCT02149394|Active Comparator|Water|The concealment of allocation was performed through the use of individual opaque envelopes numbered externally in sequence, containing information of the group randomly defined. This step was carried out by a researcher who did not take part in data collection.Thirst intensity was measured within the range from 1 to 10 according to the numeric visual analogue scale. The usual activities adopted by the nursing staff of the anesthetic recovery room were maintained for the control group that received 10 mL mineral water at room temperature in a syringe.
88873978|NCT02025426|Active Comparator|Phenylephrine|Phenylephrine for maintaining blood pressure within 10 % of baseline
88873979|NCT02025426|Active Comparator|Ephedrine|Ephedrine for maintaining blood pressure within 10 % of baseline
89530212|NCT05082779|Experimental|Cohort A3: 1 mg|Participants in fasted state will receive CS0159 1 mg or placebo once on Day 1 followed by a 7-day washout period then given in 1 mg tablet (in fed state) on Day 8.
88873980|NCT02026206|Experimental|LLLT group|low-level light therapy (LLLT) was self-performed for 20 min/day over 5 days prior to the expected onset of menstruation during three menstrual cycles.
88873981|NCT02026206|Placebo Comparator|Placebo-controlled group|Placebo low-level light therapy (LLLT) was self-performed for 20 min/day over 5 days prior to the expected onset of menstruation during three menstrual cycles. The placebo LLLT device was identical to the active device but did not radiate light as the hole was blocked.
88873982|NCT02028780|Experimental|Idarucizumab single doses|different infusion durations
88873983|NCT02028780|Experimental|Idarucizumab with dabigatran|short infusion with 2 capsules dabigatran
88873984|NCT02029872|Active Comparator|Individual plus household|Standard decolonization regimen for individual plus household: 7 day course of nasal mupirocin calcium 2% ointment applied inside the nose twice daily 4% chlorhexidine gluconate (soap) used in the shower/bath every day for 7 days. For individuals colonized within the throat we will add chlorhexidine gluconate oral rinse 0.12% used in a gargle and spit fashion twice daily for 7 days.
88873985|NCT02029872|Active Comparator|Individual alone|Standard decolonization regimen for the individual alone: 7 day course of nasal mupirocin calcium 2% ointment applied inside the nose twice daily, plus a 4% chlorhexidine gluconate (soap) used in the shower/bath every day for 7 days. For individuals colonized within the throat we will add chlorhexidine gluconate oral rinse 0.12% used in a gargle and spit fashion twice daily for 7 days.
88873986|NCT02030574|Experimental|Gemcitabine and fractionated cisplatin (combination treatment)|1 Cycle = 21 days. GC x 4 cycles ----> cystectomy Gemcitabine: 1000mg/m2, days 1 and 8 Cisplatin: 35mg/m2, days 1 and 8
88873987|NCT02030886|Other|Ocular hypertension subjects|All subjects will be monitored by Sensimed Triggerfish (TF) for 24 hours.
88873988|NCT02032212|Experimental|Sequence 1|Subjects use the unflavoured EVP on Day 1, the flavoured EVP on Day 2, the nicotine inhalator on Day 3 and the conventional cigarette on Day 4.
88873989|NCT02032212|Experimental|Sequence 2|Subjects use the flavoured EVP on Day 1, the unflavoured EVP on Day 2, the conventional cigarette on Day 3 and the nicotine inhalator on Day 4.
88873990|NCT02032212|Experimental|Sequence 3|Subjects use the nicotine inhalator on Day 1, the conventional cigarette on Day 2, the unflavoured EVP on Day 3 and the flavoured EVP on Day 4.
88873991|NCT02032212|Experimental|Sequence 4|Subjects use the conventional cigarette on Day 1, the nicotine inhalator on Day 2, the flavoured EVP on Day 3 and the unflavoured EVP on Day 4.
88873992|NCT02032680|Experimental|Web-based family psycho-education treatment|The e-health/web-based intervention provides: three therapist facilitated group forums; a function to send facilitators questions; a library of previously answered questions; and a library of educational materials.
88873993|NCT02032680|Active Comparator|In-persons Multi-Family Group Psycho-Education treatment|This arm provides the evidence based multi-family psychoeducational treatment, termed Multi-Family Group Psycho-Education (MFG) that is the standard of care in the VA.
88873994|NCT02032680|Other|Treatment as Usual|The Treatment as usual (TAU) group provides a benchmark against which to measure the impact of the two individual interventions (MFG & DSW) independent from each other. Through enhancements of TAU, such as regular monitoring which will be done in the assessment process and by the provision of information to VA psychiatrist when there are concerns or problems with the psychiatric status of their patients, we will be taking reasonable steps to ensure the safety of the participants who are assigned to TAU.
88873995|NCT02032758|Experimental|Golfers With Golfer's Cramp|Subjects in this arm will be tested with the Opal device, the Science and Motion PuttLab (SAM), and the Surface Electromyography (EMG) to collect movement parameters while putting before and after a single dose of 10 mg Propranolol.
88873996|NCT02032758|Other|Golf Pros|Subjects in this arm will be tested with the Opal device, the Science and Motion PuttLab (SAM), and the Surface Electromyography (EMG) to collect movement parameters while putting. The subjects in this arm will not receive any study drug.
88873997|NCT02033382||Healthy Controls|Age and gender matched healthy controls
88873998|NCT02033382||Patients|Participants diagnosed with Schizophrenia, schizophreniform disorder, or schizoaffective disorder, depressed type that are naive to anti-psychotic treatment.
88873999|NCT02033694||Participants With 2 Years Follow up|Participants with NIRS-IVUS imaging at baseline and assigned to follow up for Non-Index Culprit Lesion related Major Adverse Cardiac Events (NC-MACE) for 2 years
88874000|NCT02036424|Active Comparator|Bevacizumab|1.25 mg intravitreal injection given monthly during a 6 month period
88874001|NCT02036424|Active Comparator|Ozurdex|Dexamethasone intravitreal implant, 0.7 mg given every 3 months over 6 month period with a maximum of 3 injections
88874002|NCT02037204|Experimental|Cartilage repair surgery|Single-stage cartilage repair surgery using autologous chondrons (10-20%) and allogeneic MSCs (80-90%) in a fibrin glue carrier with a dosage of two million cells/ cm2 applied once during a surgical procedure.
88874003|NCT02037438|Active Comparator|CONV Arm|Conventional (CONV) care for the diagnosis and treatment of sleep disorders
88874004|NCT02037438|Experimental|PCCM ARM|Patient-Centered Outcomes and Coordinated Care Management (PCCM) for the diagnosis and treatment of sleep disorders
88874005|NCT02038218|Experimental|DM-CHOC-PEN|"Two Cohorts of patients will be treated every once every 21 days with a single infusion of DM-CHOC-PEN as an out-patient. Patients will be divided into:~Cohort 1: Patients with liver involvement or history of disease will be treated at a dose of 85.8 mg/m2 and;~Cohort 2: Patients without liver involvement or history of liver disease, will be treated at a dose of 98.7 mg/m2.~Patients in both cohorts will discontinue dosing with DM-CHOC-PEN when there are any unacceptable toxicities, progression of cancer or patient compliance."
88874006|NCT02042274|Experimental|Fish oil supplement|Fish oil supplements providing up to 3g per day of EPA and DHA
88874007|NCT02044380|Experimental|Afatinib|patient to receive a tablet containing 40 mg afatinib once a day, with the option to reduce the dose to 30 or 20 mg/day, based on individual tolerability
88874008|NCT02045238|Placebo Comparator|Normal Saline|Patients will receive inhaled normal saline, initially with a 2 hour interval, and clinical evaluation prior to each inhalation. When they attain sat>94% AND respiratory rate <60 AND RDAI score <4, the interval between inhalations will be changed to 4 hours. If they maintain these criteria for a whole 4 hour interval, they are discharged. If they do not improve enough to be discharged in 24 hours from the first inhalation, they are considered as admitted to hospital.
88874009|NCT02045238|Experimental|Hypertonic Saline|Patients will receive inhaled Hypertonic Saline 3%, initially with a 2 hour interval, and clinical evaluation prior to each inhalation. When they attain sat>94% AND respiratory rate <60 AND RDAI score <4, the interval between inhalations will be changed to 4 hours. If they maintain these criteria for a whole 4 hour interval, they are discharged. If they do not improve enough to be discharged in 24 hours from the first inhalation, they are considered as admitted to hospital.
88874010|NCT02047032|Experimental|acupuncture|BL33 and BL35 of both sides are used. Every session will last for 30 minuets and will be given every other day. There are 36 sessions for each participant in all (3 session per week, 12 weeks).
88874011|NCT02047032|Active Comparator|Solifenacin plus PFMT|Both PFMT and solifenacin will be given for 36 weeks. Solifenacin will be taken 5mg once daily, before or after meal. PFMT includes intensive exercises conducted in hospital and home exercises. Intensive exercises will be done once every week for the first 12 weeks and once every four weeks for the 13th to 36th week. Home exercises will be done three times daily for 36 weeks.
88874012|NCT02047344|Experimental|Antroquinonol (Hocena)|patients will receive one 12 week cycle of antroquinonol 200 mg t.i.d. or until disease progression, unacceptable toxicity, non compliance or withdrawal of consent by the patient, or the investigator decides to discontinue treatment, whichever comes first.
88874013|NCT02047500|Experimental|TH-302 plus Nab-paclitaxel plus Gemcitabine|
88874014|NCT02048670|Experimental|Chronic Subjective Dizziness Syndrome Subjects|Subjects diagnosed with Chronic Subjective Dizziness Syndrome (CDS) will wear the BalanceBelt while performing test involving walking and balance.
88874015|NCT02048670|Active Comparator|Healthy Subjects|Age matched healthy subjects without complaints of balance or dizziness problems will wear the BalanceBelt while performing test involving walking and balance.
88874016|NCT02051790|Experimental|Clinical Practice Scans|Approximately 250 florbetapir F 18 scans and final scan reports interpreted in a clinical setting will be collected from physicians across the country. These results will then be compared to expert panel interpretations for the same scans.
88874017|NCT02054754|Experimental|Dexanabinol Dose Level 1|Single oral dose of dexanabinol
88874018|NCT02054754|Experimental|Dexanabinol Dose Level 2|Single oral dose of dexanabinol
88874019|NCT02054754|Experimental|Dexanabinol Dose Level 3|Single oral dose of dexanabinol
88874020|NCT02054754|Experimental|Dexanabinol Dose Level 4|Single oral dose of dexanabinol
88874021|NCT02054754|Experimental|Dexanabinol Dose Level 5|Single oral dose of dexanabinol
88874022|NCT02054754|Placebo Comparator|Placebo|Single oral dose of matching placebo
88874023|NCT02057640|Experimental|Combination therapy: Panobinostat, dexamethasone, MLN9708|Panobinostat: 20mg, on day 1, 3, 5, 15, 17, 19, 28 Dexamethasone: 20mg, on day 1, 2, 8, 9, 15, 16, 28 MLN9708: 4mg on day 1, 8, 15, 28
88874024|NCT02057952|No Intervention|Usual Care Control|No intervention.
88874025|NCT02057952|Active Comparator|In Person Weight Management|Education and exercise in a community health center environment.
88874026|NCT02057952|Experimental|Video Conference Weight Management|Education and exercise delivered through video conference.
88874027|NCT02059512|Active Comparator|Group 1|Intramyocardial administration of autologous bone marrow mononuclear cells during the operation coronary artery bypass grafting 0.2 ml - 10 injection in the zone of blood supply LAD.
88874028|NCT02059512|Placebo Comparator|Group 0|Intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml - 10 injection in the zone of blood supply LAD during the operation coronary artery bypass grafting.
88874029|NCT02059512|Active Comparator|Group 2|Intramyocardial and intracoronary administration of autologous bone marrow mononuclear cells during coronary artery bypass grafting intramyocardial 0.2 ml - 10 injection in the zone of blood supply LAD.
88874030|NCT02059902|Placebo Comparator|Normal pain management|Normal saline (bolus followed by continuous infusion)
88874031|NCT02059902|Experimental|Lidocaine|Lidocaine (Pre-operative = 1.5kg/mg over a minimum of 30 minutes; peri-operative = 2.0mg/kg/hour; Post-operative = 1.5kg/mg/hour)
88874032|NCT02060058|Experimental|Patients with 32 week therapy|"For non-cirrhotic patients whose response of previous HCV therapy with PEG-IFN/RBV were relapse or partial response, PEG-IFN/RBV lead-in therapy is performed during 0-4 weeks, then add boceprevir from week 5 (boceprevir+ PEG-IFN/RBV). If HCV RNA is undetectable during 8-24 weeks, boceprevir+PEG-IFN/RBV triple therapy will be administered from week 5 to week 32.~Dosage of drugs: Boceprevir 800mg tid po, PegIntron 1.5 mcg/kg im QW, and Ribavirin 800 to 1400 mg/day PO divided BID Regimen adjusted according to body weight.~Stop trial intervention for patients with 32 week therapy: for all patients, if HCV RNA is more than 100 IU/ml at week 12 or HCV RNA is detectable at week 24, therapy will be stopped (Stop trial intervention for boceprevir, PEG-IFN and RBV for arm A)."
88874033|NCT02060058|Experimental|Patients with 48 weeks therapy|"For non-cirrhotic patients whose response of previous HCV therapy with PEG-IFN/RBV were relapse or partial response, PEG-IFN/RBV lead-in therapy is performed during 0-4 weeks, then add boceprevir from week 5 (boceprevir+ PEG-IFN/RBV). If HCV RNA is detectable at week 8 and undetectable at week 24, boceprevir+ PEG-IFN/RBV triple therapy will be administered from week 5 to week 32, followed by additional 12 weeks of PEG-IFN/RBV therapy.~Dosage of drugs: as Patients with 32 week therapy Stop trial intervention for patients with 48 weeks therapy: for all patients, if HCV RNA is more than 100 IU/ml at week 12 or HCV RNA is detectable at week 24, therapy will be stopped (Stop trial intervention for boceprevir, PEG-IFN and RBV for arm B)."
89188346|NCT00711230|Experimental|2: Low dose Placebo|"Dosage form: 1.6 mL Placebo~Administration with 2 DermaPrep patches~Frequency: every six weeks~Duration: 18 weeks (4 Placebo treatments)"
89530213|NCT05082779|Experimental|Cohort A4: 2 mg|Participants in fasted state will receive CS0159 2 mg or placebo once on Day 1.
89397803|NCT02143076||Sickle Cell Disease|Participants will complete three questionnaires during the course of the study: Demographic Questionnaire, Medical Adherence Measure Questionnaire, and Acceptability Questionnaire. All questionnaires will be completed in a private clinic room.
89397804|NCT02147210||1-Case|patients who developed CTG secondary to antibody-mediated kidney rejection (AMR), diagnosed by microscopic analysis.
89397805|NCT02147210||2-Control|patients with antibody-mediated kidney rejection (AMR) but without CTG
89397806|NCT00107978|Experimental|Telavancin|
89397807|NCT00107978|Active Comparator|Vancomycin|
89397808|NCT02143154||GBS positive women|Women wih GBS positive bacteruria with plan for treatment with vancomycin in labor, or women with positive GBS screening cultures with a plan to receive vancomycin in labor
89397809|NCT03543644|Active Comparator|Sugar-sweetened beverage (SSB)|"The SSB intervention will consist the participants' consuming their usual serving of cans SSBs (each 355 ml, 42 grams sugar) per day. The calories of the SSB group will not be matched to allow for real-world substitutions using products available on the market."
89397810|NCT03543644|Experimental|Non-nutritive sweetened beverage (NSB)|"The NSB intervention consists of substituting the participants' usual serving of cans SSBs with NSBs (each 355 ml, 0 grams sugar) per day. The calories of the NSB group will not be matched to allow for real-world substitutions using products available on the market."
89397811|NCT03543644|Experimental|Water|"The water intervention consists of substituting the participants' usual serving of cans SSBs with bottles or cans of still or sparkling water (each 355 ml bottle or can, 0 grams sugar) per day. The calories of the water group will not be matched to allow for real-world substitutions using products available on the market."
89397812|NCT02781818|Experimental|Triamcinolone Acetonide 10mg/mL|Each lesion randomized to this group will receive a single intralesional treatment with 0.1 mL of triamcinolone 10mg/mL solution.
89397813|NCT02781818|Experimental|Triamcinolone Acetonide 40mg/mL|Each lesion randomized to this group will receive a single intralesional treatment with 0.1 mL of triamcinolone 40mg/mL solution.
89397814|NCT02781818|Placebo Comparator|Normal Saline Placebo|Each lesion randomized to this group will receive a single intralesional treatment with 0.1 mL of sterile normal saline solution.
89397815|NCT02149472||Pregnant women with PPH|All pregnant women in participating hospitals are asked for their informed consent (n = 9.500). All women will complete a bleeding score generating questionnaire during their pregnancy. Only from women developing postpartum haemorrhage > 1000 cc blood samples will be drawn (n = 600).
89397816|NCT02149550|Active Comparator|NF135 n=5|Subjects will be infected with the NF135.C10 strain of Plasmodium falciparum through the bites of 5 infected Anopheline mosquitoes
89397817|NCT02149550|Experimental|NF135 n=2|Subjects will be infected with the NF135.C10 strain of Plasmodium falciparum through the bites of 2 infected Anopheline mosquitoes
89397818|NCT02149550|Experimental|NF135 n=1|Subjects will be infected with the NF135.C10 strain of Plasmodium falciparum through the bite of 1 infected Anopheline mosquito
88874034|NCT02060058|Experimental|Null responder or cirrhotic patients|"For null responder or cirrhotic patients, PEG-IFN/RBV lead-in therapy is performed during 0-4 weeks, then add boceprevir from week 5 to 48.~Dosage of drugs: as Patients with 32 week therapy Stop trial intervention for for null responder or cirrhotic patients: for all patients, if HCV RNA is more than 100 IU/ml at week 12 or HCV RNA is detectable at week 24, therapy will be stopped (Stop trial intervention for boceprevir, PEG-IFN and RBV for arm C)."
88874035|NCT02060526|Active Comparator|45 mg Q2W|rhHNS 45 mg administered intrathecally Q2W (once every 2 weeks ie, every 14 days), for 48 weeks via the surgically implanted IDDD (or LP)
88874036|NCT02060526|Active Comparator|45 mg Q4W|rhHNS 45 mg administered intrathecally Q4W (once every 4 weeks ie, every 28 days), for 48 weeks via the surgically implanted IDDD (or LP)
88874037|NCT02060526|Placebo Comparator|Placebo|The comparator group will receive no treatment with rhHNS.
88874038|NCT02060838||Acute normovolemic hemodilution (ANH)|Patients undergoing acute normovolemic hemodilution (ANH) as part of their cardiac surgery.
88874039|NCT02061384|Experimental|13-cis retinoic acid|20mg 13-cis retinoic acid twice daily (BID) with meals for 20 weeks
88874040|NCT02061384|Experimental|Calcitriol 0.25 mcg|oral calcitriol 025 mcg BID subjects 11-20 for 20 weeks
88874041|NCT02061696|Active Comparator|Standard Manual Compression|Standard manual compression at the access site applied as per standard of care protocol for sheath removal.
89397819|NCT02149550|Active Comparator|NF166 n=5|Subjects will be infected with the NF166.C8 strain of Plasmodium falciparum through the bites of 5 infected Anopheline mosquitoes
88874042|NCT02061696|Active Comparator|AXERA 2 Access System|The Vascular Access device used is the AXERA 2 Access System for patients randomized to this arm.
88874043|NCT02061774|Active Comparator|acetaminophen|1g intravenous acetaminophen over a period of 15 minutes, 15 minutes (+/- 10 minutes) prior to the anticipated time of incision and every 6 hours (+/- 30 minutes) after the initial dose for 24 hours; maximum dose of 4 grams in 24 hours
89188347|NCT00711230|Experimental|3: Medium dose DermaVir|"Dosage: 0.4 mg DNA~Dosage form: 3.2 mL DNA/PEIm nanomedicine~Administration with 4 DermaPrep patches~Frequency: every six weeks~Duration: 18 weeks (4 DermaVir treatments)"
89397820|NCT02149550|Experimental|NF166 n=2|Subjects will be infected with the NF166.C8 strain of Plasmodium falciparum through the bites of 2 infected Anopheline mosquitoes
89397821|NCT02149550|Experimental|NF166 n=1|Subjects will be infected with the NF166.C8 strain of Plasmodium falciparum through the bite of 1 infected Anopheline mosquito
89397822|NCT02149628|Active Comparator|desflurane|use desflurane as a primary anesthetics during anesthesia guided by bispectral index (BIS)
89397823|NCT02149628|Experimental|propofol|propofol infusion with target-controlled infusion(TCI) device guided by BIS
89397824|NCT02147366|Experimental|Behavioral (Lifestyle)|Only standard lifestyle modifications The prehypertensives and stage I hypertensives will be randomized to receive each of the two three experimental conditions: music along with standard lifestyle modifications or only standard lifestyle modifications in random order over the course of three months.
89397825|NCT02147366|Experimental|Behavioral (Music & lifestyle changes)|Experimental: Music along with standard lifestyle modifications The prehypertensives and stage I hypertensives will be randomized to receive each of the two three experimental conditions: music along with standard lifestyle modifications or only standard lifestyle modifications in random order over the course of three months.
89397826|NCT02147444||Non-valvular atrial fibrillation|"Patients diagnosed with non-valvular atrial fibrillation~Patients who are treated or will be treated with rivaroxaban"
89397827|NCT02927873|Experimental|RSV LD Group|RSV-seropositive infants, aged 12 to 23 months at the time of first vaccination, received 2 doses (0.5 mL each) of the RSV low dose (LD) vaccine, administered intramuscularly, one each at Day 1 and Day 31.
89188348|NCT00711230|Experimental|4: Medium dose Placebo|"Dosage form: 1.6 mL Placebo~Administration with 4 DermaPrep patches~Frequency: every six weeks~Duration: 18 weeks (4 Placebo treatments)"
89188349|NCT00711230|Experimental|5: High dose DermaVir|"Dosage: 0.8 mg DNA~Dosage form: 6.4 mL DNA/PEIm nanomedicine~Administration with 8 DermaPrep patches~Frequency: every six weeks~Duration: 18 weeks (4 DermaVir treatments)"
89188350|NCT00711230|Experimental|6: High dose Placebo|"Dosage form: 6.4 mL Placebo~Administration with 8 DermaPrep patches~Frequency: every six weeks~Duration: 18 weeks (4 Placebo treatments)"
89188351|NCT00711308|Experimental|tinzaparin|tinzaparin (innohep®)subcutaneously in a fixed dose of 175 IU anti-Xa/kg of body weight once daily for 6 months
89188352|NCT00711308|Active Comparator|acenocoumarol|tinzaparin followed by acenocoumarol for 6 months
89188353|NCT02601911|Active Comparator|Ketorolac tromethanine|This group will receive a caplet including10 mg Ketorolac tromethamine 45 minutes before applying infra alveolar nerve block injection.
89188354|NCT02601911|Active Comparator|Acetaminophen|This group receive a caplet including10 mg Ketorolac tromethamine/ 1000 mg Acetaminophen, before applying the injection.
89188355|NCT02601911|Placebo Comparator|Placebo|This group receive a caplet including placebo, before applying the injection.
89188356|NCT00711386|Experimental|Cohort A|50mg dose once daily for 7 days.
89188357|NCT00711386|Experimental|Cohort B|100mg dose once daily for 8 days.
89188358|NCT00711386|Experimental|Cohort C|200mg dose once daily for 8 days.
89188359|NCT00711386|Experimental|Cohort D|400mg dose once daily for 7 days.
89188360|NCT04101773|Other|Rubber Band Ligation (RBL)|RBL is generallya simple, inexpensive procedure. It entails a ligation of haemorrhoids using rubber bands. In RBL, a disposable suction device applies a rubber band at least 2 cm proximal to the dentate line at the base of each haemorrhoidal cushion by using an anoscope. The banding process causes necrosis of the banded tissue and slough. The resultant inflammatory reaction causes refixation of the mucosa to the underlying tissue, helping to eliminate haemorrhoidal prolapse.The end result is a return of the haemorrhoidal cushions to a more normal size and configuration, with resolution of haemorrhoidal symptoms.
89188361|NCT04101773|Other|Sutured mucopexy|A sutured mucopexy is an operation performed under general anaesthesia. At 4 cm proximal of the dentate line, a Z- shaped stitch through the rectal wall is placed and then at the upper level of the haemorrhoidal tissue, pulling up the prolapsing haemorrhoid high into the anal canal.
89188362|NCT04101773|Other|Haemorrhoidectomy|Haemorrhoidectomy involves excision of the haemorrhoidal tissue. An elliptical incision is made in the external haemorrhoidal tissue extending proximally through the dentate line to the upper limit of the haemorrhoids. The base of the haemorrhoidal complex is ligated and the haemorrhoid is excised.
89188363|NCT00711542|Active Comparator|1|Intracoronary infusion of autologous bone marrow-derived progenitor cells after NSTEMI
89188364|NCT00711542|Placebo Comparator|2|Intracoronary infusion of Placebo after NSTEMI
89188365|NCT04104347|Experimental|Metacognitive training (MCT)|
89188366|NCT04104347|Active Comparator|Support group|
89188367|NCT00711620|Experimental|Thymosin alpha 1+Standard Therapy|Patients receive treatment based on SSC guideline with additional thymosin alpha1
89188368|NCT00711620|Placebo Comparator|normal saline+standard therapy|Patients receive treatment based on SSC guideline with additional normal saline.
89188369|NCT02577380|Experimental|IPV/GBV HIV testing and counseling|For the randomized controlled trial, first-time antenatal care clients will be randomly assigned to IPV/GBV HTC HIV testing.
89188370|NCT02577380|No Intervention|Standard HIV testing and counseling|For the randomized controlled trial, first-time antenatal care clients will be randomly assigned to Standard HIV testing and counseling.
89188371|NCT02577614|Experimental|FEIBA|Single dose of commercially available FEIBA
89188372|NCT02577614|Placebo Comparator|Normal Saline|Single dose of NaCl 0.9%
89397828|NCT02927873|Experimental|RSV MD Group|RSV-seropositive infants, aged 12 to 23 months at the time of first vaccination, received 2 doses (0.15 mL each) of the RSV middle dose (MD) vaccine, administered intramuscularly, one each at Day 1 and Day 31.
89188373|NCT02577458|Experimental|CM082 plus everolimus|CM082 plus everolimus
89188374|NCT00767039|Active Comparator|1|Surfactant (beractant, Survanta initial dose 100 mg/kg and subsequent doses 100 mg/kg phospholipids every 6-12 hours, as needed for up to 4 doses), intratracheal administration to very premature infants with RDS requiring mechanical ventilation
89397829|NCT02927873|Experimental|RSV HD Group|RSV-seropositive infants, aged 12 to 23 months at the time of first vaccination, received 2 doses (0.5 mL each) of the RSV high dose (HD) vaccine, administered intramuscularly, one each at Day 1 and Day 31.
89188375|NCT00767039|Experimental|2|Surfactant (poractant, Curosurf initial dose 200 mg/kg and subsequent doses 100 mg/kg phospholipids every 12-24 hours as needed for up to 3 doses), intratracheal administration to very premature infants with RDS requiring mechanical ventilation
89188376|NCT01640522|Experimental|Collaborative Care Intervention|Care coordinator facilitates the assessment and treatment of cancer-related symptoms
89188377|NCT01640522|Active Comparator|Enhanced Usual Care|Upon evaluation of symptoms the patient will be referred for further assessment or treatment if indicated
89188378|NCT04071938|Active Comparator|Intervention group|"Physicians: 10 GPs from 10 practices who treat patient with Spinal cord injury (SCI) and 10 SCI specialists.~Patients: 270 people with SCI within 25 minutes vehicle driving distance to the GP practices will be in the intervention group"
89188379|NCT04071938|No Intervention|Control group|"Physicians: 20 GPs who treat patient with SCI will not receive any intervention. They will be completing the questionnaire (DOC) and assessed for satisfaction with collaboration with the SCI specialist.~Patients: 210 people with spinal cord injury outside the catchment area of the intervention group will be receiving usual care (no intervention)"
89397830|NCT02927873|Placebo Comparator|Placebo LD group|RSV-seropositive infants, aged 12 to 23 months at the time of first vaccination, received 2 doses (0.5 mL each) of placebo, administered intramuscularly, one each at Day 1 and Day 31.
88874044|NCT02061774|Placebo Comparator|PlaceboComparator|Placebo Comparator 0.9% NaCl 100 mL over will be administered intravenously over a period of 15 minutes, 15 minutes (+/- 10 minutes) prior to the anticipated time of incision and every 6 hours (+/- 30 minutes) after the initial dose for 24 hours
88874045|NCT02062008|Other|Cardiac patients receiving PET/MR|PET-MRI with intravenous Gadolinium and FDG. The entire study will take approximately one hour.
89397831|NCT02927873|Placebo Comparator|Placebo MD group|RSV-seropositive infants, aged 12 to 23 months at the time of first vaccination, received 2 doses (0.15 mL each) of placebo, administered intramuscularly, one each at Day 1 and Day 31.
89397832|NCT02927873|Placebo Comparator|Placebo HD group|RSV-seropositive infants, aged 12 to 23 months at the time of first vaccination, received 2 doses (0.5 mL each) of placebo, administered intramuscularly, one each at Day 1 and Day 31.
89397833|NCT01383629|No Intervention|No counselling|normal preoperative procedures prior to vitrectomy surgery
89397834|NCT01383629|Experimental|Preoperative counselling|Counselling to patient about what to expect during vitrectomy surgery under local anaesthesia
89397835|NCT02460419|Experimental|maintenance capecitabine|maintenance capecitabine plus best supportive care(BSC)
89397836|NCT02460419|Other|best supportive care|Best supportive care and following-up every 6-8 weeks
89397837|NCT01220999|Experimental|Cohort 1|Subjects received an initial loading dose of 111^In-CS-1008 (0.2 mg/kg) on Day 1, CS-1008 (6 mg/kg) on Day 8, and subsequent weekly doses of CS-1008 (2 mg/kg) on Days 15, 22, 29, 36, and 43; the Day 36 dose was also radiolabeled with 111^In. Additional 4-week cycles of weekly CS-1008 (2 mg/kg) were permitted for subjects benefiting from treatment.
89397838|NCT01220999|Experimental|Cohort 2|Subjects received an initial loading dose of 111^In-CS-1008 (1 mg/kg) on Day 1, CS-1008 (6 mg/kg) on Day 8, and subsequent weekly doses of CS-1008 (2 mg/kg) on Days 15, 22, 29, 36, and 43; the Day 36 dose was also radiolabeled with 111^In. Additional 4-week cycles of weekly CS-1008 (2 mg/kg) were permitted for subjects benefiting from treatment.
89397839|NCT01220999|Experimental|Cohort 3|Subjects received an initial loading dose of 111^In-CS-1008 (2 mg/kg) on Day 1, CS-1008 (6 mg/kg) on Day 8, and subsequent weekly doses of CS-1008 (2 mg/kg) on Days 15, 22, 29, 36, and 43; the Day 36 dose was also radiolabeled with 111^In. Additional 4-week cycles of weekly CS-1008 (2 mg/kg) were permitted for subjects benefiting from treatment.
89397840|NCT01220999|Experimental|Cohort 4|Subjects received an initial loading dose of 111^In-CS-1008 (4 mg/kg) on Day 1, CS-1008 (4 mg/kg) on Day 8, and subsequent weekly doses of CS-1008 (2 mg/kg) on Days 15, 22, 29, 36, and 43; the Day 36 dose was also radiolabeled with 111^In. Additional 4-week cycles of weekly CS-1008 (2 mg/kg) were permitted for subjects benefiting from treatment.
88874046|NCT02062710|Experimental|A, B, then C|"Subjects received the following: Period 1: single oral dose of diphenhydramine 25 mg and phenylephrine 10 mg, in naturally-flavored cocoa syrup (treatment A). Period 2: dextromethorphan syrup 30 mg (treatment B); Period 3: placebo liquid, dextrose in water, 20 mL (treatment C).~Intervention: capsaicin cough challenge testing 2 hours after study drug ingestion.Each dosing period separated by 1-2 day washout period."
88874047|NCT02062710|Experimental|A, C, then B|"Subjects received the following: Period 1: single oral doce of diphenhydramine 25 mg and phenylephrine 10 mg, in naturally-flavored cocoa syrup (treatment A); Period 2: placebo liquid, dextrose in watwer, 20 mL (treatment C); Period 3: dextromethorphan syrup 30 mg (treatment B).~Intervention: capsaicin cough challenge testing 2 hours after study drug ingestion.Each dosing period separated by 1-2 day washout period."
88874048|NCT02062710|Experimental|B, A, then C|Subjects received the following: Period 1: dextromethorphan syrup 30 mg (treatment B); Period 2: single dose of oral diphenhydramine 25 mg and phenylephrine 10 mg, in a naturally-flavored cocoa syrup (treatment A); Period 3: placebo liquid, dextrose in water, 20 mL (treatment C). Intervention: capsaicin cough challenge testing 2 hours after study drug ingestion. Each dosing period separated by 1-2 day washout period.
88874049|NCT02062710|Experimental|B, C, then A|"Subjects received the following: Period 1: dextromethorphan 30 mg syrup (treatment B); Period 2: placebo liquid, dextrose in water, 20 mL (treatment C); Period 3: single dose of oral diphenhydramine 25 mg and phenylephrine 10 mg in a naturally-flavored cocoa syrup (treatment A).~Intervention: capsaicin cough challenge testing 2 hours after study drug ingestion. Each dosing period separated by 1-2 day washout period."
88874050|NCT02062710|Experimental|C, A, then B|Subjects received the following: Period 1: placebo liquid, dextrose in water, 20 mL (treatment C); Period 2: a single oral dose of diphenhydramine 25 mg and phenylephrine 10 mg in a naturally-flavored cocoa syrup (treatment A); Period 3: dextromethorphan 30 mg syrup (treatment B). Intervention: capsaicin cough challenge testing 2 hours after study drug ingestion. Each dosing period separated by 1-2 day washout period.
89188380|NCT00662649|Experimental|Fingolimod 1.25 mg|Patients continued the same dose to which they had been randomized in the Core study (CFTY720D2301/NCT00289978), fingolimod 1.25 mg/day, in this Extension study.
89188381|NCT00662649|Experimental|Fingolimod 0.5 mg|Patients continued the same dose to which they had been randomized in the Core study, fingolimod 0.5 mg/day, in this Extension study.
89397841|NCT01220999|Experimental|Cohort 5|Subjects received an initial loading dose of 111^In-CS-1008 (6 mg/kg) on Day 1, CS-1008 (2 mg/kg) on Day 8, and subsequent weekly doses of CS-1008 (2 mg/kg) on Days 15, 22, 29, 36, and 43; the Day 36 dose was also radiolabeled with 111^In. Additional 4-week cycles of weekly CS-1008 (2 mg/kg) were permitted for subjects benefiting from treatment.
89397842|NCT03513731|Experimental|Adipose-derived stem cell injection|ADRC treatment group will receive ADRCs yielded from processing of lipoaspirate by a fluoroscopic-guided injection into the affected segment. The segment will consist of 2 joints per level and up to two levels (no more than 4 joints) injected during the procedure.
89188382|NCT00662649|Experimental|Placebo-fingolimod|Patients randomized to placebo in the Core study were re randomized to fingolimod (either 0.5 or 1.25 mg/day) in this Extension study.
88874051|NCT02062710|Experimental|C, B, then A|Subjects received the following: Period 1: placebo liquid, dextrose in water, 20 mL (treatment C); Period 2: dextromethorphan 30 mg syrup (treatment B); Period 3: a single oral dose of diphenhydramine 25 mg and phenylephrine 10 mg in a naturally-flavored cocoa syrup (treatment A). Intervention: capsaicin cough challenge testing 2 hours after study drug ingestion. Each dosing period separated by 1-2 day washout period.
88874052|NCT02063178|Experimental|Counselor-Initiated|Participants will receive 28 telephone sessions over a 12 month period by interventionists trained in behavior change skills and motivational interviewing techniques. Participants will be asked to monitor food intake and physical activity using the LoseIt website/app and weight daily using a Body Trace e-scale. Participants will receive feedback on self-monitoring through e-mail. Dietary goals will be based on weight and participants' weight-loss progress. Participants will be encouraged to replace 2 meals and a snack with meal replacements (provided). Participants will be asked to gradually increase their moderate to vigorous exercise to 225-250 minutes per week. The Toolbox includes additional treatment options (e.g., food scales, exercise videos, cookbooks) for those who wish to take advantage of them. There will be several challenges that will provide a specific goal (e.g. increase self-monitoring), with a small award for completion.
88874053|NCT02063178|Active Comparator|Self-Paced|The Self-paced group uses a less intense approach, where the participants can receive the same telephone counseling sessions as the counselor-initiated group, only if they call the counselor. Participants will be asked to monitor food intake and physical activity using the LoseIt website/app and weight daily using a Body Trace e-scale. Participants will receive feedback on self-monitoring through e-mail only upon request. Dietary goals will be based on weight and participants' weight-loss progress. Participants will be asked to gradually increase their moderate to vigorous exercise to 225-250 minutes per week.
88874054|NCT02064270|Active Comparator|Negative Pressure Wound Therapy|Single-Use Negative Pressure Wound Therapy (NPWT)
88874055|NCT02064270|Active Comparator|Standard dressings|Standard postsurgical dressings
88874056|NCT02064582|Other|Enzalutamide, Leuprolide, radiation|Single arm Enzalutamide 160 mg daily for 6 months Leuprolide acetate 22.5mg every 3 months or 45mg every 6 months Radiation therapy as standard of care
88874057|NCT02067000||Obstructive Sleep Apnea|
88874058|NCT02067468|Experimental|HPV test|Women with ASC-US cytology are HPV tested and those HPV positive are refer to Colposcopy
88874059|NCT02067468|Active Comparator|COLPOSCOPY|Women with ASC-US cytology are immediately refer to colposcopy
88874060|NCT02067468|Active Comparator|CYTOLOGY|Women with ASC-US Cytology are follow-up with cytology at 6 and/or 12 months and be referred to colposcopy if any of these cytologies is ASC-US or higher
88874061|NCT02067858|Other|Stereotactic Radiosurgery|"3 fractions x 20 Gy 4 fractions x 12 Gy~Lesion dependent"
88874062|NCT02069184|Experimental|IV Acetaminophen|IV form, total of 4 doses (each 1000 mg), each every 6th hourly to a maximum dose of 4000 mg in 24 hours.
88874063|NCT02069184|Experimental|Saline as placebo|IV form, total 4 units, each given every 6th hourly in 24 hours.
88874064|NCT02070276|No Intervention|Standard Clinical Practice|"This arm is considered the current clinical standard for spinal anesthesia; its used as a control sample and statistical reference. During the induction phase the patient is fitted with a non-invasive blood pressure monitoring, three-lead ECG, pulse oximetry and peripheral intravenous device. The pressure control is set as the standard every 5 minutes until the procedure under spinal anesthesia, the cuff pressure is placed on the arm that is going to be on top during spinal anesthesia.~Data is recorded and vital signs of the patient and is put an infusion of crystalloid (0.9% NaCl or Ringer's acetate) with administration of 500 ml during the entire procedure until the beginning of the operation."
88874065|NCT02070276|Experimental|Trans-thoracic echocardiography|"In addition to the current clinical standard (arm A of the study) a trans-thoracic echocardiography is performed with the aim of assessing patient's volume status, identifying if he is responsive to fluid and could benefit from their administration. The echocardiography is performed with the subcostal projection to assess the size of the abdominal inferior vena cava and its collapsing during breathing.~According to different pre-established parameters, the patient is defined as unresponsive to fluids or responsive. If it's not responsive, he proceed to spinal anesthesia. Otherwise investigators proceed to the administration of crystalloid (NaCl 0.9% or Hartmann's solution second clinical evaluation) and at the end he's rerun an echocardiographic assessment."
88874066|NCT02070276|Experimental|Passive Leg Raising Test|"In addition to the arm A of the study, is performed a measurement of end-tidal CO2 (EtCO2) by trans-nasal canula with a patient positioned in semi-recumbent position. After, investigators run the Passive Leg Raising Test (PLRT): the position of the bed is changed in such manner to bring the trunk from 45° to 0° and accordingly the legs from 0° to 45°. Measurements are performed before and during the maneuver : an etCO2 increasing more than 12% from baseline was interpreted as fluid-responsive.~If the patient is not responsive to fluids, the patient is moving to the spinal anesthesia. If the patient is responsive investigators proceed to bolus administration, the patient returns to the initial PLRT position and is run again the PLRT until the patient is no longer responsive to fluids."
88874067|NCT02134314|Experimental|C1-Inhibitor (Berinert) (Human) (C1INH)|35 patients will receive C1 esterase inhibitor in addition to standard of care immunosuppressive therapy.
88874068|NCT02134314|Placebo Comparator|Normal Saline|35 patients will receive placebo in addition to standard of care immunosuppressive therapy.
88874069|NCT02135016|Experimental|1% lidocaine|epidural anesthesia with 1% lidocaine 10ml before propofol TCI
88874070|NCT02135016|Experimental|2% lidocaine|epidural anesthesia with 2% lidocaine 5ml before propofol TCI
88874071|NCT02135016|Placebo Comparator|0.9% normal saline|epidural anesthesia with 0.9% normal saline 5ml before propofol TCI
88874072|NCT02135094|Experimental|Active ultrasound therapy device|Patients receive treatment from the Sam Ultrasonic Diathermy Device for 4 hours on days when their trapezius muscle pain score is at least a 3 on a scale of 0-10 (NRS). The active device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity
88874073|NCT02135094|Placebo Comparator|Placebo ultrasound therapy device|Patients apply the Sam Ultrasonic Diathermy Device for 4 hours on days when their trapezius muscle pain score is at least a 3 on a scale of 0-10 (NRS). The placebo device appears and operates identically to the active device except that it does not emit ultrasound.
89188383|NCT00662649|Experimental|Placebo-fingolimod 1.25 mg|Patients randomized to placebo in the Core study were re randomized to fingolimod 1.25 mg/day in this Extension study.
89397843|NCT03513731|Active Comparator|Corticosteroid injection|The control group will undergo standard fluoroscopy guided injection of glucocorticoids and local anesthetics.
89397844|NCT01568411|Active Comparator|TD-1211|
89397845|NCT01568411|Active Comparator|TD-1211+ itraconazole|
89397846|NCT00142415|Experimental|Cohort 1, 30 mCi/m^2 177-Lu-DOTA-cG250|Subjects received an initial single dose of 10 mg of cG250 coupled to DOTA and labeled with 30 mCi/m^2 of 177-Lu.
89397847|NCT00142415|Experimental|Cohort 2, 40 mCi/m^2 177-Lu-DOTA-cG250|Subjects received an initial single dose of 10 mg of cG250 coupled to DOTA and labeled with 40 mCi/m^2 of 177-Lu.
89397848|NCT00142415|Experimental|Cohort 3, 50 mCi/m^2 177-Lu-DOTA-cG250|Subjects received an initial single dose of 10 mg of cG250 coupled to DOTA and labeled with 50 mCi/m^2 of 177-Lu.
89397849|NCT00142415|Experimental|Cohort 4, 60 mCi/m^2 177-Lu-DOTA-cG250|Subjects received an initial single dose of 10 mg of cG250 coupled to DOTA and labeled with 60 mCi/m^2 of 177-Lu.
89397850|NCT00142415|Experimental|Cohort 5, 70 mCi/m^2 177-Lu-DOTA-cG250|Subjects received an initial single dose of 10 mg of cG250 coupled to DOTA and labeled with 70 mCi/m^2 of 177-Lu.
89397851|NCT00142415|Experimental|Cohort 6, 65 mCi/m^2 177-Lu-DOTA-cG250|Subjects received an initial single dose of 10 mg of cG250 coupled to DOTA and labeled with 65 mCi/m^2 of 177-Lu.
89397852|NCT01383551|Experimental|"Becoming Parents intervention"|"A Becoming Parents Programme consists of: (i) 3 antenatal workshops conducted over a period of 10-14 weeks in prenatal period; and (ii) support provided by trained volunteers for up to 3 months post-delivery; in addition to the usual prenatal education."
89397853|NCT01383551|No Intervention|Usual prenatal education|Attend usual prenatal classes which will be provided by the midwives in the hospital.
89397854|NCT03631745|Experimental|NAMI Mental Health 101 and NAMI FaithNet|Mental Health 101 and FaithNet
89397855|NCT03631745|No Intervention|Wait-list Control|After the 12-month follow-up, wait-list control churches will be provided with the opportunity to receive Mental Health 101 and NAMI FaithNet interventions.
89397856|NCT05420363|Experimental|traditional physical therapy + gait training on different surfaces.|Children in study group will receive designed physical therapy program in addition to gait training on different surfaces.
89397857|NCT05420363|Experimental|traditional physical therapy + traditional gait training|-Children in control group will receive designed physical therapy program in addition to traditional gait training hard surface .
89397858|NCT01383473||Leukemia Patients|6-12 year old pediatric oncology patients' perceptions of their school experiences pre and post cancer diagnosis will be done through interviews and drawings.
89397859|NCT01383473||Solid Tumor Patients|6-12 year old pediatric oncology patients' perceptions of their school experiences pre and post cancer diagnosis will be done through interviews and drawings.
89397860|NCT03631901|Active Comparator|Melatonin|melatonin 0.3mg/kg/8 hours, orally. Given only during the febrile illness.
89397861|NCT03631901|Active Comparator|Diazepam|oral diazepam 1mg/kg/day divided into 3 doses. Given only during the febrile illness.
89397862|NCT03631589|Experimental|MSCs treated|
89397863|NCT01383395|Experimental|simvastatin/cilostazol|simvastatin 40 mg on day 1 and 6, cilostazol 100 mg from day 2 to day 6
89397864|NCT05084651|Experimental|Group 1|Each participant will receive a single oral dose of ganaplacide and lumefantrine combination on Day 1 of Period 1. In Period 2, participants will receive itraconazole q.d. on Days 1 to 18 and a single dose of ganaplacide and lumefantrine combination on Day 5, approximately 2 hours after the itraconazole dose
89397865|NCT05419271|Experimental|experimental convection|session of dialysis with 9L internal convection
89397866|NCT05419271|No Intervention|free internal convection|session of dialysis with free internal convection
89397867|NCT01825187|Active Comparator|Treatment Group 1|Patients in this group will be randomized to receive the ULTRAPRO mesh
89397868|NCT01825187|Active Comparator|Treatment Group 2|Patients in this group will be randomized to receive the 3DMAX Mesh
89397869|NCT01825187|Other|Evaluation of Surgical Residents|Surgical residents will be evaluated on the ease of use and the amount of time it takes for them to perform the surgery using these two different meshes.
89397870|NCT02781584|Experimental|Cohort 1: SEL 18 mg (Non-cirrhotic)|Non-cirrhotic participants will receive selonsertib (SEL) 18 mg tablet orally once daily for 12 weeks.
89397871|NCT02781584|Experimental|Cohort 2: FIR 20 mg (Non-cirrhotic)|Non-cirrhotic participants will receive firsocostat (FIR) 20 mg tablet orally once daily for 12 weeks.
89397872|NCT02781584|Experimental|Cohort 3: CILO 30 mg (Non-cirrhotic)|Non-cirrhotic participants will receive cilofexor (CILO) 30 mg tablet once daily for 12 weeks.
89397873|NCT02781584|Experimental|Cohort 4: SEL 18 mg + CILO 30 mg (Non-cirrhotic)|Non-cirrhotic participants will receive SEL 18 mg tablet + CILO 30 mg tablet once daily for 12 weeks.
89397874|NCT02781584|Experimental|Cohort 5: SEL 18 mg + FIR 20 mg (Non-cirrhotic)|Non-cirrhotic participants will receive SEL 18 mg tablet + FIR 20 mg tablet once daily for 12 weeks.
89397875|NCT02781584|Experimental|Cohort 6: CILO 30 mg + FIR 20 mg (Non-cirrhotic)|Non-cirrhotic participants will receive CILO 30 mg tablet + FIR 20 mg tablet once daily for 12 weeks.
89397876|NCT02781584|Experimental|Cohort 7: CILO 20 mg (Cirrhotic)|Participants with Child-Pugh-Turcotte Class A cirrhosis will receive FIR 20 mg tablet once daily for 12 weeks.
89397877|NCT02781584|Experimental|Cohort 8: CILO 30 mg (Cirrhotic)|Participants with Child-Pugh-Turcotte Class A cirrhosis will receive CILO 30 mg tablet once daily for 12 weeks.
89397878|NCT02781584|Experimental|Cohort 9: SEL 18 mg + FIR 20 mg + CILO 30 mg (Non-cirrhotic)|Non-cirrhotic participants will receive SEL 18 mg tablet + FIR 20 mg tablet + CILO 30 mg tablet once daily for 12 weeks.
89397879|NCT02781584|Experimental|Cohort 10: FIR 20 mg + FENO 48 mg|Participants will receive fenofibrate (FENO) 48 mg tablet orally once daily for 2 weeks in the pretreatment phase, then FIR 20 mg tablet + FENO 48 mg tablet orally once daily for 24 weeks in the treatment phase. Participants with compensated cirrhosis due to NASH will be accepted to participate in this cohort.
89397880|NCT02781584|Experimental|Cohort 11: FIR 20 mg + FENO 145 mg|Participants will receive FENO 145 mg tablet orally once daily for 2 weeks in the pretreatment phase, then FIR 20 mg tablet + FENO 145 mg tablet orally once daily for 24 weeks in the treatment phase. Participants with compensated cirrhosis due to NASH will be accepted to participate in this cohort.
89530214|NCT05082779|Experimental|Cohort A5: 4 mg|Participants in fasted state will receive CS0159 4 mg or placebo once on Day 1.
89397881|NCT02781584|Experimental|Cohort 12: FIR 20 mg + CILO 30 mg + VAS 2g|Participants will receive Vascepa® (VAS) 2 g capsule orally twice daily for 2 weeks in the pretreatment phase, then FIR 20 mg tablet once daily + CILO 30 mg tablet once daily + VAS 2 g capsule twice daily for 6 weeks in the treatment phase. Participants with compensated cirrhosis due to NASH will be accepted to participate in this cohort.
89397882|NCT02781584|Experimental|Cohort 13: FIR 20 mg + CILO 30 mg + FENO 145 mg|Participants will receive FENO 145 mg tablet orally once daily for 2 weeks in the pretreatment phase, then FIR 20 mg tablet once daily + CILO 30 mg tablet once daily + FENO 145 mg tablet orally once daily for 6 weeks in the treatment phase. Participants with compensated cirrhosis due to NASH will be accepted to participate in this cohort.
89397883|NCT02149706|Experimental|NeuroVax|NeuroVax
89397884|NCT02149706|Placebo Comparator|IFA Incomplete Freund's Adjuvant|Incomplete Freund's Adjuvant IFA
89397885|NCT03544658|Experimental|Dental prophylaxis|Visit 1: tooth color assessment (by patient, dentist and spectrophotometer) and professional dental prophylaxis Visit 2: tooth color assessment (by patient, dentist and spectrophotometer)
89397886|NCT02147678|Experimental|Group E|Etomidate/remifentanil group. Patients in group E will be given etomidate and remifentanil during the operation, the speeds are 10~15 μg/kg/min and 0.2~0.4 μg/kg/min, respectively.
89397887|NCT02147678|Experimental|Group P|Propofol/remifentanil group. Patients in group P will be given propofol and remifentanil during the operation, the speeds are 50~75 μg/kg/min and 0.2~0.4 μg/kg/min, respectively.
89397888|NCT02155556||Healthy volunteers|
89397889|NCT02151344|Experimental|Cohort 1|Participants will receive one dose of the H7N9 A/Anhui/13 ca influenza virus vaccine at Day 0 and one dose at Day 28. They will then receive one dose of the inactivated subvirion H7N9 vaccine 1 month later.
89397890|NCT02151344|Experimental|Cohort 2|Participants will receive one dose of the H7N9 A/Anhui/13 ca influenza virus vaccine at Day 0 and one dose at Day 28. They will then receive one dose of the inactivated subvirion H7N9 vaccine 2 months later.
89397891|NCT02151344|Experimental|Cohort 3|Participants will receive one dose of the H7N9 A/Anhui/13 ca influenza virus vaccine at Day 0. They will then receive one dose of the inactivated subvirion H7N9 vaccine 2 months later.
89397892|NCT02151344|Experimental|Cohort 4|Participants will receive one dose of the H7N9 A/Anhui/13 ca influenza virus vaccine at Day 0. They will then receive one dose of the inactivated subvirion H7N9 vaccine 1 month later.
89397893|NCT02151344|Experimental|Cohort 5|Participants will receive one dose of the inactivated subvirion H7N9 vaccine at Day 0 and one dose at Day 28.
89397894|NCT02151422|Experimental|Breathing exercises|Patients will be thought 3 different exercises included yoga pranayama, diaphragmatic breathing and pursed lip breathing. Patients will be asked to repeat these exercises at least twice daily for a one month period. Also patients will be thought 4 different exercises which they could use in the event of an asthma exacerbation. Teaching will be supplemented by a breathing exercise brochure and patients will be asked to demonstrate proper technique at initial visit and at the return visit.
89397895|NCT02151500|Experimental|Stress and Health Interview|Stress and Health Interview is an experiential assessment technique
89397896|NCT02151500|No Intervention|Wait-list Control|Standard medical care until the 6-week follow-up is completed
89397897|NCT03543488||Rheumatoid Arthritis Patients|Forty women (range 25-75 years), with a class I and II RA diagnosis according to the American Rheumatism Association's 1987 revised criteria, were recruited from a university hospital's rheumatology clinic. Exclusion criteria included the presence of any cardiovascular, neuromuscular and metabolic diseases or severe limitations in mobility. Five patients were excluded for not attending the inclusion criteria, leading to a final number of 35 RA patients.
89397898|NCT03543488||Healthy Women|Thirty-five healthy women, age- and body size-matched to the RA patients, were recruited as controls (CG).
89397899|NCT02149784|Experimental|Surgical treatment group|Unresectable mCRC patients who respond to chemotherapy will receive surgical resection of primary tumor.
88874074|NCT02137512|Experimental|Closed-Loop Control System|Use of an investigational control-to-range automated insulin management (artificial pancreas) system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes in the home environment.
88874075|NCT02137512|Active Comparator|Sensor-Augmented Pump (SAP)|Use of a study-assigned commercial continuous glucose monitoring (CGM) system and commercial insulin pump
88874076|NCT02139228|Experimental|Hib CRM197|"Subjects treated with 3 doses of CRM 197 -conjugate Haemophilus influenzae type b vaccine (study vaccine): 2 doses given one month apart during study V37_07 (NCT01044316) and a booster dose of the same vaccine six months after, during study V37_07E1 (NCT01226953).~No vaccine was administered during this trial"
88874077|NCT02139228|Active Comparator|Hib TT|"Subjects treated with 3 doses of Tetanus Toxoid-conjugate Haemophilus influenzae type b vaccine (comparator vaccine): 2 doses given one month apart during study V37_07 (NCT01044316) and a booster dose of the same vaccine six months after, during study V37_07E1 (NCT01226953).~No vaccine was administered during this trial"
89188384|NCT00662649|Experimental|Placebo-fingolimod 0.5 mg|Patients randomized to placebo in the Core study were re randomized to fingolimod 0.5 mg/day in this Extension study.
88874078|NCT02139540|Other|N2O/Placebo|First session: Nitrous oxide Second session: placebo
89188385|NCT02577770|Experimental|200mg caffeine plus acupuncture|In healthy subjects
89188386|NCT02577770|Experimental|400mg caffeine plus acupuncture|In healthy subjects
89188387|NCT02577770|Placebo Comparator|Decaffeinated plus acupuncture|In healthy subjects
89397900|NCT02149784|No Intervention|Chemotherapy group|Unresectable mCRC patients who were respond to chemotherapy will continue with chemotherapy.
89397901|NCT02155634|Experimental|Lenalidomide|Lenalidomide maintenance given until disease progression. Long term follow-up 5 years post last patient randomized.
89397902|NCT02155634|No Intervention|Observation|Observation until disease progression. Long term follow-up 5 years post last patient randomized.
89397903|NCT02151578|No Intervention|nothing at home level|No intervention at community level. The study drugs (arthemeter/Lumefantrine and Cotrimoxazole) available at the health facility drug stores level and prescribed exclusively to sick children attending to the health facility for care seeking. No Community Heath Worker /Key Opinion leader (CHWs/KOLs) selected in those clusters
89530215|NCT05082779|Experimental|Cohort A6: 8 mg|Participants in fasted state will receive CS0159 8 mg or placebo once on Day 1.
88874079|NCT02139540|Other|Placebo/N2O|First session: Placebo Second session: Nitrous Oxide
88874080|NCT02146482|No Intervention|Control|Did not receive an intervention during the active portion of the study (i.e. 12 weeks). After the active portion of the study, this group was given a sit-stand computer workstation.
88874081|NCT02146482|Experimental|Sit-stand computer workstation|Given a sit-stand computer workstation to use at their place of work
88874082|NCT02148588|Experimental|Pain testing|"Completion of NPSI questionnaire~Sensory mapping of the affected limb~Quantitative Sensory Testing~Patients will have a peripheral nerve blockade"
88874083|NCT02149290||Trends-equipped LifeVest 4000|Subjects using the LifeVest 4000 modified to collect Trends data
88874084|NCT02149524|Active Comparator|Herceptin (trastuzumab)|Intravenous administration
88874085|NCT02149524|Experimental|SB3 (proposed trastuzumab biosimilar)|Intravenous administration
88874086|NCT02150460|Experimental|One-site peribulbar injection|Injection of a mixture of lidocaine 2% + adrenaline 0.125mg/ml + hyaluronidase 15 International Units (IU)/ml into the inferior medial orbital compartment
88874087|NCT02150460|Active Comparator|Two-site peribulbar injection|Injection of a mixture of lidocaine 2% + adrenaline 0.125mg/ml + hyaluronidase 15IU/ml into the infero-temporal and supero-nasal orbital compartments
89188388|NCT00766493|Experimental|GORE® Embolic Filter|Subjects treated with the GORE® Embolic Filter and an FDA-approved carotid stent.
88874088|NCT02154048|Active Comparator|ropivacaine + dexamethasone|This group will be comprised of 20 subjects who will receive an ultrasound-guided supraclavicular brachial plexus block with 30ml of ropivacaine 0.5% with 1:400,000 epinephrine and an IV preservative-free dexamethasone 8 mg injection.
88874089|NCT02154048|Placebo Comparator|ropivacaine + placebo|This group will be comprised of 20 subjects who will receive an ultrasound-guided supraclavicular brachial plexus block with 30ml of ropivacaine 0.5% with 1:400,000 epinephrine and an intravenous (IV) normal saline placebo injection.
88874090|NCT02154048|Active Comparator|ropivacaine + dexamethasone + placebo|This group will be comprised of 20 subjects who will receive an ultrasound-guided supraclavicular brachial plexus block with 30ml of ropivacaine 0.5% with both 1:400,000 epinephrine and preservative-free dexamethasone 8mg and an IV normal saline placebo injection.
88874091|NCT02154672||BRCA2 Carriers|All men identified to have a BRCA2 mutation as part of the Yale Cancer Genetic Counseling Program will be approached and offered participation in the study via our program newsletter, BRCA listserv, Facebook page and a targeted mailing
88874092|NCT02154906|Active Comparator|DFDBA|DFDBA used to graft intrabony defect
88874093|NCT02154906|Experimental|autologous platelet rich fibrin|autologous platelet rich fibrin used to graft intrabony defect
88874094|NCT02156154|Placebo Comparator|Intravenous 0.9% sodium chloride|0.9% sodium chloride infusion will be initiated before the surgical incision with 100 ml and repeated every 6 hours for the earlier of 48 postoperative hours of hospital discharge.
88874095|NCT02156154|Experimental|Intravenous Acetaminophen|Acetaminophen infusion will be initiated before the surgical incision with 1 g and repeated every 6 hours for the earlier of 48 postoperative hours of hospital discharge.
88874096|NCT02157168|No Intervention|Control Group|Each month all newly enrolled female health plan members will have an equal chance of being randomly picked by the health plan (according to a randomization scheme provided by the study team) to be invited to contact and work with a Community health worker. Those not invited will constitute the usual care control group.
88874097|NCT02157168|Other|Intervention Group|"Each month all newly enrolled female health plan members will have an equal chance of being randomly picked by the health plan (according to a randomization scheme provided by the study team) to be invited to contact and work with a Community health worker in the intervention group.~The intervention group will be made up of two sub groups. The group of individuals who accept the invitation to participate (IG1) in the intervention and receive it, and those randomized to the intervention group but who reject the opportunity to participate (IG2)."
88874098|NCT02158494|Experimental|Neurostimulation|Balance and gait training using neurostimulation modulation. 2-week in lab training (ITP), (2 in-lab training sessions and 1 home training session daily) followed by 12 weeks of training at home (HTP) (3 home training sessions daily), and a 12-week withdrawal period (no training).
88874099|NCT02158494|Sham Comparator|Minimally perceivable stimulation|Balance and gait training using non-zero, minimally perceivable stimulation (sham device). 2-week in lab training (ITP), (2 in-lab training sessions and 1 home training session daily) followed by 12 weeks of training at home (HTP) (3 home training sessions daily), and a 12-week withdrawal period (no training).
88874100|NCT02158572|Experimental|AG200-15|AG200-15 is a transdermal delivery system designed to deliver daily hormone exposure of ethinyl estradiol (EE) and levonorgestrel (LNG)
88874101|NCT02159118|Active Comparator|Manual bone marrow aspiration and biopsy procedure|Manual bone marrow aspiration and biopsy device
88874102|NCT02159118|Active Comparator|Powered bone marrow aspiration and biopsy procedure|Powered bone marrow aspiration and biopsy device
88874103|NCT02159898|Experimental|EndoMAXX Endoluminal Valve Technology (EVT)|EndoMAXX Endoluminal Valve Technology (EVT) Fully Covered Esophageal Stent with Valve
88874104|NCT02159898|Active Comparator|EndoMAXX|EndoMAXX Fully Covered Esophageal Stent
88874105|NCT02159976|Active Comparator|Sequential therapy|pantoprazole 40mg bid 10 days (D1-D10), amoxicillin 1000mg bid 5 days (D1-D5), clarithromycin 500mg bid 5 days (D6-D10), metronidazole 500mg tid 5 days (D6-D10)
89397904|NCT02151578|Experimental|Home management of malaria|"At the community level, the Community health workers/ keay opinion leader (HWs/KOLs) trained and equipped to provide the antimalarial drug (arthemeter/Lumefantrine ) to any child with fever (hot body) without any other signs of complications like impaired consciousness, convulsions, etc"
88874106|NCT02159976|Experimental|Modified bismuth quadruple therapy|pantoprazole 40mg bid 14 days (D1-D14) , amoxicillin 1000mg bid 14 days (D1-D14), tetracycline 1000mg bid 14 days (D1-D14), bismuth 600mg bid 14 days (D1-D14)
88874107|NCT02160288|Active Comparator|Botulinum Toxin-A|Patients will receive Botulinum Toxin-A (Botox) injected in the puborectalis muscle and external anal sphincter. We will use 100 units of Botox, a dose with a good safety profile that has been proven to work in previous studies performed in adults.
89530216|NCT05082779|Experimental|Cohort B1: 0.4 mg|Participants in fasted state will receive CS0159 0.4 mg or placebo once daily for a consecutive 14 days.
88874108|NCT02160288|Placebo Comparator|Normal saline|Patients will receive normal saline (placebo) injected in the puborectalis muscle and external anal sphincter.
88874109|NCT02160990|Experimental|Exenatide|Participants randomized to this arm received 5 mcg exenatide subcutaneously twice daily for 30 days.
88874110|NCT02160990|Placebo Comparator|Placebo|Participants randomized to this arm received placebo subcutaneously twice daily for 30 days.
88874111|NCT02161536|Experimental|Motus CleanC System|Colonoscopy with Motus CleanC Syetem - Device Rev 2.0 ,enrolled under protocol Rev 3.0
88874112|NCT02161536|Experimental|Motus Cleansing System Rev 2.5|Colonoscopy with MCS Rev 2.5,enrolled under protocol Rev 4.0
89188389|NCT00129896|Experimental|Myocet+Taxotere+Herceptin|Myocet 50 mg/m2; Taxotere 60 mg/m2; Herceptín 4 mg/Kg (first dose) and in the following cycles 2 mg/Kg
89188390|NCT02602535|Experimental|M.O.R.E.|Participants will attend a Mindfulness-Oriented Recovery Enhancement (MORE) group weekly for eight weeks.
89188391|NCT02602535|Active Comparator|Support Group|Participants will attend a support group weekly for eight weeks.
89188392|NCT02574338|Active Comparator|group - 1 Foley's Catheter|will have cervical ripening with intracervical extraamniotic Foley's catheter for 24 hours
89188393|NCT02574338|Active Comparator|Group - 2 Prostaglandin E1 Analogue|will have cervical ripening with intravaginal misoprostol inserted into the posterior fornix every six hours to a maximum of four doses (24 hours)
89188394|NCT00711698|Active Comparator|1|In this arm patients will be randomized to receive a bolus of narcotic followed by PCA.
89188395|NCT00711698|Active Comparator|2|In this arm patients will be randomized to the current standard of care of bolus narcotic treatment.
89188396|NCT00784043|Experimental|Bilateral|Bilaterally implanted simultaneously
89188397|NCT00784043|Experimental|Unilateral|Unilaterally implanted
89188398|NCT02555241|Experimental|One Baseline Session|Designated for participants #1 and #2. Participants complete 1 Baseline Session followed immediately by 12 weeks of standard treatment. Standard treatment will require the participant to attend clinic-based treatment sessions for 1 hour per day, 3 days per week, for 12 weeks. Standard treatment will consist of 3 components: mand training, matrix training, and stimulus equivalence training.
89188399|NCT02555241|Experimental|Two Baseline Sessions|Designated for participants #3 and #4. Participants complete a Baseline Session followed by a 12 week wait period before repeating a Baseline Session followed immediately by 12 weeks of standard treatment. Standard treatment will require the participant to attend clinic-based treatment sessions for 1 hour per day, 3 days per week, for 12 weeks. Standard treatment will consist of 3 components: mand training, matrix training, and stimulus equivalence training.
89188400|NCT02555241|Experimental|Three Baseline Sessions|Designated for participants #5 and #6. Participants complete a Baseline Session followed by two repetitions of the Baseline Session (each 12 weeks apart) and 12 weeks of standard treatment immediately following the third session. Standard treatment will require the participant to attend clinic-based treatment sessions for 1 hour per day, 3 days per week, for 12 weeks. Standard treatment will consist of 3 components: mand training, matrix training, and stimulus equivalence training.
89188401|NCT00789087|Active Comparator|1. Videothoracoscopic talc poudrage (VT)|
89188402|NCT00789087|Active Comparator|2. Talc slurry through a chest tube (DT)|
89188403|NCT00711776|Experimental|Subjects receiving new formulation in blank test group|Eligible subjects will receive acyclovir cream 5 % following single topical application.
89188404|NCT00711776|Active Comparator|Subjects receiving current formulation in blank test group|Eligible subjects will receive acyclovir cream 5 % following single topical application.
89188405|NCT00711776|Experimental|Subjects receiving new formulation in pre-test group|Eligible subjects will receive acyclovir cream 5 % following single topical application.
89188406|NCT00711776|Active Comparator|Subjects receiving current formulation in pre-test group|Eligible subjects will receive acyclovir cream 5 % following single topical application.
89188407|NCT00711776|Experimental|Subjects receiving new formulation in main-test group|Eligible subjects will receive acyclovir cream 5 % following single topical application.
89188408|NCT00711776|Active Comparator|Subjects receiving current formulation in main-test group|Eligible subjects will receive acyclovir cream 5 % following single topical application.
89188409|NCT00795171|Experimental|Docetaxel + Sunitinib|docetaxel 75mg/m2 day1 q 21d x 4 cycles, sunitinib 37.5mg/d day2 -day15 x 4 cycles
89188410|NCT00795171|Active Comparator|Taxotere|docetaxel 75mg/m2 day1 q 21d x 4 cycles
89188411|NCT00711854|Experimental|1|trimethoprim-sulfamethoxazole (TMP-SMX) plus rifampicin
89188412|NCT00711854|Active Comparator|2|Linezolid
89188413|NCT00795249|Experimental|smoker|Individuals who have a habit of chronic smoking without any coronary risk factors
89188414|NCT00795249|No Intervention|non-smoker|the age-matched healthy volunteers
89530217|NCT05082779|Experimental|Cohort B2: 1 mg|Participants in fasted state will receive CS0159 1 mg or placebo once daily for a consecutive 14 days.
88874113|NCT02161536|Experimental|Motus Cleansing System Rev 3.0|Colonoscopy with MCS Rev 3.0,enrolled under protocol Rev 5.0
89188415|NCT00795327|Experimental|1|single arm study
89188416|NCT00773279|Experimental|PDS290 --> FlexPen®|Subjects will receive trial drug with PDS290 for 12 weeks (treatment sequence 1) followed by FlexPen® for 12 weeks (treatment sequence 2)
89188417|NCT00773279|Experimental|FlexPen® --> PDS290|Subjects will receive trial drug with FlexPen® for 12 weeks (treatment sequence 1) followed by PDS290 for 12 weeks (treatment sequence 2)
89188418|NCT05003882||Arm A|Commercially available, orally ingestible CBD product A
88874114|NCT02163486|Active Comparator|Group U (UNIQUE)|Group LMA- UNIQUE, inserted according to described standard method. Between 30-40 kg, no.3. Between 50-70 kg, no. 4 Between 70-100 kg, no. 5. LMA-Unique Before SGAD is inserted, a water-based lubricant without local anesthetic, was spread on the surfaces that will touch the palate and LMA-U cuff was completely deflated.oup U (UNIQUE): Group Laryngeal Mask Airway-Unique.
88874115|NCT02163486|Experimental|Group I (I-GEL ): Group I-GEL|Group I (I-GEL): Between 30-60 kg, no. 3. Between 50-90 kg, no. 4. For > 90 kg no.5. I-GEL
88874116|NCT02164422|Experimental|Guanfacine 3mg/day|Guanfacine 3mg/day
88874117|NCT02164422|Experimental|Guanfacine 1.5mg/day|Guanfacine 1.5mg/day
88874118|NCT02164422|Placebo Comparator|Placebo|Placebo
88874119|NCT02165124|Experimental|Intervention/Bariatric Embolization|
88874120|NCT02165904|Experimental|Autologous Mesenchymal Bone Marrow Cell|All patients will be treated with the same treatment: Adult Autologous Mesenchymal Bone Marrow Cell
88874121|NCT02167074|Active Comparator|25G FNA needle|Patients referred for EUS-guided tissue acquisition of a pancreatic mass, lymph node, or other submucosal or undefined mass (non-pancreatic).
88874122|NCT02167074|Active Comparator|20G ProCore FNB needle|Patients referred for EUS-guided tissue acquisition of a pancreatic mass, lymph node, or other submucosal or undefined mass (non-pancreatic).
88874123|NCT02170662|Active Comparator|Active drug|During Part I of the study, subjects will be randomized in a blinded fashion to either placebo (vehicle that does not contain active drug) or topical bimatoprost to apply to the scalp target area every day for 16 weeks. After a 10 day washout period, each group will be crossed over to the alternate topical preparation (Part II) to apply for 16 weeks.
88874124|NCT02170662|Active Comparator|Placebo|During Part I of the study, subjects will be randomized in a blinded fashion to either placebo (vehicle that does not contain active drug) or topical bimatoprost to apply to the scalp target area every day for 16 weeks. After a 10 day washout period, each group will be crossed over to the alternate topical preparation (Part II) to apply for 16 weeks.
88874125|NCT02173392|Experimental|Brodalumab (single 1.5mL pre-filled syringe)|A single 210 mg subcutaneous (SC) dose of Brodalumab administered using a single 1.5mL pre-filled syringe injection
88874126|NCT02173392|Experimental|Brodalumab (2 pre-filled syringes [1.0mL + 0.5mL])|A single 210 mg subcutaneous (SC) dose of Brodalumab administered using 2 (1.0mL + 0.5mL) pre-filled syringe injections
88874127|NCT02178540|Other|Open label|one dose (4 capsules) of placebo
88874128|NCT02178696|Experimental|Known Placebo First|"This arm gets a placebo that they know is a placebo (called inactive), then has 2 scans performed (FMRI and PET), then a 2-3 day washout, and then gets a so-called active medication (which is also actually a placebo), and another pair of scans. Following these, participants receive 10 weeks of open-label antidepressant administration (Celexa or alternative as explained in intervention description). First line antidepressant will be Celexa unless not clinically indicated."
88874129|NCT02178696|Experimental|"Active (blinded) Placebo first group"|"This arm gets a placebo that they don't know is a placebo (called Active), then has 2 scans performed (FMRI and PET), then a 2-3 day washout, and then gets a so-called inactive medication (which participants know is a placebo), and another pair of scans. Following these, participants receive 10 weeks of open-label antidepressant administration (Celexa as explained in intervention description). First line antidepressant will be Celexa unless not clinically indicated."
88874130|NCT02179788|Experimental|Standard care plus metformin|67% of stage 2 eligible mothers will be randomly allocated to this arm. Mothers will be instructed to thoroughly empty their breasts at least 8 times per day and to take the assigned study drug.
88874131|NCT02179788|Placebo Comparator|Standard Care plus placebo|"33% of Stage 2 eligible mothers will be randomly allocated to this arm. Mothers will be instructed to thoroughly empty their breasts at least 8 times per day (Standard Care) and to take the assigned study drug. The placebo arm will be consuming methylcellulose USP Powder encapsulated in #00 opaque capsules (supplied by PCCA, Houston TX) for 4 weeks according to the following schedule:~Days 1-7, take 1 capsule with evening meal~Days 8-14, take 3 capsules with evening meal~Days 14-28 (or through completion of post-intervention data collection), take four capsules with evening meal~Actual increase in dose may occur more slowly if standard titration schedule is not well tolerated. Adjustments to schedule will be made in consultation with the adult medicine study co-investigator."
88874132|NCT02180100|Experimental|Terconazole Vaginal Suppository|Terconazole Vaginal Suppository inserted intravaginally once daily before bedtime for 6 consecutive days
88874133|NCT02180100|Active Comparator|Fluconazole|orally Fluconazole 150 mg (Pfizer Pharmaceuticals) at day 1 and day 4.
89188419|NCT05003882||Arm B|Commercially available, orally ingestible CBD product B
89188420|NCT05003882||Arm C|Commercially available, orally ingestible CBD product C
89188421|NCT05003882||Arm D|Commercially available, orally ingestible CBD product D
89188422|NCT05003882||Arm E|Commercially available, orally ingestible CBD product E
89188423|NCT05003882||Arm F|Commercially available, orally ingestible CBD product F
89188424|NCT05003882||Arm G|Commercially available, orally ingestible CBD product G
89188425|NCT05003882||Arm H|Commercially available, orally ingestible CBD product H
89188426|NCT05003882||Arm I|Commercially available, orally ingestible CBD product I
89188427|NCT05003882||Arm J|Commercially available, orally ingestible CBD product J
89188428|NCT05003882||Arm K|Commercially available, orally ingestible CBD product K
89188429|NCT05003882||Arm L|Commercially available, orally ingestible CBD product L
89188430|NCT05003882||Arm M|Commercially available, orally ingestible CBD product M
89188431|NCT05003882||Control|Waitlist control
89188432|NCT00795405|Sham Comparator|1|No exposure to sporting events
89188433|NCT00795405|Experimental|2|Exposure to sporting events
89188434|NCT04046211|Experimental|Hydrogen exposure|The first two patients will be exposed to 2.4% hydrogen gas in medical air via HFNC for 24 hours. The second two patients will be exposed to the same gas for 48 hours. The final 4 patients will be exposed to the same gas for 72 hours.
89188435|NCT00712088|Experimental|1: Group Intervention|Group level intervention
89188436|NCT00712088|Active Comparator|2: HCT|Offer of HIV counseling and testing
89188437|NCT02579226|Experimental|Part A|Part A dose-escalation will evaluate the safety and tolerability of AZD2811 monotherapy at increasing doses in patients with advanced solid tumours. Patients will receive AZD2811 on Days 1 and 4 of a 28-day cycle or Day 1 only in cycles of either 21 or 28 days.
89188438|NCT02579226|Experimental|Part B|Part B will include patients with relapsed or refractory small-cell lung cancer (SCLC). Patients will receive AZD2811 monotherapy at the recommended Phase 2 dose (RP2D).
89188439|NCT00795483|Experimental|1-ANNUAL|1. Zoledronic acid + Lifestyle modifications (experimental)
89397905|NCT02151578|Experimental|Home management of malaria and pneumonia|"At the community level, the Community health workers/ key opinion leader (HWs/KOLs) trained and equipped to provide the antimalarial drug (arthemeter/Lumefantrine ) or antibiotic (Cotrimoxazole) to any child with fever (hot body) without any other signs of complications like impaired consciousness, convulsions, etc. The treatment decision making for the CHWs/KOLs based on the algorithm"
89397906|NCT02151656|Experimental|F17464|Oral administration - During 6 weeks - 4 capsules daily
89397907|NCT02151656|Placebo Comparator|Placebo|Oral administration - During 6 weeks - 4 capsules daily
89397908|NCT03543020||Patients|Patients undergoing Radiation therapy to brain
89397909|NCT02155790|Experimental|Renal Denervation by Neurolysis|Infusion of 0.3 ml of dehydrated alcohol (96%-98%) into the peri-adventitial space of the renal artery, to achieve renal denervation by Neurolysis, via three simultaneous deployed needles, situated at the distal end of the Peregrine System Infusion Catheter.
88874134|NCT02180646|Active Comparator|High Carb then High Protein Breakfast|A high carbohydrate breakfast - 500 kcal (15% protein, 65% CHO, 20% fat) followed by a 7-day washout period, and then 7 days of eating a high protein breakfast - 500 kcal (35% protein, 45% CHO, 20% fat).
88874135|NCT02180646|Active Comparator|High Protein then High Carb Breakfast|A high protein breakfast - 500 kcal followed by a 7-day washout period, and then 7 days of eating a high carbohydrate breakfast - 500 kcal (35% protein, 45% CHO, 20% fat)
88874136|NCT02181426|Placebo Comparator|0 mg of Ketorolac|participant receives 0 mg of Ketorolac
88874137|NCT02181426|Active Comparator|7.5 mg of Ketorolac|participant receives 7.5 mg of Ketorolac
88874138|NCT02181426|Active Comparator|15 mg Ketorolac|participant receives 15 mg of Ketorolac
88874139|NCT02181426|Active Comparator|30 mg Ketorolac|participant receives 30mg of Ketorolac
88874140|NCT02184624|Experimental|Sub-Study 1|Subjects will be randomized to either use ELLIPTA inhaler first and then DISKUS/ACCUHALER inhaler or use DISKUS/ACCUHALER inhaler first and then ELLIPTA inhaler.
88874141|NCT02184624|Experimental|Sub-Study 2|Subjects will be randomized to either use ELLIPTA inhaler first and then MDI inhaler or use MDI inhaler first and then ELLIPTA inhaler.
88874142|NCT02184624|Experimental|Sub-Study 3|Subjects will be randomized to either use ELLIPTA inhaler first and then TURBUHALER inhaler or use TURBUHALER inhaler first and then ELLIPTA.
88874143|NCT02184624|Experimental|Sub-Study 4|Subjects will be randomized to either use ELLIPTA inhaler first and then HANDIHALER inhaler or use HANDIHALER inhaler first and then ELLIPTA inhaler.
88874144|NCT02184624|Experimental|Sub-Study 5|Subjects will be randomized to either use ELLIPTA inhaler first and then BREEZEHALER inhaler or use BREEZEHALER inhaler first and then ELLIPTA inhaler.
88874145|NCT02185404|Experimental|wearing the iStride device|The training will consist of four weeks of training with three training sessions performed each week. The training sessions will consist of up to thirty minutes of training with the iStride on, with breaks between walking sessions and as needed if the subject requests an additional break. Subjects will place the device on their foot in which they have the shortest step length, as measured during the pre-training gait analysis. This is typically the healthy side foot. There will also be several follow up visits following the final testing session.
88874146|NCT02186808|Other|Procera® Bridge Zirconia|Patients planned for treatment with a tooth-supported 3 to 4-unit bridge in any position of the maxilla or the mandible.
88874147|NCT02189382|Experimental|Potassium Oxalate Gel|Self Applied
88874148|NCT02189382|Other|Water|Self Applied
88874149|NCT02189850|Experimental|BLI800 - Dose 1|BLI800 oral solution
88874150|NCT02189850|Experimental|BLI800 - Dose 2|BLI800 oral solution
88874151|NCT02190552||EmboTrap® Revascularization Device|The EmboTrap® Revascularization Device is the investigational device
88874152|NCT02192814|Experimental|Lacosamide (LCM)|"On Day - 1, LCM oral tablets were administered in accordance with each subject's LCM dosage regimen in EP0009 (NCT01832038). The oral tablets were taken from EP0009 supply.~During the Treatment Period, subjects received a 30-minute infusion of intravenous (iv) LCM twice daily, once in the morning and once in the evening, for 5 days.~The daily dose of iv LCM was the same as the subject's daily dose of oral LCM in EP0009 (200 - 400 mg/day)."
88874153|NCT02195232|Experimental|Cohort A - Isoquercetin|"-- Cohort A: 500 mg, Once daily, 28 days~- For both cohorts A and B, lower extremity ultrasound will be performed at 56 days. Baseline D-dimer and correlative labs will be drawn at Day 1 and at 56 days. Patients will be followed for survival after completion of 56 days."
88874154|NCT02195232|Experimental|Cohort B - Isoquercetin|"--Cohort B: 1000 mg, Once daily, 28 days~- For both cohorts A and B, lower extremity ultrasound will be performed at 56 days. Baseline D-dimer and correlative labs will be drawn at Day 1 and at 56 days. Patients will be followed for survival after completion of 56 days."
89397910|NCT02151734|Experimental|KALOMIN™ Tab.|KALOMIN™ Tab./Placebo to Umckamin syrup
89397911|NCT02151734|Active Comparator|Umckamin syrup|Umckamin syrup/Placebo to KALOMIN™ Tab.
89397912|NCT02151812|Experimental|Agent Paclitaxel-coated balloon|drug-coated balloon dilatation of the index lesion using a single Agent(TM) balloon that completely covers the restenotic lesion
88874155|NCT02195622|Other|Lumenis VersaCut Morcellator|Lumenis VersaCut Morcellator will be utilized for prostate tissue morcellation
88874156|NCT02195622|Other|Wolf Piranha Morcellator|Wolf Piranha Morcellator will be utilized for prostate tissue morcellation
88874157|NCT02196168|Experimental|Arm I (WEE1 inhibitor MK-1775, cisplatin)|Patients receive WEE1 inhibitor MK-1775 PO BID for 5 doses beginning on day 1 and cisplatin IV over 1 hour on day 1.
88874158|NCT02196168|Active Comparator|Arm II (placebo, cisplatin)|Patients receive placebo PO BID for 5 doses beginning on day 1 and cisplatin IV over 2 hour on day 1.
89188440|NCT00795483|Other|2-CONTROL|2. Lifestyle modifications (control)
89397913|NCT02151812|Active Comparator|SeQuent Please Paclitaxel-coated balloon|drug-coated balloon dilatation of the index lesion using a single SeQuent(R) Please balloon that completely covers the restenotic lesion
89397914|NCT02155868|Experimental|Intervention|"Cerebral NIRS monitoring by means of FORE-SIGHT Universal Cerebral Oximeter MC-2030C.~Predefined protocol of interventions for correcting rSO2 desaturation (< 60%) during cardiac surgery and the first six hours after it."
89397915|NCT02155868|Placebo Comparator|Control|Only cerebral NIRS monitoring by means of FORE-SIGHT Universal Cerebral Oximeter MC-2030C during cardiac surgery and the first six hours after it.
89397916|NCT02151890|Experimental|Laparoscopic Stem Cell Transplantation.|Out of 112 high risk patients for POF diagnosis was established in 10 cases. Endometrial fractional biopsy was taken, stained with H&E stain and by IH staining by stem cell marker OCT4. Immunohistochemical expression of stem cell marker OCT4 was evaluated before and after transplantation according to Edessy Stem Cell Scoring (ESS)Laparoscopic injected of stem cell Sample in the ovaries.. Participants were followed up monthly for a period of six months by hormonal (FSH, LH and E2), clinical (resuming menstruation), US (folliculometry), histopathological (HP), and IH expression of stem cell marker OCT4 of the endometrial biopsy (stem cell positivity according to ESS) outcome.
88874159|NCT02198430||Patients|Patients with haemophilia recruited for multidisciplinary assessment of the main physical, functional and psychosocial variables.
88874160|NCT02198430||Control group|Children without hemophilia
88874161|NCT02200458|Experimental|VeinViewer|Vascular imaging technology will be used to visualize peripheral vasculature.
88874162|NCT02200536|Experimental|Test|Infant oral health promotion package
88874163|NCT02200536|Active Comparator|Control 1|Infant oral health pamphlet
88874164|NCT02200536|No Intervention|Control 2|
88874165|NCT02201394|Experimental|Loading dose|Patients with stable CVD given a single ticagrelor loading dose and aspirin loading dose
88874166|NCT02201394|Experimental|Maintenance dose|Patients with stable CVD given ticagrelor maintenance dose and aspirin maintenance dose for one week.
88874167|NCT02202252|Experimental|Single drain|"Insertion of a single drain: A negative pressure drain will be inserted below the lower flap directing to the axilla in the single drain group.~Ultrasonography after removal of the drains: One day after removal of the drains seroma under the flaps and in the axilla will be examined by ultrasonography."
88874168|NCT02202252|Experimental|Double drain|"Insertion of double drains: Two negative pressure drains will be inserted into the axilla and below the lower flap in the double drains group.~Ultrasonography after removal of the drains: One day after removal of the drains seroma under the flaps and in the axilla will be examined by ultrasonography."
88874169|NCT02203578|Experimental|Supportive care (romidepsin)|Patients receive romidepsin IV over 4 hours on days 1, 8, and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
88874170|NCT02204124|Active Comparator|Control Group|In the control group, scissors, ligatures, clips and sutures will be used for dissection and hemostasis as necessary.
89188441|NCT00795483|Experimental|3-BIENNIAL|3. Zoledronic acid + Lifestyle modifications (experimental)
89188442|NCT00712400|Active Comparator|1|Latanoprost 0.005%, Xalatan®
89188443|NCT00712400|Placebo Comparator|2|Vehicle to latanoprost (eyedrops containing the same stabilizers as latanoprost, but no active drug)
89188444|NCT00766415|Experimental|AZD1981|
89188445|NCT00766415|Placebo Comparator|Placebo|
89188446|NCT04071834||Diabetes mellitus group|Diabetic patients undergoing spinal anesthesia for lower extremity surgery
89188447|NCT04071834||Non-diabetic group|Non-diabetic patients undergoing spinal anesthesia for lower extremity surgery
89188448|NCT03015792|Experimental|Treatment (ibrutinib, lenalidomide, dexamethasone)|"PHASE I: Patients receive ibrutinib PO on days 1-28, lenalidomide PO on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity. Beginning course 25, patients receive lenalidomide PO on days 1-21 and dexamethasone PO on days 1, 8, 15, and 22. Courses repeat every 84 days in the absence of disease progression or unacceptable toxicity.~PHASE II: Patients receive ibrutinib and dexamethasone as in phase I and lenalidomide PO on days 1-21 beginning course 2. Beginning course 25, patients receive lenalidomide and dexamethasone as in phase I."
89188449|NCT00789165|Experimental|Quinidine|Patients with type I Brugada electrocardiogram (either spontaneous or following a drug challenge with sodium channel blocker) who never experienced arrhythmia-related symptoms. Patients will receive quinidine therapy at the discretion of the attending physician.
89188450|NCT00789165|Active Comparator|no therapy|Patients with asymptomatic Brugada syndrome who opted to receive no therapy following the recommendation of their attending physician
89188451|NCT00712556||Flourine 18-fluorodeoxyglucose PET|PET using fluorine 18-fluorodeoxyglucose to image cancer tumors
89188452|NCT00795561|Experimental|Day care|Patients randomised to day care treatment of NVP will be instructed to present to the day services unit where they will receive a pre-agreed fluid and anti emetic regimen.
89188453|NCT00795561|Active Comparator|Inpatient|Patients randomised to inpatient management of NVP will be admitted to hospital where they will receive a pre-agreed fluid and anti emetic regimen.
89188454|NCT00772967|Experimental|Placebo, Naproxen, Ultracet|Participants were treated with Placebo for 3 days in Treatment Period 1, Naproxen for 3 days in Treatment Period 2, and Ultracet for 3 days in Treatment Period 3. The treatment periods were separated by a 4-6 day break.
89188455|NCT00772967|Experimental|Naproxen, Ultracet, Placebo|Participants were treated with Naproxen for 3 days in Treatment Period 1, Ultracet for 3 days in Treatment Period 2, and Placebo for 3 days in Treatment Period 3. The treatment periods were separated by a 4-6 day break.
89397917|NCT02151968|Active Comparator|Traditional blind peribulbar block|
89397918|NCT02151968|Experimental|Ultrasound-guided peribulbar block|
89397919|NCT02776670|Experimental|SYSTANE BALANCE|Propylene glycol, 0.6% eye drops, 1 drop in each eye 4 times per day for 35 days
89397920|NCT02776670|Active Comparator|REFRESH OPTIVE|Lubricant eye drops, 1 drop in each eye 4 times per day for 35 days
88874171|NCT02204124|Experimental|Thunderbeat™|-In the Thunderbeat™ group, dissection and hemostasis of vessels will be performed using the Thunderbeat™ device (Olympus, Japan).
88874172|NCT02204748||DePuy Attune PS FB TKA|Individuals implanted with the DePuy Attune posterior stabilizing fixed bearing knee system implanted by a single surgeon at least three months post-operative.
88874173|NCT02206776|Placebo Comparator|Midazolam|A single dose of intranasal midazolam up to 4 mg
88874174|NCT02206776|Experimental|Ketamine|A single dose of intranasal ketamine up to 50 mg
88874175|NCT02207322|No Intervention|Standard transplant care|"Patient Enrollment and Caregiver Enrollment (within 72 hours of hospital)~-- Complete baseline data collection, and registration~Patient Randomization~Standard transplant oncology care~-- Palliative care consults only upon request~Longitudinal Data Collection (patient & family caregivers)~Week-2 of hospitalization~3-months, and 6-months post HSCT"
89397921|NCT02149862|Experimental|cancer|patients with an indication of partial or total bladder resection will have urine infrared analysis
89397922|NCT02149862|Placebo Comparator|control group|"Lithiasic patients should be operated a urinary calculation, without catheter double J, will have urine infrared analysis"
89397923|NCT02149940|Experimental|clinical pharmacy intervention|
89397924|NCT02150018||non invasive ventilation (NIV)|
89397925|NCT02150096|Active Comparator|Continuous ultrasound group|the group will be treated with 1,5 W/cm² 6 minutes in each side of the lumbar spine in 6 points around the lumbar spine
89397926|NCT02150096|Active Comparator|Pulsed ultrasound group|the group will be treated with 1,5 W/cm² 6 minutes in each side of the lumbar spine in 6 points around the lumbar spine
89397927|NCT02150096|Active Comparator|low level laser therapy group|the group will be treated with 3J during 6 minutes in each side of the lumbar spine in 6 points around the lumbar spine
89397928|NCT02150096|No Intervention|control group|group of women no treated, only evaluated in two moments and this group will be compared with orthers: laser, pulsed ultrasound and continuous ultrasound.
89397929|NCT04906226|Experimental|Intervention group|Individuals participating in the study will be divided into intervention and control groups. The individuals in the foot massage group will be given foot massage training by the researcher. Later, people with diabetes will be enabled to continue self-massage at home. To encourage the continuation of the intervention, the researcher will be called once a week by phone and her questions will be answered. At the end of the four weeks, the patient will be interviewed again and data collection forms will be filled.
89397930|NCT04906226|No Intervention|Control group|There will be no additional application other than routine to the control group, data collection forms will be applied and recorded at the beginning of the study and at the end of four weeks.
89397931|NCT02150174|Experimental|Patients with schizophrenia|
89397932|NCT02150174|Active Comparator|Healthy subjects|
89397933|NCT02156024|Placebo Comparator|placebo|placebo drink, 1 dose at a time, twice a day, duration: 4 weeks
89397934|NCT02156024|Active Comparator|Gastrodia and Uncaria Drink|Gastrodia and Uncaria Drink, 1 dose at a time, twice a day, duration: 4 weeks
89397935|NCT02150252|Experimental|BY HWT，placebo-BY HWT ， Gait parameter|
89397936|NCT02152202|Experimental|Semi-upright position|Semi-upright position defined as 45 degrees incline from horizontal of the patients bed during nocturnal sleep, for two postoperative nights. Daytime naps will be excluded. A regular pillow may be used by the patients based upon the level of comfort and also to support the head in a neutral position.
89397937|NCT02152202|Other|Control group (Supine position)|In this group patients' bed will be set into Supine/0 degree angle during sleep in the night time. Patient will be managed according to routine care
89397938|NCT02152280|Experimental|Danhong Injection|Danhong Injection 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 10 days;
89397939|NCT02152280|Placebo Comparator|Normal Saline|0.9% sodium chloride solution 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 10 days.
89397940|NCT02255084|Experimental|Group 1|"Group 1 remove self sample kit at gp consulting room or perform pap smear :~Study coordinators send mail inviting women to remove a kit for vaginal self-sampling at their general practitioner s consulting room.~Either a pap smear is perform or, at home, women perform vaginal self sampling. Then women send it to a central laboratory for HPV test (Human papillomaVirus)."
89397941|NCT02255084|Experimental|Group 2|"Group 2 perform self sample at home or pap smear :~Kit for vaginal self-sampling sent at women home. Women perform vaginal self sampling. Then women send it to a central laboratory for HPV test (Human papillomaVirus)."
89397942|NCT02150330|Active Comparator|DHEAS in DOR Group|Additional usage of DHEAS supplement in patients with DOR under ovarian hyper-stimulation protocol.
89397943|NCT02150330|Active Comparator|Normal Control|Patients under ovarian hyper-stimulation protocol. No DHEAS supplement.
88874176|NCT02207322|Experimental|transplant with early palliative care|"Standard transplant oncology care with early palliative care~Patient Enrollment and Caregiver Enrollment (within 72 hours of patient enrollment)~--Complete baseline data collection, and registration Intervention description: Inpatient palliative care intervention description: 1st visit within 72 hours of randomization, At least twice weekly follow up visits~Longitudinal Data Collection (patient & family caregivers)~Week-2 of hospitalization~3-months, and 6-months post HSCT"
89397944|NCT02150330|Active Comparator|Shame DOR Group|Patients with DOR under ovarian hyper-stimulation protocol. No DHEAS supplement.
89397945|NCT02255162|Experimental|Lenalidomide|"Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.~Participants will receive the following:~Cytarabine-intravenous, fixed dosage, given 5 times during cycle~HLA-mismatched stem-cell microtransplantation~Lenalidomide-administered daily per cycle"
89397946|NCT02156180||Early stage oral cavity / oropharyngeal cancer|Exhaled breath
89397947|NCT02152436||Before simulation-based curriculum|125 surgical interventions will be observed and outcomes will be measured before simulation-based curriculum
89397948|NCT02152436||After simulation-based curriculum|125 surgical interventions will be observed and outcomes will be measured after simulation-based curriculum
89397949|NCT02152514|Active Comparator|Intrathecal Morphine/Sufentanil and PCA|Patients will receive an intrathecal injection of Morphine 250 mcg and Sufentanil 10 mcg before the induction of anesthesia. They will have a PCA for analgesia rescue in the post-operative period.
89397950|NCT02152514|Placebo Comparator|PCA alone|Patients will NOT receive an intrathecal injection of Morphine 250 mcg and Sufentanil 10 mcg before the induction of anesthesia. They will only have a PCA for analgesia in the post-operative period.
89397951|NCT02261090|Experimental|Formulation B|Slow release (SR) tablet
89397952|NCT02261090|Experimental|Formulation C|SR tablet
89397953|NCT02261090|Experimental|Formulation D|SR tablet
88874177|NCT02207478|Experimental|ENB-GS-TBLB-X-ray Group|The guide sheath(GS) is introduced into the lesion via Electromagnetic Navigation System. The locatable guide(LG) and GS are confirmed to reach the lesion by radiograph fluoroscopy, pathologic specimens are obtained with fluoroscopic guidance.
88874178|NCT02207478|Active Comparator|GS-TBLB-X-ray group|The GS is introduced into the lesion via the working channel of a bronchoscope with radiographic fluoroscopy. Once the location of the lesion is identified by fluoroscopy, pathologic specimens are obtained under fluoroscopic guidance.
88874179|NCT02209272|Experimental|bacteriostatic saline|for ultrasound guided hip joint injection local anesthesia
88874180|NCT02209272|Active Comparator|buffered lidocaine|for ultrasound guided hip joint injection local anesthesia
88874181|NCT02210052|Experimental|Radiofrequency neurotomy subjects|Subjects with spinal hardware that are undergoing radiofrequency ablation procedures will have an additional radiofrequency cannula placed at the site of adjacent pedicle screws for temperature measurement only.
88874182|NCT02210286|Experimental|Magtein|All participants will orally take a total of 1800 mg/day for 60 days. Oral administration includes two pills 2 hours before bed time and one pill in the morning, each pill containing 600 mg of MgT-1219.
88874183|NCT02211456|Experimental|Participants|Having an ablation procedure with access to the left side of the heart
88874184|NCT02211534|Active Comparator|Pulsed Electromagnetic Field Device|Pulsed Electromagnetic Field therapy device; self-administered at home twice daily for 30 minutes.
88874185|NCT02211534|Sham Comparator|Sham Pulsed Electromagnetic Field Device|Inactive Pulsed Electromagnetic Field Therapy device; self-administered at home twice daily for 30 minutes.
88874186|NCT02213250|Experimental|BeneFIX|
88874187|NCT02214420|Active Comparator|SMV+SOF|IFN-II patients will receive 12 weeks of OLYSIO (Simeprevir) (150mg QD) + SOVALDI (Sofosbuvir) (400mg QD)
88874188|NCT02214420|Active Comparator|SMV+SOF+RBV|IFN-II patients will receive 12 weeks of OLYSIO (Simeprevir) (150mg QD) + SOVALDI (Sofosbuvir) (400mg QD) + weight-based Ribavirin 1000-1200 mg/day
88874189|NCT02215200|Experimental|Anti-Thymocyte Globulin (ATG) and Placebo|"Anti-Thymocyte Globulin (ATG)/Placebo: Anti-Thymocyte Globulin (ATG) will be administered at a dose of 2.5mg/kg as two divided IV infusions of 0.5mg/kg and 2mg/kg. First dose (0.5mg/kg) will be infused over a minimum of 12 hours, and the second dose (2mg/kg) over a minimum of 8 hours. The second dose should be given no less than 12 and no more than 24 hours after the previous dose.~Placebo(for GCSF) treatment will begin 6 hours after completion of the ATG. Placebo will be given subcutaneously every 2 weeks for a total of 6 doses"
88874190|NCT02215200|Experimental|ATG plus Granulocyte colony stimulating factor (GCSF)|"Granulocyte colony stimulating factor (GCSF) is supplied in 0.6 mL prefilled syringes for subcutaneous injection. Each syringe contains 6 mg GCSF (based on protein weight), in a sterile, clear, colorless, preservative-free solution (pH 4.0) containing acetate (0.35 mg), sorbitol (30.0 mg), polysorbate 20 (0.02 mg), and sodium (0.02 mg) in water for injection, U.S. Pharmacopeial Convention (USP). The standard 6mg dose will be given with the exception of subjects who weigh less than 45 kg.~GCSF treatment will begin 6 hours after completion of the ATG / Placebo. GCSF will be given subcutaneously every 2 weeks for a total of 6 doses"
88874191|NCT02215200|Placebo Comparator|Placebo|Placebo for ATG will be administered by IV infusion in 2 doses. Placebo for GCSF will be administered subcutaneously every 2 weeks for a total of 6 doses
88874192|NCT02216136||Breast Conservation Cohort|Breast Conservation group (Group A) with newly diagnosed breast cancer who decide to proceed with lumpectomy and radiation treatment.
88874193|NCT02216136||Mastectomy and Reconstruction Cohort|Mastectomy and Reconstruction group (Group B): This group will have mastectomy with immediate reconstruction (defined as reconstruction process starting at time of initial mastectomy surgery). They may or may not require chemotherapy and radiation depending on their cancer staging as well as multiple steps of their breast reconstruction.
88874194|NCT02216136||Mastectomy Only Cohort|Mastectomy Only Cohort: This group will have mastectomy without reconstruction. They may or may not require chemotherapy and radiation.
88874195|NCT02217618|Experimental|LY2409021|Single oral dose of 20 milligrams (mg) LY2409021.
88874196|NCT02218242|Experimental|Ultrasound|Participants in this study have elected to have surgical resection of non-small cell lung cancer tumors as part of their standard of care. During that surgical procedure, participants will also receive laparoscopic intraoperative ultrasound to assess the thoracic wall lymph nodes as part of the experimental procedure. The ultrasound procedure will add about 15 minutes to the total surgical time. Because it is laparoscopic and utilizes non-ionizing radiation, the risk to the participant is minimal.
88874197|NCT02218320||Group A|Ten HIV-infected adults will be in Group A and take the HIV medication raltegravir in combination with tenofovir and emtricitabine as their provider-prescribed antiretroviral regimen.
88874198|NCT02218320||Group B|Ten HIV-infected adults will be in Group B and take the HIV medication dolutegravir in combination with tenofovir and emtricitabine as their provider-prescribed antiretroviral regimen.
88874199|NCT02219256|Experimental|Cohort 1: TAK-079 0.0003 mg/kg|TAK-079 0.0003 mg/kg, infusion, intravenously, once.
88874200|NCT02219256|Experimental|Cohort 2-9: TAK-079 TBD|TAK-079, infusion, intravenously or subcutaneously, once. Dose to be determined from data collected in previous IV or SC Cohort(s)
88874201|NCT02219256|Placebo Comparator|Placebo to TAK-079|Placebo to TAK-079, infusion, intravenously or subcutaneously, once.
88874202|NCT02222610|Experimental|Cohort A|"Subject's will receive monthly treatment of an intravitreal injection of 0.5 mg ranibizumab for 48 weeks.~Starting at week 52, subject's will enter a treat & extend regime, if a subject achieves a dry macula. For a macula to be considered dry persistent or recurrent fluid must be resolved on spectral domain (SD)-optical coherence tomography (OCT). The interval between injections will not exceed 12 weeks. After a subject is extended beyond 4-weeks & develops recurrent disease activity, the eye is treated & the treatment interval for the next visit is reduced by 1 week, compared to the previous treatment interval. The interval between treatments will be reduced by 1-week intervals until a dry macula is again established. Once a dry macula is again achieved, the interval between visits will be extended by 1-week intervals again."
89397954|NCT02261090|Experimental|Formulation E|SR tablet
89397955|NCT02261090|Experimental|Formulation F|SR tablet
89397956|NCT02261090|Experimental|Formulation G|SR tablet
89397957|NCT02261090|Experimental|Formulation H|SR tablet
89397958|NCT02261090|Active Comparator|immediate release (IR) formulation|
88874203|NCT02222610|Experimental|Cohort B|"Subject's receive monthly treatment of IVT of 0.5 mg ranibizumab for 48 weeks. 1 week after the initial dose of IVT ranibizumab, the subject will have peripheral targeted-retinal photocoagulation (TRP) to areas of peripheral retinal ischemia based on 120° or greater wide field angiography. After the first session of TRP, subjects will have a repeat wide field angiogram at 12 weeks & 24 weeks & will receive additional TRP as needed (PRN) to areas of peripheral retinal ischemia.~Starting at week 52, subject's will enter a treat & extend regime as described in cohort A."
88874204|NCT02222610|Experimental|Cohort C|"Subject's will receive 3 consecutive monthly doses of IVT 0.5 mg ranibizumab followed by PRN treatment with 0.5 mg ranibizumab intravitreal injection. 1 week after the initial dose of IVT ranibizumab, the subject will have peripheral targeted-retinal photocoagulation (TRP) to areas of peripheral retinal ischemia. After the first session of TRP, subjects will have a repeat wide field angiogram at 12 weeks & 24 weeks & will receive additional TRP as needed (PRN) to areas of peripheral retinal ischemia.~Starting at week 52, subject's will enter a treat & extend regime as described in cohort A."
88874205|NCT02223546||healthy subject|healthy subject, every 3 hour measurement
88874206|NCT02223702|Active Comparator|amoxicillin+metronidazole|amoxicillin+metronidazole group received a combination of 500 mg of amoxicillin and 500 mg metronidazole three times per day for 7 days.
88874207|NCT02223702|Experimental|moxifloxacin|The moxifloxacin group received 400 mg moxifloxacin, once in a day for 7 days.
88874208|NCT02224404|Experimental|Fast Gelling Dressing|
88874209|NCT02224482|No Intervention|Control|Print materials
88874210|NCT02224482|Active Comparator|Intervention Group|PROGRESS
88874211|NCT02225106|Experimental|Open label methylphenidate treatment|Forced titration with methylphenidate up to a dose of 30 mg administered orally twice daily.
88874212|NCT02227758||implanted chronic migraine patients|Patients diagnosed with chronic migraine, failed 3 or more preventative drugs, with at least moderate disability, and implanted with a St. Jude Medical Conformité Européenne approved implantable neurostimulation system
88874213|NCT02227836|Experimental|Allergy Patch Testing APT|"Patient will undergo APT testing per the following protocol:~2g of dry foods will be placed in 2ml of isotonic saline solution. The mixtures will then be placed in aluminum cups (ie Finn chambers) measuring 6 or 12 mm in diameter and adhered to the patient's back.~Foods to be included will be milk, wheat, egg, soy, peanut, tree nut, fish, shellfish, beef, corn, chicken, potato, pork, legumes, barley, rye, tomato, rice, fruits~The patches will be removed at 48 hours, and results read at 72 and 120 hours after application~Reactions will be classified as negative, + (erythema and scattered papules), ++ (erythema and papules), and +++ (erythema and vesicles)."
88874214|NCT02229318|Experimental|FruitiVits|Daily administration of FruitiVits dietary supplement
88874215|NCT02229474|Experimental|CST intervention|"We will use a two-group stepped-wedge design. Group 1 will receive the intervention immediately. This will also allow group 2 to act as controls for group 1 and allow further analysis as a controlled trial, during secondary analysis.~In accordance with the CST manual protocol, patients will be allocated to groups to ensure a spread of abilities and ensure inclusivity. No group contains only one individual of a particular religion or gender, such that they may feel left out. We will allocate patients to groups to avoid excessive travel to the group meeting place, participants may be allocated to a group based on their geographical location."
88874216|NCT02229474|No Intervention|Group 2|and group 2 will have their intervention delayed until after the end of the group 1 intervention. This will also allow group 2 to act as controls for group 1 and allow further analysis as a controlled trial, during secondary analysis.
88874217|NCT02230566|Experimental|Group A: 4 mg/kg UX003|4 mg/kg UX003 QOW through Week 46
88874218|NCT02230566|Experimental|Group B: 8 Weeks Placebo then 4 mg/kg UX003|Placebo QOW for the first 8 weeks followed by 4 mg/kg UX003 QOW through Week 46
88874219|NCT02230566|Experimental|Group C: 16 Weeks Placebo then 4 mg/kg UX003|Placebo QOW for the first 16 weeks followed by 4 mg/kg UX003 QOW through Week 46
88874220|NCT02230566|Experimental|Group D: 24 Weeks Placebo then 4 mg/kg UX003|Placebo QOW for the first 24 weeks followed by 4 mg/kg UX003 QOW through Week 46
88874221|NCT02233296|Experimental|Group A|Dosing Sequence: Administration of lasmiditan 200 mg in fed state in Dosing Period 1 followed by administration of lasmiditan 200 mg in fasted state in Dosing Period 2
88874222|NCT02233296|Experimental|Group B|Dosing Sequence: Administration of lasmiditan 200 mg in fasted state in Dosing Period 1 followed by administration in lasmiditan 200 mg fed state in Dosing Period 2.
88874223|NCT02233530|Experimental|CST intervention|"Outcomes at baseline will be compared with those immediately post intervention and at four weeks post-intervention.~In accordance with the CST manual protocol, patients will be allocated to groups to ensure a spread of abilities and ensure inclusivity. No group contains only one individual of a particular religion or gender, such that they may feel left out. The investigators will allocate patients to groups to avoid excessive travel to the group meeting place, participants may be allocated to a group based on their geographical location. Individuals will be allocated to groups based on religion, gender and geographical location."
88874224|NCT02233842||Tobacco Use in Cancer Pts & Survivors|Cognitive testing (e.g. participant interview) of tobacco use in patients (pts) who have cancer and who have survived cancer.
88874225|NCT02233998|Active Comparator|Mouth Rinse 1|After brushing in your normal manner, rinse full strength twice a day with 20 mL for 30 seconds.
88874226|NCT02233998|Active Comparator|Mouth Rinse 2|After brushing in your normal manner, rinse full strength twice a day with 20 mL for 30 seconds.
88874227|NCT02233998|Placebo Comparator|Mouth Rinse 3|After brushing in your normal manner, rinse full strength twice a day with 20 mL for 30 seconds.
88874228|NCT02235870|Active Comparator|Treatment Group|In accordance with the randomization assignment, treatment arm subjects will receive a 6-month course of Balloon therapy with a nutrition and lifestyle program. Balloon treatment consists of placement of 3 balloons Obalon Intragastric Balloons in the first 3 months of therapy.
88874229|NCT02235870|Sham Comparator|Control Group|Control arm subjects will receive a single 6-month course of sham device therapy with a nutrition and lifestyle program. Sham treatment consists of placement of 3 shams in the first 3 months of therapy.
88874230|NCT02236338|Active Comparator|Radiofrequency Ablation|"Device: ClosureFAST radiofrequency catheter (VNUS Medical Technologies Inc, San Jose, CA).~Patients will have the intervention, ablation of the incompetent greater saphenous vein, using this device."
88874231|NCT02236338|Active Comparator|Laser Ablation|"Device: EVLT 980nm diode laser system (Angiodynamics, Queensbury, NY).~Patients will have the intervention, ablation of the incompetent greater saphenous vein, using this device."
88874232|NCT02237898|Experimental|MoMba Contingency Management|Study will provide access to the web-based MoMba Live Long application & Sensodrone™ carbon-monoxide sensor for purposes of researching the acceptability of the smartphone application, operating and functioning of it, and providing remote contingency management for smoking cessation to postpartum women.
88874233|NCT02237898|Active Comparator|Office contingency management|Traditional contingency management with financial incentives delivered in-person in the office for smoking cessation to postpartum women
88874234|NCT02239380|Experimental|Lorazepam|Lorazepam intravenous formulation
88874235|NCT02239770|Placebo Comparator|0 mg Nicotine Film|In Part 1, 4 participants will be allocated to this arm and receive one placebo nicotine film.
88874236|NCT02239770|Experimental|2 mg Nicotine Film|In Part 1, 4 participants will be allocated to this arm and receive one 2 mg nicotine film.
88874237|NCT02239770|Experimental|4 mg Nicotine Film|In Part 1, 4 participants will be allocated to this arm and receive one 4 mg nicotine film.
88874238|NCT02239770|Placebo Comparator|0, 0, 0, 0mg Nicotine Film Regimen|In Part 2, 4 participants will be allocated to this arm and receive one nicotine film every 3 hours (for a total of 4 films over 12 hours) in the following order: 0, 0, 0, 0 mg.
88874239|NCT02239770|Experimental|2, 2, 2, 2mg Nicotine Film Regimen|In Part 2, 4 participants will be allocated to this arm and receive one nicotine film every 3 hours (for a total of 4 films over 12 hours) in the following order: 2, 2, 2, 2 mg.
88874240|NCT02239770|Experimental|4, 4, 0, 4mg Nicotine Film Regimen|In Part 2, 4 participants will be allocated to this arm and receive one nicotine film every 3 hours (for a total of 4 films over 12 hours) in the following order: 4, 4, 0, 4 mg.
88874241|NCT02241486|Experimental|Sublingual Fentanyl Spray|Examine the efficacy and safety of sublingual fentanyl spray (Subsys) for procedural pain (dressing changes/minor debridement) in patients with burn injury.
88874242|NCT02241720|Experimental|Regorafenib treatment|
88874243|NCT02244840|Experimental|Electronic bidet and sitz bath|Electronic bidet for 3 minutes and sitz bath for 3 minutes, at another day, for each subject
88874244|NCT02244918|Active Comparator|Counseling|Participants will go to smoking cessation counseling over 12 weeks. They will be asked to participated in 5 total counseling sessions.
88874245|NCT02244918|Experimental|Counseling Plus NRT|Participants will go to smoking cessation counseling over 12 weeks. They will be asked to participated in 5 total counseling sessions. In addition to counseling, participants in this group will also take 12 weeks of a nicotine replacement therapy(NRT) (like the patch, gum or lozenge) of their choice.
88874246|NCT02246010|Experimental|Lactose-free milk|Lactose- free milk formula (Similac LF®) and anti-diarrheic diet for 7 days.
88874247|NCT02246010|No Intervention|Regular infant milk|Regular infant milk formula and anti-diarrheic diet for 7 days.
88874248|NCT02247336|Experimental|Immediate|Patients will complete a family health history platform at enrollment
88874249|NCT02247336|Active Comparator|Delayed|Patients will complete a family health history platform 12 months following enrollment
88874250|NCT02248662||Surveillance, Epidemiology, and End Results (SEER) Database|Data were obtained for women in Surveillance, Epidemiology, and End Results (SEER) with a diagnosis of ductal carcinoma in situ (DCIS) between 1990 and 2011 who had not undergone radiotherapy for DCIS and experienced a subsequent breast cancer or DCIS diagnosis.
89188456|NCT00772967|Experimental|Ultracet, Placebo, Naproxen|Participants were treated with Ultracet for 3 days in Treatment Period 1, Placebo for 3 days in Treatment Period 2, and Naproxen for 3 days in Treatment Period 3. The treatment periods were separated by a 4-6 day break.
89397959|NCT03542396|Experimental|ImPuls|Participants receive an supervised exercise intervention and behaviour change techniques for 4 weeks and, after that, they are encouraged to engage in physical activity for 8 weeks independently. During this 8-week individual phase, patients have weekly phone contacts with a psychotherapist
88874251|NCT02248662||Surveillance, Epidemiology, and End Results (SEER)-Medicare|Data were obtained for women in Surveillance, Epidemiology, and End Results (SEER)-Medicare with a ductal carcinoma in situ (DCIS) diagnosis between 1991 and 2009 who had not undergone radiotherapy for DCIS and experienced a subsequent breast cancer or DCIS diagnosis.
88874252|NCT02249052|Active Comparator|AA4500|single injection of 0.58 mg study drug
88874253|NCT02249052|Placebo Comparator|Placebo|single injection of placebo
88874254|NCT02250612|Experimental|SYL040012 (bamosiran) 0.375% eye drops|1 drop in each eye once daily for 28 consecutive days
88874255|NCT02250612|Experimental|SYL040012 (bamosiran) 0.750% eye drops|1 drop in each eye once daily for 28 consecutive days
88874256|NCT02250612|Experimental|SYL040012 (bamosiran) 1.125% eye drops|1 drop in each eye once daily for 28 consecutive days
88874257|NCT02250612|Experimental|SYL040012 (bamosiran) 1.5% eye drops|1 drop in each eye once daily for 28 consecutive days
88874258|NCT02250612|Active Comparator|Timolol maleate 0.5% ophthalmic solution|1 drop in each eye twice daily for 28 consecutive days
88874259|NCT02251236|Other|Stribild Arm|Stribild Arm is for participants taking Stribild at the time of study entry. Participants taking Stribild at the time of study entry will switch to Genvoya before the second PK.
88874260|NCT02251236|Other|Genvoya Arm|Genvoya Arm is for participants already taking Genvoya at the time of study entry. Participants taking Genvoya at the time of study entry will continue Genvoya for the second PK.
88874261|NCT02251236|Other|Untreated Arm|Untreated Arm is for participants who are not taking ART at the time of study entry. Participants will start Stribild at entry and switch to Genvoya before the second PK.
88874262|NCT02251938|Experimental|DE-109 Sirolimus|DE-109 440 μg
88874263|NCT02252562|No Intervention|Standard practice|Usual intraoperative hand hygiene (standard wall mounted devices and machine and/or cart based dispensers)
88874264|NCT02252562|Experimental|Personal hand hygiene device|Intraoperative use of personalized body worn alcohol dispensers incorporating a novel wireless tracking system [(SAGE Products Inc., Cary, Il),
88874265|NCT02252718||Children 1-18 months of age|Children aged between 1 month and 18 months admitted to the Department of Pediatrics The Medical University of Warsaw
88874266|NCT02255604|Active Comparator|intralymphatic immune therapy|"Lymphnodes in the groin are identified with ultrasound. Under ultrasound guide they are injected with 0,1 ml of alk 225 Phleum Pratense 10,000 standard quantity units/ml.~Patients receive 4 injection in total. 3 injection in the spring 2014 with one month interval and 1 injection in the spring 2015."
88874267|NCT02255604|Placebo Comparator|3 intralymphatic immune therapy|"Lymphnodes in the groin are identified with ultrasound. Under ultrasound guide they are injected with 0,1 ml of alk 225 Phleum Pratense 10,000 standard quantity units/ml.~Patients receive 3 injection in total. 3 injection in the spring 2014 with one month interval. In in the spring 2015 patients will have a placebo injection."
88874268|NCT02255604|Sham Comparator|no intralymphatic immune therapy|"Lymphnodes in the groin are identified with ultrasound. Under ultrasound guide they are injected with 0,1 ml of isotone saline.~Patients receive 4 injection in total. 3 injection in the spring 2014 with one month interval and 1 injection in the spring 2015. All injections are with isotone saline as placebo control."
88874269|NCT02256072|Experimental|Plan Your Lifespan Website|Participants in the intervention arm will navigate the Plan Your Lifespan website, a Web-based planning tool that provides information for seniors related to advanced health planning for home services in specific content areas of: hospitalizations, falls, Alzheimer's, dementia, as well as communicating with others. The Plan Your Lifespan tool is also interactive in that it allows participants to enter their information and share it with others to facilitate conversations and decision-making.
88874270|NCT02256072|Other|Go4Life Website|Participants in the attention control arm will navigate an electronic educational session via a National Institute on Aging at NIH Website, Go4Life, a website about physical activity and exercise as it is a topic of interest to seniors. Our attention control group will control for the possibility that regular contact with the study team may improve outcomes in participants randomized to the intervention website.
88874271|NCT02258256|Experimental|Sphygmo|All subjects will have blood pressure measured by both the research device (Sphygmo) and the commercially available device. All clinical decisions will be made using measurements from the commercially available device
88874272|NCT02258412|Active Comparator|Alcohol hand sanitizer foam|Alcohol foam hand sanitizer applied with 1 pump into hands, spread over hands up to the wrist and rubbed until dry. Foam will be applied twice approximately 15-30 minutes apart on one day.
89397960|NCT03542396|No Intervention|Control|Participants do not receive any intervention. Participants receive treatment as usual, which means they are on a waiting list of an outpatient unit to receive individual psychotherapeutic treatment
88874273|NCT02258412|Active Comparator|hand antiseptic with CHG and alcohol|Hand antiseptic is applied by dispensing 1 pump into hands, spreading over the hands up to the wrist, and rubbing until dry. Hand antiseptic will be used twice approximately 15-30 minutes apart on one day.
89397961|NCT02152592|No Intervention|PCM/NAPR group|paracetamol 1000 mg orally four times a day for 48 hours postoperatively and naproxen 500 mg orally twice a day for 48 hours postoperatively (standard hospital pain protocol for treatment of acute postoperative pain at home after painful day-case surgery)
89397962|NCT02152592|Active Comparator|PCM/Oxy1 group|Controlled Release oxycodone 10 mg orally twice a day for 24 hours and paracetamol 1000 mg orally four times a day for 48 hours postoperatively
89397963|NCT02152592|Active Comparator|PCM/Oxy2 group|CR oxycodone 10 mg orally twice a day for 48 hours and paracetamol 1000 mg orally four times a day for 48 hours postoperatively
89397964|NCT02152748||Glioblastoma|The aim of this study is to analyze systematically morphological and molecular changes associated with glioblastoma progression and therapy-resistance in matched pre- and post-therapeutic glioblastoma samples.
89397965|NCT03543332||Cardiac arrest|
89397966|NCT03543332||Myocardial infarction|Myocardial infarction without cardiac arrest
89397967|NCT01307423|Experimental|Apremilast 20mg|Apremilast 20mg twice daily, orally
89397968|NCT01307423|Experimental|Apremilast 30mg|Apremilast 30mg twice daily, orally
89397969|NCT01307423|Placebo Comparator|Placebo + 20mg Apremilast|Placebo + 20mg Apremilast tablets administered twice daily
88874274|NCT02260440|Experimental|Pembrolizumab and Azacitidine Arm|"9 cycles~Pembrolizumab will be given at 200 mg every 21 days.~Azacitidine will be given at 100 mg daily subcutaneous injection on days 1-5 every 21 days."
88874275|NCT02262078|Placebo Comparator|Placebo (Saline)|Participants receive normal saline, administered by inhalation over 10-15 minutes, using a nebulizer
88874276|NCT02262078|Experimental|Sodium Nitrite|Participants receive Sodium Nitrite inhalation solution, administered by inhalation over 10-15 minutes, using a nebulizer
88874277|NCT02267226|Experimental|Octafibrin|
88874278|NCT02267382|Experimental|VT-1161 Low-dose 3-month|1 VT-1161 150mg tablet and 1 placebo tablet once daily for 7 days, then once weekly for 11 weeks, followed by 2 placebo tablet once weekly for 12 weeks
88874279|NCT02267382|Experimental|VT-1161 Low-dose 6-month|1 VT-1161 150mg tablet and 1 placebo tablet once daily for 7 days, then once weekly for 23 weeks
88874280|NCT02267382|Experimental|VT-1161 High-dose 3-month|2 VT-1161 150mg tablets once daily for 7 days, then once weekly for 11 weeks, followed by 2 placebo tablet once weekly for 12 weeks
88874281|NCT02267382|Experimental|VT-1161 High-dose 24-week|2 VT-1161 150mg tablets once daily for 7 days, then once weekly for 23 weeks
89397970|NCT01307423|Placebo Comparator|Placebo + 30mg Apremilast|Placebo + 30mg Apremilast tablets administered twice daily
89397971|NCT04849052|Experimental|MASTERY Intervention|Participants will complete a positive psychology activity, work towards a physical activity goal, and use a stress reduction technique, then will complete weekly text message sessions. In the first six weeks, participants will review the activities they performed the prior week, be introduced to new material, choose activities to perform that week, and set a new physical activity goal during the text message sessions. In the final 6 weeks, participants will review progress towards prior goals, set new physical activity goals, and choose positive psychology and stress reduction skills to use that week. Finally, over the course of the program participants will complete three brief calls with a study trainer to discuss progress.
89397972|NCT04849052|Active Comparator|Attentional control|Participants will receive the same physical activity component noted in MASTERY along with added messages providing education and guidance about physical activity, from our past work. Control participants will not receive PP or midlife-related content.
89397973|NCT03542318||Active group (Experimental)|Total of 60 patients were enrolled. All patients were referred for PR from the outpatient clinics of the local general hospital. Pulmonary fibrosis was confirmed through a high resonance computed tomography scan and pulmonary function testing. Participants who required modifications to their drug therapy due to exacerbations were excluded from the study. Each participant was classified according to the modified Medical Research Council dyspnoea scale
89397974|NCT03542318||Inactive control group|A total of 60 patients were enrolled in a control group. All were referred for PR from the outpatient clinics of the local general hospital. In this group patients who requested not to carry out the intervention but participate in the investigations were enrolled. Each participant was classified according to the modified Medical Research Council dyspnoea scale, and placed in one of 5 categories (0 to 4) according to self-perceived breathlessness during daily activities
88874282|NCT02267382|Placebo Comparator|Placebo|2 placebo tablets once daily for 7 days, then once weekly for 23 weeks
88874283|NCT02267538|Experimental|Dex group|The intervention drug (dexmedetomidine hydrochloride for injection) will be administered during a period from before anesthesia induction until the end of mechanical ventilation after surgery.
88874284|NCT02267538|Placebo Comparator|Placebo group|The placebo drug (normal saline, i.e., 0.9% sodium chloride for injection) will be administered in the same way and rate for a same duration as that in the Dex group.
88874285|NCT02267772|Experimental|IV Acetaminophen|IV acetaminophen for pain control
88874286|NCT02267772|Active Comparator|IV morphine|IV morphine for pain control
89397975|NCT02152904||Peptic ulcer bleeding patients|Endoscopy
88874287|NCT02267850|Experimental|OrthoPulse™|Subjects assigned to this group receive fixed orthodontic appliance treatment in conjunction with receiving daily OrthoPulse™ treatments.
88874288|NCT02267850|Sham Comparator|Sham-Control OrthoPulse™|Subjects assigned to this group receive fixed orthodontic appliance treatment in conjunction with carrying out daily non-functional OrthoPulse™ treatments (untreated control).
88874289|NCT02268942|Experimental|HeartWare HVAD via Thoracotomy|HeartWare HVAD implanted via thoracotomy
88874290|NCT02269488|Experimental|MEDI3250|MEDI3250 Nasal spray
89397976|NCT02156336|Placebo Comparator|PLACEBO|"500 mg PLACEBO PO 2 times a day for 1 week (Week 1)~1000 mg PLACEBO PO 2 times a day for 5 weeks (Weeks 2,3,4,5,6)"
89397977|NCT02156336|Active Comparator|RANOLAZINE|"500 mg RANOLAZINE PO 2 times a day for 1 week (Week 1)~1000 mg RANOLAZINE PO 2 times a day for 5 weeks (Weeks 2,3,4,5,6)"
89397978|NCT03542240|Experimental|Curcumin|
88874291|NCT02271906|Experimental|BIBW 2992|BIBW 2992 40 mg by mouth daily for a minimum of 14 days, and until the day of surgery.
89397979|NCT02778074|Experimental|Internet Cognitive Behavioural Therapy|Participants will perform a nine-week tailored I-CBT program developed to fit CVD patients. The program consists of psychoeducation, relaxation, problem-solving and behavioral activation.
89397980|NCT02778074|Placebo Comparator|Moderated discussion forum|In this arm the participants are allocated to a non mandatory discussion forum for nine weeks. Evert week will participants discuss issues regarding their CVD. Themes discussed are suggested by the study team, and a new theme is added every week. A moderator from the study group act as a supervisor and checks that issues discussed are ok. After the nine week discussion forum the participants are offered the nine week CBT program.
89397981|NCT00911183|Experimental|Arm I (R-COP regimen)|Patients receive rituximab IV, cyclophosphamide IV, and vincristine sulfate IV on day 1. Patients also receive oral prednisone on days 1-5 and filgrastim subcutaneously (SC) on days 8-14 or pegfilgrastim SC on day 2. Treatment repeats every 21 days for at least 3 courses.
89397982|NCT00911183|Experimental|Arm II (R-COPY regimen)|Patients receive rituximab, cyclophosphamide, vincristine sulfate, prednisone, and filgrastim or pegfilgrastim as in arm I. Patients also receive liposome-encapsulated doxorubicin citrate IV on day 1. Treatment repeats every 21 days for at least 3 courses.
89397983|NCT05056805|Active Comparator|Arm A (aerobic exercise, nutritional recommendation)|Patients are encouraged to complete at least 30 minutes of moderate intensity aerobic exercise, at least 3 times per week. Patients receive nutrition consultation with a registered dietitian and monitor dietary intake. Aerobic exercises and nutrition are tracked in the Pt Pal app
89397984|NCT05056805|Experimental|Arm B (aerobic, strength exercise, nutritional recommendation)|Patients complete at least 30 minutes of moderate intensity aerobic exercise (such as brisk walking or stationary bike cycling) at least 3 times per week. Patients also complete strength exercises with resistance tubes/bands at least 2 times per week, with at least 2 sets of 8-15 repetitions of the exercises taught. Patients receive nutrition consultation with a registered dietitian and monitor dietary intake. Patients also consume a high protein snack/meal/shake (15-25 grams) within 1 hour after any strengthening exercises. Exercise activities and nutrition are tracked in the Pt Pal app.
89397985|NCT03631121|Experimental|Basalin to Lantus|the patients who are using Basalin treatment will use isodose of Lantus instead
89397986|NCT01568489|Experimental|HL-009 Liposomal Gel (0.07%)|
89397987|NCT01568489|Experimental|HL-009 Liposomal Gel (0.15%)|
89397988|NCT01568489|Experimental|HL-009 Liposomal Gel (0.30%)|
89397989|NCT01568489|Placebo Comparator|HL-009 Liposomal Gel (Placebo)|
89397990|NCT03392519||Chronic stroke|More than 3 months post-stroke Ischemic or hemorrhagic stroke
89397991|NCT05023226|Placebo Comparator|LPVS group|The general ventilator setting.
89397992|NCT05023226|Experimental|LPVS + RM group|Recruitment maneuver.
89397993|NCT01568567|Active Comparator|Double dose|One stick pack with active ingredients contains 1.0 g contains 75% GOS (galactooligosaccharide), 25% L-Rhamnose, 1x108 live bacteria (CFU) Lactobacillus reuteri and silicon dioxide
89397994|NCT01568567|Active Comparator|Single dose|One stick pack with active ingredients contains 1.0 g contains 75% GOS (galactooligosaccharide), 25% L-Rhamnose, 1x108 live bacteria (CFU) Lactobacillus reuteri and silicon dioxide
89397995|NCT01568567|Placebo Comparator|Placebo|One stick pack with placebo contains 1.0 g maltodextrin and silicon dioxide
89397996|NCT03542162|Experimental|Healaflow group|The Healaflow group consists of patients with primary RRD, but exclude proliferative vitreoretinopathy grade C or more, dialysis, retinoschisis, eyes with secondary RRD, significant corneal or lens opacity precluding vitrectomy, giant retinal tears, a follow-up period of less than 3 months, and visual loss from causes other than RRD.
89397997|NCT05420597|Experimental|Induction chemotherapy and Toripalimab|Induction chemotherapy TP regimen combined with Toripalimab, followed by cisplatin-based concurrent chemoradiation.
89397998|NCT02775344|Experimental|three dimension laparoscopy|This group of patients will have laparoscopic ovarian cystectomy performed using three-dimension laparoscopy. The procedure will be performed in usual manner.
89397999|NCT02775344|No Intervention|Two dimension laparoscopy|Two-dimension laparosocpy would be used in this group of patient. The procedure will be performed in usual manner.
89398000|NCT05420441|Experimental|Group A (Phonophoresis with chitosan group)|Patients in this group will receive chitosan through phonophoresis plus conventional treatment. For the phonophoresis parameters: pulsed ultrasonic waves (25%) of 1 MHz frequency and 1 W/cm2 intensity applied with a 5 cm diameter transducer. The total time of ultrasound application was eight minutes.Patients will also receive conventional Physical therapy program
89530218|NCT05082779|Experimental|Cohort B3: 2 mg|Participants in fasted state will receive CS0159 2 mg or placebo once daily for a consecutive 14 days.
88874292|NCT02272686|Experimental|Ibrutinib|Ibrutinib started at a daily dose of 560 mg by mouth daily for up to 3 years.
88874293|NCT02273310|Experimental|Families Taking Control|Families participate in a 1 day Problem-Solving Skills training for disease management intervention
88874294|NCT02273310|No Intervention|Delayed Intervention Control|Families are given the opportunity to complete the Problem-solving Skills training for disease management intervention after assessment time 2.
88874295|NCT02274870|Experimental|Liposome Bupivacaine,|Liposome Bupivacaine 266mg, Knee Infiltration
88874296|NCT02274870|Active Comparator|Bupivacaine HCl|Bupivacaine HCl Continuous Femoral Nerve Block (CFNB), bolus and continuous for 48 hrs)
88874297|NCT02277054|Experimental|Collagen-MPC cornea substitute|Collagen-phosphorylcholine (collagen-MPC) cornea substitute transplantation using anterior lamellar keratoplasty technique.
88874298|NCT02278146|Experimental|1) Stress urinary incontinence|Stress urinary incontinence. Diagnosed with urinary stress incontinence and treated with the ParaPatch System
88874299|NCT02278146|Experimental|2) Overactive bladder|Overactive bladder. Diagnosed with overactive bladder syndrome and treated with the ParaPatch System
88874300|NCT02279082|Experimental|DFN-02|DFN-02 to be taken during migraine attack
89398001|NCT05420441|Experimental|Group B (Phonophoresis with glucosamine group)|Patients in this group will receive glucosamine through phonophoresis plus conventional treatment. For the phonophoresis parameters: pulsed ultrasonic waves (25%) of 1 MHz frequency and 1 W/cm2 intensity applied with a 5 cm diameter transducer. The total time of ultrasound application was eight minutes.Patients will also receive conventional Physical therapy program.
89398002|NCT05420441|Active Comparator|Group C (Conventional physical therapy only)|Patients in the control group will receive the conventional treatment for knee osteoarthritis only, which will include the application of TENS, pulsed ultrasound, infrared light and exercise.
89398003|NCT05598593|Experimental|Modified TBF Conditioning Regimen|thiotepa 5mg/kg/d d-9 to d-8, cytarabine 0-4.0 g/m2/d d-7 to d-6(adjusted according to patients' age and HCT-CI index), fludarabine 30mg/m2/d d-7 to d-3, busulfan 3.2mg/m2/d d-5 to d-3
89398004|NCT01569269|Experimental|Yoga|See intervention description
89398005|NCT01569269|Experimental|Meditation|See intervention description
89398006|NCT01569269|Experimental|Reiki|see intervention description
89398007|NCT01569269|Active Comparator|Holistic Education|see intervention description
89398008|NCT02777918|Experimental|Intervention|6 recipes will be sent by post every 2 weeks for a 12 week period. Dietary recommendations will also be provided at the start of the intervention period to increase the relevance of the recipes.
89398009|NCT02777918|No Intervention|Control|Dietary recommendations will be provided at the start of the study period, such that the intervention regards the recipes, not the recommendations
89398010|NCT05337449|Active Comparator|silver diamine fluoride|
89398011|NCT05337449|Active Comparator|conventional composite resin restoration|
89398012|NCT02156414||Clinically Localized Prostatic Neoplasm|Radical Prostatectomy Extended Lymphadenectomy
89398013|NCT02150720|Experimental|Tranexamic acid|Tranexamic acid, 1g intra-articular before closing the surgery wound
88874301|NCT02279160|Experimental|APD811|Multiple dose titration to maximum tolerated dose.
88874302|NCT02279160|Placebo Comparator|Placebo|Multiple dose titration to maximum tolerated dose.
88874303|NCT02281344|Experimental|Cohort 1|Cohort 1 will receive a single dose of 20mg MMV390048.
88874304|NCT02281422|Other|Group 1 normal renal function|normal renal function (creatinine clearance > 80 mL/min)
88874305|NCT02281422|Other|Group 2 mild renal impairment|mild renal impairment (creatinine clearance 50-80 mL/min)
88874306|NCT02281422|Other|Group 3 moderate renal impairment|moderate renal impairment (creatinine clearance 30-50 mL/min)
89398014|NCT02150720|Experimental|Fibrin glue|One intra-articular dose of fibrin glue (Evicel 5mL) before closing the wound surgery,
89398015|NCT02150720|Active Comparator|Usual hemostasia|Electrocauterization
89398016|NCT04835714|Experimental|Part A with Monotherapy dose escalation|
89398017|NCT04835714|Experimental|Part B with Combination therapy dose escalation|
89398018|NCT04835714|Experimental|Part C with Combination therapy dose confirmation|
89398019|NCT04835714|Experimental|Part D with Combination therapy dose expansion|
89398020|NCT05234957|Active Comparator|Asymmetric bilateral lateral rectus recession (A-BLR)|The amount of bilateral lateral rectus recession is asymmetrically divided between both eyes, with 2mm more recession in the non-dominant eye.
89398021|NCT05234957|Active Comparator|Symmetric bilateral lateral rectus recession (S-BLR)|The amount of bilateral lateral rectus recession is equally divided between both eyes.
89398022|NCT02150798|Experimental|High fat and low carbohydrate diet|High fat low carbohydrate diet composition was 40 % of carbohydrates, 40 % of lipids (12 % saturated, 18 % monounsaturated and 10% polyunsaturated, ) and 20 % of protein for two months
88874307|NCT02281422|Other|Group 4 severe renal impairment|severe renal impairment (creatinine clearance <30 mL/min)
89398023|NCT02150798|Active Comparator|Control diet|the standard diet composition was 50 % of carbohydrates, 30 % of lipids (10 % saturated, 10 % polyunsaturated, and 10 % monounsaturated) and 20 % of protein for two months
89398024|NCT02153060|Experimental|20mg dexamethasone group|Dexamethasone 20 mg per day, 4 consecutive days
89398025|NCT02153060|Experimental|40mg dexamethasone group|Dexamethasone 40 mg per day, 4 consecutive days
89398026|NCT02927795||Spiolto Respimat|QOL measurement of COPD patients taking Spiolto Respimat
89398027|NCT03542864|Experimental|Nasogastroduodenal Protocol|Evaluation of a protocol for the treatment of excess body fat through duodenal nutrition
89398028|NCT03542864|Active Comparator|Controls|Change from Baseline Body Composition values at 1 and 3 months
89398029|NCT03542864|Other|Data analysis|Analysis and publication of data
88874308|NCT02281422|Other|Group 5 end stage renal disease|end stage renal disease, requiring haemodialysis (ESRD)
88874309|NCT02282514|Experimental|Hematopoietic Stem Cell Transplantation|The conditioning regimen will be 200 mg/kg of intravenous cyclophosphamide given in 4 equal fractions on days -5 through -2 with intravenous mesna. Rabbit antithymocyte globulin (rATG) (Thymoglobulin®) will be dosed at 0.5 mg/kg on day-5, 1.0 mg/kg on days -4 and -3, and then 1.5 mg/kg on days -2 and -1. Methylprednisolone 1000 mg will be infused intravenously before each dose of rATG. Autologous hematopoietic stem cells will be infused intravenously on day 0. A granulocyte-colony stimulating factor (G-CSF) 5-10 mcg/kg will be started on day + 5 and continued until neutrophil engraftment. Intravenous Rituxan (500mg) will be administered on days -6 and +1.
88874310|NCT02282904|Experimental|CGD Recipient|CGD patients that will undergo haplo transplantation with post-transplant cyclophosphamide as described
89398030|NCT01383239|Active Comparator|Immediate postoperative therapy|Patients will be randomized into one of two groups: immediate postoperative therapy versus 6-week delay
89398031|NCT01383239|Active Comparator|postoperative therapy delayed for 6 weeks|Patients will be randomized into one of two groups: immediate postoperative therapy versus 6-week delay.
89398032|NCT02156570|Experimental|Sofosbuvir and ribavirin|"Sofosbuvir tablet 400 mg daily Ribavirin tablet weight based dosing (1000mg <75 kg, 1200mg >/= 75kg) daily~Treatment will be for 6 weeks in all participants."
89398033|NCT05208749|Active Comparator|Rotablation|Use of rotational atherectomy first-line if NC balloon does not fully open
89398034|NCT05208749|Active Comparator|Shockwave IVL|Use of Shockwave IVLS first-line if NC balloon does not fully open
89398035|NCT02156648|Other|Feasibility study|All participants will have blood draws for biomarkers during the course of the study at visit 1, 2, 3, 4, 5, 6, 7 and 8. they will also have the speckle tracking echocardiogram at visit 1, 4, 5, 6, 7 and 8. For women 45 an over a cardiac PET scan will be performed at visit 1 and 5.
89398036|NCT05188547|No Intervention|Control|No video education, only consultation by the anesthesiologist. No knowledge test before the consultation.
89398037|NCT05188547|No Intervention|Baseline|No video education, only consultation by the anesthesiologist. Also a knowledge test before the consultation.
89398038|NCT05188547|Experimental|Video|Video education and a knowledge test directly afterwards. Consultation by the anesthesiologist after the knowledge test.
89398039|NCT05188547|Experimental|Video Augmented|Video education and consultation by the anesthesiologist directly afterwards. The knowledge test is taken after the consultation.
89398040|NCT02153294|Experimental|Ventilation with lower tidal volumes|Use of low tidal volume (4 to 6 ml/kg PBW) after intubation and during all mechanical ventilation
89398041|NCT02153294|Other|Ventilation with higher tidal volumes|Use of high tidal volume (8 to 10 ml/kg PBW) after intubation and during all mechanical ventilation
89398042|NCT05598437||A|Left eye
89398043|NCT05598437||B|Right eye
89398044|NCT02153372|Experimental|BMC2012|The large bone defect was then be bridged as per clinical standard, filled with a clinically established scaffold (ß-TCP), and 1.3 x106/ml BMC were loaded per 1 ml ß-TCP in situ.
89398045|NCT02767856|Experimental|Intense 12-hour IO-therapy Group|Participants wear 12-hour daily IO-therapy glasses for 4 weeks
89398046|NCT02767856|Active Comparator|Standard 4-hour IO-therapy Group|Participants wear 4-hour daily IO-therapy glasses for 12 weeks
88874311|NCT02283528|Experimental|Hybrid|Placement of Hybrid arch bars for open or closed reduction of mandible fractures
88874312|NCT02283528|Active Comparator|Erich|Placement of Erich archbars for open or closed reduction of mandible fractures
88874313|NCT02283840|Experimental|Cohort A1:BIA 2-093 400 mg|"One Eslicarbazepine acetate (BIA 2-093) 400 mg tablet (To-Be-Marketed Formulation, TBM)~One Eslicarbazepine acetate (BIA 2-093) 400 mg tablet (Clinical Trial Formulation, CTF)"
89398047|NCT03087851|Active Comparator|6-month group|Zoledronic acid will be administered at study day 0. If s-CTX increases above 1.26 ug/l or BMD decreases more than 5% at any site a second infusion of zoledronic acid will be administered.
88874314|NCT02283840|Experimental|Cohort A2:BIA 2-093 400 mg|One Eslicarbazepine acetate (BIA 2-093) 400 mg tablet (Clinical Trial Formulation, CTF) One Eslicarbazepine acetate (BIA 2-093) 400 mg tablet (To-Be-Marketed Formulation, TBM)
88874315|NCT02283840|Experimental|Cohort B1:BIA 2-093 600 mg|"One Eslicarbazepine acetate (BIA 2-093) 600 mg tablet (To-Be-Marketed Formulation, TBM)~One Eslicarbazepine acetate (BIA 2-093) 600 mg tablet (Clinical Trial Formulation, CTF)"
88874316|NCT02283840|Experimental|Cohort B2:BIA 2-093 600 mg|One Eslicarbazepine acetate (BIA 2-093) 600 mg tablet (Clinical Trial Formulation, CTF) One Eslicarbazepine acetate (BIA 2-093) 600 mg tablet (To-Be-Marketed Formulation, TBM)
88874317|NCT02283840|Experimental|Cohort C1:BIA 2-093 800 mg|"One Eslicarbazepine acetate (BIA 2-093) 800 mg tablet (To-Be-Marketed Formulation, TBM)~One Eslicarbazepine acetate (BIA 2-093) 800 mg tablet (Clinical Trial Formulation, CTF)"
89398048|NCT03087851|Active Comparator|9-months group|"Zoledronic acid will be administered depending on increase in s-CTX (above 1.26 ug/l) or the occurrence of an osteoporotic clinical vertebral or hip fracture, but no later than at month 3.~If s-CTX increases above 1.26 ug/l or BMD decreases more than 5% at any site a second infusion of zoledronic acid will be administered."
89398049|NCT03087851|Active Comparator|Observation group|"Zoledronic acid will be administered depending on increase in s-CTX (above 1.26 ug/l), decrease in BMD (more than 5% at any site), or the occurrence of an osteoporotic clinical vertebral or hip fracture, but no later than at month 6.~If s-CTX increases above 1.26 ug/l or BMD decreases more than 5% at any site a second infusion of zoledronic acid will be administered."
89398050|NCT02156726||Low dose FCR in Elderly/Comorbid CLL|low dose FCR
89398051|NCT02156882||TB patients and Tb suspects|Patients with confirmed tuberculosis who are treated by the National TB Programme
89398052|NCT01383083||iloprost|In the adult patient group, iloprost acceptable target dose is 2.5 ug 4-6 times/day according to the patient's compliance. Because of the concern of safety and tolerability, during the first 4 weeks of treatment, patients receive 2.5 ug twice daily. After 4 weeks, this is increased to the target dose, if iloprost is well tolerated.
89398053|NCT02153450|Experimental|Treatment (stereotactic radiosurgery, metformin hydrochloride)|"Patients receive metformin hydrochloride PO daily or BID on days -11 to -1. Patients then undergo stereotactic radiosurgery 5 days a week for 5 weeks and receive concurrent metformin hydrochloride* PO BID for 5 weeks. Patients undergo laparotomy on week 6 (or weeks 5-7). Systemic therapy continues as soon as it is considered feasible by the treating physicians.~*NOTE: Metformin hydrochloride should be stopped 2 days before laparotomy."
89398054|NCT04986137||Group 1|Acute kidney injury due to acute tubular necrosis
88874318|NCT02283840|Experimental|Cohort C2:BIA 2-093 800 mg|One Eslicarbazepine acetate (BIA 2-093) 800 mg tablet (Clinical Trial Formulation, CTF) One Eslicarbazepine acetate (BIA 2-093) 800 mg tablet (To-Be-Marketed Formulation, TBM)
88874319|NCT02284386|Experimental|Bupivacaine SNB + EXPAREL Infiltration|Spinal block with bupivacaine HCl 7.5 mg/mL. Local infiltration of EXPAREL 266 mg.
88874320|NCT02284464|Active Comparator|Steroids, tacrolimus and mycophenolate|Normal treatment arm
88874321|NCT02284464|Experimental|Tacrolimus and mycophenolate|Normal treatment for first 90 days, then steroid withdrawal carrying on with the other drugs
88874322|NCT02284854|Experimental|Group A|Day 1 to Day 8 - BIA 2-093 800 mg Day 9 to Day 14 - BIA 2-093 800 mg + CBZ 200 mg Day 15 to Day 22 - BIA 2-093 800 mg + CBZ 400 mg Day 23 to Day 35 - BIA 2-093 800 mg + CBZ 400 mg twice-daily
89398055|NCT04986137||Group 2|Acute kidney injury due to prerenal azotemia
89398056|NCT04986137||Group 3|Acute kidney injury due to hepatorenal syndrome type 1
89398057|NCT01382927||General Anesthesia|
89398058|NCT01382927||Spinal Anesthesia|
89398059|NCT05598281|Experimental|AMG 510 + Digoxin|Participants will receive digoxin on Day 1 and both AMG 510 + digoxin on Day 7.
89398060|NCT03979417||Liver fibrosis F0-F1|Blood draw and liver resection at the liver surgery
89398061|NCT03979417||Liver fibrosis F2-F3|Blood draw and liver resection at the liver surgery
89398062|NCT03979417||Liver Fibrosis F4|Blood draw and liver resection at the liver surgery
89398063|NCT03956407|Active Comparator|Active, subacute stroke|Repetitive peripheral electrical stimulation (RPES) + Motor Training. Active RPES will be administered for 2 hours. After active session of RPES, the patient will receive motor training.
88874323|NCT02284854|Experimental|Group B|Day 1 to Day 8 - CBZ 200 mg Day 9 to Day 14 - CBZ 400 mg Day 15 to Day 29 - CBZ 400 mg twice-daily Day 30 to Day 35 - BIA 2-093 800 mg + CBZ 400 mg twice-daily
88874324|NCT02285634|Experimental|Oxymetazoline 0.05%|Oxymetazoline 0.05%
88874325|NCT02285634|Experimental|Phenylephrine 0.25%|Phenylephrine 0.25%
88874326|NCT02285634|Experimental|Lidocaine 1% plus epinephrine 1:100,000|Lidocaine 1% plus epinephrine 1:100,000
88874327|NCT02285634|Placebo Comparator|Bacteriostatic 0.9% sodium chloride (NaCL)|Bacteriostatic 0.9% NaCL
88874328|NCT02287350|Experimental|diclofenac potassium oral solution|5 mg/mL, liquid form, weight-based dosing, every 6 hours, for up to 4 days.
88874329|NCT02288364|Active Comparator|1% Lidocaine|1% Lidocaine alone.
89398064|NCT03956407|Sham Comparator|Sham, subacute stroke|Sham Comparator: Sham + Motor Training. Sham will be administered for 2 hours. After sham, the patient will receive motor training
89398065|NCT03956407|Active Comparator|Active, chronic stroke|Repetitive peripheral electrical stimulation (RPES) + Motor Training. Active RPES will be administered for 2 hours. After active session of RPES, the patient will receive motor training.
88874330|NCT02288364|Active Comparator|1% Lidocaine plus sodium bicarbonate|1% Lidocaine plus 8.4% sodium bicarbonate
88874331|NCT02289222|Experimental|Pomalidomide, Dexamethasone & MK-3475|Pomalidomide is given at standard dose of 4 mg daily orally for 21 days and dexamethasone is given at 40 mg orally weekly. MK3475 will be given as an intravenous infusion at 200 mg every 2 weeks (days 1 and 14).
88874332|NCT02291016|Active Comparator|Formoterol via DPI then Formoterol via nebulizer|"Group A: Received Formoterol 12 µg via DPI and placebo via nebulizer at treatment visit #1, and Formoterol 20 µg (solution form) via nebulizer and placebo via DPI at treatment visit 2.~Placebo: The placebo used will be sterile, preservative free, normal saline for nebulizer inhalation and a matched capsule without active drug for the dry powder inhaler. All patients will receive 2 ml of normal saline with the nebulizer to match the volume of nebulized formoterol solution. Patients will receive formoterol and placebo at both study visit #1 and visit #2."
89004021|NCT03684980|Experimental|Arm C - HD-MTX (Arm Outpatient MTX Therapy in times of COVID-19)|MTX ≤ 3.5 g/m2 will be administered on Day 1, along with pre- and post- hydration. Patients will return on Day 2 for continued hydration and glucarpidase 2000 units. Glucarpidase rapidly and sustainably reduces serum MTX levels >95% without crossing the blood brain barrier, effectively resulting in systemic MTX clearance. Patients will return for bloodwork on Day 3 to document MTX clearance. Arm Outpatient MTX Therapy in times of COVID-19 will only be a single-institution arm, only open at Memorial Sloan Kettering Cancer Center.
89398066|NCT03956407|Sham Comparator|Sham, chronic stroke|Sham Comparator: Sham + Motor Training. Sham will be administered for 2 hours. After sham, the patient will receive motor training
89398067|NCT03092375|Experimental|Arm A: G/P 300 mg/120 mg QD for 12 Wks|Non-cirrhotic subjects will take Glecaprevir/Pibrentasvir (G/P) 300mg/120mg (3 Glecaprevir/Pibrentasvir (G/P) 100mg/40mg Tablets once-daily by mouth) for 12 weeks.
89398068|NCT03092375|Experimental|Arm B: G/P 300 mg/120 mg QD for 16 Wks|Non-cirrhotic subjects will take Glecaprevir/Pibrentasvir (G/P) 300mg/120mg once-daily by mouth for 16 weeks (G/P 300 mg/120 mg QD for 16 Wks)
89398069|NCT03092375|Experimental|Arm C: G/P 300 mg/120 mg QD + RBV 12 Wks|Cirrhotic subjects will take Glecaprevir/Pibrentasvir (G/P) 300mg/120mg once daily plus Ribavirin 200Mg Tablet (2-3 tablets) twice a day for 12 weeks (G/P 300 mg/120 mg QD + RBV 12 Wks)
89398070|NCT03092375|Experimental|Arm D: G/P 300 mg/120 mg QD for 16 Wks|Cirrhotic subjects will take Glecaprevir/Pibrentasvir (G/P) 300mg/120mg once daily for 16 weeks (G/P 300 mg/120mg QD for 16 Wks)
89398071|NCT04983485||Observational Group|Individuals who were diagnosed with COPD by Bolu Abant İzzet Baysal University Medical Faculty Chest Diseases Department and referred to Bolu Abant İzzet Baysal University Health Sciences Faculty Physiotherapy and Rehabilitation Department will be included in the study.
89398072|NCT01995513|Experimental|Enzalutamide & Abiraterone/prednisone|Enzalutamide (160 mg) administered as four 40-mg capsules by mouth once daily in combination with abiraterone (1000 mg) administered as four 250-mg tablets by mouth once daily and prednisone (10 mg) administered as one 5-mg tablet by mouth twice daily
89398073|NCT01995513|Active Comparator|Enzalutamide placebo & Abiraterone/prednisone|Enzalutamide placebo (placebo) capsules (identical in appearance to enzalutamide) administered as 4 capsules by mouth once daily in combination with abiraterone (1000 mg) administered as four 250-mg tablets by mouth once daily and prednisone (10 mg) administered as one 5-mg tablet by mouth twice daily.
89398074|NCT04953377|Experimental|Intervention|PFMT educational intervention including a 120 min workshop and 8 weeks of self training
89398075|NCT05038761||Type 1 or type 2 diabetes mellitus participants|Participants will be enrolled after the decision to initiate venous blood glucose testing and Continuous Glucose Monitoring (CGM) system as per investigator's routine treatment practice.
89398076|NCT05598125||Smoker_1|Begins with e-cigarette crosses over to conventional cigarette
89398077|NCT05598125||Non smoker|never smoking participants as control group
89188457|NCT00772967|Experimental|Placebo, Ultracet, Naproxen|Participants were treated with Placebo for 3 days in Treatment Period 1, Ultracet for 3 days in Treatment Period 2, and Naproxen for 3 days in Treatment Period 3. The treatment periods were separated by a 4-6 day break.
89398078|NCT05598125||Smoker_2|Begins with conventional cigarette crosses over to e-cigarette
89398079|NCT03180359|Experimental|Patient already transplanted or waiting for a transplantation|
88874333|NCT02291016|Active Comparator|Formoterol via nebulizer then Formoterol via DPI|"Group B: Received Formoterol 20 µg (solution form) via nebulizer and placebo via a DPI at treatment visit #1, and Formoterol 12 µg via a DPI with placebo via nebulizer at treatment visit 2.~Placebo: The placebo used will be sterile, preservative free, normal saline for nebulizer inhalation and a matched capsule without active drug for the dry powder inhaler. All patients will receive 2 ml of normal saline with the nebulizer to match the volume of nebulized formoterol solution. Patients will receive formoterol and placebo at both study visit #1 and visit #2."
88874334|NCT02291718|Active Comparator|Isovue 300 75mL|Isovue 300 75mL injected 120 kVp 250 mAs
88874335|NCT02291718|Active Comparator|Isovue 370 75mL|Isovue 370 75mL injected 100 kVp 240 mAs
88874336|NCT02291718|Active Comparator|Isovue 370 60mL|Isovue 370 60mL injected 100 kVp 240 mAs
88874337|NCT02292186|Experimental|Revusiran (ALN-TTRSC)|
88874338|NCT02293044|Experimental|Crest® Sensi-Stop™ Strips|Self Applied
88874339|NCT02293512|Experimental|Coping Effectiveness Training|Coping Effectiveness Training (CET) is provided in a 3-session intervention to facilitate coping strategies among individuals with tinnitus. The CET psychoeducational intervention teaches coping skills to increase understanding of stress and coping with tinnitus, and to help individuals better know how to match appropriate coping strategies, based on whether the stressful situation is changeable or not.
88874340|NCT02293512|Active Comparator|Cognitive-behavioral therapy|Cognitive-behavioral therapy (CBT) is provided in a 3-session psychoeducational intervention to reduce negative affectivity triggered by tinnitus. CBT treatments for tinnitus target the reduction of psychopathology by altering cognitive distortions, automatic thoughts, and core beliefs, as well as behavioral techniques to reduce physiological arousal.
88874341|NCT02293512|Active Comparator|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy (ACT) is provided in a 3-session psychoeducational intervention to decrease resistance to tinnitus and increase committed action based on values, despite having tinnitus.
88874342|NCT02293512|No Intervention|Wait-list control group|Wait-list control group involves no intervention. This is a 'usual care' group.
88874343|NCT02296164||MF-CTCL Patients receiving Valchlor|Patients will undergo clinical assessments and receive standard medical care, as determined by the patients' physician, in the real world setting. With the exception of protocol-required patient completed questionnaires for symptoms and Quality Of Life.
88874344|NCT02297100|Experimental|Botox upper aspect trigone|Subjects in the experimental cohort will receive a one time dose of 100 units of Onabotulinumtoxin A diluted in 10 mL of preservative free normal saline and injected in 1.0 mL boluses in a set pattern across the upper aspect of the trigone of the urinary bladder.
88874345|NCT02297100|Active Comparator|botox periphery of trigone|Each group will receive a total of 100 units of botox spread out among 10 separate injections. Subjects in the control group will have 10 injections made about the periphery of the trigone. The control cohort will receive a one time dose of Onabotulinumtoxin A using the same dilution and number of boluses, but boluses will be administered at random sites on the posterior bladder wall (excluding the trigone).
88874346|NCT02299050|Other|Cycloset|"Drug - Cycloset Cycloset 2.4 -3.2 mg/day~Other Names:~Bromocriptine Mesylate Quick Release"
88874347|NCT02302092|Experimental|Flomoxef|Flomoxef, 2g, injection, intravenously, twice daily (every 12 hours), for up to 12 days.
88874348|NCT02302092|Active Comparator|Cefepime|Cefepime, 1g, injection, intravenously, twice daily (every 12 hours) for up to 14 days.
88874349|NCT02303184|Experimental|4 mg CLS-TA + IVT aflibercept|Single unilateral, suprachoroidal injection of 40 mg/mL (4 mg in 100 µL) of CLS-TA following a 2 mg intravitreal injection of aflibercept
88874350|NCT02303184|Active Comparator|sham + IVT aflibercept|Single unilateral, suprachoroidal sham procedure following a 2 mg intravitreal injection of aflibercept
88874351|NCT02304432|Experimental|Open label DCS|Both participants received open label D-cycloserine (seromycin), 50 mg/d capsule for 8 weeks.
88874352|NCT02304432|Experimental|DCS or placebo|Randomized to DCS or placebo. Participants underwent double-blind placebo-controlled exposures to DCS for 6 weeks or placebo for 6 weeks. One participant received exposure to DCS for 6 weeks and then received placebo dosing for 6 weeks. The other participant received exposure to placebo dosing for 6 weeks and then DCS for 6 weeks.
88874353|NCT02304432|Experimental|Second open label DCS|Both participants received second open label exposures to D-cycloserine (seromycin), 50 mg/d capsule for 24 weeks.
88874354|NCT02306928||Piperacillin pharmacokinetics|Patients with suspected septic shock who are treated with piperacillin/tazobactam.
88874355|NCT02307318|Other|SoftSeal Hemostatic Pad|This is a single arm study. All patients received the SoftSeal hemostatic pad for compression following elective or urgent coronary angiogram.
88874356|NCT02307552|Experimental|All patients|All patients in the study will receive a scan of their prostate with the novel UreScan machine. All scans will be evaluated in their accuracy of detecting cancer loci within the prostate as compared to histopathological reviews of the prostate post robotic prostatectomy.
88874357|NCT02312154|Experimental|treated side (Restylane vital)|"We injected staabilized hyaluronic acid (HA)-based gel of nonanimal origin on the left side of face.~(We performed split face study)"
88874358|NCT02312154|No Intervention|untreated side (control)|We did nothing on the right side of face and we compared the results on same participants
88874359|NCT02312310|Placebo Comparator|F 0 mg|daily consumption of capsules containing 0 mg cocoa flavanol for 12 weeks
88874360|NCT02312310|Active Comparator|F 260 mg|"daily consumption of capsules containing 260 mg* cocoa flavanol for 12 weeks~*see note in Record Log regarding the change in the method of assessment of cocoa flavanol content of the capsules"
88874361|NCT02312310|Active Comparator|F 510 mg|daily consumption of capsules containing 510 mg cocoa flavanol for 12 weeks
88874362|NCT02312310|Active Comparator|F 770 mg|daily consumption of capsules containing 770 mg cocoa flavanol for 12 weeks
88874363|NCT02314104|Active Comparator|Treatment TAP, placebo local injection|Treatment TAP block was 30 mL 0.5% ropivacaine bilaterally. Placebo local injection was 2 mL of 0.9% normal saline at each port site.
88874364|NCT02314104|Active Comparator|Placebo TAP, treatment local injection|Placebo TAP was 30 mL of 0.9% normal saline bilaterally. Treatment local injection was 2 mL of 0.5% ropivacaine at each port site.
88874365|NCT02314104|Active Comparator|Treatment TAP, treatment local injection|Treatment TAP was 30 mL of 0.5% ropivacaine bilaterally. Treatment local injection was 2 mL of 0.5% ropivacaine at each port site.
88874366|NCT02314260||Labour Induction|80 primigravidas undergoing bishop score calculation, trans-vaginal ultrasound assessment of cervical length &, Modified bishop score calculation, then induction of labour at our hospital.
88874367|NCT02320812|Experimental|Treated subjects|human retinal progenitor cells
88874368|NCT02321748|Other|Montelukast|10mg montelukast alone followed by 10mg montelukast + 400mg ASP2151
88874369|NCT02321748|Other|ASP2151|10mg montelukast + 400mg ASP2151 followed by 10mg montelukast alone
88874370|NCT02322528|Other|Administration of Lotemax|An FDA approved drug (Lotemax) will be administered to both eyes to induce an inflammatory mediated response.
88874371|NCT02323854|Other|Ablation and Surgical Resection|Ablation of lung tumor; followed by surgical resection of the ablation zone.
88874372|NCT02327052||Chagas disease|The study comprised 58 subjects with Chagas disease, confirmed by two positive serologic tests.
88874373|NCT02330094|Experimental|Gabapentin|Gabapentin capsules 100 mg ter in die (TID), 200 mg TID, 300 mg TID, 400 mg TID, 600 mg TID, 900 mg TID.
88874374|NCT02330094|Placebo Comparator|Control|Placebo capsules 100 mg ter in die (TID), 200 mg TID, 300 mg TID, 400 mg TID, 600 mg TID, 900 mg TID.
88874375|NCT02330172|Active Comparator|rocuronium 0.45 - neostigmine|"when anesthetic induction, inrocuronium 0.45 mg/kg will be administered for muscle relaxation.~When the end of operation, a injection of neostigmine or sugammadex will be administered."
88874376|NCT02330172|Active Comparator|rocuronium 0.9 - sugammadex|"When anesthetic induction, rocuronium 0.9 mg/kg will be injected to rocuronium 0.9 - sugammadex group for muscle relaxation.~When the end of operation,, a injection of neostigmine or sugammadex be administered."
88874377|NCT02331108|Active Comparator|sevoflurane in 100% oxygen, age <56|The intervention will be the randomized selection of anesthetic induction technique to sevoflurane in 100% oxygen and temperatures will be recorded per protocol. Age 18-55.
88874378|NCT02331108|Active Comparator|sevoflurane in 50% nitrous, age <56|The intervention will be the randomized selection of anesthetic induction technique to sevoflurane in 50% oxygen and 50% nitrous oxide. Age 18-55.
88874379|NCT02331108|Active Comparator|propofol, age <56|The intervention will be the randomized selection of anesthetic induction technique to intravenous induction with 2.2 mg/kg propofol. Age 18-55.
88874380|NCT02331108|Active Comparator|propofol with phenylephrine, age <56|The intervention will be the randomized selection of anesthetic induction technique to intravenous induction 2.2 mg/kg propofol immediately preceded by 160 mcg intravenous phenylephrine. Age 18-55.
88874381|NCT02331108|Active Comparator|sevoflurane in 100% oxygen, age >55|The intervention will be the randomized selection of anesthetic induction technique to sevoflurane in 100% oxygen and temperatures will be recorded per protocol. Age >55.
88874382|NCT02331108|Active Comparator|sevoflurane in 50% nitrous, age >55|The intervention will be the randomized selection of anesthetic induction technique to sevoflurane in 50% oxygen and 50% nitrous oxide. Age >55.
88874383|NCT02340156|Experimental|SGT-53 with Temozolomide|SGT-53, at 3.6 mg DNA/infusion, will be administered twice weekly in a 28 day cycle starting on Day 1 (cycle 1), Day 29 (cycle 2) and Day 57 (cycle 3). Temozolomide (TMZ) will be administered by mouth daily on days 9-13 of each cycle. Patients who are responding to treatment may receive three additional cycles of SGT-53/TMZ therapy or continue on TMZ alone at investigator's discretion. Surgical resection of recurrent or progressive tumor for tumor analysis is an optional procedure. In these individuals SGT-53, at 3.6 mg DNA/infusion, will be administered twice (on days -1 and -3) in the week prior to surgery. Surgical resection is Day 0. 14-21 days post operatively and having recovered from the effects of surgery, the patients will then start cyclical TMZ with SGT-53 as described above.
88874384|NCT02343276|Placebo Comparator|Placebo|Placebo (saline solution 10 ml) in radial artery after sheath insertion
88874385|NCT02343276|Experimental|Intervention|Nitroglycerin (200 micrograms) + saline solution 10 ml in radial artery after sheath insertion
88874386|NCT02347410|Other|Investigation Group|This is a single-arm investigation. All subjects were treated with the SIFS device filled with bone graft. Posterior fixation required.
88874387|NCT02347488|Experimental|ETT holder and bite guard|Participants will have endotracheal tubes secured with tape prior to having surgery, which is the current standard of care. Following the traction test and measurement of displacement, participants will have endotracheal tubes secured with a combined Haider ETT Tube Holder and Bite Guard.
88874388|NCT02348658|Other|Fasted dosing followed by fed dosing|Dosing in the fasted state followed by fed dosing
88874389|NCT02348658|Other|Fed dosing followed by fasted dosing|Dosing in the fed state followed by fasted dosing
88874390|NCT02349438|Experimental|senofilcon A|The lenses will be worn for 2 hours in both eyes, and not dispensed
88874391|NCT02349438|Active Comparator|lotrafilcon A|The lenses will be worn for 2 hours in both eyes, and not dispensed
88874392|NCT02350998|Experimental|OTO-201|6 mg OTO-201 administered trans-tympanostomy tube
88874393|NCT02351700|Active Comparator|IV Caldolor (ibuprofen)|Intravenous (IV) Caldolor (ibuprofen) (800mg every 8 hours) initiated during surgery and oral acetaminophen 1000mg every 6 hours initiated post-operatively and continued for the duration of the hospital stay (an expected average stay of 2 days) or 48 hours, whichever comes first. Breakthrough pain will be treated with rescue narcotics (IV morphine 2-4mg every 2 hours and oral oxycodone 5-15mg every 4 hours immediately post-operatively through discharge, an expected average stay of 2 days). Hydromorphone (IV 0.5-2mg every 2 hours and oral 2-4mg every 4 hours) will be used in patients with morphine or oxycodone allergy or intolerance.
88874394|NCT02351700|Placebo Comparator|standard treatment group|IV placebo will be initiated during surgery and oral acetaminophen 1000mg every 6 hours will be initiated post-operatively and continued for the duration of the hospital stay (an expected average stay of 2 days) or 48 hours, whichever comes first. Breakthrough pain will be treated with rescue narcotics (IV morphine 2-4mg every 2 hours and oral oxycodone 5-15mg every 4 hours immediately post-operatively through discharge, an expected average stay of 2 days). Hydromorphone (IV 0.5-2mg every 2 hours and oral 2-4mg every 4 hours) will be used in patients with morphine or oxycodone allergy or intolerance.
88874395|NCT02353806|Experimental|Pregnant women taking amlodipine|Women already taking amlodipine besylate 5 mg for treatment of chronic hypertension in pregnancy who plan to breastfeed postpartum will be assigned to the single experimental arm.
89398080|NCT00948129|Active Comparator|Group I (standard care)|Participants undergo standard of care smoking cessation intervention consisting of brief advice to quit smoking, NRT, and self-help written materials.
89398081|NCT00948129|Experimental|Group II (enhanced care)|Participants undergo standard of care smoking cessation intervention as in Group I and attend a health feedback counseling session at baseline. Participants also receive access to a smoking cessation hotline telephone number and supportive text messages daily for 12 weeks.
88874396|NCT02354352|Active Comparator|Eplerenone|Eplerenone is an aldosterone antagonist used as an adjunct in the management of chronic heart failure. It is marketed under the trade name Inspra. Eplerenone is a potassium-sparing diuretic.
88874397|NCT02354352|Active Comparator|Spironolactone|Spironolactone is an aldosterone antagonist used as an adjunct in the management of chronic heart failure. It is marketed under the trade name Aldactone. Spironolactone is a potassium-sparing diuretic.
88874398|NCT02355210|Placebo Comparator|Placebo|5 g lactose given as a placebo
88874399|NCT02355210|Experimental|Probiotic 1|Bifidobacteria adolescentis BD1, 10^9
88874400|NCT02355210|Experimental|Probiotic 2|Bifidobacteria animalis subsp. lactis BB-12, 10^9
88874401|NCT02355210|Experimental|Prebiotic|galactooligosaccaride, 5 g
88874402|NCT02355210|Experimental|Synbiotic 1|galacto-oligosaccharide (5 g) and Bifidobacteria adolescentis BD1 (10^9)
88874403|NCT02355210|Experimental|Synbiotic 2|galacto-oligosaccharide (5 g) and Bifidobacteria animalis subsp. lactis BB-12 (10^9)
88874404|NCT02356692|Experimental|enfilcon A|participants randomized to wear the Enfilcon A (test) lens in one eye and Senofilcon A (control) lens in the other eye.
88874405|NCT02356692|Active Comparator|senofilcon A|participants randomized to wear the Enfilcon A (test) lens in one eye and Senofilcon A (control) lens in the other eye.
88874406|NCT02357394|Experimental|Device: Arabin Pessary|Participants randomized to this group will receive the pessary.
88874407|NCT02357394|No Intervention|Standard of Care|Patients randomized to the control group will receive standard of care for their condition. This includes surveillance of cervical length, vaginal progesterone, and emergency cerclage.
88874408|NCT02357706|Active Comparator|Group 1|Patients will be randomised to either Group 1 or Group 2. Patients in this group (group 1) will use APAP A on the first night of the evaluation, and APAP B on the second night.
88874409|NCT02357706|Active Comparator|Group 2|Patients will be randomised to either Group 1 or Group 2. Patients in this group (group 2) will use APAP B on the first night of the evaluation and APAP A on the second night.
88874410|NCT02359110|Experimental|Drug 1|Patients will receive Gabapentin 300mg tab less than 1 hour before surgery.
88874411|NCT02359110|Placebo Comparator|Drug 2|Patients will receive Methylcellulose based placebo tab less than 1 hour before surgery.
88874412|NCT02360124|Placebo Comparator|control|instructions on oral hygiene (OHI) tailored to the individual's condition will be given, and a tube of toothpaste containing 1,000 ppm fluoride (the most popular type of adult toothpaste in the Hong Kong market) will be provided. The OHI and provision of toothpaste will be repeated at 6-month intervals. In addition, distilled water as placebo with a bitter flavor added (to mimic the bitter metallic taste of SDF) will be painted onto all exposed tooth root surfaces using a small disposable brush. This procedure will be repeated after 12 and 24 months.
89398082|NCT00948129|Experimental|Group III (intensive care)|Participants undergo standard of care smoking cessation intervention as in Group I and attend a health feedback counseling session at baseline. Participants also receive access to a smoking cessation hotline telephone number, supportive text messages daily for 12 weeks, and a smoking cessation telephone call over 15 minutes weekly for 12 weeks.
89398083|NCT01382849||CAA positive microbleeders|Cerebral amyloid angiopathy (CAA) positive microbleeders
88874413|NCT02360124|Experimental|silver diammine fluoride|the subjects will receive the same intervention as those provided to subjects in the control group except that a 38% SDF solution (Saforide, Toyo Seiyaku Kasei Co. Ltd, Osaka, Japan) instead of the placebo solution will be painted onto the exposed tooth root surfaces. This treatment will be repeated after 12 and 24 months.
88874414|NCT02360124|Active Comparator|silver diammine fluoride and KI|the subjects will receive the same treatment as those provided to subjects in the control group except that a 38% SDF solution instead of the placebo solution will be painted onto the exposed tooth root surfaces and followed by painting of a saturated potassium iodide solution. This treatment will be repeated after 12 and 24 months.
88874415|NCT02364570|Active Comparator|Oral Glucose Tolerance Test|We will perform fasting measurements of flow-mediated dilation (FMD) using ultrasound, and draw a blood sample, prior to administration of the test meal. Following these baseline measurements, participants will ingest glucose (100 g). FMD will be performed intermittently post-ingestion at 30, 60, 90, 120, 150, and 180 minutes. Blood samples will be collected at 0 min (immediately prior to eating) and at 30, 60, 90, 120, 150, and 180 minutes following the ingestion of the meal. After each blood sample is obtained, the catheter will be flushed with saline in order to prevent the formation of clots and to minimize the likelihood of having to insert a needle again. Subjects will remain supine in a comfortable position for the entire duration of the test.
88874416|NCT02364570|Experimental|Glucose with Whole Eggs|We will perform fasting measurements of flow-mediated dilation (FMD) using ultrasound, and draw a blood sample, prior to administration of the test meal. Following these baseline measurements, participants will ingest glucose (75 g) with 1.5 whole eggs (cooked). FMD will be performed intermittently post-ingestion at 30, 60, 90, 120, 150, and 180 minutes. Blood samples will be collected at 0 min (immediately prior to eating) and at 30, 60, 90, 120, 150, and 180 minutes following the ingestion of the meal. After each blood sample is obtained, the catheter will be flushed with saline in order to prevent the formation of clots and to minimize the likelihood of having to insert a needle again. Subjects will remain supine in a comfortable position for the entire duration of the test.
89398084|NCT01382849||probable CAA macrobleeders|
89398085|NCT01382849||CAA negative microbleeders|
89398086|NCT01382771|Active Comparator|Intra-articular corticosteroid injection|Intra-articular corticosteroid injection in conjunction with confirmatory anesthetic medial branch blocks
89398087|NCT01382771|Placebo Comparator|Intra-articular saline injection|Intra-articular saline injections with confirmatory anesthetic medial branch blocks
89398088|NCT04819451|Experimental|MACSF group|In the experimental group, patients with intracerebral hemorrhage ruptured into the ventricle and patients with subarachnoid hemorrhage were included in the stratified random method. Use Magnesium-Rich Artificial Cerebrospinal Fluid(MACSF) in the CSF replacement, and the remaining treatments should strictly follow the guidelines as same as the control group. The total amount of replacement was generally 30ml, and the replacement was performed once every 3 days. When the RBC count in CSF is less than 100×10^6/L, the CSF is considered to be cleared. Cerebrospinal fluid replacement is performed up to four times.
89398089|NCT04819451|No Intervention|NS group|In the control group, patients with intracerebral hemorrhage ruptured into the ventricle and patients with subarachnoid hemorrhage were included according to the stratified random method. Use the normal saline (0.9% Sodium Chloride Injection) in the CSF replacement, and the remaining treatments should strictly follow the guidelines. The total amount of replacement was generally 30ml, and the replacement was performed once every 3 days. When the RBC count in CSF is less than 100×10^6/L, the CSF is considered to be cleared. Cerebrospinal fluid replacement is performed up to four times.
89398090|NCT02927171|No Intervention|Usual Care|Skilled nursing facility rehabilitation therapists provide all patients with usual standard of care.
89398091|NCT02927171|Experimental|I-STRONGER|IntenSive Therapeutic Rehabilitation for Older Skilled NursinG HomE Residents (I-STRONGER) Progressive, high-intensity strengthening and functional interventions to facilitate independence with functional activities. Skilled nursing facility rehabilitation therapists will be trained in I-STRONGER intervention and will implement to all eligible patients as new standard of care.
89398092|NCT04933253|Experimental|Experimental|this cohort will receive 2 L of warm 37celsius saline irrigation of the mediastinum prior to closure of the chest
89398093|NCT04933253|No Intervention|Control|this cohort will receive the normal standard of care as established by the primary surgeon
88874417|NCT02364570|Experimental|Glucose with Egg Whites|We will perform fasting measurements of flow-mediated dilation (FMD) using ultrasound, and draw a blood sample, prior to administration of the test meal. Following these baseline measurements, participants will ingest glucose (75 g) with 7 egg whites (cooked). FMD will be performed intermittently post-ingestion at 30, 60, 90, 120, 150, and 180 minutes. Blood samples will be collected at 0 min (immediately prior to eating) and at 30, 60, 90, 120, 150, and 180 minutes following the ingestion of the meal. After each blood sample is obtained, the catheter will be flushed with saline in order to prevent the formation of clots and to minimize the likelihood of having to insert a needle again. Subjects will remain supine in a comfortable position for the entire duration of the test.
89398094|NCT04878419|Experimental|Virtual Educational Intervention|Virtual Educational Intervention
89398095|NCT01382693|Experimental|TimeSlips group storytelling program|
89398096|NCT01382693|Active Comparator|Standard care activity program|
89398097|NCT01304511||Participants Treated|Women undergoing controlled ovarian COH for ART
89398098|NCT03087617|Active Comparator|Usual Care|Usual Care includes a lung cancer screening CT exam. Following the screen, a radiologist will analyze the CT scan image and send the results to the patient's Primary Care Physician (PCP). If the scan is read as a category 1 or 2 in the Lung Reporting and Data System (Lung-RADS), patients are provided a letter in the mail with their results. If the scan is read as a category 3, 4A, 4B, or 4X in Lung-RADS the patient will be contacted by their primary care physician's office and told to schedule a follow up appointment. Either in the letter or at the follow up appointment, patients will be given a Quitline number created specifically for this trial and maintained for the duration.
89398099|NCT03087617|Experimental|Usual Care + Imbio Smoking Cessation Report|In this arm, patients will receive the Usual Care described above and will additionally be provided with the Report. In this arm, the Report will provide the Quitline number.
89398100|NCT03087617|Active Comparator|Usual Care + Counseling|In addition to the Usual Care described above, patients in this arm will participate in a 45 minute smoking cessation counseling session. Approximately three Tobacco Treatment Specialists will be trained to ensure consistent counseling methodology. Counselors will utilize a patient centered approach grounded in Motivational Interviewing skills to elicit perceived benefits for stopping smoking and to enhance self-efficacy for stopping. A major emphasis of a call is to enroll the caller in formal cessation programs and/or convince them to use FDA approved medication as part of a quit attempt. Study participants who desire further smoking cessation support after their session will be connected with the appropriate organization.
89398101|NCT03087617|Experimental|Usual Care + Imbio Smoking Cessation Report + Counseling|In addition to the Usual Care and Counseling described above, patients in this arm will also receive the Report.
89398102|NCT00103610|Experimental|G-CSF plus plerixafor|
89398103|NCT00103610|Placebo Comparator|G-CSF plus placebo|
89398104|NCT01568801|No Intervention|Control Group|Individuals randomized into the control arm will receive usual community care services referred by the social worker from SGH and AH.
89398105|NCT01568801|Experimental|Intervention Group|Individuals in the intervention group will go through an integrated program of community based health and social care based on intake and ongoing evaluation by the SingaPACE team.
88874418|NCT02364570|Experimental|Glucose with Egg Yolks|We will perform fasting measurements of flow-mediated dilation (FMD) using ultrasound, and draw a blood sample, prior to administration of the test meal. Following these baseline measurements, participants will ingest glucose (75 g) with 2 egg yolks (cooked). FMD will be performed intermittently post-ingestion at 30, 60, 90, 120, 150, and 180 minutes. Blood samples will be collected at 0 min (immediately prior to eating) and at 30, 60, 90, 120, 150, and 180 minutes following the ingestion of the meal. After each blood sample is obtained, the catheter will be flushed with saline in order to prevent the formation of clots and to minimize the likelihood of having to insert a needle again. Subjects will remain supine in a comfortable position for the entire duration of the test.
88874419|NCT02367066|Experimental|AR-C165395XX + placebo|1st period AR-C165395XX 2nd period placebo
88874420|NCT02367066|Placebo Comparator|Placebo + AR-C165395XX|1st period Placebo for AR-C165395XX 2nd period AR-C165395XX
88874421|NCT02369172|Other|Bupropion + ASP2151|400 mg ASP2151 followed by 150 mg Bupropion
88874422|NCT02369796|Experimental|TAK-448 3 µg once weekly|TAK-448 3 µg, subcutaneous injection, once weekly on Days 1, 8, 15 and 22.
88874423|NCT02369796|Experimental|TAK-448 1 µg once weekly|TAK-448 1 µg, subcutaneous injection, once weekly on Days 1, 8, 15 and 22.
88874424|NCT02369796|Experimental|TAK-448 0.3 µg once weekly|TAK-448 0.3 µg, subcutaneous injection, once weekly on Days 1, 8, 15 and 22.
88874425|NCT02369796|Experimental|TAK-448 0.3 µg twice weekly|TAK-448 0.3 µg, subcutaneous injection, twice weekly on Days 1, 4, 8, 11, 15, 18, 22, and 25.
88874426|NCT02369796|Experimental|TAK-448 0.1 µg twice weekly|TAK-448 0.1 µg, subcutaneous injection, twice weekly on Days 1, 4, 8, 11, 15, 18, 22, and 25.
89398106|NCT02151188|Other|Bread and water|co-ingestion control session
89398107|NCT02151188|Experimental|bread with cow milk co-ingestion|co-ingestion bread with cow milk
89398108|NCT02151188|Experimental|bread with soy milk co-ingestion|co-ingestion bread with soy milk
89398109|NCT02151188|Experimental|preload cow milk|preload cow milk 30 min, then bread
89398110|NCT02151188|Experimental|preload soy milk|preload soy milk 30 min, then bread
89398111|NCT05597579||Study Group|Patients diagnosed with psychotic disorder.
88874427|NCT02370810|Experimental|experimental group|CBT-based internet-intervention for tinnitus The intervention offered is a CTB-based internet intervention, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is 8 week long e-learning intervention, with new modules introduced weekly and assignments given to practice techniques learnt.
88874428|NCT02370810|Other|weekly check-in group with delayed treatment|will complete weekly measures and commence the treatment once the experimental group completes the intervention
88874429|NCT02371356||Depressed, Medication only|Screen positive for depression and use only antidepressants during pregnancy
88874430|NCT02371356||Depressed, Psychotherapy only|Screen positive for depression and receive psychotherapy only.
88874431|NCT02371356||Depressed, Medication & Psychotherapy|Screen positive for depression and receive both antidepressants and psychotherapy.
88874432|NCT02371356||Depressed, untreated|Screen positive for depression and receive no treatment.
89398112|NCT05597579||Control Group|Healthy Controls
89398113|NCT02156960|Experimental|Denosumab and/or teriparatide treatment|Denosumab and/or teriparatide treatment in osteoporotic patients
89398114|NCT03630965|No Intervention|Group A|No CPR video
89398115|NCT03630965|Experimental|Group B|CPR video
89398116|NCT02153606|Active Comparator|Glycerin Suppository|
88874433|NCT02371356||Not depressed|Screen negative for depression and receive no treatment.
88874434|NCT02371668|Placebo Comparator|Placebo|Placebo, 5% dextrose (D-glucose) water
88874435|NCT02371668|Experimental|CR6261|CR6261, Investigational monoclonal antibody against influenza A viruses
89398117|NCT02153606|Sham Comparator|Sham Suppository|
89398118|NCT03631511|Experimental|RetroMTA|Direct pulp capping with RetroMTA (BioMTA, Daejeon, Korea)
89398119|NCT02157038|Experimental|Procedures|RNA/DNA blood sample will be collected. Participant will complete questionnaires, MRI and strength and reflex testing.
89398120|NCT01382615||Healthy Volunteers|Healthy volunteers who have agreed to have a bone marrow and/or blood harvest as part of a donation to a transplant recipient.
89398121|NCT01382615||Patients with multiple myeloma|Patients undergoing routine blood draw and bone marrow aspirates as part of their ongoing follow-up care for myeloma at the Norris Cotton Cancer Center of DHMC.
89398122|NCT02153762|Experimental|Right side|Patients were randomized to apply Locoid Lipocream on the right side of the target lesion followed by Hylatopic Plus lotion on the left side of the target lesion with the reverse order on the other side.
89398123|NCT02153762|Active Comparator|Left first|Patients were randomized to apply Locoid Lipocream on the left side of the target lesion followed by Hylatopic Plus lotion on the right side of the target lesion with the reverse order on the other side.
89398124|NCT04687631|Experimental|mFOLFOXIRI plus Cetuximab|
89398125|NCT04687631|Experimental|mFOLFOXIRI plus Bevacizumab|
89398126|NCT02159300||Patients|Patients with fibromyalgia pain Intervention: experience brain activity recording
89398127|NCT02159300||Healthy Controls|Healthy controls without chronic pain of any type.
89398128|NCT05597501|Active Comparator|CBT (cognitiv behavioural-therapy)-based|weekly psychosocial group-intervention (8 weeks) based on a CBT-manual
89398129|NCT05597501|Active Comparator|integrative therapy|weekly psychosocial group-intervention (8 weeks) based on a integrative therapy manual
89398130|NCT05597501|Active Comparator|Existential Analysis and Logotherapy|weekly psychosocial group-intervention (8 weeks) based on a Existential Analysis and Logotherapy manual
89398131|NCT04833023|Active Comparator|Haloperidol Arm|Haldol 2mg/ml oral solution
89398132|NCT04833023|Active Comparator|Olanzapine Arm|Olanzapine Actavis 5mg orodispersible tablet
89398133|NCT02159378|Other|GD with Insulin treatment|"At the end of the study patients will be divided into two groups: GD with Insulin treatment versus GD without Insulin treatment In each group, the serum fructosamines rate will be estimated with a confidence interval of 95% and compared from a Student test."
88874436|NCT02372682||Test|"Any pediatric patient (0-18 years of age) with known liver disease in whom a liver biopsy is to be performed as standard of care to assess the degree of fibrosis will also undergo an abdominal ultrasound to evaluate the liver.~Underlying diagnoses include but are not limited to biliary atresia, congenital fibrosis-cholestasis, Alagille syndrome, Caroli's disease, choledochal cyst, alpha-1-antitrypsin deficiency, progressive familial intrahepatic cholestasis (PFIC), viral hepatitis, glycogenosis, fructosemia, Wilson disease, cystic fibrosis, autosomal recessive polycystic kidney disease (ARPCKD), mesenterico-caval shunt, post liver transplant, and nonalcoholic steatohepatitis (NASH)."
88874437|NCT02372682||Control|Any pediatric patient (0-18 years of age) undergoing evaluation with an abdominal ultrasound as standard of care for evaluation for a diagnosis other than liver disease and in whom the US shows a normal liver, gallbladder, pancreas, spleen, and biliary tree will then be asked to enroll in the research study by undergoing shear wave elastography.
88874438|NCT02374164|Experimental|Treatment Sequence ABC|Febuxostat extended release (XR) 80 mg, capsules, orally, once on Day 1 of Period 1 after a high-fat meal, followed by a 7-day washout period, followed by febuxostat XR 40 mg, capsules, orally, once on Day 1 of Period 2 after a 10-hour fast, followed by a 7-day washout period, followed by febuxostat XR 80, capsules, orally, once on Day 1 of Period 3 after a 10-hour fast.
89398134|NCT02159378|Other|GD without Insulin treatment|"At the end of the study patients will be divided into two groups: GD with Insulin treatment versus GD without Insulin treatment In each group, the serum fructosamines rate will be estimated with a confidence interval of 95% and compared from a Student test."
89398135|NCT02159456|Experimental|Continuous enteral feeding|Continuous enteral feeding via infusion pump is applied for at least 7 days after the start of enteral feeding
89398136|NCT02159456|Active Comparator|Intermittent enteral feeding|Intermittent enteral feeding via gravity-based infusion is applied for at least 7 days after the start of enteral feeding.
89398137|NCT03091439|Experimental|Dalbavancin|Participants received Dalbavancin 1500 mg, intravenous (IV) administration over 30 minutes on Day 1 and on Day 8.
89398138|NCT03091439|Active Comparator|Standard of Care|Participants received an antibiotic consistent with standard of care (SOC) for osteomyelitis based on Investigator judgment. The duration of treatment will be 4-6 weeks.
89398139|NCT02153840|Experimental|PSORI-CM01（YXBCM01）granule|PSORI-CM01（YXBCM01）granule 1.1g os once a day for 12weeks.
89398140|NCT02153840|Experimental|PSORI-CM01（YXBCM01）granule low dose group|PSORI-CM01（YXBCM01） granule 5.5g os once a day for 12weeks.
89398141|NCT02153840|Placebo Comparator|placebo|Placebo granule 1.1g os once a day for 12weeks.
89398142|NCT03631823||Radio/Chemotherapy group|The participants in this group receive the concurren radio/chemotrherapy
89398143|NCT03631823||Radio/ without chemotherapy group|The participants in this group receive the radiotherapy but without chemotrherapy
89398144|NCT03631823||Healthy volunteer group|The volunteers for control group
89398145|NCT02157272|Experimental|Rivaroxaban|Rivaroxaban 20mg qd, Rivaroxaban 15mg qd if creatinine clearance between 30-49 ml/min (calculated by Cockroft-Gault equation)
89398146|NCT02157272|Active Comparator|Warfarin|To Keep an INR between 2.0 and 3.0
89398147|NCT05597423|Experimental|Massage|The massage will be applied twice a week for a period of four weeks, 10 minutes after the end of lower limb training.
89398148|NCT05597423|Placebo Comparator|Placebo|The massage cream will be applied twice a week for a period of four weeks, 10 minutes after the end of lower limb training.
89398149|NCT05597423|No Intervention|Control|The control group after 10 minutes of the end of lower limb training will remain at rest for 16 minutes.
89398150|NCT04729712|Active Comparator|Anaesthesiologist-administered ultrasound guided Erector Spinae block with catheter insertion|Patient's will be randomised to this arm of the study. This group will receive an erector spinae block with catheter insertion under ultrasound guidance under general anaesthesia. This regional anaesthesia procedure will be performed by an Anaesthesiologist with experience in performing this block.
89398151|NCT04729712|Experimental|Surgeon-administered video-assisted Paravertebral block with catheter insertion|Patient's will be randomised to this arm of the study. This group will receive a paravertebral block with catheter insertion under under thoracoscopic guidance. This regional anaesthesia procedure will be performed at the start of the operation by a surgeon with experience in performing this block.
88874439|NCT02374164|Experimental|Treatment Sequence BCA|Febuxostat XR 40 mg, capsules, orally, once on Day 1 of Period 1 after a 10-hour fast, followed by a 7-day washout period, followed by febuxostat XR 80 mg, capsules, orally, once on Day 1 of Period 2 after a 10-hour fast, followed by a 7-day washout period, followed by Febuxostat XR 80 mg, capsules, orally, once on Day 1 of Period 3 after a high-fat meal.
88874440|NCT02374164|Experimental|Treatment Sequence CAB|Febuxostat XR 80 mg, capsules, orally, once on Day 1 of Period 1 after a 10-hour fast, followed by a 7-day washout period, followed by febuxostat XR 80 mg, capsules, orally, once on Day 1 of Period 2 after a high-fat meal, followed by a 7-day washout period, followed by febuxostat XR 40 mg, capsules, orally, once on Day 1 of Period 3 after a 10-hour fast.
88874441|NCT02374398|Active Comparator|Tranexamic Acid|TXA will be provided ready-to-use as IV infusion with instructions written by the pharmacy department. The TXA dose will be 20mg/kg to be administered as a bolus over 20 minutes
88874442|NCT02374398|Active Comparator|Aquamantys System|The Aquamantys system will be used as indicated by orthopedic surgeon intraoperative. Local temperatures under 100°C are sufficient to shrink collagen fibers in the walls of blood vessels, effectively sealing the blood vessels. Simultaneous RF power and saline delivery. Power settings from 20-200 watts
88874443|NCT02374398|Active Comparator|TXA plus Aquamantys|"TXA will be provided ready-to-use as IV infusion with instructions written by the pharmacy department. The TXA dose will be 20mg/kg to be administered as a bolus over 20 minutes.~The Aquamantys system will be used as indicated by orthopedic surgeon intraoperative. Local temperatures under 100°C are sufficient to shrink collagen fibers in the walls of blood vessels, effectively sealing the blood vessels. Simultaneous RF power and saline delivery. Power settings from 20-200 watts."
89188458|NCT00772967|Experimental|Naproxen, Placebo, Ultracet|Participants were treated with Naproxen for 3 days in Treatment Period 1, Placebo for 3 days in Treatment Period 2, and Ultracet for 3 days in Treatment Period 3. The treatment periods were separated by a 4-6 day break.
88874444|NCT02374398|Placebo Comparator|Control|Saline will be provided ready-to-use as IV infusion with instructions written by the pharmacy department. The saline dose will be administered as a bolus over 20 minutes
88874445|NCT02377752|Experimental|Part A cohort 1: Olaratumab+Doxorubicin|"15 milligram per kilogram (mg/kg) of olaratumab administered intravenously (IV) on Day 1 and Day 8, and 25 milligram per square meter (mg/m2) of doxorubicin administered IV on Day 1, Day 2, and Day 3 every 21-day cycle for up to 6 cycles or until the cumulative dose of doxorubicin reached 500 mg/m2, whichever came later, followed by 15 mg/kg of olaratumab IV monotherapy on Day 1 and Day 8 in subsequent cycles. Participants may continue to receive treatment until discontinuation criteria are met~."
88874446|NCT02377752|Experimental|Part A cohort 2: Olaratumab+Doxorubicin|15 mg/kg of olaratumab administered IV on Day 1 and Day 8, and 75 mg/m2 of doxorubicin administered IV on Day 1 every 21 day-cycle for up to 6 cycles or until the cumulative dose of doxorubicin reached 500 mg/m2, whichever came later, followed by 15 mg/kg of olaratumab IV monotherapy on Day 1 and Day 8 in subsequent cycles. Participants may continue to receive treatment until discontinuation criteria are met.
88874447|NCT02377752|Experimental|Part A cohort 3 Olaratumab + Doxorubicin|20 mg/kg loading dose of olaratumab administered IV on Day 1 and Day 8 in Cycle 1, followed by 15 mg/kg IV on Day 1 and Day 8 in subsequent cycles, and 75 mg/m2 of doxorubicin administered IV on Day 1 of every 21 day-cycle up to 6 cycles or until the cumulative dose of doxorubicin reached 500 mg/m2, whichever came later, followed by 15 mg/kg of olaratumab IV monotherapy on Day 1 and Day 8 in subsequent cycles. Participants may continue to receive treatment until discontinuation criteria are met.
88874448|NCT02377752|Experimental|Part B: Olaratumab|15 mg/kg olaratumab administered IV on Day 1 and Day 8 of every 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
88874449|NCT02377986|Experimental|Experimental: BIT+In-home Decluttering|Patients who have not received the BIT workshop through our previous study (IRB 6681) will receive BIT+in-home decluttering practice.
88874450|NCT02377674|Experimental|Vascular Graft, Model COR-VG-001|A surgically implanted vascular graft for pediatric patients undergoing extracardiac total cavopulmonary connection.
88874451|NCT02378844|Active Comparator|gammaCore®-R|Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).
89188459|NCT00772967|Experimental|Ultracet, Naproxen, Placebo|Participants were treated with Ultracet for 3 days in Treatment Period 1, Naproxen for 3 days in Treatment Period 2, and Placebo for 3 days in Treatment Period 3. The treatment periods were separated by a 4-6 day break.
89188460|NCT02363010|Active Comparator|Standard Behavior Therapy for Weight Loss|Eighteen months of standard, group-based behavioral treatment for weight loss and weight loss maintenance.
89398152|NCT01382537|Active Comparator|A|
89398153|NCT01382537|Placebo Comparator|B|
89398154|NCT01382459||type 1 DM children- intervention group|will have home visits and trainings at school
89398155|NCT01382459||type 1 DM children- control group|will receive the standard care at the clinic
89398156|NCT02154074|Active Comparator|N1 group: Isoflurane & saline|for normal patients: inhale Isoflurane + the same volume of saline during operation
89398157|NCT02154074|Experimental|N2 group: Isoflurane & Dexmedetomidine|for normal patients: inhale Isoflurane + intravenous pumping Dexmedetomidine during operation
89188461|NCT02363010|Experimental|Behavior Therapy for Weight Loss with PA emphasis|Six months of standard, group-based behavioral treatment for weight loss and weight loss maintenance, followed by 12 months of standard, group-based behavioral treatment for weight loss and weight loss maintenance with a larger emphasis on physical activity goals.
89398158|NCT02154074|Active Comparator|D1 group: Isoflurane & saline|for diabetes patients: inhale Isoflurane + the same volume of saline during operation
89398159|NCT02154074|Experimental|D2 group: Isoflurane & Dexmedetomidi|for diabetes patients: inhale Isoflurane + intravenous pumping Dexmedetomidine during operation
89398160|NCT02154152|Experimental|Homoeopathic Medicine Causticum|The drug namely Causticum 200C potency shall be administered as 4 globules, prescribed once a week for 3 months with placebo to follow for the remaining period.
89398161|NCT03086447|Experimental|Experimental: Participating Subjects|Subjects who are habitual soft toric contact lens wearers, aged 18 to 40 years of age, will be dispensed the investigational contact lens to be worn from 28-36 days, to include a total of 5 visits.
89398162|NCT03086447|Active Comparator|Control: Participating Subjects|Subjects who are habitual soft toric contact lens wearers, aged 18 to 40 years of age, will be dispensed marketed contact lens to be worn from 28-36 days, to include a total of 5 visits.
89398163|NCT02159534|Experimental|Primebrain|"' Stimulation ' Infants group will receive Primebrain stimulation whose items were selected according to a Delphi process and discussed at the European Academy of Childhood Disability (2013).~This sensorimotor stimulation programme is administered at home by parents (trained and monitored by a physical therapist), once a day between term-age and 6 months of corrected age.~In addition, these infants undergo systematic monitoring for preterm and infants born with low birth weight as organized in Belgium ( INAMI convention )."
89398164|NCT02159534|Other|usual care|"Infants in the comparison group receive usual care for preterm and infants born with low birth weight as organized in Belgium ( INAMI convention )."
89398165|NCT02159612||FSHD|A cohort of adult danish patients with facioscapulohumeral muscular dystrophy is invited to perform a MRI scan.
89398166|NCT04787393||LOVE-HF-2 Participants|"Participants will have the Heartfelt device as well as a set of weighing scales installed at home.~Alerts will be raised for the patient to be seen at home or in clinic by clinician ( the clinician will be blinded to the type of alert). During this face-to-face encounter, the clinician will perform a detailed oedema assessment (recording pitting depth, time of recovery, height oedema, overall grading), ankle circumference measurement, weight measurements, and echo (Left ventricular ejection fraction, Left atrial volumes, inferior vena cava diameter, Diastolic function (E/A, E/E'), TAPSE and TR jet velocity + visually estimated mitral and tricuspid regurgitation)."
88874452|NCT02378844|Sham Comparator|gammaCore®-R Sham|Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).
89398167|NCT04666025||Observational (biospecimen collection, medical chart review)|"DONORS: Prior to HCT, sibling donors (MRD and haplo) undergo a nasopharyngeal swab per standard of care for SARS-Cov-2 testing. For MUD donors, initial testing may consist of a questionnaire. All donors undergo collection of blood and saliva at the time of granulocyte-colony stimulating factor (G-CSF). Donors' medical charts are also reviewed.~RECIPIENTS: Patients undergo a nasopharyngeal swab for SARS-Cov-2 testing at 30, 60, 90, 120 days post-HCT, and afterwards as deemed necessary by the treating physician. Patients also undergo the collection of blood and saliva specimens at days 30, 60, 90, 120, 150, and 180 post-HCT. Recipients' medical charts are also reviewed."
89398168|NCT05460455|Active Comparator|HB0034 dose group 1|8 subjects receive a multi-dose of HB0034 and 2 subjects receive a multi-dose placebo
89398169|NCT05460455|Active Comparator|HB0034 dose group 2|8 subjects receive a multi-dose of HB0034 and 2 subjects receive a multi-dose placebo
89398170|NCT05460455|Active Comparator|HB0034 dose group 3|8 subjects receive a multi-dose of HB0034 and 2 subjects receive a multi-dose placebo
89398171|NCT03104413|Experimental|Risankizumab Dose 1 (Induction Period 1)|Participants randomized to receive risankizumab dose 1 in Induction Period 1.
89398172|NCT03104413|Experimental|Risankizumab Dose 2 (Induction Period 1)|Participants randomized to receive risankizumab dose 2 in Induction Period 1.
88874453|NCT02379858|Experimental|Alvimopan (Entereg)|Alvimopan, 12mg, capsule. One 30 to 90 minutes before the scheduled start of surgery on Day 0, and twice daily beginning on POD 1 after NGT removal until hospital discharge or for a maximum of 7 days (up to 15 doses) of postoperative treatment. First post-operative dose begins after NGT removal.
88874454|NCT02379858|Placebo Comparator|Suger Pill (Control)|Placebo, 12mg capsule. One 30 to 90 minutes before the scheduled start of surgery on Day 0, and twice daily beginning on POD 1 until hospital discharge or for a maximum of 7 days (up to 15 doses) of postoperative treatment. First post-operative dose begins after NGT removal.
88874455|NCT02381418|Experimental|1|"Trivalent influenza subunit vaccine Influvac. 3x 15mcg Hemagglutinin Antigen (HA) per 0.5 ml,trivalent one injection at Day 1 "
88874456|NCT02382744|Experimental|Ultrasound Guidance|Saphenous nerve block placed using ultrasound guidance alone
88874457|NCT02382744|Experimental|Ultrasound Guidance + nerve stimulation|Saphenous nerve block placed using ultrasound guidance and nerve stimulation
88874458|NCT02384070|Experimental|Group 1|Received upstream aspirin plus clopidogrel with no intra-procedural anticoagulation for the FFR calculation with a saline bolus and drip used for placebo anticoagulation during the procedure to blind the operator
88874459|NCT02384070|Active Comparator|Group 2|Received upstream aspirin and clopidogrel plus intra-procedural anticoagulation with bivalirudin for FFR calculation
88874460|NCT02384070|Experimental|Group 3|Received only upstream single anti-platelet therapy with aspirin plus intra-procedural anticoagulation for the FFR calculation with bivalirudin
88874461|NCT02385240|Experimental|Test product|Brimonidine Topical Gel, 0.33 percent
88874462|NCT02385240|Active Comparator|Reference Product|Brimonidine Topical Gel, 0.33 percent (Reference)
88874463|NCT02385240|Placebo Comparator|Placebo gel|Placebo
88874464|NCT02385318|Experimental|Test Product|Ingenol Mebutate
88874465|NCT02385318|Active Comparator|Reference product|Ingenol Mebutate
88874466|NCT02385318|Placebo Comparator|Placebo product|Placebo gel
88874467|NCT02387268|Experimental|CleanC|Standard colonoscopy procedure using the CleanC system
88874468|NCT02387502|Experimental|Intubation with Macintosh laryngoscope|40 patients were intubated with Macintosh laryngoscope after simulating difficult laryngoscopy using rigid neck collar.
88874469|NCT02387502|Active Comparator|Intubation with MacCoy laryngoscope|40 patients were intubated with MacCoy laryngoscope after simulating difficult laryngoscopy using rigid neck collar.
89398173|NCT03104413|Placebo Comparator|Placebo (Induction Period 1)|Participants randomized to receive placebo for risankizumab in Induction Period 1.
88874470|NCT02387502|Active Comparator|Intubation with Airtraq laryngoscope|40 patients were intubated with Airtraq laryngoscope after simulating difficult laryngoscopy using rigid neck collar.
88874471|NCT02387814|Experimental|Abemaciclib: Normal Hepatic Function|Single dose of Abemaciclib administered orally on Day 1 to participants with normal hepatic function.
88874472|NCT02387814|Experimental|Abemaciclib: Mild Hepatic Impairment|Single dose of Abemaciclib administered orally on Day 1 to participants with mild hepatic impairment.
88874473|NCT02387814|Experimental|Abemaciclib: Moderate Hepatic Impairment|Single dose of Abemaciclib administered orally on Day 1 to participants with moderate hepatic impairment.
88874474|NCT02387814|Experimental|Abemaciclib: Severe Hepatic Impairment|Single dose of Abemaciclib administered orally on Day 1 to participants with severe hepatic impairment.
88874475|NCT02391714|Placebo Comparator|Oxygen (Placebo)|"100% oxygen will be administered via disposable scented nasal masks 2 minutes before, throughout and 3-5 minutes after procedure.~If you are randomized to this group, you will undergo the IUD insertion (including Povidone-Iodine or Chlorhexidine swab) using standard technique."
88874476|NCT02391714|Experimental|Nitrous Oxide (NO)|"Nitrous Oxide in a fixed dose ratio of 50% nitrous/50% oxygen will be administered via disposable scented nasal masks 2 minutes before and throughout the procedure; 100% oxygen will be given after the procedure for 3-5 minutes.~If you are randomized to this group, you will undergo the IUD insertion (including Povidone-Iodine or Chlorhexidine swab) using standard technique."
88874477|NCT02392494|Experimental|MK-1075 100 mg (Panel A)|HCV-infected participants receive a single 100 mg dose of MK-1075.
88874478|NCT02392494|Experimental|MK-1075 200 mg (Panel B)|HCV-infected participants receive a single 200 mg dose of MK-1075.
88874479|NCT02392494|Experimental|MK-1075 400 mg (Panel C)|HCV-infected participants receive a single 400 mg dose of MK-1075.
88874480|NCT02392494|Experimental|MK-1075 800 mg (Panel D)|HCV-infected participants receive a single 800 mg dose of MK-1075.
89188462|NCT02363010|Experimental|Acceptance-based Behavior Therapy with PA emphasis|Six months of standard, group-based behavioral treatment for weight loss and weight loss maintenance, followed by 12 months of group-based behavior therapy with acceptance-based strategies, and a larger emphasis on physical activity goals.
89398174|NCT03104413|Experimental|Risankizumab Dose 1 (Induction Period 2)|Participants who received placebo in Period 1 and participants with inadequate response at Week 12 in Period 1 randomized to receive risankizumab dose 1 administered by intravenous (IV) infusion in Period 2.
89398175|NCT03104413|Experimental|Risankizumab Dose 2 (Induction Period 2)|Participants with inadequate response at Week 12 in Period 1 randomized to receive risankizumab dose 2 administered by subcutaneous (SC) injection in Period 2.
89398176|NCT03104413|Experimental|Risankizumab Dose 3 (Induction period 2)|Participants with inadequate response at Week 12 in Period 1 randomized to receive risankizumab dose 3 administered by subcutaneous (SC) injection in Period 2.
89398177|NCT04536155||patient with chronic pain|
88874481|NCT02392806|Active Comparator|BabiPlus, Respiralogics|Infants randomized to the BabiPlus device will be extubated to BabiPlus Bubble CPAP device and after 72 hours, if the infant has remained extubated, will be crossed-over to the B&B Bubbler device for 24 hours
88874482|NCT02392806|Active Comparator|B&B Bubbler, B&B medical Technologies|Infants randomized to the B&B Bubbler device will be extubated to B&B Bubbler Bubble CPAP device and after 72 hours, if the infant has remained extubated, will be crossed-over to the BabiPlus device for 24 hours
88874483|NCT02394912|Experimental|Single-arm|
88874484|NCT02395692|Experimental|Treatment (methoxyamine, temozolomide)|Patients receive methoxyamine PO QD and temozolomide PO QD on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88874485|NCT02396160|Active Comparator|Treatment|2 capsules per day of the herbal formula (Urox®) with each capsule containing 420mg of a concentrated proprietary blend of extracts of Crateva nurvala stem bark, Equisetum arvense stem and Lindera aggregata root
88874486|NCT02396160|Placebo Comparator|Placebo|identical placebo vegetarian capsule containing color-matched cellulose
88874487|NCT02397564|Experimental|1|Enroll 20 patients for nonsurgical treatment of surgical scars. Half of each scar will be treated with the Er:YAG laser on the traditional ablative setting and the other half of the scar will receive Er:YAG treatment with the fractional ablative setting. The patients will receive 3 treatments at monthly intervals. They will follow up at 1 and 2 months after the treatment.
88874488|NCT02400996||Pancreatic Endocrine Neoplasms|We did an observational analysis from a prospectively maintained database of patients who underwent pancreatic surgery for neoplasms of the pancreas at Sir Ganga Ram Hospital, New Delhi, India from 1995 to 2013 and using pathological reports and preoperative CT scan as gold standard, we identified 40 patients with PENs.
89398178|NCT01382147|Experimental|S-HAM|S-HAM (S-HAMescalated for younger patients and S-HAMbasis for elderly patients)
89398179|NCT01382147|Active Comparator|TAD-HAM (younger) or HAM-HAM (elderly)|is TAD-9 - HAM for younger patients (with 2 mandatory induction cycles) and HAM (- HAM) for the elderly patients with the second HAM cycle only applied in the case of inadequate blast clearance (> 5%) in the day 16 bone marrow aspirate
89398180|NCT03630887|No Intervention|Control|Non-active prewarming. Patients will be actively warmed during the intraoperative period. Tympanic thermometer (Genius 2 Tympanic Thermometer and Base, Covidien Ltd, Mansfield, USA) will be used to measure the temperature throughout the perioperative period.
88874489|NCT02401464|Experimental|Dry syrup formulation (Group a)|One pack of the dry syrup formulation of TAK-536, containing 10 milligram (mg) of TAK-536, will be orally administered with water (200 milliliter [mL]) at breakfast to fasting participants who have fasted for 10 hours or longer since the night prior to the administration of study medication in Period 1 and, after a washout period of 6 days or more, one 10 mg tablet of TAK-536 will be orally administered with water (200 mL) at breakfast to fasting participants who have fasted for 10 hours or longer since the night prior to the administration of study medication in Period 2.
88874490|NCT02401464|Experimental|Dry syrup formulation (Group b)|One 10 mg tablet of TAK-536 will be orally administered with water (200 mL) at breakfast to fasting participants who have fasted for 10 hours or longer since the night prior to the administration of study medication in Period 1 and, after a washout period of 6 days or more, one pack of the dry syrup formulation of TAK-536, containing 10 mg of TAK-536, will be orally administered with water (200 mL) at breakfast to fasting participants who have fasted for 10 hours or longer since the night prior to the administration of study medication in Period 2.
88874491|NCT02401464|Experimental|Granule formulation (Group a)|One pack of the granule formulation of TAK-536, containing 10 mg of TAK-536,will be orally administered with water (200 mL) at breakfast to fasting participants who have fasted for 10 hours or longer since the night prior to the administration of study medication in Period 1 and, after a washout period of 6 days or more, one 10 mg tablet of TAK-536 will be orally administered with water (200 mL) at breakfast to fasting participants who have fasted for 10 hours or longer since the night prior to the administration of study medication in Period 2.
88874492|NCT02401464|Experimental|Granule formulation (Group b)|One 10 mg tablet of TAK-536 will be orally administered with water (200 mL) at breakfast to fasting participants who have fasted for 10 hours or longer since the night prior to the administration of study medication in Period 1 and, after a washout period of 6 days or more, one pack of the granule formulation of TAK-536, containing 10 mg of TAK-536, will be orally administered with water (200 mL) at breakfast to fasting participants who have fasted for 10 hours or longer since the night prior to the administration of study medication in Period 2.
88874493|NCT02401542|Active Comparator|Vofatamab plus docetaxel|"IV infusion of docetaxel, 75 mg/m2, followed by IV infusion of vofatamab, 25 mg/kg, on day one of each 21-day cycle. One additional IV infusion of vofatamab (25 mg/kg) given on Day 8 of Cycle 1.~Dosing with vofatamab and docetaxel will continue in each patient until disease progression, unacceptable toxicity, death, or study exit, including withdrawal of patient consent or study termination. Docetaxel treatment beyond 12 cycles of therapy may be considered at the discretion of the treating investigator and Medical Monitor."
88874494|NCT02401542|Placebo Comparator|Placebo plus docetaxel|"IV infusion of docetaxel, 75 mg/m2, followed by IV infusion of placebo on day one of each 21-day cycle.~One additional IV infusion of placebo given on Day 8 of Cycle 1. Dosing of docetaxel and placebo will continue in each patient until disease progression, unacceptable toxicity, death, or study exit, including withdrawal of patient consent or study termination. Docetaxel treatment beyond 12 cycles of therapy may be considered at the discretion of the treating investigator and Medical Monitor"
88874495|NCT02401542|Experimental|Vofatamab|"IV infusion vofatamab, 25 mg/kg on day one each 21-day cycle. One additional IV infusion of vofatamab (25 mg/kg) given on Day 8 of Cycle 1.~Dosing of vofatamab will continue in each patient until disease progression, unacceptable toxicity, death, or study exit, including withdrawal of patient consent or study termination."
88874496|NCT02408796|Experimental|OTO-201|6 mg OTO-201
88874497|NCT02411916|Experimental|intervention cases|patient receiving misoprostol
88874498|NCT02411916|No Intervention|controls|patients not receiving misoprostol
88874499|NCT02413008|Experimental|0.005% estriol vaginal gel|Route: Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel, containing 50 Mcg of estriol Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration
88874500|NCT02413008|Placebo Comparator|placebo vaginal gel|Route: Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel. Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration
88874501|NCT02413320|Active Comparator|Carboplatin + Paclitaxel then Doxorubicin + Cyclophosphamide|Paclitaxel (80mg/m2) given IV every week x12 weeks and Carboplatin (AUC 6) given IV every 21 days x 4 cycles, followed by Doxorubicin (60mg/m2) given IV and Cyclophosphamide (600mg/m2) given IV every 14 days X 4 cycles
88874502|NCT02413320|Active Comparator|Carboplatin + Docetaxel|Carboplatin (AUC 6) given IV and Docetaxel (75mg/m2) given IV every 21 days x 6 cycles
88874503|NCT05719038||Healthy control group|
88874504|NCT05719038||Pulmonary fibrosis after COVID-19 Pneumonia|
89398181|NCT03630887|Experimental|Prewarming during 15 minutes|Active Prewarming will be performed during 15 minutes, using a forced-air blanket (WarmTouch lower body blanket, Covidien Ltd, Mansfield, USA) over the whole body and connected to a forced-air warmer (WarmTouch Model 5900, Covidien Ltd, Mansfield, USA). Patients will be actively warmed during the intraoperative period. Tympanic thermometer (Genius 2 Tympanic Thermometer and Base, Covidien Ltd, Mansfield, USA) will be used to measure the temperature throughout the perioperative period.
88874505|NCT05719038||No pulmonary fibrosis after COVID-19 Pneumonia|
88874506|NCT05718804||Sepsis-associated kidney injury|Sepsis patients and acute kidney injury No intervention
88874507|NCT05718804||Sepsis but no renal impairment|Sepsis patients without acute kidney injury
88874508|NCT05718492|Experimental|HAIC|Treated by HAIC alone.
88874509|NCT05717868|Experimental|Kinesio-taping group|Kinesio-tape will be applied from the dorsal region (T1-T2) to the upper cervical region (C1-C2), two times weekly in a period of four weeks.
88874510|NCT05717868|Experimental|Self-mobilization group|Self-SNAG technique will be applied by the participants with the help of a towel, and performed for a four week period.
88874511|NCT05717790|Experimental|Experimental: Nimotuzumab arm|Patients will receive induction chemotherapy with nimotuzumab (200mg/w,weekly plus gemcitabine (1g/m2, d1 & 8 of every cycle) and cisplatin (80mg/m2, d1 of every cycle), every 3 weeks for 2 cycles before radiation. Definitive intensity-modulated radiotherapy (IMRT) will be given. Concurrent nimotuzumab (200mg/w,weekly, 6-7 weeks) and cisplatin (100mg/m2,every 3 weeks for 3cycles )will be administered during IMRT. After 4-6 weeks of the completion of IMRT, adjuvant nimotuzumab (200mg ) will be given every 3 weeks for 8 cycles.
89530219|NCT05082779|Experimental|Cohort B4: 4mg|Participants in fasted state will receive CS0159 4 mg or placebo once daily for a consecutive 14 days.
89530220|NCT03255265||Acute rejection|
88874512|NCT05717790|Active Comparator|Control|Patients will receive induction chemotherapy with gemcitabine (1g/m2, d1 & 8 of every cycle) and cisplatin (80mg/m2, d1 of every cycle), every 3 weeks for 2 cycles before radiation. Definitive intensity-modulated radiotherapy (IMRT) will be given. Concurrent nimotuzumab (200mg/w,weekly, 6-7 weeks) and cisplatin (100mg/m2,every 3 weeks for 3cycles )will be administered during IMRT.
89398182|NCT03630887|Experimental|Prewarming during 30 minutes|Active Prewarming will be performed during 30 minutes, using a forced-air blanket (WarmTouch lower body blanket, Covidien Ltd, Mansfield, USA) over the whole body and connected to a forced-air warmer (WarmTouch Model 5900, Covidien Ltd, Mansfield, USA). Patients will be actively warmed during the intraoperative period. Tympanic thermometer (Genius 2 Tympanic Thermometer and Base, Covidien Ltd, Mansfield, USA) will be used to measure the temperature throughout the perioperative period.
88874513|NCT05717634||TAM|Patients with previous breast cancer with hormonal receptor expression that are treated with tamoxifen.
89398183|NCT03630887|Experimental|Prewarming during 45 minutes|Active Prewarming will be performed during 45 minutes, using a forced-air blanket (WarmTouch lower body blanket, Covidien Ltd, Mansfield, USA) over the whole body and connected to a forced-air warmer (WarmTouch Model 5900, Covidien Ltd, Mansfield, USA). Patients will be actively warmed during the intraoperative period. Tympanic thermometer (Genius 2 Tympanic Thermometer and Base, Covidien Ltd, Mansfield, USA) will be used to measure the temperature throughout the perioperative period.
89398184|NCT01382069|Placebo Comparator|Placebo|Placebo
89398185|NCT01382069|Experimental|Dimethandrolone Undecanoate|DMAU group with different doses 100, 200 and 400 groups
89398186|NCT01381991|Experimental|i-scan-EGD|Examination of GE junction using conventional WL as well as i-scan mode
89398187|NCT01381835|Experimental|001|TMC435 150 mg capsule once daily for 7 days
89398188|NCT04429685|Experimental|Low Dose Ketamine|
89398189|NCT04429685|Placebo Comparator|Saline (placebo)|
88874514|NCT05717634||Ais|Patients with previous breast cancer with hormonal receptor expression that are treated with Ais.
88874515|NCT05717634||No Therapy|Patients with previous breast cancer that are not treated with none hormonal therapies.
88874516|NCT05717556|Active Comparator|single attempt catheterization|successful catheterization with a single attempt number
88874517|NCT05717556|Active Comparator|multiple attempts catheterization|successful catheterization after multiple attempts
88874518|NCT05707728||totally resection of glioma using intraoperative ultrasound|totally resection of glioma using intraoperative ultrasound
88874519|NCT05562648|Experimental|Manual therapy techniques|Myofascial release is a soft tissue method that provides removal of adhesions and tissue tension in tissues due to overload and repetitive use. These adhesions and unbalanced tissue tensions in the tissues can cause muscle weakness, numbness, pain, tingling and burning sensation. The soft tissue is palpated by the physiotherapist and pressure is applied directly to the skin until the tissue barrier is felt in the direction of restriction. Once the tissue barrier is present, it is applied for 90-120 seconds, without slipping on the skin or forcing the tissue, until the fascia complex begins to loosen and a softening sensation is achieved.
88874520|NCT05562648|Active Comparator|Electrophysical agents|Evidence levels for approaches commonly used in the clinic for the treatment of chronic low back pain were generally very low to moderate. TENS (Transcutaneous Electrical Nerve Stimulation) is the most preferred application in the treatment of chronic pain in patients who receive conventional treatment in the clinic. TENS is a physiotherapy modality used to inhibit pain by stimulating the sensory nerves by applying a low frequency electrical current.
88874521|NCT05543694|Experimental|Dural Puncture Epidural Technique|"Laboring women receiving the Dural Puncture Epidural (DPE) Technique, after a lidocaine test dose, with dose of Bupivacaine 0.25% diluted to 20 mL with isotonic sterile 0.9% saline. The first subject in the DPE group will receive an initial dose of bupivacaine 25 mg, with an endpoint being the achievement of an NRS < 3 at 30 min. Subsequent patients are administered bupivacaine doses determined by the response of the previous subject, as per the biased coin method. The subsequent up and down interval doses are bupivacaine 2.5 mg (1 mL) increments, with an anticipated dose range from 20 mg to 40 mg."
89398190|NCT04411277||T2DM Elderly on Insulin CGM|70 patients with type 2 diabetes > 65 years of age taking insulin as treatment. The sample size was calculated to estimate the minimal number of patients necessary to describe the mean TIR (minutes/day).
89398191|NCT01379417|Placebo Comparator|Maltodextrin|Maltodextrin
89398192|NCT01379417|Active Comparator|Probiotic B lactis/B longum|Bifidobacterium lactis + Bifidobacterium longum
89398193|NCT01379417|Active Comparator|Probiotic B longum|Bifidobacterium longum
89398194|NCT01379417|Active Comparator|Probiotic B lactis|Bifidobacterium lactis
89398195|NCT01384357||ultrasound,lymphadenopathy|
89398196|NCT01384279|Experimental|metformin, topiramate|
89398197|NCT01568879|Experimental|Gout Chronic Disease Management Program|
89398198|NCT01568879|Active Comparator|Usual Care|
89398199|NCT01383265|Experimental|Water method and chromoendoscopy|Combined water method with chromoendoscopy using 0.008% IC solution for screening colonoscopy
89188463|NCT00793377|Experimental|ADOC x 4 + Tam 20|Adriamycin will be given at a dose of 50 mg/m2 and docetaxel at a dose of 75 mg/m2 every 14 days for four cycles. Adriamycin will be administered as a short i.v. infusion over 15 minutes, followed immediately by a 1-hour infusion of docetaxel diluted in 250 mL NaCl. Tamoxifen 20 mg is given once daily for five years to all patients, starting with the first day of chemotherapy.
89398200|NCT01383265|Active Comparator|Water method|Control method will use plain water with the water method for screening colonoscopy
89398201|NCT01381601||Severe adverse event claims in subjects with metastatic RCC|Presence or absence of common severe treatment related adverse events (based on existence of claims) in patients with metastatic RCC. Common severe adverse event defined as Grade 3 or higher with >=5% frequency of occurence as reported in product label.
89398202|NCT05216965|Experimental|9MW2821|
89398203|NCT02823353|Experimental|Fenofibrate + UDCA|Fenofibrate (200 mg/day) in combination with ursodeoxycholic acid (13-15 mg/kg/day)
89398204|NCT02823353|Active Comparator|Monotherapy|UDCA 13-15mg/kg/day
89398205|NCT04509193||Group A|Participants with diagnoses of type 2 diabetes and non-valvular atrial fibrillation (NVAF) newly-initiated on rivaroxaban
89398206|NCT04509193||Group B|Participants with diagnoses of type 2 diabetes and non-valvular atrial fibrillation (NVAF) newly-initiated on warfarin
88874522|NCT05543694|Active Comparator|Epidural Technique|"Laboring women receiving the Conventional Epidural Technique (EPL), after receiving a lidocaine test dose with dose of Bupivacaine 0.25% diluted to 20 mL with isotonic sterile 0.9% saline. The first subject in the EPL group will receive an initial dose of bupivacaine 25 mg, with an endpoint being the achievement of an NRS < 3 at 30 min. Subsequent patients are administered bupivacaine doses determined by the response of the previous subject, as per the biased coin method. The subsequent up and down interval doses are bupivacaine 2.5 mg (1 mL) increments, with an anticipated dose range from 20 mg to 40 mg."
88874523|NCT05542602|Experimental|Social intervention|The social intervention consists of four 90-minute sessions per week delivered over eight weeks by paraprofessional staff to children with hfASD as part of their existing after-school program.
89530221|NCT03255265||No acute rejection|
88874524|NCT05542602|No Intervention|No-treatment control|Children in the no-treatment control condition will receive no after-school social programming during the active social intervention study phase.
88874525|NCT05537142|Experimental|Group 1|Participants with Normal hepatic Function
88874526|NCT05537142|Experimental|Group 2|Participants with mild hepatic impairment: Child-Pugh A (Score 5-6)
88874527|NCT05537142|Experimental|Group 3|Participants with moderate hepatic impairment: Child-Pugh B (Score 7-9)
88874528|NCT05537142|Experimental|Group 4|Participants with severe hepatic impairment: Child-Pugh C (Score 10-15)
88875444|NCT05665842|Experimental|Sleep Hygiene Training Group|"After explaining the purpose of the study and the way it was applied to the adolescents in the music practice group, the Introductory Characteristics Form for Adolescents, the Pediatric Quality of Life Inventory (PedsQL) and Adolescent Insomnia Questionary (AIQ) will be applied.~Adolescents in this group will be trained on Zoom for 4 weeks, 2 times a week, for 8 sessions (1 session 40 min). Sleep hygiene training prepared based on expert opinions and literature (Halal & Nunes, 2014; Dinis & Bragança, 2018; İşsever et al., 2021) will be given by the researcher. A Sleep Hygiene Training Booklet will be prepared for use in education and to give to adolescents after education.The Sleep Hygiene training booklet to be prepared will be prepared by the researcher and submitted for expert opinions. Adolescents who received sleep hygiene training will be reapply 15 days after the training, with the PedsQL and AIQ."
88875445|NCT05665842|No Intervention|Control Group|No attempt will be made to the adolescents who will be in the control group, and the Introductory Characteristics Form for Adolescents, the Pediatric Quality of Life Inventory (PedsQL) and Adolescent Insomnia Questionary (AIQ) will be applied on the same dates in parallel with the education and music application groups.
88875446|NCT05629416|Experimental|Cultural safety training and behaviour change intervention|- Interventions to transform the culture of healthcare systems to achieve excellence in providing culturally safe care for First Nations peoples
88875447|NCT05627388|Other|Dreem 3 System|
88875448|NCT05555082|Experimental|Massage|30 minutes of classical swedish massage given by a certified masseur 10 times monthly during 12 months
88875449|NCT05541120|No Intervention|Living Well with Diabetes|Usual care is defined as participation in Living Well with Diabetes/Virtual Diabetes Self-Management Program, PCP evaluation and management, including medication adjustment or interventions, and other types of interventions depending on clinical judgement. This may include eConsults between the provider and a pharmacist, in-person visits between the provider and the patient, synchronous telemedicine visits between the provider and the patient, and synchronous telemedicine visits between the pharmacist and the patient.
88875450|NCT05541120|Experimental|Living Well with Diabetes + Remote Patient Monitoring|Remote patient monitoring as the intervention is defined as a tablet and Bluetooth-enabled glucometer technology that collects point-of-care (POC) blood glucose data from a patient outside of a traditional clinical setting, and securely transmits this data to Epic for review and potential intervention.
88875451|NCT05515458|Experimental|Normal Renal Function|Subjects with normal renal function will receive a single 48 mg oral dose of Chiglitazar
88875452|NCT05515458|Experimental|Severe Renal Impairment|Subjects with severe renal impairment will receive a single 48 mg oral dose of Chiglitazar
88875453|NCT05460702||Luminal A|Breast cancer patients with immunohistochemically luminal A
88875454|NCT05460702||Luminal B|Breast cancer patients with immunohistochemically luminal B
88875455|NCT05460702||Triple negative|Breast cancer patients with immunohistochemically triple negative
88875456|NCT05460702||Control|The absence of any pathology in the breasts of healthy volunteers by mammography and/or ultrasound
88875457|NCT05419674|Experimental|groupA: dual therapy (vonoprazan+amoxicillin)|vonoprazan 20mg bid and amoxicillin 1000mg tid for 10 days
88875458|NCT05419674|Experimental|group B: dual therapy (rabeprazole+amoxicillin)|rabeprazole 10mg tid and amoxicillin 1000mg tid for 10 days
88875459|NCT05419674|Active Comparator|group C: bismuth-containing quadruple therapy|rabeprazole 10 mg bid, colloidal bismuth pectin 200mg bid, amoxicillin 1000mg bid and clarithromycin 500mg bid for 10 days
89530222|NCT03347981|Experimental|IOL implantation experimental|hydrophobic, trifocal intraocular lens POD F GF
88875461|NCT05386524|Experimental|SBP group|sintilimab 200mg, ivgtt，d1， bevacizumab biosimilar 15mg/kg，ivgtt d1， pegylated liposomal doxorubicin 30mg/m2 d1，q3w
88875462|NCT05357664|Experimental|Total Hip Arthroplasty|Pinnacle acetabular shells used with PINNACLE DM Metal liner and BIMENTUM ALTRX PE liner with DePuy metal or ceramic heads and DePuy femoral prostheses
88875463|NCT05357664|Experimental|Revision Total Hip Arthroplasty|Pinnacle acetabular shells used with Pinnacle DM Metal liner and BIMENTUM ALTRX PE liner with DePuy metal or ceramic heads and DePuy femoral prostheses
88875464|NCT05338554|Experimental|pcTBS|The protocol is same as the previous study: pcTBS was administered to the left M1 at 80% resting motor threshold (RMT), consisting of a burst of 3 pulses given at 50 Hz repeated every 5 Hz using repetitive transcranial magnetic stimulation device . A total of 1,200 pulses were delivered with the TMS coil positioned in a posterior-anterior (PA) direction parallel to the midline.
88875465|NCT05338554|Experimental|10HZ rTMS|The protocol is same as the previous study: 10HZ rTMS included 15 trains of 10-second stimulation given at 10 Hz to the left M1 at 80% resting motor threshold (RMT) using repetitive transcranial magnetic stimulation device , with the inter-train interval being set to 50 seconds (1500 pulses)
89530223|NCT03347981|Active Comparator|IOL implantation active comparator|hydrophilic, trifocal intraocular lens POD F
89398207|NCT01379339|Experimental|Cabazitaxel 10mg/m2|"Cabazitaxel on D1 Dose: 10mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)"
89398208|NCT01379339|Experimental|Cabazitaxel 12.5mg/m2|"Cabazitaxel on D1 Dose: 12.5mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)"
89398209|NCT01379339|Experimental|Cabazitaxel 15mg/m2|"Cabazitaxel on D1 Dose: 15mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)"
89398210|NCT01379339|Experimental|Cabazitaxel 17.5mg/m2|"Cabazitaxel on D1 Dose: 17.5mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)"
89398211|NCT01379339|Experimental|Cabazitaxel 20mg/m2|"Cabazitaxel on D1 Dose: 20mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)"
89398212|NCT01383187|Experimental|DE graft and PRP concentrate|Patients enrolled in this arm receive the innovative treatment methods consisting of application of DE graft together with PRP concentrate.
89398213|NCT01383187|Active Comparator|Standard treatment group|PAtients included into this arm will receive a standard treatment for deep-burn injuries, i.e. DE graft without the application of the PRP concentrate.
89398214|NCT02782247||Short term Hepatitis C patients|60 patients with chronic hepatitis C infection and cirrhosis who are planning to start antiviral therapy will be enrolled. Patients will be tested within 3 months prior to starting treatment. This will be repeated at 16 weeks (+/- 1 week) and again 1 calendar year after treatment initiation. Patients will have transient elastography and Indocyanine green excretion tests at each appointment.
89535486|NCT03077529|Placebo Comparator|Maltodextrin|During this period subjects will receive 7.24 grams of maltodextrin supplements three times daily for four weeks
88874529|NCT05519748|Experimental|Online psychoeducational program|The intervention group will receive an online psychoeducational program for 8 weeks. The psychoeducation package consists of 16 different sets of reading materials and post-session writing/reflection exercises, which will be delivered to the participants twice a week. The program is designed to be a brief, trauma-informed, dissociation-focused education package that aims to enable users to better understand and cope with their post-traumatic and dissociative reactions and related life challenges. There are specific psychoeducation elements in each session, such as: (1) safety issues planning, (2) understanding the impacts of trauma and stress, (3) understanding the concept of dissociation and integration of the personality, (4) identifying and coping with the post-traumatic and dissociative symptoms, (5) identifying trauma-related cognitive distortions.
88874530|NCT05519748|Other|Waitlist control|The waitlist control group will receive an online psychoeducational program for 8 weeks a week after the completion of the two-month follow-up in the intervention group. The psychoeducation package is identical to the program in the intervention group.
88874531|NCT05495568|Experimental|Switching CT-P17|"On Day 1, Week 0, patients will be enrolled in the study and receive Humira. The patients will receive initial dose of Humira (80 mg; 2 shots of 40 mg) on Day 1 and Humira (40 mg) EOW starting one week after the initial dose until Week 11.~Prior to the study drug administration at Week 13, patients will be randomized to receive either CT-P17 (40 mg) or Humira (40 mg) and the CT-P17 Switching group will receive CT-P17 (40mg) at Week 13, Week 15, Week 21, Week 23 and Week 25. The Switching group will receive Humira at Week 17 and Week 19.~From Week 27, patients will receiAve CT-P17 (40 mg) EOW only as open-label up to Week 49."
88874532|NCT05495568|Active Comparator|Humira maintenance|"On Day 1, Week 0, patients will be enrolled in the study and receive Humira. The patients will receive initial dose of Humira (80 mg; 2 shots of 40 mg) on Day 1 and Humira (40 mg) EOW starting one week after the initial dose until Week 11.~Prior to the study drug administration at Week 13, patients will be randomized to receive either CT-P17 (40 mg) or Humira (40 mg) and the Humira maintenance group will receive Humira (40mg) EOW up to Week 25.~From Week 27, patients will receive CT-P17 (40 mg) EOW only as open-label up to Week 49."
88874533|NCT05493774|Experimental|Experimental group|Virtual reality
88874534|NCT05493774|Active Comparator|Control group|High Fidelity Simulation Training
88874535|NCT05488548|Experimental|Arm 1|Patients will be assigned escalated dose according to BOIN design. The starting dose is 5 mg orally once a day for 7 consecutive days followed by 14 days of rest.
88874536|NCT05481762||Asymptomatic adult patients|
89188464|NCT00793377|Experimental|AC x 4 - Doc x 4 + Tam 20|Adriamycin will be given at a dose of 60 mg/m2 and cyclophosphamide at a dose of 600 mg/m2 every 21 days for four cycles. Thereafter, docetaxel at a dose of 100 mg/m2 is given every 21 days for four cycles. Tamoxifen 20 mg is given once daily for five years to all patients, starting with the first day of chemotherapy
88874537|NCT05476536|Experimental|experimental arm|self-management skills and healthy technology APP
89188465|NCT01419704|Experimental|Hemoglobinopathies diagnosed patients|Recipients diagnosed with Hemoglobinopathies are treated with an enriched hematopoetic stem cell infusion from living donor bone marrow
89398215|NCT02782247||Medium term Hepatitis C patients|60 patients with chronic hepatitis C infection and cirrhosis who have been successfully treated in the past 3 or 5 years (+/- 3 months). Patients will have transient elastography and Indocyanine green excretion tests at each appointment.
89398216|NCT02782247||Hepatitis B Patients|60 patients with chronic hepatitis B and cirrhosis will be tested within 3 months prior to starting treatment. This will be repeated at 16 weeks (+/- 1 week) and again 1 calendar year after treatment initiation. Patients who have started treatment past 3 or 5 years (+/- 3 months) will also be tested. Patients will have transient elastography and Indocyanine green excretion tests at each appointment.
89398217|NCT01383031|Active Comparator|Laparoscopic Cholecystectomy|Laparoscopic cholecystectomy（4 ports or 3 ports）will be performed in a routine fashion by one full time faculty member with fellowship training in laparoscopy.
89398218|NCT01383031|Active Comparator|TU-LESSC|TU-LESSC will be performed in a routine fashion which is same to CLC（conventional laparoscopic cholecystetomy）by one full time faculty member with fellowship training in laparoscopy through the conventional laparoscopic instruments.
89398219|NCT01569061|Active Comparator|Active Laser Group (ALG)|
89398220|NCT01569061|Sham Comparator|Sham Laser Group (SLG)|
89398221|NCT03631303||ICD patients with ATP/shock|10 primary prevention 2-chamber ICD patients (LVEF <35 percent) who received appropriate ICD therapy during follow-up.
89398222|NCT03631303||ICD patients without ATP/Shock|10 primary prevention 2-chamber ICD patients (LVEF <35 percent) who were free from appropriate ICD therapy during follow-up.
89398223|NCT03631303||Pacemaker-patients|10 2-chamber pacemaker-patients (LVEF >50%).
89398224|NCT05422469|Experimental|Medtronic Percept RC neurostimulator|
89398225|NCT04173949|Experimental|Ramipril 2.5 MG|Ramipril 2.5 MG orall, daily.
89398226|NCT04150133|Active Comparator|Traditional Clear Liquid Arm|Following instructions with FDA-labeled clear liquids
89398227|NCT04150133|Experimental|Low Residue Diet Arm|Following instructions for a low residue diet along with FDA-labeled clear liquids
89398228|NCT01382017|Placebo Comparator|Placebo|Placebo arm
89398229|NCT01382017|Experimental|Lasosamide 200|Lacosamide 200 mg
89398230|NCT01382017|Experimental|Lacosamide 400|Lacosamide 400 mg
89398231|NCT01382017|Active Comparator|Carbamazepine 600|Carbamazepine 600 mg
88874538|NCT05476536|No Intervention|control group|Health education leaflet
88874539|NCT05429424|Experimental|Verum acupuncture group|The study uses manual acupuncture as verum intervention.
88874540|NCT05429424|Sham Comparator|Sham control group I|The study used specific made needle with a blunt tip, Streitberger device, as sham intervention.
89398232|NCT01381523||Study-treatment naive insured adults with migraine|Adult health care plan members with a pharmacy claim for a combination product of sumatriptan and naproxen sodium (SumaRT/Nap) and propensity score matched controls with a pharmacy claim for a single-entity triptan
89398233|NCT01381523||Insured adults with migraine who switch study treatment|Adult health plan members with a pharmacy claim for SumaRT/Nap following at least one single-entity triptan pharmacy claim in the previous 6 months and propensity-score matched controls who switched from one single-entity triptan to another
89398234|NCT01381939||Induction of labor in ICP|Induction of laborin women with ICP
88874541|NCT05429424|Sham Comparator|Sham control group II|Manual acupuncture at the points unrelated to the dysphagia is another sham intervention in this study.
88874542|NCT05413824||COVID-19 survivors|Patients hospitalized at Nimes university hospital in 2021 for COVID-19 who survived.
88874543|NCT05413824||COVID-19 Deceased|Patients hospitalized at Nimes university hospital in 2021 for COVID-19 who died.
89398235|NCT01381939||Induction of labor in women with no ICP|No ICP
89398236|NCT01381939||ICP and spontanius delivery|
89398237|NCT01381445|Experimental|GW870086 0.2% &amp; GW870086 2%|GW870086 0.2%, 2% &amp; placebo each applied to an identified area for 42 days.
88874544|NCT05384652||subjects with NASH|
89398238|NCT01381445|Experimental|GW870086 2% &amp; Clobetasol Propionate|GW870086 2% &amp; placebo applied to an identified area for 42 days, while Clobetasol Propionate is applied to an area for 21 days
89398239|NCT05421845|Experimental|Lifestyle intervention group|Participants will be given mobile- and hospital-based lifestyle interventions. The mobile-based interventions including dietary guidance, exercise supervision and weight monitoring will be conducted by trained physicians through WeChat group on cell phone every 1 to 2 weeks. Participants need to report their physical activity and weight information every week through WeChat group. Hospital-based intervention is a ≥5 minutes one-to-one and face-to-face personalized lifestyle counselling leading by a trained physician every 4 weeks during <14 weeks of gestation, every 2 weeks during 14-28 weeks of gestation, and once a week during ≥28 weeks of gestation. Participants' dietary information will be collected for any 3 consecutive days chosen by participants during 12-14 weeks of gestation, 24-28 weeks of gestation and >36 weeks of gestation respectively using a food frequency questionnaire.
89398240|NCT05421845|No Intervention|control group|Participants in control group will be managed in accordance with the standard practice.
88874545|NCT05384652||subjects with simple steatosis|
88874546|NCT05384652||healthy subjects|
88874547|NCT05367102|Experimental|In Person|Participants will receive all services in person, including participating in the initial intake process, and attending all workshops.
88874548|NCT05367102|Experimental|Virtual (Zoom)|Participants will complete their intake process in person, but will complete all workshops virtually through Zoom.
88874549|NCT05365308|Experimental|Intervention: Quality Improvement tools|Quality improvement tools including: computer-assisted identification of iron deficiency anemia patients with an EHR registry, facilitated GI referral, an EHR tool for documentation, and physician education.
88874550|NCT05365308|No Intervention|Control: usual care|Physicians will be notified at the start of the study that 120 days after the study start they will receive access to the quality improvement tools available to the intervention group.
88874551|NCT05358834|Placebo Comparator|Daytime melatonin 0.0 mg|
88874552|NCT05358834|Experimental|Daytime melatonin 0.5 mg|
88874553|NCT05358834|Experimental|Daytime melatonin 3.0 mg|
88874554|NCT05358834|Placebo Comparator|Nighttime melatonin 0.0 mg|
88874555|NCT05358834|Experimental|Nighttime melatonin 0.5 mg|
89398241|NCT01568957|Experimental|Dual-task gait training|Gait training with simultaneous performance of cognitive tasks for 75% of training session.
89398242|NCT01568957|Active Comparator|Single-task gait training|Gait training (without simultaneous cognitive task performance)
89398243|NCT01379261|Active Comparator|Hypothermia treatment|1-2 liters of cold saline and central venous catheter cooling with Philips InnerCool RTx Endovascular System prior to PCI
89398244|NCT01379261|No Intervention|Standard treatment|Standard treatment
89398245|NCT05421767|Active Comparator|Low RNS-induced SBP change group|25 patients with the RNS-induced systolic BP change <20mmHg immediately after RDN
89398246|NCT05421767|Placebo Comparator|High RNS-induced SBP change group|8 patients with the RNS-induced systolic BP change >20mmHg immediately after RDN
89398247|NCT05421767|Experimental|intensive RDN group|17 patients with the initial RNS-induced systolic BP change >20mmHg immediately after RDN, received intensive RDN therapy and let the second RNS-induced systolic BP change < 20mmHg
89398248|NCT05421299||Abatacept Group|Participants with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myelogenous leukemia (CML), myelodysplastic syndromes (MDS), hodgkin lymphoma (HL), or non-hodgkin lymphoma (NHL) who have a bone marrow (BM) or peripheral blood (PB) stem cell donor who is HLA-matched at 7/8 loci (A, B, C, DRB1) who received abatacept.
89398249|NCT05421299||Comparator Group|Participants with AML, ALL, CML, MDS, HL, or NHL who have a BM or PB stem cell donor who is HLA-matched at 7/8 loci (A, B, C, DRB1) who did not receive abatacept.
88874556|NCT05336682|Experimental|LSTR with radicular instrumentation.|
88874557|NCT05336682|Experimental|LSTR with no radicular instrumentation.|
88874558|NCT05336682|Active Comparator|Conventional pulpectomy.|
89398250|NCT03083639|Experimental|Esomeprazole 40 mg Capsule + Esomeprazole 40 mg Tablet|Esomeprazole 40 mg, capsule, orally, once on Day 1 of Intervention Period 1, followed by 6 days of washout period, followed by esomeprazole 40 mg tablet, orally, once on Day 1 of Intervention Period 2.
89398251|NCT03083639|Experimental|Esomeprazole 40 mg Tablet + Esomeprazole 40 mg Capsule|Esomeprazole 40 mg, tablet, orally, once on Day 1 of Intervention Period 1, followed by 6 days of washout period, followed by esomeprazole 40 mg capsule, orally, once on Day 1 of Intervention Period 2.
89398252|NCT02927431|Experimental|Danirixin 15 mg FBE IV plus 75 mg oseltamivir|Subjects will receive double blind 15 mg FBE IV danirixin twice daily with open label 75 mg oral oseltamivir twice daily for 5 days. If a subject is discharged from the hospital in less than 5 days, treatment with IV DNX will be discontinued.
89398253|NCT02927431|Experimental|Danirixin 50 mg FBE IV plus 75 mg oseltamivir|Subjects will receive double blind 50 mg FBE IV danirixin twice daily with 75 mg oral oseltamivir twice daily for 5 days. If a subject is discharged from the hospital in less than 5 days, treatment with IV DNX will be discontinued.
89398254|NCT02927431|Placebo Comparator|Placebo of danirixin IV plus 75 mg oseltamivir|Subjects will receive double blind IV placebo of DNX twice daily with 75 mg oral oseltamivir twice daily for 5 days. If a subject is discharged from the hospital in less than 5 days, treatment with IV DNX will be discontinued.
89398255|NCT03083483|Experimental|Bilateral M1, active tDCS|Participants will complete 6 sessions of the FLS peg transfer task over a 7-day time span. Participants randomized to this cohort had tdcs applied over the bilateral M1 areas of the brain by measurement of 20% length of periauricular distance left and right of the vertex. The anode was placed on the left side and the cathode was placed on the right side.
88874559|NCT05273346|Experimental|Comprehensive Conservative TCM Treatment Group|"Traditional Chinese medicinal ointment;~Acupotomy;~Cupping therapy with bamboo cup;~Oral Chinese medicine granules."
88874560|NCT05273346|Active Comparator|Modern Medicine Conservative Treatment Program Group|"Epidural Steroid Injections (ESIs);~Interferential current therapy;~Thermal therapy;~Oral painkillers."
88874561|NCT05248776|Experimental|CPL207280 60 mg|16 participants are to receive IMP at dose 60 mg.IMP will be administered for 14 days, every morning, after a minimum 8-hours overnight fast. Participants are to be randomized.
88874562|NCT05248776|Experimental|CPL207280 120 mg|16 participants are to receive IMP at dose 120 mg. IMP will be administered for 14 days, every morning, after a minimum 8-hours overnight fast. Participants are to be randomized.
88874563|NCT05248776|Experimental|CPL207280 240 mg|16 participants are to receive IMP at dose 240 mg. IMP will be administered for 14 days, every morning, after a minimum 8-hours overnight fast. Participants are to be randomized.
89398256|NCT03083483|Experimental|SMA, active tDCS|Participants will complete 6 sessions of the FLS peg transfer task over a 7-day time span. Participants randomized to this cohort had tdcs applied over the supplementary motor area. The cathode was placed 10% of nasion-inion distance above the nasion and 15% of nasion-inion distance anterior to the vertex.
89535487|NCT03318575|Experimental|autoRIC|The autoRIC device will be used on subjects randomized to the treatment group.
88874564|NCT05248776|Experimental|CPL207280 480 mg|16 participants are to receive IMP at dose 480 mg. IMP will be administered for 14 days, every morning, after a minimum 8-hours overnight fast. Participants are to be randomized
88874565|NCT05248776|Placebo Comparator|Placebo|16 participants are to receive masking placebo tablets once daily for 14 days, every morning, after a minimum 8-hours overnight fast. Participants are to be randomized
88874566|NCT05228730|Active Comparator|AstraZeneca (ChAdOx1-S, or Vaxzevria®)-Standard Pfizer-BioNTech booster group|Received two doses of AstraZeneca as primary COVID-19 vaccine
88874567|NCT05228730|Experimental|AstraZeneca (ChAdOx1-S, or Vaxzevria®)-Fractional Pfizer-BioNTech booster group|Received two doses of AstraZeneca as primary COVID-19 vaccine
88874568|NCT05228730|Active Comparator|AstraZeneca (ChAdOx1-S, or Vaxzevria®) Standard Elasomeran booster group|Received two doses of AstraZeneca as primary COVID-19 vaccine
88874569|NCT05228730|Experimental|AstraZeneca (ChAdOx1-S, or Vaxzevria®)-Fractional Elasomeran booster group|Received two doses of AstraZeneca as primary COVID-19 vaccine
88874570|NCT05228730|Active Comparator|Pfizer-BioNTech (BNT162b2, or Comirnaty®)-Standard Pfizer-BioNTech booster group|Received two doses of Pfizer-BioNTech as primary COVID-19 vaccine
88874571|NCT05228730|Experimental|Pfizer-BioNTech (BNT162b2, or Comirnaty®)-Fractional Pfizer-BioNTech booster group|Received two doses of Pfizer-BioNTech as primary COVID-19 vaccine
88874572|NCT05228730|Active Comparator|Pfizer-BioNTech (BNT162b2, or Comirnaty®)-Standard Elasomeran booster group|Received two doses of Pfizer-BioNTech as primary COVID-19 vaccine
89398257|NCT03083483|Sham Comparator|sham tDCS|Participants will complete 6 sessions of the FLS peg transfer task over a 7-day time span. Participants in this group were either randomized into either Bilateral or SMA configurations using the same measurements, but did not receive active stimulation. Half of these subjects will be placed in the SMA configuration and the other half in the bilateral M1 electrode configuration.
89398258|NCT05421221|Experimental|olfactory training group|"12 weeks of olfactory traiing with Sniffin' sticks Duftquartett."
89398259|NCT05421221|No Intervention|no olfactory training with natural history of the disease|natural history of the disease
89398260|NCT05027893|Active Comparator|Active Comparator: The first tested group|Patients orally received film-coated tablets with either 400 mg of moxifloxacin. Film-coated tablets were administered for the first five days postoperatively, once a day, in a double-blind manner. All patients were evaluated at the postoperative follow-ups on the first, second and seventh postoperative day.
89398261|NCT05027893|Active Comparator|Active Comparator: The second tested group|Patients orally received film-coated tablets with either 400 mg of cefixime. Film-coated tablets were administered for the first five days postoperatively, once a day, in a double-blind manner. All patients were evaluated at the postoperative follow-ups on the first, second and seventh postoperative day.
89398262|NCT05027893|Placebo Comparator|Placebo Comparator: The control group|One third of patients received placebo-tablets containing indifferent substances with no antimicrobial action (99% microcrystalline cellulose, 0.5% silicon dioxide and 0.5% magnesium stearate, which were of the same colour and overall appearance as the used antibiotics. Film-coated tablets were administered for the first five days postoperatively, once a day, in a double-blind manner. All patients were evaluated at the postoperative follow-ups on the first, second and seventh postoperative day.
89398263|NCT01381783|Other|Topical anesthesia|
89398264|NCT01381367|Experimental|Vaccine|Enrolled COPD patients receiving PPSV23 pneumococcal vaccine
89398265|NCT01381367|Placebo Comparator|Normal saline|Enrolled COPD patient receiving placebo normal saline
89398266|NCT04989361|Experimental|Microneedle side|Apply soluble hyaluronic acid microneedle eye mask to the periorbital area after normal facial cleansing and skin care every night for 20 days. Press and hold for 3 minutes, and then remove it after 1 h. Every 2 days for the next 20 days, and every 3 days for the last 21 days. Follow-up time: every 20 days during the treatment period, and follow-up visits in the 2nd, 4th, 8th and 12th weeks after the treatment.
89398267|NCT04989361|Active Comparator|Non-fractional laser side|The patient received non-ablative fractional laser treatment once. Follow-up time: follow-up visits in the 2nd, 4th, 8th and 12th weeks after the treatment.
89398268|NCT01382875|No Intervention|Conventional care program|
89398269|NCT01382875|Experimental|Multi-disciplinary management program|
89398270|NCT05420987|Experimental|active arm|Jing Si herbal tea liquid packet
89398271|NCT05420987|Placebo Comparator|control arm|Jing Si herbal tea placebo
88874573|NCT05228730|Experimental|Pfizer-BioNTech (BNT162b2, or Comirnaty®)-Fractional Elasomeran booster group|Received two doses of Pfizer-BioNTech as primary COVID-19 vaccine
88874574|NCT05226234||Experimental group|
88874575|NCT05194254|Experimental|ASD|people with Autism Spectrum Disorders
88874576|NCT05194254|Active Comparator|TD|Typical Development) group of people
89398272|NCT04899193|Experimental|Sequence 1: First Reference, Then Test 1, Then Test 2|Participants will receive single dose of Reference drug (Gonal-f/Luveris injection) on Day 1 in investigation period 1 followed by Test 1 drug (Pergoveris FD) on Day 1 in investigation period 2 followed by Test 2 drug (Pergoveris Liquid) on Day 1 in investigation period 3. A washout period of 6 days will be maintained between period 1 and 2 and washout period of 17 days will be maintained between period 2 and 3.
88874577|NCT05131776|Experimental|EUS-guided oncosil injection|All patients will receive OncoSilTM during the 4th week of the first chemotherapy cycle.
88874578|NCT05118906|Experimental|BP1.4979|15 mg BID active treatment
89398273|NCT04899193|Experimental|Sequence 2: First Test 1, Then Test 2, Then Reference|Participants will receive single dose of Test 1 drug (Pergoveris FD) on Day 1 in investigation period 1 followed by Test 2 drug (Pergoveris Liquid) on Day 1 in investigation period 2 followed by Reference drug (Gonal-f/Luveris injection) on Day 1 in investigation period 3. A washout period of 6 days will be maintained between period 1 and 2 and washout period of 17 days will be maintained between period 2 and 3.
89398274|NCT04899193|Experimental|Sequence 3: First Test 2, Then Reference, Then Test 1|Participants will receive single dose of Test 2 drug (Pergoveris Liquid) on Day 1 in investigation period 1 followed by Reference drug (Gonal-f/Luveris injection) on Day 1 in investigation period 2 followed by Test 1 drug (Pergoveris FD) on Day 1 in investigation period 3. A washout period of 6 days will be maintained between period 1 and 2 and washout period of 17 days will be maintained between period 2 and 3.
88874579|NCT05118906|Placebo Comparator|Placebo|matching placebo
88874580|NCT05105802|Experimental|Mindfulness Intervention|MBI training will consist of a 4-week custom-made program that include, setting intentions and check-in with mood, audio-recorded lectures, guided meditations such as body scans, and writing events journal. Each standardized course will be unlocked as the child progresses through the program. Users will be encouraged to participate in the app-based activities for a total of 10-15 minutes every day, with a minimum of 4 days in a week, over a period of 4 weeks.
88874581|NCT05105802|Active Comparator|Cognitive Sham Application + Usual Care|Usual care recommends that the patient refrain from physical and cognitive activities for 24-48 hours after injury. After the rest period, it is recommended that low to moderate levels of physical and cognitive activity be gradually started 24-48 hours after injury. The activities should be performed at a level that does not result in recurrence or exacerbation of symptoms. Children must refrain from any activities that increase the risk of re-injury (drills with body contact or that risk falls) until fully asymptomatic and cleared by their primary care or other medical provider. We consider this arm as active as participants will be assigned to a cognitive sham app (cognitive math game) delivered via the same app (same main interface as the mindfulness intervention). However, they will not take part in the MBI program for the first 4 weeks. On a daily basis, participants will be asked questions about their stress and emotions and about their symptoms.
88874582|NCT05103072||testing all the plots|"the investigator chose the best plot of the leads for stimulation by a procedure long and exhausting for the patient and the examinator ( plot by plot )"
89188466|NCT00789243|Active Comparator|1|Prior to 20 mins of ischaemia induced by a blood pressure cuff inflated to 200 mmHg around the upper non-dominant arm, local ischaemic preconditioning will be induced by inflating a cuff around the non-dominant arm to 200 mmHg for 5 mins followed by 5 mins of reperfusion. This cycle will be repeated 3 times.
89398275|NCT04899193|Experimental|Sequence 4: First Reference, Then Test 2, Then Test 1|Participants will receive single dose of Reference drug (Gonal-f/Luveris injection) on Day 1 in investigation period 1 followed by Test 2 drug (Pergoveris Liquid) on Day 1 in investigation period 2 followed by Test 1 drug (Pergoveris FD) on Day 1 in investigation period 3. A washout period of 6 days will be maintained between period 1 and 2 and washout period of 17 days will be maintained between period 2 and 3.
89398276|NCT04899193|Experimental|Sequence 5: First Test 1, Then Reference, Then Test 2|Participants will receive single dose of Test 1 drug (Pergoveris FD) on Day 1 in investigation period 1 followed by Reference drug (Gonal-f/Luveris injection) on Day 1 in investigation period 2 followed by Test 2 drug (Pergoveris Liquid) on Day 1 in investigation period 3. A washout period of 6 days will be maintained between period 1 and 2 and washout period of 17 days will be maintained between period 2 and 3.
89398277|NCT04899193|Experimental|Sequence 6: First Test 2, Then Test 1, Then Reference|Participants will receive single dose of Test 2 drug (Pergoveris Liquid) on Day 1 in investigation period 1 followed by Test 1 drug (Pergoveris FD) on Day 1 in investigation period 2 followed by Reference drug (Gonal-f/Luveris injection) on Day 1 in investigation period 3. A washout period of 6 days will be maintained between period 1 and 2 and washout period of 17 days will be maintained between period 2 and 3.
89398278|NCT01569139||GPRD MI|Myocardial infarction, as identified in the GPRD data.
89398279|NCT01569139||MINAP MI|Myocardial infarction, as identified in MINAP data.
89398280|NCT01569139||HES MI|Myocardial infarction, as identified in HES data.
89398281|NCT01569217||respiratory muscle dysfunction patients|Neuromuscular patients
89398282|NCT01569217||diaphragmatic dysfunction|patients who present orthopnea, recruitment of accessory muscles, abdominal paradox, respiratory dysfunction or dyssynchronous movement
89398283|NCT03613675|Experimental|Video games|All participants will be asked to play 4 video games.
88874583|NCT05103072||Guide X Software|the investigator can chose the plot using a software (Guide Xt), which can delete the exhausting test
88874584|NCT05083260|Experimental|NE3107|orally administered NE3107 20 mg twice daily (BID)
88874585|NCT05083260|Placebo Comparator|placebo|orally administered placebo, twice daily
88874586|NCT05081622|Experimental|ICC-T|5 days with 9 hours of training for teachers. Core training components include teacher-student interaction, maltreatment prevention, effective discipline strategies, identifying and supporting burdened students and implementation of the training materials into the school setting
88874587|NCT05081622|No Intervention|Monitoring condition|No intervention
88874588|NCT05062668||iStent|POAG patient operated at the CHU of Amiens or the CH of Saint-Quentin of a combined cataract and iStent inject or inject W surgery from January 2018 to September 2020.
88874589|NCT05062668||cataract only|POAG patients operated only on cataract from January 2018 to September 2020.
88874590|NCT05046288|Experimental|Group 1|Participants will participate to the 3-month cycle of virtual guided tour of the MMFA and will complete assessments at M0 and at M3
88874591|NCT05046288|No Intervention|Group 2|Participants will not participate to the 3-month cycle of virtual guided tour of the MMFA but will complete assessments at M0 and at M3
88874592|NCT05016258||KONTACT MB|Adult patients needed one or multiple implant-supported fixed restoration(s)
88874593|NCT05717946|Experimental|"Group I PRO-D"|50 patients with diagnosed depressive disorders, meeting the criteria of International Classification of Diseases (ICD-11) for 6A70-73, 6A7Y, 6A7Z, taking a probiotic composed of two bacteria strains: Lactobacillus helveticus Rosell and Bifidobacterium longum Rosell.
89398284|NCT01384201||Confocal Laser Endomicroscopy|OGD by Confocal Endomicroscopy
89398285|NCT01384201||White light endoscopy|OGD by whitelight endoscopy
89398286|NCT04850443||trial group|tocilizumab siltuximab
89398287|NCT04850443||control group|conventional treatment
89398288|NCT03085927|Experimental|Arm 1-Active Music Engagement|Three 45-minute sessions with a board-certified music therapist delivered over three days. Sessions are delivered in a private setting during in-patient hospitalization. During the first visit, parent and child will receive information on common responses of young children to cancer treatment and how parents can use music play activities to support their child during treatment. The music therapist will lead parent and child in a variety of music play activities. Parent and child will receive a music kit that includes items such as hand-held rhythm instruments, puppets, and a music CD. During the second and third visit the music therapist will lead parent and child child through the music play activities, answer questions, and make suggestions for using these activities in the hospital and at home.
89535488|NCT03318575|Sham Comparator|autoRIC Sham|The autoRIC Sham device will be used on subjects randomized to the control group.
88874594|NCT05717946|Placebo Comparator|"Group II PLC-D"|50 patients with diagnosed depressive disorders, meeting the criteria of International Classification of Diseases (ICD-11) for 6A70-73, 6A7Y, 6A7Z, taking a placebo.
88874595|NCT04950894|Active Comparator|Active|HGN therapy activation at Month 1 - compared at Month 7 to Control group, continued stimulation through Month 13
88874596|NCT04950894|Other|Control|HGN therapy NOT activated at Month 1 - compared at Month 7 to Active group, stimulation will start at Month 7 + 1 Day and continue through Month 13
88874597|NCT04921410|Experimental|Biofeedback Sleeve Effects on Preventive Biomechanics|Biofeedback wearable sleeve will be utilized in at least 2 groups of athletes. This randomized group will receive an 'active' wearable device. The device will be worn during regular sport practice sessions for 8-16 weeks. The device will provide haptic feedback directly associated with potentially injurious events as determined by previously established cut-off values and artificially-intelligent algorithms.
88875466|NCT05318040|Experimental|Single ascending dose - CMS121|Subjects will receive a single oral dose of CMS121 under fed conditions.
88875467|NCT05318040|Placebo Comparator|Single ascending dose - placebo|Subjects will receive a single oral dose of placebo under fed conditions.
88875468|NCT05318040|Experimental|Multiple ascending dose - CMS121|Subjects will receive multiple oral doses of CMS121 once daily (QD) for 7 days under fed conditions.
89398289|NCT03085927|Experimental|Arm II- Audio-Storybooks|Three 45-minute sessions with a board-certified music therapist delivered over three days. Sessions are delivered in a private setting during in-patient hospitalization. Each session children/parents will choose and listen to one of three illustrated children's books with audio recorded narration.
89398290|NCT05418803|Experimental|Group1|17 subjects, Cross-over, Single dose of comparator on day1, YHP1807 on day8
89398291|NCT05418803|Active Comparator|Group2|17 subjects, Cross-over, Single dose of YHP1807 on day1, comparator on day8
89398292|NCT04401709|Experimental|Gemcitabine/Capecitabine|gemcitabine1,000 mg/m2 over 30 min D1, D8, D15 capecitabine 1660 mg/m2, D1-21
89398293|NCT04401709|Active Comparator|Capecitabine|capecitabine 2,500 mg/m2 D1-14
89398294|NCT04392583||Device: ENTACT Septal Staple|Septoplasty
89398295|NCT04497987|Experimental|Bamlanivimab (Part 1)|Participants received single Intravenous (IV) infusion of 4200 milligrams (mg) bamlanivimab.
89398296|NCT04497987|Placebo Comparator|Placebo (Part 1)|Participants received single IV infusion of Placebo.
89398297|NCT04497987|Experimental|Bamlanivimab (Part 2-Prevention)|Enrollment for Part 2 was not initiated because the efficacy of Bamlanivimab 4200 mg observed in Part 1 significantly diminished the feasibility of enrolling Part 2.
89398298|NCT04497987|Experimental|Bamlanivimab + Etesevimab (Part 2-Prevention)|Enrollment for Part 2 was not initiated because the efficacy of Bamlanivimab 4200 mg observed in Part 1 significantly diminished the feasibility of enrolling Part 2.
89398299|NCT04497987|Placebo Comparator|Placebo Comparator: Placebo (Part 2-Prevention)|Enrollment for Part 2 was not initiated because the efficacy of Bamlanivimab 4200 mg observed in Part 1 significantly diminished the feasibility of enrolling Part 2.
88874598|NCT04921410|Sham Comparator|Sham Biofeedback|Biofeedback wearable sleeve will be utilized in at least 2 groups of athletes. This randomized group will receive a 'sham' wearable device. The device will be worn during regular sport practice sessions for 8-16 weeks. The device will provide random feedback at random intervals not directly associated with potentially injurious events.
88874599|NCT04916886|Experimental|50L Scale (Age 18-59)|Single dose of 0.5ml Ad5-nCoV containing 0.5E10 vp.
88874600|NCT04916886|Experimental|500L Scale (Age 18-59)|Single dose of 0.5ml Ad5-nCoV containing 0.5E10 vp.
88874601|NCT04916886|Experimental|800L Scale (Age 18-59)|Single dose of 0.5ml Ad5-nCoV containing 0.5E10 vp.
89398300|NCT04497987|Experimental|Bamlanivimab (Part 2 - Treatment)|Enrollment for Part 2 was not initiated because the efficacy of Bamlanivimab 4200 mg observed in Part 1 significantly diminished the feasibility of enrolling Part 2.
89398301|NCT04497987|Experimental|Bamlanivimab + Etesevimab (Part 2- Treatment)|Enrollment for Part 2 was not initiated because the efficacy of Bamlanivimab 4200 mg observed in Part 1 significantly diminished the feasibility of enrolling Part 2.
89398302|NCT04497987|Experimental|Bamlanivimab (Part 3)|"Part 3 of the study is exploratory, conducted to study exploratory objectives and is not reported in this record.~[Participants received single IV infusion of 700 mg bamlanivimab.]"
89398303|NCT04497987|Experimental|Bamlanivimab + Etesevimab (Part 3)|"Part 3 of the study is exploratory, conducted to study exploratory objectives and is not reported in this record.~[Participants received single IV infusion of 700 mg bamlanivimab given with 1400 mg etesevimab.]"
89398304|NCT01381627|Active Comparator|Remifentanil|
89398305|NCT01381627|Experimental|Dexmedetomidine|
88874602|NCT04916886|Experimental|800L Scale Lot 1 (Age 13-17)|Single dose of 0.3ml Ad5-nCoV containing 0.3E10 vp.
89398306|NCT04726813|Experimental|a self-guided Internet delivered intervention|MinADHD: 7 self-help modules.
88874603|NCT04916886|Experimental|800L Scale Lot 2 (Age 13-17)|Single dose of 0.3ml Ad5-nCoV containing 0.3E10 vp.
88874604|NCT04916886|Experimental|800L Scale Lot 3 (Age 13-17)|Single dose of 0.3ml Ad5-nCoV containing 0.3E10 vp.
88874605|NCT04916886|Experimental|800L Scale Lot 1 (Age 6-12)|Single dose of 0.3ml Ad5-nCoV containing 0.3E10 vp.
88874606|NCT04916886|Experimental|800L Scale Lot 2 (Age 6-12)|Single dose of 0.3ml Ad5-nCoV containing 0.3E10 vp.
88874607|NCT04916886|Experimental|800L Scale Lot 3 (Age 6-12)|Single dose of 0.3ml Ad5-nCoV containing 0.3E10 vp.
88874608|NCT04907682|Active Comparator|Intravenous ribavirin|"standard treatment: Irrua regimen~100 mg/kg Day 1 (dose is divided: 2/3 stat, 1/3 8 hours later, maximum dose is 7g/day)~25 mg/kg days 2-7~12.5 mg/kg days 8-10"
88874609|NCT04907682|Experimental|Oral favipiravir|"Oral favipiravir~Day 1 2400mg(H0)-2400mg(H8)-1200mg(H16)~Day 2-10 1200mg twice daily (BD)"
88875469|NCT05318040|Placebo Comparator|Multiple ascending dose - placebo|Subjects will receive multiple oral doses of placebo once daily (QD) for 7 days under fed conditions.
89398307|NCT04726813|Placebo Comparator|Psycho-education|One self-guided psychoeducation module
89398308|NCT04487691|Experimental|Platelet Lysate|Inhaled nebulized platelet lysate (PL), 2-ml 1x per day for 8 weeks.
89398309|NCT04487691|Active Comparator|Saline|Inhaled nebulized normal sterile saline, 2-ml 1x per day for 8-weeks.
89398310|NCT01382641|Other|Hoya AF-1 IOL|
89398311|NCT01382641|Other|Revital Vision|
89398312|NCT04694833|Experimental|Stroke patients|Stroke patients with hemiparesis and/or cognitive impairments (such as apraxia, aphasia and hemineglect)
89398313|NCT04694833|Experimental|Healthy subjects|Subjects who do not suffer from any pathology that could affect upper-limb motor function or cognition
89398314|NCT00974571|Experimental|1|montelukast
89398315|NCT00974571|Active Comparator|2|cetirizine
89398316|NCT00974571|Placebo Comparator|3|placebo
89398317|NCT02766608|Experimental|BFF MDI 320/9.6 μg|Budesonide and Formoterol Fumarate Inhalation Aerosol 160/4.8 μg per actuation MDI/120 inhalations Taken as 2 inhalations BID
89398318|NCT02766608|Experimental|BFF MDI 160/9.6 μg|Budesonide and Formoterol Fumarate Inhalation Aerosol-80/4.8 μg per actuation MDI/120 inhalations Taken as 2 inhalations BID
89398319|NCT02766608|Experimental|FF MDI 9.6 μg|Formoterol Fumarate Inhalation Aerosol-4.8 μg per actuation MDI/ 120 inhalations Taken as 2 inhalations BID
89398320|NCT02766608|Experimental|BD MDI 320 μg|Budesonide inhalation Aerosol 160 μg per actuation MDI/120 inhalations Taken as 2 inhalations BID
89398321|NCT02766608|Other|Symbicort® TBH 400/12 μg|Symbicort Turbuhaler 400/12 μg Taken as 2 inhalations BID
88874610|NCT04880304|Experimental|ADHD diagnosis and subconcussive head impacts|"ADHD Group: Individuals clinically diagnosed with ADHD, currently taking his/her prescribed ADHD medication.~Device: Soccer Heading Soccer Heading: Subjects stood approximately 40 feet away from a JUGS soccer ball launcher and participated in 20 consecutive soccer headings, separated by one minute intervals."
89398322|NCT01382485|Active Comparator|AICBG harvesting group|Iliac crest bone graft will be harvested from the anterior iliac crest through an incision beginning 2cm posterior to the anterior superior iliac spine and carried posteriorly. A window will be made in the iliac crest and a curette will subsequently be used to harvest the cancellous bone. The incision will be closed in 3 layers. The infiltration of local anaesthetic will be at the discretion of the surgeon.
88874611|NCT04880304|Experimental|No history or current diagnosis of ADHD and subconcussive head impacts|"Non-ADHD Group: Individuals with no current or prior diagnosis of ADHD.~Device: Soccer Heading Soccer Heading: Subjects stood approximately 40 feet away from a JUGS soccer ball launcher and participated in 20 consecutive soccer headings, separated by one minute intervals."
88874612|NCT04840992|Experimental|A1a Phase I low 2 doses|Ad5-nCoV containing 0.5E10 vp, 2 doses 56 days apart, Aerogen Solo
88874613|NCT04840992|Placebo Comparator|A1b Phase I placebo low 2 doses|Placebo containing 0 vp, 2 doses 56 days apart, Aerogen Solo
88874614|NCT04840992|Experimental|A2a Phase I medium 2 doses|Ad5-nCoV containing 1E10 vp, 2 doses 56 days apart, Aerogen Solo
88874615|NCT04840992|Placebo Comparator|A2b Phase I placebo medium 2 doses|Placebo containing 0 vp, 2 doses 56 days apart, Aerogen Solo
88874616|NCT04840992|Experimental|A3a Phase I high 2 doses|Ad5-nCoV containing 2E10 vp, 2 doses 56 days apart, Aerogen Solo
88874617|NCT04840992|Placebo Comparator|A3b Phase I placebo high 2 doses|Placebo containing 0 vp, 2 doses 56 days apart, Aerogen Solo
88874618|NCT04840992|Experimental|A4a Phase I combine 2 doses|1 dose Intramuscular Injection, Ad5-nCoV containing 5E10 vp, 1 dose Aerogen Solo, Ad5-nCoV containing 2E10 vp, 56 days apart
88874619|NCT04840992|Placebo Comparator|A4b Phase I placebo combine 2 doses|6 subjects, Placebo containing 0 vp, 1 dose Intramuscular Injection, 1 dose Aerogen Solo, 56 days apart
88874620|NCT04840992|Experimental|A5a Phase I single dose|Ad5-nCoV containing 1E10 vp, 1 dose Aerogen Solo
88874621|NCT04840992|Placebo Comparator|A5b Phase I placebo single dose|6 subjects, Placebo containing 0 vp, 1 dose Aerogen Solo
88874622|NCT04840992|Experimental|B1a Phase II low 2 doses|Ad5-nCoV containing 0.5E10 vp, 2 doses 56 days apart, Aerogen Solo
88874623|NCT04840992|Placebo Comparator|B1b Phase II placebo low 2 doses (18-59)|Placebo containing 0 vp, 2 doses 56 days apart, Aerogen Solo
88874624|NCT04840992|Experimental|B2a Phase II medium 2 doses|Ad5-nCoV containing 1E10 vp, 2 doses 56 days apart, Aerogen Solo
88874625|NCT04840992|Placebo Comparator|B2b Phase II placebo medium 2 doses|Placebo containing 0 vp, 2 doses 56 days apart, Aerogen Solo
88874626|NCT04840992|Experimental|B3a Phase II high 2 doses|Ad5-nCoV containing 2E10 vp, 2 doses 56 days apart, Aerogen Solo
88874627|NCT04840992|Placebo Comparator|B3b Phase II placebo high 2 doses|Placebo containing 0 vp, 2 doses 56 days apart, Aerogen Solo
88874628|NCT04840992|Experimental|B4a Phase II combine 2 doses|1 dose Intramuscular Injection, Ad5-nCoV containing 5E10 vp, 1 dose Aerogen Solo, Ad5-nCoV containing 2E10 vp, 56 days apart
89398323|NCT01382485|Experimental|RIA harvesting group|Subjects allocated to the RIA group will have the graft harvested in a standardized fashion using the technique described by Quintero et al. Briefly, the RIA device is a single-pass reamer that is connected to an aspirator and irrigator, allowing simultaneous reaming, irrigation, and aspiration of the contents of the femoral canal. RIA head size and tube length will be chosen based on preoperative templating of anteroposterior and lateral radiographs of the donor femur (a head size of 2mm larger than the inner cortical diameter at the isthmus of the femur will be selected). Fluoroscopic imaging will be used to confirm guidewire positioning and avoid eccentric reaming. Bone graft will be harvested from the central femoral canal and from each femoral condyle in 3 separate passes.
88874629|NCT04840992|Placebo Comparator|B4b Phase II placebo combine 2 doses|Placebo containing 0 vp, 1 dose Intramuscular Injection, 1 dose Aerogen Solo, 56 days apart
88874630|NCT04840992|Experimental|B5a Phase II intramuscular single dose|Ad5-nCoV containing 5E10 vp, 1 dose Intramuscular Injection
88874631|NCT04840992|Placebo Comparator|B5b Phase II placebo intramuscular single dose|placebo containing 0 vp, 1 dose Intramuscular Injection
88874632|NCT04840992|Experimental|B6a Phase II Aerogen Solo single dose|Ad5-nCoV containing 1E10 vp, 1 dose Aerogen Solo
89398324|NCT01382407||Cetuximab|All patients who started treatment with ERBITUX® (cetuximab), as a single agent or in combination with chemotherapy.
89398325|NCT02235857|Experimental|Liposorber® LA-15 System|All study patients who meet the study eligibility criteria will undergo the extracorporeal treatment using Liposorber® LA-15 System. The participants are to be treated with the system twice weekly for the 3weeks and then once weekly for the following 6 weeks.
88874633|NCT04840992|Placebo Comparator|B6b Phase II placebo Aerogen Solo single dose|placebo containing 0 vp, 1 dose Aerogen Solo
88874634|NCT04840056||Intestinal Metaplasia|patient with history of histologically proven gastric intestinal metaplasia
88874635|NCT04840056||Atrophic gastritis|patient with history of histologically proven atrophic gastritis
88874636|NCT04793022|Experimental|TIVA-Propofol|Intravenous anesthesia with Propofol
88874637|NCT04793022|Active Comparator|Inhaled Anesthesia|General Inhaled Anesthesia
88874638|NCT04682496|Experimental|intratendon vascularization|Intratendon vascularization will be quantified using a proprietary methodology using ImageJ 1.47v image analysis software, determining the different variables related to the Doppler signal within an intratendon region of interest.
88874639|NCT04633356|Experimental|EUS-portal pressure gradient measurement (PPGM)|All patients would receive measurement of PPGM using the study device
88874640|NCT04592484|Experimental|CDK-002|
88874641|NCT04567524|Active Comparator|Arm 1|"LYN-005: capsules containing LYN-005 stellate; the 14mg dose of LYN-005 contains 3 active arms containing risperidone, and 3 inactive arms and the 28 mg dose of LYN-005 contains 6 active arms containing risperidone.~AND~IR Risperidone Matched Placebo: Orange capsule-shaped tablets containing inactive ingredient."
88874642|NCT04567524|Placebo Comparator|Arm 2|"LYN-005 Matched Placebo: Size 00EL capsules containing inactive ingredient with no stellate.~AND~IR Risperidone: Risperidone 2 mg (orange) capsule-shaped tablets."
89398326|NCT01382329|Experimental|Treatment group I / Intramuscular|85 subjects to receive 2 intramuscular vaccinations at Dose A on Days 1 and 22
89398327|NCT01382329|Experimental|Treatment group II / Intramuscular|85 subjects to receive 2 intramuscular vaccinations at Dose B on Days 1 and 22
89398328|NCT01382329|Experimental|Treatment group III / Subcutaneous|85 subjects to receive 2 subcutaneous vaccinations at Dose A on Days 1 and 22
89398329|NCT01382329|Experimental|Treatment group IV / Subcutaneous|85 subjects to receive 2 subcutaneous vaccinations at Dose B on Days 1 and 22
89398330|NCT03325231||Bladder Cancer Patients|Participants will be recruited from those who have had advanced bladder cancer (grade pT1 and above) and undergone either IC or NB procedures within the last five years. No form of payment will be offered for participation, but participants will be reimbursed for travel expenses. There will be no other inclusion or exclusion criteria in order to access a wide range of patients with potentially different values and lifestyles, and to aid in the recruitment of adequate sample sizes.
89398331|NCT05393453||patients with acute on chronic liver failure|All subjects will receive the currently routine treatment of liver failure and corresponding etiological treatment if needed. The researchers will collect various clinical examination results of the subjects in the process of diagnosis and treatment, including but not limited to blood routine, biochemistry, coagulation function, liver imaging, therapeutic drugs, etc. Complications and prognosis of patients will be recorded. Blood samples, urine and stool samples of all subjects will be collected after enrollment and stored for probably testing in the future. This study has no additional intervention and treatment for subjects.
89398332|NCT03317119|Experimental|Treatment (TAS-102, trametinib)|Patients receive trifluridine and tipiracil hydrochloride PO BID on days 1-5 and 8-12 and trametinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89398333|NCT05347589|Experimental|Post isometric relaxation of quadratus lumborum and gluteus Gluteus maximus activation exercises|
89398334|NCT05347589|Active Comparator|post isometric relaxation of the Quadratus lumborum|
89398335|NCT05347355|Experimental|Spencer technique along with conventional treatment|
89398336|NCT05347355|Experimental|Gongs Mobilization along with conventional treatment|
89398337|NCT02157350|Experimental|Panretinal Laser Photocoagulation|See interventional description.
89398338|NCT03252535|Experimental|Cellavita HD Lower Dose|The participants randomized to this group will receive a total of 9 intravenous administrations of 1x10^6 cells/weight range divided into three administrations per cycle. Each administration will occur every 30 days and cycles every 120 days (total of 3 cycles).
89398339|NCT03252535|Experimental|Cellavita HD Higher Dose|The participants randomized to this group will receive a total of 9 intravenous administrations of 2x10^6 cells/weight range divided into three administrations per cycle. Each administration will occur every 30 days and cycles every 120 days (total of 3 cycles).
89398340|NCT03252535|Placebo Comparator|Placebo Group|The participants randomized to this group will receive a total of 9 intravenous administrations divided into three administrations per cycle. Each administration will occur every 30 days and cycles every 120 days (total of 3 cycles).
89398341|NCT04356495|Sham Comparator|Vitamins|"Patients in this arm will receive a vitamin supplement (AZINC forme et vitalité®) during 10 days"
88874643|NCT04549038|Experimental|Cases|Patients randomized to the cases group will receive their nutrition over a period of 12-16 hours, with minimum 8 hours of fasting and maximum 12 hours of fasting. All patients will receive 100% of their daily nutrition.
88874644|NCT04549038|No Intervention|Controls|Patients randomized to the control group will receive the current standard of care (24-hour continuous nutrition). All patients will receive 100% of their daily nutrition.
89398342|NCT04356495|Experimental|Telmisartan|Patients in this arm will receive Telmisartan (Micardis® 20 mg) during 10 days
89398343|NCT04356495|Experimental|Ciclesonide|Patients in this arm will receive ciclesonide (Alvesco® 160 µg ) during 10 days
89398344|NCT04356495|Experimental|interferon β-1b|Patients in this arm will receive interferon β-1b (Extavia® 9,6 MUI/300 µg ) during 5 days
89398345|NCT03542084|Experimental|Intervention: Unsolicited e-consult|The PCP of intervention arm patients will receive an unsolicited e-consult by an endocrinologist offering clinical guidance on how to optimize the patients' glycemic control
88874645|NCT04481412|Experimental|Study group|(33) patients will apply topical minoxidil (5%) once daily and topical cetirizine (1%) once daily on their scalp for 6 months.
88874646|NCT04481412|Active Comparator|Control group|(33) patients will apply topical minoxidil (5%) once daily and placebo once daily on their scalp for 6 months.
88874647|NCT04475718|Other|Fourth Trimester Mobile Tool|Fourth Trimester Mobile Tool
88874648|NCT04465188|Experimental|Experimental arm|Surgical procedure to prevent retinal detachment in the unaffected eye
89398346|NCT03542084|No Intervention|Control|Control arm patients will receive usual care
89398347|NCT03230695|Active Comparator|Active stimulation + robotic therapy|"Active transcranial direct current stimulation will be applied during 20 minutes prior to robotic training.~Number of interventions sessions: 1"
89398348|NCT03230695|Sham Comparator|Sham stimulation + robotic therapy|"Sham transcranial direct current stimulation will be applied during 20 minutes prior to robotic training.~Number of interventions sessions: 1"
89398349|NCT05654961||Heart failure patients|According to the eligibility criteria specified below.
89398350|NCT02154230|Experimental|sulphate-bicarbonate-calcium water and low-calorie diet (SW-D)|"Experimental arm: Those patients assigned to this interventional arm of the study will be asked to follow a low-calorie diet. For the first 12 weeks, the diet will cover only basal metabolism expenditure ± 10%. At the end of this 12 weeks, for the following 12 weeks, patients will follow a maintenance diet which will cover both basal metabolism and physical activity expenditure. Patients will be invited to maintain the same level of physical activity preceding enrollment throughout the entire study period. During the first 4 weeks these patients will be asked to drink every morning, before breakfast, within 30 minutes, 500 mL of Acqua Santa di Chianciano® at room temperature."
89398351|NCT02154230|Active Comparator|tap water and low-calorie diet (TW-D)|Active comparator: Those patients assigned to this interventional arm of the study will be asked to follow the same low-calorie diet of the experimental arm. During the first 4 weeks these patients will be asked to drink every morning, before breakfast, within 30 minutes, 500 mL of Rome tap water at room temperature.
89398352|NCT01384045|No Intervention|Usual Care|Patients continue to receive usual diabetes care without outreach by health promotions staff.
89398353|NCT01384045|Experimental|Arm 1-Health Promotoin Outreach|Active outreach by health promotion staff to send diabetes report card and schedule services including laboratory testing and visits.
89398354|NCT04724941||REM behavior disorder +|"Individuals with REM Sleep Behavior Disorder:~All individuals will be included in a prospective, longitudinal observational study, including an annual investigation at the Department for Neurology (detailed anamnesis, neurological examination, motor assessment). Blood sampling will be performed every six months, non-motor symptoms will be assessed every three months using online surveys. All individuals can participate in an optional substudy including lumbar punctures every two years."
89398355|NCT04724941||REM behavior disorder -|"Individuals without REM Sleep Behavior Disorder with increased risk for PD:~All individuals will be included in a prospective, longitudinal observational study, including an annual investigation at the Department for Neurology (detailed anamnesis, neurological examination, motor assessment). Blood sampling will be performed every six months, non-motor symptoms will be assessed every three months using online surveys. All individuals can participate in an optional substudy including lumbar punctures every two years."
89398356|NCT02157428|Placebo Comparator|saline|patients received 20 ml of saline during 1 minute, after end of surgery.
89398357|NCT02157428|Active Comparator|flumazenil|patients received 1 mg of flumazenil, after end of surgery
89398358|NCT01383967|Experimental|LY2979165 Part A, Cohort 1|20 mg LY2979165 administered orally, daily for 14 days
89398359|NCT01383967|Experimental|LY2979165 Part A, Cohort 2|60 mg LY2979165 administered orally, daily for 14 days
89398360|NCT01383967|Experimental|LY2979165 Part A, Cohort 3|100 mg LY2979165 administered, orally daily for 14 days
89398361|NCT01383967|Experimental|LY2979165 Part A, Cohort 4|150 mg LY2979165 administered orally, daily for 14 days
89398362|NCT01383967|Experimental|LY2979165 Part B, Cohort 5|Dose to be determined by safety review of doses administered in Part A, administered, orally daily for 14 days
89398363|NCT01383967|Placebo Comparator|Placebo|Administered orally, daily for 14 days in a ratio of 3:1 in each Cohort of Part A
89398364|NCT01383967|Experimental|LY2979165 Part A, Cohort 6|250 mg LY2979165 administered orally, daily for 14 days
89398365|NCT01383967|Experimental|LY2979165 Part A, Cohort 7|400 mg LY2979165 administered orally, daily for 14 days
89398366|NCT02254928|Other|Group 1|First stimulation cycle with corifollitropin alfa (experimental) Second stimulation cycle with rFSH and HMG (active comparator)
89398367|NCT02254928|Other|Group 2|First stimulation cycle with rFSH and HMG (active comparator) Second stimulation cycle with corifollitropin alfa (experimental)
89188467|NCT00789243|Active Comparator|2|Prior to 20 mins of ischaemia induced by a blood pressure cuff inflated to 200 mmHg around the upper non-dominant arm, remote ischaemic preconditioning will be induced by inflating a cuff around the dominant arm to 200 mmHg for 5 mins followed by 5 mins of reperfusion. This cycle will be repeated 3 times.
89398368|NCT01383889|Other|Treading mill exercise|Pregnant women in this group will perform treadmill exercise during 20 minutes. The intensity of exercise will be maintained between 60% and 80% of maximum heart rate by Karvonen formula, in addition to the subjective perception of exertion on the modified Borg scale (moderate intensity).
89398369|NCT01383889|Other|Stationary bicycle exercise|Pregnant women in this group will perform exercise using a stationary bicycle. The intensity of exercise will be maintained between 60% and 80% of maximum heart rate by Karvonen formula, in addition to the subjective perception of exertion on the modified Borg scale (moderate intensity).
89398370|NCT00960141|Experimental|1|montelukast
89398371|NCT00960141|Active Comparator|2|loratadine
89398372|NCT00960141|Placebo Comparator|3|placebo
89398373|NCT02771522|Other|Active post-othodontic lesions|Imaging with the Calcivis System
89398374|NCT00759655|Other|open label|
89398375|NCT00518869|Experimental|Treatment group|PG2 plus standard chemotherapies
89398376|NCT00518869|Placebo Comparator|Placeo group|Placebo plus standard chemotherapies
89398377|NCT02255006|Experimental|active acupuncture|The participants in this group receive real acupuncture treatment at first. Afterwards crossover study is scheduled to be performed.
89398378|NCT02255006|Sham Comparator|Sham acupuncture|The participants in this group receive sham acupuncture treatment at first. afterwards crossover study is scheduled to be performed
89398379|NCT02255006|Experimental|Euglycon|Glibenclamide (Euglucon, Roche Pharma) is administered 3 hours before FMD measurement.
89398380|NCT02255006|Experimental|Celebrex|Celebrex(celecoxib, pfizer) 200mg twice daily is administered for 5 days before FMD measurement.
89398381|NCT02771366|Experimental|Fermented Papaya Preparation, then granulated sugar|Participants will start taking the Fermented Papaya Preparation (FPP) three times per day, for 8 week. Then there will be a 6 week washout period. After the washout period the participants will start taking the granulated sugar in the same way as the FPP was taken. In addition, the following test will be performed: Magnetic Resonance Spectroscopy (MRS) of the brain, functional magnetic resonance imaging (fMRI), RAND 36-item Health Survey (SF-36) questionnaire, Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) blood samples,
89398382|NCT02771366|Placebo Comparator|Granulated Sugar, then Fermented Papaya Preparation|Participants will start taking the granulated sugar three times per day, for 8 week. Then there will be a 6 week washout period. After the washout period the participants will start taking the Fermented Papaya Preparation (FPP) in the same way as the granulated sugar was taken. In addition, the following test will be performed: Magnetic Resonance Spectroscopy (MRS) of the brain, functional magnetic resonance imaging (fMRI), RAND 36-item Health Survey (SF-36) questionnaire, Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) blood samples,
89398383|NCT03396471|Experimental|Single Arm Assignment|Pembrolizumab + External Beam Radiation Therapy
89398384|NCT00103142|Experimental|PANVAC-V + PANVAC-F + DC|Patients undergo leukapheresis to obtain leukocytes for generation of autologous dendritic cells (DC). Patients then receive autologous DC loaded with vaccinia-CEA-MUC-1-TRICOM (PANVAC-V) vaccine subcutaneously (SC) and intradermally (ID) on day 1 and autologous DC loaded with fowlpox-CEA-MUC-1-TRICOM (PANVAC-F) vaccine SC and ID on days 28, 56, and 84.
89398385|NCT00103142|Experimental|PANVAC-V + PANVAC-F + GM-CSF|Patients receive PANVAC-V SC on day 1 and PANVAC-F SC on days 28, 56, and 84. Patients also receive sargramostim (GM-CSF) SC into the same injection site once daily on days 0-3, 28-31, 56-59, and 84-87.
89398386|NCT02157584|Experimental|Treatment A|Subjects will receive a single 500 mg (as free base) dose of telotristat etiprate (as 2 × 250 mg tablets) on Day 1 in a fed condition. Days 2 to 5 will be Washout Days. On Day 6, subjects will receive a single 500 mg (as free base) dose of telotristat etiprate (as 2 × 250 mg tablets) 1 in a fasted condition.
89398387|NCT02157584|Experimental|Treatment B|Subjects will receive a single 500 mg (as free base) dose of telotristat etiprate (as 2 × 250 mg tablets) on Day 1 in a fasted condition. Days 2 to 5 will be Washout Days. On Day 6, subjects will receive a single 500 mg (as free base) dose of telotristat etiprate (as 2 × 250 mg tablets) 1 in a fed condition.
88874649|NCT04465188|No Intervention|Control arm|Standard procedure of clinical practice without any surgical procedure for the unaffected fellow eye.
88874650|NCT04423458||Transplanted kidney|No intervention is required. Routine Doppler assessment + 3D scan + Shear wave elastography + MicrFlow Imaging will be immediately recorded afterwards
88874651|NCT04412616|Experimental|ZZ06 0.03 mg/kg dose group|ZZ06 0.03 mg/kg will be administered twice weekly.A cycle is defined as continuous treatment for 28 days, and the initial treatment course is 2 cycles. Patients can receive up to 6 additional cycles unless disease progression, unacceptable toxicity, or other protocol specified stopping criteria occur. After 6 cycles, additional cycles may be given upon request by the Investigator and approval by the Medical Monitor.
88874652|NCT04412616|Experimental|ZZ06 0.06 mg/kg dose group|ZZ06 0.06 mg/kg will be administered twice weekly.A cycle is defined as continuous treatment for 28 days, and the initial treatment course is 2 cycles. Patients can receive up to 6 additional cycles unless disease progression, unacceptable toxicity, or other protocol specified stopping criteria occur. After 6 cycles, additional cycles may be given upon request by the Investigator and approval by the Medical Monitor.
89398388|NCT00943683|Experimental|1|Montelukast
89398389|NCT00943683|Placebo Comparator|2|Placebo
88874653|NCT04412616|Experimental|ZZ06 0.12 mg/kg dose group|ZZ06 0.12 mg/kg will be administered twice weekly.A cycle is defined as continuous treatment for 28 days, and the initial treatment course is 2 cycles. Patients can receive up to 6 additional cycles unless disease progression, unacceptable toxicity, or other protocol specified stopping criteria occur. After 6 cycles, additional cycles may be given upon request by the Investigator and approval by the Medical Monitor.
88874654|NCT04412616|Experimental|ZZ06 0.22 mg/kg dose group|ZZ06 0.22 mg/kg will be administered twice weekly.A cycle is defined as continuous treatment for 28 days, and the initial treatment course is 2 cycles. Patients can receive up to 6 additional cycles unless disease progression, unacceptable toxicity, or other protocol specified stopping criteria occur. After 6 cycles, additional cycles may be given upon request by the Investigator and approval by the Medical Monitor.
88874655|NCT04412616|Experimental|ZZ06 0.39 mg/kg dose group|ZZ06 0.39 mg/kg will be administered twice weekly.A cycle is defined as continuous treatment for 28 days, and the initial treatment course is 2 cycles. Patients can receive up to 6 additional cycles unless disease progression, unacceptable toxicity, or other protocol specified stopping criteria occur. After 6 cycles, additional cycles may be given upon request by the Investigator and approval by the Medical Monitor.
88875470|NCT05318040|Experimental|Multiple ascending dose - Elderly cohort - CMS121|Subjects will receive multiple oral doses of CMS121 once daily (QD) for 7 days under fed conditions.
89398390|NCT02154308|Experimental|IL-YANG influenza vaccine|IL-YANG FLU Vaccine Prefilled Syringe INJ 0.5mL by intramuscular injection
89398391|NCT03542006|Experimental|Topical brinzolamide|Brinzolamide ophthalmic, given bd for 3 months
89398392|NCT02157740||Control group before telemedicine|Residents of nursing homes without telemedicine before implementation of telemedicine in nursing homes with telemedicine
89398393|NCT02157740||Control group after telemedicine|Residents of nursing homes without telemedicine after implementation of telemedicine in nursing homes with telemedicine
89398394|NCT02157740||Exposed group, before telemedicine|Residents of nursing homes with telemedicine prior implementation of telemedicine
89398395|NCT02157740||Exposed group, after telemedicine|Residents of nursing homes with telemedicine after implementation of telemedicine
89398396|NCT02154464|Active Comparator|Paracetamol|
89398397|NCT02154464|Placebo Comparator|Placebo|
89398398|NCT00911547|Experimental|1|Montelukast + Beclomethasone
89398399|NCT00911547|Experimental|2|Montelukast + Placebo inhaler
89398400|NCT00911547|Experimental|3|Placebo tablet + Beclomethasone
89398401|NCT00911547|Placebo Comparator|4|Placebo tablet + Placebo inhaler
89398402|NCT02154542|Active Comparator|Experimental A|NAVA then standard mode
89398403|NCT02154542|Active Comparator|Experimental B|Standard mode then NAVA
89398404|NCT03696771|Experimental|NJH395|Includes non-breast HER2-positive advanced malignancies
89398405|NCT02157818|Active Comparator|midazolam|midazolam IV bolus 0.05ml/kg bolus in 1minute. rescue drug(Midazolam) 1 mg, IV boluses for double blinding setting, we use saline, 0.4 mcg/kg IV bolus in 10 minutes and 0.5 mcg/kg/h, as placebo.
89398406|NCT02157818|Experimental|Dexmedetomidine|"Dexmedetomidine 0.4 mcg/kg IV bolus in 10 minutes. Dexmedetomidine 0.25-0.75 mcg/kg/h for RSS 3-5. Midazolam 1mg bolus IV pro re nata (PRN).~for double blinding setting, IV bolus 0.05ml/kg bolus in 1minute."
88874656|NCT04412616|Experimental|ZZ06 0.70 mg/kg dose group|ZZ06 0.70 mg/kg will be administered twice weekly.A cycle is defined as continuous treatment for 28 days, and the initial treatment course is 2 cycles. Patients can receive up to 6 additional cycles unless disease progression, unacceptable toxicity, or other protocol specified stopping criteria occur. After 6 cycles, additional cycles may be given upon request by the Investigator and approval by the Medical Monitor.
88874657|NCT04412616|Experimental|ZZ06 1.00 mg/kg dose group|ZZ06 1.00 mg/kg will be administered twice weekly.A cycle is defined as continuous treatment for 28 days, and the initial treatment course is 2 cycles. Patients can receive up to 6 additional cycles unless disease progression, unacceptable toxicity, or other protocol specified stopping criteria occur. After 6 cycles, additional cycles may be given upon request by the Investigator and approval by the Medical Monitor.
88874658|NCT04317300|Experimental|E-cigarette users|Participants who are regular users of e-cigarettes will be treated with a 12 week course of varenicline for stopping vaping.
88874659|NCT04300218|Experimental|iCBT-I + CAU|Participants of this arm will get access to the course of the online cognitive-behavioral therapy for insomnia (iCBT-I) for 2 months along with the treatment prescribed by a consulting doctor (care as usual - CAU). After the 2-month course participants will pass the post-treatment assessment followed by the 3-month follow-up and post-follow-up assessment
88874660|NCT04300218|Active Comparator|CAU|Participants of this arm will get a treatment prescribed by a consulting doctor (care as usual - CAU). After the 2-month course participants will pass the post-treatment assessment followed by the 3-month follow-up and post-follow-up assessment. Then provided completion of all the assessments and satisfying eligibility criteria participants of this arm will get tha access to the 2-month iCBT-I course followed by the post-treatment assessment
88874661|NCT04251390||trexo Home intervention|Participants family is renting a trexo Home from trexo. The decision to use the device was separate from this research, and the decision to do research on its use was secondary. The proposed procedures may be modified to adapt to the child and family's interest and needs. Participant will use the trexo Home in their home, school, and community.
88874662|NCT04205370|Active Comparator|Deactivated device|Wear deactivated pregnancy coach device for the remainder of pregnancy.
88874663|NCT04205370|Experimental|Active device|Wear active device for remainder of pregnancy (including 3 day run-in period)
88874664|NCT04176510|Experimental|Patient Centered Medical Home (PCMH) plus Health Coach|A health coaching intervention that employs a positive affect/self-affirmation intervention to help motivate patients to succeed at implementing self-management by setting life goals, in addition to the usual care provided for patients with multiple chronic diseases by the The Patient-Centered Medical Home (PCMH).
88874665|NCT04176510|No Intervention|Patient Centered Medical Home (PCMH)|Usual care provided for patients with multiple chronic diseases by the Patient-Centered Medical Home (PCMH).
88874666|NCT04143204||very preterm infants cohort|A prospective cohort of very preterm or very low birth weight infants from birth to corrected age 18 months.
88874667|NCT04138134||Group 1|Patients subjected to saphenectomy due to chronic venous insufficiency or varicose veins
88874668|NCT04138134||Group 2|Patients with atherosclerotic obstructive disease of lower limbs
89398407|NCT02154620|No Intervention|Plaster cast|The patient will be treated in a dorsal plaster cast for 4 weeks following the injury to the wrist
89398408|NCT02154620|Experimental|Volar plate|The patient will undergo surgery to the injured wrist with a Synthes Two-column plate (TCP) with a volar approach. Cast will be worn 2 weeks after surgery.
89398409|NCT02157896||Acute ischemic stroke|Patients who suffered from acute ischemic stroke within 12 hours for the first time before entry into the study, and had a score between 6 and 25 on the National Institutes of Health Stroke Scale (NIHSS).
89398410|NCT03542786|Experimental|i3.1|This group will have their habitual antiretroviral therapy (integrase inhibitor (INI), protease inhibitor (IP), reverse transcriptase inhibitor (ITINAN)) combined with the research product (probiotic i3.1). The prebiotic will be taken once a day during 6 months.
89398411|NCT03542786|Experimental|i3.1 + ProSeed|This group will have their habitual antiretroviral therapy combined with the probiotic (i3.1) and the prebiotic (ProSheed). The prebiotic and probiotic will be taken once a day during 6 months.
89398412|NCT03542786|Placebo Comparator|Placebo|This group will only have their habitual antiretroviral therapy. The placebo will be taken once a day during 6 months.
88875471|NCT05318040|Placebo Comparator|Multiple ascending dose - Elderly cohort - placebo|Subjects will receive multiple oral doses of placebo once daily (QD) for 7 days under fed conditions.
88875472|NCT05318040|Experimental|Food Effect - CMS121|On Day 1 of each of 2 treatment periods, a single oral dose of CMS121 will be administered following either a standard high fat/high calorie meal (Treatment A) or an overnight fast (Treatment B), as per each subject's assigned randomization sequence (AB or BA). There will be a washout of at least 7 days between doses.
89398413|NCT02154698|Active Comparator|22-gauge Standard Needle|Participants will have each node sampled starting with the standard 22G needle on the first pass followed by the ProCore 22G needle on the second pass (for a total of 8 passes)
89398414|NCT02154698|Active Comparator|22-gauge ProCore Needle|Participants will have each node sampled starting with the ProCore 22G on the first pass followed by the standard 22G needle on the second pass (for a total of 8 passes)
89398415|NCT00899379|Experimental|Treatment Sequence 1|Placebo-Rizatriptan-Rizatriptan-Rizatriptan
89398416|NCT00899379|Experimental|Treatment Sequence 2|Rizatriptan-Placebo-Rizatriptan-Rizatriptan
89398417|NCT00899379|Experimental|Treatment Sequence 3|Rizatriptan-Rizatriptan-Placebo-Rizatriptan
89398418|NCT00899379|Experimental|Treatment Sequence 4|Rizatriptan-Rizatriptan-Rizatriptan-Placebo
89398419|NCT00899379|Experimental|Treatment Sequence 5|Rizatriptan-Rizatriptan-Rizatriptan-Rizatriptan
89398420|NCT02159846||Test Group and Control Group|20 patients with established T2DM were recruited from the M-OPD, HTAA, Kuantan; and equally divided into the Test and the Control groups (10 patients in each group).These patients were either fed with 4 g daily mixed herbs (on wet weight basis) or placebo (maize starch).
89398421|NCT02159846||Test Group & Control Group|20 patients with established T2DM were recruited from the M-OPD, HTAA, Kuantan; and equally divided into the Test and the Control groups (10 patients in each group).These patients were either fed with 4 g daily mixed herbs (on wet weight basis) or placebo (maize starch).
89398422|NCT02159924||Asymptomatic|
89398423|NCT02255318|Experimental|Taurolock|Patients received Taurolock lock for 3 months administration.
89398424|NCT02255318|Placebo Comparator|Placebo|Patients received placebo lock (physiological serum) for 3 months administration.
89398425|NCT04326439|Experimental|Aflac-AML Regimen for Low Risk AML Patients|"Participants in this arm will receive the standard Aflac-AML Regimen with the following chemotherapy:~Induction-1: patients on Induction-I will receive gemtuzumab + ADE therapy based on genotyping. Lasts a total of 28 days.~Induction II - MA~Intensification I - AE~Intensification II - HD ARAC/LASP~Patients with low risk status who had low risk markers and were MRD positive at the end of Induction I and continue to be MRD positive after Induction II will come off protocol."
89398426|NCT04326439|Experimental|Aflac-AML Regimen for High Risk AML Patients|"Participants in this arm will receive standard Aflac-AML Regimen with the following chemotherapy:~Induction-1: patients will receive gemtuzumab in addition to ADE therapy based on genotyping. Induction I lasts a total of 28 days.~Induction 1 for FLT3-ITD patients - ADE (10+3+5) with GO with Sorafenib~Induction II - MA~Induction II for FLT3-ITD patients - MA with Sorafenib~Intensification I - AE~Intensification I for FLT3-ITD patients - AE with sorafenib~Intensification II - HD ARAC/LASP~Intensification II for FLT3-ITD patients - HD ARAC/LASP with sorafenib~Hematopoietic stem cell transplantation (HSCT)~If a patient is classified as High risk after Induction I, they may proceed to best allogenic donor SCT following Induction II. These patients may receive a third course of chemotherapy prior to HSCT. In cases where HSCT is not an option, patients can receive 4 cycles of chemotherapy. Only patients with FLT3-ITD mutation will receive sorafenib."
88874669|NCT03977922|Experimental|Diet group|"The diet group will be involved in a 12-week pilot nutrition program based on the anti-inflammatory diet studied by Allison and Ditor (2015). The nutrition program will entail:~Once per week (Monday mornings), nutrition program members will come to Power Cord to pick up their box of ingredients for their meals that week (Monday to Friday). Recipe cards will accompany the ingredients, and enough food will be provided for 3 meals and 2 snacks per day. The meals will be based on the anti-inflammatory diet previously studied in Allison and Ditor (2015).~10-12 online videos that cover basic kitchen/cooking skills, how to prepare the meals in the program, how to shop for healthy foods at the grocery store, etc.~At the beginning of the program each member will be provided with a few pieces of accessible kitchen equipment that will made food preparation and cooking much easier.~Once per month, we will be offering a live cooking class."
88874670|NCT03977922|No Intervention|Control group|The control group will eat their usual diet for the 12-week period.
88874671|NCT03971136|Other|Children with sickle cell disease|Child from 12 months to 18 years old admitted for vaso-occlusive crisis
88874672|NCT03946332|Experimental|Physical exercise arm|patients will benefit regularly from a physical exercises program during their hospitalization. When going back home, they will be given a practical help kit with specific equipment (dumbbell, elastic), an actimeter with heart rate monitoring (in order to have an objective collection of the physical practice in addition to a self-evaluation) and a physical exercises program on paper and video supports, that patients would have learnt during their hospitalization. Furthermore, SMS will be regularly sent to remind them to practice
89398427|NCT02255240|Experimental|Physical activity intervention|This arm will receive the physical activity intervention, which consists of three individual meetings, weekly brief counseling phone calls for 6 weeks, and provision of a video game console with three active video games.
88874673|NCT03946332|Active Comparator|controlled arm|patients will be hospitalized in the same conditions than the experimental group and will be able to practice if they want.
88874674|NCT03904914||AIS group|Patients confirmed with adolescent idiopathic scoliosis (AIS)
88874675|NCT03886740|Experimental|Tympanostomy with tubes|Tympanostomy with pressure equalization tube placement with Ventilation (Tympanostomy) Tubes
89398428|NCT03541928|Experimental|Gene Therapy, ADT, RT, and Surgery|"The investigational gene therapy, ADV/HSV-tk, will be administered by injection into the prostate at 5 x 10[11] virus particles (1.25 x 10[11] virus particles per tumor quadrant in 4 quadrants) on day 0 and day 30.~The recommended dose of Valacyclovir for this trial is 2 g orally t.i.d. for 14 days (day 1 to day 15 and days 31 to 45).~The recommended dose for Bicalutamide therapy in combination with an LHRH analogue is one 50 mg tablet once daily (morning or evening).~Leuprolide acetate 7.5mg depot injection will be injected monthly for a total of 2 months."
89398429|NCT00145795|Experimental|Kaletra + Current Dual NRTI Backbone|Patients in this arm received Kaletra in addition to their current Dual NRTI Backbone.
89398430|NCT00145795|Active Comparator|Current Regimen|Patients in this study arm continued their current regimen.
89398431|NCT01379365|Experimental|Treatment|
88874676|NCT03886740|Experimental|Eustachian tube (ET) dilation|Eustachian tube (ET) dilation with ACCLARENT AERA® Eustachian Tube Balloon Dilation System
89398432|NCT02771210|Experimental|AIN457/Secukinumab|Secukinumab 150 mg s.c. or Secukinumab 300 mg s.c., respective dose was assigned according to underlying condition, in case of PsA according to severity of concomitant Psoriasis or pre-exposure to anti-TNFα
89398433|NCT02771210|Placebo Comparator|AIN457/Secukinumab Placebo|Secukinumab Placebo s.c.
89398434|NCT01382095|Experimental|Group A|
89398435|NCT01382095|Experimental|Group B-1|
89398436|NCT01382095|Experimental|Group B-2|
88874677|NCT03876288||People presenting with the Sx of Gp|People presenting with the symptoms of gastroparesis. The three main interventions are GI neuromodulation, immunotherapy, and pyloric therapies.
88874678|NCT03818256|Experimental|CORT118335- 600 mg|Patients who meet the entry criteria for the Study CORT118335-876 will be randomized to receive 600 mg miricorilant for 12 weeks.
88874679|NCT03818256|Placebo Comparator|Placebo|Patients who meet the entry criteria for the Study CORT118335-876 will be randomized to receive placebo for 12 weeks.
88874680|NCT03812172||Blacks/Hispanics with Heart Failure|Blacks/Hispanics with heart failure due to transthyretin cardiac amyloidosis will be identified by 99mTc-PYP (or 99mTc-HDP) scintigraphy. Those with transthyretin cardiac amyloidosis will be further subtyped into those with a genetic cause (ATTRm) and those with a non-genetic cause (ATTRwt - wild type transthyretin cardiac amyloidosis).
88874681|NCT03623958|Experimental|iVATS resection|Image guided Video-assisted thoracoscopic surgery (VATS) in either one of two hybrid operating rooms and Fine Needle Aspiration (FNA) under fluoroscopy.
88874682|NCT03623958|Active Comparator|Standard VATS resection|Standard video-assisted thoracoscopic surgery (VATS) in operating room and Fine Needle Aspiration (FNA) in pathology frozen section room.
88874683|NCT03601026|Experimental|Genetic counselling|Eligible participants who are randomized will be contacted and offered an invitation to attend the intervention. Genetic counselling will be provided to participants who accept the intervention as a single 1-2 hour session by a board-certified genetic counsellor. During the genetic counselling session, participants will have the option to receive their genotype at rs2494732. Participants will be counselled regarding their individualized risk of developing and of NOT developing SMI based on family history, whether or not they choose to use cannabis, and genotype (if they accept the genetic test results). Approximately 1 month after the intervention, participants will receive a follow-up interview.
88874684|NCT03601026|No Intervention|Control group|Eligible participants who are not randomized to be offered the intervention will continue with their annual assessments as part of the parent study. These participants will receive the current standard of care (no intervention), and will not be offered or informed of the intervention.
89188468|NCT00789243|Placebo Comparator|3|Prior to 20 mins of ischaemia induced by a blood pressure cuff inflated to 200 mmHg around the upper non-dominant arm, sham will be performed by inflating a cuff to 10 mmHg for 5 mins followed by 5 mins of deflation. This cycle will be repeated 3 times.
89188469|NCT00712634|Experimental|CMV-seropositive participants|Participants are randomized to receive 1 of 4 escalating doses of CMVpp65-A*0201 peptide vaccine containing either helper T-lymphocyte (HTL) PADRE peptide or HTL tetanus toxoid peptide. Within each vaccine dose group, two participants are randomized to receive a placebo. Participants receive the vaccine or a placebo subcutaneously (SC) on days 0 and 28 in the absence of unacceptable toxicity.
89398437|NCT01382095|Experimental|Group C|
89398438|NCT00898677|Experimental|1|rizatriptan 5 mg
89398439|NCT00898677|Experimental|2|rizatriptan 10 mg
89398440|NCT00898677|Active Comparator|3|sumatriptan 100 mg
88874685|NCT03370302|Experimental|TAK-228 Once Daily|TAK-228, milled capsule, orally, once daily, on an empty stomach in a 28-day treatment cycle for up to 12 months or until disease progression or unacceptable toxicity or withdrawal of consent with a starting dose of 2 milligram (mg) in Cohort 1. Dose escalation will follow a standard 3+3 schema. If 2 mg, once daily, is safe and tolerable, then the dose will be escalated to 4 mg, once daily, until RP2D is determined.
88874686|NCT03370302|Experimental|TAK-228 Once Weekly|TAK-228, milled capsule, orally, once weekly, on an empty stomach in Cycle 1 of a 28-day treatment cycle and following a light meal from Cycle 2 for up to 12 months or until disease progression or unacceptable toxicity or withdrawal of consent with a starting dose of 20 mg in Cohort 1. Dose escalation will follow a standard 3+3 schema. If 20 mg, once weekly, is safe and tolerable, then the dose will be escalated to 30 mg, once weekly, until RP2D is determined.
88874687|NCT03347058|Other|Supportive programming|Access to a suite of resources, including digital tools, person-to-person support, and educational resources
88874688|NCT03327324|Experimental|F1U1|Sequence 1 (Facility 1/Unit 1): Baseline, then 3 Month SLUMBER Intervention, then 39 Month Sustainability.
88874689|NCT03327324|Experimental|F1U2|Sequence 2 (Facility 1/Unit 2): Baseline, then 3 Month SLUMBER Intervention, then 33 Month Sustainability
88874690|NCT03327324|Experimental|F2U2|Sequence 3 (Facility 2/Unit 2): Baseline, then 3 Month SLUMBER Intervention, then 27 Month Sustainability
88874691|NCT03327324|Experimental|F2U3|Sequence 4 (Facility 2/Unit 3): Baseline, then 3 Month SLUMBER Intervention, then 21 Month Sustainability
89188470|NCT00712634|Experimental|CMV-seronegative participants|Participants are randomized to receive 1 of 4 established doses (established in CMV-seropositive participants) of CMVpp65-A*0201 peptide vaccine containing either HTL PADRE peptide or HTL tetanus toxoid peptide. Participants receive the vaccine on days 0, 28, and 56 in the absence of unacceptable toxicity. Participants with a partial or low-level immune response receive one additional booster vaccine on day 90.
89398441|NCT00898677|Placebo Comparator|4|placebo
89398442|NCT02158130||Healthy Living|non exercise healthy living control group
89398443|NCT02158130||General Health|Exercise Group (8 KKW) One exercise group will obtain 8KKW (kcal/kg/week) over 3-4 sessions per week, which will result in each session lasting approximately 30 minutes. We will recruit 1 year post study intervention.
89398444|NCT02158130||Weight Loss|Exercise Group (20 KKW) Exercise group will obtain 20 KKW, perform in 4-5 sessions per week for approximately 50-70 minutes per session. We will recruit 1 year post study intervention.
89398445|NCT01381393||Ibandronate|The subjects with osteoporosis in postmenopausal women
89398446|NCT02154776|Experimental|LEE011 + buparlisib + letrozole|open label, dose escalation evaluating max tolerated dose of the triple combination
89398447|NCT04967157|Placebo Comparator|Placebo|Intervention: Dietary Supplement: Placebo supplement
89398448|NCT04967157|Experimental|Cognizin®|Intervention: Dietary Supplement: Citicoline supplement
89398449|NCT03388749|Experimental|Liposomal annamycin|
89398450|NCT02770820|Experimental|Treatment (autologous CD8 T cells)|Beginning 4 weeks after completion of last course of consolidation chemotherapy, patients receive autologous WT1-TCRc4 gene-transduced CD8+ TCM/TN lymphocytes IV over 1-4 hours on day 0 and again after a minimum of 3 weeks. Beginning 6 hours after the second infusion of T cells, patients also receive aldesleukin SC BID for 14 days in the absence of disease progression or unacceptable toxicity. Patients who have clinically benefitted from T cell therapy may receive additional infusions of T cells and aldesleukin at the discretion of the PI and the attending physician.
89398451|NCT01377649||Control|Age matched control subjects without PAD
88874692|NCT03327324|Experimental|F2U4|Sequence 5 (Facility 2/Unit 4): Baseline, then 3 Month SLUMBER Intervention, then 15 Month Sustainability
88874693|NCT03327324|Experimental|F3U1|Sequence 6 (Facility 3/Unit 1): Baseline, then 3 Month SLUMBER Intervention, then 9 Month Sustainability
88874694|NCT03252522|Experimental|Intervention|Capsules of broad spectrum micronutrients: a 36-ingredient blend of vitamins, minerals, amino acids, and antioxidants.
88874695|NCT03252522|Placebo Comparator|Placebo|Capsules of inactive placebo.
88874696|NCT03252522|Experimental|Open Label|All participants have the option to participate in an 8-week, naturalistic, open label follow-up in which the child will take the active micronutrient treatment; capsules of broad spectrum micronutrients.
89398452|NCT01377649||Patients with PAD|
89398453|NCT01377571|Experimental|Rotavin2H|2 doses of Rotavin-M1 vaccine, 106.3FFU/dose, 2-month separation between doses
89398454|NCT01377571|Experimental|Rotavin2L|2 doses of Rotavin-M1 vaccine, 106.0FFU/dose, 2-month interval between doses
89398455|NCT01377571|Experimental|Rotavin3H|3 doses of Rotavin-M1 vaccine, 106.3FFU/dose, 1-month interval between doses
89398456|NCT01377571|Experimental|Rotavin3L|3 doses of Rotavin-M1, 106.0FFU/dose, 1-month interval between doses
89398457|NCT04051359|Active Comparator|Standard carbohydrate (200 g) group|Assignment to treatment groups will be performed on the enrollment to the study by evaluating the dietary carbohydrate intake personal patient preferences from 3 days prospective 24 hours' food dairy. After, the randomization will be performed and GDM patients will be assigned to the standard carbohydrate (200 g) group.
88874697|NCT03191370|Active Comparator|Local Anaesthetic, no distraction|Will receive local (co-phenylcaine) anesthetic spray (Local Anesthetics,Topical) as an active comparator without distraction during the procedure.
88874698|NCT03191370|Experimental|Local Anaesthetic, with distraction|Will receive local (co-phenylcaine) anesthetic spray (Local Anesthetics,Topical) with distraction during the procedure. The simple distraction technique is the experimental intervention.
88874699|NCT03191370|No Intervention|No Local Anaesthetic without distraction|Will receive no local (co-phenylcaine) anaesthetic spray without distraction during the procedure.
89188471|NCT00662259|Experimental|alprazolam|Alprazolam, an FDA-approved drug, will be administered to 24 patients with generalized anxiety disorder.
89188472|NCT00662259|Placebo Comparator|placebo|A placebo comparator will be administered to 12 patients with generalized anxiety disorder
89398458|NCT04051359|Experimental|Low carbohydrate (130 g) group|Assignment to treatment groups will be performed on the enrollment to the study by evaluating the dietary carbohydrate intake personal patient preferences from 3 days prospective 24 hours' food dairy. After, the randomization will be performed and GDM patients will be assigned to the low carbohydrate (130 g) group.
89398459|NCT02154854|Experimental|Group A - tacrolimus half-dose|"Immunosuppressive strategy with 50 % reduction of Advagraf® daily dose at M4 (randomization) and unchanged MMF dose. Targeted tacrolimus trough level are to be higher than 3 ng/mL . If the dose is not in adequation with the dispensable units, the prescribed dose will be the closest higher dose.~Drug: Tacrolimus targeted half-dose"
89398460|NCT02154854|Experimental|Group B - tacrolimus unchanged dose|Immunosuppressive strategy will remain identical after randomization (M4): unchanged Advagraf® and MMF doses. Targeted tacrolimus trough level are to be between 7 and 12 ng/mL Drug: Tacrolimus targeted plain dose
89398461|NCT01377493|Placebo Comparator|placebo|
89398462|NCT01377493|Active Comparator|POs-Ca|
89398463|NCT01377493|Active Comparator|POs-Ca+F|
89398464|NCT02160080|Experimental|Boc+Peg-int alfa+Rbv|Boceprevir 800mg/TID+Pegylated interferon alfa+Ribavirin
89398465|NCT05422495|Experimental|Activity|cognitive-motor training : Cycléo device (COTTOS ®),
89398466|NCT05422495|Placebo Comparator|No activity|no training
89398467|NCT03541538|Active Comparator|Global manipulation|Manual therapy performed in the cervical region in a non-specific way.
89188473|NCT04070222||Natural labour group|
89188474|NCT04070222||Cesarean scar group|
89188475|NCT04070222||Cesarean with diverticulum (PCSD) group|
89188476|NCT03918876||Healty Dancers|Healthy adult dancers
89188477|NCT03918876||Injured Dancers|Injured adult dancers
89188478|NCT00712790|Experimental|Sequential Radioembolization-Sorafenib|Sorafenib (400 mg twice-daily) was initiated 14 days post-radioembolization with yttrium-90 (Y) resin microspheres given as a single procedure.
89188479|NCT02574104||Institution 1|"McGill University Health Center NICU staff~Simulate a functional NICU prior to moving patients to preserve safety at transition~STATUS: Complete"
89188480|NCT02574104||Institution 2|"Rochester University Medical Center NICU staff~Simulate a functional NICU prior to moving patients to preserve safety at transition~STATUS: Complete"
89188481|NCT02574104||Institution 3|"Parkland Memorial Hospital NICU Staff~Simulate a functional NICU prior to moving patients to preserve safety at transition~STATUS: Complete"
89188482|NCT02574104||Institution 4|"Eastern Maine Medical Center NICU Staff~Simulate a functional NICU prior to moving patients to preserve safety at transition~STATUS: Active"
89188483|NCT02574104||Institution 5|"Brigham and Women's Hospital NICU Staff~Simulate a functional NICU prior to moving patients to preserve safety at transition~STATUS: Active"
89188484|NCT02574104||Institution 6|"Centre hospitalier universitaire Sainte-Justine NICU Staff~Simulate a functional NICU prior to moving patients to preserve safety at transition~STATUS: Active"
89188485|NCT02574104||Institution 7|"Golisano Children's Hospital of Southwest Florida NICU Staff~Simulate a functional NICU prior to moving patients to preserve safety at transition~STATUS: Preparing"
89188486|NCT02574104||Institution 8|"Florida Hospital for Children NICU Staff~Simulate a functional NICU prior to moving patients to preserve safety at transition~STATUS: Preparing"
89188487|NCT02574104||Institution 9|"Memorial Hospital of South Bend NICU Staff~Simulate a functional NICU prior to moving patients to preserve safety at transition~STATUS: Pending"
89188488|NCT02574104||Institution 10|"recruiting~Simulate a functional NICU prior to moving patients to preserve safety at transition"
89188489|NCT02574104||Institution 11|"recruiting~Simulate a functional NICU prior to moving patients to preserve safety at transition"
89188490|NCT02574104||Institution 12|"recruiting~Simulate a functional NICU prior to moving patients to preserve safety at transition"
89398468|NCT03541538|Experimental|Especific manipulation|manual therapy performed specifically on the C6-7 segment
89398469|NCT05422183|Experimental|envafolimab，lenvatinib，VP-16|envafolimab：400mg，sc，d1，Q3W； lenvatinib：8 mg(BW<60 kg) OR 12 mg(BW≥60 kg)，po，qd，d1-21，Q3W； VP-16：50 mg/d, po,d1-14，Q3W
89398470|NCT00702585|Experimental|Org 36286 7.5 µg|Org 36286 7.5 µg administered as a single subcutaneous injection on the day of the onset of a spontaneous or progestagen induced withdrawal bleeding or one to two days later.
89398471|NCT00702585|Experimental|Org 36286 15 µg|Org 36286 15 µg administered as a single subcutaneous injection on the day of the onset of a spontaneous or progestagen induced withdrawal bleeding or one to two days later.
89188491|NCT02574104||Institution 13|"recruiting~Simulate a functional NICU prior to moving patients to preserve safety at transition"
89188492|NCT02574104||Institution 14|"recruiting~Simulate a functional NICU prior to moving patients to preserve safety at transition"
89188493|NCT02574104||Institution 15|"recruiting~Simulate a functional NICU prior to moving patients to preserve safety at transition"
89188494|NCT02577744|Active Comparator|Noninvasive Ventilation|Noninvasive ventilation for 15 minutes with EPAP set at 10 cmH2O and IPAP adjusted to maintain a tidal volume of 6 ml / kg ideal weight.
89188495|NCT02577744|Active Comparator|Expiratory Positive Air Pressure|EPAP through facial mask with valve spring load for 15 minutes set at 10 cmH2O.
89188496|NCT00712868|Experimental|1|Lactic Acid once a day during 21 days
89188497|NCT00712946||1|Arteriosclerosis obliterans patients undergoing elective vascular surgery
89188498|NCT00712946||2|Healthy age-matched volunteers
89188499|NCT00660699|Experimental|Arm 1 (gemcitabine, docetaxel, 5FU, radiation)|"Gemcitabine 1000 mg/m2 IV on Day 1 and Day 8 of a 21 day cycle for 2 cycles~Docetaxel 35 mg/m2 IV on Day 1 and Day 8 of a 21 day cycle for 2 cycles~5FU CIVI 225 mg/m2 per day throughout radiation (starts 3 weeks after start of cycle 2)~Radiation 5040 cGy or 5400 cGy for positive margins (starts 3 weeks after start of cycle 2). Daily dose of 1.8 Gy five days per week.~Gemcitabine 1000 mg/m2 IV on Days 1 and 8 of 21 day cycle for 2 cycles (this starts 4 weeks after radiation)~Docetaxel 35 mg/m2 IV on Days 1 and 8 of 21 day cycle for 2 cycles (this starts 4 weeks after radiation)"
89188500|NCT00713024||1|Healthy control subjects
89188501|NCT00713024||2|Patients having neuropathic pain
89188502|NCT02577068|Active Comparator|nefopam group|
89188503|NCT02577068|Active Comparator|propacetamol group|
89188504|NCT02577068|Experimental|nefopam and propacetamol group|
89188505|NCT02576834|Experimental|CTSP + SAU|10 sessions of Cognitive Therapy for Suicide Prevention (CTSP) provided over 6 months, with optional 9 booster sessions + SAU
89188506|NCT02576834|Other|Services as Usual (SAU)|client receives services they would normally receive within the community
89188507|NCT02576756||with difficult intubation|Control population
89188508|NCT02576756||without difficult intubation|Control population
89188509|NCT00582114|Active Comparator|1|Atenolol
89188510|NCT00582114|Experimental|2|Lisinopril
89188511|NCT04071314||Cystic fibrosis|Children diagnosed with cystic fibrosis. Children aged between 0 and 18 years.
89188512|NCT04071314||Hirschsprung's disease|Children diagnosed with Hirschsprung's disease. Children aged between 0 and 18 years.
89188513|NCT04071314||Obstructive sleep apnoea|Children diagnosed with obstructive sleep apnoea. Children aged between 0 and 18 years.
89188514|NCT04071314||Healthy controls|Children free of any chronic health condition. Children aged between 0 and 18 years.
89398472|NCT00702585|Experimental|Org 36286 30 µg|Org 36286 30 µg administered as a single subcutaneous injection on the day of the onset of a spontaneous or progestagen induced withdrawal bleeding or one to two days later.
89535489|NCT03119623|Active Comparator|Sacubitril/Valsartan|Sacubitril/valsartan 100mg (Dose Level 1) titrated up if tolerated to 200 mg twice daily (Dose Level 2)
89398473|NCT00702585|Experimental|Org 36286 60 µg|Org 36286 60 µg administered as a single subcutaneous injection on the day of the onset of a spontaneous or progestagen induced withdrawal bleeding or one to two days later.
89398474|NCT00702585|Placebo Comparator|Placebo|Placebo to Org 36286 administered as a single subcutaneous injection on the day of the onset of a spontaneous or progestagen induced withdrawal bleeding or one to two days later.
89398475|NCT02160158|Experimental|Cohort 1|
89398476|NCT02160158|Experimental|Cohort 2|
89398477|NCT05421871|Experimental|Spinal Stabilization Exercises|Spinal Stabilization Exercises technique
89398478|NCT05421871|Experimental|Maitland Mobilization Along With Laser Therapy|Maitland Mobilization Along With Laser Therapy technique
89398479|NCT01381315|Other|Sentinel lymph node biopsy|During surgery, 1.0 mCi of technetium-99m sulfur colloid will be injected into sub-dermal subareolar aspect of the affected breast. The KUMC Nuclear Medicine Department will be responsible for performing the injection of the isotope and dilution of the isotope using saline to a final volume of 4.0 ml or less.
89398480|NCT01381315|Other|Axillary lymph node biopsy|
89398481|NCT02160236|Active Comparator|dexketoprofen trometamol|before end of the surgery via intravenous administration 50 mg dexketoprofen trometamol in 0.9 % NaCl 100 cc
89398482|NCT02160236|Active Comparator|tenoxicam|before the end of the surgery via administration intravenous 20 mg tenoxicam in 0.9% NaCl in 100 cc
89398483|NCT02160236|Placebo Comparator|serum physiologic|before end of the surgery via administration intravenous 0.9 % NaCl 100 cc
89398484|NCT03273855|Active Comparator|Intervention|Active Comparator. Transplant from Donor A or Donor B, or Donor C or Donore D, one transplant consist of 50-80g of feacal matter.
88874700|NCT03191370|Experimental|No Local Anaesthetic, with distraction|Will receive no local (co-phenylcaine) anesthetic spray with distraction during the procedure. The simple distraction technique is the experimental intervention.
88874701|NCT03179436|Experimental|Escalation: Dose Level (DL) 1 Quavonlimab + Pembro: Cohort 1|On Cycle 1, Day 1 of the Dose Escalation Phase, advanced solid tumor participants receive a single monotherapy dose lead-in with quavonlimab at dose level 1 (DL1). On Cycle 2, Day 1, and for 3 subsequent cycles on Day 1 (Cycles 3 to 5), these participants receive quavonlimab at DL1 in combination with pembrolizumab (pembro) at pembrolizumab dose level 1 (PDL1) according to Schedule 1. For all subsequent cycles (starting with Cycle 6), all participants receive pembrolizumab monotherapy according to Schedule 1. Participants will be treated for up to 35 cycles total on study.
88874702|NCT03179436|Experimental|Escalation: DL 2 Quavonlimab + Pembro: Cohort 2|On Cycle 1, Day 1 of the Dose Escalation Phase, participants with advanced solid tumors except NSCLC receive a single monotherapy dose lead-in with quavonlimab at DL2. On Cycle 2, Day 1, and for 3 subsequent cycles on Day 1 (Cycles 3 to 5), these participants receive quavonlimab at DL2 in combination with pembrolizumab at PDL1 according to Schedule 1. For all subsequent cycles (starting with Cycle 6), all participants receive pembrolizumab monotherapy according to Schedule 1. Participants will be treated for up to 35 cycles total on study.
88874703|NCT03179436|Experimental|Escalation: DL 3 Quavonlimab + Pembro: Cohort 3|On Cycle 1, Day 1 of the Dose Escalation Phase, participants with advanced solid tumors except NSCLC receive a single monotherapy dose lead-in with quavonlimab at DL3. On Cycle 2, Day 1, and for 3 subsequent cycles on Day 1 (Cycles 3 to 5), these participants receive quavonlimab at DL3 in combination with pembrolizumab at PDL1 according to Schedule 1. For all subsequent cycles (starting with Cycle 6), all participants receive pembrolizumab monotherapy according to Schedule 1. Participants will be treated for up to 35 cycles total on study.
89188515|NCT04071080|Experimental|100mg Fluorescein disodium|100mg Fluorescein disodium will be mixed with 500mL of Gatorade and taken orally by the participant
89188516|NCT04071080|Placebo Comparator|Placebo|500mL of Gatorade taken orally by the participant
89398485|NCT03273855|Placebo Comparator|Placebo|Placebo. Patient will recieve an autologous fecal microbiota transplantation.
89398486|NCT05421559|Active Comparator|conventional approach of thyroidectomy|conventional method of thyroidectomy with ST muscle retraction
89398487|NCT05421559|Active Comparator|transection approach of thyroidectomy|method of thyroidectomy with ST muscle transection
89398488|NCT02154932|Active Comparator|double dose misoprostol|2 doses, 3 and 1 hours, prior surgery (group B, 35 cases).
89398489|NCT02154932|Active Comparator|single dose Misoprostol|intra-vaginal single dose of 400 microgram Misoprostol 1 hour pre-operatively (group A, 34 cases)
89398490|NCT05421403|Active Comparator|Surgical|
89398491|NCT05421403|Placebo Comparator|non-Surgical|
89398492|NCT02158286||Esophagectomy, Emptying from gastric tube|Validate paracetamol clearance technique to scintigraphy for measuring emptying rate from the gastric tube.
89398493|NCT02961465||Sacral Neuromodulation (SNM)|
89398494|NCT03541772|Experimental|Oncoxin-Viusid®|Radiotherapy + Chemotherapy + Oncoxin-viusid®
89398495|NCT03541772|Placebo Comparator|Placebo|Radiotherapy + Chemotherapy + Placebo
89398496|NCT03542630||fertile, without periodontitis|"Women who gave birth to at least one child, without preovious fertility treatments, and who do not have periodontitis.~Interventions:~salivary MMP8 test; periodontal examination; blood tests"
89398497|NCT03542630||fertile, with periodontitis|"Women who gave birth to at least one child, without preovious fertility treatments, and who do have periodontitis.~Interventions:~salivary MMP8 test;periodontal examination;blood tests"
89398498|NCT03542630||infertile, without periodontitis|"Women who are diagnosed with infertility of unknown cause, and who do not have periodontitis.~Interventions:~salivary MMP8 test; periodontal examination;blood tests"
89398499|NCT03542630||infertile, with periodontitis|"Women who are diagnosed with infertility of unknown cause, and who do have periodontitis.~Interventions:~salivary MMP8 test; periodontal examination; blood tests"
89398500|NCT01377415|Active Comparator|bupivacaine|a continuous flow of 5 mg/ml bupivacaine 2 ml/h 48 h
89398501|NCT01377415|Placebo Comparator|saline|saline 9 mg/ml infusion 2 ml/h 48 h
88874704|NCT03179436|Experimental|Confirmation: DL 1 Quavonlimab Schedule 1 + Pembro (NSCLC): Arm A|On Cycle 1, Day 1 of the Dose Confirmation Phase and during all subsequent cycles, participants with NSCLC receive quavonlimab at DL1 in combination with pembrolizumab at PDL1, both according to Schedule 1. Participants will be treated for up to 35 cycles total on study.
88874705|NCT03179436|Experimental|Confirmation: DL 1 Quavonlimab Schedule 2 + Pembro (NSCLC): Arm B|On Cycle 1, Day 1 of the Dose Confirmation Phase, participants with NSCLC receive quavonlimab at DL1 in combination with pembrolizumab at PDL1. On all subsequent cycles, participants receive pembrolizumab at PDL1 according to Schedule 1 and quavonlimab at DL1 according to Schedule 2. Participants will be treated for up to 35 cycles total on study.
88874706|NCT03179436|Experimental|Confirmation: DL 2 Quavonlimab Schedule 2 + Pembro (NSCLC): Arm C|On Cycle 1, Day 1 of the Dose Confirmation Phase, participants with NSCLC receive quavonlimab at DL2 in combination with pembrolizumab at PDL1. On all subsequent cycles, participants receive pembrolizumab at PDL1 according to Schedule 1 and at DL2 quavonlimab according to Schedule 2. Participants will be treated for up to 35 cycles total on study.
88874707|NCT03179436|Experimental|Confirmation: DL 2 Quavonlimab Schedule 2 + Pembro (SCLC): Arm D|On Cycle 1, Day 1 of the Dose Confirmation Phase, participants with SCLC receive quavonlimab at DL2 in combination with pembrolizumab at PDL1. On all subsequent cycles, participants receive pembrolizumab at PDL1 according to Schedule 1 and quavonlimab at DL2 according to Schedule 2. Participants will be treated for up to 35 cycles total on study.
88874708|NCT03179436|Experimental|Confirmation: DL 2 Quavonlimab Schedule 1 + Pembro (NSCLC): Arm E|On Cycle 1, Day 1 of the Dose Confirmation Phase and during all subsequent cycles, participants with NSCLC receive quavonlimab at DL2 in combination with pembrolizumab at PDL1 according to Schedule 1. Participants will be treated for up to 35 cycles total on study.
88874709|NCT03179436|Experimental|Expansion: DL1 Quavonlimab Schedule 2+PDL2 Pembro Schedule 2: Arm F|On Cycle 1, Day 1 of the Efficacy Expansion Phase and during all subsequent cycles, participants with PD-1/PD-L1 refractory melanoma receive quavonlimab at DL1 in combination with pembrolizumab at pembrolizumab dose level 2 (PDL2). Both quavonlimab and pembrolizumab will be administered according to Schedule 2 for up to 24 months on study.
88874710|NCT03179436|Experimental|Expansion: DL1 Quavonlimab Schedule 2 Monotherapy: Arm G|On Cycle 1, Day 1 of the Efficacy Expansion Phase and during all subsequent cycles, participants with PD-1/PD-L1 refractory melanoma receive quavonlimab at DL1 according to Schedule 2 for up to 24 months on study. Participants who demonstrate radiographically confirmed progressive disease in Arm G will be eligible to receive combination therapy with pembrolizumab (crossover).
88874711|NCT03179436|Experimental|Coformulation: Pembrolizumab/Quavonlimab Schedule 2: Arm I|On Cycle 1, Day 1 of the Coformulation Phase and during all subsequent cycles, participants with advanced/metastatic solid tumors receive pembrolizumab/quavonlimab according to Schedule 2 for up to 24 months on study.
88874712|NCT03179436|Experimental|Coformulation Phase in China: Pembrolizumab/Quavonlimab Schedule 2: Arm K|On Cycle 1, Day 1 of the Coformulation Phase and during all subsequent cycles, participants in mainland China with advanced solid tumors receive pembrolizumab/quavonlimab according to Schedule 2 for up to 24 months on study.
88874713|NCT03149874|Active Comparator|Hepatitis B recombinant DNA vaccine|Each Hepatitis B recombinant DNA vaccine vial contained 20 microgram of vaccine dose. Two vials will be intramuscularly injected one vial in each deltoid muscle on months zero, one, two and six.
88874714|NCT03149874|Active Comparator|Combined hepatitis A and B vaccine|Each one-milliliter dose of vaccine contains 720 ELISA units of inactivated hepatitis A virus and 20 mcg of recombinant HBsAg protein. One dose of vaccine also contains 0.45 mg of aluminum. Two vials will be intramuscularly injected one vial in each deltoid muscle on on days zero, seven, and 21.
89188517|NCT01719666|Other|isolated MPFL reconstruction|
89188518|NCT01719666|Experimental|MPFL reconstruction and Lateral retinaculum release|
89188519|NCT00582036|Active Comparator|Arm 1|Regular Sliding Scale Insulin administration for hyperglycemia
89188520|NCT00582036|Experimental|Arm 2|MiniMed Paradigm monitoring device for hyperglycemia
89188521|NCT00581360|Other|Bortezomib + Doxorubicin|Patients with incurable adenoid cystic carcinoma of the head and neck who receive doxorubicin and bortezomib
89188522|NCT00713102||1|The group includes 10189 patients with on board medical or surgical emergencies.
89188523|NCT05673564||anatomical resection group|Anatomical resection was defined as resection of 1 or more complete hepatic segments in our study, including bisegmentectomy, right hemihepatectomy, left hemihepatectomy, extended right hemihepatectomy, extended left hemihepatectomy, single segmentectomy, caudate lobectomy, or a combination of these.
89188524|NCT05673564||nonanatomical resection group|Nonanatomical resection known as wedge resection, was defined as resection of the tumor with a margin of normal parenchyma without regard to hepatic anatomy.
89188525|NCT02574182||Control subjects under 40 years|Brain MRI Simulated walking with Corvit boots Records gait parameters on Gaitrite carpet
89188526|NCT02574182||Control subjects over 60 years|Brain MRI Simulated walking with Corvit boots Records gait parameters on Gaitrite carpet
89188527|NCT02574182||MCI subjects over 60 years|Brain MRI Simulated walking with Corvit boots Records gait parameters on Gaitrite carpet
89188528|NCT01650792|Active Comparator|Aspirin|Aspirin 300mg per day for 7 days in patients with HITS on transcranial Doppler monitorization
89188529|NCT01650792|No Intervention|Best medical treatment|Best medical treatment including drugs for heart failure and hypertension will be given to both groups.
89188530|NCT00713180|No Intervention|1|Pterygium free participants
89188531|NCT00713180|Experimental|2|Pterygium participants
89188532|NCT05673122|Experimental|Implant intact with shield|Ten patients undergo flapless single immediate implant placement surgery with socket shield technique, the implant is in contact with the shield.
89188533|NCT05673122|Experimental|Implant not intact with shield|Ten patients undergo flapless single immediate implant placement surgery with socket shield technique, there was a jumping gap more than 2mm between the shield and the implant, in which the gap was grafted with Xenograft.
89188534|NCT00660387|Experimental|Levodopa-Carbidopa Intestinal Gel (LCIG) + Placebo Capsules|Participants were randomized to LCIG (levodopa, 20 mg/mL and carbidopa monohydrate, 5 mg/mL) and placebo capsules. Participants received the percutaneous endoscopic gastrostomy with jejunal extension (PEG-J) procedure for gel administration of LCIG.
89535490|NCT03119623|Active Comparator|Enalapril|Enalapril 5mg (Dose Level 1) titrated up if tolerated to 10mg twice daily (Dose Level 2)
89188535|NCT00660387|Active Comparator|Placebo Gel + Levodopa-Carbidopa Capsules|Participants were randomized to placebo intestinal gel and oral levodopa-carbidopa (levodopa, 100 mg and carbidopa, 25 mg) Immediate Release (IR) capsules. Participants received the percutaneous endoscopic gastrostomy with jejunal extension (PEG-J) procedure for gel administration of placebo.
88874715|NCT03142074||Ascending thoracic aortic aneurysm|"Biomechanical and microstructural analysis of ATAA~ECG-gated CT"
88874716|NCT03116568||IBD Case|"Pregnant women with IBD~Newborns of pregnant women with IBD~Family member of pregnant women with IBD~Siblings of newborns"
88874717|NCT03116568||Control|"Pregnant women without IBD~Newborns of pregnant women without IBD~Family member of pregnant women without IBD~Siblings of newborns"
88874718|NCT02910180||Repository Group|The Repository Group consists of patients which have donated tissue to the repository.
88874719|NCT02834052|Experimental|Phase 1|"This Run In phase is aimed to determine if poly-ICLC can be safely combined with standard dosages of pembrolizumab:~i. Pembrolizumab will be administered 200 mg intravenously (IV) every 3 weeks (q3w)~ii. Poly-ICLC will be administered intramuscularly (IM) twice weekly at one of two dose levels: 1 mg or 2 mg~Each dose level will enroll 3-6 participants, up to 12 participants total, depending on the occurrence of dose limiting toxicities (DLT) at each dosing level.~Participants may receive treatment for 1 year (~17 cycles)."
88874720|NCT02834052|Experimental|Phase 2|"In Phase 2, all participants will receive the standard pembrolizumab dose (200 mg IV q3w) in addition to the maximum tolerated dose of poly-ICLC (either 1 mg or 2 mg), as determined by the Phase 1 arm.~Up to 30 participants will be treated in Phase 2. Participants may receive treatment for 1 year (~17 cycles)."
89188536|NCT00582738|Active Comparator|CsA-TAC|Continuation of current immunosuppressive regimen (continuation of Calcineurin Inhibitor [CNI] with or without Enteric-coated mycophenolate sodium (myfortic) or mycophenolate mofetil(Cellcept)[MPA], with or without steroids) / no everolimus introduction.
89188537|NCT00582738|Experimental|everolimus|Initiation of everolimus with discontinuation of CNI/MPA, with or without steroids.
89188538|NCT00713336|Experimental|1|ZD4054 + Moxifloxacin placebo
89188539|NCT00713336|Active Comparator|2|ZD4054 placebo + Moxifloxacin
89188540|NCT00713336|Experimental|3|ZD4054 + ZD4054 placebo + Moxifloxacin placebo
89188541|NCT00713336|Placebo Comparator|4|ZD4054 Placebo + Moxifloxacin placebo
89188542|NCT00713570||A,1,II|
89188543|NCT00789711||A|
89188544|NCT00789711||B|
89188545|NCT00713726|Active Comparator|F|Patients that received continued infusion of fentanyl at a steady dose for the first 48 hours and, then, doses were gradually decreases until stop
89188546|NCT00713726|Experimental|T|Patients that received continued infusion of tramadol at a steady dose for the first 48 hours and, then, doses were gradually decreases until stop
89188547|NCT00772889|Experimental|New generation influenza vaccine GSK2186877A Group|Subjects aged ≥66 years received one dose of New generation influenza vaccine GSK2186877A.
89188548|NCT00772889|Active Comparator|Fluarix elderly Group|Subjects aged ≥66 years received one dose of Fluarix vaccine.
89188549|NCT00772889|Active Comparator|Fluarix young Group|Subjects aged 19-43 years received one dose of Fluarix vaccine.
89188550|NCT00795795|Active Comparator|with PGS|IVF cycles with Preimplantation Genetic Screening (PGS)
89188551|NCT00795795|Active Comparator|Without PGS|IVF cycle without Preimplantation Genetic Screening
89188552|NCT00793689||total thyroidectomy|patients undergoing total thyroidectomy
89188553|NCT05325983|Experimental|lemonade ice cubes|10 ml lemonade ice cubes in mouth, 45 seconds, 90 seconds, 135 seconds, 180 seconds respectively
89188554|NCT05325983|Placebo Comparator|water ice cubes|10 ml water ice cubes in mouth, 45 seconds, 90 seconds, 135 seconds, 180 seconds respectively
89188555|NCT00800553|Experimental|donepezil|donepezil, 5 mg p.o. for approx 2 weeks
89188556|NCT00800553|Placebo Comparator|placebo|placebo
89188557|NCT04103801|Experimental|Sucrose group|This group received the 2 ml of sweet solution (sucrose)
89188558|NCT04103801|Placebo Comparator|Water group|This group received the 2 ml of water
89188559|NCT00793767|Placebo Comparator|placebo|placebo
89188560|NCT00793767|Experimental|Erythropoietin|acute administration of erythropoietin
89188561|NCT04103723||patients with premedication|Patients receiving preoperative premedication with midazolam before surgery.
89188562|NCT04103723||patients without premedication|Patients without preoperative premedication before surgery.
89188563|NCT03984851||Group A: Surgicel Group|a retrospective cohort study. Two groups were assigned, the first under the care of the author [AA], in which patients of his group underwent cold dissection tonsillectomy and achieved hemostasis via surgicel (without bipolar cautery). While group B patients (consisted of 2 surgeons) underwent cold dissection tonsillectomy and attained hemostasis with bipolar cautery. The main outcome that was pursued was postoperative tonsillectomy bleeding
89188564|NCT03984851||Group B: Bipolar Cautery group|a retrospective cohort study. Two groups were assigned, the first under the care of the author [AA], in which patients of his group underwent cold dissection tonsillectomy and achieved hemostasis via surgicel (without bipolar cautery). While group B patients (consisted of 2 surgeons) underwent cold dissection tonsillectomy and attained hemostasis with bipolar cautery. The main outcome that was pursued was postoperative tonsillectomy bleeding
89188565|NCT00793845|Experimental|High risk neuroblastoma|"Conventional chemotherapy (9 cycles)~Surgery conventional chemotherapy (after 6 cycles of chemotherapy)~Tandem HDCT/autoSCT~First HDCT (cyclophosphamide, etoposide, carboplatin)~Second HDCT (total body irradiation, thiotepa, melphalan)~Local radiotherapy~Retinoic acid, interleukin-2"
89188566|NCT04099745|Experimental|CGM（continuous glucose monitoring）|Each diabetic patient received three CGM tests within 14 days of FGM monitoring, on days 1-3, 6-9 and 12-14, respectively.
89188567|NCT04099745|Experimental|FGM（Flash glucose monitoring）|Each diabetic patient received one FGM test for 14 days.
89188568|NCT00800709|Experimental|Memantine|
89188569|NCT00916331|Experimental|subcutaneous group|Vacuum drainage is indwelled in subcutaneous layer
89188570|NCT00916331|Experimental|intraarticular group|Vacuum drainage is indwelled in intraarticular space
89188571|NCT00793923|Experimental|Combination Therapy|Combination therapy (group 1): same day combination therapy with 0.05cc dose intravitreal dexamethasone injection (10mg/ml vial) and a single 0.5 mg intravitreal ranibizumab injection
88874721|NCT02756364|Active Comparator|Fulvestrant 500 mg|Fulvestrant 500 mg, intramuscularly (IM), once on Days 1 and 15 in Cycle 1, and then on Day 1 of each subsequent 28-day cycle until progressive disease, unacceptable toxicity, or withdrawal of consent (Median duration of treatment was 16.0 weeks).
88874722|NCT02756364|Experimental|Fulvestrant 500 mg + Sapanisertib 4 mg|Fulvestrant 500 mg, IM, once on Days 1 and 15 in Cycle 1, and then on Day 1 of each subsequent 28-day cycle along with the sapanisertib 4 mg, capsules, orally, once daily in each 28-day treatment cycle until progressive disease, unacceptable toxicity, or withdrawal of consent (Median duration of treatment was 20.1 and 20.3 weeks for fulvestrant and sapanisertib respectively).
88874723|NCT02756364|Experimental|Fulvestrant 500 mg + Sapanisertib 30 mg|Fulvestrant 500 mg, IM, once on Days 1 and 15 in Cycle 1, and then on Day 1 of each subsequent 28-day cycle along with sapanisertib 30 mg, capsule, orally, once weekly in each 28-day treatment cycle until progressive disease, unacceptable toxicity, or withdrawal of consent (Median duration of treatment was 17.0 weeks for fulvestrant and sapanisertib, each).
88874724|NCT02752542|Experimental|Psychotherapy|Cognitive Behavioral Therapy
88874725|NCT02752542|Experimental|Pharmacotherapy|Antidepressant medication
88874726|NCT02679378||ClearSight™ System|To assess the ability of the ClearSight™ System to detect malignant tissue less than or equal to 1 mm of margins of excised breast specimen in breast conserving surgery when compared to histopathological assessment.
88874727|NCT02649738|Experimental|Corneal tissue inlay|The treated cornea will be implanted with a thin disc of preserved corneal tissue
88874728|NCT02519322|Experimental|Arm A (nivolumab, surgery)|Patients receive nivolumab IV over 30 minutes on days 1, 15, 29, and 43. Patients then undergo surgery on day 57. After surgery, patients receive nivolumab IV over 30 minutes every 2 weeks for 13 doses in the absence of disease progression or unacceptable toxicity.
88874729|NCT02519322|Experimental|Arm B (nivolumab, ipilimumab, surgery)|Patients receive nivolumab IV over 1 hour and ipilimumab IV over 90 minutes on days 1, 22, and 43. Patients then undergo surgery on day 57. After surgery, patients receive nivolumab IV over 30 minutes every 2 weeks for 13 doses in the absence of disease progression or unacceptable toxicity.
88874730|NCT02519322|Experimental|Arm C (nivolumab, relatlimab, surgery)|Patients receive nivolumab IV over 1 hour and relatlimab IV over 1 hour on days 1 and 29. Patients then undergo surgery on day 57. After surgery, patients receive nivolumab IV over 1 hour and relatlimab IV over 1 hour every 4 weeks for 10 doses in the absence of disease progression or unacceptable toxicity.
89188572|NCT00793923|Active Comparator|Monotherapy|intravitreal injection of 0.5 mg ranibizumab
89188573|NCT01247324|Active Comparator|Interferon beta-1a 44 mcg SC|Interferon beta-1a 44 mcg SC injections three times per week (with placebo infusions matching ocrelizumab infusions every 24 weeks).
89188574|NCT01247324|Experimental|Ocrelizumab|Ocrelizumab 600 mg intravenous (IV) as 300 mg infusions on Days 1 and 15 for the first dose and as a single infusion of 600 mg for all subsequent infusions every 24 weeks, with placebo injections matching interferon beta-1a SC three times per week.
89188575|NCT00772577|Experimental|1|Aliskiren Hydrochlorothiazide(HCTZ)
89188576|NCT00772577|Active Comparator|2|Ramipril
89188577|NCT02345850|Active Comparator|Tacrolimus/Methotrexate Control Arm|"Unmanipulated bone marrow graft with Tacrolimus/Methotrexate GVHD prophylaxis. Tacrolimus will be maintained at therapeutic doses for a minimum of 90 days. Methotrexate will be dosed at 5-15mg/m^2 for a maximum of 4 doses post-transplant.~Cyclosporine may be substituted for tacrolimus if the patient is intolerant of tacrolimus or per institutional practice."
89188578|NCT02345850|Experimental|CD34 Selection Arm|"Mobilized CD34-selected Peripheral Blood Stem Cell graft~Following screening and enrollment, the donor of patients randomized to the CD34-selection arm will receive mobilization therapy with once daily Granulocyte Colony Stimulating Factor (G-CSF). Mobilization will begin on Day -5 prior to the patient's transplant date.~Leukapheresis will be performed on a continuous flow cell separator according to institutional standards and will commence on the morning of the fifth day of G-CSF treatment. The anti-coagulant used for the procedure will be acid citrate dextrose (ACD).~Decisions concerning the need for further product collection will be based on the known or projected enriched CD34+ cell content of the previously collected products."
89188579|NCT02345850|Experimental|Post Transplant Cyclophosphamide|Unmanipulated Bone Marrow Graft with Cyclophosphamide
89188580|NCT00800787|Experimental|Arm One: Nabi-HB|All subjects will be administered Nabi HB Subcutaneously
89188581|NCT04099433|Experimental|Oral Bacteriotherapy Arm|Individuals in this study arm will undergo 6 months of daily intake of an oral probiotic formulation (Vivomixx: 4 sachets/day, each sachet containing 450 billion live bacteria). Probiotic sachets are indistinguishable from placebo
89188582|NCT04099433|Placebo Comparator|Placebo Arm|Individuals in this study arm will undergo 6 months of daily intake of placebo (4 sachets/day). Placebo sachets are indistinguishable from probiotic
89188583|NCT04045977|Experimental|VR therapy group|Cardiac rehabilitation supplemented by VR therapy
89188584|NCT04045977|Active Comparator|Control Group|Cardiac rehabilitation supplemented by Schultz Autogenic Training
89188585|NCT04021667|Experimental|INDIVIDUAL BREASTFEEDING TRAINING|"Individual Breastfeeding Training: Mother and father candidates who applied to the pregnant outpatient clinic and met the study criteria were included in the study.~After the informed consent was signed, the socio-demographic questionnaire including obstetric history and breastfeeding history, IOWA infant nutrition attitude scale and Breastfeeding Self-Efficacy Scale were applied to the mother and father candidates."
89188586|NCT04021667|Experimental|GROUP BREASTFEEDING TRAINING|"Group Breastfeeding Training: Mother and father candidates who applied to the pregnant outpatient clinic and met the study criteria were included in the study.~After the informed consent was signed, the socio-demographic questionnaire including obstetric history and breastfeeding history, IOWA infant nutrition attitude scale and Breastfeeding Self-Efficacy Scale were applied to the mother and father candidates.The groups were composed of five pairs of parents."
89535491|NCT03206359||Patients|Patients with SLE
89535492|NCT03206359||Healthy subjects|
89398502|NCT02678403|Experimental|1 - TENS group|The treatment will consist of Transcutaneous electrical nerve stimulation (TENS): stimulation of the leg (frequency of 10 Hz, Biphasic, with a pulse width of 200 µs, maximal intensity below motor threshold), 45 minutes per day, in the morning before the exercise rehabilitation programme, for 3 weeks, 5 days per week.
89398503|NCT02678403|Sham Comparator|2 - SHAM group|SHAM Transcutaneous electrical nerve stimulation (TENS) : the stimulation placebo will be delivered according to the same modalities as for the TENS group but with a voltage level that vanishes automatically after 10 seconds of stimulation.
89398504|NCT02155088|Experimental|Combination Therapy: BYL719, Gemcitabine, (Nab)-Paciltaxel|Dose escalation, followed by expansion, of BYL719 in combination with Gemcitabine and (Nab)-Paclitaxel. BYL719: once daily. Gemcitabine: Days 1,8, 15 of 28-day cycle. (Nab)-Paclitaxel: Days 1,8, 15 of 28-day cycle.
89398505|NCT03625635|Experimental|Nutrition diagnosis and intervention|At baseline and 6-mo after, a nutrition diagnosis will be done by measuring body composition components with DXA and basic anthropometric measurements. Based on the results, an individualized food-based intervention will be prescribed for each patient according to her diagnosis, food preferences, cultural and socioeconomic status. Follow-up will be every 2-weeks and a different diet menu will be provided in each session by a specialized dietitian, unto 6-mo are completed and initial measurements are repeated.
89398506|NCT02160392||Endometrial biopsy|HIV + and HIV negative women underwent lower and upper genital tract sampling.
89398507|NCT02160470|Experimental|Exposure with Retrieval|Exposure Therapy with Retrieval
89398508|NCT02160470|Experimental|Exposure with Compounding|Exposure Therapy with Compound Extinction
89398509|NCT02160470|Experimental|Exposure with Retrieval and Compounding|Exposure Therapy with Retrieval and Compound Extinction
89398510|NCT02160470|Active Comparator|Therapist-Guided Exposure Therapy|Therapist-guided Exposure Therapy
89398511|NCT02160548|Placebo Comparator|'Standard care'|Standard care= Intravenous fluids, Oxygen by face mask, Intubation if necessary, Mechanical ventilation (Engstrom Pro by GE) if necessary, Cardiac monitor (Infunix IP4050), Atropine (anti-muscarinic drug; G-Atropine) by intravenous route, Pralidoxime (acetylcholinesterase reactivating oxime drug; PAM-A) by intravenous route.
89398512|NCT02160548|Experimental|'Standard care+ 2.5 mg Salbutamol'|Standard care+ 2.5 mg Salbutamol= Nebulized salbutamol (Ventolin respiratory solution) 2.5 mg stat and once only with standard care
89398513|NCT02160548|Experimental|'Standard care+ 5 mg Salbutamol'|Standard care+ 5 mg Salbutamol= Nebulized salbutamol (Ventolin respiratory solution) 5 mg stat and once only with standard care
89398514|NCT02648061||After cardiac arrest syndrome (ACAS)|adult patients after out-of-hospital cardiac arrest
89398515|NCT02158598|No Intervention|wash-out|2 months
89398516|NCT02158598|Experimental|Vitamin D chewable tablet supplementation|A chewable vitamin D tablet containing 1000 IU to be taken once a day for 2 months.
89398517|NCT02158598|Experimental|Vitamin D pill supplementation|A vitamin D pill containing 1000 IU to be taken once a day for 2 months.
89398518|NCT03082729|Other|Apremilast|Apremilast (Otezla), 30mg oral tablet twice per day for 52 weeks. Single arm, open label study.
89398519|NCT02160704|Experimental|Arm 1(IP)|Enclomiphene citrate capsules 25 mg 1x daily for 16 weeks
88874731|NCT02210988|Experimental|acupuncture|The acupuncture treatment for the intervention group was provided once daily for 2 weeks.
88874732|NCT02000934|Experimental|TAK-659 60 mg (Dose Escalation)|TAK-659 60 mg, tablet, orally, once daily in 28-day cycles until disease progression or unacceptable toxicities (up to 49 cycles).
89398520|NCT02160704|Placebo Comparator|Arm 2 (Placebo)|Placebo capsule 1x daily for 16 weeks
89398521|NCT03541382|Active Comparator|HIVST campaign arm|Community representatives will be supported to plan and administer an HIVST campaign linked to HIV care and prevention services in their communities.
89398522|NCT03541382|No Intervention|SOC arm|Standard HTS will be provided by MoH at health facilities.
89398523|NCT03542552|Active Comparator|Nifidipne|received oral nifedipine 10 mg every 20 minutes for three doses, followed by 10 mg orally every 6 hours
89398524|NCT03542552|Experimental|Magnisum sulphate|Patients in the MgSO4 group received intravenous 6 g bolus MgSO4 20% followed by a 2 g/h infusion
89398525|NCT02158676|Experimental|Prebiotic|6 g/day of prebiotic (fructooligosaccharides) for 15 days.
88874733|NCT02000934|Experimental|TAK-659 80 mg (Dose Escalation)|TAK-659 80 mg, tablet, orally, once daily in 28-day cycles until disease progression or unacceptable toxicities (up to 4 cycles).
89398526|NCT02158676|Experimental|Synbiotic|6 g/day of synbiotic (fructooligosaccharides + Lactobacillus paracasei LPC-37 + Lactobacillus rhamnosus HN001 + Lactobacillus acidophilus NCFM + Bifidobacterium lactis HN019) for 15 days.
89398527|NCT02158676|Placebo Comparator|Placebo|6 g/day of placebo (maltodextrin) for 15 days.
89398528|NCT02155166|Active Comparator|intracervical anesthesia|Intracervical anesthesia with lidocaine 2%
89398529|NCT02155166|Active Comparator|ibuprofen|ibuprofen 400 mg
89398530|NCT02155244||Common bile duct stones|Common bile duct stones traeted with ERCP
89398531|NCT02155244||CBDS|treated with ERCP combined with surgery
89398532|NCT02160860||Children|Children
89398533|NCT02158754||Corus CAD (ASGES)|Subjects receiving CorusCAD (ASGES) gene expression test as part of their diagnostic workup for typical and/or atypical symptoms of obstructive coronary artery disease.
89398534|NCT02158754||Control|Matched subjects in the same practice that did NOT receive Corus CAD (ASGES) as part of their diagnostic workup.
89398535|NCT02160938||3 year follow-up cohort|"When the infants reach 24 months of age, the Study Follow-up Specialist will send all participants an age- appropriate Ages and Stages Questionnaire (ASQ) for completion.~At as close to the age of 3 as possible, the following exams will be performed and are described below:~The Vineland-II Adaptive Behavior Scale (VABS)~Wechsler Preschool and Primary Scale of Intelligence IV (WPPSI-IV), or Wechsler Intelligence Scale for Children - Fifth Edition (WISC-V, for siblings older than 7 years 7 months, when necessary)~Children will also be photographed (for review by the study dysmorphologist)"
89530224|NCT05045183|No Intervention|Treatment A: Uncovered Wound (Negative Control)|Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist. On the randomized wound site, no treatment will be applied as the wound will be kept uncovered as a negative control.
89398536|NCT02160938||Limited follow-up cohort|Women with children who will not reach the age of 2 years 6 months by the end of our study but have a prenatally diagnosed CNV will be recruited into the limited follow-up study. Each center will describe the study to eligible women and will verbally obtain their permission to be contacted by the Study Follow-up Specialist. The Study Follow-Up Specialist will contact the patient, explain the study, and obtain full written informed consent.
89398537|NCT02155400|Experimental|Prototype development|10 patients (this phase will be terminated once prototype is confirmed ready) Intervention: prototype device
89398538|NCT02155400|Active Comparator|Treatment arm - Prototype|- 18 patients Intervention: Prototype device (heating both sole of foot and popliteal fossa with compression)
89398539|NCT02155400|Active Comparator|Control arm - Forced Air Warming Blanket|18 patients Intervention: Forced air warming blanket (Bair hugger)
89398540|NCT02155400|Active Comparator|Comparison - Sole of foot only|9 patients heating sole of foot only Intervention: prototype device
89398541|NCT02155400|Active Comparator|Comparison - Popliteal fossa only|9 patients heating popliteal fossa only Intervention: prototype device
89398542|NCT01593111|Experimental|Environmental Intervention|If randomized to this part of the study the patient will receive an individualized homebased program. In addition to general handouts provided to at Visit 3, subjects in this arm will also receive home-based education by Intervention Counselors about how indoor allergens can affect asthma and the importance of strategies for removing allergens. The goal of the intervention is to provide the patient with the knowledge and skills necessary to remove allergens from their home, and to assist them with those clean up measures. Some of the measures implemented will be specifically based on data we have previously collected from them in the clinic and from their previous home visit, while others will be general to reduce all allergen level.
89398543|NCT01593111|No Intervention|Control Group|If assigned to this group the patient will receive general health/safety related counseling. At the counselor visit following randomization, the patient will receive handouts related to general health and safety issues. They will also have visits by the Home Evaluators for assessment of the home and collection of dust samples identical to those in the treatment group (week 28 and week 44).
89398544|NCT02158832|Experimental|Acupuncture + Electrical Stimulation|Acupuncture needles are inserted beneath the skin and electrical stimulation applied for 20 minutes.
89398545|NCT02158832|No Intervention|Control|Participants who are randomized to receive no intervention will still receive physical assessment.
89398546|NCT02155478|Other|AMO ZCB00|AMO ZCB00 IOL (Abbott Medical Optics, United States): a standard IOL
89398547|NCT02155478|Active Comparator|ISERT 250|ISERT 250 (HOYA, Japan): a standard IOL
89398548|NCT04956003|No Intervention|Control Group|No intervention, but assessment of cardiometabolic health and cognition
89398549|NCT04956003|Experimental|Intervention Group|Implementing a daily 45-minute physical activity session as an integral part of learning.
89398550|NCT02163044||Statin|Patients on statin treatment
89398551|NCT00920361||1|Patients who underwent IVF
89398552|NCT02161094|Experimental|Group 1: Physicians|Give incentives to physicians based on their patient's HbA1c improvement
89398553|NCT02161094|Experimental|Group 2: Diabetic patients|Give incentives to patients based on their own HbA1c improvement
89398554|NCT02161094|Experimental|Group 3: Both Physicians and Patients|Give incentives to both based on the HbA1c improvements from the physicians' patients
89398555|NCT02161094|No Intervention|Group 4: Control group|Receive no incentive but will be provided diabetes education booklet and group education courses for DM control as usual
89398556|NCT00651807|Active Comparator|Arm 1|etonogestrel
89398557|NCT00651807|Placebo Comparator|Arm 2|Placebo
88874734|NCT02000934|Experimental|TAK-659 100 mg (Dose Escalation)|TAK-659 100 mg, tablet, orally, once daily in 28-day cycles until disease progression or unacceptable toxicities (up to 32 cycles).
89398558|NCT02161172||Mild traumatic brain injury|Traumatic brain injury patients with Glasgow coma score (GCS) of 13-15.
89398559|NCT01381081|Experimental|platelet-rich plasma intra-articular knee injections|a single intra-articular injection of PRP in knee osteoarthritis
89398560|NCT01381081|Active Comparator|Corticosteroid intra-articular knee injections|a betamethasone and bupivacaine intra-articular injection
89398561|NCT05583513||Ambulatory Heart Failure|
89398562|NCT02161250|Experimental|Resistant starch|The test beverage consumed has the resistant starch.
89398563|NCT02161250|Experimental|Control|The control beverage uses maltodextrin rather than the resistant starch.
89398564|NCT03344887|Active Comparator|RBC Transfusion from male donor|For the treatment of anemia
89398565|NCT03344887|Active Comparator|RBC Transfusion from female donor|For the treatment of anemia
89398566|NCT02161328||ICU patients undergoing a dilatative tracheotomy.|
89398567|NCT03541148|Experimental|Oncoxin-Viusid|Nutritional supplement Oncoxin-Viusid 25 mL in oral solution twice a day
89398568|NCT01377337|Active Comparator|Sodium bicarbonate|1 mEq/kg sodium bicarbonate administered intravenously immediately following the administration of the first epinephrine dose during advanced CPR.
89398569|NCT01377337|Placebo Comparator|0.9% NaCl|1 ml/kg of 0.9% NaCl (Blinded label)
89398570|NCT02158910||Aricept Group 1|Subjects starting at 5 mg Aricept and increasing their dose to 10 mg Aricept
89398571|NCT02158910||Aricept Group 2|Subject starting at 10 mg Aricept and increasing their dose to 23 mg Aricept
89398572|NCT01381003|Experimental|pCCLchimGp91s lentiviral vector transduced CD34+ cells|pCCLchimGp91s lentiviral vector transduced CD34+ cells will be infused in a volume of 50-100 mls intravenously over 30-45 minutes
88874735|NCT02000934|Experimental|TAK-659 120 mg (Dose Escalation)|TAK-659 120 mg, tablet, orally, once daily in 28-day cycles until disease progression or unacceptable toxicities (up to 41 cycles).
88874736|NCT02000934|Experimental|TAK-659 CCL (Dose Expansion)|TAK-659 100 mg, tablet, orally, once daily in 28-day cycles until disease progression or unacceptable toxicities in participants with chronic lymphocytic leukemia (CCL) (up to 6 cycles).
88874737|NCT02000934|Experimental|TAK-659 DLBCL (Dose Expansion)|TAK-659 100 mg, tablet, orally, once daily in 28-day cycles until disease progression or unacceptable toxicities in participants with diffuse large B-cell lymphoma (DLBCL) (up to 49 cycles).
88874738|NCT02000934|Experimental|TAK-659 iNHL (Dose Expansion)|Single dose TAK-659 100 mg, tablet, orally in pharmacokinetic (PK) Run-in prior to Cycle 1 followed by TAK-659 100 mg, tablet, orally, once daily in 28-day cycles until disease progression or unacceptable toxicities in participants with indolent non-hodgkin lymphoma (iNHL) (up to 32 cycles).
88874739|NCT02000934|Experimental|TAK-659 MCL (Dose Expansion)|TAK-659 100 mg, tablet, orally, once daily in 28-day cycles until disease progression or unacceptable toxicities in participants with mantle cell lymphoma (MCL) (up to 6 cycles).
88874740|NCT02000934|Experimental|TAK-659 PTLD (Dose Expansion)|TAK-659 100 mg, tablet, orally, once daily in 28-day cycles until disease progression or unacceptable toxicities in participants with post-transplant lymphoproliferative disorder (PTLD) (up to 1 cycle).
88874741|NCT01906476|Experimental|Stepped Care|Participants will receive an Internet guided cognitive behavioral treatment (iCBT) with support from a telephone coach with the possibility of being stepped up to receiving telephone cognitive behavior therapy (T-CBT) with a therapist
88874742|NCT01906476|Active Comparator|Telephone Cognitive Behavior Therapy|Participants will receive telephone-administered cognitive behavioral therapy (T-CBT).
88874743|NCT01793922|Active Comparator|PD|pneumodilation
88874744|NCT01793922|Active Comparator|POEM|peroral endoscopic myotomy
88874745|NCT05723094|Experimental|Retention Laser Group (LG)|Before the orthodontic retention phase, the Ga-Al-As diode laser(Ilase, USA) was applied to the experimental group.
88874746|NCT05723094|Placebo Comparator|Retention Control Group (CG)|Before the orthodontic retention phase, those who did not apply the Ga-Al-As diode laser (Ilase, USA) were the control group.
89188587|NCT04021667|No Intervention|Control Group|Control Group: Mother and father candidates who applied to the pregnant outpatient clinic and met the study criteria were included in the study.After the informed consent was signed, the socio-demographic questionnaire including obstetric history and breastfeeding history, IOWA infant nutrition attitude scale and Breastfeeding Self-Efficacy Scale were applied to the mother and father candidates. Routine procedures were applied to the mother and father candidates.
89188588|NCT04101305||Localised prostate cancer|Patients diagnosed with prostate cancer of moderate estimated risk suitable for and scheduled for prostatectomy with gland evacuation
89188589|NCT04101305||Stage 3 prostate cancer|Patients with diagnosed stage 3 prostate cancer
89188590|NCT04101305||Stage 4 prostate cancer|Patients with diagnosed stage 4 prostate cancer
88874747|NCT05723016||AMH < 0.5 ng/ml|
88874748|NCT05723016||AMH 0.5-0.99 ng/ml|
88874749|NCT05723016||AMH 1.0-1.49 ng/ml|
88874750|NCT05723016||AMH 1.5-1.99 ng/ml|
88874751|NCT05723016||AMH 2.0-4.99 ng/ml|
88874752|NCT05723016||AMH > 5.0 ng/ml|
88874753|NCT05722626|Experimental|Platelet-rich plasma|PRP manufactured by T_Biyoteknoloji LTD, Turkey
88874754|NCT05722626|Placebo Comparator|Normal Saline|NaCl 0.9%
88874755|NCT05722548|Experimental|Group A|Patients will be administered 100mg of Indomethacin Suppository sigle dose at the time of induction of anesthesia with Standard Medical Treatment
88874756|NCT05722548|Active Comparator|Group B|Standard Medical Treatment
88874757|NCT05722392||Two-step Radical Prostatectomy|Two-step Radical Prostatectomy
88874758|NCT05721924|Active Comparator|Pericapsular nerve group (PENG) block|The pericapsular nerve group (PENG) block is an ultrasound-guided approach, first described by Giron-Arango et al. for the blockade of the articular branches of the femoral, obturator and accessory obturator nerves that provide sensory innervation to the anterior hip capsule.
88874759|NCT05721924|Active Comparator|Supra-inguinal fascia iliaca compartment (S-FICB) block|A supra-inguinal fascia iliaca compartment block (S-FICB), a 3 in 1 block involving femoral nerve , lateral femoral cutaneous nerve and obturator nerve.
88874760|NCT05721534||Care home residents|The intervention was offered to new residents and residents that had not yet attended a consultation focusing on pharmacological treatment in The Chronic Care Model.
88874761|NCT05721534||Community-dwelling patients with chronic disease|Patients were invited for the consultation focusing on pharmacological treatment in the month of their birthday and, thereby, included randomly and consecutively throughout the study period.
88874762|NCT05721456|Active Comparator|PCV10 (Synflorix®)|
88874763|NCT05721456|Active Comparator|PCV13 (Prevenar13®)|
89188591|NCT04101305||Healthy controls|Age-matched healthy individuals free from diagnosed cancer, but with benign inflammatory prostatitis or other benign urological condition
89188592|NCT04100993||Patient group|60 participants ≥16 years of age with a confirmed diagnosis of a childhood-onset NMD
89188593|NCT04100993||Exploratory reference group|20 healthy adults ≥16 years of age
89188594|NCT04099043|Experimental|Continuous Monitoring|Single Arm, Randomized
89188595|NCT04073550|Experimental|Experimental group|Anlotinib hydrochloride capsules given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21) and topotecan 1.5mg/m2 IV d1-5.
89188596|NCT04073550|Placebo Comparator|Placebo group|Anlotinib hydrochloride placebo given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21) and topotecan 1.5mg/m2 IV d1-5.
89188597|NCT02576600|Experimental|PUPILLO|Videopupillometer Algiscan peroperative remifentanil target concentration adapted every five minutes to pupillary diameter in patients under propofol and remifentanil TCI
89188598|NCT02576600|Sham Comparator|STANDARD|peroperative remifentanil target concentration as standard practice in patients under propofol and remifentanil TCI
89188599|NCT02863770|Experimental|Contrast EUS|Undergoing EUS for pancreatic indication (cyst, pancreatitis, mass)
89398573|NCT03731702||General Individuals|Any adult working at the NCI who has not used antibiotics in the past 3 months.
89398574|NCT02158988|No Intervention|without HIPEC|"Preoperative chemotherapy 3 cycles, each cycle 21 days. Patients with negative or unknown HER-2 status receive Epirubicin 50 mg/m² infusion (maximum 100mg/d). Oxaliplatin 130 mg/m² infusion (maximum 260 mg/d) and capecitabine oral 625 mg/m² two times a day (maximum 2500 mg/d).~Patients with positive HER-2 status receive:~Cisplatin : 80 mg/m² infusion (maximum of 160 mg/d). Capecitabine: oral 1000 mg/m2 (two times a day maximum of 4000 mg/d), on day 1-14.~Trastuzumab: 8 mg/kg infusion (on cycle 1 and 6 mg/kg on cycle 2 and 3). CRS is performed and 4-12 weeks after CRS 3 cycles of postoperative chemotherapy have to be applied. In case of therapy failure patients will be continued to be treated by the responsible investigator according to his medical status."
89398575|NCT02158988|Experimental|With HIPEC|"Patients will be treated with a preoperative chemotherapy as described for the control group. EOX or CCT depending on the HER-2 status.~CRS will be performed 2 to 3 weeks after end of last chemotherapy cycle. HIPEC with mitomycin C and cisplatin either at the time of CRS or a delayed HIPEC within 5-7 days.~HIPEC:~Mitomycin C: 15 mg/m2 (max. 30 mg/ m2, max. 5 L Perfusion). Cisplatin: 75 mg/m2/L (max. 150 mg/m2, max. 5 L Perfusion). 4-12 weeks after cytoreductive surgery 3 cycles postoperative chemotherapy will be applied.~Patients may get a HIPEC intervention without surgical cytoreduction if contraindication to the drugs can be excluded.~In case of therapy failure patients will be continued to be treated by the responsible investigator according to his medical status."
89398576|NCT05225493||Hospital|Medical specialists in hospitals and their patients aged 18 years and older in the participating hospitals who are diagnosed there with an HIV indicator condition.
89398577|NCT05225493||Primary care|General practitioners and their patients aged 18 years and older in the participating general practices who are diagnosed there with an HIV indicator condition.
89398578|NCT02159144|Experimental|healthy adults|
89398579|NCT02764190|Experimental|I-ACT with Check Yourself|Adolescents complete Check Yourself which delivers personalized, motivational feedback on their health behaviors prior to their primary care appointment. Check Yourself includes the provision of age normative feedback, goal setting strategies, and strategies to highlight discrepancies. Primary care providers will receive I-ACT and the Check Yourself summary report of health risk behaviors before an adolescent patient's appointment. I-ACT will provide training in adolescent-preferred communication methods and use of Check Yourself as a framework for the provider to use motivational interviewing to consider the patients' change readiness and their personal health goals. I-ACT includes online interactive, case-based learning, with booster sessions and feedback reports to reinforce new skills.
89398580|NCT02764190|No Intervention|Usual care|In the usual care group, adolescents are asked to complete health risk screening on a computer. No personalized feedback is provided to adolescents and primary care providers do not receive I-ACT or the Check Yourself summary report of the adolescent's health risk behaviors.
89398581|NCT02161640||Control|Age/sex matched control participants, not suffering from inflammatory bowel disease or any other chronic inflammatory disease
89398582|NCT02161640||Inflammatory Bowel Disease|Patients with active or remissive inflammatory bowel disease
89398583|NCT02161796|Experimental|1: young male subjects|3x single dose of FG-4592 and a placebo
89398584|NCT02161796|Experimental|2: young female subjects|3x single dose of FG-4592 and a placebo
89398585|NCT02161796|Experimental|3: elderly male subjects|3x single dose of FG-4592 and a placebo
89398586|NCT02161796|Experimental|4: elderly female subjects|3x single dose of FG-4592 and a placebo
88874764|NCT05721456|Experimental|12-Valent Pneumococcal Conjugate Vaccine|
88874765|NCT05721300|Experimental|experience group|"patients receive NAs（EntecavirorTenofovirorTenofovir alafenamide） combine with interferon treatments for 48weeks, and then continue NAs treatment"
88874766|NCT05721300|Active Comparator|control group|"patients receive NAs treatment（EntecavirorTenofovirorTenofovir alafenamide）"
88874767|NCT05721066||POST-COVID|Patients hospitalized due to acute COVID-19 pneumonia and discharged home. No residual symptoms after recovery. Contacted by phone and invited to an in-person interview about their health conditions and a blood withdrawal for the assessment of the coagulation profile (both in standard laboratory and point-of-care device ClotPro).
88874768|NCT05721066||LONG-COVID|"Patients hospitalized due to acute COVID-19 pneumonia and discharged home. Presence of residual symptoms after recovery or new symptoms appeared after discharge not otherwise explained.~Contacted by phone and invited to an in-person interview about their health conditions and a blood withdrawal for the assessment of the coagulation profile (both in standard laboratory and point-of-care device ClotPro)."
88874769|NCT05720910|Experimental|GERONTE|The clinical model behind GERONTE is to regroup all health professionals taking care of a multimorbid patient, into a common care coordination pathway;
88874770|NCT05720910|No Intervention|CONTROL ARM|Patients included in the control arm will be managed according to the standard of care.
88874771|NCT05720598|Experimental|Patients underdoing staging laparoscopy with indocyanine green (ICG)|"Patients will undergo upper GI endoscopy one day before SL will be dissolved in sterile water, resulting in a 0.125mg/ml concentration. 2 milliliters of the solution will be injected into the submucosa of 4 peritumoral sites - 0.5ml for each site. The following day patient will undergo SL~Intraoperative application of ICG-enhanced vision will be accomplished with dedicated optical devices. Alternate usage of white light and ICG fluorescence mode will allow precise location and cT stage determination of primary tumor, followed by identification of SN and its corresponding LN station, according to Japanese Gastric Cancer Association guidelines. Identified SN will be retrieved with a high-energy device, and the LN basin will be labeled with a magnetic clip."
89188600|NCT00713804|Experimental|GC|Genetic counseling (GC): One face-to-face genetic counseling session of 1-2hours duration, with a board certified or board eligible genetic counselor which will involve, documentation of a detailed family history, discussion of: the contributors to mental illness pathogenesis, illness risk reduction strategies, chances for family members to develop mental illness (if required), supportive counseling around living with illness/risk of illness/managing illness vulnerability, and referral to support organizations as required.
89530225|NCT05045183|Active Comparator|Treatment B: Standard of Care (SoC) Adhesive Bandage|Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist. On the randomized wound site, SoC adhesive bandage will be applied. This treatment will be changed daily from Day 1 through Day 6 and all wound sites will be uncovered from Day 7 to Day 16 for assessments.
88874772|NCT05720442|Experimental|Tangweian Recipe Group|"Tangweian formula granule (30g per bag), 1 bag per time, twice a day, take it with warm water after meals.~1 mosapride citratetablet per time, 3 times a day, take it with meals."
89398587|NCT03541070|Experimental|Kinesiology taping|For tibialis anterior muscle taping, each children's feet were placed at plantar flexion and eversion position while knees were extended, and I-shaped band was applied over tibialis anterior from origin to insertion of muscle with approximately 25-50% tension of the original length of the band. No tension was applied to the first and last 5 cm section of the bands in both applications because it were used as anchor. The tapes were remained for 1 hour on skin of both quadriceps and tibialis anterior muscles, and in this time the children were rested.
89398588|NCT03077659|Experimental|NanoPac® 6 mg/mL|NanoPac® 6 mg/mL injected into the prostate lobe containing the dominant lesion at a volume of 20% prostate lobe volume
88874773|NCT05720442|Active Comparator|Mosapride Citrate Group|1 mosapride citratetablet per time, 3 times a day, take it with meals.
88874774|NCT05720286||Study group|There was only one group as the study was a non-comparative study
88874775|NCT05720208|Experimental|Therapeutic Arm|
88874776|NCT05720208|Sham Comparator|Sham Arm|
89398589|NCT03077659|Experimental|NanoPac® 10 mg/mL|NanoPac® 10 mg/mL injected into the prostate lobe containing the dominant lesion at a volume of 20% prostate lobe volume
89398590|NCT03077659|Experimental|NanoPac® 15 mg/mL|NanoPac® 15 mg/mL injected into the prostate lobe containing the dominant lesion at a volume of 20% prostate lobe volume
89398591|NCT05225181|Experimental|sequential training|first perform physical exercise followed by cognitive training
89398592|NCT05225181|Experimental|simultaneous training|perform physical exercise and cognitive tasks simultaneously
88874777|NCT05720052|Experimental|Single arm|dose exploration
89398593|NCT05225181|Active Comparator|control group|perform body stretching and health education courses
89398594|NCT05052723|Experimental|Cabozantinib and pembrolizumab|
88874778|NCT05719974|Experimental|criterion-based rehabilitation protocol|
88874779|NCT05719974|Active Comparator|conventional physical therapy program|
88874780|NCT05719896|Placebo Comparator|Placebo tablets|Posology: oral administration of 3 placebo tablets three times per day for 8 weeks.
89398595|NCT05578131|Experimental|high flow nasal oxygen|
89398596|NCT05578131|Active Comparator|face mask|
89398597|NCT05576571||HCC case|Patients are those who received radiofrequency ablation or transvascular embolization in National Taiwan University Hospital. Which excludes weakness and inability to cooperate Patients with blood test, under the condition of fully informed consent, complete blood test related tumor indicators (AFP and methylation analysis). The two data are then counted Compare.
89398598|NCT05224947|Experimental|Infant formula A|
88874781|NCT05719896|Experimental|DT01 tablets|Posology: oral administration of 3 DT01 tablets three times per day for 8 weeks.
88874782|NCT05719896|Experimental|DT01-Placebo tablets|Posology: oral administration of 2 DT01 tablets and 1 placebo tablet, three times per day for 8 weeks.
89188601|NCT00713804|Active Comparator|EB|Educational Booklet (EB): One educational booklet that provides information about the causes of mental illnesses, and the chances for relatives of affected individuals to develop mental illness will be provided to participants.
89188602|NCT00713804|No Intervention|WT|Waitlist (WT)
89398599|NCT05224947|Experimental|Infant formula B|
89188603|NCT02329470|Experimental|No device, n=50|Withdrawal of device, continuous positive airway pressure treatment during 5 nights
89398600|NCT02807883|Experimental|Blinatumomab|Blinatumomab as continuous intravenous infusion at dose of 28 µg/24 hours over 4 weeks followed by 2 week treatment-free period for 6-week treatment cycle; 4 cycles of blinatumomab at 3, 6, 9, and 12 months following hematopoietic cell transplantation (HCT).
89398601|NCT04051281|No Intervention|Just under target control|Practices whose prescribing in the past year was under the new target but who would exceed the target if they had a 5% increase in prescribing; no letter sent.
89398602|NCT04051281|Experimental|Just under target letter|"Practices whose prescribing in the past year was under the new target but who would exceed the target if they had a 5% increase in prescribing: receive a letter informing of this.~Randomization is stratified according to whether their prescribing had increased by > 5% compared to the previous year; those whose prescribing had increased had it mentioned in the letter"
88874783|NCT05719818||Treatment initiation|patients with a satisfactory oral assessment authorizing the immediate prescription of treatment.
88874784|NCT05719818||Surgical dental care|patients requiring surgical dental care before treatment initaition.
88874785|NCT05719740||45 patients in type 1 .DM|TYPE 1 DIABETES MELLITUS
88874786|NCT05719740||and 45 patients in type 2DM|TYPE 2 DIABETES MELLITUS
88874787|NCT05719662|Experimental|Weight bearing exercises|weight bearing exercises (I.e standing on preferred foot, standing with close eyes, walking forward on a line using normal stride and heel to toe gait, stepping over response speed stick on balance beam).
88874788|NCT05719662|Experimental|Jaffrey's core stability exercises|Jaffrey's core stability exercises (I.e contracting muscles, sitting on Swiss ball, Bridging, Squatting side lying bridge etc).
88874789|NCT05719506|Sham Comparator|control group 1|control group (nebulized normal saline without drug: group C) .The drugs will be prepared in 0.9% normal saline to a final volume of 3ml. Nebulization will be performed using a wall nebulizer and wall oxygen source on 4 l/min . A Research nurse who will not participate in the evaluation of sedation administered the drugs to all children in nebulizer sessions ∼30 min before transfer to the OR.
88874790|NCT05719506|Experimental|dexmedetomidine group 2|"that receive nebulized dexmedetomidine (3 μg/kg; group D),The drugs will be prepared in 0.9% normal saline to a final volume of 3ml. Nebulization will be performed using a wall nebulizer and wall oxygen source on 4 l/min . A Research nurse who will not participate in the evaluation of sedation administered the drugs to all children in nebulizer sessions ∼30 min before transfer to the OR.~Patients will be assessed for sedation score then separated from their parents and the ease of separation will be recorded."
89398603|NCT04051281|No Intervention|Over target control|"Practices whose prescribing in the past year was above the new target but who were not in the top 20% of prescribers; no letter sent~Intervention 1: Letter informing them that their practice's prescribing exceeds the new target (Letter B1)~Intervention 2: Letter informing them that their practice's prescribing exceeds the new target with a graph representing prescribing relative to the target (Letter B2)"
89398604|NCT04051281|Experimental|Over target letter|"Practices whose prescribing in the past year was above the new target but who were not in the top 20% of prescribers; receive a letter informing them that their practice's prescribing exceeds the new target (Letter B1)~Randomization is stratified according to whether their prescribing had increased by > 5% compared to the previous year; those whose prescribing had increased had it mentioned in the letter"
89398605|NCT04051281|Experimental|Over target letter with bar chart|"Practices whose prescribing in the past year was above the new target but who were not in the top 20% of prescribers; receive a letter informing them that their practice's prescribing exceeds the new target, including a bar chart showing their prescribing compared to the target (Letter B1)~Randomization is stratified according to whether their prescribing had increased by > 5% compared to the previous year; those whose prescribing had increased had it mentioned in the letter"
89398606|NCT04051281|Active Comparator|Top 20% feedback letter control|"Targeting practices that are currently in the top 20% of prescribers; letters informing them of the percentile they are on--standard practice--(Letter C1)~Randomization is stratified according to whether their prescribing had increased by > 5% compared to the previous year; those whose prescribing had increased had it mentioned in the letter"
89398607|NCT04051281|Experimental|Top 20% above target letter|"Targeting practices that are currently in the top 20% of prescribers; letters informing them that their prescribing exceeds the new target (Letter C2)~Randomization is stratified according to whether their prescribing had increased by > 5% compared to the previous year; those whose prescribing had increased had it mentioned in the letter."
89398608|NCT04051281|Experimental|Top 20% feedback letter with specific example of patient harm|"Targeting practices that are currently in the top 20% of prescribers~• Control: Current standard practice, a social norms message, that their practice is in the top 20% of prescribers (Letter C1) Targeting practices that are currently in the top 20% of prescribers; letters informing them of the percentile they are on with a specific example of a case of patient harm caused by antimicrobial resistance (Letter C3)~Randomization is stratified according to whether their prescribing had increased by > 5% compared to the previous year; those whose prescribing had increased had it mentioned in the letter."
89398609|NCT03082261|Other|All enrolled subjects|All subjects enrolled into the study with intent to treat with either a Prodigy, Prodigy MRI, or Proclaim Elite Implantable Pulse Generator (IPG).
89398610|NCT04051047|Experimental|Gemcitabine|Gemcitabine will be given at 2100 mg/m2 IV over 30 minutes within 4 hours of planned surgical procedure. The surgical procedure is standard of care.
89398611|NCT00102440|Experimental|Febuxostat 80 mg QD|
89398612|NCT00102440|Experimental|Febuxostat 120 mg QD|
89398613|NCT00102440|Active Comparator|Allopurinol 300 mg QD|
89398614|NCT04004455||Childhood cancer|Children with an established cancer diagnosis (any type) between 8-18 years old that are currently being treated for cancer (not necessarily hospitalized) in the University Hospital Brussels or Ghent.
89398615|NCT04004455||Healthy controls|Healthy children between 8-12 years old, selected based on age and sex.
89398616|NCT01380847||Renal allograft nephropathy|To evaluate urine from KTRs during the first year post-transplantation to assess whether mRNA levels of genes involved in EMT/fibrogenesis can diagnose and predict CAN, and identify patients at risk of chronic allograft dysfunction
89398617|NCT05224167|Active Comparator|Group A|patients of this group will receive 5 mg of Melatonin 12 hours and 5 mg 2 hours prior to surgery
89398618|NCT05224167|Active Comparator|Group B|patients of this group will receive 1 mg/kg of Hydroxizin 12 hours and 1 mg/ kg 2 hours prior to surgery
89398619|NCT01377259||1Tissue oxygenation change|Spinal anesthesia may result different changes of tissue oxygenation in blocked area ( upper extrimities ) and non-blocked area ( lower extrimities). The changes of tissue oxygenation saturation between upper and lower extremities in patients under spinal anesthesia for orthopedic surgery
89398620|NCT01377259||2Tissue oxygenation change|The changes of tissue oxygenation saturation between upper and lower extremities in patients under spinal anesthesia for cesarean section
89398621|NCT05223933|Experimental|Intervention fokontany|
89398622|NCT05223933|No Intervention|Control fokontany|
89398623|NCT05223777|Active Comparator|KINCISE|The KINCISE™ Surgical Automated System (KINCISE) (DePuy Synthes Products, Inc, Warsaw, IN) was developed to replace the handheld mallet traditionally used in total hip arthroplasty (THA). The device is an FDA-approved medical instrument. As such, the focus of the study does not relate to the safety and efficacy of the device, which has already been established. Instead, the current IRB proposal investigates whether there are long-term benefits to patient outcomes that differ between KINCISE-guided versus mallet THA.
89398624|NCT05223777|Placebo Comparator|Traditional Mallet|A traditional mallet will be used during surgery in this group.
89398625|NCT05409547|Experimental|PEG-G-CSF|6 mg, single dose
89398626|NCT05409547|Active Comparator|rhG-CSF|5 μg/kg, twice a day
89398627|NCT04994535|Experimental|BOTOX|BOTOX will be injected into the platysma muscle on Day 1
89398628|NCT04994535|Placebo Comparator|Placebo|Placebo will be injected into the platysma muscle on Day 1
89398629|NCT03909607|Active Comparator|SDK 0.75 mg/kg|The patients will receive sub-dissociative ketamine at a dose of 0.75mg/k
89398630|NCT03909607|Active Comparator|SDK 1.0 mg/kg|The patients will receive sub-dissociative ketamine at a dose of 1.0mg/k
89188604|NCT02329470|No Intervention|Continue using device, continuous positive airway pressure treatment n=50|Control group, Continue with device, continuous positive airway pressure treatment
88874791|NCT05719506|Experimental|ketamine group 3|"nebulized ketamine (3mg/kg; group K) ,The drugs will be prepared in 0.9% normal saline to a final volume of 3ml. Nebulization will be performed using a wall nebulizer and wall oxygen source on 4 l/min . A Research nurse who will not participate in the evaluation of sedation administered the drugs to all children in nebulizer sessions ∼30 min before transfer to the OR.~Patients will be assessed for sedation score then separated from their parents and the ease of separation will be recorded."
88874792|NCT05717322|Experimental|TENS arm|
88874793|NCT05717322|Active Comparator|non TENS arm|
88874794|NCT05717010||Group self-retaining retractor|Patients used self-retaining retractor for surgery
88874795|NCT05717010||Group Hand-held retractor|Patients used hand held retractor for surgery
88874796|NCT05716776||Group 1 short axial length (AL)|Axial length less than 21
88874797|NCT05716776||Group 2 average axial length (AL)|Axial length 21-24
88874798|NCT05716776||Group 3 long axial length (AL)|Axial length more than 24
89188605|NCT00713882||Observational|
89188606|NCT00713960||1|Patients in secondary prevention of cardiovascular disease in primary care
89188607|NCT02848092|Experimental|FOCAL+Training|
89188608|NCT02848092|Sham Comparator|Rules of the Road Training|
89188609|NCT04070066|Experimental|Digital didactic environment|Students assigned to this group will receive access to a digital didactic environment where they will have at their disposal the exchange transfusion guide and a complete video explaining the indications, the preparation of supplies and the newborn for the procedure, the management of medical devices required and a step-by-step description of the exchange transfusion technique. Finally, the student will see an integrated clinical case. This video will be developed by the neonatology and paediatric medical education teaching team in the simulation laboratory of the university using neonatal high-fidelity simulators, a simulated mother and the necessary medical equipment and supplies.
89188610|NCT04070066|Active Comparator|• Simulated scenario|The educational intervention will be developed with the students, led by the neonatology teacher, in the simulation laboratory. For the training, neonatal high-fidelity simulators, clinical history and paraclinical exams, necessary supplies for the procedure, a simulated mother, a professional nurse and a nursing assistant will be available. Training will take place in individual skill stations (identification of indications, communication, management of medical devices and procedures) and in integrated clinical scenarios.
89188611|NCT00660309|Experimental|Aliskiren|On Day 1 participants received a single oral dose of 25 mg captopril. Starting on Day 2 participants received aliskiren 300 mg tablets orally once a day for 14 days.
89188612|NCT00660309|Active Comparator|Irbesartan|On Day 1 participants received a single oral dose of 25 mg captopril. Starting on Day 2 participants received irbesartan 300 mg tablets orally once a day for 14 days.
89188613|NCT02845518|Experimental|no arms|"All patients included will undergo a cardiac Magnetic Resonance Imaging (cMRI) at the baseline visit (V1), at 3- or 6-month follow up visit (V2 or V3), at 24-month follow up visit and in case of clinical worsening during the first 24-month of follow up.~All patients will complete a questionnaire on the acceptability and tolerability of cMRI and right heart catheterization at V1, V2 or V3 and V9, right heart catheterization being performed as a routine test in pulmonary arterial hypertension.~Depending on patient agreement, 22 ml of peripheral venous blood will be taken at visits V1, V2 or V3 and V9. On one of these 3 visits a blood sample of 5 ml will be taken from the pulmonary artery during the right cardiac catheterization."
89188614|NCT00714038||1|Patients with asthma in primary care
89188615|NCT04925388|Experimental|multiplex PCR|peritoneal samples will be analysed using Unyvero IAI test and using conventional method
89188616|NCT04925388|Other|conventional method|peritoneal samples will be analysed using only conventional method
89188617|NCT04046133|Experimental|pembrolizumab|Patients with locally advanced (stage IIIA/B, T3/T4, any N, M0) anal cancer will receive pembrolizumab, an immune checkpoint inhibitor, concomitantly with standard CRT.
89398631|NCT03909607|Active Comparator|SDK 1.5 mg/kg|The patients will receive sub-dissociative ketamine at a dose of 1.5mg/k
89530226|NCT05045183|Experimental|Treatment C: Antibiotic Ointment|Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist. On the randomized wound site, antibiotic ointment will be applied. This treatment will be applied daily from Day 1 through Day 6 and all wound sites will be uncovered from Day 7 to Day 16 for assessments.
88874799|NCT05716698|No Intervention|Control Group|no Pleurotus citrinopileatus intervention
88874800|NCT05716698|Experimental|D2 10ug Pleurotus citrinopileatus Group|took D2 10ug Pleurotus citrinopileatus per day for a total of 4 weeks.
88874801|NCT05716698|Experimental|D2 100ug Pleurotus citrinopileatus Group|took D2 100ug Pleurotus citrinopileatus per day for a total of 4 weeks.
88874802|NCT05716464|Experimental|Lifestyle medicine intervention (LM)|Participants in the LM group will receive a 6-week group-based lifestyle medicine intervention.
88874803|NCT05716464|Experimental|Cognitive-behavioral therapy for depression (CBT-D)|Participants in the CBT-D group will receive a 6-week group-based cognitive-behavioral therapy for depression.
88874804|NCT05716308|Experimental|intervention group|Continuous nursing intervention was performed on the basis of the control group
88874805|NCT05716308|No Intervention|control group|discharge guidance was performed according to routine nursing intervention at the time of discharge, and the patients were informed to return to the hospital for regular review (review was performed at 1 month, 3 months, half a year, 1 year, and 2 years after discharge, respectively).
88874806|NCT05716152||Psoriasis vulgaris participants|
88874807|NCT05716152||not diseased participants|
88874808|NCT05716074|Experimental|Supervised-exercise group|This group will be given combined low-intensity exercises under the supervision of a physiotherapist.
88874809|NCT05716074|Experimental|Home-exercise group|This group will exercise at home without the supervision of a physiotherapist.
89188618|NCT00794079|Experimental|A|omega-3 fatty acids
89188619|NCT00794079|Placebo Comparator|B|corn oil
89188620|NCT02573714|Experimental|Intranasal Ketamine|Patients allocated to receive intranasal ketamine (intervention) in addition to standard pain therapy. Patients enrolled in this arm will utilize the FPS-R and follow-up PedsQL-SCD.
89398632|NCT02498925|Experimental|Behavioral Activation|"12 weeks (1 50-min session per week) of Behavioral Activation for the anhedonic adolescents.~Behavioral Activation is a psychosocial treatment for depression focused on gradually re-engaging patients with sources of reinforcement and reward in their environment (e.g., increasing activites and interpersonal interactions). In contrast to Cognitive Behavioral Therapy, and as the name implies, Behavioral Activation focuses on behavioral strategies to improve mood and places little emphasis on cognitive restructuring techniques."
88874810|NCT05715840|Experimental|safety run-in Stage(single arm) and Phase 3: SG001+Platinum-based chemotherapy±Bevacizumab|SG001 360 mg, Intravenous infusion, D1, Q3W, up to approximately 2 years ; paclitaxel 175 mg/m^2, Intravenous infusion, D1, Q3W, up to 6 cycles; cisplatin 50 mg/m^2 or carboplatin(AUC=5) , Intravenous infusion, D1, Q3W, up to 6 cycles; with or without bevacizumab 15 mg/kg, Intravenous infusion, D1, Q3W, up to approximately 2 years All treatments will be administered until disease progression or toxicity
89398633|NCT01377181||group A|the patients were accepted laparoscopic purse-string knot closing the internal hernia opening only
89398634|NCT01377181||group B|the patients were accepted the lateral umbilicus ligament covering the internal hernia opening region after the laparoscopic purse-string knot
89398635|NCT05223621||Turner|patients with Turner syndrome
89398636|NCT05223621||POI|patients with primary ovarian failure
89398637|NCT02762084|Experimental|Patidegib gel 2%|Patidegib gel 2%, applied topically, twice daily for 26 weeks
89398638|NCT02762084|Experimental|Patidegib gel 4%|Patidegib gel 4%, applied topically, twice daily for 26 weeks
89398639|NCT02762084|Placebo Comparator|Vehicle gel|Vehicle gel, applied topically, twice daily for 26 weeks
89398640|NCT03902509|Experimental|Pirfenidone|pirfenidone + basic treatment
89398641|NCT03902509|Other|Controll|with basic treatment and without pirfenidone treatment
89398642|NCT02159222|Experimental|Additional physical therapy|
88874811|NCT05715840|Placebo Comparator|Phase 3: Placebo+Platinum-based chemotherapy±Bevacizumab|Placebo, Intravenous infusion, D1, Q3W, up to approximately 2 years ; paclitaxel 175 mg/m^2, Intravenous infusion, D1, Q3W, up to 6 cycles; cisplatin 50 mg/m^2 or carboplatin(AUC=5) , Intravenous infusion, D1, Q3W, up to 6 cycles; with or without bevacizumab 15 mg/kg, Intravenous infusion, D1, Q3W, up to approximately 2 years All treatments will be administered until disease progression or toxicity
89398643|NCT03730844||Critically ill children|Children admitted to the PICU.
88874812|NCT05715762||Ventilation in supine position|Patients are ventilated in supine position.
89398644|NCT03730844||Healthy controls|Healthy controls, not admitted to the PICU, without pre-existing medical conditions.
88874813|NCT05715762||Ventilation in supine position and NO inhalation|Patients are ventilated in supine position with NO inhalation for 1 hour.
88874814|NCT05715762||Ventilation in prone position for 1 hour|Patients are ventilated in prone position for 1 hour.
89398645|NCT01380613|Active Comparator|Workshop Control|Participants receive HIV/STDs risk reduction information.
89398646|NCT01380613|Experimental|Intervention Workshop|Participants learn skills to cope with depressive symptoms and stress as well as safer sex and injection skills.
89398647|NCT02166632|Experimental|Intracapsular Injection|Patients in the experimental group will undergo direct injection of ExparelTM into the knee joint; once the total knee replacement (arthroplasty) has been completed, patients will receive a given amount of ExparelTM administered during surgery into the joint where the knee replacement (arthroplasty) (TKA) was performed.
89398648|NCT02166632|Active Comparator|Periarticular Injection|Patients in this group will undergo local injection of ExparelTM to help to reduce post-surgery pain. Once the total knee replacement (arthroplasty) has been completed, patients in this group will receive a given amount of ExparelTM administered during surgery into the soft tissues around the bone where the knee replacement (arthroplasty) (TKA) was performed.
89398649|NCT03625401|Experimental|AD-35 60 mg|AD-35 60 mg group: 2 AD-35 30 mg tablets and 1 placebo tablet
89398650|NCT03625401|Placebo Comparator|Placebo of AD-35 30 mg|Placebo group: 3 placebo tablets
89398651|NCT02161952|Experimental|Pirfenidone|Pirfenidone 400 mg capsules, orally administered thrice daily to yield a daily dose of 1200 mg during two years.
89398652|NCT02161952|Placebo Comparator|Matched equivalent placebo|Matched equivalent placebo
89398653|NCT03590145||Qatari athletes|Participants meeting general inclusion criteria.
89398654|NCT05202249|Experimental|muscle layer fixation group|
89398655|NCT05202249|No Intervention|conventional skin fixation group|
89398656|NCT04979403|Active Comparator|Usual care in physiotherapy|The usual care group will receive interventions recommended by clinical guidelines: education on the nature of LBP, advice to stay active and to continue usual activities, specific exercise programs combined with orthopedic manual therapy.
89398657|NCT04979403|Experimental|Psychologically-informed physiotherapy intervention|The psychologically-informed physiotherapy group will receive the control intervention enhanced with specific interventions targeting psychosocial factors (e.g., positive reinforcement, mindfulness-based stress reduction, diaphragmatic breathing, graded exposure). Most of these techniques are efficient to mitigate the impact of psychological factors such as anxiety and fear of movement. To standardize the psychologically-informed physiotherapy approach, physiotherapists will receive a two-day training course by a physiotherapist expert with this approach in chronic pain conditions (Alain Gaumond).
89398658|NCT03705039|Active Comparator|Treatment Group|pulsed ultrasound treatment
89398659|NCT03705039|Placebo Comparator|Control Group|sham ultrasound treatment
88874815|NCT05715762||Ventilation in prone position for 2 hours plus NO inhalation for 1 hour|Patients are ventilated in prone position for 1 hour followed by ventilation in prone position with NO inhalation for 1 hour.
88874816|NCT05715762||Ventilation in prone position for 3 hours|Patients are ventilated in prone position for 1 hour followed by ventilation in prone position with NO inhalation for 1 hour. Then they are ventilated in prone position alone for 1 hour.
88874817|NCT05715762||Ventilation in prone position for 16 hours|Patients are ventilated in prone position for 1 hour followed by ventilation in prone position with NO inhalation for 1 hour. Then they are ventilated in prone position alone for 14 hours.
88874818|NCT05715762||Ventilation in re-supine position for 3 hours|Patients are ventilated in supine position for 3 hours followed by ventilation in prone position for 16 hours.
88874819|NCT05715294|Experimental|Music Application Group|After explaining the purpose of the study and the way it was applied to behçet's patients in the music group, Introductory Information Form, Behçet's Syndrome Activity Scale (BSAS), Richards-Campbell Sleep Questionnaire (RCSQ) will be applied. Patients will listen to music composed in Uşşak makam for 50 minutes before going to bed every day for 7 days. After the first interview, the patients will be reminded of the music application by phone call and 2 text messages every day by the researcher. Interviews will be recorded on the Patient's Telephone Follow-up Form while Listening to Music. On the 8th day, the BSAS and RCSQ scales will be reapplied to the patients in the intervention group.
88874820|NCT05715294|No Intervention|Control Group|After explaining the purpose of the study and the way it was applied to behçet's patients in the control group, Introductory Information Form, Behçet's Syndrome Activity Scale (BSAS), Richards-Campbell Sleep Questionnaire (RCSQ) will be applied.No application will be made to the control group. On the 8th day, the BSAS and RCSQ scales will be reapplied to the patients.
88874821|NCT05713734||Patients|Patients with bleeding of unknown cause
88874822|NCT05713734||Controls|Healthy voluntaries without bleeding tendency
89398660|NCT03704961|Experimental|classical music|
89398661|NCT03704961|Experimental|Turkish music|
89398662|NCT03704961|Experimental|audiobook|
89398663|NCT05322447|Other|Control Group|maintenance dose of L- carnitine 6 gm/day to keep normal level (normal L-carnitine level is normal 25-50 mmol/L)
89398664|NCT05322447|Experimental|experimental group|high dose of L- Carnitine 18 gm/day as a continuous intravenous infusion to reach double the normal plasma level.
89398665|NCT03704727|Experimental|probiotic treatment|Probiotic: VSL#3 is a probiotic formula containing a mixture of 9x10^10 CFU/g Lactobacilli strains (Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, and Lactobacillus bulgaricus), 8x10^10 CFU/g Bifidum strains (Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis) and 20x10^10 CFU/g Streptococcus thermophilus. Administred orally
89398666|NCT03704649|No Intervention|Standard nutrition education|The comparison group for the participatory video intervention.
89398667|NCT03704649|Experimental|Participatory nutrition education|Intervention arm integrates participatory video model to standard girls' club sessions to promote nutrition education.
89398668|NCT05278377||Apprenti en Action (intervention group)|"Apprenti en Action consists of six, one-hour culinary workshops offered once a week during school hours."
89398669|NCT05278377||Control group|"Students in the control group do not receive the Apprenti en Action program."
89398670|NCT04050735|Experimental|Alcohol, ethyl, moderate dose|0.6 gram ethyl alcohol per kilogram of body weight
89398671|NCT04050735|Placebo Comparator|Placebo|0 gram ethyl alcohol per kilogram of body weight
89398672|NCT04784559|Experimental|Plitidepsin 1.5 mg arm|Patients will receive plitidepsin 1.5 mg/day intravenous (IV) in addition to dexamethasone on days 1 to 3.
89398673|NCT04784559|Experimental|Plitidepsin 2.5 mg arm|Patients will receive plitidepsin 2.5 mg/day IV in addition to dexamethasone on days 1 to 3.
89398674|NCT04784559|Active Comparator|Control arm|Patients will receive dexamethasone IV on Days 1 to 3. Additionally, in accordance with local treatment guidelines, patients in this group may receive a regulatory-approved antiviral treatment.
89398675|NCT03704571|Experimental|Tailored Group|In the tailored group, high-risk patients are instructed to drink the first 2 L of Polyethylene Glycol (PEG) at 19:00-21:00 hours on the day before colonoscopy at a rate of 250 ml every 15 min. On the day of the procedure, they take another 2 L PEG 4-6 h before colonoscopy. The low-risk patients were given a standard dose of 2 L PEG 4-6 h before colonoscopy.
89188621|NCT02573714|Placebo Comparator|Normal Saline|Patients allocated to receive intranasal normal saline (placebo) in addition to standard pain therapy. Patients enrolled in this arm will utilize the FPS-R and follow-up PedsQL-SCD.
89398676|NCT03704571|Active Comparator|Control Group|In the control group, all the patients drink single dose of 2 l Polyethylene Glycol (PEG) 4-6 h before colonoscopy at a rate of 250 ml every 15 min.
89398677|NCT03704493|No Intervention|Image Group|The patients were looking at a static image of a lavender flower while exercising on the treadmill.
89398678|NCT03704493|Experimental|Video Group|The patients were watching a video of a group of amateur runners while exercising on the treadmill.
89398679|NCT04050657|Experimental|Two-week appointment interval group|Orthodontic patients who come to tighten their braces every 2-weeks.
89398680|NCT04050657|Other|Eight-week appointment interval group|Orthodontic patients who come to tighten their braces every every 8-weeks.
89398681|NCT03704337|Experimental|Commercially Available Food Bar|62 g. Food Bar
89398682|NCT03704337|Placebo Comparator|Placebo|25 g. Dextrose
89398683|NCT04910763|Experimental|Resistance Exercise|Resistance exercise will be training all major muscle groups 2x/week (2 days upper body, 2 days lower body) at 40-50% 1 repetition max (RM; estimated from 10 RM baseline testing) for 3 sets of 10-12 reps. This equals 4x/week for the 3 week intervention period.
89398684|NCT03704181|Experimental|colchicine|colchicine 0,5 milligram tablet by mouth every 12 hours, for 1 year
89398685|NCT03704181|Active Comparator|placebo|"placebo tablet by mouth every 12 hours, for 1 year~pill manufactured to mimic coclchicine 0,5 mg tablet"
89398686|NCT03625011|Placebo Comparator|Placebo Group|Participants will be randomized to either Control Group or Gabapentin Group
89398687|NCT03625011|Active Comparator|Gabapentin Group|Participants will be randomized to either Control Group or Gabapentin Group
89398688|NCT04891965|Experimental|ART24 (Cohort A)|In Cohort A, subjects will receive ART24 or placebo daily for 7 days
89398689|NCT04891965|Placebo Comparator|Placebo (Cohort A)|In Cohort A, subjects will receive ART24 or placebo daily for 7 days
89398690|NCT04891965|Experimental|ART24 (Cohort B)|In Cohort B, subjects will receive ART24 or placebo daily for 28 days
89398691|NCT04891965|Placebo Comparator|Placebo (Cohort B)|In Cohort B, subjects will receive ART24 or placebo daily for 28 days
89398692|NCT03701841||PEG-rhG-CSF primary prophylaxis|Patients receiving chemotherapy who have a overall FN risk >=20% receive PEG-rhG-CSF for primary prophylaxis
89398693|NCT03701841||PEG-rhG-CSF secondary prophylaxis|Patients receiving chemotherapy who had FN or dose-limited neutropenia receive PEG-rhG-CSF for secondary prophylaxis
89398694|NCT03701685|Other|nerve grafting|The stumps of digital nerve are connected with nerve graft
89398695|NCT04775355||Observational (biospecimen collection, questionnaire)|Patients undergo collection of stool and urine samples within 2 weeks before hormone therapy or radiation therapy, after hormone therapy but before start of radiation therapy, and after completion of radiation therapy. Patients also complete a series of questionnaires prior to starting radiation therapy, mid-way through radiation therapy, and after completion of radiation therapy (within 1-3 weeks, at 3 months, and then every 6 months until 3 years from radiation completion). Patients' medical records are also reviewed.
89398696|NCT02763644|Experimental|LFG316 plus SoC|LFG316 plus SoC (excluding plasmapheresis and prohibited treatment)
89398697|NCT02763644|Experimental|All SoC first|Standard of Care then LFG316 plus SoC
89398698|NCT02162030|Other|Full ACT|Acceptance and Commitment Therapy
89398699|NCT02162030|Other|Modified ACT|Acceptance and Commitment Therapy
89398700|NCT03703713||Hyponatremia|Patients treated for hyponatremia (<125 mmol/L Sodium) in the intensive care department.
89398701|NCT04722627|Experimental|AT-752 250 mg single dose|AT-752 administered orally, 250 mg on Day 1
89398702|NCT04722627|Placebo Comparator|Placebo -single dose|Matching placebo administered orally on Day 1
89188622|NCT00794235|Other|Sorafenib and Dacarbacine|
89188623|NCT00800943|Experimental|Campath-1H|
89188624|NCT00714116|Experimental|SBI-087|
89398703|NCT04722627|Experimental|AT-752 500 mg single dose|AT-752 administered orally, 500 mg single doses on Day 1 and Day 7
89398704|NCT04722627|Placebo Comparator|Placebo- single dose|Matching placebo administered orally on Day 1 and Day 7
89398705|NCT04722627|Experimental|AT-752 1000 mg single dose|AT-752 administered orally, 1000 mg single dose on Day 1
89398706|NCT04722627|Placebo Comparator|Placebo - single dose|Matching placebo administered orally on Day 1
89398707|NCT04722627|Experimental|AT-752 1500 mg single dose|AT-752 administered orally, 1500 mg single dose on Day 1
89398708|NCT04722627|Placebo Comparator|Placebo: single dose|Matching placebo administered orally on Day 1
89398709|NCT04722627|Experimental|AT-752 - 1000 mg QD multiple doses|AT-752 - administered orally, 1000 mg once daily (QD) for 7 days
89398710|NCT04722627|Placebo Comparator|Placebo - Administered once daily (QD)|Matching placebo administered orally once daily (QD) for 7 days
89398711|NCT04722627|Experimental|AT-752 - 750 mg twice daily (BID)|AT-752 administered orally, 750 mg twice daily (BID) for 4 days plus one dose on Day 5.
89188625|NCT00801021|Experimental|Frio Oral Rinse|Prescription Mouth Rinse
89188626|NCT00796341|Experimental|1|
89188627|NCT00796341|No Intervention|2|
89398712|NCT04722627|Placebo Comparator|Placebo - Administered twice daily (BID)|Matching placebo administered orally twice daily (BID) for 4 days plus one dose on Day 5.
89398713|NCT04722627|Experimental|AT-752 - 750 mg three times daily (TID)|AT-752 administered orally, 750 mg three times daily (TID) for 4 days plus one dose on Day 5.
89398714|NCT04722627|Placebo Comparator|Placebo - Administered TID|Matching placebo administered orally (TID) for 4 days plus one dose on Day 5.
89398715|NCT04728555|Experimental|Game before RT start|Intervention of a digital game five days before start of RadioTherapy
89398716|NCT04728555|Experimental|Game after RT start|Intervention of a digital game three days after start of RadioTherapy
89398717|NCT03625167|Experimental|Treatment with petrolatum|In each healthy volunteer, one of the two forearms is randomly assigned to the intervention. This forearm is treated with petrolatum for 4 respectively 8 weeks.
89188628|NCT02575664|Experimental|Buprenorphine|Buprenorphine 5 microg/h/7days patch
89188629|NCT02575664|Placebo Comparator|Placebo|Placebo patch
89188630|NCT02554539|Experimental|Obese|Women, aged 21-45 with BMI >30
89188631|NCT02554539|Experimental|Normal weight|Women, aged 21-45 with BMI < 25
89188632|NCT02576522|Experimental|brain metastatic patients|Patients with single, large brain metastases from solid tumors
89188633|NCT00796497|Experimental|ondansetron|
89188634|NCT00714194|Other|1|Patients in the control group will receive continuous sedative infusions without daily interruption of sedatives based on the standard clinical practice of the TICU.
89188635|NCT00714194|Experimental|2|Patients in the intervention group will receive daily interruption of sedative.
89188636|NCT00796575|Experimental|CS-8080|3 mg CS-8080, 10mg CS-8080, 20 mg CS-8080
89188637|NCT00796575|Placebo Comparator|placebo|placebo
89188638|NCT00801177|Experimental|IMC-11F8 (Every week)|Cycle of therapy administered intravenously, once a week for 6 weeks, for a total of six doses per cycle.
89188639|NCT00801177|Experimental|IMC-11F8 (Every other week)|Cycle of therapy administered intravenously, every other week for 6 weeks, for a total of three doses per cycle.
89188640|NCT00581100|Active Comparator|1|etanercept 50 mg SC injection twice weekly for 12 weeks reducing to etanercept 50 mg once weekly to week 24
89188641|NCT00581100|Active Comparator|2|etanercept 50 mg SC once weekly for the complete 24 week treatment period
89188642|NCT02554461||female players|national team players
89188643|NCT02554461||male players|national team players
89188644|NCT00579098|Active Comparator|Atorvastatin|Lipitor (atorvastatin) 80 mg tablet taken once daily by mouth for 90 days
89188645|NCT00579098|Placebo Comparator|Placebo|Placebo (dummy) tablet taken once daily by mouth for 90 days
89188646|NCT00794391|Experimental|Motivational interviewing|Motivational interviewing is a client-centered, directive method for enhancing intrinsic motivation to change by exploring and resolving ambivalence (Miller & Rollnick. 1993). This 45 minutes individual motivational intervention focuses on risky injection practices.
89188647|NCT00794391|Active Comparator|Educational intervention|The educational intervention is a 45 minutes individual intervention based on a document written by the Québec ministry of health (Québec, Canada). The aim is to inform participants about safe injection practices and to show them how to use sterile injection equipment.
89188648|NCT00772109|Experimental|Fluzone Intradermal Vaccine Lot 1|Participants will receive a dose of Influenza intradermal vaccine Lot 1
89188649|NCT00772109|Experimental|Fluzone Intradermal Vaccine Lot 2|Participants will receive a dose of Influenza intradermal vaccine Lot 2
89188650|NCT00772109|Experimental|Fluzone Intradermal Vaccine Lot 3|Participants will receive a dose of Influenza intradermal vaccine Lot 3
89188651|NCT00772109|Active Comparator|Fluzone Intramuscular Vaccine|Participants will receive a dose of influenza intramuscular vaccine
89188652|NCT00801255|Experimental|Cohort A|
89188653|NCT00801255|Experimental|Cohort B|
89188654|NCT00801255|Experimental|Cohort C|
89188655|NCT00801255|Experimental|Cohort D|
89188656|NCT00801255|Experimental|Cohort E|
89188657|NCT00801255|Experimental|Cohort F|
89188658|NCT00801255|Experimental|Cohort G|
89188659|NCT04893590|Experimental|Fatigue self-management SMS intervention|The participants will receive a 12-week fatigue self-management SMS text intervention using mobile phones to target patient activation levels in people with disabilities.
89188660|NCT02577588|Experimental|re-activated T cells|Ten patients with CRC stage UICC IV under routine first line FOLFOX 6/Bevacizumab therapy are planned to receive a singular treatment with an autologous T cell product at a dose of 5x10^7 (first three or six patients) or 5x10^8 (last four or seven patients) cells.
89188661|NCT02554305|Active Comparator|Fusion oxygenation system|Fusion oxygenation machine will be used during the operation.
89188662|NCT02554305|Active Comparator|Affinity oxygenation system|Affinity oxygenation machine will be used during the operation.
89188663|NCT02554305|No Intervention|Peripheral vascular procedure|No oxygenation machine will be used in this group
89188664|NCT02554305|No Intervention|percutaneous coronary intervention|No oxygenation machine will be used in this group
89188665|NCT04069988|No Intervention|Control group|The control group (CG) received routine care and was required to physical activity for thirty minutes
89398718|NCT03625167|No Intervention|Control|The control forearm will remain untreated throughout the study.
89398719|NCT04893759|Experimental|APG-1252|
89398720|NCT04576689|Experimental|Low dose|One (1) IBE-814 IVT Implant (70 μg Dexamethasone) Route of administration: intravitreal injections
89398721|NCT04576689|Experimental|High dose|Two (2) IBE-814 IVT Implant (140 μg Dexamethasone) Route of administration: intravitreal injections
89188666|NCT04069988|Experimental|Baduanjin program|The entire program continued for 6 months (March to October 2016), and the intervention was performed for 60 min 3 times for 12-weeks ; particular attention was paid to the disease characteristics of the patients with chronic schizophrenia and to preventing excessive fatigue. Every session began with a 20-min warm-up, followed by 20 min of Baduanjin program, and ended with a cool-down session. The participants were instructed, with the assistance of a video, to practice Baduanjin program in a group by two authors who are experienced in the psychiatric nurses and had been trained in this program.
89398722|NCT04573491|Experimental|Pharmacogenetic test|Medication review including results from pharmacogenetic testing
89188667|NCT02577666|Experimental|Ecologically-Based Therapy + TAU|receives Ecologically-Based Therapy which includes the Community Reinforcement Approach, Strengths-Based Case Management (6 months) and rental assistance for housing (3 months) + TAU
89188668|NCT02577666|Experimental|Housing Only + TAU|receives 3 months of rental assistance for housing only + TAU
89188669|NCT02577666|Other|treatment as usual (TAU)|receives usual treatments/interventions (TAU) within in the community
89188670|NCT00794625|Experimental|1|During Phase 1, participants will receive a stimulant medication. If they do not respond to the stimulant, they will add valproate and behavioral family counseling to their treatment during Phase 2. If they do not respond to valproate, they will be switched to risperidone.
88874823|NCT05713656||Physiotherapy and bikefit|Physiotherapy care including a bike fit, education and exercises provided by a physiotherapist with a BikePT bronze to gold certification.
88874824|NCT05698758|Experimental|dextrometropine group|Approximately 45 - 60 minutes before cataract surgery, patients in the dextrometropine group were given dextrometropine (1.0μg.kg-1).
88874825|NCT05698758|Placebo Comparator|placebo group|Approximately 45 - 60 minutes before cataract surgery, patients in the placebo group were given 0.9% sodium chloride solution (1.0μg.kg-1).
88874826|NCT05661864|Experimental|Multi-Tiered Systems of Support for Teacher Training Evaluation|Participants will be randomized to a target practice group. The group will receive the multi-tiered systems of support (online instruction, self-monitoring, self-management) for the target practice. They will not receive instruction on the non-target practice until after study data collection concludes.
88874827|NCT05661864|No Intervention|Control|Participants will not receive intervention on the non-target practice until after study data collection concludes. This practice will serve as the comparison for the group who received intervention on the practice.
88874828|NCT05642520|Experimental|oval section abutment of a 2.9mm|"The choice of the diameter to be used as recommended by the manufacter, was determined by the mesiodistal width between the two adjacent natural teeth, in order to maintain at least 1.5mm between the implant and the adjacent tooth. When said the distance was between 5.9 and 6.3 mm, a 2.9 mm implant was placed.~Implant designs are made of a titanium and zirconium alloy (Roxolid®) with a SLActive® surface (Institut Straumann AG, Basel, Switzerland)."
88874829|NCT05642520|Placebo Comparator|circular section abutment in 3.3mm|The choice of the diameter to be used as recommended by the manufacter, was determined by the mesiodistal width between the two adjacent natural teeth, in order to maintain at least 1.5mm between the implant and the adjacent tooth. When said the distance was between 6.4 and 7.1 mm, a 3.3 mm implant was placed. Both implant designs are made of a titanium and zirconium alloy (Roxolid®) with a SLActive® surface (Institut Straumann AG, Basel, Switzerland).
88874830|NCT05598918|Experimental|early passive mobilization|ıt will begin to using an orthosis with 30* flexion of the wrist,70* flexion of metacarpophalangeal (MCP) joints,full extension of IF joints.Home exercises will be performed as passive flexion and active extension exercises with rubber band 10 times per hour on postoperative 3rd day for 3 weeks.Passive flexion and extension exercises will be performed ten times a day;four times a day on MCP+PIP+IF joints.3 weeks after repair and non-resistance active movement and tenodesis exercises will be started in presence of a physiotherapist.From the 6th week tendon gliding exercises and blocking exercises will be started.
88874831|NCT05598918|Experimental|early active mobilization|ıt will begin to using an orthosis that positions wrist in neutral position,MCP joints 50*-70* flexion,IF joints in full extension.After flexion active extension exercises,full passive flexion of fingers with the other intact hand and then keeping fingers in flexion position for 3-5 sec for 3 weeks.Rehabilitation program applied from 3rd week is the same as the passive group:3 weeks after repair and non-resistance active movement and tenodesis exercises will be started in presence of a physiotherapist.From the 6th week tendon gliding exercises and blocking exercises will be started.
89188671|NCT00794625|Experimental|2|During Phase 1, participants will receive a stimulant medication. If they do not respond to the stimulant, they will add risperidone and behavioral family counseling to their treatment during Phase 2. If they do not respond to risperidone, they will switch to valproate.
89188672|NCT00794625|Placebo Comparator|3|During Phase 1, participants will receive a stimulant medication. If they do not respond to the stimulant, they will add placebo and behavioral family counseling to their treatment during Phase 2.
89188673|NCT00714350||Simulator Group - With Display|ICU nurses who viewed the new ICU display visualization
89188674|NCT00714350||Simulator Group - Without Display|"ICU nurses who did not view the new ICU display visualization, but instead viewed a traditional spreadsheet style presentation of ICU trends of data"
89188675|NCT02577432|Active Comparator|(S) separate.|fentanyl and hyperbaric bupivacaine (sequentially)
89188676|NCT02577432|Active Comparator|(M) mixed|fentanyl and hyperbaric bupivacaine.(mixed)
89188677|NCT00714428||Group 1: Item Development|Individuals with TBI to provide input to relevant questions for quality of life measure in TBI
89188678|NCT00714428||Group 2: Item Development|Clinicians who treat those with deployment related TBI to obtain their feedback on relevant questions pertaining to quality of life measures in TBI.
89188679|NCT00714428||Group 3: Instrument Development|Individuals with deployment TBI who will complete the Beta version of the TBI QOL measure.
89188680|NCT02577276|Experimental|Tele-motion rehabilitation system|Clinicians remotely monitor subjects' motor performance using Microsoft Kinect 3D sensor tracking system in their home to record their upper limb and trunk movements as they participate in a variety of functional tasks and motor activities, which are directed by their interaction with a monitor screen in their home using uniquely adapted software to integrate key rehabilitation intervention principles.
89188681|NCT00794703|Experimental|1. Micafungin|
89188682|NCT00794703|Active Comparator|2. Itraconazole|
89188683|NCT02575430||Subjects with IRD|IRD phenotypically diagnosed as Leber congenital amaurosis (LCA) or retinitis pigmentosa (RP) caused by RPE65 or LRAT gene mutations.
89188684|NCT00772031|Active Comparator|1|Participants will receive propranolol and topiramate.
89188685|NCT00772031|Placebo Comparator|2|Participants will receive a placebo and topiramate.
89188686|NCT00796809||Biologics|Patients receiving TNF inhibitors or biologic agents
89188687|NCT00796809||DMARD|Patients receiving methotrexate without any biologic
89188688|NCT02576262||HPV-positive women，30-65 years of age|
89398723|NCT03701607||PD-L1|
89398724|NCT04718727|Placebo Comparator|Group 1|patients will receive oral placebo tablets one hour preoperatively
89398725|NCT04718727|Active Comparator|Group 2|patients will receive oral 5 mg Olanzapine tablets one hour preoperatively
88874832|NCT05582226|Experimental|ACL reconstruction utilizing stump-derived mesenchymal stem cells|This is the test group of this study. These participants will receive the augmented ACL reconstruction treatment involving extraction and injection of mesenchymal stem cells. Stem cell tissue will be harvested from each participant using the GraftNet device intraoperatively. During the intra-articular preparation phase of the reconstruction, the stem cell tissue will be applied to the ACL graft using a bovine collagen matrix.
89398726|NCT04718727|Active Comparator|Group 3|patients will receive oral 10 mg Olanzapine tablets one hour preoperatively
89398727|NCT03703557|Experimental|Sorbstar®|Odour sampling: Rub hands with Sorbstar® before and post-surgery
89398728|NCT03703557|Experimental|Dog detection|Odour sampling: Sleep over a night with a compress on the affected breast before and after surgery
89398729|NCT03703479|Experimental|A-PRF group|Socket site that will receive A-PRF clot
89398730|NCT03703479|No Intervention|control|socket site that will not receive any intervention
89398731|NCT03701529|Experimental|Sevoflurane|1.5-2.5 vol% of sevoflurane is used for maintenance of anesthesia.
89398732|NCT03701529|Active Comparator|Propofol|2-5 mcg/ml of propofol is used continuously for maintenance of anesthesia using target-controlled infusion system.
89398733|NCT04050891|No Intervention|group GA (general anesthesia)|"After pre-oxygenation general anesthesia was induced using 2mg/kg propofol, 1μg/kg of fentanyl. After loss of consciousness 0.5 mg/kg of atracurium was injected. The endotracheal tube (ETT) was placed and inflated. The patient was mechanically ventilated to adjust end tidal CO2 between 35 and 40mmHg, anesthesia was maintained using 1.2 % isoflurane diluted in 3L of 50 % oxygen mixed with air. Increments of fentanyl (0.5 μg/kg ) and atracurium 10 mg were used whenever required and the hemodynamic values were maintained within 20% of the basal values.~At the end of surgery, residual muscle relaxant was reversed with 50µg/kg neostigmine and 0.02 mg/kg atropine."
89398734|NCT04050891|Active Comparator|group RA (regional anesthesia)|received combined supraclavicular and interscalene block.The mixture of anesthetic suolution was prepared by 20 ml isobaric bupivacaine 0.5% plus 10ml lidocaine 2% plus 10ml normal saline, total volume was 40ml which is devided into 25ml for suraclavicular block and 15ml for intersalene block
89398735|NCT04553133|Experimental|PF-07104091|CDK2 monotherapy dose escalation
89398736|NCT04553133|Experimental|PF-07104091 + palbociclib + fulvestrant|CDK2 + palbociclib + fulvestrant
89398737|NCT04553133|Experimental|PF-07104091 + palbociclib + letrozole|CDK2 + palbociclib + letrozole
89398738|NCT04553133|Experimental|PF-07104091 monotherapy dose expansion (SCLC)|PF-07104091 monotherapy dose expansion (SCLC)
89398739|NCT04553133|Experimental|PF-07104091 monotherapy dose expansion (ovarian)|PF-07104091 monotherapy dose expansion (ovarian)
89398740|NCT04553133|Experimental|PF-07104091 + fulvestrant (post CDK4/6) dose expansion|PF-07104091 + fulvestrant (post CDK4/6) dose expansion
88874833|NCT05582226|Other|Standard of care ACL reconstructive surgery|This is the control group of this study. These participants will receive standard ACL reconstructive surgery without any augmentations.
88874834|NCT05557812|Experimental|non-eugenol based ZOE and Ferric Sulfate|non-eugenol based ZOE and Ferric Sulfate in primary molar pulpotomy procedures.
88874835|NCT05557812|Experimental|eugenol based zinc oxide and Ferric Sulfate|eugenol based zinc oxide and Ferric Sulfate in primary molars pulpotomies procedures.
88874836|NCT05549466|Experimental|Apatinib plus Camrelizumab and Chemotherapy|
88874837|NCT05549466|Experimental|Apatinib plus Camrelizumab|
88874838|NCT05549466|Experimental|Camrelizumab and Chemotherapy|
88874839|NCT05549466|Active Comparator|Chemotherapy|
89398741|NCT04553133|Experimental|PF-07104091 + fulvestrant (post CDK 4/6) dose escalation|CDK2+ fulvestrant (post CDK 4/6) dose escalation
89398742|NCT03703245||Experimental Dentifrice|Participants were advised to brush their teeth twice daily with a full strip of experimental dentifrice containing 67% w/w sodium bicarbonate in 3 studies and additionally 62% w/w sodium bicarbonate in 3 studies covering the entire head of the toothbrush for 1 minute.
89398743|NCT03703245||Control Dentifrice|Participants were advised to brush their teeth with control dentifrice containing 0% w/w sodium bicarbonate covering the entire head of the toothbrush for 1 minute.
89398744|NCT03701451|Experimental|decitabin and cisplatin induced chemotherapy followed by CC|Treated by demethylated drug decitabine injection combined with cisplatin induced chemotherapy followed by concurrent chemoradiotherapy
89398745|NCT04703985||Patients under the protocol of Enteral Nutrition|Patients put under the protocol of Enteral Nutrition adapted to the conditioning autograft (BEAM or Melphalan 200)
89398746|NCT03703089|Experimental|Gemcitabine and Nab-Paclitaxel|Participants received albumin-bound paclitaxel 125 mg/m^2 followed by gemcitabine 1000 mg/m^2 by intravenous infusion (IV) on Days 1, 8 and 15 of each 28 day cycle.
89398747|NCT03703011|Experimental|Interventional|Subjects aged >70 years, hospitalized in the rehabilitation geriatric ward in the Paul Brousse hospital, France, able to walk 10 meters, ready to be discharged, and a Mini mental state examination ≥ 20/30
89398748|NCT03701373|Experimental|S-1 maintenance group|S-1 maintenance
89398749|NCT03701373|Other|Observation group|Observation without anti-tumor treatment
89398750|NCT03702933||Placebo|starch
89398751|NCT03702933||High Dose|3.5 g/d D-serine adjuvant treatment
89398752|NCT03702933||Low Dose|2.1 g/d D-serine adjuvant treatment
89398753|NCT02807844|Experimental|Ph Ib: MCS110 1 mg/kg Q3W + PDR001 100 mg Q3W|Phase Ib: MCS110 1 mg/kg every 3 weeks (Q3W) + PDR001 100 mg Q3W
89398754|NCT02807844|Experimental|Ph Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W|Phase Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W
89398755|NCT02807844|Experimental|Ph Ib: MCS110 3 mg/kg Q3W + PDR001 300 mg Q3W|Phase Ib: MCS110 3 mg/kg Q3W + PDR001 300 mg Q3W
88874840|NCT05544318|Experimental|Intervention|Extra nutritional support
89398756|NCT02807844|Experimental|Ph Ib: MCS110 5 mg/kg Q3W + PDR001 300 mg Q3W|Phase Ib: MCS110 5 mg/kg Q3W + PDR001 300 mg Q3W
89398757|NCT02807844|Experimental|Ph Ib: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W|Phase Ib: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W
89398758|NCT02807844|Experimental|Ph Ib: MCS110 10 mg/kg Q3W + PDR001 300 mg Q3W|Phase Ib: MCS110 10 mg/kg Q3W + PDR001 300 mg Q3W
89398759|NCT02807844|Experimental|Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - TNBC|Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Triple negative breast cancer (TNBC)
89398760|NCT02807844|Experimental|Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - PC|Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Pancreatic cancer (PC)
89398761|NCT02807844|Experimental|Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - EC|Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Endometrial cancer (EC)
89398762|NCT02807844|Experimental|Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - ME|Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Melanoma (ME)
89398763|NCT03702855|Experimental|Tetrabenazine Tablets|Tetrabenazine Tablets 25 mg of Dr. Reddy's Laboratories Limited
89398764|NCT03702855|Active Comparator|Xenazine|Xenazine Tablets 25 mg of Lundbeck Inc.
89398765|NCT04542681|Placebo Comparator|Placebo - 1st Cycle|Subjects will receive a single SQ injection of placebo (0.9% normal saline) (n=10)
89398766|NCT04542681|Active Comparator|MANP - 1st Cycle|Subjects will receive a single SQ injection of 2.5 μg/kg MANP (n=10)
89398767|NCT04542681|Active Comparator|MANP - 2nd Cycle|Subjects will receive a single SQ injection of 5 μg/Kg MANP (n=10)
89398768|NCT02052180|Experimental|Exparel|EXPAREL arm: one vial (266 mg/20 mL) of EXPAREL (Bupivicaine Extended-Release Liposome, 13.3mg/ml), undiluted, will be administered for each of the specified procedures.
89398769|NCT02052180|Active Comparator|Control|15 cc of Marcaine 0.5% (Bupivacaine 0.5%, 5mg/ml) will be administered into the wrist per the Surgeon's Standard practice.
89398770|NCT03561402||Patients with active disease|From the cohort of patients receiving teriflunomide - 1 tablet (14 mg) daily, the investigators will identify patients that have active disease..
89398771|NCT03561402||Patients with stable disease|From the cohort of patients receiving teriflunomide (as above), the investigators will identify patients that have stable disease.
88874841|NCT05544318|No Intervention|Control|Usual care
88874842|NCT05540652|Experimental|Mindfulness-Based Queer Resilience (MBQR)|This is a single arm trial testing an internet delivered mindfulness-based intervention. All enrolled participants will receive the study intervention.
89398772|NCT02053428|Active Comparator|Gastrostomy - pull technique|Percutaneous image-guided gastrostomy using large-bore mushroom-retained catheters via the pull technique
89398773|NCT02053428|Active Comparator|Gastrostomy - push technique|Percutaneous image-guided gastrostomy using small-bore cope loop catheters via the push technique
89398774|NCT02166710|Experimental|Adductor canal femoral nerve blockade|Patients will receive continuous adductor canal femoral nerve blockade for 48 hours with a catheter connected to a pump infusing bupivacaine 0.125% and multi-modal analgesia for pain management following total knee arthroplasty. Knee extensor muscle strength will be measured at different time-points prior and after surgery.
89398775|NCT02166710|Placebo Comparator|Simulated nerve blockade|Patients will receive a simulated continuous femoral nerve block at the level of the adductor canal for 48 hours with a catheter connected to a pump infusing bupivacaine 0.125% and multi-modal analgesia for pain management following total knee arthroplasty. Knee extensor muscle strength will be measured at different time-points prior and after surgery.
89398776|NCT02053506|Experimental|Immune-enhancing nutritional beverage|This group will consume an immune-enhancing beverage and additional protein (1.2-1.5 grams•kg-1 body weight•day-1 versus the RDA of 0.8 grams•kg-1 body weight•day-1) during and after the period of sleep restriction to determine if this nutritional approach attenuate the loss of immune responsiveness.
89398777|NCT02053506|Experimental|Probiotics (BB-12)|This group will consume probiotics (BBB12) during and after the period of sleep restriction to determine if nutritional approaches attenuate the loss of immune responsiveness. Consistent with the control group, this group will consume the RDA for protein (0.8 grams•kg-1 body weight•day-1) and placebo beverage (no immune-enhancing vitamins/minerals).
89398778|NCT02763254|Experimental|baltaleucel-T|Treatment consist of up to 5 doses of 2x10E7 cells/m2 administered intravenously every 2 weeks.
89188689|NCT00801411|Experimental|Arm I|Patients receive cyclophosphamide IV and docetaxel IV over 1 hour on day 1.
88874843|NCT05520450||Intervention group|Recruitment will be based on consecutive patients receiving regular home care in the ATDOM Programme by the Primary Care Team, with prior informed consent.
88874844|NCT05517252|Experimental|Tele-Yoga Group|OSAS patients in the Tele-Yoga group will be taken to group-based Hathastyle Tele-Yoga sessions of 60 minutes three times a week for 12 weeks, simultaneously in groups of 4-5 people, in an internet-based telerehabilitation environment.
88874845|NCT05517252|Experimental|Control Group|OSAS patients in the control group will be taught unilateral basal and apical chest expansion exercises in the first session and will be followed as a home program. 3-4 thoracic extension exercises and 1-2 breathing control will be repeated 10 times. The patient will be asked to do the home program four times a day and keep a diary for the home program.
88874846|NCT05508360|Experimental|Lumbar Disc Nucleus Replacement|All patients meeting all inclusion criteria and no exclusion criteria will be considered for nucleus replacement surgery following a review by the Medical Advisory Board.
88874847|NCT05505162|Experimental|Zibotentan and EE/LNG|"Participants will receive two tablets of combined oral EE/LNG on Day 1 with PK samples obtained from pre-dose on Day 1 until post-dose on Day 6.~Participants will receive two capsules of zibotentan orally QD from Day 6 to Day 14. From Day 15 until Day 19 participants will continue to receive two capsules of zibotentan QD administered orally.~On Day 15, participants will receive two tablets of combined oral EE and LNG with PK samples obtained pre-dose on Day 15 until post-dose (Day 20)."
88874848|NCT05504304|Active Comparator|Group A: open reduction and internal fixation plus primary subtalar arthrodesis.|they will be scheduled to surgery after resolution of the edema and appearance of wrinkle sign. Lateral position and lateral extensile approach will be used. A 4 mm schanz will be inserted in the calcaneal tuberosity from lateral side to control varus and to restore calcaneal height. Lateral wall of the calcaneus will be lifted keeping it attached inferiorly. Articular surfaces of inferior surface of the talus and posterior facet of the calcaneus will be debrided thoroughly and drilled by 2 mm k-wire. tricortical iliac bone autograft will be inserted the subtalar joint. A lateral nonlocked plate will be applied to reduce the lateral wall blow out and broadening then fixation by two cannulated partially threaded 7.3 screws from the calcaneal tuberosity to the talus. We will check position by fluoroscopy then closure in two layers (subcutaneous and skin) after homeostasis. Below knee slab will be applied and non-weight bearing for six weeks.
88874849|NCT05504304|Active Comparator|Group B: conservative management then calcaneoplasty and subtalar arthrodesis.|they will be assessed upon 1st clinic visit. After at least three months patients will be scheduled for subtalar arthrodesis. A new preoperative ankle CT scan will be done. Lateral position and lateral extensile approach will be used. Lateral wall and plantar exostosis will be resected. Articular surfaces of inferior surface of the talus and posterior facet of the calcaneus will be debrided thoroughly and drilled by 2 mm k-wire. Hind foot deformity (mostly varus) will be corrected through the subtalar joint manually and checked clinically. Loss of calcaneal height will be corrected by tricortical iliac bone autograft to distract the subtalar joint then fixation by two cannulated partially threaded 7.3 screws from the calcaneal tuberosity to the talus. We will check position by fluoroscopy then closure in two layers (subcutaneous and skin) after homeostasis. Below knee slab will be applied and non-weight bearing for six weeks.
88874850|NCT05473572|Experimental|Children who stutter|Measuring stuttering severity and cortical auditory evoked potentials in a group of children who stutter then they will receive fluency shaping exercises for a period range from 2-4 months. Reassessment of cortical auditory evoked potentials and stuttering severity after the specified period
88874851|NCT05473572|No Intervention|children who do not stutter|Measuring cortical auditory evoked potentials as a comparison group
88874852|NCT05436678|Active Comparator|PrimeC|2 PrimeC tablets (total single dose 748 mg) twice daily for 6.5 days following a meal
88874853|NCT05436678|Active Comparator|Marketed ciprofloxacin and celecoxib|750 mg of ciprofloxacin and 200 mg of celecoxib, co-administered twice daily for 6.5 days following a meal
88874854|NCT05426772|Other|Healthy sedentary people|Muscle oxygenation and vital signs will be measured before, during, and after of 20 minutes aerobic exercise in an environment where suitable conditions are provided. After 3 days, kinesio taping will be added to the same program and the measurements will be repeated.
88874855|NCT05405010|Placebo Comparator|Control|Participants remain seated for 1 hour
88874856|NCT05405010|Experimental|1 min|Participants remain seated for 1 hour except for 1 minute of stair climbing and descending
88874857|NCT05405010|Experimental|3 min|Participants remain seated for 1 hour except for 3 minute of stair climbing and descending
88874858|NCT05403060|Experimental|Intervention|Educational nutritional intervention, based on the Social Cognitive Theory
88874859|NCT05403060|No Intervention|Control|Regular school education, without educational nutritional intervention
88874860|NCT05352282|Active Comparator|Group A|
88874861|NCT05352282|Active Comparator|Group B|
88874862|NCT05343624|Other|CGM Arm|continuous glucose meter is placed on the abdomen
88874863|NCT05333328|Experimental|OFS with endocrine|Among ER+HER2- premenopausal patients with N1 who undergoes primary breast surgery, the patients with a genomic low risk using the multigene-assay (OncoFREE®) will be included in this arm.
88874864|NCT05322330|Experimental|XPO-1 Inhibitor+CAR-T Cells|XPO-1 Inhibitor plus CAR-T Cells
88874865|NCT05319990||PANDA, T1D|New participants with T1D will be enrolled at the University of Colorado and University of Washington.
88874866|NCT05319990||PANDA Sub Study, Former CROCODILE Participants|Participants will be enrolled from the existing CROCODILE study (COMIRB # 19-1282), adding longitudinal follow-up to completed kidney biopsies and baseline data and biosample acquisition.
88874867|NCT05720754|Experimental|DQS+HEM|Participants in the DQS+ group used DQS 1 drop 3 times/per day with heated eye mask for 2 weeks
88874868|NCT05720754|Active Comparator|DQS|Participants in the DQS group used DQS 1 drop 3 times/per day for 2 weeks
88874869|NCT05720754|Active Comparator|HEM|Participants in the HEM group used heated eye mask 3 times/per day for 2 weeks
88874870|NCT05311020|Placebo Comparator|Placebo drink|
88874871|NCT05311020|Experimental|Pitaya Ovule Extract Drink|
88874872|NCT05301504|Experimental|Group 1|n=6 participants vaccinated with a single dose of ChAdOx1 biEBOV 5×10^9 vp
88874873|NCT05301504|Experimental|Group 2|"n=6 participants vaccinated with a single dose of ChAdOx1 biEBOV 2.5×10^10 vp~Note: The DSMB may recommend increasing the size of group 2 to n=9 in the event of higher than expected reactogenicity"
88874874|NCT05301504|Experimental|Group 3|n=11 participants vaccinated with a single dose of ChAdOx1 biEBOV 5×10^10 vp
88874875|NCT05301504|Experimental|Group 4|"n=25 participants vaccinated with a two doses of ChAdOx1 biEBOV at the final selected dose, based on safety data for groups1-3. The second dose is administered after 12 weeks.~Note:The dose for group 4 will be selected following a review of safety data to 28 days post vaccination for all previous participants (groups 1 to 3"
88874876|NCT05286684|Experimental|Study process|Consultation, Cerebral and medullary MRI, lumbar puncture, CSF sampling, blood sample, collection of breast fluid
88874877|NCT05251038|Experimental|Experimental Group|"Patients will either receive a combination of:~Sotorasib + Liposomal Irinotecan (nal-IRI) + 5 Fluorouracil (5FU) + Leucovorin (LV)~OR~Sotorasib + Gemcitabine (GEM) + Nab-paclitaxel~*The combination of therapy received is based on the participants prior therapy and of the discretion of their treating physician"
88874878|NCT05244096||COVID+|COVID + positive individuals from March 15 2020 to Nov 30, 2021
88874879|NCT05239338||PREFACE: Vanderbilt-Ingram Cancer Center|Patient recruitment and follow-up, longitudinal collection of data and multiple biospecimen at pre-defined study timepoints, objective assessment of health behaviors/habits, individual interviews.
88874880|NCT05220306|Experimental|Device Arm|Participants will use the MouthLab device for monitoring their vital signs
88874881|NCT05203692|Experimental|DS-7011a|"Stage 1: Healthy participants who will be randomized to receive a single intravenous (IV) ascending dose of DS-7011a (starting dose 0.1 mg/kg).~Stage 2: Healthy participants who will be randomized to receive a single subcutaneous (SC) ascending dose of DS-7011a (starting dose will be centered around estimated therapeutic dose confirmed in Stage 1).~Stage 3: Healthy Japanese participants who will be randomized to receive an IV dose of DS-7011a (based on estimated therapeutic dose confirmed in Stage 1)."
88874882|NCT05203692|Placebo Comparator|Placebo|Healthy participants who will be randomized to receive a single dose of placebo.
88874883|NCT05195502||Screening colonoscopy patients|Patients referred for out-patient colonoscopy in the Danish Colorectal Screening program
89188690|NCT00801411|Active Comparator|Arm II|Patients receive cyclophosphamide IV and doxorubicin hydrochloride IV on day 1.
88874887|NCT05173428|Experimental|Interventional Gruop|Online motivational interviews based on the transtheoretic model with the intervention group will be held via zoom. Data collection forms will be applied to the intervention group at the first interview, at the 3rd month as an interim monitoring, and at the 6th month as the final monitoring.
88874888|NCT05173428|No Intervention|Control Gruop|No intervention will be made to the control group, and data collection forms will be applied at the first interview and 6 months after the first interview.
88874889|NCT05166018|Experimental|SuMO Patient|"92 data will be collected during the patient care episode. Among the 92 criteria, 63 are pre-operative, 29 are post-operative in order to provide an evolutionary prediction during the management of the patient.~Post-operative follow-up criteria making it possible to establish the scalability or non-scalability of the quality of life after the surgical procedure.~The results will be compared to the prediction proposed by the machine learning algorithm."
88874890|NCT05151822|Experimental|Virtual reality mask|"Realization of the following examinations with virtual reality mask :~Training session~Acceptability of the device before and after surgery~Monitoring of the device during surgery"
88874891|NCT05132478|Active Comparator|Standard Video|A video simulation of a patient-surgeon discussion about treatment options for low-risk thyroid cancer WITHOUT emotionally supportive statements
88874892|NCT05132478|Experimental|Emotionally Supportive Video|A video simulation of a patient-surgeon discussion about treatment options for low-risk thyroid cancer WITH emotionally supportive statements
88874893|NCT05117970|Experimental|Intervention|Patients randomized to intervention will have access to the screening tool.
88874894|NCT05117970|No Intervention|Control|Patients randomized to control will continue routine practice.
88874895|NCT05103540|Experimental|Intervention|Comprehensive theory-based suicide behavior program
88874896|NCT05103540|No Intervention|Control|No intervention will be given to the group
88874897|NCT05101044|Experimental|Acceptance-based Behavioral Therapy (ABBT) Intervention|All recruited individuals will receive ABBT intervention. ABBT involves 2 sessions delivered within about a week of each other, consisting of a 20-25 minute session 1, and a 10 minute session 2.
88874898|NCT05071872||Rotarex®S|Treatment performed with Rotarex®S
88874899|NCT05071872||Aspirex®S|Treatment performed with Aspirex®S
89398779|NCT02053662||Bladder Cancer Patients|Patients with muscle invasive bladder cancer. A sample collection of donated cancer and normal adjacent tissues, blood and urine which will be prospectively obtained from patients through the Tissue Procurement Shared Resources (TPSR) and The Ohio State University Comprehensive Cancer Center Biospecimen and Biorepository Resource (BBR) as needed.
89398780|NCT02166866||Experimental arm|
88874903|NCT05027646|Experimental|Part 1 - Bioequivalence|Bioequivalence will be measured in approximately 42 healthy male and female subjects at a single center in the US to achieve at least 33 completers.
88874904|NCT05027646|Experimental|Part 2 - Adhesion|Adhesion will be measured in approximately 90 healthy male and female subjects are planned to be enrolled at a single center in the US.
89188691|NCT02579148|Experimental|HUCMSC injection|once intracavernous injection of 15,000,000 Human Umbilical Cord Mesenchymal Stem Cells
89188692|NCT02579148|Experimental|collagen scaffolds/HUCMSC injection|once intracavernous injection of collagen scaffolds loaded with 15,000,000 Human Umbilical Cord Mesenchymal Stem Cells
89188693|NCT04577066|Experimental|Group 1 (GA2)|Volunteers will be exposed to GA2-infected mosquito bites.
89188694|NCT04577066|Active Comparator|Group 2 (GA1)|Volunteers will be exposed to the GA1-infected mosquito bites.
89188695|NCT04577066|Placebo Comparator|Group 3 (Placebo)|Volunteers will be exposed to uninfected mosquito bites.
88874905|NCT05006976|Active Comparator|NSAC health only|Treatment as usual (TAU) at NSAC, following a digital survey of health problems and the provision of a condensed report of this survey to clinician prior to consultation.
88874906|NCT05006976|Experimental|NSAC health + MBW|Treatment as usual (TAU) at NSAC, following a digital survey of health problems as well as Motivation, Barriers for return to work and Work environment (MBW), and the provision of a condensed report of this survey to clinician prior to consultation.
88874907|NCT04988646|Experimental|Acyclovir Tablet|Participants received Acyclovir Tablet 200 mg or 400 mg with 240 mL of water
88874908|NCT04988646|Active Comparator|Zovirax® Tablet|Participants received Zovirax® Tablet 200 mg or 2x200 mg with 240 mL of water
88874909|NCT04905264||Adults admitted in participating Rehabilitation Units for Severe Acquired Brain Injuries|Adults admitted in study's participants Rehabilitation Units for Severe Acquired Brain Injuries from the 1st of July 2021 to the 31st of December 2023. Patients entered into these units more than 14 weeks after the acute event are excluded
88874910|NCT04854798|Experimental|Ultrasound Group|Daily ultrasound application to the spleen of approximately 18 minutes for up to 7 days, in addition to standard clinical care.
88874911|NCT04854798|No Intervention|Control Group|Control Group
88874912|NCT04764318||Remote patient monitoring for hypertension|All intervention practices will receive communication by email explaining RPM procedures, ordering, use, and financial implications. We will also present this information at practice meetings. Primary care clinicians at these sites will receive clinical decision support (Epic Best Practice Alert) for patients meeting primary or secondary eligibility criteria. It will be at the discretion of the primary care clinicians when to offer or refer patients to RPM.
88874913|NCT04764318||Remote patient monitoring with care management|All intervention practices will receive communication by email explaining RPM procedures, ordering, use, and financial implications. We will also present this information at practice meetings. Primary care clinicians at these sites will receive clinical decision support (Epic Best Practice Alert) for patients meeting primary or secondary eligibility criteria. It will be at the discretion of the primary care clinicians when to offer or refer patients to RPM. In addition, PCPs will receive lists of candidate patients. Care managers will assist with the outreach to patients to offer RPM when recommended by the PCP, will monitor and support patient use of the remote monitor, and will promote action on the part of the patient or PCP when uncontrolled hypertension is present.
88874914|NCT04764318||Usual care|Medicare patients from non-intervention primary care practices in Northwestern Medical Group will contribute EHR data but will not have any new procedures put in place.
88874915|NCT04754334|Placebo Comparator|Placebo|placebo dosed QD
89398781|NCT03624855||Description of BJI due to Pseudomonas aeruginosa|patients having bone and joint infection on implant due to Pseudomonas aeruginosa
88874916|NCT04754334|Experimental|ORMD-0801|ORMD-0801 8 mg QD
89188696|NCT00714506|Experimental|Intervention|lifestyle weight reduction - low fat eating, low calorie and physical activity
89398782|NCT02805972|Experimental|Naloxone, then Placebo|4 mg / 0.1 ml Naloxone at visit 1, followed by 0.1 ml saline (Placebo) at visit 2 (with a washout period in between the two visits)
89398783|NCT02805972|Experimental|Placebo, then Naloxone|0.1 ml saline (Placebo) at visit 1, followed by 4 mg / 0.1 ml Naloxone at visit 2 (with a washout period in between the two visits)
89398784|NCT03702699||KOA group|Patients in this group will receive auricular point detection which is accomplished by the novel auricular point detector device. There is no addition to the patient's routine care.
89398785|NCT03702699||Control group|This group includes healthy subject, for whom no treatment will be performed. Only auricular point detection by the auricular point detector will be conducted.
89398786|NCT03032523|Experimental|Remote Monitoring CGM Group|Participants wear a CGM that is blinded at bedside (to participant and clinical staff) but remotely monitored by study staff. If a blood sugar less than 46 mg/dl occurs, the study staff receive a notification and ask the clinical staff to perform a confirmation standard of care glucose test.
89398787|NCT03032523|No Intervention|Blinded CGM Group|Participants wear a blinded CGM during the study period. Values are blinded to study staff, participant, and clinical staff.
89398788|NCT05661084|Experimental|tACS(AG) + tDCS(PFC) combo active|Participants (Ps) will undergo 20min of daily home-based tACS active + tDCS active intervention over the left angular gyrus and prefrontal cortex for 4 weeks by their trained caregiver/administrators (As).
89398789|NCT05661084|Active Comparator|tACS(AG) active + tDCS(PFC) sham|Participants (Ps) will undergo 20min of daily home-based tACS active + tDCS sham intervention over the left angular gyrus and prefrontal cortex for 4 weeks by their trained caregiver/administrators (As).
89398790|NCT05661084|Active Comparator|tACS(AG) sham + tDCS(PFC) active|Participants (Ps) will undergo 20min of daily home-based tACS sham + tDCS active intervention over the left angular gyrus and prefrontal cortex for 4 weeks by their trained caregiver/administrators (As).
89398791|NCT05661084|Sham Comparator|tACS(AG) sham + tDCS(PFC) sham|Participants (Ps) will undergo 20min of daily home-based tACS sham + tDCS sham intervention over the left angular gyrus and prefrontal cortex for 4 weeks by their trained caregiver/administrators (As).
89398792|NCT03701217|Experimental|Eltrombopag treatment|Eltrombopag 25mg bid, starts from the day when platelet count decreases lower than 30×10'9/L, and the treatment lasts for at least 5 days, and stops until platelet count goes up to more than 30×10'9/L, after consolidation therapy in AML patents. Platelet transfusion application is routinely done when platelet count is lower than 20×10'9/L or active hemorrage happens to patients.
89398793|NCT03701217|Active Comparator|Eltrombopag free|Eltrombopag treatment is not performed in this group. Platelet transfusion application is routinely done when platelet count is lower than 20×10'9/L or active hemorrage happens to patients.
89398794|NCT02052258|Experimental|oxytocin|
89398795|NCT03701139|Experimental|posterior capsulotomy|Primary posterior capsulotomy will be performed to remove the primary posterior capsule opacification after posterior capsule polishing during phacoemulsification.
89398796|NCT03701139|Active Comparator|Nd:YAG laser capsulotomy|Nd:YAG laser capsulotomy will be performed 1 month postoperative to remove the primary posterior capsule opacification.
89398797|NCT02053740|Experimental|R-S-Y-R-T|We added R-S-Y-R-T (500 mg 3 times per day) for 6 months
89398798|NCT02053740|Other|Routine western medicine|We kept routine western medicine only (as control group)
89398799|NCT02053818|Active Comparator|Remifentanil|Remifentanil the basic opioid drug in anesthesia
88874917|NCT04749732|Experimental|WalkingPad plus Psychological Intervention - PsyWPad Group|The participants in Experimental Group 1 will receive a prescription of an HBET consisting of a walking plan with a duration greater than 30 min per session, frequency of at least three sessions per week, use of near-maximal pain during training as claudication pain endpoint, with the support of a behavioral motivational intervention delivered by a health psychologist.
89398800|NCT02053818|Active Comparator|Sufentanil|Sufentanil the basic opioid drug in anesthesia
89398801|NCT03702387|No Intervention|Control Group|Patients in this group will have standard intravenous regional anesthesia (IVRA) performed before the start of their surgery.
89398802|NCT03702387|Experimental|Esmarch Reapplication Group|Patients in this group will have all the standard intravenous regional anesthesia (IVRA) procedures performed before the start of their surgery with one exception: After standard intravenous regional anesthesia (IVRA) is performed, The elastic Esmarch bandage will be reapplied again on the same arm then will be released. then the surgery will be initiated. the only difference between groups is that the Esmarch reapplied group will be applied the esmach two times. First time, at the standard standard intravenous regional anesthesia (IVRA) before the lidocaine injection and second time, after the injection is completed.
89398803|NCT03031899||Rose Bengal positive lesion and biopsy|Lesions that were stained positive with rose bengal were biopsied and assessed for dysplasia
89398804|NCT03031899||Toluidine blue positive lesion and biopsy|Lesions that were stained positive with toluidine blue were biopsied and assessed for dysplasia
89398805|NCT03700983|Experimental|Nutri-PEITC jelly|a single serving of 200 g Nutri-PEITC jelly
89530227|NCT05045183|Experimental|Treatment D: Antibiotic Ointment Plus SoC Adhesive Bandage|Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist. On the randomized wound site, antibiotic ointment plus SoC adhesive bandage will be applied. This treatment will be applied and changed daily from Day 1 through Day 6 and all wound sites will be uncovered from Day 7 to Day 16 for assessments.
88874918|NCT04749732|Experimental|WalkingPad plus Virtual Assistant - CyberWPad Group|The participants in Experimental Group 2 will receive a prescription of an HbET consisting of a walking plan with a duration greater than 30 min per session, frequency of at least three sessions per week, use of near-maximal pain during training as claudication pain endpoint, with the support of a virtual assistant that will give motivational support.
88874919|NCT04749732|Active Comparator|Paper WalkingPad group - PaperWPad Group|The participants in the Active Control Group will receive a prescription of an HbET consisting of a walking plan with a duration greater than 30 min per session, frequency of at least three sessions per week, use of near-maximal pain during training as claudication pain endpoint, with the support of a behavioral motivational intervention delivered by a health psychologist.
88874920|NCT04748796|Experimental|Experimental group|2 days with landiolol IV + usual care
89188697|NCT00714506|Active Comparator|Control|physical activity plus successful aging health education
89398806|NCT03700905|Experimental|Neoadjuvant/adjuvant Nivolumab and Ipilimumab|"Neoadjuvant dose with Nivolumab 3mg/kg after randomization within 2 weeks before surgery~Surgical resection of primary tumor including neck dissection according to standard of care~6-7 weeks risk-adapted adjuvant radio(-chemo)therapy 56-66 Gy (chemotherapy Cisplatin 100 mg/m2 on days 1, 22, 43, or Cisplatin once weekly (40mg/m2) for high risk patients only), start within 6 weeks post-surgery~Arm Ia:~• Adjuvant administration of Nivolumab 3mg/kg i.v. d1 every 2 weeks within 6 weeks after end of radiotherapy until progression or up to 6 months~Arm Ib:~• Adjuvant administration of Nivolumab 3mg/kg i.v. d1 every 2 weeks and Ipilimumab 1mg/kg i.v. d1 every 6 weeks within 6 weeks after end of radiotherapy until progression or up to 6 months"
89398807|NCT03700905|Active Comparator|Surgical resection + adjuvant radio(-chemo)therapy|"Surgical resection of primary tumor including neck dissection according to standard of care~6-7 weeks risk-adapted adjuvant radio(-chemo)therapy 56-66 Gy (chemotherapy Cisplatin 100 mg/m2 on days 1, 22, 43 or Cisplatin once weekly (40mg/m2) in high risk patients), start within 6 weeks post-surgery~Standard follow-up"
89398808|NCT03702153|Experimental|Infected abdominal wall group|A cohort of 40 patients carrying an active chronic mesh infection (mesh sinus, exposed mesh or mesh related enteric fistulas) resulting from a previous hernia repair, with or without an associated recurrent ventral hernia, and submitted to abdominal wall reconstruction with synthetic mesh.
89398809|NCT03702153|Active Comparator|Clean control group|A cohort of 40 patients with ventral hernias, and submitted to clean ventral hernia repair with synthetic mesh.
89398810|NCT03700827|Experimental|Resistance Training Group|Resistance training will consist of 3 whole body circuits per week for 3 weeks lasting approximately 1 hour per session. All major muscle groups will be involved (leg press, bent-over-row, bench press, back squat, dumbbell jump squats, dead-lifts, and weighted abdominal crunches). Each participant will go through each circuit three times with 30 seconds between each exercise and 2 minutes between each set.
89398811|NCT03700827|Experimental|Aerobic Training Group|Aerobic interval training will consist of 3 sessions/week for 3 weeks for approximately 45-50 minutes per session depending on exercise energy expenditure. There will be two periods of intervals. The first period will be 3 minutes of high-intensity activity and the second period will be reduced to moderate-intensity for 2 minutes. The speed/incline will change depending on the participants perception or Borg's rating of perceived exertion. Intensity will be measured using Lactate levels after each session.
89398812|NCT03700827|No Intervention|Control Group|The control group must attend sessions but will not exercise.
89398813|NCT03700749|Active Comparator|2%chlorhexidine + non-coated suture|2%alcoholic chlorhexidine + non-coated suture. Intervention: skin preparation with 2%alcoholic chlorhexidine in combination with non-coated suture for abdominal fascial closure.
89398814|NCT03700749|Active Comparator|2%chlorhexidine + coated suture|2%alcoholic chlorhexidine + triclosan-coated suture. Intervention: skin preparation with 2%alcoholic chlorhexidine in combination with triclosan-coated suture for abdominal fascia closure.
89398815|NCT03700749|Active Comparator|10% povidone-iodine + non-coated suture|10% povidone-iodine and non-coated suture. Intervention: skin preparation with 10% povidone-iodine in combination with non-coated suture for abdominal fascial closure.
89398816|NCT03700749|Active Comparator|10%povidone-iodine + coated suture|10%povidone-iodine/triclosan-coated suture. Intervention: skin preparation with 10% povidone-iodine in combination with triclosan-coated suture for abdominal fascial closure.
89398817|NCT03086369|Experimental|Phase1b: Olaratumab 15 mg/kg + Nab-paclitaxel + Gemcitabine|Participants received intravenous (IV) infusions of olaratumab 15 milligrams per kilogram (mg/kg), nab-paclitaxel 125 milligrams per meter square (mg/m^2) and gemcitabine 1000 mg/m^2 on days 1, 8, 15 of a 28-day cycle until disease progression or a criterion for discontinuation were met.
89398818|NCT03086369|Experimental|Phase1b: Olaratumab 20 mg/kg + Nab-paclitaxel + Gemcitabine|Participants received intravenous infusions of olaratumab 20 mg/kg, nab-paclitaxel 125 mg/m^2 and gemcitabine 1000 mg/m^2 on days 1, 8, 15 of a 28-day cycle until disease progression or a criterion for discontinuation were met.
89398819|NCT03086369|Experimental|Phase1b (cohort expansion): Olaratumab 20 mg/kg + Nab-paclitaxel + Gemcitabine|"Following a protocol amendment, cohort expansion arm was added in phase 1b with new participants enrolled to confirm the safety of the olaratumab 20 mg/kg dose prior to opening the Phase 2. Participants received intravenous infusions of olaratumab 20 mg/kg, nab-paclitaxel 125 mg/m^2 and gemcitabine 1000 mg/m^2 on days 1, 8, 15 of a 28-day cycle until disease progression or a criterion for discontinuation were met."
89398820|NCT03086369|Experimental|Phase 2: Olaratumab + Nab-paclitaxel + Gemcitabine|Participants received intravenous infusions of olaratumab 20 mg/kg loading dose on days 1, 8, 15 of cycle 1 followed by 15 mg/kg on days 1, 8, 15 of all subsequent cycles, in combination with nab-paclitaxel 125 mg/m^2 and gemcitabine 1000 mg/m^2 on days 1, 8, 15 of a 28-day cycle until disease progression or a criterion for discontinuation were met.
88874921|NCT04748796|Active Comparator|Control group|usual care according to the attending physician and following the guidelines of surviving sepsis campaign.
88874922|NCT04744194|Active Comparator|Nordic hamstring exercise program|Participants are required to kneel on a gym mat keeping their hips in a slightly flexed position and to slowly lower themselves in a controlled manner as far as they could towards the ground. When they can no longer lower themselves as such, they are instructed to utilise their arms to buffer the fall and touch their chest off the ground, while maintaining tension in their hamstrings. Once their chest touches the ground they are instructed to immediately return to the starting position by pushing up with their hands
88874923|NCT04744194|Experimental|Assisted nordic hamstring exercise program|Participants are required to kneel on a gym mat keeping their hips in a slightly flexed position and to slowly lower themselves in a controlled manner as far as they could towards the ground. During this exercise, participants are attached to a weighted pulley cable system via a chest attachment. A sufficient amount of assistance is given to allow the participant to lower to 30 degrees of knee flexion. When they can no longer lower themselves as such, they are instructed to utilise their arms to buffer the fall and touch their chest off the ground, while maintaining tension in their hamstrings. Once their chest touches the ground they are instructed to immediately return to the starting position by pushing up with their hands
88874924|NCT04725084||High Flow Nasal Cannula oxygen therapy treatment|Patients treated only by high flow nasal cannula oxygen therapy
88874925|NCT04725084||Non-Invasive Ventilation treatment|Patients treated by non-invasive ventilation (combined or not with HFNC)
89398821|NCT03086369|Placebo Comparator|Phase 2: Placebo + Nab-paclitaxel + Gemcitabine|Participants received intravenous infusions of placebo, nab-paclitaxel 125 mg/m^2 and gemcitabine 1000 mg/m^2 on days 1, 8, 15 of a 28-day cycle until disease progression or a criterion for discontinuation were met.
89398822|NCT03700593||Single Port Robotic Colorectal Surgery Patients|All patients who undergo a single port robot colorectal surgery.
89398823|NCT00101582|Experimental|Palifermin|Participants received a single intravenous dose of palifermin at 180 μg/kg three days before the start of radiotherapy, and then 7 once weekly palifermin doses at the same dose level during a 7-week radiotherapy/chemotherapy course.
89398824|NCT00101582|Placebo Comparator|Placebo|Participants received a single IV dose of placebo three days before the start of radiotherapy, and then 7 once weekly placebo doses during a 7-week radiotherapy/chemotherapy course.
89398825|NCT05326373|Active Comparator|Healthy Group|Subjects without gingivitis (</= 3 bleeding sites) will use stannous fluoride toothpaste
89398826|NCT05326373|Active Comparator|Unhealthy Group|Subjects with gingivitis (>/= bleeding 20 sites) will use stannous fluoride toothpaste
89398827|NCT03370107|Active Comparator|Active rTMS and H coil|
89398828|NCT03370107|Placebo Comparator|sham rTMS and Hcoil|
89398829|NCT01379105|Other|electromyography|The electrical activity of the femoral bicep muscle of the right thigh was recorded by a four channel EMG system with using superficial bipolar active electrodes (pre-amplified) with acquisition software and signal processing. The sampling frequency was 2,000 Hz, and the amplifier had a high-pass filter at 20 Hz and a low-pass filter at 500 Hz; a 12-bit analogical converter and computer completed the system
89398830|NCT02166944|Experimental|tamoxifen|tamoxifen 40 mg daily for one year
89398831|NCT02166944|Placebo Comparator|placebo|placebo drugs
88874926|NCT04725084||Continuous Positive Airway Pressure treatment|Patients treated by continuous positive airway pressure (combined or not with HFNC)
88874927|NCT04707846|Experimental|Bright Light Therapy|Individuals will receive bright blue light therapy using glasses developed by AYO. During treatment blocks for bright blue light therapy, participants will receive a text message within an hour of their self-reported wake time instructing them to use their designated light therapy device for 30 minutes. Bright blue light therapy will be administered in 2 treatment periods each 2 weeks in length (4 weeks total). Bright blue light treatment has been previously identified as an efficacious treatment for fatigue. It has also been shown in a number of studies that the blue wavelength of light is a key component to the shift of fatigue measures in patient reported outcomes.
88874928|NCT04707846|Active Comparator|Dim Light Therapy|Individuals will receive dim blue light therapy using glasses developed by AYO. During treatment blocks for bright blue light therapy, participants will receive a text message within an hour of their self-reported wake time instructing them to use their designated light therapy device for 30 minutes. Dim blue light therapy will be administered in 2 treatment periods each 2 weeks in length (4 weeks total).
88874929|NCT04707846|No Intervention|Usual Care|During usual care periods, participants will be instructed to abstain from use of AYO light therapy devices, and instructed to treat their fatigue as they normally would. Usual care will be presented in 2 periods each 2 weeks in length (4 weeks total).
88874930|NCT04673994||Chronic Stroke|Individuals 40-80 years old who have had a stroke 6 months to 5 years ago.
88874931|NCT04673994||CON|Control group (CON) comprised of age- and sex-matched healthy adults.
88874932|NCT04673994||CONyoung|Healthy, young adult control group (CONyoung) who are age 18-30 years old.
88874933|NCT04628442||TIP-OB (Office-Based)|Those in TIP-OB will be undergoing regularly scheduled office-based procedures at the otolaryngology clinic at UCSF Mount Zion campus. The investigators will be collecting nasal mucus and blood samples during each of their visits to the clinic, up to 9 times.
88874934|NCT04628442||TIP-OR (Operating Room)|Those in TIP-OR will be undergoing regularly scheduled surgeries in the operating room at UCSF Parnassus or Mount Zion campus. The investigators will be collected nasal polyp tissue, nasal mucus if possible, and blood samples during each of their surgeries, up to 9 times. The investigators will also collect inferior turbinate tissue if consented to.
88874935|NCT04625244|No Intervention|Group 1: In-person therapy|Standard of care, in-person therapy with a Certified Hand Therapist (CHT)
89188698|NCT00580866|Experimental|Joint Active Systems Brace (JAS Brace)|Elbow is placed in a brace to apply an extension force
89188699|NCT00580866|No Intervention|PT Only Group|No brace is used
89398832|NCT03238677|Experimental|Biofeedback, Massed->Distributed|Sequenced biofeedback Mass Practice--> Distributed Scheduling
89398833|NCT03238677|Active Comparator|No Biofeedback, Distributed|Speech Motor Chaining with no biofeedback. 2 sessions/wk for 10 weeks
89398834|NCT03238677|Experimental|Biofeedback, Distributed|Sequenced biofeedback, 2 sessions/wk for 10 weeks
89398835|NCT03238677|Experimental|No Biofeedback, Massed-> Distributed|Speech Motor Chaining with no biofeedback. Mass Practice--> Distributed Scheduling
89398836|NCT03540836|Experimental|Relacorilant 3x100mg softgel capsules|Relacorilant (3x100 mg softgel capsules)
89398837|NCT03540836|Experimental|Relacorilant 3x100mg hard-shell capsules|Relacorilant (3x100 mg hard-shell capsules)
89398838|NCT03540836|Experimental|Relacorilant 6x50mg hard-shell capsules|Relacorilant (6x50mg hard-shell capsules)
89398839|NCT05274737|Experimental|Initial Immobilization with the novel sling|20 patients will be placed in the novel sling after surgery for the first two weeks. For the second two weeks (days 15-28) they will crossover and utilize the standard abduction sling. For the final two weeks (days 29-42) they will choose their preferred sling type and use it for the remainder of six week immobilization period.
89398840|NCT05274737|Experimental|Initial Postoperative Immobilization with the standard abduction sling|20 patients will be placed in the traditional abduction sling after surgery for the first two weeks. For the second two weeks (days 15-28) they will crossover and utilize the novel sling. For the final two weeks (days 29-42) they will choose their preferred sling type and use it for the remainder of six week immobilization period.
88874936|NCT04625244|Experimental|Group 2: Home therapy program|Participants will be sent video links to three therapy videos demonstrating postoperative recovery exercises, starting 4 weeks after surgery.
88874937|NCT04609722|Experimental|intervention group|Solution-Focused Support Program will apply to the participants.
88874938|NCT04609722|No Intervention|control group|No intervention will be applied to the parents in the control group.
88874939|NCT04599816|Active Comparator|levosimendan administration at a dose of 3 mcg/kg after anesthesia induction|levosimendan will be administered at a dose of 3 mcg/kg after anesthesia induction
88874940|NCT04599816|Active Comparator|levosimendan administration at a dose of 6 mcg/kg after anesthesia induction|levosimendan will be administered at a dose of 6 mcg/kg after anesthesia induction
88874941|NCT04599816|Active Comparator|levosimendan administration at a dose of 12 mcg/kg after anesthesia induction|levosimendan will be administered at a dose of 12 mcg/kg after anesthesia induction
88874942|NCT04572204||Conservative group|
88874943|NCT04572204||interventional group|
88874944|NCT04566276|Experimental|Adult Cohort 1: 10 µg|12 healthy adults aged 18-55 years will receive 10 µg of the vaccine IM
88874945|NCT04566276|Experimental|Adult Cohort 2: 25 µg|12 healthy adults aged 18-55 years will receive 25 µg of the vaccine IM
89398841|NCT02255630|Experimental|Salbutamol inhalation|Study participants will be exposed to 1600ug salbutamol 30min prior to exercise
88874946|NCT04566276|Experimental|Adult Cohort 3: 50 µg|12 healthy adults aged 18-55 years will receive 50 µg of the vaccine IM
88874947|NCT04566276|Experimental|Elderly Cohort 1 :10 µg|12 elderlies aged 56-75 years will receive 10 µg of the vaccine IM
88874948|NCT04566276|Experimental|Elderly Cohort 2: 25 µg|12 elderlies aged 56-75 years will receive 25 µg of the vaccine IM
88874949|NCT04566276|Experimental|Elderly Cohort 3: 50 µg|12 elderlies aged 56-75 years will receive 50 µg of the vaccine IM
88874950|NCT04566276|Experimental|Phase 2: ChulaCov19 vaccine Dose 50 ug|adults between 18 and 59 years of age will receive 2 IM ChulaCov19 vaccine Dose 50 ug vaccinations; administered 21days apart (on Day 1 and Day 22 ±3)
88874951|NCT04566276|Other|Phase 2: Placebo|adults between 18 and 59 years of age will receive 2 IM saline vaccinations; administered 21days apart (on Day 1 and Day 22 ±3)
89188700|NCT00801567|Experimental|1|All subjects will receive the intervention (MRS scan).
89188701|NCT00771953|Experimental|Apricoxib|Apricoxib 400mg once a day
89398842|NCT02255630|Experimental|Placebo inhalation|Study participants will be exposed to 1600ug salbutamol 30min prior to exercise
89398843|NCT02163122|Experimental|NAC Followed by EEC|This arm will undergo allergy assessment first by NAC. After a rest and washout period, the same individuals will undergo assessment in an EEC.
89398844|NCT02163122|Experimental|EEC Followed by NAC|This arm will undergo allergy assessment first in an EEC. After a rest and washout period, the same individuals will undergo assessment by NAC.
89398845|NCT02163122|Experimental|Dose-finding Phase|An initial group of 6 to 12 participants with cat allergy as defined by the eligibility criteria will undergo a single-visit, stepwise dose-escalating nasal allergen challenge only, with the aim of estimating the most appropriate single dose of allergen to use in the randomized phase. Eligible participants who participate in the dose-finding phase may proceed to the randomized phase of the trial after a minimum 28-day washout period.
89398846|NCT04507269|Experimental|VIR-2218|Drug: VIR-2218 VIR-2218 given by subcutaneous injection
89398847|NCT04507269|Placebo Comparator|Placebo|Drug: Placebo Saline given by subcutaneous injection
89398848|NCT02162264||E2020|
89398849|NCT03700515|Placebo Comparator|Placebo|Saline infusion
89398850|NCT03700515|Experimental|EPO|Erythropoetin infusion (9 IU/kg)
89398851|NCT03700515|Experimental|EPO II|Erythropoetin infusion (20 IU/kg)
89398852|NCT02167100||Retained in Care|Each patient who had at least 2 practice visits separated by ≥90 days in a year involving HIV laboratory monitoring until 31st of March 2014.
89398853|NCT02167100||Lost to follow-up (LTFU)|Each patient who had at 2 practice visits separated by ≥90 days in a year involving HIV laboratory monitoring but did not maintain regular attendance at HHMP until 31st March, 2014.
89398854|NCT05113277|Experimental|Tonic Immobility Psychoeducation (TIP)|Participants in the experimental condition will receive the TIP intervention.
88874952|NCT04563390|Experimental|Projection-based augmented reality exposure therapy|Intervention group that receives the projection-based augmented reality to carry out the exposure therapy for cockroach phobia.
88874953|NCT04563390|Experimental|In vivo exposure|Intervention group that receives traditional in vivo exposure therapy for cockroach phobia.
88874954|NCT04563390|No Intervention|WL Control|Waiting list control group.
88874955|NCT04535310|Experimental|Daily Disposable Contact Lens|All subjects are fit into Precision1® contact lenses. Subjects are requested to wear the lenses for a total of two weeks.
88874956|NCT04531878|Experimental|BSEP trafficking abnormal group|Patients with ABCB11 missense mutations that were speculated to affect the BSEP trafficking
88874957|NCT04509414|Experimental|dexmedetomidine|2ug/kg intranasal atomized dexmedetomidine
88874958|NCT04509414|Active Comparator|midazolam|0.2mg/kg intranasal atomized midazolam
88874959|NCT04417764|Experimental|TACE combined PD-1 knockout T cell treatment|
88874960|NCT04320342|Experimental|BDP/FF/GB - CHF 5993|Two inhalations twice daily of BDP/FF/GB (100/6/12.5μg) for a period of 52 weeks via pressurized metered dose inhaler
88874961|NCT04320342|Active Comparator|BDP/FF - CHF 1535|Two inhalations twice daily of BDP/FF (100/6μg) for a period of 52 weeks via pressurized metered dose inhaler
88874962|NCT04307550|Experimental|Isopropyl Alcohol|10 inhalations of an isopropyl alcohol pad held within 2cm from the nares
88874963|NCT04307550|Placebo Comparator|Sterile Saline|10 inhalations of a sterile saline pad held within 2cm from the nares
88874964|NCT04299594||sickle cell disease patients|150 black patients with sickle cell disease living in France, 20 to 40 years old will be included in this study
88874965|NCT04297488|Experimental|INR(oral probiotic capsules containing 3 billion Bifidobacterium and 1 billion Lactobacillus)|Participants will receive oral probiotic capsules containing 3 billion Bifidobacterium and 1 billion Lactobacillus once daily for 6 months.
88874966|NCT04240314|Experimental|Cohort 1 (Minimal Efficacious Dose)|The Minimal Effective Dose (MED) will be delivered.
89398855|NCT05113277|Placebo Comparator|Health Education Training (HET)|Participants in the control condition will receive the HET intervention.
89398856|NCT03702075|Experimental|Experimental group|Patients allocated to the experimental group were included in a self-administered program combining self-myofascial release using foam rollers and roller balls and active upper limb neurodynamic exercises. It consisted of three sessions of 50-60 minutes per week for 4 consecutive weeks.
88874967|NCT04208412|Experimental|Part 1|Subjects received a single dose of 600 mg KVD900.
88874968|NCT04208412|Experimental|Part 2 - Sequence 1: 600 mg KVD900, Then Placebo|Subjects received a single dose of 600 mg KVD900 to treat the first eligible HAE attack. Following resolution of this attack, subjects received a second single dose of placebo to treat the second eligible HAE attack.
89398857|NCT03702075|No Intervention|Control group|Those patients allocated to the control group received a booklet with information regarding neck pain and explaining basic exercises for active mobilization and stretching with pictures and a short text.
89398858|NCT03700359|Experimental|Anlotinib/Lobaplatin/Etoposide|EL regimen for 4 cycles followed by Anlotinib Hydrochloride maintenance therapy
88874969|NCT04208412|Experimental|Part 2 - Sequence 2: Placebo, Then 600 mg KVD900|Subjects received a single dose of placebo to treat the first eligible HAE attack. Following resolution of this attack, subjects received a second single dose of 600 mg KVD900 to treat the second eligible HAE attack.
88874970|NCT04156854|Experimental|Subjects with heart failure|Subjects admitted to the hospital for acute decompensation of chronic systolic heart failure will have a Quantitated Blood Volume Analysis blood test done
89188702|NCT00771953|Placebo Comparator|Placebo|Placebo once a day
89188703|NCT02576028|Other|standard treathment|two sessions of 45 minutes of active exercises for 10 days
89398859|NCT03700359|Active Comparator|Lobaplatin/Etoposide|EL regimen for 4 cycles
89398860|NCT02167178||Volunteers receiving 0.9% NaCl|Volunteers receiving 0.9% NaCl to optimise stroke volume
89398861|NCT02167178||Volunteers receiving gelofusine|Volunteers receiving gelofusine to optimise stroke volume
89398862|NCT01379027|No Intervention|a treatment as usual (TAU) control condition|Participants will receive recruitment information, go on the study website to enroll and complete assessments over the study web site but will not receive the study intervention.
89398863|NCT01379027|Experimental|Pure self-help Internet CBT for depression|Participants will receive TAU plus access to the study website for the self-help Internet CBT for depression, consisting of access to the Internet site without any contact with therapist
89398864|NCT01379027|Experimental|Guided self-help Internet CBT|Participants will receive TAU plus Guided self-help Internet CBT, consisting of access to the Internet site plus brief, periodic telephone contacts with therapists
89398865|NCT01379027|Experimental|Stepped-Care Internet CBT condition|This consists of a Stepped-Care Internet CBT condition, starting with TAU + Pure self-help CBT and progressing to Guided self-help CBT if adequate progress is not observed early on
89398866|NCT03625089|Active Comparator|Group 1 - FRS arm|Both group will participate in the nurse-led programme on CV risk screening and carotid ultrasound for carotid plaque assessment. Subjects in group 1 will initiate Atorvastatin treatment (20mg daily per oral) if their Framingham Risk Score >10%
89398867|NCT03625089|Experimental|Group 2 USG arm|Subjects in group 2 will initiate Atorvastatin treatment (20mg daily per oral) if they had carotid plaque upon carotid ultrasound findings..
89398868|NCT03730220||Induction of labour|
89398869|NCT01378949|Active Comparator|PsCB Group|Ultrasound-Guided Psoas Compartment Block will be used in patients for pain relief after THA
89398870|NCT01378949|Active Comparator|FICB Group|Ultrasound-Guided Fascia Iliaca Compartment Block will be used in patients for pain relief after THA
89398871|NCT01378949|Active Comparator|Patient-Controlled Analgesia|Patient-controlled analgesia will be used for pain relief after THA
89398872|NCT03701997||EXCOR Pediatric|Pediatric (age 0 - 21) patients who are transplant eligible in need of mechanical circulatory support and are supported with the EXCOR® Pediatric
89398873|NCT03540446|Experimental|Standard stimulation|Group A will be treated with First Relief Treatment at standard stimulation.
89398874|NCT03540446|Experimental|sweep stimulation|Group B will be treated with First Relief Treatment at sweep stimulation.
89398875|NCT03540446|Experimental|Placebo|Group C will be treated with First Relief Treatment, receiving a placebo.(dummy device with no electrical stimulation)
89398876|NCT01381133|Experimental|CBOP without ACC|
88874971|NCT04095858|Experimental|Efprezimod alfa Treatment|Efprezimod alfa: IV infusion, 480 mg (day -1), 240 mg (day +14) and 240 mg (day +28); Tacrolimus: begin on day -3. IV [0.03 mg/kg/day] or by mouth (PO) [0.045 mg/kg/dose] dosing is permitted; Methotrexate: given IV at a dose of 15 mg/m^2/dose once daily on Day 1 after hematopoietic cell transplantation (HCT), and at a dose of 10 mg/m^2/dose on days 3, 6, and 11 after HCT.
88874972|NCT04095858|Placebo Comparator|Placebo|Placebo (Saline solution): 100 ml IV infusion, Day -1, Day 14, Day 28. Tacrolimus: begin on day -3. IV [0.03mg/kg/day] or PO [0.045 mg/kg/dose] dosing is permitted; Methotrexate: given IV at a dose of 15 mg/m^2/dose once daily on Day 1 after HCT, and at a dose of 10 mg/m^2/dose on days 3, 6, and 11 after HCT.
88874973|NCT04092348||study group|children aged 2-17 years and diagnosed as new cases of acute lymphoblastic leukemia
88874974|NCT04092348||control group|healthy age- and sex-matched children without ahistory of any malignancies
89188704|NCT02576028|Experimental|FM associated to standard treathment|the same intervention of CG except on days 2 and 7 where one session treatment was replaced with a FM treatment.
89398877|NCT01381133|Experimental|CBOP with ACC|
89398878|NCT01381133|Experimental|MET/CBT 7 without ACC|
89398879|NCT01381133|Experimental|MET/CBT 7 with ACC|
89398880|NCT02163200||pressure of total hip replacement|Patients 60 y.o. or more both sex with a history of hip arthropathy without previous bedsores or CVA
89398881|NCT01381055|Experimental|Pentoxifylline plus antimony|
89398882|NCT01381055|Placebo Comparator|Placebo plus antimony|
89398883|NCT01380977|Experimental|Impact of Crime group intervention|
89398884|NCT01380977|Active Comparator|Treatment as usual|
88874975|NCT04073862|Other|Stepped-Care TF-CBT|The study participants will receive Stepped-Care Trauma-Focused Cognitive-Behavioral-Therapy (SC-TF-CBT).
88874976|NCT04008108|Experimental|Patient with urinary incontinence|Patient with urinary incontinence
88874977|NCT03958266||MyIBD Care - Study Group|Will have traditional face to face outpatient contacts replaced with a novel mobile phone application supported via a digital clinician portal
89398885|NCT02163278|Experimental|DBPR108|
89398886|NCT02163278|Placebo Comparator|matching placebo|
89398887|NCT02167334|Experimental|positive pressure ventilation|Positive Pressure Ventilation with a 4 cmH2O inhale pressure, a positive end-expiratory pressure of 4 cm H2O, a trigger 2, an inspiratory slope of 0, an inhaled oxygen fraction of 100% administered at a 10 L / min flow.
89398888|NCT02167334|Active Comparator|Oxygenation with simple breathing mask|spontaneously breathing preoxygenation with adapted face mask, to restrict leakage, at 10L/min oxygen, with inhaled fraction of 100% and a 2 L balloon volume.
89398889|NCT03122613|Active Comparator|Curcumin|Dietary supplements of Curcumin capsules
89398890|NCT03122613|Placebo Comparator|Curcumin Placebo|Identical looking placebo of the active arm
89398891|NCT03700281|No Intervention|Control|No intervention
89398892|NCT03700281|Experimental|Messaging|Group will be sent flu vaccine promotion messages via text, email and U.S. Mail
89398893|NCT03700281|Experimental|Messaging plus incentive|Group will be sent flu vaccine promotion messages via text, email and U.S. Mail, and will be eligible to receive a gift card as incentive for receiving flu vaccine
89398894|NCT03630575|Experimental|Newborns exposed in-utero to psychoactive substances|
89398895|NCT03540368|Experimental|Tranexamic acid injection|Group with tranexamic acid injection
89398896|NCT03540368|Placebo Comparator|Placebo|Group with Placebo
89398897|NCT02162342||Rehabilitative intervention|Surgical intervention, orthotics or injections of muscle/nerve medications as prescribed by the treating physician and unrelated to the study.
89398898|NCT02167412||Syncope without POTS|Patients meeting syncope criteria without POTS. There will be no intervention for this study arm.
89398899|NCT03086135|Experimental|Bone-conduction hearing device|The bone-conduction hearing device Osia system allows a direct bone-conduction through an osseointegrated implant. A magnet allows the external Sound Processor to be placed in the correct position over the implanted system including an inner magnet.
89398900|NCT02162498|Experimental|Feeding buddies intervention|Sites receiving a comprehensive feeding buddy program implemented by the Window of Opportunity program.
89398901|NCT02162498|No Intervention|Standard of care|Sites from Window of Opportunity program who are not yet receiving the comprehensive feeding buddies program and are only receiving standard of care PMTCT support.
89398902|NCT03700125|Experimental|ECMO resuscitation|6 patients who meet the eligibility criteria will be treated by pre-hospital advanced physician/ paramedic cardiac arrest team that is ECMO capable and can establish ECMO flow within 30 minutes of collapse
89398903|NCT02163512||Non-refractory ascites|
88874978|NCT03937986|Placebo Comparator|Placebo|Subjects will be maintained on oral placebo. Cocaine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.
88874979|NCT03937986|Experimental|Suvorexant Dose 1|Subjects will be maintained on oral suvorexant dose 1. Cocaine will be administered acutely during suvorexant dose 1 maintenance. Placebo will be administered acutely during suvorexant dose 1 maintenance.
88874980|NCT03937986|Experimental|Suvorexant Dose 2|Subjects will be maintained on oral suvorexant dose 2. Cocaine will be administered acutely during suvorexant dose 2 maintenance. Placebo will be administered acutely during suvorexant dose 2 maintenance.
88874981|NCT03937986|Experimental|Suvorexant Dose 3|Subjects will be maintained on oral suvorexant dose 3. Cocaine will be administered acutely during suvorexant dose 3 maintenance. Placebo will be administered acutely during suvorexant dose 3 maintenance.
88874982|NCT03836196|Experimental|Combined radiation treatment|Combined low-dose-rate brachytherapy and external beam radiation therapy
88874983|NCT03835884|Experimental|AR-13503 Implant 10.6 Dose|Single dose of AR-13503 Implant 10.6 Dose (10.6 µg) administered as an intravitreal implant into a single eye of up to 6 subjects (3 nAMD and 3 DME) who will be followed for 24 weeks
88874984|NCT03835884|Experimental|AR-13503 Implant 21.2 Dose|Single dose of AR-13503 Implant 21.2 Dose (21.2 µg) administered as intravitreal implants into a single eye of up to 6 subjects (3 nAMD and 3 DME) who will be followed for 24 weeks
88874985|NCT03835884|Experimental|AR-13503 Implant 42.4 Dose|Single dose of AR-13503 Implant 42.4 Dose (42.4 µg) administered as intravitreal implants into a single eye of up to 6 subjects (3 nAMD and 3 DME) who will be followed for 24 weeks
88874986|NCT03835884|Experimental|AR-13503 Implant 63.6 Dose|Dose of AR-13503 Implant 63.6 Dose (63.6 µg) administered into a single eye of up to 5 subjects (DME) who will be followed for 24 weeks. Subjects may qualify to receive an additional dose at Week 12.
88874987|NCT03813030|Experimental|Pilot Study|Dermal-sampling visit: Measurement of dermal pharmacokinetic (PK) parameter (AUC, Cmax) of lidocaine/ prilocaine using dermal open flow microperfusion (dOFM) and dermal microdialysis (dMD) after topical application of Lidocaine 2.5% and Prilocaine 2.5% cream in 6 participants. Additionally systemic appearance of lidocaine/prilocaine is measured by blood sampling.
88874988|NCT03813030|Experimental|Pivotal Study|"Dermal-sampling visit: Measurement of dermal pharmacokinetic (PK) parameter (AUC, Cmax) of lidocaine/ prilocaine using dermal open flow microperfusion (dOFM) and dermal microdialysis (dMD) after topical application of Lidocaine 2.5% and Prilocaine 2.5% cream in 20 participants. Additionally systemic appearance of lidocaine/prilocaine is measured by blood sampling.~Clearance Visit: Clearance of lidocaine will be evaluated after intravenous infusion of lidocaine."
88874989|NCT03738150|Experimental|Sotatercept|Each participant will receive SOC plus sotatercept at a dose of 0.3 mg/kg SC for Cycle 1. (Each cycle will be 21 days.) From Cycle 2 through Cycle 9, the dose will be escalated to 0.7 mg/kg SC. Dosing will be every three weeks during the 24-week treatment period and 18-month extension period.
88874990|NCT03718728|Active Comparator|Standard group|A personalized diet and physical exercise recommendations.
88874991|NCT03718728|Experimental|Mind&Life (standard + intervention) group|A personalized diet and physical exercise recommendations plus the acceptance and mindfulness-based group intervention program.
88874992|NCT03654690|No Intervention|Control|Participants will receive SMS text message reminders to get tested for HIV in a clinic.
88874993|NCT03654690|Active Comparator|Standard Self-Testing|Participants will receive an HIV self-test kit in the mail with no standardized follow-up from counselors.
88874994|NCT03654690|Experimental|Enhanced Self-Testing|Participants will receive an HIV self-test kit and will be contacted via telephone for counseling within 24 hours of opening their test.
88874995|NCT03653052|Experimental|Durvalumab|Patients with advanced oesophageal cancer will be administered with 1500mg of durvalumab once every 4 weeks for up to 6 months.
88874996|NCT03640728||ETV|patients receive entecavir 0.5 mg/day orally.
88874997|NCT03640728||TDF|patients receive Tenofovir Disoproxil Fumarate 300 mg/day orally.
88874998|NCT03640728||TAF|patients receive Tenofovir alafenamide 25 mg/day orally.
88874999|NCT03607500|Experimental|Caloric Intake Reduction|The intervention group will be seen by the kidney disease dietician at all clinical visits for the first 3 months (weekly for month 1, every other week for months 2 and 3). During months 2 and 3, in the weeks that the patients are not in clinic, they will receive telephone calls from the dietician. Thus the intervention involves weekly assessment for the first 3 months (in person or over the telephone). After 3 months, the patient will not receive any further active dietary intervention from the dieticians unless the patient wishes to continue using the dieticians advice per clinic protocol.
89188705|NCT02554227||Spondylodiscitis|vertebral osteomyelitis, erosive osteochondrose
88875000|NCT03607500|No Intervention|Standard of care|The standard of care arm will receive dietary guidance per current University of Michigan Transplant Center policy, where a one time face-to-face visit is provided in the first month after kidney transplant and then as requested by the patient or referred by physician.
88875001|NCT03567174|Experimental|Integrated care van (ICV)|ICV visits neighborhoods served by the mobile syringe service program weekly. ICV provides a range of services targeted to people who inject drugs - HIV testing, HCV testing, PrEP, MAT, wound care, case work services, on-site medical management and linkage.
88875002|NCT03567174|No Intervention|Control|No additional services provided.
88875003|NCT03562572|Experimental|Ischemia driven revascularization|In the ischemia driven complete revascularisation strategy group all flow limiting (FFR ≤ 0.80) lesions will receive treatment by PCI and stenting. The non-IRA PCI should be performed during the same intervention. Exceptions can be made for complex lesions where the operator estimates that the revascularisation procedure will require significant contrast overload, which may lead to deterioration of cardiac and renal function of the patient.
88875004|NCT03562572|Active Comparator|Usual care group|In the randomised to usual care group the procedure will stop after the PCI of the culprit artery and the patient will be referred to his treating cardiologist and/ or heart team who will decide whether a staged PCI of the non- IRA artery should take place. If the treating cardiologist (after advise of the heart team) decides to perform the non-IRA PCI revascularisation, than such treatment should take place within six weeks from the primary PCI in order to count as a scheduled staged PCI procedure.
88875005|NCT03522870|Experimental|Flash Glucose Monitoring System|People selected to this group will using flash glucose monitoring system continuously on Week 2-14 and Week 14-26.
88875006|NCT03522870|Active Comparator|SMBG|People selected to this group will using SMBG continuously on Week 2-14 and Week 14-26.
88875007|NCT03445650|Experimental|ADX-102 1% Topical Dermal Cream (reproxalap)|
88875008|NCT03445650|Placebo Comparator|Vehicle of ADX-102 Topical Dermal Cream|
88875009|NCT03202758|Other|Durvalumab + Tremelimumab + FOLFOX|"Durvalumab for 12 months~Tremelimumab for up to 4 doses/cycles~FOLFOX"
88875010|NCT03186534|Experimental|2GETHER|2GETHER is an HIV prevention and relationship education program designed for young male couples. 2GETHER consists of 4 sessions (2 group sessions, 2 individualized couple session) administered over the course of 1 month (1 session per week). Group sessions focus on developing skills related to sexual health and relationship functioning, including HIV prevention in couples, communication skills, coping skills, problem-solving and acceptance. Individualized couple sessions focus on implementation of skills specific to the needs of each couple.
88875011|NCT03186534|Active Comparator|Positive Affect Enhancement|The control condition is a positive affect enhancement program for couples. This is an active and attention-matched control condition. Group sessions focus on developing various coping skills that aim to enhance positive emotions in couples, and individualized couple sessions focus on skills implementation.
88875012|NCT03122262|Active Comparator|Tenofovir Alafenamide|Descovy: Tenofivir alafenamide tablets 25mg daily, Emtricitabine 200mg daily
88875013|NCT03122262|Active Comparator|Dolutegravir|Dolutegravir 50mg daily, Truvada 500mg daily
88875014|NCT03122262|Active Comparator|Atripla|Atripla: Efavirenz 600mg daily, Tenofovir Disoproxil Fumarate 300mg daily, Emtricitabine 200mg daily
88875015|NCT03055416|Other|Mobile Men App Prototype|Prototype of physical activity mobile app geared for African-American men.
88875016|NCT03042546|Active Comparator|Calcium Sulphate|
88875017|NCT03042546|Active Comparator|PMMA|
88875018|NCT03042546|Active Comparator|Nothing|
88875019|NCT02948244|Active Comparator|Group A - Active/Placebo|Participants will receive 3 months of creatine monohydrate followed by a 6 week washout period followed by 3 months of placebo.
88875020|NCT02948244|Active Comparator|Group B - Placebo/Active|Participants will receive 3 months of placebo followed by a 6 week washout period followed by 3 months of creatine monohydrate.
88875021|NCT02734134|Active Comparator|One-stage exchange|One surgery where the infected implants are removed and the hip or knee joint are 'washed out' before new joint replacement implants are re-implanted during the same surgical procedure.
88875022|NCT02734134|Active Comparator|Two-stage exchange|Two surgeries; during the first surgery the infected implants are removed and a spacer is placed in the hip or knee joint in place of the implants. A second surgery to re-implant the hip or knee joint replacement implants is performed if and when the infection has cleared.
88875023|NCT02654340||Participants with Tuberous Sclerosis Complex (TSC)|Üarticipants diagnosed with Tuberous Sclerosis Complex (TSC) aged between 2 months and 50 years.
88875024|NCT02561754|Active Comparator|Face-To-Face/CD|Delivery: Face-to-face Diet: Conventional diet
88875025|NCT02561754|Experimental|Technology delivery/CD|Delivery: Technology Diet: Conventional diet
88875026|NCT02561754|Experimental|Technology delivery/eSLD|Delivery: Technology Diet: enhanced Stop Light Diet
88875027|NCT02545998|No Intervention|Standard care|Patients will receive a face-to-face asthma review
88875028|NCT02545998|Active Comparator|Telehealthcare|Patients will receive a telephone consultation and e-mail with attached PAAP and video link
88875029|NCT02524938|Experimental|Treatment group|Chlorogenic Acid (CGA) 400mg/day (CGA-enriched coffee)
88875030|NCT02524938|Sham Comparator|Control group|Conventional coffee (habitual diet)
88875031|NCT02524626|Sham Comparator|Sham stimulation|no stimulation of vagus nerve
88875032|NCT02524626|Active Comparator|Vagus stimulation|Stimulation of the vagus nerve at the beginning and the end of the surgery
88875033|NCT02420652|Experimental|Arm I (metformin hydrochloride, aspirin)|Patients receive metformin hydrochloride PO BID and aspirin PO QD for 6 months in the absence of disease progression or unacceptable toxicity.
88875034|NCT02420652|Placebo Comparator|Arm II (metformin hydrochloride placebo, aspirin placebo)|Patients receive metformin hydrochloride placebo PO BID and aspirin placebo PO QD for 6 months in the absence of disease progression or unacceptable toxicity.
89398904|NCT02163512||Refractory ascites|
89398905|NCT02163590|Experimental|2Hz mobilisation|A bilateral postero-anterior mobilisation applied to the fourth thoracic vertebra, at a 2Hz frequency.
89398906|NCT02163590|Experimental|0,5Hz mobilisation|A bilateral postero-anterior mobilisation applied to the fourth thoracic vertebra, at a 0,5Hz frequency.
89398907|NCT02163590|Placebo Comparator|Placebo|A simulation technique, that mimic the other groups, in this case only manual contact will be applied, without any oscillation.
89398908|NCT02167568||Corpus callosum agenesis/dysgenesis|patients with Corpus callosum agenesis/dysgenesis
89398909|NCT02167568||parents|parents of patients with corpus callosum agenesis/dysgenesis
89398910|NCT02163668|Experimental|Yoga group|8 months of progressive Yoga training
89398911|NCT02163668|No Intervention|Control group|No training, just pre and post testing
89398912|NCT02167646|Other|Bilaterally innervated flap|Two nerve branches attached with the flap for sensory reconstruction.
89398913|NCT02163980|Placebo Comparator|Caudal ropivacaine + normal saline|1.5ml kg-1 ropivacaine 0.15% with normal saline (Control group, n=40).
89398914|NCT02163980|Experimental|Caudal ropivacaine + dexmedetomidine|1.5ml kg-1 ropivacaine 0.15% with dexmedetomidine 1 μg kg-1 (DEX group, n=40)
89398915|NCT02164058|Experimental|TandemHeart System + PCI|TandemHeart System prior to percutaneous coronary intervention
88875035|NCT02257242|Experimental|Vincristine sulfate liposome injection 1.8 mg/m^2|Treatment with the combination of rituximab, bendamustine and vincristine sulfate liposome injection will be repeated every 4 weeks for a maximum of 6 cycles. Dose-limiting toxicities will be evaluated during the first cycle of therapy.
88875036|NCT02257242|Experimental|Vincristine sulfate liposome injection 1.95 mg/m^2|Treatment with the combination of rituximab, bendamustine and vincristine sulfate liposome injection will be repeated every 4 weeks for a maximum of 6 cycles. Dose-limiting toxicities will be evaluated during the first cycle of therapy.
88875037|NCT02257242|Experimental|Vincristine sulfate liposome injection 1.98 mg/m^2|Treatment with the combination of rituximab, bendamustine and vincristine sulfate liposome injection will be repeated every 4 weeks for a maximum of 6 cycles. Dose-limiting toxicities will be evaluated during the first cycle of therapy.
89398916|NCT02164058|Active Comparator|PCI|Percutaneous coronary intervention
89398917|NCT02164136|Experimental|L-PANP-TME|Laparoscopy-assisted pelvic autonomic nerve preservation total mesorectum excision for male mid-low rectal cancer patients
89398918|NCT02164136|Active Comparator|O-PANP-TME|Open pelvic autonomic nerve preservation total mesorectum excision for male mid-low rectal cancer patients
89398919|NCT01380821||SPECT|Patients clinically indicated to undergo myocardial SPECT in our institution.
89398920|NCT02162654|Active Comparator|Remote ischemic preconditioning|Inflation of a blood pressure cuff around an arm with the patient under general anesthesia prior to start aneurysm treatment
89398921|NCT02162654|Sham Comparator|Sham preconditioning|Sham inflation of a blood pressure cuff around an arm with the patient under general anesthesia prior to start aneurysm treatment
89398922|NCT04733222|Experimental|Perturbation training|"Participants randomized to the treadmill perturbation training will initially perform three sessions performed within a week followed by a booster-session after six months."
89398923|NCT04733222|Active Comparator|Treadmill walking|"Participants randomized to the walking group will undergo three initial sessions within a week and a booster-session after six months."
89398924|NCT01378793|No Intervention|Standard of Care|Participants will be asked to continue doing whatever their healthcare providers advise for their insomnia, but not to start any new treatments during the study. They will also be given a sleep hygiene handout as a standard of care. After six weeks, they will be reassessed and then provided the opportunity to engage in the web-based acupressure intervention.
88875038|NCT02257242|Experimental|Vincristine sulfate liposome injection 2.04 mg/m^2|Treatment with the combination of rituximab, bendamustine and vincristine sulfate liposome injection will be repeated every 4 weeks for a maximum of 6 cycles. Dose-limiting toxicities will be evaluated during the first cycle of therapy.
88875039|NCT02257242|Experimental|Vincristine sulfate liposome injection 2.10 mg/m^2|Treatment with the combination of rituximab, bendamustine and vincristine sulfate liposome injection will be repeated every 4 weeks for a maximum of 6 cycles. Dose-limiting toxicities will be evaluated during the first cycle of therapy.
88875040|NCT02257242|Experimental|Vincristine sulfate liposome injection 2.14 mg/m^2|Treatment with the combination of rituximab, bendamustine and vincristine sulfate liposome injection will be repeated every 4 weeks for a maximum of 6 cycles. Dose-limiting toxicities will be evaluated during the first cycle of therapy.
88875041|NCT02257242|Experimental|Vincristine sulfate liposome injection 2.19 mg/m^2|Treatment with the combination of rituximab, bendamustine and vincristine sulfate liposome injection will be repeated every 4 weeks for a maximum of 6 cycles. Dose-limiting toxicities will be evaluated during the first cycle of therapy.
88875042|NCT02257242|Experimental|Vincristine sulfate liposome injection 2.22 mg/m^2|Treatment with the combination of rituximab, bendamustine and vincristine sulfate liposome injection will be repeated every 4 weeks for a maximum of 6 cycles. Dose-limiting toxicities will be evaluated during the first cycle of therapy.
88875043|NCT02257242|Experimental|Vincristine sulfate liposome injection 2.24 mg/m^2|Treatment with the combination of rituximab, bendamustine and vincristine sulfate liposome injection will be repeated every 4 weeks for a maximum of 6 cycles. Dose-limiting toxicities will be evaluated during the first cycle of therapy.
88875044|NCT02034630|Experimental|Busulfan|First dose: busulfan (120 mg/m2 ivs once daily) (if age<1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study
88875045|NCT02025036|Experimental|Capecitabine-oxaliplatin-radiotherapy|"oxaliplatin：65mg/m2，d1，8，22, 29,I.V.or d1, 8, 22, 29, 43, 50, 64, 71,I.V.plus,capecitabine: 625mg/m2, bid d1-5; q1w, po,6 weeks or 12 weeks in total.~radiotherapy： 50-50.4Gy ，1.8-2 Gy/d，5d/w."
88875046|NCT02025036|Active Comparator|cisplatin with 5-FU and radiotherapy|"cisplatin: 75mg/m2 d1，29 or d1, 29, 57, 85, 5-Fu：750mg/m2 CIV24h d1-4，d29-32 or d1-4，d29-32, d57-60, d85-88.~radiotherapy： 50-50.4Gy ，1.8-2 Gy/d，5d/w."
88875047|NCT02025036|Experimental|Capecitabine and radiotherapy|capecitabine: 625mg/m2, bid d1-5; q1w, po,6 weeks or 12 weeks in total, radiotherapy： 50-50.4Gy ，1.8-2 Gy/d，5d/w.
88875048|NCT02002572|Experimental|Mimic facial muscle from 3T MRI data|
88875049|NCT01943916|Experimental|Imagio OA/US (US and OA/US)|Imagio OA/US (gray scale and opto-acoustic)
88875050|NCT01943916|Experimental|Imagio gray scale ultrasound|Imagio gray scale ultrasound alone
88875051|NCT01825356|Active Comparator|Dorsal Cheilectomy no Amniotic Membrane Tissue Implantation|Dorsal cheilectomy is a surgery for hallux rigidus(degenerative arthritis and stiffness due to bone spurs that affect the joint at the base of the big toe). No amniotic membrane will be used for this group.
89188706|NCT02553837|Experimental|Treatment only|Drug: Hantavax injectionSchedule: The basic vaccination(0, 1, 2months) and The boost vaccination(13months)
89188707|NCT00621244|Experimental|Arm 1, Group X|
88875052|NCT01825356|Experimental|Dorsal Cheilectomy-Amniotic Membrane Tissue Implantation|Dorsal cheilectomy procedure with the addition of the amniotic membrane. Amniotic membrane represents a biologic therapy that has the ability to actively regulate myrofibroblast formation and activity within the joint space and surgical site
88875053|NCT01768338|Experimental|Ofatumumab combined with SB-485232|Otatumumab: 1000 mg IV for 4 weeks. SB-485232: escalating doses (3 ug/kg up to 30 ug/kg) for 8 weeks.
88875054|NCT01564368|Experimental|Diffusion Weighted-MRI|Participants on all arms of the I-SPY II trial will undergo diffusion-weighted magnetic resonance imaging as described in the ACRIN 6698 protocol. The experimental component/intervention is whether DW-MRI can predict therapeutic response in neoadjuvant treatment for breast cancer.
88875055|NCT01533636||Healthy Control|This group will be comprised of healthy individuals without evidence of lung disease.
88875056|NCT01533636||Cystic Fibrosis|This group will be comprised of individuals who have been diagnosed with cystic fibrosis.
88875057|NCT01345344|Experimental|Cognitive-Behavioral Therapy|8 individual weekly visits with a psychologist for pain-related CBT.
89188708|NCT00621244|Experimental|Arm 1, Group Y|
89188709|NCT00621244|Experimental|Arm 2, Group X|
89188710|NCT00621244|Experimental|Arm 2, Group Y|Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF), every other week, as part of a 28-day treatment cycle. Group Y is a sub-arm, based on disease indication.
89188711|NCT02553759|Experimental|Effective movement|This group will see a 1-minute video showing an individual performing a cervical rotation movement to each side, first 10 times towards the right and then 10 times towards the left. The movement will be performed effectively over the entire course of the cervical path, approximately 80º
89188712|NCT02553759|Active Comparator|Ineffective movement|This group will see a 1-minute video showing an individual performing a cervical rotation movement ineffectively, without achieving the maximum cervical travel, performing approximately 40º. First, 10 movements towards the right will be performed and then 10 towards the left
89188713|NCT04021901||F21|balloon diameter F21
89188714|NCT04021901||F24|balloon diameter F24
89398925|NCT01378793|Active Comparator|Relaxation Acupressure|In addition to being given a sleep hygiene handout as a standard of care, participants will be asked to apply pressure on each of following points (bilaterally where indicated). There are 5 acupoints with 4 of the acupoints performed on both the left and the right sides of the body giving a total of 9 points to stimulate. Each of the 9 acupoints will be stimulated for 3 minutes per point giving a total treatment time of 27 minutes done once daily.
89398926|NCT01378793|Active Comparator|Stimulating Acupressure|In addition to being given a sleep hygiene handout as a standard of care, participants will be asked to apply pressure on each of following points (bilaterally where indicated). There are 6 acupoints with 4 of the acupoints performed on both the left and the right sides of the body giving a total of 10 points to stimulate. Each of the 10 acupoints will be stimulated for 3 minutes per point giving a total treatment time of 30 minutes done once daily.
89398927|NCT02162888|Other|Eagle-BDM; Teva-BDM; Teva-BDM|Eagle-BDM: IV Teva-BDM: IV
89398928|NCT02162888|Other|Teva-BDM; Eagle-BDM;Teva-BDM|Eagle-BDM: IV Teva-BDM: IV
89188715|NCT00801645|Experimental|Obese exercise|
89398929|NCT02162888|Other|Teva-BDM, Teva-BDM, Eagle-BDM|Eagle-BDM: IV Teva-BDM: IV
89398930|NCT04494867|Experimental|Core warming|Patients receive the Attune Medical Esophageal Heat Transfer Device (EnsoETM) and undergo core warming
89398931|NCT04494867|Active Comparator|Standard of Care|Patients receive standard temperature management and treatment
89398932|NCT01569035|Active Comparator|warfarin|oral anti coagulant
89398933|NCT02762708|Active Comparator|Roux-en-Y Gastric Bypass (RYGB)|Subjects between the ages of 20-65 years of age seen for weight management in the Nutrition Clinic at Mayo Clinic, who have been approved for RYGB.
89398934|NCT02762708|Sham Comparator|Caloric restriction|Subjects between the ages of 20-65 years of age, with diagnosis of Type 2 diabetes mellitus or impaired fasting glucose. Subjects will undergo caloric restriction alone to mimic weight loss seen after gastric bypass surgery.
89398935|NCT02762708|Active Comparator|Exendin-9,39|Four subjects who have undergone RYGB surgery will be studied 4 weeks after surgery. Subjects will be randomized to receive an infusion of Exendin-9,39 or normal saline.
89398936|NCT02762708|Placebo Comparator|Normal Saline|Four subjects who have undergone RYGB surgery will be studied 4 weeks after surgery. Subjects will be randomized to receive an infusion of Exendin-9,39 or normal saline.
89398937|NCT03699969|Experimental|Hypofractionated dose escalated VMAT|Hypofractionated dose escalated VMAT radiotherapy
89398938|NCT03699969|No Intervention|Conventional concurrent chemoradiation|Conventional concurrent chemoradiation
89398939|NCT03841565|Experimental|Treatment (pomalidomide, daratumumab, dexamethasone)|Patients receive pomalidomide PO QD on days 1-21 and daratumumab IV on days 1, 8, 15, and 22 of cycles 1-2, days 1-15 of cycles 3-6, and day 1 of subsequent cycles. Patients also receive dexamethasone PO on days 1, 8, 15, and 22 of cycles 1-12. Cycles every 28 days in the absence of disease progression or unacceptable toxicity.
89398940|NCT02162966|Experimental|High Dose Colistin|High dose colistin protocol
89398941|NCT02162966|Active Comparator|Standard Dose Colistin|Standard dose of colistin
89398942|NCT02839317||Biological in pediatric CD|75 pediatric-onset CD Biological
88875058|NCT01345344|Active Comparator|Disease Education|8 individual weekly visits with a psychologist for fibromyalgia education (this is an active comparator arm, matched for provider contact).
88875059|NCT01345344|No Intervention|Healthy Controls|No intervention.
89398943|NCT02839317||Biological in pediatric controls|75 pediatric controls matched on gender, age and area of residence Biological
88875061|NCT00596154|Experimental|1|Rituximab, methotrexate (MTX), procarbazine and vincristine (R-MPV). The peripheral blood stem cell (PBSC) harvest procedure will be performed at the discretion of the hematology attending (usually after the 1st or 2nd cycle of R-MPV)and high dose chemotherapy Busulfan, Thiotepa, and Cyclophosphamide. Patients will be off study at the time of death. All patients will be followed for survival every 6 months throughout their lifetime. Survival status may be obtained by phone call, clinical visit or medical records (e.g. physician notes/laboratory results of clinic or hospital visit.
88875062|NCT00474318||Adolescents with severe obesity|Adolescents and young adults with severe obesity
88875063|NCT00281658|Experimental|Paclitaxel and Lapatinib (Blinded)|Paclitaxel and Lapatinib (Blinded)
89188716|NCT00801645|No Intervention|Obese Control|
89398944|NCT02839317||Biological in elderly CD|75 elderly-onset CD Biological
89398945|NCT02839317||Biological in elderly controls|75 elderly controls matched on gender, age and area of residence Biological
89398946|NCT04697420|Experimental|Group (P)|the patients were received paravertebral block to control pain postoperatively.
89398947|NCT04697420|Experimental|Group (T)|the patients were received transversus abdomins plane (TAP) block to control pain postoperatively.
89398948|NCT04919525|Experimental|TrainPain Intervention|Daily TrainPain protocol - gamified sensory perceptual training
89398949|NCT03540290|Active Comparator|Mechanical instrumentation and oral hygiene instructions|
89398950|NCT03540290|Experimental|Modification of the implant supported prostheses|
88875064|NCT00281658|Active Comparator|Paclitaxel and Placebo (Blinded)|Paclitaxel and Placebo (Blinded)
88875065|NCT00281658|Other|Open Label - Monotherapy (Extension Phase)|Open Label - Monotherapy (Lapatinib)
88875066|NCT00281658|Other|Open Label - Combination Therapy (Extension Phase)|Open Label - Combination Therapy (Lapatinib and Paclitaxel)
89188717|NCT00801645|Experimental|Lean Exercise|
89188718|NCT00801645|No Intervention|Lean Control|
89398951|NCT01595321|Experimental|SBRT and FOLFIRINOX|The first 6 patients will receive SBRT and FOLFIRINOX only.
89398952|NCT01595321|Experimental|Cyclophosphamide, Vaccine, SBRT, and FOLFIRINOX|The last 12 patients will receive cyclophosphamide, Vaccine, SBRT, and FOLFIRINOX.
89398953|NCT02167724|Experimental|Patients with schizophrenia|
89398954|NCT03699813||scoliosis bleeding management based on aPTT/PT|"Bleeding and coagulopathy during surgery managed by clinical approach and aPTT/PT tests.~Blood loss, consumption of fresh frozen plasma (FFP), red blood cell units consumption and time to aPTT/PT tests result will be analysed."
89398955|NCT03699813||scoliosis bleeding management based on ROTEM|Bleeding and coagulopathy during surgery managed by ROTEM. Blood loss, consumption of fresh frozen plasma (FFP), red blood cell units consumption and time to aPTT/PT tests result will be analysed.
88875067|NCT02417376|Active Comparator|Experimental|"Periodontal intervention in the form of scaling and root planing by:~ultrasonic piezoelectric scaler (frequency of 28-36 KHz) and~gracey curets (set of 7 instruments number 1-14) to remove supra and subgingival calculus on teeth, is completed in two appointments of 45 to 60 min, within 24 hours"
89398956|NCT02164214|Experimental|patients PSORIATIC ARTHRITIS|etanercept Treatment
89398957|NCT02164214|Active Comparator|patients RHEUMATOID ARTHRITIS|etanercept Treatment
89398958|NCT03698565|Experimental|PPI and ANI measurements|"The intervention is the nerve stimulation of the ulnar nerve for evaluation / realization of PPI by videopupillometry.~The realization of PPI and ANI measurements is carried out at the end of the surgical procedure, it implies a maintenance of the anesthesia for approximately 5 additional minutes."
89398959|NCT03768947|Experimental|Heat Therapy Arm|Participants in this open-label pilot study will undergo heat therapy via hot water immersion (hot-tub).
88875068|NCT02417376|No Intervention|Control|No periodontal intervention in any form.
88875069|NCT02417532|Experimental|Rehabilitation using REX|Exercises using Rex mobility assist device
88875070|NCT02417844|Active Comparator|Tamsulosin HCl|
89398960|NCT03699735|Active Comparator|Hearing Aid with beam form principle_A|Device: Hearing Aid beam former principle_A (simulation of real ear condition). Each participant will be fitted with the 3 different beam former (directionality change) principles on the same hearing aid, saved to 3 manual programs. Beam former principle is a sound processing algorithm to focus to a target source in a noisy situation to improve the speech intelligibility and comfort. The experimental conditions vary in their parametrization to result in different degrees of beam forming and good speech quality.
89398961|NCT03699735|Experimental|Hearing Aid with beam form principle_B|Device: Hearing Aid beam former principle_B. Each participant will be fitted with the 3 different beam former (directionality change) principles on the same hearing aid, saved to 3 manual programs. Beam former principle is a sound processing algorithm to focus to a target source in a noisy situation to improve the speech intelligibility and comfort. The experimental conditions vary in their parametrization to result in different degrees of beam forming and good speech quality.
89398962|NCT03699735|Experimental|Hearing Aid with beam form principle_C|Device: Hearing Aid beam former principle_C. Each participant will be fitted with the 3 different beam former (directionality change) principles on the same hearing aid, saved to 3 manual programs. Beam former principle is a sound processing algorithm to focus to a target source in a noisy situation to improve the speech intelligibility and comfort. The experimental conditions vary in their parametrization to result in different degrees of beam forming and good speech quality.
89398963|NCT02164292||ALPPS group|"Patients with small future liver remnant who are operated with the Associating Liver Partition and Portal vein ligation for Staged hepatectomy approach"
89398964|NCT03722849|Experimental|Chronic cough participant|"Twenty-five (25) Idiopathic chronic cough patients, defined as refractory to disease modifying therapies (eg anti-asthma medications), will be recruited.~Participants will attend two sessions. In the first they will inhale in a single breath a nebulized solutions of increasing doses of Adenosine Triphosphate (ATP; 0.2-300 microM) and capsaicin (0.5-125 microM) to determine their individual cough and urge-to-cough thresholds. In the second session, participants will undergo functional brain imaging (fMRI) for 1 hour while inhaling over 24 seconds randomly administered nebulized solutions of saline, or threshold doses of ATP or capsaicin."
89398965|NCT03722849|Experimental|Healthy control participant|"Twenty-five (25) appropriately age and sex matched healthy non-smoking individuals will be recruited as the comparison group.~Participants will attend two sessions. In the first they will inhale in a single breath a nebulized solutions of increasing doses of ATP (0.2-300 microM) and capsaicin (0.5-125 microM) to determine their individual cough and urge-to-cough thresholds. In the second session, participants will undergo fMRI for 1 hour while inhaling over 24 seconds randomly administered nebulized solutions of saline, or threshold doses of ATP or capsaicin."
89398966|NCT03699657|Active Comparator|RFA with DSM mode|RFA is performed in dual switching mode using a separable clustered electrode (Octopus®) and a three-channel dual-generator unit.
89398967|NCT03699657|Active Comparator|RFA with SSM mode|RFA is performed in single switching mode using a separable clustered electrode (Octopus®) and a three-channel dual-generator unit.
89398968|NCT02170844|Experimental|BIBR 1048 MS (Japanese)|Japanese subjects received an increasing dose (50 mg to 150 mg) of BIBR 1048 MS
88875071|NCT02417844|Active Comparator|Tamsulosin|
88875072|NCT02418312|Active Comparator|histamine-2 receptor antagonist group|famotidine 40mg qd for 6 months.
88875073|NCT02418312|Placebo Comparator|placebo group|placebo for 6 months.
89398969|NCT02170844|Placebo Comparator|BIBR 1048 MS Placebo (Japanese)|Japanese subjects will receive placebo of BIBR 1048 MS
89398970|NCT02170844|Experimental|BIBR 1048 MS (Caucasian)|Caucasian subjects received an increasing dose (50 mg to 150 mg) of BIBR 1048 MS
89398971|NCT02170844|Placebo Comparator|BIBR 1048 MS Placebo (Caucasian)|Japanese subjects will receive placebo of BIBR 1048 MS
89398972|NCT03624465|Experimental|Levita Magnetic Surgical System|Levita Magnetic Surgical System use of surgical tool
89398973|NCT02170922|Experimental|Sequence 1|BIBR 1048 MS tablet (fasted) - BIBR 1048 MS solution (fasted) - BIBR 1048 MS tablet after high fat meal
89398974|NCT02170922|Experimental|Sequence 2|BIBR 1048 MS solution (fasted) - BIBR 1048 MS tablet (fasted) - BIBR 1048 MS tablet after high fat meal
89398975|NCT03698253|Experimental|Regorafenib plus FOLFIRI|"Regimen for treatment consists of irinotecan (180 mg/m2 as a 120-min IV infusion for UGT1A1 genotyping (TA6/TA6) and UGT1A1 genotyping (TA6/TA7); 120 mg/m2 as a 120-min IV infusion for UGT1A1 genotyping (TA7/TA7)), followedby Leucovorin (400 mg/m2 IV infusion over 2 hours), and 5-FU (2800 mg/m2 IV infusion over a 46-hour period), repeated every 2 weeks.~After every 2 cycles of each different dose of irinotecan, if adverse events (AEs) are under the grade 2, we will escalate the dose of 30 mg/m2. The estimated maximal dose of irinotecan is 260 mg/m2 for UGT1A1 genotyping (TA6/TA6); 240 mg/m2 for UGT1A1 genotyping (TA6/TA7); 180 mg/m2 for UGT1A1 genotyping (TA7/TA7).~Regorafenib is administered at adjusted doseage of 120 mg daily for 3 weeks in a 4-week cycle."
89398976|NCT01380587||Acute Lymphoblastic Leukemia|We will invite patients with newly diagnosed acute lymphoblastic leukemia in the Department of Hematology, who had not received anticancer therapy and regardless the subtype and immunophenotype of the disease.
89398977|NCT02164370||non-pregnant controls|Acid-base in healthy non-pregnant women in childbearing age
89398978|NCT02164370||healthy pregnant control group|healthy pregnant volunteers matched in gestational age to cases
88875074|NCT02418546|Active Comparator|In-Person Nutritional Counseling|Participants in the in-person nutritional counseling arm will meet with a Registered Dietitian at every clinic visit and will also receive regular phone calls to monitor weight and food intake. Participants' individual dietary needs will be calculated using baseline calorie consumption, weight history, disease status and current activity level.
89398979|NCT02164370||severe pre-eclampsia|Acid-base in severe pre-eclampsia
89398980|NCT02167958|Experimental|Treatment|"Day -6, -5 Fludarabine 30 mg/M2 IV over 30-60 minutes Cyclophosphamide 14.5 mg/kg IV over 1-2 hours*, Mesna 14.5 mg/kg IV in 4 divided doses~Day -4 through -2 Fludarabine 30 mg/M2 IV over 30-60 minutes~Day -1 Total Body Irradiation 200 cGy, donor apheresis~Day 0 T cell replete PBSC~Days 3, 4 Cyclophosphamide 50 mg/kg IV Mesna 50 mg/kg IV in 4 divided doses~Day 5 Begin tacrolimus ,mycophenolate, and G-CSF"
89398981|NCT03698175|Experimental|Three good things exercise|
89398982|NCT03698175|Placebo Comparator|Unspecific childhood memory recall exercise|
89398983|NCT01384331|Active Comparator|Group 1 Marvelon ,placebo|"7 days daily intake of oral capsule containing Marvelon ethinyl oestradiol 30micrograms plus desogestrel 150 micrograms followed by 14 days oral placebo capsules containing starch for 21 day treatment Cycle"
89398984|NCT01384331|Active Comparator|Marvelon|"21 days daily intake of oral capsules containing ethinyl oestradiol 30micrograms plus desogestrel 150 micrograms~for one cycle of 21 days"
89398985|NCT01384331|Active Comparator|NuvaRing|21 days NuvaRing contraceptive vaginal ring releasing ethinyl oestradiol 15micrograms plus etonorgestrel 120 micrograms dailyleft in situ for 21 days Treatment will be for 21 days
89398986|NCT01384331|Placebo Comparator|Starch capsule|21 days daily oral placebo capsules Treatment will be for one 21 day cycle
89398987|NCT03699423|Active Comparator|0.01% atropine eye drops|Participants will receive one drop per eye every night for two weeks
88875075|NCT02418546|Experimental|E-Health App for Nutritional Counseling|Participants randomized to the e-Health App arm with receive nutritional counseling using the e-Health Application. Participants will enter weights at home and complete electronic food records using the App. Participants' individual dietary needs will be calculated using baseline calorie consumption, weight history, disease status and current activity level. Participants will receive these calorie recommendations through the Application.
88875076|NCT02418546|No Intervention|Standard Care|Participants are allowed to receive all usual treatments and medications. Participation in other research studies is allowed.
88875077|NCT02421354|Experimental|Treatment (nivolumab)|Patients receive nivolumab IV over 60 minutes once every 2 weeks for 8 doses and then once every 12 weeks thereafter. Treatment may continue for up to 4 years in the absence of disease progression or unacceptable toxicity.
89188719|NCT00916409|Experimental|NovoTTF-100A device in combination with Temozolomide|patients will be treated continuously with the NovoTTF-100A device, in addition to Temozolomide. NovoTTF-100A treatment will consist of wearing four electrically insulated electrode arrays on the head. The treatment enables the patient to maintain regular daily routine.
89398988|NCT03699423|Active Comparator|0.02% atropine eye drops|Participants will receive one drop per eye every night for two weeks
89398989|NCT03699423|Active Comparator|0.03% atropine eye drops|Participants will receive one drop per eye every night for two weeks
89398990|NCT02164448|Experimental|dexmedetomidine group|
89398991|NCT02164448|Placebo Comparator|control group|
89398992|NCT02164526||No treatment|
89398993|NCT03697941||Surgical cut-down and arterial puncture under direct vision|
89398994|NCT03697941||Percutaneous arteriotomy closed with closure device|
89398995|NCT01380509|Experimental|A|Subjects received kali product under fasting conditions
89398996|NCT01380509|Active Comparator|B|Subjects received Searle product under fasting conditions
89398997|NCT03699267||UBR TRAM / GBA|Patients scheduled for unilateral breast reconstruction surgery with TRAM flap whose anesthetic plan adopted by the anesthetist was general balanced anesthesia
89398998|NCT03699267||UBR TRAM / GBA + TAP|Patients scheduled for unilateral breast reconstruction surgery with TRAM flap whose anesthetic plan adopted by the anesthetist was general balanced anesthesia combined with US-guided bilateral TAP block
88875078|NCT02422290|Experimental|Adolescents and young adults with OCD|All participants will be receive the intravenous ketamine infusion.
88875079|NCT02425956|Experimental|MRI imaging of liver|GE Optima/Discovery® MRI imaging data of the liver and surrounding tissues will be acquired using 1.5T and 3.0T GE Healthcare (GEHC) IDEAL IQ scans and commercially available 1.5T MRI scans conducted according to the FerriScan®
89188720|NCT00916409|Active Comparator|Temozolomide alone, as the best known standard of care|Patients will be treated with Temozolomide, as the best known standard of care for Glioblastoma Multiforme patients.
89188721|NCT00659529|Experimental|1|All subjects will receive oral sildenafil three times per day during the study. Study endpoints will be measured before the treatment period and at the end of the treatment period.
88875080|NCT02427672|Experimental|Anodal stimulation|Participants in the active stimulation group will undergo anodal bilateral transcranial direct current stimulation (tDCS) of the dorsolateral prefrontal cortex. tDCS will be delivered by a battery-driven, constant-current stimulator connected to three saline-soaked surface sponge electrodes. Two anodal electrodes (25cm2) will be placed over the dorsolateral prefrontal cortex bilaterally and one cathodal electrode (35cm2) will be placed at the back of the neck. Scalp electrodes will be positioned over the F3 and F4 according to the 10-20 EEG international system. A current of 1mA will be applied for 20 minutes and the current will be ramped up and down at the beginning and end of the stimulation period.
88875081|NCT02427672|Sham Comparator|Sham stimulation|The sham transcranial direct current stimulation condition will involve the same placement of the electrodes, current intensity, and ramp time as the real tDCS condition, but stimulation will only last for 30 seconds.
88875082|NCT02427750|Experimental|Trivalent Influenza Vaccine|One injection of Agrippal®
88875083|NCT02430090|Experimental|Levobupivacaine|"Levobupivacaine, a local anesthetic agent, is indicated for the production of local or regional anesthesia or analgesia for surgery, for oral surgery procedures, for diagnostic and therapeutic procedures, and for obstetrical procedures.~Injection Surgical anaesthesia~Adult: Epidural block: 50-100 mg (10-20 ml) of a 0.5% solution or 75-150 mg (10-20 ml) of a 0.75% solution. Caesarean section: 75-150 mg (15-30 ml) of a 0.5% solution. Spinal block: 15 mg (3 ml) of a 0.5% solution. Max: 150 mg/dose; 400 mg/day. Injection Peripheral nerve block~Read more: http://www.ndrugs.com/?s=levobupivacaine#ixzz3Xvp0iS5T"
88875084|NCT02430090|Experimental|Levobupivacaine + fentanyl|"Fentanyl - Used for: Producing anesthesia for surgery and treating pain before, during, and after surgery.Fentanyl is a narcotic (opioid) analgesic. It works in the brain and nervous system to cause anesthesia and decrease pain.~Indications:~Adult: PO Breakthrough cancer pain As a loz: Initially, 200 mcg over 15 minutes for an episode of breakthrough pain; may repeat once after 15 minutes if needed. Not more than 4 unit doses/day. IV Adjunct to general anesth Patients w/ spontaneous resp: Initial: 50-200 mcg, w/ supplements of 50 mcg. Patients w/ assisted ventilation: Initial: 300-3,500 mcg (up to 50 mcg/kg), w/ supplements of 100-200 mcg depending on response.~Read more: http://www.ndrugs.com/?s=fentanyl#ixzz3XvpAcULL"
88875085|NCT02430090|Experimental|Levobupivacaine + sufentanil|"Sufentanil is a synthetic opioid analgesic. Sufentanil exerts its principal pharmacologic effects on the central nervous system. Its primary actions of therapeutic value are analgesia and sedation.~Maintenance: Additional doses of 0.5-10 mcg/kg may be given if needed. Max (total dose): 30 mcg/kg. Post-op pain Initial: 30-60 mcg. Additional doses of up to 25 mcg may be given at intervals of ≥1 hr if needed. Epidural Pain relief during labour and delivery W/ bupivacaine: 10-15 mcg w/ or w/o epinephrine. May repeat dose twice at intervals of ≥1 hr till delivery. Max (total dose): 30 mcg.~Read more: http://www.ndrugs.com/?s=sufentanil#ixzz3XvqVyLzx"
88875086|NCT02431572|Experimental|Metastatic Melanoma to the Brain (Cohort A)|"Assess Inflammation (PBR PET)~Immunotherapy~Assess Inflammation (PBR PET)"
88875087|NCT02431572|Experimental|Primary Brain Tumor (Cohort B)|"Assess Inflammation (PBR PET)~Immunotherapy~Assess Inflammation (PBR PET)"
88875088|NCT02431572|Experimental|Primary Brain Tumor (Cohort C)|"Chemoradiation~Assess inflammation (PBR PET)~Follow Patients"
88875089|NCT02431650|Experimental|OZ439|"Each participant in the cohort will be inoculated on Day 0 with ~2,800 viable parasites of Plasmodium falciparum-infected human erythrocytes (BSPC) administered intravenously. when PCR quantification of all participants is ≥ 5,000 parasites/mL, they will receive a single dose of 480 mg of piperaquine phosphate to clear blood stage parasitemia. When gametocytemia is at the peak (approximately 15 days after administration of piperaquine), participants will be randomised to receive either OZ439 or a control group (primaquine treatment).~In the first cohort 500 mg OZ439 will be administered as a single dose. Doses used in subsequent cohort(s) will be determined following a review of observed safety and pharmacodynamic drug effects."
89188722|NCT02575508|Experimental|Treatment (oxaliplatin, irinotecan, fluorouracil, BGJ398)|Patients receive oxaliplatin IV over 2 hours, irinotecan hydrochloride IV over 90 minutes, and fluorouracil IV continuously over 46 hours on days 1 and 15. Patients also receive pan FGFR kinase inhibitor BGJ398 PO QD on days 8-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89188723|NCT00795015|Active Comparator|leuven|these patients had their IV insulin controlled by using the protocol adapted from van den Berghe et al. University of Leuven, Belgium, NEJM Nov. 2001
89188724|NCT00795015|Active Comparator|glucommander|these subjects had IV insulin controlled by a computer program called the glucommander described by Davidson, P et al Diabetes Care Oct. 2005
89188725|NCT04045899|Active Comparator|ProSeal Laryngeal Mask Airway Group|ProSeal LMA was inserted in 50 patients
89188726|NCT04045899|Experimental|Air-Q LMA Group|Air-Q LMA was inserted in 50 patients
89188727|NCT04045899|Experimental|Ambu AuraGain LMA Group|Ambu AuraGain was inserted in 50 patients
89188728|NCT02575586|Experimental|Dry Needling into MTrPs.|Intervention-Dry Needling: Deep Dry Needing into the medial Myofascial Trigger Point of the soleus muscle.
89188729|NCT02575586|Active Comparator|Dry Needling out of MTrPs.|Control-Dry Needling: Deep Dry Needling distal to Myofascial Trigger Point of the soleus muscle (in the same taut band).
89188730|NCT00795093||1|552 GERD patients, partial responders to PPI treatment
89188731|NCT00714818|Experimental|GC|One face-to-face genetic counseling session of 1-2hours duration, with a board certified or board eligible genetic counselor which will involve, documentation of a detailed family history, discussion of: the contributors to mental illness pathogenesis, illness risk reduction strategies, chances for family members to develop mental illness (if required), supportive counseling around living with illness/risk of illness/managing illness vulnerability, and referral to support organizations as required.
89188732|NCT00714818|Active Comparator|EB|Educational Booklet: One educational booklet that provides information about the causes of mental illnesses, and the chances for relatives of affected individuals to develop mental illness will be provided to participants
89188733|NCT00714818|No Intervention|WT|Waitlist
89398999|NCT03699267||M + UBR TRAM / GBA|Patients scheduled for partial/total or totalization mastectomy followed by TRAM reconstruction whose anesthetic plan adopted by the anesthetist was general balanced anesthesia
89399000|NCT03699267||M + UBR TRAM / GBA + TAP|Patients scheduled for partial/total or totalization mastectomy followed by TRAM reconstruction whose anesthetic plan adopted by the anesthetist was general balanced anesthesia combined with US-guided bilateral TAP block
89188734|NCT00843700|Experimental|Interpersonal Psychotherapy|Interpersonal Psychotherapy, 16 individual sessions within 32 weeks
89188735|NCT00843700|Active Comparator|Individual Psychotherapy|Individual Psychotherapy, 16 individual sessions within 32 weeks
89188736|NCT00796887|Experimental|Niaspan® 500mg|
89188737|NCT00796887|Experimental|Niaspan® 1000mg|
89188738|NCT00796887|Placebo Comparator|Placebo|
89188739|NCT00578942|Experimental|Campath Purged Non-myeloablative ASCT|Campath Purged Non-myeloablative Allo Stem Cell Transplant (ASCT) in lymphoma, myeloma, or marrow failure: leukemia or myelodysplasia; and solid tumors
89188740|NCT00835822|Experimental|A|Arm treated with Investigational product.
89188741|NCT00835822|Placebo Comparator|B|Arm treated with placebo.
89188742|NCT02553213|Experimental|LSG group|Laparoscopic sleeve gastrectomy
89188743|NCT02553213|Experimental|LRYGB group|Laparoscopic Roux-en-Y gastric bypass
89188744|NCT02553213|Other|Control group|Caloric restriction
88875090|NCT02431650|Active Comparator|Primaquine|"Each participant in the cohort will be inoculated on Day 0 with ~2,800 viable parasites of Plasmodium falciparum-infected human erythrocytes (BSPC) administered intravenously. when PCR quantification of all participants is ≥ 5,000 parasites/mL, they will receive a single dose of 480 mg of piperaquine phosphate to clear blood stage parasitemia. When gametocytemia is at the peak (approximately 15 days after administration of piperaquine), participants will be randomised to receive either OZ439 or a control group (primaquine treatment).~Primaquine is a positive control for OZ439, to be administered 15 mg as a single dose."
88875091|NCT02433366||Patients|
88875092|NCT02433366||Physicians|
88875093|NCT02435706|Experimental|Flapless immediate implant placement group|Flapless placement of immediate implant and temporary crown
88875094|NCT02435706|Active Comparator|Flap assisted immediate implant placement group|Flap elevation prior to placement of immediate implant and temporary crown
88875095|NCT02437344|Experimental|CI-581aa|CI-581aa will be administered 24 hours after last opioid use, and followed by naltrexone dosing
88875096|NCT02440308|Experimental|68Ga-DOTA-Bombesin PET/MRI|Patients receive 68Ga-DOTA-Bombesin IV and then undergo PET/MRI approximately 1 hour later.
88875097|NCT02444988|Active Comparator|0.9% Saline|Patients in an ICU block randomized to physiologically-balanced isotonic fluid will receive 0.9% Saline whenever isotonic intravenous fluid administration is ordered by the treating provider.
88875098|NCT02444988|Active Comparator|Physiologically-balanced|Patients in an ICU block randomized to physiologically-balanced isotonic fluid will receive Plasma-Lyte© A or Lactated Ringer's whenever isotonic intravenous fluid administration is ordered by the treating provider.
88875099|NCT02446314|Placebo Comparator|Placebo|Formulation containing inert artificially colored maltodextrin, once daily, in a 2-hard capsule regimen
88875100|NCT02446314|Experimental|Wild Blueberry Powder - 450mg|Formulation containing 225 mg wild blueberry powder + 22.5 mg L-Cysteine + 2.5 mg L-Glutathione + 250 mg placebo powder, once daily, in a 2-hard capsule regimen
88875101|NCT02446314|Experimental|Wild Blueberry Powder - 900 mg|Formulation containing containing 450 mg wild blueberry powder + 45 mg L-Cysteine + 5 mg L-Glutathione once daily, in a 2-hard capsule regimen
88875102|NCT02446314|Experimental|Wild Blueberry extract 100mg|Formulation containing containing 100 mg wild blueberry powder + 10 mg L-Cysteine + 1 mg L-Glutathione + 389 mg of placebo, once daily, in a 2-hard capsule regimen
88875103|NCT02448654|Active Comparator|Tolcapone|100mg tolcapone three times a day for 7 days then 100mg once a day on day 8
89188745|NCT02575274|Experimental|JHS COL-HAP91 + JHS HAP-91|Surgical flaps debridement with plastic curette Implacare Hu-Friedy, cleaning the surface with chlorhexidine gel 2% 3 minutes and irrigation with saline solution 0.9 %. Bone defects will be treated with JHS COL-HAP91 (porous hydroxyapatite + collagen) + JHS HAP-91 (porous hydroxyapatite). Amoxicillin 500 mg 3 times/day 7 days, Tylenol 750 mg 3 times/day, and Nimesulide 100 mg 2 times/day will be prescribed.
89188746|NCT02575274|Other|surgical and mechanical debridement|Surgical flaps: All groups will receive the same surgical treatment for implant surface decontamination. Surgical intervention will be performed with full thickness mucoperiosteal flaps. Debridement with plastic curette Implacare Hu-Friedy, cleaning the surface with chlorhexidine gel 2% 3 minutes and irrigation with saline solution 0.9 %. Amoxicillin 500 mg 3 times/day 7 days, Tylenol 750 mg 3 times/day and Nimesulide 100 mg 2 times/day will be prescribed.
89188747|NCT00843934|Experimental|anti-cancer agent|
89188748|NCT00805701|Active Comparator|0.5mg Avodart|.5mg avodart capsule orally once a day during 13 months
89188749|NCT00805701|Placebo Comparator|Placebo|placebo capsule orally daily for 13 months
89188750|NCT00714896|Other|1|Assessment only + referral list to State quitline and smoking cessation education classes at Kaiser
89399001|NCT01378715|Active Comparator|Rosuvastatin|Patients with coronary artery disease referred for coronary angiography and subsequently PCI will be enrolled and randomized to pre-treatment with rosuvastatin (20mg 12 hours prior + 20mg immediately prior PCI).
89399002|NCT01378715|No Intervention|Control|Patients with coronary artery disease referred for coronary angiography and subsequently PCI will be enrolled and randomized to no-pretreatment with rosuvastatin.
88875104|NCT02448654|Placebo Comparator|Sugar Pill|Sugar pill
88875105|NCT02449356|Experimental|prone position endotracheal tube(PPT)|the subjects of this arm are given the prone ventilation endotracheal tube which contains fixed device, fixed rope.
88875106|NCT02449356|No Intervention|traditional endotracheal tube(TT)|the subjects of this arm are given the routine endotracheal tube.
88875107|NCT02449434||Severe Tooth Wear|"Severe tooth wear with a BEWE score of 12 and at least one score of 3 in three quadrants Adult 18 years or older No missing anterior teeth Minimum of at 10 teeth in the upper and 10 teeth in the lower jaw No anterior crowns/ bridges or implants Written consent to the study~There was no intervention - just a questionnaire for each group"
88875108|NCT02449434||Without Tooth Wear|"BEWE score of 10 or lower and no score of 3 on any surface of any tooth (clinically classified as no or mild erosive tooth wear) Adult 18 years or older No missing anterior teeth Minimum of at 10 teeth in the upper and 10 teeth in the lower jaw No anterior crowns/ bridges or implants Written consent to the study~There was no intervention - just a questionnaire for each group"
88875109|NCT02451150|Experimental|Azilsartan 5 mg|Weight <50 kg: azilsartan 5 mg, tablets, orally, once, after breakfast on Day 1.
88875110|NCT02451150|Experimental|Azilsartan 10 mg|Weight ≥50 kg: azilsartan 10 mg, tablets, orally, once, after breakfast on Day 1.
89188751|NCT00714896|Experimental|2|Participants will receive self-help information handouts, expert system intervention that includes a stage-based manual and individualized written feedback reports plus in-person brief stage-appropriate counseling at baseline and 3-month assessment. Current smokers who indicate desire to quit smoking or former smokers who indicate high cravings for cigarettes will be offered nicotine replacement medications. Participants will receive three telephone counseling sessions delivered between baseline and 3 month at weeks 2, 4 and 8. As-needed telephone check-calls will be provided to participants on and 2 days after quit date, or to participants who have quit smoking and anticipate high risk situations.
89188752|NCT04042948|Experimental|Experimental Group|preventive use non-steroidal anti-inflammatory drugs to before the removal of drainage tube
88875111|NCT02452866|Experimental|SYM-1219|All pateints recieved single dose SYM-1219 Containing 2 Grams of Secnidazole
89188753|NCT04042948|No Intervention|Control Group|without any intervention when remove the drainage tube
89188754|NCT00796965|Experimental|1|
89188755|NCT00796965|Placebo Comparator|2|
89188756|NCT00765245|Experimental|Arm I: Lenalidomide|
89188757|NCT00765245|Experimental|Arm II: Lenalidomide and Rituximab IV|Patients receive lenalidomide as in arm I and rituximab IV on day 8 of courses 1, 3, 5, 7, 9, and 11 in the absence of disease progression or unacceptable toxicity.
89188758|NCT02546518|Experimental|Moniri Otovent|A face mask is connected to a tube to which a coloured balloon is attached. The tube is also connected to ambu bag balloon. A safety valve is used to prevent too high air pressure. The ambu bag balloon is hidden in a green soft toy in the form of frog. The parent and the child hold the face mask against the mouth and the child blows the balloon. On need, mainly in the beginning of treatment course, the parent presses the frog's abdomen in order to fill the balloon with air. During the first week day, a low pressure balloon is used, then it is changed with a higher pressure balloon. Full compliance for the treatment is defined as 20 blows (5 minutes) in the morning and evening for one month.
89188759|NCT02546518|Active Comparator|Tympanostomy tube in the ear drum|Operation for insertion of tympanostomy tube under general anesthesia.
89188760|NCT00801879|Active Comparator|Mupirocin ointment|0.25g mupirocin calcium ointment, 2% in each nostril twice daily for 5 days (repeated monthly for up to 8 months)
89188761|NCT00801879|Placebo Comparator|Placebo ointment|0.25g in each nostril twice daily for 5 days (repeated monthly for up to 8 months)
89188762|NCT00718484|Experimental|A|On Day 1 of each cycle (21 days), 150 mg/m2 IV (intravenous) palifosfamide tris and 75 mg/m2 IV doxorubicin are administered on the same day. Doxorubicin administration will be initiated approximately 60 minutes after the completion of palifosfamide tris dosing. Palifosfamide tris alone is administered on Days 2 and 3, every 3 weeks (one 21-day cycle).
89188763|NCT00718484|Active Comparator|B|On Day 1 of each cycle, 75 mg/m2 doxorubicin is administered IV.
89188764|NCT00841126|Experimental|Magnesium iron hydroxycarbonate|
89188765|NCT00841126|Active Comparator|Lanthanum carbonate|
89188766|NCT00841126|Placebo Comparator|Placebo|
89188767|NCT02553369||Enrolled patients|Patient randomly enrolled in the study within a cohort of patient followed for HIV infection.
89188768|NCT02575040|Other|Fecal microbiota transplantation|Fecal microbiota transplantation only
89188769|NCT00718562|Experimental|Nilotinib|
89188770|NCT00801957|Experimental|1|tacrolimus ointment 0.03%
89399003|NCT04818515|Experimental|Atogepant, Ubrogepant, and Coadministration|Participants will receive oral tablets of ubrogepant, followed be oral tablets of atogepant, followed by administration of oral tablets of atogepant and ubrogepant in combination, for a 30 day interventional period and a 7 day follow up period.
89399004|NCT02760602|Experimental|Solanezumab|Solanezumab given intravenously (IV) once every 4 weeks for up to 2 years.
89188771|NCT00801957|Active Comparator|2|hydrocortisone acetate 1% and butyrate 0.1%
89188772|NCT00801957|Other|3|Control group vaccination and challenge dose only
89188773|NCT02572544|Experimental|Participants|All participants perform all exams under 3 conditions, that is baseline, single pinhole glasses, and multiple pinhole glasses
89188774|NCT00916565||Experimental milk-based infant formula|
89188775|NCT00916565||Control milk-based infant formula|
89188776|NCT00916565||Breastfed Reference Group|
89188777|NCT02547688|Other|Nasal High Flow|All subjects are in this group
89188778|NCT00714974|No Intervention|1|Standard of care
89188779|NCT00714974|Experimental|2|Sedation based on BIS value, oer treating physician discretion.
89188780|NCT00836134|Experimental|1|rectus sheath block
89188781|NCT00836134|Active Comparator|2|local anesthetic infiltration
89188782|NCT00797043||Photon/Proton Radiation Therapy|Data consolidation and analysis
89188783|NCT00715052|Experimental|1|40 consecutive one hour treatments at 1.5 ATA with 100% O2
89188784|NCT00715052|No Intervention|2|
89188785|NCT00782795|Active Comparator|Pioglitazone|30 mg pioglitazone (Actos) tablet taken once daily for 48 weeks.
89188786|NCT00782795|Placebo Comparator|sugar pill (placebo)|1 sugar pill (placebo) taken once daily for 48 weeks.
89188787|NCT00841282|Active Comparator|1|Water Infusion in lieu of Air Insufflation Colonoscopy
89188788|NCT00841282|Placebo Comparator|2|Air Insufflation Colonoscopy
89188789|NCT00841360||HIV Positive|"Participant self-discloses as HIV positive.~Sexually experienced females between the ages of 13 and 24 years old and of African American race, Hispanic/Latina ethnicity, or mixed-race/ethnicity, which must include African American race and/or Hispanic/Latina ethnicity."
89188790|NCT00841360||HIV Negative|"Participant self-discloses as HIV negative (based on receiving a negative HIV test within 12 months prior to study consent).~Sexually experienced females between the ages of 13 and 24 years old and of African American race, Hispanic/Latina ethnicity, or mixed-race/ethnicity, which must include African American race and/or Hispanic/Latina ethnicity."
89399005|NCT02760602|Experimental|Placebo|Placebo given IV once every 4 weeks for up to 2 years.
89399006|NCT04129073||Cardiac arrest patients admitted to Intensive Care treatment|Intensive Care treatment; Utilization of neuroprognostication tools
89399007|NCT04687241|Experimental|Almonertinib|
89399008|NCT04687241|Placebo Comparator|Placebo Almonertinib|
89399009|NCT00976131|Placebo Comparator|Arm A Placebo|"Patients will begin taking their study pills (CoQ10) on the morning of Cycle 2 Day 3 (11-15 days prior to Cycle 3), and will continue taking the study pills through the morning of their Cycle 3 infusion (Day 1 Cycle 3). Patients will then be crossed-over to the alternative condition. On the morning of Cycle 3 Day 3, patients will begin taking their study pills (CoQ10 placebo) and will continue taking the study pills through the morning of their Cycle 4 infusion (Day 1 Cycle 4).~Infusion will be standard of care chemotherapy with doxorubicin and cyclophosphamide."
89399010|NCT00976131|Experimental|Arm B CoQ10|"Patients will begin taking their study pills (CoQ10 placebo) on the morning of Cycle 2 Day 3 (11-15 days prior to Cycle 3), and will continue taking the study pills through the morning of their Cycle 3 infusion (Day 1 Cycle 3). Patients will then be crossed-over to the alternative condition. On the morning of Cycle 3 Day 3, patients will begin taking their study pills (CoQ10) and will continue taking the study pills through the morning of their Cycle 4 infusion (Day 1 Cycle 4).~Infusion will be standard of care chemotherapy with doxorubicin and cyclophosphamide."
89399011|NCT01384253|Experimental|Phase I: Dose escalation|In preparation for the study, patients screened and eligible will have a peritoneal catheter placed and the evening prior to the injection of the labeled antibody will receive furosemide. Herceptin will be administered IV followed by a single IP infusion of ²¹²Pb-TCMC-Trastuzumab. Serial sampling of blood, urine, and dosimetry will be performed following treatment to determine the toxicity, pharmacokinetics, immunogenicity, and antitumor effects.
89399012|NCT03697863||Noninvasive Adjusted Ventilatory Assist|
89399013|NCT03697863||Noninvasive Pressure Support|
89399014|NCT03631277|Experimental|photo-activated oral disinfection|photo-activated oral disinfection is an advanced technology utilizing two non-toxic components, a photo-activating liquid and a LED light source that selectively target and abolish cariogenic bacteria and periodontal pathogens
89399015|NCT03631277|Active Comparator|calcium hydroxide|Calcium hydroxide is the gold standard for pulp capping, it permits reparative dentin bridge formation, maintains pulp vitality, protects the pulp against harmful stimuli and has antimicrobial effect
88875112|NCT02452944|Experimental|US-IFI group|"ultrasound-guided obturator nerve block with interfascial injection approach group (US-IFI; experimental group)~The stimulating needle without nerve stimulator advanced via an ultrasound to position the needle tip on the fascia between adductor longus and adductor brevis muscles. 10mL of local anesthetics were slowly injected. The needle was reinserted to position the needle tip on the fascia between adductor brevis and adductor magnus muscles, another 5mL of LA was injected.~After that, the needle was reinserted to the same spots attached with nerve stimulator at 1.0 mA. If adductor muscle twitching was shown, another 5mL of LA was injected, and it was documented as 'fail'."
88875113|NCT02452944|Active Comparator|US-NS group|ultrasound-guided obturator nerve block with nerve stimulating approach group (US-NS; control group) The stimulating needle attached to a nerve stimulator advanced via an ultrasound to position the needle tip on the fascia between adductor longus and adductor brevis muscles. The nerve stimulator was then turned on, and the stimulation current started at 0.5 mA. If adductor muscle twitching was observed on the sonogram even at the stimulation current 0.3mA, 10mL of local anesthetics were slowly injected. The needle was reinserted to position the needle tip on the fascia between adductor brevis and adductor magnus muscles. The stimulation current started at 0.5 mA. If adductor muscle twitching was visualized on the sonogram even at 0.3mA, another 5mL of LA was injected.
88875114|NCT02460666|Experimental|Tai-Chi Chih Classes|Participants will engage in 12 weekly 60 minute Tai-Chi-Chih classes.
88875115|NCT02460666|Active Comparator|Health Education and Wellness Classes|Participants will engage in 12 weekly 60 minute Health Education and Wellness classes.
88875116|NCT02461992|Experimental|Intravenous infusion of Xyntha|observation arm
88875117|NCT02462070|Experimental|IDP-118 Lotion|Lotion
88875118|NCT02462070|Active Comparator|IDP-118 Vehicle Lotion|Vehicle Lotion
88875119|NCT02462148|Experimental|4 mg Perineural Dexamethasone Group|4 mg of dexamethasone will be included in the saphenous nerve block mixture including 20 ml of 0.25% bupivacaine with 1:400,000 epinephrine. No systemic dexamethasone will be given.
88875120|NCT02462148|Experimental|1 mg Perineural Dexamethasone Group|1 mg of dexamethasone will be included in the saphenous nerve block mixture including 20 ml of 0.25% bupivacaine with 1:400,000 epinephrine. No systemic dexamethasone will be given.
88875121|NCT02462148|Placebo Comparator|Placebo Group|This group will receive only the saphenous nerve block mixture including 20 ml of 0.25% bupivacaine with 1:400,000 epinephrine. Dexamethasone will not be administered to this group systemically or perineural.
88875122|NCT02462382|Active Comparator|Ropivacaine infusion|270cc of Ropivacaine infusion at 5cc per hour. All patients will receive a reservoir for their catheters containing 280cc of either ropivacaine or saline that will infuse at a rate of 6cc per hour. The reservoirs will be attached in the operating room at the completion of the rotator cuff repair. Patients will be randomized intraoperative to receive either the ropivacaine or the saline.
88875123|NCT02462382|Placebo Comparator|Saline infusion|270cc of Normal Saline infusion at 5cc per hour. All patients will receive a reservoir for their catheters containing 280cc of either ropivacaine or saline that will infuse at a rate of 6cc per hour. The reservoirs will be attached in the operating room at the completion of the rotator cuff repair. Patients will be randomized intraoperative to receive either the ropivacaine or the saline.
88875124|NCT02464176|Experimental|4 mg dexamethasone group|Following lumbar plexus nerve block administration using bupivacaine and epinephrine, 4 mg of systemic dexamethasone will be administered to this group intravenously. The volume given intravenously will be identical for all groups.
89399016|NCT02171000|Experimental|BIBR 1048|BIBR 1048 MS
89399017|NCT01378637|Experimental|AMES Leg treatment|An investigational device flexes and extends the ankle over a range of 30 degrees while vibrators stimulate the tendons attached to muscles that move the foot. The subject's task is to assist the motion of the device by pulling or pushing with the foot. Feedback of ankle torque or the electrical signal produced by the muscles (EMG) while the subject is assisting the motion is provided during the 30 treatment sessions.
89399018|NCT03697785|Experimental|Beacon Caresystem with weaning advice|Beacon care system set up to give weaning advice and options to accept or reject advice.
89399019|NCT03697785|Other|Beacon Caresystem for monitoring only|Beacon care system attached but only for data collection purposes. No advice will be given.
89399020|NCT02168036||Patients with lung disease|General admission criteria for this project will require at least one of the following: (1) symptoms consistent with pulmonary disease with mediastinal lymph node involvement ; (2) chest X-ray and chest CT scan consistent with lung disease and mediastinal lymph node involvement; (3) Individuals with a lung biopsy consistent with lung disease and presenting with enlarged mediastinal lymph nodes; and (4) patients with diseases of organs with known association with lung disease and mediastinal lymph node involvement.
88875125|NCT02464176|Experimental|8 mg dexamethasone group|Following peripheral nerve block using bupivacaine and epinephrine administration, 8 mg of systemic dexamethasone will be administered to this group intravenously. The volume given intravenously will be identical for all groups.
88875126|NCT02464176|Placebo Comparator|Control Group|Normal saline will be used as a placebo control group given at the same time and in the same manner as the experimental groups following peripheral nerve block administration. The volume given intravenously will be identical for all groups.
88875127|NCT02466126|Experimental|bCBT/Direct Referral|A brief cognitive behavioral therapy intervention that offers 6 active- treatment sessions, each lasting 30 to 40 minutes, and telephone booster sessions to maintain changes.
88875128|NCT02466126|No Intervention|Enhanced Usual Care (EUC)|Participants are provided with educational information on depression and will be encouraged to seek additional depression care options through their primary care providers.
88875129|NCT02467842|Experimental|NBP607-QIV|Participants aged 19 years and older received a 0.5mL single intramuscular dose of Quadrivalent Inactivated Cell Culture-derived Influenza Vaccine containing 4 virus strains; A/H1N1, A/H3N2, B/Yamagata, B/Victoria on Day 0
88875130|NCT02467842|Active Comparator|NBP607-Y|Participants aged 19 years and older received a 0.5mL single intramuscular dose of Trivalent Inactivated Cell Culture-derived Influenza Vaccine containing 3 virus strains; A/H1N1, A/H3N2, B/Yamagata on Day 0
88875131|NCT02467842|Active Comparator|NBP607-V|Participants aged 19 years and older received a 0.5mL single intramuscular dose of Trivalent Inactivated Cell Culture-derived Influenza Vaccine containing 3 virus strains; A/H1N1, A/H3N2, B/Victoria on Day 0
88875132|NCT02468154|Experimental|splint|Splint is placed under the cast of children affected by spasticity who have to keep the heel unloaded.
88875133|NCT02468154|Active Comparator|standard care|To avoid pressure at the heel placing and maintaining the limb with the cast on cushions or folded sheets so that the heel is not resting on the bed plane
88875134|NCT02468700|Experimental|OTX-DP|OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use
88875135|NCT02468700|Placebo Comparator|PV|PV (placebo drug delivery vehicle)
88875136|NCT02469870|Experimental|Autism Parent Trainer (APT)|Practiced Routines was a facilitated program. It was organized into four modules that included a total of seven videos ranging from 3-13 minutes each. The topics overlapped with those in the TR program, but included more explicit information on function-based strategies, as well as mindfulness practice. Participants were assigned six fillable forms, and provided supplemental data collection tools. Additional resources focused on mindfulness and PBS within family routines. Eighteen brief guided audio meditations were available to participants via the Practiced MindTM mobile application. The meditations focused on bringing the parents' awareness to both internal and external experiences and helping them act intentionally.
88875137|NCT02469870|Active Comparator|Teaching Routines (Control|Teaching Routines was entirely self-directed. The program included eight modules with videos for each ranging 3 - 5 minutes in duration. The topics were antecedent-behavior-consequence method, creating task analyses, antecedent-based strategies, communication, reinforcement, teaching methods, and overcoming obstacles. Participants were assigned six activities using fillable forms and provided additional resources including examples, a glossary of terms, and a list of websites. No feedback was given to the parents apart from the automated completion responses. The participants were given access to the TR LMS for the duration of the study, but post and follow-up assessments were completed at 6 and 10 weeks (i.e., same as the PR condition).
88875138|NCT02470494|Experimental|Sound amplificatoin via EarLens CHD|Sound amplification provided via the EarLens CHD for subjects with hearing impairment.
88875139|NCT02472522|Placebo Comparator|Ropivacaine|Patients satisfying inclusion criteria will receive Subarachnoid Block with Bupivacaine Heavy 0.5% (11 mg/2.2 ml) with 25 micrograms of fentanyl. At the end of the procedure, bilateral TAP block will be performed using Landmark Technique with 2.5 mg/kg of ropivacaine diluted with 0.9% saline to a total volume of 40 ml (20 ml each side)
88875140|NCT02472522|Experimental|Ropivacaine + Dexmedetomidine|Patients satisfying inclusion criteria will receive Subarachnoid Block with Bupivacaine Heavy 0.5% (11 mg/2.2 ml) with 25 micrograms of fentanyl. At the end of the procedure, bilateral TAP block will be performed using Landmark Technique with addition of Dexmedetomidine 1 micrograms/kg to with 2.5 mg/kg of ropivacaine diluted with 0.9% saline to a total volume of 40 ml (20 ml each side) for the TAP block
88875141|NCT02476032|Experimental|Prof applied oxalate|Subjects will be randomized to either receive the Prof applied oxalate Crest Sensi-Stop strip (Procter & Gamble™). The oxalate strip contains 3% dipotassium oxalate desensitizing gel. The placebo strip is blank. The strips will be placed by a licensed dental professional and will be in place for 10 minutes. Subjects will be instructed to not rinse their mouth, drink, eat or brush their teeth for 30 minutes after completion of the treatment.
88875142|NCT02476032|Active Comparator|Self-applied oxalate|Participants randomized to the Active Comparator Group will have the following intervention: Intervention: self-applied oxalate (Crest Sensi-Stop strip Procter & Gamble™), which contains 3% dipotassium oxalate desensitizing gel. The strip will be placed by the participant, following the manufacturer's directions. The strip will be left in place for 10 minutes. Subjects will be instructed to not rinse their mouth, drink, eat or brush their teeth for 30 minutes after completion of the treatment.
89399021|NCT02261168|Other|Standardized living protocol|Subjects are kept at the research facility to adhere to a standardized living protocol, mimicking a normal daily living situation. During the study, multiple tests will be performed, including muscle biopsies, blood draws, MRS measurements and indirect calorimetry.
89399022|NCT03699189|Experimental|Immediate ANAIS|Participants that attend the training course immediately.
89399023|NCT03699189|No Intervention|Delayed ANAIS|Participants that attend the training course a year later.
88875143|NCT02476032|Sham Comparator|Prof applied placebo|Subjects will be randomized to either receive the Prof applied placebo Crest Sensi-Stop strip (Procter & Gamble™). The oxalate strip contains 3% dipotassium oxalate desensitizing gel. The placebo strip is blank (sham). The strips will be placed by a licensed dental professional and will be in place for 10 minutes. Subjects will be instructed to not rinse their mouth, drink, eat or brush their teeth for 30 minutes after completion of the treatment.
89399024|NCT02164604|Experimental|Ranibizumab|All eyes receive one intravitreal injection with 0.03ml ranibizumab
89399025|NCT02168114|Experimental|Duchenne Muscular Dystrophy|This arm will only include subjects that have a confirmed diagnosis of Duchenne Muscular Dystrophy. Subjects in this arm will not undergo any exercising, and will only be imaged by Optical and Magnetic Resonance Imaging and Spectroscopy techniques at a single time point.
88875144|NCT02476890|Experimental|Placebo then gefapixant 100 mg/Healthy (Sequence A)|Healthy participants in Sequence A received a single dose of placebo in treatment Period 1 then a single dose of gefapixant 100 mg in treatment Period 2. There was a minimum 48-hr washout between Periods 1 & 2.
88875145|NCT02476890|Experimental|Gefapixant 100 mg then placebo/Healthy (Sequence B)|Healthy participants in Sequence B received a single dose of gefapixant 100 mg in treatment Period 1 then a single dose of placebo in treatment Period 2. There was a minimum 48-hr washout between Periods 1 & 2.
88875146|NCT02476890|Experimental|Placebo then gefapixant 100 mg/Chronic Cough (Sequence A)|Chronic Cough participants in Sequence A received a single dose of placebo in treatment Period 1 then a single dose of gefapixant 100 mg in treatment Period 2. There was a minimum 48-hr washout between Periods 1 & 2.
89399026|NCT02168114|Experimental|Non-affected Subjects|This arm will contain subjects that are not affected by Duchenne Muscular Dystrophy. These subjects will undergo concentric exercising of one forearm, and eccentric exercising of the contralateral forearm. Two days following the exercising, subjects will undergo Optical Imaging and Magnetic Resonance Imaging and Spectroscopy.
89399027|NCT04676048|Experimental|ASC618|Experimental Arm
89399028|NCT03697473|Active Comparator|Nordic Hamstring Exercise Group|Participants were required to kneel on a gym mat keeping their hips in a slightly flexed position and to slowly lower themselves in a controlled manner as far as they could towards the ground. When they could no longer lower themselves as such, they were instructed to utilise their arms to buffer the fall and touch their chest off the ground, while maintaining tension in their hamstrings. Once their chest touched the ground they were instructed to immediately return to the starting position by pushing up with their hands.
89399029|NCT03697473|Experimental|Hip Extension Exercise Group|The participant lay on an exercise bench at a 45° angle with their hips held just over the top of the bench, their trunk erect and hips extended and their heel supported. Participants slowly flexed their hip until they reached 90° from the starting position and were then required to return to the starting position by extending through the hip while maintaining a neutral pelvic and trunk posture throughout. This exercise was then repeated on the opposite leg
88875147|NCT02476890|Experimental|Gefapixant 100 mg then placebo/Chronic Cough (Sequence B)|Chronic Cough participants in Sequence B received a single dose of gefapixant 100 mg in treatment Period 1 then a single dose of placebo in treatment Period 2. There was a minimum 48-hr washout between Periods 1 & 2.
88875148|NCT02480166|Experimental|8 weeks SOF/LED|Patients that are treatment naïve and without cirrhosis will be assigned to 8 weeks of treatment with fixed-dose combination sofosbuvir (400 mg) and ledipasvir (90 mg) daily.
88875149|NCT02480166|Experimental|12 weeks SOF/LED|Patients that are either treatment experienced or are cirrhotic will be assigned to 12 weeks of treatment with fixed-dose combination sofosbuvir (400 mg) and ledipasvir (90 mg) daily.
88875150|NCT02481258|Experimental|Ataciguat (HMR1766)|200mg taken daily for 12 months
88875151|NCT02481258|Placebo Comparator|Matching Placebo|Taken Daily for 12 months
88875152|NCT02483676|Experimental|Treadmill+anklebot|This group will receive gait training on a treadmill while wearing the anklebot with the adaptive control system.
88875153|NCT02483676|Active Comparator|Treadmill only|This group will receive gait training on a treadmill, without use of the anklebot.
88875154|NCT02486016|Experimental|Duragesic Reference Fentanyl TDS|Each volunteer participates in two procedure days using the Duragesic reference (RLD) fentanyl TDS with heating applied for one hour at hour 11 and hour 18, respectively.
88875155|NCT02486016|Active Comparator|Apotex Generic Fentanyl TDS|Each volunteer participates in two procedure days using the Apotex generic fentanyl TDS with heating applied for one hour at hour 11 and hour 18, respectively.
88875156|NCT02486016|Active Comparator|Mylan Generic Fentanyl TDS|Each volunteer participates in two procedure days using the Mylan generic fentanyl TDS with heating applied for one hour at hour 11 and hour 18, respectively.
88875157|NCT02486328|Other|Group MM|2 mg midazolam and 20mg meperidine given intravenously and additional 1-2mg midazolam and 20mg meperidine (wtih a maximum total of 5 mg midazolam and 50 mg meperidine) given when FPS greater than 3
88875158|NCT02486328|Other|Group RP|100 mcg/kg/min propofol infusion and 1 mcg/kg remifentanil bolus administered and additional 0,5 mcg/kg remifentanil bolus given when FPS greater than 3
88875159|NCT02491788|Experimental|Drug|10 mg of suvorexant 30 minutes prior to daytime sleep opportunity
89399030|NCT04571645|Experimental|Dociparstat sodium (DSTAT)|Treatment with standard intensive induction, reinduction, or consolidation chemotherapy and Dociparstat 4 mg/kg IV bolus on Day 1, administered 30 minutes after completion of the first dose of idarubicin or daunorubicin, followed by Dociparstat 0.25 mg/kg/hr via continuous IV infusion 24 hours daily for 5 or 7 days.
89399031|NCT04571645|Placebo Comparator|Placebo|Treatment with standard intensive induction, reinduction, or consolidation chemotherapy and Placebo IV bolus on Day 1, administered 30 minutes after completion of the first dose of idarubicin or daunorubicin, followed by Placebo via continuous IV infusion 24 hours daily for 5 or 7 days.
89399585|NCT03685617|Active Comparator|Dual chamber pacemaker|"Patients with sinus node disfunction: sinus node disfunction with obvious clinical symptoms, including sinus pause; patients with chronotropismus disfunction; patients have to take some medicine due to some diseases, but the medicine may result to sinus bradycardia.~Adult Acquired Atrioventricular Block (AVB): (1). Third degree or advanced atrioventricular block in any block part with symptomatic bradycardia (2). Patients taking other antiarrhythmic drugs in long term, which could result in third degree or advanced AVB (in any block part) and symptomatic bradycardia;~Patients with acute myocardial infarction (AMI) and AVB:~(1). Patients with His-Purkinje system persistent second degree AVB and retardant or third degree AVB after STEMI; (2). Patients with temporary severe second degree AVB or third degree AVB (block part under atrioventricular node) and retardant; 4. Patients with carotid sinus hypersensitivity or neurogenic syncope of the heart;"
89399586|NCT03685617|Experimental|His bundle pacemaker|His Bundle Pacemaker: All of the Criteria Inclusion of dual chamber pacemaker excluding patients with block part under the his bundle;
89399587|NCT02182856|Experimental|Ipratropium bromide/salbutamol sulphate|"Randomised sequence of four different treatments~Ipratropium bromide 500 µg/salbutamol sulphate 3 mg~Ipratropium 500 µg~Salbutamol sulphate 3 mg~Salbutamol sulphate 6 mg"
89399588|NCT03685383|Experimental|intervention group: eCPR + CytoSorb|In addition to standard treatment in patients undergoing eCPR in the intervention group the CytoSorb removal column will be added to the ECLS-system (intervention: CytoSorb removal column in eCPR).
89399589|NCT03685383|Active Comparator|control group: eCPR - CytoSorb|Patients in the control group will receive standard treatment established for eCPR patients on our ICU. This standard treatment includes, among others, targeted temperature management (TTM) for the first 72 hours. For the use of ECLS as well as TTM we are following well established standard operating procedures (control: standard eCPR (va-ECMO)).
89399590|NCT02182934|Experimental|Ginsana|
89399591|NCT02182934|Placebo Comparator|Placebo|
89399592|NCT03692949|Experimental|LY3451838 Part A|Single ascending doses, administered intravenously (IV)
89399593|NCT03692949|Experimental|LY3451838 Part B|Single doses administered subcutaneously (SC)
89399594|NCT03692949|Placebo Comparator|Placebo Part A|Matching single doses administered intravenously (IV)
89399595|NCT03692949|Placebo Comparator|Placebo Part B|Matching single doses administered subcutaneously (SC)
89399596|NCT02183012|Experimental|A: Ibuprofen extrudate, fed state|
89399597|NCT02183012|Experimental|B: Ibuprofen extrudate, fasted state|
88921914|NCT06074458|Active Comparator|Diabetes Dashboard and Community Health Worker|Participants diabetes technology devices will be linked to a remote patient monitoring dashboard and will have access to a Smartphone application, as well as scheduled and as needed visits with a community health worker.
89399598|NCT02183012|Active Comparator|C: Ibuprofen lysinate tablet, fed state|
88921915|NCT06071416|Active Comparator|Group 1 BCP alone|Lateral bone augmentation with biphasic calcium phosphate BCP bone substitute application
89399599|NCT02183012|Active Comparator|D: Ibuprofen lysinate tablet, fasted state|
88921916|NCT06071416|Active Comparator|Group 2 BCP with I-PRF|Lateral bone augmentation with biphasic calcium phosphate BCP bone substitute application with addition of injectable platlet rich fibrin I-PRF
89399600|NCT02183012|Active Comparator|E: Ibuprofen tablet, fed state|
89399601|NCT02183012|Active Comparator|F: Ibuprofen tablet, fasted state|
89399602|NCT03683121||the traditional follow-up group|The dose and notes for the use of the Non-selective beta blockers were informed during outpatient follow-ups for the patients with a history of esophageal variceal bleeding
89399603|NCT03683121||Non-traditional follow-up|The dose and notes for the use of the Non-selective beta blockers were informed during telephone or WeChat follow-ups for the patients with a history of esophageal variceal bleeding
89399604|NCT03683121||Combine of Group1 and Group2|The dose and notes for the use of the Non-selective beta blockers were informed during outpatient follow-ups for the patients with a history of esophageal variceal bleeding,and the patients were followed up by telephone or WeChat again on the same day.
89399605|NCT03536468||Patients pending complete tooth loss|Will be recruited patients pending tooth loss, ages between 18 and 65 years, whose dental conditions have previously been identified
89399606|NCT03688737|Placebo Comparator|control group|"A) Control group:~Has Surgical procedures von Langenbeck technique  to repair cleft palate and will come for follow up visit at day of surgery, 1st day and 3rd day for placebo device like LLL and come for follow up visits at 5th day ,2 weeks, month and 3 months postoperative"
89399607|NCT03688737|Active Comparator|study group|"B) Study group:~This group will be subjected to the same surgical procedure von Langenbeck technique to repair cleft palate but low level laser Therapy will be at day of surgery, 1st day and 3rd day and come for follow up visits at 5th day ,2 weeks, month and 3 months postoperative"
89399608|NCT02180048|Active Comparator|400 mg of caffeine/day (Two 200mg pills/day)|One phase of treatment will have participants consume two 200 mg-caffeine pills day (total of 400 mg of caffeine/ d) for 7 days.
89399609|NCT02180048|Active Comparator|200 mg of caffeine/day (One 200mg pill and one placebo pill)|This arm will receive one 200 mg caffeine pill and one sugar pill (placebo pill)
89399610|NCT02180048|Placebo Comparator|Two placebo pills/day|This arm will have participants consume two placebo pills each day.
89399611|NCT03688659|Other|vancomycin,gentamycin in endocarditis|patients with infective endocarditis will recieve intravenous infusion Vancomycin 30 mg/kg/day for 4:6 weeks and intravenous Gentamycin 3mg/kg/day for 2 weeks
89399612|NCT02180126||Positive ANCA|Patients with borderline positive ANCA results.
89399613|NCT03683043|Active Comparator|Transabdominal guided transfer|In the trans-abdominal guided embryo transfer group, the patients' bladder were filled by 500-700 ml saline; in order to enhance the visualization. The trans-abdominal probe is applied on pelvis by an assistant nurse or the attending gynecologist intern
89399614|NCT03683043|Active Comparator|Transvaginal guided transfer|the trans-vaginal guided embryo transfer group had their bladder emptied by the gynecologist via catheter prior to transfer or else the patient was asked to void. The speculum is applied followed by insertion of the outer sheath of the transfer catheter. The speculum is removed with caution; to maintain the outer sheath in place. The TVUS probe is applied vaginally and endometrium is visualized before transfer. The transfer is done through an inner catheter applied to the already inserted outer sheath
89399615|NCT02180204|Experimental|Tenecteplase|Tenecteplase 0.25 mg/kg IV - Maximum dose: 25 mg
89399616|NCT02180204|Active Comparator|Alteplase|Alteplase 0.9 mg/kg IV - Maximum dose: 90 mg
89399617|NCT03685227|No Intervention|Control|Participant will lie quietly for 90 minutes. They will be allowed to sleep.
89399618|NCT03685227|Experimental|Yoga Nidra|Participant will practice yoga nidra (using a recording) during the first 30 minutes of the 90 minute measurement period. Then they will be allowed to sleep.
89399619|NCT02183090|Experimental|Meloxicam ampoule|
89399620|NCT02183090|Active Comparator|Meloxicam tablet|
89399621|NCT02752802|Active Comparator|Treatment|The treatment group will include standard of care for diagnostic angiogram along with the utilizization of the DyeVert system.
89399622|NCT02752802|Active Comparator|Control|The control group will include standard of care for diagnostic coronary angiograms.
89399623|NCT02180282|Experimental|Acne Treatment|Acne treatment using the M22-IPL acne filter
89399624|NCT02177474|Experimental|Telephone based peer support|The telephone based peer support was delivered by 11 women with chd aged 54 to 73 years, living all over Germany. Participants could call according to their needs during scheduled times on workdays.
89399625|NCT02177474|Other|Waitlist Group|Waitlist condition with delayed telephone based peer support starting at 5 months
89399626|NCT02180360|Experimental|Capoeira training group|"The Capoeira training was performed during eight weeks, twice a week with duration of 60min each session, divided in 1) initial part: 10min warm-up with activities of low intensity or the ginga used in Capoeira; 2) main part: from the Basic Programmed Lesson (40min) and ; 3) final part: Capoeira presentation of 10min. In this last moment, the participants remained in a circle and, in pairs, executed the movements practiced earlier in the sessions. In order to perform the Basic Programmed Lesson, the activities were divided in four stages, composed by ginga and other movements: dodging, unbalancing, traumatizing and acrobatic. The volunteers would perform the initial part of the basic lesson (ex. 1st stage) and afterwards, when performing the subsequent part (ex. 2nd stage), would first repeat the 1st basic lesson, with the purpose of continuing the learning process and improving the previous lesson."
89399627|NCT02180360|No Intervention|Control group|The Control group did not perform any physical exercise during the intervention period (eight weeks).
89399628|NCT02177552|Experimental|Experimental chemotherapy|Intravenous carboplatin (C) AUC5 day 1 plus intravenous docetaxel (T) 60 mg/m2 day 1 plus oral capecitabine (X) 1000 mg/m2 twice daily from day 1-14, every 4 weeks.
88875520|NCT03712410|Active Comparator|Group 1 (PISCES face to face)|"Family caregivers will receive three sessions of the PISCES intervention in person. The agenda for the first face to face visit for caregivers (suggested timeline 5-7 days after hospice admission) includes an explanation of the purpose of the visit/call. During the first session, the interventionist works on steps one and two of the ADAPT model, namely Attitude and Defining the Problem and Setting Realistic Goals. During the second visit (suggested timeline 11-13 days after hospice admission) the interventionist covers steps three and four of the ADAPT model. Step three encourages caregivers in being creative and generating alternative solutions. Step four focuses on predicting the consequences and developing a solution plan. The third visit (suggested timeline 16-18 days after hospice admission) focuses on step five, namely trying out the solution plan and determining if it works."
88875521|NCT03712410|Experimental|Group 2 (PISCES delivered in a hybrid format)|In this group, participants will receive the PISCES intervention in three sessions; however, the first session will be delivered face to face and the other two via video. The three intervention sessions will be scheduled with a suggested timeline between days 5 and 18 of the hospice admission. The first session will take place in person (suggested timeline 5-7 days after hospice admission). After the first session where the in-person encounter will allow for the establishment of rapport between the interventionist and the caregiver, the second session (suggested timeline 11-13 days after hospice admission) and the third session (suggested timeline 16-18 days after hospice admissions) will be conducted via live videoconferencing. If the caregiver already has access to a computer and Internet, they will utilize the videoconferencing solution. If videoconferencing is not feasible, the sessions will be delivered over the regular phone.
89399629|NCT02177552|Other|Standard chemotherapy|Intravenous epirubicin (E) 50 mg/m2 day 1 plus intravenous oxaliplatin (O) 130 mg/m2 day 1 plus oral capecitabine (X) 625 mg/m2 twice daily continuously, every 3 weeks
89399630|NCT03682653|Active Comparator|Azithromycin|a single dose of Azithromycin will be administered to infants between their 8-27th days of life
89399631|NCT03682653|Placebo Comparator|Placebo|a single dose of placebo will be administered to infants between their 8-27th days of life
89399632|NCT04548128||Treatment Arm|The treatment arm will have the HM3 LVAS implanted utilizing a technique other than full median sternotomy (e.g. thoracotomy).
88921917|NCT06066203|Experimental|Study treatment|Participants receive GNC-035 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
89399633|NCT03684993|Experimental|Arabic gum extract|natural product Arabic gum (acacia gum) prepared as a mouthwash
89399634|NCT03684993|Experimental|Licorice root extract|natural product Licorice (Glycyrrhiza Glabra) root extract prepared as a mouthwash
89399635|NCT03684993|Active Comparator|Chlorhexidine|chemical agent Chlorhexidine as a mouthwash
89399636|NCT03684915|Experimental|rotary files|"Pre-operative radiograph showing all roots and their apices.~Local anaesthetic (to enable use of rubber dam clamp).~Rubber dam isolation.~Removal of caries.~Removal of roof of pulp chamber.~Removal of any remains of coronal pulp tissue with sharp sterile excavator or large bur in slow hand piece.~Identify root canals.~Irrigate with normal saline (0.9%)~Estimate working lengths of root canals keeping 2 mm short of the radiographic apex.~Insert rotary files into canals and debride the canals lightly and gently.~Irrigate the root canals.~Dry canals with pre-measured paper points, keeping 2 mm from root apices.~Canals will be dried with paper points, obturated by injecting Metapex. (Meta Biomed - Metapex Root Canal Filling Material)~Stainless steel crown will be performed"
88921918|NCT06064526||Group 1|The source population for this study is adult participants with severe asthma treated with dupilumab in routine clinical practice in the UK.
89011490|NCT01643356|Active Comparator|Resistant Starch|Women assigned to this arm will receive the group based behavioral intervention plus the recommendation to consume provided resistant starch to control hunger
89536668|NCT03066453|Experimental|Standard cure|Antibiotic IV (Nebcin) 14 days and 14 days of tobramycin IV associated with one or more other antibiotic (s) IV in routine care
88875522|NCT03712410|Experimental|Group 3 (PISCESplus)|"PISCESplus is meant to be an enhanced version of the PISCES intervention including the original problem solving therapy modules with the addition of positive reappraisal elements. The suggested timeline for the first session which will be in person is 5-7 days after hospice admission. At the end of the first session, the interventionist will ask the caregiver to take the time to think about and identify some positive aspects of caregiving.~At the end of the second session (which is scheduled to take place via video approx. 11-13 days after admission) the interventionist will ask the caregiver to go over the benefits or positive aspects of caregiving that they had identified and ask them to comment as to why they perceive these as positive or beneficial.~The third session will also take place via video."
88875523|NCT03712410|Experimental|Group 4 (PISCESplus online)|Participants in this group receive the PISCES plus intervention (the PISCES intervention with the enhancement of the positive reappraisal elements) delivered fully online. All assessments and sessions take place online.
88875524|NCT03139344|Experimental|Acute gene regulation: low frequency|Adaptations in gene regulation in response to single-session low-frequency exercise.
88875525|NCT03139344|Experimental|Acute gene regulation: high frequency|Adaptations in gene regulation in response to single-session high-frequency exercise.
88875526|NCT03139344|Experimental|Training study: low frequency|Adaptations in gene regulation, systemic metabolic markers, and patient-report metrics in response to training with low-frequency exercise.
88875527|NCT03139344|Experimental|Training study: high frequency|Adaptations in gene regulation in response to training with high-frequency exercise.
88875528|NCT03139344|No Intervention|Comparator cohort|Participants will undergo selected outcome measures to provide comparison values for Experimental arms.
88875529|NCT02960646|Experimental|Treatment (peripheral blood stem cell transplantation)|Patients receive melphalan IV over 30 minutes on day -6 and fludarabine phosphate IV over 1 hour on days -6 to -3. Patients undergo TBI on day -2 and CD45RA depleted peripheral blood stem cell transplantation on day 0. Patients also receive cyclophosphamide IV over 3 hours on days 3-4. Beginning on day 5, patients receive tacrolimus IV for 2 weeks and PO for at least 4 months. Beginning on day 7, patients receive filgrastim SC daily. Patients with CD20 positive lymphoma may receive rituximab IV on days -13, -6, 1, and 8.
88875530|NCT02909556|Experimental|ACURATE neo AS|
88875531|NCT02894658|Experimental|Lipiflow system|Treatment through the use of heat and pulsatile pressure.
88875532|NCT02894658|Active Comparator|Fellow eye warm compresses|Warm compresses to fellow eye and daily treatment with eyelid scrubs.
88875533|NCT02758626|Active Comparator|Ataluren Followed By Placebo|Cross Over Design: Treatment Period 1 with Ataluren (Week 0/Day 1 to Week 12), Washout Period (Week 12 to Week 16), crossover to Placebo Treatment Period 2 (Week 16 to Week 28), and Follow-up (Week 28 to Week 32).
88875534|NCT02758626|Active Comparator|Placebo Followed by Ataluren|Treatment Period 1 with Placebo (Week 0/Day 1 to Week 12), Washout Period (Week 12 to Week 16), crossover to Treatment Period 2 with Ataluren(Week 16 to Week 28).
88875535|NCT02678832||Cancer patients|breast cancer prostate cancer colorectal cancer
88875536|NCT02678832||Physicians|working in in- and outpatient care
88875537|NCT02678832||Oncology nurses|working in in- and outpatient care
88875538|NCT02587572|Experimental|LMSCs 10 million IV|A total of 10 subjects will receive: A single peripheral intravenous (IV) infusion of 10 x10^6 (10 million) of LMSCs to be administered on day 1.
88875539|NCT02587572|Placebo Comparator|Placebo (Plasmalyte A,HSA) IV|10 subjects will receive: A single peripheral intravenous (IV) infusion of Plasmalyte A containing human serum albumin (HSA) to be administered on day 1.
88875540|NCT02587572|Experimental|LMSCs 20 million IV|10 subjects will receive: A single peripheral intravenous (IV) infusion of 20x10^6 (20 million) LMSCs to be administered on day 1.
88875541|NCT02587572|Experimental|LMSCs100 million IV|10 subjects will receive: A single peripheral intravenous (IV) infusion of 100x10^6 (100 million) LMSCs to be administered on day 1.
88875542|NCT02357784|Experimental|Current Perception Threshold Testing|The subjects in this study will undergo Current Perception Threshold Testing and fill out several questionnaires both before their Sacral Nerve Modulator device implantation and again 3 months after the device implantation.
88875543|NCT02022384||study patients|Blood sample and life quality questionnaires
88875544|NCT01448616|No Intervention|Run-in Phase|Women will first participate in a run-in phase with twice daily swabbing.
88875545|NCT01448616|Experimental|Study Drug Phase: TDF|Participants will take tenofovir disoproxil fumarate (TDF) tablets and apply a placebo vaginal gel. Participants will begin treatment and swab the genital region twice daily for 5 more weeks. Study drugs will be administered once daily.
88875546|NCT01448616|Experimental|Study Drug Phase: Vaginal TFV Gel|Participants will take oral placebo tablets and apply a tenofovir 1% (TFV) vaginal gel. Participants will begin treatment and swab the genital region twice daily for 5 more weeks. Study drugs will be administered once daily.
88875547|NCT01448616|Placebo Comparator|Study Drug Phase: Double Placebo|Participants will take oral placebo tablets and apply a placebo vaginal gel. Participants will begin treatment and swab the genital region twice daily for 5 more weeks. Study drugs will be administered once daily.
88875548|NCT01320696|Experimental|Cohort 1|50 subjects will be randomized 1:1:1:1:1 to 5 dose groups (10 subjects per treatment group) to receive 2 intramuscular injections of RG reassortant A/H9N2 influenza vaccine on Day 1 and Day 22
88875549|NCT01320696|Experimental|Cohort 2|After a safety data review of the first 50 subjects, a further 225 subjects will be randomized 1:1:1:1:1 to 5 dose groups and will receive 2 intramuscular injections of RG reassortant A/H9N2 influenza vaccine on Day 1 and Day 22
88875550|NCT00853632|Other|Device - CEP Mitral Valve|
89399637|NCT03684915|Active Comparator|manual files|All steps as that of intervention group are to be followed except step (j) instead of it; a manual files will be inserted into the canals for debridement lightly and gently
89399638|NCT02177630||Magnetic resonance imaging and endomyocardial biopsy|Magnetic resonance imaging and endomyocardial biopsy
89399639|NCT04059315||Retrospective cross sectional study|"This is an Epidemiological observational analytic study where the subjects sustained with oral and maxillofacial trauma will be divided into the two-time-frame;~1st, retrospective study between 1 June 2011 to 31 May 2019"
89399640|NCT04059315||Prospective cohort study|2nd prospective study on 1 June 2019 to 1 June 2021.
89399641|NCT04062279||case group|patients diagnosed with idiopathic paaarkinson's disease according to the clinical criteria.
89399642|NCT03623685|Experimental|voluson 8|
88875551|NCT00074412|Experimental|2A|For infants: extended treatment with NVP
88875552|NCT00074412|Placebo Comparator|2B|For infants: extended treatment with NVP placebo
88875553|NCT02618772|Placebo Comparator|Intranasal Saline|0.08ml/kg of saline to a maximum of 2ml intranasally with an atomizer MAD-300
88875554|NCT02618772|Active Comparator|Intranasal Midazolam|0.08ml/kg (0.4mg/kg of 5mg/ml IV solution) intranasal midazolam, to a maximum of 2ml (10mg), with an atomizer MAD-300
88875555|NCT02619396|Active Comparator|"Group 20 W / LSI 4"|Patients elected to atrial fibrillation (AF) ablation and randomized to Combination 1 of radiofrequency (RF) power and Lesion Size Index (LSI) on left atrial (LA) posterior wall
88875556|NCT02619396|Active Comparator|"Group 40 W / LSI 4"|Patients elected to atrial fibrillation (AF) ablation and randomized to Combination 2 of radiofrequency (RF) power and Lesion Size Index (LSI) on left atrial (LA) posterior wall
88875557|NCT02619396|Active Comparator|"Group 20 W / LSI 5"|Patients elected to atrial fibrillation (AF) ablation and randomized to Combination 3 of radiofrequency (RF) power and Lesion Size Index (LSI) on left atrial (LA) posterior wall
88875558|NCT02619396|Active Comparator|"Group 40 W / LSI 5"|Patients elected to atrial fibrillation (AF) ablation and randomized to Combination 4 of radiofrequency (RF) power and Lesion Size Index (LSI) on left atrial (LA) posterior wall
88875559|NCT02620878|Experimental|AP|"Experimental arm: A closed-loop control system (artificial pancreas) will be used during night and day for 72 hours (3 days) with the aim of automate insulin infusion by an insulin pump to control glucose level. AP is composed of a CGM device (Dexcom G4), an insulin pump (Accu Chek Spirit combo, Roche), and a model predictive control algorithm that is embedded in a smartphone and wirelessly linked to the CGM device and insulin pump. A remote monitoring will be ensured all the time the AP will be active and study team will be present in the camp.~Patients will be randomly assigned to receive either 3 days of automated closed-loop insulin delivery (intervention) followed by 3 days of sensor -augmented pump therapy (control), or the inverted sequence"
88875560|NCT02620878|Active Comparator|SAP|"Active Comparator: Sensor Augmented Pump (SAP teraphy : CGM + insulin pump) will be used for 72 hours during day and night (3 days).~Patients will be randomly assigned to receive either 3 days of SAP (Control) followed by 3 days of automated closed-loop insulin delivery (intervention), or the inverted sequence"
88875561|NCT02621892|Experimental|50mg BID|Tenapanor
88875562|NCT02621892|Placebo Comparator|Placebo|Placebo
88875563|NCT02624700|Experimental|A: Pemetrexed + Sorafenib|Pemetrexed 500 mg/m2 IV Day 1 + Sorafenib 400mg PO twice each day on Days 1-5 of each 14-day cycle
88875564|NCT02624700|Experimental|B: Pemetrexed + Sorafenib|Pemetrexed 375mg/m2 intravenously (IV) Day 1 + Sorafenib 200mg by mouth twice daily on days 1-5, every 21 days of each cycle.
88875565|NCT02625402|Experimental|Interactive decision aid|Group receiving brief interactive decision aid. The decision aids are the Shared Decision Points for hip and knee osteoarthritis from Healthwise
89011491|NCT01643395|Experimental|vertebroplasty|
89011492|NCT01643395|Other|conservative therapy (brace)|
89399643|NCT02756078|Active Comparator|Group 1 (TEST / CONTROL wear sequence)|Subjects randomly assigned to the TEST Contact Lens or the CONTROL Contact Lens in the TEST / CONTROL wearing sequence will wear each of the study lenses for 4 weeks according to the manufacturer's guidelines. Subjects will be dispensed the other (second) lens type at the second dispense visit.
89399644|NCT02756078|Active Comparator|Group 2 (CONTROL / TEST wear sequence)|Subjects randomly assigned to the TEST Contact Lens or the CONTROL Contact Lens in the CONTROL / TEST wearing sequence will wear each of the study lenses for 4 weeks according to the manufacturer's guidelines. Subjects will be dispensed the other (second) lens type at the second dispense visit.
89399645|NCT02030132|Active Comparator|Feedback 50th Percentile|At the end of each week, participants will be told (by email or text, based on the participant's preference) the team's average daily step count for the previous week based on all 7 days. They will also be told the average for the 50th percentile in their arm. If the team's average daily step count is ≥ 7000 steps, the team will be eligible for the weekly lottery.
89399646|NCT02030132|Experimental|Feedback 75th Percentile|At the end of each week, participants will be told (by email or text, based on the participant's preference) the team's average daily step count for the previous week based on all 7 days. They will also be told the average for the 75th percentile in their arm. If the team's average daily step count is ≥ 7000 steps, the team will be eligible for the weekly lottery.
89399647|NCT02030132|Experimental|Feedback 50th Percentile + Forgiveness|At the end of each week, participants will be told (by email or text, based on the participant's preference) the average team's average daily step count for the previous week based on the best 5 of 7 days. They will also be told the average for the 50th percentile in their arm. If the team's average daily step count (best 5 of 7 days) is ≥ 7000 steps, the team will be eligible for the weekly lottery.
89189440|NCT05809804|Experimental|Age range of 18 to 44 years olds|The initial dose of esketamine was set as 0.06 mg / kg, and the injection time of esketamine was 5 s. One minute after injection of esketamine, sufentanil 0.4 μg / kg was injected within 5 s, and the number of coughs within 1 min after injection was recorded. According to the evaluation of sufentanil-induced cough, the dose of esketamine was adjusted. If the patient had no cough ( negative reaction ), the dose of esketamine in the next patient was reduced until the cough reaction occurred. If the patient had a cough reaction ( positive reaction ), the dose of esketamine in the next patient was increased until the cough disappeared. The dose ratio of adjacent esketamine was 1.1. Each group was selected from the previous patient with positive reaction until the 7 groups of positive and negative reactions appeared alternately, and the test was completed.
89189441|NCT05809804|Experimental|Age range of 45 to 59 years olds|The initial dose of esketamine was set as 0.06 mg / kg, and the injection time of esketamine was 5 s. One minute after injection of esketamine, sufentanil 0.4 μg / kg was injected within 5 s, and the number of coughs within 1 min after injection was recorded. According to the evaluation of sufentanil-induced cough, the dose of esketamine was adjusted. If the patient had no cough ( negative reaction ), the dose of esketamine in the next patient was reduced until the cough reaction occurred. If the patient had a cough reaction ( positive reaction ), the dose of esketamine in the next patient was increased until the cough disappeared. The dose ratio of adjacent esketamine was 1.1. Each group was selected from the previous patient with positive reaction until the 7 groups of positive and negative reactions appeared alternately, and the test was completed.
88875566|NCT02625402|Experimental|Video decision aid|Group receiving long video decision aids. The decision aids are the hip or knee DVD and Booklets for hip and knee osteoarthritis from Health Dialog
88875567|NCT02627118|Experimental|Dialyzer Comparison|2 MONTHS OF DIALYSIS WITH THE FRESENIUS 160NR followed by 2 MONTHS OF DIALYSIS WITH THE NIPRO ELISIO-15H
88875568|NCT02631954|Experimental|TR Group|Test drug: Vorico Injection 200mg(Voriconazole) Wash out: 7 days Reference drug: Vfend® IV 200mg
88875569|NCT02631954|Experimental|RT group|Reference drug: Vfend® IV 200mg Wash out: 7 days Test drug: Vorico Injection 200mg(Voriconazole)
88875570|NCT02632812|Experimental|Rebamipide & Naproxen|Rebamipide 100 mg effervescent granules (oral) Twice daily (total dose = 200 mg) for 7 days
88875571|NCT02632812|Placebo Comparator|Placebo & Naproxen|Sugar pill manufactured to mimic Rebamipide 100 mg effervescent granules (oral) Twice daily for 7 days
88875572|NCT02633358|Experimental|Therapeutic hypothermia group|Anti-inflammatory effect of therapeutic hypothermia. The hypothesis is anti-inflammatory effect triggered by IL-6 trans-signaling
88875573|NCT02633358|No Intervention|Control group|No therapeutic hypothermia for controlled data.
88875574|NCT02634684|Active Comparator|dextroamphetamine|"Drug: Dexedrine, dextroamphetamine, d-amphetamine.~Dosage form, frequency and duration: Each participant receives a single pill of placebo or active drug (dextroamphetamine 10 mg) 30 minutes after arriving at the lab. The participant then completes approximately 6 hours of testing in the laboratory. The participant stays at the lab for 7.5 hours in order to monitor physical condition in case the participant received the active pill One week later, that participant receives a single pill of the alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and one active pill, separated by one week."
88875575|NCT02634684|Placebo Comparator|Placebo|"Drug: Dexedrine, dextroamphetamine, d-amphetamine~Dosage form, frequency and duration: Each participant receives a single pill of placebo or active drug (dextroamphetamine 10 mg) 30 minutes after arriving at the lab. The participant then completes approximately 6 hours of testing in the laboratory. The participant stays at the lab for 7.5 hours in order to monitor physical condition in case the participant received the active pill One week later, that participant receives a single pill of the alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and one active pill, separated by one week."
88875576|NCT02635542|Active Comparator|Group CIS|Continual neuromuscular blockade (standard therapy) during general anesthesia will be provided with cisatracurium (CIS), with 0.2mg/kg IV given as an initial dose and repeated dosing determined by neuromuscular blockade monitoring (peripheral nerve stimulator maintained at 1-2 twitches).
88875577|NCT02635542|Experimental|Group SUX|A single dose of neuromuscular blockade (experimental group) will be provided at the start of anesthesia with succinylcholine (SUX), with 1mg/kg IV given as an initial dose and no repeat dosing.
88875578|NCT02636712||ImageReady™ MR Conditional Pacing System|"Subject must have the ImageReady™ System as their initial (de novo) pacing system implant~Subject has a Class I or II indication for implantation of a pacemaker according to the CSPE guidelines"
88875579|NCT02637804|Active Comparator|stenfilcon A vs narafilcon A (Group 1)|Participants are randomized to wear either stenfilcon A lens pair or narafilcon A lens pair, bilaterally, for 1 week during the cross over study.
89011493|NCT01643551||LVAD Group|18 years and older Planning to undergo VAD implantation
89189442|NCT05809765|Other|Group 1 dialysis on Mondays, Wednesdays, and Fridays|8-week breath training by using a disposable, flow-oriented, Triflow three-ball incentive spirometer.
89189443|NCT05809765|Other|Group 2 dialysis on Tuesdays, Thursdays, and Saturdays|8-week breath training by using a disposable, flow-oriented, Triflow three-ball incentive spirometer.
89189444|NCT05809726|Experimental|Manual lymph drainage group|Manual lymph drainage; neck drainage, abdominal drainage, stimulation of axillary lymph nodes, and right arm drainage were performed by following a special technique and sequence. MLD was applied in a comfortable position while the patient was lying in the supine position. It took an average of 20 minutes.
89189445|NCT05809726|Sham Comparator|Sham manual lymph drainage group|Sham manual lymph drainage; deep pressure was applied from distal to proximal with rapid movements to the right extremity to which the cold pressure test was applied. Fingers, dorsal and palmar surfaces of the hand, forearm, elbow, and upper arm were applied in order. The application was performed while the patient was lying in the supine position and lasted an average of 20 minutes.
89189446|NCT05809726|No Intervention|Control Group|Participants in the control group were asked to lie on their backs for 10 minutes without speaking in a quiet, calm environment. At the end of 10 minutes, the patient was placed in a sitting position again and the third evaluation was performed.
89437438|NCT03912012|Other|Children and adolescent with a history of type 1 diabetes|Children and adolescent from 10 to 18 years old, with a history of type 1 diabetes for at least 10 years. Glomerular hyper filtration and endothelial dysfunction will be evaluate.
89399648|NCT02030132|Experimental|Feedback 75th Percentile + Forgiveness|At the end of each week, participants will be told (by email or text, based on the participant's preference) the team's average daily step count for the previous week based on the best 5 of 7 days. They will also be told the average for the 75th percentile in their arm. If the team's average daily step count (best 5 of 7 days) is ≥ 7000 steps, the team will be eligible for the weekly lottery.
88875580|NCT02637804|Active Comparator|stenfilcon A vs delefilcon A (Group 2)|Participants are randomized to wear either stenfilcon A lens pair or delefilcon A lens pair, bilaterally, for 1 week during the cross over study.
88875581|NCT02638974|Experimental|Medical Skin Camouflage|This arm will use medical skin camouflage for 6 weeks
89399649|NCT02183246|Experimental|Porfiromycin + Radiotherapy|
89399650|NCT02183246|Placebo Comparator|Placebo + Radiotherapy|
89399651|NCT02183324|Experimental|Low dose of BI 1356 BS|
89399652|NCT02183324|Experimental|Medium dose of BI 1356 BS|
89399653|NCT02183324|Experimental|High dose of BI 1356 BS|
89399654|NCT02183324|Placebo Comparator|Placebo|
89399655|NCT02183402|Experimental|Digoxin with BI 1356|
89399656|NCT02183402|Active Comparator|Digoxin|
88875582|NCT02638974|No Intervention|Wait List Control|This arm will receive medical skin camouflage at the end of the study
88875583|NCT02639286|Placebo Comparator|Placebo|Placebo administered subcutaneously (SC)
88875584|NCT02639286|Experimental|ISIS 304801|300 mg of study drug administered via SC
88875585|NCT02642952||Open-graft group|Patients treated for abdominal aortic aneurysm with open graft will be measured for central hemodynamics and arterial stiffness by non-invasive methods.
88875586|NCT02642952||Endograft group|Patients treated for abdominal aortic aneurysm with endograft will be measured for central hemodynamics and arterial stiffness by non-invasive methods.
89399657|NCT02183480|Experimental|Linagliptin, low dose|
89399658|NCT02183480|Experimental|Linagliptin, medium dose|
89399659|NCT02183480|Active Comparator|Linagliptin, high dose|
89399660|NCT05141864|Active Comparator|Acmella oleracea gel group|Formulation with Acmella oleracea will be used during the digital rectal examination.
89399661|NCT05141864|Active Comparator|Lidocaina gel group|The lidocaine gel will be used during the digital rectal examination.
88875587|NCT05588544|Active Comparator|SRP only|Periodontal treatment by scaling and root planning
88875588|NCT05588544|Experimental|SRP + laser|Periodontal treatment by Laser-assisted scaling and root planning
89399662|NCT05141864|Placebo Comparator|Ultrasound gel group|The ultrasound gel will be used during the digital rectal examination.
89399663|NCT02177864|Experimental|Fiber|
89399664|NCT02177864|Placebo Comparator|Placebo|
89399665|NCT02180516||Meloxicam|
89399666|NCT02180516||Other NSAIDs|
89399667|NCT03537872|Experimental|Miner-Friendly (MF) Cohort|"Subjects will be enrolled over the 9-month enrollment period and will receive additional integrated strategies available at a miner-friendly service venue.~Miner-Friendly (MF) Service Venues TB/HIV Integration Strategies."
89399668|NCT03537872|Active Comparator|Public Sector (PS) Cohort|"Subjects will be enrolled over the 9-month enrollment period and will receive the usual integrated care for the management of TB and HIV at a public sector health facility.~Public Sector (PS) Health Facilities TB/HIV Integration Strategies"
88875589|NCT05588076||normal endometrial|
88875590|NCT05588076||endometrial lesions|
88875591|NCT05587218|Experimental|Self-production|L2 lexical items self-produced at learning
88875592|NCT05587218|Active Comparator|Perception|L2 lexical items heard or observed an additional time at learning
88875593|NCT05585658|Active Comparator|Erythropoietin alpha Eprex®|Group/cohort/Arm 1 (participating 21 volunteers): Eprex® injection 4,000 IU will be administered subcutaneously on Day 1; and wash out for 4 weeks. GBPD002 injection 4,000 IU/1 mL will be administered subcutaneously on Day 29.
89399669|NCT02183636|Experimental|Treatment 1 (T1)|Linagliptin/pioglitazone, FDC formulation C5
89399670|NCT02183636|Experimental|Treatment 2 (T2)|Linagliptin/pioglitazone, FDC formulation C8
89399671|NCT02183636|Active Comparator|Reference (R)|Linagliptin tablet and pioglitazone tablet (Actos®)
89399672|NCT05141786|Experimental|MRG002|MRG002 will be administrated via intravenous infusion of 2.6 mg/kg once on Day 1 of every 3 weeks (21-day cycle).
89399673|NCT02180750|Experimental|Intervention: Memory Work Therapy|Residential week intervention consisting of memory box, memory book, tree of life, Active Citizen book, all activities facilitated.
89399674|NCT02180750|Active Comparator|Control: standard care|Usual care services.
89399675|NCT02183714|Experimental|Songha Night ®|
89399676|NCT02183714|Placebo Comparator|Placebo|
89399677|NCT02256410|Experimental|Stimulation|Patients will undergo 6 sessions, each including 20 minutes of stimulation. These are given after the Nervomatrix device determines the peak pain regions for each patient, and selects to stimulate the top 10 regions with least skin resistance. The frequency of stimulation is 8Hz, at an intensity matched for each patient's tolerance, without inflicting any pain. The location of the stimulations will change in accordance to the changes in the peak pain regions, reflecting changes in tissue physiology possibly linked to clinical improvements.
89399678|NCT02256410|Sham Comparator|sham stimulation|Patients will undergo 6 sessions, each including 20 minutesof sham stimulation (no stimulation). These are given after the Nervomatrix device determines the peak pain regions for each patient, and selects to stimulate the top 10 regions with least skin resistance.
89399679|NCT02183948|Experimental|oxytocin|nasal spray
89399680|NCT02183948|Placebo Comparator|Placebo|nasal spray
89399681|NCT02184026|Experimental|Exposure, Relaxation, & Rescripting Therapy-Child|Exposure, Relaxation, & Rescripting Therapy-Child utilizes behavioral and cognitive therapy techniques of exposure therapy and cognitive restructuring.
89399682|NCT03537716|Experimental|Treatment Group|Treatment with the investigational device - High Intensity Focused ElectroMagnetic system
89399683|NCT05141630|Experimental|group with axillary sentinel or targeted lymph node biopsy alone|The patients with stage II to III breast cancer with biopsy-confirmed nodal metastases who convert to cN0 following NAC is recruited. Eligible patients are treated with axillary sentinel or targeted lymph node biopsy alone. Post-surgery radiation therapy will be administered at the discretion of the radiologist and the nodal radiotherapy must be conducted in patients with low nodal disease.
89399684|NCT02178020||knee arthroplasty, standard polyethylene|total knee arthroplasty with Standard Compression Molded tibial Polyethylene Liner
89399685|NCT02178020||knee arthroplasty, Highly Cross-Linked (XLP) polyethylene|knee arthroplasty with Highly Cross-Linked tibial Polyethylene Liner
89399686|NCT02184104|Active Comparator|Aeroshot|A single 100 mg caffeine dose administered using the Aeroshot device.
89399687|NCT02184104|Active Comparator|Energy Drink|A single 100 mg caffeine dose administered as an oral solution.
89399688|NCT02184182|Experimental|VLS ablation/portal ligation/hepatectomy|"Step1:~exploratory laparoscopy to exclude extrahepatic disease~right portal vein ligation if surgically feasible~RF/MW ablation on the future line of transection (of segment 4 close to left lateral lobe)~radiological portal embolization within 48h form the laparoscopic procedure if the right portal vein ligation is not feasible CT volumetric scan to evaluate the left lateral lobe hypertrophy after 9±2 from Step 1~Step 2: only if FRL/body weight > 0.5~- laparoscopic/laparotomic right trisectionectomy"
89399689|NCT02180906||Patients with NSTI|Definition: An infection that requires acute hospitalization with intensive care treatment and/or surgery as a consequence of severe soft tissue infection in subcutis, muscle and/or fascia and are spreading along tissue structures.
89399690|NCT02184260|Experimental|Metamizole|
89399691|NCT02184260|Placebo Comparator|Placebo|
88875594|NCT05585658|Experimental|Erythropoietin alpha, GBPD002|"Group/cohort/Arm 2 (participating 21 volunteers):GBPD002 PFS (Pre-Filled Syringe) 4,000 IU/ 1 mL (Erythropoietin alfa 4,000 IU) will be administered subcutaneously on Day 1.And wash out for 4 weeks (28 days from the 1st injection day). Eprex® inj. (Injection) 4,000 IU (Erythropoietin alfa 4,000 IU) will be administered subcutaneously on Day 29.~Total 42 volunteers participated in the clinical trial."
88875595|NCT05522634|Experimental|TJAOA101|Once enrolled, participants will be administrated TJAOA101 and followed by a 3-month medication cycle. The usage of this herbal compound is to take orally twice a day(two sacks per). Add it to about 200ml warm water and take it half an hour before breakfast in the morning and half an hour before bedtime in the evening except menstrual period.
88875596|NCT05510856|Experimental|Duloxetine|group 1
89399692|NCT02178176|Experimental|Education, encouragement, card sort|
89399693|NCT02178176|Active Comparator|Education, encouragement|
89399694|NCT05140928|Active Comparator|Dadiah Pudding|The mother received 1 cup or 100 g dadiah pudding containing 75-gram dadiah which provide ±260 kcal energy, 6.12g protein, 23.31g fat, 6.49g carbohydrate, and 6.1x 109 CFU/ml lactic acid bacteria.
89399695|NCT05140928|Placebo Comparator|Pudding without dadiah|The mother received 1 cup or 100 g pudding without dadiah containing ±75 kcal energy, 0.3g protein, 0.45 g fat, and 16.2g carbohydrate.
89399696|NCT02180984|Active Comparator|BED randomized to rTMS|"30 obese individuals currently diagnosed with BED and meeting criteria for the study will be randomized to active rTMS treatment.~Intervention: Neurosoft device targeting the left DLPFC (neuro-navigational method).~Proposed schedule of treatment:~20 sessions of neuronavigated rTMS, one session per day, 3 days/week over approximately 7 weeks. Focal rTMS will be performed using a Neurosoft device and a 'figure of eight' coil. Brainscience Neuronavigation will be used to guide the placement of the coil to the target PFC region using a template MRI for all participants. The coil will be placed at a 45° angle to the mid-sagittal line to induce a posterior to anterior current in the underlying neural tissue. For the real treatment condition, stimulation will target the left DLPFC at 110% of the resting motor threshold. Each session of 10 Hz stimulation will apply 1000 pulses to the left hemisphere, with a duty cycle of 5s on and 55s off, for a total stimulation time of 20 min."
89399697|NCT02180984|Sham Comparator|Sham BED TMS|"30 obese individuals currently diagnosed with BED will be randomized to receive sham TMS treatment. Blinded to participants and study staff, except to the doctor applying the TMS treatment.~Intervention: Neurosoft device targeting the left DLPFC (neuro-navigational method).~Proposed schedule of treatment:~20 sessions of neuronavigated rTMS, one session per day, 3 days/week over approximately 7 weeks. Focal rTMS will be performed using a Neurosoft device and a 'figure of eight' coil. Brainscience Neuronavigation will be used to guide the placement of the coil to the target PFC region using a template MRI for all participants. The coil will be placed at a 45° angle to the mid-sagittal line to induce a posterior to anterior current in the underlying neural tissue. Sham treatment condition, will follow the same protocol however no real TMS will be delivered."
88875597|NCT05510856|Experimental|Gabapentin|group 2
88875598|NCT05510856|Experimental|Lacosamide|group 3
89399698|NCT02180984|No Intervention|Control (obese non BED)|15 controls, obese but without a current or past diagnosis of BED will complete the baseline measurements only.
89399699|NCT02180984|No Intervention|Controls (normal weight)|15 controls, normal weight and without a current or past diagnosis of BED will complete baseline measures only.
89399700|NCT02181062|Experimental|Walking Intervention|"4-week series of twice-weekly 1-hour group-based case-manager-led interactive sessions.~The intervention will provide the knowledge necessary to improve stroke risk factors. Case manager group leaders will teach that seeing a healthcare provider regularly and monitoring blood pressure prevents strokes; all participants will be provided with the National Institute on Aging booklet, How to Talk to your Doctor and the contact information for their healthcare provider.~Participants will be given a pedometer and be trained to use it to measure steps, with the goal of reaching 10,000 steps each day.~The intervention will utilize attribution retraining to teach seniors that stroke risk factors including sedentary lifestyle should not be attributed to old age."
89399701|NCT02181062|No Intervention|Wait-list control|After 3 months, participants will be invited to participate in the intervention. No additional measures or outcomes will be recorded.
89399702|NCT03684837|Active Comparator|D vitamine|a dose for week
89399703|NCT03684837|Placebo Comparator|D vitamine placebo|a dose for week
89399704|NCT03902691|Experimental|Pegol-Sihematide|Participants received Pegolsihematide by intravenous injection once every 4 weeks.
89399705|NCT03902691|Active Comparator|ESPO (Recombinant Human Erythropoietin Injection）|ESPO administration 1 to 3 times per week.
89399706|NCT03808155|Active Comparator|Tamsulosin|The study specific product Tamsulosin 0.4mg, a tablet which is taken once a day per os five days prior to the operation and two days after the operation.
89399707|NCT03808155|Placebo Comparator|Placebo Oral Tablet|The placebo is taken once a day per os five days prior to the operation and two days after the operation.
88875599|NCT05462028|No Intervention|control group|Only received conventional therapy comprised of standardized treatment and regular rehabilitation (i.e., postural training, facilitation techniques, stretching exercise, and strengthening exercise) prescribed by a rehabilitation physician and performed at 3 to 6 days after admission for five 60-minute sessions per week by the physical, occupational, and speech therapists in the rehabilitation center of the medical center.
89399708|NCT03677583|Experimental|Duckweed|daily lunch with 150-180g wet weight duck weed
89399709|NCT03677583|Active Comparator|Spinach|daily lunch with 150-180g wet weight spinach
89399710|NCT02752958|Experimental|stannous fluoride|This was a non-comparative design study, all the participants applied dentifrice containing stannous fluoride for 1 timed minute, twice daily (morning and evening) for 24 weeks.
89399711|NCT02185664|Active Comparator|Landmark technique|The landmark technique is the standard technique used for internal jugular vein cannulation.
88875600|NCT05462028|Placebo Comparator|exercise group|The exercise group will receive extra 5 days of 30-minute lower-limb ergometer exercise training in addition to the conventional therapy.
88875601|NCT05462028|Sham Comparator|wearable leg vibration training group|The wearable leg vibration training group will receive extra 5 days of 30-minute wearable leg vibration of lower limbs combined with 30-minute lower-limb ergometer exercise training at post-vibration session, in addition to the conventional therapy.
89399712|NCT02185664|Experimental|Static Ultrasound technique|Static ultrasound technique was used to assist internal jugular vein cannulation.
88875602|NCT05462028|Experimental|lower-extremity weight bearing vibration training group|The lower-extremity weight bearing vibration training group will receive extra 5 days of 30-minute lower-extremity weight bearing vibration combined with30-minute lower-limb ergometer exercise training at post-vibration session, in addition to the conventional therapy.
88875603|NCT05393466|Experimental|Phase Ia Dose Escalation|The number of patients enrolled will be determined based on the maximum number required to establish the RP2D according to a Bayesian Optimal Interval (BOIN) method and will depend on the true DLT rate. Up to 24 patients will be enrolled for the dose-finding part.
88921919|NCT06061003|Other|Fractured Model Group|All participants will receive 1 hour training on anatomy and pathophysiology of toric wrist fractures. After lecture completed, the Fractured Model Group will engage in a 1-hour hands-on practical session in the laboratory, working with wrist fracture models.
89399713|NCT02185742|Experimental|Strength Based Case Management|Strength Based Case Management
89399714|NCT02185742|No Intervention|Contemporary, HIV+ Jail Detainees|No intervention
89399715|NCT02181218|Experimental|Dose Level 0 (starting dose) (8 mg/m2 romidepsin)|"Romidepsin will be administered intravenously (IV) over 2 hours on Days 2 and 8;~Gemcitabine IV over 30 minutes on Day 1~Oxaliplatin IV over 2 hours on Day 1~Dexamethasone orally on Days 1-4~Pegfilgrastim subcutaneously on Day 3~Drugs may be administered in any order on Day 1.~Each cycle is 21 days.~May continue on therapy for up to 8 cycles total if achieving adequate disease control (CR, PR, or stable disease) and without significant toxicity"
89399716|NCT02181218|Experimental|Dose Level 1 (10 mg/m2 romidepsin)|"Romidepsin will be administered intravenously (IV) over 2 hours on Days 2 and 8;~Gemcitabine IV over 30 minutes on Day 1~Oxaliplatin IV over 2 hours on Day 1~Dexamethasone orally on Days 1-4~Pegfilgrastim subcutaneously on Day 3~Drugs may be administered in any order on Day 1.~Each cycle is 21 days.~May continue on therapy for up to 8 cycles total if achieving adequate disease control (CR, PR, or stable disease) and without significant toxicity"
89399717|NCT02181218|Experimental|Dose Level 2 (12 mg/m2 romidepsin)|"Romidepsin will be administered intravenously (IV) over 2 hours on Days 2 and 8;~Gemcitabine IV over 30 minutes on Day 1~Oxaliplatin IV over 2 hours on Day 1~Dexamethasone orally on Days 1-4~Pegfilgrastim subcutaneously on Day 3~Drugs may be administered in any order on Day 1.~Each cycle is 21 days.~May continue on therapy for up to 8 cycles total if achieving adequate disease control (CR, PR, or stable disease) and without significant toxicity"
89399718|NCT02184650||Premature infants|Premature infants with a GA < 32 weeks
89399719|NCT03536234|Experimental|Triptorelin (GnRH analogue)|
89399720|NCT03536234|No Intervention|Control group|
89399721|NCT03682497|Active Comparator|Spironolactone|Spironolactone treatment for 28 days
89399722|NCT03682497|Experimental|AZD9977|AZD9977 treatment for 28 days
89399723|NCT02950922|Experimental|RVT-501 0.2% ointment|RVT-501 0.2% ointment BID x 28 days (30 adults, 20 adolescents)
89399724|NCT02950922|Experimental|RVT-501 0.5% ointment|RVT-501 0.5% ointment BID x 28 days (30 adults, 20 adolescents)
89004022|NCT03684980|Experimental|Arm D -Rituximab + MTX + Glucarpidase|Up to 12 patients will be included in Arm D of this study. Cycles will be 14 days long. All patients will receive MTX 3.5 g/m2 administered Day 1 of each cycle (+/- 7 days, a minimum of 14 days required between doses). Glucarpidase will be administered 24 hours (+/- 2 hr) after start of MTX infusion except in cycles 1-2 of Cohort B. Dose of glucarpidase will be 2000 units in Cohort A (first 4 patients) and 1000 units in Cohort B (remaining 8 patients). Patients in Arm D will receive 8 cycles of treatment. Cycles 1 and 2 will be administered in patient while Cycles 3-8 may be in the outpatient setting. Concurrent chemotherapy such as vincristine, procarbazine, and/or ibrutinib may be administered at the investigator's discretion and in accordance with standard of care. In Cohort B, all cycles will be administered with rituximab 500 mg/m2. Rituximab should be administered prior to glucarpidase (window -4 days).
89004023|NCT03684980|Experimental|Arm E-glucarpidase 1000u + MTX standard of care|Study treatment consists of glucarpidase 1000u, to be administered at least 24 hours after start of standard of care MTX. Patients will have a standard of care methotrexate level drawn within 6 hours of planned glucarpidase administration to confirm eligibility (must reflect MTX > 100 nmol/L)
89004024|NCT03663933|Experimental|1/RIC Arm|Reduced Intensity Conditioning Arm
89004025|NCT03663933|Experimental|2/IOC Arm|Immunosuppression Only Conditioning Arm
89004026|NCT03663933|No Intervention|3/donor arm|Healthy Donor- Donors for recipients in arm 1 or arm 2
89004027|NCT03646513||SMF Short Modular Femoral Stem Implanted Subjects|Subjects who have been implanted with the SMF Short Modular Femoral Stem for primary total hip arthroplasty.
89004028|NCT03644732||SEEG Group|Group with SEEG analysis (Pre-surgical SEEG assessment)
89399725|NCT02950922|Placebo Comparator|Vehicle ointment|Vehicle ointment BID x 28 days (30 adults, 20 adolescents)
89004029|NCT03642067|Experimental|Cohort A/B: Nivolumab and Relatlimab|480mg/160mg (co-administered)
89004030|NCT03642067|Experimental|Cohort C: Nivolumab and Relatlimab|480mg/ 960mg or 480mg/480mg (sequential administration)
89004031|NCT03642067|Experimental|Cohort C: Nivolumab and Relatlimab (co-administration)|480mg/160mg (co-administration)
89004032|NCT03639077|Experimental|Allograft bone alone|
89004033|NCT03639077|Experimental|Allograft and xenograft mixture|
89004034|NCT03594422|Experimental|HQP1351 30mg|30 mg QOD(Minor subjects will be enrolled based on weight)
89004035|NCT03594422|Experimental|HQP1351 40mg|40 mg QOD(Minor subjects will be enrolled based on weight)
89004036|NCT03594422|Experimental|HQP1351 50mg|50 mg QOD
89004037|NCT03594422|Experimental|HQP1351 20mg|20 mg QOD (Minor subjects will be enrolled based on weight)
89004038|NCT03564873|Experimental|Phase I|Up to 18 patients will be enrolled to one of three cohorts to receive various doses of omacetaxine over a 28 day cycle. Azacitidine will be given at the standard dose over a 28 day cycle.
89004039|NCT03564873|Experimental|Phase II|Up to 33 patients will be enrolled to receive the maximum tolerated dose (determined in phase I) over a 28 day cycle. Azacitidine will be given at the standard dose over a 28 day cycle.
89004040|NCT03547908|Experimental|B/F/TAF|B/F/TAF + placebo to match DTG + placebo to match F/TDF for 96 weeks.
89004041|NCT03547908|Active Comparator|DTG+F/TDF|DTG + F/TDF + placebo to match B/F/TAF for 96 weeks.
89004042|NCT03547908|Experimental|Open-label Extension Phase: B/F/TAF|After Week 96, participants will continue to take their blinded study drug and attend visits every 12 weeks until the End of Blinded Treatment Visit. Following the End of Blinded Treatment Visit, participants in a country where B/F/TAF FDC is not available will be given the option to receive B/F/TAF FDC in an open-label extension phase for up to 48 weeks, or until the product becomes accessible through an access program, or until Gilead elects to discontinue the study in that country, whichever occurs first.
89004043|NCT03539029||Control group|age and sex matched healthy control persons
89004044|NCT03539029||Surgery|patients with ankle fracture treated surgically
89004045|NCT03539029||Conservative treatment|patients with ankle fracture treated conservatively
89004046|NCT03538600||Healthy Volunteers|healthy volunteers
89004047|NCT03528603|Experimental|Oleocanthal-Rich Extra Virgin Olive Oil|Extra Virgin Olive Oil that is high in the phenolic oleocanthal, but contains similar amounts of total phenolics as the Oleocanthal-Low Extra Virgin Olive Oil
89004048|NCT03528603|Placebo Comparator|Oleocanthal-Low Extra Virgin Olive Oil|Extra Virgin Olive Oil that is low in the phenolic oleocanthal, but contains similar amounts of total phenolics as the Oleocanthal-Rich Extra Virgin Olive Oil
89004049|NCT03518086|Placebo Comparator|Placebo Intravenous (IV) Every 4 Weeks (Q4W)|Placebo given as an IV infusion Q4W on Weeks 0, 4, 8 for 12 weeks.
89004050|NCT03518086|Experimental|300 Milligram (mg) Mirikizumab IV Q4W|300 mg mirikizumab given as an IV infusion Q4W on Weeks 0, 4, 8 for 12 weeks.
89004051|NCT03518086|Placebo Comparator|Placebo IV Q4W Maximum Extended Enrollment (ME2)|Placebo given as an IV infusion Q4W on Weeks 0, 4, 8 for 12 weeks.
88875604|NCT05393466|Experimental|Phase Ib Expansion Study|Based on clinical data obtained from Part 1a, up to 24 patients with advanced NSCLC harboring EGFR C797S mutation will be enrolled in this dose expansion part of the study. One or more dose levels may be investigated dependent on emerging data. The sample size will be determined based on practical considerations.
88875605|NCT05393466|Experimental|Phase II Study|The phase II part will be conducted using a Bayesian Optimal Phase 2 (BOP2) method with efficacy monitoring based on cumulative information on Objective Response Rate (ORR). The BOP2 method will consist of 2 interim looks occurring when the number of evaluable patients reaches the pre-specified values of 10 and 20 and a final analysis when a total of 30 patients are evaluable.
88875606|NCT05281770||Erenumab|Patients will be treated with this drug within standard of care treatment
88875607|NCT05281770||Galcanezumab|Patients will be treated with this drug within standard of care treatment
88875608|NCT05281770||Fremanezumab|Patients will be treated with this drug within standard of care treatment
88875609|NCT05225610|Experimental|VALSALVA Group|40 Patients will perform the Valsalva manoeuvre before starting propofol injection by blowing into rubber tubing connected to a sphygmomanometer and raising the mercury column to 30 mmHg for at least 20 seconds and 5 ml saline will be administered in 5 seconds.
88875610|NCT05225610|Experimental|DEXMED Group|40 patients will receive the tube between the lips, however, the manoeuvre will not be performed in this group, patients will receive 0.5 µg/kg Dexmedetomidine diluted in 5 ml saline in 5 seconds as a sedating dose prior to injection of propofol.
88875611|NCT05225610|Placebo Comparator|CONTROL Group|40 patients will receive the tube between the lips, however, the manoeuvre will not be performed in this group and only 5 ml saline will be administered over 5 seconds.
88875612|NCT05185830|Experimental|Interactive robot|Children in the interactive robot will be mobilized for the first time with interactive robots.
88875613|NCT05185830|No Intervention|Control group|Children in the control group will be mobilized with nurses
88875614|NCT05079906|Other|Main study arm|All subjects will have their SFA lesion assessed with FFR measurement.
88875615|NCT05079906|Other|Sub-study|Last 50 enrolled subjects will have HD-IVUS in addition to FFR.
89399726|NCT04059627|Experimental|Experimental arm|"Participants were introduced to Heart-Track mobile app system and its navigational characteristics with standardised instructions. Each participant then performed a self-directed Cardiac rehabilitation session using the app."
89399727|NCT02184728|No Intervention|EMMA(TM)|"A small capnograph for measuring ET-CO2 - the EMMA capnometer~1"
88875616|NCT04922190|Experimental|Physical Activity Coaching|Participants will receive up to 5 coaching sessions by a physical or occupational therapist. The intervention will focus on facilitating physical activity engagement and development of specific and measurable goals. The recommended program will be individualized to each participant but will primarily focus on increasing general physical activity (e.g. steps per day) as well as engagement in moderate intensity aerobic exercise a minimum of three times per week. At the follow up sessions the therapist will review progress with the current exercise plan and progress and discuss barriers and facilitators for exercise engagement. Participants will have the option to use a Fitbit or other device to monitor their heart rate and physical activity during the course of the intervention period.
88875617|NCT04444050|Experimental|Part 1 Single Ascending Dose (SAD): Panel 1|
88875618|NCT04444050|Experimental|Part 1 SAD: Panel 2|
88875619|NCT04444050|Experimental|Part 1 SAD: Panel 3|
88875620|NCT04444050|Experimental|Part 1 SAD: Panel 4|
89399728|NCT03469791|Active Comparator|Micro-decompression alone|In Surgical treatment of Degenerative Spondylolisthesis patients are operated on with a midline-precerving decompression without fusion
89399729|NCT03469791|Active Comparator|Decompression and instrumented fusion|In Surgical treatment of Degenerative Spondylolisthesis patients are operated on with a decompression followed by an instrumental fusion with or without an additional Cage
89399730|NCT02184806|Experimental|1- orthotopic graft|
89399731|NCT02184806|Experimental|2- heterotopic graft|
88875621|NCT04444050|Experimental|Part 1 SAD: Panel 5|
88875622|NCT04444050|Experimental|Part 1 SAD: Panel 6|
88875623|NCT04444050|Experimental|Part 1 SAD: Optional Split-dose Panel|
88875624|NCT04444050|Experimental|Part 2 Multiple Ascending Dose (MAD): Panel 1|
88875625|NCT04444050|Experimental|Part 2 MAD: Panel 2|
88875626|NCT04444050|Experimental|Part 2 MAD: Panel 3|
88875627|NCT04444050|Experimental|Part 2 MAD: Panel 4|
88875628|NCT04444050|Experimental|Part 2 MAD: Optional (to be determined) Panel|
88875629|NCT04444050|Experimental|Part 3 MAD in Japanese Participants (J-MAD): Panel 1|
88875630|NCT04444050|Experimental|Part 3 J-MAD: Panel 2|
88875631|NCT04444050|Experimental|Part 3 J-MAD: Panel 3|
88875632|NCT04444050|Experimental|Part 3 J-MAD: Optional (to be determined) Panel|
88875633|NCT04225416||Hemodialysis patients|Patients undergoing hemodialysis
88875634|NCT04225416||Peritoneal dialysis patients|Patients undergoing peritoneal dialysis
89004052|NCT03518086|Experimental|300 mg Mirikizumab IV Q4W ME2|300 mg mirikizumab given as an IV infusion Q4W on Weeks 0, 4, 8 for 12 weeks.
89399732|NCT02185898|Active Comparator|Leading U.S. tobacco-burning non-menthol cigarette|Leading U.S. non-menthol cigarette
89399733|NCT02185898|Active Comparator|Leading U.S. tobacco-burning menthol cigarette|Leading U.S. menthol cigarette
89399734|NCT02185898|Experimental|Electronic cigarette #1|VUSE® (menthol flavor, 29 mg nicotine)
89399735|NCT02185898|Experimental|Electronic cigarette #2|VUSE® (original flavor, 29 mg nicotine)
89399736|NCT02185898|Experimental|Electronic cigarette #3|VUSE® (original flavor, 14 mg nicotine)
89399737|NCT02185898|Experimental|U.S. Market-sample electronic cigarettes (two brands)|blu™ (any variety) and NJOY® (any variety)
89399738|NCT02185976|Active Comparator|cartoon|paediatric patients undergoing general anesthesia. This group will choose a cartoon movie to watch throughout the preparation until the induction of anesthesia
89399739|NCT02185976|No Intervention|routine|paediatric patients undergoing general anesthesia
89399740|NCT02186054|Other|Imaging- MRI examinations|Liver MRI imaging will be performed on 50 patients.
88875635|NCT03693846|Experimental|Nivolumab and Ipilimumab|Treatment will consist of Nivolumab 480mg every 4 weeks and Ipilimumab 1mg/kg every 8 weeks. Subjects will continue on study therapy until disease progression, unacceptable toxicity, withdrawal of consent, or 24 months of therapy.
88875636|NCT03529890|Experimental|Radio-Immunotherapy before cystectomy|Single arm treatment with Nivolumab during a neoadjuvant radiation therapy of the pelvis before radical cystectomy with standardized pelvic lymphadenectomy
89399741|NCT02030444|No Intervention|Standard diagnostic work-up|All patients will undergo todays' standard work-up (examination for diagnosing and staging) of lung cancer. This will be individualized for each patient according to current guidelines.
89399742|NCT02030444|Experimental|Extensive diagnostic work-up|All patients will in addition to standard diagnostic work-up undergo PET-MRI and systematic mediastinal and hilar lymph node mapping using EBUS-TBNA (endobronchial ultrasound transbronchial needle aspiration of lymph nodes).
89399743|NCT03684681|Other|Peer Navigator|Current standard of care
88875637|NCT02751060||patients with coronary heart disease symptoms|
88875638|NCT02703480|Experimental|All Study Participants - d-PTFE|The proposed study design is a randomized controlled trial, split mouth design, to compare the two different vertical augmentation procedures: Titanium mesh (Ti-mesh) technique and Guided Bone Regeneration (GBR) technique with a high-density polytetrafluoroethylene (d-PTFE) membrane.
88875639|NCT02703480|Experimental|All Study Participants - Ti-mesh|The proposed study design is a randomized controlled trial, split mouth design, to compare the two different vertical augmentation procedures: Titanium mesh (Ti-mesh) technique and Guided Bone Regeneration (GBR) technique with a high-density polytetrafluoroethylene (d-PTFE) membrane
88875640|NCT01690728|Active Comparator|Physical Activity|40 min exercise supervised by physiotherapists two times weekly in six month.
88875641|NCT01690728|No Intervention|Control Group|These participants follows the standard post surgery follow-up consisting of counseling by dietitians, nurses and doctors.
88875642|NCT00938106|Experimental|(MR BT) in Cervix Cancer|
88875643|NCT00793806||Medical Tool|Diffuse Optical Spectroscopy measurements will be compared to a variety of laboratory parameters routinely measured in Chronic Inflammation and Oxidative Stress in Chronic Kidney Disease
88875644|NCT00580944|Experimental|Port Wien Stain Birthmark|Combined alexandrite and pulsed dye laser treatment of port wine stain birthmarks
88875645|NCT00540306||Diagnostic Tool|Changes in physiological and optical properties in healthy pre-menopausal breast tissue during the menstrual cycle using Diffuse Optical Spectroscopy
88875646|NCT02644278|Experimental|VX-984 120 mg + PLD 40 mg/m^2|
88875647|NCT02644278|Experimental|VX-984 240 mg + PLD 40 mg/m^2|
88875648|NCT02644278|Experimental|VX-984 480 mg + PLD 40 mg/m^2|
89399744|NCT03684681|Other|Social Worker|Current standard of care
89399745|NCT02181686||Sentus QP group|Patients with standard indication for CRT-D therapy who will be implanted with Sentus QP LV lead and the BIOTRONIK HF-T QP device.
89399746|NCT02181686||VR-T/DR-T group|Patients with standard indication for ICD therapy who will be implanted with either single chamber ICD or dual chamber ICD of the Iperia ICD family
89399747|NCT03677505|Experimental|KoMAC group|Orotracheal intubation with KoMAC videolaryngoscope
89399748|NCT03677505|Active Comparator|Macintosh group|Orotracheal intubation with Macintosh laryngoscope
89399749|NCT02805660|Experimental|Phase 1: Dose Escalation - 50 mg|The Phase 1 dose escalation established the recommended phase 2 dose (RP2D) of mocetinostat. Participants with advanced solid tumors were included in this Phase.
89399750|NCT02805660|Experimental|Phase 1: Dose Escalation - 70 mg|The Phase 1 dose escalation established the recommended phase 2 dose (RP2D) of mocetinostat. Participants with advanced solid tumors were included in this Phase.
89399751|NCT02805660|Experimental|Phase 1: Dose Escalation - 90 mg|The Phase 1 dose escalation established the recommended phase 2 dose (RP2D) of mocetinostat. Participants with advanced solid tumors were included in this Phase.
89437439|NCT03911986|Other|Immediate External Loop Recorder|Participants randomized to the Immediate External Loop Recorder group will be monitored for the duration of the first week of the study using the Novacor R-Test 4.
88875649|NCT02644278|Experimental|VX-984 720 mg + PLD 40 mg/m^2|
88875650|NCT02645760|Active Comparator|Core stabilization exercise|7-weeks of core stabilization exercise
88875651|NCT02645760|Active Comparator|conventional treatment|7-weeks of conventional treatment include therapeutic ultrasound and hot pack
88875652|NCT02648022|Experimental|Integrated Care|Consisted of brief mental health interventions and case management provided in a collaborative treatment environment.
88875653|NCT02648022|No Intervention|Usual Care|"The usual care group received standard of care required for HCV patients as currently performed in each clinic. All usual care patients were evaluated by their HCV Clinic treatment team, usually consisting of clinical nursing staff, the treating physician, and a clinic psychiatrist or psychologist"
88875654|NCT02648178|Active Comparator|HALO G6|HALO cigalike model
88875655|NCT02648178|Active Comparator|HALO Triton|HALO tank model
88875656|NCT02648646|Experimental|Single Arm - Intervention|Receives Otago Exercise Programme and Walk with Ease
88875657|NCT02648880|Experimental|Exercise Group|Participants will complete an exercise program in addition to standard care. Participants will start the exercise program within four weeks of their diagnosis and decision to undergo neoadjuvant treatment and continue until surgery. Participants will be encouraged to complete three sessions per week for at least eight weeks during neoadjuvant therapy. Exercise intensity, components, and time will be recorded for each exercise session. Participants will schedule their sessions with the exercise specialists administering the program, typically taking place between 8AM and 4PM, Monday through Friday.
88875658|NCT02648880|Active Comparator|Standard Care|Participants in the Standard Care group will receive no exercise intervention, but will continue to receive standard follow-ups, treatments and services from their oncology team.
88875659|NCT02649192|Active Comparator|Influenza Virus Vaccine Plus Vitamins A and D|Participants receive influenza virus vaccine and Vitamins A and D supplement on Day 0 and Day 28.
88875660|NCT02649192|Placebo Comparator|Influenza Virus Vaccine Plus Placebo|Participants receive influenza virus vaccine and matched placebo on Day 0 and Day 28.
88875661|NCT02650440|Experimental|Novel Protocol|Progressive decrease of speed and guidance force on robotic gait training. Initial speed is 1.4 km/h and final speed is 1.0 km/h.
88875662|NCT02650440|Experimental|Standard Protocol|Progressive increase of speed and decrease of guidance force on robotic gait training. Initial speed is 1.4 km/h and final speed is 1.9 km/h.
88875663|NCT02652390|Experimental|Methylprednisolone 80 mg|Local injection of 80 mg Methylprednisolone into the carpal tunnel
88875664|NCT02652390|Experimental|Methylprednisolone 40 mg|Local injection of 40 mg Methylprednisolone into the carpal tunnel
88875665|NCT02652390|Placebo Comparator|Placebo|Local injection of saline into the carpal tunnel
88875666|NCT02652780|Experimental|GS010-treated Eyes|Each participant will have one eye randomly selected to receive a single injection of GS010 and the other eye will receive a sham injection. GS010-treated Eyes: GS010 is a recombinant adeno-associated viral vector serotype 2 (rAAV2/2) containing the wild-type ND4 gene (rAAV2/2-ND4). Participants will receive a single dose of GS010 in one of their randomly selected eyes, via intravitreal injection containing 9E10 viral genomes in 90μL balanced salt solution (BSS) plus 0.001% Pluronic F68®.
88875667|NCT02652780|Sham Comparator|Sham-treated Eyes|Each participant will have one eye randomly selected to receive GS010 and the other eye will receive a sham injection. Eyes receiving sham injection will undergo the same preparatory procedures as eyes receiving GS010 injection, including pupillary dilation, topical anti-infection and topical anesthetic procedures. Sham Intravitreal injection will be performed by applying pressure to the eye at the location of a typical intravitreal injection procedure using the blunt end of a syringe without a needle.
88875668|NCT02653560|Experimental|Potassium magnesium Citrate (KMgCit) arm|Potassium magnesium citrate will be prepared by mixing potassium citrate, magnesium citrate and/or citric acid by Meta Pharm Development. The content of each sachet will be dissolved in 250 ml water and will be drunk with breakfast and again with dinner during the KMgCit Phase, to deliver 40 meq K, 20 meq Mg and 74 meq citrate per day for 4 weeks
88875669|NCT02653560|Experimental|Potassium citrate arm|A special sachet formulation containing 20 meq K/sachet will be made for the study by Meta Pharm Development. The contents of a sachet will be added to 250 ml water and drunk with breakfast and dinner, to deliver 40 meq K (as citrate) per day during the Potassium Citrate Phase for 4 weeks.
88875670|NCT02653560|Experimental|Potassium chloride arm|Potassium chloride will contain 20 meq KCl per sachet. During the Potassium Chloride Phase, subjects will dissolve the content of each sachet in 250 ml water and ingest it with breakfast and again with dinner, to deliver 40 meq K (as chloride) per day for 4 weeks
88875671|NCT02653560|Placebo Comparator|Placebo|Placebo will comprise microcrystalline cellulose, equivalent in volume in each sachet as other test products. During the Placebo Phase, subjects will dissolve the entire content of a sachet in 250 ml water and drink it with breakfast and again with dinner for 4 weeks.
88875672|NCT02653872|Experimental|AZD7986 (alone) Treatment period 1|AZD7986 (15 mg/mL) 25 mg dosage administered alone
88875673|NCT02653872|Active Comparator|Verapamil (with AZD7986) Treatment period 2|Daily administration of verapamil (240 mg, extended release formulation) on Days 1 to 10 plus administration of single dose AZD7986 (25 mg) on Day 5
88875674|NCT02653872|Active Comparator|Itraconazole (with AZD7986) Treatment Period 3|Itraconazole (200 mg, oral solution formulation 10 mg/mL) administered twice on Day 1 and then daily Days 2 to 11 plus single dose AZD7986 (25 mg, tbc) on Day 6
88875675|NCT02653872|Active Comparator|Diltiazem (with AZD7986) Treatment period 3|Diltiazem (360 mg, extended release formulation) administered Days 1 to 13 plus single dose AZD7986 (25 mg) on Day 8
88875676|NCT02654652|Experimental|Symbiotic|Patients will receive the symbiotic product LactoFos twice a day during seven days after surgical treatment. The intervention consists of giving twice a day a sachet of 6g of symbiotic diluted in 20mL of water via nasoenteric tube for seven days, totaling the administration of 14 sachets per intervention.
88875677|NCT02654652|Placebo Comparator|Maltodextrin|Patients will receive 6g of maltodextrin twice a day during seven days after surgical treatment.
88875678|NCT02654808|Active Comparator|Standard trocar/ IAP 15 mmHg|Patients who are randomized into this arm will have their laparoscopic procedures performed with the standard trocar insufflator at an intra-abdominal pressure (IAP) of 15 mmHg.
89011494|NCT01643551||Cardiac Surgery Group|18 years or older Planning to undergo valve or coronary bypass surgery
89189447|NCT05809674||Adult Cohort|"Aged 21 and above~Ability to provide informed consent~42 normal controls: No diabetes and free from clinically relevant eye disease that interferes with the aim of the study i.e. glaucoma, diabetic retinopathy, age-related macular degeneration, uveitis, or vascular occlusive diseases~76 subjects with pathological myopia (up to -12 dioptres) or staphyloma"
88875679|NCT02654808|Active Comparator|Standard trocar/ IAP 10 mmHg|Patients who are randomized into this arm will have their laparoscopic procedures performed with the standard trocar insufflator at an intra-abdominal pressure (IAP) of 10 mmHg.
88875680|NCT02654808|Active Comparator|AirSeal trocar/ IAP 15 mmHg|Patients who are randomized into this arm will have their laparoscopic procedures performed with the AirSeal trocar insufflator at an intra-abdominal pressure (IAP) of 15 mmHg.
88875681|NCT02654808|Active Comparator|AirSeal trocar/ IAP 10 mmHg|Patients who are randomized into this arm will have their laparoscopic procedures performed with the AirSeal trocar insufflator at an intra-abdominal pressure (IAP) of 10 mmHg.
88875682|NCT02655354|Experimental|Intervention|The intervention aims to prevent the development of chronic PTSD and depressive symptoms, alcohol use problems, and enduring physical disability in survivors of both traumatic brain injury(TBI) and non-TBI injuries. The intervention utilizes a computerized decision support tool to flexibly target these multiple conditions including and includes care management, motivational interviewing, cognitive behavioral therapy elements, psychotropic drugs, and psychotherapy elements.
88875683|NCT02655354|No Intervention|Usual Care|Enhanced standard care practices will be administered to this arm. This enhancement is sharing distressing emotional symptoms at recruitment with the attending nursing staff to address with patient subject.
88875684|NCT02655510|Experimental|F-652|Participants will receive 10 μg/kg, 30 μg/kg or 45 μg/kg of F-652 on Day 1 and Day 7 via slow intravenous infusion. Three patients with MELD 11-20 will receive 10 μg/kg of F-652. Pharmacokinetic testing will be completed on these subjects. If evaluations demonstrate safety and efficacy signals, the next 3 patients will receive 30 μg/kg. If pharmacokinetic testing demonstrates safety and efficacy signals, the next 3 patients will receive 45 μg/kg. After demonstrating absence of side effects in this group, patients in MELD 21-28 will follow the same dose escalation regiment as the MELD 11-20 group.
88875685|NCT02657538|Active Comparator|Near infrared transillumination|Near infrared transillumination is applied for initial enamel caries lesion detection.
88875686|NCT02657538|Active Comparator|Visual caries detection + BW|visual caries detection + bite wing radiography (BW): considered as gold standard in caries diagnostics.
88875687|NCT02657928|Experimental|Treatment (ribociclib and letrozole)|Patients receive ribociclib PO daily and letrozole PO daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88875688|NCT02658240|Active Comparator|Compartment Block|Fascia iliaca compartment block (FICB) with ropivacaine and epinephrine after surgery
88875689|NCT02658240|Active Comparator|Infiltration|Periarticular infiltration with ropivacaine and epinephrine prior to closing the incision
88875690|NCT02660112|Experimental|(+)-Epicatechin|Total daily dose 75mg (+)-Epicatechin; 25mg cap three times per day by mouth for 24 weeks
88875691|NCT02661126|Experimental|Moderate RI Participants|Participants with an estimated glomerular filtration rate (eGFR) of ≥30 mL/min/1.73m^2 to <60 mL/min/1.73m^2 take 2 MK-3682B FDC tablets on Day 1 after fasting for 10 hours.
88875692|NCT02661126|Experimental|Severe RI Participants|Participants with an eGFR of ≥15 mL/min/1.73m^2 to <30 mL/min/1.73m^2 take 2 MK-3682B FDC tablets on Day 1 after fasting for 10 hours.
88875693|NCT02661126|Experimental|Healthy Participants|Healthy participants (creatinine clearance [CLcr] ≥80 mL/min) take 2 MK-362B FDC tablets on Day 1 after fasting for 10 hours. Healthy participants are matched to RI participants based on mean age, body mass index (BMI) and gender.
88875694|NCT02661828|Active Comparator|Taper A Regimen|Participants taking an antidepressant for at least four weeks and no longer wish to take the antidepressant medication will undergo a Two-Week Taper Regimen to discontinue their medication.
88875695|NCT02661828|Active Comparator|Taper B Regimen|Participants taking an antidepressant for at least four weeks and no longer wish to take the antidepressant medication will undergo a One-Week Taper Regimen to discontinue their medication.
88875696|NCT02662608|Experimental|Brontictuzumab|1.5 mg/Kg of Brontictuzumab single agent intravenously every three weeks.
88875697|NCT02665260|Active Comparator|Cantharidin with occlusion|Cantharidin 0.7% topical with occlusion
88875698|NCT02665260|Experimental|Cantharidin without occlusion|Cantharidin 0.7% topical without occlusion
88875699|NCT02665260|Placebo Comparator|Placebo with occlusion|Placebo topical with occlusion
88875700|NCT02665260|Placebo Comparator|Placebo without occlusion|Placebo topical without occlusion
88875701|NCT02665728|Experimental|BLI400|BLI400 Laxative
88875702|NCT02666352|Experimental|Moderate HI Participants|On Day 1, participants with moderate HI will receive a single oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast.
88875703|NCT02666352|Experimental|Severe HI Participants|On Day 1, participants with severe HI will receive a single oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast.
88875704|NCT02666352|Experimental|Healthy Participants|On Day 1, participants with normal hepatic function will receive a single oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast.
88875705|NCT02666508|Active Comparator|Plaque identifying toothpaste|A 30 day supply of daily syringes containing a plaque identifying toothpaste with targetol
88875706|NCT02666508|Active Comparator|Non-plaque identifying toothpaste|A 30 day supply of daily syringes containing an identical non plaque identifying toothpaste without targetol
89189448|NCT05809674||Children Cohort|"Aged 10 to 18~23 subjects with low to moderate myopia (-0.75 to -6 dioptres)~23 subjects with high myopia (more than -6 dioptres)~Ability of legal representative and subject to provide informed consent"
89399752|NCT02805660|Experimental|Phase 2: Combination Regimen - Cohort 1|Participants with non-small cell lung cancer (NSCLC) who were naïve to treatment with immunotherapy, and had a tumor with no/low programmed cell death ligand 1 (PD-L1) expression were included in this cohort.
89011495|NCT01643590|Placebo Comparator|Placebo|
89011496|NCT01643590|Experimental|15 mg dose of JVS-100|15 mg dose of JVS-100
88875707|NCT02669784|Active Comparator|Low Dose Contrast (40mL)|CTA of the chest: 40 mL of intravenous contrast at a rate of 5mL/sec. A region of interest (ROI) to trigger the scan will be placed in the aortic arch. If scan is performed using high pitch helical mode, the scan delay will be increased by 2 seconds. The Low Dose scan will then be compared to the standard of care high dose scan of the same area taken at a previous date.
88875708|NCT02669784|Active Comparator|Low Dose Contrast (50mL)|CTA of the abdomen OR or CTA of the chest and abdomen or CTA of the abdomen and pelvis or CTA of the chest, abdomen and pelvis: 50 mL of intravenous contrast at a rate 5mL/sec. A region of interest (ROI) to trigger the scan will be placed in the aortic arch. If scan is performed using high pitch helical mode, the scan delay will be increased by 2 seconds. The Low Dose scan will then be compared to the standard of care high dose scan of the same area taken at a previous date.
88875709|NCT02671032|Experimental|Implantation with Nucleus CI532 cochlear implant|All participants will receive the same treatment - Implantation with Nucleus CI532 cochlear implant.
88875710|NCT02672514|Active Comparator|MiECC|"Coronary artery bypass grafting is used with the help of cardiopulmonary bypass (CPB). The technique used in this arm based on the minimally invasive extracorporeal circulation system (MiECC). MiECC has been developed based on the concept of a closed total CPB circuit. The basic elements are a centrifugal pump, a membrane oxygenator and an arterial filter. The priming volume compared to CECC could be reduced. The complete circuit is heparin-coated for maximizing the biocompatibility.~CPB was performed under normothermic conditions of 36°C. Retrograde autologous priming was performed for all patients with stable hemodynamic circulation."
88875711|NCT02672514|Active Comparator|CECC|"Coronary artery bypass grafting is used with the help of cardiopulmonary bypass (CPB). The technique used in this arm based on the conventional extracorporeal circulation system (CECC). The CECC is an opened circulation system. The basic elements are a membrane oxygenator, a centrifugal pump, an open perfusion system containing the venous hard shell cardiotomy reservoir and the arterial line filter.~CPB was performed under normothermic conditions of 36°C. Retrograde autologous priming was performed for all patients with stable hemodynamic circulation, leading to a reduction of the priming volume. The CECC flow was set as required in order to maintain a mean arterial pressure (MAP) between 50 and 75 mmHg."
88875712|NCT02673138|Active Comparator|Basal interruption|Subjects will undergo basal interruption without canagliflozin during an overnight stay on the research unit
88875713|NCT02673138|Experimental|Basal interruption with canagliflozin|Subjects will undergo basal interruption with canagliflozin during an overnight stay on the research unit
88875714|NCT02673372|Active Comparator|Morphine Group|intravenous Morphine given at 0.1 mg/kg as intravenous infusion (10 min) with a maximum dose of 10 mg.
88875715|NCT02673372|Experimental|Ketamine Group|Ketamine administered in sub-dissociative doses 0.3 mg/kg as a intravenous infusion (10 min)
88875716|NCT02673918|Experimental|Part 1: Rehabilitation after surgery for breast cancer|Home-based upper-body rehabilitation with online support
88875717|NCT02673918|Experimental|Part 2: Rehabilitation after radiation for breast cancer|Home-based upper-body rehabilitation with online support
88875718|NCT02677428|Experimental|Remotely Delivered Benefits Counseling|Veterans will complete three intervention modules online. For the first module, Veterans will be instructed on how to use the website and its purpose; will be asked about their perception of the relationship between disability benefits and work. An explanation of relationship between disability benefits and work will be provided. For the second module, Veterans' feelings and attitudes towards employment will be solicited. Motivational Interviewing exercises will be implemented; barriers to work including the disabling condition and consideration of treatment for disabling conditions will be reviewed. An action plan will be developed. For the third module, inquiries will be made regarding the Veteran's reaction to the service-connection decision; information will be provided on how to appeal the decision. Veterans will be asked to reconsider work and financial goals in light of service-connection award. Their action plan will be reviewed. Follow-up resources will be provided.
88875719|NCT02677428|Active Comparator|Control|The control condition will involve referrals to VA websites and represents enhanced treatment-as-usual. A Veteran who completes a Compensation examination ordinarily has no further treatment or referral as part of the Compensation examination. The information about benefits-related websites controls for having information available about benefits and receiving encouragement to pursue that information. The control condition involves being urged to explore links to three VA websites with Compensation & Pension-related information: (a) the Veterans Benefits Administration (VBA) website with links about VA disability compensation, (b) the VBA site with fact sheets about the different types of benefits available to Veterans, and (c) the VBA websites for the local C&P office where issues pertaining to an individual Veteran's specific application are addressed.
88875720|NCT02677740|Experimental|Inhibitory rTMS (1 Hz)|Subjects are exposed to a 20-min inhibitory rTMS intervention that transiently suppresses the excitability of cortical structures beneath the site of stimulation. Subjects undergo MRI and MRS both before and right after the rTMS intervention.
88875721|NCT02677740|Experimental|Excitatory rTMS (5 Hz)|Subjects are exposed to a 20-min excitatory rTMS intervention that transiently increases the net excitability of cortical structures beneath the site of stimulation. Subjects undergo MRI and MRS both before and right after the rTMS intervention.
89011497|NCT01643590|Experimental|30 mg dose of JVS-100|30 mg dose of JVS-100
89189449|NCT05809661||deney grubu|"adult patients with intestinal stoma: The first interview: the patients were informed about the purpose of the study and signed informed consent form. The training booklet was delivered to them. Their contact information was obtained and the contact information of the researcher (navigator nurse) was shared with them. They were told that they could call the navigator nurse, send a message to him/her, take a photo of the stoma and share it with his/her when necessary, when they had physical, social, and psychological problems in the stoma or in line with their changing needs. In the next 3 months, they were informed about the applications to be made within the scope of the study (phone calls, information messages and videos, guidance and appointment planning). Appointment was scheduled for the next interview in 3 months.~."
89399753|NCT02805660|Experimental|Phase 2: Combination Regimen - Cohort 2|Participants with non-small cell lung cancer (NSCLC) who were naïve to treatment with immunotherapy, and had a tumor with high programmed cell death ligand 1 (PD-L1) expression were included in this cohort.
89437440|NCT03911986|Other|Delayed External Loop Recorder|Participants randomized to the Delayed External Loop Recorder group will be monitored for the duration of the second week of the study using the Novacor R-Test 4.
88875722|NCT02678442|Active Comparator|FNB first, then FNA|In an endoscopic ultrasound-guided procedure, Shark Core Fine Needle Biopsy (FNB) will be performed first, followed by Fine Needle Aspiration (FNA).
88875723|NCT02678442|Active Comparator|FNA first, then FNB|In an endoscopic ultrasound-guided procedure, Fine Needle Aspiration (FNA) will be performed first, followed by Shark Core Fine Needle Biopsy (FNB).
88875724|NCT02679690|Experimental|Standard dietary sodium education|Standard dietary sodium education provided to patients with heart failure using voice over powerpoint presentation.
88875725|NCT02679690|Experimental|color-coded cue cards|The use of a color-coded cue cards to educate patients with heart failure on dietary sodium. The education regarding the use of the color-coded cue card was provided using a voice over powerpoint presentation.
88875726|NCT02680158|Experimental|Sequence 1-Intranasal: Extranasal: Sham|Oculeve device, intranasal (test) application for approximately 3 minutes followed by oculeve device, extranasal (control) application for approximately 3 minutes followed by sham device, intranasal (control) application, for approximately 3 minutes on Day 0. There was rest period of 60 minutes before proceeding to the next application.
88875727|NCT02680158|Experimental|Sequence 2-Intranasal: Sham: Extranasal|Oculeve device, intranasal (test) application for approximately 3 minutes followed by sham device, intranasal (control) application for approximately 3 minutes followed by oculeve device, extranasal (control) application for approximately 3 minutes on Day 0. There was rest period of 60 minutes before proceeding to the next application.
88875728|NCT02680158|Experimental|Sequence 3-Extranasal: Intranasal: Sham|Oculeve device, extranasal (control) application for approximately 3 minutes followed by oculeve device, intranasal (test) application for approximately 3 minutes, followed by sham device (control), intranasal application for approximately 3 minutes on Day 0. There was rest period of 60 minutes before proceeding to the next application.
88875729|NCT02680158|Experimental|Sequence 4-Extranasal: Sham: Intranasal|Oculeve device, extranasal (control) application for approximately 3 minutes followed by sham device (control), intranasal application for approximately 3 minutes followed by oculeve device, intranasal (test) application for approximately 3 minutes on Day 0. There was rest period of 60 minutes before proceeding to the next application.
88875730|NCT02680158|Experimental|Sequence 5-Sham: Intranasal: Extranasal|Sham device (control), intranasal application for approximately 3 minutes followed by oculeve device, intranasal (test) application for approximately 3 minutes followed by oculeve device, extranasal (control) application for approximately 3 minutes followed by on Day 0. There was rest period of 60 minutes before proceeding to the next application.
88875731|NCT02680158|Experimental|Sequence 6-Sham: Extranasal: Intranasal|Sham device (control), intranasal application for approximately 3 minutes followed by oculeve device, extranasal (control) application for approximately 3 minutes followed by oculeve device, intranasal (test) application for approximately 3 minutes followed by on Day 0. There was rest period of 60 minutes before proceeding to the next application.
88875732|NCT02681172|Experimental|Neuraceq (florbetaben 18F) PET scan|"A single dose of 300 Megabecquerels (8.1 millicuries) Neuraceq will be administered per subject.~The applied florbetaben radioactive dose will be ± 20%."
88875733|NCT02682030|Active Comparator|Treatment group A|Subjects randomized to group A will be fitted for and issued a mechanical High Frequency Chest Compression Device (HFCC) device for home use. Subjects will be instructed to use the HFCC device 2-3 times per day for 15-30 minutes each. Subjects will be instructed to keep a device usage, concomitant medication, and adverse event diary.
88875734|NCT02682030|Active Comparator|Treatment group B- HFCC and Cough Assist|Subjects randomized to group B will be fitted for and issued a mechanical High Frequency Chest Compression Device (HFCC) device and will also be issued a cough assist device. Subjects will be instructed in the use of both devices. The HFCC device should be utilized 2-3 times per day for 15-30 minutes each followed by a session with the cough assist. Subjects will be instructed to keep a device usage, concomitant medication, and adverse event diary.
88875735|NCT02682420|Other|endoAVF|
88875736|NCT02682498|Active Comparator|EXPAREL® Bupivacaine Liposome Suspension|Instead of injecting the standard joint injection for a case of total knee arthroplasty, Exparel-Liposomal Bupivicaine will be administered at the end of the surgery. A new sustained-release local anesthetic solution (Bupivacaine Liposome Injectable Suspension) will be injected into the soft tissues around the join after surgery. Exparel is a novel-composition of bupivacine in which the drug is dissolved into liposomes which release it slowly over a period of 72 hours.
89011498|NCT01643629|Other|Study arm A|Study arm A will include subjects receiving three doses of Autologous Human Platelet Lysate at an interval of one month each.
89399754|NCT02805660|Experimental|Phase 2: Combination Regimen - Cohort 3|Participants with non-small cell lung cancer (NSCLC) who have been previously treated with an anti-programmed cell death ligand 1 (PD-L1) or anti-programmed cell death 1 (PD-1) agent with clinical benefit response followed by progression of disease were included in this cohort.
88875737|NCT02682498|Active Comparator|Standard periarticular joint injection|A standard joint injection of 100ml (Clonidine 80 mcg, Epinephrine 0.5mg, Ketorolac 30mg, Ropivacaine 246.25mg, and Sodium Chloride 0.9% 48.45 ml) will be injected into the soft tissues around the joint after surgery.
88875738|NCT02684136|Experimental|suvorexant|9 nights of 20 mg suvorexant
89399755|NCT02805660|Experimental|Phase 2: Combination Regimen - Cohort 4|Participants with non-small cell lung cancer (NSCLC) who have been previously treated with an anti-programmed cell death ligand 1 (PD-L1) or anti-programmed cell death 1 (PD-1) agent who had progression of disease ≤ 16 weeks after initiation of treatment were included in this cohort.
88875739|NCT02684136|Placebo Comparator|placebo|9 nights placebo
88875740|NCT02684604||unexplained infertility patients|44 patients diagnosed to have unexplained infertility
88875741|NCT02684604||Fertile women|44 fertile women
88875742|NCT02687412|Experimental|Fast-track Surgery|Pre-operative: Assessment, counseling and education; preoperative nutritional drink up to 4 h prior to surgery, bowel preparation, only oral intestinal cleaner，antimicrobial prophylaxis and skin preparation; preoperative treatment with carbohydrates (patients without diabetes). Intraoperative : fast solid food before 6 h and liquid food Intake of clear fluids 2 h before anaesthesia; avoiding hypothermia keeping temperature at 36 ±0.5℃, antiemetics at end of anaesthesia. Post-operative : Postoperative glycaemic control; postoperative nausea and vomiting (PONV) control; early postoperative diet(3-6 h after surgery).
88875743|NCT02687412|Other|Traditional surgery|"pre-operative assessment：pre-operative fasting at least 8h, bowel preparation for traditional surgery, Antimicrobial prophylaxis and skin preparation or mechanical bowl until liquid stool Intraoperative: keeping the intra-operative lowtemperature at 34.7±0.6 degree centigrade.~Post-operative: 6 h after surgery, patients resumed a liquid diet, patients began to take solid diet after anal exhaust"
88875744|NCT02693262|Experimental|CLS Mode on Biotronik CRT-D|All 15 patients will be randomized to this group. Their device will be set in the CLS mode for 1 week.
88875745|NCT02693262|Active Comparator|Accelerometer Mode on Biotronik CRT-D|All 15 patients will be randomized to this group. Their device will be set in the accelerometer rate responsive mode for 1 week.
88875746|NCT02695290|Experimental|Afatinib|
88875747|NCT02695446|Other|Oral ER Minocycline - Up to 2mg/kg|Oral extended release minocycline - up to 2mg/kg once a day for 30 days.
88875748|NCT02696070|Other|Sham of Provant|Sham of Provant
88875749|NCT02696070|Other|Active Treatment|Active Provant Treatment
88875750|NCT02697240|Experimental|Intravenous citrulline|Intravenous citrulline at a bolus dose over 5 minutes and then a continuous rate for the next 23 hours.
88875751|NCT02698566|Experimental|Ranibizumab PFS|Healthcare professionals (HCPs) will administer ITV injections of ranibizumab 0.5 mg delivered via PFS to enrolled patients (1 injection to each patient) on Day 1.
88875752|NCT02698800|Experimental|Blue blocking (BB)|Wearing of BB lenses.
88875753|NCT02698800|Placebo Comparator|Clear|Wearing of clear lenses
88875754|NCT02699970||Selected features|"No intervention is administered to the selected features. They only need to be observed by the pathologist.~The features are part of tissue that is present on a slide. This slide is fully scanned and the digital image is than viewed by the pathologist who indicates if he can see the feature. By repeating the scan three times and having the pathologist view three times, the consistency of the feedback can be monitored. The consistency is a measure on how repeatable and reproducible the scanner is. To be very clear: the scanner does not do anything to the tissue. It only takes a digital 'photo' of the tissue. It is no treatment or intervention. It just takes a picture."
88875755|NCT02657226||Intensive Monitoring of Renal Function|Urine output measurements recorded at least every 2 hours within the first 48 hours of ICU admission and serum creatinine measurements recorded daily for 3 days following ICU admission.
88875756|NCT02657226||Less-Intensive Monitoring of Renal Function|Urine output measurements with gaps of more than 3 hours recorded during the first 48 hours of ICU admission and fewer than 3 days of serum creatinine measurements after ICU admission.
89399756|NCT02186132|Experimental|Atropine 0.6 mg|Atropine 0.6 mg intravenous
88875757|NCT02701062|Other|LAA Exclusion with AtriClip®|LAA Exclusion with AtriClip®: AtriClip® is used per label and is not experimental.
88875758|NCT02701062|Active Comparator|Medical Management|Medical Management: Standard of Care Oral Anticoagulation Therapy at the discretion of the Investigator.
88875759|NCT02704104|Experimental|AC5 Topical Hemostatic Device|The intervention in this arm is the application of a topical hemostatic agent (AC5) to a freshly excised skin lesion
88875760|NCT02704104|Placebo Comparator|Control|The intervention in this arm is the application of saline (Control) to a freshly excised skin lesion
89399757|NCT02186132|Active Comparator|Atropine 1.2 mg intravenous|Atropine 1.2 mg intravenous
89399758|NCT03682419|Experimental|VKA Patients|Single Arm - blood collection by venepuncture and fingerstick in patients undergoing Warfarin Therapy
89399759|NCT03682419|Experimental|non-Vka Patients|Single Arm - blood collection by venepuncture and fingerstick in patients not undergoing Warfarin Therapy
88875761|NCT02705352|Experimental|5-Fluorouracil|Antimetabolite will be injected 2 weeks after periocular reconstruction with full thickness skin graft. Injection will be repeated every 2 weeks for a total of up to 4 injections.
89011499|NCT01643629|Other|Control Arm B|Control arm B will include subjects receiving Standard therapy
88875762|NCT02705352|Placebo Comparator|Normal saline|Normal saline will be injected 2 weeks after periocular reconstruction with full thickness skin graft. Injection will be repeated every 2 weeks for a total of up to 4 injections.
88875763|NCT02707146|Experimental|Tablet in the waiting room|"Patients in the intervention arm will be met in the waiting room prior to their primary care visit and will use the Visit Planner tool application on the tablet"
88875764|NCT02707146|Active Comparator|Health Education Handout|Patients in the control arm will be met in the waiting room prior to their primary care visit and will be given an educational pamphlet on health lifestyle to review
88875765|NCT02707770|Experimental|Ambulatory oxygen|Patient will use ambulatory oxygen during pulmonary rehabilitation programme (flow rate determined at the initial assessment to a maximum flow rate of 6 litres per minute)
88875766|NCT02707770|Placebo Comparator|Room air|Patient will breath on room air during pulmonary rehabilitation programme
88875767|NCT02708238|Experimental|Group A|All enrolled infants randomized to Group A will receive a standardized extract of Chamomilla L., Melissa Officinalis L. and tyndallized Lactobacillus Acidophilus (H122), administered at the dose of 1 ml twice a day of a commercially available solution
88875768|NCT02708238|Active Comparator|Group B|All enrolled infants randomized to Group B will receive Lactobacillus reuteri DSM 17938 administered at the dose of 108 colony-forming units (CFU)/day in 5 drops of a commercially available oil suspension
88875769|NCT02708238|Active Comparator|Group C|All enrolled infants randomized to Group C will receive simethicone, given at a dose of 60 mg in 15 drops two times per day of a commercially available solution
88875770|NCT02708862|Experimental|Preoxygenation|All participants were enrolled in a single arm in which they underwent 4 interventions in series: 1) Simple mask at 60 L/min for 3 minutes 2) Non-rebreather at 15 L/min for 3 min 3) Non-rebreather at 60 L/min for 3 minutes 4) Bag valve mask at 15 L/min for 3 minutes
88875771|NCT02709018|Experimental|Losartan|Losartan flexibly dosed from 25-100 mg per day over 10 weeks
88875772|NCT02709018|Placebo Comparator|Placebo|Placebo flexibly dosed from 25-100 mg per day over 10 weeks
88875773|NCT02713230|Active Comparator|EXPAREL 133 mg|10 mL EXPAREL (bupivacaine liposome injectable suspension) expanded with 10 mL normal saline as single-injection brachial plexus block (interscalene or supraclavicular) ≥1 h preoperatively
88875774|NCT02713230|Active Comparator|EXPAREL 266 mg|20 mL EXPAREL (bupivacaine liposome injectable suspension) as single-injection brachial plexus block (interscalene or supraclavicular) ≥1 h preoperatively
88875775|NCT02713230|Placebo Comparator|Placebo|20 mL normal saline as single-injection brachial plexus block (interscalene or supraclavicular) ≥1 h preoperatively
88875776|NCT02713698||Group 1 (≥18 years, BMI<35kg/m2)|Patients with 18 or more years presenting for inpatient nose and ear surgery.
88875777|NCT02713698||Group 2 (≥18 years, ≥35kg/m2)|Patients with 18 or more years presenting for inpatient bariatric surgery.
88875778|NCT02713698||Group 3 (≥65 years)|Patients with 65 or more years presenting for orthopaedic surgery.
88875779|NCT02714400|Active Comparator|Venlafaxine|50mg of Venlafaxine before sleep
88875780|NCT02714400|Placebo Comparator|Placebo|One piece of placebo before sleep
88875781|NCT02716506||Symptomatic POP|POP surgery in year 2015
88875782|NCT02716818|Experimental|Chronocort®|Chronocort® will be provided as 5mg, 10mg and 20mg capsules for oral administration. The starting dose for each subject will be based on the subjects previous glucocorticoid therapy dose and then dose titrated to effect.
88875783|NCT02716818|Active Comparator|standard glucocorticoid therapy|Subjects in this arm will continue previous oral glucocorticoid therapy titrated to effect.
88875784|NCT02719158|Experimental|6 mg OTO-201|6 mg OTO-201 (sustained-release suspension of ciprofloxacin), single 0.1 mL supra-tympanostomy tube (STT) administration to the affected ear(s)
88875785|NCT02719158|Experimental|12 mg OTO-201|12 mg OTO-201 (sustained-release suspension of ciprofloxacin), single 0.2 mL supra-tympanostomy tube (STT) administration to the affected ear(s)
88875786|NCT02719158|Sham Comparator|Sham (empty syringe)|Sham (empty syringe), single 0.1 mL STT administration to the affected ear(s)
88875787|NCT02719938|Experimental|Specialty Palliative Care|Specialty inter-disciplinary Palliative Care consultation during hospitalization with post-discharge collaborative care by a Palliative Care Nurse Practitioner and outpatient primary care physician. Clinical care will be augmented by evidence-based educational materials for dementia caregivers.
88875788|NCT02719938|No Intervention|Control|Usual care.
88875789|NCT02723916|Experimental|Intervention: ezParent Program|
88875790|NCT02723916|Active Comparator|Control: Health-e Kids App|
88875791|NCT02726178|Experimental|Advil® Pediatric drops for infants|"Oral ibuprofen (Advil® Pediatric drops for infants less than 3 months of age; Wyeth-Ayerst 40 mg/ml, DIN 2242522), at a dosage of 5 mg/kg/dose.~The drug was administered 30 minutes prior to immunization, and then at 8 and 16 hours following the immunization for a total of 3 doses."
88875792|NCT02726178|Placebo Comparator|Control|"Oral placebo: composed of sodium stearate 0.25g + lactose 0.5g + 15 ml of simple syrup, with a measured osmolarity of about 750 mosml/kg.~The drug (or placebo) was administered 30 minutes prior to immunization, and then at 8 and 16 hours following the immunization for a total of 3 doses."
88875793|NCT02727816|Experimental|filcon IV I (BC 8.6) / ocufilcon D (pair one)|Participants were randomized to a test and control lens for each pair in a contralateral design.
88875794|NCT02727816|Experimental|filcon IV I (BC 8.7) / ocufilcon D (pair two)|Participants were randomized to a test and control lens for each pair in a contralateral design.
88875795|NCT02727816|Experimental|methafilcon A (BC 8.6) / ocufilcon D (pair three)|Participants were randomized to a test and control lens for each pair in a contralateral design.
88875796|NCT02727816|Experimental|methafilcon A (BC 8.7) / somofilcon A (pair four)|Participants were randomized to a test and control lens for each pair in a contralateral design.
88875797|NCT02727894||Screening Group|CRC diagnosed by screening was defined as cancer diagnosed by primary screening colonoscopy, or colonoscopy after a positive immunochemical based faecal occult blood test i(FOBT) in patients without symptoms invited to examination according to the national screening programme policy
88875798|NCT02727894||Non-screening Group|Symptomatic CRC was defined as cancer diagnosed in symptomatic patients.
89399760|NCT02030522|Experimental|Prospective Treatment Cohort of ART|The target population (n=200) of persons treated with the intervention, Accelerated Resolution Therapy, will consist of U.S. service members and veterans who have symptoms indicative of a current diagnosis of PTSD. No age limit or duration of symptoms of PTSD will be imposed for study eligibility, and it is anticipated that most, if not all, of eligible and enrolled participants will have had prior deployments to conflicts dating back to the 1970s, including the Vietnam War, Persian Gulf conflict, and wars in Iraq and Afghanistan. No person will be excluded on the basis of race, ethnicity, gender, or disability.
89399761|NCT02181764|Experimental|KRN23|Single SC administration on day 1
89399762|NCT02184884||MACE group|the patients with MACE after OPCAB
89399763|NCT02184884||no MACE group|the patients without MACE after OPCAB
89399764|NCT03536780|Experimental|Avelumab and Gemcitabine|
89399765|NCT02052336|Experimental|CJ-12420 200 mg + Clarithromycin 500mg|CJ-12420 200mg QD for 5 days + Clarithromycin 500mg BID for 5 days
89399766|NCT02052336|Active Comparator|CJ-12420 200mg|CJ-12420 200mg QD for 5 days
89399767|NCT02052336|Active Comparator|Clarithromycin 500mg|Clarithromycin 500mg BID for 5 days
89399768|NCT02181920|Experimental|Metamizole - Diclofenac|metamizole followed by diclofenac
89399769|NCT02181920|Experimental|Diclofenac - Metamizole|diclofenac followed by metamizole
89399770|NCT02181920|Experimental|Metamizole - Placebo|metamizole followed by placebo
88875799|NCT02730234|Experimental|JetStream XC with balloon angioplasty|The intervention consists of JetStream atherectomy of femoropopliteal in-stent restenosis using the JetStream XC device followed by adjunctive balloon angioplasty in all patients.
88875800|NCT02733588|Experimental|G-Pump™ (glucagon infusion)|0.15 or 0.3 mg G-Pump™ (glucagon infusion) administered from OmniPod® pump
88875801|NCT02734056|Experimental|Music|The intervention to be administered is music
88875802|NCT02734056|Experimental|Control|There is no intervention listed here because this is the control group, in which there will be no intervention.
88875803|NCT02735382|Experimental|EHR-based referral to quit line|"Clinics will use an EHR-based fully-electronic HIPAA-compliant tool to refer their adult patients who use tobacco to the telephone tobacco quitline for tobacco cessation counseling and medication.~Intervention: Behavioral: Tobacco quitline EHR referral"
88875804|NCT02735382|Active Comparator|Fax-based referral to quit line|"Clinics will use a paper fax tool to refer their adult patients who use tobacco to the telephone tobacco quitline for tobacco cessation counseling and medication.~Intervention: Behavioral: Tobacco quitline Fax referral"
88875805|NCT02735382|Experimental|EHR-based Clinic Staff|Clinics will use an EHR-based fully-electronic HIPAA-compliant tool to refer their adult patients who use tobacco to the telephone tobacco quitline for tobacco cessation counseling and medication. Staff in these clinics will complete surveys to address Aim 4 of the study.
88875806|NCT02735382|Active Comparator|Fax-based referral to quit line Clinic Staff|Clinics will use a paper fax tool to refer their adult patients who use tobacco to the telephone tobacco quitline for tobacco cessation counseling and medication. Staff in these clinics will complete surveys to address Aim 4 of the study.
89399771|NCT02181920|Experimental|Placebo - Metamizole|placebo followed by metamizole
89399772|NCT02185118|Experimental|oxygen plus isoflurane/sevoflurane|"All human peripheral blood mononuclear cells (PBMCs) were from patients with non sepsis/non SIRS/non infection.~The above cells were treated with oxygen or oxygen plus isoflurane/sevoflurane after stimulation of lipopolysaccharide/plasma from septic patients."
89399773|NCT02186288||Adult ICU patients|
89399774|NCT02807376|Active Comparator|Surgeon's 'standard of care' stapler|Surgeon's standard of care stapler
89399775|NCT02807376|Experimental|Ethicon Powered Vascular Stapler|Ethicon Powered Vascular Stapler
89399776|NCT02256566|Experimental|emotional memory training exercise|study training exercise - Emotional Faces Memory Task (EFMT)
89399777|NCT02256566|Active Comparator|memory training exercise|an active control exercise (CT)
89399778|NCT02053896||ISU302|15~60U/kg (once every 2 weeks for 6 months)
89399779|NCT02186366|Experimental|Abdominal Massage Therapy|Abdominal Massage Therapy , 30 minutes, three times one week for 6 weeks
89399780|NCT02186366|Active Comparator|Buspirone|Buspirone by mouth 5mg three times per day for 6week
89399781|NCT02053974|Active Comparator|Spironolactone|patients who randomized to spironolactone administered arm
89399782|NCT02053974|Placebo Comparator|Placebo|Patients who randomized to placebo administered arm
89399783|NCT02185196|Active Comparator|Vitamin D3|Vitamin D3, Doses form: 20,000 IU vitamin D3 in children <6 months, 50,000 IU in children 6-12 months and 1,00,000 IU in children 13-59 months of age on first day and thereafter 10,000 IU for next 4 days.
89399784|NCT02185196|Placebo Comparator|Miglyol-oil|20,000 IU Miglyol-oil in children <6 months, 50,000 IU in children 6-12 months and 1,00,000 IU in children 13-59 months of age on first day and thereafter 10,000 IU for next 4 days.
89399785|NCT02052492|Experimental|Cohort A: EF-022 100 ng once weekly|Intra-Muscular injections of EF-022 100 ng once weekly for a period of 8 weeks
89399786|NCT02052492|Experimental|Cohort B: EF-022 500 ng once weekly|Intra-Muscular injections of EF-022 500 ng once weekly for a period of 8 weeks
89399787|NCT02052492|Experimental|Cohort C: EF-022 1000 ng once weekly|Intra-Muscular injections of EF-022 1000 ng once weekly for a period of 8 weeks
89399788|NCT02052492|Experimental|Expanded Cohort|the expanded cohort, 24 Patients will be allocated to receive either 100ng, 500ng or 1000ng weekly treatment as detailed below: The first 18 patients will be assigned to alternating doses of either 100ng or 500ng in a sequential manner (each patient will be assigned to a single dose). A decision regarding adding a 1000ng dose cohort vs. continuing with the 100ng and 500ng doses will be based on a discussion of the interim analysis results.
89399789|NCT02181998|Active Comparator|tenecteplase + unfractioned heparin|
88875807|NCT02737332|Active Comparator|Zytiga® (Abiraterone Acetate)|1,000 MG (4 x 250 mg qd)
88875808|NCT02737332|Experimental|SoluMatrix™ (Abiraterone Acetate)|500 mg (4 x 125 mg qd)
88875809|NCT05446428||Any SLE Disease Activity|
88875810|NCT05446428||Moderate to severe SLE Disease Activity|
89399790|NCT02181998|Experimental|tenecteplase + enoxaparin|
89189450|NCT05809661||kontrol grubu|"adult patients with intestinal stoma: The first interview: the patients were informed about the purpose of the study and signed informed consent form. All of the data collection tools were filled out. Their questions about stoma care were answered. Training booklet was handed down to them. An appointment was scheduled for the next interview 3 months later.~The second interview (3 months after the first interview): A few days before the interview, they were called up and reminded of their appointment. The relevant forms were filled out with them at the end of the 3rd month. Their questions about stoma care were answered. An appointment was scheduled for the next interview 3 months later."
88875811|NCT05446116|Active Comparator|femoral puncture|Under local anaesthesia, the femoral artery was punctured and 6F sheath was inserted. Splenic artery was catheterized using 4- or 5-F catheters (Cobra C2 cat or Simmons II catheter Imager-Boston Scientific Natick, Massachusetts). Embolization was done using Embospheres (Biosphere Medical, Rockland, MA) 700-900 μ in diameter.
88875812|NCT05446116|Active Comparator|Radial puncture|The left radial artery was preferred due to shorter distance from the left wrist to the splenic artery in comparison to the right wrist; also the left radial access theoretically decreases the risk of cerebral emboli. Under local anaesthesia and ultrasound guidance, the radial artery was punctured and 5- or 6-F sheath was introduced. After sheath insertion, the radial cocktail (2.5 mg of verapamil, 100 μg of nitroglycerin, and 5,000 units of heparin) was injected through the sheath over one minute after dilution with 20 ml of blood to decrease the discomfort during injection.
88875813|NCT05445960|Active Comparator|Tourniquet|This arm will have a tourniquet placed around the thigh inflated to 250mmHg for the duration of surgery (until splint placed) or 2 hours, whichever is shorter, during ankle fracture surgery.
88875814|NCT05445960|No Intervention|No Tourniquet|This arm will have a tourniquet placed around the thigh but NOT inflated for the duration of ankle fracture surgery.
88875815|NCT05445180|Experimental|Psychosis patients with cannabis use (Abstinent)|Psychosis patients with cannabis use will receive contingency management to encourage cannabis abstinence for 28 days
88875816|NCT05445180|No Intervention|Psychosis patients with cannabis use (Non-abstinent)|Psychosis Patients with cannabis use who will continue to use cannabis as usual
88875817|NCT05445180|Experimental|Non-Psychiatric controls with cannabis use (Abstinent)|Non-Psychiatric controls with cannabis use will receive contingency management to encourage cannabis abstinence for 28 days
88875818|NCT05445180|No Intervention|Non-Psychiatric controls with cannabis use (Non-abstinent)|Non-Psychiatric Controls with cannabis use will continue to use cannabis as usual
88875819|NCT05445180|No Intervention|Non-Psychiatric Controls without cannabis use|Non-Psychiatric controls without cannabis use
88875820|NCT05445102|Experimental|autogenous demineralized dentin graft as bone substitute in treatment of intrabony defect|
88875821|NCT05444088|Experimental|Adebrelimab in combination with Bevacizumab|
89189451|NCT05809635||Best Vitelliform Macular Dystrophy (VMD) Participants|Participants with a clinical picture of Retinitis pigmentosa with dominant and recessive variants in the BEST1 gene
89189452|NCT05809544|Experimental|WELT-IP|Eligible subjects were able to access WELT-IP (an investigational digital therapeutic) on a mobile device (iOS and Android) as scheduled to receive CBT-I.
88875822|NCT05444088|Experimental|Adebrelimab in combination with Bevacizumab and SHR-8068 RP2D1|
88875823|NCT05444088|Experimental|Adebrelimab in combination with Bevacizumab and SHR-8068 RP2D2|
89189453|NCT05809544|Sham Comparator|Sham|Eligible subjects were able to access a sham app downloaded on a mobile device (iOS and Android) which included sleep diary and general content regarding sleep.
89189454|NCT05809518|Experimental|Propofol Group|"Patient sedation after cardiac surgery at the intensive care unit.~Sedation group (Pr):~continuous infusion of propofol using a syringe pump at the dose of 1-1.5 mg / kg / h"
89189455|NCT05809518|Experimental|Dexmedetomidine group|"Patient sedation after cardiac surgery at the intensive care unit.~Sedation group Dexmedetomidine (Dx):~continuous infusion of Dexmedetomidine using a syringe pump at the dose of 0.5-1.0 mcg/ kg / h"
89189456|NCT05809518|Experimental|Dexmedetomidine and propofol group|"Patient sedation after cardiac surgery at the intensive care unit.~Sedation group DxPr:~continuous infusion of propofol using a syringe pump at the dose of 0.5-1.5 mg / kg / h and dexmedetomidine 0.2-0.7 mcg\kg\h"
89189457|NCT05809492|Experimental|Patients with a diagnosis of cystic fibrosis, FEV1(functional expiratory volume)< 40%|calculation of the maximum exercise capacity using the a-step test
89189458|NCT05809492|Experimental|Patients with a diagnosis of cystic fibrosis, FEV1(functional expiratory volume)< 40-70%|calculation of the maximum exercise capacity using the a-step test
89399791|NCT02054052|Experimental|Bevacizumab|Bevacizumab 100 mg, intrapleural injection treating maliganant pleural or percardial effusion
89399792|NCT02186444||PHI Navigator|Personalized Health Information Navigator (PHIN).
88875824|NCT05443854|Experimental|Aminoglycosides intervention|"Systematic aminoglycoside therapy using Amikacin at a dose of 25 to 30 mg/Kg per dose, at a rate of a maximum of 1 infusion per day will be delivered.~Recommended duration will be of three days or until microbiological documentation."
88875825|NCT05443854|Experimental|Lack of protective isolation intervention|Protective isolation will be avoided until ICU discharge is deemed possible. Specific measures regarding nutrition (including avoidance of food consider at risk of fungal contamination) and water protection will be maintained.
89399793|NCT02186444||NCI Information Booklets (IB)|National Cancer Institute (NCI) Information Booklets (IB).
89399794|NCT02051244||Subjective memory loss|Subjects who report memory loss, that may or may not be confirmed by an informant, but have normal cognitive tests ( MMSE scores of 27 or above out of 30. SLUMS scores of 20-30 for subjects with less than 8 years of education or 27-30 for those who have 12 or more years of education).
89399795|NCT02051244||Mild Cognitive Impairment|Subjects with Mild Cognitive Impairment - defined as being problems with memory, language or another essential cognitive ability that are severe enough to show up on cognitive tests but not to interfere with daily life. MMSE score of 23-27 out of 30. SLUMS score of 16-19 for subjects with less than 8 years of education or 20-26 for those who have 12 or more years of education.
89399796|NCT02051244||Control|Subject who do not report memory loss and have normal cognitive tests. MMSE of 27 or above out of 30. SLUMS score of 20-30 for subjects with less than 8 years of education or 27-30 for those who have 12 or more years of education.
88875826|NCT05443854|Other|No systematic aminoglycosides intervention|Antibiotic therapy and prophylaxis will be in line with more recent IDSA and ESCMID guidelines - standard arm
88875827|NCT05443854|Other|Protective isolation intervention|Protective isolation will be provided systematically as currently practiced in participating centers - standard arm
88875828|NCT05443776|Experimental|Study group biomaterial 1|
88875829|NCT05443776|Experimental|Study group biomaterial 2|
88875830|NCT05443776|Experimental|Study group biomaterial 3|
88875831|NCT05443776|Experimental|Study group biomaterial 4|
88875832|NCT05443776|Experimental|Study group biomaterial 5|
88875833|NCT05443776|Experimental|Study group biomaterial 6|
88875834|NCT05443308||Alzheimer Disease|patients with presumed Alzheimer disease and no known vascular, psychiatric or other major diseases age > 60 years
88875835|NCT05443308||Small vessel disease|"patients diagnosed with small vessel disease of the brain by MRI and presumed cognitive dysfunction and no other known psychiatric or other major diseases.~age > 60 years"
88875836|NCT05443308||Healthy subjects|"Age-matched subjects with no known vascular, psychiatric or other major diseases.~age > 60 years"
88875837|NCT05443152|Experimental|Experimental Arms|Prenatal attachment scale answered. In the first stage, pregnant women were trained to implement fetal movement count and position tracking. The training was provided face to face and lasted 30-45 minutes. How to determine the position of the fetus and I. and II. Leopold maneuvers are also taught. In the second stage, the pregnant women were interviewed twice a week by telephone.Thus, it was provided that pregnant women had fetal tracked at least once a day, at any time of the day, when the fetus was awake and most active, in a suitable position and a comfortable environment, for at least 15-20 minutes continuously for four weeks. Pregnant women phoned the researcher when they wanted. At the same time, the participants continued to their routine prenatal care. The mother attachment scale was answered at least 1 month after the birth of the women.
88875838|NCT05443152|No Intervention|No İntervention Arms|Prenatal attachment scale answered. The pregnant women continued to their routine prenatal care. No intervention was applied to the pregnant women in addition to their routine prenatal care.The pregnant women were called about whether continuing their routine care or having any problems during the research. The mother attachment scale was answered at least 1 month after the birth of the women.
88875839|NCT05442996|Experimental|HLX35+HLX10|Subjects will receive HLX35 in combination with HLX10 therapy, every 2 weeks as one treatment cycle.
88875840|NCT05442918||General Surgery|All patients undergoing either elective laparoscopic/open cholecystectomy, laparoscopic/open hiatus hernia repair, laparoscopic/open inguinal hernia repair, laparoscopic/open umbilical hernia repair or laparoscopic ventral wall hernia repair.
88875841|NCT05442918||Bariatric Surgery|Participants undergoing elective bariatric surgery (laparoscopic sleeve gastrectomy or roux-en-y gastric bypass). Those in the bariatric arm must have been on a VLCD pre operatively
89399797|NCT02186522||Critical Care Patients|Patients staying in the ICU for at least 48 hours, requiring external support of one or more organs (invasive ventilation, inotropes/vasopressors or renal replacement therapy) and who are not expected to die within 48 hours of study entry.
89399798|NCT02051322|Experimental|Jet Nebulizer|Nebulization with a jet nebulizer and a classic mask
89399799|NCT02051322|Experimental|Trunk Mask Nebulizer|Nebulization with a je nebulizer and a trunk mask
89399800|NCT02051322|Experimental|Aerobika Nebulizer|Nebulization with an Aerobika
89399801|NCT02185352|Experimental|Inductional BEEP regimen|"Induction BEEP regimen:~Every 3 weeks a cycle for a total of 3 cycles (around 2 months)~Bevacizumab 15mg/kg IVF on D1~Etoposide 70 mg/m2 IVF QD, D2-4~Cisplatin 70 mg/m2 IVF on D2~WBRT:~3000cGy in 10 fractions"
89399802|NCT02185352|No Intervention|WBRT alone|"standard WBRT:~3000cGy in 10 fractions"
89399803|NCT02051400|Experimental|Intubation with the McGrath® MAC video laryngoscope|Participants perform five intubation attempts using the airway manikin with the normal airway setting. After completing the normal airway session, the participants performed another five attempts with the neck immobilization setting using a neck collar.
89399804|NCT02051400|Experimental|Intubation with the GlidesScope® Ranger video laryngoscope|Participants perform five intubation attempts using the airway manikin with the normal airway setting. After completing the normal airway session, the participants performed another five attempts with the neck immobilization setting using a neck collar.
89536669|NCT03066453|Experimental|Short cure|antibiotic IV (Nebcin)14 days but with only 5 days of tobramycin IV followed 9 days of inhaled tobramycin (Tobi Inhalant Product) associated with one or more other antibiotic (s) IV in routine care
89536670|NCT03558711|Experimental|study group|
88875842|NCT05442762||Global Database of Vaccine Related Posts|Tweets in English from Twitter and posts from weico from 2015 to 2022 for all vaccines. The investigators only included posts from individual accounts and excluded those from news, organizational accounts, or verified users.
89399805|NCT02051400|Experimental|Intubation with Macintosh laryngoscope|Participants perform five intubation attempts using the airway manikin with the normal airway setting. After completing the normal airway session, the participants performed another five attempts with the neck immobilization setting using a neck collar.
89399806|NCT02052570||Children post-HSCT|Children post-HSCT age 10-16 yrs of age who had allogeneic transplant who are within 5 years of transplant and returned to school in past 12-24 months after previously attending school pre-transplant
89399807|NCT02052570||Parents of children post-HSCT|Parents of children post-HSCT (children in focus group) will participate in focus group with other parents to discuss the challenges and successes of their child returning to school following HSCT.
89399808|NCT02052570||Teachers of children post-HSCT|Teachers of children post- HSCT (children in focus group) will participate in focus group with other teachers to discuss the challenges and successes of children returning to school post HSCT
89399809|NCT02052570||PBMT provider of child post-HSCT|PBMT provider of child-post HSCT (child in focus group) will participate in in focus group with other PBMT providers to discuss the successes and challenges of coordinating school reentry in child post-HSCT
89399810|NCT02054208|Experimental|NEUROSTEM (hUCB-MSCs)- low dose|human umbilical cord blood derived mesenchymal stem cells Low dose: 1 x 10^7cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals
89399811|NCT02054208|Experimental|NEUROSTEM (hUCB-MSCs) - high dose|human umbilical cord blood derived mesenchymal stem cells High dose: 3 x 10^7 cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals
89399812|NCT02054208|Placebo Comparator|Placebo|normal saline 2mL, doses separated by 4 weeks for a total of 3 doses
89399813|NCT02190110||Suspected pulmonary embolism patients|Adult patients (more than 18 years old) suspected of PE will be recruited at the time of the medical evaluation and before a final diagnosis is established
88875843|NCT05442762||Global Database of HPV Vaccine Related Posts|Tweets in English from Twitter and posts from weico from 2015 to 2022 for HPV vaccine. The investigators only included posts from individual accounts and excluded those from news, organizational accounts, or verified users.
88875844|NCT05442528||Experimental: FIX replacement therapy.|Subject's previous treatment plan will be followed
88875845|NCT05441046|Experimental|Genakumab|genakumab plus tislelizumab 200 mg
88875846|NCT05422170||Patients undergoing transfemoral TAVI|Patients receiving 125 U/kg unfractioned heparin for periprocedural anticoagulation and 500U Protamine / 1000U Heparin at the end of the procedure
88875847|NCT05412264|Experimental|Website intervention|Website access: 12 Weekly emails, access to website with goal setting and recording steps
88875848|NCT05412264|No Intervention|Delayed access|Will not receive access to the program/website until they complete their 16 week assessments
88875849|NCT05404152||Ederly|Elderly Admitted to Nursing homes
88875850|NCT05394870|Experimental|study group|
88875851|NCT05394870|Active Comparator|control group|
88875852|NCT05350332|Experimental|Negative Pressure Ventilator|Participants with obstructive sleep apnea (OSA) who are being evaluated for surgical treatment of their OSA and having a routine clinical DISE will have their lung volume increased with a non-invasive negative pressure ventilator. Participants will also have a pulmonary function test performed per routine clinical protocol, but for research purposes only (i.e., not part of usual care).
88875853|NCT05350332|Experimental|Transcutaneous Phrenic Nerve Stimulation|Participants with obstructive sleep apnea (OSA) who are being evaluated for surgical treatment of their OSA and having a routine clinical DISE will have their lung volume increased with transcutaneous phrenic nerve stimulation. Participants will also have a pulmonary function test performed per routine clinical protocol, but for research purposes only (i.e., not part of usual care).
88875854|NCT05340270|Experimental|PD-1 inhibitor + GP Group|PD-1 inhibitor plus GP chemotherapy as Neoadjuvant Therapy followed by IMRT combined with cisplatin concurrent chemotherapy
88875855|NCT05340270|Active Comparator|GP Group|GP chemotherapy as Neoadjuvant Therapy chemotherapy followed by IMRT combined with cisplatin concurrent chemotherapy
88875856|NCT05321472||group for training the algorithm|This group of images is used for training the algorithm of the artificial intelligence
89399814|NCT02052726|Experimental|Arm Label: Month 0, 1 and 3 Schedule|
89399815|NCT02052726|Experimental|Day 1, 8, and 30 Schedule|
89399816|NCT02185430|Placebo Comparator|Control group|saline solution
89399817|NCT02185430|Active Comparator|dexmedetomidine group|dexmedetomidine
89399818|NCT03536390|Placebo Comparator|Placebo|one chewable tablet once daily in morning.
89399819|NCT03536390|Experimental|Methylphenidate Hydrochloride Extended Release Chewable Tablet|one chewable tablet once daily in morning.
89399820|NCT03561480|Experimental|Ferric carboxymaltose group|Ferinject®to be administered as IV drip infusion or undiluted bolus injection to consented patients with postoperative anemia after total knee arthroplasty.
89399821|NCT03561480|Active Comparator|Placebo group|Placebo(0.9% Normal Saline) to be administered as IV drip infusion or bolus injection to consented patients with postoperative anemia after total knee arthroplasty.
89399822|NCT02190188|No Intervention|No specific treatment|No specific treatment after partial meniscectomy
89399823|NCT02190188|Other|Wedge Insole with 5mm wedge angel|Participants wear a wedge insole after partial meniscectomy
89399824|NCT02190188|Other|Knee Brace|Participants wear a knee brace after partial meniscectomy
89399825|NCT03561870|Experimental|Olaparib|
88875857|NCT05321472||group for testing the algorithm|This group of images is used for testing the algorithm of the artificial intelligence
88875858|NCT05289414|Active Comparator|Radiofrequency|first group of patients will be sujected to radiofrequency treatment
88875859|NCT05289414|Active Comparator|Greater occipital nerve vlock|second group of patients will be sujected to Greater occipital nerve block
88875860|NCT05269368|Experimental|No wicking|Absence of Wicking after intervention
88875861|NCT05269368|Active Comparator|Control|Wicking after intervention
88875862|NCT05266404|Experimental|Treatment A (Test Formulation): Dapagliflozin/Sitagliptin FDC tablet|Subjects will receive single dose of dapagliflozin/sitagliptin fixed dose combination (FDC) (test formulation).
88875863|NCT05266404|Active Comparator|Treatment B (Reference Formulation): Dapagliflozin+Sitagliptin|Subjects will receive single dose of dapagliflozin 10 mg tablet + sitagliptin 100 mg tablet co-administered as individual tablets (reference formulation).
88875864|NCT05212584|Experimental|CD7 CAR T cells|Dose escalation phase: CD7 CAR T cells will be transduced with a lentiviral vector to express a CD7 CARs. with an escalation approach, 1 e6 to 7 e6 CAR-T cells/kg
88875865|NCT05206188|Experimental|Experimental|Study participants randomized to the experimental condition will receive IPS services as usual in conjunction with the MWW intervention.
88875866|NCT05206188|No Intervention|Control|Study participants randomized to the control condition will receive IPS services as usual.
88875867|NCT05184738|Experimental|Oligomeric nutritional formula arm (Bi1 peptidic)|Individuals will receive a Oligomeric nutritional formula.
88875868|NCT05184738|Other|Standard arm|Individuals will receive a Standard nutritional formula.
88875869|NCT05175924|Experimental|Virtual reality|In the Aquarium VR group, virtual reality headset compatible with iPhone 7 (Apple) was used to distract attention. Before use, the headsets were tested on five children for face fit and visibility of the application used. Written and verbal consent of the children and their parents was obtained to test the headsets. The children who tested the headsets were not included into the study. The headset offered a soft and comfortable experience in contact with the skin due to its leather and pad covering. It also had a wide viewing angle and an optical zoom button. Due to its noise isolation function, it did not disturb anyone or make noise.
89189459|NCT05809492|Experimental|Patients with a diagnosis of cystic fibrosis, FEV1(functional expiratory volume)> 70%|calculation of the maximum exercise capacity using the a-step test
89399826|NCT02185508||Lumbar spine surgery with IONM|Patients diagnosed with 1 or 2 level lumbar disk disease and radicular symptoms who underwent decompressive surgery, and for whom IONM records exist.
88875870|NCT05150418|Experimental|Oxygen|Oxygen 15 l/min administered with face mask with reservoir.
88875871|NCT05150418|Placebo Comparator|Room air|Room air 15 l/min administered with face mask with reservoir.
88875872|NCT05146206||Patients on RYALTRIS|Patients who are currently using RYALTRIS nasal spray.
88875873|NCT05146206||Patients on DYMISTA|Patients who are currently using DYMISTA nasal spray.
88875874|NCT05127564|Experimental|DRF: Chinese Participants|Chinese participants will receive DRF Dose 1, oral capsules, twice daily (BID), from Day 1 to Day 4 and DRF Dose 1, oral capsules, once daily (QD), on Day 5.
88875875|NCT05127564|Experimental|DRF: Caucasian Participants|Caucasian participants will receive DRF Dose 1, oral capsules, BID, from Day 1 to Day 4 and DRF Dose 1, oral capsules, QD, on Day 5.
88875876|NCT05063604|Experimental|Citalopram 20-40 mg|Participants received citalopram 20 mg tablet once or twice daily for 12 weeks.
88875877|NCT05063604|Experimental|Psychotherapy|Participants received one psychotherapy session weekly for 12 weeks.
88875878|NCT05051514||No-Mild Severity OSAS|Mild sleep apnea: An Apnea-Hypopnea Index (AHI) of five to 14 events per hour.
88875879|NCT05051514||Moderate to Severe OSAS|Moderate sleep apnea: An Apnea-Hypopnea Index (AHI) of 15 to 29 events per hour.Severe sleep apnea: An Apnea-Hypopnea Index (AHI) of 30 or more events per hour.
88875880|NCT04960332|No Intervention|Standard treatment|Group A: Standard wound closure with staples and conventional wound dressing.
88875881|NCT04960332|Experimental|Prevena|Group B: Wound closure with staples and Negative Pressure Wound Therapy (PREVENA PLUS™ Incision Management System).
88875882|NCT04940364|Experimental|Cohort 1|Pozelimab: Single-dose SC on day 1
89399827|NCT02054286|Experimental|Group 1: THV01 (5.10E+6 TU) or Placebo|5.10E+6 TU (transducing unit) of THV01-1 (Week 0) OR matching placebo; 5.10E+6 TU (transducing unit) of THV01-2 (Week 8) OR matching placebo
88875883|NCT04940364|Experimental|Cohort 2|Pozelimab: Single-dose IV on day 1
88875884|NCT04940364|Experimental|Cohort 3|Pozelimab: Single-dose SC on day 29 Cemdisiran: Single-dose SC on day 1
88875885|NCT04940364|Experimental|Cohort 4|Pozelimab: Single-dose SC on day 1 Cemdisiran: Single-dose SC on day 1
88875886|NCT04940364|Experimental|Cohort 5|Optional Pozelimab: Single-dose SC on day 1 or day 29 Cemdisiran: Single-dose SC on day 1
88875887|NCT04940364|Experimental|Cohort 6|Pozelimab: Single-dose IV on day 1
88875888|NCT04844736|Other|Radiology Treatment Planning/Review|After patient consultation and enrollment, the patient will undergo routine CT simulation to initiate the radiation treatment planning process. The treating physician will contour the gross tumor volume (GTV) including the involved primary lung tumor and/or the involved lymph nodes. If the initial radiology review reflects concern for inadequate target volume delineation, the case will be flagged for multidisciplinary discussion between the radiation oncologist and radiologist.
88875889|NCT04814706||Group C|Patients drank carbohydrate fluid 2 hours prior to surgery.
88875890|NCT04660422||Pre-COVID-19 ACP baseline|"Two six-month control periods prior to the wide-scale implementation of the intervention, allow us to measure a baseline rate of ACP activity and identify the pre-COVID-19 ACP baseline rate and a COVID-19 ACP baseline rate.~September 15, 2019 - March 14, 2020,"
88875891|NCT04660422||COVID-19 rate|"Two six-month control periods prior to the wide-scale implementation of the intervention, allow us to measure a baseline rate of ACP activity and identify the pre-COVID-19 ACP baseline rate and a COVID-19 ACP baseline rate.~March 15, 2020 - September 14, 2020"
88875892|NCT04660422||ACP rate|ACP rate during the implementation period, which begins December 15, 2020 and continues for six months, to the rates in the previous two control periods December 15, 2020-June 15, 2021
88875893|NCT04649580||Online Survey|
88875894|NCT04649580||One-to-one interviews|
88875895|NCT04601922||Emergency Medicine Consultants|
88875896|NCT04601922||General Practitioners|
88875897|NCT04601922||Acute care nursing staff|
88875898|NCT04601922||Patients presenting with suspected cardiac chest pain|
88875899|NCT04376658||Cohort 1 (Coalition I)|Adult hospitalized patients with proven or suspected SARS-Cov-2 infection with up to 4L/minute oxygen supply through nasal catheter.
88875900|NCT04376658||Cohort 2 (Coalition II)|Adult hospitalized patients with proven or suspected SARS-Cov-2 infection needing oxygen supplementation > 4L/min on nasal catheter or HFNC or NIV or MV or ECMO.
88875901|NCT04376658||Cohort 3 (Coalition III)|Adult hospitalized patients with proven or suspected SARS-Cov-2 infection with moderate or severe ARDS according to the Berlin definition
88875902|NCT04376658||Cohort 4 (Coalition IV)|Adult hospitalized patients with proven SARS-Cov-2 infection and D-dimer above the upper limit of the normal range
88875903|NCT04376658||Cohort 5 (Coalition VI)|Adult hospitalized patients with proven SARS-Cov-2, needing oxygen supplementation to maintain SpO2 > 93%, and two or more of the following inflammatory tests: D-dimer > 1,000 ng/mL; C reactive protein (CRP) > 5 mg/dL; Ferritin > 300 mg/dL; Lactate dehydrogenase (LDH) > upper limit of normal
88875904|NCT04352010|Experimental|"Online-Intervention Res-Up!"|Participants in the Res-Up! group get access to Res-Up! while waiting for psychotherapy or in addition to psychotherapy. Participants will answer questionnaires after inclusion as well as six and twelve weeks later.
88875905|NCT04352010|Experimental|"Online-Intervention REMOTION"|Participants in the REMOTION group get access to REMOTION while waiting for psychotherapy or in addition to psychotherapy. Participants will answer questionnaires after inclusion as well as six and twelve weeks later.
88875906|NCT04352010|Experimental|Wait-control group|Participants in the wait-control group will not get access to the online-tools while waiting for psychotherapy or while in psychotherapy. Participants will answer questionnaires after inclusion, six weeks later and twelve weeks later.They get access to one of the online-tools after 12 weeks.
88875907|NCT04194372||Metabolic Patient|"Patients with a metabolic desease, defined as~Metabolic Syndrom~Diabetic~Obese"
88875908|NCT04185792||Patients with spinal cord injury|NBSS, Qualiveen and SF-Qualiveen questionnaires will be administered to participants.
88875909|NCT04185792||Patients with multiple sclerosis|NBSS, Qualiveen and SF-Qualiveen questionnaires will be administered to participants.
88875910|NCT04076202|Experimental|Cementless Vanguard DD RP|Patients receiving a total knee prosthesis
88875911|NCT03947814|Experimental|Part A: Normal renal function (control group)|Participants with normal renal function (glomerular filtration rate [GFR] greater than or equal to [>=] 90 milliliters per minute [mL/min]) will receive single oral dose of 600 mg pimodivir as 2*300 mg tablets.
88875912|NCT03947814|Experimental|Part A: Severe renal impairment or ESRD|Participants with severe renal impairment (GFR >=15 to less than [<]30 mL/min) who are not on dialysis or end stage renal disease (ESRD) (GFR <15 mL/min) not yet on dialysis will receive single oral dose of 600 mg pimodivir as 2*300 mg tablets.
88875913|NCT03947814|Experimental|Part B (Optional): Mild renal impairment|Participants with mild renal impairment (GFR >=60 mL/min to <90 mL/min) will receive single oral dose of 600 mg pimodivir as 2*300 mg tablets.
88875914|NCT03947814|Experimental|Part B (Optional): Moderate renal impairment|Participants with moderate renal impairment (GFR >=30 to <60 mL/min) will receive single oral dose of 600 mg pimodivir as 2*300 mg tablets.
88875915|NCT03797586|Experimental|Electroacupuncture group|Bilateral ST25,SP14, ST37 will be used in the EA group. For ST25 and SP14, 0.30×50mm or 0.30×75mm needles will be vertically inserted to the muscle layer of the abdominal , where patients will feel sharp pain and acupuncturists will feel resistance from the needle tip. For ST37, 0.30×40 mm needles will be vertically inserted approximately 15 mm deep, followed by three-time manipulation of even lifting and twisting method to elicit the sensation of deqi. Then paired alligator clips of the EA apparatus will be attached to the needle holders of the bilateral ST25, SP14, and ST37. EA stimulation will be retained for 30 minutes with a continuous wave of 10 Hz and current intensity of 0.5 to 4 mA.
88875916|NCT03797586|Sham Comparator|Sham electroacupuncture group|Bilateral sham ST25, SP14, and ST37 will be used in the SA group. After sterilizing the skin, 0.30×40mm needles will be straightly inserted at the sham points about 2-3mm until they can be fixed on the skin when attached by the alligator clips. No manipulation will be used, and no deqi sensation are elicited for all sham points. The bilateral sham ST25, SP14, and ST37 points will be attached by the same EA apparatus with a continuous wave of 10 Hz and current intensity of 0.1 to 0.2 mA for 30 minutes with only the initial 30 seconds on.
88875917|NCT03770130|Experimental|Dexmedetomidine treatment group|Anaesthesia will be maintained with sevoflurane inhalation, of which the concentration will be adjusted to maintain the BIS value between 40 and 60. Muscle relaxation will be maintained with rocuronium or cisatracurium. Analgesia will be maintained with remifentanil (administered via continuous infusion), sufentanil (administered via continuous infusion or intermittent injection), or fentanyl (administered via intermittent injection). In addition to this, patients will receive an initial loading dose of dexmedetomidine of 1μg/kg over 10 min after the induction of anaesthesia followed by a continuous infusion of 0.5μg/kg/h until the end of surgery.
88921920|NCT06061003|Other|Standard Anatomic Model Group|All participants will receive 1 hour training on anatomy and pathophysiology of toric wrist fractures.After lecture completed, the Standard Anatomic Model Group will engage in a 1-hour hands-on practical session in the laboratory, working with standard anatomical wrist models.
88921921|NCT06060548||Patients with PVCs|Patients referred for management of symptomatic or asymptomatic PVCs. Patients presenting with PVCs and ventricular arrhythmias will be monitored using ILRs from the time of their initial presentation of PVCs.
89189460|NCT05809440|Experimental|Intervention Group|A 20-minute mindful breathing session guided by a trained medical doctor. The session consisted of four 5-minute breathing exercises done consecutively. Participants were instructed to close their eyes and bring their attention to their breathing, and re-direct their attention back to their breathing once they were distracted.
89189461|NCT05809440|No Intervention|Control Group|No intervention was provided for control group.
89399828|NCT02054286|Experimental|Group 2: THV01 (5.10E+7 TU) or Placebo|5.10E+7 TU (transducing unit) of THV01-1 (Week 0) OR matching placebo; 5.10E+7 TU (transducing unit) of THV01-2 (Week 8) OR matching placebo
89399829|NCT02054286|Experimental|Group 3: THV01 (5.10E+8 TU) or Placebo|5.10E+8 TU (transducing unit) of THV01-1 (Week 0) OR matching placebo; 5.10E+8 TU (transducing unit) of THV01-2 (Week 8) OR matching placebo
89437441|NCT03909321|No Intervention|Control group|The Control group will not be submitted to intervention and will be instructed not to engage in any kind of structured physical exercise training and to keep the life activities identified at baseline.
89437442|NCT03909321|Experimental|Beach tennis training group|The Beach Tennis (BT) group will perform two sessions per week of the Beach Tennis training. This intervention will last 12 weeks.
88875918|NCT03770130|Placebo Comparator|Control group|Anaesthesia will be maintained with sevoflurane inhalation, of which the concentration will be adjusted to maintain the BIS value between 40 and 60. Muscle relaxation will be maintained with rocuronium or cisatracurium. Analgesia will be maintained with remifentanil (administered via continuous infusion), sufentanil (administered via continuous infusion or intermittent injection), or fentanyl (administered via intermittent injection). In addition to this, patients will receive an equal volume initial loading dose of 0.9% saline over 10 min after the induction of anaesthesia followed by an equal volume continuous infusion until the end of surgery.
88875919|NCT03758664|Experimental|ICP-192|The initial dose of ICP-192 is 2 mg, QD, and dose escalation schedule may be modified based on the safety and PK from the previous dose. Tentatively seven dose levels will be evaluated.
88875920|NCT03694626|Active Comparator|Healthy Control subjects|
88875921|NCT03694626|Active Comparator|TBI Patients without photosensitivity|
88875922|NCT03694626|Active Comparator|Migraine patients without photosensitivity|
88875923|NCT03694626|Active Comparator|Migraine patients with photosensitivity|
88875924|NCT03694626|Active Comparator|TBI patients with photosensitivity|
88875925|NCT03670914|Experimental|WatchPAT 200 and In-Lab Study|Patients who are referred to the sleep center for an overnight study that are narcotic users will be offered to the opportunity to participate in the study. Patients who fulfill the inclusion exclusion criteria and have given informed consent will undergo a standard in-lab polysomnography while simultaneously wearing the WatchPAT200 device.
89189462|NCT05809336|Experimental|inosine group|Participants will receive inosine + PD-1/PD-L1 inhibitor ± chemotherapy/targeting,every 2 or 3 weeks, until the subject's disease progresses, death, intolerable adverse events, the investigator determines that there is no benefit from continued treatment or other termination criteria are met (pregnancy, individual patient reasons or co-morbidities), the subject requests withdrawal from the study, withdrawal of informed consent, and loss of visit
89189463|NCT05809336|Active Comparator|non-inosine group|Participants will receive PD-1/PD-L1 inhibitor ± chemotherapy/targeting, every 2 or 3 weeks .until the subject's disease progresses, death, intolerable adverse events, the investigator determines that there is no benefit from continued treatment or other termination criteria are met (pregnancy, individual patient reasons or co-morbidities), the subject requests withdrawal from the study, withdrawal of informed consent, and loss of visit
88875926|NCT03642834|Experimental|ICP-105 Single Arm|ICP-105 of multiple dose levels, dose escalation steps may be modified based on the safety from the previous dose.
88875927|NCT03449784||patients with dyslipidemia non achieving LDL-C target|patients with dyslipidemia non achieving LDL-C target
89189464|NCT05809245|Experimental|Corneal neurotization|Patients will undergo the corneal neurotization as described in the protocol. Their pre and post-procedure corneal sensation will be measured as a primary outcome measure. Secondary outcome measures will include visual acuity, corneal opacity, NEI VFQ, and confocal microscopy.
89189465|NCT05809232|Active Comparator|CARES-guided Group|The Intervention
89189466|NCT05809232|No Intervention|Non CARES-Guided Group|The control - Participants randomized to the control arm will continue to have their routine Pre-Anesthesia Assessment on the electronic form, without the CARES calculator calculations, as per current practice
89189467|NCT05809206|Experimental|Glutes maximus Strengthening group|Twenty patients received Strengthening exercises for Glutes maximus muscle and conventional physical therapy (corrective exercises and ultrasound).
89189468|NCT05809206|Experimental|Glutes Medius Strengthening group|Twenty patients received Strengthening exercises for Glutes medius muscle and conventional physical therapy (corrective Exercises and therapeutic ultrasound (US).
89189469|NCT05809206|Active Comparator|Conventional treatment group|Twenty Patients received conventional therapy (corrective exercises and ultrasound).
89189470|NCT05809167|Experimental|VEN+AZA+Modified BUCY|
89189471|NCT05809154||Neurogenic lower urinary tract dysfunction|Lower urinary tract dysfunction due to any neurological condition like spinal cord injury, multiple sclerosis and others.
89189472|NCT05809154||Non-Neurogenic lower urinary tract dysfunction|Lower urinary tract dysfunction in absence of any neurological pathology.
89189473|NCT05809154||Chronic pelvic pain|Chronic pelvic pain as defined by the EAU guidelines.
89189474|NCT05809154||Urodynamic normal Bladder function|Normal urodynamic findings and absence of chronic pelvic pain.
89189475|NCT05809102|Other|Minimal incisions|Repair of Zone II using minimal incisions
89189476|NCT05809076|Experimental|real tACS|
89189477|NCT05809076|Sham Comparator|sham tACS|
89189478|NCT05809063||cardiovascular patients|neonates that have cardiovascular diseases
89189479|NCT05809063||respiratory patients|neonates that have respiratory diseases
89189480|NCT05809063||gastrointestinal diseases|neonates that havegastrointestinal diseases
89189481|NCT05809063||renal patients|neonates that have renal diseases
89189482|NCT05809063||central nervous system diseases|neonates that have central nervous system diseases
88875928|NCT03449784||patients with dyslipidemia achieving LDL-C target|patients with dyslipidemia achieving LDL-C target
88875929|NCT03447834|Experimental|Selective intracoronary hypothermia + PPCI|Patients will be eligible for this study if they are admitted for acute anterior wall ST-elevation myocardial infarction with total ST-segment deviation of at least 5 mm. If the patient has TIMI grade flow 0 or 1, the experimental arm will be treated by selective intracoronary hypothermia just before and after reperfusion, in addition to routine PPCI.
89189483|NCT05809063||metabolic patients|neonates that have metabolic diseases
89189484|NCT05809063||endocrinal patients|neonates that have endocrinal diseases
89189485|NCT05809050||control group|represents the control group ( ITP cases
89189486|NCT05809050||AL group|cases of AcuteLeukemia.
89189487|NCT05809037|Active Comparator|Active Stimulation for right hemiparesis patients|Active non-invasive transauricular vagus nerve stimulation over left ear in post-stroke right hemiparesis
89399830|NCT02186756|Experimental|EMG-Biofeedback and Usual Care|"Patients in the intervention group started EMG-biofeedback training within three days after inclusion. In total 14 sessions of EMG-biofeedback training were applied. They started with three sessions of therapy in week 1-3 and had one session per week in week 4-8.~Patients were encouraged to do a home exercise program, in which they consciously relaxed the muscle analogously to the biofeedback session for about 15 minutes per day. Additionally, they should try to apply the techniques in stressful situations, for example appointments at the dentist's."
89399831|NCT02186756|No Intervention|Usual care|The patients in the control group had only two encounters with the therapist in the eight week interval. At these encounters pain was assessed by a visual analogue scale and their trapezius muscle activity was measured during 5 minutes analogously to the intervention group. However, afterwards they did not continue with muscle straining and relaxation.
89399832|NCT02184338|Experimental|BIRB 1017 BS in single rising doses|
89399833|NCT02184338|Placebo Comparator|Placebo|
89189488|NCT05809037|Sham Comparator|Sham Stimulation for right hemiparesis patients|Sham non-invasive transauricular vagus nerve stimulation over left ear in post-stroke right hemiparesis
89399834|NCT02190344|Experimental|Functionality of 8-channel paddle coil system|
89399835|NCT02054364|Experimental|FBT and CRT|Family-Based Treatment combined with Cognitive Remediation Therapy (15 sessions of each)
89399836|NCT02054364|Experimental|FBT and art therapy|Family-Based Treatment combined with art therapy (15 sessions of each)
89399837|NCT02186912|Experimental|mandible|Nobel Active Nobel Procera IBO
89399838|NCT02186912|Experimental|maxilla|Nobel Active Nobel Procera IBO
88875930|NCT03447834|Other|Standard PPCI|The control group will receive routine PPCI.
88875931|NCT03064074|Experimental|Stage 1 Low dose|"There are a total of 6 study visits within approximately a 6 month timespan. Investigators will evaluate the safety of a single administration of fresolimumab in adult patients with OI. Subjects will receive a single-dose of 1 mg/kg of fresolimumab (n=4).~At each study visit, the participant may have the following testing done:~Physical exam~Vitals~Blood draw for safety labs, pharmacokinetics, etc~If the participant is female, she will have a pregnancy test~EKG~DXA~Infusion of the study drug"
88875932|NCT03064074|Experimental|Stage 2 High dose|"There are a total of 6 study visits within approximately a 6 month timespan. Investigators will evaluate the safety of a single administration of fresolimumab in adult patients with OI. Subjects will receive a single-dose of 4 mg/kg of fresolimumab (n=4).~At each study visit, the participant may have the following testing done:~Physical exam~Vitals~Blood draw for safety labs, pharmacokinetics, etc~If the participant is female, she will have a pregnancy test~EKG~DXA~Infusion of the study drug"
88875933|NCT03064074|Experimental|Stage 2 Repeat dose every 6 months|"Fresolimumab will be administered every six months for a total treatment period of 12 months (n=4). The dose to be administered (1 or 4 mg/kg) will be chosen after completion of Stage 1. The primary Stage 2 endpoint will be safety measures assessed over 12 months. The secondary endpoints will be changes in markers of bone remodeling, bone mineral density, estimated strength.~At each study visit, participants may have the following testing done:~Physical exam~Vitals~Blood draw for safety labs, pharmacokinetics, etc~If the participant is female, she will have a pregnancy test~EKG~DXA~Infusion of the study drug~Skeletal survey~Peripheral quantitative CT (pQCT) of the forearm~Quality of Life Surveys~Pulmonary function test~Walk test"
88875934|NCT03064074|Experimental|Stage 2 Repeat doses every 3 months|"Fresolimumab will be administered every three months for a total treatment period of 12 months (n=4). The dose to be administered (1 or 4 mg/kg) will be chosen after completion of Stage 1. The primary Stage 2 endpoint will be safety measures assessed over 12 months. The secondary endpoints will be changes in markers of bone remodeling, bone mineral density, estimated strength.~At each study visit, participants may have the following testing done:~Physical exam~Vitals~Blood draw for safety labs, pharmacokinetics, etc~If the participant is female, she will have a pregnancy test~EKG~DXA~Infusion of the study drug~Skeletal survey~Peripheral quantitative CT (pQCT) of the forearm~Quality of Life Surveys~Pulmonary function test~Walk test"
88875935|NCT03012282|Experimental|Diagnostic (CT perfusion sequence)|Patients undergo CT perfusion sequence during the first 40 seconds of the baseline standard of care CT scan and during follow-up CT scans at 2 and possibly 4 months after chemotherapy, at 4-6 weeks after radiation therapy, or prior to definitive surgery.
88875936|NCT02945436|Active Comparator|SOC + SOC|Participants will receive current standard of care (SOC) for HIV counseling, testing, and referral at both visit 1 and visit 2.
88875937|NCT02945436|Experimental|SOC + SUBI|Participants will receive SOC at visit 1 and the experimental substance use brief intervention (SUBI) at visit 2.
89189489|NCT05809037|Active Comparator|Active Stimulation for left hemiparesis patients|Active non-invasive transauricular vagus nerve stimulation over left ear in post-stroke left hemiparesis
89399839|NCT02186990|Active Comparator|propofol|
89399840|NCT02186990|Active Comparator|etomidate|
89399841|NCT02186990|Active Comparator|propofol-etomidate|
89399842|NCT05657028|Experimental|Group D (Dexmedetomidine)|In the Dexmedetomidine group, patients will be given IV bolus infusion of dexmedetomidine
89399843|NCT05657028|Experimental|Group L (Lidocaine)|In the Lidocaine group, the patients will be given an IV bolus infusion of lidocaine
89399844|NCT02187068|Experimental|Dexmedetomidine obese 1|10 obese patients scheduled for elective laparoscopic surgery were given dexmedetomidine dexmedetomidine 0.5 μg.kg-1 iv over 10 minutes and then dexmedetomidine 0.25 mcg.kg-1.h-1 for approximate 2 h (range 58-320 min). Blood samples were taken at 2, 5, 10, 15, 20, 30, 45, 60, 90, 120 min after beginning dexmedetomidine administration, and at 0, 2, 5, 10, 20, 30, 60, 90, 120, 240 and 360 min after stopping infusion.
89399845|NCT02187068|Experimental|Dexmedetomidine obese 2|10 obese patients scheduled for elective laparoscopic surgery were given dexmedetomidine dexmedetomidine 0.5 μg.kg-1 iv over 10 minutes and then dexmedetomidine 0.5 mcg.kg-1.h-1 for approximate 2 h (range 58-320 min). Blood samples were taken at 2, 5, 10, 15, 20, 30, 45, 60, 90, 120 min after beginning dexmedetomidine administration, and at 0, 2, 5, 10, 20, 30, 60, 90, 120, 240 and 360 min after stopping infusion.
89399846|NCT02187068|Experimental|Dexmedetomidine non-obese 1|10 non-obese patients scheduled for elective laparoscopic surgery were given dexmedetomidine dexmedetomidine 0.5 μg.kg-1 iv over 10 minutes and then dexmedetomidine 0.25 mcg.kg-1.h-1 for approximate 2 h (range 58-320 min). Blood samples were taken at 2, 5, 10, 15, 20, 30, 45, 60, 90, 120 min after beginning dexmedetomidine administration, and at 0, 2, 5, 10, 20, 30, 60, 90, 120, 240 and 360 min after stopping infusion.
89399847|NCT02187068|Experimental|Dexmedetomidine non obese 2|10 non-obese patients scheduled for elective laparoscopic surgery were given dexmedetomidine dexmedetomidine 0.5 μg.kg-1 iv over 10 minutes and then dexmedetomidine 0.5 mcg.kg-1.h-1 for approximate 2 h (range 58-320 min). Blood samples were taken at 2, 5, 10, 15, 20, 30, 45, 60, 90, 120 min after beginning dexmedetomidine administration, and at 0, 2, 5, 10, 20, 30, 60, 90, 120, 240 and 360 min after stopping infusion.
89004053|NCT03507257||Early Onset Alzheimer's Disease (EOAD)|"Diagnosis of NIA-AA criteria of MCI due to AD or probable AD dementia~Amyloid positive status (florbetaben PET scan with evidence of elevated amyloid as determined by a central read)~CDR score ≤ 1.0~flortaucipir (18F-AV-1451) PET scanning"
89399848|NCT02054442|Experimental|Arm A: MTX in combination with cetuximab|"The dosage of cetuximab will be i.v. 400 mg/m2 over a period of 2h for the first infusion, followed by infusions of 250 mg/m2 over 1 hour once weekly. Cetuximab will be dissolved in 500 ml NaCl 0.9%.~Premedication: H1-receptor antagonist and dexamethasone.~The dosage of MTX (Methotrexate) will be i.v. 40 mg/m2 once weekly, administered within 5-10 minutes. MTX will be dissolved in 50 ml NaCl 0.9%.~Premedication: ondansetron 8 mg.~Treatment will be continued until progressive disease, unacceptable toxicity or refusal by patient."
89399849|NCT02054442|Active Comparator|Arm B: MTX|"The dosage of MTX (Methotrexate) will be i.v. 40 mg/m2 once weekly, administered within 5-10 minutes. MTX will be dissolved in 50 ml NaCl 0.9%.~Premedication: ondansetron 8 mg.~Treatment will be continued until progressive disease, unacceptable toxicity or refusal by patient."
89399850|NCT02185586|Experimental|LALC|lower abdominal laparoscopic cholecystectomy
89399851|NCT02185586|Experimental|SLC|single laparoscopic cholecystectomy
89399852|NCT02185586|Placebo Comparator|UALC|upper abdominal laparoscopic cholecystectomy
89399853|NCT02038296|Experimental|Group 1|Group 1 received single-drug (doxorubicin)transarterial chemoembolization.
89399854|NCT02038296|Experimental|Group 2|Group 2 received double-drug (doxorubicin and mitomycin C)transarterial chemoembolization
89004054|NCT03507257||Cognitively Normal (CN) Controls|"Meets criteria for cognitively normal, based on an absence of significant impairment in cognitive functions and activities of daily living~Mini-Mental State Exam score between 26-30~CDR score = 0~flortaucipir (18F-AV-1451) PET scanning"
89399855|NCT02038296|Experimental|Group 3|Group 3 were treated with triple-drug (doxorubicin, mitomycin C and gemcitabine)transarterial chemoembolization.
89399856|NCT02053038|Experimental|iFR|Treatment guided by iFR
89399857|NCT02053038|Active Comparator|FFR|Treatment guided by FFR
89399858|NCT02187146||ART population|Patients undergoing IVF/ICSI/FET treatment at the Birmingham Womens Fertility Centre 2013-2014
89004055|NCT03507257||Early Onset non-Alzheimer's Disease (EOnonAD)|"Diagnosis of NIA-AA criteria of MCI due to AD or probable AD dementia~Amyloid negative status (florbetaben PET scan with no evidence of elevated amyloid as determined by a central read)~CDR score ≤ 1.0~flortaucipir (18F-AV-1451) PET scanning"
89004056|NCT03489278||Affected|Affected with ALS or a related disorder.
89004057|NCT03485209|Experimental|Part A: Tisotumab Vedotin - Q3W Schedule|Tisotumab Vedotin every 3 weeks
89004058|NCT03485209|Experimental|Part B: Tisotumab Vedotin - 3Q4W Schedule|Tisotumab Vedotin on Days 1, 8, and 15 of 28-day cycle
89004059|NCT03485209|Experimental|Part C: Tisotumab Vedotin - 2Q4W Schedule|Tisotumab Vedotin on Days 1 and 15 of every 28-day cycle in participants with SCCHN or sqNSCLC
89004060|NCT03485209|Experimental|Part D: Tisotumab Vedotin Combination Therapy - Q3W Schedule|Tisotumab vedotin + pembrolizumab + (carboplatin or cisplatin). Given on Day 1 of every 21-day cycle.
89004061|NCT03485209|Experimental|Part E: Tisotumab Vedotin - 2Q4W Schedule|Tisotumab Vedotin on Days 1 and 15 of every 28-day cycle in participants with SCCHN in the second- or third-line setting
89399859|NCT02053194|Experimental|Pharmacist-led educational intervention|Participants will receive an educational brochure on an inappropriate prescription they are currently taking from their pharmacists. Participants' physicians will receive an evidence-based pharmaceutical opinion for the same medication.
89399860|NCT02053194|No Intervention|Control|Participants in the control group will be wait-listed and observed for 6 months prior to receiving the intervention.
89399861|NCT02190578|Experimental|Diagnostic: Reveal G4|Subjects tested with investigational devices and approved comparator assay algorithms for HIV
89399862|NCT03536078|No Intervention|Phototherapy at hospital|Newborns with icterus that receive treatment while being admitted to hospital.
89399863|NCT03536078|Experimental|Home phototherapy|Newborns with icterus receiving phototherapy at home.
89399864|NCT02190656||Anterior resection|Patients having had an anterior resection for rectal cancer who are more than 12 months post surgery
89399865|NCT02804178|Experimental|ATR-101|Ascending dose levels of ATR-101 beginning with 125 mg by mouth twice per day up to 1000 mg twice per day.
89399866|NCT02190734|Other|wheelchair, walking on treadmill, walking overground|Sitting in wheel chair Gait training on treadmill Gait training overground
89399867|NCT02187380||Control group|Pharmacists received no depression training, delivered usual care to patients starting a new treatment with depression.
89399868|NCT02187380||Intervention group|Pharmacists received a depression training day and provided structured medication counselling to patients starting a new treatment with antidepressants
89399869|NCT02054598|No Intervention|Control group|Usual care.
89399870|NCT02054598|Experimental|Intervention group|Decision aid and navigation
89399871|NCT02190812|Experimental|Forearm supporter|This study measured the effect of proper forearm supporter to alleviate pain and improve the wrist and grip strength in the subjects with tennis elbow.
89399872|NCT02190812|Experimental|Grip ball|In this study a portable grip ball training system is developed. This study use the grip ball to train the wrist muscle. It's expected to reduce the risk of injury of the elderly in their daily lives.
89399873|NCT02054676|Experimental|Classification assessment.|Random group of the partially edentulous individuals will be assessed according to prepared classification evaluation protocol during dental implant treatment period. Cone-beam computed tomography preoperative evaluation will be made during preoperative stage. Intraoperative edentulous jaw segment parameters evaluation, endosseous dental implant placement parameters assessment during intraoperative stage will be made. Dental implant position evaluation during early postoperative stage will be made. Medications will be prescribed. Late postoperative soft tissue evaluation of edentulous jaw segment will be made during final crown placement. Cone-beam computed tomography analysis results will be compared with subsequent stages assessment results to evaluate reliability of the classification.
89399874|NCT02256956|Active Comparator|Amitriptyline first, Placebo second|Amitriptyline first, Placebo second
89399875|NCT02256956|Active Comparator|Placebo first, Amitriptyline second|Placebo first, Amitriptyline second
89399876|NCT02187536|Experimental|Telmisartan combined with Simvastatin|Telmisartan once daily (day 1 to day 6) and Simvastatin given once (day 6)
89399877|NCT02187536|Active Comparator|Simvastatin and telmisartan placebo|Telmisartan placebo once daily (day 1 to day 6) and Simvastatin given once (day 6)
89399878|NCT02056158||HIV Negative Early COPD Smokers|HIV Negative Early COPD Smokers
89399879|NCT02056158||HIV Negative COPD Smokers|HIV Negative COPD Smokers
89399880|NCT02056158||HIV Negative Nonsmokers|HIV Negative Nonsmokers
89399881|NCT02056158||HIV Negative Smokers|HIV Negative Smokers
89399882|NCT02056158||HIV Positive Smokers|HIV Positive Smokers
89399883|NCT02056158||HIV Positive Nonsmokers|HIV Positive Nonsmokers
89399884|NCT02056158||HIV Positive COPD Smokers|HIV Positive COPD Smokers
89399885|NCT02056158||HIV Positive Early COPD Smokers|HIV Positive Early COPD Smokers
89399886|NCT02256722|Experimental|Treatment A|
89399887|NCT02256722|Experimental|Treatment B|
89399888|NCT02256722|Experimental|Treatment C|
89399889|NCT02256722|Experimental|Treatment D|
89399890|NCT02256722|Active Comparator|Treatment E|
89004062|NCT03485209|Experimental|Part F: Tisotumab Vedotin Combination Therapy - Q2W Schedule|Tisotumab Vedotin + pembrolizumab. Tisotumab Vedotin given on Days 1, 15, and 29 of every 6-week cycle. Pembrolizumab given on Day 1 of every 6-week cycle.
89011500|NCT01643746|Active Comparator|Supera stent|The Supera stent is a novel interwoven nitinol stent design with high flexibility and radial strength. The radial force of the Supera stent is 4 times higher than comparable nitinol stent.
89189490|NCT05809037|Sham Comparator|Sham Stimulation for left hemiparesis patients|Sham non-invasive transauricular vagus nerve stimulation over left ear in post-stroke left hemiparesis
89399891|NCT05655624|Experimental|Group A|Pursed lip Breathing along Mat Pilates Training
89399892|NCT05655624|Active Comparator|Group B|pursed lip breathing without Mat Pilates Training
89399893|NCT02190890|Experimental|Dry needling: 4 local twitch responses|Deep dry needling in the active myofascial trigger point in the upper trapezius muscle. The muscle fibers were repeatedly perforated by rapidly inserting and partially withdrawing the needle from the MTrP until 4 local twitch responses were elicited.
89399894|NCT02190890|Experimental|Dry needling: 6 local twitch responses|Deep dry needling in the active myofascial trigger point in the upper trapezius muscle. The muscle fibers were repeatedly perforated by rapidly inserting and partially withdrawing the needle from the MTrP until 6 local twitch responses were elicited.
89399895|NCT02190890|Experimental|Dry needling: Until no more local twitch responses elicited|Deep dry needling in the active myofascial trigger point in the upper trapezius muscle. The muscle fibers were repeatedly perforated by rapidly inserting and partially withdrawing the needle from the MTrP until no more local twitch responses were elicited.
89399896|NCT02190890|Active Comparator|Control|The needle was inserted 1.5 cm away from the trigger point in the trapezius muscle and withdrawn without any consecutive insertion.
89399897|NCT02056314|Active Comparator|brochure|The participants will be given a brochure that describes problem gambling and recommends methods of staying in control of gambling such as coping skills.
89399898|NCT02056314|Experimental|electronic tutorial|The participants will be given an electronic tutorial that will explain how to stay in control of their gambling including information about coping skills, warning signs, and information about myths related to gambling.
89399899|NCT02190968|Experimental|Mindful Mood Balance|An 8 session internet intervention targeting residual depressive symptoms.
89399900|NCT02190968|Active Comparator|Usual Depression Care|Usual Depression Care through Kaiser Permanente Colorado
89399901|NCT02056470|Experimental|Freedom Total Knee Replacement|Freedom Total Knee
89399902|NCT02187614|Experimental|Diclofenac and Placebos|Participants in this group will receive a Diclofenac 75 mg intramuscular injection, and two placebo saline solutions intravenously.
89399903|NCT02187614|Active Comparator|Morphine and Placebos|Participants in this group will receive Morphine 0.1 mg/kg intravenously, along with an additional intravenous placebo and an intramuscular placebo injection.
89399904|NCT02187614|Active Comparator|Paracetamol and Placebos|participants in this group will receive intravenous Paracetamol 1 gm solution, along with an additional intravenous placebo and an intramuscular placebo injection.
89399905|NCT02030678|Experimental|irinotecan Hydrochloride|Irinotecan monotherapy (trade name: Aili; batches 180103AG [40 mg] and 171231AG [100 mg]) will be administered intravenously at a dose of 100 mg/m2 on days 1 and 8 of each 3-week cycle.
89399906|NCT02054832||Glycosade|A prospective cohort design will be used to assess the impact on sleep and continue to monitor safety of Glycosade.
89399907|NCT03677349|Experimental|Resensitized group|Patients with resensitized free flap by neurorrhaphy
88875938|NCT02945436|Experimental|SUBI + SUBI|Participants will receive the SUBI at both visit 1 and visit 2.
89399908|NCT03677349|Experimental|Non Resensitized group|Patients without resensitized free flap by neurorrhaphy.
89399909|NCT02187692|No Intervention|TAU|Treatment as Usual (TAU) vs meta-cogntive training (MCT) condition will be contrasted. In the TAU patients attend regular day programm that includes psychoeducation, social training, vocational rehabilitation, psychotherapy. The MCT condition is an active condition that includes structuralized therapy modules twice a week for four weeks (eight modules in total). There will be no additional differences in the interventions between two groups. Participants will be randomized from patients from the same population into two conditions.
89399910|NCT02187692|Experimental|MCT|Treatment as Usual (TAU) vs meta-cogntive training (MCT) condition will be contrasted. In the TAU patients attend regular day programm that includes psychoeducation, social training, vocational rehabilitation, psychotherapy. The MCT condition is an active condition that includes structuralized therapy modules twice a week for four weeks (eight modules in total). There will be no additional differences in the interventions between two groups. Participants will be randomized from patients from the same population into two conditions.
89399911|NCT02058732|Active Comparator|ALS patients receivng stem cells|Amyotrophic lateral sclerosis(ALS)subjects, who will be receiving stem cells, will undergo a brief clinical evaluation and questionnaire that will last approximately 20 to 30 min. Subjects will be asked to undergo magnetic resonance imaging(MRI)scans of the cervical spine and brain that will last approximately 60 minutes.
89399912|NCT02058732|Active Comparator|ALS patients not receiving stem cells|Amyotrophic lateral sclerosis(ALS)patient who will not be receiving stem cells, will have an MRI that lasts approximately 60 minutes. This MRI will be repeated at three different time points. Subjects will have an initial MRI, then another at both 6 and 12 months after the initial magnetic resonance imaging(MRI)scan. Subjects will also complete a clinical examination which will take approximately 30 minutes for each MRI. The follow-up magnetic resonance imaging(MRI)scans done for ALS patients who do not receive stem cells are part of routine clinical studies and therefore subjects will not be billed.
89399913|NCT03684603|Active Comparator|Acoustic cueing|The melody will be played during training and during slow wave sleep.
89399914|NCT03684603|Sham Comparator|Control|The melody will be played during training.
89399915|NCT02054988|Experimental|caffeine|"three cups of coffee will be administered for 10 days (on chronic phase) and two cups of coffee will be consecutively administered for acute evaluation."
88875939|NCT02945436|Experimental|SUBI + SOC|Participants will receive the SUBI at visit 1 and SOC at visit 2.
89399916|NCT02054988|Active Comparator|not caffeine|not caffeine will be administered for the duration of the study
89399917|NCT03682341||Group A|Patients with ovarian endometriosis cyst
89399918|NCT03682341||Group B|Patients with ovarian teratoma cyst
89399919|NCT02187926||Roflumilast|Roflumilast will be administered according to the prescribing information of the approved label in Greece.
89399920|NCT02055066|Experimental|Arm 1|ARGX-111 0.3 mg/kg
89399921|NCT02055066|Experimental|Arm 2|ARGX-111 1.0 mg/kg
89399922|NCT02055066|Experimental|Arm 3|ARGX-111 3.0 mg/kg
89399923|NCT02055066|Experimental|Arm 4|ARGX-111 10 mg/kg
89399924|NCT03684525|Experimental|Extraction of primary canines only|"A total of 43 patients with unilateral mesioangular displaced maxillary canines Interceptive treatment: Extraction of both maxillary primary canines will be held at baseline visit At Baseline (T0): Clinical examinatiion + CBCT scan and then both primary canines will be extracted At 6 month follow-up (T1): Clinical examination only At 12 month follow-up: Clinical examination +/- CBCT scan~Treatment Plan :~If displaced canine is not erupted and no improvement in position radiographically is noticed, patient will be referred to orthodontic/oral surgery department~If Canine is emerged to oral cavity: No further CBCT scan will be taken~If Position of canine is improved radiographically: Follow up untill canine emerges, total observation time is 18 months"
89399925|NCT03684525|No Intervention|Control group- no extraction|"A total of 43 patients with unilateral mesioangular displaced maxillary canines At Baseline (T0): Clinical examinatiion + CBCT scan , no extraction At 6 month follow-up (T1): Clinical examination At 12 month follow-up: Clinical examination +/- CBCT scan~Treatment Plan :~If displaced canine is not erupted and no improvement in position radiographically is noticed, patient will be referred to orthodontic/oral surgery department~If Canine is emerged to oral cavity: No further CBCT scan will be taken~If Position of canine is improved radiographically: Follow up untill canine emerges, total observation time is 18 months"
89399926|NCT04615754|Experimental|3-OHB vs Saline|3-OHB will be infused for 2.5 hours in IPAH (n=5) and CETPH (n=5) patients- 6 in each group is recruited for taking drop-out into account
89399927|NCT04615754|Experimental|Saline vs 3-OHB|Saline will be infused for 2.5 hours in IPAH (n=5) and CETPH (n=5) patients- 6 in each group is recruited for taking drop-out into account
89399928|NCT02058810|Other|Conventional nasal Oxygen|Conventional nasal Oxygen as needed
89399929|NCT02058810|Other|Nasal high flow|Nasal high flow therapy with FiO2 40% and flow of 40l/min for at least 48h
89399930|NCT03677271|Other|Physical Activity|
88875940|NCT02445456|Experimental|Ex-vivo|Patients with relatively advanced rectal cancer who are scheduled to undergo radical surgery to excise rectal tumour and mesorectum. They will receive endoscopic Sienna+ injection (magnetic tracer) 5 days before planned surgery. They will then undergo surgery to excise rectal cancer. The excised specimen will be examined using the Sentimag probe and by standard histology to assess for lymph nodes ex-vivo.
88875941|NCT02445456|Experimental|In-vivo|Patients with early rectal cancer scheduled to undergo local excision of a rectal tumour by transanal endoscopic microsurgery (TEM). They will receive endoscopic Sienna+ injection (magnetic tracer) 5 days before planned surgery, and have an MRI scan to assess tracer spread. They will then undergo TEM surgery to excise the rectal cancer. During surgery the Sentimag probe will be used to locate the sentinel lymph node so it can be surgically removed. The excised specimen will be examined by standard histology.
88875942|NCT02316132|Active Comparator|Stress|Injection of corticotropin releasing factor
89399931|NCT02191124|Experimental|measurement-based care|MBC allows psychiatrists to individualize treatment decisions for each patient based on the change of psychopathology and tolerance toward antidepressants. Treatment decisions were made by treating psychiatrists according to ratings of self-report scales obtained at each treatment visit. Paroxetine was started at 20mg/day and then raised to 30mg/day by week 4, 40mg/day by week 6, 50mg/day by week 8 and 60mg/day by week 10. Mirtazapine was started at 15mg/day and raised to 30mg/day by week 1 and 45mg/day by week 4. Dose adjustments were dependent on how long a patient had received a particular dose, symptom changes and side effects.
89399932|NCT02191124|Active Comparator|Standard treatment|Patients in the ST group are treated by their psychiatrists according to their clinical needs as judged at each outpatient visit, receiving either open-label paroxetine (20-60mg/day) or mirtazapine (15-45mg/day) within the therapeutic dose range.
89399933|NCT03677193|Experimental|Experimental arm|
89399934|NCT02193698|Experimental|Lenalidomide+Dexamethasone|Cycle1 : Lenalidomide 15mg/day (day 1-21) Cycle2-6 : Lenalidomide 25mg/day (day 1-21) Dexamethasone 20mg/day (day 2. 9, 16, 23)
89399935|NCT02055144||Non squamous histology|patients with advanced, non-squamous non-small cell lung cancer treated with cisplatin (or carboplatin) and pemetrexed. Maintenance with pemetrexed is allowed.
89399936|NCT02055144||Squamous histology|patients with advanced squamous non-small cell lung cancer treated with cisplatin (or carboplatin) and gemcitabine
89399937|NCT03682185|Experimental|Timed Activity Intervention Protocol|The timed activity group will involve 4 in-home visits and 4 brief telephone education sessions provided over 4 weeks. The timed activity intervention provides activities delivered at specific times in the daily cycle. The in-home sessions are spaced weekly so that the participants can have the opportunity to practice the activity with the interventionist and then on their own. During each session, the interventionist will reinforce activity use, review problem solving approaches, and provide education.
89399938|NCT03682185|Active Comparator|Attention-Control Condition|This condition will contain no active elements beyond its nonspecific components, and no theoretical basis to support an effect on CRDs. The attention-control group will also involve 4 in-home visits and 4 brief telephone education sessions. The attention control group will receive printed educational and training materials from the Alzheimer's Association and the NIH on home modification, health promotion, talking to your doctor, and advanced care planning that coincide with session content.
89399939|NCT02191202||Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI)|
89399940|NCT03561168||Developmental Delay|Children under age 3 who underwent MRI brain with anesthesia for the indication of Developmental Delay (between the dates of Dec 13, 2015 - Dec 13, 2016) at our institution.
89399941|NCT03561168||Seizure|Children under age 3 who underwent MRI brain with anesthesia for the indication of Seizure (between the dates of Dec 13, 2015 - Dec 13, 2016) at our institution.
89399942|NCT03561168||Developmental Delay and Seizure|Children under age 3 who underwent MRI brain with anesthesia for the indication of Developmental Delay and Seizure (between the dates of Dec 13, 2015 - Dec 13, 2016) at our institution.
89399943|NCT02055300|Experimental|LY03005 - 20|LY03005 Dose Strength 20mg
89399944|NCT02055300|Experimental|LY03005 - 40|LY03005 Dose Strength 40mg
89399945|NCT02055300|Experimental|LY03005- 80|LY03005 Dose Strength 80mg
89399946|NCT02055300|Experimental|LY03005 - 120|LY03005 Dose Strength 120mg
89399947|NCT02055300|Experimental|LY03005 - 160|LY03005 Dose Strength 160 mg
88875943|NCT02316132|Placebo Comparator|Control|Injection of 0.9% saline 10 ml
88875944|NCT01770756|Experimental|Enhancing willpower using active skills|This group will use active tasks such as learning skills using hands to enhance willpower.
88875945|NCT01770756|Experimental|Enhancing willpower using passive tasks|This group will use passive tasks such as taking still postures to enhance willpower.
88875946|NCT01276002|No Intervention|No stenting|Control group, no stenting of the pancreatic duct in case of a disrupted duct
88875947|NCT01276002|Active Comparator|Pancreatic duct stenting|in case of a disrupted pancreatic duct, patients will undergo pancreatic duct stenting in this arm
89399948|NCT02055300|Experimental|LY03005 - 200|LY03005 Dose Strength 200mg
89399949|NCT02055300|Experimental|LY03005 - 120 - Fed|LY03005 120mg under Fed Conditions
89399950|NCT02055300|Active Comparator|Pristiq|Pristiq - 50mg
89399951|NCT02055300|Placebo Comparator|Placebo|Placebo
88875948|NCT05452746|Experimental|Acupuncture|
89399952|NCT02056860||Group 1 will receive 15 Hz|Group 1 (n=30), these subjects will receive 10 minutes of High Frequency Oscillation at 15 Hz at .75 cm on day 1. Then will have a 24 hour washout. On day 2 will receive 10 minutes of low Frequency Oscillation at 15 Hz at 1.25 cm.
89399953|NCT02056860||Group 2 will receive 30 Hz|Group 2 (n=30), these subjects will receive 10 minutes of High Frequency Oscillation at 30 Hz at .75 cm on day 1. Then will have a 24 hour washout. On day 2 will receive 10 minutes of low Frequency Oscillation at 30 Hz 1.25 cm.
88875949|NCT05452746|Active Comparator|Treatment as usual|
88875950|NCT05452434|Experimental|Experimental group|300 cases, mirabegron 50mg QD + behavior intervention (timed urination + left head wagging 3 times and right head wagging 3 times in urgent urination) for 12 weeks.
88875951|NCT05452434|Active Comparator|Control group|300 cases, mirabegron 50mg QD for 12 weeks
88875952|NCT05451342||ARDS|Patients who meet the diagnostic criteria of ARDS
88875953|NCT05451342||Non-ARDS|Patients without ARDS
88875954|NCT05450874||Training cohort|
88875955|NCT05450874||Validation cohort|
88875956|NCT05450172||Consecutive patients scheduled for thoracic surgery|
88875957|NCT05449938|Experimental|Thick periodontal phenotype|Stage II and stage III periodontitis Patient with thick periodontal phenotype will be enrolled using probe transparency method .
88875958|NCT05449938|Active Comparator|Thin periodontal phenotype|Stage II and stage III periodontitis Patient with thin periodontal phenotype will be enrolled using probe transparency method.
88921922|NCT06056258|Active Comparator|VL-NL-02|Two capsules to be taken 45±10 mins before sleep (after dinner) for 21 days.
88921923|NCT06056258|Placebo Comparator|Placebo|Two capsules to be taken 45±10 mins before sleep (after dinner) for 21 days.
89399954|NCT02056860||Group 3 will receive 60 Hz|Group 3 (n=30), these subjects will receive 10 minutes of High Frequency Oscillation at 60 Hz 2 .75 cm on day 1. Then will have a 24 hour washout. On day 2 will receive 10 minutes of low Frequency Oscillation at 60 Hz at 1.25 cm.
89399955|NCT02056860||Group 4 will receive 100 Hz|Group 4 (n=30), these subjects will receive 10 minutes of High Frequency Oscillation at 100 Hz at .75 cm on day 1. Then will have a 24 hour washout. On day 2 will receive 10 minutes of low Frequency Oscillation at 100 Hz at 1.25 cm.
89399956|NCT02056860||Phase II Optimal Frequency|Participants in Phase II will undergo 10 minutes of HFO at the optimal frequency as determined during Phase I.
89399957|NCT02191280|Experimental|Antistax®, low dose|
89399958|NCT02191280|Experimental|Antistax®, high dose|
89399959|NCT02191280|Placebo Comparator|Placebo|
89399960|NCT03684369|Experimental|Augmented TENS|Transcutaneous electrical nerve stimulation applied to each leg separately while participants perform steady submaximal contractions.
89399961|NCT03684369|Sham Comparator|Sham|Transient (10 s) application of transcutaneous electrical nerve stimulation applied to each leg separately while participants perform steady submaximal contractions .
89399962|NCT03684291||Group V|The patients in this group are ventilated using VCV (Volume Control Ventilation) mode (FiO2 50%, Tidal volume: 6-8 ml/kg (ideal body weight), frequency: 12/minute, I/E ratio: 1/2, PEEP not applied)
89399963|NCT03684291||Group P|The patients in this group are ventilated using PCV-VG (Volume Guaranteed Pressure Control Ventilation) mode (FiO2 50%, Tidal volume: 6-8 ml/kg (ideal body weight), frequency: 12/minute (EtCO2 kept between 35-40 mmHg), Pressure limit: 30 cm H2O, I/E:1/2, PEEP not applied)
89399964|NCT02193854|Experimental|Mobile phone|"General practitioners (GPs) received TD consultation through Sana system.~Mobile phones with Sana system installed were provided to 10 rural GPs from three different districts of Mongolia."
89399965|NCT02055378|Experimental|auricular acupoint stimulation|Five auricular acupoints were selected for taping stimulation by using a 1-mm alloy ball by fingers three times a day, each time for five minutes over the five selected acupoints. Topical 0.125% atropine was given nightly.
89399966|NCT02055378|Active Comparator|Atropine|topical 0.125% atropine was given nightly during the study period.
89399967|NCT04558190|Experimental|Lipid infusion + MitoQ|Subjects undergo a hyperinsulinemic isoglycemic clamp preceded by MitoQ administration and intravenous lipid infusion
89189491|NCT05809024|Experimental|single Arm|Hormone receptor positive,HER2 negative participants will receive letrozole as neoadjuvant endocrine therapy，if ki67 was higher than 10% after two weeks,CDK4/6 Inhibitor was added.
89189492|NCT05808985|Experimental|Butyrate|Take butyric acid (sodium butylate 600mg 2 tablets, BodyBio⒭ per day)
89399968|NCT04558190|Placebo Comparator|Lipid infusion + placebo|Subjects undergo a hyperinsulinemic isoglycemic clamp preceded by placebo administration and intravenous lipid infusion
89399969|NCT04558190|No Intervention|Control|Subjects undergo a hyperinsulinemic isoglycemic clamp
89399970|NCT04558190|Other|Lipid infusion + beta2-agonist|Subjects undergo a hyperinsulinemic isoglycemic clamp with intravenous infusion of lipid and salbutamol
89399971|NCT03441321|Experimental|Group I (focusing on tanning and healthy body image)|Participants periodically read the content on the study-specific private and hidden Facebook group related to living a healthy lifestyle including avoiding tanning and excessive ultraviolet exposure, managing stress, healthy eating, promoting physically active lifestyles, and promoting a healthy body image, and participate in the group by providing reactions, commenting on the posts, or by sharing study relevant information within the group for 8 weeks.
89399972|NCT03441321|Active Comparator|Group II (focusing on other health topics)|Participants participate in private and hidden Facebook groups that utilize content from the intervention content library related to other health topics of interest (e.g., physical activity, healthy eating, alcohol misuse prevention, stress reduction, sleep) for 8 weeks.
89399973|NCT02191358||"Tested patients (prospective)"|Patients whose providers decide to have them undergo testing via the YouScript Personalized Prescribing System will be recruited for the study. Data will be gathered at baseline and 120 days later. The decision to utilize YouScript and all treatment decisions will be made at the discretion of the provider in accordance with their usual care practice, and will be made prior to the decision to participate in the study.
88875959|NCT03018912|Experimental|Sleep VS|"Patients check-in for their primary care physician visit and are provided a Sleep VS survey packet. Investigators or research associates will review the Sleep VS, and patients that screen positive on their Sleep VS will be asked to complete an extended set of sleep questions. A triaging algorithm will be available based on answers to the extended sleep questions to assist the primary care physician with assessment and triaging care. Patients that screen negative will not be asked the extended sleep questions nor will they be brought to the attention of the primary care physician and proceed with usual care."
89011501|NCT01643746|Active Comparator|LifeStent|LifeStent is likely the best reference nitinol stent for comparison because a low restenosis rate has been reported at 1 year with low target revascularization.
89399974|NCT02191358||"Untested patients (retrospective)"|Patients for comparison to the prospectively followed patients will be derived from Inovalon's MORE2 healthcare database. Patients meeting the same enrollment criteria (excluding the YouScript testing) will be matched on key characteristics to the tested patients. Outcomes will be compared between the prospectively enrolled patients undergoing pharmacogenetic testing with the YouScript Personalized Prescribing System at the discretion of their treating physician.
89399975|NCT03676959|Experimental|ZKAB001 5mg/kg|Three or six patients will be treated with the dose of 5 mg/kg/time of ZKAB001 IV bi-weekly. DLT will be observed within 28 days after administration.
89399976|NCT03676959|Experimental|ZKAB001 10 mg/kg|Three or six patients will be treated with the dose of 10 mg/kg/time of ZKAB001 IV bi-weekly. DLT will be observed within 28 days after administration.
88875960|NCT03018912|No Intervention|Usual Care|"Patients check-in for their primary care physician visit and proceed with usual care. Although the sleep vital sign will not be collected, the medical providers can still use the extended sleep questionnaire and triaging algorithm, if in the course of caring of the patient a potential sleep disorder is recognized."
88875961|NCT05449860|Experimental|Patients with recurrent hepatocellular carcinoma after locoregional treatment|Patients with chronic liver disease have recurrent hepatocellular carcinoma which is diagnosed on contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI).
88875962|NCT05449782|Other|Healthy participants: Cocoa flavanol - Placebo|Healthy participants receiving cocoa flavanols on first study day and placebo on second study day
88875963|NCT05449782|Other|Healthy participant: Placebo - Cocoa flavanol|Healthy participants receiving placebo on first study day and cocoa flavanols on second study day
88875964|NCT05449782|Other|Type 2 diabetes participants: Cocoa flavanol - Placebo|Participants with type 2 diabetes receiving cocoa flavanols on first study day and placebo on second study day
88875965|NCT05449782|Other|Type 2 diabetes participants: Placebo - Cocoa flavanol|Participants with type 2 diabetes receiving placebo on first study day and cocoa flavanols on second study day
88875966|NCT05449704|Experimental|Sequence A|
89399977|NCT03676959|Experimental|ZKAB001 15 mg/kg|Three or six patients will be treated with the dose of 15 mg/kg/time of ZKAB001 IV bi-weekly. DLT will be observed within 28 days after administration.
89399978|NCT02059044|Experimental|ISTOP-ADE|Interactive Voice Response System + Pharmacist
88875967|NCT05449704|Experimental|Sequence B|
88875968|NCT05449158|Experimental|LAP Group|Control of left atrial pressure changes by adjusting pacemaker frequency
88875969|NCT05449158|No Intervention|Control Group|General pacemaker rate setting
89399979|NCT02059044|No Intervention|Routine care|Routine care
89399980|NCT04917146||Caregivers (CG)|Caregivers of patients with systemic Scleroderma
89399981|NCT03755973|Experimental|CFA plus step-down rFSH (1A)|"A single dose of 150 IU of CFA followed by daily rFSH will be administered. The initial rFSH administration will be dosed between 100 IU and 200 IU according to the following criteria:~200 or 300 IU: <3 follicles above 13 mm visible on transvaginal ultrasound;~150 IU, >2 follicles above 13 mm and circulating day-8 follicle-stimulating hormone (FSH) levels ≤20 IU/mL.~100 IU, >2 follicles above 13 mm and circulating day-8 FSH levels >20 IU/mL;~Subjects will perform a step-down daily rFSH dose (fixed decreases in the dosing of 25 IU/day) until the triggering criteria are met or a minimum of 50 IU/day is reached. Subjects with <3 follicles above 13 mm visible will maintain 200 IU/day of rFSH until this criterion is met, initiating a fixed 25 IU/day stepdown protocol only from then onwards."
89399982|NCT03755973|Experimental|CFA plus fixed daily dose rFSH (1B)|A single dose of 150 IU of CFA followed by a fixed daily rFSH dosing protocol of 200 or 300 IU will be administered as ovarian stimulation
89399983|NCT03755973|Active Comparator|Fixed daily dose rFSH only|A fixed daily rFSH dosing protocol of 200 or 300 IU will be administered as ovarian stimulation
88875970|NCT05449080||Cases|subjects with type 2 5-alpha reductase deficiency
88875971|NCT05447832||1/Children aged between 1-5 years from the emergency department|Children who have attended the emergency department at St Mary's Hospital, with an acute attack of wheezing. These families will be asked to use the lung function monitoring and the wheeze detection device every night for 2 weeks, while recording symptoms and medication use in the last 24 hours.
88875972|NCT05447832||2/Children aged between 1-5 years admitted electively for wheezing investigation|Children who have been admitted electively for investigations of their wheezing at the Brompton Hospital. These children/families will be asked to do the lung function monitoring and the wheeze detection device once per week for 4 months, while recording symptoms and medication use in the last 24 hours.
88875973|NCT05447754|Experimental|Combined RAGT and TBT|Participants will be treated with Lokomat for 40 minutes, twice a week for 5 weeks, and RAGT with a body weight support system and combined TBT for 40 minutes each session 3 times a week. During RAGT, 30-40% of each participant's body weight will be taken with the body weight support system. In patients without drop foot and knee instability in the sessions after the first session, the body weight will be reduced by 10% and progression will be achieved. The speed of the treadmill will be adjusted between 1.2-2.6 km/h and the maximum speed tolerated by the patient will be reached during the sessions. TBT exercises 3 times a week for 40 minutes (weight transfer to the paretic leg during sitting and standing, weight transfer during sitting and standing with or without an assistive device) will be personalized according to the patient. Progression of exercises will be provided by adding upper extremity and trunk activities in addition to exercises.
88875974|NCT05447754|Active Comparator|TBT Only|Participants were given balance exercises (weight transfer to the paretic leg during sitting and standing, weight transfer during sitting and standing without an assistive device, walking on a flat surface to the forward and sideways) for 5 weeks, 5 times a week and for 40 minutes in each session. lying down while sitting and standing) will be applied.
88875975|NCT05447364|Experimental|75 mg of Pregabalin|Participant received 1 tab of 75 mg of Pregabalin and 1 tab of placebo
89189493|NCT05808946|Experimental|Alpha-Lipoic Acid Group|
89399984|NCT02191436||Patients with haemophilia|Hemophilia patients (children, youth and adults) and parents of children with hemophilia under 18
89399985|NCT02055534|Experimental|Nutritional counseling|Nutritional counseling consists in: personalized dietary prescription associated with regular (every 3 weeks) dietetic advise by a registered dietician. Follow-up evaluations take place also during the visits scheduled by the Amyloidosis Center
89399986|NCT02055534|Other|General dietary advices|General dietary advices are provided. Follow-up evaluations take place during the visits scheduled by the Amyloidosis Center
89399987|NCT03681717|Experimental|Virtual Reality|Participants are distracted by wearing the virtual reality headset and watching a roller coaster app during laceration repair with sutures.
89399988|NCT03681717|No Intervention|Control (Standard-of-Care)|Participants are distracted with Standard-of-Care by doctors, nurses, nurse practitioners, child life specialists and/or parents.
89399989|NCT03623451|Experimental|Chinese Medicine Formula|All 100 patients were treated with Chinese Medicine Formula(CMF) for three menstrual cycles.
89399990|NCT02056938|Experimental|ATG|"The first infusion of Thymoglobuline® begins before the kidney reperfusion. In case of a patient with a functional arteriovenous fistula or a high-flow venous catheter, the infusion of Thymoglobuline® can begin just after the randomization pre operatively. When the patient has no available arteriovenous fistula for the Thymoglobuline® infusion, it is necessary to install a high-flow vein (central vein) by the anesthesiologist, and to begin the perfusion as soon as possible intra-operatively before the reperfusion of the kidney. The dose of Thymoglobuline® per infusion is 1.5mg/kg. The duration of each infusion is between 6 to 24 hours.~The total duration of the Thymoglobuline® administration is 4 days (starting at and including the first day of the surgery)."
88875976|NCT05447364|Active Comparator|150 mg of Pregabalin|Participant received 2 tabs of 75 mg of Pregabalin
89399991|NCT02056938|Active Comparator|Basiliximab|The first infusion of Simulect® begins within the two hours before the surgery. There is no need of central venous catheter or arteriovenous fistula to infuse the Simulect®. The duration of the infusion is 30 minutes. Each dose of Simulect® is 20 mg. The first infusion of Simulect® is displayed on Day 0 (within the two hours before the surgery) and the second infusion 3 days afterward (Day 4).
89399992|NCT02059200|Experimental|MBCL + TAU|This cohort receives the Mindfulness Based Compassionate Living program in addition to treatment as usual.
89399993|NCT02059200|No Intervention|TAU|This cohort receives treatment as usual of any nature, e.g. psychotherapy, antidepressant medication etc.
89399994|NCT03536000||Healthy women|"200 Pregnant women~Over 18 years~Healthy~With the ability to understand and sign the informed Consent~With the ability to attend the established controls~Fetal echocardiography using the aCMQ-Strain method (Automated Cardiac Motion Quantification) at 24, 28, 32 and 36 weeks of gestation"
89399995|NCT03536000||Intrauterine Growth restriction|"Pregnant women~Over 18 years~Intrauterine Growth Reestriction(IUGR): fetuses with percentile Growth <p3 or <p10 with vascular Doppler alteration.~With the ability to understand and sign the informed Consent~With the ability to attend the established controls~Fetal echocardiography using the aCMQ-Strain method (Automated Cardiac Motion Quantification) at 24, 28, 32 and 36 weeks of gestation"
89399996|NCT03536000||Preeclampsia|"Pregnant women~Over 18 years~Preeclampsia: elevated blood pressure + Ratio Prot/Creatinin in urine> 30 mg / mmol creatinin~With the ability to understand and sign the informed Consent~With the ability to attend the established controls~Fetal echocardiography using the aCMQ-Strain method (Automated Cardiac Motion Quantification) at 24, 28, 32 and 36 weeks of gestation"
89399997|NCT03536000||Diabetes Mellitus type 1|"Pregnant women~Over 18 years~Diabetes mellitus type1~With the ability to understand and sign the informed Consent~With the ability to attend the established controls~Fetal echocardiography using the aCMQ-Strain method (Automated Cardiac Motion Quantification) at 24, 28, 32 and 36 weeks of gestation"
89399998|NCT02059356||Non-cirrhotic patients with cognitive impairment|
89399999|NCT02191670||METALYSE®|
89400000|NCT02188082|Experimental|IvabRadine hemisulfate Sustained-release Tablets|5-15mg qd
89400001|NCT02188082|Placebo Comparator|placebo|5-15mg qd
88875977|NCT05446974|Experimental|Nursing intervention|Nurses randomly assigned by applying a random selection method
89189494|NCT05808946|Active Comparator|Control Group|
89400002|NCT02057094|Placebo Comparator|Control|Dining facility recovery feeding only, no supplemental protein consumed (an isoenergetic, carbohydrate supplement will be consumed by those assigned to the Control group)
89400003|NCT02057094|Active Comparator|Protein|"Consume dining facility food with:~2, 20 g whey protein supplements daily (for ~27 days)~1, 40 g casein protein supplement daily (for ~27 days)"
89400004|NCT02057094|Active Comparator|High-Protein|"Consume dining facility food with:~2, 40 g whey protein supplements daily (~27 days)~1, 50 g casein protein supplement daily (~27 days)"
89400005|NCT02917941|Experimental|Ixazomib 4 mg + Lenalidomide 25 mg + Dexamethasone 40 mg|Ixazomib 4 mg, capsules, orally on Days 1, 8, and 15 plus lenalidomide 25 mg, capsule, orally, once daily on Days 1 through 21 and dexamethasone 40 mg, tablet, orally on Days 1, 8, 15, and 22 of a 28-day cycle up to 32 cycles.
89400006|NCT02055690|Experimental|Phase Ib/II: Fosbretabulin & Pazopanib|"Phase Ib:~Fosbretabulin and Pazopanib in combination. Fosbreatabulin dose will be in the range of 45mg/m2- 60 mg/m2 delivered by infusion every week for 3 weeks of a 4 week cycle until disease progression. Pazopanib will be either 600 mg or 800mg taken orally each day of 28 day cycle until disease progression.~The phase II dose of both drugs will be determined by the Phase Ib component which is a dose finding exercise.~Phase II:~Fosbretabulin and Pazopanib in combination. Fosbretabulin 54mg/m2 delivered by infusion every week for 3 weeks of a 4 week for 28 day cycle until disease progression. Pazopanib 600mg taken orally each day for 28 day cycle until disease progression"
89400007|NCT02055690|Active Comparator|Phase II: Pazopanib|Pazopanib 800mg taken orally each day of 28 day cycle until disease progression
89400008|NCT04301258||Articular Cartilage Defect of the Knee|Patients, who undergo an articular cartilage repair of the knee using ProChondrix CR.
89189495|NCT05808894|Experimental|extended transection group|the patients in extended transection group obtain extended pancreatic neck transection during laparoscopic pancreaticoduodenectomy.
89189496|NCT05808894|No Intervention|conventional transection group|the patients in conventional transection group obtain conventional pancreatic neck transection during laparoscopic pancreaticoduodenectomy.
89189497|NCT05808868||OSA screening|To
89189498|NCT05808855|Experimental|skin adhesive|two-component skin adhesive Glubran Tiss 2®
88875978|NCT05446974|No Intervention|Non-intervention|Nurses randomly assigned by applying a random selection method
88875979|NCT05446896|Experimental|AR group|participants in the AR group were guided by AR-based instructions and requested assistance with the head-mounted device.
88875980|NCT05446896|No Intervention|manual group|Participants in the manual group used a printed manual and made a phone call for assistance.
89189499|NCT05808855|Active Comparator|suture-based wound closure|suture-based wound closure
89400009|NCT04301258||Articular Cartilage Defect of the Ankle|Patients, who undergo an articular cartilage repair of the ankle using ProChondrix CR.
88875981|NCT05446818|Active Comparator|Flavanol first|Subjects will receive over 8 days both cocoa flavanols (CF) and placebo (P) capsules on alternating days. Sequence of this arm is: CF-P-CF-P-CF-P-CF-P
89400010|NCT04301258||Articular Cartilage Defect of the Foot|Patients, who undergo an articular cartilage repair of the foot using ProChondrix CR.
88875982|NCT05446818|Active Comparator|Placebo first|Subjects will receive over 8 days both cocoa flavanols (CF) and placebo (P) capsules on alternating days. Sequence of this arm is: P-CF-P-CF-P-CF-P-CF
88875983|NCT05444322|Experimental|RD14-01 cell infusion|Infused i.v. in a single dose
89400011|NCT04301258||Articular Cartilage Defect of the Hip|Patients, who undergo an articular cartilage repair of the hip using ProChondrix CR.
89400012|NCT03684135|Experimental|Use of cosmetics during chemotherapy and thermal cure|Use of cosmetics during chemotherapy and post-treatment thermal cure
89400013|NCT02038608|Experimental|PET|
89400014|NCT02193932|Experimental|EEG Triggered fMRI using Micro Maglink|EEG Triggered fMRI to be performed using the Micro Maglink
89400015|NCT03741699|Experimental|Arm 1 - experimental group|Treatment with 150 IU/day rLH, administered subcutaneously for 4 consecutive days prior to COS (with a starting dose of 225 IU/day rFSH and 75 IU/day rLH for 18 days maximum in a short antagonist protocol).
89189500|NCT05808361|Experimental|physical exercise|Rehabilitation program includes physical exercises, started in the first 3 days after the patient's body temperature returned to normal.
89400016|NCT03741699|No Intervention|Arm 2 - control (no pre-treatment) group|The subjects assigned to this group will not receive any treatment in the four days prior to COS (with a starting dose of 225 IU/day rFSH and 75 IU/day rLH for 18 days maximum in a short antagonist protocol).
88875984|NCT05439018|Experimental|Integrated Neuromuscular Inhibition|Integrated Neuromuscular Inhibition in addition to traditional treatment will be received three times a week for eight weeks. Integrated Neuromuscular Inhibition will be contain three combined manual treatment ( ischemic compression , strain counter strain , Muscle energy technique )
88875985|NCT05439018|Active Comparator|traditional treatment|traditional treatment will be received three times a week for eight weeks . traditional treatment in Form of stretching and strenghthening of cervical muscles and postural advices
88875986|NCT05418036|Other|Consecutive patients elegible for outpatient sotalol indication|Single Group
88875987|NCT05392920||Obese children and adolescents|Obese children and adolescent patients
88875988|NCT05378178|Experimental|Phase I：Dose escalation|HS-10381 given orally QD of various dose strengths administered in 21 day dosing cycles.
89400017|NCT03535064|Experimental|Schools received hand hygiene workshop|Schoolgirls of randomly assigned schools attended one-hour Arabic handwashing workshop conducted by the principal investigator one week after submitting all baseline questionnaires. Workshops included video-clip and interactive lecture about common infections in schools, methods of transmission, and hand washing procedure and time. Puzzle games related to hand hygiene were distributed among schoolgirls. Posters with cartoon princess picture promote for hand hygiene were also distributed among the schools.
89400018|NCT03535064|No Intervention|Schools with did not receive hand hygiene workshop|Schoolgirls in control group followed their usual hand washing procedure. When the study ended, schoolgirls of control school were exposed to the same intervention by the same investigator.
89400019|NCT02055846|Experimental|prostate cancer|Realisation of blood sample, urinary sample and tumor biopsy
89400020|NCT02191748|Active Comparator|Needling|Needling is a procedure in which a needle is inserted into normally pigmented skin on the rim of a vitiligo patch and then is pushed into the center of the patch, theoretically moving healthy, pigmented skin cells into the vitiligo patch. Saline, which doesn't affect repigmentation in vitiligo, will be injected into the patch at multiple sites spaced approximately 1 cm apart with 0.1-0.2 cc of saline injected at each site.
89400021|NCT02191748|Experimental|Needling and Triamcinolone|During the process of needling, the needle will be attached to a syringe filled with a steroid, which is then injected into the patch, enabling delivery of the steroid directly to the affected area. Triamcinolone (concentration: 2.5 mg/cc) will be injected into the patch at multiple sites spaced approximately 1 cm apart with 0.1-0.2 cc of triamcinolone injected at each site.
89400022|NCT02191748|No Intervention|No treatment|No treatment will be done to these vitiligo patches as a control.
89400023|NCT03676881||Mild Cognitive Impairment (MCI)|30 MCI patients their study partners will be part of the 'Computerized cognitive battery- Cognigram (CG) project and 30 MCI with their study partners will be part of The NeuroCatch™ Platform (NCP) project.
88875989|NCT05316714|Experimental|IPP Nanofat Grafting|Nanofat surgical grafting in albuginea penile tunica
89189501|NCT05808361|Experimental|exercises and massage|Rehabilitation programs include physical exercises, and chest massage in an electrostatic field, started in the first 3 days after the patient's body temperature returned to normal.
89189502|NCT05808361|No Intervention|Control|Patients received treatment according to the temporary guideline without any rehabilitation program.
89189503|NCT05808283||Those with anemia according to WHO definition (Group 1)|
89189504|NCT05808283||Those without anemia according to WHO definition (Group 2)|
89400024|NCT03676881||Cognitively normal subjects (CN)|30 CN participants who are cognitively normal that will be part of the 'Computerized cognitive battery- Cognigram (CG) project and 30 CN will be part of The NeuroCatch™ Platform (NCP) project.
89400025|NCT02191826|Experimental|SOM0226 single dose|
89400026|NCT02191826|Experimental|SOM0226 multiple doses|
89400027|NCT01333956|Placebo Comparator|Control|Patients will receive 0mg of pregabalin
88875990|NCT05234346|Experimental|150 mg 5-ALAPhosphate + SFC|2 capsules in the morning after breakfast (before 11 AM) and 1 capsule in the evening after a snack or after dinner (before 8 PM) orally with water for 21 days.
89400028|NCT01333956|Experimental|50mg Arm|Patients will receive 50mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of post-operative day (POD)14 and one capsule at bedtime POD15, POD16.
89400029|NCT01333956|Experimental|100mg Arm|Patients will receive 100mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.
89400030|NCT01333956|Experimental|150mg Arm|Patients will receive 150mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.
89400031|NCT02055924|Experimental|Ibrutinib and immunochemotherapies|Combination of immunochemotherapies (R-DHAP or R-DHAOx) and ibrutinib
89400032|NCT02191904|Active Comparator|Truview EVO2®|Patients were randomly assigned into three groups with the sealed envelope method according to the laryngoscope type, which we had and we were used to; Macintosh type, Truview EVO2® type and Airtraq® type laryngoscopes were used in direct laryngoscopy Group DL (n=50), Truview EVO2® Group TV (n=50) and Airtraq® Group ATQ (n=50), respectively.
89400033|NCT02191904|Active Comparator|Airtraq®|Patients were randomly assigned into three groups with the sealed envelope method according to the laryngoscope type, which we had and we were used to; Macintosh type, Truview EVO2® type and Airtraq® type laryngoscopes were used in direct laryngoscopy Group DL (n=50), Truview EVO2® Group TV (n=50) and Airtraq® Group ATQ (n=50), respectively
89400034|NCT02191904|Active Comparator|Direct laryngoscopy|Patients were randomly assigned into three groups with the sealed envelope method according to the laryngoscope type, which we had and we were used to; Macintosh type, Truview EVO2® type and Airtraq® type laryngoscopes were used in direct laryngoscopy Group DL (n=50), Truview EVO2® Group TV (n=50) and Airtraq® Group ATQ (n=50), respectively
88875991|NCT05234346|Placebo Comparator|Placebo|
89400035|NCT02188238||Saliva Sample Collection|Collection of stimulated whole mouth saliva . Whole mouth saliva is collected through stimulation by inert gum, and collecting saliva in a sterile tube.
89400036|NCT02057328|Active Comparator|NEBIVOLOL|Patients of the group of nebivolol will take 5 mg of nebivolol daily in the morning. At the end of the first month of treatment, patients classified in the normal BP range based on the results of ABPM (24h SBP/DBP < 130/80 mm Hg) will continue on the same medication scheme. Patients still classified in the stage I hypertensive range the nebivolol group will receive 10 mg of nebivolol daily in the morning. At the end of the 6th month patients classified in the normal BP range based on the results of ABPM will continue on the same medication scheme. Patients classified in the stage I hypertensive range 12,5 mg hydrochlorothiazide will be added. The end of the 12-month period from the beginning of the study indicates the completion of the project.
89400037|NCT02057328|Active Comparator|TELMISARTAN|Patients of the group of telmisartan will take 40 mg of telmisarta daily in the morning. At the end of the first month of treatment, patients classified in the normal BP range based on the results of ABPM (24h SBP/DBP < 130/80 mm Hg) will continue on the same medication scheme. Patients classified in the stage I hypertensive range will receive 80 mg of telmisartan daily in the morning. The same procedure will be repeated at the end of the 6th month from the beginning of the study. Patients classified in the normal BP range will continue on the same medication scheme. For patients still classified in the stage I hypertensive range12,5 mg of hydrochlorothiazide will be added. The end of the 12-month period from the beginning of the study indicates the completion of the project.
89400038|NCT02188316|Active Comparator|Jumbo forceps polypectomy|89 patients were randomized to jumbo forceps arm and 120 diminutive colorectal polyps were removed by jumbo forceps polypectomy.
89400039|NCT02188316|Active Comparator|Hot biopsy electrocauterization|90 patients were randomized to hot biopsy forceps arm and 117 diminutive colorectal polyps were removed by hot biopsy electrocauterization.
89400040|NCT02057484||Organ transplant patients treated with Advagraf|To evaluate long-term graft survival in patients treated with Advagraf
88875992|NCT05028426||Traditional method of care|Patients managed according to the traditional care protocol without an enhanced recovery program
88875993|NCT05028426||Some elements of a fast-track program|operative and postoperative techniques were modified according to a fast-track program
89400041|NCT02191982|Experimental|Intervention|This arm will begin the Walk With Ease program after the completion of chemotherapy.
89400042|NCT02191982|Active Comparator|Wait List Control|The arm will begin the Walk With Ease program three months after completion of chemotherapy.
89400043|NCT02192060|Experimental|Test|Using of a suspension containing Triclosan
88875994|NCT05028426||Full enhanced recovery program|Patients were managed in an enhanced recovery program (elements of the previous fast-track program were modified and preoperative education was added)
89400044|NCT02192060|Placebo Comparator|Control|Using of a suspension without Triclosan or other active ingredient
88875995|NCT05021172|Experimental|Arm I (Passport to Health booklet, ePrognosis)|Participants receive Passport to Health booklet and complete ePrognosis before scheduled primary care visit.
88875996|NCT05021172|Active Comparator|Arm II (usual care)|Participants receive usual care before scheduled primary care visit.
89400045|NCT02188394|Experimental|Anesthetic blockades with bupivacaine|Patients will receive a bilateral greater occipital nerve blockade with bupivacaine 0,5%
89400046|NCT02188394|Placebo Comparator|Isotonic saline injection|Patients will receive a bilateral occipital injection with isotonic saline
89400047|NCT02194010||Participants evaluated at INC sites|Participants being evaluated at the INC sites will participate in both the DSI and HMSN-R-ODS by completing these PROs during their visit.
89400048|NCT02194010||INC Contact Registry|INC Contact Registry completes the HMSN-R-ODS on web http://rarediseasesnetwork.epi.usf.edu/INC/
89400049|NCT02192138|Experimental|Therapeutic thoracentesis|Patients with pleural effusion who require therapeutic thoracentesis will be enrolled into the study
89400050|NCT01333722|Placebo Comparator|Placebo|placebo, 1 oral tablet every 12 hours
89400051|NCT01333722|Experimental|Hydrocodone/Acetaminophen Extended Release|hydrocodone/acetaminophen extended release, 1 oral tablet every 12 hours
89400052|NCT02188472|Active Comparator|Penicillin V|Penicillin V 2 tablets of 330 mg twice dayly for 7 days
89400053|NCT02188472|Active Comparator|Trimethoprim|2 Tablet Trimethoprim of 100 mg twice daily for 7 days
89400054|NCT02188472|Placebo Comparator|Placebo|2 Placebo Tablets twice daily for 7 days
89400055|NCT02057562||Routine colonoscopy|Patients receiving routine colonoscopy (for a multitude of indications) at the study centers are eligible for participation
89400056|NCT02188550|Experimental|Single|This is a single arm, non-randomized, open-label study with a combination of everolimus and letrozole once a day dosing . Each cycle would be 28days and patients would be scanned after every 3 cycles for response, until disease progression is documented
88875997|NCT04962048|Experimental|pulse-synchronized negative pressure (PSNP) device|One leg will be treated with the pulse-synchronized negative pressure (PSNP). The other leg serves as non-treated control.
88875998|NCT04949568|Experimental|Diabetes Self-Management Behaviors|Self-Management Education Program The culturally tailored Diabetes Self-Management Education Program involves the following: 1) an initial 45-minute face-to-face private consultation collaboratively determining goals; followed by 2) six 2-hour weekly educational interactive sessions in a format TBD by aim 1. We will deliver culturally targeted written materials and presentations in these sessions. Participants will be asked to practice self-management behaviors concurrently and for four additional weeks.
89400057|NCT02038374|Experimental|severe asthma atopic|
89189505|NCT05808140|No Intervention|Control group|Standard endoscopic spinal surgery
89400058|NCT02038374|Experimental|asthma non atopic|
89400059|NCT02059590|Experimental|Pyridinylmethyl-14C-labeled isavuconazonium sulfate|single dose
89400060|NCT02192216|Experimental|Exercise & Chemotherapy|Following a control period during active chemotherapy the patients undergo ten weeks of supervised exercise comprised of resistance and aerobic training in combination with protein supplementation during ongoing chemotherapy.
89400061|NCT02056002|Active Comparator|Usual Care|"Standard CPAP educational training~Educational Brochures~Educational DVD videos mailed to participant"
89400062|NCT02056002|Experimental|Peer-Buddy System|"Two 30-minute in person sessions with Peer Buddy~Standard CPAP training~Eight phone conversations with Peer Buddy over 3 months~Subsequent 3 months use of phone system to contact Peer Buddy as needed~One Month Visit:~-Home visit to collect CPAP information~Three Month Visit:~Questionnaires~Psycho Motor Vigilance Test (PVT) Video Game~Collect CPAP information~Measure weight~Measure blood pressure~Six Month Visit:~Questionnaires~PVT (Video game)~Collect CPAP information~Measure Weight~Measure Blood Pressure~Evaluate the program and Peer Buddy"
89400063|NCT02192294|Experimental|Bosutinib|
89400064|NCT05620134|Experimental|Dose Escalation|Escalating repeated doses of JK08 administered as a subcutaneous injection. A cycle of treatment is defined as 21 days, in which three doses of JK08 will be planned for administration.
89400065|NCT05620134|Experimental|Dose Expansion - Melanoma Cohort|JK08 administered at the maximum-tolerated dose/recommended Phase 2 dose as a subcutaneous injection in patients with melanoma.
89400066|NCT05620134|Experimental|Dose Expansion - Colorectal Cancer Cohort|JK08 administered at the maximum-tolerated dose/recommended Phase 2 dose as a subcutaneous injection in patients with colorectal cancer.
89400067|NCT05620134|Experimental|Dose Expansion - Breast Cancer Cohort|JK08 administered at the maximum-tolerated dose/recommended Phase 2 dose as a subcutaneous injection in patients with breast cancer.
89400068|NCT05620134|Experimental|Dose Expansion - Mixed Solid Tumors Cohort|JK08 administered at the maximum-tolerated dose/recommended Phase 2 dose as a subcutaneous injection in patients with a mix of solid tumors.
89400069|NCT02188628|Experimental|H-Man|H-Man is a novel, portable, inexpensive end-effector upper limb robot.
89400070|NCT02188628|Active Comparator|Additional Conventional Therapy|Repetitive goals based arm therapy
89400071|NCT02057796|Experimental|Xpert MTB/RIF®, Determine TB LAM, Chest X-ray|"Arm1 Extensive TB screening:~In this arm, point-of-care tests for TB will be used at randomization (in all patients) and at each scheduled or unscheduled follow-up visit (in patients with signs or symptoms suggestive of TB and no clear alternative diagnosis); TB treatment will only be prescribed to patients with a diagnosis of TB"
89400072|NCT02057796|Experimental|Rifampin, isoniazid, pyrazinamide, ethambutol|"Arm 2: Systematic Empiric treatment (Rifampicin,isoniazid, pyrazinamide, ethambutol) ART~In this arm, all patients will start a systematic 6-month TB treatment at randomization. TB screening tests will not systematically be used neither at randomization nor while patients are on TB treatment."
88875999|NCT04949568|No Intervention|Usual Type 2 Diabetes Care|The usual care arm will receive the clinic's standard type 2 diabetes care and remain under their providers' care for the duration of the study.
89400073|NCT03681171|Experimental|Children with CP|Children with CP (9-15 years old) participated in a therapeutic dance program to improve physical, physiological and cognitive outcomes.
89400074|NCT02192372||metabolic syndrome|Presence of 3 or more of these components: high fasting glucose (fasting serum glucose ≥ 100 mg/dl or drug treatment for elevated blood glucose), abdominal obesity (given as waist circumference > 102 cm in men and > 88 cm in women), high blood pressure (≥130/≥85 mmHg or drug treatment for hypertension), hypertriglyceridemia (serum triglycerides ≥150 mg/dl), low high-density lipoprotein cholesterol (<40 mg/dl in men and <50 mg/dl in women).
89400075|NCT02192372||control|Age and sex adjusted control subjects
89400076|NCT03676569|Experimental|Experimental group|Autologous ADRC transplantation in autoimmune refractory epilepsy
89400077|NCT02059746||Vaginal birth|"Patients in the group give birth vaginally.~Intervention: Questionnaires sent by mail"
89400078|NCT02059746||Cesaren section|"Patients in this group give birth via cesarean section.~Intervention: Questionnaires sent by mail"
89400079|NCT02192450|Active Comparator|Insulin glargine|"Each treatment arm last for 12 months - 3 months of run-in/cross-over and 9 months of maintenance.~Patients will be randomised (1:1) to treatment with basal-bolus therapy with insulin aspart/degludec or insulin aspart/glargine in random order.~After 12 months of treatment patients will cross-over to the other basal-bolus therapy.~Insulin degludec and insulin glargine is administered once daily at the evening meal and insulin aspart is administered three times daily before the main meals."
89400080|NCT02192450|Experimental|Insulin degludec|"Each treatment arm last for 12 months - 3 months of run-in/cross-over and 9 months of maintenance.~Patients will be randomised (1:1) to treatment with basal-bolus therapy with insulin aspart/degludec or insulin aspart/glargine in random order.~After 12 months of treatment patients will cross-over to the other basal-bolus therapy.~Insulin degludec and insulin glargine is administered once daily at the evening meal and insulin aspart is administered three times daily before the main meals."
89400081|NCT03680937||Immature oocytes vitrified before in vitro maturation|Immature oocytes will be vitrified using closed system vitrification with a semiautomatic method. After warming, a maturation culture will be performed during 36 hours
89400082|NCT03680937||Immature oocytes vitrified after in vitro maturation|A maturation culture of immature oocytes will be performed in vitro during 36 hours. After IVM, mature oocytes will be vitrify in closed system by a semi-automatic method.
89400083|NCT03680937||Fresh oocytes|The culture of immature oocytes will be performed during 36 hours
89400084|NCT03535454||Factory workers|
89400085|NCT03535454||Nurses|
89400086|NCT03535454||Janitors|
89400087|NCT03535454||Data automation employees|
89400088|NCT02038530||No Ultrasound|Low Clinical Pretest Probability and D-dimer < 1000 ug/L; Moderate Clinical Pretest Probability and D-dimer < 500 ug/L
89400089|NCT02038530||Ultrasound Required|Low Clinical Pretest Probability and D-dimer 1000 - 3000 ug/L; Moderate Clinical Pretest Probability and D-dimer 500 - 3000 ug/L; High Clinical Pretest Probability
89400090|NCT02188862||Rheumatic heart disease cases|Patients with rheumatic heart disease as defined in the case criteria
89400091|NCT02188862||Population controls|Individuals from the general population divided into new controls (recruited specifically for this study) and existing controls (recruited to previous population genetics studies in the region)
89400092|NCT03676491|Experimental|Experimental Group|"Music Intervention: Participants listen to music minimum 30 minutes at bedtime for a period of 4 weeks wearing accelerometer.~Participants are monitored for a 4 week follow up period wearing accelerometer"
89400093|NCT03676491|No Intervention|Waitlist Control Group|"No intervention: Participants are monitored for a period of 4 weeks wearing accelerometer.~Participants are monitored for a 4 week follow up period wearing accelerometer."
89400094|NCT02192528||cardiac surgical patients|patients undergoing a cardiac surgical procedure
89400095|NCT02060136||Study group|Men presenting to the urology clinic with lower urinary tract symptoms
89400096|NCT03680703|Experimental|Internet|Guided self-help behavioral weight loss treatment delivered via the internet
89400097|NCT03680703|Experimental|Internet Plus Phone|Guided self-help behavioral weight loss treatment delivered via the internet with weekly phone consultations
89400098|NCT02188940|Active Comparator|Exercise, dietary and behavioral therapy|The interventions of active comparator will be education program, dietary and behavioral therapy and exercise training.
89400099|NCT02188940|Sham Comparator|Dietary and behavioral therapy|The intervention in sham comparator will be education program, dietary and behavioral therapy and stretching and breathing exercise.
88876000|NCT04944810||Magnetic bariatric surgery|Perform a bariatric surgery using the magnetic device like a second assitant in the steps of the surgery in order to perform the surgery with less incisions and with the same safety
88876001|NCT04914702||Everion® only|Two Everion® devices, one for the day and one for the night, to be switched every morning and evening, will be given to the participants for the duration of 2 weeks (fourteen days) with the instruction to wear all the time, with exception of the time needed for the patients' hygiene.
88876002|NCT04914702||CORE® only|A CORE® device will be given to the participants for the duration of 2 weeks (fourteen days) with the instruction to wear it all the time, with exception of the time needed for battery charging and the patients' hygiene.
89400100|NCT03560856|Other|Fulvestrant 500mg + palbociclib 125 mg|Patients will be treated by Fulvestrant 500mg (day 1 and day 15) and then on Day 1 of each subsequent cycle and every 28 days with palbociclib 125 mg daily for 3 weeks on/1 week off (3/1 schedule).
89400101|NCT03676413|Experimental|Test (T)|Fluticasone propionate 100 mcg and Salmeterol 50 mcg inhalation powder/Respirent Pharmaceuticals
89400102|NCT03676413|Active Comparator|Reference (R)|ADVAIR DISKUS® 100/50 mcg inhalation powder pre-dispensed/GSK
89400103|NCT03676413|Placebo Comparator|Placebo|
89400104|NCT02257034|Experimental|Taichi|patients exercise with Tai chi
89400105|NCT02257034|Sham Comparator|Control|patients under exercise of dance
89400106|NCT03561324|Experimental|Use of IntraOperative Imaging Probe|The sterilized (Imaging Beta Probe) IBP will be used intraoperatively in surgical wounds for localization of tumor sites and detecting completeness of excision vs. positive margins.
89400107|NCT03676335|Experimental|0.3 g: 0.15 mg（1)&Hypromellose Eye Drops|Sixty subjects will be treated with CsA eye gel: 0.3 g: 0.15 mg, 1 times daily, The treatment period is 12 weeks. The basic medicine is Hypromellose Eye Drops, 3 times daily for 12 weeks.
88876003|NCT04914702||Everion® first, CORE® second|"Two Everion® devices, one for the day and one for the night, to be switched every morning and evening, will be given to the participants for the duration of 2 weeks (fourteen days) with the instruction to wear all the time, with exception of the time needed for the patients' hygiene.~Then a CORE® device will be given to the participants for the duration of 2 weeks (fourteen days) with the instruction to wear it all the time, with exception of the time needed for battery charging and the patients' hygiene."
89400108|NCT03676335|Experimental|0.3 g: 0.15mg（2)&Hypromellose Eye Drops|Sixty subjects will be treated with CsA eye gel: 0.3 g: 0.15 mg, 2 times daily, interval of about 12 hours, The treatment period is 12 weeks. The basic medicine is Hypromellose Eye Drops, 3 times daily for 12 weeks.
89400109|NCT03676335|Experimental|0.3 g: 0.3 mg &Hypromellose Eye Drops|Sixty subjects will be treated with CsA eye gel: 0.3 g: 0.3 mg, 1 times daily, The treatment period is 12 weeks. The basic medicine is Hypromellose Eye Drops, 3 times daily for 12 weeks.
89400110|NCT03676335|Active Comparator|0.4 ml: 0.2 mg &Hypromellose Eye Drops|Sixty subjects will be treated with CsA for eye emulsion: 0.4 ml: 0.2 mg, 2 times daily, interval of about 12 hours, The treatment period is 12 weeks. The basic medicine is Hypromellose Eye Drops, 3 times daily for 12 weeks.
89400111|NCT04841486||"with history of spontaneous termination of pregnancy group"|pregnant women in the first trimester of pregnancy with history of spontaneous termination of pregnancy
89400112|NCT04841486||"without history of spontaneous termination of pregnancy group"|pregnant women in the first trimester of pregnancy without history of spontaneous termination of pregnancy
89189506|NCT05808140|Experimental|0.5mg/kg ICG group|The patients receive 0.5mg/kg ICG intravenous injection before surgery. The search for lumbar nerve roots is performed with the assistance of fluoroscopic endoscopic imaging equipment. And the procedure follows standard endoscopic spinal surgery procedures.
89189507|NCT05808140|Experimental|1mg/kg ICG group|The patients receive 1mg/kg ICG intravenous injection before surgery. The search for lumbar nerve roots is performed with the assistance of fluoroscopic endoscopic imaging equipment. And the procedure follows standard endoscopic spinal surgery procedures.
88876004|NCT04914702||CORE® first, Everion® second|"A CORE® device will be given to the participants for the duration of 2 weeks (fourteen days) with the instruction to wear it all the time, with exception of the time needed for battery charging and the patients' hygiene.~Then two Everion® devices, one for the day and one for the night, to be switched every morning and evening, will be given to the participants for the duration of 2 weeks (fourteen days) with the instruction to wear all the time, with exception of the time needed for the patients' hygiene."
88876005|NCT04914702||Everion® and CORE® simultaneously|Two Everion® devices, one for the day and one for the night, to be switched every morning and evening, and one CORE® will be given to the participants for the duration of 2 weeks (fourteen days) with the instruction to wear all the time, with exception of the time needed for the patients' hygiene.
89400113|NCT02260128|Experimental|Gum chewing|"This intervention group will receive chewing gum four times daily following surgery. Each of which they are encouraged to chew for 30 minutes.~Gum chewing is terminated when one of the primary end points occurs."
89400114|NCT02260128|No Intervention|Control group|This group will receive the normal postoperative treatment. Occurence of primary end points are registrered.
89400115|NCT02192840|Active Comparator|rDES Group|"Regular drug-eluting stent implantation, one of the following:~Device: LucChopin (Balton, Poland) Device: Prolim (Balton, Poland) Device: Xience Pro (Abott Vascular) Device: Biomatrix (Biosensors) Device: Promus (Boston Scientific) Device: Cypher (Cordis) Device: Taxus (Boston Scientific) Device: Coroflex Please (BBraun) Device: Resolute Integrity (Medtronic)"
89400116|NCT02192840|Experimental|BiOSS Group|New dedicated bifurcation stent BiOSS Expert (Balton, Warsaw, Poland) implantation
89400117|NCT03676179|Active Comparator|unicompartment knee arthroplasty and patella denervation|UKA and patella denervation
89400118|NCT03676179|Experimental|unicompartment knee arthroplasty and patella non-denervation|UKA and patella non-denervation
89400119|NCT02058030|Other|3cm head elevation|Insertion of ProSeal laryngeal mask airway
89400120|NCT02058030|Active Comparator|6cm head elevation|Insertion of ProSeal laryngeal mask airway
89400121|NCT02189096||No change from current practice|"Phase 1 (4 months)~No change from current practice. Each Paramedic crew routinely documents patient observations in an electronic Patient Report Form (ePRF) on every patient encounter. These physiological parameters will be electronically captured. The data will be used to calculate NEWS and screen for Sepsis (2 or more modified SIRS criteria [signs of systemic inflammation] and suspicion of infection) by the study investigators. An estimate will be made of the time of completion of the ePRF in relation to patient transport."
89400122|NCT02189096||NEWS and Sepsis Screening|"Phase 2 (4 months)~The ten crews will undertake implementation of NEWS and Sepsis Screening. Each Paramedic crew will continue to routinely document patient observations in an electronic Patient Report Form (ePRF) on every patient encounter. These physiological parameters will be used to calculate NEWS and screen for Sepsis (2 or more modified SIRS criteria and suspicion of infection). The NEWS will be available to the paramedic crew.~If NEWS is greater than or equal to 4 or the patient screens positive for Sepsis, the patients transfer will be as per normal protocol but receiving ED staff will receive the information about NEWS score and Sepsis screening as part of a structured handover."
89400123|NCT02189096||Point of care lactate measurement|"Phase 3 ( 4 months)~The ten crews will undertake Point of Care Lactate measurement when NEWS ≥ 4 or when the patient screens positive for Sepsis. Each Paramedic crew will continue to routinely document patient observations in an electronic Patient Report Form (ePRF) on every patient encounter. These physiological parameters will be used to calculate NEWS and screen for Sepsis (2 or more modified SIRS criteria and suspicion of infection).~If NEWS is greater than or equal to 4 or the patient screens positive for Sepsis, then a Lactate will be measured on the CG4+ i-STAT cartridge. The lactate level, along with the NEWS score and sepsis screening, will be given to the receiving ED staff as part of a structured handover."
89400124|NCT03683979|Experimental|Interpretation bias modification program|Participants in this arm will complete a computer-based training program two times in the lab. Participants will complete the first training session in the lab during their initial visit and they will return to the lab one week later to complete the second session.
89400125|NCT03683979|Sham Comparator|Control training program|Participants in this arm will complete a sham training program two times in the lab. The program will look similar in length and design to the experimental training program, but the content of the program will remain affectively neutral. As in the experimental condition, participants will complete the first training session in the lab during their initial visit and they will return to the lab one week later to complete the second session.
88876006|NCT04899804||Validity and Reliability Group|This study will be completed in two phases. In the first phase, the participants included in the study will be evaluated first by tele-assessment. One hour later, all assessments will be repeated face-to-face procedures by the researchers; thus, the validity of the tele-assessment method will be determined. Before the tele-assessment, participants will be informed about having a chair whose floor-to-seat height is 48 cm and tape measure. In the second phase of the study, to determine the reliability of the tele-assessment method, all tests will be applied to the previously tested participant by the same researcher one week later and at the same time of the day using only the tele-assessment method.
89189508|NCT05808140|Experimental|2mg/kg ICG group|The patients receive 2mg/kg ICG intravenous injection before surgery. The search for lumbar nerve roots is performed with the assistance of fluoroscopic endoscopic imaging equipment. And the procedure follows standard endoscopic spinal surgery procedures.
89189509|NCT05807698|Experimental|experimental|Assigned Interventions Laughter therapy session will be applied online for 25-30 minutes once a week for 2 months by the researcher who has the Laughter therapy certificate to the application group. In the laughter therapy session, the practices of introducing the practitioner and introducing the therapy, breathing exercises for a healthy life, keeping the rhythm accompanied by music, turning the laughter that started as if it were childlike games into reality will be carried out.
89400126|NCT02189174|Experimental|CLR457|
89400127|NCT01370694|Experimental|MK-8808 Combination Therapy|Participants received MK-8808 375 mg/m^2 intravenously (IV) + cyclophosphamide 750 mg/m^2 IV + vincristine 1.4 mg/m^2 IV (maximum dose of 2 mg IV) on Day 1 each cycle, plus prednisolone 40 mg/m^2, orally on Days 1 to 5 of each cycle for a maximum of 8 cycles. Participants receiving clinical benefit could remain on MK-8808 375 mg/m^2 IV starting 8 weeks after last dose of combination therapy, every 2 months for up to 2 years.
89400128|NCT02256878|Experimental|BIRT 2584 XX + Amitriptyline|"BIRT 2584 XX:~Days 1 and 2: twice daily (bid) Days 3 to 21: once daily (qd)~Amitriptyline:~Single dose on day -8, day 1, and day 15"
89400129|NCT03676101|Experimental|9-valent HPV Recombinant Vaccine|
89400130|NCT03676101|Placebo Comparator|Placebo|
89189510|NCT05806073|Experimental|Elective neck dissection|patient underwent elective neck dissection(level I-III) as initial treatment, along with the excision of the primary tumor
89400131|NCT02058186|Active Comparator|Atopic dermatitis patients: Active|Atopic dermatitis patients: age 1-18 years old
89400132|NCT02058186|Placebo Comparator|Atopic dermatitis patients: Placebo|Atopic dermatitis patients: age 1-18 years old
89400133|NCT02189330|Experimental|Tafamidis|
89400134|NCT02189330|Experimental|Tafamudus Free Acid|
89400135|NCT02189330|Experimental|20 mg new soft gelatin capsule|
88876007|NCT04881708|No Intervention|Current Care Group|The current care group will receive the standard of care currently in place within the subspecialty practices in the Department of Surgery, Mayo Clinic Rochester. This includes postoperative inpatient care directed by the surgical team, including timing of discharge and follow-up.
88876008|NCT04881708|Active Comparator|Remote Care Group|Patients randomized to the remote monitoring arm will engage in a Connected Care Remote Patient Monitoring (RPM) Complex Care program. RPM Complex Care programs utilize established and standardized equipment, logistics/reverse logistic, engagement methods, and nursing clinical practice. Use of RPM Complex Care programs in this manner, is considered standard practice. Patients will be monitored for 30 days by the Connected Care nursing team as is standard for surgical RPM Complex Care programs.
88876009|NCT04532658|Experimental|Intervention arm|Surgeons randomly assigned to the intervention arm
88876010|NCT04532658|No Intervention|Control arm|Surgeons randomly assigned to the control arm
89400136|NCT02189330|Experimental|4 capsules of 20 mg tafamidis of commercial formulation|
88876011|NCT04522206|Experimental|Patients undergoing elective spine surgery|
88876012|NCT04510116|Experimental|AIM preventive intervention|Families were assigned to receive a 6 session, 12 hour prevention program in their community.
88876013|NCT04510116|No Intervention|Control|Families were assigned to no intervention control.
89400137|NCT02189330|Experimental|4 capsules of 12.2 mg tafamidis of free acid tablet|
89400138|NCT03676023||Pulmonary Hemorrhage|Patients treated for pulmonary hemorrhage with inhaled Transexamic Acid
89400139|NCT02059824|Experimental|Eyelid|The selection of the laterality of the eyelid will be randomized
89400140|NCT03633279|Experimental|Branched Chain Amino Acid|Branched Chain amino acid 10 grams packet (L-Isoleucine (952 Mg), L-Leucine (1904 Mg.), L-Valine(1144 Mg). one packet at 6pm and two at 9pm.
89400141|NCT03633279|Placebo Comparator|Placebo|Equinitrogenous amount of lactoalbumin 2.1 grams, and equicaloric amount with 4.0 g saccharose and 3.0 g mannitol for a total of 33.6 kcal/packet.(one packet at 6pm and two at 9pm)
89400142|NCT02189408|Experimental|PRP|one intraoperative application of PRP in the interventional group
89400143|NCT02189408|No Intervention|Control|No application of any substance during knee arthroscopy
89400144|NCT03683745||Maryland|Maryland is a county in southeast Liberia. Survey clusters based on catchment populations served by community health volunteers (CHVs) around 24 district health facilities (primary sampling unit). Clusters will constitute ~600 people (~100 households) with population-weighted cluster selection applied. In total, 80 clusters will be required. CHVs would conduct house-to-house visits to develop a full census and listing of all possible cases using broad case definitions. Full details of all potential cases will then be passed to an expert verification team based at the closest health facility. Suspected cases will arrive at the health facility over a 10-day verification period to receive a diagnosis using clinical examination and/or laboratory confirmation.
89400145|NCT02257190|Experimental|Control (Con)|No exercise intervention.
89400146|NCT02257190|Experimental|Interval Walking - 3 min intervals (IW3)|One hour of classical interval walking exercise (repeated cycles of 3 min of fast and 3 min of slow walking.
89400147|NCT02257190|Experimental|Interval Walking - 1 min intervals (IW1)|One hour of fast alternating interval walking exercise (repeated cycles of 3 min of fast and 3 min of slow walking
89400148|NCT02058342|Experimental|Active Play at Home Intervention|Participant parents in the intervention arm will receive: 1) Active Play at Home curriculum and equipment, 2) Training session on Active Play at Home curriculum, 3) counseling on physical activity scheduling, identification of barriers, motivational strategies, 4) phone calls to check on compliance and issues with doing the program at home
89400149|NCT02058342|No Intervention|Wait-listed control|Participants will attend the baseline visit to do baseline measurements but will not receive any materials related to the Active Play at Home curriculum and will also not be contacted by phone during the control 24 weeks. After they serve as control group, they will be provided with the opportunity to receive the intervention.
89400150|NCT03680391||early postoperative feeding|103 patients will have early postoperative oral fluids and semisolid food after 6 hours of cesarean section irrespective to intestinal sounds ,flatus or stool passage
89400151|NCT03680391||Late postoperative feeding|97 patient will start oral fluids 6 hours with no solid or semi solid until after passage of flatus or stool
89400152|NCT03534908||NAFLD group|those with NAFLD
89400153|NCT03534908||Control group|those without NAFLD
89400154|NCT03680313||Hypertension group|"All adult patients (above 18 year of age) were recruited between May, 2016 and June 2017, at Duc Giang General Hospital. The inclusion criteria are as followed:~Patients have never been diagnosed with hypertension.~Has been diagnosed with primary hypertension, but not take any treatment."
89400155|NCT03680313||Control group|A group of normal people with the similar age to hypertension group was recruited as control group at the same time
89400156|NCT02260206|Experimental|Colchicine|Impact of Colchicine therapy on arrhythmia Recurrence after Acute Pericardial Effusion following Catheter Ablation of Atrial Fibrillation
89400157|NCT02260206|No Intervention|No intervention|No intervention
89400158|NCT02192918|Experimental|Airbrush|Participants will receive the American Academy of Dermatology Sun Smart pamphlet at the baseline session. It has brief tips for reducing skin cancer risk, but does not mention sunless tanning or relaxation activities. Participants will also complete 4 airbrush tan sessions, once every two weeks, over the course of 2 months. Participants will receive access to one of each of the following after the 6-month assessment at no cost: massage, pedicure, yoga class, and dance class. Participants will schedule these activities on their own and the study staff will arrange for payment for the appointment.
89400159|NCT02192918|Experimental|Airbrush Plus|Participants will receive the American Academy of Dermatology Sun Smart pamphlet at the baseline session. It has brief tips for reducing skin cancer risk, but does not mention sunless tanning or relaxation activities. Participants will also complete 4 airbrush tan sessions, once every two weeks, over the course of 2 months. Additionally, they may choose 8 sessions, 1 per week, of the following activities at no cost: massage, pedicure, yoga class, or dance class. These activities are being given as healthy alternatives to the relaxation sensation of indoor tanning.
89400160|NCT02192918|Active Comparator|Delayed Airbrush Plus|Participants will receive the American Academy of Dermatology Sun Smart pamphlet at the baseline session. It has brief tips for reducing skin cancer risk, but does not mention sunless tanning or relaxation activities. Participants will also receive access to one of each of the following after the 6-month assessment at no cost: airbrush tan, massage, pedicure, yoga class, and dance class.
89400161|NCT03683589||Study group|"Participants will receive deuterated water for 10 days before undergoing bariatric surgery.~Liver biopsy collected, lipids extracted and DNL measured via GC/MS."
89400162|NCT02060292||COPD|Stable, Non hypoxaemic, without history of vascular disease
89400163|NCT02060292||Healthy smokers|Age matched, smokers without COPD
89400164|NCT03535610|Experimental|Embolization|Uterine Embolization with PVA Microspheres
89400165|NCT03535532|Experimental|unilateral laparoscopic adrenalectomy|subjects allocated in this group will be given unilateral laparoscopic adrenalectomy as treatment.
89400166|NCT03535532|Active Comparator|standard medical treatment|subjects allocated in standard medical treatment group will be given conservative medicine treatment.
89400167|NCT02058576|Experimental|Sequence AB|Subjects will receive Treatment A (commercially available combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg) in period 1 and Treatment B (combination of second generation dutasteride 0.5 mg and tamsulosin HCL 0.4 mg combination) in period 2 orally once daily under fed condition.
89400168|NCT02058576|Experimental|Sequence BA|Subjects will be randomized to receive Treatment B (combination of second generation dutasteride 0.5 mg and tamsulosin HCl 0.4 mg combination) in period 1 and Treatment A (commercially available combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg) in period 2 orally once daily under fed condition.
88876014|NCT04505592|Experimental|Tenecteplase|First 20 patients randomized to treatment will receive tenecteplase 0.25 mg/kg (maximum 25 mg). Last 20 patients randomized to treatment will receive tenecteplase 0.50 mg/kg (maximum 40 mg).
88876015|NCT04505592|Placebo Comparator|Placebo|Placebo control
89400169|NCT03675867||Obese teenagers|
89400170|NCT02192996|Other|Probiotics supplementation|"Five very low birth weight (VLBW) infants enrolled within 2 days of birth, with a weight < 1300 g and gestational age < 29 weeks and without any malformation or metabolic disease at birth were supplemented with two daily doses of a mixture of Bifidobacterium breve and Lactobacillus salivarius , probiotic strains isolated from human milk during their first weeks of life. The lyophilized powder has contained at least 1x10^9 colony forming units (CFU) per doses of each one of the probiotic bacteria."
89400171|NCT02058654|Experimental|Creatine Group|Whey protein (30 g) and creatine supplement (5 g) shaken with 250-300 ml water in a blender bottle, and the full shake to be taken twice a day for 14 days.
89400172|NCT02058654|Placebo Comparator|Placebo Group|Whey protein (30 g) and bulking agent powder (5 g) shaken with 250-300 ml water in a blender bottle, and the full shake to be taken twice a day for 14 days.
89400173|NCT03680235|Active Comparator|Group I: (standard information about pregnancy, breastfeeding)|Participants receive standard information about pregnancy and breastfeeding. Participants may also participate in a focus group with their partner/spouse or family members after the baby's birth.
89400174|NCT03680235|Experimental|Group II (information about breastfeeding and cancer)|Participants receive standard information about pregnancy and breastfeeding as well as information about breastfeeding and breast cancer. Participants may also participate in a focus group with their partner/spouse or family members after the baby's birth.
89400175|NCT03535220||Observational/ Interventional|Hematologic Disease
89400176|NCT02660424|Experimental|VX-150, placebo|Sequence 1: VX-150 in Treatment Period 1→washout→ placebo in Treatment Period 2
88876016|NCT04460508|Experimental|Mecapegfilgrastim|Patients were administered pegylated rhG-CSF 6mg once at the 3rd day of every chemotherapy cycle.
88876017|NCT04460508|Active Comparator|rhG-CSF|Patients were administered pegylated rhG-CSF 6 ug/kg/day from the 3rd day of every chemotherapy cycle.
88876018|NCT04415892|Other|Healthy volunteers|Young, healthy male volunteers to characterize the DBF changes upon cinnamaldehyde and capsaicin, including the reproducibility.
88876019|NCT04415892|Other|Paclitaxel Patients|Group of patients after treatment with paclitaxel.
89400177|NCT02660424|Experimental|placebo, VX-150|Sequence 2: placebo in Treatment Period 1→washout→ VX-150 in Treatment Period 2
89400178|NCT03675789||STEMI|50 STEMI patients treated with standard therapy undergoing to primary percutaneous coronary internention (PPCI). Thromboaspiration will be performed whenever possible (when the anatomy of the coronary artery - curve and size- allowed it) in all patients with a TIMI Flow 0 and in all patients with a visible thrombus if TIMI Flow was 1 or more.
89400179|NCT03675789||Stable angina|50 stable angina (SA) patients on standard therapy, undergoing to intracoronary blood aspiration during elective diagnostic and/or interventional coronary procedure, matched for age, sex and comorbidities with the 50 STEMI patients.
89400180|NCT03675789||Controls|50 outpatients without coronary heart disease, matched for age gender and comorbidities like diabetes and hypertension with the 50 STEMI patients. Peripheral blood samples will be collected during routine patient monitoring.
89400181|NCT02189564|Active Comparator|Intrinsic reward|Feedback about good performance
89400182|NCT02189564|Experimental|Intrinsic and extrinsic reward|Feedback about good performance + money
89400183|NCT02189564|Experimental|Intrinsic reward (average performance)|Feedback about random selection of trials
89400184|NCT03680079|Other|Youth with type 1 diabetes|A group of 16 teens (ages 13-18) with poorly -controlled type 1 diabetes will be recruited to participate in this study.
89400185|NCT02189642||Genito-Urinary/Urology Surgical Procedure Types|Pediatric patients undergoing circumcision, orchidopexy, hypospadias repair, hernia repair, cystoscopy, pyeloplasty, and ureteral reimplants or ureteral stents.
89400186|NCT02189642||Otolaryngology Surgical Procedure Types|Pediatric patients undergoing tonsil and/or adenoid removal, tympanostomy, tympanoplasty, and mastoidectomy.
89400187|NCT02189642||Orthopaedics Surgical Procedure Types|Patients undergoing hip and knee arthroscopies, hardware removal, and tendon lengthening.
89400188|NCT02189642||Plastic Surgery Surgical Procedure Type|Pediatric patients undergoing alveolar cleft repair.
89400189|NCT02060448|Experimental|2wk baseline + awareness (+ reappraisal)|"Participants in this arm will first undergo a two-week baseline phase. Participants who evidence a significant decrease in non-suicidal self-injurious thoughts and behaviors, or SITBs, (i.e., responders) after emotion awareness training will go straight to a four-week follow-up, and not receive cognitive reappraisal. Participants who evidence a less than satisfactory response in non-suicidal SITBs (i.e., partial responders) after emotion awareness training will return to a two-week baseline phase before receiving cognitive reappraisal, and then enter a four-week follow-up. Participants who evidence little to no response in non-suicidal SITBs (i.e., non-responders) after emotion awareness training will immediately receive cognitive reappraisal and then enter a four-week follow-up."
89400190|NCT02060448|Experimental|2wk baseline + reappraisal (+ awareness)|"Participants will first undergo a two-week baseline phase. Participants who evidence a significant decrease in non-suicidal SITBs (i.e., responders) after cognitive reappraisal will go straight to a four-week follow-up, and not receive emotion awareness training. Participants who evidence a less than satisfactory response in non-suicidal SITBs (i.e., partial responders) after cognitive reappraisal will return to a two-week baseline phase before receiving emotion awareness training, and then enter a four-week follow-up. Participants who evidence little to no response in non-suicidal SITBs and behaviors (i.e., non-responders) after cognitive reappraisal will immediately receive emotion awareness training and then enter a four-week follow-up."
89400191|NCT02060448|Experimental|4wk baseline + awareness (+ reappraisal)|"Participants in this arm will first undergo a four-week baseline phase. Participants who evidence a significant decrease in non-suicidal SITBs (i.e., responders) after emotion awareness training will go straight to a four-week follow-up, and not receive cognitive reappraisal. Participants who evidence a less than satisfactory response in non-suicidal SITBs (i.e., partial responders) after emotion awareness training will return to a two-week baseline phase before receiving cognitive reappraisal, and then enter a four-week follow-up. Participants who evidence little to no response in non-suicidal SITBs (i.e., non-responders) after emotion awareness training will immediately receive cognitive reappraisal and then enter a four-week follow-up."
89400192|NCT02060448|Experimental|4wk baseline + reappraisal + (awareness)|"Participants in this arm will first undergo a four-week baseline phase. Participants who evidence a significant decrease in non-suicidal SITBs (i.e., responders) after cognitive reappraisal will go straight to a four-week follow-up, and not receive emotion awareness training. Participants who evidence a less than satisfactory response in non-suicidal SITBs (i.e., partial responders) after cognitive reappraisal will return to a two-week baseline phase before receiving emotion awareness training, and then enter a four-week follow-up. Participants who evidence little to no response in non-suicidal SITBs (i.e., non-responders) after cognitive reappraisal will immediately receive emotion awareness training and then enter a four-week follow-up."
89400193|NCT03675633||FEUrea in decompensated liver cirrhosis|FEUrea for the differential diagnosis of AKI in patients with cirrhosis and ascites Specifically, the ability of FEUrea to distinguish between ATN versus Pre renal azotemia and HRS
88876020|NCT04415892|Other|Paclitaxel Controls|Group of healthy volunteers, matched for sex, age and BMI with the group of Paclitaxel Patients.
88876021|NCT04415892|Other|Oxaliplatin Patients|Group of patients after treatment with oxaliplatin.
88876022|NCT04415892|Other|Oxaliplatin Controls|Group of healthy volunteers, matched for sex, age and BMI with the group of Oxaliplatin Patients.
88876023|NCT04415892|Other|Longitudinal Paclitaxel Patients|Group of patients who are treated with paclitaxel.
88876024|NCT04415892|Other|Longitudinal Oxaliplatin Patients|Group of patients who are treated with oxaliplatin.
88921924|NCT06055231|Experimental|Arm 1 (Vape followed by Joint)|Patients receive a vape device with THC containing liquid and consume the provided amount in up to 10 minutes. 7 to 14 days later patients receive a cannabis joint and smoke the provided joint in up to 10 minutes. Patients also undergo blood sample collection throughout the study.
88921925|NCT06055231|Experimental|Arm II (Joint followed by Vape)|Patients receive a cannabis joint and smoke the provided joint in up to 10 minutes. 7 to 14 days later patients receive a vape device with THC containing liquid and consume the provided amount in up to 10 minutes. Patients also undergo blood sample collection throughout the study.
89400194|NCT03517254|Experimental|Glutamine and strength training program|Three times per week, standardized and supervised resistance training by physicians will be conducted at the National Institute of Rehabilitation for 6 weeks of follow up. At the beginning and at the end of the training session, the experimental group will receive by mouth 10 grams of glutamine dissolved in 120 milliliters of water, all participants and team of researchers will not be aware of the supplement.
89400195|NCT03517254|Placebo Comparator|Placebo and strength training program|Three times per week a standardized and supervised resistance training by physicians will be conducted at the National Institute of Rehabilitation for 6 weeks after discharge. At the beginning and at the end of the training session, the placebo group will receive by mouth10 grams of maltodextrin dissolved in 120 milliliters of water. All participants and team of researchers will not be aware of the supplement content.
89400196|NCT02189876|Experimental|FemAALES|Females of African American Legacy Empowering Self Intervention. A nine session, theoretically grounded small group intervention.
89400197|NCT02189876|Active Comparator|Standard of Care|A one-time STD/family planning testing and counseling session provided to all study participants.
89400198|NCT03675555|Active Comparator|M (Mirtazapine) (Merta) group:(n=100)|
88813150|NCT01836926|Active Comparator|laparoscopic intersphincteric resection .|"instruments used: 4 or 5 laparoscopic trocars (two or three (10-mm) trocar, Two 5-mm trocars and a 12-mm trocar with reducers),Three 5-mm fenestrated grasping forceps, Five-millimetre coagulating shears, a 5-mm straight grasping forceps, Harmonic scalpel, 5 or 10 mm, a 10-mm fenestrated forceps, a 10-mm dissector,5 mm Bipolar grasper, a 5-mm needle holder, Twelve-millimetre linear staplers~intervention:~Trocar Placement and Exposure~Rectosigmoid Mobilization and Control of Inferior Mesenteric Vessels~Taking Down the Splenic Flexure~rectal dissection till the levator ani muscle and resection of thye lateral ligaments~then the peranal phase as in the laparotomy approach."
88813151|NCT01837004|Experimental|CORTEX|The CORTEX group will attend 10, 2-hour sessions for a period of four weeks prior to the initial exercise program start. One hour will be devoted to computerized training (stationary dual-task & cognitive control training, self-priming, certainty training) whereas the other hour will be devoted to exergaming involving non-stationary, dual-task training.
88813152|NCT03210584||Imaging measurements|All subject of the study have a knee osteoarthritis (OA) and are going to have a knee prosthetic surgery with cartilage excision. Multimodal evaluation is conducted on ex vivo human cartilage samples (2 samples per patient are selected : healthy and severely degraded).
89400199|NCT03675555|Active Comparator|D (Dexamethasone) (Dex) group: (n=100)|
89400200|NCT03675555|Placebo Comparator|C (Control) group: (n=100)|
89400201|NCT02190032|Active Comparator|Control group|"Intubating a manufacturer-provided-angled double-lumen tube (=Conventional-angled group,MallinckrodtTM endotracheal tube, Covidien)"
89400202|NCT02190032|Experimental|Tube angle modification|The angle of the double lumen tube(MallinckrodeTM endotracheal tube) is modified individually.At sniffing position, the distal tip of the tube is placed at the patient's cricoid cartilage level and the tube is bent at the intersection point of the two airway axes (oropharyngeal axis and tracheal axis) with an angle between the two axes.
89400203|NCT03679923|Experimental|NEM® brand eggshell membrane|NEM, 500 mg, #0 capsule, once daily orally for 2 weeks
89400204|NCT03679923|Placebo Comparator|Placebo|Placebo, 500 mg, #0 capsule, once daily orally for 2 weeks
89400205|NCT02060994||37-38 weeks|"Children who were born by elective Cesarean section after 37-38 gestational weeks.~Intervention: No intervention."
89400206|NCT02060994||39 week or more|Children who were born by elective Cesarean section after 39 gestational weeks or more Intervention: No intervention.
88813153|NCT01561469||Linezolid observational cohort|
88813154|NCT01561469||Vancomycin observational cohort|
88813155|NCT01837082|Active Comparator|Iron|ferric carboxymaltose
88813156|NCT01837082|Placebo Comparator|Placebo|Sodium chloride 0.9%
88813157|NCT01837160||Healthy Volunteers|"10 patients with normal echocardiogram studies and no history of ischaemic heart disease.~Patients to recieve CT-PET with fluciclatide, cardiac MRI scan, CT-coronary angiogram and echocardiogram."
88813158|NCT01837160||Moderate Aortic Stenosis (n=10)|"Patients with moderate aortic stenosis. Patients are to recieve Cardiac MRI, CT-PET scan, echocardiography and CT-coronary angiogram scan at baseline.~They will undergo repeat cardiac MRI scan and echocardiogram at 12 - 24 months."
88813159|NCT01837160||Mild Aortic Stenosis (n=10)|"Patients with mild aortic stenosis. Patients are to recieve Cardiac MRI, CT-PET scan, echocardiography and CT-coronary angiogram scan at baseline.~They will undergo repeat cardiac MRI scan and echocardiogram at 12 - 24 months."
88813160|NCT01837160||Severe aortic Stenosis (n=10)|"Patients with severe aortic stenosis. Patients are to recieve Cardiac MRI, CT-PET scan, echocardiography and CT-coronary angiogram scan at baseline.~They will undergo repeat cardiac MRI scan and echocardiogram at 12 - 24 months."
88813161|NCT01837160||Severe Aortic Stenosis for AVR (n=10)|"Patients with severe aortic stenosis proceeding to aortic valve replacement. Patients are to recieve Cardiac MRI, CT-PET scan, echocardiography and CT-coronary angiogram scan at baseline.~They will undergo a repeat CT-PET scan 3 months after the operation.~They will undergo repeat cardiac MRI scan and echocardiogram at 12 months after the operation."
88813162|NCT01561703|Experimental|Anitibiotic|Patients will receive postoperative antibiotic after surgery.
88813163|NCT01561703|No Intervention|Control|Patients will NOT receive postoperative antibiotic
88813164|NCT01837238|Experimental|beta-hydroxy beta-methylbutyrate|Calcium-HMB (3g) will be consumed daily for 6 months by all participants assigned to the HMB group.
88813165|NCT01837238|Placebo Comparator|Placebo|The placebo group will consume non-nutritive placebo pills daily for 6 months.
88813166|NCT01460303|Experimental|OPTION-vf patient controlled catheter|"Patients who fail postop bladder challenge and are randomized to OPTION-vf arm will be instructed in the use and care of this catheter, discharged home with it in place and given an appointment between 5-10 days postop for a bladder challenge."
89400207|NCT02194166|Experimental|Pre-Randomization (Trastuzumab IV)|Trastuzumab IV will be given during the first 4 cycles for all participants before randomization for SC administration. A dose of 6 milligrams per kilogram (mg/kg) will be given every 3 weeks. All the participants will require a loading dose on Day 1 of Cycle 1, so they will receive 8 mg/kg followed by 6 mg/kg, 3 weeks later and then 3-weekly. Concurrent administration during the first 4 cycles of trastuzumab IV with paclitaxel/docetaxel will have to be performed in accordance with local hospital practice.
89400208|NCT02194166|Experimental|Group A: Trastuzumab SC (First Vial Formulation, then SID)|Participants will receive 7 cycles of SC trastuzumab 600 mg with assisted administration using a conventional syringe and needle (SC vial formulation) followed by 7 cycles of SC trastuzumab 600 mg SID administration after cross-over.
89400209|NCT02194166|Experimental|Group B: Trastuzumab SC (First SID, then Vial Formulation)|Participants will start with 7 cycles of SC trastuzumab 600 mg administration via SID and after cross-over will receive 7 injections of trastuzumab 600 mg with assisted administration using a conventional syringe and needle (SC vial formulation).
89400210|NCT03679845|Experimental|Sarilumab Arm|200 mg of sarilumab every two weeks
89400211|NCT02061072||Population pharmacokinetic estimation|Patients with severe or moderate hemophilia A or B, providing sparse data for population PK estimation
89400212|NCT02194244|Experimental|Granules Fasted|
89400213|NCT02194244|Experimental|Granules Fed|
89400214|NCT02194244|Active Comparator|Tablet Fasted|
89400215|NCT02194244|Active Comparator|Tablet Fed|
89400216|NCT03679533|Active Comparator|Active Cranberry Study Food|
89400217|NCT03679533|Placebo Comparator|Placebo Study Food|
89400218|NCT02194322|Experimental|BIBN 4096 BS - in single rising doses|
89400219|NCT02194322|Placebo Comparator|Placebo|
89400220|NCT03675399|Experimental|Supra-threshold isometric exercise|Participants will perform 10 isometric external rotation supra-threshold contractions of the affected shoulder, each held for 15 seconds, with resting intervals of 15 seconds between contractions.
89400221|NCT03675399|Experimental|Infra-threshold isometric exercise|Participants will perform 10 isometric external rotation infra-threshold contractions of the affected shoulder, each held for 15 seconds, with resting intervals of 15 seconds between contractions.
89400222|NCT03675399|No Intervention|Control|Participants will remain resting.
89400223|NCT03802188||SLE Cohort|Investigators will use existing data collected on adult SLE patients enrolled into respective study cohorts from participating centers.
89400224|NCT03802188||Qualitative group|For the interviews, patients with SLE who are currently or have taken Hydroxychloroquine will be recruited from rheumatology clinics in Calgary and Montreal to participate in an interview and/or participate in a brief survey.
88876025|NCT04256070|Experimental|Education, tele-consultation and training booklet|"Informed Consent Form will be taken in written from those who agree to participate in the research.~In the first intervention, Information Form Based on Watson's Human Care Theory, Chronic Obstructive Pulmonary Disease Self-efficacy Scale, St. George Quality of Life Scale, Respiratory Function Test Form data will be collected. Subsequently, education, counseling nursing care and education booklet based on Watson's Human Care Theory will be given.~Teleconsultation based on Watson's Human Care Theory will be given during the intervention at weeks 2, 4, 6, 8 and 10.~24-hour tele-consultancy will be given on subjects determined for the management of COPD in case of necessity at the request of the individual.~In the last intervention in the 12th week, face to face with the individual, Consultancy based on Watson Human Care Theory, Self-efficacy Scale, St. George Quality of Life Scale, Respiratory Function Test Form, Telephone Interview Evaluation Form will be applied."
88876026|NCT04256070|No Intervention|Standart care, no intervention|"Informed Consent Form will be taken in writing from those who agree to participate in the research.~At the first meeting, Information Form Based on Watson Human Care Theory, Self-efficacy Scale, St. George Quality of Life Scale, Respiratory Function Test Form data will be collected.~Interventions will not be applied to individuals in this group and routine treatment and follow-up will continue.~- COPD Self-efficacy Scale, face-to-face meeting at the end of the 12th week. George Quality of Life Scale, Respiratory Function Test Form will be repeated.~A training booklet for COPD management will be provided."
89400225|NCT02195882|Experimental|Exercise program|
89400226|NCT02193308|Experimental|Telmisartan/Amlodipine FDC|
89400227|NCT02193308|Active Comparator|Telmisartan + Amlodipine mono|
89400228|NCT03683199|Experimental|Cleft lip nasal deformity|"•Anthropometric evaluation of the nose (will be measured pre and post-operative) This represents the objective evaluation. It will be done by measuring the angles and ratios of the nose and its relation to the face. Common parameters will be measured from the photos (frontal, oblique, lateral and basal views) for all the patients to compare the pre-operative measures with the post-operative ones.~MSCT flesh mode will be used to measure nose related angels and ratios. It also gives idea about nasal skeleton pre-operative for proper design of the operative strategy, and it will be done post-operative for assessment and comparizon."
89400229|NCT02195960|Placebo Comparator|placebo|intake corn extract poor in anthocyanins: three daily stick packs containing water-soluble extract from corn cobs poor in anthocyanins
88876027|NCT04226118|No Intervention|Control Group|Patients who have a peripheral venous access by a classic procedure, without using a Vein Illumination System.
89400230|NCT02195960|Active Comparator|intake anthocyanin-rich corn extract|intake anthocyanin-rich corn extract: three daily stick packs containing water-soluble extract from high-anthocyanin rich corn cobs
89400231|NCT02060604|Experimental|Ketorolac + Ranibizumab|3 monthly ranibizumab, then as needed plus ketorolac eyedrops TID
89400232|NCT02060604|Active Comparator|Ranibizumab Alone|3 monthly ranibizumab, then as needed
89400233|NCT03679455|Experimental|Treatment arm|Obinutuzumab (RO5072759) 25 MG/ML; Obinutuzumab will be administered by iv. infusion as an absolute (flat) dose of 1000 mg.
89400234|NCT02193386|Active Comparator|Usual Care|No intervention, no follow-up, only registration of usual therapy
89400235|NCT02193386|Experimental|Intervention period|Predefined, evidence-based program and support
89400236|NCT02061150||Asymptomatic newborns that had sepsis workup|Evaluation of medical records of asymptomatic newborns that had sepsis workup in the first 48 hours of life.
89400237|NCT03315143|Experimental|Sotagliflozin|Sotagliflozin 200 mg tablet once daily, with possible up-titration in the first 6 months to 400 mg, for up to 28.9 months.
89400238|NCT03315143|Placebo Comparator|Placebo|Matching placebo to sotagliflozin 200 mg once daily, with possible up-titration in the first 6 months to matching placebo to sotagliflozin 400 mg, for up to 29.6 months.
89400239|NCT02194400|Placebo Comparator|Placebo|Saline infusion
89400240|NCT02194400|Experimental|RSLV-132|0.3 - 10 mg/kg experimental drug
89400241|NCT02062086|Other|Population 1|"(Community-dwelling older adults) will participate in the study for approximately 65 days.~Population 1 will absorb deuterated creatine 30 mg, a non-radioactive, stable isotope of creatine, for the estimation of muscle mass in humans.~The estimation of muscle mass will be made on 2 separate occasions in the community-dwelling elderly population in order to assess reproducibility of the method when tested approximately 60 days apart."
89400242|NCT02062086|Other|Population 2|"(Hip-fracture patients) will participate in the study for approximately 35 days during their in-hospital period, followed by 30 during their post-discharge period, so for a total period of at least 65 days.~Population 2 will absorb deuterated creatine 30 mg, a non-radioactive, stable isotope of creatine, for the estimation of muscle mass in humans.~In the hip fracture population, estimation of muscle mass by the D3 creatine method will be performed on up to 3 separate occasions to assess whether the method is sensitive enough to detect decreases in muscle mass that may occur during the recovery period after hip fracture."
89400243|NCT03675165|Experimental|Intervention|Participants receive a tailored version of Laura King's 'Best Possible Self' intervention: a brief, self-administered, psychological intervention. It is fundamentally a writing exercise, whereby recipients are asked to spend 10 minutes writing about their best possible future self and the steps they need to take to become that person. This helps the individual set goals while facilitating positive affect. Our version of the task has people focus on their health-related goals in particular.
89400244|NCT03675165|No Intervention|Waiting List Control|Participants are informed that they are on a waiting list and will receive the intervention at the end of the study.
89400245|NCT02194478|Other|8 Week Meditation|Allina Health employees undergoing 8 week meditation intervention
89400246|NCT02061228|No Intervention|Control arm|Women undergoing exogenous gonadotropin ovarian stimulation for ART in an antagonist downregulated cycle.
89400247|NCT02061228|Experimental|Induced endometrial injury arm|Women undergoing exogenous gonadotropin ovarian stimulation for ART in an antagonist downregulated cycle. Additionally, they will undergo an endometrial biopsy on the 6th day of ovarian stimulation using a Pipelle de Cornier® (CCD International, Paris, France).
89400248|NCT04715204|Active Comparator|Formula-75/Formula-100|This arm is the control. Formula-75/Formula-100 are the standard formula recommended by WHO to treat severely malnourished children.
89437443|NCT03909061|Experimental|Immediate Training (no follow up)|Individuals may decide to participate in the research study training program, but not in any follow up questionnaires. This group will have immediate access to the independent maintenance training materials. They will complete data collection measures embedded in the maintenance training program, including demographics, Online Learning Readiness Scale (OLRS), Moorong Self Efficacy Scale (MSES), Patient Reported Outcome Measurement Information System (PROMIS), Assistive Technology Module Questionnaire (ATM-Q), and the Wheelchair Maintenance Training Questionnaire (WMT-Q).
88813167|NCT01460303|Active Comparator|Transurethral catheter w/leg bag|"Patients who fail postop bladder challenge and are randomized to indwelling catheter with leg bag arm will be instructed in the use and care of this catheter, discharged home with it in place and given an appointment between 5-10 days postop for a bladder challenge."
88813168|NCT01837316|Experimental|FF/VI|A single dose inhalation of FF/VI 100/25 mcg in the morning
88813169|NCT01837316|Placebo Comparator|Placebo|A single dose inhalation of matching placebo in the morning
88813170|NCT01839422|Experimental|Controls|Memory assessment. Brain imaging examination MRI.
88813171|NCT01839422|Experimental|Beginner Alzheimer's Disease patients|Memory assessment. Brain imaging examination MRI.
88813172|NCT01839422|Experimental|Severe Alzheimer's Disease patients|Memory assessment. Brain imaging examination MRI.
88813173|NCT01460927|Other|TriActive+ RF|Healthy male or female subjects 30-60 years of age, having at least two facial sub-areas (left peri-orbital, right peri-orbital or peri-oral) with visible lines/wrinkles and elastosis, which correlate to a score of 2-6 on the Fitzpatrick Classification of Wrinkling and Degree of Elastosis.
88813174|NCT01839500||Cohort I: HER2-Positive mGC Treated With Trastuzumab|HER2-positive metastatic gastric cancer (mGC) participants who are treated with trastuzumab will be included in this cohort. As this is an observational study, treatment schedule will be at the clinician's discretion in accordance with routine care practice and not dictated by the protocol.
88813175|NCT01839500||Cohort II: HER2-Positive mGC not Treated With Trastuzumab|HER2-positive mGC participants who are not treated with trastuzumab will be included in this cohort.
88813176|NCT01839500||Cohort III: HER2-Positive non-mGC|HER2-positive non-mGC participants will be included in this cohort.
88813177|NCT01839500||Cohort IV: HER2-Negative mGC|HER2-negative mGC participants will be included in this cohort.
88813178|NCT01839500||Cohort V: HER2-Negative non-mGC|HER2-negative non-mGC participants will be included in this cohort.
88813179|NCT05565677||Patients with lung cancer|Patients with a presumptive diagnosis of lung cancer for whom surgical resection or sampling will be clinically indicated according to the standard practices of the Cardiothoracic Department of AHEPA University Hospital of Thessaloniki, will be enrolled in this prospective study once they give written informed consent for specimen imaging. Surgical resections will be performed per standard of care and there will be no difference in patients' clinical management depending on the acquisition or not of surgical specimens. Patients with altered mental status and those who are unable or unwilling to provide informed consent will be excluded from this study.
88813180|NCT04379726||patients with CFRD|Patients with diagnosis of CFRD, after OGTT
88813181|NCT04379726||patients without CFRD|Patients without diagnosis of CFRD, after OGTT
88813182|NCT01461473|Active Comparator|Positive Airway Pressure|Participants randomized to standard clinical Positive Airway Pressure (PAP) treatment for Obstructive Sleep Apnea (OSA).
88813183|NCT01461473|Active Comparator|Oral Appliance|Subjects randomized to standard Oral Appliance (OA) treatment for Obstructive Sleep Apnea (OSA).
88813184|NCT00901316|Experimental|Routine Measures|
88813185|NCT00901316|Experimental|Bleach Baths|
89400249|NCT04715204|Experimental|High Energy Oral Nutrition Supplement|High energy oral nutrition supplement (ONS) has energy density of 1.5 kcal/ml, with protein-energy ratio of 8.9% and complete micronutrients. It is also named as enteral formula and can be used as a sole source of nutrition. It comes as a ready-to-drink bottled package of 200 mL each. The nutrition fact fulfills the requirement of BPOM (Indonesian Food and Drug Authority) for Special Medical Purpose. The ready-to-drink formula is a safe option to treat severely malnourished patient in terms of hygiene assurance of formula. In Indonesia, many severely malnourished children come from areas with poor access to clean water and proper sanitation. The high energy ONS is beneficial for children who cannot tolerate large volume of feeding.
89400250|NCT04715204|Experimental|Standard Energy Oral Nutrition Supplement|Standard energy oral nutrition supplement (ONS) has energy density of 1 kcal/ml, with protein-energy ratio of 9.6% and complete micronutrients. It is also named as enteral formula and can be used as a sole source of nutrition. It comes as a ready-to-drink bottled package of 200 mL each. The nutrition fact fulfills the requirement of BPOM (Indonesian Food and Drug Authority) for Special Medical Purpose. The ready-to-drink formula is a safe option to treat severely malnourished patient in terms of hygiene assurance of formula. In Indonesia, many severely malnourished children come from areas with poor access to clean water and proper sanitation.
89400251|NCT02060682||Navvus Catheter FFR|The Navvus Catheter is a rapid exchange microcatheter with a pressure sensor at the distal tip that measures Fractional Flow Reserve measurements to guide PCI treatment strategy.
89400252|NCT02194556|Experimental|Sequential and maintenance icotinib|Patients are administered with sequential and maintenance icotinib plus chemotherapy. Gemcitabine 1000mg/m2 iv d1 and d8, cisplatin 75mg/m2 iv d1, icotinib 125 mg is administered orally three times per day at d 8-21, every 3 weeks for a cycle. After receiving a maximum of 4-cycle treatment, non-progressive patients continue to receive icotinib as maintenance treatment until disease progression or intolerable toxicity.
89400253|NCT02194556|Active Comparator|Maintenance icotinib|Gemcitabine 1000mg/m2 iv d1 and d8, cisplatin 75mg/m2 iv d1. After receiving a maximum of 4-cycle treatment, non-progressive patients continue to receive icotinib (125 mg three times per day) as maintenance treatment until disease progression or intolerable toxicity.
89400254|NCT02193464||inflammatory bowel disease|
89400255|NCT03679377|Experimental|Mandibular slotplate|Mandibular slotplates are placed during BSSO surgery and their clinical usefullness is tested. Afterwards the plates are removed and the osteotomy is fixated by three bicortical screws.
89400256|NCT02062242|Experimental|Transvaginal electrical stimulation|Patients treated with transvaginal electrical stimulation.
89400257|NCT02062242|Experimental|Palpation|Patients treated with vaginal palpation.
88876028|NCT04226118|Experimental|Experimental Group|Patients who have a peripheral venous access by a procedure using a Vein Illumination System.
88876029|NCT04176354||Palbociclib + an aromatase inhibitor|Adult metastatic breast cancer patients who initiated Palbociclib + an aromatase inhibitor as first line therapy between Feb 3, 2015 to 3 months prior to date of data cutoff in the Flatiron Health Analytic Database.
89400258|NCT02062242|Experimental|Palpation with posterior pelvic tilt|Patients treated with vaginal palpation associated with posterior pelvic tilt and contraction of accessory muscles.
89400259|NCT02062242|Experimental|Control group|Patients receive verbal instructions related to the pelvic floor and its contraction.
88876030|NCT04176354||Palbociclib + Letrozole|Adult metastatic breast cancer patients who initiated Palbociclib +Letrozole as first line therapy between Feb 3, 2015 to 3 months prior to date of data cutoff in the Flatiron Health Analytic Database.
89400260|NCT02194634|Experimental|Conbercept treatment group|Conbercept injection and sham laser treatment at day 0 for 1st time, the investigators will decide whether the subjects need to get repeated treatment according to monthly assessment.
89400261|NCT02194634|Active Comparator|Laser treatment group|Laser treatment and sham injection at day 0 for 1st time, the investigators will decide whether the repeated laser treatment is needed according to monthly results during the visit after 3 months.
89400262|NCT03679143|Experimental|ZSP1273(single dose)-100 mg(Cohort 1)|ZSP1273 100 mg /Placebo
89400263|NCT03679143|Experimental|ZSP1273(single dose)-200 mg(Cohort 2)|"ZSP1273 200mg/Placebo~Enrollment into Cohort 2 will begin upon assurance of tolerance for Cohort 1."
89400264|NCT03679143|Experimental|ZSP1273(single dose)-400 mg(Cohort 3)|"ZSP1273 400mg/Placebo~Enrollment into Cohort 3 will begin upon assurance of tolerance for Cohort 2."
89400265|NCT03679143|Experimental|ZSP1273(single dose)-600 mg(Cohort 4)|"ZSP1273 600 mg/Placebo~Enrollment into Cohort 4 will begin upon assurance of tolerance for Cohort 3."
89400266|NCT03679143|Experimental|ZSP1273(single dose)-900 mg(Cohort 5)|"Drug:ZSP1273 900 mg/Placebo 900mg；~Enrollment into Cohort 5 will begin upon assurance of tolerance for Cohort 4."
89400267|NCT03679143|Experimental|ZSP1273(single dose)-1200 mg(Cohort 6)|"ZSP1273 1200 mg/Placebo~Enrollment into Cohort 6 will begin upon assurance of tolerance for Cohort 5."
89400268|NCT03679143|Experimental|ZSP1273(Food Effect)-Cohort 7|"Drug:ZSP1273 /Placebo； Period 1 (Day1 to Day5): Subjects receive ZSP1273/Placebo under the fasting or fed condition ,respectively on Day1.~Period 2 (Day 8 to Day12): Subjects receive ZSP1273/Placebo under the fed or fasting condition, respectively on Day 8."
89400269|NCT03679143|Experimental|ZSP1273(multiple doses)-Low Dose(Cohort 8)|"while fasted or fed according to the results of Cohort FE~ZSP1273 /Placebo for 5 Days."
88876031|NCT04176354||Letrozole|Adult metastatic breast cancer patients who initiated Letrozole as first line therapy between Feb 3, 2015 to 3 months prior to date of data cutoff in the Flatiron Health Analytic Database.
88876032|NCT04128540|Other|Control group|This group will receive fentanyl infusion only
88876033|NCT04128540|Active Comparator|ESPB group|This group will receive fentanyl infusion plus Ultrasound guided ESPB
88876034|NCT05448612|Experimental|Active Release Technique|In ART the particular muscle is taken from shortened to lengthened position or vice versa. Duration of treatment will be of 8-15min
88876035|NCT05448612|Experimental|Muscles Energy Technique|In METs,the protocol will perform for 3 repetitions per day and thrice a week for 5 week.
88921928|NCT06044818||Healthy|
89400270|NCT03679143|Experimental|ZSP1273(multiple doses)-Median Dose(Cohort 9)|"while fasted or fed according to the results of Cohort FE~ZSP1273/Placebo for 5 Days."
89400271|NCT03679143|Experimental|ZSP1273(multiple doses)-High Dose(Cohort 10)|"while fasted or fed according to the results of Cohort FE~ZSP1273/Placebo for 5 Days."
89400272|NCT02061462|No Intervention|Standard Group|Recipients of lungs procured from brain dead donors.
89400273|NCT02061462|Active Comparator|EVLP-DCD Group|Recipients of lungs procured from DCD donors, reconditioned/evaluated by EVLP
89400274|NCT02030912|Active Comparator|3 doses of amoxicillin daily for 7 days|Cohort A: 3 doses of amoxicillin daily for 7 days (n=14). Follow up 12 months.
89400275|NCT02030912|Active Comparator|2 doses of minocycline daily for 5 days|Cohort B: 2 doses of minocycline daily for five days (n=14). Follow up 12 months.
88876036|NCT04104438|Active Comparator|Basiliximab with Delayed TAC|"Basiliximab~Dose #1: 20mg IV within 2 hours of transplant~Dose #2: 20mg IV Post-operative day #4~Tacrolimus (with basiliximab induction) o Beginning day #5 post-transplant or when SCr < 1.8 mg/dl (subjects off dialysis) to six months: 0.03-0.1mg/kg q12h PO to maintain whole blood trough concentration of 4-6ng/mL~Mycophenolate mofetil~o 1000 mg po bid~Corticosteroids (SOC): Per UCLA protocol~Post-operative taper:~Post-op day 1- methylprednisolone 50mg IVP Q6H~Post-op day 2- methylprednisolone 40mg IVP Q6H~Post-op day 3- methylprednisolone 30mg IVP Q6H~Post-op day 4- methylprednisolone 20mg IVP Q6H~Post-op day 5- methylprednisolone 20mg IVP Q12H~Post-op day 6- methylprednisolone 10mg IVP Q12H until taking PO, then change to: prednisone 20mg PO QAM"
88876037|NCT04104438|Active Comparator|Basliximab, Delayed TAC with Everolimus|"Basiliximab~Tacrolimus (with basiliximab induction)~o Beginning day #5 post-transplant or when SCr < 1.8 mg/dl (subjects off dialysis) to POD 30: 0.03-0.1mg/kg q12h PO to maintain whole blood trough concentration of 4-6ng/mL~Mycophenolate mofetil o 1000 mg po bid up to POD 30: reduce mycophenolate mofetil following achievement of steady state everolimus (POD 35) as clinically indicated~Corticosteroids (SOC): Per UCLA protocol~Everolimus (delayed)~o Add by POD 30: 1 mg po bid and adjusted to maintain whole blood trough concentrations of 3-8 ng/ml."
88876038|NCT04104438|No Intervention|Control: standard TAC with steroids and MMF|"Tacrolimus (without basiliximab induction)~Beginning day #1 post-transplant to six months: 0.03-0.1mg/kg q12h po to maintain whole blood trough concentration of 5-12ng/mL~Six months to one year: maintain whole blood trough concentration of 5-10ng/mL~Mycophenolate mofetil~o 1000 mg po bid~Corticosteroids (SOC): Per UCLA protocol"
88876039|NCT04007640|Other|Volunteer patient|1st stage: To adjust the transducer, test and validate pancreatic MRI sequences on volunteers without history of known pancreatic disorders. Adjustment of MRI parameters is needed to optimize data acquisition, especially in obese patients. Moreover, an external material (transducer) has to be applied on the abdomen. The right position has to be tested and specified before stages 2 and 3 of the study. We aim to include volunteers without history of known pancreatic disorders for the Stage 1, meaning volunteers without personal history or symptoms suggesting pancreatic disorders.
89400276|NCT02030912|Placebo Comparator|2 doses of placebo daily for 5 days|Cohort C: 2 doses of placebo daily for five days (n=14). Follow up 12 months.
89400277|NCT03675009|Other|Early Intervention|Educational curriculum will be delivered earlier in the timeframe after IAQ monitoring has initiated.
89400278|NCT03675009|Other|Late Intervention|Educational curriculum will be delivered later in the timeframe after IAQ monitoring has initiated.
89400279|NCT02062320||PRE-PCAPS|Parturients who underwent delivery by Caesarean Section in the period October 2009 - September 2010
89400280|NCT02062320||POST-PCAPS|Parturients who underwent delivery by Caesarean Section in the period November 2010 - October 2011.
89400281|NCT02196116|Active Comparator|Group 1|Controls
89400282|NCT02196116|Experimental|Group 2|Cognitively-impaired subjects without dementia and without memory
89400283|NCT02196116|Experimental|Group 3|Cognitively-impaired subjects without dementia and with memory
89400284|NCT02060916|Experimental|PAZ320|Patients will all take part in the control arm of the study and then be crossed over into treatment with PAZ320 at two different dosages.
89400285|NCT02257268|Experimental|Change behavior group|Change behavior group = Group of change behavior including physical activity and healthy habits promotion.
89400286|NCT02257268|No Intervention|Control group|Control group = Group that will not receive the VAMOS program as intervention.
88921929|NCT06044818||Depression|
88921930|NCT06043817|Experimental|Part 1: Dose Escalation|
88921931|NCT06043817|Experimental|Part 2: RP2D Selection|
88921932|NCT06043817|Experimental|Part 3: Dose Expansion|
89400287|NCT02063256|Active Comparator|7 NUTS a day|the patients allocated to this arm will be instructed to supplement their diet with 7 nuts a day (whole shelled weight around 75 grams)
89400288|NCT02063256|Experimental|Diet modification|the patients allocated to this arm will be instructed to modify their diet allowing more intake of PUFA rich food avoiding saturated fat rich food
89400289|NCT02797080|Experimental|interferon γ-1b|ACTIMMUNE® will be administered 3 times per week (TIW) by subcutaneous (SC) injection.
89400290|NCT02196194||tiotropium|
89400291|NCT03534830||eLASV > 38.5|exposed group of patients with an eLASV at or above 38.5 on a pre-operative MRI.
89400292|NCT03534830||eLASV < 38.5|non-exposed group of patients with an eLASV less than 38.5 of pre-operative MRIs
89400293|NCT02915835|Active Comparator|riociguat|Riociguat 0.5 mg, 1 mg, 1.5 mg, 2 mg and 2.5 mg administered TID; dose titration starting with 1.0 mg (planned up-titration every 2 weeks, with possibility of dose reduction for tolerability; 0.5 mg is the lowest dose and 2.5 mg is the highest dose to be administered)
89400294|NCT02915835|Placebo Comparator|Placebo|Matching placebo tablets: 0.5 mg, 1 mg, 1.5 mg, 2 mg and 2.5 mg administered TID; dose titration starting with 1.0 mg matching placebo tablet.
89400295|NCT02194712||travellers|travellers with recent (<12 weeks) high risk water contact are included in the study and asked to provide samples for CAA testing
89400296|NCT01370616|Experimental|Ertapenem sodium|Participants received 1.0 g intravenous (IV) ertapenem sodium as a single daily dose at Hour 0 infused over a 30-minute interval , and IV piperacillin/tazobactam-matching placebo at Hours 8 and 16 infused over a 30-minute interval, for 5 to 28 days. Participants may be switched to Amoxicillin/clavulunate potassium 625 mg administered orally, twice daily, from Day 6 to Day 28
89400297|NCT01370616|Active Comparator|Piperacillin/tazobactam sodium|Participants received 4.5 g IV piperacillin/tazobactam at Hours 0, 8, and 16 infused over a 30-minute interval, for 5 to 28 days. Participants may be switched to Amoxicillin/clavulunate potassium 625 mg administered orally, twice daily, from Day 6 to Day 28
89400298|NCT02197052||Computer Based Survey Arm|Participants randomized to the computer based self-completed survey arm were issued a tablet computer to answer survey questions. All participants were encouraged to ask for technical assistance if needed at any point, and like in the face-to-face interviews, electronic survey could be re-initiated at the point of discontinuation after any interruption. Those in the tablet survey arm also could complete the survey in their preferred language and all were additionally given headsets so they could use audio assist with identical, pre-recorded questions in the selected language.
89400299|NCT02197052||Face-to-face interview arm|Participants randomized to this condition were interviewed in-person by a fully bilingual (English-Spanish), bi-cultural research assistant trained in cultural humility, standard research protocols and interviewing practices. Interviews were conducted in clinical rooms in respondent's preferred language, were easily interrupted for medical care, and the survey could be re-initiated at the point of discontinuation after any interruption. Participant responses during face-to-face interviews were recorded by the research assistant on paper and later recorded electronically.
89400300|NCT02196272|Experimental|Nurse-led email program through email|In addition to usual care and educational program, the intervention group will also receive email alerts and phone calls from the nurse care manager (NCM).
89400301|NCT02196272|No Intervention|Management of diabetic patients|Usual care, educational program and usual management of Diabetic patients
89400302|NCT02688881|Experimental|sirolimus|sirolimus 1mg will be administered orally daily
89004063|NCT03485209|Experimental|Part G: Tisotumab Vedotin Combination Therapy - Q2W Schedule|Tisotumab Vedotin + pembrolizumab + carboplatin. Tisotumab Vedotin and carboplatin given on Days 1, 15, and 29 of every 6-week cycle. Pembrolizumab given on Day 1 of every 6-week cycle.
89400303|NCT02196350|Experimental|Intervention A: Diet|Intervention A: One week of very low calorie diet, 12 weeks of low calorie diet; exercise according to the Dutch Norm for Healthy Behaviour (Nederlandse Norm Gezond Bewegen).
89400304|NCT02196350|Experimental|Intervention B: Exercise|"Intervention B: Combination of strength and endurance training, 3 x per week 60 minutes according to the Exercise Program Diabetes (Beweegprogramma Diabetes).~Healthy isocaloric diet."
89400305|NCT02196350|Experimental|Intervention C: Diet and Exercise|"Intervention C: one week very low calorie diet, followed by 12 weeks healthy isocaloric diet.~One week exercise according to the Dutch Norm for Healthy Behaviour (Nederlandse Norm Gezond Bewegen) followed by 12 weeks strength and endurance training (3 x per week 60 minutes) according to the Exercise Program Diabetes (Beweegprogramma Diabetes)"
89400306|NCT02196350|No Intervention|Control - Historical data|Historical data from the GPs Information System from 60 newly diagnosed type 2 diabetes patients in the last five years will be used as control.
89400307|NCT02197208|Active Comparator|Spontaneous NC|Timing by the onset of LH surge as shown daily blood monitoring of serum estradiol and LH levels
89400308|NCT02197208|Experimental|hCG induced NC|Timing by giving hCG when the dominant follicle reaches >=17mm in diameter on ultrasound monitoring
89400309|NCT02062476|Experimental|Treatment with Lactobacillus GG|extensively hydrolyzed casein formula containing LGG
89400310|NCT02062476|No Intervention|Children at diagnosis|
88813186|NCT02501928|Experimental|Fesoterodine PR 4 mg|Fesoterodine PR 4 mg for 28 or 40 weeks in open-label treatment period
89400311|NCT04243889|Experimental|NEOX Cord 1K applied fetoscopically|Patients intending to undergo open in-utero spina bifida repair, will be offered to be screened for an alternative minimally invasive approach. All eligible pregnant mothers' fetuses within the trial will receive NEOX Cord 1K® as a spinal cord cover to close the developmental defect. In some cases, at the discretion of the Neurosurgeon, NEOX Cord 1K® may be required to cover the skin. All eligible subjects meeting all inclusion criteria but none of the exclusion criteria may be enrolled.
89400312|NCT03630497|Experimental|Period 1 Single Dose SD1 (first dose)|"Period 1 Group SD1 a single IV infusion of first single dose of BN201 (n=6) or placebo (n=2)~Comparison of BN201 treatment with Placebo"
89400313|NCT03630497|Experimental|Period 1 Single Dose SD2 (second dose)|"Period 1 Group SD2 a single IV infusion of second single dose of BN201 (n=6) or placebo (n=2)~Comparison of BN201 treatment with Placebo"
88813187|NCT02501928|Experimental|Fesoterodine PR 8 mg|Fesoterodine PR 8 mg for 28 or 40 weeks in open-label treatment period
88813188|NCT02501928|Experimental|Fesoterodine BIC 2 mg|Fesoterodine BIC 2 mg for 28 weeks in open-label treatment period
88813189|NCT02501928|Experimental|Fesoterodine BIC 4 mg|Fesoterodine BIC 4 mg for 28 weeks in open-label treatment period
88813190|NCT01461863|Active Comparator|protein calorie supplement|250 gm daily of specially designed porridge plus standard multivitamin
88813191|NCT01461863|Placebo Comparator|Multivitamin|Standard multivitamin control
88813192|NCT00907088|Active Comparator|1|
88813193|NCT00907088|Experimental|2|
88813194|NCT04379804|Active Comparator|Lateral approach|Following the ligation of upper pole vessels, the thyroid lobe lobe was pulled anteromedially and the RLN was dissected within the carotid triangle at the level of inferior thyroid artery. The tissue between the carotid artery and the trachea was dissected gently parallel to the direction of the nerve until the nerve is identified visually and,or by hand held stimulation probe. After the identification of RLN, the vessels of inferior thyroid lobe was ligated. The nerve was dissected along its course to the entry point, and then the thyroid lobe was totally dissected from the trachea and the lobectomy was completed. If adverse EMG changes were encountered during lateral approach, traction was released immediately and waited for recovery.
88813195|NCT04379804|Active Comparator|Cranio-caudal approach|Following the ligation of upper pole vessels, the upper pole was retracted antero-medially to expose crico-pharyngeal muscle. The RLN nerve was identified at the point of entry both visually and with hand held stimulation probe. The RLN dissection was proceeded craniocaudally by the division of the suspensory ligaments of the berry through the level of inferior thyroid artery. After the identification and visualitzation of the RLN through its whole course, the medial and inferior vessels of the thyroid gland were dissected and ligated. Then, the lobe was dissected from the trachea and lobectomy was completed.
88876040|NCT04007640|Other|Obese volunteers with indication for hepatic MRI|2nd stage: To validate and assess pancreatic MRI sequences on obese volunteers with indication for hepatic MRI , in relation with acceptable resolution and field of view criteria applicable to the typical anteroposterior diameters found in obese persons. For Magnetic Resonance Elastography (MRE), the amplitude setting of the MRE transducer will be adapted to the size of obese patients, in addition to the aforementioned adjustments to spatial resolution and field of view sizes. The effect of frequency on MRE data quality will be investigated. The effects of respiratory motion will be investigated; indeed in obese patients respiration amplitude is typically low and this enables to acquire data in free breathing mode over long periods of time, which offers more possibilities (notably in terms of averaging, spatial resolution, mechanical wave sampling rate) than when constraining acquisition parameters with a maximum breath hold time of less than 20s.
88876041|NCT04007640|Other|Obese patient|3rd stage: To assess the relevance of MRI to diagnose specific pancreatic lesions in obese patients validated at the microscopic level. We will analyze MRI of obese patients and non-obese patients with a planned pancreatic surgery. It will be possible to compare imaging with histology performed on resected parenchyma
88876042|NCT04007640|Other|Non obese patients|3rd stage: To assess the relevance of MRI to diagnose specific pancreatic lesions in obese patients validated at the microscopic level. We will analyze MRI of obese patients and non-obese patients with a planned pancreatic surgery. It will be possible to compare imaging with histology performed on resected parenchyma
88876043|NCT04007640|Other|Overweight patients|3rd stage: To assess the relevance of MRI to diagnose specific pancreatic lesions in obese patients validated at the microscopic level. We will analyze MRI of obese patients and non-obese patients with a planned pancreatic surgery. It will be possible to compare imaging with histology performed on resected parenchyma
88876044|NCT03703206|Experimental|ACB + iPACK|Patients scheduled for TKA will be randomized to receive an adductor canal block with an additional ultrasound guided injection of local anesthetic between the popliteal artery and the capsule of the knee (iPACK).
88876045|NCT03703206|No Intervention|ACB w/o iPACK|Patients enrolled in this arm will receive the standard of care adductor canal block (ACB) prior to their total knee arthoplasty.
88876046|NCT03476928|Experimental|Treatment Group A1|4 treatment periods of 12 weeks, each separated by 1 bleeding episode
88876047|NCT03476928|Experimental|Treatment Group A2|2 treatment periods of 24 weeks, separated by 2 bleeding episodes
88876048|NCT03427320|Experimental|[131]I-IAZA whole body and SPECT imaging|Injection of a single dose of 185MBq ( range 150-220MBq) of [131]I-IAZA prior to whole body imaging acquisition at 0-1 hrs,1-3 hrs , 4-8 hrs,19-36 hrs,41-72 hrs and 6-8 days post-injection. SPECT CT of target lesion(s) will be acquired at 19-36 hrs post injection.
88876049|NCT03086616|Experimental|Newly Diagnosed DIPG|Convection Enhanced Delivery (CED) of Nanoliposomal irinotecan (nal-IRI): Nal-IRI given directly into the tumor using a method called CED to newly diagnosed DIPG subjects after completion of radiotherapy. CED will be performed every 4-8 weeks. Drug concentration will start at 20mg/ml and escalate up to 40 mg/ml concentration.
88876050|NCT03026712|Experimental|Real tDCS|
88876051|NCT03026712|Sham Comparator|Sham tDCS|
88876052|NCT02952924|Placebo Comparator|Parts 1a and 1b: SAD in Healthy Volunteers (Placebo)|In Part 1a, participants will receive a single oral dose of placebo matching to RO7049389 film coated tablet on Day 1. In Part 1b, minimum 8 participants from Part 1a will be selected and 2 of whom will receive another single dose of placebo matching to RO7049389 on Day 16 after eating the standard United States - Food and Drug Administration (US FDA)-recommended high-fat and high-calorie breakfast.
88876053|NCT02952924|Experimental|Parts 1a and 1b: SAD in Healthy Volunteers (RO7049389)|In Part 1a, participants will receive a single oral dose of RO7049389 film coated tablet on Day 1 in dose-escalation cohorts with a starting dose of 150 milligrams (mg). The doses for subsequent cohorts will be defined by an adaptive approach based on the safety and PK data in previously-dosed healthy volunteers. In Part 1b, minimum 8 participants from Part 1a will be selected and 6 of whom will receive another single dose of RO7049389 on Day 16 after eating the standard US FDA-recommended high-fat and high-calorie breakfast.
88876054|NCT02952924|Placebo Comparator|Part 1c: MAD in Healthy Volunteers (Placebo)|Participants will receive placebo matching to RO7049389 film coated tablet from Days 1 to 13 (either once a day [QD] or twice a day [BID]) and a single dose of placebo matching to RO7049389 film coated tablet in the morning of Day 14. Participants will also receive a single dose of midazolam solution (100 micrograms [mcg]) on Day -1 and Day 14.
88876055|NCT02952924|Experimental|Part 1c: MAD in Healthy Volunteers (RO7049389)|Participants will receive RO7049389 film coated tablet from Days 1 to 13 (either QD or BID; dose and regimen will be decided based on the available PK and safety data) and a single dose of RO7049389 film coated tablet in the morning of Day 14. Participants will also receive a single dose of midazolam solution (100 mcg) on Day -1 and Day 14.
88876056|NCT02952924|Placebo Comparator|Part 2: POM in Chronic HBV Participants (Placebo)|Participants will receive placebo matching to RO7049389 film coated tablet from Days 1 to 27 (either QD or BID) and a single dose of placebo matching to RO7049389 film coated tablet in the morning of Day 28.
88876057|NCT02952924|Experimental|Part 2: POM in Chronic HBV Participants (RO7049389)|Participants will receive RO7049389 film coated tablet from Days 1 to 27 (either QD or BID; dose and regimen will be decided based on the available PK and safety data) and a single dose of RO7049389 film coated tablet in the morning of Day 28.
88876058|NCT02952924|Experimental|Part 3: POM in NUC-Suppressed CHB Participants (Cohort A)|Participants will receive RO7049389 on top of a NUC for 48 weeks at a dose determined from Part 2. NUC therapy will be administered per local label or guidelines.
88876059|NCT02952924|Experimental|Part 3: POM in Treatment-Naive CHB Participants (Cohort B)|Participants will receive RO7049389 for 4 weeks, followed by RO7049389 with an added NUC for 44 weeks. RO7049389 will be administered at a dose determined from Part 2. NUC therapy will be administered per local label or guidelines.
89400314|NCT03630497|Experimental|Period 1 Single Dose SD3 (third dose)|"Period 1 Group SD3 a single IV infusion of third single dose of BN201 (n=6) or placebo (n=2)~Comparison of BN201 treatment with Placebo"
89400315|NCT03630497|Experimental|Period 1 Single Dose SD4 (fourth dose)|"Period 1 Group SD4 a single IV infusion of fourth single dose of BN201 (n=6) or placebo (n=2)~Comparison of BN201 treatment with Placebo"
89400316|NCT03630497|Experimental|Period 2 Single Dose SD1 (fifth dose)|"Period 2 Group SD1 a single IV infusion of fifth single dose of BN201 (n=6) or placebo (n=2)~Comparison of BN201 treatment with Placebo"
89400317|NCT03630497|Experimental|Period 2 Single Dose SD2 (sixth dose)|"Period 2 Group SD2 a single IV infusion of sixth single dose of BN201 (n=6) or placebo (n=2)~Comparison of BN201 treatment with Placebo"
89400318|NCT03630497|Experimental|Period 2 Single Dose SD3 (seventh dose)|"Period 2 Group SD3 a single IV infusion of seventh single dose of BN201 (n=6) or placebo (n=2)~Comparison of BN201 treatment with Placebo"
89400319|NCT03630497|Experimental|Period 2 Single Dose SD4 (Optional)|"(Optional) Period 2 Group SD4 a single IV infusion of eighth single dose of BN201 (n=6) or placebo (n=2)~Comparison of BN201 treatment with Placebo"
89400320|NCT03630497|Experimental|Multiple Dose MD1|"MD1 once daily IV infusions of first multiple dose BN201 (n=6) or placebo (n=2) for 5 consecutive days~Comparison of BN201 treatment with Placebo"
89400321|NCT03630497|Experimental|Multiple Dose MD2|"MD2 once daily IV infusions of second multiple dose BN201 (n=6) or placebo (n=2) for 5 consecutive days~Comparison of BN201 treatment with Placebo"
88876060|NCT02952924|Experimental|Part 3: POM in Treatment-Naive CHB Participants (Cohort C)|Participants will receive RO7049389 + NUC + Pegylated-Interferon (Peg-IFN) for 48 weeks. RO7049389 will be administered at a dose determined from Part 2. NUC and Peg-IFN therapy will be administered per local label or guidelines.
88876061|NCT02823834||PROFEMUR® Gladiator Plasma Femoral Stems|Single study group either previously implanted with the following combination of components: PROFEMUR® Gladiator Plasma Femoral Stems, PROCOTYL® L Beaded Acetabular Shells, Polyethylene or Ceramic Liners, and Metal or Ceramic Femoral Heads.
88876062|NCT02770638|Experimental|Scoop Stretcher|Participant wearing light sports clothing will start with forty five minutes laid supine on the scoop stretcher with 'triple immobilisation ' (rigid cervical collar, two headblocks and fastening straps). Followed by a forty five minute washout period (participant can mobilise freely). Participants will complete the observation with forty five minutes laid supine on the long back spinal board with 'triple immobilisation ' (rigid cervical collar, two headblocks and fastening straps).
88876063|NCT02770638|Active Comparator|Long Back Spinal Board|Participant wearing light sports clothing will start with forty five minutes laid supine on the long back spinal board with 'triple immobilisation ' (rigid cervical collar, two headblocks and fastening straps). Followed by a forty five minute washout period (participant can mobilise freely). Participants will complete the observation with forty five minutes laid supine on the scoop stretcher with 'triple immobilisation ' (rigid cervical collar, two headblocks and fastening straps).
88876064|NCT02509962|Experimental|Slow sodium tablets|Increased dietary salt intake
88876065|NCT02476500|Active Comparator|Experts|Surgically experienced gynecologists with a personal history of at least 30 LLETZ procedures will undergo a Video Training and subsequently will perform LLETZ on a Training model. Their performance will be scored by using a 23-item OSATS scheme. The exact time Frame for the OSATS-assessment is within 1 hour after the Video Training.
88876066|NCT02476500|Experimental|Novices|Medical students with no previous experience in gynecological surgery will undergo a Video Training and subsequently will perform LLETZ on a Training model. Their performance will be scored by using a 23-item OSATS scheme. The exact time Frame for the OSATS-assessment is within 1 hour after the Video Training.
88876067|NCT02199366||Cardiac magnetic resonance (cardiac MRI)|Participants will have a cardiac MRI at baseline and within 1 year after completion of radiation therapy.
88876068|NCT02021448|Other|Obesity: BMI > 30 kg/m2|Annual visits among 3 years. During each visit different testings are performed in order to detect an obesity-hypoventilation syndrome (OHS) Polygraphy/Polysomnography, Blood sampling, EKG, Lung function testing, Arterial blood gases, Thoracic radiography, Six-minute walk test, Respiratory questionnaires
88876069|NCT01415310||Geriatric psychiatry|Elderly patients with psychiatric disorders in geriatric psychiatry units
88876070|NCT00860730|Experimental|Perceval S|
88876071|NCT00677586|Experimental|1|simultaneous resection of liver metastasis and the rectal primary tumor
88876072|NCT00677586|Active Comparator|2|staged resection of the liver metastasis and the rectal primary tumor
88876073|NCT05454930|No Intervention|Typical Commute|Participants spend two hours in automobile, on heavily trafficked roadways, without active filtration of air pollutants
89400322|NCT02197286|Experimental|Vitamin D (cholecalciferol)|Intervention: Capsules containing the active ingredient, cholecalciferol @ 4,000 international units (IU). One capsule daily, oral administration for 10 weeks.
89400323|NCT02197286|Placebo Comparator|Placebo|"Daily matching placebo gelatin capsule (also contains microcrystalline cellulose).~Capsules are identical in size, color and taste to experimental drug."
88876074|NCT05454930|Other|Typical Commute, Filtered Air|Participants spend two hours in automobile, on heavily trafficked roadways, with active filtration of air pollutants
89189511|NCT05806073|Experimental|Therapeutic neck dissection|Patient underwent therapeutic neck dissection(level I-V) as initial treatment, along with the excision of the primary tumor
88876075|NCT05454774|Experimental|Arm of BBM 002|1×10^13 vg/kg, Single-dose treatment.
88876076|NCT05454540|Active Comparator|TRANSCRANIAL MAGNETIC STIMULATION|repetitive TRANSCRANIAL MAGNETIC STIMULATION (rTMS) will be applied over the precuneus. The rTMS treatment will consist of two phases: an intensive phase and a maintenance phase. The intensive phase will involve 2 weeks of treatment, 5 days per week (10 sessions, 1.600 pulses per day at 20 Hz for a total of 16.000 pulses). The maintenance phase will consist of 1 session of treatment every week for 50 weeks (80.000 pulses)
89189512|NCT05802420|Experimental|MRD-guided|Patients with elevated MRD from baseline at the first imaging assessment but without radiographic progressive disease will receive a later-line therapy.
89400324|NCT01378247|No Intervention|Treatment as usual|Pharmacological treatment, patient information and counselling according to international and national guidelines by health professionals specialized in heart failure.
89400325|NCT01378247|Experimental|Family Focused Nursing|Family Focused Nursing and treatment as usual
89400326|NCT03674775|Active Comparator|Intervention Group Providers|DART QI Program Participation
89400327|NCT03674775|No Intervention|Control Group Providers|Usual Care
89400328|NCT02197364||ILD, Other respiratory diseases, Healthy control group|"ILD: those with interstitial lung disease.~Other respiratory diseases: those with other respiratory disease including pulmonary tuberculosis, pneumonia, bronchiectasis, chronic obstructive pulmonary disease.~Healthy control group: those who is healthy."
89400329|NCT02197442|Experimental|Test|Valsartan Tablets USP 320 mg DIVIS
89400330|NCT02197442|Active Comparator|Reference|Diovan® (Valsartan) 320 Tablets
89400331|NCT03672669|Active Comparator|Advanced Platelet Rich Fibrin (A-PRF)|A-PRF was applied into the tooth socket after mandibular third molar surgery.
89400332|NCT03672669|Active Comparator|Leukocyte- and platelet-rich fibrin (L-PRF)|L-PRF was applied into the tooth socket after mandibular third molar surgery.
89400333|NCT02194790|Experimental|community-based Integrated CKD care|Standard CKD care + multidisciplinary team and home visit by community care team
88876077|NCT05454540|Sham Comparator|SHAM TRANSCRANIAL MAGNETIC STIMULATION|SHAM TMS will be applied over the precuneus. The sham rTMS treatment will consist of two phases: an intensive phase and a maintenance phase. The intensive phase will involve 2 weeks of treatment, 5 days per week (10 sessions, 1.600 pulses per day at 20 Hz for a total of 16.000 pulses). The maintenance phase will consist of 1 session of treatment every week for 50 weeks (80.000 pulses)
88876078|NCT05454384||Forensic Medicine|The group of consultation records requested from the Department of Forensic Medicine
88876079|NCT05454384||Oncology|The group of consultation records requested from the Department of Oncology
88876080|NCT05454384||Neonatology|The group of consultation records requested from the Department of Neonatology
88876081|NCT05454384||Otorhinolaryngology|The group of consultation records requested from the Department of Otorhinolaryngology
89400334|NCT02194790|No Intervention|Conventional CKD care|standard CKD care
89400335|NCT02062788|Experimental|ORS group|Oral rehydration solution (ORS) treated group
89400336|NCT02062788|No Intervention|Non-ORS group|Oral rehydration solution (ORS) untreated group
89400337|NCT02196428|Other|Telemonitoring and Teleconsultation|
89400338|NCT02061618|No Intervention|Usual Care|
88876082|NCT05454384||Neurology and Neurosurgery|The group of consultation records requested from the Department of Neurology and Neurosurgery
88876083|NCT05454384||Pediatrics|The group of consultation records requested from the Department of Pediatrics
88876084|NCT05454384||Emergency Medicine|The group of consultation records requested from the Department of Emergency Medicine
88876085|NCT05454384||Other Departments|The group of consultation records requested from the Departments such as Plastic and Reconstructive Surgery, Cardiovascular Surgery, Internal Medicine, Ophthalmology, Urology, Gastroenterology, Palliative Care, Pulmonology, Sleep Medicine, and Infectious Diseases.
88876086|NCT05453838|Other|New product - Original product|All subjects will receive first product A and then product B. In addition, the reference product will also be received (three times a glucose solution during the trial).
88876087|NCT05453838|Other|Original product - New product|All subjects will receive first product B and then product A. In addition, the reference product will also be received (three times a glucose solution during the trial).
88876088|NCT05453448|Experimental|tenofovir alafenamide|tenofovir alafenamide,Gilead Sciences,capsule,25 mg,once a day,Continuous use for 48 weeks.
88876089|NCT05453448|Experimental|entecavir|entecavir,Fujian cosunter pharmaceutical co.LTD,capsule,0.5mg,once a day,Continuous use for 48 weeks.
88876090|NCT05453214|Experimental|Fludrocortisone arm|10 hospitalised COVID-19 patients meeting inclusion criteria will receive fludrocortisone 0.1 mg tablets in addition to dexamethasone 6 mg / 24 hours and standard care
88876091|NCT05452980|Active Comparator|sleeve gastrectomy|For standard sleeve gastrectomy (SG), a sleeve was fashioned starting 4 cm proximal to the pylorus using serial applications of an 60 stapler over a 36Fr oro-gastric bougie. A security distance of 15 mm lateral to the esophagus is respected to reduce the risk of high leak.
88876092|NCT05452980|Experimental|SG with reestablishment of the acute angle of His|A sleeve was fashioned starting 4 cm proximal to the pylorus using serial applications of an 60 stapler over a 36Fr oro-gastric bougie. A security distance of 15 mm lateral to the esophagus is respected to reduce the risk of high leak. Three stitches using nonabsorbable 2-0 Prolone were performed to reestablish the acute angle of His: anterior gastric fundus with esophagus, gastric fundus with left crural diaphragm, posterior gastric fundus with left crural diaphragm.
88876093|NCT05451498|Experimental|Creatine Pre-Exercise|Consumes creatine within one hour before training and placebo within one hour after training
88876094|NCT05451498|Experimental|Creatine Post-Exercise|Consumes placebo within one hour before training and creatine within one hour after training
88876095|NCT05451498|Placebo Comparator|Placebo|Consumes placebo within one hour before training and placebo within one hour after training
89400339|NCT02061618|Experimental|Bollywood Dance Exercise|Participants in the Bollywood Dance Exercise group will take part in an 8-week dance intervention. The dance classes will take place 2 times per week, approximately 60 minutes per class, for 8 weeks total.
89400340|NCT04102280|Other|Hemodiafiltration HDF|Three consecutive treatment weeks and one follow-up week per patient. Each treatment week includes three hemodiafiltration HDF sessions and is assigned to one type of dialyzer: FX P600 Fresenius Medical Care, comparator Xevonta Hi 15 (B. Braun) and comparator Elisio 150H (Nipro)
89400341|NCT03560622|Active Comparator|ET cohort|Ten adults with refractory ET (ET cohort) will undergo multi-modality neuroimaging (structural imaging, diffusion tensor imaging (DTI), task-based functional MRI (t-fMRI), and resting state functional MRI (rs-fMRI)). In addition the ET cohort will also undergo imaging with the identical protocol immediately after and 24 hours after FUS-T.
89400342|NCT03560622|Experimental|control cohort|Twenty adult healthy controls (control cohort) will undergo multi-modality neuroimaging (structural imaging, diffusion tensor imaging (DTI), task-based functional MRI (t-fMRI), and resting state functional MRI (rs-fMRI)).
88876096|NCT05448300|Active Comparator|Water exchange|This group of participants receives water exchange colonoscopy with the computer-aided polyp detection system.
89400343|NCT03534674|Experimental|Intervention|Participants assigned to the intervention group will receive a single oral loading dose of 100,000 IU vitamin D3 on the day of hospital admission for aHSCT, with subsequent vitamin D3 2000 IU daily.
89400344|NCT03534674|No Intervention|Control|Participants assigned to the control group will be advised to take our current vitamin D regimen (2000 IU vitamin D3 daily).
89400345|NCT02063334|Active Comparator|Vitamin D3|2000 micrograms of vitamin D3 in two doses during one day
89400346|NCT02063334|Placebo Comparator|Placebo|Placebo in two doses during one day
89400347|NCT02031068|Active Comparator|Treatment-as-usual (TAU)|"The TAU program will be implemented after the initial assessment. It will consist of 2 components:~An initial education session by an occupational therapist, relating to outcome from concussion and managing symptoms~A school consultation to provide teacher education, recommend accommodations, and facilitate return to school"
89400348|NCT02031068|Experimental|Behavioral:Active Rehabilitation Program|"The active rehabilitation program will be implemented for a maximum of 6-8 weeks. Each participant will be followed by regular weekly telephone calls or personal follow-up relating to outcome from concussion and managing symptoms. The participant will receive TAU (above) in addition to the 4 components listed below:~Sub-maximal aerobic training for up to 15 minutes~Light coordination and sport-specific exercises for up to 10 minutes~Visualization and imagery techniques~Home program.~A physiotherapist will supervise the rehabilitation."
88876097|NCT05448300|Active Comparator|Air insufflation|This group of participants receives air insufflation colonoscopy the computer-aided polyp detection system.
89400349|NCT02063412||XELOX|Capecitabine (Xeloda) 1000mg/m2 po bid x 14 days Oxaliplatin (Eloxatin) 130mg/m2 iv over 2 hrs d1 Q3w x 8 cycles
89400350|NCT02063412||XP|Cisplatin (CDDP) 80 mg/m2 iv over 3 hrs d1 Capecitabine (Xeloda) 1000 mg/m2 po bid d1-14, Q3w
89400351|NCT02063412||FOLFOX|Leucovorin 200 mg/m2 iv over 2 hrs before 5-FU, d1 and d2 5-FU 400mg/m2 iv bolus and then 600 mg/m2 iv over 22 hrs, d1 and d2 Q2w
89400352|NCT02063412||FP|Cisplatin (CDDP) 100 mg/m2 iv d1 5-FU 1000 mg/m2/d civi d1-5, Q4w
89400353|NCT02194946|Active Comparator|CKD-related management group|"Patients in basic care group are provided with basic western medicine treatment according to Kidney Disease: Improving Global Outcomes(KDIGO) and The National Kidney Foundation Kidney Disease Outcomes Quality Initiative(KDOQI) guidelines but not prescribed any Chinese herbal medicine.~The basic western medicine treatment mainly includes dietary protein restriction(0.6g/kg·d, for Chinese), Blood pressure control, treating anemia with erythropoietin,treatment of abnormal calcium-phosphate metabolism, and treatment of fluid, electrolyte and acid-base disorders."
89400354|NCT02194946|Experimental|CM therapies group|Participants will receive CM therapies and CKD-related management concurrently. One or several the following CM patterns will be allowed: a. Chinese herbal formula via oral administration; b. Chinese patent medicine via oral administration; c. Chinese herbal formula via colonic administration; d. Chinese patent medicine via colonic administration.
89400355|NCT02063490|Experimental|Adherence support|"One-time preparatory intervention offering adherence prerequisites (knowledge, social support and skills)~+ One-year monthly individualised counselling sessions with a standardised intervention sheet listing the most prevalent problems with possible solutions"
89400356|NCT02063490|No Intervention|Control arm|Standard care
89400357|NCT01378169||SIRS patients|Every patient, without exclusion criteria, presenting with SIRS during an hospitalization in ICU.
88876098|NCT05354466|Experimental|Sugammadex as reversal agent|
88876099|NCT05354466|Active Comparator|Neostigmine as reversal agent|
89400358|NCT02062866|Active Comparator|Purse-String|Surgical wounds are healed via suturing.
89400359|NCT02062866|Active Comparator|Second Intent|Surgical wounds are allowed to heal without sutures.
89400360|NCT02195024|Active Comparator|cardiac MRI group|• All subjects of the MRI group will undergo a predefined series of magnetic resonance heart scans ≥ six (6) weeks after device exchange
89400361|NCT02195024|No Intervention|No MRI group|Patients that refuse to undergo cMRI for any reason but accept to attend the trial can be further observed according to the protocol
89400362|NCT02195102||transcatheter aortic valve Replacement|Patients with symptomatic severe aortic stenosis who are not candidates for surgical aortic valve replacement because of coexisting illnesses.
89400363|NCT03533972|Experimental|Test group|subjects will be provided with Ashwagandha capsules 500 mg twice daily, after meals with plain water for 1 month
89400364|NCT03533972|Placebo Comparator|Control group|subjects will be provided with placebo capsules.
89400365|NCT02916927|Experimental|Ketamine IV infusion|Ketamine 0.3 mg/kg in 100 mL normal saline minibag infused over 15 minutes. Placebo: 10 mL normal saline in syringe pushed over 1 minute. Masking: placebo normal saline minibags and placebo syringes will appear identical to the normal saline minibus and syringes with ketamine.
88876100|NCT05347602|Other|Phase 1: double-blinded placebo-controlled Supplement vs Placebo|Phase 1 (8 weeks): Supplement and Placebo groups ingested 3 oz of Supplement and Placebo per day respectively for the first four weeks as a loading dose, and then switched to 2 oz per day for weeks 5 - 8. This phase was double-blinded.
88876101|NCT05347602|No Intervention|Washout Phase|"Phase 2 (4 weeks): Both groups underwent a month-long wash out period, during which they did not ingest any of the Supplement or Placebo. This lasted from weeks 9-12. This phase was not double-blinded as all participants and the researchers were aware of the wash-out procedure."
89189513|NCT05802420|No Intervention|Routine treatment|Patients with elevated MRD from baseline at the first imaging assessment but without radiographic progressive disease will continued their current therapy.
89400366|NCT02916927|Active Comparator|Ketamine IV push|Ketamine 0.3 mg/kg in a syringe pushed over 1 minutes. Placebo: 100 mL normal saline minibag infused over 15 minutes. Masking: placebo normal saline minibags and placebo syringes will appear identical to the normal saline minibus and syringes with ketamine.
89400367|NCT02197598|Experimental|Selincro® (nalmefene) 18 mg, tablets|One tablet orally for 12 weeks on days when the patient perceives a risk of drinking alcohol, preferably 1-2 hours prior to the anticipated risk of drinking.
89400368|NCT02196662|Experimental|Treatment A|IBD98-M: mesalamine-sodium hyaluronate 200mg-28.75mg X2
89400369|NCT02196662|Experimental|Treatment B|IBD98-M without HA: Mesalamine 200mg X2
89400370|NCT02196662|Experimental|Treatment C|Delzicol 200 mg X2
89400371|NCT02195180|Experimental|standard of care combined with ERY001|standard of care = Gemcitabine or folfox
88876102|NCT05347602|Active Comparator|Phase 3: Supplement|Phase 3 (8 weeks): Both groups took the Supplement at 3 oz per day as a loading dose for four weeks (weeks 13 - 16), and then 2 oz per day for the final four weeks (weeks 17 - 20). This phase was open labeled, as all participants and the researchers were aware that all participants were ingesting the Supplement.
88876103|NCT05346432|Experimental|PS23|The PS23 belongs to Lactobacillus paracasei group, 2 caps daily use.
89400372|NCT02195180|Sham Comparator|standard of care alone|standard of care = Gemcitabine or folfox
89400373|NCT03672591||HFpEF patients|Patients suffering from heart failure with preserved ejection fraction
89400374|NCT03672591||Control group|Subjects without HFpEF who participated in different studies during which renal clearance examination has been performed with the constant infusion input clearance technique in our Clinical Research Center (clin. gov. numbers: NCT00627952, NCT01835678, NCT00136188, NCT00905528, NCT00160745)
89400375|NCT03623529|Experimental|Active Comparator: LJPC-501|LJPC-501 Angiotensin II Solution for infusion
89400376|NCT03623529|Placebo Comparator|Placebo Comparator: Placebo|0.9% sodium chloride solution
89400377|NCT02195258||salbutamol|
89400378|NCT02197676|Experimental|SGI-110|
89400379|NCT02916693|Experimental|Mirabegron|Participants take 25- 50mg oral Mirabegron tablets daily for 12 weeks,
88876104|NCT05346432|Experimental|heat-treated PS23|PS23 heat-treated, 2 caps daily use.
89400380|NCT02195336|Experimental|dMRT, Bevacizumab, Chemotherapy|"dMRT: Magnetic Resonance Tomograph, Baseline, day 8, day 28, day 92, progression/relapse.~Bevacizumab: 7.5mg/kg every 3 weeks for 3 cycles. Standard of care NSCLC first-line chemotherapy, doublets containing paclitaxel and carboplatin are preferred, every 3 weeks for 3 cycles.~Thereafter Bevacizumab 7.5mg/kg every 3 weeks until progression/relapse or unacceptable toxicity."
89400381|NCT03679065|Active Comparator|P (Paracetamol) group:(n=100)|
89400382|NCT03679065|Active Comparator|D (Dexamethasone) (Dex) group: (n=100)|
89400383|NCT03679065|Placebo Comparator|Placebo|
89400384|NCT02196740|Active Comparator|creosote|Creosote ，once，three weeks Triple Antibiotic Paste ，none
88876105|NCT05346432|Placebo Comparator|placebo|The placebo capsule contains microcrystalline cellulose, 2 caps daily use.
88876106|NCT05236140|Experimental|Perineal electrical stimulation (Stimulation group)|Perineal electrical stimulation will be performed in lithotomy position via a stimulation device (Enraf Nonius Myomed 632) with perineal surface electrodes. Perineal electrical stimulation will be performed three days a week, 20 minutes a day, a total of 24 sessions for 8 weeks. The stimulation parameters are frequency at 50 Hz, a 5-10s work-rest cycle, and a 300ms pulse width. The symmetric biphasic pulse wave could be delivered over a range of 1-100mA (according to the patient's discomfort level feedback). In this application, three surface electrodes which had 2 cm diameters were used; two electrodes symmetrically at the perianal region (medial to ischial tuberosity); and one electrode at the leg (ground-neutral electrode). Surface electrodes will be used individually for each patient. Perineal electrical stimulation sessions will be performed by an experienced urogynecology rehabilitation nurse.
89400385|NCT02196740|Experimental|Triple Antibiotic Paste|Triple Antibiotic Paste,once,three weeks creosote,none
89400386|NCT02197754|Experimental|Polyphenol Diet|After 2 weeks of adaptation to a controlled diet, polyphenol-rich fruits (berries and apple) and beverages (tea) will be fed (8 wks) as part of a controlled diet (10 wks total).
89400387|NCT02195492||Synvisc®|
89400388|NCT02195570|Experimental|QSN with CM (QSN-CM).|Women will receive standard of care Quit Smoking Now tobacco education and support plus prize-based contingency management. Their smoking status will be monitored from quit date through 3 months postpartum via carbon monoxide and salivary cotinine levels. Women will earn chances to win prizes each time they test negative for smoking according to biochemical measures.
89400389|NCT02195570|Active Comparator|QSN Only|Women receive the standard of care Quit Smoking Now tobacco education and support only. Smoking status will be monitored from quit date through 3 months postpartum via carbon monoxide and salivary cotinine levels. Incentives are given for providing breath and salivary samples but are not contingent on smoking status.
88876107|NCT05236140|No Intervention|Control group|Subjects in the control group will go through baseline assessment and will not receive treatment or instructions to perform pelvic floor exercises at home. After 8 weeks they will be submitted to the final assessment. After the final evaluation, they will be invited to start treatment in the urogynecological rehabilitation unit.
89004064|NCT03472924|Experimental|Kinesio Tape|Kinesiotaping of the peroneus longus according to the guidelines provided by the Kinesio Taping Association (Kase, K. 2016) followed by standardized set of therapeutic exercises that are commonly implemented in ankle rehabilitation programs.
89400390|NCT03678987||SSc on MMF|"Patients with systemic sclerosis using mycophenolate mofetil (mycophenolic acid, MMF) since >3 months.~During a 6 hour time period, P-MPA concentration will be measured 4 times."
89400391|NCT02197832|Experimental|EA|in the cycle immediately preceding the scheduled FET treatment, an endometrial biopsy would be arranged on day 21-23 of the menstrual cycles and they will be instructed to use non-hormonal means of contraception during that cycle.
89400392|NCT02197832|Placebo Comparator|Control|The procedure was performed in a standard approach using a Pipelle catheter (Pipelle de Cornier, Laboratoire C.C.D., France). The pipelle catheter was introduced through the cervix but not into the uterine cavity, only entering the endocervical canal as control.
89400393|NCT03672513|Placebo Comparator|Placebo Supplemented Group|Placebo control
89400394|NCT03672513|Experimental|Magnesium Supplemented Group|Magnesium Group
89400395|NCT03672513|Experimental|Zinc Supplemented Group|Zinc Group
89400396|NCT02195648|Experimental|Suboccipital inhibition|The intervention group will receive a session of 20 minutes (5 minutes for the patient's reception, 10 for treatment and the following 5 minutes for rest and hemodynamic stabilization), twice a week for 4 weeks. The intervention will consist of suboccipital muscle inhibition and interferential current on the occipital muscles.
89400397|NCT02195648|No Intervention|Control|No intervention will be done to the participants during the study. After study completion, the participants will be offered to receive the therapy.
89400398|NCT02919345|Experimental|Dapagliflozin|Dapagliflozin 10 mg in addition to Metformin 1500 mg
88876108|NCT05144490|Experimental|Bodyweight Exercise|"A standardized 11-minute bodyweight exercise session that involves a 1-minute warm-up followed by 5, 1-minute bouts of exercise at a self-selected challenging pace, interspersed with 1-minute periods of low-intensity exercise for recovery."
89400399|NCT02919345|Active Comparator|Glibenclamide|Glibenclamide 5mg in addition to Metformin 1500 mg
89400400|NCT02195726|Sham Comparator|Sham remote ischemic preconditioning'|In the control group Sham remote ischemic preconditioning will be performed with inflation of 10 mmHg more than baseline
89400401|NCT02195726|Experimental|Remote ischemic preconditioning|"In the experimental group, patients will receive for four times 5-minute inflations of a blood pressure cuff to 200 mmHg around the upper non dominant arm (or if systolic pressure is more than 150 mmHg, inflation will reach 50 mmHg upper than baseline), followed by 5-minute intervals of reperfusion.~In subjects presenting with BMI > 30 a dedicated blood pressure cuff for obese patients will be used. Coronary angiography will be performed in 45 minutes from last inflation"
89400402|NCT02919189|Experimental|Visible light exposure Red 30 lux|The participants will be exposed to red fluorescent light at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
88876109|NCT05144490|No Intervention|Non-Exercise Control|An 11-minute period of quiet sitting.
88876110|NCT05137704||Participant With ADHD|The record available for ADHD participants in primary care-based electronic medical records in the CPRD database linked to secondary care based episodic claims data available in HES database will be assessed.
88876111|NCT04971096|Experimental|PS23|The PS23 belongs to Lactobacillus paracasei group, 2 caps daily use.
88876112|NCT04971096|Experimental|heat-treated PS23|PS23 heat-treated, 2 caps daily use.
88876113|NCT04971096|Placebo Comparator|placebo|The placebo capsule contains microcrystalline cellulose, 2 caps daily use.
88876114|NCT04971096|No Intervention|Healthy Control|No intervention
88876115|NCT04880616|Experimental|Sequence 1|In treatment period 1 participants will receive increasing doses of NBI-827104 for 28 days. After a 14-day washout period, participants will receive matching placebo for 28 days in treatment period 2.
88876116|NCT04880616|Experimental|Sequence 2|In treatment period 1 participants will receive matching placebo for 28 days. After a 14-day washout period, participants will receive increasing doses of NBI-827104 for 28 days in treatment period 2.
88876117|NCT04720404|Experimental|Mindfulness Based Stress Reduction program|Healthcare workers in the MBSR arm will be invited to participate in an adapted online MBSR program added to support as usual
88876118|NCT04720404|Active Comparator|Daily self-help mindfulness exercises via YouTube-channel|Healthcare workers in the self-help arm will be invited to follow a self-help program with mindfulness/compassion exercises of 30 minutes per day via YouTube channel
88876119|NCT04683900|Experimental|Standard of Care + Mediterranean Diet|Participants will be given standard of care for constipation (handout) plus individualized diet education on the Mediterranean diet and instructed to follow the diet during the 8-week intervention period. Diet education will be administered by a study dietitian and followed with weekly phone calls to ensure compliance, improve adherence to the diet and monitor for adverse events.
88876120|NCT04683900|Active Comparator|Standard of Care|Participants will be given standard of care for constipation (handout) to utilize during the 8-week intervention period. A study dietitian will follow up with weekly phone calls to support adherence and monitor for adverse events.
88876121|NCT04608396|Experimental|AXS-05|
88876122|NCT04608396|Placebo Comparator|Placebo|
88876123|NCT04561128|Experimental|SHR-1819|Experimental: SHR-1819
88876124|NCT04561128|Placebo Comparator|Placebo|Placebo comparator: placebo
88876125|NCT04095624|Experimental|Opioid Taper Group|Patients randomized to the taper group will have baseline pain score, opioid medication use, and patient reported outcomes 4-6 weeks prior to elective thoracolumbar, lumbar, or lumbosacral spinal fusion surgery. They will receive a scheduled tapering protocol, with a goal of 10-15% reduction in their weekly opioid use, along with weekly phone calls from a study coordinator assessing their ability to taper and pain scores. After surgery, they will receive 6 weekly phone calls from the coordinator, to assess their postoperative opioid medication use and pain scores. At the 6th week phone call, and 3 month and 6 month clinic postoperative clinic visits, they will also repeat patient reported outcome measures.
88876126|NCT04095624|Active Comparator|Control Group|Patients randomized to the control group will have baseline pain score, opioid medication use, and patient reported outcomes 4-6 weeks prior to elective thoracolumbar, lumbar, or lumbosacral spinal fusion surgery. They will receive no recommendation or guidance in their preoperative opioid pain medication use, but will received weekly phone calls from a study coordinator assessing their preoperative pain scores. After surgery, they will receive 6 weekly phone calls from the coordinator, to assess their postoperative opioid medication use and pain scores. At the 6th week phone call, and 3 month and 6 month clinic postoperative clinic visits, they will also repeat patient reported outcome measures.
88876127|NCT03651336|Other|Single-arm longterm follow-up ARGOS-IO Sensor Pressure System|The ARGOS-IO sensor was already implanted in a previous study as ARGOS-01 or ARGOS-02.
89400403|NCT02919189|Experimental|Visible light exposure Red 120 lux|The participants will be exposed to red fluorescent light at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
89400404|NCT02919189|Experimental|Visible light exposure Blue 30 lux|The participants will be exposed to blue fluorescent light at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
89400405|NCT02919189|Experimental|Visible light exposure Blue 120 lux|The participants will be exposed to blue fluorescent light at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
88876128|NCT03395340|Experimental|Ruxolitinib cream|Investigational cream to 1 location; vehicle cream to 2nd location
88876129|NCT03395340|Placebo Comparator|Vehicle cream|Investigational cream to 1 location; vehicle cream to 2nd location
88876130|NCT03341676|Experimental|Dexamethasone|8ml IV 3.3mg/mL dexamethasone
88876131|NCT03341676|Placebo Comparator|Placebo|8ml IV 0.9% w/v saline
89400406|NCT02919189|Experimental|Visible light exposure Green 30 lux|The participants will be exposed to green fluorescent light at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
89400407|NCT02919189|Experimental|Visible light exposure Green 120 lux|The participants will be exposed to green fluorescent light at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
89400408|NCT02919189|Experimental|Visible light exposure White 30 lux|The participants will be exposed to white fluorescent light at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
89400409|NCT02919189|Experimental|Visible light exposure White 120 lux|The participants will be exposed to white fluorescent light at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
89400410|NCT02195804|Experimental|Ranitidine HCL ODT Vanilla-Mint|
89400411|NCT02195804|Experimental|Ranitidine HCL ODT RM Vanilla-Mint|
89400412|NCT02195804|Active Comparator|Ranitidine HCL|Maximum Strength ZANTAC 150®
89400413|NCT03672435||proparacaine|Received topical proparacaine 0.5% with routine antibiotic-steroid ointment in operative eye(s) following strabismus surgery
89400414|NCT03672435||No proparacaine|Received no topical proparacaine 0.5% but did receive routine antibiotic-steroid ointment in the operative eye(s) following strabismus surgery
89400415|NCT03534128|Experimental|Spatial navigation evaluation|
89400416|NCT03674463|Experimental|LCAR-B4822M treatment group|r/r multiple myeloma patients will be treated with LCAR-B4822M CAR-T cells with a escalation approach, 0.5x10^6- 2.0x10^6 CAR-T cells/kg.
89400417|NCT03674385|Experimental|vitamin E group|30 patient
89400418|NCT03674385|Active Comparator|control group|clomiphene
88876132|NCT03121716|Experimental|SHR-1210, gemcitabine and cis-platinum|Subjects receive SHR-1210 200mg (Day 1) and gemcitabine 1000mg/m2 (Day 1 and Day 8)and cis-platinum 80mg/m2 (Day 1) of each 21-day cycle for at most 6 cycles, followed by SHR-1210 200mg every three weeks (Q3W) maintenance for the remainder of the study or until documented PD.
88876133|NCT02714634|Experimental|methotrexate + targeted therapy group|"Methotrexate or leflunomide +~targeted therapy chosen by investigator"
88876134|NCT02714634|Active Comparator|Triple therapy|Triple therapy using 3 conventional disease modifying drugs (DMARDs)
88876135|NCT00553800|Experimental|Bevacizumab & Erlotinib|bevacizumab 15 mg/kg intravenous every three weeks and erlotinib pill 150 mg by mouth every day
88876136|NCT02747628|Placebo Comparator|C group, (n=20)|C group (n=20) (placebo group) each patient received transdermal placebo patch, identical placebo patches custom-made by 1-800-Patches (Salt Lake City, UT) placed 2 hours preoperatively for acute postoperative pain after laparoscopic cholecystectomy.
88876137|NCT02747628|Active Comparator|TDN group, (n=20)|TDN group (n=20) each patient received transdermal therapeutic system- nicotine (15 mg/16 h),Nicorette® invisi 15mg patch releasing 15mg of nicotine over 16h, produced by Lohmann Therapie-System, Germany placed 2 hours preoperatively for acute postoperative pain after laparoscopic cholecystectomy.
88876138|NCT02747628|Active Comparator|TDM group, (n=20)|TDM group (n=20) each patient received transdermal therapeutic system- melatonin (7 mg/8h),melatonin sleep patch from Respro Labs ™ containing 7 mg of melatonin placed 2 hours preoperatively for acute postoperative pain after laparoscopic cholecystectomy.
88876139|NCT02748096|Experimental|Patient Specific Instrumentation|Patients undergoing unicompartmental knee replacement with the additional aid of patient specific instrumentation.
89400419|NCT02197910|Active Comparator|High content of wheat bioactive peptides|100 gr pasta/day, containing around 15 mg bioactive peptides (High content of wheat bioactive peptides)
89400420|NCT02197910|Placebo Comparator|Low dose of wheat bioactive peptides|100 gr pasta/day, containing around 3 mg bioactive peptides
89400421|NCT02574455|Experimental|Sacituzumab Govitecan|Participants will receive sacituzumab govitecan on Days 1 and 8 of a 21-day treatment cycle for up to 29.6 months. Participants will continue treatment until progression of disease requiring treatment discontinuation or occurrence of unacceptable adverse events (AEs).
89400422|NCT02574455|Active Comparator|Treatment of Physician's Choice (TPC)|Participants will receive TPC (ie, eribulin, capecitabine, gemcitabine, or vinorelbine), administered as a single-agent regimen that is selected by the investigator before participant randomization. Participants will continue treatment until progression of disease requiring treatment discontinuation or occurrence of unacceptable AEs.
89400423|NCT02196896|Experimental|deprexis®|Patients in this arm use deprexis® as an additional treatment during their inpatient stay and as an aftercare intervention.
89400424|NCT02196896|Placebo Comparator|Information|Patients in this arm receive online information about depression as a placebo comparator in addition to their treatment during their inpatient stay and as an aftercare intervention.
89400425|NCT02197988|Active Comparator|Transversus Abdominis Plane Block|Transversus Abdominis Plane Block Exparel 1.33% (20ml Volume)
89400426|NCT02197988|Active Comparator|Thoracic Epidural Anesthesia|Thoracic Epidural Anesthesia 0.125% bupivicaine with 2 mcg/ml Fentanyl
89400427|NCT03672357|Experimental|Laparoscopic liver resection|Laparoscopic hepatectomy
89400428|NCT03672357|Other|Open liver resection|Open hepatectomy
89400429|NCT02795832|Experimental|Cohort 1a|ZPL-5212372 1% w/w Ointment BID
89400430|NCT02795832|Placebo Comparator|Cohort 1b|Placebo Ointment BID
89400431|NCT02795832|Experimental|Cohort 2a|ZPL-5212372 1% w/w Ointment BID
89400432|NCT02795832|Placebo Comparator|Cohort 2b|Placebo Ointment BID
89400433|NCT02795832|Experimental|Cohort 3a|ZPL-5212372 1% w/w OIntment BID
88876140|NCT02748096|Active Comparator|Conventional Instrumentation|Patients undergoing unicompartmental knee replacement using standard instrumentation.
88876141|NCT02754570|Experimental|Pilocarpine group|Subjects with open-angle glaucoma and ocular hypertension that are currently taking latanoprost
89011502|NCT04529200|Experimental|1. Comprehensive fall prevention protocol group (CARE)|every week protocol change for every patient according to 1 repetition maximum
89400434|NCT02795832|Placebo Comparator|Cohort 3b|Placebo Ointment BID
89400435|NCT02196974|Experimental|cryobiopsy|
89400436|NCT03678909||Hypoplastic Left Heart Disease|Patients with congenital hypoplastic left heart disease who will undergo surgical palliation with Norwood procedure or DKS or Damus-Kaye-Stansel procedure
89400437|NCT02201030|Experimental|NBP606|13-valent pneumococcal conjugate vaccine
89400438|NCT02201030|Active Comparator|Prevnar13|13-valent pneumococcal conjugate vaccine
89400439|NCT03674073|Experimental|Microwave Ablation + Neoantigen Vaccines|The HCC patients will be treated firstly by Microwave Ablation, and then treated by courses of Neoantigen Vaccines.
89400440|NCT03674073|Active Comparator|Microwave Ablation|The HCC patients will be treated only by Microwave Ablation.No vaccine will be used.
89400441|NCT02198534||ophthalomogically normal subjects|
89400442|NCT03678597|Experimental|Handling Medium Supplemented with Latrunculin B|
89400443|NCT03678597|No Intervention|handling Medium as it is.|
89400444|NCT02198066|Other|Dry Sterile Dressing|Subjects in this study arm received a dry sterile dressing (Primapore®, Smith & Nephew), a one-piece, peel-and-stick, non-transparent dressing. This dressing is the standard of care at the study facility for this population and was left in place for either 24 to 48 hours.
89400445|NCT02198066|Active Comparator|Metallic Silver Dressing|Subjects in this arm received a metallic silver dressing (Acticoat Post-Op®, Smith & Nephew), a one-piece, peel-and-stick and non-transparent dressing. This dressing is an absorbent postoperative dressing consisting of a nanocrystalline silver-coated polyurethane layer, a white polyurethane foam and an adhesive coated waterproof polyurethane film layer. Acticoat Post-Op may be left in place over a wound for up to 7 days. The manufacturers note that the product should not be used in patients with known silver allergies and that it may cause transient discoloration of the skin.
89400446|NCT02198066|Active Comparator|Ionic Silver Dressing|Subjects in this arm received an ionic silver dressing (Dermanet Ag®, DeRoyal), a semi-transparent dressing that includes silver, alginate, and maltodextrin. The dressing was cut to fit the incision and then covered with a transparent dressing (Transseal®, DeRoyal). This dressing should not be used on patients with known sensitivity to alginates (a seaweed based component).
89400447|NCT03673995|Experimental|Myo-inositol+L-tyrosine|One sachet per day containing 2000 mg myo-inositol, 500 mg L-tyrosine, 40 mcg chromium picolinate, 55 mcg selenium, 200 mcg folic acid for improving PCOS symptoms.
89400448|NCT03673917|Experimental|Educational video|The educational video on skin cancer for cosmetologists
89400449|NCT03673917|Active Comparator|Control video|A publicly accessible healthy lifestyle video on YouTube, which did not contain any information on skin cancer
89400450|NCT02198612|Other|Manual puncture point compression|Manual puncture point compression following a diagnostic or therapeutic procedure by endovascular technique involving retrograde femoral puncture point with 5F guide catheter
89400451|NCT01378091|Experimental|Lenalidomide, Docetaxel, Prednisone|Subjects will receive this drug combination during a treatment phase and an extension phase.
89400452|NCT02794974|Experimental|with perivascular block|1. ultrasound-guided intermediate cervical plexus block (20ml ropivacaine 0.75%) 2. facial nerve block (cervical branch) (5ml prilocaine 1%) 3. perivascular block (5ml prilocaine 1%)
88876142|NCT02756910||Surgery Patients >1.5 Hrs|Use esophageal catheter for core temperature monitoring, Foley catheter for bladder temperature monitoring, and iThermonitor (WT701) for axillary temperature monitoring
88876143|NCT02760264|Experimental|Dose Level Group 1|Participants enrolled in Dose Level Group 1 will receive vamorolone 0.25 mg/kg/day.
89400453|NCT02794974|Experimental|without perivascular block|1. ultrasound-guided intermediate cervical plexus block (20ml ropivacaine 0.75%) 2. facial nerve block (cervical branch) (5ml prilocaine 1%)
89400454|NCT03673839|Active Comparator|Animal proteins (crossover)|
88876144|NCT02760264|Experimental|Dose Level Group 2|Participants enrolled in Dose Level Group 2 will receive vamorolone 0.75 mg/kg/day.
88876145|NCT02760264|Experimental|Dose Level Group 3|Participants enrolled in Dose Level Group 3 will receive vamorolone 2.0 mg/kg/day.
88876146|NCT02760264|Experimental|Dose Level Group 4|Participants enrolled in Dose Level Group 4 will receive vamorolone 6.0 mg/kg/day.
88876147|NCT02764164|Experimental|Intervention Active tDCS|Affected subjects receiving up to 2 milliamps (mA) active tDCS, open label
88876148|NCT02767128|Experimental|Fer-In-Sol Orally|Patients will receive A single oral dose of Fer-In-Sol at 3 mg Fe/kg body weight (bw).
89400455|NCT03673839|Experimental|Plant-based protein blends type 1 (crossover)|
89400456|NCT03673839|Experimental|Plant-based protein blends type 2 (crossover)|
89400457|NCT03673839|Experimental|Plant-based protein blends type 3 (crossover)|
89400458|NCT02201186|Experimental|manuka honey enema treatment|Study patients diagnosed with acute pouchitis after bowel surgery for ulcerative colitis will perform manuka honey enemas twice a day for 30 days.
89400459|NCT01384097||Conventional care|patients treated by conventional haemodynamic care intraoperatively
89400460|NCT01384097||Haemodynamic algorithm|patients treated within a goal-directed haemodynamic algorithm intraoperatively
88876149|NCT02767128|Experimental|Shohl's solution followed by Fer-In-Sol Orally|Patients will receive a single oral dose of Oracit Shohl's solution 0.67 mEq/L (0.7ml/kg bw) followed after 10 minutes by Fer-In-Sol at 3 mg Fe/kg bw.
89400461|NCT02063568|Active Comparator|Low dose oxytocin infusion|oxytocin will be administered as an intravenous infusion at a rate of 0.33 units/min starting after fetal delivery upon umbilical cord clamping and continuing for a total of 30 minutes
89004065|NCT03472924|No Intervention|Control|Baseline measures followed by standardized set of therapeutic exercises that are commonly implemented in ankle rehabilitation programs, but no use of kinesiotape.
88876150|NCT02767128|Experimental|Triferic Orally|Patients will receive a single oral dose of Triferic at 3 mg Fe/kg bw.
88876151|NCT02767128|Experimental|Shohl's solution followed by Triferic Orally|Patients will receive a single oral dose of Oracit Shohl's solution 0.67 mEq/L (0.7 ml/kg bw) administered 10 minutes prior to a single oral dose of Triferic at 3 mg Fe/kg bw.
88876152|NCT02767128|Experimental|Shohl's solution followed immediately by Triferic|Patients will receive a single oral dose of Oracit Shohl's solution 0.67 mEq/L (0.7 ml/kg bw) followed immediately by a single oral dose of Triferic at 3 mg Fe/kg bw.
89004066|NCT03468426|Experimental|BI 836880 + ezabenlimab|
89011503|NCT04529200|Active Comparator|2. Conventional balance training group|conventional protocol commonly used for rehabilitation
88876153|NCT02767128|Experimental|Triferic via IV|Patients will receive IV Triferic iron 6.6 mg diluted in an appropriate amount of D5W administered as a 120 mL infusion intravenously for 4 hours.
88876154|NCT02767128|No Intervention|Baseline|baseline serum iron profile will be determined for each patient. no study drug will be administered.
88876155|NCT02769702|Experimental|Intervention|Acthar 80 IU SC twice w eek
88876156|NCT02770014|Experimental|EGFR mutation Positive, Treatment With Erlotinib|Eligible EGFR mutations include exon 19 deletion or exon 21 L858R mutation. Erlotinib will be initially dosed at a pre-determine dosage daily, and it will be given on a 6-week cycle with treatment administered on an outpatient basis
88876157|NCT02771340|Experimental|ICON-1 0.3 mg Singe Dose|Patients will receive a single intravitreal dose of ICON-1 0.3 mg
89189514|NCT05802407|Experimental|MRD-guided|Patients with elevated MRD from baseline at the first imaging assessment but without radiographic progressive disease will receive a later-line therapy.
89189515|NCT05802407|No Intervention|Routine treatment|Patients with elevated MRD from baseline at the first imaging assessment but without radiographic progressive disease will continued their current therapy.
89189516|NCT05802394|Experimental|MRD-guided|Patients with elevated MRD from baseline at the first imaging assessment but without radiographic progressive disease will receive a later-line therapy.
89189517|NCT05802394|No Intervention|Routine treatment|Patients with elevated MRD from baseline at the first imaging assessment but without radiographic progressive disease will continued their current therapy.
89189518|NCT05797272|Experimental|Fetuses with BHFS|Fetuses of pregnant women confirmed with BHFS
89189519|NCT05783050|Active Comparator|Wei Nasal Jet Tube Group (Group W)|After induction of anesthesia, the Wei Nasal Jet Tube was placed in the patients.
88876158|NCT02771340|Experimental|ICON-1 0.3 mg Repeat Dosing|Patients will receive two intravitreal doses of ICON-1 0.3 mg, one week apart
89189520|NCT05783050|Active Comparator|Nasal Cannula Oxygen Support Group (Group N)|After the induction of anesthesia, the Nasal Cannula Oxygen Cannula was placed in the patients.
89189521|NCT05778786|Experimental|Test/Control|Eligible subjects who are habitual soft contact lens wearers will be randomized into the Test/Control sequence, to wear bilaterally two different study lenses, one at a time, for a minimum of 8 hours per day for at least 5 days during each wear period, over two wear periods (test then control) with a washout period of 7+/-2 days duration between wear periods.
89189522|NCT05778786|Experimental|Control/Test|Eligible subjects who are habitual soft contact lens wearers will be randomized into the Control/Test sequence, to wear bilaterally two different study lenses, one at a time, for a minimum of 8 hours per day for at least 5 days during each wear period, over two wear periods (control then test) with a washout period of 7+/-2 days duration between wear periods.
89189523|NCT05773456|Experimental|Sushi and wakame salad|231 microgram of iodine per serving
89189524|NCT05773456|Active Comparator|Potassium iodide supplement|225 microgram of iodine per tablet
89189525|NCT05767840|Experimental|mgGap-IG|MhGap-IG intervention to be delivered to depression and self-harm cohorts
89189526|NCT05809375|Active Comparator|Coping Skills Training Group|Coping skills training (CST) will be given to the intervention group in line with the goals of the International Headache Society. Of the participants included in this study, the ones in the intervention group will be evaluated before and after the intervention.
89189527|NCT05809375|No Intervention|Control Grup|The participants in the control group will be evaluated at the beginning and after four weeks. CST will be given to the control group participants, if they want to, after the final evaluation.
89189528|NCT05766163|Active Comparator|DaVinci system|Robot-assisted radical prostatectomy is carried out through daVinci platform.
89189529|NCT05766163|Experimental|Hugo system|Robot-assisted radical prostatectomy is carried out through Hugo platform.
89189530|NCT05766163|Experimental|Versius system|Robot-assisted radical prostatectomy is carried out through Versius platform.
89189531|NCT05764876|Active Comparator|Azithromycin|Participants in the control arm will receive standard treatment for yaws which azithromycin .
89189532|NCT05764876|Experimental|Linezolid|Participants in the experimental arm will receive oral linezolid treatment.
88876159|NCT02771340|Experimental|ICON-1 0.6 mg Repeat Dosing|Patients will receive two intravitreal doses of ICON-1 0.6 mg, one week apart
88876160|NCT02771574|Experimental|Part A: Lyo avexitide 0.05 mg/kg|Participants will receive lyophilized avexitide (Lyo avexitide) twice daily for 3 days
88876161|NCT02771574|Experimental|Part A: Lyo avexitide 0.15 mg/kg|Participants will receive Lyo avexitide twice daily for 3 days
88876162|NCT02771574|Experimental|Part A: Lyo avexitide 0.35 mg/kg|Participants will receive Lyo avexitide twice daily for 3 days
88876163|NCT02771574|Experimental|Part A: Lyo avexitide 0.46 mg/kg|Participants will receive Lyo avexitide twice daily for 3 days
88876164|NCT02771574|Experimental|Part B: Liq avexitide 0.38 (±0.03) mg/kg|Participants will receive liquid avexitide (Liq avexitide) twice daily for 3 days
88876165|NCT02772432|Experimental|3RP treatment|An adapted version of the Relaxation Response Resiliency Program (3RP) for parents of children with specific learning disabilities. The adapted program incorporates the three prongs of the 3RP: RR elicitation, stress awareness, and adaptive strategies.
88876166|NCT02772432|Active Comparator|Waitlist control|An adapted version of the Relaxation Response Resiliency Program (3RP) for parents of children with specific learning disabilities.
88876167|NCT02772666|Experimental|O-Glass|All study participants who were diagnosed Relative Afferent Pupillary defect(RAPD) positive according to expert specialist investigations, were enrolled in this study. They were all examined with new device named O-Glass.
89189533|NCT05748678|Experimental|Use of the compression apparel|All participants
89189534|NCT05747118||Intervention|People with type 2 diabetes or MODY in the training group
89189535|NCT05747118||Control|People with type 2 diabetes or MODY in the control group
89189536|NCT05741190||myope|Patients with myopia
89189537|NCT05741190||Hypermetrope|Patients with hypermetropia
89189538|NCT05741190||Astigmatic|Patients with Astigmatism
89189539|NCT05723458|Active Comparator|Cream containing Turmeric, Black Seeds, Flaxseed, and Medicago Sativa|
89189540|NCT05723458|Placebo Comparator|Placebo cream containing vaseline|
89004067|NCT03464305|Experimental|Aspirin|Patients treated with acetylsalicylic acid 80 mg once daily for 5 years. Patients will be stratified according to the admission of adjuvant chemotherapy.
89400462|NCT02063568|Active Comparator|High dose oxytocin infusion|oxytocin will be administered as an intravenous infusion at a rate of 1.33 units/min starting after fetal delivery upon umbilical cord clamping and continuing for a total of 30 minutes
89400463|NCT02257502|Experimental|aflibercept|intravitreal injection of aflibercept (EYLEA)
89400464|NCT01380119|Experimental|V7|Oral pill containing heat-killed Mycobacterium vaccae
89400465|NCT01380119|Placebo Comparator|Placebo pill|Identically appearing placebo pills
89400466|NCT02063646|Placebo Comparator|Placebo|"The placebo is a capsule with same appearance and organoleptic properties as the active product, containing no active component.~Dose: 2 capsules per day, one capsule at least 1 hour after breakfast and one capsule at least one hour after dinner, with a glass of water."
89400467|NCT02063646|Experimental|Polyphenol-rich extract|"The test product is a food supplement named Neurophenol. It is presented as a hard-shell capsule containing polyphenol-rich extracts.~Dose: 2 capsules per day, one capsule at least 1 hour after breakfast and one capsule at least one hour after dinner, with a glass of water."
89400468|NCT02198144|Other|barbershop-based BP measurement|BP monitoring by barbershop based Barbers and BP lowering medication(s)
89400469|NCT03678519||Exposed workers|Flour mills workers exposed to health hazards
89400470|NCT01383941||Subjects with Mild to Severe Asthma|This is an epidemiologic, multi-center, cross-sectional study to define the phenotypic characteristics of Difficult-to-Treat asthma, among children receiving one year of guidelines-based therapy for asthma and rhinitis/rhinosinusitis.
89400471|NCT03672123||APE with RVD|RVD (right ventricle disfunction) defined according to ESC (European Society of Cardiology) criteria
89004068|NCT03464305|Placebo Comparator|Placebo|Patients treated with placebo. Patients will be stratified according to the admission of adjuvant chemotherapy.
89004069|NCT03460977|Experimental|Dose Escalation (Part 1A)|Participants with SCLC, CRPC and FL will receive PF-06821497 at escalating dose levels
89004070|NCT03460977|Experimental|Dose Escalation (Part 1B)|Participants with FL will receive PF-06821497 at escalating dose levels
89004071|NCT03460977|Experimental|Dose Escalation (Part 1C)|Participants with CRPC will receive PF-06821497 at escalating dose levels.
89004072|NCT03460977|Experimental|Dose Escalation (Part 2A)|Participants with CRPC and SCLC will receive PF-06821497 at escalating dose levels in combination with SOC.
89004073|NCT03460977|Experimental|Dose Expansion (Part 2B)|Participants with CRPC will receive PF-06821497 in combination with SOC or SOC alone.
89004074|NCT03460977|Experimental|Japan Cohort|Participants with CRPC will receive PF-06821497 at one or two doses
89004075|NCT03460977|Experimental|China cohort|Participants will receive PF-06821497 at one or two doses
89189541|NCT05722535|No Intervention|Delayed MDPT|Families assigned to the control condition will receive the MDPT after study completion.
89400472|NCT03672123||APE without RVD|RVD defined according to ESC criteria
89400473|NCT02201264||Primary PCI for STEMI patients|Primary PCI for patients presenting with ST elevation MIs
89400474|NCT02450123|Experimental|sunitinib|sunitinib 50mg will be administered orally once a day 42 days.Study treatment will be continued until objective disease progression.
89400475|NCT02063802|Active Comparator|metformin and healthy habits program|1 gr per day. (250mg tablets). The patient takes 2 tablets with breakfast and 2 tablets with dinner and 2 placebo tablets with food by mouth for four months.
89400476|NCT02063802|Experimental|Conjugated Linoleic Acid and healthy habits|Total dose: 3gr per day (500mg capsules). The patient takes 2 capsules with breakfast, 2 capsules with lunch and 2 capsules with dinner by mouth for four months.
89400477|NCT02063802|Placebo Comparator|Placebo and healthy habits program|Total dose 6 tablets per day. The patient takes 2 tablets with breakfast, two tablets with lunch and two tablets with dinner by mouth for four months.
89400478|NCT03672045|Active Comparator|Carbetocin 10mcg|Patient is given 10 mcg of carbetocin intravenously over 1 minute, immediately upon delivery of the fetal head.
89004076|NCT03380078|Active Comparator|Standard|Programs assigned to the Standard condition will receive standard EBI training only
89004077|NCT03380078|Experimental|TEAMS Leadership Institute (TLI) ONLY|Programs assigned to the TLI ONLY condition will receive standard EBI training for providers and leaders will participate in TLI.
89004078|NCT03380078|Experimental|Motivational Enhancement (TIPS for Training) ONLY|Programs assigned to the TIPS ONLY condition will receive enhanced TIPS EBI training for providers.
89004079|NCT03380078|Experimental|TIPS + TLI|Programs assigned to the TIPS + TLI condition will receive TIPS EBI training for providers and leaders will participate in TLI
89004080|NCT03378765||African origin adults|African origin adults from Ghana, Jamaica, Seychelles, South Africa and USA between the ages of 30- 50.
89004081|NCT03361852|Experimental|Neo Vax|"Neo Vax is injected into up to 4 different anatomic site.~NeoVax may be administered within +/- 1 day of the scheduled administration date for days 4 and 8,~Within +/-3 days of the scheduled administration date for days 15 and 22~Within +/-7 days of days 78 and 134.~Participants will receive Rituximab weekly x 4 weeks per institutional standard"
89189542|NCT05722535|Experimental|MDPT|Families randomized to the intervention condition will receive the MDPT after they complete the baseline survey.
89400479|NCT03672045|Active Comparator|Carbetocin 20mcg|Patient is given 20 mcg of carbetocin intravenously over 1 minute, immediately upon delivery of the fetal head.
89400480|NCT03672045|Active Comparator|Carbetocin 40mcg|Patient is given 40 mcg of carbetocin intravenously over 1 minute, immediately upon delivery of the fetal head.
89400481|NCT03672045|Active Comparator|Carbetocin 60mcg|Patient is given 60 mcg of carbetocin intravenously over 1 minute, immediately upon delivery of the fetal head.
89400482|NCT03672045|Active Comparator|Carbetocin 80mcg|Patient is given 80 mcg of carbetocin intravenously over 1 minute, immediately upon delivery of the fetal head.
89400483|NCT03672045|Active Comparator|Carbetocin 100mcg|Patient is given 100 mcg of carbetocin intravenously over 1 minute, immediately upon delivery of the fetal head.
89400484|NCT02198300|Active Comparator|rDES Group|regular drug-eluting stent implantation in coronary lesion within bifurcation LucChopin Xience Promus Resolute Integrity Biomatrix Prolim
89400485|NCT02198300|Experimental|BiOSS LIM Group|BiOSS LIM® stent implantation into coronary lesion within bifurcation.
89400486|NCT03673761||Cushing's syndrome|"a) Patients with Sd Cushing (SC): 40 women (25-60 years) with SC, with controlled hypercortisolism after treatment and without clinical / biochemical signs of relapse for more than 5 years.~This group will under go the following procedures:~muscle MRI~dual-energy x-ray absorptiometry~muscle ultrasounds~blood testing"
89400487|NCT03673761||acromegaly|"b) Patients with acromegaly: 40 patients of both sexes (25-60 years) with GH / Insulin-like-Growth Factor (IGF-I) controlled after treatment and without clinical / biochemical signs of relapse for more than 5 years.~This group will under go the following procedures:~muscle MRI~dual-energy x-ray absorptiometry~muscle ultrasounds~blood testing"
89400488|NCT03673761||Healthy controls|"Controls: n = 40; normal healthy control paired by age, sex and BMI will be included.~This group will under go the following procedures:~muscle MRI~dual-energy x-ray absorptiometry~muscle ultrasounds~blood testing"
89400489|NCT03560232|Active Comparator|Cefazolin + Gentamicin|"[Cefazolin]~Initial dose:~Cefazolin 2g IV x1 dose (patient weight < 120kg)~Cefazolin 3g IV x1 dose (patient weight >/= 120kg)~Subsequent dose:~Cefazolin 2g IV every 8 hrs (CrCl >/= 40 mL/min)~Cefazolin 2g IV every 12 hrs (CrCl 20-39 mL/min)~Cefazolin 2g IV every 24 hrs (CrCl < 20 mL/min)~Duration:~24 hrs post-op after soft tissue coverage or total of 72 hrs, whichever comes first~[Gentamicin]~Initial dose:~If Patient age </= 80 years old: 5 mg/kg adjusted body weight x1 dose (Max dose 500 mg)~If Patient age >80 years old: 3 mg/kg adjusted body weight x1 dose (Max dose 300 mg)~Subsequent dose:~Pharmacy Consult to dose gentamicin~Duration:~24 hrs post-op after soft tissue coverage or total of 72 hrs, whichever comes first"
89400490|NCT03560232|Active Comparator|Ceftriaxone|"Initial dose:~Ceftriaxone 2g IV x1 dose~Subsequent dose:~Ceftriaxone 2g IV every 24 hours~Duration:~One dose post-op after soft tissue coverage or total of 72 hours, whichever comes first"
89400491|NCT03560232|Active Comparator|Ampicillin/Sulbactam|"Initial dose:~Ampicillin/Sulbactam 3g IV x1 dose~Subsequent dose:~Ampicillin/Sulbactam 3g IV every 6 hours (CrCl >/= 30 mL/min)~Ampicillin/Sulbactam 3g IV every 12 hours (CrCl 15-29 mL/min)~Ampicillin/Sulbactam 3g IV every 24 hours (CrCl <15 mL/min)~Duration:~24 hours post-op after soft tissue coverage or total of 72 hours, whichever comes first"
88876168|NCT02772666|Active Comparator|Swinging Flash light Test|All study participants who were diagnosed Relative Afferent Pupillary defect(RAPD) positive according to expert specialist investigations were also examined with manual diagnostic method, Swinging Flash light Test(SFT). The standard and most common method for Marcus-Gunn test is Swinging Flashlight Test (SFT), which needs a dark room, and the patient will be asked to look toward a distant object, so the pupils are not focused. The patient is asked to gaze into the distance, and the examiner swings the beam of a penlight back and forth from one pupil to the other, and observes the size of pupils and reaction in the eye that is lit.
88876169|NCT02773758|Experimental|Stannous Fluoride Dentifrice|Participants will be instructed to topically dose a dry toothbrush with a full strip of toothpaste, then brush each of the two selected sensitive test teeth first, followed by the whole mouth thoroughly for at least 1 minute twice daily (morning and evening). Participants will be permitted to rinse with tap water.
88876170|NCT02773758|Other|Sodium monofluorophosphate Dentifrice|Participants will be instructed to topically apply a full brush head of toothpaste to a dry toothbrush, then brush the whole mouth thoroughly for at least 1 minute. Participants will be permitted to rinse with tap water.
88876171|NCT02773836||Greek cohort|Participants recruited from Greece will receive a questionnaire at pre- and post- intervention
88876172|NCT02773836||German cohort|Participants recruited from Germany will receive a questionnaire at pre- and post- intervention
88876173|NCT02773836||Romanian Cohort|Participants recruited from Romania will receive a questionnaire at pre- and post- intervention
88876174|NCT02773836||Spanish Cohort|Participants recruited from Spain will receive a questionnaire at pre- and post- intervention
88876175|NCT02773836||Hungarian Cohort|Participants recruited from Hungary will receive a questionnaire at pre- and post- intervention
88876176|NCT02773836||Polish cohort|Participants recruited from Poland will receive a questionnaire at pre- and post- intervention
88876177|NCT02774226|Experimental|Tetrahydrobiopterin (BH4)|Blood samples, flow-mediated dilation, arterial stiffness, lung function, and microvascular function will be performed at baseline and 12 weeks following 5mg/kg of Kuvan® or sapropterin dihydrochloride which is a synthetic preparation of the dihydrochloride salt of naturally occurring tetrahydrobiopterin (BH4), taken once a day.
89400492|NCT03560232|Active Comparator|Piperacillin/Tazobactam|"Initial dose:~Piperacillin/Tazobactam 4.5g IV x1 dose over 30 minutes~Subsequent dose:~Piperacillin/Tazobactam 3.375g IV every 8 hours over 4 hours (CrCl >/= 20 mL/min)~Piperacillin/Tazobactam 3.375g IV every 12 hours over 4 hours (CrCl < 20 mL/min)~Duration:~24 hours post-op after soft tissue coverage or total of 72 hours, whichever comes first"
89400493|NCT03560232|Other|Clindamycin + Gentamicin|"Patients with known Penicillin allergy will receive:~[Clindamycin]~Initial dose:~Clindamycin 900mg IV x1 dose~Subsequent dose:~Clindamycin 600mg IV every 8 hours~Duration:~24 hours post-op after soft tissue coverage or total of 72 hours, whichever comes first~[Gentamicin]~Initial dose:~If Patient age </= 80 years old: 5 mg/kg adjusted body weight x1 dose (Max dose 500 mg)~If Patient age >80 years old: 3 mg/kg adjusted body weight x1 dose (Max dose 300 mg)~Subsequent dose:~Pharmacy Consult to dose gentamicin~Duration:~24 hours post-op after soft tissue coverage or total of 72 hours, whichever comes first"
89400494|NCT02196935||ERCP/EUS|All patients who undergo ERCP and EUS for clinical indications will undergo a detailed prospective assessment of clinical course.
89400495|NCT03533192|Experimental|Receipt of It's Your Game...Keep it Real|It's Your Game...Keep it Real is an HIV, STI, and teen pregnancy prevention program
89400496|NCT03533192|No Intervention|Usual care|Students received their regular health education.
89400497|NCT02140463||metastatic cancer|metastatic gastrointestinal cancer metastatic genitourinary cancer other rare cancer lung cancer
88876178|NCT02774226|Experimental|Antioxidant Cocktail|Blood samples, flow-mediated dilation, arterial stiffness, lung function, and microvascular function will be performed at baseline and 12 weeks following an anti-oxidant cocktail (vitamin C 1000 mg, vitamin E 400 IU, and alpha lipoic acid 600 mg) taken once a day.
88876179|NCT02774616|Other|Ilivia ICD Family|Implant of the new Ilivia ICD Family. Device measurements, pre-defined programming and Adverse Event Reporting
88876180|NCT02774616|Other|Plexa ICD lead|Implant of the new Plexa ICD lead. Device measurements and Adverse Event Reporting
88876181|NCT02774616|Other|Ilivia ICD and Plexa lead|Implant of the new Ilivia ICD Family and the new Plexa lead. Device measurements, pre-defined programming and Adverse Event Reporting
88876182|NCT02774850||Early Discharge Management|Discharge to outpatient management during neutropenia within 3 days after chemotherapy completion in a given course
89189543|NCT05721651|Experimental|Experimental|Fruquintinib+PD-1
89189544|NCT05717478|Experimental|Experimental|Socket preservation after extraction with Proteo-Graft (Noricum S.L.) with a particle size of 0.25-1.00 mm, without using a barrier membrane.
89189545|NCT05717478|Active Comparator|Control|Conventional treatment (socket preservation therapy). Post-extraction socket preservation with Bio-Oss® (Geistlich Pharma AG, Switzerland) with a particle size of 0.25-1.00 mm, hereinafter BO, and protection with a barrier membrane, Bio-Gide® ( Geistlich Pharma AG, Switzerland).
89189546|NCT05716763|Experimental|Tramadol hydrochloride 5mg/mL oral solution (IMP 08P1902F0)|
89189547|NCT05716763|Active Comparator|Tramadol hydrochloride 100mg/mL oral solution (Contramal(r))|
89189548|NCT05716503|Experimental|Study group (A)|Study group (A): Will Receive negative pressure wound therapy dressings before skin grafting to prepare the wound bed and after skin grafting.
89189549|NCT05716503|Experimental|Control group (B)|Control group (B): Will Receive once daily dressing with antibiotic ointment and gauze before and after skin grafting.
89189550|NCT05703841|Experimental|Cohort 1: JNJ-77242113 Dose 1|Participants will receive a single oral dose of JNJ-77242113 Dose 1 on Day 1.
89189551|NCT05703841|Experimental|Cohort 2: JNJ-77242113 Dose 2|Participants will receive a single oral dose of JNJ-77242113 Dose 2 on Day 1.
89189552|NCT05703841|Experimental|Cohort 3: JNJ-77242113 Dose 3|Participants will receive a single oral dose of JNJ-77242113 Dose 3 on Day 1.
89189553|NCT05700942|Experimental|High Dose Intervention|tsDCS will be delivered to the lumbar region of the spinal cord during LT using a commercially available stimulation unit (Soterix Medical, Inc., New York, NY). tsDCS electrodes are comprised of a 10x5 cm carbon rubber electrode encased in a saline-soaked sponge. The anode electrode will be placed on the skin over the spinal processes of the 11th and 12th thoracic vertebrae, and the two cathode electrodes will be placed on each side of the umbilicus. For the high dose group, a standard dosage of 30 continuous minutes of 2.5 mA stimulus will be used.
89189554|NCT05700942|Active Comparator|Low Dose Intervention|tsDCS will be delivered to the lumbar region of the spinal cord during LT using a commercially available stimulation unit (Soterix Medical, Inc., New York, NY). tsDCS electrodes are comprised of a 10x5 cm carbon rubber electrode encased in a saline-soaked sponge. The anode electrode will be placed on the skin over the spinal processes of the 11th and 12th thoracic vertebrae, and the two cathode electrodes will be placed on each side of the umbilicus. The low dose condition will use an identical montage and stimulation arrangement, except the stimulation will be delivered briefly at the beginning and end of the stimulation period (30 seconds) with a three-second ramp.
89189555|NCT05697718|Experimental|group 1|Human umbilical cord mesenchymal stem cells（hMSCs）5.0×10^7 cells
89189556|NCT05697718|Experimental|group 2|Human umbilical cord mesenchymal stem cells（hMSCs）10.0×10^7 cells
89189557|NCT05697718|Experimental|group 3|Human umbilical cord mesenchymal stem cells（hMSCs）20.0×10^7 cells
89189558|NCT05691062|Experimental|PEEK|Medtronic Capstone
89189559|NCT05691062|Experimental|Titanium|Medtronic Adaptix
89400498|NCT02201342|Experimental|Udenafil Dose Level 1 qd|Udenafil tablet dose Level 1 daily for 5 days
88876183|NCT02774850||Inpatient Management|Remain hospitalized during chemotherapy-induced neutropenia
88876184|NCT02775240|Active Comparator|Digoxin|On Day 1, subjects will receive a single 0.5 mg (2 x 0.25 mg) oral dose of digoxin.
89189560|NCT05682092|Active Comparator|WonderLab Collagen Tripeptide Drink|"25ml/bottle, containing the following ingredients per 25ml serving:~Collagen 6000 mg~Vitamins C 250 mg~Hyaluronic acid 50 mg~Nicotinamide 0.45 mg"
89189561|NCT05682092|Placebo Comparator|Ordinary Drink|"25ml/bottle, containing the following ingredients per 25ml serving:~Peach juice 8 mg~Erythritol 10 mg"
89189562|NCT05679648||Rheumatoid arthritis patients|
89189563|NCT05679648||control|
89189564|NCT05678660||Long Group|Older adults individuals with longstanding HIV, stable and on antiretroviral therapy for at least 7 years
89189565|NCT05678660||Short Group|Older adults living with HIV, on stable antiretroviral treatment for at least 1 but not more than 2 years,
89189566|NCT05678465|Experimental|FIXATION|"Lightweight macroporous mesh at least 15x10cm will be placed in preperitoneal space and fixated with use of histoacryl glue.~Mesh - B Braun® Optilene Mesh® or BD® SoftMesh® Glue - Histoacryl® LapFix"
89189567|NCT05678465|Experimental|NON-FIXATION|"Standard, 3-D, anatomical mesh will be placed in preperitoneal space without the use of fixating materials.~Mesh - BD® 3D Max® Mesh or Medtronic® Dextile Anatomical Mesh®"
89189568|NCT05678088|Experimental|Supervised Oropharyngeal Exercises|The participant will perform the oropharyngeal exercises that strengthen the tongue and pharyngeal muscles. The protocol will be delivered via a tablet-based app. The speech language pathologist will call or conduct videoconference visits with participants 1, 3, 5, 7 and 9 weeks after the baseline assessment to provide re-training (if needed) and to troubleshoot technical issues related to the use of the app.
89400499|NCT02201342|Experimental|Udenafil Dose Level 1 bid|Udenafil Dose Level 1 twice daily for 5 days.
89011504|NCT01643785|Experimental|with Endonase|Second-line quadruple therapy [PPI(pantoprazole 40mg, lansoprazole 30mg, esomeprazole 40mg, rabeprazole 20mg, omeprazole 20mg) Bid, tetracycline 500 mg QID, metronidazole 500mg Tid, tripotassium dicitrate bismuthate 300mg QID] plus 20,000 units of pronase (endonase), BID for 7 days
89400500|NCT02201342|Experimental|Udenafil Dose Level 2 qd|Udenafil tablet dose level 2 once daily for 5 days.
89400501|NCT02201342|Experimental|Udenafil Dose Level 2 bid|Udenafil tablet dose level 2 twice daily for 5 days
89400502|NCT02201342|Experimental|Udenafil Dose Level 3 qd|Udenafil tablet dose level 3 daily for 5 days
89400503|NCT02201342|No Intervention|No Drug|No drug
89400504|NCT02063958|Experimental|SNX-5422|Open-label administration of SNX-5422 capsules dosed in the morning once every other day (qod) for 21 days (11 doses), followed by a 7 day drug free period. Dose escalation will be based on safety defined as 1 or less dose limiting toxicities during the first 28 day cycle at any dose level. Dose escalation will not exceed a dose of 100 mg/m2 SNX-5422 qod even if the MTD has not been identified. Subjects will receive daily oral everolimus in the PM about the same time every day for 28 days.
89400505|NCT01378013||Elective sugery|"Patients entering into elective surgery. These will be divided into three subgroups:~A. Patients with cancer. This will include patients with malignancy of the gastrointestinal and colorectal tract (including those excised by microsurgery) cancer of the breast or solid tumours of the kidney.~B. Patients with benign diseases of the bowel requiring surgery e.g. inflammatory bowel disease C. Benign surgical conditions, usually operated on in a day surgery setting. These will specifically be of the biliary tree (gall stones) and the anterior abdominal wall (e.g. Hernia surgery)"
89400506|NCT01378013||Acute (emergency) surgery|"Patients presenting to Accident and emergency under the care of the general surgery on call team will be recruited into this study group. This study group will have the following subgroups:~A. Acute abdominal pain, as per the previous ethical clearance B. Patients with acute sepsis thought to be of surgical origin. C. Patients suffering major trauma with an Injury severity score of >15, multiple injuries, who require surgery or who have >1 organ system that is failed or who are admitted to the intensive care department."
89400507|NCT03560544|Experimental|Breaking up sitting time|A behaviour-change intervention to break up prolonged sitting in the workplace
89400508|NCT03560544|No Intervention|Control|The participants in the control group will continue their daily activities as normal without any form of information about the intervention.
89400509|NCT03963830|Experimental|MOVE UP-Sustainability|12-week lifestyle intervention focusing on diet and activity
89400510|NCT01377935||Patients exposed to Saxagliptin|
89400511|NCT01377935||Patients exposed to OAD in classes other than DPP4 inhibitors|OAD - Oral Antidiabetic Drug
89400512|NCT02201498|Active Comparator|Formocresol/OZE|Conventional pulpotomy technique, with formocresol and zinc oxide eugenol
89400513|NCT02201498|Active Comparator|Biodentine|New technique, with biodentine
89400514|NCT02061852|Active Comparator|Physiotherapy|Traditional techniques
89400515|NCT02061852|Experimental|simeox|Medical device
89400516|NCT02201576|Experimental|Bortezomib|Five plasma exchanges, two cycles of bortezomib + dexamethasone, 4 courses of polyclonal intravenous immunoglobulins
89400517|NCT02201576|Active Comparator|Control|Five plasma exchanges, dexamethasone, 4 courses of polyclonal intravenous immunoglobulins
89400518|NCT02201654|Other|EBUS patients|All patients in our study are in the same arm, as each patient serves as their own internal control. More specifically, each enrolled patient will receive both traditional EBUS (with the usage of stylet) and experimental EBUS (EBUS without a stylet) at each lymph node that is included in the experimental analysis.
89400519|NCT02061930||single crowns supported by implants|single crowns supported by implants placed in the anterior maxilla region, periodontally healthy
89400520|NCT03533738|Experimental|Food selection 1|To consume vegetables followed by meat & rice together
89400521|NCT03533738|Experimental|Food selection 2|To consume meat followed by vegetables & rice together
89400522|NCT03533738|Experimental|Food selection 3|To consume as follows: vegetables, meat, rice
89400523|NCT03533738|Experimental|Food selection 4|To consume vegetables followed by meat and rice together
89400524|NCT03533738|Experimental|Food selection 5|To consume rice followed by vegetables & meat together
89400525|NCT01377857|Experimental|Opt-In|Opt-in refers to a default of no test - patients must ask for the test in order to receive it. Patients are informed of the availability of rapid testing. They are tested only if they request the test.
88876185|NCT02775240|Experimental|Maribavir|On Day 8 through Day 15, subjects will receive a 400 mg (2 x 200 mg) BID oral dose of maribavir. Subjects will be given the second dose of maribavir approximately 12 hours after the first dose. On Day 13, subjects will receive a coadministration of a single 0.5 mg (2 x 0.25 mg) oral dose of digoxin and a single 30 mg oral dose of dextromethorphan given with the morning dose of maribavir.
89400526|NCT01377857|Experimental|Opt-Out|Opt-out has a default to test - patients are informed that they will receive a rapid HIV screening test unless they decline it. Patients will be tested unless they decline.
89400527|NCT01377857|Experimental|Active Choice|In the active choice treatment, there is no default; patients must actively accept or actively decline the test.
89400528|NCT01377857|Experimental|$1 Incentive|When offering the HIV test, study staff will inform subjects that the ED is offering cash incentives to promote HIV testing (and that the test is also free), and will inform them of that day's value.
89400529|NCT01377857|Experimental|$5 Incentive|When offering the HIV test, study staff will inform subjects that the ED is offering cash incentives to promote HIV testing (and that the test is also free), and will inform them of that day's value.
89400530|NCT01377857|Experimental|$10 Incentive|When offering the HIV test, study staff will inform subjects that the ED is offering cash incentives to promote HIV testing (and that the test is also free), and will inform them of that day's value.
88876186|NCT02775240|Active Comparator|Dextromethorphan|On Day 1, subjects will receive a single 30 mg oral dose of dextromethorphan.
88876187|NCT02777268|Experimental|Infacort 0.5 mg|Multi-particulate granules from 1 (0.5 mg) capsule
88876188|NCT02777268|Experimental|Infacort 2 mg|Multi-particulate granules from 1 (2 mg) capsule
88876189|NCT02777268|Experimental|Infacort 5 mg|Multi-particulate granules from 1 (5 mg) capsule
88876190|NCT02777268|Experimental|Infacort 10 mg|Multi-particulate granules from 1 (10 mg) capsule
88876191|NCT02777268|Active Comparator|Hydrocortisone|1 (10 mg) tablet
88876192|NCT05350020|Experimental|Solu-Cortef® in deltoid muscle|Solu-Cortef® in deltoid muscle
88876193|NCT05350020|Experimental|Solu-Cortef® in thigh muscle|Solu-Cortef® in thigh muscle
88876194|NCT05350020|Experimental|Hydrocortisone 100mg/ml in deltoid muscle|Hydrocortisone 100mg/ml in deltoid muscle
88876195|NCT05350020|Experimental|Hydrocortisone 100mg/ml in thigh muscle|Hydrocortisone 100mg/ml in thigh muscle
88876196|NCT05349942|Experimental|Intraoral scanning and data acquisition|
89189569|NCT05678088|Active Comparator|Unsupervised Oropharyngeal Exercises|The participant will perform the oropharyngeal exercises that strengthen the tongue and pharyngeal muscles. The protocol will be delivered via a tablet-based app. After the initial training there will be no further scheduled interactions with the study staff except during the follow-up telephone calls and study visits.
89189570|NCT05678088|Sham Comparator|Supervised Sham Exercises|The participant will perform sham control exercises that have no impact on oropharyngeal (e.g., base of the tongue) muscle strength. The speech language pathologist will call or conduct videoconference visits with participants 1, 3, 5, 7 and 9 weeks after the baseline assessment to provide re-training (if needed) and to troubleshoot technical issues related to the use of the app.
89189571|NCT05676177|Experimental|Main study arm|"All consenting participants will be invited to the radiology department during the medical screening rounds or at a different day (at their convenience). They will be scanned on both MRI and CT using dedicated protocols. Both scans will be conducted at the same day within a time-frame of 6 hours of each other. No follow up visit will be required.~MRI would be performed on a 3 Tesla magnet using a dedicated short protocol consisting of axial and coronal T2-weighted scans for anatomic assessment, and a dual-echo scan to assess for liver fat. The scan time would be less than 10 minutes.~CT scans will be performed using a single CT device. Ultra-low dose dual energy CT (ULD-DECT) scanning protocol parameters liver fat measurement (estimated scan time - less than 2 minutes)."
89189572|NCT05670431||4th-grade students of a dentistry faculty|
89189573|NCT05670431||5th-grade students of a dentistry faculty|
89189574|NCT05670431||Dentists|
89189575|NCT05670431||Specialist dentists|
89189576|NCT05670431||Laypeople|
89189577|NCT05655052|Experimental|working grup 1: Virtual Reality (VR) Group|"From the preparation stage of the IUD until the IUD application process is completed, after the internet connection is provided with a smart phone for the image, by clicking on the youtube.com link, Relaxation (https://www.youtube.com/watch?v=H1iboKia3AQ) nature video will be provided and virtual reality glasses will be provided.~Virtual reality glasses to be used in the research are not a medical device. This device is a technological glasses that works with compatible smartphones. The practice of watching nature videos with VR during the IUD application with this device is within the framework of midwifery care practices and is not a treatment option for any treatment method, tool or disease. Although the video watched with VR has no effect on medical treatment and care within the framework of midwifery care, it does not have any harmful effects on women. The participant can withdraw from this study at any time without giving any reason."
89189578|NCT05655052|Experimental|Working Group 2: Distraction Cards Implementation Group|From the preparation stage of the IUD procedure to the completion of the IUD application process, distraction cards containing five optical illusion figures, one of the distraction techniques, will be shown to the women by the researcher . Distraction cards consist of picture cards with various hidden pictures and patterns. These hidden pictures and patterns are such that individuals can only see when they look carefully. During the process, the women will focus on the cards and be distracted by asking what they see on the cards by communicating face-to-face with the researcher women about the pictures and shapes they see on the cards. Thus, it is thought that the cards with optical figures on the distraction cards will enable women to focus and reduce pain and anxiety. Display of cards will take approximately 3-5 minutes
89189579|NCT05655052|No Intervention|Control Group|Unlike the study group, women included in the control group will not only be shown video watching applications with virtual glasses and distraction cards. The maintenance and applications in the routine IUD application will be done exactly.
89189580|NCT05651321||stroke patients|Participants were tested for different taste perception thresholds using a three-point difference test, with samples materials for basic taste stimuli were used, i.e. reference substances tartaric/citric acid (acidic), quinine hydrochloride/caffeine (bitter), anhydrous sodium chloride (salty), sucrose (sweet), and quercetin/alum (astringent) were used to prepare different tastes and concentrations of liquids. The subjects will then evaluate the appearance (color, texture), taste, flavor, and texture of the six different flavored enteral nutrition preparations. The subjects will then perform manual sensory evaluation of the appearance (color, texture), odor, taste, texture, and other properties of the 6 different flavored enteral nutrition preparations.
89189581|NCT05651321||cancer patients|Participants were tested for different taste perception thresholds using a three-point difference test, with samples materials for basic taste stimuli were used, i.e. reference substances tartaric/citric acid (acidic), quinine hydrochloride/caffeine (bitter), anhydrous sodium chloride (salty), sucrose (sweet), and quercetin/alum (astringent) were used to prepare different tastes and concentrations of liquids. The subjects will then evaluate the appearance (color, texture), taste, flavor, and texture of the six different flavored enteral nutrition preparations. The subjects will then perform manual sensory evaluation of the appearance (color, texture), odor, taste, texture, and other properties of the 6 different flavored enteral nutrition preparations.
88876197|NCT05349786|Experimental|Intervention Group|A physical activity program lasting at least 30 minutes each session was applied to HF patients in the intervention group, three days a week for three months. A pedometer was used to visualize the walking performed in the physical activity program and to record reliably. Weekly phone calls and monthly home visits were made to the patients in order to determine the continuation of the medical treatment and walking program used by the patients, to increase their motivation and to detect or intervene in any situation related to the walking program.
88876198|NCT05349786|No Intervention|Non-Intervention Group|The individuals in the control group, were pre-tested, evaluated at the first, second, and third months, and followed up in the process without any intervention. Patients were reminded that they should continue their routine medical treatment and not start any physical activity program.
88876199|NCT05349708|Experimental|Participant|Patients who were sent home with the intervention post-surgery
88876200|NCT05349708|No Intervention|Historical controls|
88876201|NCT05349396|Experimental|Eszopiclone Test Product T-1|Participants will receive one tablet of the Test T-1 formulation containing Eszopiclone 3mg. The tablets will be taken with water and in a fasting condition.
89400531|NCT01377857|Experimental|Early Questionnaire|At a time that does not interfere with patients' medical care, patients will be approached by a member of the research team to consent to and complete a short (3 minutes) questionnaire. The questionnaire is designed to elicit two things: subjective risk of infection (e.g., What are the chances you have HIV? [Not possible, Unlikely, Possible, Likely, Certain]) and objective risk of infection (e.g., In the past year, have you given anyone drugs or money for sex?). The questionnaire will be administered as one of two timing treatments - a) at the beginning of care, before the patient is offered an HIV test (Early questionnaire) or b) after the patient has been offered an HIV test (Late questionnaire).
89400532|NCT01377857|Experimental|Late Questionnaire|At a time that does not interfere with patients' medical care, patients will be approached by a member of the research team to consent to and complete a short (3 minutes) questionnaire. The questionnaire is designed to elicit two things: subjective risk of infection (e.g., What are the chances you have HIV? [Not possible, Unlikely, Possible, Likely, Certain]) and objective risk of infection (e.g., In the past year, have you given anyone drugs or money for sex?). The questionnaire will be administered as one of two timing treatments - a) at the beginning of care, before the patient is offered an HIV test (Early questionnaire) or b) after the patient has been offered an HIV test (Late questionnaire).
89400533|NCT01377857|Experimental|FITD Questionnaire|"There will be two versions of the early questionnaire: one standard Early questionnaire, and one with an additional question: If you were offered an HIV test as part of your routine health care at no cost, would you get tested? The two questionnaires will be otherwise identical."
89400534|NCT01377857|Experimental|Free|When offering the HIV test, study staff will inform subjects that the ED is offering HIV testing (and that the test is also free); no monetary incentive will be offered.
89400535|NCT02198378|Active Comparator|Morphine|Morphine group: administration of morphine will start with a 0.05 mg/kg bolus followed by reinjection of 2 mg every 5 minutes until effective analgesia is obtained, defined as NRS ≤ 3.
89400536|NCT02198378|Experimental|MEOPA and paracetamol|"The patient will be equipped with a facemask delivering MEOPA.The gas flow received by the patient is adapted to his/her ventilation.~During the same time, an intravenous injection of 1 g paracetamol will be administered."
89400537|NCT02063100|Experimental|Shenyankangfu tablets and Losartan potassium 100mg|
89189582|NCT05651321||healthy people|Participants were tested for different taste perception thresholds using a three-point difference test, with samples materials for basic taste stimuli were used, i.e. reference substances tartaric/citric acid (acidic), quinine hydrochloride/caffeine (bitter), anhydrous sodium chloride (salty), sucrose (sweet), and quercetin/alum (astringent) were used to prepare different tastes and concentrations of liquids. The subjects will then evaluate the appearance (color, texture), taste, flavor, and texture of the six different flavored enteral nutrition preparations. The subjects will then perform manual sensory evaluation of the appearance (color, texture), odor, taste, texture, and other properties of the 6 different flavored enteral nutrition preparations.
89189583|NCT05648435||Sepsis patients|No interventions
89189584|NCT05648435||Healthy controls|No interventions
89400538|NCT02063100|Experimental|Shenyankangfu tablets and Losartan potassium 50mg|
89400539|NCT02063100|Experimental|Losartan potassium 50mg|
89400540|NCT02063100|Experimental|Shenyankangfu tablets|
89400541|NCT02063100|Experimental|Losartan potassium 100mg|
89400542|NCT01377779|Experimental|Intercoat treatment|women treated by Intercoat gel following hysteroscopy for retained products of conception
89400543|NCT01377779|Placebo Comparator|Control group|No additional treatment following hysteroscopy was performed
89400544|NCT02198846|Experimental|Insulin pump|insulin pump
89400545|NCT02198846|Active Comparator|conventional treatment|intensification of conventional treatment
89400546|NCT02064192||ICD Group (n=1500)|First ICD device implantation (after baseline assessments) is not part of this observational study and is carried out in the responsibility of the treating physician, all ICD-devices will undergo unique standard programming to ensure comparability of ICD shock events between patients.
89400547|NCT02064192||Control Group (n=750)|Patients who fulfill inclusion criteria but do not receive an ICD device will be followed as part of the Control Group
89400548|NCT01379885|Active Comparator|Standard technique|Children in the ST group will receive vapocoolant spray and arm gripping adjacent to the injection site performed by MA 1(immunizer). A second MA (MA 2) will perform the visual distraction by descending contralateral arm vibration using the massage instrument (buzzer).
89400549|NCT01379885|Experimental|Parent participation technique|The children in the PPT group will receive the same sequence, except that the parent/caregiver will administer the visual distraction rather than by MA2
89400550|NCT02198924|Experimental|Parecoxib and Celecoxib|"Patients in the study group are supplied sequential treatment with Parecoxib 40 mg intravenously (IV) twice daily (Q12h) for the first 3 days post-surgery followed by Celecoxib 200mg orally twice daily (Q12h) up to 6 weeks post-surgery.~Patient-controlled intravenous analgesia (PCIA) with Morphine is administrated to all the subjects starting immediately post-anesthesia and ending at 24h after operation. As long as oral intake is feasible, both the two groups may receive centrally-acting analgesic Tramadol Hydrochloride Sustained release tablets (TRAMCONTIN) as rescue analgesia if VAS score≧3."
89400551|NCT02198924|Placebo Comparator|placebo|"Patients in the control group are supplied with the corresponding placebo with the same instructions.~Patient-controlled intravenous analgesia (PCIA) with Morphine is administrated to all the subjects starting immediately post-anesthesia and ending at 24h after operation. As long as oral intake is feasible, both the two groups may receive centrally-acting analgesic TRAMCONTIN (Tramadol Hydrochloride Sustained release tablets) as rescue analgesia if VAS score≧3."
89400552|NCT02201732|Experimental|Arm A : Operative hysteroscopy|operative hysteroscopy with direct visualization
89400553|NCT02201732|Active Comparator|Arm B : Aspirative curettage|curettage is the standard surgical treatment in most centers
89400554|NCT05462093|Other|Additional sequences with MRCP+ and LiverMultiscan|PSC patients that undergo annual, standard care, MRI of the liver and MRCP will undergo additional Liver Multiscan sequences, taking approximately 15 minutes. After the MRI is performed, post-processing analysis named MRCP+ and LiverMultiscan will be performed without patient involvement.
89400555|NCT02201888|Experimental|Computer-assisted cognitive training|Patients in this arm of the trial carried out computerized online training drawn from the Feskits program (www.feskits.com), chosen to have attention, memory and executive function components. Specifically the sessions included the following exercises: sustained attention (4 minutes), attention/perception (5 minutes), working memory (8 minutes), auditory and visual memory (8 minutes), executive function (10 minutes), language (6 minutes), and games (4 minutes).
89400556|NCT02201888|Active Comparator|Computerized active condition|Patients allocated to this condition completed the same number of sessions as the cognitive training group but followed a computerized typing program (www.rapidtyping.com). This had similar design characteristics to the CRT condition, in that it was hierarchically organized with exercise level of difficulty being adjusted to the individual's level of performance and feedback being given at the end of each exercise. Additionally, patients in this condition played computerized games requiring typing (crosswords, word puzzles, etc) and were taught basic internet navigation by a supervisor. Exposure to the computer was of equivalent duration to the CRT condition.
89400557|NCT02201888|Placebo Comparator|Treatment as usual|Patients in this condition participated in their (individually variable) daily rehabilitative activities. Patients allocated to the other two conditions also participated in these activities
89400558|NCT02201966||Female gymnasts with low back pain|Subset of competitive female gymnasts who report significant low back pain that affects their ability to perform gymnastics.
89400559|NCT02201966||Female gymnasts without low back pain|Subset of competitive female gymnasts who deny significant low back pain that affects their ability to perform gymnastics.
88876202|NCT05349396|Experimental|Eszopiclone Test Product T-2|Participants will receive one tablet of the Test T-2 formulation containing Eszopiclone 3mg. The tablets will be taken with water and in a fasting condition.
88876203|NCT05349396|Active Comparator|Eszopiclone Referent Product|Participants will receive one tablet of the marketed reference formulation containing Eszopiclone 3mg. The tablet will be taken with water and in a fasting condition.
88876204|NCT05348148|Active Comparator|Oral Levocetirizine|Patients in Levocetirizine group will use oral antihistamine (Levocetirizine) only
88876205|NCT05348148|Active Comparator|Combined Intranasal Mometasone Furoate with oral Levocetirizine|Patients in combined Intranasal Mometasone Furoate with oral Levocetirizineintranasal group will use combined intranasal corticosteroids (intranasal Mometasone Furoate) with oral antihistamine (Levocetirizine)
89400560|NCT02065440|Active Comparator|Ebastine/Pseudoephedrine|administration of ebastine/pseudoephedrine 1cap/day for 1 week.
89400561|NCT02065440|Placebo Comparator|placebo|administration of placebo pill 1 cap/day for 1week
88876206|NCT05348148|Active Comparator|Combined Intranasal Mometasone Furoate with oral Levocetirizine plus intranasal Oxymetazoline|The other in combined Intranasal Mometasone Furoate with oral Levocetirizine plus intranasal Oxymetazoline group will use combined intranasal corticosteroids (intranasal Mometasone Furoate) with oral antihistamine (Levocetirizine) plus one-week intranasal decongestant (intranasal Oxymetazoline)
88876207|NCT05348070||Operated Non-Ruptured Endometrioma Group|It consists of patients who were found to have endometrioma in their clinical follow-ups and decided to operate as a result of the evaluations. The patients were operated under elective conditions.
88876208|NCT05348070||Operated Ruptured Endometrioma Group|Rupture of endometrioma, which is a rare gynecological emergency. This group consists of endometrioma patients requiring urgent/subacute operation such as acute abdominal pain, hemodynamic instability, intra-abdominal bleeding. The patients were operated after completing the necessary preparations
88876209|NCT05266482|Experimental|Intervention group|Next to the usual care, patients also get the opportunity to download and read a personal report.
88876210|NCT05266482|No Intervention|Control group|Patients will receive the usual care.
88876211|NCT05457192||Moderate diabetic polyneuropathy (DPN)|65 patients of both sexes (males & females) with type II DM with moderate polyneuropathy will be included. Patients will be enrolled and assessed for their eligibility to participate in this study. Their body mass index (BMI) will range from 20:30 kg/m2, age will range from 40-60 years, postprandial blood sugar more than 200 mg/dl, duration of diabetic illness five years ago or more and serum Hb1AC will be between 7% and 14%. All the patients suffering from moderate polyneuropathy according to Toronto Clinical Neuropathy Scoring System (TCSS) (score nine to 11 points), and Neuropathy Impairment Score in the lower limbs (NIS-LL) (The muscle power of the lower limbs will be more than grade 2 and less than grade 4)
88876212|NCT05456022|Experimental|Quercetin drug.|
88876213|NCT05456022|Experimental|Quercetin-encapsulated PLGA-PEG nanoparticles|
88876214|NCT05456022|Active Comparator|Doxorubicin chemotherapeutic drug|
89400562|NCT02202122||Study Group|OSA Scoring
88876215|NCT05455788||Patients undergoing Cardiac valve replacement|
88876216|NCT05455554||CLI (Critical Limb Ischemia)|CLI cohort is a population of individuals with CLI, at least one active lower extremity wound and planned lower extremity revascularization. CLI cohort patients will receive Flowmet-D measurements in addition to standard of care therapy following intervention.
88876217|NCT05455554||HBO (Hyperbaric Oxygen)|HBO cohort is a subset of the CLI cohort who will undergo hyperbaric oxygen therapy in the post-operative setting who will receive Flowmet-D measurements before and after their therapy.
89400563|NCT02064348|Experimental|Arm 1: semaglutide + moxifloxacin placebo|Subjects will receive a single dose of moxifloxacin placebo both before the start of semaglutide treatment and at the end of the semaglutide treatment.
89400564|NCT02064348|Active Comparator|Arm 2A:|"Semaglutide placebo + moxifloxacin/moxifloxacin placebo:~Subjects will receive moxifloxacin before the start of semaglutide placebo treatment and moxifloxacin placebo at the end of the semaglutide placebo treatment."
88876218|NCT05455398|Experimental|Round window niche enlargement group|The round window niche was surgically removed by general anesthesia, the round window membrane was opened as entirely as possible, and the blockage of the round window membrane was carefully identified.
88876219|NCT05455398|Active Comparator|Drum chamber injection group|Methylprednisolone (40 mg) was injected via puncture in the posterior quadrant of the tympanic membrane once daily for 7 d. Patients were instructed to remain supine for 30 min to keep the drug in the tympanic chamber and to avoid swallowing to prevent drug flow from the eustachian tube.
88876220|NCT05455242|Experimental|Habit Formation Interventions|Single subject design used for individual control (A-B design). During baseline phase (A), participants completed self-care activities ratings once per week for 4 weeks. During intervention phase (B), participants engaged in weekly sessions to address goals related to diabetes self-management and guided in habit formation. Participants engaged in intervention for 10 weeks, in accordance with habit formation recommendations by Lally et al. (2010). Each weekly session were held virtually (telephone or Zoom) and lasted 30-60 minutes, beginning with administration of the SDSCA and SRBAI. Participants were instructed in ongoing context-specific implementation intention to promote occupational participation in DSM through habit formation. This instruction included continued education and context modification recommendations. At two week intervals, additional areas of DSM were added until each were covered: blood glucose monitoring, nutrition, medication management, and physical activity.
88876221|NCT05455164|Other|Without supplementation, followed by Supplementation with Dietary Fibre|"For the first two weeks, subjects were given eucaloric prepared meals typical of Indonesian diet, which has low protein and low DF contents (contain less than 15 g/d of DF and protein content less than 15% of total macronutrient distribution range).~After two weeks of washing periods, all of the subjects were given eucaloric prepared meal which contain high protein and DF (contain 25-30 gram DF and protein content between 30-40% of total macronutrient distribution range). At the end of interventions, waist circumference, body weight, body composition, fasting plasma glucose, uric acid, and total cholesterol were measured again. Half of DF content in food came from natural occurring fiber from fruit, vegetables and whole grains, the other half (50%) come from IMO-based fiber supplement (FibercremeⓇ, PT. Lautan Natural Krimerindo, Mojokerto, Indonesia"
88876222|NCT05451420|Experimental|Group A|PegIFN α- 2b monotherapy, 180 μg/ week, 68 weeks of treatment, 24 weeks of follow-up after drug withdrawal
88876223|NCT05451420|Active Comparator|Group B|Patients had a lead-in period of 16 weeks before baseline, pegifn α- 2b single drug treatment for 24 weeks, 4 weeks after drug withdrawal, 16 weeks of introduction period, pegifn α- 2b was followed up for 24 weeks. The plan of the induction period is as follows: 1) from the first day of the induction period, GM-CSF is injected subcutaneously ® one hundred μg/ piece, produced by Xiamen Tebao Bioengineering Co., Ltd.), 100 μg/ day, 5 consecutive days, one cycle every 4 weeks, 4 consecutive cycles. 2) On the third day of the induction period, recombinant hepatitis B vaccine (Saccharomyces cerevisiae) (1.0ml/HBsAg 60 per dose) was injected subcutaneously μg. Shenzhen Kangtai Biological Products Co., Ltd.), 60 μ g. Once every 4 weeks for 4 consecutive cycles, the course of treatment was 68 weeks, and the patients were followed up for 24 weeks.
88876224|NCT05324124|Experimental|Selpercatinib (Period 1)|Selpercatinib will be administered orally on Day 1 either in fast or fed state.
88876225|NCT05324124|Experimental|Selpercatinib (Period 2)|Selpercatinib will be administered orally on Day 8 either in fast or fed state.
88876226|NCT05305092||chemotherapy|Premenopausal breast cancer patients receiving chemotherapy (including preoperative neoadjuvant chemotherapy) and endocrine therapy after surgery
88876227|NCT05305092||Endocrine therapy|Premenopausal breast cancer patients receiving endocrine therapy alone after surgery
88876228|NCT05305092||Healthy control|Healthy non-cancer controls
88876229|NCT05273814|Experimental|Tislelizumab+Bevacizumab+Pemetrexed|"Bevacizumab，7.5mg/kg，d1; Pemetrexed，500mg/m2，d1; Tislelizumab，200mg，d4; Q3W for 4 cycles;~Maintenance treatment ： Tislelizumab，200mg，d1; Bevacizumab，7.5mg/kg，d1; Q3W for 2 years"
88876230|NCT05215080|Experimental|Treatment group|Group of infants aged 6-7 months that given organic formula milk three times a day for three months. Each serving contains 7 spoons (1 spoon contain 4,6 grams) of milk powder and 210 ml of water.
88876231|NCT05006118|Experimental|Radio-labeled rodatristat ethyl 600 mg|Single dose of rodatristat ethyl 600 mg as an oral suspension containing a mixture of [12C]-rodatristat ethyl and [14C]-rodatristat ethyl to contain approximately 600 microcuries (uCi) of radioactivity
88876232|NCT04867044||STUDY GROUP|patient diagnosed with fibromyalgia according to the American College of Rheumatology 2010 diagnostic criteria
88876233|NCT04867044||CONTROL GROUP|healthy women volunteers
88876234|NCT04784208||Arm 1-Healthy Volunteers|"Arm 1: Subjects from the general population who are naïve to their hypothyroid status.~The Subjects will be randomly selected and will be equally stratified between genders and socio-economics statuses from places where groups of general populations are located"
88876235|NCT04784208||Arm 2- Hypothyroid treatment naïve patients|The subjects will be identified and selected from clinical settings such as hospitals, clinics and certified laboratories.
89400565|NCT02064348|Experimental|Arm 2B:|"Semaglutide placebo + moxifloxacin placebo/moxifloxacin:~Subjects will receive moxifloxacin placebo before the start of semaglutide placebo treatment and moxifloxacin at the end of the semaglutide placebo treatment."
89400566|NCT02202200|Experimental|PD-0332991|
89400567|NCT02202278||ovarian hyperstimulation patients|Moderate OHSS is defined as abdominal distension and discomfort, nausea with or without vomiting, ovarian enlargement (ovarian size of 8-12 cm) and ascites that revealed by ultrasonografic examination. Severe OHSS criteria is defined as ovarian enlargement, ascites with or without hydrothorax, haematocrit >45%, weight gain >2 kg, white blood cell count >15.000, oliguria, creatinine of 1.0-1.5, creatinine clearance of >50 ml/min, liver dysfunction.
89400568|NCT02202278||without ovarian hiperstimulation|Control group is composed of patients who underwent long luteal protocol but do not demonstrate symptoms of OHSS
88876236|NCT04775004|Active Comparator|Bone marrow venting procedure (BMVP)|Subjects randomized in the OR to undergo BMVP surgical augmentation
88876237|NCT04775004|Active Comparator|Platelet rich plasma (PRP)|Subjects randomized in the OR to undergo PRP surgical augmentation
88876238|NCT04504188|Experimental|Heart Rate Monitor Enhanced Treatment Optimization|Subjects will wear an FDA-approved WCD with a 3 month follow-up period. Heart rate (HR) will be continuously monitored by the WCD.
88876239|NCT04063956|Experimental|Cognitive training group|Multi-domain adaptive internet-based training program, including processing speed, attention, long-term memory, working memory, flexibility, calculation, and problem solving. 4 x 40 minutes per week, for 12 weeks.
88876240|NCT04063956|Active Comparator|Active-control group|Fixed, primary difficulty level tasks. 4 x 40 minutes per week, for 12 weeks.
88876241|NCT04024878|Experimental|Stanfard Platinum|"A total of 5 NeoVax immunizations will be administered over a 3-week period~Two booster vaccinations will be given at Week 12~Nivolumab administered by intravenous (IV) infusion over 30 minutes every 2 weeks."
88876242|NCT04024878|Experimental|Stanfard Platinum with Surgical or Core Needle Biopsy|"A total of 5 NeoVax immunizations will be administered over a 3-week period~Two booster vaccinations will be given at Week 12~Nivolumab administered by intravenous (IV) infusion over 30 minutes every 2 weeks.~Will undergo required surgical or core needle biopsy at first recurrence with progression free interval"
88876243|NCT04004520|Experimental|Virtual Reality with Meditation|Participants will receive a virtual reality and audio guided mindfulness meditation program available at (https://guidedmeditationvr.com/)
89400569|NCT02064504|Experimental|Sequence 1|Participants will receive the study treatment in the following order: ABFCED in each period (one per period). Where A=GSK961081 administered from DISKUS, B=GSK961081 Single strip (SS) administered from DPI, C=GSK961081 Dual Strip (DS) administered from DPI with a filled (lactose) second strip (DS configuration), D=GSK961081/fluticasone furoate (GSK961081/FF) administered from DPI (GSK961081 higher dose), E=FF DS administered from DPI with a filled (lactose) second strip (dual strip configuration), F=GSK961081/FF administered from DPI (GSK961081 lower dose).
88876244|NCT04004520|Other|Virtual Reality Control|Participants will receive a virtual reality of historic photographs and written narratives program (https://lookingglassvr.com/)
88876245|NCT04004520|Other|Audio Control|Participants will receive an online audio-only guided mindfulness meditation available at (https://www.uclahealth.org/marc/mindful-meditations).
88876246|NCT03686514|Experimental|H3N2 birth cohort|The H3N2 cohort consists of participants born between 1968-1977.
88876247|NCT03686514|Experimental|H1N1 birth cohort|The H1N1 cohort consists of participants born between 1948-1957.
88876248|NCT03004248|Experimental|DaxibotulinumtoxinA 40 units|Biological/Vaccine: Botulinum Toxins, Type A Intramuscular injection
88876249|NCT02529930|Experimental|Cohort 1: 3mg VB10.16 Vaccine|VB10.16 Immunotherapy (DNA vaccine): Biological/Vaccine Vaccination time points: Week 0, Week 3, Week 6, 3mgs per vaccination
88876250|NCT02529930|Experimental|Cohort 2: 3mg VB10.16 Vaccine|VB10.16 Immunotherapy (DNA vaccine): Biological/Vaccine Vaccination time points: Week 0, Week 4, Week 8, 3mgs per vaccination
88876251|NCT00039780|Active Comparator|1|Tavocept (BNP7787)
88876252|NCT00039780|Placebo Comparator|2|0.9% Sodium Chloride Soln.
88876253|NCT04961034|Other|classic KPE|the classic management of biliary atresia as described
88876254|NCT04961034|Other|modified KPE|we added 2 sutures posterior, one on each side and two anterior. this will hang the jejunal loop to promote tension free anastomosis
88876255|NCT04951518||Van Positive|Large Vessel Occlusion Positive
89400570|NCT02064504|Experimental|Sequence 2|Participants will receive the study treatment in the following order: BCADFE in each period (one per period)
88876256|NCT04951518||Van Negative|Large Vessel Occlusion Negative
88876257|NCT04945356|Experimental|upper limb virtual training|6-week virtual training of the affected upper limb using the Physiotec application
88876258|NCT04902300||Adolescent|adolescent attending high school
88876259|NCT04845282|Experimental|Graded Protein plus Resistance Training|This group will participate in a progressive resistance training program and will be instructed to consume a diet with a gradation of protein over the 12 week study duration.
88876260|NCT04845282|Active Comparator|RDA Protein plus Resistance Training|This group will participate in a progressive resistance training program and will be instructed to consume a diet with the recommended daily allowance of protein over the 12 week study duration.
89400571|NCT02064504|Experimental|Sequence 3|Participants will receive the study treatment in the following order: CDBEAF in each period (one per period)
89400572|NCT02064504|Experimental|Sequence 4|Participants will receive the study treatment in the following order: DECFBA in each period (one per period)
89400573|NCT02064504|Experimental|Sequence 5|Participants will receive the study treatment in the following order: EFDACB in each period (one per period)
88876261|NCT04763226|Experimental|Part A Furosemide|
88876262|NCT04763226|Experimental|Part B (SAD)|Single Ascending Dose (SAD)
88876263|NCT04695678||residents and staff of all nursing homes in Solingen|each study participant receives a single nasal/pharyngeal swab
88876264|NCT04695678||staff of one single nursing home in Solingen|each study participant receives a weekly nasal/pharyngeal swab for six months
88876265|NCT04636008|Experimental|Experimental arm|Sintilimab+Hypofractionated radiotherapy
88876266|NCT04549428|Experimental|Atezolizumab|Atezolizumab will be administered at a fixed dose of 1,200 mg by intravenous infusion every 21 days on an outpatient basis until progression, intolerance or loss of clinical benefit, according to the its approved prescribing information. Palliative radiation therapy will be delivered concomitant to the 2nd dose of atezolizumab as a single fraction of 8 Gy
88876267|NCT06085378|Experimental|Urinary Kallidinogenase for injection|Patients in this arm will be given urinary kallidinogenase for injection, 0.15 peptide nucleic acids(PNA), once a day for 10 days
88876268|NCT06085378|Placebo Comparator|Placebo|An inactive substance identical in appearance to the urinary kallidinogenase for injection, once a day for 10 days
88876269|NCT06085365|Placebo Comparator|Placebo Group|normal diet group
88876270|NCT06085365|Experimental|Immunonutrition Group|Immunonutrition (Suyusu) 250ml oral twice one day d1-d21 for two cycles
89400574|NCT02064504|Experimental|Sequence 6|Participants will receive the study treatment in the following order: FAEBDC in each period (one per period)
89400575|NCT02198456||3D echocardiography|
89400576|NCT02202356|Experimental|ALS-008176 Single Dose|Single dose of ALS-008176 administered orally as a suspension
89400577|NCT02202356|Placebo Comparator|Placebo Single Dose|Single dose of placebo administered orally as a suspension
89400578|NCT02202356|Experimental|ALS-008176 Multiple Doses|Multiple doses of ALS-008176 administered orally as a suspension
89400579|NCT02202356|Placebo Comparator|Placebo Multiple Doses|Multiple doses of placebo administered orally as a suspension
89400580|NCT03560154|Experimental|Whole Body Vibration Training|whole body vibration application will be performed in the range of 25-40 Hz, with amplitude 1-2 mm, 30-60 seconds (30-45 seconds) application and resting times of 60 seconds, 2-5 sets each session. In TVT training; Eight kinds of exercises will be provided, including 3 sessions per week for 4 weeks. The duration of each session will vary between 8-30 minutes. The frequency, amplitude, and duration of the TVT will be gradually increased from the lowest intensity to the level that the patient can tolerate. 8 exercises will be applied: for lower extremity; high squat, deep squat, right/left lunge, calf raise, for upper extremity; front raise, bent over lateral, biceps curl, and cross over. Before TVT application, 5-8 min. warm-up exercises will be applied. If desaturation (<88%) develops during the training in the patient, an oxygen mask will be used to ensure adequate oxygenation. Also, as a home program; respiratory exercises will be taught every day of the week for 10 minutes a day.
89400581|NCT03560154|No Intervention|Home respiratory exercises|Respiratory exercises will be taught to the patient. Duration of the respiratory exercises is at least 10 minute per session, 7 days a week for 4 weeks. A weekly phone call will be provided and exercise will be followed.
89400582|NCT01569425|Experimental|Lifestyle counseling|Lifestyle counseling, with high calorie breakfast
89400583|NCT01569425|Active Comparator|Life Counseling|Diet with high calorie dinner
88876271|NCT06085352|Experimental|Receive Investigational TetraLens BCL|At random, one eye will receive the contact lens that contains the tetracaine HCL
88876272|NCT06085352|Sham Comparator|Receive standard bandage contact lens|At random, one eye will receive the standard of care bandage contact lens
89400584|NCT02199158|Experimental|Argon Laser Peripheral Iridoplasty|ALPI was applied with a VISULAS diode laser of 532 nm (Carl Zeiss Meditec, Dublin, CA) by the same ophthalmologist (JML). Twenty to 40 spots of 400 mW power with 500 microns of size and duration of 500 ms were applied. Power was modified arbitrarily until an effective iris contraction was obtained. It was considered an effective contraction as that which causes a concentric movement around the laser spot, with minimal iris pigmentation and immediate angle opening observed through the lens mirrors using a Goldmann lens. Power was lowered if there was any bursting sound perceived, pigment dispersion, air bubbles or considerable pain.
88876273|NCT06085287|Experimental|CAU+EMT groups|CAU+EMT group will continue their current interventions and medications as usual. The existing interventions and medications will be recorded and serve as covariates included in outcome analysis. Besides, CAU+EMT group will receive a total of 30 sessions of EMT within 12 weeks (2 - 3 sessions/week).
88876274|NCT06085287|No Intervention|CAU Group|CAU group will continue their current interventions and medications as usual. The existing interventions and medications will be recorded and serve as covariates included in outcome analysis.Those who are initially assigned to CAU group will receive EMT for 12 weeks after they complete the trial. The post-trial treatment will serve as a compensation for their participation.
89400585|NCT02067936|Active Comparator|Group A propofol + remifentanil|Propofol highest dose, remifentanil lowest dose, TOL 90% according to Bouillon model
89400586|NCT02067936|Active Comparator|Group B propofol + remifentanil|Propofol intermediate high, remifentanil intermediate low, TOL90% according to the Bouillon Model
89400587|NCT02067936|Active Comparator|Group C propofol + remifentanil|propofol intermediate low+ remifentanil intermediate high: TOL 90% according to the Bouillon interaction model
89400588|NCT02067936|Active Comparator|group D propofol + remifentanil|propofol lowest dose+ remifentanil highest dose: TOL 90% according to the Bouillon model
89400589|NCT05461937|Experimental|'Getting things done after stroke' - an online executive function intervention|
89400590|NCT05461937|Active Comparator|Stroke psychoeducation|
89400591|NCT02916446|Experimental|Viaskin Peanut 250 mcg|Viaskin Peanut 250 mcg, daily administration
88876275|NCT06085261|Experimental|home-based telerehabilitation|Remotely supervised telerehabilitation at home will be conducted for 8 weeks, comprising lower limb aerobic training, individualized strength training and respiratory training exercises.
88876276|NCT06085261|Active Comparator|center-based traditional rehabilitation|Participants will undertake an aerobic, strength and respiratory training program of similar intensity and duration to the home-based program, at their site of recruitment.
88876277|NCT06085248|Active Comparator|Walking without personalized rhythmic auditory stimulation|Subjects will complete a 6MWT without any auditory cues
88876278|NCT06085248|Experimental|Walking with personalized rhythmic auditory stimulation|Subjects will complete a 6MWT with personalized rhythmic auditory cues
88876279|NCT06085235|Experimental|exercise|15min of cycling at moderate intensity
88876280|NCT06085235|No Intervention|video control|watching a video on healthy living
89400592|NCT02916446|Placebo Comparator|Placebo|Placebo patch, daily administration
89400593|NCT01377545|Active Comparator|Local Anesthetic Via Catheter|30mL of Lidocaine (local Anesthetic) will be injected via a perineural catheter at hour 0.
89400594|NCT01377545|Active Comparator|Local Anesthetic Via Needle|30mL of Lidocaine (local Anesthetic) will be injected via a needle at hour 0.
89400595|NCT01379807|Experimental|panitumumab + docetaxel + cisplatino|
89400596|NCT02031380|Experimental|Open angle glaucoma - iDropper device|Device
89400597|NCT02064660|Experimental|single arm|A series of acupressure sessions within six months from the baseline
89400598|NCT02202512|Experimental|BI 1060469 low dose|Low-Dose,Tablet,oral administration with 240 ml water,over 10 days
89400599|NCT02202512|Experimental|BI 1060469 high dose|High-Dose,Tablets,oral administration with 240 ml water, over 10 days
89400600|NCT02202512|Active Comparator|Cimetidine|
89400601|NCT02202512|Active Comparator|Naproxen|
89400602|NCT02202512|Experimental|BI 1021958|High-Dose,Tablets,oral administration with 240 ml water, over 10 days
89400603|NCT02065752|Experimental|Treatment A|Each participant will receive a single dose of 1 tablet of canagliflozin (CANA), 100 mg, and 2 tablets of metformin extended release (MET XR), 500 mg, administered together under fed conditions.
89400604|NCT02065752|Experimental|Treatment B|Each participant will receive a single dose of 2 tablets of CANA/MET XR FDC, formulation 1, under fed conditions.
89400605|NCT02065752|Experimental|Treatment C|Each participant will receive a single dose of 2 tablets of CANA/MET XR FDC, formulation 2, under fed conditions.
89400606|NCT01379729|Active Comparator|Group A|Patients with loss of long-term function after intraportal implantation
89400607|NCT01379729|Active Comparator|Group B|Patients that are candidates for islet cell transplantation
89400608|NCT02202668|Experimental|TRS|
89400609|NCT02064738|No Intervention|Normal diet|Two weeks of unaltered diet
89004082|NCT03361852|Experimental|NeoVax and pembrolizumab|"Neo Vax is injected into up to 4 different anatomic site.~NeoVax may be administered within +/- 1 day of the scheduled administration date for days 4 and 8,~Within +/-3 days of the scheduled administration date for days 15 and 22~Within +/-7 days of days 78 and 134.~Patients will receive pembrolizumab every 3 weeks starting on day 78~Participants will receive Rituximab weekly x 4 weeks per institutional standard"
89004083|NCT03361436|Experimental|Treatment (eribulin mesylate, IMRT, surgery)|Patients receive eribulin mesylate IV over 2-5 minutes on days 1 and 8 and undergo intensity-modulated radiation therapy QD 5 days a week beginning on day 8 of cycle 1. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients may undergo surgery within 3-10 weeks after radiation therapy.
89400610|NCT02064738|Experimental|Low omega-6/high omega-3 diet|Restricting daily intake of omega-6 fatty acids to less than 4 grams and increasing omega-3 fatty acids to 3 grams
89400611|NCT02202824|Experimental|Survey questionnaire version 1|Study participants will receive version 1 of the survey questionnaire
89400612|NCT02202824|Experimental|Survey questionnaire version 2|Study participants will receive version 2 of the survey questionnaire
89400613|NCT02202824|Experimental|Survey questionnaire version 3|Study participants will receive version 3 of the survey questionnaire
89400614|NCT05461781|Experimental|distal radial artery|Distal radial aretry for primary percutaneous coronary intervention in STEMI patients
89400615|NCT05461781|Active Comparator|proximal radial artery|Proximal radial aretry for primary percutaneous coronary intervention in STEMI patients
89400616|NCT02206412||HMGB1 group|
89400617|NCT05057442||Anterior Cruciate Ligament Reconstruction|
89004084|NCT03309332|Experimental|Device|Subjects implanted with the AMPLATZER™ PFO Occluder.
89400618|NCT05461625|Sham Comparator|ACL|Anterior cruciate ligament reconstruction without additional procedure
89400619|NCT05461625|Active Comparator|ACL + ALL anatomic|Anterior cruciate ligament reconstruction and anatomic anterolateral ligament reconstruction
89400620|NCT05461625|Active Comparator|ACL + ALL tenodesis|Anterior cruciate ligament reconstruction and anterolateral ligament tenodesis
89400621|NCT02202902|Experimental|Group 1 : 1H magnetic resonance spectroscopy and CMRI|Group 1 : Cushing's syndrome patients with diabetes mellitus or glucose intolerance
89400622|NCT02202902|Experimental|Group 2 : 1H magnetic resonance spectroscopy and CMRI|Group 2: Cushing's syndrome patients with normal glucose intolerance
89400623|NCT02202902|Experimental|Group 3 : 1H magnetic resonance spectroscopy and CMRI|age-, sex- and BMI-matched healthy volunteers
89400624|NCT03560076||Group 1|One medical surgical unit in seven acute care facilities in which nurses have received SBIRT training and implementation strategies and are randomized to Group 1 implementation
89400625|NCT03560076||Group 2|One medical surgical unit in seven acute care facilities in which nurses have received SBIRT training and implementation strategies and are randomized to Group 2 (delayed) implementation
89400626|NCT02206490|Active Comparator|Naltrexone Study Drug|Subjects will take naltrexone 4.5 mg daily for three months.
89400627|NCT02206490|Placebo Comparator|Naltrexone placebo|Subjects will take a 3 month course of a placebo pill identical in appearance to the naltrexone study drug.
89400628|NCT02206490|Active Comparator|dextromethrophan study drug|subjects will take a sustained release dextromethorphan pill twice a day.
89400629|NCT02206490|Placebo Comparator|dextromethoprhan placebo|Subjects will take a 3 month course of a placebo pill identical in appearance to the dextromethorphan study drug.
89400630|NCT02068170||patients treated with a potentional QT-prolonging drug|
89400631|NCT02203058|Experimental|Pursed-lips breathing|All patients performed both tests (six-minute walk test and Glittre ADL test) with pursed-lips breathing.
89400632|NCT02203058|Placebo Comparator|No pursed-lips breathing|All patients performed both tests (six-minute walk test and Glittre ADL test) without pursed-lips breathing.
89400633|NCT02206568|Experimental|URAL vs. Insulin lispro|Each subject will randomly be allocated to a treatment sequence consisting of 2 dosing visits during which the subject in a euglycaemic clamp setting will receive either a single dose of insulin lispro or URAL at predefined fixed dose levels in a randomized order.
89400634|NCT02203136||Muscle Invasive Bladder Cancer (MIBC)|During bladder cancer surgery, whole genome gene expression array assays obtained on tumor biopsy specimens. Analysis to determine biologic subtypes which will then be correlated with final pathology, identifying the subtype(s) associated with noc-MIBC. 3 Tesla pelvic magnetic resonance imaging (MRI) performed four weeks after bladder cancer surgery.
89400635|NCT02068326|Experimental|Mentalization Based Treatment|"the experimental intervention is a year-long manualized program that comprises four components:~Five individual case-formulation sessions,~MBT-I, an introductory pedagogical program for patients (three weekly sessions)~MBT-G, MBT-program in groups (37 weekly sessions)~MBT-P, a psychoeducation program for the patients' parents or parents substitutes (six sessions)."
89400636|NCT02068326|Active Comparator|Treatment As Usual|Participants randomized to the control group will receive Treatment As Usual (TAU). TAU is defined as comprising at least 12 monthly individual supportive sessions provided by non-MBT trained mental health professionals in the Department of Child and Adolescent Psychiatry in Region Zealand. Additional supportive sessions or other types of intervention may be offered to the patients according to the needs of the patients as evaluated by mental health professionals responsible for his/hers treatment. Hence, TAU may vary considerably in number and type of intervention across clinics and patients. All mental health services delivered during the treatment period to patients in the TAU group will be monitored and registered.
89400637|NCT02206646||Metalyse|weight-adjusted dose
89400638|NCT02419417|Experimental|Monotherapy Treatment|Patients treated at various doses and schedules
89400639|NCT02419417|Experimental|Combination Therapy|Patients treated at selected doses and schdules
89400640|NCT02206724|Experimental|STEREOTACTIC BODY RADIOTHERAPY|STEREOTACTIC BODY RADIOTHERAPY to the prostate gland
89400641|NCT02203214||Ligamys|All patients treated with Ligamys can be included in the study. Patients must meet all of the inclusion criteria and none of the exclusion criteria to be enrolled.
89400642|NCT02068404|Other|Nifedipine|
88876281|NCT06085196|Experimental|Mindful walking|Complete a 24-session outdoor mindful walking intervention over 3 months
88876282|NCT06085196|Other|Delayed mindful walking group|Option to complete a delayed 24-session mindful walking
88876283|NCT06085183|Placebo Comparator|Saline|48 subjects treated with 5 ml of saline then crossover to treatment arm
88876284|NCT06085183|Experimental|High Dose|24 subjects randomly treated with 5 mL of drug
88876285|NCT06085183|Experimental|Low Dose|24 subjects randomly treated with 2.5 mL of drug
88876286|NCT06085170||Group I|Group I (women with PCOs on ultrasound)
88876287|NCT06085170||Group II|group II(Group II will be women rated to have a normal voice as assessed using Auditory-Perceptual Evaluation of Voice, these women have a regular menstrual cycles and no PCOS on ultrasound)
88876288|NCT06085118||Patient|Infants up to and including 8 months of age (up to 8 months and 29 days), treated for a suspected or confirmed cow protein allergy.
88876289|NCT06085079|Experimental|2-week dosing|Subjects will self-administer subcutaneous injection of ixekizumab during the baseline week (Week 0) using a loading dose of 160 mg of subcutaneous ixekizumab (Taltz), followed by 80 mg of subcutaneous ixekizumab Q2 weeks for 24-weeks.
88876290|NCT06085079|Experimental|4-week dosing|Subjects will self-administer subcutaneous injection of ixekizumab during the baseline week (Week 0) using a loading dose of 160 mg of subcutaneous ixekizumab (Taltz), followed by 80 mg of subcutaneous ixekizumab Q4 weeks for 24-weeks.
88876291|NCT06085027|Experimental|The Epifaith® syringe|
88876292|NCT06085027|Active Comparator|The plastic syringe|
88876293|NCT06085014||Prospective cohort|Patients with paroxysmal AF with clinical indication to first transcatheter ablation procedure of AF by pulmonary vein isolation
88876294|NCT06085014||Retrospective cohort|Patients who underwent ablative procedure in the two years prior to the start of the study
88876295|NCT06085001||Women with preeclampsia|women with symptoms of preeclampsia from antenatal clinic or triage will be offered Lumella test along with traditional blood tests. If Lumella test is positive which will be compared with the traditional blood test results. Once 50 positive cases have been analysed the study results will be submitted to NICE.
88876296|NCT06084975||Kimura technique (KT)|Spleen preservation is accomplished by sparing the splenic vessels.
89400643|NCT02257658|Experimental|Doxycycline|Subjects in the doxycycyline arm will receive Doxycycline, oral, 100 mg, once daily for 36 weeks.
89400644|NCT02257658|Active Comparator|Incentive|Subjects in the incentive arm will receive escalating payments for remaining STI free at Weeks 12, 24 and 36.
89400645|NCT02068482|Active Comparator|1a USDD|Rifaximin 200 mg 6 tbs per day per 15 days/ month for 2 months
89400646|NCT02068482|No Intervention|1b USDD|Patients control, no drug
89400647|NCT02068482|No Intervention|Control group|Control Group, no disease, no drug
89400648|NCT02206802||Predicted as non-responders|Patients that the minoxidil response in-vitro diagnostic kit predicted as non-responders. 5% minoxidil topical foam will be administered to subjects in this group.
89400649|NCT02206802||Predicted as responders|Patients that the minoxidil response in-vitro diagnostic kit predicted as responders. 5% minoxidil topical foam will be administered to subjects in this group.
89400650|NCT02065986|Experimental|Arm A: Immediate offer of Truvada-PrEP|Immediate offer of Truvada (once daily tablet containing 300mg tenofovir disoproxil (TDF) and 200mg of emtricitabine (FTC)
89400651|NCT02065986|Other|Arm B: Deferred (12m) offer of Truvada-PrEP|Access to Truvada from 12 months after enrolment
89400652|NCT02068560|Experimental|dDAVP infusion|During the 9 hour study period, the subjects will receive three doses of dDAVP infusion (0.0003micrg/kg, 0.0005micrg/kg, 0.004micrg/kg).
89400653|NCT01377103|Placebo Comparator|Placebo|Placebo Gel
89400654|NCT01377103|Active Comparator|Testosterone Supplementation|Testosterone Gel
89400655|NCT02206958|Other|No treatment control group|No treatment control group
89400656|NCT02206958|Experimental|Behavioral Urinary Incontinence Treatment|12 week program combining behavioral treatments for urinary incontinence and physical activity
89400657|NCT02068638|Experimental|IHE first, CONT second, CSII and MDI therapy|IHE: intermittent high intensity exercise: integration of 10 s maximal sprints every 10 minutes in a continuous low to moderate intensity exercise of 90 minutes CONT (occurring after a washout period of 2-8 weeks): continuous moderate intensity exercise of 90 minutes
89400658|NCT02068638|Experimental|CONT first, IHE second,CSII and MDI therapy|CONT: continuous moderate intensity exercise of 90 minutes. IHE (occurring after a washout period of 2-8 weeks): intermittent high intensity exercise: integration of 10 s maximal sprints every 10 minutes in a continuous low to moderate intensity exercise of 90 minutes
89400659|NCT02068638|Experimental|GLU first, GLUFRU second, CSII and MDI therapy|GLU: ingestion of a 6% carbohydrate solution (consisting of 100 g glucose dissolved in 1000 ml tap water) over a continuous moderate exercise of 90 minutes. GLU FRU (occurring after a washout period of 2-8 weeks): ingestion of a 20% carbohydrate solution (consisting of 100 g glucose + 100 g fructose dissolved in 1000 ml tap water) over a continuous moderate exercise of 90 minutes. CSII = continuous subcutaneous insulin infusion. MDI=multiple daily injections.
88876297|NCT06084975||Warshaw technique (WT)|Spleen preservation is accomplished by sacrificing the splenic vessels and maintaining vascularity through the preserved short gastric and left gastroepiploic vessels.
88876298|NCT06084962|Experimental|Administration of DeepTag-GPRC5D Targeted CAR T-cells|Dose escalation follows the standard 3+3 dose escalation design. A total of 3 dose levels are set for subjects.
88876299|NCT06084949|Experimental|Nordic walking group or inspiratory muscle training|In experimental group, investigator will coordinate with the patients with mild-to-moderate knee osteoarthritis to take the Nordic walking, while the patients with end-stage knee osteoarthritis to take inspiratory muscle training. All participants are required to maintain their daily activities and routine management.
88876300|NCT06084949|No Intervention|Control group|In control group, participants are required to maintain their daily activities and routine management.
88876301|NCT06084923||Patients who discontinued ibrutinib|CLL patients enrolled in the front-line GIMEMA LLC1114 study twho discontinued ibrutinib due to reasons other than CLL progression, Richter syndrome, malignancy or death, or lost to the follow-up.
88876302|NCT06084910|Experimental|Experimental Group|Caregiver-child dyads that receive the Cultural Pride Reinforcement for Early School Readiness (CPR4ESR) intervention
88876303|NCT06084910|Active Comparator|Treatment-As-Usual Control Group|Caregiver-child dyads that receive standard Reach Out and Read intervention without additional emphasis on cultural pride
89400660|NCT02068638|Experimental|GLU-FRU first, GLU second, CSII therapy|GLU-FRU : ingestion of a 20% carbohydrate solution (consisting of 100 g glucose + 100 g fructose dissolved in 1000 ml tap water) over a continuous moderate exercise of 90 minutes. GLU (occurring after a washout period of 2-8 weeks): ingestion of a 10% carbohydrate solution (consisting of 100 g glucose dissolved in 1000 ml tap water) over a continuous moderate exercise of 90 minutes. CSII = continuous subcutaneous insulin infusion. MDI=multiple daily injections.
89400661|NCT01377025|Experimental|Sorafenib blinded Phase|400 mg Sorafenib bid until PD
89400662|NCT01377025|Placebo Comparator|Placebo blinded Phase|Two tbl. in the morning and two tbl. in teh evening until PD
89400663|NCT01377025|Experimental|Sorafenib Open Phase|400 mg Sorafenib bid until PD
89400664|NCT02207036|Experimental|Facebook intervention|Assignment to private group on Facebook with 3 months of content delivered to the group.
89189585|NCT05645497||Patient with medical device FACET FIXATION|The FACET FIXATION group include all the patients with Lumbar Spinal Stenosis who underwent an open technique for decompression, specifically laminectomies, concomitant to FACET FIXATION from November 2017 (and having more than 2 years postop to date).
89189586|NCT05645497||Patient with medical device Pedicle Screw|The Pedicle Screw group consiste of all the patients with Lumbar Spinal Stenosis who underwent an open technique for decompression, specifically laminectomies, concomitant to Pedicle Screw fixation from 2015 to 2016.
89400665|NCT02207036|Active Comparator|Referral|Referral to smokefree.gov website
89400666|NCT03630757|Experimental|Treatment|While holding the patient's head with the therapist's hands,the cervical spinous processes with the fingertips palpitate to the occipital condyle towards the proximal.Then the fingers of both hands applied pressure to the axis in the space between the occipital condyle and the spinous process
89400667|NCT03630757|Placebo Comparator|Group 2|reaching to the feet while sitting together with warming and cooling periods
88876304|NCT06084871||Patient Blood Management group|Three pillars of patient blood management will be applied
88876305|NCT06084871||Control group|Control
88876306|NCT06084858|Experimental|Dialysate Bicarbonat modification|Dialysate bicarbonate prescription will be modified from low (27 mmol/l) to high (37 mmol/l) in a step-wise fashion
88876307|NCT06084819|Experimental|Venetoclax Combined With CACAG Regimen|Venetoclax combined with CACAG regimen for relapsed/refractory AML. Recipients were randomized and those entering the experimental group received azacytidine,cytarabine,aclacinomycin,chidamide,venetoclax and granulocyte colony-stimulating factor. Azacytidine was used as 75 mg/m2/day from day 1 to day 7.Cytarabine was used as 75-100 mg/m2 bid from day 1 to day 5. Aclacinomycin was used as 20 mg/day on days 1,3,5. Chidamide was used as 30 mg/day on days 1,4,8,11. Venetoclax was used as 400 mg/day from day 1 to day 14.Granulocyte colony-stimulating factor was used as 300 ug/day from day 0 until agranulocytosi recovery.
88876308|NCT06084819|Active Comparator|Best-Available Therapy(BAT) Regimen|BAT regimen for relapsed/refractory AML.Recipients were randomized and those entering this group received FLAG/CLAG/MAE/DCAG/HAA/HAD regimen.
88876309|NCT06084806|Experimental|Advanced non small cell lung cancer (NSCLC) patients|Patients will undergo two [18F]F AraG PET/CT scans within 7 days of each other prior to receiving treatment
88876310|NCT06084780|Experimental|Intestinal, Multivisceral or Modified Multivisceral Transplantation|Participants will undergo intestinal or modified multivisceral transplantation according to their disease extent. Participants will be followed for 12 months from the day of transplantation. Participants will undergo routine clinical follow-up according to standard protocols for the management of participants after visceral organ transplantation and standard oncological follow-up for participants with PMP.
88876311|NCT06084741|Active Comparator|Drain group|In Group A the investigators will put intraabdominal drains
88876312|NCT06084741|Experimental|No drain group|The investigators will not put any intraabdominal drains
88876313|NCT06084715||Nutritional support group|Participants in this group will be enrolled in Benin and will receive nutritional support from the hospital where they receive care. They will be followed for 12 months.
88876314|NCT06084715||Standard of care group|Participants in this group will be enrolled in Togo and will not receive nutritional support from the hospital where they receive care. They will be followed for 12 months.
88876315|NCT06084650||waldenstrom macroglobulinemia patients|
88876316|NCT06084650||healthy patients matched age and sex without waldenstrom macroglobulinemia and ocular disease|
88876317|NCT06084637|Experimental|autologous microfat (MG)|Patient will be hospitalized in outpatient surgery. A blood sample will be collected and a lipoaspiration will be performed under local anesthesia during the same operation by the nurses and the surgeon. Then, biological products will be immediately prepared, and a preparation of autologous MG will be injected intra-articularly by th same surgeon.
88876318|NCT06084637|Experimental|Platelet-rich plasma (PRP)|Patient will be hospitalized in outpatient surgery. A blood sample will be collected and a lipoaspiration will be performed under local anesthesia during the same operation by the nurses and the surgeon. Then, biological products will be immediately prepared, and a preparation of autologous PRP will be injected intra-articularly by th same surgeon.
88876319|NCT06084637|Experimental|Microfat autologous-Platelet-rich plasma (MG-PRP)|Patient will be hospitalized in outpatient surgery. A blood sample will be collected and a lipoaspiration will be performed for the preparation during the same operation by the nurses and the surgeon. Then, biological products will be immediately prepared, and autologous microfat associated with a preparation of autologous PRP will be injected intra-articularly by th same surgeon.
88876320|NCT06084624|Experimental|Rebamipide mouthwash|Rebamipide mouthwash will be administered four times daily for one week or till healing
88876321|NCT06084624|Active Comparator|Betamethasone mouthwash|Betamethasone mouthwash of will be administered four times daily for one week or till healing
88876322|NCT06084611|Experimental|Provox Life HME|Use of Provox Life HMEs and attachment
88876323|NCT06084611|No Intervention|Control - No HME|Control group is current standard of Care in Brazil, which is not using an HME
89400668|NCT02203292|Active Comparator|Liberal|Liberal transfusion strategy. Patients will have red blood cells transfused only if Hb < 9.0 g/dL
89400669|NCT02203292|Experimental|Restrictive|Restrictive transfusion strategy. Patients will have red blood cells transfused only if Hb < 7.0 g/dL
89400670|NCT02066064|Experimental|Group A|Subjects will undergo complete standard colonoscopy, followed by G-EYE(TM) Colonoscopy
89400671|NCT02066064|Active Comparator|Group B|Subject will undergo G-EYE(TM) colonoscopy followed by standard colonoscopy
89400672|NCT05353075|Other|Sub Occipital Muscle Inhibition|Subjects in this group will receive only Sub Occipital Muscle Inhibition Technique and heating pad for 10 minutes.
89400673|NCT05353075|Experimental|Sub Occipital Inhibition with Hold Relax Agonist Contraction|Subjects in this group will receive Sub Occipital Inhibition and Hold Relax Agonist Contraction of hamstrings.
89400674|NCT02207192||Morbidly obese|Consecutive morbidly obese adults (BMI over or equal to 40 kg/m2) scheduled for bariatric surgery were prospectively recruited.Subjects with respiratory and cardiac history (asthma, Chronic obstructive pulmonary disease, heart failure) were excluded.
89400675|NCT02068716||Adults with HAIs|"Adult cardiac surgery patients who develop infections in hospitals within 30 days post surgery.~We will exclude patients presenting with endocarditis."
89400676|NCT03579121|Experimental|Pharmacogenomic (PGx) guided|Subjects will have Pharmacogenomic (PGx) testing preoperatively. The pharmacists will review results and make recommendations to the anesthesia and orthopedic teams for perioperative anesthesia and analgesia. The teams will use this information to drive clinical decisions as they see fit.
89400677|NCT03579121|Active Comparator|Control|Subjects will undergo Pharmacogenomic (PGx) preoperatively but the results will be sealed until completion of treatment and clinicians will not have access to this information. These patients will undergo standard treatment dosing and medication selection.
89400678|NCT02203370||all patients|All patients will be measured throughout the procedure with both devices. There no further separation into groups as both sensors can be placed on the same patient.
89400679|NCT05037786|Active Comparator|Powerpoint group|In the control group, there will be a face-to-face intervention of 15 minutes of education on pain explained by Verbal form with supporting Powerpoint presentation. The educational intervention will be carried out by one of the Unicaja Baloncesto Physiotherapists (research assistant), previously instructed by the research team.
89400680|NCT05037786|Experimental|Infographic group|In the intervention group, the same pain education will be carried out, explained verbally but with the support of an infographic instead of a Powerpoint. The educational intervention will be carried out by one of the Unicaja Baloncesto Physiotherapists (research assistant), previously instructed by the research team.
89400681|NCT02203448||FACET WEDGE spinal system|The FACET WEDGE spinal system provides additional stability to a spinal segment to enhance fusion conditions.
89400682|NCT02066142|Active Comparator|Tomosynthesis|Tomosynthesis will be compared to Ultrasound
89400683|NCT02066142|Other|Ultrasound|Ultrasound (sensitivity and specificity) will be compared to Tomosynthesis
89400684|NCT02068872|Experimental|Sleeve Gastrectomy|To assess the safety, tolerability and feasibility of sleeve gastrectomy in the perioperative period following liver transplantation in obese (BMI of > 40 or > 35 kg/m2 in the presence of at least one major obesity related co-morbidities (e.g. type 2 diabetes, hypertension, sleep apnea, heart disease, etc) adult subjects aged 18-75 years of age.
89400685|NCT02342275|Active Comparator|Propranolol|Propranolol
89400686|NCT02342275|Active Comparator|Atenolol|Atenolol
89400687|NCT02207270|Experimental|Same day discharge|Patients who experienced uncomplicated PCI as well as an uncomplicated 6-hour observation period, will be randomly assigned to same day discharge.
89400688|NCT02207270|Other|Overnight stay standard care|Patients who experienced uncomplicated PCI, as well as an uncomplicated 6-hour observation period, will be randomly assigned to an overnight stay, generally considered standard care.
89400689|NCT02068950|Other|Progressive resistance training|12 weeks, 3 sessions per week, 7 exercises (leg press, leg curl, hamstring curl, chest press, lateral pull down, sit-ups and back extensions). In general 2-3 sets of 8-15 repetitions will be performed following a progression plan starting with more repetitions at lower intensity progressing to fewer repetitions at higher intensity during the 12-week period (American College of Sports Medicine Position Stand).
89400690|NCT01827553|Experimental|Induction CT, chemoradiotherapy|Induction chemotherapy with gemcitabine or FOLFIRINOX; Radiotherapy, 28 x 1.8 Gy; Chemotherapy, gemcitabine;
89400691|NCT01827553|Active Comparator|Induction CT, chemotherapy|Induction chemotherapy with gemcitabine or FOLFIRINOX; Chemotherapy with gemcitabine or FOLFIRINOX according to induction chemotherapy
89400692|NCT02069028||Low intensity intervention|human oriented interventions with less consideration to the system based act including, but not limited to, education, training, sepsis profile and posters with protocol algorithms.
89400693|NCT02069028||Intermediate intensity intervention|interventions that lie in between human oriented and system oriented Including, but not limited to, sepsis protocols, daily audits, feedback and clinical pathway
88876324|NCT06084585|Active Comparator|Study Product A (High-dose 2X)|"Amway uric acid lowering product: 5g/sachet, containing the following active ingredients:~Celery seed (functional raw material)~Dasiphora mandshurica (functional raw material)~Cichorium intybus L. (functional raw material)~Lotus leaf (functional raw material)~Tart cherry (functional raw material)~γ-cyclodextrin~Erythritol~Silicon dioxide~Resistant dextrin~Black tea essence"
89400694|NCT02069028||High intensity intervention|system based interventions with less involvement of human effect including, but not limited to, electronic alert systems and sepsis response team.
89400695|NCT02207348|Experimental|Liraglutide 0.6 mg s.c. with FlexPen®|
89400696|NCT02207348|Experimental|Liraglutide 0.6 mg s.c. with the PDS290 pen-injector|
89400697|NCT02066454|Experimental|Apixaban|oral direct anti-Xa anticoagulant
89400698|NCT03526484|Active Comparator|Standard of Care|The control group will have a urine sample taken for a urinalysis prior to their procedure, which will have a reflex urine culture done if urinalysis results are positive. The results of the urinalysis will be reported to the doctor performing the procedure. The provider may require participants to take antibiotics and/or delay their procedure as a result of the urinalysis.
89400699|NCT03526484|Experimental|Experimental|The experimental group will have a urine sample taken for a urinalysis prior to their procedure, which will have a reflex urine culture done if urinalysis results are positive. The results of the urinalysis will NOT be reported to the doctor performing the procedure. Instead, the provider will conduct the procedure without looking at or acting upon the results of the urinalysis. The urinalysis and urine culture results will be monitored by the research team, and the participant will be informed if the urine culture results are positive for an infection.
89400700|NCT02207426|Experimental|TobrAir® 6.0|Tobramycin 75mg inhalation solution
89400701|NCT02207426|Experimental|TOBI® / PARI LC® PLUS Nebulizer|Tobramycin 300mg nebulizer solution
89400702|NCT02207426|Experimental|TOBI® Podhaler™|Tobramycin 112mg (4x28mg) inhalation powder
89400703|NCT00777491|Experimental|5-FU and Cisplatin + BID Irradiation|Within 8 weeks following pre-study transurethral resection (TUR) patients receive 2.5 weeks of induction chemoradiotherapy (induction 5-fluorouracil, induction cisplatin, induction BID radiation therapy). Consolidation chemoradiotherapy begins 7-14 days following post-induction chemoradiotherapy endoscopic response evaluation. Patients achieving a complete response receive 1.5 weeks of consolidation chemoradiotherapy (consolidation 5-fluorouracil, consolidation cisplatin, consolidation BID radiation therapy). Patients without a complete response undergo radical cystectomy. Outpatient adjuvant chemotherapy (adjuvant gemcitabine, adjuvant cisplatin) begins 4-5 weeks following the post-consolidation endoscopic evaluation or 8-12 weeks following radical cystectomy, and continues for 12 weeks.
88876325|NCT06084585|Active Comparator|Study Product B (Low-dose X)|"Amway uric acid lowering product: 5g/sachet, containing the following active ingredients:~Celery seed (functional raw material)~Dasiphora mandshurica (functional raw material)~Cichorium intybus L. (functional raw material)~Lotus leaf (functional raw material)~Tart cherry (functional raw material)~γ-cyclodextrin~Erythritol~Silicon dioxide~Resistant dextrin~Black tea essence"
88876326|NCT06084585|Placebo Comparator|Placebo|"Placebo product: 5g/sachet, containing the following active ingredients:~Maltodextrin~Pigment~Erythritol~Bitters~Essence of flavor"
88876327|NCT06084572||GERD patients|
88876328|NCT06084559|Sham Comparator|Placebo (ambient hypoxic air at 2840m)|Ambient hypoxic air at 2840 m will be applied via a facial mask with reservoir
88876329|NCT06084559|Experimental|SOT (high flow supplemental oxygen therapy)|SOT (supplemental oxygen therapy) at a flow of 10 l/min will be applied via a facial mask with reservoir
88876330|NCT06084546|No Intervention|Standard care with geko™ W3 device|Current geko™ device incorporating hydrogel adhesive designated KM40A
88876331|NCT06084546|Active Comparator|Standard care with geko™ X-W3|Next generation geko™ device incorporating new hydrogel adhesive designated KM40C
88876332|NCT06084507|Experimental|Treatment A|Single oral dose of ritonavir at -12 hours prior to GST-HG171/ritonavir dosing, followed by single oral dose of GST-HG171/ritonavir under fasted conditions. Ritonavir will continue to be dosed at 12 hours and 24 hours GST-HG171 dosing.
89189587|NCT05642767||Patients with pseudomonas aeruginosa infections|"All patients suffer from infections that can be caused by pseudomonas aeruginosa.~Clinical Data will be obtained as:~Data about clinical manifestations including fever, expectoration, pus from wounds, urinary symptoms, symptoms of upper respiratory tract infections, and symptoms of otitis externa.~Samples will be cultured on cetrimide agar.~Antibiotic sensitivity testing will be done by disc diffusion method according to CLSI.~Molecular detection to efflux genes and some virulence genes by PCR."
89189588|NCT05642767||Patients with infections other than pseudomonas aeruginosa|"Data about clinical manifestations including fever, expectoration, pus from wounds, urinary symptoms, symptoms of upper respiratory tract infections, and symptoms of otitis externa.~Samples will be cultured on different culture media and automated identification by Vitek system."
89189589|NCT05639829|Experimental|Weekday time-restricted eating|The intervention consisted of 8 weeks of ad libitum TRE with a 12-8 pm 8-hour eating window on weekdays. Participants received instructions to only consume water, black coffee, or black tea from 8 pm to 12 pm on weekdays and during the weekend, where there were no restrictions on eating timing. No other dietary or physical activity instructions were given.
89189590|NCT05635656|Experimental|Digital symptom mapping and biofeedback treatment|
89189591|NCT05633823|Experimental|Game group|Children and parents will be introduced to mobile application game training and they will be provided to download the application to their mobile device or tablet. The data collection forms will be applied again immediately after the children complete each part of the game, 4 months and 6 months after the training.
89189592|NCT05633823|No Intervention|Control group|No application will be made to children and parents, and the forms will be re-applied 4 months and 6 months after the first application of the data collection forms.
89189593|NCT05626166|Placebo Comparator|control group|Group I (Control group; n=30) which will receive mesalamine 1000 mg three times daily plus placebo tablets twice daily for 3 months.
89189594|NCT05626166|Experimental|diosmin group|Group II: (Diosmin group; n=30) which will receive mesalamine 1000 mg three times daily plus diosmin 600 mg twice daily for 3 months.
89189595|NCT05624138|Placebo Comparator|placebo|"Group I Placebo group n=32 Patients will receive 12 cycles of modified FOLFOX-6 regiment plus placebo tablets 2mg daily throughout the twelve chemotherapy cycles. The chemotherapy cycles will be received every 2 weeks and will be as follows:~Day 1 and Day 15: Oxaliplatin 85 mg/m2 intravenous infusion in 250-500 mL 5% dextrose solution and leucovorin 400 mg/m2 intravenous infusion in 5% dextrose solution both were given over 120 minutes at the same time in separate bags using a Y-line access, followed by 5-fluorouracil 400 mg/m2 intravenous bolus given over 2-4 minutes, followed by 5-fluorouracil 2400 mg/m2 intravenous infusion in 500 mL 5% dextrose solution as a 46-hour infusion."
89198947|NCT04902274|Experimental|Transcranial Direct Current Stimulation plus Physical Therapy|Participants in the experimental group will receive the current standard of care in ankle inversion sprain rehabilitation plus a 20-minute application of tDCS during each treatment session via the Halo Sport (Halo Neuroscience, San Francisco, CA) headset. The rehabilitation program will be standardized among all patients and will consist of therapeutic exercises, manual physical therapy, and other modalities. Rehabilitation sessions will be performed 2x weekly and sessions will last approximately 45 to 60 minutes.
88876333|NCT06084507|Experimental|Treatment B|Single oral dose of ritonavir at -12 hours prior to GST-HG171/ritonavir dosing, followed by single oral dose of GST-HG171/ritonavir under fed conditions. Ritonavir will continue to be dosed at 12 hours and 24 hours GST-HG171 dosing.
88876334|NCT06084494|Experimental|Test Condition 1|Variable Test Condition 1 WBGT 28 °C Clothing High Visibility Air Temperature 40 °C RH % 20 % Vapor Pressure 2.3 kPa Walking Speed 5 km/h Time 70 min
89400704|NCT00777491|Experimental|Gemcitabine + QD Irradiation|Within 8 weeks following pre-study transurethral resection (TUR) patients receive 2.5 weeks of induction chemoradiotherapy (induction gemcitabine and induction QD radiation therapy). Consolidation chemoradiotherapy begins 7-14 days following post-induction chemoradiotherapy endoscopic response evaluation. Patients achieving a complete response receive 1.5 weeks of consolidation chemoradiotherapy (consolidation gemcitabine and consolidation QD radiation therapy). Patients without a complete response undergo radical cystectomy. Outpatient adjuvant chemotherapy (adjuvant gemcitabine and adjuvant cisplatin) begins 4-5 weeks following the post-consolidation endoscopic evaluation or 8-12 weeks following radical cystectomy, and continues for 12 weeks.
89400705|NCT02207582|Experimental|Verum Prefrontal tRNS|2mA of tRNS (DC-Stimulator, NeuroConn GmbH, Germany) with a zero offset will be applied to the left and right dorsolateral prefrontal cortex. Treatment will consist of 15 days with 20 minutes stimulation per day. Voltage will be ramped at the begin and end of a stimulation for 10 seconds.
89400706|NCT02207582|Placebo Comparator|Placebo Prefrontal tRNS|2mA of tRNS (DC-Stimulator, NeuroConn GmbH, Germany) with a zero offset will be applied to the left and right dorsolateral prefrontal cortex. Treatment will consist of 15 days with 20 minutes stimulation per day. Voltage will be ramped at the begin and end of a stimulation for 10 seconds. Placebo stimulation will consist of just applying the ramps at the begin and end of the stimulation.
89400707|NCT01376947||Nulliparous|Nulliparous women who were submitted to IUD device insertion
89400708|NCT01376947||Multiparous with no cesaraen section|Multiparous women with no cesarean sections that were submitted to IUD device insertion
89400709|NCT01376947||Mulitparous with cesarean section|multiparous women with a cesarean section that were submitted to IUD insertion
89400710|NCT02069106|Experimental|Pro-Omega LDL|3 capsules 1000 mg BID for 8 weeks
88876335|NCT06084494|Experimental|Test Condition 2|Variable Test Condition 2 WBGT 28 °C Clothing High Visibility Air Temperature 40 °C RH % 20 % Vapor Pressure 2.3 kPa Walking Speed 8 km/h Time 70 min
88876336|NCT06084494|Experimental|Test Condition 3|Variable Test Condition 3 WBGT 28 °C Clothing High Visibility Air Temperature 31 °C RH % 70 % Vapor Pressure 3.1 kPa Walking Speed 5 km/h Time 70 min
88876337|NCT06084494|Experimental|Test Condition 4|Variable Test Condition 4 WBGT 28 °C Clothing High Visibility Air Temperature 31 °C RH % 70 % Vapor Pressure 3.1 kPa Walking Speed 8 km/h Time 70 min
89400711|NCT02069106|Placebo Comparator|Placebo|3 capsules BID for 8 weeks
89400712|NCT02199392|Experimental|Lenvatinib 24 mg|The Pretreatment Phase will have two periods: Screening and Baseline 1. The Treatment Phase will have three periods: Treatment Period 1, Treatment Period 2, and Treatment Period 3 with a Baseline 2 assessment prior to Treatment Period 2 and a Baseline 3 assessment prior to Treatment Period 3. In the Treatment Phase, subjects will take a single oral dose of 24 mg lenvatinib on three separate occasions (Period 1, Day 1; Period 2, Day 15; and Period 3, Day 43). In Period 2, Day 15, subjects will also take a single oral dose of 600 mg po rifampin. In Period 3, subjects will receive 600 mg rifampin po daily for 21 days (Period 3, Days 29 to 49). On Day 43 of Period 3, subjects will take 24 mg lenvatinib in addition to the rifampin.
89400713|NCT03630445|Experimental|Isomaltooligosaccharides (IMOs)|"Isomaltooligosaccharides (IMOs) incorporated into a yogurt test meal.~IMOs are a mixture of short-chain carbohydrates with a purported slow digestion property."
89400714|NCT03630445|Experimental|Xtend® sucromalt|"Xtend® sucromalt incorporated into a yogurt test meal.~Sucromalt is derived from a combination of sucrose (cane or beet sugar) and maltose (corn sugar), yet it has been found to be slowly digested."
88876338|NCT06084442|Active Comparator|combined lateral rectus muscle recession 7mm and hang back technique.|"The technique of combined LR recession 7mm and hang back technique:~A. The muscle is exposed in the usual manner and locking suture is passed through full thickness of the LR muscle using nonabsorbable ethibond suture.~B. The muscle is cut from its insertion site. C. Marking the sclera for the rectus muscle recession. a Measurement from the limbus, or b measurement from the original insertion site.~D. Passage of the needles in the sclera using the crossed swords Technique E. The muscle has been pulled up to its new insertion point and the sutures have been tied and cut and the remainder of the procedure is identical to the standard hang-back method.~The"
89400715|NCT03630445|Experimental|Combination of IMOs and Xtend® sucromalt|Combination of IMOs and Xtend® sucromalt incorporated into a yogurt test meal.
88876339|NCT06084442|Active Comparator|combined lateral rectus muscle recession 7mm and Z- tenotomy technique.|"The technique of lateral rectus muscle Z-tenotomy:~A. The muscle is exposed in the usual manner and two hemostats are each placed 80% of the way across the muscle (or tendon) from opposite borders. The hemostats are placed 3 or 4 mm apart.~B. The posterior hemostat is removed, and scissors are used to cut across the muscle in the crushed area. By cutting the muscle in the crushed area, bleeding is kept to a minimum.~C. The hemostat nearer the insertion is removed, and the muscle is cut along the crushed area using small snips with scissors.~D. lengthening of the muscle will occur. Any bleeding is controlled with pressure.~E. After the distal myotomy has been performed, in a very tight muscle, a No. 15 Bard Parker blade can be used to divide the tendon fibers, cutting against the muscle hook. This can be accomplished with a scraping motion with the knife blade at nearly right angles to avoid scleral perforation."
88876340|NCT06084351|Experimental|Convalescent Plasma|
89400716|NCT03630445|Experimental|Raw corn starch|"Raw corn starch incorporated into a yogurt test meal.~Raw corn starch is uncooked starch from corn. Because it is not cooked, it has a slow digestion property."
88876341|NCT06084351|Active Comparator|Standard of care|
88876342|NCT06084325||FND Patients|Group of patients with functional neurological disorders
89400717|NCT03630445|Experimental|Maltodextrin|"Maltodextrin incorporated into a yogurt test meal.~Maltodextrin is a type of starchy carbohydrate (polysaccharide) composed of units of D-glucose (simple sugars). The maltodextrin used for this study had a fast digestion property."
89400718|NCT02069262|Experimental|angiography combination laparoscopy|All patients were randomized to receive either mesenteric angiography alone or angiography combination laparoscopy in a 1:1 ratio. Randomization was performed computer-generated list using a randomly permuted block design. To ensure concealed randomization, the randomization code was put in opaque envelope and kept by researchers not performing angiography or angiography combination laparoscopy. Both patients and investigators were unaware of the randomization sequence. Those who developed rebleeding during the observation would be crossed over to the other investigation modality. Patients with negative findings on the initial assigned investigation but who developed rebleeding would undergo further investigation to localize the site of bleeding.
89400719|NCT02069262|Placebo Comparator|angiography alone|All patients were randomized to receive either mesenteric angiography alone or angiography combination laparoscopy in a 1:1 ratio. Randomization was performed computer-generated list using a randomly permuted block design. To ensure concealed randomization, the randomization code was put in opaque envelope and kept by researchers not performing angiography or angiography combination laparoscopy. Both patients and investigators were unaware of the randomization sequence.
89400720|NCT02199470||C-peptide minimal detectable|C-peptide level between 0,01-0,08 ng/mL
89400721|NCT02199470||C-peptide sustained|C-peptide level between higher or equal to 0,08 ng/mL
89400722|NCT02199470||C-peptide not detectable|C- peptide level equal to or lower than 0,01 ng/mL
89400723|NCT01379495|No Intervention|Usual Care|Burns victims will receive information according to the service routine
89400724|NCT01379495|Experimental|educational program+telephone follow up|Burns victims will participate in an educative program including telephone follow-up during six months after hospital discharge
89400725|NCT03559920|Experimental|Sevoflurane group|Patients who are sedated using sevoflurane
89400726|NCT03559920|Active Comparator|Intravenous sedation group|Patients who are sedated using propofol
89400727|NCT02203760|Experimental|Pazopanib plus Gemcitabine|Arm A: Pazopanib 800 mg orally once daily plus Gemcitabine 1000 mg/m2 i.v. over 30 min d 1 and d 8 q3w or
89400728|NCT02203760|Active Comparator|Pazopanib|Pazopanib 800 mg orally once daily
89400729|NCT01379131||GPRD patients|"All patients included in up to standard GPRD practices that agreed to the linkage with the MINAP database are included in this cohort."
89400730|NCT02064972||Patients undergoing allo-HSCT, who manifest GvHD.|Patients undergoing allo-HSCT, that manifest GvHD. Patients undergoing allo-HSCT will have CEC count performed at the following timepoints: T1 (baseline), T2 (pre-transplant), T3 (engraftment), T4 (GvHD onset) and T5 (post-GvHD). All patients will also be checked for CEC at day + 28.
89400731|NCT03703271|Active Comparator|chemotherapy|Methotrexate 0.4mg/kg·d, im ,*5d started at the first day of cycle, two weeks a cycle
89400732|NCT03703271|Experimental|study group|hysteroscopic repeat curettage
89400733|NCT03532802|Active Comparator|Metoprolol Succinate|Metoprololsuccinat
89400734|NCT03532802|Placebo Comparator|Placebo oral capsule|Placebo
89400735|NCT03430531|Experimental|Sphenopalatine ganglion block|Sphenopalatine ganglion block: this block will be performed by inserting swabs, with lidocaine squirted on them, into each nostril and reaching the nasopharyngeal wall.
89400736|NCT02066532|Experimental|Ruxolitinib/Trastuzumab|Jakafi (Ruxolitinib) and Trastuzumab (Herceptin) - 21 day cycle until disease progression
88876343|NCT06084325||Healthy control|Age matched group control of healthy participant
88876344|NCT06084299|Experimental|Treatment (autologous tumor infiltrating lymphocytes)|Post-NMA lymphodepletion, patients are infused with their autologous TIL followed by IL-2 administration.
88876345|NCT06084286|Experimental|CAR-T cell therapy|Dual-targeting CLDN18.2 and PD-L1 CAR-T cells
89400737|NCT02065050|No Intervention|Usual Care|Individuals in the usual care arm will not receive frequent contact by the study team. Individuals will be seen by a study team clinician 1 year after discharge to review diabetes management and obtain pertinent study related data.
89400738|NCT02065050|Experimental|Continued care|team-based care: Individuals in the continued care arm will be frequently contacted by the study team (consisting of endocrinologists, nurse practitioners, and health coaches) over the course of one year post-discharge. The team will monitor blood sugars and other health data, altering management as needed.
89400739|NCT04088513|Experimental|Aspirin|Drugs:Aspirin
89400740|NCT04088513|Active Comparator|Clopidogrel|Drugs:Clopidogrel
89400741|NCT02207660||Cisplatin,P-HDFL|The general principles for patients schedule for P-HDFL regimen treatment were as followings: patients must have had white cell count > 3000/mm3, platelet count > 100000/mm3, a normal serum creatinine (≦1.5 mg/dL) or a measured creatinine clearance ([urine creatinine level (mg/dL) X 24-hr urine amount (mL)]/[serum creatinine level (mg/dL) X 1,440 min]) of ≧ 40 mL/min [12,15], total bilirubin ≦ 2 mg/dL, and transaminase (≦3X the upper normal limits). Also, patients needed to have measurable disease by radiographic studies (plain X-ray, CT or MRI scans), no serious active underlying medical issues, and Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
89400742|NCT02069340|Experimental|Arm I (zoledronic acid over 15 minutes)|Patients receive zoledronic acid IV over 15 minutes on day 1.
89400743|NCT02069340|Experimental|Arm II (zoledronic acid over 30 minutes)|Patients receive zoledronic acid IV over 30 minutes on day 1.
89400744|NCT02199548||Study Participants|All enrolled participants will take part in a face-to-face interview.
88876346|NCT06084273|Experimental|Bobath Exercises|Bobath Exercises
88876347|NCT06084273|Experimental|Breathing Exercises,Breathing Exercises, Bobath Exercises|Breathing Exercises,Breathing Exercises, Bobath Exercises
88876348|NCT06084221|No Intervention|OFR Team Practice as Usual|Data are collected regarding standard OFR Team practice and outcomes before implementation of the FORTRESS Intervention
88876349|NCT06084221|Experimental|FORTRESS|Participating counties receive both training in data-driven decision making and inventory of overdose-prevention strategies
88876350|NCT06084208|Experimental|Robotic Navigational Bronchoscopy|Patients undergoing biopsy with the Ion Endoluminal System
89400745|NCT02069418|Experimental|Experimental arm|All patients will be in the same arm. Patients are going to have two 18F-FLT-TEP and two 18F-FDG-TEP : the first ones during the two weeks before the beginning of erlotinib and the second ones will occur during the second week after the initiation of erlotinib. The order of TEP is not definite : 18F-FLT-TEP may be planned first or reciprocally. A period of 48 hours must separate two TEP.
89400746|NCT02207738|Experimental|microneedling radiofrequency device|microneedling radiofrequency
89400747|NCT02207738|Active Comparator|bipolar radiofrequency device|bipolar radiofrequency treatment
89400748|NCT04422847|Experimental|intervention group (3D protective obturator)|Patients enrolled in the intervention group will have an intraoral scan of the palate, alveolar arch, and upper vestibular area before surgery. Based on this 3D visualization of precise anatomical conditions in the oral cavity, a form (negative unique impression of the upper jaw and palato-alveolar conditions) for casting of a protective obturator (splint), used during intubation to cover the defect of the alveolar arch and palate will be created on a 3D printer, in cooperation with the Faculty of Mechanical Engineering (Department of Mechanics of Bodies, Mechatronics and Biomechanics) of Brno University of Technology. For the production of the obturator, a silicone certified for use in the oral cavity will be used.
89400749|NCT04422847|No Intervention|control group|The standard procedure without the 3D obturator.
89400750|NCT02208128|No Intervention|Receptor-Tyrosinkinase-Inhibitor|Guidelines-oriented therapy with approved systemic medications for renal cell carcinoma individually for each patient (Receptor-Tyrosinkinase-Inhibitor) (e.g.Sunitinib, Pazopanib, Bevacizumab, Everolimus, Axitinib, Temsirolimus). With 1.progression turning to second line treatment with one of the upper mentioned medications. Third line therapy due to the individual molecular modifications for each patient.
89400751|NCT04411771|Experimental|Extended Assessment - Given shCBT|"The extended assessment includes screening instruments, a structured interpretation of the screening instruments, a structured interview and a medical anamnesis. If deemed appropriate, the patient can be offered treatment with guided self help. If the patient's problem is not deemed appropriate for this type of care or if the patient is not interested in guided self-help, they are offered brief interventions (BI).~In the primary analysis, only patients given shCBT are included"
89400752|NCT04411771|Active Comparator|Screening Assessment - Suitable for shCBT but given BI|"The screening assessment includes screening instruments and a contextual interview. Patients in this arm will always be treated with brief interventions.~In the primary anaysis, only patients suited for shCBT are included, as decided from an algorithm based on data from their screening."
88876351|NCT06084182|Other|Patient group|Patients with a definite diagnosis of MS according to McDonald diagnostic criteria
88876352|NCT06084182|No Intervention|Control Group|Healthy individuals
88876353|NCT06084169|Active Comparator|Intensity SL IOL|29 patients will be implanted bilaterally with Intensity SL IOL
89400753|NCT04411771|Experimental|Extended Assessment - All patients|"Same as the other arm marked as Experimental, but for the purpose of a secondary analysis all patients randomized to Extended Assessment are included, regardless of if they start shCBT or BI"
89400754|NCT04411771|Active Comparator|Screening Assessment - All patients|"Same as the other arm marked as Active comparator, but for the purpose of a secondary analysis all patients randomized to Screening Assessment are included, regardless of if they are suiteble for shCBT or not."
89400755|NCT03119883|Experimental|Group I (biospecimen collection)|EX-VIVO: After an overnight fast of 6 hours, patients undergo collection of bone marrow aspirate samples.
89400756|NCT03119883|Experimental|Group II (biospecimen collection, glutamine, glucose)|IN VIVO: After an overnight fast of 6 hours, patients receive 13-carbon labeled glutamine or 13-carbon-labeled glucose IV over 90 minutes. Patients also undergo collection of blood and bone marrow aspirate samples.
88876354|NCT06084169|Active Comparator|Panoptix IOL|29 patients will be implanted bilaterally with PanOptix IOL
88876355|NCT06084156|Experimental|HSK7653 and Metformin|
88876356|NCT06084130|Experimental|Zolpidem|The participants in Zolpidem group will receive 10 milligrams zolpidem contained in white-color opaque medicine capsule prepared by the pharmacist. The participants will be advised to take the medication 30 minutes prior to the bedtime until the 1-week follow up visit.
88876357|NCT06084130|Placebo Comparator|Placebo|The participants in Placebo group will receive placebo which is corn-starch contained in identical white-color opaque medicine capsule. The participants will be advised to take the medication 30 minutes prior to the bedtime until the 1-week follow up visit.
88876358|NCT06084078||Telehealth cohort|Individuals who opt to do the screening using telehealth. Telehealth using video assisted techniques or using telephone.
88876359|NCT06084078||In-person cohort|Individuals who are willing to travel to the hospital for in-person screening and follow-up
89400757|NCT02069496||Subjects who receive Arepanrix®|Subjects who receive Arepanrix® as per routine practice
89400758|NCT02066610|Experimental|PN selenium and formula sodium selenate|Parenteral nutrition (PN) with selenium and sodium selenate supplementation of infant formula
88876360|NCT06084065|Experimental|Ring arm|
88876361|NCT06084052|Other|Path Active|All participants will use the device. There is no comparator.
88876362|NCT06083961|Experimental|Alirocumab|The treatment group patients will receive an additional PCSK9 inhibitor (alirocumab 300mg once) at emergency departement in addition to statin therapy, which is conventional medication given for acute ischemic stroke.
88876363|NCT06083961|No Intervention|Standard of care|The control group patients will receive standard and conventional acute ischemic stroke treatment, which includes statin therapy.
88876364|NCT06083935|Active Comparator|Metformin + Combined oral contraceptive|Metformin (Glucophage ® 500 tablets twice daily)+ Combined oral contraceptive (standard therapy) (Yassmin ® film-coated tablets 3 mg of drospirenone and 0.03 mg of ethinyl estradiol once daily daily)
89400759|NCT02066610|Experimental|PN selenium and formula sodium selenite|Parenteral nutrition (PN) with selenium and sodium selenite supplementation of infant formula
89400760|NCT02066610|Experimental|PN without selenium and formula sodium selenate|Parenteral nutrition (PN) without selenium and sodium selenate supplementation of infant formula
89400761|NCT02066610|Experimental|PN without selenium and formula sodium selenite|Parenteral nutrition (PN) without selenium and sodium selenite supplementation of infant formula
89400762|NCT03077711|Active Comparator|Patients with recurrent UTIs arm 1|Patients are randomized to receive methenamine hippurate in one arm if they are diagnosed with recurrent urinary tract infections.
89400763|NCT03077711|Active Comparator|Patients with recurrent UTIs arm 2|Patients are randomized to receive trimethoprim in the other arm if they are diagnosed with recurrent urinary tract infections.
89400764|NCT03673683|Active Comparator|Usual Care|Sedation and ventilation weaning that is non-protocol-based and primarily medically-driven.
89400765|NCT03673683|Experimental|SANDWICH protocol|A protocol-based intervention for managing sedation and ventilation weaning.
89400766|NCT03533426|Active Comparator|Pump based patient controlled analgesia|"Analgesia is maintained using disposable silicon ballon pump Accufuser containing morphine 0.2 mg/ml, 8mg ondansetron plus and 180 mg ketorolac. The infusion rate is 5 ml / h and lockout interval of 15min. the hourly delivered morphine dose is 1-1.8 mg & the pump is sufficient for about 60 hours according to patient response."
89400767|NCT03533426|Active Comparator|serratus anterior plane catheter block|"Linear ultrasound transducer (superficial) 6-12 MHz is utilized to count the ribs up to 4th or 5 th rib in the mid-axillary line. Musculature of thoracic wall is identified sonographically,an echogenic needle 14-16 G, 100 mm is inserted in plane with the U/S probe towards the plane deep to the serratus anterior muscle. Under real - time U/S, single shot of 20ml contrast medium iohexol = omnipaque 150 mg I2 / ml is injected to check the plane and level (T3-T8/9) of SAPB.A reinforced radiopaque catheter is threaded through the needle and its final position underneath the plane of serratus anterior muscle is confirmed fluoroscopically. 20ml 0.25% levobupivacaine (Chirocaine).Analgesia is maintained using 0.125% levobupivacaine infusion at a rate of 7-12 ml/h according to patient response."
89400768|NCT02069574|Experimental|severe periodontitis group|non-surgical periodontal therapy
89400769|NCT02069574|Experimental|Moderate periodontitis group|non-surgical periodontal therapy
89400770|NCT02069574|No Intervention|healthy control|No treatment
89400771|NCT04374019|Experimental|Arm C: Ivermectin|Ivermectin
89400772|NCT04374019|Experimental|Arm D: Camostat Mesilate|Camostat Mesilate
89400773|NCT04374019|Experimental|Arm E: Artemesia annua|Artemesia annua tea or coffee
89400774|NCT04374019|Experimental|Arm F: Artesunate|Artesunate
89400775|NCT02199704|Other|No control or comparison arm.|This case series study has no control or comparison arm. There is only one arm being evaluated (the self directed parenting intervention).
89400776|NCT03678363|Experimental|interventional group A|2 tai chi session per week during 4 month (M0 to M4)
89400777|NCT03678363|Placebo Comparator|Control group B|2 tai chi session per week during 2 month (M2 to M4)
89400778|NCT02199782|Active Comparator|Welsh|Participants will complete the cognitive assessment in Welsh and in English these will be compared to assess whether first language Welsh speakers perform better in Welsh.
89400779|NCT02199782|Active Comparator|English|Participants will complete the cognitive assessment in Welsh and in English these will be compared to assess whether first language Welsh speakers perform better in Welsh.
89400780|NCT02069808|Experimental|Group B: Follistim and Menopur|"Group B: N=25 subjects~Cycle day 2 start Follistim 200 U/day up to 11 days duration.~Cycle day 2 start Menopur (menotropins) 75 U/day up to 11 days duration.~Add GnRH antagonist Ganirelix 250 µg/day starting 5 days before GnRH agonist trigger.~GnRH agonist Leuprolide Acetate (Lupron) 1 mg subcutaneous injection 36 hours prior to egg collection.~Transvaginal ultrasound guided needle aspiration of oocytes 36 hours after Lupron trigger."
89400781|NCT02069808|Active Comparator|Group A: Follistim only|"Group A: N=25 subjects~Cycle day 2 start Follistim 250 U/day up to 11 days duration.~Add GnRH antagonist Ganirelix 250 µg/day starting 5 days before GnRH agonist trigger.~GnRH agonist Leuprolide Acetate (Lupron) 1 mg subcutaneous injection 36 hours prior to egg collection.~Transvaginal ultrasound guided needle aspiration of oocytes 36 hours after Lupron trigger."
89400782|NCT03678207||Potential Undiagnosed HTN|
89400783|NCT02199860|Experimental|SD I - single rising doses|
89400784|NCT02199860|Experimental|SD II - single rising doses|
89400785|NCT02199860|Experimental|SD II - single rising doses + Placebo|
89400786|NCT02199860|Placebo Comparator|Placebo|
89400787|NCT03673605|Experimental|Rivaroxaban|
88876365|NCT06083935|Experimental|Diosmin /Hesperidin + Combined oral contraceptive|Diosmin /Hesperidin (Daflon two tablets 500 mg daily)+ Combined oral contraceptive((Yassmin ® film-coated tablets 3 mg of drospirenone and 0.03 mg of ethinyl estradiol once daily daily)
88876366|NCT06083935|Active Comparator|Diosmin /Hesperidin +Metformin + Combined oral contraceptive combination|Diosmin /Hesperidin (Daflon two tablets 500 mg daily) +Metformin (Glucophage ® 500 tablets twice daily) + Combined oral contraceptive combination (Yassmin ® film-coated tablets 3 mg of drospirenone and 0.03 mg of ethinyl estradiol once daily daily
89400788|NCT03673605|Active Comparator|Warfarin|
89400789|NCT02069886|Experimental|deferasirox|single arm. all patients will receive deferasirox
89400790|NCT04311463|Experimental|Paroxetine hydrochloride followed by PAXIL|
89400791|NCT04311463|Experimental|PAXIL followed by paroxetine hydrochloride|
89400792|NCT02203994|Experimental|extracorporeal shock wave therapy (ESWT)|"one-time treatment of the spastic muscle/ spastic muscles (adductor muscles and/ or M. triceps surae) with extracorporeal shock wave therapy (device: Duolith® SD 1 T-Top (Storz Medical AG, Tägerwilen, Switzerland))"
89400793|NCT03070587|Experimental|Positive Affect Training for SAD|The intervention will be conducted in groups with 68 participants and 2 facilitators/therapists per group. The groups will meet once a week for 12 successive weeks and each session will be approximately 60 minutes long.
88876367|NCT06083779||Patients with endometrial cancer|the 108 patients with early to mid-stage endometrial cancer, more than 50% were in FIGO stages I/II.
88876368|NCT06083779||healthy people|108 healthy people
88876369|NCT06083727||primigravida|
88876370|NCT06083727||multigravida|
89004085|NCT03284710|Active Comparator|Group 1: ALVAC-HIV + gp120/MF59|Participants will receive the ALVAC-HIV (vCP2438) vaccine in the left deltoid at months 0, 1, 3, 6, and 12, and Bivalent Subtype C gp120/MF59 in the right deltoid at months 3, 6, and 12. All injections are via needle and syringe.
89400794|NCT03070587|No Intervention|Wait list Control|These participants will not be given an intervention until after they have completed the study.
89004086|NCT03284710|Active Comparator|Group 2: ALVAC-HIV + gp120/Al(OH)3|Participants will receive the ALVAC-HIV (vCP2438) vaccine in the left deltoid at months 0, 1, 3, 6, and 12, and Bivalent Subtype C gp120 admixed with Al(OH)3 Suspension in the right deltoid at months 3, 6, and 12. All injections are via needle and syringe.
89004087|NCT03284710|Active Comparator|Group 3: ALVAC-HIV + gp120/MF59|Participants will receive the ALVAC-HIV (vCP2438) vaccine in the left deltoid and Bivalent Subtype C gp120/MF59 in the right deltoid at months 0, 1, 6, and 12. All injections are via needle and syringe.
89004088|NCT03284710|Active Comparator|Group 4: ALVAC-HIV + gp120|Participants will receive the ALVAC-HIV (vCP2438) vaccine in the left deltoid at months 0, 1, 3, 6, and 12, and Bivalent Subtype C gp120 in the right deltoid at months 3, 6, and 12. All injections are via needle and syringe.
89004089|NCT03237286|Experimental|Ketamine + Cognitive Training|
89004090|NCT03237286|Sham Comparator|Ketamine + Sham Training|
89004091|NCT03237286|Placebo Comparator|Saline + Cognitive Training|
89004092|NCT03232931|Experimental|Multisensory Intervention|Preterm infants in the NICU who are randomized to receive a multisensory intervention, in addition to the standard of care. The multisensory intervention uses recordings of the parents' voices and nurturing touch administered in the NICU during 12 to 23 sessions of standardized, therapist-administered, auditory-tactile stimulation, dispersed over a 2 to 3 week period. The intervention includes 2 components: (1) holding and light pressure containment of the infant against the hospital-gown covered chest of the therapist for tactile and non-specific auditory stimulation simultaneous with (2) playing of mother's voice contingent on infant pacifier sucking. Additionally, a gauze square scented with parent's skin will be used to provide olfactory stimulation.
89004093|NCT03232931|Other|Standard of Care|Preterm infants in the NICU who are randomized to receive the standard of care. The standard care for preterm infants in the NICU currently follows medical protocols of skin-to-skin holding and exposure to recordings of parent's voice.
89004094|NCT03188809|Active Comparator|femoral nerve block|Bupivacaine 0.25% will be applied to the catheter at 6 hours, when the first dose of catheter is inserted.
89004095|NCT03188809|Active Comparator|adductor canal block|Bupivacaine 0.25% will be applied to the catheter at 6 hours, when the first dose of catheter is inserted.
89004096|NCT03179553||HIE|Babies admitted to the neonatal unit with suspected mild, moderate or severe hypoxic ischaemic encephalopathy .
89400795|NCT02065128||Healthy Volunteers|Capsaicin cough challenge test. The ILS participants will be asked to attend two study visits at the pulmonary function laboratory at SMH; one before behavioural therapy and one after. The healthy volunteers will be asked to attend one study visit. At each of these study visits, the ILS participants will complete the Leicester Cough Questionnaire (LCQ) (Appendix B) and the Dyspnea Index (DI) Questionnaire (Appendix C). The LCQ is a valid assessment tool for evaluating the impact of cough on QoL.19 The DI is a short, validated questionnaire used to quantify a patient's symptoms of dyspnea.20 Following completion of the questionnaires, participants will complete a capsaicin cough challenge test, which is discussed in the following section.
89004097|NCT03179553||Healthy|Babies who are inpatients in the postnatal ward, born following uncomplicated pregnancy and delivery.
89004098|NCT03173703|Experimental|Test Arm|Test Arm are subjects to be implanted with test article -XenoSure patch. The interventions include: Repair/reconstruction of the diseased vessel; Implant the XenoSure patch
89004099|NCT03173703|Active Comparator|Control Arm|Test Arm are subjects to be implanted with B. Braun's Vascular-Patch.The interventions include: Repair/reconstruction of the diseased vessel; Implant the Vascular-Patch.
89004100|NCT03159247|Experimental|eyeGuide|Two personalized eHealth interventions aimed to improve glaucoma medication adherence.
89004101|NCT03155997|Experimental|150 mg Abemaciclib + Endocrine Therapy|Participants received Abemaciclib orally at 150 milligrams (mg) twice daily with at least 6 hours between doses for up to 2 years or until evidence of disease recurrence or other discontinuation criteria were met, whichever occurs first. Endocrine therapy (physicians' choice) standard-of-care was administered according to package label until discontinuation criteria were met.
89004102|NCT03155997|Other|Endocrine Therapy|Endocrine therapy (physicians' choice) standard-of-care was administered according to package label until discontinuation criteria were met.
89004103|NCT03153384||one both experimental and control arm|Each patient experiences two methods of blood cultures.
89004104|NCT03110861|Experimental|Pulsta® Transcatheter Pulmonary Valve|Pulsta® Transcatheter Pulmonary Valve (TaeWoong Medical Co., Ltd. Korea)
89004105|NCT03103750|Experimental|Calcitriol then placebo|Healthy volunteers will receive a baseline MRI. On the night before and day of testing, subjects will receive two doses of calcitriol (3.0mcg total), followed by PHNO injection and PET Scan #1. After PET Scan #1, subjects will receive a Dexedrine dose, followed by PHNO injection and PET Scan #2. A minimum of six days later, subjects will receive two doses of placebo for the night before and day of testing, followed by a third PHNO injection and PET scan #3. After PET scan #3, subjects will receive another Dexedrine dose, followed by PHNO injection and PET scan #4.
89004106|NCT03103750|Experimental|Placebo then Calcitriol|Healthy volunteers will receive a baseline MRI. On the night before and day of testing, subjects will receive two doses of placebo, followed by PHNO injection and PET Scan #1. After PET Scan #1, subjects will receive a Dexedrine dose, followed by PHNO injection and PET Scan #2. A minimum of six days later, subjects will receive two doses of calcitriol (3.0mcg total) for the night before and day of testing, followed by a third PHNO injection and PET scan #3. After PET scan #3, subjects will receive another Dexedrine dose, followed by PHNO injection and PET scan #4.
89004107|NCT03066440|Placebo Comparator|Normal Saline|Intervention: intravenous solutions containing only normal saline as the primary base during the entire treatment of diabetic ketoacidosis.
89400796|NCT02065128||Irritable Larynx Syndrome Patients|Capsaicin cough challenge test. The ILS participants will be asked to attend two study visits at the pulmonary function laboratory at SMH; one before behavioural therapy and one after. The healthy volunteers will be asked to attend one study visit. At each of these study visits, the ILS participants will complete the Leicester Cough Questionnaire (LCQ) (Appendix B) and the Dyspnea Index (DI) Questionnaire (Appendix C). The LCQ is a valid assessment tool for evaluating the impact of cough on QoL.19 The DI is a short, validated questionnaire used to quantify a patient's symptoms of dyspnea.20 Following completion of the questionnaires, participants will complete a capsaicin cough challenge test, which is discussed in the following section.
89400797|NCT03678051|Active Comparator|Treatment as Usual (TAU)|Standard of care
89400798|NCT03678051|Experimental|TAU+CBT4CBT|TAU with access to the CBT4CBT program
89400799|NCT01569503|Experimental|VSN|VNS therapy
89400800|NCT04296565|Other|Usual Care|Usual Care condition involves receipt of educational materials about brain health and healthy lifestyles as well as regular contact with study staff.
89400801|NCT04296565|Experimental|WATER+CT|This is an 8 month long two phase intervention. The first phase consists of 6 months of thrice weekly pool based physical activity occurring at the Palo Alto VA Health Care System. After completion of the 6 month long water based physical activity, participants transition to a ten session cognitive training program at the Palo Alto VA. The cognitive training classes are approximately two hours in length and will be spread over ten sessions across 4 weeks.
89400802|NCT03677895|Experimental|patients with rotator cuff disorders|patients with rotator cuff disorders, including impingment, rotator cuff disorders and rotator cuff tear receiving hyaluronic acid injection over subacromial bursa
89400803|NCT04295005||All patients who started an Empagliflozin therapy|
89400804|NCT04295005||All patients who started a DPP-4 inhibitor therapy|
89400805|NCT04295005||All patients who started a Sitagliptin therapy|
89400806|NCT04295005||All patients who started a GLP-1 receptor agonist therapy|
89400807|NCT03174353|Experimental|Lanreotide arm|Single arm study. A single deep subcutaneous dose of lanreotide (Somatuline Depot 120 Mg/0.5Ml) will be administered prior to planned resection on the day of surgery.
89400808|NCT02260284|Experimental|Yaotong points acupuncture|patients under the treatment of Yaotong ponts penetration mode
89400809|NCT02260284|Active Comparator|standardized acupuncture|patients under the treatment of standardized acupuncture
89400810|NCT02260284|Other|the usual care|In the usual care group, participants received no study-related care-just the care, if any, that they and their physicians chose: mostly massage and physical therapy visits and continued use of medications (mostly nonsteroidal anti-inflammatory drugs (NSAIDS)).
89400811|NCT03673449|Experimental|SilkBridge treatment|Surgery for digital nerve reconstruction with SilkBridge
89400812|NCT05214235||Metformin|Patients who use metformin to control blood sugar level.
89400813|NCT05214235||Sitagliptin|Patients who use sitagliptin to control blood sugar level.
89400814|NCT02204306|Other|TSER *2/*2 *2/*3|Patients with TSER *2/*2 *2/*3 genotypes will be assigned to this group and receive standard chemotherapy contains fluorouracil. (FOLFOX 6/XELOX/SOX)
88876371|NCT06083701|Experimental|Linperlisib plus Chidamide|Linperlisib combined with chidamide
89400815|NCT02204306|Other|TSER*3/*3 (fluorouracil)|Patients with TSER*3/*3 genotype will be randomly assigned to fluorouracil group (FOLFOX 6/XELOX/SOX) or non-fluorouracil group (DC or DO).
89400816|NCT02204306|Other|TSER*3/*3 (non-fluorouracil)|Patients with TSER*3/*3 genotype will be randomly assigned to fluorouracil group (FOLFOX 6/XELOX/SOX) or non-fluorouracil group (DC or DO).
89400817|NCT03439319|Active Comparator|MyndMove® therapy|Non-invasive Functional Electrical Stimulation (FES) technique with surface electrodes to stimulate from 3 to 8 muscles to create purposeful movements in one or both hands/arms
89400818|NCT03439319|Active Comparator|Intensive Conventional therapy|Using Conventional therapy which focuses exclusively on the purposeful movements in one or both hands/arms
89400819|NCT05208151|Active Comparator|Creative Drama Group|
89400820|NCT05208151|No Intervention|Control Group|
89400821|NCT02199938||musculoskeletal tumors|Patients with suspected or confirmed bone or soft tissue tumors undergoing biopsy or surgery
89400822|NCT02069964||Prospective hemi-neck RT|
89400823|NCT04080947|Placebo Comparator|Control group|26 patients will receive placebo (Control group)
89400824|NCT04080947|Experimental|Montelukast group|26 patients will receive montelukast 10 mg/ day
89400825|NCT02208284|Experimental|Cohort 1-PF-06427878 or placebo|Single ascending doses of PF-06427878 or placebo to investigate the safety, tolerability, and PK.
89400826|NCT02208284|Experimental|Cohort 2-PF-06427878 or placebo|Single ascending doses of PF-06427878 or placebo to investigate the safety, tolerability, and PK.
89400827|NCT02208284|Experimental|Cohort 3-PF-06427878 or placebo|Single ascending doses of PF-06427878 or placebo to investigate the safety, tolerability, and PK.
89400828|NCT02066688|Experimental|FA|Patients receive oral folic acid pill 1 mg daily for 36 months in the absence of unacceptable toxicity or any other adverse effects (FA Arm).
89400829|NCT02066688|Experimental|FA+Ca|Patients receive oral folic acid pill 1 mg+ calcium 1200mg +vitamin D3 250 IU daily for 36 months in the absence of unacceptable toxicity or any other adverse effects(FA+Ca arm).
88876372|NCT06083688|Experimental|Intermittent Preventive Treatment with dihydroartemisinin-piperaquine (IPT-DP)|All students are treated at each intervention. Treatment will be with DP (females less than 13 years old and all males) or chloroquine (females 13 years old or older).
88876373|NCT06083688|Experimental|Intermittent Preventive Treatment with sulfadoxine-pyrimethamine plus chloroquine (IPT-SPCQ)|All students are treated at each intervention. Treatment will be with SP and CQ (females less than 13 years old and all males) or chloroquine (females 13 years old or older).
89004108|NCT03066440|Experimental|Lactated Ringers|Intervention: intravenous solutions containing only lactated ringers as the primary base during the entire treatment of diabetic ketoacidosis.
89400830|NCT02066688|Experimental|Ca|Patients receive oral calcium 1200mg +vitamin D3 250 IU daily for 36 months in the absence of unacceptable toxicity or any other adverse effects (Ca Arm).
89400831|NCT02066688|Placebo Comparator|blank control group|Patients receive oral placebo once daily for 36 months in the absence of unacceptable toxicity or any other adverse effects.
89400832|NCT03671733|Experimental|Liraglutide|Administered subcutaneously (s.c., under the skin) once daily for 12 weeks.
89400833|NCT03671733|Experimental|Exenatide|Administered subcutaneously (s.c., under the skin) twice daily for 12 weeks.
89400834|NCT03671733|Experimental|Exenatide Microspheres for Injection|Administered subcutaneously (s.c., under the skin) once weekly for 12 weeks.
89400835|NCT02200016|Experimental|SAX|Ultrasound guided short axis (SAX) placement of sciatic nerve catheters
89400836|NCT02200016|Active Comparator|LAX|Ultrasound guided long axis (LAX) placement of sciatic nerve catheters
89400837|NCT03119363|Experimental|Experimental Light|The experimental systematic light exposure consists of exposure to light to reduce cancer-related fatigue. This group will self-administer 30 minutes of light from commercially available light glasses (AYO) each morning for 4 weeks. The AYO light glasses is a lightweight pair of glasses that emits light from LEDs at a distance of 15 millimeters (15mm, 0.015m) from the eye.
89400838|NCT03119363|Active Comparator|Comparison Light|The active comparator condition consists of exposure to light to reduce cancer-related fatigue. This group will self-administer 30 minutes of light from commercially available light glasses each morning for 4 weeks.
89400839|NCT02070042|Experimental|Omega- 3 Fatty Acid|The patient will receive oxybutynin 5 mg twice daily (BID). The patients in the study group will receive a 0.9 gm capsule of Omega-3 BID. The amount of medication was chosen based on dosage used in prior studies and the current FDA recommendations to not exceed 2gm/day of omega-3 in dietary supplementation.
89400840|NCT02070042|Placebo Comparator|Placebo|Seagate® Extra Virgin Olive oil capsules
88876374|NCT06083688|Experimental|Intermittent Preventive Treatment with sulfadoxine-pyrimethamine plus amodiaquine (IPT-SPAQ)|All students are treated at each intervention. Treatment will be with SP and AQ (females less than 13 years old and all males) or chloroquine (females 13 years old or older).
88876375|NCT06083688|No Intervention|Control|Students will not receive preventive treatment.
88876376|NCT06083636||Hashimoto's hypothyroidism|Group of 100 patients with Hashimoto's hypothyroidism using levothyroxine
88876377|NCT06083636||Hypothyroidism after thyroidectomy after thyroid carcinoma|Group of 100 patients with hypothyroidism after thyroidectomy after thyroid carcinoma using levothyroxine
88876378|NCT06083636||Central hypothyroidism|Group of 100 patients with central hypothyroidism using levothyroxine
88876379|NCT06083636||Hypothyroidism during treatment for Graves' Disease|Group of 100 patients with hypothyroidism during treatment for Graves' Disease using levothyroxine
89400841|NCT04059081|Experimental|GC chemotherapy|"Before administration of GC chemotherapy, all patients must undergo pretreatment bone marrow biopsy. The pretreatment BM biopsy must include at least 1 long core biopsy samples and 10 cc of aspirate.~Obinutuzumab 1000mg fixed dose will be administered intravenously (Day 1,8,15 for cycle 1 and D1 for subsequent cycles). Chlorambucil 0.5mg/kg will be administered orally (D1,15 for all cycles).~28 days are considered as one cycle, and cycles will be repeated every 4-weeks for a total of 6 cycles."
89400842|NCT03671655|Experimental|Drug-eluting stent|Drug-eluting stent is nitinol stent coated with Paclitaxel drug Other Names: Zilver PTX stent Zilver Paclitaxel stent
89400843|NCT03671655|Active Comparator|Bare metal stent|Bare metal stentis Nitinol alloy self expandable stent. Other Names: Bare metal stent Nitinol stent SMART Stent Viabahn stent
89400844|NCT02204384|Experimental|HFD Meal: high fiber from food|HFD Meal: high amount of fiber from diet food sources (total fiber 9.7g; soluble fiber 5.4g)
88876380|NCT06083636||Healthy controls|100 healthy euthyroid controls
88876381|NCT06083623|Experimental|TNM001|
88876382|NCT06083623|Placebo Comparator|Placebo|
88876383|NCT06083597||Chronic pelvic pain of venous origin|Women who are thought to have chronic pelvic pain of venous origin will be interviewed to determine the impacts of their pain on physical, social and emotional aspects of their health and well being.
88876384|NCT06083597||Chronic pelvic pain of non-venous origin|Women who are thought to have chronic pelvic pain of a non-venous origin will be interviewed to determine the impacts of their pain on physical, social and emotional aspects of their health and well being. They will be asked of the concepts identified by the women with venous origin CPP apply to them and if the impacts of the pain are similar or differ.
88876385|NCT06083584||Positive controls|6 patients already in database. The 6 confirmed splicing mutations are: DCTN1 (NM_004082.5): c.3209G>T, OPTN (NM_001008211.1) : c.1613-7T>G, FUS (NM_004960.4) : c.764+8T>A, GRN (NM_002087.4): c.835+1G>A, GRN (NM_002087.4): c.709-3C>G, SPG11 (NM_025137.4): c.3039-5T>G
88876386|NCT06083584||Negative controls|30 patients with familial hypercholesterolemia. The absence of splicing anomalies in the SLA genes after confirmation by RT-PCR followed by Sanger sequencing of the absence of anomalies for the 6 variants listed above for each of the 30 individuals.
88876387|NCT06083584||Exploratory cohort|156 ALS: 20 ALS patients with splice variants predicted to be deleterious by in silico prediction software; 136 panel-analysis-negative ALS patients (priority will be given to familial ALS)
88876388|NCT06083532|Experimental|PAP induced at an intensity of 70% 1RM（One-Repetition Maximum）combined with complex training|PAP induced at an intensity of 70% 1RM combined with complex training was shown over the 12 weeks.
89400845|NCT02204384|Experimental|HFS Meal: High fiber from supplement|HFS Meal: high amount of soluble fiber from guar gum supplement (HFS; total fiber 9.1g; soluble fiber 5.4g) - Fiber Mais, Nestlé
89400846|NCT02204384|Experimental|UF Meal: usual amount of fiber|UF Meal: usual amount of fiber (total fiber 2.4g; soluble fiber 0.8g)
89400847|NCT01377311|Experimental|1|Patients suffering from unilateral limbal stem cell insufficiency. Remove the abnormal surface tissue on the lesion cornea, transplant the amniotic membrane with cultured limbal stem cells on the denuded cornea. Cover with contact lens after operation, and apply topical antibiotics and steroids.
89400848|NCT02208440|Sham Comparator|Best Repair of torn Rotator Cuff|Subjects will undergo surgical intervention (usually arthroscopy) to perform debridement, acromioplasty if deemed necessary, long head of biceps tenotomy, and at least partial repair.
89400849|NCT02208440|Active Comparator|InSpace™ system|Subjects will undergo surgical intervention (usually arthroscopy or mini invasive) of debridement, acromioplasty if deemed necessary with or without long head of biceps tenotomy, and placement of the InSpace™ system.
89400850|NCT03671577|Experimental|Active Treatment|four week computerized intervention designed to reduce fear of intimacy
89400851|NCT03671577|No Intervention|Wait List Control|Participants will continue as usual and will be given the option to receive the active treatment after completion of the study
89004109|NCT03037632|Experimental|Communication Tool|
89400852|NCT02200094||Outpatients with essential hypertension|
89400853|NCT01370538|Experimental|Esomeprazole 20 mg|
89400854|NCT01370538|Placebo Comparator|Placebo|
89004110|NCT03037632|No Intervention|No Communication Tool|
89004111|NCT02974088|Experimental|Neem-based lotion plus louse comb|Neem-based conditioning lotion plus head louse detection and removal comb
89004112|NCT02974088|Experimental|Neem-based lotion plus grooming comb|Neem-based conditioning lotion plus regular grooming comb
89400855|NCT03623295||Cohort study population|For the main cohort study, we will include 500 patients with moderate or mild hemophilia A and 500 patients with moderate or mild hemophilia B.
89400856|NCT03623295||Sub study population|A subset of 200 patients of the cohort study population will be investigated in more detail by longitudinal data collection.
89400857|NCT03248297|Experimental|Azithromycin and amoxicillin placebo|Patients in this arm will receive 1 gram oral azithromycin as a single dose and amoxicillin placebo.
89400858|NCT03248297|Experimental|Azithromycin + amoxicillin|Patients in this arm will receive 1 gram oral azithromycin and 2 grams oral amoxicillin in a single dose.
89400859|NCT03248297|Placebo Comparator|Usual Care|This arm will consist of routine care at the clinical sites (which is usually no antibiotic). They will receive placebo (for azithromycin) and placebo (for amoxicillin)
89400860|NCT02208518||Elastography analysis|Consecutive patients undergoing for upper endoscopy ultrasound
89400861|NCT02199626|Experimental|CCE-2|Second generation of Colon capsule endoscopy in pediatric Crohn's disease
89400862|NCT02208596|Experimental|Group A|In group A, propofol (1%) was mixed with etomidate in the ration of 1:1 (volume). The mixture will be injected continuously until the eyelash reflex disappears. During the operation, supplementary mixture will be administered if the patient has spontaneous movement that hampered the conduct of the procedure.
89400863|NCT02208596|Experimental|Group B|In group B, propofol (1%) was mixed with etomidate in the ration of 7:5 (volume). The mixture will be injected continuously until the eyelash reflex disappears. During the operation, supplementary mixture will be administered if the patient has spontaneous movement that hampered the conduct of the procedure.
89400864|NCT02208596|Experimental|Group C|In group C, propofol (1%) will be injected continuously until the eyelash reflex disappears. During the operation, supplementary propofol will be administered if the patient has spontaneous movement that hampered the conduct of the procedure.
89400865|NCT02070120|Experimental|Chemoresection|4 once weekly outpatient intravesical instillations 40mg Mitomycin C
89400866|NCT02070120|Other|Surgical Management|Surgical management according to local practice
89400867|NCT03673215|Experimental|A|
89400868|NCT03673215|Experimental|B1|
89400869|NCT03673215|Placebo Comparator|B2|
89004113|NCT02946255|Experimental|Welcome Basket Brief (WBbr)|The brief version of the Welcome Basket (WBbr) was developed based upon the observation in feasibility testing that for some participants much of the benefit of this approach appeared to be centred upon the visits immediately prior and subsequent to discharge. In the WBbr the same core components will be present, albeit in an abbreviated form with one 30-60 minute visit in the week prior to discharge and a single, 3-hour visit in the week subsequent to discharge in which the welcome basket would be delivered, core CAT strategies discussed and implemented, and some basic orientation to community resources undertaken. This brief version of the intervention has not to date been studied.
89400870|NCT03673215|Experimental|C1-1|
89400871|NCT03673215|Placebo Comparator|C1-2|
89400872|NCT03673215|Experimental|C2-1|
89400873|NCT03673215|Placebo Comparator|C2-2|
89400874|NCT03673215|Experimental|C3-1|
89400875|NCT03673215|Placebo Comparator|C3-2|
89400876|NCT02200172|Active Comparator|Melatonin|A single daily sublingually administered tablet of 3mg non-animal synthetic source melatonin (immediate-release) at 21.00 hours (±1 hour), starting on Study Day 1 and stopping on Study Day 28 of admission or earlier in the event of death or discharge.
89400877|NCT02200172|Placebo Comparator|Placebo|A single daily sublingually administered tablet of placebo at 21.00 hours (±1 hour), starting on Study Day 1 and stopping on Study Day 28 of admission or earlier in the event of death or discharge.
89400878|NCT03673137|Experimental|Synchronous treatment group|Gemcitabine was administered over 30 minutes immediately following percutaneous irreversible electroporation. Gemcitabine was then given once weekly for 2 weeks, followed by a week of rest from treatment. Subsequent cycles consisted of once weekly infusions for 3 consecutive weeks out of every 4 weeks.Treatment continued until disease progression was detected by mRECIST or there was unacceptable toxicity.
89400879|NCT03673137|Active Comparator|Traditional treatment group|The initial gemcitabine administration was on day 7 following IRE treatment. Once weekly infusions for 3 consecutive weeks out of every 4 weeks.Treatment continued until disease progression was detected by mRECIST or there was unacceptable toxicity.
89400880|NCT02066766||Subjects with diabetes mellitus (type 2)|
89400881|NCT02204540|Experimental|Monitoring by webcam|Participants will perform a task for a mock clinical study (e.g., swallowing a pill, consuming food) while being recorded and monitored by webcam.
89400882|NCT02204540|Active Comparator|In-person monitoring|Participants will perform a task for a mock clinical study (e.g., swallowing a pill, consuming good) while being monitored in-person.
89400883|NCT02066844|Active Comparator|Standard Manual Needle Injection|2cc of Celestone and 5cc of Lidocaine will be administered by the nurse or surgeon
89400884|NCT02066844|Experimental|Navigator Injection|2cc of Celestone and 5cc of Lidocaine will be administered using the Navigator by the nurse or surgeon
89400885|NCT03669783|Active Comparator|treatment VAD|Vincristin, Actinomycin-D and Doxorubicin
89400886|NCT03669783|Experimental|treatment VCE|Vincristin, Carboplatin and Etoposide
89400887|NCT02204618|Experimental|cochlear implantation|Our experimental protocol relies on real life therapeutic strategy, where a cochlear implant may be proposed once CROS and bone conductions systems have failed. Thus, all subjects enrolled in our study will try CROS and bone conduction devices. If these trials are ineffective, the remaining subjects will be randomized between two arms (cochlear implantation vs 6 months abstention followed by cochlear implantation).
88876389|NCT06083532|Experimental|PAP induced at an intensity of 80% 1RM combined with complex training|PAP induced at an intensity of 80% 1RM combined with complex training was shown over the 12 weeks.
88876390|NCT06083532|Experimental|PAP induced at an intensity of 90% 1RM combined with complex training|PAP induced at an intensity of 90% 1RM combined with complex training was shown over the 12 weeks.
88876391|NCT06083532|Active Comparator|Routine warm-up combined with complex training|Routine warm-up combined with complex training was shown over the 12 weeks.
89536671|NCT02471495|Experimental|Synergo® RITE + MMC|"Induction~Patients will receive 8 weekly treatments of Synergo® RITE + MMC, using the Synergo® System. Each treatment lasts about 60 minutes and consists of two 30-minute cycles with 40 mg MMC/50 ml sterile water for injection each cycle. These 8 treatments will be followed by a pause (see Table 1), after which a follow-up cystoscopy (first follow-up control) will be conducted during Weeks 12-13 (from the first treatment).~Maintenance~Patients will receive one Synergo® RITE + MMC treatment every 6 weeks. Each treatment lasts about 60 minutes and consists of two 30-minute cycles with 40 mg MMC/50 ml sterile water for injection each cycle. Maintenance treatments will be given until the end of 12 months after the patient's first induction treatment."
88876392|NCT06083441||Acute Brain Injury (ABI)|Patients that have suffered an ABI resulting in Coma (Glasgow Coma Scale (GCS) < 9) will undergo SeeMe and CRS-R assessment once a day until hospital discharge
88876393|NCT06083441||Control|Healthy subjects will undergo SeeMe and CRS-R assessment once.
88876394|NCT06083415|Experimental|6 to 8 years old girls, presenting with a breast flare-up|Girls aged 6 to 8 years old with breast flare (isolated or not) and scheduled for pediatric day hospital stay
88876395|NCT06083402|Active Comparator|Active|Participants receive 1 HyaCera™ capsule orally once daily for 12 weeks
88876396|NCT06083402|Placebo Comparator|Placebo|Participants receive 1 placebo capsule orally once daily for 12 weeks
88876397|NCT06083389|Active Comparator|traditional technique of facial exercises along with electrical stimulation of facial muscles.|facial muscle exercise active exercises will be initiated, which is performed in front of a mirror in sitting position. The patient will be instructed for activities like blowing air in the mouth, nasal flaring, smiling, raising and frowning of the eyebrows, opening and closing of the eye, clenching of the teeth and holding straw in mouth, suck and blow out air, show as if blowing a balloon for 20 minutes each session, for 3 sessions/ week for 6 weeks.
88876398|NCT06083389|Active Comparator|Kabat technique arm along with stimulation of facial muscles.|"During the Kabat rehabilitation session, the patients will perform specific diagonal and spiral movements, involving the following three muscle fulcrums:~Upper fulcrum: includes the frontalis, corrugator & orbicularis oculi muscles.~Intermediate fulcrum: includes the common elevator muscle of the upper lip and nasalis.~Lower fulcrum: includes the risorius, zygomaticus major, the orbicularis oris and buccinator. (Khanzada et al., 2018).~The manipulation of these three fulcra will be carried out by utilizing contralateral contraction and the basic proprioceptive stimulation comprising stretching, maximal resistance, manual contact and verbal input.~Kabat sessions will be 3 sessions / week for 6 weeks."
88876399|NCT06083350|Experimental|Yeast beta-glucan|Yeast beta-glucan capsules, 250mg，taken with meals, two capsules twice a day
88876400|NCT06083350|Placebo Comparator|Starch|Starch capsule, 250mg, taken with meals, two capsules twice a day
88876401|NCT06083337|No Intervention|Standard of care management|Patients will receive standard of care treatment.
88876402|NCT06083337|Experimental|Coronary inflammation-based management|Participants classified as moderate risk (FAI-Score 75th-89th percentile for the RCA or the LAD or ≥ 95th percentile for the LCx) or CaRi-Heart risk≥ 5% and <10%) will receive atorvastatin 40mg daily, if they do not already receive statin therapy, while if they already receive statin, it will be discontinued and they will be given atorvastatin 80 mg daily. Participants classified as high risk (FAI-Score≥ 90th percentile for the RCA or the LAD or CaRi-Heart risk≥ 10%) will receive atorvastatin 80 mg daily and colchicine 0.5 mg daily. Tolerance and compliance will be monitored during the study follow-up and participants will be informed at enrollment about possible treatment side effects. In case of colchicine intolerance, colchicine will be discontinued. If the patient cannot tolerate atorvastatin, then half dose may be prescribed daily. In case of severe adverse events related to atorvastatin, atorvastatin will be discontinued and the participant will withdraw from the study.
88876403|NCT06083324||General cancer patients|All patients undergoing treatment for cancer on an exercise regimen
89400888|NCT02204618|Other|6 months initial abstention|Our experimental protocol relies on real life therapeutic strategy, where a cochlear implant may be proposed once CROS and bone conductions systems have failed. Thus, all subjects enrolled in our study will try CROS and bone conduction devices. If these trials are ineffective, the remaining subjects will be randomized between two arms (cochlear implantation vs 6 months abstention followed by cochlear implantation).
89400889|NCT02067078|Experimental|Combined saphenous nerve and obturator nerve block|
89400890|NCT02067078|Experimental|Saphenous nerve block|
89400891|NCT02067078|Active Comparator|Local infiltration analgesia|
89400892|NCT03673059|Experimental|OTC Eczema Moisturizer Regimen|Subjects who were assigned to use an over-the-counter (OTC), oatmeal-containing eczema therapy moisturizing cream. The product is classified as an OTC monograph drug.
89400893|NCT03673059|Experimental|Cosmetic Moisturizer Regimen|Subjects who were assigned to use a non-fragranced, dry skin daily moisturizer classified as a cosmetic (i.e. non-OTC).
89400894|NCT05461235|Experimental|Anti-PD-1 antibody combined with autologous DC and NK cells|"Anti-PD-1 antibodies (one of six options)~Pembrolizumab: 2 mg/kg or 200 mg by intravenous infusion every 3 weeks~Nivolumab:3 mg/kg or 240 mg by intravenous infusion every 2 weeks~Sintilimab: 200 mg by intravenous infusion every 3 weeks~Toripalimab: 3 mg/kg or 240 mg by intravenous infusion every 2 weeks~Camrelizumab: 200 mg by intravenous infusion every 2 or 3 weeks, or 3 mg/kg by intravenous infusion every 3 weeks~Tislelilzumab: 200mg by intravenous infusion every 3 weeks. DC, NK cells. 50ml of peripheral blood is collected 1 day before the dosing cycle for in vitro isolation and expansion of DC and NK cells; the first infusion of DC and NK cells (not less than 1x10^6 cells/Kg) is completed on day 14."
89400895|NCT02204696||Tonsillectomy|All participants will undergo baseline sleep study, a second preoperative sleep study after a period of watchful waiting, and a postoperative sleep study.
89400896|NCT02070198|Experimental|Long acting FSH and GnrH antagonist|Woman in long acting FSH and GnRH antagonist arm receive an initial dose of 150 mcg Corifollitropin alfa on second day of the menstrual cycle followed by a fixed daily dose of 0.25 mg of GnRH antagonist on day 7 of the cycle onwards. On the ninth day of the cycle, a daily fixed dose of 300 IU of recombinant FSH will be administered until the day of ovulation triggering.
89400897|NCT02070198|Experimental|daily FSH and GnRH antagonist|Woman in daily FSH and GnRH antagonist arm receive a fixed dose of 300 IU of recombinantFSH starting 3 day of the menstrual cycle followed by a fixed daily dose of 0.25 mg of GnRH antagonist on day 7 of the cycle onwards until the day of ovulation triggering.
89400898|NCT02070198|Experimental|Triptorelin and recombinant FSH|Women in triptorelin and recombinant FSH arm receive a fixed dose of 0.05 mg of triprorelin from the 1 day of the menstrual cycle followed by a fixed dose of 300 IU of recombinant FSH starting 3 day until the day of HCG administration.
89400899|NCT03672981|Experimental|Supportive Care (aerobic exercise and resistance training)|Patients undergo moderately intense aerobic/cardiovascular exercise over 30-60 minutes and complete 1-2 sets of 8 to 10 resistance/strength training exercises, 8 to 12 repetitions of each exercise, 3 days per week for 12 weeks. Patients also participate in weekly phone calls with an exercise physiologist to ensure adherence to the program and to provide support.
89400900|NCT02208674|No Intervention|Usual Care|Primary care provider-delivered screening and treatment for risk factors (hypertension, albuminuria, dyslipidemia) per usual care.
89400901|NCT02208674|Experimental|Protocolized, pharmacist-delivered CKD Action Plan|Protocolized, pharmacist-delivered screening and treatment for risk factors (hypertension, albuminuria, dyslipidemia) per KDIGO and JNC-8 recommendations.
89400902|NCT02070354||Group 1|New clinic visit in GI Nutrition (prior to bariatric surgery).
89400903|NCT02070354||Group 2|1 month prior to bariatric surgery
89400904|NCT02070354||Group 3|6 months after bariatric surgery
89400905|NCT02070354||Group 4|12 months after bariatric surgery
89400906|NCT02070354||Group 5|24 months after bariatric surgery
89400907|NCT02070354||Group 6|≥ 36 months after bariatric surgery
89400908|NCT03672903|Experimental|Intervention|Subjects in this arm will carry heavy weight vests for three weeks.
89400909|NCT03672903|Placebo Comparator|Control|Subjects in this arm will carry light weight vests for three weeks.
89400910|NCT02204774||Dilatated or aneurysmatic Aorta|Complete cohort, which will be followed over 3 years
89400911|NCT02067156|Experimental|G-202 (Mipsagargin)|G-202 (Mipsagargin) administered by intravenous infusion on 3 consecutive days of a 28-day cycle
89400912|NCT04058613|Experimental|Albumin|Albumin infusions will be given at a dose of 40 g twice weekly till a steady albumin level of 4.0g/dl is reached followed by 100ml of 20% albumin at least once in two weeks to maintain a steady albumin level of 4.0g/dl along with the standard medical therapy
89400913|NCT04058613|Placebo Comparator|Placebo|Placebo
89400914|NCT02067234|Active Comparator|Routine Care/Education|Patient will be assessed by MD and provided education by nurse
89400915|NCT02067234|Experimental|Psychoeducation/Coping Prevention|Patient will be assessed by MD and will meet with psychologist to obtain psychoeducation about coping, behavioral strategies, and sleep hygiene
88876404|NCT06083324||Head and neck cancer patients|All patients undergoing treatment for head and neck cancer on an exercise regime
88876405|NCT06083324||Colorectal cancer patients|All patients undergoing treatment for colorectal cancer on an exercise regime
88876406|NCT06083324||Pancreatic cancer patients|All patients undergoing treatment for pancreatic cancer on an exercise regime
88876407|NCT06083324||Metastatic breast cancer patients|All patients undergoing treatment for metastatic breast cancer on an exercise regime
88876408|NCT06083311|Experimental|Probiotic|Participants in this arm will receive a daily dose of 3x10^9 Colony Forming Units (CFU) of a live bacterium, corresponding to 1 capsules daily for 28 days
88876409|NCT06083311|Placebo Comparator|Placebo|Participants in this arm will receive an equivalent placebo for 28 days
88876410|NCT06082817|Experimental|Active|Participants will receive 50mg oral testosterone undecanoate daily, have pharmacokinetics assessed and complete validated instruments
89400916|NCT02801747|Experimental|Condition 1|Receives a core intervention session and the navigation intervention component (long duration; that is, up to 6 months).
89400917|NCT02801747|Experimental|Condition 2|Receives a core intervention session, the focused support group component, and the navigation intervention component (short duration, that is, up to 3 months).
89400918|NCT02801747|Experimental|Condition 3|Receives a core intervention session, the peer mentorship component, and the navigation intervention component (short duration, that is, up to 3 months).
89400919|NCT02801747|Experimental|Condition 4|Receives a core intervention session, the peer mentorship component, the focused support group component, and the navigation intervention component (long duration, that is, up to 6 months).
89400920|NCT02801747|Experimental|Condition 5|Receives a core intervention session, the pre-adherence preparation component, and the navigation intervention component (short duration, that is, up to 3 months).
89400921|NCT02801747|Experimental|Condition 6|Receives a core intervention session, the pre-adherence preparation component, the focused support group component, and the navigation intervention component (long duration, that is, up to 6 months).
89400922|NCT02801747|Experimental|Condition 7|Receives a core intervention session, the pre-adherence preparation component, the peer mentorship component, and the navigation intervention component (long duration, that is, up to 6 months).
89400923|NCT02801747|Experimental|Condition 8|Receives a core intervention session, the pre-adherence preparation component, the peer mentorship component, and the navigation intervention component (short duration, that is, up to 3 months).
88876411|NCT06082726|Experimental|small intestinal delivery capsules|Participants will ingest small intestinal delivery capsules filled with short-chain fatty acids.
88876412|NCT06082726|Experimental|Colon-delivery capsules|Participants will ingest colon-delivery capsules filled with short-chain fatty acids.
88876413|NCT06082232|Active Comparator|Group M (midazolam group)|includes thirty patients who receive intrathecal 4 mL (20 mg) 0.5% hyperbaric bupivacaine and 1 mg midazolam (8 units of 5 mg/mL preservative-free midazolam loaded in a 40 unit insulin syringe).
88876414|NCT06082232|Active Comparator|Group D(dexmedetomidine group)|includes thirty patients who receive intrathecal 4 mL (20 mg) 0.5% hyperbaric bupivacaine and 5 mcg dexmedetomidine (2 units of 100 mcg/mL preservative-free dexmedetomidine loaded in a 40 unit insulin syringe).
89400924|NCT02801747|Experimental|Condition 9|Receives a core intervention session, the Motivational Interviewing sessions component, and the navigation intervention component (short duration, that is, up to 3 months).
89400925|NCT02801747|Experimental|Condition 10|Receives a core intervention session, the Motivational Interviewing sessions component, the focused support group component, and the navigation intervention component (long duration, that is, up to 6 months).
89400926|NCT02801747|Experimental|Condition 11|Receives a core intervention session, the Motivational Interviewing sessions component, the peer mentorship component, and the navigation intervention component (long duration, that is, up to 6 months).
88876415|NCT06082232|Placebo Comparator|Group C(control group)|includes thirty patients who receive intrathecal 4 mL (20 mg) 0.5% hyperbaric bupivacaine and 0.5 mL of 0.9% saline .
88876416|NCT06082206|Experimental|TPVB Group|Bupivacaine 0.25% 20 ml was injected between the costotransverse ligament and the parietal pleura.
88876417|NCT06082206|Experimental|PECS Group|bupivacaine 0.25% 10 ml
89400927|NCT02801747|Experimental|Condition 12|Receives a core intervention session, the Motivational Interviewing sessions component, the peer mentorship component, the focused support group component, and the navigation intervention component (short duration, that is, up to 3 months).
89400928|NCT02801747|Experimental|Condition 13|Receives a core intervention session, the Motivational Interviewing sessions component, the pre-adherence preparation component, and the navigation intervention component (long duration, that is, up to 6 months).
89400929|NCT02801747|Experimental|Condition 14|Receives a core intervention session, the Motivational Interviewing sessions component, the pre-adherence preparation component, the focused support group component, and the navigation intervention component (short duration, that is, up to 3 months).
88876418|NCT06081231||AndroidAPS-rt-CGM|AndroidAPS-rt-CGM consisted of an insulin pump, a rt-CGM, and an AndroidAPS algorithm residing on an Android smartphone.
88876419|NCT06080958|Active Comparator|High negative pressure group|A high negative pressure amplitude is applied over the flaps
88876420|NCT06080958|Active Comparator|Low negative pressure group|A low negative pressure amplitude is applied over the flaps
88876421|NCT06080958|Placebo Comparator|Control group|Conventional dressing is applied over the flaps
88876422|NCT06078293|Experimental|Exercise|All participants in this single-arm trial will be in the exercise arm and receive the home-based exercise program.
88876423|NCT06077214|Experimental|Experiemental|Subjects will be treated with liposomal bupivacaine (study drug) after undergoing bariatric surgery.
88876424|NCT06077214|Active Comparator|Standard of Care|Subjects will be treated with standard bupivacaine after undergoing bariatric surgery.
89400930|NCT02801747|Experimental|Condition 15|Receives a core intervention session, the Motivational Interviewing sessions component, the pre-adherence preparation component, the peer mentorship component, and the navigation intervention component (short duration, that is, up to 3 months).
89400931|NCT02801747|Experimental|Condition 16|Receives a core intervention session, the Motivational Interviewing sessions component, the pre-adherence preparation component, the peer mentorship component, the focused support group component, and the navigation intervention component (long duration, that is, up to 6 months).
89400932|NCT03533270||Urethroplasty|Patients with traumatic urethral injury associated with pelvic fractures who underwent urethroplasty
89400933|NCT03671499|Experimental|Social Cognitive Theory based text messages|The study only contains 1 arm. All participants will receive the same experimental protocol. Participants will receive daily text messages and bi-weekly newsletters for reducing sedentary behavior based on Social Cognitive Theory.
88876425|NCT06077032|Experimental|garlic extract|"Garlic will be collected from Medicinal Plant station, Pharmacognosy Department, Faculty of Pharmacy, Assiut University.~The fresh garlic bulbs will be crushed. Extraction will be done using maceration method with Ethanol for 24 h at room temperature.~Freeze-drying method will be used to remove solvent and give dry powder. Dry powder will be mixed with isopropyl alcohol in a ultrasonic bath to solve thoroughly.~The soluble garlic extract will be added to a mixture of Polyethylene Glycol. The topical garlic formulation will be prepared for each time for two weeks-use and will be kept in dark glass containers in refrigerator till prescription.~•Group 1: will apply Vaseline over the normal skin surrounding the lesion(s) then a cotton soaked with garlic extract (15%) solution will be applied under occlusion with a plastic tape for one hour and then washed by tap water daily for 6 weeks."
88876426|NCT06077032|Experimental|chlorhexidine|"Chlorhexidine 4% (Laries, manufactured by: Smartec Egypt) will be diluted with equal amount of distilled water to obtain a concentration of 2%.~•Group 2: will apply Vaseline over the normal skin surrounding the lesion(s) then a cotton soaked with topical chlorhexidine (2%) solution will be applied under occlusion with a plastic tape for one hour and then washed by tap water daily for 6 weeks."
88876427|NCT06077032|Placebo Comparator|group3|•Group 3: (control) will use normal saline 0.9% as a placebo (they will be treated later on after completion of the study using any of the standard therapies for non-genital warts).
88876428|NCT06076798||Wear AFGen1|Wear AFGen1 for 7 days. ECG co-measurement with 12 lead device at start and end of wear period
88876429|NCT06075654||Athletic Group|athletic females complaining of primary dysmenorrhea, they participated in the exercise for the last ≥ 6 months, did exercises for ≥ 3 days/ week, and practiced (swimming, basketball, volleyball, gymnastics, judo, wrestling, karate, and boxing.
88876430|NCT06075654||Non-Athletic Group|Non-athletic females complaining form primary dysmenorrhea who are have not participated in any physical activity before
88876431|NCT06074302|Experimental|Treatment of radial cheek lines with RHA Redensity|"A total of 20 patients with facial fine lines of the cheeks/radial cheek lines will be treated with RHA Redensity. They will receive 2 treatments.~During the first treatment visit, up to 2cc of RHA Redensity will be injected in a microdroplet technique per cheek. The boundaries of the injection area will be defined by the nasolabial fold, nasojugal groove, palpebromalar groove, mandible, and preauricular crease. Patients will return in 4 weeks for another treatment visit using the same technique. At 8 weeks, they will return for a follow-up visit."
88876432|NCT06073158|Other|Anastomosis group|Esophageal biopsies collected during the anastomosis for the patient with esophageal atresia
88876433|NCT06073158|No Intervention|Control group|Esophageal biopsies collected during a standard care endoscopy for patient with esophageal atresia during the first year of life
88876434|NCT06071247|Experimental|Use 3D printed models group|This group will use 3D printed models for preoperative simulation planning and then undergo surgery
88876435|NCT06071247|No Intervention|Not use 3D printed models group|This group will undergo surgery directly without using 3D printed models.
88876436|NCT06058572|Experimental|Tab Rifaximin with Allogeneic stem cell transplant|Tab Rifaximin 200 mg will be given orally twice daily from day -8 to day +60 of allogeneic stem cell transplant in acute leukemia patients. This will be in addition to standard of care post transplant treatment
88876437|NCT06058572|Active Comparator|Allogeneic stem cell transplant|Allogeneic stem cell transplant: Standard of care treatment including standard anti GVHD measures, antibiotic support and transfusions as needed.
88876438|NCT06058260||Children With Thalassemia (Cases)|Hematological Disease which are a heterogeneous group of single gene disorders, inherited in an autosomal recessive manner ( Thalassemia Syndrome )
88876439|NCT06058260||Healthy Children ( Controls )|Healthy Children free from any chronic illness
88876440|NCT06058221|Experimental|Hybrid technique|
89400934|NCT02070432|Experimental|LUZ11 PDT|"Study consists of two phases, in each participant:~Dose-finding phase with sequential periods in which single-ascending doses of LUZ11 will be titrated up to a dose that shows to be effective following photoirradiation of small spots of tumor surface.~Final PDT session with the previously identified individual effective dose."
89400935|NCT02208752|Active Comparator|Exercises|exericises on motor control and strengthening exercises on the Rotator Cuff
89400936|NCT02208752|Placebo Comparator|Control group- No exercises|No exercises
89400937|NCT02067312|Experimental|Thai massage|The participants will receive a thirty minutes session of Thai massage onto the trapezius muscle
88876441|NCT06058221|Active Comparator|Supraglottic airway|
88876442|NCT06042933|Experimental|Group A|early oral intake 6 hours postoperative.
88876443|NCT06042933|Active Comparator|Group B|delayed oral intake after 72 hours
89400938|NCT02067312|Sham Comparator|Sham Microwave diathermy|The participants will receive a thirty minutes session of Sham microwave diathermy onto the trapezius muscle
89400939|NCT02200406|Other|Desvenlafaxine|"Open-label pilot study~Desvenlafaxine will be administered during 56 consecutive days~Desvenlafaxine will be administered in the morning at a 50 mg dose during weeks 1 and 2, and at 50-100 mg doses (based on the study psychiatrist's judgment) during the 6 following weeks."
89400940|NCT03533348||Fasting arm|Patients will need at least 4 hours of fasting prior to contrast-enhanced CT scans.
89400941|NCT03533348||No fasting|Patients are allowed to eat and drink freely prior to contrast-enhanced CT scans.
89400942|NCT02204852|Experimental|Iloprost+eptifibatide|Co-administration of 1 ng/kg/min Ilomedin® and 0.5 µg/kg/min Integrilin® as 48h continuous i.v infusions
89400943|NCT02204852|Placebo Comparator|Saline|Double dummy 0.9% saline as 48h continuous i.v infusion
89400944|NCT02067390||Vancomycin|Vancomycin
89400945|NCT02067390||Linezolid|Linezolid
89400946|NCT02258048||Patients with cirrhosis|
88876444|NCT06034353|Active Comparator|Basic group|Lifestyle Modifications: General education about healthy life style and diet. Education : general awareness about disease and medication Pill Planner: Pill planner will be provided to keep them adherent to their medication Counselling: Counsel the patients about there medication dosage, frequency and appropriate time.
88876445|NCT06034353|Experimental|Advanced|Lifestyle Modifications: Specific education on keto-diet, yoga and meditation Education : Specific disease education targeting medication adverse drug reaction (ADR), seizure chart management Pill Planner: Pill planner will also be provided to this group Counselling: Cognitive Behavioral therapy will be provided
89400947|NCT02071836|Experimental|Right Turns web application|Right Turns web application
89400948|NCT02071836|Active Comparator|Treatment as usual|Treatment as usual
88876448|NCT05992181|No Intervention|control group|With the speech therapy already in place in the department.
88876449|NCT05992181|Experimental|experimental group|With the speech therapy already in place in the department, plus access to videos and the introduction of early orofacial stimulation.
88876450|NCT05980169|Experimental|Cohort A|In this arm, patients with newly diagnosed gynecologic cancer starting chemotherapy treatment with carboplatin and paclitaxel will receive up to 8 cycles of SensoniQ treatment along with their chemotherapy (weekly or every 21 days depending on the regimen).
88876451|NCT05980169|Experimental|Cohort B|In this arm, gynecologic cancer patients with persistent neuropathy following treatment with carboplatin and paclitaxel will receive a 30 minute SensoniQ treatment twice weekly for 4 weeks.
88876452|NCT05978362|Experimental|With capsular repair|This technique consists of inserting the capsule during the operation according to Latarjet.
88876453|NCT05978362|Active Comparator|Without capsular repair|Latarjet technique without capsular repair
88876454|NCT05958888|Experimental|Front of package food label|4 labels (3 sodium labels, 1 control barcode label) are shown on an image of a soup can
88876455|NCT05955937|Experimental|Step 1. Core HF intervention period|All sites will be trained in an evidence-based clinical care bundle for HF, to ensure standardized basic HF care across the participating RRHs in the study. For this service bundle which will augment self-care (Core-HF), the investigators will train providers in an evidence-based HF clinical care service bundle including a care protocol (treatment algorithm for HF), self-care training for patients and providers, and medication stock management prior to introducing the digital health intervention (Medly Uganda, described in Arm 2).
88876456|NCT05955937|Experimental|Step 2. Core-HF plus Medly Uganda digital health intervention|Medly Uganda will utilize a patient-facing mobile health application designed to improve self-care among patients with HF. Its principal components are: 1) a patient-facing mobile application that processes patient-reported symptoms and generates algorithm-driven messages to guide self-care and symptom management and 2) a clinician- facing internet dashboard that monitors symptom reports and facilitates nurse-guided management recommendations and physician backup support. The project will support an integrated, digital interface at participating hospitals to monitor and intervene with patients who are using the mobile health application.
88876457|NCT05954702|Active Comparator|Conventional Esophagectomy group|Patients with malignant esophagus neoplasms randomized to Conventional Esophagectomy will undergo to an esophagectomy, immediately followed by an esophagus reconstruction trough esophagogastroplasty.
88876458|NCT05954702|Experimental|Supercharged TRAM esophagectomy group|Patients with malignant esophagus neoplasms randomized to Supercharged TRAM esophagectomy will undergo to esophagectomy, immediately followed by supercharged esophagogastroplasty.
88876459|NCT05942521|Experimental|Very brief extinction|Enrolled participants would receive very brief extinction approximately 25 minutes per day for 2 days.
88876460|NCT05942521|Sham Comparator|Very brief neutral extinction|Enrolled participants would receive very brief neutral extinction for approximately 25 minutes per day for 2 days.
88876461|NCT05942521|Active Comparator|Clearly visible extinction|Enrolled participants would receive clearly visible extinction therapy for approximately 25 minutes per day for 2 days.
88876462|NCT05942352|Placebo Comparator|Placebo|Enrolled participants would accept intravenous administration of 250ml saline per day for 15 days, then 50 mg placebo tablet by mouth would be maintained for 1 year.
88876463|NCT05942352|Experimental|Ligustrazine short-term treatment|Ligustrazine hydrochloride was administered intravenously by dissolving 40mg in 250ml saline per day for 15 days. Then, a 50 mg placebo tablet by mouth would be maintained for 1 year
88876464|NCT05942352|Experimental|Ligustrazine maintenance treatment|Ligustrazine hydrochloride was administered intravenously by dissolving 40mg in 250ml saline per day for 15 days，then, a 50 mg Ligustrazine tablet by mouth would be maintained for 1 year.
88876465|NCT05936489|Other|LNZ101|Aceclidine 1.75% / Brimonidine combination (non-preserved) ophthalmic solution
88876466|NCT05936489|Other|LNZ100|Aceclidine 1.75% (non-preserved) ophthalmic solution
88876467|NCT05934903|Experimental|Stimulation|The tDCS device will stimulate with a 2mA current during sessions. Both arms receive application of the device for 3 sessions of 2x 30 minute active application with 30 minutes rest in between.
88876468|NCT05934903|Sham Comparator|Sham Stimulation|The tDCS device will stimulate with a 0mA current during sessions (sham). Both arms receive application of the device for 3 sessions of 2x 30 minute active application with 30 minutes rest in between.
89400949|NCT02204930|Experimental|Haemostat|PeproStat
89400950|NCT03559842||Surgery patients|Obese patients undergoing laparoscopic sleeve gastrectomy
89400951|NCT03559842||Non-surgery patients|Obese patients not undergoing laparoscopic sleeve gastrectomy (delayed or refused proposed treatment)
89400952|NCT02200484|Experimental|Parent Training/Obesity Prevention|Mother-child dyads randomized to the active intervention in the pilot study will be administered 8 weeks of a combined parenting training and obesity prevention program that was adapted through analysis of formative research interviews with adolescent mothers with feedback from an expert panel of multidisciplinary research team members and community members.
89400953|NCT02200484|Active Comparator|8-week Wellness Program (Control)|Participants randomized to control condition during intervention piloting will receive print-based health and wellness materials once weekly for 8-weeks + 2 follow up telephone calls at the beginning and conclusion of the 8-week program.
89400954|NCT02070510|Experimental|Victim and perpetrator compounds|Subjects receive two different victim compounds (lisinopril and warfarin) and two different perpetrator compounds (placebo semaglutide with carrier and oral semaglutide). Each dosing occasion is separated by a 7-day wash-out period.
89400955|NCT02258126|Active Comparator|Control group|healthy lifestyle education including healthy lifestyle education, supportive therapy and behavioral advice for both children and parents to improve nutrition and physical activity
89400956|NCT02258126|Experimental|Exercise group|multidisciplinary intervention program including healthy lifestyle education, supportive therapy and behavioral advice for for both children and parents to improve nutrition and physical activity and supervised exercise.
89400957|NCT02070666|Experimental|Protective ventilation arm|"Low tidal volumes (from 4 to 6 milliliters(mL)/kilogram (kg) of predicted body weight (PBW)~Plateau pressure less than 25 centimeter of water (cmH2O)~Minimum PEEP of 5 cmH2O."
89400958|NCT02070666|Active Comparator|Control group|"Traditional-sized tidal volumes (from 8 to 10 mL/kg PBW)~Plateau pressure less than 25 cmH2O~Minimum PEEP of 5 cmH2O."
89400959|NCT02200562|Experimental|Ipilimumab and Dabrafenib|
89400960|NCT02070822||TACE patients, for HCC|unresectable HCC patients
89400961|NCT02205008|Active Comparator|Arm A|curative resection of the stomach with D2 plus intraperitoneal chemotherapy plus adjuvant systemic chemotherapy with S-1
89400962|NCT02205008|Placebo Comparator|Arm B|curative resection of the stomach with D2 plus adjuvant systemic chemotherapy with S-1
89400963|NCT02067546|Experimental|Experimental toilet seat|Experimental toilet seat for 1 month
89400964|NCT02067546|Sham Comparator|Standard toilet seat|Standard toilet seat for 1 month
89400965|NCT02067624|Experimental|Thai massage|The participants will receive a thirty minutes session of Thai massage onto the wrist extensor groups muscle for 9 sessions
89400966|NCT02067624|Sham Comparator|Sham Ultrasound therapy|The participants will receive a thirty minutes session of sham ultrasound therapy onto the wrist extensor groups muscle for 9 sessions
89400967|NCT02208908||Patient with cancer hospitalize inpalliative situation|"An accurate assessment of the oral condition and proper care will be carried out on day 2 (J2) of hospitalization and repeated on the day of hospital discharge by the nurse detached service, regardless of caregivers.~An assessment of the traceability of clinical assessment and appropriate treatment prescribed or will be conducted on day 3 and repeated the day of the release of hospitalization (or day 15) from information recorded in the patient record"
89400968|NCT02072070|Experimental|TissueGene-C|Single intra-articular injection to the damaged knee joint at a dose of 1.8 x 10^7 cells
89400969|NCT02072070|Placebo Comparator|Placebo|Single intra-articular injection to the damaged knee joint
89400970|NCT02205086|Other|Diagnosis|Test diagnostic decision support software
89400971|NCT02200640|Experimental|Low dose of Micardis®|
89400972|NCT02200640|Experimental|High dose of Micardis®|
88876469|NCT05932732|Other|HydraFacial Syndeo Treatment|Three HydraFacial Syndeo Treatment will be performed 28 days apart at the Pflugerville site.
89400973|NCT02200640|Active Comparator|Low dose of COZAAR®|
89400974|NCT02200640|Active Comparator|High dose of COZAAR®|
89400975|NCT02067702||Limb Cooling Assessment of ET Control|Healthy, volunteers with no known dermatological lesions, sensitivity to cold, or peripheral vascular disease.
88876470|NCT05932732|Other|Hydrafacial Elite MD Treatment|hree HydraFacial Elite MD Treatment will be performed 28 days apart at the Houston site.
88876471|NCT05902325|Experimental|Mepolizumab 100mg injection|Mepolizumab 100mg SC once every 4 weeks for 48 weeks (twelve injections)
88876472|NCT05876910|Experimental|Voice and Electrocorticography (ECoG) recording during Speech Production Tasks|Participants produce speech following visual cues on a computer while ECoG signals for neural activity and voice was recorded during their inpatient hospitalization at the University of California, San Francisco (UCSF).
88876473|NCT05840302|Experimental|Pain Neuroscience Education|The Pain Neuroscience Education program takes place over ten days consisting of providing knowledge about the neurophysiology and central processes of pain (nociceptive pathways, inhibitory circuits, peripheral and central sensitization, nervous system plasticity) as well as psychosocial factors and beliefs contributing to chronic pain. Workshops will use experimental data from neuroscience, but also analogies, brainstorming or games. Questions are proposed to the patient at the end of each theme.
88876474|NCT05840302|Active Comparator|Back School|The Back School program takes place over ten days. It begins with a presentation of spinal economy, which consists of promoting the protection of the back. Then, the anatomy and biomechanics of the spine as well as the most common spinal pathologies are presented. On this biomechanical basis, the other sessions consist in indicating the gestures and postures to adopt, always according to the protection policy, in different situations. These different sessions alternate between theory and practical exercises.
88876475|NCT05839457|Experimental|Intervention group|Empowerment Pilot
88876476|NCT05839457|No Intervention|Control group|
88876477|NCT05826171|Experimental|Group 1|High-Intensity Aerobic Exercise Prior to Balance Training
88876478|NCT05826171|Active Comparator|Group 2|Low-Intensity Exercise Prior to Balance Training
89400976|NCT02067702||Limb Cooling Assessment of ET Experimental|Patients with known essential tremor for at least a year, and +2 or worse action or kinetic tremor of one or both upper limbs involving at least the forearm and/or hand.
89400977|NCT02200718|Experimental|NeuroVax|NeuroVax consists of a Trivalent TCR Peptide Formulation in IFA V Beta Peptides BV5S2, BV6S5 and BV13S1 emulsified in incomplete Freund's adjuvant
89400978|NCT02200718|Placebo Comparator|IFA Incomplete Freund's Adjuvant|IFA Incomplete Freund's Adjuvant is a vaccine adjuvant composed of a light mineral oil a surfactant system designed to make a water-in-oil emulsion
89400979|NCT02070900|No Intervention|Standard of Care|Sites implementing Option B+ for pregnant and lactating women according to the standard of care prescribed by the Ministry of health and Child Care national guidelines
89400980|NCT02070900|Experimental|POC Plus|Sites implementing Option B+ according to the standard of care prescribed by the Ministry of Health and Child Care, as well as programmatic mentoring and POC CD4 machines
89400981|NCT02208986|Active Comparator|0.2mg Triptorelin|Ovulation trigger with 0.2mg Triptorelin in one subcutaneous injection.
89400982|NCT02208986|Active Comparator|0.3mg Triptorelin|Ovulation trigger with 0.3mg Triptorelin in one subcutaneous injection.
89400983|NCT02208986|Active Comparator|Active Comparator: 0.4mg Triptorelin|Ovulation trigger with 0.4mg Triptorelin in one subcutaneous injection.
89400984|NCT02200796|Experimental|Low Protein Meal|Low Protein Test Meal (15 g)
89400985|NCT02200796|Experimental|Moderate Protein Meal|Moderate Protein Meal (30 g)
89400986|NCT02200796|Experimental|High Protein Meal|High Protein Meal (45g)
89189596|NCT05624138|Active Comparator|ketotifen oral tablets|"Group II ketotifen group n=32 Patients will receive 12 cycles of modified FOLFOX-6 regiment plus ketotifen tablets 2mg daily throughout the twelve chemotherapy cycles. The chemotherapy cycles will be received every 2 weeks and will be as follows:~Day 1 and Day 15 : Oxaliplatin 85 mg/m2 intravenous infusion in 250-500 mL 5% dextrose solution and leucovorin 400 mg/m2 intravenous infusion in 5% dextrose solution both were given over 120 minutes at the same time in separate bags using a Y-line access, followed by 5-fluorouracil 400 mg/m2 intravenous bolus given over 2-4 minutes, followed by 5-fluorouracil 2400 mg/m2 intravenous infusion in 500 mL 5% dextrose solution as a 46-hour infusion"
89189597|NCT05619601||500 women|500 women discharged alive after a hospitalization for a type 1 acute myocardial infarction with significant coronary artery disease.
89400987|NCT02200796|Experimental|Control Meal|High Carbohydrate Control Meal (7 g of protein)
89400988|NCT02067780|Experimental|The intervention (CRP-guided) group|500 mg (one tablet) of oral levofloxacin daily of levofloxacin for 7 days unless the serum CRP decrease by at least 50% from baseline value. Measurements of serum CRP were done at ED admission, at day-2, day-4 and day-6 and made available to the attending physicians.
89189598|NCT05619601||500 men|500 age (±2 years) and ECG (STEMI/NSTEMI) locally matched men discharged alive after a hospitalization for a type 1 acute myocardial infarction with significant coronary artery disease.
89189599|NCT05610800|Active Comparator|Exenatide, NRT, and Smoking Cessation Counseling|Participants will receive once weekly exenatide injections, daily nicotine patches (NRT), and once weekly individual smoking cessation counseling sessions.
89189600|NCT05610800|Placebo Comparator|Placebo, NRT, and Smoking Cessation Counseling|Participants will receive once weekly saline injections, daily nicotine patches (NRT), and once weekly individual smoking cessation counseling sessions.
89400989|NCT02067780|Experimental|The standard care (control) group|500 mg of levofloxacin per day for the first two days. Thereafter, oral tablet of placebo was prescribed according to CRP values as in CRP guided group to keep the blindness of the study.
89400990|NCT02205164|Experimental|Palonosetron + Aprepitant|Oral aprepitant will be given on days 1-3 (day 1, 125 mg 1 h before chemohterapy; days 2-3, 80 mg) multiple intravenous bolus of palonosetron 0.25 mg, 30 minutes before chemotherapy, every other single days, for a minimum of 2 administration (day 1, 3), in case of a 3 days chemotherapy regimen, and a maximum of 5 doses (day 1,3,5,7, 9) in case of a 10 days chemotherapy.
89400991|NCT02205164|Active Comparator|Palonosetron|multiple intravenous bolus of palonosetron 0.25 mg, 30 minutes before chemotherapy, every other single days, for a minimum of 2 administration (day 1, 3), in case of a 3 days chemotherapy regimen, and a maximum of 5 doses (day 1,3,5,7, 9) in case of a 10 days chemotherapy.
89400992|NCT02072304|Experimental|web-based CBT|Web-based CBT group : The intervention is made up of 8 internet modules based on behavioral activation, cognitive behavioral therapy
89400993|NCT02072304|Active Comparator|supportive care|supportive care group will receive supportive care for treating depression by e-mail per a week for 8 weeks
89400994|NCT02071056||history of visceral cancer|
89400995|NCT02257814|No Intervention|Control Group|Control group
89400996|NCT02257814|Experimental|Incredible Years|incredible years intervention
89400997|NCT02257814|Experimental|Preschool PATHS|Preschool PATHS (Promoting Alternative Thinking Strategies)
89400998|NCT02257814|Experimental|Tools of the Mind|Tools of the Mind
89400999|NCT02200874||before NST-implementation (group A)|Patients with a NRS of 3 or more than 3 or NUTRIC score of 4 or more than 4 within the first three days after admittance to hospital. Time point: Before implementation of Nutrition Support Team (NST).
88876479|NCT05806385|No Intervention|Standard of Care Arm:|Control arm: Stage I/II TNBC patients will receive neoadjuvant chemotherapy followed by lumpectomy/mastectomy with sentinel node biopsy +/- axillary dissection.
89401000|NCT02200874||After NST-implementation (group B)|Patients with a NRS of 3 or more than 3 or NUTRIC score of 4 or more than 4 within the first three days after admittance to hospital. Time point: After implementation of Nutrition Support Team (NST).
89401001|NCT02076282||Healthy volunteers 1 MRI scan|"Healthy volunteers, recruited at the UMC Utrecht, older than 18, who do not meet the exclusion criteria of the department of Radiology.~Healthy volunteers will receive 1 MRI scan without contrast agent."
89401002|NCT02076282||Patients with stage III NSCLC, 1 MRI scan|"Patients with histopathologically or cytologically proven stage III NSCLC (excluding T4N0), older than 18, with a recent (≤ 21 days) GFR value available~Patients will receive 1 MRI scan with contrast agent."
89401003|NCT02200952||Patients at risk of OHSS|Patients at risk of OHSS on the oocytes triggering day with an oestradiol > 4000pg/ml or a number of follicles greater than 24 of a diameter greater than 12 mm
89401004|NCT02071212|Active Comparator|Clopidogrel|Loading dose 600 mg .Mainatinance dose 75 mg QD
89401005|NCT02071212|Experimental|Ticagrelor|Loading dose 180 mg . Maintenance 90 mg BID
89401006|NCT03396770|Active Comparator|Control group|Standard clinical routine
89401007|NCT03396770|Experimental|Nephrocheck group|Nephrocheck test
89401008|NCT02072382|Experimental|Metformin|Metformin 850 mg twice a day for eight weeks versus Placebo
88876480|NCT05806385|Experimental|Intervention 1|Cryoablation Alone Arm: Intervention with cryoablation alone followed by neoadjuvant chemotherapy followed by lumpectomy/mastectomy with sentinel node biopsy +/- axillary dissection.
88876481|NCT05806385|Experimental|Intervention 2|Cryoablation + PD1 Inhibitor Arm: Intervention with cryoablation + Pembrolizumab followed by neoadjuvant chemotherapy followed by lumpectomy/mastectomy with sentinel node biopsy +/- axillary dissection.
88876482|NCT05788185|Experimental|RVM-V001 30 µg -BNT162b2 subjects|RVM-V001-30 µg administered as a single dose of by intramuscular injection on Day 1 on BNT162b2 subjects
89401009|NCT02209220|Active Comparator|Automatic positive airway pressure|Automatic positive airway pressure treatment of obstructive sleep apnea
89401010|NCT02209220|Active Comparator|Continuous positive airway pressure|Continuous positive airway pressure for the treatment of obstructive sleep apnea
89401011|NCT02072460|Experimental|vestibular signals determination|vestibular signals determination by electromyography and electroencephalography associated to approaches from psychophysics
89401012|NCT02205242|Experimental|Azithromycin|"N = 250 From day 1 up to and including day 3: 500 mg azithromycin PO once a day From day 4 up to and including day 90: 250 mg azithromycin PO once every 2 days~N= 30 During 7 days post discharge from hospital (0 months), 3 months and 9 months, the patient will wear the Dynaport® which will register the patient's physical activity"
89401013|NCT02205242|Placebo Comparator|Placebo|"N = 250 From day 1 up to and including day 3: 500 mg placebo PO once a day From day 4 up to and including day 90: 250 mg placebo PO once every 2 days~N= 30 During 7 days post discharge from hospital (0 months), 3 months and 9 months, the patient will wear the Dynaport® which will register the patient's physical activity"
89401014|NCT02072538||Pre-discharge stress testing|Stress-testing (e.g. treadmill exercise test, stress-echochardiography)
89401015|NCT02072538||Post-discharge stress testing|Stress-testing (e.g. treadmill exercise test, stress-echochardiography)
89401016|NCT02071368|Experimental|Treatment A|Each participant will receive a single dose of 1 tablet of canagliflozin (CANA), 300 mg, and 2 tablets of metformin extended release (MET XR), 500 mg, administered together under fed conditions.
89401017|NCT02071368|Experimental|Treatment B|Each participant will receive a single dose of 2 tablets of CANA/MET XR FDC (2 x [150 mg/500 mg]) formulation 1, under fed conditions.
89401018|NCT02071368|Experimental|Treatment C|Each participant will receive a single dose of 2 tablets of CANA/MET XR FDC (2 x [150 mg/500 mg]), formulation 2, under fed conditions.
89401019|NCT02205320|Experimental|Treatment Sequence I (DRL, A, B)|Patients will receive study drugs in the following cross-over sequence: DRL_PG, Pegfilgrastim Form A, Pegfilgrastim Form B. Each drug is administered as a single, 6 mg, subcutaneous injection.
88876483|NCT05788185|Experimental|RVM-V002 30 µg -BNT162b2 subjects|RVM-V001-30 µg administered as a single dose of by intramuscular injection on Day 1 on BNT162b2 subjects
88876484|NCT05788185|Experimental|RVM-V001 (15 µg) + RVM-V002 (15 µg) co-administration -BNT162b2 subjects|RVM-V001 (15 µg) + RVM-V002 (15 µg) co-administration; a single dose of RVM-V001 in the left arm deltoid muscle and then followed immediately with a single dose of RVM-V002 in the right arm deltoid muscle on Day 1 on BNT162b2 subjects
88876485|NCT05788185|Experimental|RVM-V001 30 µg|RVM-V001-30 µg administered as a single dose of by intramuscular injection on Day 1 on BBIBP-CorV or CoronaVac subjects
88876486|NCT05788185|Experimental|RVM-V002-30 µg|RVM-V002-30 µg administered as a single dose of by intramuscular injection on Day 1 on BBIBP-CorV or CoronaVac subjects
88876487|NCT05788185|Experimental|RVM-V001 (15 µg) + RVM-V002 (15 µg) co-administration|RVM-V001 (15 µg) + RVM-V002 (15 µg) co-administration; a single dose of RVM-V001 in the left arm deltoid muscle and then followed immediately with a single dose of RVM-V002 in the right arm deltoid muscle on Day 1 on BBIBP-CorV or CoronaVac subjects
89189601|NCT05597930|Experimental|Thumb then wrist orthosis|
88876488|NCT05785065|Experimental|Mycophenolate mofetil|2 to 4 capsules of mycophenolate mofetil twice daily.
89401020|NCT02205320|Experimental|Treatment Sequence II (DRL, B, A)|Patients will receive study drugs in the following cross-over sequence: DRL_PG, Pegfilgrastim Form B, Pegfilgrastim Form A. Each drug is administered as a single, 6 mg, subcutaneous injection.
89401021|NCT02205320|Experimental|Treatment Sequence III (A, DRL, B)|Patients will receive study drugs in the following cross-over sequence: Pegfilgrastim Form A, DRL_PG, Pegfilgrastim Form B. Each drug is administered as a single, 6 mg, subcutaneous injection.
89401022|NCT02205320|Experimental|Treatment Sequence IV (A, B, DRL)|Patients will receive study drugs in the following cross-over sequence: Pegfilgrastim Form A, Pegfilgrastim Form B, DRL_PG. Each drug is administered as a single, 6 mg, subcutaneous injection.
89401023|NCT02205320|Experimental|Treatment Sequence V (B, A, DRL)|Patients will receive study drugs in the following cross-over sequence: Pegfilgrastim Form B, Pegfilgrastim Form A, DRL_PG. Each drug is administered as a single, 6 mg, subcutaneous injection.
89401024|NCT02205320|Experimental|Treatment Sequence VI (B, DRL, A)|Patients will receive study drugs in the following cross-over sequence: Pegfilgrastim Form B, DRL_PG, Pegfilgrastim Form A. Each drug is administered as a single, 6 mg, subcutaneous injection.
89401025|NCT02076360|Experimental|Preop Video|This arm will watch an instructional video in addition to their normal preoperative visit with the physician.
89401026|NCT02076360|No Intervention|No video|This arm will receive only the normal preoperative visit with the physician without the additional video
89401027|NCT03402841|Experimental|Olaparib|"Olaparib will be supplied as film-coated tablets containing 150 mg or 100 mg of olaparib.~Patients will be administered olaparib orally twice daily (bid) at 300 mg."
89401028|NCT02209298||CoreValve Transcatheter Valve|Medtronic CoreValve SystemTM is designed to replace the native or surgical bioprosthetic aortic heart valve without open heart surgery and without concomitant surgical removal of the failing valve. The support frame is manufactured by Nitinol, which has multi-level, self-expanding properties and is radiopaque. The bioprosthesis is manufactured by suturing valve leaflets and a skirt from a single layer of porcine pericardium into a tri-leaflet configuration. The bioprosthesis is processed with alpha-amino oleic acid (AOA™), which is a compound derived from oleic acid, a naturally occurring long-chain fatty acid. AOA™ is an antimineralization treatment shown to reduce both early and late valvular calcification.
89401029|NCT02072616|Experimental|Sample for Circulating Tumoral Cells|Sampling of Circulating Tumoral Cells will be done after Pancreatic adenocarcinoma diagnosis
89401030|NCT02209376|Experimental|Arm 1|
89401031|NCT02072694|Experimental|75 grams of glucose plus water solution|"In the group with 10 volunteers with obesity, some of them are submitted first to the 75 grams of glucose plus water solution (meal challenge) and in another time to only water.~Also, in the group with 10 volunteers without obesity, some of them are submitted first to the 75 grams of glucose plus water solution (meal challenge) and in another time to only water."
89401032|NCT02072694|Placebo Comparator|Pure water.|"In the same group with 10 volunteers with obesity, some of them are submitted first to only water (control) and in another time to the 75 grams of glucose plus water solution (meal challenge).~Also, in the same group with 10 volunteers without obesity, some of them are submitted first to only water (control) and in another time to the 75 grams of glucose plus water solution (meal challenge)."
89401033|NCT02205398|Experimental|c-MET positive mCRC and HNSCC|c-MET positive and K/NRAS WT mCRC and c-MET positive HNSCC patients
89401034|NCT02071524|Active Comparator|Cristalloid|group cristalloid (ringer lactate)
89401035|NCT02071524|Active Comparator|colloids|colloid: cristalloid in according to cardiac output
88876489|NCT05785065|Placebo Comparator|Placebo|2 to 4 capsules of placebo twice daily.
88876490|NCT05784285|Experimental|Community-based activity program|Engagement in 8-week community-based activity program.
88876491|NCT05779033|Placebo Comparator|control group|will receive scapular stabilization exercises 3 times per week for 4 weeks.
88876492|NCT05779033|Active Comparator|study group (A)|will receive scapular stabilization exercises and Kinesiotape 3 times per week for 4 weeks
88876493|NCT05779033|Active Comparator|study group (B)|will receive scapular stabilization exercises and Ultrasound 3 times per week for 4 weeks.
88876494|NCT05779020|Experimental|QIV-IB/dose 0.25ml|Butantan Quadrivalent Influenza Vaccine (split virion, inactivated)/dose 0.25ml
88876495|NCT05779020|Experimental|QIV-IB/dose 0.50ml|Butantan Quadrivalent Influenza Vaccine (split virion, inactivated)/dose 0.50ml
88876496|NCT05779020|Active Comparator|TIVV-IB|Butantan Trivalent Influenza Vaccine (split virion, inactivated)/dose 0.25ml containing Influenza B virus - Victoria lineage
88876497|NCT05779020|Active Comparator|TIVY-IB|Butantan Trivalent Influenza Vaccine (split virion, inactivated)/dose 0.25ml containing Influenza B virus - Yamagata lineage
88876498|NCT05756803|Experimental|Low Intensity Acoustic Shockwave Therapy|The device applies a low-intensity shockwave to the surface of the penis using an ultrasound gel as the coupling agent. The low-intensity shockwave therapy device will be used with the purpose of improving penile blood flow and restoring sexual function in men with impaired erectile function.
88876499|NCT05751096|Active Comparator|LIFU - CRPS|Real LIFU application for CRPS cohort.
88876500|NCT05751096|Sham Comparator|SHAM - CRPS|Sham LIFU application for CRPS cohort.
88876501|NCT05751096|Active Comparator|LIFU - FM|Real LIFU application for FM cohort.
89189602|NCT05597930|Experimental|Wrist then thumb orthosis|
89189603|NCT05596383|Experimental|Intervention group|Vitamin D, dosage form chewable tablet, dosage 5000 IU, frequency every day, duration six months
88876502|NCT05751096|Sham Comparator|SHAM - FM|Sham LIFU application for FM cohort.
88876503|NCT05742919|Experimental|NNC0194-0499 12 mg|Participants will receive a single subcutaneous (s.c.) dose of 12 milligrams (mg) NNC0194-0499 on Day 1.
88876504|NCT05742919|Experimental|NNC0194-0499 30 mg|Participants will receive a single s.c. dose of 30 mg NNC0194-0499 on Day 1.
88876505|NCT05742919|Experimental|NNC0194-0499 96 mg|Participants will receive a single s.c. dose of 96 mg NNC0194-0499 on Day 1.
89189604|NCT05596383|Placebo Comparator|control group|Placebo (microcrystalline,calcium carbonate, sodium starch), dosage form chewable tablet, frequency every day, duration six month
89189605|NCT05594745|Active Comparator|Xiidra|one drop BID for 9 months
89401036|NCT02220608|Experimental|Arm 1: Dose Level 1 (Bortezomib & G-CSF)|G-CSF will be administered daily for 5 days (Days 1-5). On Day 4 at approximately 1800 hours, bortezomib will be administered. Apheresis will begin on Day 5 either 15 or 18 hours following Day 4 bortezomib dose; 20L of peripheral blood will be processed with a cumulative target collection goal of > 6.0x106 CD34+cells/kg. If the target collection goal is not met after one apheresis procedures, up to three additional days of G-CSF and apheresis may be repeated.
89401037|NCT02220608|Experimental|Arm 2: Dose Level 2 (Bortezomib & G-CSF)|G-CSF will be administered daily for 5 days (Days 1-5). On Day 4 at approximately 1800 hours, bortezomib will be administered. Apheresis will begin on Day 5 either 15 or 18 hours following Day 4 bortezomib dose; 20L of peripheral blood will be processed with a cumulative target collection goal of > 6.0x106 CD34+cells/kg. If the target collection goal is not met after one apheresis procedures, up to three additional days of G-CSF and apheresis may be repeated.
89401038|NCT02076438|Placebo Comparator|Placebo|Placebo capsules
89401039|NCT02076438|Experimental|Probiotics|Lactobacillus Rhamnosus GG 10 billion cfu BID
89401040|NCT04207879||weight loss group|Dynamic changes in body composition, biochemical metabolomics and gut microbiome will be reported among overweight and obese patients.
89401041|NCT02209688|Experimental|ESR 1150 CL dose escalation fasted|
89401042|NCT02209688|Experimental|ESR 1150 CL fed|
89401043|NCT02209688|Placebo Comparator|Placebo|
89401044|NCT02076516|Experimental|Drug-eluting stent: CORACTO®|Single arrm
89401045|NCT02220686|Experimental|Offer and Report Protocol|Physician advice to stop smoking, referral to state Quitline, and physician considers prescribing nicotine replacement therapy.
89401046|NCT02220686|No Intervention|Usual Care|Physician will follow their institution's standard of care for smoking cessation.
89401047|NCT03630367|Experimental|study group|women will receive dexamethasone 8 mg intramuscular every 8 hours plus single injection of L-carnitine 1 gm slow intravenous
89401048|NCT03630367|Active Comparator|control group|women will receive dexamethasone 8 mg intramuscular every 8 hours plus single injection of saline 1 gm slow intravenous
89401049|NCT02258282|Experimental|Etanercept|Patients under the treatment of 50 mg Etanercept
88876507|NCT05713461|Experimental|obese women without metabolic syndrome|Women with obesity and without metabolic syndrome
88876508|NCT05713461|Experimental|obese women with metabolic syndrome|Women with obesity and with metabolic syndrome
89401050|NCT02258282|Sham Comparator|Control|Patients under the treatment of traditional DMARDs
89401051|NCT01376869|Active Comparator|102mg extract 1 hops|Equivalent to 0.5g dry weight
89401052|NCT01376869|Active Comparator|410mg extract 1 hops|Equivalent to 2g dry weight
89401053|NCT01376869|Active Comparator|79mg extract 2 hops|Equivalent to 0.5g dry weight
88876509|NCT05669235||Long covid|Women who present symptoms after suffering from COVID-19, consistent with long covid.
88876510|NCT05669235||Covid|Women who have passed COVID-19 without consequences.
88876511|NCT05656417||Haplotype 1|Participants will attend a screening visit where they will provide a saliva sample for DNA sequencing. Participants will then be separated into two groups based on their gene profile. Participants in Group 1 will have a specific haplotype of the gene of interest. The groups will undergo a 2-week period of thorough oral hygiene and prophylactic treatment to achieve excellent gingival health. Participants in both groups will then cease all oral hygiene for a period of 3 weeks, where a state of gingivitis will develop. At the end of the 3 weeks, normal oral hygiene will be reinstated and prophylactic treatment offered as required for a further 2 weeks.
89011505|NCT01643785|No Intervention|without Endonase|Second-line quadruple therapy [PPI(pantoprazole 40mg, lansoprazole 30mg, esomeprazole 40mg, rabeprazole 20mg, omeprazole 20mg) Bid, tetracycline 500 mg QID, metronidazole 500mg Tid, tripotassium dicitrate bismuthate 300mg QID] for 7 days
89189606|NCT05594745|Active Comparator|Systane|One drop QID for 9 months
89401054|NCT01376869|Active Comparator|316mg extract 2 hops|Equivalent to 2g dry weight
89401055|NCT01376869|Placebo Comparator|Placebo|
89401056|NCT02076594|Experimental|Docetaxel & Oxaliplatin & Capecitabine|Patients will receive cycles every 3 weeks of Docetaxel (35 mg/ m2, intravenous at days 1 and 8 by 1-hour infusion)and Oxaliplatin (80 mg/ m2, intravenous at day 1 by 2-hour infusion) and Capecitabine (750 mg/ m2, oral tablets of 500 and 150 mg, x2 daily for 2 weeks)
89401057|NCT02076594|Experimental|Epirubicin & Oxaliplatin & Capecitabine|Patients will receive cycles every 3 weeks of Epirubicin (50 mg/ m2, intravenous on day 1 by 2-hour infusion)and Oxaliplatin (130 mg/ m2, intravenous on day 1 by 2-hour infusion) and Capecitabine (625 mg/ m2,oral tablets of 500 and 150 mg, x2 daily for 3 weeks)
89401058|NCT02258360|Active Comparator|24 hours hypothermia|Therapeutic hypothermia for 24 hours after reaching target temperature
89401059|NCT02258360|Experimental|48 hours hypothermia|Therapeutic hypothermia for 48 hours after reaching target temperature
89401060|NCT04175509|Active Comparator|Rectal acetaminophen|Patients will receive two 650mg suppositories rectally of acetaminophen for a total dose of 1300mg at the end of surgery.
89401061|NCT04175509|Active Comparator|Intravenous acetaminophen|Patients will receive one dose of 1000mg of acetaminophen, administered intravenously, at the end of surgery.
89536672|NCT04983381|Experimental|Education Group|Participants were grouped as; those who were given information about vaginal examination in the training group (n=40) and those who were not given information about vaginal examination in the control group (n=40).
89401062|NCT02220842|Experimental|Arm 1 Cohort A (Safety Evaluation):Atezolizumab + Obinutuzumab|Relapsed/refractory FL and DLBCL participants will receive obinutuzumab alone on Days 1, 8, and 15 of Cycle 1 (Cycle length = 21 days), followed by atezolizumab and obinutuzumab on Day 1 of Cycles 2-8, and then atezolizumab alone on Day 1 of Cycle 9 and every cycle thereafter until unacceptable toxicities or disease progression.
89401063|NCT02220842|Experimental|Arm 1 Cohort B (Expansion): Atezolizumab + Obinutuzumab|Relapsed/refractory FL participants will receive atezolizumab and obinutuzumab as per schedule and dose decided from the safety evaluation stage, until unacceptable toxicities or disease progression.
89401064|NCT02220842|Experimental|Arm 1 Cohort C (Expansion): Atezolizumab + Obinutuzumab|Relapsed/refractory DLBCL participants will receive atezolizumab and obinutuzumab as per schedule and dose decided from the safety evaluation stage, until unacceptable toxicities or disease progression.
89401065|NCT02220842|Experimental|Arm 2 Cohort D (Safety Evaluation):Atezolizumab + Tazemetostat|Relapsed/refractory DLBCL participants will receive atezolizumab (on Day 1) and tazemetostat (on Days 1-21) of each 21-day cycle until unacceptable toxicities or disease progression.
89401066|NCT02220842|Experimental|Arm 2 Cohort E (Expansion): Atezolizumab + Tazemetostat|Relapsed/refractory DLBCL participants will receive atezolizumab and tazemetostat as per schedule and dose decided from the safety evaluation stage, until unacceptable toxicities or disease progression.
89401067|NCT02072850||Myocardial infarction|Patients presenting with acute-ST elevation myocardial infarction referred for emergency invasive management by primary or rescue percutaneous coronary intervention.
89401068|NCT02205554|Active Comparator|Omnitram-Tramadol-Placebo|Omnitram 20 mg every 6 hours for 9 doses, followed by Tramadol 50 mg every 6 hours for 9 doses, followed by Placebo every 6 hours for 9 doses.
89401069|NCT02205554|Active Comparator|Tramadol-Placebo-Omnitram|Tramadol 20 mg every 6 hours for 9 doses, followed by Placebo every 6 hours for 9 doses, followed by Omnitram 20 mg every 6 hours for 9 doses.
89401070|NCT02205554|Active Comparator|Placebo-Omnitram-Tramadol|Placebo every 6 hours for 9 doses, followed by Omnitram 20 mg every 6 hours for 9 doses, followed by Tramadol 50 mg every 6 hours for 9 doses.
89401071|NCT02076672|Experimental|Artichoke WPC|Artichoke WPC 500 mg capsules. Dose = 1000 mg (2 - 500 mg capsules) just before breakfast and 1000 mg (2 - 500 mg capsules) before dinner. Duration: daily for a period of 90 days.
89401072|NCT01379053||Staphylococcus Patients|Patients suspected of having Methicillin-resistant and/or methicillin-susceptible staphylococcus aureus.
89401073|NCT01379053||Control|Healthy volunteer
89401074|NCT02076750|Experimental|Vitamin D3 (cholecalciferol) 10,000 IU per 10 kg body weight|Vitamin D3 (cholecalciferol) will be administered orally at a dose of 10,000 IU per 10 kg body weight weekly for 6 consecutive weeks. The maximum dose will be 50,000 IU weekly for patients weighing 50 kg or greater.
88876512|NCT05656417||Haplotype 2|Participants will attend a screening visit where they will provide a saliva sample for DNA sequencing. Participants will then be separated into two groups based on their gene profile. Group 2 will comprise of participants who possess a second distinct haplotype in the same gene of interest as Group 1. This group will undergo the same study procedures as Haplotype Group 1.
88876513|NCT05637216|Experimental|Breast Conservation Surgery with Losartan|Participants who underwent breast conservation surgery will take losartan in a 25 milligram oral capsule once daily starting day one of radiation therapy until one year following the completion of radiation therapy.
88876514|NCT05637216|Placebo Comparator|Breast Conservation Surgery with Placebo|Participants who underwent breast conservation surgery will take placebo in a 25 milligram oral capsule once daily starting day one of radiation therapy until one year following the completion of radiation therapy.
88876515|NCT05637216|Experimental|Mastectomy with Losartan|Participants who underwent a mastectomy will take losartan in a 25 milligram oral capsule once daily starting day one of radiation therapy until one year following the completion of radiation therapy.
89401075|NCT02076750|Active Comparator|Vitamin D3 (cholecalciferol) 5,000 IU per 10 kg body weight|Vitamin D3 (cholecalciferol) will be administered orally at a dose of 5,000 IU per 10 kg body weight weekly for 6 consecutive weeks. The maximum dose will be 25,000 IU weekly for patients weighing 50 kg or greater.
89401076|NCT05262608|Experimental|Intervention/Treatment|Subjects will receive a regimen of Olaparib tablets 300 mg twice daily until radiographic disease progression (assessed by the investigator according to RECIST1.1 and PCWG 3) or intolerable adverse events (assessed by the investigator according to the actual clinical situation).
89401077|NCT02073006|Active Comparator|Natural Fibre Supplement|2 doses per day for 4 weeks
89401078|NCT02073006|Placebo Comparator|Placebo|2 doses per day for 4 weeks
89401079|NCT02205632|Other|High myopic patients with lacker craks|
89401080|NCT02205632|Other|High myopic patients without lacker cracks|
89401081|NCT01380457|Experimental|A|Subjects received the test formulated product manufactured by Pharmaceutics International, Inc. and marketed by Par Pharmaceutical, Inc. under fasting conditions
89401082|NCT01380457|Active Comparator|B|Subjects received the reference listed drug manufactured by Banner Pharmacaps, Inc. and marketed by Unimed Pharmaceutical, Inc.
89401083|NCT02071602|Placebo Comparator|Placebo|Placebo infused for up to 72 hours IV
89401084|NCT02071602|Active Comparator|CD-NP 5 ng/kg/min|CD-NP 5 ng/kg/min infused for up to 72 hours IV
89401085|NCT02071602|Placebo Comparator|CD-NP 10 ng/kg/min|CD-NP 10 ng/kg/min infused for up to 72 hours IV
89401086|NCT02205710|Experimental|Computerized cognitive training|Series of gamified tasks.
89401087|NCT02205710|Placebo Comparator|Computerized game training|Series of gamified tasks.
89401088|NCT05159089|Active Comparator|Nordic Walking Group|Each group will be received 26 sessions of nordic walking. In each session, the intensity will be controlled and expected to be between 3 to 5 in the Borg scale adaptation. Patients will receive a schedule with all three-month sessions.
89401089|NCT05159089|Experimental|Physical activity base on SEM (Socioecological models)|The intervention group based on SEM will apply nordic walking in the same way as the Nordic Walking group. However, in this group, instructors will apply a SEM (instructors will not be the same as in the Nordic Walking group): in each session, the instructors in charge of the Nordic Walking will be also in charge to prescribe the PA.
89401090|NCT05159089|No Intervention|Congrol group|Control group outcomes assessment will be the same as the intervention group. However, they will receive common health care professional advice. A common health care professional advice used to recommend patients to walk more and do more PA or physical exercise at the gym. Visits with doctors and nurses will be the same as the intervention group. The difference will be that at intervention group nurses will refer participants to the instructor's physiotherapist to promote PA throughout nordic walking and use the SEM to apply it.
89401091|NCT02071680|Other|Iodine-123 Meta-iodobenzylguanidine|123I-mIBG administration followed by nuclear imaging pre-ablation and post-ablation
89401092|NCT05239052|Experimental|computer intervention group|stroke subjects with wheelchair users completed computer screen tasks with affected arm or bilateral arm movement
89401093|NCT05239052|Active Comparator|conventional long-term care services group|stroke subjects with wheelchair users receive conventional long-term care services
89401094|NCT05138107|Experimental|Skin Graft Burn Patients Experimental Site|Both placebo and active cosmetic scar spray will be applied to different parts of the same scar on each participant. The active and the placebo spray will both be applied to the designated area of each scar twice per day. The amount sprayed will cover the designated area of the scar and then be massaged into to scar and surrounding skin with each application. This will be done twice daily for the nine-month duration of the study.
89401095|NCT05138107|Placebo Comparator|Skin Graft Burn Patients Placebo Site|Both placebo and active cosmetic scar spray will be applied to different parts of the same scar on each participant. The active and the placebo spray will both be applied to the designated area of each scar twice per day. The amount sprayed will cover the designated area of the scar and then be massaged into to scar and surrounding skin with each application. This will be done twice daily for the nine-month duration of the study.
89401096|NCT02071758|Experimental|20 mcg LEISH-F3 + 5 mcg SLA-SE Vaccine|Three intramuscular injections of LEISH-F3 + SLA-SE at Days 0, 28, and 56. High dose of antigen and low dose of SLA-SE adjuvant.
89401097|NCT02071758|Experimental|20 mcg LEISH-F3 + 10 mcg GLA-SE Vaccine|Three intramuscular injections of LEISH-F3 + GLA-SE at Days 0, 28, and 56. High dose of antigen and high dose of GLA-SE adjuvant.
89401098|NCT02071758|Experimental|5 mcg LEISH-F3 + 10 mcg GLA-SE Vaccine|Three intramuscular injections of LEISH-F3 + GLA-SE at Days 0, 28, and 56. Low dose of antigen and high dose of GLA-SE adjuvant.
89401099|NCT02071758|Experimental|20 mcg LEISH-F3 + 10 mcg SLA-SE Vaccine|Three intramuscular injections of LEISH-F3 + SLA-SE at Days 0, 28, and 56. High dose of antigen and high dose of SLA-SE adjuvant.
89401100|NCT01380301|Experimental|Miltefosine and Antimony|Miltefosine 1,5 to 2,5 mg x k x d during 14 days simultaneously with meglumine antimoniate 20 mg x kg x d during 10 days
88876516|NCT05637216|Placebo Comparator|Mastectomy with Placebo|Participants who underwent a mastectomy will take placebo in a 25 milligram oral capsule once daily starting day one of radiation therapy until one year following the completion of radiation therapy.
89401101|NCT01380301|Active Comparator|Miltefosine alone|Miltefosine 1,5 to 2,5 mg x kg x d during 14 days
89401102|NCT02205866|Active Comparator|Group A|Non Obese patients
89401103|NCT02205866|Experimental|Group B|Obese patients
89401104|NCT02076828|Experimental|Fe-OH-PM (Santafer® sp.)(Group II)|The patients in Group II were treated with Fe-OH-PM (Santafer® sp.), 6 mg/kg/day orally.
89401105|NCT02076828|Experimental|Fe-Zn (Ferro Zinc® sp.)(Group III)|The patients in Group III were treated with Fe-Zn (Ferro Zinc® sp.), 6 mg/kg/day orally
88876517|NCT05628337|Experimental|Texting intervention group|Subjects will receive specific health-related texts
88876518|NCT05628337|Placebo Comparator|Control group|Subjects will receive general text messages without health information
88876519|NCT05623176||Current routine of non-standardised laparotomy care|
89401106|NCT02076828|Experimental|Fe-S (Ferro Sanol® sp.)(Group I)|The patients in Group I were treated with Ferro Sanol® sp., 6 mg/kg/day orally
88876520|NCT05616585|Experimental|Pharmacokinetic|Single Day Intervention of 10 test foods
89401107|NCT02221076|Experimental|Confocal Laser Endomicroscopy (CLE)|The patient will undergo a 10 minutes endomicroscopy procedure to obtain real time microscopical images of healthy and malignant tissue of the targeted organs.
89401108|NCT02076984|Other|Group A|laparoscopic incisional or ventral hernia repair use of lightweight polypropylene mesh fixed by titanium tacks
88876521|NCT05616585|Experimental|Dose Response|Six day, 3 level (zero, medium, high dose) controlled feeding study
88876522|NCT05612984|Experimental|Calcium aspirin multiple micronutrients|"500 mg elemental calcium (as 1250 mg calcium carbonate) 81 mg aspirin~1 tablet United Nations International Multiple Micronutrient Antenatal Preparation (UNIMMAP) formula, which is a Multiple Micronutrient Supplement (MMS) for pregnant women"
88876523|NCT05612984|Active Comparator|Iron folic acid|60 mg iron + 400 μg folic acid given as a combined tablet
88876524|NCT05604014|Experimental|My Health Coach|Participants receive the My Health Coach app and try it on their personal smartphones for 6 weeks.
89401109|NCT02076984|Other|Group B|laparoscopic incisional or ventral hernia repair use of lightweight polypropylene mesh fixed by U shaped absorbable tacks
89401110|NCT02221154|Experimental|Inofolic®|standard ovarian stimulation and Inofolic®
88876525|NCT05594017|Experimental|Scopolamine (5ug/kg)|"Subjects will receive a dose of scopolamine (5ug/kg) on each day. Approximately 15 minutes after administration, the participant will then complete either an episodic or a spatial memory task session.~If the patient completed the sham session already, this session will take place the day following the initial session, or at least four half-lives after the first session."
89401111|NCT02221154|Active Comparator|Gonadotropins;Folic Acid|standard ovarian stimulation without Inofolic®
89401112|NCT02079870|Experimental|Sema|Two 12-week treatment periods separated by a wash-out period of 5-7 weeks. Finally, a follow-up visit is performed 5-7 weeks after last dosing
89401113|NCT02079870|Placebo Comparator|Placebo|
89401114|NCT02209844|Experimental|BI 44847 powder|single rising dose reconstituted with natrosol solution
89401115|NCT02209844|Placebo Comparator|Placebo|reconstituted with natrosol solution
89401116|NCT02073084|Other|Sequence A|Sequence A
89401117|NCT02073084|Other|Sequence B|Sequence B
89401118|NCT02073084|Other|Sequence C|Sequence C
89401119|NCT02073084|Other|Sequence D|Sequence D
89401120|NCT03899701|Experimental|PEC I and PEC II block|Ultrasound guided nerve block group.
89401121|NCT02221388|Active Comparator|BI 671800 ED capsules|
89401122|NCT02221388|Experimental|BI 671800 HEA tablet in fasted state|
89401123|NCT02221388|Experimental|BI 671800 HEA EC tablet in fasted state|
89401124|NCT02221388|Experimental|BI 671800 HEA tablet in fed state|
89401125|NCT02221388|Experimental|BI 671800 HEA EC tablet in fed state|
89401126|NCT02221388|Experimental|BI 671800 HEA, 50 mg tablet in fasted state|
89401127|NCT03787849|Active Comparator|Sevoflurane|All children will receive inhalation anesthesia with sevoflurane through facial mask in concentrations between 3-8% for anesthesia induction . After induction and peripheral vein puncture, the anesthesia will be maintained only with sevoflurane 3% until completion of the procedure.
89401128|NCT03787849|Active Comparator|Propofol|All children will receive inhalation anesthesia with sevoflurane through facial mask in concentrations between 3-8% until lost of conscience and peripheral vein puncture. After that, sevoflurane will be turned off and its clearance will be analyzed through gas analyzer monitor. From here, anesthesia will be maintained as total venous with continuous propofol infusion 100 mcg.kg.min-1 until completion of the procedure.
89401129|NCT02073240||Enhanced TB IC Package|"Facilities randomized to the intervention group will receive the following:~Skills-based training for TB IC focal points~Audits and Feedback of performance data~TB IC collaborative (including mentoring)~Checklists"
88876526|NCT05594017|Placebo Comparator|Placebo|"Subjects will receive saline (5ug/kg) via IV on each day. Approximately 15 minutes after administration, the participant will then complete either an episodic or a spatial memory task session.~If the patient completed the scopolamine session already, this session will take place the day following the initial session, or at least four half-lives after the first session."
88876527|NCT05591274|Experimental|Interactive VR|Patients will be wearing a virtual reality headset preloaded with an interactive VR scenario.
89189607|NCT05592717||Yutiq group|Patients will receive YUTIQ® 0.18 mg as an intravitreal injection in the designated study eye and will be followed for 36 months after treatment.
89401130|NCT02073240||Usual Care Group|Usual Care group will receive available TB IC training/education alone.
89401131|NCT03671343|Experimental|Intervention : Physical rehabilitation|"The Arm Physical rehabilitation will benefit from the implementation of the Loss of Mobility Prevention program set up in the Department of Aging Medicine of the Center Hospitalier Lyon Sud (CHLS) of Pr BONNEFOY."
89401132|NCT03671343|No Intervention|Control : optimized medical treatment|"The Arm Optimized medical treatment will not benefit from the implementation of the Loss of Mobility Prevention program."
89401133|NCT02205944|No Intervention|Control Group|The control group will receive routine vascular access pre-op teaching and care.
89401134|NCT02205944|Experimental|Normal Exercise Group|"Group 1 (Normal Exercise Group): progressive handgrip exercise~Group 2 (Restricted Blood Flow Exercise Group): progressive handgrip exercise with controlled tourniquet"
88876528|NCT05591274|Experimental|Static VR|Patients will be wearing a virtual reality headset preloaded with a static, non-interactive VR scenario.
88876529|NCT05591274|No Intervention|Control|Patients will not be wearing any virtual reality headset.
88876530|NCT05588167||Affected|Patients with Niemann-Pick Disease, type C
88876531|NCT05581108|Experimental|Juice PLUS+® OMEGA|The Juice Plus+®Omega Blend capsules contain the following ingredients: DHA and EPAenriched oil of the micro algae Schizochytrium sp., pomegranate seed oil, coating agent: pullulan; raspberry seed oil, sea buckthorn oil 9, release agent: silicon dioxide; high oleic safflower seed oil, tomato seed oil, orange oil, vanilla oil, antioxidant: rosemary extract.
89401135|NCT02077062||study (hepatectomy) group|patients undergoing hepatectomy for malignant neoplasm
89401136|NCT02077062||control (non hepatectomy) group|patients undergoing intestinal resections (not incluiding hepatectomy) for malignant neoplasm
89401137|NCT03671265|Experimental|SHR-1210 + Chemotherapy + Radiotherapy|"Radiotherapy(IMRT or VMAT): 95%PTV 54Gy/30 fraction,95%PTV 60Gy/30 fraction ,5 fractions per week, for 6 weeks. Radiation begun the day on which first dose of SHR-1210.~SHR-1210 (200mg fixed dose every 2 weeks, one cycle is four weeks, total 8 cycles ) will be administered as an intravenous infusion over 30 minutes.~Chemotherapy: Docetaxel 25mg/m2/w, intravenous infusion on days 1, 8, 15, 22, total 4 cycles; Cisplatin 25mg/m2/w, intravenous infusion on days 1, 8, 15, 22;, total 4 cycles.~Apatinib: 250mg/d，PO Qd(4 weeks after Radiotherapy, until the end of 8th ycle )"
89401138|NCT02077218|Experimental|Diagnostic (CT and blood biomarkers)|Patients undergo cardiac CT and collection of blood samples for analysis of hs-CRP via quantitative immunoturbidimetry and Lp-PLA2 via ELISA.
89401139|NCT03729427|Experimental|Treatment Arm|ESP Block
89401140|NCT03729427|No Intervention|Control Arm|Standard of Care
89401141|NCT03671187|Experimental|Smoking|8 week exercise program consists of breathing exercises, strength training and endurance training
89401142|NCT03671187|Experimental|Ex- Smoking|8 week exercise program consists of breathing exercises, strength training and endurance training
89401143|NCT02073318|Experimental|Balance training|
89401144|NCT02073318|Active Comparator|Control|Control group received 4 weeks upper extremities exercise in sitting position
89536673|NCT04983381|No Intervention|Control Group|Women were not given information about vaginal examination in the control group
88876532|NCT05581108|Placebo Comparator|Matched placebo|Placebo capsules consist of medium chain triglycerides oil+ excipients like silicon dioxide aerosil, lecithin, vanilla flavor, orange oil, water and hypromellose(shell).
88876533|NCT05579392|Experimental|Bright Light Therapy via ReTimer glasses, Then Placebo|Participants will wear their device for 60 minutes every morning for 28-days (4 weeks)
88876534|NCT05579392|Experimental|No Bright Light Therapy via placebo glasses, Then Bright Light Therapy|Participants will wear their placebo device for 60 minutes every morning for 28-days (4 weeks)
88876535|NCT05576038|Active Comparator|L-Tryptophan|"L-tryptophan* supplements (Tryptan, Valeant Canada LP): each treatment capsule contains 500 mg of L-Tryptophan; talc and magnesium stearate.~Study participants will be instructed to take 2 x 500 mg capsules (1000 mg) every 8 hrs, three times a day. (total daily dose: 3000 mg) for a total of 3 weeks.~Instructions will be printed on the label of the pill container."
88876536|NCT05576038|Placebo Comparator|Freedom SimpleCap Powder|"500 mg of SimpleCap Powder. Study participants will be instructed to take 2 x 500 mg capsules (1000 mg) every 8 hrs, three times a day. (total daily dose: 3000 mg) for a total of 3 weeks.~Instructions will be printed on the label of the pill container."
88876537|NCT05529069|Experimental|Pirtobrutinib (LOXO-305) and Venetoclax (combination)|Participants will have study visits every week during Cycle 1, and then on Day 1 of every cycle for the first year. After that, they will have study visits on Day 1 of every 2 cycles.
88876538|NCT05528770|Active Comparator|Full closed-loop (FCL) with Bolus Priming System (BPS) followed by FCL without BPS|"Two separate 24-hour periods during where fully closed loop (FCL) control is used with & without the Bolus Priming system (BPS) active (BPS is designed to recognize meal ingestion & deliver a quick priming dose of insulin prior to extreme blood sugar excursions.) These will be separated by a 24-hour challenge period which will involve further meal & exercise challenges. During these 24-hour periods, participants will be followed for the experimental meals as part of the Study Controller Sessions to compare blood glucose control with & without the BPS. The study meals & activities will be standardized between study sessions.~During a washout period, we will test the RocketAP system in FCL with further challenges:~A session of high-intensity interval training~A high-carbohydrate, high-fat meal~Ingestion of a bolus of simple sugar"
88876539|NCT05528770|Active Comparator|Full closed-loop (FCL) without Bolus Priming System (BPS) followed by FCL with BPS|"Two separate 24-hour periods during where fully closed loop (FCL) control is used with & without the Bolus Priming system (BPS) active (BPS is designed to recognize meal ingestion & deliver a quick priming dose of insulin prior to extreme blood sugar excursions.) These will be separated by a 24-hour challenge period which will involve further meal & exercise challenges. During these 24-hour periods, participants will be followed for the experimental meals as part of the Study Controller Sessions to compare blood glucose control with & without the BPS. The study meals & activities will be standardized between study sessions.~During a washout period, we will test the RocketAP system in FCL with further challenges:~A session of high-intensity interval training~A high-carbohydrate, high-fat meal~Ingestion of a bolus of simple sugar"
88876540|NCT05525000|Experimental|Participants aged over 35|Participants run through our validation protocol
88876541|NCT05523596|Experimental|Dose Level 1|ICM20
88876542|NCT05523596|Experimental|Dose Level 2|ICM20 and benznidazole ascending dose 2
88876543|NCT05523596|Experimental|Dose Level 3|ICM20 and benznidazole ascending dose 3
88876544|NCT05523596|Experimental|Dose Level 4|ICM20 and benznidazole ascending dose 4
88876545|NCT05502796||Patient|Male and female ages 2-45 years old
88876546|NCT05482568|Experimental|SHR-A1811 combined with Pyrotinib/SHR-A1811 combined with SHR-1316|
88876547|NCT05477147|Experimental|Treatment Group|Patients undergoing catheter ablation that qualify after initial screening.
88876548|NCT05476796|Experimental|Trifluridine/Tipiracil + Oxaliplatin ± nivolumab|"Trifluridine/Tipiracil will be administered with a 14-day schedule (35 mg/m² twice-daily [BID] for 5 days followed by 9 days of recovery) until disease progression or intolerable toxicity.~Oxaliplatin will be administered intravenously on day 1 of each treatment cycle (infusion duration: 2 hours), every 2 weeks. The first cycle will be administered at level -1 (70 mg/m²) and then increased to 85 mg/m² (if feasible) from the cycle 2 to 8 or until disease progression, whatever occurs first. In case of limiting-oxaliplatin neuropathy and in all cases after 8 cycles, oxaliplatin will be stopped and Trifluridine/Tipiracil will be continued alone until disease progression or intolerable toxicity.~± nivolumab 240 mg (infusion duration 30 minutes, every 2 weeks) until disease progression or intolerable toxicity for a maximum of 2 years."
88876549|NCT05476796|Active Comparator|FOLFOX ± nivolumab|"Folinic Acid 400 mg/m² (or 200 mg/m² if L-folinic acid) + oxaliplatin 85 mg/m² (infusion duration: 2 hours) followed by 5-FU bolus 400 mg/m² and then 5-FU 2400 mg/m² as a 46-hour continuous infusion. Treatment repeated every 14 days. In case of limiting-oxaliplatin neuropathy and in all cases after 8 cycles, oxaliplatin will be stopped and 5-FU (simplified LV5FU2 regimen) or capecitabine (1000 mg/m² BID during 2 weeks every 3 weeks) will be continued alone until disease progression or intolerable toxicity.~± nivolumab 240 mg (infusion duration 30 minutes, every 2 weeks) until disease progression or intolerable toxicity for a maximum of 2 years."
88876550|NCT05456997||Cushings syndrome|Patients with Cushing's syndrome treated medically prior to adrenalectomy
88876551|NCT05456997||Phaeochromocytoma and paraganglioma (PPGL)|Patients with PPGL treated medically prior to adrenalectomy
88876552|NCT05456997||Conn's syndrome|Patients with Conn's syndrome treated medically prior to adrenalectomy
89011537|NCT01644799|Experimental|lenalidomide and idelalisib|"Lenalidomide:~Lenalidomide will be administered orally on days 1-21 followed by 7 days of rest, every 28 days. A treatment cycle will be considered 28 days in length. In the absence of intolerable toxicity or disease progression, lenalidomide will be given for a total of 12 cycles.~Idelalisib:~Dosing is fixed in all cohorts receiving idelalisib at 150 mg orally (twice daily) for 12 cycles, with the exception of dose modifications for toxicity."
88876553|NCT05433493|Experimental|Intervention group|"Participants who meet the inclusion criteria will be randomly assigned to the intervention group receiving individual CS or to the control group receiving treatment as usual (participating in the activities previously established in their individual intervention plan).~Participants in the intervention group will participate in two individual CS sessions per week for 12 weeks in addition to their treatment as usual. The sessions will include the same protocol in every participant site."
88876554|NCT05433493|No Intervention|Control group|Participants in the control group will receive treatment/activities as usual, participating in the activities previously established in their individual intervention plan.
88876555|NCT05427084|Active Comparator|Active|Canagliflozin 300mg PO daily
88876556|NCT05427084|Placebo Comparator|Placebo|Placebo PO daily
88876557|NCT05414123||Breast Cancer|Subjects with Breast Cancer of all subtypes and independent of Hormone status who have a confirmed or suspicious Leptomeningeal Metastasis by Investigator assessment of radiographic image and clinical evaluation and cytology
88876558|NCT05414123||Non-Small Cell Lung Cancer|Subjects with Non-Small Cell Lung Cancer of all subtypes who have a confirmed or suspicious Leptomeningeal Metastasis by Investigator assessment of radiographic image and clinical evaluation and cytology
88876559|NCT05394818|Experimental|SHR-A2009|
88876560|NCT05391503|Active Comparator|Active treatment|Active light therapy
88876561|NCT05391503|Placebo Comparator|Control treatment|Placebo light therapy
88876562|NCT05384821|Experimental|Single Arm - Vincristine + Irinotécan + Témozolomide + Etoposide + Cis-Retinoic acid|Metronomic chemotherapy : Vincristine + Irinotécan + Témozolomide + Etoposide + Cis-Retinoic acid
88876563|NCT05377723|Experimental|Neodyne Device|After eligible patients have provided informed consent, the side of the abdomen to be treated with the Neodyne Device will be randomly selected by opening a sealed randomization envelope. The selected side will be treated with the Neodyne Device through the full study. The Neodyne Device will be applied to a portion of the abdominal incision by the health care provider at 1 week (4-8 days) after the procedure. The other portion of the abdominal incision (Arm Title: Control) will serve as the control and will be treated per the investigator's standard of care. Subjects will return to the Investigator's office for a total of 8 weeks for application and removal of the Neodyne Dressing.
88876564|NCT05377723|Other|Control|See above
88876565|NCT05369260|Experimental|Cervical and scapular stabilization group|In this arm cervical and scapular stabilization exercises will be applied based on the telerehabilitation method via videoconference for 8 weeks, one day a week , 45-60 minutes for each session.
88876566|NCT05369260|Experimental|Cervical and core stabilization group|In this arm cervical and core stabilization exercises will be applied based on the telerehabilitation method via videoconference for 8 weeks, one day a week , 45-60 minutes for each session.
88876567|NCT05368350|Experimental|Active tDCS treatment|This pilot study has one treatment arm with open-label treatment and will examine improvement of speech output, verbal fluency, and other cognitive deficits associated with primary progressive aphasia (PPA) and progressive apraxia of speech (PAOS), by utilizing 1 milliamp transcranial direct current stimulation (tDCS) active treatment applied to pre-supplementary motor area for 20 minutes over 10 sessions. There will be baseline testing, and follow up testing immediately after and 8 weeks after completion of treatment.
88876568|NCT05317455|Placebo Comparator|Placebo|capsule with excipient only, no active drug.
88876569|NCT05317455|Active Comparator|Dichloroacetate|sodium salt of dichloroacetate, 1000mg
88876570|NCT05293197|Experimental|SonoCloud®|SonoCloud® : dose escalation 6 cycles of sonication
88876571|NCT05281198|Experimental|Experimental: tart cherry|dietary supplement: tart cherry juice
88876572|NCT05281198|Placebo Comparator|Placebo|dietary supplement: placebo juice
88876573|NCT05217459|Experimental|Self-expanding intracranial drug stent system|All patients receive Percutaneous transluminal angioplasty and stenting with self-expanding intracranial drug stent system (Temporary abbreviations: SINOMED IS-DES)
88876574|NCT05207085|Experimental|Valbenazine|Participants randomized1:1 to receive valbenazine
88876575|NCT05207085|Placebo Comparator|Placebo|Participants randomized 1:1 to receive placebo
88876576|NCT05206695|Experimental|Multi-condition Pathway Intervention|The multi-condition pathway intervention consists of pathways clinicians select from to guide the care of children with asthma, pneumonia, or bronchiolitis. Key implementation strategies include audit and feedback, plan-do-study-act cycles, and electronic order sets.
88876577|NCT05206695|No Intervention|Standard of Care|Hospitals randomized to the control arm will not receive the multi-condition pathway intervention or any external supports for implementation. They will continue to provide current standards of care.
88876578|NCT05201469|Experimental|VIB4920|"Participants will receive VIB4920 1500 mg intravenously at Weeks 0, 2, 4, 8, 12, 16, 20, and 24.~Participants will also receive methylprednisolone 1000 mg at Week 0 and will begin MMF 2-3 g per day and prednisone 25 mg per day, tapered to ≤ 5 mg per day from Week 8."
88876579|NCT05201469|Placebo Comparator|VIB4920 Placebo|"Participants will receive VIB4920 placebo intravenously at Weeks 0, 2, 4, 8, 12, 16, 20, and 24.~Participants will also receive methylprednisolone 1000 mg at Week 0 and will begin MMF 2-3 g per day and prednisone 25 mg per day, tapered to ≤ 5 mg per day from Week 8."
88876580|NCT05199285|Experimental|Treatment (nivolumab, ipilimumab)|Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
88876581|NCT05198518|Experimental|Microcurrent TENS device|A handheld micro-current TENS emitter device, which applies a small current of electricity to the forehead and maxillary region
88876582|NCT05198518|Sham Comparator|Sham device|The sham device appears identical to the active device while emitting no therapeutic microcurrent.
88876583|NCT05175664||MCI|Patients suffering from mild cognitive impairment (MCI) due to Alzheimer's disease.
88876584|NCT05175664||AD|Patients diagnosed with mild to moderate Alzheimer's disease (AD)
88876585|NCT05175664||NDD|Patients under investigation of a neurodegenerative disease (NDD)
88876586|NCT05175664||DLB|Patients diagnosed with Dementia with Lewy Bodies (DLB)
88876587|NCT05175664||VaD|Patients with vascular dementia (VaD)
88876588|NCT05175664||FTD|Frontotemporal dementia (FTD)
89401145|NCT02209922|Active Comparator|Transcranial direct current stimulation|"ARM1: Transcranial direct current stimulation (tDCS) intervention and simultaneous balance training.~Participants underwent tDCS(2mA) brain stimulation (20 minutes) and simultaneous balance training(20 minutes) for 5 consecutive days,for 1 week."
89401146|NCT02209922|Sham Comparator|ARM 2|ARM2: Sham tDCS and simultaneous balance training(20 minutes) for 5 consecutive days,for 1 week.
89401147|NCT03671031||isolated roux loop|isolated roux loop reconstruction following pancreaticoduodenectomy as the first group.
89401148|NCT03671031||single loop|single loop reconstruction following pancreaticoduodenectomy as the second group.
89401149|NCT02881957|Placebo Comparator|Control|Placebo control (simple oral syrup)
88876589|NCT05175664||NPH|Normal pressure hydrocephalus (NPH)
88876590|NCT05175664||Healthy Controls|Healthy Controls without brain disease
88876591|NCT05148156|Experimental|Urolift|This is a single-arm study involving 1 year of follow-up. Study intervention involves a one-time administration of Urolift prior to SBRT for prostate cancer treatment.
88876592|NCT05146700|Experimental|Restrictive oxygen|"- Lowest oxygen delivery possible (≥21%) ensuring an SpO2 target = 94% either using no supplemental oxygen, a nasal cannula, a non-rebreather mask or manual/mechanical ventilation (intubated trial participants)~and~- Only trial participants receiving an FiO2 = 0.21 can saturate >94%~Pre-oxygenation as usual prior to intubation is permitted"
88876593|NCT05146700|Active Comparator|Liberal oxygen|"- 15 L O2/min flow for non-intubated trial participants in the pre-hospital phase, the trauma bay and during intrahospital transportation. In the operating room, intensive care unit, post-anesthesia care unit and ward the flow can be reduced to ≥12 L O2/min if the arterial oxygen saturation is ≥98%~or~- FiO2 = 1.0 for intubated trial participants in the pre-hospital phase, the trauma bay and during intrahospital transportation. In the operating room, intensive care unit, post-anesthesia care unit and ward the FiO2 can be reduced to ≥0.6 if the arterial oxygen saturation is ≥98%"
88876594|NCT05138393|Experimental|Active self-corrective exercises|An active self-correction tailored to the individual type of curve and clinical presentation will be applied with the aim to correct the scoliosis in all three planes. Patients will also be informed and educated in task oriented activities of daily living. Training goals are directed towards postural control, spinal stability, muscular stabilization and endurance in corrective postures. Patients will have outpatient sessions once every two weeks the first 3 months and perform the exercises at home in 30-minutes sessions three times per week. Patients are encouraged to continue with non-specific self-mediated physical activities of moderate intensity at least 60 minutes daily. Compliance will be monitored through a mobile application (Physitrack) where the patients record their sessions and can have contact with the research personnel. A cognitive behavioral therapy approach to reinforce physical activity will be performed every 6 months.
88876595|NCT05138393|Active Comparator|Observation|Patients are encouraged to continue with non-specific self-mediated physical activities of moderate intensity at least 60 minutes daily, for the entirety of the study. A cognitive behavioral therapy approach to reinforce physical activity will be performed every 6 months.
88876596|NCT05136976|Placebo Comparator|Placebo|"Patient with anti-MAG neuropathy will be included. They will randomized in placebo or Rituximab group.~They will have the same premedications prior to rituximab or placebo infusions:~IV Dexchlorpheniramine Maleate IV: 10 mg~IV Methylprednisolone: 40 mg~PO Paracetamol : 1 gram"
88876597|NCT05136976|Active Comparator|Rituximab|"Patient with anti-MAG neuropathy will be included. They will randomized in placebo or Rituximab group.~They will have the same premedications prior to rituximab or placebo infusions:~IV Dexchlorpheniramine Maleate IV: 10 mg~IV Methylprednisolone: 40 mg~PO Paracetamol : 1 gram"
88876598|NCT05136352|Active Comparator|adductor canal block|loco-regional analgesia with adductor canal block (ACB) method (for anterior cruciate ligament reconstruction )
88876599|NCT05136352|Experimental|iPACK block|loco-regional analgesia with iPACK block (infiltration between the popliteal artery and the capsule of the posterior knee) ((for anterior cruciate ligament reconstruction )
89011538|NCT01644838|Experimental|Promethazine|25 mg of promethazine
89011539|NCT01644838|Experimental|Hyoscine|20 mg of hyoscine
89011540|NCT01644877|Experimental|DAS181|DAS181-F02, 4.5 mg qd x 10 days
89401150|NCT02881957|Experimental|Vitamin D3|Cholecalciferol/Vitamin D3 (540,000 IU orally or by feeding tube once)
89401151|NCT02073396||Patients|Patients diagnosed with coronary disease or atrial fibrillation. All the patients will undergo Global Thrombosis Test.
89401152|NCT02206022|Experimental|Remifentanil|Patients who undergone a Central Venous Catheter (CVC) insertion under remifentanil infusion
89401153|NCT02206022|Placebo Comparator|Placebo|Patients who undergone a Central Venous Catheter (CVC) insertion under placebo infusion
89401154|NCT02077296||Preoperative chemoradiotherapy|The group consists of patients aged ≥18 with a pathohistological diagnosis of locally advanced rectal adenocarcinoma (<15 cm from the anal verge). They are found eligible for preoperative chemoradiotherapy (chemotherapy: oral capecitabine / radiotherapy: 45-50 Gy in total; fractions of 1.8-2 Gy) and surgery (stage 2 or 3 rectal cancer).
89401155|NCT02221466||diabetic patients|Diabetic patients given HBOT
89401156|NCT02221466||None diabetic patients|None diabetic patients given HBOT
89401157|NCT02073552|Active Comparator|High volume|"Two 5 mg bisacodyl tablets It is a stimulant laxative with local action.~Polyethylene glycol 4000: 16 envelopes (70 g of powder each). It includes electrolytes and sodium sulfate."
89401158|NCT02073552|Experimental|Low volume|"Two 5 mg bisacodyl tablets, taken in the same way as for the high volume group.~Macrogol 3350 plus ascorbic acid: 4 envelopes, 2 containing 112 g polyethylene glycol and electrolytes and 2 with 2 g of ascorbic acid."
89401159|NCT03022461||Ongoing HM3 CE Mark study patients|The study will include the ongoing HM3 CE Mark study patients that have consented to continue the long term follow-up data collection.
89401160|NCT02210156|Placebo Comparator|Placebo|Two envelopes of the product in 240 ml of water in a disposable cup, 90 days of actual consumption.
89401161|NCT02210156|Experimental|Omniplus Supreme|Two envelopes of the product in 240 ml of water in a disposable cup, 90 days of actual consumption.
89437444|NCT03909061|Experimental|Immediate Training (with follow up)|Individuals may decide to participate in the research study, but do not want to be randomized. After consent is obtained, these individuals will be directed immediately to the baseline questionnaires (see above) before and after the wheelchair maintenance training. Participants may also be asked to complete a user satisfaction survey.
89401162|NCT02080026|Experimental|CPS-immunization|"In this group a total of four CPS-immunizations will be performed, with bites from 15 Plasmodium infected mosquitoes per immunization, over a period of four months, during which volunteers will take chloroquine prophylaxis.~14 weeks after the last immunization, these volunteers will undergo Controlled Human Malaria Infection (CHMI) by exposure to bites from 5 Plasmodium falciparum sporozoite infected mosquitoes.~If a subject develops a malaria infection he/she will be treated with atovaquone/proguanil (Malarone). At the end of the study any subjects that did not develop a malaria infection will also be treated with atovaquone/proguanil (Malarone)."
89401163|NCT02080026|Other|Control|"This group will take chloroquine prophylaxis during the same period as the immunization group, but will not receive CPS-immunizations.~10 weeks after stopping chloroquine prophylaxis, these volunteers will undergo Controlled Human Malaria Infection (CHMI) by exposure to bites from 5 Plasmodium falciparum sporozoite infected mosquitoes.~If a subject develops a malaria infection he/she will be treated with atovaquone/proguanil (Malarone). At the end of the study any subjects that did not develop a malaria infection will also be treated with atovaquone/proguanil (Malarone)."
89401164|NCT02206178|Experimental|acetaminophen|"The purpose of this study is to assess the effectiveness of acetaminophen in association with N-acetylcysteine.~The objective of this study is to evaluate if the association in healthy volunteers of acetaminophen and N-acétylcystéine~- decrease the antinociceptive effect of acetaminophen in comparison to a group control~- and if this antinociceptive effect may depend of the genetic polymorphism of GSH enzyme"
89401165|NCT02206178|Placebo Comparator|placebo|"- decrease the antinociceptive effect of acetaminophen in comparison to a group control~- and if this antinociceptive effect may depend of the genetic polymorphism of GSH enzyme"
89401166|NCT02080104|Active Comparator|intravenous 10 ıu oxytocin|group which 2 ampul prophylactic oxytocin given for third stage of labour intravenously after vaginal delivery
89401167|NCT02080104|Experimental|intramusculer 10 ıu oxytocin|group which oxytocin administered intramusculary after vaginal delivery
89401168|NCT02211326|Experimental|genotype-guided group|Interventions：on day1~day3, patients received dose according to IWPC formula (PGx-1) included clinical variables and genotype data for VKORC1, CYP2C9*1, CYP2C9*2, and CYP2C9*3; on day4~day7, patients received dose according to Lenzini formula consisted of clinical variables, VKORC1, CYP2C9*2, CYP2C9*3 and previous INR and dosing information (PGx-2); and on day8, the clinicians adjusted the dose according to observed INR.The overall follow-up period is 12 weeks.
89401169|NCT02211326|Active Comparator|control group|Interventions：on day1~day3, patients were given initial dose (2.25mg); and starting from day4, the clinicians began to adjust the dose for patients according to observed INR.The overall follow-up period is 12 weeks.
89401170|NCT02077452|Experimental|HMS5552 dose 1|HMS5552 25~400mg. Oral administration, twice per day.
89401171|NCT02077452|Experimental|HMS5552 dose 2|HMS5552 25~400mg. Oral administration, twice per day.
89401172|NCT02077452|Experimental|HMS5552 dose 3|HMS5552 25~400mg. Oral administration, twice per day.
89401173|NCT02077452|Experimental|HMS5552 dose 4|HMS5552 25~400mg. Oral administration, once per day.
89401174|NCT02077452|Experimental|HMS5552 dose 5|HMS5552 25~400mg. Oral administration, twice per day.
89401175|NCT03462979|Experimental|Open Results with home testing|Participants in the open results arm will be provided with Gluten Detective home testing kits (immunochromatographic lateral flow tests) at week 8 of the study for immediate qualitative (yes/no) feedback about the presence of biomarkers of gluten in their stool and/or urine. During the period from week 8 to week 30, participants will be contacted a total of 6 times at random intervals to collect and test urine samples and complete a questionnaire.Additionally, participants will be given 4 stool test kits, with instructions that they may use these at times of their choosing and will report results and reasons for test use, if any. During this time participants will also keep a diary of suspected gluten exposures. All samples collected will be returned during the week 30 study visit.
88876600|NCT05128838|Experimental|RISE Intervention|Working one-on-one with the PI (a licensed occupational therapist (OT) and behavior change expert), participants will set goals and develop practical strategies in order to establish sustainable positive habits around lifestyle areas such as physical activity, nutrition, stress management, sleep, self-efficacy, and spiritual well-being. Motivational interviewing, cognitive behavioral therapy, and patient education will accompany intensive collaborative problem-solving and creation of accountability structures to create increased self-efficacy for health self-management.
88876601|NCT05123222|Experimental|ZIKV-SJRP/2016-184 Strain|Dose of 10ˆ2 PFU
88876602|NCT05123222|Experimental|ZIKV-Nicaragua/2016 Strain|Dose of 10ˆ2 PFU
88876603|NCT05123222|Placebo Comparator|Placebo|PlasmaLyte
88876604|NCT05109026||Older people|Members of the population aged 65 years and older.
88876605|NCT05109026||Recent migrants|Members of the population who are recent migrants to the community.
88876606|NCT05109026||Members of the travelling community|Members of the population who are members of the travelling community.
88876607|NCT05109026||Perinatal women.|Members of the population who are pregnant or within a year of giving birth.
88876608|NCT05109026||Lone-parents|Members of the population who are raising children alone.
88876609|NCT05109026||Individuals with physical disabilities|Members of the population who have a physical disability.
88876610|NCT05109026||Secondary school students|Members of the population attending secondary school.
88876611|NCT05109026||Remote workers|Members of the population currently working from home.
88876612|NCT05107310|Experimental|Navigation group 1 ARSN|Augmented reality surgical navigation (ARSN). Pedicle screw placement using the Philips ClarifEye system combined with Philips Allura for imaging.
88876613|NCT05107310|Active Comparator|Control group 1 FH|Free hand (FH) surgical technique. Pedicle screw placement using conventional free hand technique.
88876614|NCT05107310|Experimental|Navigation group 2 IRSN|Infrared surgical navigation (IRSN). Pedicle screw placement using Brainlab Curve 1.2 combined with Medtronic o-arm for imaging.
88876615|NCT05107310|Active Comparator|Control group 2 FH|Free hand (FH) surgical technique. Pedicle screw placement using conventional free hand technique.
89011541|NCT01644877|Placebo Comparator|Lactose Placebo|placebo, 4.5 mg qd x 10 days
88876617|NCT05101213|Experimental|Treatment for viral infections (virus-specific CTLs)|Patients receive virus-specific CTLs intravenously (IV) over 30 minutes. Patients with partial response, stable disease, or progressive disease may receive up to 8 additional infusions of virus-specific CTL at least 2 weeks between each infusion.
88876618|NCT05090722|Experimental|The PureWick Urine Collection System|The PureWick Urine Collection System is intended for non-invasive urine output management. It pulls urine through tubing that is connected to a collection canister for proper disposal. It is designed to be used by patients, caregivers, or healthcare professionals in both home environments and professional care facilities.
88876619|NCT05073588|Active Comparator|Indo Mediterranean diet|Indian version of Mediterranean diet will be given to NAFLD children
88876620|NCT05073588|Active Comparator|Calorie restricted Diet|Diet restricted in calories will be given to NAFLD children
88876621|NCT05040282|Other|Etonogestrel 68 mg implant|Women will be subjected to etonogestrel 68 mg implant insertion (Implanon NXT; Organon, USA Inc) according to manufacture instructions. The insertion will be within the first 5 days of the menstrual cycle
88876622|NCT05039801|Experimental|Part A (IACS-6274)|Patients receive IACS-6274 PO throughout the study.
88876623|NCT05039801|Experimental|Part B (IACS-6274, bevacizumab, paclitaxel)|Patients receive IACS-6274 PO, paclitaxel IV, and bevacizumab IV throughout the study.
88876624|NCT05039801|Experimental|PART C: (IACS-6274) with capivasertib|Patients receive IACS-627 PO, with capivasertib PO throughout the study.
88876625|NCT05034198|No Intervention|Stakeholder Input|Behavioral health staff (BHS) will be asked to complete two semi-structured qualitative interviews and a set of surveys. The first interview will be about perceived barriers and facilitators on utilizing a remote training platform. The second interview will cover perceived feasibility and acceptability of the proposed training, consultation, and the implementation of evidence-based practices. The surveys will ask about the perceived acceptability, appropriateness, and feasibility of the remote training platform.
88876626|NCT05034198|No Intervention|Asynchronous Training Development|Mental health trainers with expertise in the treatment of externalizing and internalizing behavior disorders will video-record the training modules and produce them using lecture capture technology (i.e., showing speaker and Power Point slides on a split screen). Each training module will be approximately 45 minutes long.
88876627|NCT05034198|Experimental|Initial Mini-Tiral|BHS will be given a procedures manual with instructions on how to access the video-recorded training modules on-demand. All participants will take part in this mini-trial. Immediately after BHS watch the videos, they will be asked to complete three brief surveys regarding the appropriateness, feasibility and acceptability of each training module and provide comments about each.
88876628|NCT05032183|Experimental|Treatment (tagraxofusp, chemotherapy)|See Detailed Description
88876629|NCT05032079|Experimental|Treatment Arm|
88876630|NCT05026125|Active Comparator|Group control|3 μg/kg (Ideal Body Weight) of Remifentanil
88876631|NCT05026125|Experimental|Group Active|3 μg/kg (Ideal Body Weight) plus 30% of Remifentanil
88876632|NCT05012943|Experimental|ARCT-154|Each participant is planned to receive a two-dose vaccination series of ARCT-154 at a dose of 5 µg with 28 day interval in the first vaccination series.
88876633|NCT05012943|Placebo Comparator|Placebo|Each participant is planned to receive a two-dose vaccination series of placebo (normal saline) with 28 day interval in the first vaccination series.
88876634|NCT05012943|Active Comparator|Astra Zeneca COVID-19 vaccine|Each participant is planned to receive a two-dose vaccination series of Astra Zeneca COVID-19 vaccine with 28 day interval in the first vaccination series.
88876635|NCT04997369|Experimental|Catheterless group|
88876636|NCT04995315||PK Deficiency Diagnosed Participants|Participants will receive online user access to the CBB. Participants will complete 2 CBB assessments on Study Day 0 and Study Day 90.
88876637|NCT04994990|Active Comparator|Standard Dosing Group|
88876638|NCT04994990|Experimental|Half Standard Dosing Group|
88876639|NCT04992260|Experimental|Experimental Group|subjects will receive two doses of inactivated COVID-19 vaccine on day 0 and day 28.
88876640|NCT04992260|Placebo Comparator|Control Group|subjects will receive two doses of placebo on day 0 and day 28.
88876641|NCT04990895|No Intervention|Control group|Participants in the control group will have a planned clinic follow-up visit prior to each scheduled chemotherapy appointment. Although they will not be asked to complete PROs in between clinic visits, they will be asked to respond to a series of HRQOL questionnaires at baseline, at 6 months (±2 weeks) from enrollment, and at completion of neoadjuvant/adjuvant systemic therapy if this date differs from the 6-month time point by more than 4 weeks. A satisfaction questionnaire will also be administered at the end of study.
88876642|NCT04990895|Experimental|Intervention|Participants in the intervention group will also have a planned clinic follow-up visit prior to each scheduled chemotherapy appointment. They will be asked to complete a series of HRQOL questionnaires at baseline, at 6 months, and at completion of neoadjuvant/adjuvant chemotherapy to evaluate their HRQOL and satisfaction levels with their care. In addition, however, they will also receive an email reminder at the mid-way point between scheduled clinic visits to prompt them to enter ePROs via the REDCap online system, including measures such as the ESASr, the EORTC-QLQ C30 and EORTC-BR23 or EORTC-CR29 and specific symptom questionnaires.
88876643|NCT04984317|Experimental|Botox Injection|One-time injection of 100U BOTOX (onabotulinumtoxin A) into the fundus of the bladder under direct visualization via cystoscopy.
88876644|NCT04981184|Other|Gait and balance measurement|"Gait analysis with surface electromyography measurement: surface electromyography signals (of affected and non-affected legs), gait and stance parameters are collected while the patient walks for 30 seconds on the treadmill with integrated sensor equipment (for measuring the force distribution).~Balance analysis with Biodex balance system SD: measurements of postural stability, fall risk, limits of stability, sensory integration are collected."
89011542|NCT01644955|Experimental|Treatment (carboplatin)|Patients will undergo surgery, which includes tumor resection and catheter placement, in the operating room and then receive carboplatin administered intracerebrally by convection enhanced delivery.
88876645|NCT04977479|Active Comparator|Blinded Active Vaccine 2|Participants who experienced a systemic allergic reaction after receiving their first full dose of the Pfizer-BioNTech or Moderna COVID-19 vaccine receives one dose of the active mRNA COVID-19 vaccine (0.3mL) intramuscularly followed by a wash out period of 24 hours then crossover to receive placebo (0.3 mL normal saline) intramuscularly.
88876646|NCT04977479|Placebo Comparator|Blinded Placebo|Participants who experienced a systemic allergic reaction after receiving their first full dose of the Pfizer-BioNTech or Moderna COVID-19 vaccine receives one dose of the placebo (0.3 mL normal saline) intramuscularly followed by a wash out period of 24 hours then crossover to receive the active mRNA COVID-19 vaccine (0.3mL) intramuscularly.
89401176|NCT03462979|No Intervention|Blinded (sample collection only)|Participants in the blinded arms will not be given a test kit but will be given sample collection materials. During the period from week 8 to week 30 of the study, participants will be contacted a total of 6 times at random intervals, instructed to collect urine samples, and complete a questionnaire. Participants will also keep a diary of suspected gluten exposures. All samples collected will be returned during the week 30 study visit. After completion of sample collection, all participants will be unblinded and notified of the results once the samples have been processed.
89401177|NCT02073630|Other|Healthy subjects|healthy subjects will receive either sham or active cerebellar stimulation
88876647|NCT04977479|Experimental|Open-Label Booster Vaccine|Participants who did not suffer from a COFAR grade 3 or higher reaction after blinded active vaccine 2 were offered to receive booster dose of the active mRNA COVID-19 vaccine (0.3 mL) intramuscularly 5 months later.
88876648|NCT04976621|Experimental|Behavioral Activation (BA) intervention group|Participants in the BA group will receive BA treatment and treatment as usual. BA is a brief behavioral treatment that helps people define goals, create and execute plans to attain them, and engage in meaningful activities. The BA intervention will be delivered in 6 sessions over 3 months by Occupational Therapists trained in BA for post-TBI depression. BA sessions will be conducted in an office at the VA rehabilitation clinic or the home, depending on the veteran's preference.
88876649|NCT04976621|Other|Treatment as Usual Control Group|Participants in the Control group receive treatment as usual (TAU), which is usual care provided by the VA medical center.
88876650|NCT04974515|Experimental|Low intensity application of eXciteOSA|Participants will receive the eXciteOSA device intervention at low intensity application for 20 minutes per day for 6 consecutive weeks.
88876651|NCT04974515|Active Comparator|High intensity application of eXciteOSA|Participants will receive the eXciteOSA device intervention at high intensity application for 20 minutes per day for 6 consecutive weeks.
88876652|NCT04954690|Placebo Comparator|Usual Care|Patients randomized to usual care will receive recommendations for exercise based on the Surgeon General's recommendations for physical activity among adults as well as the American Heart Association and American College of Sports Medicine recommendations for older individuals or individuals with chronic conditions. These guidelines are applicable to this patient population. Patients will not receive coaching but will receive accelerometers to obtain data for comparison to the intervention groups at each time point (baseline, 8 weeks, and 3 months post-KT).
88876653|NCT04954690|Active Comparator|Weekly Coaching|Weekly coaching per the SPaRKT protocol with titrated increases in physical activity and resistance exercise
88876654|NCT04954690|Active Comparator|Weekly Coaching + Caregiver Participation|Weekly coaching per the SPaRKT protocol with titrated increases in physical activity and resistance exercise with the addition of caregiver participation to promote adherence and engagement
88876655|NCT04947189|Experimental|Seviteronel, dexamethasone and docetaxel|"Part 1: Seviteronel will be administered orally beginning with 450 mg (3 x 150 mg tablets) once daily along with 0.5 mg dexamethasone, continuously in 28-day cycles with docetaxel 75mg/m2 administered intravenously 3 weekly.~Part 2: The recommended phase 2 dose for seviteronel (established in Part 1) once daily along with 0.5 mg dexamethasone, continuously in 21-day cycles with docetaxel 75mg/m2 administered intravenously 3 weekly."
89189608|NCT05592717||traditional therapy group|Patients were treated with glucocorticoids alone or glucocorticoids combined with immunosuppressants and were followed for up to 36 months.
88876656|NCT04916678|No Intervention|Control|The control period is a 5-day period during which no psychologist is available. ER cares will be provided as usual.
88876657|NCT04916678|Experimental|Intervention|The intervention period is a 5-day period during which trained psychologists are available in the ER and will provide a R-TEP EMDR intervention for patients selected with high risk of PCLS and who may provide psychotherapeutic care or reassurance to other patients should they be identified in need of help.
88876658|NCT04912479|No Intervention|control|Patients will be given a plan to reduce progressively their dosage of Benzodiazepin every 2 weeks. Over a 6-month period they will receive a phone call from the hospital twice a month to reinforce their motivation.
88876659|NCT04912479|Experimental|intervention group|In addition to the progressive withdrawal of BZD, patients will be given a connected watch that provide them with information on their sleep quality and their performed activities. They will also receive a check-up phone call twice a month over a 6-month period.
88876660|NCT04883359||Healthy Volunteers|From the Washington, D.C. metropolitan area
88876661|NCT04858620|No Intervention|No treatment|
88876662|NCT04858620|Experimental|Treatment|
89401178|NCT02073630|Other|Dystonia|dystonic patients will receive either sham or active cerebellar stimulation
89401179|NCT02206256|Active Comparator|Low calorie diet|Low calorie diet 2 weeks pre-operatively
89401180|NCT02206256|Active Comparator|Omega-3 fatty acid capsules|2 times a day 1 capsule for 4 weeks before gastric bypass surgery
88876663|NCT04858620|Placebo Comparator|Placebo|Saline nasal spray, 2 puffs per nostrils, every 6 hours
89401181|NCT04749290|Experimental|Study Formula|a Cow's Milk Based Infant Formula Containing Both OPO and CPP for term infants (JunLeBao ZhiZhen)
89401182|NCT04749290|Active Comparator|Comparator Formula|Commercially available infant formula without OPO for term infants (JunLeBao LeChun)
89401183|NCT04749290|No Intervention|Human Milk Reference Group|Human milk
89401184|NCT02691793|Experimental|sunitinib|sunitinib 50 mg will be administered orally daily
89401185|NCT05764603|Experimental|Participants|
89401186|NCT02073786|Active Comparator|Lightwand|Conventional lightwand intubation will performe for intubation
89401187|NCT02073786|Experimental|Optiscope|Rigid video stylet, manufactural named Optiscope, will perform for intubation
89401188|NCT04747886|Active Comparator|WW Only|Participants will receive 3-month access to the WW digital program.
89401189|NCT04747886|Experimental|WW + PolyRules!|Participants will receive 3-month access to the WW digital program and the PolyRules! app.
89401190|NCT02077608||Hyaluronan enriched transfer media|Embryos are incubated at least 10 minutes in hyaluronan enriched embryo transfer media before transfer
89401191|NCT02077608||Control group|Embryos are incubated in embryo transfer media containing low concentration of hyaluronan for at least 10 minutes before transfer
89401192|NCT02221544|Experimental|rTMS treatment followed by Sham|A course of low-frequency repetitive transcranial magnetic stimulation (rTMS) delivered over the supplementary motor area (SMA) followed by rTMS maintenance period (1 month) and followed by sham treatment in order to show the efficacy of treatment
89401193|NCT02221544|Experimental|Sham treatment followed by rTMS|A course of sham followed by followed by sham maintenance period (1 month) and than followed by low-frequency repetitive transcranial magnetic stimulation (rTMS) delivered over the supplementary motor area (SMA) in order to show the effectiveness of rTMS
89401194|NCT02221622|Experimental|Allopregnanolone 2 mg|Drug: Allopregnanolone injection (intravenous solution) once per week for 12 weeks
89401195|NCT02221622|Experimental|Allopregnanolone 4 mg|Drug: Allopregnanolone injection (intravenous solution) once per week for 12 weeks
89401196|NCT02221622|Experimental|Allopregnanolone 6-18 mg|Drug: Allopregnanolone injection (intravenous solution) once per week for 12 weeks
89401197|NCT02221622|Placebo Comparator|Placebo|Drug: Placebo injection (intravenous solution) once per week for 12 weeks
89401198|NCT02077686|Experimental|Education - Diabetes and Travel|"Patients randomized to this arm, will participate immediately in the education module Diabetes and Travel"
89401199|NCT02077686|No Intervention|Waiting-list control group|Patients in the control group will get the education with the education module after completion of the 6-month follow-up
88876664|NCT04854486|Experimental|Treatment Group|Xylitol + GSE
88876665|NCT04854486|Placebo Comparator|Control placebo|Saline
89401200|NCT01380223|Experimental|Dose-escalation Cohort 1|4 treatment periods consisting of a 2 hour placebo infusion (single blind) followed by a 6 hour infusion of study drug or placebo. Each subject will receive 3 active ascending doses of study drug and 1 dose of placebo randomized into the sequence of escalating doses in a double-blind manner. Treatment periods occur at least 7 days apart.
89401201|NCT01380223|Experimental|Dose-escalation Cohort 2|4 treatment periods consisting of a 2 hour placebo infusion (single blind) followed by a 6 hour infusion of study drug or placebo. Each subject will receive 3 active ascending doses of study drug and 1 dose of placebo randomized into the sequence of escalating doses in a double-blind manner. Treatment periods occur at least 7 days apart.
89401202|NCT01380223|Experimental|Dose-escalation Cohort 3|4 treatment periods consisting of a 2 hour placebo infusion (single blind) followed by a 6 hour infusion of study drug or placebo. Each subject will receive 3 active ascending doses of study drug and 1 dose of placebo randomized into the sequence of escalating doses in a double-blind manner. Treatment periods occur at least 7 days apart.
89401203|NCT01380223|Experimental|Dose-escalation Cohort 4|4 treatment periods consisting of a 2 hour placebo infusion (single blind) followed by a 6 hour infusion of study drug or placebo. Each subject will receive 3 active ascending doses of study drug and 1 dose of placebo randomized into the sequence of escalating doses in a double-blind manner. Treatment periods occur at least 7 days apart.
89401204|NCT02074020|Experimental|Blisibimod|
89401205|NCT02074020|Placebo Comparator|Placebo|
89401206|NCT05764525|Experimental|VVZ-149 Injections|
89401207|NCT05764525|Placebo Comparator|Placebo|
89401208|NCT02213276|Experimental|Healthy males|Oral glucose tolerance test (OGTT) and intravenous glucose tolerance test (IVGTT).
89401209|NCT02074098|Experimental|a 65 cm bed height|1) Bed height : approximately 65cm (Lowest)
89401210|NCT02074098|Experimental|a 95cm bed height|2) Bed height : approximately 95cm (highest)
88876668|NCT04810260|Active Comparator|HIV +|Patients will have the application and use it to increase their awareness about their medical condition.
88876669|NCT04810260|Active Comparator|HIV -|Patients will have the application and use it to increase their awareness about their medical condition.
89401211|NCT05764447|Experimental|Combined Qigong Baduanjin and Self-administered Acupressure Intervention|The intervention will last 16 weeks, including twice-weekly supervised group sessions. The first 8 weeks will focus on training of qigong Baduanjin and self-administered acupressure. The duration of each group session will be 90 min. From week 9 onwards, the group sessions will be shortened to 60 min twice a week led by the BQ master. For self-practice prescription, participants will be instructed to practice the combined BQ and acupressure intervention three times a week (30 min each time) on the days without group sessions.
89401212|NCT05764447|Active Comparator|Wait-list Control Group|The control group will be offered a free modality of their choice after the last follow-up. The participants will receive usual care alone during the study period.
89401213|NCT02221856|Experimental|Motion View|
89401214|NCT02221856|Active Comparator|Conventional Orthodontic Treatment|
89401215|NCT01380067||Group A|the patients were subjected laparoscopic purse-string knot for closing the internal hernia opening
89401216|NCT01380067||Group B|the lateral umbilicus ligament was used to cover the internal hernia opening after the laparoscopic purse-string knot
89401217|NCT02080182|Active Comparator|Acetylcysteine|Effervescent tablet of acetylcysteine 600 mg dosing according to weight, until 5 days. Dose for patients more than 30 kg: 1.5 tablet daily 8.5-30 kg: 1 tablet daily less than 8.5 kg: 70 mg/kg
89401218|NCT02080182|Placebo Comparator|Placebo|Placebo effervescent tablet of acetylcysteine 600 mg dosing according to weight, until 5 days. Dose for patients more than 30 kg: 1.5 tablet daily 8.5-30 kg: 1 tablet daily: more than 30 kg: 1.5 tablet daily 8.5-30 kg: 1 tablet daily less than 8.5 kg: 70 mg/kg
89401219|NCT02224898||Definite/Suspected Chronic Pancreatitis|Patients with diagnosis of chronic pancreatitis with at least two of the following features: clinical course consistent with chronic pancreatitis, calcification in the pancreas on US/CT/EUS, ERCP showing ductal abnormalities (Cambridge Classification), exocrine insufficiency, histology showing irregular fibrosis, acinar cell loss, islet cell loss, and inflammatory cell infiltrates, or other features suggestive of chronic pancreatitis (such as pancreatic pseudocyst). The study group will also include patients with suspected chronic pancreatitis based on history of documented pancreatitis with lingering symptoms or signs of early chronic pancreatitis on imaging. Subjects will be asked to complete 30 days of mobile mindfulness therapy, for 2-30 minutes daily.
89401220|NCT02224898||Healthy Control Group|Patients with no history of chronic gastrointestinal symptoms lasting greater than 8 weeks, no gastrointestinal disease or condition diagnosis, and are not currently experiencing gastrointestinal symptoms. Subjects will be asked to complete 30 days of mobile mindfulness therapy, for 2-30 minutes daily.
89401221|NCT02080338|Experimental|0.018 bracket slot system|Participants treated using 0.018-inch orthodontic bracket slot system
89401222|NCT02080338|Active Comparator|0.022 bracket slot system|Participants treated using 0.022-inch orthodontic bracket slot system
89401223|NCT02750930|Experimental|Albiglutide arm|Subjects will receive 50 milligrams (mg) albiglutide liquid drug product once weekly via auto-injector for 26 weeks.
89401224|NCT05462743||group for training the algorithm|This group of images is used for training the algorithm of the artifical intelligence
89401225|NCT05462743||group for testing the algorithm|This group of images is used for testing the algorithm of the artifical intelligence
89401226|NCT02080416|Experimental|Nelfinavir|Nelfinavir twice daily on days 1-14 of a 14-day cycle for 4 cycles
89401227|NCT05462665|Experimental|intervention|Nursing intern students (n:39) will be given theory training about tPA treatment
89189609|NCT05592561|Experimental|Caffeine group|Subjects will receive 200 mg of caffeine powder which was obtained from a 200 mg capsule (Hard Eight Nutrition, LLC, dba, Bulk Supplements, Henderson, Nevada). Researchers will break open the capsule and mix with water and 5/8 tsp of crystal light immediately before subjects ingest the randomly assigned treatment.
89401228|NCT05462665|Experimental|Control|Nursing intern students (n:39) will be given theory training and simulation training about tPA treatment
89401229|NCT02080494|No Intervention|Control|No tranexamic acid given
89401230|NCT02080494|Experimental|Tranexamic Acid|15 mg/kg preoperative IV dose followed by another 15 mg/kg IV dose three hours after the initial dose
89401231|NCT02224976|Experimental|Intensified training|Volunteers will increase exercise training by 30% from baseline
89401232|NCT02080572||Parkinson's Disease with DBS|Individuals with Parkinson's disease and deep brain stimulation will be recruited.
88876670|NCT04805437|Experimental|3D TLSO|A 3-dimensional Boston brace will be designed to the patient's individual type of scoliosis. In-brace radiographs will be performed after prescription. Reinforcement of the assigned intervention will be performed in conjunction with reassessment every 6 months. Patients are encouraged to use the brace for 20 hours per day and to also continue with physical activities for the entirety of the study. Compliance will be monitored with a heat sensor built in the brace that measures wearing time.
88876671|NCT04805437|Active Comparator|Standard TLSO|A standard Boston brace will be designed to the patient's individual type of scoliosis. In brace radiographs will be performed after prescription. Reinforcement of the assigned intervention will be performed in conjunction with reassessment every 6 months. Patients are encouraged to use the brace for 20 hours per day and to also continue with physical activities for the entirety of the study. Compliance will be monitored with a heat sensor built in the brace that measures wearing time.
89189610|NCT05592561|Placebo Comparator|Placebo|flavored water (sweetened with crystal light powder, 0.5 tsp) will be provided to subjects without any caffeine powder added.
89401233|NCT02213744|Experimental|MM-302 + trastuzumab|MM-302 + trastuzumab
89401234|NCT02213744|Active Comparator|Chemotherapy of Physician's Choice plus trastuzumab|Chemotherapy limited to one of the following: Gemcitabine, Capecitabine or Vinorelbine
89401235|NCT02077764||Controls, healthy individuals|controls
89401236|NCT02077764||Heart transplanted patients|Patients
89401237|NCT01378741|Active Comparator|Propofol|Upon arrival to ICU patients will receive a propofol 2-6mg/kg infusion until tracheal extubation
88876672|NCT04790487|Experimental|Chlorpheniramine|Chlorpheniramine (CPM)
88876673|NCT04790487|Placebo Comparator|Control|Saline
88876674|NCT04789239|Experimental|SZC + MRA treated heart failure patients|"Optimal dose of SZC, which is an approved drug for hyperkalemia in Sweden.~The subject is treat with 5 mg daily however it can be reduced to once every second day, or inreased to as much as as 10 mg daily, depending on measured potassium levels. This is combined with a mineralcorticoid receptor antagonist (spironolacton or eplerenon), 25 mg or 50 mg depending on what dose they could tolerate."
89011543|NCT01644994|Experimental|intracavitary cisplatin-fibrin|single dose local intracavitary cisplatin-fibrin application after pleurectomy/decortication
89401238|NCT01378741|Active Comparator|Dexmedetomidine|Upon arrival to ICU patients will receive dexmedetomidine bolus of 0.4mcg/kg followed by an infusion of 0.2-0.7mcg/kg per hour for a maximum period of 24 hours.
89401239|NCT02080650|Other|Prostate cancer|Mesenchymal-marker based ferrofluid (c-MET)
89401240|NCT02080650|Other|Renal cell carcinoma|Mesenchymal-marker based ferrofluid (c-MET)
89401241|NCT02080650|Other|Bladder cancer|Mesenchymal-marker based ferrofluid (c-MET)
89401242|NCT02080650|Other|Gastric cancer|Mesenchymal-marker based ferrofluid (c-MET)
89401243|NCT02080650|Other|Colorectal cancer|Mesenchymal-marker based ferrofluid (c-MET)
89401244|NCT02080650|Other|Pancreatic cancer|Mesenchymal-marker based ferrofluid (c-MET)
89401245|NCT02080650|Other|Non-small cell lung cancer|Mesenchymal-marker based ferrofluid (c-MET)
88876675|NCT04789239|Placebo Comparator|Placebo + MRA treated heart failure patients|The subject is treat with placebo drug, 5 mg once daily, however it can be reduced to once every second day, or increased to as much as as 10 mg daily, depending on measured potassium levels. This is combined with the dose of mineralcorticoid receptor antagonist (spironolacton or eplerenon) 25 mg or 50 mg depending on what dose they could tolerate.
88876676|NCT04786119|Experimental|CORI Robotics|Subjects having robotic assisted knee arthroplasty as decided by their doctor and treated with CORI Robotics.
88876677|NCT04745754|Experimental|Intervention Condition|The trial will test the efficacy of an embedded primary care provider (PCP) model (experimental condition) in which PCPs are trained in survivorship and then embedded within an oncology practice to care for low-risk, early stage breast and colorectal cancer survivors who will be transitioned at 6-36 months post-treatment for comprehensive survivorship care.
88876678|NCT04745754|No Intervention|Control Condition|Usual care for breast and colorectal cancer survivors (oncology-led model).
89401246|NCT02080650|Other|Advanced MET amplified solid tumor|Mesenchymal-marker based ferrofluid (c-MET)
89401247|NCT02077842|Experimental|Nasal CPAP|The experimental group will receive nasal continuous positive airway pressure at 10cmH20 for one hour in the Post Anesthetic Care Unit.
89401248|NCT02077842|Active Comparator|Low Flow Oxygen|The control group will receive standard therapy of low flow oxygen via simple mask at 8 litres per minute.
89401249|NCT02461849|Experimental|Imatinib|Imatinib 400mg qd daily Until disease progression, patient's refusal
89401250|NCT02225054|Placebo Comparator|Ropivacaine,Normal Saline,Saline Bolus|Ropivacaine 15 mL 0.5% Normal Saline mL 0.9% Saline Bolus
89401251|NCT02225054|Experimental|Ropivacaine,Dexmedetomidine,Saline Bolus|Ropivacaine15 mL 0.5% Dexmedetomidine0.5 u/kg Saline Bolus
89401252|NCT02225054|Active Comparator|Ropivacaine,Saline,Dexmedetomidine|Ropivacaine 15 mL 0.5% Normal Saline 1 mL 0.9% Dexmedetomidine single IV bolus 0.5 u/kg over 30 minutes
89401253|NCT02080728|Experimental|TAP-Bloc|
89401254|NCT02080728|Placebo Comparator|Control|
89401255|NCT05136794||Opioid free anaesthesia|patient anesthtesized with lidocaine
89401256|NCT05136794||Opioid anaesthesia|patients anesthetized with sufentanil
89401257|NCT05095298|No Intervention|Control Group|Participants volunteered not to receive the third dose of vaccine, and agreed to be followed-up for 1 year
89401258|NCT05095298|Experimental|Inactivated Vaccine Group|Participants volunteered to receive the third dose of inactivated vaccine
89401259|NCT05095298|Experimental|Recombinant subunit protein vaccine|Participants volunteered to receive the third dose of subunit protein vaccine
89401260|NCT05095298|Experimental|mRNA vaccine Group|Participants volunteered to receive the third dose of mRNA vaccine ( To be enrolled, the vaccine has not been approved in China)
89401261|NCT02222012|Active Comparator|single channel|
89189611|NCT05592561|Experimental|Theanine group|200mg pure theanine powder (Hard Eight Nutrition, LLC, dba, Bulk Supplements, Henderson, Nevada) + 8 oz water+ 0.55 tsp crystal light will be ingested.
89401262|NCT02222012|Experimental|"Two channels Multiway stimulator coil® (Brainsway Ltd.)"|
89401263|NCT02214758|Other|Dietary counseling|
89401264|NCT02214758|Other|Oral health counseling|
89401265|NCT02214758|No Intervention|nutrition no counseling|
89401266|NCT02214758|No Intervention|oral health no counseling|
89401267|NCT02222090||patients who have been prescribed warfarin|
89401268|NCT02222090||patients who have been prescribed apixaba|
89401269|NCT03078907|Experimental|Selexipag|Selexipag is up-titrated from Day 1 to Week 12 to the individualized highest tolerated dose (HTD), which can range from 200 mcg b.i.d. to 1600 mcg b.i.d., in 200 mcg steps starting with 200 mcg b.i.d. Then, the dose is increased in increments of 200 mcg b.i.d., usually at weekly intervals, depending on the dose tolerability. Up-titration is followed by a stable maintenance treatment period at the highest tolerated dose, from Week 13 to Week 24.
89401270|NCT03078907|Placebo Comparator|Placebo|Regimen and titration scheme similar to those in the selexipag group
89401271|NCT02225210|Experimental|Group dexmedetomidine ,dexmedetomidine|Continuous pump infusion dexmedetomidine with loading dose of 0.4μg.kg-1 for 10 minutes ,then followed by maintenance dose of 0.2~0.7µg.kg-1 to maintain Sedation-Agitation Scale between 3 and 4.
89401272|NCT02225210|Active Comparator|Group midazolam,midazolam,fentanyl|Quickly inject midazolam and fentanyl with loading dose of 0.1mg.kg-1 and 1 μg.kg-1 separately until attaining Sedation-Agitation Scale between 3 and 4,then followed by maintenance dose of 0.05~0.1mg.kg-1.h-1 and fentanyl 0.5~1μg.kg-1.h-1 separately.
89401273|NCT02216942|Active Comparator|Vitapex|Endodontic treatment using Vitapex
89401274|NCT02216942|Experimental|Guedes Pinto Paste|Endodontic treatment using Guedes Pinto
89401275|NCT02225288|Experimental|Group A|Period 1: Apply one E2022 tape to the designated site (back or upper arm) for 24 hours (applying in the morning and removing next morning) Period 2: Apply one E2022 tape to the designated site (back or upper arm, but different from Period 1) for 24 hours (applying in the morning and removing next morning) Period 3: Apply one E2022 tape to back (contralateral to Period 1 and 2). After the specified intervals (Group A: 48 hours), apply a new E2022 tape to the same site (for 24 hours after the first and second applications [applying in the morning and removing next morning])
89401276|NCT02225288|Experimental|Group B|Period 1: Apply one E2022 tape to the designated site (back or upper arm) for 24 hours (applying in the morning and removing next morning) Period 2: Apply one E2022 tape to the designated site (back or upper arm, but different from Period 1) for 24 hours (applying in the morning and removing next morning) Period 3: Apply one E2022 tape to back (contralateral to Period 1 and 2). After the specified intervals (Group B: 72 hours), apply a new E2022 tape to the same site (for 24 hours after the first and second applications [applying in the morning and removing next morning])
89401277|NCT02225288|Experimental|Group C|Period 1: Apply one E2022 tape to the designated site (back or chest) for 24 hours (applying in the morning and removing next morning) Period 2: Apply one E2022 tape to the designated site (back or chest, but different from Period 1) for 24 hours (applying in the morning and removing next morning) Period 3: Apply one E2022 tape to back (contralateral to Period 1 and 2). After the specified intervals (Group C: 96 hours), apply a new E2022 tape to the same site (for 24 hours after the first and second applications [applying in the morning and removing next morning])
89401278|NCT02225288|Experimental|Group D|Period 1: Apply one E2022 tape to the designated site (back or chest) for 24 hours (applying in the morning and removing next morning) Period 2: Apply one E2022 tape to the designated site (back or chest, but different from Period 1) for 24 hours (applying in the morning and removing next morning) Period 3: Apply one E2022 tape to back (contralateral to Period 1 and 2). After the specified intervals (Group D: 120 hours), apply a new E2022 tape to the same site (for 24 hours after the first and second applications [applying in the morning and removing next morning])
89401279|NCT05462275|Experimental|Test group|There is only one group to evaluate this observational study.
89401280|NCT02225444||OsteoAMP treatment group|The OsteoAMP treatment group contains patients randomized to receive their own bone (retrieved from the surgical site) augmented with the OsteoAMP growth factor to assist with posterolateral arthrodesis at 1 or 2 adjacent levels between L1-S1.
89401281|NCT05462197|Experimental|Qigong Wuqinxi group|The Wuqinxi version adopted by this research is the Health Qigong Wuqinxi newly compiled in mainland China in 2003. There are only 10 movements in total. It is practiced three times a week for 3 months, including group practice once a week, 50 minutes each time, and the other two times of independent practice, the same 50 minutes each time, and the practice form must be filled out.
89401282|NCT05462197|No Intervention|control group|The control group was carried out according to the original daily activities without any intervention activities
89401283|NCT02217020|Experimental|FOLFOXIRI|patients received FOLFOXIRI alone for 4 cycles before surgery.
89401284|NCT03249714|Experimental|OMB 20 mg|Ofatumumab 20 mg subcutaneous injection on Days 1,7, 14 and every 4 weeks for 24 weeks in Core. Core placebo patients received loading dose at Weeks 25 and 26 and then all Extension patients received dose every 4 Weeks up to Week 48.
89401285|NCT03249714|Placebo Comparator|Placebo|Placebo subcutaneous injection matching to ofatumumab every 4 weeks for 24 weeks in Core
89401286|NCT02217098|Active Comparator|GIC Restorations|Restorations using Glass Ionomer Cement
89401287|NCT02217098|Experimental|Compomer Restorations|Restorations using Compomer
89401288|NCT02217098|Experimental|Carbomer Restorations|Restorations using Glass Carbomer
89401289|NCT02218502|Other|If simple rules are conclusive|All patients included will undergo an ultrasound scan in which both the RMI and simple ultrasound-based rules are applied. This scan will take place in the hospital of inclusion. For 80% of all patients, this will be the only intervention.
89401290|NCT02218502|Other|If simple rules are inconclusive|If the simple ultrasound-based rules, used in the first ultrasound scan, yield an inconclusive result (approx. 20% of all patients), patients are refered to the center hospital to undergo a second ultrasound (by an expert) and a DW-MRI scan. Furthermore, these group of patients will be asked to give an extra blood sample in order to perform translational research and validate new biomarkers in the diagnosis of ovarian cancer.
89401291|NCT05461651|Sham Comparator|Knee arthroplasty|Knee arthroplasty without addition of antibiotic wash oraz antibitiotic powder to the surgery site
89401292|NCT05461651|Active Comparator|Knee arthroplasty + vancomycin|Knee arthroplasty with addition of vancomysin powder to the surgery site
88876679|NCT04720053|Experimental|Wearable brain sensing wellness device headband system|Subject diagnosed with fibromyalgia at Mayo Clinic GIM Fibromyalgia Clinic will receive a wearable brain sensing wellness device headband system, and will be given a demonstration of the mindfulness sessions, with detailed instructions on how to begin each session.
88876680|NCT04706793|Experimental|Etrasimod 2 mg|
88876681|NCT04706793|Placebo Comparator|Placebo|
88876682|NCT04694131|Other|MS|All participants will receive all conditions and the order of all conditions will be counterbalanced across participants. Statistical comparisons will be within-subjects. There will be two experiment days, during which TMS will be delivered during the behavioral tasks (spatial task trials and encoding phase of the memory task). Participants will receive TMS delivered to parietal cortex on one day and vertex stimulation on the other day. Each experiment day will include one block of TMS delivered prior to task trial onsets and one block delivered simultaneously with trial onsets.
89401293|NCT02080806|Active Comparator|Mechanical insufflation exsufflation|Application of cough assist machine as part of the regular physiotherapy
89401294|NCT02225522|No Intervention|Standard Care|Patients in this arm receive standard genetic evaluation without the addition of next generation sequencing for the diagnosis of their presumed genetic condition
89401295|NCT02225522|Experimental|Rapid whole genome sequencing (StatSeq)|Patients in this arm will receive standard of care genetic evaluation and next generation sequencing of their genome to achieve rapid diagnosis of genetic conditions.
89401296|NCT04749589||iron deficient|ferritin<30 or Transferine saturation<.2
89011544|NCT01645033|Experimental|TAU plus computerized CBT|Standard treatment (TAU) plus a short session using a computer program containing computerized CBT to understand risks related to sexual and other behaviors and how those risks relate to spread of infections.
89189612|NCT05592561|Experimental|Tyrosine group|2000 mg pure tyrosine powder (Hard Eight Nutrition, LLC, dba, Bulk Supplements, Henderson, Nevada) +8 oz water + 0.5 tsp crystal light will be ingested.
89189613|NCT05592548|Experimental|Study|Single arm study: split face treatment
89401297|NCT04749589||iron replete|opposite of the other group
89401298|NCT02080884||CLL patients on Mabthera (rituximab)|
89401299|NCT04748731|Experimental|Experimental Group. Video-feedback intervention.|A weekly online brief intervention using video-feedback and psycho-educational materials on early parenting (detailed description of the intervention on section 5).
89401300|NCT04748731|Other|Control Group. Psycho-educational intervention|They will receive weekly information on parenting in the 1st year of life. They will have direct contact (via WhatsApp) with a child psychologist to ask questions about the material and to refer to specialized support if needed.
89401301|NCT05236478||CoviMouv' program|Patients who have benefited from the CoviMouv' program (supervised physical activity program + therapeutic education program) will be included.
89401302|NCT05236478||control group|Patients with autonomous physical activity at home or with a community-based physiotherapist will be included. They will have support for the resumption of an adapted physical activity in autonomy, according to the results of the aerobic and anaerobic tests carried out during the initial evaluation (delivery of a training booklet).
89401303|NCT01378663||Post congenital cardiac surgery pain management|All patients that underwent congenital cardiac surgery from 2004 till 2010 and required PCA or NCA.
89401304|NCT02925117|Placebo Comparator|Placebo|Participants randomized to receive placebo once daily (QD) for 16 weeks in Period 1. At Week 16 participants were re-randomized to receive 30 mg upadacitinib or placebo once a day for 72 weeks in Period 2.
89401305|NCT02925117|Experimental|Upadacitinib 7.5 mg|Participants randomized to receive upadacitinib 7.5 mg QD for 16 weeks in Period 1. At Week 16 participants were re-randomized to receive 7.5 mg upadacitinib or placebo QD for 72 weeks in Period 2.
89401306|NCT02925117|Experimental|Upadacitinib 15 mg|Participants randomized to receive upadacitinib 15 mg QD for 16 weeks in Period 1. At Week 16 participants were re-randomized to receive 15 mg upadacitinib or placebo QD for 72 weeks in Period 2.
89401307|NCT02925117|Experimental|Upadacitinib 30 mg|Participants randomized to receive upadacitinib 30 mg QD for 16 weeks in Period 1. At Week 16 participants were re-randomized to receive 30 mg upadacitinib or placebo QD for 72 weeks in Period 2.
89401308|NCT04634149|Experimental|Group A: Moderate Hepatic Impairment|
89401309|NCT04634149|Experimental|Group B: Severe Hepatic Impairment|
89401310|NCT04634149|Experimental|Group C: Normal Hepatic Function|
89401311|NCT05056298|Experimental|Insole and Exercise group|will contain 17 patients, they will receive the custom made arch support insole in addition to the strengthening of foot muscles both intrinsic and extrinsic muscles.
89401312|NCT05056298|Active Comparator|Exercise group|will contain 17 patients, they will receive the standard insole in addition to the strengthening of foot muscles both intrinsic and extrinsic muscles.
88876683|NCT04677049|Experimental|Niacin|"Niacin controlled release technology (CRT):~Niacin CRT™ is to be started 7 days before concurrent Radiation Therapy (RT)- Temozolomide (TMZ) treatment.~Chemo/Radiation Therapy:~For all patients, regardless of the phase of the study, concurrent RT and TMZ for 6 weeks followed by 6-12 cycles of monthly TMZ will be given.~Concurrent Temozolomide:~TMZ will be administered from the first to the last day of RT at 75 mg/m2 orally (PO) for a maximum of 49 days.~Monthly Temozolomide:~Cycles of chemotherapy Day 1 to Day 5 every 28 days will start 28 days (+/- 2 days) after the end of RT-TMZ. First cycle of TMZ is administered at 150 mg/m2 Day 1-Day 5 by mouth (PO) and increased to 200 mg/m2 Day 1-Day 5 PO from cycle 2 onwards if well tolerated. While 6 cycles are standard of care, the Neuro-Oncologist may continue up to 12 cycles if clinically appropriate."
88876684|NCT04650100|Experimental|PENG group|For the PENG group, the ultrasound-guided PENG block (20 ml of Ropivacaine 4.75 mg/ml) is performed before the surgery.
88876685|NCT04650100|No Intervention|Control group|No additional intervention, only standard care
88876686|NCT04610801|No Intervention|No treatment|No treatment given
88876687|NCT04610801|Experimental|Treatment|Xylitol plus Grapefruit Seed Extract (Xlear) nasal spray, 2 puffs per nosetrils, every 6 hours
88876688|NCT04610801|Placebo Comparator|Placebo|Saline nasal spray, 2 puffs per nosetrils, every 6 hours
88876689|NCT04607148|Experimental|Galegenimab 20 mg Q4W|Participants will receive 20 milligrams (mg) galegenimab via ITV injection every 4 weeks (Q4W).
88876690|NCT04607148|Experimental|Galegenimab 20 mg Q8W|Participants will receive 20 mg galegenimab via ITV injection every 8 weeks (Q8W).
88876691|NCT04607148|Experimental|Galegenimab 10 mg Q4W|Participants will receive 10 mg galegenimab via ITV injection Q4W.
88876692|NCT04607148|Experimental|Galegenimab 10 mg Q8W|Participants will receive 10 mg galegenimab via ITV injection Q8W.
89401313|NCT02074332|Experimental|Intervention|Physical activity guidance Health education
89401314|NCT02074332|No Intervention|Control|Receive no intervention
89401315|NCT04102735|Active Comparator|Over-the-nose facemask|The AF541 oro-nasal mask is used with the over-the-nose mask cushion.
89401316|NCT04102735|Experimental|Under-the-nose facemask|The AF541 oro-nasal mask is used with the under-the-nose mask cushion.
89401317|NCT02080962|Experimental|30 Gy in 5 fractions of 6 Gy|tumors ≤ 2 cm in diameter: 5 fractions of 600 cGy, once a day, five times a week - TDF: 89
89401318|NCT02080962|Experimental|40 Gy in 10 fractions of 4 Gy|tumors > 2-5 cm in diameter: 10 fractions of 400 cGy, once a day, five times a week - TDF: 96
88876693|NCT04603326||Non-manifesting LRRK2 mutation carriers|Patients must have confirmed LRRK2 G2019S mutation Age 30 years or older at date of informed consent.
88876694|NCT04603326||LRRK2 Parkinson Disease (PD) Participants:|Patients must have confirmed LRRK2 G2019S mutation Patients must meet the MDS criteria for Parkinson's disease Disease duration: any Age 30 years or older at time of PD diagnosis.
88876695|NCT04603326||Idiopathic PD (iPD) Particpants:|Patients must meet the MDS criteria for Parkinson's disease. Disease duration: any Age 30 years or older at time of PD diagnosis.
88876696|NCT04603326||Control (C) Participants:|Age 30 years or older at date of informed consent.
88876697|NCT04591483||Affected|Patients with Stargardt-like macular dystrophy 3 who are >= 10 years of age.
89401319|NCT01379911|Active Comparator|Yogurt with added inulin|Yogurt with 6g of added inulin
89401320|NCT01379911|Placebo Comparator|Regular yogurt|Regular yogurt without added inulin
89401321|NCT05235152|Active Comparator|Usual individual physiotherapy care|Participants with either low back pain, rotator cuff related pain, patellofemoral pain syndrome or lateral ankle sprain will received usual/individual physiotherapy care over a period of 12-weeks for the treatment of their musculoskeletal conditions if randomized in this group.
89004114|NCT02946255|Experimental|Welcome Basket (WB)|"Peer Support Workers (PSWs) hold 1-2 meetings with clients (30-60 minutes) in the 2-week period before they are discharged from hospital. They describe the program and undertake an assessment. From this assessment the two core components of the intervention are initiated. First, a welcome basket is created for the client. The PSW also forms a plan with the client about tours of their neighbourhood to familiarize them with the local resources and support them in building confidence in accessing their local communities. These activities will take place through weekly visits (2 hours/visit) in the 4 weeks immediately following discharge. WB will be provided in combination with core Cognitive Adaptation Training (CAT) compensatory interventions."
89004115|NCT02946255|Active Comparator|Treatment As Usual|Treatment as usual (TAU) involves the typical discharge procedures for clients from Unit 2, Forensic and EPU wards at CAMH. It includes referral to outpatient psychiatric services and relevant community supports with the transition facilitated by inpatient social work staff.
89004116|NCT02944071|Experimental|(Ranger & Ranger LE) and Ranger DCB|"The working length is 80cm and 135cm for Ranger DCB catheter and 90 cm and 150cm for Ranger SL and Ranger LE DCB catheter.~Multiple interventions:~Prior to or during Index Procedure:~Prior to treatment of the index limb, successful (< 30% residual stenosis) treatment of ipsilateral iliac inflow lesions may be performed~Prior to treatment of the index limb, successful treatment of the arteries of the non-index limb may be performed~Prior to treatment of the index limb, absence of clinical complications such as embolism, thrombosis, severe dissection, vessel rupture must be confirmed."
89004117|NCT02899793|Experimental|Pembrolizumab|Pembrolizumab 200 mg, Q3W, IV Infusion, Day 1 of each 3 week cycle
89004118|NCT02835313|Experimental|FAST+SAM|Subjects participate in fast walking training in combination with a step activity monitoring program
89004119|NCT02835313|Active Comparator|FAST|Subjects participate in fast walking training
89004120|NCT02835313|Active Comparator|SAM|Subjects participate in a step activity monitoring program
89004121|NCT02677896|Experimental|Enzalutamide + Androgen Deprivation Therapy (ADT)|Participants received 160 mg enzalutamide orally once daily during double-blind treatment period until radiographic progression was documented or until the participants started an investigational agent or new therapy for treatment of prostate cancer or until any other discontinuation criterion was met. Eligible participants who received enzalutamide during double-blind treatment period and provided informed consent to take part in open-label period continued to receive 160 mg enzalutamide orally once daily in open-label period until disease progression, unacceptable toxicity or any other discontinuation criteria were met. ADT (either bilateral orchiectomy or Luteinizing hormone-releasing hormone (LHRH) agonist/antagonist) was maintained during study treatment as per standard of care and provided by the site's pharmacy stock.
89004122|NCT02677896|Placebo Comparator|Placebo + Androgen Deprivation Therapy (ADT)|Participants received matching placebo orally once daily during double-blind treatment period until radiographic progression was documented or until the participants started an investigational agent or new therapy for treatment of prostate cancer or until any other discontinuation criterion was met. ADT (either bilateral orchiectomy or LHRH agonist/antagonist) was maintained during study treatment as per standard of care and provided by the site's pharmacy stock.
89004123|NCT02677896|Experimental|Placebo followed by Enzalutamide|Eligible participants who received enzalutamide matching placebo during double-blind treatment period and provided informed consent to take part in open-label period switched to receive 160 mg enzalutamide orally once daily in open-label period until disease progression, unacceptable toxicity or any other discontinuation criteria were met. ADT (either bilateral orchiectomy or LHRH agonist/antagonist) was maintained during study treatment as per standard of care and provided by the site's pharmacy stock.
89004124|NCT02675231|Experimental|150 mg Abemaciclib + 8 mg/kg Trastuzumab + 500 mg Fulvestrant|150 milligram (mg) abemaciclib given orally every 12 hours (Q12H) of a 21-day cycle; plus 8 milligram per kilogram (mg/kg) trastuzumab intravenous (IV) infusion on Day 1 of the cycle then a 6 mg/kg maintenance dose IV infusion on Day 1 of each subsequent cycle; plus 500 mg fulvestrant intramuscularly (IM) on day 1, 15 and 29 and then once every 4 weeks thereafter.
89004125|NCT02675231|Experimental|150 mg Abemaciclib + 8 mg/kg Trastuzumab|150 mg abemaciclib given orally Q12H of a 21-day cycle; plus 8 mg/kg trastuzumab IV infusion on Day 1 of the cycle then a 6 mg/kg maintenance dose IV infusion on Day 1 of each subsequent cycle.
89004126|NCT02675231|Active Comparator|8 mg/kg Trastuzumab + Standard of Care Chemotherapy|8 mg/kg trastuzumab IV infusion on Day 1 of a 21-day cycle then a 6 mg/kg maintenance dose IV infusion on Day 1 of each subsequent cycle plus standard of care single agent chemotherapy of physician's choice administered according to product label
89004127|NCT02648477|Experimental|Cohort 1 (pembrolizumab, doxorubicin hydrochloride)|"Patients receive pembrolizumab IV over 30 minutes on day 1 and doxorubicin hydrochloride IV on day 1. Treatment repeats every 3 weeks for 6 courses, and then continues for up to 24 months with pembrolizumab alone in the absence of disease progression or unacceptable toxicity.~Patients who stop pembrolizumab with stable disease or better may receive additional pembrolizumab therapy for up to 1 year if they progress after stopping study treatment."
89189614|NCT05580159|Experimental|SW-BIC-213|Intervention Name :COVID-19 mRNA vaccine Type :Investigational Vaccine Dose :Formulation mRNA Unit Dose Strength(s) :0.5ml; Dosage Level(s) :0.25ml; Route of Administration: injection Intramuscular
89401322|NCT05235152|Experimental|Group-supervised physiotherapy training programs|Participants with either low back pain, rotator cuff related pain, patellofemoral pain syndrome or lateral ankle sprain will received group-supervised physiotherapy training programs over a period of 12-weeks for the treatment of their musculoskeletal condition if randomized in this group.
89401323|NCT02077920|Experimental|Chlorhexidine before intubation|Group A: Oropharyngeal decontamination with chlorhexidine before intubation, n=48. Oral cleansing with chlorhexidine will be performed before endotracheal intubation, and every 6 hours after intubation.
89401324|NCT02077920|Experimental|Chlorhexidine after intubation|Group B: Oropharyngeal decontamination with chlorhexidine after intubation, n=48. Oral cleansing with chlorhexidine will be performed every 6 hours after endotracheal intubation.
89401325|NCT02077920|Experimental|Subglottic secretion drainage|"Group C: Suctioning of subglottic secretions, n=48. Oral cleansing with chlorhexidine will be performed before endotracheal intubation and every 6 hours after intubation, and fiberoptic bronchoscopy-guided suctioning of subglottic secretions will be performed at 10:00 a.m. every day. The procedure will be as follows:~Routine cleaning of the bronchoscope.~Oral or nasal insertion of the bronchoscope (according to the decision of the attending physician based on the patient's condition). Rinsing of the subglottic region with 5-20 mL of chlorhexidine solution followed by suctioning. The rinsing procedure will be repeated 3-5 times.~Routine cleaning of the bronchoscope. The patient will be monitored during all procedures."
89401326|NCT02077920|Experimental|0.9% sodium chloride injection|Group D: 0.9% sodium chloride injection, n=48. After endotracheal intubation, oral cleansing with normal saline will be performed every 6 hours.
89401327|NCT03630133|Experimental|Intracept System Ablation|Single Arm
89401328|NCT05232890|Experimental|Datterino tomato purée from hydroponic technology|100% Italian datterino tomato purée deriving from hydroponic technology (soilless) with particular characteristics such as nickel free and zero residue.
89401329|NCT05232890|Active Comparator|Datterino tomato purée from conventional cultivation|100% Italian datterino tomato purée deriving from conventional cultivation.
89401330|NCT02081040||Infratentorial dysphagia patients|Infratentorial brain lesion patients with confirmed evidence of dysphagia
89401331|NCT02081040||Supratentorial dysphagia patients|Supratentorial brain lesions\ patients with confirmed evidence of dysphagia
89401332|NCT02081040||Brain lesion patients without dysphagia|Brain lesion patients with no evidence of dysphagia
89401333|NCT03630523|Other|Vaccination|Arm contains all subjects; vaccination with Influvac Tetra will be administered at start of study, response will be measured in 7 and 21 days.
89189615|NCT05580159|Active Comparator|SARS-Cov-2 Vaccina(Vero Cell ) Inactivated|Intervention Name: COVID-19 Inactivated Vaccine Type : Control Vaccine Dose :Inactive Unit Dose Strength(s) : 0.5ml; Route of Administration Intramuscular : injection Intramuscular
89401334|NCT02225756|Experimental|Cyclosporine A dose 1|
89401335|NCT02225756|Experimental|Cyclosporine A dose 2|
89401336|NCT02225756|Placebo Comparator|Placebo|
89401337|NCT02074488|Experimental|Fall Prevention Exercises|Participant provided with Balancing Act exercise curriculum for completion at least fifteen minutes three times a week over a six month period.
89401338|NCT02074488|Other|Informational brochure|Participant receives an informational brochure and orientation to brochure contents.
89401339|NCT02220062|Active Comparator|EUS-CPN group|Group that be performed by Endoscopic ultrasound guided bilateral celiac plexus neurolysis
88876698|NCT04560712|Experimental|Arm I (acupuncture, usual care)|Beginning the day after surgery, patients undergo acupuncture sessions over 25 minutes QD for up to 7 days. Patients also undergo usual care including preoperative visits to the primary surgical team, anesthesia preoperative evaluation, referrals to other specialties for perioperative evaluation and optimization of comorbid conditions if necessary, surgical operations, postoperative hospitalization, and post-discharge clinic visits.
88876699|NCT04560712|Active Comparator|Arm II (usual care)|Patients undergo usual care including preoperative visits to the primary surgical team, anesthesia preoperative evaluation, referrals to other specialties for perioperative evaluation and optimization of comorbid conditions if necessary, surgical operations, postoperative hospitalization, and post-discharge clinic visits.
88876700|NCT04551170|Experimental|Theophylline|Theophylline capsules by mouth once daily or Theophylline elixir by mouth q6h (dose determined by serum drug levels)
89189616|NCT05579938|Active Comparator|Verum Lozenges|Active enzyme-containing lozenges to be consumed 5 times per day for 4 days
89189617|NCT05579938|Placebo Comparator|Identical Placebo Lozenges|Placebo lozenges to be consumed 5 times per day for 4 days
89401340|NCT02220062|Experimental|EUS-CGN group|Group that be performed by Endoscopic ultrasound guided celiac ganglia neurolysis
89401341|NCT02074566|Other|2 times 1|PVI will be performed using a cryoballoon ablation application time of 2 times 1 minute
89401342|NCT02074566|Other|2 times 2|PVI will be performed using a cryoballoon ablation application time of 2 times 2 minutes
88876701|NCT04551170|Placebo Comparator|Placebo|Placebo capsule by mouth once daily or Placebo elixir by mouth q6h
88876702|NCT04542057|Experimental|Arm 1|Ensifentrine Nebulized Suspension; 3 mg twice daily for 24 weeks
88876703|NCT04542057|Placebo Comparator|Arm 2|Ensifentrine Placebo Nebulized Solution; twice daily for 24 weeks
88876704|NCT04526613||'healthy' LTBI+ controls who are negative for all of the conditions|'healthy' LTBI+ controls who are negative for all of the listed conditions
88876705|NCT04526613||healthy LTBI negative controls with none of the above conditio|healthy LTBI negative controls with none of the above conditions
88876706|NCT04526613||LTBI+ and helminth infection (positive stool qPCR and/or serol|LTBI+ and helminth infection (positive stool qPCR and/or serology)
88876707|NCT04526613||LTBI+ and severe to moderate malnutrition (BMI <17 kg/m2)|LTBI+ and severe to moderate malnutrition (BMI <17 kg/m2)
88876708|NCT04526613||LTBI+ and uncontrolled DM (HbA1c >8%)|LTBI+ and uncontrolled DM (HbA1c >8%)
89401343|NCT02074566|Other|2 times 3|PVI will be performed using a cryoballoon ablation application time of 2 times 3 minutes
89401344|NCT01379833||Subjects|Subjects are patients with CIDP
89401345|NCT01379833||Controls|Controls are age-matched people without CIDP
89401346|NCT02225834|Experimental|early Atorvastatin treatment|Ischemic stroke patients treated with with atorvastatin 80 mg at admission until discharge
89401347|NCT02225834|No Intervention|no early treatment with atorvastatin|Ischemic stroke patients not treated with with atorvastatin 80 mg until discharge
89401348|NCT02077998|Experimental|Diagnostic (carbon C 14 oxaliplatin and oxaliplatin)|"PHASE 0: Patients receive carbon C 14 oxaliplatin IV over 2 minutes on day 1.~PHASE II: Patients receive oxaliplatin IV over 2 hours on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity."
89401349|NCT05461183||Readmission/ SMM post-delivery discharge|All women aged 15-49 who were readmitted up to six weeks post-delivery discharge and/or experienced at least one SMM event up to six weeks post-delivery
89401350|NCT05461183||De novo readmission/ SMM post-delivery discharge|All women aged 15-49 who were readmitted up to six weeks post-delivery discharge and/or experienced at least one SMM event post-delivery, excluding those who experienced a SMM in the two months before delivery or during delivery hospitalization
89401351|NCT05461183||No post-delivery discharge readmission/ SMM at any time (CONTROL)|All women aged 15-49 who did not experience post-delivery discharge readmission and/or SMM at any time
88876709|NCT04526613||LTBI+ with more than one of the conditions defined in groups 1|LTBI+ with more than one of the conditions defined in groups 1-3
89401352|NCT02225912|Experimental|PrevinC|PrevinC contains isopropyl alcohol, sesame oil, aloe vera oil extract, and lemon oil.
89401353|NCT02225912|Placebo Comparator|Control solution|The control solution (distilled water and lemon oil) was similar in color, oily consistency and odor to that of PrevinC.
89401354|NCT02074644|Experimental|Prostatic Arterial Embolization|Selective catheterization of the prostatic arteries followed by slow injection of Bead Block 300-500 or PVA 100+200 micra particles under fluoroscopic control.
89401355|NCT02074644|Sham Comparator|Sham procedure|Selective catheterization of the prostatic arteries followed by removal of the catheter with no particles injected.
89401356|NCT02222324|Placebo Comparator|Treatment A|Placebo
89401357|NCT02222324|Experimental|Treatment B|E2609 Low dose
89401358|NCT02222324|Experimental|Treatment C|E2609 High dose
88876710|NCT04522570|Active Comparator|laser ablation|Percutaneous Laser Ablation for the treatment of metastatic cervical lymph nodes with > 0.8 cm diameter with biopsy-proven diagnosis of differentiated thyroid carcinoma or medullary thyroid carcinoma.
88876711|NCT04522570|Active Comparator|cryoablation|Percutaneous cryoablation for the treatment of metastatic cervical lymph nodes with > 0.8 cm diameter with biopsy-proven diagnosis of differentiated thyroid carcinoma or medullary thyroid carcinoma.
88876712|NCT04522570|Active Comparator|Radiofrequency ablation|Percutaneous radio frequency ablation for the treatment of metastatic cervical lymph nodes with > 0.8 cm diameter with biopsy-proven diagnosis of differentiated thyroid carcinoma or medullary thyroid carcinoma.
89401359|NCT02222324|Active Comparator|Treatment D|Moxifloxacin
88876713|NCT04520503||Pre EEG group|This cohort includes all participants in this study. EEG sensor will be attached to the patient's forehead before induction of anesthesia. Patterns of EEG and data will be obtained
88876714|NCT04518748|Experimental|Y-90 SIRT followed by SBRT|Y-90 SIRT followed by SBRT
88876715|NCT04514757|Experimental|Intervention Group|Active tVNS (Parasym device, Parasym Health, Inc, London, UK) will be performed with a clip attached to ear at 20 Hz, 250ms at a current just below discomfort threshold for one hour twice a day, starting on post-day 0. Stimulation will continue until 5 days post-operatively or discharge.
88876716|NCT04514757|Sham Comparator|Control Group|Sham tVNS will be performed by attaching the Parasym device to the ear and setting output to 0. Stimulation will continue until 5 days post-operatively or discharge.
88876717|NCT04505267|Experimental|Treatment (NBTXR3, RT)|Patients receive NBTXR3 IT or intranodally on day 1. Within 15 days, patients undergo RT 5 times weekly (Monday-Friday) over 3 weeks for a total of 10-15 fractions.
89401360|NCT02074722||Healthy Subjects|Healthy Subjects
89401361|NCT02220140|No Intervention|Control|Service as usual
89401362|NCT02220140|Experimental|Intervention group|Participants are offered access to the web based resilience program and are invited to join a short introduction course.
89401363|NCT02074800|Experimental|Part 1|Participants will receive either 1.4 or 2.8 mg/kg of either Sp2/0-derived CNTO 328 or CHO-derived CNTO 328 or placebo.
89401364|NCT02074800|Experimental|Part 2|Participants will receive 1.4 mg/kg of either Sp2/0-derived or CHO-derived CNTO 328.
89401365|NCT04504045|Experimental|Metformin|Patients will receive metformin 1000-2000 mg daily for 12 weeks.
89401366|NCT02225990|Active Comparator|Standard of Care, Sub-Acute|This group will receive standard of care stroke rehabilitation therapy.
89401367|NCT02225990|Active Comparator|Standard of Care, Chronic|This group will receive standard of care stroke rehabilitation therapy.
89401368|NCT02225990|Experimental|Experimental Group, Sub-Acute|This group consists of sub-acute stroke patients who are between three weeks and six months post-stroke and will receive the QualPro protocol. If the participant is an inpatient at Shands Rehabilitation Hospital at the beginning of the study, his/her first three weeks of research therapy sessions will take place at the Shands Rehabilitation Hospital. After being discharged, the remainder of the study sessions will take place at either UF Health Rehab Center- Magnolia Parke or in the North Tower (6th floor) physical therapy department of Shands Hospital.
89401369|NCT02225990|Experimental|Experimental Group, Chronic|This group consists of chronic stroke patients who are greater than six months post-stroke and will receive the QualPro protocol. The study sessions will take place at either UF Health Rehab Center-Magnolia Parke or in the North Tower (6th floor) physical therapy department of Shands Hospital.
89401370|NCT03283488|Experimental|Mirtazapine|Tablets of 15mg mirtazapine will be used according to randomization. At the first visit, patients will be instructed to take one tablet at night for better tolerability. From the second week, if there is good tolerance, they will take two tablets at night until the end of the study.
89401371|NCT03283488|Active Comparator|Megestrol|Tablets of 160mg megestrol will be used according to randomization. At the first visit, patients will be instructed to take one tablet at night for better tolerability. From the second week, if there is good tolerance, they will take two tablets at night until the end of the study.
89401372|NCT02258204|Placebo Comparator|tPA-placebo|"tPA infusion : 0.9 mg/kg (90 mg maximum), 10% of the total dose is administered as an initial IV bolus dose over 1 minute and the remainder of the dose is infused over 60 minutes.~Saline infusion : 0.15 mL/kg IV bolus (maximum 15 mL) followed by an IV infusion of 0.15 mL/kg over 60 minutes (maximum 15 mL)."
89401373|NCT02258204|Experimental|tPA-ketamine|"tPA infusion : 0.9 mg/kg (90 mg maximum), 10% of the total dose is administered as an initial IV bolus dose over 1 minute and the remainder of the dose is infused over 60 minutes.~Ketamine infusion : 0.15 mg/kg IV bolus (maximum 15 mg) followed by an IV infusion of 0.15 mg/kg over 60 minutes (maximum 15 mg)."
89401374|NCT04448743||Covid-19 patients|
89401375|NCT04448743||patients with coronary artery disease|
89401376|NCT04448743||healthy volunteers|
89401377|NCT02226068|Other|CsA-ECP|Sequence of therapy: First ciclosporin was given and after relapse extra corporal photopheresis was given
89401378|NCT02226068|Other|ECP-CsA|Sequence of therapy: First extra corporal photopheresis was given and after relapse ciclosporin was given
89401379|NCT02081274||patients who underwent surgery for congenital heart disease|patients who underwent surgery for congenital heart disease between 2009 and 2013 in Samsung Medical Center
89401380|NCT05424991|Experimental|comedy movie group|The anxiety level of the patients in the experimental group was measured. Afterwards, each patient watched a comedy movie for 25 minutes. Anxiety levels were re-measured 25 minutes after watching the comedy movie. Pain levels were measured after the anesthesia effect disappeared in the postoperative period. Afterwards, each patient watched a comedy movie for 25 minutes. Pain levels were re-measured 25 minutes after watching the comedy movie.
89401381|NCT05424991|No Intervention|No treatment group|In the follow-up of the patient, no application was made other than clinical protocols. Anxiety scale was filled preoperatively, and anxiety level was evaluated again 25 minutes later. Pain level was evaluated in the postoperative period. Pain levels were evaluated again at the end of the same period with the experimental group without any intervention.
89401382|NCT02081352|Active Comparator|DermaPure™|DermaPure™ in combination with standard care comprising surgical debridement, covered by a non-adherent silicone wound contact layer, a wound cavity filler (if required), a secondary foam wound dressing and appropriate off-loading footwear.
89401383|NCT02081352|Sham Comparator|Standard care|Standard care comprising surgical debridement, covered by a non-adherent silicone wound contact layer, a wound cavity filler (if required), a secondary foam wound dressing and appropriate off-loading footwear.
89401384|NCT02222402|Experimental|INTRA-DIALYTIC EXERCISE TRAINING|"Using a modified cycle ergometer, aerobic exercise will be performed in a semi-recumbent position, 3 times per week during the first two hours of haemodialysis. The initial prescription will be set in the moderate intensity range of 40-60% of peak aerobic capacity, progressing to 75% level by the end of the intervention.~Twice per week patients will also complete lower extremity muscular conditioning exercise, using ankle weights, after the aerobic cycling exercise."
89401385|NCT02222402|No Intervention|HAEMODIALYSIS RENAL REPLACEMENT THERAPY|"Haemodialysis is the most common dialysis (renal replacement) treatment for kidney failure.~They may also receive dietary advice, counselling, input from social workers, and other forms of educational support."
89401386|NCT01378585|Experimental|Treatment 1|Test drug treatment: 3 x 490 mg DLBS1033 daily
89401387|NCT01378585|Placebo Comparator|Treatment 2|Placebo treatment: 3 x 1 tablet daily
88876720|NCT04447872|Active Comparator|Luteal phase ovarian stimulation (LPOS)|Patients will present in the luteal phase, and will begin 150 IU hMG and 300 IU recombinant FSH daily, as well as oral Clomiphene citrate 100mg daily for the first five days of the stimulation. FSH can then be titrated per patient response. Gonadotropin releasing hormone antagonist (Ganirelix, Organon; and cetrorelix, Serono) will be started per criteria. Once patients are ready for ovulation trigger, 5-10,000 units of human chorionic gonadotropin, +/- GnRH agonist (i.e Luprolide acetate 40 IU), will be administered. All metaphase II oocytes obtained by oocyte retrieval will be fertilized with intracytoplasmic sperm injection (ICSI) or IVF. Embryos will be cultured to the blastocyst stage and vitrified on day 5-7 with or without embryo biopsy for genetic analysis.
88876721|NCT04447872|Active Comparator|Luteal estradiol priming protocol|In the luteal phase, the patient will begin Estradiol patches 0.1mg QOD. She will also take daily Gonadotropin releasing hormone (GnRH) antagonist (Ganirelix, Organon; and cetrorelix, Serono) for three days. With menses, she will begin 150 IU hMG, 300 IU recombinant FSH daily, and oral Clomiphene citrate 100mg qd (for five days). FSH can be titrated per patient response. GnRH antagonist will be started per criteria. 5-10,000 units of human chorionic gonadotropin, +/- GnRH agonist (i.e Luprolide acetate 40 IU) will be administered for ovulation trigger. All metaphase II oocytes obtained by oocyte retrieval will be fertilized with intracytoplasmic sperm injection (ICSI) or IVF. Embryos will be cultured to the blastocyst stage and vitrified on day 5-7 with or without embryo biopsy for genetic analysis.
88876722|NCT04422951|Experimental|Wise interventions plus behavioral Rx|Wise social psychological interventions (growth mindset and values self-affirmation) plus a usual care behavioral intervention for weight control.
89437445|NCT03909061|Experimental|Randomized Training|Individuals may decide to participate in the research study and agree to be randomized. These individuals will be immediately randomized into an immediate or a wait list control group. The immediate will receive the wheelchair maintenance training program after completing the baseline questionnaires. The wait list control group will wait approximately 6 months before receiving the independent maintenance training program.
89437446|NCT03899428|Experimental|Immune Checkpoint Therapy|The subjects will receive durvalumab 1500 mg Q4W
88876723|NCT04422951|Active Comparator|Education plus behavioral Rx|Health education plus a usual care behavioral intervention for weight control
88876724|NCT04410302||Ancillary-correlative (biospecimen collection)|Patients undergo collection of tumor tissue samples during standard of care tumor biopsy or surgical resection to establish PDXs. Patients may also undergo collection of blood, saliva, and urine samples to compare DNA abnormalities to noncancer cells in order to determine if they were present before the cancer started or developed with it.
88876725|NCT04404088|Experimental|Treatment (acalabrutinib, lenalidomide, rituximab)|Patients receive acalabrutinib PO BID on days 1-28. Beginning cycle 2, patients receive lenalidomide PO QD on days 1-21 and rituximab IV on days 1, 8, 15, and 22 of cycle 2 and day 1 of subsequent cycles. Treatment repeats every 28 days for 13 cycles in the absence of disease progression or unacceptable toxicity.
88876726|NCT04340570|Experimental|Intervention|Receives pharmacist home televisit for medication management
88876727|NCT04340570|No Intervention|Usual Care|Usual care for outpatient medication management
88876728|NCT04335292|Experimental|Treatment Arm|"First-line treatment = osimertinib, 80 mg, oral, daily; Second-line treatment = platinum (carboplatin or cisplatin) + pemetrexed chemotherapy, prescribed as per institutional standards; Third-line treatment = osimertinib rechallenge, 80 mg, oral, daily.~Patients may enter the study at first-line treatment, second-line treatment, or third-line treatment. This is dependent on meeting the eligibility criteria."
88876729|NCT04317534|Experimental|Arm A- Pembrolizumab|Pembrolizumab 400mg IV every 6 weeks x 9 cycles
88876730|NCT04317534|No Intervention|Arm B - Observation|Observation only
88876731|NCT04294901|Experimental|Gabapentin (Gaba)|Patients prescribed gabapentin with a total daily dose >1800mg without exclusion criteria who have a primary care appointment with a provider in the Gaba cohort
88876732|NCT04294901|Experimental|Diabetes (DM)|Patients prescribed either insulin or a sulfonylurea meeting inclusion/exclusion criteria who have a primary care appointment with a provider in the DM cohort
89401388|NCT02220218|Experimental|Treatment Sequence ABDC|Treatment A (canagliflozin and metformin immediate release [IR] fixed dose combination [FDC] tablet 50 milligram [mg]/500 mg orally under fed condition) on Day 1 of treatment period 1, followed by Treatment B (canagliflozin tablet 50 mg along with metformin IR tablet 500 mg orally under fed condition) on Day 1 of treatment period 2, followed by Treatment D (canagliflozin tablet 50 mg along with metformin IR tablet 500 mg orally under fasted condition) on Day 1 of treatment period 3, then Treatment C (canagliflozin and metformin IR FDC tablet 50 mg/500 mg orally under fasted condition) on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
89401389|NCT02220218|Experimental|Treatment Sequence BCAD|Treatment B (canagliflozin tablet 50 mg along with metformin IR tablet 500 mg orally under fed condition) on Day 1 of treatment period 1, followed by Treatment C (canagliflozin and metformin IR FDC tablet 50 mg/500 mg orally under fasted condition) on Day 1 of treatment period 2, followed by Treatment A (canagliflozin and metformin IR FDC tablet 50 mg/500 mg orally under fed condition) on Day 1 of treatment period 3, then Treatment D (canagliflozin tablet 50 mg along with metformin IR tablet 500 mg orally under fasted condition) on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
89401390|NCT02220218|Experimental|Treatment Sequence CDBA|Treatment C (canagliflozin and metformin IR FDC tablet 50 mg/500 mg orally under fasted condition) on Day 1 of treatment period 1, followed by Treatment D (canagliflozin tablet 50 mg along with metformin IR tablet 500 mg orally under fasted condition) on Day 1 of treatment period 2, followed by Treatment B (canagliflozin tablet 50 mg along with metformin IR tablet 500 mg orally under fed condition) on Day 1 of treatment period 3, then Treatment A (canagliflozin and metformin IR FDC tablet 50 mg/500 mg orally under fed condition) on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
89437447|NCT03899428|Experimental|Target Therapy|The subjects will receive tyrosine kinase inhibitors, including sorafenib, lenvatinib, regorafenib, or cabozantinib, daily
89437448|NCT03897205|Experimental|Imlifidase|Subjects randomized to imlifidase treatment received one intravenous dose of imlifidase, 0.25 mg/kg, administered over 15 minutes.
88876733|NCT04294901|Experimental|Proton Pump Inhibitor (PPI)|Patients prescribed a PPI meeting inclusion/exclusion criteria who have a primary care appointment with a provider in the PPI cohort
88876734|NCT04276922|Experimental|Visual Arts Group|Visual Arts group - sketch journals
88876735|NCT04276922|Experimental|Music Group|Music group involves music-listening exercises (such as lyric analysis, patient-chosen, music for relaxation and/or visualization) and active music making.
88876736|NCT04276922|Experimental|Dance/Movement Group|Dance/Movement group - movement check-in, gentle physical warm-up, and then either a structured or improvisational movement process.
88876737|NCT04276922|Experimental|Writing/Poetry Group|Writing/Poetry group uses writing workshops using integral elements of good writing.
88876738|NCT04276922|Experimental|Control Group|Surveys at baseline and 12 weeks later.
88876739|NCT04267315|Active Comparator|Active|3 weekly sessions of TPI. Participants will undergo 1mL injections of 1% lidocaine in the muscles identified with either active or latent trigger points at the initial assessment. The same muscles will be injected at all procedures.
88876740|NCT04267315|Sham Comparator|Placebo|3 weekly sessions of subcutaneous saline injections. Participants will undergo 0.2mL subcutaneous saline injections superficial to the trigger points identified at initial assessment. The same superficial sites will be injected in all procedures.
88876741|NCT04260607|Experimental|Experimental-Ketamine|single dose IV Ketamine (Ketalar) 0.5mg/kg in 100ml Normal Saline infused over 40 minutes
88876742|NCT04260607|Placebo Comparator|Placebo-Saline|100ml Normal Saline infused over 40 minutes
88876743|NCT04260347||Actilyse® (alteplase) pre-approval|
89437449|NCT03897205|Active Comparator|Plasma Exchange|Subjects randomized to plasma exchange (PE) treatment received 5-10 sessions of PE, as judged by the investigator. Immunoadsorption (IA) could replace PE, at the discretion of the investigator.
88876744|NCT04260347||Actilyse® (alteplase) post-approval|
88876745|NCT04259411|Experimental|MitraClip|Subject will receive MitraClip procedure with MitraClip NTR System or MitraClip XTR System.
88876747|NCT04198558|Experimental|Dose Level 1|MEDI0618 or placebo
88876748|NCT04198558|Experimental|Dose Level 2|MEDI0618 or placebo
88876749|NCT04198558|Experimental|Dose Level 3|MEDI0618 or placebo
89401391|NCT02220218|Experimental|Treatment Sequence DACB|Treatment D (canagliflozin tablet 50 mg along with metformin IR tablet 500 mg orally under fasted condition) on Day 1 of treatment period 1, followed by Treatment A (canagliflozin and metformin IR FDC tablet 50 mg/500 mg orally under fed condition) on Day 1 of treatment period 2, followed by Treatment C (canagliflozin and metformin IR FDC tablet 50 mg/500 mg orally under fasted condition) on Day 1 of treatment period 3, then Treatment B (canagliflozin tablet 50 mg along with metformin IR tablet 500 mg orally under fed condition) on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
89401392|NCT03559452|No Intervention|Control|Immobilisation without prior exercise
89401393|NCT03559452|Experimental|Muscle damage|300 bilateral knee extensor eccentric contraction performed immediately prior to immobilisation
89401394|NCT02081430|Experimental|CT Manipulation|Prone cervicothoracic manipulation
89401395|NCT02081430|Active Comparator|Upper trapezius stretch|Passive sustained stretch to upper trapezius muscle
89401396|NCT02081430|No Intervention|Control|8 Minute wait
89401397|NCT02222480|Experimental|Fimasartan 60 mg, Hydrochlorothiazide 12.5 mg|Combination of Fimasartan/Hydrochlorothiazide 60/12.5mg
89401398|NCT02222480|Experimental|Fimasartan 60 mg, Hydrochlorothiazide 25 mg|Combination of Fimasartan/Hydrochlorothiazide 60/25mg
89401399|NCT02222480|Experimental|Fimasartan 120 mg, Hydrochlorothiazide 12.5 mg|Combination of Fimasartan/Hydrochlorothiazide 120/12.5mg
89401400|NCT02222480|Experimental|Fimasartan 120 mg, Hydrochlorothiazide 25 mg|Combination of Fimasartan/Hydrochlorothiazide 120/25mg
89401401|NCT02222480|Placebo Comparator|Placebo|placebo
89401402|NCT03669471||FAIS group|Subjects who have had a hip arthroscopy for femoroacetabular impingement during the preceding 6-30 months
89401403|NCT02081508|Experimental|Unfilled interference|Interference onset: delayed test at 540000 ms
89401404|NCT02081508|Experimental|Early interference|Interference onset: delayed test at 0 ms
89401405|NCT02081508|Experimental|Mid interference|Interference onset: delayed test at 360000 ms
89401406|NCT02081508|Experimental|Late interference|Interference onset: delayed test at 180000 ms
89401407|NCT02258438|Experimental|Uninterrupted sitting|Patient will refrain from any structured activity and reduce any daily life activity. The patient will spend 24 hours in the calorimeter room. During the 24 hours the patient will remain sedentary for the 24 hours but will be able to watch TV, computer work or read.
88876750|NCT04198558|Experimental|Dose Level 4|MEDI0618 or placebo
88876751|NCT04198558|Experimental|Dose Level 5|MEDI0618 or placebo
88876752|NCT04198558|Experimental|Dose Level 6|MEDI0618 or placebo
89401408|NCT02258438|Experimental|Sitting + 1 bout of activity|The patient will be asked to perform the 45 minutes of moderate-exercise intervention in the morning once per day for two days in their daily life. This bout of exercise will be supervised by study staff on one of the treadmills On day 3 the patient will report at the Clinical and Translational Research Center (CTRC) of the University Hospital of Colorado and will spend 24hr in the room calorimeter. During the day, you will be asked to sit quietly in a chair, except to rise from the chair to void, and to perform one bout of 45-min moderate-intensity walking on a treadmill.
89401409|NCT02258438|Experimental|Sitting + microbursts of activity|The patient will be asked to refrain from any structured exercise running, swimming, lifting weights, yoga, dancing, etc.) for two days but to walk for the 5 minute intervention each hour between 1000 and 1800. On day 3, The patient will report at the CTRC of the University Hospital of Colorado and will spend 24hr in the room calorimeter. During the day, the patient will be asked to rise from the seated position every hour for 9 hours from 1000 to 1800 to complete 5 min moderate-intensity walking on a treadmill, which represents a total of 45 min.
89401410|NCT03670875|Experimental|Agave inulin|Agave inulin 2.3 g, by mouth, every 12 hours for 3 months. Plus recommendations to decrease calories intake an do exercise.
89189618|NCT05568953|Experimental|Arm 1 (JE-YF17D vaccine followed by YF17D vaccine)|28 subjects will receive one dose of the JE-YF17D vaccine (Imojev, Sanofi Pasteur, 0.5mls (4.0 - 5.8 log plaque forming units [PFU])) on Day 0 followed by one dose of the YF17D vaccine (Stamaril, Sanofi Pasteur, 0.5mls (3 - 4 log PFU) ) on Day 28.
89401411|NCT03670875|Experimental|Curcumin|Curcumin 600 mg (turmeric 600 + black pepper 5 mg) by mouth, daily for 3 months. Plus recommendations to decrease calories intake an do exercise.
88876753|NCT04198558|Experimental|Dose Level 7|MEDI0618 or placebo
88876754|NCT04198558|Experimental|Dose Level 8|MEDI0618 or placebo
88876755|NCT04198558|Experimental|Dose Level 9|MEDI0618 or placebo
88876756|NCT04193527|Experimental|DaTSCAN™ ioflupane (123I) injection|Participants with Parkinsonian Syndrome (PS), Essential Tremor (ET), and Healthy Volunteers (HV) received a single dose of DaTSCAN™ ioflupane (123I) injection. Single photon emission computed tomography (SPECT) imaging was performed between 3 to 6 hours post-injection and lasted approximately 20 minutes to 1 hour.
88876757|NCT04191824|Active Comparator|Immediate Return of Results|Immediate return of results to inform participant of APOL1 status (either positive or negative).
88876758|NCT04191824|Active Comparator|Delayed Return of Results|Delayed return of results of APOL1 status (either positive or negative) after the completion of the 6 month final study visit.
89401412|NCT03670875|Experimental|Omega 3 Fatty Acids|O3FA 600 mg (eicosapentaenoic acid 360; docosahexaenoic acid 240) Three times a day by mouth, every 8 hours for 3 months. Plus recommendations to decrease calories intake an do exercise.
88876759|NCT04186416||Patients less than 6 months old|Patients less than 6 months old admitted to the pediatric surgical ICU of the Necker-Enfants Malades university hospital and for whom volume expansion is indicated.
88876760|NCT04186416||Patients between 6 and 12 months old|Patients between 6 and 12 months old admitted to the pediatric surgical ICU of the Necker-Enfants Malades university hospital and for whom volume expansion is indicated.
88876761|NCT04186416||Patients between 1 and 6 years old|Patients between 1 and 6 years old admitted to the pediatric surgical ICU of the Necker-Enfants Malades university hospital and for whom volume expansion is indicated.
88876762|NCT04186416||Patients between 6 and 10 years old|Patients between 6 and 10 years old admitted to the pediatric surgical ICU of the Necker-Enfants Malades university hospital and for whom volume expansion is indicated.
88876763|NCT04172259|Experimental|ACHP-THP|Doxorubicin liposome（PLD）35 mg/m2 Cyclophosphamide（CTX）600 mg/m2 Trastuzumab：first cycle 8mg/kg，then 6mg/kg Pertuzumab：first cycle 840mg，then 420mg Docetaxel（DOC）75 mg/m2 every 3 weeks paclitaxel (PTX) 175 mg/m2 every 3 weeks or paclitaxel (PTX) 80 mg/m2 every week albumin-bound paclitaxel 260 mg/m2 or albumin-bound paclitaxel 100 mg/m2 every week
88876764|NCT04172259|Active Comparator|EC-THP|Epirubicin（EPI）90 mg/m2 Cyclophosphamide（CTX）600 mg/m2 Trastuzumab：first cycle 8mg/kg，then 6mg/kg Pertuzumab：first cycle 840mg，then 420mg Docetaxel（DOC）75 mg/m2 every 3 weeks paclitaxel (PTX) 175 mg/m2 every 3 weeks or paclitaxel (PTX) 80 mg/m2 every week albumin-bound paclitaxel 260 mg/m2 or albumin-bound paclitaxel 100 mg/m2 every week
88876765|NCT04155424|Experimental|Eculizumab|"All participants will receive open-label eculizumab by intravenous infusion during the Primary Treatment Period, starting on Day 1 and for a total of 52/53 weeks. The dosing regimen will be based on the participant's body weight. As body weight changes during the study, the participant's weight cohort and dose may change accordingly.~After completing the 52/53-week Primary Treatment Period, participants may continue receiving eculizumab in the Extension Treatment Period for 104 weeks."
88876766|NCT04103216|Active Comparator|Intervention arm NItazoxanide with probiotics|"Child will be receive the Nitazoxanide treatment for 3 days with probiotics (L reuteri DSM 17938 ) for 7days. The doses of Nitazoxanide will be twice a day for 3 days and dosage will be 5 ml every 12 hours with food. The Nitazoxanide oral suspension contain 100mg/5ml.~L reuteri DSM 17938 will be 2×108 CFU and will receive 5 drops orally twice daily for a consecutive 7 days."
88876767|NCT04103216|Placebo Comparator|Intervention arm Nitazoxanide with placebo|"Child will be receive the Nitazoxanide treatment for 3 days with placebo for 7days. The doses of Nitazoxanide will be twice a day for 3 days and dosage will be 5 ml every 12 hours with food. The Nitazoxanide oral suspension contain 100mg/5ml.~Placebo will receive 5 drops orally twice daily for a consecutive 7 days."
88876768|NCT04103216|No Intervention|Control arm|Child will received the standard supportive care normally provided for Cryptosporidium infections
88876769|NCT04079296|Experimental|Phase 1 ASP7517 Dose Escalation|Two single doses of ASP7517 will be administered intravenously at up to 3 dose levels and will be based on the assessment of safety variables, including the occurrence of dose limiting toxicities (DLTs).
88876770|NCT04079296|Experimental|Phase 2 ASP7517 Dose Expansion|Up to six single doses of ASP7517 will be administered intravenously at the dose levels determined from the Dose Escalation phase.
88876771|NCT04075747|Experimental|Arm A|
88876772|NCT04075747|Experimental|Arm B|
88876773|NCT04075747|Experimental|Arm C|
88876774|NCT04061746|Experimental|Group A Treatment|2.5 x 10^6 MSC per kg will be infused intravenously on Day 1
88876775|NCT04061746|Placebo Comparator|Group B Placebo|Plasmalyte with 0.5% Human Serum Albumin will be infused intravenously on Day 1
88876776|NCT04022213|Experimental|Group A|Participants with DSRCT who have undergone GTR of their abdominopelvic disease and who have no definitive radiological evidence of disease in liver or outside the abd/pelvis. Patients if deemed of likely benefit to the patient after completing IP RIT plus WAP-IMRT, or will be mandated if ANC is persistently <500/ul despite use of G-CSF for >1 week, or if patients experience life threatening febrile neutropenia.
88876777|NCT04022213|Experimental|Group B|DSRCT patients who have macroscopic residual disease OR who have previously experienced progression of disease while on treatment but have subsequently had a GTR
88876778|NCT04022213|Experimental|Group C|Participants with tumors other than DSRCT and will be enrolled onto an assessment arm to determine eligibility. Immunohistochemistry to assess B7H3 expression will be performed on frozen or paraffin embedded tissue using omburtamab (frozen tissue) or a commercially available anti-B7H3 antibody (if paraffin embedded).
88876779|NCT03992456|Experimental|Arm A (panitumumab)|Patients receive panitumumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days for a maximum of 24 cycles in the absence of disease progression or unacceptable toxicity.
88876780|NCT03992456|Active Comparator|Arm B (regorafenib, trifluridine and tipiracil hydrochloride)|Patients receive trifluridine and tipiracil hydrochloride PO BID on days 1-5 and 8-12, or regorafenib PO QD on days 1-21, at the discretion of the treating physician. Treatment repeats every 28 days for a maximum of 24 cycles in the absence of disease progression or unacceptable toxicity.
89189619|NCT05568953|Experimental|Arm 2 (YF17D vaccine followed by JE-YF17D vaccine)|28 subjects will receive one dose of the YF17D vaccine (Stamaril, Sanofi Pasteur, 0.5mls (3 - 4 log PFU)) on Day 0 followed by one dose of the JE-YF17D vaccine (Imojev, Sanofi Pasteur, 0.5mls (4.0 - 5.8 log plaque forming units [PFU]) on Day 28.
89401413|NCT03670875|Other|Control|Recommendations to decrease calories intake an do exercise.
89401414|NCT02078076|Experimental|Magnetic Resonance Cardiac Imaging (with Gadolinium)|
88876781|NCT03960424|Experimental|Diabetes Telemonitoring (DTM)|"Diabetes Telehealth Management (DTM), based on the 2018 ADA Standards for Type 2 Diabetes (T2D), uses smart devices to share information between patients, caregivers, and clinicians. DTM includes:1) weekly real time virtual visit between patient and clinician 2) vital signs monitoring/interpretation 3) diabetes management 4) patient interactive educational videos and teach back quizzes, reinforcing self-management strategies 5) a caregiver app with supportive capability."
88876782|NCT03960424|Active Comparator|Comprehensive Outpatient Management (COM)|"Comprehensive Outpatient Management (COM) is the most realistic evidence-based comparator, in that it is the most frequently recommended and used option for US T2D patients. COM, like DTM, is consistent with the 2018 American Diabetes Association (ADA) Standards which include, but are not limited to, past medical and family history, social history, medications, screening, physical examination, laboratory evaluation, etc.Patients are instructed to monitor blood glucose (within physician recommendations), and have routine or well visits every 3 months. Patients can set appointments with a T2D educator. COM patients will receive monthly calls from the study Registered Nurse (RN) to collect data."
88876783|NCT03945812|Active Comparator|Granulocyte Colony Stimulating Factor Arm|"Women in this group will receive G-CSF with conventional hormonal therapy:~Estradiol valerate 6mg/day from day 2 of menstrual cycle Vaginal sildenafil citrate 25mg / 6 hours Then frozen embryo transfer will be performed."
88876784|NCT03945812|Active Comparator|Platelet Rich Plasma Arm|"Women in this group will receive PRP with conventional hormonal therapy:~Estradiol valerate 6mg/day from day 2 of menstrual cycle Vaginal sildenafil citrate 25mg / 6 hours Then frozen embryo transfer will be performed."
88876785|NCT03945812|Placebo Comparator|Saline|"Women in this group will receive saline with conventional hormonal therapy:~Estradiol valerate 6mg/day from day 2 of menstrual cycle Vaginal sildenafil citrate 25mg / 6 hours Then frozen embryo transfer will be performed."
88876786|NCT03927131|Experimental|QIV-IB|Inactivated split-virion quadrivalent influenza vaccine
88876787|NCT03927131|Active Comparator|TIVV-IB|Inactivated split-virion trivalent Influenza Vaccine containing Influenza B virus - Victoria lineage
88876788|NCT03927131|Active Comparator|TIVY-IB|Inactivated split-virion trivalent Influenza Vaccine containing Influenza B virus - Yamagata lineage
88876789|NCT03927131|Experimental|QIV-IB Lot A|Inactivated split-virion quadrivalent influenza vaccine - Lot A
88876790|NCT03927131|Experimental|QIV-IB Lot B|Inactivated split-virion quadrivalent influenza vaccine - Lot B
88876791|NCT03927131|Experimental|QIV-IB Lot C|Inactivated split-virion quadrivalent influenza vaccine - Lot C
88876792|NCT03915470|Experimental|XF-73|0.3 mL applications in each naris of 0.2% w/w XF-73 nasal gel for a cumulative dose of 6.0 mg of XF-73.
88876793|NCT03915470|Placebo Comparator|Placebo|0.3 mL applications in each naris of placebo to match XF-73 nasal gel.
88876794|NCT03813381|Experimental|Intervention Arm (IA)|Patients randomized in the Intervention Arm (IA) will be given personalized diet based on calorie and protein restriction. Calorie restriction will be up to 600 kcal below patients' energy requirements and the amount of protein will be 0.8g of protein/Kg body weight mostly form plant-origin food.
88876795|NCT03813381|No Intervention|Control Arm (CA)|Participants in the CA will be given information about the importance of a healthy lifestyle in reducing the risk of cancer and will receive a leaflet based on WCRF/AICR recommendations.
88876796|NCT03791970|Experimental|DCB for post-dilation|DCB was used for post-dilation after stent placement. The DCB for post-dilation in this study is Orchid 035 DCB Catheter.
88876797|NCT03791970|Active Comparator|POBA for post-dilation|POBA was used for post-dilation after stent placement. POBA Catheter for post-dilation in this study can be Mustang, Dorado or others balloon catheters.
88876798|NCT03776487|Experimental|Treatment (chemotherapy, immunotherapy, IMRT)|"INDUCTION CHEMOTHERAPY: Patients receive oxaliplatin IV over 2 hours and fluorouracil IV over 48 hours on day 1. Treatment repeats every 14 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.~Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 1. Treatment with nivolumab repeats every 2 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Beginning course 4, patients also receive fluorouracil IV continuously for 5 days per week and undergo 25 fractions of IMRT for 5 weeks. Patients undergo surgical resection 5-7 weeks after completing radiation therapy.~Within 8-12 weeks post-surgery, patients with residual disease may receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 2 weeks for 8 courses (16 weeks) then every 4 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity."
88876799|NCT03751436|Experimental|Treatment (venetoclax, enzalutamide)|Patients receive venetoclax PO QD and enzalutamide PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88876800|NCT03750903|Experimental|Aerobic Exercise|Participants will engage in an aerobic exercise program meeting thrice weekly for a period of 12 weeks.
88876801|NCT03750903|Active Comparator|Stretching and Balance Training|Participants will engage in a balance and stretching comparator condition meeting thrice weekly for 12 weeks.
88876802|NCT03735875|Experimental|Treatment (venetoclax, quizartinib)|Patients receive quizartinib PO QD on days 1-28 and venetoclax PO QD beginning on day 8 of cycle 1. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. Patients may continue treatment beyond 24 cycles at the discretion of the treating physician.
88876803|NCT03723694|Active Comparator|650 mg of Cocoapro flavanols|Daily, each subject will consume either two cocoa flavanol-containing capsules twice a day with a meal.
88876804|NCT03723694|Placebo Comparator|0mg Cocoapro flavanols|Daily, each subject will consume either ttwo placebo-containing capsules twice a day with a meal.
88876805|NCT03629327|Active Comparator|ASA 325mg|Daily uptake of 325mg ASA
88876806|NCT03629327|Active Comparator|No drug|no drug
89401415|NCT02226146|Experimental|Bertilimumab|Intravenous injection over 30 minutes of 10 mg/kg of Bertilimumab in physiological solution (PBS)
89401416|NCT01379677|Other|Single arm|This is an Head to Head Comparison between Rubidium-82 PET and Tc-99m-MIBI SPET with CTA as gold standard. All the patients will undergo the three imaging protocols.
89401417|NCT03670797||controlled diabetic patients|
89401418|NCT03670797||uncontrolled diabetic patients|
89401419|NCT02220296|Experimental|Part 1 insulin 338|
89401420|NCT02220296|Placebo Comparator|Part 1 placebo|
89401421|NCT02220296|Experimental|Part 2 insulin 338|
89401422|NCT02220296|Active Comparator|Part 2 insulin glargine|
89401423|NCT02078154||Deep Venous Thrombosis (DVT)|DVT diagnosed by imaging technique with a low or moderate Wells score
88876807|NCT03629327|Active Comparator|ASA 81mg|daily uptake of 81mg ASA
88876808|NCT03575468|Experimental|Enhanced E-cigarette Coaching (EEC)|The EEC intervention calls will include assessment of e-cigarette use and discussion about how and why e-cigarettes are being used on every call. In addition to the standard quitline cessation program, the enhanced program will include education (via quit coaches and two tailored quit guides), behavioral support tailored to dual users, and shared decision making strategies to address how and why FDA-approved quitting aids and ENDS are being used and to develop an integrated quit plan based on callers' decisions.
88876809|NCT03575468|Active Comparator|Quitline treatment as usual (TAU)|The standard tobacco quitline program is a proactive 5-call intervention grounded in social cognitive theory and the U.S. Public Health Service clinical practices guidelines for treating tobacco use and dependence. All enrollees in the study are eligible for 2-8 weeks of nicotine replacement therapy (depending on their standard quitline benefit offering), if they medically qualify and/or return a medical override letter from their doctor.
88876810|NCT03570801|Experimental|Expert Panel Review|"For patients who are randomized to receive an expert panel review, de-identified lumbar MRI (sagittal and key axial images), 36-inch standing plain radiographs (if available), and flexion and extension radiographs will be uploaded into a web-based platform and reviewed. These will be submitted for an Expert Panel Review.~Images will be reviewed through a Spine Expert's Network, consisting of physicians involved in this study who will each offer their opinion as to which of two surgical treatment groups (decompression alone or decompression with fusion) they would choose for the patient. The results of this review will be discussed between the patient and the patient's physician. Together, they will determine the best surgical approach."
88876811|NCT03570801|No Intervention|No Expert Panel Review|For patients not receiving the expert panel review, they will discuss with their surgeon the best surgical option and proceed as they would in standard of care.
88876812|NCT03555981|Experimental|Early KMC|Continuous kangaroo mother care started within 24h of hospital admission, aiming for minimum 18h/day and until hospital discharge with encouragement of KMC at home
88876813|NCT03555981|Active Comparator|Standard care|Standard care under radiant heater or incubator until clinical stability criteria are met then intermittent or continuous Kangaroo mother care started at >24h of hospital admission until hospital discharge with encouragement of KMC at home
88876814|NCT03513744|Experimental|infant formula containing five HMOs|
88876815|NCT03513744|No Intervention|infant formula|
89401424|NCT03670719|Experimental|Manual Therapy and Exercise Group|Combination of manual therapy and exercises for chronic cervical pain
89401425|NCT03670719|Active Comparator|Exercise Group|Only exercises for chronic cervical pain
88876816|NCT03513744|No Intervention|breast milk group|
89401426|NCT02074878|Experimental|Crixotinib 200 mg and Sunitinib Cohort 1|Crizotinib 200mg, twice daily and Sunitinib 25.0mg once daily
89401427|NCT02074878|Experimental|Crixotinib 250 mg and Sunitinib Cohort 2|Crizotinib 250 mg, twice daily with Sunitinib 25.0 mg once a day
89401428|NCT02074878|Experimental|Crizotinib & Sunitinib 37.5 mg Cohort 3|Crizotinib 250 mg, twice daily with Sunitinib 37.5 mg once a day
89401429|NCT02258672|Experimental|Prehabilitation program|Participants will be physically trained before undergoing surgery
89401430|NCT02258672|No Intervention|Control|Patients will follow the normal course of care provided by the hospital
89401431|NCT01379599|Experimental|Brief motivation intervention|Brief motivation intervention was implemented with enrollees identified with heroin and cocaine use who were allocated to the experimental group. The aim was to test the ability of a peer-delivered intervention to reduce risk of HIV and STIs related to sexual behaviors (condom use and sex while high on drugs.
88876817|NCT03460236||PRP|Symptomatic early knee osteoarthritis subjects who have elected to receive PRP treatment.
89401432|NCT01379599|No Intervention|control group|Care as usual.
89401433|NCT02220374|Experimental|Supportive Finger Tape|Participants will be randomised to either placebo or supportive taping
89401434|NCT02081664|Other|Lifestyle intervention|life-style oriented group program together with an individualized treatment program using therapies out of the spectrum of Complementary and Alternative Medicine (CAM)
89401435|NCT03075163|Experimental|Acupressure|Manual pressure will be applied on the wrists bilaterally.
89401436|NCT03075163|Active Comparator|Ondansetron|Ondansetron (Zofran) is used for the treatment of nausea and vomiting.
89401437|NCT02258750|Experimental|Polydextrose|Tomato soup enriched with added polydextrose
89401438|NCT02258750|Placebo Comparator|Control|Tomato soup without added polydextrose
89401439|NCT02220530||Sedation group|Colonoscopies performed with conscious sedation with iv midazolam and fentanyl
89401440|NCT02220530||Control group|Colonoscopies performed without sedation.
89401441|NCT02078232|Experimental|19G flex needle puncture|puncture of head of pancreas
89401442|NCT02078232|Active Comparator|22G needle puncture|puncture of head of pancreas
89401443|NCT02226224||early gastric cancer|EUS examination on the specimen right after surgery mark the deepest invasive site on the specimen
89401444|NCT02226224||Locally Advanced Gastric Cancer|EUS examination on the specimen right after surgery mark the deepest invasive site on the specimen
89401445|NCT02226224||early esophagus cancer|EUS examination on the specimen right after surgery mark the deepest invasive site on the specimen
89401446|NCT02226224||locally advanced esophagus cancer|EUS examination on the specimen right after surgery mark the deepest invasive site on the specimen
89401447|NCT02075034|Experimental|560 mg morning/280 mg afternoon|Two 280 mg capsules of rigosertib will be taken in the morning and one 280 mg capsule of rigosertib will be taken in the afternoon.
89401448|NCT02075034|Experimental|420 mg morning and afternon|One 280 mg capsule and two 70 mg capsules of rigosertib will be taken in the morning and one 280 mg capsule and two 70 mg capsules of rigosertib will be taken in the afternoon.
89401449|NCT02075034|Experimental|280 mg TID|One 280 mg capsule of rigosertib will be taken in the morning, one 280 mg capsule of rigosertib will be taken at mid-day, and one 280 mg capsule of rigosertib will be taken in the afternoon.
89401450|NCT03670563|Experimental|Exercise 1|Short foot exercise protocol instructed utilizing verbal instruction, passive modeling, active-assisted modeling, and active modeling.
89401451|NCT03670563|Active Comparator|Exercise 2|Short foot exercises plus NMES. Short foot exercise protocol instructed utilizing verbal instruction, passive modeling assisted by neuromuscular electric stimulation (NMES), active-assisted modeling assisted by neuromuscular electric stimulation, and active modeling.
88876818|NCT03450122|Experimental|Cohort 0 (cyclophosphamide, T cells, aldesleukin)|Participants receive cyclophosphamide IV over 30-60 minutes on day -2 and autologous NY-ESO-1-specific CD8-positive T lymphocytes IV over 60 minutes on day 0. Then, 6 hours later and twice a day for 14 days, receive aldesleukin SC in the absence of disease progression or unacceptable toxicity.
88876819|NCT03450122|Experimental|Cohort 1 (cyclophosphamide, T cells, aldesleukin, LV305)|Participants receive cyclophosphamide, autologous NY-ESO-1-specific CD8-positive T lymphocytes, and aldesleukin as in Cohort 0. Participants also receive dendritic cell-targeting lentiviral vector ID-LV305 ID on days 1, 22, 43, and 64 in the absence of disease progression or unacceptable toxicity.
88876820|NCT03382834|Experimental|Arm A: Tamoxifen + Vorinostat|From Day 0 to Day 38, participants will receive tamoxifen orally once a day. On Days 35 and 38, participants will receive a single dose of vorinostat orally.
88876821|NCT03382834|Active Comparator|Arm B: Vorinostat alone|Day 0 to Day 38 will be an observation period with no tamoxifen. On Days 35 and 38, participants will receive a single dose of vorinostat orally.
88876822|NCT03368742|Experimental|SGT-001 - Dose Level 1|Single IV infusion of SGT-001 at starting dose
88876823|NCT03368742|Experimental|SGT-001 - Dose Level 2|Single IV infusion of SGT-001 at next ascending dose
88876824|NCT03368742|No Intervention|Untreated Control|Untreated control group. After 1 year, treatment-eligible control patients will receive SGT-001 at the selected dose.
88876825|NCT03350516|Experimental|Daily 500 mg Calcium|
88876826|NCT03350516|Active Comparator|Daily1500 mg Calcium (Standard dose)|
89401452|NCT03670563|No Intervention|Control|No exercise intervention; continue normal physical activity, but do not start any new exercise programs
89401453|NCT02226302||Female Group 2|Females with BMI >30 kg/m2 who are having a hysterectomy for benign conditions
89401454|NCT02226302||Females Group 1|Females with BMI <30 kg/m2 who are having a hysterectomy for benign conditions
88876827|NCT03348670|Experimental|Abiraterone - Usual|"ZYTIGA - Abiraterone~Combined Chemotherapy (high dose)~ZYTIGA - abiraterone acetate tablet, film coated plus RAYOS - prednisone tablet, delayed release plus ORGOVYX - relugolix tablet, film coated~Usual Approach Group (high dose)"
89401455|NCT02226302||Males|2 males with BMI <30 kg/m2 and 2 males with BMI >30 kg/m2
89401456|NCT02226380|Experimental|mFOLFOX6,chemotherapy regimen|oxaliplatin 85 mg/m2 and folinic acid 400 mg/m2 are administered intravenously for 2 hours on day 1 following by 5-FU at 2,400 mg/m2 by continuous infusion for 46hours every 2 weeks for 3 cycles before performing surgery
89401457|NCT02078388||Breast cancer,Doxorubicin|Breast cancer patients who received at least one cycle of doxorubicin-containing adjuvant chemotherapy for treatment of early stage breast cancer at least 12 months ago and who had a pre-doxorubicin echocardiography done at NUHS will be enrolled. Study subjects will donate one sample of blood (20ml) for genetic and biomarker studies related to breast cancer and anthracyclines pharmacodynamics. An echocardiography will be performed to measure left ventricular ejection fraction, and compared with the subject's pre-doxorubicin echocardiography done at NUH. Correlative analysis will be performed between genetic variants and left ventricular ejection change.
89401458|NCT02222636|Placebo Comparator|Group 1,Normal saline,1 milliliter|Patients will be assigned to receive intranasal normal saline 1 milliliter
89401459|NCT02222636|Experimental|Group 2,dexmedetomidine 1μg.kg-1,1 milliliter|Patients will be assigned to receive intranasal dexmedetomidine( 1μg.kg-1) 1 milliliter
89401460|NCT02222636|Experimental|Group 3,dexmedetomidine 2μg.kg-1,1 milliliter|Patients will be assigned to receive intranasal dexmedetomidine( 2μg.kg-1 )1 milliliter
89401461|NCT02081820||aneurysmal subarachnoid hemorrhage|observational, no intervention
88876828|NCT03348670|Experimental|Abiraterone - Study|"ZYTIGA - Abiraterone~Combined Chemotherapy (low dose)~ZYTIGA - abiraterone acetate tablet~ZYTIGA - abiraterone acetate tablet plus RAYOS - prednisone tablet, delayed release plus ORGOVYX - relugolix tablet, film coated~Usual Approach Group (low dose)"
89401462|NCT04058223||PPH/DST|Patients underwent hemorrhoidopexy by PPH or DST stapler.
89401463|NCT02222792||Septic patient group|The septic patient group will be comprised of patients presenting with bone and joint prosthetic device infection confirmed by intraoperative microbiological culture (at least 2 deep positive samples for the same bacterial strain).
89401464|NCT02222792||Non-septic patient group|The non-septic patient group will be comprised of prosthetic patients presenting with symptoms of mechanical loosening, and whose deep intraoperative samples have all proved negative
89401465|NCT02222792||Intermediate group|An intermediate group will be comprised of patients with only one deep positive sample.
89401466|NCT03559374||Pregnant women|Consenting women will provide samples to be tested with Vanadis NIPT system.
89401467|NCT04058145|Experimental|Pembrolizumab+AMD3100 q3w|"Pembrolizumab is administered intravenously on day 1 of each cycle~AMD3 100 is administered via injection subcutaneously on day 1 of each cycle"
89401468|NCT04058145|Experimental|Pembrolizumab+AMD3100 weekly|"Pembrolizumab is administered intravenously on day 1 of each cycle~AMD3 100 is administered via injection subcutaneously on a weekly basis"
89401469|NCT04058145|Experimental|Pembrolizumab+AMD3100|"Pembrolizumab is administered intravenously~AMD3 100 is administered via injection subcutaneously"
89401470|NCT02075112|Experimental|Soy isoflavone|Study treatment: Soy isoflavone in combination with radiation therapy & cisplatin
89401471|NCT03078751|Experimental|Ribociclib + adjuvant endocrine therapy (ET)|"Patients in this arm took Ribociclib in combination with standard adjuvant endocrine therapy.~ET was one of these 4: Letrozole, Anastrozole, Exemestane, Tamoxifen (Tamoxifen no longer permitted after protocol amendment 2)"
89401472|NCT03078751|Placebo Comparator|Placebo + adjuvant endocrine therapy (ET)|Patients in this arm took Placebo in combination with standard adjuvant endocrine therapy. ET was one of these 4: Letrozole, Anastrozole, Exemestane, Tamoxifen
89401473|NCT02223026|Experimental|Linagliptin/metformin fed|
89401474|NCT02223026|Active Comparator|Linagliptin/metformin fasted|
89401475|NCT02075190|Experimental|Treatment Group|Participants randomized to receive remediation training intervention delivered online (60 days of online training)
89401476|NCT02075190|Active Comparator|Control Group|Participants randomized to receive online gaming intervention (60 days of online play)
89401477|NCT02226614|Experimental|head cooling|head cooling
89401478|NCT02075268|Other|10 mg, 30 mg|To compare PKPD of prasugrel 10 or 30 mg, 4 subjects will be given 10 mg of prasugrel (one tablet of 10 mg of Effient) on day 1 as a single oral dose and another 4 subjects will be given 30 mg of prasugrel (3 tablets of 10 mg of Effient) on day 1 as a single oral dose.
89401479|NCT02231060||AIE after Cardiac Arrest|Male and female patients with AIE following CA.
88876829|NCT03308942|Experimental|Stage 1 (Cohort 1): Niraparib plus Pembrolizumab|Participants with locally advanced and metastatic NSCLC (all histologies) with no prior systemic chemotherapy or PD-1/programmed death-ligand 1 (PD-L1) inhibitor treatment and whose tumors have high PD-L1 expression (tumor proportion score [TPS]: >= 50 percent [%]) will receive combination of niraparib and a PD-1 inhibitor; pembrolizumab.
88876830|NCT03308942|Experimental|Stage 1 (Cohort 2): Niraparib plus Pembrolizumab|Participants with locally advanced and metastatic NSCLC (all histologies) with no prior systemic chemotherapy or PD-1/PD-L1 inhibitor treatment and whose tumors have PD-L1 expression (TPS: 1% to 49%) will receive combination of niraparib and a PD-1 inhibitor; pembrolizumab.
88876831|NCT03308942|Experimental|Stage 1 (Cohort 3): Niraparib|Participants with locally advanced and metastatic squamous NSCLC who have been previously treated with both platinum and either PD-1 or PD-L1 inhibitor will receive single agent niraparib.
88876832|NCT03308942|Experimental|Stage 2 (Cohort 1A): Niraparib plus TSR-042 (Dostarlimab)|Participants with locally advanced and metastatic NSCLC (all histologies) with no prior systemic chemotherapy or PD-1/PD-L1 inhibitor treatment and whose tumors have high PD-L1 expression (TPS: >= 50%) will receive combination of niraparib and a PD-1 inhibitor; TSR-042 (Dostarlimab).
89189620|NCT05568953|Experimental|Arm 3 (Inactivated JE vaccine followed by YF17D vaccine)|14 subjects will receive one dose of the inactivated JE vaccine (Ixiaro, Valneva, 0.5mls) on Day 0 followed by one dose of the YF17D vaccine (Stamaril, Sanofi Pasteur, 0.5mls (3 - 4 log PFU)) on Day 28.
89401480|NCT01378507|Experimental|Endoscopic Submucosal Dissection|Single-arm for ESD procedure and retrospective surgical procedure(Laparoscopy, Open surgery)data collection
89401481|NCT02078466|No Intervention|Control group|Usual care
89401482|NCT02078466|Experimental|Assessment of functional ability|Assessment of functional ability and follow-up at home
89401483|NCT02223104|Active Comparator|Sensura|Ostomy pouch
89401484|NCT02223104|Experimental|Flexima Active|Ostomy pouch
89401485|NCT01379443|Active Comparator|Parental reports of their children|Parental report of family-centered processes of care (MPOC) Parent mental health Parent perceived social support
89401486|NCT01379443|No Intervention|Integration of service provider teams|Network co-alition teams were measured using the Integration of Human Services Measure, the Partnership Synergy Measure and a Network Capacity Measure were employed at the CEO level.
89401487|NCT02231138|Experimental|Abelmoschus manihot (AM)|"age above 12 years old (including 12)：huangkui capsule are given orally at 2.5 g three times per day~age between 6-12 years old(including 6):huangkui capsule are given orally at 1.5 g three times per day~age under 6 years old：huangkui capsule are given orally at 1.0 g three times per day"
89189621|NCT05563896||China|We plan to enroll 200 healthy adults in this study at five different international sites (China, Iran, Kenya, Senegal, UAE). Forty subjects will be enrolled at each site. Previous studies showed energy requirements varied with sex and age of the participants. Therefore, in each site, 20 males and 20 females will be recruited respectively. The samples will comprise individuals aged 18-50. Half will be male and half female. Half of the samples will be collected in 'summer' (June, July and August) and half in 'winter' (October, November and December). The same individuals will not be measured in both seasons.
89401488|NCT02075424|Experimental|salivery sampling by a biomnis swab|"Each call operator will have a series of salivary sampling taken when assigned to call reception, to the unit deployment station and to the assessment station.~Only one sampling will occur to doctors who are assigned to a single workstation.~Sampling will be taken every 15 minutes during one hour and half and one last sample will be taken 2 hours after the call For each participant, a serie of control-samples will be taken during a day off and during a security break."
89401489|NCT05111119|Experimental|Making PrEP Smart|The Making PrEP Smart intervention is a mobile-based application which provides PrEP adherence reminders and supports HIV-self and partner testing for cis- and transgender women.
89401490|NCT02075502|Experimental|Exercise therapy|Claudication, no peripheral revasc
89401491|NCT02075502|Placebo Comparator|Exercise advice|Claudication, no peripheral revasc
89401492|NCT02075502|Experimental|lower extremity ET, exercise therapy|
89401493|NCT02075502|Placebo Comparator|lower extremity ET, exercise advice|
89401494|NCT02075502|Experimental|Peripheral open intervention, exercise therapy|
89401495|NCT02075502|Placebo Comparator|Peripheral open intervention, exercise advice|
89401496|NCT02477384|Active Comparator|8mm-TIPS|Patients in this group would underwent TIPS placement with 8mm-diameter ePTFE-covered stents.
89401497|NCT02477384|Active Comparator|EVL plus propranolol|Patients in this group would underwent sequential endoscopic variceal ligation and propranolol treatment.
89401498|NCT03709771||VEGF inhibitor alone|
89401499|NCT03709771||Immune Checkpoint Inhibitor (ICI) alone|
89401500|NCT03709771||Combination (VEGF inhibitor + ICI, or combination of ICI)|
89401501|NCT03709771||No treatment|
89401502|NCT02075580|Experimental|psychological support|Arm A will undergo psychological support and standard care prior and post TIVAD (Totally Implantable Venous Access Devices) insertion Arm B will undergo standard care prior and post TIVAD insertion
89401503|NCT02075580|No Intervention|standard care|this arm does not receive psychological support before and after Totally Implantable Venous Access Devices positioning
89401504|NCT02226692||nonspecific chronic low back pain|Physical examination and follow-up assessment by questionnaires at 2, 4, 6, and 12 months
89401505|NCT05001295|Experimental|Physical Activity|
89401506|NCT05001295|Placebo Comparator|Daily Live|
89401507|NCT02226770|Other|ICD|Implantation of an Implantable Cardioverter Defibrillator (ICD) in patients with heart failure
89401508|NCT04335253|Experimental|Multiple Ascending Dose|Dose escalation according to cohort allocation
89401509|NCT03780114||interns|intern pediatric dentists
89401510|NCT02231216|Experimental|Rhinoseptoplasty and turbinectomy|Patients submitted to rhinoseptoplasty associated to Endoscopic partial turbinectomy.
89401511|NCT02231216|Active Comparator|Rhinoseptoplasty|Patients submitted only to rhinoseptoplasty, without turbinectomy procedure.
89401512|NCT03633721|Active Comparator|HIV positive; cannabis|HIV positive women will be given cannabis and tested
89401513|NCT03633721|Active Comparator|HIV positive; placebo|HIV positive women will be given placebo and tested
89401514|NCT03633721|Active Comparator|HIV negative; cannabis|HIV negative women will be given cannabis and tested
89401515|NCT03633721|Active Comparator|HIV negative; placebo|HIV negative women will be given placebo and tested
89401516|NCT02081898|No Intervention|control group|weight maintenance diet
89401517|NCT02081898|Experimental|low calorie diet (LCD) group|approximate 100 kcal/d calorie deficit
89401518|NCT02081976|Active Comparator|Standard Care Group|Dental therapist providing standard periodontal treatment
89401519|NCT02081976|Experimental|Integrated Care Group|a combined treatment approach of Dental Therapist, Dental Hygienist, Cardiologist along with counselor
89401520|NCT02231294||Idiopathic Parkinson's Disease Patients|
89401521|NCT04962139|Experimental|ON101 Cream plus Standard of Care|ON101 cream will be applied twice daily for up to 20 weeks to the Target Ulcer. The SOC will include evaluation to ensure adequate blood flow, wound cleaning, removal of necrotic, infected and/or nonviable tissue by debridement, maintenance of a moist wound environment via regular dressing changes, and management of infection through oral antibiotics, if necessary.
89401522|NCT04962139|Placebo Comparator|Vehicle Cream plus Standard of Care|"Vehicle cream will be applied twice daily for up to 20 weeks to the Target Ulcer.~The SOC will include evaluation to ensure adequate blood flow, wound cleaning, removal of necrotic, infected and/or nonviable tissue by debridement, maintenance of a moist wound environment via regular dressing changes, and management of infection through oral antibiotics, if necessary."
89401523|NCT02223416|Experimental|RGB-10|
89401524|NCT02223416|Active Comparator|Forsteo|
89401525|NCT02082054|Experimental|PSE 120 mg, CM 8 mg, Atr 0.36 mg|Pseudoephedrine 120 mg,chlorpheniramine 8 mg, atropine 0.36 mg tablet dosed BID for 7.5 days
89401526|NCT02082054|Experimental|PSE 120 mg, CM 8 mg, Atr 0.24 mg|Pseudoephedrine 120 mg, chlorpheniramine 8 mg, atropine 0.24 mg tablets dosed BID for 7.5 days
89401527|NCT02082054|Experimental|PSE 120 mg, CM 8 mg, Atr 0.12 mg|Pseudoephedrine 120 mg, chlorpheniramine 8 mg, atropine 0.12 dosed BID for 7.5 days
89401528|NCT02082054|Active Comparator|PSE 120 mg, CM 8 mg|"Pseudoephedrine 120 mg, chlorpheniramine 8 mg white, scored, tablets with M27 on scored side and plain on the other side"
89401529|NCT02082054|Experimental|Atropine 0.24 mg|Atropine 0.24 mg tablets dosed BID for 7.5 days
89401530|NCT02231372||chronic obstructive airways disease patients|
89401531|NCT04923529|Experimental|TAS-102|Single group assignment of TAS-102 in Patients with Advanced, Refractory Pancreatic Adenocarcinoma
89401532|NCT03559296||Study Group|patients with postmastectomy lymphedema who will undergo ultrasonographic assessment of postmastectomy lymphedema and circumferential tape measurement of arm
89401533|NCT02884544|Experimental|HLD100 10mg|HLD100 (dextroamphetamine sulfate) DR/ER capsules (10mg)
89401534|NCT02884544|Experimental|HLD100 20mg|HLD100 (dextroamphetamine sulfate) DR/ER capsules (20mg)
89401535|NCT02884544|Experimental|HLD100 30mg|HLD100 (dextroamphetamine sulfate) DR/ER capsules (30mg)
88876833|NCT03308942|Experimental|Stage 2 (Cohort 2A): Niraparib plus TSR-042 (Dostarlimab)|Participants with locally advanced and metastatic NSCLC (all histologies) with no prior systemic chemotherapy or PD-1/PD-L1 inhibitor treatment and whose tumors have PD-L1 expression (TPS: 1% to 49%) will receive combination of niraparib and a PD-1 inhibitor; TSR-042 (Dostarlimab).
88876834|NCT03301857|Experimental|Denosumab|"Cohort A (subjects who are still being treated with denosumab when 20062004 completes): 120 mg administered subcutaneously (SC) every 4 weeks (Q4W).~For subjects undergoing retreatment with denosumab: 120 mg administered SC on Days 1, 8, 15 and 28 then every 4 weeks subsequently."
88876835|NCT03301857|No Intervention|Safety Follow up|"Subjects still receiving treatment will have follow-up study visits in the clinic every 6 months while receiving denosumab (Cohort A).~Subjects who completed denosumab treatment and were in safety follow-up at the conclusion of 20062004 will have follow-up visits performed every 6 months via telephone or in-person clinic visit (Cohort B)."
88876836|NCT03291431|Active Comparator|Active iTBS|Participants will be randomized to active or sham iTBS.
88876837|NCT03291431|Sham Comparator|Sham iTBS|Participants will be randomized to active or sham iTBS.
88876838|NCT03289949|Other|Project 1: Occupancy of psilocybin/ketanserin|After baseline MRI & 5-HT2AR PET-imaging, participants will be allocated to undergo either one oral dose of psilocybine or one oral dose of ketanserin. After drug administration, participants will undergo two CIMBI-36 PET scans.
89004128|NCT02648477|Experimental|Cohort 2 (pembrolizumab, anti-estrogen therapy)|"Patients receive pembrolizumab IV over 30 minutes on day 1 and an aromatase inhibitor (exemestane, anastrozole, or letrozole) PO QD on days 1-21. Treatment repeats every 3 weeks for 24 months in the absence of disease progression or unacceptable toxicity.~In both arms, patients who stop pembrolizumab with stable disease or better may receive additional pembrolizumab therapy for up to 1 year if they progress after stopping study treatment."
89401536|NCT02884544|Experimental|HLD100 40mg|HLD100 (dextroamphetamine sulfate) DR/ER capsules (40mg)
89401537|NCT02226926|Experimental|Aggrenox|Dipyridamole extended release / Acetylsalicylic acid
89401538|NCT02226926|Active Comparator|Persantin Retard|Dipyridamole extended release
89401539|NCT02226926|Active Comparator|Acetylsalicylic acid|
89401540|NCT02075892|Active Comparator|Mushroom Blend|4 grams daily; oral; 7 and 21 days
89401541|NCT02075892|Placebo Comparator|Placebo|4 grams maltodextrin, oral, 7 and 21 days
89401542|NCT02227004||MRI in patients with Pacemaker or ICD|Perform MRI in patients with pacemaker or ICD and evaluate patient and device safety
89401543|NCT02924883|Experimental|Trastuzumab Emtansine + Atezolizumab|Atezolizumab 1200 milligrams (mg) intravenous (IV) infusion or matching Placebo followed by trastuzumab emtansine 3.6 milligrams per kilogram (mg/kg) IV infusion on Day 1 Cycle 1 and thereafter on Day 1 of each 21-day cycle until disease progression, unmanageable toxicity, or study termination by the Sponsor (approximately 29 months)
89401544|NCT02924883|Active Comparator|Trastuzumab Emtansine + Placebo|Placebo matched to atezolizumab followed by trastuzumab emtansine 3.6 mg/kg IV infusion on Day 1 Cycle 1 and thereafter on Day 1 of each 21-day cycle until disease progression, unmanageable toxicity, or study termination by the sponsor (approximately 29 months)
89401545|NCT02075970|Experimental|Epoetin Alpha study 1|"Epoetin Alpha Tthe number of separate doses (per kg) to be given over 4 weeks by day of age will not exceed 10. These will be administered as follows: day of life (DOL) 2 (1200 U), DOL 4 (600 U), DOL 5 (600 U), DOL 6 (600U), DOL 7 (600 U), DOL 9 (600 U), DOL 14 (600 U), DOL 15 (600 U), DOL 16 (1200 U), and DOL 28 (600 U). The greatest dose in any 1 wk period is 3600 U.~Infant study 1 Drug Intervention: all infants will be treated with Epoetin Alpha during the first four weeks of life to provide data for determining: 1) the PK/PD model determined optimized Epoetin Alpha dosing schedule; and 2) clinical and laboratory covariates predictive of which infants are good and poor Epoetin Alpha responder."
89401546|NCT02075970|Placebo Comparator|Epoetin Alpha study 2|"Epoetin Alpha dosing schedule will be determined based on the results of Infant Study 1.~Infant Study 2 is a randomized, masked study to test the hypothesis that optimized Epoetin Alpha treatment of VLBW infants predicted to be good responders will result in the elimination of RBCTx relative to poor responders.~Infant Study 2 in Years 4 and 5 will make use of the knowledge acquired in Infant Study 1 to test the central hypothesis that RBCTX can be eliminated in the majority of good Epoetin Alpha responders by optimal administration of Epoetin Alpha, but only marginal reductions in RBCTx will occur in the poor Epoetin Alpha responders."
89401547|NCT02075970|Experimental|Biotinylated red blood cells|Individual fetal RBC lifespans will be determined by administering biotinylated red blood cells, both autologous and allogeneic, simultaneously. Left over red blood cells are examined to determine red cell survival.
89401548|NCT03432325|Experimental|Neural Enabled Prosthesis|Neural Enabled Prosthesis Treatment Group
89401549|NCT02231450|Experimental|Patients with mild hepatic impairment (Group1)|8 patients with mild hepatic impairment will be administered a single oral dose of 60 mg Lu AE58054
89401550|NCT02231450|Experimental|Patients with moderate hepatic impairment (Group 2)|8 patients with moderate hepatic impairment will be administered a single oral dose of 60 mg Lu AE58054.
89401551|NCT02231450|Experimental|Healthy subjects (Group 3)|8 healthy subjects will be administered a single oral dose of 60 mg Lu AE58054.
89401552|NCT02078622||COPD, Education and Case Management|Respiratory Therapist Education and Case Management
89401553|NCT02259062|Active Comparator|Music listening|
89401554|NCT02259062|Experimental|Music listening with brief mindfulness|
89401555|NCT02259062|Placebo Comparator|Audio book intervention|
89401556|NCT02078700|Experimental|early palliative care programme|Patients will be proposed to be followed by the Palliative Care Team
89401557|NCT05763277||Ate-Bev|Individuals diagnosed with advanced hepatocellular carcinoma and treated with atezolizumab-bevacizumab between the ages of 18-80 were included. According to the recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Organ Dysfunction, patients with comorbidities were excluded.
89401558|NCT02227082|Experimental|radiotherapy and olaparib|radiotherapy: 61.18 Gy olaparib: dose escalating
88876839|NCT03289949|Other|Project 2: Long term effects of psilocybin|"After baseline MRI & CIMBI-36 PET-imaging, participants will receive one dose of oral psilocybine intervention. One and 12 weeks after dosing, participants will undergo post-intervention PET-scan.~Subproject B: After baseline MRI & UCB-J PET-imaging, participants will receive one dose of oral psilocybine intervention. One week after dosing, participants will undergo post-intervention UCB-J PET-scan.~Subproject C: After baseline MR imaging, participants will receive one dose of oral psilocybine (25 mg) or placebo. One month after dosing, participants will undergo a post-intervention MRI scan."
88876840|NCT03289949|Other|Project 3: Functional connectivity|After baseline MRI scanning and CIMBI-36 PET, participants will undergo one psilocybine-intervention fMRI scan and one ketanserin-intervention fMRI scan. If P2 shows there are long term effects of psilocybine on 5-HT2AR levels, psilocybine will be fixed as the second intervention. If not, interventions will be randomized.
88876841|NCT03261401|Placebo Comparator|Part A: Placebo (Pooled)|Participants received capsules containing 50 milligram (mg) of placebo matched similar to M5717 on Day 1 after 8 hours fasting-period followed by a 4-hour post-dose.
88876842|NCT03261401|Experimental|Part A: Cohort 1 SAD: M5717 50 mg|Participants received single ascending dose (SAD) of 50 mg M5717 on Day 1 after 8 hours fasting-period followed by a 4-hour post-dose fast.
89004129|NCT02632721|Experimental|Phase I dose escalation: BI 836858 20 mg + decitabine (intensive)|Dose escalation.
88876843|NCT03261401|Experimental|Part A: Cohort 2 SAD: M5717 100 mg|Participants received SAD of 100 mg M5717 on Day 1 after 8 hours fasting-period followed by a 4-hour post-dose fast.
88876844|NCT03261401|Experimental|Part A: Cohort 3 SAD: M5717 200 mg|Participants received SAD of 200 mg M5717 on Day 1 after 8 hours fasting-period followed by a 4-hour post-dose fast.
89004130|NCT02632721|Experimental|Phase I dose escalation: BI 836858 40 mg + decitabine (intensive)|Dose escalation.
89401559|NCT03670485|Experimental|Revised sequential activation protocol|"Apply 4 channel electrical stimulation device with a revised sequential activation protocol.~It sequentially activates Rt. suprahyoid m (ch 1), Lt. suprahyoid m (ch 2), thyrohyoid m (ch 3), sternothyroid m (ch 4) with 4 channel electrical stimulation device."
89401560|NCT03670485|No Intervention|control subject|Apply 4 channel electrical stimulation device without any stimulation
89401561|NCT02227160|Experimental|Psychosocial group intervention|Subjects will seek outpatient counseling, support groups, in addition to 10 weekly group meetings
88876845|NCT03261401|Experimental|Part A: Cohort 4 SAD: M5717 400 mg|Participants received SAD of 400 mg M5717 on Day 1 after 8 hours fasting-period followed by a 4-hour post-dose fast.
89401562|NCT02227160|Active Comparator|Control|Subjects will seek outpatient counseling and support groups only
88876846|NCT03261401|Experimental|Part A: Cohort 5 SAD: M5717 600 mg|Participants received SAD of 600 mg M5717 on Day 1 after 8 hours fasting-period followed by a 4-hour post-dose fast.
88876847|NCT03261401|Experimental|Part A: Cohort 6 SAD: M5717 1000 mg|Participants received SAD of 1000 mg M5717 on Day 1 after 8 hours fasting-period followed by a 4-hour post-dose fast.
88876848|NCT03261401|Experimental|Part A: Cohort 7 SAD: M5717 1250 mg|Participants in SAD received an oral dose of 1250 mg M5717 on Day 1 after 8 hours fasting-period followed by a 4-hour post-dose fast.
88876849|NCT03261401|Experimental|Part A: Cohort 8 SAD: M5717 1800 mg|Participants in SAD received an oral dose of 1800 mg M5717 on Day 1 after 8 hours fasting-period followed by a 4-hour post-dose fast.
88876850|NCT03261401|Experimental|Part A: Cohort 9 SAD: M5717 2100 mg|Participants in SAD received an oral dose of 2100 mg M5717 on Day 1 after 8 hours fasting-period followed by a 4-hour post-dose fast.
88876851|NCT03261401|Experimental|Part C: Challenge Cohort 2 M5717 150 mg|Participants received single oral dose of 150 mg M5717 (eight days after the administration of intravenous malaria inoculum) on Day 1 after 8 hours fasting-period followed by a 4-hour post-dose fast.
88876852|NCT03261401|Experimental|Part C: Challenge Cohort 1 M5717 400 mg|Participants received single oral dose of 400 mg M5717 (eight days after the administration of intravenous malaria inoculum) on Day 1 after 8 hours fasting-period followed by a 4-hour post-dose fast.
88876853|NCT03261401|Experimental|Part C: Challenge Cohort 3 M5717 800 mg|Participants received single oral dose of 800 mg M5717 (eight days after the administration of intravenous malaria inoculum) on Day 1 after 8 hours fasting-period followed by a 4-hour post-dose fast.
88876854|NCT03191461||Cancer Patients|Cancer patients with Stage I-III breast cancer or lymphoma that have received an anthracycline agent during treatment at least 2 years prior to enrollment in this study. Adenosine stress test MRI will be performed.
88876855|NCT03191461||Healthy Controls|Age-matched Healthy Control to cancer survivor with no history of cancer or anthracycline treatment. Adenosine stress test MRI will be performed.
88876856|NCT03166644|Experimental|Control Group|Patients with major abdominal surgery
88876857|NCT03166644|Experimental|Intervention Group|Patients with standard practice
88876858|NCT03043976|Active Comparator|feedback and goal-setting group|At the baseline, patients will fill a questionnaire about their quality of life (SF36), will perform a 6'walk test (6MWT), will undertake a blood sample (BNP). In the run-in period (1 week) patients will wear an Actigraph GT9X Link device which only displays the time and the battery level; all activity data will be recorded. Then participants will wear an Actigraph GT9X Link device which shows real time data about the number of steps and will upload their data via the Study Admin Mobile application for smartphones/tablets. Patients will be asked to aim for an average specified number of steps/day week by week and will receive a weekly report with results from the previous week and targets to achieve. After 8 weeks, patients will attend visit 2 (6MWT, SF36 and BNP assessment) and will carry on wearing the activated device for 8 weeks receiving weekly feedbacks and targets. After 8 weeks patients will attend visit 3 (6MWD, SF36 and BNP will be assessed) which is the end of the study.
88876859|NCT03043976|Active Comparator|Control group|At the baseline, patients will fill a questionnaire about their quality of life (SF36), will perform a 6'WT and will undertake a blood sample (BNP). After a run-in period (1 week) with an Actigraph GT9X Link device disabled from showing the number of steps, patients will wear an Actigraph GT9X Link device which still only displays time and battery level and will upload data via the Study Admin Mobile application for smartphones/tablets without receiving any feedback. After 8 weeks, patients will be assessed (SF36, 6'WT, BNP) and will start to wear a new device enabled to display the daily step count. Patients will be asked to aim for an average specified number of steps/day, receiving a weekly summary of the previous week with targets to achieve week by week. After 8 weeks, patients will be assessed (6'WT, SF36, BNP) and will carry on wearing the device and receiving feedbacks and targets for a further 8 week period, after that patients will be finally assessed (SF36, 6'WT, BNP)
88876860|NCT03043976|Placebo Comparator|newly diagnosed patients|"In the week leading up to their inpatient admission for diagnostic investigations, patients who are treatment-naïve will be given the Actigraph GT9X Link device which will only display the time and the charge level of the battery. Patients will be asked, as well, to fill a questionnaire about their quality of life, to perform a 6MWT and a blood sample (BNP). As soon as patients start the drug therapy, patients will wear a second Actigraph GT9X Link device still disabled from showing real time data about the number of daily steps. Participants will not receive any feedback during the whole period and will be asked, as well, to upload the data collected through the remote mobile system. At their first clinical assessment (after about 4 or 5 weeks), 6'WT, BNP and questionnaire about quality of life will be reassessed.~If patients are not being started on drug therapy then they will be withdrawn from the study"
88876861|NCT02998528|Active Comparator|Platinum doublet chemotherapy|Specified dose on specified days
89401563|NCT02223494|Experimental|Terbogrel|
89401564|NCT03373435|Experimental|Treatment Group 1|patients will receive two dose regimens of exendin 9-39 and one placebo
89401565|NCT03373435|Experimental|Treatment Group 2|patients will receive two dose regimens of exendin 9-39 and one placebo (in a different sequence than Treatment Group 1)
89401566|NCT03670407|No Intervention|Control group|Participants who opt not to go ahead with ovarian fragmentation.
89401567|NCT03670407|Experimental|Study group|Participants who opt for ovarian fragmentation.
89401568|NCT01369680|Experimental|Ketamine 0.25 mg/kg/dose|The first three subjects were administered 0.25 mg/kg/dose oral ketamine.
89401569|NCT01369680|Experimental|Ketamine 0.5 mg/kg/dose|The second group of three subjects were administered 0.5 mg/kg/dose oral ketamine.
89401570|NCT01369680|Experimental|Ketamine 1 mg/kg/dose|The third group of three subjects were administered 1 mg/kg/dose oral ketamine.
89401571|NCT01369680|Experimental|Ketamine 1.5 mg/kg/dose|The fourth group of three subjects were administered 1.5 mg/kg/dose oral ketamine.
89401572|NCT03670329|Experimental|URGO2875|Dressing
89401573|NCT04780321|Active Comparator|Anti-SARS-CoV-2 Monoclonal Antibody dose 1/2/3|use Anti-SARS-CoV-2 Monoclonal Antibody,dose 1/2/3 to treat COVID-19
89401574|NCT04780321|Placebo Comparator|Placebo|use placebo to treat COVID-19
89401575|NCT02078778|Experimental|Treatment|Patients with hypertension and moderate to severe OSA is treated with CPAP for 3 months.
89004131|NCT02632721|Experimental|Phase I dose escalation: BI 836858 80 mg + decitabine (intensive)|Dose escalation.
89004132|NCT02632721|Experimental|Phase I Extension A: BI 836858 80 mg + decitabine (intensive)|Extension phase.
89004133|NCT02632721|Experimental|Phase I Extension B: BI 836858 80 mg + decitabine (standard)|Extension phase.
89004134|NCT02576509|Experimental|Nivolumab|Nivolumab specified dose on specified days
89004135|NCT02576509|Active Comparator|Sorafenib|Sorafenib specified dose on specified days
89004136|NCT02552836|Experimental|Interpersonal Psychotherapy (IPT)|Patients assigned to IPT will receive 12 sessions of individual therapy of approximately 50 minutes duration. Therapy will be manualized and slightly adapted to meet the needs of patients with Parkinson's Disease. Therapy focuses on one of four interpersonal events that are linked with onset or maintenance of depression (role transition, role disputes, unresolved grief, and interpersonal deficits).
89401576|NCT03669393|Experimental|THR-317|
89401577|NCT02076048||Previous LCPUFA Supplementation|Children between the ages of 7 and 10 that were previously enrolled in a study of supplemented LCPUFA formula.
89401578|NCT03670173|Experimental|Osalmid|Participants are initially given oral capsules with 0.5g tid osalmid daily for two weeks. Thereafter, the dosage will be increased by 0.25g tid every two weeks as tolerated by participants to a maximum daily dosage of 1.0g tid for up to one year. One course of osalmid treatment lasts four weeks. Response will be assessed at the end of each treatment course, and patients who have achieved MR (minor remission) or more than MR at the end of the fourth course will continue to take 1.0g tid osalmid daily for consolidation / maintenance therapy. Otherwise, patients who have not achieved MR at the end of the fourth course and patients who are assessed for PD (progression of disease) at the end of each course will receive salvage treatment, such as a combined treatment of osalmid and dexamethasone or the VCD (bortezomib, cyclophosphamide and dexamethasone) regimen.
89401579|NCT02076126||Gastric aspirate|L/S ratio on the gastric aspirates are retrospectively compared with the possible development of RDS
89401580|NCT02076126||Hypopharyngeal secretion|L/S ratio on the hypopharyngeal secretions are retrospectively compared with the possible development of RDS
89401581|NCT02076204|Experimental|Home visiting|Home visiting group: Women will be randomized so that 60 percent can receive home visiting services and 40 percent are in the control group. Home visiting for low-income, pregnant women - whereby individualized in-home services (including direct education, assessments, and referrals to community resources) are provided to families - has been identified by the Strong Start initiative as one promising method for reaching women who are vulnerable to poor birth outcomes.
89401582|NCT02076204|No Intervention|Non-Home Visiting|Control group: As described above, women will be randomized so that 60 percent can receive home visiting services and 40 percent are in the control group.The home visiting program will provide control group families with referrals to other appropriate services in the community.
89401583|NCT01378039|Other|Budesonide|patients who gave their agreement were randomised to 3 months treatment with either inhaled budesonide (400 µg BD) or placebo
89401584|NCT02473341|Experimental|Bovine colostrum|"Protein 1.5 gm/kg/day, energy (kcal) 30-40/day, B complex vitamins daily. Pasteurized Bovine colostrum as a freeze dried powder (20 gm thrice a day) for 4 weeks.~+ Antibiotics + Diuretics +Terlipressin for HRS + acid suppression for prophylaxis against gastrointestinal hemorrhage + EVL for variceal bleed +drugs for HE if indicated"
89401585|NCT02473341|Placebo Comparator|Placebo|"Protein 1.5 gm/kg/day, energy (kcal) 30-40/day, B complex vitamins daily. Placebo (Pasteurised Milk Powder) 20 gms thrice a day for 4 weeks~+ Antibiotics + Diuretics + drugs for HE + Terlipressin for HRS + acid suppression for prophylaxis against gastrointestinal hemorrhage + EVL for variceal bleed + if indicated."
89401586|NCT03240679|Active Comparator|Endoscopic submucosal resection with Extracelluar Matrix|Subjects with lesions that lift and are amenable to cap-assisted endoscopic submucosal resection (EMR) will receive extracellular matrix (ECM) to the defect site.
89189622|NCT05563896||Sénégal|Forty subjects will be enrolled at Senegal site.In Senegal site, 20 males and 20 females will be recruited respectively. The samples will comprise individuals aged 18-50. Half will be male and half female. Half of the samples will be collected in 'summer' (June, July and August) and half in 'winter' (October, November and December). The same individuals will not be measured in both seasons.
89189623|NCT05563896||Kenya|Forty subjects will be enrolled at Kenya site.In Kenya site, 20 males and 20 females will be recruited respectively. The samples will comprise individuals aged 18-50. Half will be male and half female. Half of the samples will be collected in 'summer' (June, July and August) and half in 'winter' (October, November and December). The same individuals will not be measured in both seasons.
89401587|NCT03240679|No Intervention|Endoscopic submucosal resection standard of care|Subjects with lesions that lift and are amenable to cap-assisted endoscopic submucosal resection (EMR) will receive standard of care.
89004137|NCT02552836|Active Comparator|Supportive Psychotherapy (SP)|Patients assigned to SP will receive 12 sessions of individual therapy of approximately 50 minutes duration. SP strives to create a supportive therapeutic relationship by emphasizing non-specific therapeutic interactions and techniques. Therapy will be manualized,
89004139|NCT02408861|Experimental|Treatment (nivolumab, ipilimumab)|Patients receive nivolumab IV over 30 minutes on day 1. Patients in dose level 2 also receive ipilimumab IV over 90 minutes on day 1 of every third cycle of nivolumab, and patients in dose level -2 also receive ipilimumab IV over 90 minutes on day 1 of every sixth cycle of nivolumab. Treatment repeats every 14 days for up to 46 cycles of nivolumab (with ipilimumab if receiving dose level 2 or -2) in the absence of disease progression or unacceptable toxicity.Patients undergo blood sample collection throughout the study. Patients undergo PET and CT scan during screening and on study. Patients undergo bone marrow biopsy on screening and may undergo it during follow up.
89401588|NCT02083224||Cancer patients|
89401589|NCT01377961|Active Comparator|Arm1: Metabolic Syndrome Volunteers|
89401590|NCT01377961|Active Comparator|Arm 2:Previously Diagnosed diabetic patients|
89401591|NCT02074956|Experimental|Cohort 1 AERAS-404|"H4 Antigen at 5 ug IC31 Adjuvant 500 nmol~2 doses at Study days 0 and 56"
89401592|NCT02074956|Experimental|Cohort 2 AERAS-404|"H4 Antigen at 15 ug IC31 Adjuvant 500 nmol~2 doses at Study days 0 and 56"
89004140|NCT02398656|Experimental|Tenecteplase (tNK)|Experimental: TNK-tPA (0.25mg/kg) given as a single, intravenous bolus immediately upon randomization. Experimental treatment will be administered as a single intravenous bolus over 1-2 minutes as per the standard manufacturers' instructions for use. Tenecteplase, a genetically engineered mutant tissue plasminogen activator, has a longer half-life, is more fibrin specific, produces less systemic depletion of circulating fibrinogen, and is more resistant to plasminogen activator inhibitor than alteplase.
89004141|NCT02398656|Active Comparator|Control (Antiplatelet Agents)|Control: Patients will be treated with standard of care based antiplatelet treatment - choice at the discretion of the investigator. Low dose aspirin (single agent) will be the choice of most physicians, some will chose to use the combination of aspirin and clopidogrel. As this is a multi-centre, international trial where local practices will vary, rather than mandating a specific antiplatelet agent, we will allow the local investigator to chose which antithrombotic regime should be used. Standard of care medication(s) should be given immediately upon randomization.
89401593|NCT02074956|Experimental|Cohort 3 AERAS-404|"H4 Antigen at 50 ug IC31 Adjuvant 500 nmol~2 doses at Study days 0 and 56"
89401594|NCT02074956|Experimental|Cohort 4 AERAS-404|"H4 Antigen at 150 ug IC31 Adjuvant 500 nmol~2 doses at Study days 0 and 56"
89401595|NCT02074956|Experimental|Cohort 5 AERAS-404|"H4 Antigen at 5 ug or 15 ug IC31 Adjuvant 100 nmol Placebo - sterile buffer~2 doses at Study days 0 and 56"
89401596|NCT03558750|Experimental|Treatment (nivolumab, rituximab, lenalidomide)|Nivolumab give by IV over 60 minutes on days 1 and 15, rituximab IV on day 1, and lenalidomide by mouth once per day on days 1-21. Repeats every 28 days for up to of 8 courses in the absence of disease progression or unacceptable toxicity. Patients with partial response or stable disease at the end of 8 cycles will be offered lenalidomide and nivolumab maintenance for up to 12 courses.
89401597|NCT02083302|Experimental|Treatment1|The Treatment1 group received SCREAM Theater Dose 1, SCREAM Theater Dose 2 and SCREAM Theater Dose 3.
89004142|NCT02386917|Active Comparator|Gastric bypass|40 patients will undergo gastric bypass
89004143|NCT02386917|Active Comparator|Very low calorie diet|40 patients will undergo a very low calorie diet
89004144|NCT02386917|No Intervention|Gall bladder operation|20 patients will be asked to undergo one pharmacokinetic study only, and then finish the study. They will not undergo any weight loss intervention.
89004145|NCT02374242|Active Comparator|Cohort 1 Nivolumab Monotherapy|Nivolumab 3mg/kg every 2 weeks, until disease progression, withdrawn consent, unacceptable toxicity or death.
89189624|NCT05563896||United Arab Emirates|Forty subjects will be enrolled at UAE site.In UAE site, 20 males and 20 females will be recruited respectively. The samples will comprise individuals aged 18-50. Half will be male and half female. Half of the samples will be collected in 'summer' (June, July and August) and half in 'winter' (October, November and December). The same individuals will not be measured in both seasons.
89401598|NCT02083302|Experimental|Treatment2|The Treatment2 group received SCREAM Theater Dose 1, SCREAM Theater Dose 2, SCREAM Theater Dose 3 and SCREAM Theater Dose 4.
89401599|NCT02083302|Other|Control|The control group received SCREAM Theater Dose 1.
89401600|NCT03559140|Experimental|Group A|"The R25 (size 25/ .08) instrument was used in thin and curved root canals, and R40 files (40/ .06) were used in wide root canals. Three in-and-out pecking motions were used with an amplitude of not more than 3 mm until reaching the estimated working length.~After the procedure cryotherapy will be applied as follows:~Patients assigned to this group receive a final irrigation (application of cryotherapy) with 5 mL cold (2.5oC) 17% EDTA followed with 20 mL cold (2.5oC) sterile saline solution delivered to the WL using a cold (2.5oC) sterile microcannula attached to the Endo Vac System (Kerr Endo) for 5 minutes"
89401601|NCT03559140|Experimental|Group B|"Canals were prepared as in group A, Patients assigned to this group receive (application of criotherapy)~A final irrigation will be applied with 5 mL cold (2.5oC) 17% EDTA followed with 20 mL cold (2.5oC) sterile saline solution delivered to the WL using a cold (2.5oC) sterile microcannula attached to the Endo Vac System (Kerr Endo) for 5 minutes. was applied. as follows:~Patients assigned to this group receive a final irrigation (application of cryotherapy) with 5 mL cold (2.5oC) 17% EDTA followed with 20 mL cold (2.5oC) sterile saline solution delivered to the WL using a cold (2.5oC) sterile microcannula attached to the Endo Vac System (Kerr Endo) for 5 minutes"
89401602|NCT03559140|Experimental|Control Group (CG)|"The R25 (size 25/ .08) instrument was used in thin and curved root canals, and R40 files (40/ .06) were used in wide root canals. Three in-and-out pecking motions were used with an amplitude of not more than 3 mm until reaching the estimated working length. Reciproc instruments were used in one tooth only (single use).~The group will receive the irrigant solution at room temperature. as follows:~they will receive a final irrigation ( application of irrigant at room temperature) with 5 mL (room temperature) 17% EDTA followed with 20 mL (room temperature) sterile saline solution delivered to the WL using a sterile microcannula attached to the Endo Vac System (Kerr Endo) for 5 minutes."
89401603|NCT02082366|Active Comparator|conventional irrigated ablation catheter|"TCD testing during procedure from trans-septal puncture until completion using a conventional irrigated ablation catheter.~Intervention: TCD monitoring of microembolic signal during procedure"
89004146|NCT02374242|Active Comparator|Cohort 2 Nivolumab Monotherapy|Nivolumab 3mg/kg every 2 weeks, until disease progression, withdrawn consent, unacceptable toxicity or death.
89401604|NCT02082366|Active Comparator|nMARQ circumferential irrigated catheter|"TCD testing during procedure from trans-septal puncture until completion using the nMARQ circumferential irrigated catheter.~Intervention: TCD monitoring of microembolic signal during procedure"
88876862|NCT02998528|Experimental|Nivolumab plus platinum doublet chemotherapy|Specified dose on specified days
89401605|NCT02082444|Experimental|Having lunch/skipping lunch|Lunch ad libitum on test day 1 and no lunch on test day 2. Water at libitum was constantly available on both days.
89401606|NCT02082600|Experimental|Sleep deprivation|Exercise induced-muscle damage protocol followed by 60h of sleep deprivation (two nights) and one night of normal sleep (rebound).
89401607|NCT02082600|Experimental|Normal sleep|Exercise induced-muscle damage protocol followed by 3 nights of normal sleep
89401608|NCT02078934|Experimental|Weight Loss|Patients with complex incisional/ventral hernias who are too obese to undergo hernia repair.
89401609|NCT03074149||Idiopathic Pulmonary Fibrosis (IPF) patients with less than 6 months diagnosis|
89401610|NCT03074149||Idiopathic Pulmonary Fibrosis (IPF) patients with equal or more than 6 months diagnosis|
89401611|NCT03558594|Experimental|Hypnosis|Participant will have one brief meeting with a clinician in which they will learn about hypnosis and be provided with an informational booklet and with audiorecordings of hypnosis exercises. Participants will be encouraged to listen to the hypnosis recordings as much as they would like, whenever they would like to listen. The recordings are short inductions followed by therapeutic suggestions, including post-hypnotic suggestions. Participants will relax in a comfortable position with their eyes closed and will simply listen to the audio recordings that will include an induction followed by suggestions for decreased pain and improvement in co-morbid symptoms (e.g., improved mood and optimism, relaxation, sleep quality).
89401612|NCT03558594|Experimental|Mindfulness|Participant will have one brief meeting with a clinician in which they will learn about mindfulness meditation and be provided with an informational booklet and with audio recordings of mindfulness exercises. Participants will learn Vipassana meditation by listening to audio recordings, which is the specific form of mindfulness meditation (MM) typically implemented in mindfulness research. The emphasis is placed upon developing focused attention on an object of awareness, such as the breath. This focus is then expanded to include a more open, non-judgmental monitoring of any sensory, emotional, or cognitive events.Participants will be encouraged to listen to the meditation recordings as much as they would like, whenever they would like to listen.
88876863|NCT02998528|Experimental|Nivolumab plus Ipilimumab|Specified dose on specified days
88876864|NCT02933255|Experimental|Lead-in mCRPC Cohort|PROSTVAC-V on week 0 followed by booster injection called PROSTVAC-F every 2 weeks. When administered on the same day, the preferred order of administration is PROSTVAC first followed by nivolumab. Participants will undergo sigmoidoscopies on week 9 and restaging scans on week 12. If no PD, option to continue treatment every 2 weeks until intolerance or progression. Option to extend nivolumab interval to 4 weeks after 1 year
88876865|NCT02933255|Experimental|Neoadjuvant Cohort|PROSTVAC-V on week 0 followed by booster injection called PROSTVAC-F on 2, 4 and 8 weeks. When administered on the same day, the preferred order of administration is PROSTVAC first followed by nivolumab. Participants will undergo prostatectomy on week 9.
88876866|NCT02897427||Screening (specimen collection, HPV testing)|"STAGE I: Participants fill out a survey and undergo collection of blood and oral rinse samples.~STAGE II: Participants complete a head and neck exam by using brushing of the oropharyngeal mucosa, a thorough oropharyngeal exam including narrow band imaging, collection of oral rinse sample, transcervical ultrasonography of the neck lymph nodes and oropharynx, anoscopy, penile exam, and complete Papanicolaou/HPV testing. Participants undergo repeat oropharyngeal screening, oral HPV DNA test, oral HPV integration testing, ultrasound, and blood sample collection once every year for 5 years. Select participants will provide oral rinse sample by mail every six months."
88876867|NCT02828917|Experimental|MedJ-01 drug eluting stent|MedJ-01 Ridaforolimus eluting coronary stent system
88876868|NCT02768090|Experimental|Skin Patch|Sweat will be collected from inflammatory and neoplastic skin lesions with an FDA approved diagnostic skin patch for analysis with mass spectrometry
88876869|NCT02736045|No Intervention|Control|Sham control. Subjects will be asked to write a journal (per week).
88876870|NCT02736045|Experimental|emWave|Our approach will be to test the impact of a behavioral intervention through a smartphone application, emWave software, which will be provided to all our subjects. The intervention (emWave) is a tool that reduces stress by allowing individuals to be less reactive, think clearly, and make good decisions, especially under pressure. Fifty medical residents with high burnout symptoms will be randomized to receive an 8-week intervention.
88876871|NCT02726997|Experimental|Treatment (durvalumab, carboplatin, paclitaxel, questionnaire)|"NEOADJUVANT CHEMOTHERAPY: Before debulking surgery, patients receive durvalumab and carboplatin IV over 1 hour on day 1, and paclitaxel IV over 3 hours on days 1, 8, and 15. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo debulking surgery.~SURGERY: After 3 courses of chemotherapy, patients undergo debulking laparoscopic surgery.~ADJUVANT THERAPY: Beginning after debulking surgery, patients receive carboplatin IV over 1 hour on day 1, paclitaxel IV over 3 hours on days 1, 8, and 15, and durvalumab IV over 1 hour on day 1. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive durvalumab IV over 1 hour on day 1 and 15. Treatment repeats every 28 days for up to 7 courses in the absence of disease progression or unacceptable toxicity."
88921933|NCT06042179|No Intervention|Standard of Care PT|Standard of care PT services to included 3 to 5 therapy sessions per week, each session averaging between 20 to 50 minutes, delivered throughout the hospitalization. No specific instructions will be given to therapists providing standard of care PT, except that they cannot implement error augmentation training. Generally, standard of care PT during the initial hospitalization following acute stroke is provided with targeted patient-specific goals and typically primarily focuses on mobility and gait training. Most sessions are geared toward bed mobility, transfers and gait training with therapeutic exercises provided to target any muscle weakness identified.
89401613|NCT03558594|No Intervention|No intervention|Participants will enroll in the study, but do not select a study intervention. They will complete study assessments on the same schedule as those participants who select either experimental arm.
89401614|NCT02751320|Experimental|Experimental Dentifrice1|Participants will brush their natural teeth with a pre-wetted toothbrush and their assigned dentifrice for one timed minute, ensuring the enamel specimens retained within their mouths are not directly brushed. Participants should then rinse their mouths with 15ml of tap water for approximately 10s.
89401615|NCT02751320|Experimental|Experimental Dentifrice 2|Participants will brush their natural teeth with a pre-wetted toothbrush and their assigned dentifrice for one timed minute, ensuring the enamel specimens retained within their mouths are not directly brushed. Participants should then rinse their mouths with 15ml of tap water for approximately 10s.
89401616|NCT02751320|Experimental|Experimental Dentifrice 3|Participants will brush their natural teeth with a pre-wetted toothbrush and their assigned dentifrice for one timed minute, ensuring the enamel specimens retained within their mouths are not directly brushed. Participants should then rinse their mouths with 15ml of tap water for approximately 10s.
89401617|NCT02751320|Placebo Comparator|Reference Product 1|Participants will brush their natural teeth with a pre-wetted toothbrush and their assigned dentifrice for one timed minute, ensuring the enamel specimens retained within their mouths are not directly brushed. Participants should then rinse their mouths with 15ml of tap water for approximately 10s.
89401618|NCT02751320|Active Comparator|Reference Product 2|Participants will brush their natural teeth with a pre-wetted toothbrush and their assigned dentifrice for one timed minute, ensuring the enamel specimens retained within their mouths are not directly brushed. Participants should then rinse their mouths with 15ml of tap water for approximately 10s.
89401619|NCT02751320|Active Comparator|Reference Product 3|Participants will brush their natural teeth with a pre-wetted toothbrush and their assigned dentifrice for one timed minute, ensuring the enamel specimens retained within their mouths are not directly brushed. Participants should then rinse their mouths with 15ml of tap water for approximately 10s.
89401620|NCT02079012|Experimental|Intervention group|"Receives:~An information session~A 10-week walking program (with documents, pedometer and three information sessions about motivation, a healthy diet and smoking cessation)~A physical activity diary (which also functions as a tool to check protocol-compliance)~Measurements"
89401621|NCT02079012|No Intervention|Control group|Only receives measurements.
89401622|NCT02082756|Experimental|Bifidobacterium viable pharmaceutics|Bifidobacterium viable pharmaceutics, 2 Capsules, 2/day, 12 weeks
89401623|NCT02082756|Experimental|Berberine Hydrochloride|Berberine Hydrochloride, 0.5g, 2/day, 12 weeks
89401624|NCT02082756|No Intervention|lifestyle counseling|
89401625|NCT02223572|Experimental|osteoporotic hip fracture|
89401626|NCT04615845|Experimental|Cellgram-DC-PC|Cellgram-DC-PC is injected subcutaneously near the inguinal lymph nodes
89401627|NCT02259140|Active Comparator|Proximal Femoral Resection Arthroplasty|A 10-12 cm direct lateral incision will be made distally from the greater trochanter. The abductors of the hip are detached with sharp dissection. A capsulotomy is performed. The femur is exposed in a supra-periosteal manner (2 cm distal to the lesser trochanter) at the level of the ischium; transverse osteotomy will then be performed. The joint capsule will be sutured to itself. The iliopsoas tendon and the abductor tendons are attached to the capsule. The quadriceps will be brought around the proximal femoral stump and sutured to medial tissues.
89437450|NCT03890861|Experimental|Physical activity intervention|The intervention group will target 150 minutes of moderate to vigorous aerobic physical activity and two days of strength training, consistent with the current physical activity recommendations. Participants will engage in 2 days per week of supervised activity at community facilities. These participants will be requested to engage in an additional 30 minutes of moderate to vigorous aerobic physical activity two days per week at home.
89401628|NCT02259140|Experimental|Subtrochanteric Valgus Osteotomy|A 10-12 cm direct lateral incision will be made distally from the greater trochanter. The medial half of the abductors may be incised off the greater trochanter for repair. The femoral head is resected at the base of the neck. The ligamentum teres is incised off the head and preserved. A lateral closing wedge osteotomy is performed below the lesser trochanter. 3.5 or 4.5 5 hole locking/non-locking surgeon-contoured plate ( 45⁰) will be used to stabilize the osteotomy. Femoral torsion will be corrected. The psoas tendon will attach the ligamentum teres to the lesser trochanter. The anterior and posterior capsule is sutured together creating interposition tissue. If the ligamentum teres was sutured to the lesser trochanter, the capsule will not close, but will be covered by the psoas tendon.
89401629|NCT03559764|Experimental|Anti-BCMA CAR T cells|Total dose of 0.5-6 millions /kg cells will be administered at day -2, day -1 and day 0 by split dose (30%, 30% and 40% respectively).
89401630|NCT02082834|Experimental|EVAR|
88876872|NCT02718911|Experimental|LY3022855 + Durvalumab (Dose Escalation)|"Cohort D1A: LY3022855 (25 mg,QW)+Durvalumab (750mg,Q2W):~25 mg LY3022855 administered once weekly (QW) intravenously (IV) in combination with 750 mg durvalumab administered every 2 weeks (Q2W) IV. Treatment may continue until disease progression or discontinuation.~Cohort D2A: LY3022855 (50 mg,QW)+Durvalumab (750mg,Q2W) 50 mg LY3022855 administered QW intravenously (IV) in combination with 750 mg durvalumab administered Q2W IV. Treatment may continue until disease progression or discontinuation.~Cohort D3A: LY3022855 (75 mg,QW)+Durvalumab (750mg,Q2W) 75 mg LY3022855 administered QW intravenously (IV) in combination with 750 mg durvalumab administered Q2W IV. Treatment may continue until disease progression or discontinuation.~Cohort D4A: LY3022855 (100 mg,QW)+Durvalumab (750mg,Q2W) 100 mg LY3022855 administered QW intravenously (IV) in combination with 750 mg durvalumab administered Q2W IV. Treatment may continue until disease progression or discontinuation."
88876873|NCT02718911|Experimental|LY3022855 + Tremelimumab (Dose Escalation)|"Cohort T1A: LY3022855 (50 mg,QW) +Tremelimumab (75mg,Q4W):~50 mg LY3022855 administered QW intravenously (IV) in combination with 75 mg tremelimumab administered every 4 weeks (Q4W) IV. Treatment may continue until disease progression or discontinuation.~Cohort T2A: LY3022855 (100 mg,QW) +Tremelimumab (75mg,Q4W) 100 mg LY3022855 administered QW intravenously (IV) in combination with 75 mg tremelimumab administered Q4W IV. Treatment may continue until disease progression or discontinuation.~Cohort T3A: LY3022855 (100 mg,QW) +Tremelimumab (225 mg,Q4W) 100 mg LY3022855 administered QW intravenously (IV) in combination with 225 mg tremelimumab administered Q4W IV. Treatment may continue until disease progression or discontinuation.~Cohort T4A: LY3022855 (100 mg,QW) +Tremelimumab (750 mg,Q4W) 100 mg LY3022855 administered QW intravenously (IV) in combination with 750 mg tremelimumab administered Q4W IV. Treatment may continue until disease progression or discontinuation."
88876874|NCT02718911|Experimental|LY3022855 + Durvalumab (Expansion)|"Cohort B-1: NSCLC LY3022855+ Durvalumab:~100 mg LY3022855 administered QW intravenously (IV) in combination with 750 mg durvalumab administered Q2W IV. Treatment may continue until disease progression or discontinuation.~Cohort B-1: OVARIAN LY3022855+ Durvalumab:~100 mg LY3022855 administered QW intravenously (IV) in combination with 750 mg durvalumab administered Q2W IV. Treatment may continue until disease progression or discontinuation."
88876875|NCT02707887|Placebo Comparator|Treatment as Usual|Patients are offered substance use group therapy including relapse prevention. They are also provided medical consultation on an ongoing basis as needed.
88876876|NCT02707887|Active Comparator|LETS ACT|The Life Enhancement Treatment for Substance Use (LETS ACT) involves the discussion of the treatment rationale, identification of values and goals in various life areas and activities in line with chosen life areas, and training for patients to identify their cycle of negative mood and behavior using forms to track their daily goals.
88876877|NCT02707887|Active Comparator|LETS ACT-SE|Participants assigned to the smartphone-enhanced LETS ACT (LETS ACT-SE) condition will be provided the exact same treatment as outlined in LETS ACT, except that LETS ACT-SE participants will record their daily goals using smartphone technology.
89189625|NCT05563896||Iran|Forty subjects will be enrolled at Iran site.In Iran site, 20 males and 20 females will be recruited respectively. The samples will comprise individuals aged 18-50. Half will be male and half female. Half of the samples will be collected in 'summer' (June, July and August) and half in 'winter' (October, November and December). The same individuals will not be measured in both seasons.
88921934|NCT06042179|Experimental|Frequent PT services|This group will receive physical therapy services twice a day Monday through Friday and daily Saturday and Sunday. Most sessions are geared toward bed mobility, transfers and gait training with therapeutic exercises provided to target any muscle weakness identified.
89198948|NCT04902274|Sham Comparator|Sham Transcranial Direct Current Stimulation plus Physical Therapy|Participants in the sham control group will receive the current standard of care in ankle inversion sprain rehabilitation plus a 20-minute sham tDCS treatment, where the patient is wearing the tDCS headset, but stimulation is only applied for 30 seconds of the 20-minute period. The rehabilitation program will be standardized among all patients and will consist of therapeutic exercises, manual physical therapy, and other modalities. Rehabilitation sessions will be performed 2x weekly and sessions will last approximately 45 to 60 minutes.
89198949|NCT00958906|Experimental|Intravitreal infliximab|
89401631|NCT02259218||Ancillary-Correlative|Prospectively collected blood, urine, and tissue samples are analyzed for potential predictive biomarkers via metabolomic and other molecular profiling.
89401632|NCT01377883|Sham Comparator|Standard intervention|"Preparation and information: the doctor and nurse explained the steps of the procedure: placing EMG electrodes, wiping the area with an alcohol swab, cooling with ethyl chloride, needle insertion into the muscle and the importance of EMG noise.~Memory change and positive reinforcement: medical staff present spoke to the child positively and offered prizes, among which the child could choose.~Volunteer attendance: as part of the control session, receiving no particular instructions in relation to the child's potential pain during the procedure."
89401633|NCT01377883|Experimental|clown care|Cognitive coping: encouraging a child to cope with the challenge. Imagery: a cognitive technique used to encourage the child to cope with the pain and distress of the procedure by imagining a pleasant object or experience Empowerment: the child is made to feel empowered by controlling the actions of the clown Reflecting emotions: the clown, sensing the state of the child, plays it out in an exaggerated fashion.
89401634|NCT02083458|Experimental|axillary vein catheterization|Catheterization of the axillary vein based on anatomical landmark.
89401635|NCT02231528|Experimental|Use of ultrasound with active GPS|
89401636|NCT02231528|Active Comparator|Use of ultrasound with inactive GPS|
89401637|NCT02079090|Active Comparator|Ketofol|Patient will receive 0.5 mg/kg Ketamine, and 2 minutes later receive 1 mg/kg Propofol.
89401638|NCT02079090|Experimental|Fentofol|Patient will receive 1 microgram/kg Fentanyl, and 2 minutes later receive 1 mg/kg Propofol.
89401639|NCT04931641|Experimental|50 mg oral iron as ferrous fumarate (FeFum) with 7.5 g galacto-oligosaccharides|
89401640|NCT04931641|Placebo Comparator|50 mg oral iron as ferrous fumarate (FeFum) with 7.5 g maltodextrin|
89401641|NCT04937270|Experimental|High frequency application time is 5 minutes|The group which treats for 5 minutes by using the high-frequency therapy device
89401642|NCT04937270|Experimental|High frequency application time is 7 minutes|The group which treats for 7 minutes by using the high-frequency therapy device
89401643|NCT04937270|Experimental|High frequency application time is 9 minutes|The group which treats for 9 minutes by using the high-frequency therapy device
89401644|NCT04937270|Active Comparator|Superficial heat therapy|Group treated with superficial heat therapy for 20 minutes
88876879|NCT02605551|Active Comparator|OMT Group|During the initial visit, the subject will have his BP recorded manually by the osteopathic physician in a standardized fashion. The subject will then undergo the OMT protocol and have his BP recorded again immediately afterwards. This will represent the conclusion of the initial visit. There will be 2 subsequent visits about 2-3 weeks apart that will be identical to this visit. Following the third visit, the next follow-up will be 2 months afterwards. However, the patient will only have his BP checked, and will not undergo an OMT treatment. The final visit will be another 2 months afterwards and will also be a simple BP check with no OMT treatment. The principles of lifestyle modification (diet/exercise/weight loss) will also be discussed at each visit.
89004147|NCT02374242|Active Comparator|Cohort 3 Nivolumab and Ipilimumab|Nivolumab 1mg/kg every 3 weeks x four doses and ipilimumab 3mg/kg every 3 weeks x four doses. After 12 weeks, nivolumab 3mg/kg alone every 2 weeks until disease progression, withdrawn consent, unacceptable toxicity or death.
89198950|NCT00882219|Experimental|Xience V®|
89198951|NCT00959062|Experimental|clonidine|
89401645|NCT02079168|Experimental|Cohort 1|Treatment with RXI-109 at the site of one excised keloid and a placebo at the site of a second excised keloid. Dosing to begin at the time of surgery.
89401646|NCT02079168|Experimental|Cohort 2|Treatment with RXI-109 at the site of one excised keloid and a placebo at the site of a second excised keloid. Dosing to begin two weeks after surgery.
89401647|NCT04898959||Group 1|Lower extremity amputees
89401648|NCT02227472||Sickle Cell Disease|All participants who meet eligibility requirements and consent to the study will complete evaluation of cognitive and pre-academic skills, and parent questionnaires.
89401649|NCT02083536|Experimental|LDFWART + Docetaxel|"This study has 6 treatment cycles given at 3 weeks intervals ± 3 days. A cycle is defined as 1 treatment of morning Docetaxel and afternoon Low Dose Fractionated Whole Abdominal Radiation Therapy (LDFWART). The first day of the first treatment is designated study day 1."
89401650|NCT03629899|Experimental|RETINA IMPLANT Alpha AMS|"After implantation surgery, every single sub-test will be performed with randomized implant activation (ON or OFF). During every trial of each sub-test there will be a study coordinator and a technician. The study coordinator will have a set randomization examination schedule while the technician will record patient response without knowledge of the randomization examination schedule. The patient, technician and investigator will all be masked to the testing conditions."
89401651|NCT02231606|No Intervention|Group 1: Pure Control|Provision of glasses prescription only
89401652|NCT02231606|Experimental|Group 2: Free Glasses|Free glasses for all, no upgrade glasses offered
89401653|NCT02231606|Experimental|Group 3: Free + Upgrade Glasses 1|Free glasses for all, optional purchase from range of spectacles, cheapest RMB100 (Mean price paid for glasses by Control families in Seeing is Learning I, subtracting one SD)
89401654|NCT02231606|Experimental|Group 4: Free + Upgrade Glasses 2|Free glasses for all, optional purchase from range of spectacles, cheapest RMB200 (Mean price paid for glasses by Control families in Seeing is Learning I, adding one SD)
89401655|NCT02083614|Experimental|clamping|to clamp or release the catheter for 2 days before removal
89401656|NCT02083614|No Intervention|no clamping|
89401657|NCT04629937|Experimental|SPECT acquisitions|All patients will undergo SPECT acquisitions with both multipurpose CZT camera and cardiac dedicated CZT camera.
89401658|NCT02231684|Experimental|s.c. 0.5 mg (1 mg/ml) followed by s.c. 0.5 mg (3 mg/ml)|
89401659|NCT02231684|Experimental|s.c. 0.5 mg (3 mg/ml) followed by s.c. 0.5 mg (1 mg/ml)|
89401660|NCT02231684|Experimental|s.c. 0.5 mg (3 mg/ml) followed by s.c. 0.5 mg (10 mg/ml)|
89401661|NCT02231684|Experimental|s.c. 0.5 mg (10 mg/ml) followed by s.c. 0.5 mg (3 mg/ml)|
89401662|NCT02231684|Experimental|s.c. 0.5 mg (1 mg/ml) followed by s.c. 0.5 mg (10 mg/ml)|
89401663|NCT02231684|Experimental|s.c. 0.5 mg (10 mg/ml) followed by s.c. 0.5 mg (1 mg/ml)|
89401664|NCT02231684|Experimental|i.v. 0.25 mg (1 mg/ml) followed by s.c. 0.5 mg (1 mg/ml)|
89401665|NCT02231684|Experimental|s.c. 0.5 mg (1 mg/ml) followed by i.v. 0.25 mg (1 mg/ml)|
89401666|NCT02227550|Experimental|Apixaban|Xa group: factor Xa inhibitor Apixaban min. 30 days 5 mg twice daily (fix dose)
89401667|NCT02227550|Active Comparator|Vitamin K antagonist|VKA group: any Vitamin K antagonist (VKA), INR 2-3 , min. 30 days prescribed as in clinical routine
89401668|NCT03558906||Aggressive Periodontitis|These individuals had minimum PD ≥6 mm and CAL ≥5 mm on eight or more teeth; at least three of these were other than central incisors or first molars. Radiographic alveolar bone loss was ≥30% of root length affecting at least three permanent teeth other than first molars and incisors. The severe destruction pattern was not commensurate with amount of plaque accumulation.
89401669|NCT03558906||Chronic periodontitis|These individuals had at least four non-adjacent teeth with sites with PD ≥6 mm and CAL ≥5 mm. They had also ≥50% alveolar bone loss in at least two quadrants that was commensurate with amount of plaque accumulation. BOP was >50% in the whole mouth.
89401670|NCT03558906||Gingivitis|Gingivitis patients exhibited no sites with CAL >2 mm and no detectable alveolar bone loss in the radiography. BOP was >50% in the whole mouth.
89401671|NCT03558906||Healthy|Periodontally healthy volunteers exhibited no sites with PD >3 mm and CAL >2 mm as well as no radiographic evidence of alveolar bone loss. BOP was <15% in the whole mouth.
89401672|NCT02206035|Experimental|Tacrolimus, Methotrexate and Tocilizumab (Tac/MTX/Toc)|Patients enrolled in the clinical trial will receive tacrolimus per institutional guidelines at doses to maintain therapeutic levels and continued until at least Day 90 posttransplant. Methotrexate will be dosed at 15 mg/m2 Day +1 and 10mg/m2 Days +3, +6 and +11. Tocilizumab will be administered intravenously at a dose of 8 mg/kg at Day -1
89401673|NCT02227628|Placebo Comparator|Sugary Beverage|Sugary Beverage
89401674|NCT02227628|Experimental|Acai beverage|Acai Polyphenolics
89401675|NCT02082990|Active Comparator|Face-to-Face Brief Intervention Group|One face-to-face Brief Intervention which is provided by General Practitioner or Nurse
89401676|NCT02082990|Experimental|Online Brief Intervention Group|Primary care-based facilitated access to an alcohol reduction website (Brief Intervention)
89401677|NCT02079324|Experimental|GX-051|GX-051 intratumoral injection
89401678|NCT02258828|Experimental|Memantine|Subjects initially received memantine 5 mg once daily, which was increased weekly by 5 mg/day in divided doses to a dose of 20 mg/day
89401679|NCT02258828|Placebo Comparator|Placebo|Patient received matched placebo
89401680|NCT02083068|Experimental|Experimental|10 individuals per sub- group to be immunized with the Vaccine PvCS N+C at month 0 and the Vaccine PvCS N+C+R at months 2 and 6
89401681|NCT02083068|Placebo Comparator|Control|six individuals for each sub- group to be immunized with placebo SSN Montanide ISA-51
88876880|NCT02605551|Placebo Comparator|Control Group|Patients in this arm will only receive lifestyle modification recommendations at each visit, along with a BP check. No antihypertensive medication changes will be made unless indicated by the guidelines.
89401682|NCT02228018|Experimental|CALSA and FRI repeatability|CT-Scan No medication used
89198952|NCT00959062|Placebo Comparator|placebo|
89401683|NCT02083146||Patients with CAD|Acute coronary syndromoe (ACS) patients who were admitted to the coronary care unit.
89401684|NCT02228252|Experimental|20 g whey protein (-15 min)|20 g whey protein dissolved in 200 milliliter (mL) Water. Consumed as a pre-meal 15 min prior to the main meal.
89401685|NCT02228252|Experimental|20 g whey protein (-30 min)|20 g whey protein dissolved in 200 milliliter (mL) Water. Consumed as a pre-meal 30 min prior to the main meal.
89401686|NCT02228252|Experimental|20 g casein|20 g casein dissolved in 200 milliliter (mL) Water. Consumed as a pre-meal 15 min prior to the main meal.
89401687|NCT02228252|Experimental|20 g gluten protein|21.5 g gluten protein dissolved in 200 milliliter (mL) Water. Consumed as a pre-meal 15 min prior to the main meal.
89401688|NCT02083770|Experimental|Cancer Clinical Trials Education Program|Cancer Clinical Trials Education Program is offered to English- and Spanish-speaking Hispanics in the experimental arm. This program was designed to promote increased clinical trials literacy among Hispanic Americans. Increased clinical trials knowledge and a better understanding of clinical trials is anticipated to create more positive attitudes, and perceptions about clinical trials among Hispanic Americans.
89401689|NCT02083770|Placebo Comparator|Neighborhood Watch Education Program|The Neighborhood Watch Program created by the Bureau of Justice Assistance and the National Crime Prevention Council was selected for inclusion in the control arm of this study. It provided participants with a program of equivalent length and format, as well as an equivalent focus on improving the well-being of Hispanic Americans. It also provided an opportunity to evaluate the impact of the Neighborhood Watch Program.
89401690|NCT02228330|Experimental|uni-lateral obturator nerve block|"Patients scheduled for TUR for bladder tumor Intervention: uni-lateral obturator nerve block.~non-blocked obtorator side of each patient will be used as control"
89401691|NCT04524715|Experimental|Active Treatment Group|LLLT Treatment using an UltraSlim red/IR LED device along with all standard treatment measures for COVID19.
89401692|NCT04524715|Sham Comparator|Control Group|Treatment using a Sham comparator along with all standard treatment measures for COVID19.
88876881|NCT02573896|Experimental|NK cells with Dinutuximab & Lenalidomide|Patients in this arm will receive a designated dose of NK cells on Day 5 and 17.5 mg/m2/dose of dinutuximab on Day 1-4. Patients on Dose Level 4 will also receive 25mg/m2/dose of Lenalidomide during Day -6 through 14 of treatment.
88876882|NCT02542267|Other|Gore VIABAHN Endoprosthesis|Gore VIABAHN Endoprosthesis deployed to treat failed non-covered stent(s) in the Superficial Femoral Artery
88876883|NCT02480283||Control|Subjects aged 18 to 55 who have never used cannabis by self report (validated via urine drug screen), who have never used tobacco/cigarettes and have the capacity to give informed consent.
88876884|NCT02480283||Cannabis Smokers|The exposed cohort will have daily or near daily cannabis smoking histories equivalent to a minimum of 20 joint years (number of joints smoked per day multiplied by years of cannabis smoking), will not have a significant tobacco/cigarette smoking history and will be able to provide informed consent.
89401693|NCT02083848|Other|7T MRI|All subjects are entered into a single arm.
89401694|NCT04933370|Active Comparator|Industry standard stimulation|Industry standard stimulation settings
89401695|NCT04933370|Sham Comparator|Experimental stimulation|Experimental stimulation settings
89401696|NCT02223728|Experimental|Treatment Condition|Telehealth Lifestyle Program
89401697|NCT02223728|Sham Comparator|Attention Control Condition|Health Education Program
89401698|NCT02079402|Active Comparator|Liberal (target-guided) fluid resuscitation|"Noradrenaline to MAP >= 65 mmHg.~Fluid boluses may be given as long as hemodynamic variables improve (dynamic or static variable(s) of choice). A fluid bolus is to be followed by evaluation of effect 30 minutes after the intervention at the latest.~'Variable(s) of choice' refers to the variable(s) used to assess hemodynamic improvement.~Only isotonic crystalloids are to be given as resuscitation fluid; the type of isotonic crystalloid is free of choice."
89401699|NCT02079402|Experimental|Conservative (trigger-guided) fluid resuscitation|"Noradrenaline to MAP >= 65 mmHg.~A fluid bolus of 250-500 ml may be given followed by evaluation of effect 30 minutes after the intervention at the latest if one of the following occurs:~Plasma lactate concentration ≥ 4 mmol/l at point-of-care testing.~Severe hypotension (MAP < 50mmHg).~Mottling beyond edge of kneecap.~Severe oliguria (only in the first 2 hours after randomisation). Severe oliguria defined as urine output ≤ 0.1 ml/kg/hour IBW last hour.~Only isotonic crystalloids are to be given as resuscitation fluid; the type of isotonic crystalloid is free of choice."
89401700|NCT02591953|Experimental|Ultrasound-guided Injection|Injection performed with ultrasound-guidance
89401701|NCT02591953|Active Comparator|Landmark-guided Injection|Injection performed at point of maximal tenderness along biceps tendon
89401702|NCT01938495|Experimental|NeuRx® Diaphragm Pacing System™ (DPS)|Patients randomized to the experimental arm will receive The NeuRx® Diaphragm Pacing System™ (DPS) device. Under general anesthesia, the intramuscular electrodes are surgically implanted in the diaphragm.
89401703|NCT01938495|No Intervention|Standard of Care|patients randomized to the standard of care arm will not have the Diaphragm Pacing System surgically implanted but will receive standard medical care.
89401704|NCT02223806|Active Comparator|Self-assessment of uterine tonus|Uterine tonus assessment every 15 minutes for 2 hours by educated patient, which is standard-of-care.
89401705|NCT02223806|Experimental|Midwife uterine tonus assessment|Uterine tonus assessment every 15 minutes for 2 hours by midwive.
88876885|NCT02477202|Experimental|Mirena® IUD|This is a non-randomized study of the effect of Mirena® IUD use of at least 10 days before an RRSO or RRS on cell proliferation within the FTF and when available within ovarian CICs in women aged 35 through 50. The study will compare the results from 14 women using Mirena® with the results from 28 normally cycling women identified under MSK IRB Protocol #14-165 described above; all patients will be aged 35-50 years, and will have undergone the RRSO at MSK. To date we have identified approximately 100 suitable controls and are continuing to identify further suitable controls among women who have recently undergone RRSOs at MSK. The balancing/matching factors will be BRCA status (BRCA1/BRCA2/BRCA-ve), age (35-39/40-44/45-50), parity (nulliparous/parous), and BMI (<30/30+ kg/m^2). As each Mirena® patient completes the study and is deemed evaluable, she will be matched on each of these factors with 2 controls.
88876886|NCT02416128|Active Comparator|Iritis prevention after LPI: prednisolone|To use prednisolone acetate after and peripheral laser iridotomy to determine efficacy and side effects compared to arm 2.
88876887|NCT02416128|Experimental|Iritis prevention after LPI: euphrasia|To use euphrasia after and peripheral laser iridotomy to determine efficacy and side effects compared to arm 1.
89189626|NCT05563233|Experimental|Helfer Skin Tap|"Helfer Skin Tap (rhythmic tapping of the skin at the injection site to relax the muscles during injection) is an effective method in reducing pain in intramuscular applications in studies performed with the injection technique.~Before the injection, the observer nurse will fill in the demographic data form, measure the child's heart rate, blood pressure and SpO2 values, and apply the pain and fear assessment scale. In addition, the pain and fear scale will be evaluated by the child and the parent.~During the intramuscular injection to be applied to the ventrogluteal region, the level of pain and fear will be examined using the Helfer skin tap technique.~5 minutes after the injection, the pain and fear level of the children in all groups will be re-evaluated by the child, the mother and the observing nurse. After the procedure, pulse, blood pressure and SpO2 values will be measured and recorded by the observing nurse."
89401706|NCT02084004|Experimental|Bifidobacterium viable pharmaceutics|Bifidobacterium viable pharmaceutics, 2 Capsules, 2/day, 12 weeks
89401707|NCT02084004|Experimental|Berberine Hydrochloride|Berberine Hydrochloride, 0.5g, 2/day, 12 weeks
89401708|NCT02084004|No Intervention|lifestyle counseling|
89401709|NCT02223884|Experimental|weekly docetaxel and carboplatin|
89401710|NCT02079480|Experimental|Panel 1: BMS-986090 (0.5 mg) or Placebo|"BMS-986090 0.5 mg solution single dose subcutaneously once~OR~Placebo matching with BMS-986090 0 mg solution single dose subcutaneously once"
89401711|NCT02079480|Experimental|Panel 2: BMS-986090 (3 mg) or Placebo|"BMS-986090 3 mg solution single dose subcutaneously once~OR~Placebo matching with BMS-986090 0 mg solution single dose subcutaneously once"
89401712|NCT02079480|Experimental|Panel 3: BMS-986090 (10 mg) or Placebo|"BMS-986090 10 mg solution single dose subcutaneously once~OR~Placebo matching with BMS-986090 0 mg solution single dose subcutaneously once"
89401713|NCT02079480|Experimental|Panel 4: BMS-986090 (30 mg) or Placebo + KLH (1 mg)|"BMS-986090 30 mg solution single dose subcutaneously once~OR~Placebo matching with BMS-986090 0 mg solution single dose subcutaneously once~And Keyhole limpet hemocyanin (KLH) 1 mg solution single intramuscular dose once"
89401714|NCT02079480|Experimental|Panel 5: BMS-986090 (100 mg) or Placebo + KLH (1 mg)|"BMS-986090 100 mg solution single dose subcutaneously once~OR~Placebo matching with BMS-986090 0 mg solution single dose subcutaneously once~And KLH 1 mg solution single intramuscular dose once"
88876888|NCT02330653|Experimental|Fecal Microbiota Transplant (FMT)|Induction retention enema for the first week of treatment followed by once weekly administration of 15 capsules of study treatment (the equivalent of 7.5 grams of human stool) will be (administered within 60 minutes of thawing once weekly) for 7 weeks. After completing 8 weeks of blinded study treatment, study subjects on FMT who have shown improvement will be given the option to receive open-label maintenance FMT weekly for an additional 8 weeks of once weekly FMT capsule administration.
88876889|NCT02330653|Placebo Comparator|Placebo|Induction placebo enema for the first week of treatment followed by once weekly administration of 15 capsules of study placebo (administered within 60 minutes of thawing once weekly) for 7 weeks. After completing 8 weeks of blinded study placebo, study subjects on placebo who DO NOT demonstrate improvement will be given the option to receive open-label maintenance FMT weekly for an additional 8 weeks, beginning with a FMT induction enema followed by 7 weeks of weekly FMT capsule administration.
88876890|NCT02218606|Experimental|Abiraterone acetate 1000 mg po daily + prednisone 5 mg po BID|Arm 1: Abiraterone acetate 1000 mg po daily + prednisone 5 mg po BID
88876891|NCT02218606|Experimental|Cabazitaxel 25 mg/m2 IV + abiraterone acetate 1000 mg po daily|Arm 2: Cabazitaxel 25 mg/m2 IV + abiraterone acetate 1000 mg po daily + prednisone 5 mg po BID
88876892|NCT02096055|Experimental|Arm I (guadecitabine)|"INDUCTION THERAPY: Patients receive guadecitabine SC on days 1-5. Courses repeat every 4-6 weeks for 2-3 courses in the absence of disease progression or unacceptable toxicity. Patients achieving a CR or CRp continue on to Maintenance therapy; patients not achieving CR or CRi but deriving clinical benefit may continue to Maintenance therapy at the discretion of the PI.~MAINTENANCE THERAPY: Patients receive guadecitabine as in Induction therapy. Courses repeat every 4-8 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity."
88876893|NCT02096055|Experimental|Arm II (CLOSED) (guadecitabine)|"INDUCTION THERAPY: Patients receive guadecitabine SC on days 1-10. Courses repeat every 4-6 weeks for 2-3 courses in the absence of disease progression or unacceptable toxicity. Patients achieving a CR or CRp continue on to Maintenance therapy; patients not achieving CR or CRi but deriving clinical benefit may continue to Maintenance therapy at the discretion of the PI.~MAINTENANCE THERAPY: Patients receive guadecitabine SC on days 1-5 (days 1-10 of courses 1 and 2). Courses repeat every 4-8 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity."
88876894|NCT02096055|Experimental|Arm III (guadecitabine, idarubicin)|"INDUCTION THERAPY: Patients receive guadecitabine SC on days 1-5 and idarubicin IV over up to 1 hour on days 1-2. Courses repeat every 4-6 weeks for 2-3 courses in the absence of disease progression or unacceptable toxicity. Patients achieving a CR or CRp continue on to Maintenance therapy; patients not achieving CR or CRi but deriving clinical benefit may continue to Maintenance therapy at the discretion of the PI.~MAINTENANCE THERAPY: Patients receive guadecitabine SC on days 1-5 and idarubicin IV over up to 1 hour on day 1. Courses repeat every 4-8 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity."
88876895|NCT02096055|Experimental|Arm IV (CLOSED) (guadecitabine, cladribine)|"INDUCTION THERPAY: Patients receive guadecitabine SC and cladribine IV over up to 1 hour on days 1-5. Courses repeat every 4-6 weeks for 2-3 courses in the absence of disease progression or unacceptable toxicity. Patients achieving a CR or CRp continue on to Maintenance therapy; patients not achieving CR or CRi but deriving clinical benefit may continue to Maintenance therapy at the discretion of the PI.~MAINTENANCE THERAPY: Patients receive guadecitabine SC and cladribine IV over up to 1 hour on days 1-5. Courses repeat every 4-8 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity."
88876896|NCT02017717|Experimental|Arm N:Nivolumab|Cohort 1, 1c, 1d and 2: Nivolumab specified dose on specified days
88876897|NCT02017717|Experimental|Arm N + I:Nivolumab + Ipilimumab|"Cohort 1: Nivolumab specified dose on specified days + Ipilimumab specified dose on specified days, then Nivolumab specified dose on specified days~Cohort 1b: Nivolumab specified dose on specified days + Ipilimumab specified dose on specified days, then Nivolumab specified dose on specified days"
88876898|NCT02017717|Active Comparator|Arm B: Bevacizumab|Cohort 2: Bevacizumab specified dose on specified days
88876899|NCT01761305|Experimental|Brace|Hypercorrective night-time brace worn 8 hours per night. A prescription of general physical activity will be provided at a dose of 60 minutes per day. Instructions regarding physical activity will be delivered during a one hour session.
88876900|NCT01761305|Experimental|Scoliosis specific exercises.|Scoliosis specific exercises. The intervention will be delivered in 3 x 90 minute sessions, once per month during the first 3 months. An additional session will be provided every 6 months for the entirety of the study. A prescription of general physical activity will be provided at a dose of 60 minutes per day.
88876901|NCT01761305|Active Comparator|Self-mediated physical activity.|A prescription of general physical activity will be provided at a dose of 60 minutes per day. Instructions will be delivered during a 1 hour session.
89401715|NCT02079480|Experimental|Panel 6: BMS-986090 (100 mg) or Placebo|"BMS-986090 100 mg solution single dose intravenously once~OR~Placebo matching with BMS-986090 0 mg solution single dose intravenously once"
89401716|NCT02079480|Experimental|Panel 7: BMS-986090 (300 mg) or Placebo + KLH (1 mg)|"BMS-986090 300 mg solution single dose subcutaneously once~OR~Placebo matching with BMS-986090 0 mg solution single dose subcutaneously once~And KLH 1 mg solution single intramuscular dose once"
89401717|NCT02079480|Experimental|Panel 8: BMS-986090 (750 mg) or Placebo|"BMS-986090 750 mg solution single dose intravenously once~OR~Placebo matching with BMS-986090 0 mg solution single dose intravenously once"
89401718|NCT02079480|Experimental|Panel 9: BMS-986090 (150 mg) or Placebo|"BMS-986090 150 mg solution subcutaneously once weekly for 4 weeks~OR~Placebo matching with BMS-986090 0 mg solution subcutaneously once weekly for 4 weeks"
89401719|NCT02569489|Experimental|HBI-8000, Paclitaxel, Trastuzumab|HBI-8000 at the assigned dose twice weekly while receiving weekly paclitaxel and trastuzumab for a minimum of 8 weeks (2 treatment cycles)
89401720|NCT02079558|Experimental|Oxytocin|A single 100 microgram IV dose of carbetocin after operation
89401721|NCT02079558|Experimental|Carbetocin|A standard 30 international units (IU) IV infusion of oxytocin during two hours
88876902|NCT01539863|Experimental|Treatment at regular intervals|Participants will be scheduled to receive the intervention, maintenance care, i.e. care on a regular basis throughout the study period.Care may consist of manual treatment but also of e.g. advice concerning exercises, ergonomic adaptation and stress management
88876903|NCT01539863|Active Comparator|Treatment as needed|Participants will receivethe intervention, i.e.care only when requested by them, i.e. when experiencing a relapse or deterioration
88876904|NCT01148550||Group 1|Mitochondrial Hepatopathy Disease Group
88876905|NCT01148550||Group 2|Subjects with Suspected Mitochondrial Hepatopathy who do not meet the enrollment criteria for Group 1 Subjects with Suspected Mitochondrial Hepatopathy who do not meet the enrollment criteria for Group 1
88876906|NCT00942331|Active Comparator|Arm I (gemcitabine hydrochloride, cisplatin, placebo)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and cisplatin IV and placebo IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive placebo IV over 30-90 minutes every 21 days in the absence of disease progression or unacceptable toxicity.
89401722|NCT03629821|Experimental|Ballet|Subjects who will receive the experimental protocol.
89401723|NCT03629821|No Intervention|Control|Subjects who will not receive the experimental protocol, only will be on a wait list.
89401724|NCT04058379|Experimental|CT scan|During this study each patient will have 3 CT scans : D0, D1 and D3. A daily follow up during first seven days in ICU, then a follow up at D28 if still in hospital, and a phone call at M6 for neurological outcome
89401725|NCT04057755|Experimental|Botulinum toxin A vs placebo|50 Allergan units (diluted in 0,5 ml sterile NaCl) or 0,5 ml of sterile NaCl will be injected in the bulbocavernosus muscle just inside the hymenal ring. The injection with the same substance, dose and volume will be repeated after 3 months.
89401726|NCT04057755|Active Comparator|Botulinum toxin A|50 Allergan units (diluted in 0,5 ml sterile NaCl) will be injected in the bulbocavernosus muscle just inside the hymenal ring. The injection with the same substance, dose and volume will be repeated after 3 months.
89401727|NCT04057755|Placebo Comparator|NaCl|0,5 ml of sterile NaCl will be injected in the bulbocavernosus muscle just inside the hymenal ring. The injection with the same substance and volume will be repeated after 3 months.
88876907|NCT00942331|Experimental|Arm II (gemcitabine hydrochloride, cisplatin, bevacizumab)|Patients receive gemcitabine hydrochloride and cisplatin as in arm I. Patients also receive bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab IV over 30-90 minutes every 21 days in the absence of disease progression or unacceptable toxicity.
88876908|NCT00828919|Experimental|Treatment|Patients continue the same treatment (axitinib monotherapy or in combination with crizotinib) as in prior axitinib study
88876909|NCT00827372|Experimental|Pazopanib Treatment|Pazopanib 800 mg orally once each day (maximum total duration of treatment = 24 weeks)
89535493|NCT04463121|Experimental|Acute CNT pacing signals testing|"Acute study procedure will be carried out prior to a pacemaker implantation or replacement: pacemaker Right Atrial (RA) and Right Ventricular (RV) leads will be positioned according to standard procedure for pacemaker implant and connected to a Moderato® System IPG, via a single use, sterile Pacing System Analyzer (PSA) cable. The Moderato IPG will deliver CNT signals.~Furthermore, a standard conductance catheter in the left ventricle will measure cardiac volumes and pressure. Arterial blood pressure will be obtained as well.~A range of CNT signal parameters will be used to assess the effect on sympathetic activity at different positions of the RV pacing lead while ventricular pressure and volume and arteial pressure signals will be assesed for cardiac function, sympathetic activity and blood pressure. The effects of CNT signal over a range of parameter settings will be studied for the different RV lead positions."
89535494|NCT03318419|Experimental|Cladribine group|Cladribine in combination of GAP (G-CSF priming, low dose cytarabine, and Pegaspargase) will be administrated in this arm
88876910|NCT00687856||LVAD Recipients|Participants who have had or are about to have a left ventricular assist device (LVAD) implanted
88876911|NCT00590902|Experimental|1 - OSI-774|
88876912|NCT00577122|Experimental|Cohort I (MPA)|Medroxyprogesterone progesterone acetate (MPA) will be administered orally as a single daily dose.
88876913|NCT00577122|Experimental|Cohort II (MPA, low-dose chemotherapy)|"Medroxyprogesterone progesterone acetate (MPA) will be administered orally as a single daily dose.~Cyclophosphamide will be administered orally as a single daily dose. Methotrexate will be administered twice daily on days 1 and 2 of each week."
88876914|NCT00419770|Experimental|B|Deferasirox
89198953|NCT04296981|Experimental|video-based patient information|Viewing an explanatory video (8 minutes) to improve communication and understanding of stroke issues and stages of the continuum of care
89401728|NCT02139709|Experimental|Ganglioside|1.0 gram ZETA dairy lipid powder (Fonterra NZ)
89401729|NCT02139709|Placebo Comparator|Placebo|1.0 gram milk fat fraction void of ganglioside
89401730|NCT03669315|Active Comparator|Active cTBS treatment|Active cTBS will be administered with a Magventure MagPro Stimulator R30 using a butterfly coil. TBS consists of bursts of 3 pulses separated by 20ms (i.e. 50 Hz), with each triplet being repeated every 200 ms (i.e. 5 Hz). Stimulus intensities will be set at 80% of AMT. The investigators will use 2 trains of 600 pulses each separated by 1 minute (a total of 1200 pulses).
89401731|NCT03669315|Sham Comparator|Sham cTBS treatment|Sham cTBS will be administered with a Magventure MagPro Stimulator R30 using a butterfly sham coil. The same active cTBS configuration will be used.
89401732|NCT04527367||VHD patients|Patients with moderate and severe valvular heart diseases
89401733|NCT03669003|Experimental|Gelfoam|Gelfoam slurry will be injected at the end of the biopsy procedure.
89401734|NCT03669003|Active Comparator|Standard procedure|Standard procedure of lung biopsy
89401735|NCT04429399|Other|High positive end-expiratory pressure Ventilation|patient ventilated fixing high level of positive end expiratory pressure
89535495|NCT03221647||Controls|Intestinal biopsies from controls, affected by gastroesophageal reflux,
88876915|NCT00419770|Placebo Comparator|A|
88876916|NCT00129701|Experimental|Patients attending|Patients recruited to have a telephone consultation and then at the next appointment a face-to-face appointment
89401736|NCT04429399|Other|Low positive end-expiratory pressure Ventilation|patient ventilated fixing low level of positive end expiratory pressure
89401737|NCT05763745|Experimental|Point of Care Ultrasound|
89401738|NCT04313959|Active Comparator|Local anesthetic|Patients assigned for local anesthetic group will receive a single-shot ultrasound-guided erector spine plane block with 25 mL of 0.2% of ropivacaine
89401739|NCT04313959|Active Comparator|Local anesthetic + steroid|Patients assigned for local anesthetic + steroid group will receive a single-shot ultrasound-guided erector spine block plane with 25 mL of 0.2% of ropivacaine with 5 mg dexamethasone
89401740|NCT03073213|Experimental|Ixekizumab single dose|Participants received single dose of 80mg Ixekizumab by subcutaneous injection.
89401741|NCT03073213|Experimental|Ixekizumab Multiple Regimen 1 (80mg Q2W)|Participants received multiple doses of Ixekizumab starting with 160mg initial dose followed by 80mg every two weeks (Q2W) by subcutaneous injection.
89401742|NCT03073213|Experimental|Ixekizumab Multiple Regimen 2 (80mg Q4W)|Participants received multiple doses of 80mg Ixekizumab starting with 160mg initial dose followed by 80mg every four weeks (Q4W) by subcutaneous injection.
89401743|NCT03070483|Experimental|Vitamin D|Participants will all receive supplementation with cholecalciferol 5000 IU and calcium citrate 1000 mg daily for 3 months
89401744|NCT03914599||Neurological Disorder|For all neurological disorder participants an electromyography (EMG) study will be done to determine nerve conduction speed, and a blood draw will be completed for genetic (DNA) testing. Motor measures, cognitive measures and surveys will be completed to assess walking and brain processing speed. Four optional assessments will be offered and only completed if the participant consents to them and include: optical coherence tomography (pictures of the back of the eye), visual evoked potential (to evaluate the nerve pathways of the eye), brain MRI, and skin biopsy. For participants with a diagnosis of Charcot Marie Tooth (CMT) disease, they will have an additional Neuropathy Score to assess disease severity.
89401745|NCT03914599||Healthy Control|An electromyography (EMG) study will be done to determine nerve conduction speed, and a blood draw will be completed for genetic (DNA) testing. Motor measures, cognitive measures and surveys will be completed to assess walking and brain processing speed. Four optional assessments will be offered and only completed if the participant consents to them and include: optical coherence tomography (pictures of the back of the eye), visual evoked potential (to evaluate the nerve pathways of the eye), brain MRI, and skin biopsy.
89401746|NCT04386187|Experimental|Arm 1: Experimental Feeding|Small glutathione-rich meals will be prepared and delivered to participants for 12 weeks.
89401747|NCT04386187|Active Comparator|Arm 2: Education Control|Standard of care medical nutrition education for type 2 diabetes will be provided in the form of electronic handouts and web-based resources.
89401748|NCT04107727|Experimental|Quizartinib|"Induction: Cytarabine continuous IV infusion 200 mg/m2 (days 1-7), Idarubicin IV infusion 12 mg/m2 (days 1-3), oral quizartinib (dose defined in safety run-in phase) 14 days (8-21) (dose will be halved with strong CYP3A inhibitor), up to 2 cycles of 35 days.~Consolidation: Cytarabine IV infusion 1,5-3 g/m2 (days 1, 3, 5), oral quizartinib (dose defined in safety run-in phase) 14 days (6-19) (dose will be halved with strong CYP3A inhibitor), up to 4 cycles of 35 days.~Maintenance: oral quizartinib 60mg/day (dose will be halved with strong CYP3A inhibitor), up to 12 cycles of 28 days"
89401749|NCT04107727|Placebo Comparator|Placebo|"Induction: Cytarabine continuous IV infusion 200 mg/m2 (days 1-7), Idarubicin IV infusion 12 mg/m2 (days 1-3), oral placebo (dose defined in safety run-in phase) 14 days (8-21) (dose will be halved with strong CYP3A inhibitor), up to 2 cycles of 35 days.~Consolidation: Cytarabine IV infusion 1,5-3 g/m2 (days 1, 3, 5), oral placebo (dose defined in safety run-in phase) 14 days (6-19) (dose will be halved with strong CYP3A inhibitor), up to 4 cycles of 35 days.~Maintenance: oral placebo 60mg/day (dose will be halved with strong CYP3A inhibitor), up to 12 cycles of 28 days."
88876917|NCT00076310|Experimental|Cisplatin + Docetaxel + OSI-774|"Cisplatin 75 mg/m^2 IV every 21 days.~Docetaxel 60 mg/m^2 IV repeated every 21 days.~OSI-774 100 mg oral administered daily. May have a dose escalation of 150 mg pending on prior dose toleration. Patients will continue on daily OSI-774 until a study endpoint or removal from study is reached."
88876918|NCT04498416||Group 1 Post-Traumatic Stress Disorder (PTSD)|children with an identified traumatic history
88876919|NCT04498416||Group 2 Pathology|children with psychological follow-up treatment for a psychiatric disorder, without traumatic history;
89198954|NCT04009564|Experimental|Date seeds filtered coffee|Each participant will consume this arm in a visit has been allocated by Latin Square randomisation order: 45 g of date seeds coffee in 280 ml of boiled water, coffee flavour and brown food colouring ( made using a filter coffee machine). it will be served in a paper cup with lid
88876920|NCT04498416||Group 3 Control|children without traumatic experience and without psychiatric or psychological follow-up treatment.
88876921|NCT04350606|Experimental|PF-006462700 group|All enrolled participants will be administrated PF-006462700.
88921935|NCT06042179|Experimental|Error Augmentation Training|Will receive error augmentation training 3-5x/wk while inpatient Standard of care PT with the addition of error augmentation principles (making hard tasks harder and increasing difficulty of tasks with added resistance to already weakened muscles) to address at least 2 stroke deficits or limitations.
88876922|NCT04335240|Experimental|Music Therapy Intervention|"This protocol is a Family Centered Care Music Therapy Intervention. The methodologies will provide early intervention from the first days of hospitalization in NICU and consist of music therapy sessions both active (parental chant, live music and lullaby) and receptive (listening to recorded tracks). The music therapy accompanies the newborn and the parents during the hospitalization and focuses its attention on the emotional-relational care, according to the different needs that they will develop over time.Therapy sessions will be performed starting from three times per week, on three different days of the week, during the entire hospitalization of the enrolled infants. After discharge music therapy treatment will be performed once a week until twelve months of corrected age.~Stress level of infants and parents and neurobehavioral and neurological development of children will be assessed."
89401750|NCT05763433||ambulatory upper limb bone surgery carried out under axillary PNB|Patients will receive a slow intravenous injection of 0.1mg/kg max 10 mg intravenous dexamethasone in a 2cc syringe (5 mg/cc dexamethasone) after PNB is performed, prior to tourniquet placement and the start of surgery.
89401751|NCT01074151||Pregnant patients exposed to Cymbalta|Pregnant patients exposed to Cymbalta (duloxetine) at any time during pregnancy, beginning on or after the first day of the last menstrual period
89401752|NCT05762809|Experimental|Kinesiophobia tests|Patients were assessed using the Tampa Scale of Kinesiophobia (TSK-17), Knee injury and Osteoarthritis Outcome Score (KOOS), and Oxford Knee score (OKS). Ten minutes cycling with light resistance on a stationary bike was used for warm up before the physical tests. Quadriceps and hamstring muscle isokinetic strength was assessed at 60°/sec and 180°/sec using a Humac Norm Isokinetic dynamometer (Stoughton, United States). Functional performance was tested with the single-leg hop test for distance and the Y-balance test for anterior reach. The non-operated leg was tested first. All physical tests were supervised by the same specialized physiotherapists.
89401753|NCT05203783|Active Comparator|Control Group|The control group will receive only McKenzie exercises for 7 days.
89401754|NCT05203783|Experimental|Experimental Group|The experimental group will receive Kinesio tape application in addition to McKenzie exercises for 7 days.
89401755|NCT02786329|Active Comparator|TIVA + lidocaine|"TIVA-L. Patients allocated to receive TIVA (propofol-fentanyl) with lidocaine infusion.~Interventions: TIVA+lidocaine"
88876923|NCT04335240|No Intervention|No music therapy intervention|Music therapy is not administered in this group. Control group (no music therapy). During the entire hospital stay, newborn babies will receive standard care in use in the neonatal intensive care unit.
88876924|NCT04301154|Experimental|Arm 1 (n=10): HIVIS DNA / MVA-CMDR|"Arm 1 (n=10) will receive 1500 micrograms (0.5ml) HIVIS DNA IM by needle-free injection at weeks 0 and 4 followed by intramuscular (IM) needle injection of 1 X 108 IU/mL (1ml) MVA-CMDR at weeks 24 and 36 in the same arm as HIVIS DNA.~Participants who have been randomized to receive HIVIS DNA and MVA-CMDR alone (ARM 1) will be administered Cervarix after week 72, the last study follow-up visit, if required."
88876925|NCT04301154|Experimental|Arm 2 (n=10): HIVIS DNA + Cervarix/ / MVA-CMDR|Arm 2 (n=10) will receive 0.5 ml of Cervarix IM by needle injection followed by 1500 micrograms (0.5ml) per injection of HIVIS DNA IM by a needle-free injection device in the skin above (proximal to) the Cervarix injection (within 1.5 cm). They will receive 1 X 108 IU/mL (1ml) MVA-CMDR IM by needle injection at weeks 24 and 36 in the same arm as HIVIS DNA. They will also receive 0.5 ml Cervarix at the time of the first MVACMDR injection in the opposite arm from the MVA injection at week 24.
88876926|NCT04301154|Experimental|Arm 3 (n=5): Cervarix|Arm 3 (n=5) will receive 0.5 ml of Cervarix by IM needle injection at weeks 0, 4 and 24.
88876927|NCT04239846|Experimental|AC-701|AC-701 Topical Gel 0.3%
88876928|NCT04239846|Placebo Comparator|Placebo|Placebo Gel
88876929|NCT04233060|Experimental|CS3005|
88876930|NCT04040790|Experimental|Healthy volunteers|15 healthy volunteers for trials with passive artificial iris
88876931|NCT04027998||Carpal tunnel syndrome|group of carpal tunnel syndrome patients
88876932|NCT04027998||Control group|group of healthy controls
88876933|NCT03707184|Experimental|Diagnostic (fluciclovine F18, PET/CT)|Patients receive fluciclovine F18 intravenously (IV) over 30 seconds and undergo PET/CT scan over 60 minutes at baseline, 3 months and at approximately 6 months of radium-223 therapy.
88876934|NCT03556800|Experimental|0.5 gm of EstroCream (VML-0203)|
88876935|NCT03556800|Experimental|0.75 gm of EstroCream (VML-0203)|
88876936|NCT03556800|Experimental|1.25 gm of EstroCream (VML-0203)|
89401756|NCT02786329|Placebo Comparator|TIVA+placebo|TIVA-P. Patients allocated to receive TIVA without lidocaine (placebo). Intervention: TIVA+placebo (saline infusion)
89401757|NCT02786329|Placebo Comparator|Sevoflurane+placebo|"Sevo-P. Patients allocated to receive Sevoflurane anesthesia without lidocaine infusion (placebo).~Intervention: sevoflurane anesthesia +placebo (saline infusion)"
89401758|NCT02786329|Active Comparator|Sevoflurane+lidocaine|"Sevo-L. Patients allocated to receive sevoflurane anesthesia with lidocaine infusion for the first 48 h postoperatively.~Intervention: sevoflurane anesthesia+ lidocaine infusion"
89401759|NCT05762029||Group A|Due to respiratory and circulatory failure caused by acute server poisoning, patients accepting extracorporeal membrane oxygenation for treatment.
89535496|NCT03221647||GCD CD (Gluten Containing Diet CD)|Intestinal biopsies from GFD patients had with negative serology (anti-tTg antibodies between 0 and 1.5 U/ml and EMA negative) and normal biopsy (Marsh T0-1).
89535497|NCT03221647||GFD CD (Gluten Free Diet CD)|Intestinal biopsies from GCD-CD patients with villous atrophy (Marsh T3a-c) had positive serology (anti-tTg antibodies >30 U/ml and EMA positive) ).
89535498|NCT03076827|Experimental|Group A|Group to begin surgery(total hip replacement or hip hemi-arthroplasty) in the morning
89535499|NCT03076827|Experimental|Group P|Group to begin surgery(total hip replacement or hip hemi-arthroplasty) in the afternoon
88876937|NCT03556800|Active Comparator|1.25 EstroGel|
88876938|NCT03551886|Experimental|Experimental app|This is the Advanced Emotion App that we initially developed in phase 1 and are now enhancing in phase 2.
88876939|NCT03551886|Active Comparator|Comparison app|This is the Basic Emotion App, which is an alternative intervention app that controls for time and attention.
88876940|NCT04741620|Active Comparator|Capsaicin 10microM|10mL capsaicin 10microM solution 3 times/day during 14 consecutive days (2 weeks).
88876941|NCT04741620|Active Comparator|Piperine 150microM|10mL Piperine 150microM solution 3 times/day during 14 consecutive days (2 weeks).
88876942|NCT04741620|Active Comparator|Cinnamaldehyde 756,6microM + zinc 70microM|10mL Cinnamaldehyde 756,6microM + zinc 70microM solution 3 times/day during 14 consecutive days (2 weeks).3 times/day during 14 consecutive days (2 weeks).
88876943|NCT04741620|Active Comparator|Citric acid 457,5microM (pH=3,5)|10mL Citric acid 457,5microM (pH=3,5) solution 3 times/day during 14 consecutive days (2 weeks).3 times/day during 14 consecutive days (2 weeks).
88876944|NCT04741620|Active Comparator|Capsaicin 10microM + Citric acid 457,5microM (pH=3,5)|10mL Capsaicin 10microM + Citric acid 457,5microM (pH=3,5) solution 3 times/day during 14 consecutive days (2 weeks).3 times/day during 14 consecutive days (2 weeks).
88876945|NCT04741620|Placebo Comparator|Placebo|10mL placebo solution 3 times/day during 14 consecutive days (2 weeks).3 times/day during 14 consecutive days (2 weeks).
88876946|NCT03034902|Experimental|Combined EEG and fNIRS|EEG is electroencephalography. fNIRS is functional near infrared spectroscopy. The EEG+NIRS recordings will be obtained via an extended EEG cap that is applied to the subject's head. Changes in neuronal activity and hemodynamics will be measured.
88876947|NCT02952846|No Intervention|Before algorithm|Observational
88876948|NCT02952846|Experimental|After algorithm|Algorithm for tapering of analgosedation
88876949|NCT00800514|Experimental|active|
88876950|NCT02780622|Experimental|First Warfarin Then Warfarin and Oseltamivir|Participants will receive warfarin (on Days 1-5) in Treatment Period 1, followed by a washout period of at least 4 days (maximum 8 days). Participants will then receive oseltamivir 75 milligram (mg) (orally twice daily on Days 1-4 and once on Day 5) and warfarin in Treatment Period 2, and attend a follow-up visit 4-12 days after the last dose in Treatment Period 2. Participants will continue receiving warfarin once daily at a prescribed usual dose throughout the study.
88876951|NCT02780622|Experimental|First Warfarin and Oseltamivir Then Warfarin|Participants will receive oseltamivir 75 mg (orally twice daily on Days 1-4 and once on Day 5) and warfarin in Treatment Period 1, followed by a washout period of at least 4 days (maximum 8 days). Participants will then receive warfarin (on Days 1-5) in Treatment Period 2, and attend a follow-up visit 4-12 days after the last dose in Treatment Period 2. Participants will continue receiving warfarin once daily at a prescribed usual dose throughout the study.
88876952|NCT02781480|Experimental|Low dose AAV-RPE65|Subretinal administration of a single low dose of range AAV-RPE65
88876953|NCT02781480|Experimental|Intermediate dose AAV-RPE65|Subretinal administration of a single intermediate dose of range AAV-RPE65
88876954|NCT02781480|Experimental|High dose AAV-RPE65|Subretinal administration of a single high dose of range AAV-RPE65
88876955|NCT02783820|Experimental|MMV390048 40 mg|MMV390048 40 mg, tablets, single dose
88876956|NCT02783820|Placebo Comparator|Placebo to match MMV390048 40 mg|Placebo to match MMV390048 40 mg, tablets, single dose
88876957|NCT02783820|Experimental|MMV390048 80 mg|MMV390048 80 mg, tablets, single dose
89535500|NCT03321851|Other|V-Sensor Device User|This diagnostic medical device is designed to detect the user's 5 vital signs. Each user tests two sensors, each sensor is mounted on a smartphone. Each vital sign is compared to an equivalent reference device obtained by the healthcare provider.
88876958|NCT02783820|Placebo Comparator|Placebo to match MMV390048 80 mg|Placebo to match MMV390048 80 mg, tablets, single dose
88876959|NCT02783820|Experimental|MMV390048 120 mg|MMV390048 120 mg, tablets, single dose
88876960|NCT02783820|Placebo Comparator|Placebo to match MMV390048 120 mg|Placebo to match MMV390048 120 mg, tablets, single dose
88876961|NCT02783898|Experimental|Study|All STUDY arm participants will be given an AliveCor Heart Monitor and trained in the use of the device. They will be followed up at 90 days. If a participants allocated to the Study arm, gets an episode of palpitations or pre-syncope and is able to record an AliveCor Heart Monitor ECG during the episode, the participant will email the ECG recorded by the AliveCor app directly to the study team. The study team will review the ECG. If specialist follow-up is not required the study team will inform the participant of this and ask them to arrange general practitioner follow up. If the participant records a serious significant arrhythmia during the study period, the study team will alert the participant immediately and refer them to the cardiac electrophysiology service.
88876962|NCT02783898|No Intervention|Control|All CONTROL arm participants will receive no other intervention. Participants in both groups will be admitted, referred or discharged by the treating clinician according to current hospital protocols. Participants in both groups will be followed up at 90 days through hospital electronic patient record (EPR) systems and through a standardised written questionnaire and follow-up telephone call including symptoms and contact with medical services, satisfaction and compliance.
88876963|NCT02784444|Active Comparator|MSDC-0602K Dose 1 capsules|MSDC-0602K Dose 1 capsule taken once daily for 360 days
88876964|NCT02784444|Active Comparator|MSDC-0602K Dose 2 capsules|MSDC-0602K Dose 2 capsules taken once daily for 360 days
88876965|NCT02784444|Active Comparator|MSDC-0602K Dose 3 capsules|MSDC-0602K Dose 3 capsules taken once daily for 360 days
88876966|NCT02784444|Placebo Comparator|Placebo capsules|Matching Placebo capsule taken once daily for 360 days
88876967|NCT02787564|Experimental|Free Fruit and Vegetables|After baseline assessment of food intake patterns, the intervention will consist of providing free fruits and vegetables of their choice for a period of four weeks which will be provided fresh each week. At baseline and at the end of the 4-week period, a FFQ, two 24h-recalls and a questionnaire on consumed fruit and vegetable variety will be administered.
88876968|NCT02787564|No Intervention|Control Goup|At baseline and at the end of the 4-week period, a FFQ, four 24h-recalls and a questionnaire on consumed fruit and vegetable variety will be administered. At the end of the intervention period they receive once a basket of free fruits and vegetables.
89198955|NCT04009564|Experimental|Normal filtered coffee|Each participant will consume this arm in a visit has been allocated by Latin Square randomisation order: 6 g of coffee in 280 ml of boiled water (made using a filter coffee machine) it will be served in a paper cup with lid
89535501|NCT03221179|Experimental|RO7049665|Participants will be administered a single SC dose of RO7049665 administered in up to 4 SC injection.
88876969|NCT02788188|Experimental|Cohort 1|Cohort 1: 1mg/kg SAB-301 in normal (9%) saline; concentration 1mg/mL (0.1%)
88876970|NCT02788188|Placebo Comparator|Placebo|Normal (0.9%) saline in approximately the same volume as each cohort in the experimental drug arm.
88876971|NCT02788188|Experimental|Cohort 2|Cohort 2: 2.5 mg/kg SAB-301 in normal (9%) saline; concentration 1mg/mL (0.1%)
88876972|NCT02788188|Experimental|Cohort 3|Cohort 3: 5mg/kg SAB-301 in normal (9%) saline; concentration 4mg/mL (0.4%)
88876973|NCT02788188|Experimental|Cohort 4|Cohort 4: 10mg/kg SAB-301 in normal (9%) saline; concentration 4mg/mL (0.4%)
88876974|NCT02788188|Experimental|Cohort 5|Cohort 5: 20mg/kg SAB-301 in normal (9%) saline; concentration 20mg/mL (2%)
89401760|NCT05203549||Gastric cancer patients|Patients with gastric cancer will undergo tumor biopsy before receiving neoadjuvant therapy, conversion therapy, or palliative therapy
88876975|NCT02788188|Experimental|Cohort 6|Cohort 6: 50mg/kg SAB-301 in normal (9%) saline; concentration 20mg/mL (2%)
88876976|NCT02791308|Experimental|Pimecrolimus Cream, 1%|Pimecrolimus Cream, 1% (Actavis)
88876977|NCT02791308|Active Comparator|Elidel Cream, 1%|Reference listed drug: Elidel 1% cream (Valeant Pharmaceuticals North America LLC)
88876978|NCT02791308|Placebo Comparator|Vehicle Cream|Cream vehicle of the test product (Actavis)
88876979|NCT02796144|Active Comparator|Lorcaserin and Metformin|"Lorcaserin will be administered in dosages of 10 mg with a maximum dose of 20 mg.~Metformin will be administered in dosages of 500 mg with a maximum dose of 2,000 mg."
88876980|NCT02796144|Active Comparator|Lorcaserin|Lorcaserin will be administered in dosages of 10 mg with a maximum dose of 20 mg.
88876981|NCT02796144|Placebo Comparator|Placebo|Matching placebos will be administered for each active drug.
88876982|NCT02796300|Active Comparator|Bioflo Goup|This group will have dialysis using the Bioflo catheter.
88876983|NCT02796300|Active Comparator|Palindrome Group|This group will have dialysis using the Palindrome catheter.
89401761|NCT02231762|Experimental|Lanreotide Autogel 120mg & Temozolomide|"Combination phase for first 6 months: Lanreotide Autogel 120 mg and Temozolomide.~Followed by either 6 months Lanreotide Autogel 120 mg maintenance or 6 months of no treatment."
89401762|NCT04540484||ALGH Physicians|Attending physicians on the medical staff, fellow physicians, and resident physicians that work at Advocate Lutheran General Hospital (ALGH) from March 1st, 2020 and forward.
89401763|NCT04540484||Household Members|Household members above age 18 who lived in household of ALGH physician who tested positive for COVID-19 IgG antibodies, and who lived with that physician for at least 2 consecutive weeks.
89401764|NCT01687335||cancerous patients|the patients benefiting from treatment by chemotherapy.
89401765|NCT01676181|Active Comparator|Adenotonsillectomy|Total removal of tonsils and adenoids with cold steel
88876984|NCT02796924|Experimental|Patients|30 sessions of high-frequency (20Hz) repetitive stimulation applied over the right temporal-parietal junction in patients with psychogenic non-epileptic seizures using a MagStim Rapid2 Transcranial Magnetic Simulation machine.
88876985|NCT02798952|Experimental|HBV Group|Subjects received a single challenge dose of Engerix-B Kinder.
88876986|NCT02800356|Experimental|Pseudodrusen|Subthreshold 577 nm yellow wavelength laser photo-coagulator
88876987|NCT02800356|Experimental|Geographic atrophy|Subthreshold 577 nm yellow wavelength laser photo-coagulator
88876988|NCT02801370|Experimental|OTO-201|
88876989|NCT02801370|Sham Comparator|Control|
88876990|NCT02803164|Other|Vacuum-assisted dressing|Eligible subjects will receive negative pressure wound therapy during surgery.
88876991|NCT02803164|Other|Historical control group for comparison|Retrospective review of subjects medical records with open chest wounds who were treated with the traditional treatment techniques.
88876992|NCT02806908|Placebo Comparator|Placebo|Once daily dosing
88876993|NCT02806908|Active Comparator|JZP-110|150 mg/day for first 3 days and 300 mg/day for next 4 days
88876994|NCT02813070|Experimental|Healthy volunteers|185 MBq [18F] Flutemetamol
88876995|NCT02813070|Experimental|Mild cognitive impairment|185 MBq [18F] Flutemetamol
88876996|NCT02813070|Experimental|Alzheimer's Disease|185 MBq [18F] Flutemetamol
88876997|NCT02815644|Experimental|empagliflozin/linagliptin FDC|empagliflozin/linagliptin fixed-dose combination (FDC) film-coated tablet
88876998|NCT02816346|Experimental|Cohort 1: target dose of 500 CFU|"Shigella sonnei 53G: Investigational Product: One dose of Shigella sonnei rehydrated challenge strain 53G (Lot 1794) suspension in 2 mL of cold sterile water combined and diluted in cold, sterile normal saline 0.9% (i.e. challenge suspension).~Mode of Administration: After a 90 minute fast subjects will drink the 120 mL of sodium bicarbonate (to neutralize gastric acidity) and then drink the challenge suspension within 5 minutes.~Received target dose of 500 colony-forming units (CFU) of Shigella sonnei 53G (actual dose: 510, 717, 588, and 567 CFU)."
88876999|NCT02816346|Experimental|Cohort 2: target dose of 1000 CFU|"Shigella sonnei 53G: Investigational Product: One dose of Shigella sonnei rehydrated challenge strain 53G (Lot 1794) suspension in 2 mL of cold sterile water combined and diluted in cold, sterile normal saline 0.9% (i.e. challenge suspension).~Mode of Administration: After a 90 minute fast subjects will drink the 120 mL of sodium bicarbonate (to neutralize gastric acidity) and then drink the challenge suspension within 5 minutes.~Received target dose of 1000 colony-forming units (CFU) of Shigella sonnei 53G (actual dose: 817 CFU), since the attack rate of shigellosis for Cohort 1 was below the protocol target of 60%."
88921936|NCT06042179|Experimental|Frequent Intense PT|This group will receive therapy services twice per day Monday through Friday and daily Saturday and Sunday, with implementation of error augmentation training each session. This includes standard of care PT with the addition of error augmentation principles (making hard tasks harder and increasing difficulty of tasks with added resistance to already weakened muscles) to address at least 2 stroke deficits or limitations.
88921937|NCT06041334|Other|Study volunteers|
88921938|NCT06039605|No Intervention|Control|This group will only receive motor training, which consists of 10 trials of motor training per day across 3 days, followed by a one-week follow-up of 2 trials.
89401766|NCT01676181|Active Comparator|Adenotonsillotomy|Partial removal of tonsils with coblation and total removal of adenoids with cold steel
89401767|NCT04614051|Experimental|Cellgram-DC|Cellgram-DC is injected Subcutaneous injection near the upper arm lymph nodes
88877000|NCT02816346|Experimental|Cohort 3: target dose of 1000 CFU|"Shigella sonnei 53G: Investigational Product: One dose of Shigella sonnei rehydrated challenge strain 53G (Lot 1794) suspension in 2 mL of cold sterile water combined and diluted in cold, sterile normal saline 0.9% (i.e. challenge suspension).~Mode of Administration: After a 90 minute fast subjects will drink the 120 mL of sodium bicarbonate (to neutralize gastric acidity) and then drink the challenge suspension within 5 minutes.~Received target dose of 1000 colony-forming units (CFU) of Shigella sonnei 53G (actual dose: 913 CFU. Although the target dose was the same as Cohort 2, the safety monitoring committee felt that the per-protocol a priori definition of shigellosis was too restrictive and that increasing the dose above 1000 CFU may lead to unnecessarily high toxicity."
88877001|NCT02816346|Experimental|Cohort 4: target dose of 1500 CFU|"Shigella sonnei 53G: Investigational Product: One dose of Shigella sonnei rehydrated challenge strain 53G (Lot 1794) suspension in 2 mL of cold sterile water combined and diluted in cold, sterile normal saline 0.9% (i.e. challenge suspension).~Mode of Administration: After a 90 minute fast subjects will drink the 120 mL of sodium bicarbonate (to neutralize gastric acidity) and then drink the challenge suspension within 5 minutes.~Received target dose of 1500 colony-forming units (CFU) of Shigella sonnei 53G (actual dose: 1760 CFU) since the attack rate of shigellosis for Cohort 2 and 3 was below the protocol target of 60%."
88877002|NCT02816346|Experimental|Cohort 5: target dose of CFU|"Shigella sonnei 53G: Investigational Product: One dose of Shigella sonnei rehydrated challenge strain 53G (Lot 1794) suspension in 2 mL of cold sterile water combined and diluted in cold, sterile normal saline 0.9% (i.e. challenge suspension).~Mode of Administration: After a 90 minute fast subjects will drink the 120 mL of sodium bicarbonate (to neutralize gastric acidity) and then drink the challenge suspension within 5 minutes.~Received target dose of 1150 colony-forming units (CFU) of Shigella sonnei 53G (actual dose: 1760 CFU) as the final confirmatory cohort since it was felt that the disease rate and profile of Cohort 4 was appropriate."
88877003|NCT02820324|Experimental|Treatment 1 Oliceridine|
88877004|NCT02820324|Experimental|Treatment 2 Oliceridine|
88877005|NCT02820324|Experimental|Treatment 3 Oliceridine|
88877006|NCT02820324|Placebo Comparator|Treatment 4 Placebo|
88877007|NCT02820324|Active Comparator|Treatment 5 Morphine|
88877008|NCT02820870|Experimental|Primary Care Intervention Group|"Primary care providers will receive a generated print-out of statin recommendations for patient whose current medication therapy is not consistent with the new guidelines (i.e., are guideline discordant). Each day the research assistant will deliver a hardcopy of these patient specific recommendations to the teamlets for their use. In addition, providers will receive monthly audit and feedback reports on the percentage of their patients meeting the guidelines."
88877009|NCT02820870|No Intervention|Usual Care Group|PACT teams that were not randomized to the intervention will serve as a usual care group and will be expected to follow the VA guidelines and HEDIS measures as part of the VA national roll-out.
88877010|NCT02821104||Healthy Adolescents|Healthy non Hispanic white adolescents
88877011|NCT02821338|Active Comparator|Sequence 1|The treatments will be administered according to a randomly assigned pre-generated sequence involving the randomized, four-period, two sequence, fully replicate crossover design. Two study drugs involved are: Lamotrigine Extended Release (generic) and Lamictal XR (brand).
88877012|NCT02821338|Active Comparator|Sequence 2|The treatments will be administered according to a randomly assigned pre-generated sequence involving the four-period, two sequence, fully replicate crossover design. Two study drugs involved are: Lamotrigine Extended Release (generic) and Lamictal XR (brand).
88877013|NCT02823600|Other|RetinaVue 100 camera|Participants will have a retinal screening completed by study staff using the FDA-approved RetinaVue 100 hand-held camera
88877014|NCT02829294|Experimental|Treatment|E002 - cerumen removal aid will be placed into the ear canal of enrolled subjects for 15 to 30 minutes
88877015|NCT02830074|Experimental|The BEST Program|a combined sleep and PAP adherence program, called the BEST program (Best practices PAP + patient Education + ongoing Support and Training)
88877016|NCT02830074|Active Comparator|Sleep Education and standard SDB treatment|This program includes non-directive sleep education plus standard treatment of SDB.
88877017|NCT02835846|Experimental|Estrogen Arm|The intervention for this study is an estrogen cream (i.e., Premarin Cream®). Women in this study will receive this estrogen cream and apply it to their vagina twice weekly for 12 weeks
88877018|NCT02837328|Experimental|Oral Magnesium Supplement|400 mg Magnesium Citrate 1x daily for 12 weeks
88877019|NCT02837328|Placebo Comparator|Placebo|Placebo pill resembling 400 mg Magnesium Citrate 1x daily for 12 weeks
88877020|NCT02839902|Experimental|TAK-085 4g|A dose of 2 g of omega-3-acid ethyl esters (TAK-085) capsule is orally administered immediately after meal twice a daily (totally 4g per a day) for 8 weeks, plus a stable HMG-CoA reductase inhibitor regimen (started ≥4 weeks prior to informed consent) at a consistent dose.
88877021|NCT02839902|Experimental|Control Group|Stable HMG-CoA reductase inhibitor regimen at a consistent dose only.
88877022|NCT02840916|Experimental|verum laser acupuncture|verum laser acupuncture
88877023|NCT02840916|Sham Comparator|sham laser acupuncture|sham laser acupuncture (no laser output)
88877024|NCT02842242|Experimental|Open Label|MYK-461
88877025|NCT02844582|Experimental|Treatment (cabazitaxel, prednisone)|Patients receive cabazitaxel IV over 1 hour on day 1 and prednisone PO BID on days 1-21. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
88877026|NCT02845674|Experimental|OTX-101 0.09%|0.09% cyclosporine nanomicellar solution
88877027|NCT02845752|Active Comparator|Stiolto Respimat|Two actuations of Stiolto Respimat inhaler, taken once daily for 7 days. After a washout period of 14 days, participants will then receive matching Placebo for 7 days.
88877028|NCT02845752|Placebo Comparator|Placebo Respimat|Two actuations of Placebo Respimat inhaler, taken once daily for 7 days. After a washout period of 14 days, participants will then receive matching Placebo for 7 days.
88877029|NCT02849184|Experimental|suvorexant|Suvorexant (20mg for 64 years or younger; 15mg for 65 years or older) in oral administration, once daily before bedtime; Treatment duration: 2 weeks
88877030|NCT02849184|Placebo Comparator|placebo|Placebo in oral administration, once daily before bedtime; Treatment duration: 2 weeks.
89401768|NCT01377363||Not treatment|Locally recurrent breast carcinoma or metastatic
89401769|NCT03623217||Kidney transplant participants receiving tacrolimus|Transplant participants who have received tacrolimus twice daily for a minimum of 6 months to a maximum of 12 months after the surgery, and who are within 1 month of switching to the once daily regimen of modified release tacrolimus.
89401770|NCT03668145|Experimental|MSC group|mesenchymal stem cell transplantation via peripheral vein: 0.1-1x10E6 MSCs/kg body weight administered via peripheral vein at week 0, 4, 8 plus UDCA.
89401771|NCT03668145|Placebo Comparator|control|placebo infusions (placebo infusion differs from the experimental infusion in only that placebo has no mesenchymal stem cells) will be administered via peripheral vein at week 0, 4, 8 plus UDCA.
89401772|NCT02228486|Active Comparator|Cue Exposure Therapy and verum tDCS|During alcohol cue exposure, an active tDCS with a duration of 15 minutes and 2 mA is applied to the left dorsolateral prefrontal cortex (F3, anode) and a reference electrode placed over Fp2 (electrode positions determined by the international 10-20 system). The electrodes are rectangular (35cm2).
89401773|NCT02228486|Placebo Comparator|Cue Exposure Therapy and sham tDCS|During alcohol cue exposure, a placebo tDCS is used with electrodes placed over the left dorsolateral prefrontal cortex (F3, anode) and a reference electrode placed over Fp2 (electrode positions determined by the international 10-20 system). The electrodes are rectangular (35cm2). There is a 20 second ramp going up until 2 mA and back to 0 again at the beginning and the end of the placebo stimulation with no active stimulation during the cue exposure.
89401774|NCT02228486|No Intervention|Waiting list control group|The Cue-Reactivity of patients assigned to this arm will be measured twice with an interval of 5 weeks. Afterwards, patients will take part in the cue exposure therapy like subjects assigned to the active arms of the study
89401775|NCT03668925|Experimental|"Group Case"|patient diagnosed with hidrosadenitis suppurativa
89401776|NCT03668925|Active Comparator|"Group control"|patient without hidrosadenitis suppurativa
89401777|NCT01191957|Active Comparator|I. V. Busulphan plus Cyclophosphamide|Conventional conditioning regimen with intravenous (i.v.) Busulphan (Busilvex), 12.8 mg/kg followed by Cyclophosphamide, 120 mg/kg iv.
89401778|NCT01191957|Experimental|I. V. Busulphan plus Fludarabine|Reduced toxicity conditioning regimen with intravenous (i.v.)Busulphan (Busilvex), 12.8 mg/kg plus Fludarabine, 4 x 40 mg/m².
88877031|NCT02849418|Experimental|GSK1358820 Injection 200 U|Subjects will receive a single treatment with 200 U GSK1358820 injection (30 mL of study drug will be administered as 30 injections, each of 1.0 mL) in the detrusor of bladder, using cystoscopy and under local anesthesia. General anesthesia may be used excluding neuromuscular blocking agents. If the criteria for re-treatment between 12 to 36 weeks after first treatment are met, subjects will receive a second treatment with GSK1358820. Following this, subjects could receive another re-treatment up to 36 weeks after the first treatment, upon meeting the criteria, provided a minimum of 12 weeks elapse since previous treatment.
89401779|NCT02231996||gene mutation|
89401780|NCT01913912|Active Comparator|Lisdexamfetamine dimesylate (LDX)|Children will continue their therapeutic dose of LDX during the DBPC phase (which is determined during the titration phase). Before each testing session there will be a washout period of at least 48 hours; the optimal dose of LDX will be given the morning of the testing at the DRUG unit. For blinding purpose we will blindfold the children when taking LDX at the DRUG unit.
89401781|NCT01913912|Placebo Comparator|Sugar pill|Children will continue their therapeutic dose of LDX during the DBPC phase (which is determined during the titration phase). Before each testing session there will be a washout period of at least 48 hours; the placebo will be given the morning of the testing at the DRUG unit. For blinding purpose we will blindfold the children when taking placebo at the DRUG unit.
89401782|NCT02228798||Rivaroxaban|Patients currently taking rivaroxaban that have atrial fibrillation and require surgery or a procedure.
89401783|NCT02228798||Dabigatran|Patients currently taking dabigatran that have atrial fibrillation and require surgery or a procedure.
89401784|NCT02228798||Apixaban|Patients currently taking apixaban that have atrial fibrillation and require surgery or a procedure.
89401785|NCT02276066|Active Comparator|Inhospital group at day 14|This group of sepsis participants will remain hospitalized after day 14. A normal saline dilution of Iohexol 0.5-1 ml will be given IV push. Blood or urine will be collected prior to the injection and at approximately 1, 2, 3, and 4 hours after the injection for glomerular filtration rate measurements. This test will be repeated in one year. In addition to or as an option would be to have a timed urine collection to determine clearance of urea and creatinine can be performed instead of the saline dilution of Iohexol 0.5-1 ml and/or an estimated of GFR using serum creatinine and cystatin C measurement using calculations from blood samples.
89401786|NCT02276066|Other|Released from hosptial prior to day 14|This group of sepsis participants will be released from the hospital prior to day 14. A normal saline dilution of Iohexol 0.5-1 ml will be given IV push. Blood or urine will be collected prior to the injection and at approximately 1, 2, 3, and 4 hours after the injection for glomerular filtration rate measurements. This test will be repeated in one year. In addition to or as an option would be to have a timed urine collection to determine clearance of urea and creatinine can be performed instead of the saline dilution of Iohexol 0.5-1 ml and/or an estimated of GFR using serum creatinine and cystatin C measurement using calculations from blood samples.
89535502|NCT03221179|Placebo Comparator|Placebo|Participants will be administered a single SC dose of matching placebo formulation administered in up to 4 SC injections.
89535503|NCT05010447|Experimental|Study Group|Participants receive the Virtual Coach App for one week at the beginning of their therapy and one week towards the end of their therapy.
88877032|NCT02849418|Placebo Comparator|Placebo Injection|Subjects will receive a single treatment with placebo (30 injections, each of 1 mL) in the detrusor of bladder, using cystoscopy and under local anesthesia. General anesthesia may be used excluding neuromuscular blocking agents. If the criteria for re-treatment between 12 to 36 weeks after first treatment are met, subjects will receive treatment with GSK1358820. Following this, subjects could receive another re-treatment up to 36 weeks after the first treatment, upon meeting the criteria, provided a minimum of 12 weeks elapse since previous treatment
88877033|NCT02856828|Experimental|Digital Image Enhancement (DIE) Group|A novel digital image enhancement technology will be used intraoperatively
89535504|NCT03221101|No Intervention|Long Term Oxygen Therapy alone|Long Term oxygen therapy is prescribed according to the guidelines
88877034|NCT02856828|No Intervention|Control Group|Standard intraoperative imaging will be used intraoperatively
89401787|NCT01050855|Experimental|RIC: Distal Campath|"Day Treatment~Day - 22 Inpatient: Alemtuzumab (Campath) test dose IV or SQ (subcutaneously) (subcutaneously) over 2 hours~Day - 21 to-19 Alemtuzumab IV/ SQ (subcutaneously)~Day - 7 to -3 Readmission to hospital Fludarabine IV~Day - 2 Melphalan IV~Day - 1 Begin cyclosporine infusion~Day 0 Transplant: Bone marrow or cord blood infusion"
89401788|NCT01050855|Experimental|RIC:Intermediate Campath|"Day Treatment~Day - 14 to-10 Inpatient: Alemtuzumab (Campath) IV or SQ (subcutaneously)~Day - 7 to -3 Fludarabine IV~Day - 2 Melphalan 140 mg/m2 IV~Day - 1 Cyclosporine infusion starts~Day 0 Transplant: Bone marrow or cord blood infusion"
89401789|NCT01050855|Experimental|RIC: Mini Busulfan|"Day Treatment~Day - 8 Alemtuzumab (Campath) IV or SQ (subcutaneously)~Day - 7 Alemtuzumab (Campath) IV or SQ (subcutaneously)~Day - 6 Alemtuzumab (Campath) IV or SQ (subcutaneously) Busulfan IV Fludarabine IV~Day - 5 Alemtuzumab (Campath) IV or SQ (subcutaneously) Busulfan IV Fludarabine IV~Day - 4 Alemtuzumab (Campath) IV or SQ (subcutaneously) Fludarabine IV~Day - 3 Fludarabine IV~Day - 2 Fludarabine IV Cyclosporine infusion~Day - 1 Rest~Day 0 Transplant: Bone marrow or cord blood infusion"
89401790|NCT04459286|Active Comparator|Standard of Care (SOC)|Participants in this arm will receive SOC alone, which will be as determined by the clinical team at the treatment centres in line with the current National Interim Guidelines for Clinical Management of COVID-19
89401791|NCT04459286|Experimental|SOC plus Intervention|Participants in this arm will receive SOC plus study intervention composed of orally administered nitazoxanide and atazanavir/ritonavir tablets
88877035|NCT02861118||Cohort 1: Crohn's Disease|Participants with Crohn's disease who received biological treatment between June 2011 and June 2013.
88877036|NCT02861118||Cohort 2: Ulcerative Colitis|Participants with ulcerative colitis who received biological treatment between June 2011 and June 2013.
88877037|NCT02862912|Experimental|Chloroprocaine (CP)|Patients in CP group will receive 3% 2-chloroprocaine 50 mg (1.67 ml) and fentanyl 15 mcg (0.3 ml)
88877038|NCT02862912|Active Comparator|Bupivacaine (BUP)|Patients in BUP group will receive hyperbaric 0.75% bupivacaine 9 mg (1.4 ml), with fentanyl 15 mcg (0.3 ml), with saline (0.3 ml) to bring the volume to ~ 2 ml
89189627|NCT05563233|Experimental|Shotblocker|"Shotblocker is a flat, horseshoe-shaped device with short, non-sharp 2 mm thick blunt protrusions that connect with the skin, and a hole in the middle to expose the injection site used to reduce pain during subcutaneous or intramuscular injection applications.~Before the injection, the observer nurse will fill in the demographic data form, measure the child's heart rate, blood pressure and SpO2 values, and apply the pain and fear assessment scale. In addition, the pain and fear scale will be evaluated by the child and the parent.~During the intramuscular injection to be applied to the ventrogluteal region, the level of pain and fear will be examined by using Shot Blocker.~5 minutes after the injection, the pain and fear levels of the children in all groups will be re-evaluated by the child, the mother and the observing nurse. After the procedure, pulse, blood pressure and SpO2 values will be measured and recorded by the observing nurse."
89189628|NCT05563233|No Intervention|control group|"Before the injection, the observer nurse will fill in the demographic data form, measure the child's heart rate, blood pressure and SpO2 values, and apply the pain and fear assessment scale. In addition, the pain and fear scale will be evaluated by the child and the parent.~The level of pain and fear will be examined during intramuscular injection into the ventrogluteal region without any intervention.~5 minutes after the injection, the pain and fear level of the children in all groups will be re-evaluated by the child, the mother and the observing nurse. After the procedure, pulse, blood pressure and SpO2 values will be measured and recorded by the observing nurse."
89189629|NCT05558085|Experimental|EFNEP Group|Subjects will receive the EFNEP Eat Smart Being Active class series.
89189630|NCT05558085|No Intervention|Control Group|Subjects will receive no EFNEP intervention.
89401792|NCT03669939||Communication strategy|Primary Care providers who see HIV patients and follow them on opiates for chronic pain to receive communication strategies developed by the study team wit the guidance from the HV community and providers
89401793|NCT03669939||Standard of Care|Primary Care Providers - who see HIV patients and follow them on opiates for chronic pain will receive education on the the standard information about the CDC Guidelines
89401794|NCT02229032||Dravet Sydrome|Patients with Dravet Syndrome who are self-seeking therapy with Charlotte's Web strain of medical marijuana with the assistance of a medical marijuana doctor, but are still naïve to therapy
88877039|NCT02864706|Experimental|EVEROLIMUS|patients received everolimus (Certican), low-exposure CsA (Neoral), mycophenolate mofetil (MMF) and corticosteroids with CsA withdrawal after 7-11 weeks
88877040|NCT02864706|Active Comparator|Control|patients received standard CsA, MMF and corticosteroids
89198956|NCT04009564|Placebo Comparator|Placebo|Each participant will consume this arm in a visit has been allocated by Latin Square randomisation order: 280 of boiled water, coffee flavour and brown food colouring it will be served in a paper cup with lid
88877041|NCT02865720|Experimental|Subjects 2 to 5 years of age|500 U of CINRYZE will be administered by IV infusion twice weekly for 12 weeks
89004148|NCT02342782|Experimental|Treatment (yttrium Y 90 basiliximab, BEAM, AHCT)|Patients receive yttrium Y 90 basiliximab IV on days -21 and -14, carmustine IV over 1-2 hours on days -7 and -6, cytarabine IV BID on days -5 to -2, etoposide IV BID on days -5 to -2, and melphalan IV on day -1. Patients undergo autologous hematopoietic stem cell transplant on day 0.
88877042|NCT02865720|Experimental|Subjects 6 years of age and older|1000 U of CINRYZE will be administered by IV infusion twice weekly for 12 weeks.
89004149|NCT02327845||Affected|Affected with any of the diseases that are the focus of study by the CReATe Consortium, including ALS, ALS-FTD, HSP, PLS, PMA and MSP.
89004150|NCT02327845||Unaffected|Unaffected family members of enrolled affected individuals.
89004151|NCT02210078|Experimental|Treatment (allogeneic CMV-specific cytotoxic T-lymphocytes)|Patients receive allogeneic cytomegalovirus-specific cytotoxic T-lymphocytes IV. Patients with partial response, stable disease, or progressive disease may receive an additional dose of allogeneic cytomegalovirus-specific cytotoxic T-lymphocytes at a minimum of 2 weeks from the first infusion.
88877043|NCT02867202|Experimental|Intrauterine balloon|The heart-shaped intrauterine balloon is designed to fit into the cavity of the uterus,and removed on the 7th day after surgery. And hysteroscopy was taken out again after two or three months to re-evaluate the uterine adhesions.
88877044|NCT02867202|Experimental|intrauterine device Plus Foley Catheter|Intrauterine Contraceptive Device Plus Foley Catheter are inserted into the uterine after hysteroscopic adhesiolysis. Foley Catheter is removed after three days while intrauterine device is removed at the second hysteroscopy. Uterine adhesions are judged again at the second hysteroscopy.
88877045|NCT02871570|Experimental|Moderate Hepatic Impairment|A single dose of IV Rivipansel over 20 minutes
88877046|NCT02871570|Experimental|Normal Hepatic Function|A single dose of IV Rivipansel over 20 minutes
88877047|NCT02873286|Experimental|Group 1 - Single Low Dose / Booster|First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)
88877048|NCT02873286|Experimental|Group 2 - Two Low Doses|First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)
88877049|NCT02873286|Experimental|Group 3 - Single High Dose / Booster|First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)
89004152|NCT02174016|Experimental|Ketogenic diet|All subjects will be started on ketogenic diet formula feeding after enrollment for 2 weeks.
88877050|NCT02873286|Experimental|Group 4 - Two High Doses|First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)
88877051|NCT02873286|Experimental|Group 5 - Placebo|First dose (Week 0): placebo; Second dose (Week 4): placebo; (intramuscular vaccinations)
88877052|NCT02874066|Experimental|PTV/r/OBV/DSV|Paritaprevir/ritonavir/ombitasvir (PTV/r/OBV, 75mg/50mg/12.5mg per tablet, Viekirax): 2 tablets per os per day Dasabuvir (DSV, 250 mg per tablet, Exviera): 1 tablet per os twice per day Treatment duration: 12 weeks
88877053|NCT02874846|Experimental|Netarsudil Ophthalmic Solution 0.02%|1 drop in each eye (OU) daily
88877054|NCT02874846|Placebo Comparator|Netarsudil Ophthalmic Solution Vehicle|1 drop in each eye (OU) daily
88877055|NCT02880228|Experimental|Treatment (lenalidomide, dexamethasone, pembrolizumab)|Patients receive lenalidomide PO daily on days 1-21 and dexamethasone PO daily on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive pembrolizumab IV over 30 minutes on days 1 and 22 of course 1, day 15 of course 2, and day 8 of course 3. Courses 1-3 repeat beyond 3 courses in the absence of disease progression or unacceptable toxicity. Patients may undergo stem cell transplantation after 4 courses of treatment.
88877056|NCT02880852|Experimental|Belimumab 10 mg/kg|In this open label study, a single dose of 10 mg/kg Belimumab will be administered intravenously in Chinese subjects with systemic lupus erythematosus.
88877057|NCT02886234|Experimental|Mindfulness training (MT)|Eight, 30-minute phone delivered MT sessions once a week for 8 weeks
88877058|NCT02886234|Active Comparator|Health Coaching (HC)|Eight, 30-minute phone delivered HC sessions once a week for 8 weeks
88877059|NCT02887404|Experimental|Spine surgery analgesic pathway|"Before surgery the subject will be given one time oral dose Acetaminophen (1000 mg ) and gabapentin (600 mg).~During surgery the subject will receive an infusion of ketamine (5 mcg/kg/min) and lidocaine (1.5 mg/kg/hr start before the incision and decreased to 1 mg/kg/hr at start of closing and continued to PACU and stop at the first oral intake).~After surgery, the surgical team will manage pain medication and will consult acute pain management team as needed."
89004153|NCT02161263||Quality of Vision after LASIK surgery|Questionnaire
88877060|NCT02887404|Active Comparator|Usual care|"Placebo- Before surgery the subject will be given one time placebo oral dose Acetaminophen (1000 mg ) and gabapentin (600 mg).~Placebo- During surgery the subject will receive a placebo infusion of - ketamine (5 mcg/kg/min) and lidocaine (1.5 mg/kg/hr start at incision and decreased to 1 mg/kg/hr at start of closing and continued to PACU and stop at the first oral intake).~After surgery, the surgical team will manage pain medication and will consult acute pain management team as needed."
88877061|NCT02889510|Other|liraglutide|7-week subcutaneous liraglutide treatment once daily
88877062|NCT02889510|Other|placebo|7-week subcutaneous placebo treatment once daily.
88877063|NCT02893878||Vaccinated_Fluarix Tetra Group|Volunteered subjects who received GlaxoSmithKline's (GSK's) influenza vaccination (Fluarix Tetra) in approximately 10 volunteer practices.
88877064|NCT02893878||Vaccinated_Non GSK Group|Volunteered subjects who received Non-GSK influenza vaccination in approximately 10 volunteer practices.
88877065|NCT02893878||Vaccinated_Unknown Group|Volunteered subjects who received influenza vaccination (GSK or Non-GSK not known) in approximately 10 volunteer practices.
89401795|NCT02229110|Active Comparator|Signal|In addition to usual care, there will be an automatic signal in the electronic medical record (EMR) upon opening that will show the reader that the patient is currently not treated in the correct treatment setting and it simultaneously will give advice to which treatment allocation this patient should be transferred to.
89401796|NCT02229110|No Intervention|No signal|Patients receive usual care, consisting of 4 office visits yearly
89401797|NCT03023397|Other|Der f treated Non-smoker|
89401798|NCT03023397|Other|Der f treated Cigarette smoker|
89401799|NCT03023397|Other|Der f treated E-cig user|
89004154|NCT02157883|Experimental|AZD9291 alone, AZD9291+itraconozole|Sequential treatments of AZD9291 alone followed by AZD9291+itraconazole, with a washout period in between.
88877066|NCT02899650|Experimental|Young Fit|Young (18-39 yrs) people who have endurance training habit
88877067|NCT02899650|Experimental|Young Unfit|Young (18-39 yrs) people who have sedentary lifestyle.
88877068|NCT02899650|Experimental|Older Fit|Older (50-80 yrs) people who have endurance training habit
88877069|NCT02899650|Experimental|Older Unfit|Older (50-80 yrs) people who have sedentary lifestyle
89535505|NCT03221101|Active Comparator|Non invasive ventilation|"Home non invasive ventilation is prescribed with the following settings~PS mode~IPAP according to clinical and hemodynamic tolerance~EPAP according to air trapping~RR around 12/ min.~LOT for SaO2 > 90%~Monitoring with capnometry for settings validation"
89198957|NCT04038411|Experimental|PD-1 Antibody, chidamide, lenalidomide and etoposide|PD-1 Antibody: 240mg, d1, Chidamide: 20mg, twice a week, Lenalidomide: 25mg, d1-14 Etoposide:100mg/m2, d1-3 and 21 days made one treatment cycle.
89401800|NCT02229188|Active Comparator|Problem Solving Therapy|Problem Solving Therapy is an evidence-based behavioral treatment for late life depression proven effective with different geriatric groups including ambulatory; medically ill; older adults with executive dysfunctions; and more recently, low-income, disabled older adults.
89401801|NCT02229188|Experimental|Evolution|Evolution is a plasticity intervention in the form of a video driving game that targets the cognitive conflict network.
89401802|NCT02229188|Placebo Comparator|Words|Words is a challenging crosswords type of game that will serve as the placebo comparator to Evo.
89401803|NCT02223962|Experimental|Physical activity|The fitbit Ultra was used to provide real-time feedback on physical activity. An experienced physiotherapist contacted the subjects 3 times a week to receive information about the amount of steps from the previous days. In agreement with the patient, a new goal for the coming weeks was set and patients were motivated to achieve their individual goal.
89401804|NCT02223962|Placebo Comparator|Usual Care|During the hospital stay, the patients in the control group will be informed about the beneficial effects of being physically inactive.They will not receive feedback about their activities performed and will not be stimulated to become more active.
89401805|NCT02229266|Experimental|NK cells|Infusion of haploidentical NK cells after immunosuppression with cyclophosphamide and fludarabine, followed by immunostimulatory treatment with interleukin-2
89535506|NCT03321773|Experimental|triple therapy plus bismuth therapy|pantoprazole 40mg twice daily for 14 days, amoxicillin 1g twice daily for 14 days, clarithromycin 500mg twice daily for 14 days, bismuth subcitrate 240mg twice daily for 14 days.
89401806|NCT02229266|Active Comparator|Control Intervention|1 cycle of consolidation chemotherapy with high-dose cytarabine
89401807|NCT01944566|Experimental|heavy armpit odour|subjects with heavy armpit odour
89401808|NCT02224040|Experimental|Ceftriaxone I.V|The participants in this arm will receive the following drug and dosage: adult: Ceftriaxone intravenous 2 gr once a day. Pediatric: intravenous 75 mg/kg ceftriaxone once a day (maximum dose 2.5 g/day). Patients will receive antibiotic treatment until defervescence and for 3 days afterwards. Patients will be hospitalized during the entire treatment course (including the afebrile period).
88877070|NCT02899884||Cohort 1|Participants with cancer pain that is adequately controlled with opioids were observed for a period of 1 month in this observational study.
88877071|NCT02902146|Active Comparator|Bougie|On the first intubation attempt, this arm will attempt to place a bougie into the trachea, followed by an endotracheal tube.
88877072|NCT02902146|Active Comparator|No bougie (endotracheal tube first)|On the first intubation attempt, this arm will attempt to place an endotracheal tube into the trachea directly.
88877073|NCT02902770|Active Comparator|Lidocaine and normal saline push|1.5mg/kg IV Lidocaine Drip (given over 10 minutes) and normal saline push
89198958|NCT04009642||Type 2 Diabetes|
88877074|NCT02902770|Active Comparator|Ketorolac and normal saline drip|IV Ketorolac Tromethamine 30mg push and 10 minute normal saline drip
88877075|NCT02902770|Active Comparator|Lidocaine and Ketorolac|IV Lidocaine Drip and IV Ketorolac Push
88877076|NCT02903394|Experimental|mLCI imaging|mLCI device images cervical epithelium
88877077|NCT02907918|Experimental|Palbociclib + letrozole + trastuzumab +/- goserelin|"Neoadjuvant palbociclib + letrozole (plus goserelin if premenopausal) + trastuzumab for a total of 16 weeks, consisting of (4) 28-day cycles~Definitive surgery will be performed preferably within 6 weeks after the end of Cycle 4. Letrozole and trastuzumab will continue until the day of surgery. Letrozole will continue to be taken daily and trastuzumab will be given every 3 weeks per standard of care guidelines. Adjuvant therapy following definitive surgery will be at the discretion of the treating physician"
89004155|NCT02148003|Active Comparator|RFA at 90 degrees Celsius|Radiofrequency ablation (RFA) of the lumbar facets nerve supply will be performed at 90 degrees Celsius
89401809|NCT02224040|Experimental|Ceftriaxone I.V+Azithromycin P.O|The participants in this arm will receive the following drugs and dosages: adult: 2 g intravenous ceftriaxone and 500 mg oral azithromycin once a day. Pediatric: intravenous 75 mg/kg ceftriaxone once a day and oral 20 mg/kg azithromycin suspension once a day. Patients will receive antibiotic treatment until defervescence and for 3 days afterwards. Patients will be hospitalized during the entire treatment course (including the afebrile period).
89004156|NCT02148003|Active Comparator|RFA at 80 degrees Celsius|Radiofrequency ablation (RFA) of the lumbar facets nerve supply will be performed at 80 degrees Celsius
89401810|NCT02224040|Experimental|Azithromycin P.O|The participants in this arm will receive the following drug and dosage: adult: azithromycin oral 500 mg once a day. Pediatric: oral 20 mg/kg azithromycin suspension once a day (maximum dose 1000 mg/day). Patients will receive antibiotic treatment until defervescence and for 3 days afterwards.
89401811|NCT02224040|Experimental|Azithromycin P.O+Cefixime P.O|The participants in this arm will receive the following drugs and dosages: adult: 500 mg azithromycin and 400 mg cefixime. Pediatric: oral 20 mg/kg azithromycin suspension once a day and oral 10 mg/kg cefixime. Patients will receive antibiotic treatment until defervescence and for 3 days afterwards.
89401812|NCT04448834|Experimental|Treatment|A single cycle of blinatumomab which includes 4 weeks of CIVI of blinatumomab followed by a 2 week treatment free interval
89401813|NCT04429178||women in the 1st trimester of pregnancy.|
89401814|NCT04429178||women in the 2nd trimester of pregnancy.|
88877078|NCT02908620|Experimental|One spray CTY-5339-A, then one spray CTY-5339-CB|A single spray of CTY-5339-A Anesthetic Spray (14.0% benzocaine and 2.0% tetracaine HCl) tested over a 60 minute session, followed by a 4-14 day washout period, followed by a single spray of CTY-5339-CB Anesthetic Spray (14.0% benzocaine) tested over a 60 minute session.
88877079|NCT02908620|Experimental|2 sprays CTY-5339-A, then 1 spray CTY-5339-CB +1 spray placebo|Two sprays of CTY-5339-A Anesthetic Spray (14.0% benzocaine and 2.0% tetracaine HCl) tested over a 60 minute session, followed by a 4-14 day washout period, followed by a single spray of CTY-5339-CB Anesthetic Spray (14.0% benzocaine) and a single spray of vehicle control (CTY-5339-P) (sprayed outside the circumscribed area to avoid dilution of active drug) tested over a 60 minute session.
88877080|NCT02908620|Experimental|One spray of CTY-5339-CB, then one spray CTY-5339-A|A single spray of CTY-5339-CB Anesthetic Spray (14.0% benzocaine) tested over a 60 minute session, followed by a 4-14 day washout period, followed by a single spray of CTY-5339-A Anesthetic Spray (14.0% benzocaine and 2.0% tetracaine HCl) tested over a 60 minute session.
88877081|NCT02908620|Experimental|1 spray CTY-5339-CB +1 spray placebo, then 2 sprays CTY-5339-A|A single spray of CTY-5339-CB Anesthetic Spray (14.0% benzocaine) and a single spray of vehicle control (CTY-5339-P) (sprayed outside the circumscribed area to avoid dilution of active drug) tested over a 60 minute session, followed by a 4-14 day washout period, followed by a two sprays of CTY-5339-A Anesthetic Spray (14.0% benzocaine and 2.0% tetracaine HCl) tested over a 60 minute session.
88877082|NCT02910102|Other|Sequence AB|RVT-101 35 mg in Period II and Placebo in Period IV
88877083|NCT02910102|Other|Sequence BA|Placebo in Period II and RVT-101 35 mg in Period IV
88877084|NCT02911818|Active Comparator|CMS-Alone|Lifestyle counseling, as currently recommended by the CMS.
88877085|NCT02911818|Active Comparator|CMS-Liraglutide|CMS lifestyle counselling plus liraglutide.
88877086|NCT02911818|Active Comparator|Multi-Component Intervention|CMS-Liraglutide plus a 1000-1200 kcal/day portion-controlled diet prescribed for 12 weeks.
88877087|NCT02911818|Active Comparator|12-Week Extension Study: Phentermine Group|After the 1-year trial, half the participants who join the extension study will be randomized to phentermine 15.0 mg/d in a double-blind fashion, while continuing to take liraglutide. They will also continue to receive monthly lifestyle counseling. To be eligible for the extension study, participants must have been assigned to one of two medication groups in the original study.
88877088|NCT02911818|Active Comparator|12-Week Extension Study: Placebo Group|After the 1-year trial, half the participants who join the extension study will be randomized to placebo in a double-blind fashion, while continuing to take liraglutide. They will also continue to receive monthly lifestyle counseling. To be eligible for the extension study, participants must have been assigned to one of two medication groups in the original study.
88877089|NCT02912364|Experimental|Eslicarbazepine|Randomized to eslicarbazepine 800mg po bid in crossover design.
88877090|NCT02912364|Experimental|Carbamazepine|Randomized to carbamazepine 400mg po bid in crossover design.
88877091|NCT02913924|Experimental|Clonazepam|"Clonazepam will be taken twice per day in the morning and in the evening. Clonazepam is given in a fixed flexible dose schedule with the dose titrated to 2mg per day or the maximum tolerated dose. Clonazepam will be taken for the first 8 weeks of the trial."
88877092|NCT02913924|Placebo Comparator|Placebo|Placebo will be taken twice per day in the morning and in the evening. Placebo will be taken for the first 8 weeks of the trial.
88877093|NCT02916498|Active Comparator|Bipolar then alternative field shape stimulation|Boston Scientific's Precision SPECTRA™ Spinal Cord Stimulation System: Spinal cord stimulation for the management of chronic neuropathic pain programmed with bipolar stimulation for 21 days, then alternative field shape stimulation for 21 days
89401815|NCT04429178||women in the 3rd trimester of pregnancy.|
89401816|NCT04429178||non-pregnant women|
89401817|NCT02224118|Experimental|CNTO 3649 10 mcg/kg (single dose)|A single dose of 10 microgram per kilogram (mcg/kg) of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men.
89401818|NCT02224118|Experimental|CNT0 3649 30 mcg/kg (single dose)|A single dose of 30 mcg/kg of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men.
89401819|NCT02224118|Experimental|CNTO 3649 100 mcg/kg (single dose)|A single dose of 100 mcg/kg of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men.
89401820|NCT02224118|Experimental|CNTO 3649 300 mcg/kg (single dose)|A single dose of 300 microgram per kilogram (mcg/kg) of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men.
89401821|NCT02224118|Experimental|CNT0 3649 30 mcg/kg (multiple dose)|Participants with type 2 diabetes mellitus will be administered 30 mcg/kg CNTO 3649 as subcutaneous injection once a week for 4 weeks.
89401822|NCT02224118|Experimental|CNTO 3649 100 mcg/kg (multiple dose)|Participants with type 2 diabetes mellitus will be administered 100 mcg/kg CNTO 3649 as subcutaneous injection once a week for 4 weeks.
89401823|NCT02224118|Placebo Comparator|Placebo|Matching placebo to CNTO 3649 will be administered to both healthy volunteers and participants with type 2 diabetes mellitus.
89401824|NCT04415684|Experimental|Test Arm|
89401825|NCT02232308|Experimental|Nizatidine|Nizatidine (150 mg) will be administered once daily for the first 3 days, then twice daily for days 4-9, and once on day 10.
88877094|NCT02916498|Experimental|Alternative then bipolar field shape stimulation|Boston Scientific's Precision SPECTRA™ Spinal Cord Stimulation System: Spinal cord stimulation for the management of chronic neuropathic pain programmed with alternative field shape stimulation for 21 days, then bipolar stimulation for 21 days
88877095|NCT02917122|Placebo Comparator|sertraline + sham tDCS|Patients will take sham tDCS.
88877096|NCT02917122|Active Comparator|sertraline + active tDCS|Patients will take 12 tDCS sessions (30min for each session): first 10 consecutive sessions for two weeks (Monday to Friday), and then 2 follow-up sessions scheduled 2 and 4 weeks after the consecutive treatment.
89401826|NCT02232308|Experimental|Lisinopril|Lisinopril (10 mg) will be administered once daily for the first 3 days, then twice daily for days 4-9, and once on day 10.
89401827|NCT02232308|Experimental|Nizatidine plus Lisinopril|Nizatidine (150 mg) and Lisinopril (10 mg) will be administered once daily for the first 3 days, then twice daily for days 4-9, and once on day 10.
89401828|NCT02232308|Placebo Comparator|Placebo|Placebo capsules to match active drug will be administered once daily for the first 3 days, then twice daily for days 4-9, and once on day 10.
89401829|NCT02229500|Active Comparator|Control|Inulin control, 10g/d for 7 days. Isotope and appetite measurements on day 7
88877097|NCT02917278|Experimental|Meals|High-protein renal-specific meals
88877098|NCT02917278|No Intervention|Control|No Meals
88877099|NCT02921412|No Intervention|enfilcon A (habitual)|All participants wear enfilcon A toric lens (habitual) and then refitted with fanfilcon A toric lenses.
89401830|NCT02229500|Experimental|Delivery system 1|Delivery system, 28.5% w/w propionate, 10g/d for 7 days. Isotope and appetite measurements on day 7.
89401831|NCT02229500|Experimental|Delivery system 2|Delivery system, 54% w/w propionate, 10g/d for 7 days. Isotope and appetite measurements on day 7.
89401832|NCT02229734|Experimental|Radiation plus Androgen Supression|Radiation plus Androgen Suppression give as stereotactic radiation 7gray (Gy) per week x 5 weeks and leuprolide 45mg every 6 months for 18 months
88877100|NCT02921412|Active Comparator|fanfilcon A|All participants wear enfilcon A toric lens (habitual) and then refitted with fanfilcon A toric lenses.
88877101|NCT02921490|Experimental|PET/MR recipients|All recruited patients will undergo FDG PET/MR of the lumbar spine as the single arm of the study.
88877102|NCT02922582|Experimental|DepoTXA 400mg|400mg Intracapsular at the end of surgery one time
88877103|NCT02922582|Experimental|DepoTXA 800mg|800mg Intracapsular at the end of surgery one time
88877104|NCT02922582|Experimental|DepoTXA 1200mg|1200mg Intracapsular at the end of surgery one time
88877105|NCT02922582|Active Comparator|IV Tranexamic acid (TXA)|1 g of IV TXA at the end of surgery
89401833|NCT02224196|Experimental|manual ventilation|
89401834|NCT02224196|Active Comparator|pressure-controlled ventilation|
89401835|NCT02258516|Experimental|behavioral intervention|"Patient education for self-management called CHIME 3-M will be delivered"
89401836|NCT02258516|Active Comparator|control|attention control arm received phone calls to discuss non-heart failure related health topics
88877106|NCT02922738|Experimental|Intervention - VisualDx Arm|Arm had 2 levels: provider (cluster) level and patient level. Providers, randomly assigned to the intervention arm, refer to VisualDx when they saw a patient who presented with a skin problem. Their patients were assigned to the intervention group and interviewed about the outcomes of their treatment.
88877107|NCT02922738|No Intervention|Control - Usual Care Arm|Arm had 2 levels: provider (cluster) level and patient level. Providers, randomly assigned to control, did not refer to VisualDx but could refer to other information sources or none per usual care. Their patients were assigned to the control group and interviewed about the outcomes of their treatment
89401837|NCT02232464||ADHD group|Adults with clinical diagnosis of ADHD according to the DSM-IV criteria
89401838|NCT02232464||Control group|Age-, sex-, and IQ-matched healthy controls without lifetime diagnosis with ADHD
89401839|NCT04333160|Experimental|JTA-004|single knee intra-articular injection of JTA-004 solution (2ml)
89401840|NCT04333160|Placebo Comparator|placebo|single knee intra-articular injection of saline solution (2ml)
89401841|NCT04333160|Active Comparator|Hylan G-F 20|single knee intra-articular injection of Hylan G-F 20 (6ml)
88877108|NCT02925078|Other|<2 mm mucosa thickness|A Biohorizons Tapered Internal Implant, Laser-Lok, Resorbable Blast Textured (RBT) will be placed in subjects that have <2 mm mucosa thickness.
88877109|NCT02925078|Other|≥2 mm mucosa thickness|A Biohorizons Tapered Internal Implant, Laser-Lok, Resorbable Blast Textured (RBT) will be placed in subjects that have ≥2 mm mucosa thickness.
89401842|NCT02224352|Experimental|Single-Arm Study|Functional neuromuscular electrical stimulation of abdominal-wall muscles triggered by an airway pressure signal
89401843|NCT04778774|Experimental|Adductor canal block group|Adductor canal block group
88877110|NCT02925858|Experimental|Intervention|Intraoperative infusion of ketamine
88877111|NCT02925858|Placebo Comparator|Control|Control group receiving a saline infusion
89401844|NCT04778774|Experimental|Femoral nerve block group|Femoral nerve block group
89401845|NCT02224430||schizophrenia/schizoaffective disorder|Participants with schizophrenia/schizoaffective disorder.
89198959|NCT04009642||Non Diabetic|
89401846|NCT02258906|Experimental|Ulinastatin group|Patients in the ulinastatin group are given ulinastatin during operation.
89401847|NCT02258906|Placebo Comparator|control group|Patients in the control group receive the same volume of normal saline during operation.
89535507|NCT03321773|Active Comparator|reverse hybrid therapy|(pantoprazole 40mg twice daily for 7 days, amoxicillin 1 g twice dailyfor 7 days, clarithromycin 500 mg twice daily for 7 days, and metronidazole 500 mg twice daily for 7 days) followed by (pantoprazole 40mg twice daily for 7 days and amoxicillin 1 g twice daily for 7 days)
89535508|NCT03225703|Active Comparator|Exercise Leg|Left or right leg randomly assigned as exercise leg in a unilateral, exercise intervention. This will be a progressive exercise programme with the aim being to complete 50 multidirectional hops completed daily. (Hopping)
89535509|NCT03225703|No Intervention|Non exercise Leg|Randomly assigned non-exercise, control leg.
89535510|NCT03077217|Active Comparator|the high-dose rifaximin|The high-dose rifaximin group was given rifaximin 1200 mg/day for 8 weeks.
89401848|NCT02258984|Other|Open physician access to Venus 1000 CVP data|
89401849|NCT02258984|Other|No open physician access to Venus 1000 CVP data|
89401850|NCT04325906|Active Comparator|high flow nasal cannula only|Receive high flow nasal cannula only
89401851|NCT04325906|Experimental|HFNC plus prone positioning|Receive high flow nasal cannula plus prone positioning
89535511|NCT03077217|Active Comparator|the low-dose rifaximinl group|The low-dose rifaximin group was given rifaximin 800 mg/day for 8 weeks.
89535512|NCT03077217|Placebo Comparator|the control group|The control group didn't receive rifaximin treatment
89535513|NCT02487017|Sham Comparator|Transcatheter Arterial Chemoembolization|Transcatheter Arterial Chemoembolization treatment according to NCCN guidelines，patients will receive 5-FU Hepatic arterial infusion,3 cycles at least.
89535514|NCT02487017|Experimental|DC-CIK|After accepting concurrent TACE according to NCCN guidelines,patients will receive 3 cycles of DC-CIK treatment at least.
89535515|NCT05001243|Experimental|Experimental PBOHB|Pilocarpine, brimonidine, Oxymetazoline combined with Hyaluronic Acid and Bromfenac combined in an ophthalmic solution to be randomly instilled in one eye.
89535516|NCT05001243|Active Comparator|Pilocarpine 5 mgs|Pilocarpine was instilled in the other oye.
89535517|NCT05001243|Active Comparator|Brimonidine 0.5 mgs|Brimonidine was instilled in the other eye.
89401852|NCT02229812||thrombolytic therapy in stroke|
89401853|NCT02229890||Acute ischemic stroke within three hours after symptom onset|
89401854|NCT02230046|Experimental|Sequence 1 (ABC)|Participants will receive a single oral 1000 milligram [mg] dose of abiraterone acetate in all 3 periods under fasted conditions as: Treatment A (current commercial formulation, 4*250 mg uncoated tablets) in Period 1, Treatment B (current commercial formulation, 4*250 mg coated tablets) in Period 2 and Treatment C (new composition, 2*500 mg coated tablets) in Period 3.
89401855|NCT02230046|Experimental|Sequence 2 (BCA)|Participants will receive a single oral 1000 milligram [mg] dose of abiraterone acetate in all 3 periods under fasted conditions as: Treatment B (current commercial formulation, 4*250 mg coated tablets) in Period 1, Treatment C (new composition, 2*500 mg coated tablets) in Period 2 and Treatment A (current commercial formulation, 4*250 mg uncoated tablets) in Period 3.
89401856|NCT02230046|Experimental|Sequence 3 (CAB)|Participants will receive a single oral 1000 milligram [mg] dose of abiraterone acetate in all 3 periods under fasted conditions as: Treatment C (new composition, 2*500 mg coated tablets) in Period 1, Treatment A (current commercial formulation, 4*250 mg uncoated tablets) in Period 2 and Treatment B (current commercial formulation, 4*250 mg coated tablets) in Period 3.
89535518|NCT04492631|Experimental|Probiotic|Powdered probiotic with a carrier.
89535519|NCT04492631|Placebo Comparator|Placebo|Carrier only.
89535520|NCT05005143||Paroxysmal AF ablation|Patients with standard indications to paroxysmal AF ablation
89535521|NCT03225469|Experimental|reinforced family member education group|Regular instructions will be given to all patients during the colonoscopy appointment. At least one family member who lives with the patient together will be given instruction at the basis of patent education.
89401857|NCT02230046|Experimental|Sequence 4 (ACB)|Participants will receive a single oral 1000 milligram [mg] dose of abiraterone acetate in all 3 periods under fasted conditions as: Treatment A (current commercial formulation, 4*250 mg uncoated tablets) in Period 1, Treatment C (new composition, 2*500 mg coated tablets) in Period 2 and Treatment B (current commercial formulation, 4*250 mg coated tablets) in Period 3.
89401858|NCT02230046|Experimental|Sequence 5 (BAC)|Participants will receive a single oral 1000 milligram [mg] dose of abiraterone acetate in all 3 periods under fasted conditions as: Treatment B (current commercial formulation, 4*250 mg coated tablets) in Period 1, Treatment A (current commercial formulation, 4*250 mg uncoated tablets) in Period 2 and Treatment C (new composition, 2*500 mg coated tablets) in Period 3.
89401859|NCT02230046|Experimental|Sequence 6 (CBA)|Participants will receive a single oral 1000 milligram [mg] dose of abiraterone acetate in all 3 periods under fasted conditions as: Treatment C (new composition, 2*500 mg coated tablets) in Period 1, Treatment B (current commercial formulation, 4*250 mg coated tablets) in Period 2 and Treatment A (current commercial formulation, 4*250 mg uncoated tablets) in Period 3.
89401860|NCT02230202||Healthy control|Healthy control that meets inclusion/exclusion criteria. Single blood draw and flow-mediated dilation (FMD).
89401861|NCT02230202||Stage III or IV CKD patients|Stage III or IV CKD patients that meets inclusion/exclusion criteria. Single blood draw and flow-mediated dilation (FMD).
88877112|NCT02933034|Experimental|Coronary Disease|Participant receive 2 cardiac MRI procedures: MEMRI and DEMRI.
89401862|NCT02230202||Post-transplant patients|Stage III or IV CKD Post-transplant patients that meets inclusion/exclusion criteria. Single blood draw and flow-mediated dilation (FMD).
88877113|NCT02933502|Experimental|DSXS topical product|treatment with DSXS once daily for 28 days
89401863|NCT02224586||light treatment|clinical routine treatment according to the doctor's advice
89401864|NCT02224742|Experimental|LeucoPatch|Usual care supplemented by the application of LeucoPatch centrifugates that comprise autologous fibrin patches containing living white cells and platelets
88877114|NCT02935062|Active Comparator|Traditional Phonological Therapy|This intervention will be intermediated by the traditional model cycles. This approach has the principle of treating the suppression of operant phonological processes in child's speech, from the awareness of sound-target characteristics operating in that phonological process.
88877115|NCT02935062|Experimental|Software Phonological Therapy- SIFALA|This intervention will be intermediated by the software SIFALA. The software SIFALA, allows to select target segments using the Modelo de Estratos (second model Strata), based on the level segment of production and complexity of distinctive features, from the child's sound system analysis and planned generalizations. It also seeks the treatment of phonological disorders, by selection stimulus words in more favorable environments and playful activities with computer resource for the correct production of the target segment in the words stimulus, promoting the spread segments.
88877116|NCT02935062|Placebo Comparator|Placebo Therapy|No interventional group. This group will be the sham group. The proposed activities will be fun games on the computer, there is no relationship with speech and it will be not emphasized the correct sound production, will only play activities.
88877117|NCT02936076|Active Comparator|Exercise condition|Participants randomized to the exercise condition will participate in a 12-week exercise training program. The exercise intervention will consist of both supervised and unsupervised exercise sessions and progress to 200 minutes/week of moderate-intensity exercise. Exercise bouts will be spread across 4-6 days and be at least 20 minutes in duration. During supervised visits, heart rate will be monitored by a member of the research staff to ensure that exercise is within the prescribed intensity range and ratings of perceived exertion and feeling state will be assessed periodically. Unsupervised exercise will be verified using objective physical activity monitors.
88877118|NCT02936076|Placebo Comparator|Delayed exercise condition|Participants randomized to the delayed exercise condition will be asked not to change their exercise or eating habits over the 12-week period and will complete the same assessment measures as the exercise condition. However, following the completion of the 12-week period, participants will be given two options: 1) receive a one-on-one session with an exercise physiologist at our center and receive a written exercise program, and at this time point all study obligations will be completed, or 2) complete the identical exercise protocol as the 'exercise' condition.
88877119|NCT02937168|Experimental|Part 1: PET/CT Scan|Healthy participants will have 2 PET/CT scan in Part 1: within 7 days of eligibility being confirmed, and 7 days after the first PET/CT scan. Participants will receive Fluorodeoxyglucose F-18 (FDG) as part of the PET/CT procedures and will provide sputum/blood samples.
89401865|NCT02224742|Active Comparator|Usual care|Usual care provided in a multidisciplinary foot care clinic, in accordance with international guidelines
89401866|NCT03068455|Experimental|nivolumab + ipilimumab|Specified Dose on Specified Days
89401867|NCT03068455|Experimental|nivolumab|Specified Dose on Specified Days
89401868|NCT02230280|Other|The intervention cohort.|A community transition and rehabilitation intervention that includes a mobile health solution
89401869|NCT03067987|Active Comparator|720 shockwave therapy|5 daily sessions of shockwave therapy within a week (Monday, Tuesday, Wednesday, Thursday, Friday), in which 720 shocks of treatment energy will be applied in every session to each treated region (left and right corpora cavernosa and crura).
89401870|NCT03067987|Active Comparator|600 shockwave therapy|"Three sessions of shockwave therapy per week (Monday, Wednesday, Friday) for 2 consecutive weeks, in which 600 shocks of treatment energy will be applied in every session to each treated region (left and right corpora cavernosa and crura)~Following the last treatment session, each patient will resume his baseline consumption of phosphodiesterase 5 inhibitor, in terms of type and dose of drug, for the remainder of study duration."
89401871|NCT02259296|Experimental|Lower eGFR for AVF creation|
89401872|NCT02259296|Active Comparator|Higher eGFR for AVF creation|
89401873|NCT02232854|Experimental|Depression training/supervision program|"A complex intervention, which will include:~Primary Health Care team training in depression~A focus group, after training~Telephone monitoring of patients~Web-based supervision of clinicians"
89401874|NCT02232854|No Intervention|Usual Care|Patients in the control group will receive all the interventions that are guaranteed for persons with depression in Chile: treatment in Primary Health Care clinics with the Primary Health Care team and referral to the regional specialized psychiatric service.
89401875|NCT04207736|Active Comparator|Reproxalap Ophthalmic Solution (0.25%)|
89401876|NCT04207736|Placebo Comparator|Vehicle Ophthalmic Solution|
89401877|NCT02232932|Experimental|CAPECITABINE-Radiotherapy -Liver Transplantation|Neoadjuvant Radio-Chemotherapy (RC) and Liver Transplantation (LT)
89401878|NCT02232932|Active Comparator|RESECTION|Liver resection
89401879|NCT02230358|Other|Regional anesthesia (RA)|Regional anesthesia (RA) for a carotid endarterectomy Interventions: Regional anesthesia (RA), blood gas analysis, 'Transcranieller Doppler' (Transcranial Doppler ultrasonography), invasive arterial blood pressure measurement, arterial blood gas measurement, neurological control, Near-infrared spectroscopy (NIRS) monitoring, oxygen supply (not invasive 'Vigileo')
89401880|NCT02230358|Other|General anesthesia (GA)|General anesthesia (GA) for a carotid endarterectomy Interventions: General anesthesia, blood gas analysis, 'Transcranieller Doppler' (Transcranial Doppler ultrasonography), invasive arterial blood pressure measurement, arterial blood gas measurement, neurological control, NIRS monitoring, oxygen supply (not invasive 'Vigileo')
89401881|NCT02230436|Experimental|Early drain removal|Removing drain(s) on postoperative day 3 (n = 72)
89401882|NCT02230436|Experimental|Late drain removal|Removing drain(s) on postoperative day 4 or later (n = 72)
89401883|NCT02230514|Experimental|XCEL-MT-OSTEO-ALPHA and surgery|"ex-vivo expanded autologous mesenchymal stromal cells fixed in allogenic bone tissue"
89401884|NCT02230514|Other|Autologous iliac crest and surgery|Standard treatment
89401885|NCT04132466|Experimental|Enrolled Subjects|Adult subjects who met eligibility criteria and provided written informed consent to participate
88877120|NCT02937168|Experimental|Part 2: Reslizumab|Reslizumab 3.0 milligrams/kilogram (mg/kg) will be administered by intravenous (IV) infusion, over 20 to 50 minutes, at Baseline (Day 1) of Part 2. PET/CT scan will be done on Weeks 2, 4 and 6. Participants will receive FDG as part of the PET/CT procedures and will provide sputum/blood samples.
88877121|NCT02937168|Placebo Comparator|Part 2: Placebo|Matching placebo will be administered by IV infusion at Baseline (Day 1) of Part 2. PET/CT scan will be done on Weeks 2, 4 and 6. Participants will receive FDG as part of the PET/CT procedures and will provide sputum/blood samples.
88877122|NCT02937558|Experimental|CSI-Glucagon (Double-Blind Phase - 2 days)|Glucagon solution delivered as a continuous subcutaneous infusion via a patch pump at a starting dosage of 5 mcg/kg/hr.
88877123|NCT02937558|Placebo Comparator|Placebo (Double-Blind Phase - 2 days)|Vehicle solution delivered as a 24-hour continuous subcutaneous infusion via a patch pump.
88877124|NCT02937558|Experimental|CSI-Glucagon (Open-label Phase - Up to 28 days)|Glucagon solution delivered as a continuous subcutaneous infusion via a patch pump at a starting dosage of 5 mcg/kg/hr.
88877125|NCT02938494|Experimental|IDP-123 Lotion|Lotion
89401886|NCT02233010||kidney function normal group|kidney function normal group : defined by the normal level of NGAL after post operation 4hrs
89401887|NCT02233010||kidney function decreased group|kidney function decreased group : defined by the increased level of NGAL after post operation 4hrs
88877126|NCT02938494|Active Comparator|Tazorac Cream|Cream
88877127|NCT02938494|Active Comparator|Vehicle Lotion|Lotion
89198960|NCT00882297|Active Comparator|1|Transversal approach guided placement
89401888|NCT04098848|Experimental|Intradialytic exercise|Cycling exercise 30 minutes a time, three times a week during hemodialysis
89401889|NCT04098848|No Intervention|Control group|not participate in cycling exercise during hemodialysis
89401890|NCT03518138|Experimental|Group 1, study drug|65 patients treated with Q-122, 100 mg BID
89401891|NCT03518138|Placebo Comparator|Group 2, placebo|65 patients treated with placebo
89401892|NCT04066634|Experimental|Assist in Diagnosis|The Vivio Analysis Software is an analysis software that assists in identifying suspected systolic murmurs associated with aortic stenosis. The Vivio Analysis Software is used with the Vivio System, a non-invasive device used for the detection and amplification of sounds from the heart and arteries.
89401893|NCT03494504|Experimental|Reproxalap Ophthalmic Solution (0.25%)|
89401894|NCT03494504|Experimental|Reproxalap Ophthalmic Solution (0.5%)|
89401895|NCT03494504|Placebo Comparator|Vehicle Ophthalmic Solution|
89401896|NCT04049864|Experimental|All subjects|All subjects will receive the vaccine and be followed per the schedule of procedures.
89401897|NCT03475706|Experimental|Solabegron immediate release tablets low dose|
89401898|NCT03475706|Experimental|Solabegron immediate release tablets high dose|
88877128|NCT02938494|Active Comparator|Vehicle Cream|Cream
88877129|NCT02941614||Intervention|Newly diagnosed breast cancer patients will be offered a brief distress screening questionnaire, the Patient Health Questionnaire (PHQ), around the time of their breast cancer diagnosis and again at subsequent transitions in care as appropriate (e.g., the initiation of chemotherapy).
88877130|NCT02941614||Control|Newly diagnosed breast cancer patients will experience usual care.
88877131|NCT02941692|Experimental|Oxytocin|Participants randomized to this condition will receive 40 IU dose of intranasal oxytocin.
89198961|NCT00882297|Active Comparator|2|Longitudinal approach guided placement
89198962|NCT00883467|Other|1|baseline MR signal prior to, during and 30 minutes after an ischemic period of 20 minutes
88877132|NCT02941692|Placebo Comparator|Placebo|Participants randomized to this condition will receive a matching dose of intranasal saline spray as placebo.
88877133|NCT02942160|Experimental|EN3835 Active|EN3835 0.84mg (Collagenase Clostridium Histolyticum)
88877134|NCT02953860|Experimental|Fulvestrant with Enzalutamide|500mg of Fulvestrant will be given IM on days 1, 15, 28, then every 4 weeks as per standard of care (SOC) and 160mg of Enzalutamide will be given, in conjunction with Fulvestrant, PO daily.
88877135|NCT02956044|Active Comparator|Group 1: Bexagliflozin alone|
88877136|NCT02956044|Active Comparator|Group 1: Metformin alone|
89401899|NCT03475706|Placebo Comparator|Placebo Comparator|
89401900|NCT04035200|Experimental|V117957 1 mg|V117957 tablets taken orally at bedtime
89401901|NCT04035200|Experimental|V117957 2 mg|V117957 tablets taken orally at bedtime
89401902|NCT04035200|Placebo Comparator|Placebo|Placebo to match V117957 tablets taken orally at bedtime
89401903|NCT03997838|Experimental|VVZ-149 Injections|
89401904|NCT03997838|Placebo Comparator|Placebo|
89401905|NCT03986138|Experimental|gadopiclenol-enhanced MRI then gadobutrol-enhanced MRI|Cross-over design: each patient receives gadopiclenol for the first MRI and then gadobutrol for the second MRI
89401906|NCT03986138|Experimental|gadobutrol-enhanced MRI then gadopiclenol-enhanced MRI|Cross-over design: each patient receives gadobutrol for the first MRI and then gadopiclenol for the second MRI
89401907|NCT02234336||Subjects with HCM|All subjects will undergo noncontrast echocardiography, contrast echocardiography and cardiac MRI.
88877137|NCT02956044|Active Comparator|Group 1: Bexagliflozin + Metformin|
88877138|NCT02956044|Active Comparator|Group 2: Bexagliflozin alone|
88877139|NCT02956044|Active Comparator|Group 2: Glimepiride alone|
88877140|NCT02956044|Active Comparator|Group 2: Bexagliflozin + Glimepiride|
88877141|NCT02956044|Active Comparator|Group 3: Bexagliflozin alone|
88877142|NCT02956044|Active Comparator|Group 3: Sitagliptin alone|
88877143|NCT02956044|Active Comparator|Group 3: Bexagliflozin + Sitagliptin|
88877144|NCT02956122|Experimental|Study Part 1 - All Participants - GLASSIA|Participants to receive GLASSIA (intravenously) and methylprednisolone or equivalent steroid (either IV or oral per investigator discretion)
88877145|NCT02956122|Experimental|Study Part 2 - GLASSIA|Participants to receive GLASSIA (intravenously) and methylprednisolone or equivalent steroid (either IV or oral per investigator discretion)
88877146|NCT02956122|Placebo Comparator|Study Part 2 - Albumin (Control)|Participants to receive control (intravenously) and methylprednisolone or equivalent steroid (either IV or oral per investigator discretion)
89401908|NCT02234492|Active Comparator|Rosuvastatin|Rosuvastatin 10mg once daily for 6 months.
89401909|NCT02234492|No Intervention|No rosuvastatin|No rosuvastatin- this group will continue with their current medical therapy for 6 months.
89401910|NCT01529996|Experimental|YAG laser|
88877147|NCT02956746|Experimental|Imovax, SYN023|Subjects will receive SYN023 and 5 doses of Imovax rabies vaccine
88877148|NCT02956746|Active Comparator|Imovax, human rabies immune globulin|Subjects will receive HyperRAB ST (human rabies immune globulin) and 5 doses of Imovax rabies vaccine
88877149|NCT02956746|Experimental|RabAvert, SYN023|Subjects will receive SYN023 and 5 doses of RabAvert rabies vaccine
88877150|NCT02956746|Active Comparator|RabAvert, human rabies immune globulin|Subjects will receive HyperRAB ST (human rabies immune globulin) and 5 doses of RabAvert rabies vaccine
88877151|NCT02961894|Experimental|Revolution Treatment Arm|This is a single-arm study. All eligible and participating patients will be treated wit the Revolution™ Peripheral Atherectomy System.
88877152|NCT02963376|Active Comparator|0.05 mL/kg DDFPe|This study is a randomized, placebo controlled, blinded escalating dose study designed to determine the maximum tolerated dose to intravenous administration of DDFPe. At each of the three dose levels 0.10, 0.17 mL/kg) six subjects will receive DDFPe and two will receive placebo.
88877153|NCT02963376|Placebo Comparator|0.05 mL/kg Placebo|This study is a randomized, placebo controlled, blinded escalating dose study designed to determine the maximum tolerated dose to intravenous administration of DDFPe. At each of the three dose levels 0.10, 0.17 mL/kg) six subjects will receive DDFPe and two will receive placebo.
88877154|NCT02963376|Active Comparator|0.10 mL/kg DDFPe|This study is a randomized, placebo controlled, blinded escalating dose study designed to determine the maximum tolerated dose to intravenous administration of DDFPe. At each of the three dose levels 0.10, 0.17 mL/kg) six subjects will receive DDFPe and two will receive placebo.
89401911|NCT01529996|Active Comparator|Pulse Dye Laer|
89401912|NCT03933410|Experimental|KB195|KB195 is a novel glycan
89401913|NCT03303170|Experimental|Sebacia Microparticles|
89401914|NCT03303170|Active Comparator|Nd:Yag Laser|
89401915|NCT03928184|Experimental|0.07 mg lorecivivint|One intra-articular injection of 0.07 mg lorecivivint in 2 ml vehicle
89401916|NCT03928184|Placebo Comparator|Vehicle|One intra-articular injection of 0 mg lorecivivint in 2 ml vehicle
89401917|NCT02259374|Active Comparator|TAP BLOCK 0.2% ROPIVACAINE|"Patients randomised into this group will receive bilateral TAP block (single shot) with 0.2% ropivacaine after hysterectomy.~Intervention: TAP block Dose: 20 ml 0.2% ropivacaine"
89401918|NCT02259374|Active Comparator|TAP BLOCK 0.4% ROPIVACAINE|"Patients randomised into this group will receive bilateral TAP block (single shot) with 0.4% ropivacaine after hysterectomy.~Intervention: TAP block Dose: 20 ml 0.4% ropivacaine"
89401919|NCT03204422||Children's group|no intervention. participants, whose age was 5 to 18 years, were enrolled in Children's group.
89401920|NCT03204422||Adults group|no intervention. participants, whose age was over 18 years, were enrolled in Adults group.
89401921|NCT03197870|Experimental|AKB-9778 15mg Daily|AKB-9778 15 mg (QD); To maintain masking, subjects will receive BID dosing with masked study medication administered as one dose of active and one dose of matching placebo
89401922|NCT03197870|Experimental|AKB-9778 15mg Twice Daily|AKB-9778 15 mg (BID)
89401923|NCT03197870|Placebo Comparator|Placebo Twice Daily|Placebo Group: SC Phosphate-Buffered-Saline (PBS) (BID)
88877155|NCT02963376|Placebo Comparator|0.10 mL/kg Placebo|This study is a randomized, placebo controlled, blinded escalating dose study designed to determine the maximum tolerated dose to intravenous administration of DDFPe. At each of the three dose levels 0.10, 0.17 mL/kg) six subjects will receive DDFPe and two will receive placebo.
88877156|NCT02963376|Active Comparator|0.17 mL/kg DDFPe|This study is a randomized, placebo controlled, blinded escalating dose study designed to determine the maximum tolerated dose to intravenous administration of DDFPe. At each of the three dose levels 0.10, 0.17 mL/kg) six subjects will receive DDFPe and two will receive placebo.
88877157|NCT02963376|Placebo Comparator|0.17 mL/kg Placebo|This study is a randomized, placebo controlled, blinded escalating dose study designed to determine the maximum tolerated dose to intravenous administration of DDFPe. At each of the three dose levels 0.10, 0.17 mL/kg) six subjects will receive DDFPe and two will receive placebo.
88877158|NCT02967354|Experimental|Healthy control|Healthy control
88877159|NCT02967354|Experimental|Obese with oral antidiabetic drugs|BMI>30, Type 2 diabetes treated with oral antidiabetic drugs
88877160|NCT02967354|Experimental|Obese, treated with oral antidiabetic drugs + insulin|BMI>30, Type 2 diabetes treated with oral antidiabetic drugs + insulin
89189631|NCT05556200|Experimental|Experiment|"Eligible patients enrolled receive camrelizumab 200 mg, iv, d1, every 21 days (3 mg/kg if weight <50 kg) in combination with apatinib 250 mg, po, qd for neoadjuvant treatment for 8 cycles.~Patients evaluated after neoadjuvant therapy with pCR receive 9 cycles of postoperative adjuvant camrelizumab (200 mg, iv, or 3 mg/kg if weight <50 kg, d1,q3W) + apatinib (250 mg, po, qd).~Patients with non-pCR after neoadjuvant therapy receive adjuvant chemotherapy of the physician's choice (TPC)."
89401924|NCT04921982|Experimental|Propranolol|
89401925|NCT04921982|Placebo Comparator|Placebo|
89401926|NCT04889222|Experimental|Pulse oximeters|All subjects who are enrolled into the test group and participate in data collection receive the noninvasive pulse oximeter sensors.
89401927|NCT04874324|Experimental|WCK 2349|"WCK 2349 800mg, 1000mg, and 1200mg . 1 dose given orally twice daily at 12 hourly interval for five days.~Dosage form : Oral"
89401928|NCT04874324|Placebo Comparator|Placebo|Matching Placebo administered as Oral
88877161|NCT02967354|Experimental|Normal weight, treated with oral antidiabetic drugs|BMI 20-26. Type 2 diabetes treated with oral antidiabetic drugs
88877162|NCT02967354|Experimental|Normal weight, treated with oral antidiabetic drugs + insulin|BMI 20-26. Type 2 diabetes treated with oral antidiabetic drugs + insulin
88877163|NCT02967510|Experimental|0.005% estriol vaginal gel|Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel, containing 50 Mcg of estriol Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration
88877164|NCT02967510|Experimental|0.002% estriol vaginal gel|Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel, containing 50 Mcg of estriol Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration
89189632|NCT05549622|Other|Low-soluble fiber diet|
89189633|NCT05549622|Active Comparator|High-soluble fiber diet|
89401929|NCT04866056|Experimental|Treatment(Jaktinib+Azacitidine)|Patients receive azacitidine subcutaneously (SC) on days 1-7 and Jaktinib orally (PO) twice daily (BID) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89401930|NCT03911102|Experimental|Cohort 1: DAXI 12 U|DAXI for injection for the treatment of moderate to severe Lateral Canthal Lines (LCL)
89401931|NCT03911102|Experimental|Cohort 2: DAXI 24 U|DAXI for injection for the treatment of moderate to severe Lateral Canthal Lines (LCL)
89401932|NCT03911102|Experimental|Cohort 3: DAXI 36 U|DAXI for injection for the treatment of moderate to severe Lateral Canthal Lines (LCL)
89401933|NCT03911102|Experimental|Cohort 4: DAXI 48 U|DAXI for injection for the treatment of moderate to severe Lateral Canthal Lines (LCL)
89401934|NCT04789148|Experimental|4 IU oxytocin - 24 IU oxytocin - placebo|Main visit 1: 4 IU intranasal oxytocin; Main visit 2: 24 IU intranasal oxytocin; Main visit 3: intranasal placebo
89401935|NCT04789148|Experimental|4 IU oxytocin - placebo - 24 IU oxytocin|Main visit 1: 4 IU intranasal oxytocin; Main visit 2: intranasal placebo; Main visit 3: 24 IU intranasal oxytocin
89401936|NCT04789148|Experimental|24 IU oxytocin - 4 IU oxytocin - placebo|Main visit 1: 24 IU intranasal oxytocin; Main visit 2: 4 IU intranasal oxytocin; Main visit 3: intranasal placebo
88877165|NCT02967510|Experimental|0.0008% estriol vaginal gel|Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel, containing 50 Mcg of estriol Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration
89401937|NCT04789148|Experimental|24 IU oxytocin - placebo - 4 IU oxytocin|Main visit 1: 24 IU intranasal oxytocin; Main visit 2: intranasal placebo; Main visit 3: 4 IU intranasal oxytocin
89401938|NCT04789148|Experimental|Placebo - 4 IU oxytocin - 24 IU oxytocin|Main visit 1: intranasal placebo; Main visit 2: 4 IU intranasal oxytocin; Main visit 3: 24 IU intranasal oxytocin
88877166|NCT02967510|Placebo Comparator|estriol vaginal gel|Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel, containing 50 Mcg of estriol Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration
89401939|NCT04789148|Experimental|Placebo - 24 IU oxytocin - 4 IU oxytocin|Main visit 1: intranasal placebo; Main visit 2: 24 IU intranasal oxytocin; Main visit 3: 4 IU intranasal oxytocin
89401940|NCT03892772|Experimental|SAS0421a, SAS0421b and SAS0421c|Participants will take SAS0421a, SAS0421b and SAS0421c for 3 days. Half doses will be given on the first night.
89401941|NCT03892772|Active Comparator|SAS0421a and SAS0421b|Participants will take SAS0421a and SAS0421b for 3 days. Half doses will be given on the first night.
88877167|NCT02968134|Other|Posaconazole|The study will enrol eight patients with presumed or confirmed systemic fungal infections, who are admitted to ICU
88877168|NCT02968368|Experimental|Oral ferric maltol|30mg capsules BID
88877169|NCT02968368|Placebo Comparator|Oral placebo|Matching placebo capsules BID
89401942|NCT03892772|Active Comparator|SAS0421c|Participants will take SAS0421c for 3 days. Half doses will be given on the first night.
88877170|NCT02968758|Experimental|Accuracy Testing|Comparison between GenePOC PCR and Reference Method
88877171|NCT02968914|Active Comparator|Benralizumab by Accessorized Pre-Filled Syringe|Drug administration by Accessorized Pre-Filled Syringe. A total of 180 subjects will be randomized and will be stratified by weight group (55 to 69.9 kg, 70 to 84.9 kg and 85 to 100 kg). Within each of the 3 weight groups, subjects will be randomized 1:1:1:1:1:1 to 1 of the 6 combinations of treatment (APFS) with injection site (upper arm, abdomen or thigh)
88877172|NCT02968914|Other|Benralizumab by Autoinjector|Drug administration by Autoinjector A total of 180 subjects will be randomized and will be stratified by weight group (55 to 69.9 kg, 70 to 84.9 kg and 85 to 100 kg). Within each of the 3 weight groups, subjects will be randomized 1:1:1:1:1:1 to 1 of the 6 combinations of treatment (APFS) with injection site (upper arm, abdomen or thigh)
88877173|NCT02970006|Experimental|neurovisual stimulation|Participants in this study will be adults who have already undergone implantation of SCS for the treatment of their pain conditions. The study involves no further treatment or intervention. Subjects will be approached for participation in this study during their routine postoperative clinical visit to the Center for Neuromodulation at the Ohio State University (OSU).All eligible patients will undergo a one-day visit for the virtual reality and full body illusion intervention. This research will also investigate leg embodiment and leg analgesic effects during SCS integrated with different patterns of virtual leg illumination.
89189634|NCT05542212|Experimental|TMS treatment group|"Receive ICI test and MATRICS test.~Receive active iTBS treatment on the dlPFC for 4 weeks, 1 treatment a day and 5 days a week."
89401943|NCT03892772|Placebo Comparator|Placebo|Participants will take placebos for 3 days.
89401944|NCT03172910|Experimental|Cohort 1|ciraparantag (60 mg)
89401945|NCT03172910|Experimental|Cohort 2|ciraparantag (120 mg)
89401946|NCT03172910|Experimental|Cohort 3|ciraparantag (180 mg)
89401947|NCT03172910|Experimental|Cohort 4|ciraparantag (30 mg)
89401948|NCT03172910|Placebo Comparator|Placebo|placebo (saline for injection)
89401949|NCT04684940|Experimental|Valoctocogene roxaparvovec Open Label|Single administration of valoctocogene roxaparvovec at a dose of 6E13 vg/kg in Active Inhibitor Population (Part A) and Prior Inhibitor Population (Part B).
89401950|NCT03881852|Experimental|AXS-12 (reboxetine)|
89401951|NCT03881852|Placebo Comparator|Placebo|
89401952|NCT03818828|Experimental|TTAX01|TTAX01 will be applied directly to the wound surface and fixed with sterile adhesive strips, plus a secondary foam dressing held in place by multi-layer compression bandaging. A single layer of the test article should cover the entire open surface of the wound. TTAX01 may overlap onto adjacent healthy tissue and must be fenestrated prior to or after fixture. The material is to be applied once every 4 weeks unless the wound shows evidence of healing, in which case product will be withheld; or, if the test article has been accidentally dislodged within 1-week post application, it may be replaced at the subsequent treatment visit.
89401953|NCT03723668||OPTN data system|In the US, data on the donors and kidney transplant recipients will be obtained using registry data from the Organ Procurement and Transplantation Network (OPTN). The OPTN data system includes data on all donors, waitlisted candidates, and transplant recipients in the US, as submitted by the members of the Organ Procurement and Transplantation Network. The Health Resources and Services Administration (HRSA) of the US Department of Health and Human Services oversees the activities of the OPTN contractor.
89437451|NCT03890861|Active Comparator|Active control|The active control group will be based on a low-intensity activity program and a healthy aging educational component. The physical activities will include stretching, balance training, flexibility, relaxation, and practicing activities of daily living. The successful aging education component will cover topics including avoiding scams, fall prevention, living wills, and dementia awareness.
88877174|NCT02970162|Experimental|amifampridine phosphate|amifampridine phosphate 10 mg (amifampridine equivalent) by mouth, 30 to 80 mg total daily dose, 3 to 4 times per day for 4 days
88877175|NCT02970162|Placebo Comparator|placebo (for amifampridine phosphate)|placebo by mouth 3 to 4 times per day for 4 days
88877176|NCT02970552|Active Comparator|Vaginal Progesterone|Daily self-administered vaginal progesterone
88877177|NCT02970552|Placebo Comparator|Placebo|Daily self-administered indistinguishable placebo
88877178|NCT02971488||Persons who inject drugs (PWID)|The study population comprises persons who visit the Cañada Real Galiana shantytown on the outskirts of Madrid, where 90% of illegal drugs in the region are sold and consumed.
88877179|NCT02973438|Experimental|Spinal Cord Injury (SCI) Intermittent Hypoxia then SHAM|This arm of individuals with SCI will receive Intermittent Hypoxia (IH) and following a 3 week washout, SHAM treatment interventions.
88877180|NCT02973438|Experimental|Control (CON) Intermittent Hypoxia then SHAM|This arm of non injured control subjects will receive Intermittent Hypoxia (IH) and following a 3 week washout, SHAM treatment interventions.
88877181|NCT02973438|Experimental|Spinal Cord Injury (SCI) SHAM then Intermittent Hypoxia|This arm of individuals with SCI will receive SHAM and following a 3 week washout, Intermittent Hypoxia (IH) treatment interventions.
88877182|NCT02973438|Experimental|Control (CON) SHAM then Intermittent Hypoxia|This arm of non injured control subjects will receive SHAM and following a 3 week washout, Intermittent Hypoxia (IH) treatment interventions.
88877183|NCT02973516|Experimental|P03277 triphasic imaging|P03277 will be administered in order to acquire triphasic liver imaging
88877184|NCT02974296|Experimental|new target TMS|new target transcranial magnetic stimulation guided by MRI
88877185|NCT02974296|Active Comparator|standard TMS|standard transcranial magnetic stimulation
88877186|NCT02978508|Experimental|Permethrin Cream, 5%|Permethrin Cream 5%, topical cream, 60g, maximum of two doses over 28 day treatment duration.
88877187|NCT02978508|Active Comparator|Elimite|"Elimite™ 60g, topical, marketed by Prestium Pharma, Inc. (Prestium), the branded subsidiary of Renaissance Pharma, maximum of two doses over 28 day treatment duration."
88877188|NCT02979054|Experimental|T4020|1 drop every other day during 5 days
88877189|NCT02979054|Placebo Comparator|Saline solution|1 drop every other day during 5 days
88877190|NCT02979444|Experimental|Mothers and Babies Groups Home-Visitor|Women who participate in the home-visitor led arm will receive the intervention from a paraprofessional home-visitor and complete assessments at baseline, post-intervention, and 12 and 24 weeks postpartum.
88877191|NCT02979444|Experimental|Mothers and Babies Groups Clinician|Women who participate in the mental health consultant led arm will receive the intervention from a mental health consultant and complete assessments at baseline, post-intervention, and 12 and 24 weeks postpartum.
88877192|NCT02979444|No Intervention|Control|Women who participate in the control arm will not receive the intervention but will complete assessments at baseline, 8 weeks post-baseline, and 12 and 24 weeks postpartum.
88877193|NCT02881008|Experimental|Arm A|Myrcludex B 0.5 mg daily for 12 weeks, followed by 12 weeks follow-up period
88877194|NCT02881008|Experimental|Arm B|Myrcludex B 1 mg daily for 12 weeks, followed by 12 weeks follow-up period
88877195|NCT02881008|Experimental|Arm C|Myrcludex B 2 mg daily for 12 weeks, followed by 12 weeks follow-up period
88877196|NCT02881008|Active Comparator|Arm D|Entecavir 0.5 mg daily for 24 weeks
88877197|NCT02881008|Experimental|Arm E|Myrcludex B 5 mg daily for 12 weeks, followed by 12 weeks follow-up period
88877198|NCT02881008|Experimental|Arm F|Myrcludex B 10 mg daily for 24 weeks, followed by 12 weeks follow-up period
88877199|NCT02987868|Active Comparator|Supplement 1st day, placebo 2nd day|Administration of oral supplement (proprietary amino acid derivative blend). Half of the participants took the Amino acid supplement first day and half of the participants took the Amino acid supplement second day.
88877200|NCT02987868|Placebo Comparator|Placebo 1st day, supplement 2nd day|Half of the participants took the placebo first day and half of the participants took placebo second day.
88877201|NCT02988882|Experimental|OTX-DP|OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use
88877202|NCT02988882|Placebo Comparator|PV|PV (placebo drug delivery vehicle)
88877203|NCT02992236|Placebo Comparator|Placebo|Infusion (6 hours) of Saline
88877204|NCT02992236|Active Comparator|VAS203|Infusion (6 hours) of VAS203 (10 mg/kg)
88877205|NCT02994732|Experimental|[14C]-BVD-523 600mg single dose|Open-label, nonrandomized, absorption, metabolism, and excretion study of [14C]-BVD-523 administered as a 600 mg (approximately 200 µCi) oral dose to 6 healthy male subjects following at least an 8-hour fast from food (not including water).
88877206|NCT03001674|Experimental|IABP recipient|Referred for clinically indicated right heart catheterization with intervention of IABP placement prior to LVAD surgery.
88877207|NCT03001674|Experimental|Control|Control subjects undergoing left heart catheterization with an LV ejection fraction > 50%, and without a history of heart failure symptoms who did not receive IABP therapy were enrolled.
88877208|NCT03002454|Experimental|99mTc MDP Injection:neutron-bombardment|Oncologic indication for which a bone scan would normally be indicated. Participant having recently had a bone scan using Technetium (99mTc) Medronate Injection USP labeled with 99mTc derived from fission-sourced 99Mo. The images of the 99mTc MDP Injection-neutron-bombardment will be compared to the previous (on file) images from the 99mTc MDP Injection-fission
88877209|NCT03004638|Experimental|MEDI6012 40 mg|Participants received 3 doses of 40 milligram (mg) MEDI6012 IV on Days 1, 8, and 15.
88877210|NCT03004638|Placebo Comparator|Placebo|Participants received 3 doses of placebo matching with MEDI6012 intravenously (IV) on Days 1, 8, and 15.
88877211|NCT03004638|Experimental|MEDI6012 120 mg|Participants received 3 doses of 120 mg MEDI6012 IV on Days 1, 8, and 15.
88877212|NCT03004638|Experimental|MEDI6012 300 mg|Participants received 3 doses of 300 mg MEDI6012 IV on Days 1, 8, and 15.
88877213|NCT03004638|Experimental|MEDI6012 IV Push|Participants received 3 doses of MEDI6012 by IV push as 300 mg loading dose on Day 1, and maintenance doses of 150 mg and 100 mg on Day 3 and Day 10, respectively.
88877214|NCT03004638|Placebo Comparator|Placebo IV Push|Participants received 3 doses of placebo matching with MEDI6012 by IV push. A loading dose on Day 1 and maintenance doses on Days 3 and 10.
88877215|NCT03009162|Experimental|Renal impaired participants|Participants received single 200 milligrams (mg) oral tablet of lasmiditan.
88877216|NCT03009162|Experimental|Healthy participants|Participants received single 200 mg oral tablet of lasmiditan.
89401954|NCT03723668||CRISTAL registry|In France, data on the donors and recipients in the French cohort will be obtained from the national CRISTAL registry, initiated in 1996 and maintained by the Agence de la Biomédecine, which prospectively collects data on all potential donors and organ transplant candidates, along with their outcomes. By law, data collection is provided by all organ procurement organizations and transplant centers in France; research studies based on the national CRISTAL registry are part of the transplant assessment activities and do not require institutional review board approval.
89401955|NCT03124862|Experimental|Test group|The subjects will be enrolled into the test group and will receive ARM sensor.
89401956|NCT02804282|Experimental|sc2Wear Furosemide Combination Product|Drug-device combination product of buffered furosemide injection, (Furosemide Injection Solution), 8 mg/mL, and patch pump (sc2Wear Furosemide Pump) for subcutaneous administration of 80 mg dose delivered over 5 hours.
89401957|NCT03789656|Experimental|Paltusotine|
89401958|NCT00974870|Experimental|needling treatment|Needling treatment applied to half of the face at each study visit
88877217|NCT03009396|Experimental|RHB-104 - patients on ACTIVE therapy in RHB-104-01 study|Subjects who were on the active therapy arm in the RHB-104-01 clinical study will continue to receive RHB-104 at 5 capsules twice a day in addition to the standard of care they received in the RHB-104-01 clinical study
88877218|NCT03009396|Experimental|RHB-104 - patients on PLACEBO therapy in RHB-104-01 study|Subjects who were on the active therapy arm in the RHB-104-01 clinical study will receive RHB-104 at 5 capsules twice a day in addition to the standard of care they received in the RHB-104-01 clinical study. The RHB-104 will be ramped up beginning at 1 capsule twice per day in week 1 increasing to 2 capsules twice per day in week 2, 3 capsules twice per day in week 3, 4 capsules per day in week 4 and achieving 5 capsules per day for the remainder of the study.
89401959|NCT00974870|No Intervention|Control|No treatment applied to half of the face
89401960|NCT02233244|Other|CTX-4430 and midazolam|Midazolam 2 mg solution once, CTX-4430 100 mg tablet once per day for 7 days, Midazolam 2 mg solution once
89401961|NCT02259530|Experimental|Integrated Psychotherapeutic Intervention|Integrated treatment of khat use disorder and PTSD
89401962|NCT02234648|Placebo Comparator|Placebo|The PLA supplement consisted of a commercially available, less than 5% fruit, cordial (Protein - Trace, Carbohydrate 260 mg•mL-1, Sodium 0.02 mg•mL-1, Fibre-Trace and Anthocyanins-Trace for colour), mixed with water, whey protein isolate (Arla Foods Ltd., Leeds, UK) and maltodextrin (MyProtein Ltd., Northwich, UK) until matched for carbohydrate and calorie content of the MC.
89401963|NCT02234648|Active Comparator|60mL tart Montmorency cherry juice|One bolus of 60mL of tart Montmorency cherry (MC) juice mixed with 100mL of water. Independent analysis of MC (Atlas Biosciences, 2010) provided the following compositional data; Fat 0.028 mg•mL-1, Protein 31.47 mg•mL-1, Carbohydrate 669.4 mg•mL-1, Cholesterol < 0.01 mg•mL-1, Sodium 0.691 mg•mL-1, Calcium 0.137 mg•mL-1 and Iron 0.026 mg•mL-1. Additionally, according to the manufacturers guidelines (Cherry Active, Hanworth, UK),
89401964|NCT02234726|Experimental|Early Childhood Development Program|"Treatment clusters will be assigned a trained Child Development Agent (CDA) who will have four main tasks and responsibilities: 1) biweekly screening and management (including referral) of acute malnutrition in children; 2) encouragement of caregivers to utilize routine care services for children; 3) screening for symptoms of acute diseases including malaria, diarrhea, and pneumonia and referral for diagnosis and treatment; and 4) organization and mentoring of biweekly caregiver meetings to discuss parenting and promote early childhood cognitive stimulation.~Amendment: during second year extension, CDAs are responsible for organizing and mentoring biweekly (i.e., fortnightly) caregiver meetings. They no longer conduct household visits."
89401965|NCT02234726|No Intervention|Control|Children residing in comparison health zones will only receive baseline and end line evaluations of their health and developmental status. There will be no active intervention in the comparison areas during the course of the study.
89535522|NCT03225469|No Intervention|regular education group|Regular instructions will be given to the patients during the colonoscopy appointment. There will be nothing specially for family members.
88877219|NCT03010488|Experimental|Rapid Sleep Shift|Assigned Sleep Times designed to shift sleep times over several days from Baseline to desired through morning light therapy while wearing goggles.
88877220|NCT03010488|Active Comparator|Gradual Sleep Shift|Assigned Sleep Times designed gradually shift sleep from current to desired sleep times while using morning light therapy while wearing goggles.
88877221|NCT03010800|Experimental|With Yoni.Fit|Subjects will perform the Abbreviated Pad Test with the Yoni.Fit first, then without the Yoni.Fit.
88877222|NCT03010800|Experimental|Without Yoni.Fit|Subjects will perform the Abbreviated Pad Test without the Yoni.Fit first, then with the Yoni.Fit.
88877223|NCT03012594|Experimental|Lanreotide|Open label
88877224|NCT03014700|Active Comparator|Cryoprecipitate Arm|Subject will be administered Cryoprecipitate to control bleeding after open heart surgery when randomized to Cryoprecipitate group
88877225|NCT03014700|Active Comparator|Fibrinogen Concentrate Arm|Subject will be administered Fibrinogen Concentrate to control bleeding after open heart surgery when randomized to Fibrinogen Concentrate group
88877226|NCT03017508|Experimental|BHV-0223 (Sublingual Riluzole)|Participants will be given one dose of BHV-0223 (sublingual riluzole) 35mg before performing a 10 minute speech task. Participants will then be assessed every hour for the next three hours. There will be 2 to 10 days of washout period between the randomly assigned arms of the study.
88877227|NCT03017508|Placebo Comparator|Placebo|Participants will be given one dose of an identical looking sublingual placebo before performing a 10 minute speech task. Participants will then be assessed every hour for the next three hours. There will be 2 to 10 days of washout period between the randomly assigned arms of the study.
88877228|NCT03020004|Experimental|Danoprevir,Ritonavir, Peg-IFN,RBV|Participants will receive a combination of Ritonavir-boosted Danoprevir 100mg/100mg BID, subcutaneous injection of weekly peginterferon alfa-2a at 180 mcg and oral Ribavirin (RBV)1000/1200 mg/day (bodyweight<75/≥75 kg) for 12 weeks.
89189635|NCT05542212|Sham Comparator|TMS Sham Control Group|"Receive ICI test and MATRICS test.~Receive sham TMS treatment on the dlPFC for 4 weeks, 1 treatment a day and 5 days a week."
89401966|NCT02234804|Experimental|Medtronic Resolute Integrity stent|Comparing Medtronic Resolute Integrity and Xience Prime for stent strut apposition in the SB ostium
89401967|NCT02234804|Experimental|OCT|OCT to guide wire recrossing and reduce stent strut malapposition after kissing balloon dilatation.
89401968|NCT02234804|Active Comparator|Angiography|Angiography to guide wire recrossing and reduce stent strut malapposition after kissing balloon dilatation.
89401969|NCT02234804|Active Comparator|Xience Prime stent|Comparing Medtronic Resolute Integrity and Xience Prime for stent strut apposition in the SB ostium
89401970|NCT02234882|Experimental|Rosuvastatin and BMS-663068|Treatment A: Rosuvastatin, single dose (SD) Treatment B: BMS-663068 administered on specified days Treatment C: Combination BMS-663068 and Rosuvastatin administered on specified days
89401971|NCT05627726|Experimental|PelviSense-assisted pelvic floor muscle training group|Women allocated to the PelviSense-assisted pelvic floor muscle training (PFMT) group will perform PFMT to contract their urethras while the wearable sensors are positioned close to the vagina (to measure pubococcygeus muscle activation). Exercises will be performed in antigravity (supine or side-lying) positions and will progress to against-gravity positions (sitting/ standing).
89401972|NCT05627726|Active Comparator|Pelvic floor muscle training (PFMT) alone group|Pelvic floor muscle training (PFMT) alone group: Women allocated to the PFMT alone group will perform unassisted PFMT. Exercise parameters, technique, and progression will be similar to those for the PelviSense-assisted PFMT group, but exercises will be performed without the PelviSense.
89401973|NCT02234960||Cohort of RA Participants|Participants with RA treated with tocilizumab at a dose and duration at the discretion of physician in accordance with the summary of product characteristics as per routine clinical practice were observed for a period of 6 months with the length of entire study for 24 months.
89401974|NCT02235038|Active Comparator|Low carbohydrate diet|
89401975|NCT02235038|Active Comparator|Moderate carbohydrate diet|
89401976|NCT02235038|Active Comparator|High carbohydrate diet|
89401977|NCT02235116||Patients who responded to the survey|
89401978|NCT03727334|Experimental|Treatment|For the treatment arm, the participants will complete the intervention protocol following the first in-person study visit 7 months post-injury. The intervention involves 16 weeks of online, in-home spatial navigation training. During the 16 weeks, the participant will complete exercises for 1 hour/day, 5 days a week.
89401979|NCT03727334|No Intervention|Control|The control arm participants will receive their typical standard of care; they will not complete the intervention but will complete all of the in-person visits at the same post-injury time-points as the treatment group.
89401980|NCT03727022|Experimental|0.07 mg SM04690|Intra-articular injections of 0.07 mg SM04690 in 2 mL vehicle
89401981|NCT03727022|Placebo Comparator|Vehicle|Intra-articular injections of 0 mg SM04690 in 2 mL vehicle
88877229|NCT03020082|Experimental|Danoprevir, Ritonavir, Peg-IFN,RBV|Participants will receive Ritonavir- boosted Danoprevir 100mg/100mg BID in combination with subcutaneous injection of weekly peginterferon alfa-2a at 180 mcg and RBV administered orally 500mg (5 tablets)( body weight <75Kg) BID, 600mg (6 tablets) BID body weight ≥75Kg for 12 weeks.
88877230|NCT03020472|Experimental|2008-2009 FluMist LAIV (Intranasal)|2008-2009 FluMist LAIV (Intranasal) Seasonal live, attenuated influenza vaccine
89401982|NCT02259686|Experimental|Protocol 1. Apelin 1mg doses|5 Healthy volunteers
88877231|NCT03020550||GERD Patients|Subjects with active GERD symptoms.
89401983|NCT02259686|Experimental|Protocol 2. Apelin 5mg doses|5 Healthy volunteers
88877232|NCT03026556||Dabigatran vs. Rivaroxaban|OAC treatment naïve NVAF patients with at least one prescription claim for dabigatran, rivaroxaban (new oral anticoagulant or NOAC).
88877233|NCT03026556||Dabigatran vs. Apixaban|OAC treatment naïve NVAF patients with at least one prescription claim for dabigatran, or apixaban (new oral anticoagulant or NOAC).
88877234|NCT03028974|Other|Group A: 2-4 yo LAIV4 (Return)|Participants are given quadrivalent live, attenuated influenza vaccine (LAIV4)/ FluMist® . For children requiring 2 doses of vaccine, a second immunization will be given at Day 28-32 after Dose 1. All participants in this group will be asked to return annually for repeat immunization per ACIP guidelines and blood sample collection.
88877235|NCT03028974|Other|Group B: 2-4 yo LAIV4 (Single Yr)|Participants are given LAIV4/ FluMist® and participate for single year. For children requiring 2 doses of vaccine, a second immunization will be given at Day 28-32 after Dose 1.
88877236|NCT03028974|Other|Group C: 2-4 yo LAIV4 (Swab/Single Yr)|Participants are given LAIV4/ FluMist® and participate for single year. NP swabs are collected; no blood samples will be collected for this group. For children requiring 2 doses of vaccine, a second immunization will be given at least 28 days after Dose 1.
89189636|NCT05542212|No Intervention|Normal Control|1. Receive ICI test and MATRICS test.
89401984|NCT02259686|Experimental|Protocol 3. Apelin 10mg single dose|5 Healthy volunteers
89401985|NCT02259764|Experimental|KUC 7483 CL - single rising dose|"Treatment 1: KUC 7483 CL - low dose~Treatment 2: KUC 7483 CL - medium dose~Treatment 3: KUC 7483 CL - high dose~In treatment 3 the same subjects as in treatment 2 received drug immediately after the ingestion of a standardized high fat meal"
89401986|NCT02259764|Placebo Comparator|Placebo|
89401987|NCT02233322|Experimental|iron supplements|all subjects will receive iron supplementation based on iron levels in blood
89401988|NCT02233400|Experimental|Treatment|Group 1 (treatment) will receive IV acetaminophen (1g in 100 ml of 0.9% normal saline IV Q 6hrs for 24 hours) plus IV narcotics (2-4 mg IV Q2hrs PRN) for the first 6 hours post-surgery followed by IV narcotics (2-4 mg IV Q2hrs PRN)/ PO narcotics (Oxycodone 5-10 ml PO Q4 hrs PRN) for the remaining 18 hours.
89401989|NCT02233400|No Intervention|Control|Group 2 (control) will receive IV normal saline (100 ml of 0.9% normal saline IV Q 6hrs for 24 hours) plus IV narcotics (2-4 mg IV Q2hrs PRN) for the first 6 hours post-surgery followed by IV narcotics (2-4 mg IV Q2hrs PRN)/ PO narcotics (Oxycodone 5-10 ml PO Q4 hrs PRN) for the remaining 18 hours.
89401990|NCT03067441|Experimental|Open-Label bempedoic acid|bempedoic acid 180 mg tablet
89401991|NCT03687632|Experimental|Single arm - active|ST266 eye drops given to the study eye for 28 days (112 doses total will be administered).
89401992|NCT02235194|Active Comparator|Amino Acids, Chromium - Picolinate|Verum drink containing the dietary supplements is taken with a test meal. INsulin and glucose response is documented for 180 minutes.
89401993|NCT02235194|Placebo Comparator|Placebo Drink|Placebo Drink containing aroma only is taken with a test meal. INsulin and glucose response is documented for 180 minutes.
89401994|NCT03684278|Active Comparator|Infusion of 5 mg/kg Infliximab|Infliximab (Remicade) to be administered as a one time intravenous infusion in 250 ml (500 ml if patient weighs over 100 kg) 0.9% sodium chloride solution over a period of 2 hours. Dosage calculated at 5 mg of Infliximab, per kg of patient body weight.
89401995|NCT03684278|Active Comparator|Infusion of 10 mg/kg Infliximab|Infliximab (Remicade) to be administered as a one time intravenous infusion in 250 ml (500 ml if patient weighs over 100 kg) 0.9% sodium chloride solution over a period of 2 hours. Dosage calculated at 10 mg of Infliximab, per kg of patient body weight.
89401996|NCT03684278|Placebo Comparator|0.9% Sodium Chloride (Placebo)|250 ml (500 ml if patient weighs over 100 kg) 0.9% Sodium Chloride to be administered as a one time intravenous infusion over a period of 2 hours.
88877237|NCT03028974|Other|Group D: 6 - 23 mos old IIV4 (Return)|Participants are given a quadrivalent inactivated influenza vaccine (IIV4)/ Fluzone® . For children requiring 2 doses of vaccine (vaccine-naïve), a second immunization will be given at Day 28-32 after Dose 1. Participants are asked to return annually for repeat immunization per ACIP guidelines and blood sample collection.
89401997|NCT02726659|Experimental|Celecoxib|Adjunct celecoxib in 6 week treatment
88877238|NCT03028974|Other|Group E: 6 - 23 mos old IIV4 (Single Yr)|Participants are given IIV4/ Fluzone® and participate for a single year. For children requiring 2 doses of vaccine (vaccine-naïve), a second immunization will be given at Day 28-32 after Dose 1.
89401998|NCT02726659|Placebo Comparator|Placebo|Adjunct placebo in 6 week treatment
88877239|NCT03028974|Other|Group F: 9-13/18-49 yo LAIV4 (Single Yr)|Participants 9-13 year old and 18-49 year old are given LAIV4/ FluMist® . Participants will participate for a single year.
88877240|NCT03028974|Other|Group G: 9-13/18-49 yo IIV4 (Single Yr)|Participants 9-13 year old and 18-49 year old are given IIV4/ Fluzone® and participate for single year.
88877241|NCT03029988|Experimental|Cohort 1|Subjects will receive 50 µg tilmanocept radiolabeled with 2.0 millicuries (mCi) Tc99m through a single IV injection.
88877242|NCT03029988|Experimental|Cohort 2|"Subjects will receive 200 µg tilmanocept radiolabeled with 2.0 mCi Tc99m through a single IV injection.~If it was determined that additional enrollment would not provide meaningful data, for example no metastatic liver lesions were visualized by Tc 99m tilmanocept for any of the subjects in the cohort, enrollment into Cohort 2 would begin and 3 subjects would be enrolled followed by a review of the imaging and safety data."
88877243|NCT03033108|Experimental|Emixustat Dose 1|lowest dose of once-daily oral emixustat
88877244|NCT03033108|Experimental|Emixustat Dose 2|middle dose of once-daily oral emixustat
88877245|NCT03033108|Experimental|Emixustat Dose 3|highest dose of once-daily oral emixustat
88877246|NCT03035760|Experimental|1|3 mg/kg orally once daily for 5 days (n = 8)
88877247|NCT03035760|Experimental|2|7.5 mg/kg orally once daily for 5 days (n = 8)
88877248|NCT03035760|Experimental|3|15 mg/kg orally once daily for 5 days (n = 8)
88877249|NCT03035760|Experimental|4|3 mg/kg orally, one dose received following a fast (n=6) or high fat meal (n=6) on Day 1 and crossed over to opposite arm to receive drug following high fat meal or fast on Day 8
88877250|NCT03036384|Experimental|Cohort 1 : HB prilocaine 2%, 45mg|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be administrated at the dose initial of 45 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 30, 35, 40, 45, 50, 55mg.
88877251|NCT03036384|Experimental|Cohort 2 : HB prilocaine 2%, (30-55mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be administrated at the dose initial of 45 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 30, 35, 40, 45, 50, 55mg.
88877252|NCT03036384|Experimental|Cohort 3 : HB prilocaine 2%, (30-55mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be administrated at the dose initial of 45 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 30, 35, 40, 45, 50, 55mg.
89401999|NCT03660878|Experimental|Reproxalap Ophthalmic Solution (0.25%)|
89402000|NCT03660878|Experimental|Reproxalap Ophthalmic Solution (0.5%)|
89402001|NCT03660878|Placebo Comparator|Vehicle Ophthalmic Solution|
89402002|NCT05197543||BRRA group|Rupture risk of asymptomatic AAAs in this group was estimated using Biomechanical rupture rist assessment (BRRA). BRRA considers an AAA as a pressure vessel and estimates its risk of rupture by comparing its wall stress to wall strength
89402003|NCT05197543||Maximal diameter group|Rupture risk of asymptomatic AAAs in this group was estimated by a classical approach based on a maximal diameter.
89402004|NCT04452578|Experimental|Experimental: Recipient of HCV positive heart graft|A single center, open-label, pilot study examining 10 adult HCV negative heart transplant subjects who will receive an HCV infected graft. Target start date for antiviral therapy will be within 3 months after heart transplantation.
89402005|NCT05190211|Experimental|Telerehabilitation Group (TG)|
89198963|NCT00883467|Other|2|baseline MR signal prior to, during and 30 minutes after an ischemic period of 20 minutes with additional 5 minutes of cuff stenosis directly after cuff release
89402006|NCT05190211|Experimental|Video Group (VGr)|
89402007|NCT03951961|Experimental|Midostaurin|50 mg Midostaurin bid for 12 months
89402008|NCT03940105|No Intervention|Control|For 3 days during the control snack pattern, the participants will be asked to complete dietary recalls concerning their afternoon and evening snacking behavior. The participants will use the Automated Self-Administered 24-hour Recall (ASA24) system which was developed by the National Cancer Institute.
89402009|NCT03940105|Active Comparator|Standard Packout|This packout contains a variety of foods to be consumed, ad libitum, throughout the remainder of the day following the standardized lunch.
89402010|NCT03940105|Active Comparator|Large Package Packout|This packout contains a variety of foods to be consumed, ad libitum, throughout the remainder of the day following the standardized lunch. It differs from the Standard Packout in that the package sizes of all the foods are larger (though food amount remains the same).
89402011|NCT03940105|Active Comparator|Variety Packout|This packout contains a variety of foods to be consumed, ad libitum, throughout the remainder of the day following the standardized lunch. It differs from the Standard Packout in that there is about twice as much snack variety (though food amount remains the same).
88877253|NCT03036384|Experimental|Cohort 4 : HB prilocaine 2%, (30-55mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be administrated at the dose initial of 45 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 30, 35, 40, 45, 50, 55mg.
89402012|NCT02232542|Experimental|Duloxetine - low dose|
88877254|NCT03036384|Experimental|Cohort 5 : HB prilocaine 2%, (30-55mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be administrated at the dose initial of 45 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 30, 35, 40, 45, 50, 55mg.
88877255|NCT03036384|Experimental|Cohort 6 : HB prilocaine 2%, (30-55mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be administrated at the dose initial of 45 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 30, 35, 40, 45, 50, 55mg.
88877256|NCT03036384|Experimental|Cohort 7 : HB prilocaine 2%, (30-55mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be administrated at the dose initial of 45 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 30, 35, 40, 45, 50, 55mg.
88877257|NCT03036384|Experimental|Cohort 8 : HB prilocaine 2%, (30-55mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be administrated at the dose initial of 45 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 30, 35, 40, 45, 50, 55mg.
88877258|NCT03036384|Experimental|Cohort 9 : HB prilocaine 2%, (30-55mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be administrated at the dose initial of 45 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 30, 35, 40, 45, 50, 55mg.
88877259|NCT03036384|Experimental|Cohort 10 : HB prilocaine 2%, (30-55mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be administrated at the dose initial of 45 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 30, 35, 40, 45, 50, 55mg.
88877260|NCT03040362|Experimental|[14C]-lasmiditan|[14C]-lasmiditan administered as a 200 mg (approximately 100 µCi) oral solution
88877261|NCT03041298||All included patients|All included patients underwent MR mammography with Dotarem
88877262|NCT03042702|Experimental|Kevetrin 250 mg/m2 IV Cohort 1|Kevetrin 250 mg/m2 IV per dose every other day (q.o.d.)/ 3 doses per week (750 mg/m2 per week), for 3 weeks (single cycle; total 9 doses) Follow-up For 3 weeks after Kevetrin treatment ends
88877263|NCT03042702|Experimental|Kevetrin 350 mg/m2 IV Cohort 2|Kevetrin 350 mg/m2 IV per dose every other day (q.o.d.)/ 3 doses per week (1050 mg/m2 per week), for 3 weeks (single cycle; total 9 doses) Follow-up For 3 weeks after Kevetrin treatment ends
88877264|NCT03044028|Experimental|NMES preoperative and postoperative|Subject will be given NMES CyMedica Orthopedics QB1 e-vive™ system device to use preoperative and will continue to use postoperatively until end of study
89198964|NCT00883467|Other|3|short time preconditioning, other details according arm 2
89402013|NCT02232542|Experimental|Duloxetine - high dose|
89402014|NCT02232542|Placebo Comparator|Placebo|
89402015|NCT02620033|No Intervention|Standard Care|Those assigned to the standard care group will follow the routine pre- and post-operative care for patients whose undergoing radical prostatectomy.
89402016|NCT02620033|Active Comparator|Yoga therapy group|Those assigned to the yoga therapy group will be asked to participate in yoga session three times in a week for 6 weeks prior to the scheduled surgery and then re-initiated 3 weeks after the surgery for another 6 weeks. Each session will be approximately 60 - 75 minutes. These yoga session will be held at Nydia's Yoga Therapy Studio, located in San Antonio, TX, under the guidance of certified yoga instructor, Dr. Nydia Tijerina Darby, PT, DPT, MS, who's the owner of the studio and co-investigator of this study. The yoga exercise will be tailored to patient's comfort level.
89402017|NCT02235350|Experimental|Action Observation Treatment (AOT)|Conventional physiotherapy + Action Observation Treatment
89402018|NCT02235350|Sham Comparator|Observation of videos with no motor content (MNO)|Conventional physiotherapy + Observation of videos with no motor content (MNO)
89402019|NCT05181787||AF|Patients with AF
89402020|NCT05181787||AF and stroke|Patients with AF complicated with stroke
89402021|NCT04306250|Experimental|anterior approach for apical fixation to the SSL|In this group the apical fixation will be done using the anterior access, ie dissection through the anterior vaginal wall.
89402022|NCT04306250|Active Comparator|posterior approach for apical fixation to the SSL|In this group the apical fixation will be done using the posterior access, ie fixation through the vaginal posterior wall.
89402023|NCT02600923|Experimental|Palbociclib + Letrozole|palbociclib and letrozole combination
89402024|NCT05539976||Healthy participants who perform taste evaluations|A maximum of 10 healthy adult participants will complete a maximum of 30 taste assessment days, to evaluate the taste characteristics of iberdomide or mezigdomide on each taste assessment day.
89402025|NCT02232776|Experimental|Losartan treatement|All patients had received losartan treatment for 24 weeks.
89402026|NCT03847519|Experimental|Safety Phase Part A|"Enroll subjects with metastatic squamous or non-squamous NSCLC who have become refractory or intolerant to standard therapy. ADXS-503 monotherapy will be evaluated at 2 planned escalating dose levels:~Dose level 1: 1e8 CFU of ADXS-503, IV, every 3 weeks until disease progression, unacceptable toxicity, or another treatment discontinuation criterion is met.~Dose level 2: 5e8 CFU of ADXS-503, IV, every 3 weeks until disease progression, unacceptable toxicity, or another treatment discontinuation criterion is met."
88877265|NCT03044028|Experimental|NMES postoperative only|Subject will be given NMES CyMedica Orthopedics QB1 e-vive™ system device to use postoperatively and will continue to use until end of study
88877266|NCT03044028|No Intervention|No intervention|Subject will not be given device and will undergo the standard rehab protocol alone
88877267|NCT03044418||anesthesia with laser tube|The special endotracheal (ET) laser tube is tested during endolaryngeal laser surgery. Anesthesia type is the total intravenous anesthesia with propofol. We tested the application of ET laser tube in propofol anesthesia.
88877268|NCT03046212|Experimental|Electrical stimulation|This group received application of transcutaneous electrical nerve stimulation (TENS) associated with conventional physical therapy (exercises).
88877269|NCT03046212|Active Comparator|Physical therapy|This group received only conventional physical therapy (exercises).
88877270|NCT03048006||All included patients|All included patients underwent MRI with Dotarem
88877271|NCT03051672|Experimental|Pembrolizumab With Radiation|"pembrolizumab : 200 mg intravenously 2 to 7 days prior to radiotherapy (RT) and on day 1 of repeating 21-day cycles. Treatment up to 35 cycles.~Palliative radiation: a total dose of 20 Gy in 5 fractions"
88877272|NCT03052530|Experimental|Sapphire II PRO|Single arm with investigational Sapphire II PRO 1.0 and 1.25 mm PTCA dilatation catheters
88877273|NCT03055650|Experimental|iLux 2020 System|Meibomian gland treatment (Day 0) according to instructions for use (IFU)/User Manual
88877274|NCT03057132|Experimental|Cavilon Advanced Skin Protectant|Cavilon Advanced Skin Protectant
88877275|NCT03057366|Experimental|[14C]-Pevonedistat 25 mg/m^2|[14C]-pevonedistat (containing approximately 60-98 mCi [approximately 2.22-3.626 MBq] of radioactive tracer), infusion, intravenously, single dose on Day 1 of Week 1 in Part A. After completion of Part A, participants will have opportunity to continue into Part B. Participant will receive Pevonedistat 25 mg/m^2, infusion, intravenously, single dose on Days 1, 3 and 5 of each 21 day cycle, for up to 12 cycles along with docetaxel 75 mg/m^2, infusion, intravenously, over 1 hour on Day 1 of each 21 day cycle; or pevonedistat 20 mg/m^2, infusion, intravenously, single dose on Days 1, 3 and 5 of each 21 day cycle, for up to 12 cycles, followed by paclitaxel 175 mg/m^2, infusion, intravenously, over 3 hours along with carboplatin 20 mg/m^2, infusion, intravenously, over 30 minutes on Day 1 of 21 each cycle up to 12 cycles. Based on investigator and sponsor discretion, participants deriving benefits will continue to receive current combination therapy or pevonedistat alone beyond 12 cycles.
88877276|NCT03060486|Experimental|HYBENX®|1 cc of mixture of hydroxybenzenesulfonic acid (37%) and hydroxymethoxybenzene acids (23%), sulfuric acid (28%), and water (12%) for 20 sec
89402027|NCT03847519|Experimental|Safety Phase Part B|"Enroll subjects with metastatic squamous or non-squamous NSCLC. ADXS-503 will be evaluated at 2 planned escalating dose levels in combination with a fixed dose of pembrolizumab:~Dose level 1: 1e8 CFU of ADXS-503 + 200 mg of pembrolizumab, IV, every 3 weeks for up to 2 years or until disease progression, unacceptable toxicity, or another treatment discontinuation criterion is met.~Dose level 2: 5e8 CFU of ADXS-503 + 200 mg of pembrolizumab, IV, every 3 weeks for up to 2 years or until disease progression, unacceptable toxicity, or another treatment discontinuation criterion is met."
89402028|NCT03847519|Experimental|Efficacy Phase Part C|"Enroll subjects with metastatic squamous or non-squamous NSCLC.~1e8 CFU of ADXS-503 + 200 mg of pembrolizumab, IV, every 3 weeks for up to 2 years or until disease progression, unacceptable toxicity, or another treatment discontinuation criterion is met."
89402029|NCT02221687|Experimental|Synbiotic formula|"Synbiotic formula : standard formula enriched with a prebiotic fiber and a probiotic strain~Dose : variable number of powder scoops, adapted to the infant's age and weight, and addition of the defined amount of water, according to the Dose and Drinking Amount table.~Route : oral, ad libitum~Duration of product intake:~Synbiotic IF : 5 months of consumption (from the inclusion until 6 months completed of age)~Synbiotic FoF: 6 months of consumption (from 6 to 12 months of age)"
88877277|NCT03061812|Experimental|Rovalpituzumab tesirine|"Rovalpituzumab tesirine IV administration (dosing based on actual body weight) on Day 1 of a 42-day cycle for 2 cycles, with up to 2 additional cycles permitted.~Dexamethasone coadministered orally (PO) twice daily at a dose of 8 mg on Day -1, Day 1, and Day 2 of each 42-day cycle in which rovalpituzumab tesirine is administered."
88877278|NCT03061812|Active Comparator|Topotecan|Topotecan given as an intravenous (IV) infusion over 30 minutes at a dose of 1.5 mg/m^2 on Days 1 to 5 of each 21-day cycle.
88877279|NCT03063294|Active Comparator|Toolkit only|Clinics in this arm are given access to an online care coordination toolkit.
88877280|NCT03063294|Experimental|Toolkit plus coaching|Clinics in this arm are given access to an online care coordination toolkit plus quality improvement support from a distance-based coach.
89189637|NCT05540080|Experimental|Evaluation of change in adipose and muscle layer thickness|Evaluation of change in adipose and muscle layer thickness between pre-treatment and post-treatment based on MRI imaging and waist circumference measurements
89198965|NCT00883467|Other|4|long time preconditioning, other details according arm 2
89198966|NCT00963118|Placebo Comparator|placebo|Rice powder based nutrition bar
88877281|NCT03064152|No Intervention|Control|Patients who experience postpartum hemorrhage will receive standard of care for labor and delivery, cesarean delivery, and postpartum care. Transfusion will be based on standard of care utilizing clinical criteria of hemodynamics (noninvasive blood pressure, heart rate, arterial line if deemed clinically useful) and coagulation labs (PT, activated partial thromboplastin time (aPTT), fibrinogen, complete blood count). In addition to standard of care, additional ROTEM blood assays will be performed at any time routine coagulation labs are sent. Providers in the control group will be blinded to ROTEM results.
88877282|NCT03064152|Experimental|ROTEM|Patients will receive standard of care for labor and delivery, cesarean delivery, and postpartum care. Transfusion will be based on standard of care utilizing clinical criteria of hemodynamics (noninvasive blood pressure, heart rate, arterial line if deemed clinically useful) and coagulation labs (PT, aPTT, fibrinogen, complete blood count). In addition to standard of care, additional ROTEM blood assays will be performed at any time routine coagulation labs are sent. Providers in the ROTEM group will receive real-time ROTEM results and a previously validated ROTEM-based transfusion algorithm for PPH.
88877283|NCT03067506||Participants With Major Depressive Disorder (MDD)|Participants with MDD were provided with an Apple watch on which brief cognitive and mood tests were evaluated daily up to 6 weeks.
88877284|NCT03070470|Active Comparator|Ranolazine|Ranolazine 1500 mg two times per day for 2.5 days
88877285|NCT03070470|Active Comparator|Verapamil|Verapamil 120 mg immediate release (IR) morning and afternoon doses on Days 1 and 2, 240 mg extended release (ER) evening dose on Days 1 and 2, and 120 mg IR morning dose on Day 3
88877286|NCT03070470|Active Comparator|Lopinavir / Ritonavir|Lopinavir / Ritonavir 800 mg / 200 mg two times per day for 2.5 days
88877287|NCT03070470|Active Comparator|Chloroquine|Chloroquine 1000 mg on Day 1, 500 mg on Day 2, 1000 mg on Day 3
88877288|NCT03070470|Placebo Comparator|Placebo|Placebo capsules
88877289|NCT03070470|Active Comparator|Dofetilide and Diltiazem|"In one period subjects receive Dofetilide 0.125 mg on Day 1, 0.375 mg on Day 3.~In a second period (randomized cross-over) subject receive Diltiazem 120 mg IR morning dose on Day 8, 240 mg ER evening dose on Days 8 and 9, and 120 mg IR on Day 10 with coadministration of 0.25 mg dofetilide on Day 10."
88877290|NCT03070548|Experimental|ADME|1 mg talazoparib containing100 μCi of 14C-radiolabeled talazoparib
89004158|NCT02085148|Experimental|Sequential dosing schedule|Expansion phase: Schedule B - Sequential dosing schedule: Of a 21-day cycle, regorafenib will be dosed sequentially, following administration of VI: Vincristine：intravenous bolus, 1.5 mg/m2 (0.05 mg/kg for subjects ≤ 10 kg), Day 1 and Day 8. Irinotecan: intravenously over 1 hour, 50mg/m2/day, Day 1 to Day 5. Regorafenib: orally, at a starting dose level of 72 mg/m2 (subjects 2 to less than 18 years old) or 60 mg/m2 (subjects 6 to less than 24 months old) once daily, Day 8 to Day 21.
89189638|NCT05532215|Experimental|Misoprostol|400 mcg of sublingual misoprostol as two 200 mcg misoprostol tablets at the point of starting the uterine incision at caesarean section, then bolus administration of 10 IU of intravenous oxytocin followed by an infusion of 20 IU of oxytocin in 500 ml of normal saline at a rate of twenty drops per minute to run over eight hours.
89189639|NCT05532215|Placebo Comparator|Placebo|Two sublingual placebo tablets similar to the misoprostol tablets at the point of starting the uterine incision at caesarean section, then bolus administration of 10 IU of intravenous oxytocin followed by an infusion of 20 IU of oxytocin in 500 ml of normal saline at a rate of twenty drops per minute to run over eight hours.
89189640|NCT05528497|Experimental|VR+|For patients in the experimental group, using the virtual reality headset, the caregiver will place the headset on the patient as she is laid on the surgical table. The caregiver will ensure that the patient can see and hear the sequence that is being performed. The caregiver can then proceed to the different stages of ovocyte retrieval. Once the procedure is finished, the caregiver tells the patient that she can remove the headset
89189641|NCT05528497|No Intervention|Control|For patients in the control group, without a headset, the oocyte retrieval procedure will not be modified.
89189642|NCT05525026|Experimental|Non-invasive facial remodeling|Treatment with the BTL-785-7 applicator to the BTL-785F system.
89189643|NCT05524766|Experimental|BTL-785-7 Treatment|Subjects will be enrolled for an active treatment with BTL-785F device (BTL-785-7 applicator) for improvement of overall facial appearance and muscle tone in patients injected with botulinum toxin.
89189644|NCT05524766|No Intervention|Control|Two (2) patients will be enrolled in the control group study and will not receive any treatment. Following the completion of the investigation, the control group patients will be offered the same treatment course as the active group.
89189645|NCT05524740|Experimental|BTL-785-7 Treatment|Treatment with BTL-785F device (BTL-785-7 applicator)
89189646|NCT05524662|Experimental|BTL-785-7 Treatment|Subjects will be enrolled for an active treatment with BTL-785F device (BTL-785-7 applicator) for non-invasive facial rejuvenation.
89189647|NCT05524662|No Intervention|Control|One subject will serve as a control.
89189648|NCT05509322|Experimental|Invitation to fertility consult with subsidy|This group will be invited to purchase a fertility consult, and will be offered a subsidy if they choose to purchase the consult.
89189649|NCT05509322|Active Comparator|Invitation to fertility consult without subsidy|This group will be invited to purchase a fertility consult at full price.
89189650|NCT05509322|No Intervention|Control (no invitation)|This group will not receive invitations to purchase a fertility consult.
89189651|NCT05505240|Experimental|Cold temperature|18°C
89189652|NCT05505240|Experimental|Room temperature|22°C
89189653|NCT05505240|Experimental|Thermoneutral temperature|28°C
89189654|NCT05505240|Experimental|Hot temperature|38°C
89189655|NCT05500014|Experimental|Biofortified potato|500 g of biofortified, cooked potato, comsumed over 5 consecutive days (500g for each day, for a total of 2500 g of cooked potato). Potato meals will be labelled with a total of 3 mg 57FeSO4.
89189656|NCT05492630|Experimental|HEC73077 tablets|Single-Dose Study: There will be a total of 7 dose cohorts. Multiple-dose Study: There will be a total of 4 dose cohorts.
89402030|NCT02221687|Placebo Comparator|Control formula|"Control formula : standard formula without pre and probiotic~Dose : variable number of powder scoops, adapted to the infant's age and weight, and addition of the defined amount of water according to the Dose and Drinking Amount table.~Route: oral, ad libitum~Duration of product intake:~Control IF : 5 months of consumption (from the inclusion until 6 months completed of age)~Control FoF : 6 months of consumption (from 6 to 12 months of age)"
89402031|NCT02221687|No Intervention|Breast-fed group|"- Breast milk as exclusive feeding (no more than one formula meal per day), from birth until at least 4 months of age. Then, when the mother decides to stop breastfeeding, the infants can consume any formula on parent's choice respecting forbidden products list.~Dose:~Breast milk : on demand~Route : oral, ad libitum~Duration of product intake:~Breast milk : at least 4 month (from birth until at least 4 months of age)"
89402032|NCT02235428|Experimental|Ipratropium bromide|
89402033|NCT02235428|Active Comparator|Salbutamol|
89402034|NCT02235506|Experimental|epidural infusion|In epidural infusion group, a lumbar epidural catheter was placed at the L3-4 level using loss-ofresistance procedure. ropivacaine 0.2% and fentayl 2mcg/ml were infused at a rate of 5ml/hr from the end of operation,
89402035|NCT02235506|Experimental|femoral sciatic|In femoral sciatic group, the femoral and sciatic nerve are located using ultrasound and 0.2% ropivacain is injected. A catheter is inserted to femoral nerve. From the end of operation, 0.2% ropivacaine was infused through the femoral catheter at a rate of 5ml/hr.
89402036|NCT03070171|Experimental|Dabigatran Etexilate Capsule|
89402037|NCT03070171|Experimental|Dabigatran Etexilate Tablet|
88877291|NCT03072186|Experimental|near-infrared light nasal endoscope used with ICG|ICG will be administered to identify the blood supply at two distinct stages of endonasal cranial base surgery and tumor dissection: before intradural dissection and during tumor dissection.
89402038|NCT02262572|Experimental|Telmisartan /HCTZ - compression tablet (DC)|
89402039|NCT02262572|Experimental|Telmisartan /HCTZ - dry granulation tablet (DG)|
89402040|NCT02262572|Active Comparator|Telmisartan /HCTZ - present commercial formulation|
89402041|NCT02235584|Experimental|Dexamethasone|This is a before-after study. All subjects are administered dexamethasone 2mg BID for 5 days.
89402042|NCT02235662|Experimental|TFV IVR|TFV IVR is an intravaginal ring 55.0 mm in diameter, consisting of single segment of polyurethane tubing with an outer diameter of 5.5 mm and filled with white TFV-containing paste. Used for one month, the IVR delivers 8-10 mg/day TFV.
89402043|NCT02235662|Experimental|TFV/LNG IVR|TFV/LNG IVR is an intravaginal ring 55.0 mm in diameter, consisting of two segments of polyurethane tubing with an outer diameter of 5.5 mm: a longer segment containing white TFV paste and a shorter one (20 mm) with a white LNG core. Used for one month, the IVR delivers 8-10 mg/day TFV and 20 μg/day LNG.
88877292|NCT03072732|Other|study arm 1 - below left axilla|20 patients undergoing hemodialysis, with at least 10 of these patients having congestive heart failure, will have the u-Cor system placed below left axilla and the ZOE Fluid Status Monitor
88877293|NCT03072732|Other|study arm 2-upper left pectoral area|20 patients undergoing hemodialysis, with at least 10 of these patients having congestive heart failure, will have the u-Cor system placed on the upper left pectoral area and the ZOE Fluid Status Monitor
88877294|NCT03074682|Experimental|Lifeflow|Participants in this arm will use the Lifeflow device to administer fluid in a simulation in a simulation setting.
88877295|NCT03074682|Active Comparator|Push/Pull|Participants in this arm will use the Push/Pull method to administer fluid in a simulation in a simulation setting.
88877296|NCT03074682|Active Comparator|Pressure Bag|Participants in this arm will use a Pressure Bag to administer fluid in a simulation in a simulation setting.
88877297|NCT03078504|Experimental|Experimental arm|The patients will have the blood flow rate adjusted on CRRT gradually increased to assess the effect on hemodynamics
88877298|NCT03080142|Experimental|Group 1|Single injection of Exparel
89189657|NCT05492630|Placebo Comparator|HEC73077 placebo tablets|Single-Dose Study: There will be a total of 7 dose cohorts. Multiple-dose Study: There will be a total of 4 dose cohorts.
88877299|NCT03080142|Active Comparator|Group 2|Injection of Ropivicaine (Naropin) bolus and placement of Ropivicaine catheters
88877300|NCT03085836|Experimental|TAK-438 10 milligram (mg) Once Daily|TAK-438 10 mg, tablets, orally, once daily on Days 1, 3-9. Participants were required to fast for a minimum of 10 hours prior administration of assigned treatment.
89189658|NCT05492383|Experimental|Patients with severe symptomatic AS undergoing TAVI|Patients with severe symptomatic AS undergoing a TAVI procedure with a THV for which rapid pacing is considered necessary during valve implantation
89189659|NCT05478915|Experimental|patients with TMJ anterior disc displacement|patients had clinically limited mouth opening and by MRI we found anterior disc displacement
89189660|NCT05471947|Experimental|Treatment|Treatment of hand lentigines with 15% trichloroacetic acid + 3% glycolic acid
89402044|NCT02235662|Placebo Comparator|Placebo Intravaginal Ring|Intravaginal ring 55.0 mm in diameter, consisting of two segments of polyurethane tubing with an outer diameter of 5.5 mm containing no active experimental ingredients. Used for one month.
89402045|NCT05167981|Experimental|RETAIN Programming|The experimental group receives the full set of RETAINWORKS intervention activities.
89402046|NCT05167981|No Intervention|Control|The control group receives information and referral to partner services.
89402047|NCT02262650|Active Comparator|Telmisartan alone|
89402048|NCT02262650|Experimental|Telmisartan + Clopidogrel (concomitantly)|
89402049|NCT02262650|Experimental|Telmisartan + Clopidogrel (consecutively)|
89402050|NCT02262650|Active Comparator|Clopidogrel alone|
89402051|NCT02235740|Experimental|Afuresertib 125 mg+ Carfilzomib (Part 1)|Approximately 8 subjects will receive Afuresertib 125 mg daily starting Cycle 1 Day 2 + Carfilzomib 20 mg/m^2: Cycle 1, Day 1, 2; Cycle 2, Day 1. Carfilzomib 27 mg (increased dosage of 27 mg/meter (m)^2 will be administered only if tolerated): Cycle 1, Days 8, 9, 15, and 16; Cycle 2, Days 2, 8, 9, 15, and 16; Cycle 3 and onwards, Days 1, 2, 8, 9, 15, and 16 of each cycle
89437452|NCT03889119|Active Comparator|Elekta Versa HD|This study seeks to investigate biochemical failure rates for patients treated with SBRT utilizing Elekta machines, as well as obtain quality of life data and assess the intrafraction motion in approximately 15 patients for 5 years following SBRT.
88877301|NCT03085836|Experimental|TAK-438 20 mg Once Daily|TAK-438 20 mg, tablets, orally, once daily on Days 1, 3-9. Participants were asked to fast for a minimum of 10 hours prior administration of assigned treatment.
88877302|NCT03085836|Experimental|TAK-438 20 mg Twice Daily|TAK-438 20 mg, tablets, orally, once on Day 1 and twice daily on Days 3-9. Participants were asked to fast for a minimum of 10 hours prior to breakfast, followed by administration of assigned treatment 0.5 hours after breakfast and dinner.
88877303|NCT03088800|Active Comparator|Oral Ibuprofen|Oral Ibuprofen at 10mg/kg dose and placebo of equal volume
88877304|NCT03088800|Active Comparator|Oral APAP|Oral APAP at 15 mg/kg and placebo of equal volume
88877305|NCT03088800|Active Comparator|Oral Ibuprofen and Oral APAP|Oral Ibuprofen at 10mg/kg dose and APAP at 15mg/kg dose.
88877306|NCT03092934|Experimental|25 milligrams (mg) LY3295668 (Phase 1)|25 milligrams (mg) LY3295668 twice daily (BID) administered orally in 21-day cycles.
88877307|NCT03092934|Experimental|50 mg LY3295668 (Phase 1)|50 mg LY3295668 BID administered orally in 21-day cycles.
88877308|NCT03092934|Experimental|75 mg LY3295668 (Phase 1)|75 mg LY3295668 BID administered orally in 21-day cycles.
88877309|NCT03092934|Experimental|25 mg LY3295668 (Phase 2)|25 mg LY3295668 BID administered orally in 21-day cycles.
88877310|NCT03095976|Experimental|Test group|Application of Amnion-Chorion allograft membrane (ACM) on the root surface of periodontally diseased teeth in conjunction with corticocancellous allograft bone substitute covered by ACM in a combination GTR treatment of periodontal intrabony and furcation defects.
88877311|NCT03096444|Experimental|Topical KeAmLi combo|Topical KeAmLi-combo (ketamine 10%, amitriptyline 5%, and lidocaine 5%) will be applied to one four 4 x 4 cm predefined skin areas on the ventral forearms during one of two study visits. The pre-treatment will occur under topical occlusion for 30 minutes to allow the ointment to be adsorbed. Following this, residual ointment will be removed and sensory testing, strictly within the pretreated area, will commence.
88877312|NCT03096444|Experimental|Topical ketamine|Topical ketamine 10% will be applied to one four 4 x 4 cm predefined skin areas on the ventral forearms during one of two study visits. The pre-treatment will occur under topical occlusion for 30 minutes to allow the ointment to be adsorbed. Following this, residual ointment will be removed and sensory testing, strictly within the pretreated area, will commence.
88877313|NCT03096444|Experimental|Topical amitriptyline|Topical amitriptyline 5% will be applied to one four 4 x 4 cm predefined skin areas on the ventral forearms during one of two study visits. The pre-treatment will occur under topical occlusion for 30 minutes to allow the ointment to be adsorbed. Following this, residual ointment will be removed and sensory testing, strictly within the pretreated area, will commence.
88877314|NCT03096444|Experimental|Topical lidocaine|Topical lidocaine 5% will be applied to one four 4 x 4 cm predefined skin areas on the ventral forearms during one of two study visits. The pre-treatment will occur under topical occlusion for 30 minutes to allow the ointment to be adsorbed. Following this, residual ointment will be removed and sensory testing, strictly within the pretreated area, will commence.
88877315|NCT03096444|Placebo Comparator|Topical vehicle|Topical vehicle (PCCA Lipoderm) will be applied to one four 4 x 4 cm predefined skin areas on the ventral forearms during one of two study visits. The pre-treatment will occur under topical occlusion for 30 minutes to allow the ointment to be adsorbed. Following this, residual ointment will be removed and sensory testing, strictly within the pretreated area, will commence.
88877316|NCT03100500|Experimental|QMF149|All eligible patients take QMF149 150/320 μg once daily over 52 weeks.
89535523|NCT05397899|Experimental|AHT group|This group will receive Abdominal hypopressive exercises. Each AHT will be repeated 3-5 times with 1 min rest between exercises (shift to new posture, lying,sitting and standing). Between 6 and 15 hypopressive exercises (HEs) will be performed within each session based on the participant's mastery of the exercises and readiness to progress, for 6 weeks.
89535524|NCT05397899|Active Comparator|General exercise group|This group will receive general exercises (Bridging, knee to chest, Straight leg rise) these will be repeated 3-5 times with 1 min rest between exercises. Between 6 and 15 repetitions will be performed within each session based on the participant's mastery of the exercises and readiness to progress. Each exercise to be repeated 3-5 times per set, and participants will be asked to perform technique once daily for 6 weeks
89535525|NCT05010135||Healthy Subject|Aged 60 and over. Male or Female. Able to give consent, and attend the assessment centre for the balance and gait weight distribution assessment.
88877317|NCT03100968|Active Comparator|Palpation Group|The palpation group will have an epidural placed after manual palpation of the spine.
88877318|NCT03100968|Active Comparator|Ultrasound Group|The ultrasound group will have an epidural placed after identifying midline with the ultrasound.
88877319|NCT03104322|Other|Observation sequence|Period 1: patientMpower platform+usual care for 8 weeks; Period 2: usual care alone for 8 weeks
88877320|NCT03107754|Placebo Comparator|Standard paracervical block|A paracervical block will be administered with 20 cc of 1% lidocaine, which is our standard office protocol
88877321|NCT03107754|Experimental|Buffered lidocaine paracervical block|A paracervical block will be administered with 20 cc of 1% lidocaine buffered with 8.4% sodium bicarbonate
88877322|NCT03118596|Active Comparator|I-gel|Fibreoptic guided tracheal intubation through I-gel
88877323|NCT03118596|Active Comparator|LMA Protector|Fibreoptic guided tracheal intubation through Protector
88877324|NCT03124368|Experimental|Group 1: Danicopan 100 mg TID (Sentinel)|All participants received 100 milligrams (mg) of danicopan three times per day (TID) during the Treatment Period.
88877325|NCT03124368|Experimental|Group 2: Danicopan up to 200 mg TID|All participants received not more than 200 mg of danicopan TID depending on the available safety, pharmacokinetic, and pharmacodynamic data from Group 1 (Sentinel) during the Treatment Period.
89535526|NCT05010135||Vertebral fracture subjects|"Aged 60 or over. Male or Female. Able to give consent, and attend the assessment centre for the balance and gait weight distribution assessment.~Have been diagnosed by doctors to have the vertebral fracture"
89535527|NCT03225391|Experimental|Nap 1|Subjects who take, during a night shift, first a nap from 0:00 to 3:00 hours and, after 6 weeks of lavage, another nap from 3:00 to 6:00 hours.
89535528|NCT03225391|Experimental|Nap 2|Subjects who take, during a night shift, first a nap from 3:00 to 6:00 hours and, after 6 weeks of lavage, another nap from 0:00 to 3:00 hours.
89189661|NCT05468567||Military person with acoustic trauma (experimental group)|Active or reserve military member, diagnosed with acoustic trauma for at least one month. Participants will be instructed to localize a sound emitted in their environment using a virtual reality setup.
89189662|NCT05468567||Normal hearing volunteers (control group)|Person without known hearing loss.
89189663|NCT05468502|Experimental|Dose escalation|Four different doses were set, and three subjects in each dose plan received human umbilical cord mesenchymal stem cell injection successively. Each subject received a single dose of 6.0*10^6, 3.0*10^7, 6.0*10^7, and 9.0*10^7 cells / person.
89189664|NCT05466032||First year TouroCOM osteopathic medical students|As required by the Touro College of Osteopathic Medicine curriculum, all first year osteopathic students are enrolled in Osteopathic Manual Manipulation (OMM). This course meets three hours per week for the duration of the school year and teaches students about different osteopathic dysfunctions, as well as techniques for how to treat them.
89189665|NCT05466032||Master of Science TouroCOM students|Students enrolled in the Master of Science in Interdisciplinary Studies in Biological and Physical Sciences at TouroCOM complete almost all of the same courses as the osteopathic medical students, but are not exposed Osteopathic Manual Manipulation (OMM). This cohort will act as the control as they undergo similar environmental stress, but will not learn about common osteopathic dysfunctions or their treatments.
89189666|NCT05465681|Experimental|HR20013 for injection+dexamethasone|
89189667|NCT05463601|Experimental|Mecapegfilgrastim +dalpiciclib + endocrine therapy|Mecapegfilgrastim / dalpiciclib / Endocrine therapy (exemestane, fulvestrant, letrozole, tamoxifen)
89189668|NCT05463601|Active Comparator|dalpiciclib + endocrine therapy|dalpiciclib / Endocrine therapy (exemestane, fulvestrant, letrozole, tamoxifen)
89189669|NCT05462015|Experimental|Elastic band|The experimental group received a 35-minute training course for 2 weeks, 3 times a week, each time during the hospitalization. A total of 4 assessments were performed: baseline (pre-intervention), after third-time intervention, post-intervention, and one week after the intervention.
89189670|NCT05462015|Active Comparator|Control|The control group was given routine rehabilitation exercise
89189671|NCT05438082|Experimental|Antibiotic Prophylaxis|one dose of either Trimethoprim (if < 2 months) or Trimethoprim-Sulfamethoxazole (if ≥ 2 months) or placebo in suspension. Dosing regimen for the active treatment (Trimethoprim) will be based on weight (5mg/kg of Trimethoprim component) with a maximum dosage of 320mg.
89189672|NCT05438082|Placebo Comparator|Placebo|The placebo group will receive an equal volume of placebo suspension that has been developed to have the same colour and taste as the antibiotic to preserve blinding.
89189673|NCT05432245|Experimental|Treatment group|
89402052|NCT02235740|Experimental|Afuresertib 150 mg+ Carfilzomib (Part 1)|Approximately 8 subjects will receive oral Afuresertib 150 mg daily starting Cycle 1 Day 2 + Carfilzomib 20 mg/m^2: on Cycle 1, Day 1, 2; Cycle 2, Day 1. Carfilzomib 27 mg/m^2 (increased dosage of 27 mg/m^2 will be administered only if tolerated): Cycle 1, Days 8, 9, 15, and 16; Cycle 2, Days 2, 8, 9, 15, and 16; Cycle 3 and onwards, Days 1, 2, 8, 9, 15, and 16 of each cycle
89189674|NCT05418283|Active Comparator|Exercise|12-week aerobic exercise program will be applied (3/week)
89189675|NCT05418283|No Intervention|Control|No intervention will be applied.
89189676|NCT05414448|No Intervention|ENDOAID|CADe system will be used during withdrawal phase of colonoscopy.
89437453|NCT03889119|Other|Agility Systems|This study seeks to investigate biochemical failure rates for patients treated with SBRT utilizing Agility Systems, as well as obtain quality of life data and assess the intrafraction motion in approximately 15 patients for 5 years following SBRT.
89402053|NCT02235740|Experimental|Afuresertib 100 mg+ Carfilzomib (Part 1)|An additional arm with 100 mg of afuresertib may be evaluated if the other 2 arms are not tolerated. Approximately 8 subjects will receive Afuresertib 100 mg daily starting Cycle 1 Day 2 + Carfilzomib 20 mg/m^2: on Cycle 1, Day 1, 2; Cycle 2, Day 1. Carfilzomib 27 mg/m^2 (increased dosage of 27 mg/m^2 will be administered only if tolerated): Cycle 1, Days 8, 9, 15, and 16; Cycle 2, Days 2, 8, 9, 15, and 16; Cycle 3 and onwards, Days 1, 2, 8, 9, 15, and 16 of each cycle
88877326|NCT03124602|Experimental|Test Subject|All subjects are enrolled into the test group and all subjects receive the noninvasive Red Diamond Disposable Pulse Oximeter Sensor
89402054|NCT02235740|Experimental|Afuresertib/carfilzomib (Part 2)|Approximately 50 subjects will receive Afuresertib Recommended Phase 2 Dose (RP2D) daily starting Cycle 1 Day 1 + Carfilzomib 20 mg/m^2 Cycle 1, Day 1, 2. Carfilzomib 27 mg (increased dosage of 27 mg/m^2 will be administered only if tolerated): Cycle 1, Days 8, 9, 15 and 16; Cycle Days 1, 2, 8, 9, 15 and 16 of each cycle; Cycle 3 and onwards, Days 1, 2, 8, 9 and 15 and 16 of each cycle.
89402055|NCT02235740|Active Comparator|Carfilzomib (Part 2)|Approximately 50 subjects will receive Carfilzomib 20 mg/m^2: Cycle 1, Day 1, 2. Carfilzomib 27 mg/m^2 (increased dosage of 27 mg/m^2 will be administered only if tolerated): Cycle 1, Days 8, 9 15, and 16; Cycle 2, Days 1, 2, 8, 9, 15 and 16 of each cycle; Cycle 3 and onwards, Days 1, 2, 8, 9, 15 and 16 of each cycle.
89402056|NCT03629431|Active Comparator|postoperative standard care|Standard care after surgery in postoperative unit
89402057|NCT03629431|Experimental|Prophylactic non-invasive ventilation|Prophylactic noninvasive ventilation in postoperative and intensive care unit
89402058|NCT05163925||EUROSETS ECMOLIFE SYSTEM|"Thirty consecutive patients that require ECLS and who receive the EUROSETS ECMOLIFE SYSTEM will be included. ECMOLIFE System is a perfusion system enabling operation and monitoring of extracorporeal circulation. ECMOLIFE System operates, powers, controls and regulates ECMOLIFE Centrifugal Pump which represents the disposable blood pump. ECMOLIFE System, when used in combination with ECMOLIFE Centrifugal Pump, is suitable for full or partial cardiac, circulatory and pulmonary support.~ECMOLIFE System is composed by an active programmable console (ECMOLIFE Console), a bearing-less motor driver (ECMOLIFE Motor driver), and sensors for blood parameters detection (flow rate, pressure, temperature, SvO2 and Hb). The console is equipped with an integrated back-up which in case of primary unit failure may be operated in combination with a back-up motor driver and flowmeter (besides, the ECMOLIFE system includes an Heater cooler device)."
89402059|NCT04476836|Experimental|AAT group|Animal-assisted therapy will be provided one 1-hour session per week for 48 weeks.
88877327|NCT03124758|Experimental|Noninvasive Hemoglobin Sensor|All subjects are enrolled into the test group and all subjects received the Noninvasive Hemoglobin Sensor (Rainbow Reusable DCI, DCIP)
88877328|NCT03124836|Experimental|R2-25 Sensor|All subjects will be enrolled in the test group and will receive R2-25 Pulse Oximeter Sensor
88877329|NCT03125226|Experimental|Supportive care (TracelT hydrogel)|Patients undergo transurethral resection of bladder tumors and receive TracelT hydrogel via injection. Patients undergo standard of care radiation therapy within 8 weeks of TracelT hydrogel placement.
88877330|NCT03127956|Experimental|Olumacostat Glasaretil Gel, 5.0%|Olumacostat Glasaretil Gel, 5.0%, applied twice daily to the face
88921939|NCT06039605|Experimental|tDCS1|This group will receive motor training concurrent with 20 minutes of either sham or active tDCS. Sham tDCS will be a 30-second ramp up from 0 to 2 milliamps (MA), then a 30-second ramp-down from 2 mA to 0 mA. The next 18 minutes will have no stimulation (0 mA), starting at minute 19 with 30-second ramp up from 0 to 2 milliamps (MA), then a 30-second ramp-down from 2 mA to 0 mA. Active tDCS will ramp up to 2 mA in the first 30 seconds, then stay at 2 mA for 19 minutes, then ramp down to 0 mA.
88921940|NCT06039605|Experimental|tDCS2|This group will first read some information about tDCS based on cited studies. They will then receive the same motor training and tDCS as the tDCS1 arm.
89189677|NCT05414448|Experimental|ENDOAID with ENDOCUFF|CADe system and mucosal exposure device (ENDOCUFF) will be used during withdrawal phase of colonoscopy.
89189678|NCT05410561|Experimental|TeleTx intervention|The evidence-based manualized psychosocial program is via telehealth and uses adaptations of cognitive behavioral therapy and motivational interviewing.
89402060|NCT04476836|No Intervention|control group|routine care
89402061|NCT02001961||Heart failure|Patients will be recruited from the heart failure clinic by their consultant. These will include patients who are due to have a MRI scan for clinical reasons and those who volunteer to participate. Voluntary subjects will be over 8 years.
89402062|NCT02001961||Control|Control subjects will be identified after being referred for an MRI scan and being allocated to a non-cardiac MRI with gadolinium contrast.
89402063|NCT02604680|Experimental|BLI1100-1|Topical gel
89402064|NCT02604680|Experimental|BLI1100-2|Topical gel
89402065|NCT02604680|Experimental|BLI1100-3|Topical gel
89402066|NCT02604680|Experimental|BLI1100-4|Topical gel
89402067|NCT02604680|Placebo Comparator|Placebo|Topical gel
89402068|NCT03629353|Experimental|intubation group|The enrolled patients will be oxygenated by endotracheal tube during operation.
89402069|NCT03629353|Experimental|THRIVE group|The enrolled patients will be oxygenated by intubationless high flow nasal cannula during operation.
89402070|NCT05762731||First degree relatives of lung cancer patients|Age 50-75, men or women, smokers or non-smokers. Being first degree relatives (siblings, children and parents) of lung cancer subjects. Having no known lung cancer before.
89402071|NCT05762731||Control group|Non-lung cancer subjects who are not related any lung cancer patients
89437454|NCT03877991|Experimental|CBD-sesame oil capsule|12 volunteers will receive a single oral dose of CBD in a sesame oil vehicle filled in a capsule, with 200 mL of water. The dose of CBD to be administrated is 90 mg.
89437455|NCT03877991|Experimental|CBD-LNL capsule|12 volunteers will receive a single oral dose of CBD-LNL formulation filled in a capsule, with 200 mL of water. The dose of CBD to be administrated is 90 mg.
89402072|NCT02235818|Active Comparator|Kinesiotape (KT)|Kinesiotape was used only on the affected side as per the manufacturer instructions. With the elbow extended, wrist fully flexed and fingers pointed down 24, KT was applied with slight stretch (10-15%) and paper off tension to the lateral arm beginning just above the bony portion of lateral epicondyle. Once the top strand was anchored, KT was applied along the side of elbow such that hole in the tape was over lateral epicondyle of the elbow. Two strands of tape followed the lateral forearm and ended at around beginning of the distal one third of forearm. Once the support was applied, KT was gently rubbed to activate the glue.
89402073|NCT02235818|Active Comparator|Counterforce elbow brace|The counterforce brace was approximately 5cm wide with velcro attachment for adjustable girth. It had gel pack for extra support on extensor muscle mass. With the elbow extended, brace was applied 2.5cms below the lateral epicondyle. A feeling of comfortable compression, as reported by the patients was used to adjust the brace.
88877331|NCT03132246||Infected|"Trauma patients that were considered at risk for infection after fracture fixation. Inclusion criteria included open fractures, proximal tibia fractures, pilon fractures, and calcaneus fractures treated with surgical fixation. Each patient enrolled in the study provided 1-3 blood samples. These blood samples were tested using basic science techniques to determine the level of exposure to a staphylococcal biofilm each patient has experienced over a period of time.~The only intervention patients experience are non-standard of care blood draws. The blood is then tested in a basic science laboratory.~Patients were enrolled if presented as high risk but later separated into the Infected Group or the Not Infected Group based on whether or not they went on to develop an infection post surgery. All patients in this group went on to develop an infection."
88877332|NCT03132246||Not Infected|"Trauma patients that were considered at risk for infection after fracture fixation. Inclusion criteria included open fractures, proximal tibia fractures, pilon fractures, and calcaneus fractures treated with surgical fixation. Each patient enrolled in the study provided 1-3 blood samples. These blood samples were tested using basic science techniques to determine the level of exposure to a staphylococcal biofilm each patient has experienced over a period of time.~The only intervention patients experience are non-standard of care blood draws. The blood is then tested in a basic science laboratory.~Patients were enrolled if presented as high risk but later separated into the Infected Group or the Not Infected Group based on whether or not they went on to develop an infection post surgery. All patients in this group did not go on to develop an infection."
88877333|NCT03138798|Experimental|Laboraide TM dental support device|Receive Laboraide
89402074|NCT03135704|Active Comparator|"Re Spine Mattress"|"Adults suffering low back pain will treat their low back pain using the Re Spine mattress"
88877334|NCT03138798|No Intervention|Control Group|Patients will give consent in the first stage of labor. Subsequently, randomization will be performed using sealed envelopes opened at the time of pushing in the second stage of labor. Women assigned to Group B will not receive a Laboraide TM dental support device. Duration of the second stage and time spent pushing will be recorded. Obstetric management will not be altered by group assignment.
88877335|NCT03138876|Other|EEG Cap|Single arm study, where every participant gets assessed by EEG cap and then standard EEG. Some subjects may be treated with anti-seizure medications before standard EEG, due to ethical responsibility, if clear NCSE is identified on cap EEG. If the subject is treated with anti-seizure medication, the primary care provider will choose which medication will be given.
88877336|NCT03139032|Experimental|APD334|APD334 active treatment for 12 weeks.
88877337|NCT03139578|Experimental|C 8.5\C 9.0\T 8.5\T 9.0|Subjects randomized to this sequence received Control lens (base curve 8.5 on the left eye and 9.0 on the right eye) during the first period and then received Test lens (base curve 8.5 on the left eye and 9.0 on the right eye) during the second period.
88877338|NCT03139578|Experimental|C 9.0\C 8.5\T 9.0\T 8.5|Subjects randomized to this sequence received Control lens (base curve 9.0 on the left eye and 8.5 on the right eye) during the first period and then received Test lens (base curve 9.0 on the left eye and 8.5 on the right eye) during the second period.
89004159|NCT02085148|Experimental|Concomitant dosing schedule|Expansion phase: Schedule A - Concomitant dosing schedule: Of a 21-day cycle, regorafenib will be concomitantly administered with vincristine and irinotecan (VI): Vincristine: intravenous bolus, 1.5 mg/m2 (0.05 mg/kg for subjects ≤ 10 kg), Day 1 and Day 8. Irinotecan: intravenously over 1 hour, 50 mg/m2/day, Day 1 to Day 5. Regorafenib: orally, at a starting dose level of 72 mg/m2 (subjects 2 to less than 18 years old) or 60 mg/m2 (subjects 6 to less than 24 months old) once daily, Day 1 to Day 14.
89189679|NCT05410561|Active Comparator|Enhanced Usual Care (EUC)|EUC will include brief psychoeducation about AUD and resources for treatment.
89198967|NCT00963118|Experimental|Angelica keiskei|Angelica keiskei (green leafy vegetable) based nutrition bar
89198968|NCT00963118|Experimental|Glycine max|Glycine max (black soybeans) based nutrition bar
89402075|NCT03135704|Active Comparator|Physiotherapy|Adults suffering low back pain will treat their low back pain using conventional physiotherapy protocols
89402076|NCT03644017|Experimental|WRAPSODY Stent Graft|All subjects will receive treatment via WRAPSODY Stent Graft Placement.
89402077|NCT00158054|Experimental|Intervention Condition (INT)|Enhanced depression care: Participants assigned to INT condition will be given an information brochure describing the intervention. This description will include an overview of the two elements of treatment (Problem Solving Therapy (PST), pharmacotherapy), the choice that the participant has for which element of treatment they will receive, and the stepped care aspect of treatment.
89402078|NCT00158054|Other|Usual Cardiologic Care Condition (UCC)|Referred depression care: Participants assigned to the usual cardiologic care condition (UCC) condition will be scheduled for their next follow-up visit and thanked for their time.
89402079|NCT04476524||Study Arm|Patients who present with AF as the primary diagnosis to the ER will have their chart reviewed
89402080|NCT04476524||Historical Cohort|Historical control arm will be selected from chart review of emergency department prior to the commencement of this study after propensity matching with age and sex.
89402081|NCT05075044|Experimental|Experimental Group|A total 400 HIV-infected subjects receive three doses inactivated COVID-19 vaccine on day 0, day 21 and day 111, respectively .
89402082|NCT03135964|Active Comparator|foam|PU foam dressing from KCI
89402083|NCT03135964|Active Comparator|gauze|Polyhexamethylene biguamide (PHMB) impregnated gauze (Kerlix AMD, Covidien)
89402084|NCT05762653||Case|Cases are adult patients with type-2 diabetes, who undergo endoscopic ultrasound examination for any non-pancreatic indication.
89402085|NCT05762653||Control|Controls are adult, non-diabetic patients, who undergo endoscopic ultrasound examination for any non-pancreatic indication.
88877339|NCT03139578|Experimental|T 8.5\T 9.0\C 8.5\C 9.0|Subjects randomized to this sequence received Test lens (base curve 8.5 on the left eye and 9.0 on the right eye) during the first period and then received Control lens (base curve 8.5 on the left eye and 9.0 on the right eye) during the second period.
88877340|NCT03139578|Experimental|T 9.0\T 8.5\C 9.0\C 8.5|Subjects randomized to this sequence received Test lens (base curve 9.0 on the left eye and 8.5 on the right eye) during the first period and then received Control lens (base curve 9.0 on the left eye and 8.5 on the right eye) during the second period.
88877341|NCT03141372|Active Comparator|Autofill Void Trial|"Patients who randomize to the autofill void trial will be allowed to urinate at any time within the first 3 hours after surgery. The amount urinated will be recorded using a commode specimen collection measurer. The PVR will be measured. If PVR > 100 mL, the void trial will be considered failed and a Foley catheter will be replaced."
89402086|NCT01413529|Experimental|HEART to HAART|HEART to HAART intervention is designed to enhance ongoing adherence counseling by providing (1) real time information about medication adherence (using Wisepill device); (2) periodic assessment of medication side effects, depressive symptoms and drug use frequency (as these are linked to poor adherence among drug users) using ecological momentary assessment and (3) tailored education, recommendation and encouragement based on assessments. The participant (using their phone) and their adherence team (using a clinician interface) can jointly track real time changes in adherence increasing the potential for shared decision-making.
89402087|NCT01413529|Active Comparator|Adherence counseling|Adherence counseling with the addition of a smart phone control
89402088|NCT01337960|Experimental|Arm 1|Seated robot training group. Participants at least 6 mos. post-stroke will use the ankle robot in a seated visuo-motor training paradigm. They will train on the robot 3x weekly for 6-weeks (18 sessions) by playing videogames with the paretic ankle. They will be evaluated on outcomes at baseline, post-6 weeks training, and again after a 6-week retention period with no training.
88877342|NCT03141372|Active Comparator|Backfill Void Trial|"About 300 mL of fluid will be instilled into the bladder and the Foley will then be removed. The participant will be given up to 1 hour to urinate and the amount urinated will be recorded using a commode specimen collection measurer. The PVR will be measured. If PVR > 100 mL or if the patient is unable to void within the hour, the void trial will be considered failed and a Foley catheter will be replaced."
88877343|NCT03141528|Active Comparator|Instructor-led learning|This group will train their technical CPR-skills with supervision by a tutor (either general practitioner or medical student, all trained in CPR teaching)
88877344|NCT03141528|Experimental|Self-learning|This group will Train alone without supervision and without communicating with the other participants.
88877345|NCT03145818||Veterans|Veterans will be the primary group for whom the VD-HCBS Program is implemented. Veterans enrolled in VD-HCBS will be functionally impaired
88877346|NCT03145818||Caregivers|Caregivers support Veterans independence in their home and community
88877347|NCT03145818||VHA Coordinators|VHA VD-HCBS Coordinators allow the program to operate within the VA
88877348|NCT03145818||ADNA Coordinators|ADNA Coordinators engage with the Veteran, Caregivers, and VA Coordinators to ensure the Veteran is able to maintain independence
88877349|NCT03147690|Experimental|All Study Participants|All subjects will have an abdominal non-contrast ultrasound performed. Lumason will then be administered at a dose of 0.03mL/kg up to a maximum dose of 2.4mL and a contrast-enhanced ultrasound will be performed. The dose will be given twice, for a total maximum dose per subject of 4.8mL
89189680|NCT05410249||Patients with primary ITP|Patients with primary ITP and aged 18 and older will be included in the study. Patients under 18 and those with proven secondary ITP [as cases initiated by or associated with infections due to human immunodeficiency virus (HIV-associated), hepatitis B virus, or hepatitis C virus-associated secondary ITP] will be excluded. Moreover, patients with accompanying autoimmune disorders such as systemic lupus erythematosus (SLE) and patients of malignancies were excluded.
88877350|NCT03148236|Active Comparator|Vitamin C|
88877351|NCT03148236|Placebo Comparator|Placebo|
88877352|NCT03148470|Experimental|intermittent theta burst stimulation|intermittent theta burst stimulation (iTBS) + Sham iTBS
88877353|NCT03148470|Experimental|continuous theta burst stimulation|continuous theta burst stimulation (cTBS) + Sham cTBS
88877354|NCT03149172|Experimental|Equimatrix®|Equimatrix® + Mucograft or alternatives
88877355|NCT03149172|Experimental|Bio-Oss®|Bio-Oss® + Mucograft or alternatives
88877356|NCT03149172|Experimental|Endobon®|Endobon® + Mucograft or alternatives
88877357|NCT03150108|Experimental|Non-Hispanic Caucasians|Subjects will receive single dose of 100 microgram (mcg) rhPTH(1-84) subcutaneous (SC) injection on Day 1.
88877358|NCT03150108|Experimental|Participants of Japanese Descent|Subjects will receive single dose of 100 mcg rhPTH(1-84) SC injection on Day 1; On days 4 and 7, either 25 mcg or 50 mcg SC injection. A washout period of 73 hours will be maintained between each single doses (100 mcg, 50 mcg and 25 mcg) in a cross-over fashion.
88877359|NCT03154710|Experimental|Web-application follow up|Patients will have a clinical and biological exam every 3 months and a web-mediated follow up. Patients will have to connect to the MOOVCARE application every 14 days to complete a questionnaire about their symptoms. Imaging will be performed in the event of an alert or clinical problem
88877360|NCT03154710|No Intervention|Standard|Patients will have the usual follow up (Clinical and biological exam every 3 months and imaging every 6 months)
88877361|NCT03160170|Experimental|Use of Cobb device|Use of SISTER device during surgery
88877362|NCT03160170|No Intervention|Control|Standard exposure technique and instruments will be used during surgery
88877363|NCT03162354|Experimental|Intervention Sites|"At the four intervention sites, investigators will deploy active, multifaceted, implementation strategies designed to promote CDR acceptability and application as an AHT screening tool. These strategies will include physician training with onsite visits, monthly booster training emails, access to an AHT probability calculator, audit and site-specific feedback, and local information sharing sessions designed to address local barriers to CDR acceptance and application."
89402089|NCT01337960|Experimental|Arm 2|Treadmill training with ankle robot group. Participants at least 6 mos. post-stroke will wear the ankle robot during treadmill locomotor training. They will walk on a treadmill with the ankle robot adjusted to promote paretic ankle engagement during 3 x weekly training sessions over 6 weeks (18 sessions). They will be evaluated on outcomes at baseline, post-6 weeks training, and again after a 6-week retention period with no training.
89402090|NCT01337960|Active Comparator|Arm 3|Treadmill only group. This group will consist of participants at least 6 mos. post-stroke who engage in treadmill training 3x weekly for 6 weeks without robotic support. They will be volunteers from another treadmill training study and evaluated on outcomes at baseline and post-6 weeks training. They will not receive retention testing at 12 weeks because they will be continuing with regular treadmill training beyond the 6-week period.
89402091|NCT03136042|Experimental|physiotherapists maneuvers|physiotherapy techniques
89402092|NCT03136042|Active Comparator|hypertonic saline 3%|four nebulizations with 3% hypertonic saline.
89402093|NCT03136042|Active Comparator|saline + physiotherapy maneuvers|1 nebulizations + physiotherapy techniques
89402094|NCT02571998|Experimental|Treatment|Omiganan (CLS001) Topical Gel applied once daily
89402095|NCT02571998|Placebo Comparator|Vehicle Gel|Vehicle Topical Gel applied once daily
89402096|NCT04379986|Experimental|Standardized measures in the cardiac catheterization laborator|Immediately after coronary angiography, intra-arterial BP waveforms will be recorded using a fluid-filled catheter via right femoral or radial access. The catheter will be flushed before any waveform recordings is made. At first, the catheter will be positioned in the aorta for 3 minutes of stable BP waveforms recording. Intracoronary nitroglycerin will be administered at a dose of 300 µg, newly preceding 3 minute of recording. At the end of the coronary angiography, additional 3 minutes of recording will be performed in the aorta.
89189681|NCT05410249||normal individuals|The control group will be age-matched and sex-matched normal healthy volunteers.
89189682|NCT05397379|Experimental|HEC96719 0.25 mg|Oral dose once daily for 12 weeks
88877364|NCT03162354|No Intervention|Control Sites|"At the four matched control sites, physicians will engage in AHT screening as usual."
88877365|NCT03163134|No Intervention|No Lumbar Drain Group|Group of patients that did not receive a lumbar drain after surgery
88877366|NCT03163134|Experimental|Lumbar Drain Group|Group of patients that received a lumbar drain after surgery
89402097|NCT04379986|Experimental|Standardized measures in the intensive care unit|Invasive BP monitoring is a commonly used technique in the ICU and is used to guide many intensive care unit therapies. Enrolled patients must have had an arterial catheter in place at the time of inclusion to the study. Arterial catheterization will be performed by the intensive care team according to current medical guidelines. No arterial catheters were placed for the sole purpose of this study. The Senbiosys device will be placed on the opposite arm of the arterial catheter for simultaneous measurements.
89437456|NCT03877991|Experimental|CBD powder form capsule|12 volunteers will receive a single oral dose of CBD in powder form filled in a hard gelatin capsule, with 200 mL of water. The dose of CBD to be administrated is 90 mg.
88877367|NCT03163758|Experimental|rTMS treatment group|The rTMS treatment group received a 10-day real repetitive transcranial magnetic stimulation (rTMS) treatment beginning within 1 week after stroke onset.
88877368|NCT03163758|Sham Comparator|sham group|The sham group received a 10-day sham repetitive transcranial magnetic stimulation (rTMS) treatment beginning within 1 week after stroke onset.
88877369|NCT03164538|Experimental|Positive Psychology + Motivational Interviewing|Participants will complete weekly positive psychology exercises and will systematically set goals related to physical activity. Study trainers will review the positive psychology exercises on the phone each week and will use motivational interviewing techniques to facilitate goal setting.
88877370|NCT03164538|Active Comparator|Diabetes Education|Participants will speak on the telephone each week with a study trainer. During these calls, the trainer will provide education about a health behavior related to diabetes health (physical activity, medication adherence, diet).
88877371|NCT03169062|Experimental|All patients|Gated Stationary Chest Tomosynthesis
88877372|NCT03170388|Experimental|IDP-126 Gel|Gel
88877373|NCT03170388|Active Comparator|IDP-126 Component A|Component A
88877374|NCT03170388|Active Comparator|IDP-126 Component B|Component B
88877375|NCT03170388|Active Comparator|IDP-126 Component C|Component C
88877376|NCT03170388|Placebo Comparator|IDP-126 Vehicle Gel|Vehicle Gel
88877377|NCT03172884|Experimental|BAY80-6946/Healthy subject|Healthy subjects
88877378|NCT03172884|Experimental|BAY80-6946/moderate hepatically impaired patients|Patients with Child-Pugh B (score 7-9) at the screening visit
88877379|NCT03172884|Experimental|BAY80-6946/severe renal impaired patients|Patients with eGFR 15-29 mL/min/1.73 m^2 at the screening visit based on the Modification of Diet in Renal Disease (MDRD) equation
88877380|NCT03172884|Experimental|BAY80-6946/severe hepatically impaired patients|Patients with Child-Pugh C (score 10-15) at the screening visit
88877381|NCT03174366|Experimental|Intervention Group, receiving medication|Subjects in this group will be receiving medication (denosumab)
88877382|NCT03177798|Experimental|Icatibant then Placebo|"Icatibant will be intravenously infused at a rate of 50 ug/kg/h for 1 hour prior to the initiation of dialysis and continue through hemodialysis (4 hours)~1 week washout~Placebo will be intravenously infused at the same rate of Icatibant (50 ug/kg/h) for 1 hour prior to the initiation of dialysis and continue through hemodialysis (4 hours)"
88877383|NCT03177798|Experimental|Placebo then Icatibant|"Placebo will be intravenously infused at the same rate of Icatibant (50 ug/kg/h) for 1 hour prior to the initiation of dialysis and continue through hemodialysis (4 hours)~1 week washout~Icatibant will be intravenously infused at a rate of 50 ug/kg/h for 1 hour prior to the initiation of dialysis and continue through hemodialysis (4 hours)"
88877384|NCT03178344|Experimental|Sham Stimulation, then Alpha Stimulation|"Participants receive sham stimulation at the first session, followed by a 5-9 day washout period and alpha stimulation at the second session.~Sham Stimulation mimics the physical effects of stimulation, with up to one minute of stimulation during the session. Sham stimulation is delivered using the XCSITE100 Stimulator Sham.~Participants will receive 2 mA of alternating current stimulation at a frequency of 10 Hz for 40 minutes. tACS stimulation is delivered using the XCSITE100 Stimulator tACS."
88877385|NCT03178344|Experimental|Alpha Stimulation, then Sham Stimulation|"Participants receive alpha stimulation at the first session, followed by a 5-9 day washout period and sham stimulation at the second session.~Participants will receive 2 mA of alternating current stimulation at a frequency of 10 Hz for 40 minutes. tACS stimulation is delivered using the XCSITE100 Stimulator tACS.~Sham Stimulation mimics the physical effects of stimulation, with up to one minute of stimulation during the session. Sham stimulation is delivered using the XCSITE100 Stimulator Sham."
88877386|NCT05364216|Other|Group C|The general anesthesia was used.In this group, cognitive function was evaluated by MMSE and MoCA scale on one day before surgery, one day after surgery, and three months after surgery. Acute postoperative pain was was evaluated by VAS after extubation , one day after surgery, Chronic postsurgical pain was evaluated by VAS on three months after surgery.
88877387|NCT05364216|Experimental|Group T|Group T received 0.375% ropivacaine 20ml thoracic paravertebral nerve block combined with general anesthesia under ultrasound guidance after anesthesia induction.
88877388|NCT05364216|Other|Non-surgical controls|Age and sex-matched community people are included for three sessions of MMSE test evaluation for calculation of POD incidence as normal control to in Z value calculation of POD incidence to rule out learning effect.
88877389|NCT05353920|Experimental|Cognitive traiinig|
88877390|NCT05353920|Active Comparator|Active control|
88877391|NCT05304000|Active Comparator|Mindfulness Meditation|5 minutes a day of mindfulness meditation practice for 28 days (passive attention to breath) delivered remotely through a video link.
88877392|NCT05304000|Experimental|Cyclic Sighing Breathing|5 minutes a day of active breathwork practice for 28 days delivered remotely through a video link. The protocol consists of slow inhales until lungs felt full then one more inhale to maximally fill the lungs, followed up a slow exhale. Repeat this cycle for 5 minutes.
88877393|NCT05304000|Experimental|Box Breathing|5 minutes a day of active breathwork practice for 28 days delivered remotely through a video link. The protocol consists of equal duration of inhale, hold, exhale, hold cycles. The duration of the cycle is determined by the participant's comfort level with holding. (e.g. 4 sec inhale, 4 sec hold, 4 sec exhale, 4 sec hold). Repeat this cycle for 5 minutes.
89402098|NCT05202691|Experimental|Group 1 (Physical Therapy+Magnetic Field Therapy)|"Physical Therapy Protocol plus Magnetic Field Therapy~A protocol of physical therapy treatment including:~Manual therapy techniques for inhibition of piriformis, quadratus lumbaris, and paravertebral muscles in prone position and bilaterally.~2 functional techniques applied to the sacrum in prone position.~A myofascial release of ligaments inserted to the sacrum in prone position and bilaterally.~Manual therapy technique for inhibition of psoas-iliacus muscle in supine position and bilaterally.~Stretching techniques of piriformis, gluteal and paravertebral muscles in supine position and bilaterally.~Active gluteus maximus contraction in supine position bilaterally.~To this protocol, a 15 minutes of Magnetic Field Therapy using the Zimmer EmfieldPro device (Zimmer MedizinSysteme, Germany) applied to the lumbosacral region in prone position is added."
89402099|NCT05202691|Active Comparator|Group 2 (Physical Therapy)|"Physical Therapy Protocol alone:~The same Physical Therapy Treatment protocol with a sham magnetic intervention applying in the same region with a disconnected Zimmer EmfieldPro device (Zimmer MedizinSysteme, Germany) during 15 minutes."
89189683|NCT05397379|Experimental|HEC96719 0.35 mg|Oral dose once daily for 12 weeks
89189684|NCT05397379|Experimental|HEC96719 0.5 mg|Oral dose once daily for 12 weeks
88877394|NCT05304000|Experimental|Cyclic Hyperventilation with Retention|5 minutes a day of active breathwork practice for 28 days delivered remotely through a video link. The protocol consists of 30 breaths (inhale deeply through the nose and exhale passively through the mouth) and after those 30 breaths, to exhale all their air via their mouth and to calmly wait with lungs empty for 15 seconds. Repeat this cycle for 5 minutes.
89402100|NCT02784002|Experimental|Ridinilazole (SMT19969)|200 mg capsule of Ridinilazole (SMT19969) twice a day for 10 days
88877395|NCT05133882|Experimental|Arm 1|Queue 1:Clifutinib Besylate:30mg qd d8-21;Daunorubicin 60 mg/m2 qd d1-3;Cytarabine 100 mg/m2 qd d1-7 Queue 1:Clifutinib Besylate:30mg qd d1-28 ;Azacitidine 75 mg/m2 qd d1-7
88877396|NCT05133882|Experimental|Arm 2|Queue 1:Clifutinib Besylate:40mg qd d8-21;Daunorubicin 60 mg/m2 qd d1-3;Cytarabine 100 mg/m2 qd d1-7 Queue 1:Clifutinib Besylate:40mg qd d1-28 ;Azacitidine 75 mg/m2 qd d1-7
88877397|NCT05133882|Experimental|Arm 3|Queue 1:Clifutinib Besylate:60mg qd d8-21;Daunorubicin 60 mg/m2 qd d1-3;Cytarabine 100 mg/m2 qd d1-7 Queue 1:Clifutinib Besylate:60mg qd d1-28 ;Azacitidine 75 mg/m2 qd d1-7
88877398|NCT05015400|Experimental|Fluid Increase|The increased fluid intervention arm will begin on day 2 after the onset of bleeding (day 1) of their phase 1 menses through day 5. For the increased fluid intake intervention, participants will a) consume an additional 64 oz (1.89 L) of plain water only on top of habitual fluid intake and b) aim to at least urinate 5 times per day.
88877399|NCT05015400|No Intervention|Fluid Habitual|The fluid habitual non-intervention arm will a) maintain normal fluid intake volume and beverage choices and a) urination frequency.
88877400|NCT04936074|Experimental|Muscle preserving selective laminectomy (L-group)|Muscle-preserving selective laminectomy with a posterior midline incision and dissection through the nuchal fascia. The spinous processes are split in the midline using a high-speed burr/ultrasound knife and without disturbing the deep extensor muscles on either side. Angulating away from the midline, the spinous processes are divided at their bases. Laminectomy is performed with a width no more than 2-3 mm wider than the dural borders. The facet joints are not exposed. Finally, the split spionous processes are sutured together. No collar or restrictions will be used in either group.
88877401|NCT04936074|Active Comparator|Laminectomy with instrumented fusion (LF-group)|Laminectomy with instrumented fusion with a midline incision over the appropriate levels defined as the same levels as the extension of laminectomy plus one level above and below but not extending beyond C3-C7. Soft tissue dissection and retraction is performed to identify osseous landmarks. Special care is taken to spare muscle attachments on C2 and C7. Spinal instrumentation is performed with lateral mass or pedicle screws (C3-C7) combined with rod fixation. Laminectomy is performed with a width not extending more than 2 mm outside the dural borders. Facet joint injury should be avoided. Special care is taken to spare the C7 spinous process and distal half of C7 lamina. The sagittal alignment is corrected before spinal fixation. No collar or restrictions will be used in either group.
88877402|NCT04933344||patients having had BJI or PJI treated with daptomycin|patients having an osteoarticular infection treated with daptomycin and which developped eosinophilic pneumonia or elevation of CPK
88877403|NCT04847544|Experimental|ADX-629 300 mg administered orally twice daily (BID) for up to 28 days.|
88877404|NCT04847544|Placebo Comparator|Placebo administered orally BID for up to 28 days.|
88877405|NCT05406804|Experimental|Breast milk olfactory stimulation care|Let premature babies smell their mother's breast milk
88877406|NCT05406804|Active Comparator|Routine care|Prevent premature babies from smelling their mother's breast milk
88877407|NCT05406648|Experimental|Intervention|20g of Morus nigra concentrate administration for 12 weeks
88877408|NCT05406648|No Intervention|Control|No intervention throughout the study
88877409|NCT05406492||Patients udergoing ECMO|Population who have been taking antibiotics or antiplatelets or sedatives/analgesics during Extracorporeal Membrane Oxygenation
89004160|NCT02085148|Experimental|Dose escalation|Dose escalation phase: This phase of the study has been completed
89189685|NCT05397379|Experimental|HEC96719 0.25 mg bid|Oral dose twice daily for 12 weeks
89189686|NCT05397379|Placebo Comparator|Placebo|Oral dose once or twice daily for 12 weeks
89189687|NCT05395416|Experimental|HEC74647PA+HEC110114 100 mg/200 mg|Phase II: HCV GT 1-6 participants were medicated with HEC74647PA Capsules 100 mg or200 mg once daily and HEC110114 tablets 600 mg once daily
89189688|NCT05395416|Experimental|HEC74647PA+HEC110114|Phase III: HCV GT 1-6 participants were medicated with HEC74647PA Capsules 100 mg /200 mg once daily and HEC110114 tablets 600 mg once daily
89189689|NCT05395416|Placebo Comparator|Placebo|Phase III: HCV GT 1-6 participants were medicated with HEC74647PA Placebo Capsules once daily and HEC110114 Placebo tablets once daily
89402101|NCT02784002|Active Comparator|Fidaxomicin|200 mg tablet of Fidaxomicin twice a day for 10 days
88877410|NCT05406336|No Intervention|No Information from Machine Learning Algorithm|The investigators will create case vignettes to assess clinician hypertension management behavior, specifically antihypertensive medication intensification among individuals with uncontrolled blood pressure (BP). This arm will not include information from a machine learning algorithm designed to predict uncontrolled BP at a follow up visit.
89402102|NCT04362046|Experimental|Hysteroscopic uterine resection|This is a prospective single-arm surgical intervention trial.
89402103|NCT05202613||Dorage group|"HIV-1 infected patients~aged > 50 years old~naive patients receiving doravirine-based regimens~experienced patients with persistent HIV RNA < 50 copies/mLfor at least 6 months, who switched to doravirine-based regimens, because of toxicity, convenience or other reasons."
89402104|NCT05202613||Control group|HIV negative subjects, matched for age and Charlson Index score (to evaluate comorbidity impact)
89402105|NCT02233556|Experimental|Memantine|This study has only one arm. i.e. Single dose of memantine 20mg
89402106|NCT04932733|Experimental|Elderly isometric exercise|Quadriceps isometric exercise.
89402107|NCT04932733|Active Comparator|Young isometric exercise|Quadriceps isometric exercise.
89402108|NCT05228132|Experimental|Pristine™ Long-Term Hemodialysis Catheter|The Pristine™ Long-Term Hemodialysis Catheter is a chronic hemodialysis catheter consisting of a dual lumen radiopaque shaft with a pre-formed split tip, which enables long-term vascular access for hemodialysis. The device is intended to be used in patients suffering from chronic kidney disease. The Pristine™ Catheter will be placed according to the Instructions for Use (IFU).
89402109|NCT04914637|Active Comparator|interlaminar epidural steroid injection plus dry needling|"Fluoroscopy-guided cervical interlaminar epidural steroid injection will be administered to patients with chronic neck pain due to cervical disc herniation. Also, dry needling will be applied to the active trigger points for the patients in this group.~Interlaminar epidural steroid injection will be applied at week 0, while dry needling will be applied in 3 sessions per week (week 0, week 1, week 2). The first session of the dry needling will be in the same day with interlaminar epidural steroid injection."
89402110|NCT04914637|Sham Comparator|interlaminar epidural steroid injection plus sham dry needling|"Fluoroscopy-guided cervical interlaminar epidural steroid injection will be administered same as the arm titled interlaminar epidural steroid injection plus dry needling. The only difference in the interventions in this arm is that dry needling is applied without penetrating the skin. The blunt tip of the needle will be used in sham intervention.~Interlaminar epidural steroid injection will be applied at week 0, while sham dry needling will be applied in 3 sessions per week (week 0, week 1, week 2)"
89402111|NCT04914637|Other|interlaminar epidural steroid injection only|Only interlaminar epidural steroid injection will be administered to patients in this arm with the same method as in the other arms (one session, week 0). No dry needling or sham dry needling will be used.
89402112|NCT02235896|Other|Education/Behavior Modification|Education/Behavior modification program
89402113|NCT04905433|Experimental|Cardiac rehabilitation with breathing retraining|A cardiac rehabilitation program for 3 days/week (day after day) for 12 weeks(including aerobic, and resisted exercise, with educational sessions, and counseling), with a breathing retraining (using breathing calisthenics, and inspiratory muscle training)
89402114|NCT04905433|Active Comparator|cardiac rehabilitation|A cardiac rehabilitation program for 3 days/week (day after day) for 12 weeks(including aerobic, and resisted exercise, with educational sessions, and counseling) only
89402115|NCT04264390|Experimental|M2M|Participants will receive and be instructed to follow-along with 4 weeks of movement-to-music videos. Participants will also receive periodic behavioral coaching calls from a telecoach.
89402116|NCT04264390|No Intervention|Wait-list control|Participants will wait 4 weeks before starting the M2M program. Participants will be instructed to resume their normal daily activities during the wait-period.
89402117|NCT02235974|Experimental|Acute/Early|Intervention: A 20-hour dose of early intensive upper extremity motor training therapy will be initiated within 30 days post-stroke.
89402118|NCT02235974|Experimental|Sub-acute/Outpatient|Intervention: A 20-hour dose of sub-acute intensive upper extremity motor training therapy will be initiated within 2 to 3 months post-stroke.
89402119|NCT02235974|Experimental|Chronic|Intervention: A 20-hour dose of chronic intensive upper extremity motor training therapy will be initiated 6 to 9 months post-stroke
89402120|NCT02235974|Placebo Comparator|Control|Intervention: Usual and customary care. No additional therapy will be initiated during the 1-year study.
88877411|NCT05406336|Experimental|Information from Machine Learning Algorithm|The investigators will create case vignettes to assess clinician hypertension management behavior, specifically antihypertensive medication intensification among individuals with uncontrolled blood pressure (BP). This arm will include information from a machine learning algorithm designed to predict uncontrolled BP at a follow up visit about whether the algorithm predicts that the patient will have uncontrolled BP at the next visit.
89189690|NCT05394207|Experimental|GROUP 1 (Investigational product)|23 patients Investigational product: L. casei DG® (Lactobacillus paracasei CNCM I-1572) containing 8 billion of live cells daily + Vitamin D 4.000 U.I. daily.
89189691|NCT05394207|Placebo Comparator|GROUP 2 (Comparator)|23 patients The comparator product is an identical matching placebo daily + Vitamin D 4.000 U.I. daily.
89198969|NCT00963118|Experimental|Angelica keiskei + Glycine max|Angelica keiskei (green leafy vegetable) and glycine max (black soybeans) based nutrition bar
89402121|NCT04240288|Other|Control Arm|Participants randomized to the control arm will be managed with the current standard of care including daily white blood cell count and vital sign documentation. The control group will also have daily procalcitonin levels drawn but the results will not be used to make decisions regarding antibiotic duration. Antibiotics will be given orally or intravenously at the discretion of the treating physician and will be given for a 10-day course, the current standard of care.
89535529|NCT05009745|Experimental|Intervention|"The intervention will be PGT-A strategy involving trophectoderm biopsy and comprehensive chromosome screening (CCS) using Next Generation Sequencing (NGS). All embryos will be frozen after the biopsy procedure and transferred in a subsequent frozen-thawed embryo transfer. Embryo selection for transfer will be based on morphological criteria and the genetic screening result.~Only euploid embryos or mosaic euploid embryos deemed suitable to be transferred will be replaced into the uterus in a subsequent frozen-thawed embryo transfer cycles."
89402122|NCT04240288|Experimental|Treatment Arm|These participants will be managed with procalcitonin-guided antibiotic therapy. An index procalcitonin will be drawn within 24 hours of admission followed by daily procalcitonin levels. Per standard of care, patients will have daily white blood cell counts drawn and regular vital sign documentation. Antibiotics will be given orally or intravenously at the discretion of the treating physician. Antibiotics in this arm will be stopped once the procalcitonin value drops to ≤80% of its index value or to <0.5 ng/ml. Extension of antibiotics for more than 24 hours past this time will be documented.
89402123|NCT02236052|Experimental|Non-adjuvanted low dose of quadrivalent VLP vaccine|A single non-adjuvanted low dose of quadrivalent VLP vaccine
89402124|NCT02236052|Experimental|Non-adjuvanted medium dose of quadrivalent VLP vaccine|A single non-adjuvanted medium dose of quadrivalent VLP vaccine
89402125|NCT02236052|Experimental|Non-adjuvanted high dose of quadrivalent VLP vaccine|A single non-adjuvanted high dose of quadrivalent VLP vaccine
89402126|NCT02236052|Experimental|Adjuvanted low dose of quadrivalent VLP vaccine|A single low dose of quadrivalent VLP vaccine mixed with Alhydrogel®
89402127|NCT02236052|Experimental|Adjuvanted high dose of quadrivalent VLP vaccine|A single high dose of quadrivalent VLP vaccine mixed with Alhydrogel®
89402128|NCT02236052|Placebo Comparator|Placebo|A single dose of Placebo
89402129|NCT04238494|Experimental|Frail/prefrail|Fried's criteria >3 = frail, 1 or 2 = prefrail The 5 Fried criteria mainly target the muscle function: low muscle strength, decreased physical activity and low gait speed. One refers to depressive symptoms with the use of 2 CES-D (Centre for Epidemiologic Studies - Depression Scale) questions and one to nutrition with the weight loss criteria. The second most famous definition of frailty was developed by ROCKWOOD and MITNISIKI (2). It describes frailty as the accumulation of deficits including cognitive, functional and social alterations
89402130|NCT04238494|Other|non frail|No Fried's criteria
89402131|NCT03077737|Experimental|Population health management|Population health management for smoking cessation in low-income smokers: the Choose to Change intervention
89402132|NCT03077737|Active Comparator|Enhanced usual care|Usual clinic-based care enhanced by an EHR system that can deliver an electronic referral for quitline treatment
89402133|NCT03062449|Active Comparator|L-Serine Gummy Arm|L-serine will be presented in gummies containing 1g serine each. Subjects randomized into the L-serine arm will take 15 grams of L-Serine (15 gummies containing 1g of L-serine) orally twice daily for 246 days after the initial ascending dose period to confirm tolerability of the dose.
89402134|NCT03062449|Placebo Comparator|Placebo Gummy Arm|Placebo gummies containing no L-serine will be packaged in the same manner as that of the L-Serine gummy arm and be given to patients to take two times a day.
89402135|NCT04233268||Critically ill children|Children with severe infection requiring mechanical ventilation
89402136|NCT04233268||Non critically ill cohort|Children with severe infection admitted to hospital but not requiring mechanical ventilation
88877412|NCT05405946|Experimental|Computerized Cognitive Remediation Intervention and Treatment as Usual (CCRT+TAU)|"Participants with a diagnosis of schizophrenia / schizoaffective disorder undergo Computerized CRT and the usual treatment.~Three evaluations are carried out, each one divided into two sessions: an evaluation before the start of treatment, a second evaluation after finishing the Computerized CRT (after 40 sessions), and a third evaluation (follow-up) 6 months after finishing the Computerized CRT."
89402137|NCT04233268||Profiling of the respiratory microbiome|Mechanically ventilated children of any cause admitted to PICU
89402138|NCT05202457||Cirrhosis|Patients with cirrhosis undergoing urgent and elective surgery
89402139|NCT04085146|Experimental|Optimal PEEP|Individualized optimal PEEP will be provided during the laparoscopic period of surgery. Optimal PEEP will be determined by the automated procedure of step-wised decrease in the amount of PEEP of the anesthesia ventilator Aisys Care Station (GE Healthcare, Madison, Wisconsin, USA).
89402140|NCT04085146|Active Comparator|Conventional PEEP|A same amount of PEEP of 7 centimeter hydrogen dioxide will be provided during the laparoscopic period of surgery.
89402141|NCT02800915|Experimental|Intervention, telemedicine and multidisciplinary cooperation|The intervention group will be offered regular multidisciplinary outpatient follow-up via telemedicine.
89402142|NCT02800915|Active Comparator|Control, multidisciplinary guidance on request.|The control group will receive guidance based on existing routines (on-site consultations at the wound clinic and telephone consultations), and based on initiative taken by the local healthcare service/ patient/ next of kin.
89402143|NCT04908592|Active Comparator|D Group (50 patients)|
89402144|NCT04908592|Placebo Comparator|C Group (50 patients)|
89198970|NCT00882375|Experimental|Nicotine|Nicotine
89402145|NCT02761603|Active Comparator|Healthy Aging Practice-centered Instruction (HAPI)|24 hours of group instruction in which experts present on a variety of health-related topics followed by class discussion, goal-setting, and goal review. Themes will include: sleep, nutrition, mental health, social support, bone-health, diabetes prevention, cognitive wellness, and resilience.
89402146|NCT02761603|Experimental|Tai Chi (CHI)|24 hours of group instruction in 8 meditative Tai Chi movements.
89402147|NCT01567033|Experimental|Intervention|Intervention participants received HEALTH, which embedded a lifestyle intervention derived from DPP within the standard PAT curriculum
89402148|NCT04783987||Healthy Control Group|Walking Assessments will be practised under dual and single task conditions.
88877413|NCT05405946|Active Comparator|Treatment as Usual (TAU)|"Participants with a diagnosis of schizophrenia / schizoaffective disorder undergo the usual treatment.~Two evaluations will be carried out, also divided into two sessions: a first baseline evaluation and a second evaluation 5 months later, after receiving the usual treatment. After this second evaluation, the Computerized CRT is then started to guarantee ethics in all patients.~The evaluation is not carried out at 6 months since they will also have received the intervention."
88877414|NCT05405712|Experimental|Marigold APP|Participants randomized to receive the APP will be enrolled in an app based peer support program
88877415|NCT05405712|No Intervention|CONTROL|In the control arm participants will receive existing standardized peer recovery support resources from SAMHSA
88877416|NCT05405634||Patients with chronic analfissure|1. Consecutive patients referred to the outpatient clinic at the Digestive Disease Centre, Bispebjerg Hospital in Denmark for botox injection for chronic anal fissure. Thus, the included patients will likely all have tried conservative treatment before referral, and are expected to represent a more homogeneous subset with longer standing disease, less spontaneous improvement, and a higher likelihood of being compliant with suggested therapy
88877417|NCT05405634||Patients with an indication for fissurectomy|Consecutive patients with an indication for revision of the fissure and anal injection of botulinum toxin in general anaesthesia
88877418|NCT05405634||Healthy volunteers|Healthy volunteers. These will be recruited among staff at the Digestive Disease Centre, Bispebjerg Hospital, Denmark.
88877419|NCT05405478|Experimental|use of omalizumab in patients with refractory nasal polyp|15 patients group with arrival criteria
88877420|NCT05405478|Experimental|control group patients with refractory nasal polyp|15 patient that with arrival criteria cant arrive in the patients group
88877421|NCT05333952|Experimental|Pulmonary vein isolation + Waveform Periodicity Group|Pulmonary vein isolation + Substrate ablation
88877422|NCT05333952|Other|Pulmonary vein isolation group|Pulmonary vein isolation (Conventional treatment)
88877423|NCT05276310|Experimental|IMC-002|Dose escalation will follow the traditional 3+3 design.
88877424|NCT05233254|Experimental|Patients with L4-5 disc herniation|In the light of the reference research, it was estimated that it could reach an effect size of 0.6 according to the sample size measurement made with at least 80% power and 0.05 margin of error, and 18 individuals with LDH (9 men, 9 women) were planned to participate in this study. Since data loss was predicted to be 20%, it was decided to include a total of 22 patients for the study.
88877425|NCT05169918|Active Comparator|Control group|
88877426|NCT05169918|Experimental|Training Group|
88877427|NCT05083806|Experimental|Pompe disease|Actual condition
88877428|NCT05083806|Active Comparator|Muscular dystrophy|Different known condition
88877429|NCT05083806|Active Comparator|Healthy volunteer|Healthy control
88877430|NCT05023512|Experimental|Message 1|Participants will be randomized to receive version #1 of 2 different versions of a message from the Massachusetts Department of Public Health regarding the COVID-19 vaccination.
88877431|NCT05023512|Experimental|Message 2|Participants will be randomized to receive version #2 of 2 different versions of a message from the Massachusetts Department of Public Health regarding the COVID-19 vaccination.
88877432|NCT04890366|Experimental|Alteplase plus Dimethyl Fumarate|
88877433|NCT04890366|No Intervention|Alteplase|
88877434|NCT04723368|Experimental|Automated flying Drone carrying an Automated external defibrillator (AED)|Five drone systems are setup to be deployed in suspected OHCA cases as a complement to EMS. This is a single-arm intervention evaluating time benefit of drone delivery of AEDs in suspected OHCA.
88877435|NCT04098978|Experimental|Pharmacist Drug Therapy Management|
88877436|NCT03811470||1|Patients with diabetes mellitus including: type 1 or type 2 diabetes mellitus, monogenetic diabetes, pancreatogenic diabetes, drug-induced diabetes, other forms
88877437|NCT03780426|Experimental|tSMS left motor cortex (sham right)|30 min of tSMS applied to the left motor cortex with sham on the right motor cortex
88877438|NCT03780426|Experimental|tSMS right motor cortex (sham left)|30 min of tSMS applied to the right motor cortex with sham on the left motor cortex
88877439|NCT03058614|Active Comparator|CEUS arm|On postoperative day 1 (unless not clinically indicated), each subject will undergo CEUS with an administration of Lumason via their pre-placed nephrostomy tube.
88877440|NCT03058614|Active Comparator|CT scan plus capping trial arm|On postoperative day 1 (unless not clinically indicated), subjects' pre-placed nephrostomy tube will be capped and they will undergo a low dose non-contrast abdominal CT scan.
88877441|NCT03048240|Experimental|"perPDT"|Single arm : per-operative PhotoDynamic Therapy (perPDT) during the surgery of Glioblastoma excision.
88877442|NCT02893800|Other|Himatic locating system|Locating system watch with GPS-technology (free available) Main functions: telephone function and location upon request via smartphone
88877443|NCT02893800|Other|ReSOS locating system|Locating system watch with GPS-technology (free available) Main functions: telephone function and location upon request via smartphone
88877444|NCT02856126|Experimental|HAIC plus sorafenib|Procedure/Surgery: Hepatic arterial infusion chemotherapy Drug: HAIC Regimen Drug: Oral Sorafenib
88877445|NCT02856126|Active Comparator|TACE plus sorafenib|Procedure/Surgery: Transarterial chemoembolization Drug: TACE regimen Drug: Oral Sorafenib
88877446|NCT01705626||Participants diagnosed with small fiber polyneuropathy no obvious etiology|Participants aged between 18 and 85 years, diagnosed with small fiber polyneuropathy of no obvious etiology, without diagnosis of alcoholism and not undergoing chemotherapy for cancer
88877447|NCT00404430||Exacerbated COPD patients|Patients with exacerbated COPD
88877448|NCT00404430||Stable COPD patients|Patients with stable COPD
88877449|NCT04682574|Active Comparator|vitamin C|The dose would be 30 grams a day (10 grams TDS) for 3 days with standard treatment
88877450|NCT04682574|No Intervention|Placebo|Distill water in the same dose with same standard treatment
88877451|NCT04589364|Experimental|abobotulinum toxin A|"Abobotulinum Toxin Type A (Dysport) dose was investigated:~dose: 100 units ( various units each site depend on clinical )"
88877452|NCT04589364|Experimental|neubotulinum toxin A|"Neubotulinum Toxin Type A (Neuronox) dose was investigated:~dose: 33.33 units ( various units each site depend on clinical )"
88877453|NCT04553484|Experimental|Measuring cardiovascular performance and blood flow|
89198971|NCT00882375|Placebo Comparator|Placebo|Placebo
88877454|NCT04492488|Experimental|Solid Tumors|Phase I Dose Escalation: MRG002 will be administrated by an IV infusion of escalating doses (starting dose of 2.2 mg/kg, followed by 2.6 mg/kg) on Day 1 of every 3 weeks (21-day cycle).
88877455|NCT04492488|Experimental|Locally Advanced or Metastatic Gastric/GEJ Cancer|MRG002 will be administrated by an IV infusion on Day 1 of every 3 weeks (21-day cycle).
88877456|NCT04473924|Experimental|Body surface area-based mycophenolate dosing|Intervention group will receive mycophenolate mofetil 750 mg/m^2/day divided into twice daily dosing.
88877457|NCT04473924|Active Comparator|Standard (fixed) dosing|Active comparator group will receive standard fixed dosing of mycophenolate mofetil 1000 mg twice daily.
88877458|NCT04251546||Observational group|Patients with suspected prostate cancer with a PSA test value of 4-10 ng / mL
88877459|NCT04131192|Experimental|z650 and Gemcitabine|Z650:250 or 300 or 200 mg/d, starting on the 2nd day, once a day, continuous administration, or about half an hour after a meal Gemcitabine: intravenously at 1000 mg/m2 on Days 1, 8, of a 21-day cycle FOR the 4-6 cycles
88877460|NCT04123626|Experimental|QR-1123 Single dose - dose level 1|Open label Single dose cohort: dose level 1
88877461|NCT04123626|Experimental|QR-1123 Single dose - dose level 2|Open label Single dose cohort: dose level
88877462|NCT04123626|Experimental|QR-1123 Single dose - dose level 3|Open label Single dose cohort: dose level 3
88877463|NCT04123626|Experimental|QR-1123 Single dose - dose level 4|Open label Single dose cohort: dose level 4
88877464|NCT04123626|Experimental|QR-1123 Single dose - dose level 5|Open label Single dose cohort: dose level 5
88877465|NCT04123626|Experimental|Repeat dose cohort 1|Double-masked, randomized, sham controlled, Repeat dose cohort. Dose levels will be determined following DMC review of obtained safety and efficacy data.
88877466|NCT03925116|No Intervention|usual care|"women who present for birth control to the gynecology office will see their physician in the usual fashion for review, counseling and contraception decision/initiation.~Follow up phone call will be done at 2 weeks, 3, 6 and 12 months to discuss contraception initiation and continuation."
88877467|NCT03925116|Experimental|Contraceptive pathway|"Women who present for birth control to the gynecology office will be recognized by the front desk and offered a tablet which which will:~collect relevant medical history~provide educational material on birth control options~provide a link to bedsider.com for further information~They will then discuss the tablet information/history with the medical assistant, who will answer any remaining questions. They will then see the physician/APN.~Follow up phone call will be done at 2 weeks, 3, 6 and 12 months to discuss contraception initiation and continuation."
88877468|NCT03923868|Experimental|dose escalation in healthy subjects|
88877469|NCT03923868|Experimental|dose escalation in hyperuricemia patients|
88877470|NCT03883074|Experimental|GERDOff® Plus|hyaluronic acid with chondroitin + sulphate + magnesium trisilicate Melt in mouth tablets (1100 mg). 1 tablet q.i.d. (three after meals, one before resting) for 3 consecutive weeks. After three weeks of wash-out period,patients will take either placebo or GERDOff® Plus q.i.d. (three after meals, one before resting) for another three weeks.
88877471|NCT03883074|Placebo Comparator|Placebo|Placebo melt in mouth tablets (1100 mg). 1 tablet q.i.d. (three after meals, one before resting) for three consecutive weeks. After three weeks of wash-out period,patients will take either placebo or GERDOff® Plus q.i.d. (three after meals, one before resting) for another three weeks.
88877472|NCT03708900|Experimental|LCI699 (osilodrostat)|Subjects with cushing's disease taking LCI699 (osilodrostat)
88877473|NCT03670836|Experimental|Dilapan group|"Patients who are randomized to receive Dilapan, will have 3-5 rods of Dilapan-S® inserted in their cervix by the supervising provider, under aseptic precautions with a speculum exam, either digitally or using a sponge forceps, as per manufacturer's recommendations. The Bishop score at the time of eligibility assessment and number of rods inserted will be recorded. Dilapan will be left in cervix for 12 hours. Patients will be allowed to ambulate, shower and have light meals as long as they meet the criteria based on institutional guidelines for intermittent fetal heart monitoring. Nothing per vagina including douching and no bathing is allowed."
88877474|NCT03670836|Experimental|Misoprostol group|Patients who are randomized to Misoprostol group, after the baseline assessment and a reassuring cardiotocograms (CTG) monitoring for 20 minutes to a maximum of 6 doses. All subjects will have continuous fetal monitoring. A dose will be held if patient is noted to have uterine tachysystole, hyperstimulation, fetal heart tracing abnormalities or 3 or more painful uterine contractions over a period of 10 minutes (indicating onset of labor). Administration of Misoprostol will be done by the nurse assigned to the patient.
88877475|NCT03626142||Left DLPFC aTBS stimulation|Patients who have received accelerated theta burst stimulation delivered to the left dorsolateral prefrontal cortex on the inpatient unit at Stanford
88877476|NCT03626142||ACC aTBS stimulation|Patients who have received accelerated theta burst stimulation delivered to the anterior cingulate cortex on the inpatient unit at Stanford
88877477|NCT03626142||ECT|Patients who have received ECT on the inpatient unit at Stanford
88877478|NCT03449628|Experimental|L. casei DG®|"Interventions: Lactobacillus paracasei CNCMI1572 (At least 24 billion live cells per capsule)~1 capsule, b.i.d. for 12 weeks"
88877479|NCT03449628|Placebo Comparator|Placebo|"Interventions : capsules for oral use, indistinguishable from active product.~1 capsule, b.i.d. for 12 weeks"
88877480|NCT03409614|Other|Chemo|Part 1: Chemotherapy
88877481|NCT03409614|Experimental|REGN2810+Chemo Part 1|Part 1: REGN2810+chemo
88877482|NCT03409614|Experimental|REGN2810+AbbrevChemo+ipi|Part 1: REGN2810+abbrev chemo+ipi
88877483|NCT03409614|Experimental|Placebo+Chemo|Part 2: Placebo plus chemo
88877484|NCT03409614|Experimental|REGN2810+Chemo Part 2|Part 2: REGN2810+chemo
88877485|NCT02916732||Module 1|Identification and monitoring of pregnant women who develop clinical signs of acute infection due to ZIKV (standard monitoring report)
88877486|NCT02916732||Module 2|Monitoring of pregnant women with a suspected embryofetopathy (standard monitoring report)
88877487|NCT02916732||Module 3|Trimester biological collection of all pregnant women during the outbreak of Zika (standard monitoring report)
88877488|NCT02916732||Module 4|Biological collection of maternal blood and cord blood collected during the delivery
88877489|NCT02916732||Module 5|Biological collection of maternal blood and fetal tissues of pregnant women whose pregnancies started during the outbreak of Zika , ends in an spontaneous abortion, Induced abortion or intrauterine fetal demise
89402149|NCT04783987||Case Group|Walking Assessments will be practised under dual and single task conditions.
89402150|NCT05762497|Experimental|Laryngectomized patients|
89402151|NCT04759768|Experimental|Intranasal Nalmefene|Nalmefene hydrochloride nasal spray, 3mg, 1 spray
89402152|NCT04759768|Active Comparator|Intramuscular Nalmefene|Nalmefene injection, 1mg, 1 injection
89402153|NCT04754113|Experimental|prone position|patients from supine to prone for at least 3 hours than re-supine
89402154|NCT04721392|Experimental|Mental fatigue - No Robot|During a 15 minute trial, the participant will relocate a box of 5 kilograms between ground level and shoulder height. During this task, the participants are asked to perform the serial seven task, continuously subtracting seven from a given number between 900 and 950. Afterwards, the participant will perform a 60- minute Stroop task and is asked to repeat this abovementioned physical dual-task.
89402155|NCT04721392|Experimental|Mental fatigue - Exoskeleton|During a 15 minute trial, the participant will wear the Laevo exoskeleton and will relocate a box of 5 kilograms between ground level and shoulder height. During this task, the participants are asked to perform the serial seven task, continuously subtracting seven from a given number between 900 and 950. Afterwards, the participant will perform a 60- minute Stroop task and is asked to repeat this abovementioned physical dual-task.
88877490|NCT02767830|Experimental|Excercise and Nutrition Program|Children and their care givers will receive 5 lectures on nutrition and exercise and will be given a weekly running program. At the end of the study children will be encouraged to participate in an annual 0.25-0.5 mile race.
88877491|NCT02651844|Experimental|Mifepristone|Tablets of Mifepristone 200 mg p.o. once a day during 14 days between biopsy and surgery after confirming inclusion criteria
88877492|NCT02341716|Active Comparator|Walk advice|All WA patients receive best medical treatment (BMT) including control of risk factors for arteriosclerosis, simvastatin 40 mg daily, aspirin 75 mg daily and are recommended outdoor walking with Nordic Poles at least 30 minutes at least three times per week. The WA patients are unsupervised during the study period and are followed by a blinded observer at baseline, three, six and 12 months.
88877493|NCT02341716|Active Comparator|Hospital-based supervised exercise|All SET patients receive the same basic treatment as WA patients: best medical treatment (BMT) including control of risk factors for arteriosclerosis, simvastatin 40 mg daily, aspirin 75 mg daily and recommendation of outdoor walking with Nordic Poles at least 30 minutes at least three times per week. The SET group in addition receives three times weekly during six months in-hospital muscle exercise therapy in a group supervised by a physiotherapist. After the six months of supervised exercise therapy, the SET patients are recommended to continue the same muscle exercise therapy at home, but without feedback, between seven and 12 months.
88877494|NCT02341716|Active Comparator|Home-based supervised exercise|All HET patients receive the same basic treatment as WA patients: best medical treatment (BMT) including control of risk factors for arteriosclerosis, simvastatin 40 mg daily, aspirin 75 mg daily and recommendation of outdoor walking with Nordic Poles at least 30 minutes at least three times per week. The HET group patients in addition perform the same muscle exercise therapy three times weekly during six months as the SET patients, but in their homes, and are supervised and given feedback by phone calls every 14th day by a physiotherapist. After six months of supervised exercise therapy, the HET patients are recommended to continue the same muscle exercise therapy, but without feedback, between seven and 12 months.
88877495|NCT02155452||With ALA|Patients with malignant glioma. 25 patients will be provided the ALA for inducing fluorescence
88877496|NCT02155452||Without ALA|5 tumor tissue samples from ACTREC tumor tissue repository will be obtained. These would be malignant gliomas or other brain tumor samples where ALA is usually not administered and will be used as controls and for calibration purposes
88877497|NCT01952340|Experimental|Flaxseed|30 grams of milled flaxseed on its own or baked into food products (ie: bagels, muffins, and snack bars)
88877498|NCT01952340|Placebo Comparator|Wheat/Mixed Dietary Oils|A combination of wheat, pecans, and/or mixed dietary oils on its own or baked into food products (ie: bagels, muffins, and snack bars)
88877499|NCT01463670|Experimental|lenalidomide|The proposed study is designed as a Phase II, multi-center trial of lenalidomide intensification in patients with asymptomatic POD while on low dose lenalidomide maintenance after HDM/ASCT or on continuous/maintenance therapy after initial treatment.
88877500|NCT00682032|Experimental|AIM 2: subjects with suspected or definitive NSCLC diagnosis|1 (one) 250mg beta-glucan capsule 3 times a day for 14 days
88877501|NCT00682032|Experimental|AIM 3: subjects with resectable NSCLC|1 (one) 250mg beta-glucan capsule 3 times a day for 10 to 20 days
88877502|NCT00151398|Experimental|A|
88877503|NCT00151398|Experimental|B|
88877504|NCT00151398|Experimental|C|
88877505|NCT00151398|Active Comparator|D|
89402156|NCT04721392|Placebo Comparator|No Mental fatigue - No Robot|During a 15 minute trial, the participant will relocate a box of 5 kilograms between ground level and shoulder height. During this task, the participants are asked to perform the serial seven task, continuously subtracting seven from a given number between 900 and 950. Afterwards, the participant will watch a 60- minute neutral documentary and is asked to repeat this abovementioned physical dual-task.
89402157|NCT04721392|Placebo Comparator|No Mental fatigue - Exoskeleton|During a 15 minute trial, the participant will wear the Laevo exoskeleton and will relocate a box of 5 kilograms between ground level and shoulder height. During this task, the participants are asked to perform the serial seven task, continuously subtracting seven from a given number between 900 and 950. Afterwards, the participant will watch a 60- minute neutral documentary and is asked to repeat this abovementioned physical dual-task.
89402158|NCT04745455|Other|Cow's milk based infant formula containing prebiotics, probiotics and postbiotics|
88877506|NCT03181308|Experimental|TRC105 plus Nivolumab|
88877507|NCT03184428||Implantation of IOL L313|Patients who have undergone a cataract surgery with implantation of the monofocal MICS IOL L313 more than 3 Years ago will be asked about the Treatment for Postoperative observation and survey.
88877508|NCT03187002|Experimental|Transcutaneous electrical nerve stimulation (TENS)|Transcutaneous electrical nerve stimulation (TENS)
88877509|NCT03187002|Active Comparator|Moderate IV Sedation|Fentanyl, versed
88877510|NCT03193398|Experimental|BTRX-246040|40 mg administered orally as 1 capsule QD for 1 week, followed by 80 mg as 2 capsules QD for 7 weeks.
88877511|NCT03193398|Placebo Comparator|Placebo|administered orally as 1 capsule QD for 1 week, followed by 2 capsules QD for 7 weeks.
89402159|NCT05738200|Experimental|Nordic Hamstring Exercise|A 4-week (10 session), progressive, Nordic Hamstring Exercise (NHE) protocol will be used for this study.
89402160|NCT05738200|No Intervention|Control|Patients randomized to the control group will be instructed to avoid any changes to their normal routine (e.g., physical activity level, strength training, etc.). An investigator not involved in data collection will communicate with patients in the control group on a weekly basis to ensure they have not changed their physical activity level and do not have any questions. Patients randomized to the control group will participate in a minimum of 2 study visits at baseline and 4 weeks. These individuals will have the option to open enroll in the intervention group at the completion of their original 4-week study period. Those who choose to enroll in the intervention group at this time will return for 11 additional visits to complete the NHE protocol (visits 3-12) and final assessment (visit 13)
89402161|NCT05738122|Experimental|Intervention (Journal Group)|Participants in the Intervention group are provided with the 60-day self-guided emotion regulation journals upon enrolment in the study. These participants complete surveys at 2 weeks, 1 month, and 2 months. After the 60-day period, these participants also complete an exit interview and a follow-up survey.
89402162|NCT05738122|No Intervention|Control (Waitlist Group)|Participants in the Waitlist group complete a 2-week, 1-month and 2-month survey. After the 60-day period, they receive access to the 60-day self-guided emotion regulation journal for their own use.
89402163|NCT05201677|Experimental|High myopia with axial length between 26 mm and 28 mm|The patients' axial length is between 26 mm and 28 mm
89402164|NCT05201677|Experimental|High myopia with axial length more than 28 mm|The patients' axial length is more than 28 mm
89402165|NCT05738044||COPD patients|"Patient meets diagnose of COPD refering to Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2022 will be included."
89402166|NCT05738044||Bronchiectasis patients|Patients diagnosed with bronchiectasis (according to the Chinese consensus, patient's previous chest CT examination must show bronchiectasis)
88877512|NCT03194334|No Intervention|Control|continued their omnivorous diet throughout the entire study
88877513|NCT03194334|Experimental|Veg+Pla|vegetarian + placebo: switch to a lacto-ovo-vegetarian diet for 6 months and are supplemented with placebo pills instead of beta-alanine and creatine
88877514|NCT03194334|Experimental|Veg+ creatine and beta-alanine|switch to a lacto-ovo-vegetarian diet for 6 months and are supplemented with 1 g of creatine monohydrate (2 capsules of 500 mg) and 0.8 g of beta-alanine (1 Carnosyn® tablet) each day
88877515|NCT03199872|Experimental|RV001V|RV001 Vaccine 0.1 mg/mL (RV001V). RV001V consists of the peptide RV001 and the adjuvant Montanide ISA 51.
88877516|NCT03202134||opioid free anesthesia (OFA)|The method of reaching OFA: Dexmedetomidine was given in a first loading dose 15 minutes before induction, a second loading dose at induction followed by an infusion for maintenance. Lidocaine is given as a loading dose at induction followed by infusion for maintenance. A Ketamine loading dose is given at induction with an extra bolus before incision followed by an infusion.
88877517|NCT03202134||opioid anesthesia (OA)|OA was induced with sufentanil and continued with extra boli or a continuous infusion of remifentanil.
88877518|NCT03204942|Active Comparator|PRF on DRG|Patients will receive Pulsed Radiofrequency (PRF) on Dorsal root ganglion(DRG) of the selected metastatic painful dorsal vertebrae, with temperature 42°C for 480 sec.,2 active cycles per second of 20 milliseconds each , with a voltage output 40 to 60-V range, impedance ranges between 150 and 400 Ohms at all levels using Fluroscopic guidance (FG).
88877519|NCT03204942|Active Comparator|TRF on DRG|Patients will receive Thermal Radiofrequency (TRF) on Dorsal root ganglion(DRG) of the selected metastatic painful dorsal vertebrae, with temperature 80°C for 90 sec.,2 cycles, using Fluoroscopic guidance (FG) .
88877520|NCT03204942|Active Comparator|Control group|The control group will have identical needle placement and preparation like the 2 previous groups without the RF lesion, but with the injection of particulate Betamethasone steroids and local anesthetic on DRG of the selected metastatic painful dorsal vertebrae, using Fluoroscopic guidance (FG).
88877521|NCT03207438|Experimental|Quetiapine XR 50mg|Quetiapine XR 50mg OD for 6 weeks
88877522|NCT03207438|Placebo Comparator|Placebo 1|Placebo OD for 6 weeks
88877523|NCT03207438|Experimental|Quetiapine XR 150-300mg|Quetiapine XR 150-300mg OD for 6 weeks
88877524|NCT03207438|Placebo Comparator|Placebo 2|Placebo OD for 6 weeks
88877525|NCT03218592|Experimental|Maraviroc|12 Healthy subjects will dose with Maraviroc Pill and we will collect blood and hair over all three phases
88877526|NCT03218592|Experimental|Dolutegravir|12 Healthy volunteers will dose with Dolutegravir Pill and we will collect blood and hair over all three phases
88877527|NCT03218592|Experimental|Truvada|12 healthy volunteers will dose with Truvada Pill and we will collect blood and hair over all three phases
88877528|NCT03219294|Active Comparator|Moderate Neuromuscular Blockade (NMB)|Intubating dose of Vecuronium 0.1 mg/kg (IBW) and re-dosing with 0.0125 to 0.05 mg/kg as needed to achieve and maintain 1 to 2 train-of-four (TOF) contractions. Redosing in this manner is a current clinical practice.
88877529|NCT03219294|Active Comparator|Deep NMB|Deep NMB: Intubating dose of Vecuronium 0.2 mg/kg (IBW) and re-dosing with 0.025 to 0.1 mg/kg to achieve and maintain zero twitches in the TOF, and post tetanic count (PTC) of 1 to 2 contractions. This level of blockade is new to the practice since approval of the drug for use at Maine Medical Center (MMC) but is in common use since the advent of Sugammadex.
89402167|NCT04676191|Experimental|Patients with sleep disorders, cardiorespiratory or neuromuscular disorders|
89402168|NCT02570282|Experimental|Sildenafil|SST-6007 is a white to off-white cream containing 5% (w/w) sildenafil citrate
89402169|NCT02570282|Placebo Comparator|Placebo|Placebo IP will be the same as SST-6007 without the active ingredient, sildenafil citrate. It will be matched in appearance, smell, consistency, and color to SST-6007
89402170|NCT05737888|Experimental|fMRI Neurofeedback|The participants receive visual feedback (displayed on a screen) related to BOLD activity from their auditory cortices, and they are asked to learn to down-regulate it.
88921941|NCT06039605|Experimental|tDCS3|This group will first read some information about tDCS based on cited studies, but different cited studies than the tDCS2 arm. They will then receive the same motor training and tDCS as the tDCS1 and 2 arms.
89402171|NCT05737888|Experimental|EEG Neurofeedback|The participants receive visual feedback (displayed on a screen) related to the ratio of alpha to delta localized activity from their auditory cortices, and they are asked to learn to up-regulate it.
89402172|NCT05737888|Active Comparator|Cognitive Behavioral Therapy|Group therapy is provided by trained clinicians for research participants. Participants are confronted with tinnitus-inducting situations and trained to use diverse cognitive and behavioral coping skills to reduce the subjective impact of tinnitus burden. Such coping skills include relaxation, distraction, and de-catastrophizing, among other strategies.
89189692|NCT05391360|Experimental|Freethiadine tablets|part 1(Health volunteer): single-Dose Study: There will be a total of 5 dose cohorts: 5 mg、10 mg、200 mg(food effect)、400 mg、600 mg; multiple-dose study: 100 mg、200 mg、300 mg、150 mg
89402173|NCT02564744|Experimental|Debio 1562|Participants with a diagnosis of relapsed and/or refractory (R/R) Diffuse Large B Cell Lymphoma (DLBCL), Follicular Non-Hodgkin's Lymphoma (FL), Marginal Zone Lymphoma (MZL)/Mucosa-associated Lymphoid Tissue (MALT), Mantle Cell Lymphoma (MCL) or other Non-Hodgkin's Lymphoma (NHL) with the Sponsor's approval, will receive Debio 1562 and Rituximab in 3 different parts of study i.e., Safety run in, Part 2 and Expansion (Part 3). Participants in Part 2 will be enrolled in two parallel cohorts (Cohort A and Cohort B).
89402174|NCT05201599|Experimental|Flexible ureteroscope with intelligent control of renal pelvic pressure(FURL-ICP)|Patients will be placed in supine lithotomy position with 60-90° oblique on the affected side upward. A pressure measuring ureteral access sheath (UAS) (11-14Fr) is inserted into the proximal ureter along the guidewire without fluoroscopic guidance. The pressure sensory and suctioning channels are connected to the irrigation and suctioning platform.
89402175|NCT05201599|No Intervention|Traditional flexible ureteroscope(f-URL)|Each procedure is completed under general anesthesia in lithotomy position. A semi-rigid ureteroscopy is used to place a 0.032-inch guidewire. A pressure measuring ureteral access sheath (UAS) (11-14Fr) is inserted into the proximal ureter along the guidewire without fluoroscopic guidance. The irrigation and suctioning platform will be not used. A 7.5 Fr flexible ureteroscopy is used to break the stone with a holmium laser (fiber diameter 200 µm). A basket is used to remove the stone fragments. A 4-6Fr ureteral stent is left for 2 weeks after the operation. Stone composition is analyzed. If the UAS is failed to be placed, ureteral stent will be placed for 2 weeks and a second stage traditional f-URL will be performed.
89402176|NCT03110536||2h assessment|The assessment of the burnout syndrome will be carried out at the beginning of the triage shift and after 2 hours.
89402177|NCT03110536||4h assessment|The assessment of the burnout syndrome will be carried out at the beginning of the triage shift and after 4 hours.
89402178|NCT03110536||6h assessment|The assessment of the burnout syndrome will be carried out at the beginning of the triage shift and after 6 hours.
89402179|NCT02564588|Experimental|Dasotraline|Dasotraline 4, 6, 8 mg
89402180|NCT02564588|Placebo Comparator|Placebo|Placebo Comparator
89402181|NCT03110302|Active Comparator|Office-based telehealth (OBT)|Veterans come to a VA clinic and meet with a therapist via telehealth, using videoconferencing technology
89402182|NCT03110302|Active Comparator|Home-based telehealth (HBT)|Veterans stay at home and meet with the therapist via telehealth, using videoconferencing technology
89402183|NCT03110302|Experimental|In home, in person (IHIP)|Therapist goes to the Veterans' homes to provide the psychotherapy
89402184|NCT04049500||Clinicians|Five practices will be selected from NYULH ambulatory practice sites to represent the spectrum of provider settings within the system. These sites will be the clinical partners for the adaptation of the dDPP tool suite
89402185|NCT05759767|Active Comparator|Tamsulosin|Children in this group will receive medical expulsive therapy in the form of (tamsulosin at a dose of 0.01 mg/kg once daily for 3 weeks after ESWL session.
89402186|NCT05759767|Placebo Comparator|Placebo|Children in this group will receive Placebo for 3 weeks after ESWL session.
88877530|NCT03219840|Experimental|CPC + Xylitol chewing gum, then Xylitol only chewing gum|Cetylpyridinium Chloride (CPC) 0.09% + Xylitol chewing gum and then Xylitol only chewing gum All subjects will be instructed to chew four times a day, for at least 60 seconds, after which they expectorated. Cetylpyridinium Chloride (CPC) 0.09% + Xylitol chewing gum will be used for the first 21 days, then there will be a washout period of 21 days, and finally Xylitol only chewing gum will be used for the last 21 days.
88877531|NCT03219840|Experimental|Xylitol only chewing gum, then CPC + Xylitol chewing gum|Xylitol only chewing gum and then Cetylpyridinium Chloride (CPC) 0.09% + Xylitol chewing gum All subjects will be instructed to chew four times a day, for at least 60 seconds, after which they expectorated. Xylitol only chewing gum will be used for the first 21 days, then there will be a washout period of 21 days, and finally Cetylpyridinium Chloride (CPC) 0.09% + Xylitol chewing gum will be used for the last 21 days.
88877532|NCT03222414|Experimental|Arm A: Conical then Cylindrical|BP recording with noninvasive conical Ultracheck Curve BP cuff and direct invasive arterial pressure monitoring; then with traditional cylindrical BP cuff and direct invasive arterial pressure monitoring
88877533|NCT03222414|Active Comparator|Arm B: Cylindrical then Conical|BP recording with noninvasive traditional cylindrical BP cuff and direct invasive arterial pressure monitoring; then with conical Ultracheck Curve BP cuff and direct invasive arterial pressure monitoring
88877534|NCT03223272|Experimental|Reserpine|Subjects will receive open-label reserpine 0.1 mg daily for 4 weeks.
89402187|NCT02561234|Experimental|AEB1102 Dose Escalation Cohort 1|3 patients dosed at 0.01 mg/kg until MTD determined
89402188|NCT02561234|Experimental|AEB1102 Dose Escalation Cohort 2|4 patients dosed at 0.02 mg/kg until MTD determined
88877535|NCT03224520|Experimental|Fully enhanced|Peer recruitment and recommender CTHC
88877536|NCT03224520|Experimental|Recommender CTHC only|Recommender CTHC and standard online recruitment
88877537|NCT03224520|Experimental|Peer recruitment only|Peer recruitment and standard CTHC
88877538|NCT03224520|Experimental|Standard|Standard online recruitment and standard CTHC
88877539|NCT03237156|Experimental|TAK-906 50 mg; Cohort 1|TAK-906 50 milligram (mg) capsules, orally, once daily on Day 1 as Single Dose Period followed by TAK-906 50 mg capsules, orally, twice daily from Day 3 to 7 as Multiple Dose Period.
88877540|NCT03237156|Placebo Comparator|TAK-906 Placebo; Cohort 1|TAK-906 Placebo capsules, orally, once daily on Day 1 as Single Dose Period followed by TAK-906 Placebo capsules, orally, twice daily from Day 3 to 7 as Multiple Dose Period.
88877541|NCT03237156|Experimental|TAK-906 100 mg; Cohort 2|TAK-906 100 mg capsules, orally, once daily on Day 1 as Single Dose Period followed by TAK-906 100 mg capsules, orally, twice daily from Day 3 to 7 as Multiple Dose Period. Cohort 2 will be conducted after Cohort 1.
88877542|NCT03237156|Placebo Comparator|TAK-906 Placebo; Cohort 2|TAK-906 Placebo capsules, orally, once daily on Day 1 as Single Dose Period followed by TAK-906 Placebo capsules, orally, twice daily from Day 3 to 7 as Multiple Dose Period. Cohort 2 will be conducted after Cohort 1.
88877543|NCT03237156|Experimental|TAK-906 10 mg; Cohort 3|TAK-906 10 mg capsules, orally, once daily on Day 1 as Single Dose Period followed by TAK-906 10 mg capsules, orally, twice daily from Day 3 to 7 as Multiple Dose Period.
88877544|NCT03237156|Placebo Comparator|TAK-906 Placebo; Cohort 3|TAK-906 Placebo capsules, orally, once daily on Day 1 as Single Dose Period followed by TAK-906 Placebo capsules, orally, twice daily from Day 3 to 7 as Multiple Dose Period.
89402189|NCT02561234|Experimental|AEB1102 Dose Escalation Cohort 3|4 patients dosed at 0.04 mg/kg until MTD determined
89402190|NCT02561234|Experimental|AEB1102 Dose Escalation Cohort 4|4 patients dosed at 0.08 mg/kg until MTD determined
89402191|NCT02561234|Experimental|AEB1102 Dose Escalation Cohort 5|3 patients dosed at 0.12 mg/kg until MTD determined
89402192|NCT02561234|Experimental|AEB1102 Dose Escalation Cohort 6|4 patients dosed at 0.18 mg/kg until MTD determined
89402193|NCT02561234|Experimental|AEB1102 Dose Escalation Cohort 7|5 patients dosed at 0.27 mg/kg until MTD determined
89402194|NCT02561234|Experimental|AEB1102 Dose Escalation Cohort 8|7 patients dosed at 0.40 mg/kg until MTD determined
89402195|NCT02561234|Experimental|AEB1102 Dose Escalation Cohort 9|7 patients dosed at 0.33 mg/kg until MTD determined MTD determined at 0.33 mg/kg
89402196|NCT02561234|Experimental|AEB1102 Expansion|Uveal: 11 patients dosed at 0.33 mg/kg Cutaneous Melanoma: 11 dosed at 0.33 mg/kg SCLC: 13 patients dosed at 0.33 mg/kg
89402197|NCT03949036|Experimental|target of Stroke Volume Variation ≤ 6%|The rate of intraoperative fluid administration will be adjusted to achieve the target of Stroke Volume Variation ≤ 6%. A crystalloid bolus of 200 ml will be repeatedly administered every 20 min until the target was achieved. The basal rate of fluid administration will be 3 ml/kg/hr.
89004161|NCT02080520|Active Comparator|Nattokinase|Oral nattokinase 2,000 fibrinolytic units daily
89004162|NCT02080520|Placebo Comparator|Placebo|Matched placebo daily
89402198|NCT03949036|Active Comparator|target of Stroke Volume Variation ≤ 12%|The rate of intraoperative fluid administration will be adjusted to achieve the target of Stroke Volume Variation ≤ 12%. A crystalloid bolus of 200 ml will be repeatedly administered every 20 min until the target was achieved. The basal rate of fluid administration will be 3 ml/kg/hr.
89402199|NCT04606693|No Intervention|Patients with negative diagnosis of SAHS|Patients with low risk or negative diagnosis of SAHS will follow conventional management of their AF, according to the usual criteria of the Arrhythmia Unit
89402200|NCT04606693|Other|Patients with positive diagnosis of SAHS|Patients with intermediate or high risk of SAHS and positive diagnosis
89402201|NCT03136900|Experimental|Study Diet|Enteral diet made of Nutrilon without lactose® fortified by concentration
88877545|NCT03239106|Experimental|open label|All participants will receive Apremilast 30 mg BID.
88877546|NCT03239574|Experimental|MightySat Test group|The subjects will be enrolled into the test group and will receive the MightySat investigational pulse oximeter.
88877547|NCT03242148|Experimental|Toffee Nasal Pillows Mask|Participants will be placed on this arm for a total of 14 +- 5 days from visit 2. participants will be using the Toffee mask during this treatment arm
88877548|NCT03257202|No Intervention|Control|No topical treatment
88877549|NCT03257202|Experimental|Clindamycin alone|topical clindamycin alone using Clindamycin 1% Gel
88877550|NCT03257202|Experimental|Benzoyl peroxide alone|topical benzoyl peroxide alone using Benzoyl Peroxide 5% Gel
88877551|NCT03257202|Experimental|Clindamycin and benzoyl peroxide|Topical clindamycin and topical benzoyl peroxide together using BenzaClin 5%-1% Topical Gel
88877552|NCT03260790|Experimental|PCV13 and PPSV23|Participants randomized to receive PPSV23 primed with PCV13. Participants will receive PCV13 8 weeks prior to receiving PPSV23
88877553|NCT03260790|Active Comparator|PPSV23|Participants randomized to receive PPSV23 alone
88877554|NCT03261960|Experimental|Experimental Arm|BLI4700 Bowel Preparation
89004163|NCT02035787|Experimental|Metformin|Metformin, 850 mg. twice daily.
89004164|NCT02022982|Experimental|Palbociclib and PD-0325901|"Palbociclib by mouth once a day, every day for 3 weeks every 4 in each cycle.~PD-0325901 by mouth twice a day, every day for 3 weeks every 4 in each cycle. ."
89004165|NCT01897688|Experimental|Islet Cell Transplant|All qualified subjects will be put on United Network for Organ Sharing (UNOS) Islet Transplant wait list for potential islet cell transplant.
89402202|NCT03136900|Active Comparator|Control Diet|Enteral diet made of Nutrilon without lactose® fortified by Maltodextrin and oil supplementation.
89402203|NCT02750306|Experimental|Suvorexant|Participants will receive 1 suvorexant tablet every night for up to 4 weeks. After 2 weeks of double-blind treatment at 10 mg, participants' suvorexant dose may be increased to 20 mg if their Clinical Global Impression of Insomnia Severity (CGI-S) is ≥3 and investigators feel they can tolerate the increased dose.
89402204|NCT02750306|Placebo Comparator|Placebo|Participants receive 1 placebo-matching suvorexant tablet every night for up to 4 weeks. After 2 weeks of double-blind treatment at 10 mg, participants' placebo-matching dose can be increased to 20 mg if their CGI-S is ≥3 and investigators feel they can tolerate the increased dose.
89402205|NCT03941704|Experimental|Low Glycemic Index|Pulse-based diet
89402206|NCT03941704|Active Comparator|Moderate Glycemic Index|Regular diet
89402207|NCT01816165|Experimental|Acipimox|Drug: acipimox
89402208|NCT01816165|Placebo Comparator|Placebo|Drug: Placebo
89402209|NCT03136822|Other|Control|Standard dressing
89402210|NCT03136822|Experimental|Treatment|Standard dressing + Wound dressing (DERMALIX)
89402211|NCT04476680|Active Comparator|Military recruits|Vitamin D supplementation (1000 IU/day D3 for 4 weeks, and 400 IU/d D3 as a maintenance dose)
89402212|NCT04476680|No Intervention|No intervention|
89402213|NCT04952350|Active Comparator|Atorvastatin|"All patients will be randomized to receive atorvastatin 40 mg once daily orally for a maximum of 28 days. All patients will receive the standard of care according to recent local hospital protocol. Antiviral treatment will be allowed and will be reported.~Administration in unconscious or ventilated patients: The patients will receive the drug (divided into 4 quadrants) through a nasogastric tube."
89402214|NCT04952350|Placebo Comparator|Control|"All patients will be randomized to receive the placebo once daily orally for a maximum of 28 days. All patients will receive the standard of care according to recent local hospital protocol. Antiviral treatment will be allowed and will be reported.~Administration in unconscious or ventilated patients: The patients will receive the drug through a nasogastric tube.~Placebo will resemble the original drug as regards the drug package, the tablet color, consistency, and size."
89402215|NCT03890588|Experimental|CKD enhanced clinical decision support (CKD-CDS Intervention)|Priority Wizard CDS tool is enhanced to incorporate chronic kidney disease(CKD) management. This presents patients and their primary care providers (PCPs) multiple opportunities to consider an evolving array of timely, evidence-based treatment options to improve CKD care. The CDS also provides CV risk factor management like the basic Priority Wizard present in the usual care arm.
89402216|NCT03890588|No Intervention|Usual Care|A basic Priority Wizard CDS tool for cardiovascular (CV) risk factor management (previously know as the CV Wizard) includes algorithmically derived identification of high CV risk patients and prioritized treatment suggestions for lipids, Blood Pressure (BP), glycemic control, weight, tobacco, and aspirin use based on distance from goal, current medications, labs, allergies, and safety considerations. Has no decision support specific to CKD care.
89402217|NCT04812808|Experimental|Bazedoxifene administered in addition to standard chemotherapy protocol|
89402218|NCT01780675|Active Comparator|Prophylactic Cranial Irradiation|Radiation. Prophylactic Cranial Irradiation: 10 times 2.5 Gy (total 25 Gy)
89402219|NCT01780675|Experimental|Hippocampal Avoidance PCI|Radiation. Hippocampal Avoidance PCI. 10 times 2.5 Gy (total 25 Gy).
89402220|NCT02262884|Active Comparator|AIS @ 12mmHg pressure|SurgiQuest AirSeal Insufflation System (AIS) set at 12mmHg pressure for the management of pneumoperitoneum during Robotic Partial Nephrectomy.
89402221|NCT02262884|Active Comparator|AIS @ 15mmHg pressure|SurgiQuest AirSeal insufflation System (AIS) set at 15 mmHg pressure for the management of pneumoperitoneum during Robotic Partial Nephrectomy.
89402222|NCT02262884|Active Comparator|CIS @ 15mmHg pressure|Conventional Insufflation System (CIS) set at 15mmHg pressure for the management of pneumoperitoneum during Robotic Partial Nephectomy.
88877555|NCT03261960|Active Comparator|Control Arm|FDA Approved Bowel Preparation
89402223|NCT03888872|Experimental|Group I|Group I (Study): will consist of 20 patients with diabetic neuropathy and will receive High tone power therapy in addition to selected physical therapy program (Wobble board training, AROM exercises for both UL & LL, gentle manual stretching exercises for both UL & LL and graduated gait training). for 10 sessions every other day, each session for 1.45 hours (60 minutes for HiTop and 45 minutes for selected physical therapy program).
89402224|NCT03888872|Experimental|Group II|Group II (Control): will consist of 20 patients with diabetic neuropathy and will receive selected physical therapy program only same as group I. For 10 sessions every other day, each session for 45 minutes.
89402225|NCT04788550|Active Comparator|Toothpaste group|Control group using fluoridated toothpaste
89402226|NCT04788550|Experimental|Fluoride Varnish group|Fluoride varnish (5% sodium fluoride) application on 3 months interval
89402227|NCT04788550|Experimental|CPP-ACP plus crème group|CPP-ACP plus crème application 2 times daily
89402228|NCT01677988|Experimental|Chemotherapy, Chemoradiation, Surgery|Neoadjuvant Chemotherapy- Modified FOLFIRINOX chemotherapy Day 1 and Day 15 of 28 day cycles for 3 cycles with growth factor support Chemoradiation Surgical Resection
89402229|NCT03864536|No Intervention|No-contact control|No-contact control
89402230|NCT03864536|Active Comparator|Psychoeducation control|Receives general psychoeducation on dementia prevalence, prognosis, and risk factors,
89402231|NCT03864536|Experimental|Psychoeducation + CogRx|Receives same general psychoeducation on dementia and will also receive personalized information on their risk factor profile and develop a tailored 3-month intervention plan, which will consist of simple evidence-based strategies to implement at home.
89402232|NCT04538599|Experimental|RD13-01 cell infusion|
88877556|NCT03273270|Experimental|Active TMS|1 Hz repetitive transcranial magnetic stimulation
88877557|NCT03273270|Placebo Comparator|Sham TMS|No active stimulation
89402233|NCT02233634|Active Comparator|CAD Patients|Administration of Oxygen via a mask, Hyperventilation, Combination of Oxygen administration and Hyperventilation, long breath-holds
89402234|NCT02233634|Active Comparator|Healthy Volunteers (Control Group)|Administration of Oxygen via a mask, Hyperventilation, Combination of Oxygen administration and Hyperventilation, long breath-holds
89402235|NCT04692220||Patients with an Adverse Drug Events or Drug-Related Problems|Patients with an Adverse Drug Events or Drug-Related Problems
89402236|NCT04692220||Patients without an Adverse Drug Events or Drug-Related Problems|Patients without an Adverse Drug Events or Drug-Related Problems
88877558|NCT03273426|Experimental|Core needle Biopsy|Ultrasound-guided core needle biopsy (14G, ≥5 cores recommended) for complete clinical response (cCR) or near-cCR predicted by MRI.
89198972|NCT00963196|Active Comparator|One unsuccessful trial|Patients with one unsuccessful previous antidepressant trial
89402237|NCT04508413|Other|KB295|
89402238|NCT02233712|Experimental|Group 1|G17DT; 250 µg dose administered at 0, 1, and 3 weeks.
89402239|NCT02233712|Experimental|Group 2|G17DT; 100 µg dose administered at 0, 1, and 3 weeks.
89402240|NCT02233712|Experimental|Group 3|G17DT; 500 µg dose administered at 0, 1, and 3 weeks.
89402241|NCT02233712|Experimental|Group 4|G17DT; 500 µg dose administered at 0, 2, and 6 weeks.
89402242|NCT04689490||Dyspnea|Patients with prior hospitalization because of COVID-19, with succesful hospital discharge, who underwent at least a first-time follow-up from the index event, and present persistent dyspnea.
89402243|NCT04689490||Control|Patients with prior hospitalization because of COVID-19, with succesful hospital discharge, who underwent at least a first-time follow-up from the index event, fully recovered, without persistent dyspnea.
89402244|NCT02262962|No Intervention|Usual Well-Child Care|No change in Well-Child Visits.
89402245|NCT02262962|Experimental|Redesigned Well-Child Care|The Redesigned Well-Child Visits will be enhanced using a newly-designed model of care. Parents will have access to Parent Coach during child's routine well visits, Well Baby Help Line, Well-Visit Planner, and text messaging services (HealthyTxt).
88877559|NCT03273426|Experimental|Vacuum-assisted biopsy|Vacuum-assisted biopsy (10G, ≥5 cores recommended) for complete clinical response (cCR) or near-cCR predicted by MRI.
88877560|NCT03274518|Active Comparator|Online Hemodiafiltration|"The olHDF technique combines diffusion with high convection rates in which the dialysis fluid, free of toxins and pyrogens, is used to prepare the replacement fluid.~The online module of dialysis machine prepares the replacement fluid by a cold sterilization process. There is a cross-flow water preparation, in order to avoid the accumulation of possible contaminants. The addition of bicarbonate and acid solutions to water follows the process. Next, the ready-for-infusion dialysis solution is passed through another ultrafilter prior to being infused into patients."
88877561|NCT03274518|Experimental|Expanded Hemodialysis|More recently, membranes with high cutoff values, but with tight pore size distribution have been developed. The main concept is to keep both cutoff and retention onset values close to each other, but with a cutoff value lower than of albumin. This should allow removal of middle-to-high weight range uremic toxins, with very low albumin leak. Thus, these membranes, denominated high retention onset (HRO) membranes, allow performing both diffusive and convective processes in a conventional hemodialysis machine.
88877562|NCT03275766|Active Comparator|DLPFC facilitatory|"repetitive transcranial magnetic stimulation (rTMS) of 15 Hz over left DLPFC~usually effective in depression treatment, probably no specific effect on psychomotor slowing"
88877563|NCT03275766|Experimental|preSMA/SMA inhibitory|"repetitive transcranial magnetic stimulation (rTMS) of 1 Hz over preSMA/SMA~should inhibit overactive premotor cortices"
88877564|NCT03275766|Experimental|preSMA/SMA facilitatory|"intermittend theta burst stimulation (iTBS) over preSMA/SMA~should facilitate neural activity within premotor cortices"
88877565|NCT03275766|Sham Comparator|sham TMS|"sham rTMS with a placebo coil over occipital cortex~should have no effect at all (no transcranial magnetic stimulation, only sound)"
88877566|NCT03278886|Experimental|Low dose naltrexone|Participants randomized to this group will receive low dose naltrexone (4.5 mg) for 8 weeks.
88877567|NCT03278886|Experimental|Nalmefene|Participants randomized to this group will receive nalmefene (18 mg) for 8 weeks.
88877568|NCT03281538|Experimental|CR845 0.5mcg/kg|CR845 0.5mcg/kg IV medication administered three times/week after dialysis
88877569|NCT03285984|Experimental|Test product 1|Participants will brush once (1.5g ± 0.05g of Test product 1), under supervision of study staff for one timed minute
88877570|NCT03285984|Experimental|Test product 2|Participants will brush once (1.5g ± 0.05g of Test product 2), under supervision of study staff for one timed minute
88877571|NCT03285984|Experimental|Test product 3|Participants will brush once (1.5g ± 0.05g of Test product 3), under supervision of study staff for one timed minute
88877572|NCT03285984|Experimental|Test product 4|Participants will brush once (1.5g ± 0.05g of Test product 4), under supervision of study staff for one timed minute
88877573|NCT03287310|Experimental|Subjects receiving GSK3511294 in Cohort 1|Six subjects in Cohort 1 will receive a single SC dose of 2 mg GSK3511294.
88877574|NCT03287310|Placebo Comparator|Subjects receiving placebo in Cohort 1|Two subjects in Cohort 1 will receive a single SC dose of placebo.
88877575|NCT03287310|Experimental|Subjects receiving GSK3511294 in Cohort 2|Six subjects in Cohort 2 will receive a single SC dose of 10 mg GSK3511294.
88877576|NCT03287310|Placebo Comparator|Subjects receiving placebo in Cohort 2|Two subjects in Cohort 2 will receive a single SC dose of placebo.
88877577|NCT03287310|Experimental|Subjects receiving GSK3511294 in Cohort 3|Nine subjects in Cohort 3 will receive a single SC dose of 30 mg GSK3511294.
88877578|NCT03287310|Placebo Comparator|Subjects receiving placebo in Cohort 3|Three subjects in Cohort 3 will receive a single SC dose of placebo.
88877579|NCT03287310|Experimental|Subjects receiving GSK3511294 in Cohort 4|Nine subjects in Cohort 4 will receive a single SC dose of 100 mg GSK3511294.
88877580|NCT03287310|Placebo Comparator|Subjects receiving placebo in Cohort 4|Three subjects in Cohort 4 will receive a single SC dose of placebo.
88877581|NCT03287310|Experimental|Subjects receiving GSK3511294 in Cohort 5|Six subjects in Cohort 5 will receive a single SC dose of 300 mg GSK3511294.
88877582|NCT03287310|Placebo Comparator|Subjects receiving placebo in Cohort 5|Two subjects in Cohort 5 will receive a single SC dose of placebo.
88877583|NCT03292614||Multifocal intraocular lens implantation|Patients who have undergone a cataract surgery with implantation of a multifocal intraocular lens LS313 MF30, Oculentis Berlin, will be invited for Measurements of the postoperative refraction
88877584|NCT03292692|Experimental|OurRelationship|Online Intervention
88877585|NCT03292692|No Intervention|Waitlist Control|2 month waiting period before couples can receive intervention
88877586|NCT03295266|Experimental|Moderate Hepatic Impairment (Panel A)|Participants with moderate HI (estimated glomerular filtration rate [eGFR] of ≤60mL/min/1.73m^2) receive a single IV dose of MK-3866 (150 mg) on Day 1.
88877587|NCT03295266|Experimental|Severe Hepatic Impairment (Panel B)|Participants with severe HI (eGFR of ≤50 mL/min/1.73m^2) receive a single IV dose of MK-3866 (150 mg) on Day 1.
88877588|NCT03295266|Experimental|Healthy Matched Controls (Panel C)|Healthy participants receive a single IV dose of MK-3866 (150 mg) on Day 1.
88877589|NCT03296280||Early Intervention|This cohort of 10 facilities will undergo early training by participating in the first 6 POCUS course sessions during FY17
88877590|NCT03296280||Late Intervention|This cohort of 10 facilities will undergo late training by participating in the last 6 POCUS courses during FY17.
88877591|NCT03301272|Experimental|Onabotulinumtoxin A Injection, then Placebo|Participants first receive Onabotulinumtoxin A Injection and following a 3-month washout, they receive Placebo
88877592|NCT03301272|Experimental|Placebo, then Onabotulinumtoxin A Injection|Participants first receive placebo injection and following a 3-month washout, they receive Onabotulinumtoxin A Injection.
89402246|NCT02233790|Experimental|Ticagrelor|
89402247|NCT02233790|Active Comparator|Clopidogrel|
88877593|NCT03303144|Experimental|Triferic via Hemodialysate|Triferic will be mixed with the liquid bicarbonate concentrate used in the preparation of the hemodialysate solution. This will result in a final Triferic iron concentration in the dialysate of 2 µM (110 µg/L). The patients will receive Triferic over 4 hrs at one hemodialysis session.
88877594|NCT03303144|Experimental|Triferic via IV infusion( pre-dialyzer)|Patients will receive a single 6.5-mg dose of Triferic iron administered IV over 3 hrs during hemodialysis via arterial blood line (pre-dialyzer)
88877595|NCT03303144|Experimental|Triferic via IV infusion (post-dialyzer)|Patients will receive a single 6.5-mg dose of Triferic iron administered IV over 3 hrs during hemodialysis via venous blood line (post-dialyzer)
88877596|NCT03306420|Experimental|Part IA Dose Escalation: M4112 100 mg|Participants received an oral dose of 100 milligrams (mg) M4112 twice daily in 28-day cycles, starting from Day 1 of each cycle until confirmed disease progression or unacceptable toxicity (up to 15 Months).
88877597|NCT03306420|Experimental|Part IA Dose Escalation: M4112 200 mg|Participants received an oral dose of 200 mg M4112 twice daily in 28-day cycles, starting from Day 1 of each cycle until confirmed disease progression or unacceptable toxicity (up to 15 Months).
88877598|NCT03306420|Experimental|Part IA Dose Escalation: M4112 400 mg|Participants received an oral dose of 400 mg M4112 twice daily in 28-day cycles, starting from Day 1 of each cycle until confirmed disease progression or unacceptable toxicity (up to 15 Months).
88877599|NCT03306420|Experimental|Part IA Dose Escalation: M4112 600 mg|Participants received an oral dose of 600 mg M4112 twice daily in 28-day cycles, starting from Day 1 of each cycle until confirmed disease progression or unacceptable toxicity (up to 15 Months).
88877600|NCT03306420|Experimental|Part IA Dose Escalation: M4112 800 mg|Participants received an oral dose of 800 mg M4112 twice daily in 28-day cycles, starting from Day 1 of each cycle until confirmed disease progression or unacceptable toxicity (up to 15 Months).
88877601|NCT03312348|Experimental|Infrared Imaging undertaken|Infrared imaging of Region Of Interest in study participants
88877602|NCT03315702||control／mechanical ventilation|venous blood samples collected from patients twice，relatively before mechanical ventilation and 3rd hour after mechanical ventilation
88877603|NCT03315780|Experimental|Dulaglutide, Placebo|Dulaglutide 0.75 mg administered subcutaneously (SC) once weekly for 4 weeks in period 1 followed by placebo administered SC once weekly for 4 weeks in Period 2. There is a 4 to 6 week washout period between Period 1 and Period 2.
88877604|NCT03315780|Experimental|Placebo, Dulaglutide|Placebo administered SC once weekly for 4 weeks in Period 1 followed by Dulaglutide 0.75 mg administered SC for 4 weeks in Period 2. There is a 4 to 6 week washout period between Period 1 and Period 2.
88877605|NCT03319134|Experimental|active anodal HD-tDCS|Active anodal HD-tDCS stimulation applied during memory task
88877606|NCT03319134|Sham Comparator|sham HD-tDCS|Sham HD-tDCS stimulation during memory task for comparison
88877607|NCT03319134|Experimental|active cathodal HD-tDCS|Active cathodal HD-tDCS stimulation applied during memory task
88877608|NCT03329352|Experimental|F&P Full-Face Mask|Participants will be placed on this arm for a total of 14 ± 5 days from Visit 2. Participants will be using the trial full-face mask during this treatment arm. Participants on the extension will use for a further six months after Visit 3.
88877609|NCT03330834|Experimental|Single Arm|CAR-T cells to treat advanced lung cancer. This study has only one arm. All participators will attend the screening and meet the set criteria for the clinical treatment. PD-L1 CAR-T cells are infused on day 0 with 10%, day 3 with 30% and day 7 with 60% , (1-2)×10^6/kg PD-L1 CAR-T cells total.
88877610|NCT03334734|Experimental|PBTZ169, 160 mg|2 capsules 80 mg of PBTZ169 once a day for 14 days
88877611|NCT03334734|Experimental|PBTZ169, 320 mg|4 capsules 80 mg of PBTZ169 once a day for 14 days
88877612|NCT03334734|Experimental|PBTZ169, 640 mg|8 capsules 80 mg of PBTZ169 once a day for 14 days
88877613|NCT03334734|Active Comparator|Isoniazid, 600 mg|2 tablets 300 mg of Isoniazid once a day for 14 days
88877614|NCT03334812|Experimental|LNA043 20mg/ml|LNA043 20mg/ml single dose
88877615|NCT03334812|Placebo Comparator|Matching placebo to 20mg|Matching placebo to 20mg/3ml, single dose
88877616|NCT03334812|Experimental|LNA043 40mg/ml|LNA043 40mg/ml single dose
88877617|NCT03334812|Placebo Comparator|Matching placebo to 40mg|Matching placebo to 40mg/4ml, single dose
88877618|NCT03336450|Experimental|SHP615|Participants will receive a single age-specific dose (approximately 0.25 to 0.5 milligram per kilogram [mg/kg] as midazolam) of SHP615 oromucosal solution through buccal route upon onset of seizures.
88877619|NCT03338556|Active Comparator|Cohort A - PrEP-001|PrEP-001 6400 μg/day, equally divided over both nostrils, on 2 consecutive days. Dosed Day - 7 and Day - 6 prior to intranasal challenge with HRV-16 (Day 0).
88877620|NCT03338556|Placebo Comparator|Cohort A - Placebo|Placebo matching PrEP-001, equally divided over both nostrils, on 2 consecutive days. Dosed Day - 7 and Day - 6 prior to intranasal challenge with HRV-16 (Day 0).
88877621|NCT03338556|Active Comparator|Cohort B- PrEP-001|PrEP-001 6400 μg/day, equally divided over both nostrils, on 2 consecutive days. Dosed Day - 4 and Day - 3 prior to intranasal challenge with HRV-16 (Day 0).
88877622|NCT03338556|Placebo Comparator|Cohort B - Placebo|Placebo matching PrEP-001, equally divided over both nostrils, on 2 consecutive days. Dosed Day - 4 and Day - 3 prior to intranasal challenge with HRV-16 (Day 0).
88877623|NCT03606408|Other|osilodrostat|open label, with patients receiving same dose as provided in the parent study
88877624|NCT03256968|Experimental|ataluren administration|dose of the drug administered (mg/kg body weight)
88877625|NCT03339570||Orthopedic treatment|This is the prospective cohort which includes 20 patients presenting three-four proximal humeral fracture who were treated non-surgically and followed prospectively during 12 months.
88877626|NCT03340350|Experimental|Minocycline|Minocycline 100 mg/day 1 to 7 and 200 mg/day 8 to end of week 12
89198973|NCT00963196|Active Comparator|One successful trial|Patients with one previous successful antidepressant trial
89004166|NCT01892670|Experimental|Filtered whole blood|"Leukocyte-reduced whole blood, 2 hours holding-time after collection. Gravitational filtration.~Device: Terumo IMUFLEX WB(Whole blood)-SP(saving platelets) collection bag system"
89004167|NCT01892670|Experimental|Unfiltered whole blood|"Non-leukocyte-reduced whole blood, 2 hours holding-time after collection.~Device: Terumo IMUFLEX WB-SP collection bag system"
89189693|NCT05391360|Placebo Comparator|Freethiadine placebo tablets|part 1(Health volunteer): single-Dose Study: There will be a total of 5 dose cohorts: 5 mg、10 mg、200 mg(food effect)、400 mg、600 mg; multiple-dose study: 100 mg、200 mg、300 mg、150 mg
89189694|NCT05391360|Experimental|Freethiadine tablet|part 2(Patients with chronic hepatitis B): There will be a total of 4 dose cohorts:100 mg、200 mg(BID or QD)、300 mg
89189695|NCT05391360|Active Comparator|entecavir tablets|part 2(Patients with chronic hepatitis B): 0.5 mg
89189696|NCT05386407|Experimental|telemedically assisted guided oropharyngeal + nasal (OP+N) self-sampling (GSS): OP+N GSS|After performing the telemedically assisted OP+N GSS procedure, the patients will continue to be sampled by HCP OP+N and HCP NP.
89189697|NCT05386407|Experimental|unsupervised OP+N self-sampling (USS): OP+N USS|"Written instructions on how to perform a self-test will be provided, representing the instructions that come along with a commercially available rapid test set. An instructional online video tutorial or similar would also account as the latest state of the art.30 However, this has not yet been implemented comprehensively with all available test sets.~After performing the OP+N USS procedure, the patients will continue to be sampled by HCP OP+N and HCP NP."
89189698|NCT05374993|Experimental|3TBA Procedure|
89189699|NCT05374980|Experimental|Yogurt|Drink a bottle of 200ml yogurt every morning and evening for 8 weeks
89189700|NCT05374980|Placebo Comparator|Placebo|Drink a bottle of 200ml placebo every morning and evening for 8 weeks
89189701|NCT05374980|No Intervention|Healthy volunteer|Patients with Helicobacter pylori negative (ΔUBT<2%) need blood test and collect stool samples at first, and collect stool samples again after 2 months.
89189702|NCT05372523||Trauma+ & PTSD|Patients diagnosed with significant trauma exposure and PTSD
89189703|NCT05372523||Trauma+ & No PTSD|Patients diagnosed with significant trauma exposure but no PTSD
89189704|NCT05372523||No trauma or PTSD|Healthy adults without known major psychiatric disorders
89189705|NCT05371743||ITP patients|"Patients will be recruited from the internal department- hematology unit outpatient clinic of El Minia University Hospital in collaboration with the clinical pathology department of El Minia University Hospital and the biochemistry department of Minia and Sohag University. Exclusion criteria:~Secondary causes of ITP as systemic lupus erythematous (SLE), viral infections (HIV, hepatitis B or C infections)~Other underlying medical diseases that may cause thrombocytopenia as:~malignancy~megaloblastic anemia~aplastic anemia~lymphoproliferative disorders~liver disease~renal impairment~pregnancy~Organomegally and/or lymphadenopathy.~Recent history of vaccination.~Recent evidence of bacterial infection."
89189706|NCT05371743||normal individuals|Blood samples will be taken from normal individuals.
89189707|NCT05366764|Experimental|SAR443765|Single dose administration of SAR443765
89189708|NCT05366764|Placebo Comparator|Placebo|Placebo to match SAR443765
89189709|NCT05357378|Experimental|Experimental Arm - HIT Reverse HRS|Subjects in the Experimental Arm will receive the HIT Reverse HRS Investigational Device. Implantation of the Investigational Device is performed using standard surgical procedures for THA, as described in the Instructions for Use (IFU). The control hip systems will be implanted in accordance with their respective IFU, which are also in line with standard surgical approaches for THA.
89004168|NCT01892670|Experimental|Warm-filtered whole blood|"Leukocyte-reduced whole blood, no holding-time after collection. Gravitational filtration.~Device: Terumo IMUFLEX WB-SP collection bag system"
89189710|NCT05357378|Active Comparator|Control Arm|Subjects in the Control Arm will receive one of the already-marketed semi- constrained uncemented hip systems using a metal-on-highly-cross-linked polyethylene (XLPE) or ceramic-on-XLPE bearing combination.
89189711|NCT05355207|Experimental|TRL1068|all subjects will receive a single intravenous dose of 15 mg/kg of TRL1068 on Day 1
89189712|NCT05337280|Experimental|Imagio OA/US|Imagio OA/US Imaging
89189713|NCT05319041|Experimental|Active herbal capsules|"Wei's Qi Ju Gan Lu Formula is a herbal formulation initiated by the senior TCM collaborator, Prof Wei QP. This TCM formulation is prescribed to treat the dry eye patients with liver-kidney yin deficiency. The treatment regulation aims to nourish the Liver and Kidney, enrich yin deficiency, in order to promote tears production, hence treatment of Dry Eye."
89189714|NCT05319041|Placebo Comparator|Placebo capsules|Placebo capsule which contains 0.5g maltodextrin without any herbs medicine.
89189715|NCT05314335|Experimental|Reflexology socks+Walking|In the first interview; patient diagnosis form and Constipation Quality of Life scale will be applied. In order to evaluate the routine bowel habits of the patients, no application will be made in the first week and the patients will be asked to complete the Defecation Diary, Visual Comparison Scale and the Bristol Stool Consistency Scale for 1 week when defecation occurs. Afterwards, the reflexology socks designed by the researcher for the patients; will be told to wear and walk 30 minutes after breakfast and dinner for 30 minutes 3 days a week (Monday, Wednesday and Friday). Patients will be asked to continue the application for 4 weeks. The patients will be administered the Defecation Diary, the Visual Comparison Scale, and the Bristol Stool Consistency Scale when defecation occurs daily during the application. In addition, on the 30th day of the application, the Constipation Quality of Life Scale will be administered to the patients again.
89198974|NCT00963196|Active Comparator|No previous trial|Patients with no prior antidepressant therapy
89198975|NCT00882453||Group 1|
89198976|NCT04860778|Experimental|BDNF Essentials|A proprietary blend of botanical extracts and isolates.
89198977|NCT00883545|Experimental|Woman endoscopist|
89198978|NCT00883545|Active Comparator|Usual care|
89198979|NCT04812340|Active Comparator|High intensity Circuit training|Intervention will consist of 6 series with 3 minutes rest period between the series. The series will consist of burpees, skipping, 1 legged squats, leg levers, and push-ups. the exercise volume will be increased progressively over 8 weeks.
89402248|NCT02547818|Active Comparator|Group I|ALZT-OP1a active capsules for inhalation and ALZT-OP1b placebo capsules for oral administration.
89402249|NCT02547818|Active Comparator|Group II|ALZT-OP1a active capsules for inhalation and ALZT-OP1b active tablets for oral administration.
88877627|NCT03340428|Experimental|Transition Community Adherence Club (TCAC)|Participants in this arm will be referred to join a facilitated group setting for HIV on release from incarceration. This arm will provide HIV care services in a facilitated group setting to provide medical and psychosocial needs of participants.
88877628|NCT03340428|No Intervention|Care as usual (CAU)|Care as usual participants will be referred to routine clinic HIV care on release from corrections.
88877629|NCT03341910|Experimental|DFD-03 Lotion, 0.1%|DFD-03 Lotion, 0.1% to be applied twice daily approximately 12 hours apart, for 1 minute and rinsed off
88877630|NCT03341910|Active Comparator|Tazorac Cream, 0.1%|Tazorac Cream, 0.1% to be applied once in the evening and left overnight for approximately 12 hours
88877631|NCT03341910|Placebo Comparator|Vehicle Lotion|Vehicle Lotion to be applied twice daily for 1 minute and rinsed off
88877632|NCT03341910|Placebo Comparator|Vehicle Cream|Vehicle Cream to be applied once in the evening and left overnight for approximately 12 hours
88877633|NCT03343080|Experimental|Buffered Lidocaine|"At the induction of anesthesia, patients will be breathing 100% oxygen via a face mask and then, become anesthetized according to a standard protocol and at the discretion of the attending anesthesiologist.~For cardiac surgery patients randomized to the buffered lidocaine arm, the operating room registered respiratory therapist (OR RRT) will inflate the endotracheal tube cuffs with the study drug containing 1.8% lidocaine plus 0.76% sodium bicarbonate until abatement of the air leak at 20 cm of water.~The intervention will take place while in the operating room. The room nurse anesthetist (CRNA) or anesthesiologist will be aware of the amount of solution instilled in the ETT cuff. The patient will remain intubated after the surgery is complete and will be taken to the cardiac surgical ICU."
88877634|NCT03343080|Placebo Comparator|Air|"At the induction of anesthesia, patients will be breathing 100% oxygen via a face mask and then, become anesthetized according to a standard protocol and at the discretion of the attending anesthesiologist.~For cardiac surgery patients randomized to the air arm, the operating room registered respiratory therapist (OR RRT) will inflate the endotracheal tube cuffs with air until abatement of the air leak at 20 cm of water.~The intervention will take place while in the operating room. The room nurse anesthetist (CRNA) or anesthesiologist will be aware of the amount of air in the ETT cuff. The patient will remain intubated after the surgery is complete and will be taken to the cardiac surgical ICU."
88877635|NCT03345108|Experimental|Test Denture Adhesive (Conventional Application)|Test denture adhesive will be applied to participants' dentures via conventional pattern of application.
88877636|NCT03345108|Experimental|Test Denture Adhesive (Continuous strip Application)|Test denture adhesive will be applied to participants' dentures via continuous strips pattern of application.
88877637|NCT03345108|Other|Negative Control|Participants will not apply any denture adhesive in this treatment arm.
88877638|NCT03346902|Placebo Comparator|Placebo|"Drug: : Placebo: 0.9% Sodium Chloride Injection~Injection of Placebo into area of scarring (forehead)"
88877639|NCT03346902|Active Comparator|EB001|Drug: EB-001 Injection of EB-001 into area of scarring (forehead)
88877640|NCT03349632|Other|DD T2/Oasys 1-Day|Verofilcon A contact lenses and senofilcon A contact lenses worn in both eyes, each product, for 1 week on a daily wear basis, as randomized
88877641|NCT03349632|Other|DD T2/MyDay|Verofilcon A contact lenses and stenfilcon A contact lenses worn in both eyes, each product, for 1 week on a daily disposable basis, as randomized
88877642|NCT03349632|Other|DD T2/Moist|Verofilcon A contact lenses and etafilcon A contact lenses worn in both eyes, each product, for 1 week on a daily disposable basis, as randomized
89198980|NCT04812340|Active Comparator|Low intensity interval training|the intervention will consist of 4 series of Low-intensity exercises with 3 minutes of rest. the series will comprise of jogging and walking. the Exercise volume will be increased gradually.
88877643|NCT03350724|Experimental|episil wound dressing|Episil is a wound dressing material intended for the management of pain and relief of pain by adhering to the mucosal surface of the mouth, soothing oral lesions of various etiologies. episil is an oromucosal liquid that transforms in situ to a bioadhesive oromucosal gel by uptake of small amounts of aqueous fluid.
88877644|NCT03350724|Active Comparator|PeriAcryl90 wound dressing|PeriAcryl90 is a cyanoacrylate wound dressing.
89402250|NCT02547818|Active Comparator|Group III|ALZT-OP1a placebo capsules for inhalation and ALZT-OP1b active tablets for oral administration.
89402251|NCT02547818|Placebo Comparator|Group IV|ALZT-OP1a placebo capsules for inhalation and ALZT-OP1b placebo tablets for oral administration.
89402252|NCT04457440|Active Comparator|Intensive Lifestyle Intervention (ILI)|The ILI will consist of 8 group-based 90-min sessions focusing on modifying dietary and exercise habits with the goal of reducing 450kcal of daily calories and increasing physical activity to 150 minutes of exercise per week.
89402253|NCT04457440|Experimental|ILI enhanced with cognitive behavioral sleep intervention|The ILI+Sleep intervention will consist of the same 8 sessions of ILI with additions of sleep components in each session.
89402254|NCT02234024|Experimental|Supplementation of gangliosides|Supplementation of dairy-derived concentrated gangliosides
89402255|NCT02520076|Experimental|AAT treated group|Study subjects will receive Alpha-1 Antitrypsin (AAT) study drug intravenously in 4 doses over 15 days around the time of their transplant. The islets will also be prepared in a solution of AAT.
89402256|NCT03752918|Experimental|MDMA|MDMA (1.5mg/kg)
89402257|NCT03752918|Placebo Comparator|Niacin|Niacin (250mg)
89402258|NCT04259320|Experimental|Beeswax containing barrier|Beeswax containing barrier will be given to the breastfeeding mother within the first 24 hours. After breastfeeding, it can be placed on the breast after it is expected to dry a little.Outside of breastfeeding and bathing, it will be constantly attached to the breasts.
89402259|NCT04259320|Experimental|Breast milk|After breastfeeding, 2-3 drops of breast milk are applied to the nipple and areola. After the milk has dried, the breasts are closed. This application should be done at least 5 times a day.
89402260|NCT04259320|No Intervention|No treatment- control|It is a group that does not use any method to prevent nipple cracks. All follow-ups in the experimental groups are done.
89402261|NCT02546960|Experimental|ExPEC4V (4 : 4 : 4 : 4)|Participants will be stratified according to their age in 2 groups >=18 to <50 years and >=50 years. Part 1: In age group >= 18 to <50 years, participants will receive single vaccination of ExPEC4V dose (4 : 4 : 4 : 4) as an intramuscular (i.m) injection into deltoid muscle. The ExPEC4V doses contain polysaccharide antigen (in microgram [mcg]) from the ExPEC serotypes O1A, O2, O6A, and O25B. Participants in >=50 years group will be enrolled in stepwise,dose-escalating procedure. In step 1, lowest dose of ExPEC4V (4:4:4:4) or Placebo will be given, in step 2 either of 2 medium doses of ExPEC4V or placebo and in step 3, either of 2 highest doses of ExPEC4V or placebo. Participants will be enrolled into subsequent steps only if vaccination in previous steps is deemed safe based on review of safety data by the IDMC. Participants will be enrolled into Part 2 only if vaccination in Part 1 is deemed safe based on the review of safety data through Day 8 by the IDMC.
89402262|NCT02546960|Experimental|ExPEC4V (4 : 4 : 4 : 8)|Participants will be stratified according to their age in 2 groups >=18 to <50 years and >=50 years. Part 1: In age group >= 18 to <50 years, participants will receive single vaccination of ExPEC4V dose (4 : 4 : 4 : 8) as an i.m injection into deltoid muscle. The ExPEC4V doses contain polysaccharide antigen (in mcg) from the ExPEC serotypes O1A, O2, O6A, and O25B. Participants in >=50 years group will be enrolled in stepwise,dose-escalating procedure. In step 1, lowest dose of ExPEC4V or Placebo will be given, in step 2 either of 2 medium doses (4 : 4 : 4 : 8/8 : 8 : 8 : 8) of ExPEC4V or placebo and in step 3, either of 2 highest doses of ExPEC4V or placebo. Participants will be enrolled into subsequent steps only if vaccination in previous steps is deemed safe based on review of safety data by the IDMC. Participants will be enrolled into Part 2 only if vaccination in Part 1 is deemed safe based on the review of safety data through Day 8 by the IDMC.
89402263|NCT02546960|Experimental|ExPEC4V (8 : 8 : 8 : 8)|Participants will be stratified according to their age in 2 groups >=18 to <50 years and >=50 years. Part 1: In age group >= 18 to <50 years, participants will receive single vaccination of ExPEC4V dose (8 : 8 : 8 : 8) as an i.m injection into deltoid muscle. The ExPEC4V doses contain polysaccharide antigen (in mcg) from the ExPEC serotypes O1A, O2, O6A, and O25B. Participants in >=50 years group will be enrolled in stepwise,dose-escalating procedure. In step 1, lowest dose of ExPEC4V or Placebo will be given, in step 2 either of 2 medium doses (4 : 4 : 4 : 8/8 : 8 : 8 : 8) of ExPEC4V or placebo and in step 3, either of 2 highest doses of ExPEC4V or placebo. Participants will be enrolled into subsequent steps only if vaccination in previous steps is deemed safe based on review of safety data by the IDMC. Participants will be enrolled into Part 2 only if vaccination in Part 1 is deemed safe based on the review of safety data through Day 8 by the IDMC.
89402264|NCT02546960|Experimental|ExPEC4V (8 : 8 : 8 : 16)|Participants will be stratified according to their age in 2 groups >=18 to <50 years and >=50 years. Part 1: In age group >= 18 to <50 years, participants will receive single vaccination of ExPEC4V dose (8 : 8 : 8 : 16) as an i.m injection into deltoid muscle. The ExPEC4V doses contain polysaccharide antigen (in mcg) from the ExPEC serotypes O1A, O2, O6A, and O25B. Participants in >=50 years group will be enrolled in stepwise,dose-escalating procedure. In step 1, lowest dose of ExPEC4V or Placebo will be given, in step 2 either of 2 medium doses of ExPEC4V or placebo and in step 3, either of 2 highest doses (8 : 8 : 8 : 16/16 : 16 : 16 : 16) of ExPEC4V or placebo. Participants will be enrolled into subsequent steps only if vaccination in previous steps is deemed safe based on review of safety data by the IDMC. Participants will be enrolled into Part 2 only if vaccination in Part 1 is deemed safe based on the review of safety data through Day 8 by the IDMC.
89535530|NCT05009745|No Intervention|Control arm|Women in the control arm will have the fresh embryo transfer procedure on day 5 following egg collection, or a frozen-thawed embryo transfer as first line over a fresh embryo transfer, if clinically indicated. Embryo selection for transfer will be based on morphological criteria.
88877645|NCT03365154|Experimental|Treatment Group|Patients with occlusive arterial disease who meet the study criteria and provide informed consent will receive atherectomy treatment with the investigational device.
88877646|NCT03365778|Active Comparator|Patient Educational Intervention group|Patients receive educational materials regarding selective laser trabeculoplasty (SLT) versus topical medication (ophthalmic eye drops) to lower eye pressure.
88877647|NCT03365778|Placebo Comparator|Usual care group|Patients receive standard of care.
88877648|NCT03365778|Other|Ophthalmologist Educational Intervention group|General ophthalmologists, ophthalmology residents, and glaucoma specialists in the Wills Eye Hospital physician contact database receive online survey and educational slide presentation regarding selective laser trabeculoplasty (SLT).
88877649|NCT03368898||Estradiol valerate|Women who were treated with E2V for HMB for 3 months.
88877650|NCT03368898||LNG-IUD|Women who were treated with LNG-IUD for HMB for 4 years.
88877651|NCT03368898||Micronized Progesterone|Women who were treated with Micronized Progesterone for HMB for 3 months.
88877652|NCT03369756|Other|Prontosan Solution and Gel|Treatment with Prontosan® Wound Irrigation Solution and Prontosan® Wound Gel over 4 week period
88877653|NCT03373890|Experimental|Short burst Interval Treadmill Training High Frequency|Participants receive short burst interval treadmill training for a total of 20 sessions. They are randomized to receive it either 5x/week for 4 weeks
89198981|NCT00882531|Experimental|Isotretinoin|
89198982|NCT00882531|Placebo Comparator|placebo|
89402265|NCT02546960|Experimental|ExPEC4V (16 : 16 : 16 : 16)|Participants will be stratified according to their age in 2 groups >=18 to <50 years and >=50 years. Part 1: In age group >= 18 to <50 years, participants will receive single vaccination of ExPEC4V dose (16 : 16 : 16 : 16) as an i.m injection into deltoid muscle. The ExPEC4V doses contain polysaccharide antigen (in mcg) from the ExPEC serotypes O1A, O2, O6A, and O25B. Participants in >=50 years group will be enrolled in stepwise,dose-escalating procedure. In step 1, lowest dose of ExPEC4V or Placebo will be given, in step 2 either of 2 medium doses of ExPEC4V or placebo and in step 3, either of 2 highest doses (8 : 8 : 8 : 16/16 : 16 : 16 : 16) of ExPEC4V or placebo. Participants will be enrolled into subsequent steps only if vaccination in previous steps is deemed safe based on review of safety data by the IDMC. Participants will be enrolled into Part 2 only if vaccination in Part 1 is deemed safe based on the review of safety data through Day 8 by the IDMC.
89402266|NCT02546960|Placebo Comparator|Placebo|Participants will be stratified according to their age in 2 groups >= 18 to <50 years and >=50 years. Part 1: Participants will receive matching placebo to ExPEC4V as an intramuscular injection into the deltoid muscle. Participants will be enrolled into Part 2 only if vaccination in Part 1 is deemed safe and well tolerated based on the review of safety data through Day 8 by the IDMC.
89402267|NCT02234102|Active Comparator|Paroxysmal Atrial Fibrillation (PAF)|Endoscopically guided laser ablation
89402268|NCT02234102|Active Comparator|Persistent Atrial Fibrillation|Endoscopically guided laser ablation
89402269|NCT02263196|Experimental|alcohol and povidone iodine|the efficacy of combination of alcohol and povidone iodine on inflammation related to vascular access
89402270|NCT02263196|Experimental|combination of alcohol and betadin|the efficacy of combination of alcohol and povidone iodine on infection related to vascular access
89402271|NCT03343834|Other|EBV+ allograft population|"Retrospective study (n=80) : Patient who underwent HSCT, in Saint-Antoine hospital, between 2010-2015, treated by rituximab for high level EBV-DNAemia (above 3.3 log copies/mL).~Prospective study (n=58) : Patients who underwent HSCT, in Saint-Antoine hospital and la Pitié-Salpêtrière, in 2016-2017, treated by rituximab for high level EBV-DNAemia (above 10 000c/mL), And/or having post-transplant lymphoproliferative diseases(PTLD) Concerned population Allogeneic hematopoietic stem cell transplantation (allo-HSCT) patients with a high Epstein-Barr virus (EBV) viral load"
89402272|NCT05160506|Experimental|Hydrocortisone|Patients in this arm will be administered 100 mg of hydrocortisone in 50 milliliters of saline solution by nursing staff every 8 hours for 72 hours as per standard clinical procedures (9 administrations)
89402273|NCT05160506|Placebo Comparator|Placebo|Patients in this arm will be given matching placebo (50ml 0.9%NACL) by nursing staff every 8 hours for 72 hours (9 administrations)
89402274|NCT02236286|Experimental|Exercise|Subjects will participate in a 90-minute, group (6 per group) exercise session 3 days per week for 6 weeks (18 sessions). The theoretical basis for our novel Agility Boot Camp (ABC) exercise program is based on research that identified the primary neurophysiological and cognitive constraints that limits balance and mobility in PD. The exercises are designed as a circuit with several types of movement-skills specifically focused on improving different postural domains with cognitive challenges such as memorized sequences and dual tasking.
89402275|NCT02236286|Active Comparator|Chronic Disease Management Education|Subjects will also receive (cross-over) six weeks of educational classes. The Education program will teach subjects, chronic disease self-management - how to live better with their parkinsonism. Classes will consist of 6 subjects per group meeting for 90 minute sessions, once a week for six weeks. Subject will do an additional 120 minutes of relaxation at home/week.
89402276|NCT05094778|Other|single-portal group|The patients in single-portal group were treated with single-portal palm approach
89402277|NCT02509598|Experimental|Tc99m tilmanocept and Vital Blue Dye (optional)|0.5 mCi, 50 ug of Tc99m tilmanocept single administration. Optionally, 1-3 mL of vital blue dye, single administration (per institution's standard of care).
89004169|NCT01892670|Experimental|Forced warm-filtration of whole bood|"Leukocyte-reduced whole blood, no holding-time after collection. Forced filtration.~Device: Terumo IMUFLEX WB-SP collection bag system"
89004170|NCT01892670|Experimental|RCC produced from cold-stored whole blood|"RCC production from 7 days old, cold-stored, leukocyte-reduced whole blood. Units stored for another 35 days. (42 days of storage in total).~Devices: Terumo IMUFLEX WB-SP/WB-RP collection bag systems."
89402278|NCT02926573|Active Comparator|Gabapentin|Gabapentin liquid by mouth or Per Tube 300mg twice a day
89402279|NCT02926573|Placebo Comparator|Placebo|Placebo liquid by mouth or Per Tube twice a day
89402280|NCT04477018|Experimental|Iron and Vitamin C|28 mg iron bis-glycinate chelate and 240 mg vitamin C
89402281|NCT04477018|Active Comparator|Iron|28 mg iron bis-glycinate chelate
89402282|NCT04477018|Placebo Comparator|Placebo|Matched placebo tablets
89402283|NCT02236442|No Intervention|Usual care|First arm : Passive recording head pain, linked symptoms, treatment used and diagnosis.
89402284|NCT02236442|Experimental|After protocol recommendation care|Recording head pain, linked symptoms, treatment used and diagnosis after intervention that is recommendation to use global headache treatment protocol
88813196|NCT01462253|Experimental|Clofarabine, Cyclophosphamide|"Clofarabine concentrate for solution for infusion should be filtered using a 0.2 micron filter and diluted to a final concentration between 0.15 mg/mL and 0.4 mg/mL with 0.9% sodium chloride injection USP or European Pharmacopeia (EP) normal saline (NS), or 5% dextrose injection (D5W) USP or EP prior to infusion.~Cyclophosphamide should be prepared for parenteral use by adding 0.9% sterile sodium chloride solution. Solutions of cyclophosphamide may be injected intravenously without further dilution or may be infused following further dilution: Dextrose Injection, USP (5% dextrose), Dextrose and Sodium Chloride Injection, USP (5% dextrose and 0.9% sterile sodium chloride), 5% Dextrose and Ringer's Injection."
88813197|NCT01837394|Active Comparator|Block arm|Ultrasound guided block of the SN and ONP with 7.5 ml of Ropivacaine 7.5 mg/ml injected at each site, respectively, immediately prior to induction of general anesthesia. Standard postoperative analgesia with paracetamol 1 g every 6 hours and Morphine 5 mg as needed. Ondansetron or Metoclopramide as needed for nausea.
89402285|NCT05737654|Experimental|Augmented reality glasses group|Two days a week (12 weeks in total), each session will be 60 minutes in total, and moderate exercise will be done with AR glasses.
89402286|NCT05737654|No Intervention|Control group|No intervention/application will be made to the children who will be included in the control group.
89402287|NCT02261402|Experimental|Medisinstart|Patients in this arm will receive the service; Medisinstart
89198983|NCT00923403|Placebo Comparator|Placebo Comparator|control dairy milk
88813198|NCT01837394|Placebo Comparator|Placebo arm|Ultrasound guided placebo block of the SN and ONP with 7.5 ml of isotonic saline solution injected at each site, respectively, immediately prior to induction of general anesthesia. Standard postoperative analgesia with paracetamol 1 g every 6 hours and Morphine 5 mg as needed. Ondansetron or Metoclopramide as needed for nausea.
89198984|NCT00923403|Experimental|experimental|plant sterol enriched soymilk
89402288|NCT02261402|No Intervention|Current Practice|Patients in this arm will receive the current pharmacy practice of advice and guidance with their new medicine. This involves dispensing the medicine and briefly providing information regarding its use and potential side-effects.
89402289|NCT03629275|Experimental|CTX0E03 Drug Product and delivery device|20 million neural stem cells
88813199|NCT00902018|Experimental|eltrombopag|10 ITP patients were treated with daily oral eltrombopag 75mg for 2 weeks and complete testing was done at weekly intervals 3 times they then were allowed to receive long-term eltrombopag
89402290|NCT03629275|Sham Comparator|Placebo|Sham Surgery
88813200|NCT00902018|Experimental|romiplostim|3 of the patients who received eltrombopag were also treated with romiplostim 10 micrograms/kg weekly for 2 weeks with the same complete testing done at weekly intervals three times after a washout period > 1 month they then resumed long-term eltrombopag
88813201|NCT00902018|Sham Comparator|healthy controls|no intervention single blood draw with complete studies
88813202|NCT04974762|Active Comparator|Wound infiltration|Standard intervention - surgical infiltration with local anesthetics
88813203|NCT04974762|Experimental|Truncal blocks|Truncal block for anesthetics
88813204|NCT01462565|Experimental|All subjects|Subjects enter the study already taking current marketed FLOLAN (epoprostenol sodium) and continue for 4 weeks (run-in). At baseline, they will be swopped to the new thermo stable formulation of epoprostenol sodium for 4 weeks (or longer if they continue in the extension phase of the study).
88813205|NCT03210896|No Intervention|Main Group|100 subjects (70 T2D and 30 Controls) consent to provide 1 venous blood sample, 1 capillary blood sample and 3 breath samples using IMSPEX, Bio-VOC and ReCIVA breath samplers.
88813206|NCT03210896|Experimental|Sub Group I|20 subjects from the main group (10 T2D and 10 Controls) to remain after providing the above samples. These patients will stay for an additional 3 hours and provide 1 capillary blood sample and 3 breath samples using IMSPEX, Bio-VOC and ReCIVA breath samplers at the following time intervals: 5, 30, 60, 120 & 180 minutes.
88813207|NCT03210896|No Intervention|Sub Group II|5 control subjects consent to provide 1 venous blood sample, 1 capillary blood sample and 3 breath samples using IMSPEX, Bio-VOC and ReCIVA breath samplers. This will be followed by 1 capillary blood sample and 3 breath samples every hour for a total of 5 hours.
88813208|NCT02473614|Experimental|Music Glove|Music Glove is a glove with sensors attached to the tips of all 5 fingers. The glove is connected to a software musical program like guitar hero. Participants will follow the rhythm or musical notes of the songs and move their fingers accordingly. Participants are reinforced with biofeedback that includes visual and auditory cues when the correct sequences are achieved.
88813209|NCT02473614|Active Comparator|Conventional Hand Exercise Program|Conventional Hand Exercise Program includes range of motion exercises, strengthening exercises, coordinating exercises of the hand and fingers. This exercise program is designed by an occupational therapist and is a general exercise program that a stroke patient will receive when he/she is being discharged from the hospital.
88813210|NCT01837628|Active Comparator|Lidocaine gel|Intraurethral Lidocaine gel 2%
89402291|NCT05737498|Experimental|experimental|Transcranial direct current stimulation will use to deliver a constant direct current through two surface electrodes, Anodal stimulation will applied according to the 10-20 international system for EEG electrode placement, over F3 of the dorsolateral prefrontal cortex (DLPFC), while the cathode will placed over the contralateral supraorbital area with 1.5 ma intensity for 20 min with working memory task on alternate days for two weeks.
89402292|NCT05737498|No Intervention|memory task training group|working memory task training for 20 min for two weeks
88813211|NCT01837628|Experimental|Paraffin Oil|Intraurethral injection
88813212|NCT04973280||Healthcare Professionals (HCPs)|The PASS will be conducted among HCPs in a representative sample of EEA countries where REBLOZYL is commercially available. A sample of HCPs from EEA countries who manage care for patients with certain haematologic conditions and who may/do prescribe REBLOZYL will be recruited from the target population of HCPs who were sent the REBLOZYL aRMMs in these countries. The final list of countries to be included may include 1) only countries where reimbursement has been sought and gained, 2) a geographically representative sample (e.g., northern, southern, eastern, and western EU Members States to the degree possible based on the first criteria), 3) a mixture of countries with higher and lower REBLOZYL usage, and 4) other feasibility considerations such as the ability to conduct direct-to-HCP non-market research studies.
88813213|NCT05565365|Placebo Comparator|Transversalis fascia plane (TFP) block|Patients will receive unilateral US-TFP block with bupivacaine 15 minutes before skin incision
88813214|NCT05565365|Active Comparator|Erector Spinae Plane (ESP) Block|Patients will receive unilateral US-ESP block with bupivacaine 15 minutes before skin incision
89402293|NCT05201131||Rezum procedure|
88813215|NCT00908882|Experimental|Enhanced PTSD Health Buddy and Motivational Interviewing|Veterans with PTSD who smoke are exposed to an intervention which included a 90-day smoking cessation curriculum that is integrated into the PTSD Health Buddy Program and weekly motivational interviewing counseling by a nurse plus usual smoking cessation care
88813216|NCT00908882|No Intervention|Usual PTSD Health Buddy Care|Veteran with PTSD who smoke randomly assigned to this arm received standard of care for smoking cessation and used the standard PTSD Health Buddy
88813217|NCT04972812||Usual care|Acute stroke patients receiving usual care
88813218|NCT01462877|Other|Fenofibrate arm|
88813219|NCT04972656|Experimental|Ambrisentan|Monotherapy using ambrisentan will start at a dose of 5 mg (once daily) and will be up-titrated to 10 mg (once daily) after 4 weeks apart if patients are tolerable.
88813220|NCT04972656|Placebo Comparator|Placebo|Placebo tablet
88813221|NCT03210506|Experimental|experimental group|patients who were untreated ever in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly till 48 weeks.
88877654|NCT03373890|Active Comparator|Short Burst Interval Treadmill Training Low Frequency|Participants receive short burst interval treadmill training for a total of 20 sessions. They are randomized to receive it either 2x/week for 10 weeks
88877655|NCT03375294|Experimental|Nitrous Oxide|PTSD patients in this arm will receive a single inhalation dose of 50% nitrous oxide and 50% oxygen for 1 hour
89189716|NCT05314335|Other|Just walking|In the first interview, patient diagnosis form and Constipation Quality of Life scale will be applied. In order to evaluate the routine bowel habits of the patients, no application will be made in the first week and the patients will be asked to complete the Defecation Diary, Visual Comparison Scale and the Bristol Stool Consistency Scale for 1 week when defecation occurs. Subsequently, patients will be instructed to walk for 30 minutes, 3 days a week (Monday, Wednesday, and Friday), 30 minutes after breakfast and dinner. Patients will be asked to continue the application for 4 weeks. The patients will be administered the Defecation Diary, the Visual Comparison Scale and the Bristol Stool Consistency Scale when defecation occurs daily during the application. In addition, on the 130th day of the application, the Constipation Quality of Life Scale will be administered to the patients again.
89189717|NCT05308225|Experimental|STI-6129|Seven dosing cohorts will be evaluated: 0.67 mg/kg, 0.88 mg/kg, 1.18 mg/kg, 1.56 mg/kg, 2.08 mg/kg, 2.77 mg/kg, 3.68 mg/kg where STI-6129 will be intravenously administered once as part of a 4-week treatment cycle.
89189718|NCT05303844|Experimental|H101 + Tislelizumab|(Dose escalation and cohort expansion) H101 administered by Intraperitoneal injection in combination with Tislelizumab administered intravenously (IV).
89189719|NCT05297019|Experimental|Arm 1: Mild pressure HBOT|"Mild pressure HBOT: 100% O2 @ 4.2 PSI for 100 minutes 3x/week for 6 weeks, 2 weeks off, and then an additional 4 weeks of therapy. Followed by 3 months of no treatment"
89189720|NCT05297019|Experimental|Arm 2: High pressure HBOT|"High pressure HBOT: 100% O2 @ 14 PSI for 100 minutes 3x/week for 6 weeks, 2 weeks off, and then an additional 4 weeks of therapy. Followed by 3 months of no treatment"
89189721|NCT05297019|Experimental|Arm 3: Crossover Arm|Patients will have 3 months of no treatment, and then be randomized to receive either high pressure or mild pressure HBOT
89189722|NCT05280574||Monitoring without any interventions|All patients will only be monitored with the GE Portrait Monitor with out any interventions.
89189723|NCT05280574||Patients will be randomized to blinded or unblinded GE Portrait monitoring.|All patients will be monitored with the GE Portrait Monitor. Patients who are randomized to the unblinded GE Portrait monitoring might be intervened if the clinicians believe that the alarm is clinically meaningful. Blinded GE Portrait Monitoring will not receive clinicians believe clinically
89189724|NCT05279313|Experimental|Centanafadine Hydrochloride|"Adolescents (13 to 17 years of age, inclusive) to receive 328.8 mg daily.~Children (4 to 12 years of age, inclusive) will receive weight-based doses of centanafadine ranging from 82.2 mg to 328.8 mg daily"
89189725|NCT05278364|Experimental|Dose-escalation and Dose-expansion|"Dose-escalation Phase:~Multiple doses of SY-5007 for oral administration.~Dose Expansion Phase:~RP2D of SY-5007 as determined during Dose Escalation."
89189726|NCT05277844|Active Comparator|Arm 1: Continuation of TKI therapy alone|Patients in this arm will continue to receive standard treatment of TKI alone
89189727|NCT05277844|Experimental|Arm 2: Continuation of TKI therapy + Local Consolidative Radiation therapy to 1-5 sites|Patients will receive local consolidate radiation therapy to all oligo-metastatic sites plus radiation therapy to primary disease in addition to TKI
89189728|NCT05274659|Active Comparator|KJ103 dose group 1|KJ103 single dose
89189729|NCT05274659|Active Comparator|KJ103 dose group 2|KJ103 single dose
89189730|NCT05274659|Active Comparator|KJ103 dose group 3|KJ103 single dose
89189731|NCT05274659|Active Comparator|KJ103 dose group 4|KJ103 single dose
89189732|NCT05274659|Active Comparator|KJ103 dose group 5|KJ103 single dose
89189733|NCT05274659|Placebo Comparator|Matching placebo for each dose group|placebo, single dose
89189734|NCT05274061|Experimental|Accelerated, Intensive, Multi-Couple Cognitive Behavioral Couples Therapy (AIM-CBCT for PTSD)|This is a single-arm study in which each couple will receive AIM-CBCT. The intervention is described in the section below.
89189735|NCT05272137||ECAP-controlled, closed-loop SCS|Spinal cord stimulation that measures and records evoked compound action potentials (ECAPs) and automatically adjusts the stimulation current to maintain a consistent ECAP amplitude
89189736|NCT05263739|Experimental|ESG206 dose level 1|ESG206 will be administered intravenously at dose level 1 every two weeks in a 28-day cycle.
89189737|NCT05263739|Experimental|ESG206 dose level 2|ESG206 will be administered intravenously at dose level 2 every two weeks in a 28-day cycle.
89189738|NCT05263739|Experimental|ESG206 dose level 3|ESG206 will be administered intravenously at dose level 3 every two weeks in a 28-day cycle.
89189739|NCT05263739|Experimental|ESG206 dose level 4|ESG206 will be administered intravenously at dose level 4 every two weeks in a 28-day cycle.
89189740|NCT05263739|Experimental|ESG206 dose level 5|ESG206 will be administered intravenously at dose level 5 every two weeks in a 28-day cycle.
89189741|NCT05262621|Experimental|Music intervention combined with progressive muscle relaxation|Music intervention combined with progressive muscle relaxation.
89189742|NCT05262621|No Intervention|Control group|no music therapy will be done.
89189743|NCT05260606||Patients with NSCLC who will have FDG PET/CT before and during ICI Tx|There is no difference from the treatment schedule performed in usual clinical setting except for an additional F-18 FDG PET/CT scan. Detailed plan of ICI treatment and patient management (dose, administration date, treatment period, and follow-up) follows the standard protocol of our institution in this study.
89189744|NCT05260164|Experimental|HIFEM+RF|"The subjects will be enrolled and assigned into one study arm and will be required to complete four (4) treatment visits.~Both flanks will be treated simultaneously with the BTL-899 device for 30 minutes per session."
89189745|NCT05257538|Active Comparator|FMT enema|FMT enema 3-5 days after standard antibiotic treatment
89189746|NCT05257538|Placebo Comparator|plasebo enema|placebo
89189747|NCT05249998|Experimental|Interventional group|"Patients will receive the usual care, with the intervention of the multidisciplinary team which defines with the patient the objectives of the stay and the inter-stay period, without specific therapeutic education on adapted physical activity, nutrition and eating behaviour."
89189748|NCT05249998|No Intervention|Standard care group|Patients will benefit from the activities already proposed as part of the usual practice and in addition a multidisciplinary staff will take place in order to interpret the assessments of the patients included and to direct the patients according to their phenotypic profile towards the different programmes of adapted physical activity.
89189749|NCT05248672|Experimental|150 mg QD|CT1812 150 mg QD
89189750|NCT05248672|Experimental|150 mg BID|CT1812 150 mg BID
89189751|NCT05248672|Experimental|300 mg QD|CT1812 300 mg QD
89189752|NCT05236946|Active Comparator|Upfront Cranial Radiotherapy|Stereotactic radiosurgery or Whole brain radiotherapy upfront in asymptomatic brain metastases
89189753|NCT05236946|Experimental|Observation (Delayed Cranial Radiotherapy)|Observation (Delayed Cranial radiotherapy) of Asymptomatic brain metastases
89189754|NCT05234424|Active Comparator|THRIVE 40 L/min|40 L/min with 100% oxygen for 10 minutes.
89189755|NCT05234424|Experimental|THRIVE 100 L/min|100 L/min with 100% oxygen for 10 minutes.
89189756|NCT05216419|Experimental|case group|"One dose of 30,000 IU of D-mac is taken once 15 days prior to surgery."
89189757|NCT05216419|No Intervention|control group|"There is no 30,000 IU of D-mac to be taken."
89189758|NCT05212714|Experimental|taVNS Treatment|n = 20
89189759|NCT05212714|Sham Comparator|Sham Comparator|n = 10
89189760|NCT05205863|Experimental|Cofact Dose 1|
89189761|NCT05205863|Experimental|Cofact Dose 2|
89189762|NCT05205863|Placebo Comparator|Placebo|
89189763|NCT05196529|Experimental|Inspiratory muscle training|The 8-week inspiratory muscle training protocol consists of using 80% of maximal inspiratory pressure (determined in lab), 3x per week, 6 sets of 6 repetitions. Each set will be separated by decreasing lengths of time over the 8 weeks starting at a 30 second interim. This totals 36 inhalations 3 times per week. Progress will be determined via weekly phone calls with the participants and progress will also be logged by participants over the 8 weeks.
89189764|NCT05196464|Other|VA primary care patients|VA primary care patients with psychological distress are being enrolled
89189765|NCT05195866|Active Comparator|Group A - CRP POCT|Participants assigned to Group A will take C-reactive protein (CRP) point of care test (POCT) during a check-up with their healthcare worker (HCW). The assistant investigator will attend the child's consultation with the local HCW and complete the case report form (CRF). Consequently, the CRP result will be recorded in the CRF, which will be the basis for choosing a treatment, depending on its result.
89189766|NCT05195866|No Intervention|Group B - Usual care|HCWs will also consult children who have been randomised to Group B. The assistant investigator will complete the CRF for these children, but the CRP POCT will not test them. They will receive the treatment prescribed by the HCW as usual care
89004171|NCT01892670|Experimental|RCC produced from cold-stored non-filtered whole blood|"RCC production from 7 days old, cold-stored, non-leukocyte-reduced whole blood. Units stored for another 35 days. (42 days of storage in total).~Devices: Terumo IMUFLEX WB-SP/WB-RP(removing platelets) collection bag systems."
89004172|NCT01824745|Experimental|Arm I (SCP-BCS template booklet and counseling)|Participants receive SCP-BCS template booklet and receive counseling sessions with a patient navigator for 40 minutes twice weekly for 4 sessions.
89189767|NCT05192226|Experimental|Counterfactual Strategy Intervention|After participants finish describing past events where they were unable to participate or engage in physical activity and have identified barriers which impacted their events they just described, participants will be randomly assigned to conditions. Participants in the counterfactual strategy condition will engage in counterfactual strategies on barriers they believe they could have reasonably acted on to increase physical activity in their described event(s) that would have led to a better outcome. After identifying the counterfactual strategies, participants will then select three counterfactual strategies they just identified that they could use at some point in the upcoming week, any obstacles to using that counterfactual strategy, ways to overcome those obstacles, their intention to use the counterfactual strategy over the next week, and how likely they think the counterfactual strategy would have happened and led to the better outcome.
89189768|NCT05192226|No Intervention|Control|Participants will be asked to describe past events where they were unable to participate or engage in physical activity. All participants will walk through the NIMHD framework with a researcher and be guided to identify barriers at various domains and levels of influence, which impacted their events they just described. After barrier identification, participants will be asked to select three barriers to talk aloud and list out additional details about the barriers identified.
89189769|NCT05187195|Experimental|Telerehabilitation-video group|This group will perform their exercises with prepared personalized exercise videos through the telerehabilitation system 3 days a week for 8 weeks.
89189770|NCT05187195|Experimental|Telerehabilitation-brochure group|This group will perform exercises with personalized exercise brochures defined through the telerehabilitation system 3 days a week for 8 weeks.
89189771|NCT05177770|Experimental|SRF617 in combination with etrumadenant and zimberelimab|All patients will receive SRF617 administered in combination with etrumadenant (AB928) and zimberelimab (AB122).
89189772|NCT05175313||normal people|people who don't complain of respiratory diseases will be examined by chest ultrasound and pulmonary function test.
89189773|NCT05175313||obstructive respiratory diseases|the patients who are diagnosed with either COPD or asthma.
89189774|NCT05175313||restrictive respiratory diseases|patient with either ILD
89189775|NCT05175053|Experimental|Early RRT group|Patients who will undergo renal replacement therapy (RRT) within 6 hours of diagnosis of stage 2 acute kidney injury (AKI).
89189776|NCT05175053|Active Comparator|Delayed RRT group|Patients who will undergo renal replacement therapy (RRT) if one of the absolute indications for RRT is present.
89189777|NCT05150626|Experimental|Sequence A administered DBPR108|Subjects will receive a single dose of DBPR108 100 mg under fasted condition, following a low-fat meal and a standard meal.
89189778|NCT05150626|Experimental|Sequence B administered DBPR108|Subjects will receive a single dose of DBPR108 100 mg following a low-fat meal and standard meal, under fasted condition.
89189779|NCT05150626|Experimental|Sequence C administered DBPR108|Subjects will receive a single dose of DBPR108 100 mg following a standard meal, under fasted condition, following a low-fat meal.
89189780|NCT05149625|Experimental|Dexcom G6|
89189781|NCT05149625|No Intervention|Traditional self-blood glucose measurement|
89189782|NCT05144737|Other|Immediate Intervention Group|Participants in the immediate intervention group will immediately begin 6 months of the adapted DPP lifestyle intervention with a Lifestyle Coach and remote monitoring of blood pressure and body composition. This will be followed by a 6-month observation period where the intervention (Lifestyle Coach) will be withdrawn. In this period, participants will be evaluated for the maintenance of lifestyle changes.
89189783|NCT05144737|Other|Delayed Intervention Group|Participants in the delayed intervention group will receive remote monitoring of blood pressure and body composition for the 1st 6 months (without the Lifestyle Coach) and then will receive the adapted DPP lifestyle intervention with a Lifestyle Coach after 6 months.
89189784|NCT05138250|Experimental|Treatment arm (all participants, not randomised)|All participants will be treated with mepolizumab, a 100mg dose every 4 weeks for 1 year (13 doses)
89189785|NCT05128409|Active Comparator|XKH001 Injection|XKH001 Injection,hypodermic injection，single dose，5 dose cohorts: 0.5 mg/kg, 1.67 mg/kg, 3.34 mg/kg, 5.0 mg/kg and 10.0 mg/kg.
89402294|NCT02261480||Group A: Documented Prior History|"Pediatric and adult participants with sickle cell disease (SCD) with a documented prior history of parvovirus B19 infection (aplastic crisis).~Group A participants will have blood draw and nasopharyngeal wash on day 1 only. Nasopharyngeal wash will be optional for Group A."
89402295|NCT02261480||Group B: No Prior History|"Pediatric and adult participants with SCD who have never had a documented parvovirus B19 infection (aplastic crisis).~Group B participants will have blood draw and nasopharyngeal wash on day 1 only. Nasopharyngeal wash will be optional for Group B."
89402296|NCT02261480||Group C: Suspected and/or Confirmed|"Sickle cell disease patients with suspected and/or confirmed acute parvovirus B19 infection, the latter defined as febrile illness with anemia without adequate compensatory reticulocytosis.~Group C participants will have blood draw and nasopharyngeal wash on day 1, day 7±4 days, day 30±7 days, and day 120±14 days."
89402297|NCT05759611|Other|Control group (CTRL)|
89402298|NCT05759611|Experimental|Experimental group (RMT)|
89402299|NCT00158860|Experimental|Valaciclovir|Participants received double blinded treatment of oral dose of Valacyclovir 1 g given as 2 x 500 mg caplets QD for 6 months (24 weeks).
89402300|NCT00158860|Placebo Comparator|Placebo|Participants received double blinded treatment of oral dose of matching placebo to Valacyclovir 1 gram (g) given as 2 x 500 milligram (mg) caplets once daily (QD) for 6 months (24 weeks).
89402301|NCT02234258|Experimental|Cognitive behavioral social skills|In Cognitive behavioral social skills training (CBSST), skills-based CBT is used to teach individuals how to correct inaccurate dysfunctional thoughts that interfere with goal-directed activities, including defeatist expectancies, low self-efficacy beliefs, and anomalous beliefs. SST focuses on behaviorally-based instruction of interpersonal social skills, utilizing role-modeling, rehearsal, corrective feedback, and positive reinforcement to facilitate learning. In the modified version of CBSST used in this project: 1) we will strengthen the focus on corrective feedback from successful social interactions; 2) focus on normalization and destigmatization of attenuated psychotic symptoms; 3) add motivational interviewing techniques to promote treatment engagement; and 4) use examples and role plays. CBSST will be delivered in three 6-session modules (i.e., Cognitive Skills, Social Skills, and Problem Solving Skills), a total of 18 90-minute group sessions.
89402302|NCT02234258|Active Comparator|Psychoeducation|The purpose of this alternative treatment is to match CBSST for the nonspecific effects of therapist contact and interest, social interaction and support. Common factors include client expectancy, providing a rationale for change, therapist factors and therapeutic alliance. The psychoeducation group will meet weekly, for a total of 18 90-minute sessions. Therapists will follow brief guidelines as to what they can and cannot do. In each session the therapists will ask how the previous week had been. Any crises will be dealt with, and advice will be offered to help with any immediate problems. No active CBT or SST techniques will be taught or used. Psychoeducational information about high risk for psychosis will be offered. There will be a focus on listening, reflecting and empathizing, and demonstrating uncritical acceptance and genuineness. Social exchanges amongst participants will be encouraged.
89402303|NCT05201053||Mild acute pancreatitis|Groups are defined by the Revised Atlanta classification. Anticipated 60% mild, 30% moderate and 10% severe patients
89402304|NCT05201053||moderately severe acute pancreatitis|Groups are defined by the Revised Atlanta classification. Anticipated 60% mild, 30% moderate and 10% severe patients
89402305|NCT05201053||severe acute pancreatitis|Groups are defined by the Revised Atlanta classification. Anticipated 60% mild, 30% moderate and 10% severe patients
89402306|NCT03629665|Active Comparator|rTMS and naming combined with ILAT|Interventions: Repetitive navigated Transcranial Magnetic Stimulation, picture naming and Intensive Language Action Therapy
89402307|NCT03629665|Sham Comparator|sham rTMS and naming combined with ILAT|Interventions: sham Repetitive navigated Transcranial Magnetic Stimulation, picture naming and Intensive Language Action Therapy
88813222|NCT03210506|No Intervention|control group|patients who were untreated ever in immune-active phase took Nucleoside Analogues for maintenance treatment.
88813223|NCT03210272|Experimental|Single rising dose part|Group of healthy male volunteers receive rising single doses of BI 1358894
88813224|NCT03210272|Experimental|Food effect part|Group of healthy male volunteers receive single doses of BI 1358894 with and without food
88813225|NCT02500758|Experimental|Parachlorometaxylenol|Reducing bacterial load after preoperative surgical scrubbing using 3% PCMX. Both hands have been prepared by preparatory handwash.
88813226|NCT02500758|Active Comparator|Clorhexidine digluconate|Reducing bacterial load after preoperative surgical scrubbing using 4% CHG. Both hands have been prepared by preparatory handwash.
88813227|NCT01839812|Other|cosyntropin stimulation test|All patients enrolled in the study are administered cosyntropin stimulation tests to assess their adrenal response.
88813228|NCT01837706||Emergency Room Patients|
88813229|NCT02500056|Active Comparator|OM group|Optilene LP mesh
88813230|NCT02500056|Active Comparator|UM group|Ultrapro mesh
88813231|NCT01463267|Active Comparator|Device 2 passive|Device 2 will NOT remind patients to take medications
89402308|NCT02490488|Experimental|Masitinib & gemcitabine|Participants receive masitinib (6 mg/kg/day), given orally twice daily, plus gemcitabine 1000 mg/m² administered by 30 minutes infusion once a week during 3 weeks followed by 1 week without infusion.
89402309|NCT02490488|Placebo Comparator|Placebo & gemcitabine|Participants receive placebo (6 mg/kg/day), given orally twice daily, plus gemcitabine 1000 mg/m² administered by 30 minutes infusion once a week during 3 weeks followed by 1 week without infusion.
89402310|NCT02261558|Experimental|Clinical Improvisation Instrumental Music Therapy|Clinical Music Therapy session, 20 minutes. Focus on instrumental improvisation
89402311|NCT02261558|Experimental|Clinical Vocal Improvisation|Clinical Music Therapy session, 20 minutes. Focus on vocal improvisation
89402312|NCT02261558|No Intervention|Control Group|Participants enrolled in control group will complete the same study design, without having a clinical music improvisation
89402313|NCT02471222|Experimental|ADS-5102 (amantadine HCl extended release)|
89402314|NCT02471222|Placebo Comparator|Placebo|
89402315|NCT05094310|Experimental|Acupuncture group|Patients with breast cancer who experienced fatigue were measured by the Brief Fatigue Inventory(BFI) scale and other Fatigue related questionnaire. Breast cancer patients diagnosed with cancer related fatigue are included in our clinical study，and those patients will receive acupuncture treatment. The position of acupuncture refers to the principle of acupuncture treatment of traditional Chinese medicine. According to ICD-10-CD code R53.0, the diagnosis of CRF is determined by the experience of diminished energy or other physical and psychological symptoms every day or almost every day for two consecutive weeks in the past month. We collected patients' blood to detect fatigue related SNP.
89402316|NCT02649062|Experimental|NGM282 Dose 1|NGM282
89402317|NCT02649062|Experimental|NGM282 Dose 2|NGM282
89402318|NCT02649062|Placebo Comparator|Placebo|Placebo
89402319|NCT05093998|Experimental|Group 1.|AV5080 at a daily dose of 160 mg
89402320|NCT05093998|Placebo Comparator|Group 2.|Placebo
89402321|NCT02264756||Ward CAP|Adult immune-competent patients admitted to ward with clinical diagnosis of community-acquired pneumonia will be potentially exposed to ASP review
89402322|NCT03067129|Experimental|Cohort 1: Adult Formulation; 12 to < 18 years|Adolescents aged 12 to < 18 years old received the adult formulation of glecaprevir (GLE)/pibrentasvir (PIB) 100 mg/ 40 mg co-formulated film-coated tablets for a once daily (QD) total dose of 300 mg/120 mg by mouth for 8, 12, or 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience.
88813232|NCT01463267|Active Comparator|Device 2 active|Device 2 will remind patients to take medications
89004173|NCT01824745|Active Comparator|Arm II (SCP-BCS template booklet)|Participants receive SCP-BCS template booklet and receive standard follow-up care.
89402323|NCT03067129|Experimental|Cohort 2: Pediatric Formulation; 9 to < 12 years|"Children aged 9 to < 12 years old received a pediatric formulation of GLE + PIB as small film-coated granules taken with a small amount of food once daily for 8, 12, or 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience.~The initial proposed dose for children 9 to < 12 years old (30 to < 45 kg) was GLE 200 mg + PIB 75 mg. After PK analysis from the first 6 enrolled participants the dose was adjusted to GLE 250 mg + PIB 100 mg."
89402324|NCT03067129|Experimental|Cohort 3: Pediatric Formulation; 6 to < 9 years|"Children aged 6 to < 9 years old received a pediatric formulation of GLE + PIB as small film-coated granules taken with a small amount of food once daily for 8, 12, or 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience.~The initial proposed dose for children 6 to < 9 years old (20 to < 30 kg) was GLE 160 mg + PIB 60 mg. After PK analysis from the first 6 enrolled participants the dose was adjusted to GLE 200 mg + PIB 80 mg."
89402325|NCT03067129|Experimental|Cohort 4: Pediatric Formulation; 3 to < 6 years|"Children aged 3 to < 6 years old received a pediatric formulation of GLE + PIB as small film-coated granules taken with a small amount of food once daily for 8, 12, or 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience.~The initial proposed dose for children 3 to < 6 years old (12 to < 20 kg) was GLE 120 mg + PIB 45 mg. After PK analysis from the first 5 enrolled participants the dose was adjusted to GLE 150 mg + PIB 60 mg."
89535531|NCT03205891|Experimental|Brentuximab Vedotin + TAK228|"Participants receive Brentuximab Vedotin by vein on Day 1 of each cycle.~Participants take TAK228 by mouth either every day, or on a 5 days on/2 days off schedule. The study doctor will tell participant how often to take the study drug.~Each cycle is 21 days.~Participant monitors glucose (sugar) levels at home with a glucose monitor during the first 2 months participant is taking the study drug."
88813233|NCT01463267|Active Comparator|Device 1 active|Device 1 will remind patients to take their medications
88813234|NCT01463267|Placebo Comparator|Device 1 Passive|Device 1 will NOT remind patients to take medications.
88813235|NCT04379648|Other|Posttraumatic stress disorder|cohort of patients with Posttraumatic stress disorder PTSD
88813236|NCT01839890|Experimental|Bare metal Stent plus Paclitaxel Balloon|Conventional bare metal Stent plus Paclitaxel Eluting Balloon(Pantera Lux)®
88813237|NCT01839890|Active Comparator|Bare metal Stent|Conventional Bare Stent
88813241|NCT02205983|Experimental|2 mg hydromophone|Healthy adult volunteers will receive 2 mg hydromophone. Hydromorphone is a mu-opioid agonist used clinically for pain management. Plasma concentrations of hydromorphone peak approximately 60 min after ingestion.
88813242|NCT02205983|Experimental|4 mg hydromphone|Healthy adult volunteers will receive 4 mg hydromophone. Hydromorphone is a mu-opioid agonist used clinically for pain management. Plasma concentrations of hydromorphone peak approximately 60 min after ingestion
88813243|NCT02205983|Experimental|1000 mg acetaminophen|Healthy adult volunteers will receive 1000 mg acetaminophen. Acetaminophen is a COX inhibitor that is used clinically as an analgesic and antipyretic. The dose administered here has been shown to reduce neural and subjective responses to social rejection, and it also peaks about 60 min after ingestion.
88813244|NCT02205983|Placebo Comparator|Dextrose|Healthy adult volunteers will recieve Dextrose (placebo).
88813245|NCT01839968||Study patients|Acute coronary syndrome patients with a recent loading dose of prasugrel (6-24h)
88813246|NCT04969692|No Intervention|non-warming group|
88813247|NCT04969692|Active Comparator|warming group|
88813248|NCT01838096|Experimental|THA|
88813249|NCT05565053|Active Comparator|Bilateral Erector Spinae Plane Block|Bilateral Erector Spinae Plane Block
89189786|NCT05128409|Placebo Comparator|XKH001 Placebo Injection|XKH001 Placebo Injection,hypodermic injection，single dose，4 dose cohorts: 1.67 mg/kg, 3.34 mg/kg, 5.0 mg/kg and 10.0 mg/kg.
89189787|NCT05126927|Experimental|68Ga-NODAGA-SNA006|A PET contrast agent to assess the level of tumor tissue-infiltrating CD8 + T cells in patients with solid tumors
89189788|NCT05126524||Loco-regional Anaesthesia in Video or Robot-assisted Thoracic Pulmonary Surgery|Patients with loco-regional Anaesthesia in Video or Robot-assisted Thoracic Pulmonary Surgery are eligible for this study
88813250|NCT05565053|Active Comparator|Trigger Point Injection|Trapezius muscle Trigger Point Injection
89189789|NCT05117034|Experimental|Morphine|Intraoperative intravenous administration of 0.08 mg/kg morphine at dura closure.
89189790|NCT05117034|Placebo Comparator|Placebo|Intraoperative intravenous administration of 0.08 ml/kg NaCl 0.9% at dura closure.
89189791|NCT05110105|Experimental|Intervention|Participants will receive interactive board game health education.
89189792|NCT05110105|Active Comparator|Control|Participants will receive conventional health education.
89189793|NCT05109078|Experimental|[14C]- Rongliflozin|Patients will receive single dose of [14C]- Rongliflozin (Suspension, 50mg/100μCi)
89189794|NCT05108766|Experimental|Tildrakizumab|Subjects will receive 100 mg subcutaneous (SC) Tildrakizumab at Week 0 and Week 4, 100 mg subcutaneous placebo at Week 12. Subjects entered the extension study after completion of the base study and will receive 100 mg subcutaneous Tildrakizumab at Week 16, 28, 40, and 52.
89189795|NCT05108766|Placebo Comparator|Placebo|Subjects will receive 100 mg subcutaneous placebo at Week 0 and Week 4, and 100 mg subcutaneous Tildrakizumab at Week 12. Subjects entered the extension study after completion of the base study and will receive 100 mg subcutaneous Tildrakizumab at Week 16, 28, 40, and 52.
89189796|NCT05106777|Experimental|Surufatinib|Drug: Surufatinib Surufatinib will be given orally.
89189797|NCT05096208|Experimental|RSVpreF vaccine Group 1|RSVpreF
89189798|NCT05096208|Experimental|RSVpreF vaccine Group 2|RSVpreF
89189799|NCT05096208|Experimental|RSVpreF vaccine Group 3|RSVpreF
89189800|NCT05096208|Placebo Comparator|Placebo dose|Placebo
89189801|NCT05093920|Active Comparator|Drug Eluting Bead Transarterial Chemoembolization|Drug Eluting Bead Transarterial Chemoembolization
89189802|NCT05093920|Active Comparator|conventional Transarterial Chemoembolization|conventional Transarterial Chemoembolization
89189803|NCT05069727|Active Comparator|Group 1, Regular Protocol|Participants will bolus (insulin), based on carbohydrate content in each meal
89189804|NCT05069727|Experimental|Group 2, Simplified protocol|Participants will bolus (insulin), based on three sets of meal set of meals announcement
89189805|NCT05064358|Experimental|Cohort 1: Participants receiving belantamab mafodotin at dose level (DL) 1|
89189806|NCT05064358|Experimental|Cohort 2: Participants receiving belantamab mafodotin at DL 2|
89189807|NCT05064358|Experimental|Cohort 3: Participants receiving belantamab mafodotin at DL 3|
89189808|NCT05064358|Experimental|Cohort 4: Participants receiving belantamab mafodotin at DL 4|
89189809|NCT05064358|Experimental|Cohort 5: Participants receiving belantamab mafodotin at DL4 with alternative dose modification|
89189810|NCT05060471|Experimental|Intervetional group|Neoadjuvant PD-1 antibody toripalimab combined with docetaxol and cisplatin, followed by radiotherapy and concurrent toripalimab
89189811|NCT05052879|Experimental|TORONTO 20 + 30/60|"The study is double-dummy. The patient must take 2 tablets before the sexual intercourse, as follows:~1 tablet of Toronto association, oral;~1 tablet of tadalafil placebo, oral."
88813251|NCT01837784||Elderly patients|
88813252|NCT01837784||Patients with diabetes mellitus|
88813253|NCT01837784||Patients with heart failure|
88813254|NCT01837784||Patients with resistant hypertension|
88813255|NCT02206217|No Intervention|Single vision spectacle lens|Single vision lens with power for correcting distance refraction.
89189812|NCT05052879|Active Comparator|TADALAFIL|"The study is double-dummy. The patient must take 2 tablets before the sexual intercourse, as follows:~1 tablet of tadalafil , oral;~1 tablet of Toronto association placebo, oral."
88813256|NCT02206217|Experimental|Multiple-Segment spectacle lens|A multifocal spectacle lens that corrects distance refraction and provides myopic defocus at the same time.
88813257|NCT03210038|Active Comparator|Rigid cystoscopy, water based gel on introitus|Rigid cystoscopy, Wolf 17FR. Pad soaked with water based gel put on introitus for 5 minutes prior to procedure.
88813258|NCT03210038|Active Comparator|Rigid cystoscopy, esracain gel based on introitus|Rigid Cystoscopy, Wolf 17FR. Pad soaked with Esracain (Lidocaine) put on the introitus for 5 minutes prior to procedure.
89189813|NCT05049707|Placebo Comparator|Control|The control arm will receive an equivalent volume of normal saline as the treatment group
89189814|NCT05049707|Experimental|IV magnesium|We will randomize patients in the treatment group to receive either a 50 mg/kg bolus of intravenous magnesium preoperatively followed by a magnesium infusion of 15mg/kg/hr, to be given after intraoperative neuromonitoring staff have been able to record baseline neurological data.
89189815|NCT05043805|Active Comparator|Dextromethorphan|add on therapy
89189816|NCT05043805|Placebo Comparator|placebo|add on therapy
89189817|NCT05033483|Experimental|Iron Supplement|65.7 mg of iron as ferrous fumarate
89189818|NCT05033483|Active Comparator|Placebo|0 mg of iron
89189819|NCT05026047|Experimental|patients consulting in an infectious disease department|no comparator
89189820|NCT05013918||Hospitalized people in Nursing Home|
88877656|NCT03377244|Experimental|HBHS|Participants in the Healthy Bodies Healthy Souls (HBHS) arm received the Wholeness, Oneness, Righteousness, Deliverance Diabetes Prevention Program Lifestyle Intervention (WORD DPP) with the addition of church-level policy changes to support the individual behavioral intervention of the WORD DPP. The WORD DPP is a faith-based diabetes prevention curriculum that teaches participants to connect faith and health to have a healthy weight, eat healthy, and be physically active. The WORD DPP includes 16 modules that are intended to be delivered over a 24 week period, each module approximately 90 minutes in length. Church-level changes to support healthier behaviors include improvements in food purchasing and preparation for events, physical activity programs, and increased congregational engagement in health promotion activities.
88877657|NCT03377244|Active Comparator|HBHS Policy|Participants in the HBHS Policy arm included members of churches enrolled in the HBHS study who did not receive the WORD DPP intervention (ie, these participants were exposed to only the church-level policy changes). Church-level changes to support healthier behaviors include improvements in food purchasing and preparation for events, physical activity programs, and increased congregational engagement in health promotion activities.
88877658|NCT03377244|Other|WORD DPP|Participants in the Wholeness, Oneness, Righteousness, Deliverance Diabetes Prevention Program Lifestyle Intervention (WORD DPP) arm included participants enrolled in a separate DPP study without the church-level policy changes (ie, these participants received only the WORD DPP intervention). The WORD DPP is a faith-based diabetes prevention curriculum that teaches participants to connect faith and health to have a healthy weight, eat healthy, and be physically active. The WORD DPP-LI includes 16 modules that are intended to be delivered over a 24 week period, each module approximately 90 minutes in length.
88877659|NCT03379662|Experimental|Erchonia HLS Laser|The Erchonia HLS Laser is administered 8 times across 4 weeks for 5 minutes each time to the skull at the base of the brain and temporal areas.
88877660|NCT03379662|Placebo Comparator|Placebo Laser|The Placebo Laser is administered 8 times across 4 weeks for 5 minutes each time to the skull at the base of the brain and temporal areas.
88877661|NCT03379740|Experimental|Product Exposure Sequence 1|"Subjects will be randomized to follow a sequence of product exposure comprised of :~Subject's own e-cigarette; P4M3-1.7%; P4M3-1.7%LA; P4M3-3%LA; and P4M3-4%LA"
88877662|NCT03379740|Experimental|Product Exposure Sequence 2|"Subjects will be randomized to follow a sequence of product exposure comprised of :~Subject's own e-cigarette; P4M3-1.7%LA; P4M3-1.7%; P4M3-3%LA; and P4M3-4%LA"
88877663|NCT03390114|Experimental|SHUTi Cognitive Behavioral Therapy|SHUTi (www.myshuti.com) is an evidence-based, cognitive-behavioral, online intervention for insomnia.
89004174|NCT01808937||Morphea|Those having the condition morphea or other synonymous diagnosis (such as localized scleroderma, linear scleroderma, Parry-Romberg syndrome, en coup de sabre)
89189821|NCT05008185||Regenerative Peripheral Nerve Interface|symptomatic neuroma is excised, and the end of the peripheral nerve is implanted into a small denervated free muscle graft harvested from the patient
89189822|NCT05008185||Traction Neurectomy|simple excision and traction neurectomy
89402326|NCT03136120||Subjects with suspected fibrotic ILD|Eligible subjects will receive nebulized ipratropium bromide 500 mcg for 10 minutes. The subjects will be sedated for bronchoscopic procedure as per routine practice for subjects having bronchoscopy. Cryobiopsy samples for this study will be taken after samples required for diagnosis has been taken and it is safe to do so. One to three endobronchial forceps biopsy samples will be taken from up to 5 subjects to allow comparison of proximal and distal drug distribution.
89402327|NCT01625390|Experimental|Arm 1|
89402328|NCT01625390|Active Comparator|Arm 2|
89402329|NCT01625390|Experimental|Arm 3|
89402330|NCT01679236|Active Comparator|Mindfulness Training for Smokers|Mindfulness Training for Smokers (MTS) is a 7-week intervention that provides instruction in mindfulness very similar to the way it is taught in Mindfulnes-Based Stress Reduction. In addition MTS provides mindfulness training targeted to specific smoking relapse challenges. The MTS intervention was designed around a weekly curriculum that provides instruction to help participants learn practices including mindfulness meditation, mindful walking and mindful eating. MTS participants are instructed to practice meditation 30 minutes per day with a guided meditation CD.
89402331|NCT01679236|Active Comparator|Interactive Learning for Smokers|Interactive Learning for Smokers (ILS) is a 7-week intervention that provides a closely matched active control group for MTS, but with substantive education and skills training for smoking cessation. To this end, ILS combines elements of two smoking cessation programs, the American Lung Association, Freedom from Smoking program and The Mayo Clinic Nicotine Dependence Center program. ILS participants were asked to practice 30 minutes of silent non-directed walking per day throughout the intervention and were instructed to use non-directed walking for relaxation, stress reduction and as a strategy for managing urges and withdrawal symptoms.
89402332|NCT01625234|Experimental|Phase I: X-396 (ensartinib)|Dose escalation starting at 25 mg, oral once or twice a day, 28-day cycle. Number of Cycles: until progression or unacceptable toxicity develops
89402333|NCT01625234|Experimental|Phase II: X-396 (ensartinib)|RP2D 225mg stratified based on prior treatment and CNS activity
88877664|NCT03390114|No Intervention|Usual Care|Patients randomized to the Usual Care group will be encouraged to follow-up with their primary care or HIV provider. There will be no formal interaction with the participants between the Entry Visit and the Week 10 Visit. However, the participants will be encouraged to contact the study team for any changes in their condition. There will be no restrictions on the care that can be received, although we will assess changes in care during the trial.
88877665|NCT03391986|Active Comparator|Pyonex needles|This arm will receive modified battlefield auricular acupuncture using SEIRIN® Pyonex™ Acupuncture Needles.
88877666|NCT03391986|Placebo Comparator|Placebo adhesives|This arm will receive placement of adhesives using the modified battlefield auricular acupuncture placement points using 12 mm Plasters.
88877667|NCT03391986|No Intervention|Routine Care|This arm will receive no intervention.
88877668|NCT03392532|Other|AOHG toric, then AO toric|Lotrafilcon B toric contact lenses with HYDRAGLYDE, followed by lotrafilcon B toric contact lenses, as randomized. Each product worn in both eyes for approximately 30 minutes, with a 30-45 minute washout between the removal of Pair 1 and insertion of Pair 2.
88877669|NCT03392532|Other|AO toric, then AOHG toric|Lotrafilcon B toric contact lenses, followed by lotrafilcon B toric contact lenses with HYDRAGLYDE, as randomized. Each product worn in both eyes for approximately 30 minutes, with a 30-45 minute washout between the removal of Pair 1 and insertion of Pair 2.
88877670|NCT03395808|Other|AVE-901 50mg|IV Tramadol
88877671|NCT03395886||remifentanil group|Eligible patients will receive a continuous infusion of remifentanil starting with 0.05 μg/kg/min. The doses will be adjusted according to the sedation satisfaction (sedation target is to achieve NIV-intolerance score 1-2), and the maximum dose is 0.12 μg/kg/min.
88877672|NCT03395886||dexmedetomidine group|Eligible patients will receive a continuous infusion of dexmiditomidine starting with 0.5 μg/kg/h. The doses will be adjusted according to the sedation satisfaction (sedation target is to achieve NIV-intolerance score 1-2), and the maximum dose is 1 μg/kg/h.
88877673|NCT03396432|Active Comparator|Video Laryngoscopy for endotracheal (ET) Placement|"Device:~Storz C-MAC Video Laryngoscope"
88877674|NCT03396432|Active Comparator|Direct Laryngoscopy for ET Placement|"Device:~Miller Laryngoscope"
88877675|NCT03398928|Experimental|Acupuncture|Acupuncture for delirium treatment
88877676|NCT03398928|No Intervention|Standard care|Standard conventional delirium care at the discretion of the department medical staff
88877677|NCT03400800|Experimental|Inclisiran|Inclisiran sodium 300 milligrams (mg) (equivalent to 284 mg inclisiran) in 1.5 milliliters (mL) will be administered as a SC injection on Day 1, Day 90, and then every 6 months.
89402334|NCT03629587||Patients presented H pylori positive|Upper endoscopy, Gastric biopsy, CBC, VITAMIN B12 level, iron studys, folic acid level, bone marrow aspirate
88877678|NCT03400800|Placebo Comparator|Saline Solution|Placebo (1.5 mL) will be administered as a SC injection of saline solution on Day 1, Day 90, and then every 6 months.
88877679|NCT03410628|Experimental|gammaCore Active Device|open label
89004175|NCT01386619|Experimental|NK cell DLI|
89004176|NCT01386437||Fungal infections|Patients with or without inherited or acquired abnormalities of immune function manifesting mucocutaneous and/or invasive fungal infections
89402335|NCT03629587||Patients with H pylori negative|Upper endoscopy, Gastric biopsy, CBC, VITAMIN B12 level, iron studys, folic acid level, bone marrow aspirate
89402336|NCT02264834|Active Comparator|Control group|Lumbar epidural analgesia during the labour and end up after delivery Levobupivacaine 0.1% + Sufentanil 0.2 µg/mL
89402337|NCT02264834|Experimental|Ambulatory group|Lumbar epidural analgesia during the labour and end up after delivery Levobupivacaine 0.07% + Sufentanil 0.3 µg/mL
89402338|NCT05762419|Experimental|Focused ultrasound using oral etoposide|All patients enrolled in the study will be treated with oral etoposide after receiving focused ultrasound (FUS) treatment with microbubbles and neuro-navigator-controlled sonication.
88877680|NCT03410862|Experimental|Elderberry Extract|Patients will be supplied a liquid Elderberry Extract used to treat their confirmed human influenza. The dosage of the assigned medication will be 15 ml, or 1 tablespoon. Participants aged 5-12 will be asked to take the medication 2 times per day (morning/night) for a period of 5 days. Participants aged 13 and above will be asked to take the medication 4 times per day (morning/noon/afternoon/night) for a period of 5 days.
88877681|NCT03410862|Placebo Comparator|Placebo|Patients will be supplied a liquid Placebo medication (similar in appearance and taste of Elderberry Extract) used to treat their confirmed human influenza. The dosage of the assigned medication will be 15 ml, or 1 tablespoon. Participants aged 5-12 will be asked to take the medication 2 times per day (morning/night) for a period of 5 days. Participants aged 13 and above will be asked to take the medication 4 times per day (morning/noon/afternoon/night) for a period of 5 days.
89402339|NCT04568408||Sleep study participants|Adults presenting sleep difficulties or poor sleep quality that are performed a Polisomnography study in a Sleep Unit at hospital.
89402340|NCT04458103|Experimental|prospective interventional cohort|The prospective interventional cohort will consist of patients undergoing LVAD implantation at Massachusetts General Hospital. These patients will receive an RVAD (either the ProtekDuo or Impella RP) prior to or during LVAD implantation.
89402341|NCT04458103|No Intervention|retrospective control cohort|The historical control cohort will consist of retrospective data collection on patients who have undergone LVAD implantation in the past. This group will be age and sex matched with the enrolled prospective interventional patients.
88877682|NCT03415152||Omacor (Omega-3-acid ethyl esters)|Adult patients with history of myocardial infarction not earlier than 6 months ago and/or with diagnosis of hypertriglyceridemia who having been prescribed Omacor for at least 6 months.
88877683|NCT03416946|Active Comparator|Custom Block Instrumentation|Patients-specific custom cutting blocks using the Smith and Nephew Visionaire system
88877684|NCT03416946|Active Comparator|Traditional Instrumentation|Traditional cutting methods for Total Knee Replacement
88877685|NCT03418662|No Intervention|Control Arm (Standard Colonoscopy)|Standard colonoscopy with no device attachment.
88877686|NCT03418662|Experimental|EndoRings Colonoscopy|Colonoscopy with EndoRings device attached to the distal end of the scope.
88877687|NCT03423186|Experimental|Dose group 1|SOBI003 dose 3 mg/kg once weekly for 24 weeks
88877688|NCT03423186|Experimental|Dose group 2|SOBI003 dose 10 mg/kg once weekly for 24 weeks
89402342|NCT02264912||stent-PCI patients|Consecutive patients, who underwent intracoronary stent implantation, have been included regardless of whether percutaneous coronary intervention (PCI) was performed on urgent or elective basis.
89402343|NCT01437722|Experimental|1% SPL7013 Gel|
89402344|NCT01437722|Experimental|3% SPL7013 Gel|
88877689|NCT03429270|Experimental|Urodynamics Arm|
88877690|NCT03429348|No Intervention|No additional rehabilitation|No additional rehabilitation will be done
88877691|NCT03429348|Other|Sauna rehabilitation|An additional rehabilitation in a sauna will be done
88877692|NCT03430050|Active Comparator|Progesterone|Prometrium 200mg. Take one pill in the evening on day 1 with water. Take one pill twice a day on days 2-4. Take one pill on morning day 5.
88877693|NCT03430050|Placebo Comparator|Placebo|Placebo. ake one pill in the evening on day 1 with water. Take one pill twice a day on days 2-4. Take one pill on morning day 5.
88877694|NCT03430206|No Intervention|Control|Control subjects will undergo their scheduled procedure and recovery with the usual care. Following recovery from anesthesia, a brief questionnaire will be provided to applicable patients or their parents / guardians / representatives.
88877695|NCT03430206|Experimental|Intervention|Treatment subjects will undergo the scheduled procedure, with the difference being that a high-flow nasal cannula will be applied prior to the start of the procedure and removed following the procedure's conclusion. While applied, the cannula will deliver high- flow rate oxygen, air, or a mixture of variable oxygen concentration (21-100%) depending on the surgical conditions and requirements. The rate will be set at 1-2L/kg/min with a maximum of 70L/min. Participants in the treatment arm will then proceed to the recovery area as usual. Following recovery from anesthesia, a brief questionnaire will be provided to applicable patients or their parents / guardians / representatives.
88877696|NCT03433794|Placebo Comparator|Control|The control group spent 60 minutes on an online education session (Lilly for Better Health) directed at other health behaviors besides alcohol. The site provides practical tips on general well-being such as healthy eating, physical activity, and stress management, as well as provides information on managing health conditions such as diabetes, heart disease and depression. Their email 2 weeks later contained only a reminder to participate in follow-up surveys.
88877697|NCT03433794|Active Comparator|Intervention Only|Participants navigated through Alcohol 101 Plus (TM) for 60 minutes. This is an online intervention, free to institutions and individuals. It is a combination of several intervention components, including alcohol education, personalized feedback, attitude-focused strategies, and skills training. It also included a virtual bar, where participants provide basic information such as sex, weight, and state of residence so that the program can provide tailored information on blood alcohol content (BAC) as well as state regulations regarding legal limits. Their email 2 weeks later contained only a reminder to participate in follow-up surveys.
89402345|NCT01437722|Placebo Comparator|placebo gel|
89402346|NCT02263352|Experimental|Lycored soft gels , Scaling and Rootplaning.|Systemic Lycored soft gels,(Jagsonpal Pharma) was given orally 8mgms/day for 2 months and Scaling and rootplaning (otherwise known as conventional periodontal therapy, non-surgical periodontal therapy, or deep cleaning, is the process of removing or eliminating the etiologic agents - dental plaque, its products, and calculus) which was performed at baseline
89402347|NCT02263352|Experimental|Scaling and Rootplaning only.|Scaling and rootplaning(otherwise known as conventional periodontal therapy, non-surgical periodontal therapy, or deep cleaning, is the process of removing or eliminating the etiologic agents - dental plaque, its products, and calculus) which was performed at baseline.
89402348|NCT01435226|Active Comparator|Arm 1|GS-5885 90 mg QD + GS-9451 200 mg QD + tegobuvir 30 mg BID + RBV BID
89402349|NCT01435226|Active Comparator|Arm 2|GS-5885 90 mg QD + GS-9451 200 mg QD + tegobuvir 30 mg BID + RBV placebo BID
89402350|NCT01435226|Active Comparator|Arm 3|GS-5885 90 mg QD + GS-9451 200 mg QD + tegobuvir placebo BID + RBV BID
89402351|NCT01679002|Experimental|Group A|"BIA 2-093 900 mg once-daily period followed by BIA 2-093 450 mg twice-daily period followed by oxcarbazepine 450 mg twice-daily period~BIA 2-093 450 mg od - BIA 2-093 450 mg bid - OXC 900 mg bid"
89402352|NCT01679002|Experimental|Group B|"BIA 2-093 450 mg twice-daily period followed by oxcarbazepine 450 mg twice-daily period followed by BIA 2-093 900 mg once-daily period~BIA 2-093 450 mg bid - OXC 450 mg bid - BIA 2-093 900 mg od"
89402353|NCT01679002|Experimental|Group C|"oxcarbazepine 450 mg twice-daily period followed by BIA 2-093 900 mg once-daily period followed by BIA 2-093 450 mg twice-daily period~OXC 450 mg bid - BIA 2-093 900 mg od - BIA 2-093 450 mg bid"
89402354|NCT01428362|Experimental|Placebo/VI-1121|Subjects received placebo during first treatment period and active treatment with VI-1121 during the second treatment period.
88877698|NCT03433794|Experimental|Intervention-plus-Booster|Participants navigated through Alcohol 101 Plus (TM) for 60 minutes. This is an online intervention, free to institutions and individuals. It is a combination of several intervention components, including alcohol education, personalized feedback, attitude-focused strategies, and skills training. It also included a virtual bar, where participants provide basic information such as sex, weight, and state of residence so that the program can provide tailored information on blood alcohol content (BAC) as well as state regulations regarding legal limits. Importantly, their email 2 weeks later contained a reminder to participate in follow-up surveys, plus personalized feedback based on participant reported perceived alcohol norms, actual alcohol norms, and reported harm reduction strategies.
88877699|NCT03440424|Experimental|Cohort A: Mild Hepatic Impairment (Child Pugh Class A)|Participants with mild hepatic impairment will receive a single 10 milligram (mg) dose (1 × 10 mg lemborexant [E2006] tablet) in the morning with 240 milliliters (mL) of water following an overnight fast of at least 10 hours.
89402355|NCT01428362|Experimental|VI-1121/Placebo|Subjects received active treatment with VI-1121 during the first treatment period and placebo during the second treatment period.
89402356|NCT02261870|Experimental|ALL_patients|MRI T2 quantification : heart transplant patients will have 4-6 MRI exams for T2 quantification during their first year after transplantation.
89402357|NCT04409509|Experimental|CSL312|Garadacimab, Factor XIIa Antagonist Monoclonal Antibody administered intravenously
89402358|NCT04409509|Placebo Comparator|Placebo|CSL312 diluent administered intravenously
89402359|NCT02262104|Experimental|Intensive exercise|Intensive strengthening and balance exercises 1 hour twice a week 12 weeks. Lead by physiotherapists.
89402360|NCT02262104|Placebo Comparator|Control|Control group activities: Social activities one hour twice a week. Light physical activities, reading, conversation, games. Lead by occupational therapist or nursing staff
89402361|NCT02263430|Experimental|Deep Brain Stimulation|Stimulation is on.
88877700|NCT03440424|Experimental|Cohort B: Moderate Hepatic Impairment (Child Pugh Class B)|Participants with moderate hepatic impairment will receive a single 10 mg dose (1 × 10 mg lemborexant [E2006] tablet) in the morning with 240 mL of water following an overnight fast of at least 10 hours.
89004177|NCT01364168||First ever acute ischemic stroke|Patients over 18 years and without prior stroke according to WHO criteria, displaying an ischemic stroke, onset within the last 7 days, language German
89004178|NCT01309711||HIE|Moderate of severe neonatal encephalopathy
89402362|NCT02263430|Sham Comparator|Placebo|Stimulation is off.
89402363|NCT02610296|Active Comparator|QPI-1002|QPI-1002 Injection, single dose
89402364|NCT02610296|Placebo Comparator|Placebo|isotonic saline
89402365|NCT04401865|Experimental|Pulsed, Accelerated|5 mW, 10 sec on, 10 sec off, 24 minutes of illumination Intervention: PXL-330 Platinum device for crosslinking with Peschke riboflavin solution
89402366|NCT04401865|Active Comparator|Conventional|4 mW, 10 sec on, 10 sec off, 30 minutes of illumination Intervention: PXL-330 Platinum device for crosslinking with Peschke riboflavin solution
89402367|NCT02609048|Placebo Comparator|Placebo Dose|Placebo Capsule Two Capsules Daily
89402368|NCT02609048|Experimental|Seladelpar / MBX-8025 50 mg Dose|MBX-8025 50 mg capsule One Capsule Daily
89402369|NCT02609048|Experimental|Seladelpar / MBX-8025 200 mg Dose|MBX-8025 100 mg capsules (2 taken once daily)
89402370|NCT02262182|Experimental|KP group|PEP delivery by EzPAP® device with manual chest physiotherapy .
89402371|NCT02262182|Placebo Comparator|KM group|Manual chest physiotherapy only;
89402372|NCT02262338|Experimental|Treated subjects|AGT-182 solution for infusion will be administered intravenously at doses of 1.0 mg/kg or 3.0 mg/kg weekly for 8-13 weeks.
89402373|NCT01678924|Experimental|AGN-214868 Dose 1|AGN-214868 Dose 1 given as injections into the area of pain on Day 1.
89004181|NCT01089517|Active Comparator|Lucentis|
89004182|NCT01089517|Experimental|E10030 low dose plus Lucentis|
89004183|NCT01089517|Experimental|E10030 high dose plus Lucentis|
89004184|NCT00861367|Active Comparator|1|aspirin 100mg
89402374|NCT01678924|Experimental|AGN-214868 Dose 2|AGN-214868 Dose 2 given as injections into the area of pain on Day 1.
89402375|NCT01678924|Placebo Comparator|AGN-214868 Placebo (Vehicle)|AGN-214868 placebo (vehicle) given as injections into the area of pain on Day 1.
89402376|NCT01678924|Experimental|AGN-214868 Dose 3|AGN-214868 Dose 3 given as injections into the area of pain on Day 1.
89402377|NCT02265302|Experimental|BIIL 284 BS oral solution|
89402378|NCT02265302|Experimental|BIIL 284 BS WIF tablets|
89402379|NCT02265302|Placebo Comparator|Placebo|
89004185|NCT00861367|Placebo Comparator|2|empty capsule
89004186|NCT00667563|Experimental|Gardasil Vaccination|Vaccination with the Quadrivalent Human Papillomavirus Recombinant vaccine (0.5 mL Gardasil®) by intramuscular (IM) injection at Day 0, Weeks 8 and 24.
89004187|NCT00638898|Experimental|Arm I|See Detailed Description
89004188|NCT00626964||Lifestyle or bariatric surgery|Morbid Obesity with BMI >= 40 kg/m2 or BMI >= 35 with Comorbidity
89004189|NCT00585507|Experimental|single|fulvestrant 500mg
89004190|NCT00525720|Experimental|Brachytherapy - Participants with < 35% biopsy core|Brachytherapy implant procedure lasting 1-2 hours. Questionnaires taking 30 total minutes.
89004191|NCT00525720|Experimental|Brachytherapy - Participants with > 35% biopsy core|Brachytherapy implant procedure lasting 1-2 hours. Questionnaires taking 30 total minutes.
89004192|NCT00515372|Active Comparator|Intervention Group|Weekly phone calls lasting about 30 minutes. Lists of professional resources and referral recommendations will be provided.
89004193|NCT00515372|Other|Usual Care Group|Lists of professional resources and referral recommendations will be provided.
89004194|NCT00496522|Other|Proton Beam Therapy|Proton Beam Therapy - A total dose of up to 70 CGE given at 2.0 CGE per daily fraction for 35 fractions.
89402380|NCT02263742|Experimental|Peer whole health|Peer whole health intervention will be compared to the treatment as usual at Wellness Center to assess healthcare choice and outcomes
89402381|NCT02263742|Active Comparator|EBPs at Wellness Center|EBPs at Wellness Center will be the active comparative to measure healthcare choice and outcomes with the peer whole health intervention
89402382|NCT02265380|Experimental|Treatment with OptiVein|The patient will have an IV catheter placed with the use of OptiVein device.
89402383|NCT02265380|Active Comparator|Treatment with Vasofix Certo|The patient will have an IV catheter placed with the use of Vasofix Certo device.
89402384|NCT02262416|Placebo Comparator|controls|Normal saline of equivalent volume
89402385|NCT02262416|Active Comparator|case|0.5mg Leuprolide acetate injection
89402386|NCT01577654|Experimental|Arm A: EC145 alone|EC145 alone
89402387|NCT01577654|Experimental|Arm B: EC145 + Docetaxel|EC145 + Docetaxel
89402388|NCT01577654|Active Comparator|Arm C: Docetaxel alone|Docetaxel alone
89402389|NCT02608502|Experimental|Treatment Group A|RSV-F Vaccine (0.5mL Injection)
89402390|NCT02608502|Placebo Comparator|Treatment Group B|Phosphate Buffer Placebo (0.5mL Injection)
89402391|NCT02262494|Other|Suspected first episode of DVT|"The study population consists of patients presenting with suspected first episode of DVT at the Nîmes University Hospital.~Intervention: portable venous compression ultrasonography Intervention: venous compress ultrasonography Intervention: Doppler ultrasound of the lower limbs"
89535532|NCT02490761||Study cohort|Patients aged 65 years or over admitted to a geriatric ward in 2 hospitals for more than 3 days
88877701|NCT03440424|Experimental|Cohort C: Healthy Participants (Control)|Healthy participants matched to participants with hepatic impairment in Cohorts A and B (matched with regards to age, sex, body mass index [BMI]) will receive a single 10 mg dose (1 × 10 mg lemborexant [E2006] tablet) in the morning with 240 mL of water following an overnight fast of at least 10 hours.
88877702|NCT03444090|Experimental|Insertion/withdrawal colon polypectomy|For participants assigned in the experimental group, the colon is washed and the debris is suctioned as the colonoscopy is slowly inserted from rectum to cecum. Deliberate and systematic inspection of the mucosa is performed with adequate insufflation during both insertion and withdrawal phases.Colon polypectomy for polyp size <10 mm will be performed when they are identified during insertion and withdrawal of the colonoscope. Colon polypectomy for polyp size >10 mm will be performed only during withdrawal of the scope.
88877703|NCT03444090|Active Comparator|Withdrawal colon polypectomy|For participants assigned in the control group, deliberate mucosa inspection and colon polypectomy will be performed exclusively on colonoscopy withdrawal.During insertion, minimal mucosal inspection and insufflation are applied to efficiently advance the instrument into cecum.
88877704|NCT03448068|Experimental|Ketamine Therapy|"Ketamine 0.3 mg/kg (IBW) bolus with induction.~Ketamine infusion 0.2 mg/kg/hr. (IBW) initiated after induction and terminated after 24 hours.~Ketamine infusion will not be titrated.~Remaining care will be identical to standard therapy group."
88877705|NCT03448068|Active Comparator|Standard Therapy|"Calculation ideal body weight (IBW)~Pre-op dexamethasone~Pre-op midazolam at discretion of anesthesiologist~Anesthesia Induction - Propofol and fentanyl, anesthesiologist discretion. Neuromuscular block with succinylcholine and/or rocuronium at discretion of anesthesiologist. Orotracheal intubation.~Anesthesia Maintenance - Sevoflurane/rocuronium. Addl. doses of fentanyl, discretion of anesthesiologist.~Emergence from anesthesia - Acetaminophen, Ketorolac and Ondansetron unless contraindicated. Sugammadex depending on twitch response per drug manufacturer recommended protocol.~Post-Op Analgesia - Hydromorphone, acetaminophen and ketorolac~Other post-op care as per usual surgical routine"
88877706|NCT03453060|Experimental|E-WE Thrombin Dose 1|Participants will receive a single intravenous dose of 0.5 mcg/kg E-WE Thrombin.
88877707|NCT03453060|Experimental|E-WE Thrombin Dose 2|Participants will receive a single intravenous dose of 1.0 mcg/kg E-WE Thrombin.
88877708|NCT03453060|Experimental|E-WE Thrombin Dose 3|Participants will receive a single intravenous dose of 2.0 mcg/kg E-WE Thrombin.
88877709|NCT03453060|Experimental|E-WE Thrombin Dose 4|Participants will receive a single intravenous dose of 4.0 mcg/kg E-WE Thrombin.
88877710|NCT03453060|Placebo Comparator|Placebo|Participants will receive a single intravenous dose of placebo.
88877711|NCT03457116|Active Comparator|NSAIDS|400mg of Ibuprofen
88877712|NCT03457116|Active Comparator|Opiates|Norco (hydrocodone 5mg- acetaminophen 325mg)
88877713|NCT03459612|Placebo Comparator|Placebo|Placebo administered orally in one of four study periods.
88877714|NCT03459612|Experimental|100 milligrams (mg) Lasmiditan|100 mg lasmiditan administered orally in one of four study periods.
88877715|NCT03459612|Experimental|200 mg Lasmiditan|200 mg lasmiditan administered orally in one of four study periods.
88877716|NCT03459612|Active Comparator|Diphenhydramine|50 mg diphenhydramine administered orally in one of four study periods.
88877717|NCT03463512|Experimental|Racecadotril plus standard treatment oral rehydration solution|
88877718|NCT03463512|Active Comparator|ORS (standard treatment)|
88877719|NCT03467412|Experimental|0.00625 μg FOL-005|50 μl solution (a total dose of 0.00625 μg FOL-005) injected intradermally three times per week for 12 weeks.
88877720|NCT03467412|Experimental|0.025 μg FOL-005|50 μl solution (a total dose of 0.025 μg FOL-005) injected intradermally three times per week for 12 weeks.
88877721|NCT03467412|Experimental|0.050 μg FOL-005|50 μl solution (a total dose of 0.050 μg FOL-005) injected intradermally three times per week for 12 weeks.
88877722|NCT03467412|Experimental|0.100 μg FOL-005|50 μl solution (a total dose of 0.100 μg FOL-005) injected intradermally three times per week for 12 weeks.
88877723|NCT03467412|Placebo Comparator|Placebo|50 μl solution (placebo) injected intradermally three times per week for 12 weeks.
88877724|NCT03468816|Experimental|A-B-A|Investigational device is Absorbest moisture sensor in variant A and variant B, placed on the backside of the wound dressing DryMax Extra Soft. Participants performed three dressing changes. They first received variant A, at next dressing change they received variant B, and on the third dressing change they received variant A again. No washout periods.
88877725|NCT03468816|Experimental|B-A-B|Investigational device is Absorbest moisture sensor in variant A and variant B, placed on the backside of the wound dressing DryMax Extra Soft. Participants performed three dressing changes. They first received variant B, at next dressing change they received variant A, and on the third dressing change they received variant B again. No washout periods.
88877726|NCT03473184|Experimental|Single Cohort (Healthy Volunteers)|Single cohort received diacerein 1% ointment
88877727|NCT03473886|Experimental|Intervention Arm: PP-MI|Participants will complete an 8-week group physical activity and positive psychology program, in which they will complete exercises related to increasing positive emotions and physical activity during and between the group sessions. They will track their activity (steps) and set personalized physical activity goals each week, as complete a group walk or indoor exercise during the group sessions. We will ask questions about participants' health and health behaviors, and ask them to wear a physical activity monitor at the beginning and end of the program.
88877728|NCT03475992|Experimental|Pre-diagnosed breast cancer|"Low-power microwave breast imaging system.~Core needle biopsy performed ≥14 days before the microwave breast investigation"
88877729|NCT03475992|Experimental|Pre-diagnosed breast cyst|"Low-power microwave breast imaging system.~No prior biopsy"
88877730|NCT03475992|Experimental|Pre-diagnosed benign lesion|"Low-power microwave breast imaging system.~Core needle biopsy performed ≥14 days before the microwave breast investigation"
89402392|NCT02265458|Experimental|Musical intervention and sensory isolation|30 minutes musical intervention during NIV will be administrated, along with sensory isolation (mask obscuring the eyes)
89402393|NCT02265458|Active Comparator|Sensory isolation|Sensory isolation
89402394|NCT02265458|No Intervention|Standard of care|Standard of care
88877731|NCT03476850|Active Comparator|QL Block|Blocks will be performed under the supervision of a regional anesthesia attending experienced in the performance QL blocks. QL block will be performed using ropivacaine 0.375% 20ml each side for a total volume of 40cc.
89402395|NCT01423058|Experimental|Momelotinib|
89402396|NCT01575470|Experimental|bone marrow mononuclear cells|a bone marrow harvest will be performed within 36 hours of injury followed by a single intravenous infusion of autologous bone marrow mononuclear cells (BMMNCs)
89402397|NCT02236364|Experimental|New device for OPTICAL determination of blood glucose level|
89402398|NCT05735782||Case-Control|Case group: Participants with persistent symptoms post-COVID-19 more than12 weeks after COVID-19 acute infection Control group: Participants without persistent symptoms after a COVID-19 acute infection.
89402399|NCT03135392|Active Comparator|Breast Reconstruction with Artificial Implant|Participants undergoing unilateral reconstruction: patient will serve as internal control with contralateral breast and reconstructed breast will be compared to all other reconstructed breasts. Participants undergoing bilateral reconstruction: reconstructed breasts will be compared to all other reconstructed breasts
89402400|NCT03135392|Active Comparator|Autologous Breast Reconstruction without Neurotization|Participants undergoing autologous tissue (her own tissue from other areas of the body) reconstruction which do not have their nerves reconstructed during surgery
89402401|NCT03135392|Experimental|Autologous Breast Reconstruction with Neurotization|Participants undergoing autologous tissue (her own tissue from other areas of the body) reconstruction which have a nerve connected (neurotized) during surgery.
89402402|NCT02265536|Experimental|LY3022855 - 1.25 mg/kg Dose A|1.25 milligram per kilogram (mg/kg) LY3022855 administered intravenously (IV), once every two weeks. Treatment is 6 week cycle. Participants may receive multiple cycles if they are deriving clinical benefit.
89402403|NCT02265536|Experimental|LY3022855 - Dose B|LY3022855 administered IV. Participants may receive multiple cycles if they are deriving clinical benefit.
88877732|NCT03476850|Active Comparator|TAP Block|Blocks will be performed under the supervision of a regional anesthesia attending experienced in the performance TAP blocks. TAP block will be performed using ropivacaine 0.375% 20ml each side for a total volume of 40cc.
88877733|NCT03477006|Experimental|LTLR-WB|Receiving 2 units of low titer, leucocyte reduced, platelet replete whole blood initiated in the prehospital setting during air medical transport and continued (up to 6 units of whole blood followed by standard component resuscitation) thru the early in-hospital phase of care
88877734|NCT03477006|No Intervention|Standard Care|Receiving standard prehospital air medical care and standard of care component (1:1:1) trauma resuscitation thru the early in-hospital phase of care
89402404|NCT02265536|Experimental|LY3022855 - Dose C|LY3022855 administered IV. Participants may receive multiple cycles if they are deriving clinical benefit.
89402405|NCT02265536|Experimental|LY3022855 - Dose D|LY3022855 administered IV. Participants may receive multiple cycles if they are deriving clinical benefit.
89402406|NCT04413292||Group A|21 patients with lung cancer
89402407|NCT04413292||Group B|21 patients with various benign lung diseases
88877735|NCT03478254||Vaccination adherence|All type 1 diabetes adults patients attended in Ciudad Real General University Hospital willl be checked for Influenza Vaccination status, Pneumococcal Vaccination status and Hepatitis B Virus (HBV) status.
89402408|NCT04413292||Group C|Healthy controls
89402409|NCT04413292||Group D|15 patients with malignant pleural mesothelioma (MPM)
89402410|NCT04413292||Group E|16 patients having various benign pleural diseases
89402411|NCT01418222|Experimental|A|
89402412|NCT01418222|Active Comparator|B|
89402413|NCT05092906|Active Comparator|Lumbar puncture with standard of care|
89402414|NCT05092906|Experimental|Lumbar puncture with hypnosis add-on therapy|
89402415|NCT01413932|Experimental|HT-2157|
88877736|NCT03480048|Experimental|Breastfeeding and weight loss support|Participants receive a combination of in-person, phone, and online support for breastfeeding and postpartum weight management.
88877737|NCT03480048|No Intervention|Usual care|Participants receive usual care from their prenatal care provider.
88877738|NCT03485976|Experimental|Ixekizumab treatment arm|Ixekizumab 160 mg subcutaneous injection at week 0, followed by 80 mg subcutaneous injections at week 2, 4, 6, 8, 10, 12, 16, and 20
88877739|NCT03486990|Experimental|Part A, Cohort 1: 0.1 mg/kg|TIMP-GLIA 0.1 mg/kg, infusion, intravenously, once on Day 1.
88877740|NCT03486990|Experimental|Part A, Cohort 2: 0.5 mg/kg|TIMP-GLIA 0.5 mg/kg, infusion, intravenously, once on Day 1.
89402416|NCT01413932|Placebo Comparator|Placebo|
89402417|NCT02925793|Placebo Comparator|Vehicle Cream|Vehicle cream applied topically to all affected or commonly affected areas twice-daily for 8 weeks
89402418|NCT02925793|Experimental|1% DS107 Cream|1% DS107 cream applied topically to all affected or commonly affected areas twice-daily for 8 weeks
89402419|NCT02925793|Experimental|5% DS107 Cream|5% DS107 cream applied topically to all affected or commonly affected areas twice-daily for 8 weeks
89402420|NCT01256762|Experimental|Imetelstat + Paclitaxel (with or without bevacizumab)|
89402421|NCT01256762|Experimental|Paclitaxel (with or without bevacizumab) alone|
89402422|NCT03135158||Women in labor|All participants who have a vaginal delivery
89402423|NCT02268188|Experimental|Supportive Care (Harvesting Health program)|Participants undergo a series of 10 education and training sessions over 1 hour every 2 weeks, comprising education on current research, evidence-based health guidelines, application techniques, reference materials specific to extended-stage cancer survivors, and recommendations and personal health goals for survivorship. The guidelines described in class are part of a nutrition intervention and an exercise intervention with personal and group goal setting over the course of the study.
89402424|NCT04351945||Blood test|Patients will have a blood test to define hormone levels.
89402425|NCT05761717|Experimental|3+3|Neoantigen mRNA Personalised Cancer in combination with Stintilimab Injection. This study is a 3+3 dose escalation design.Participants will receive a total of 6 cycles of PCV every 21 days
89402426|NCT01252628|Experimental|PX-866 (SCCHN)|Phase 2 (Squamous Cell Carcinoma of the Head and Neck)
89402427|NCT01252628|Active Comparator|Cetuximab (SCCHN)|Phase 2 (Squamous Cell Carcinoma of the Head and Neck)
89402428|NCT01252628|Experimental|PX-866 (CRC)|Phase 2 (Colorectal Carcinoma)
89402429|NCT01252628|Active Comparator|Cetuximab (CRC)|Phase 2 (Colorectal Carcinoma)
89402430|NCT05206669|Experimental|Cancer Messages - Young Adults|Messages providing information about the use of HPV vaccines to prevent cancer.
89402431|NCT05206669|Experimental|Cancer Messages - Parents of Adolescents|Messages providing information about the use of HPV vaccines for their adolescent children to prevent cancer.
89402432|NCT05206669|Experimental|Genital Wart Messages - Young Adults|Messages providing information about the use of HPV vaccines to prevent genital warts.
88877741|NCT03486990|Experimental|Part A, Cohort 3: 1.0 mg/kg|TIMP-GLIA 1.0 mg/kg, infusion, intravenously, once on Day 1.
89402433|NCT05206669|Experimental|Genital Wart Messages - Parents of Adolescents|Messages providing information about the use of HPV vaccines or their adolescent children to prevent genital warts.
88877742|NCT03486990|Experimental|Part A, Cohort 4: 2.0 mg/kg|TIMP-GLIA 2.0 mg/kg, infusion, intravenously, once on Day 1.
88877743|NCT03486990|Experimental|Part A, Cohort 5: 4.0 mg/kg|TIMP-GLIA 4.0 mg/kg, infusion, intravenously, once on Day 1.
88877744|NCT03486990|Experimental|Part A, Cohort 6: 8.0 mg/kg|TIMP-GLIA 8.0 mg/kg, infusion, intravenously, once on Day 1.
89402434|NCT05206669|Active Comparator|Control Messages - Young Adults|Messages providing information about HPV vaccines that did not mention prevention of other diseases or conditions.
89402435|NCT05206669|Active Comparator|Control Messages - Parents of Adolescents|Messages providing information about HPV vaccines for their adolescent children that did not mention prevention of other diseases or conditions.
89402436|NCT01239758|Experimental|ACE-031 (Extension of cohort 1 from core study, A031-03)|
89402437|NCT01239758|Experimental|ACE-031 (Extension of cohort 2 from core study, A031-03)|
89402438|NCT01239758|Experimental|ACE-031 (Extension of cohort 3 from core study, A031-03)|
89402439|NCT05206045||Patients with Sezary syndrome|Adult patient with Sezary syndrome diagnosed between 1998 and 2020
89402440|NCT01236638|Experimental|Momelotinib|
88877745|NCT03486990|Experimental|Part B, Cohort 1: 2.0 mg/kg|TIMP-GLIA 2.0 mg/kg, infusion, intravenously, once on Days 1 and 8.
88877746|NCT03486990|Experimental|Part B, Cohort 2: 4.0 mg/kg|TIMP-GLIA 4.0 mg/kg, infusion, intravenously, once on Days 1 and 8.
88877747|NCT03486990|Experimental|Part B, Cohort 3: 8.0 mg/kg|TIMP-GLIA 8.0 mg/kg, infusion, intravenously, once on Days 1 and 8.
88877748|NCT03490110|Experimental|State regulation skill training|This arm utilizes a training system designed to strengthen goal-directed cognitive-emotional state regulation skills. The emphasis is on practice and active application of skills across a range of challenge contexts. Digital scenarios provide experiential learning opportunities, allowing Veterans to apply skills to tackle challenges that are calibrated to maximize learning. Coaches guide learning for successful application of skills to challenges in personal life.
88877749|NCT03490110|Active Comparator|Treatment-as-usual|In this arm, participants receive clinical care as usual in VA and other clinics.
88877750|NCT03495648|Experimental|Walking Group (Low Engagers)|Subjects will participate in a walking group led by a community organizer as a means to get to a local farmer's market. Low engagers are defined as those participants who walked to the market two or fewer times during the program.
88877751|NCT03495648|Experimental|Walking Group (High Engagers)|Subjects will participate in a walking group led by a community organizer as a means to get to a local farmer's market. High engagers are defined as those participants who walked to the market three or more times during the program.
88877752|NCT03496428|Other|Dental implant Impression Techniques|"Dental implant impressions- Different Techniques An customized impression coping will be created based on the provisional crown emergence profile which will be used to perform a silicone implant impression. A conventional cast will be created based on the silicone impression and an extra-oral scanner reading will be performed with a 3shape D2000.~An intra-oral scanner (Trios, 3Shape) will be used to scan the entire arch. The STL file created will be compared and tooth positions and soft tissues discrepancies will be determined"
89402441|NCT04349371|Experimental|CQ group|Participants will receive CQ supply for 3 months. Patients will receive a supply of 36 -- 250 mg tabs or placebo that will last 3 months (enough for taking two tabs of 250mg for every day for one week and then two tabs of 250mg for 1 day a week thereafter for study duration of 3 months). Subjects with severe GI intolerance can take 1 tablet of 250mg daily for the first week and 1 tablet per week for the remainder of the 3 month study duration. Patients will attend 1 in person visits (month 0) and an additional visit during month 3 if possible with the physician where they will be evaluated for safety assessments including vital signs, physical exams, blood collection, and assessment of endpoints. During month 1, 2, and 3 participants will be followed up regarding concomitant medications and adverse events over the phone call.
89402442|NCT04349371|Placebo Comparator|Placebo group|Participants will receive placebo supply for 3 months. Patients will attend 1 in person visits (month 0) and an additional visit during month 3 if possible with the physician where they will be evaluated for safety assessments including vital signs, physical exams, blood collection, and assessment of endpoints. During month 1, 2, and 3 participants will be followed up regarding concomitant medications and adverse events over the phone call.
89402443|NCT01410188|Experimental|OPA-6566 low dose|Treatment with OPA-6566 low dose
89402444|NCT01410188|Experimental|OPA-6566 medium dose|Treatment with OPA-6566 medium dose
89402445|NCT01410188|Experimental|OPA-6566 high dose|Treatment with OPA-6566 high dose
89402446|NCT01410188|Active Comparator|Latanoprost|Treatment with Latanoprost
89402447|NCT01410188|Placebo Comparator|Placebo|Placebo
89402448|NCT01410188|Experimental|OPA-6566 additional dose|Treatment with OPA-6566 additional dose
89402449|NCT01408082|Experimental|ISV-502|
89402450|NCT01408082|Active Comparator|AzaSite|
89402451|NCT01408082|Active Comparator|Dexamethasone|
89402452|NCT01408082|Placebo Comparator|Vehicle|
89402453|NCT03071263|Experimental|Group 1 - Patiromer|spironolactone + blinded patiromer
89402454|NCT03071263|Experimental|Group 2 - Placebo|spironolactone + blinded placebo
89402455|NCT04462484|No Intervention|Control group|No intervention
88877753|NCT03496974|Experimental|Group A: 200 mg cohort|The dose of bermekimab for Group A is 200 mg (2ml of the 100 mg/ml formulation)
88877754|NCT03496974|Experimental|Group B: 400 mg cohort|The dose of bermekimab for Group B is 400 mg (2ml of the 200 mg/ml formulation) administered weekly by subcutaneous injection
88877755|NCT03498300|Experimental|Experimental|A single dose of Tdap vaccine at GA 27 - 36 weeks
88877756|NCT03498300|No Intervention|Active comparator|dT vaccine as standard protocol
88877757|NCT03501264|Experimental|Intervention group|This group receives the game
88877758|NCT03501264|Active Comparator|Control Group|This group receives LGBTQ resources only
88877759|NCT03503292|Experimental|CYP2D6 rapid metabolizer|Participants with CYP2D6 rapid metabolizer status will received granisetron for for post operative nausea and vomiting prophylaxis and treatment
88877760|NCT03503292|Experimental|CYP2D6 normal metabolizer|Participants with CYP2D6 poor or normal metabolizer status will received 4mg ondansetron for post operative nausea and vomiting prophylaxis and treatment
88877761|NCT03506724|Other|Oral nifedipine|Oral medication 10mg and 20mg
88877762|NCT03506724|Other|Intravenous labetalol|intravenous medication 20mg, 40mg, 80 mg
88877763|NCT03507036|Experimental|Treatment|"All patients will undergo treatment with Profound system device. Using the radiofrequency and temperature setting within the FDA approved limits (460 +/- 5kHz and 65-75°C +/- 1°C), patients will be treated one time over the entire suprapatellar region bilaterally and followed for a 6 month period. The acute effect of the radiofrequency application will be determined by subjective and objective analysis using standard, close-up, 3D, cross-polarized, high resolution ultrasound, optical coherence tomography, transepidermal water loss measurements, and/or BTC 2000 measurements.~Biopsies will be taken using 0.33mm WellTech Rapid Core 0.33mm Biopsy Punch. Biopsies will allow investigators to correlate changes seen in skin measurements with histology and gene expression."
88877764|NCT03509766|Experimental|Skin testing|All subject both allergic and non-allergic will be tested. There is only one (1) arm.
89402456|NCT04462484|Experimental|Intervention group|Videoconference
89402457|NCT02268266|Other|Single-arm study|Early mobilization of patients after stroke or spinal cord injury. Monitoring of vital parameters during mobilization of healthy subjects
89402458|NCT01546532|Experimental|RLX030|RLX030 as intravenous infusion for 24 hours.
89402459|NCT01546532|Placebo Comparator|Placebo|Placebo as intravenous infusion for 24 hours.
89402460|NCT04314115|Active Comparator|Mindfulness|A brief intervention in mindfulness will be administered
89402461|NCT04314115|Active Comparator|Systemic therapy|A brief systemic therapy intervention will be administered
89402462|NCT04314115|Active Comparator|Cognitive behavioral therapy and positive psychology|A brief intervention of traditional cognitive behavioral therapy with positive psychology elements will be administered
89402463|NCT04314115|No Intervention|Waiting list|Waiting list, as a control group
89402464|NCT02265614|Experimental|PGS|blastocyst biopsy and chromosomal analysis
88877765|NCT03511638|Experimental|Bausch & Lomb DVisc40|Ophthalmic viscosurgical device
88877766|NCT03511638|Active Comparator|Alcon VISCOAT®|Ophthalmic viscosurgical device
88877767|NCT03519282|Experimental|Test Multifocal Toric Lens|comfilcon A multifocal toric lens
88877768|NCT03519282|Active Comparator|omafilcon A Multifocal Toric Lens|Control multifocal toric lens
88877769|NCT03520998|Experimental|GRF6019 Low Dose|Subjects will receive a low dose of GRF6019 for 5 consecutive days at Week 1 and Week 13.
88877770|NCT03520998|Experimental|GRF6019 High Dose|Subjects will receive a high dose of GRF6019 for 5 consecutive days at Week 1 and Week 13.
88877771|NCT03525210|Other|HIV patients|All HIV patients will receive the study vaccines
88877772|NCT03525210|Other|SOT patients|All SOT patients will receive the study vaccines
89402465|NCT02265614|No Intervention|control|regular IVF
89402466|NCT02263898|Experimental|Treatment (LGX818, MEK162)|Patients receive LGX818 PO QD and MEK162 PO BID continuously for 8 weeks followed by intermittent dosing in subsequent cycles (3 weeks off therapy, 5 weeks on therapy). Cycles repeat every 8 weeks in the absence of disease progression or unacceptable toxicity.
89402467|NCT01403636|Experimental|mantle cell|50 mg twice daily: no eating for 2 hours prior and 1 hour after dose
89402468|NCT01403636|Experimental|follicular lymphoma|50 mg twice daily: no eating for 2 hours prior and 1 hour after dose
89402469|NCT01403636|Experimental|CLL/SLL|50 mg twice daily:no eating for 2 hours prior and 1 hour after dose
89402470|NCT01403636|Experimental|Diffuse large B cell lymphoma|50 mg twice daily:no eating for 2 hours prior and 1 hour after dose
89402471|NCT03629509|Other|Pre-Intervention|"The BEFORE decision aid will be available for use on the RUBY communication portals (Twitter, Facebook and study portal)~Data will be collected 6 weeks before the implementation of the BEFORE decision aid in RUBY sites to establish a baseline"
89402472|NCT03629509|Experimental|BEFORE Decision Aid Intervention|"Evaluate more intensive strategies to promote use of the BEFORE decision aid through:~We will advertise the availability of the BEFORE decision aid with posters placed in clinic areas at each RUBY site, and will have small handouts available to be distributed in clinic.~We will conduct an educational intervention describing and promoting the use of the BEFORE decision aid and general oncofertility information to nurses and support staff at each RUBY site. This will include an optional 1hr informational webinar, direct outreach and training of nurses/support staff on the use of the tool."
88877773|NCT03532308|Experimental|Intervention|Daily Fermented Soy (two 12.5g packets/day) (~1 ounce/day) taken between the time of enrollment and radical prostatectomy (RP). Clinical assessment of both groups will take place 1) at baseline, and 2) just prior to RP, estimated at between 4 and 10 weeks from baseline/enrollment. Length of time in the study will vary for each subject, depending on how far out their prostatectomy will occur; all prostatectomies will be scheduled to occur between 4-10 weeks post-baseline.
88877774|NCT03532308|Placebo Comparator|Placebo|Daily (matched dose) taken between the time of enrollment and radical prostatectomy (RP). Clinical assessment of both groups will take place 1) at baseline, and 2) just prior to RP, estimated at between 4 and 10 weeks from baseline/enrollment. Length of time in the study will vary for each subject, depending on how far out their prostatectomy will occur; all prostatectomies will be scheduled to occur between 4-10 weeks post-baseline.
88877775|NCT03532776|Experimental|Podofilox Gel 0.5 %|Podofilox Gel 0.5% twice a day, three days following by four days of discontinuation, up to four cycles
88877776|NCT03532776|Active Comparator|Condylox Topical Gel 0.5%|Condylox Topical Gel 0.5% twice daily, three days following by four days of discontinuation, up to four cycles
88877777|NCT03532776|Placebo Comparator|Placebo Gel|Subjects in this arm will receive a vehicle that matches the test product, except for the inclusion of the active ingredient
88877778|NCT03533244|Placebo Comparator|Vehicle Eye Drops|One drop, three times daily to the study eye for 28 days
88877779|NCT03533244|Experimental|0.1% AG-86893 Eye Drops|One drop, three times daily to the study eye for 28 days
89189823|NCT05007964|Experimental|Spatz4 subjects|Subjects will be studied in an open label multi-center center study which will examine the usability of the adjustment process and success of the process. .
89189824|NCT04997187|Experimental|Bacillus coagulans group|This group takes Bacillus coagulans for 12 weeks.
88877780|NCT03533244|Experimental|0.3% AG-86893 Eye Drops|One drop, three times daily to the study eye for 28 days
88877781|NCT03541356|Placebo Comparator|Placebo|
88877782|NCT03541356|Active Comparator|L-dopa 35 mg|
88877783|NCT03541356|Active Comparator|L-dopa 70 mg|
88877784|NCT03541356|Active Comparator|L-dopa 140 mg|
88877785|NCT03541356|Active Comparator|L-dopa 70 mg/carbidopa 7 mg|
88877786|NCT03545412|Experimental|Microfocused ultrasound with visualization|
88877787|NCT03546270|Experimental|Swimming|Participants performed SWM training (combination of free style, breast stroke, and backstroke) for 20 weeks. For the first 5 weeks subjects swam 25-30 minutes/day, 3-4 days/week at ~60% of maximal heart rate. As their overall level of fitness and exercise skill improved, the intensity and duration of exercise increased to 40-45 minutes/day, 3-4 days/week at an intensity of 70-75% of the HRmax. Target HR was adjusted based on the observation that maximal heart rate during SWM is approximately 12 beats/min lower than that during running. Each subject was instructed to swim continuously except during the time needed for checking a target heart rate
88877788|NCT03546270|No Intervention|Control|Participants in the non-exercising control group did not participate in a supervised exercise program and visited the laboratory at the same frequency as participants in the swim intervention and underwent recreational activities such as board games
88877789|NCT03549234|Experimental|Erector Spinae (single injection)|
88877790|NCT03549234|Active Comparator|Paravertebral (single injection)|
88877791|NCT03557658|Experimental|Hepatic Impaired|Subjects with hepatic impairment conforming to the Child-Pugh class B (total score 7-9)
89004195|NCT00469339||cohort of Mexican-American households|cohort of Mexican-American households
89189825|NCT04997187|Placebo Comparator|Control group|This group takes placebo for 12 weeks.
88877792|NCT03557658|Experimental|Healthy Volunteer|Subjects with normal hepatic function
88877793|NCT03564444|Experimental|Bivalent influenza vaccine|A single dose of bivalent vaccine (10^7±5 fluorescent focus unit of 2 cold-adapted, attenuated, temperature-sensitive, 6:2 reassortant influenza strain) will be administered as intranasal spray on Day 1
88877794|NCT03564444|Placebo Comparator|Placebo|A single dose of placebo matched to bivalent influenza vaccine will be administered as intranasal spray on Day 1.
88877795|NCT03567252|Experimental|Walking Group|Participants in this group will join an established walking group and travel by foot 1 kilometer to a local Farmer's Market. They will also receive handouts about nutrition information and nutritional choices.
88877796|NCT03567252|No Intervention|Non-Walking Group|Participants in this group will have no walking requirement. They will receive handouts about nutrition information and nutritional choices.
88877797|NCT03569748|Experimental|IQOS|HEAT NOT BURN REDUCED RISK PRODUCT
88877798|NCT03569748|Active Comparator|E-CIG|ELECTRONIC CIGARETTE REDUCED RISK PRODUCT
88877799|NCT03572478|Experimental|Combination Therapy (Phase 1b Cohort)|Participants will receive rucaparib plus nivolumab in 4 week cycles.
88877800|NCT03572478|Experimental|Rucaparib (Phase 2b Randomized Cohort)|Participants randomized to receive rucaparib alone in 4 week cycles.
88877801|NCT03572478|Experimental|Nivolumab (Phase 2b Randomized Cohort)|Participants randomized to receive nivolumab alone in 4 week cycles.
88877802|NCT03572478|Experimental|Combination Therapy (Phase 2b Randomized Cohort)|Participants randomized to receive rucaparib plus nivolumab in 4 week cycles. Participants will receive rucaparib alone in cycle 1 and begin nivolumab on day 1 of Cycle 2.
89189826|NCT04992247|Experimental|COVI-MSC|Allogeneic culture-expanded adipose-derived mesenchymal stem cells (MSCs)
89189827|NCT04992247|Placebo Comparator|Placebo|Excipient
88877803|NCT03574818|Experimental|Arm 1|"Chemotherapy and Necitumumab Regimen Gemcitabine 1250mg/m2 IV over 30 minutes, days 1 and 8 following necitumumab, Cisplatin 75mg/m2 IV over 60 minutes, day 1, immediately following gemcitabine,each cycle is 3 weeks (21 days).~Necitumumab 800mg absolute dose IV over a minimum of 60 minutes, days 1 and 8 prior to chemotherapy regimen Each cycle is 3 weeks (21 days).~The regimen will be given for a total of 3 cycles.~The regimen will be given for a total of 3 cycles."
88877804|NCT03575754|Experimental|Interventional|This arm utilizes the investigational device, as specified in protocol.
88877805|NCT03593538|Experimental|Low Dose Metformin|Days 1-7: Metformin 500 mg per day; Days 8-14: Metformin 500 mg and 1 Placebo capsule per day; Days 15-23: Metformin 500 mg and 2 Placebo capsules per day
88877806|NCT03593538|Experimental|High Dose Metformin|Days 1-7: Metformin 500 mg per day; Days 8-14: Metformin 1000 mg per day; Days 15-23: Metformin 1500 mg per day
89189828|NCT04986501|Experimental|MucoPEG|Arm being compared to against Biotene
88877807|NCT03593538|Placebo Comparator|Placebo|Days 1-7: 1 Placebo capsule per day; Days 8-14: 2 Placebo capsules per day; Days 15-23: 3 Placebo capsules per day
88877808|NCT03610464|Experimental|Study patients (AMPH EROS)|All patients treated with extended-release oral suspension (AMPH EROS) that contains 2.5 mg/mL amphetamine base
88877809|NCT03613818|Experimental|eCHECKUP TO GO|Brief, web-based alcohol intervention
88877810|NCT03613818|No Intervention|Control|Assessment only
89189829|NCT04986501|Active Comparator|Biotene|Arm being compared against MucoPEG
89189830|NCT04982913|Experimental|Single dose of HEC116094（Part A, Cohort 1）|Healthy subjects receive sinele dose of HEC116094
89189831|NCT04982913|Experimental|Single dose of HEC116094（Part A, Cohort 2）|Healthy subjects receive sinele dose of HEC116094 or matching placebo
89189832|NCT04982913|Experimental|Single dose of HEC116094（Part A, Cohort 3）|Healthy subjects receive sinele dose of HEC116094 or matching placebo
89189833|NCT04982913|Experimental|Single dose of HEC116094（Part A, Cohort 4，Fed/Fasting）|Following an overnight fast of at least 10 hours, a single dose of HEC116094 will be administered on 2 separate occasions (fasting and after meal) in a randomized crossover fashion with different food restrictions.
89189834|NCT04982913|Experimental|Single dose of HEC116094（Part A, Cohort 5）|Healthy subjects receive sinele dose of HEC116094 or matching placebo
89189835|NCT04982913|Experimental|Single dose of HEC116094（Part A, Cohort 6）|Healthy subjects receive sinele dose of HEC116094 or matching placebo
89189836|NCT04982913|Experimental|Single dose of HEC116094（Part A, Cohort 7）|Healthy subjects receive sinele dose of HEC116094 or matching placebo
89189837|NCT04982913|Experimental|Mulltiple doses HEC116094（ Part B, Cohort 1）|Healthy subjects receive multiple doses of HEC116094 or matching placebo
89189838|NCT04982913|Experimental|Mulltiple doses HEC116094（ Part B, Cohort 2）|Healthy subjects receive multiple doses of HEC116094 or matching placebo
89189839|NCT04982913|Experimental|Mulltiple doses HEC116094（ Part B, Cohort 3）|Healthy subjects receive multiple doses of HEC116094 or matching placebo
89189840|NCT04982913|Experimental|Mulltiple doses HEC116094（ Part B, Cohort 4）|Healthy subjects receive multiple doses of HEC116094 or matching placebo
88877811|NCT03614130|Other|LID011121 (OD) / Biofinity (OS)|LID011121 contact lens worn in the right eye, with comfilcon A contact lens worn in the left eye, as randomized, for approximately 6 nights of extended (overnight) wear
88877812|NCT03614130|Other|Biofinity (OD) / LID011121 (OS)|Comfilcon A contact lens worn in the right eye, with LID011121 contact lens worn in the left eye, as randomized, for approximately 6 nights of extended (overnight) wear
88877813|NCT03618030|Experimental|Active Treatment|PRC-063 25, 35, 45, 55, 70, 85, or 100 mg
89004196|NCT00350129||1|healthy vasospastic subjects
88877814|NCT03618030|Placebo Comparator|Placebo Treatment|Matched placebo
89189841|NCT04982913|Experimental|The interaction with Oseltamivir of HEC116094（ Part C）|Healthy subjects received HEC116094 in cycle 1, Oseltamivir in cycle 2, and a combination of HEC116094 and Oseltamivir in cycle 3.There are washout periods between the first cycle and the second cycle and between the second cycle and the third cycle
89189842|NCT04981899|Experimental|Main arm|"Patients will receive 6 cycles of nivolumab at the fixed dose of 40 mg, with subsequent assessment of response by PET-CT. Patients with CR will proceed to ASCT.~Patients with <CR after nivolumab monotherapy will be treated with 2 cycles of a combination of nivolumab at the fixed dose 40 mg, ifosfamide, carboplatin and etoposide (NICE-40), with subsequent PET-CT assessment."
89189843|NCT04956887|Experimental|Intervention|The study intervention, AKL-T01 (Akili Interactive), is a digital, app-based intervention designed to target and improve cognition through an engaging video game-based software experience delivered on an iPad.
88877815|NCT03619590||Exposure Group|Pregnant women who were exposed to Twinrix within 28 days prior to conception or at any time during pregnancy. Reporting of exposed pregnancies is voluntary and prospective.
89004197|NCT00350129||2|healthy non-vasospastic subjects
89402473|NCT03629509|Other|Post-Intervention|Data will be collected after the BEFORE decision aid has been implemented in each RUBY site regarding the recommendation of fertility resources, most useful/least useful tool, and use of the BEFORE decision aid.
89402474|NCT05200663|Experimental|"Tamoxifen"|Group A patients will receive tab tamoxifen 10 mg twice a day for total of six months.
89402475|NCT05200663|Active Comparator|"Tamoxifen and Antioxidant"|Group B patients will receive tab tamoxifen 10 mg twice a day and cap. vit E 400mg once a day for total of six months.
89402476|NCT02268344|Active Comparator|Grass SD9 Stimulator|Brief intraoperative electrical stimulation of the spinal accessory nerve (ESSAN) continuously at 20 Hz, 10-15V for 60 minutes immediately following neck dissection.
89402477|NCT02268344|No Intervention|No Stimulation|No stimulation will be performed in this group, and patients will simply have the neck dissection as planned. No sham stimulation is required, as all outcome measures are performed by individuals not present in the operating room, and therefore, blinded to the treatment arm.
88877816|NCT03623334|Experimental|Dose Level A: IGRT 3.33Gy x 15 Fractions|Image-guided radiation therapy (IGRT) dose of 3.33Gy for 15 fractions (total dose = 50 Gy) which is given over the course of about 3 weeks
88877817|NCT03623334|Experimental|Dose Level B: IGRT 3.67Gy x 15 Fractions|Image-guided radiation therapy (IGRT) dose of 3.67Gy for 15 fractions (total dose = 55 Gy) which is given over the course of about 3 weeks
89004198|NCT00001532||1|Subjects with pulmonary disease or possible pulmonary disease and Relatives
89402478|NCT05758519|Experimental|QLS1128|
89402479|NCT05758519|Placebo Comparator|Placebo|
89402480|NCT02268422|Experimental|7 day patch|Buprenorphine transdermal system (BTDS) 2nd generation
89402481|NCT02268422|Active Comparator|7 Day Patch|1st Generation BTDS: Butrans
89402482|NCT01522196|Active Comparator|Varespladib|48 hour continuous infusion delivered intravenously (IV)
89402483|NCT01522196|Placebo Comparator|Placebo|48 hour continuous infusion delivered intravenously (IV)
89402484|NCT01236404|Experimental|PB1023 Injection|Subcutaneous injection PB1023
89402485|NCT01236404|Placebo Comparator|Placebo (0.9% Sodium Chloride Injection)|Subcutaneous Injection Placebo
89402486|NCT02268578|Active Comparator|Transcranial Direct Current Stimulation|Subjects will receive a total of 5 sessions on consecutive days. During each session, 2 mA of tDCS will be applied for 20 minutes over the left DLPFC (active or sham). The electrodes will have the size of 35cm2 each. Direct current will be transferred by a saline-soaked pair of surface sponge electrodes and delivered b y a specially developed, battery driven, constant current stimulator with a maximum output of 2mA.
89402487|NCT02268578|Sham Comparator|Sham TDCS|For sham-controlled tDCS subjects, the same montage will be used; however current will be applied for only 30 seconds - this is a reliable method of sham stimulation as sensations arising from tDCS treatment occur only at the beginning of application as also demonstrated by a randomized study (Gandiga et al. 2006).
88877818|NCT03623334|Experimental|Dose Level C: IGRT 4.00Gy x 15 Fractions|Image-guided radiation therapy (IGRT) dose of 3.67Gy for 15 fractions (total dose = 60 Gy) which is given over the course of about 3 weeks
88877819|NCT03630198|Active Comparator|Corticosteroid with lidocaine|This arm will include an injection mixture of corticosteroid and lidocaine
88877820|NCT03630198|Experimental|Corticosteroid with normal saline|This arm will include a mixture of corticosteroid and normal saline. The purpose of normal saline is to keep the volume and concentration similar when compared to the injections containing lidocaine.
88877821|NCT03633084|Experimental|RBM-007 Injectable Solution - 0.2 mg|No additional information.
88877822|NCT03633084|Experimental|RBM-007 Injectable Solution - 1.0 mg|No additional information.
88877823|NCT03633084|Experimental|RBM-007 Injectable Solution - 2.0 mg|No additional information.
88877824|NCT03637296|Experimental|Critical time intervention|Individuals who receive intensive care management during and following discharge from the inpatient medical unit.
89004199|NCT00001532||2|Healthy
89402488|NCT04220671|Experimental|Intervention|Standard dose measles vaccine, 0.5 ml
89402489|NCT04220671|Placebo Comparator|Control|Saline injection, 0.5 ml
89402490|NCT01400594|Experimental|HTU-520 Patch|Subjects will receive HTU-520 patch in a 1:1 ratio for 48 weeks applied to all toenails.
89402491|NCT01400594|Placebo Comparator|Placebo Patch|Subjects will receive placebo patch in a 1:1 ratio for 48 weeks applied to all toenails.
89402492|NCT05049343|Experimental|SAGE-904 then Placebo|SAGE-904 in combination with ketamine, followed by a washout period, followed by placebo in combination with ketamine.
89402493|NCT05049343|Placebo Comparator|Placebo then SAGE-904|Placebo in combination with ketamine, followed by a washout period, followed by SAGE-904 in combination with ketamine.
88877825|NCT03637296|No Intervention|Treatment as usual|Individuals who receive routine care management during and following discharge from the inpatient medical unit.
89402494|NCT01569919|Experimental|TroVax®|In this single-arm study, all participants will receive 9 injections of the TroVax® vaccine, plus standard cisplatin and pemetrexed chemotherapy.
89402495|NCT05205187||Healthy group|Healthy people in the community.
89402496|NCT05205187||Non-Borrmann IV group|Patients with Borrmann types I, II and III gastric cancer.
88877826|NCT03637842|Active Comparator|Lorcaserin XR|Lorcaserin XR 20mg daily
88877827|NCT03637842|Placebo Comparator|Placebo|Placebo Oral Capsule
88877828|NCT03638622|Experimental|Aminolevulinic acid (ALA) and Photodynamic Therapy (PDT)|Aminolevulinic Acid (ALA) administration, Photodynamic Therapy (PDT) treatment using LED (Light-emitting diode) light source and follow-up.
88877829|NCT03643692|Experimental|ARISES|Observational study using wearable technologies to collect data and evaluate blood glucose correlations against physiological and environmental case parameters. Useful associations will assist the development of the CBR/machine learning algorithm and identify wearable devices for the final ARISES platform.
88877830|NCT03645954|Active Comparator|Femoral Nerve Block|The femoral nerve block will be performed under the ultrasound guidance by a single injection of local anesthetic around all the femoral nerve branches inside the proximal part of the femoral triangle.
88877831|NCT03645954|Active Comparator|Femoral Triangle & Adductor Canal Blocks|"These two blocks will be performed together.~Firstly, the femoral triangle block will be performed under the ultrasound guidance by a single injection of local anesthetic at the level where the medial border of the sartorius muscle intersects the medial border of the adductor longus muscle. Local anesthetic will be injected laterally to the femoral artery.~Secondly, the adductor canal block will be performed under the ultrasound guidance by a single injection of local anesthetic at the level where the femoral vessels (artery and vein) dive deeper from the sartorius muscle. Local anesthetic will be injected under the femoral artery."
88877832|NCT03647046|Experimental|Customized Scleral Lens|A customized scleral lens will be compared with a non-customized scleral lens in subjects with Keratoconus through vision tests.
88877833|NCT03649932|Experimental|L-citrulline 100 mg/kg/day|50 mg/kg given two times a day (100 mg/kg/day) for total 7 days.
88877834|NCT03649932|Experimental|L-citrulline 200 mg/kg/day|100 mg/kg given two times a day (200 mg/kg/day) for total 7 days
88877835|NCT03649932|Experimental|L-citrulline 300 mg/kg/day|150 mg/kg given two times a day (300 mg/kg/day) for total 7 days.
88877836|NCT03655080|Experimental|nab-Paclitaxel and Radiation Therapy|"10 fractions of 3Gy radiation therapy will be delivered.~A total of 4 chemoradiation blocks should be delivered ideally in consecutive days~On day 1 of the chemoradiation block, nab-paclitaxel is delivered in the morning followed by radiotherapy the latest possible and ideally at least 6 hours later (no earlier than 4 hours after the start of nab-paclitaxel)~On day 2, radiotherapy is delivered in the morning, ideally within 24 hours from the start of nab-Paclitaxel infusion the previous day~There will be 2 radiation fractions that won't be part of any chemoradiation block and can be placed anywhere before, after, or between blocks"
88877837|NCT03663816|Experimental|Healthy men and women|Participants will serve as their own control. Balance and gait measures will be collected during an initial visit and after one week of using the experimental foot device
88877838|NCT03669354||Cohort SMT|Initiation in 2013 of long-term management with SMT, and no OAT for 12 months after initiating SMT
88877839|NCT03669354||Cohort OAT|Initiation in 2013 of long-term management with OAT, and no SMT for 12 months after initiating OAT
88877840|NCT03669354||Cohort SMTX|Any occurrence of SMT for cLBP in 2013, followed by initiation in 2013 of long-term management with OAT
89402497|NCT05205187||Borrmann IV group|Patients with Borrmann type IV gastric cancer.
89402498|NCT01399580|Placebo Comparator|Group A - Placebo QD|
89402499|NCT01399580|Active Comparator|Group B - Low dose Atrasentan QD|
88877841|NCT03669354||Cohort OATX|Any occurrence of OAT for cLBP in 2013, followed by initiation in 2013 of long-term management with SMT
88877842|NCT03674970|Experimental|Random Nicotine Delivery|One 0 mg or 4 mg nicotine film every 3-4 hours for a total of four films per day (not to exceed three non-consecutive 4 mg films in one day) for 6 weeks.
89402500|NCT01399580|Active Comparator|Group C - High dose Atrasentan QD|
89402501|NCT04069585|Experimental|RHA® Redensity with new anesthetic agent|"Split-face injection of RHA® Redensity with new anesthetic agent in the perioral rhytids on one side of the mouth and RHA® Redensity with lidocaine in the perioral rhytids in the other side of the mouth.~Up to 3 mL injected per side."
88877843|NCT03674970|Active Comparator|Steady State Nicotine Delivery|One 2 mg nicotine film every 3-4 hours for a total of four films per day for 6 weeks.
88877844|NCT03674970|Placebo Comparator|Placebo Control|One 0 mg nicotine film every 3-4 hours for a total of four films per day for 6 weeks.
88877845|NCT03679494|Experimental|SDM intervention group|Using shared decision making support tool for intervention
88877846|NCT03679494|No Intervention|Usual care group|No intervention, just continue using usual care
89402502|NCT04069585|Experimental|RHA® Redensity with lidocaine|"Split-face injection of RHA® Redensity with lidocaine in the perioral rhytids on one side of the mouth and RHA® Redensity with new anesthetic agent in the perioral rhytids in the other side of the mouth.~Up to 3 mL injected per side."
89402503|NCT03969433|Experimental|Phase I|Data collections are performed with TMSi Porti system and CTG (reference)
88877847|NCT03685968|Experimental|Glidescope AVL|
88877848|NCT03685968|Experimental|King Vision Channeled VL|
88877849|NCT03685968|Experimental|King Vision Non-Channeled (Standard) VL|
88877850|NCT03687450|Experimental|Intervention (Yoga) Arm|Received a weekly 60-minute yoga-based class over 6 weeks with direction for a 5-10 minute daily home practice.
89402504|NCT03969433|Experimental|Phases II-III-IV|Data collections are performed with the Bloomlife sensor and CTG (reference)
89402505|NCT00157196|Experimental|Tecemotide(L-BLP25)+Cyclophosphomide+best standard of care|
89535533|NCT05010057|Experimental|New Zealand blackcurrants (NZBC)|1 NZBC capsule (containing 300 mg active cassis containing 105 mg of anthocyanins, i.e. 35-50 % delphinidin-3-rutinoside, 5-20 % delphinidin-3-glucoside, 30-45 % cyanidin-3-rutinoside, 3-10 % cyanidin-3-glucoside), consumed in the morning, for 12 days.
89402506|NCT03066193|Experimental|Dronabinol and Palmitoylethanolamide|All participants will be titrated up on Dronabinol dose during the first week of the trial (2.5mg Dronabinol for 3 days and then 5mg Dronabinol for 4 days increasing to 10mg Dronabinol for the remainder of the trial). Dronabinol will only be increased to 10mg at the week 1 assessment if the subject is tolerating the 5mg dose of Dronabinol and the Dronabinol may be reduced based on patient side-effects. All participants will receive two 400mg tablets of PEA daily for the same 12 weeks that they receive the Dronabinol.
89402507|NCT02265926|Experimental|N95|Intervention: N95 mask material
89402508|NCT03922321|Experimental|RVT-1401|RVT-1401 680 milligrams (mg) weekly for two weeks followed by 340 mg weekly for four weeks, administered subcutaneously
89402509|NCT02263976|Experimental|BEA 2180 BR|single rising doses
89402510|NCT02263976|Placebo Comparator|Placebo|
89402511|NCT02263976|Experimental|Sub-Study|
89402512|NCT02264054|Experimental|[14C]talsaclidine, oral|single dose of 20 mg oral solution
89402513|NCT02264054|Active Comparator|[14C]talsaclidine, iv|single dose of 20 mg intravenous (iv) infusion
89402514|NCT01503944|Other|Dementia with Lewy Bodies|
89402515|NCT01503944|Other|Parkinson's disease|
89402516|NCT01503944|Other|Healthy Elderly Volunteers|
89402517|NCT01503944|Other|Alzheimer's Disease|
89402518|NCT01382654|Experimental|epinastine 0.1%|nasal spray 2 sprays to each nostril for a total of 3 doses
88877851|NCT03687450|No Intervention|No-treatment Control Arm|Waitlist control-- group received one session of yoga-based class at the completion of the study.
88877852|NCT03687684|Experimental|Japanese Cohort 1-A; TAK-831 100 mg + TAK-831 300 mg|TAK-831 100 milligrams (mg), tablets, orally, once daily on Day 1, followed by TAK-831 300 mg, tablets, orally, once daily on Day 9 in healthy Japanese participants.
88877853|NCT03687684|Experimental|Japanese Cohort 1-B; TAK-831 100 mg + Placebo|TAK-831 100 mg, tablets, orally, once daily on Day 1 followed by TAK-831 matching placebo, tablets, orally, once daily on Day 9 in healthy Japanese participants.
88877854|NCT03687684|Experimental|Japanese Cohort 1-C; Placebo + TAK-831 300 mg|TAK-831 matching placebo, tablets, orally, once daily on Day 1 followed by TAK-831 300 mg, tablets, orally, once daily on Day 9 in healthy Japanese participants.
88877855|NCT03687684|Experimental|Japanese Cohort 2; TAK-831 300 mg|TAK-831 300 mg or TAK-831 matching placebo, tablets, orally, once daily on Day 1 followed by TAK-831 300 mg or TAK-831 matching placebo, tablets, orally, once daily from Day 4 to Day 17 in healthy Japanese participants.
88877856|NCT03687684|Experimental|Chinese Cohort 3; TAK-831 600 mg|TAK-831 600 mg or TAK-831 matching placebo, tablets, orally, once daily on Day 1 followed by TAK-831 600 mg or TAK-831 matching placebo, tablets, orally, once daily from Day 4 to Day 17 in healthy Chinese participants. This cohort is optional and will be decided to run based on the data of Cohorts 1 and 2. The dose will be defined based on the result of Cohort 1 or Cohort 2.
88877857|NCT03687684|Experimental|Japanese Cohort 4; TAK-831 600 mg|TAK-831 600 mg or TAK-831 matching placebo, tablets, orally, once daily on Day 1 followed by TAK-831 600 mg or TAK-831 matching placebo, tablets, orally, once daily from Day 4 to Day 17 in healthy Japanese participants. This cohort is optional and will be decided to run based on the data of Cohorts 1 and 2. The dose will be defined based on the result of Cohort 1 or Cohort 2.
89402519|NCT01382654|Experimental|epinastine 0.1% with taste masking agent|nasal spray 2 sprays to each nostril for a total of 3 doses
89402520|NCT01382654|Experimental|epinastine 0.2%|nasal spray 2 sprays to each nostril for a total of 3 doses
89402521|NCT01382654|Experimental|epinastine 0.2% with taste masking agent|nasal spray 2 sprays to each nostril for a total of 3 doses
89402522|NCT01382654|Active Comparator|azelastine 0.1%|nasal spray 2 sprays in each nostril for a total of 3 doses
88877858|NCT03687684|Experimental|Japanese Cohort 5; TAK-831|TAK-831 50 mg or TAK-831 matching placebo, tablets, orally, once daily on Day 1 followed by TAK-831 50 mg or TAK-831 matching placebo, tablets, orally, once daily from Day 4 to Day 17 in healthy Japanese participants.
89189844|NCT04956887|Placebo Comparator|Placebo|Patients assigned to the control group will receive no intervention, as is typical for those with Covid-19 with respect to cognitive functioning.
89402523|NCT01378676|Placebo Comparator|Matching Placebo|
89402524|NCT01378676|Experimental|Active Drug Low Dose (CK-2017357 125 mg)|
89402525|NCT01378676|Experimental|Active Drug Mid Dose (CK-2017357 250 mg)|
89402526|NCT01378676|Experimental|Active Drug High Dose (CK-2017357 375 mg)|
89402527|NCT01377662|Placebo Comparator|Placebo|
89402528|NCT01377662|Experimental|OND-PR002 and MPh-IR|
89402529|NCT01371578|Experimental|Arm 2|"AM Dosing: One GS-5885 30 mg tablet, two GS-9451 100 mg tablets, orally with RBV and with food.~PM Dosing: RBV with food.~PEG, 180 µg, will be administered weekly by subcutaneous injection for the specified period of time (see Study Design). Pegasys® prefilled syringes (Hoffman-La Roche) will be supplied by Gilead Sciences."
89402530|NCT02268734||Sporadic Medullary Thyroid Cancer|Patients with diagnosis of locally relapsed and or metastatic sporadic MTC surgically treated (total thyroidectomy)
89402531|NCT01225640|Experimental|PNU-100480 600 mg BID|
89402532|NCT01225640|Experimental|PNU-100480 1200 mg QD|
89402533|NCT01225640|Active Comparator|RHZE|conjugated tablet with 4 drug combination of RHZE, Rifafour® e275 will be used in countries where can be sourced locally
89402534|NCT01208168|Experimental|Active drug|
89402535|NCT01208168|Placebo Comparator|Vehicle alone|
89402536|NCT01677910|Experimental|250 mg Telotristat Etiprate|Following a 3 to 4-week run-in period on stable-dose somatostatin analog (SSA) therapy (octreotide or lanreotide) participants were randomized to receive one 250 mg telotristat etiprate tablet plus one placebo-matching telotristat etiprate tablet administered three times daily for 12 Weeks in the double-blind treatment period, followed by a 36 week open-label extension period.
89402537|NCT01677910|Experimental|500 mg Telotristat Etiprate|Following a 3 to 4-week run-in period on stable-dose SSA therapy (octreotide or lanreotide) participants were randomized to receive, one telotristat etiprate 250 mg plus one placebo-matching telotristat etiprate tablet administered 3 times daily for 1 week, followed by two telotristat etiprate (250 mg) tablets administered three times daily for 11 weeks in the double-blind treatment period, followed by a 36 week open-label extension period.
89535534|NCT05010057|Placebo Comparator|Placebo (PLA)|1 placebo capsule (containing 300 mg microcrystalline cellulose M102), consumed in the morning, for 12 days.
89189845|NCT04955600||elderly patients with multimorbidity, relatives, health care personal|The care team consists of four nurses, two of whom are employed by the region and two by the municipality, 20 municipally employed assistant nurses and one physician. Other professions associated with the team are psychologist, dietitian, pharmacist, counsellor, physiotherapist, occupational therapist, and family consultants. All participants in the team will be invited to participate in the study. The technology will be place in 20-25 patients' home and patients and family members will be invited to participate in the study. Self-care education will be given to the patients and family members according to the middle-range theory of self-care of chronic illness.
89189846|NCT04955587||Patients with longstanding complicated fatigue|The participants receive no intervention as part of this study.
89189847|NCT04955587||Healthy controls|The participants receive no intervention as part of this study.
89189848|NCT04955587||Controls with rheumatic disease|The participants receive no intervention as part of this study.
89402538|NCT01677910|Placebo Comparator|Placebo|Following a 3 to 4-week run-in period on stable-dose SSA therapy (octreotide or lanreotide) participants were randomized to receive two placebo-matching telotristat etiprate tablets administered three times daily for 12 weeks in the double-blind treatment period, followed by a 36 week open-label extension period.
89402539|NCT01677910|Experimental|Telotristat Etiprate Open-Label Extension|Patients previously assigned to 250 mg or 500 mg three times daily of telotristat etiprate were administered two 250 mg telotristat etiprate tablets three times daily in a 36 week open-label extension (OLE) period. Patients previously assigned to placebo were administered one 250 mg telotristat etiprate tablet plus one placebo-matching tablet three times daily for one week, followed by two 250 mg telotristat etiprate tablets three times daily for 35 weeks.
89402540|NCT01499420|Experimental|CSL112|
88813259|NCT03210038|Active Comparator|Flexible cystoscopy, water based gel on introitus|Flexible cystoscopy, Olympus 16FR. Pad soaked with water based gel put on introitus for 5 minutes prior to procedure.
88813260|NCT03210038|Active Comparator|Flexible cystoscopy, Esracain gel based on introitus|Flexible cystoscopy, Olympus 16FR. Pad soaked with Esracain (Lidocaine) put on the introitus for 5 minutes prior to procedure.
88813261|NCT02472756||Follicular Lymphoma Participants|Previously treated adult participants with relapsed/refractory FL will receive rituximab in combination with chemotherapy regimen. All treatments prescribed during the observation period will be at the treating physician's discretion. Participants will be followed up for safety and efficacy evaluation in accordance with routine practice, up to 30 months.
88813262|NCT01837940|Placebo Comparator|Placebo|
88813263|NCT01837940|Active Comparator|dietary supplement|Lactobacillus reuteri DSM 17938
88813264|NCT01464359|Experimental|Patients with Acute Myelogenous Leukemia|Patients with chemotherapy refractory Acute Myelogenous Leukemia (AML) after a double T-cell depleted (TCD) umbilical cord blood (UCB) transplantation where the smaller unit is activated overnight in interleukin-2 (IL-2). IL-2 will be given three times weekly for 6 doses beginning on days+3 and days +60 to expand UCB-derived natural killer (NK) cells in vivo.
88813265|NCT01838018||PKAN|This group consists of individuals diagnosed with PKAN using a combination of MRI and PANK2 gene sequencing.
88813266|NCT01838018||Healthy volunteers|This is a control group of healthy volunteers, matched with the PKAN group for age and sex.
88813267|NCT03210740|Experimental|AM001 Cream, 7.5%|A white to off-white Cream free from any foreign particles
88813268|NCT03210740|Placebo Comparator|Vehicle Cream|A white to off-white Cream free from any foreign particles
88813269|NCT05564897|Experimental|Combination of H101 with Camrelizumab treatment|Patients receive a combination therapy of PD-1 inhibitor Camrelizumab with oncolytic adenovirus H101 for up to 1 years. Camrelizumab are administered at dose of 200 mg i.v. every 3 weeks. H101 are instilled intravesically with a dose of 5×10*11 Vp in a 50 mL normal saline solution via a catheter, and dwell time is 1 to 2 hours,. Intravesical H101 is instilled weekly for 6 weeks for both induction and maintenance treatments.
88813270|NCT01838252|Experimental|Hyaluronic acid|Patients in this arm will receive hyaluronic acid fillers to the lower lid.
88813271|NCT01838252|Sham Comparator|Saline|
88813272|NCT01838330|Experimental|Chronic Kidney Disease Stage 3-4|Study participants with stage 3 or 4 CKD will receive 15 grams/day of soluble fiber psyllium for the first week, followed by 30 grams/day of a soluble fiber psyllium for 4 months.
88813273|NCT01838330|No Intervention|Chronic Kidney Disease Stage 1-2|Study participants with stage 1 or 2 CKD will not receive study treatment
88813274|NCT02498652|Experimental|RDEA3170 2.5 mg, 7.5 mg and 15 mg|RDEA3170 2.5 mg, 7.5 mg and 15 mg once daily (qd) in combination with allopurinol 300 mg (qd and twice daily (bid))
88813275|NCT02498652|Experimental|RDEA3170 5 mg, 10 mg and 20 mg|RDEA3170 5 mg, 10 mg 20 mg qd in combination with allopurinol 300 mg (qd and bid)
88813276|NCT01838408|Experimental|EZ2go Complete|EZ2go complete: Peg 3350, Magnesium Citrate and Simethicone
88813277|NCT01838408|Active Comparator|LoSo Prep ™|LoSo Prep ™: Magnesium citrate and Bisacodyl
88813278|NCT01835990|Experimental|geko|For subjects randomized to the experimental treatment arm, one gekoTM device will be applied to each leg according to the manufacturer's instructions by the subject's primary care nurse. All nurses applying the devices must be trained on proper application technique. The old devices will be removed and new devices applied daily. The subject will continue to use the devices until he or she exits the study.
88813279|NCT01835990|Active Comparator|IPCs|The control treatment will consist of the hospital's standard IPC devices. The IPCs will be applied to each leg by the subject's primary care nurse according to the manufacturer's instructions. They will continue to be applied until exit from the study. At the time of withdrawal from the study, the decision regarding continued use of IPCs will be made by the treating physician.
88813280|NCT01838486|Experimental|Bladder Thermal Distention (BTD)|Continuous irrigation of the bladder with warm saline (up to 45 Celsius) using the PelvixTT system
88813281|NCT03213158|Experimental|Highly sensitized kidney transplant candidates|The study population will include all highly sensitized kidney transplant candidates on the waitlist for more than 24 months at University of Wisconsin.
88813282|NCT02498418|Experimental|Generic Rifaximin 200 mg Tablets|Participants will receive a generic rifaximin 200 mg tablet 3 times daily orally for 3 days.
88813283|NCT02498418|Active Comparator|Xifaxan 200 mg Tablets|Participants will receive a xifaxan 200 mg tablet 3 times daily orally for 3 days.
88877859|NCT03688542|Experimental|Intervention|Nursing Homes allocated to the Intervention arm will enact the Quality Circle Deprescribing Module and create a local deprescribing consensus and implementation strategy.
88877860|NCT03688542|No Intervention|Control|Nursing Homes allocated to the Control arm will not enact the intervention.
88877861|NCT03697122|Experimental|HHBC and Forced Air Warming|Patients admitted to intensive care unit hypothermic (≤ 35 C) following surgical procedures involving cardiopulmonary bypass. Will be rewarmed with heated humidified breathing circuits (ANAPOD) and standard forced air warming blankets.
88877862|NCT03704376|Active Comparator|Femoral Nerve Blockade|Ultrasound guided FNB (30 ml of 0.2% ropivacaine with 100 mcg clonidine using a 22-gauge 40 mm ProBloc II insulated needle; Kimberly-Clark, Roswell, Georgia) below the inguinal ligament using a high-frequency linear ultrasound transducer (4-12 Hz; Mindray M7; Mindray North America, Mahwah, NJ) with stimulator confirmation.
88877863|NCT03704376|Active Comparator|Adductor Canal Blockade|Ultrasound guided ACB (15 ml of 0.2% ropivacaine with 100 mcg clonidine using a 22-gauge 40 mm ProBloc II insulated needle; Kimberly-Clark, Roswell, Georgia) at the mid-thigh using a high-frequency linear ultrasound transducer (4-12 Hz; Mindray M7; Mindray North America, Mahwah, NJ).
88877864|NCT03709602||Adolescents ages 11 to 14 years|Adolescents ages 11 to 14 years who have received 1 dose of the HPV vaccine series between January 2017 and December 2017
88877865|NCT03709602||Parent of adolescents|Parents as defined as the adolescent's biological mother or father, step-parents, or legal guardian, and who self-identified as the primary caregiver of the adolescent child and most likely to make medical decisions for the adolescent.
88877866|NCT03709602||Cohort of Adolescents From Electronic Health Record (EHR)|A cohort of adolescents ages 11 to 14 who received 1 dose of the HPV vaccine from January 2017 to December 2017 within the university's health system network. The cohort was followed from January 2018 to February 2019 to assess vaccine completion within a 14-month period.
88877867|NCT03711396|Experimental|Advance Care Planning Group Visits - amnestic Mild Cognitive Impairment|Participants with amnestic Mild Cognitive Impairment will attend group visits to discuss advance care planning with their study partners. Group visits will last up to two hours and be help up to twice.
88877868|NCT03711396|Experimental|Advance Care Planning Group Visits - Care Partners|Care partners of persons with amnestic Mild Cognitive Impairment will attend group visits, with the person with Mild Cognitive Impairment, to discuss advance care planning. Group visits will last up to two hours and be help up to twice.
88877869|NCT03715452||DyeVert Plus Contrast Reduction System|DyeVert Plus Contrast Reduction System
88877870|NCT03716076|Experimental|Participant receives 50 mcg of carbetocin post-delivery.|Participant receives 50 mcg of carbetocin post-delivery.
88877871|NCT03716076|Experimental|Participant receives 100 mcg of carbetocin post-delivery.|Participant receives 100 mcg of carbetocin post-delivery.
88877872|NCT03835728|Active Comparator|Treatment Arm|Ocrelizumab will be administered 3 times over a 1 year study period. Subjects will receive a dose of 300 mg at week 0 (baseline) and again at week 2. The final dose of 600 mg will be administered at week 24.
88877873|NCT03835728|Placebo Comparator|Treatment Placebo Arm|Saline will be used as the matching placebo
88877874|NCT03848910|Experimental|Investigational device - Sound Processor|
88877875|NCT03861780|Experimental|Project X 26ml|3.15% w/v CHG (chlorhexidine gluconate) / 70% v/v IPA (isopropyl alcohol) contained within a saturated at use applicator. 26ml volume. Single use.
88877876|NCT03861780|Experimental|Project X 5.1ml|3.15% w/v CHG (chlorhexidine gluconate) / 70% v/v IPA (isopropyl alcohol) contained within a saturated at use applicator. 5.1ml volume. Single use.
88877877|NCT03861780|Active Comparator|Prevantics Maxi Swabstick|3.15% w/v CHG (chlorhexidine gluconate) / 70% v/v IPA (isopropyl alcohol). Swabstick. Single use.
88877878|NCT03889158|Experimental|Acute Inflammation|All participants will receive the typhoid vaccination (intramuscular injection, 0.5 mL, 1 time).
88877879|NCT03889158|Experimental|Ascorbic Acid|All participants will receive ascorbic acid (Vit C) on two occasions [oral pill, 2g, 2x (baseline, during acute inflammation)].
88877880|NCT04018794|Experimental|Behavioral/organizational skills intervention plus mobile app|Behavioral/organizational skills intervention plus mobile application (16, 20-30 minute sessions, twice/weekly for 8 weeks)
88877881|NCT04096482|Experimental|Standard 30° 4mm Endoscope Followed by Peregrine Endoscope|Participants will receive an endoscopy with the standard 30° 4mm endoscope followed by an endoscopy with the Peregrine Drivable ENT Scope.
88877882|NCT04138758||Patients initiating Tiotropium+Olodaterol therapy|
88877883|NCT04138758||Patients initiating Long-acting beta agonist/inhaled corticosteroid therapy|
88877884|NCT04323852|Experimental|vitamin D|35 patients that pass the inclusion criteria and do not have exclusion criteria that will receive Vitamin D for 3 days and each time 3 doses of 50000 units
88877885|NCT04323852|Placebo Comparator|control group|35 patients that will receive placebo for 3 days and each day for 3 doses
89189849|NCT04929600|Experimental|Experimental|One pill of sacubitril/valsartan (200mg tablet) + one pill of matching placebo of amlodipine daily. If possible, dosage titration should be conducted.
89402541|NCT01499420|Placebo Comparator|Placebo|
89402542|NCT01498328|Experimental|Group 1a: Bevacizumab Naïve with Bevacizumab + rindopepimut.|About half of the patients who have never received treatment with bevacizumab will receive rindopepimut/GM-CSF in a blinded fashion in combination with bevacizumab.
89402543|NCT01498328|Experimental|Group 1b: Bevacizumab Naïve with Bevacizumab + KLH control|About half of the patients who have never received treatment with bevacizumab will receive KLH in a blinded fashion in combination with bevacizumab.
89402544|NCT01498328|Experimental|Group 2 and 2C: Refractory to Bevacizumab|Patients with progressive disease while currently on or within two months after discontinuing bevacizumab will be administered rindopepimut/GM-CSF while continuing (or restarting if they had stopped bevacizumab).
89535535|NCT03221023|Experimental|Vancomycin|These patients will receive intrawound Vancomycin-saline and IV antibiotics
89535536|NCT03221023|Placebo Comparator|Saline|These patients will receive intrawound saline + IV antibiotics alone
89402545|NCT04537000|No Intervention|control group|The strategies of red blood cell transfusion for the pediatric patients in this group will be made by the attending doctors in charge based on the current transfusion guidelines. The attending doctors decide when to start blood red cell transfusion and order the volume of the blood red cell as the usual clinical practice.
89402546|NCT04537000|Experimental|study group|For study group, the clinical condition score must be identified every time red blood cell transfusion is considered. The strategies of red blood cell transfusion for the pediatric patients in this group, including the trigger and the volume, will be made based on the comparison between the clinical condition score and the Hb concentration.
89402547|NCT01497704|Experimental|YN968D1|Active therapy arm for safety evaluation
89402548|NCT03135626|Experimental|Biodentine|Biodentine pulpotomy agent
89402549|NCT03135626|Experimental|ProRoot MTA|ProRoot MTA pulpotomy agent
89402550|NCT03135626|Experimental|MTA Plus|MTA Plus pulpotomy agent
89402551|NCT03135626|Active Comparator|Ferric Sulfate 20% Dental Gel|Ferric Sulfate %20 Dental Gel pulpotomy agent
89402552|NCT02266160|Experimental|1|"71 tinnitus patients treated with 2 gram EMLA 5% cream a day for 4 days, 4 hours a day.~we will compare the questionnaires results before and after 4 days of treatment to see whether EMLA cream changes the degree of suffer from tinnitus"
89402553|NCT02266160|Sham Comparator|2|71 tinnitus patients using cetomacrogol cream (lotion cream, does not contain any drug) for 4 days. these patients will fulfill the questionnaires as the investigational group.
89402554|NCT05731570|Experimental|Intervention|cognitive rehabilitation programme. 1h session per week x 10 weeks
89402555|NCT05731570|No Intervention|Control|The control group receives treatment as usual, this is, participants will carry on with the care they were receiving prior to entry in the study.
89402556|NCT01491932|Experimental|AFQ056|Patients entering the study will be titrated to target dose of AFQ056 twice daily or the highest tolerated dose at weekly intervals.
89402557|NCT03911713|Active Comparator|Ivacaftor|Participants received IVA 150 milligrams (mg) orally every 12 hours (q12h) in the treatment period for 12 weeks.
89402558|NCT03911713|Experimental|VX-561: 25 mg|Participants received VX-561 25 mg orally daily (qd) in the treatment period for 12 weeks.
89402559|NCT03911713|Experimental|VX-561: 50 mg|Participants received VX-561 50 mg orally qd in the treatment period for 12 weeks.
89402560|NCT03911713|Experimental|VX-561: 150 mg|Participants received VX-561 150 mg orally qd in the treatment period for 12 weeks.
89402561|NCT03911713|Experimental|VX-561: 250 mg|Participants received VX-561 250 mg orally qd in the treatment period for 12 weeks.
89402562|NCT05730244|Placebo Comparator|Placebo|a solution consisting of alcohol base, green food colouring and glycerin
89402563|NCT05730244|Active Comparator|Treatment|Cassia alata extract
89402564|NCT02264132|Experimental|Pramipexole ER tablet versus Pramipexole IR tablet|
89402565|NCT02264132|Experimental|Pramipexole IR tablet versus Pramipexole ER tablet|
89402566|NCT01366820|Experimental|NNZ-2566|20 mg/kg intravenous bolus infusion of NNZ-2566 over 10 minutes followed by a continuous intravenous infusion of 6 mg/kg/h (n=133) intravenous infusion of NNZ-2566 for a total of 72 consecutive hours.
89004200|NCT05720884|Experimental|acupuncture group|A total 10 acupoints of bilateral PC6, PC5, SP3, KI3, and ST36 will be chosen for the intervention group, also known as the acupuncture group. The depth of acupuncture will be varied by participant by participant. After acupuncture needles be inserted, the needles will be manually manipulated to obtain pre-determined sensation, the De Qi. Then, acupuncture will remain inserted for 20 minutes.
89402567|NCT01366820|Placebo Comparator|Sodium Chloride (0.9%) for Injection|Intravenous bolus infusion of Sodium Chloride (0.9%) for Injection over 10 minutes followed by a continuous intravenous infusion of Sodium Chloride (0.9%) for Injection for a total of 72 consecutive hours.
89402568|NCT05728762|No Intervention|Regular LEDs|Students will accept regular LEDs with a spectrum of 430-630 nm for lighting in the classroom.
89402569|NCT05728762|Experimental|Novel LEDs|Students will accept novel LEDs with a spectrum of 430-780 nm for lighting in the classroom.
89402570|NCT03910153|Placebo Comparator|Placebo - (Age 30-50 years)|
89402571|NCT03910153|Experimental|MSPrebiotic - (Age 30-50 years)|
89402572|NCT03910153|Placebo Comparator|Placebo - (Aged 70 years and above)|
89402573|NCT03910153|Experimental|MSPrebiotic - (Aged 70 years and above)|
89402574|NCT01192880|Experimental|Bitopertin 10 mg + Antipsychotics|Treatment Period 1: Participants will receive bitopertin 10 milligrams (mg) tablet orally once daily for 24 weeks. Treatment Period 2: Participants will receive bitopertin 10 mg tablet orally once daily for 28 weeks (up to Study Week 52). After Week 52 there will be a 4-week washout period for at least 50 percent (%) of participants (up to Week 56). Long-Term Extension: After Week 56, participants will enter the long term extension period and continue to receive bitopertin 10 mg tablet orally once daily up to 3 years. In addition, throughout the study, participants will continue their same stable antipsychotic treatment as they were receiving prior to entry in the study.
89535537|NCT02490839|Experimental|High-dose dual therapy|group A-high-dose dual therapy ( rabeprazole 20 mg, tablet, qid + amoxicillin 750 mg, capsule, qid for 14 days)
88813284|NCT02498418|Placebo Comparator|Placebo|Participants will receive a rifaximin placebo tablet 3 times daily orally for 3 days.
89535538|NCT02490839|Active Comparator|Bismuth-containing quadruple therapy|group B-bismuth-containing quadruple therapy (rabeprazole 20 mg, tablet, bid + tripotassium dicitrate bismuthate 300 mg, tablet, qid + metronidazole 250 mg, tablet, qid + tetracycline 500 mg qid, capsule, for 10 days)
89402575|NCT01192880|Experimental|Bitopertin 20 mg + Antipsychotics|Treatment Period 1: Participants will receive bitopertin 20 mg tablet orally once daily for 24 weeks. Treatment Period 2: Participants will receive bitopertin 20 mg tablet orally once daily for 28 weeks (up to Study Week 52). After Week 52 there will be a 4-week washout period for at least 50% of participants (up to Week 56). Long-Term Extension: After Week 56, participants will enter the long term extension period and continue to receive bitopertin 20 mg tablet orally once daily up to 3 years. In addition, throughout the study, participants will continue their same stable antipsychotic treatment as they were receiving prior to entry in the study.
89402576|NCT01192880|Placebo Comparator|Placebo|Treatment Period 1: Participants will receive bitopertin matching placebo tablet orally once daily for 24 weeks. Treatment Period 2: Participants will receive bitopertin matching placebo tablet orally once daily for 32 weeks (up to Study Week 56). Long-Term Extension: After Week 56, participants will enter the long term extension period and will be switched to (in blinded manner) bitopertin 10 mg tablet orally once daily up to 3 years. In addition, throughout the study, participants will continue their same stable antipsychotic treatment as they were receiving prior to entry in the study.
89402577|NCT05728060||chronic radiation enteritis|Non-surgically treated cervical cancer patients develop chronic radiation enteritis after radiation therapy.
89402578|NCT05728060||No chronic radiation enteritis after radiotherapy|Patients with non-surgical cervical cancer do not develop chronic radiation enteritis after radiation therapy.
89402579|NCT05728060||Patients with cervical cancer|Patients with cervical cancer did not undergo any treatment.
89402580|NCT03629197|Experimental|Communication skills training|Intervention clinicians will receive 2 standardized patient visits. The first visit will consist of an 8 minute video on the development of 5 key communication skills, a 10-12 minute role-play session to practice using these skills, and 8-10 minutes of constructive feedback. The 2nd visit will include only the role-play and feedback components. Clinicians will also get a printed pocket card and pamphlet explaining the targeted communication skills in more detail.
89402581|NCT03629197|Active Comparator|Control|Control clinicians will receive a written summary of the 2016 CDC opioid prescribing guidelines, which include recommendations for best practices for use of opioids to treat chronic non-cancer pain. CDC guidelines will serve as an attention control.
89402582|NCT04540744|Experimental|Treatment Sequence AB|Participants will receive a single oral dose of fixed dose combination (FDC) of macitentan/tadalafil (10 milligram [mg]/20 mg) in fasted conditions (test) (Treatment A) in treatment period 1 followed by a single oral dose of a free combination of 10 mg macitentan and 20 mg tadalafil in fasted conditions (reference) (Treatment B) in treatment period 2 on Day 1. Study drug intake in subsequent treatment periods in an individual participant will be separated by a washout period of at least 10 days.
89402583|NCT04540744|Experimental|Treatment Sequence BA|Participants will receive Treatment B in treatment period 1 followed by Treatment A in treatment period 2 on Day 1. Study drug intake in subsequent treatment periods in an individual participant will be separated by a washout period of at least 10 days.
89402584|NCT05375734|Experimental|treatment group|Tislelizumab combined with Anlotinib Tislelizumab：200 mg，ivgtt，d1，Q3W Anlotinib： 10mg P.O d1-d14, Q3W
89402585|NCT01489046|Experimental|Arm 1: BMS-986001 (100 mg) + Placebo + Efavirenz + Lamivudine|
89402586|NCT01489046|Experimental|Arm 2: BMS-986001 (200 mg) + Placebo + Efavirenz + Lamivudine|
89402587|NCT01489046|Experimental|Arm 3: BMS-986001 (400 mg) + Efavirenz + Lamivudine|
88877886|NCT04381728|Experimental|Womed Leaf|"At the end of the hysteroscopic myomectomy, Womed Leaf is delivered in the uterus thanks to a 5mm diameter, flexible inserter. Then an endovaginal ultrasound will be performed to assess the positioning of the uterine film.~Another ultrasound will be performed at 2 hours, prior to patient discharge in order to record images of the uterine film deployment.~A second look hysteroscopy will performed at 4-8 weeks to evaluate the presence of intrauterine adhesion."
88877887|NCT04420572|Experimental|ozone injection group|ozone injection will be applied in three doses (1st, 4th, 7th and 10th days) for a total of 4 doses. In ozone injection applications, 1st dose 25 gamma, 2nd dose 20 gamma, 3rd and 4th dose 15 gamma 10 cc ozone will be injected.
88877888|NCT04420572|Experimental|steroid injection group|1ml betamethasone will be used for steroid injection.
89004201|NCT05720884|Placebo Comparator|placebo group|Ten other points, which are not official acupoints and those are not on the median nerve or peroneal nerve, will be chosen for the placebo group.
89402588|NCT01489046|Experimental|Arm 4: Tenofovir (300 mg) + Efavirenz + Lamivudine|
89402589|NCT02266238|Experimental|Group 1|DSA guided percutaneous balloon dilatation to expand the stenosis of arteriovenous fistula
89402590|NCT02266238|Experimental|Group 2|Ultrasound guided percutaneous balloon dilatation to expand the stenosis of arteriovenous fistula
89402591|NCT02266238|Experimental|Group 3|Surgical reconstruction of the stenosis to reconstruction the lumen of arteriovenous fistula
89402592|NCT05012488||Morton Neuroma + pes planus|The effect of unilateral morton neuroma on gait parameters and foot pressure distribution in patients with bilateral pes planus will be investigated. Foot pressure distributions and gait parameters of the patients; foot rotation, step length, stance phase percentage, swing phase percentage, cadence, velocity, rerefoot pressure, midfoot pressure and forefoot pressure will be recorded with Zebris FDM -T ( Force distiribution Measurement Treadmill ) system. Zebris is a name of company in German .
89402593|NCT05012488||Morton Neuroma + pes cavus|The effect of unilateral morton neuroma on gait parameters and foot pressure distribution in patients with bilateral pes cavus will be investigated. Foot pressure distributions and gait parameters of the patients; foot rotation, step length, stance phase percentage, swing phase percentage, cadence, velocity, rerefoot pressure, midfoot pressure and forefoot pressure will be recorded with Zebris FDM -T ( Force distiribution Measurement Treadmill ) system. Zebris is a name of company in German .
89402594|NCT02264210|Experimental|Intervention group|Icotinib 125 mg three times daily (375 mg per day) orally for 12 months.
89402595|NCT02264210|No Intervention|Observation group|Observation.
89402596|NCT01423396|Other|standard care|Follow up with city doctor with recommendation HAS French guidelines
88877889|NCT04709484|Experimental|USG-guided steroid injection group|In the USG-guided group, steroid injection will be made to the area where the fascia is thickened under USG guidance. The content of the steroid solution will be 1 ml of 1% Lidocaine + 1 ml (40 mg) methylprednisolone.
89402597|NCT01423396|Experimental|optimal care of VRF|Monitoring according to the strict recommendations of the HAS French guidelines
89402598|NCT02264288|Experimental|3 x 10^6 cells|Human Placenta Derived cells (PDA-002) administered intramuscularly (IM) on Study Days 1 and 8
88877890|NCT04709484|Experimental|Palpation-guided steroid injection group|In the palpation-guided group, the most painful point will be found by palpation on the calcaneus bone and steroid injection will be made to that part. The content of the steroid solution will be 1 ml of 1% Lidocaine + 1 ml (40 mg) methylprednisolone.
88877891|NCT03541980|Active Comparator|Intervention|Patients allocated to receive IV acetaminophen
88877892|NCT03541980|Placebo Comparator|Placebo|Patients allocated to receive IV normal saline placebo
88877893|NCT04511520|Experimental|Physical training|Integrated Rehabilitation consisting of exercise training (minimum 3 times a week for a total of 6 months)
88877894|NCT04511520|Experimental|Trimetazidine|Treatment of trimetazidine in addition to standart therapy
88877895|NCT04511520|No Intervention|Control|Standard follow-up at the participating heart center
88877896|NCT04491240|Experimental|EXO-1|Participants (n=10) in this group will receive standard therapy and exosomes of the first type.
88877897|NCT04491240|Experimental|EXO-2|Participants (n=10) in this group will receive standard therapy and exosomes of the second type.
88877898|NCT04491240|Placebo Comparator|Placebo|Participants (n=10) in this group will receive standard therapy and inhalation placebo solution.
88877899|NCT04463004|Active Comparator|Intervention|Treatment infusion
88877900|NCT04463004|Placebo Comparator|Control|Placebo infusion
89402599|NCT02264288|Experimental|10 x 10^6 cells|10 x 10^6 Human Placenta Derived cells (PDA-002) administered intramuscularly on Study Days 1 and 8
89402600|NCT02264288|Experimental|30 x 10^6 cells|30 x 10^6 Human Placenta Derived cells (PDA-002) administered intramuscularly on Study Days 1 and 8
88877901|NCT04430634|Experimental|ABDC|Subjects use MybluTM e-cigarette product variant A (2.4 % nicotine) ad libitum for 2 days, then switch to use variant B (3.6% nicotine) for 2 days, then D (4.0% nicotine) for 2 days and then C (2.5% nicotine) for 2 days. A washout period of 12 hours product abstinence is observed between product variants. For each product variant, in the morning of the second product use day, a controlled product use session is performed (10 puffs taken at 30-second intervals, with puffs 3 seconds in duration).
88877902|NCT04430634|Experimental|BCAD|Same as previous arm, but in a different randomization order.
88877903|NCT04430634|Experimental|CDBA|Same as previous arm, but in a different randomization order.
88877904|NCT04430634|Experimental|DACB|Same as previous arm, but in a different randomization order.
89402601|NCT02264288|Placebo Comparator|Placebo|Identically matching placebo administered IM on Study Days 1 and 8
89402602|NCT01401556|Experimental|Case Manager Intervention|Osteoporosis case-managers will identify older fracture patients in Emergency Departments and Fracture Clinics; arrange bone mineral density (BMD) tests; meet with patients to counsel them and go over their results; and then offer and prescribe bisphosphonate treatment to those with low BMD.
89402603|NCT01401556|Active Comparator|Multifaceted quality improvement intervention|Active-comparator control consisting of telephone-based education for patients and treatment guidelines with reminders for family physicians
89402604|NCT01180634|Experimental|1|Inhaled MP-376 (Aeroquin)
89189850|NCT04929600|Active Comparator|Comparator|One pill of amlodipine (5mg tablet) + one pill of matching placebo of sacubitril/valsartan daily. If possible, dosage titration should be conducted.
89189851|NCT04925648|Active Comparator|Cohort A|Dasatinib 100mg once daily orally for 14 Days
89402605|NCT01180634|Placebo Comparator|2|Placebo
89402606|NCT05697250|Experimental|Group 1 - low power laser settings|4-6 Watts, short pulse mode. 0.4 - 0.6 J at 10 Hz.
89402607|NCT05697250|Experimental|Group 2 - high power laser settings|16-18 Watts, short pulse mode. 0.4 J / 40 Hz, 0.6 J / 30 Hz or 0.8 J / 20 Hz.
89402608|NCT02264366|Experimental|At Risk Group: ACCELERATION program|"This At Risk Group will include ;People at risk of cancer referred from UHN partners and community practices. Also included in this group are; First Nations population of BC, Asians and South Asian populations from Greater Vancouver and the working population of the City of Richmond employees. At the Montreal site users of the YMCA with risk factors for, or family history of, cancer and other chronic diseases will be targeted. And finally, in Nova Scotia the At Risk Group will be identified as being at risk of cancer and other chronic diseases referred from community practices and from the workplace population of the Capital District Health Authority (CDHA).~Intervention: Motivational Communication for Health Behavior management"
89402609|NCT02264366|Experimental|Friends & Family -ACCELERATION Program|This group includes family and friends of cancer survivors and family and friends of cardiac & COPD rehab patients. The intervention includes Motivational Communication for Health Behavior management
89402610|NCT05693506|No Intervention|Control Group Arm A|Arm A: Usual care in the investigating hospitals + questionnaires on daily eating habits, feeling of self-efficacy, etc.
89402611|NCT05693506|Experimental|Experimental Group Arm B|Arm B: Usual care in the investigating hospitals + Classic cooking workshops (number of 6) + questionnaires on daily eating habits, feeling of self-efficacy, etc.
89402612|NCT05693506|Experimental|Experimental Group C|Arm C: Usual care in the investigating hospitals + Cooking workshops in the form of culinary challenges (number of 6) + questionnaires on daily eating habits, feeling of self-efficacy...
89402613|NCT02268890|Experimental|Bortezomib|Participants will receive a 1.3 milligram per square meter per dose (mg/m^2/dose) of bortezomib intravenously on Days 1, 4, 8, and 11.
89402614|NCT04918108||inflammatory subphenotype|
89402615|NCT02268968|Experimental|Lidocaine|Intervention: Topical lidocaine gel 2% (0.3 ml/kg) will be applied once only to the nostrils and nasal CPAP prong 5 minutes prior to the application of nasal CPAP
89402616|NCT02268968|No Intervention|Control|No topical lidocaine will be used prior to application of nasal CPAP
89402617|NCT04480294|Experimental|Part 1a Treatment group 1|Intervention: Drug1: HRS5091, dose 1; Drug2: Placebo Healthy subjects
89402618|NCT04480294|Experimental|Part 1a Treatment group 2|Intervention: Drug1: HRS5091, dose 2; Drug2: Placebo Healthy subjects
89402619|NCT04480294|Experimental|Part 1a Treatment group 3|Intervention: Drug1: HRS5091, dose 3; Drug2: Placebo Healthy subjects
89402620|NCT04480294|Experimental|Part 1a Treatment group 4|Intervention: Drug1: HRS5091, dose 4; Drug2: Placebo Healthy subjects
89402621|NCT04480294|Experimental|Part 1a Treatment group 5|Intervention: Drug1: HRS5091, dose 5; Drug2: Placebo Healthy subjects
89402622|NCT04480294|Experimental|Part 1b Treatment group 3|Intervention: Drug1: HRS5091, dose 3; Drug2: Placebo Healthy subjects Food effect
89402623|NCT04480294|Experimental|Part 1c Treatment group 6|Intervention: Drug1: HRS5091, dose 3; Drug2: Placebo Healthy subjects
89402624|NCT04480294|Experimental|Part 2 Treatment group 7|Intervention: Drug1: HRS5091, dose 3; Drug2: Placebo CHB subjects
88877905|NCT04430634|Experimental|EFHG|Subjects use MybluTM e-cigarette product variant E (3.6 % nicotine) ad libitum for 2 days, then switch to use variant F (2.4% nicotine) for 2 days, then H (3.6% nicotine) for 2 days and then G (4.0% nicotine) for 2 days. A washout period of 12 hours product abstinence is observed between product variants. For each product variant, in the morning of the second product use day, a controlled product use session is performed (10 puffs taken at 30-second intervals, with puffs 3 seconds in duration).
89402625|NCT04480294|Experimental|Part 2 Treatment group 8|Intervention: Drug1: HRS5091, dose 4; Drug2: Placebo CHB subjects
89402626|NCT04480294|Experimental|Part 2 Treatment group 9|Intervention: Drug1: HRS5091, dose 5; Drug2: Placebo CHB subjects
89402627|NCT01359566|Active Comparator|Arbaclofen placarbil 15 mg BID|Arbaclofen placarbil (XP19986 SR4) 15 mg every morning and every evening
89402628|NCT01359566|Active Comparator|Arbaclofen placarbil 30 mg BID|Arbaclofen placarbil (XP19986 SR4) 30 mg every morning and every evening
88877906|NCT04430634|Experimental|FGEH|Same as previous arm, but in a different randomization order.
88877907|NCT04430634|Experimental|GHFE|Same as previous arm, but in a different randomization order.
89189852|NCT04925648|Active Comparator|Cohort B|Dasatinib 100mg once daily and Darolumatide 600 mg twice daily orally for 14 Days
89402629|NCT01359566|Active Comparator|Arbaclofen placarbil 45 mg BID|Arbaclofen placarbil (XP19986 SR4) 45 mg every morning and every evening
89402630|NCT01359566|Placebo Comparator|Placebo|Placebo every morning and every evening
89402631|NCT04904770|Experimental|Scoop stretcher|A scoop stretcher will be used as device to perform spinal stabilization
89402632|NCT04904770|Active Comparator|Vacuum mattress|A vacuum mattress will be used as device to perform spinal stabilization
89402633|NCT04379284||Pregnant women - positive COVID19 test|Pregnant women of any gestational age 8 weeks through delivery with a positive COVID19 test, with or without physical symptoms
89402634|NCT04379284||Pregnant women - negative or unknown COVID19 test|Pregnant women experiencing any respiratory or other physical symptoms of COVID19 at onset of labor, with negative or uncertain COVID19 test results
89189853|NCT04908553|Other|low dose group|Remimazolam Tosilate for Injection 0.1mg/kg at induction
89402635|NCT01356914|Experimental|Treatment A: BMS-914392|
89402636|NCT01356914|Experimental|Treatment B: BMS-914392|
89402637|NCT01356914|Experimental|Treatment C: BMS-914392|
89402638|NCT01356914|Placebo Comparator|Treatment D: Placebo|
89189854|NCT04908553|Other|medium dose group|Remimazolam Tosilate for Injection 0.15mg/kg at induction
89189855|NCT04908553|Other|high dose group|Remimazolam Tosilate for Injection 0.2mg/kg at induction
89189856|NCT04906174||Observational (medical record review)|Patients' medical records are reviewed retrospectively.
89189857|NCT04899479|Experimental|SGLT-2 inhibitor|The SGLT-2 inhibitor group will receive SGLT-2 inhibitor once daily until the end of the study period.
89189858|NCT04899479|Placebo Comparator|Control|The control group will not receive any additional drugs.
89189859|NCT04895293|Experimental|RBM-007 Injectable Solution - 2.0 mg|Single intravitreal injection in study eye
89189860|NCT04861844|Experimental|Mindfulness training|
89189861|NCT04861844|Active Comparator|Active listening|
89189862|NCT04861415|Active Comparator|Conventional Fractionated Radiation|"Prostate Only Radiation - 37.5Gy in 15 daily fractions to the prostate and proximal/entire seminal vesicle~Prostate + Nodal Radiation - 46Gy in 23 daily fractions to the prostate, seminal vesicle and regional lymph nodes"
89189863|NCT04861415|Experimental|Stereotactic Body Radiotherapy|"Prostate Only Radiation - 25Gy in 5 fractions to the prostate and proximal/entire seminal vesicle~Prostate + Nodal Radiation - 25Gy in 5 fractions to the prostate, seminal vesicle and regional lymph nodes"
89189864|NCT04859426|Experimental|Mild Hepatic Impairment|Subjects will receive a single dose of 100 mg DBPR108.
89189865|NCT04859426|Experimental|Moderate Hepatic Impairment|Subjects will receive a single dose of 100 mg DBPR108.
89189866|NCT04859426|Experimental|Normal hepatic function|Subjects will receive a single dose of 100 mg DBPR108.
89189867|NCT04852367|Active Comparator|Arm A (Doxorubicin)|a single intravenous dose of Doxorubicin, 50 mg/ m2 in 250 mL of normal saline or 5% dextrose over a 30-min infusion is delivered as per local practice.
89189868|NCT04852367|Experimental|Arm B (ThermoDox + Focused Ultrasound)|under general anaesthetic, patients receive FUS, which is moved through the target tumour volume to raise the bulk tumour temperature above the thermal release threshold. At presumed target temperature, a single intravenous dose of ThermoDox®, 50 mg/ m2 in 250 mL of normal saline or 5% dextrose over a 30-min infusion is delivered concurrently to FUS, in line with the pharmacy manual provided by the manufacturer. FUS will continue following infusion, for no longer than two hours from infusion commencing.
89189869|NCT04850703|Experimental|Premature Ejaculation participants who receive Brain Weak Currents in IFG brain cortex|"Participants receive tRNS (weak currents < 2 mA) sessions at IFG brain cortex for 25 minutes 2 times a day 3 times per week during 3 weeks.~After 4 hours they end the last session, a new brain mapping is performed."
89189870|NCT04850703|Active Comparator|Premature Ejaculation participants who take Dapoxetine|Participants take 1 tablet of the drug between 1 and 3 hours before the brain mapping
89189871|NCT04850703|Sham Comparator|Placebo Group|Participants who do not take medication or receive tRNS sessions
89189872|NCT04850703|Other|Controls|44 Healthy humans not clinically not diagnosed with LPD and withouth expression the LPE endophenotype. In this way, the investigators what would be the patients diagnosed clinically with LPE who present the endophenotype or neurophysiological biomarker of LPE.
89189873|NCT04843787|Experimental|Experimental: Multiple Ascending Dose Cohort 1|Intervention: SLV213, 8 subjects will receive 200mg oral doses twice a day for seven consecutive days.
89189874|NCT04843787|Placebo Comparator|Placebo Comparator: Multiple Ascending Dose Cohort 1|Intervention: Placebo, 4 subjects will receive an equivalent number of oral doses twice a day for seven consecutive days.
89535539|NCT03077373|Experimental|Counseling letter (intervention group)|Intervention group: Individuals in this group complete a tablet PC-supported assessment at baseline and 12-month follow-up, both at the general practice. At months 4 and 7, follow-up data are collected by study team members via phone call. According to the assessments (baseline, month 4, and month 7), participants receive three counseling letters aiming to increase moderate-to-vigorous physical activity and to reduce sedentary time. Additionally, individuals who were daily smokers at baseline, receive three counseling letters aiming to foster the motivation to quit smoking. The first letter is accompanied by a self-help manual covering specific information relevant for the particular stage of motivation to change smoking behavior.
89189875|NCT04843787|Experimental|Experimental: Multiple Ascending Dose Cohort 2|Intervention: SLV213, 8 subjects will receive 400mg oral doses twice a day for seven consecutive days.
89189876|NCT04843787|Placebo Comparator|Placebo Comparator: Multiple Ascending Dose Cohort 2|Intervention: Placebo, 4 subjects will receive the equivalent number of oral doses twice a day for seven consecutive days.
89189877|NCT04843787|Experimental|Experimental: Multiple Ascending Dose Cohort 3|Intervention: SLV213, 8 subjects will receive 800mg oral doses once a day for seven consecutive days.
89189878|NCT04843787|Placebo Comparator|Placebo Comparator: Multiple Ascending Dose Cohort 3|Intervention: Placebo, 4 subjects will receive the equivalent number of oral doses once a day for seven consecutive days.
89189879|NCT04843787|Experimental|Experimental: Multiple Ascending Dose Cohort 4|Intervention: SLV213, 30 subjects will receive the MTD (200mg twice a day, 400mg twice a day or 800 mg once a day) oral doses for seven consecutive days.
89189880|NCT04843787|Placebo Comparator|Placebo Comparator: Multiple Ascending Dose Cohort 4|Intervention: Placebo, 15 subjects will receive the equivalent number of oral doses once a day or twice a day for seven consecutive days.
89189881|NCT04836520|Experimental|SHR6390+anatrozole|Hormone receptor positive, HER2 negative participants will receive SHR6390 in combination with anatrozole before surgery.
89189882|NCT04831840||Female participants with recurrent urinary tract infections (RUTI).|Patients with RUTIs (Group A) will provide two urine samples. One urine sample is a clean catch and the other is a catheterized specimen. Both will be sent for analysis. A perineal swab will also be collect and analyzed for each patient.
89535540|NCT03077373|No Intervention|No counseling letter (control group)|Control group: Individuals in this group complete a tablet PC-supported assessment at baseline and 12-month follow-up, both in the general practice. At months 4 and 7, follow-up data are collected by study team members via phone call.
88877908|NCT04430634|Experimental|HEGF|Same as previous arm, but in a different randomization order.
89189883|NCT04831840||Female control patients without RUTIs|Patients without RUTIs (Group B) will provide two urine samples. One urine sample is a clean catch and the other is a catheterized specimen. Both will be sent for analysis. A perineal swab will also be collect and analyzed for each patient.
89189884|NCT04831801||Female patients with overactive bladder (OAB)|Patients with urgency and frequency syndrome with or without pelvic pain (Group A) will provide two urine samples. One urine sample is a clean catch and the other is a catheterized specimen. Both will be sent for analysis. A perineal swab will also be collect and analyzed for each patient.
89189885|NCT04831801||Female control patients without LUTS|Patients without LUTS (Group B) will provide two urine samples. One urine sample is a clean catch and the other is a catheterized specimen. Both will be sent for analysis. A perineal swab will also be collect and analyzed for each patient.
89189886|NCT04820946||various episodic mood disturbances patient group|A group of patients with various episodic mood disturbances was used as a clinical case control group.
89189887|NCT04820946||Disruptive Mood Dysregulation Disorder (DMDD) patient group|DMDD patients referred to the hospital for suicidal behaviors between 2013 and 2018 in terms of diagnostic stability, psychiatric comorbidity, and psychosocial factors.
89189888|NCT04806399|No Intervention|Usual Care Control Group|
89189889|NCT04806399|Active Comparator|Outreach Contact with Decision Counseling Group|
89189890|NCT04802070|Experimental|CIK|
89402639|NCT04885816|Experimental|Drug Eluting Balloon (DEB)|High Bleeding Risk patients treated with 2.5 - 4.0 mm drug-eluting balloons (DEB). Bailout stenting is permitted in case of a flow-limiting dissection or significant recoil (>30% in main branch and >50% side-branch), includes both stable coronary artery disease (SCAD) and acute coronary syndromes (ACS) patients undergoing elective Percutaneous Coronary Intervention (PCI).
89402640|NCT04885816|Active Comparator|Drug Eluting Stents (DES)|High Bleeding Risk patients treated with 2.5 - 4.0 mm drug-eluting stents (DES). Includes both stable CAD and ACS patients undergoing elective PCI.
89402641|NCT03135314|Active Comparator|Hypoxia Cocoa flavanol|Exercise or cognitive test in (acute) hypoxic condition after 7 days of cocoa flavanol intake
89402642|NCT03135314|Placebo Comparator|Hypoxia Placebo|Exercise or cognitive test in (acute) hypoxic condition after 7 days of placebo intake
89402643|NCT03135314|Active Comparator|Normoxia Cocoa flavanol|Exercise or cognitive test in normoxic condition after 7 days of cocoa flavanol intake
88877909|NCT04429932|Experimental|Product use sequence ABDC|Subjects use MybluTM e-cigarette product variant A (2.4% nicotine) ad libitum for 2 days, then switch to use variant B (2.4% nicotine) for 2 days, then D (2.4% nicotine) for 2 days and then C (2.4% nicotine) for 2 days. A washout period of 12 hours product abstinence is observed between product variants. For each product variant, in the morning of the second product use day, a controlled product use session is performed (10 puffs taken at 30-second intervals, with puffs 3 seconds in duration).
88877910|NCT04429932|Experimental|Product use sequence BCAD|Same as previous arm, but in a different randomization order.
88877911|NCT04429932|Experimental|Product use sequence CDBA|Same as previous arm, but in a different randomization order.
88877912|NCT04429932|Experimental|Product use sequence DACB|Same as previous arm, but in a different randomization order.
88877913|NCT04429932|Experimental|Product use sequence EFHG|Subjects use MybluTM e-cigarette product variant E (1.2% nicotine) ad libitum for 2 days, then switch to use variant F (1.2% nicotine) for 2 days, then H (2.4% nicotine) for 2 days and then G (2.4% nicotine) for 2 days. A washout period of 12 hours product abstinence is observed between product variants. For each product variant, in the morning of the second product use day, a controlled product use session is performed (10 puffs taken at 30-second intervals, with puffs 3 seconds in duration).
89189891|NCT04798690||Growth hormone|Growtropin®-II
89189892|NCT04797143||control group|patients in control group receive standard care
89189893|NCT04797143||intervention group|intervention group after implementation of a MCP
89189894|NCT04791956|Experimental|Prebiotic|Inulin-type fructans
89189895|NCT04791956|Placebo Comparator|Placebo|Maltodextrin
89189896|NCT04788940||AMI patients treated with PCI|Acute myocardial infarction patients who underwent percutaneous coronary intervention and cardiac magnetic resonance imaging
89189897|NCT04771091|Experimental|Mesure of head-perineum distance by transperineal ultrasound|A mesure of head-perineum distance by ultrasound will be realized at the beginning of maternal pushing efforts by a junior gynecologist.
89189898|NCT04765150||Observational (electronic health record review, 3 T MRI)|"RETROSPECTIVE: Patients' medical records are reviewed.~PROSPECTIVE: Patients undergo additional 3T MRI imaging over 30 minutes before, during, or after their standard of care 3T MRI for a total of 1.5 hours."
89189899|NCT04753021|Experimental|Exercise|Progressive exercise training
89189900|NCT04751422||Observational (data collection)|Patients' medical data is collected retrospectively.
89189901|NCT04727996|Experimental|Sitravatinib/Tislelizumab|All patients will receive sitravatinib 120 mg orally once daily in combination with tislelizumab 200 mg IV once every 3 weeks until disease progression, unacceptable toxicity, or withdrawal of consent.
89189902|NCT04704700|Active Comparator|patient with inspace device|
89402644|NCT03135314|Placebo Comparator|normoxia placebo|Exercise or cognitive test in normoxic condition after 7 days of placebo intake
89402645|NCT03135470||Current practice group|All plenipotentiary ambulatory surgery patients, with informed consent, during the three month study period
89402646|NCT03135470||Standard operating protocol group|All plenipotentiary ambulatory surgery patients, with informed consent, during the three month study period after creating and informing standardized operating protocol
89402647|NCT03135470||Mobile phone app group|All plenipotentiary ambulatory surgery patients during the three month study period with informed consent to use mobile phone app in assesment of pain and pain medication
89402648|NCT04865614||Etomidate group|Patients who received etomidate for induction of anaesthesia during interventional mitral valve repair (Mitraclip)
88877914|NCT04429932|Experimental|Product use sequence FGEH|Same as previous arm, but in a different randomization order.
89402649|NCT04865614||Sevoflurane group|Patients who received sevoflurane for induction of anaesthesia during interventional mitral valve repair (Mitraclip)
89402650|NCT01483898|Experimental|ixmyelocel-T|
88877915|NCT04429932|Experimental|Product use sequence GHFE|Same as previous arm, but in a different randomization order.
88877916|NCT04429932|Experimental|Product use sequence HEGF|Same as previous arm, but in a different randomization order.
88877917|NCT04409886|Experimental|HBOT (Hyperbaric Oxygen Therapy)|Hyperbaric Oxygen Therapy in Non-ventilated COVID-19 Patients (HBOT)
88877918|NCT04399980|Active Comparator|Intervention|Treatment infusion
88877919|NCT04399980|Placebo Comparator|Control|Placebo infusion
89402651|NCT01483898|Placebo Comparator|Placebo|
89402652|NCT04847908|Experimental|High-intensity interval exercise intervention|Change according to definition.
89402653|NCT05377918|Experimental|Spiritual Diary Group|"-What did you feel today? Spiritual Diary: According to the randomization, the participants in Cluster 1 were asked to write their bad/good memories about the four elements (self, others/family, nature, God/God) in John Fisher's Four Domains model, ask family, others, and God/ God was asked to write down his wishes and wishes, and the child in this group generally wrote the question What did I feel today? in his diary."
89402654|NCT05377918|Experimental|Diary Group|"What Did You Do Today? Diary: According to randomization, the children in the Cluster 2 group were asked to write down their daily activities and activities (eating, watching TV, time spent with their friends at school, etc.) and the children in this group were asked to generally ask, What did I do today? answered the question."
89402655|NCT05377918|No Intervention|Control Group|Control Group
89402656|NCT02269046|Experimental|Acupuncture and moxibustion|"therapeutic lifestyle change~Group I:Juque (RN14), Tianshu (ST25, bilateral), Fenglong (ST40, bilateral), Zusanli (ST 36, bilateral), Sanyinjiao (SP6, bilateral)~Group II: Pishu (BL20, bilateral), Xinshu (BL15, bilateral), Ganshu (BL18, bilateral), Shenshu (BL23, bilateral)~Group I and II will change alternatively every other week .~Once per day five days per week."
88877920|NCT04397094|Experimental|Theracal LC|Theracal LC was used as a medicament to cover root stumps of asymptomatic thirty primary molars with vital pulp exposures. Teeth were followed up clinically and radiographically for 12 months.
88877921|NCT04397094|Active Comparator|Formocresol|Formocresol was used as a medicament to cover root stumps of asymptomatic thirty primary molars with vital pulp exposures. Teeth were followed up clinically and radiographically for 12 months.
89402657|NCT02269046|Active Comparator|Simvastatin|"therapeutic lifestyle change~simvastatin~oral administration with 10mg per day~seven days per week for 12 weeks."
89402658|NCT02269046|Other|waiting list|- therapeutic lifestyle change
89402659|NCT01483742|Experimental|Combination without RO5024048|Ritonavir-boosted danoprevir in combination with Pegasys (peginterferon alfa-2a) and ribavirin in treatment-naïve patients
89402660|NCT01483742|Experimental|Combination with RO5024048|RO5024048 added to the combination treatment (ritonavir-boosted danoprevir in combination with Pegasys [peginterferon alfa-2a] and ribavirin) in prior null responder patients
88877922|NCT04385238||Pregnant Women|Pregnant women who are 18 years of age or older.
88877923|NCT04385238||Post-partum women|Women who gave birth within the last 6 months who are 18 years of age or older.
88877924|NCT04383132|Experimental|Abdominal Binder Intervention Group|Patients randomized to Abdominal Binder Intervention Group will have the abdominal binder secured firmly between Spina iliaca anterior superior and subcostal area to the abdomen just prior the colonoscopy.
88877925|NCT04383132|Sham Comparator|Sham Group|Sham Group will have the abdominal binder secured firmly between Spina iliaca anterior superior and subcostal area to the abdomen just prior the colonoscopy but it will be loosened just prior the procedure
88877926|NCT04335552|Active Comparator|Standard of care|
89402661|NCT03065023|Experimental|Group A: Cutaenous lesions|Participants with transdermally/transmucosally injectable tumors including cutaneous, subcutaneous or lymph node injectable tumors received escalating doses of MK-4621 via intratumoral (IT)/intralesional (IL) injection twice each week (Q2W) over a period of 4 weeks. Participants may have continued to receive study treatment beyond Cycle 1 for the remaining duration of the study as long as clinical benefit (no overt clinical progression or toxicity considered to be intolerable as per Investigator's assessment) was present (up to approximately 2 years).
89402662|NCT03065023|Experimental|Group B: Liver lesions|Participants with injectable liver tumors or liver metastases were to receive escalating doses of MK-4621 via intratumoral (IT)/intralesional (IL) injection once each week over a period of 4 weeks. Participants were to have been able to continue to receive study treatment beyond Cycle 1 for the remaining duration of the study as long as clinical benefit (no overt clinical progression or toxicity considered to be intolerable as per Investigator's assessment) was present (up to approximately 2 years). (Group B was not started. Development will continue with new protocol.)
88877927|NCT04335552|Experimental|Standard of care plus hydroxychloroquine|Standard of care plus hydroxychloroquine for 5 days
88877928|NCT04335552|Experimental|Standard of care plus azithromycin|Standard of care plus azithromycin for 5 days
88877929|NCT04335552|Experimental|Standard of care plus hydroxychloroquine plus azithromycin|Standard of care plus hydroxychloroquine plus azithromycin for 5 days
89402663|NCT04691128|Experimental|Desflurane inhalational anesthesia|
89402664|NCT04691128|Active Comparator|Propofol total intravenous anesthesia|
89402665|NCT04207918|Experimental|Neoadjuvant Chemoradiotherapy（NCRT）|NCRT arm receives intensity-modulated radiotherapy concurrently with S-1（40-60/m2/d，orally twice a day） and nimotuzumab（400mg/d，by intravenous infusion once a week）.
89402666|NCT02269202|Experimental|Midazolam and crobenetine|
89402667|NCT02269202|Placebo Comparator|Midazolam and placebo|
89402668|NCT02266316|Experimental|Mask|Using mask that warms air at the mouth by utilising body heat
89402669|NCT02266316|No Intervention|No mask|Not using any mask that warms air at the mouth by utilising body heat
89402670|NCT04655638|Experimental|High Flow Nasal Therapy|High flow nasal therapy
89402671|NCT04655638|Active Comparator|Conventional Oxygen Therapy|Conventional Oxygen therapy
89402672|NCT02266394|Active Comparator|Mesenchymal stem cell delivery|To determine hemodynamic and immunologic changes associated with intra-renal delivery of adipose-derived MSC into human subjects with advanced RVD.
89402673|NCT02266394|Active Comparator|Mesenchymal stem cell delivery with stent placement|To test adjunctive delivery of MSC to individuals with advanced RVD undergoing renal artery stenting.
89402674|NCT03614923|Experimental|Etokimab 300 mg + 150 mg Q4W|Participants received a 300 mg loading dose of etokimab administered by subcutaneous injection at Week 0 then 150 mg etokimab by subcutaneous injection every 4 weeks (Q4W) up to Week 12 (Weeks 4, 8, and 12). Participants also used mometasone furoate nasal spray (MFNS) of 2 actuations (50 μg/actuation) in each nostril twice daily (BID).
89402675|NCT03614923|Experimental|Etokimab 300 mg + 150 mg Q8W|Participants received a 300 mg loading dose of etokimab administered by subcutaneous injection at Week 0 then etokimab 150 mg by subcutaneous injection every 8 weeks (Q8W) up to Week 12 and placebo at Weeks 4 and 12. Participants also used MFNS of 2 actuations (50 μg/actuation) in each nostril BID.
89402676|NCT03614923|Placebo Comparator|Placebo|Participants received placebo subcutaneous injection once every 4 weeks up to Week 12. Participants also used MFNS of 2 actuations (50 μg/actuation) in each nostril BID.
89402677|NCT01353248|Active Comparator|Arm 1|GS-5885, GS-9451 and Tegobuvir in combination with ribavirin (Copegus®) for 24 weeks.
89402678|NCT01353248|Active Comparator|Arm 2|GS-5885, GS-9451 and Tegobuvir in combination with ribavirin (Copegus®) for 12 or 24 weeks.
89402679|NCT05095636|Active Comparator|apatinib monotherapy|Apatinib，500 mg，po., qd, q2w
89402680|NCT05095636|Experimental|Apatinib Combined With Camrelizumab|Apatnib，250 mg，po., qd，q2w; Camrelizumab，200mg， ivgtt，d1, q2w
89402681|NCT05756959|Experimental|PBM therapy + SVS|Low lever red light therapy with single vision spectacles
89402682|NCT05756959|Experimental|Peripheral defocus spectacles|a spectacles with special design with peripheral myopic defocus to control myopia progression
89402683|NCT05756959|Experimental|PBM +Peripheral defocus spectacles|Low lever red light therapy with a spectacles with special design with peripheral myopic defocus to control myopia progression
89402684|NCT05756959|Placebo Comparator|Control|single vision spectacles only as the control
89402685|NCT02264444|Experimental|Cholecystectomy visualization|All patients will undergo a standard single site cholecystectomy and will have their operation recorded and scored for visualization.
89402686|NCT05095558|Experimental|MST|standard chemotherapy with microtransplantation
89402687|NCT05095558|No Intervention|CT|standard chemotherapy only, without microtransplantation
89402688|NCT01343966|Experimental|Part 1: Subcutaneous cohort exp|
89402689|NCT01343966|Experimental|Part 2: Intravenous cohort exp|
89189903|NCT04704700|Placebo Comparator|patient without inspace device|
89402690|NCT01343966|Placebo Comparator|Part 1: Subcutaneous cohort|Repeating subcutaneous injection
89402691|NCT01343966|Placebo Comparator|Part 2: Intravenous cohort|Repeating intravenous infusion
89402692|NCT03540277|Experimental|"Prevention Program young In Favor of Myself, active parents"|"The program young In Favor of Myself will be delivered to adolescence aged 10-12, over 3 months. The program contains nine weekly, 90-min sessions that focus on Media literacy, self-esteem, self-image and body image. The parents will also participate by a phone app that will pass the parents activities to do with their children, in parallel to the program. All participants will complete a self-report questionnaire at baseline, after the program ends, and three months after the completion of the program."
89402693|NCT03540277|Active Comparator|"Prevention Program young In Favor of Myself, passive parents"|"The program young In Favor of Myself will be delivered to adolescence aged 10-12, over 3 months. The program contains nine weekly, 90-min sessions that focus on Media literacy, self-esteem, self-image and body image. The parents won't participate in the program, they will get only a brochure about Media literacy, self-esteem, self-image and body image. All participants will complete a self-report questionnaire at baseline, after the program ends, and three months after the completion of the program."
89402694|NCT03540277|No Intervention|control group|The control group will not receive the intervention program. The control group will complete the same self-report questionnaire as the intervention group at baseline, after the program ends, and three months after the completion of the program.
89402695|NCT05095480|Experimental|Lesstat|Those who received Lesstat
89402696|NCT05095480|Placebo Comparator|Placebo|Those who received Lesstat
89402697|NCT04438408||severe asthma patient|Adult patients (≥ 18 years) with diagnosis of severe asthma for at least 12 months
89189904|NCT04692623|Experimental|Moxfloxacin Group|In this arm 30 healthy volunteers were selected and they were given Moxifloxacin drug.
89402698|NCT06091891|Active Comparator|Control|
89189905|NCT04692623|Experimental|Gemifloxacin Group|In this arm 30 healthy volunteers were selected and they were given Gemifloxacin
89402699|NCT06091891|Experimental|ROTEM-guided|
89402700|NCT06091852|Experimental|Intrinsically labelled milk protein|20 grams of protein dissolved in 500 mL of water
89402701|NCT06091839|Active Comparator|anchor technique|In the anchor technique , the suture was secured first at the heel region after entering the artery and the vein in an inside-out fashion, and a surgical knot was tied, after which the suture was run continuously across the lateral margins of anastomosis, entering the vein outside-in and the artery inside-out, from heel (proximal end of arteriotomy) to toe (distal end). Then the suture was run to complete suturing the medial margins from heel to toe, entering the artery outside-in and the vein inside-out, and final knots were taken.
89402702|NCT06091839|Active Comparator|parachute technique|In the parachute technique, suture was first secured at 11 o'clock position entering both vessels in an inside-out fashion, then continuous suturing was commenced towards 5 o'clock position across the heel, entering the vein outside-in and the artery inside-out, without approximating the vessels. Then, gentle traction was applied on the sutures to allow even distribution of tension along the suture-line and 'parachuting' or approximation of vessel walls together. The suture was then run in a continuous fashion across the proximal margin (toward surgeon) and across the toe region, and finally, surgical knots were applied at midway on the distal margin.
89402703|NCT06091826|Experimental|NFL-101|100 μg per subcutaneous injection (in each arm), two injections at day 1
89402704|NCT06091826|Placebo Comparator|Placebo|Water for Injection (WFI), two injections at day 1
89402705|NCT06091800||control group (periodontally healthy)|no attachment loss, probing pocket depth ≤ 3 mm, minimal bleeding on probing ≤ 10%, and no radiographic bone loss
89402706|NCT06091800||periodontitis group|interdental clinical attachment level ≥ 5 mm, probing pocket depth ≥ 6 mm, radiographic bone loss extending to the middle or apical thirds of the root, mid-crest defect, and a history of ≤4 teeth loss of periodontal origin
89402707|NCT06091787|Experimental|Study Arm|This group will recieve Tab Ursodeoxycholic acid 450mg twice daily from the day after donor hepatectomy till post operative day 10.
89402708|NCT06091787|Active Comparator|Control Arm|This group will receive standard medical therapy following donor hepatectomy.
89402709|NCT06091748|Experimental|PET/CT imaging with 68Ga-DOTATOC|
89402710|NCT06091722||1|Mild group, the scores of both clinicians were ≤ grade 1
89402711|NCT06091722||2|Moderate group, one doctor scored grade 2, and the other doctor scored 1~2;
89402712|NCT06091722||3|Moderate group, one doctor scored grade 2, and the other doctor scored 1~2;
89402713|NCT06091709|Experimental|MEET-R Group|Participants will follow the MEET-R that will include stretching, strengthening and core stabilization exercises, and education material pertaining to the proper posture during work.
89402714|NCT06091709|Other|Control Group|The control group is allowed to opt for self-care management of back pain in the form of medications, rest, conventional physiotherapy, and a home exercise plan. They are also allowed to change their self-care management during the study period; information about the use of the alternative management will be recorded. The information on self-care management will be gathered after 6 weeks at the end of the intervention
89402715|NCT06091696|Experimental|study group|Inspiratory muscle training will be conducted using a pressure threshold loading device (Threshold Inspiratory Muscle Training, Respironics, Pittsburg, PA, USA). By using a spring-loaded one-way valve, this device provides air flow-independent resistance to inspiration at a detectable intensity. Patients will start training with a MIP of 40%. The intensity of training will be adjusted every week based on MIP measurement.
89402716|NCT06091696|Active Comparator|control group|Warm-up and cool-down periods of 5 minutes each in addition to light aerobic activity will be performed by patients in both groups. Aerobic exercise training will be done through selected activities for 30 minutes /3 times per week for 8 weeks.
89402717|NCT06091683|Experimental|Adjuvant pressurized intraperitoneal aerosol chemotherapy (PIPAC)|Preliminary laparoscopic exploration of the abdominal cavity and adjuvant pressurized intraperitoneal aerosol chemotherapy (PIPAC) with oxaliplatin and concurrent intravenous infusion of 5-fluorouracil and folinic acid.
89402718|NCT06091644|Other|Evaluation of device performances in normal and difficult airway management|"Each endotracheal intubation (ETI) attempt could enhance the participant's experience in the next attempt. Hence, the order of use of ETI devices was randomized to avoid experience-based bias. Six subgroups were needed to determine the order in which the SMSS would use the devices based on a permutation of three because three ETI devices were planned to be used in total. Accordingly, participants were randomized into six groups using the Random Team Generator.~Six experiment stations were set up. Normal airway manikins (NAMs) were used in the first three stations, and difficult airway manikins (DAMs) were used in the subsequent three. The interventions were to be conducted by the participants using NAMs first, followed by DAMs in the predetermined randomization order. Participants were assisted by an experienced assistant researcher in ETI during their attempts to extend the ETT, who also check the intubation accuracy with a bag valve mask (BVM) at the end of the intervention."
89402719|NCT06091631|Experimental|Magnesium sulfate|will receive magnesium sulfate inhation
89402720|NCT06091631|No Intervention|Control|Will receive distilled water vaporization
89402721|NCT06091605|Experimental|Omega roll envelope flap (OREF) technique|"Patients will undergo peri-implant soft tissue augmentation procedures accompanied by the placement of healing abutments at the uncovering of the inserted osseo-integrated implants, 12 weeks after the initial stage of implant placement.~Omega roll envelope flap (OREF) technique will be done around the placed healing abutment, then suturing will be done."
89535541|NCT03205969|Experimental|Functional mobile game|Functional mobile game for chemotherapy side effect education
88877930|NCT04321980|Experimental|Cohort 1|Subjects in Cohort 1 will be administered 4 mg/kg OP-101 as a subcutaneous (SC) injection.
88877931|NCT04321980|Experimental|Cohort 2|Subjects in Cohort 2 will be administered 8 mg/kg OP-101 as a SC injection.
89004202|NCT05720130|Experimental|[212Pb]Pb-ADVC001|There is only a single treatment arm. Participants with metastatic Castration Resistant Prostate Cancer that have received prior Androgen Receptor Pathway Inhibitors (e.g., Abiraterone, Enzalutamide) and chemotherapy (or can have declined chemotherapy), who have not been previously treated with [177Lu]Lu-PSMA radioligand therapy. Four cohorts will receive escalating doses of 60 MBq, 90 MBq, 120MBq and 150MBq of [212Pb]Pb-ADVC001. Participants will receive a dose via intravenous injection every 6 weeks (+/- 2 weeks) for no more than 4 cycles.
89004203|NCT05717439||PTSD positive|Subjects meet criteria for PTSD, with or without comorbid Generalized Anxiety Disorder or Major Depressive Disorder
89004204|NCT05717439||Primary GAD|Subjects DO NOT meet criteria for PTSD, but meet criteria for Generalized Anxiety Disorder
89004205|NCT05717439||Primary MDD|Subjects DO NOT meet criteria for PTSD, but meet criteria for Major Depressive Disorder
89004206|NCT05717439||Comorbid GAD/MDD|Subjects DO NOT meet criteria for PTSD, but meet criteria for Generalized Anxiety Disorder and Major Depressive Disorder
89004207|NCT05717439||Trauma-positive, PTSD/GAD/MDD-negative|Subjects have trauma exposure meeting DSM-5-TR Criterion A, but DO NOT meet criteria for PTSD, GAD, or MDD
89004208|NCT05717439||Trauma-negative|Subjects DO NOT have trauma exposure meeting DSM-5-TR Criterion A and DO NOT meet criteria for PTSD, GAD, or MDD
89004209|NCT05712941|Experimental|Letrozole 2.5mg by mouth once a day (QD) + Lerociclib 150mg by mouth twice a day (BID)|
89004210|NCT05712941|Placebo Comparator|Letrozole 2.5mg by mouth once a day (QD) + Placebo|
89004211|NCT05709457|Experimental|RCT Participants|Women and children who participated in the earlier study.
89004212|NCT05709457|No Intervention|Non-RCT participants|Women and children in the same communities included in the earlier study who did not participate in that study.
89004213|NCT05701007||Patients diagnosed with metastatic castration sensitive prostate cancer (mCSPC)|
89004214|NCT05701007||Patients diagnosed with metastatic castration resistant prostate cancer (mCRPC)|
89004215|NCT05694936|Experimental|Experimental arm (n=60)|Panitumumab 6 mg/kg IV every 2 weeks or cetuximab 500 mg/m2 IV every 2 weeks, with sodium valproate oral continuously in a twice daily dose (target daily dose of 20 mg/kg/d at Cycle 1 Day 13, then dose adjusted to maintain serum VPA levels within the target range of 50-100 μg/mL)
89535542|NCT02486861||culprit plaque|correlation of OCT characteristics of culprit plaque with incidence of major adverse cardiovascular events (MACEs defined as the composite of death from cardiac causes, non- fatal MI, clinically driven target vessel revascularization (TVR), or re-hospitalization due to unstable or progressive angina according to Braunwald Unstable Angina Classification) and clinical baseline characteristics.
89004216|NCT05694936|Active Comparator|Control arm (n=30)|Panitumumab 6 mg/kg IV every 2 weeks or cetuximab 500 mg/m2 IV every 2 weeks
89004218|NCT05687188||Retrospective Cohort|Retrospective chart review and sample analysis of both pathologically confirmed Pancreatic Ductal Adenocarcinoma (PDAC) cases and non-Cancer control cases.
89004219|NCT05687188||Prospective Cohort|Blood samples, tissue samples and data will be collected from all participants as applicable.
89004220|NCT05668923|Experimental|Speech sound stimulation|Speech sound stimulation via behavioral, electrophysiological, and magnetic resonance imaging-based tasks
89004221|NCT05647772|Experimental|Group 1: Standalone App|Standalone parenting app called UseIt!
89004222|NCT05647772|Experimental|Group 2: App plus Coach|Standalone parenting app called UseIt! plus a coach.
89004223|NCT05647772|Active Comparator|Group 3: Control App|Control condition: mindfulness app called SmilingMind.
89189906|NCT04684238|Active Comparator|Drug: Midazolam|Midazolam for sedation in the ICU
89004224|NCT05646303|Experimental|Psilocybin|2 oral doses of 25mg psilocybin capsules
89004225|NCT05646303|Placebo Comparator|Placebo|2 oral doses of placebo (microcrystalline cellulose) capsules
89004226|NCT05630209|Experimental|Blood Brain Barrier Disruption (BBBD)|Exablate MR Guided Focused Ultrasound for Blood Brain Barrier Disruption with Doxorubicin for treating pediatric patients with DIPG
89004227|NCT05615623|Experimental|Blood Brain Barrier Disruption (BBBD)|Exablate MR Guided Focused Ultrasound for Blood Brain Barrier Disruption with Doxorubicin for treating pediatric patients with DIPG
89004228|NCT05601765|Active Comparator|Standard communication pathways after discharge|"Patients who need contact within 72 hours of discharge are advised to call the bed section, from where they were discharged. Telephone counseling can be provided by the nurses available at the time of calling (e.g., questions for medical treatment, precautions after surgery etc.).~If deemed relevant, the patient may be asked to appear in person at the ward (e.g., for the examination of wounds).~If more serious conditions are suspected, a doctor or emergency department will be contacted by the nurse for assessment, triage and possibly readmission.~Patients who need contact after 72 hours of discharge are advised to call the outpatient clinic, if they have planned attendances here, or alternatively their own general practitioner or home care nurse.~Standard communication pathways between healthcare professionals across sectors are electronic correspondences and telephone inquiries."
89189907|NCT04684238|Experimental|Drug: Isoflurane|Volatile for sedation in the ICU
89189908|NCT04638543|Experimental|ABP-671|The study will consist of three sequential groups with escalating total daily ABP-671 doses. Each group is further divided into two dose cohorts with either QD or BID dosing.
89011506|NCT01643824|Experimental|Proton Beam Therapy|"Prescription dose to PTV as according to the following dose escalation schema: Arml 1: 60 GyE /10 fx, 6GyE fraction dose, 5 days/week, for HCC free from the alimentary tract (i.e., stomach, duodenum, esophagus, small and large bowel) (more than 2cm from clinical target volume), TLV30 <40%, and/or RLV30 <30%) Arm 2: 50 GyE /10 fx, 5GyE fraction dose, 5 days/week, for HCC close to the alimentary tract (less than 2cm from clinical target volume) but not contact with the alimentary tract, TLV30<50% and RLV30<40% Arm 3: 35 GyE /10 fx, 4GyE fraction dose, 5 days/week, for HCC contact to the alimentary tract (contact with clinical target volume), TLV30<60%, and/or RLV30<50%~Dose prescription : 95% isodose volume of prescribed dose encompassed PTV"
89011507|NCT04528966|Experimental|Treatment Group|Group that have received whole-body vibration treatment in addition to conventional physiotherapy
89189909|NCT04638543|Placebo Comparator|Placebo|
89402722|NCT06091605|Active Comparator|Envelope flap combined with a sub-epithelial connective tissue graft|"Patients will undergo peri-implant soft tissue augmentation procedures accompanied by the placement of healing abutments at the uncovering of the inserted osseo-integrated implants, 12 weeks after the initial stage of implant placement.~An envelope split thickness flap will be made at the concerned implant site and a connective tissue graft will be harvested from the tuberosity and then adapted to the placed healing abutment at the surgical site and suturing will be done."
89402723|NCT06091592||Patient ( cancer)|. The colorectal cancer patient group included clinical stage 1-3 patients of both sexes. Patients with metastatic disease, those who received neoadjuvant therapy, those who received systemic chemoradiotherapy, those who had any known systemic inflammatory or autoimmune disease, those with another concurrent malignancy, and those who had been previously diagnosed and treated for another malignancy were excluded from the study.
89402724|NCT06091592||Control (healthy volunteer)|The control group included healthy volunteers who had undergone screening colonoscopy within the last month, had no pathology, had not been diagnosed with any malignant disease before, had no known systemic inflammatory or autoimmune disease, and had not been diagnosed with inflammatory bowel disease.
89402725|NCT06091579|Experimental|Part A (SAD Cohort 1): TPIP|Participants in the single ascending dose (SAD) Cohort 1 received a single dose of TPIP at Dose A, Dose B, or Dose C by oral inhalation on Day 1.
89402726|NCT06091579|Experimental|Part A (SAD Cohort 2): TPIP or Placebo|Participants in SAD Cohort 2 received a single dose of TPIP at Dose D or matching placebo by oral inhalation on Day 1.
89402727|NCT06091579|Experimental|Part A (SAD Cohort 3): TPIP or Placebo|Participants in SAD Cohort 3 received a single dose of TPIP at Dose E or matching placebo by oral inhalation on Day 1.
89402728|NCT06091579|Experimental|Part B (MAD Cohort 1): TPIP or Placebo|Participants in the multiple ascending dose (MAD) Cohort 1 received TPIP at Dose B, Dose C or matching placebo, once daily (QD) by oral inhalation on Days 1 through 7.
89402729|NCT06091579|Experimental|Part B (MAD Cohort 2): TPIP or Placebo|Participants in MAD Cohort 2 received TPIP up to Dose D or matching placebo, QD by oral inhalation on Days 1 through 7.
89402730|NCT06091553|Active Comparator|Duloxetine alone (as monotherapy)|Duloxetine alone (as monotherapy)
89402731|NCT06091553|Active Comparator|Duloxetine augmented with gabapentin (as combined therapy)|Duloxetine augmented with gabapentin (as combined therapy)
88877932|NCT04288752|Experimental|VR101 Lubricating Intravaginal Ring|VR101 is a clear, flexible, torus-shaped lubricating intravaginal ring (IVR) manufactured from hollow tubing formed from Excipient Grade Thermoplastic Urethane Pathway® Polymer PY-PT42DE35 by hot-melt extrusion. Subjects randomized to this arm will be asked to use each ring for 7 days and replace with a new ring each week for 4 weeks. This will be followed by an optional 2-week open-label extension with active rings and a 1-week follow-up.
88877933|NCT04288752|Sham Comparator|Sham Ring|"Performance of VR101 will be compared to that of an inactive ring. Subjects randomized to this arm will be asked to use each ring for 7 days and replace with a new ring each week for 4 weeks. This will be followed by an optional 2-week open-label extension with active rings and a 1-week follow-up.~Sham rings are visually identical to VR101 Lubricating Intravaginal Rings, but no lubricating solution was added."
88877934|NCT04287036|Experimental|Test/Control|Eligible Subjects aged 18 to 39 years (inclusive) who are habitual soft contact lens wearers will be randomized into sequence, Test/Control
88877935|NCT04287036|Experimental|Control/Test|Eligible Subjects aged 18 to 39 years (inclusive) who are habitual soft contact lens wearers will be randomized into sequence, Control/Test.
88877936|NCT04284930|Experimental|Depobupivacaine|Group 1 will receive an injection of 166mg of Depobupivacaine diluted in 60 ml.
88877937|NCT04284930|Active Comparator|OnQ Pump|Group 2 : The OnQ group will receive an infiltration via an OnQ soaker catheter of 0.25% bupivacaine at 4 ml/hour.
88877938|NCT04284930|Active Comparator|bupivacaine|Group 3: The 0.25% bupivacaine patients will receive 2mg/kg of 0.25% bupivacaine.
89402732|NCT06091553|Active Comparator|Duloxetine augmented with amitriptyline (as combined therapy)|Duloxetine augmented with amitriptyline (as combined therapy)
89402733|NCT06091553|No Intervention|control|control
89402734|NCT06091527|Experimental|Yoga practice|Yoga practice groups
89402735|NCT06091527|Active Comparator|Education|Education module group
89402736|NCT06091488|Experimental|Experimental|Patients with anterior cruciate ligament injury, in which the patient's own autologous tendons cannot be used, will be treated with the ligamentous reconstruction device.
89402737|NCT06091475|Experimental|Withdrawal of treatment with eplerenone or spironolactone, and empagliflozin and dapalgiflozin|Gradual, supervised withdrawal of ineralocorticoid receptor antagonists (spironolactone or eplerenone) and sodium glucose cotransporter 2 inhibitor (dapagliflozin or empagliflozin) over 4-16 weeks. Continued monitoring off study therapies during the cross-over phase.
88877939|NCT04267770|Experimental|circadian insulin infusion rates|Initial variable basal rates aim to replicate circadian changes in insulin requirements and are derived from total basal insulin in adults over 24 years old, and from weight in adults aged 18 to 24 years.
88877940|NCT04267770|Active Comparator|flat rates|flat basal rate
88877941|NCT04252092|Experimental|Sensory Group|15 patients who will be applied 15 sessions of sensory training
88877942|NCT04252092|Experimental|Electrical Stimulation Group|15 patients who will be applied 15 sessions of electrical stimulation
88877943|NCT04204200|Active Comparator|Allocated to conventional vitamin C (n= 22)|"Received allocated conventional vitamin C (n= 22)~Did not receive allocated conventional vitamin C (n= 0)"
88877944|NCT04204200|Active Comparator|Allocated to liposomal vitamin C (n= 22)|"Received allocated liposomal vitamin C (n= 22)~Did not receive allocated liposomal vitamin C (n= 0)"
88877945|NCT04204200|Placebo Comparator|Allocated to placebo (n= 22)|"Received allocated intervention (n= 22)~Did not receive allocated intervention (n= 0)"
88877946|NCT04179474|Experimental|Part 1 (Intervention A then B then D)|Intervention A: Single oral dose of ubrogepant 100 mg tablet on Day 1 under fasted conditions; followed by Intervention B: Single subcutaneous (SC) injection of erenumab 140 mg on Day 8; followed by Intervention D: Ubrogepant 100 mg tablet orally once daily on Days 12, 13, 14 and 15 under fasted conditions.
88877947|NCT04179474|Experimental|Part 2 (Intervention A then C then D)|Intervention A: Single oral dose of ubrogepant 100 mg tablet on Day 1 under fasted conditions; followed by Intervention C: Two SC injections of galcanezumab 120 mg on Day 8; followed by Intervention D: Ubrogepant 100 mg tablet orally once daily on Days 12, 13, 14 and 15 under fasted conditions.
88877948|NCT04174638|Experimental|"Intervention Group"|The intervention group received 15 minute motivational interviewing based on Watson's Theory of Human Caring once a month for 12 weeks and one session 30 minutes education with educational booklet based on Watson's Theory of Human Caring.
88877949|NCT04174638|No Intervention|"Control Group"|The control group received routine hemodialysis treatment and nursing care in the hemodialysis unit.
89402738|NCT06091475|No Intervention|Continued treatment with eplerenone or spironolactone, and empagliflozin and dapagliflozin|Continuation of usually prescribed pharmacological therapy over 16 weeks followed by cross-over to withdrawal of SGLT2i and MRA over the subsequent 4-16 weeks.
89402739|NCT06091462|Experimental|virtual reality group|"Participants in the intervention group will log into the virtual reality-based interactive therapeutic patient education program with a username and password to be defined for them on the hadi.hacettepe.edu.tr website. After completing the dementia module in this program, the participants will complete the application by switching to the virtual reality-based interactive therapeutic patient education program."
89402740|NCT06091462|No Intervention|control group|Participants in the control group, on the other hand, will not receive any educational intervention other than standard education. In parallel with the completion of the application by the participants in the intervention group, the participants in the control group will complete the post-tests.
88877950|NCT04152642|Active Comparator|Marketed Mouth Rinse|dry mouth rinse to be taken up to 5x a day, at least twice a day, 15 ml for 30 seconds. Subjects will be restricted from using mouth rinse, acclimation products, eating or drinking for 4-hours after first use (on-site) on Day 1 and Day 4.
88877951|NCT04152642|Experimental|Experimental Mouth Rinse|dry mouth rinse to be taken up to 5x a day, at least twice a day, 15 ml for 30 seconds. Subjects will be restricted from using mouth rinse, acclimation products, eating or drinking for 4-hours after first use (on-site) on Day 1 and Day 4.
88877952|NCT04152642|Sham Comparator|Water/Negative Control|subjects will swallow 15 ml of water (on-site). Subjects will be restricted from using mouth rinse, acclimation products, eating or drinking for 4-hours after water intake (on-site) on Day 1 and Day 4.
88877953|NCT04150224|Experimental|Cohort 1 (C1A), PBTZ169|Two doses of PBTZ169: 640 mg OD fasted and 640 mg OD after meal. Wash-out period ≥6 days.
88877954|NCT04150224|Experimental|Cohort 1 (C1B), PBTZ169|Two doses of PBTZ169: 640 mg OD after meal and 640 OD mg fasted. Wash-out period ≥6 days.
89402741|NCT06091449|Experimental|High fidelity simulation|The Faculty of Nursing has a simulation laboratory to enable students to realize their professional skills in a high-reality environment. The laboratory has all the equipment that should be found in a clinic, such as a high-reality simulation mannequin, nurse's table, patient bed, shelves, monitors, bedside oxygen systems, treatment and emergency response carts.Lab; It consists of 3 sections: application room, control room and analysis room.
89402742|NCT06091449|Experimental|High fidelity simulation and virtual reality|"The modular education and virtual reality-based simulation program is currently actively available on the hadi.hacettepe.edu.tr website. Students who will benefit from this program can access the program after defining a username and password.The application of high-fidelity simulation is the same in both groups."
89402743|NCT06091436|Experimental|GenSci094|Participants received a single subcutaneous (SC) injection of 150 µg or 100µg GenSci094 on day 2 or 3 of the menstrual cycle (Stimulation Day 1); 7 daily SC injections from Stimulation Days 1 to 7 with placebo-recFSH; followed by daily SC injections with 150 IU or225IU recFSH up to the day of hCG. Daily SC injections of Ganirelix were administered from Stimulation Day 5 to the day of hCG; at which time a single dose of hCG was given when 3 follicles >= 17 mm. On the day of oocyte pick up (OPU) daily doses of progesterone were started and continued for up to 6 weeks or menses.
89402744|NCT06091436|Active Comparator|recFSH|Participants received a single SC injection of placebo GenSci094 on day 2 or 3 of the menstrual cycle (Stimulation Day 1); 7 daily SC injections with 150 IU or 225IU recFSH from Stimulation Days 1 to 7; followed by daily SC injections with 200 IU recFSH up to the day of hCG. Daily SC injections of Ganirelix were given from Stimulation Day 5 to the day of hCG; at which time a single dose of hCG was administered when 3 follicles >= 17 mm. On the day of OPU daily doses of progesterone were started and continued for up to 6 weeks or menses.
89402745|NCT06091384|Experimental|Inspiratory Muscle Strength Training|Using a handheld device, participants will perform 30 breaths a day at 75% of maximal inspiratory pressure, six days a week, for 6 weeks.
89402746|NCT06091384|Sham Comparator|Sham- Inspiratory Muscle Training|Using a handheld device, participants will perform 30 breaths a day at 15% of maximal inspiratory pressure, six days a week, for 6 weeks.
89402747|NCT06091345|Experimental|Midodrine+Albumin+SMT|"Albumin infusion 1g/kg/day (max 20g) every two weeks (if pre-infusion serum albumin is < 3.5 gm/dl Plus~Midodrine starting at 0.25mg/kg/day in divided doses, increased to 0.5mg/kg/day after 7 days if MAP does not increase by >10% .~In addition, standard medical therapy will be administered to patients in both the arms."
89402748|NCT06091345|Active Comparator|Midodrine+SMT|• Midodrine starting at 0.25mg/kg/day in divided doses, increased to 0.5mg/kg/day after 7 days if MAP does not increase by >10% In addition, standard medical therapy will be administered to patients in both the arms.
89402749|NCT06091332|Experimental|High-dose sirolimus group|Participants will receive oral sirolimus with a target blood concentration of 10-15ng/ml continuously for 12 months.
89402750|NCT06091332|Experimental|Low-dose sirolimus group|Participants will receive oral sirolimus with a target blood concentration of 3-7ng/ml continuously for 12 months
89402751|NCT06091332|Placebo Comparator|Placebo control group|Participants will receive oral placebo(starch formulation) for 12 months.
89402752|NCT06091319||Acute atherosclerotic disease event group|Patients with a recent ACS (i.e. STEMI or NSTEMI), stroke or transient ischemic attack.
89402753|NCT06091319||Control|A control population of patients with known vascular disease but without recent ACS, stroke/TIA.
89402754|NCT06091280|Experimental|Respiratory Muscle Strength Training|"Pursed Lip Breathing: Participants will perform two sets of 10 repetitions twice per day.~Inspiratory Muscle Strength Training (IMST): The participant will use an IMST trainer provided by the study (Threshold Inspiratory Muscle Strength Trainer). This exercise is repeated for a 3-minute duration, followed by a rest period of 2 minutes. This cycle is repeated for 6 cycles over a 30-minute timespan. This exercise will be performed 3 times/week on alternating days.~Expiratory Muscle Strength Training (EMST): The participant will use an EMST trainer (EMST 150) provided by the study. This exercise is repeated for a 3-minute duration, followed by a rest period of 2 minutes. The cycle is repeated for 6 cycles over a 30-minute timespan. This exercise will be performed 3 x/week on opposite days of the inspiratory muscle strength training."
89402755|NCT06091241|Other|Group 1: Erector Spinae Plane blocks|Erector Spinae Plane blocks
89402756|NCT06091241|Other|Group 2: Transversus Abdominis Plane blocks|Transversus Abdominis Plane blocks
89402757|NCT06091228|No Intervention|Control- No tongue scraping full length of study|Oral hygiene instructions before and after non-surgical treatment without inclusion of tongue scraper
89402758|NCT06091228|Experimental|Test 1 - tongue scraping full length of study|Oral hygiene instructions before and after non-surgical treatment with inclusion of tongue scraper
89402759|NCT06091228|Experimental|Test 2 - tongue scraping only after non-surgical therapy|Oral hygiene instructions before and after non-surgical treatment with inclusion of tongue scraper only after treatment
88877955|NCT04150224|Experimental|Cohort 2 (C2), PBTZ169|Single dose of PBTZ169: 960 mg fasted
88877956|NCT04150224|Experimental|Cohort 3 (C3), PBTZ169|Two doses of PBTZ169: 640 mg twice a day (fasted) with a 12-hour interval; total daily dose - 1280 mg
89402760|NCT06091202|Active Comparator|CORPs Intervention|"The CORPs Intervention is a nurse-led intervention. During the pilot the CORPs intervention includes:~An intake assessment with a Nurse Care Manager at the start of the study by phone or video to discuss the patient's pain experience, care options, and goals.~A check-in appointment with a Nurse Care Manager around 2-weeks by phone/video to follow-up on options and goals discussed during the intake appointment."
89402761|NCT06091202|Placebo Comparator|Minimally Enhanced Usual Care (MEUC)|"The Minimally Enhanced Usual Care (MEUC) comparator during the pilot includes:~1) One-time consult placed to a VA pain team."
88877957|NCT04150224|Experimental|Cohort 4 (C4), PBTZ169|Single dose of PBTZ169: 1280 mg fasted
89402762|NCT06091163|Experimental|Ketogenic Diet (KD)|Participants allocated to this condition will receive 6-weeks of home-delivered pre-prepared ketogenic diet (KD) meals (3 meals/day, snacks) from a vetted ketogenic diet food supplier. The 6-week intervention includes a weekly 30-minute dietary counselling call with a registered dietitian to support following a ketogenic diet. Participants receive educational materials with information about foods that are compatible with the diet, common symptoms and how to manage them, and strategies to help maintain the diet during and after the 6-week intervention period.
89402763|NCT06091163|Placebo Comparator|Phytonutrient Diet (PD)|Participants in the control group will receive weekly 30-minute dietary counselling with a registered dietitian and be asked to increase vegetable consumption and reduce saturated fat intake as part of a phytonutrient diet (PD). Participants will receive food vouchers every 2-weeks to help purchase food items or replacements that support high vegetable, low saturated fat intake. This aims to be a plausible placebo dietary treatment for depression. There is no clear evidence that these manipulations will change depression severity. The dietitian will provide materials to explain the diet and suggest foods by colour with supporting recipe suggestions.
89402764|NCT06091150|Experimental|Patients with direct carotid cavernous fistula|Endovascular management using coils , detachable balloons or embolizing agents
89402765|NCT06091137||Non-appendectomy controls|
89402766|NCT06091137||Appendectomy cases|
89402767|NCT06091072|Experimental|Patients scheduled for sentinel node procedure|This is a single-center observational feasibility study to evaluate the overall performance of the surgical navigation system during robotic surgery, without impact on the surgical procedure itself. The duration of this study will be approximately 2.5 years. Patients scheduled for a sentinel node procedure at the NKI are eligible for inclusion. Patients are informed about the study before the planned surgery and, after being provided with the necessary information regarding participation in the study, will be asked for informed consent. No additional risk is expected using the NDI navigation setup. Patients will receive some additional radiation due to the CT scan during surgery; a perioperative CBCT scan (~ 4 mSv) is acquired. This extra dose is low, considering other standard imaging in these patients like, pre-operative imaging with SPECT/CT scans. After surgery, no further participation or cooperation of the patient is required.
89402768|NCT06091033|Experimental|Fermented rice group|This group takes black rice (Oryza Sativa L.) extract fermented with Lactobacillus for 8 weeks.
89402769|NCT06091033|Placebo Comparator|Control group|This group takes a placebo for 8 weeks.
89402770|NCT06090994|Experimental|Huaier Granule|Huaier granules should be taken continuously for at least 6 months until the end of the study, intolerable toxicity, withdrawal from the study for any reason, disease progression or death, whichever occurs first; Or the researcher determines that the subject no longer benefits. During the treatment period with Huaier Granules, the experimental group subjects are prohibited from using any other anti-tumor treatment regimen or other immune modulators (specific instructions shall prevail).
89402771|NCT06090994|No Intervention|Standard treatment|This includes the standard radiotherapy and chemotherapy regimen recommended by researchers in combination with the latest guidelines and clinical routines. The standard chemotherapy regimen includes Xelox regimen, mFOLFOX regimen, etc. Please refer to the drug manual for specific usage. The control group subjects are forbidden to use Huaier Granules or traditional Chinese patent medicines and simple preparations with similar efficacy or indications to Huaier Granules or other immunomodulators (the specific instructions shall prevail).
88877958|NCT04150224|Experimental|Cohort 5 (C5), PBTZ169|Multiple administration of PBTZ169: 1280 mg once a day after meal for 14 days
88877959|NCT04116684|Experimental|Intervention Group (digital BP monitoring)|This group will receive a Withings digital BP monitor to transmit recordings to the study team who will make medication adjustments.
88877960|NCT04116684|No Intervention|Standard of care BP monitoring|This group will use a standard BP cuff and record and transmit data to their medical team as instructed by their providers or if they are concerned.
88877961|NCT04102956|Experimental|Kallikrein+Standard treatment group|The Kallikrein+Standard treatment group was given kallikrein through intravenous injection to treatment for 0.15 PNA/day+standard treatment medicine based on the guidelines for the treatment of acute ischemic stroke for 14 ± 5 days.
88877962|NCT04102956|No Intervention|Standard treatment group|The Standard treatment group was only given standard treatment medicine based on the guidelines for the treatment of acute ischemic stroke for 14 ± 5 days.
89189910|NCT04628377||Diagnostic Accuracy Cohort|Patients are subgroup of previously published study (JACC Cardiovascular Intervention 2020;13:1155-67), which evaluated invasive physiologic indices from culprit and non-culprit vessels of acute myocardial infarction patients. From the study cohort, 31 STEMI patients who underwent IMR measurement in culprit vessel after successful revascularization will be analyzed. In these patients, diagnostic accuracy of angiography-derived IMR will be compared with invasive IMR.
88877963|NCT04086576|Experimental|Commercial Smartphone-paired breathalyzers-Set 1|All subjects will first be given a priming dose of alcohol containing vodka designed to raise the blood alcohol content based on weight and gender. Blood alcohol content will first be measured with three commercial smartphone-paired breathalyzers: Drivesafe Evoc, Alcohoot, and BacTrack Pro which will be tested in a randomized order and recorded. Participants blood alcohol content will also be measured using the Intoxilyzer 240, a police grade breathalyzer device After the tertiary dose of alcohol, a nurse will perform a blood draw on the participants, which will be used to determine blood alcohol content.
89011508|NCT04528966|Active Comparator|Control group|Group that have received conventional physiotherapy only
89402772|NCT06090981|Experimental|Early bolus surfactant replacement therapy|Neonates randomized to this group will receive early bolus surfactant replacement therapy within 2hr of life
89402773|NCT06090981|No Intervention|Standard care|Neonates randomized to this group will be managed as per standard protocol in the neonatal unit.
89402774|NCT06090955|Experimental|Dexmedetomidine group|Patients in the dexmedetomidine group will be administered a bolus of 0.3 ug/kg intravenous dexmedetomidine over 10 min before anesthetic induction. After bolus injection, a continuous infusion of 0.3 ug/kg/hr of intravenous dexmedetomidine will be administered until the end of surgery.
89402775|NCT06090955|Experimental|Lidocaine group|Patients in the lidocaine group will receive a bolus of 1.5 mg/kg intravenous lidocaine over 10 min before induction of anesthesia. A continuous infusion of 1.5 mg/kg/hour of systemic lidocaine will be administered until the end of the surgery.
89402776|NCT06090955|Placebo Comparator|Control group|Patients in the control group will be administered equal volumes of 0.9% saline using the identical application scheme.
89402777|NCT06090942|Experimental|Cognitive training|Smartphone-based cognitive training
89402778|NCT06090942|No Intervention|Usual care|No intervention
89402779|NCT06090929|Experimental|Patients with STN-DBS|Patients accepted DBS implanted at the baseline
89402780|NCT06090929|No Intervention|Patients without STN-DBS|Patients only accepted medication treatment before the end point
89402781|NCT06090916|Active Comparator|ARM I (Standard of care)|Patients receive standard nutrition care and record dietary intake and physical activity using Myfitness Pal smartphone application on study.
89402782|NCT06090916|Experimental|ARM II (Dietary intervention)|Patients undergo malnutrition screening with a registered dietician at baseline and participate in 12 weekly nutrition support sessions and those at moderate to high risk for malnutrition receive a personalized diet prescription on study. Patients also record dietary intake and physical activity using Myfitness Pal smartphone application on study.
89402783|NCT06090903|Experimental|Screening (MRI)|Patients undergo one MRI scan over approximately 1 hour prior to surgery.
89402784|NCT06090890|Active Comparator|control group|DAPT (aspirin+1 P2Y12 receptor antagonist) + Lipid-lowering drugs + hypoglycemic drugs and hypotensive drugs (if necessary)
89402785|NCT06090890|Experimental|Colchicine group|DAPT (aspirin+1 P2Y12 receptor antagonist) + Lipid-lowering drugs + hypoglycemic drugs and hypotensive drugs (if necessary) + Colchicine (0.5mg QD, orally)
89402786|NCT06090890|Experimental|Prednisone group|DAPT (aspirin+1 P2Y12 receptor antagonist) + Lipid-lowering drugs + hypoglycemic drugs and hypotensive drugs (if necessary) + Prednisone (0.5mg/kg QD, orally)
89011509|NCT01643863||Cohort|
89198985|NCT00963274|Experimental|bortezomib + romidepsin|Bortezomib via a short intravenous infusion (3-5 seconds) followed by romidepsin via a 4 hour intravenous infusion weekly x 3 every 4 weeks. In order to identify appropriate doses, different subjects will be treated with different drug doses and observed for the effects, especially the side effects associated with higher doses.
89198986|NCT00882609|Active Comparator|TC-MDP Bone Scan|Patients without known bone metastases who are newly diagnosed with ≥ stage 3 breast cancer, ≥ stage 3 lung cancer, or ≥ stage 2 prostate cancer (and/or PSA >10 micrograms/L), including patient with recurrent breast, lung or prostate cancer; Patient is scheduled to undergo a conventional bone scan
89402787|NCT06090851|Active Comparator|verum|pralines containing nitrate 3x day (200mg nitrate per day)
89402788|NCT06090851|Placebo Comparator|placebo|pralines without nitrate
89402789|NCT06090838|Experimental|Intervention, BPA|Will receive questionnaires, exercise testing and BPA at baseline, follow up with questionnaires and exercise testing will be done at 6,12 and 24 months.
89402790|NCT06090838|No Intervention|Control, no BPA|Will receive questionnaires, exercise testing at baseline. Due to the crossover design, they will receive BPA at 6 months. Follow up with questionnaires and exercise testing will be done at 6,12 and 24 months.
89402791|NCT06090825||Pancreatic cancer patients|
89402792|NCT06090812||acute brain injury|The included population was patients with acute brain injury, protected from acute cerebrovascular events, traumatic brain injury, and acute cerebral edema. Assessment of stress levels, Ultrasound evaluation of volume status, right heart function, and pulmonary edema.
89402793|NCT06090786|Other|MRD evaluation|Evaluation of MRD at pre-defined timepoints in AML patients treated with Azacitidine and Venetoclax
89402794|NCT06090760|Experimental|Mindfulness Intervention Group|Mindfulness training will be provided to the participant after randomization for dealing with social media use.
89402795|NCT06090760|No Intervention|Waitlist Control Group|No mindfulness training will be provided to the participants.
89402796|NCT06090747|Active Comparator|Evaluate the effect of hybrid educational intervention in Lifestyle behavior.|Group 1: hybrid educational intervention
89402797|NCT06090747|Experimental|Evaluate the effect of hybrid personalized intervention in Lifestyle behavior|Group 2: hybrid personalized lifestyle intervention delivered by a multidisciplinary team of specialists in oncology, nutrition, psychology, rehabilitation and mindfulness.
89402798|NCT06090708|No Intervention|Control group|Children with acute gastroenteritis received standard hospital care and the prescribed medication of control group for acute gastroenteritis.
89402799|NCT06090708|Experimental|Probiotic Study Group|Children with acute gastroenteritis received fresh probiotic yogurt (1st day of production) for three consecutive days in addition to standard hospital care and prescribed medication for acute gastroenteritis.
89402800|NCT06090682||Cognitive Impairment (CI) group and No Cognitive Impairment (NCI) group|"We intend to recruit 200 patients with primary PD to undergo DBS surgery or only TMS treatment according to whether the surgical indication is available. We will observe the changes in cognitive function of patients before and after different brain stimulation treatments.~Parkinson's disease patients with cognitive impairment after brain stimulation were divided into cognitive impairment group, and those without cognitive impairment after treatment were divided into no cognitive impairment group"
89402801|NCT06090656|Active Comparator|Bevacizumab combined with Sintilimab|Bevacizumab combined with sintilimab, sindilizumab 200 mg IV d1, Q3W, combined with bevacizumab 15 mg/kg IV d1, Q3W treatment, treatment continued until disease progression, development of intolerable toxic reactions
89402802|NCT06090656|Sham Comparator|Transcatheter arterial chemoembolization|Transcatheter arterial chemoembolization, patients were treated with cTACE, and the efficacy was assessed by repeat CT/MRI 1 month after the initial treatment, and if the tumor still had arterial phase enhancement, TACE treatment could be supplemented until treatment failure and withdrawal of consent.
89402803|NCT06090643|Active Comparator|Arm II (usual care)|Physicians and clinic staff provide and patients recieve CRC screening usual care throughout the trial.
89402804|NCT06090643|Experimental|Group I (education, feedback, consult, FIT kit, text message)|Physicians and clinic staff receive ongoing training, education, and feedback on CRC screening, and utilize point-of-care clinical decision support tool throughout the trial. Patients receive CRC screening recommendations from provider, a FIT kit with culturally tailored instructions, consultation with clinic staff, and text message reminders throughout the trial.
89402805|NCT06090630|Experimental|Diagnostic (DWI, magnetic resonance spectroscopic imaging)|Participants undergo DWI over 15 minutes and MR spectroscopic imaging over 45 minutes.
89402806|NCT06090552|Other|Letter, AD, PREPARE|Letter about ACP, PREPARE advanced directive (AD), PREPARE website
89402807|NCT06090552|Other|Letter, AD, PREPARE, reminders|Letter, AD, PREPARE plus reminder text/phone messages
89402808|NCT06090552|Other|Letter, AD, PREPARE, reminders, healthcare naviagator, patient reported engagement|Letter, AD, PREPARE website plus reminders plus a healthcare navigator on ACP documentation (discussions and careplans, primary outcome) and patient-reported ACP engagement
89402809|NCT06090526||cases group|. first group (case group) will include 40 patients who will be suspected to have urinary septicemia at intensive care units of Ain Shams university.
89402810|NCT06090526||control group|Second group (control group) will include 40 nonhospitalized, healthy age and sex matched adults.
89198987|NCT00882609|Experimental|F18-Fluoride PET/CT|Patients without known bone metastases who are newly diagnosed with ≥ stage 3 breast cancer, ≥ stage 3 lung cancer, or ≥ stage 2 prostate cancer (and/or PSA >10 micrograms/L), including patient with recurrent breast, lung or prostate cancer; Patient is scheduled to undergo a conventional bone scan
89198988|NCT00883623|Experimental|Treatment Arm|Treatment Arm
89402811|NCT06090487|Other|Group sacubitril: (study group)|This group includes (15) patients who will have 200 mg twice daily oral (5) sacubitril-valsartan 1 month before the operation.
89402812|NCT06090487|Other|Group dapagliflozin: (control group):|This group includes (15) patients who will have a 10 mg single oral dose (4) 1 month before the operation.
89402813|NCT06090461||naltrexone 8mg and bupropion 90mg extended-release oral tablet (NB)|A total daily dosage of two NB 8 mg/90 mg tablets twice daily (32 mg/ 360 mg) is reached at the start of Week 4, following titration.
89402814|NCT06090461||lorcaserin|A total of one 10 mg tablet administered orally twice daily; or one 20 mg tablet administered orally once daily.
89402815|NCT06090435|Experimental|Therapeutic exercise plus motor imagery|
89402816|NCT06090435|Experimental|Therapeutic exercise plus action observation|
89402817|NCT06090435|Active Comparator|Therapeutic exercise|
89402818|NCT06090422|Experimental|Intervention group|Ketamine, 0,8 mg/kg body weight, given as four single doses (biweekly for two weeks)
89402819|NCT06090422|Active Comparator|Control group|Midazolam, 0,8 mg/kg body weight, given as four single doses (biweekly for two weeks)
89402820|NCT06090409|Experimental|Free/Subsidized Community Supported Agriculture (CSA) produce along with education.|Patients who self-elect to enroll in subsidized/free Community-supported agriculture produce shares will also receive Education on the benefits of a plant-based diet.
89402821|NCT06090409|Active Comparator|Education Alone|Patients will receive educational information about the benefits of plant-based eating.
89402822|NCT06090318|Experimental|Milademetan (RAIN-32) in Combination With Atezolizumab|"Milademetan (RAIN-32): 260 mg orally on 3 consecutive day sets with a minimum of 14 days and a maximum of 21 days between the first day of each 3- day dosing set.~Atezolizumab: Atezolizumab IV infusion is to be administered on Day 1 of each 28- day cycle."
89402823|NCT06090292|Experimental|Real TUS + Real FES|"Participants will receive Real TUS using a 2 channel transducer with parameters' of sonication being 120s train of 20ms ultrasound bursts, repeated every 200ms (Pulse Repetition Frequency (PRF)=5Hz). The Power of Real tbFUS will be set at 20W. This will be followed by motor point stimulation (MPS) of the right and left hand and forearm muscles i.e. Opponens Pollicis Brevis (OPB), 1st Lumbrical and First Dorsal Interosseous (FDI) muscles triggered in congruence with the voluntary effort of the participant during execution of bilateral functional tasks involving the use of two and three finger pinch grip (e.g.: picking up and moving marbles, ball bearings etc.). Parameters of stimulation will be 40 Hz frequency, 300 microsecs pulse duration, amplitude as per participant tolerance and total stimulation time 30 mins with ON time of 4 secs and OFF time of 4 secs."
89402824|NCT06090292|Experimental|Real TUS +Sham FES|"Participants will receive Real TUS using a 2 channel transducer with parameters' of sonication being 120s train of 20ms ultrasound bursts, repeated every 200ms (Pulse Repetition Frequency (PRF)=5Hz). The Power of Real tbFUS will be set at 20W. This will be followed by motor point stimulation (MPS) of the right and left biceps and long finger flexors triggered in congruence with the voluntary effort of the participant during execution of bilateral functional tasks involving the use of two and three finger pinch grip (e.g.: picking up and moving marbles, ball bearings etc.). Parameters of stimulation will be 40 Hz frequency, 300 microsecs pulse duration, amplitude as per participant tolerance and total stimulation time 30 mins with ON time of 4 secs and OFF time of 4 secs."
89402825|NCT06090292|Experimental|Sham TUS +Real FES|"The Sham tbFUS paradigm will consist of 120s train of 20ms ultrasound bursts, repeated every 200ms (Pulse Repetition Frequency (PRF)=5Hz), however the ultrasound head will be flipped so that the active side faces away from the head. This will be followed by motor point stimulation (MPS) of the right and left hand and forearm muscles i.e. Opponens Pollicis Brevis (OPB), 1st Lumbrical and First Dorsal Interosseous (FDI) muscles triggered in congruence with the voluntary effort of the participant during execution of bilateral functional tasks involving the use of two and three finger pinch grip (e.g.: picking up and moving marbles, ball bearings etc.). Parameters of stimulation will be 40 Hz frequency, 300 microsecs pulse duration, amplitude as per participant tolerance and total stimulation time 30 mins with ON time of 4 secs and OFF time of 4 secs."
89402826|NCT06090253|Experimental|Active|Gerotechnology enhanced multi-component exercise or Football training sessions.
89402827|NCT06090253|Experimental|General community-dwelling aged cohort|Gerotechnology enhanced multi-component exercise.
89402828|NCT06090253|Experimental|Geriatric symptoms|Walking exercise and slow sports and exercise.
89402829|NCT06090253|Experimental|Chronic disease burden|Walking exercise and slow sports and exercise.
89402830|NCT06090253|Experimental|Frail|Elderly home gym training service.
88877964|NCT04086576|Experimental|Commercial Smartphone-paired breathalyzers-Set 2|All subjects will first be given a priming dose of alcohol containing vodka designed to raise the blood alcohol content based on weight and gender. Blood alcohol content will first be measured with three commercial smartphone-paired breathalyzers: BACtrack Vio, Drinkmate, and Floome which will be tested in a randomized order and recorded. Participants blood alcohol content will also be measured using the Intoxilyzer 240, a police grade breathalyzer device After the tertiary dose of alcohol, a nurse will perform a blood draw on the participants, which will be used to determine blood alcohol content.
88877965|NCT04075812|Experimental|Neuromuscular Stimulator|Neuromuscular Stimulator is setup and calibrated, various spatial and temporal stimulation patterns will be tested to evoke wrist/hand movements in various sequences of individual and combined movements.
89402831|NCT06090253|No Intervention|Control|No training session will be provided.
89402832|NCT06090214|Experimental|Cases: adenocarcinoma of the ethmoid Group1|Liquid biopsy at the inclusion (V0), d8-d10 (V1) and m2-m3 (V2) of postoperative follow-up.
88877966|NCT04061694|Experimental|Digital Immediate loading|Single dental implant installed with the assistance of fully guided-surgery, submitted to immediate loading with restorations fabricated with the help of intraoral scanning and 3D printing
88877967|NCT04061694|Other|Immediate loading|Historic cohort subjected to immediate loading
89402833|NCT06090214|Active Comparator|Age-matched controls Group 2|Liquid biopsy at the inclusion (V0) only
89402834|NCT06090214|Active Comparator|Exposition-matched controls Group 3|Liquid biopsy at the inclusion (V0) only
89402835|NCT06090188|Experimental|experimental group|Subjects in the experimental group received a series of culture-based multicomponent cognitive training activities via research assistants (RAs) and caregivers of the centres for 8 weeks, then provided by caregivers of the day care centre for 8 weeks with RAs providing assistance with the activity process.
89402836|NCT06090188|Active Comparator|comparison group|Participants in the comparison group received these activities via two RAs and day care caregivers for 16 weeks.
89198989|NCT00959218|Experimental|Dronabinol|
89198990|NCT00959218|Placebo Comparator|Placebo|
89402837|NCT06090149|Experimental|CPAP/APAP INTERVENTION WITH AND WITHOUT OXYGEN SUPPORT|Patients in this group will be selected from the Sleep Disorder Center database for printing data on hypoxemia below 90% during the night and for treatment received (CPAP/APAP and/or oxygen therapy). And from available data in PSCUH data systems on patient diagnoses, previous results of studies (results of blood gas tests), and recommended treatments on hospital and outpatient disease cards, which will include indications of possible chronic hypoxemia. The selected patients will be called (telephone visit) and, if agreed, will be scheduled for study time. Consequently, if the consent questionnaire was signed, a study will be launched following an evaluation of the inclusion and exclusion criteria.
89402838|NCT06090136|Experimental|TPN171H|5 mg TPN171H tablets，single dose,oral
88877968|NCT04057248|Experimental|Digital platform and CDE coaching intervention for patients with type 2 Diabetes|"Patients provided with digital platform and connected devices. They undergo digital and human (CDE) intervention based on patient captured clinical data.~Clinical parameters (HbA1C, weight, lipids profile, etc.) before and after intervention is assessed."
89402839|NCT06090123|Experimental|TPN171H and Itraconazole|Single dose of 10mg TPN171H on Day 1, 200mg Itraconazole(QD) on Days 3-5, 10mg TPN171H and 200mg Itraconazole on Day 6.
89402840|NCT06090123|Experimental|TPN171H and Rifampicin|Single dose of 20mg TPN171H on Day 1, 600mg Rifampicin(QD) on Days 3-9, 20mg TPN171H and 600mg Rifampicin on Day 10.
89402841|NCT06090097|Experimental|KneeBRIGHT Group|The interventional group will conduct all exercises during the 10-week therapy regimen using the KneeBRIGHT electromyogram sensors and game software.
89402842|NCT06090097|Active Comparator|Control Group|The control group will conduct all exercises following a standard physical therapy regimen.
89402843|NCT06090006|Other|No comparison group|In our study sites, a contemporaneous comparison group is not required since no routine screening is currently taking place, and as a result, assessments at baseline will serve as the counterfactual for internal comparisons
89198991|NCT04009954||Delayed transit|CRC patients with delayed gut transit recovery( first time defecation >3 day )
89402844|NCT06089993|Experimental|Exercise|Resistance exercise involves 4 exercises (bench pull, bench press, leg extension and unilateral leg press), that are performed at 75% of maximum, determined from 3-RM test.
89402845|NCT06089993|Experimental|Rest|One hour rest.
89402846|NCT06089941||Detection of circulating tumoral DNA|Blood assessment to detect circultating tumoral DNA
89402847|NCT06089902||adult > 30 years|All adult patient > 30 yrs undergoing diagnosis (incidental or not) of anomalous aortic origin of coronary arteries
89402848|NCT06089902||Juvenile < 30 yrs|All young patient <30 yrs undergoing diagnosis (incidental or not) of anomalous aortic origin of coronary arteries
89402849|NCT06088875|Experimental|Group N (Nebulization group)|Patients will receive a mixture of 2% lidocaine 10 ml and dexmedetomidine 1 μg/kg nebulization + saline 10 ml via spray-as-you-go technique.
89402850|NCT06088875|Experimental|Group S (Spray-as-you-go)|Patients will receive a mixture of 2% lidocaine 10 ml and dexmedetomidine 1 μg/kg via spray-as-you-go technique + saline 10 ml nebulization.
88877969|NCT04053270|Experimental|Group A|Group A was administered active implants on Days 0, 120, 240 and placebo implants on Days 60, 180, 300
89198992|NCT04009954||Normal transit|CRC patients with normal gut transit recovery( first time defecation <=3 day )
89198993|NCT00678210|Experimental|1|
89402851|NCT06088836|Experimental|Group I (Retrolaminar block group)|Patients received ultrasound guided Retrolaminar block bolus dose of 20 ml 0.25% bupivacaine then continuous infusion at a rate of 0.1 mL/kg/hr. for 4 days
89402852|NCT06088836|Experimental|Group II (Erector spinae plane block group)|Patients received ultrasound guided Erector spinae plane block bolus dose of 20 ml 0.25% bupivacaine then continuous infusion at a rate of 0.1 mL/kg/hr. for 4 days
89402853|NCT06088511|Experimental|The Experimental Group|Participants in the Experimental Group will attend an implementation program guided by the Self-Determination Theory (SDT). The 12-week intervention consists of a 4-week, group-based, face-to-face supervised sessions conducted by a well-trained Research Assistant, plus an 8-week self-management phase.
89198994|NCT00678210|Experimental|2|
89402854|NCT06088511|No Intervention|The Control Group|Participants in The Control Group will attend 4-weekly, group-based, regular face-to-face health talks about managing sarcopenia with the exact dosage provided to the intervention group.
89402855|NCT06088446|Active Comparator|Supplementary Intrapulpal injection|Supplementary Intrapulpal injections were given using a 30-gauze needle with sufficient back pressure.
88877970|NCT04053270|Placebo Comparator|Group B|Group B was administered placebo implants on Days 0, 120, 240 and active implants on Days 60, 180, 300
88877971|NCT04051710|Experimental|Group-I (Test)|One inhalation of Beclomethasone dipropionate HFA, 0.04 mg/ INH (Test) twice daily.
88877972|NCT04051710|Active Comparator|Group-II (Reference)|One inhalation of QVAR® 40 mcg (Beclomethasone dipropionate HFA), Inhalation Aerosol twice daily.
88877973|NCT04051710|Placebo Comparator|Group-III (Placebo)|One inhalation of Placebo Inhalation Aerosol twice daily.
88877974|NCT04047342||Standard welcome email|The standard welcome email mentions the benefits of enrollment (maintaining good health and saving money on insurance premiums), the average premium savings, the ease of the registration process, and the deadline for registering and having health measures on file, plus it provides registration steps and hyperlinks for registering and finding free health screenings where health measures can be collected and registered at one convenient time and location.
89198995|NCT00678210|Experimental|3|
89198996|NCT00678210|Placebo Comparator|4|
89402856|NCT06088446|Active Comparator|Intraligamentary injection|Intraligamentary injections were given using an intraligamentary syringe with back-pressure after a failed primary inferior alveolar nerve block.
89402857|NCT06087510|Active Comparator|Low-dose group|Patient-controlled analgesia is established with esketamine 50 mg, dexmedetomidine 200 microgram, and sufentanil 4 microgram/kg (maximum 250 microgram), diluted with normal saline to 200 ml, and programmed to administer 2-ml boluses with a lockout interval of 8 minutes and a background infusion rate at 1 ml/h.
89402858|NCT06087510|Experimental|medium-dose group|Patient-controlled analgesia is established with esketamine 100 mg, dexmedetomidine 200 microgram, and sufentanil 4 microgram/kg (maximum 250 microgram), diluted with normal saline to 200 ml, and programmed to administer 2-ml boluses with a lockout interval of 8 minutes and a background infusion rate at 1 ml/h.
89402859|NCT06087510|Experimental|High-dose group|Patient-controlled analgesia is established with esketamine 150 mg, dexmedetomidine 200 microgram, and sufentanil 4 microgram/kg (maximum 250 microgram), diluted with normal saline to 200 ml, and programmed to administer 2-ml boluses with a lockout interval of 8 minutes and a background infusion rate at 1 ml/h.
89402860|NCT06086067|Experimental|Aerobic session in luteal phase|The aerobic exercise session will begin with a 3 min resting period (sitting quietly on the cycle ergometer (0 W), followed by a 3 min warm-up at 40 W and a stepwise intensity increase by 20 W / min (to control for day-to-day variations in exercise response) until the 5% of Pmax from IET above PLTP1 is achieved (i.e. moderate steady state walking or low-intensity running or cycling). This target workload will be maintained for 30 min. Active and passive recovery periods of 3 min each will be the same as the incremental test. This session will be held on day 21 of menstruation.
89402861|NCT06086067|Experimental|Aerobic session in follicular phase|The aerobic exercise session will begin with a 3 min resting period (sitting quietly on the cycle ergometer (0 W), followed by a 3 min warm-up at 40 W and a stepwise intensity increase by 20 W / min (to control for day-to-day variations in exercise response) until the 5% of Pmax from IET above PLTP1 is achieved (i.e. moderate steady state walking or low-intensity running or cycling). This target workload will be maintained for 30 min. Active and passive recovery periods of 3 min each will be the same as the incremental test. This session will be held on day 3 of menstruation.
89198997|NCT00959296||Patients with a device implant|Patients implanted and consented at a study center with a market-released Medtronic implantable drug pump, spinal cord stimulator, deep brain stimulator, or sacral nerve stimulator.
89198998|NCT00611715|Experimental|First line/hormone-therapy naive|
89198999|NCT00611715|Experimental|Second-line/prev hormone-therapy tx|
89199000|NCT00963352||Patients operated for colon cancer|
89402862|NCT06085599|Experimental|Progressive relaxation exercise group|Sociodemographic information form, numerical pain scale and kinesiophobia scale were applied to the patients in the experimental group after liver transplantation. They were shown 15 minutes progressive relaxation exercises prepared by Mark Connelly and Jennifer Bickel on Youtube, and then the numerical pain scale and kinesiophobia scale were applied again.
89402863|NCT06085599|No Intervention|Control group|No application other than clinical protocols was performed in the follow-up of the patient. In the control group, sociodemographic information form, kinesiophobia scale and numerical pain scale were applied after liver transplantation. No intervention was made. Then, the kinesiophobia scale and numerical pain scale were applied again.
89402864|NCT06083207|Experimental|IBI3003|
89402865|NCT06082687||de-identified human tissue|This Project will receive de-identified human tissue from cooperating institutions for unknown/undisclosed donors.
89199001|NCT04722718|Experimental|Sintilimab+Apatinib+Albumin-Bound Paclitaxel(Nab-Paclitaxel)+Carboplatin|Drug:Sintilimab;Drug:Apatinib;Drug:Albumin-Bound Paclitaxel(Nab-Paclitaxel);Drug:Carboplatin
89402866|NCT06082258|No Intervention|usual care|Patients followed by general practitioners with no specific education on long COVID or somatic symptom disorders
89402867|NCT06082258|Experimental|intervention|Patients followed by general practitioners who have received a training in long COVID and somatic symptom disorders diagnosis and treatment, with reimbursement of three long consultations
89402868|NCT06080542|Experimental|Aerobic session|The aerobic exercise session will begin with a 3 min resting period (sitting quietly on the cycle ergometer (0 W), followed by a 3 min warm-up at 60 W and a stepwise intensity increase by 20 W / min (to control for day-to-day variations in exercise response) until the 5% of Pmax from IET above PLTP1 is achieved (i.e. moderate steady state walking or low-intensity running or cycling). This target workload will be maintained for 30 min. Active and passive recovery periods of 3 min each will be the same as the incremental test.
89402869|NCT06080542|Experimental|High-intensity interval training|Our elastic band protocol is a modification of the HIIT protocols used by previous authors changing body weight exercises by exercises with TheraBand CLX. The exercise program is chosen to involve large muscle groups simulating conventional bodybuilding exercises by applying the external load to the elastic band's resistance. Four exercises of upper limb (bench press, seated dumbbell, shoulder press, and seated row) and four of lower limb (squats, stiff-legged deadlift, hamstring curl exercise, and quadriceps curl exercise) are chosen, which are intercalated in the program without doing two consecutive exercises of the same area. All exercises are done with both arms or legs at the same time.
89402870|NCT06077305||Registry Study on Microcirculatory Disorders in Acute Ischemic Stroke|Establish a Chinese registry platform for microcirculatory disorders after acute ischemic stroke; use this registry platform to record the prevalence, diagnosis and treatment information, and prognosis of microcirculatory disorders after acute ischemic stroke.
89402871|NCT06077305||Registry Study on Microcirculatory Disorders in Ischemic Stroke during Recovery Period|Establish a national registry platform for microcirculatory disorders in ischemic stroke during recovery period; use this registry platform to record the prevalence, diagnosis and treatment information, and prognosis of microcirculatory disorders in ischemic stroke during recovery period.
89402872|NCT06077305||Registry Study on Microcirculatory Disorders in CSVD|Establish a national registry platform for microcirculatory disorders in CSVD; use this registry platform to record the prevalence, diagnosis and treatment information, and disease outcome of microcirculatory disorders in CSVD.
89402873|NCT06068153|Experimental|Treatment Arm|Sotorasib + Lenvatinib
89402874|NCT06067542|Experimental|Study group using chlorhexidine toothpaste after wisdom tooth extraction|22 patients, 17 females and 5 males, 44 bilateral, similarly positioned fully impacted impacted lower third molars were extracted. Bilateral impacted wisdom teeth of the patients were randomly selected. After the operation, the experimental group received Dentasave 0.2% chlorhexidine toothpaste containing chlorhexidine
89402875|NCT06067542|Placebo Comparator|Control group using chlorhexidine-free toothpaste after wisdom tooth extraction|Bilateral impacted wisdom teeth of the patients were randomly selected. After the operation, the control group was given toothpaste with the same ingredients as the study group but without chlorhexidine.
89402876|NCT06056999||A. pure ground-glass nodule|Patients with pure ground-glass nodules (GGNs).
89402877|NCT06056999||B. part-solid nodule|Patients with part-solid nodules (PSNs).
89402878|NCT06056999||C. solid nodule|Patients with solid nodules (SNs).
89402879|NCT06053463|Experimental|Lens wear experience|Subject will wear contact lenses for about a month during the day.
89402880|NCT06049810|Experimental|Group 3|Participants receive Dose 1 IBI112 through week 8 & Dose 2 IBI112 on week 20 & Dose 1 IBI112 through week 44
89402881|NCT06049810|Experimental|Group 4|Participants receive Dose 1 IBI112 through week 8 & Dose 3 IBI112 through week 44
89402882|NCT06049810|Experimental|Group 6|Participants receive Dose 1 IBI112 through week 8 & Dose 3 IBI112 on week 20 & Dose 1 IBI112 through week 44
89402883|NCT06049810|Placebo Comparator|Group 5|Participants receive Dose 1 IBI112 through week 8 & Dose 3 IBI112 on week 20 & placebo through week 44
89402884|NCT06049810|Experimental|Group 1|Participants receive Dose 1 IBI112 through week 8 & Dose 2 IBI112 through week 44
89402885|NCT06049810|Placebo Comparator|Group 2|Participants receive Dose 1 IBI112 through week 8 & Dose 2 IBI112 on week 20 & placebo through week 44
89402886|NCT06049420|Experimental|Active|participants that have received a referral, and opt-in for the adjunctive treatment plan
89402887|NCT06046625||Head-neck cutaneous Squamous cell carcinomas|Patients with high risk cutaneous squamous cell carcinoma in the head neck region, receiving regular multidisciplinary care.
89402888|NCT06044116||Calculator design|5.000 patients of the entire cohort of 6.000 patients will be used for the design of the risk calculator
89402889|NCT06044116||Internal validation|1.000 patients of the entire cohort of 6.000 patients will be used for the design of the risk calculator
89402890|NCT06044116||External validation|Another surgical group from outside Spain will be contacted for external validation
89199002|NCT00883701||COPD patients|COPD patients who undergo exacerbation
89199003|NCT00883701||Non COPD patients (controls)|Subjects who undergo respiratory infection (acute bronchitis) without COPD or other respiratory illness
89402891|NCT06038565|Experimental|"Randomization to CPAP with higher change of impedance as measured by EIT. Arm A-1"|"After comparing change of impedance as measured by electrical impedance tomography while supported on RAM cannula ventilator CPAP versus occlusive interface bubble CPAP, the participants in this arm are placed on the CPAP that had a greater change of impedance (or less pressure rate product as measured by the esophageal balloon manometry if the change of impedance between the two CPAP modalities are clinically similar).~In this Arm A-1, these subjects had higher change in impedance while supported on RAM cannula ventilator CPAP"
89402892|NCT06038565|Experimental|"Randomization to CPAP with higher change of impedance as measured by EIT. Arm A-2"|"After comparing change of impedance as measured by electrical impedance tomography while supported on RAM cannula ventilator CPAP versus occlusive interface bubble CPAP, the participants in this arm are placed on the CPAP that had a greater change of impedance (or less pressure rate product as measured by the esophageal balloon manometry if the change of impedance between the two CPAP modalities are clinically similar).~In this Arm A-2, these subjects had higher change in impedance while supported on occlusive mask bubble CPAP"
88877975|NCT04047342||Loss frame email|"The loss frame email recommends that GHP members not throw away a precise dollar amount in savings (over $2,000) by not participating and that they can therefore avoid missing out on substantial gains (i.e., savings) by taking action.~This intervention frames the status quo as a state from which recipients, via inaction, are slated to forfeit a sizable and precise monetary amount to which they should otherwise feel entitled (via loss aversion and the endowment effect). People tend to be risk-seeking in the domain of losses; therefore, this intervention is hypothesized to increase enrollment in the hope of achieving zero loss by meeting program goals, as opposed to a sure loss via inaction."
89199004|NCT04649710|Experimental|Cohort 1: Dose 1 or placebo|Chinese participants
89199005|NCT04649710|Experimental|Cohort 2: Dose 2 or placebo|Chinese participants
89402893|NCT06038565|Active Comparator|"Randomization to standard of care - a 'one size fits all' approach. Arm B-1"|"Currently, the approach to which CPAP modality is chosen for these newborns is defaulted to the preferred CPAP of the Neonatal Intensive Care Unit (NICU) where the newborn is hospitalized.~In this Arm B-1, these subjects are randomized 1:1 to RAM cannula ventilator CPAP"
89402894|NCT06038565|Active Comparator|"Randomization to standard of care - a 'one size fits all' approach. Arm B-2"|"Currently, the approach to which CPAP modality is chosen for these newborns is defaulted to the preferred CPAP of the NICU where the newborn is hospitalized.~In this Arm B-2, these subjects are randomized 1:1 to occlusive mask bubble CPAP"
89402895|NCT06032182|Experimental|Intervention|15 sessions of the combined cognitive remediation training and social recovery therapy intervention.
89402896|NCT06032182|Active Comparator|Control|15 sessions of social recovery therapy alone.
89402897|NCT06030505||Case patients|Collection of medical data in a non-identifying way (demographic data, medical history, clinical data, microbiological data) to meet the objectives of the research.
89402898|NCT06030505||Control patients|Collection of medical data in a non-identifying way (demographic data, medical history, clinical data, microbiological data) to meet the objectives of the research.
88877976|NCT04022694|Active Comparator|Calorie/Control Poster|This poster will display images of both SSBs and low or no sugar beverages with calories listed below the beverages. It will simply state that those beverages are sold in the school store.
88877977|NCT04022694|Experimental|SSB Warning and Non-SSB Promotion Poster|This poster will display images of both SSBs and low or no sugar beverages with calories listed below the beverages. In addition, the message will state that SSBs are high in sugar and should be avoided, while low or no sugar beverages are healthier options and should be chosen.
89199006|NCT04649710|Experimental|Cohort 3: Dose 1 or placebo|Korean participants
89402899|NCT06026917|Experimental|Toludesvenlafaxine hydrochloride sustained-release tablets|40 mg/tablet, 80mg/tablet, 40 mg~160mg each time, once a day, for 42 days
89402900|NCT06018831|Experimental|Urine and Ultrasound Screening|About 10,000 children called KunQi Cohort are born in Jiangsu Province(8,000 in Kunshan and 2,000 in Qidong) and about 3,000 born in Shanghai. Children will receive urine and ultrasound screening in 0-3 months ,and complete 3 to 6 years of follow-up( at least one type screening every year)
89402901|NCT06014697||Non-invasive lesion|Lesion with histological confirmation of a actinic keratosis or Bowens disease (non-invasive lesions).
89402902|NCT06014697||Invasive lesion|Lesion with histological confirmation of a squamous cell carcinoma (invasive lesions).
89402903|NCT06004284|Active Comparator|control group|Only ergonomics training will be given to the control group.
89402904|NCT06004284|Experimental|exercise group|Participants will be given training including stretching and core exercises along with ergonomics training.
88877978|NCT04022694|No Intervention|Baseline for Calorie/Control Poster|We will collect baseline data from a group of students before posting the Calorie/Control Poster in the control school.
89402905|NCT06003595||Surgical stabilization of rib fractures (SSRF) and subsequent hardware removal|Patients treated at the Department of Thoracic Surgery at the University Hospital Basel between 01.09.2017 and start date Remove Study with a diagnosis of rib fracture and with surgical stabilization of rib fracture and subsequent hardware removal will be identified.
89402906|NCT05997602|Experimental|FCN-159|Experimental: FCN-159 Dosage form:tablet Specification: 1mg，4mg Dose: FCN-159 5mg/m² (Maximum dose does not exceed 8mg), orally, once daily
89402907|NCT05983965|Experimental|Cohort A|T-cell Lymphomas
88877979|NCT04022694|No Intervention|Baseline for SSB Warning and Non-SSB Promotion Poster|We will collect baseline data from a group of students before posting the SSB Warning and Non-SSB Promotion Poster in the intervention school.
88877980|NCT04015440|Experimental|HBMT|
88877981|NCT04015440|Placebo Comparator|Placebo|
88877982|NCT04030104|Active Comparator|Imagio IUS|Read 1 (Control): History + Mammogram (if available) + IUS (Imagio Ultrasound) stills and videos provided), IUS Probability of Malignancy (POM) and Breast Imaging Reporting and Data System (BI-RADS) scored and the data form then locked.
88877983|NCT04030104|Experimental|Imagio (IUS+OA)|Read 2 (Test): History + Mammogram (if available) + IUS (stills and videos provided), and Imagio (IUS+OA) (stills and videos provided). Imagio (IUS+OA) POM and Breast Imaging Reporting and Data System (BI-RADS) assigned after viewing the SenoGram® output. The dataform is locked.
88877984|NCT04027218|Active Comparator|Current clinical practice-Dry heat|"The standardized and approved Clinical and Laboratory Standards Institute (CLSI) GP41-A6 venipuncture guide has been established for clinical current practice so far. According to vein cannulation procedure CLSI GP41-A6, an elastic compressor will be applied (Synthetic rubber-latex compressor tape, UNIDIX®, Madrid, Spain) provided by the hospital.~1 period (current clinical practice) and 2 period (dry heat) or 1 period (dry heat) and 2 period (current clinical practice)."
88877985|NCT04027218|Active Comparator|Current clinical practice- Hihg pressure|"The standardized and approved CLSI GP41-A6 venipuncture guide has been established for clinical current practice so far. According to vein cannulation procedure CLSI GP41-A6, an elastic compressor will be applied (Synthetic rubber-latex compressor tape, UNIDIX®, Madrid, Spain) provided by the hospital.~1 period (current clinical practice) and 2 period (high pressure) or 1 period (high pressure) and 2 period (current clinical practice)."
89199007|NCT04649710|Experimental|Cohort 4: Dose 2 or placebo|Korean participants
89535543|NCT02486861||non culprit plaque|correlation of OCT characteristics of non culprit plaque of culprit plaque with incidence of major adverse cardiovascular events (MACEs defined as the composite of death from cardiac causes, non- fatal MI, clinically driven target vessel revascularization (TVR), or re-hospitalization due to unstable or progressive angina according to Braunwald Unstable Angina Classification) and clinical baseline characteristics.
89535544|NCT03205735||normal DPD result group|patients group with a normal DPD result
88877986|NCT04027218|Active Comparator|Current clinical practice-Combination|"The standardized and approved CLSI GP41-A6 venipuncture guide has been established for clinical current practice so far. According to vein cannulation procedure CLSI GP41-A6, an elastic compressor will be applied (Synthetic rubber-latex compressor tape, UNIDIX®, Madrid, Spain) provided by the hospital.~1 period (current clinical practice) and 2 period (combination of dry heat and high pressure) or 1 period (combination of dry heat and high pressure) and 2 period (current clinical practice)."
89402908|NCT05978323|Experimental|Brief intervention|Intervention Group: Short face-to-face intervention interviews will be conducted with individuals in the intervention group. Interviews will be held in primary healthcare organizations' meeting rooms. Brief intervention interviews will be conducted with the intervention group. It was determined as the first evaluation and the follow-ups on the 1st day, 15th day, 1st month, 3rd month, and the last evaluation (6th month). Brief interventions, 5A for those who are ready to change their behavior (Ask, Advise, Assess, Assist, Arrange); Those who are not ready to change their behavior 5R (Relevance, Risks, Rewards, Roadblocks, Repetition) model will be used. Brief intervention interviews will take an average of 20-30 minutes. The talks will include awareness of overweight and obesity, a healthy diet, and exercise. By the researcher's prepared will be used for individuals with low health literacy educational materials.
88877987|NCT04026750|Experimental|Pitolisant|
88877988|NCT04026750|Placebo Comparator|Matching placebo|
89199008|NCT00885573|Other|Sleep apnea subjects|"Patients with suspected sleep apnea syndrome will have nocturnal polysomnography. According to the number of respiratory events per hour of sleep, patients will be classified as sleep apnea or controls. All the patients will be blindly assessed for pharyngeal sensitivity the morning following the nocturnal recording."
89535545|NCT03205735||elevated DPD result group|patients group with an elevated DPD result
88877989|NCT04020822|Experimental|Subjects Wearing Guardian Sensor (3)s|Each subject will wear 4 Guardian Sensor (3)s connected to a Guardian Link (3) Transmitter and/or Guardian Connect Transmitter for 11 days of sensor wear.
89199009|NCT00761670|Active Comparator|1|
89402909|NCT05978323|No Intervention|Control|The control group will not be intervened except for the first and last face-to-face evaluation. At the end of the research, training materials for weight loss will be given.
88877990|NCT03979872|Active Comparator|Arm 1: Skin Cancer Education Only|Participants will be randomized to receive education only.
88877991|NCT03979872|Experimental|Arm 2: Skin Cancer Education + UV Photo|Participants randomized to receive education + UV photo will have a UV light photo taken of their face to show UV damage in the skin that is invisible to the naked eye in addition to receiving skin cancer education.
89199010|NCT00761670|Active Comparator|2|
89199011|NCT00963586||HNC Maastricht|Patients treated for HNC in the University Hospital Maastricht/MAASTRO clinic, the Netherlands
88877992|NCT03979872|Experimental|Arm 3: Skin Cancer Education + MC1R Testing|Participants randomized to receive education + genetic testing will be asked to provide a saliva sample for MC1R testing in addition to receiving skin cancer education.
88877993|NCT03979872|Experimental|Arm 4: Skin Cancer Education + UV Photo + MC1R Testing|Participants randomized to receive education + UV photo + genetic testing will have a UV light photo taken of their face, Submit a saliva sample for MC1R testing, and receive skin cancer education.
88877994|NCT03993210|Experimental|GYN Cancer Cases|"Confirmed diagnosis of primary or recurrent gynecological (GYN) malignancies.~Routine clinical standard of care pelvic magnetic resonance imaging (MRI) along with advanced techniques Magnetic Resonance Fingerprinting (MRF) and Q-space Trajectory Imaging (QTI) will be performed using a clinical 3T MRI scanner lasting 30-45 minutes with an additional 10-15 minutes for the advanced scans. Per protocol, patient undergoes one scan on visit day 1 and is followed for up to 4 years."
89402910|NCT05976490|Experimental|NeuroPathways Open Pilot|"Enrolled patients will receive an intervention guide with information about navigating life with a brain tumor diagnosis, and will participate in four weekly or biweekly, individual sessions with a clinician (e.g. nurse or behavioral health specialist).~Participants will be asked to complete surveys at baseline, 8 weeks and 12 weeks, as well as an exit interview after the intervention."
89199012|NCT00963586||HNC Groningen|Patients treated for HNC in the University Medical Center Groningen, the Netherlands
89535546|NCT03077295|Experimental|High Fibre to High-Protein (HF-HP)|"Phase 1: no intervention, habitual diet for 4 days and then 3day maintenance diet~Phase 2: consumption of HF meals for 4 weeks~Phase 3: washout for 1 week, controlled maintenance diet~Phase 4: consumption of HP meals for 4 weeks"
89402911|NCT05976490|Experimental|NeuroPathways Pilot RCT|"Enrolled patients will receive an intervention guide with information about navigating life with a brain tumor diagnosis, and will participate in four weekly or biweekly, individual sessions with a clinician (e.g. nurse or behavioral health specialist).~Participants will be asked to complete surveys at baseline, 8 weeks and 12 weeks."
89402912|NCT05976490|Active Comparator|Usual supportive care|"Participants will receive usual supportive care, which includes referral to cancer center supportive care services (e.g., social work) upon request from the patient, caregiver, or clinician.~Participants will be asked to complete surveys at baseline, 8 weeks and 12 weeks."
89402913|NCT05971849|Experimental|kisspeptin, GnRH|IV administration of kisspeptin 112-121; 24-hour infusion. IV administration of GnRH; up to one bolus.
89402914|NCT05962970|Active Comparator|CACB|continuous adductor canal block
89402915|NCT05962970|Placebo Comparator|Control group|sham continuous adductor canal block - ShACB
89402916|NCT05961176||Infants and Children Admitted to the CCCU at SickKids|
89402917|NCT05955469|Active Comparator|FS4 then TFS4|Cochlear Implant with FS4 first during 6 weeks then with TFS4 during 6 weeks
88877995|NCT03993210|Active Comparator|GYN Benign Controls|"Benign gynecological (GYN) fibroids.~Routine clinical standard of care pelvic magnetic resonance imaging (MRI) along with advanced techniques Magnetic Resonance Fingerprinting (MRF) and Q-space Trajectory Imaging (QTI) will be performed using a clinical 3T MRI scanner lasting 30-45 minutes with an additional 10-15 minutes for the advanced scans. Per protocol, patient undergoes one scan on visit day 1 and is followed for up to 4 years."
89402918|NCT05955469|Active Comparator|TFS4 then FS4|Cochlear Implant with TFS4 first during 6 weeks then with FS4 during 6 weeks
88877996|NCT03988374|Active Comparator|0% Baking Soda Dentifrice|
88877997|NCT03988374|Active Comparator|20% Baking Soda Dentifrice|
88877998|NCT03988374|Active Comparator|35% Baking Soda Dentifrice|
88877999|NCT03976752|No Intervention|Pre-drug|Participants enrolled in the pre-drug arm will not receive any drug. At visit 2, they will undergo blood, urine, penile swab, cheek swab, rectal swab and rectal biopsy collection.
88878000|NCT03976752|Experimental|Genvoya - 2 and 48 hours specimen collection|Specimen collection 2 hours after taking the medication in the clinic (visit 4), and 48 hours after taking the medication in the clinic (visit 5).
88878001|NCT03976752|Experimental|Genvoya - 4 and 72 hours specimen collection|Specimen collection 4 hours after taking the medication in the clinic (visit 4), and 72 hours after taking the medication in the clinic (visit 5).
88878002|NCT03976752|Experimental|Genvoya - 24 and 96 hours specimen collection|Specimen collection 24 hours after taking the medication in the clinic (visit 4), and 96 hours after taking the medication in the clinic (visit 5).
88878003|NCT03976752|Experimental|Genvoya - Single time point specimen collection|Specimen collection 8 hours after taking the medication in the clinic (visit 4).
89402919|NCT05955040|Active Comparator|Treatment Group|Treatment of elevated blood pressures (120 or greater systolic OR 80 or greater diastolic)
88878004|NCT03974802|Experimental|somofilcon A (habitual) lens, then fanfilcon A (test) lens|Participants are habitual wearers of somofilcon A lens and refitted with fanfilcon A lens.
88878005|NCT03966924|Experimental|Rotational fractional resection (1.5mm Diameter Device)|Single treatment of skin resection and with and without focal lipectomy (removal of loose skin and fat)
88878006|NCT03965754||No email|No email will be sent out to this subset of GHP members during the week that the other emails are sent.
88878007|NCT03965754||Standard email reminder|The standard email reminder mentions the average premium savings, the speed and ease of starting the process, and the deadline for registering and having health measures on file, plus it provides two button links for registering and finding free health screenings where health measures can be collected and registered at one convenient time and location.
88878008|NCT03965754||Social norms email|The social norms email notes that a majority (78%) of GHP members' colleagues had enrolled in 2018, it provides a testimonial from a medical director at Geisinger's Commonwealth School of Medicine, stating the ways in which myHealth Rewards helped that doctor personally, and it emphasizes the simplicity and ease of taking the first step toward enrollment.
89199013|NCT00963664|Experimental|Interferon and lovastatin treatment|Patients receive outpatient treatment with lovastatin (oral) and interferon alfa-2b (subcutaneous injection) as per protocol parameters.
89402920|NCT05955040|No Intervention|Non-treatment Group|Non-treatment of blood pressures between 120-139 systolic and 80-89 diastolic
89402921|NCT05954104|Active Comparator|Group A|About 20 patients suffering from Alopecia areata , they will receive topical vit D3 analogue (calcipotriol) 0.005% twice daily for 3 months with follow up
89402922|NCT05954104|Active Comparator|Group B|About 20 patients suffering from Alopecia areata , they will be injected by PRP intra lesional for 3 consecutive sessions 4weeks apart.
89402923|NCT05954104|Active Comparator|Group C|About 20 patients suffering from Alopecia areata they will receive combined therapy ( PRP and topical vit D3 analogue).
89402924|NCT05954104|Active Comparator|Group D|About 20 of Healthy control group .
89402925|NCT05944224|Experimental|SPH4336|
89402926|NCT05944224|Experimental|Cadonilimab|
88878009|NCT03965754||Loss framing|"The loss framing email suggests that GHP members are currently throwing away a precise dollar amount (over $2,000) by not participating and that they can therefore avoid missing out on substantial gains (i.e., savings) by taking action."
88878010|NCT03962634|Experimental|Kovanaze Nasal Spray (Pediatrics)|Children >20 kg who require pulpotomy, restorative procedures, SS crowns in one maxillary tooth
89402927|NCT05944224|Experimental|SPH4336+ Cadonilimab|
88878011|NCT03962634|Active Comparator|Articaine Injections (Pediatrics)|Children >20 kg who require pulpotomy, restorative procedures, or stainless steel crowns in one maxillary tooth
88878012|NCT03933774|Experimental|Tretinoin 0.05% cream group|Tretinoin 0.05% cream 25g for 1 month, applied on the half side of the face after randomization, once a day every night
88878013|NCT03933774|Placebo Comparator|Placebo|PHYSIOGEL Daily Moisture Therapy Creme 150ml for 1 month, applied on the other half side of the face once a day every night
88878014|NCT03933618|Other|anastrazole-clomiphene-placebo|anastrozole for eight weeks then clomiphene for eight weeks then placebo for eight weeks
88878015|NCT03933618|Other|anastrazole-placebo-clomiphene|anastrozole for eight weeks then placebo for eight weeks then clomiphene for eight weeks
88878016|NCT03933618|Other|clomiphene-anastrazole-placebo|clomiphene for eight weeks then anastrozole for eight weeks then placebo for eight weeks
88878017|NCT03933618|Other|clomiphene-placebo-anastrazole|clomiphene for eight weeks then placebo for eight weeks then anastrozole for eight weeks
88878018|NCT03933618|Other|placebo-clomiphene-anastrazole|placebo for eight weeks then clomiphene for eight weeks then anastrozole for eight weeks
88878019|NCT03933618|Other|placebo-anastrazole-clomiphene|placebo for eight weeks then anastrozole for eight weeks then clomiphene for eight weeks
88878020|NCT03930264|Active Comparator|Imurek®,|Generic name : Azathioprine Trade name : Imurek® 50mg tablet Dosage form : Tablet containing 50 mg azathioprine Dose : 1 x Imurek 50mg Tablet per treatment period under fasting conditions Mode of administration : Orally Manufacturer : Aspen Pharma Trading Limited, Dublin, Ireland Country of origin : Ireland
88878021|NCT03930264|Experimental|Jayempi™|"Generic name : Azathioprine~Trade name : (Jayempi™) 10 mg/ mL Oral solution Dosage form : Oral suspension containing 10 mg/mL Azathioprine Dose : 1 x 5mL (50 mg) of Jayempi™ Oral Suspension 10mg/mL per treatment period under fasting conditions Mode of administration : Orally Manufacturer : Nova Laboratories Ltd. Country of origin : Leicester, UK"
88878022|NCT03919422|Active Comparator|IC group|Interscalene brachial plexus-Cervical plexus
88878023|NCT03919422|Experimental|ICTP group|Interscalene brachial plexus-Cervical plexus combined with T2 Paravertebral blockade
88878024|NCT03926208|Active Comparator|Control|Subjects in this group will receive the standard chlorhexadine prep of the foot (standard of care) prior to surgery, and a cotton swab will be collected from the hallux nail fold.
88878025|NCT03926208|Experimental|Soak and Scrub|In addition to the standard chlorhexadine prep of the foot prior to surgery, subjects in this group will also receive a betadine soak and scrub of the foot, and a cotton swab will be collected from the hallux nail fold.
88878026|NCT03901092|Experimental|Flortaucipir PET Scan|Scans previously acquired from Study A16 (NCT02516046) and A05 (NCT02016560) will be read by independent, blinded readers.
88878027|NCT03887286|Experimental|treatment group|All participants to receive standard transthoracic echocardiogram and hand held echocardiogram
88878028|NCT03882528|Experimental|Infective controls|Controlled Human Malaria Infection (CHMI) will consist of exposure to Plasmodium falciparum sporozoites through the bites of infected mosquitoes. Beginning 5 days after the challenge, subjects will be evaluated daily for the development of malaria infection using a blood smear.
88878029|NCT03881670|Placebo Comparator|Lotrafilcon B|
88878030|NCT03881670|Active Comparator|Lotrafilcon B Hydraluxe|
88878031|NCT03861000|Experimental|Whole body PET Scan with intravenous 11C-T-1650|10 mCi of 11C-T-1650 given intravenously once followed by a Whole Body PET scan. This was done for whole body dosimetry calculations.
88878032|NCT03861000|Experimental|Brain PET scan with 11C-T-1650 and blocking with BPN14770|Baseline brain PET scan (scan 1) with 20 mCi of 11C-T-1650 given intravenously, followed by a second Brain PET scan (scan 2) 90-180 minutes after first dose administration of BPN14770 50mg given orally. A third brain PET scan (scan 3) is performed after the last dose of BPN14770. 20 mCi of 11C-T-1650 is given intravenously with each PET scan. BPN14770 50mg given orally twice a day for a total of seven doses. BPN14770 is a PDE4D-inhibitor.
88878033|NCT03863496|Other|Neuromuscular scoliosis|Efficacy of Surgical Treatment by Different Pedicle Screw Systems in Pediatric Neuromuscular Spinal Deformity
88878034|NCT03856944|Experimental|ReSTOR Toric|Patients will be bilaterally implanted, with the Toric ReSTOR +2.5D model implanted in the dominant eye and the Toric ReSTOR +3.0D model implanted in the non-dominant eye. Patients will self-select for multifocal implantation.
88878035|NCT03865446|Experimental|Cohort 1 (Dacomitinib)|severe hepatic impairment group
89199014|NCT00677820|Experimental|Trivalent influenza virus vaccine|Frozen trivalent vaccine containing new strains
88878036|NCT03865446|Experimental|Cohort 2 (Dacomitinib)|normal hepatic function
88878037|NCT03868254||Implant|Chart review was conducted in participants with open angle glaucoma who underwent placement of the implant XEN 45 Gel Stent as a standalone procedure from 1 January 2014 to 1 October 2015. For each eye selected, all retrospective data available from baseline (day when decision was made to implant XEN 45 Gel Stent) until the last visit was extracted from existing medical records.
88878038|NCT03868254||Implant + Phaco|Chart review was conducted in participants with open angle glaucoma who underwent placement of the implant XEN 45 Gel Stent in combination with phacoemulsification (Phaco) from 1 January 2014 to 1 October 2015. For each eye selected, all retrospective data available from baseline (day when decision was made to implant XEN 45 Gel Stent) until the last visit was extracted from existing medical records.
89402928|NCT05943340|No Intervention|Control group|Patients that are undergoing immobilization period after a distal radius fracture.
89402929|NCT05943340|Experimental|Experimental group|Patients that are undergoing immobilization period after a distal radius fracture.
89199015|NCT00677820|Placebo Comparator|Placebo|treatment with placebo
89199016|NCT00611559|Experimental|Infanrix hexa Preservative-Free Formulation Group|Subjects received a booster dose of the preservative-free formulation of Infanrix™ hexa
89199017|NCT00611559|Active Comparator|Infanrix hexa Preservative-Containing Formulation Group|Subjects received a booster dose of the preservative-containing formulation of Infanrix™ hexa
89011545|NCT01645033|Active Comparator|Treatment as Usual (TAU)|"This is the infectious disease orientation that would normally be received at this clinic to address risky behavior. This orientation generally includes individual and group therapy sessions that discuss behaviors and the resulting risk of sexually or drug-related infections (for example: use of a condom). Sessions will generally include items such as:~Teaching about the treatment program~Teaching important ideas about sexual behaviors risks~Increasing knowledge about specific sexually transmitted diseases~Discussions of ways to reduce or minimize spread of diseases related to drug use [for example, Hepatitis and Human Immunodeficiency virus (HIV, the virus responsible for causing AIDS)]"
89011546|NCT01645150|Experimental|Strength training group|12 weeks of progressive strength training
89199018|NCT00611559|Active Comparator|Infanrix penta Preservative-Free Formulation Group|Subjects received a booster dose of the preservative-free formulation of Infanrix™ penta.
88878039|NCT03862482|Active Comparator|Brånemark® 2, Swede-Vent® 2, Screw-Vent® 1 (Configuration 1)|Device placement: B (Brånemark® dental implant) placed at two sites, SW (Swede-Vent® dental implant) placed at two sites, SC (Screw-Vent® dental implant) placed at one site
88878040|NCT03862482|Experimental|Brånemark® 1, Swede-Vent® 2, Screw-Vent® 2 (Configuration 2)|Device placement: B (Brånemark® dental implant) placed at one site, SW (Swede-Vent® dental implant) placed at two sites, SC (Screw-Vent® dental implant) placed at two sites
88878041|NCT03862482|Experimental|Brånemark® 2, Swede-Vent® 1, Screw-Vent® 2 (Configuration 3)|Device placement: B (Brånemark® dental implant) placed at two sites, SW (Swede-Vent® dental implant) placed at one site, SC (Screw-Vent® dental implant) placed at two sites
88878042|NCT03848208|Experimental|Cohort 1: Cytisine 6.0 mg|Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
88878043|NCT03848208|Placebo Comparator|Cohort 1: Placebo|Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
88878044|NCT03848208|Experimental|Cohort 2: Cytisine 9.0 mg|Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
88878045|NCT03848208|Placebo Comparator|Cohort 2: Placebo|Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
88878046|NCT03848208|Experimental|Cohort 3: Cytisine 12.0 mg|Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
89535547|NCT03077295|Experimental|High Protein to High-Fibre (HP-HF)|"Phase 1: no intervention, habitual diet for 4 days and then 3day maintenance diet~Phase 2: consumption of HP meals for 4 weeks~Phase 3: washout for 1 week, controlled maintenance diet~Phase 4: consumption of HF meals for 4 weeks"
88878047|NCT03848208|Placebo Comparator|Cohort 3: Placebo|Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
89011547|NCT01645150|No Intervention|Control group|No intervention
89011548|NCT01645189|Experimental|Test drug|Idursulfase-beta
89199019|NCT00963742|Experimental|Lenstec Softec HD IOL implantation|390 eyes of 390 study subjects all receiving the investigational IOL; IOL implanted after surgical removal of cataract
89004229|NCT05601765|Experimental|Digital team-based communication after discharge|"Patients will be given access to digital communication with their healthcare team across sectors who are involved in their treatment and care after hospital discharge (eDialogue). They will be set up in a messenger-like tool on the day of discharge, and relevant healthcare professionals will be connected. Individually, the patients will define who they would like to involve, and consent is given digitally. The minimum participants for each patient will be the patient and/or their closest relative, the orthopaedic surgeon, a nurse from the outpatient clinic and a secretary. Patients will have access to eDialogue for 60 days after discharge, and the response rate is set to be 24 hours on weekdays. On weekends and public holidays, patients are informed that they cannot expect a response. If the primary healthcare professional is registered to be on vacation or other absence, substitutes within the respective health professional groups will be included."
89004230|NCT05587946|Experimental|Intervention/treatment|"Implementation steps 1-4 of the Control Group will be done.~The patient will be informed about the virtual reality application.~The patient will be told that they can remove their glasses at any time and stop participating in the study.~2 minutes before the endoscopy process starts, the previously determined video will be started by putting on the Virtual Reality Glasses.~Glasses will be worn from the beginning to the end of the procedure.~The patient will be observed during the procedure. The data obtained during the observation will be noted.~After the endoscopy procedure; State Anxiety Scale, Visual Comparison Scale will be re-applied and vital signs will be measured and recorded in the Patient Follow-up Form.~After the endoscopy procedure, patients will be given an interview appointment on the same day to collect the data of the qualitative part of the study.~Semi-Structured Interview Form will be applied in the interview."
89199020|NCT00963898|Experimental|Mental Retardation|
89199021|NCT00761904|Experimental|receipt of free generic samples|
89199022|NCT00761904|No Intervention|usual prescribing|
89199023|NCT00963976|Experimental|Target systolic BP < 150 mmHg|Systolic blood pressure will be reduced to <150 mmHg within 1 hour of randomization.
89199024|NCT00963976|Active Comparator|Target systolic BP < 180 mmHg|Systolic blood pressure will be reduced, to <180 mmHg within 1 hour of randomization.
89402930|NCT05937672|Experimental|Cold Atmospheric Plasma (CAP)|We are proposing an open-label extension study of a floating electrode-dielectric barrier device (FE-DBD), a Cold Atmospheric Plasma (CAP) device for the treatment of Verrucae Vulgaris and Molluscum Contagiosum. While novel to the medical field, and especially to dermatology, there are already a number of publications regarding its use on human skin in adults and children. CAP devices utilize noble gases (such as helium) to deliver plasma state matter to the skin. As its name implies, the generated plasma stream is of near skin temperature and it exists on normal atmospheric pressure. During the generation of the plasma there is no electric contact with the patient. The treatment does not increase skin surface temperature and the used helium gas, the same as used for balloons, being a noble gas does not cause a chemical reaction with the skin. The flow of the gas is slow, thus there is no mechanical effect on the skin.
89402931|NCT05935410|Experimental|DM Social Needs Intervention|A trained health educator will deliver the manualized DM Social Needs intervention. Participants will receive 6-monthly sessions of diabetes education and skills training, and problem solving and resolution of social needs via telephone.
89402932|NCT05935410|Active Comparator|Usual Care|Participants in the usual care arm will receive mailed diabetes education materials in accordance with recommendations from the American Diabetes Association (ADA) monthly
89402933|NCT05931471|Experimental|Yogurt Consumption|Participants will complete a 2-week baseline with no yogurt intake, followed by a three-week yogurt intervention, and then a 2-week follow-up period with no yogurt intake.
89402934|NCT05930405|Experimental|programmed intermittent epidural bolus group|All subjects received a standardised epidural solution containing 0.2% ropivacaine and 0.4（male）/0.3（famale）μg/ml sufentanil. The PIEB group is programmed for intermittent infusion with （0.1*kg）ml pumped every two hours. The lockout time for both groups is 60 min.
88878048|NCT03848208|Experimental|Cohort 4: Cytisine 15.0 mg|Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
89535548|NCT02490527|Placebo Comparator|Statin only|The subject will consume simvastatin (40mg) and placebo once daily for 3 months.
89535549|NCT02490527|Experimental|Statin and epicatechin|The subject will consume simvastatin (40mg) and pure epicatechin capsules (50mg) once daily for 3 months.
88878049|NCT03848208|Placebo Comparator|Cohort 4: Placebo|Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
88878050|NCT03848208|Experimental|Cohort 5: Cytisine 18.0 mg|Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
88878051|NCT03848208|Placebo Comparator|Cohort 5: Placebo|Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
88878052|NCT03848208|Experimental|Cohort 6: Cytisine 21.0 mg|Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
88878053|NCT03848208|Placebo Comparator|Cohort 6: Placebo|Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
88878054|NCT03848208|Experimental|Cohort 7: Cytisine 24.0 mg|Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
88878055|NCT03848208|Placebo Comparator|Cohort 7: Placebo|Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
88878056|NCT03848208|Experimental|Cohort 8: Cytisine 27.0 mg|Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
88878057|NCT03848208|Placebo Comparator|Cohort 8: Placebo|Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
88878058|NCT03848208|Experimental|Cohort 9: Cytisine 30.0 mg|Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
88878059|NCT03848208|Placebo Comparator|Cohort 9: Placebo|Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
88878060|NCT03858894|Experimental|Drug Arm: DE-117 QD|DE-117 Ophthalmic Solution QD (20:00) and Vehicle (8:00; no active DE-117 ingredient) QD
88878061|NCT03858894|Experimental|Test Arm: DE-117 BID|DE-117 Ophthalmic Solution BID Twice daily (20:00 and 8:00)
88878062|NCT03856164|Active Comparator|Tranexamic acid|Tranexamic Acid for intravenous administration.
88878063|NCT03856164|Placebo Comparator|Placebo|Normal saline for intravenous administration.
88878064|NCT03849690|Experimental|TAK-906 25 mg; Esomeprazole 40 mg + TAK-906 25 mg|TAK-906 25 milligram (mg), capsule, orally, once on Day 1 of Study Period 1, followed by a washout period of at least 4 days, further followed by esomeprazole 40 mg, capsule, orally, once daily on Days 1 to 5 along with TAK-906 25 mg, capsule, orally, once on Day 4 of Study Period 2.
88878065|NCT03843372|Experimental|First night HFNC group|The first night will receive high flow nasal cannula (HFNC) therapy and the second night accept continuous positive airway pressure (CPAP) therapy.
89199025|NCT00964054|Experimental|Public Health Dose of Exercise (PHD)|17.5 kcal per kilogram per week
89199026|NCT00964054|Active Comparator|Low Dose Exercise (LD)|7.0 kcal per kilogram per week
89199027|NCT02559258|Experimental|Cohort 1|
89199028|NCT02559258|Experimental|Cohort 2|
89199029|NCT02559258|Experimental|Cohort 3|
89199030|NCT02559258|Experimental|Cohort 4|
88813285|NCT03219476|Experimental|Neoadjuvant endocrine therapy treatment (physician's choice)|Once enrolled, patients would be treated with the current standard-of-care endocrine therapy. Choice of endocrine therapy (aromatase inhibitors or tamoxifen) would be decided by medical oncologist, following a review of the patient's medical history and menstrual status. The patient would be treated with endocrine therapy in a neoadjuvant setting for four weeks, with dosing continuing until surgery.
88813286|NCT02472366|Other|laser|laser with or without prior history of intraocular corticosteroid therapy
88813287|NCT02472366|Other|laser and anti-VEGF|laser and anti-VEGF therapy with or without prior history of intraocular corticosteroid therapy
88813288|NCT01724606|Experimental|Radiotherapy with Sorafenib|This is a single institution, open label, prospective, phase I clinical trial using standard 3+3 design. Histologically confirmed metastatic adenocarcinoma of the breast with radiologic evidence of new and/or progressive brain metastases (BM) with a clinical indication for WBRT will be enrolled.
88813289|NCT04201704|Active Comparator|Liberal IV Fluid|"Maintenance fluid rate calculated by 4-2-1 formula for patients <110kg: 4 mL/kg for first 0-10kg + 2 mL/kg for 11-20kg + 1 mL/kg for each kg >20kg~Patients >110kg maintenance 150 mL/hr~Bolus Criteria: change in 1 of: >20% decrease in systolic blood pressure 50th percentile for age and sex, >20% increase in heart rate over 50th percentile for age, base excess > -5mmol/L, blood lactate >2mmol/L, AND urine output (UO) <1 mL/kg/hr if <50kg or <50 mL/hr if >50kg~If criteria met: bolus 20 mL/kg if <50kg or 1 L if ≥50 kg~For transfusion: give 10 mL/kg packed red blood cells, platelets, or fresh frozen plasma up to 250 mL. If >25kg give 250 mL.~Diuresis- after minimum 24hrs: if UO <2 mL/kg/hr (or <100 mL/hr if >50 kg) continue maintenance rate and bolus per initial phase. If UO >2 mL/kg/hr (or >100 mL/hr if >50kg), and lactate, systolic blood pressure, heart rate, creatinine are normal then lower IV fluid rate to ½ maintenance rate and then to keep vein open once on regular feeds"
88813290|NCT04201704|Experimental|Restricted IV Fluid|"Maintenance fluid rate calculated by 70% of 4-2-1 formula if <110 kg: 4 mL/kg for first 0-10 kg, + 2 mL/kg for 11-20 kg, + 1 mL/kg for every kg >20 kg~Patients >110 kg: maintenance is 105 mL/hr~If same bolus criteria met: 10 mL/kg for patients <50kg, or 500 mL if ≥50 kg~If meet transfusion criteria: transfuse 10 mL/kg with packed red blood cells, platelets, or fresh frozen plasma by weight up to 250 mL. Patients >25 kg get 250 mL per transfusion~Diuresis (after minimum 24 hrs): if UO <1 mL/kg/hr (or <50 mL/hr if >50 kg) then continue IV fluids at maintenance rate and bolus as needed. If UO 1-2 mL/kg/hr (or 50-100 mL/hr if >50 kg) then decrease IV rate to ½ maintenance rate. If UO >2 mL/kg/hr (or >100 mL/hr if >50 kg), and Lactate, systolic blood pressure, heart rate, creatinine normal then reduce to keep vein open and consider Furosemide for goal UO >2-4 mL/kg/hr (100-200 mL/hr if >50 kg) until euvolemic"
89199031|NCT02559258|Experimental|Cohort 5|
89004231|NCT05587946|No Intervention|Control group|"Hands will be washed.~The right patient will be determined, the procedure will be explained to the patient and permission will be obtained.~A Patient Identification Form will be applied to the individual before the endoscopy procedure.~Before the endoscopy procedure; State Anxiety Scale will be applied in the first 10 minutes, and Visual Comparison Scale will be applied in the first 5 minutes. Vital signs will be measured within the first 5 minutes and recorded on the Patient Follow-up Form. Then the individual will be taken to the endoscopy procedure.~The patient will be observed during the procedure. The data obtained during the observation will be noted.~After the endoscopy procedure; State Anxiety Scale, Visual Comparison Scale will be applied again and vital signs will be measured and recorded in the Patient Follow-up Form."
89004232|NCT05574361|Experimental|Hypothermic Machine Perfusion|Hypothermic Machine Perfusion with Organ Recovery Systems LifePort Liver Transporter system
89004233|NCT05553925|Experimental|Intervention Implementation|At least 5,000 patients from the participating BWH practices/sites will receive the combined intervention (online weight management program with patient navigator support and personalized coaching) as part of standard of care for overweight and obesity.
89004234|NCT05540626|No Intervention|Standard of Care Arm|Baseline tremor power without stimulation (SOC arm) over the first month of the study. Subjects in the SOC arm will be asked to measure their tremor severity by doing daily postural holds with the Cala Trio device without actual stimulation.
89199032|NCT00964132|Experimental|NRX194204|
89199033|NCT02558868|Experimental|Oxaliplatin + Irinotecan|Irinotecan：160 mg/m2，iv 120 min，d1 q2w oxaliplatin: 85 mg/m2，iv 120 min，d1 q2w
89402935|NCT05930405|Active Comparator|continuous epidural infusion group|All subjects received a standardised epidural solution containing 0.2% ropivacaine and 0.4（male）/0.3（famale）μg/ml sufentanil. The CEI group was infused continuously at a rate of （0.05*kg）ml/h. The lockout time for both groups was 60 min.
89402936|NCT05930158|Active Comparator|Pulmonary Rehabilitation Group|Patients in this group will continue the classic rehabilitation programs determined in the Pulmonary Rehabilitation Unit. The program will continue for 8 weeks, 2 sessions per week.
89004235|NCT05540626|Experimental|Intervention with the Cala Trio device (CTD) arm|Tremor power after stimulation with Cala Trio. Subjects in the intervention arm will wear the device at home for a period of 12 months, during which they will deliver 40 min stimulation sessions, which can be started and stopped on demand.
89004236|NCT05507008|Experimental|Ketone Supplementation|Subjects will ingest 2 daily doses of Kenetik ketone drink supplementation for 14 days.
89004237|NCT05501821|Experimental|Part A, dose escalation monotherapy|KBA1412 monotherapy, given intravenously, Q3W, multiple dose levels
89199034|NCT02558868|Active Comparator|Irinotecan|Irinotecan：180 mg/m2，iv 120 min，d1 q2w
89199035|NCT00611247|Experimental|Methylated AGAT Promoter (Group 1)|Induction: 200 mg/m2/day oral Temozolomide x 7 days
89199036|NCT00611247|Experimental|Un-Methylated AGAT Promoter (Group 2)|Priming: 100 mg/m2/day oral Temozolomide x 14 days, followed by Induction: 200 mg/m2/day oral Temozolomide x 7 days
89402937|NCT05930158|Experimental|Dual Task Exercises Group|"The patients in this group will continue the determined rehabilitation programs, during the walking and balance exercises in the program, they will also do the cognitive exercises that are different from the patients in the Pulmonary Rehabilitation group. The program will continue for 8 weeks, 2 sessions per week. Walking exercises and balance exercises will be planned for 15 minutes each. The intensity of the walking exercise will be planned as moderate intensity according to the results of 6 MWT, it will start with the warm-up period and end with a cool-down. A treadmill will be used for the exercise.~Balance exercises program will consist of tandem walking (walking with the heel touching the toe of the other foot), standing on one foot (eyes open-closed), walking in a straight line, and standing on soft ground with eyes closed.~Cognitive exercises to be added during walking and balance exercises will be given as a dual task."
89402938|NCT05930158|No Intervention|Healthy Controls|Dual-task performances of healthy individuals with similar demographic characteristics in COPD patients will be compared. For this, the demographic information of healthy volunteers will be recorded, and the Timed Up and Go Test, which will be done as a dual task and a single task, and the 10-meter Walk Test will be evaluated.
88878066|NCT03843372|Active Comparator|First night CPAP group|In contrast, the first night will receive continuous positive airway pressure and the second accept high flow nasal cannula therapy.
88878067|NCT03822078|Placebo Comparator|Placebo|Participants received a single subcutaneous injection of placebo to denosumab on day 1.
88878068|NCT03822078|Experimental|Denosumab|Participants received a single subcutaneous dose of denosumab on day 1. Doses included 0.03, 0.1, 0.3, 1.0, and 3.0 mg/kg.
88878069|NCT03806556|Experimental|Tranexamic Acid|Doses will be given intravenous (IV). Doses are administered every 8 hours or three times daily (TID) per the discretion of the treating investigator. TXA dose will be 10mg/kg, diluted in normal saline to a total volume of 15 milliliters (mL).
88878070|NCT03806556|Placebo Comparator|Placebo|Doses will be given intravenous (IV). Doses are administered every 8 hours or TID per the discretion of the treating investigator. Normal saline will be administered at a total volume of 15mL.
88878071|NCT03809052|Experimental|A1 - 5 mg GB1211 single dose and Placebo|6 healthy subjects are administered 5 mg of GB1211 capsules orally as a single dose in the fasted state. 2 subjects receive placebo. 2 subjects (1 active and 1 placebo) will be dosed at least 24 hours before the remaining subjects, where continuation to dose the remaining subjects will be at the Investigator's discretion.
88878072|NCT03809052|Experimental|A2 - 20 mg GB1211 single dose and Placebo|6 healthy subjects are administered 20 mg of GB1211 capsules orally as a single dose in the fasted state. 2 subjects receive placebo. 2 subjects (1 active and 1 placebo) will be dosed at least 24 hours before the remaining subjects, where continuation to dose the remaining subjects will be at the Investigator's discretion.
88878073|NCT03809052|Experimental|A3 - 50 mg GB1211 single dose (food effect cohort) and Placebo|6 healthy subjects are administered 50 mg of GB1211 capsules orally as a single dose. 2 subjects receive placebo. 2 subjects (1 active and 1 placebo) will be dosed at least 24 hours before the remaining subjects, where continuation to dose the remaining subjects will be at the Investigator's discretion. Each subject will participate in 2 treatment periods separated by a minimum of 7 days. In Treatment Period 1 doses will be administered in the fasted state, in Treatment Period 2 doses will be administered 30 minutes after the start of a high fat breakfast. Subjects will receive the same treatment in both periods.
88878074|NCT03809052|Experimental|A4 - 100 mg GB1211 single dose and Placebo|6 healthy subjects are administered 100 mg of GB1211 capsules orally as a single dose in the fasted state. 2 subjects receive placebo. 2 subjects (1 active and 1 placebo) will be dosed at least 24 hours before the remaining subjects, where continuation to dose the remaining subjects will be at the Investigator's discretion.
88878075|NCT03809052|Experimental|A5 - 200 mg GB1211 single dose and Placebo|6 healthy subjects are administered 200 mg of GB1211 capsules orally as a single dose in the fasted state. 2 subjects receive placebo. 2 subjects (1 active and 1 placebo) will be dosed at least 24 hours before the remaining subjects, where continuation to dose the remaining subjects will be at the Investigator's discretion.
89189911|NCT04628377||Prognosis Cohort|Prognosis cohort, in which angiography-derived IMR will be measured in the culprit vessel after successful revascularization. Those patients have follow-up data after 10 years from index procedure. This cohort is STEMI subgroup derived from Institutional registry of Samsung Medical Center, whose results were previously published (JACC Cardiovascular Intervention. 2019 Apr 8;12(7):607-620.) Among 490 STEMI patients from the overall study cohorts, 309 patients with available angiograms and who were suitable for angiographic FFR and IMR measurement will be analyzed. Primary clinical outcome will be cardiac death at 10 years from index procedure. Secondary outcome will be any myocardial infarction, ischemia-driven revascularization, definite or probable stent thrombosis, congestive heart failure admission at 10 years from index procedure.
89189912|NCT04621019|Experimental|Non-invasive lipolysis and circumference reduction of the abdomen|The treatment administration phase consists of four (4) treatment visits, delivered at least 1 week apart. Follow-ups visits at 1 month and 3 months after the final treatment will be held.
89189913|NCT04592094|Experimental|Blueback® Physio|Classic protocole with the use of Blueback® Physio during physiotherapy sessions, , and using the Blueback® Physio in the active mode (patient and physiotherapists see the biofeedback in real time)during the tests required by the protocol of the study.
88878076|NCT03809052|Experimental|B1 - GB1211 multiple ascending doses, 50mg BID and Placebo|GB1211 administered orally twice daily over 10 days. 8 healthy subjects received GB1211 and 3 subjects will receive placebo. Following review of data in Part A (Cohorts A1 to A6), subjects received twice daily (BID) doses under fasted conditions on Days 1 to 9, inclusive, and a final single dose administration on the morning of Day 10 in accordance with the randomisation schedule.
88878077|NCT03809052|Experimental|B2 - GB1211 multiple ascending doses, 100mg BID and Placebo|GB1211 administered orally twice daily over 10 days. 8 healthy subjects received GB1211 and 3 subjects will receive placebo. Following review of data in Part A (Cohorts A1 to A6), subjects received twice daily (BID) doses under fasted conditions on Days 1 to 9, inclusive, and a final single dose administration on the morning of Day 10 in accordance with the randomisation schedule..
88878078|NCT03809052|Experimental|A6 - 50mg GB1211 single dose and Placebo|8 healthy subjects are administered 50 mg (10 x 5mg capsules) or placebo without sentinel dosing. Optional cohort, as was added following dose-escalation analysis.
88878079|NCT03809052|Experimental|A7 - 400 mg GB1211 single dose and Placebo|8 healthy subjects are administered 400 mg (8 x 50mg capsules) or placebo without sentinel dosing. Optional cohort, as was added following dose-escalation analysis.
88878080|NCT03809052|Experimental|Part A - Placebo for GB1211|In Part A - 2 subjects from each arm (A1-A5) will receive placebo.
89189914|NCT04592094|No Intervention|Standard Care|Classic protocole without the use of Blueback® Physio during physiotherapy sessions, and using the Blueback® Physio in the blind mode during the tests required by the protocol of the study
89189915|NCT04586348|Experimental|Low Iodine Supplement|Iodine (potassium iodide) 20 μg Beta carotene (All trans-beta- carotene) 1500 μg; Vitamin E (dl-alphatocopheryl acetate) 13.5 mg AT; Vitamin D3 (cholecalciferol) 10 μg; Vitamin C (ascorbic acid granular) 60 mg; Niacinamide 18 mg; Pantothenic acid (calcium d- pantothenate) 6 mg; Vitamin B6 (DC pyridoxine hydrochloride) 1.9 mg; Vitamin B1 (thiamine mononitrate) 1.4 mg; Vitamin B2 (riboflavin) 1.4 mg; Biotin 30 μg; Vitamin B12 (methyl-cobalamin) 2.6 μg; Folic Acid 0.4 mg; Levomefolic acid 0.1 mg; Calcium (carbonate DC) 250 mg; Magnesium (oxide granular) 50 mg; Iron (ferrous fumarate) 20 mg; Zinc (oxide) 10 mg; Manganese (sulphate) 2 mg; Copper (sulphate) 1 mg; Selenium (rice chelate) 30 μg
88878081|NCT03809052|Experimental|Part B - Placebo for GB1211 (BID)|Part B - 3 subjects from each arm B1 and B2 will receive placebo.
88878082|NCT03812328|Experimental|SelK2 and Enoxaparin|I.V., single-dose (SelK2) and SC, QD for up to 10 ± 2 days (Enoxaparin)
88878083|NCT03812328|Active Comparator|Enoxaparin|SC, QD for up to 10 ± 2 days
88878084|NCT03812328|Experimental|SelK2|I.V., single-dose
89402939|NCT05929027|Active Comparator|Treatment Arm G1|The interventions will consist of 5 daily sessions over 3 weeks. Because the interventions are self-administered, the sessions are unsupervised in the sense that the sessions do not include synchronous therapy provided by a clinician or a therapist. Instead, during each week, the intervention will include 2 short (less than 15 minutes) telemedicine check-in appointments (not standard of care) provided by a licensed occupational therapist for the purposes of assessing safety and providing guidance for the unsupervised sessions. The intervention will focus on stretches, warm-up and strengthening exercises aimed at improving hand function.
88878085|NCT03816696|Experimental|DTG followed by GSK3640254 followed by DTG+GSK3640254|Subjects will receive DTG 50 mg QD on Days 1 through 5 in Period 1 followed by a wash-out period of 4 days. Subjects will then receive GSK3640254 200 mg QD on Days 1 through 7 in Period 2 followed by co-administration of DTG 50 mg QD with GSK3640254 200 mg QD on Days 1 through 7 in Period 3.
88878086|NCT03815292|Experimental|MMH-MAP|Tablet for oral use. Dose per administration: 2 tablets. 2 tablets twice daily (4 tablets/day). The tablets should be held in mouth without chewing until complete dissolution. The duration of treatment will be 24 weeks.
88878087|NCT03815292|Placebo Comparator|Placebo|Placebo for 24 weeks, according to the MMH-MAP dosing regimen.
88878088|NCT03809910|Experimental|Prototype PTB (Gum line mode)|Participants will brush their teeth with prototype power toothbrush in Gum line mode with a fluoride toothpaste
88878089|NCT03809910|Experimental|Prototype PTB (Combined mode)|"Participants will brush their teeth with prototype power toothbrush in Gum line mode with a fluoride toothpaste. Following this, participants will brush their teeth with prototype power toothbrush in 'Interdental' mode with a fluoride toothpaste."
88878090|NCT03809910|Sham Comparator|Reference MTB|Participants will brush their teeth with manual toothbrush and fluoride toothpaste.
88878091|NCT03809910|Active Comparator|Reference PTB|Participants will brush their teeth with reference power toothbrush and fluoride toothpaste.
88878092|NCT03806790|Experimental|LEO 90100 foam|calcipotriol hydrate 52.2 µg/g [equivalent to 50.0 µg/g calcipotriol] plus betamethasone dipropionate 0.643 mg/g
88878093|NCT03806790|Active Comparator|Dovobet® ointment|calcipotriol hydrate 52.2 µg/g [equivalent to 50.0 µg/g calcipotriol] plus betamethasone dipropionate 0.643 mg/g
88878094|NCT03805386|Active Comparator|Standard of Care|Subjects will be prescribed the standard amount of opioids that are typically prescribed by our practice after surgery. Oxycodone 5mg 1-2 tablets every 4 hours as needed for pain. 30 tablets will be provided.
88878095|NCT03805386|Experimental|Patient Directed Care|Subject directed arm will be prescribed the number of opioids that the patient decides to be appropriate after discussion with the surgeon. This can be as low as 0 pills and as much as 30 pills as described in the standard care.
88878096|NCT03802344|Experimental|MC2-01 Cream|MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0,005%/0,064%) cream. One application daily for 8 weeks
89189916|NCT04586348|Active Comparator|Standard Iodine Supplement|Iodine (potassium iodide) 200 μg Beta carotene (All trans-beta- carotene) 1500 μg; Vitamin E (dl-alphatocopheryl acetate) 13.5 mg AT; Vitamin D3 (cholecalciferol) 10 μg; Vitamin C (ascorbic acid granular) 60 mg; Niacinamide 18 mg; Pantothenic acid (calcium d- pantothenate) 6 mg; Vitamin B6 (DC pyridoxine hydrochloride) 1.9 mg; Vitamin B1 (thiamine mononitrate) 1.4 mg; Vitamin B2 (riboflavin) 1.4 mg; Biotin 30 μg; Vitamin B12 (methyl-cobalamin) 2.6 μg; Folic Acid 0.4 mg; Levomefolic acid 0.1 mg; Calcium (carbonate DC) 250 mg; Magnesium (oxide granular) 50 mg; Iron (ferrous fumarate) 20 mg; Zinc (oxide) 10 mg; Manganese (sulphate) 2 mg; Copper (sulphate) 1 mg; Selenium (rice chelate) 30 μg
89189917|NCT04577001|Experimental|Letrozole Group|Subjects with hepatopulmonary syndrome will get the study drug letrozole
88878097|NCT03802344|Active Comparator|Cal/BDP combination|Calcipotriene/betamethasone (Calcipotriene/betamethasone dipropionate, w/w 0,005%/0,064%) cream. One application daily for 8 weeks
88878098|NCT03802344|Placebo Comparator|Vehicle|One application daily for 8 weeks
88878099|NCT03799614|Experimental|Lower dose vibration|RMBand lower dose vibration
88878100|NCT03799614|Experimental|Higher dose vibration|RMBand higher dose vibration
88878101|NCT03796260|Experimental|F1 to F06 Crossover|Participants first randomized to this arm will receive a single oral dose of entrectinib F1 (test formulation) on Day 1 of Period 1 after a standardized meal. This dose will be followed by a minimum 14-day washout period, after which participants will receive a single oral dose of entrectinib F06 (reference formulation) under fasted conditions on Day 1 of Period 2 (Periods 1 and 2 = 6 days).
88878102|NCT03796260|Experimental|F06 to F1 Crossover|Participants first randomized to this arm will receive a single oral dose of entrectinib F06 (reference formulation) on Day 1 of Period 1 after a standardized meal. This dose will be followed by a minimum 14-day washout period, after which participants will receive a single oral dose of entrectinib F1 (test formulation) under fasted conditions on Day 1 of Period 2 (Periods 1 and 2 = 6 days).
88878103|NCT03796182|Experimental|Sequence 1|Patients in sequence 1 will received treatment A (metformin) in Period 1 then complete at least 4 days of washout and continue to period 2 where treatment B (PF-04965842 + metformin) will be administered.
88878104|NCT03796182|Experimental|Sequence 2|Patients in Sequence 2 will start treatment B (PF-04965842 + metformin) then go through a washout period of at least 4 days and continue to Period 2 where treatment A (metformin) will be administered.
88878105|NCT03779724|Experimental|isokinetic exercise|The isokinetic dynamometer (Biodex Multijoint Pro 3) was used for isokinetic exercises. The isokinetic exercise program was implemented over eight weeks, twice a week on non-consecutive days under the supervision of a doctor. The number of repetitions undertaken by the patients over the program were as follows: first week 5 at 60°/s and 10 at 180°/s, second week 10 at 60°/s and 15 at 180°/s, third week 15 at 60°/s and 20 at 180°/s, fourth week 20 at 60°/s and 30 at 180°/s, and in the last four weeks 20 at 60°/s and 40 at 180°/s angular velocities. Each block of 10 repetitions were performed as a set.
88878106|NCT03779724|Active Comparator|home exercise|The patients undertook lower extremity strengthening and balance exercises three times a week for eight weeks without supervision. They started with three repetitions, which was gradually increased to 10-15. The patients were called two times a week to inquire about exercise continuity and encouraged to undertake the recommended exercises.
88878107|NCT03786744|Experimental|ASD CB-MNC injection.|ASD CB-MNC injection from different donors and standard therapy.
88878108|NCT03786744|Other|Standard therapy.|Patients with standard therapy as control group.
88878109|NCT03790878|Experimental|Mindful Breathing|Participants receive training in a mindful breathing skill to regulate their emotional distress during a stressor task. They will then receive one week of reminders to use this skill, delivered through their mobile phones.
88878110|NCT03790878|Active Comparator|Habituation|Participants receive an exposure/habituation intervention to regulate their emotional distress during a stressor task. They will then receive one week of reminders, delivered through their mobile phones.
88878111|NCT03790878|Placebo Comparator|Control|Participants complete the stressor task with no emotion regulation training. Similar to the other conditions, they will then receive one week of reminders, delivered through their mobile phones to test for placebo effects.
88878112|NCT03789474|No Intervention|Group A|No intervention was done ,served as a control group.
88878113|NCT03789474|Experimental|Group B|Intervention:peristaltic pneumatic compression device was placed on the legs of the patient and was active. HUNTLEIGH FLOWTRON ACS900 calf length device was used.
88878114|NCT03765996|Active Comparator|Decongestive Physiotherapy|This group received Complex Decongestive Physiotherapy.
88878115|NCT03765996|Experimental|Decongestive Physiotherapy plus taping|This group received Complex Decongestive Physiotherapy, and also applying taping to anastomosis regions.
88878116|NCT03765762|Experimental|GRF6019|Subjects will receive intravenously 250 mL of GRF6019 each day for 5 consecutive days.
88878117|NCT03765762|Placebo Comparator|Placebo|Subjects will receive intravenously 250 mL of placebo each day for 5 consecutive days.
88878118|NCT03756012|Active Comparator|Low Pulse Width (<500 μsec)|Spinal Cord Stimulation System will be programmed to pulse widths <500 μsec.
88878119|NCT03756012|Active Comparator|High Pulse Width (>1000 μsec)|Spinal Cord Stimulation System will be programmed to pulse widths >1000 μsec
88878120|NCT03748992|Experimental|gNO|Subjects will be receiving nitric oxide every week day for 3 weeks.
88878121|NCT03748758|Active Comparator|Drug: OP0201 (30 mg)|Cohort A- 30 mg per day X 14 days
88878122|NCT03748758|Placebo Comparator|Drug: Placebo|Cohort A- 0 mg per day X 14 days Cohort B- 0 mg per day X 14 days
88878123|NCT03748758|Active Comparator|Drug: OP0201 (60 mg)|Cohort B-60 mg per day X 14 days
88878124|NCT03745092|Experimental|NBO group|Between the two time 30min-EEG recordings, the patients in the NBO group would receive NBO (8L/min, via face mask) for 45min.
88878125|NCT03745092|Placebo Comparator|Control group|Between the two time 30min-EEG recordings, the patients in the control group would have a rest (lying, sitting or walking) for 45min.
88878126|NCT03744780|Experimental|ACT Workshop for Emotional Eating|All participants will be assigned to a one-day intervention using Acceptance and Commitment Therapy (ACT) techniques to help reduce emotional eating.
88878127|NCT03730116||the patients with HT and concomitant stable CAD|
88878128|NCT03729960|Other|LENA|Lena device with Fitbit and Cocooncam being optional
88878129|NCT03729024|Experimental|Light adjustable lens (LAL) and Light Delivery Device (LDD)|
88878130|NCT03728790|No Intervention|Usual Care|Usual care group patients will be assigned to the usual care given to patients with hypertensive disorders of pregnancy at Columbia University Irving Medical Center (CUIMC). This involves a prescription for a blood pressure cuff if they do not already have one, with which they will be asked to measure their blood pressure twice per day. They will be asked to keep a log of their blood pressure measurements and to bring that log to their next provider visit.
89189918|NCT04577001|Placebo Comparator|Placebo Group|Subjects with hepatopulmonary syndrome will get the study placebo
88878131|NCT03728790|Experimental|Remote Patient Monitoring|Remote Patient Monitoring patients will use a Bluetooth-enabled blood pressure cuff, which will transmit blood pressure measurements via Bluetooth from the monitor to a tablet, which is able to be accessed by nurses staffing a remote clinical care center. Patients will also be prompted to answer surveys assessing symptoms of preeclampsia. The nurses will review measurements and survey results, which will be flagged in order of urgency. The measurements uploaded into the remote monitoring system will also be reviewed at the patient's next provider visit.
89189919|NCT04576078|Experimental|NEFOPAM 60mg PO/ 8 hours|Oral administration of nefopam 60mg 2 hours before the surgery following by 60mg each 8h for 24h.
89535550|NCT05000775|Experimental|G-Niib|G-NiiB®, a patent-protected microbiome immunity formula, composed of naturally occurring food-grade bacteria approved by health authorities, has been developed by a group of CUHK gastroenterology experts.
89189920|NCT04576078|Placebo Comparator|Placebo|Oral administration of a placebo 2 hours before the surgery following by one administration each 8h for 24h.
89199037|NCT04038177|Experimental|Superset strength training|This is the experimental group that performs strength training with sets and rest intervals programmed in a superset manner
89199038|NCT04038177|Active Comparator|Traditional strength training|This is the comparator group that engages in strength training with sets and rest intervals programmed in accordance with the recommendations from The American College of Sports Medicine
88878132|NCT03727854|Experimental|Premeal protein group|Premeal protein enriched bar with dietary modification
88878133|NCT03727854|Other|Dietary modofication only group|Dietary modification only
89199039|NCT00885651|Experimental|1|Metoprolol for 10 days followed by placebo for 7 days.
88813291|NCT01720004|Experimental|Repeated Use of Hands-and-Knees|The intervention was repeated use of hands-and-knees position during labour. Participants were asked to try it for at least 15 minutes every hour, from randomization until delivery. They were not required to use it for delivery.
88813292|NCT01720004|No Intervention|Usual care|Participants were asked to refrain from using hands-and-knees position at any time from randomization to delivery. They were free to use any other position.
88813293|NCT03836534||patient coming to the emergency department|the group studied only concern adult adults consulting in the emergency departments and leaving after their consultations, during the permanence of care
88878134|NCT03544242|Active Comparator|Control group|
88878135|NCT03544242|Experimental|Pre-Isolation Infusion|
88813294|NCT04967742|Experimental|A group: 1 booster dose of UB-612 vaccine 100 μg|1 booster dose for subjects at UB-612 vaccine 10 μg in V-122 study.
88813295|NCT04967742|Experimental|B group: 1 booster dose of UB-612 vaccine 100 μg|1 booster dose for subjects at UB-612 vaccine 30 μg in V-122 study.
88878136|NCT03544242|Experimental|Post-Isolation Infusion|
89535551|NCT05000775|Placebo Comparator|Placebo|Placebo
88813296|NCT04967742|Experimental|C group: 1 booster dose of UB-612 vaccine 100 μg|1 booster dose for subjects at UB-612 vaccine 100 μg in V-122 study.
88813297|NCT03753750|Experimental|Actual stimulation|Subjects enrolled in the
88813298|NCT03753750|Sham Comparator|Sham stimulation|
88813299|NCT01720082|Active Comparator|Single incision laparoscopic appendectomy|Acute appendicitis with surgical indication
88813300|NCT01720082|Active Comparator|Multiport Laparoscopic appendectomy|Acute appendicitis with surgical indication
88813301|NCT01838720|Experimental|zero ischemia laparoscopic RFA assisted TE|RFA will be performed for 1 to 4 cycles for 4 to 12 minutes each depending on tumor size and depth. The tumor then will be laparoscopic enucleation without hilar clamping.
88813302|NCT01838720|Active Comparator|conventional laparoscopic partial nephrectomy|Renal hilum will be accurately isolated and then the artery only will be clamped during surgery.
88813303|NCT01838798||Study population|"See in inclusion/exclusion criteria.~Interventions: Baseline activities; Clinical interview with a psychologist; Telephone interview 2 months after ICU discharge; Clinical interview with a psychologist ."
88813304|NCT03219164|Experimental|AZLI + Placebo|75 mg/ml of aztreonam will be administered thrice daily (TID) for 14 days followed by placebo to match (PTM) aztreonam TID for 14 days.
88813305|NCT03219164|Experimental|AZLI|75 mg/ml of aztreonam will be administered TID for 28 days.
88813306|NCT01838954|Active Comparator|Short-wave diathermy|Short-wave diathermy device turned on
88813307|NCT01838954|Placebo Comparator|control|Short-wave diathermy device turned off
88813308|NCT01566461|Experimental|Drug-Coated Balloon (DCB)|IN.PACT Admiral: Balloon Angioplasty
88813309|NCT01566461|Active Comparator|Standard PTA|Standard Percutaneous Balloon Angioplasty (PTA) Balloon: Balloon Angioplasty
88878137|NCT03500406|Sham Comparator|Group 1 - Control|No treatment will be administered and men will not have to delay their IPP procedure
88878138|NCT03500406|Experimental|Group 2 - PTT 3x daily x 3 months|Men will utilize penile traction therapy for 30 minutes three times daily for the 3 months prior to placement of their IPP
88878139|NCT03423654|Experimental|Training Group|Spatial training
89535552|NCT02490449|Experimental|Exprerimental group|medication after diet
89535553|NCT02490449|Active Comparator|control group|medication before diet
88878140|NCT03423654|Other|Control Group|Letter number matching
88878141|NCT03370536|Experimental|Patients with AF|Patients with AF and planned to undergo first catheter procedure
88878142|NCT03161964|Experimental|Propranolol|After enrollment and the initial two-week continuous glucose monitoring assessment, study subjects randomized to the Propranolol Arm will be treated with Propranolol 80 Mg Oral Capsule, Extended Release daily for four weeks.
88878143|NCT03161964|Experimental|Placebo|After enrollment and the initial two-week continuous glucose monitoring assessment, study subjects randomized to the Placebo Arm will be treated with matching placebo oral capsule daily for four weeks.
88878144|NCT03078270|Other|Open-label|10 participants will be recruited for an open-label study. All will receive the active medication and complete depression and anxiety surveys at baseline, 4-weeks, and 8-weeks post injection. All participants will receive botulinum toxin A.
89004238|NCT05501821|Experimental|Part B, expansion monotherapy|KBA1412 monotherapy, given intravenously, Q3W, at fixed dose as defined in dose-escalation phase (Part A)
89199040|NCT00885651|Placebo Comparator|2|Placebo for 7 days followed by Metoprolol for 10 days
88878145|NCT03078270|Placebo Comparator|Double-Blind|30 participants will be recruited for a double-blind, comparison study. Participants will be randomized to the active or control groups. Each will receive an injection (active medication or placebo) and will complete a depression and anxiety survey at baseline, 4-weeks and 8-weeks post injection. Participants in the active group will receive botulinum toxin A; participants in the control group will receive a placebo.
88878146|NCT03042780|Experimental|FOLFIRINOX Treatment|Participants will receive modified FOLFIRINOX which consists of 85 mg/m^2 of oxaliplatin, 400 mg/m^2 of leucovorin over the first 2 hours, 165 mg/m^2 of irinotecan in a 90-minute infusion on day 1, followed by a continuous, 46-hour infusion of 5-FU at a dosage of 2,400 mg/m^2. A cycle will be repeated every 14 days. Granulocyte colony-stimulating factor (G-CSF) prophylaxis will be allowed after each cycle. Participants will undergo re-staging studies every 8 weeks. Participants will receive up to 12 cycles during the study. Additional cycles will be determined per investigators' discretion.
88878147|NCT03017040|Experimental|Scapholunate tear|Subjects with a full scapholunate tear will have a CT scan and fluoroscopy images taken
88878148|NCT03017040|Active Comparator|Control Wrist|Subjects will have a CT scan and fluoroscopy image taken of the contralateral wrist serve as the control.
88878149|NCT02985840|Active Comparator|Ondansetron|Ondansetron (4 mg) followed by two 5 ml normal saline flush
88878150|NCT02985840|Experimental|Ondansetron plus dexamethasone|Ondansetron (4 mg), followed by dexamethasone (4 mg), followed by a single 5 ml normal saline flush
88878151|NCT02974686|Active Comparator|Interventional (EVR)|Patients experiencing gastrointestinal adverse effects in the first year post transplant will be converted from mycophenolate to everolimus
88878152|NCT02974686|Active Comparator|Prior Agent (MPA)|Patient will have baseline data collected while on MPA for comparison with EVR
89199041|NCT00885729|Experimental|Stem cells|Cartilage defect are treated surgical either with chondrocytes or stem cells
89199042|NCT00885729|Active Comparator|Rehabilitation|Active rehabilitation program
88878153|NCT02966184|No Intervention|Benzalkonium chloride (BAC) Albuterol|This arm includes the current standard of care which patients receive at the institution. No interventions will be made within this group of patients.
88878154|NCT02966184|Experimental|Preservative Free Albuterol|This arm includes the preservative free albuterol which is being investigated. Treatment for this arm will follow current standards of care, with the only difference being the albuterol formulation.
88878155|NCT02950896||intraoperative FHR monitoring|Intraoperative fetal heart rate (FHR) monitoring
89199043|NCT00883935|Experimental|Sequence 2|In the first treatment period, all subjects will receive GSK1349572 30mg q24h for 5 days (treatment A). In period two, subjects will receive GSK1349572 30mg q24h in combination with ATV 400mg q24h (treatment C) for 14 days. There will be no washout between treatment periods. Day 1 of Period 2 will be the day after Day 5 of Period 1. Subjects will have a screening visit within 30 days prior to the first dose of study drug, two treatment periods, and a follow-up visit 7-14 days after the last dose of study drug.
88878156|NCT02877732|Experimental|Concussed Subject|EYE-SYNC eye-tracking device, Level of Alertness, SCAT-3 subtests (Symptom, Immediate memory, Balance and Orientation), Simple Reaction Time subtest of ANAM-SRT and DEM. Investigators will be collecting medical history and demographics from each subject.
88878157|NCT02877732|Active Comparator|Control Subject|EYE-SYNC eye-tracking device, Level of Alertness, SCAT-3 subtests (Symptom, Immediate memory, Balance and Orientation), Simple Reaction Time subtest of ANAM-SRT and DEM. Investigators will be collecting medical history and demographics from each subject.
88878158|NCT02808390|Experimental|80 mg BID|GED-0507-34-Levo 80 mg BID for 8 Weeks
88878159|NCT02808390|Experimental|160 mg BID|GED-0507-34-Levo 160 mg BID for 8 Weeks
88878160|NCT02808390|Experimental|Placebo|Placebo BID for 8 Weeks
88878161|NCT02744352|Active Comparator|continuous IBP block|Subjects will receive 60 hour continuous infraclavicular brachial plexus block (0.2% of ropivacaine at 8 milliliter/hour) with initial four intermittent 5ml bolus (20ml) of 0.5% Ropivicaine given preoperatively to help with operative and postoperative pain
88878162|NCT02744352|Active Comparator|single shot IBP block|Subjects will receive single shot infraclavicular brachial plexus block with 20ml bolus of 0.5% ropivicaine given preoperatively to help with operative and postoperative pain
89535554|NCT03205501|Experimental|IV-tracer EMI-137|"IV-administration of EMI-137: all patients will receive 0.13 mg/kg of the fluorescent tracer EMI-137 intravenously.~Molecular Fluorescence Endoscopy: approximately 2,5 hours after tracer administration, Molecular Fluorescence Endoscopy will be performed with additional measurements of fluorescence signals."
88878163|NCT02745210|Experimental|Experimental|13C Magnetic resonance (MR) spectroscopy.
88878164|NCT02679066|Active Comparator|Sugar-tong splint|Patients are placed in a sugar-tong splint for immobilization of the distal radius fracture.
88878165|NCT02679066|Active Comparator|Short Forearm Cast|Patients are placed in a short forearm cast, with bivalve, for immobilization of the distal radius fracture.
88878166|NCT02590068|Experimental|Hepatitis C infected volunteers|Zoster vaccine live (Zostavax), 0.65 ml dose, administered subcutaneously to Hepatitis C infected volunteers
88878167|NCT02590068|Active Comparator|Healthy volunteers|Zoster vaccine live (Zostavax), 0.65 ml dose, administered subcutaneously to healthy volunteers
88878168|NCT02587650|Experimental|Arm A (capmatinib)|Patients with MET fusion receive capmatinib PO BID on day 1-28. Courses repeat every 28 days in the absence of disease progression or unaccepted toxicity.
88878169|NCT02587650|Experimental|Arm B (ceritinib)|Patients with ALK fusion receive ceritinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unaccepted toxicity.
88878170|NCT02587650|Experimental|Arm C (regorafenib)|Patients with RET or BRAF fusion receive regorafenib PO QD on day 1-21. Courses repeat every 28 days in the absence of disease progression or unaccepted toxicity.
88878171|NCT02587650|Experimental|Arm D (entrectinib)|Patients with NTRK1, NTRK2, NTRK3, OR ROS1 fusion receive entrectinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unaccepted toxicity.
89004239|NCT05501821|Experimental|Part C, expansion combination therapy|KBA1412 in combination with pembrolizumab, given intravenously, Q3W, KBA1412 at fixed dose as defined in dose-escalation phase (Part A), Pembrolizumab at fixed dose
89004240|NCT05487586||ceftazidime avibactam group|Receive ≥1 dose of ceftazidime avibactam in routine practice; Aged ≥ 18 years old at the time of the informed consent signature.
89402940|NCT05929027|Experimental|Treatment Arm G2|The intervention will consist of 5 daily sessions over 3 weeks. Because the interventions are self-administered, the sessions are unsupervised in the sense that the sessions do not include synchronous therapy provided by a clinician or a therapist. Instead, during each week, the intervention will include 2 short (less than 15 minutes) telemedicine check-in appointments (not standard of care) provided by a licensed occupational therapist for the purposes of assessing safety and providing guidance for the unsupervised sessions. In this treatment arm, participants will use a knob-like computer interface connected to a tablet. The tablet features a series of game-like tasks to be carried out by moving the interface with the fingers. The target intervention is scheduled for 1.5 hours per day, which is typically divided into two sessions of 40 minutes with a 10-minute break in between.
89402941|NCT05929027|No Intervention|Control Group (CG)|Unlike G1 and G2, the CG will remain in the standard of care treatment plan but will not receive any additional therapy. That is to say, participants will follow standard therapy plans as dictated by normal post-stroke hospital discharge planning. The only difference from the standard of care will be that participants in CG will still receive identical check-in appointments with follow-up questions concerning recovery and activities.
89402942|NCT05923489|Experimental|Routine Angiography Follow-up (RAF) group|Patients in the RAF group will have routine angiography follow-up at 12 months after revascularization.
88878172|NCT02514252|Experimental|Fentanyl Sublingual Spray (FSS)|Hospitalized participants asked to complete a number of surveys at baseline. Participants then receive one single dose of intravenous opioid rescue for their first episode of breakthrough pain, and then receive up to 4 doses of FSS for subsequent episodes of breakthrough pain. Initial FSS starting dose is proportional to the patient's morphine equivalent daily dose (MEDD). Symptom questionnaire completed at baseline and after last dose of FSS while hospitalized. Mental ability tests given while hospitalized 30 minutes after first dose of current pain medication, and 30 minutes after each FSS dose. At the time of discharge, if FSS was helpful in controlling participant's pain, they are then able to continue with FSS use for 1 month. Participants given study diary to document pain level, how many times FSS used, and any side effects experienced each day.
88878173|NCT02434146|Experimental|Supportive care (topical phenylephrine solution)|Patients undergoing a cyclophosphamide and total body irradiation regimen receive topical phenylephrine solution via spray to the oral mucosa 15-20 minutes prior to each cyclophosphamide infusion, 25-30 minutes after the beginning of each cyclophosphamide infusion, and 15-20 minutes prior to each radiation treatment.
88878174|NCT02431494|Active Comparator|BLP arm (Blue Light Phototherapy)|In this arm participants will receive 5 BLP sessions at 1 week intervals. The duration of each session will be approximately 20 minutes. At each session, the affected areas of the participant's face will be exposed to a light source using blue light phototherapy machine between 15 to 20 minutes.
88878175|NCT02431494|Active Comparator|MCT arm (Microcurrent Therapy)|In this arm participants will receive 5 MCT sessions 1 week intervals using MCT machine. The duration of each session will be approximately 45 minutes. The investigators will place one electrode in one of the regional areas of the lymph nodes or affected area (i.e. the forehead) and move the second electrode systematically from the affected area towards the stationary electrode. Once the entire affected area has been covered, the investigators will move the first electrode to another regional area of the lymph nodes or affected area and the process will be repeated. This will continue until all of the affected areas have been treated.
88878176|NCT02431494|Active Comparator|Combination of BLP and Microcurrent|In this arm participants will receive 5 BLP and 5 MCT sessions at 1 week intervals. At each session, participants will receive MCT portion as described in above followed by BLP portion as described above. These visits will last approximately 65 minutes.
88878177|NCT02382588|Experimental|Gancyclovir gel|0.15% gancyclovir gel to be applied in the affected eye 5 times per day for a week, followed by 3 times per day for an additional 7 days or until the healing of the dendrite, whichever is earlier.
88878178|NCT02382588|Placebo Comparator|hypromellose gel|0.3% hypromellose gel to be applied in the affected eye 5 times per day for a week, followed by 3 times per day for an additional 7 days.
88878179|NCT02345460|Experimental|Treatment (FOLFIRINOX)|Patients receive FOLFIRINOX regimen comprising irinotecan hydrochloride IV over 90 minutes, oxaliplatin IV over 120 minutes, leucovorin calcium IV over 120 minutes, and fluorouracil IV over 1-2 minutes and then continuously over 46 hours on day 1. Treatment repeats every 14 days for 6 courses in the absence of disease progression or unacceptable toxicity.
88878180|NCT02345772|Experimental|Treatment Protocol|Hormonal therapy with fulvestrant 500 mg will be administered intramuscularly on days 1, 15 of the first cycle, and thereafter on day 1 of every 28-day cycle for up to 5 cycles before surgery. Docetaxel (T) 75 mg/m2 every 3 weeks will be given for four cycles. Trastuzumab (H, 8mg/kg for 1st cycle, then 6 mg/kg in subsequent cycles before and after surgery), pertuzumab (P, 840 mg for 1st cycle, then 420 mg in subsequent 3 cycles) will be given concurrently with docetaxel for a total of 4 cycles before surgery.
88878181|NCT02280252|Experimental|Concurrent Paclitaxel and RT|"Patients will be administered pre-operatively over 12 weeks either:~Paclitaxel, 30mg/m^2 twice per week, intravenously over 1 hour on a Monday/Thursday or Tuesday/Friday schedule~Abraxane, 30mg/m^2 twice per week, intravenously administered over 30 minutes, on a Monday/Thursday or Tuesday/Friday schedule~Patients will concurrently receive 6 weeks of radiation therapy, weeks 2-7:~Patients will receive a total dose to the breast, axilla and supraclavicular area of 45 Gy at 1.8 Gy/fraction, +14 Gy to the area of the original palpable tumor at 2 Gy/fraction (32 fractions)"
89402943|NCT05923489|Active Comparator|Routine Clinical Follow-up (RCF) group|Patients in the RCF group will have routine clinical follow-up at 12 months after revascularization, and the physician will decide whether further invasive testing is needed.
89402944|NCT05919745|Experimental|Ibuprofen group or Test Group|Subjects will be given ibuprofen 600mg tab 1h prior to surgery.
89402945|NCT05919745|Placebo Comparator|Placebo group or Control group|Subjects will be given a placebo tab 1h prior to surgery.
89402946|NCT05917223|Experimental|Milk protein ingestion|Consuming 20 g of Milk Protein dissolved in 350mL of water, one time at the experiment visit
89535555|NCT03077139|Experimental|Arms|Pacing wires used to stimulate ventricles in a synchronous matter
89189921|NCT04561557|Experimental|CAR T cells therapy，Dose level 1: 0.5 × 10^6 CAR-T cells/Kg|"The tolerability and safety of CT103A cells will be assessed in an initial dose of 0.5×10^6 CAR-T cells/Kg and three subjects will be enrolled firstly. If no dose-limiting toxicity (DLT) occurs and at least one subject benefits from the treatment, there will be two options for the investigator based on the available data: 1) three more subjects will be enrolled in the 0.5 × 10^6 CAR-T cells/Kg group and DLT will be evaluated in a total of six subjects; 2) another three subjects will be treated with 1 × 10^6 CAR-T cells/Kg instead of 0.5 × 10^6 CAR-T cells/Kg.~If DLT occurs in one of the first three subjects, three more subjects will be enrolled in this cohort to reach the total subjects of six."
88878182|NCT02266914|Experimental|Arm 1|Patients who have received a cardiac transplant at The Ohio State University Ross Heart Hospital will undergo Magnetic Resonance Elastography (MRE) (using a Magnetic Resonance Elastography driver) within 24-48 hours of standard of care biopsy. Results of both will be compared to determine if MRE can successfully predict cardiac transplant rejection.
88878183|NCT02262000|Experimental|A - 7.5 Gy x 10 daily fractions|Radiotherapy: 7.5 Gy x 10 daily fractions delivered with VMAT or regular IMRT at West Virginia University.
88878184|NCT02262000|Experimental|B - 12 Gy x 5 daily fractions|Radiotherapy: Optional schedule of 12 Gy x 5 daily fractions can may also be used ONLY in situations where dose constraints for organs at risk can be EASILY met while optimal PTV coverage is achieved
89535556|NCT02486783||Baseline controls (no signs of infection)|Neonates admitted for serial blood draws for uncomplicated hyperbilirubinemia
89535557|NCT02486783||Signs of infection A|No infection: antibiotics stopped after 48 hours; negative cultures
89535558|NCT02486783||Signs of infection B|Clinical infection: 7 day antibiotics; negative cultures
88878185|NCT02248740|Active Comparator|Radiofrequency Ablation|"Device: ClosureFast radiofrequency catheter (VNUS Medical Technologies Inc, San Jose, CA).~Patients will have the intervention, ablation of the incompetent small saphenous vein, using this device."
88878186|NCT02248740|Active Comparator|Laser Ablation|"Device: EVLT 980nm diode laser system (Angiodynamics, Queensbury, NY).~Patients will have the intervention, ablation of the incompetent small saphenous vein, using this device."
88878187|NCT02242578|Experimental|Active|Active rTMS stimulation (1 Hz rTMS, 10 Hz rTMS)
88878188|NCT02242578|Experimental|Placebo|Sham rTMS stimulation (1 Hz rTMS, 10 Hz rTMS)
88878189|NCT02133534|Experimental|Atorvastatin|Subjects will be treated with atorvastatin 10 mg/day for 30 days. The study team will obtain one blood and urine sample at baseline prior to starting atorvastatin therapy, and again after 30 days of drug therapy. The study team will do ultrasound imaging of the arm in which a probe will be placed over the blood vessels to measure the diameter of the artery and how this changes after a blood pressure cuff is inflated and then deflated. Subjects will take one nitroglycerine tablet during the ultrasound imaging.
88878190|NCT02009982|Experimental|Cardioneuroablation|Patients in this group will receive the cardioneuroablation procedure using the Biosense Webster Navistar ThermoCool Diagnostic/Ablation Deflectable Tip Catheter
88878191|NCT02009982|No Intervention|Standard Medical Thearpy|Patients in this group will not receive the cardioneuroablation and will continue to be managed using standard medical therapy
88878192|NCT02013414|Experimental|3D ultrasound-guided biopsy|Participants will have a 3D ultrasound-guided biopsy of the prostate rather than the standard of care 2D ultrasound-guided biopsy.
88878193|NCT02015910|Experimental|Januvia (Sitagliptin)|Sitagliptin 100 mg a day for 12 weeks
88878194|NCT02015910|Placebo Comparator|Placebo|Placebo
89189922|NCT04561557|Experimental|CAR T cells therapy，Dose level 2: 1 × 10^6 CAR-T cells/Kg|If neither DLT nor efficacy is shown in the first three subjects, the dose of CAR-T cells will be increased to 1 × 106 CAR-T cells/kg to assess DLT.
89189923|NCT04561557|Experimental|CAR T cells therapy，Dose level 3: 0.25 × 10^6 CAR-T cells/Kg|If DLT occurs in two subjects, whether to test the safety and efficacy in 0.25 × 10^6 CAR-T cells/kg group will be determined by the investigator based on the initial data of efficacy, PK and PD.
89189924|NCT04561258|Experimental|Low Dose Cohort|A single infusion of ≥1x10e8 and <1x10e9 genetically modified T cells.
89189925|NCT04561258|Experimental|High Dose Cohort|A single infusion of ≥1x10e9 and <5x10e9 genetically modified T cells.
89189926|NCT04560127|Experimental|Camrelizumab combination with Apatinib|Apatinib (250mg p.o. q.d.) combined with Camrelizumab (200mg, iv, q2w)
89189927|NCT04555616|Placebo Comparator|Control Group|Alzheimer's disease patients and caregivers.
89189928|NCT04555616|Experimental|Standard Environmental Design|Alzheimer's disease patients and caregivers.
89189929|NCT04555616|Experimental|Individualized Environmental Design Protocol|Alzheimer's disease patients and caregivers.
89189930|NCT04549337|Experimental|4X4|"An exercise training protocol with a duration of 38 minutes consisting of a 10 minutes warm up with a heart rate of 60-70% of HRmax followed by 4 intervals of 4 minutes at an intensity that will induce at least 85% of HRmax (we will start with 75% of watt max).~Each interval is separated by 3-minute active pauses, biking at 50-70% of HRmax. Following this a 3-minute cooldown (at warm up intensity) will be performed."
89402947|NCT05917223|Experimental|Corn protein ingestion|Consuming 20 g of Corn protein isolation dissolved in 350mL of water, one time at the experimental visit
89402948|NCT05917223|Experimental|Corn+Pea protein ingestion|Consuming 20 g of Corn+Pea protein isolation dissolved in 350mL of water, one time at the experimental visit
88878195|NCT01996410|Active Comparator|Chemotherapy 1 Acupuncture|"Chemotherapy 1: This group will receive Adriamycin (60mg/m2) and Cytoxan (600mg/m2) concurrently on day 1 every 2 weeks for 4 cycles followed by Taxol (175mg/m2) on day 1 every 2 weeks for 4 cycles. Patients on this regimen who randomize to the experimental (acupuncture) group will undergo acupuncture on the morning of every treatment for a total of 8 acupuncture sessions. Both groups will complete a MDASI on day 3 (+/- 1 days) of each cycle of chemotherapy for a total of 8 MDASI forms."
88878196|NCT01996410|Active Comparator|Chemotherapy 2 Acupuncture|"Chemotherapy 2: This group will receive Adriamycin (60mg/m2) and Cytoxan (600mg/m2) on day 1 every 2 weeks for 4 cycles followed by Taxol (80mg/m2) on day 1 weekly for 12 cycles. Patients who randomize to the experimental (acupuncture) group will undergo acupuncture the morning of every treatment day of the adriamycin/cytoxan cycles; they will receive acupuncture for every third Taxol treatment, beginning with the first treatment. They will receive a total of 8 acupuncture sessions: 4 with the adriamycin/cytoxan cycles and 4 with the Taxol cycles. Both groups will fill out MDASI on day 3 (+/- 1 days) of each Adriamycin/Cytoxan cycle; they will also fill out the MDASI on day 3 (+/- 1 days) of every third Taxol treatment for a total of 8 MDASI forms."
88878197|NCT01996410|Active Comparator|Chemotherapy 3 Acupuncture|"Chemotherapy 3: In the adjuvant setting- This group will receive Taxotere (75mg/m2) and Cytoxan (600 mg/m2) on day 1 every 3 weeks for 4 cycles. Patients on this regimen who randomize to the experimental (acupuncture) group will undergo acupuncture on the morning of every Taxotere/Cytoxan for a total of 4 acupuncture sessions. Both groups will complete a MDASI on day 3 (+/- 1 days) of each cycle of chemotherapy for a total of 4 MDASI forms."
88878198|NCT01996410|Active Comparator|Chemotherapy 4 Acupuncture|"Chemotherapy 4: In the neoadjuvant setting- This group will receive Taxotere (75 mg/m2), Carboplatin (AUC 6), Perjeta (840 mg loading fixed dose, followed by 420 mg maintenance fixed dose) day 1 every 3 weeks for 6 cycles. Patients on this regimen who randomize to the experimental (acupuncture) group will undergo acupuncture on the morning of every Taxotere/Carboplatin/Perjeta treatment for a total of 6 acupuncture sessions. Both groups will complete a MDASI on day 3 (+/- 1 days) of each cycle of chemotherapy for a total of 6 MDASI forms."
88878199|NCT01996410|No Intervention|Chemotherapy 1 No Acupuncture|"Chemotherapy 1: This group will receive Adriamycin (60mg/m2) and Cytoxan (600mg/m2) concurrently on day 1 every 2 weeks for 4 cycles followed by Taxol (175mg/m2) on day 1 every 2 weeks for 4 cycles. Patients on this regimen who randomize to the experimental (acupuncture) group will undergo acupuncture on the morning of every treatment for a total of 8 acupuncture sessions. Both groups will complete a MDASI on day 3 (+/- 1 days) of each cycle of chemotherapy for a total of 8 MDASI forms."
89402949|NCT05917223|Experimental|Non-protein, low energy|Consuming 20 g of carbohydrate dissolved in 350mL of water, one time at the experimental visit
88878200|NCT01996410|No Intervention|Chemotherapy 2 No Acupuncture|"Chemotherapy 2: This group will receive Adriamycin (60mg/m2) and Cytoxan (600mg/m2) on day 1 every 2 weeks for 4 cycles followed by Taxol (80mg/m2) on day 1 weekly for 12 cycles. Patients who randomize to the experimental (acupuncture) group will undergo acupuncture the morning of every treatment day of the adriamycin/cytoxan cycles; they will receive acupuncture for every third Taxol treatment, beginning with the first treatment. They will receive a total of 8 acupuncture sessions: 4 with the adriamycin/cytoxan cycles and 4 with the Taxol cycles. Both groups will fill out MDASI on day 3 (+/- 1 days) of each Adriamycin/Cytoxan cycle; they will also fill out the MDASI on day 3 (+/- 1 days) of every third Taxol treatment for a total of 8 MDASI forms."
88878201|NCT01996410|No Intervention|Chemotherapy 3 No Acupuncture|"Chemotherapy 3: In the adjuvant setting- This group will receive Taxotere (75mg/m2) and Cytoxan (600 mg/m2) on day 1 every 3 weeks for 4 cycles. Patients on this regimen who randomize to the experimental (acupuncture) group will undergo acupuncture on the morning of every Taxotere/Cytoxan for a total of 4 acupuncture sessions. Both groups will complete a MDASI on day 3 (+/- 1 days) of each cycle of chemotherapy for a total of 4 MDASI forms."
88878202|NCT01996410|No Intervention|Chemotherapy 4 No Acupuncture|"Chemotherapy 4: In the neoadjuvant setting- This group will receive Taxotere (75 mg/m2), Carboplatin (AUC 6), Perjeta (840 mg loading fixed dose, followed by 420 mg maintenance fixed dose) day 1 every 3 weeks for 6 cycles. Patients on this regimen who randomize to the experimental (acupuncture) group will undergo acupuncture on the morning of every Taxotere/Carboplatin/Perjeta treatment for a total of 6 acupuncture sessions. Both groups will complete a MDASI on day 3 (+/- 1 days) of each cycle of chemotherapy for a total of 6 MDASI forms."
88878203|NCT01980342|Experimental|Efavirenz|Healthy, reproductive-age women using the etonogestrel contraceptive implant who will take a two-week course of efavirenz 400 mg orally each night.
88878204|NCT01881984|Experimental|Ravicti|Open Label Study
88878205|NCT01878786|Experimental|ERL & TAC|Concentration controlled everolimus(ERL) & Low dose tacrolimus(TAC) + corticosteroid withdraw
88878206|NCT01878786|Experimental|ERL & TAC --> MMF/MPA|Concentration controlled everolimus & low dose tacrolimus --> mycophenolate mofetil (MMF) at Month 3 + corticosteroid
89189931|NCT04549337|Active Comparator|6X1|"An exercise training protocol with a duration of 38 minutes consisting of a 10 minutes warm up on 30% of watt-max followed by 6 intervals of 1 minute at 100% of the watt-max.~Each interval is interspersed by 3-minute active pauses at 30% of watt-max. Following this a 7-minute cooldown (at warm up intensity) will be performed."
89189932|NCT04549337|Active Comparator|10-20-30|"An exercise training protocol with a duration of 38 minutes consisting of a 10 minutes warm up at 60-70% of HRmax followed by 3 intervals of 5 minutes interspersed by 3 minutes on 50-70% of HRmax.~Each interval consists of 5 minutes of 5 repeated 30-20-10 intervals, consisting of 30 seconds at easy pace, 20 seconds at medium pace and 10 seconds at all-out. Following this a 7-minute cooldown (at warm up intensity) will be performed."
89189933|NCT04541914|Experimental|Validation group|Evaluation for diagnostic efficacy of peripheral blood marker-based molecular diagnostic method for antibody-mediated rejection (AMR) in ABO blood type incompatible kidney transplant (ABOiKT)
89189934|NCT04536532|Experimental|HEC121120 tablets|part 1(Health volunteer): single-Dose Study: There will be a total of 6 dose cohorts: 25 mg、50 mg、100 mg、400 mg、600 mg、800 mg food effect：200 mg multiple-dose study: 200 mg part 2(Patients with chronic hepatitis B): There will be a total of 3 dose cohorts:100、200、400 mg
89402950|NCT05913375|Experimental|Cardiac radioablation|Patients with ventricular tachycardia will undergo cardiac radiosurgery with one fraction of 20 Gy to the arrhythmia substrate, as determined by the electrophysiological cardiac mapping.
89535559|NCT02486783||Signs of infection C|Sepsis: positive bacterial blood culture
89402951|NCT05893797|Experimental|Connected Management Platform|Participants with type 1 and type 2 diabetes wearing continuous glucose monitoring (CGM) will receive insulin lispro via the Tempo Pen as part of the connected insulin management platform.
89402952|NCT05891886|Experimental|Supplemental oxygen delivered by facemask|"Patients with acute PE will be randomized to breathing supplemental oxygen by non-rebreather face mask first.~Subjects will alternate treatments (supplemental oxygen or room air) every 30 minutes for 90 minutes (e.g. T=30, T=60, T=90) and then will maintain their treatment (oxygen or room air) for a total of 180 minutes."
89402953|NCT05891886|Active Comparator|Room air delivered by facemask|"Patients with acute PE will be randomized to breathing room air by non-rebreather face mask first.~Subjects will alternate treatments (supplemental oxygen or room air) every 30 minutes for 90 minutes (e.g. T=30, T=60, T=90) and then will maintain their treatment (oxygen or room air) for a total of 180 minutes."
89402954|NCT05883930|Experimental|"Transtheoretical Model (TTM)-based Let's Move mobile software program"|"Transtheoretical Model (TTM)-based Let's Move mobile software program developed for the experimental group will be applied for 12 weeks. Students will be given smart wristbands. Smart wristband data (step numbers) will be integrated into the program. Through this program, students will fill in the pre-test, post-test and follow-up test (at 6 months) and the sedentary lifestyle TTM Sedentary Life Scales (Stages of Change questionnaire, Self-Efficacy and Decision Making scales) and daily step count values.The body mass index, fat and muscle ratios of the students will be evaluated by the researcher. They will be asked to add these values to the program."
88878207|NCT01878786|Experimental|Standard dose TAC + MMF/MPA|Standard dose of tacrolimus + mycophenolate mofetil + corticosteroid withdraw
88878208|NCT01851174|Experimental|Gemcitabine and nab-Paclitaxel|"Gemcitabine (1,000 mg/m^2) administered intravenously on days 1 and 15, every 28 days~nab-Paclitaxel (125 mg/m^2) administered intravenously on days 1 and 15, every 28 days"
89535560|NCT02486783||Signs of infection D|Meningitis: positive bacterial CSF culture
88878209|NCT01846182|Active Comparator|Group 1|60 mg of duloxetine in the AM for 20 weeks and placebo in PM
88878210|NCT01846182|Active Comparator|Group 2|300 mg of pregabalin in the PM for 20 weeks and placebo in AM
88878211|NCT01846182|Placebo Comparator|Group 3|placebo in the AM & PM for 20 weeks
88878212|NCT01800162|Active Comparator|Uterine evacuation, then MTX for some|Subjects will undergo a uterine evacuation. If hCG levels do not sufficiently decrease after the uterine evacuation, the subject will be treated with methotrexate. If hCG levels do sufficiently decrease after the uterine evacuation, no further treatment is required.
88878213|NCT01800162|Active Comparator|Empiric treatment with MTX for all|Subjects will be treated with methotrexate, receiving one dose on day 0 and a subsequent dose on day 4. Additional doses will be administered as needed based on hCG levels.
88878214|NCT01800162|Active Comparator|Expectant Management|Subjects will have their PPUL expectantly managed using serum hCG monitoring.
88878215|NCT01794936|Experimental|VTI Probe|During robotic-assisted laparoscopic prostatectomy, the VTI Doppler probe (test) will utilized to measure blood blow within the neurovascular bundles. This is to be completed after the bladder neck and seminal vesicles are identified and dissected. To use the probe, the assistant surgeon will place the Doppler probe within the abdomen and systematically move it cephalad along the lateral prostate pedicles to identify NVB vessels. The Doppler flow in these regions will be quantified as arterial (strong) flow, venous (minimal) flow or no flow. The procedures will proceed by dissecting the lateral margin of prostate step by step up to the gland's apex. Blood loss and the time required to identify and dissect the NVB will be recorded.
88878216|NCT01794936|No Intervention|Non-Probe|Patients randomized to not receive probe evaluation.
88878217|NCT01756560|Active Comparator|control|in this group, plain bupivacaine will be used to block femoral and sciatic nerve
88878218|NCT01756560|Experimental|Dexamethasone|Bupivacaine mixed with dexamethasone will be used to block femoral and sciatic nerve
88878219|NCT01738698|Experimental|SPD489 40mg|
88878220|NCT01738698|Experimental|SPD489 100mg|
88878221|NCT01738698|Experimental|SPD489 160mg|
88878222|NCT01738698|Placebo Comparator|Placebo|
88878223|NCT01717482|Active Comparator|Metformin|Metformin 850mg twice a day
88878224|NCT01717482|Placebo Comparator|Observation|Standard of Care Observation
88878225|NCT01702896|Experimental|Interleukin-2|Interleukin-2 will be used in this group
88878226|NCT01682928|Active Comparator|IV/Oral Hydration and Bedrest|"Maternal BP (sitting)~Pulse Pressure~Pulse~Urine Specific Gravity BID~Fetal Heart Rate~Maternal Body Weight US Procedures~AC/EFW~Umbilical Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})~Uterine Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})~AFI (Baseline, day 3, 7 {or Discharge})~ALL ITEMS ABOVE MUST BE COMPLETED BEFORE:~1 Liter Water PO over 2 hours~1 Liter IV Fluid Bolus (NS) then titrated to 75 ml\hr for duration of the study participation~Strict I/O's~Vital signs"
89004241|NCT05482477|Experimental|preoperative TEAS group|Receive a TEAS on bilateral Neiguan (PC6) Yintang (GV29) and Zusanli (ST36) by the transcutaneous electrical stimulators to provide an altered frequency 2/100 Hz, disperse-dense waves, and adjusted intensity which was less than 10 mA, 30 min before anesthesia.
88878227|NCT01682928|Active Comparator|Hydrotherapy Group|"Maternal BP (sitting)~Pulse Pressure~Pulse~Urine Specific Gravity BID~Fetal Heart Rate~Maternal Body Weight US Procedures~AC/EFW~Umbilical Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})~o 1 hour +/- 30 minutes after submersion therapy~Uterine Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})~o 1 hour +/- 30 minutes after submersion therapy~AFI (Baseline, day 3, 7 {or Discharge}) o 1 hour +/- 30 minutes after submersion therapy~ALL ITEMS ABOVE MUST BE COMPLETED BEFORE:~1 Liter Water PO over 2 hours~1 Liter IV Fluid Bolus (NS) then titrated to 75 ml\hr for duration of the study participation~Strict I/O's~Vital signs~HYDROTHERAPY TWICE DAILY FOR 3-7 DAYS o Blood pressure, pulse, pulse pressure, body weight, and fetal heart rate before and after submersion therapy"
88878228|NCT01683864|Experimental|positive cytology with HIPEC|gastric cancer cytology positive with HIPEC Mytomycin and cisplatin intraoperative
88878229|NCT01683864|No Intervention|positive cytology without HIPEC|gastric cancer cytology positive without HIPEC
88878230|NCT01683864|No Intervention|negative cytology without HIPEC|gastric cancer with negative cytology
88878231|NCT01648296|Experimental|Dosimetry Group|A total of 12 subjects will receive a single intravenous injection of[18F]FluorbetaOx followed by PET-CT imaging. Four normal healthy volunteer subjects and 8 subjects with or without Type 2 Diabetes Mellitus with Chronic Dilated Cardiomyopathy.
88878232|NCT01648296|Experimental|Kinetic Dynamic Group|A total of 38 subjects will receive a single intravenous injection of [18F]FluorbetaOx, [11C]Palmitate, and [15O]Water followed by PET-CT imaging. Ten normal healthy volunteer subjects and 28 subjects with or without Type 2 Diabetes Mellitus of which 18 subjects will have Chronic Dilated Cardiomyopathy and 10 obese subjects with a Body Mass Index of ≥ 30kg/m2.
88878233|NCT01608906|Experimental|continuous low dose intravenous heparin infusion|titrated to a PTT of 40-45
88878234|NCT01608906|Active Comparator|subcutanous heparin 5000 units 3 times/day|standard of care
88878235|NCT01602198|Active Comparator|Exelon transdermal patch|Exelon [rivastigmine] transdermal patch
88878236|NCT01602198|Placebo Comparator|Placebo transdermal patch|Placebo transdermal patch
88878237|NCT01577628|Other|Group 1: Lipikar Balm AP|Daily application of Lipikar Balm AP starting at birth
88878238|NCT01577628|No Intervention|Group 2: No intervention control group|Subjects may use a moisturizer if they wish to but no instruction or product is provided
88878239|NCT01550562|Placebo Comparator|Sham Stimulation|Sham subthreshold spinal cord stimulation therapy
88878240|NCT01550562|Active Comparator|Treatment 1|subthreshold spinal cord stimulation therapy
88878241|NCT01550562|Experimental|Treatment 2|subthreshold spinal cord stimulation therapy
88878242|NCT01545648|Experimental|denosumab|"Dosage: 120 mg, monthly for total of 6 months, then every 12 weeks for 2 doses, for a total treatment course of one year~Route of administration: subcutaneous injection"
88878243|NCT01527942|Experimental|Arm 1 - Active Drug|Preoperative administration of 1,000 mg IV Acetaminophen will be administered after induction of general anesthesia and prior to incision and every 6 hours thereafter for 24 hours.
89535561|NCT03225235|Experimental|Hypofractionated Stereotactic SBRT|"By assuming a hypofractionated irradiation scheme, it is assumed that between the fractions sublethal radiation damage is being treated and the time factor does not significantly affect RT result. The SBRT fractional dose was determined on the basis of a Biologically Effective Dose (BED) calculation using a linear-square model, which assumes that α / β takes the following values for:~tumor (RS) = 1.5~Late rectal and bladder complications = 3.0~early rectal and bladder complications = 10.0."
88878244|NCT01527942|Placebo Comparator|Arm 2 - Placebo|Preoperative IV Placebo (0.9 Sodium Chloride 100 ml) will be administered after induction of general anesthesia and prior to incision and every 6 hours thereafter for 24 hours.
88878245|NCT01507584|Active Comparator|Prostaglandin Analogue|WDT protocol Visit 1 - (WDT after washout) 20 Visit 2 - (WDT with treatment) 20 Visit 3 - (WDT with PGA or BB add-on) 20 (PGA + BB)
88878246|NCT01507584|Active Comparator|Carbonic Anhydrase Inhibitor|WDT protocol Visit 1 - (WDT after washout) 20 Visit 2 - (WDT with treatment) 20 Visit 3 - (WDT with PGA or BB add-on) 20 (CAI+ BB)
88878247|NCT01483872|Experimental|NAC/Tigecycline/Heparin combination lock solution|A combination of the above three drugs will form the catheter lock solution that will be instilled into the catheter
88878248|NCT01483872|Placebo Comparator|Standard anticoagulant (heparin or citrate)|Standard anticoagulant (heparin or citrate)
88878249|NCT01385280|Experimental|Arm I|Patients receive oral therapeutic estradiol once daily on days 1-3, twice daily on days 4-7, and thrice daily on days 8-90. Beginning on day 98, patients receive oral exemestane once daily in the absence of disease progression or unacceptable toxicity. Also laboratory biomarker analysis and enzyme-linked immunosorbent assay will be taken for correlative studies.
88878250|NCT01365156|Experimental|EPLND + Chemoradiation|Group 1: Extraperitoneal laparoscopic lymphadenectomy followed by chemoradiation therapy
88878251|NCT01365156|Active Comparator|Chemoradiation|Group 2: standard-of-care chemoradiation therapy only
88878252|NCT01350258|Experimental|Transplant Treatment Group|All patients treated on this research study.
88878253|NCT01319760|Sham Comparator|Standard of care|Patients in the control arm will be treated with standard of care for post-PCI STEMI patients in accordance with the the 2004 ACC/AHA Guidelines for the Management of Patients with ST-elevation Myocardial Infarction.
88878254|NCT01319760|Experimental|Impella 2.5|24 hours of support with the Impella 2.5 post-PCI for acute myocardial infarction.
88878255|NCT01302444|Active Comparator|Tadalafil|first 4 weeks are for adjusting treprostinil dose, then Tadalafil 40mg daily for 12 weeks, Group is randomly chosen from entire cohort
88878256|NCT01302444|Placebo Comparator|Placebo|first 4 weeks for adjusting treprostinil dose, then Placebo for 12 weeks
88878257|NCT01292070|Experimental|Control-Experimental arm|Each subject will serve as their own control with the left arm receiving the control protein (Histamine prick, intradermal diluent and intradermal CAT) and right arm receiving the experimental protein (GFD).
88878258|NCT01284504|Experimental|Celecoxib|Celecoxib, 200 mg tab
88878259|NCT01284504|Placebo Comparator|Placebo|placebo, tab
88878260|NCT01204788|Experimental|Arm 1 (Prophylactic Arm)|Prophylactic Treatment (standard of care prophylactic antibiotics) + Prophylactic White Cell Transfusion
88878261|NCT01204788|Experimental|Arm 2 (Therapeutic Arm)|Prophylactic Treatment (standard of care prophylactic antibiotics) + Therapeutic White Cell Transfusion
88878262|NCT01183416|Experimental|3F8 monoclonal antibody and 13-cis-Retinoic Acid|This phase II, open-label, single arm trial assesses the anti-NB activity of high-dose 3F8 (80 mg/m2/day), which is used in cycles 1-2, with return to standard 3F8 dosage (20 mg/m2/day) in subsequent cycles. The patients are post-transplant and in 1st complete/very good partial remission (CR/VGPR),89 with no evidence of NB by standard studies, but are at high risk for relapse.
88878263|NCT01169610|Experimental|Varenicline|
88878264|NCT01166724|Active Comparator|Sirolimus|patients will be switched from Tacrolimus to Sirolimus
89189935|NCT04536532|Placebo Comparator|HEC121120 placebo tablets|part 1(Health volunteer): single-Dose Study: There will be a total of 6 dose cohorts: 25 mg、50 mg、100 mg、400 mg、600 mg、800 mg food effect：200 mg multiple-dose study: 200 mg part 2(Patients with chronic hepatitis B): There will be a total of 3 dose cohorts:100、200、400 mg
89189936|NCT04536532|Active Comparator|entecavir tablets|part 2(Patients with chronic hepatitis B): 0.5 mg
89189937|NCT04536532|Placebo Comparator|entecavir placebo tablets|part 2(Patients with chronic hepatitis B): 0.5 mg
89189938|NCT04526158|Experimental|Mobile+Group LAMP Mindfulness-Based Intervention|8 weekly, synchronous interactive online group sessions; access to mobile app and a study website, with an accompanying workbook.
89189939|NCT04526158|Experimental|Mobile LAMP Mindfulness-Based Intervention|8 weekly asynchronous sessions, delivered on mobile app and study website, with an accompanying workbook; 3 engagement calls at the middle, beginning and end of the program.
89189940|NCT04526158|No Intervention|Usual Care|Engagement in usual care for 12 months as participants normally would. After the entire follow-up period is complete (12 months), participants in the usual care arm are given access to the Mobile LAMP materials MBI training on the app and study website, and the accompanying workbook.
89189941|NCT04518566|No Intervention|Placebo|Patients in control arm will have FitBit. However, there are no personalised nudges given to the patients in the control arm. Occasional reminders to encourage adherence to wearing of the FitBit will be sent.
89189942|NCT04518566|Experimental|Nudges|Patients in the intervention arm will be given a FitBit device and will be encouraged to wear it as often as possible. Using FitBit built-in tracking technologies such as PurePulse and SmartTrack54, patient's daily activities such as number of steps taken, sedentary time, heart rate, sleep time and exercise will be captured and synced to the adaptive intervention platform as developed in Phase 2 for real-time tracking.
89189943|NCT04508634|Experimental|laparoscopic sleeve gastrectomy|laparoscopic sleeve gastrectomy
89189944|NCT04508634|Active Comparator|Metformin Group|Metformin Group
89189945|NCT04490512|Experimental|FluBHPVE6E7|Multiple administration of FluBHPVE6E7
89189946|NCT04490512|Placebo Comparator|Placebo|Multiple administration of buffer solution
89189947|NCT04484194|Experimental|eHA Screening|Patients receiving eHA screening tool.
89189948|NCT04480502|Experimental|Cohort A|Patients treated with 300 mg of single agent envafolimab every three weeks
89189949|NCT04480502|Experimental|Cohort B|Patients treated with envafolimab in combination with ipilimumab. Envafolimab will be given at 300 mg every three weeks. Ipilimumab will be given at 1 mg/kg every three weeks for a total of four doses.
89189950|NCT04480502|Experimental|Cohort C|Patients treated with 600 mg of single agent envafolimab every three weeks
89189951|NCT04480502|Experimental|Cohort D|Patients treated with envafolimab in combination with ipilimumab. Envafolimab will be given at 600 mg every three weeks. Ipilimumab will be given at 1 mg/kg every three weeks for a total of four doses.
89189952|NCT04455867||UHN Toronto Rehab|Participants with prediabetes of T2DM undertaking a 6-month stepped hybrid (home and clinic based) aerobic plus resistance exercise intervention as per the site's standard protocol (Diabetes Exercise and Healthy Lifestyle Program).
89189953|NCT04455867||Sunnybrook Health Sciences Centre|Participants with prediabetes or T2DM receiving care from an outpatient service at Sunnybrook Health Sciences Centre.
89189954|NCT04447092|Experimental|Gemcitabine/Nab-paclitaxel|Gemcitabine/Nab-paclitaxel + pembrolizumab
89189955|NCT04447092|Experimental|FOLFIRINOX|FOLFIRINOX + pembrolizumab
89189956|NCT04437134||On-line exercise and education|Exercise (12 sessions) and education (2-3 sessions) delivered on-line. Patients attend both the exercise and educational sessions by logging on to virtual rooms using links sent out by e-mail. The sessions are led and supervised by GLA:D certified physiotherapists.
89189957|NCT04437134||On-site exercise and education|Exercise (12 sessions) and education (2-3 sessions) delivered on-site. Patients attend both the exercise and educational sessions at physiotherapy clinics in Denmark. The sessions are led and supervised by GLA:D certified physiotherapists.
89189958|NCT04414813|Experimental|hAESCs treatment|50 millions hAESCs are transplanted to participants with PD.
89189959|NCT04379921|No Intervention|Control|Participants will receive standard care.
88878265|NCT01166724|No Intervention|Tacrolimus|Patient will stay on Tacrolimus
88878266|NCT01151904|Experimental|COMBIGAN® with Latanoprost|Patients on current latanoprost monotherapy that qualify for study entry will have COMBIGAN® (brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution) added to the latanoprost for 12 additional weeks.
88878267|NCT01110174|Experimental|HD PET/CT|utilization of PET/CT for diagnostic of breast cancer progression.
88878268|NCT01115244|Experimental|Dapsone gel, 5%|ACZONE™ (dapsone) Gel, 5% will be applied to one elbow or knee, randomized at time of enrollment. Application will be topical to the same location twice daily (morning and evening) for six weeks.
88878269|NCT01115244|No Intervention|Not treated|One arm of the patient will be left untreated.
88878270|NCT01079598|Other|Treatment|RF ablation with ClosureRFS Stylet
88878271|NCT01031550|Active Comparator|standard anesthetic management|standard anesthetic management with propofol 100-150mcg/kg/min
88878272|NCT01031550|Experimental|preconditioning with 2 MAC isoflurane group|After induction, anesthesia will be maintained with 1MAC (minimum alveolar concentration) of Isoflurane according to age and end-expiratory concentration. Thirty minutes before the anticipated inflow occlusion and commencement of liver transaction, Isoflurane concentration will be gradually increased to 2 MAC over a period of 5 minutes (induction) and maintained at 2 MAC for 10 minutes (preconditioning). Then the concentration of Isoflurane will be decreased to 1 MAC during next 15 minutes (washout).
89189960|NCT04379921|Experimental|Apple Watch and App|Participants will receive standard care, and an Apple Watch to record activity through the App.
89402955|NCT05883930|Experimental|control group|No intervention will be made in the control group. A smart bracelet will be given as a gift in order to follow the step counts of the students. Students will fill in pre-test, post-test and follow-up test (at 6 months) and sedentary lifestyle TTM Sedentary Life Scales (Stages of Change questionnaire, Self-Efficacy and Decision Making scales) and daily step count values via online forms. The body mass index, fat and muscle ratios of the students will be evaluated by the researcher. These values will be recorded.
89402956|NCT05875623|Experimental|Intervention|"In the intervention group, the clinical pharmacist will apply the MALPIP criteria on all the admission and discharge medications. The pharmacists can access the full MALPIP list at https://sites.google.com/moh.gov.my/malpip/home.~The intervention will consist of 4 steps: i) pharmacist review using MALPIP criteria to detect PIM, ii) discussion with doctors for deprescribing decision iii) discussion with patients and documentation of shared decision iv) follow up patients at 6, 12, and 18 months.~Pharmacists will perform the reviewing and checking by themselves and discuss the suggestions with doctors during daily medical ward rounds. The attending doctors will decide whether to deprescribe based-on pharmacists suggestions. Then, the pharmacists will discuss the deprescribing proposal with the patients and record the decision."
88878273|NCT00986310|Active Comparator|fluoxetine|Patients will be randomized to receive either 20 mg/day of fluoxetine (one pill) or placebo (one pill), to be started one week prior to the scheduled hospital admission date. The dose will be increased to two pills per day on day 1 of hospitalization bringing the total dose of fluoxetine to 40 mg/day in patients randomized to receive this medication. On the day of discharge from the hospital, the study medication will be reduced to 1 pill per day and the patient will be instructed to stop the medication one week following discharge.
89535562|NCT04993521|Active Comparator|bilateral superficial cervical plexus block (BSCPB)|Analgesia obtained by a ultrasound guided cervical plexus block using lidocain
89535563|NCT04993521|Active Comparator|local wound infiltration (LWI)|Analgesia obtained by local wound infiltration of lidocain
88878274|NCT00986310|Placebo Comparator|Placebo|Patients will be randomized to receive either 20 mg/day of fluoxetine (one pill) or placebo (one pill), to be started one week prior to the scheduled hospital admission date. The dose will be increased to two pills per day on day 1 of hospitalization. On the day of discharge from the hospital, the study medication will be reduced to 1 pill per day and the patient will be instructed to stop the medication one week following discharge.
88878275|NCT00907218|Experimental|1|Adults who meet DSM-IV-TR criteria for ADHD and smoke cigarettes.
88878276|NCT00895284|Experimental|Robot|Robotic hysterectomy
88878277|NCT00895284|Active Comparator|Standard|Standard hysterectomy
88878278|NCT00903396|Experimental|Arm I|Patients receive palonosetron hydrochloride IV on day 1.
88878279|NCT00903396|Experimental|Arm II|Patients receive palonosetron hydrochloride IV on days 1 and 4.
89189961|NCT04375826|Active Comparator|Epidural analgesia|Only Epidural analgesia is used for this group
88878280|NCT00903396|Placebo Comparator|Arm III|Patients receive placebo IV on day 1.
88878281|NCT00903396|Placebo Comparator|Arm IV|Patients receive placebo IV on days 1 and 4.
88878282|NCT00875394|Experimental|1|sitagliptin + metformin
88878283|NCT00875394|Active Comparator|2|metformin + any other oral antidiabetic drug
88878284|NCT00875394|Active Comparator|3|metformin
88878285|NCT00832572|Experimental|Placebo-Ranolazine|Participants were randomized to receive placebo to match ranolazine during Weeks 1 to 6, then ranolazine during Weeks 7 to 12.
88878286|NCT00832572|Experimental|Ranolazine-Placebo|Participants were randomized to receive ranolazine during Weeks 1 to 6, then placebo to match ranolazine during Weeks 7 to 12.
88878287|NCT00811590|Experimental|All patients|All participants enrolled.
88878288|NCT00749658|Active Comparator|Bupropion + Placebo Varenicline|Bupropion + Placebo Varenicline \Varenicline + Placebo Bupropion; Varenicline + Placebo Bupropion \Bupropion + Placebo Varenicline
88878289|NCT00749658|Active Comparator|upropion + Varenicline|Bupropion + Varenicline \Varenicline + Placebo Bupropion; Varenicline + Placebo Bupropion \Bupropion + Varenicline
88878290|NCT00738972|Active Comparator|Valsartan 80 mg + Paravastin 40 mg|Participants who were administered Valsartan 80 mg plus paravastin 40 mg by mouth daily for one year. (Group A)
88878291|NCT00738972|Active Comparator|Valsartan 80 mg + Simvastatin 40 mg|Participants who were administered Valsartan 80 mg plus simvastatin 40 mg by mouth daily for one year. (Group B)
88878292|NCT00738972|Experimental|Valsartan 80 mg + Simvastatin 40 mg / Ezetimibe 10 mg|Participants who were administered Valsartan 80 mg plus simvastatin 40 mg / ezetimibe 10 mg by mouth daily for one year. (Group C)
89189962|NCT04375826|Active Comparator|Preperitoneal analgesia and IV-PCA|This group is given with both preperitoneal analgesia and Intravenous Patient Controlled Analgesia (IV-PCA)
88878293|NCT00738972|Active Comparator|Valsartan 80 mg|Participants who were administered Valsartan 80 mg by mouth daily for one year. (Group D)
88878294|NCT00726180|Experimental|Treatment arm|
88878295|NCT00704496|Placebo Comparator|Placebo|Placebo
88878296|NCT00704496|Active Comparator|Pseudoephedrine|Pseudoephedrine is a 240 mg PO per day
88878297|NCT00692094|Experimental|1|Subjects will be given 0.5 mg at a time when melatonin should delay the timing of their body clock. If the subject's body clock responds successfully to the dose, the dose will be reduced gradually until the lowest effective dose is found. If the treatment does not work, the subject will be taken off treatment and later entered into a new treatment regimen.
88878298|NCT00692094|Experimental|2|Subjects will be given 0.5 mg at a time when melatonin should advance the timing of their body clock. If the subject's body clock responds successfully to the dose, the dose will be reduced gradually until the lowest effective dose is found. If the treatment does not work, the subject will be taken off treatment and later entered into a new treatment regimen.
88878299|NCT00692094|Experimental|3|Subjects will be given a larger dose (up to 10 mg) at a time when the melatonin should advance the timing of the body clock. If the subject's body clock responds successfully to the dose, the dose will be reduced gradually until the lowest effective dose is found. If the treatment does not work, the subject will be taken off treatment and later entered into a new treatment regimen.
88878300|NCT00692094|Experimental|4|Subjects will be given a larger dose (up to 20 mg) at a time when the melatonin should advance the timing of the body clock. If the subject successfully responds to the treatment, the dose will be reduced gradually until the lowest effective dose is determined (down to 0.025 mg). If the treatment does not work, the subject will be taken off treatment and later entered into a new treatment regimen.
88878301|NCT00676026|Experimental|Zolpidem 1|Zolpidem will be administered twice to each participant; once in the follicular and luteal phases of the menstrual cycle.
88878302|NCT00676026|Experimental|Progesterone 2|Progesterone will be administered twice to each participant; once in both the follicular and luteal phases of the menstrual cycle.
88878303|NCT00676026|Experimental|Fluoxetine 3|Fluoxetine will be administered twice to each participant; once in both the follicular and luteal phases of the menstrual cycle.
88878304|NCT00679926|Experimental|Once daily|Patients taking 4 (four) lopinavir/ritonavir (200mg/50mg tablets) and 1 (one) tenofovir (300mg tablet) every 24 (twenty four) hours.
88878305|NCT00680316|Experimental|Dornase alfa|
88878306|NCT00680316|Placebo Comparator|Placebo|
88878307|NCT00656916|Experimental|Fluticasone Propionate|440 micrograms twice daily by oral inhalation.
89189963|NCT04371224|Experimental|NaliCap|nal-IRI/Capecitabine
89189964|NCT04371224|Active Comparator|NAPOLI|nal-IRI/5-FU/LV
89189965|NCT04368455|Experimental|Primary Care Clinic|Physician participants will receive the self-directed app based curriculum. The physician participants will engage in the VR simulations independently.Next, we will implement VICTORI with staff including nurses and medical assistants in groups of up to 15-20 participants (phase II; secondary outcome). Staff will watch a 5-minute video on evidence-based practices in recommending the HPV vaccine and observe a facilitator and clinician participating in the VICTORI VR simulations, and then engage in a 5-minute debriefing.
89189966|NCT04368455|Active Comparator|Control Primary Care Clinic|Physician participants will receive the self-directed app based curriculum component of VICTORI though will not undergo the VR simulations.
89189967|NCT04363242|Experimental|Part A|Dose escalation of SYN125. Each dose level (low, medium, high) will be tested in a cohort of 3 patients. If no dose-limiting toxicity (DLT) is observed in the 3 patients, dose escalation will continue to the next SYN125 dose level.
89189968|NCT04363242|Experimental|Part B|Dose escalation of SYN125 administered with a fixed-dose of SYN004 (SYN004 will be administered immediately after SYN125 infusion is complete, if tolerated). Once cohorts with low and medium dose levels in Part A are completed and no DLTs are observed per cohort, Part B with the SYN125 low dose level + SYN004 will start and run in parallel with Part A. The high dose of SYN125 in a cohort in Part A will begin along with Part B.
89189969|NCT04343183|Active Comparator|HBOT treatment group|Patients will receive hyperbaric oxygen therapy
89402957|NCT05875623|No Intervention|Control|"In the control arm, pharmacists, patients and doctors are not purposefully blinded but are not aware of the intervention (i.e. the MALPIP tool). Designated pharmacist at the control sites identifies patients who match the eligibility requirements and enroll them into the trial after obtaining consent.~Patients in the control arm will receive routine care and support that they entitled to from the medical team and clinical pharmacists. Preadmission medication will be reconciled by a clinical pharmacist using the standard procedures, including medication history assessment form (CP1), pharmacotherapy review (CP2) and the clinical pharmacy report form (CP3)."
88878308|NCT00656916|No Intervention|Observational Group|Comparator group, no intervention.
88878309|NCT00629850|Experimental|Powerlung Performer|The arm will receive the lung trainer device to use for 10 weeks
88878310|NCT00629850|No Intervention|Control|Control. This arm will not receive any device
88878311|NCT00619242|Experimental|sorafenib|sorafenib 2 tablets by mouth
88878312|NCT00601848|Experimental|Photodynamic Therapy|PDT
88878313|NCT00586716|Other|Group 1 intravenous immune globulin|Intravenous immunoglobulin for: patients who do not have a living donor, have a PRA greater than 30% for 3 consecutive months, and have one positive crossmatch with a cadaveric donor while on kidney transplant waiting list
88878314|NCT00586716|Other|Group 2 intravenous immune globulin|Intravenous immune globulin for patients who have living donors with positive crossmatch results.
88878315|NCT00571194|Other|peritoneal dialysis (CCPD)|PK profile of pravastatin
88878316|NCT00570258|Placebo Comparator|2|"Fulvestrant: 250 mg IM Q 4 weeks~Placebo: 150 mg PO QD"
88878317|NCT00570258|Active Comparator|1|"Fulvestrant: 250 mg IM Q 4 weeks~Erlotinib: 150 mg PO QD"
88878318|NCT00568698|Experimental|Hydroxyurea|
88878319|NCT00568698|Placebo Comparator|Placebo|
89004242|NCT05482477|Experimental|Intraoperative TEAS group|Receive a TEAS on bilateral Neiguan (PC6) Yintang (GV29) and Zusanli (ST36) by the transcutaneous electrical stimulators to provide an altered frequency 2/100 Hz, disperse-dense waves, and adjusted intensity which was less than 10 mA, from 30 min before anesthesia to the end of surgery
89535564|NCT02452177|Experimental|Vitamin D|Patients in this group were treated with oral vitamin D at a dose of 1200 IU per day for 2 months.
88878320|NCT00569868|Experimental|Velcade|"Treatment on this study will last 2 cycles. Each cycle consists of 3 weeks, or 21 days. After you have gone off study, you will be followed every three months for approximately 2 years.~Each cycle will consist of 3 weeks (21 days) according to the schedule below.~DRUG ROUTE DOSE DAYS Velcade IV 1.3 mg/m2 1,4,8, and 11 This 21-day period will be considered one treatment cycle; Cycle 2 would commence on Day 22 (Cycle 2, Day 1). Patients may continue to receive treatment every 21 days, provided there is no evidence of disease progression or no unacceptable toxicity for a two cycles."
88878321|NCT05600478||Japan|A group of ICU physical therapists working in Japan.
88878322|NCT05600478||Philippines|A group of ICU physical therapists working in the Philippines.
88878323|NCT05600478||Taiwan|A group of ICU physical therapists working in Taiwan.
88878324|NCT05600166||Experimental group|Participants were treated with artificial dermal repair materials in combination with growth factors.
88878325|NCT05600166||Control group|Cases treated with a double layer of artificial dermal repair material
88878326|NCT05599542|Experimental|Solution-oriented approach group|A preliminary assessment of the pregnant woman's thoughts on breastfeeding was made and the EARS (Eliciting, Amplifying, Reinforcing and Start Over) process was applied. Eliciting, Amplifying, Reinforcing and Start Over process guides the second and subsequent sessions in a sequential order.
88878327|NCT05599542|Experimental|Hypno-breastfeeding group|A preliminary assessment was made about the pregnant woman's thoughts on breastfeeding. In the hypno-nursing philosophy, affirmation, relaxation, imagination and visualization techniques were used in order to positively affect the subconscious mind during the breastfeeding process.
89535565|NCT02452177|Placebo Comparator|Placebo|
89535566|NCT03205189|Other|Pre-operative prescription group|This group will have a pre-operative prescription delivered during the preoperative anesthesia clinic.
89402961|NCT05866432|Experimental|Datopotamab-deruxtecan|Datopotamab-deruxtecan (DS-1062a) 6.0 mg/kg body weight i.v. on day 1 once every three weeks
89402962|NCT05856084|Experimental|Low dose vaccine group in adults aged 30 to 49 years|Participants aged 30 to 49 years will be vaccinated with 2 doses of low dose recombinant herpes zoster vaccine (CHO cells) on a 0, 2 month schedule, administered intramuscularly (IM).
89189970|NCT04343183|No Intervention|Standard of Care group|Patients will not receive hyperbaric oxygen therapy and will receive the current standardized treatment protocol
88878328|NCT05599542|Other|control group|Data were collected with the Introductory Information Form at the first interview (admission to the postpartum service) with the women in the control group. Post-test data were collected with Primiparous Breastfeeding Motivation Scale and Insufficient Milk Perception Scale at 16-24 hours postpartum.
88878329|NCT05599230||CF patients before (3 days) and during (14 days) ETI treatment|"Patients over 12 years old and eligible will start ETI treatment ( current standart treatment).~Morning: Elexacaftor 100 mg, Tezacaftor 50 mg, Ivacaftor 75 mg, 2 tablets~Evening: Ivacaftor 150 mg"
88878330|NCT05599152||ticagrelor/prasugrel Group|Patients with acute myocardial infarction who underwent percutaneous coronary intervention and maintained aspirin and ticagrelor/prasugrel as standard therapy.
88878331|NCT05599152||clopidogrel Group|In patients with acute myocardial infarction who underwent percutaneous coronary intervention, discontinued ticagrelor/prasugrel and switched to clopidogrel
88878332|NCT05573256|Experimental|Group 1 (Sleep hygiene education together with lavender oil inhalation)|the participants assigned to Group 1 will be given sleep hygiene education and instructed how to apply lavender oil inhalation. The participants will be provided with charts on sleep hygiene education and lavender oil inhalation and shown how to regularly keep daily records using their charts. The participants in this group will be given a copy of the sleep hygiene education brochure and lavender oil in a 10 ml bottle.
88878333|NCT05573256|Experimental|Group 2 (Sleep hygiene education)|The participants assigned to Group 2 will only be given sleep hygiene education. They will be provided with a copy of the sleep hygiene education brochure and a chart on which to record their sleep hygiene practices.
88878334|NCT05573256|Experimental|Group 3 (Lavender oil inhalation)|The participants assigned to Group 3 will only be instructed on how to apply lavender oil inhalation and keep regular daily records on the chart given. The participants in this group will be given lavender oil in a 10 ml bottle.
89189971|NCT04329364|Experimental|Laser Haemorrhoidoplasty (LAH)|treatment that we would like to study
89402963|NCT05856084|Experimental|High dose vaccine group in adults aged 30 to 49 years|Participants aged 30 to 49 years will be vaccinated with 2 doses of high dose recombinant herpes zoster vaccine (CHO cells) on a 0, 2 month schedule, administered intramuscularly (IM).
89402964|NCT05856084|Placebo Comparator|Placebo group in adults aged 30 to 49 years|Participants aged 30 to 49 years will be vaccinated with 2 doses of placebo on a 0, 2 month schedule, administered intramuscularly (IM).
89402965|NCT05856084|Experimental|Low dose vaccine group in adults aged 50 years and older|Participants aged 50 years and older will be vaccinated with 2 doses of low dose recombinant herpes zoster vaccine (CHO cells) on a 0, 2 month schedule, administered intramuscularly (IM).
89402966|NCT05856084|Experimental|High dose vaccine group in adults aged 50 years and older|Participants aged 50 years and older will be vaccinated with 2 doses of high dose recombinant herpes zoster vaccine (CHO cells) on a 0, 2 month schedule, administered intramuscularly (IM).
89402967|NCT05856084|Active Comparator|Shingrix® group in adults aged 50 years and older|Participants aged 50 years and older will be vaccinated with 2 doses of Shingrix® on a 0, 2 month schedule, administered intramuscularly (IM).
89402968|NCT05856084|Placebo Comparator|Placebo group in adults aged 50 years and older|Participants aged 50 years and older will be vaccinated with 2 doses of placebo on a 0, 2 month schedule, administered intramuscularly (IM).
89402969|NCT05853601|Experimental|Single Dose Theophylline|Single dose of theophylline or aminophylline (5mg/kg IV) given within 12 hours after birth
89402970|NCT05853601|Experimental|Repeat Dose Theophylline|Loading dose of theophylline or aminophylline (5mg/kg IV) given within 12 hours of birth, with two subsequent doses (1.2 mg/kg IV) given at12 and 24 hours after the loading dose
89402971|NCT05853601|No Intervention|Standard treatment|Infants cared for according to standard practice.
89402972|NCT05853341|Experimental|RID-TDS 13.3 mg/24 h|3 consecutive applications of 1 patch (1st patch for 4 days, 2nd patch for 3 days, 3rd patch for 4 days) covering an 11-day period
89402973|NCT05853341|Active Comparator|Exelon® 13.3 mg/24 h|11 consecutive applications of 1 patch (each patch will be applied for 1 day) covering an 11-day period
89189972|NCT04329364|Active Comparator|Conventional Open Haemorrhoidectomy (COH)|gold standard treatment as comparator
89402974|NCT05851586|Experimental|Supervised exercise + home exercise program|The intervention group (supervised exercise) which will receive supervised strengthening and stretching exercises by a licensed physical therapist in a group setting 2 times per month for 30 minutes each session as well as a home exercise program with general stretching and strengthening exercises for various body parts (focusing on neck, thoracic spine, lumbar spine, shoulder and hand/wrist) that will be identical to the home exercise program only group.
89402975|NCT05851586|Active Comparator|Home exercise program only|The home exercise program only group will be provided with a written home exercise program consisting of general stretching and strengthening exercises for various body parts (focusing on neck, thoracic spine, lumbar spine, shoulder and hand/wrist). The exercise programs will be identical for both the supervised exericse and the home exercise program only groups.
89402976|NCT05851534|No Intervention|Standard care|Receiving standard preoperative care
89402977|NCT05851534|Experimental|Best practice program|Implementation of best practice preoperative optimisation program
89402978|NCT05849805|Experimental|Intracalvaria bone marrow injection group|Y-3 ，Intracalvaria bone marrow injection , continuous medication for 3 days, with standard treatment and management according to the related guidelines.
89402979|NCT05849805|Sham Comparator|Conventional treatment group|standard treatment and management according to related guidelines
89402980|NCT05849051|Experimental|Newly developed warnings with images|Participants receive newly developed warnings intervention
89402981|NCT05849051|Experimental|FDA proposed text-only warnings|Participants receive FDA proposed text only warning intervention
89402982|NCT05849051|No Intervention|Control group, no intervention|Participants do not receive an intervention
89189973|NCT04327336|Active Comparator|Manual|In this group non invasive mechanical ventilation will be manually titrated during a polysomnography. The Philips A40 ventilator will be used in Spontaneous-Timed (ST) mode.
89402983|NCT05848830|Active Comparator|DM1 + HBEXT + MIS|Participants will be asked to undergo 16 weeks of home-based training and asked to take one dose of a multi-ingredient supplement per day.
89189974|NCT04327336|Active Comparator|Automatic|In this group the ventilator will run in an automatic mode (AVAPS) with the same Phillips A40 ventilator.
89402984|NCT05848830|Placebo Comparator|DM1 + HBEXT + PLA|Participants will be asked to undergo 16 weeks of home-based training and asked to take one dose of a multi-ingredient supplement placebo per day.
89402985|NCT05848830|No Intervention|CONTROL|Healthy control subjects who will not undergo study intervention and will be used for baseline measurements and outcomes.
89402986|NCT05835063|Experimental|We Chatt communication tool|
89402987|NCT05835063|Placebo Comparator|Usual care|
89402988|NCT05822089|Experimental|Monofocal IOL I vs. enhanced monofocal IOL I|The investigational devices are approved intraocular lenses (IOLs) intended to be implanted after phacoemulsification in individuals suffering from age-related cataract with the need of cataract surgery. In Arm one (I) participants will receive a monofocal IOL (ZCB00) vs. an enhanced monofocal IOL (ICB00)
89402989|NCT05822089|Experimental|Monofocal IOL II vs. enhanced monofocal IOL I|The investigational devices are approved intraocular lenses (IOLs) intended to be implanted after phacoemulsification in individuals suffering from age-related cataract with the need of cataract surgery. In Arm two (II) participants will receive a monofocal IOL (Sensar 1AAB00) vs. an enhanced monofocal IOL (ICB00)
89402990|NCT05822089|Experimental|Monofocal IOL III vs. enhanced monofocal IOL II|The investigational devices are approved intraocular lenses (IOLs) intended to be implanted after phacoemulsification in individuals suffering from age-related cataract with the need of cataract surgery. In Arm three (III) participants will receive a monofocal IOL (Vivinex XY1)vs. an enhanced monofocal IOL (Vivinex Impress).
89402991|NCT05822089|Experimental|Enhanced monofocal IOL II vs. enhanced monofocal IOL II|The investigational devices are approved intraocular lenses (IOLs) intended to be implanted after phacoemulsification in individuals suffering from age-related cataract with the need of cataract surgery. In Arm four (IV) participants will receive an enhanced monofocal IOL (Vivinex Impress) bilateral with a monovision target
89402992|NCT05822089|Experimental|Monofocal IOL III vs. enhanced monofocal IOL IV|The investigational devices are approved intraocular lenses (IOLs) intended to be implanted after phacoemulsification in individuals suffering from age-related cataract with the need of cataract surgery. In Arm five (V) participants will receive an enhanced monofocal IOL (EnVista) vs. an enhanced monofocal IOL (LuxSmart)
89402993|NCT05822089|Experimental|Enhanced Monofocal IOL V vs. enhanced monofocal IOL V with irregular astigmatism|The investigational devices are approved intraocular lenses (IOLs) intended to be implanted after phacoemulsification in individuals suffering from age-related cataract with the need of cataract surgery. In Arm five (VI) participants will receive an enhanced monofocal IOL (Acrysof IQ Vivity) in both eyes if irregular astigmatism is observed.
89402994|NCT05817643|Active Comparator|Dose Under Fed Condition|Investigational Drug is administered with a meal
89402995|NCT05817643|Active Comparator|Dose Under Fasted Condition|Investigational Drug is administered after fasting
89402996|NCT05814705|Active Comparator|Protein supplement|
89402997|NCT05814705|Experimental|Protein supplement with Urolithin A|
89402998|NCT05805215|Experimental|Active TIS of the hippocampus|Participants will undergo Active TIS of the hippocampus as one of the 3 conditions within the trial in randomized order.
89402999|NCT05805215|Experimental|Active TIS of the precuneus|Participants will undergo Active TIS of the precuneus as one of the 3 conditions within the trial in randomized order.
89403000|NCT05805215|Placebo Comparator|High-frequency stimulation|High frequency >1Khz stimulation; Assumption: The intrinsic low-pass filtering of electrical signals by the neural membrane prevents neural electrical activity from following very high-frequency oscillating (e.g., > 1 kHz) electric fields.
89403001|NCT05800717|Other|Treatment|Receives SCISM-D.
89403002|NCT05800288||EleveldTCI|Patients who received Midazolam premedication bolus (0.03 mg/kg) before general anesthesia conducted with Eleveld TCI model (this model was choosen at anesthesiologist's discreption)
89403003|NCT05800288||Schnider TCI|Patients who received Midazolam premedication bolus (0.03 mg/kg) before general anesthesia conducted with SchniderTCI model (this model was choosen at anesthesiologist's discreption)
89403004|NCT05799729||CeK 0.1|Data about Continuous infusion with Concentration at the effector site of Ketamine (CeK) set (at anesthesiologist's discretion) at 0.1 ug/ml for at least 30 minute and BIS during a propofol-remifentanil general anesthesia will be correlated.
89403005|NCT05799729||CeK 0.2|Data about Continuous infusion with Concentration at the effector site of Ketamine (CeK) set (at anesthesiologist's discretion) at 0.2 ug/ml for at least 30 minute and BIS during a propofol-remifentanil general anesthesia will be correlated.
89403006|NCT05799729||CeK 0.4|Data about Continuous infusion with Concentration at the effector site of Ketamine (CeK) set (at anesthesiologist's discretion) at 0.4 ug/ml for at least 30 minute and BIS during a propofol-remifentanil general anesthesia will be correlated.
89403007|NCT05799729||CeK 0.6|Data about Continuous infusion with Concentration at the effector site of Ketamine (CeK) set (at anesthesiologist's discretion) at 0.1 ug/ml for at least 30 minute and BIS during a propofol-remifentanil general anesthesia will be correlated.
89403008|NCT05797441|Experimental|EMPOWER|The goals of EMPOWER are to increase patients' self-efficacy for managing their PTSD, enable the maintenance or building upon gains made in TFT through the continued application of TFT skills, and encourage engagement in meaningful life activities. The program includes a Veteran workbook and four planned therapist contacts over the twelve weeks following TFT completion. The intervention includes: self-monitoring of symptoms, continued practice of TFT skills, engagement in meaningful activities, goal setting, and therapist support.
89535567|NCT03205189|Other|Postoperative prescription group|This group will receive the postoperative prescription.
89403009|NCT05797441|Active Comparator|Treatment As Usual|The comparison condition will be TAU following completion of TFT. In the spirit of TAU, providers will not be restricted in the type or intensity of services offered. Depending on local clinic policy or norms, providers randomized to TFT may provide post-TFT treatment themselves or Veterans may be referred to other providers and/or back to the clinician who referred the Veteran to TFT. If providers would have typically discharged Veterans following TFT, that is also allowable.
89403010|NCT05796778|Experimental|subomohyoid suprascapular nerve|superficial probe of ultrasound was placed in the transverse plane to visualize the superior trunk in the short axis. The suprascapular nerve was identified as it branched off from the superior trunk and traced until it coursed beneath the inferior belly of the omohyoid muscle.
89403011|NCT05796778|Active Comparator|Interscalene brachial plexus|ultrasound-guided interscalene block involves imaging the C5 and C6 roots at approximately the level of the cricoid cartilage, just distal to where they emerge from behind their respective transverse processes and where they lie in the groove between the anterior and middle scalene muscles
89403012|NCT05775185||Orbital radiotherapy|The study includes only one group of patients treated with orbital radiotherapy for 2-week period, a total dose of 20 Gy, 2Gy for each session.
89403013|NCT05773976|Other|Potential candidates, that according the investigator judgment could be treated with one of IPs|"At V0, as per clinical practice, only one of the below reported IPs products can be dispensed to the enrolled subject, depending on investigator clinical evaluation and decision:~Afomill Refreshing Soothing~Afomill Anti-redness Eye Drops~Iridil"
89403014|NCT05773963|Other|At V0, as per clinical practice, only 1 of the IPs products can be assigned to the enrolled subject|At V0, as per clinical practice, only 1 of the IPs products can be assigned to the enrolled subject
89403015|NCT05769010|Experimental|Arm 1|HER2-positive: SHR-A1811
89403016|NCT05769010|Experimental|Arm 2|HER2-positive: SHR-A1811 and pyrotinib
89403017|NCT05769010|Experimental|Arm 3|HER2-positive: SHR-A1811 and bevacizumab
89403018|NCT05769010|Experimental|Arm 4|HER2-low: SHR-A1811
89403019|NCT05762146|Experimental|Riociguat +Propylthiouracil +Perphenazine|"Triple combination therapy group:~○ each patient in this group will receive two doses (8 +/- 2 hours between doses) of orally administered combination therapy of riociguat, propylthiouracil, and perphenazine, in addition to standard of care."
89403020|NCT05762146|No Intervention|standard of care|Control group: each patient in this group will receive only standard of care
89403021|NCT05756023|Active Comparator|PCOs Patients|To compare the pregnancy rate at IVF / ICSI cycles in patients with PCOs
89403022|NCT05756023|Active Comparator|Non PCOs Patients|To compare the pregnancy rate at IVF / ICSI cycles in patients with without PCOs
89403023|NCT05747690|Experimental|KIO015 - Cohort 1|One injection of KIO015 on the hemi-face. The untreated hemi-face is used as a comparator.
89403024|NCT05747690|Experimental|KIO015 - Cohort 2|3 injections at one month interval on the hemi-face. The untreated hemi-face is used as a comparator.
89403025|NCT05741918|Experimental|Pediatric Intensive Care Units Patients|Patients under 18 admitted in pediatric intensive care unit
89403026|NCT05741047|Active Comparator|a2 Group|The group consuming a2Milk skim milk powder (1L) containing A2 β-casein only
89403027|NCT05741047|Placebo Comparator|Control Group|The group consuming Yili skim milk powder (1L) containing A1 and A2 β-caseins
89403028|NCT05740514|Experimental|Twelve-week Exercise|Study participants will participate in an exercise program consisting of aerobic and resistance exercise. This arm will last twelve weeks.
89403029|NCT05740514|Experimental|One-week Detraining|Study participants will undergo unilateral knee immobilization for a one-week period.
89403030|NCT05740514|Experimental|Four-week Re-training|Study participants will once again participate in an exercise program consisting of aerobic and resistance exercise. This arm will last four weeks.
89189975|NCT04318964|Experimental|TAEST16001 cells treat tumor antigen NY-ESO-1|"The dose escalation was carried out according to the principle of 3 + 3 increase. Four dose levels (calculated by the number of tcr-t positive cells) were set up: the dose level was 1: 5 × 108 ± 30%; the dose level was 2: 2 × 109 ± 30%; the dose level was 3: 5 × 109 ± 30%; the dose level was 4: 1.2 × 1010 ± 30%. Three patients in the first group, if there is no DLT, they will be enrolled in the next higher dose group; if one of the three patients in a certain dose group has DLT, three patients in the group will be supplemented with the same dose and method. If DLT occurred in 1 or more of the 3 cases, the dose increase was stopped. The former dose was defined as MTD; if DLT did not occur in 3 cases, the dose increased to the next group. Dose escalation is not allowed for the same patient."
89403031|NCT05739162|Experimental|Endoscopic Sleeve Gastroplasty (ESG)|Participants undergo Endoscopic Sleeve Gastroplasty (ESG). Following the 6-week transitional diet after undergoing the ESG procedure, participants will start the lifestyle intervention.
89403032|NCT05739162|Active Comparator|Diet and Exercise|Participants receive lifestyle intervention only for 24 months
89403033|NCT05737199|Experimental|MK-3475 (Pembrolizumab)|Treatment with MK-3475 (pembrolizumab) 200 mg.
89403034|NCT05732376|Experimental|3D Printed Endoscopy Training Model Group|
89403035|NCT05732376|Active Comparator|Ready-Made Endoscopy Training Model Group|
88878335|NCT05573256|No Intervention|Group 4 (Routine care)|"Participants assigned to Group 4 will be given routine care and no application will be made.~Patient care and follow-up are routinely performed as follows: Following the patient's admission to the clinic, the first evaluation of the patient is made by the ostomy and wound care nurses within 24 hours, and patient education is initiated accompanied by the primary caregiver from the family. Throughout the period from admission to clinic to discharge, the ostomy care and education of the patient is repeated by the ostomy and wound care nurses every 72 hours. In addition, the patient and caregiver are given the contact information of the ostomy and wound care nurses and informed that they can call them at any time when they need it after discharge from the hospital."
88878336|NCT05533476|Experimental|Multi Sensory Stimulation And Priming|8 weeks, 30 minutes per day home based MuSSAP training.
88878337|NCT05533476|Experimental|Intensive Usual Care (Upper Limb)|8 weeks, 30 minutes per day home based Intensive Usual Care (Upper Limb).
89189976|NCT04306900|Experimental|Combo 1|TTX-030 plus budigalimab plus mFOLFOX6
89403036|NCT05732363||1|"The population will consist of patients, who have participated in the MUSCLE study and have received bariatric surgery at the CON / MCL. A potential subject who meets any of the following criteria will be excluded from participation in this study:~Inability to communicate in either Dutch or English~Weight over 204 kilograms (due to limitations of the DXA)~Pregnancy~Pacemaker"
89403037|NCT05721378|Experimental|Permissive Weight Bearing group|Rehabilitation following the Permissive Weight Bearing (PWB) protocol
89403038|NCT05721378|Active Comparator|Restrictive Weight Bearing group|Rehabilitation following the Restrictive Weight Bearing (RWB) protocol
89403039|NCT05716789|Experimental|CPR asseement|determine the success rate of CPR in Emergency room and factors predicting successful CPR
89403040|NCT05705726|Experimental|facia iliaca block|
89403041|NCT05705726|Experimental|Precedex and ketamine|
89403042|NCT05705479|Experimental|Bankart + Remplissage Procedure|Bankart Procedure: the participant will be placed in the lateral decubitus or beach chair position. Standard diagnostic arthroscopy will be performed. The anterior capsulolabral complex will be freed from the anterior aspect of the scapular neck. The anterior aspect of the scapular neck will be decorticated using a motorized burr. A capsuloligamentous repair will be performed with the capsule shifted from inferior to superior and repaired on the glenoid face. The number of anchors used for the repair will be left to the discretion of the surgeon. Patients will be given a sling for 4 weeks, and participation in sports will not be allowed for 6 months.
89403043|NCT05705479|Experimental|Latarjet Procedure|Open or Arthroscopic coracoid transfer (Latarjet Procedure): This procedure may be performed through small incisions (minimally invasive) but may require a larger incision in some cases. It involves the transfer of a nearby bony structure (the coracoid process) to the front of the shoulder joint (glenoid). This bone will then provide support to prevent the shoulder joint from dislocating.
89403044|NCT05703360|Experimental|Waitlist Group|Those randomly assigned to the waitlist group will complete initial inclusion tests and baseline tests at Visit 1. They will receive no intervention during Period 1 (week 1-6) and then repeat baseline tests at Visit 2. Next they will perform the VR audiovisual stimulation during Period 2 (week 7-12) and then repeat baseline tests post-intervention at Visit 3.
88878338|NCT05403762|Experimental|ESENTA™ Skin Barrier Spray|In the intervention group I, standardized mild skin cleansing regimen and daily topical application of a film-forming skin protectant at the exposed skin areas will be applied by nursing staff.
89403045|NCT05703360|Experimental|VR Intervention First|Those randomly assigned to the intervention-first group will complete initial inclusion tests and baseline tests at Visit 1. They will perform the VR audiovisual stimulation during Period 1 (week 1-6) and then repeat baseline tests at Visit 2. They will receive no intervention during Period 2 (week 7-12) and then repeat baseline tests at Visit 3.
89403046|NCT05702463|Experimental|EC ASA 162 mg once daily for 7 days|EC ASA 162 mg once daily for 7 days
89403047|NCT05702463|Experimental|EC ASA 81 mg twice daily for 7 days|EC ASA 81 mg twice daily for 7 days
89403048|NCT05702463|Experimental|chewable ASA 40 mg twice daily for 7 days|chewable ASA 40 mg twice daily for 7 days
89403049|NCT05700747|Experimental|Health Through Activity (HTA) Intervention|"Participants will undergo study procedures as outlined:~Complete a baseline survey regarding activity level and quality of life.~Attend 6 weekly study visits at the MGH Institute of Health Professions IMPACT Practice Center.~Attend final study visit and complete the Satisfaction survey and an individual, semi-structured interview with site staff to supply feedback about the program.~After six weeks, complete the Satisfaction survey again."
89403050|NCT05676684|Experimental|[Dapagliflozin] - [Spironolactone] - [Dapagliflozin + Spironolactone]|"Drug will be administered according to sequence:~Dapagliflozin [week 1-12] - Spironolactone [week 17-28] - Dapagliflozin + Spironolactone [week 33-44]"
89403051|NCT05676684|Experimental|[Dapagliflozin] - [Dapagliflozin + Spironolactone] - [Spironolactone]|"Drug will be administered according to sequence:~Dapagliflozin [week 1-12] - Dapagliflozin + Spironolactone [week 17-28] - Spironolactone [week 33-44]"
89403052|NCT05676684|Experimental|[Spironolactone] - [Dapagliflozin] - [Dapagliflozin + Spironolactone]|"Drug will be administered according to sequence:~Spironolactone [week 1-12] - Dapagliflozin [week 17-28] - Dapagliflozin + Spironolactone [week 33-44]"
89403053|NCT05676684|Experimental|[Spironolactone] - [Dapagliflozin + Spironolactone] - [Dapagliflozin]|"Drug will be administered according to sequence:~Spironolactone [week 1-12] - Dapagliflozin + Spironolactone [week 17-28] - Dapagliflozin [week 33-44]"
89403054|NCT05676684|Experimental|[Dapagliflozin + Spironolactone] - [Spironolactone] - [Dapagliflozin]|"Drug will be administered according to sequence:~Dapagliflozin + Spironolactone [week 1-12] - Spironolactone [week 17-28] - Dapagliflozin [week 33-44]"
89403055|NCT05676684|Experimental|[Dapagliflozin + Spironolactone] - [Dapagliflozin] - [Spironolactone]|"Drug will be administered according to sequence:~Dapagliflozin + Spironolactone [week 1-12] - Dapagliflozin [week 17-28] - Spironolactone [week 33-44]"
89403056|NCT05672680|Placebo Comparator|Placebo|"Normal Saline:~For patients weighing <100 kg, a total of 50 ml ((25 ml on each side of the abdominal wall) will be received. If patients weigh>100 kg, a total of 60 ml (30ml on each side of the abdominal wall) will be received."
89403057|NCT05672680|Experimental|Experimental|0.25% bupivacaine: For patients weighing <100 kg, a total of 50 ml ((25 ml on each side of the abdominal wall) will be received. If patients weigh>100 kg, a total of 60 ml (30ml on each side of the abdominal wall) will be received.
89403058|NCT05668676|Experimental|Interventional group|
88878339|NCT05403762|Experimental|Hydrophobes Basisgel DAC|In the intervention group II, standardized mild skin cleansing regimen and daily topical application of a hydrophobic skin protectant at the exposed skin areas will be applied by nursing staff.
88878340|NCT05403762|No Intervention|Standard Care|In the control group, standardized mild skin cleansing regimen without application of an additional skin protectant will be conducted by nursing staff.
89403059|NCT05668676|Active Comparator|Control group|
89403060|NCT05667376|Other|Study group|Study group treated with curcumin gel
89403061|NCT05661981||Adult and pediatric patients|Undergoing cardiac and/or vascular repair or reconstruction surgery
89403062|NCT05631938|Experimental|Group 1: Normal Renal Function|Participants with normal renal function receive a 3 mg single dose of cytisinicline.
89403063|NCT05631938|Experimental|Group 2: Mild Renal Impairment|Participants with mild renal impairment receive a 3 mg single dose of cytisinicline.
89403064|NCT05631938|Experimental|Group 3: Moderate Renal Impairment|Participants with moderate renal impairment receive a 3 mg single dose of cytisinicline.
89403065|NCT05631938|Experimental|Group 4: Severe Renal Impairment|Participants with severe renal impairment receive a 3 mg single dose of cytisinicline.
88878341|NCT05330442|No Intervention|CoCM alone|In the CoCM alone arm, participants will have access to treatment as usual from the CM.
89189977|NCT04306900|Experimental|Combo 2|TTX-030 plus budigalimab plus docetaxel
89403066|NCT05631938|Experimental|Group 5: ESRD Participants Undergoing Dialysis|Participants with ESRD undergoing dialysis receive a 3 mg single dose of cytisinicline on 2 occasions: after and prior to a dialysis session.
89403067|NCT05624957|Experimental|lidocaine|The patients will undergo shoulder arthroscopy with lidocaine epinephrine fluids irrigation.
89403068|NCT05624957|Placebo Comparator|control group|The patients will undergo shoulder arthroscopy with epinephrine fluids irrigation only.
89403069|NCT05624775|Experimental|Virtual Culinary Medicine|
89403070|NCT05619432|Experimental|Group A: Clinic Setting|Participants will complete their virtual reality (VR) visual training program by visiting a local clinic and using the head-mounted display (HMD) provided. Participants will receive initial training on using the device and software and are expected to complete their 6-weeks of visual training independently at the clinic. Additional training and FAQ materials will be available on site for participants to use as reference.
89535568|NCT02486705|Active Comparator|PTSD Family Coach Basic|PTSD Coach basic provides an iOS mobile app with extensive information about caregiving for family members of those with PTSD and additional support resources.
88878342|NCT05330442|Experimental|CoCM+WET|In the CoCM+WET intervention arm, patients will be encouraged to receive WET.
88878343|NCT05288946|Experimental|local segmental control and closed kinetic chain|the patients will receive local segmental control and closed kinetic chain three times a week for four weeks
88878344|NCT05288946|Experimental|local segmental control and open kinetic chain|the patients will receive local segmental control and open kinetic chain three times a week for four weeks
89189978|NCT04306900|Experimental|Combo 3|TTX-030 plus mFOLFOX6
89189979|NCT04306900|Experimental|Combo 4|TTX-030 plus pembrolizumab
89403071|NCT05619432|Experimental|Group B: Home Setting|Participants will complete their virtual reality (VR) visual training program from their own homes using a head-mounted display (HMD) that is on loan for the study. Participants will receive initial training on using the device and software at the clinic and will take home the HMD to complete their 6-weeks of visual training independently from home. Additional training and FAQ materials will be given to participants to use as reference.
89403072|NCT05619289|Active Comparator|Vitamin D2 (Ergocalciferol)|One time, oral dose of Vitamin D2 administered via 6 50,000 IU Ergocalciferol capsules. Capsules will be encapsulated and masked to be indistinguishable from placebo.
89403073|NCT05619289|Placebo Comparator|Placebo|One time, oral dose of 6 placebo capsules filled with inert powder and encapsulated and masked to be indistinguishable from active comparator.
89403074|NCT05604690|Experimental|Treatment Arm: Cohort 1 and 2|"Subjects will receive 2 doses of Avacc 10 via intranasal application.~Cohort 1 will receive a low dose of Avacc 10~Cohort 2 will receive a high dose of Avacc 10.~Dosage Form: Liquid Unit Dose: Investigational product (IP) in Phosphate Buffered Saline Route of Administration: Intranasal Physical Description: Slightly opalescent in glass vial"
89403075|NCT05604690|Active Comparator|OMV Arm: Cohort 1 and 2|"Subjects will receive 2 doses of Outer Membrane Vesicles (OMV) comparator via intranasal application.~Dosage Form: Liquid Unit Dose: OMV comparator in TRIS/sucrose buffer Route of Administration: Intranasal Physical Description: Slightly opalescent in glass vial"
89403076|NCT05604690|Placebo Comparator|Placebo Are: Cohort 1 and 2|Subjects will receive 2 doses of placebo via intranasal application. Dosage Form: Liquid Unit Dose: Placebo in TRIS/sucrose buffer Route of Administration: Intranasal Physical Description: Clear, colorless in glass vial
89403077|NCT05600296|Active Comparator|Ilioinguinal/iliohypogastric nerve block (IINB)|evaluate the postoperative analgesic effects with using ultrasound-guided ilioinguinal/iliohypogastric nerve block (IINB) in children scheduled for elective open inguinal herniotomy.
89403078|NCT05600296|Active Comparator|IINB+ Spermatic cord block|evaluate the postoperative analgesic effects with using ultrasound-guided IINB + spermatic cord block (SCB) in children scheduled for elective open inguinal herniotomy.
89403079|NCT05594225|Experimental|Virtual Neuromuscular/Dual-Task Training|The vNDTT strategy incorporates lower body strength exercises with landing stabilization focus. Exercises will begin after the initial study visit and last for 8 weeks.
89403080|NCT05594225|No Intervention|Standard-of-care|Participants will be provided routine instructions related to physical activity and rehabilitation exercises
89403081|NCT05590338|Experimental|Part A: GSK1070806|Participants in Part A will receive single dose of GSK1070806 intravenous (IV) infusion
89403082|NCT05590338|Experimental|Part B: GSK1070806|Participants in Part B will receive single dose of GSK1070806 IV bolus
89403083|NCT05590338|Placebo Comparator|Part A: Placebo|Participants in Part A will receive single dose of placebo
89403084|NCT05585580|Experimental|Serplulimab, lenvatinib and paclitaxel/Paclitaxel for Injection (Albumin Bound)/Paclitaxel liposome|Patients will be treated with serplulimab combined with lenvatinib and paclitaxel/ Paclitaxel for Injection (Albumin Bound)/Paclitaxel liposomefor 6 cycles, followed by serplulimab combined with lenvatinib maintenance therapy until disease progression, intolerable adverse reactions, or withdrawal of treatment consent.
89403085|NCT05577819|Experimental|Patients 65 and older with Heart Failure with Preserved Ejection Fraction|Patients 65 years and older presenting to Massachusetts General Hospital with a known diagnosis of HFpEF and without a diagnosis of amyloidosis in the ambulatory (outpatient) setting will undergo a 99Tc-Pyrophosphate Scan to identify Cardiac Amyloidosis
89403086|NCT05577533|Other|O-Kidia battery|"A one-time visit will be performed in children aged 7 to 12 years old as follow :~Children will be playing on a series of games with a touch screen tablet while video, EEGs and digit trajectories data will be collected from this mobile device~Video recording of the participants during the tablet testing via the intrinsic camera - 30 min~Assessments - Paper and tablet psychometric tests will be used during the administrations, 1h45~Child health questionnaires - Questionnaires will be completed by children and parents during the visit, 20 min for each"
89403087|NCT05559437|Experimental|Quadratus Lumborum Block group|Quadratus lumborum group (Q) (n=30): patients will receive Quadratus Lumborum Block using 20 mL of 0.25% Levo-bupivacaine
88878345|NCT05288946|Active Comparator|traditional therapy|the patients will receive traditional therapy three times a week for four week
88878346|NCT05164614|Experimental|RT-102 Group 1|In 15 subjects, a RaniPill capsule containing 20 µg of PTH will be administered and serial blood samples will be collected for PK analysis.
88878347|NCT05164614|Experimental|RT-102 Group 2|In 15 subjects, a RaniPill capsule containing 80 µg of PTH will be administered and serial blood samples will be collected for PK analysis.
88878348|NCT05164614|Active Comparator|SC Group|In 10 subjects, 20 µg of Forteo will be administered subcutaneously and serial blood samples will be collected for PK analysis.
88878349|NCT05164614|Experimental|Part 2; Group 1|In up to 7 subjects, once-a-day repeat dosing with RT-102 (20 mcg) for 7 days in healthy post-menopausal or surgically sterile with bilateral oophorectomy women.
88878350|NCT05164614|Experimental|Part 2; Group 2|In up to 12 subjects, once-a-day repeat dosing with RT-102 (20 mcg) for 7 days in healthy women.
88878351|NCT05001048|Experimental|Low Altitude|Participants will be assessed at an altitude of <1050m.
88878352|NCT05001048|Experimental|Early Acclimatization to High Altitude|Participants will be assessed on day 2 or 3 of a high-altitude expedition at 3,800m.
88878353|NCT05001048|Experimental|Late Acclimatization to High Altitude|Participants will be assessed on day 9 or 10 of a high-altitude expedition at 3,800m.
88878354|NCT04954638||sodium hypochlorite|group 1: control group with sodium hypochlorite desinfection
88878355|NCT04954638||hyperpure chlorine dioxide|group 2: study group with hyperpure chlorine dioxide desinfection
88878356|NCT04906200|Experimental|Group A (YES portal)|Patients receive access to YES portal for 9 months. Patients also complete surveys at baseline and 3, 6, and 9 months.
89189980|NCT04306900|Experimental|Combo 5|TTX-030 plus budigalimab (selected tumors evaluated in expansion)
89189981|NCT04306900|Experimental|Combo 6|TTX-030 plus budigalimab plus nab-paclitaxel + gemcitabine
89189982|NCT04306900|Experimental|Combo 7|TTX-030 plus nab-paclitaxel + gemcitabine
89189983|NCT04306900|Experimental|Combo 8|Budigalimab plus mFOLFOX6
88878357|NCT04906200|Active Comparator|Group B (usual care)|Patients receive usual care for 9 months. Patients also complete surveys at baseline and 3, 6, and 9 months. After 9 months, patients may also receive access to YES portal for 3 months.
88878358|NCT04848870||Sjögren patients|Patients in specialized consultations for Sjögren's patients in the oral medicine department of the Charles Foix Hospital AP-HP France
88878359|NCT04772742|Experimental|Eptinezumab|"Double-Blind Treatment Phase (at baseline): 100 mg eptinezumab by IV infusion~Open-Label Treatment Phase (at week 12): 100 mg eptinezumab by IV infusion"
88878360|NCT04772742|Placebo Comparator|Placebo|"Double-Blind Treatment Phase (at baseline): Placebo by IV infusion~Open-Label Treatment Phase (at week 12): 100 mg eptinezumab by IV infusion"
88878361|NCT04702386||Focus groups|Children aged 8 years or more participating in a focus group with the study psychologist
88878362|NCT04702386||Individual interviews|All children who have an individual interview with the study psychologist
88878363|NCT04575090|No Intervention|Arm 1 (Observational Arm)|Patients in substudy 1 will be identified by the PI from the clinic as individuals who are currently experiencing statin related muscle complaints or who have had severe reactions to statins in the past. There is going to be only one visit which will last for apprximately 3.5 hrs. Subjects will have height, weight and vitals measured. They will be asked pain and and demographic questionnaire. They will have their blood draw and will undergo MRS.
88878364|NCT04575090|Experimental|Arm 2 (Interventional Experimental Arm)|"Subjects with statin related muscle complaints were enrolled in this arm and will have 3 visits. First visit is screening visit which will last for about 2 hrs and the next 2 visits will last for about 3.5 hrs. The screening visit will occur 2 weeks prior to visit 1.~Subjects will have height, weight and vitals measured. They will be asked pain and and demographic questionnaire. They will have their blood draw and will undergo MRS.~Some volunteers who do/do not regularly exercise or are/are not active in sports may be asked to exercise prior to the MRS. This exercise may be in the form of hand grasps, toe-raises, bicycling on a stationary bike or walking on a treadmill. Exercise will be limited to up to one hour, during which time the subject's vital signs and blood oxygenation will be monitored. During the scan, the subject's heart rate and respiratory rate may be monitored"
88878365|NCT04575090|Experimental|Arm 3 (Interventional Control Arm)|"Subjects with no statin related muscle complaints were enrolled in this arm and will have 3 visits. First visit is screening visit which will last for about 2 hrs and the next 2 visits will last for about 3.5 hrs. The screening visit will occur 2 weeks prior to visit 1.~Subjects will have height, weight and vitals measured. They will be asked pain and and demographic questionnaire. They will have their blood draw and will undergo MRS.~Some volunteers who do/do not regularly exercise or are/are not active in sports may be asked to exercise prior to the MRS. This exercise may be in the form of hand grasps, toe-raises, bicycling on a stationary bike or walking on a treadmill. Exercise will be limited to up to one hour, during which time the subject's vital signs and blood oxygenation will be monitored. During the scan, the subject's heart rate and respiratory rate may be monitored"
89403088|NCT05559437|Experimental|Ilioinguinal/Iliohypogastric Nerve Block group|Ilioinguinal/Iliohypogastric Nerve Block group (I) (n=30): patients will receive Ilioinguinal/Iliohypogastric Nerve Block using 5 mL of 0.25%Levo- bupivacaine
89403089|NCT05556525|Active Comparator|Arm I (EBUS TBNA)|Patients undergo robotic EBUS TBNA on study.
89189984|NCT04288687|Other|Niraparib Arm (only arm)|Niraparib 200 mg by mouth daily (2 x 100 mg pills) on a 28 day cycle
89403090|NCT05556525|Experimental|Arm II (EBUS TBNA, nCLE, fluorescein)|Patients undergo EBUS TBNA, nCLE, and receive fluorescein IV on study.
89403091|NCT05552664|Other|Arm 1|Arm information details will not be provided at this time in order to preserve scientific integrity and will be updated once the study has resulted.
89403092|NCT05552664|Other|Arm 2|Arm information details will not be provided at this time in order to preserve scientific integrity and will be updated once the study has resulted.
89403093|NCT05552664|Other|Arm 3|Arm information details will not be provided at this time in order to preserve scientific integrity and will be updated once the study has resulted.
89403094|NCT05552664|Other|Arm 4|Arm information details will not be provided at this time in order to preserve scientific integrity and will be updated once the study has resulted.
89403095|NCT05552430|Experimental|Skills-Based VR|Participants will complete daily skills-based Virtual Reality (VR) sessions for 8 weeks (an average of 6 minutes per day) to determine the feasibility of at-home VR technology to aid the recovery of acute orthopedic musculoskeletal injuries. The VR device software is equipped with pain-specific treatment modules (e.g., Pain Education, Relaxation/Interoception, Mindful Escapes, and Pain Distraction Games) derived from evidence-based principles of cognitive behavioral therapy (CBT), mindfulness, and pain neuroscience education.
89403096|NCT05548517|Experimental|Time restricted eating and calorie restriction|Subjects will be asked to adhere to a calorie-restricted diet and will be counseled by a dietitian for diet and lifestyle behavior education. In addition, they will be asked to only consume calories during a 9-hour window (15:9).
89403097|NCT05548517|Active Comparator|Calorie restriction alone|Subjects will be asked to adhere to a calorie-restricted diet and will be counseled by a dietitian for diet and lifestyle behavior education. They will be advised to continue to consume foods throughout the day and into the evening.
89403098|NCT05543265|No Intervention|Control|Routine postpartum care
89403099|NCT05543265|Experimental|Facilitated Transition|Behavioral science informed interventions to assist in the transition from postpartum to primary care providers
89403100|NCT05541952|Experimental|Intervention|The intervention arm will receive the 0.1 milliliter (mL) dose of BCG vaccine intradermally in the deltoid muscle region at the lower insertion level on the upper outer face of the right arm. When this recommendation can not be followed, the participant will be excluded from the study.
89403101|NCT05541952|No Intervention|Control|Participants assigned to the control arm will not receive any intervention and will be followed up with QFT and Genexpert for the detection of Mtb infection or diagnosis of tuberculosis.
88878366|NCT04302948|No Intervention|Treatment as usual|TaU includes screening for anti-HCV using a rapid point-of-care (PoC) test to screen for exposure to HCV followed by counseling, brief education and referral to provider for further evaluation for HCV treatment.
89403102|NCT05540457|Experimental|Non-Invasive Blood Pressure (NIPB)Monitors|"NIPB Tablo Brachial Cuff (Intermittent): Will be placed contralateral to the access arm. Blood pressure measurements will be collected pre-dialysis, every 30minutes during dialysis, and post-dialysis.~VitalStream Monitor (Continuous):A cuff will be applied to the middlefinger ipsilateral to the accessarm. Blood pressuremeasurements will be collectedpre-dialysis, continuously duringdialysis, and post-dialysis."
89403103|NCT05523817|Experimental|DLPFC Salience network target|iTBS delivered four times daily to an individually defined salience network representation in left dorsolateral prefrontal cortex (DLPFC).
89403104|NCT05523817|Experimental|DLPFC Control network target|iTBS delivered four times daily to an individually defined control network representation in left dorsolateral prefrontal cortex (DLPFC).
89403105|NCT05523817|Experimental|DLPFC Default network A target|iTBS delivered four times daily to an individually defined default network A representation in left dorsolateral prefrontal cortex (DLPFC).
89403106|NCT05523817|Experimental|dmPFC Default network B target|iTBS delivered four times daily to an individually defined default network B representation in left dorsomedial prefrontal cortex (DMPFC).
89189985|NCT04271579|Active Comparator|Unilateral lymphnode dissection|Salvage lymphnode dissection is performed on the PSMA PET positive side, according to template (obturator, iliac external, iliac internal, iliac commun) and possibly including other anatomical pelvic regions
89403107|NCT05523817|Experimental|vmPFC limbic-reward network target|iTBS delivered four times daily to an individually defined reward network representation in left ventromedial prefrontal cortex (vMPFC).
89403108|NCT05523817|Sham Comparator|SHAM stimulation|SHAM iTBS delivered four times daily to an individually defined SHAM region in left dorsolateral prefrontal cortex (DLPFC).
89403109|NCT05521048|Experimental|Single Arm Open Label|Open Label
89403110|NCT05500508|Experimental|Escalation|"Dose escalation of DFMO with AMXT1501 fixed dose will follow a 3 + 3 dose escalation design.~The AMXT 1501 starting dose administered in the first cohort will be 1200mg total daily dose (200 mg capsules; 3 capsules in morning; 3 capsules in evening) along with IV DFMO administered in continuous infusion at 2mL/hr over a 28 days per cycle. The patient can be treated for additional 28 day treatment cycles as deemed appropriate by their study investigator. Dose escalation of DFMO alone will increase per cohort."
89403111|NCT05500508|Experimental|Expansion|The expansion cohort will include up to 40 evaluable patients at a proposed RP2D level of AMXT1501 and DFMO defined by AMXT1501-101A study to further characterize safety at proposed RP2D dose level with repeat dosing, and characterize early anti-tumor activity.
89403112|NCT05498597|Experimental|AMT-151 Dose Escalation|
89403113|NCT05493189|No Intervention|Control Group|Participants with no additional autonomous training sessions.
89403114|NCT05493189|Experimental|Intervention Group|Participants exposed to 2 additional autonomous training sessions (after 2 and 6 months).
89403115|NCT05483621|Experimental|Hormonal therapy Group|Administration of hormonal therapy (as Beta HCG (5000 IU I.M) twice weekly for three months
89403116|NCT05483621|Other|L-carnitine Group (Control)|Administration of L-carnitine 1000 mg twice daily for three months
89403117|NCT05482880||head-neck cutaneous Squamous cell carcinomas|Patients with high risk cutaneous squamous cell carcinoma of the head-neck area receiving regular, multidisciplinary care.
89403118|NCT05472207||Patients with cardiovascular diseases|Recording clinical data - especially risk parameters - from patients suffering from cardiovascular diseases
89403119|NCT05471492|Experimental|Treatment Group 1|PF-06480605 150 mg
89403120|NCT05471492|Placebo Comparator|Treatment Group 2|Placebo
88878367|NCT04302948|Experimental|Rapid PoC RNA testing|Intervention arm includes Tau ( screening for anti-HCV using a rapid point-of-care (PoC) test, and a rapid PoC screening test for HCV RNA, counseling plus, brief education and referral to a provider for further evaluation for HCV treatment. Rapid HCV RNA testing will be conducted using Cepheid Xpert (r) system.
88878368|NCT04234152|Experimental|MV Photo-protection|Includes infants in whom the new procedure of MV separation and photo-protection will be applied. This arm will be stratified to male and female 1:1
88878369|NCT04234152|Placebo Comparator|Standard of care|Includes infants in whom the standard method of preparation and infusion of PN will be applied. This arm will be stratified to male and female 1:1
88878370|NCT04100772|Experimental|vaccine 1A|Subjects received one dose of PCV13i at 18 to 49 years old
88878371|NCT04100772|Experimental|vaccine 2A|Subjects received one dose of PCV13i at 50 years old and above
88878372|NCT04100772|Experimental|vaccine 3A|Subjects received one dose of PCV13i at 6 to 17 years old
88878373|NCT04100772|Experimental|vaccine 4A|Subjects received one dose of PCV13i at 2 to 5 years old
88878374|NCT04100772|Experimental|vaccine 5A|Subjects received two doses of PCV13i at 7 months to 2 years old
88878375|NCT04100772|Experimental|vaccine 6A|Subjects received three doses of PCV13i at 3,4,5 months of age
88878376|NCT04100772|Experimental|vaccine 7A|Subjects received three doses of PCV13i at 2,4,6 months of age
88878377|NCT04100772|Active Comparator|vaccine 7B|Subjects received three doses of PCV13 at 2,4,6 months of age
88878378|NCT04012008|Active Comparator|Standard care|"Regular follow-up by internists every 3 month~May consult nephrologists case-by-case"
88878379|NCT04012008|Experimental|Comprehensive care|"Regular follow-up by nephrologists every 1-3 month~Multidisciplinary team consisting pharmacists, nurses, and dieticians"
88878380|NCT03634410||Employed|people aged +50 and currently employed
88878381|NCT03634410||Unemployed|people aged +50 and currently unemployed
88878382|NCT03634410||Early retirement|people aged +50 and currently on early retirement
88878383|NCT03634410||Disability pension|people aged +50 and currently on disability pension
88878384|NCT03472872|Experimental|Ketorolac Arm|The patient will receive a 0.9% normal saline bolus of 1,000ml at 500ml/hr, 25mg diphenhydramine IV, 10mg prochlorperazine IV, 15mg ketorolac in 100mL 0.9% normal saline IVPB
88878385|NCT03472872|Experimental|Acetaminophen Arm|The patient will receive a 0.9% normal saline bolus of 1,000ml at 500ml/hr, 25mg diphenhydramine IV, 10mg prochlorperazine IV, 1,000mg acetaminophen in a 100ml IVPB
88878386|NCT02836470|Experimental|LB1148|Active
89403121|NCT05464537|Active Comparator|Unipolar Polarity Switch Left and CAI-OPR-LAAP Right|
88878387|NCT02836470|Placebo Comparator|Placebo|Placebo
88878388|NCT02808702|Experimental|Cognitive-behavioral therapy|Twelve weekly sessions of individual cognitive-behavioral therapy
88878389|NCT02411526|Experimental|Cohort 1|60 mg of ZX003 administered 4 times (every 4 weeks)
88878390|NCT02411526|Experimental|Cohort 2|90 mg of ZX003 administered 4 times (every 4 weeks)
88878391|NCT02411526|Experimental|Cohort 3|120 mg of ZX003 administered 4 times (every 4 weeks)
88878392|NCT02411526|Active Comparator|Cohort 4|Risperdal Consta administered 5 times (once every 2 weeks) NOTE: Oral risperidone 2 mg will be given with the first injection of Risperdal Consta and continued for 3 weeks (and then discontinued) to ensure adequate therapeutic plasma concentrations from Risperdal Consta.
88878393|NCT02400060|Experimental|Supportive (text messages and interactive exchanges)|Patients receive daily text messages reminding them to take AHT and weekly interactive surveys delivered by a smart phone app for 3 months.
89403122|NCT05464537|Active Comparator|CAI-OPR-LAAP Left and Unipolar Polarity Switch Right|
89403123|NCT05462730|Active Comparator|Methylprednisolone|A five minutes bolus infusion of 250 mg (4 mL) methylprednisolone to inhibit inflammatory damage following ST-segment elevation myocardial infarction. The infusion of methylprednisolone will be given in the pre-hospital setting prior to primary PCI.
89403124|NCT05462730|Placebo Comparator|Isotonic saline|A bolus infusion of 4 mL isotonic saline (NaCl 0.9%).
89403125|NCT05457933|Experimental|Dapagliflozin group|Dapagliflozin 10 mg, every day before breakfast. Glargine insulin 300 Units/mL, average dose: 10-20 U/day; Insulin lispro 100 Units/mL, average dose: 10-30 U/day
89403126|NCT05457933|Active Comparator|Basal-bolus group|Glargine insulin; 300 Units/mL, average dose: 10-20 U/day; Insulin lispro 100 Units/mL, average dose: 10-30 U/day
89403127|NCT05456724|Experimental|A (TO-O-1001)|Drug: TO-O-1001 Dose level: 0.05% and 0.1% Dosage form: ophthalmic solution Route of administration: topical ocular
89403128|NCT05456724|Placebo Comparator|B (Placebo)|Dosage form: ophthalmic solution Route of administration: topical ocular
89403129|NCT05450159|Experimental|Intervention group|Participants in the intervention group will watch their respective training video individually approximately four to six weeks after their baseline visit. Each training video will be 20-25 minutes in length where they will receive voice-over feedback on their driving from a member of the study team alongside video clips taken from the device of their behind-the-wheel performance. They will also receive a written summary of their feedback to keep at the end of their feedback session.
89403130|NCT05450159|Active Comparator|Control group|Four to six weeks after their first baseline visit, control group participants individually will watch a 30-minute (generic) video that describes the benefits and challenges of aging-in-place that discusses the importance of community mobility in later life. At the end of their session, participants will be given a government brochure on this topic.
89403131|NCT05447312|Experimental|Adaptive Music Intervention (AM)|The intervention will be an adaptive music program, in which participants will listen to music provided by the research team that has been enhanced with frequencies that elicit positive moods using the Pi Electronic Venus speaker for 30 minutes, at least 4 times in a week over 4 weeks.
89403132|NCT05447312|Active Comparator|Traditional Music Intervention (TM)|The intervention will be traditional music therapy, in which participants will listen to music provided by the research team that has not been enhanced with frequencies using the Pi Electronic Venus speaker for 30 minutes, at least 4 times in a week over 4 weeks.
89403133|NCT05447312|No Intervention|Control Group|The control intervention will be an audiobook provided by the research team that participants will listen to using the Pi Electronic Venus speaker for 30 minutes, at least 4 times in a week over 4 weeks.
89403134|NCT05438953|Experimental|PEP Vaccinated|
89403135|NCT05438953|Experimental|PrEP Vaccinated|
88878394|NCT00564876|Experimental|Treatment|Neoadjuvant dasatinib is to be administered as an oral dose of 70 mg PO twice daily on a continuous basis for 3 weeks prior to surgery. Patients will begin adjuvant dasatinib (70 mg PO twice daily) between 4-6 weeks after standard adjuvant therapy is complete or 4-8 weeks after surgery for those patients that do not receive adjuvant chemotherapy. Adjuvant dasatinib will be given on a continuous basis for up to 3 months after adjuvant chemotherapy or after surgery if no adjuvant chemotherapy is given.
88878395|NCT00558870|Active Comparator|Morphine Only|"Morphine - Arm 1: 2 Doses of Slow-Release Morphine PO Every 12 Hours, Every Day for 15 Days (plus or minus 3 days).Immediate-release morphine may be used, if needed, for pain."
89535569|NCT02486705|Experimental|PTSD Family Coach Full|PTSD Family Coach full provides an iOS mobile app with extensive information about caregiving for family members of those with PTSD, additional support resources, tools for coping with caregiving-related stress, and tools for self-monitoring stress symptoms.
89535570|NCT03220633|Experimental|ATB-346|Subjects given single dose (SAD cohorts) or multiple doses over a 14 day period (MAD cohorts) of ATB-346.
88878396|NCT00558870|Active Comparator|Morphine + Methadone|"Arm 2: 1 Dose of Slow-Release Morphine PO Every 12 Hours, Every Day for 15 Days (plus or minus 3 days).).Immediate-release morphine may be used, if needed, for pain.~1 Dose of Methadone PO Every 12 Hours, Every Day for 15 Days (plus or minus 3 days)"
89535571|NCT03220633|Placebo Comparator|Placebo|Subjects given single dose (SAD cohorts) or multiple doses over a 14 day period (MAD cohorts) of placebo.
89403136|NCT05434130|Experimental|High Dose Exercise|The investigators will provide exercise dose recommendations for initial visit until symptom resolution, and revise upon symptom resolution (to use for the subsequent 8 weeks). These include intensity (target HR) and volume (frequency/duration). Intensity is calculated as 90% of the HR at the end of the exercise test. The volume recommendation is 150 mins/week (~30 min/day; 5 days/week). The mode of exercise is another consideration. This will be left to participant preference, so that the investigators do not exclude potential participants due to lack of access to specific exercise equipment.
89403137|NCT05434130|No Intervention|Standard-of-care|Participants are instructed to perform activity in line with physician recommendations. This consists of a general recommendation (no specific HR/volume) or symptom limited physical activity.
89403138|NCT05426057|Experimental|eHealth Familias Unidas|Participants in this group will receive eHealth Familias Unidas-Mental Health. The intervention consists of nine video parent group sessions, one video adolescent session, and four family sessions (parents participate in a total of 13 sessions, adolescents participate in a total of five sessions) that will be delivered by a facilitator to the parent-child dyad via web-conferencing software across 13 weeks.
89403139|NCT05426057|No Intervention|Prevention as Usual Control|In this condition, participants will not receive an intervention, only the standard of care services which may include information and referral.
89403140|NCT05416307|Experimental|ELA026|"Cohort 1: Single dose escalation up to 3.0 mg/kg IV or SC~Cohorts 2-4: dose, route, and frequency of administration (IV or SC) to be determined"
89403141|NCT05415085|Experimental|Culprit-first PCI|In this arm, primary PCI with stent implantation will be performed prior to the demonstration of the whole coronary tree. The suspected culprit artery will be demonstrated first and the PCI will be performed.
89403142|NCT05415085|No Intervention|Culprit-last PCI|In this arm, primary PCI with stent implantation will be performed after the demonstration of the whole coronary tree. The suspected culprit artery will be demonstrated after the contralateral side and then PCI will be performed. This is the common approach.
89403143|NCT05412758|Experimental|Oesophageal/GOJ cancer|"AROMA 1: 216 treatment naive patients with oesophageal/GOJ cancer will be recruited to undertake an augmented breath test.~BIORESOURCE: 75 treatment naive patients with oesophageal/GOJ cancer will be recruited for biosample collection at the time of their staging laparoscopy procedure."
89403144|NCT05412758|Experimental|Gastric cancer|"AROMA 1: 216 treatment naive patients with gastric cancer will be recruited to undertake an augmented breath test.~BIORESOURCE: 75 treatment naive patients with gastric cancer will be recruited for biosample collection at the time of their staging laparoscopy procedure."
89403145|NCT05412758|Experimental|Control/ normal patients with upper gastrointestinal symptoms|"AROMA 1: 216 control subjects will be recruited to undertake an augmented breath test.~BIORESOURCE: 75 control subjects will be recruited for biosample collection at the time of their routine endoscopy procedure."
89403146|NCT05412277|Other|VIA Disc NP|HCT/P: VIA Disc Nucleus Pulposus Allograft
89403147|NCT05409833||Group 1|Patients aged ≥ 60 years old with symptomatic carpal tunnel syndrome submitted to surgery
88878397|NCT00548886|Experimental|Epinephrine|Healthy pediatric subjects will receive epinephrine. Epinephrine infusion will begin at 0.025 ug/kg/minute, for ten minutes.The epinephrine infusion will then be increased to 0.05 ug/kg/minute for five minutes. The epinephrine infusion will then be increased to a maximal dose of 0.1 ug/kg/minute for five minutes. The epinephrine infusion is then discontinued.
88878398|NCT00538980|Experimental|All patients|Patients will receive a once-daily oral administration of dasatinib at a dose of 100 mg QD (two 50 mg tablets taken together each day) for the duration of the study with the modifications as indicated. If the platelet count remains above 600,000/microL or the spleen remains enlarged in the absence of leukopenia or other side effects, the dose of dasatinib may be escalated to 120 mg QD (two 50 mg tablets plus one 20 mg tablet taken together each day).
88878399|NCT00529464|Experimental|Colposcopy|Colposcopy - a direct magnified inspection of cervix
88878400|NCT00529464|Experimental|Colposcopy + Fluorescence Spectroscopy|Colposcopy - a direct magnified inspection of cervix + Fluorescence Spectroscopy - electromagnetic spectroscopy which analyzes fluorescence from a sample.
88878401|NCT00529464|Experimental|Colposcopy + LEEP Procedure|Colposcopy - a direct magnified inspection of cervix + loop electrosurgical excision procedure (LEEP) - thin, low-voltage electrified wire loop to cuts out cervix abnormal tissue.
88878402|NCT00519090|Experimental|Nilotinib (AMN107)|
88878403|NCT00519090|Active Comparator|Imatinib|
88878404|NCT00506064|Experimental|Melatonin|0.15 mg/kg capsules by mouth daily
88878405|NCT00506064|Placebo Comparator|Placebo|Starch capsules by mouth daily
88878406|NCT00478062|Experimental|Cell vaccine after initial therapy for Hodgkin lymphoma|Hodgkin's antigens-GM-CSF-expressing cell vaccine after initial therapy.
88878407|NCT00470574|Experimental|Vaccine Therapy and QS21|"Patients receive sialyl Lewisª -keyhole limpet hemocyanin conjugate vaccine subcutaneously (SC) and QS21 immunoadjuvant SC once in weeks 1, 2, 3, 7, and 19 in the absence of disease progression or unacceptable disease.~Blood samples are collected periodically and evaluated for circulating tumor cells and reactivity against sialyl Lewisª antigen in ELISA and/or immunoprecipitation-western blot assays.~After completion of study treatment, patients are followed every 3 months"
88878408|NCT03053700|Active Comparator|Treatment with bromonide 0.33% gel|Patients would be treated with full face application of bromonide 0.33% gel once daily for three months. Half of the patients' face would recieve this treatment alone.
88878409|NCT03053700|Active Comparator|Treatment with bromonide 0.33% gel & IPL|Patients would be treated with full face application of bromonide 0.33% gel once daily for three months. Half of the patients' face would be subjected to three IPL treatment sessions three weeks apart from each other.
88878410|NCT00442260|Experimental|Abraxane dose escalation + fixed dose DOXIL|Limited dose-escalation study of Abraxane and fixed dose of DOXIL in order to identify correct dose and side effect profile of the combination.
88878411|NCT00386724|Experimental|Precision Spinal Cord Stimulation|Single arm Precision Spinal Cord Stimulation System with Artisan Surgical Lead
88878412|NCT00325572|Active Comparator|Oral zinc and vitamin C supplementation|Participant will receive oral zinc and vitamin C supplementation based on the child's weight. Blood levels of zinc, copper, liver and renal function as well as blood counts will be measured. Copper to zinc ratio will be calculated at 6 and 16 weeks
88878413|NCT00325572|Placebo Comparator|Oral Placebo|Participant will receive placebo liquid with volume based on child's weight to match the amount given to participants in the experimental group.
88878414|NCT00333762|Experimental|SPAM and SWCS|Smart Power Assistance Module (SPAM) Smart Wheelchair Component System (SWCS)
88878415|NCT00145704|Active Comparator|Growth Hormone only|No bisphosphonate therapy given, participants will take Vitamin D 400 IU daily for 18 months, as well as calcium carbonate 500 mg twice a day for 18 months.
88878416|NCT00145704|Experimental|Growth Hormone & Bisphosphonate Therapy|Bisphosphonate Therapy-Risedronate 35 mg once a week for 18 months, Vitamin D 400 IU daily for 18 months and calcium carbonate 500 mg twice daily for 18 months
88878417|NCT00108342|Active Comparator|Nicotine Replacement Treatment (NRT) Sampling|"Sampling = 3 minute testing of each of 6 NRTs (3 forms x 2 dosages)~2 mg and 4 mg nicotine gum; 2 mg and 4 mg nicotine lozenges; frequent and infrequent puffing on a nicotine inhaler (can yield 4 mg from 10 mg device)."
88878418|NCT00108342|Sham Comparator|NRT Computer Learning|Computer learning: learning about 6 NRTs (3 forms x 2 dosages) by computer only
89403148|NCT05409833||Group 2|Patients aged ≥ 60 years old without symptomatic carpal tunnel syndrome submitted to hand surgery
88878419|NCT00090870|Experimental|PEG-Intron, BM-CSF and thalidomide|
88878420|NCT00074724|Active Comparator|Medical Therapy|All medical interventions know to improve outcomes in patients with ischemic left ventricular dysfunction.
88878421|NCT00074724|Active Comparator|CABG|Surgical revascularization in conjunction with optimal medical therapy.
88878422|NCT00058188|Experimental|Arm I|Patients receive zoledronate IV over 15 minutes on day 1 and oral calcium gluconate and oral cholecalciferol daily. Courses repeat every 3 months for 12 months in the absence of toxicity.
88878423|NCT00058188|Active Comparator|Arm II|Patients receive oral calcium gluconate and oral cholecalciferol as in arm I.
88878424|NCT00003726|Experimental|Lepirudin|Dose level 1: 10 mg once daily -> (total dose, 10 mg/d) Dose level 2: 15 mg once daily -> (total dose, 15 mg/d) Dose level 3: 10 mg twice daily -> (total dose, 20 mg/d) Dose level 4: 15 mg twice daily -> (total dose, 30 mg/d) Dose level 5. 20 mg twice daily -> (total dose, 40 mg/d) Dose level 6: 25 mg twice daily -> (total dose, 50 mg/d)
88878425|NCT02595996|Experimental|Treatment|Patients will be given propranolol in escalating doses
88878426|NCT03198156|Experimental|Transcranial Direct Current Stimulation|Active tDCS for 30 minutes daily for 4 sessions
88878427|NCT03198156|Sham Comparator|Sham stimulation|Sham stimulation sessions will be for 30 minutes daily for each of the 4 sessions; however, active stimulation for this arm of the study is only for 30 seconds; yet, will be applied at the same intensity as the Active arm of the study, albeit for only 30 seconds.
89189986|NCT04271579|Active Comparator|bilateral Lymphnode dissection|In addition, a salvage lymphnode dissection is performed on the opposite side with resection of the corresponding fields, which were taken on the PSMA-PET positive side
89403149|NCT05408962||OMNI - omnivorous|Healthy omnivorous adults with ages between 18 and 65 years and having the reported dietary regimen for at least 1 year, free from any chronic condition such as metabolic, digestive, renal, haematological, endocrine or oncological diseases and presenting no food intolerances or eating disorders.
89403150|NCT05408962||LOV - lacto-ovovegetarians|Healthy lacto-ovovegetarians adults with ages between 18 and 65 years and having the reported dietary regimen for at least 1 year, free from any chronic condition such as metabolic, digestive, renal, haematological, endocrine or oncological diseases and presenting no food intolerances or eating disorders.
89403151|NCT05408962||VEG - vegan|Healthy vegan adults with ages between 18 and 65 years and having the reported dietary regimen for at least 1 year, free from any chronic condition such as metabolic, digestive, renal, haematological, endocrine or oncological diseases and presenting no food intolerances or eating disorders.
89403152|NCT05408611|Experimental|Experimental (acupressure) group|Acupressure (complementary and integrative medicine method) Acupressure will be applied individually to the experimental group for 18-20 minutes three times a day for three menstrual cycles (approximately 3 months). Data collection forms will be applied 4 times in total, before the intervention, within 5 minutes after acupressure, at the end of Cycle 1 and cycle 2 (each cycle is 28 days).
89403153|NCT05408611|Placebo Comparator|Plasebo group|"Placebo acupressure will be performed at any point within 1.5 cm of the actual acupressure points.~Plasebo acupressure will be applied individually to the experimental group for 18-20 minutes three times a day for three menstrual cycles (approximately 3 months). Data collection forms will be applied 4 times in total, before the intervention, within 5 minutes after acupressure, at the end of Cycle 1 and cycle 2 (each cycle is 28 days)."
89403154|NCT05406531|Experimental|Mindfulness-Based Cognitive Therapy (MBCT-Ca) - online|MBCT-Ca uses cognitive behavioral therapy (CBT) methods in collaboration with mindfulness meditative practices and similar psychological strategies.
89403155|NCT05406531|Experimental|Positive Psychology - online|Positive psychology is focused on the character strengths and behaviors that allow individuals to build a life of meaning and purpose.
89403156|NCT05406531|Experimental|Autogenic Training - online|Autogenic training is a relaxation technique focusing on promoting feelings of calm and relaxation to help reduce stress and anxieties.
89403157|NCT05406531|No Intervention|Waiting list|No intervention.
89403158|NCT05400694|Experimental|Chocolate milk|Chocolate milk with reduced added sugar
89403159|NCT05400694|Experimental|Chocolate milk with whey protein|Chocolate milk with reduced added sugar and added whey protein
89004243|NCT05482477|Experimental|Postoperative TEAS group|Receive a TEAS on bilateral Neiguan (PC6) Yintang (GV29) and Zusanli (ST36) by the transcutaneous electrical stimulators to provide an altered frequency 2/100 Hz, disperse-dense waves, and adjusted intensity which was less than 10 mA, once a day, 30 minutes each time for 7 consecutive days after operation
89004244|NCT05482477|Experimental|Pre-and post-operative TEAS group|Receive a TEAS on bilateral Neiguan (PC6) Yintang (GV29) and Zusanli (ST36) by the transcutaneous electrical stimulators to provide an altered frequency 2/100 Hz, disperse-dense waves, and adjusted intensity which was less than 10 mA, from 1 day before operation to 7 days after operation, once a day, 30 minutes each time.
89004245|NCT05482477|Experimental|Perioperative TEAS group|Receive a TEAS on bilateral Neiguan (PC6) Yintang (GV29) and Zusanli (ST36) by the transcutaneous electrical stimulators to provide an altered frequency 2/100 Hz, disperse-dense waves, and adjusted intensity which was less than 10 mA, 30 min before the induction of anesthesia to the end of the surgery, 1 day before operation, and on the 1st, 2nd and 3rd days after surgery, 30 min once a day.
89189987|NCT04269512|Active Comparator|extended lymph node dissection|Patients randomized to arm A undergo bilateral lymph node dissection in the pelvic area as part of prostatectomy. At least 10 lymph nodes must be removed.
89189988|NCT04269512|No Intervention|standard without lymph node dissection|Application of standardized surgical technique without extensive lymph node dissection. If, contrary to expectation, intraoperative suspicion of lymphogenic metastasis results, a lymph node dissection is performed and the patient is excluded from the study (freedom of the surgeon).
89189989|NCT04269161|Experimental|Automatic Oxygen Control|In this arm, an automatic oxygen control device will be used to make adjustments to the blend of oxygen and air supplied to the subject.
89403160|NCT05400694|Experimental|Chocolate milk with casein|Chocolate milk with reduced added sugar and added casein
89189990|NCT04269161|No Intervention|Manual Oxygen Control|In this arm, a nurse will manually make adjustments to the blend of oxygen and air supplied to the subject as in the standard of care.
89403161|NCT05400694|Experimental|Chocolate milk with alpha-lactalbumin|Chocolate milk with reduced added sugar and added alpha-lactalbumin
88878428|NCT04422210|Experimental|Dose Escalation (Arm A1) (Maintenance only)|Cohort A1: Participants with ES-SCLC who completed 4-6 cycles of carboplatin and etoposide first-line induction chemotherapy, with or without atezolizumab, were administered continuous maintenance therapy with Venetoclax (400mg) once daily (QD) from Day 1 to 21 and Atezolizumab (1200mg) every 3 weeks (Q3W) on Day 1.
89403162|NCT05400694|Experimental|Chocolate milk with glycomacropeptide|Chocolate milk with reduced added sugar and added glycomacropeptide
89403163|NCT05400590||Case patients with aniridia|
89403164|NCT05400590||Control patients without aniridia|
89403165|NCT05392075||COVID-19 diagnosis|The study will enroll all subjects who received care at Methodist Dallas Medical Center between August 1, 2021 and February 28, 2022, and were diagnosed with COVID-19. COVID-19 diagnosis for the purpose of this study is either a positive COVID-19 antigen or a positive COVID-19 PCR test.
88878429|NCT04422210|Experimental|Dose Escalation (Arm A2) (Maintenance only)|Cohort A2: Participants with ES-SCLC who completed 4-6 cycles of carboplatin and etoposide first-line induction chemotherapy, with or without atezolizumab, were to be administered continuous maintenance therapy with Venetoclax (800mg) once daily (QD) from Day 1 to 21 and Atezolizumab (1200mg) every 3 weeks (Q3W) on Day 1.
88878430|NCT04422210|Experimental|Dose Escalation (Arm A3) (Maintenance only)|Cohort A3: Participants with ES-SCLC who completed 4-6 cycles of carboplatin and etoposide first-line induction chemotherapy, with or without atezolizumab, were to be administered continuous maintenance therapy with Venetoclax (200mg) once daily (QD) from Day 1 to 21 and Atezolizumab (1200mg) every 3 weeks (Q3W) on Day 1. This cohort maybe explored if Dose-Limiting Toxicities (DLTs) are experienced and adverse events are thought to be potentially mitigated with a lower dose of venetoclax.
89403166|NCT05389644|Experimental|Dorsal circuit (DLPFC) stimulation|This arm will involve stimulation of the dorsal apathy-relevant circuit. Specifically, a target will be individually selected based on resting-state functional connectivity with a given subject's dorsal striatum.
89403167|NCT05389644|Experimental|Ventral circuit (vmPFC) stimulation|This arm will involve stimulation of the ventral apathy-relevant circuit. Specifically, a target will be individually selected based on resting-state functional connectivity with a given subject's ventral striatum.
89403168|NCT05389644|Sham Comparator|Sham stimulation|This arm will involve sham stimulation to a prefrontal target.
89403169|NCT05388760|Experimental|Cohort 1 (6 to <12 years) - tralokinumab dose regimen A|
89004246|NCT05482477|Sham Comparator|Sham TEAS group|the electrodes were placed at the same time as the perioperative TEAS group, but the electronic stimulation was not applied and they were told that the TEAS treatment have no feeling
89403170|NCT05388760|Experimental|Cohort 1 (6 to <12 years) - tralokinumab dose regimen B|
89403171|NCT05388760|Experimental|Cohort 2 (2 to <6 years) - tralokinumab dose regimen C|
89403172|NCT05388760|Experimental|Cohort 2 (2 to <6 years) - tralokinumab dose regimen D|
89403173|NCT05386927||GDM group|Pregnant women with positive OGTT results at 24-28 gestational weeks
89403174|NCT05386927||Control group|Pregnant women with negative OGTT results at 24-28 gestational weeks, and had baseline data that matched those in the GDM group
89403175|NCT05376371|Experimental|CJC-TraC Intervention|Incarcerated individuals with HIV, hepatitis C, or substance use disorder readying for release will enroll in the CJC-TraC intervention intended to assist in transitioning their health care.
89403176|NCT05362916|Experimental|Letermovir|40 patients with CMV infection will be treated with Letermovir
89403177|NCT05362916|No Intervention|Controls|20 patients with CMV infection will not be given Letermovir
89403178|NCT05355623|Active Comparator|amniotic membrane graft|patients in which the surgical vaginal repair will be done with the application of a sterilized (gamma irradiated) amniotic membrane.
89403179|NCT05355623|Active Comparator|surgical vaginal repair|patients in which the surgical vaginal repair will be done without any graft.
89403180|NCT05347667|Experimental|Pre-Ovulation Unilateral Resistance Exercise|One leg will undergo 2 sessions of unilateral resistance exercise during the follicular phase of the menstrual cycle (pre-ovulation).
89403181|NCT05347667|Experimental|Post-Ovulation Unilateral Resistance Exercise|One leg will undergo 2 sessions of unilateral resistance exercise during the luteal phase of the menstrual cycle (post-ovulation).
89403182|NCT05344534|No Intervention|Control|assessment only through online survey
89004247|NCT05482477|No Intervention|Control group|receive standardised perioperative management such as preoperative health education, optimize anaesthesia scheme, intraoperative heat preservation, and reduce surgical trauma.
89004248|NCT05461170|Experimental|Cohort 1a (VIR-2218)|Participants will receive multiple doses of VIR-2218 for up to 96 weeks total
89004249|NCT05461170|Experimental|Cohort 1b (VIR-3434)|Participants will receive multiple doses of VIR-3434 for up to 96 weeks total.
89403183|NCT05344534|Experimental|LOCI|Leadership and Organizational Change for Implementation strategy
89403184|NCT05338892||Cohort 1|Participants with r/r DLBCL who were treated with at least 2 prior systemic therapies in the real-world setting
89403185|NCT05335408|Experimental|Vario-group|Patients in this group recieve the Acunex Vario IOL bilaterally during the cataract surgery.
89403186|NCT05335408|Active Comparator|Vivity-group|Patients in this group recieve the Alcon Acrysof IQ Vivity IOL bilaterally during the cataract surgery.
89403187|NCT05323734|Experimental|Ganaxalone (GNX)|oral suspension, 3 times a day (TID)
89403188|NCT05323734|Placebo Comparator|Placebo matching GNX|oral suspension, TID
89403189|NCT05317000|Active Comparator|Arm A: 5-azacytidine|"Patients will receive 5-azacytidine 75mg/m2 IV daily x 5. Treatment must begin on a Monday.~Patients will receive anti-emetic premedication with prochlorperazine 10 mg IV, a 5HT3 antagonist per institutional guidelines, aprepitant or fos-aprepitant, and prn lorazepam on day 1. Day 2-5 patients will receive prochlorperazine 10 mg IV. Subsequent day 5HT3 antagonist therapy will be determined per institutional guidelines, as recommendations vary based on the half-life of the agent chosen. PRN lorazepam can be used days 2-5.~Dexamethasone will be reserved for patients who are not controlled by the initial regimen.~A single cycle of 5-azacytidine will be administered and the patient scheduled for surgery in the period of day 16 through day 18."
89403190|NCT05317000|Active Comparator|Arm B: Nivolumab|"Nivolumab will be administered at a dose of 240 mg IV day 1 and day 15. Treatment must be given on a Monday or Tuesday.~No premedication will be given. Patients will be observed following the initial dose of nivolumab per institutional Surgery will be scheduled in the period of day 16 through day 18."
89403191|NCT05317000|Experimental|Arm C: Combination 5-azacytidine and Nivolumab|"Patients will receive 5-azacytidine 75mg/m2 IV daily x 5. Treatment must begin on a Monday. 5-azacytidine will be given prior to nivolumab on day 2.~Patients will receive anti-emetic premedication with prochlorperazine 10 mg IV, a 5HT3 antagonist per institutional guidelines, aprepitant or fos-aprepitant, and prn lorazepam on day 1. Day 2-5 patients will receive prochlorperazine 10 mg IV. Subsequent day 5HT3 antagonist therapy will be determined per institutional guidelines, as recommendations vary based on the half-life of the agent chosen. PRN lorazepam can be used days 2-5.~Nivolumab will be administered at a dose of 240 mg IV day 2 and day 16. No additional premedication will be given on day 16. Dexamethasone will be reserved for patients whose nausea and/or emesis is not controlled by the initial regimen. Surgery will be scheduled in the period of day 17 through day 18."
89403192|NCT05299086|Placebo Comparator|As needed INCs|"Use placebo everyday, and INCs as needed when the nasal symptom aggravated~INCs = Fluticasone furoate nasal spray Placebo = Normal saline nasal spray~Doses Fluticasone furoate nasal spray (27.5 mg/spray) age<12 yr:1 spray once daily 12 yr and older: 2 sprays once daily Normal saline nasal spray age<12 yr:1 spray once daily 12 yr and older: 2 sprays once daily"
89403193|NCT05299086|Active Comparator|Regular INCs|"Use INCs everyday, and placebo as needed when the nasal symptom aggravated~INCs = Fluticasone furoate nasal spray Placebo = Normal saline nasal spray~Doses Fluticasone furoate nasal spray (27.5 mg/spray) age<12 yr:1 spray once daily 12 yr and older: 2 sprays once daily Normal saline nasal spray age<12 yr:1 spray once daily 12 yr and older: 2 sprays once daily"
89403194|NCT05298345|Experimental|Anthem Strong Families Family Champions Program Primary Services|Participants receive TYRO Leadership curriculum in 6 2-hour weekly sessions for a total of 12 hours, and Core Communication curriculum in 1-3 sessions for a total of 6 hours.
89403195|NCT05293145|Experimental|Building Futures Program Primary Services|Youth enrolled in the AVANCE-Houston Building Futures Program will receive primary services in either a 7 week workshop or one weekend delivery.
89189991|NCT04259047|Experimental|Diabetes Regulation for Eyesight and Memory (DREAM)|DREAM is a behavioral treatment for diabetes mellitus (DM), as well as a secondary prevention strategy for dementia. DREAM acts to reinforce DM self-care and address negative beliefs about medications and physicians, which compromise glycemic control in African Americans (AAs). In DREAM, race-concordant community health workers (CHWs) will: 1) deliver in-home DM education tailored to AAs with MCI; 2) use action plans to reinforce diabetes self-care; 3) facilitate telehealth visits with a DM nurse educator to improve DM self-care and address participants' health beliefs; and 4) increase primary care physicians' (PCP) awareness of participants' cognitive deficits and health beliefs to optimize treatment of DM. .
89403196|NCT05292963|Experimental|Fatherhood Works Program delivered in-person|Participants receive 26 hours of Nurturing Fathers curriculum, delivered in person. Participants also receive employment supports, case management, and financial literacy training.
89004250|NCT05461170|Experimental|Cohort 2a (VIR-2218)|Participants will receive multiple doses of VIR-2218 for 96 weeks.
89535572|NCT04992819|No Intervention|Control Group|"Preterm infants in NICU are fed with breast milk and bottle. Although the date is written on expressed breast milk, it is usually not given by checking its suitability for the time of day. Experiment is about labeling breast milk by time of day before giving it to babies. There is no extra intervention during feeding. The breastmilk of the control group patients will be given without matching according to the clinical routine practice.~Demographic data, anthropometric measurements (weight, height, head circumference of all babies will be recorded in the Baby Monitoring Form created by the researcher."
88878431|NCT04422210|Experimental|Dose Escalation (Arm B1) (Induction + Maintenance)|Cohort B1: Participants with ES-SCLC were to be administered non-continuous induction therapy with Venetoclax (200mg) once daily (QD) from Day 1 to 7, Atezolizumab (1200mg) every 3 weeks (Q3W) on Day 1, Carboplatin (5mg/mL/min) on Day 1 and Etoposide (100mg/m^2) on Days 1-3. Participants who tolerated study treatment without excessive toxicity, and had not undergone disease progression were to be then proceeded to maintenance treatment with venetoclax plus atezolizumab. The venetoclax dose for the maintenance setting in Arm B will be the dose that has been cleared in the maintenance only arm (Arm A) of the study (maintenance RP2D, RP2D-M).
88878432|NCT04422210|Experimental|Dose Escalation (Arm B2) (Induction + Maintenance)|Cohort B2: Participants with ES-SCLC were to be administered non-continuous induction therapy with Venetoclax (400mg) once daily (QD) from Day 1 to 7, Atezolizumab (1200mg) every 3 weeks (Q3W) on Day 1, Carboplatin (5mg/mL/min) on Day 1 and Etoposide (100mg/m^2) on Days 1-3. Participants who tolerated study treatment without excessive toxicity, and had not undergone disease progression were to be then proceeded to maintenance treatment with venetoclax plus atezolizumab. The venetoclax dose for the maintenance setting in Arm B will be the dose that has been cleared in the maintenance only arm (Arm A) of the study (maintenance RP2D, RP2D-M).
88878433|NCT04422210|Experimental|Dose Escalation (Arm B3) (Induction + Maintenance)|Cohort B3: Participants with ES-SCLC were to be administered non-continuous induction therapy with Venetoclax (800mg) once daily (QD) from Day 1 to 7, Atezolizumab (1200mg) every 3 weeks (Q3W) on Day 1, Carboplatin (5mg/mL/min) on Day 1 and Etoposide (100mg/m^2) on Days 1-3. Participants who tolerated study treatment without excessive toxicity, and had not undergone disease progression were to be then proceeded to maintenance treatment with venetoclax plus atezolizumab. The venetoclax dose for the maintenance setting in Arm B will be the dose that has been cleared in the maintenance only arm (Arm A) of the study (maintenance RP2D, RP2D-M).
88878434|NCT04422210|Experimental|Dose Escalation (Arm B4) (Induction + Maintenance)|Cohort B4: Participants with ES-SCLC were to be administered non-continuous induction therapy with Venetoclax (800mg) once daily (QD) from Day 1 to 14, Atezolizumab (1200mg) every 3 weeks (Q3W) on Day 1, Carboplatin (5mg/mL/min) on Day 1 and Etoposide (100mg/m^2) on Days 1-3. Participants who tolerated study treatment without excessive toxicity, and had not undergone disease progression were to be then proceeded to maintenance treatment with venetoclax plus atezolizumab. The venetoclax dose for the maintenance setting in Arm B will be the dose that has been cleared in the maintenance only arm (Arm A) of the study (maintenance RP2D, RP2D-M).
88878435|NCT04422210|Experimental|Dose Expansion|If the Recommended Phase II Dose (RP2D) for Venetoclax during induction is established, then the dose-expansion cohort would continue to test venetoclax in both induction and maintenance. Participants would be administered non-continuous induction therapy with Venetoclax (RP2D-I/induction RP2D), Atezolizumab (1200mg) every 3 weeks (Q3W) on Day 1, Carboplatin (5mg/mL/min) on Day 1 and Etoposide (100mg/m^2) on Days 1-3 followed by continuous maintenance therapy with Venetoclax (RP2D-M) and Atezolizumab (1200mg) every 3 weeks (Q3W) on Day 1. If significant toxicity and DLTs in induction precluded identification of an RP2D for venetoclax in induction treatment, then the safety and efficacy of venetoclax would only be investigated in dose-expansion in the maintenance setting. Participants would be administered continuous maintenance therapy with Venetoclax (RP2D-M) and Atezolizumab (1200mg) every 3 weeks (Q3W) on Day 1.
88878436|NCT04010370||Healthy individuals|Cross-Sectional. No intervention. Patients of both sexes who are not sedentary or who participate in heavy physical activities and residents of the metropolitan area of Guadalajara
88878437|NCT00000264|Placebo Comparator|0 g/Kg ethanol +/- 30% nitrous oxide|
88878438|NCT00000264|Active Comparator|0.35 g/Kg ethanol +/- 30% nitrous oxide|
88878439|NCT00000264|Active Comparator|0.7 g/Kg ethanol +/- 30% nitrous oxide|
88878440|NCT00000318|Experimental|1|Maintenance treatment with daily medication
88878441|NCT00000318|Experimental|2|Maintenance treatment with thrice-weekly medication
89004251|NCT05461170|Experimental|Cohort 2b1 (VIR-3434)|Participants will receive multiple doses of VIR-3434 for 96 weeks.
89189992|NCT04259047|Active Comparator|Enhanced Usual Care (EUC)|EUC consists of home visits by a CHW in which general DM education is provided.
89403197|NCT05292963|Experimental|Fatherhood Works Program delivered virtually|Participants receive 26 hours of Nurturing Fathers curriculum, delivered virtually over Zoom. Participants also receive employment supports, case management, and financial literacy training.
89403198|NCT05284240|Experimental|Auryon Laser Treatment Arm|Auryon Laser to be used on target lesion in the below the knee artery.
89403199|NCT05283330|Experimental|²¹²Pb-DOTAM-GRPR1|In the dose escalation portion, a classic 3+3 design will be utilized. Doses will be increased by approximately 30% in subsequent cohorts. The maximum total dose that may be administered to a subject per cycle is 5.5 mCi +/- 10%. The maximum total dose that may be administered to a subject in the MAD regimen is 24 mCi over 4 cycles.
89403200|NCT05279495|Other|Loaded CANNAXR|"In a double-blinded fashion, 250 mg CANNAXR cream and 250 mg VEHICLE cream will be randomized for application to a delineated 50 cm2 area of either the left or right, hip/buttocks skin twice daily for 2 weeks.~In a double-blinded fashion, 250 mg CANNAXR cream and 250 mg VEHICLE cream will be randomized for application to a delineated 50 cm2 area of either the left or right, hip/buttocks skin twice daily for 2 weeks."
88878442|NCT00000372|Experimental|Glycine|The patients will undergo a 2 week single blind placebo lead in followed by an 8 week randomly assigned double blind treatment phase with 30 grams of glycine in 7 ounces of lemonade twice a day in addition to clozapine treatment.
88878443|NCT00000372|Placebo Comparator|Placebo|The patients will undergo a 2 week single blind placebo lead in followed by an 8 week randomly assigned double blind treatment phase with 30 grams of placebo powder in 7 ounces of lemonade twice a day in addition to clozapine treatment.
88878444|NCT00000372|Experimental|D-Cycloserine|The patients will undergo a 2 week single blind placebo lead in followed by an 8 week randomly assigned double blind treatment phase with D-cycloserine in addition to clozapine treatment.
89403201|NCT05279326|Experimental|Intervention arm|Participants will receive virtual SMAs and usual care. Virtual SMAs will last 90 minutes, every 3 weeks, in 18 weeks through an online platform, at no cost to participants beyond the use of the device and the internet.
89403202|NCT05279326|No Intervention|Control arm|Participants will be at usual care and follow their usual contact with health services.
89403203|NCT05272566||Infants|"30 healthy, term infants are recruited for 2 purposes:~To study the development of gut bacteria and viruses over time~To use as donors in a separate trial"
89403204|NCT05272566||Mothers|"30 healthy pregnant women are recruited along with their infants~To compare gut bacteria and viruses with those of their children~To screen for disease transferrable by breastfeeding"
88878445|NCT00000396|Experimental|1|Education in Arthritis Self-Help Course
88878446|NCT00000450|Active Comparator|Naltrexone Tablet|
88878447|NCT00000450|Placebo Comparator|Matched Placebo Tablet|
88878448|NCT00000774|Experimental|1|Patients who will receive rgp120/HIV-1MN
88878449|NCT00000774|Experimental|2|Patients who will receive rgp120/HIV-1SF2
88878450|NCT00000774|Placebo Comparator|3|Patients who will receive the placebo counterpart of 120/HIV-1MN
88878451|NCT00000774|Placebo Comparator|4|Patients who will receive the placebo counterpart of rgp120/HIV-1SF2
88878452|NCT00000930||A|HIV-infected individuals enrolled in HIVNET D01
88878453|NCT00000930||B|Individuals with newly acquired HIV infection
88878454|NCT00000936|Experimental|Induction|subjects receiving hOKT3 induction therapy
88878455|NCT00000936|Active Comparator|Induction Free Therapy|Patients not receiving induction therapy
88878456|NCT00000948|Experimental|1|Participants will be broken into 3 groups. Each group will receive ART and escalating doses of aldesleukin. All participants will then receive that maximum tolerated dose of aldesleukin.
88878457|NCT00000948|Active Comparator|2|All participants will receive ART
88878458|NCT00001458||Cardiovascular|subjects with cardiovascular symptoms or known disease.
88878459|NCT00001626|Experimental|A|D1-4 cyclophosphamide 50 mg/kg IV, then cyclosporine starting on d14 at 12 mg/kg/d for 6 months
88878460|NCT00001626|Experimental|B|ATG at 40 mg/kg/d for 4 days then cyclosporine at 12 mg /kg/d for 6 months
88878461|NCT00001686||Cohort A|Children and adults with cancer (or a pre-cancer syndrome or rare disease), between the age(s) of 2 years - 40 years, who present with disease manifestations of special interest to POB investigators.
88878462|NCT00002484|Experimental|external beam radiotherapy|Patients undergo 3-dimensional conformal external beam radiotherapy 5 days a week for 8-10 weeks.
88878463|NCT00002550|Experimental|RT + chemotherapy followed by surgery + chemotherapy|Induction radiation therapy (RT) + concurrent induction chemotherapy followed by surgery and additional chemotherapy
88878464|NCT00002550|Active Comparator|RT + chemotherapy followed by chemotherapy + RT|Induction RT + concurrent induction chemotherapy followed by additional chemotherapy + RT
89004252|NCT05461170|Experimental|Cohort 2b2 (VIR-3434)|Participants will receive multiple doses of VIR-3434 for 96 weeks.
89004253|NCT05461170|Experimental|Cohort 2c (VIR-2218 + VIR-3434)|Participants will receive multiple doses of VIR-2218 + VIR-3434 for 96 weeks total
88878465|NCT00002556|Active Comparator|ARM A (VBMCP)|"INDUCTION PHASE: Patients receive VBMCP comprising vincristine sulfate IV on day 1, carmustine IV on day 1, melphalan PO on days 1-4, cyclophosphamide IV on day 1, and prednisone PO on days 1-7. Treatment repeats every 35 days for 2 courses in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION PHASE: Patients receive VBMCP as in the induction phase. Courses repeat every 35 days in the absence of disease progression or unacceptable toxicity."
88878466|NCT00002556|Experimental|Arm B (VBMCP, high dose cyclophosphamide, r alpha 2b IFN)|"INDUCTION PHASE: Patients receive VBMCP comprising vincristine sulfate IV on day 1, carmustine IV on day 1, melphalan PO on days 1-4, cyclophosphamide IV on day 1, and prednisone PO on days 1-7. Treatment repeats every 35 days for 2 courses in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION PHASE: Patients receive vincristine sulfate, carmustine, and melphalan as in the induction phase, high-dose cyclophosphamide IV on days 1-4 and prednisone PO on days 1-4 during courses 3 and 5. Patients receive VBMCP as in the induction phase during even numbered courses. Patients receive recombinant interferon alfa-2b SC on days 1, 3, 5, 8, 10, 12, 15, 17, 19, and 22 during odd courses beginning course 7. Treatment repeats every 35 days for courses 3-5, every 21 days for even courses beginning course 6, and every 22 days for odd courses beginning course 7 in the absence of disease progression or unacceptable toxicity."
88878467|NCT00002574|Experimental|Arm I|Single-Agent Chemotherapy plus Biological Response Modifier Therapy. Homoharringtonine, HH, NSC-141633; plus Interferon alfa (Schering), IFN-A, NSC-377523.
88878468|NCT00002586|Experimental|13-cis retinoic acid|13-cis retinoic acid 50 mg/d
88878469|NCT00002586|Experimental|13-Cis Retinoic Acid and Tocopherol|13-Cis Retinoic Acid (50 mg/day) Tocopherol (800 mg/day)
88878470|NCT00002586|No Intervention|Observation|Observation
88878471|NCT00002610|Experimental|STRATUM A|Treatment of children in Stratum A will be determined by the site of relapse and the presence of microscopic or gross residual disease after attempted surgical excision of the relapse.
88878472|NCT00002610|Experimental|Stratum B|All children who received combination chemotherapy with Regimen EE - 4A as their initial therapy for Wilms tumor will receive Regimen I and radiation therapy to the site of recurrence. All patients will receive prophylactic trimethoprim /sulfamethoxazole
89189993|NCT04257994||patients with arrhythmic disorders|Participants will include patients diagnosed with a heritable arrhythmic disorder (including arrhythmogenic, hypertrophic and dilated cardiomyopathy, cardiac sarcoidosis as well as cardiac channelopathies; Long QT syndrome, Brugada syndrome and catecholaminergic polymorphic ventricular tachycardia) followed at the Inherited Cardiac Conditions (ICC) service of St. George's University Hospitals NHS Foundation Trust as well as family members of victims of SCD evaluated at the same clinic for risk assessment and diagnosis.
89189994|NCT04229992|Active Comparator|GG genotype and magnesium treatment|Participants who have the GG genotype will be assigned to magnesium glycinate
89189995|NCT04229992|Placebo Comparator|GG genotype and placebo|Participants who have the GG genotype will be assigned to placebo group
88878473|NCT00002610|Experimental|STRATUM C|All children who received combination chemotherapy with Regimen DD - 4A as their initial therapy for Wilms tumor will be treated with the following chemotherapy. All patients will receive prophylactic trimethoprim/sulfamethoxazole
89189996|NCT04229992|Active Comparator|GA/AA genotype and magnesium treatment|Participants who have the GA/AA genotype will be assigned to magnesium glycinate
89189997|NCT04229992|Placebo Comparator|GA/AA genotype and Placebo|Participants who have the GA/AA genotype will be assigned to placebo group
89189998|NCT04229472|Experimental|Normal subject control group|High density mapping of left atrial voltages in patients with supraventricular tachycardia
88878474|NCT00002610|Experimental|STRATUM D|Six week cycles of chemotherapy will be given to all patients who do not have progressive disease at the time of each week 0 re-evaluation.
88878475|NCT00002622|Active Comparator|Talc slurry via chest tube|talc slurry via chest tube
88878476|NCT00002622|Active Comparator|Talc via insufflation|4 to 5 grams talc via insufflation through direct or videoscopic thoracoscopy, one time
88878477|NCT00002664|Experimental|Treatment|
88878478|NCT00002670|Active Comparator|Radiation therapy|Radiation therapy - 60 Gy in 6 weeks (2 Gy once a day, 5 x a week)
88878479|NCT00002670|Experimental|Radiation therapy plus cisplatin|Radiation therapy - 60 Gy in 6 weeks (2 Gy once a day, 5 x a week) plus Cisplatin-100 mg/m2 i.v. on days 1,22 and 43 with radiation therapy.
88878480|NCT00002676|Experimental|CHOD + BVAM + WBRT|Patients 70 years old and younger with newly diagnosed, biopsy-proven PCNSL received one cycle of CHOD followed by two cycles of BVAM. Patients then received WBRT, 30.6 Gy, if a complete response was evoked, or 50.4 Gy if the response was less than complete; both doses were given in 1.8-Gy daily fractions.
88878481|NCT00002682|Experimental|Antibiotic Treatment|
88878482|NCT00002706|Experimental|Arm I|Patients undergo vaginal hysterectomy and BSO via laparoscopy.
88878483|NCT00002706|Active Comparator|Arm II|Patients undergo total abdominal hysterectomy and BSO via conventional laparotomy.
88878484|NCT00002718|Experimental|Candidates for transplant|Pts stratified by number of HLA-incompatible alleles(1 vs 2 or 3). Harvest:Begin 6-10 d before transplant,allogeneic BM is harvest & tx in vitro. Begin 5-6 d before transplant,G-CSF-stimulated,PBSC harvest,selected for CD34+ cells,& treatment in vitro. If doable,ABM harvest in event of allogeneic graft failure. Myeloablation:Pts u/g TBI 3x d days -9 to -6, thiotepa IV over 4hrs days -5 & -4, & cyclophosphamide IV days -3 & -2. Transplant:CD34+, E-rosette & T-cell-depleted PBSC infuse over 15mins & T-cell-depleted bone marrow infused over 1-5mins day 0. Pts get G-CSF IV over 30 min begin day 1 & continue til blood counts recover & tapering. Pts get anti-thymocyte globulin IV over 4-6hrs days 8,10,12,&14 & oral methylprednisolone days 8-14 followed by tapered doses days 15-17. See detailed description for more details.
88878485|NCT00002760|Other|Antiandrogen withdrawal|"antiandrogen therapy withdrawn; patient who progress will be crossed over to Arm 1A: 400 mg ketoconazole PO tid and hydrocortisone 30 mgs PO q am and 10 mgs PO qhs until treatment is no longer effective"
88878486|NCT00002760|Active Comparator|Antiandrogen withdrawal + therapy|Ketoconazole and hydrocortisone
88878487|NCT00002772|Experimental|High dose chemo|sequential high dose chemotherapy with doxorubicin, paclitaxel and cyclophosphamide with filgrastim support
89189999|NCT04229472|Experimental|Atrial fibrillation group|High density mapping of left atrial voltages
88878488|NCT00002772|Experimental|chemo with autologous stem cell support|conventional chemotherapy with doxorubicin and cyclophosphamide followed by autologous stem cell support
88878489|NCT00002784|Active Comparator|Standard chemotherapy|EC/AC x 4 followed by CMF x 3 and tamoxifen to 5 years after randomization.
88878490|NCT00002784|Experimental|Dose-intensive EC|High-dose EC x 3 supported by peripheral blood progenitor cells and tamoxifen to 5 years after randomization.
88878491|NCT05752578||Subjects with HIV infection|Both male and female subjects, over 18 years of age, on antiretroviral therapy, native speakers of Italian
88878492|NCT05752578||Healthy control subjects|Both male and female subjects, over the age of 18 years, no neurological or psychiatric conditions that would alter test performance, native speakers of Italian
88878493|NCT05752422|Experimental|Active transcranial Photobiomodulation (t-PBM)|Active t-PBM will be delivered to the forehead using the Niraxx Smart Headband (gen 1). Daily treatments of 40 min
88878494|NCT05752422|Sham Comparator|Sham t-PBM|To the subjects belonging to the sham arm the sham treatment sessions will be performed using the same device, during the same time but the device will not be turned on.
88878495|NCT05751954|Other|Arm Label|All patients who undergo total knee arthroplasty and met inclusion and exclusion criteria
88878496|NCT05751876||Women with adenomyosis under dienogest|Perimenopausal women with symptomatic adenomyosis receiving dienogest
88878497|NCT05751798|Experimental|OSE-279 100 mg|Dose Level 1: OSE-279 100 mg
88878498|NCT05751798|Experimental|OSE-279 300 mg|Dose Level 2: OSE-279 300 mg
89190000|NCT04229472|Experimental|AcQMap atrial fibrillation group|High density mapping of left atrial voltages and AcQMap propagation patterns alongside cardiac MRI
89190001|NCT04221230|Experimental|BTRX-335140|BTRX-335140
89190002|NCT04221230|Placebo Comparator|Placebo|Placebo
89190003|NCT04218786|Active Comparator|Colchicine Group|This group will receive low dose colchicine, 0.5 mg.
89190004|NCT04218786|Placebo Comparator|Placebo group|This group will receive a placebo drug with a similar shape and mass as that to experimental drug
88878499|NCT05751798|Experimental|OSE-279 500 mg|Dose Level 3: OSE-279 500 mg
88878500|NCT05751564|Experimental|"Ready to inject MSC product"|"Cryopreserved ready to inject Umbilical Cord (UC) derived MSC"
88878501|NCT05751564|Active Comparator|Resuspended MSC product|Umbilical Cord (UC) derived MSC in suspension media
88878502|NCT05751486|Experimental|JS001sc Q3W|
88878503|NCT05751486|Experimental|JS001sc long period|
88878504|NCT05751486|Experimental|JS001 IV (if applicable)|the Safety Monitor Committe (SMC) will discuss whether to conduct an IV cohort and determine the dose/frequency of the IV cohort, based on the initial safety and clinical pharmacological data of triprilimab injection in combination with the GP regimen;
88878505|NCT05751486|Experimental|Additional cohort (if applicable)|The exploration of additional dosing/frequency will be discussed by the SMC based on prior safety and clinical pharmacological data
88878506|NCT05751408||Stiff knee gait|Subjects referred to clinical 3D gait analysis because of a clinical question related to stiff knee gait
88878507|NCT05751408||Foot surgery|Subjects referred to clinical 3D gait analysis because of a clinical question related to foot surgery
88878508|NCT05751330|Experimental|patients affected by Cardioinhibitory Neurocardiogenic Syncope|
88878509|NCT05751252|Experimental|0.0625 mg|Test the efficacy of Ganirelix administered subcutaneously at single-dose regimen of 0.0625 mg in 10 women with PCOS, in rectifying LH pulse frequency and LH amplitude
88878510|NCT05751252|Experimental|0.025 mg|Test the efficacy of Ganirelix administered subcutaneously at single-dose regimen of 0.025 mg in 10 women with PCOS, in rectifying LH pulse frequency and LH amplitude.
88878511|NCT05751018|Experimental|pyrotinib|
88878512|NCT05750784|Other|total knee arthroplasty using the active robotic system using the kinematic alignment concept|Total knee arthroplasty using the active robotic surgical system TSolution One TCAT, and system for planning TPlan
88878513|NCT05750784|Other|total knee arthroplasty using the active robotic system using the mechanical alignment concept|Total knee arthroplasty using the active robotic surgical system TSolution One TCAT, and system for planning TPlan
88878514|NCT05750706||Acute lymphoblastic leukemia, no invasive fungal infection|
88878515|NCT05750706||Acute lymphoblastic leukemia, invasive fungal infection|
88878516|NCT05750394|Active Comparator|Single Layer Closure|"Single layer closure using the following technique:~a. Closure of the myometrium and serosa with one (1) 0 V-Loc 90 suture on a GS-24 needle using an unlocked technique. The endometrium should be excluded."
88878517|NCT05750394|Active Comparator|Double Layer Closure|"Double layer closure using the following technique:~Closure of the full thickness of the myometrium with one (1) Monocryl suture on a CT needle using a running locked technique. The endometrium should be excluded.~Imbrication of the first layer with one (1) Monocryl suture on a CT needle using a running un-locked technique"
88878518|NCT05750394|Active Comparator|Triple Layer Closure|"Triple layer closure of Endometrium, Myometrium and Serosa (EMS) using one of the the following two techniques:~Closure of the endometrium and 2-4 mm of internal myometrium with one (1) 2-0 V-Loc 90 suture on a GS-21 needle using an unlocked technique~Closure of the remaining myometrium and serosa with one (1) 0 V-Loc 90 suture on a GS-24 needle using an unlocked technique~or~Closure of the endometrium and 2-4 mm of internal myometrium with one (1) 2-0 V-Loc 90 suture on a GS-21 needle using an unlocked technique~Closure of the remaining myometrium with one (1) 0 V-Loc 90 suture on a GS-24 needle using an unlocked technique~Closure of the serosa with one (1) 2-0 V-Loc 90 suture on a GS-21 needle using an unlocked technique"
88878519|NCT05749692||The COVID-19 infected group|Functional dyspepsia patients infected with COVID-19
88878520|NCT05749614|Experimental|Group 1|
88878521|NCT05749614|Experimental|Group 2|
88878522|NCT05749536||Asthma|With positive asthma test
88878523|NCT05749536||Healthy|With no signs of asthma
88878524|NCT05749380|Other|1A(RT)|Patients (AmBisome, DKF-5122)
88878525|NCT05749380|Other|1B(TR)|Patients (DKF-5122, AmBisome)
88878526|NCT05749380|Other|2A(RT)|Healthy subjects (AmBisome, DKF-5122)
88878527|NCT05749380|Other|2B(TR)|Healthy subjects (DKF-5122, AmBisome)
88878529|NCT05749224|Experimental|Patients Who Have Temporomandibular Joint Disorder|Helkimo index will be applied to the patients have temporomandibular disorder.
88878530|NCT05749224|Experimental|Healthy Controls|Helkimo index will be applied to healthy people.
88878531|NCT05748912|Experimental|Therapeutic bronchoscopy for removal of mucus plugs|Protocol A: This protocol will study 10 patients with asthma who have CT (Computed Tomography) evidence of mucus plugs in their airways. Screening data will be reviewed to determine participant eligibility. Participants who meet all eligibility criteria will participate in a bronchoscopy done on one lung for the first 5 participants, and if single lung mucus removal is well tolerated then we will perform bronchoscopies on both lungs for the next 5 participants.
88878532|NCT05748756|Experimental|Test group|
88878533|NCT05748756|Active Comparator|Control group|
89403205|NCT05267236|Experimental|Treatment-On Demand Format|Treatment group participants receive TYRO Couples curriculum in an on-demand format that is delivered in five 2-hour weekly sessions for a total of 10 hours.
88878534|NCT05743374|Other|Normal diet|One arm will be given dietary advice that is always given to patients with ulcerative colitis.
88878535|NCT05743374|Active Comparator|E400 elimination|The other arm will be given advice to eliminate E400 substances with special regard to carragenan, CMC and polysorbates.
88878536|NCT05743296||Cross-sectional study, no arm|"Experimental: Training with the virtual reality program (MOTOCOG)~Training consists of 26 minutes task-specific training."
88878537|NCT05739396|Experimental|core stabalization|The core stability exercises will be used for core stabilization training of group (A) in addition to traditional physical therapy. The core stability program included 3 levels. Each exercise lasted 5 min, and the children shifted from one exercise to the next after the complete performance of the preceding exercise. The first (simple) level included supine abdominal draw-in (20 repetitions), abdominal draw-in with both knees to the chest (10-20 repetitions), and supine twist (10-20 repetitions). The second (medium) level included pelvic bridging (3e5 repetitions) and twist with a medicine ball (10e20 repetitions). Finally, the third (difficult) level included bridging with the head on a physio ball (the position was held for 3-5 s, followed by a slow relaxation phase, with 10-20 repetitions)
88878538|NCT05739396|Experimental|rebound therapy|Rebound exercises will be applied for group B. this group will receive rebound exercise training in addition to traditional physical therapy . Rebound exercises were conducted on a mini-trampoline and BOSU ball. Passive bouncing will be conducted while the child was standing with his/her feet a shoulder-width apart. The therapist will held the child's legs while applying upward and downward movement. The bouncing started slowly. The child then will progress to include the rebound exercises, starting with active bounce, where in a hands free manner the therapist will ask the child to speed up or slow down the bounce rate according to the child's abilities
88878539|NCT05739240|Other|no 3D model|
88878540|NCT05739240|Other|3D model|
88878541|NCT05688228||Abortion|Adult women performing a medical or surgical abortion
88878542|NCT05677698|Experimental|Peppermint oil|Peppermint oil has an effect on menopausal symptoms
88878543|NCT05677698|Experimental|Lemon oil|Lemon oil has an effect on menopausal symptoms.
88878544|NCT05677698|Placebo Comparator|almond oil|Almond oil has an effect on menopausal symptoms.
88878545|NCT05667168|Experimental|High power laser|"The application of high-intensity laser on cervical muscles, 50J/cm2, 980nm, 0 Hz, on processus mastoideus and porus acusticus externus.~Administration of tinnitus intensity on scale 0-10 and questionary."
88878546|NCT05667168|Experimental|Low power laser|The application of low-intensity laser on cervical muscles, 4J/cm2, 980nm, 0 Hz, on processus mastoideus and porus acusticus externus. Administration of tinnitus intensity on scale 0-10 and questionary.
88878547|NCT05667168|Experimental|Radio-frequention therapy|Applying radio-frequentation current on cervical muscles, 10-50% of intensity, 0 Hz. Administration of tinnitus intensity on a scale of 0-10 and questionary.
88878548|NCT05667168|Experimental|Manual therapy of temporomandibular joint,.|A manual physiotherapeutic approach to the temporomandibular joint will treat participants. Administration of tinnitus intensity on a scale of 0-10 and questionary.
88878549|NCT05667168|Experimental|Manual therapy of the cervical spine.|A manual physiotherapeutic approach to the cervical spine will treat participants. Administration of tinnitus intensity on a scale of 0-10 and questionary.
88878550|NCT05667168|Active Comparator|Physical exercising.|Participants will be treated by physical exercising in closing and opening muscle chains. Administration of tinnitus intensity on a scale of 0-10 and questionary.
88878551|NCT05667168|Active Comparator|Cognitive therapy|Participants will be treated with cognitive therapy by a psychologist. Administration of tinnitus intensity on a scale of 0-10 and questionary.
88878552|NCT05667168|Placebo Comparator|Life style.|Participants will be treated only by modulation of their lifestyle. Administration of tinnitus intensity on a scale of 0-10 and questionary.
89403206|NCT05267236|Experimental|Control-Virtual or In-Person Format|Control group participants receive TYRO Couples curriculum in a live format (virtual or in-person) that is delivered in five 2-hour weekly sessions for a total of 10 hours.
89403207|NCT05262777|Experimental|GP0112|GP0112 Single injection and optional touch up injection and re-treatment with GP0112
89403208|NCT05262777|Active Comparator|Restylane Lyft Lidocaine|Restylane Lyft Lidocaine Single injection and optional touch up injection and re-treatment with Restylane Lyft Lidocaine
89403209|NCT05261802|Experimental|AVANCE-Houston FRAMEWorks Program Weekly Workshop Format|Participants in this arm receive 14 hours of Survival Skills for Healthy Families curricula over 7 weeks. Participants also receive employment supports and case management services.
88878553|NCT05636358|Experimental|Home-based hypnotherapy|"The intervention includes existing home-based hypnotherapy self-exercises in MP3 format for a period of three months.~The intervention group of children with FAP or IBS in primary care receives the home-based hypnotherapy self exercises in addition to care as usual by their GP according to the guideline commissioned by the Dutch Society of GPs."
88878554|NCT05636358|No Intervention|Control|The control group of children with FAP or IBS in primary care will receive only care as usual by their GP. After the end of the study, the control group will also receive access to the home-based hypnotherapy exercises, if desired.
88878555|NCT05628870|Experimental|HRS-1358|Daily oral dosages of HR-1358
88878556|NCT05625282|Active Comparator|control|Weil osteotomy and plantar plate repair
89403210|NCT05261802|Experimental|AVANCE-Houston FRAMEWorks Program Weekend Retreat Format|Participants in this arm receive 14 hours of Survival Skills for Healthy Families in a compressed format during a 16-hour weekend retreat, followed by a 2-hour reflections workshop two weeks later. Participants also receive employment supports and case management services.
88878557|NCT05625282|Experimental|intervention|Weil osteotomy alone
88878558|NCT05623254|Other|TAU + MINDF (Treatment-as -Usual + Mindfulness)|Treatment-as-usual combined with weekly mindfulness sessions delivered on-line for patients and caregivers (a specific platform for on-line sessions will be used)
88878559|NCT05612022||Group 1. Patients with AVF as first line HD access option.|24 consecutive patients in need of AVF enrolled at the Nephrology and Dialysis unit of the ASST-Papa Giovanni XXIII of Bergamo.
88878560|NCT05612022||Group 2. Patients with AVG as first line HD access option.|20 consecutive patients in need of AVG enrolled at the Nephrology and Dialysis unit of the ASST-Papa Giovanni XXIII of Bergamo.
88878561|NCT05574582|Experimental|Arthroscopic assisted Cancellous chips graft reconstruction|"The arthroscopic technique is potentially less invasive with minimal donor site morbidity and potentially faster time to union because of minimal trauma to the ligament structures, joint capsule, and the tenuous blood supply. It may also have advantageous osteogenic properties compared to a structural graft.~Currently, studies have reported similar union rates, patient reported outcomes score, and functional score compared to open graft technique. Results in patients with gross deformity are debated with some studies favoring conventional open structural graft and other found no difference in outcome between the techniques."
88878562|NCT05574582|Active Comparator|Open cancellous graft reconstruction|Convention open technique with debridement of the nonunion side, insertion of cancellous graft from the iliac crest and osteosynthesis with compression screw is currently commonly applied in scaphoid nonunion.
88878563|NCT05497674|Experimental|rongliflozin and/or rifampicin|on Day 1, subjects will receive a single dose administration of rongliflozin, followed by a washout period of 4 days. Starting On Day 5, subjects will administer rifampicin once a day (QD) for 10 consecutive days ( Day 5 to Study Day 14) , comprising of a single dose administration of rongliflozin on Study Day 11.
88878564|NCT05497674|Experimental|rongliflozin and/or probenecid|on Day 1, subjects will receive a single dose administration of rongliflozin, followed by a washout period of 4 days. Probenecid will be administrated twice a day from Day 5 to Day 9, and another single dose administration of rongliflozin on Day 6.
88878565|NCT05485740|Experimental|study group|the study group received the same exercise training program in addition to cognitive multisensory rehabilitation program
88878566|NCT05485740|Experimental|control group|the control group which received the selected exercise program
88878567|NCT05437926||Light skin|Light skin Fitzpatrick 1-2 approximately 1/3 with normal sinus rhythm, 1/3 with atrial fibrillation and 1/3 with premature beats
88878568|NCT05437926||Dark skin|Dark skin Fitzpatrick 5-6 approximately 1/3 with normal sinus rhythm, 1/3 with atrial fibrillation and 1/3 with premature beats
88878569|NCT05437068|Experimental|Oral Nutritional Supplement (ONS) Group|Two servings per day in addition to dietary counseling
88878570|NCT05435508|Experimental|Pain Neurosicence Education + Pre-anesthetic Assessment|Pain neuroscience education + Pre-anesthetic Assessment. Pain neuroscience education can be defined as an educational session or sessions describing the neurobiology and neurophysiology of pain, and pain processing by the nervous system.
88878571|NCT05435508|Other|Pre-anesthetic Assessment (Usual Care)|The pre-anesthetic assessment is the clinical study that allows evaluating the physical condition, personal, pathological and surgical history together with laboratory tests to be able to establish a surgical risk in order to define the best anesthetic plan that the patient requires according to the surgical event.
88878572|NCT05403372|Experimental|InterShunt PAS-C|
88878573|NCT05377164||Vegetarian group|
88878574|NCT05377164||Omnivorous group|
88878575|NCT05377164||Low carbohydrate group|
88878576|NCT05360628|Experimental|D-0120 plus Allopurinol|D-0120 dosing followed by Allopurinol and combination treatment
88878577|NCT05360628|Experimental|Allopurinol plus D-0120|Allopurinol dosing followed by D-0120 and combination treatment
88878578|NCT05326932|Experimental|Intervention group|Mechanical thrombectomy to be initiated as soon as possible after randomisation.
88878579|NCT05326932|No Intervention|Control group|Patients assigned to the control group will avoid treating MT and only receive the standard medical treatment according to local guidelines.
88878580|NCT05312112||Venetoclax|Venetoclax in newly diagnosed AML
88878581|NCT05312112||FLT3 inhibitors|FLT3 inhibitors including gilteritinib in relapsed AML
88878582|NCT05266170||Normal adults|aerobic and anaerobic exercises
88878583|NCT05259462|Experimental|Group-active virtual reality gaming|Participants will undergo the intervention.
88878584|NCT05248854|Experimental|Sensorimotor exercise training|SM program included combination of traditional hip and knee exercise, various balance and proprioceptive exercises.
88878585|NCT05248854|Experimental|Core Stabilization exercise training|Core stabilization exercise program contained traditional hip and knee ROM exercise combining the core stabilization as mat activities
89004254|NCT05461170|Experimental|Cohort 3 (VIR-3434)|Participants will receive multiple doses of VIR-3434 for 48 or 96 weeks.
89403211|NCT05256992|Experimental|Treatment-Ray of Hope|Treatment group participants receive standard and enhanced services. Standard services are delivered as primary services to participants in both study groups under a shared condition, and they are: 20 hours of TYRO Dads curricula and 6 hours of Core Communication curricula. Finally, only the treatment group receives 10 hours of the Ray of Hope curriculum as an enhanced service. Optional services are available to both study groups by selecting 1-3 hours of coursework from a menu of courses in the Mini-Clinic that address a variety of needs.
89190005|NCT04202692|Experimental|GERDOff Plus|Hyaluronic acid + chondroitin sulphate + magnesium trisilicate melt in mouth tablets (1100 mg). 1 tablet q.i.d. (three after meals, one before resting) for 3 consecutive weeks. After three weeks of wash-out period,patients will take either placebo or GERDOff Plus q.i.d. (three after meals, one before resting) for another three weeks.
89403212|NCT05256992|Experimental|Control-No Ray of Hope Curriculum|Only standard services are delivered to participants in the control group under a shared condition with the treatment group, and they are: 20 hours of TYRO Dads curricula and 6 hours of Core Communication curricula. Optional services are available to both study groups by selecting 1-3 hours of coursework from a menu of courses that address a variety of needs.
89403213|NCT05253443|Experimental|Mentalizing Imagery Therapy and caregiver skills mobile application|
89403214|NCT05253443|Active Comparator|Caregiver skills mobile application|
89403215|NCT05244447|Experimental|Primary Services|Primary services: Participants receive 12 hours of Relationships Smarts Plus, 3 hours of Mind Matters and 1 hour of Money Habitudes workshops over the course of 10
88878586|NCT05244174|Active Comparator|Biliary stent|Biliary stent by ERCP is indicated both in palliative treatment, because of biliary duct decompression improves patient comfort by decreasing itching and jaundice, as in the treatment of the disease itself, because of it lets reach non-toxic levels of bilirubin which is necessary for chemotherapeutic treatment.
89004255|NCT05461170|Placebo Comparator|Cohort 4 (NRTI)|Participants will receive NRTI for 12 weeks, then assign to Cohort 2c or Cohort 3.
89403216|NCT05244421|Experimental|Primary Services|Primary services: Participants receive 16 hours of 24/7 Dads curricula, 4 hours of Healthy Relationships workshops, and 4 hours of Economic Stability workshops over the course of 8 weeks. Participants also receive ongoing job readiness support and post-employment support.
88878587|NCT05244174|Experimental|Biliary and pancreatic stent|During ERCP, the cannulation of the main pancreatic duct may be performed for the placement of a pancreatic duct stent, which is performed routinely as a prophylaxis of post-ERCP acute pancreatitis in patients at risk. In patients with pancreatic cancer, the placement of a pancreatic stent could improve pancreatic secretion by clearing the main pancreatic duct and thus it could improve fat digestion and nutritional status of patients, avoiding the need for PERT
88878588|NCT05241522|Active Comparator|Tilmanocept Dose - 0.050 mg|
88878589|NCT05241522|Active Comparator|Tilmanocept Dose - 0.20 mg|
88878590|NCT05241522|Active Comparator|Tilmanocept Dose - 0.40 mg|
88878591|NCT05226858||Trauma patients with suspected blunt traumatic aortic injury (BTAI)|All trauma patients with suspected BTAI at the emergency department who require both transesophageal echocardiography (TEE) and computed tomography angiography (CTA).
88878592|NCT05218668|Experimental|Fasudil|Oral fasudil up to 240 mg/day
88878593|NCT05118360|Experimental|Part 1-ASC41 2mg|ASC41 2mg for 52 weeks.
88878594|NCT05118360|Placebo Comparator|Part1-placebo|Matching placebo for 52 weeks.
88878595|NCT05118360|Experimental|Part 2-ASC41 4mg|ASC41 4 mg for 52 weeks.
88878596|NCT05118360|Placebo Comparator|Part2-placebo|Matching placebo for 52 weeks.
88878597|NCT05096364|Experimental|AK111 Regimen 1|AK111 Regimen 1 - subcutaneous injection every 4 weeks up to 60 weeks
89190006|NCT04202692|Placebo Comparator|Placebo|Placebo melt in mouth tablets (1100 mg). 1 tablet q.i.d. (three after meals, one before resting) for three consecutive weeks. After three weeks of wash-out period, patients will take either placebo or GERDOff Plus q.i.d. (three after meals, one before resting) for another three weeks.
89403217|NCT05240742||Dutch COVID-19 patients|"The study population consists of Dutch (former) COVID-19 patients who have been included in one of the cohorts and categorized in various subgroups:~Patients who suffered from (confirmed) COVID-19 and were admitted to the hospital ward.~Patient who suffered from (confirmed) COVID-19 and were admitted to the ICU.~Patients who suffered from (confirmed or suspected) COVID-19 at home.~Patients who suffered from (confirmed) COVID-19 and were in need of inpatient or outpatient rehabilitation after infection at home or in the hospital (ward and/or ICU)."
88878598|NCT05096364|Experimental|AK111 Regimen 2|AK111 Regimen 2 - subcutaneous injection every 4 weeks up to 60 weeks
88878599|NCT05096364|Experimental|AK111 Regimen 3|AK111 Regimen 3 - subcutaneous injection every 4 weeks up to 60 weeks
88878600|NCT05096364|Experimental|AK111 Regimen 4|AK111 Regimen 4 - subcutaneous injection every 4 weeks up to 60 weeks
88878601|NCT05096364|Placebo Comparator|Placebo to AK111|Placebo to AK111-Placebo subcutaneous injection, then 1:1 randomized to AK111 Regimen 3 or Regimen 4 at week 12
88878602|NCT05048940|Experimental|HETEROLOGOUS VACCINE|COVID-19 Vaccine Janssen, injectable suspension
88878603|NCT05048940|Active Comparator|HOMOLOGOUS VACCINE|Spikevax (Moderna), injectable dispersion
88878604|NCT05046990||RAC evaluation|Patients older than 18 years without previous history of Hp infection or eradication undergoing a gastroscopy
88878605|NCT04987164||Feminabiane CBU Consumers|Group of consumers of Feminabiane CBU : 2 tablets of Feminabiane CBU® every day, to be swallowed with a glass of water.
88878606|NCT04987164||Control group|Control group of non consumers of Feminabiane CBU
88878607|NCT04945590|Experimental|Latino/Hispanic Virtual Intervention Program|Latino/Hispanic individuals will participate in culturally tailored virtual intervention program following a community-based collaborative design.
88878608|NCT04935684|Experimental|Group 1: Fecal Microbiota Transplantation (FMT)|"Patients randomized in the FMT group will received FMT. FMT product will be made by the the pharmacy of the Clermont-Ferrand University Hospital from stools of healthy volunteer donors within 6 hours after defecation in order to preserve the viability of the bacteria. The preparation will be standardized: 50g aliquots will be prepared and diluted in 250mL of 0.9% NaCl containing 10% glycerol, until a homogeneous suspension is obtained. The preparation will be rapidly frozen at -80°C until use, with a maximum shelf life of 18 months."
88878609|NCT04935684|No Intervention|Group 2: no intervention|"The comparator group will be constituted by patients randomized in the no FMT group. For ethical reasons, these patients will not receive any FMT and therefore no enema or colic preparation. No placebo will be administered. Prophylactic anti-infective treatments can be introduced at any time."
88878610|NCT04927806|Experimental|SilverKnight group|Silver Knight is an anti-microbial additive that uses silver ions to disrupt the normal enzymatic activities of bacteria
88878611|NCT04927806|No Intervention|Control group|The control group uses standard ventilator circuits.
89403218|NCT05240742||Dutch controls who did not experience COVID-19|One of the cohorts, the POPCOrn cohort, is a community-based cohort which partly consists of controls who did not experience COVID-19
89403219|NCT05239754|Experimental|Primary Services|Primary services: Participants receive 16 hours of 24/7 Dads curricula and at least 2 hours of career readiness workshops over the course of 9 weeks. Participants also receive ongoing job readiness support and post-employment support.
89403220|NCT05237466|Experimental|RECLAIM: Reducing Clutter and Increasing Meaning|Participants will receive a combination of motivational interviewing and sorting practice to reduce hoarding symptoms.
89403221|NCT05237466|Active Comparator|Sorting Practice|Participants will receive sorting practice only to reduce hoarding symptoms.
88878612|NCT04911894|Experimental|Phase Ia Dose-Escalation Stage: IBI321|
89004256|NCT05408429|Experimental|2-Dose 20vPnC Group|Pneumococcal conjugate vaccine (2 doses approximately 2 months apart)
89403222|NCT05229874|Experimental|Carbon nanoparticle suspension injection (CNSI) group|CNSI (50 mg/dose) was produced by Chongqing Lesmei Pharmaceutical Co., Ltd.: Carbon nanoparticles were marked in the endoscopy division 1 day before surgery, and CNSI was injected submucosally at 4 points (proximal side, distal side, and left and right sides) 0.5-1 cm from the tumor edge under endoscopy. The test dose for each point was approximately 0.25 ml.
89403223|NCT05229874|Active Comparator|Indocyanine green (ICG) group|"ICG (25 mg/dose) was produced by Dandong Yichuang Pharmaceutical. ICG was marked in the endoscopy division 1 day before surgery and injected submucosally at 4 points (proximal side, distal side, and left and right sides) 0.5-1 cm from the tumor edge under endoscopy. The test dose for each point was approximately 0.5 ml.~Both procedures were performed by a designated medical practitioner."
89403224|NCT05227352|Experimental|Biophilic experience|Healthcare workers will experience the biophilic-designed room
89403225|NCT05221970|Other|Mindfulness-Based Cognitive Therapy (MBCT-Ca) - online|MBCT uses cognitive behavioral therapy (CBT) methods in collaboration with mindfulness meditative practices and similar psychological strategies.
89403226|NCT05221970|Other|Positive Psychology - online|Positive psychology is focused on the character strengths and behaviors that allow individuals to build a life of meaning and purpose.
89403227|NCT05221970|Other|Autogenic Training - online|Autogenic training is a relaxation technique focusing on promoting feelings of calm and relaxation to help reduce stress and anxieties.
89403228|NCT05221970|No Intervention|Waiting list|No intervention.
89403229|NCT05215730|Active Comparator|Copper oxide dressings (COD)|"MedCu wound dressings with copper oxide (COD) (Copper Arm)."
89403230|NCT05215730|Active Comparator|"Vacuum-assisted closure (VAC) treatment (VAC Arm)"|"Negative Pressure Wound Therapy (NPWT) known also as Vacuum-assisted closure (VAC) treatment (VAC Arm)."
89530958|NCT03235531|Active Comparator|CIWA Protocol Only|"Interventions to decrease symptoms of AWS will be made based on the CIWA tool~CIWA Score 9-14: 1 mg IV push lorazepam~CIWA Score >15: 2 mg IV push lorazepam~Patients who have a known history of alcohol withdrawal seizures or who have received greater than 4 mg IV lorazepam per CIWA protocol will be placed on a scheduled lorazepam regimen, 1 mg every 6 hours. The primary managing service may increase the scheduled lorazepam regimen above 1mg every 6 hours if needed to control withdrawal symptoms. Scheduled lorazepam will be discontinued or de-escalated following a 24-hour period in which no additional lorazepam was received per CIWA protocol."
89190007|NCT04201119|Experimental|With Oxiris|
89190008|NCT04201119|No Intervention|Without Oxiris|
88878613|NCT04848402|Experimental|On-Body Delivery System (OBDS)/Multiple Bolus Injector|On-Body Delivery System (OBDS)/Multiple bolus injector used to administer placebo subcutaneously (SC).
88878614|NCT04848402|Experimental|Single Auto Injector|Single auto injector used to administer placebo SC.
88878615|NCT04836780|Experimental|Dexamethasone|Dexamethasone base 6 mg once daily for seven days
88878616|NCT04836780|Active Comparator|Standard of care|Standard care therapy
89190009|NCT04198831|Experimental|acupuncture group|Receiving acupuncture and moxibustion treatment
89190010|NCT04198831|Sham Comparator|sham acupuncture group|Receiving sham acupuncture and sham moxibustion treatment
89190011|NCT04198818|Experimental|Dose escalaltion study of HH2710|to determin the MTD of HH2710 and/or Recommended Phase II dose (RP2D).
89190012|NCT04195542||women in obstetric ward in Rennes CHU|women in obstetric ward in Rennes CHU
89190013|NCT04195542||CHU professionals|All CHU professionals contacted via their email address
88878617|NCT04793724|Experimental|Simeox first|Patients who will undergo Simeox intervention first. After three months cross-over to PARI O PEP intervention.
88878618|NCT04793724|Active Comparator|PARI O PEP first|Patients who will undergo PARI O PEP intervention first. After three months cross-over to Simeox intervention.
88878619|NCT04782492|Experimental|Y-composite graft|The saphenous vein is anastomosed to the middle portion of the left internal thoracic artery as Y-composite fashion. Then, left anterior descending artery, if targeted, is bypassed with left internal thoracic artery. Other native coronary arterial targets are bypassed with saphenous vein graft.
88878620|NCT04782492|Active Comparator|aortocoronary conduit|The saphenous vein is anastomosed to the ascending aorta as aortocoronary fashion. Then, left anterior descending artery, if targeted, is bypassed with left internal thoracic artery. Other native coronary arterial targets are bypassed with saphenous vein graft.
88878621|NCT04723680||Early dose finding cohort|People with Haemophilia who took part in the early dose finding studies
88878622|NCT04723680||Subsequent studies group cohort|People with haemophilia who took part in subsequent gene therapy studies
88878623|NCT04723680||Withdrawn/ineligible Cohort|People with haemophilia who were withdrawn or proved ineligible
88878624|NCT04723680||Not interested cohort|People with haemophilia who are definitely not interested in gene therapy
88878625|NCT04723680||Not offered cohort|People with haemophilia who are interested in gene therapy but have not been the opportunity to take part
88878626|NCT04705818|Experimental|Cohort A: pancreatic cancer|Patients with pancreatic cancer will be treated by durvalumab prescribed in association with tazemetostat
88878627|NCT04705818|Experimental|Cohort B: not MSI-H or MMR-deficient colorectal cancer|Patients with colorectal cancer will be treated bydurvalumab prescribed in association with tazemetostat
88878628|NCT04705818|Experimental|Cohort C: metastatic solid tumor|Patients with metastatic solid with positive interferon gamma signature and/or presence of tertiary lymphoid structurestumor will be treated bydurvalumab prescribed in association with tazemetostat
88878629|NCT04705818|Experimental|Cohort D: soft-tissue sarcoma|Patients with soft-tissue sarcoma will be treated by durvalumab prescribed in association with tazemetostat
88878630|NCT04703712|Active Comparator|Lens extraction combined with goniosynechialysis group|One hundred and fifty-eight patients with advanced angle-closure glaucoma underwent phacoemulsification combined with goniosynechialysis.
89403231|NCT05204446|Experimental|GROW Project|"(GROW Group): Live interactive telehealth-based group meetings will be held for 60 minutes per week over six weeks using Zoom for Telehealth, a HIPAA-compliant platform provided by the PI's institution. A teen group (n=8 per cohort) and a parent group (n=8 per cohort) will be run concurrently but separately, with coordinating topics. Each group meeting will introduce and facilitate discussion of information and CBT-oriented topics for coping and management of CD. Participants will be encouraged to use their audio and video to engage with the interventionist and each other. Between sessions, resources sent through text-based SMS messages using Twilio HIPAA-compliant software 3x/week as reminders of skills and goals for the week."
88878631|NCT04703712|Active Comparator|Trabeculectomy Group|One hundred and fifty-eight patients with advanced angle-closure glaucoma underwent trabeculectomy.
89190014|NCT04177758|Placebo Comparator|Control|Patients randomized to the control arm will receive placebo tablets and advised to consume their medication similar to the treatment arm.
89190015|NCT04177758|Experimental|Treatment|Patients randomized to the experimental arm of the study will receive 50,000IU of vitamin D3 following surgery and asked to take the medication orally following surgery.
89190016|NCT04172805|Experimental|anlotinib combined with Toripalimab|Anlotinib 12mg orally per day, two weeks on , one week off; 240 mg of toripalimab (fixed dose) every three weeks.
89530959|NCT02506907||Atherosclerotic|Patients with atherosclerotic intracranial stenosis
88878632|NCT04637724|Experimental|active tDCS|active prefrotal tDCS: 20 mins pes tDCS session, twice a day for 5 days. Total of 10 ative tDCS sessions.
88878633|NCT04637724|Sham Comparator|Sham tDCS|Sham prefrontal tDCS: sham stimulation 20 mins per session, twice a day for 5 days. Total of 10 sham stimulation sessions
88878634|NCT04626804|Experimental|1 Test the usability, perceptions, and acceptability of R/S|Dyads will use the R/S unit for 90 days, unless they request it to be removed prior to the end of the study. . The primary outcome is a caregiver-assessed measure usability.
88878635|NCT04610736|Experimental|Single arm|Temozolomide 40 mg/ml, Oral suspension
89004257|NCT05408429|Experimental|1-Dose 20vPnC Group|Pneumococcal conjugate vaccine
89004258|NCT05408429|Active Comparator|13vPnC Group|Pneumococcal conjugate vaccine
89403232|NCT05204446|No Intervention|Care-As-Usual|Participants assigned to the control group (n=32 dyads) will receive care as usual, which consists of appointments in the Celiac Disease Clinic (at diagnosis, 3 months post-diagnosis, 6 months post-diagnosis, and annually after diagnosis thereafter). These appointments consist of a gastrointestinal physician or nurse practitioner, dietitian, GFD educator, and psychologist for 40-minute consultations each.
89403233|NCT05204446|Experimental|GROW+ Project|"(GROW+ Group): Will include the GROW Project with enhanced behavioral strategies and materials identified from phase 2 data (e.g., group discussion about GIP testing, text-based check-ins, etc.) In addition, teens in GROW+ will be encouraged to complete a minimum of 2 GlutenDetect tests per week (12 total) and report results in REDCap (Research Electronic Data Capture, a secure, web-based survey application) throughout the intervention."
89403234|NCT05198349|Experimental|M1069|
88878636|NCT04610190|Experimental|Training with Gait Enhancing and Motivating System (GEMS-H) Robot|Training consists of 15 minutes task-specific training and 20-30 minutes functional gait training on varied environments with device.
89403235|NCT05197959|No Intervention|Group A-Control|Participants in this arm will not experience any intervention during a 4 week period of time. Participants will experience their standard medical care.
89403236|NCT05197959|Experimental|Group B-rTMS and sensorimotor training|Repetitive transcranial magnetic stimulation (rTMS) will be delivered at 10 Hz, 2000 pulses targeting the hand representation of the left primary motor cortex. Immediately following rTMS, participants will perform sensorimotor training. Nerve stimulation will be applied to the second through fifth digits and the wrist of the affected limb to cue movement. This intervention will be performed approximately 4 days per week for 4 weeks. In addition, participants will experience their standard medical care.
89403237|NCT05197959|Experimental|Group C-Sensorimotor training|Participants will perform sensorimotor training intervention. Nerve stimulation will be applied to the second through fifth digits and the wrist of the affected limb to cue movement. This intervention will be performed approximately 4 days per week for 4 weeks. In addition, participants will experience their standard medical care.
89403238|NCT05194007|Experimental|Experimental -Frondanol|Eligible participants will receive Frondanol capsule orally (1000 mg capsule twice daily) for 6 months
89403239|NCT05194007|Placebo Comparator|Placebo|Eligible participants will receive placebo capsule (twice daily) for 6 months
88878637|NCT04591236|Experimental|Gait training with brain stimulation|Treadmill gait training and transcranial direct current stimulation (tDCS) on the leg motor areas
88878638|NCT04591236|Active Comparator|Gait training with sham brain stimulation|Treadmill gait training and anodal sham transcranial direct current stimulation (tDCS) on the leg motor areas
88878639|NCT04575324|Experimental|Intervention Arm|Participants will receive the telemedicine linkage intervention.
88878640|NCT04575324|No Intervention|Control Arm|Participants will receive a standard referral to an in-person MOUD treatment appointment, which typically occurs within 24-72 hours. They also receive a bus pass to cover transportation (both directions), as well as an appointment reminder card.
89403240|NCT05186077||Healthy Controls|These participants will not have any psychiatric disorder as assessed by a structured clinical interview for psychiatric disorders.
88878641|NCT04529538|Experimental|Group1: nOPV1 (IPV History)|15-20 healthy adults fully vaccinated against polio exclusively by IPV will be administered 1 vaccination of novel OPV type 1 (nOPV1) containing 10^6.5 CCID50/dose.
88878642|NCT04529538|Active Comparator|Group 2: mOPV1 (IPV History)|15-20 healthy adults fully vaccinated against polio exclusively by IPV will be administered 1 vaccination of mOPV1 containing 10^6.0 CCID50/dose.
88878643|NCT04529538|Experimental|Group 3: nOPV1 (OPV History)|30-50 healthy adults fully vaccinated against polio by OPV will be administered 2 vaccinations of nOPV1 containing 10^6.5 CCID50/dose, given 28 days apart.
88878644|NCT04529538|Active Comparator|Group 4: mOPV1 (OPV History)|15-25 healthy adults fully vaccinated against polio by OPV will be administered 2 doses of mOPV1containing ≥ 10^6.0 CCID50/dose, given 28 days apart
88878645|NCT04529538|Experimental|Group 5: nOPV3 (IPV History)|15-20 healthy adults fully vaccinated against polio exclusively by IPV will be administered 1 vaccination of nOPV3 containing 10^6.5 CCID50/dose.
89403241|NCT05186077||Treatment-Responsive BD|This group will be composed of participants who have BDI or BDII and have most recently been depressed but are currently in remission with evidence-based treatments for bipolar disorder
89403242|NCT05186077||Treatment-Refractory BD|This group will be composed of participants who have BDI or BDII, are currently depressed or manic with their current episode lasting at least 6months and not responding to 2 or more adequate evidence-based treatments for BDI or BDII.
89403243|NCT05176132||OBESE (BMI>30)|BMI above 30 kg/m2 and being 18 to 60 years of age. Since the initiative is open for the general obese population, the investigators did not define the size of the cohort, but expect around 500 referrals per year.
89403244|NCT05176132||CONTROL Normal weight (BMI 20-25)|100 persons with normal weight (BMI 20 - 25 kg/m2) 18 to 60 years of age
89403245|NCT05176132||CONTROL Overweight (BMI 25-30)|100 persons with overweight (BMI 25 - 30 kg/m2) 18 to 60 years of age
89403246|NCT05175521|Placebo Comparator|Eucalyptus Oil Scent|Eucalyptus oil diluted in mineral oil 1:20
89403247|NCT05175521|Active Comparator|Isopropyl Alcohol Vapors|Isopropyl Alcohol 70%
89403248|NCT05169424||Stiolto initiators|"Chronic obstructive pulmonary disease (COPD) patients who initiated with Stiolto Respimat (Tiotropium + Olodaterol (5/5 micrograms (mcg)) in the existing real-world data from the Commercial Insurance and Medicare beneficiaries data using administrative claims between 15 September 2016 and 31st March 2020.~All participants had enrolled 1 year before the index date (starting from 15 September 2017)."
89403249|NCT05169424||Trelegy initiators|"COPD patients who initiated with Trelegy Ellipta (Fluticasone Furoate + Umeclidinium + Vilanterol (100/62.5/25 mcg) in the existing real-world data from the Commercial Insurance and Medicare beneficiaries data using administrative claims between 15 September 2016 and 31st March 2020.~All participants had enrolled 1 year before the index date (starting from 15 September 2017)."
89403250|NCT05165576|Experimental|Child-centered communication|The child's preparation for the MRI scanning is conducted using a child-centered communication type of interaction
88878646|NCT04529538|Active Comparator|Group 6: mOPV3 (IPV History)|15-20 healthy adults fully vaccination against polio by exclusively IPV will be administered 1 vaccination of mOPV3 containing ≥ 10^5.8 CCID50/dose.
88878647|NCT04529538|Experimental|Group 7: nOPV3 (OPV History)|30-50 healthy adults fully vaccinated against polio by OPV will be administered 2 vaccinations of nOPV3 in a dose of 10^6.5 CCID50/dose, given 28 days apart.
88878648|NCT04529538|Active Comparator|Group 8: mOPV3 (OPV History)|15-25 healthy adults fully vaccinated against polio by OPV will be administered 2 vaccinations of mOPV3 containing ≥ 10^5.8 CCID50/dose, given 28 days apart.
88878649|NCT04521114|Experimental|Leronlimab 700 mg|Leronlimab 700 mg SC weekly injection
89403251|NCT05165576|Active Comparator|Magnetic Resonance Imaging (MRI) Simulation Toy|The child's preparation for the MRI scanning is conducted through provision of general information about the MRI exam simulated with an MRI toy
89403252|NCT05165576|No Intervention|General information about the Magnetic Resonance Imaging (MRI) exam|The child's preparation for the MRI scanning is based on the provision of routine information about the MRI exam
88878650|NCT04521114|Experimental|Leronlimab 350 mg|Leronlimab 350 mg SC weekly injection
89403253|NCT05165186|Experimental|Video Intervention Arm|For participants randomized to the video intervention arm, participants will be shown two videos about Advanced Care Planning, and then they will be asked questions regarding the usefulness of the video and their comfort with the video
89403254|NCT05165186|No Intervention|Control Arm|For participants randomized to the control group arm, participants will review an informational sheet, which covers the same information as the videos shown to the intervention arm.
88878651|NCT04521114|Placebo Comparator|Placebo|Placebo SC weekly injection
88878652|NCT04510272|Experimental|High risk critically ill patients|Critically ill patients requiring vasopressor support or mechanical ventilation will receive aloud real time ICU diary reading intervention
88878653|NCT04494360||Healthy Participants|Healthy participants (men and women) who have, or are likely to have, NAFLD will be enrolled in the study.
88878654|NCT04471974|Experimental|Safety Cohort|Patients receive 96mg pembrolizumab IV over 30 minutes on day 1, BET bromodomain inhibitor ZEN-3694 PO QD and enzalutamide PO QD on days 1-21. Patients not on enzalutamide prior to study enrollment or have previously discontinued enzalutamide receive BET bromodomain inhibitor ZEN-3694 beginning on day 1 of cycle 2. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
88878655|NCT04471974|Experimental|Cohort A: Transdifferentiated mCRPC|Patients receive pembrolizumab IV over 30 minutes on day 1, BET bromodomain inhibitor ZEN-3694 PO QD and enzalutamide PO QD on days 1-21. Patients not on enzalutamide prior to study enrollment or have previously discontinued enzalutamide receive BET bromodomain inhibitor ZEN-3694 beginning on day 1 of cycle 2. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
88878656|NCT04471974|Experimental|Cohort B: mCRPC without evidence of transdifferentiation|Patients receive pembrolizumab IV over 30 minutes on day 1, BET bromodomain inhibitor ZEN-3694 PO QD and enzalutamide PO QD on days 1-21. Patients not on enzalutamide prior to study enrollment or have previously discontinued enzalutamide receive BET bromodomain inhibitor ZEN-3694 beginning on day 1 of cycle 2. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
88878657|NCT04470648||hosted in the center and HCWs at the epidemic period|"people hosted in the health care or in the women center and health care workers working in one these centers during the epidemic time.~People with initial positive SARS-COV2 serology will have a second blood test to mesure atibodies kinetic"
88878658|NCT04389216|Experimental|Radiofrequency|Radiofrequency Ablation of breast cancer tumour by Cool-tip electrode.
88878659|NCT04360824|Active Comparator|Standard of Care|1) Patients randomized to the standard of care arm will receive standard prophylactic dose enoxaparin (40 mg subcutaneously daily if BMI <30kg/m2 and 30 mg subcutaneously twice daily or 40 mg subcutaneously twice daily if BMI ≥ 30kg/m2).
88878660|NCT04360824|Other|Interventional|2) Patients randomized to the intervention arm will receive intermediate-dose enoxaparin (1 mg/kg Subcutaneously daily if BMI<30 kg/m2 or 0.5 mg/kg Subcutaneously twice daily if BMI ≥ 30kg/m2).
88878661|NCT04331652|Experimental|Polypectomy without anesthesia or analgo-sedation|Patient will undergo polypectomy without anesthesia.
88878662|NCT04288128||SCA early-manifest and premanifest patients|This cohort is defined by individuals with a SARA score between 0 and 15 (both values included).
89403255|NCT05155046|Experimental|18F-DCFPyL imaging|18F-DCFPyL imaging with routine imaging (mpMRI)
88878663|NCT04288128||Control participants|This cohort is defined by individuals with a SARA score less than 5 and no significant neurological symptoms.
89403256|NCT05150691|Experimental|DB-1303 Dose Level 1|Enrolled Subjects will receive a single-dose of DB-1303 at Dose Level 1 on Day 1 of each cycle Q3W
88878664|NCT04261296|Experimental|Dry needling|Arm 1: Dry needling group. Dry needling will be done with painful trigger point and it will be waited for about 20 minutes. This treatment will be repeated once a week for 3 weeks.No medication is used in this treatment.
89403257|NCT05150691|Experimental|DB-1303 Dose Level 2|Enrolled Subjects will receive a single-dose of DB-1303 at Dose Level 2 on Day 1 of each cycle Q3W
88878665|NCT04261296|Experimental|balneotherapy|Arm 2: Balneotherapy A total of 15 sessions, 20 minutes a day, 5 days a week for 3 weeks, will be held in the spa, which operates within the body of Kırşehir Ahi Evran University Physical Therapy and Rehabilitation Center.
88878666|NCT04261296|Experimental|Dry needling + balneotherapy|Arm3: dry needling + balneotherapy Both of these methods will be applied to patients in the third group.
88878667|NCT04243590||Neonatal brachial plexus palsy|"25 patients will be included. The level of the brachial plexus lesion will be recorded. Parents of all patients were asked to fill in the Turkish version of the Hand-at-Home Questionnaire and in addition, the upper extremity section of the Pediatric Outcomes Data Collection Instrument (PODCI) in patients with OBP."
88878668|NCT04243590||Unilateral cerebral palsy|"25 patients will be included. The level of Manual Ability Classification System (MACS) will be recorded. Parents of all patients were asked to fill out the Turkish version of the Hand-at-Home Questionnaire at Home, as well as the Children's Hand-Use Experience Questionnaire (CHEQ) in patients with CP."
88878669|NCT04198350|Experimental|Islet implantation|
88878670|NCT04174716|Experimental|IDX-1197|Patient will be receive IDX-1197HCl once daily for 28 continuous days
88878671|NCT04159740||Endometriosis - Cases|Premenopausal women with suspected endometriosis, planning to undergo laparoscopic surgery.
88878672|NCT04159740||Controls|Premenopausal women without endometriosis, planning to undergo laparoscopic surgery for non-cancer indications including elective salpingectomy, tubal ligation or surgical procedures for abnormal uterine bleeding
88878673|NCT04122924|Experimental|Intervention Group|A three months home-based abdominal muscle training program.
88878674|NCT04122924|No Intervention|Control Group|The control group will have no intervention, and will be asked not to attend any specific supervised abdominal muscle training program during the 3 months intervention period.
88878675|NCT04055298|Other|Patients|"The study will be performed at the Walk-in-Clinic (WIC) and Interdisciplinary Emergency Department (ED) of the cantonal hospital of Baden, Switzerland. During their stay at the WIC or ED the patients will be invited to use the triage-symptom-checker SMASS-Triage.~In this study, the patient's self-triage using a symptom checker will be compared with the urgency assessments conducted by three interdisciplinary panels of physicians (panel A, B and C). In order to appropriately reflect the complex interaction in medical decision-making, which usually leads to a low inter-rater reliability, the cases assessed to be undertriaged by panel A, are subsequently assessed a second time by two panelist of panel B. Cases which are adjudged to be undertriaged by all panelist (panel A and B), are assessed for a risk to health or life by panel C. The risk assessments of panel C will be based on the structured reports generated by the symptom-checker and the discharge summaries of the WIC/ED."
88878676|NCT04049214|Other|Meditation|Two guided meditations will be provided to participants. They will be asked to meditate twice daily, once in the morning once before bed, for a total time of 12 minutes per day. Surgical treatment and postoperative care will be provided by surgeon preference and usual practice, including post-operative pain medications. For 12 weeks patients will maintain a daily meditation log, medication log and complete daily pain assessment questionnaire.
88878677|NCT04042038|Experimental|CBT|Intensive CBT (20 sessions in 1 month)
88878678|NCT04042038|No Intervention|Waiting-list|Waiting-list
88878679|NCT03990792|Experimental|e-predictD intervention|In this arm, patients will receive a personalized intervention to prevent depression based on ICTs, risk predictive algorithms and decision support systems (DSS) for patients and General Practitioners (GPs).
88878680|NCT03990792|Active Comparator|m-Health control|In this arm, patients will continue receiving the usual care from their GPs. In addition, they will use an App with the same appearance as the e-predictD App but it will only send weekly messages about physical and mental health management. This intervention is not personalized and does not include GP training and GP-patient interview.
88878681|NCT03952338|Experimental|Nutrition Coupons|Participants in the FMNCP group will receive 16 coupon sheets (each sheet contains $21 in coupons) over 10-15 weeks (households with 5-8 individuals will receive 32 coupon sheets) to purchase fruits, vegetables, dairy, meat/poultry/fish, eggs, nuts, and cut herbs at participating BC farmers' markets. To ensure participants receive all 16 coupon sheets, community partners will provide two coupon sheets per household during the first 1-6 weeks of the intervention. Participants in the FMNCP group will also be invited to participate in nutrition skill-building activities (e.g., cooking classes) offered by community partners throughout the intervention period, however participation is not required (this is consistent with the existing FMNCP).
88878682|NCT03952338|No Intervention|Control|No intervention provided. Participants will be eligible to participate in the BC Farmers' Market Nutrition Coupon Program during the next farmers' market season (i.e. one year following the current intervention).
88878683|NCT03941106|Experimental|Left aTMS|
88878684|NCT03941106|Experimental|Right aTMS|
88878685|NCT03903666|Experimental|Cohort|47 Down syndrome patients age from 4 to 16
89403258|NCT05150691|Experimental|DB-1303 Dose Level 3|Enrolled Subjects will receive a single-dose of DB-1303 at Dose Level 3 on Day 1 of each cycle Q3W
89403259|NCT05150691|Experimental|DB-1303 Dose Level 4|Enrolled Subjects will receive a single-dose of DB-1303 at Dose Level 4 on Day 1 of each cycle Q3W
89403260|NCT05150691|Experimental|DB-1303 Dose Level 5|Enrolled Subjects will receive a single-dose of DB-1303 at Dose Level 5 on Day 1 of each cycle Q3W
88878686|NCT03853356||Lumbar spondylodesis involving 1-2 levels (L4-L5 and/or L5-S1)|All surgical procedures to be performed during this clinical trial are part of the routine procedures for lumbar spondylodesis by using transforaminal lumbar interbody fusion (TLIF) and posterior lumbar interbody fusion (PLIF) techniques in the 1-2 levels (L4-L5 and/or L5-S1). Patients will receive surgery according to standard procedures.
88878687|NCT03846570|Active Comparator|Formoterol-beclomethasone|Formoterol (fumarate dehydrate) 12 microg - beclomethasone (dipropionate) 200 microg administered BID, per inhalation using '100/6' Metered Dose Inhaler.
88878688|NCT03846570|Placebo Comparator|Placebo|Matching placebo (identically package) administered BID
88878689|NCT03838848|Experimental|Cohort A|Subjects with Non-small Cell Lung Cancer (NSCLC) (failed or did not tolerant to platinum-containing regime and did not treat with programmed cell death protein 1/the programmed death-ligand 1 (PD1/PDL-1) checkpoint inhibitor previously) will receive KN046 3 milligram per kilogram (mg/kg), every other weeks (Q2W)
88878690|NCT03838848|Experimental|Cohort B|Subjects with NSCLC (failed or did not tolerant to platinum-containing regime and did not treat with PD1/PDL-1 checkpoint inhibitor previously) will receive KN046 5 mg/kg, Q2W
88878691|NCT03838848|Experimental|Cohort C|Subjects with NSCLC (failed or did not tolerant to platinum-containing regime and failed to PD1/PDL-1 checkpoint inhibitor) will receive KN046
88878692|NCT03838848|Experimental|Cohort D|1L NSCLC (EGFR-sensitive mutation (Ex19del or L858R), progression after at least one line treatemtn of EGFR TKIs, and no prior systemic platinum-containing chemotherapy), will receive KN046 5 mg/kg Q3W in combination with pemetrexed and carboplatin
88878693|NCT03838848|Experimental|Cohort E|≥ 2L NSCLC (failure or intolerance of 1L platinum-doublet chemotherapy; and failure of PD-1/PD-L1 checkpoint inhibitor therapy), will receive KN046 in combination with ningetinib
88878694|NCT03787602|Experimental|Cohort 1, Arm 1|KRT-232 will be administered orally, once daily (QD) on Days 1-7 in a 21-day cycle.
88878695|NCT03787602|Experimental|Cohort 1, Arm 1b|KRT-232 will be administered orally, once daily (QD) on Days 1-5 in a 23-day cycle.
88878696|NCT03787602|Experimental|Cohort 1, Arm 2b|KRT-232 will be administered orally, once daily (QD) on Days 1-5 in a 28-day cycle.
88878697|NCT03787602|Experimental|Cohort 1, Arm 3|KRT-232 will be administered orally, once daily (QD) on Days 1-7 in a 21-day cycle.
88878698|NCT03787602|Experimental|Cohort 1, Arm 5|KRT-232 will be administered orally, once daily (QD) on Days 1-7 in a 28-day cycle.
88878699|NCT03787602|Experimental|Cohort 1 Expansion|KRT-232 will be administered orally, once daily (QD) per Cohort 1 RP2D dose and schedule.
88878700|NCT03787602|Experimental|Cohort 2, Arm 1 KRT-232 in combination with avelumab|KRT-232 will be administered orally, once daily (QD) on Days 1-5, in combination with avelumab 800 mg IV on Day 1 and 15 in a 28-day cycle.
89190017|NCT04150458|Experimental|Fluorocholine PET/CT|The sole study-specific procedure is a single 18F-fluorocholine positron emission tomography / computed tomography (PET/CT). Subjects will receive 9 mCi 18F-fluorocholine IV, 5 to 120 minutes prior to PET/CT. 18F-fluorocholine PET/CT studies will be performed on hybrid PET/CT scanners which combine a dedicated, full-ring PET scanner with a multi-slice spiral CT scanner.
89190018|NCT04147208|Experimental|Combination group|Subjects will receive 96 weeks of GLS4+RTV+ETV.
88878701|NCT03787602|Experimental|Cohort 2, Arm 2 KRT-232 in combination with avelumab|KRT-232 will be administered orally, once daily (QD) on Days 1-7, in combination with avelumab 800 mg IV on Day 1 and 15 in a 28-day cycle.
89190019|NCT04147208|Active Comparator|Entecavir monotherapy|Subjects received 96 weeks of entecavir treatment
89190020|NCT04137510|Experimental|Orsiro|
89190021|NCT04137510|Active Comparator|Resolute Onyx|
89190022|NCT04120688|Active Comparator|Effect on surgery|Duration of surgery, degree of manipulation of the transplant
89190023|NCT04120688|Active Comparator|Success of transplantation|Normal eruption and root development of the transplant
89190024|NCT04085991|Experimental|131I-PSMA-1095 Radioligand Therapy (RLT)|Intravenous injection of 100 mCi of 131I-PSMA-1095 RLT, Q8 weeks up to a maximum of 4 doses
89190025|NCT04072991|Active Comparator|Low FODMAP diet|As part of their treatment for IBS participants may be randomised to a low FODMAP diet
88878702|NCT03787602|Experimental|Cohort 2 Expansion|KRT-232 will be administered orally, once daily (QD) per RP2D dose and schedule, in combination with avelumab 800 mg IV on Day 1 and 15 in a 28-day cycle.
89190026|NCT04072991|Active Comparator|Gluten Free Diet|As part of their treatment for IBS participants may be randomised to a gluten free diet
89190027|NCT04072991|Active Comparator|British Dietetic Association diet|As part of their treatment for IBS participants may be randomised to the BDA diet
89190028|NCT04047771|Experimental|SCB-313|
89403261|NCT05150691|Experimental|DB-1303 Dose Expansion 1|Enrolled Subjects will be randomized to receive a single-dose of DB-1303 on a selected dose level 1 or dose level 2 Day 1 of each cycle Q3W
89403262|NCT05150691|Experimental|DB-1303 Dose Expansion 2|Enrolled Subjects will receive a single-dose of DB-1303 on a selected dose level (RP2D) Day 1 of each cycle Q3W
89403263|NCT05150691|Experimental|DB-1303 Dose Expansion 3|Enrolled Subjects will receive a single-dose of DB-1303 on a selected dose level (RP2D) Day 1 of each cycle Q3W
88878703|NCT03787602|Experimental|Cohort 3|KRT-232 will be administered orally, once daily (QD) per Cohort 1 RP2D dose and schedule.
88878704|NCT03787602|Experimental|Cohort 4|KRT-232 will be administered orally, once daily (QD) per Cohort 1 RP2D dose and schedule.
88878705|NCT03778164|Experimental|Fast Track Intervention|This arm refers to the new Partner Services-Sexual Health intervention offered to contacts by the Partner Services program
88878706|NCT03778164|Active Comparator|Standard of Care|This arm refers to the current standard practice for partners contacted by the Partner Services program
88878707|NCT03745170|Experimental|Sintilimab+ Oxaliplatin +capecitabine|
88878708|NCT03745170|Active Comparator|placebo +Oxaliplatin + Capecitabine|
88878709|NCT03711786|Active Comparator|Basic implementation package|Ten Malawi non-communicable diseases clinics will be randomized 1:1 to one of two implementation strategies to be used for two years followed by a 12-month follow-up period.
88878710|NCT03711786|Experimental|Enhanced implementation package|Ten Malawi non-communicable diseases clinics will be randomized 1:1 to one of two implementation strategies to be used for two years followed by a 12-month follow-up period.
88878711|NCT03701490|Experimental|Prolutex|
88878712|NCT03701490|Experimental|Progeffik|
88878713|NCT03723720||Patients after colonoscopy over 50 years|All colonoscopies in patients over 50 years of age (screening, surveillance, diagnostic) excluding therapeutic, IBD, management of complications and sigmoidoscopies
89190029|NCT04025931|Experimental|chidamide combined with Toripalimab|"chidamide 30mg orally twice a week;~240 mg of toripalimab (fixed dose) every three weeks.~Repeat every three weeks. Patients with disease control (CR + PR + SD) and tolerable adverse reactions continued to take medication until the researchers concluded that patients were not suitable to continue medication or the efficacy evaluation was disease progression (PD). No other antineoplastic treatment can be given during the treatment."
89190030|NCT04003103|Experimental|Islatravir 60 mg|60 mg islatravir + placebo for islatravir administered once monthly, orally in capsule form for 24 weeks
88878714|NCT03694392||Flublok Recipients|Kaiser Permanente Northern California members aged 18-64 years who receive Flublok Quadrivalent vaccine.
88878715|NCT03694392||SD-IIV Recipients|Kaiser Permanente Northern California members aged 18-64 years who receive standard dose inactivated influenza vaccine (SD-IIV).
88878716|NCT03691974|Experimental|Fasinumab|
88878717|NCT03691974|Placebo Comparator|Placebo|
88878718|NCT03675360|Experimental|Low-Carbohydrate Diet|"Behavioral modification to reduce carbohydrate consumption. Target <40 g net carbohydrates per day for first 3 months; <60 g net carbohydrates per day for months 4 onwards. The intervention will consist of 4 weekly individual counseling sessions, followed by 4 group sessions held every other week, with phone follow-ups in between group sessions. For the last 3 months of the study, there will be 3 monthly group sessions and 3 telephone follow-ups.~At baseline, participants will receive written information with standard physical activity recommendations."
88878719|NCT03675360|No Intervention|Usual Diet|"No dietary intervention.~At baseline, participants will receive written information with standard dietary advice and standard physical activity recommendations."
88878720|NCT03571776|Active Comparator|Surgery|Laparoscopic ovarian cystectomy
88878721|NCT03571776|Active Comparator|Sclerotherapy|US-aspiration and alcohol sclerosis
88878722|NCT03306576|Experimental|ELS Extra composite|Commercially available composite resin restorative that will be used for direct restoration as per manufacturer's instructions
88878723|NCT03306576|Active Comparator|ELS composite|Commercially available composite resin restorative that will be used for direct restoration as per manufacturer's instructions
88878724|NCT03272022||women|never-pregnant women
88878725|NCT03272022||pregnant women|pregnant
88878726|NCT03207984|Active Comparator|Control SCTG|Root coverage surgery with subepithelial connective tissue graft to an extensive treat multiple gingival recessions in aesthetic areas
88878727|NCT03207984|Experimental|Test CM|Root coverage surgery with Mucograft® collagen matrix to treat an extensive multiple gingival recessions in aesthetic areas
88878728|NCT02972034|Experimental|A: MK-8353 BID Continuous+Pembro|Participants receive MK-8353 orally (PO) two times each day (BID) on Days 1 through 21 of each 21-day cycle PLUS pembrolizumab (pembro) 200 mg intravenously (IV) on Day 1 of each 21-day cycle for up to 35 cycles.
89190031|NCT04003103|Experimental|Islatravir 120 mg|120 mg islatravir administered once monthly, orally in capsule form for 24 weeks
89190032|NCT04003103|Placebo Comparator|Placebo|Placebo for islatravir administered once monthly, orally in capsule form for 24 weeks
89190033|NCT03999216|Active Comparator|Loop only|Participants will receive a loop diuretic for up to the first 72 hours of hospitalization. The specific drug, dose and route are left to the treating providers.
88878729|NCT02972034|Experimental|B: MK-8353 QD Continuous+Pembro|Participants receive MK-8353 PO once each day (QD) on Days 1 through 21 of each 21-day cycle PLUS pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
88878730|NCT02972034|Experimental|C: MK-8353 QD 1 Week On/1 Week Off+Pembro|Optional Arm: Participants receive MK-8353 PO QD on Days 1 to 7, Days 15 to 21 and Days 29 to 35 PLUS pembrolizumab 200 mg IV on Day 1 and Day 22 of each 42-day period (based on 2 cycles of 21 days) for up to 35 cycles.
88878731|NCT02972034|Experimental|D: MK-8353 QD Run-in→MK-8353 QD Continuous+Pembro|Optional Arm: Participants undergo an MK-8353 PO QD run-in period from Day -14 to Day -1 prior to Cycle 1 during which they receive MK-8353 PO QD. After the run-in period, participants receive MK-8353 PO QD on Days 1 through 21 of each 21-day cycle PLUS pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 36 cycles.
88878732|NCT02882802|Experimental|Mindfulness Based Stress Reduction|Mindfulness Based Stress Reduction (MBSR) is a group-based intervention in which participants are taught different mindfulness meditation practices, including body scan (focusing attention to different areas of the body in sequence), sitting meditation (focusing attention to one's breathing), and Hatha yoga postures (focusing attention to different body sensations during gentle stretching). Participants also are taught how to practice mindfulness while engaging in ordinary activities including walking, standing, and eating. MBSR consists of 8, two-hour weekly sessions and will be delivered in group format. MBSR groups will be delivered virtually.
88878733|NCT02882802|Active Comparator|Trauma Recovery Education Class|Trauma Recovery Education Class (TREC): TREC is a group based treatment that focuses on providing information on PTSD and traumatic reactions. TREC provides psycho-education to Veterans on PTSD, including common reactions to trauma and the role of avoidance, common problems associated with PTSD, as well as common barriers to care (e.g., stigma, maladaptive beliefs, fear). Additional content focuses on problem identification and goal setting, discussion of current problems and life issues, and treatment planning. TREC consists of 8, one-hour weekly sessions. TREC groups will be delivered virtually.
88878734|NCT02454972|Experimental|lurbinectedin (PM01183)|lurbinectedin (PM01183) 4 mg vials of powder for concentrate for solution for infusion
89190034|NCT03999216|Active Comparator|Loop + Thiazide|Participants will receive a loop+thiazide diuretic for up to the first 72 hours of hospitalization. The specific drugs, doses and routes are left to the treating providers.
89403264|NCT05150691|Experimental|DB-1303 Dose Expansion 4|Enrolled Subjects will receive a single-dose of DB-1303 on a selected dose level (RP2D) Day 1 of each cycle Q3W
89403265|NCT05150691|Experimental|DB-1303 Dose Expansion 5|Enrolled Subjects will receive a single-dose of DB-1303 on a selected dose level (RP2D) Day 1 of each cycle Q3W
88878735|NCT02140944||Pre-Transplant Cohort|HIV-1 infected participants, enrolled prior to transplant, who receive a heterozygous or homozygous CCR∆32 cord blood transplant
88878736|NCT02140944||Post-Transplant Cohort|HIV-1 infected participants, enrolled within 2 years after transplant, who receive a homozygous CCR∆32 cord blood transplant
88878737|NCT02025270|Other|Laboratory and Clinical|60 ml of Bone marrow will aspirated for stem cells isolation and preparation. 5 ml of stem cells prepared according to GMP rules injected into rete testis.
88878738|NCT01649388|Experimental|FCR001|Recipients 3-12 months post-living kidney transplantation undergo non-myeloablative conditioning followed by infusion of an enriched hematopoietic stem cell product derived from the same living donor's peripheral blood stem cells
88878739|NCT01394016|Experimental|LY2835219|
88878740|NCT00978822|Experimental|Clevidipine butyrate injectable emulsion|
88878741|NCT00063882|Experimental|EBRT + Brachytherapy|External beam radiation therapy (EBRT) and transperineal interstitial permanent brachytherapy (100/110)
88878742|NCT00063882|Active Comparator|Brachytherapy Only|Transperineal interstitial permanent brachytherapy (125/145)
88878743|NCT00002796|Experimental|Treatment (fluorouracil, phenylbutyrate, indomethacin, IFN-G|"Phase I: Patients receive 5-FU IV over 24 hours on day 1; phenylbutyrate IV over 120 hours and oral indomethacin daily on days 2-6; and interferon gamma subcutaneously on days 2, 4, and 6. Courses repeat weekly in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of 5-FU until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which less than 2 of 6 patients experience dose-limiting toxicity (DLT).~Phase II: Patients receive 5-FU, phenylbutyrate, indomethacin, and interferon gamma as in phase I at the MTD."
88878744|NCT00002832|Experimental|Decitabine + Stem Cell Transplantation|
88878745|NCT00002838|Experimental|Combination Chemotherapy + PSCT|PSCT = Peripheral Stem Cell Transplantation
89403266|NCT05150691|Experimental|DB-1303 Dose Level 6|Enrolled Subjects will receive a single-dose of DB-1303 at Dose Level 6 on Day 1 of each cycle Q3W
89403267|NCT05150691|Experimental|DB-1303 Dose Level 7|Enrolled Subjects will receive a single-dose of DB-1303 at Dose Level 7 on Day 1 of each cycle Q3W
89403268|NCT05150691|Experimental|DB-1303 Dose Expansion 6|Enrolled Subjects will receive a single-dose of DB-1303 on a selected dose level (RP2D) Day 1 of each cycle Q3W
89403269|NCT05150691|Experimental|DB-1303 Dose Expansion 7|Enrolled Subjects will receive a single-dose of DB-1303 on a selected dose level (RP2D) Day 1 of each cycle Q3W
89403270|NCT05150691|Experimental|DB-1303 Dose Expansion 8|Enrolled Subjects will receive a single-dose of DB-1303 on a selected dose level (RP2D) Day 1 of each cycle Q3W
89403271|NCT05150691|Experimental|DB-1303 Dose Expansion 9|Enrolled Subjects will be randomized to receive a single-dose of DB-1303 on a selected dose level 1 or dose level 2 on Day 1 of each cycle Q3W
89403272|NCT05150691|Experimental|DB-1303 Dose Expansion 10|Enrolled Subjects will receive a single-dose of DB-1303 on a selected dose level (RP2D) Day 1 of each cycle Q3W along with ritonavir and itraconazole to assess the DDI potential
89403273|NCT05150691|Experimental|DB-1303 Dose Expansion 11|Enrolled Subjects will receive a single-dose of DB-1303 on a selected dose level (RP2D) Day 1 of each cycle Q3W
89403274|NCT05150691|Experimental|DB-1303 Dose Expansion 12|Enrolled Subjects will receive a single-dose of DB-1303 on a selected dose level 1 or dose level 2 in combination with Pertuzumab on Day 1 of each cycle Q3W
89403275|NCT05150691|Experimental|DB-1303 Dose Expansion 13|Enrolled Subjects will receive a single-dose of DB-1303 on a selected dose level (RP2D) Day 1 of each cycle Q3W
88878746|NCT00002844|Experimental|Cyclophosphamide + TBI + BMT|TBI = Total Body Irradiation and BMT = Bone Marrow Transplantation (allogeneic or autologous bone marrow)
88878747|NCT00002862|Experimental|Arm I|Groups of 3-6 patients receive escalating doses of oral perillyl alcohol three times per day until the maximum tolerated dose or recommended phase II dose is determined. Treatment at the assigned dose continues until disease progression or unacceptable toxicity intervenes. Patients with stable disease after 8 weeks of treatment are removed from study.
89403276|NCT05139160|Experimental|Whey protein isolate|Whey protein isolate is the 'gold standard' of protein supplements due to being rich in essential amino acids and leucine. Leucine is a key amino acid the is required to stimulate muscle protein synthesis. Muscle protein synthesis is the major mechanism the underpins muscle growth. The whey protein would ostensibly serve as a positive control.
89190035|NCT03989401|Experimental|Multimedia video education|The experimental group conducted multimedia video education while admission.
89403277|NCT05139160|Experimental|Plant based protein isolate|Current plant-based protein isolates available contain insufficient amounts of leucine, and are less digestible, resulting in a reduced muscle protein synthesis responses. The plant based protein would ostensibly serve as a negative control.
89403278|NCT05139160|Experimental|Plant based protein isolate + leucine|Enriching plant-based protein with leucine will increase the 'quality' of said protein source and theoretically should have similar muscle protein synthetic responses to whey protein.
89403279|NCT05132491|Experimental|Online Training Program|An online intervention for people with disabilities intended to increase social skills and interest in coding careers.
89403280|NCT05129527|Experimental|InspirerMundi app plus usual care|Patients, in addition to usual care, will be invited to use the InspirerMundi app for 4 months to support adherence to preventive inhaled medication and their asthma self-management.
89403281|NCT05129527|Active Comparator|Usual care|Patients in the control group will maintain usual care during the study.
89403282|NCT05126784|Experimental|AVT03 Arm|AVT03 (denosumab) is the proposed biosimilar for Prolia (denosumab). Subjects in this arm will receive a single 60mg dose of AVT03 (denosumab) as a subcutaneous injection.
89403283|NCT05126784|Active Comparator|Prolia Arm|Prolia(denosumab) is the proposed comparator for AVT03 (denosumab). Subjects in this arm will receive a single 60mg dose of Prolia (denosumab) as a subcutaneous injection.
89403284|NCT05122806|Other|Bioexalk cohort|All patients included in Explore ALK GFPC 03-2019 study who agree to participate in Bioexalk.
89403285|NCT05114187|Experimental|Education Intervention|
89403286|NCT05114187|Active Comparator|Education Control|
88878748|NCT00002880|Experimental|Etoposide|Oral etoposide for relapsed or refractory non-Hodgkin's lymphoma
88878749|NCT00002946|Experimental|Arm I|atients enrolled on the bioavailability portion of this study receive one dose of IV penclomedine over 1 hour followed by 2 weeks of rest. At the end of two weeks, they receive oral penclomedine for 5 days every 28 days. The starting dose is determined by a single primary patient who has been administered oral penclomedine and observed for dose limiting toxicity (DLT). [Bioavailability portion completed as of 3/98.] Those not on the bioavailability portion of study start on a standard design dose escalating schedule in which patients enroll in cohorts of 3. Patients are administered oral penclomedine daily for 5 days. This treatment repeats every 4 weeks. The MTD is defined as the dose immediately below that at which 2 patients experience DLT. Treatment repeats for 6 courses or until severe toxicity or tumor progression is observed.
88878750|NCT00002952|Experimental|Arm A|Melan-A peptide loaded PBMCs (sc, q3wk x 3), rhIL-12 (4 mcg, sc, days 1, 3 and 5 of every 3 wk cycle)
88878751|NCT00002970|Experimental|Arm I|"GROUP 1: Patients receive a 1 hour infusion of compound 506U78 daily for 5 days in the absence of neurologic toxicity. The course repeats every 21 days. If a first relapse T-cell ALL study of higher priority is not open, then the patient may continue to receive the drug every 21 days for a maximum of 2 years provided that the patient has achieved a second complete response.~GROUPS 2 and 4: Patients receive compound 506U78 every 21 days for a maximum of 2 years, in the absence of disease progression. After 3 courses a patient may be given CNS prophylaxis with triple intrathecal therapy (TIT), consisting of methotrexate, cytarabine and hydrocortisone after consultation with study coordinator. TIT should be given every 12 weeks.~GROUP 3: Patients receive compound 506U78 every 21 days for a maximum of 2 years, in the absence of disease progression. TIT will be given on day 1 of weeks 1-4, 6, 9 and every 6 weeks for 12 weeks, and then every 9 weeks thereafter. This stratum is open."
88878752|NCT00002994|Experimental|Monoclonal antibody + interleukin 2|"Cycle 1: low dose IL2 days 1-7; MoAb day 7; intermediate dose IL-2 days 8-10; Low dose IL2 days 11-20.~Cycle 2 & all subsequent cycles: MoAb day 1; intermediate dose IL2 days 1-3; low dose IL2 days 4-14"
88878753|NCT00003006||Group 1|At the time of thoracotomy and pulmonary resection, patients have samples of bone marrow, primary tumor, and intrathoracic lymph nodes harvested. The presence of occult metastases in bone marrow and lymph nodes is assessed using immunohistochemistry or reverse transcriptase-polymerase chain reaction.
88878754|NCT00003048|Experimental|Amifostine|Amifostine IV 2 weeks, followed by 2 weeks rest (4 week cycle)
88878755|NCT00003084|Experimental|Arm I (Estramustine + Etoposide)|Arm I: Oral Estramustine 3 x day + oral Etoposide 2 x day on days 1-14 + Paclitaxel IV over 1 hour Day 2, repeats every 21 days.
88878756|NCT00003084|Experimental|Arm II (Chemotherapy + Ketoconazole)|Arm II: Doxorubicin IV Days 1, 15, and 29, Vinblastine IV Days 8, 22, and 36, Oral Ketoconazole 3 x day on Days 1-7, 15-21, + 29-35, and Oral Estramustine 3 x day on Days 8-14, 22-28, and 36-42; 6 weeks of alternating chemotherapy and 2 weeks rest, for 8 week course.
88878757|NCT00003120|Active Comparator|paclitaxel 3 cycles|paclitaxel given for 3 cycles
89190036|NCT03989401|No Intervention|None multimedia video education|The control group conducted usual nursing of oral face-to-face education on admission.
89403287|NCT05098509|Active Comparator|RAD011 40 milligrams per kilogram (mg/kg)|Participants were administered 40 mg/kg of RAD011 orally daily with food.
89403288|NCT05098509|Active Comparator|RAD011 20 mg/kg|Participants were administered 20 mg/kg of RAD011 orally daily with food.
89403289|NCT05098509|Active Comparator|RAD011 10 mg/kg|Participants were administered 10 mg/kg of RAD011 orally daily with food.
89403290|NCT05098509|Placebo Comparator|Placebo|Participants were administered a placebo matching to RAD011, orally daily with food.
89403291|NCT05092451|Experimental|Cyclophosphamide|Cyclophosphamide is dosed per adjusted body weight for patients weighing > 20% above their ideal body weight using the calculation.
89403292|NCT05092451|Experimental|CAR.70/IL15-transduced CB-NK cells|Patients will receive a single flat dose of CAR-NK.
89403293|NCT05092451|Experimental|Fludarabine phosphate|Fludarabine is dosed using actual body weight.
89403294|NCT05072977|Experimental|TransPRK|
89403295|NCT05072977|Active Comparator|Alcohol PRK|
89403296|NCT05068752|Experimental|Vemurafenib in Combination with Sorafenib|
89403297|NCT05051293||male cirrhotic with hypotension|Patients with cirrhosis have decreased spontaneous vascular resistance leading to hypotension.
89403298|NCT05051293||male cirrhotic without hypotension|The concentration of estrogen in cirrhotic patients is thought to increase by fourfold compared to individuals without cirrhosis.
89403299|NCT05049044||Cohort 1: cRT-CT+IO|Concomitant radio-chemotherapy and consolidation immunotherapy (cRT-CT+IO)
89403300|NCT05049044||Cohort 2: sRT-CT+IO|Sequential radio-chemotherapy and consolidation immunotherapy (sRT-CT+IO)
89403301|NCT05049044||Cohort 3: cRT-CT|Concomitant radio-chemotherapy (cRT-CT)
89403302|NCT05049044||Cohort 4: sRT-CT|Sequential radio-chemotherapy (sRT-CT)
88813310|NCT01830062|Experimental|CACS and NIRS|All patients will undergo NIRS to at least 2 major epicardial vessels as a research related intervention. Patients will be considered to be enrolled in the trial upon completion NIRS evaluation. Patients who had a clinically indicated CT with CACS evaluation within 3 months prior to the cardiac catheterization with NIRS evaluation will not have any other research related interventions. Patients who have not had a clinically indicated CT with CACS within 3 months prior to the cardiac catheterization with NIRS evaluation will have the CACS after NIRS imaging prior to discharge from the hospital.
88813311|NCT01725698|Experimental|Stemcell|Mesenchymal stem cell, HA-CaSO4, ¬BMP-2, and Implant
88813312|NCT01720238||Group 1|Entecavir Therapy
88813313|NCT01720238||Group 2|Lamivudine plus Adefovir Dipivoxil Therapy
88878758|NCT00003120|Experimental|paclitaxel for 12 cycles|paclitaxel given for 12 cycles
88878759|NCT00003126|Experimental|Interleukin-2 (IL-2)|Patients randomized to this arm will receive one course of IL-2 [600,000 U/kg every 8 hours on post-operative days 1 to 5 and days 15 to 19 (maximum 28 doses)].
89403303|NCT05049044||Cohort 5: CT|Chemotherapy only (CT)
89403304|NCT05049044||Cohort 6: CT+IO|Chemotherapy plus immunotherapy (CT+IO)
89403305|NCT05049044||Cohort 7: RT|Radiation therapy only (RT)
89403306|NCT05049044||Cohort 8: IO|Immunotherapy only (IO)
89403307|NCT05049044||Cohort 9: TT|Targeted therapy only (TT)
89403308|NCT05049044||Cohort 10: BSC|Best supportive care only (BSC)
89403309|NCT05042505|Active Comparator|Dapa Group|Patients with diabetes mellitus will receive dapagliflozin 10 mg once daily. Glycemic equipoise will be maintained between the two groups by adjusting insulin doses and/or metformin and/or sulfonylurea; maintaining target fasting glucose, post-prandial glucose and glycated hemoglobin (HbA1c) in accordance with the ADA 2021
89403310|NCT05042505|Active Comparator|Sita Group|Patients with diabetes mellitus will receive sitagliptin 100 mg once daily.Glycemic equipoise will be maintained between the two groups by adjusting insulin doses and/or metformin and/or sulfonylurea; maintaining target fasting glucose, post-prandial glucose and glycated hemoglobin (HbA1c) in accordance with the ADA 2021
89403311|NCT05036876|Experimental|Degludec|"Study participants with type 2 diabetes undergoing elective coronary artery bypass graft (CABG) surgery will receive 100% of the total daily dose (TDD) given as a basal bolus regimen with degludec once daily plus rapid-acting insulin glulisine before meals.~Degludec insulin 100 Units/mL, average dose: 30-40 U/day; Insulin glulisine 100 Units/mL, average dose: 20-40 U/day"
89403312|NCT05036876|Active Comparator|Glargine U300|"Study participants with type 2 diabetes undergoing CABG surgery will receive 100% of the total daily dose (TDD) given as a basal bolus regimen with glargine U300 once daily plus rapid-acting insulin glulisine before meals.~Glargine U300;300 Units/mL, average dose: 30-40 U/day; Insulin glulisine 100 Units/mL, average dose: 20-40 U/day"
88813314|NCT03836222|Experimental|PCS499 MR Tablet Prototype 2|600 mg single dose
88813315|NCT03836222|Active Comparator|Trental MR tablet 400mg|single dose
88813316|NCT03836222|Experimental|PCS499 MR Tablet Prototype 4|600mg single dose
88813317|NCT03836222|Experimental|PCS499 MR Tablet Prototype 1|600mg single dose
88813318|NCT03836222|Active Comparator|Trental MR Tablet|400 mg multiple dose
88813319|NCT03836222|Experimental|PCS499 MR Tablet 900mg|multiple dose
88813320|NCT03836222|Experimental|PCS499 MR Tablet 600mg|multiple dose
88813321|NCT02471586|Active Comparator|Coronary PCI guided by IVUS|"Intervention = Coronary stenting with planned drug eluting stent (DES).~Stenting will be performed with IVUS guidance according to local standard practice. IVUS imaging is required pre and post stent implantation.~At the end of the procedure, a final IVUS imaging run must be performed.~After the final IVUS run, a blinded OCT imaging run shall be performed to document final stent dimensions and results."
88813322|NCT02471586|Active Comparator|Coronary PCI guided by OCT|"Intervention = Coronary stenting with planned drug eluting stent (DES).~Stenting will be performed with OCT guidance according to the algorithm described in the protocol. OCT imaging is required pre and post stent implantation.~At the end of the procedure, a final OCT imaging run must be performed."
88813323|NCT02471586|Active Comparator|Coronary PCI guided by Angiography|"Intervention = Coronary stenting with planned drug eluting stent (DES).~Stenting will be performed with angiography guidance according to local standard practice.~At the end of the procedure, a blinded OCT shall be performed to document final stent dimensions and results."
88878760|NCT00003126|No Intervention|Observation|Patients randomized to this arm will receive their normal medical care
88878761|NCT00003162|Active Comparator|3.0 Gy x 10 fractions in two weeks|3.0 Gy x 10 fractions for a total dose of 30.0 Gy in two weeks
88878762|NCT00003162|Experimental|8.0 Gy x 1 fraction|8.0 Gy x 1 fraction for a total dose of 8.0 Gy in a single dose
88878763|NCT00003192|Experimental|Arm A|9-aminocamptothecin (25 mcg/m2/hr x 120hrs, days 1-5 and 8-12 of each 3 week cycle)
88878764|NCT00003018|Experimental|Chemotherapy|dipyridamole: 75mg/dose, PO, Days 1-28 of 5 week cycle; fluorouracil: 200 mg/m^2/day, continuous IV, Days 1-28 of 5 week cycle; leucovorin calcium: 30 mg/m^2/day, IV, Days 1,8,15,22 of 5 week cycle; mitomycin C: 10 mg/m^2, IV, Day 1 of 6 week cycle (for only 4 cycles)
88878765|NCT00003204|Experimental|Arm I (cyclophosphamide, fludarabine)|Patients receive cyclophosphamide IV over 30-45 minutes on day 1 and fludarabine IV over 10-20 minutes on days 1-5. Treatment repeats every 28 days in the absence of disease progression for a minimum of 4 courses and a maximum of 6 courses.
88878766|NCT00003204|Experimental|Arm II (cyclophosphamide, vincristine, prednisone)|Patients receive cyclophosphamide IV over 30-45 minutes and vincristine IV on day 1, and oral prednisone on days 1-5. Treatment repeats every 21 days in the absence of disease progression for a minimum of 6 courses and a maximum of 8 courses.
88878767|NCT00003204|Experimental|Arm III (rituximab)|Patients receive maintenance therapy with rituximab (IDEC-C2B8 monoclonal antibody) IV weekly for 4 weeks. Courses repeat every 6 months for 2 years. Maintenance therapy begins 4 weeks after the last chemotherapy.
88878768|NCT00003204|No Intervention|Arm IV (no intervention)|Patients undergo no maintenance therapy and are observed. Patients are followed every 3 months for 2 years, every 6 months for the next 3 years, and then annually thereafter.
88878769|NCT00003210|Experimental|Treatment (interleukin-12)|Patients receive interleukin-12 subcutaneously twice a week. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.
89190037|NCT03971617|Experimental|Hydrogen tablets|The ingredient in the tablet producing H2 is magnesium. Each tablet contains 80 mg magnesium, a safe level well below the recommended daily dietary allowance of 420 mg for men/ 320 mg for women. Dissolving one tablet in 250 mL of water will achieve a saturating H2 concentration of approximately 1.6 ppm. Twice a day subjects will dissolve a tablet into water and drink the effervescent water.
88878770|NCT00003234|Experimental|Stratum 1 - Soft Tissue Sarcoma|See detailed description.
88878771|NCT00003234|Experimental|Stratum 2 - CNS Tumors|See detailed description.
88878772|NCT00003234|Experimental|Stratum 3 - Neuroblastoma|See detailed description.
88878773|NCT00003276|Experimental|irinotecan|Patients receive a 90 minute continuous infusion of irinotecan on days 1, 8, 15, and 22 for 4 weeks, followed by a 2 week rest period. Courses of treatment are repeated every 42 days. Patients continue treatment in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 1 year, then every 6 months for the next 4 years.
88878774|NCT00003282|Experimental|Diagnostic (EF5)|Patients receive etanidazole derivative EF5 IV over 1-2 hours beginning approximately 24 hours prior to surgery. Tumors are then resected or biopsied after Eppendorf needle electrode measurements.
88878775|NCT00003288|Experimental|Arm I|See arm description.
89190038|NCT03971617|Placebo Comparator|Placebo tablets|effervescent placebo tablets will also contain 80 mg magnesium but do not generate hydrogen-enriched water
89190039|NCT03965585||Primary Infertility|Women with a diagnosed primary infertility undergoing hysteroscopy before IVF.
89190040|NCT03965585||Secondary Infertility|Women with a diagnosed secondary infertility undergoing hysteroscopy before IVF.
88878776|NCT00003330|Experimental|Arm I|See detailed description.
88878777|NCT00003384|Experimental|Diagnostic|"Patients undergo a Pap smear followed by a ThinPrep cervical cell specimen collection at the time of direct colposcopic examination. Patients then undergo a cone biopsy of the cervix using loop electrosurgical excision procedure with an endocervical curettage, an excisional cone biopsy of the cervix with or without endocervical curettage, or a hysterectomy. Patients who are perimenopausal or postmenopausal or have a negative cervical cone biopsy also undergo endometrial biopsy or curettage. The Pap smear specimen is analyzed to determine MN antigen expression and the ThinPrep specimen is analyzed for the presence of high-risk human papilloma virus and to determine MN antigen and other marker (e.g., P16) expression.~Patients who do not undergo hysterectomy are followed every 6 months for 2 years. All other patients are followed at 4, 26, and 30 weeks."
88878778|NCT00003432|Experimental|carcinoembryonic antigen RNA-pulsed DC cancer vaccine|carcinoembryonic antigen RNA-pulsed DC cancer vaccine
88878779|NCT00003516|Experimental|Antineoplastons|Antineoplaston therapy (Atengenal + Astugenal) capsules orally six to seven times a day. Treatment continues in the absence of disease progression or unacceptable toxicity. absence of disease progression or unacceptable toxicity.
88878780|NCT00003522|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
88878781|NCT00003528|Experimental|Arm I|Patients receive raltitrexed intravenously over 15 minutes once weekly for 3 weeks followed by 1 week of rest. Treatment continues in the absence of disease progression and unacceptable toxicity.
89190041|NCT03965585||Recurrent miscarriages|Women with recurrent miscarriages undergoing hysteroscopy before IVF.
89190042|NCT03964909|Experimental|Diagnostic (fMRI, CVR MRI, rs-fMRI)|Patients undergo standard of care fMRI, CVR MRI over 3 minutes, and rs-fMRI over 6 minutes 1 month before and within 6 weeks after standard of care surgery.
89403313|NCT05031962||CELLIS Breast (Porcine Acellular Dermal Matrix, PADM)|Implant-based breast reconstruction following mastectomy using the CELLIS Breast matrix
88878782|NCT00003534|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
88878783|NCT00003546|Experimental|gemcitabine + radiation|Patients receive radiation therapy 5 days per week for 5 1/2 weeks and gemcitabine IV over 30 minutes not greater than 2 hours prior to radiation therapy twice weekly. This combination radiation therapy and chemotherapy is followed by 2 weeks of rest. Patients with stable or responding disease receive a higher dose of gemcitabine IV over 30 minutes weekly for 3 weeks followed by 1 week of rest. This 4 week course is repeated 3 more times for a total of 16 weeks of gemcitabine therapy alone. Patients are followed every 2 months for the first year and then every 3 months for the next 2 years or until disease progression. Upon documentation of disease progression, patients are followed every 3 months for survival and secondary malignancy.
88878784|NCT00003564|Experimental|Arm I (Procarbazine + Isotretinoin)|Arm I: Oral procarbazine once daily on days 1-14 every 28 days, and Oral isotretinoin every 12 hours on days 15-28 every 28 days; 6 courses of combined therapy, then continue oral isotretinoin alone on days 15-28 of each 28 day course.
88878785|NCT00003564|Experimental|Arm II (Procarbazine Alone)|Arm II: Oral Procarbazine once daily on days 1-14 followed by 2 weeks of rest for a total of 6 courses of treatment.
88878786|NCT00003588|Experimental|Arm I|Patients undergo laparoscopy for p53 assessment and catheter placement. Patients receive daily intraperitoneal injections of adenovirus p53 (Ad-p53) for 5 days every 3 weeks. Treatment is repeated every 21 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients each are treated at each dose level of Ad-p53. The maximum tolerated dose is defined as the dose at which no more than 1 of 6 patients experiences dose limiting toxicity.
88878787|NCT00003594|Experimental|irinotecan + leucovorin + fluorouracil|"Patients receive irinotecan IV over 90 minutes followed by leucovorin calcium IV over 15 minutes and fluorouracil IV once a week for 4 weeks followed by 2 weeks of rest. Courses repeat every 6 weeks.~Treatment continues in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed before treatment, during treatment (arm specific), and after completion of treatment.~Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter."
88878788|NCT00003594|Experimental|oxaliplatin + leucovorin + fluorouracil|"Patients receive oxaliplatin IV over 2 hours on day 1 and leucovorin calcium IV over 2 hours plus fluorouracil IV over 22 hours on days 1 and 2. Courses repeat every 2 weeks.~Treatment continues in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed before treatment, during treatment (arm specific), and after completion of treatment.~Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter."
88878789|NCT00003594|Experimental|oxaliplatin + irinotecan|"Patients receive oxaliplatin IV over 2 hours and irinotecan IV over 30 minutes on day 1. Courses repeat every 3 weeks.~Treatment continues in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed before treatment, during treatment (arm specific), and after completion of treatment.~Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter."
88878790|NCT00003600|Experimental|epoetin alfa|Patients receiving chemotherapy are randomized to receive epoetin alfa subcutaneously once a week for a maximum of 16 weeks Quality of life is assessed at randomization and monthly throughout study. Patients are followed every 6 months for 1 year.
89403314|NCT05010200|Experimental|Cohort 1 - Primary treatment cohort|Patients receive the personalized genomic vaccine (PGV) and Poly-ICLC.
89403315|NCT05010200|Experimental|Cohort 2 - Secondary treatment cohort|Patients receive the personalized genomic vaccine (PGV) and Poly-ICLC, and CDX-301
89403316|NCT05010200|Experimental|Cohort 3 - Expansion treatment cohort|An expansion cohort if the treatment of all 3 together has not triggered a safety stopping event.
89403317|NCT05010174||Observational, long-term safety follow-up of patients who have received MDR product|Only patients who have received treatment with MDR product will be eligible for this study.
89403318|NCT04983615|Experimental|fentanyl-based sedation group|
88878791|NCT00003600|Placebo Comparator|placebo|Patients receiving chemotherapy are randomized to receive placebo subcutaneously once a week for a maximum of 16 weeks. Quality of life is assessed at randomization and monthly throughout study. Patients are followed every 6 months for 1 year.
88878792|NCT00003612|Experimental|Schedule A: paclitaxel + carboplatin + trastuzumab|"Patients receive paclitaxel IV over 3 hours followed by carboplatin IV over 30 minutes and then trastuzumab (Herceptin) IV over 90 minutes on day 1 of week 1. Treatment repeats every 3 weeks for up to 8 courses in the absence of disease progression or unacceptable toxicity. Patients then receive trastuzumab IV over 30 minutes every 3 weeks until disease progression.~Patients are followed every 3 months for 2 years and then every 6 months thereafter."
88878793|NCT00003612|Experimental|Schedule B: paclitaxel + carboplatin + trastuzumab|"Patients receive paclitaxel IV over 1 hour followed by carboplatin IV over 15 minutes on day 1 of weeks 1-3 and trastuzumab IV over 90 minutes immediately after carboplatin on day 1. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive trastuzumab IV over 30 minutes every 3 weeks until disease progression.~Patients are followed every 3 months for 2 years and then every 6 months thereafter."
88878794|NCT00003648||Group 1|Patients, family members, and control individuals complete an extended telephone interview, an extended personal interview, and an epidemiological survey, and contribute a blood specimen. Blood and tumor specimens are examined for the specific pattern of immunohistochemical expression of hMSH2 and HMLH1 to determine the frequency or lack of expression of these two protein products. Patients may be contacted periodically (about every 3 years) to update information about health, health practices, and family history. Patients do not receive the results of the genetic testing and the results do not influence the type or duration of treatment.
88878795|NCT00003666|Experimental|HMAF|treatment of refractory or relapsed NSCLC with HMAF
88878796|NCT00003714|Experimental|Pyrazoloacridine|
88878797|NCT00003744|Experimental|Intercalcated Duct|"The first group, referred to as intercalated duct will include Aadenoid cystic carcinoma, acinic cell carcinoma, malignant mixed tumor, polymorphous low grade adenocarcinoma, undifferentiated carcinoma, and adenocarcinoma.~- Gemcitabine iv 30 min infusion on days 1,8, and 15 of each 28 day cycle.~-- Participants will be evaluated for response at the end of cycle 2 and at the end of every even cycle thereafter."
89004259|NCT05405439|Experimental|TQB3823 tablets + abiraterone acetate tablets + prednisone acetate tablets|TQB3823 tablets + abiraterone acetate tablets + prednisone acetate tablets，28 days as a treatment cycle.
89190043|NCT03959683|Active Comparator|Trilogy device|Trilogy Lithotrite to fragment urinary tract calculi in the kidney, ureter and bladder
89190044|NCT03959683|Active Comparator|ShockPulse-SE|ShockPulse-SE Lithotripsy System to fragment urinary calculi in the kidney, ureter and bladder
89403319|NCT04983615|Active Comparator|midazolam-based sedation group|
88878798|NCT00003744|Experimental|Excreatory Duct|"The second group, referred to as excretory duct, will include: squamous cell carcinoma and mucoepidermoid carcinoma.~Gemcitabine iv 30 min infusion on days 1,8, and 15 of each 28 day cycle.~Participants will be evaluated for response at the end of cycle 2 and at the end of every even cycle thereafter."
88878799|NCT00003750|Experimental|DG2 positive relapsed or refractory solid tumors|The initial hu14.18-IL2 fusion protein (FP) dose will be 2 mg/m2 given intravenously over 4 hours, daily for 3 days. Five separate dose levels are scheduled: 2 mg/m²/dose (IV over 4 hours) x 3 days, 4 mg/m²/dose (IV over 4 hours) x 3 days, 6 mg/m²/dose (IV over 4 hours) x 3 days, 8 mg/m²/dose (IV over 4 hours) x 3 days, 10 mg/m²/dose (IV over 4 hours) x 3 days.
88878800|NCT00003762|Experimental|Arm I: docetaxel + gemcitabine|"Patients receive docetaxel IV over 1 hour on day 1 followed by gemcitabine IV over 30 minutes on days 1, 8, and 15. Patients continue treatment every 28 days for a maximum of 6 courses in the absence of unacceptable toxicity or disease progression. Patients with either stable disease or complete/partial response who discontinue treatment after 4-6 courses may be eligible for NCCTG-97-24-51.~Quality of life is assessed before treatment and before each course of therapy.~Patients are followed every 3 months for 1 year, then every 3 months for 5 years."
88878801|NCT00003762|Experimental|Arm II: docetaxel + gemcitabine|"Patients receive docetaxel IV over 1 hour and gemcitabine IV over 30 minutes on days 1 and 15. Patients continue treatment every 28 days for a maximum of 6 courses in the absence of unacceptable toxicity or disease progression. Patients with either stable disease or complete/partial response who discontinue treatment after 4-6 courses may be eligible for NCCTG-97-24-51.~Quality of life is assessed before treatment and before each course of therapy.~Patients are followed every 3 months for 1 year, then every 3 months for 5 years."
88878802|NCT00003762|Experimental|Arm III: docetaxel + gemcitabine|"Patients receive docetaxel IV on day 1 and gemcitabine IV on days 1, 8, and 15. Patients continue treatment every 28 days for a maximum of 6 courses in the absence of unacceptable toxicity or disease progression. Patients with either stable disease or complete/partial response who discontinue treatment after 4-6 courses may be eligible for NCCTG-97-24-51.~Quality of life is assessed before treatment and before each course of therapy.~Patients are followed every 3 months for 1 year, then every 3 months for 5 years."
88878803|NCT00003786|Experimental|Arm A|MGI-114 (11mg/m2/day x 5 days every 28 days)
88878804|NCT00003828|Experimental|vinorelbine|vinorelbine 30 mg/m2/week IV bolus over approximately 6-10 minutes
89004260|NCT05400499||Parkinson's disease with DBS|This is the only group. The patients in this group will have bilateral subthalamic region deep brain stimulator. They will be recruited after they are therapeutically optimized on stimulation as well as medical therapy.
89190045|NCT03958929|Experimental|Education group|Subjects will be asked to watch a 5-10 min education film two times (pre-op one day and post-op one day).
89190046|NCT03958929|No Intervention|Control group|Standard patient procedure that includes a pre-operative discussion with an ophthalmologist about glaucoma surgery, during which the surgeon gains the patient's informed consent. Subjects will not be asked to watch education film..
89190047|NCT03945448|Experimental|Single dose liposomal Amphotericin and fluconazole|"Experimental:~Single dose Ambisome 10mg/kg and Fluconazole 800mg for two weeks ,400mg for 8 weeks and 200mg upto 6 months. (standard of care therapy)"
89403320|NCT04975308|Experimental|Imlunestrant|Imlunestrant administered orally.
88878805|NCT00003834|Experimental|oxaliplatin + leucovorin + fluorouracil|Patients receive oxaliplatin IV over 2 hours on day 1, then leucovorin calcium IV over 2 hours with fluorouracil IV bolus, followed by fluorouracil IV over 22 hours on days 1 and 2. Courses repeat every 2 weeks. Patients with stable disease continue treatment in the absence of disease progression or unacceptable toxicity or until disease is resectable. Patients who achieve complete response (CR), partial response (PR) with unresectable disease, or PR but are not surgical candidates continue treatment in the absence of disease progression or unacceptable toxicity. Patients who demonstrate a response are treated until best response or until disease is deemed resectable. Patients who achieve a CR or PR and are resected may receive 2 to 4 additional courses of therapy at the discretion of the investigator. Patients are followed every 3 months for 1 year and then every 6 months for 2 years.
88878806|NCT00003846|Experimental|Treatment|See detailed description.
88878807|NCT00003858|Experimental|Mitoxantrone|Patients receive mitoxantrone IV over 10-30 minutes every 21 days. Treatment continues for a maximum of 6 courses in the absence of unacceptable toxicity or disease progression. Patients are followed every 3 months for the first 3 years, and then every 6 months for the next 3 years or until disease progression.
88878808|NCT00003900|Experimental|irinotecan + docetaxel|Patients receive irinotecan IV over 90 minutes immediately followed by docetaxel IV over 60 minutes on day 1. Treatment is repeated every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 5 years or until death.
88878809|NCT00003906|Active Comparator|Group 1|Tamoxifen and placebo
88878810|NCT00003906|Experimental|Group 2|Raloxifene and Placebo
88878811|NCT00003930|Experimental|Arm 1|Transurethral surgery with chemotherapy and radiation therapy followed by either selective bladder preservation or radical cystectomy followed by adjuvant chemotherapy.
88878812|NCT00003954|Experimental|Treatment (Melphalan and PBSCT before TBI and Donor PBSCT)|"CONDITIONING REGIMEN: Patients receive high-dose melphalan IV over 15-20 minutes on day -2.~TRANSPLANTATION: Patients undergo autologous bone marrow or PBSCT on day 0.~NON-MYELOABLATIVE CONDITIONING REGIMEN: Beginning 40-120 days after autologous transplant, patients undergo TBI on day 0.~TRANSPLANTATION: Patients undergo donor PBSCT on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine IV BID on days -1 and 0 and PO BID on days 1-80 with taper based on evaluation of disease response and GVHD. Patients also receive mycophenolate mofetil PO BID on days 0-27.~POST TRANSPLANT DLI: Beginning 4 weeks after immunosuppression, patients achieving persistent or progressive disease may undergo DLI over 30 minutes every 4 weeks for up to 3 treatments."
88878813|NCT00003966|Experimental|Arm A Lower dose|"This is a randomized, multicenter study. All patients initially receive the same dose of defibrotide IV over 2 hours every 6 hours on day 1. On day 2, patients are randomized to 1 of 2 doses of defibrotide.~- Arm I: On days 2-14, patients receive a lower dose of defibrotide IV over 2 hours every 6 hours.~In both arms, courses repeat every 14 days in the absence of disease progression or unacceptable toxicity"
88878814|NCT00003966|Experimental|Arm B Higher Dose|"This is a randomized, multicenter study. All patients initially receive the same dose of defibrotide IV over 2 hours every 6 hours on day 1. On day 2, patients are randomized to 1 of 2 doses of defibrotide.~- Arm II: On days 2-14, patients receive a higher dose of defibrotide IV over 2 hours every 6 hours.~In both arms, courses repeat every 14 days in the absence of disease progression or unacceptable toxicity"
88878815|NCT00003996|Experimental|chemotherapy + carmustine + etoposide + cisplatin + radiation|Patients receive pre-irradiation chemotherapy consisting of carmustine IV over 1 hour on days 1-3 and oral etoposide on days 1-21 and 29-49 immediately followed by cisplatin IV over 1-2 hours on days 1-3 and 29-31. Treatment repeats every 8 weeks for 2 courses. Patients receive concurrent cranial radiotherapy daily over 8 weeks during course 2. Patients then receive carmustine IV over 1-2 hours every 8 weeks for 4 courses. Treatment continues in the absence of disease progression or unacceptable toxicity. Quality of life is assessed before the study, prior to each treatment course, every 4 months for 1 year, every 6 months for 4 years, and then annually for 5 years. Patients are followed every 4 months for 1 year, every 6 months for 4 years, annually for 5 years, and then for survival.
88878816|NCT00004032|Experimental|Treatment (ALVAC-hB7.1, recombinant interferon gamma)|Patients receive ALVAC-hB7.1 infected tumor cells intraperitoneally (IP) on days 4, 11, and 18. Patients also receive interferon gamma IP on days 8, 10, 15, and 17. In the absence of disease progression, up to 6 courses of therapy may be given. If insufficient tumor cells are available to continue treatment with tumor cell derived vaccine, interferon gamma may be given alone.
89403321|NCT04975308|Active Comparator|Investigator's Choice of Endocrine Therapy|Investigator's choice of exemestane administered orally or fulvestrant administered intramuscularly (IM). See local approved label for additional instructions.
89403322|NCT04975308|Experimental|Imlunestrant plus Abemaciclib|Imlunestrant plus abemaciclib administered orally.
89403323|NCT04962698|Experimental|Healthy participants|All participants will receive seven types of interventions in random order. The types of interventions are the same across subjects.
89403324|NCT04962698|Experimental|Post-Stroke participants|All participants will receive three types of interventions in random order. The types of interventions are the same across subjects.
89403325|NCT04958252|Experimental|Part A: BI 1569912 low dose|
89403326|NCT04958252|Experimental|Part A: BI 1569912 lower medium dose|
89403327|NCT04958252|Experimental|Part A: BI 1569912 higher medium dose|
89403328|NCT04958252|Experimental|Part A: BI 1569912 high dose|
89403329|NCT04958252|Experimental|Part B: BI 1569912 low dose|
89403330|NCT04958252|Experimental|Part B: BI 1569912 high dose|
89403331|NCT04958252|Experimental|Part C: BI 1569912|
88813324|NCT03835988|Experimental|Geniculate Artery Embolization|Patients undergoing geniculate artery embolization. Patients will be assessed and followed post-procedurally to detect changes in knee pain and function. Medication use, adverse events and performance based tests of physical function will also be recorded. A pre-procedural MRI will be compared to a 6 month post-procedure MRI to assess for changes in synovitis and assess for complications.
88813325|NCT01830218||Obstetric anesthesia and analgesia|Women in labor undergoing anesthesia care
89403332|NCT04958252|Placebo Comparator|Placebo|
89403333|NCT04948333|Experimental|ABL001|Participants will be treated with 80 mg of ABL001 (40 mg BID or 80mg QD). In patients not achieving MMR at 48 weeks or losing the response after the week 48 assessment up to week 108, asciminib dose may be escalated to 200 mg q.d. if in the investigator's opinion the patient may benefit from the escalation.
89403334|NCT04943965||Patient undergoing a cardiac surgery|Patients undergoing cardiac surgeries listed in inclusion criteria will be in this group.
89403335|NCT04943965||Clinicians|Clinicians defined as physicians (e.g. attendings, fellows, residents) or advanced practice providers (e.g. nurse practitioners and physician assistants) will be in this group.
89403336|NCT04940663|Other|Ecological Momentary Assessment|EMA collected daily (4x/day) for two weeks
89403337|NCT04931810|Experimental|All Nations Breath of Life|ANBL is a culturally tailored smoking cessation program that incorporates group-based and individual counseling. Participants may elect to take pharmacotherapy, but are not required to do so.
88813326|NCT00910208|Experimental|Patient-controlled analgesia 1 mg demand dose|0.1 mg/kg morphine loading dose plus PCA with 1.0 mg morphine demand dosing every 6 minutes
88813327|NCT00910208|Experimental|Patient-controlled analgesia 1.5 mg demand dose|0.1 mg/kg morphine loading dose plus PCA with 1.5 mg morphine demand dosing every 6 minutes
88813328|NCT00910208|Active Comparator|Non-Patient-controlled analgesia comparison group|0.1 mg/kg morphine loading dose plus additional analgesia as needed
88813329|NCT01566539|Experimental|Healthy Volunteers - Intranasal Vasopressin (AVP)|The AVP group of healthy volunteers will self-administer vasopressin solution prior to completing the PD task.
89403338|NCT04931173|Active Comparator|Group A: IV and Oral antibiotics (IVA+OA)|Patients will receive cefazolin 2g IV and metronidazole 500 mg IV administered by the anesthesiologist within 60 minutes prior to the skin incision on the day of surgery. Standardized re-dosing of cefazolin 2g IV will occur every 4 hours and metronidazole 500 mg IV will occur every 8 hours during the surgical procedure. Following surgery, no further IVA will be given for SSI prophylaxis. In addition, patients will self-administer 1g neomycin and 1g metronidazole orally at 1500, 1700 and 2300 hours the day before surgery. Following this, they will not receive any further OAs for SSI prophylaxis.
89530960|NCT05472701|Experimental|Whole Food Plant-Based (WFPB)|2 meals/day of traditional plant proteins (tofu, quinoa, black beans) and minimized intake of processed food, eggs, and dairy
88878817|NCT00004038|Experimental|Arm I|Patients undergo biopsy of one of their skin nodules prior to any treatment. Patients receive the Ad-p53 gene therapy in one nodule and injection of a second nodule with Dulbecco's phosphate buffered saline. The next day, patients begin chemotherapy, which may be given weekly and continues every 21-28 days for up to 6 courses. On day 3, patients return for biopsy of injected nodules. Biopsies are only performed during the first course. Patients may receive further injections of the Ad-p53 gene with subsequent courses of chemotherapy, for up to six courses.
88878818|NCT00004050|Experimental|Leuvectin|2 intratumoral injections of 1000 ug of Leuvectin
88878819|NCT00004056|Experimental|Chemo + STEM cell|See detailed description.
88878820|NCT00004074|Experimental|Treatment (IL12 and trastuzumab)|Patients receive an initial loading dose of trastuzumab IV over 90 minutes on day 1 of the first week and a maintenance dose of trastuzumab IV over 30-90 minutes on day 1 of each subsequent week. Patients receive IL-12 IV on days 2 and 5 beginning on week 3. Treatment with maintenance trastuzumab and IL-12 repeats weekly for 14 weeks in the absence of disease progression or unacceptable toxicity. Patients with stable or responding disease continue treatment for up to 38 additional weeks.
88878821|NCT00004188|Experimental|Arm I (unpurged PBSC collection)|Induction-3 wks (cyclophosphamide day 0&1, doxorubicin hydrochloride & vincristine sulfate day 0-2 & filgrastim(G-CSF) day 3 crs 1,2,4 & 6.) Crs 3 & 5 (etoposide day 0-2, cisplatin day 0-3, G-CSF day 4). Pts undergo unpurged PBSC collection until the target cell count is reached. Surgical resection of the tumor after crs 5 of induct. CR, VGPR, PR after induct receive consolidation (melphalan day -7 to -5, carboplatin & etoposide day -7 to -4. purged peripheral blood stem cell transplantation infusion day 0, G-CSF 4 hrs post transplant. Day 66, isotretinoin 2x day/14 days. Isotretinoin every 4 wks 6 crs. After consol (28 days from stem cell infusion), radiation therapy 1x day/7 days. Not undergoing autologous bone marrow transplantation receive maintenance(cyclophosphamide 30 mins, topotecan hydrochloride days 0-4, G-CSF day 5). Maint every 3 wks/3 crs. Radiation therapy and Isotretinoin 2x day/14 days then every 4 wks for 6 crs.
89403339|NCT04931173|Active Comparator|Group B: IV antibiotics, MBP and oral antibiotics (IVA+MBP+OA)|Patients will receive IVA and OA per Group A. In addition, patients will stay on clear fluids and self-administer a 2L polyethylene glycol MBP orally, between 1500 and 2300 hours on the day before surgery.
89403340|NCT04927897||Observational|In addition to standard workup and treatment, patients will undergo pre-operatively, after induction of general anaesthesia, an endorectal ultrasound and rigid rectoscopy as study procedures if these are not part of standard workup yet.
89403341|NCT04922983|Sham Comparator|Group I: Placebo isometric measure, no injection|Group I: no isometric yoga-like exercise, no injection given.
89403342|NCT04922983|Placebo Comparator|Group II Isometric yoga-like exercise, placebo injection given|Group II isometric yoga-like exercise, injection of preservative-free normal saline.
89403343|NCT04922983|Active Comparator|Group III: True isometric exercise, botulinum injection|Group III: Isometric yoga-like exercise, botulinum injection given
89403344|NCT04922983|Active Comparator|Crossover|After the three months, Arm I and Arm II patients will be given botulinum injections, and Group I will be given the proper yoga-like exercise. These two arms will constitute a further comparator with their own performances in the first 3 months of the study.
89403345|NCT04918173|Experimental|Atenativ treatment|Patients will receive a single intravenous infusion of Atenativ for PK analysis. Patients will receive a single intravenous dose followed by maintenance doses administered every 24 hours for approximately 2-7 days for surgical patients and approximately 5 days for parturients
89403346|NCT04917679|Experimental|Combination group|Eltrombopag plus diacerein
89403347|NCT04917679|Placebo Comparator|Monotherapy group|Eltrombopag monotherapy
89403348|NCT04905316|Experimental|Canakinumab with Chemoradiation and Durvalumab|Treatment will consist of canakinumab (ACZ885) administered as a subcutaneous injection every 3 weeks for 3 cycles concurrent with standard of care concurrent chemoradiation, followed by canakinumab administered intravenously every 4 weeks for up to 12 total infusions concurrent with standard of care durvalumab. Canakinumab (ACZ885) will be dosed at 200mg via subcutaneous injection every 3 weeks x 3 injections that will start with concurrent chemoradiation, followed by 200mg via intravenous infusion every 4 weeks x 12 infusions that will start with the initiation of durvalumab. Canakinumab (ACZ885) will be concurrent with thoracic chemoradiation and durvalumab therapy for up to 15 cycles, or until disease progression or unacceptable toxicity, whichever occurs first. Patients that come off treatment for progression, or have progression after completion of all protocol-related therapy, can be followed for survival outcomes by chart review based on standard of care evaluations.
89004261|NCT05399771|Experimental|Thermofield temperature controlled radiofrequency device|Participants will serve as their own control, by heating one leg and not the other. The radiofrequency device consists of a 4 by 6 inch heating pad connected to a temperature controller. The pad will be applied to the back of the leg and will covered using a compression stocking. The other leg will receive a pad and compression stocking, but radiofrequency will not be applied (no heating).
89190048|NCT03945448|Active Comparator|fluconazole (standard of care)|Standard of care pre-emptive treatment fluconazole 800mg for two weeks ,400mg for 8 weeks and 200mg upto 6 months
88813330|NCT01566539|Experimental|Healthy Volunteers - Intranasal Oxytocin (OT)|The OT group of healthy volunteers will self-administer oxytocin solution prior to completing the PD task.
88813331|NCT01566539|Placebo Comparator|Healthy Volunteers - Intranasal Placebo|The placebo group of healthy volunteers will self-administer a placebo spray prior to completing the PD task.
88813332|NCT01566539|Experimental|Within Subject Group|Some healthy volunteer participants who received drug in their first session will receive placebo in their second session and vice-versa prior to completing the PD task. For each gender, half will receive AVP in one session and placebo in the other session, and half will receive OT in one session and placebo in the second session. In each group, half of the subjects will receive drug first and half will receive placebo first. Additionally, a group of subjects who receive placebo the first time will receive placebo the second time.
89004262|NCT05376553|Experimental|Cohort A|"3 cycles of Cemiplimab-TP induction chemotherapy will be delivered in cohort A.~Cemiplimab-TP chemotherapy will be given every 21 days starting on days 1, 22 and 43, etc. (+ 2 days) with TP given on days 1, 22, and 43 (+/- 2 days) and Cemiplimab given on days 14, 35, 56 (+/- 2 days).~Patients in cohort A will get 3 doses of Cemiplimab during induction therapy."
89403349|NCT04878185|Experimental|Exercise|"A high-intensity, home-based, exercise program consisting of inspiratory muscle training (IMT), endurance- and functional strength exercise. The sessions will supervised by a physiotherapist during six occasions and start 2-3 weeks before surgery. IMT will be conducted with an intensity starting from 50 % of maximal capacity, with a self-reported effort of 5-7 on the Borgs CR-10 scale. Endurance and functional strength exercises will be performed at a self-reported effort of 7-8. Interval training, chair stand- and step-up exercises will be key components of the exercise program. Furthermore, the program will include task-specific exercises based on the participants self-expressed needs.~On non-supervised days, participants will perform IMT twice a day as well as endurance and strength training, 2-3 days per week with 1-2 days per week of active recovery in the form of moderate intensity walks. This will be monitored with an activity journal and an accelerometer."
89403350|NCT04878185|No Intervention|Control group|Participants in the control group receive pre- and postoperative care as usual. In addition, they will be encouraged to follow the WHO guidelines of moderate intensity aerobic physical activity for at least 150 min per week. Their activity level will be monitored with an accelerometer.
89403351|NCT04859985|Experimental|SELUTION SLR DEB|Device: SELUTION SLR DEB. For patients randomized to the DEB strategy, all target lesions should be treated with DEB after appropriate lesion preparation, but provisional DES implantation is acceptable if the angiographic result is considered insufficient either after lesion preparation of after DEB treatment (poor flow, dissection type C or higher, residual stenosis > 30%). For bifurcation lesions, when both main and side- branch are considered to require treatment, a DEB should be used for both.
89403352|NCT04859985|Other|DES|Device: Drug Eluting Stent. For patients randomized to the DES strategy, all target lesions should be treated with DES, but use of a SELUTION SLR™ DEB or any other device is acceptable if a DES cannot be delivered to the target lesion. For bifurcation lesions, if the side-branch requires treatment it should be treated with another DES or with POBA, at the discretion of the operator, but not with a DEB.
89530961|NCT05472701|Experimental|Plant-Based Meat Alternatives (PBMA)|2 servings/day of plant-based meat alternatives (Beyond Beef, Impossible Burger, Gardein Chick'n)
89530962|NCT05472701|Experimental|Animal|2 servings/day of traditional meat products (beef burger, pork, chicken)
89530963|NCT03232255|Experimental|Treatment Group|
88813333|NCT01566539|Experimental|Faces Task - Vasopressin (AVP)|Healthy volunteers between the ages of 21-30 years will receive Faces Intranasal Vasopressin (AVP) prior to completing the Faces task during fMRI scanning.
88813334|NCT01566539|Placebo Comparator|Faces Task - Placebo|Healthy volunteers between the ages of 21-30 years will receive placebo prior to completing the Faces task during fMRI scanning.
88813335|NCT01566539|Experimental|Empathy Task - Oxytocin (OT)|Healthy volunteers between the ages of 18-30 years will receive placebo at scan 1 and OT at scan 2 prior to completing an empathy task.
89004263|NCT05376553|Experimental|Cohort B|"In cohort B first dose of Cemiplimab will be given 7 days prior to TP followed by TP given on days 1,22,43 (+/- 2 days) and Cemiplimab given on days 14, 35, 56 (+/- 2 days).~Patient in cohort B will get 4 doses of Cemiplimab during induction therapy."
89004264|NCT05374759||Group 1|Patients with sepsis who develop AKI
89004265|NCT05374759||Group 2|Patients with sepsis who do not develop AKI
89004266|NCT05367661|Experimental|Part A: Healthy Volunteers: Single ascending doses|Six dose groups ranging from 15mg to 500mg, under fasting condition.
89004267|NCT05367661|Experimental|Part A: Healthy Volunteer: Single Ascending dose under fed condition|60mg under fed condition.
89004268|NCT05367661|Experimental|Part A: Otherwise Healthy volunteer with Class I or Class II obesity, Single Ascending dose|125mg, under fasting condition.
89004269|NCT05367661|Experimental|Part B: Healthy Volunteers: Multiple Ascending doses|5 dose groups with doses ranging from 30mg to 500mg. Given daily for 14 days, under fasting condition.
89403353|NCT04859218|Experimental|ABO non-identical transfusion|All study patients will participate in the study for two consecutive transfusion episodes (a transfusion episode is defined as a clinic visit where 2 RBC units are transfused) and will receive an ABO identical product at one transfusion episode and an ABO non-identical product for the other episode. Randomization will dictate the order of the transfusion. The number of RBCs given for each study transfusion episode will be identical 2 RBC units.
89403354|NCT04859218|Active Comparator|ABO identical transfusion|All study patients will participate in the study for two consecutive transfusion episodes (a transfusion episode is defined as a clinic visit where 2 RBC units are transfused) and will receive an ABO identical product at one transfusion episode and an ABO non-identical product for the other episode. Randomization will dictate the order of the transfusion. The number of RBCs given for each study transfusion episode will be identical 2 RBC units.
89403355|NCT04855435|Experimental|MBS8(1V270)|Treatment arm (single arm study)
89403356|NCT04847921|Experimental|people who use drugs with severe Gram-positive infections|As per inclusion and exclusion criteria
89403357|NCT04842890|Other|Stereotactic body radiation therapy (SBRT) with Pencil Beam Scanning (PBS) proton therapy|
89403358|NCT04839523|Experimental|Exufiber|Treatment with Exufiber gelling fiber dressing
89403359|NCT04839523|Experimental|Exufiber Ag+|Treatment with Exufiber Ag+ silver-coated, gelling fiber dressing
89403360|NCT04837573|Experimental|Group 1 Intervention, Weeks 1-8|During Weeks 1-8, Group 1 receives the Intervention and Group 2 receives no treatment.
89403361|NCT04837573|Active Comparator|Group 2 Intervention, Weeks 9-16|During Weeks 9-16, Group 2 receives the Intervention and Group 1 receives no treatment.
89403362|NCT04832321|No Intervention|No intervention: V1: Control|This version of the survey questionnaire depicts a young man with no symptoms of alcohol use disorder
89004270|NCT05355909|No Intervention|controll group|Standard of care without preoperative fitness program
89403363|NCT04832321|Experimental|Experimental: V2: Alcohol Use Disorder|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young man with symptomatic, untreated alcohol use disorder."
89403364|NCT04832321|Experimental|Experimental: V3: Alcohol Use Disorder + Treatment with Response|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young man with symptomatic, untreated alcohol use disorder who is successfully treated with complete response."
89403365|NCT04832321|Experimental|Experimental: V4: Alcohol Use Disorder + Treatment with Relapse|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young man with symptomatic, untreated alcohol use disorder who is successfully treated with partial relapse."
89403366|NCT04832321|Experimental|Experimental: V5: Alcohol Use Disorder + Economic Impact|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young man with symptomatic, untreated alcohol use disorder whose untreated alcohol use disorder negatively affects his family's finances."
89403367|NCT04832321|Experimental|Experimental: V6: Alcohol Use Disorder + Economic Impact + Treatment with Response|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young man with symptomatic, untreated alcohol use disorder whose untreated alcohol use disorder negatively affects his family's finances, who is then successfully treated with complete response."
89403368|NCT04832321|Experimental|Experimental: V7: Alcohol Use Disorder + Economic Impact + Treatment with Relapse|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young man with symptomatic, untreated alcohol use disorder whose untreated alcohol use disorder negatively affects his family's finances, who is then successfully treated with partial relapse and continued negative economic impact."
89403369|NCT04805203|Other|blood samples|4 blood samples per patient maximum (at diagnosis of covid19, during intensive care if applicable, at revecory of covid 19 and 6 months after recovery.
89403370|NCT04804098|Active Comparator|15 Minute Non-linear Compression Profile|Compression Profile/Schedule 1 = 15 minute non-linear, Total Time Interval of Compression to treatment depth = 15 minutes Rate (slope) of compression = Non-Linear rate of compression = 2 fsw/min to a depth of 13 fsw, then 3 fsw/min up to a depth of 35 fsw, then 5 fsw/min to arrival at the treatment depth of 45 fsw
89403371|NCT04804098|Active Comparator|15 Minute Linear Compression Profile|Compression Profile/Schedule 2 = 15 minute linear, Total Time Interval of Compression to treatment depth = 15 minutes Rate (slope) of compression = Linear rate of compression = 4.5 fsw/min to arrival at the treatment depth 45 fsw
89004271|NCT05355909|Experimental|Interventional group|After randomisation the patients will obtain a two week personalised fitness program to improve the preoperative fitness
89004272|NCT05342896|Experimental|MIND diet intervention|3-month intervention of dietary counseling to adhere to the MIND diet
89004273|NCT05342896|Experimental|MIND-plus-FB intervention|3-month intervention of dietary counseling to adhere to the MIND diet plus Forest Bathing intervention
88878822|NCT00004188|Experimental|Arm II (unpurged PBSC collection)|Induction-3 wks (cyclophosphamide day 0&1, doxorubicin hydrochloride & vincristine sulfate day 0-2 & filgrastim(G-CSF) day 3 crs 1,2,4 & 6.) Crs 3 & 5 (etoposide day 0-2, cisplatin day 0-3, G-CSF day 4). Immunocytology + PBSC undergo purged autologous bone marrow collection or repeat purged or unpurged PBSC collection. Surgical resection of the tumor after crs 5 of induct. CR, VGPR, PR after induct receive consolidation (melphalan day -7 to -5, carboplatin & etoposide day -7 to -4. Unpurged peripheral blood stem cell transplantation infusion day 0, G-CSF 4 hrs post transplant. Day 66, isotretinoin 2x day/14 days. Isotretinoin every 4 wks 6 crs. After consol (28 days from stem cell infusion), radiation therapy 1x day/7 days. Not undergoing autologous bone marrow transplantation receive maintenance(cyclophosphamide 30 mins, topotecan hydrochloride days 0-4, G-CSF day 5). Maint every 3 wks/3 crs. Radiation therapy and Isotretinoin 2x day/14 days then every 4 wks for 6 crs.
88878823|NCT00004242|Experimental|Arm I|See detailed description.
88878824|NCT00004266|Experimental|Nifedipine|Daily nifedipine at a dose adjusted for high blood pressure. Cholestyramine or gemfibrozil is administered per National Cholesterol Education Program guidelines. Diuretics and doxazosin may be given concurrently.
88878825|NCT00004266|Experimental|Lisinopril|Daily lisinopril at a dose adjusted for high blood pressure. Cholestyramine or gemfibrozil is administered per National Cholesterol Education Program guidelines. Diuretics and doxazosin may be given concurrently.
88878826|NCT00004266|Experimental|Nifedipine and simvastatin|Daily nifedipine at a dose adjusted for high blood pressure, and simvastatin at a dose adjusted for high low-density lipoproteins. Supplemental cholestyramine may be given as needed. If cholestyramine is not tolerated or if triglycerides are high, gemfibrozil is substituted for cholestyramine.
88878827|NCT00004266|Experimental|Lisinopril and simvastatin|Lisinopril at a dose adjusted for high blood pressure and simvastatin at a dose adjusted for high low-density lipoproteins.
88878828|NCT00004554|Experimental|Sertraline|sertraline
88878829|NCT00004554|Experimental|Naltrexone|naltrexone
88878830|NCT00004554|Experimental|Nal/Sert|naltrexone/sertraline
88878831|NCT00004554|Placebo Comparator|Placebo|Placebo
88878832|NCT00004578|Active Comparator|1|Group 1, n=32 initiated with ABT-378 & ritonavir; after 3 wks stavudine and lamivudine was added.
88878833|NCT00004578|Active Comparator|2|Group II patients (n=68) to be randomized after all Group I patients are enrolled and safety analysis is completed.
88878834|NCT00004842|Experimental|Budesonide|Oral budesonide
89530964|NCT02506829|Active Comparator|Usual care|Usual care in hospital, referral to a smoking cessation Quitline on discharge from hospital.
88878835|NCT00004932|Experimental|260 mg/m2 imatinib mesylate (ST571)|
88878836|NCT00004932|Experimental|340 mg/m2 imatinib mesylate (ST571)|
88878837|NCT00004932|Experimental|440 mg/m2 imatinib mesylate (ST571)|
88878838|NCT00004932|Experimental|570 mg/m2 imatinib mesylate (ST571)|
88878839|NCT00004992|Placebo Comparator|Placebo|
88878840|NCT00004992|Active Comparator|Metformin|
88878841|NCT00004992|Active Comparator|Intensive Lifestyle|
88878842|NCT00005022|Experimental|Arm 1|Large field radiation therapy 36 Gy, 1.8 Gy/fx/D/5 days/4 weeks, boost 1.8 Gy/D x 2 days, then BID x last 3 days.
88878843|NCT00005022|Experimental|Arm 2|Large field radiation therapy 36 Gy, 1.8 Gy/fx/D/5 days/4 weeks, boost 1.8 Gy/BID x last 5 days.
88878844|NCT00005022|Experimental|Arm 3|Large field radiation therapy 32.4 Gy, 1.8 Gy/fx/D/5 days x 18 fx, boost just in pm @ 1.8 Gy/fx on days 19 & 20, then boost 1.8 Gy BID x last 5 days.
88878845|NCT00005022|Experimental|Arm 4|Large field radiation therapy 28.8 Gy, 1.8 Gy/fx/5 days x 16 fx, boost just in pm @ 1.8 Gy/fx on days 17-20, then boost 1.8 Gy BID x last 5 days.
88878846|NCT00005022|Experimental|Arm 5|Large field radiation therapy 36 Gy, 1.8 Gy/fx/D 5 days/4 weeks, boost 1.8 Gy/D x 2 days, then BID x last 3 days.
88878847|NCT00005022|Experimental|Arm 6|Large field radiation therapy 25.2 Gy, 1.8 Gy/fx/5 days x 14 fx, boost just in pm @ 1.8 Gy/fx on days 15-20, then boost 1.8 Gy BID x last 5 days.
88878848|NCT00005028|Experimental|Arm I|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15 and bryostatin 1 IV over 1 hour on days 2, 9, and 16. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.
88878849|NCT00005064|Experimental|Treatment (bortezomib)|Patients receive PS-341 IV bolus twice weekly for 4 weeks followed by 2 weeks of rest. Treatment continues for a maximum of 12 courses in the absence of unacceptable toxicity or disease progression.
88878850|NCT00005076|Experimental|EgFR antibody|
88878851|NCT00005094|Experimental|Arm I (celecoxib)|Patients receive celecoxib twice a day for 3 years.
88878852|NCT00005094|Placebo Comparator|Arm II (placebo)|Patients receive placebo twice a day for 3 years.
88878853|NCT00005502||Residents of Olmsted County, MN with elevated Troponins|Anyone admitted to St Marys or Rochester Methodist Hospitals who have an elevated troponin during their hospitalization and are residents of Olmsted County, MN
88878854|NCT00005520||African American hydrochlorothiazide|300 African American hypertensives were treated with hydrochlorothiazide 25 mg daily for 4 weeks.
88878855|NCT00005520||European American hydrochlorothiazide|300 European American hypertensives were treated with hydrochlorothiazide 25 mg daily for 4 weeks
88878856|NCT00005520||African American candesartan|300 African American hypertensives were treated with candesartan 16 mg daily for 2 weeks followed by 32 mg daily for 4 weeks
88878857|NCT00005520||European American candesartan|300 European American hypertensives were treated with candesartan 16 mg daily for 2 weeks followed by 32 mg daily for 4 weeks
89004274|NCT05342896|No Intervention|Control group|For the control group, the participants will be received routine care.
89403372|NCT04802655|Experimental|Exergame Group (EG)|In addition to routine NDT training, Structured Exergame Program for upper extremity and trunk control will be applied in this group. Xbox one - Kinect supported video games will be selected for video-game based exergame program. The Video games to be included in the Exergame program will be selected by Analytical Hierarchy Process. Program will consist 40 minutes of exergame sessions and 15 sessions total. Sessions will be applied 2 times a week, and It is planned to complete in 8 weeks.
88878858|NCT00005592|Experimental|Rituxan + IDEC-In2B8, Rituxan + IDEC-Y2B8|For the first treatment, 250 mg/m2 Rituxan infusion and injection of IDEC-In2B8 (Indium- radioactive label) is given. If therapy is continued, approximately 1 week later a second infusion of Rituximab (250 mg/m2) is given followed by an infusion of IDEC-Y2B8 (Yttrium-radioactive label).
88878859|NCT00005604|Experimental|Treatment (rhIl-12, IL-2)|Patients receive interleukin-12 (IL-12) IV on days 1 and 4 for 6 weeks. Beginning on day 4 of the third week, patients receive interleukin-2 (IL-2) subcutaneously 1 hour before and 20 hours after each dose of IL-12. On subsequent courses, IL-2 and IL-12 are administered on days 1 and 4 of each week. Treatment continues for 6 weeks in the absence of disease progression or unacceptable toxicity. Patients with disease response may continue treatment until complete response or disease progression.
88878860|NCT00005610|Experimental|sargramostim|"Patients receive aerosolized sargramostim (GM-CSF) over 10-15 minutes twice daily for 7 days. Treatment repeats every 2 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Quality of life is assessed at baseline and prior to course 5.~Patients are followed every 2 months for at least 1.5 years."
88878861|NCT00005622|Other|Cy/TBI|cyclophosphamide and total body irradiation (TBI)
88878862|NCT00005640|Experimental|Mapping and Biopsy|Lymph node mapping and sentinel lymph node biopsy. Patients undergo preoperative endoscopy with injection of technetium Tc 99m sulfur colloid around tumor followed by celiotomy and intraabdominal exploration. At 30 minutes following injection, patients undergo lymphatic mapping with a gamma probe and biopsy of the sentinel lymph node(s). Following biopsy and mapping, patients undergo resection of primary tumor.
88878863|NCT00005646|Experimental|Paclitaxel|Patients receive paclitaxel for up to 4 cycles. One cycle = weekly drug for 6 weeks and 2 weeks rest
89190049|NCT03941873|Experimental|Sitravatinib monotherapy|Two dose levels of sitravatinib as monotherapy, 80 mg once daily and 120 mg once daily, will be evaluated in participants with unresectable locally advanced or metastatic HCC or G/GEJ cancer. A modified 3+3 design will be used in the dose escalation to confirm recommended Phase 2 dose (RP2D)
88878864|NCT00005676||VA-HIT and FOS|VA-HIT cohort: men with established CHD and low HDL-C FOS cohort: men without CHD
88878865|NCT00005724|Other|Minimal Intervention Group|Pamphlets on healthy eating mailed to participants.
88878866|NCT00005724|Experimental|Health Counselor Intervention Group|Food for Heart program, a structured diet treatment program for low-income patients with high cholesterol, given by health counselor at 4 treatment visits.
88878867|NCT00005724|Experimental|Computer Program Intervention Group|User-friendly interactive computer program providing dietary counseling tailored to the needs of the participant.
88878868|NCT00005772|Experimental|Hypothermia|Induced Whole-body hypothermia (with a target esophageal temperature of 33.5°C) for 96 hours
88878869|NCT00005772|Placebo Comparator|Normothermic|Placebo: Normothermic control group (with esophageal temperature at or near 37.0°C) for 96 hours
88878870|NCT00005796|Experimental|Single arm|PCV therapy
88878871|NCT00005808|Experimental|Part 1 (lutetium texaphyrin, LEEP)|Patients receive lutetium texaphyrin IV over 5-20 minutes. Patients undergo in vivo tissue assessment by spectrometer at 0, 1, 3, 5, 12, and 24 hours and loop electrical excision procedure (LEEP) at 24 hours after lutetium texaphyrin infusion.
88878872|NCT00005808|Experimental|Part 2 (lutetium texaphyrin, laser therapy, LEEP)|Patients receive lutetium texaphyrin IV over 5-20 minutes. A laser delivers 730 nm of light to the cervix for 4, 8, or 16 minutes. Patients undergo LEEP at 4, 8, or 12 hours after exposure of the cervix to the light source.
88878873|NCT00355524|Experimental|Group A with >= 20 kg to < 30 kg body weight|300 milligram (mg) of TMC114 tablet with 50 mg (which is equivalent to 0.625 milliliter [mL]) of ritonavir liquid (80 milligram/milliliter [mg/ml]) will be administered orally twice daily.
88878874|NCT00355524|Experimental|Group A with >= 30 kg to < 40 kg body weight|300 mg of TMC114 tablet with 50 mg (which is equivalent to 0.625 milliliter [mL]) of ritonavir liquid (80 milligram/milliliter [mg/ml]) will be administered orally twice daily.
88878875|NCT00355524|Experimental|Group A with >= 40 kg to < 50 kg body weight|450 mg of TMC114 tablet with 100 mg of ritonavir capsule will be administered orally twice daily.
88878876|NCT00355524|Experimental|Group B with >= 20 kg to < 30 kg body weight|375 mg of TMC114 tablet with 50 mg (which is equivalent to 0.625 mL) of ritonavir liquid (80 mg/mL) will be administered orally twice daily.
89403373|NCT04802655|Active Comparator|Activity Based Exercise Group (AG)|In addition to routine NDT training, Goal Directed Activity Based Exercises for upper extremity and trunk will be applied to this group. Program will consist 40 minutes of exergame sessions and 15 sessions total. Sessions will be applied 2 times a week, and It is planned to complete in 8 weeks.
89403374|NCT04801953|Active Comparator|Nimodipine|During surgery a nimodipine soaked gel foam pad is administered to the cranial nerves VII and VIII
89403375|NCT04801953|Placebo Comparator|Placebo|During surgery a sodium chloride soaked gel foam pad is administered to the cranial nerves VII and VIII
89403376|NCT04797000|Experimental|Eltrombopag Arm|Participants randomized to a 1: 1 ratio will take eltrombopag.
89403377|NCT04797000|Placebo Comparator|Placebo Arm|Participants randomized to a 1: 1 ratio will take Placebo.
89403378|NCT04795427|Experimental|asciminb arm|Patients will receive asciminib (40 mg BID continuous)
89403379|NCT04795427|Experimental|best available treatment arm|Patients will receive best available therapy chosen by investigator
89403380|NCT04792281||Patients with suspected native valve endocarditis|
89403381|NCT04789707||KERATOCONUS group|"All workers with keratoconus all stages followed at the service of ophthalmology in CHU Gabriel Montpied, Clermont-Ferrand, Auvergne.~The investigators only assessed data from usual routine practice. Patients answer the auto questionnaire in last minutes of consultation."
89403382|NCT04789707||CONTROL group|"workers with good visual acuity consulting in ophthalmology service of Clermont-Ferrand.~The investigators only assessed data from usual routine practice. Patients answer the auto questionnaire in last minutes of consultation."
88878877|NCT00355524|Experimental|Group B with >= 30 kg to < 40 kg body weight|450 mg of TMC114 tablet with 60 mg (which is equivalent to 0.75 mL) of ritonavir liquid (80 mg/mL) will be administered orally twice daily.
88878878|NCT00355524|Experimental|Group B with >= 40 kg to < 50 kg body weight|600 mg of TMC114 tablet with 100 mg of ritonavir capsule will be administered orally twice daily.
88878879|NCT00355524|Experimental|Participants with >= 50 kg body weight|600 mg of TMC114 tablet with 100 mg of ritonavir capsule will be administered orally twice daily.
88878880|NCT00355680|Experimental|1|Aurolab Green Laser
88878881|NCT00355680|Active Comparator|2|Available Green Laser
88878882|NCT00356460|Experimental|1 - Part 1|Dose Group
88878883|NCT00356460|Experimental|2 - Part 1|Dose Group
88878884|NCT00356460|Experimental|3 - Part 1|Dose Group
88878885|NCT00356460|Experimental|4 - Part 1|Dose Group
88878886|NCT00356460|Experimental|5 - Part 1|Dose Group
88878887|NCT00356460|Experimental|6 - Part 1|Dose Group
88878888|NCT00356460|Experimental|1 (Part 2)|
88878889|NCT00356460|Experimental|2 (part 2)|
88878890|NCT00356616|Experimental|A|Trizivir+ Tenofovir 2/day
88878891|NCT00356616|No Intervention|B|antiretroviral treatment optimizated by genotyp
88878892|NCT00356928|Experimental|Cyclophosphamide + T cells|Conditioning regimen with cyclophosphamide followed by donor T cells on Day 0.
88878893|NCT00357240|Active Comparator|A1|
88878894|NCT00357240|Active Comparator|A2|
88878895|NCT00357240|Experimental|A3 I|
88878896|NCT00357240|Experimental|A3 II|
88878897|NCT00357240|Active Comparator|B1|
88878898|NCT00357240|Active Comparator|B2|
88878899|NCT00357240|Experimental|B3 I|
88878900|NCT00357240|Experimental|B3 II|
88878901|NCT00357318|Experimental|Treatment (sunitinib malate, bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes on days 1, 15, and 29 and oral sunitinib malate (SU11248) once daily on days 1-28. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.
88878902|NCT00357474|Active Comparator|chemotherapy|Transarterial chemoembolization (TACE)
88878903|NCT00357474|Active Comparator|ethanol|Percutaneous ethanol injection therapy (PEIT)
88878904|NCT00357708|Experimental|Treatment (decitabine, vorinostat)|"Patients receive decitabine IV over 1 hour on days 1-5 and oral vorinostat (SAHA) three times daily on days 6-19. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 6 patients receive escalating doses of decitabine and SAHA until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, 10 additional patients are treated at that dose."
88878905|NCT00357786|Experimental|A|Enzyme replacement for Fabry's Disease
88878906|NCT00357942|Experimental|C group I|Morphine mouthwash and placebo i.v.(24 hours) Added on standard analgesic treatment (paracetamol and patient controlled analgesia, morphine)
88878907|NCT00357942|Active Comparator|C group II|Placebo mouthwash and morphine i.v.(24 hours) Added on standard analgesic treatment (paracetamol and patient controlled analgesia, morphine)
88878908|NCT00357942|Placebo Comparator|C group III|Placebo mouthwash and placebo i.v. (24 hours) Added on standard analgesic treatment (paracetamol and patient controlled analgesia, morphine)
88878909|NCT00358410|Experimental|GW679769|120mg once a day
89403383|NCT04781231|Experimental|MusicCare® device|The device consists of a headset and a touch pad. The patient can choose the style of music he prefers among 5. The 'U-shaped sequence' offered by MusicCare® is based on the principle of hypnoanalgesia. Musical induction is personalized according to the patient's preference. It will gradually lead to a hypnotic state of consciousness modified by variations in musical components such as rhythm, frequencies, orchestral formation and volume. A listening session lasts about 20 minutes.
89403384|NCT04781231|Active Comparator|Device with quiet recorded music|An mp3 device with headphones will be given to the patient. Caregivers will launch a quiet 20-minute music playlist
89403385|NCT04781231|Other|Usual management of anxiety|
89403386|NCT04771130|Experimental|Parts 1 and 2: AML Cohorts|Participants with AML will receive BGB-11417 and azacitidine on a 28-day cycle.
88878910|NCT00358410|Placebo Comparator|Placebo|Placebo once a day
88878911|NCT00358488|Experimental|GSK159797 (10, 15, and 20mcg)|GSK159797 (10, 15, and 20mcg)
88878912|NCT00358488|Experimental|salbutamol|salbutamol
88878913|NCT00358488|Experimental|salmeterol 50mcg|salmeterol 50mcg
88878914|NCT00358488|Placebo Comparator|placebo|placebo
89403387|NCT04771130|Experimental|Parts 1 and 2: MDS Cohorts|Participants with MDS will receive BGB-11417 and azacitidine on a 28-day cycle.
89403388|NCT04771130|Experimental|Part 3: AML and MDS Cohorts|Participants with AML and MDS will receive BGB-11417 and azacitidine on a 28-day cycle. A subset of the participants will receive a modified second cycle of treatment to explore drug-drug interactions (DDI) with posaconazole.
89403389|NCT04771130|Experimental|Part 3: AML and MDS Cohort|Participants with MDS and R/R AML (China only) will receive BGB-11417 on a 28-day cycle.
89403390|NCT04765709|Experimental|BRIDGE single arm|"Treatment plan:~Part 1: induction with durvalumab plus histology-based chemotherapy regimen.~Part 2: patients with a sufficient tumor shrinkage to be considered eligible for part 2 and they will be treated concomitantly with durvalumab and radiotherapy.~Part 3: patients with partial response or stable disease after part 2 will be eligible for durvalumab maintenance, for up to 2 years or until disease progression or unacceptable toxicity."
88878915|NCT00358566|Active Comparator|Gemcitabine|Gemcitabine alone treatment.
88878916|NCT00358566|Experimental|GV1001|GV1001 in sequential combination with Gemcitabine
88878917|NCT00359190|Experimental|Lapatinib receivers|Subjects with treatment-naïve breast tumors will be administered lapatinib 1500 mg once daily, 1000 mg once daily, or 500 mg twice daily for a minimum of 9 days and maximum of 15 days prior to surgical resection..
88878918|NCT00359268||1|Any patient with a condition or disease whose etiology is unknown.
88878919|NCT00359658|Experimental|1|prednisolon withdrawal: reduction of maintenance dosage, 0,5 mg of the daily dose every week till withdrawal; Mycophenolatmofetile administration: start doses 250 mg, increase of the daily dose about 250 mg every week till reaching 2 g/daily; Cyclosporin A reduction: 8 weeks after starting prednisolon withdrawal and Mycophenolatmofetile administration reduction of Cyclosporin A trough level till a range from 50 to 90 mg/ml
88878920|NCT00359814|Experimental|1|Azathioprine administration: was stopped at day 0; Mycophenolatmofetile administration: was started with 250 mg/daily at day 1, the start dose was increased about 250 mg/daily every week till 2 g/daily; Cyclosporin A reduction: Cyclosporin A trough level reduction started after week 8. The new target range was 50 to 90 ng/ml
88878921|NCT00359892|Experimental|Obatoclax Mesylate|Obatoclax Mesylate 60mg
88878922|NCT00359970|Active Comparator|Azithromycin 500 mg plus Placebo|a single 500 mg dose of Azitrhomycin at the start of treatment; a single loading dose of placebo at the start of treatment and then a dose of placebo after each loose stool
88878923|NCT00359970|Active Comparator|Azithromycin 1000 mg plus Placebo|a single 1000 mg dose of Azitrhomycin at the start of treatment; a single loading dose of placebo at the start of treatment and then a dose of placebo after each loose stool
88878924|NCT00359970|Experimental|Azithromycin 500 mg plus Loperamide|a single 500 mg dose of Azitrhomycin at the start of treatment; a single 4 mg loading dose of Loperamide at the start of treatment and then 2 mg Loperamide after each loose stool
88878925|NCT00360438|Experimental|Rasburicase|
88878926|NCT00360594|Experimental|1|Acamprosate
89403391|NCT04764175|Experimental|Telephone All Nations Breath of Life|This is a culturally targeted smoking cessation program developed for American Indian communities. It includes individual telephone counseling, text messaging, and educational materials.
89403392|NCT04764175|Active Comparator|Comparison Program|This is a non-culturally targeted smoking cessation program. It includes individual counseling, text messaging, and educational materials.
89403393|NCT04761328|Experimental|Cessation of treatment|If the patient is randomized to this arm, they will be asked to stop their immunotherapy
89403394|NCT04738097|Experimental|intervention|Intervention group will be treat with ASA 325 mg stat and ticagrelor 180 mg stat, then ASA 80 mg daily and ticagrelor 90 mg BID for 21 days.
89403395|NCT04738097|Active Comparator|control|control group will be treat with ASA 325 mg stat and clopidogrel 300 mg stat, then ASA 80 mg and clopidogrel 75 mg daily for 21 days.
89403396|NCT04726891|Active Comparator|Continued M2M + SNS for 9 weeks|Participants who successfully watch and exercise at or above 40 minutes per week will continue doing M2M + SNS for the remaining 9 weeks of the study.
89403397|NCT04726891|Active Comparator|Augmented M2M + SNS + IBC for 9 weeks|Some participants with sub-optimal adherence in the first treatment stage will be randomized to one of two treatment groups in the second treatment stage. these participants will receive M2M plus social networking support augmented with individualized behavioral coaching. Individualized behavioral coaching involves a weekly coaching session to improve self-regulatory skills based on prior and individualized exercise prescription. The exercise prescriptions are determined by the coach and individual based on their current activity level and a 4-week goal. An example of tailoring the exercise prescribed involves setting a goal of completing the exercise routine one time for the upcoming week instead of three times. The coach will be trained in motivational interviewing to help the participant modify their exercise habits.
89403398|NCT04726891|Active Comparator|Switched M2M Live for 9 weeks|The remaining half of participants with sub-optimal adherence in the first treatment stage will switch to another M2M-based home exercise intervention, M2M Live. M2M Live involves one-on-one tele-exercise training with an M2M instructor, which provides accountability and immediate, tailored feedback along with custom movements and music. During the first week of M2M Live, the participant will set a schedule to meet with the M2M instructor 1 time each week for an exercise session. The M2M Live instructors are also trained in motivational interviewing in order to coach participants through any barriers to changing their exercise behavior.
89403399|NCT04726891|Active Comparator|Continued M2M + IBC for 6 weeks|Participants who successfully watch and exercise at or above 40 minutes per week will continue doing M2M + SNS for the remaining 6 weeks of the study.
89530965|NCT02506829|Experimental|Financial Incentives|Usual care in hospital, referral to a smoking cessation Quitline on discharge from hospital. Financial incentives for: a) speaking with a coach from the Smoker's Quitline ($50), b) completion of another community-based smoking-cessation program ($50), and/or c) use of pharmacotherapies for smoking cessation at 2 weeks ($50); and d) for smoking cessation, confirmed with the use of a cotinine test at 2 months ($150); and e) for smoking cessation, confirmed with the use of a cotinine test at 6 months after study enrollment ($250).
88878927|NCT00360594|Placebo Comparator|2|Placebo
88878928|NCT00361530|Active Comparator|Pravastatin|Patient has 10mg oral administration of Pravastatin per day. It starts within one month from their entry and continues every day until the end of the study or its endpoints.
88878929|NCT00361530|No Intervention|No intervention|Patient has no intervention.
88878930|NCT00362778|Sham Comparator|Serum saline|
88878931|NCT00362856|Placebo Comparator|Placebo + Gluten|placebo TID + gluten 800 mg TID administered orally in capsules
88878932|NCT00362856|Placebo Comparator|Placebo + Gluten placebo|placebo TID + gluten placebo TID administered orally in capsules
88878933|NCT00362856|Other|Larazotide acetate 8 mg + Gluten placebo|Safety Control Arm. Larazotide acetate 8 mg TID + gluten placebo TID administered orally in capsules
88878934|NCT00362856|Active Comparator|Larazotide acetate 0.25 mg + Gluten|Larazotide acetate 0.25 mg TID + gluten 800 mg TID administered orally in capsules
88878935|NCT00362856|Active Comparator|Larazotide acetate 1 mg + Gluten|Larazotide acetate 1 mg TID + gluten 800 mg TID administered orally in capsules
88878936|NCT00362856|Active Comparator|Larazotide acetate 4 mg + Gluten|Larazotide acetate 4 mg TID + gluten 800 mg TID administered orally in capsules
89530966|NCT03232177|Experimental|Anagre Cap.|twice a day
88878937|NCT00362856|Active Comparator|Larazotide acetate 8 mg + Gluten|Larazotide acetate 8 mg TID + gluten 800 mg TID administered orally in capsules
88878938|NCT00362934|Experimental|1|
88878939|NCT00362934|Active Comparator|2|
88878940|NCT00363714|Experimental|1|Single intravitreal injection
88878941|NCT00363714|Experimental|2|Single intravitreal injection
88878942|NCT00363714|Experimental|3|Single intravitreal injection
88878943|NCT00363714|Experimental|4|Single intravitreal injection
88878944|NCT00363714|Experimental|5|Single intravitreal injection
88878945|NCT00363714|Experimental|6|Single intravitreal injection
88878946|NCT00363948|Placebo Comparator|P|
88878947|NCT00363948|Experimental|E|
88878948|NCT00364104|Experimental|A|A 10-day course of Hp infection sequential eradication therapy plus 6-weeks of iron supplementation
88878949|NCT00364104|Experimental|B|The 10-day course of Hp infection sequential eradication therapy only plus 6-weeks of matching placebo of iron supplementation
88878950|NCT00364104|Experimental|C|6-weeks of iron supplementation only plus 10-days of matching placebo of Hp infection eradication therapy
88878951|NCT00364104|Placebo Comparator|D|
88878952|NCT00364416||001|
88878953|NCT00364572|Placebo Comparator|1|Two injections of epidural saline 2 weeks apart
88878954|NCT00364572|Experimental|Epidural injection of etanercept|Two injections of epidural etanercept 2 weeks apart
88878955|NCT00364650|Placebo Comparator|I|Placebo
88878956|NCT00364650|Experimental|II|Probiotic supplement
88878957|NCT00366210|Experimental|Expanded CI therapy|3.5 hours of training for the more-affected arm set in the laboratory for 15 consecutive weekdays
88878958|NCT00366210|Placebo Comparator|Placebo Control|Stretching, movement exercises, and EMG biofeedback for the same duration as the experimental intervention.
88878959|NCT00366210|No Intervention|Usual & Customary Care Control|Treatments available to participants as part of their regular medical care, such as conventional physical or occupational therapy. For some participants, this would involve no treatment, since all participants were more than one year post stroke.f standard clinical care.
88878960|NCT00366288||1|
88878961|NCT00366288||2|
88878962|NCT00366288||3|
88878963|NCT00366288||4|
88878964|NCT00366288||5|
88878965|NCT00366288||6|
88878966|NCT00366288||7|
88878967|NCT00366834|Placebo Comparator|Control|ondansetron 8 mg oral twice daily on Day 1-3 and dexamethasone 8 mg IV on Day 1 + placebo
88878968|NCT00366834|Experimental|Single dose oral|ondansetron 8 mg oral twice daily on Day 1-3 and dexamethasone 8 mg IV + casopitant 150 mg on Day 1
88878969|NCT00366834|Experimental|3-day oral|ondansetron 8 mg oral twice daily on Day 1-3 and dexamethasone 8 mg IV + casopitant 150 mg on Day 1 + 50 mg on days 2 & 3
88878970|NCT00366834|Experimental|3-day IV/oral|ondansetron 8 mg oral twice daily on Day 1-3 and dexamethasone 8 mg IV on Day 1 + 90 mg IV casopitant on day 1 and 50 mg oral casopitant on days 2 & 3
88878971|NCT00366990|Active Comparator|weight loss and sodium intake reduction|Behavioral and weight loss intervention, including a low sodium diet. Study goals are a 10% weight loss, 200 minutes of moderate physical activity a week, such as walking, and a 50% reduction in sodium intake.
88878972|NCT00366990|Placebo Comparator|weight loss and normal sodium intake|Behavioral and weight loss intervention, with regular sodium intake. Study goals are a 10% weight loss, 200 minutes of moderate physical activity a week, such as walking.
88878973|NCT00367302|Experimental|1|Buprenorphine maintenance
88878974|NCT00367302|Active Comparator|2|Methadone maintenance
88878975|NCT00368160|Experimental|1|eszopiclone 3 mg
88878976|NCT00368160|Placebo Comparator|2|Placebo tablet
88878977|NCT00368706|Experimental|1|
88878978|NCT00368706|Active Comparator|2|
88878979|NCT00368784||1|Individuals ages 12-85 with an immune mediated skin disease, such as psoriasis, scleroderma, or mycosis fungoides. Peripheral blood and/or check swabs will be collected from participants ages 12- 85 years old. These samples will then be used to characterize the inflammatory cells as described above.
88878980|NCT00368784||2|Age-Matched Controls without immune mediated skin diseases. Peripheral blood and/or check swabs will be collected from participants ages 12- 85 years old. These samples will then be used to characterize the inflammatory cells as described above.
88878981|NCT00369018|Active Comparator|MAL 3|
88878982|NCT00369018|Active Comparator|MAL 12|
89403400|NCT04726891|Active Comparator|Augmented M2M + SNS + IBC for 6 weeks|Some participants with sub-optimal adherence in the first treatment stage will be randomized to one of two treatment groups in the second treatment stage. these participants will receive M2M plus social networking support augmented with individualized behavioral coaching. Individualized behavioral coaching involves a weekly coaching session to improve self-regulatory skills based on prior and individualized exercise prescription. The exercise prescriptions are determined by the coach and individual based on their current activity level and a 4-week goal. An example of tailoring the exercise prescribed involves setting a goal of completing the exercise routine one time for the upcoming week instead of three times. The coach will be trained in motivational interviewing to help the participant modify their exercise habits.
88878983|NCT00369018|Active Comparator|HAL 10, 3|
88878984|NCT00369018|Active Comparator|HAL 10, 12|
88878985|NCT00369018|Active Comparator|HAL 40, 3|
88878986|NCT00369018|Active Comparator|HAL 40, 12|
88878987|NCT00369174|Experimental|Treatment (rosiglitazone maleate)|Patients receive oral rosiglitazone once daily. Treatment continues for 12 weeks in the absence of unacceptable toxicity.
88878988|NCT00369408|Experimental|1|naltrexone (50 mg orally) for 12-week treatment period
88878989|NCT00369408|Placebo Comparator|2|placebo for 12-week treatment period
88878990|NCT00370110|Experimental|Itopride|
88878991|NCT00370110|Other|Placebo|
88878992|NCT00370344|Active Comparator|Laparoscopic cholecystectomy|Operation by experts in laparoscopy.
88878993|NCT00370344|Active Comparator|Small-incision open cholecystectomy|Operation by experts in small-incision cholecystectomy.
88878994|NCT00370500|Experimental|A|There is only one arm in this study. All probands receive quetiapine.
88878995|NCT00370812|Active Comparator|A|AMT with conventional medical therapy
88878996|NCT00370812|Active Comparator|B|Medical treatment alone
88878997|NCT00371280|Active Comparator|1|Pegged unpegged hydroxyapatite orbital implantation
88878998|NCT00371280|Active Comparator|2|Unpegged hydroxyapatite orbital implantation
88878999|NCT00371592|Experimental|1|Participants will receive acyclovir for 24 weeks
88879000|NCT00371592|Placebo Comparator|2|Participants will receive acyclovir placebo for 24 weeks
88879001|NCT00371748|Experimental|Arm 1|
88879002|NCT00371748|Other|Arm 2|Historical Comparator: control data derived from a TAXUS V de novo lesion and stent size-matched cohort randomized to receive a single, planned 2.25 mm DES
88879003|NCT00371748|Other|Arm 3|Historical Comparator: control data derived from a TAXUS V de novo lesion size-matched cohort randomized to receive a 2.25 mm or 2.5 mm BMS
88879004|NCT00371904|Experimental|1|
88879005|NCT00371904|Active Comparator|2|
88879006|NCT00372138|Experimental|PRP + autologous thrombin|simultaneous perioperative PRP and autologous thrombin in the aneurysm sac, during the endovascular treatment of unruptured abdominal aortic aneurysms
88879007|NCT00372216|Active Comparator|1|Pre-hospital loading dose of 600 mg Clopidogrel as early as possible (in addition to standard infarction therapy)
88879008|NCT00372216|No Intervention|2|Standard infarction therapy (without study-specific additions, no Clopidogrel before angiography)
88879009|NCT00372294|Active Comparator|1|Classic regimen (Pyrimethamine-Sulfadiazine + Prednisolon)
88879010|NCT00372294|Active Comparator|2|Intravitreal Clindamycin & Dexamethasone
88879011|NCT00372684||1|with severe malaria hospitalized in ICU
88879012|NCT00372684||2|with uncomplicated malaria
88879013|NCT00372762|Active Comparator|Furosemide|Patients will be assigned to furosemide therapy (20mg to 80mg) orally, once or twice daily for an 8-week period.
89190050|NCT03941873|Experimental|Sitravatinib plus Tislelizumab|The combination dose escalation of sitravatinib (80 mg once daily and 120 mg once daily; modified 3+3 design) with tislelizumab (200 mg every 3 weeks, in both cohorts) will be evaluated in unresectable locally advanced or metastatic HCC or G/GEJ cancer participants . If the combination dose of 80 mg sitravatinib and 200 mg tislelizumab has been declared tolerable, the dose of sitravatinib will be escalated to 120 mg and tislelizumab will remain fixed at 200 mg. Approximately 12 to 24 evaluable participants will be treated. The dose of tislelizumab during dose escalation for the combination will be kept fixed at 200 mg
88879014|NCT00372762|Active Comparator|Bumetanide|Patients will be assigned to bumetanide therapy at an equipotent dose to furosemide therapy (1mg bumetanide is equivalent to 40mg furosemide)for an 8-week period.
88879015|NCT00372840|Experimental|Arm I|Patients receive a specific print intervention manual entitled Facing Forward Series: Life After Cancer Treatment and a general print intervention fact sheet entitled The Cancer Information Service, Questions and Answers.
88879016|NCT00372840|Active Comparator|Arm II|Patients receive the general print intervention fact sheet entitled The Cancer Information Service, Questions and Answers.
88879017|NCT00372918|Other|1|Transnasal Esophagoscopy
88879018|NCT00373074|Active Comparator|15 cc|15 cc of blood used for Epidural Blood Patch
88879019|NCT00373074|Active Comparator|20 cc|20 cc of blood used for Epidural Blood Patch
88879020|NCT00373074|Active Comparator|30 cc|30cc of blood used for Epidural Blood Patch
88879021|NCT00373152|Experimental|RadioFrequency Ablation for Breast Cancer|
88879022|NCT00373230|Experimental|1|Internet based telemedicine weight maintenance program
88879023|NCT00373230|Active Comparator|2|In person weight maintenance monthly consultations
88921944|NCT06038175|Experimental|vHIT testing|For the research portion of this study, following standard of care examinations listed above, the patient would have a vHIT headset placed on their head for approximately 3-5 minutes to test if they exhibit corrective saccadic movements and to measure gain reduction to identify vestibular hypofunction. During vHIT testing a commercially available mono-ocular video oculography system will be donned on the patient. Subjects will be instructed to maintain fixation at a target from 1 m distance. A study team member will deliver at least 5 head impulses per side in the horizontal and vertical planes with unpredictable timing and direction. A neurotologist will then evaluate the VOR gain or the ratio of eye velocity over-head velocity. The presence of refixation (catch-up) saccades, either overt or covert, will be evaluated by the study team. In line with previous literature, the vHIT testing will be considered to be abnormal if VOR gain is <0.8 in the presence of refixation saccades .
88921945|NCT06038175|Active Comparator|Standard of Care|The intervention group will be compared to standard of care provided to patients currently admitted for dizziness. Standard of care includes National Institute of Health Stroke Scale evaluation, evaluation by a neurologist, and a CT scan or MRI if warranted.
88921946|NCT06035549|Experimental|Culturally Tailored Digital Resilience-Building|The Culturally Tailored Resilience-Building intervention will be provided to East Asian immigrants with cancer and their family caregivers.
88921947|NCT06031584|Experimental|Study treatment|Participants received BL-M07D1 therapy in the first cycle (3 weeks). Participants who had a clinical benefit could receive additional cycles of additional treatment. Administration will be discontinued because of disease progression or intolerable toxicity or for other reasons.
88921948|NCT06030076||Tildrakizumab|Participants who have been prescribed tildrakizumab to manage moderate-to-severe plaque psoriasis according to summary of product characteristic (SmPC) in routine clinical practice settings will be observed prospectively for up to 28 weeks.
88921949|NCT06029257||Tildrakizumab|Participants who have been prescribed tildrakizumab in the treatment of plaque psoriasis with a manifestation in the genital area according to SmPC in routine clinical practice settings will be observed prospectively for up to 52 weeks.
88921950|NCT06028997|Experimental|Intervention arm|
88921951|NCT06028165|Active Comparator|CAG group|Patients who underwent coronary artery bypass grafting based on conventional coronary angiography
88921952|NCT06028165|Active Comparator|CT-FFR group|Patients who underwent coronary artery bypass grafting based on cardiac computed tomography-derived fractional flow reserve
88921953|NCT06027008|Experimental|Mechanical Insufflation-Exsufflation|Invasively ventilated patients will receive MI-E until successful extubation or for a maximum of 7 days. MI-E will be given in the morning and afternoon each calendar day. Patients will be pre-oxygenated with FiO2 100% prior to disconnection from the ventilator; additional 15 litres oxygen can be added; A pre-set program is used: three times three cycles with a 2-second insufflation and an immediate 2-second exsufflation. The cycles of the MI-E session will be performed with a positive and negative pressure of 40 cmH2O. The program is set up with the possibility of auto-triggering by the patient.
89004275|NCT05332483|Experimental|Arm 1 - Megestrol|All study participants will receive Megestrol acetate, 160 mg daily (two 40mg tablets twice a day), for a minimum of 18 days.
89190051|NCT03941873|Experimental|Anti-PD-1/PD-L1 Antibody Naïve or R/R HCC (Monotherapy)|
88813336|NCT01566539|Placebo Comparator|Empathy Task - Placebo|Healthy volunteers between the ages of 18-30 years will receive placebo at scan 1 and placebo at scan 2 prior to completing an empathy task.
88813337|NCT01566539|Experimental|Anxious and Depressed Subjects - OT|Depressed or anxious men between the ages of 18 and 22 will receive intranasal OT prior to completing the Prisoner's Dilemma game task and MRI scan.
88813338|NCT01566539|Placebo Comparator|Anxious and Depressed Subjects - Placebo|Depressed or anxious men between the ages of 18 and 22 will receive intranasal placebo prior to completing the Prisoner's Dilemma game task and MRI scan.
89190052|NCT03941873|Experimental|Anti-PD-1/PD-L1 antibody naive HCC(Combination)|
89190053|NCT03941873|Experimental|Anti-PD-1/PD-L1 antibody refractory/resistant HCC|
89190054|NCT03941873|Experimental|Anti-PD-1/PD-L1 antibody naive G/GEJ cancer|
89530967|NCT02499731|Experimental|Strong Hearts, Healthy Communities|Full Intervention participants will meet twice per week for one hour each time, for approximately 6 months plus monthly community meetings and events. Participants will learn and practice good nutrition and physical activity for improved individual, family and community health.
88879024|NCT00373932|Experimental|MOBILE-A|Coached exercise persistence intervention
88879025|NCT00373932|Active Comparator|MOBILE-B|Self-monitored exercise persistence intervention
88879026|NCT00374634|Active Comparator|"Individual or standard rFSH dose"|"Patients were randomized to recieve individual (50, 75 or 100 IU/day) or standard (75 IU/day) rFSh dose. The individual dose was prescribed according to a dosage nomogram based on the patient's body weight (kg) and the total antral follicle count (Freiesleben NC et al., RBMOnline 2009;17:632-64)."
88879027|NCT00374634|Active Comparator|"Standard rFSH dose"|"Standard dose of rFSH"
88879028|NCT00374946||A|THA. Bearing of Zirconia head and UHMWPE liner
88879029|NCT00374946||B|THA. Bearing of CO-Cr-Mo head and liner
88879030|NCT00374946||C|THA. Head og Zirconia head and UHMWPE moulded in shell (Asian)
88879031|NCT00374946||D|THA. Head and shell og Alumina ceramic
88879032|NCT00375024|Other|1: Patient Navigator|Patients will meet with a Patient Navigator regarding their treatment and any related concerns.
88879033|NCT00375024|Other|2: Without Navigator|Patient will work with existing clinic staff, which does not include a Patient Navigator.
88879034|NCT00375102|Experimental|Acup|Acupuncture
88879035|NCT00375102|Experimental|RR|Relaxation Response
88879036|NCT00375102|No Intervention|UC|Usual Care
88879037|NCT00375258|Experimental|1|Active
88879038|NCT00375258|Placebo Comparator|2|
88879039|NCT00375336||1|Patients with aortic stenosis (mean transvalvular aortic gradient ≥30 mm Hg) plus angiographically significant coronary artery disease (more than 50% diameter stenosis)
88879040|NCT00375336||2|Patients with nonobstructive aortic sclerosis (mean gradient ≤10 mmHg) plus angiographically significant coronary artery disease (more than 50% diameter stenosis)
88879041|NCT00375336||3|Patients with normal aortic valve plus angiographically significant coronary artery disease (more than 50% diameter stenosis)
89190055|NCT03941587|Active Comparator|Aflibercept + RF-PDT|"Patients with symptomatic macular PCV (n=80) as confirmed by Indocyanine green Angiography(ICGA) will be treated with Aflibercept (dosage=2mg/0.05ml) through an intravitreal injection + RF-PDT ( 6mg/m2 intravenous infusion of Verteporfin followed by laser light at a dose rate of 25 Joules/cm2) at baseline.~Aflibercept- 1st treatment (baseline) followed by minimum retreatment interval of 4 weeks (from Baseline to week 8) and then retreatment at intervals of 4 weeks pro re nata (PRN) retreatment( week 12-48). Primary endpoint at week 52.~RF-PDT treatment at baseline followed by pro re nata (PRN) at 12 week intervals.~At each visit, subjects will be assessed based on BCVA, ophthalmic examination and Optical Coherence Tomography (OCT)"
89190056|NCT03941587|Active Comparator|Aflibercept + sham RF-PDT|"Patients with symptomatic macular PCV (n=80) as confirmed by Indocyanine green Angiography(ICGA) will be treated with Aflibercept (dosage=2mg/0.05ml) through an intravitreal injection, at baseline. A minimum of 1 injection(baseline) followed by minimum pro re nata (PRN) retreatment interval of 4 weeks ( from baseline to week 8) and then a minimum of 4 weeks retreatment thereafter (week 12-48). Primary endpoint at week 52.~Sham RF-PDT treatment at baseline followed by pro re nata (PRN) at 12 week intervals.~At each visit, subjects will be assessed based on Best Corrected Visual Acuity (BCVA), ophthalmic examination and Optical Coherence Tomography (OCT)"
89190057|NCT03941171|Experimental|Group 1|PAO+usual+PRT
88879042|NCT00375570|Experimental|1|ME-609
88879043|NCT00375648|Experimental|zoledronate|
88879044|NCT00375726|Experimental|1|One subcutaneous vaccination with rDEN3/4delta30(ME) vaccine (10^3 PFU dose) into the deltoid region of either arm.
88879045|NCT00375726|Experimental|2|One subcutaneous vaccination with rDEN3/4delta30(ME) vaccine (10^5 PFU dose) into the deltoid region of either arm. This arm may enroll after Arm 1 depending on the immunological response of Arm 1.
88879046|NCT00375726|Experimental|3|One subcutaneous vaccination with rDEN3/4delta30(ME) vaccine (10^1 PFU dose) into the deltoid region of either arm. This arm may enroll after Arm 1 depending on the immunological response of Arm 1.
88879047|NCT00375726|Placebo Comparator|4|One subcutaneous vaccination with placebo into the deltoid region of either arm.
88879048|NCT00375882|Other|cochlear implantation with mild hypothermia|
88879049|NCT00376272|Experimental|1|
88879050|NCT00376272|Placebo Comparator|2|
88879051|NCT00376350|Experimental|High dose manipulation|High dose spinal manipulation + ultrasound
88879052|NCT00376350|Experimental|Moderate dose manipulation|Moderate dose manipulation + low dose massage + ultrasound
88879053|NCT00376350|Experimental|Low dose manipulation|low dose spinal manipulation + moderate dose massage + ultrasound
88879054|NCT00376350|Other|High dose masssage|high dose massage + ultrasound
88879055|NCT00376584|Placebo Comparator|Placebo → MK-0524A 2g|Following an 8-week active run-in (MK-0524A 1g (4 Weeks) then MK-0524A 2g (4 weeks) participants will be administered MK-0524A Placebo for 5 days (drug holiday) followed by MK-0524A 2 g for the remainder of the study (7 days).
88879056|NCT00376584|Active Comparator|Placebo → Extended Release (ER)-Niacin 2g|Following an 8-week active run-in (MK-0524A 1g (4 Weeks) then MK-0524A 2g (4 weeks) participants will be administered MK-0524A Placebo for 5 days (drug holiday) followed by ER-Niacin 2g for the remainder of the study (7 days)
88813339|NCT01566539|Experimental|Healthy Volunteers - Lorazepam|Healthy normal men between the ages of 18 and 22 will receive lorazepam prior to completing the Prisoner's Dilemma game task and MRI scan.
89190058|NCT03941171|Active Comparator|Group 2|PRT
89190059|NCT03930524|No Intervention|Assessment Only|Control
89190060|NCT03930524|Experimental|Early-college Universal|Prior to beginning their first semester of college, incoming students will receive personalized normative feedback (PNF) comparing their experiences to other college students their age, as well as up to 4 self-monitoring surveys over the course of the semester.
89190061|NCT03930524|Experimental|Early-college No Coach (automated email)|Students from the early-college universal arm, who flag on one of the self-monitoring surveys are invited to engage in a web-based resource or in-person consultation to improve well-being, with a particular emphasis on alcohol use.
89190062|NCT03930524|Experimental|Early-college Coach|Students from the early-college universal arm, who flag on one of the self-monitoring surveys are invited to correspond with an online health coach who will use motivational interviewing strategies to encourage engagement in a web-based resource or in-person consultation to improve wellbeing, with a particular emphasis on alcohol use.
89190063|NCT03930524|Experimental|Later-college Universal|After beginning their first semester of college, students will receive personalized normative feedback (PNF) comparing their experiences to other college students their age, as well as up to 4 self-monitoring surveys over the course of the semester.
89190064|NCT03930524|Experimental|Later-college No Coach (automated email)|Students from the later-college universal arm, who flag on one of the self-monitoring surveys are invited to engage in a web-based resource or in-person consultation to improve wellbeing, with a particular emphasis on alcohol use.
89190065|NCT03930524|Experimental|Later-college Coach|Students from the later-college universal arm, who flag on one of the self-monitoring surveys are invited to correspond with an online health coach who will use motivational interviewing strategies to encourage engagement in a web-based resource or in-person consultation to improve wellbeing, with a particular emphasis on alcohol use.
89403401|NCT04726891|Active Comparator|Switched M2M Live for 6 weeks|The remaining half of participants with sub-optimal adherence in the first treatment stage will switch to another M2M-based home exercise intervention, M2M Live. M2M Live involves one-on-one tele-exercise training with an M2M instructor, which provides accountability and immediate, tailored feedback along with custom movements and music. During the first week of M2M Live, the participant will set a schedule to meet with the M2M instructor 1 time each week for an exercise session. The M2M Live instructors are also trained in motivational interviewing in order to coach participants through any barriers to changing their exercise behavior.
88879057|NCT00376584|Experimental|MK-0524A 2g|Following an 8-week active run-in (MK-0524A 1g (4 Weeks) then MK-0524A 2g (4 weeks) participants will be administered MK-0524A 2g for the remainder of the study (approximately 2 weeks).
88879058|NCT00376740|Experimental|Immediate zoledronic acid|Patients on this arm will receive zoledronic acid every 6 months during 2.5 years of letrozole therapy starting within 3 months of the start of letrozole therapy. (5 doses of zoledronic acid)
88879059|NCT00376740|Active Comparator|Delayed zoledronic acid|Patients on this arm will receive zoledronic acid during the 2.5 years of letrozole treatment only after the T-score on bone mineral density testing falls below minus 2.0.
89403402|NCT04712565|Experimental|Astra Tech Implant System Profile EV|Implants with sloped marginal configuration without bone augmentation are used.
89403403|NCT04712565|Active Comparator|Astra Tech Implant System EV|Implants with regular neck design and GBR procedure fixed with two membrane pins will be used.
89403404|NCT04707716|Experimental|conometric concept (Acuris system)|single implant crown retention using friction only
89403405|NCT04707716|Active Comparator|screw retention|screw retained implant Crown fixation
89403406|NCT04707716|Active Comparator|cementation|cement retained implant Crown fixation
89403407|NCT04666623|Active Comparator|intranasal esketamine (56mg)|
88879060|NCT00376896|Experimental|GW876008 20mcg|GW876008 20mcg
89403408|NCT04666623|Placebo Comparator|placebo|
89403409|NCT04654117|No Intervention|Baseline|Following completing the online tutorial, each agency will have a baseline lasting 3-6 weeks (this will be staggered by agency).
89403410|NCT04654117|Experimental|Treatment (Consultation)|Consultation will be conducted in 4-week phases that correspond to the three consultation components. The phases will occur in a randomized order. During a given phase, no components of any other phases will be provided. Feedback phase. Consultees will submit 5-minute clips of session recordings of their Project ImPACT session with their enrolled family for feedback. Oral feedback will be provided by the consultant and peers. Case support phase. The consultant will lead the group in problem-solving common barriers that providers experience with their cases. Skill rehearsal phase. The consultant will lead skill rehearsal practices in which providers role play elements of a Project ImPACT session.
88879061|NCT00376896|Experimental|GW876008 200mcg|GW876008 200mcg
88879062|NCT00376896|Placebo Comparator|Placebo|Placebo
88879063|NCT00377130|No Intervention|Arm I- Usual psychological care|Usual psychological care- no intervention
88879064|NCT00377130|Experimental|Self administered Stress Management|Self-Administered Stress Management Training Plus Usual Psychosocial Care
88879065|NCT00377208|Active Comparator|Intervention Condition|Receives web-based feedback specific to their blood-pressure and other health-related conditions.
88879066|NCT00377208|No Intervention|Control Condition|The control group receives preventative feedback, general to the population.
88879067|NCT00377286|Placebo Comparator|2|1500 mg of lite lemonade
88879068|NCT00377286|Active Comparator|1|1500 mg glucosamine in 16 oz lite lemonade 1 time daily for 6 months
89199044|NCT00883935|Experimental|Sequence 1|In the first treatment period, all subjects will receive GSK1349572 30mg q24h for 5 days (treatment A). In period two, subjects will receive GSK1349572 30mg q24h in combination with ATV/RTV 300/100mg q24h (treatment B) for 14 days. There will be no washout between treatment periods. Day 1 of Period 2 will be the day after Day 5 of Period 1. Subjects will have a screening visit within 30 days prior to the first dose of study drug, two treatment periods, and a follow-up visit 7-14 days after the last dose of study drug.
88879069|NCT00377442|Experimental|1|
88879070|NCT00377442|Experimental|2|
88879071|NCT00377442|Experimental|3|
88879072|NCT00377598|Experimental|TAK-583 5 mg QD|
88879073|NCT00377598|Experimental|TAK-583 25 mg QD|
88879074|NCT00377598|Experimental|TAK-583 50 mg QD|
88879075|NCT00377598|Experimental|TAK-583 100 mg QD|
88879076|NCT00377598|Placebo Comparator|Placebo QD|
88879077|NCT00377910|Active Comparator|1, drug|Injections of polidocanol
88879078|NCT00377910|Placebo Comparator|2 drug|injections of lidocaine
88879079|NCT00377988||001|Transdermal Contraceptive System In each 4-week period exposed subjects will wear a transdermal patch containing 6 mg norelgestromin and 0.75 mg EE worn for each of 3 consecutive weeks with no patch the 4th week.
88879080|NCT00377988||002|Norgestimate-containing oral contraceptives with EE NGM-OCs with 34 mcg of EE taken during each 4 week period for 21 consecutive days then no pill or a drug-free pill 7 days.
89199045|NCT00675948|Experimental|Sativex|Active treatment
88879081|NCT00378066|Active Comparator|Bevacizumab|Bevacizumab, capecitabine and oxaliplatin for metastatic colorectal cancer, 1st line treatment
88879082|NCT00378144|Experimental|1|Pseudoephedrine/Paracetamol
88879083|NCT00378612|Experimental|Cypher® sirolimus eluting coronary stent|All pts were given the Cypher sirolimus eluting coronary stent in this open-label, single-arm, non-randomized trial
88879084|NCT00378690|Active Comparator|Continuous Androgen Deprivation (CAD)|
88879085|NCT00378690|Experimental|Intermittent Androgen Deprivation (IAD)|
88879086|NCT00379392|Experimental|Mental Imagery and CIT|Mental Imagery and Constraint Induced Therapy
88879087|NCT00379392|Active Comparator|Mental Imagery only|Mental Imagery only
88879088|NCT00379470|Active Comparator|Best Standard of Care|Patients randomized to the BSC group will be treated with one chemotherapy according to the BSC practiced at each center.
89536674|NCT02474459|Active Comparator|iPad-based Clinical Support Care|Subjects in this treatment arm will receive deep brain stimulation (DBS) programming at regular intervals as part of routine clinical care. DBS stimulation programming will be performed using an iPad-based decision support system. Outcomes will be measured using the Unified Parkinson's Disease Rating Scale (UPDRS), Parkinson's Disease Questionnaire (PDQ-39) and the Multi-Dimensional Caregiver Strain Index (MCSI).
89190066|NCT03923322|Experimental|Botanical Tincture|The 12-week study includes a 2-week screening, 8-week treatment, and 2-week withdrawal periods. A 2-week screening period will be used to establish the presence and persistence of trial entry criteria and train patients in the mode of data collection. Participants randomly assigned to the Botanical Tincture arm at Week 2 will take 2.5 ml by mouth once a day at any time during the day that they choose. Participants who received Botanical Tincture during the study will be followed by a 2-week randomized withdrawal design to address the need for maintenance treatment to prevent sign or symptom recurrence. The participant will be randomly reassigned to receive either Botanical Tincture or placebo at a dosage of 2.5 ml once a day by mouth at any time during the day that they prefer.
89190067|NCT03923322|Placebo Comparator|Placebo|Participants randomly assigned to placebo arm at Week 2 will take 2.5 ml by mouth once a day at any time during the day that they choose during the 8-week treatment period.
89190068|NCT03917420|Experimental|Tenofovir/Emtricitabine|Participants will take 5 once daily doses above noted combination tab at 200mg/300mg before each sampling visit
89190069|NCT03917147||AUB in Post-Menopause|Abnormal Uterine Bleeding (AUB) in Post-Menopause
89190070|NCT03917147||Endometrial Thickening in post-menopause|Ultrasonographic detection of Thickened Endometrium in post-menopause
89190071|NCT03917147||Endometrial Thickening in pre-menopause|Ultrasonographic detection of Thickened Endometrium in pre-menopause
89190072|NCT03917147||Pharmacological history of Tamoxifen-related therapy regimens|Patients who had been treated with Tamoxifen
89190073|NCT03902067|Experimental|UC-MSC|UC-MSC transplantation
89190074|NCT03902067|Placebo Comparator|Control Group|Routine treatment
89190075|NCT03892720|Experimental|Treatment (SBRT)|Patients undergo stereotactic body radiation therapy with either standard radiation treatment software or HyperArc software technology for 2-3 fractions per week over a 2-week period for 5 fractions.
89190076|NCT03886077||Hepatitis C Negative Donor Hearts|Hearts for transplantation that are not infected with Hepatitis C. (Negative NAT)
88879089|NCT00379470|Experimental|NovoTTF-100A|
88879090|NCT00379548|No Intervention|1|Control group- subjects are on the Asian diet for the entire duration of the study
88879091|NCT00379548|Experimental|2|Asian and Caucasian subjects switch from an Asian Diet to a Western Diet midway through the study.
88879092|NCT00379626|Experimental|cognitive and hormone treatment|cognitive and hormone (Leuprorelin) treatment
88879093|NCT00380406|Placebo Comparator|Placebo|Placebo
88879094|NCT00380406|Active Comparator|depot GnRHa (Leuprolide acetate (LA) 11.25 mg intramuscularly)|
88879095|NCT00380484|Experimental|1|Budesonide
88879096|NCT00380484|Active Comparator|2|Montelukast
88879097|NCT00380562|Experimental|Volunteer|High intensity volunteering (15 hours a week or greater) in Baltimore City Schools with children in grades K-3
88879098|NCT00380562|No Intervention|Control|Usual activities
88879099|NCT00380640|Experimental|1|
88879100|NCT00380640|Experimental|2|
88879101|NCT00380796||Cohort 1|
88879102|NCT00381108|Experimental|Pomegranate Tablet|
88879103|NCT00381108|Placebo Comparator|Placebo Tablet|
88879104|NCT00381342|Experimental|Exenatide 5 mcg/exenatide 5 mcg|Exenatide 5 mcg; then exenatide 5 mcg
88879105|NCT00381342|Experimental|Exenatide 5 mcg/exenatide 10 mcg|Exenatide 5 mcg, then exenatide 10 mcg
88879106|NCT00381342|Placebo Comparator|Placebo|Placebo in volumes equivalent to exenatide
88879107|NCT00381420|Experimental|1|sirolimus-coated Bx Velocity stent
88879108|NCT00381420|Active Comparator|2|uncoated Bx Velocity stent
88879109|NCT00381576|Experimental|A|12 weeks of resistance training
88879110|NCT00381654|Experimental|A|Daily oral administration of AV-412
88879111|NCT00381732|Placebo Comparator|1|placebo tablet
88879112|NCT00381732|Active Comparator|2|2.5 mg tadalafil tablet
88879113|NCT00381732|Active Comparator|3|5 mg tadalafil tablet
88879114|NCT00382356|Experimental|study drug|Open label, single arm
88879115|NCT00382434||EPh Present|the emergency pharmacist is present in the ED when the medical care is provided
88879116|NCT00382668||A|
88879117|NCT00382668||B|
88879118|NCT00382668||C|
88879119|NCT00382980|Experimental|7.5-|7.5 mcg of vaccine without adjuvant administered on Days 0 and 28.
88879120|NCT00382980|Experimental|45-|45 mcg of vaccine without adjuvant administered on Days 0 and 28.
89190077|NCT03886077||Hepatitis C Infected Donor Hearts|Hearts for transplantation that are infected with Hepatitis C. (Positive NAT).
89190078|NCT03870815||CABG|Patients with CAD who undergoing CABG
89403411|NCT04654117|No Intervention|Follow Up|During the follow-up period, consultation will not occur, and providers will continue implementing Project ImPACT with their cases. Eight weeks post-consultation, providers will submit a recorded Project ImPACT session with their enrolled family. Providers and caregivers will complete a final online questionnaire.
89403412|NCT04649398||oral nimodipine|60mg of nimodipine is orally administered every 4 h,
89403413|NCT04649398||intra-venous nimodipine|nimodipine is continuously administered intra-venously, starting with 0.5 mg/h on day 1 and increased every day for 0.5 mg/h to a maximum dose of 2.0mg/h on day 4
89403414|NCT04649398||intra-arterial nimodipine|during endovascular procedure 2mg of nimodipine is infused via a microcatheter into the internal carotid artery for 20 minutes
89403415|NCT04648189|Experimental|Single dose cetuximab prior to surgery|A single dose of cetuximab, 400mg/m2, will be administered 72 to 48 hours prior to surgery
89403416|NCT04622514|Experimental|Village doctor-led telemedicine integrated care|To empower village doctors, a new technology-based model of AF care was established in the intervention group. A digital health support platform was developed by our research team, and a network of teams consisting of village doctors and AF specialists in our research team was established in the intervention group. With the aid of this telemedicine platform, village doctors can receive more support from AF specialists in providing integrated AF care to the rural elderly with AF.
89403417|NCT04622514|Active Comparator|Enhanced usual care|Usual care plus intensified education to patients, their family members, and their village doctors.
89403418|NCT04622085|Experimental|ANIMERS Chiara LA|
89403419|NCT04622085|Active Comparator|JUVÉDERM VOLUMA®|
89403420|NCT04612231|Active Comparator|T-STEP Intervention|The T-STEP is a comprehensive 12-week transition program that will be delivered in a community college setting. The curriculum includes 36 hours of group-based instruction delivered within a traditional school academic semester (i.e., 24 ninety-minute classes across 12 weeks). Students also participate in a weekly community-based internship to practice the skills learned in the intervention group (2 hours per week for 12 weeks). In addition, students participate in 12 hours of manualized individual counseling services that are traditionally available on a college campus (e.g., job exploration/career counseling, academic counseling, and self-advocacy counseling).
88879121|NCT00382980|Placebo Comparator|Placebo|Placebo administered on Days 0 and 28.
88879122|NCT00382980|Experimental|15+|15 mcg of vaccine with aluminum hydroxide adjuvant administered on Days 0 and 28.
88879123|NCT00382980|Experimental|7.5+|7.5 mcg of vaccine with aluminum hydroxide adjuvant administered on Days 0 and 28.
89403421|NCT04612231|Active Comparator|Counseling Only Intervention|Participants in the Counseling Only condition will receive the same manualized counseling sessions that are included in the T-STEP program. Specifically, 12 hours of individual counseling focused on job exploration/career counseling, academic counseling, and self-advocacy counseling.
89403422|NCT04609514|Experimental|Learn to Quit-HIV|A smartphone app developed by the research team designed for people with HIV that provides Acceptance and Commitment Therapy skills to address smoking cessation. This app intervention is combined with an 8-week course of nicotine replacement therapy (NRT) patches, along with technical smartphone coaching for the first 4 weeks of the study.
89403423|NCT04609514|Active Comparator|QuitGuide|A smartphone app developed by the National Cancer Institute which uses smoking cessation recommendations contained in the US DHHS (United States Department of Health and Human Services) Clinical Practice Guidelines. This app intervention is combined with an 8-week course of nicotine replacement therapy (NRT) patches, along with technical smartphone coaching for the first 4 weeks of the study.
89403424|NCT04608149||Subjects treated with Carpediem system|All patients who receive CRRT with the Carpediem™ system, as prescribed by the investigator, will be offered participation in the post market surveillance study after obtaining parental consent.
89403425|NCT04603261||eGFR <30 mL/min/1.73m2|Patients with eGFR <30 mL/min/1.73m2 in absence of dialysis referred for an elective procedure with intravascular administration of iodinated contrast material at Maastricht UMC+.
89403426|NCT04603261||eGFR 30-59 mL/min/1.73m2|For each included patient with eGFR <30 mL/min/1.73m2, two patients matched for age, sex and contrast procedure type will be included: one with eGFR 30-59 mL/min/1.73m2 and one with eGFR >=60 mL/min/1.73m2.
89403427|NCT04603261||eGFR >=60 mL/min/1.73m2|For each included patient with eGFR <30 mL/min/1.73m2, two patients matched for age, sex and contrast procedure type will be included: one with eGFR 30-59 mL/min/1.73m2 and one with eGFR >=60 mL/min/1.73m2.
89403428|NCT04599335|Experimental|HA + Lidocaine|
89403429|NCT04599335|No Intervention|Negative|
89403430|NCT04562532|Experimental|Firehawk group|Participants implant Firehawk stent(s)
89403431|NCT04562532|Active Comparator|2nd generation DES|Participants implant Everolimus eluting stents (Xience family - Abbott Vascular, Promus family- Boston Scientific, Synergy - Boston Scientific), or Zotarolimus eluting stents (Resolute/Onyx family and Endeavor- Medtronic), or Sirolimus eluting stents (Orsiro- Biotronik)
89403432|NCT04547374||Cohort 1 - GaH Intervention|Cohort 1 - GaH intervention group
89403433|NCT04547374||Cohort 2 - Standard-of-care control group|"Cohort 2 - Standard-of-care control group~*Importantly, these individuals are eligible for referral to GaH at the discretion of their physicians.*"
89403434|NCT04533646|Experimental|Fixed Dosing, Followed by Carbohydrate Counting|Dosing of premeal insulin with fixed doses
89403435|NCT04525196|Experimental|Physical activity.|Patients will benefit a physical activity program during their dialysis session.
89403436|NCT04525196|No Intervention|No physical activity.|Patients will have access to their dialysis sessions without additional physical activity.
88879124|NCT00382980|Experimental|15-|15 mcg of vaccine without adjuvant administered on Days 0 and 28.
88879125|NCT00383136|Experimental|1|Tirofiban
88879126|NCT00383136|Active Comparator|2|Abciximab
88879127|NCT00383214|Active Comparator|Epratuzumab|360 mg/m2 or 720 mg/m2 delivered by slow intravenous infusion
88879128|NCT00383214|Placebo Comparator|Placebo|Intravenous
88879129|NCT00383370|Experimental|ITV-1|VEGF Trap formulation 1
88879130|NCT00383370|Experimental|ITV-2|VEGF Trap formulation 2
89403437|NCT04523064|Active Comparator|SGLT2i (empagliflozin)|Empagliflozin 25 mg 1 time day for three months
89403438|NCT04523064|No Intervention|Standard of care|Standard care treatment of diabetes patients in our center
89403439|NCT04521634||Acute Stroke + Diabetes|People who have experienced and acute stroke and also have diabetes
88813340|NCT01725776|Experimental|Inhaled milrinone 5 mg|Inhaled milrinone 5 mg(as for the injectable solution)
88813341|NCT01830296|Active Comparator|Remifentanil+Morphine|Morphine(M) Remifentanil+Morphine(MR)
88813342|NCT01830296|Active Comparator|IV morphine PCA|IV remifentanil+morphine PCA
88813343|NCT05564819|Experimental|Treatment group|After recovering and returning to the ward, acetaminophen (10mg/kg) was taken orally immediately; once every 6 hours, a total of 4 times.
88813344|NCT05564819|Placebo Comparator|placebo group|The same amount of sterilized water was administered orally at the same time points.
88813345|NCT01725854|Experimental|Relaxation Response Training|The Military tailored RR training program will consist of six weekly small group sessions which involve group presentations, in-group skill building exercises, and at-home assignments. Groups will contain 5-8 participants who are active-duty Soldiers enrolled in either Respect-MIL or the Interdisciplinary Pain Management Center (IPMC).
88813346|NCT01725854|No Intervention|Standard of Care|Participants randomized to the control group will receive standard care through their providers at Respect-MIL or at the IPMC. Participants randomized to the control group will remain on the wait list for further standard care. After the collection of the final data point, these participants will also have the option to participate in an abbreviated, two-hour version of the RR training.
88813347|NCT03409952|Active Comparator|Group A: LaseMD and DUAL 1927nm Laser|Group A subjects will receive split-side study treatments comparing two devices: LaseMD compared to the DUAL 1927nm laser.
88813348|NCT03409952|Active Comparator|Group B: LaseMD Optimized|Group B subjects will receive LaseMD Optimized Treatments based on Group A treatment data.
88813349|NCT01567943|Experimental|Contingency Management|Contingency Management plus treatment as usual
88813350|NCT01567943|No Intervention|Non-contingent control group|Treatment as usual plus reinforcement for attendance
88813351|NCT04378322|Active Comparator|Nutrition and food purchasing tool + telenutrition|Participants will use an online nutrition and food purchasing tool in addition to telenutrition.
88813352|NCT04378322|Active Comparator|Nutrition and food purchasing tool|Participants will use an online nutrition and food purchasing tool.
88813353|NCT04378322|Active Comparator|Nutrition education tool|Participants will be exposed to an online nutrition education materials.
88813354|NCT01467557||1-Day ACUVUE TruEye contact lens users|1-Day ACUVUE TruEye contact lens users
88813355|NCT01467557||1-Day ACUVUE MOIST contact lens users|1-Day ACUVUE MOIST contact lens users
88813356|NCT01725932|Experimental|Culturally adapted CBT based Self Help|Culturally sensitive cbt based self help intervention, which consists of 6 regular chapters and 2 additional chapters. The self help intervention involves family to improve compliance with the intervention
88813357|NCT01725932|No Intervention|Care As Usual|Control Group
88813358|NCT01720394|Experimental|Cervical ripening balloon|primary treatment with the cervical ripening balloon on day 1. removal of the balloon latest after 12 h. If no progression of labor (Bishop Score ≥ 9 and/or cervical opening ≥ 3 cm) continuing of standard treatment using dinoprostone vaginal-inserts on day 2 and if necessary on day 3.
88813359|NCT01720394|Active Comparator|Propess|Primary treatment using dinoprostone-vaginal-inserts on day 1-3 if no progression of labor (Bishop Score ≥ 9 and/or cervical dilatation ≥ 3 cm)
88813360|NCT01467947|Experimental|Berinert|
88813361|NCT01568021||OZURDEX®|Single dose of dexamethasone 700 ug intravitreal implant (OZURDEX®) which may be repeated over 1 year as per standard of care in clinical practice. No intervention was administered in this study.
88813362|NCT00910520|Experimental|onabotulinumtoxinA|OnabotulinumtoxinA (botulinum toxin Type A) 100 U injected into the detrusor at Day 1, followed by a repeat injection of onabotulinumtoxinA 100 U after a minimum of 12 weeks (if applicable).
88813363|NCT00910520|Other|placebo/onabotulinumtoxinA|Placebo (normal saline) injected into the detrusor at Day 1, followed by an injection of onabotulinumtoxinA (botulinum toxin Type A) 100 U after a minimum of 12 weeks (if applicable).
88813364|NCT01568255|Experimental|Vitamin D Treatment|Vitamin D Treatment Group
88813365|NCT01568255|Placebo Comparator|Placebo Group|Placebo at 50,000IU for 8 weeks
88813366|NCT01720472||Community, Physical Performance|
89403440|NCT04521634||Acute stroke|People without diabetes who have experienced and acute stroke
89403441|NCT04497584|Experimental|Afatinib + Prednisone|"Afatinib 40 mg PO daily~Prednisone 40 mg PO daily starting 7 days after Afatinib"
89403442|NCT04489771|Experimental|Belzutifan 200 mg|Participants receive 200 mg of belzutifan by oral administration, once a day (QD), until disease progression or discontinuation.
88879131|NCT00383370|Experimental|ITV-2 OL|VEGF Trap formulation 2 open label, higher concentration
88879132|NCT00383526|Experimental|Study Group 1|
88879133|NCT00383526|Active Comparator|Study Group 2|
88879134|NCT00383994|Experimental|Immunotherapy with NK Cell, Rituximab + GM-CSF|"Immunotherapy in Non-myeloablative Allogeneic Stem Cell Transplantation~GM-CSF = Granulocyte-Macrophage Colony-Stimulating Factor"
88879135|NCT00384228|Experimental|Nilotinib|
88879136|NCT00384462||1|Premature Infants (32-35 wks. GA) who are less than six months of age at start of RSV season and followed until May of the following year.
88879137|NCT00384462||2|Premature newborns (32-35 wks. GA) who are born during the current RSV season and discharged from the hospital after 01 Dec and followed until May of the next year.
88879138|NCT00384540|Other|Cardiovascular events vs Dobutamine stress echocardiography|
88879139|NCT00384696||Smoking Cessation|Treatment to help quit smoking, including written self-help materials, counseling, and 4 week supply of nicotine patch plus 5 MD Anderson Visits.
88879140|NCT00385086|Experimental|TNF-alpha blocker|Treatment with TNF-alpha blocker
88879141|NCT00385086|Active Comparator|Placebo|Treatment with placebo
88879142|NCT00385242|Active Comparator|PET guided Therapy|Patients will be randomized to undergo positron emission tomography aspart of their clinical work up
89403443|NCT04489771|Experimental|Belzutifan 120 mg|Participants receive 120 mg of belzutifan by oral administration, QD, until disease progression or discontinuation.
89403444|NCT04488757|Other|Study Arm|All participants enrolled in the study will undergo baseline fMRI and baseline and follow-up (4-month post-baseline) assessment of stress physiology (i.e., allostatic load). Treatment as usual information will be gathered for all participants to assess observational intervention response.
89403445|NCT04480840|Placebo Comparator|Placebo|
89403446|NCT04480840|Experimental|PLN-74809 Dose Level 1|Dose: 40 mg;
89403447|NCT04480840|Experimental|PLN-74809 Dose Level 2|Dose: 80 mg; PLN-74809 Dose Level 2 following PLN-74809 Dose Level 1
89403448|NCT04480840|Experimental|PLN-74809 Dose Level 3|Dose: 160 mg; PLN-74809 Dose Level 3 following PLN-74809 Dose Level 2
88879143|NCT00385242|Active Comparator|Standard care|Patients will be randomized to standard care will under go other types of imaging or work up for revascularization without PET imaging.
88879144|NCT00385476||Patient Medication Knowledge Tool|Assessment of Cancer patients' knowledge of their medications in an outpatient acute care setting
88879145|NCT00385632||1|Participants following a drug conservation (DC) regimen in which ART was stopped or deferred until CD4 cell count dropped below 250 cells/mm3, initiated until CD4 cell count was at least 350 cells/mm3, and then followed by episodic ART based on CD4 cell count
88879146|NCT00385632||2|Participants following a viral suppression (VS) regimen in which ART was continued to keep viral loads as low as possible, regardless of CD4 cell count
88879147|NCT00385710|Experimental|valproic acid|Depakine
88879148|NCT00385710|Placebo Comparator|Placebo|Placebo
88879149|NCT00385866|Active Comparator|Comparison Group|The control or lesser intervention group, will receive cancer screening information on a quarterly basis, with no facilitation of services.
88879150|NCT00385866|Active Comparator|Intervention group|The intervention group are those participants who were randomly assigned to receive facilitation of services in the form of patient navigation for the duration of the study.
88879151|NCT00386178|Experimental|1|Vitamin E supplement rich in gamma tocopherol
88879152|NCT00421668|Experimental|Multivitamins|Vitamins C, E, B1, B2, niacin, B6, folate, and B12
88879153|NCT00421668|Experimental|Multivitamins + Zinc|Vitamins C, E, B1, B2, niacin, B6, folate and B12, and zinc
88879154|NCT00421668|Experimental|Zinc|zinc
88879155|NCT00421668|Placebo Comparator|Placebo|placebo
88879156|NCT00421824|Experimental|A|
88879157|NCT00421824|Experimental|B|
88879158|NCT00421902|Experimental|Acupuncture|Acupuncture of the patients
88879159|NCT00422682|Experimental|1|BSI-201 + topotecan
88879160|NCT00422682|Experimental|2|BSI-201 + temozolomide
88879161|NCT00422682|Experimental|3|bsi-201 + gemcitabine
88879162|NCT00422682|Experimental|4|bsi-201 + carboplatin/paclitaxel
88879163|NCT00422838||1|Chronic HCV Genotype 1 monoinfection, never had interferon and ribavirin treatment
88879164|NCT00422838||2|Chronic HCV Genotype 2 or 3 monoinfection,never had interferon and ribavirin treatment
88879165|NCT00422916|Experimental|intervention arm|Lifestyle Intervention based on Nutrition Treatment, exercise Treatment and behavorial treatment
89403449|NCT04480840|Experimental|PLN-74809 Dose Level 4|Dose: 320 mg; PLN-74809 Dose Level 4 following PLN-74809 Dose Level 3
89403450|NCT04475952||Oropharyngeal squamous cell carcinoma|
89403451|NCT04475952||Oesophageal squamous cell carcinoma|
89403452|NCT04475952||Control|
89403453|NCT04467840|Experimental|Opaganib|In addition to standard of care, opaganib will be administered orally with 2 x 250 mg capsules (500 mg) every 12 hours. When required this may be made into a suspension form and may be administered by nasogastric tube.
89403454|NCT04467840|Placebo Comparator|Placebo|In addition to standard of care, a matching placebo will be administered orally with 2 x 250 mg capsules (500 mg) every 12 hours. Where required this may be made into a suspension form and may be administered by nasogastric tube.
89403455|NCT04452877|Experimental|Dabrafenib in combination with trametinib|Dabrafenib 150 mg twice daily, trametinib 2 mg once daily
89403456|NCT04445883|Experimental|Study Group A|Study group A will include patients from the medical unit on 6S100 in addition to the Rehab units on 6N400/500. Participants in Study Group A will be receiving mealtime assistance from volunteers via the Eating Matters Program.
89403457|NCT04445883|No Intervention|Control Group B|Control Group B will include participants from the Rehab Unit on 4N400 and the Medical unit on 6S200.
89403458|NCT04444869|Other|Open label single-arm study|All patients will receive concurrent cisplatin and radiation therapy with radiation dose de-escalation to clinically and radiologically uninvolved lymph nodes.
89403459|NCT04430569|Experimental|Alteplase|
89403460|NCT04430569|Placebo Comparator|Placebo|
89403461|NCT04421924|Experimental|Thrombelastogram (TEG)|Patients in the TEG group will receive prothrombin complex concentrates (PCC) at a dose of 10 IE/kg of ideal body weight, when R-time was greater than 40 minutes (2400 sec) and they will receive platelet transfusion in the amount of 1 apheresis unit when MA was below 30 mm.
89403462|NCT04421924|Experimental|Standard of Care (SOC)|In the SOC group, patients will receive PCC at the dose of 10 IE /kg of ideal body weight when the PT is below 50% and/or INR>1.8 and/or received platelet transfusion in the amount of 1 apheresis when platelet count is below 50 G/L
89403463|NCT04383223|No Intervention|YLH Historical Control Group|"Participants in this group will have the following phases:~Screening~Single visit assessment"
89403464|NCT04383223|Experimental|YLH iTransition Intervention Group|"Participants in this group will have the following phases:~Screening~Baseline Visit~Follow-Up visits at 6, 12 and 18 month~Interview visits for selected YLH around 3 and 9 month"
89403465|NCT04383223|Experimental|Provider Group|"Participants in this group will have the following phases:~Screening~Baseline Visit~Follow-Up visits at 6, 12 and 18 month~Interview visits for selected YLH around 3, 9 and 15 month"
89403466|NCT04383223|Experimental|Transition Champion Group|"Participants in this group will have the following phases:~Screening~Baseline Visit and Follow-Up visits at 6, 12 and 18 month~Interview visits for selected YLH around 3, 9 and 15 month"
89403467|NCT04362748|Experimental|Dose Escalation Phase|Determine the maximum tolerated dose (MTD) or the recommended phase 2 dose RP2D of AMG 256.
89403468|NCT04362748|Experimental|Dose Expansion Phase: Group 1|Participants will be administered with the MTD or RP2D of AMG 256 identified in the dose escalation part of the study.
89403469|NCT04362748|Experimental|Dose Expansion Phase: Group 2|Participants will be administered with the MTD or RP2D of AMG 256 identified in the dose escalation part of the study.
89403470|NCT04361240||Ancillary Cohort|No Intervention: Subjects will be followed before, during and for up to 1 year after radiation with echocardiogram, blood draw, and symptoms and activity survey.
89403471|NCT04353622|Active Comparator|Robot-assisted Treatment|Rehabilitation protocol was applied with robotic device (HOUSTONBIONİCS ExoRehab UE1).
89403472|NCT04353622|Active Comparator|Conventional Physiotherapy|Conventional physiotherapy program included neurophysiological approaches.
88813367|NCT01720628||Behçet's patients|Serum levels of angiogenin, bFGF, VEGF levels in Behçet's patients with ocular involvement group, without ocular involvement group and control group
88813368|NCT01569191|No Intervention|No Treatment|Exposure to grass pollen only
88813369|NCT01569191|Active Comparator|Artificial Tear Supplement|Preservative free Hypromellose Eye Drops BP 0.3% w/v preservative free - MHRA product licence number:23097/0006
88813370|NCT01569191|Active Comparator|Cold compress|Cooled gel eye mask http://www.visiondirect.co.uk/vision-direct/eye-gel-mask-blue
88813371|NCT01569191|Active Comparator|Anti-allergic Medication|ELESTAT® (epinastine HCl ophthalmic solution) 0.05% Initial U.S. Approval: 2003 H1 histamine receptor antagonist indicated for the prevention of itching associated with allergic conjunctivitis
89403473|NCT04335656|Experimental|Treatment Group|Subjects will be randomized to the treatment or placebo group. The treatment is a capsule taken by mouth once a day for 6 months.
89403474|NCT04335656|Placebo Comparator|Placebo Group|Subjects will be randomized to the treatment or placebo group. The placebo is a capsule taken by mouth once a day for 6 months.
89403475|NCT04308109|No Intervention|Control|No intervention, the same as the current state of education. Caregivers will still complete the teaching and post-discharge surveys (QDTS and PDCDS) and be followed for a year after discharge.
89403476|NCT04308109|Experimental|Active study|In addition to the current state of education, the active study group will undergo highly realistic simulation. This involves the use of a highly realistic tracheostomy mannequin and audiovisual devices which will be used to replicate emergent clinical situations. If home invasive ventilation is anticipated, a home ventilator will be used. Caregivers will complete the teaching and post-discharge surveys (QDTS and PDCDS) and be followed for a year after discharge.
89403477|NCT04308109|Active Comparator|Active control|In addition to the current state of education, the active control will undergo low-fidelity simulation that approximates the highly realistic clinical scenarios except with the use of a low-fidelity doll equipped with a tracheostomy and without the audiovisual inputs. If home invasive ventilation is anticipated, a home ventilator will be used. Caregivers still complete the teaching and post-discharge surveys (QDTS and PDCDS) and be followed for a year after discharge.
89403478|NCT04300335|Experimental|High Risk - Individual Exercise|Patients who show an increased fracture risk and/or increased risk of fall in the screening assessments and are therefore allocated to an individualized personal training.
89403479|NCT04300335|Experimental|Low Risk - Group Exercise|Patients who show neither increased fracture risk nor increased risk of fall in the screening assessments and are therefore allocated to the exercise group.
89403480|NCT04295499|Experimental|Test Device: Qualis Silicone Hydrogel Soft Contact Lens|Test lenses will be worn on a daily wear basis for up to one month with removal for cleaning, disinfection, and storage prior to sleeping. Subjects will be instructed to wear the test lenses at least 6 hours a day, a minimum of 5 days per week. The Test Device is investigational and not cleared/approved by the US FDA.
89403481|NCT04295499|Active Comparator|Control Device: Acuvue Vita Monthly Contact Lens|Test lenses will be worn on a daily wear basis for up to one month with removal for cleaning, disinfection, and storage prior to sleeping. Subjects will be instructed to wear the test lenses at least 6 hours a day, a minimum of 5 days per week. The Control Device is cleared by the US FDA.
89403482|NCT04280562|Experimental|"Real SPR"|"Participants will receive the device which will run the real Sana Pain Reliever (SPR) protocol and a tablet with a mobile application to record pain levels and other questionnaires"
89403483|NCT04280562|Sham Comparator|Sham SPR|Participants will receive the device which will run a sham SPR protocol and a tablet with a mobile application to record pain levels and other questionnaires
89403484|NCT04274296||Control|Control-cohort in which no change in care is needed
89403485|NCT04274296||Advisory|Cohort in which advisory is activated
89403486|NCT04273516|Experimental|Intervention|Tablet Rivaroxaban 2.5 mg 2 times daily plus ASA 80 mg daily
89403487|NCT04273516|Placebo Comparator|Comparator|Tab ASA 80 mg daily plus placebo ( similar to rivaroxaban tablet) 2 times daily
89403488|NCT04267926|Placebo Comparator|Placebo|Placebo
88879166|NCT00422916|No Intervention|waiting list|waiting 6 months for Intervention without any intervention
88879167|NCT00423072||1|children with cleft palate birth-24 months of age
89403489|NCT04267926|Active Comparator|20mg of MitoQ|20mg of oral mitoquinol
89403490|NCT04267926|Active Comparator|40mg of MitoQ|40mg of Oral Mitoquinol
89403491|NCT04255433|Experimental|Tirzepatide|Tirzepatide administered subcutaneously (SC) once a week.
89403492|NCT04255433|Active Comparator|Dulaglutide|Dulaglutide administered SC once a week.
89403493|NCT04236128|Experimental|Intervention Group|The intervention group will receive the same usual care as the control group plus be enrolled in the integrated discharge monitoring system.
89403494|NCT04236128|Active Comparator|Control Group|The control group will receive usual follow up care that is currently provided at the 3 participating centres.
88879168|NCT00423228|Experimental|ZT-1|ZT-1 (investigational product)
88879169|NCT00423228|Active Comparator|Donepezil|Donepezil
88879170|NCT00423306|Experimental|Single Arm|
88879171|NCT01799070||CHS|
88879172|NCT01799382|Experimental|EBUS-TBNA + Rapid on-site evaluation|Patients in this arm will undergo rapid-on site evaluation of samples obtained with EBUS-TBNA
88879173|NCT01799382|Active Comparator|EBUS-TBNA|Patients in this arm will undergo EBUS-TBNA without rapid on-site evaluation
89190079|NCT03870815||PCI|Patients with CAD who undergoing PCI with DES
89190080|NCT03853473|No Intervention|Standard of Care|Study participants will receive standard of care.
89403495|NCT04231110|Experimental|FMT and vedolizumab|People who are initiating vedolizumab per standard of care for ulcerative colitis will also be offered FMT weekly for 6 weeks.
89403496|NCT04225819|Experimental|Vitamin D3 supplement|Two- 5,000 IU capsules, taken daily with a meal
89403497|NCT04225819|Placebo Comparator|Placebo|Two placebo capsules, taken daily with a meal
89403498|NCT04219904|Experimental|Diagnostic (PET/MRI)|Patients receive fludeoxyglucose F-18 and gadobutrol IV over 1 minute and undergo PET/MRI over 90-120 minutes.
89403499|NCT04217330|Experimental|Intervention|Pulmonary rehabilitation programs assigned to the intervention group will offer eligible participants the choice of participating in an 8-week program of either home-based pulmonary rehabilitation or traditional centre-based pulmonary rehabilitation.
89403500|NCT04217330|Active Comparator|Control|Pulmonary rehabilitation programs assigned to the control group will offer eligible participants the opportunity to participate in an 8-week centre-based pulmonary rehabilitation program, as per current practice.
88813372|NCT03409874|Experimental|Dry Needling and Spinal Manipulation|
89403501|NCT04199871|Experimental|Group1|dichoptic 3D movies
89403502|NCT04199871|Sham Comparator|Group 2|dichoptic standard movies
89403503|NCT04198415||Venetoclax Participants|Participants prescribed and treated with venetoclax.
89530968|NCT02499731|Experimental|Strong Hearts, Healthy Women|Strong Hearts, Healthy Women minimum intervention participants meet once per month for an hour each time for 6 months. Participants will learn and discuss techniques and strategies to improve personal health.
88813373|NCT03409874|Active Comparator|Interocclusal Appliance, NSAIDs and TMJ Mobs|
88813374|NCT01726010|Experimental|22-G Procore Needle|
88813375|NCT01726088|Active Comparator|modafinil|Study participants randomized to the active arm of the study will take modafinil 100mg capsules orally each day for 4 weeks.
88813376|NCT01726088|Placebo Comparator|Sugar Pill|Study participants randomized to the placebo arm of the study will take matching capsules orally each day for 4 weeks.
88813377|NCT01726166|Active Comparator|Suprapubic Aspiration|A trained physician or neonatal nurse practitioner utilizing U/S guidance at the bedside will perform the SPA. An U/S machine is readily available for use in each NICU.
88813378|NCT01726166|Active Comparator|Urinary Catheterization|"The infants will have the procedure done by NICU nurses who have been trained in performing this procedure.~If the randomly assigned infant passes urine spontaneously during a UC attempt after complete perineal cleansing and the urine is collected as a clean catch sample, then this infant will be analysed in the assigned group (intention to treat)."
88813379|NCT01720706|Experimental|Acute|The RFA Loosely wound thermal coil electrode will be inserted directly or percutaneously into the lesion, depending on the imaging modality (US or CT guidance) and deployed with same method as previously described in the 'delayed group'. Energy will be delivered using the single timed heating cycle. Treatment will be monitored with B mode US. Once the cycle is completed, the probe will be removed and the planned surgery will continue with partial or radical nephrectomy.
88813380|NCT01720706|Experimental|Delayed|Using an electrically insulated 12ga introducer with trocar is inserted percutaneously into the renal tumor. The needle tip will be placed 20mm from the center of the target. The trocar is removed and co-axially (i.e. within the introducer), a core biopsy of the lesion is performed with a 14-18 gauge needle. The radiofrequency applicator with a 14ga cannula containing the RFA Loosely wound thermal coil electrode is then optimally positioned and locked into the introducer. On approximately day 6-10, a partial or radical nephrectomy will be performed in the usual way.
88813381|NCT00911612|Experimental|Colesevelam|Participants received colesevelam 1.875 g twice daily
88813382|NCT00911612|Placebo Comparator|Placebo|Participants received an inert capsule matching the study drug twice daily, as prepared by the Mayo Clinic research pharmacy
88813383|NCT01469039|Experimental|ALKS 9072|
88813384|NCT01469039|Placebo Comparator|Placebo|
88813385|NCT01720784|Placebo Comparator|Placebo|
88813386|NCT01720784|Experimental|Low dose (1.5 g DF)|
88813387|NCT01720784|Experimental|High dose (2.25 gDF)|
88813388|NCT01720862||Episodic migraineurs|Those with migraines >2 and < 12 times per month.
88813389|NCT01720862||Chronic migraineurs|Those with migraines greater than 14 days per month.
88813390|NCT01720862||Controls|Those without headaches other than occasional hangover, cold, flu headaches.
88813391|NCT01726244|No Intervention|Control group|Habitual Clinical Practice
88813392|NCT01726244|Experimental|Intervention Group|Multidisciplinary intervention consisting in controlling disease and stress associated to it, and modifying eating habits. A Nurse, nutritionist and a psychologist will be the responsible of these educational sessions. it will be three educational sessions. Patients with a BMI lower than 20 or bigger than 30 will be receive a closer follow up by nutritionist. In addition, patients with a score of 9 or more in the Patients Health Questionnaire-9 questionnaire will be also a closer follow up with the psychologist.
88813393|NCT01569737||ella|
88813394|NCT03409484|Active Comparator|Concord Grape Juice|100% Concord Grape Juice
88813395|NCT03409484|Sham Comparator|Low flavonoid low essence beverage|Low flavonoid low essence beverage
88813396|NCT03409484|Sham Comparator|Low flavonoid beverage|Low flavonoid beverage
88813397|NCT01726478|Active Comparator|2.5 units oxytocin|Administration of 2.5 units of oxytocin intravenously after clamping of umbilical cord
88813398|NCT01726478|Placebo Comparator|10 units oxytocin|Administration of 10 units of oxytocin after clamping of umbilical cord
88813399|NCT04379492|Experimental|Arm A - hydroxycholoroquine|Participants will receive hydroxycholoroquine (200-mg tablets) 2 tablets orally q12h for 2 doses on day 1 (load), followed by 1 tablet orally q12h for days 2-5.
88813400|NCT04379492|Placebo Comparator|Arm B - placebo|Participants will receive placebo
88813401|NCT02470806|Experimental|PICO System|Negative Pressure Wound Therapy (NPWT) at 80mmHg (nominal) +/- 20 mmHg to the wound surface
89403504|NCT04196556|Experimental|Active Families|Usual care plus intervention active families. This intervention, based on the methodology of meaningful learning, will have two components: group education directed to parents (caregivers) and education directed to children in the reviews in consultation. The group intervention will consist of 6 sessions, with a biweekly / monthly frequency, will be taught as determined in the program monitoring annex, in the 3 months after the initial assessment. The content of the sessions is defined in attached annex. Regarding the proposed methodology, it has nuances and tools different from the traditional ones to achieve significant learning in the field of health. It is based on participatory methods and a more profound modification of knowledge, skills, emotions and attitudes than the brief advice that is used in family intervention in scheduled consultations.
89403505|NCT04196556|Active Comparator|Control group|"Usual care:~The activities included in the Service for Attention to Patients with Childhood Obesity will be carried out in the Madrid's Primary Healthcare Standardized Service portfolio, which establishes a monthly follow-up in the first 6 months and bimonthly of month 6 to 12. To this At least the child and the primary caregiver, the child's educational agent, will be consulted and will receive support documentation to exercise and reinforce their role."
89403506|NCT04192773|Experimental|IV lidocaine|"1000mg/hour IV lidocaine administered for up to 30 minutes (500mg max). Patients will be continuously monitored by a nurse every 5 (±2) minutes to check specifically for vital signs (BP, HR, and RR), patient tinnitus levels, and reports of side effects.~The infusion is continued until any of the following criteria are met: 1) the patient has completed the 30-minute infusion; 2) the patient reports intolerable or concerning side effect, such as dizziness, nausea, or vomiting; 3) the patient experiences bradycardia <50 and a drop of systolic blood pressure (BP) more than 20 mmHg and diastolic pressure more than 10 mmHg during the infusion; 4) the patient reports that tinnitus is resolved, or 5) the patient wishes to stop the study.~Serum lidocaine levels will be drawn by a research nurse upon completion of MRI. The Tinnitus Handicap Inventory, the Tinnitus Functional Index, and the Visual Analog Scale will be administered after IV infusion."
89403507|NCT04182464|Experimental|Sucralose|The intervention will consist of capsules filled with pure sucralose. Each capsule will contain 90 mg of sucralose. Participants will be asked to consume one capsule in each meal (three per day) in order to achieve an ingestion of 270 mg of sucralose, this quantity corresponds approximately to the 30% of the acceptable daily intake (ADI) of sucralose for a lean person. This was calculated based on the ADI established by the joint FAO/WHO expert committee on food additives (JECFA) of 15 mg per kg of body weight per day of sucralose.
89403508|NCT04182464|Placebo Comparator|Placebo|The intervention will consist of capsules filled with placebo (cornstarch). Each capsule will contain 90 mg of cornstarch. Participants will be asked to consume one capsule in each meal (three per day) in order to achieve an ingestion of 270 mg of placebo, this quantity is in order to match the sucralose consumed in the intervention group.
89530969|NCT03232099|Experimental|Red Wine group (RW)|After a two weeks washout period,in the intervening period with red wine, patients will receive 250 mL / day of red wine per Day, 5 days a week, for 3 weeks.
88879174|NCT01799616|Experimental|Pamidronate|In total, 48 patients will need to be recruited. These patients will be randomly assigned to one of the two groups, with each group comprising 24 patients: one group will be given pamidronate and the other placebo
88879175|NCT01799616|Other|Placebo|In total, 48 patients will need to be recruited. These patients will be randomly assigned to one of the two groups, with each group comprising 24 patients: one group will be given pamidronate and the other placebo
88879176|NCT01799772|Experimental|Comprehensive behavioral intervention|"It will involve regular contacts over 6 month period. It will include 2 weekly contacts for weeks 1-6, weekly contacts for weeks 7-8, bi-weekly contact for months 3-4, and monthly contact for months 5-6. There is a combination of 20 individual and group-based sessions.~It is a combination of 4 components: a) Evidence-based exercise program, b) Physical activity promotion, c) Healthy nutrition guidance, and d) Self-management."
88879177|NCT01799772|Active Comparator|Standard of Care Exercise Program (SCE)|The SCE will be delivered by a physical therapist. It represents the typical rehabilitation after TKA surgery. It is expected to provide small and short-lived functional improvement. Subjects will participate in 12 supervised sessions (2 x/week, for 6 weeks). The SCE consists of: a) lower extremity range of motion and stretching exercises, b) lower extremity strengthening exercises of moderate intensity, and d) endurance exercises using treadmill.
88879178|NCT01799850|Active Comparator|Actos|Actos 30 mg daily
88879179|NCT01799850|Placebo Comparator|placebo|double blind placebo controlled
88879180|NCT01792050|Placebo Comparator|Arm 1A: Docetaxel + Placebo|Arm 1A: Docetaxel 75 mg/m^2 IV given every 3 weeks (on day 8 of 21 day cycle), plus placebo PO BID (days 1-14 of 21 day cycle).
88879181|NCT01792050|Experimental|Arm 1B: Docetaxel + Indoximod|Arm 1B: Docetaxel 75 mg/m^2 IV given every 3 weeks (on day 8 of 21 day cycle), plus Indoximod 1200 mg PO BID (days 1-14 of 21 day cycle).
88879182|NCT01792050|Placebo Comparator|Arm 2A: Paclitaxel + Placebo|Arm 2A: Paclitaxel 80 mg/m^2 IV given weekly x3 followed by a week of rest (28 day cycle), plus placebo PO BID (days 1-21 of 28 day cycle).
88879183|NCT01792050|Experimental|Arm 2B: Paclitaxel + Indoximod|Arm 2B: Paclitaxel 80 mg/m^2 IV given weekly x3 followed by a week of rest (28 day cycle), plus Indoximod 1200 mg PO BID (days 1-21 of 28 day cycle).
88879184|NCT01790256|Active Comparator|Cereve Sleep System at 14-16 degrees C.|Active
88879185|NCT01790256|Active Comparator|Cereve Sleep System at 30 degrees C|Active
88879186|NCT01790100|Experimental|VX-135 low dose in combination with ribavirin|12 weeks of VX-135 in combination with ribavirin
88879187|NCT01790100|Experimental|VX-135 high dose in combination with ribavirin|
88879188|NCT01791660|Experimental|Zeltiq Coolsculpting System|non-invasive device designed to cool subcutaneous fat without affecting adjacent or underlying structures.
88879189|NCT01793220|Experimental|SMS Reminder|A text message reminder service will be sent 7 and 1 days(s) prior to the patients appointment at their Psychosis Community Service.
88879190|NCT01793220|No Intervention|No SMS Reminders|The service user will not be sent text message reminders prior to each appointment at their Psychosis Community Service
88879191|NCT01795014||Controls|Healthy volunteers with no family history of glaucoma, an increased or asymmetrical cup/disc ratio or any other optic disc structural change (notching, disc hemorrhage) or an IOP above 21 mmHg that could suggest possible glaucoma suspects.
89403509|NCT04158635|Experimental|Treatment (bosentan, nab-paclitaxel, gemcitabine) - Participant 1-9|"Patients receive bosentan PO BID on days 8-21 of cycle 1 and days 1-21 of subsequent cycles.~Patients also receive nab-paclitaxel IV over 30 minutes and gemcitabine IV over 30 minutes on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
89403510|NCT04158635|Experimental|Treatment (bosentan, nab-paclitaxel, gemcitabine) - Participant 10-12|"Patients receive bosentan PO BID on days -7 to 21 and days 1-21 of subsequent cycles.~Patients also receive nab-paclitaxel IV over 30 minutes and gemcitabine IV over 30 minutes on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
89403511|NCT04158635|Experimental|Treatment (bosentan, nab-paclitaxel, gemcitabine) - Participant 13-21|"Patients receive bosentan PO BID on days 1-21 of cycle 1 and days 1-21 of subsequent cycles.~Patients also receive nab-paclitaxel IV over 30 minutes and gemcitabine IV over 30 minutes on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
88879192|NCT01795014||Primary open-angle Glaucoma|Patients with a characteristic optic disc damage (based on cup/disc ratio, thinning of neuroretinal rim, notching, disk hemorrhages, etc.) and visual field defects, with at least one measurement of IOP of >21 mmHg required
89403512|NCT04148482|Active Comparator|Genotype of interest group|Individuals with desired genetic susceptibility will receive a standardized and an election meal in a full-day clinic visit.
88879193|NCT01795014||Normal Tension Glaucoma|Patients with a characteristic optic disc damage (based on cup/disc ratio, thinning of neuroretinal rim, notching, disk hemorrhages, etc.) and visual field defects, with at maximum recorded IOP of < 21 mmHg
88879194|NCT01797588|Active Comparator|adductor-canal block and periarticular infiltration|Adductor-canal block,performed prior to surgery using ultra sound guidance by an anesthetist, with a total of 30mL of 0.33% ropivacaine injected into the area surrounding the saphenous nerve. Periarticular infiltration, performed intra-operatively by the surgeon, involves administering a 110 mL solution of ropivacaine 300mg, preservative free morphine 10mg, ketorolac 30mg mixed in normal saline into the knee.
89190081|NCT03853473|Experimental|Remote Ischemic Preconditioning|Study participants will perform remote ischemic preconditioning daily, at home, from study enrollment to their date of surgery.
89199046|NCT00675948|Experimental|GW-2000-02|Active treatment
89403513|NCT04148482|Placebo Comparator|Control|Individuals without genotype of interest (i.e., carrying the opposite genotype) will receive a standardized and an election meal in a full-day clinic visit.
89403514|NCT04141761|Experimental|Treatment Group|
89403515|NCT04141761|Placebo Comparator|Placebo Group|
89403516|NCT04119258||Psychiatric patients|Psychiatric outpatient care patients with major depressive disorder, anxiety disorders, post-traumatic stress disorder, obsessive-compulsive disorder, or illness anxiety disorder who have just completed cognitive-behavioral therapy.
89403517|NCT04113863|Active Comparator|ARM A - Anastrozole|Anastrozole at the dosage of 1 mg/die. Treatment will last 28 days
88879195|NCT01797588|Active Comparator|adductor-canal block|The adductor-canal block only group will receive an adductor-canal block prior to surgery in the block room using ultra sound guidance by an anesthetist. After the adductor-canal is located a total of 30mL of 0.33% ropivacaine will be injected into the area surrounding the saphenous nerve. Participants will also receive 110mL of normal saline administered as follows: the first 20mL aliquot is injected into the posterior capsule and the medial and lateral ligaments just prior to implantation; after the implants have been cemented and curing, another 20mL is infiltrated to the quadriceps and retinacular tissues. The remaining solution (~60mL) is used to infiltrate the muscle, subcutaneous tissues.
88879196|NCT01797588|Active Comparator|periarticular infusion group|Periarticular infiltration,performed intra-operatively,involves administering a 110 mL solution of ropivacaine 300mg, preservative free morphine 10mg, ketorolac 30mg mixed in normal saline into the knee. It will be administered as follows: the first 20mL aliquot is injected into the posterior capsule and the medial and lateral ligaments just prior to implantation; after the implants have been cemented and curing, another 20mL is infiltrated to the quadriceps and retinacular tissues. The remaining solution (~60mL) is used to infiltrate the muscle, subcutaneous tissues.
88879197|NCT01799460||CR/CTR group|The complete remission group treated by the Comprehensive Treatment Regimen
88879198|NCT01799460||NR/CTR group|The non-remission group treated by the Comprehensive Treatment Regimen
88879199|NCT01799460||CR/IA group|The complete remission group treated by Immunosuppressive Agents
88879200|NCT01799460||NR/IA group|The non-remission group treated by Immunosuppressive Agents.
88879201|NCT02994030||Participants with Duchenne Muscular Dystrophy (DMD)|Participants diagnosed with Duchenne Muscular Dystrophy (DMD) aged between 2 months and 50 years
88879202|NCT02994966|Experimental|Surrosense|Subjects randomized to this group will receive standard care, including appropriate off-loading and footwear as well as wear SurroSense Rx® in-shoe pressure-sensing arrays, which provide visual and auditory/vibratory feedback alerts (relating to high plantar pressures) and offloading guidance to a watch display intended to assist in the recurrence of diabetic foot ulcers. They will also be advised to perform daily self-checks of their feet for redness, callous and wounds. A daily checklist will be provided to participants to evaluate compliance.
88879203|NCT02994966|Active Comparator|Standard care|Subjects randomized to this group will receive standard care, including appropriate off-loading and footwear. They will also be advised to perform daily self-checks of their feet for redness, callous and wounds. A daily checklist will be provided to participants to evaluate compliance.
88879204|NCT02991846||Patients with cGVHD|All consecutive patients undergoing allogenic stem cell transplant for any underlying disease who develop chronic graft-versus-host disease (cGVHD)
88879205|NCT02992080|Other|Cystic fibrosis Patients|
89403518|NCT04113863|Experimental|ARM B - Anastrozole + ATRA|Anastrozole at the dosage of 1mg/die in combination with ATRA at the total dosage of 45mg/m2/die (two daily administrations of 22.5 mg/m2 each). Treatment will last 28 days
89403519|NCT04073979|Experimental|Mistral|"The Mistral is an investigational device intended for percutaneous trans-catheter repair in high risk for surgery individuals suffering from functional Tricuspid Regurgitation (TR).~The device system is to be used only in accordance with the approved Investigational Plan on subjects who have signed an informed consent form. Device use is limited to the approved study investigators."
89403520|NCT04071652|Experimental|Mistral|"The Mistral is an investigational device intended for percutaneous trans-catheter repair in high risk for surgery individuals suffering from functional Tricuspid Regurgitation (TR).~The device system is to be used only in accordance with the approved Investigational Plan on subjects who have signed an informed consent form. Device use is limited to the approved study investigators."
89403521|NCT04026048|Experimental|Cognitive Behaviour Therapy for Insomnia (CBT-I)|Participants will receive individualized CBT-I delivered by video-conferencing over the course of eight weeks.
88879206|NCT02992080|Other|Patients without fibrosis cystic|
88879207|NCT02992080|Other|Cystic fibrosis Patients (secondary use of samples)|
88879208|NCT02995434|Experimental|Intervention Group|Participants will be randomly assigned to the intervention group (50 in total).The VR intervention will be identical for each participant and consist of a PC running the immersive virtual reality application with a Virtual Reality headset 110 degrees field of view head mounted display. The VR will be a set of commercial exploratory virtual environment games designed for the HTC Vive headset. The intervention will be used for one month to enable customization to the therapy and record data over a long enough period of time to account for individual short- term changes in pain experience. Participants will be asked to use the VR therapy every day with a time exposure of 30 minutes for four consecutive weeks. There will be one rest day a week (normally a Sunday) where no therapy is given.
88879209|NCT02995434|Active Comparator|Control Group|The control group will be exposed to 2D PC equivalent versions of the same multimedia experiences but on their PC screen (without the Virtual Reality headset use). These will be functionally similar to the VR experiences.
88879210|NCT02999880|Experimental|Polychromatic layering (Control):|Using and mixing different composite shades, opalescents and intensives.
88879211|NCT02999880|No Intervention|Dual-shade layering (Intervention):|Only two composite resin material shades the opaque dentin composite and enamel shade composite.
88879212|NCT02999724|Experimental|gabapentin|gabapentin 300-600 mg 1 hour preop
88879213|NCT02999724|Placebo Comparator|placebo|placebo capsule(s) 1 hour preop
88879214|NCT02999490|No Intervention|Controls|The controls are intravenous injected of 185 to 370 MBq 18F-FDG.Then,the controls sleep for an hour in a quiet room before scanning.
88879215|NCT02999490|Experimental|Patients|The patients are intravenous injected of 185 to 370 MBq 18F-FDG.Then,the patients sleep for an hour in a quiet room before scanning.
88879216|NCT02999568||Experimental|Women who practice high level of physical activity, as defined by International Physical Activity Questionnaire, for the past 3 years
88879217|NCT02999568||Control group|Women who practice low level of physical activity, as defined by International Physical Activity Questionnaire, for the past 3 years
89403522|NCT04026048|Experimental|Waitlist Control Group|Participants in the waitlist control group will be required to monitor their sleep with sleep diaries for 7 weeks. They will receive CBT-I delivered by video-conferencing immediately after the waiting period.
89403523|NCT04023110|Experimental|Carvedilol|"Carvedilol will be initiated at 3.125mg twice daily and uptitrated as tolerated in a stepwise fashion to a maximum dose of 25mg twice daily or to a systolic blood pressure (SBP) of 110-120mmHg or heart rate (HR) of 50-55 beats per minute (bpm). Patients will start carvedilol in the evening after first dose of chemotherapy and will continue on medication for 12 months.~Clinical, echocardiographic, and biomarker data will be collected on all patients at baseline and standardized time intervals during and after therapy at approximately 3, 6, 9, 12, and 24 months."
89004276|NCT05330507||Wellinks Intervention|Following inpatient hospitalization for COPD exacerbation, participants will receive 16 weeks of access to Wellinks (i.e., connected spirometer and pulse oximeter, virtual respiratory therapist sessions with pulmonary rehabilitation, virtual health coaching sessions, mobile app access, COPD-related education). The 16-week period is comprised of a 30-day post-discharge program followed by a 12-week intensive period, which vary by frequency of contact with respiratory therapists/health coaches.
89004277|NCT05330507||Matched Controls|A matched control dataset will be extracted from electronic medical records of the participating healthcare system. Participants will be matched on an index COPD-related hospitalization and other key factors, utilizing propensity score matching (i.e., number of COPD-related hospitalizations in prior year, severity of COPD, age).
89004278|NCT05326165|Experimental|Compression therapy|"Participants will receive a ready to wear compression sleeve and glove with embedded sensor.~Compression sleeve will be set to 20-30mm Hg pressure with instructions to wear for 12 hours a day for four consecutive weeks.~Participants will also receive a journal to record usage and standard of care post-operative lymphedema monitoring and education and asked to fill out questionnaires."
89004279|NCT05301192|Experimental|Angiotensin-(1-7)|Participants will receive intravenous angiotensin-(1-7) at one study visit for 110 minutes. Angiotensin-(1-7) will be given in escalating doses of 2 ng/kg/min, 4 ng/kg/min, and 8 ng/kg/min. Each of these doses will be infused for 10 minutes. Following the dose escalation, angiotensin-(1-7) will be given at 8 ng/kg/min for an additional 80 minutes. Infusion rates will be calculated for each participant based on body mass.
89190082|NCT03845244|Active Comparator|Flow reduction first group|Flow reduction first -> FiO2 reduction -> conventional oxygen therapy
89004280|NCT05301192|Placebo Comparator|Saline|Participants will receive intravenous saline at one study visit for 110 minutes total. The volume of saline will match the volume of angiotensin-(1-7) infused. Infusion rates will be calculated for each participant based on body mass.
89190083|NCT03845244|Active Comparator|FiO2 reduction first group|FiO2 reduction first -> flow reduction -> conventional oxygen therapy
89403524|NCT04023110|No Intervention|Usual Care|Clinical, echocardiographic, and biomarker data will be collected on all patients at baseline and standardized time intervals during and after therapy at approximately 3, 6, 9, 12, and 24 months.
89403525|NCT04021290|Experimental|Participants receiving DTG/3TC FDC|Eligible participants will be randomized to receive 50 milligrams (mg)/300 mg DTG/3TC FDC therapy from Day 1 up to 52 weeks. Participants who complete 52 weeks of treatment will have the opportunity to continue receiving DTG/3TC FDC once daily in the continuation phase.
89403526|NCT04021290|Active Comparator|Participants receiving CAR|Eligible participants will continue to receive CAR from Day 1 up to 52 weeks.
89403527|NCT04010708||IOMUM|Pregnant women
89403528|NCT03998618|Experimental|Acceptance and Commitment Therapy|Patients in the ACT arm will learn new and more adaptive ways to respond to fatigue.
89403529|NCT03998618|Active Comparator|Education/Support|Patients in the education/support arm will discuss their cancer-related concerns and receive education on services available in their medical center and community.
89403530|NCT03984084||externally recruited participants|Self-referred affected and non-affected participants responding to advertisements
89403531|NCT03984084||In-house patients|Patients seeking treatment in the outpatient clinic of the Max-Planck-institute of Psychiatry
89403532|NCT03973281|Active Comparator|Materna Prep Device|Materna Prep Device
89403533|NCT03973281|Other|Standard of Care (SOC)|Standard of Care (SOC)
89403534|NCT03971591|Experimental|Immediate Lifestyle program|The Intervention will be conducted in cohorts of 15-20. We anticipate there will be 5-6 cohorts over the course of the study. Men assigned to the Guided Lifestyle Program will participate in twice weekly sessions - the first weekly session will be 120 minutes in length with the first hour addressing lifestyle change education and strategies, the second hour will be supervised exercise with strength training. The second weekly session will be a one-hour supervised exercise session with strength training. Men will also receive 2-3 text messages weekly. They will also receive a participant informational binder with health and exercise information and tools as directed by ACS nutrition and physical activity guidelines.
88879218|NCT02999256|Placebo Comparator|Placebo|"130ml serving twice daily (immediately before breakfast and dinner) for 20 days.~Placebo composition: Water (100ml), Cherry Squash Concentrate (30ml), Citric Acid (1.5g), Maltodextrin (24.75g), Black Food Colouring (2ml)."
88879219|NCT02999256|Experimental|Montmorency Tart Cherry Juice|"130ml serving twice daily (immediately before breakfast and dinner) for 20 days.~MTCJ Composition: 100ml water and 30ml Montmorency tart cherry concentrate (Cherry Active, Sunbury, UK)."
89190084|NCT03845244|Active Comparator|Simultaneous reduction group|Simultaneous (Flow and FiO2) reduction -> conventional oxygen therapy
89403535|NCT03971591|Other|Waitlist Control|In the waitlist control arm, the men will not receive any intervention for 16-weeks. After the 16-week assessment, men randomized to this arm will crossover to the intervention arm.
89403536|NCT03956277||Observational PUG|Patients receive gastrostomy via percutaneous ultrasound gastrostomy.
89403537|NCT03937726|Experimental|Boiled peanut Oral Immunotherapy|Desensitisation using boiled peanut
88879220|NCT02999334|No Intervention|Individual ANC (standard care)|Individual ANC is the standard of care. Women arrive at the clinic and and are provided ANC services on a first come, first serve basis. While waiting women who are present listen to a health lecture. Women then complete laboratory tests, including HIV testing (at the first visit), then meet individually with a midwife for a brief one-on-one physical assessment. Four ANC visits are recommended.
88879221|NCT02999334|Experimental|Group ANC (intervention)|Women in CP-based group antenatal care (intervention) arrive at clinic at the scheduled appointment time and go directly to the group space. The same group of 12 women and the midwife and co-facilitator are present at each session. Women measure and record their own vital signs and weight. Each then has a brief one-on-one assessment with the midwife in the group space room. Instead of health lectures, the group engages in facilitated and interactive discussions using activities. Four ANC visits are recommended.
88879222|NCT02998866|Other|Multi-center, prospective outcomes registry|The study is a multi-center, prospective outcomes registry
89403538|NCT03937726|Active Comparator|Conventional Oral immunotherapy|Desensitisation using defatted peanut flour
89403539|NCT03927638||Normal Weight|Group is determined based upon subjects weight status. Subjects will preform computer work in the seated and standing position in a counterbalanced manner while metabolic and cardiovascular measurements are made.
89403540|NCT03927638||Overweight/Obese|Group is determined based upon subjects weight status. Subjects will preform computer work in the seated and standing position in a counterbalanced manner while metabolic and cardiovascular measurements are made.
89403541|NCT03924791|Experimental|Transforaminal Epidural Injection|Transforaminal Epidural Injection containing 1,5 mL lidocaine 2% and 40mg methylprednisolone acetate for injections L3 or below Transforaminal Epidural Injection containing 1,5 mL lidocaine 1% and 10mg dexamethasone for injections above L3
88813402|NCT02470806|Active Comparator|tNPWT System|Traditional NPWT (tNPWT) from -25 mmHg and up to -200 mmHg; intensity settings of either low, medium and high; delivery modes of continuous or intermittent. The pressure, intensity and delivery settings will be left to the Investigator's discretion at each study treatment visit.
88813403|NCT00912002|Experimental|MK-0941|MK-0941
88813404|NCT01726556|Active Comparator|Rigid thoracoscopy|Rigid thoracoscopy would be done using a rigid thoracoscope manufactured by Richard Wolf GmbH, Knittlingen, Germany.
88813405|NCT01726556|Active Comparator|Semirigid thoracoscopy|The semirigid thoracoscope employed is a model LTF-160Y1, manufactured by Olympus Medical Systems Corporation, Tokyo, Japan.
88813406|NCT03409250|Other|1-Arm study|prospective, 1-arm, monocenter, investigator initiated study Intravitreal injection with Lucentis (Ranibizumab)
88813407|NCT01569815|Experimental|LCZ696 400 mg|LCZ696 400 mg once daily for 5 days
88813408|NCT01726634|Experimental|Elastic Tapping|
88813409|NCT01726712|No Intervention|Routine Care|
88813410|NCT01726712|Active Comparator|Supportive Contact|
88813411|NCT01469585|Active Comparator|Sub-antimicrobial doxycycline|Women will take sub-antimicrobial doxycyline in addition to the continuous oral contraceptive pill.
88813412|NCT01469585|No Intervention|Continuous Oral Contraceptive Pill|Women will take only the continuous oral contraceptive.
88813413|NCT01720940|Experimental|continuous vancomycin infusion|
88813414|NCT01720940|Active Comparator|intermittent vancomycin infusion|vancomycin in this arm will be administered as intermittent infusion
88813415|NCT03409172|Experimental|Control group (CTr)|No counseling or nutritional therapy and no exercise
88813416|NCT03409172|Experimental|Moderate intensity continuous training (MICT)|"Follow-up during a period of 8 weeks of supervised ergometer-based moderate-intensity continuous training based on HRmax (MICT).~MICT:~3 sessions per week~intensity at 65-75% HRmax~time-effort per session: 50 min"
88813417|NCT03409172|Experimental|High Intensity Interval Training (HIIT)|"Procedures: Follow-up during a period of 8 weeks of supervised ergometer-based high intensity interval training based on HRmax (HIIT).~HIIT:~3 sessions per week~10 bouts of one minute at 90% HRmax interspersed by one minute at 40% HRmax~time-effort per session: 25 min"
88813418|NCT01721018|Experimental|HSV1716|Single Arm Phase I/II study of intra-pleural HSV1716 administration.
88813419|NCT01721174|Active Comparator|SEMS only|Endoscopic retrograde cholangiopancreatography (ERCP) would be performed under standard operating conditions to confirm the length of the biliary stricture, diameter, and position. An uncovered self expanding metallic stent (SEMS) would be inserted to bypass the site of narrowing (Niti-S biliary uncovered metallic stent; Taewoong Medical, Gimpo City, Korea)
88813420|NCT01721174|Active Comparator|EBRFA and SEMS|Endoscopic retrograde cholangiopancreatography (ERCP) would be performed under standard operating conditions to confirm the length of the biliary stricture, diameter, and position. The radiofrequency ablation (EBRFA) catheter would be placed under fluoroscopic guidance across the biliary stricture. The Habib EndoHPB (EMcision UK, London, United Kingdom) radiofrequency ablation catheter with energy delivered by an RFA generator would be used to apply RFA to the entire length of the stricture, sequential applications would be applied to complete treatment throughout the length of the stricture without significant overlap of treated areas. Patients would undergo 2 sessions of EBRFA 2 weeks apart. A plastic stent would be inserted in between the 2 sessions. An uncovered SEMSs (Niti-S biliary uncovered metallic stent; Taewoong Medical, Gimpo City, Korea) would be placed after the second EBRFA.
88813421|NCT01726868|Experimental|Liposorber LA-15 System|
88813422|NCT03408938||Continuous Hb monitoring with Masimo Radical|"Plethysmography Variability Index (PVI) is a measure of the dynamic changes in the perfusion index (PI) that occur during the respiratory cycle . PVI = ﴾PI Max - PI Min﴿ ÷ PI Maxx 100 %.~PVI has the potential to provide useful information concerning changes in the balance between intrathoracic airway pressure and intravascular fluid volume. Trending of PVI may be useful in monitoring surgical patients, both intraoperatively and postoperatively, for appropriate hydration states. For example, a rising PVI may indicate developing hypovolemia and gives an alarm for the need of appropriate fluid and or blood products transfusion supported by the patient hemoglobin level"
88813423|NCT01363908|Experimental|SPD602 (26 mg/kg)|Oral SSP-004184AQ taken once daily for 48 weeks
88813424|NCT01363908|Experimental|SPD602 (36 mg/kg)|Oral SSP-004184AQ taken once daily for 48 weeks. Starting dose based on transfusion burden and iron overload status. Doses may range from 8-60mg/kg/day depending on clinical response.
88813425|NCT01363908|Experimental|SPD602 (16 mg/kg)|A single dose given in the initial pharmacokinetic phase.
88813426|NCT00915590|Experimental|Placebo first, then IL-1RA|It is our intent that 10 patients will complete a course of treatment with placebo, followed by a course of treatment with 5% custom made topical IL-1Ra.
88813427|NCT00915590|Experimental|IL-1RA first, then Placebo|It is our intent that 10 patients will complete a course of treatment with 5% custom made topical IL-1Ra, followed by a course of treatment with placebo
88813428|NCT03408782||No drainage|Those patients that underwent surgery and no drain was inserted at the end of the procedure
89403542|NCT03924791|No Intervention|Oral pain medication|Patients will receive oral pain medication according to general practitioner guidelines.
89403543|NCT03916237|No Intervention|CONTROL|Control group
89403544|NCT03916237|Experimental|GROUP A no referral|Screener does not document need for home visit or medical legal partnership referral.
89403545|NCT03916237|Experimental|GROUP B1 home assessment only|Screener documents need for home assessment. Home assessment does not document need for home remediation. Screener does not document need for medical legal partnership.
89403546|NCT03916237|Experimental|GROUP B2 home assessment only|Screener documents need for home assessment. Home assessment does not document need for home remediation. Screener documents need for medical legal partnership.
89403547|NCT03916237|Experimental|GROUP C1 home assessment and remediation|Screener documents need for home assessment. Home assessment documents need for home remediation. Screener does not document need for medical legal partnership.
89403548|NCT03916237|Experimental|GROUP C2 home assessment and remediation|Screener documents need for home assessment. Home assessment documents need for home remediation. Screener documents need for medical legal partnership.
89403549|NCT03916237|Experimental|D medical legal partnership only|Screener does not document need for home assessment. Screener does not document need for medical legal partnership.
89403550|NCT03915548|Experimental|The Behavioral Activation/ Problem Solving Intervention|BA/PS teaches survivors to a) systematically examine the reasons an activity is challenging, b) set achievable short-term goals that have the potential to improve participation, c) brainstorm solutions including activity adaptations and environmental modifications, d) construct and implement a detailed action plan, and e) evaluate the results and level of goal attainment. The structured process gives participants repeated practice in goal reengagement that leads them progressively closer to their long-term functional goals. The BA/PS framework integrates the cognitive-behavioral therapies of Behavioral Activation and Problem-solving Treatment and incorporates concepts from an occupational therapy theory called the Person-Environment-Occupational Performance Model.
89530970|NCT03232099|Active Comparator|Abstemious|After a two weeks washout period,in the Abstemious period, patients should not consume any kind of alcohol beverages, for 3 weeks
88921954|NCT06027008|No Intervention|Standard airway care|Patients in the control group will receive usual airway care which includes endotracheal suctioning and manual hyperinflation used when indicated based on clinical signs as part of regular airway care. Care protocols for endotracheal suctioning and manual hyperinflation are predefined. As with the intervention arm, there will be no use of saline instillation during suctioning. Manual hyperinflation technique is described in the care protocol of the intensive care unit and ICU nurses are trained to perform this technique.
88921955|NCT06018662|No Intervention|Control|Routine department therapy
89190085|NCT03844568|Experimental|nasal CPAP group|Applying nocturnal nasal continuous positive airway pressure in additional to usual pneumonia treatment
89530971|NCT02499653|Experimental|Psychological Intervention|In addition to the standard care, subjects are participating in a brief psychological support, which will include elements of psychological well-being's promotion and cognitive restructuring exercises (mindfulness).
89190086|NCT03844568|No Intervention|Control group|Usual pneumonia treatment
89190087|NCT03841760|Experimental|PSMA PET/CT|One (1) PSMA PET/CT scan with with either PSMA-11 or DCFPyL
89190088|NCT03833102||Colonized patients' group (CPG)|all adult patients hospitalized in or consulting the Rennes University Hospital, known as S. aureus colonized could be included. In our institution, S. aureus colonization in the nostrils is screened in all patients supposed to undergo neurosurgical or orthopedic surgery.
89403551|NCT03915548|Active Comparator|Attention Control Condition|"Investigators provide education regarding nine cancer survivorship topics (i.e., healthy diets, physical activity, lymphedema management, smoking cessation, stress management, communication with providers, body image and sexuality, communication with social supports, work accommodations) during the control telephone contacts. The control condition will match the intervention in terms of the number of sessions, the delivery by telephone, use of an occupational therapist, and the use of homework between sessions (i.e., reading the education materials for the control condition versus executing the action plan for the BA/PS condition)."
89403552|NCT03879447||Lumbar stenosis group|Lumbar stenosis patients will be administered integrative Korean medicine treatment consisting of herbal medicine, Chuna manual medicine, bee venom pharmacopuncture and pharmacopuncture, acupuncture, electroacupuncture, cupping, and other interventions, as needed.
89403553|NCT03879447||Lumbar spondylolisthesis group|Lumbar spondylolisthesis patients will be administered integrative Korean medicine treatment consisting of herbal medicine, Chuna manual medicine, bee venom pharmacopuncture and pharmacopuncture, acupuncture, electroacupuncture, cupping, and other interventions, as needed.
89403554|NCT03860883|Experimental|Arm A (Wide Local Excision = 1cm Margin)|1cm Wide Local Excision margin + Sentinel Lymph Node Biopsy +/- Reconstruction
89403555|NCT03860883|Active Comparator|Arm B (Wide Local Excision = 2cm Margin)|2 cm Wide Local Excision margin + Sentinel Lymph Node Biopsy +/- Reconstruction
89530972|NCT02499653|Active Comparator|Videos|The subjects assigned in the Control Group watch some videos relating to the management of their disease.
89190089|NCT03833102||SAB patients' group (SAB)|"all adult patients with SAB could be included. S. aureus colonization in the nostrils will be systematically screened immediately after the first result of positive S. aureus blood culture. Two subgroups will be individualized depending on the SOFA Score:~Severe patients~Non-severe patients"
88813429|NCT03408782||Drainage|Those patients that underwent surgery and one or several drains were inserted at the end of the procedure.
88813430|NCT01570829|Experimental|Dietressa|Tablet for oral use. 1 tablet 6 times a day. The duration of Dietressa therapy is 24 weeks.
88813431|NCT01570829|Placebo Comparator|Placebo|Tablet for oral use. 1 tablet 6 times a day. The duration of Placebo therapy is 24 weeks.
88813432|NCT01721642|Experimental|Apica Cardiovascular ASC Device|Access, stabilisation and closure with the Apica Cardiovascular ASC Device
88813433|NCT03408626|Experimental|papain chemomechenical caries removal agent (brix 3000)|papain chemomechenical caries removal agent (Birx 3000) and the exclusive Encapsulating Buffer Emulsifier (EBE) technology claim it has effective and selective proteolytic action
88813434|NCT03408626|Placebo Comparator|conventional|conventional 330 bur
88813435|NCT01471457|Experimental|Trimo-San group|Pessary wearers are instructed to apply one fingertip (approx 1 tablespoon) of Trimo-San gel inside the vagina or to the pessary (for women removing and cleaning pessary before reinsertion after cleaning) once nightly
88813436|NCT01471457|No Intervention|Control group|Pessary wearers are informed on standard care of pessary, which includes topical estrogen application if they are using. Pessary wearers do not use Trimo-San gel
88813437|NCT03408548|Placebo Comparator|Placebo|Scaling root planning + two lozenge per day not containing Bifidobacterium animalis lactis HN019 for 30 days.
88813438|NCT03408548|Experimental|Probiotic|Scaling root planning + two lozenge per day containing Bifidobacterium animalis lactis HN019 (10x9 colony-forming units) for 30 days.
88813439|NCT02497404|Experimental|5 Azacytidine|Patients will be given a five day course of subcutaneous 5-azacytidine, followed by a reduced intensity conditioning regimen of fludarabine and melphalan with or without total body irradiation prior to an allogeneic hematopoietic stem cell transplantation from a related or unrelated HLA matched donor.
88813440|NCT03408470|Experimental|TD-1473 Oral Capsule & [14C]-TD-1473 IV bolus|Cohort 1 - One oral dose and IV bolus administered 1 hr after oral dose of TD-1473
88813441|NCT03408470|Experimental|[14C]-TD-1473 Oral Capsule|Cohort 2 - One oral dose
88813442|NCT01573169|Experimental|low weight molecular heparin|enoxaparin 0.4 ml subcutaneous per day
88813443|NCT01573169|Placebo Comparator|standard therapy|Graduated compression stockings and/or intermittent pneumatic compression and/or early mobilization
88813444|NCT01727492|Placebo Comparator|sugar pill|
88813445|NCT01727492|Active Comparator|Antioxidantia|Dosage: 600mg n-acetylcystein and 200mg magnesium intake: 1 hour before leisure noise exposure above 100dB of at least 30 minutes frequency: 4 separate events (2x placebo, 2x antioxidants)
88813446|NCT05522309|Experimental|Dose Escalation and Dose Expansion|ET0111 will be administered orally once daily in 21 days treatment cycles.
88879223|NCT02998632|Experimental|Interventional|"Patients will receive 2 gm of amoxicillin 1 hour before surgery. Mouthwash 0.12% chlorhexidine solution for 30 seconds immediately before surgery.~Inferior alveolar nerve block and long buccal nerve anesthesia using articane HCl 4% with 1:100,000 adrenaline local anesthetic solution.~Flap will be reflected in intraoral donor site to completely expose bone. Autogenous bone graft will be obtained and will be ground. MPM (Mineralized plasmatic matrix) will be prepared. Implant fixture/s will be inserted. Uncovered fixture threads and bone defect will be covered by MPM. Osstell will be used to measure fixture primary stability in ISQ units. Sutures will be placed. Sutures will be removed 7 days later. Immediate postoperative CBCT will be performed. Antibiotic (combination of 500mg amoxicillin and 125mg clavulanic acid) and analgesic and anti-inflammatory (Ibuprofen 600mg) will be prescribed."
88879224|NCT02998632|Active Comparator|Comparator|"Patients will receive 2 gm of amoxicillin 1 hour before surgery. Mouthwash 0.12% chlorhexidine solution for 30 seconds immediately before surgery.~The patient will receive inferior alveolar nerve block and long buccal nerve anesthesia using articane HCl 4% with 1:100,000 adrenaline local anesthetic solution Flap will be reflected in intraoral donor site to completely expose bone. Autogenous bone graft will be obtained and will be ground. Implant fixture/s will be inserted. Uncovered fixture threads and bone defect will be covered by autogenous bone graft and covered by titanium membrane.~Osstell instrument will be used to measure and record fixture primary stability in ISQ units.~Sutures will be placed. Sutures will be removed 7 days later. Immediate postoperative CBCT will be performed. Antibiotic (combination of 500mg amoxicillin and 125mg clavulanic acid) and analgesic and anti-inflammatory (Ibuprofen 600mg) will be prescribed."
88879225|NCT02998242|Active Comparator|RT alone|symptomatic bony metastatic site(s) receive SBRT less than 5 fractions
88879226|NCT02998242|Experimental|RT with apatinib|selected dose administered PO during and after SBRT
88879227|NCT02998320|Experimental|Genvoya|Genvoya (E/C/F/TAF) Tablet (oral use) : 150/150/200/10 mg, one tablet each day for 28 days
88879228|NCT02998086|Experimental|Individual (1:1)|Individual, 1:1 version of the Promoting Resilience in Stress Management for Parents (PRISM-P) intervention
88879229|NCT02998086|Experimental|Group|Group-based version of the Promoting Resilience in Stress Management for Parents (PRISM-P) intervention
88879230|NCT02998086|No Intervention|Usual Care|Usual non-directed psychosocial supportive care
88879231|NCT02997696|Experimental|Experimental arm 1|ONO-4474 low dose every day for 4 weeks
88879232|NCT02997696|Experimental|Experimental arm 2|ONO-4474 high dose every day for 4 weeks
88879233|NCT02997696|Placebo Comparator|Placebo arm|Placebo matching ONO-4474 every day for 4 weeks
88879234|NCT02997852|Experimental|Therapy dog visitation|The TDV will consist of a 10-minute visit from the same Faithful Paws animal handler and her dog. Each therapy dog meets obedience, temperament, and health standards appropriate to therapy dog visitation in hospital settings. The dog will be leashed and under control of the animal handler and the TDV will be casual and not restrict the handler with conversing, which is standard practice in TDV. Visual and tactile contact with the dog will be promoted by the animal handler. Per hospital protocol, the patient will be assisted in washing his/her hands before and after the TDV and the dog will be placed on the bed or remain at the bedside in close proximity allowing petting. A clean sheet will be placed over the patient when the dog is placed on the bed. The research staff will collect data before and after each arm of the study.
88879235|NCT02997852|No Intervention|Control|Usual care in the intensive care unit.
88879236|NCT02997930|Experimental|Elderly Hip Fracture|Postoperative assess cognitive function in elderly subjects after fracture hip surgery. Measure function connectivity and DTI (diffusion tensor imaging) via: fMRI. Subjective measures will include: Montreal Cognitive Assessment (MoCA), Digital Clock Drawing Test Command and Copy, Wide Range Achievement Test reading subtest, Hopkins Verbal Learning Test (HVLT), General Depression Scale (GDS)
88879237|NCT02997774|Active Comparator|Standard Dialysis|Patient will undergo dialysis at 36.5 degrees Celsius to assess if this affects the liver function and perfusion
88879238|NCT02997774|Experimental|Cooler Dialysis|Patient will undergo dialysis at 35 degrees Celsius to assess if this affects the liver function and perfusion
88879239|NCT02997618|Active Comparator|Control|"1. Usual care (control)~Usual care given to patients on AAA surveillance. This includes six-monthly or annual ultrasound measurements of AAA, attendance to surveillance clinic and written (APPENDIX A) and verbal advice on managing cardiovascular risk. This advice will be based on current widely available NHS patient information15 and consists of the following information with regard to:~Smoking Exercise Weight Diet"
88921956|NCT06018662|Experimental|Interventional|Anesthetics, antimicrobials and analgesics are selected and age/weight doses are calculated using the medication management mobile application
88921957|NCT06018064|Experimental|Interventional Arm|Subjects who are placed in the Prone Positioner for evaluation
89403556|NCT03859466|Experimental|Intervention Arm|In the intervention arm, 300 shockwave impulses per coronary supply territory, at an energy flux density of 0.38mJ/mm2 and a frequency 3Hz, are applied in direct contact with the ischaemic myocardium of the left ventricle. The intervention is performed during CABG surgery after bypasses are fully established while still on cardiopulmonary bypass.
89403557|NCT03859466|No Intervention|Sham Control Arm|In the sham control arm, the same manipulations are performed with an inactive shockwave applicator in direct contact with the ischaemic myocardium of the left ventricle as in the intervention arm. The sham treatment is performed during CABG surgery after bypasses are fully established while still on cardiopulmonary bypass.
89403558|NCT03854799|Experimental|CHEMORADIOTHERAPY PLUS AVELUMAB|"CHEMORADIOTHERAPY PLUS AVELUMAB:~CAPECITABINE 825 mg/sqm/bid p.o. 5 days/week EXTERNAL-BEAM IRRADIATION 50.4 GY in 28 fractions over 5.5 weeks AVELUMAB 10 mg/Kg ev over 1 hour every 2 weeks at days 1, 14, 28, 42, 56, 70"
89403559|NCT03851380||Treatment Resistant Major Depression|Patients with treatment resistant major depression
89403560|NCT03851380||COVID Stress|Veterans with COVID-19-related distress
89403561|NCT03829787||Bipolar without Anxiety or Substance Use Disorder|Subjects who are diagnosed with bipolar disorder but do not have any current anxiety or substance use disorders
89403562|NCT03829787||Bipolar disorder with a current anxiety disorder only|Subjects who are diagnosed with bipolar disorder and a current anxiety disorder (generalized anxiety disorder, panic disorder, and/or social phobia) but not a current substance use disorders
89403563|NCT03829787||Bipolar disorder with a current anxiety disorder and a current|Subjects who are diagnosed with bipolar disorder and a current anxiety disorder (generalized anxiety disorder, panic disorder, and/or social phobia) AND a current substance use disorders
89403564|NCT03829787||Bipolar disorder with a current substance use disorder only|Subjects who are diagnosed with bipolar disorder & a substance use disorders but not a current anxiety disorder
89403565|NCT03829787||Healthy Volunteers|
88879240|NCT02997618|Experimental|Community Based Exercise Programme|"Community based-exercise (in addition to usual care) with the choice of either:~Home-based exercise training Participants choosing to exercise at home will follow the programmes intended for this setting, with each exercise designed to be possible without the need for specialist equipment.~Gym-based exercise training Participants will exercise at their nearest Life Leisure LTD gym, following one of the instructor designed programmes , using a combination of aerobic and resistance equipment, as well as simple floor exercises.~Duration and Frequency At least 50 minutes of exercise per day on three non-consecutive days of the week for 20 weeks."
88879241|NCT02997384||General practitioner|
88879242|NCT02997384||gynecologist|
88879243|NCT02997384||radiologist|
88879244|NCT02997540||female breast ultrasound exam|females with at least one benign or probably benign mass, up to 2 cm in size, in one breast, detected during a standard-of-care breast ultrasound examination
88879245|NCT02997306|Experimental|Superior/Medial Running Sutures|In this cohort, the running sutures will be randomized to be oriented on Superior/Medial half of the scar, and the remaining half of the scar will be closed with simple interrupted sutures.
88879246|NCT02997306|Experimental|Inferior/Lateral Running Sutures|In this cohort, the running sutures will be randomized to be oriented on Inferior/Lateral half of the scar, and the remaining half of the scar will be closed with simple interrupted sutures.
89403566|NCT03806283||Cohort 1 no Preeclampsia|Cohort 1: 26 mothers with no diagnosis of preeclampsia during pregnancy (13 male, 13 female neonate) Omental Biopsy and placental collection will be performed
88879247|NCT02996916|Active Comparator|Olmesartan|Olmesartan 10-40mg daily
88879248|NCT02996916|Active Comparator|Amlodipine|Amlodipine 2.5-10mg daily
89403567|NCT03806283||Cohort 2 mild or severe Preeclampsia|Cohort 2: 26 mothers with diagnosis of mild or severe preeclampsia during pregnancy (13 male, 13 female neonate) Omental Biopsy and placental collection will be performed
89403568|NCT03802877|Active Comparator|Resource bank|The web-based resource bank includes information and perspectives about GDM, nutrition, and physical activity. The information is presented through video capsules, on-line text, printable pdfs, and podcasts. It is presented by health care professionals and patients.
89403569|NCT03802877|Experimental|Resource bank and ePlatform|In addition to resource bank access, participants will receive a digital scale, physical activity monitor (pedometer), and ePlatform log-in information. They will track daily weights and step counts. They will receive prompts to access educational and motivational tools based on the data that they enter and whether or not they enter data. The investigators will use the ePlatform developed by StepsCount, a Canadian pedometer company with a well-developed ePlatform for pedometer data upload, tracking, and automated messaging. The company is permitting us further customization for study purposes. Data will be uploaded onto a secure cloud-based platform controlled by the pedometer and digital scale companies.
89403570|NCT03802877|Experimental|Resource bank and health coach|"In addition to resource bank access, the coach will contact the participant weekly (telephone, text, email) to discuss progress and challenges in terms of achieving physical activity goals, rate of GWG, and maintaining health eating patterns, as well as any concerns.Participants not randomized to a coaching strategy will be advised to consult with their treating healthcare team directly if they develop symptoms of concern.~The coach will encourage participants to track their weight gain and physical activity (e.g., walks, classes, activity lists, etc.) and to share this information. However, they will not have access to the study ePlatform and will not be provided with pedometers or digital scales."
89403571|NCT03802877|Experimental|Resource bank with ePlatform and coach|Participants will have resource bank access as well as ePlatform and coaching interventions.The health coach will have access to the data on the ePlatform. They will receive telephone calls from the research assistant/health coach if they are off target despite the platform tools and support. They will be encouraged to consult the resource bank and will brainstorm with the health coach to decide how to achieve their GWG and step count targets.
89403572|NCT03800914|Experimental|High Intensity Interval Training|Participants will undergo a twice-weekly supervised exercise training program for eight weeks. Each session will involve 36 minutes of interval aerobic exercise on a cycle ergometer alternating every 30 seconds between 100% of peak work rate, achieved on the cardiopulmonary exercise test (CPET), plus upper and lower resistance training.
89403573|NCT03800914|Active Comparator|Traditional pulmonary rehabilitation|Participants will undergo a twice-weekly supervised exercise training program for eight weeks. Each session will involve 30 minutes of continuous aerobic exercise on a cycle ergometer at 60% of the peak work rate achieved on the CPET, plus upper and lower resistance training.
89403574|NCT03758651||Williams syndrome - Onsite participation|Individuals with Williams syndrome who will participate in the study at Massachusetts General Hospital (MGH)
88879249|NCT02997150|Experimental|IL-2 low dose|
88879250|NCT02996838|Experimental|TQ-B3234|TQ-B3234 QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
88921958|NCT06017908|Experimental|PPPD patients|Virtual Reality will be used to execute the RDT and OKAN in PPPD patients.
89403575|NCT03758651||Williams syndrome - Convention participation|Individuals with Williams syndrome (WS) who will have a more limited evaluation at a convention focusing on WS, such as the WS Association convention.
89403576|NCT03758651||Williams syndrome - Remote participation|Individuals with Williams syndrome (WS) who will participate in the study remotely by filling out a questionnaire and providing information by mail.
88879251|NCT02996604|Experimental|Low-He point(ST36)|Zusanli (ST36, the Low-He point of stomach) is the most important point for gastrointestinal disorder, including functional dyspepsia. Everyone in the group will be punctured at unilateral Zusanli.
88879252|NCT02996604|Experimental|Mu point(CV12)|Zhongwan (CV12, the Mu point of stomach) is also good at regulating gastric function. Everyone in the group will be punctured at Zhongwan.
88921959|NCT06017908|Experimental|Healthy patients|Virtual Reality will be used to execute the RDT and OKAN in healthy PPPD patients.
89403577|NCT03758651||Healthy Controls|Healthy individuals without Williams syndrome who will participate in the study at the Massachusetts General Hospital
89403578|NCT03757091|Active Comparator|Arm A (flexible intubation scope)|Patients undergo flexible scope intubation up to 2 attempts following induction of general anesthesia and adequate manual ventilation. In case of failed 2 attempts, patients undergo a third attempt utilizing another technique or device.
89530973|NCT03231865||Preoperative patients|Patients present themselves before an operation to the Anesthesiologist. They are screened for study eligibility.
89403579|NCT03757091|Experimental|Arm B (flexible intubation scope,video laryngoscope)|Patients undergo flexible scope intubation and video laryngoscopy up to 2 attempts following induction of general anesthesia and adequate manual ventilation. In case of failed 2 attempts, patients undergo a third attempt utilizing another technique or device.
89403580|NCT03733197|Experimental|Culture specific|"The culture-specific arm may entail FIT kits plus barbers as motivational interviewers."
89403581|NCT03733197|Experimental|Control|Distribution of CRC screening brochures & FIT (Fecal Immunochemical Test) kits by barbers
89403582|NCT03724136|Active Comparator|Arm 1|Intravenous Bone Marrow Stem Cell (BMSC) Fraction
89403583|NCT03724136|Active Comparator|Arm 2|Intravenous Bone Marrow Stem Cell (BMSC) Fraction combined with Near Infrared Light exposure .
89403584|NCT03724136|Active Comparator|Arm 3|Intravenous Bone Marrow Stem Cell (BMSC) Fraction combined with Intranasal topical Bone Marrow Stem Cell (BMSC) Fraction.
89403585|NCT03714204|Experimental|Transcendental Meditation Group|Participants assigned to this group each received the intervention of 5 initial class instructions in the Transcendental Meditation technique, followed by 6 additional classes over the 4-month study period. Group participants were expected to practice the technique for 20 minutes twice per day for 4-months.
89403586|NCT03714204|No Intervention|Control Group|Participants assigned to this group served as wait-list controls
89004281|NCT05296512|Experimental|PEMBROLIZUMAB and LENVATINIB|"The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits.~The names of the study drugs involved in this study are:~Lenvatinib~Pembrolizumab~Treatment will continue until progression of disease or unacceptable toxicity. Participants will be followed for up to 36 months after discontinuation of study treatment."
89004282|NCT05290857|Experimental|High thrombotic risk|For patients at high thrombotic risk, DOACs will be resumed within 7 days of clinical hemostasis after GI bleeding.
89004283|NCT05290857|Experimental|Moderate thrombotic risk|For patients at moderate thrombotic risk, DOACs will be resumed between 7 and 14 days of clinical hemostasis after GI bleeding.
89004284|NCT05244525|Experimental|Treatment|
89004285|NCT05244525|Active Comparator|Control Group|
89004286|NCT05220358|Experimental|FTR+suppressive regimen|addition of fostemsavir 600 mg PO BID to the stable suppressive HIV regimen in immunologic non responders
89403587|NCT03702920|Experimental|SMT+ PE-A 5%|PE-A 5% will be performed using 5% albumin (Albutein 5%) as the main replacement fluid administered intravenously.
89403588|NCT03702920|Active Comparator|Standard Medical Treatment (SMT)|Standard medical treatment (SMT) will be administered according to institution standards.
89403589|NCT03674346|Experimental|Hypnoanalgesia group|It is performed by a radiologist technologist who has been trained in Ericksonian hypnoanalgesia in the Hospices Civils de Lyon and has been practicing it regularly for 1 year.
89403590|NCT03674346|Other|MEOPA Group|The pain management will be done exclusively by a mask delivering the equimolecular mixture of oxygen and nitrous oxide (MEOPA)
89403591|NCT03672643|Other|single arm|Crizotinib
89403592|NCT03658967|Active Comparator|Lymfactin® (1x10E11 vp)|Lymfactin® will be administered as a single dose via perinodal injection in a volume of 2 mL.
89403593|NCT03658967|Placebo Comparator|Placebo (0.9% physiological saline)|Placebo will be administered as a single dose via perinodal injection in a volume of 2 mL.
89403594|NCT03641924||PTSD|Veterans diagnosed with DSM-V PTSD
89403595|NCT03630705|Experimental|Group 1: MenACYW Conjugate Vaccine (Mexico)|Participants aged 2 months (at the time of enrollment) received Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus toxoid (MenACYW) Conjugate vaccine at the age of Months 2, 6, and 12 along with Prevnar 13®, Hexacima®, vaccines at the age of Months 2, 4, 6 and 12; RotaTeq® vaccine at the age of Months 2, 4 and 6 and measles, mumps, rubella (MMR®II) vaccine at the age of Month 12.
89403596|NCT03630705|Active Comparator|Group 2: Menveo® (Mexico)|Participants aged 2 months (at the time of enrollment) received Menveo® vaccine at the age of Months 2, 4, 6, and 12 along with Prevnar 13®, Hexacima® vaccines at the age of Months 2, 4, 6 and 12; RotaTeq® vaccine at the age of Months 2, 4 and 6, and MMR®II vaccine at the age of Month 12.
89530974|NCT02496143|Experimental|Cohort 1|500 mg EC-18 dose or placebo
88813447|NCT01727570|No Intervention|Nutrition Counselling|Patients will be asked to fill out a three day record of all food and drink consumed. Patients will be given an appointment with the nutritionist approximately 4 weeks before surgery to go over their regular diet and advice will be given on how to improve the nutritional quality of their diet
88813448|NCT01727570|Active Comparator|Nutrition Supplementation|Patients will be asked to fill out a three day record of all food and drink consumed. An appointment with the nutritionist will be given approximately 4 weeks before surgery to go over their regular diet and advice will be given on how to improve the nutritional quality of the diet. Patients will also be given a supply of nutritional supplements to take orally (by mouth) every day. These supplements include a whey protein isolate (Immunocal®, Immunotec Inc), omega-3 fatty acids from fish oil, and vitamins/minerals.
88813449|NCT03001895|Experimental|18F-DCFPyL PET/CT|18F-DCFPyL PET/CT Scan
88813450|NCT01727648|Experimental|RT in sequential combination with dCIT|The participants will received 2 weeks of RT therapy and followed by 2 weeks of distributed CIT therapy. The treatment principles of RT and distributed CIT are the same with those described in the monotherapy of RT or dCIT, respectively.
88813451|NCT01727648|Experimental|Distributed Constraint-Induced Therapy|The dCIT group will focus on restriction on movement of the unaffected hand by placement of the hand in a mitt for 6 hours/day and intensive training of the affected UL in functional tasks for 1.5 hours/weekday over the 4 weeks. Participants in this group will focus on the intensive training of the affected arm in functional activities with behavioral shaping.
88814803|NCT03035006|Experimental|Lipotecan based chemoradiotherapy|Patients will receive Lipotecan based CCRT. Lipotecan will be given as a 30-minute (±3 minutes) iv infusion qw for 6 weeks at the predefined dose level for each cohort. A total of 6 doses of Lipotecan will be administered to each patient in conjunction with RT at 3.5 Gy per fraction for 16 fractions. During CCRT period, Lipotecan should be given within 2 hours prior to the start of RT, and the Lipotecan and RT should be delivered on the same day, unless any conditions fulfils with the dose interruption standards. Radiotherapy treatment, at the allocated dose level, is only permitted if the normal tissue dose constrain criteria are maintained
89403597|NCT03630705|Experimental|Group 3: MenACYW Conjugate Vaccine (Russian Federation)|Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 3, 6, and 12 along with Prevnar 13® vaccine at the age of Months 2, and 4.5; Pentaxim® vaccine at the age of Months 3, 4.5, and 6; ENGERIX-B® vaccine at the age of Month 6 and MMR vaccine at the age of Month 12.
89403598|NCT03630705|Other|Group 4: Routine Pediatric Vaccines (Russian Federation)|Participants aged 2 months (at the time of enrollment) received Prevnar 13® vaccine at the age of Months 2, and 4.5; Pentaxim® vaccine at the age of Months 3, 4.5, and 6; ENGERIX-B® vaccine at the age of Month 6 and MMR vaccine at the age of Month 12.
89403599|NCT03606746|Experimental|Investigational Arm|A low-dose Total Lymphoid Irradiation (TLI) and anti-thymocyte globulin (ATG) combined with a single IV infusion of MDR-103 and standard anti-rejection medications in past recipients of HLA Zero-mismatch living donor kidney transplants.
89530975|NCT02496143|Experimental|Cohort 2|1000 mg EC-18 dose orplacebo
88879253|NCT02996604|Active Comparator|He-Mu-point combination(ST36 and CV12)|In traditional Chinese acupuncture theory，synergistic effect can be produced by acupoints combination and the He-Mu-point combination is a classical acupoints combination formula for gastrointestinal diseases. Everyone in the group will be punctured at unilateral Zusanli and Zhongwan.
88879254|NCT02996526||Intact Vocal Cord Mobility|Patients with normal laryngeal function post thoracic surgery
88879255|NCT02996526||Vocal Cord Dysfunction|Patients with abnormal vocal cord movement of 1 or both vocal cords post thoracic surgery
88879256|NCT02996370|Active Comparator|Test group- ı shape incision|Second stage surgery was made I shape incision technique .
88879257|NCT02996370|Active Comparator|Control group- midcrestal incision|In the control group second stage surgery was made using the conventional method, midcrestal technique.
88879258|NCT02996214|Experimental|LP group|Liposome paclitaxel(Lipusu®) plus cisplatin. Paclitaxel liposome Sterile injection powder 175 mg/m^2, given on day 1 of a 21-day cycle, for 4-6 cycles. Cisplatin 75 mg/m^2, given on day 1 of a 21-day cycle, for 4-6 cycles.
88879259|NCT02996214|Active Comparator|GP group|Gemcitabine (Gemzar®) plus cisplatin. Gemcitabine hydrochloride for injection 1000 mg/m^2, given on days 1 and 8 of a 21-day cycle, for 4-6 cycles. Cisplatin 75 mg/m^2, given on day 1 of a 21-day cycle, for 4-6 cycles.
88879260|NCT02996058|Active Comparator|DEX I 0.35µg/kg /h|the infants will receive a maintenance dose of 0.35µg/kg /h of Dexmedetomidne without a loading dose and guided by the assessed sedation scale
88879261|NCT02996058|Active Comparator|DEX II 0.5µg/kg /h|the infants will receive a maintenance dose of 0.5µg/kg /h of Dexmedetomidne without a loading dose and guided by the assessed sedation scale.
88879262|NCT02996136|Experimental|Nasal Swab|Nasal Swab
88879263|NCT02996136|Experimental|Nasopharyngeal Swab|Nasopharyngeal Swab
88879264|NCT02995512|Experimental|Myocardial Infarction (MI) Patients|
88921961|NCT06015841|Placebo Comparator|Placebo|Early PD subjects receive placebo at pre-defined time points over 74 weeks.
88921962|NCT06015841|Experimental|ACI-7104.056 at Dose A|Early PD subjects receive dose A of ACI-7104.056 at pre-defined time points over 74 weeks.
88921963|NCT06015841|Experimental|ACI-7104.056 at Dose B (optional)|Early PD subjects receive dose B of ACI-7104.056 at pre-defined time points over 74 weeks. This arm is optional.
89403600|NCT03605654|Experimental|Investigational Arm|A low-dose Total Lymphoid Irradiation and anti- thymocyte globulin combined with a single infusion of MDR-102 post-kidney transplant and standard anti-rejection medications in recipients of 1, 2, or 3 out of 6 human leukocyte antigen (HLA)-mismatched, living donor kidney transplants
89403601|NCT03605654|Active Comparator|Active Control Arm|Standard anti-rejection medications that would be given to kidney transplant recipients who are outside the study
89004287|NCT05206955|Experimental|Tadalafil Group|Study participants will receive 10 mg of Tadalafil daily for 1 week, then 20 mg daily for 1 week, and finally 40 mg daily for 50 weeks for a total therapy time of 52 weeks. Tadalafil will be taken orally in capsule form once daily.
89004288|NCT05206955|Placebo Comparator|Placebo Group|Study participants will receive a placebo capsule that looks identical to the Tadalafil capsule. The placebo will be taken orally once daily for 52 weeks.
89004289|NCT05197829|Experimental|Continuous Glucose Monitoring|
89004290|NCT05197829|Active Comparator|Care Coordination|
89004291|NCT05186311|Experimental|Test product|BD MiniDraw™ Capillary Blood Collection System
89403602|NCT03605654|Experimental|Non-Randomized Exploratory Arm|A low-dose Total Lymphoid Irradiation and anti- thymocyte globulin combined with a single infusion of MDR-102 post-kidney transplant and standard anti-rejection medications in recipients of 4, 5, or 6 out of 6 human leukocyte antigen (HLA)-mismatched, living donor kidney transplants
89403603|NCT03603730|Experimental|taVNS|Active or inactive taVNS
89530976|NCT02496143|Experimental|Cohort 3|2000 mg EC-18 dose or placebo
89530977|NCT02496143|Experimental|Cohort 4|4000 mg EC-18 dose or placebo
89530978|NCT02499419||Healthy|Individuals without any known heart/ respiratory/ metabolic problems that might limit their exercise capacity
89530979|NCT02499419||Mild MVP|0 or 1 of the following secondary risk factors: Mild MR Flail leaflet Left atrial diameter > 40 mm Atrial fibrillation Age ≥ 50
89530980|NCT02499419||Moderate MVP|2 or more of the above secondary risk factors.
89403604|NCT03591510|Experimental|Chemotherapy followed by Midostaurin|"In Part 1, midostaurin with standard induction (Block 1 induction according to local practice, Block 2 induction containing fludarabine, cytarabine, daunorubicin/idarubicin) and consolidation (Block 3: cytarabine + mitoxantrone, Block 4: cytarabine + etoposide, Block 5: cytarabine) followed by single agent midostaurin post-consolidation therapy.~In Part 2, midostaurin with standard induction (Block 1 induction according to local practice, Block 2 induction containing cytarabine + mitoxantrone) and consolidation (Block 3: cytarabine + etoposide, Block 4: cytarabine + mitoxantrone, Block 5: cytarabine) followed by single agent midostaurin post-consolidation therapy."
89403605|NCT03577418|Experimental|Clinician-facilitated educational intervention|
89403606|NCT03577418|Active Comparator|Enhanced usual care|
88879265|NCT02995590|Experimental|MRI of lung motion during breathing|"A medical history will be obtained defining any present and past history of respiratory illnesses, medications, and hospitalizations and the ability to have MR imaging.~A urine pregnancy test will be done for women of childbearing potential, who report the possibility that they might be pregnant.~Before and after MR imaging, a physical exam, spirometry, and a baseline %PO2 will be performed.~During the MR imaging procedure, the subject's heart rate and blood oxygen saturation will be monitored using an MR compatible pulse oximeter.~Once positioned in the MR scanner, conventional proton images of the thorax will be obtained to define the lung boundaries for subsequent image alignment. -Free breathing conventional MR imaging will be performed.~Hyperpolarized helium 3 imaging will be performed at breath hold."
88879266|NCT02995200|Experimental|Group Post-Stroke|2 sessions of in-home accelerometer based feedback about paretic arm use
88879267|NCT02995200|No Intervention|Healthy Control Group|
89403607|NCT03545386|Experimental|FMT|
89403608|NCT03545386|Placebo Comparator|Placebo|
89530981|NCT02499419||Severe MVP|1 or more of the following primary risk factors: EF < 50% MR ≥ moderate
88879268|NCT02995044|Experimental|SPF evaluation|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
88879269|NCT02995122|Experimental|SPF evaluation|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
88879270|NCT02994888||all patients|All patients will be treated with cetuximab 500mg/m2 every 2 weeks until the time of progression
88879271|NCT02994810|Experimental|Intervention group|Guidelines and review of the breastfeeding techniques.
88879272|NCT02994810|No Intervention|Control group|The control group will receive home visits only when the baby is 6 months of life, they will be re-evaluated by the researchers as the practice of exclusive breastfeeding and the technical and nursing management, and will be asked about the main difficulties encountered in maintaining breastfeeding.
88879273|NCT02994342|Active Comparator|Vaginal gel, Medical Device Class 2A|Every subject has been treated for 56 consecutive days, twice daily with a vaginal application
88879274|NCT02994342|No Intervention|Lifestyle counseling|Every subject has been observed for 56 consecutive days
88879275|NCT02994186||Surgical Weight Loss|Patients in this group are those that will be undergoing bariatric surgery (either Roux-en-Y gastric bypass or vertical sleeve gastrectomy).
88879276|NCT02994186||Medical Weight Loss|Patients in this group are those who are being enrolled in a supervised medical weight loss program.
88879277|NCT02993952|Active Comparator|Active stimulation|A constant current (anodic) of 2mA will be applied for 20 minutes on the Primary motor cortex.
88879278|NCT02993952|Sham Comparator|Sham stimulation|A constant current (sham) of 2mA will be applied, but the stimulator will be turned off after 30 seconds on the Primary motor cortex.
88879279|NCT02993874|Experimental|Creatine|Creatine monohydrate (Cr) Loading - 4 doses of 5g / day for 7 days Maintenance - 1 dose of 3g / day for 49 days Clinical treatment (30-45 minutes of walking, 3 times per week)
89199047|NCT02529696||Medical device, accelerometer|A wrist and chest accelerometer will be worn for the duration of stay in the ICU. Data will be generated from patient movement and recorded. Neither the generated data or the worn devices will influence care team's decisions during the patients' stay.
88879280|NCT02993874|Placebo Comparator|Placebo|Dextrose Loading - 4 doses of 5g / day for 7 days Maintenance - 1 dose of 3g / day for 49 days Clinical treatment (30-45 minutes of walking, 3 times per week)
88879281|NCT02993718|Experimental|Dexmedetomidine|Intraoperative sedation is performed by using dexmedetomidine.
88879282|NCT02993718|Experimental|Propofol|Intraoperative sedation is performed by using propofol
88879283|NCT02993640|Experimental|vasopressin + nitro|vasopressin + nitroglycerin in simultaneous infusion
88879284|NCT02993562||Hypothyroid patients|Hypothyroid patients treated with Levothyroxine as part of normal treatment.
88879285|NCT02993562||Healthy volunteers|Matched on age and BMI. 18 Persons.
88879286|NCT02993484|Experimental|non-diabetic Sham control|Heart tissue obtained from non-diabetic patients undergoing surgery will not receive drugs or ischemia
88879287|NCT02993484|Experimental|non-diabetic Ischemia reperfusion|Heart tissue from non-diabetic patients undergoing surgery will not receive drugs but will receive ischemia
88879288|NCT02993484|Experimental|non-diabetic Ischemic preconditioning|Heart tissue from non-diabetic patients undergoing surgery will not receive drugs but will receive short periods of ischemia prior to index ischemia
88879289|NCT02993484|Experimental|non-diabetic Dimethyl malonate|Heart tissue from non-diabetic patients undergoing surgery will receive a drug (Dimethyl Malonate) prior to index ischemia
89403609|NCT03543969|Experimental|Arm A: BRAF-MEK Inhibitor Therapy|Participants will receive 450 mg Encorafenib daily, along with 45 mg Binimetinib twice daily and 240 mg Nivolumab IV every 2 weeks.
89403610|NCT03543969|Active Comparator|Arm B|Participants will receive 240 mg Nivolumab IV every 2 weeks
89403611|NCT03539458|Experimental|Device Arm|All subjects will undergo procedure with the Tendyne Mitral Valve System.
89403612|NCT03534180|Experimental|Treatment (venetoclax, romidepsin)|Patients receive venetoclax PO QD on days 1-28 and romidepsin IV on days 1, 8, and 15. Treatment repeats every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity.
89190090|NCT03832322||Water exchange colonoscopy|During the insertion phase of the first-pass colonoscopy, water exchange (WE) method was used. WE entailed the infusion of water to open the lumen and sequentially suction of water. When the cecum was reached and after most of the water was suctioned to collapse the cecal lumen, CO2 was opened during the withdrawal phase of the first-pass colonoscopy. After the first complete withdrawal of the colonoscope, a second colonoscopic examination aided by CO2 insufflation during insertion and withdrawal was performed by the same endoscopist. The colonoscope was reinserted into the cecum as quickly as possible, and the entire colon was re-examined. Polyp resection was carried out during insertion and withdrawal of the first- and second-pass examinations.
89403613|NCT03494166|No Intervention|Low Need Benchmark or Follow-up|In the low need benchmark or follow-up group, survivors completed detailed baseline and 13-week assessments (about 30-40 minutes) over the telephone. A brief assessment (about 5 minutes) at week 4 over the telephone was used to assess symptoms.
89403614|NCT03494166|Experimental|High Need A: Start with SMSH alone for 4 weeks|Participants were mailed the printed Symptom Management and Survivorship Handbook (SMH). The Group A participant was called every week for 4 weeks to ask about symptoms and suggest strategies from the SMH to relieve symptoms. After 4 weeks, participants were re-randomized to continue in SMH for 8 more weeks or to add Telephone Interpersonal Counseling (TIPC) Intervention for the subsequent 8 weeks. If the TIPC was added, the counselor called the participant once per week for about 35-40 minutes to assess and discuss interpersonal relationships, communication, social support, managing symptoms and survivorship. At week 13, the participant completed the second assessment.
89530982|NCT02499107|Experimental|Rice treatment|Dietary Intervention: Ad libitum intake of white rice
89530983|NCT02499107|Experimental|Pasta treatment|Dietary Intervention: Ad libitum intake of pasta
88879290|NCT02993484|Experimental|Diabetic Sham control|Heart tissue obtained from diabetic patients undergoing surgery will not receive drugs or ischemia
89403615|NCT03494166|Experimental|High Need B: Start with SMSH+TIPC|Participants were called every week for the first 8 weeks using a combination of TIP-C and SMH. The counselor called to assess and discuss interpersonal relationships, communication, social support, managing symptoms and survivorship. At the end of 8 weeks, the final 4 calls followed the SMSH alone protocol. At week 13, the second assessment was conducted.
89403616|NCT03477591|Experimental|Evidence + PDA|Evidence-based information on PSA testing such as blog posts, plain language evidence summaries and web resource ratings (quality-appraised online resources), plus a blog post on PDAs and the relevant decision aid from the Portal database
89403617|NCT03477591|Experimental|Evidence only|The same evidence-based information as group 1 (Evidence + PDA), but without the PDA to quantify the effect of accessing evidence through the Portal alone
88879291|NCT02993484|Experimental|Diabetic Ischemia reperfusion|Heart tissue from diabetic patients undergoing surgery will not receive drugs but will receive ischemia
88879292|NCT02993484|Experimental|Diabetic Ischemic preconditioning|Heart tissue from diabetic patients undergoing surgery will not receive drugs but will receive short periods of ischemia prior to index ischemia
89403618|NCT03477591|Sham Comparator|Attention control|Information on how to distinguish high from low-quality health information, not specific to cancer screening or PDAs
89530984|NCT02499107|Experimental|boiled and mashed potato treatment|Dietary Intervention: Ad libitum intake of boiled and mashed potato
88879293|NCT02993484|Experimental|Diabetic Dimethyl malonate|Heart tissue from diabetic patients undergoing surgery will receive a drug (Dimethyl Malonate) prior to index ischemia
88879294|NCT02993328|Experimental|SAN021 Serum|SAN021 is a serum containing 10% East Indian Sandalwood Oil. It is packaged in an amber glass bottle with a dropper top. The dose is 5 drops per 1% BSA involvement twice daily.
88879295|NCT02993328|Placebo Comparator|SAN021 Placebo|SAN021 Placebo is a serum that does not contain East Indian Sandalwood Oil however, does contain a synthetic sandalwood fragrance. It is packaged in an amber glass bottle with a dropper top. The dose is 5 drops per 1% BSA involvement twice daily.
88879296|NCT02993094|Experimental|Ixazomib/Carboplatin|"Accelerated dose-escalation phase with a single-patient cohort per dose level until defined DLT is observed during cycle 1, or until dose level 4 is reached. At this dose level the cohort is expanded to three patients and dose escalation reverts to a conventional 3+3 escalation design.~Intervention (experimental): Ixazomib; po; 3mg escalated to 4mg; day 1, 8, 15 Intervention (backbone): AUC 1.5 escalated to AUC 2.5; day 1, 8, 15"
89530985|NCT02499107|Experimental|Baked french fries treatment|Dietary Intervention: Ad libitum intake of baked french fries
89403619|NCT03477539|Experimental|Treatment (daratumumab, ASCT, lenalidomide)|"CONSOLIDATION I: Patients receive daratumumab IV on days 1, 8, 15, and 22 of cycles 1-2, and on days 1 and 15 of cycles 3-4. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION II: Beginning 8 weeks after completion of daratumumab cycle 2 or 4, patients undergo ASCT.~MAINTENANCE: Within 14 days after completion of day 100 visit post-SCT, patients receive daratumumab IV on day 1 and lenalidomide PO daily on days 1-21. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients who are still maintaining response continue to receive daratumumab IV every 3 months in the absence of disease progression or unacceptable toxicity."
89403620|NCT03476837|Experimental|Behavioral Treatment|Following baseline, the CHWs will deliver three doses of the intervention to the treatment (intervention) group over a 6-month period with follow-up at 12 months for all WCGs. At 1, 3, and 6 months, WCGs will receive motivational interviewing, educational materials and biofeedback based on the child's saliva sample and WCG's carbon monoxide.
89403621|NCT03476837|Active Comparator|Control|WCGs will receive educational materials in the mail at 1, 3, and 6 months.
89403622|NCT03476642|Active Comparator|Ropivacaine with Epinephrine|Group RE will have 20mL of 0.5% Ropivacaine with epinephrine injected at the left or right T5 transverse process.
89403623|NCT03476642|Active Comparator|Ropivacaine without Epinephrine|Group R will have 20mL of 0.5% Ropivacaine without epinephrine injected at the left or right T5 transverse process.
89403624|NCT03474913||Standard MRI first|Patients will have a standard of care MRI, then consent to study participation and have an upright MRI.
89403625|NCT03474913||MRIs in random order|Patients will consent to participate in the study, then do two MRIs in random order.
89403626|NCT03446521||Test group|Patients undergoing liver transplantation, no intervention (study-specific) is planed
88879297|NCT02993016|Experimental|patient-specific instruments group|procedure: PSI (patient-specific instruments) will be used as the cutting guide in total knee arthroplasty.
88879298|NCT02993016|Active Comparator|conventional instruments group|procedure: Conventional instruments will be used as the cutting guide in total knee arthroplasty.
88921964|NCT06015841|Experimental|ACI-7104.056 at Dose C (optional)|Early PD subjects receive dose C of ACI-7104.056 at pre-defined time points over 74 weeks. This arm is optional.
89199048|NCT00885885|Experimental|1|Panitumumab+FOLFOX 4
89403627|NCT03446521||Control Group|Respective organ donors of the included liver recipients, no intervention (study-specific) is planed
89403628|NCT03432286|Experimental|Galcanezumab|"Galcanezumab administered by SQ injection.~Participants may be eligible for optional open-label extension at the end of the double-blind period."
89403629|NCT03432286|Placebo Comparator|Placebo|"Placebo administered by SQ injection.~Participants may be eligible for optional open-label extension at the end of the double-blind period."
89403630|NCT03378167|Experimental|MICROBIOTA|Patients randomized to the INTERVENTION arm will receive a baseline fecal microbiota transplant (FMT) colonoscopic infusion at Week 0, followed by twice-weekly oral microbiota capsule (OMC) therapy for 6 weeks (including Week 0). (n = 30)
89199049|NCT00885885|Experimental|2|Panitumumab+FOLFIRI
89403631|NCT03378167|Placebo Comparator|PLACEBO|Patients randomized to the CONTROL arm will receive a baseline normal saline (NS) colonoscopic infusion at Week 0, followed by twice-weekly dextrose-containing oral placebo capsule (OPC) therapy for 6 weeks (including Week 0). (n = 15)
89403632|NCT03377816|Experimental|Art Therapy|The AT intervention is an 8-week group intervention comprised of 8 1.5 hour weekly sessions conducted by an experienced Art Therapist who received special training in conducting the treatment protocol as designed.
89403633|NCT03377816|Sham Comparator|Mandala group|The comparison group will color prefabricated shapes. The same art materials as in the intervention group will be on the table as will the same instrumental music.
89403634|NCT03367156|Experimental|Group I (dexamethasone)|Patients receive dexamethasone PO BID on days 1-28 in the absence of disease progression or unacceptable toxicity.
88879299|NCT02992860|Experimental|Treatment Arm|JNJ-56022473 will be given intravenously to all subjects at a dose of 9 mg/kg once every 14 days for an initial treatment period of 3 months (6 infusions). Responders will then receive up to 20 additional infusions whereas for non-responders the initial treatment will be followed by a up to 9 months observation period without further JNJ-56022473 treatment. Thus, the individual study duration for a subject will be approx. 1 year. A follow up visit will be performed after 3 months after last study drug administration for all patients to track pregnancy status according to IB.
88879300|NCT02992938|Experimental|Acetazolamide|250 mg VO of acetazolamide will be administered the day of the surgery 2 hours before anesthesia induction
88879301|NCT02992938|Placebo Comparator|Placebo|An oral tablet without active principle acetazolamide but with the same physical characteristics will be administered the day of the surgery 2 hours before anesthesia induction
89403635|NCT03367156|Active Comparator|Group II (placebo, dexamethasone)|Patients receive placebo PO BID on days 1-14 and dexamethasone PO BID on days 15-28 in the absence of disease progression or unacceptable toxicity.
88879302|NCT02992704|Experimental|PEG 24 weeks|peginterferon alpha 2a 180mcg for 24 weeks
88879303|NCT02992704|Experimental|PEG 48 weeks|peginterferon alpha 2a 180mcg 48 weeks
88879304|NCT02992704|No Intervention|Control|No treatment for 72 weeks
88879305|NCT02992470|Experimental|Hydrolyzed oyster extract|A 250 mg, film-coated oblong (rectangle) shaped tablet of oyster extract
88879306|NCT02992470|Placebo Comparator|Placebo|A 250 mg, film-coated oblong (rectangle) shaped tablet of maltodextrin
88879307|NCT02992548|Experimental|pravastatin group|Use of pravastatin 20mg to 40mg
88879308|NCT02992626|Experimental|starting with dog|Participants in this arm complete the first session in the presence of a dog. The second session is under control condition in the presence of a stuffed toy dog.
88879309|NCT02992626|Experimental|starting with control|Participants in this arm complete the first session under control condition in the presence of a stuffed toy dog while the second session the tests are completed in the presence of a dog.
88879310|NCT02992392|Experimental|Liposic|Liposic was applied to one eye of patients in this group
88879311|NCT02992392|Experimental|Tears Naturale Forte|Tears Naturale Forte was applied to one eye of patients in this group
89403636|NCT03363945|Active Comparator|MDR-101|A single dose will be administered via IV infusion post-kidney transplant.
89403637|NCT03363945|No Intervention|Control Arm|Subjects randomized to this arm will receive the standard anti-rejection medications that would be given to kidney transplant recipients who are outside the study.
89403638|NCT03358979||Severe eye dryness|
89403639|NCT03358979||absence of eye dryness|
89403640|NCT03346772|Experimental|Influenza vaccination cohort|Adults will receive one intramuscular dose of seasonal quadrivalent inactivated influenza vaccine, as indicated for standard of care.
89190091|NCT03832322||CO2 insufflation colonoscopy|During the first-pass colonoscopy, the procedure was performed in the usual fashion, with minimal CO2 insufflation to aid insertion. Cleaning of colon was predominantly performed during withdrawal. After the first complete withdrawal of the colonoscope, a second colonoscopic examination aided by CO2 insufflation during insertion and withdrawal was performed by the same endoscopist. The colonoscope was reinserted into the cecum as quickly as possible, and the entire colon was re-examined. Polyp resection was carried out during insertion and withdrawal of the first- and second-pass examinations.
89190092|NCT03828968|Other|Bladder scan|Bladder scan performed on resident in homes for aged
89190093|NCT03802656|Experimental|Anterior Vertebral Body Tethering|Subjects who will be undergoing the anterior vertebral body tethering surgery.
88879312|NCT02992314|Experimental|Metaqil™ Oral Rinse|"In this arm the test article, Metaqil ™ oral rinse, a proprietary formulation of agents including Monk fruit extract, which can minimize the metallic taste in the mouth caused by the patient's medications.~Subjects rinse twice a day with 10 mL of the oral rinse for 30 seconds for 30 days.~They will note, in the daily oral hygiene diary, the date and time of brushing and rinsing."
88879313|NCT02992314|Placebo Comparator|Placebo Oral Rinse|This arm will use a placebo with out the active ingredients same way the experimental arm do.
88879314|NCT02992158|Experimental|behavioral activation|The core principles of the BA model are: (1) the key to changing how people feel is helping them change what they do, (2) changes in life can lead to depression, and short-term coping strategies may keep people stuck over time, (3) the clues to figuring out what will be antidepressant for a particular client lie in what precedes and follows the client's important behaviors, (4) structure and scheduling of activities should follow a plan, not a mood, (5) change will be easier when starting small, (6) activities that are naturally reinforcing should be emphasized, (7) the therapist should act as a coach, (8) a problem-solving empirical approach should be emphasized with recognition that all results are useful, (9) patients should be encourages to not just talk, do! (10) possible and actual barriers to activation should be examined. Patients can also receive medications in this arm.
88879315|NCT02992158|Other|treatment-as-usual|Patients will receive psychotherapy (and potentially medications) as part of treatment-as-usual provided in the CMHC setting.
88879316|NCT02991768|Experimental|Entocort EC|Subjects will take 6mg Entocort EC by mouth daily for 8 weeks.
88879317|NCT02991768|Placebo Comparator|Placebo|Subjects will take 6mg matching placebo pill daily for 8 weeks.
88879318|NCT02991612|Experimental|Rifaximin Treatment Group|Rifaximin 400mg bid for 2 months,
88879319|NCT02991612|No Intervention|Control Group|Receive routine endoscopic treatment without having rifaximin for 2 months
88879320|NCT02991534|Other|Arm 1|"The investigators will use a nonrandomized stepped wedge design to evaluate the implementation in four VA Women's Practice Based Research Network (PBRN) sites. In this nonrandomized stepped wedge design, the intervention is turned on when a primary care provider (PCP) uses a CV screening template which maps to the patient CV self-screener. This design relies on sequential roll-out to participating sites over time, while using other sites as controls until they begin implementation. The investigators will use nonrandomized stepped wedges (rather than randomized) given their suitability for studying implementation. The design explicitly considers the timing of implementation spread and addresses the statistical issues introduced by lack of randomization in implementation starts and processes. The investigators will analytically compensate for the design by collecting patient-, provider-, and site-level data that may be associated with timing of the adoption of each intervention."
88879321|NCT02991378|Experimental|Intervention group|"Subjects in this group will receive the Children's emotional and stress coping program which train the children the emotional self-regulation skills and stress coping skill with a standardized protocol."
88879322|NCT02991378|No Intervention|Control group|"Subjects in this group will not receive the Children's emotional and stress coping program."
88879323|NCT02991222|Experimental|SPARC001 type I|Treatment type I
88879324|NCT02991222|Experimental|SPARC001 type II|Treatment type II
88879325|NCT02991222|Active Comparator|Reference001 type I|Treatment type I
88879326|NCT02991222|Active Comparator|Reference type II|Treatment type II
89190094|NCT03797482||Intra-operative tumour tissue biopsies|Intra-operative tumour tissue biopsies will be collected for all patients
89403641|NCT03302299|Experimental|Isoniazid & pyridoxine|Isoniazid 300 mg oral tablet: 300 mg daily by mouth for 6 months. Pyridoxine 25 mg oral tablet: 25mg daily by mouth for 6 months.
89403642|NCT03297125||Eligible Subjects|All enrolled subjects undergoing Optune therapy.
89403643|NCT03276962|Experimental|R012-20 Group|Subjects will receive full doses of RTS,S/AS01E at Month 0, Month 1, Month 2 and a full dose at Month 20.
88879327|NCT02990832|Experimental|Exciton|Treatment of diabetic foot ulcer with Exciton Exsalt wound dressing
88879328|NCT02990754|Experimental|Intervention Group|Individuals attending one or more fearless physical activity events
88879329|NCT02990676|Experimental|Computerised cognitive training group|Participants will be asked to complete the training programme provided using HAPPYneuron software for a minimum of 30 minutes 3 times a week for 12 weeks. The intervention will be completed in participant homes with the help of email or telephone reminders, as preferred.
88879330|NCT02990676|No Intervention|Control group|Asked to continue as normal
88879331|NCT02990442|Experimental|rTMS|treatment with repetitive transcranial magnetic stimulation for 30 days
88879332|NCT02990286|Experimental|Rituximab with Mycophenolate Mofetil|
89535573|NCT04992819|Experimental|Chronobiological Approach Nutrition Model|"Preterm infants in NICU are fed with breast milk and bottle. Although the date is written on expressed breast milk, it is usually not given by checking its suitability for the time of day. The milk of the intervention group patients will be matched circadian and given to the babies. Intervention group's breast milk is labeling by time of day before the each feeding. In the intervention group, a label containing the time of expressed breastmilk will be affixed. Circadian matched milk will be provided at each feeding.~intervention is;n the intervention group, a label containing the time of expressed breastmilk will be affixed. In the milk preparation room, breast milk will be stored in a separate refrigerator as 08:00-19:59 day milk and 20:00-07:59 night milk.~Demographic data, anthropometric measurements (weight, height, head circumference of all babies will be recorded in the Baby Monitoring Form created by the researcher."
89536675|NCT02474459|Active Comparator|Standard Clinical Care|Subjects in this treatment arm will receive DBS programming at regular intervals as part of routine clinical care. Outcomes will be measured using the Unified Parkinson's Disease Rating Scale (UPDRS), Parkinson's Disease Questionnaire (PDQ-39) and the Multi-Dimensional Caregiver Strain Index (MCSI).
88879333|NCT02990286|Placebo Comparator|Placebo of rituximab with Mycophenolate Mofetil|
88879334|NCT02990208|Experimental|VR exposure + diaphragmatic breathing|Virtual Reality Exposure Therapy + Diaphragmatic breathing
88879335|NCT02990208|Active Comparator|VR exposure|Virtual Reality Exposure Therapy
88879336|NCT02990052|Active Comparator|Volar plating|Volar fixed-angle plating for dislocated distal radius fracture after closed reduction.
88879337|NCT02990052|Active Comparator|Conservative treatment|Primary conservative treatment (closed reduction and casting) for dislocated distal radius fracture.
88879338|NCT02999958|No Intervention|Control|Sequential culture media without addition of antioxidants
88879339|NCT02999958|Active Comparator|Treatment|Sequential culture media with the addition of antioxidants
88879340|NCT02995746|Experimental|0.7mg dexamethasone intravitreal implant|Single intravitreal implantation of 0.7mg dexamethasone with a six month follow up period
89190095|NCT03781973|No Intervention|Pre-intervention|"Those whose last pediatric visit was in the year before the intervention (2018).~Medical record data abstracted from patient charts at the time of the final pediatric visit."
89199050|NCT04077762|Active Comparator|Radial access|Radial access for cardiac catheterization. Radial access will be performed using ultrasound guidance and a micropuncture needle or catheter-over-needle system, as per the local standard of care.
88879341|NCT02990364|Active Comparator|Control: EMLA Topical Product|"This represents the control group and it is the traditional analgesic used for circumcisions.~EMLA cream is a eutectic mixture of 2.5% lidocaine and 2.5% prilocaine, used as a topical anaesthetic to diminish pain from cutaneous procedures. Seventy minutes prior to circumcision, the newborn will be placed in the circumcision mold with the legs restrained, and attached to a monitor. 1 gram of EMLA cream will be applied by the nurse to the penis using a syringe and then wrapped with a dressing (Tegaderm). After sixty minutes the Tegaderm and drug will be removed, and the infant will be left to settle until the circumcision."
88879342|NCT02990364|Active Comparator|EMLA + Sucrose|"There is high-quality evidence for the beneficial effect of sucrose (24%) with non-nutritive sucking (pacifier dipped in sucrose) or 0.5 mL of sucrose orally in preterm and term infants. To assess this, 10 ml of sucrose (24%) will be given to the infant during the course of the circumcision.~In combination to the EMLA cream, the infant will be given sucrose during the circumcision to test the effects of sucrose and sucking on pain management."
88879343|NCT02990364|Active Comparator|EMLA + Sucrose + Ring Block|"Ring block will be done with 1% lidocaine without epinephrine injected in a band around the penis halfway along the shaft. Ten minutes prior to circumcision, the newborn will be placed in the circumcision mold with the legs restrained, and attached to a monitor. A total of 2 mg/kg of 1% lidocaine without epinephrine will be used to perform the ring block and will be injected in a band around the penis. The block will be done by the circumciser.~In combination with the ring block, EMLA + sucrose will be given during the circumcision."
88879344|NCT02990364|Active Comparator|EMLA + Sucrose + DPNB|"Dorsal penile nerve block (DPNB) will be done with 1% lidocaine without epinephrine injected at two sites at the base of the penis (2 and 10 o'clock). Ten minutes prior to circumcision, the newborn will be placed in the circumcision mold with legs restrained, and attached to a monitor. A total of 2 mg/kg of 1% lidocaine without epinephrine will be used to perform the block, and equal aliquots in milliliters will be injected at the two sites at the base of the penis. The block will be done by the circumciser.~In combination with the DPNB, EMLA + sucrose will be given during the circumcision."
88879345|NCT01270074|Experimental|azithromycin liquid preparation|azithromycin will be given at a dose of 10mg/kg given three times per week from three months of age to three years of age
88879346|NCT01270074|Active Comparator|inert liquid preparation|inert liquid preparation will be given three times per week from three months of age to three years of age
88879347|NCT01270230|Experimental|Comparison Group, Standard HIV-CT|The comparison group will receive standardized HIV counseling and testing (HIV-CT), with referrals to case management.
88879348|NCT01270230|Experimental|Intervention Group, Bruthas Counseling|Participants assigned to this arm receive four individual HIV prevention counseling sessions.
88879349|NCT01270308|Experimental|Lansoprazole DR Capsules 30 mg|Lansoprazole DR Capsules 30 mg of Dr.Reddy's Laboratories Limited
88879350|NCT01270308|Active Comparator|Prevacid 30 mg Capsules|Prevacid 30 mg Capsules of TAP Pharmaceuticals Inc. USA
89190096|NCT03781973|Other|Early Intervention|"Those whose last pediatric visit was in the year immediately after the start of the intervention (2019).~The intervention will begin on Jan 1, 2019 and includes the following :~Data Platform: Medical record data abstracted from patient charts at the time of the final pediatric visit. .~Quality performance feedback reports: We will generate centre-level performance reports. Centres will be able to compare their performance to that of all other centres and to achievable benchmarks.~Patient transition experience surveys at the final pediatric visit and 12 months later.~Diabetes teams may direct patients and families to online transition resources."
88879351|NCT01270386|Experimental|Apatinib|Apatinib 750 mg qd p.o. and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
88879352|NCT01270386|Placebo Comparator|Placebo|Placebo qd p.o., and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
88879353|NCT01270698|Experimental|IMMU-130|
89403644|NCT03276962|Experimental|R012-14-mD Group|Subjects will receive a full dose of RTS,S/AS01E at Month 0, Month 1, Month 2 and yearly full doses at Month 14, Month 26, Month 38.
89403645|NCT03276962|Experimental|Fx012-14-mFxD Group|Subjects will receive a full dose of RTS,S/AS01E at Month 0, Month 1 and RTS,S/AS01E 1/5th dose at Month 2, Month 14, Month 26, Month 38.
88879354|NCT01270854|Experimental|Plasmalyte|Administration of Plasmalyte A as the standard intravenous fluid during the first 24 hours after arrival to the hospital
88879355|NCT01270854|Active Comparator|Normal Saline|Administration of Normal Saline as the standard intravenous fluid during the first 24 hours after arrival to the hospital
88879356|NCT01270932|Experimental|Lenalidomide and Dexamethasone|"Lenalidomide:Daily for 21 days of a 28 day cycle~Dexamethasone:Days 1-4, 9-12, 17-20 for the first cycle and then weekly dexamethasone from cycles 2-4."
88879357|NCT01271088|Experimental|N-acetylcysteine|N-acetylcysteine: Experimental N-acetylcysteine 600 mg twice daily + vancomycine and/or amikacin
88879358|NCT01271088|No Intervention|Control|Vancomycine and/or amikacin alone
88879359|NCT01271166|Experimental|Glivec®, modified FOLFOX, Avastin®|
88879360|NCT01271556|Experimental|1, salmeterol, saline infusion|In 10 COPD patients and 10 healthy subjects, tiotropium and long-acting and short-acting beta-2 agonists were withdrawn at least 72 hours if assumed, 24 hours, and 12 hours, respectively, prior to each test day. Salmeterol 50 mcg on days A was administered between 8 AM and 10 AM. Patients and healthy subjects underwent a rapid 50-minute 750-ml 0.9% saline infusion 240 minutes after inhalatory treatment (salmeterol 50 mcg MDI), and mixed venous blood was withdrawn for measurements of hematocrit (Htc), Hb, and albumin concentration 10 minutes before and 10 minutes after the infusion. 240 and 290 minutes after inhalatory treatment, pulmonary function tests were performed.
88879361|NCT01271556|Placebo Comparator|2, placebo, saline infusion|In 10 COPD patients and 10 healthy subjects, tiotropium and long-acting and short-acting beta-2 agonists were withdrawn at least 72 hours if assumed, 24 hours, and 12 hours, respectively, prior to test day. Placebo was administered between 8 AM and 10 AM. Patients and healthy subjects underwent a rapid 50-minute 750-ml 0.9% saline infusion 240 minutes after inhalatory treatment (placeboI), and mixed venous blood was withdrawn for measurements of hematocrit (Htc), Hb, and albumin concentration 10 minutes before and 10 minutes after the infusion. 240 and 290 minutes after inhalatory treatment, pulmonary function tests were performed.
88879362|NCT01271556|Active Comparator|3, salmeterol, no saline infusion|In 10 COPD patients and 10 healthy subjects, tiotropium and long-acting and short-acting beta-2 agonists were withdrawn at least 72 hours if assumed, 24 hours, and 12 hours, respectively, prior to test day. Salmeterol 50 mcg on days A was administered between 8 AM and 10 AM. 240 and 290 minutes after inhalatory treatment, pulmonary function tests were performed.
88879363|NCT01271556|Placebo Comparator|4, placebo, no saline infusion|In 10 COPD patients and 10 healthy subjects, tiotropium and long-acting and short-acting beta-2 agonists were withdrawn at least 72 hours if assumed, 24 hours, and 12 hours, respectively, prior to test day. Placebo was administered between 8 AM and 10 AM. 240 and 290 minutes after inhalatory treatment (placebo), pulmonary function tests were performed.
88879364|NCT01272024|Active Comparator|Information/Education Group|Assistance in using Symptom Management Toolkit
88879365|NCT01272024|Experimental|Nurse Intervention|Participants are given intensive nurse contacts to reduce uncertainty and maximize problem solving, and later, to transition to the treatment phase of their cancer.
88879366|NCT01272102||Glaucoma|subjects with glaucoma
88879367|NCT01272258|Experimental|Arm 1|PRO 140
89403646|NCT03276962|Experimental|Fx017-mFxD Group|Subjects will receive a full dose of RTS,S/AS01E at Month 0, Month 1 and RTS,S/AS01E 1/5th dose at Month 7, Month 20, Month 32.
88879368|NCT01272258|Placebo Comparator|Arm 2|Placebo
88879369|NCT01272336|Active Comparator|AIH/Sham|Subjects with chronic, motor-incomplete SCI receive AIH and then SHAM
88879370|NCT01272336|Active Comparator|Sham/AIH|Subjects with chronic, motor-incomplete SCI receive SHAM and then AIH
88879371|NCT01272414|Experimental|BoTox Treatment|Subjects receive BoTox injection to levator complex
88879372|NCT01272414|Placebo Comparator|Saline injection|Saline injection to levator complex
88879373|NCT01272492|Experimental|Computer Use|Participants use the computer with the infant/toddler nutrition/feeding education modules
88879374|NCT01272492|No Intervention|Control|Only answers survey questions.
89403647|NCT03276962|Experimental|Control Group|Subjects will receive rabies vaccine at Month 0, Month 1, Month 2.
89403648|NCT03275805|Active Comparator|12 weeks Pavlik Treatment Arm|This arm will receive 12 weeks of full-time Pavlik Harness treatment. Patients will most likely begin the 12-week regiment at their first visit to our hip clinic.
88879375|NCT01272570||Aromatase Inhibitor|"Diagnosis of BCa- Histologic confirmed diagnosis of BCa: Stage 0, I, II, or III with no evidence of metastatic disease.~Treatment- AI as clinically indicated (AI may be anastrozole, exemestane or letrozole). Subjects may have had prior tamoxifen or raloxifene. Subjects may have had chemotherapy and/or radiation therapy. Must be within the first year of consecutive AI therapy. If a subject started AI, discontinued, then restarted, they will be accepted into the study as long as the past therapy did not exceed 12 months and the current therapy has not exceeded 12 months."
88879376|NCT01272570||Control|• No Diagnosis of cancer.- Patients must not have a diagnosis of any cancer (Not including a history of thyroid or skin cancer).
88879377|NCT01272648|Active Comparator|Rehabilitation|note intervention
88879378|NCT01272648|Placebo Comparator|Control|same radiotherapy but no rehabilitation
88879379|NCT01273116|Experimental|CWS in Hospital|CWS in Hospital in addition to usual care
88879380|NCT01273272|Experimental|Cognitive Behavioral Therapy (CBT)|Comprehensive, CBT-based, multi-component treatment. Comprehensive CBT intervention in addition to standard treatment
88879381|NCT01273272|Active Comparator|Treatment as usual (TAU)|Standard Treatment (medical and psychosocial)
88879382|NCT01273350|Other|Single arm|"Single arm observational study looking at a low risk cohort of individuals with carotid stenosis"
88879383|NCT01273428|Active Comparator|HP011-101|
88879384|NCT01273428|Active Comparator|HP828-101|
88879385|NCT01273428|Other|Standard Care|
88879386|NCT01273506|Experimental|001|tapentadol (CG5503) ER 25-mg TRF 50 mg TRF single oral dose
89190097|NCT03781973|Other|Post-Intervention|"Those whose last pediatric visit was in the second year after the intervention (2020).~The intervention includes the following :~Data Platform: Medical record data abstracted from patient charts at the time of the final pediatric visit. .~Quality performance feedback reports: We will generate centre-level performance reports. Centres will be able to compare their performance to that of all other centres and to achievable benchmarks.~Patient transition experience surveys at the final pediatric visit and 12 months later.~Diabetes teams may direct patients and families to online transition resources."
89403649|NCT03275805|Experimental|6 weeks Pavlik Treatment Arm|This arm will receive treatment to normalization, but for no less than 6 weeks. Patients will begin their treatment around the time of their first visit to our designated hip clinic.
89403650|NCT03262935|Experimental|(vic-)trastuzumab duocarmazine|SYD985, every 3 weeks (Q3W)
89403651|NCT03262935|Active Comparator|Physician's choice|"Lap/Cap~T/Cap~T/Vino~T/Eri"
89403652|NCT03225625|Experimental|Paraspinal|Bilateral paraspinal injection of bone marrow derived stem cells (BMSC) at spinal cord injury level, superior to injury level and inferior to injury level. Following paraspinal injection remaining BMSC provided intravenous and intranasal.
88879387|NCT01273506|Experimental|002|tapentadol (CG5503) ER 50-mg TRF 50 mg TRF single oral dose
88879388|NCT01273662|Experimental|Axitinib|
88879389|NCT01273740|Experimental|External support|Bypass graft with external support
88879390|NCT01273740|Experimental|No external support|Bypass with graft without external support
88879391|NCT01273974|Experimental|intradermal influenza vaccine|
88879392|NCT01273974|Active Comparator|intramuscular influenza vaccine|
88879393|NCT01274130|Experimental|Ranitidine|
88879394|NCT01274130|Experimental|Verapamil|
88879395|NCT01274364|Experimental|JADE|Patients will receive comprehensive assessments at baseline and again after 12-months. In the interim between these two time points patients will receive protocol-driven diabetes care using a web-based disease management program (JADE), delivered by a trio-team comprising of a trained doctor, nurse and physician assistant.
88879396|NCT01274364|Active Comparator|DIAMOND|Patients will receive comprehensive assessments at baseline and again after 12-months. In the interim between these two time points patients will be managed according to 'usual care' procedures.
88879397|NCT01274598|Experimental|Lactobacillus Rhamnosus GG, ATCC 53103 (LGG)|Lactobacillus rhamnosus GG ATCC 53103 1 x 10^10 twice a day for 28 days
88879398|NCT01274676|Active Comparator|carotid stenting with MOMA|
88879399|NCT01274676|Active Comparator|Carotid stenting with filter wire EZ|
88879400|NCT01274754||erythromycin group|Patients of erythromycin group: 25mg/kg erythromycin intravenously 12 hours before surgery and 12 hours after the end of surgery.
88879401|NCT01274754||control group|no administration of erythromycin
88879402|NCT01274910|Active Comparator|Fish oil group|Treatment Group.
88879403|NCT01274910|Placebo Comparator|Control group|Placebo group
88879404|NCT01275378|Active Comparator|Collaborative Care Plus|Collaborative care model with specific theory-based elements to address common reasons for ADHD treatment failure
88879405|NCT01275378|Active Comparator|Traditional Collaborative Care|Traditional collaborative care, in which care managers serve as intermediaries between primary care physicians and specialists
88879406|NCT01275612|Experimental|Cell therapy|
88879407|NCT01275690||subjects with PH undergoing right heart catheterization|
88879408|NCT01275768|Experimental|Experimental arm|Insertion and activation of the endo-biliary RF catheter at the site of the stricture before insertion of a Self-expandable Metal Stent (SEMS)
88879409|NCT01275768|Placebo Comparator|Control arm|Insertion and sham activation of the endo-biliary RF catheter at the site of the stricture before insertion of a SEMS
88879410|NCT01275924|Active Comparator|Tightrope|Treatment with Tightrope Syndesmosis Repair Kit
88879411|NCT01275924|Active Comparator|Syndesmotic screw|Treatment with a quadricortical syndesmotic screw
89403653|NCT03225625|Experimental|Paraspinal EX|"Bilateral paraspinal injection of bone marrow derived stem cells (BMSC) at spinal cord injury level, superior to injury level and inferior to injury level. Following paraspinal injection remaining BMSC provided intravenous and intranasal.~Exoskeleton or equivalent stimulation following this treatment."
89190098|NCT03773003|Active Comparator|Arm 1: Tumor disease w/o fatigue|Group receiving probiotics.
89190099|NCT03773003|Placebo Comparator|Arm 2: Tumor disease w/o fatigue|Group receiving placebo (corn starch)
89190100|NCT03773003|Active Comparator|Arm 3: Healthy control group|Group receiving probiotics
89190101|NCT03773003|Placebo Comparator|Arm 4: Healthy control group|Group receiving placebo (corn starch)
89190102|NCT03766438|Experimental|Intervention|The intervention group will view the 12-minute digital storytelling intervention that has been previously pilot-tested, in addition to usual clinical care.
88879412|NCT01276080|Experimental|1|Donepezil Hydrochloride 10 mg Tabletof OHM Laboratories, Inc.
89190103|NCT03766438|No Intervention|Control|The comparison group will receive usual clinical care.
89190104|NCT03713528|Other|Treatment Group|The treatment group includes any patient with an acute perioperative periprosthetic infection, acute hematogenous infection, or unresectable infection with a gram positive organism sensitive to vancomycin and treated with intraoperative intraosseous vancomycin. Additionally, patients will be treated with at least 4 weeks of IV antibiotics under guidance of an infectious disease specialist, and indefinite antibiotic chronic suppression.
89403654|NCT03225625|Experimental|Paraspinal VR|"Bilateral paraspinal injection of bone marrow derived stem cells (BMSC) at spinal cord injury level, superior to injury level and inferior to injury level. Following paraspinal injection remaining BMSC provided intravenous and intranasal.~Virtual Reality or equivalent visualization following this treatment."
88879413|NCT01276080|Active Comparator|2|ARICEPT® (donepezil hydrochloride) 10 mg Tablet of Eisai, Inc.
89403655|NCT03206762|Experimental|Jetstream Atherectomy+Ranger DCB or Medtronic IN.PACT DCB|Jetstream Atherectomy used in conjunction with the Ranger DCB or Medtronic IN.PACT DCB
88879414|NCT01276158|Active Comparator|Ultrasound|Arterial line placed with Ultrasound guidance.
88879415|NCT01276158|Active Comparator|Doppler|Arterial line placed with doppler guidance
88879416|NCT01276548|Experimental|Genexol®-PM plus Carboplatin|
88879417|NCT01276548|Active Comparator|Genexol® plus Carboplatin|
88879418|NCT01276626|Experimental|Bifidobacterium longum|
88879419|NCT01276626|Placebo Comparator|Maltodextrin|
88879420|NCT01276782|Placebo Comparator|Pregnant SLE|Pregnant SLE patients with autoimmune thyroid antibodies will be randomized to levothyroxine or Placebo
88879421|NCT01276938|Active Comparator|IORT 21 Gy|Single fraction 21 Gy Intraoperative Radiation Therapy for breast tumors with diameter between 10 and 25 mm
88879422|NCT01276938|Experimental|IORT 18 Gy|Single fraction 18 Gy Intra Operative Radiation Therapy in breast tumors smaller than 10 mm.
88879423|NCT01277094|Experimental|1|
88879424|NCT01277094|Placebo Comparator|2|
88879425|NCT01277172|Experimental|Group 1 / PBO-326|This group will be treated three cycles with PBO-326, after the third cycle the patients will receive Mabthera for another three cycles.
88879426|NCT01277172|Active Comparator|Group 2 / Mabthera|This group will be treated three cycles with Mabthera, after the third cycle the patients will receive PBO-326 for another three cycles.
88879427|NCT01277172|Experimental|Group 3 / PBO-326|This group will be treated six cycles with PBO-326
88879428|NCT01277172|Active Comparator|Group 4 / Mabthera|This group will be treated six cycles with Mabthera
88879429|NCT01277328||Cohort|Cohort
88879430|NCT01277406|Experimental|4SC-201+FOLFIRI|
89190105|NCT03709511|No Intervention|Conventional Treatment Group|Participants in the control group will receive the usual care protocol. On the day of admission, a registered nurse in cardiac ward will provide operating skills of deep breathing, cough exercises, and incentive spirometry, then patients will be instructed to perform the respiratory exercise as much as they can during the hospitalization without supervision. These participants will not receive additional rehabilitation interventions, unless individual indications are present.
89199051|NCT04077762|Active Comparator|State-of-the-art femoral access|Femoral access for cardiac catheterization. Femoral access will be obtained using state-of-the-art techniques (ultrasound and fluoroscopic guidance for arterial puncture, immediate femoral angiography after obtaining access and use of a vascular closure device whenever possible).
89403656|NCT03206762|Active Comparator|POBA+DCB (Ranger or IN.PACT)|POBA and then DCB treatment (Ranger or IN.PACT)
88879431|NCT01277406|Active Comparator|FOLFIRI|
88879432|NCT01277562||Breast Cancer|Non-metastatic breast cancer with recent diagnosis of osteopenia or osteoporosis
88879433|NCT01277562||Prostate Cancer|Non-metastatic prostate cancer with recent diagnosis of osteopenia or osteoporosis
88879434|NCT01277640|Placebo Comparator|matched placebo|
88879435|NCT01277640|Placebo Comparator|universal placebo|
88879436|NCT01277640|Active Comparator|dapivirine|
88879437|NCT01277874|Active Comparator|Nasal CPAP|Standard Nasal CPAP
88879438|NCT01277874|Active Comparator|Oscillatory NCPAP|NCPAP will be given to infant via prongs in the infant's nose. A Bird Industries pneumatic oscillating diaphragm to drive a Bird Industries phasatron which is attached by T-connector to the NCPAP patient circuit.
88879439|NCT01277952|Experimental|DBS Surgery|Deep brain stimulation (DBS) will be the treatment option in this study along with behavioral interventions for participants with severe disability due to Traumatic Brain Injury (TBI) 24 months post their injury, the participants will have severe disabilities in behavioral and emotional self-regulation, cognitive impairments and somatic symptoms.
88879440|NCT01278108|Experimental|1|single ascending doses
88879441|NCT01278108|Placebo Comparator|2|single dose placebo
88879442|NCT01278108|Experimental|3|multiple dose, 7 days, capsules (dosing depends on outcome of single-dose part; can be once or twice daily).
88879443|NCT01278108|Placebo Comparator|4|multiple dose, capsules, 7 days; scheme to match that of Study Arm 3.
88879444|NCT01278420|Other|Tecnis MF|
88879445|NCT01278420|Other|ReSTOR|
88879446|NCT01278576|Experimental|Intramuscular ending Targeting|Botox 200 units placed at the upper 2/10-3/10 length of the GCM
88879447|NCT01278576|Active Comparator|Midbelly Targeting|A total of 200 units will be placed at the four quadrants of the midbelly portion of the GCM.
88879448|NCT01278654|Active Comparator|Personal incentive|If participants attain their walkstation usage goal, they are entered into bi-weekly lotteries to win money.
88879449|NCT01278654|Active Comparator|Token incentive|Participants who attain their walkstation usage goal will be entered into a bi-weekly prize to win a token reward.
88879450|NCT01278810|Experimental|Icaritin|
88879451|NCT01278966|Experimental|The Modified Atkins Diet|Treatment with the Modified Atkins Diet for 6 months
88879452|NCT01279122|No Intervention|Nanoflex IOL|
88879453|NCT01279278|No Intervention|Control|
89530986|NCT02499107|Experimental|Fried french fries treatment|Dietary Intervention: Ad libitum intake of fried french fries
89403657|NCT03200847|Experimental|Pembrolizumab with All-Trans Retinoic Acid|Patients will receive pembrolizumab infusions every three weeks. Patients will also receive 3 days of all-trans retinoic acid treatment surrounding each of the first 4 infusions of pembrolizumab, beginning one day prior to the infusion (a total of 12 days of all-trans retinoic acid).
88879454|NCT01279278|Experimental|Co-signed Letter|
88879455|NCT01279356||Patients with liver diseases of various etiologies|"viral hepatitis~cholestatic liver diseases~auto-immune hepatitis~NAFLD~ALD~sarcoidosis of the liver"
88879456|NCT01279434|Experimental|Vitamin E plus Pentoxiphyllin|
89190106|NCT03709511|Active Comparator|Cardiac Rehabilitation Group|"The intervention group will receive the PORT protocol, contains education, IMT, ACBT, EM. Participants will be provided information about the cardiac surgery and adverse effect on postoperative recovery, and the importance of PORT program.~An inspiratory threshold-loading device is used for IMT. Participants will be instructed to breathe in as forcefully as possible before slowly breathing out five times and then rest for one minute, followed by another set of five breaths. Patients will complete three sessions of ACBT consisting of breathing control, thoracic expansion exercises and forced expiratory techniques. The mobilization protocol will be performed via a progressive approach, consisting of 6 steps. EM will be personalized to each patient."
89190107|NCT03708562|Other|endoAVF|
89199052|NCT00610935|Placebo Comparator|Placebo|Placebo intramuscular injection
89403658|NCT03190317||HIV-infected Veterans who use MHV|This group represents the population of HIV-infected Veterans active in care at a VA health system, who have been diagnosed with HIV and use MHV.
89403659|NCT03190317||HIV-infected Veterans who do not use MHV|This group represents the population of HIV-infected Veterans active in care at a VA health system, who have been diagnosed with HIV and do not use MHV.
89403660|NCT03190317||Providers and staff of HIV-infected veteran|This groups represents the population of providers and staff who utilize the MHV portal to deliver care for HIV-infected veterans.
89403661|NCT03184545|Experimental|EMS and PT|Group 1: Electrical Muscle stimulation (EMS) and Physical therapy (PT).
89403662|NCT03184545|Active Comparator|Only PT|Group 2: Only Physical therapy (PT).
89190108|NCT03705845|Placebo Comparator|Control|One 430 mg olive oil softgel daily for 24 weeks. Each placebo softgel of 430 mg olive oil will contain no tocotrienol or tocopherols at detectable levels.
89190109|NCT03705845|Active Comparator|Intervention|One 430 mg tocotrienol softgel daily for 24 weeks. Each tocotrienol softgel (DeltaGold® Tocotrienol 70%) contains 430 mg tocotrienol (90% δ-tocotrienol+10% γ-tocotrienol) with a 70% purity, representing 300 mg tocotrienol.
89190110|NCT03669718|Experimental|Active ISA101b and cemiplimab.|ISA101b 3 times plus cemiplimab every 3 weeks for up to 24 months
89199053|NCT00610935|Experimental|Peramivir|Single intramuscular injection of 300mg peramivir
88879457|NCT01279434|Active Comparator|Vitamin E|
88879458|NCT01279512|Experimental|Metformin reciepiants|Infertile overweight women with PCO who received Metformin
88879459|NCT01279512|Experimental|Acarbose reciepiants|Infertile overweight women with PCO who received Acarbose
88879460|NCT01279668|Experimental|Montelukast|
88879461|NCT01279668|Placebo Comparator|Placebo|
88879462|NCT01279746||ultrasond compression of deep veins|
88879463|NCT01279902|Experimental|Rituximab plus CHOP Immunochemotherapy|"Interventions: conventional R-CHOP every 3 weeks for 3 cycles~Rituximab 375 mg/M2 IV day 1~Cyclophosphamide 750 mg/M2 IV day1~Vincristine 1.5 mg/M2 (max. 2 mg) IV day1~Prednisolone 50 mg bid day 1-5, every 3 weeks"
88879464|NCT01279044|Active Comparator|1|HIV testing with adapted Personalized Cognitive Risk-reduction Counseling intervention (PCC)
89403663|NCT03102632|No Intervention|Usual Water Intake|For the first 6 months of the study, the participants will continue their usual water intake.
89403664|NCT03102632|Experimental|High Water Intake|After a 6 month period of usual water intake, a high water intake daily amount will be prescribed for 1 year.
89403665|NCT03030417|Experimental|Treatment Arm|LMP744 will be administered IV over 1 hour on days 1-5 of each 28-day cycle
88879465|NCT01279044|Placebo Comparator|2|HIV testing with information only
88879466|NCT01278342|Active Comparator|Sandostatin LAR high dose Alone|All patients were treated with Sandostatin LAR 40 mg i.m. every 28 days for 3 months. Following biochemical assessment, patients with controlled GH and IGF-I after 3 months of Sandostatin LAR monotherapy continued to receive Sandostatin LAR 40 mg i.m. every 28 days for an additional 4 months.
88879467|NCT01278342|Experimental|Sandostatin LAR high dose + Pegvisomat|All patients were treated with Sandostatin LAR 40 mg i.m. every 28 days for 3 months. Following biochemical assessment, patients with uncontrolled GH and or IGF-I received Sandostatin LAR40 mg every 28 days in combination with weekly doses of pegvisomant 70 mg subcutaneously (s.c.) for a further 4 months
88879468|NCT01278342|Experimental|Sandostatin LAR high dose + Cabergoline|"All patients were treated with Sandostatin LAR 40 mg i.m. every 28 days for 3 months. Following biochemical assessment, patients with uncontrolled GH and or IGF-I received Sandostatin LAR 40 mg every 28 days in combination with weekly cabergoline for a further 4 months, with cabergoline doses as follows:~st week: 0.25 mg twice a week (0.50 mg/week)~nd week: 0.50 mg/week twice a week (1 mg/week)~rd week: 0.50 mg four times a week (2 mg/week)~th week: 0.50 mg daily (3.5 mg/week) Subsequent 3 months: 0.50 mg daily (3.5 mg/week)"
88879469|NCT01278030|No Intervention|Control group|Patients will be implanted according to the standard of care with the LV lead in the traditional LV lead position.
88879470|NCT01278030|Experimental|3D echo-guided LV lead placement group|Information about left ventricular mechanical dyssynchrony and the location of the site of latest mechanical activation based on Real-Time 3-Dimensional Echocardiography (RT3DE) will be available to the physician at the time of implant. This location will be used as the target for optimal LV lead placement.
88879471|NCT01277718|Experimental|Treatment A first, then Treatment B, followed by Treatment C|Treatment A in Period 1: One 20-mg tablet of cobimetinib will be administered orally with 240 milliliters (mL) room temperature water after at least an 8-hour fast. Treatment B in Period 2: 20 mg oral rabeprazole will be administered once daily for 4 days starting on Day -4. On Day 1, 20 mg rabeprazole will be administered in fasted state followed by one 20-mg tablet of cobimetinib administration orally with 240 mL room temperature water after at least an 8-hour fast. Treatment C in Period 3: 20 mg oral rabeprazole will be administered once daily for 4 days starting on Day -4. On Day 1, 20 mg rabeprazole will be administered in fasted state. Approximately 30 minutes later, participants will be provided a standardized Food and Drug Administration (FDA) high-fat meal, and approximately 30 minutes after starting meal, one 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water. There will be a 13-day washout between cobimetinib doses of each period.
89403666|NCT02956447|Experimental|Kisspeptin Bolus and Baseline Sampling|Blood sampling every 10 minutes over two 12-hour periods. One 12-hour period without any intervention. One 12-hour period consisting of administration of 10 boluses of kisspeptin 112-121 0.24 nmol/kg intravenously (IV) in a 10-hour period and one bolus of gonadotropin-releasing hormone (GnRH) at hour 11.
89403667|NCT02956447|Experimental|Pulsatile Kisspeptin|Subcutaneous (SC) administration of kisspeptin 112-121 0.24 nmol/kg IV every 90 minutes over eight days using a portable pump. One-time bolus of kisspeptin 112-121 2.4 nmol/kg IV (if necessary).
89403668|NCT02948426|Experimental|Dose Level 1 - Sylatron 25µg (0.1 µg/ml); Actimmune 5mg (0.02µg/ml)|Sylatron 25µg (0.1 µg/ml); Actimmune 5mg (0.02µg/ml). The autologous monocytes cell product in 250ml total volume of investigational combination (monocytes + ACTIMMUNE + SYLATRON) is infused via the intraperitoneal catheter over 30-60 min +/- 10 min every 28 days +/- 7 days until disease progression, limiting toxicity, intercurrent medical issues, or patient withdrawal.
89536676|NCT05315063|Experimental|Eccentric Training|Once achieved, this flexed hip position will be held for 5 seconds. This procedure will be repeated 6 times with no rest between repetitions
88879472|NCT01277718|Experimental|Treatment A first, then Treatment C, followed by Treatment B|Treatment A in Period 1: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast. Treatment C in Period 2: 20 mg oral rabeprazole will be administered once daily for 4 days starting on Day -4. On Day 1 of the treatment period, 20 mg rabeprazole will be administered in fasted state. Approximately 30 minutes later, participants will be provided a standardized FDA high-fat meal, and approximately 30 minutes after starting meal, one 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water. Treatment B in Period 3: 20 mg oral rabeprazole will be administered once daily for 4 days starting on Day -4. On Day 1 of treatment period, 20 mg rabeprazole will be administered in fasted state followed by one 20-mg tablet of cobimetinib administration orally with 240 mL room temperature water after at least an 8-hour fast. There will be a 13-day washout between cobimetinib doses of each period.
88879473|NCT01276236|Experimental|Treatment Arm (Maraviroc)|The subjects in this arm will receive Maraviroc as treatment, while continuing their current antiretroviral medication regimen.
88879474|NCT01275222|Experimental|Phase l: RAD001 20mg/week|RAD001 20 mg was given once a week.
88879475|NCT01275222|Experimental|Phase l: RAD001 2.5mg/day + Glivec 600mg/day|RAD001 2.5 mg was given in combination with Glivec/Gleevec 600mg/day.
89403669|NCT02948426|Experimental|Dose Level 2 - Monocytes (75x10^6); Sylatron 25µg (0.1µg/ml); Actimmune 5mg (0.02µg/ml)|Monocytes (75x10^6); Sylatron 25µg (0.1µg/ml); Actimmune 5mg (0.02µg/ml). The autologous monocytes cell product in 250ml total volume of investigational combination (monocytes + ACTIMMUNE + SYLATRON) is infused via the intraperitoneal catheter over 30-60 min +/- 10 min every 28 days +/- 7 days until disease progression, limiting toxicity, intercurrent medical issues, or patient withdrawal.
89403670|NCT02948426|Experimental|Dose Level 3 - Monocytes (750x10^6); Sylatron 25µg (0.1µg/ml); Actimmune 5mg (0.02µg/ml)|Monocytes (750x10^6); Sylatron 25µg (0.1µg/ml); Actimmune 5mg (0.02µg/ml). The autologous monocytes cell product in 250ml total volume of investigational combination (monocytes + ACTIMMUNE + SYLATRON) is infused via the intraperitoneal catheter over 30-60 min +/- 10 min every 28 days +/- 7 days until disease progression, limiting toxicity, intercurrent medical issues, or patient withdrawal.
88879476|NCT01275222|Experimental|Phase l: RAD001 5mg/day + Glivec 600mg/day|RAD001 5 mg was given in combination with Glivec/Gleevec 600mg/day.
88879477|NCT01275222|Experimental|Phase l: RAD001 2.5mg/day + Glivec 800mg/day|RAD001 2.5 mg was given in combination with Glivec/Gleevec 800mg/day.
89403671|NCT02948426|Experimental|Dose Level 4 - Monocytes (750x10^6); Sylatron 250µg (1µg/ml); Actimmune 50mg (0.2µg/ml)|Monocytes (750x10^6); Sylatron 250µg (1µg/ml); Actimmune 50mg (0.2µg/ml). The autologous monocytes cell product in 250ml total volume of investigational combination (monocytes + ACTIMMUNE + SYLATRON) is infused via the intraperitoneal catheter over 30-60 min +/- 10 min every 28 days +/- 7 days until disease progression, limiting toxicity, intercurrent medical issues, or patient withdrawal.
89403672|NCT02948426|Experimental|EX1 Dose Expansion Arm|10 additional patients will be treated at the maximum tolerated dose (MTD)
89403673|NCT02942927|Experimental|TAPER|"The intervention is medication reduction. This arm is comprised of:~Medication reconciliation~Identification of patient priorities for care~Identification of medications that are potentially appropriate for discontinuation/dose reduction~Linked pharmacist/family physician consultations with patient to discuss medication with intention to reduce~Identification of medications for trial of discontinuation/dose reduction (shared decision making)~Pause of medication and clinical monitoring"
89403674|NCT02942927|No Intervention|Control|Standard of Care as wait list control. Control group will be offered intervention as part of usual clinical care at 6 months.
89403675|NCT02936024|Experimental|Intervention Group: Two-Stage GSLO Technique|Gubernaculum-sparing laparoscopic orchidopexy will be done in two stages
89403676|NCT02936024|Other|Control Group: One-Stage GSLO Technique|Gubernaculum-sparing laparoscopic orchidopexy will be done in a single stage
88879478|NCT01275222|Experimental|Phase ll - Stratum l (first-line resistant/refractory): RAD001 2.5mg/day + Glivec 600mg/day|All first-line resistant/refractory patients received RAD001 2.5mg/day in combination with Glivec/Gleevec at a dose of 600mg/day.
89403677|NCT02910700|Experimental|Arm A (NDT, CLOSED)|Patients receive nivolumab IV over 30 minutes on day 1, dabrafenib PO BID on days 1-28, and trametinib PO QD on days 1-28. Cycles repeats every 28 days for up to 3 years in the absence of disease progression or unacceptable toxicity.
88879479|NCT01275222|Experimental|Phase ll - Stratum ll: (post second-line therapy): RAD001 2.5mg/day + Glivec 600mg/day|All post-second-line patients received RAD001 2.5mg/day in combination with Glivec/Gleevec at a dose of 600mg/day
88879480|NCT01275144|Experimental|LY2216684+lorazepam, placebo+lorazepam|Oral 18 mg doses of LY2216684 on days 1-6 with a single oral 1 mg dose of lorazepam on day 3 in treatment period 1. Oral doses of placebo on days 1-6 with a single oral 1 mg dose of lorazepam on day 3 in treatment period 2. There is a washout period of at least 7 days between dosing periods.
88879481|NCT01275144|Experimental|Placebo+Lorazepam, LY2216684+Lorazepam|Oral doses of placebo on days 1-6 with a single oral 1 mg dose of lorazepam on day 3 in treatment period 1. Oral 18 mg doses of LY2216684 on days 1-6 with a single oral 1 mg dose of lorazepam on day 3 in treatment period 2. There is a washout period of at least 7 days between dosing periods.
88879482|NCT01275066|Placebo Comparator|Placebo|
88879483|NCT01275066|Experimental|BMN 110 Weekly|
88879484|NCT01275066|Experimental|BMN 110 Every Other Week|
88879485|NCT01273038|Active Comparator|SenSura|The reference product is the CE marked and launched SenSura product which is commercially available
88879486|NCT01273038|Experimental|Morfeus|The test product is the product with the proposed new Morfeus filter
88879487|NCT01272180|Experimental|ABCWY+OMV|"Subjects in this group received two doses of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine plus Outer Membrane Vesicles (OMV) administered two months apart."
88879488|NCT01272180|Experimental|ABCWY+qOMV|"Subjects in this group received two doses of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine plus one quarter dose of Outer Membrane Vesicles (qOMV) administered two months apart."
88879489|NCT01272180|Active Comparator|rMenB+OMV|"Subjects in this group received two doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine,administered two months apart."
89403678|NCT02910700|Experimental|Arm B (NT, closed to accrual)|Patients receive nivolumab IV over 30 minutes on day 1 and 15, and trametinib PO QD on days 1-28. Cycles repeats every 28 days for up to 3 years in the absence of disease progression or unacceptable toxicity.
89403679|NCT02910700|Experimental|Arm C (NEB)|Patients receive nivolumab IV over 30 minutes on day 1 and 15, encorafenib PO QD on days 1-28, and binimetinib PO BID on days 1-28. Cycles repeats every 28 days for up to 3 years in the absence of disease progression or unacceptable toxicity.
89403680|NCT02888262||Patients with bipolar disorder|Patients with newly diagnosed bipolar disorder
89403681|NCT02888262||Healthy first generation relatives|Healthy first generation relatives to the included patients
89403682|NCT02888262||Healthy individuals|Healthy individuals without a family history of psychiatric disorders
89403683|NCT02876185||Patients with glaucoma|Patients presenting an open-angle glaucoma or ocular hypertension
89403684|NCT02763917|Active Comparator|Active Air Purifier|Two portable air purifiers containing HEPA filters will be placed in the bedroom and room where the participant reports spending the most time. We have chosen to deploy two air purifiers because we have observed a 50% reduction in indoor PM concentrations with two air purifiers. Participants will be instructed to run the air purifiers continually. Participants will receive educational materials about environmental factors that are important for asthma health and environmental modification strategies. Participants will also receive educational materials about health benefits of maintaining a normal weight.
89530987|NCT02506283|Experimental|cooling intervention|subjects in this study receive a single pre-exercise (3x MVC) or post-exercise intervention (3x 30 counter movement jumps), consisting of an external cooling application (Zamar Therapy CT clinic) applied to both thighs. Both interventions have a duration of 20 minutes and a temperature of 8°C
88879490|NCT01272180|Active Comparator|MenACWY|"Subjects in this group received a dose of placebo followed by one dose of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine administered two months later."
88879491|NCT01271712|Experimental|Regorafenib (Stivarga, BAY73-4506)|Participants received Regorafenib (Stivarga) 160 mg (4 x 40 mg tablets) per os once daily, 3 weeks on therapy followed by 1 week off therapy to comprise a cycle of 4 weeks
89403685|NCT02763917|Placebo Comparator|Placebo Air Purifier|Homes in the control group will receive placebo air purifiers that have the internal air filters removed, but which will run normally. Participants will receive educational materials about environmental factors that are important for asthma health and environmental modification strategies, and educational materials about health benefits of maintaining a normal weight. At the end of the study, participants in the control group will receive active air purifiers. A control group is needed to ensure that reduced pollutant levels and health effects are not due to temporal trends and 'placebo effects' of being enrolled in an intervention trial. Participants will also be informed that being in the study does not prevent them from purchasing and using air cleaners during the study period.
88879492|NCT01271712|Placebo Comparator|Placebo|Participants received matching Placebo tablets per os once daily, 3 weeks on therapy followed by 1 week off therapy to comprise a cycle of 4 weeks
88879493|NCT01271010|Experimental|Rituximab + Fludarabine + Cyclophosphamide|Participants received rituximab 375 milligrams per square meter (mg/m^2) intravenously (IV) on Day 1 of Cycle 1, then 500 mg/m^2 IV on Day 1 of each subsequent cycle; fludarabine 25 mg/m^2 IV or 40 mg/m^2 orally on Days 1-3 of each cycle and cyclophosphamide 250 mg/m^2 IV or 250 mg/m^2 orally on Days 1-3 of each cycle. Treatment duration was 6 cycles, 28 days each.
88879494|NCT01270620|Active Comparator|Propofol|Patients will receive propofol as general anesthetics.
88879495|NCT01270620|Active Comparator|Desflurane|Patients will receive desflurane as general anesthetics.
88879496|NCT01270464|Placebo Comparator|Placebo|Placebo administered intravenously (iv) once every 4 weeks, for a total of 4 doses.
88879497|NCT01270464|Experimental|Reslizumab - 0.3 mg/kg|0.3 mg/kg, administered intravenously (iv) once every 4 weeks, for a total of 4 doses
88879498|NCT01270464|Experimental|Reslizumab - 3.0 mg/kg|3.0 mg/kg, administered intravenously (iv) once every 4 weeks, for a total of 4 doses.
88879499|NCT01279590|Experimental|PPD10558|Dosing will be forced-titrated as follows: 40 mg orally twice daily for 4 weeks and 80 mg orally twice daily for 8 weeks
88879500|NCT01279590|Active Comparator|Atorvastatin|Dosing will be forced titrated as 40 mg orally once daily for 4 weeks, and 80 mg orally once daily for 8 weeks
88879501|NCT01279590|Placebo Comparator|Placebo|Dosing will be 2 placebo capsules twice daily for 12 weeks
88879502|NCT01271790|Active Comparator|Arm 1|GS-9451 and Tegobuvir (GS-9190) in combination with Pegasys® and Copegus® for 16 or 24 weeks; Pegasys® and Copegus® may be continued for up to 48 weeks total duration depending on individual response to therapy
88879503|NCT01271790|Active Comparator|Arm 2|GS-9451 (active) and Tegobuvir (GS-9190) placebo in combination with Pegasys® and Copegus® for 24 weeks; Pegasys® and Copegus® may be continued for up to 48 weeks total duration depending on individual response to therapy
88879504|NCT01271790|Placebo Comparator|Arm 3|Placebo matching Tegobuvir (GS-9190) and GS-9451 in combination with Pegasys® and Copegus® for 24 weeks; Pegasys® and Copegus® will be continued for up to 48 weeks total duration
88879505|NCT01270152|Experimental|group 50 mg ascorbic acid|this arm received a dose of 50 mg of ascorbic acid administered inside the catheter and maintained for up to 60 minutes
88879506|NCT01270152|Experimental|group 100mg ascorbic acid|this arm received a dose of 100 mg of ascorbic acid administered inside the catheter and maintained for up to 60 minutes
89536677|NCT05315063|Experimental|Muscle Energy Technique (PIR)|muscle energy technique
88879507|NCT01270152|Experimental|group 200mg ascorbic acid|this arm received a dose of 200 mg of ascorbic acid administered inside the catheter and maintained for up to 60 minutes
88879508|NCT01274988|Experimental|Deep Brain Stimulation|Continuous deep brain stimulation of bilateral nucleus accumbens
88879509|NCT01274988|Active Comparator|Standard Control|methadone maintenance treatment
88879510|NCT01278498|Experimental|escitalopram|prevention of poststroke depression in patients with acute stroke.
88879511|NCT01278498|Placebo Comparator|placebo|prevention of poststroke depression in patients with acute stroke.
88879512|NCT01279980|Active Comparator|Epidural|Subjects will have an epidural catheter placed to provide postoperative pain relief. This is standard care for those undergoing an enhanced recovery program.
88879513|NCT01279980|Active Comparator|Painbuster|Subjects will have a local anaesthetic wound catheter inserted into the wound at time of surgery rather than an epidural for the provision of postoperative pain relief.
88879514|NCT00249834|Experimental|Gonal-f 112.5 IU|
88879515|NCT00249834|Experimental|Gonal-f 37.5 IU|
88879516|NCT00249834|Experimental|Gonal-f 75 IU|
88879517|NCT00249834|Experimental|Gonal-f 150 IU|
88879518|NCT00249834|Experimental|Gonal-f 187.5 IU|
88879519|NCT00249834|Experimental|Gonal-f 225 IU|
88879520|NCT00249834|Experimental|Gonal-f 262.5 IU|
88879521|NCT00249834|Experimental|Gonal-f 300 IU|
88879522|NCT00249444|Active Comparator|Mirtazapine|Mirtazapine will be administered on a fixed-flexible schedule, with dose titrated up to 60 mg per day or the maximum tolerated dose.
88879523|NCT00249444|Placebo Comparator|Placebo|placebo
88879524|NCT00249288|Experimental|Folate|Participants will receive a 2 mg/ day dose of folate, for 12 weeks
88879525|NCT00249288|Placebo Comparator|Placebo|Participants will receive a 2 mg/ day dose of placebo, for 12 weeks
88879526|NCT00247962|Experimental|A|
88879527|NCT00247962|Active Comparator|B|
88879528|NCT00247416|Other|1 No Dex|No Dexamethasone
88879529|NCT00247416|Experimental|2 Dex|Dexamethasone
89403686|NCT02603562|Experimental|ATYR1940|Participants received ATYR1940 intravenous (IV) infusion at doses of 0.3, 1.0, and 3.0 milligrams/kilograms (mg/kg) once weekly using intraparticipant dose escalation for 12 weeks.
89403687|NCT02586727|Active Comparator|six week dosing regimen arm|Patients will receive an intravitreal aflibercept injection the first visit, and then again every six weeks. Treatment will be given at each visit.
89403688|NCT02586727|Active Comparator|treat and extend dosing regimen arm|Patients will receive an intravitreal aflibercept injection the first visit, again at the second visit at 6 weeks, and then begin treat and extend from second injection forward. Patients with decreased radiation maculopathy by one grade or more will extend re-evaluation by two weeks. Patients with increased radiation maculopathy by one grade or more will have re-evaluation decreased by one week. Patients that show no maculopathy grade change will remain at the same re-evaluation interval.
89403689|NCT02579239|Experimental|Group A - FSHD|Participants with FSHD will receive single dose of placebo intravenous (IV) infusion followed by ATYR1940 IV infusion at doses of 0.3 up to 1.0 milligrams/kilograms (mg/kg) once weekly for 8 weeks and then twice weekly for 4 weeks using intraparticipant dose escalation for up to 12 weeks.
89403690|NCT02579239|Experimental|Group B - LGMD2B and FSHD|Participants with LGMD2B and FSHD will receive single dose of placebo IV infusion followed by ATYR1940 IV infusion at doses of 0.3 up to 1.0 and 3.0 mg/kg once weekly for 8 weeks and then twice weekly for 4 weeks using intraparticipant dose escalation for up to 12 weeks.
89403691|NCT02567201|Experimental|Electrophysiological assessment of Healthy subjects|Experiences 1, 2 and 3 with healthy subjects
89403692|NCT02567201|Experimental|Electrophysiological assessment of patients|Experiences 1, 2 and 3 with patients
89403693|NCT02555358|Experimental|A（DOX）|Interventions：This arm wil receive four cycles of DOX (docetaxel 60mg/m2 on day 1,oxaliplatin 130mg/m2 on day 1 and capecitabine 1,000 mg/m2 per day on days 1 to 14, repeated every 3 weeks) as neoadjuvant therapy and four cycles of Xelox (capecitabine 1,000 mg/m2 per day on days 1 to 14 and oxaliplatin 130mg/m2 on day 1, repeated every 3 weeks) as adjuvant therapy
88879530|NCT00246090|Experimental|1|
88879531|NCT00246012|Experimental|Intetumumab 3 mg/kg [Phase 1 (Part 1)]|Intetumumab will be administered at the dose of 3 milligram per kilogram (mg/kg) as intravenous infusion (a fluid or a medicine delivered into a vein by way of a needle) over a period of 2 hours (hr) (± 15 minutes) once every 3 weeks until the occurrence of dose limiting toxicities (DLTs). If after an evaluation of the preliminary single-dose pharmacokinetics, receptor saturation is not observed at the 3 mg/kg or 5 mg/kg dose level, that dose of intetumumab will be discontinued in Part 1 and participants will be treated at the highest, documented safe dose level at which receptor saturation is observed.
89403694|NCT02555358|Active Comparator|B（Xelox）|Interventions：This arm wil receive four cycles of Xelox (capecitabine 1,000 mg/m2 per day on days 1 to 14 and oxaliplatin 130mg/m2 on day 1, repeated every 3 weeks) as neoadjuvant therapy and four cycles of Xelox as adjuvant therapy
89403695|NCT02555358|Active Comparator|C（Xelox）|Interventions：This arm wil receive eight cycles of Xelox (capecitabine 1,000 mg/m2 per day on days 1 to 14 and oxaliplatin 130mg/m2 on day 1, repeated every 3 weeks) as adjuvant therapy.
89403696|NCT02532231|Experimental|Treatment (nivolumab)|Patients receive nivolumab IV over 1 hour on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. After cycle 6, patients may receive nivolumab on day 1 only. After cycle 12, patients may receive nivolumab on day 1 of every 3 cycles. Patients experiencing disease progression may go back to receiving treatment on days 1 and 15 of each cycle.
89403697|NCT02497365|Experimental|Group A: Besifloxacin|Patients presenting with bacterial keratitis. These patients will be treated with besifloxacin ophthalmic suspesnion 0.6%, initially 6x a day and tapered down as the patient's condition improves based on the clinical judgement of the treating physician.
89403698|NCT02497365|Active Comparator|Group B: Fortified Antibiotics|Patients presenting with bacterial keratitis. These patients will be treated initially with fortified cefazolin and vancomycin drops every 1 hour around the clock (24hours) for a minimum of 48 hours, and will subsequently have their dosages tapered gradually by the treating physician as is the standard of care for bacterial keratitis.
89403699|NCT02476396||patient-subject|Patients will be recruited from the population of patients scheduled to undergo carotid endarterectomy or stenting (endovascular) for established clinical indications. These indications include patients scheduled to have a carotid endarterectomy or stenting due to the presence of a high-grade atherosclerotic cervical internal carotid artery stenosis with or without clinical symptoms, following the ACAS or NASCET criteria (carotid artery stenosis of 60% or greater without clinical symptoms; stenosis 70% or greater with clinical symptoms).
89403700|NCT02476396||patient-control|The controls will be recruited by the patient-subjects. The investigators will ask their patient-subjects to speak to a spouse or family member to see if they are interested in participating. If they do have an interest they will contact the research team/study coordinator(s). In case, a spouse or a family member is accompanying the patient-subject, they will be recruited at the same time as the patient-subject.
88879532|NCT00246012|Experimental|Intetumumab 5 mg/kg [Phase 1 (Part 1)]|Intetumumab will be administered at the dose of 5 mg/kg as intravenous infusion over a period of 2 hr (± 15 minutes) once every 3 weeks until the occurrence of DLTs. If after an evaluation of the preliminary single-dose pharmacokinetics, receptor saturation is not observed at the 3 mg/kg or 5 mg/kg dose level, that dose of intetumumab will be discontinued in Part 1 and participants will be treated at the highest, documented safe dose level at which receptor saturation is observed.
88879533|NCT00246012|Experimental|Intetumumab 10 mg/kg [Phase 1 (Part 1)]|Intetumumab will be administered at the dose of 10 mg/kg as intravenous infusion over a period of 2 hr (± 15 minutes) once every 3 weeks until the occurrence of DLTs.
88879534|NCT00246012|Experimental|Dacarbazine + intetumumab 5 mg/kg [Phase 1 (Part 2)]|Intetumumab will be administered at the dose of 5 mg/kg as intravenous infusion over a period of 2 hr (± 15 minutes) once every 3 weeks for 8 cycles until no evidence of disease progression or unacceptable toxicity. If participants respond to therapy with stable disease (SD) or better, they will be considered eligible to receive up to 8 cycles of extended administrations. Commercially available dacarbazine will be administered at the dose of 1000 milligram per meter-square (mg/m^2) intravenously over a period of 60 minutes (± 30 minutes) prior to intetumumab infusion.
88879535|NCT00246012|Experimental|Dacarbazine + intetumumab 10 mg/kg [Phase 1 (Part 2)]|Intetumumab will be administered at the dose of 10 mg/kg as intravenous infusion over a period of 2 hr (± 15 minutes) once every 3 weeks for 8 cycles until no evidence of disease progression or unacceptable toxicity. If participants respond to therapy with SD or better, they will be considered eligible to receive up to 8 cycles of extended administrations. Commercially available dacarbazine will be administered at the dose of 1000 mg/m^2 intravenously over a period of 60 minutes (± 30 minutes) prior to intetumumab infusion.
88879536|NCT00246012|Experimental|Dacarbazine + placebo [Phase 2]|Placebo will be administered intravenously over a period of 2 hr (±15 minutes). Commercially available dacarbazine will be administered at the dose of 1000 mg/m^2 intravenously over a period of 60 minutes (± 30 minutes) prior to placebo infusion. In case participants are unable to tolerate dacarbazine even after 2 dose reductions, they will be given the option to continue with 10 mg/kg intetumumab alone.
88879537|NCT00246012|Experimental|Intetumumab 5 mg/kg [Phase 2]|Intetumumab will be administered at the dose of 5 mg/kg as intravenous infusion over a period of 2 hr (± 15 minutes) once every 3 weeks for 8 cycles until no evidence of disease progression or unacceptable toxicity. If participants respond to therapy with SD or better, they are considered eligible to receive up to 8 cycles of extended administrations.
89536678|NCT02474147|Experimental|Type 2 diabetics|Patients with type 2 diabetes Interventions: processed meat hamburger and vegan sandwich
89536679|NCT02474147|Active Comparator|Obese subjects|Obese subjects without diabetes Interventions: processed meat hamburger and vegan sandwich
88879538|NCT00246012|Experimental|Intetumumab 10 mg/kg [Phase 2]|Intetumumab will be administered at the dose of 10 mg/kg as intravenous infusion over a period of 2 hr (± 15 minutes) once every 3 weeks for 8 cycles until no evidence of disease progression or unacceptable toxicity. If participants respond to therapy with SD or better, they are considered eligible to receive up to 8 cycles of extended administrations.
88879539|NCT00246012|Experimental|Dacarbazine + intetumumab 10 mg/kg [Phase 2]|Intetumumab will be administered at the dose of 10 mg/kg as intravenous infusion over a period of 2 hr (± 15 minutes) once every 3 weeks for 8 cycles until no evidence of disease progression or unacceptable toxicity. If participants respond to therapy with SD or better, they are considered eligible to receive up to 8 cycles of extended administrations. Commercially available dacarbazine will be administered at the dose of 1000 mg/m^2 intravenously over a period of 60 minutes (± 30 minutes) prior to intetumumab infusion.
89403701|NCT02458690|Experimental|eIMPACT|eIMPACT is a 12-month, modernized, collaborative, stepped care intervention consisting of (1) computerized and telephonic cognitive-behavioral therapy for depression and (2) select antidepressant medications included in an algorithm optimized for cardiovascular disease risk reduction. It is a collaborative care intervention in which a multidisciplinary team delivers established depression treatments consistent with patient preference. It uses a stepped, flexible, treat-to-target approach that modernizes the IMPACT intervention by harnessing technology to minimize staff and space requirements. Interventions are Beating the Blues, Problem Solving Treatment in Primary Care, and select FDA-approved antidepressants. The treatment team consists of a depression clinical specialist, a supervising MD with expertise in primary care and IMPACT, and the patients' primary care providers.
89403702|NCT02458690|Active Comparator|Usual Care|Patients and their primary care providers are informed of the depressive disorder diagnosis, and follow-up is encouraged. There are no restrictions on the care received. The Eskenazi Health primary care clinics utilize a team care approach, with PCPs supported by embedded behavioral health clinicians and affiliated psychiatrists.
89403703|NCT02446457|Experimental|Cohort I (rituximab, pembrolizumab)|Patients receive rituximab IV over 4-8 hours on days 1, 8, 15, and 22. Patients also receive pembrolizumab IV over 1 hour on day 2 every 3 weeks for up to 16 cycles (1 year) in the absence of disease progression or unacceptable toxicity.
89403704|NCT02446457|Experimental|Cohort II (rituximab, pembrolizumab, lenalidomide)|Patients receive rituximab IV over 4-8 hours on days 1, 8 and 15 of cycle 1, and day 1 of cycle 2. Patients also receive pembrolizumab IV over 1 hour on day 2 every 3 weeks for up to 2 years, and lenalidomide PO on days 1-14 every 3 weeks for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
88879540|NCT00245856|Experimental|Treatment of Upper Extremity DVT|Participants received dalterparin followed by warfarin or received dalterparin monotherapy for the treatment of upper extremity DVT
88879541|NCT00245466|Experimental|Degarelix 80/80 + 40|In the main study (FE200486 CS02; NCT00819247) loading doses of degarelix 80 mg were given on Days 0 and 3. Maintenance doses of 40 mg were given on days 28, 56, 84, 112 and 140. In the extension study (FE200486 CS02A) the same maintenance dose of degarelix was given once every 4 weeks.
88879542|NCT00245466|Experimental|Degarelix 40/40 + 40|In the main study (FE200486 CS02; NCT00819247) loading doses of degarelix 40 mg were given on Days 0 and 3. Maintenance doses of 40 mg were given on days 28, 56, 84, 112 and 140. In the extension study (FE200486 CS02A) the same maintenance dose of degarelix was given once every 4 weeks.
88879543|NCT00245466|Experimental|Degarelix 80 + 20|In the main study (FE200486 CS02; NCT00819247) one loading dose of degarelix 80 mg was given on Days 0. Maintenance doses of 20 mg were given on days 28, 56, 84, 112 and 140. In the extension study (FE200486 CS02A) the same maintenance dose of degarelix was given once every 4 weeks.
88879544|NCT00244764|Experimental|Pazopanib|All patients receive GW786034. At week 12, some subjects will be randomized based on response (SD) and the others will remain on drug. After the interim analysis, the design was changed to an open label, single arm study with all subjects receiving pazopanib.
88879545|NCT00244764|Placebo Comparator|Placebo|All patients receive GW786034. At week 12, some subjects will be randomized based on response (SD) and the others will remain on drug. After the interim analysis, the design was changed to an open label, single arm study with all subjects receiving pazopanib.
88879546|NCT00244374|Experimental|AIC, Hepatitis A & B vaccine|Subjects randomized to a public health department clinic, the Adult Immunization Clinic (AIC), for administration of viral hepatitis immunizations at Month 1, 2, 6.
88879547|NCT00244374|Experimental|AIC, Outreach, Hepatitis A & B vaccine|AIC + outreach: Subjects randomized to a public health department clinic, the Adult Immunization Clinic (AIC)) for administration of viral hepatitis immunizations at Month 1, 2, 6, plus outreach worker adherence support to receive all immunizations
88879548|NCT00244374|Experimental|SEP, Hepatitis A & B vaccine|SEP only: Subjects randomized to a set of syringe exchange programs for administration of viral hepatitis immunizations at Month 1, 2, 6.
88879549|NCT00244374|Experimental|SEP, Outreach, Hepatitis A & B vaccine|Subjects randomized to a set of syringe exchange programs for administration of viral hepatitis immunizations at Month 1, 2, 6, plus outreach worker adherence support to receive all immunizations
88879550|NCT00242658|Experimental|Tailored Physical Activity Intervention Group|Four feedback reports aimed to increase physical activity.
88879551|NCT00242658|No Intervention|No Tailored Physical Activity Intervention Group|General reports on preventive screening based on responses to preventive screening questions.
88879552|NCT00242580|Experimental|Verteporfin and Triamcinolone 1 mg|Participants received Verteporfin photodynamic therapy and 1 mg triamcinolone acetonide intravitreal injection at the baseline visit. After the baseline visit, these participants received Verteporfin and triamcinolone acetonide 1 mg at every 3 month visit up to Month 9 only if leakage was detected on the fluorescein angiogram. At the 1.5, 4.5, 7.5 and 10.5 month follow-up visits participants received a sham injection. Starting from Month 12, if patients experienced ≥ 10 letters vision loss from the previous visit, they were treated at the investigators' discretion with available standard of care therapy.
89004292|NCT05182112|Experimental|Radiation Therapy (RT) and Chemotherapy|Upon enrollment in the study, patients will undergo radiation simulation. Protocol therapy will start upon completion of RT planning (1-2 weeks). Chemoradiation will be initiated 1-2 weeks later depending on RT planning and consist of whole liver irradiation (WLI).
89190111|NCT03669718|Placebo Comparator|Placebo and cemiplimab|Placebo 3 times plus cemiplimab every 3 weeks for up to 24 months
89190112|NCT03668457|Experimental|Intervention to Patients|Only patients receive intervention
89004293|NCT05175248|Experimental|Plant-based Intervention Group|Intervention group participants will adopt a low-fat, plant-based diet for 12 weeks. Participants will be provided with a commercially available supplement containing 100 micrograms of vitamin B12 and asked to take it daily during the study. Alcoholic beverages will be limited to 1 per day. Participants will be asked to keep their physical activity level constant.
89190113|NCT03668457|Experimental|Intervention to Psychiatrists|Psychiatrists receive the intervention. Their associated patients do not receive direct intervention although indirect intervention through professionals
89190114|NCT03668457|Experimental|Mixed Intervention|Patients and Psychiatrists associated with these patients receive intervention
89190115|NCT03668457|Other|Control|Psychiatrists provide the usual care Patients receive usual care
89190116|NCT03649555|Experimental|[18F]-FTC-146|[18F]-FTC-146
89190117|NCT03644966|Experimental|Probiotic + Antibiotic|50 subjects to receive probiotic supplement once daily for 6 months in capsule form, in addition to standard antibiotic regimen for treatment of UTI.
89190118|NCT03644966|Active Comparator|Placebo + Antibiotic|50 subjects to receive placebo once daily for 6 months in capsule form, in addition to antibiotic regimen for treatment of UTI.
89190119|NCT03642990|Experimental|NIAGEN®)|Daily oral administration of nicotinamide riboside 300 mg (150 mg a.m. and p.m.) for one week with dose escalation to 1000 mg (500 mg a.m. and p.m.) for remaining 11 weeks.
89190120|NCT03639311|Experimental|Participants receiving Injection CAB LA plus RPV LA|The eligible participants in the arm (participants from LATTE, who were administered oral CAB 30 mg plus RPV 25 mg, who successfully complete Week 300) will receive their first dose CAB LA (600 mg) plus RPV LA (900 mg) injections within 2 hours of the final oral dose of LATTE given on the same day. The second loading injections will be administered 1 month after initial loading dose (CAB LA 600 mg plus RPV LA 900 mg), with subsequent injections (CAB LA 600 mg + RPV LA 900 mg) occurring Q2M thereafter. Participants will continue to receive the treatment until the study intervention is locally approved and commercially available. HAART therapy will be initiated within 8 weeks after the last Q2M injection.
89190121|NCT03639311|Experimental|Participants receiving Oral DTG plus RPV|The eligible participants in the arm (participants from LATTE, who were administered oral CAB 30 mg plus RPV 25 mg, who successfully complete Week 300) will receive their first dose of the DTG 50 mg plus RPV 25 mg, once daily as oral regimen on Day 1 until Month 12. Participants will continue to receive the treatment until the study intervention is locally approved and commercially available.
89190122|NCT03633825|No Intervention|Control|
89190123|NCT03633825|Experimental|Intervention|
89190124|NCT03630146|Experimental|iPeer2Peer Mentorship|10 sessions of 20-30 minute Skype video calls conducted over 5-12 weeks.
89190125|NCT03630146|Active Comparator|Waitlist Control Group|The control group will receive standard care but without the iPeer2Peer program.
89190126|NCT03608410|Experimental|PRO intervention|Weekly PRO questionnaires Quality of life every 2 months
89190127|NCT03608410|No Intervention|Standard of care|Quality of life every 2 months
89190128|NCT03582475|Experimental|Treatment (pembrolizumab, platinum-based chemotherapy)|Participants receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 3 weeks for 2 years in the absence of disease progression or unacceptable toxicity. Participants also receive standard of care chemotherapy comprising either etoposide IV on days 1-3 and cisplatin IV or carboplatin IV on day 1 (Cohort 1), or etoposide IV on days 1-3, carboplatin IV on day 1, and docetaxel IV on day 1 (Cohort 2). Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
89199054|NCT00761982|Other|bone marrow stem cells|Procedure: Infusion of autologous CD34+ stem cells into middle cerebral artery.
89403705|NCT02445222|Other|Previously treated CAR-T patients|Patients who previously were exposed to lentiviral-based CART cell therapy
89403706|NCT02404402|Experimental|Active LED|Active LED Treatment
89403707|NCT02404402|Sham Comparator|Sham LED|Inactive (sham) LED Treatment
89403708|NCT02369562||Dental implant patients|All patients rehabilitated with dental implants.
89403709|NCT02339909|Active Comparator|Control|"The intervention for the Control group consists of the standard invitation letter from the Screening service. (The trial is testing the impact of the different invitation letters on the primary outcome of screening attendance.)"
89536680|NCT02474147|Active Comparator|Healthy lean controls|Healthy lean controls Interventions: processed meat hamburger and vegan sandwich
89403710|NCT02339909|Experimental|Fixed Incentive|"The intervention for the fixed incentive group consists of the standard invitation letter from the Screening service, with additional text offering a fixed financial incentive (£10) if they attend screening. (The trial is testing the impact of the different invitation letters on the primary outcome of screening attendance.)"
89403711|NCT02339909|Experimental|Probabilistic Incentive|"The intervention for the probabilistic incentive group consists of the standard invitation letter from the Screening service, with additional text offering a probabilistic financial incentive (entry into a lottery offering at least a 1 in 100 chance to win £1000) if they attend screening. (The trial is testing the impact of the different invitation letters on the primary outcome of screening attendance.)"
89403712|NCT02336217|Experimental|Functioning App|These subjects have the complete algorithm functioning and communicated via the App.
89403713|NCT02336217|Placebo Comparator|Non-functioning App|These subjects receive routine instructions via the App but not the complete algorithm.
89403714|NCT02308280|Experimental|Bortezomib post-transplantation|"Non myeloablative allogeneic transplantation followed by Bortezomib for 1 year after a Bortezomib-based induction and autologous stem cell transplantation.~Bortezomib: 1,3 mg/m2 subcutaneously every 2 weeks for 26 injections."
89403715|NCT02256644||Million Veteran Program (MVP) participants|Veterans who are currently enrolled in the Million Veteran Program.
89403716|NCT02210715|Experimental|switch to Isentress|28 subjects will be prescribed Raltegravir at the standard dose of 400 mg p.o. b.i.d. for 24 months.
89403717|NCT02210715|Active Comparator|Continue usual antiretroviral therapy|28 subjects will continue with their normal cART treatment, as prescribed by their treating physician.
89403718|NCT02124421|Active Comparator|CRS with adjuvant IV/IP chemotherapy|Patients undergo cytoreductive surgery (CRS) alone with IV/IP combination adjuvant chemotherapy. Day 1: IV paclitaxel (135 mg/m2), day 2: IP cisplatin (75 mg/m2), and day 8: IP paclitaxel (60 mg/m2) given every 21 days for a total of 6 cycles. Standard of care treatment. Administration of quality of life questionnaires throughout study duration of follow-up
89403719|NCT02124421|Experimental|CRS/HIPEC with adjuvant IV chemotherapy|Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) administered using carboplatin for 90 minutes. Adjuvant systemic IV combination chemotherapy with carboplatin and paclitaxel (Carboplatin AUC 6, Paclitaxel 175mg/m2) will be given every 21 days for a total of 6 cycles. Administration of quality of life questionnaires throughout study duration of follow-up
89403720|NCT02076113|Active Comparator|Ventral|Ventral Decompression with Fusion
89403721|NCT02076113|Active Comparator|Dorsal|Dorsal Decompression with Fusion or Dorsal Laminoplasty
89403722|NCT01989143|Experimental|SAD Cohorts 1-8 Experimental Arm|
89403723|NCT01989143|Placebo Comparator|SAD Cohorts 1-8 Placebo Arm|
89403724|NCT01989143|Experimental|MAD Cohorts 9-11 Experimental Arm|
89403725|NCT01989143|Placebo Comparator|MAD Cohorts 9-11 Placebo Arm|
89403726|NCT01989143|Experimental|MAD Cohort 12 Experimental Arm|
89403727|NCT01989143|Placebo Comparator|MAD Cohort 12 Placebo Arm|
89403728|NCT01927250|Experimental|Okada Health and Wellness program|12,166 Japanese volunteers with/without illness, who were interested in practicing Okada Health and Wellness program for 3 consecutive months.
89403729|NCT01914900|Experimental|induction TPF chemotherapy|Each patient will receive induction CT, consisting of TPF (docetaxel 75 mg/sm and cisplatin 80 mg/sm day 1 and 5 fluorouracil 800 mg/sm each day in continuous infusion day 1-4, according to Paccagnella et al, ASCO 2008) for 3 cycles every 21 days, followed by surgery.
89403730|NCT01703455|Experimental|Sorafenib 400 mg twice daily|Sorafenib 400 mg twice daily, on a continuous basis (each morning and evening), in 4 week cycles
89403731|NCT01599559|Experimental|observation|Follow up visits are scheduled from randomization. Patients will be seen at 3-months intervals for 24 months, then every 6 months until 5 years from randomization.
89403732|NCT01599559|Active Comparator|mediastinal irradiation|Radiotherapy will be delivered in this phase III protocol, as alternative to observation, as consolidation treatment in patients achieving a CR status (PET/CT scan negative) at the end of R-chemotherapy, with a total dose of 30 Gy.
89403733|NCT01586910|Experimental|Medtronic CoreValve® System TAVI|Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)
89403734|NCT01586910|Active Comparator|SAVR|Surgical Aortic Valve Replacement (SAVR)
89403735|NCT01496976|Experimental|Immunotherapy|Combination Regimen Followed by Consolidative Therapy: Ofatumumab/High Dose Methylprednisolone (HDMP) plus Ofatumumab/Lenalidomide
89403736|NCT01438034|Experimental|Kisspeptin, GnRH|Intravenous (IV) administration of kisspeptin 112-121 0.24 nmol/kg and GnRH 75 ng/kg
89403737|NCT01409161|Experimental|Treatment (tretinoin, arsenic trioxide, gemtuzumab ozogamicin)|"INDUCTION: Patients receive tretinoin PO BID, arsenic trioxide IV over 1-2 hours daily, and gemtuzumab ozogamicin IV over 2 hours once at weeks 1-4.~CONSOLIDATION: Patients achieving CR receive arsenic trioxide IV 5 days per week during weeks 1-4, 9-12, 17-20, and 25-28 and tretinoin PO BID for 2 weeks on and 2 weeks off. Treatment repeats every 8 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity."
89403738|NCT01401907|Experimental|Early Palliative Care|Subjects receive standard of care with early palliative care.
88879553|NCT00242580|Experimental|Verteporfin and Triamcinolone 4 mg|Participants received Verteporfin photodynamic therapy and 4 mg triamcinolone acetonide intravitreal injection at the baseline visit. After the baseline visit, these participants received Verteporfin and triamcinolone acetonide 4 mg at every 3 month visit up to Month 9 only if leakage was detected on the fluorescein angiogram. At the 1.5, 4.5, 7.5 and 10.5 month follow-up visits participants received a sham injection. Starting from Month 12, if patients experienced ≥ 10 letters vision loss from the previous visit, they were treated at the investigators' discretion with available standard of care therapy.
88879554|NCT00242580|Active Comparator|Verteporfin and Pegaptanib|Participants received Verteporfin photodynamic therapy and 0.3 mg Pegaptanib at the baseline visit. After the baseline visit, these participants received pegaptanib every 1.5 months up until and including the 10.5 month visit. After the baseline visit, these participants also received verteporfin at every 3 month visit up to Month 9 only if leakage was detected on the fluorescein angiogram. Starting from Month 12, if participants experienced ≥ 10 letters vision loss from the previous visit, they were treated at the investigator's discretion with available standard of care therapy.
89403739|NCT01401907|No Intervention|Standard of Care|Subjects receives standard of care
89403740|NCT01169194||Affected|Patients with IBD
89403741|NCT01169194||Unaffected|Individuals who do not have IBD
89403742|NCT01140516|Active Comparator|Trimethoprim|Prophylactic Antibiotics
89403743|NCT01140516|Placebo Comparator|Simple syrup|2mg/kg,orally until febrile UTI occurs or until completion of the study if the patients do not develop any UTI.
89403744|NCT01138020|Experimental|Arm 1|Cognitive intervention
89403745|NCT01138020|Active Comparator|Arm 2|Educational intervention
89403746|NCT01068210|Experimental|Aerobic Training|A customized and supervised endurance exercise training program that will last 4 months (16 weeks). The regimen will be tailored to the individual fitness level. The exercise program will consist of three supervised sessions per week. During each session, the participant will cycle on a stationary bicycle at moderate intensity for approximately 30-60 minutes.
89403747|NCT01068210|Experimental|Resistance Training|A customized and supervised resistance exercise training program that will last 4 months (16 weeks). Resistance training will be performed on stationary weight machines, modification in equipment may be made by Exercise Physiologist. Patients will be progressively trained to perform two to three sets of 75-85% of maximal strength The participant will be trained to perform different resistance exercise, alternating between lower and upper body muscle groups. The exercise program will consist of three supervised sessions per week. Each session will last approximately 30-60 minutes.
89403748|NCT01068210|Experimental|Combined Aerobic and Resistance Training|A customized and supervised endurance exercise training program that will last 4 months (16 weeks). The regimen will be tailored to the individual fitness level, and will be a combination of Arm A and Arm B, described above. At each session, the participant will complete aerobic training on a stationary bicycle and also resistance training using stationary weight machines. The exercise program will consist of three supervised sessions per week. Each session will last approximately 30-90 minutes.
88879555|NCT00241644|Experimental|Rotarix 3-Dose Group|Subjects received 3 doses of Rotarix™ vaccine given concomitantly with routine EPI vaccines.
88879556|NCT00241644|Experimental|Rotarix 2-Dose Group|Subjects received 1 dose of placebo followed by 2 doses of Rotarix™ vaccine given concomitantly with routine EPI vaccines.
88879557|NCT00241644|Placebo Comparator|Placebo Group|Subjects received 3 doses of placebo given concomitantly with routine EPI vaccines.
88879558|NCT00245622|Experimental|Tovaxin Autologous T cell vaccine|2.0 mL subcutaneous formulated with 30-45 million autologous myelin reactive T cells
88879559|NCT00245622|Placebo Comparator|Placebo|2.0 mL subcutaneous injections without autologous myelin reactive T cells
88879560|NCT03800784|Experimental|18F-DCFPyL Injection|A single dose of 9±1 mCi (333±37 MBq) IV injection of 18F-DCFPyL
88879561|NCT03809754|Experimental|OCT-guided PCI|
88879562|NCT03809754|Sham Comparator|Angiography-guided PCI|
88879563|NCT03809676||heaart transplant recipients|
88879564|NCT03809676||healthy controls|
89535574|NCT03224923|Experimental|Personalized Treatment Algorithm|"A DAPT score using various patient demographics will be calculated:~If score under 2, patients will receive only aspirin 81 mg once daily~If DAPT score is ≥ 2~A point-of-care bedside genetic test using a buccal swab will be conducted in order to determine medication regimen~Those with a positive genetic test (presence of CYP2C19*2 or CYP2C19*3), will receive 60mg Ticagrelor twice daily~Those with a negative genetic test (absence of CYP2C19*2/*3) will receive 75mg clopidogrel once daily"
89535575|NCT03224923|Active Comparator|Long-Term Ticagrelor|Patients will be given 60mg Ticagrelor twice daily with no aspirin
89535576|NCT03321461|Experimental|TMTP1|The TMTP1-ICG (WuXi AppTec, Shanghai, China) powder was diluted in 20 ml of aqueous sterile water to a concentration of 1.0 mg/mL. Then TMTP1-ICG spray was applied thoroughly to the ectocervix for 30 minutes. After cleaned by NS, fluorescent detected sites will be removed.
88879565|NCT03809832||Patients with COPD|Patients established on home non-invasive ventilation for COPD admitted for respiratory review will have a microbiological sampling of the ventilator humidifier
88879566|NCT03809832||Patients with OHS|Patients established on home non-invasive ventilation for obesity hypoventilation syndrome admitted for respiratory review will have a microbiological sampling of the ventilator humidifier
88879567|NCT03808974|Experimental|Intervention|The intervention group will be shown an educational video
88879568|NCT03808974|Active Comparator|Control|The control group will be given an educational leaflet
88879569|NCT03808896|Active Comparator|bougie-assisted intubation|use bougie as guide, intubation with loading endotracheal tube under direct or video laryngoscopy
88879570|NCT03808896|Active Comparator|intubation with epiglottic lifting|Lifting of epiglottis with stylet-equipped endotracheal tube to assist intubation under direct or video laryngoscopy
89535577|NCT03321461|Active Comparator|ICG|The ICG (WuXi AppTec, Shanghai, China) powder was diluted in 20 ml of aqueous sterile water to a concentration of 1.0 mg/mL. ICG spray was applied thoroughly to the ectocervix for 30 minutes. After cleaned by NS, fluorescent detected sites will be removed.
88879571|NCT03808896|No Intervention|Traditional intubation|intubation under direct or video laryngoscopy without epiglottis lifting nor bougie-assited
88879572|NCT03809130|Experimental|Arm I (Untire application)|Patients use Untire application intervention after baseline up to 6 months.
88879573|NCT03809130|Active Comparator|Arm II (Untire application)|Patients use Untire application intervention after 3 months up to 6 months.
88879574|NCT03808428|Experimental|Ankle Group|Integrated with force and motion sensors to identify gait phase and classify user walking intention using machine learning control algorithm.
88879575|NCT03808116|Experimental|SmartBx biopsy collection|"Biopsy cores will be collected from the breast during US guided biopsy procedure.~The number of cores taken will be decided per the physician discretion according to the clinical demand.~Additional two biopsy core will be taken the SmartBx cassette"
88879576|NCT03808038||No Diary Group|Group completed daily questionnaires for four weeks, a weekly questionnaire at the end of each week, and a monthly questionnaire at the end of the study
88879577|NCT03808038||Diary Start Group|Group completed bladder diaries in week 1, daily questionnaires in week 1, a weekly questionnaire at the end of each week, and a monthly questionnaire at the end of the study
89535578|NCT05004753|Experimental|Artemisinin 500mg|The dose regimen will be in cycles. In a cycle a subject will receive Artemisinin 500 mg capsule once daily plus SOC on Day 1 to Day 5 followed by 5 days off (no dosing of Artemisinin) or SOC alone. A subject can have a total of consecutive 3 cycles maximum. Here SOC is Standard of Care as per CLINICAL MANAGEMENT PROTOCOL: COVID-19, Government of India Ministry of Health and Family Welfare Directorate General of Health Services (EMR Division)
89535579|NCT05004753|Active Comparator|Standard of Care|Standard of Care as per CLINICAL MANAGEMENT PROTOCOL: COVID-19, Government of India Ministry of Health and Family Welfare Directorate General of Health Services (EMR Division) Mild Patients: HYDROXYCHLOROQUINE Moderate Patients: Dexamethasone - OD for 05
89535580|NCT02486471|Other|Observational approach|Wait and see
89535581|NCT02486471|Active Comparator|Use of Monsel´s Paste|cervical coagulation using a hemostatic agents, ie monsel´s paste
88879578|NCT03808038||Daily Start Group|Group completed daily questionnaires in week 1, bladder diaries in week 2, a weekly questionnaire at the end of each week, and a monthly questionnaire at the end of the study
88879579|NCT03807960|Experimental|visual|The video about patient controlled analgesia device (PCA) usage will shown to the patients via notebook.
88879580|NCT03807960|Experimental|written|The written form which include the same knowledge will give to the patient for reading.
88879581|NCT03807960|Other|control|The anesthesiologist will describe the PCA usage as in the routine care to the control group patients.
89403749|NCT01068210|Active Comparator|Progressive Stretching Group (Attention-Control)|A customized and supervised progressive stretching program that will last 4 months (16 weeks). The progressive stretching program will consist of a series of stretching exercises alternating between lower and upper body muscle groups/joints. This program will consist of three exercise sessions a week. Each session will last approximately 30-60 minutes.
89403750|NCT00984399|Experimental|vaginal 17β-estradiol, questionnaire , symptom checklist|This is a prospective longitudinal pilot study, and the targeted patient population is postmenopausal women with breast cancer being treated with adjuvant aromatase inhibitors who are initiated on vaginal 17β-estradiol to relieve symptoms of atrophic vaginitis.
89199055|NCT04049448|Experimental|ABX464 50 mg|All subjects will receive ABX464 administered at 50 mg o.d for an overall period of 2 years (104 weeks)
89403751|NCT02915016|Experimental|Group 1: DNA-HIV-PT123 + Placebo + Protein/MF59|Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/MF59 vaccine in their right deltoid at Months 3 and 6.
89403752|NCT02915016|Experimental|Group 2: DNA-HIV-PT123 + Placebo + Protein/AS01B|Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/AS01B vaccine in their right deltoid at Months 3 and 6.
88813479|NCT01574807|Experimental|mepivacaine + lidocaine followed by lidocaine + lidocaine|A repeated measures design utilizing a single group of subjects was employed with each subject serving as his/her own control. Each subject received two interventions: 1.) 1.8 cc 3% mepivacaine and 1.8 cc 2% lidocaine with 1:100,000 epinephrine (3% mepivacaine/2% lidocaine with epinephrine - combination 1) and 2.) 1.8 cc 2% lidocaine with 1:100,000 epinephrine followed by 1.8 cc 2% liocaine with 1:100,000 epinephrine at two seperate appointments spaced 2 weeks apart.
88813480|NCT01574807|Experimental|lidocaine + lidocaine followed by mepivacaine plus lidocaine|A repeated measures design utilizing a single group of subjects was employed with each subject serving as his/her own control. Each subject received two interventions: 1.) 1.8 cc 2% lidocaine with 1:100,000 epinephrine and 1.8 cc 2% lidocaine with 1:100,000 epinephrine and 2.) 1.8 cc 3% mepivacaine and 1.8 cc 2% lidocaine with 1:100,000 epinephrine followed by 1.8 cc 2% liocaine with 1:100,000 epinephrine at two separate appointments spaced two weeks apart.
88813481|NCT01722500||10 year old children|500 children with mean age 10.5 years from each of 12 countries
88813482|NCT01575275|Experimental|Diagnostic (aminolevulinic acid)|Patients receive aminolevulinic acid PO 2-4 hours before surgery.
88813483|NCT03408158|No Intervention|HPA antigen and antibodies|Investigate the positive rate of HPA antibodies, the distribution and the specificity of HPA antigen and antibodies in Chinese blood disease patients.
89403753|NCT02915016|Experimental|Group 3: DNA-HIV-PT123 + Placebo + Protein/AS01B|Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/AS01B vaccine in their right deltoid at Months 3 and 6.
88813484|NCT03408158|No Intervention|necessity of HPA antibodies screening|Investigate the connection between times of platelet transplantation and HPA antibody titer, which providing statistical data for evaluating the necessity and setting screening time and standards of HPA antibodies screening.
89190129|NCT03579784|Experimental|Durvalumab+Olaparib+Paclitaxel|"st cycle : Paclitaxel+Olaparib~Olaparib 150mg bid on D1-28~Paclitaxel 80 mg/m2 mg iv on D1, D8, D15~nd cycle and thereafter: Durvalumab+Olaparib+Paclitaxel :~Olaparib 150mg bid on D1-28~Durvalumab 1.5 g iv on D1~Paclitaxel 80 mg/m2 mg iv on D1, D8, D15 Every 4 weeks~During first 4 weeks, palictaxel/olaparib dual combination will be used. Since 2nd cycle, palictaxel/olaparib/Durvalumab combination will be used."
89004294|NCT05175248|No Intervention|Control Group|Control group participants will be asked to maintain their usual diet for the duration of the 12-week study period. Participants will be provided with a commercially available supplement containing 100 micrograms of vitamin B12 and asked to take it daily during the study. Alcoholic beverages will be limited to 1 per day. Participants will be asked to keep their physical activity level constant. At the conclusion of the 12 weeks, control group participants will be offered instruction in the plant-based diet.
89004295|NCT05166213||Chronic back pain|
89004296|NCT05166213||Clinically significant menopausal complaints|
89004297|NCT05166213||Parkinson's disease|
89004298|NCT05166213||Migraine|
89004299|NCT05166213||Cancer-related emesis/nausea|
89004300|NCT05162053|Experimental|Ultra-rapid metabolizers group|A 7-day cross-dosing of vicagrel and clopidogrel between two cycles
89004301|NCT05162053|Experimental|Rapid metabolizers group|A 7-day cross-dosing of vicagrel and clopidogrel between two cycles
89004302|NCT05162053|Experimental|Normal metabolizers group|A 7-day cross-dosing of vicagrel and clopidogrel between two cycles
89004303|NCT05162053|Experimental|Intermediate metabolizers group|A 7-day cross-dosing of vicagrel and clopidogrel between two cycles
89004304|NCT05162053|Experimental|Poor metabolizers group|A 7-day cross-dosing of vicagrel and clopidogrel between two cycles
89004305|NCT05149898|Experimental|Open-label|Open-label
89004306|NCT05138341|Experimental|Mechanical Minimal Invasive Surgical (MIS) management|Minimally invasive hematoma evacuation with the Artemis Neuro Evacuation Device with medical management
89004307|NCT05138341|No Intervention|Best Medical Management (MM)|Best medical management per standard of care
89004308|NCT05125380|Active Comparator|1- Triage arm for HPV pos women|HPV positive women
89004309|NCT05125380|Experimental|2- Triage arm for HPV pos women|HPV positive women
89004310|NCT05110443|Other|Main arm|Patients will perform a D-WB PET/CT scan as a substitute for their clinical PET.
89004311|NCT05109494|Active Comparator|Conventional Fractionated|radiation treatments will be delivered daily, delivered over a maximum of 7 weeks from the first treatment, surgery will be within 5-14 days of completion of RT
89199056|NCT02303028|Experimental|Topotecan and Pazopanib|Low dose Topotecan will be given metronomically in combination with Pazopanib at the dose level assigned at study entry
89004312|NCT05109494|Experimental|Hypofractionated|the maximum frequency of treatment will be every day and the minimum frequency will be every other day, delivered over a maximum of 3 weeks from the first treatment, surgery will be within 5-14 days of completion of RT
89004313|NCT05087680|Active Comparator|Control Group|Control group will include one 30-minute PrEP education session.
89004314|NCT05087680|Experimental|ACTPrEP|ACTPrEP will include a 60-minute initial session and 30-minute sessions at 2, 6, and 12 weeks.
89190130|NCT03571984|Experimental|Moving on ABC Plus|Moving on ABC Plus is combination of two interventions. The culturally adapted CBT and Moving on ABC. CBT will be integrated with The Moving on After Breast Cancer (ABC), which has been developed by Dr Anneela Saleem who suffered from breast cancer. The integrated intervention will consist of 12 sessions (60-90 minutes). The first 8 sessions will be delivered weekly and the last four sessions will be delivered fortnightly
88921965|NCT06014125|Experimental|psychoeducation program group|In addition to the usual treatment, the experimental group will receive a tele-education programme on depression in 5 individual remote sessions. During these sessions, the symptoms of the illness will be discussed, as well as health and diet measures, the destigmatisation of the illness, mobilisation of family and friends, the various treatments for depression and, finally, an assessment of what has been learned, which will be sent to the general practitioner with the patient's agreement.
89190131|NCT03571984|No Intervention|Routine Care|This will consist of routine assessment and management as usually conducted by oncology clinics and general practice. GP's will be informed about the psychiatric diagnosis.
89190132|NCT03564171|No Intervention|Standard of Care|Patients will receive standard treatment without added intervention.
89190133|NCT03564171|Experimental|Intervention|"These patients will receive standard treatment plus multimodal intervention (prehabilitation program) including :~exercise, nutritional counseling, stress counseling, smoking cessation) before starting chemotherapy."
89190134|NCT03553563|Experimental|Group1|Initial healing phase (8 weeks), D961H 10 mg once-daily; Maintenance phase (24 or 44 weeks), D961H 10 mg once-daily
89190135|NCT03553563|Experimental|Group2|Initial healing phase (8 weeks), D961H 20 mg once-daily; Maintenance phase (24 or 44 weeks) starts with D961H 10 mg once-daily and may be increased to 20 mg once-daily based on investigator's discretion
89190136|NCT03553563|Experimental|Group3|D961H 10 mg once-daily (32 or 52 weeks)
89190137|NCT03553563|Experimental|Group4|D961H starts with 10 mg once-daily, and may be increased to 20 mg once-daily based on investigator's discretion (32 or 52 weeks)
89199057|NCT00884091||Healthy Adults|"Chinese in origin~Healthy~No medication at least two weeks before the study"
89199058|NCT02287818|Placebo Comparator|Placebo|Placebo plus Febuxostat
89403754|NCT02915016|Experimental|Group 4: DNA-HIV-PT123 + Placebo + Protein/MF59|Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/MF59 vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.
89190138|NCT06063733|Experimental|Digital PLB intervention|"Participants will perform the following tasks during the intervention:~Register a personal account on the theory-based pursed lip breathing intervention protocol software system installed on smartphones(DT-PLB).~Acquire knowledge and skills related to pursed lip breathing by watching instructional videos.~Practice Pursed Lip Breathing for 10 minutes per session, three times daily for eight weeks, as per reminders and guidance provided by the software.~Earn health points by completing specific actions as instructed.~Optionally post individual texts on the peer forum for peer support within the DT-PLB software.~Complete two outcome assessments as scheduled."
89190139|NCT06063655|Experimental|Water, Hydration Multiplier, Sugar-Free|"Subjects will undergo three 90-min cycling bouts at 70-80% maximal hear rate, 86-89 degrees Fahrenheit, and approximately 50% relative humidity spaced 1-2 weeks apart. Subjects will be provided with a different test drink after each cycling bout at an amount equivalent to150% of sweat losses and evaluated for rehydration.~Subjects randomly assigned to this arm will be provided with the experimental/placebo conditions in the following order: water, Liquid IV Hydration Multiplier, and Liquid IV Sugar-Free Hydration Multiplier."
89190140|NCT06063655|Experimental|Water, Sugar-Free, Hydration Multiplier|"Subjects will undergo three 90-min cycling bouts at 70-80% maximal hear rate, 86-89 degrees Fahrenheit, and approximately 50% relative humidity spaced 1-2 weeks apart. Subjects will be provided with a different test drink after each cycling bout at an amount equivalent to150% of sweat losses and evaluated for rehydration.~Subjects randomly assigned to this arm will be provided with the experimental/placebo conditions in the following order: water, Liquid IV Sugar-Free Hydration Multiplier, and Liquid IV Hydration Multiplier."
89190141|NCT06063655|Experimental|Hydration Multiplier, Sugar-Free, Water|"Subjects will undergo three 90-min cycling bouts at 70-80% maximal hear rate, 86-89 degrees Fahrenheit, and approximately 50% relative humidity spaced 1-2 weeks apart. Subjects will be provided with a different test drink after each cycling bout at an amount equivalent to150% of sweat losses and evaluated for rehydration.~Subjects randomly assigned to this arm will be provided with the experimental/placebo conditions in the following order: Liquid IV Hydration Multiplier, Liquid IV Sugar-Free Hydration Multiplier, and water."
89190142|NCT06063655|Experimental|Hydration Multiplier, Water, Sugar-Free|"Subjects will undergo three 90-min cycling bouts at 70-80% maximal hear rate, 86-89 degrees Fahrenheit, and approximately 50% relative humidity spaced 1-2 weeks apart. Subjects will be provided with a different test drink after each cycling bout at an amount equivalent to150% of sweat losses and evaluated for rehydration.~Subjects randomly assigned to this arm will be provided with the experimental/placebo conditions in the following order: Liquid IV Hydration Multiplier, water, and Liquid IV Sugar-Free Hydration Multiplier."
89190143|NCT06063655|Experimental|Sugar-Free, Water, Hydration Multiplier|"Subjects will undergo three 90-min cycling bouts at 70-80% maximal hear rate, 86-89 degrees Fahrenheit, and approximately 50% relative humidity spaced 1-2 weeks apart. Subjects will be provided with a different test drink after each cycling bout at an amount equivalent to150% of sweat losses and evaluated for rehydration.~Subjects randomly assigned to this arm will be provided with the experimental/placebo conditions in the following order: Liquid IV Sugar-Free Hydration Multiplier, water, and Liquid IV Hydration Multiplier."
89199059|NCT02287818|Experimental|AC-201|AC-201 CR tablet plus Febuxostat
89199060|NCT02542449|Active Comparator|Globes®|Partecipants received twice a day for 3 months Globes® (Pharmextracta, Pontenure, Piacenza, Italy) formulated to be enteric-coated and containing 150 mg/dose of Greenselect Phytosome® and pure piperine (15 mg/dose) from Piper nigrum L.
88879582|NCT03807726|Experimental|Intervention Group|Both standard usual care and the integrated breastfeeding education program (IBEP) will be provided to the participants in the intervention group. The integrated interventions are consisted of 1) four sessions of simulation breastfeeding education to build up the participants' performance accomplishment and vicarious learning including breastfeeding knowledge, skill, and self-efficacy; 2) two sessions of breastfeeding mindfulness training to equip women and their partners with stress reduction skills for their emotional arousal during breastfeeding; 3) a series of postpartum professional support to offer verbal persuasion in enhancing their breastfeeding skills and levels of self-efficacy. The details of each education components are presented at the following section.
88879583|NCT03807726|No Intervention|Control Group|The mother and her partner in the control group will receive the standard usual care provided at the study site. The study site hospital where follows the 10 steps of the Baby Friendly Hospital Initiative will provide breastfeeding care during prenatal check-up and postpartum care. The standard care protocols encompass elements such as prenatal breastfeeding consultation using breastfeeding pamphlets, and postpartum care like skin to skin contact, rooming- in, and breastfeeding consultation using pamphlets. The pregnant women need to register for childbirth class which contains only one breastfeeding class by themselves if needed. After delivery, the mothers are taught on breastfeeding knowledge and skills by the nurses at the postpartum ward or nursey.
88879584|NCT03807570|Experimental|Morus Alba L. extract|Morus Alba L. extract 30 ml/day for 12 weeks
88879585|NCT03807570|Placebo Comparator|Placebo|Placebo 30 ml/day for 12 weeks
88879586|NCT03807258|Experimental|COPD patients group|COPD patients undergoing transcranial magnetic stimulation (TMS) evaluations.
88879587|NCT03807258|Active Comparator|Controls group|Healthy matched controls undergoing transcranial magnetic stimulation (TMS) evaluations.
88879588|NCT03807180|Other|Group of Tai Chi|Group of Tai Chi intervention include 18 patients with AS. Tai Chi exercise method, which is composed of combination of physical exercise and relaxation techniques, will be applied by an experienced physiotherapist who is trained with Tai Chi. The training will take 60 minutes, 2 days a week and 10 weeks in total.
88879589|NCT03807180|No Intervention|Group of control|Conventional exercises are stretching for the cervical, thoracic and lumbar flexibility, shoulder circumference, hamstring and erector spinal muscles, strengthening exercises for abdominal, back and proximal muscles. The exercises that will be taught in detail to each stage of the patient will be performed at home by the patient for 60 minutes, 2 days a week. The patients will be inspected and controlled by monthly controls.
88879590|NCT03806712||patient|patient with advanced, non curative hematological malignancies multi method questionary, at least 1 hour per patient
89190144|NCT06063655|Experimental|Sugar-Free, Hydration Multiplier, Water|"Subjects will undergo three 90-min cycling bouts at 70-80% maximal hear rate, 86-89 degrees Fahrenheit, and approximately 50% relative humidity spaced 1-2 weeks apart. Subjects will be provided with a different test drink after each cycling bout at an amount equivalent to150% of sweat losses and evaluated for rehydration.~Subjects randomly assigned to this arm will be provided with the experimental/placebo conditions in the following order: Liquid IV Sugar-Free Hydration Multiplier, Liquid IV Hydration Multiplier, and water."
88879591|NCT03806712||hematologist|medical practitioner of platelet transfusion multi method questionary, at least 1 hour per hematologist
88879592|NCT03806712||Nurses|nurses working in hematology, practicing platelet transfusion multi method questionary, at least 1 hour per nurse
88879593|NCT03807024||OAB-wet|The diagnosis of OAB in each patient was based on the presence of at least one episode of urgency in her three-day bladder diary and with the absence of stress urinary incontinence. The presence of at least one episode of urgency associated incontinence was defined to be OAB-wet.
88879594|NCT03807024||OAB-dry|The diagnosis of OAB in each patient was based on the presence of at least one episode of urgency in her three-day bladder diary and with the absence of stress urinary incontinence. The absence of urgency associated incontinence was defined to be OAB-dry.
88879595|NCT03806868|Active Comparator|Intervention group|The Intervention group will receive a voucher for ordering foods (ONLY omega-3 rich foods) weekly (4 times).
88879596|NCT03806868|Sham Comparator|Control group|The Control group will receive a voucher for ordering foods in general (any type of foods) weekly (4 times). Participants will NOT be limited to purchasing foods rich in omega-3.
89190145|NCT06063616|Experimental|Reiki group|Level I Reiki was applied to 9 points and nearby areas for 30 minutes, three sessions a week, for a total of four weeks, in the first three hours of the HD treatment, by the researcher who completed his second level training according to the Usui method, in line with the Reiki/Sham Reiki Application Protocol.
89403755|NCT02915016|Experimental|Group 5: DNA-HIV-PT123 + Placebo + Protein/AS01B|Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.
89403756|NCT02915016|Experimental|Group 6: DNA-HIV-PT123 + Placebo + Protein/AS01B|Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.
89403757|NCT02915016|Experimental|Group 7: Placebo + Protein/AS01B|Participants will receive placebo in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.
89403758|NCT02915016|Placebo Comparator|Group 8: Placebo|Participants will receive placebo in both their right and left deltoids at Months 0, 1, 3, and 6.
89403759|NCT03859414|Active Comparator|Therapeutic Dose 1|Single dose administration of CHF 5993 100/6/12.5 µg pMDI 2 inhalations. Total dose of CHF 5993 pMDI = 200/12/25 µg
89403760|NCT03859414|Active Comparator|Therapeutic Dose 2|Single dose administration of CHF 5993 200/6/12.5 µg pMDI 2 inhalations. Total dose of CHF 5993 pMDI = 400/12/25 µg
89403761|NCT03859414|Active Comparator|Supra-therapeutic Dose|Single dose administration of CHF 5993 100/6/12.5 µg pMDI 8 inhalations Total dose of CHF 5993 pMDI = 800/48/100 µg
89403762|NCT03859414|Placebo Comparator|Placebo|Single dose administration of CHF 5993 pMDI placebo
89403763|NCT05095324||control|the infection patients who didn't have organ failure according to the SOFA score: 1. respiratory system: PaO2/FiO2≥<400 mmHg; 2. MAP≥70mmHg; 3. Liver: Bilirubin<1.2mg/dL; 4. Renal system: Creatinine<1.2mg/dL or Urine output≥500ml/d; 5. Platelets≥150×10^9/L; 6. nervous system:Glasgow coma score=15.
89403764|NCT05095324||organ failure|the patients who had sepsis in follow up period: 1. respiratory system:PaO2/FiO2<400mmHg; 2. Circulation: MAP<70mmHg or administration of vasopressors required; 3. Liver: Bilirubin≥1.2mg/dL; 4. Renal system: Creatinine≥1.2mg/dL or Urine output<500ml/d; 5. Coagulation: Platelets<150×10^9/L; 6. nervous system: Glasgow coma score <15.
89403765|NCT01170650|Experimental|Arm A|EC145 + Pegylated Liposomal Doxorubicin (PLD)
89403766|NCT01170650|Active Comparator|Arm B|placebo + Pegylated Liposomal Doxorubicin (PLD)
89403767|NCT01168310|Experimental|1|
89403768|NCT01168310|Experimental|2|
89403769|NCT01168310|Experimental|3|
89403770|NCT01168310|Experimental|4|
89403771|NCT01168310|Experimental|5|
89403772|NCT01168310|Active Comparator|6|
89403773|NCT01168310|Placebo Comparator|7|
89403774|NCT04464928||User interests|Facebook advertisements arm
89403775|NCT04464928||User characteristics|Google advertisements arm
89403776|NCT01472198|Experimental|Simtuzumab (open-label)|Participants will receive simtuzumab 700 mg plus gemcitabine in cycles of 28 days for up to 3 years.
88879597|NCT03806478|Experimental|0.5 µg|Intranasal (IN) nanoparticles - 0.5 micrograms. The study is planned to include 1 dose of APH 1105 / 0.5 µg, administered twice a week for 12 weeks, for a total of 24 doses.
88879598|NCT03806478|Experimental|1.0 µg|Intranasal (IN) nanoparticles - 1.0 micrograms. The study is planned to include 1 dose of APH 1105 / 1.0 µg, administered twice a week for 12 weeks, for a total of 24 doses.
89190146|NCT06063616|Sham Comparator|Sham Reiki group|Sham Reiki was applied to 9 points and nearby areas in accordance with the Reiki/Sham Reiki Application Protocol, for a total of four weeks, three sessions per week, for 30 minutes, in the first three hours of the HD treatment, by two students who had not received Reiki training, and were given training on the application by the researcher.
89190147|NCT06063564|Active Comparator|Wait-List Control|Complete questionnaires at baseline (administered electronically or by mail). Follow-up measures will be administered immediately following their clinic visit and at 6-months after the clinic visit electronically and by mail. A PREVENT action plan (behavior change prescription, community resources, and education) will be provided to the patient via email after the completion of the follow-up measurement.
89199061|NCT02542449|Placebo Comparator|Placebo|Partecipants received twice a day for 3 months placebo (undistinguishable from Globes in terms of size, shape, taste, odor, primary and secondary packaging).
89199062|NCT00762060||Active|Surgical site continuous local anesthetic infusion with ONQ silver Soaker System
89403777|NCT01472198|Experimental|Simtuzumab 200 mg (randomized)|Participants will receive simtuzumab 200 mg plus gemcitabine in cycles of 28 days for up to 3 years.
89403778|NCT01472198|Experimental|Simtuzumab 700 mg (randomized)|Participants will receive simtuzumab 700 mg plus gemcitabine in cycles of 28 days for up to 3 years.
89403779|NCT01472198|Placebo Comparator|Placebo (randomized)|Participants will receive placebo to match simtuzumab plus gemcitabine in cycles of 28 days for up to 3 years.
89403780|NCT02087982||Seniors|"The study will be based on a 6-months assessment period, with two consecutive monitoring visits on enrollment.~Patient follow-up after 3 months will be conducted by telephone and monitoring after 6 months will be carried out as part of a routine consultation.~Each subject will have a BGA (Brief Geriatric assesment)."
88879599|NCT03806478|Experimental|2.0 µg|Intranasal (IN) nanoparticles - 2.0 micrograms. The study is planned to include 1 dose of APH 1105 / 2.0 µg, administered twice a week for 12 weeks, for a total of 24 doses.
88879600|NCT03806478|Placebo Comparator|Placebo|Intranasal (IN) Placebo nanoparticles. The study is planned to include 1 dose of placebo drug administered twice a week for 12 weeks, for a total of 24 doses.
88879601|NCT03806088||patients of chronic kidney disease|no interventions
88879602|NCT03806010||Quantitative sensory testing|QST will be performed at baseline two weeks and 2 months
88879603|NCT03805776|Experimental|Interventional|Will observe intermittent fasting
88879604|NCT03805776|No Intervention|Control|
88879605|NCT03805620|Active Comparator|Phys Group|physical training group
88879606|NCT03805620|Active Comparator|Cog Group|cognitive training group
88879607|NCT03805620|Experimental|Phys-Cog Group|combined physical-cognitive training group
88879608|NCT03805620|No Intervention|Con Group|educational control group
88879609|NCT03805542|No Intervention|Control group|I-stage nephrostomy（Double J stent placement under cystoscopy） and II-stage operation
88879610|NCT03805542|Experimental|I-stage operation group|Disinfection of pelvis with 0.5% iodophors
89403781|NCT04575610|Experimental|PF-06650833 + Standard of Care|Subjects randomized to the PF-06650833 arm of the study will receive 200 mg IR suspension formulation every 6 hours (via nasogastric [NG] tube, orogastric [OG] tube, or equivalent) if unable to take tablets by mouth (PO). All dosing of PF-06650833 will be in addition to current hospital SOC therapy.
89403782|NCT04575610|Active Comparator|Placebo + Standard of Care|Matching placebo tablets will be administered.
89403783|NCT02269358|Experimental|Addition of methotrexate|Addition SC methotrexate at 15 mg/m2, not to exceed 25 mg/m2 . Patients in remission after 4 weeks will reduce their dose by halve. patients not in remission will continue the full dose until 12 weeks.
89403784|NCT04504240|Experimental|Group A: FAMOTIDINE treatment group|FAMOTIDINE 40mg to 60mg 8hourly in an empty stomach along with other treatments.
89403785|NCT04504240|Active Comparator|Group B: Control group|Treatment as given with a PPI.
89403786|NCT04464304|Active Comparator|Virtual Reality|Patients will be provided with a commercially-available VR device for use up to 15 minutes at bedside.
89403787|NCT04464304|Sham Comparator|Smartphone|Patients will be provided with a commercially-available smartphone device for use up to 15 minutes at bedside.
89403788|NCT02269436|Experimental|sNN0029 infusion solution|
89403789|NCT02264522|Experimental|Single Arm|"All patients will be enrolled in the same intervention arm. Interventions are implemented based in 1-4 event levels on the device. Interventions include: Place dialysis chair into position 3, Decrease dialysate temperature, Decrease ultrafiltration rate by 25%, and Decrease ultrafiltration rate by 50%."
89403790|NCT02084316|Experimental|One4All|Participants with HIV-positive screening results on EIA will immediately have their blood drawn for CD4 and VL tests. Participants will receive post-screening test counseling. Two venous blood samples will be collected-one for immediate numeration of CD4 T-lymphocytes in the same hospital lave using PIMA POC CD4 analyzer and the other for later VL testing at the province CDC which takes 10-15 days. Participant will be notified in person of their CD4 results on the same day and provided post-CD4 test counseling. Counseling in the One4all intervention has been modified from the national SOC guidelines due to the different order of tests and the shortened time period between screening and CD4 testing. The participant will be provided with a tentative assessment of ART eligibility based on CD4 results and other factors. Those who are eligible for ART are encouraged to seek HIV care at the study hospitals via China's National Free ART program.
89403791|NCT02084316|Active Comparator|Standard of Care|"The control condition is the current standard of care (SOC) utilized within the county hospitals in Guangxi China. This SOC has some variability between counties but in general follows the national policies. After the initial positive screening on EIA and subsequent repeat screening, participants will receive post-screening test counseling. Participants will then be tested by WB either at the same visit or a subsequent visit. The WB is sent offsite.~After WB test results are reported to the hospital, the health care provider will contact the participant by phone. The participant will be asked to return to the hospital for results and post-WB test counseling. At this visit, a blood sample will be collected for CD4 testing, and an initial epidemiological investigation will be carried out.~Once CD4 test results are available, participants must be located again to inform them of their results and ART eligibility and to provide post-CD4 test counseling."
89403792|NCT02269514|Active Comparator|Own Brand Cigarette|Own Brand Cigarette
89403793|NCT02269514|Experimental|Electronic Cigarette #1|VUSE® (original flavor, 14mg nicotine)
89403794|NCT02269514|Experimental|Electronic Cigarette #2|VUSE® (original flavor, 29mg nicotine)
89403795|NCT02269514|Experimental|Electronic Cigarette #3|VUSE® (original flavor, 36mg nicotine)
89403796|NCT02269514|Active Comparator|Leading U.S. Nicotine Gum|Leading U.S. Nicotine Gum
89403797|NCT03465982|Active Comparator|Standard Interval Time Arm|Minimally invasive surgery after 8 weeks from chemoradiation treatment
88879611|NCT03805152|Active Comparator|Neuronox(R) intramuscular injection|Neu-botulinum Toxin Type A (Neuronox(R) - botulinum toxin type A product by medyceles company , Korea) 50 units Intramuscular injection in the affected neck muscle that cause cervical dystonia every 12 weeks for 24 weeks ( 2 times , 12 week interval)
88879612|NCT03805152|Active Comparator|Dysport (R) intramuscular injection|Abo-botulinum Toxin Type A (Dysport (R) - botulinum toxin type A product by IPEN company, France ) 250 unit Intramuscular Injection in the affected neck muscle that cause cervical dystonia every 12 weeks for 24 weeks (2 times , 12 week interval)
88879613|NCT03804840|Placebo Comparator|Placebo|
88879614|NCT03804840|Active Comparator|7.5 mg THC|
88879615|NCT03804840|Active Comparator|15 mg THC|
88879616|NCT03804762|Experimental|patients received treatment of TS-RECS|
88879617|NCT03804450|Experimental|Test group|The root canals were instrumented using Pro-taper next rotary files till size X3. REPs via blood clot using calcium hydroxide were then applied
88879618|NCT03804450|Experimental|Control group|The root canals were instrumented using Pro-taper next rotary files till size X5. REPs via blood clot using calcium hydroxide were then applied.
89199063|NCT00762060||Control|Hospital standard of care for pain management (Patient controlled analgesia or epidural)
89403798|NCT03465982|Active Comparator|Delayed Interval Time Arm|Minimally invasive surgery after 12 weeks from chemoradiation treatment
89403799|NCT02084394||no intervention|Contact with enrolled subjects requires application of ceberal oximetry electrodes and the concommittent ultrasound of the temporal artery. Deemed interventional by JHUIRB but no actual intervention done to subject.
89403800|NCT01332812|Experimental|Dexamethasone, POCD, psycological tests|"Subjects will be randomly assigned in two groups: For the Dexamethasone group, 8mg of dexamethasone will be administered intravenously before the induction of general anesthesia. For Control Group, no Dexamethasone will be administered.~Tests for evaluation of quality of life, depressive symptoms and neuropsychological battery to assess general mental status, learning, attention, visuospatial perception, immediate memory, operational and executive skills and recall, including processing speed. This assessment will be applied before surgery, and 3, 7, 21, 90 and 180 days after surgery."
89403801|NCT01332812|Sham Comparator|Control, POCD, psycological tests|"Subjects will be randomly assigned in two groups: For the Dexamethasone group, 8mg of dexamethasone will be administered intravenously before the induction of general anesthesia. For Control Group, no Dexamethasone will be administered.~Tests for evaluation of quality of life, depressive symptoms and neuropsychological battery to assess general mental status, learning, attention, visuospatial perception, immediate memory, operational and executive skills and recall, including processing speed. This assessment will be applied before surgery, and 3, 7, 21, 90 and 180 days after surgery."
89403802|NCT02079792|Active Comparator|Lying Head Back Position|Subjects randomized to the LHB position will be instructed to lay supine on the clinical table, with their head hanging over the edge of the bed as far as possible without discomfort. Subjects will be instructed to administer budesonide 1mg/2cc nebules daily for 12 weeks using the MAD syringe, in the head position to which they were randomized.
89403803|NCT02079792|Experimental|Head Down and Forward Position|Subjects randomized to the HDF position will be instructed to kneel down, placing the top of their head on the ground and forehead close to the knees with the nostrils facing upwards. Subjects will be instructed to administer budesonide 1mg/2cc nebules daily for 12 weeks using the MAD syringe, in the head position to which they were randomized.
89403804|NCT03408652|Experimental|Arm A|bone targeted treatment (denosumab or zoledronic acid)
89403805|NCT03408652|No Intervention|Arm B|no specific treatment
89403806|NCT01332656|Experimental|Arm A|Ombrabulin, Paclitaxel and Carboplatin
89403807|NCT01332656|Placebo Comparator|Arm B|Placebo, Paclitaxel and Carboplatin
89403808|NCT02084472|Active Comparator|study 1: aqueous cream and baby oil|enrolled patients in this arm use either aqueous cream or baby oil as a soap substitute
89004315|NCT05073458|Experimental|Group A: Parsaclisib|Participants will receive parsaclisib for 24 weeks (double-blind period). Participant who completed the double-blind period and tolerating the study treatment upon investigator's opinion will continue into open-label period for an additional 24 weeks. Participants may then continue to receive parsaclisib in a long-term extension period.
89004316|NCT05073458|Placebo Comparator|Group B: Placebo followed by Parsaclisib|Participants will receive placebo for 24 weeks (double-blind period). Participants who completed the double-blind period will receive parsaclisib in the 24 week open-label period. Participants may then continue to receive parsaclisib in a long-term extension period.
89199064|NCT00886041|Other|laparoscopy group|laparoscopy
89403809|NCT02084472|Active Comparator|study 2: emulsifying ointment and cetomacrogol|patients in this study arm continue to use emulsifying ointment and cetomacrogol as a moisturiser, the current standard of care in our institution
89004317|NCT05056831|Experimental|Group I (physical activity intervention)|Patients attend face-to-face mind-body sessions focused on stretching, breathing, and relaxation twice a week and receive targeted text messages daily on their smartphone for 8 weeks.
89190148|NCT06063564|Experimental|PREVENT Intervention|"Complete questionnaires at baseline (administered electronically or by mail). Follow-up measures will be administered immediately following the clinic visit, and monthly for 6-months after the clinic visit electronically and by mail~At the clinic visit, the provider will use the PREVENT tool to discuss CVH risk. A community health worker (CHW) will deliver a tailored behavioral change plan inclusive of patient-centered community resources. The CHW will provide ongoing support with goals and social needs for 6-months."
89190149|NCT06063551|Experimental|Testicular Biopsy|Patients meeting eligibility criteria are offered experimental procedure of testicular biopsy for clinical storage and use in laboratory research. The intervention does not involve a drug or device.
89190150|NCT06063525||childhood onset schizophrenia (COS)|diagnosis of schizophrenia under the age of 13 years.
89190151|NCT06063525||schizophrenia (SZ)|patients with schizophrenia with and age of onset later than 13 years
89190152|NCT06063525||autism spectrum disorder (ASD)|dual diagnosis of schizophrenia and ASD, including SZ with ASD, COS with ASD
89190153|NCT06063512|Experimental|Group A (sweet orange oil group)|Aromatherapy with inhalers will be carried out in an open clinical setting. Three drops of sweet orange oil will be dispensed into a cotton wick of the inhaler, The children will be asked to inhale the aroma from the inhalers for 2 minutes followed by an induction period of 15 minutes.
89190154|NCT06063512|No Intervention|For Group B (Control Group)|No aromatherapy inhalation
89190155|NCT06063473|Experimental|Trifarotene Cream 0.005%|The study medication will be applied topically once daily at bedtime to the affected areas of the face as a thin layer, avoiding contact with the mouth, eyes, and other mucous membranes, for 84 consecutive days.
89004318|NCT05056831|Active Comparator|Group II (usual care)|Patients receive usual care.
89004319|NCT04992637|Experimental|ClockWork|Participants who are randomized to treatment will receive the ClockWork intervention
89004320|NCT04992637|Active Comparator|Usual Care|Participants will receive usual care during the postpartum period.
89530988|NCT02506283|Sham Comparator|thermoneutral intervention|subjects in the control group receive a single pre-exercise (3x MVC) or post-exercise (3x 30 counter movement jumps) sham intervention, consisting of a 20 minute external thermoneutral application (Zamar Therapy CT clinic) applied to both thighs. Both sham interventions have a duration of 20 minutes and a temperature of 32°C.
89530989|NCT02506439|Experimental|10 mcg Vitamin D3|White-skinned women will receive Cholecalciferol (Vitamin D3) 10 mcg [400 IU] daily
88879619|NCT03804372|Experimental|Study group|Patients will receive Rituximab+Chemotherapy+TAF for 6 months, followed by TAF as monotherapy for further 12 months. All subjects will receive TAF 1-3 weeks before Rituximab+Chemotherapy and withdrawn 12 months after the completion of chemotherapy.
88879620|NCT03803982|Experimental|Deep Neuromuscular Blockade, Sugammadex|All patients will receive anesthetic induction and maintenance as per routine using a combination of propofol, opioids, dexamethasone, and 0.6 mg/kg of rocuronium for induction. Patients will also receive lidocaine 1 mg/kg/hour IV infusion, followed by 3-5 mg of morphine equivalents prior to extubation. Patient monitoring will be according to local practice and consist of electrocardiography, blood pressure, heart rate and bispectral index monitoring. Neuromuscular function will be monitored every 20 minutes using a standardized nerve monitor. After induction and intubation, patients in the Deep Neuromuscular Blockade group (experimental group) will receive additional rocuronium to achieve a NMB blockade of TOF of 0 twitch and maintained at this level until reversal.
88879621|NCT03803982|No Intervention|Standard Anesthetic|Patients in the standard anesthetic (or control group) will also receive anesthetic induction as per routine using a combination of propofol, opioids, dexamethasone, and rocuronium, with a lidocaine infusion. Patient monitoring will be similar to the experimental group, with electrocardiography, blood pressure, heart rate, and bispectral index monitoring. Patients in the control group will receive rocuronium 30 mg intravenous prior to intubation, followed by repeated 10 mg doses to reach a TOF of 1-2 twitches.
88879622|NCT03804294||vitamin D-ART|Infertile couples who undergo their ﬁrst IVF/ICSI and IUI cycle in Reproductive Medicin Center of Peking university Third Hosiptal.
89530990|NCT02506439|Experimental|20 mcg Vitamin D3|White-skinned women will receive Cholecalciferol (Vitamin D3) 20 mcg [800 IU] daily
89530991|NCT02506439|Placebo Comparator|Placebo|White-skinned women will receive a Placebo supplement, identical in appearance and taste to the active product
89530992|NCT04497701|Experimental|PEG-rhG-CSF group|Patients received subcutaneous injection of PEG-rhG-CSF(Jinyouli®)24~72 hours after the end of chemotherapy, 100µg/kg, once in each chemotherapy cycle.
88879623|NCT03803670||acute lymphoblastic leukemia patients|We observed within adult patients with ALL three groups of patients: patients without central nervous system (CNS) involvement, patients with manifest CNS involvement and patients with occult CNS involvement.
88921966|NCT06014125|No Intervention|control group|The control group will receive their usual care from their GP. An educational booklet on depression will be provided to patients at the start of the study.
88879624|NCT03803514||Treated group (rEPO)|"Patients with ESRD in HD, and medical indication of recombinant EPO for management of anemia (Hb < 10 g/dL). Ambulatory hemodialysis 3 times per week.~Recombinant beta-epoetin (Recormon) will be used, according to current recommendations.~Clinical and laboratory data will be obtained before and during the study. The primary outcome (changes of plasma intact FGF23) will be measured during the follow-up, up to 12 weeks."
89437457|NCT03872960|Experimental|Intervention Arm: Expedited transfer to a CAC|The intervention arm consists of activation of the pre-hospital triaging system currently in place for post-arrest STE patients. This involves pre-alert of the CAC and strategic delivery of the patient to the catheter laboratory (24 hours a day, 7 days a week). Patients will receive definitive post-resuscitation care: intubation and ventilation, where necessary, targeted temperature management, and goal directed therapies including evaluation and identification of underlying cause of arrest with access to immediate reperfusion if necessary. Prognostication will occur no earlier than 72 hours post-cardiac arrest to prevent premature withdrawal of life-sustaining treatment. Transfer times estimated from the 40-patient pilot are anticipated to be 100 minutes (median; IQR 75 to 113) from time of arrest to the designated centre.
88879625|NCT03803514||Control group|"Patients with ESRD and HD, without medical indication of recombinant EPO (Hb > 10 g/dL). Ambulatory hemodialysis 3 times per week.~Follow-up for 3 months, similar than rEPO group. Clinical and laboratory data will be obtained before and during the study, similar periods than rEPO group.~The primary outcome (changes of plasma FGF23) will be measured every 2 week during the evaluation period."
89535582|NCT03224689|Experimental|PEEK Femoral|Subjects with a primary diagnosis of end-stage symptomatic primary knee osteoarthritis who require a uni-lateral knee prosthesis and have been evaluated as appropriate candidates for a total knee arthroplasty by the Investigator will be invited to take part in this clinical investigation.
88879626|NCT03803358|Experimental|cycle exercise with additional NIV|In the intervention group (exercise training with non-invasive ventilation) exercise NIV pressures will be optimally adjusted to each individual patient to decrease TcPCO2 values. An IPAP of at least 15 cmH20 will be used to provide sufficient pressure to relief patients breathing muscles. Nocturnal NIV will be continued.
88879627|NCT03803358|Active Comparator|cycle exercise without NIV|In the control Group (standard exercise training without NIV ), patients will be execute cycle exercise without additional NIV (usual care). Nocturnal NIV will be continued.
88879628|NCT03803124|Active Comparator|Tolvaptan|"Drug: Tolvaptan~1 tablet before renography"
88879629|NCT03803124|Placebo Comparator|Placebo|"Placebo~1 tablet before renography"
88879630|NCT03802734|Experimental|Mindful Meditation App|Group A will be given a free subscription to a mindful meditation phone app for six months. They will also be given an actigraph and a general pregnancy and sleep information leaflet.
88879631|NCT03802734|No Intervention|No Meditation App|Group B will be given an actigraph and a general pregnancy and sleep information leaflet only.
88879632|NCT03802032|Experimental|Study Group|15g of Topical Xylocaine gel
88879633|NCT03802032|Placebo Comparator|Control group|15g of KY Jelly
88879634|NCT03802266|Experimental|Electromagnetic Navigation group|Electromagnetic Navigation Guided Transthoracic Needle Aspiration
88879635|NCT03802266|Active Comparator|CT group|CT-guided Transthoracic Needle Aspiration
88879636|NCT03801798|Experimental|NAs antivirals + GC1102 180,000 IU|"All patients are currently being treated with long-term NA treatment(more than 24 weeks) and will continue using these during the study.~Each vial contains 1mL of study drug or placebo; Single IV bolus injection of 18mL~V2 to V17 : IV bolus injection twice a week~V18 to V33 : IV bolus injection once a week"
88879637|NCT03801798|Placebo Comparator|NAs antivirals + GC1102 Placebo|"All patients are currently being treated with long-term NA treatment(more than 24 weeks) and will continue using these during the study.~Each vial contains 1mL of study drug or placebo; Single IV bolus injection of 18mL~V2 to V17: IV bolus injection twice a week~V18 to V33: IV bolus injection once a week"
88879638|NCT03801252|Experimental|Cefazolin + Azithromycin|Women will be randomized 1:1 to receive cefazolin 2 grams intravenously at the start of the labor induction and every 8 hours thereafter for a maximum of three doses and azithromycin 500 mg intravenously once at the start of the labor induction
88879639|NCT03801252|Placebo Comparator|Placebo + Placebo|Women will be randomized 1:1 to receive placebo intravenously at the start of the labor induction and every 8 hours thereafter for a maximum of three doses and placebo intravenously once at the start of the labor induction
88879640|NCT03801018||Parents who have used the donation of gametes|
88879641|NCT03801018||Children born of gametes donation|
88879642|NCT03801096|Experimental|Narrative Based Therapuetic Assessment|
88879643|NCT03801096|Active Comparator|Health Education (HE)|
88879644|NCT03800706|Experimental|TQB2450|
88879645|NCT03800550|Experimental|Treatment Sequence 1: Bedaquiline and Clarithromycin|Participants will receive bedaquiline on Day 1 in Period 1, followed by clarithromycin on Days 1-14 and bedaquiline on Day 5 in Period 2. There will be washout period of at least 28 days starting on Day 1.
89403810|NCT02266784|Experimental|Contingency Management (CM)|ADHD (N=20) & CTRL (N=20). Participants will earn compensation, based upon smoking abstinence via a Contingency Management (CM) system. This level of compensation will increase by the same amount each visit based upon abstinence. In addition, escalating bonus payments will be available for evidence of continued abstinence. The first 10 visits will be daily weekdays. The following 9 visits will be over three weeks. The final 3 treatment visits will occur weekly. The 2nd & 3rd type visits CM payments will be based upon monitoring participants' cotinine levels. A missed visit or elevated CO level will lead to 1) no CM payment for that day; 2) resetting the contingencies such that the next CO sample that is below the criterion will result in payment equal to the first day. If there is a lapse, participants' contingencies will be reinstated at their previous highest level post 3 abstinent days. Also follow-up visits at 3 and 6 months.
89403811|NCT02266784|Other|Treatment as Usual|ADHD (N=20). Transdermal nicotine skin patches (i.e. Habitrol) will be used along with supportive counseling in the treatment as usual groups. Visit schedules will coincide with the visit schedules for the CM groups (daily visits for 1st 2 weeks, 3X weekly visits for weeks 3-5, 1x weekly visit for weeks 6-8). A standard regimen of nicotine replacement with which the study team has experience will be used: four weeks of 21 mg/d beginning on the QD, two weeks of 14 mg/d and two weeks of 7 mg/d. Also follow-up visits at 3 and 6 months.
88921967|NCT06012708|Experimental|Dose Level 1|
88921968|NCT06012708|Experimental|Dose Level 2|
88921969|NCT06012708|Experimental|Dose Level 3|
89403812|NCT02090790|Active Comparator|iv dexamethasone|perioperative 2ml 8 mg ıv dexamethasone
89403813|NCT02090790|Active Comparator|femoral dexamethasone|femoral block was performed postoperative 30 ml 0,5 % bupivacaine added 2 ml 8 mg dexamethasone
89403814|NCT02090790|Placebo Comparator|serum physiologic|
89403815|NCT04959916|Experimental|Group Meta-Cognitive Therapy|Group Meta-Cognitive Therapy (Group-MCT)
89403816|NCT02084550|Active Comparator|Vaminolac|Intravenous Vaminolac during 3 hours, with an infusion rate of 1,6ml/kilogram bodyweight/h.
89403817|NCT02084550|Placebo Comparator|Saline|Intravenous saline during 3 hours, with an infusion rate of 1,6ml/kilogram bodyweight/h.
89403818|NCT04946110|Experimental|Electromagnetic stimulation|Electromagnetic stimulation of the phrenic nerve.
89403819|NCT01443728|Experimental|Vitamin D3 100,000 IU|Oral vitamin D3, 100,000 IU [2.5 mg] given once a month
89403820|NCT01443728|Active Comparator|Vitamin D3 12,000 IU|Standard dose oral vitamin D3 12,000 IU [0.3 mg] given once a month
89403821|NCT02088138|Experimental|Functional Electrical Stimulation|"Functional Electrical Stimulation~In the intervention group the FES was applied in the medial and lateral vastus of both thighs targeting the movement of knee extension. The application frequency was 15 Hz, lasting 40 minutes, pulse width of 0.5 ms, time ON 5s, time OFF 10s, ramp-up of 0 or 1s, descent ramp 2s and intensity as tolerance patient."
89403822|NCT02088138|Experimental|FES placebo|"Functional Electrical Stimulation placebo~The placebo group received functional electrical stimulation with the same parameters in the intervention group, except that the intensity of stimulation did not lead to visible or palpable contraction."
88813485|NCT03408158|Experimental|matched platlet infusion|Enable platelet donors'common HPA antigen to be typed and blood disease patients to be same type infusion of main HPA antigen as possible as early.The investigators compare the differences of platelet count between patients with same type infusion of main HPA antigen and not.
88813486|NCT03001973||LN patients|Patients diagnosis as lupus nephritis
89403823|NCT05092048||CML patient|≥18 years old CML patiente
89403824|NCT01324466|Placebo Comparator|Vehicle|Vehicle
88813487|NCT01728272|Experimental|blood concentration of metoprolol|how does off-pump miniperfusion and perfusion CABG influence the absorption of metoprolol after CABG
88813488|NCT03007823|Experimental|High-activity natural killer|In this group, the patients will receive multiple high-activity natural killer (HANK) immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
88813489|NCT03007823|No Intervention|Control|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
88813490|NCT01728350|Experimental|Treatment|Participants in this arm will participate in a novel structured volunteering intervention called HOPE - Helping Others through Purpose and Engagement. This intervention involves orientation, training, volunteer placement assistance, and problem solving and support.
88813491|NCT01728350|No Intervention|Control|Participants who are randomized to the control arm will be offered the HOPE intervention at the conclusion of study.
88813492|NCT01728506|Experimental|Weight Loss & Exercise|Single arm intervention of a 24 week weight loss and exercise intervention.
88813493|NCT03408002|No Intervention|control group|no intervention
88813494|NCT03408002|Experimental|Psychological intervention|"Psychological intervention using the Four elements technique elaborated by Shapiro and reported in M. Luber (2009) during a psychological consultation conducted the day before surgery."
88813495|NCT04378088||Group 1 - experts|"Evaluation of 15 images for each of the proposed 3 grade scale (45 images in total), randomly distributed to validate de scale; images will be assessed twice by the participants with a two-week interval in both study phases (the random distribution will vary between both evaluations).~Together with the assessment of each image the participant is invited to choose one of possible three clinical actions (do nothing, wash with water and wash with simethicone)"
88813496|NCT04378088||Group 2 - mix experts/trainee|"If intra and interobserver rates in group 1 are >0.7 proceed to group 2 evaluation with the same intervention.~Evaluation of 15 images for each of the proposed 3 grade scale (45 images in total), randomly distributed to validate de scale; images will be assessed twice by the participants with a two-week interval in both study phases (the random distribution will vary between both evaluations).~Together with the assessment of each image the participant is invited to choose one of possible three clinical actions (do nothing, wash with water and wash with simethicone)"
89403825|NCT01324466|Active Comparator|Active|Active NB-001(0.3%)
88879646|NCT03800550|Experimental|Treatment Sequence 2: Clarithromycin and Bedaquiline|Participants will receive clarithromycin on Days 1-14 and bedaquiline on Day 5 in Period 1, followed by bedaquiline on Day 1 in Period 2. There will be a washout period of at least 28 days starting after bedaquiline administration on Day 5.
89403826|NCT04740346|Experimental|3 months follow-up|Patients will be follow-up every 3 months after gastrectomy.
88879647|NCT03800472|Experimental|GLPG3312 SAD IR (Part 1)|Single doses of GLPG3312 IR
88879648|NCT03800472|Placebo Comparator|Placebo SAD IR (Part 1)|Single doses of Placebo IR
88879649|NCT03800472|Experimental|GLPG3312 SAD MR (Part 2)|Single doses of GLPG3312 MR
88879650|NCT03800472|Placebo Comparator|Placebo SAD MR (Part 2)|Single doses of Placebo MR
89403827|NCT04740346|Active Comparator|6 months follow-up|Patients will be follow-up every 6 months after gastrectomy.
88879651|NCT03800472|Experimental|GLPG3312 FE MR (Part 3)|Single dose of GLPG3312 MR in fed and fasted state
89403828|NCT05479188|Active Comparator|Minimal Invasive Extracorporeal Circulation (MiECC)|Patients undergoing cardiac surgery with Minimal Invasive Extracorporeal Circulation.
89403829|NCT05479188|Active Comparator|Conventional cardiopulmonary Bypass (cCPB)|Patients undergoing cardiac surgery with conventional cardiopulmonary bypass.
89403830|NCT02090868||Pre Introduction|Pre tool introduction cohort 22 patient participants who will receive standard care (no patients were recruited)
88879652|NCT03800472|Experimental|GLPG3312 MAD MR (Part 4)|Multiple doses of GLPG3312 MR
89403831|NCT02090868||Nurses|12 nurse participants who will take part in 2 focus group interviews and a teaching session (6 nurse participants were recruited)
89403832|NCT02090868||Post Introduction|Pre tool introduction cohort 22 patient participants who's ability to eat and drink orally will be assessed using the Oral Intake Screening Tool (no patient participants were recruited)
88879653|NCT03800472|Placebo Comparator|Placebo MAD MR (Part 4)|Multiple doses of Placebo MR
88879654|NCT03800472|Experimental|GLPG3312 MAD MR optimized (Part 4)|Multiple doses of GLPG3312 MR
88879655|NCT03800472|Placebo Comparator|Placebo MAD MR optimized (Part 4)|Multiple doses of Placebo MR
88879656|NCT03800316|Experimental|Synchronous Video Consultation|Testing the feasibility of a synchronous video consultation in the field prior to emergency department arrival.
88879657|NCT03805698|Experimental|Platelet-rich Plasma (PRP) group|"Twenty-four (24) subjects undergoing arthroscopic debridement for triangular fibrocartilage complex (TFCC) tears will be treated intraoperatively with platelet-rich plasma (PRP) (24 subjects).~Intervention: use of Cascade device; Autologous Fibrin & Platelet System; once processed, the platelet-rich plasma (PRP)is injected into the debrided wrist"
88879658|NCT03805698|Active Comparator|Standard Treatment group|"Twenty-four (24) subjects undergoing arthroscopic debridement for triangular fibrocartilage complex (TFCC) tears will undergo treatment, as is standard of care, followed by no treatment with platelet-rich plasma (PRP)(24 subjects).~Intervention: No platelet-rich plasma (PRP) injection into debrided wrist"
88879659|NCT03804684|Experimental|Healthy Controls|Healthy subjects between 21 and 80 years of age with no eye diseases (normal appearing optic nerve and retina, intraocular eye pressure less than 19 millimeters of mercury, normal and reliable standard automatic perimetry, and spherical refraction less than 3 diopters and cylinder correction equal to 2 diopters or less. All subjects will perform Standard Automatic Perimetry Humphrey Field Analyzer and visuALL Field Analyzer to measure peripheral and central visual field.
89403833|NCT01312454|Experimental|AL-59412C Concentration 1|AL-59412C injectable solution, single intravitreal injection
89403834|NCT01312454|Experimental|AL-59412C Concentration 2|AL-59412C injectable solution, single intravitreal injection
89403835|NCT01312454|Active Comparator|Travoprost|Travoprost injectable solution, single intravitreal injection
89403836|NCT01312454|Placebo Comparator|Vehicle|AL-59412C Vehicle, single intravitreal injection
89403837|NCT02090946||parental experiences|interviews
89403838|NCT01310114|Experimental|Cohort 1|1 unit PDA001 [approximately 2 x 108 cells] in 240 mL per infusion on Day 1.
88879660|NCT03804684|Experimental|Mild and Moderate Glaucoma|Subjects between 21 and 80 years of age with Mild or Moderate Glaucoma. Eyes will have a reliable standard automatic perimetry with no more than -6 mean deviation (Mild) and between -6 mean and -12 mean deviation (Moderate). Spherical refraction will be less than 3 diopters and cylinder correction equal to 2 diopters or less. All subjects will perform Standard Automatic Perimetry Humphrey Field Analyzer and visuALL Field Analyzer to measure peripheral and central visual field.
89403839|NCT01310114|Experimental|Cohort 2A - Experimental|1 unit PDA001 [approximately 2 x 108 cells] or placebo in 240 mL per infusion on Day 1
89403840|NCT01310114|Experimental|Cohort 2B - Experimental|4 units PDA001 [approximately 8 x 108 cells] or placebo in 240 mL per infusion on Day 1
89403841|NCT04090918||Group 1: Abdominal surgery with POAF|Twenty patients undergoing abdominal surgery with new-onset atrial fibrillation
89403842|NCT04090918||Group 2: Abdominal surgery without POAF|Twenty patients undergoing abdominal surgery without new-onset atrial fibrillation matching patients in group 1 on age, sex and comorbidities.
89403843|NCT02088294|No Intervention|Non-intervention control|No intervention will be delivered.
89437458|NCT03872960|No Intervention|Control Arm: Current standard of care|The control arm comprises the current standard of pre-hospital advanced life support (ALS) care management for patients with ROSC following cardiac arrest of suspected cardiac aetiology. The patient is conveyed to the geographically closest emergency department. Management thereafter will be as per standard hospital protocols however as in the intervention arm, prognostication is to be delayed in trial patients until at least 72 hours post arrest.
89403844|NCT02088294|Experimental|Lifestyle Education (LS)|"The lifestyle curriculum will be taught in twice weekly after-school sessions of ~1.25 hours, one physical activity and one nutrition-related, delivered over 12-weeks during the course of a single academic semester. The lifestyle program will utilize the Shape Up curriculum of SOSMentor, a community non-profit collaborator, modified to seamlessly integrate key concepts of the non-diet philosophy of Intuitive Eating. The curriculum fully encompasses health-promoting nutrition and physical activity practices consistent with consensus recommendations ."
89403845|NCT02088294|Experimental|LS + Stress Reduction Guided Imagery|"In addition to the after school lifestyle classes, participants will receive group Interactive Guided Imagery (IGI) consisting of standard stress reduction imagery practices, delivered once weekly for 12 weeks as an after school class of ~1.25 hours. The group IGI will be delivered by certified facilitators in the context of the facilitated group process known as Council, a group communication process used by many indigenous and other cultures."
89403846|NCT02088294|Experimental|LS + Activity/Eating Guided Imagery|"In addition to the after school lifestyle classes, participants will receive group Interactive Guided ImagerySM (IGI) delivered once weekly for 12 weeks as an after school class of ~1.25 hours. The group IGI will be delivered by certified facilitators in the context of the facilitated group process known as Council, a group communication process used by many indigenous and other cultures. Participants in this arm will receive stress reduction IGI for 4 wks, plus 8 weekly sessions with IGI content designed to promote physical activity and healthy eating."
89403847|NCT01305824|Active Comparator|PRT 201 (10 micrograms)|
88879661|NCT05318430|Experimental|Experimental group|the closed-suction drainage device will be placed subcutaneously when closing the incision
88879662|NCT05318430|No Intervention|Control group|the closed-suction drainage device will not be placed subcutaneously when closing the incision
88921970|NCT06012708|Experimental|Dose Level 4|
89403848|NCT01305824|Placebo Comparator|Placebo|
89403849|NCT01305824|Active Comparator|PRT-201 (30 micrograms)|
89403850|NCT03323749|Experimental|Part 1: Elamipretide|40 mg (0.5mL) elamipretide subcutaneous (SC) daily
89403851|NCT03323749|Placebo Comparator|Part 1: Placebo|Placebo SC daily
89403852|NCT03323749|Experimental|Part 2: Elamipretide open label|Elamepretide 40 mg (0.5 mL) SC daily
89403853|NCT02084784|Experimental|Indocyanine green & methylene blue,|Subcutaneous injection around the areola with 2-4 points Methylene blue with 1ml of 1% Indocyanine green with 1ml of 0.5%
89403854|NCT02266862||Study Group|The purpose of this study is to evaluate the location within the renal artery of maximal angular displacement before and after fenestrated endovascular aortic repair (FEVAR) using CT with end-inspiration and end-expiration CT images before and after repair.
89403855|NCT02091024|Experimental|ECG (Ecklonia cava extract)|ECE 200mg, twice a day
88921971|NCT06010329|Experimental|Single arm, Open label|Participants will receive sutetinib maleate capsule taken orally with (preferred) or without food, at the dose directed by the Investigators, 28 days for a cycle.
89403856|NCT02091024|Placebo Comparator|Placebo|Placebo 200mg, twice a day
89403857|NCT03135236|Experimental|Parent training|All registered participants will participate in a series of trainings (3 separate) on sexuality education.
89403858|NCT02084862|Experimental|Ultrasound|Ultrasound guided percutaneous tracheostomy
89403859|NCT02084862|Active Comparator|Bronchoscopy|Bronchoscopy guided percutaneous tracheostomy
89403860|NCT03240601|Sham Comparator|Subthreshold|Individuals will undergo their standard physical therapist directed locomotor training while receiving transcutaneous spinal cord stimulation. The stimulation intensity will briefly ramp up to the lowest intensity that is first detected by the participant and then ramped down to a level no longer detected by the participant. Participants will continue their locomotor training.
89403861|NCT03240601|Experimental|Active|Individuals will undergo their standard physical therapist directed locomotor training while receiving transcutaneous spinal cord stimulation. The stimulation intensity will ramp up slowly to a level that produces parasthesia (tingling) throughout the lower extremity. This intensity will be applied for 30 minutes while participants continue their locomotor training.
89403862|NCT03135080|Experimental|Long-term HEAD START Training|Fifteen surgeons will participate in long-term HEAD START practice once live surgical training is complete. Each week the participant will complete 2 surgeries on the HEAD START device and mark the surgery number on the cartridge. Monthly, the participant will send the accumulated cartridges to Addis for review by a senior trichiasis surgery trainer. The trainer will evaluate the cartridges and then will discuss his/her impression of the surgeries with the participant during a regular monthly call. He/she will also note the findings on a standardized form. Practice will continue for approximately 4-6 months, depending on the length of the rainy season and time of enrollment.
88879663|NCT05744154|Experimental|Audit & feedback with educational outreach and facilitation|The intervention includes: 1) refinement with end users, 2) an A&F report sent to local governing authorities presenting for each practice: performance compared to peers (simple A&F), a summary message indicating if action is required and a list of potential actions, 3) educational materials (a clinical vignette; consequences of the practice; links to practice guidelines, clinical decision rules and shared decision-making tools; a case review tool), 4) virtual educational meetings with the local trauma Medical Director, trauma program manager and data analyst, and 5) two virtual facilitation visits 2 and 4 months after the transmission of the report to support committees in preparing their action plan.
88879664|NCT05744154|Other|Simple audit & feedback|The control arm will receive the quality improvement intervention currently in place in the Québec Trauma Care Continuum (i.e. simple A&F report presenting their performance compared to peers on quality indicators measuring adherence to high-value care and risk-adjusted outcomes) with the addition of quality indicators on low-value care (already planned by provincial authorities for the 2023 evaluation cycle). Simple A&F was chosen for the control because it is standard practice in Québec and in most integrated trauma systems and the effectiveness of A&F for de-implementation has been documented.
88879665|NCT05743920|Experimental|Self-help Forest Bathing Group|Participants in the FB group will perform forest bathing activity at the Chinese University of Hong Kong for two session.
88879666|NCT05743920|Other|Wait List Group|
88879667|NCT05743530|Experimental|TENS - transcutaneous electrical nerve stimulation|
88879668|NCT05743530|Placebo Comparator|Placebo|
88879669|NCT05743452|Experimental|CS@Mg|The patient was treated by GBR with magnesium calcium silicate scaffold for alveolar bone defect.
88879670|NCT05743218|Experimental|liver meridian group|Four acupoints; LR3 Taichong, LR5 Ligou, LR8 Ququan, and LR12 Jiman. Based on the national standard of the People's Republic of China in 2006 (GB/T 12346-2006). The patient will be in a supine position. Taichong will be punctured at a 25-mm depth using a 0.35×25-mm filiform needle, Ligou will be punctured at a 15-20-mm depth with a 0.35×25-mm filiform needle, Ququan at a 20-25-mm depth with a 0.30×40-mm filiform needle, and an acute pulse of 15-20 mm. Each acupoint will be subject to a small amount of uniform lifting and twisting to the degree of local acid distension. An auxiliary needle (0.16×13 mm) will be inserted approximately 5 mm into the needle, 2 mm proximal to the heart of each acupoint along the meridian. The negative electrode will be connected to the main point, and the positive electrode will be connected to the auxiliary needle, and connect the electroacupuncture instrument. The needles will be retained for 30 min respectively, once every other day, 36 treatments.
88879671|NCT05743218|Active Comparator|stomach meridian group|Four acupoints have been selected for the gastric meridian group, including ST42 Chongyang, ST40 Fenglong, ST36 Zusanli, and ST31 Biguan. The acupoint locations are based on the national standard of the People's Republic of China in 2006 (GB/T 12346-2006). The patient will be supine during the procedure, and the needles will be routinely sterilized. Straight needling will be performed in the hip region using a 0.30×50-mm-filiform needle, a 0.30×50-mm filiform needle in Zusanli, and a 0.30×40-mm filiform needle in Fenglong. A 0.35×25-mm filiform needle will be used to stimulate Chongyang for 10-15 mm, and each acupoint will be gently and evenly lifted, inserted, and twisted to local acid distension. Electroacupuncture will be applied in the same manner as for the liver meridian group. The needles will be retained for 30 min respectively, once every other day, then thrice weekly for a total of 36 treatments in the three groups.
89403863|NCT03135080|Active Comparator|Standard of Care|Once live surgical training is complete, fifteen surgeons will commence live surgery without supervision until the rainy season begins. Then they will break for the rainy season, per the typical practice. The trainer will assess their skill levels on live surgery at the end of training and again at the start of the surgical season in the fall.
89403864|NCT02091180|Experimental|Mannitol|Patients will receive 0.5g/kg of 20% intravenous (i.v.) mannitol infusion over 10 minutes immediately before induction of anesthesia
88879672|NCT05743218|Placebo Comparator|non-acupoint acupuncture group|Four points: (1) On the lateral thigh, between the vastus lateralis and biceps femoris, the midpoint of the popliteal stria, and the highest point of the greater trochanter. (2) On the lateral side of the calf, beside the level of Zusanli, and at the lateral edge of the tibia. (3) On the fibular side of the calf, the midpoint of the stomach meridian, and the bile meridian, 3 cm above the tip of the lateral malleolus and in front of the hanging bell. (4) On the lateral side of the calcaneus, and the servant enters the midpoint of the line connecting the posterior edge of the calcaneus at the same level. The 0.30×25-mm filiform needles are inserted straight for 3-5 mm at the points, the needles can stand without Deqi. The auxiliary needle will be inserted and electroacupuncture will be connected (same as in the other group). The internal wire of the electroacupuncture instrument will be interrupted, no current passed through. The treatment time is the same as the other two groups.
89403865|NCT02091180|Placebo Comparator|Control|Patients will receive normal saline
89403866|NCT03949738||Adult patients with ARDS|Adults patients fulfilling the Berlin criteria for ARDS
89190156|NCT06063473|Active Comparator|AKLIEF® Cream (Trifarotene 0.005%, Galderma Laboratories)|The study medication will be applied topically once daily at bedtime to the affected areas of the face as a thin layer, avoiding contact with the mouth, eyes, and other mucous membranes, for 84 consecutive days.
89190157|NCT06063473|Placebo Comparator|Placebo Control|The study medication will be applied topically once daily at bedtime to the affected areas of the face as a thin layer, avoiding contact with the mouth, eyes, and other mucous membranes, for 84 consecutive days.
89190158|NCT06063395||Patient undergoing open surgery on the abdominal aorta by laparotomy|
89190159|NCT06063369|Experimental|Palmitoylethanolamide 1200 mg|"Dose: PEA 1200 mg given in 300 mg capsules (2 capsules twice daily) Route of administration: oral Duration and frequency: study medication will be provided to patients in bottles every two weeks for the duration of the study (three dispensations).~Formulation: PEA Dosing scheme: Patients will be instructed to take two capsules twice daily for the 42 days of the study."
89190160|NCT06063369|Placebo Comparator|Matching placebo|"2 capsules twice daily identical to study arm. Route of administration: oral Duration and frequency: pills will be provided to patients in bottles every two weeks for the duration of the study (three dispensations).~Formulation: placebo in identical capsules. Dosing scheme: Patients will be instructed to take two capsules twice daily for the 42 days of the study."
89190161|NCT06063304||Healthy Volunteers|This group consists of healthy volunteers with no history of knee joint pain (refer to inclusion/exclusion criteria for more details). They will be scanned once and their scans will be used as the baseline to compare the early knee osteoarthritis patient data with. 10 healthy volunteers will be recruited.
89190162|NCT06063304||Knee Osteoarthritis Patients|This group consists of early knee osteoarthritis patients (refer to inclusion/exclusion criteria for more details). They will be scanned 4 times over a period of 2 years (at enrolment, 6 months, 12 months and 24 months after enrolment) to see how the disease progresses. Their scans will be compared with the baseline healthy volunteer scans to check for any differences in anatomy and tissue properties. 60 knee osteoarthritis patients will be recruited.
89190163|NCT06063291|Experimental|Cohort 1|The study will consist 4 cohorts of 8 healthy subjects who will be randomised to receive a single oral dose of ID110521156 of placebo.
89190164|NCT06063291|Experimental|Cohort 2|The study will consist 4 cohorts of 8 healthy subjects who will be randomised to receive a single oral dose of ID110521156 of placebo.
89190165|NCT06063291|Experimental|Cohort 3|The study will consist 4 cohorts of 8 healthy subjects who will be randomised to receive a single oral dose of ID110521156 of placebo.
89535583|NCT02486549|Experimental|Supraclavicular Block|Ultrasound guided supraclavicular block with 20 ml of 0.25% bupivacaine will be performed
88879673|NCT05742750|Experimental|Camrelizumab + apatinib and chemotherapies (gemcitabine and cisplatin)|"Apatinib is a multi-target TKI, which selectively inhibits VEGFR-2.~Camrelizumabb is a anti-human PD-1 monoclonal antibody."
89403867|NCT03134924|Experimental|Experimental condition|The WASH (Women's and Sexual Health) intervention included the elements of the enhanced standard of care condition and in addition, a group-based, culturally-tailored intervention to enhance the uptake of the recommendations. Facilitators covered an intervention manual on risks associated with IVP, symptoms of vaginal infections, vaginal health, women's experience with alternative methods for vaginal care, and communication with partners about vaginal health and the risks associated with IVP.
89403868|NCT03134924|Other|Enhanced Standard of Care|"This study provided an enhanced standard of care (SOC+) comparison condition, consisting of a genital tract examination, collection of a vaginal swab with gram stain of vaginal secretions, diagnosis of BV using the Nugent criteria and provision of medication (oral metronidazole) within 48 hours of the examination in women with Nugent score of 7-10, regardless of the presence of symptoms. In addition, at baseline, participants received an individual education session on the risk of engaging in IVP, advice to discontinue IVP, and tips for healthy vaginal hygiene, emphasizing avoiding IVP and suggesting replacing IVP by external vaginal cleansing."
89403869|NCT02084940||GnRH antagonist depot, Degarelix|Women receive 20 mg of Degarelix on the first day of menstrual cycle followed by a fixed dose of 225 IU of recombinant FSH on the second day until the day of ovulation triggering
89403870|NCT05755321||BMI<25 and T2DM|10 Subjects with Body Mass Index (BMI) <25 with Type 2 Diabetes Mellitus (T2DM) of both sex.
89403871|NCT05755321||BMI<25 without T2DM|10 Subjects with Body Mass Index (BMI) <25 without Type 2 Diabetes Mellitus (T2DM) of both sex.
89403872|NCT05755321||BMI>30 and T2DM|10 Subjects with Body Mass Index (BMI) >30 with Type 2 Diabetes Mellitus (T2DM) of both sex.
89403873|NCT05755321||BMI>30 without T2DM|10 Subjects with Body Mass Index (BMI) >30 without Type 2 Diabetes Mellitus (T2DM) of both sex.
89403874|NCT02269748|Experimental|Root coverage with Tunnel (TT)|The tunnel technique with subepithelial connective tissue graft (TT+SeCTG) will be utilized to cover the denude root surface
89403875|NCT02269748|Active Comparator|Coronally advanced flap (CAF+SeCTG)|The Coronally advanced flap with subepithelial connective tissue graft (CAF+SeCTG) will be utilized to cover the denude root surface
89403876|NCT02269826|Experimental|Vagisan® Moisturising Cream|non-hormonal vaginal cream for the treatment of vulvovaginal dryness
89403877|NCT02269826|Active Comparator|Gynomunal® vaginal gel|non-hormonal gel
89403878|NCT02269904|Active Comparator|Fluorouracil Implants and Xelox regimes|"Fluorouracil Implants: 800mg, implanted in the abdominal cavity during operation.~Xelox regimes: Capecitabine,1000 mg/m2，PO.BID, from D1 to D14; Oxaliplatin, 130 mg/m2，IV, D1 in each cycle. The cycle will repeated every 21 days till 6 cycles finished."
89403879|NCT02269904|Active Comparator|Xelox regimes|Xelox regimes: Capecitabine,1000 mg/m2，PO.BID, from D1 to D14; Oxaliplatin, 130 mg/m2，IV, D1 in each cycle. The cycle will repeated every 21 days till 6 cycles finished.
89403880|NCT04540198|Experimental|GamePlan4Care (GP4C)|Participants in this arm will have access to full functionality and content of the online system GamePlan4Care (GP4C) including educational resources, skills training, and support tailored to their unique caregiving needs. Additional individualized feedback will be automatically generated based on responses to online questions and will include links to relevant site educational/skill-building content. Participants will be assigned a Dementia Care Specialist who will facilitate caregiver interactions with the online material and provide skills training via telephone or web-video conference. Study participants assigned to GP4C will receive 9 automated emails and 4 phone calls over a 6-month period.
89403881|NCT04540198|Active Comparator|Resources4Care (R4C)|"Participants in this arm will receive access to Resources4Care (R4C), a feature-limited version GamePlan4Care system. R4C will serve as an online hub for articles and videos about Alzheimer's disease and dementia. Educational topics will included information on: 1) Alzheimer's Disease & Dementia, 2) Caregiving, 3) Caregiver Stress and 4) Home Safety. R4C will present a page on each topic with active links to two additional online sources on the same topic. Study participants assigned to R4C will receive two emails from their DCS encouraging the caregiver to review specific education materials. Each email will be followed by brief check-in calls (15-min each) at three months and five months after randomization."
88879674|NCT05742516|Experimental|GOS|Galactooligosaccharide consumption through the prebiotic product Bimuno.
88879675|NCT05742516|Placebo Comparator|Placebo|Maltodextrin powder
88879676|NCT05742360||OSA subjects with the excessively sleepy symptom subtype treated with CPAP|Patients with the excessively sleepy symptom subtype who accept CPAP therapy
89403882|NCT03557112|Experimental|the treatment group|TPF regimen induction chemotherapy combined with nimotuzumab concurrent radiotherapy concurrent chemoradiotherapy
88879677|NCT05740878|Experimental|immunonutrients ONS|the intervention group received ONS which contained immunonutrients (omega 3 and anthocyanin)
88879678|NCT05740878|Active Comparator|standard ONS|the control group received standard ONS (isocaloric)
88879679|NCT05740332|Experimental|All participants|1 mL of alcohol foam hand sanitizer automatically dispensed into hands, spread over hands and rubbed until dry.
88879680|NCT05737992|Experimental|Exercise group|Patients in the intervention group will do high intensity interval training (HIIT) in water. In this study, HIIT training will be short intervals (30 seconds) of movements and 15 seconds of rest.Exercises will be done in a floating position in the deep part. The intervention will be done 3 sessions weekly. The length will be 8 weeks.
88879681|NCT05737992|No Intervention|Control group|The patients will continue their usual medication and their usual physical activity.
88879682|NCT05557266|Experimental|Mindfulness-based intervention (MBI)|A 8-week mindfulness-based intervention. From 15 to 30 minutes of practice per session, three times/week through audio guided meditations.
88879683|NCT05557266|Active Comparator|Physical exercise (PE)|A 8-week physical exercise intervention. From 15 to 30 minutes of practice per session, three times/week through workout videos.
88879684|NCT05557266|No Intervention|Wait list (WL)|The participants will continue their work activity as usual. This arm will be invited to a mindfulness training once the study finished.
88879685|NCT05543928|Placebo Comparator|Cohort 1 and Cohort 2 Placebo|
88879686|NCT05543928|Experimental|Cohort 1 and Cohort 2 CTAP101 Capsule|
88879687|NCT05502978|Experimental|Intervention group|The intervention group is third trimester pregnant women with 37 weeks of gestation who received blended education. Blended education is provided by cadres and nutritionists, both online and offline. Education consists of online assistance with digital booklets, videos via WhatsApp by cadres and consultation with nutritionists as well as home visits (offline/face-to-face) by cadres and the research team. One education is done during the third trimester at 37 weeks of gestation, second education is done at 38 weeks' gestation, the third education is done when the baby is 3 months old, all three of which are done online. Mother will be visited every month by cadres and the research team from birth to 7 month old. Consultation with a nutritionist is carried out via WhatsApp calls at critical times the failure rate in IYCF practice was for infants aged 1 month, 3 months, 6 and 7 months
88879688|NCT05441124|Experimental|Mindfullness Based Stress Reduction|Mindfullness Based Stress Reduction (MBSR) therapy
88879689|NCT05441124|No Intervention|Control|Control
88879690|NCT05435742|Experimental|SON-080 Dose Level 1|20 µg SON-080 SC administration TIW
88879691|NCT05435742|Experimental|SON-080 Dose Level 2|60 µg SON-080 SC administration TIW
88879692|NCT05435742|Placebo Comparator|Matching Placebo|Matching placebo 20 µg SON-080 SC administration TIW
88879693|NCT05347992||Standard of Care|Cohort(1) of the study will collect longitudinal blood samples from participants who are on the standard of care treatment for Systemic lupus erythematosus (SLE) based on Cohort specific inclusion criteria
88879694|NCT05347992||Biologics|Cohort(2) of the study will collect longitudinal blood samples from participants who are on biologics treatment for Systemic lupus erythematosus (SLE) based on Cohort specific inclusion criteria
88879695|NCT05343468|Experimental|Experimental|Singe-arm: the assistive digital software was implemented as an intervention to all participants.
89535584|NCT02486549|Active Comparator|Interscalene block|Ultrasound guided inter scalene block with 20ml of 0.25% bupivacaine will be performed.
89535585|NCT03224611|No Intervention|Control group|"The flexible LMA is inserted using index finger technique"
89535586|NCT03224611|Active Comparator|Light wand group|The flexible LMA is inserted using light wand as a stylet
88879696|NCT05311800|Experimental|High intensity interval training - BIKE (HIIE BIKE)|10 cycles of speeding up for 45 s at 80-thPHR followed by pedaling slowly (40% thPHR) for 1m30s (37min30s)
88879697|NCT05311800|Experimental|High intensity interval training - RUN (HIIE RUN)|9 cycles of speeding up for 45 s at 80-thPHR followed by pedaling slowly (40% thPHR) for 1m30s (35min15s)
88879698|NCT05045898|Experimental|Control group|plantar massage
88879699|NCT05045898|Experimental|Intervention group|plantar massage and textured insoles
89535587|NCT03318185|Experimental|gasless single-port laparoscopic surgery|radical resection of rectal carcinoma is performed by gasless single-port laparoscopic-assisted surgery.
89535588|NCT03318185|Sham Comparator|conventional laparoscopic surgery|radical resection of rectal carcinoma is performed by conventional laparoscopic surgery.
88879702|NCT04601454|Experimental|Spinal Cord Stimulation|Enrolled subjects are implanted with a rechargeable spinal cord stimulation system that is activated and programmed to on-label parameters.
88879703|NCT04509726|Experimental|EBV TCR-T|
89190166|NCT06063291|Experimental|Cohort 4|The study will consist 4 cohorts of 8 healthy subjects who will be randomised to receive a single oral dose of ID110521156 of placebo.
88879704|NCT04446078|Experimental|PEEK - All-on-4|Patients rehabilitated with a PEEK-acrylic resin prosthesis supported by immediate function dental implants inserted through the All-on-4 concept
89190167|NCT06063278|Experimental|BN Group|Patients will take part of a Therapeutic BN Group
89190168|NCT06063278|No Intervention|Waiting List|Participants will be in the waiting list.
89535589|NCT03224533||No Nuts|"All other foods that did not include walnuts or other nuts were classified as no nuts (NN)."
89535590|NCT03224533||Other Nuts|"Foods codes describing nuts that are not walnuts (i.e. cashew nuts, pistachios, etc.) or nut-containing foods that do not commonly contain walnuts (e.g. granola) were classified as other nuts (ON)."
89403883|NCT03557112|Active Comparator|the control group|TPF regimen induction chemotherapy combined with cisplatin concurrent radiotherapy concurrent chemoradiotherapy
89403884|NCT01300208|Experimental|Cohort 1|CC-11050 (50 milligrams twice per day and Placebo)
89403885|NCT01300208|Experimental|Cohort 2|CC-11050 (100 milligrams twice per day and Placebo)
89190169|NCT06063265|Experimental|IATP|
89190170|NCT06063265|No Intervention|Control|
89403886|NCT01300208|Experimental|Cohort 3|CC-11050 (200 milligrams twice per day and Placebo)
89403887|NCT02085018|Experimental|Omeprazole|Omeprazole 20 milligrams twice a day taken for 90 days
89403888|NCT02085018|Placebo Comparator|Matched placebo|Matched placebo twice a day taken for 90 days
89403889|NCT05091814||Radiotherapy (Yes or no) - Exercise (YES or NO)|with or without radiotherapy
89403890|NCT05091814||MMO (in mm)|with or without radiotherapy
89403891|NCT02091336|Active Comparator|Glyburide|Glyburide 2,5 mg
89403892|NCT02091336|Active Comparator|Metformin|Metformin 500mg bid
89403893|NCT01442090|Active Comparator|Everolimus|Participants will receive everolimus (10 mg) orally daily until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
89403894|NCT01442090|Experimental|GDC-0980|Participants will receive GDC-0980 (40 mg) orally daily until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
89403895|NCT02085096|Experimental|Problem-Solving Therapy|A problem-solving therapy training program will be provided to the spouses/significant others of men diagnosed with prostate cancer. The purpose of this study is to test the efficacy of problem-solving therapy on the spouses of prostate cancer patients.
89403896|NCT02085096|Placebo Comparator|Standard Supportive Care|Participants who are randomized to this arm will be encouraged to use whatever supporting care is recommended to them by their health provider.
89403897|NCT04475042|Active Comparator|Group A|Dapagliflozin - washout period - placebo
89403898|NCT04475042|Active Comparator|Group B|Placebo - washout period - Dapagliflozin
89403899|NCT02088450|Active Comparator|Active treatment|Active treatment with nitrendipine (10-40 mg/day). If necessary, the dihydropyridine calcium-channel blocker was combined with or replaced by enalapril maleate (5-20 mg/day), hydrochlorothiazide (12.5-25 mg/day), or both drugs.
89403900|NCT02088450|Placebo Comparator|Placebo|Placebo tablets were identical to the study drugs with a similar schedule.
89403901|NCT03688828|Experimental|Probiotics|Saccharomyces boulardii + Esomeprazole + Amoxicillin + Clarithromycin + Bismuth potassium citrate
88879705|NCT04384302|Experimental|Visual training|"Pre-specidied visual training methods that use: the Marsden ball, tables that uses green-red visual stimuli, physical reation in response to the visual stimuli that uses the flippers or the preselected distances.~One set of exercises per week was prepared.~Each visual training will last for 15 minutes and should be performed by the participant in their home (using the telemedicine devices to control the conduction of each exercise) 3 times a week."
89190171|NCT06063252|No Intervention|controlgroup|Usual care
89190172|NCT06063252|Experimental|intervention group|receive self-management intervention
89190173|NCT06063200|Other|crossover 1: methylphenidate, placebo|methylphenidate (single dose, oral, 20 mg, immediate release) followed by placebo (single dose, oral)
89190174|NCT06063200|Other|crossover 2: placebo, methylphenidate|placebo (single dose, oral) followed by methylphenidate (single dose, oral, 20 mg, immediate release)
89190175|NCT06063174|No Intervention|Baseline-Only|Baseline-only condition will be cross-sectional, and participants will be only completing the first portion of the study. Participants in this arm will be asked to wear a research-grade smartwatch for at least one week and complete the baseline package at one time point which includes self-reported questionnaires, micro-blood collection, and optional stool collection.
89190176|NCT06063174|Active Comparator|Active Control|Active control condition will be longitudinal. Participants in this arm will be asked to wear a research-grade smartwatch for at least 24 weeks and complete the baseline package as well as two follow-ups over a period of 24 weeks. After completing the baseline package, participants in the active control group will receive a 12 week psychoeducation training on stress and health called the Environmental Education Program.
89190177|NCT06063174|No Intervention|Nonactive Control|Nonactive control condition will be longitudinal. Participants in this arm will be asked to wear a research-grade smartwatch for at least 24 weeks and complete the baseline package as well as two follow-ups over a period of 24 weeks. After completing the baseline package, participants in the nonactive control group will not be receiving any forms of intervention. Participants in this program called the Follow-up Program will be tracked over 12 weeks in parallel to participants receiving an intervention and another 12 weeks after.
89190178|NCT06063174|Experimental|CAL STAR Personalized Intervention|CAL STAR Personalized Intervention condition will be longitudinal. Participants in this arm will be asked to wear a research-grade smartwatch for at least 24 weeks and complete the baseline package as well as two follow-ups over a period of 24 weeks. After completing the baseline package, participants will be assigned to one of the five CAL STAR Personalized Intervention training programs (Think Well, Be Well, Eat Well, Sleep Well, Move Well programs) depending on their score on a self-reported survey called Consequences of Stress Scale (CSS). Based on the CSS score, a participant will be assigned to one of the five programs to work on a domain that is dysregulated when they are stressed. When eligible for multiple, their availability to attend coaching sessions and preferences will be accounted for, or they will be randomly assigned to conditions for which they are eligible.
89403902|NCT03688828|Active Comparator|Quadruple Therapy|Esomeprazole + Amoxicillin + Clarithromycin + Bismuth potassium citrate
89403903|NCT02091492|Active Comparator|Teriparatide|Teriparatide 20µg daily subcutaneous injection for 12 weeks after proximal humerus fracture
88879706|NCT04295772|Experimental|DOR/ISL|Pediatric participants with HIV-1 infection receive DOR/ISL for 96 weeks.
88879707|NCT04160286||ECT|Group of patients receiving ECT during their hospitalization.
88879708|NCT04160286||Non-ECT|Group of patients not receiving ECT during their hospitalization.
89199065|NCT00886041|Active Comparator|ovarian stimulation group|ovarian stimulation and timed intercourse for 3 cycles followed by ovarian stimulation and intrauterine insemination for another 3 cycles
89199066|NCT05278923|No Intervention|clean airway|CPR and endotracheal intubation in an airway without regurgitation
89199067|NCT05278923|Experimental|regurgitation airway|CPR and endotracheal intubation in an airway with regurgitation
89403904|NCT02091492|Placebo Comparator|Placebo-Teriparatide|Placebo-Teriparatide 20 µg daily subcutaneous injection for 12 weeks after proximal humerus fracture
89403905|NCT02266940|Experimental|200mg DS-1971a oral suspension fasted|200 mg DS 1971a given as oral suspension in fasted condition
89403906|NCT02266940|Experimental|200 mg DS-1971a tablet fasted|single 200 mg DS 1971a oral tablet in fasted condition
89403907|NCT02266940|Experimental|200 mg DS-1971a tablet fed|single 200 mg DS 1971a oral tablet given in fed condition
89004321|NCT04979546|Experimental|Intensive PROMs Intervention Arm|The intervention group will be asked to complete PROM questionnaires at baseline, 6 months, and 12 months via an online web-based delivery system. The treating neurologist will be prompted to view the text response to the 3-item prompt in addition to the PROM questionnaire scores for participants in the interventional group. Treating neurologist will also be alerted if participates reach certain critical threshold scores or decrement on their PROM questionnaires. Participants randomized to the intervention group will be asked to complete CSQ and CollaboRATE questionnaires at baseline and at 12 months.
89199068|NCT00610857|Experimental|Anti-CTLA4 monoclonal antibody and HDI|Specific Aim #1: Test the hypothesis that the combination of IFNa-2b and anti-CTLA-4 monoclonal antibody will improve the response rate in patients with recurrent inoperable AJCC stage III and stage IV melanoma. Our therapeutic target is achieving, with acceptable toxicity, a 20% or better rate of objective response, CR or PR by RECIST criteria, as compared to the 5% to 10% expected in patients eligible for study. Study size is planned in terms of our primary efficacy endpoint, objective response.
89403908|NCT04011358|Other|Patient|Patient with Retinal Vein Occlusion
89403909|NCT04011358|Other|Patient control|Patient with no Retinal Vein Occlusion
89403910|NCT03981952|Experimental|Cohort A (Step 1)|Individuals receive one dose of either 6.25 µg of the trivalent vaccine or placebo. Subsequent blood samples are taken for immunological testing.
89403911|NCT03981952|Experimental|Cohort B (Step 2)|Individuals receive one dose of either 12.5 µg of the trivalent vaccine or placebo. Subsequent blood samples are taken for immunological testing.
89403912|NCT03981952|Experimental|Cohort C (Step 3)|Individuals receive one dose of either 25 µg of the trivalent vaccine or placebo. Subsequent blood samples are taken for immunological testing.
89403913|NCT03981952|Experimental|Cohort D|Individuals receive one or two doses of the highest, well-tolerate dose among Cohorts A-C of the trivalent vaccine or placebo. Subsequent blood samples are taken for immunological testing.
89403914|NCT02269982||men with mCRPC prior to enzalutamide/abiraterone|
89403915|NCT02091570|Placebo Comparator|Nutrition bar|50 g nutrition bar
89403916|NCT02091570|Experimental|Nutrition Bar 1|50 g nutrition bar with additional 2 g of milk-based nutrient
89403917|NCT02091570|Experimental|Nutrition bar 2|50 g nutrition bar with additional 3 g of milk-based nutrient
89403918|NCT03838120|Other|Bupivacaine 0,5% Single arm study|Bupivacaine 0,5% Single arm study
89403919|NCT02091648|Experimental|I Can Cope Intervention|"Participants randomized to the I Can Cope condition will receive 6 face-to-face individualized sessions over a 2-month period. Each session will last 50 minutes and take place at the child's school either during approved times during the school day or as part of the after-school program. Sessions are psychoeducational and experiential and include opportunities for the child with asthma to: (1) learn about the pathophysiology of asthma; (2) understand the biological impact of stress on the body; (3) learn the relationship among thoughts, feelings, actions, and asthma; (4) acquire a set of coping skills to help deal with asthma-related and day-to-day stressors in their lives, and (5) receive training in biofeedback-assisted relaxation techniques."
89403920|NCT02091648|Active Comparator|Standard Education Intervention|"this group will receive the standard American Lung Association Open Airways for Schools program. This program includes six 40-minute sessions covering the National Heart Lung and Blood Institute recommendations for asthma education."
89403921|NCT02091648|No Intervention|No treatment control|"This group will receive no treatment during the course of the study and will have the option to receive the Open Airways program after their participation in the study is complete."
89403922|NCT04475120|Experimental|Liposomal Lacroferrin|Thirty-two patients (14 hospitalised and 18 in home-based isolation) belonging to the first group received oral and intranasal liposomal bLf. BLf capsules for oral use containing 100 mg of bLf encapsulated in liposome while bLf nasal spray had about 8 mg/ml of bLf encapsulated in liposome. BLf, contained in both products, was tested by SDS-PAGE and silver nitrate staining and its purity was about 95%. The bLf iron saturation was about 5% as detected via optical spectroscopy at 468 nm based on an extinction coefficient of 0.54 (100% iron saturation, 1% solution). The scheduled dose treatment of liposomal bLf for oral use was 1gr per day for 30 days (10 capsules per day) in addition to the same formulation intranasally administered 3 times daily (a total of about 16 mg/nostril)
89437459|NCT03862469|Other|Study Procedure (all participants)|"Diagnostic Phase (2 months): at-home urine hormone testing and completion of daily online surveys.~Individualized Task (-6 to -2 days from the subsequent menstrual cycle)"
89437460|NCT03861117|Experimental|Assisted strategy|Ability to be weaned is determined with pressure support and positive end-expiratory pressure.
88879709|NCT03888066|Experimental|Group 1: Patiromer|Subjects will be randomized to receive a daily dose of patiromer with possible dose adjustments based on subsequent local serum potassium levels.
89403923|NCT04475120|Active Comparator|SOC therapy|Thirty-two hospitalized patients belonging to the second group were only treated with SOC regimen according to the national guidelines at the time of the enrollment: lopinavir/ritonavir cps 200/50 mg, 2x2/day (alternatively darunavir 800 mg 1 cp/day+ritonavir 100 mg 1 cp/day or darunavir/cobicistat 800/150 mg 1 cp/day), chloroquine 500 mg, 1x2/day or hydroxychloroquine cp 200 mg, 1x2/day. SOC regimen lasted from 5 to 20 days, with timing to be established according to clinical course.
89403924|NCT04475120|No Intervention|Home-based isolation|Twenty-eight patients, in home-based isolation, belonging to the third group did not receive any therapy.
89403925|NCT04475120|No Intervention|Healthy volunteers|A control group, comprising 32 healthy volunteers, did not receive any treatment or placebo.
89403926|NCT03821038|Experimental|CYT107|Intravenous (IV) administration of CYT107 at 10 μg/kg twice a week for 3 weeks
88879710|NCT03888066|Placebo Comparator|Group 2: Placebo|Subjects will be randomized to receive a daily dose of placebo with possible dose adjustments based on subsequent local serum potassium levels.
88879711|NCT03467256|Experimental|experimental|Patients will receive lymphodepleting chemotherapy, one hour prior to infusion of CAR T-cells patients will receive tocilizumab IV 8 mg/kg (max 800 mg) over 1 hour. Patients then receive CD19-CAR T cells IV on day 0.
88879712|NCT03418740||FA Children|Children between the ages of 2 and 18 with genetically confirmed Friedreich's Ataxia
89403927|NCT03821038|Placebo Comparator|Placebo|Intravenous (IV) administration of the same volume of NaCl 0.9% twice a week for 3 weeks
89403928|NCT02208024|Experimental|Stereotactic Body Radiation Therapy|5 fractions of 6.6 Gy delivered twice weekly with each fraction separated by greater than 48 hours over 15 days
89403929|NCT03664804|Other|Participants with Early Manifest Stage I or II HD|No study drug was administered in this study
88879713|NCT03326388|Experimental|Selumetinib Intermittent Dosing|Phase 1 of the study to evaluate Intermittent Dosing (Selumetinib given twice daily on 5 out of 7 days) in children with NF1 and inoperable plexiform neurofibromas. The Maximum tolerated dose will define the Recommended phase 2 dose of selumetinib.
89403930|NCT01155362|Experimental|1 unit Human Placenta-Derived Cells PDA001|1 unit PDA001 in 240 millilters (mL) infused intravenously in one arm on Day 0 and Day 7.
89403931|NCT01155362|Experimental|4 units Human Placenta-Derived Cells PDA001|4 units PDA001 in 240 mL infused intravenously in one arm on Day 0 and Day 7.
89403932|NCT01155362|Placebo Comparator|vehicle control|4 units placebo in 240 mL infused intravenously in one arm on Day 0 and Day 7.
89403933|NCT01155362|Experimental|8 units Human Placenta-Derived Cells PDA001|4 units PDA-001 in 240 mL infused intravenously in each arm on Day 0 and Day 7 or 8 units PDA-001 in 240 mL infused intravenously in one arm on Day 0 and Day 7
89403934|NCT03279718|Experimental|periodontal treatment|
89403935|NCT03279718|No Intervention|only oral hygiene instruction, no treatment|
89403936|NCT02088528|Active Comparator|Aurolab glaucoma drainage device|
89199069|NCT00672984|Experimental|Immediate-release Guanfacine HCl|
89403937|NCT02088528|Active Comparator|Trabeculectomy with mitomycin-c|
89403938|NCT02272010|Experimental|Experimental diet|Altered n-6 and n-3 fatty acid intake.
89403939|NCT02272010|Active Comparator|Comparator Diet|Diet standardized to usual n-6 and n-3 intake.
89403940|NCT02091804|Active Comparator|Wait-List group|Individuals randomized to the control group will receive the intervention program immediately after their 3-month research visit.
89403941|NCT02091804|Experimental|Immediate Group|Individuals randomized to the Immediate group will receive the intervention program immediately after completing the baseline assessment.
89403942|NCT03634150|Experimental|Single arm Nerofe followed by Doxorubicin|IV treatment of Nerofe 96 mg\m2 followed by IV Doxorubicin 10mg\m2 Once weekly
89403943|NCT02085330|Experimental|Hyperbaric oxygen therapy|Hyperbaric oxygen therapy
89403944|NCT02085330|No Intervention|Standard follow up|
89403945|NCT01148498|Experimental|Group 1|Older adults with mild Dementia Alzheimer's Type (DAT)
89403946|NCT01148498|Experimental|Group 2|Older adult controls with possible Alzheimer's Disease Pathology
89403947|NCT01148498|Experimental|Group 3|Older adult controls with no evidence of Alzheimer's Disease
89403948|NCT01148498|Experimental|Group 4|Younger subjects who are assumed to have no cognitive impairment
89403949|NCT05090956|Experimental|control|MRI exam; The sequences to be performed will be presented to the subject according to the focus to be performed. maximal duration of the exam: 2 hours (including subject set up)
89403950|NCT02092038|Experimental|Preoperative chemoradiation|Stereotactic biopsy of brain tumor, then partial brain irradiation and temozolomide, followed by craniotomy and tumor resection, followed by temozolomide
89403951|NCT02272166|Active Comparator|propofol|Hypnotic used in this arm is exclusively intra-venous propofol.
89403952|NCT02272166|Active Comparator|sevoflurane|Hypnotic used in this arm is exclusively inhaled sevoflurane.
89403953|NCT04438252|Experimental|Cariescan pro|device for early caries detection
89403954|NCT04438252|Experimental|ICDAS II|Index for caries detection
89403955|NCT02085564||GEJ-cancer patients consideres resectable|All patients have biopsy verified GEJ-cancer, and has been considered for intend curative resection by a multidisciplinary panel of specialists.
89403956|NCT01139216|Experimental|Daikenchuto (TU-100) 7.5g/day|Daikenchuto (TU-100) 2.5g TID (7.5g/day)
88879714|NCT03265080|Experimental|Part A|"Dose cohorts of 3 participants each will be treated. Initiation of dosing will be staggered by at least 4 weeks for participants in the first cohort, also known as intra-cohort staggering.~Two dose levels of ADXS-NEO will be explored: 1 x 10^9 and 1 x 10^8 colony forming unit (CFU)."
88879715|NCT03265080|Experimental|Part B|Two dose levels of ADXS-NEO will be explored (i.e., 1 x 10^8 and 5 x 10^8 CFU) in combination with 200 mg of pembrolizumab.
89403957|NCT01139216|Experimental|Daikenchuto (TU-100) 15g/day|Daikenchuto (TU-100) 5g TID (15g/day)
89403958|NCT01139216|Placebo Comparator|Placebo|Placebo TID
88879716|NCT03265080|Experimental|Part C|ADXS-NEO will be explored at 1 x 10^8 CFU in combination with 200 mg of pembrolizumab in an expansion cohort.
89403959|NCT03246568|Active Comparator|Pulmonary vein isolation alone|PVI by cryo-balloon ablation without linear ablation
89403960|NCT03246568|Experimental|Renal nerve denervation|PVI by cryo-balloon ablation without linear ablation plus bilateral RND using a multi-electrode renal denervation catheter.
89403961|NCT01138436|Experimental|MEBO Wound Ointment (MEBO)|Topical application once a day
89403962|NCT01138436|Active Comparator|Standard of Care|Application of Profore multilayer compression bandage system
89403963|NCT02088684|Experimental|LEE011 + BKM120 + fulvestrant|LEE011 - 28 day cycles (21 days followed by a 7 day break - dose escalating) BKM120 - daily (dose escalating) fulvestrant - i.m. - 500 mg given on day 1 and day 15 of Cycle 1, then on Day 1 of each subsequent cycle.
89403964|NCT02088684|Experimental|LEE011 + BYL719 + fulvestrant|LEE011 - 28 day cycles (21 days followed by a 7 day break - dose escalating) BYL719 - daily (dose escalating) fulvestrant - i.m. - 500 mg given on day 1 and day 15 of Cycle 1, then on Day 1 of each subsequent cycle.
88814804|NCT03034694|Placebo Comparator|Routine Care|The first group will be randomized to routine care of receiving or not receiving a dermatology consult in the hospitalized setting based on the clinical decision of the hospitalist. The patients will see the research coordinator who will take images and for a teledermatology assessment, however, these assessments will not be placed in the chart and the treating hospitalist will not know.
88814805|NCT03034694|Experimental|Teledermatology INtervention|The second arm will be patient randomized to teledermatology intervention. These patients will be imaged by the research coordinator, then the assessment will be placed in the chart for the hospitalist to see although final treatment decisions are still made by the hospitalist.
88814806|NCT05710991|Active Comparator|Sleep Hygiene Workshop|The Sleep Hygiene workshop contains psychoeducation on sleep hygiene and has been modified to target the transitions and concerns faced by perinatal individuals. Sleep hygiene is commonly utilized as a treatment for insomnia in general practice, with the information provided through verbal advice and a sleep hygiene info sheet. As such, the sleep hygiene protocol used in this study reflects standard care commonly offered to perinatal individuals outside of our specialized clinic.
88814807|NCT05710991|Experimental|Cognitive Behavioural Therapy for Insomnia Workshop|The Cognitive Behavioural Therapy (CBT) for Insomnia workshop contains empirically supported strategies for insomnia that have been modified to target the transitions and concerns faced by perinatal individuals. CBT is the first-line treatment for insomnia and promising research on CBT for insomnia specifically during pregnancy and postpartum is emerging.
88814808|NCT03031184|Experimental|Mirtazapine|15mg of Mirtazapine over encapsulated to produce a blinded product that looks identical to the other arms. Starting dose is one capsule per day, escalating to 2 capsules per day after 2 weeks if no side effects and up to 3 capsules per day after 4 weeks.
88814809|NCT03031184|Placebo Comparator|Placebo|Lactose powder encapsulated to produce a blinded product that looks identical to the other arms. Starting dose is one capsule per day, escalating to 2 capsules per day after 2 weeks if no side effects and up to 3 capsules per day after 4 weeks.
88814810|NCT03034616|Experimental|ex vivo activation|"'OLIVA device' in patients that undergo oophorectomy on the cortex of the removed ovary we will perform 5 parallel slashes 3 cm long.~this will be followed by investigation by the pathologist as to the depth of cuts."
88814811|NCT03034616|Active Comparator|in vivo activation|'OLIVA device' in patients undergoing oophorectomy before the resection from is pedicle on cortex of the ovary we will perform 5 parallel slashes 3 cm long. following oophorectomy investigation by the pathologist as to the depth of cuts and proximity to blood vessels.
88814812|NCT03034616|Active Comparator|POI OLIVA|'OLIVA device' in patients with premature ovarian failure and following safety data from arm 2 activation by ovarian slashing will be performed laparoscopically by closed cutting device (OLIVA). follow-up by sonography and hormonal markers of ovarian activity
88814813|NCT02238977|Active Comparator|Fluoxetine|Fluoxetine up to 20 mg orally daily for 12 weeks. Flexible dosing between a minimum of 10 mg daily and 20 mg daily as tolerated.
88814814|NCT02238977|Experimental|Bupropion|Bupropion sustained release (SR) 150 mg orally twice per week
88814815|NCT00945854|Active Comparator|Wholegrain cereal diet|Treatment with a diet based on wholegrain cereals and foods with low glycemic index
88814816|NCT00945854|Active Comparator|Refined cereal diet|Treatment with a diet based on refined cereals and foods with high glycemic index
88814817|NCT02239289|Experimental|Biofeedback|Subjects will be provided with four sessions of supervised biofeedback training
88814818|NCT03031028|Other|ketogenic diet|Ketogenic diet
88814819|NCT03034382|Experimental|Morphine|5 mg morphine in 5ml volume injected as adjuvants to 10 ml of lidocaine and epinephrine 1:400,000.
88814820|NCT03034382|Experimental|Nalbuphine|5 mg nalbuphine in 5ml volume injected as adjuvants to 10 ml of lidocaine and epinephrine 1:400,000.
88814821|NCT03034382|Experimental|Morphine and Nalbuphine|"5 mg morphine and 5 mg nalbuphine in 5 ml volume are injected as adjuvants to 10 ml of lidocaine and epinephrine 1:400,000.~combination of 5 mg morphine and 5 mg nalbuphine in 5 ml volume are injected perineurally as adjuvants for 10 ml of lidocaine + epinephrine 1:400,000 in ultrasound guided interscalene block"
88814822|NCT03034382|Placebo Comparator|Bupivacaine 0.5%|10 ml of lidocaine 1% and epinephrine 1:400,000 and 5 ml of Bupivacaine 0.5% in interscalene block.
88814823|NCT01664741|Active Comparator|Nicotine patch - transdermal|21 mg nicotine patch
88814824|NCT01664741|Placebo Comparator|Placebo NRT|Matching placebo patch
88814825|NCT01664741|No Intervention|Healthy non-smoker comparison|Demographically-matched women and men who have never smoked
89403965|NCT02088684|Experimental|LEE011 + fulvestrant|LEE011 - 28 day cycles (3 weeks on, 1 week off) or (continuous daily dosing - dose escalating) fulvestrant - 500 mg i.m. given on Day 1 and Day 15 of Cycle 1, then on Day 1 of each subsequent cycle.
89403966|NCT01137968|Experimental|imetelstat plus standard of care|imetelstat plus standard of care (bevacizumab or observation)
89403967|NCT01137968|Other|Standard of care|Bevacizumab or observation
89403968|NCT03278002||Group/Cohort Information|This is a US multi-center, prospective, real world, observational drug registry enrolling patients actively treated with Uptravi. Participating patients will be followed prospectively for a maximum of 18 months from the date of enrollment into the registry.
89403969|NCT03557814|Active Comparator|LED01|Conventional non-surgical periodontal therapy plus LED light irradiation from T0-T1
89403970|NCT03557814|Active Comparator|LED02|Conventional non-surgical periodontal therapy plus LED light irradiation from T1-T2
88879717|NCT03258606||Individuals with affected capacity to consent|Individuals with who were unable to consent and were allowed by protocol to give surrogate consent.
89199070|NCT00672984|Active Comparator|Moxifloxacin HCl|
89199071|NCT00672984|Placebo Comparator|Placebo|
89403971|NCT03557814|Sham Comparator|Control|Conventional non-surgical periodontal therapy without LED light irradiation
89403972|NCT02249910|Experimental|Semaglutide|
89403973|NCT02936596|Experimental|Ursodeoxycholic acid + immunosuppressive agents group|Ursodeoxycholic acid + immunosuppressive agents
89403974|NCT02936596|Active Comparator|Ursodeoxycholic acid group|Ursodeoxycholic acid
89403975|NCT02088762||1 cm safety margin|1 cm safety margin
89403976|NCT02088762||2 cm safety margin|2 cm safety margin
89403977|NCT02267018|Active Comparator|nCPAP|Nasal continuous positive airway pressure is a frequently used modality for non-invasive respiratory support in preterm infants.
89403978|NCT02267018|Active Comparator|NIHFV|Non-invasive high-frequency ventilation is a relatively new modality that is being utilized to support preterm infants and prevent the need for invasive ventilation, but this particular modality is has not been well studied to date.
89403979|NCT03557736|Experimental|Home-HIT|Home-based high-intensity interval training: participants performed 12 weeks of simple body weight exercises in a place of their own choosing 3x/week
89403980|NCT03557736|Experimental|Home-MICT|Home-based moderate-intensity interval training: participants performed 12 weeks of continuous exercise (running, swimming or cycling) in a place of their own choosing 3x/week
89403981|NCT03557736|Experimental|Lab-HIT|Laboratory-based high-intensity interval training: participants performed supervised cycle exercise under laboratory conditions 3x/week for 12 weeks
89403982|NCT02267096|Experimental|Telephone Counseling (TC)|The TC arm will receive the list of minimal treatment interventions plus 3-6 sessions of stepped-care, proactive, telephone counseling.
89403983|NCT02267096|Active Comparator|Minimal Treatment|The minimal treatment intervention includes a list of print, online, national telephone quitline phone number, and in-person cessation resources that is sent to participants.
89403984|NCT02085642|Experimental|Acupuncture|True acupuncture
89403985|NCT02085642|Sham Comparator|Sham needle|Retractable acupuncture needles will be used. No true transcutaneous needling through the skin
89403986|NCT02398396|Experimental|Open Label: 4CMenB (Bexsero®)|
89403987|NCT04476134||patients with adverse events|patients underwent adverse events after cardiac surgery
89403988|NCT02092194|Active Comparator|Standard Dose online HDF|Proposed target convection volume; 16.8-21.5 L/treatment (70-90 mL/min)
89403989|NCT02092194|Experimental|High Dose online HDF|Proposed target convection volume; 33-43 L/treatment (140-180 mL/min).
89403990|NCT03096808|Experimental|Adaptive Radiotherapy|Eligible patients will receive IMRT of 60-70Gy in 30-35 once-daily fractions with or without concurrent chemotherapy according to the current standard of care.
89199072|NCT00886197||GERD|"Symptomatic reflux subjects who receive esophagogastroscopy, aged from 20 to 70 years old.~Patients with typical reflux symptoms (heartburn and/or acid regurgitation) at least 3 times per week in recent 4 months."
89199073|NCT02543697|Experimental|Adrenal venous sampling|Patients going trough an adrenal venous sampling to find out if hypercortisolism is uni or bilaterally produced.
89403991|NCT04476056|Experimental|Chronic Pancreatitis + Malnutrition|Malnourished patients with chronic pancreatitis will receive intensified nutritional therapy for 6 months.
89403992|NCT03090022|Active Comparator|Mesh implantation|Prior to closure of the abdominal wall a mesh will be implanted in a standardized fashion
89403993|NCT03090022|Active Comparator|Single running suture of abdominal fascia|The closure of the abdominal wall a Standard technique will be applied using a running suture
89403994|NCT02267174|Other|Standardized OR to ICU handoff|A standardized handoff process for conducting OR to ICU handoffs will be implemented in two intensive care units without a standard process.
89403995|NCT02085798||Group 1|Low or intermediate-1 risk MDS patients according to IPSS
89403996|NCT02085798||Group 2|Intermediate-2 risk MDS patients according to IPSS
89403997|NCT02085798||Group 3|Any risk CMML patients according to CPSS
89403998|NCT05377138|Experimental|MYDAWA clients|MYDAWA clients determined to be eligible for PrEP or PEP can order them online and have them delivered a small fee. This is not currently the standard of care in Kenya. Those who are not in the study can only receive PrEP or PEP at healthcare facilities in Kenya.
89403999|NCT05628584|Experimental|High FODMAP|
89404000|NCT05628584|Placebo Comparator|LOW FODMAP|
89404001|NCT02088840||stem cell tranplant|All patients undergoing autologous or allogeneic stem cell tranplant for any underlying disease
89404002|NCT05628506|Experimental|intervention group|
89404003|NCT05628506|No Intervention|control group|
89404004|NCT02427490|Active Comparator|Unenhanced Monitoring|Family caregivers of cancer patients receiving outpatient palliative care will complete standardized questionnaires at the time of study enrollment and two, four, and eight weeks after study enrollment.
89404005|NCT02427490|Experimental|Problem-Solving Intervention|Family caregivers of cancer patients receiving outpatient palliative care will use videoconferencing tools to participate in three problem-solving sessions with a member of the research team.
89404006|NCT05626946||Nursing Home resident from Grand Nancy area with Advanced Practice Nurse intervention|Patients aged 75 years and over, resident in Nursing Home at the time of inclusion, and received at least once in the emergency room of the Nancy Hospital during the period concerned. Inclusion in the group with IPA intervention for Nursing Home residents of the Grand Nancy area where the Advanced Practice Nurse is authorised to intervene.
89404007|NCT05626946||Nursing Home resident outside Grand Nancy area without Advanced Practice Nurse intervention|Patients aged 75 years and over, resident in Nursing Home at the time of inclusion, and received at least once in the emergency room of the Nancy Hospital during the period concerned. Inclusion in the control group for Nursing Home residents outside the Grand Nancy area without the Advanced Practice Nurse intervention.
89404008|NCT02088918|Active Comparator|Nateglinide+Metformin|coadministration of nateglinide and metformin
89404009|NCT02088918|Experimental|Nateglinide/Metformin|Nateglinide/Metformin tablet
89404010|NCT02419378|Experimental|alemtuzumab|"Administration of 2 courses of alemtuzumab at an interval of 1 year. Course 1: Intravenous infusion of 12 mg alemtuzumab per day on 5 consecutive days.~Course 2: Intravenous infusion of 12 mg alemtuzumab per day on 3 consecutive days."
89404011|NCT05628272|Experimental|Experimental group|granulocyte stimulating factor(5ug/kg/d) +infusion of umbilical cord blood mononuclear cells, each infusion ≥1×10^8, once a week
89404012|NCT05628272|Placebo Comparator|control group|granulocyte stimulating factor 5ug/kg/d
88879718|NCT02554500|Experimental|Intact scaphoid bone|"Group A (n=20): Consent-capable male and female patients ≥18 years of age who have an intact scaphoid bone.~Intervention: Remote Ischemic Preconditioning (by Blood Pressure Cuff)"
89404013|NCT02092272|Experimental|instructional exercise video source|instructional exercise video source
89404014|NCT02092272|No Intervention|Standard Therapy|Standard Therapy
89404015|NCT05375500|Experimental|Digital Therapeutic Arm|measure the treatment effects of digital therapeutic intervention
89404016|NCT01097096|Active Comparator|CAD106 150μg + Adjuvant 1 at middle dose|
89404017|NCT01097096|Active Comparator|CAD106 150μg + Adjuvant 1 at low dose|
89404018|NCT01097096|Placebo Comparator|Placebo + Adjuvant 1 at middle dose|
89404019|NCT01097096|Active Comparator|CAD106 150μg + Adjuvant 2 at middle dose|
89404020|NCT01097096|Active Comparator|CAD106 150μg + Adjuvant 2 at low dose|
89404021|NCT01097096|Placebo Comparator|Placebo + Adjuvant 2 at middle dose|
89404022|NCT01097096|Active Comparator|CAD106 450μg + either Adjuvant 1 or 2 at middle dose|
89404023|NCT01097096|Active Comparator|CAD106 450μg + either Adjuvant 1 or 2 at low dose|
88879719|NCT02554500|Experimental|Intact metacarpal bone|"Group B (n=20): Consent-capable male and female patients ≥18 years of age who have an intact metacarpal bone.~Intervention: Remote Ischemic Preconditioning (by Blood Pressure Cuff)"
88879720|NCT02554500|Experimental|Fractured scaphoid bone|"Group C (n=20): Consent-capable male and female patients ≥18 years of age who have a fractured scaphoid bone.~Intervention: Remote Ischemic Preconditioning (by Blood Pressure Cuff)"
88879721|NCT02554500|Experimental|Fractured metacarpal bone|"Group D (n=20): Consent-capable male and female patients ≥18 years of age who have a fractured metacarpal bone.~Intervention: Remote Ischemic Preconditioning (by Blood Pressure Cuff)"
89199074|NCT00762138|Other|Autologel System|Autologel System produces platelet rich plasma gel
89404024|NCT01097096|Placebo Comparator|Placebo + either Adjuvant 1 or 2 at middle dose|
89404025|NCT02085876||Patients requiring a liver biopsy|
89404026|NCT05375422|Experimental|SARAH group|The SARAH group will receive an exercise book containing 7 mobility exercises and 4 strength exercises that are performed using elastic materials that provide progressive degrees of resistance to movement. Patients will be guided in person by a trained professional, so that they are carried out without their presence, in the home environment, daily and monitored at periodically scheduled meetings. A total of 4 face-to-face meetings will be held during the 3-month follow-up. The SARAH group and the control group will receive information related to joint protection, use of splints, assistive devices and other general advice, as needed, will receive some booklets to reinforce the guidelines. The program will last 12 weeks, with 4 face-to-face meetings lasting 40 minutes and monitored in periodically scheduled meetings.
89404027|NCT05375422|Active Comparator|Control group|"Control group will receive information related to joint protection, use of splints, assistive devices and other general advice, as needed, will receive some booklets to reinforce the guidelines.~After 12 weeks, the control group will also be invited to perform the SARAH protocol exercises."
88879722|NCT02554500|Experimental|Intact metatarsal bone|"Group B (n=20): Consent-capable male and female patients ≥18 years of age who have an intact metatarsal bone.~Intervention: Remote Ischemic Preconditioning (by Blood Pressure Cuff)"
89404028|NCT02092428|Experimental|Image Quality|Healthy volunteers and patients will undergo non-contrast MRI or contrast-enhanced MRI to compare image quality between contrast and non-contrast scans.
89404029|NCT02092428|Experimental|Diagnostic Accuracy|Healthy volunteers and patients will undergo non-contrast MRI or contrast-enhanced MRI to assess the diagnostic accuracy of coronary MRI in detecting CAD as compared to conventional x-ray angiography
89404030|NCT02783404|No Intervention|Control|Receiving no prophylaxis
89404031|NCT02783404|Active Comparator|Amoxicillin|"Receiving 2 gr oral Amoxicillin before any dental manipulation and following endotracheal intubation~Intervention: Drug: Amoxicillin"
89404032|NCT02783404|Experimental|Amoxicillin-Potassium Clavulanate|"Receiving 2gr/125 mg oral Amoxicillin-Potassium Clavulanate before any dental manipulation and following endotracheal intubation~Intervention: Drug: Amoxicillin-Potassium Clavulanate"
89404033|NCT05503290|No Intervention|Control|
89404034|NCT05503290|Active Comparator|Lullaby Project|Participants assigned to the intervention group will meet virtually with a professional musician for 5-7 sessions over the course of 10 weeks. Each session will last approximately 1.5 hours and will be conducted via Zoom.
89437461|NCT03861117|Active Comparator|Non assisted strategy|Ability to be weaned is determined with T-piece.
89437462|NCT03850964|Active Comparator|Part B (Severe Anemia) Pazopanib - 150 mg|150 mg pazopanib oral capsules (six 25 mg placebo capsules daily).
89437463|NCT03850964|Placebo Comparator|Part B (Severe Anemia) Placebo|Placebo oral capsules (six 25 mg placebo capsules daily).
89437464|NCT03850964|Active Comparator|Part B (Severe Epistaxis) Pazopanib - 150 mg|Pazopanib 150 mg oral daily dosing (six 25 mg Pazopanib capsules).
88879723|NCT02424084|Experimental|Intact scaphoid bone|"Group A (n=20): Consent-capable male and female patients ≥18 years of age who have an intact scaphoid.~Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
88879724|NCT02424084|Experimental|Intact metacarpal bone|"Group B (n=20): Consent-capable male and female patients ≥18 years of age who have an intact metacarpal bone.~Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
89404035|NCT05096806|Active Comparator|Usual care plus TENS|"Participants in this group will receive transcutaneous electrical nerve stimulation (TENS) and usual care.~TENS treatment will perform in the region of the knee and the extensor muscles for 20 minutes, 2 times a week. 4 electrodes will be placed, 2 on the proximal region of the internal and external vastus, and the other 2 on the distal region of the motor plate.~Usual care will consist in home exercises with toning exercises of the extensor apparatus, pelvic region and musculoskeletal stretching exercises of 2 weekly sessions, the recommendation of daily activity of walking for 1 hour daily as an active lifestyle and the recommendation of the reduction of body weight in the case of being above normal weight. There will be a total of 6 face-to-face sessions at the rate of 2 weekly sessions"
89404036|NCT05096806|Experimental|Usual care plus Acupuncture|"Participants in this group will receive acupuncture treatment and usual care.~Acupuncture treatment will consist in 20-minute semi-standardized acupuncture sessions, 2 times a week. The intervention will consist of the insertion of 8 needles: 4 in points located in the knee (points St34, St35, XiYan and Sp10) and 4 more sensitive to palpation points located between the knee and the ankle. Stimulation will be performed to obtain local spasm response, the needles will be left for 20 minutes and then removed. The needles will be sterile disposable silicone needles of 0.20x20mm and 0.20x40mm.~Usual care will be the same described in the Usual care plus TENS group"
89404037|NCT01097018|Active Comparator|Perifosine + Capecitabine|Perifosine 1 tablet daily + Capecitabine BID days 1 - 14 every 21 days
88879725|NCT02424084|Experimental|Fractured scaphoid bone|"Group C (n=20): Consent-capable male and female patients ≥18 years of age who have a fractured scaphoid.~Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
89190179|NCT06063148|Experimental|Enrolled Participant|During routine arterial blood gas sampling, a coordinator will measure SpO2 from a similar extremity. SpO2 data will be recorded using Masimo Radical-7 oximeters. To minimize ambient light interference or optical cross talk from other SpO2 sensors, all the SpO2 sensors will be fully shielded with cloth wraps provided by Masimo. Each enrolled infant will undergo simultaneous blood gas sampling and SpO2 measurement for each routine blood gas collected. Up to a total of 10 SpO2 measurements will be collected, paired with 10 blood gas samples collected as part of routine care, though We anticipate about 3 paired samples (SaO2 and SpO2) per enrolled infant.
89404038|NCT01097018|Placebo Comparator|Placebo + Capecitabine|Placebo 1 tablet daily + Capecitabine BID days 1 - 14 every 21 days
89404039|NCT05096650|Experimental|platelet rich plasma|Each case will receive 3 sessions of injection therapies with one month interval. The practitioner will inject 2ml of platelet rich plasma with fan and linear method into photoaging areas in one side of the midface in one session of treatment.
89404040|NCT05096650|Other|platelet poor plasma|Each case will receive 3 sessions of injection therapies with one month interval. The practitioner will inject 2ml of platelet rich plasma with fan and linear method into photoaging areas in the other side of the midface in one session of treatment.
88879726|NCT02424084|Experimental|Fractured metacarpal bone|"Group D (n=20): Consent-capable male and female patients ≥18 years of age who have a fractured metacarpal bone.~Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
89404041|NCT02088996|Active Comparator|IT and LWD on high power|IT and LWD on high power
89404042|NCT02088996|Placebo Comparator|LWD on low power|LWD on low power
89404043|NCT05096572|Experimental|Group 1|Subjects will receive VIM stimulation for two weeks, followed by VIM+PSA stimulation for two weeks, and finally PSA stimulation for two weeks.
88879727|NCT02424084|Experimental|Intact metatarsal bone|"Group B (n=20): Consent-capable male and female patients ≥18 years of age who have an intact metatarsal bone.~Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
88879728|NCT00340002||Pregnant women|Pregnant women aged 18 years and older
88879729|NCT05310006|Experimental|High Speed Resistance Exercise (HSRE)|Exercise sessions performed using eight times (sets) with 4-5 repetitions at 70-75% of the maximal strength. The concentric phase was performed as fast as possible, and the eccentric phase was carried out for 2 s.
88879730|NCT05310006|Experimental|Traditional Resistance Exercise (TRE)|Exercise sessions were performed using four sets of 8-10 repetitions at 70-75% of the maximal strength. The concentric and eccentric phases were carried out for 2 s.
89404044|NCT05096572|Experimental|Group 2|Subjects will receive VIM+PSA stimulation for two weeks, followed by PSA stimulation for two weeks, and finally VIM stimulation for two weeks.
89404045|NCT05096572|Experimental|Group 3|Subjects will receive PSA stimulation for two weeks, followed by VIM stimulation for two weeks, and finally VIM+PSA stimulation for two weeks.
89404046|NCT01096862|Experimental|Group 1|lowest dose
89404047|NCT01096862|Experimental|Group 2|low dose
89404048|NCT01096862|Experimental|Group 3|high dose
89404049|NCT01096862|Experimental|Group 4|highest dose
89404050|NCT01096862|Experimental|Group 5|medium dose
89404051|NCT01096862|Placebo Comparator|Placebo|Matching placebo
89404052|NCT02092506|Active Comparator|triple therapy|10 day triple therapy (PPI, amoxicillin 1g, clarithromycin 500mg twice daily)
89404053|NCT02092506|Active Comparator|Concomitant therapy|10-day concomitant therapy (PPI, amoxicillin 1g, clarithromycin 500mg, metronidazole 400mg twice daily).
88879731|NCT05310006|No Intervention|Control Session (CS)|Participants remained seated in a comfortable chair listening to music and/or talking with study investigators for approximately 30 min.
88879732|NCT05313282|Experimental|treatment group|combination of hepatic arterial infusion chemotherapy (HAIC) of oxaliplatin, 5-fluorouracil and leucovorin (mFOLFOX7) , targeted drugs (Apatinib 250mg), and anti-PD-1 immunotherapy (Camrelizumab 200mg)
88879733|NCT05313282|Active Comparator|control group|combination of targeted drugs (Apatinib 250mg), and anti-PD-1 immunotherapy (Camrelizumab 200mg)
88879734|NCT05315622|Experimental|Intervention|Bilateral vertebral manipulation of the T12-L1 vertebra
88879735|NCT05315622|Placebo Comparator|Placebo|Application of slight manual tension to the vertebra without reaching a manipulation thrust
88879736|NCT05318274|Experimental|ARM I|Radiotherapy treatment with high hypofractionation, 26 Gy in 5 fractions to the whole breast.
89404054|NCT02092506|Active Comparator|sequential therapy|10-day sequential therapy (PPI and amoxicillin 1 g twice daily x 5 days followed by PPI, clarithromycin 500mg, metronidazole 400mg twice daily x 5days)
89404055|NCT02089074|Experimental|drug use counselling|Pharmacist conducting drug reconciliation, medication reviews and drug use counselling during hospitalisation. Follow up telephone calls 1 week, 1 month, 2 months and three months after discharge from hospital
88879737|NCT05318274|Active Comparator|ARM II|Radiotherapy treatment with standard hypofractionation, 42.5 Gy in 16 fractions with simultaneous integrated increase of 5.5 Gy to the tumor bed in high-risk patients.
89404056|NCT02089074|No Intervention|Control group|The patients in the control group receive no intervention just treatment and follow up according to national standards
89404057|NCT01092104|Experimental|TBR-652 25 mg QD|TBR 25 mg QD for 10 days
88879738|NCT05312034|Experimental|Application of an antimicrobial stewardship program in ICUs|Application of an antimicrobial stewardship program in Brazilian ICUs using machine learning techniques and an educational model
88879739|NCT05311722|Experimental|Dexmedetomidine|Inj.dexmedetomidine 0.5mcg/kg diluted in 10ml N/s given as iv infusion over 10 minutes
88879740|NCT05311722|Experimental|Ketamine|Inj.ketamine 0.5mg/kg diluted in 10ml N/s given as iv infusion over 10 minutes
88879741|NCT05311722|Experimental|Tramadol|Inj.tramadol 0.5mg/kg diluted in 10ml N/s given as iv infusion over 10 minutes
88879742|NCT05311644||Included|All participants that cesed VIT between 2005 and 2019, and did not withdraw his consent to participate to the study.
88879743|NCT05314062|Active Comparator|Ferrous sulfate (FeSO4)|FeSO4 supplements containing 54 mg elemental iron
89404058|NCT01092104|Placebo Comparator|Placebo|Matching Placebo QD for 10 days
88879744|NCT05314062|Experimental|Ferrous sulfate-enriched Aspergillus oryzae (Ao iron)|Ao iron supplements containing 54 mg elemental iron
88879745|NCT05317884|No Intervention|No Contact|No reminder sent
88879746|NCT05317884|Experimental|Reminder|Reminder email with contact information to set an appointment will be sent 12 weeks before the appointment.
88879747|NCT03215940|Active Comparator|Delta-9-Tetrahydrocannabinol's (Delta-9-THC) effects on pain|This arm will be testing the analgesic effects of orally dosed Delta-9-Tetrahydrocannabinol on subjects with chronic non-cancer pain.
88879748|NCT03215940|Active Comparator|Cannabidiol's (CBD) effects on pain|This arm will be testing the analgesic effects of orally dosed Cannabidiol on subjects with chronic non-cancer pain.
88879749|NCT03215940|Placebo Comparator|Placebo|This Placebo arm will act as the control as standard of care medications will be continued through the study. This arm will allow us to compare the analgesic effects of the other two arms with the standard of care treatments for chronic non-cancer pain.
88879750|NCT03219762|Experimental|Nab-paclitaxel|Nab-paclitaxel (30-min infusion) 100 mg/sqm weekly on days 1, 8, 15 q 28 days.
88879751|NCT03219918|Active Comparator|With EndoRings|Colonoscopy is performed with the use of the cap-device EndoRings II Distal Attachment to be attached to the tip of the colonoscope
88879752|NCT03219918|No Intervention|NO EndoRings|Colonoscopy is performed conventionally without any caps
88879753|NCT03219996||non-survivor group|
88879754|NCT03219996||survivor group|
88879755|NCT03219606|Experimental|education arm|Participants in education arm will have an organized education course of modified Rodnan Skin Scoring.
88879756|NCT03218904|Experimental|Glucose intake|Experiment 1: study day 1- single oral dose of glucose study day 2- single oral dose of glucose with U-13C-glucose
88879757|NCT03218904|Experimental|Carbohydrates intake|Experiment 2: study day 1-single oral dose of uncooked cornstarch study day 2-single oral dose of uncooked cornstarch with U-13C-glucose study day 3-single oral dose of Glycosade® study day 4-single oral dose of Glycosade® with U-13C-glucose
88879758|NCT03219138|No Intervention|Electromyography|Neuromuscular function was monitored, using evoked electromyography of the adductor pollicis muscle with a neuromuscular transmission module by a non-blinded investigator.
88879759|NCT03219138|Experimental|Acceleromyography|Immediately after extubation the blinded anaesthesiologist tested with an uncalibrated acceleromyography on the contralateral arm.
88879760|NCT03219060|Experimental|Intervention group|MI based four individual sessions
88879761|NCT03219060|Active Comparator|Control group|Brief advice following 5As
88879762|NCT03218436|Active Comparator|CAP cohort|Cold Atmospheric plasma intervention
88879763|NCT03218436|No Intervention|Control cohort|no intervention
88879764|NCT03218280|Active Comparator|Antioxidant Therapy|
88879765|NCT03218280|No Intervention|Antioxidant Free|
89404059|NCT01092104|Experimental|TBR-652 50 mg QD|TBR-652 50 mg QD for 10 days
89404060|NCT01092104|Experimental|TBR-652 75 mg QD|TBR-652 75 mg QD for 10 days
89404061|NCT01092104|Experimental|TBR-652 100 mg QD|TBR-652 100 mg QD for 10 days
89404062|NCT01092104|Experimental|TBR-652 150 mg|TBR-652 150 mg QD for 10 days
89404063|NCT02092584|Active Comparator|CVD, Omega-3|patients with Cardiovascular disease who receive 4g/d omega-3
89404064|NCT02092584|Placebo Comparator|CVD, Placebo|patients with cardiovascular disease who receive 4 cap of placebo/day
89404065|NCT01128530|Experimental|JNJ-32729463|JNJ-32729463 250 mg tablet and matching linezolid placebo twice daily
89404066|NCT01128530|Active Comparator|linezolid|linezolid 600 mg tablet and matching JNJ-32729463 placebo twice daily
89404067|NCT02660086|Experimental|Personalized feedback|Emails and letters providing personalized nutrition feedback about food choices and health, social norms, and financial incentives for healthy food choices
88879766|NCT03218124|Experimental|remifentanil|"After skin suture, a predetermined Effect site remifentanil concentration will be achieved. Starting from 1.5 ng/ml in the first patient and increased or decreased by 0.2 ng/ml intervals based on the previous patient response: up if cough present, down otherwise (Dixon's up and down method)."
88879767|NCT03217500|Experimental|Corneal epithelial autograft|pterygium resection combined with femtosecond laser assisted corneal epithelial autograft
88879768|NCT03217500|Active Comparator|Limbal conjunctival autograft|pterygium resection combined with diamond knife assisted limbal conjunctival autograft
88879769|NCT03217500|Active Comparator|Simple removal|Simple removal of pterygium
88879770|NCT03217734|Placebo Comparator|ADA and Placebo|Adalimumab 40 mg, Subcutaneous, Bi-Weekly, 16 Weeks Placebo, Tablet, Oral, Weekly, 16 Weeks
88879771|NCT03217734|Active Comparator|ADA and MTX|Adalimumab 40 mg, Subcutaneous, Bi-Weekly, 16 Weeks Methotrexate, 2.5 mg Tablet, 10 mg Weekly, Oral, 16 Weeks
88879772|NCT03217032|Experimental|YUVA-GT-F801|Gene transfer to treat Hemophilia A
88879773|NCT03216876|Experimental|Healthy Controls|Healthy subjects will assigned to ursolic acid taken orally as a single dose of 40 mg, 80 mg, and 120 mg
88879774|NCT03216876|Experimental|PSC Single Dose|PSC subjects will assigned to ursolic acid taken orally as a single dose of 40 mg, 80 mg, and 120 mg
88879775|NCT03216876|Experimental|PSC Multiple Dose|PSC subjects assigned to treatment with daily oral ursolic acid at the dose determined to be optimal in the first phase of the study. The treatment will last for 24 weeks with an off-treatment follow up of 28 weeks
88879776|NCT03216330||Case|"Consented to participate in the Data Registry (H16-00264) prior to their physician appointment at the BC Women's Health Centre.~New or re-referred to the BC Women's Health Centre for Pelvic Pain and Endometriosis.~Endometriosis (previously surgically diagnosed, or current endometrioma, or current nodule)~Willing and committed to indicating pain scores and menstrual data on a REDCap survey every day for 6 weeks after the test date.~At least 18 years old"
89404068|NCT02660086|No Intervention|Control|Monthly letters with general nutrition information
88879777|NCT03216330||Control|"Reproductive aged female with no suspected or diagnosed endometriosis.~Have not experienced any sexual pain scores over 4/10 on a 11-point numeric rating scale, as determined on an online questionnaire prior to test day.~At least 18 years old"
88879778|NCT03216408|Experimental|Neuronox|Botulinum toxin type A for Injection
88879779|NCT03216408|Active Comparator|Botox|Botulinum toxin type A for Injection
88879780|NCT03216564|Experimental|Intervention Group|Participants are treated with angiotensin converting enzyme inhibitor/angiotensin receptor blocker (ACEI/ARB) AND active vitamin D (Calcitriol) 0.25 micrograms orally per day for 26 weeks.
89404069|NCT02086032|Experimental|micronized progesterone|1 mg 17 beta-estradiol plus 100 mg micronized progesterone taken orally once a day for 3 months.
89404070|NCT02086032|Experimental|dydrogesterone|1mg 17 beta-estradiol plus 10 mg dydrogesterone taken orally once a day for 3 months.
89404071|NCT01128452|Placebo Comparator|Placebo|Placebo
89404072|NCT01128452|Experimental|EVT 101|EVT 101
89404073|NCT02092740||Seminoma|Seminoma
88879781|NCT03216564|No Intervention|Usual Care|Participants are treated with ACEI/ARB alone for 26 weeks.
88879782|NCT03216174|Experimental|NESS-EFTR|This arm will be received non-exposure simple suturing endoscopic full-thickness resection after sentinel lymph node navigation
89404074|NCT02092740||Non-Seminoma|Non-Seminoma
89404075|NCT02092818||Group 1|Patients who have been prescribed Adempas for a medically appropriate use
89404076|NCT05626868||Patients for spine surgery in prone position|
89404077|NCT02267408|Experimental|Fearon algorithm dosing|Warfarin adjustment using the Fearon algorithm
89404078|NCT02267408|Active Comparator|Standard dosing|Warfarin adjustment using standard dosing
89404079|NCT05376826|Experimental|Prefrail and Frail CLD Patients|Nurse- led Physical Therapy include Video based range of Motion Exercises for 10-20 min.
89404080|NCT05376826|No Intervention|Control Group|Routine Interventions
88879783|NCT03215862|Active Comparator|Control|
88879784|NCT03215862|Experimental|Experimental|
88879785|NCT03216018|Experimental|"Experimental: Prevention Program In Favor of Resilient Self"|"The program In Favor of Resilient Self delivered to adolescence aged 15-17, over 3 months. The program contained nine weekly 90-min sessions that focus on enhancing self- resilience, self-esteem, self-image, body image. All participants will complete a self-report questionnaire at baseline, conclusion and 3 months after program conclusion."
89404081|NCT03902444||Credo® Stent and NeuroSpeed® PTA balloon catheter|Patients treated with Credo® Stent and NeuroSpeed® PTA balloon catheter in the clinical routine
89404082|NCT02092896|Placebo Comparator|Placebo + Insulin + Study 2|Study 2: Cognitive performance test
89404083|NCT02092896|Experimental|Liraglutide + Insulin + Study 2|Study 2: Cognitive performance test
89404084|NCT02092896|Experimental|Liraglutide + Insulin + Study 1|Study 1: Gastric emptying test
89404085|NCT02092896|Placebo Comparator|Placebo + Insulin + Study 1|Study 1: Gastric emptying test
89404086|NCT05096026|Experimental|Standard PCP Outreach|These patients were sent standard outreach messages to promote COVID-19 vaccination.
89404087|NCT05096026|Experimental|Culturally Tailored PCP Outreach|These patients were sent messages similar to those in the Standard PCP Outreach Group, but with additional culturally tailored content.
89437465|NCT03850964|Placebo Comparator|Part B (Severe Expistaxis) Placebo|Placebo oral capsules (six 25 mg placebo capsules daily).
89004322|NCT04979546|Active Comparator|Control Arm|The control group will be asked to complete PROM questionnaires at baseline and 12 months via an online web-based delivery system. The treating neurologist will only be prompted to view the text response to the 3-item prompt, and will not be able to access the PROM questionnaire scores for participants in the control group (unless critical values are reached on questionnaires - see below). Treating neurologist will also be alerted if participates reach certain critical threshold scores or decrement on their PROM questionnaires. Participants randomized to the intervention group will be asked to complete CSQ and CollaboRATE questionnaires at baseline and at 12 months.
89404088|NCT05096026|No Intervention|Usual Care|These patients were not sent the above study outreach messages, but may have received other messages from their local medical centers or counties.
89404089|NCT02092974|Experimental|tDCS + SSRI|
89004323|NCT04979052|Active Comparator|Interferon-Gamma|Recombinant Interferon-Gamma 1b combined with standard therapy
89004324|NCT04979052|No Intervention|Standard of care|Standard of care antifungal therapy according tot ESCMID/EFISG (Europe) or ISDA (US) guidelines.
89004325|NCT04978350|Experimental|Educational Workbook Arm|Participants in the Educational Workbook Arm will receive an electronic PDF version of an educational workbook via email on cascade screening in families with Lynch Syndrome. Genetic counselors will introduce the workbook to enrolled patients with Lynch Syndrome. Patient participants will use the activities and information in the workbook to communicate about Lynch Syndrome with family members.
89004326|NCT04976231||Treatment Naive|subjects who are naïve to ERT and start treatment with idursulfase
89004327|NCT04976231||Treatment less than 3 years|Subjects who have received ERT for <3 years
89004328|NCT04976231||Treatment over 3 years|Subjects who have received ERT for 3 or more years
89004329|NCT04947475|Experimental|Screening, Brief Intervention, & Referral to Treatment (SBIRT) Program|There are two objectives to the Brief Intervention. First, the BI is designed to inform potential participants on the risks of substance misuse, abuse, and dependency by illustrating the potential hazards and adverse health consequences. Second, the BI aims to motivate potential participants to reduce risky behavior (e.g., continued drug use) and seek treatment for their substance dependence disorder.
89404090|NCT02092974|Placebo Comparator|tDCS + placebo|
89404091|NCT02092974|Sham Comparator|sham-tDCS + SSRI|
89004330|NCT04934683|Active Comparator|Routine Pressure Management with etomidate induction|Etomidate will be used as an induction agent.
89004331|NCT04934683|Active Comparator|Routine Pressure Management with propofol induction|Propofol will be used as an induction agent.
89004332|NCT04934683|Active Comparator|Tight Pressure Management with etomidate induction|Etomidate will be used as an induction agent.
89004333|NCT04934683|Active Comparator|Tight Pressure Management with propofol induction|Propofol will be used as an induction agent.
89404092|NCT02092974|Placebo Comparator|sham-DCS + placebo|
89404093|NCT02093052|Experimental|Attachment and Biobehavioral Catch-up|Attachment and Biobehavioral Catch-up - 10 session intervention to enhance nurturance and following the lead
89404094|NCT02093052|Active Comparator|Developmental Education for Families|Developmental Education for Families - 10 session intervention that targets cognitive development
89404095|NCT02093052|No Intervention|Low-risk|Low-risk comparison group
89437466|NCT03850964|Experimental|Part C Pazopanib - 150 mg|Pazopanib 150 mg oral daily dosing (six 25 mg Pazopanib capsules).
89437467|NCT03849963||Hyperpolarized [13C]pyruvate|Hyperpolarized stable isotope injection ([13C]pyruvate) during magnetic resonance spectroscopic imaging
89437468|NCT03848091||Antibiotic pretreatment|patients having had an antibiotic pretreatment before a one-step exchange arthroplasty
89535591|NCT03224533||Walnuts with other nuts|"food codes describing nut mixes and foods that commonly include walnuts were classified as walnuts with other nuts (WwON)"
89404096|NCT05097508|Experimental|Group A: Patients will receive Atracurium.|Baseline RE and SE will be recorded. Anesthesia will be induced by propofol (dose 2-3 mg/kg) and fentanyl as analgesia (dose 1-2 mg/kg). Tracheal intubation will be facilitated with atracurium (dose 0.5 mg/kg) after an acceleromyography count of 0. Anesthesia will be maintained with isoflurane in an air-O2 mixture (FiO2 0.6, 2 L/min). Mechanical ventilation will be maintained at a tidal volume of 5-7 ml/kg. Ventilator frequency will be adjusted for maintenance of an ETCO2 of 35-40 mmHg. After equilibrium for 30 minutes SE, RE and the difference between them will be recorded at MAC 0.8 and MAC 1 at two levels of muscle relaxation assessed by TOF value of 50% and 100%. Atracurium (dose 0.005-0.01 mg/kg/min) will be administered as a continuous IV infusion adjusted until 50% and 100% depression of T1 ( first twitch by acceleromyography) will be observed. The entire experiment ended before the start of surgery.
88879786|NCT03216018|No Intervention|No Intervention: control group|The control group didn't receive the intervention program, instead they received a lesson on healthy nutrition. The control group will complete the same self-report questionnaire as the intervention group at baseline, conclusion and 3 months after program conclusion.
88879787|NCT03215472|Experimental|DASH Cloud intervention|In group 1, participants will be instructed to input their dietary intake daily for three months using the Nutritionix app. A participant's data will automatically be uploaded from the Nutritionix app via the API that links the device with DASH Cloud. DASH Cloud will run an algorithm and send daily or weekly feedback text messages reflecting DASH adherence. The intervention components include tailored feedback texts, and behavioral skills training videos.
88879788|NCT03215472|Experimental|Dash Light|Group 2 participants will be asked to use the Nutritionix app daily and receive publicly available written materials on the DASH diet.
88879789|NCT03216096|Experimental|3% DE-089 ophthalmic solution|
88879790|NCT03215238||neurosurgical patients|Neurosurgical patients undergoing craniotomies for tumor. 25 subjects
88879791|NCT03215238||Neurointerventional patients|Patients undergoing neurointerventional procedures under general anesthesia. 25 subjects
88879792|NCT03215082|Experimental|Experimental|The intervention will be an individualized impairment-based program based on a pre-determined sequence. A minimal intervention for all participants randomized to the intervention group at all sites will include general oculomotor and gaze stabilization retraining as tolerated. Intervention activities will be recorded and described in detail in a treatment log.
89404097|NCT05097508|Experimental|Group R: Patients will receive rocuronium.|Baseline RE and SE will be recorded. Anesthesia will be induced by propofol (dose 2-3 mg/kg) and fentanyl as analgesia (dose 1-2 mg/kg). Tracheal intubation will be facilitated with rocuronium (dose 0.6 mg/kg) after an acceleromyography count of 0. Anesthesia will be maintained with isoflurane in an air-O2 mixture (FiO2 0.6, 2 L/min). Mechanical ventilation will be maintained at a tidal volume of 5-7 ml/kg. Ventilator frequency will be adjusted for maintenance of an ETCO2 of 35-40 mmHg. After equilibrium for 30 minutes SE, RE and the difference between them will be recorded at MAC 0.8 and MAC 1 at two levels of muscle relaxation assessed by TOF value of 50% and 100%. Rocuronium (dose 0.01-0.012 mg/kg/min ) will be administered as a continuous IV infusion adjusted until 50% and 100% depression of T1 ( first twitch by acceleromyography) will be observed. The entire experiment ended before the start of surgery.
89404098|NCT02089152|Other|Cluster A|General education for prevention of diabetic complications in year 1, Melioidosis prevention education in years 2, 3 and 4.
89404099|NCT02089152|Other|Cluster B|General education for prevention of diabetic complications in year 1 and 2, Melioidosis prevention education in year 3 and 4.
88879793|NCT03215082|Active Comparator|Control|Standard care for mild TBI consists mainly of general education, energy conservation, academic adaptations, and restricting children and adolescents from participation in vigorous physical activities as well as complex cognitive activities until complete symptom resolution. It is the usual approach promoted by various associations and consensus groups. In addition, in all participating centers, children and teens requiring musculoskeletal approaches to address neck pain/dysfunction will receive it as indicated, based on the clinical judgment of the local team. Participants with moderate and severe TBI will also receive rehabilitation activities as planned in their respective centers. The standard care intervention will be recorded and described in detail in a treatment log.
89004334|NCT04932031||Study group|Adult females with newly diagnosed early-stage (stages I III) non-metastatic breast cancer receiving neoadjuvant or adjuvant chemotherapy that includes paclitaxel or docetaxel
88879794|NCT03214926|Experimental|Moving Through Glass intervention|Participants were asked to use Moving Through Glass (MTG) intervention on Google Glass for at least once a day for 3 weeks. MTG intervention includes 4 difference guided-dance/movement modules for the participants.
88879795|NCT03214848|No Intervention|Standart of Care|Standard of care at the clinic is to discuss the abortion procedure without specific contraceptive counseling given prior to the day of abortion procedure.
88879796|NCT03214848|Experimental|Contraceptive education prior to abortion|Addition (to the standard or care) of a brief phone contraceptive education with optional financial counseling referral prior to abortion visit.
88879797|NCT03214692|Experimental|Gum Arabic|The patients will receive 30 grams of Gum Arabic dissolved in 200 ml of water to ingest orally
88879798|NCT03214458|Other|Nasal high flow with oxygen|During HFNC-oxygen, oxygen will be passed through a heated humidifier (AIRVO-2, Fisher and Paykel Healthcare) and applied continuously through large-bore binasal prongs (Optiflow+ Fisher and Paykel Healthcare), with a gas flow rate of 20-35 liters per minute or as high as the patient will tolerate and an FiO2 to keep Arterial oxygen saturation (SaO2) > 90%. Temperature will be adjusted based on patient's comfort and range from 34-37 degrees based on prior experience.
88879799|NCT03214536|Experimental|erector spinae block|bilateral erector spine block with 20 ml 0,375% ropivacaine
88879800|NCT03214770|Experimental|Light-cured calcium silicate|This biomaterial calcium silicate is manufactured to have an anti-bacterial effect on micro-organisms within the dentin, thus allowing the inhibition of bacterial growth therefore no caries will progress. Material is injected and light-cured within the dentin and sealed with a restoration.
88879801|NCT03214770|Active Comparator|Light-cured calcium hydroxide|This biomaterial calcium hydroxide is manufactured to have an anti-bacterial effect on micro-organisms within the dentin, thus allowing the inhibition of bacterial growth therefore no caries will progress. Material is injected and light-cured within the dentin and sealed with a restoration.
89404100|NCT02089152|Other|Cluster C|General education for prevention of diabetic complications in year 1, 2 and 3, Melioidosis prevention education in year 4.
89404101|NCT02093130|Experimental|Pomegranate Juice|Eight ounces of 100% Pomegranate Juice daily
89404102|NCT02093130|Placebo Comparator|Placebo|Eight ounces of Placebo juice daily. The Placebo is engineered to look and taste the same as the Pomegranate Juice and contains the same vitamins and minerals as the Pomegranate Juice. Because the Placebo juice does not come from actual pomegranates, it does not contain the polyphenols contained in the Pomegranate Juice.
89404103|NCT02089308|Other|Treatment-Sequence 1|"Subjects will be randomly assigned to one of 2 treatment-sequence groups with 2 treament periods.~Treatment -Sequence 1 : Period 1 (test drug) + period 2 (reference)~The duration of each treatment period will be 3 days. Each patch will be applied for 24 hours."
89404104|NCT02089308|Other|Treatment-Sequence 2|"Subjects will be randomly assigned to one of 2 treatment-sequence groups with 2 treament periods.~Treatment-sequence 2 : Period 1 (reference) + period 2 (test drug)~The duration of each treatment period will be 3 days. Each patch will be applied for 24 hours."
89404105|NCT01678144|Experimental|Medtentia Annuloplasty Ring (MAR)|All eligible patients underwent surgical mitral valve repair using annuloplasty device - Medtentia Annuloplasty Ring (MAR)
88879802|NCT03214614|Experimental|GLPG2451 multiple dose|Multiple doses of GLPG2451 oral suspension at up to 3 dose levels in ascending order
88879803|NCT03214614|Placebo Comparator|Placebo multiple dose|Multiple doses of Placebo oral suspension
88879804|NCT03214614|Experimental|GLPG2451/GLPG2222|Multiple doses of GLPG2451 oral suspension combined GLPG2222 oral suspension at up to 2 dose levels
88879805|NCT03214614|Placebo Comparator|Combined Placebo multiple dose|Multiple doses of Combined Placebo oral suspension
88879806|NCT03214146|Experimental|HYNRCS-Allo inj.|"2 cycles of HYNRCS-Allo inj. with 6 months interval through intrathecal injection.~*1 cycle of HYNRCS-Allo inj. is 2 times administration with 28 days interval by intrathecal."
89004335|NCT04928482|Experimental|27 session group|Participants in this arm will receive 27 sessions of backward walking training.
89404106|NCT02086266|Experimental|PILATES|Weekly Pilates sessions, guided by a specialized physiotherapist. The duration of the treatment was 10 weeks, and each session lasted 45 to 50 minutes. All subjects received instruction to perform specific daily home exercises.
89404107|NCT02086266|Active Comparator|PFMT and AES|For also 10 weeks, the participants went trough anal electrical stimulation associated with Pelvic Floor Muscle Training, supervised by a specialized physiotherapist. All subjects received orientation to perform the same pelvic floor exercises at home.
89404108|NCT02086344|Experimental|TLH_plus_PBS|TLH plus PBS
89404109|NCT02086344|Active Comparator|TLH _adnexal preservation|Standard TLH without PBS
89404110|NCT00153920|Experimental|bortezomib|Participants received intravenous bortezomib on a 3-week dosing cycle: 1.3 mg/m2 on days 1, 4, 8 and 11 followed by 10 day rest period for up to 8 cycles or for 2 cycles beyond complete response. Participants with progressive disease or unacceptable toxicity discontinued treatment.
89404111|NCT02093286||Pentabio Vaccine|1 dose of Pentabio vaccine, 0.5 ml Will be given intramuscularly
89404112|NCT05095714|Experimental|Enhanced screening|Half-yearly liver ultrasound and fast-MRI
89404113|NCT05095714|Active Comparator|Screening recommendations|Half-yearly liver ultrasound
89404114|NCT02086422|Active Comparator|ivabradine|Exercise with ivabradine
89404115|NCT02086422|Placebo Comparator|Placebo|Exercise with placebo
89404116|NCT05376436||Exercise challenge test (ECT) with and without nose clip (NC).|"All participants after receiving informed consent were invited for 2 visits. Visit 1 - ECT performed with NC. Visit 2 - ECT performed without NC. Demographic and clinical data and measurements of vital signs, exercise data and lung functions were recorded.~ECT completed on treadmill.~Questionnaires:~Total Nasal Symptom Score (TNSS 0-6). Asthma Control Test (ACT 5-25) . Positive ECT = drop in FEV1 >12% from baseline"
89404117|NCT01073228|Active Comparator|EVP-6124 0.3 mg|one 0.3 mg capsule every day for 183 days
88879807|NCT03213756|Experimental|Preoperative isometric exercise (PIE) group|In the PIE group, the patients will perform daily preoperative exercise protocol based on isometric exercises using hand grip and elastic bands. They will perform this protocol for at least six and ideally eight weeks before surgery.
88879808|NCT03213756|No Intervention|Control group|Control group patients will follow the usual surgical waiting list protocol (Estimated 1,5-2 months).
88879809|NCT03213444|Active Comparator|Quimioterapy 1|adjuvant chemotherapy with 5-FU isolated
89190180|NCT06063122|Sham Comparator|Control Group: Non-contingent exposure to recorded mother's voice|Participants will receive 20 minutes of non-contingent recorded mother' voice during two 20-minute sessions, with a maximum of 2 sessions per day. Recordings are played through the smallTalk speaker device in passive mode, which limits play time to 20-minute exactly and volume to 45 dB in the A-weighted scale as per American Academy of Pediatrics recommendations. For these sessions, the therapist will remain at bedside with the infant and the device, as if they were administering the intervention. Nurses do not typically remain at bedside for the procedure due to workload issues and the low risk of the intervention.
89404118|NCT01073228|Active Comparator|EVP-6124 1 mg|one 1 mg capsule every day for 183 days
88879810|NCT03213444|Active Comparator|Quimioterapy 2|adjuvant chemotherapy with 5-FU associated with oxaliplatin
88879811|NCT03213600|Active Comparator|transcranial Direct Current Stimulation ( tDCS )|Intensity : 1,5mA Duration : 20 minutes stimulation over frontal (F3/F4) electrodes
88879812|NCT03213600|Sham Comparator|transcranial Direct Current Stimulation ( tDCS)|Intensity : 1,5mA Duration : 20 minutes stimulation over parietal(CP3 CP4) electrodes
89404119|NCT01073228|Active Comparator|EVP-6124 2 mg|one 2 mg capsule every day for 183 days
89404120|NCT01073228|Placebo Comparator|Placebo|Placebo every day for 183 days
89404121|NCT03558282||Maxillary Anterior Implant|Subjects who have a single implant restoration in the maxillary anterior position with sufficient baseline data. Recession observation and crown contour observation of the implant will be completed.
88879813|NCT03213522|Active Comparator|Pelvic Floor Physical Therapy|PFPT group will be treated/educated with/on therapeutic exercise, which includes, but not limited to, the pelvic brace, pelvic floor muscle exercise, and diaphragmatic breathing. If the patient is presenting with hypertonia of lower extremity muscles and/or muscles connecting to or part of the pelvic floor, the patient may be instructed on gentle static stretching and/or treated with passive stretching and diaphragmatic breathing.
88879814|NCT03213522|Active Comparator|CranioSacral Therapy|Modified Upledger Institute 10-step protocol. Sequence of hand placements (for this protocol)/type of intervention which will mirror many of the treatment sequences described in the systematic review by Jakel and von Hauenschild (2012).
88879815|NCT03213054|Experimental|OBP-301 + Radiation|OBP-301 administration on the Day 1, Day 18 and Day 32 with standard course of radiation(total 60 Gy) for 6 weeks.
88879816|NCT03213288|Active Comparator|Delphinidin type anthocyanins|Bilberry extract
88879817|NCT03213288|Active Comparator|Cyanidin type anthocyanins|Black rice extract
88879818|NCT03213288|Placebo Comparator|Placebo|No anthocyanins
88879819|NCT03212820|Experimental|Biologic drilling|drilling at low speed
88879820|NCT03212820|Active Comparator|conventional drilling|drilling at conventional or high speed
88879821|NCT03212664|Other|Exercise|Schroth-based physical therapy exercises for patients who agree to participate in exercises. Will be compared to observation-only treatment
88879822|NCT03212898|Experimental|Intervention|Specific pharmacist-led anticoagulation care
89404122|NCT02660242|No Intervention|Control|No basal insulin adjustment, no carbohydrate intake (until glucose drops <70 mg/dL).
89404123|NCT02660242|Active Comparator|Basal insulin reduction|Basal insulin reduction to 50% five minutes before the start of exercise.
89404124|NCT02660242|Active Comparator|Glucose Tabs|Dextrose tabs orally (20 grams) five minutes before the start of exercise and at 30 minutes of exercise (total 40 grams).
89404125|NCT02660242|Experimental|G-Pen Mini™ (glucagon injection)|Glucagon (150 µg) five minutes before the start of exercise (SQ-abdomen).
89404126|NCT02089386|Experimental|Tamoxifen|Tamoxifen 20 mg daily for 12 weeks
89404127|NCT03557580|Active Comparator|IS-5-MN R|Isosorbide-5-mononitrate extended-release tablet, Single oral dose 40mg
89404128|NCT03557580|Experimental|IS-5-MN T1|Isosorbide-5-mononitrate extended-release tablet, Single oral dose 40mg
89404129|NCT03557580|Experimental|IS-5-MN T2|Isosorbide-5-mononitrate extended-release tablet, Single oral dose 40mg
88879823|NCT03212898|No Intervention|Control|The control group will receive usual care; no interventions will be administered.
89404130|NCT05627960|Experimental|AG-01 treated group phase 1A|For dose escalation, subjects will be treated with increasing doses of AG01 from 1 mg/kg to 8 mg/kg. The duration of each treatment cycle is 28 days with two infusions of AG01 every 14 days.
88879824|NCT03212586|Experimental|Dose escalation BAY1902607|Dose 1 to 9 of BAY1902607
89404131|NCT05627960|Experimental|AG-01 1B triple negative breast cancer treated group|"TNBC is defined as ER and/or PR < 1% by IHC, HER2 <3+ by IHC and/or FISH negative, subjects must have received 1 or more standard of care (SOC) therapies for metastatic TNBC.~If PD(L)1-positive, must have received a combination of chemotherapy and a PD (L)-1 agent (Pembrolizumab), unless not a candidate for these therapies If gBRCA 1 or 2 mutation is present, must have received SOC therapies including a PARPi, unless not a candidate for these therapies.~Sacituzumab Govitecan ADC is FDA approved for treatment of advanced TNBC, prior exposure to this therapy does not preclude eligibility in the current study."
89404132|NCT05627960|Experimental|AG-01 1B Hormone-resistant breast cancer|Hormone-resistant breast cancer is defined as, ER and/or PR >1%, HER2 <3+ by IHC and/or FISH negative, received 1 or more hormonal (HT) therapies or HT/CD4/6 kinase inhibitor or HT/MTOR inhibitor for treatment of metastatic breast cancer. If the tumor has known PIK3CA mutation, HT/Alpelisib combination should be considered unless not a candidate for this therapy.
89404133|NCT05627960|Experimental|AG-01 1B NSCLC|Subjects with metastatic/recurrent NSCLCA failed 2 or more SOC therapies, including platinum-based chemotherapy and an anti-PD (L) -1 agent (sequentially or consecutively), Subjects with sensitizing mutations/alterations/rearrangements are eligible if received 1 or more SOC agent/s targeting these mutations unless not a candidate for these therapies.
89404134|NCT05627960|Experimental|AG-01-1B mesothelioma|Subjects with mesothelioma who received at least 1 SOC therapy for metastatic/recurrent mesothelioma per NCCN guidelines or not a candidate for SOC therapy.
89404135|NCT02089542|Experimental|MB and fluorescent imaging|Single arm study for the development of a protocol stipulating the optimum dose and time to peak near infra-red fluorescence from intraoperative injection of low dose Methylthioninium chloride
89404136|NCT01295060|Experimental|Octreotide Implant|
89404137|NCT05374876|Other|Investigational hand therapy (IHT)] intervention targeting the nervous system|
89404138|NCT05374876|Other|Traditional occupational therapy intervention targeting compensatory strategies (TOT)|
89404139|NCT02086656|Experimental|open label|Single arm, open label
89404140|NCT01294202|Experimental|AT13387 and imatinib|AT13387 administered on days 1, 8 and 15, imatinib administered daily
89404141|NCT05098990|Experimental|Jinfukang oral liquid+Platinum-based doublet chemotherapy|"The usage cycle of Jinfukang oral liquid will be consistent with platinum-based doublet chemotherapy. Jinfukang oral liquid will be taken at day 5 after chemotherapy, and will be taken continuously 3 times per day and 30 mL per time at least 4 cycles. The usage of platinum-based doublet chemotherapy will be performed following the details described at the Primary Lung Cancer Diagnosis and Treatment Guidelines and Chinese Society of Clinical Oncology (CSCO) Guidelines for the Diagnosis and Treatment of Non-small Cell Lung Cancer."
89404142|NCT05098990|Active Comparator|Platinum-based doublet chemotherapy|"The usage of platinum-based doublet chemotherapy will be performed following the details described at the Primary Lung Cancer Diagnosis and Treatment Guidelines and Chinese Society of Clinical Oncology (CSCO) Guidelines for the Diagnosis and Treatment of Non-small Cell Lung Cancer."
89404143|NCT02093442|Experimental|Endometrial injury|Women allocated to this group will be submitted to endometrial injury before undergoing endometrial preparation for embryo transfer.
88879825|NCT03212586|Placebo Comparator|Dose escalation Placebo|Dose 1 to 9 of matching placebo
88879826|NCT03211806|Experimental|Sedentary behavior intervention group|This group will wear an activity monitor linked to a smartphone app that will send prompts aimed at interrupting prolonged sedentary bouts
88879827|NCT03211806|Active Comparator|Monitoring-only group|This group will wear a bluetooth-enabled activity monitor but will not be prompted to change behavior
89004336|NCT04928482|Active Comparator|18 session group|Participants in this arm will receive 18 sessions of backward walking training.
88879828|NCT03212040|Active Comparator|14 gauge needle biopsy|breast biopsy will be performed with 14 gauge needle
88879829|NCT03212040|Active Comparator|16 gauge needle biopsy|breast biopsy will be performed with 16 gauge needle
88879830|NCT03211884|Experimental|Problem-solving therapy|Couched within Bandura's social-cognitive theory, self-management refers to the process by which individuals accept responsibility for and take action to change their behaviors, obtain knowledge related to their situation (e.g., behavioral manifestations of a TBI) through increased awareness and use of effective personal resources (e.g., skill in every-day problem-solving). This ultimately enhances the caregivers' confidence that they can cope with caregiving and behavior-related stressors in the care recipient.
88879831|NCT03211884|No Intervention|Usual Care|Usual care was defined as various military caregiver organizations, support groups and services available to all family caregivers of combat Veterans (e.g., Military OneSource; Operation We Are Here; Veterans Administration Program of Comprehensive Assistance for Family Caregivers; American Red Cross Military and Veteran Caregiver Network; Project New Hope; Wounded Veteran Family Care; Women for Wounded Warriors).
88879832|NCT03211728|Experimental|experimental group|
88879833|NCT03211728|Placebo Comparator|placebo group|
89404144|NCT02093442|No Intervention|Control|Women allocated to this group will NOT be submitted to endometrial injury before undergoing endometrial preparation for embryo transfer.
89404145|NCT01071902|Experimental|Moxidex|Moxidex otic solution
89404146|NCT01071902|Active Comparator|Moxifloxacin|Moxifloxacin otic solution
89404147|NCT01071902|Placebo Comparator|Vehicle|Vehicle
89404148|NCT05082766|Experimental|DefenAge 8-in-1 BioSerum supplemented with enhanced concentration of defensins|Enrolled subjects will all receive enhanced DefenAge 8-in-1 BioSerum to be applied on the face including periorbital area.
89404149|NCT02086734||mRCC patients assessed with Perfusion CT|Study population consists of patients with metastasized renal cancer eligible for AAT with either Sunitinib (Sutent®), Pazopanib (Votrient ®), Sorafenib (Nexavar®) evaluated with Perfusion-CT
89404150|NCT01284530|Experimental|Conversion-25|25 mg
88879834|NCT03211572|Experimental|Endocrine Therapy|Anastrozole 1 mg (postmenopausal) or tamoxifen 20mg (premenopausal) are to be taken orally each evening and would be started exactly 2 weeks prior to their surgery.
88879835|NCT03211494|Active Comparator|Conventional lung protective ventilation|Use of conventional lung protective ventilation, according to the ARDSnet guidelines
88879836|NCT03211494|Active Comparator|INTELLiVENT-ASV|Use of INTELLiVENT-ASV
88879837|NCT03211650|Experimental|hyaluronic acid + platelet-rich plasma|Intra-articular injections of hyaluronic acid combined with platelet-rich plasma
88879838|NCT03211650|Active Comparator|platelet-rich plasma|Intra-articular injections of platelet-rich plasma
89404151|NCT01284530|Experimental|Conversion-50|50 mg
88879839|NCT03211650|Active Comparator|hyaluronic acid|Intra-articular injections of hyaluronic acid
88879840|NCT03211182|Experimental|lifestyle intervention group|The intervention group was given healthy lifestyle education and individualized counseling by well-trained case manager at baseline, and follow-up phone counseling thereafter.
88879841|NCT03211182|No Intervention|control group|The control group was given general verbal and written health behavior information to prevent diabetes at baseline without specific individualized advice.
88879842|NCT03211260|Experimental|EQUISTASI|Equistasi is a nanotechnology for proprioceptive focal stimulation. Every patient will receive four patches to be placed on both legs for 4 weeks.
88879843|NCT03211104|Experimental|curcumin|"Curcumin extracted from curcuma longa linn.~formulation : curcumin powder 240mg/capsule~general name : Diferuloylmethane~Taking curcumin 3 times a day(1,440mg/day) for 6 months at the first off treatment in patients with prostate cancer receiving intermittent androgen deprivation therapy"
88879844|NCT03211104|Placebo Comparator|control|The control group Take a placebo containing lactose and vitamin B2. Reddish brown capsules with the same shape as curcumin.
88879845|NCT03210636|Experimental|With Use of LapSpace|evaluate ease of use, safety evaluations, surgeon and clinician feedback
89404152|NCT01284530|Experimental|Conversion-100|100 mg
89404153|NCT01284530|Experimental|Conversion-200|200 mg
89404154|NCT03556878|Experimental|Fitted TranS-C|Fitted TranS-C involves 4 x 20-30 minute sessions. It involves selected cross-cutting, core and optional modules from Standard TranS-C.
89404155|NCT05069116||pre-Covid era|
88879846|NCT03210792|Active Comparator|CCO Rib Splint|Subjects were applied Chrisofix® Chest Orthosis (Manufactured Rib Splint) for Rib Fractures treatment.
88879847|NCT03210792|Experimental|Handmade Rib Splint|Subjects were applied Handmade Rib Splint for Rib Fractures treatment.
88879848|NCT03210870|Other|Intervention|In-person nutritional education classes
88879849|NCT03210870|No Intervention|Control|no in-person nutritional education classes
88879850|NCT03210948|Experimental|RTE-guided EUS-FNA|"The needle will be then inserted into the most suspicious part (dark blue) of the lesion as assessed at real time elastography."
88879851|NCT03210948|Active Comparator|Conventional EUS-FNA|A 25 G needle with a central stylet to protect the aspiration channel of the needle will be introduced though the endoscope's working channel.
88879852|NCT03210402|Active Comparator|Elevated night pacing on|
88879853|NCT03210402|Placebo Comparator|Elevated night pacing off|
88879854|NCT03210168|Experimental|BioFe Medical Food|Escalating consumption of BioFe in a single cohort of up to 40 subjects with iron deficiency.
88879855|NCT03210246|Experimental|COC + Vilaprisan|COC + Vilaprisan (BAY 1002670)
88879856|NCT03210246|Placebo Comparator|COC + Placebo|COC + Placebo
88879857|NCT03210324|Experimental|Mifepristone A group|Mifepristone tablets for 12 weeks with two follow-up
88879858|NCT03210324|Experimental|Mifepristone B group|Mifepristone tablets for 12 weeks with four follow-up
88879859|NCT03210324|Experimental|Mifepristone C group|Mifepristone tablets for 24 weeks with four follow-up
88879860|NCT03210480|Experimental|Group 1|Lithium sulphate prolonged-release 660 mg
88879861|NCT03210480|Active Comparator|Group 2|Lithium carbonate immediate-release 150 mg and 300 mg
89404156|NCT05069116||Covid-era|
89404157|NCT01126970|Placebo Comparator|Placebos.|Velneperit Placebo q.d.+ Orlistat Placebo t.i.d.
89404158|NCT01126970|Experimental|Velneperit 400 mg|Velneperit 400 mg q.d.
89404159|NCT01126970|Active Comparator|Orlistat 120 mg|Orlistat 120 mg t.i.d.
89404160|NCT01126970|Experimental|Velneperit 400 mg + Orlistat 120 mg|Velneperit 400 mg q.d.and Orlistat 120 mg t.i.d
89404161|NCT03557424|Experimental|Polyglucosamine Glucomannan normal dose|Patients received the single dose Polyglucosamine und Glucomannan (0,5 g resp. 1 g per Stick) three times per day over 65 days. The drug is administered as a powder which is dissolved in water. The solution is taken orally.
89437469|NCT03846492|Experimental|Active tDCS|The direct current will be delivered at 2 mA intensity via rubber electrodes in saline- soaked sponges for 30 min per day for 2 weeks, 5 days/week. Inhibitory stimulation will be delivered to the frontal lobes.
89404162|NCT03557424|Experimental|Polyglucosamine Glucomannan high dose|Patients received the higher dose of Polyglucosamine und Glucomannan (1 g resp. 1,34 g per Stick) three times per day over 65 days. The drug is administered as a powder which is dissolved in water. The solution is taken orally.
89190181|NCT06063122|Experimental|Intervention Group: Contingent exposure to recorded mother's voice|Participants will receive 20 minutes of contingent recorded mother' voice also at 45 dBA, during two 20-minute sessions, with a maximum of 2 sessions per day. The smallTalk Active system integrates a wireless, lightweight and sealed sensor unit that securely fits into a Philips NICU Soothie pacifier. The speaker device is factory set to communicate constantly with the sensor unit, and to only deliver a predetermined 10 seconds of recorded parent's voice upon detection of a suck that meets a pressure threshold, which is automatically set by the speaker device.
89190182|NCT06063096|Active Comparator|Allulose Dose 1|Fruit-flavoured drink with allulose at Dose 1 (2.5 g per 120 ml)
88879862|NCT03210012||1|Three dives with different gas mixture : AIR (21% di O2 e 79% di N2), NITROX 32 (32% di O2 e 68% di N2) and TRIMIX (21% O2, 44% N2 e 35% He)
88879863|NCT01830036||Quality of Life (SF12), 2-channel Polygraphy|cardiological treatment
88879864|NCT01830114|Experimental|Web app evaluation group|
88879865|NCT01830192|Other|Training set|We evaluate the clinical, ultrasound and laboratory features to predict endometrial cancer disease preoperative
88879866|NCT01830192|Other|VERIFICATION SET|We evaluate the clinical, ultrasound and laboratory features to predict endometrial cancer disease preoperative
88879867|NCT01830348|Active Comparator|DSC127|DSC127 0.03% in a vehicle gel (hydroxyethyl cellulose (HEC) with parabens)
88879868|NCT01830348|Placebo Comparator|Vehicle gel|Vehicle gel comprising HEC with parabens
88879869|NCT01830582|Experimental|1 A|The patients will undergo the standard pre chemoradiation MRI scan, followed by a repeat research scan 24 hours (+/- 6 hours) after their first radiation treatment. Then they will get another research MRI scan during the second week (+/- 5 days) of radiation. Finally they will get a standard post chemoradiation MRI scan prior to surgery.
88879870|NCT01830582|Experimental|1 B|The patient will undergo the standard pre chemoradiation MRI scan, followed by a repeat research scan 48 hours (+/- 6 hours) after their first radiation treatment. Then they will get another research MRI scan during the third week (+/- 5 days) of radiation. Finally they will get a standard post chemoradiation MRI scan prior to surgery.
88879871|NCT01830582|Experimental|1 C|The patient will undergo the standard pre chemoradiation MRI scan, followed by a repeat research scan 72 hours (+/- 6 hours) after their first radiation treatment. Then they will get another research MRI scan during the fourth week (+/- 5 days) of radiation. Finally they will get a standard post chemoradiation MRI scan prior to surgery.
89190183|NCT06063096|Active Comparator|Allulose Dose 2|Fruit-flavoured drink with allulose at Dose 2 (4.3 g per 120 ml)
89190184|NCT06063096|Placebo Comparator|Placebo Comparator: Control (CON)|Control drink containing high fructose corn syrup.
89190185|NCT06063070|Experimental|Fluzoparib + Bevacizumab|"Fluzoparib capsule: oral administration, 3 capsules/dose (150 mg/ dose), twice a day, in the morning and evening, before/after meals can be taken orally, it is recommended to take orally within 0.5h after breakfast and dinner, continuous administration. Every 3 weeks is a treatment cycle.~Bevacizumab injection: intravenous, 15 mg/kg, every 3 weeks for a treatment cycle until disease progression or intolerable toxicity, up to a total of 15 months."
89190186|NCT06063057|Experimental|low-dose experimental group|phase Ⅰ: 18~59 years old,6~12 years old,6~71 months old; phase Ⅱ：6~71 months old
89190187|NCT06063057|Experimental|medium-dose experimental group|phase Ⅰ: 18~59 years old,6~12 years old,6~71 months old; phase Ⅱ：6~71 months old
89190188|NCT06063057|Experimental|high-dose experimental group|phase Ⅰ: 18~59 years old,6~12 years old,6~71 months old; phase Ⅱ：6~71 months old
88879872|NCT01830582|Experimental|2|The last patient patients that will undergo a standard pre-chemoradiation MRI scan, followed by a repeat research scan either 24, 48 or 72 hours (+/- 6 hours) after their first radiation treatment. Then they will get another research MRI scan during the second, third or fourth week (+/- 5 days) of radiation. Finally they will get a standard post chemoradiation MRI scan prior to surgery.
88879873|NCT01830660|Experimental|hetrombopag|hetrombopag either at 2.5,5,10,20,30 or 40mg, p.o. once daily
88879874|NCT01830660|Placebo Comparator|placebo|Subjects will be randomized (5:1 eltrombopag : placebo) to receive either eltrombopag or placebo.
88879875|NCT01830738|Experimental|Peri-umbilical single-port|"Patients in this arm have a hysterectomy via a single-port peri-umbilical laparoscopic surgical technique.~Intervention: Single-port, peri-umbilical hysterectomy"
88879876|NCT01830738|Active Comparator|Multi-port|"Patients in this arm have a hysterectomy via a conventional multi-port laparoscopic surgical technique.~Intervention: Multi-port hysterectomy"
88879877|NCT01830894|Experimental|spontaneous ICH bleeding|An initial Baseline MRI is to be done within 6-24 hours from the bleeding. second MRI which serves as review - on the 3rd -5th day after bleeding
88879878|NCT01830894|Experimental|chronic sub dural bleeding|An initial Baseline MRI is to be done at the time of diagnosis. second MRI which serves as review -within two weeks.
88879879|NCT01830894|Experimental|acute sub-dural bleeding|An initial Baseline MRI is to be done within 6-24 hours from the bleeding. second MRI which serves as review - within two weeks.
88879880|NCT01831128||ASV Treatment|AutoSet CS, PaceWave
89190189|NCT06063057|Active Comparator|Active control group|phase Ⅰ: 6~71 months old; phase Ⅱ：6~71 months old
89190190|NCT06063044||Respiratory system group|the patients who diagnosed as rhinitis, asthma and conjunctivitis were assigned to the respiratory system group
89190191|NCT06063044||Skin system group|the patients who diagnosed as urticaria and atopic dermatitis were assigned to the skin system group
89190192|NCT06063044||Multiple systems group|the patients who diagnosed with a combination of symptoms from different systems were assigned to the multiple systems group
89190193|NCT06063018|Experimental|RC48 + Tislelizumab|Durg：RC48: intravenous drip, 2mg/kg, D1, repeated once every 2 weeks. Durg ：Tislelizumab: intravenous drip, fixed dose 600 mg, D1, repeated once every 6 weeks.
89190194|NCT06062953|Experimental|Melatonin|
89190195|NCT06062953|Experimental|Quetiapine|
89190196|NCT06062953|Placebo Comparator|Placebo|
89190197|NCT06062940||Primary Care Practice|We recruited 10 primary care practices from across Colorado, from all regions of the state (e.g., Eastern Plains, Mountain West, Front Range), and a mix of rural and urban practices of varying sizes. We recruited both practice staff and patients for this cohort.
89437470|NCT03846492|Sham Comparator|sham tDCS|Sham tDCS will use the same parameters except that the device will automatically turn off after a certain duration.
89404163|NCT03557424|Placebo Comparator|Placebo|Patients received Placebo three times per day over 65 days. The Placebo is administered according to the respective Intervention (Drug: Placebo Comparator: Placebo) as a powder which is dissolved in water. The solution is taken orally.
89404164|NCT05626400|Experimental|CD-7 CART|Patients will be treated with CD7 CAR-T cells
89404165|NCT05057572|Experimental|Carvedilol with Standard Medical Treatment|Arm A will receive carvedilol plus standard medical therpy,Carvedilol: will be started with initial dose of 3.125 mg BD then After 3 days, increase the dose to 6.25 mg BD, Maximum dose would be 12.5 mg BD, the same shall be switch to Maximum tollrated dose if SBP >90, HR >55.
88879881|NCT01831128||Control|No ASV treatment
88879882|NCT01831206|Experimental|Collagen cross-linking|Collagen cross-linking with standard treatment
89404166|NCT05057572|Active Comparator|Standard Medical Treatment|- Arm B will receive standard medical therapy.SMT (as described) that is Grade II ascites - Lasilactone (20/50) OD then Change after 1 week as per response, monitor diuretic intolerance.
89404167|NCT01124708|Placebo Comparator|Placebo|Placebo will be provided as white, opaque gelatin capsules in sham strengths of 1mg, 5mg, and 25mg
89404168|NCT01124708|Active Comparator|TC-5619|TC-5619-238 will be provided as white, opaque gelatin capsules in strengths of 1mg, 5mg, and 25mg (as free base). Subjects will take 1mg TC-5619, 5mg TC-5619, 25mg TC-5619, one capsule once daily p.o.
89404169|NCT02089620|Active Comparator|Yasmin|Yasmin is an oral contraceptive pill containing (Disperinone 3mg+Ethinylestradiol 0.3mg) will be administered once daily orally by the woman from day 2 of the cycle for 21 days each month for 3 months in addition to a daily placebo.
89437471|NCT03833206|Experimental|1 PDC-1421 Capsule|1 PDC-1421 Capsule, trice daily, p.o. after meal for 28 days
88879883|NCT01831206|No Intervention|standard treatment|Standard treatment alone
88879884|NCT01831284||heroin injecting drug users|Sigmoidoscopy with biopsy, in medically stable active injecting drug users
88879885|NCT01831284||healthy controls|Sigmoidoscopy with biopsy, in non-injecting controls-
89404170|NCT02089620|Active Comparator|Calver|Calver is a calcium supplement drug containing (ca 1000mg+vit D400 I.U) given to the woman continuously for 3 months in addition to placebo for 21 days
89404171|NCT02089620|Placebo Comparator|Placebo|A daily oral placebo will be given to the patients daily for 3 months in addition to a placebo similar to COC for 21 days
88879886|NCT01831284||Former heroin injection drug users|Sigmoidoscopy with biopsy, in former injectors of heroin with or without other agents
89404172|NCT02093598|Experimental|Temsirolimus|25 mg administered intravenously, infused over a 30- to 60-minute period once weekly for 28 days (Total doses: 4 doses).
88879887|NCT01831362|Experimental|Focused Attention (FA)|This 8 week program consists solely of focused attention practices, i.e. selected attention to an object (breath etc) and deselection of other stimuli
88879888|NCT01831362|Experimental|Open-Monitoring (OM)|This 8-week program consists solely of open monitoring practices, or noticing and/or labeling the contents of ongoing experience ( thoughts, body sensations, emotions, seeing, hearing etc) without focusing on or deselecting any stimuli
88879889|NCT01831362|Experimental|Mindfulness-Based Cognitive Therapy (MBCT)|The 8 week MBCT program follows the 2nd Edition (2012) manual (Segal, Williams, Teasdale) and includes both focused attention and open- monitoring practices
88879890|NCT01831518|Experimental|CRT Eligible|ACC/AHA/HRS/ESC guidelines for device-based therapy
88879891|NCT01831674|Experimental|Metformin Hydrochloride Extended-Release Tablets USP 750|Metformin Hydrochloride Extended-Release Tablets USP 750 mg of Ipca Laboratories Ltd, India
88879892|NCT01831674|Active Comparator|GLUCOPHAGE®XR|GLUCOPHAGE®XR tablet 750 mg of Bristol-Myers Squibb Company, USA
88879893|NCT01831752||Type 1 Diabetes Melitus|Subjects aged 12 through 75, previously diagnosed with type 1 diabetes mellitus, currently using insulin to treat their diabetes.
88879894|NCT01831830|No Intervention|control condition|The control group receives two attention-control calls.
88879895|NCT01831830|Experimental|The Veterans' in-home program|The VIP intervention consists of 8 sessions (up to 6 in the home and 2 phone calls) from an occupational therapist. This is delivered to Veterans and their family members.
88879896|NCT01832064|Experimental|Mailed Chronic Disease Self-Management|Mailed Chronic Disease Self-Management Program: self management information and self assessment
88879897|NCT01832220||PiZZ not on therapy|Individuals with the PiZZ genotype not on augmentation therapy.
88879898|NCT01832220||PiZZ on therapy|Individuals with the PiZZ genotype on augmentation therapy.
88879899|NCT01832220||PiMZ not on therapy|Individuals with the PiMZ genotype not on augmentation therapy.
88879900|NCT01832220||PiMM with COPD|Individuals with the PiMM genotype and COPD.
88879901|NCT01832298|Experimental|Simmitecan Hydrochloride for Injection|Dissolving in 2ml water for injection, then transfering to 500 mL of 5% dextrose for i.v.90 minutes
88879902|NCT01832376|Experimental|Ultrasound guided needle lavage|Ultrasound guided needle lavage
88879903|NCT01832454|Other|Intra thecal inj of autologous MNC|Intra thecal inj of autologous MNC
89404173|NCT01124552|Experimental|RT001 Botulinum toxin Type A (Dose A)|RT001 (Botulinum toxin Type A)
89404174|NCT01124552|Experimental|RT001 Botulinum toxin type A (Dose B)|RT001 (Botulinum Toxin Type A)
89404175|NCT01124552|Other|Dose C|Vehicle Control
89404176|NCT01124552|Placebo Comparator|Dose D|Placebo
88879904|NCT01832844|Active Comparator|"Group  with scan prior to infiltration "|
88879905|NCT01832844|Placebo Comparator|"Group  without scan "|"Patients will have a dummy lumber spine evaluation in order to put patients in blind conditions"
88879906|NCT01832922|Experimental|Significant Comorbidiities|Significant comorbidities as defined by Cumulative Illness Rating Score (CIRS) of ≥7.
88879907|NCT01832922|Active Comparator|Significant renal dysfunction|Significant renal dysfunction defined as CrCL 15-40 mL/min, but not receiving dialysis.
88879908|NCT01833000|Other|newborn suspected to suffer from necrotizing enterolitis|Cerebral and splanchnic ear infrared spectroscopy (NIRS) and mesenteric Doppler
88879909|NCT01833156|Experimental|patient with local edema by histamin|Measuring at 3 locations (on the histmin spot, at 5 cm and 10 cm border (is the control) at 7 times: T0 - T10 minutes - T20 - T30 - T45 - T60 - T75
89004337|NCT04920344|Active Comparator|GROUP I - Low Risk Recurrence (transoral surgery, clinical observation))|After standard of care transoral surgery, patients whose small tumor was removed completely and have only one lymph node involved will undergo clinical observation.
88879910|NCT01833234||People with epilepsy|People with epilepsy who have have had at least one seizure in the prior year.
89190198|NCT06062940||Cardiology Practice|We recruited 2 cardiology practices from across Colorado, from all regions of the state (e.g., Eastern Plains, Mountain West, Front Range), and a mix of rural and urban practices of varying sizes. We recruited both practice staff and patients for this cohort.
88879911|NCT01833312|Experimental|Hypothermia|Best medical treatment + hypothermia 34-35°C for 24h
88879912|NCT01833312|No Intervention|Control|Best medical treatment
89404177|NCT02087124|Experimental|0g whey protein|0g whey protein dissolved in 200 milliliter (mL) water.
89404178|NCT02087124|Experimental|10g whey protein|10g whey protein dissolved in 200 milliliter (mL) water.
89404179|NCT02087124|Experimental|20g whey protein|20g whey protein dissolved in 200 milliliter (mL) water.
89404180|NCT05627882||Standard ERCP|Patients undergoing ERCP with standard side viewing scope
89437472|NCT03833206|Experimental|2 PDC-1421 Capsules|2 PDC-1421 Capsule, trice daily, p.o. after meal for 28 days
89437473|NCT03830749|Experimental|Single Arm|Eltrombopag Oral Tablet 25-75 mg daily for 12 weeks plus pulsed dexamethasone
88879913|NCT01833390|Experimental|HXe MRI lung ventilation|Each subject will inhale a dose of HXe gas (up to one liter HXe) while lying inside an MRI scanner. A high-resolution 3D map of the lung spaces filled with HXe gas will be acquired during a short breath-hold. Additionally, proton MRI of the chest cavity will be recorded during the same breath-hold for registering the lung boundaries. All subjects will undergo Pulmonary Function Tests. Subjects suffering from obstructive lung disease will have Tc-99m DTPA lung scintigraphy performed for comparing with HXe images.
88879914|NCT01833624|Active Comparator|Sondalis® HP|The Control Group that will receive Sondalis ® HP (a whole-peptide formula).
88879915|NCT01833624|Experimental|Peptamen® AF|In this arm, patients have enteral nutrition with Peptamen® AF
88879916|NCT01833702||Automated response|Canned responses are provided at the end of daily entries
88879917|NCT01833702||No automated feedback|Canned responses are not provided at the end of daily entries
88879918|NCT01833780||GBS carriage status|
88879919|NCT01833780||GBS status during labor|
88879920|NCT01834014|Experimental|mFOLFOX + Bmab|mFOLFOX plus bevacizumab
89190199|NCT06062901|Experimental|Health services research (Survivorship ECHO)|Participants attend 6 sessions of Survivorship ECHO educational intervention over 1 hour each, every 2 weeks for 12 weeks. Participants may optionally participate in a one-on-one interview to give feedback about the sessions over 30 minutes.
89190200|NCT06062875|Active Comparator|adalimumab|adalimumab 40 mg every 2 weeks
89190201|NCT06062875|No Intervention|Placebo|placebo injection (saline) every 2 weeks.
89190202|NCT06062862|Active Comparator|The Incentive Spirometer group|The respiratory muscle training program has the following parameters: Duration: 20 minutes per session, Intensity: Clinical adjustment of training intensity based on actual participants' status across session time, holding time, and repetitions. Frequency: 30 per set, with each is 5-6 times. The procedure for the respiratory muscle training program is as follows: a deep slow inspiration while lips fitted around mouthpiece. Visual feedback is provided to the patient, such as a ball rising to a preset marker, to motivate them during the exercise. The patient is instructed to get the planned flow at preset amount. The patient is asked to maintain breathing in along 2-3 seconds. These guidelines should be followed during respiratory muscle training
89190203|NCT06062862|Active Comparator|The Breather Respiratory Muscle Trainer group|Utilizing a pre-session checklist can improve the success rate of using the breather for respiratory muscle training. The following items should be included in the checklist: Check the patient's posture, ensuring that they are in a comfortable crook lying or sitting position, initial easiest resistances by manipulating both dials to one, ensure the patient is using the diaphragmatic breathing technique, as this is crucial for the proper use of the breather, and make sure that the patient secures lips on mouthpiece.
89190204|NCT06062823|Experimental|Afatinib|Afatinib given as monotherapy daily in a 28-days cycle.
89190205|NCT06062797|Experimental|Mixed Reality|Fracture visualization via Mixed Reality Viewer
89190206|NCT06062797|Active Comparator|X-ray or CT scan|Fracture visualization via X-ray or CT scan
89190207|NCT06062771|Experimental|FIDIAL PLUS|Solution of NaHA 20 mg/1.1 ml pre-filled syringe for intraocular use. 1.8% solution of sodium hyaluronate that is derived from a bacterial fermentation (not of animal origin).
89190208|NCT06062771|Active Comparator|IAL®-F|Solution of NaHA 20 mg/1.1 ml pre-filled syringe for intraocular use. Animal derived 1.8% sodium hyaluronate OVD.
89190209|NCT06062758|Experimental|Nursing Students|The study population will consist of fourth-year students (n=72) of Fenerbahçe University Faculty of Health Sciences, Department of Nursing, Turkish Nursing Program. Sampling calculation and sample selection will not be made in the study, aiming to reach the entire population.
89535592|NCT03224533||Walnuts with high certainty|"Foods consisting entirely or mostly of walnuts were classified as walnuts with high certainty (WwHC)"
88879921|NCT01834014|Active Comparator|mFOLFOX + Cmab|mFOLFOX plus cetuximab
88879922|NCT01834092|Active Comparator|Fresh frozen plasma|2 portions of FFP will be transfused prior to reperfusion
88879923|NCT01834092|Experimental|Fresh non-frozen plasma|2 portions of non-frozen plasma will be transfused prior to reperfusion
88879924|NCT01834170|Experimental|Intratumoral gemcitabine injection|Intratumoral injection of gemcitabine by means of endoscopic ultrasound.
88879925|NCT01834482|Active Comparator|Modified Atkins diet plus KetoCal|Patients will receive the modified Atkins diet in combination with a KetoCal tetrapak daily for the first month. The second month, no tetrapaks will be given.
88879926|NCT01834482|Active Comparator|Modified Atkins diet|Patients will receive the modified Atkins diet for the first month. The second month, they will be given the choice to also use KetoCal in addition to the modified Atkins diet if they choose to do so.
88879927|NCT01834638|Experimental|ABT-126 low dose|ABT-126 low dose
88879928|NCT01834638|Experimental|ABT-126 middle dose|ABT-126 middle dose
88879929|NCT01834638|Experimental|ABT-126 high dose|ABT-126 high dose
88879930|NCT01834794|Experimental|MET/CBT/CM plus NRT|"Motivational Enhancement Therapy, Cognitive Behavior Therapy, Contingency Management plus Nicotine Replacement Therapy (MET/CBT/CM) + NRT~Behavioral Treatment for Cannabis plus Behavioral Treatment for Tobacco: both primarily delivered by computer. Additional NRT."
88879931|NCT01834950|Experimental|Trastuzumab|The study is a single arm prospective study, aiming at identifying biomarkers of early response to trastuzumab
88879932|NCT01835106|Active Comparator|Epidural|Epidural catheter is used postoperatively
88879933|NCT01835106|Experimental|Fascia Iliaca Compartment|Fascia iliaca compartment catheter is used postoperatively
88879934|NCT01835184|Experimental|Treatment (cabozantinib-s-malate, vemurafenib)|Patients receive cabozantinib-s-malate PO QD and vemurafenib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88879935|NCT01835340|Experimental|propofol|Propofol Patients will receive propofol anesthesia on the study day
88879936|NCT01835574|Other|Conditional Cash Transfer and Cognitive-behavioral aftercare|Pre- and post- CCT+AC intervention comparison
88879937|NCT01835652|Active Comparator|Active Exercise|Aerobic Exercise Intervention (stationary cycling)
88879938|NCT01835652|Other|Passive Exercise|Passive Exercise (stretching and balance based exercise)
88879939|NCT01835730|Experimental|PE0139 Injection|Single subcutaneous injection of PE0139, 40 mg/mL
88879940|NCT01835730|Placebo Comparator|Placebo|Single subcutaneous injection of 0.9% Sodium Chloride (NaCl) (Placebo)
88879941|NCT01835886|Experimental|Performs stair-climbing|Performs stair climbing
88879942|NCT01836120|Experimental|Raltitrexed plus Docetaxel|
88879943|NCT01836120|Active Comparator|Docetaxel|
88879944|NCT01836588|Active Comparator|gentle tissue extraction (curettage)|"Object of this study is the evaluation of two different methods of gaining cervical tissue in order to determine whether, and if so in what extent, a CIN is existent. The first method is a cervical biopsy, the second method is a gentle tissue saving curettage of the cervix uteri. Also is to be investigated that the latter method shows a reduction of pain and morbidity after the procedure.~For this reason the pathological outcome of the two methods will be compared to the result of a conisation, which will be received by the patient to cure their cervical lesions."
88879945|NCT01836588|Active Comparator|conventional cervix biopsy|"Object of this study is the evaluation of two different methods of gaining cervical tissue in order to determine whether, and if so in what extent, a CIN is existent. The first method is a cervical biopsy, the second method is a gentle tissue saving curettage of the cervix uteri. Also is to be investigated that the latter method shows a reduction of pain and morbidity after the procedure.~For this reason the pathological outcome of the two methods will be compared to the result of a conisation, which will be received by the patient to cure their cervical lesions."
88879946|NCT01836822|Experimental|Bronchoscopic lymph node sampling|Several different sampling techniques will be used in each patient. They include: EBUS guided transbronchial needle aspiration (EBUS-TBNA), EBUS guided transbronchial forceps biopsy (EBUS-TBFB), large bore (19G) histologic needle biopsy of the mediastinal lymph nodes, forceps biopsy of bronchial mucosa in central and peripheral bronchi
88879947|NCT01836900|Active Comparator|Standard Therapy|Endoscopic therapy with Standard Clip + injection of epinephrine solution or thermal therapy + injection of epinephrin-solution
88879948|NCT01836900|Experimental|OTSC (Over The Scope Clip)|Endoscopic therapy with Application of OTSC Clip and Injection of epinephrin-solution
88879949|NCT01836978|No Intervention|Control|Patients in this group will follow standard MUHC clinical guidelines. This group will receive general instructions, by the preoperative clinic nurse, on exercises (breathing, ankle rotation) to be done before and after surgery. They will also be seen by a nutritionist who will provide general counseling for healthy eating.
88879950|NCT01836978|Experimental|Prehabilitation|Patients in this group will follow the multimodal protocol consisting of nutritional counseling with Immunocal® whey protein supplementation, an individualized physical exercise program, and stress reduction strategies.
88879951|NCT01837758||Dialysis|Platelet function will be documented during the first 48 hours of veno-venous hemofiltration using the Multiplate system.
89190210|NCT06062745|Experimental|18F-fluciclovine|"Participants with low prostate-specific membrane antigen (PSMA) expression or neuroendocrine prostate cancer will receive:~18F-fluciclovine PET/CT within 6 weeks of standard of care exam and 68Ga-PSMA PET/CT~2x Blood test at time of 18F-fluciclovine PET/CT and prior to treatment as determined by participants primary oncologist"
89190211|NCT06062732|Experimental|Intervention|Face It programme, including pre-programme one-to-one and group sessions, 5-day intensive programme, and post-programme one-to-one and group sessions
89437474|NCT03825536|Experimental|Oral methamphetamine, Then Placebo oral capsule|Participants will be randomized to oral methamphetamine first then placebo oral capsule using a random number generator. When oral methamphetamine is administered, an initial 10 mg of oral methamphetamine study drug will be administered to assess tolerability, followed by a subsequent 15 mg oral dose two hours later. Then the participant will receive the placebo oral capsule for their second treatment phase starting at approximately Day 77. For the placebo treatment, one placebo capsule will be administered orally on treatment day, followed by a second oral placebo capsule two hours later.
88879952|NCT01837836|Experimental|Health education|The arm includes all the villages under study. Health education will be provided targeting following groups: 1. Home makers 2. School children 3. Water tank operators.
88879953|NCT01837992|Active Comparator|Standard dose|Participants will receive a standard 3-day treatment course of artemether-lumefantrine at the standard age-based dosage, and will be administered the standard recommended primaquine dose of 0.25mg/kg for 14 consecutive days.
88879954|NCT01837992|Active Comparator|High dose|Participants will receive a standard 3-day treatment course of artemether-lumefantrine at the standard age-based dosage, and will be administered a primaquine dose of 0.5mg/kg/day for 14 consecutive days.
89190212|NCT06062732|Active Comparator|Control|Services as usual
89190213|NCT06062719|Active Comparator|control|80-mg bolus of PPI alone (control group= A), followed by continuous intravenous (IV) infusion at 8 mg/h for a total of 72 hours
89404181|NCT04925830|Experimental|BF Group|Participants of the BF group are connected with a plethysmograph and a respiration belt in order to assess HRV indices. HRV-BF is principally given by means of a vertical bar graph dynamically varying in height and two graphic curves referring to the heart rate (in beats per minute) and physiological breathing pattern, (inspiration and expiration). Each nirHEG- BF session occurs after a ten-minute pause from the end of the HRV-BF training. nirHEG-BF is principally given by means of a vertical bar graph dynamically varying in height and represented on a computer monitor. The height of the change according to the hemodynamic response measured at each of the three prefrontal points (Fp1, Fpz, Fp2) To maintain motivation, the bar graph is associated with a game-like animation (puzzle) signaling successful regulation, e.g. by forwarding motion of the pieces of a puzzle.
88879955|NCT01837992|Other|Control|Participants will receive a standard 3-day treatment course of artemether-lumefantrine at the standard age-based dosage, but will not receive primaquine until the time of confirmed recurrent parasitaemia or completion of 3 months follow up.
88879956|NCT01838382|Experimental|laparoscopic hysterectomy group|female patients undergoing total laparoscopic hysterectomy.
89404182|NCT04925830|No Intervention|No BF Group|The no BF group receive the same sensors and is exposed to the same environment of the BF group but real time biofeedback of physiological parameters (HRV and hemodynamic response) is deactivated so that participants can watch documentary videos without interruption.
88879957|NCT01838460|Experimental|6 mg dose of sublingual nicotine tablets|6 mg dose of sublingual nicotine tablets, single dose.
88879958|NCT01838460|Active Comparator|PSWM 0.5 g (16 mg nicotine/g)|Swedish portion snus, smokeless tobacco, PSWM 0.5 g (16 mg nicotine/g), single dose
89404183|NCT02087202|Experimental|magnesium|magnesium is added perioperatively to those patients undergoing staged total knee arthroplasty and other surgeries.
89404184|NCT02087202|Experimental|ketamine|ketamine is administered to those patients undergoing stated TKA and other operations.
89404185|NCT02087202|Placebo Comparator|control|normal saline (placebo) is administered to the patients.
89404186|NCT01283594|Experimental|Tozadenant (SYN115) 60 mg BID|Tozadenant tablets, white-coated, modified-oval tablets manufactured in 60 mg dosage strengths.
89404187|NCT01283594|Experimental|Tozadenant (SYN115) 120 mg BID|Tozadenant tablets, white-coated, modified-oval tablets manufactured in 60 mg dosage strengths.
88879959|NCT01838460|Active Comparator|PSWL 1.0 g (8 mg nicotine /g)|Swedish portion snus, smokeless tobacco, PSWL 1.0 g (8 mg nicotine /g), single dose
89404188|NCT01283594|Experimental|Tozadenant (SYN115) 180 mg BID|Tozadenant tablets, white-coated, modified-oval tablets manufactured in 60 mg dosage strengths.
89404189|NCT01283594|Experimental|Tozadenant (SYN115) 240 mg BID|Tozadenant tablets, white-coated, modified-oval tablets manufactured in 60 mg dosage strengths.
89404190|NCT01283594|Placebo Comparator|Sugar Pill|White-coated, modified-oval placebo tablets.
89404191|NCT02087280||Anorexia Nervosa|
89404192|NCT02087280||Healthy controls|
89404193|NCT04861870|Experimental|Intervention|See intervention description
88879960|NCT01838460|Active Comparator|PSWL 1.0 g (16 mg nicotine /g)|Swedish portion snus, smokeless tobacco, PSWL 1.0 g (16 mg nicotine /g), single dose
88879961|NCT01838460|Active Comparator|PSWL (8 mg nicotine /g) 2x1.0 g|Swedish portion snus, smokeless tobacco, PSWL (8 mg nicotine /g) 2x1.0 g, single dose
88879962|NCT01838538|Experimental|Bevacizumab+TC|The treatment group were accepted intraperitoneal injection with bevacizumab (avastin) 300mg after each intraperitoneal hyperthermic perfusion chemotherapy for 6 weeks.
88879963|NCT01838538|Active Comparator|TC|patients were treated with TC chemotherapy (paclitaxel 135mg/m2 ,iv d1+ carboplatin AUC=5, iv d1), 1 time/3 weeks for 6 weeks, and with intraperitoneal hyperthermic perfusion chemotherapy combined with intraperitoneal cisplatin 40mg/m2，1 time/2 weeks for 6 weeks
88879964|NCT01838772|Other|Pegylated-Interferon and Ribavirin|"Pegylated-interferon 1.5 microgr/kg, subcutaneously, once weekly for 48 weeks*. Ribavirin, weight-based dosage, divided in two daily doses for 48 weeks*.~*patients with genotype 2 and 3, moderate liver fibrosis, and rapid virologic response will receive therapy for 24 weeks."
88879965|NCT01838928|Experimental|Bupivacaine|
88879966|NCT01839006||patients with supranormal renal function|Patients with preoperative HN and supranormal renal function in DTPA renography
88879967|NCT01839084|Experimental|Xenon|Gaseous anesthetic, dosage: 60% (v/v) in 40% oxygen, continuous application during surgery
89404194|NCT04861870|No Intervention|Control|Participants randomized into the control arm are surveyed at the same time points as intervention participants, but did not receive any intervention.
88879968|NCT01839084|Active Comparator|Isoflurane|Inhalative anesthetic, dosage: 1.2% (v/v) in 40% oxygen/medical air , continuous application during surgery
89404195|NCT02089698|Active Comparator|Reversed tip|Reversed Kelman tip
88879969|NCT01839162|Experimental|Pelvic drape|Pelvic shield drape over the patient
88879970|NCT01839162|Experimental|Arm drape|Right radial arm drape over the patient
88879971|NCT01839162|Experimental|Pelvic and arm drape|Pelvic and arm drpaes placed over the patient
88879972|NCT01839162|Sham Comparator|No drapes|Standard radioprotection devices
89404196|NCT02089698|Experimental|Mini-flared|Mini-flared Kelman tip
89404197|NCT04437784|Active Comparator|Laparoscopic Trans-Abdominal Pre-Peritoneal (Lap TAPP group))|Both hernias were treated by laparoscopic trans-abdominal pre-peritoneal repair using 2 separate meshes fixed by endoscopic tackers
89404198|NCT04437784|Active Comparator|Open Pre-Peritoneal Repair ( Open PP group)|Both hernias were treated by open pre-peritoneal single mesh repair with suture fixation
89404199|NCT04437784|Active Comparator|Bilateral Lichtenstein repair (LICHT group)|treated by bilateral standard Lichtenstein repair using 2 separate meshes with suture fixation
89404200|NCT01282346|Experimental|SOLX Gold Shunt|
89404201|NCT02093676|Experimental|parents counseling|parents counseling guided by the experiment protocol
88879973|NCT01839240|Experimental|Treatment (azacitidine, cytarabine, and mitoxantrone)|"INDUCTION: Patients receive azacitidine IV over 10-40 minutes or SC QD on days 1-5, cytarabine IV over 4 hours on days 6 and 10, and mitoxantrone hydrochloride IV over 60 minutes on days 6 and 10.~CONSOLIDATION: Patients receive azacitidine IV over 10-40 minutes or SC QD on days 1-5. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients ineligible for allogeneic stem cell transplantation continue on to maintenance.~MAINTENANCE: Patients receive azacitidine IV over 10-40 minutes or SC QD on days 1-5. Courses repeat every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity."
88879974|NCT01839474|Experimental|CPAP|Children will be placed on nasal CPAP until they have an age appropriate respiratory rate and receive standard medical therapy.
88879975|NCT01839474|No Intervention|Control|Children will receive standard medical therapy.
88879976|NCT01839552|Experimental|Fentanyl Citrate Nasal Spray (FCNS)|Treatment for breakthrough pain with Fentanyl Citrate Nasal Spray (FCNS)
88879977|NCT01839630||Group 1|
88879978|NCT01839786||PHTN patients|2. Patients who underwent RHC in the past and were diagnosed with PHTN (retrospective arm)
88879979|NCT01839864|Experimental|Promotora plus standard care model|Promotora plus standard physical screening exam, hemoglobin A1c levels, lipid panels, fasting glucose, height, weight, BMI, Complete Blood Count
88879980|NCT01839942||no gap closure|no hernia gap closure
88879981|NCT01839942||extracorporal gap closure|"extracorporal hernia gap closure~extracorporal suturing of gap"
88879982|NCT01839942||intracorporal gap closure|intracorporal hernia gap closure
88879983|NCT01834248|Experimental|Treatment (CDX-1401, Poly ICLC, decitabine)|Patients receive DEC-205/NY-ESO-1 fusion protein CDX-1401 SC and ID and poly-ICLC SC on days -14 and 15 of course 1 and on day 15 for courses 2-4. Patients also receive decitabine IV over 1 hour on days 1-5. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
88879984|NCT01833858|Placebo Comparator|Placebo +rFSH|Patients received rFSH injections with a placebo starting on cycle day 3 of the stimulation cycle until the day of hCG trigger administration.
88879985|NCT01833858|Active Comparator|Low dose HCG with rFSH|Low dose hCG (200 IU per day) will be given daily with rFSH when at least six follicles of 12 mm will be observed and E2 levels are higher than 600 ng/l, until the day of the hCG trigger administration
88879986|NCT01834872|Experimental|Amigo|Ablation completed with Amigo
88879987|NCT01834872|Active Comparator|Manual|Ablation completed with manual catheter
88879988|NCT01836432|Experimental|FOLFIRINOX + Algenpantucel-L (HAPa) Immunotherapy|"Arm 1A: SOC FOLFIRINOX + Algenpantucel-L (HAPa) Immunotherapy~Day 71-80 Disease evaluated: New distant disease = salvage regimen Gem/Nab-Paclitaxel (6 cycles) + HAPa given days 8 and 22 for up to 18 doses total.~Day 71-80 Disease evaluated: No distant disease = 5-FU or capecitabine plus Radiation+ HAPa on days 1 and 15 of Chemoradiotherapy.~Post-Chemoradiation Disease evaluation: surgically resectable = surgery + adjuvant SOC Gemcitabine + HAPa given 1 and 15 for up to 18 doses total.~Post-Chemoradiation Disease evaluation: not eligible for surgical resection (Stable) = continue FOLFIRINOX bi-weekly + HAPa bi-weekly 7 days offset from FOLFIRINOX up to18 doses of algenpantucel-L Immunotherapy.~Post-Chemoradiation Disease evaluation: non-eligible for surgical resection (Progression) = salvage Gem/Nab-Paclitaxel (6 cycles) + HAPa given days 8 and 22 for up to 18 doses total."
88879989|NCT01836432|Active Comparator|FOLFIRINOX (SOC) ALONE|"Arm 2A: FOLFIRINOX (Oxaliplatin 85 mg/m^2 IV over 2 hours; Irinotecan 180 mg/m^2 IV over 90 minutes; Leucovorin 400 mg/m^2 IV over 2 hours; Fluorouracil 2.4 g/m^2 IV over 46 hours) given days 1, 15, 29, 43 & 57~Day 71-80 Disease eval: New disease = salvage Gem/Nab-Paclitaxel: nab-paclitaxel 125mg/m^2 IV over 30-40 minutes followed by gemcitabine 1000 mg/m^2 IV over 30-60 minutes for 3 weeks (days 1, 8 and 15) with 1 week rest~Day 71-80 Disease eval: No disease = 5-FU or capecitabine plus Radiation (5-FU continuous IV infusion of 200-250 mg/m^2/day given 5-7 days each week over 5.5 weeks or Capecitabine 825 mg/m^2 PO BID M-F) concurrently with external beam radiation given at 1.8 Gy per fraction for 28 fractions total dose of 50.4 Gy~Post-XRT Disease eval: surgically resectable = surgery + adjuvant SOC Gemcitabine~Ineligible for surgical resection & stable disease = continue FOLFIRINOX~Ineligible for surgical resection & progressive disease = salvage Gem/Nab-Paclitaxel"
89004338|NCT04920344|Experimental|GROUP II - Medium Risk Recurrence (transoral surgery, EBRT 50Gy)|Patients whose tumor was removed completely but has certain features that make it more likely to come back such as growth around the nerves or into the vessels, or has more than one lymph nodes involved, will undergo external body radiation therapy (EBRT) RT 50Gy for 5 weeks in the absence of disease progression or unacceptable toxicity.
89404202|NCT04826458|Experimental|A. electronic diary (TreC-Onco)|"At the baseline visit, each patient assigned to arm A will be provided with the electronic diary (installed on a smart phone or tablet), the oral medication for the first treatment cycle and the appointment for the next cycle. The patient will be instructed on how to use the electronic diary, and the user manual will also be given. This app allows patients to record parameters related to their health state (e.g. medications, blood pressure, weight, fever, side effects or other symptoms) and through the alarm function, it reminds the patient to take the tablets, indicating the exact dosage. In addition, the patient can also indicate the dose reduction or the omission."
89404203|NCT04826458|Other|B. paper diary|Patients assigned to arm B will be provided with a paper diary, oral medication for the first treatment cycle and the appointment for the next cycle. The patient will be instructed on how to use the paper diary.
89404204|NCT02087358||Stress and craving|This 3 weeks study examines the correlation between stress and alcohol using an ecological, prospective design. Participants will be given phone calls 4 times a day for 3 weeks, assessing perceived stress and alcohol related craving.
89404205|NCT01281254|Placebo Comparator|Placebo plus PLD|Arm B: PLD 50 mg/m2 IV every 4 weeks (Q4W) and blinded AMG 386 placebo IV weekly (QW)
89404206|NCT01281254|Experimental|AMG386 plus PLD|Arm A: PLD 50 mg/m2 IV every 4 weeks (Q4W) and blinded AMG 386 15 mg/kg IV weekly (QW)
88879990|NCT01836432|Experimental|Gemcitabine/Nab-Paclitaxel+Algenpantucel-L HAPa Immunotherapy|"Arm 1B: Gemcitabine/Nab-Paclitaxel + Algenpantucel-L (HAPa) Immunotherapy~Day 71-80 Disease evaluated: New distant disease = salvage regimen FOLFIRINOX + HAPa given every 14 days (alternate weeks of FOLFIRINOX) for up to 18 doses total.~Day 71-80 Disease evaluated: No distant disease = 5-FU or capecitabine plus Radiation + HAPa on days 1 and 15 of Chemoradiotherapy.~Post-Chemoradiation Disease evaluation: surgically resectable = surgery + adjuvant SOC Gemcitabine + HAPa given days 1 and 15 for up to 18 doses total.~Post-Chemoradiation Disease evaluation: not eligible for surgical resection (Stable) = continue Gem/Nab-Paclitaxel + HAPa given on days 8 and 22 for up to18 doses of algenpantucel-L Immunotherapy.~Post-Chemoradiation Disease evaluation: non-eligible for surgical resection (Progression) = salvage FOLFIRINOX + HAPa given every 14 days (alternate weeks of FOLFIRINOX) for up to 18 doses total."
88879991|NCT01836432|Active Comparator|Gemcitabine/Nab-Paclitaxel (SOC) Alone|"Arm 2B: Gemcitabine/Nab-Paclitaxel (SOC) Alone~SOC Gem/Nab-Paclitaxel: nab-paclitaxel 125mg/m^2 IV over 30-40 minutes followed by gemcitabine 1000 mg/m^2 IV over 30-60 minutes for 3 weeks with 1 week rest. Given on days 1, 8, 15, 29, 36, 43, 57, 64 and 71~Day 71-80 Disease evaluated: New distant disease = salvage FOLFIRINOX given every 14 days~Day 71-80 Disease evaluation: No disease = 5-FU or capecitabine plus Radiation (5-FU continuous IV infusion of 200-250 mg/m^2/day given 5-7 days each week over 5.5 weeks or Capecitabine 825 mg/m^2 PO BID M-F) concurrently with external beam radiation given at 1.8 Gy per fraction for 28 fractions total dose of 50.4 Gy~Post-XRT Disease eval: surgically resectable = surgery + adjuvant SOC Gemcitabine~Ineligible for surgical resection & stable disease = continue gem/nab-paclitaxel given for 3 weeks (days 1, 8 and 15) with 1 week rest~Ineligible for surgical resection & progressive disease = salvage FOLFIRINOX given every 14 days"
88879992|NCT01720056|Active Comparator|Verapamil|Verapamil 2.5 mg/mL injection sc intralesionally
88879993|NCT01720056|Active Comparator|Kenalog 10|Kenalog 10 mg/mL injection sc intralesionally
88879994|NCT01720134||after legislation 1st july 2003|2003-2006
88879995|NCT01720134||before legislation 1st july 2003|1999-2003
88879996|NCT01720212|Experimental|Single dose group|
88879997|NCT01720212|Experimental|Multiple dose group|
88879998|NCT01720290|Experimental|Rep|
88879999|NCT01720290|Active Comparator|Met|
89190214|NCT06062719|Experimental|study|octreotide adjunctive group, in addition to the pantoprazole (Study group= B) for 72 h, received a 100-μg bolus of octreotide, followed by continuous IV infusion of 50 μg/h for a total of 72 hours
89404207|NCT02087436|Active Comparator|Taperloc Complete Standard|Group one will receive a total hip replacement with Taperloc Complete Standard. Taperloc Complete Standard is designed after the philosophy of a flat tapered wedge. It has evolved to incorporate the Reduced Distal and Microplasty stems to better address all patient anatomies, and facilitate multiple surgical techniques.
88880000|NCT01720290|Active Comparator|Rep + met|
88880001|NCT01720368||1st Group of 50 patients|
88880002|NCT01720368||2nd Group of 50 patients|
88880003|NCT01720914||Critically ill patient|
88880004|NCT01720992|Experimental|Group A|A theory-based action planning toolkit will be distributed to Group A participants.
88880005|NCT01720992|Other|Group B|Group B is a wait list control
88880006|NCT01721148|Other|Cohort Dose Escalation|open label dose escalation study of ASLAN002 administered orally on a once daily schedule to subjects with advanced or metastatic solid tumours, who have either progressed on standard therapy or for whom standard therapy is not known
88880007|NCT01721304|Experimental|Adaptive Conjoint Analysis|Computerized survey to elicit preferences
88880008|NCT01721304|No Intervention|Usual care|Patients are counseled by their physician as usual
88880009|NCT01721382|Experimental|Sitagliptin|Treatment with sitagliptin
88880010|NCT01721538|Experimental|Therapy arm|Non-drug therapeutic weight reduction program (15 weeks)
88880011|NCT01721538|Placebo Comparator|Control arm|Lecture on healthy nutrition (1 hour)
88880012|NCT01721616|Active Comparator|Cefazolin|single antibiotic
88880013|NCT01721616|Active Comparator|Cefazolin + Azitrhromycin|double antibiotic
88880014|NCT01721694|Experimental|azithromycin 1.5%/Loteprednol 0,5% + placebo|fixed combination of azithromycin 1.5% / Loteprednol 0,5% eye drops + placebo eye drops
88880015|NCT01721694|Active Comparator|azithromycin 1.5% + Loteprednol 0,5% (separately)|azithromycin 1.5% + Loteprednol 0,5% eye drops (separately)
89404208|NCT02087436|Active Comparator|Taperloc Complete Microplasty|Group one will receive a total hip replacement with Taperloc Complete Microplasty.Taperloc Complete Microplsty cementless stem is designed to transmit load to the proximal femur, thereby preserving bone density, and preventing long term instability and loosening secondary to proximal bone resorption.
89404209|NCT05104138||Half fluence photodynamic therapy|Patients with central serous chorioretinopathy, treated by half-fluence photodynamic therapy
89404210|NCT05104138||Oral Eplerenone|Patients with central serous chorioretinopathy, treated by oral eplerenone
89404211|NCT05627804|Experimental|Moderate hypoxia|The participant will perform different exercise modes under moderate hypoxia (fraction oxygen: 16.5%). Blood samples immediately after exercise oral glucose tolerance test will be collected.
89404212|NCT05627804|Other|Control normoxia|The participant will not perform any exercise under normoxia and moderate hypoxia. Blood samples of oral glucose tolerance test will be collected.
89404213|NCT04437082||Normal|no pre-existing conditions
89404214|NCT04437082||Glaucoma|diagnosis of glaucoma
89404215|NCT04437082||Retina|diagnosis of retina pathology
89404216|NCT04437082||Cornea|diagnosis of corneal condition
89404217|NCT03072043|Experimental|Phase 1b Dose Escalation|Participants will receive intravenous infusions of APR-246 as a lead-in phase on days -14 to -11 starting at Dose Level 1 prior to starting cycle #1 of combination therapy with azacitidine. Combination therapy will consist of APR-246 on days 1-4 and azacitidine on days 4-10 (or days 4-5 and 8-12) of a 28 day cycle.
88880016|NCT01722006||Pairing group|Paired, high reward, oral methamphetamine (20 mg) vs placebo Paired, low reward, oral methamphetamine (20 mg) vs placebo Paired, no reward, oral methamphetamine (20 mg) vs placebo Unpaired, oral methamphetamine (20 mg) vs placebo
89190215|NCT06062706||Open|Open donor hepatectomy approach: a portion of the liver is resected from a living donor using the traditional open surgical technique, involving a large incision to access the liver directly. This method is most commonly used in living donor liver transplantation nowadays.
89190216|NCT06062706||Laparoscopic|Laparoscopic donor hepatectomy is a minimally invasive surgical approach where a portion of the liver is resected from a living donor using small incisions and specialized instruments.
89404218|NCT03072043|Experimental|Phase 2 Treatment|Participants will be treated with APR-246 administered at the maximum tolerated dose (MTD) with azacitidine on a 28 day cycle utilizing the same dosing schedule as in Phase 1b.
89404219|NCT03777228||Control|Individuals without traumatic brain injury
89404220|NCT03777228||Mild TBI|Individuals with mild traumatic brain injury
89404221|NCT03777228||Moderate to Severe TBI|Individual with moderate to severe traumatic brain injury
89404222|NCT05626010|Active Comparator|control group|acetaminophen 1g iv dripping
89404223|NCT05626010|Experimental|experimental group|the combination of acetaminophen 1g and ibuprofen 300mg iv dripping
89404224|NCT04766398|Active Comparator|KHK7791|During the dosing period, subjects administer the study drug (KHK7791 or placebo) twice daily just before meals in a double blind. The starting dose of the study drug is 5 mg at a time, and the dose is adjusted in the range of 5, 10, 20, and 30 mg at a time based on the dose adjustment criteria described in the study protocol. Dosage adjustment is performed step by step.
89404225|NCT04766398|Placebo Comparator|Placebo|During the dosing period, subjects administer the study drug (KHK7791 or placebo) twice daily just before meals in a double blind. The starting dose of the study drug is 5 mg at a time, and the dose is adjusted in the range of 5, 10, 20, and 30 mg at a time based on the dose adjustment criteria described in the study protocol. Dosage adjustment is performed step by step.
89404226|NCT02093832||Total hip arthroplasty|
89404227|NCT02089854|Experimental|endocrine therapy|toremifene 60mg PO. per day for premenopausal and perimenopausal patients; anastrozole 1mg PO. per day for postmenopausal patients
88880017|NCT01722084|Experimental|Community-eùbedded reproductive health interventions|Members of communities that belonged to the intervention arm were exposed to complex interventions addressing different target groups (adolescents, parents, authorities and health providers) and focusing on various behaviours that were related to communication about sexuality, information seeking, access to health care and safe sexual intercourse.
88880018|NCT01722084|No Intervention|Community members without intervention|
88880019|NCT01722396|Experimental|Vitamin D|
88880020|NCT01722630|No Intervention|control|Patients received intravenously saline solution at 5 ml/Kg/h
88880021|NCT01722630|Experimental|dopamine|Patients received intravenously saline solution at 5 ml/Kg/h and dopamine at 3 mcg/Kg/min
88880022|NCT01722630|No Intervention|crystalloids|Patients received intravenously saline solution at 10 ml/Kg/h
88880023|NCT01722942|Active Comparator|ICD group|ICD implantation will be performed according to the Institution protocol of each participating center; single-chamber devices are preferred and programming should prioritize the patient's own pace, avoiding ventricular stimulation.
88880024|NCT01722942|Active Comparator|Amiodarone Group|"Patients randomized for this group will receive amiodarone hydrochloride (once a day) according to the following regimen:~Initial oral loading dose of 600 mg/day for 10 days on an outpatient basis;~After the loading period, an oral dose between 200 and 400 mg/day should be maintained until study termination. The determination of the optimal maintenance dose will be left at the discretion of each investigator; this dose may be based on the therapeutic response on 24-hour Holter monitoring, resting heart rate (HR), side effects, prolonged corrected QT interval (QTc), etc. Dose adjustments will be allowed throughout the study period provided the maintenance dose is kept between 200 and 400 mg/day. If the patient cannot tolerate the minimum 200 mg/day dose, amiodarone should be discontinued permanently and treatment should be considered interrupted."
88880025|NCT01723020|Experimental|AMG 232|AMG 232 is an anti-cancer agent.
89404228|NCT02089854|No Intervention|observation|
88880026|NCT01723098|No Intervention|Control|Sedentary pregnant women
88880027|NCT01723098|Experimental|Exercise group|
88880028|NCT01723176||Patients in Cardiopulmonary Failure|patients in cardiopulmonary failure
88880029|NCT01723332|Experimental|Intervention|Clinical based educational and self management intervention.
88880030|NCT01723332|No Intervention|Usual Care|Youth seen in the Cardiology clinic see a nurse only to measure weight, height, and blood pressure. They rely on their cardiologist for information about their heart condition. The approach and amount of time taken by each cardiologist with a youth varies.
88880031|NCT01723410|Experimental|Writing condition|Subjects will be asked to write about other individuals in their lives.
88880032|NCT01723410|Placebo Comparator|Writing|Subjects will be asked to write about places or objects in their lives.
88880033|NCT01723488|Experimental|Tau diagnostic|Experimental: Tau diagnostic [F18] T808
88880034|NCT01723644|Other|PCT guidance|"Group of patient  Procalcitonin  where the initiation and the stop of the antibiotic treatment are made according to a strategy guided by the PCT"
89404229|NCT02093910|Experimental|Monosialotetrahexosylganglioside|each patient in this arm received velcade+dexamethasone (VD) regimen（bortezomib,1.3mg/㎡，subcutaneously injection，d1,8,15,22；dexamethasone,20mg d1-2, 8-9,15-16,22-23）every 4 weeks; and monosialotetrahexosylganglioside was used at the dosage of 100mg/d intravenously at d1-2,8-9,15-16,22-23 every cycle.
88880035|NCT01723644|Other|clinical reassessment|Group of patient where the initiation and the stop of the antibiotic treatment make following on clinical criteria and paraclinic not including the PCT.
89404230|NCT04636216|Experimental|Community Parent Education Program (COPE) parent training program|Parents will enroll in an 8-week, group parenting program.
89404231|NCT04437160|Experimental|Adjuvant chemotherapy|"Adjuvant chemotherapy for triple negative breast cancer with residual invasive disease (invasive breast tumor size≥1cm and/or positive axillary lymph nodes) after taxanes and platinum based neoadjuvant chemotherapy.~Adjuvant chemotherapy regiments: Epirubicin 80-90mg/m2 IV or Pirarubicin 50mg/m2 IV + Cyclophosphamide 600mg/m2 IV, q21d*4cycles."
89404232|NCT04437160|No Intervention|Observation|No adjuvant chemotherapy for triple negative breast cancer with residual invasive disease (invasive breast tumor size≥1cm and/or positive axillary lymph nodes) after taxanes and platinum based neoadjuvant chemotherapy.
89404233|NCT01265264|Experimental|ulodesine Placebo + Allopurinol 300mg|Oral dose administered daily for 84 days.
89404234|NCT01265264|Experimental|ulodesine 5mg + Allopurinol 300mg|Oral dose administered daily for 84 days.
89404235|NCT01265264|Experimental|ulodesine 10mg + Allopurinol 300mg|Oral dose administered daily for 84 days.
89404236|NCT01265264|Experimental|ulodesine 20mg + Allopurinol 300mg|Oral dose administered daily for 84 days.
88880036|NCT01723800|Experimental|Treatment (pemetrexed, carboplatin, PI3K inhibitor BKM120)|Patients receive pemetrexed disodium IV over 10 minutes followed by carboplatin IV over 30 minutes on day 1, and PI3K inhibitor BKM120 PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients may receive courses of PI3K inhibitor BKM120 alone or PI3K inhibitor BKM120 and pemetrexed disodium after 4-6 courses with carboplatin in the absence of unacceptable toxicity or disease progression.
88880037|NCT01723878||Cohort|
88880038|NCT01723956|Active Comparator|Arm B|LEEP treatment of CIN 2/3 cervical lesion in HIV positive women (standard of Care)
89404237|NCT01265264|Experimental|ulodesine 40mg + Allopurinol 300mg|Oral dose administered daily for 84 days.
88880039|NCT01723956|Experimental|Arm A|Cryotherapy treatment of CIN 2/3 cervical lesions
88880040|NCT01724034|Experimental|Daily Lung Ultrasound|"If there is no lung sliding - evaluation for pneumothorax or mainstream intubation.~If lung ultrasound shows normal pattern - search for reversible airway obstruction or venous embolism. If the patient has COPD, non invasive ventilation must be used as mode of discontinuing mechanical ventilation.~If lung ultrasound shows intersticial syndrome - evaluate the need to negativate hydric balance before the next spontaneous breathing trial.~If findings are asymmetrical - search for new or uncontrolled infection. If there is simple pleural effusion - researchers should determine a negativation of hydric balance or perform thoracocentesis.~If there are signs of complicated pleural effusion - a new image technique should be performed as evaluated by the surgical team."
88880041|NCT01724034|No Intervention|Control Group|
88880042|NCT01724268|Experimental|Pred + Meth|"Prednisolone : 10 mg daily~+ Methotrexate : 25 mg/ day~ARM 1 Treatment Arm"
88880043|NCT01724268|Active Comparator|Anti TNF + Meth|"Etanrcept: 50 mg; Adalimumab: 40 mg; Infliximab: 3mg/kg~+ Methotrexate 25 mg per day Control Arm"
88880044|NCT01724424|Experimental|melatonin 20mg|2 x 10mg capsules of melatonin, single dose. Blood sampling and physiological measures (blood pressure, ECG, oxygen saturation) every 30 mins for 6 hours.
88880045|NCT01724424|Experimental|melatonin 30mg|3 x 10mg capsules of melatonin, single dose. Blood sampling and physiological measures (blood pressure, ECG, oxygen saturation) every 30 mins for 6 hours.
88880046|NCT01724424|Experimental|Melatonin 50mg|5 x 10mg capsules of melatonin, single dose. Blood sampling and physiological measures (blood pressure, ECG, oxygen saturation) every 30 mins for 6 hours.
88880047|NCT01724424|Experimental|Melatonin 100mg|10 x 10mg capsules of melatonin, single dose. Blood sampling and physiological measures (blood pressure, ECG, oxygen saturation) every 30 mins for 6 hours.
88880048|NCT01724502|Experimental|Obese Non-Diabetic Subjects|All subjects on this arm will undergo exercise and muscle biopsies.
89404238|NCT02089932|Placebo Comparator|group B: control bupivacaine group|Patient in this group will receive 25 ml bupivacaine 0.5% plus 1 ml normal saline peri-neurally
89404239|NCT02089932|Experimental|Group B-DEX 25 : Peri-neural Dexmedetomidine|Patients in this group will receive 25 ml of 0.5% bupivacaine plus 1 ml (25 microgram) Dexmedetomidine peri-neurally
89404240|NCT02089932|Experimental|Group B-DEX 50:Peri-neural Dexmedetomidine|Patients in this group will receive 25 ml of 0.5% bupivacaine plus 1 ml (50 microgram) Dexmedetomidine peri-neurally
89404241|NCT02089932|Experimental|Group B-DEX 75:Peri-neural Dexmedetomidine|Patients in this group will receive 25 ml of 0.5% bupivacaine plus 1 ml (75microgram) Dexmedetomidine peri-neurally
89404242|NCT05374486|Experimental|NeuroExo|NeuroExo is a device which includes a robotic exoskeleton that you were in your affected arm to assist you with arm movements, a headset that you wear on your head to measure your brain activity and detect your intention to move, and a graphical user interface that allows you to initiate and stop neurotherapy, and track your motor performance.
89404243|NCT02093988|Experimental|Topical and Intravenous TXA|
89404244|NCT02093988|Active Comparator|Intravenous TXA only|
89404245|NCT05204953||1|patients diagnosed to have myelodysplastic syndrome
89404246|NCT05204953||2|healthy control subjects
89404247|NCT05221996|Experimental|Resistance exercise for 10 min|Resistance circuit training of 10 min
89404248|NCT05221996|Experimental|Resistance exercise for 20 min|Resistance circuit training of 20 min
89404249|NCT05221996|Experimental|Resistance exercise for 30 min|Resistance circuit training of 30 min
89190217|NCT06062706||Robotic|Robotic donor hepatectomy is an advanced, minimally invasive surgical technique where a portion of the liver is resected from a living donor using robotic instruments. This method is known to provide enhanced precision, improved ergonomics, and superior 3D visualization.
89190218|NCT06062693|Experimental|smart sensor egg training|An interactive hand trainer with integrated sensors was developed and can be used as input devices to a training which runs on the smartphone or tablet computer to train different finger, hand, and wrist functions.
89190219|NCT06062680|Experimental|Treatment group A|Take Herombopag Olamine Tablets 7.5mg 4h after high-fat meal in the first cycle, and take Herombopag Olamine Tablets 7.5mg on an empty stomach in the second cycle. In the third cycle, take Herombopag Olamine Tablets 7.5mg 30min after a standard meal;
89404250|NCT03557268||On a GnRHa|Half of subjects will be on a puberty blocker or gonadotropin-releasing hormone analogue
89190220|NCT06062680|Experimental|Treatment group B|Take Herombopag Olamine Tablets 7.5mg on an empty stomach in the first cycle, and take Herombopag Olamine Tablets 7.5mg 30min after a standard meal in the second cycle. In the third cycle, Herombopag Olamine Tablets 7.5mg were taken 4h after a high-fat meal
89404251|NCT03557268||Not on GnRHa|Half of subjects will NOT be on a puberty blocker or gonadotropin-releasing hormone analogue
89404252|NCT01037036|Experimental|Latanoprost Punctal Plug Delivery System followed by Xalatan|Subjects will have the Latanoprost Punctal Plug Delivery System placed for 4 week or until loss of efficacy. After removal of the Latanoprost Punctal Plug Delivery system, subjects will administer adjunctive Xalatan eye drops once daily for 2 weeks. This is a single arm study.
89404253|NCT04360694|Experimental|Incremental hemodialysis|Procedure: Incremental hemodialysis. It consists in reducing the frequency or number of sessions per week with which patients start the HD treatment. The experimental group will start with one session/week, then the number of weekly sessions will be increased to two and later to three as per criteria for progression
89404254|NCT04360694|Active Comparator|Conventional hemodialysis|Procedure: Conventional hemodialysis. It is controlled through usual clinical practice, based on starting the HD treatment with three sessions per week (control group).
89404255|NCT02250066|Other|Study group 1|Received high monounsaturated fat diet
89404256|NCT02250066|Other|Study group 2|Received high carbohydrate diet
89404257|NCT02250066|No Intervention|Control Group|Control group was encouraged to follow the Food Guide Pyramid
89404258|NCT03069313|Experimental|Arm I|Oral Vitamin B12
89404259|NCT02267486||Alzheimer Dementia (AD)|Patients with dementia caused by Alzheimer's disease
89404260|NCT02267486||Non-dementia|Patients with cognitive concern without dementia
89404261|NCT02094066|Active Comparator|tranexamic acid|preoperative ıv 50 mg/kg tranexamic acid infusion at 45 minutes
89404262|NCT02094066|Sham Comparator|serum physiologic|preoperative 100 cc serum physiologic
89404263|NCT02090010|Active Comparator|GroupC|Group C means Control group which use Seldinger technique for subclavian catheterization. The aimed vessel(subclavian vein) is punctured with a sharp hollow needle, syringe is detached and guidewire is advanced through the lumen of the needle, and the needle is removed. After that catheter is passed over the guidewire into the vessel.
89404264|NCT02090010|Experimental|Group MS|Group MS means experimental group which use modified Seldinger technique for subclavian catheterization. The aimed vessel is punctured with the needle that is covered with guiding sheath. After vessel is punctured, guiding sheath is instatntly slid over the needle into the vessel. The needle is removed, guidewire is advanced through the sheath, central catheter is placed into the vessel.
89404265|NCT01033292|Experimental|BSI-201|BSI-201 in combination with gemcitabine and carboplatin.
89404266|NCT03068767|Experimental|Vitamin D group|Patients receiving vitamin D supplement (2000 IU/day) for 2 months
89404267|NCT03068767|No Intervention|Control group|Patients without receiving vitamin D supplement
89404268|NCT02094144|Other|exercise group (brisk walking program)|The intervention is named brisk walking program. It consists on achieve 40 minutes of brisk walking 3d/wk for 6 months (two supervised sessions and one session performed one their own per week with a detailed program). The intensity of the program is adapted to the heart rate work and gradually increases over the 6-month program
89404269|NCT02094144|Other|control group (physical activity habits)|The Intervention consists on maintain the lifestyle and especially their physical activity habits during 6 months
89404270|NCT02267720|Active Comparator|Ketac Molar|Occlusal-proximal ART restorations - Ketac Molar
88880049|NCT01724502|Experimental|Type 2 Diabetic Subjects|All subjects on this arm will undergo exercise and muscle biopsies.
88880050|NCT01724502|Experimental|Healthy Control Subjects|All subjects on this arm will undergo exercise and muscle biopsies.
88880051|NCT01724736|Placebo Comparator|Placebo Comparator:|Celluose 10g - Matches the total dietary fiber content of NM504 as well as the color and taste. Subjects take 1 dose within 1h prior to either breakfast or lunch and a 2nd dose within 1h prior to the evening meal for 4 weeks.
88880052|NCT01724736|Active Comparator|NM504:|Cobiotic formula of GRAS ingredients with a total dietary fiber content of 10g. Subjects take 1 dose within 1h prior to either breakfast or lunch and a 2nd dose within 1h prior to the evening meal for 4 weeks.
88880053|NCT01724814|Experimental|Cohort S1|HM12460A Dose 1 (1.2 nmol/kg) or placebo
88880054|NCT01724814|Experimental|Cohort S2|HM12460A Dose 2 (2.4 nmol/kg) or Placebo
88880055|NCT01724814|Experimental|Cohort S3|HM12460A Dose 3 (4.8 nmol/kg) or Placebo
88880056|NCT01724814|Experimental|Cohort S4|HM12460A Dose 4 (9.6 nmol/kg) or Placebo
89404271|NCT02267720|Experimental|Vitro Molar|Occlusal-proximal ART restorations - Vitro Molar
89404272|NCT02090166|Other|lung cancer diagnosis|"4 arms will be included in the study:~The groups sample size is as follows:~Group 1 - Healthy non smoker- 75 subjects Group 2 - Healthy smoker- 75 subjects Group 3 - Patients diagnosed as having COPD- 150 subjects Group 4 - Patients with diagnosis of lung cancer- 650 subjects~A blood test will be taken from each patient."
89404273|NCT01110902|Experimental|AGO178C 0.5 mg /day|
88880057|NCT01724814|Experimental|Cohort S5|HM12460A Dose 5 (14.4 nmol/kg) or Placebo
88880058|NCT01724814|Experimental|Cohort S6|HM12460A Dose 6 (19.2 nmol/kg) or Placebo
88880059|NCT01724970|Experimental|PLMA|ProSeal
88880060|NCT01724970|Experimental|SLMA|Supreme LMA
88880061|NCT01725048|Active Comparator|Mirtazapine|Treatment with oral mirtazapine, dosed once daily, for 9 weeks, with starting dose of 7.5 milligrams (mg) daily up to 30mg daily.
88880062|NCT01725048|Active Comparator|Citalopram|Treatment with Citalopram, once daily, for 9 weeks, with dosages starting at 10mg once daily to 40mg once daily.
88880063|NCT01725204|Experimental|Dasatinib + PegIFN|Dasatinib 100mg OD for three months single drug, with subsequent addition of PegIFN 15 μg/ week for 3 months. If well tolerated (less than grade 2 non-hematological or grade 3 hematological AE) the dose should be increased to 25μg weekly for the remaining 9 months on combination treatment. Thereafter dasatinib will be given as monotherapy. Patients will be followed for 24 months totally.
88880064|NCT01725360|Experimental|montelukast|A leukotriene receptor antagonist (LTRA, montelukast) is added to a basic treatment of inhaled corticosteroids (ICS) + long-acting betamimetics (LABA) in well-controlled patients with asthma.
88880065|NCT01725516|Experimental|Myofascial release technique|
88880066|NCT01725594|Experimental|Cohort A1, Dose Level 1: CAT 2003 or placebo fasting|Single dose
88880067|NCT01725594|Experimental|Cohort A2, Dose Level 2: CAT 2003 or placebo fasting|Single dose
88880068|NCT01725594|Experimental|Cohort A3, Dose Level 3: CAT 2003 or placebo fasting|Single dose
88880069|NCT01725594|Experimental|Cohort A4, Dose Level 4: CAT 2003 or placebo fasting|Single dose
88880070|NCT01725594|Experimental|Cohort A5, Dose Level 5: CAT 2003 or placebo fasting|Single dose
89404274|NCT01110902|Experimental|AGO178C 1 mg / day|
89404275|NCT01110902|Placebo Comparator|Placebo|
89404276|NCT05204173|Experimental|Intraperitoneal|Sintilimab 200mg intravenous (IV) infusion on day 1, PTX 50 mg/m2 IV and PTX 20 mg/m2 intraperitoneal infusion on Days 1 and 8 plus oral S-1 80 mg/m2 for 14 consecutive days every 3 weeks.
89404277|NCT05204095||Referral group|The patients with severe cataracts in this group need a referral to a higher-level hospital for further treatment.
89190221|NCT06062680|Experimental|Treatment group C|Take Herombopag Olamine Tablets 7.5mg 30min after standard meal in the first cycle, and take Herombopag Olamine Tablets 7.5mg 4h after high-fat meal in the second cycle. In the third cycle, Herombopag Olamine Tablets 7.5mg were taken on an empty stomach
89404278|NCT05204095||Observation group|The patients with mild cataracts or transparent lenses in this group do not need a referral to a higher-level hospital for further treatment and keep regular examinations.
89404279|NCT01025648|Experimental|T1 - E004 90 mcg/actuation|T1 - E004 (epinephrine inhalation aerosol) 90 mcg/actuation - treatment by 2 actuations of E004 at 90 mcg/actuation
89404280|NCT01025648|Experimental|T2 - E004 125 mcg/actuation|E004 (epinephrine inhalation aerosol), 125 mcg, 2 actuations
89190222|NCT06062615|Active Comparator|Total knee replacement (TKR) without Omnibot system|The participant will undergo TKR utilizing conventional techniques.
89404281|NCT01025648|Experimental|T3 - 160 mcg/actuation|E004 (epinephrine inhalation aerosol), 160 mcg - E004 (epinephrine inhalation aerosol), 160 mcg/ actuation, 2 actuations
89404282|NCT01025648|Experimental|T4 - 220 mcg/actuation|E004 (epinephrine inhalation aerosol), 220 mcg - 220 mcg/actuation, 2 actuations
89404283|NCT01025648|Active Comparator|A - Active control|epinephrine inhalation aerosol, CFC propelled 220 mcg Epinephrine Inhalation Aerosol, CFC-MDI, 2 actuations
89404284|NCT01025648|Placebo Comparator|P, Placebo HFA|E004 placebo single treatment with 2 inhalations
89404285|NCT03020745|Experimental|Part 1, Cohort A : GSK3389404 30 mg SC or Placebo|Enrolled subjects (HBeAg-positive and/or HBeAg negative) will receive single SC injection of GSK3389404 30 mg or matching placebo
89404286|NCT03020745|Experimental|Part 1, Cohort B: GSK3389404 60 mg SC or Placebo|Enrolled subjects (HBeAg-positive and/or HBeAg negative) will receive single SC injection of GSK3389404 60 mg or matching placebo
89404287|NCT03020745|Experimental|Part 1, Cohort C: GSK3389404 120 mg SC or Placebo|Enrolled subjects (HBeAg-positive and/or HBeAg negative) will receive single SC injection of GSK3389404 120 mg or matching placebo
89404288|NCT03020745|Experimental|Part 1, Cohort C1 (optional): GSK3389404 120 mg SC or Placebo|Enrolled subjects (HBeAg-positive and/or HBeAg negative) will receive single SC injection of GSK3389404 120 mg or matching placebo
89404289|NCT03020745|Experimental|Part 1, Cohort D: GSK3389404 </= 240 mg SC or Placebo|Enrolled subjects (HBeAg-positive and/or HBeAg negative) will receive single SC injection of GSK3389404 <= 240 mg or matching placebo
89404290|NCT03020745|Experimental|Part 2: GSK3389404 or placebo SC|Enrolled subjects will receive different parallel dose level and regimens of GSK3389404 or placebo SC at dose determined in part 1. The treatments for Part 2 are 60 mg GSK3389404 weekly, 120 mg bi-weekly GSK3389404, 120 mg GSK3389404 weekly or placebo.
89404291|NCT01110746|Experimental|Formulation A|Single Injection
89404292|NCT01110746|Experimental|Formulation B|Single Injection
88880071|NCT01725594|Experimental|Cohort A2: Dose Level 2: CAT 2003 or placebo fed|Single dose
88880072|NCT01725594|Experimental|Cohort A3: Dose level 3:CAT 2003 or placebo fed|Single dose
88880073|NCT01725594|Experimental|Cohort B1: Dose level 6: CAT 2003 or placebo|Multiple dose for 14 days
88880074|NCT01725594|Experimental|Cohort B2: Dose level 7: CAT 2003 or placebo|Multiple dose for 14 days
88880075|NCT01725594|Experimental|Cohort B3: Dose level 8: CAT 2003 or placebo|Multiple dose for 14 days
89404293|NCT05208775|Experimental|PDT group|After enrollment, patients were injected with photosensitizer at a dose of 2mg/kg, and received photodynamic irradiation 48 hours later.
89404294|NCT05208775|Active Comparator|ESD group|Patients received standard ESD treatment after enrollment
88880076|NCT01725594|Experimental|Cohort B4: Dose level 9: CAT 2003 or placebo|Multiple dose for 14 days
88880077|NCT01725672|Active Comparator|Part A and B:Arm 1: 500 mg metformin XR / 1 mg glimepiride IR|In Part A and Part B of the study, subjects will receive single dose oral tablets of 500 mg metformin XR and 1 mg glimepiride IR on Day 1 of the respective period per randomized sequence
89190223|NCT06062615|Active Comparator|Total knee replacement (TKR) with Omnibot|The participant will undergo a robotic assisted TKR utilizing the Omnibot Knee System
89404295|NCT05623280||Indocyanine green|Injection around the areola with 2-4 points Indocyanine green with 2ml of 1.25mg/mL; Achieve Intraoperative fluorescence images by Near-Infrared I ( NIR-I ) fluorescence imaging instrument.
88880078|NCT01725672|Active Comparator|Part A and B:Arm 2: 1000 mg metformin XR / 2 mg glimepiride IR|In Part A and Part B of the study, subjects will receive single dose oral tablets of 1000 mg metformin XR and 2 mg glimepiride IR on Day 1 of the respective period per randomized sequence
89404296|NCT02946853|Active Comparator|CRT-D|Patients will be randomized at enrollment. Patients in this arm of the study will receive cardiac resynchronization therapy with defibrillator (CRT-D).
88880079|NCT01725672|Experimental|Part A:Arm 3: 500 mg metformin XR and 1 mg glimepiride XR|In Part A of the study subjects will receive single oral dose of 500 mg metformin XR and 1 mg glimepiride XR (FDC1) film coated tablet containing release controlling polymers on Day 1 of the respective period per randomized sequence
89404297|NCT02946853|Experimental|CRT-D and AVJ Ablation|Patients in this arm of the study will receive CRT-D and undergo atrioventricular junctional (AVJ) ablation.
89404298|NCT02267798|Experimental|arm training combined with FES|"Arm training protocol Training sessions will last for 60 minutes and will focus on repetitive tasks that incorporate multidirectional reaching actions. In this robot-assisted therapy a robot manipulator applies forces to the paretic arm during goal-directed movements.~Functional electrical stimulation protocol Experimental group will receive up to 40 minutes of FES after arm training. The device consists of a battery powered programmable stimulator and a forearm-wrist-hand orthosis containing 5 electrodes positioned to provide reliable activation of muscles. The intensity of stimulation will be set to a level that provided comfortable and consistent activation of the extensor and flexor muscles to achieve whole hand opening and functional grasping."
89404299|NCT02267798|Active Comparator|conventional therapy|The conventional rehabilitation program will consist of physiotherapy sessions (100 min/day) following an individualized approach. The program aims at the restoration of mobility and daily living competence, Specific exercises for the affected upper limb will include, bilateral tasks and facilitation techniques based on neuro-developmental treatment.
89404300|NCT02895841|No Intervention|Standard of Care|Patients will continue with their normal Standard of Care for their condition
89404301|NCT02895841|Experimental|SMART app wearable device|"Patients will be given a wearable such as a Microsoft Band accelerometer to track movement, heart rate, galvanic skin response and sleep, which will be collected in combination with the data from the SMART visual dashboard. Data will be sent to the SMART dashboard as well as stored on the iPad/iPod touch via software from the manufacturer. Participants having a wearable device will receive the education intervention (such as haptic prompted texts that state 'try and walk today', 'have you had enough water today', 'make sure to take deep breaths')."
89404302|NCT02267876||BD VIPER LT|
89404303|NCT05762185|Experimental|nursing consultation|
89404304|NCT02267954|Experimental|50% Prices/50% Calories|"The participant is exposed to the baseline menu, but the prices are edited to be at 50% of the actual price (e.g., a $1 coffee is listed as costing $.50) and the calorie labels are edited to be at 50% of the actual content (e.g., a 500 calorie Large Fries is listed as having 250 calories). In addition, the baseline mistakes are still included.~This is the Menu edited intervention."
89404305|NCT05622968|Active Comparator|Intervention|Women who are planned for elective delivery for obstetric indication(s) and undergo outpatient induction of labour using Foley catheter
89404306|NCT05622968|Placebo Comparator|Control|Women who are planned for elective delivery for obstetric indication(s) and undergo inpatient induction of labour using intravaginal prostaglandin
89404307|NCT05622032||haploidentical HSCT patients|Patients receiving HSCT from a haploidentical donor. They also receive a treatment called cyclophosphamide as part of the protocol to prevent graft versus host disease at day 3 and 4 after transplantation.
89404308|NCT05622032||HLA-matched HSCT patients|Patients who receive HSCT from a HLA-matched donor.
89404309|NCT03667989|Other|123I-MIBG CZT SPECT|Patients with ischemic and non-ischemic heart failure with indications for CRT. Assessment of cardiac sympathetic innervation by 123IMIBG CZT SPECT.
89404310|NCT01020968|Experimental|Ixmyelocel-T|The treatment arm of the study will receive catheter-based injections of the study cellular product.
89404311|NCT01020968|Placebo Comparator|Vehicle Control|will receive approximately 12-20 intramyocardial injections of 0.4 mL each of vehicle control.
88880080|NCT01725672|Experimental|Part A:Arm 4: 1000 mg metformin XR and 2 mg glimepiride XR|In Part A of the study subjects will receive single oral dose of 1000 mg metformin XR and 2 mg glimepiride XR (FDC1) film coated tablet containing release controlling polymers on Day 1 of the respective period per randomized sequence
88880081|NCT01725672|Experimental|Part B:Arm 5: 500 mg metformin XR and 1 mg glimepiride XR|In Part B of the study subjects will receive single oral dose of 500 mg metformin XR and 1 mg glimepiride XR (FDC3) tablet coated with release controlling polymers on Day 1 of the respective period per randomized sequence
89190224|NCT06062563|Experimental|Anlotinib+ penpulimab|Anlotinib：12 mg once daily for 2 weeks, followed by a rest of 1 week (21-day cycle)； Penpulimab：200mg Q3 W
89404312|NCT02268032|Experimental|Vaginal ring 1 (VRD)|20 women using DHEA (VRD) for 2 menstrual cycles
89404313|NCT02268032|Experimental|Vaginal ring 2 (VRaA)|20 women using another androgenic agent (VRaA) for 2 menstrual cycles
89404314|NCT02268032|Experimental|Vaginal ring 3 (VR2A)|20 women using fixed combination of 2 androgenic agents (VR2A) for 2 menstrual cycles
89404315|NCT03019965|Active Comparator|Intermittent Piperacillin/tazobactam|Piperacillin/tazobactam 300mg/kg/day, divided into 4 doses/day, diluted in 5% glucose solution, at a concentration of 50mg/ml, to be administered in 30 minutes infusion every 6 hours.
89404316|NCT03019965|Experimental|Continuous Piperacillin/tazobactam|Piperacillin/tazobactam initial doses 75mg/kg in 30 minutes infusion, immediately thereafter continue 300mg/kg/day, diluted in 5% glucose solution, at a concentration of 50mg/ml, to be administered in 24 hours infusion every 24 hours, as determined by antibiotic stability at room temperature.
88880082|NCT01725672|Experimental|Part B:Arm 6: 1000 mg metformin XR and 2 mg glimepiride XR|In Part B of the study subjects will receive single oral dose of 1000 mg metformin XR and 2 mg glimepiride XR (FDC4) tablet coated with release controlling polymers on Day 1 of the respective period per randomized sequence
88880083|NCT01725906|Active Comparator|Empirical therapy|selection of antibiotic according to medication history
88880084|NCT01725906|Experimental|Genotypic resistance guided therapy|selection of antibiotics according to genotypic resistance
89404317|NCT03019965|Active Comparator|Intermittent Imipenem|Imipenem 80mg/kg/day, divided into 4 doses/day, diluted in 0.9% saline solution, at a concentration of 7mg/ml, to be administered in 60 minutes infusion every 6 hours.
88880085|NCT01726062|Experimental|Motivational Interviewing plus Incentives|
89404318|NCT03019965|Experimental|Extended Imipenem|Imipenem initial doses 20mg/kg in 60 minutes infusion, immediately thereafter continue 80mg/kg/day, divided into 4 doses/day, diluted in 0.9% saline solution, at a concentration of 7mg/ml, to be administered in 6 hours infusion every 6 hours, as determined by antibiotic stability at room temperature.
89404319|NCT03019965|Active Comparator|Intermittent Meropenem|Meropenem 100mg/kg/day, divided into 3 doses/day, diluted in 0.9% saline solution, at a concentration of 7mg/ml, to be administered in 60 minutes every 8 hours.
89404320|NCT03019965|Experimental|Extended Meropenem|Meropenem initial doses 35mg/kg in 60 minutes infusion, immediately thereafter continue 100mg/kg/day, divided into 3 doses/day, diluted in 0.9% saline solution at a concentration of 7mg/ml, to be administered in 8 hours infusion every 8 hours, as determined by antibiotic stability at room temperature.
89404321|NCT02268110|Experimental|Supervised exercise therapy|Participants will receive 12 sessions with a physiotherapist where they will receive instructions on body mechanics, and be given a progressive abdominal exercise program
89404322|NCT02268110|Experimental|Abdominal binding|Participants will be fitted for an abdominal binder and asked to wear it for a period of 12 weeks.
89404323|NCT02268110|Experimental|Exercise therapy and Abdominal Binding|Participants will attend 12 sessions with a physiotherapist, and receive an abdominal binder
89404324|NCT02268110|No Intervention|Control|Participants will not receive an intervention during the study period
88880086|NCT01726062|Other|Conventional Care (CC)|
88880087|NCT01726140|Experimental|TREATMENT|Helmet CPAP
88880088|NCT01726140|Active Comparator|CONTROL|Venturi Mask
88880089|NCT01726218||Stroke patients|
89404325|NCT03623061||Low Fibrinogen Level|Anonymised low fibrinogen adult samples from the laboratory (Low fibrinogen concentrations). Samples to be tested on the F-Point device and standard Clauss Fibrinogen assay.
89404326|NCT03623061||Normal Fibrinogen Level|Healthy non pregnant females presenting for elective gynaecology surgery (Normal non pregnant fibrinogen concentrations) Samples to be tested on the F-Point device and standard Clauss Fibrinogen assay.
89404327|NCT03623061||High Fibrinogen Level|Healthy pregnant females presenting for elective caesarean section (Normal term pregnancy fibrinogen levels) Samples to be tested on the F-Point device and standard Clauss Fibrinogen assay.
89404328|NCT01468831|Placebo Comparator|Placebo|Participants injected with bevacizumab for three months followed by PRN dosing and placebo twice daily for 24 months
89404329|NCT01468831|Experimental|Minocycline|Participants injected with bevacizumab for three months followed by PRN dosing and 100mg minocycline twice daily for 24 months
88880090|NCT01726218||Healthy Control|
88880091|NCT01726296|Experimental|Health services research (educational intervention)|Health care providers complete an educational intervention based on NCCN guidelines in CRC and NSCLC survivorship care comprising a power point presentation reviewing evidence and prompts for addressing survivorship care components; and an electronic paper copy sample survivorship care plan that can be adapted and distributed at each participating site.
88880092|NCT01726374|Experimental|One cycle adjuvant BEP(500)|Etoposide 165 mg/m2 IV infusion - days 1, 2, 3 Cisplatin 50 mg/m2 IV infusion - days 1, 2 Bleomycin 30,000 IU IV infusion - days 1 (or 2), 8, 15
88880093|NCT01726530|Active Comparator|Transdermal fentanyl patch|Transdermal fentanyl patch, 50 mcg/hour, was attached to the patient's chest wall at 10 pm the day before surgery
88880094|NCT01726530|Placebo Comparator|Placebo|Placebo patch was attached to the patient's chest wall at 10 pm the day before surgery
88880095|NCT01726608|Active Comparator|Radiofrequency neurotomy|Active Radiofrequency Neurotomy
88880096|NCT01726608|Placebo Comparator|Sham|Sham radiofrequency neurotomy
88880097|NCT01726686|Active Comparator|Ropivacaine in the pump|The intra-articular Continuous Infusion Pump is filled with Ropivacaine,10 mg/ml, set at 2 ml/hour for 48 hours postoperatively.
88880098|NCT01726686|Placebo Comparator|Placebo in the pump|The intra-articular Continuous Infusion Pump is filled with NaCl, set at 2 ml/hour for 48 hours postoperatively.
88880099|NCT01726764|Experimental|Metformin|"7 days of pretreatment with metformin before full pharmacokinetics and other goals are investigated.~Minimum 1 week of washout after this period. 3 weeks of pretreatment with St John's Wort and the last 7 days metformin is ingested again, and the same effect parameters as described above is performed again"
88880100|NCT01726842||Normal Controls|Structurally normal eye with equal visual acuity and normal stereopsis.
89190225|NCT06062524|Experimental|WeFlow-EndoSeal Aorta Vascular Plug System|WeFlow-EndoSeal Aorta Vascular Plug System
89190226|NCT06062498|Experimental|Elacestrant Monotherapy|Elacestrant (345 mg) will be taken orally once daily for each 28-day cycle. Courses repeat until progressive disease.
89404330|NCT03667911|No Intervention|Control Group|Only routine patient education on bowel preparation of colonoscopy. Give oral instructions on bowel preparation(including definition, significance, correct steps as well as dietary limitations) by a well-trained nurses or doctors. Written instructions are offered, which have the some contents.
89190227|NCT06062498|Experimental|Combination Therapy|"Patients will receive either:~Elacestrant 345 mg orally once daily~+ Palbociclib 125 mg orally once daily for 21 days out of 28-day cycle OR Abemaciclib 150 mg orally twice daily OR Ribociclib 600 mg orally once daily for 21 days out of 28-day cycle"
89190228|NCT06062485|Experimental|Experimental|
89404331|NCT03667911|Experimental|Virtual-reality Group|Watch virtual reality videos after routine patient education(both oral and written instructions). Videos give instructions on correct steps of bowel preparation, points for attention, as well as actual images of bowel during colonoscopy in the case of both excellent and unsatisfactory bowel preparation.
89404332|NCT05627414|Experimental|Disitamab Vedotin Combined With Sintilimab and S-1|30 HER2 overexpression unresectable gastric cancer patients will enrolle and treate with Disitamab Vedotin, Sintilimab and S-1. During the study period, imaging examinations were conducted every 6-12 weeks to evaluate the tumor and whether it reached the operable standard. The scheme and duration of postoperative adjuvant treatment were determined by the investigator according to the patient's conditions (Sintilimab was recommended to be maintained for 1 year, and other drugs were increased or decreased according to the patient's conditions).
88880101|NCT01726842||Referral required|"Diagnosed with amblyopia or constant strabismus, categorized based on the GSE.~Amblyopia:~VA <20/40 and 2 logMAR lines difference in normal eye~Mild amblyopia (>20/40)~Moderate amblyopia (20/40 and <20/100)~Severe amblyopia (≥20/100 or worse)~Bilateral amblyopia: >4 years age VA<20/40 OU including high hyperopia or high astigmatism.~Strabismus:~Constant: >2 PD at near and or distance.~Intermittent: strabismus that could be controlled intermittently either through fusional mechanisms or a compensatory head position.~Amblyogenic factor categorization:~'Anisometropia'- (1.5 Diopters (D) or more difference in refractive error between the two eyes.~'hypermetropia' (≥3.5 D),~'myopia' (≥-4.0 D),~'astigmatism' (≥1.5 D).~'structural abnormalities' of the eye will not be excluded, but will be considered to have vision loss if visual acuity is 20/40 or worse."
88880102|NCT01726842||Borderline|(no long-term harm to patient if referral is delayed, however the patient does have conditions that might benefit from monitoring): Equal visual acuity and no structural abnormality with any of the following: Amblyogenic factor, intermittent strabismus, structural abnormalities, refractive error, reduced stereopsis.
88880103|NCT01726920|Experimental|naratriptan + naproxen|Fixed-dose combination of naratriptan + naproxen
88880104|NCT01726920|Active Comparator|naratriptan|
88880105|NCT01726920|Active Comparator|naproxen|
88880106|NCT01726998|Experimental|Lokomat Group|
89404333|NCT01675882|Experimental|Viaskin Peanut 50 mcg|
88880107|NCT01726998|Active Comparator|conventional gait training group|
88880108|NCT01727076|Experimental|Treatment (recombinant interleukin-15)|Patients receive recombinant interleukin-15 SC daily on days 1-5 of weeks 1 and 2. Treatment repeats every 28 days (4 weeks) for up to 6 courses in the absence of disease progression or unacceptable toxicity.
88880109|NCT01727232||Standard regimen|Patients received the standard regimen (i.e 4 weekly infusions of 375 mg/m2)of rituximab
89404334|NCT01675882|Experimental|Viaskin Peanut 100 mcg|
89404335|NCT01675882|Experimental|Viaskin Peanut 250 mcg|
89404336|NCT01675882|Placebo Comparator|Viaskin Placebo|
88880110|NCT01727232||Rheumatoid arthritis regimen|Patients received the RA regimen (i.e two infusions of 1000 mg, 2 weeks apart) of rituximab
88880111|NCT01727388|Experimental|lateral decubitus|The digital rectal examination is performed in lateral decubitus i.e. curled up position . The patient in left lateral decubitus if the examiner is right handed and right lateral decubitus if the examiner is left handed.
89190229|NCT06062459|Experimental|Group A|MCE Group
89190230|NCT06062459|Experimental|Group B|BT Group
89190231|NCT06062459|Experimental|Group C|Combined MCE & BT Group
88880112|NCT01727388|Active Comparator|supine decubitus|The digital rectal examination is performed supine, spread legs, feet on the examination table. The examiner is in the patient's right side if he is right handed and in the patient's left side if he is left-handed.
88880113|NCT01727466|Experimental|Facing Your Fears|FYF is a group CBT approach to managing anxiety symptoms in children with high-functioning autism spectrum disorders and anxiety.
89190232|NCT06062459|Other|Group D|Control Group
89190233|NCT06062407||Stroke subjects without fall risk|The patient was diagnosed with a stroke with a berg score of not less than 40.
89190234|NCT06062407||Stroke subjects with fall risk|The patient was diagnosed with a stroke with a berg score of less than 40.
89190235|NCT06062407||Healthy subjects|No history of stroke with normal lower limb motor function and balance
89190236|NCT06062355|Experimental|HRS-9815 injection|
89190237|NCT06062277|Other|Single Arm Study|"Paired cohort before and after study. Each participant will act as their own control.~All participants will receive the intervention: study drug colchicine 0.5mg orally once daily for a treatment period of 30 days."
88880114|NCT01727544|Active Comparator|Surgical Group|patients will undergo a primary transmastoid and tegmen mini-craniotomy cartilage cap occlusion surgery.
89190241|NCT06062212||Transpulmonary pressure group|
89190242|NCT06062186|Placebo Comparator|Placebo|650 mg of placebo, given as two capsules containing maltodextrin
89190243|NCT06062186|Experimental|AmaTea Max Guayusa extract|650 mg of AmaTea Guayusa Extract, given as two capsules
89190244|NCT06062186|Experimental|Lion's Mane|1000 mg of Lion's Mane, given as two capsules
89190245|NCT06062160|Experimental|Experimental|Experimental group received deep Therapeutic Touch two time at 10th and 40nd hours after cesarean section.
89190246|NCT06062160|No Intervention|Control|There will be no intervention in the control group. Routine maintenance will be given.
89404337|NCT03018249|Active Comparator|Arm I (medroxyprogesterone acetate, hysterectomy)|Patients receive medroxyprogesterone acetate IM on day 1 and undergo hysterectomy between days 21-24.
88880115|NCT01727544|No Intervention|Non Surgical Group|patients meet the same criteria but will elect not to undergo surgery
89190247|NCT06062121|Experimental|motor-cable-driven system|Receive motor-cable-driven system
89190248|NCT06062082||Pheochromocytoma|Patients operated on for pheochromocytoma by unilateral adrenalectomy
89190249|NCT06062082||Control|Patients operated on for adrenal tumor other than pheochromocytoma by unilateral adrenalectomy
88880116|NCT01727622||Controls|ASL-MRI and FDG-PET will be compared for ability to discriminate between Control subjects and adults with Mild Cognitive Impairment (prodromal AD). A lumbar puncture will be obtained in a proportion of the participants.
88880117|NCT01727622||Mild Cognitive Impairment|ASL-MRI and FDG-PET will be compared for ability to discriminate between Control subjects and adults with Mild Cognitive Impairment (prodromal AD). A lumbar puncture will be obtained in a proportion of the participants.
88880118|NCT01727856||Rehabilitation Measurement Tool|This single arm consists of all subjects which will interact with the tool under invstigation.
88880119|NCT01727934|Experimental|Miravirsen sodium|Miravirsen will be dosed as single subcutaneous injections. Subjects will receive 5 weekly doses at 7 mg/kg then 4 every other week doses at 5 mg/kg.
88880120|NCT01728012||eGFR >=60ml/min/1.73m2|Patients with an estimated glomerular filtration rate of >=60 ml/min/1.73m2.
88880121|NCT01728012||eGFR 45-60ml/min/1.73m2|Patients with estimated glomerular filtration rate >=45 ml/min/1.73m2 and <60ml/min/1.73m2.
89190250|NCT06062030|Experimental|test group|"Investigational Products (DWJ1609) Number of tablets: 20 tablets in total Drinking water: 2,550 mL in total~The day before the colonoscopy [Day 1] ▶ Common: Eat a light breakfast the day before the examination, or take only clear fluids.~Take 10 tablets of DWJ1609 with 425 mL of water in the early evening (18:00-20:00) the day before the test, followed by 2 more doses of 425 mL of water for 1 hour (takes a total of 1,275 mL of water).~On the day of colonoscopy [Day 2]~▶ Common: On the day of the examination, only clear liquids should be taken before the examination. Complete the clinical trial medication and additional water intake at least 2 hours prior to the test or at the time indicated by the tester In the evening before the test, take 10 additional DWJ1609 tablets with 425 mL of water in the morning (04:00~08:00), 10 to 12 hours after taking DWJ1609, followed by 2 more doses of 425 mL of water for 1 hour (Total 1,275 mL of water)."
89190251|NCT06062030|Active Comparator|control group|"Control Products (DWC202304) Number of tablets: 28 tablets in total Drinking water: 2,550 mL in total~The day before the colonoscopy [Day 1] Take 14 tablets of DWC202304 with 425 mL of water in the early evening (18:00 to 20:00) the day before the test, followed by 2 more doses of 425 mL of water for 1 hour (takes a total of 1,275 mL of water).~On the day of colonoscopy [Day 2]~▶ Common: On the day of the examination, only clear liquids should be taken before the examination. Complete the clinical trial medication and additional water intake at least 2 hours prior to the test or at the time indicated by the tester In the evening before the test, take 14 additional DWC202304 tablets with 425 mL of water in the morning of the test (04:00~08:00), 10 to 12 hours after taking DWC202304, and then take 425 mL of water twice for 1 hour (total 1,275 mL of water)."
89404338|NCT03018249|Experimental|Arm II (medroxyprogesterone acetate, entinostat, hysterectomy)|Patients receive medroxyprogesterone acetate IM on day 1 and entinostat PO on days 1, 8, and 15. Patients undergo hysterectomy between days 21-24.
89404339|NCT01018550|Experimental|AMG 853|
89404340|NCT01018550|Placebo Comparator|Placebo|
89404341|NCT05380154|Experimental|Test group|Botulinum Toxin A type for injection (Botulax®)
89404342|NCT05380154|Active Comparator|control group|Botulinum Toxin A type for injection (BOTOX®, Bao Tuo Shi®)
89404343|NCT05378984|Active Comparator|Dark Chocolate|
89404344|NCT05378984|Active Comparator|Milk Chocolate|
89404345|NCT05378984|Active Comparator|White Chocolate|
89404346|NCT05374252|Experimental|Experimental Group|Concurrent PD-1 antibody sintilimab combined with mytomicin C, 5-fluorouracil, and IMRT, followed by adjuvant sintilimab
89404347|NCT05374252|Active Comparator|Control Group|Concurrent mytomicin C and 5-fluorouracil combined with IMRT
89404348|NCT00912158|Active Comparator|CPAP + ST|Continuous positive airway pressure (CPAP) and Standard medical therapy (ST)
89404349|NCT00912158|Active Comparator|BiPAP + ST|Bilevel positive airway pressure (BiPAP) and standard medical therapy (ST)
88880122|NCT01728090|Experimental|Hand sanitizer|"Intervention classrooms received alcohol-based hand sanitizer and a programme educational.~Characteristics of the hydroalcoholic gel (ALCO ALOE GEL): chlorhexidine digluconate at 20% solution, phenoxyethanol 1%, benzalkonium chloride 0.%. aloe Barbadensis 5%, Renat ethyl alcohol 70%, excipients c.s.p. 100 ml. Alcohol of between 65 - 70% degrees, pondus Hydrogenium (pH) = 7-7,5."
88880123|NCT01728090|No Intervention|Control|No hand sanitizer or educational programme were used
88880124|NCT01728168||Atopic|Subjects with either documented allergy, neurodermatitis, allergic asthma, allergic rhinitis, and/or a positive atopic score based on the criteria of Erlangen (>10 points).
88880125|NCT01728168||Non-atopic|Subjects without atopy.
88880126|NCT01728480|Experimental|Treatment (entolimod, IMRT, cisplatin)|Patients undergo IMRT 5 times per week for 7 weeks, receive cisplatin IV once weekly for 7 weeks, and entolimod SC on days 1, 8, 15, 22, 29, 36, and 43.
88880127|NCT01728558|Other|Early Goal Directed Sedation|"Early Goal Directed Sedation process of care involves:~Early delivery of proposed intervention, shortly after initiating mechanical ventilation;~Effective analgesia provided simultaneously and early (analgesia first).~Regular and frequent assessment of patient wakefulness/sedative state;~Avoidance of benzodiazepines and minimisation of use of propofol;~Reduced overall sedation depth with targeted light sedation; Patients randomised to the EGDS arm will receive a sedative infusion of Dexmedetomidine withor without minimal propofol in order to maintain a RASS of -2 to +1.~Dexmedetomidine infusion will be continued until sedation is no longer clinically indicated up to a maximum of 28 days after enrolment."
89404350|NCT00912158|Active Comparator|ST|Standard Medical therapy (ST)
89404351|NCT04438096|Experimental|100 mg|
88880128|NCT01728558|Active Comparator|Standard care Sedation Arm|Patients randomised to the standard care sedation arm will receive process of care sedation directed by the treating clinician. Based on the information from our observational study and the EGDS Pilot trial, most patients in this group are likely to receive midazolam and /or propofol. These agents will be infused to achieve the default target of Light sedation (RASS -2 to +1) whenever clinically appropriate and as specified by the treating clinician. The use remifentanil or dexmedetomidine for initial and maintenance sedation will be precluded.
88880129|NCT01728948||Group 1|
88880130|NCT01729104|Experimental|Phase I: Carfilzomib + Lenalidomide + Rituximab|Phase I: Four primary dose levels of carfilzomib plus lenalidomide (carfilzomib 20 mg/27 mg + lenalidomide 20 mg, carfilzomib 20 mg/36 mg + lenalidomide 20 mg, carfilzomib 20mg/45 mg + lenalidomide 20 mg, carfilzomib 20 mg/56 mg + lenalidomide 20 mg,) evaluated with a fixed dose of rituximab (375 mg/m2 weekly for 4 weeks). Alternate dose levels using 15 mg of lenalidomide in combination with carfilzomib and rituximab evaluated if MTD is exceeded with 20 mg of lenalidomide.
88880131|NCT01729104|Experimental|Phase II: Mantle Cell Lymphoma Group|"Phase II: Patients enrolled at recommended dose level (MTD) of Carfilzomib established in Phase I of the study.~Phase II Lenalidomide Dose: 20 mg by vein on Days 1-21 of each cycle.~Phase II Rituximab Dose: 375 mg/m2 by vein on Days 1, 8, 15, and 22 of Cycle 1 and 2. For Cycles 3 - 12, given on Day 1. For Cycles 13 and beyond, given on Day 1 every other cycle for up to 24 months."
88880132|NCT01729104|Experimental|Phase II: Follicular, Marginal Zone, DLBCL Group|"Group consists of : Patients with follicular lymphoma (FL) grade 1 - 3, marginal zone lymphoma (MZL), or non-germinal center B-cell diffuse large B-cell lymphoma (DLBCL).~Phase II: Patients enrolled at recommended dose level (MTD) of Carfilzomib established in Phase I of the study.~Phase II Lenalidomide Dose: 20 mg by vein on Days 1-21 of each cycle.~Phase II Rituximab Dose: 375 mg/m2 by vein on Days 1, 8, 15, and 22 of Cycle 1 and 2. For Cycles 3 - 12, given on Day 1. For Cycles 13 and beyond, given on Day 1 every other cycle for up to 24 months."
89404352|NCT04438096|Experimental|200 mg|
88880133|NCT01729182||Nexium|
88880134|NCT01729260|Experimental|Mebendazole|All study participants will receive study drug; Mebendazole.
88880135|NCT01729416|Experimental|Water Exchange Colonoscopy|The intervention will be water exchange colonoscopy in patients who are randomized to have screening colonoscopy with water exchange colonoscopy.
88880136|NCT01729416|Active Comparator|Air colonoscopy|The intervention will be colonoscopy using the traditional air method in patients who are randomized to have screening colonoscopy with air colonoscopy.
88880137|NCT01729572|Experimental|Experimental: Tele-medicine monitoring|Tele-medicine monitoring of medication adherence will be given to the study group as an add-on to routine out-patient treatment
89404353|NCT04438096|Experimental|300 mg|
89404354|NCT04438096|Placebo Comparator|Placebo|
89404355|NCT01015430|Placebo Comparator|Placebo (for RO4917523 ascending doses)|
89404356|NCT01015430|Placebo Comparator|Placebo (for RO4917523 fixed dose)|
89404357|NCT01015430|Experimental|RO4917523 ascending doses|
89404358|NCT01015430|Experimental|RO4917523 fixed dose|
89404359|NCT02923245|Experimental|POCUS|Patients will be given consecutive IV fluid boluses until a full bladder is visualized by the ED physician on POCUS or the patient endorses maximal bladder fullness on a 0-4 Likert Scale. The patient will then have a transabdominal pelvic ultrasound performed by a radiologist or ultrasound technician.
88880138|NCT01729572|No Intervention|No Intervention: Control Rutine out-patient treatment|routine out-patient treatment will be given to the control group
88880139|NCT01729650|Experimental|Physical and diet educational group|group educational PA program (basically walking) of 24 sessions over 12 weeks, and diet (16 sessions in the first 8 weeks), carried out by mental health nurses.
88880140|NCT01729650|No Intervention|Usual clinical care|
88880141|NCT01729806|Experimental|Arm A (ipilimumab and rituximab)|Patients receive rituximab IV over 2-6 hours once weekly in weeks 1-4 and ipilimumab IV over 90 minutes once weekly in weeks 1, 4, 7, and 10. Patients then receive ipilimumab IV over 90 minutes and rituximab IV over 2-6 hours once every 12 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity.
88880142|NCT01729806|Experimental|Arm B (ipilimumab and rituximab)|Patients receive rituximab IV over 2-6 hours once weekly in weeks 1-4 and ipilimumab IV over 90 minutes once weekly in weeks 3, 6, 9, and 12. Patients then receive ipilimumab IV over 90 minutes and rituximab IV over 2-6 hours once every 12 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity.
88880143|NCT01729962||Agreement Cohort|All subjects in the agreement portion of the study will have a single measurement performed with each device, the Nidek optical biometer, predicate device and ultrasound reference device. Each device will be operated by a different operator.
88880144|NCT01729962||Precision Cohort|All subjects in the precision portion of the study will each be paired with one Nidek optical biometer and with one predicate device for a total of three Nidek optical biometer/predicate device pairs. Each of the three device pairs will be designated one and only one operator. All subjects in the precision portion of the study will have their measurements repeated three times on each of three Nidek optical biometer and predicate device pairs.
88880145|NCT01721850|Active Comparator|control formula|infants are fed a commercial stage 1 infant formula during the first 4 months of life, according to protocol
88880146|NCT01721850|Experimental|intervention formula 1 group|infants are fed hydrolyzed infant formula containing pre- and probiotics during the first 4 months of life, according to protocol
88880147|NCT01721850|Experimental|intervention formula 2 group|infants are fed hydrolyzed infant formula containing pre- and probiotics during the first 4 months of life, according to protocol
88880148|NCT01729884|Experimental|Treatment (HER-2/neu peptide vaccine)|Patients receive HER-2/neu peptide vaccine ID once monthly for 3 months.
88880149|NCT01724112|Experimental|LY2940094|40 mg administered orally as 1 capsule QD for 8 weeks.
88880150|NCT01724112|Placebo Comparator|Placebo|Administered orally as 1 capsule QD for 8 weeks.
88880151|NCT01722864|Experimental|COV155|COV155, loading dose of 3 tablets followed by 2 tablets every 12 hours for 10 to 35 days.
88880152|NCT01724658|Experimental|Testosterone undecanoate|testosterone undecanoate 40 mg orally twice a week plus progynova 1mg oral daily
88880153|NCT01724658|Placebo Comparator|placebo|placebo twice a week with progynova 1 mg oral daily
88880154|NCT01049334|Experimental|flurbiprofen 8.75 mg lozenge|Participants sucked flurbiprofen 8.75mg lozenge every 3-6 hours up to 5 lozenges a day as needed for pain for 7 days.
88880155|NCT01049334|Placebo Comparator|Placebo lozenge|Participants sucked vehicle placebo lozenge every 3-6 hours up to 5 lozenges a day as needed for pain for 7 days.
88880156|NCT01048944|Active Comparator|Bupropion SR|150 mg bid bupropion SR
88880157|NCT01048944|Active Comparator|Nicotine Patch|21mg, 14mg, 7mg
88880158|NCT01048944|Placebo Comparator|Placebo Patch and Placebo Pill|Individuals were placed on both a placebo patch that were the same size as active patches given to the Nicotine Patch group and were also given placebo pills were the same size and identically packaged as the active pills (bupropion) given to the Bupropion SR group.
88880159|NCT01048944|No Intervention|Delayed-quit control|Smoke for 67 days while others have quit, then quit.
89404360|NCT02923245|No Intervention|Usual Care|Patients will be given consecutive IV fluid boluses until the patient endorses sensation of maximum bladder fullness on a 0-4 Likert Scale. The patient will then have a transabdominal pelvic ultrasound performed by a radiologist or ultrasound technician
89404361|NCT05103748|Active Comparator|Traditional vestibular rehabilitation|The patient shook his head horizontally and looked in the direction of head rotation. Repeated 10 times, and then shook his head with eyes closed and repeated 10 times. The patient holds a small visual target to practice. The small visual target is placed about 30cm in front of the patient. The subject moves his head back and forth while keeping his sight on the target.
89404362|NCT05103748|Experimental|Cognitive and vestibular dual task training|The patient shook his head horizontally and looked in the direction of head rotation. Repeated 10 times, and then shook his head with eyes closed and repeated 10 times. The patient holds a small visual target to practice. The small visual target is placed about 30cm in front of the patient. The subject moves his head back and forth while keeping his sight on the target. Besides, patients wear headphones to listen to the numbers at the same time. The numbers contain 1 and 2, and they are played randomly. They shake their heads when they hear 1, and nod when they hear 2. The training takes 30 minutes, once a day in the morning and evening.
89404363|NCT04399486|Experimental|Aquatic Physical Therapy|
89404364|NCT04399486|Active Comparator|Land-based Physical Therapy|
89404365|NCT03668535|Active Comparator|Bladder Filling arm|Group A have triple-way urethral catheter insertion before establishment of anaesthesia. Evaluation of the drained urine is done (including: amount, character, and simple for culture and sensitivity). Instillation of 200 ml sterile saline is done by 50 ml syringe through the irrigation way. The irrigation way is closed temporarily by artery forceps. After laparotomy the bladder may be deflated by 50 ml or further inflated by 50 ml if needed to allow comfortable dissection.
89404366|NCT03668535|Active Comparator|Bladder deflation arm|Group B have Foley's catheter is inserted as usual. The catheter is connected freely to urinary bag.
89404367|NCT00908648|No Intervention|1|standard white light
89404368|NCT00908648|Experimental|2|Narrow Band Imaging
89004339|NCT04920344|Experimental|GROUP III - High Risk Recurrence (transoral surgery, EBRT 60Gy, cisplatin 30 mg/m2)|"Patients whose tumor has a positive margin, which means the tumor could not be removed with healthy tissue around it or tumor grows significantly outside the lymph node will undergo EBRT RT 60 Gy for 6 weeks and receive cisplatin intravenously (IV) weekly 30mg/m2 for 6 weeks in the absence of disease progression or unacceptable toxicity."
89004340|NCT04888000|Other|single|Educational intervention.
89190252|NCT06062004|Active Comparator|Control|group A, SMILE procedure with lenticule diameter of 6.5 mm
89404369|NCT04437940||Covid-19 positive women|Women with nasofarangeal Covid-19 PCR test is positive
89404370|NCT01014806|Experimental|Low dose|
89404371|NCT01014806|Experimental|High dose|Investigational Influenza VLP Vaccine 60ug/strain
89404372|NCT01014806|Active Comparator|TIV|Trivalent Influenza Vaccine 15ug/strain, Commercially Licenced
89404373|NCT03667833|Experimental|shoulder brace with comfortable tension|"Self-comfortable tension of strap will be adjusted by subject's feedback with comfortable feeling as please feel postural correction by shoulder brace without tight pressure."
89404374|NCT03667833|Experimental|shoulder brace with forced tension|Forced tension, the self-comfortable tension of strap will be increased till forced tension of strap using buckles.
89190253|NCT06062004|Active Comparator|Study cases|group B, SMILE procedure with lenticule diameter of 7.0 mm
89404375|NCT05102968|Active Comparator|Rehabilitation with mobile application|Patients self-managed rehab exercise with a supportive mobile application
89404376|NCT05102968|Active Comparator|Rehabilitation under supervision|Patients received supervised physical therapy
89437475|NCT03825536|Experimental|Placebo oral capsule, Then Oral methamphetamine|Participants will be randomized to a placebo oral capsule first, then oral methamphetamine using a random number generator. For the placebo treatment, one placebo capsule will be administered orally on treatment day, followed by a second oral placebo capsule two hours later. Then the participant will receive the oral methamphetamine capsule for their second treatment phase starting at approximately Day 77. When oral methamphetamine is administered, an initial 10 mg of oral methamphetamine study drug will be administered to assess tolerability, followed by a subsequent 15 mg oral dose two hours later.
89437476|NCT03825289|Experimental|Treatment (trametinib, hydroxychloroquine)|Patients receive trametinib PO QD on days 1-28 and hydroxychloroquine PO QD or BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89437477|NCT03822897|Other|Two Treatment Options|"Option #1 - Radiotherapy 35 fractions, 5/wk, 7 wks 70Gy/56Gy Cisplatin 100mg/m2 on day 1, 22 and 43 or 40mg mg/m2/wk for 7 wks~Option #2 - Radiation only-35 fraction, 6/wk, 6wks 70Gy/56Gy"
89437478|NCT03815448|Experimental|Methotrexate|Methotrexate 2.5mg/ tablet, oral, once a week, 2-6 tablets each time
89404377|NCT03667755|Experimental|fast track recovery|Participants will attend dietitian clinic to have anthropometry & dietary assessment on the same day of admission (before admission). Subjects are given a specific drink to their group on the evening prior to surgery and three hours before operation. The CHO-P group received 474ml (evening drink) or 237ml (3 hours prior to operation drink) of a lactose-free clear tea-colour fruit flavoured fluid contains 14% whey protein, 86% carbohydrates and 0% lipids. Participants fast for solids for 6 hours from the operation. Participants will be given clear fluid (2 packs Resource peach) within 24 hours post-surgery (without present of bowel sound) and reviewed by dietitian. Staff nurse in-charged will monitor anesthetic risk of drinking whey protein and ensure subject to finish specific drinks prior surgery. When they tolerated at least 500ml of clear fluids, they were given a regular solid diet.
89404378|NCT03667755|No Intervention|conventional|Participants will attend dietitian clinic to have anthropometry & dietary assessment on the same day of admission (before admission). Participants followed conventional operation procedure whereby fasting start 12am until operation. On the first day of post-operation day, participants will be reviewed by gynaecologist and dietitian. They are allowed for clear fluid once there is bowel sound. After tolerated clear fluid, they will proceed for nourishing fluid, then soft diet and they were given a regular solid diet.
88880160|NCT01048866|Experimental|flurbiprofen 8.75 mg lozenge|Participants were instructed to suck one study (flurbiprofen 8.75 mg) lozenge and efficacy assessments were taken in the clinic. Upon discharge, participants were instructed to use another study medication lozenge every 3-6 hours, up to a total of 5 study lozenges in 24 hours. Following efficacy assessments, participants were again instructed to use study medication lozenge every 3-6 hours, up to a total of 5 study lozenges per day (plus rescue medication if needed) for the remaining time in the 7 day study.
88880161|NCT01048866|Placebo Comparator|placebo lozenge|Participants were instructed to suck one study (placebo) lozenge and efficacy assessments were taken in the clinic. Upon discharge, participants were instructed to use another lozenge every 3-6 hours, up to a total of 5 study lozenges in 24 hours. Following efficacy assessments, participants were again instructed to use a lozenge every 3-6 hours, up to a total of 5 study lozenges per day (plus rescue medication if needed) for the remaining time in the 7 day study.
88880162|NCT01048788|Experimental|OPC|
88880163|NCT01048242|Experimental|Ramelteon|Ramelteon 8 mg oral before bedtime
88880164|NCT01048242|Placebo Comparator|sugar pill|
88880165|NCT01047306||No Treatment|This is a longitudinal, prospective, observational, natural history study of patients with MPS IIIA to identify potential surrogate endpoints for future ERT trials via standardized clinical, biochemical, neurocognitive, developmental, behavioral and imaging measures.
88880166|NCT01046682|Active Comparator|Salsalate|
88880167|NCT01046682|No Intervention|Usual care|
88880168|NCT01044732|Experimental|Group A - COLO, then TER|"Complete examination with standard colonoscope (COLO) followed by complete examination with Third Eye Retroscope (TER) used in conjunction with standard colonoscope"
88880169|NCT01044732|Active Comparator|Group B - TER, then COLO|"Complete examination with Third Eye Retroscope (TER) used in conjunction with standard colonoscope, followed by complete examination with standard colonoscope (COLO) alone"
88880170|NCT01044498|Experimental|Tocilizumab 8 mg/kg + Ortho-Novum® 1/35 (Group 1)|Patients with rheumatoid arthritis received Ortho-Novum® 1/35 daily on Days 1-21 of 3 consecutive 28-day cycles. On the first day of Cycle 2, patients received tocilizumab 8 mg/kg administered intravenously.
88880171|NCT01044498|Other|Ortho-Novum® 1/35 (Group 2)|Healthy volunteers received Ortho-Novum® 1/35 tablets daily on Days 1-21 of one 28-day cycle.
88880172|NCT01043874|Experimental|Nilotinib|400 mg BID
89190254|NCT06060522|Active Comparator|Multi-detector computed tomography (MDCT )|Multi-detector computed tomography (MDCT ) will be performed for 8 patients performed using CT scanner (SOMATOM Emotion6, Siemens, Germany). The protocol was 200 mAs, 120 kVp, 512 × 512 matrix, 1.172 pitch, 64 × 0.625 mm section collimation, 2 mm slice thickness, 0.6 mm section reconstruction
88880173|NCT01042938|Active Comparator|Curcumin C3 Complex|Patients take 2.0 grams curcumin (four 500mg capsules) three times daily by mouth for prescribed course of radiation treatment (~4-7 weeks).
88880174|NCT01042938|Placebo Comparator|Placebo|Patients take 2.0 grams placebo (four 500mg capsules) three times daily by mouth for prescribed course of radiation treatment (~4-7 weeks).
88880175|NCT01042158|Other|Tadalafil and ambrisentan upfront therapy|This will be a 36-week, single group, open label study assessing the effects of Tadalafil plus Ambrisentan combination therapy in patients with pulmonary arterial hypertension associated with the scleroderma spectrum of disease (PAH-SSD).
88880176|NCT01046916|Experimental|TAK-700|
88880177|NCT03408912|Other|CMR and angiography FFR|Patients will undergo both CMR and angiography to acquired FFR.
88880178|NCT03405870|Experimental|Lipid|Infusion of drug (Smoflipid) will occur over a 16.5 hour period given once per day for the first two days of study enrollment.
88880179|NCT03405870|No Intervention|Control|Control patients will receive no experimental drug (ie, usual care)
88880180|NCT03409302|Experimental|The ALGEapp (Brief i-ACT intervention)|The intervention builds on a previously unpublished face-to-face protocol for greek-speaking chronic pain sufferers (developed by Karekla & Vasiliou, 2013) and has been simplified and modified to produce a self-help digital internet-based modality, namely the ALGEApp. ALGEApp consists of a total of 4 approximately one-hour sessions, which are structured to be completed by the users in sequence within a time frame of 2-8 weeks (depending on the rate of completion by each user). The intervention is guided, which implies that an animated character (an Avatar) guides the user throughout the whole duration of the intervention. ALGEApp contains experiential and audiovisual psycho-educational material based on ACT, adopted for the Greek-Cypriot culture.
88880181|NCT03409302|Active Comparator|Active Control group|The Active control group will have access only to limited component of the ALGEApp intervention, namely the Bonus section, which contains limited psycho-educational information regarding pain management.
88880182|NCT03409224||Adults 18-99|Adults who are undergoing cryoablation
88880183|NCT03409146||Term Patients|"Approximately 80 pregnant women monitored in labor between 37 and 42 weeks' gestation will be necessary to complete the study. Subjects will have a singleton >37 week pregnancy.~Subjects will be recruited for the study in the following groups :~At least 10 patients with Body Mass Index (BMI) < 30 kg/m2 At least 10 patients with BMI 30-34.9 kg/m2 At least 10 patients with BMI ≥ 35 kg/m2"
88880184|NCT03409068|Experimental|C2-C4 compartment block|Experimental: the C2-C4 compartment anesthetic block is performed by injecting Levobupivacaine 0.375% 20 mL between the posterior face of the middle scalenous muscle, the anterior face of the posterior scalene muscle and the lower plane of the sternoscleidomastoid muscle.
88880185|NCT03409068|Active Comparator|Costagliola block|Active Comparator: the Costagliola anesthetic block is performed by injecting Levobupivacaine 0.375% 20 mL injected in the posterior margin of the sternocleidomastoid muscle and along the anterior border of the same muscle.
88880186|NCT03408990||Sleep study for clinical reasons|Children referred to sleep study for clinical reasons
88880187|NCT03408990||Healthy|Healthy children, no relevant pathologies
88880188|NCT03408834|Active Comparator|pulse variability index|fluid management performed by pulse variability index
88880189|NCT03408834|Placebo Comparator|conventional fluid management|fluid management performed by conventional fluid management
88880190|NCT03408288||Nurses|
88880191|NCT03408288||Urologists|
88880192|NCT03408210|Active Comparator|total body irradiation|Patient receives preparative therapy including cyclophosphamide and total body irradiation (TBI) of 10 Gy on Days -4 through -1, and starts immunosuppressive therapy using cyclosporine or tacrolimus, methotrexate-based prophylaxes, followed by peripheral blood stem cell transplantation and granulocyte colony-stimulating factor administration.
88880193|NCT03408210|Experimental|total marrow and lymphoid irradiation|Patient receives preparative therapy including cyclophosphamide and total marrow and lymphoid irradiation of 12 Gy on Days -6 through -2, and starts immunosuppressive therapy using cyclosporine or tacrolimus, methotrexate-based prophylaxes, followed by peripheral blood stem cell transplantation and granulocyte colony-stimulating factor administration.
89190255|NCT06060522|Active Comparator|CBCT scans|CBCT will be performed for 8 patients with an exposure performed at 15 mA, 85 KV and at a field of view 7.5 cm x 14.5 cm x 14.5 cm.
89190256|NCT06060353|Experimental|Regulation Focused Psychotherapy (RFP-C)|
89190257|NCT06060353|Active Comparator|Parental Awareness and Child Social Skills Group|
89190258|NCT06060236|Experimental|ibuprofen|ibuprofen intravenous 800 mg
89190259|NCT06060236|Experimental|dexketoprofen|dexketoprofen intravenous 50 mg
89190260|NCT06059820||Conservative treatment group|The main group (prospective) will consist of patients who received conservative therapy. The expected number of observations in the main group will be 50 patients.
89190261|NCT06059820||Surgical treatment group|The control group (historical control) will be comprised of 50 patients who underwent surgery previously at the Sklifosovsky Research Institute for Emergency Medicine.
89190262|NCT06059378|Other|AI-assisted classification for diminutive polyps during a colonoscopy procedure|AI-assisted classification for diminutive polyps during a colonoscopy procedure using the CAD-eye detection and classification system for patienst who agree to undergo optical diagnosis of diminutive colorectal polyps
89190263|NCT06059274|Experimental|Topical serum|An investigational topical serum containing hyaluronic acid, vitamin B5, madecassoside and La Roche-Posay Thermal Spring Water
89190264|NCT06058169|Experimental|Whole Body Training (12 week)|
89190265|NCT06057311|Experimental|Hippotherapy Group|"The sessions for the HTG were conducted on horseback by a leader, side walker, and physiotherapist while the child was mounted on the horse. Before mounting, the child was dressed in the safety equipment of a helmet and rider vest by the physiotherapist and was directed to mount the horse from the mounting steps. In the first week of training, the cases received adaptation training. Within the training, 7 min of simple sitting on the horse were performed. In this position, the child was able to caress the horse's neck with one or both hands, rest while the horse walked, and 10 standing (or for those who could not do this, the horse was in a standing position)n the stirrups exercises were performed while holding the retaining strap."
89190266|NCT06057311|Experimental|Equine-Assisted Activities Therapy Group|Under the guidance of the physiotherapist, the children in the EAATG performed routine care of the horse, such as grooming, feeding, and hoof care. During equine-assisted activities, the physiotherapist ensured the correct positioning of the child's body when approaching the horse using equipment and during movement. The study participants groomed the horse, wiped the horse's feathers with a towel, combed the mane, checked the hooves, cleaned out any grit, and performed the procedures for the horse to go out. Finally, the child gave food and water to the horse, said farewell and left the therapy area.
89404379|NCT01014572|Experimental|Aerobic Exercise Training + Placebo|
89404380|NCT01014572|Experimental|Tai Chi and/or Yoga Training + Placebo|
88880194|NCT03408132|Experimental|FE203799 5 mg|FE203799 5 mg subcutaneous injection
88880195|NCT03408054|No Intervention|Control group|No oxytocin desensitization (pretreatment), no nitroglycerin
88880196|NCT03408054|Active Comparator|Oxytocin desensitized - no nitroglycerin|Pretreated with oxytocin, no nitroglycerin exposure
88880197|NCT03408054|Active Comparator|Oxytocin desensitized - plus nitroglycerin|Pretreated with oxytocin followed by nitroglycerin exposure
88880198|NCT03408054|Active Comparator|Non oxytocin desensitized - plus nitroglycerin|No oxytocin pretreatment, followed by nitroglycerin exposure
88880199|NCT03407976|Experimental|Apatinib and Pembrolizumab, all patients|
88880200|NCT03407898||C-mac D blade used for intubation|
88880201|NCT03407898||mcgrath X blade used for intubation|
88880202|NCT03407820|Active Comparator|1st random 50% of cohort|Absorbable Chromic gut sutures
88880203|NCT03407820|Active Comparator|2nd random 50% of cohort|Non-absorbable Nylon sutures
88880204|NCT03407742|Experimental|Intervention|CAPAS Youth Parenting Intervention
88880205|NCT03407742|No Intervention|Wait-list control|Participants allocated to this condition were offered the parenting intervention until all T2 assessments of the intervention arm were completed
88880206|NCT03407664||Men Screened for AAA in England|Men invited into the NHS AAA Screening programme in England in the years 2013-2017.
88880207|NCT03407586|Other|Diagnostic STI care|All participants underwent point-of-care STI testing, and if diagnosed with a STI were offered immediate therapy, and expedited therapy if indicated.
88880208|NCT03407508|Placebo Comparator|Baseline|No dietary changes.
89404381|NCT01014572|Experimental|Aerobic Exercise Training + Alagebrium|
89404382|NCT01014572|Experimental|Tai Chi and/or Yoga Training + Alagebrium|
89404383|NCT04437316|Active Comparator|Low Level Laser|therapeutic laser
89404384|NCT04437316|Placebo Comparator|Placebo Low Level Laser|non-therapeutic laser
89404385|NCT01013324|Experimental|Single Arm|All subjects will receive single-agent XL147 dosed daily
89404386|NCT04437550|Experimental|high-intensity|
89404387|NCT04437550|Experimental|low-intensity|
89404388|NCT00905606|Experimental|1|Topiramate Tablets, 25 mg
89404389|NCT00905606|Active Comparator|2|Topamax® Tablets, 25 mg
89404390|NCT01002950|Experimental|ACU-4429 tablet|
89404391|NCT01002950|Placebo Comparator|Matching placebo tablet|
88880209|NCT03407508|Placebo Comparator|Comparison of Diets|Okinawan-based Nordic Diet or Control Diet.
88880210|NCT03407352|Active Comparator|Passive Video Game Play|Participants will play video games in a seated position for 60 minutes.
89404392|NCT01676896|Experimental|Asthma in-school class|Provided in 16 15-minute sessions (4 hours total didactic time); scheduled 3 sessions/week. The content is provided by trained asthma educators. The Asthma Plan for Kids (AP-K) is a 7-step curriculum for children to use when responding to asthma symptoms. Skills practice with placebo metered dose inhaler (MDI) and peak expiratory flow (PEF) meters with PEF score interpretation. Topics include (a) identifying lung function, asthma warning signs, symptoms, and triggers; (b) learning skills to manage symptoms, including PEF meter score interpretation, communication with adults (e.g. teachers, coaches, family members), medication use and MDI technique; (c) evaluating asthma symptoms and the effectiveness of management; and (d) discussing how to stay active in a safe manner.
89437479|NCT03815448|Placebo Comparator|Placebo|Placebo 2.5mg/ tablet,oral,once a week,2-6 tablets each time
89437480|NCT03811314|Experimental|Strength training|Muscle strength training programs
89437481|NCT03811314|Experimental|Aerobic training|Aerobic training programs
89437482|NCT03811314|Experimental|Isokinetic training|Isokinetic training
88880211|NCT03407352|Experimental|Active Video Game Play|Participants will play dance dance revolution (video game that requires lower body movement) for 60 minutes.
88880212|NCT03406416|Experimental|Suprachoroidal retinal prosthesis|Prototype wide view suprachoroidal retinal prosthesis
88880213|NCT03406026|Experimental|Balance System Protocol Stroke|Balance System Protocol Stroke differentiates 2 levels of difficulty in relation to the patient's condition and progressively according to their evolution. If the patient maintains stability in standing for at least 30 s, he starts in Level 2 and otherwise he will remain in Level 1 until he acquires it. In level 1 the progression of exercises is: 1.Pressure stimulation of the foot support points; 2.Proprioceptive ankle work; 3.Sit-to-stand work and vice versa; 4.Sit-to-stand work with delayed affection. In level 2, the progression of exercises is: 1.Standing unbalances; 2.Standing on Balance-pad; 3.Work to get monopodal support; 4.Balance pad in monopodal support; 5.Monopodal support work with closed eyes.
88880214|NCT03406026|Active Comparator|Control Stroke|The program of Control Stroke arm is based on an integral and rehabilitative approach in which the patient follows a personalized plan of exercises and therapies according to the deficits of each patient, the previous situation, the personal concerns with In order to perform a person-centered approach.
88880215|NCT03405948|Experimental|botulinum toxin|injection of Botulinum toxin
88880216|NCT03405948|Placebo Comparator|placebo|Injection of saline serum (placebo)
89404393|NCT01676896|Experimental|Asthma Day Camp|The asthma day camp is provided in a single day session (5.5 hours total) by trained camp staff. The same skills (i.e., placebo metered dose inhaler (MDI) and peak expiratory flow (PEF) meters) and topics [a) identifying lung function, asthma warning signs, symptoms, and triggers; (b) learning skills to manage symptoms, including PEF meter score interpretation, communication with adults (e.g. teachers, coaches, family members), medication use and MDI technique; (c) evaluating asthma symptoms and the effectiveness of management; and (d) discussing how to stay active in a safe manner] are covered as those in the asthma in-school classes.
89404394|NCT01676896|Sham Comparator|Health Promotion in-school class|The mock comparison follows the in-school format of 16 15-minute sessions; scheduled 3 sessions/week. The content is provided by trained health educators and includes skills practice (i.e., handwashing and brushing teeth) and health promotion topics of nutrition, healthy snacks, preventing colds, and safe exercise.
88880217|NCT03405636|Experimental|Xeltis Pulmonary Valved Conduit|PV Conduit for RVOT reconstruction
88880218|NCT03405402|Experimental|Experimental group|Allo-immunization detected (positive response for irregular antibodies 2 to 4 weeks after a blood transfusion)
89404395|NCT03017235|Experimental|NaP/MC Oral Solution|Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Acid (NaP/MC) Oral Solution
88880219|NCT03405402|Other|Control group|Allo-immunization not detected
88880220|NCT03405324|Active Comparator|active tDCS|a single session over the primary motor cortex with constant current of 2mA intensity was applied for 20 minutes with a 5-second ramp phase at the beginning applied to the participant patient before chemotherapy .
88880221|NCT03405324|Sham Comparator|sham tDCS|a single session over the primary motor cortex with constant current of 2mA intensity was applied for 20 minutes with a 5-second ramp phase at the beginning applied to the participant patient before chemotherapy switched off after 30 second without the patient knowledge .
88880222|NCT03405246|Active Comparator|KIDFIT SAFE|The Control Group will be provided 12 web-based monthly Homestyles Safe Guides about safe home environments for raising children and related material emailed monthly to the moms. KIDFIT Safe web site targets environmentally safe childcare related topics such as use of sun screen, avoidance of choking hazards, pet safety, protection from electrical appliances, etc. KIDFIT Safe participants will attend both baseline and 12 month clinical visits.
88880223|NCT03405246|Experimental|KIDFIT HEALTHY|The KIDFIT intervention group combines traditional in-person and electronic participant contacts, including two scheduled individual visits with a nutrition coach, coaching calls throughout the year, and monthly group videoconferencing-type sessions. KIDFIT Healthy participants will attend both baseline and 12 month clinical visits.
88880224|NCT03405168|Experimental|routine therapy plus moxifloxacin|Routine therapy (chemotherapy, endocrine therapy or target therapy) is according to physician's choice.
89404396|NCT03017235|Active Comparator|PREPOPIK®|
89404397|NCT00905372|Experimental|LY2062430|
88880225|NCT03404934|Experimental|C-REX group|After resection of the disease in colon, the intestinal ends will be anastomosed by the investigational device, i.e. C-REX LapAid and C-REX DMH/DMHC included in the C-REX Ring-locking Procedure.
88880226|NCT03404856|Other|Treatment with ORL-1G - D-galactose|
88880227|NCT03404622|Active Comparator|Postplacental IUCD Insertion during Cesarean section|IUCD inserted postplacental removal
88880228|NCT03404622|Active Comparator|6 Week Post-Cesarean Insertion of IUCD|IUCD inserted after six weeks post Cesarean section delivery
88880229|NCT03404466|Experimental|experimental group one|10 mg of Hypidone Hydrochloride tablets
88880230|NCT03404466|Experimental|experimental group two|20 mg of Hypidone Hydrochloride tablets
88880231|NCT03404232|Active Comparator|Group 1|patients with their first surgical intervention at the lumbar spine receive the Dynesys DTO device (Zimmer Spine, Inc.).
88880232|NCT03404232|Active Comparator|Group 2|patients with a previous surgical decompression but non-fusion procedure after lumbar spinal stenosis surgery receive the Dynesys DTO device (Zimmer Spine, Inc.).
89404398|NCT00905372|Placebo Comparator|Placebo|
88880233|NCT03404232|Active Comparator|Group 3|patients with the medical history of PLIF-/TLIF-technique and later onset of symptomatic ASD within the superior adjacent segment receive the Dynesys DTO device (Zimmer Spine, Inc.).
88880234|NCT03403764|Experimental|Wellness Intention Transmission Groups|"Aim of this part of the study is to examine whether intention broadcasted from an Intention Host Device (a device which stores and transmits an intention) will affect self-compassion, general wellness, and awakening. 300 trial participants will be randomly allocated to 1/3 in control and 2/3 in the experimental IHD group, respectively. Differences in outcomes between control and experimental groups are expected.~To address potential bias, those who enter the study but drop out are compared to those who complete the study to gauge potential differences between the two groups, and will report on this potential bias in the published manuscript."
88880235|NCT03403764|No Intervention|Independent Control Group|"Due to the global, emergent entanglement phenomenon, the investigators are curious if the investigators can test this idea within the context of the proposed study. The investigators added an additional but smaller control group which will complete the same three questionnaires for the first 6 months only and will be unaware of the larger study being conducted. These 50 subjects will be told they are completing the questionnaires in the context of a distinct, separate study and will be unaware of the Consciousness Field Project."
88880236|NCT03403530|Active Comparator|case group|'IgM rich immunoglobulin' intravenous infusion in the dose of 5 ml/ kg/ dose over 3 hours once a day for 3 days.
88880237|NCT03403530|Placebo Comparator|control group|antibiotics only
88880238|NCT03403452|Experimental|arm for Apatinib|500 mg,p.o.,qd
88880239|NCT03403296||CLASSIC cohort|Patients with stage II-III GC who underwent D2 resection were randomized (1:1) after surgery to receive adjuvant capecitabine and oxaliplatin (eight three-week cycles of oral capecitabine 1000 mg/m² twice daily on days 1-14 plus intravenous oxaliplatin 130 mg/m² on day 1) for 6 months or observation alone. Assessment whether patients were disease free were done by abdominal CT or MRI and chest radiograph at regular intervals as planned by protocol.
88880240|NCT03403140|Experimental|Single arm|"Enerceptan®. Injectable Solution in prefilled syringes~Source: GEMABIOTECH S. A. Formulation per unit:~1,0 ml of Enerceptan® contains 50 mg solution of Etanercept /Once a week Methotrexate 15 to 25 mg / Once a week"
88880241|NCT03402984|Experimental|Acotiamide|Acotiamide 100 mg t.i.d. for 3 weeks. Intake of medication 10 minutes before meal.
88880242|NCT03402984|Placebo Comparator|Placebo|Placebo tablets, t.i.d. for 3 weeks. Intake of placebo 10 minutes before meal.
88880243|NCT03402672|Experimental|AWAITS|Participants who meet criteria will receive the AWAITS self-administered, e-health application intervention.
89404399|NCT05208788||Renal transplant patients - group 1|Renal transplant patients with stable renal function parameters (mean SCr (or cystatin C) or mean eGFR based on creatinine and / or cystatin C defined as changes ≤ ±15 % for at least three consecutive ambulatory controls).
88880244|NCT03402594|No Intervention|No oxygen|No oxygen supplementation given
88880245|NCT03402594|Active Comparator|Low flow oxygen|Oxygen cannula with a flow rate of 2 liter/minute
88880246|NCT03402594|Experimental|High flow oxygen|Heated humidified high flow oxygen cannula (Optiflow; temperature of 34°C and fractional inspired oxygen of 0.24) with a flow rate of 20 liter/minute
88880247|NCT03402516|Experimental|18.5Fr resector|Used of a 18.5Fr bipolar resector for hysteroscopic myomectomy. Cervical dilatation would be performed until Hegar bougie number 7 and then a classic hysteroscopic resection will be performed with a 18.5Fr bipolar resector.
88880248|NCT03402516|Active Comparator|26Fr resector|Used of a 26Fr bipolar resector for hysteroscopic myomectomy. Cervical dilatation would be performed until Hegar bougie number 10 and then a classic hysteroscopic resection will be performed with a 24Fr bipolar resector.
88880249|NCT03402438|Experimental|Normal (healthy subjects)|Healthy subjects matched for age, body weight and gender to the groups with renal impairment
88880250|NCT03402438|Experimental|Mildly renal impaired|Subjects with renal impairment and an estimated glomerular function rate between equal or above 60 and below 90 ml/min/1.75 m*2
89190267|NCT06057311|Other|Control Group|The children in the control group were evaluated at the same time as the other groups but were not included in any therapy. All assessments were conducted at baseline and 6 weeks later. When the study was completed, the subjects in this group were permitted 10 sessions of hippotherapy if they so wished.
88880251|NCT03402438|Experimental|Moderately renal impaired|Subjects with renal impairment and an estimated glomerular function rate between equal or above 30 and below 60 ml/min/1.75 m*2
88880252|NCT03402438|Experimental|Severely renal impaired|Subjects with renal impairment and an estimated glomerular function rate between below 30 ml/min/1.75 m*2
88880253|NCT03402360|Experimental|Virtual Reality rehabilitation group|The Virtual Reality group will perform upper extremity motor rehabilitation and neurocognitive rehabilitation based on virtual reality training.
89190268|NCT06056843|Experimental|Intervention arm|Triage of clinical breast examination positive women using handheld ultrasound by non-radiologists.
89190269|NCT06055530||School aged children in Ethiopia|A number of school aged children in Ethiopia from 5-7 different schools in the Jimma region.
88880254|NCT03402360|Active Comparator|Control group|The Control group will perform the same motor and neurocognitive rehabilitation but with the virtual reality turned off.
88880255|NCT03402204|Experimental|Simvastatin 10 mg|Simvastatin 10 mg
88880256|NCT03402204|Experimental|Simvastatin 40 mg|Simvastatin 40 mg
88880257|NCT03402048|Active Comparator|control arm|"At discretion of the treating phisician. Common chemotherapic regimens include:~Gemcitabine at 1000 or 1250 mg/m2 IV (in the vein) on day 1 and 8 of each 21 day cycle.~Carboplatin at an AUC of 5 IV on day 1 of each 21 day cycle plus Gemcitabine at 1000 mg/m2 IV on Day 1 and 8 of each 21 day cycle.~Carboplatin at an AUC of 5 IV on Day 1 of each 21 day cycle plus Pemetrexed 500mg/m2 on day 1 IV on Day 1 of each 21 day cycle.~Vinorelbine 30 mg/m2 IV on day 1 and day 8 every 3 of each 21 day cycle.~Number of Cycles: to a maximum of 6 cycles until progression or unacceptable toxicity."
89437483|NCT03811314|Experimental|Isotonic training|Isotonic training
89437484|NCT03807817|Experimental|Moderate Alcohol|
88880258|NCT03402048|Experimental|experimental arm|"Treatment prescriptions will be based on gene analysis:~Carboplatin at an AUC of 6 IV (in the vein) on day 1 of each 21 day cycle.~Gemcitabine at 1000 mg/m2 IV on day 1 and 8 of each 21 day cycle.~Carboplatin at an AUC of 5 IV on day 1 of each 21 day cycle plus Gemcitabine at 1000 mg/m2 IV on Day 1 of each 21 day cycle.~Carboplatin at an AUC of 5 IV on Day 1 of each 21 day cycle plus Pemetrexed at 500 mg/m2 IV on Day 1 of each 21 day cycle.~Pemetrexed 500mg/m2 IV on Day 1 of each 21 day cycle.~Docetaxel 75 mg/m2 IV on Day 1 of each 21 day cycle. Or Vinorelbine 30 mg/m2 IV on day 1 and day 8 of each 21 day cycle.~Number of Cycles: to a maximum of 6 cycles until progression or unacceptable toxicity."
88880259|NCT03401892|Experimental|Patients with a history of NAION|patients with a history of non-arteritic anterior ischemic optic neuropathy (NAION) in one eye
88880260|NCT03401892|Experimental|Healthy control subjects|healthy age-and sex- matched control subjects
88880261|NCT03401580|Experimental|Viena II - 160/10|Fixed-dose, 160mg +10 mg, orally, once daily.
88880262|NCT03401580|Experimental|Viena II - 190/10|Fixed-dose, 190mg + 10 mg, orally, once daily.
88880263|NCT03401580|Experimental|Viena II - 160/12|Fixed-dose, 160mg + 12 mg, orally, once daily.
88880264|NCT03401580|Experimental|Viena II - 190/12|Fixed-dose, 190mg + 12 mg, orally, once daily.
88880265|NCT03401502|Experimental|Treatment groups|Ranolazine 1000 mg
88880266|NCT03401502|Placebo Comparator|Control group|Placebos
88880267|NCT03401424|Experimental|improved Warren-type style|Minimally invasive treatment improved Warren-type cholangiocarcinoma reconstruction is easy
88880268|NCT03401424|Active Comparator|Roux-en-Y style|Early open cholecystectomy reconstruction surgery using Roux-en-Y style
88880269|NCT03401346|Experimental|INP104|Single dose 1.45 mg Dihydroergotamine Mesylate (DHE), administered by I123 Precision Olfactory Delivery (POD) device nasal spray (INP104)
88880270|NCT03401346|Active Comparator|D.H.E. 45 Injection (IV)|Single dose 1 mg Dihydroergotamine Mesylate (DHE) for intravenous injection
88880271|NCT03401346|Active Comparator|Migranal Nasal Spray|Single dose 2 mg Migranal Nasal Spray Dihydroergotamine Mesylate (DHE)
88880272|NCT03401268|Experimental|Patient cohort|The study population will include 24 patients, that are either already on IVIG or are eligible for ScIG as initial Ig replacement, that will undergo Ig replacement with subcutaneous immunoglobulin (ScIG) for a total of 6 months.
88880273|NCT03400878|Active Comparator|BCG-JAPAN|Infants randomised to receive BCG-JAPAN at discharge from the Maternity Ward will receive one 0.05 ml dose of Mycobacterium bovis BCG live attenuated BCG-JAPAN vaccine (Japan BCG Laboratory, Tokyo, Japan) by intradermal injection in the left deltoid region.
88880274|NCT03400878|Active Comparator|BCG-RUSSIA|BCG-RUSSIA Infants randomised to receive BCG-RUSSIA at discharge from the Maternity Ward will receive one 0.05 ml dose Mycobacterium bovis BCG live attenuated vaccine BCG-RUSSIA (Serum Institute of India, Pune, India) by intradermal injection in the left deltoid region.
89190270|NCT06055530||School aged children in Uganda|A number of school aged children from Uganda. Children from 5-7 different schools will be in the group.
89437485|NCT03807817|Experimental|Low Alcohol|
88880275|NCT03400722|Experimental|DUOSTIM group|Pergoveris 150 -300 IU start from day 2 of the cycle up to the day of trigger, GnRH antagonist 0,25 mg start from day 7-8 of the cycle up to the day of trigger, final trigger of ovarian stimulation - GnRH-a 0,2 mg, oocyte retrieval 35 hours after trigger, stop period for 5 days, after stop period start Pergoveris 150 - 300 IU start up to the day of trigger, GnRH antagonist 0,25 mg start from day 6 of ovarian stimulation up to the day of trigger, final trigger of ovarian stimulation - GnRH-a 0,2 mg, oocyte retrieval 35 hours after trigger. After oocyte retrieval fertilization will be carried out by IVI or ICSI, the development of embryos will be carried out up to blastocyst stage, then blastocyst vitrification will be performed.
88880276|NCT03400722|Experimental|Modified Shanghai Protocol group|Clomiphene 50 mg start from day 2-3 of the cycle up to the day of trigger, Pergoveris 150 - 300 IU - 6,8, 10 days of the cycle, final trigger of ovarian stimulation - GnRH-a 0,2 mg, oocyte retrieval 35 hours after trigger, after stop period for 2-3 days start Pergoveris 150 - 300 IU up to the day of trigger, final trigger of ovarian stimulation - GnRH-a 0,2 mg, oocyte retrieval 35 hours after trigger. After oocyte retrieval fertilization will be carried out by IVI or ICSI, the development of embryos will be carried out up to blastocyst stage, then blastocyst vitrification will be performed.
88880277|NCT03400644|Active Comparator|With Collar|Subjects are prescribed with custom-made rigid cervical collar which are to be worn for 3 weeks postoperatively
88880278|NCT03400644|No Intervention|Without Collar|Subjects do not need to wear any cervical collar postoperatively
88880279|NCT03400566|Experimental|Narrative (target)|Children will receive the story featuring the target vegetable and NO sensory experience.
88880280|NCT03400566|Experimental|Narrative+ experiential (target)|Children will receive the story featuring the target vegetable and experiential learning with the target vegetable.
88880281|NCT03400566|Active Comparator|Narrative (control)|Children will receive the story featuring the control vegetable and NO sensory experience.
88880282|NCT03400566|Active Comparator|Narrative+ experiential (control)|Children will receive the story featuring the control vegetable and experiential learning with the control vegetable.
88880283|NCT03400488|Experimental|AZD5718|Randomized subjects will receive orally once daily dose of AZD5718 oral suspension on Day 1 (SAD) and MAD from Days 3 to 10. On Day 2, no dose will be given. These procedures will be repeated in all cohorts.
88880284|NCT03400488|Placebo Comparator|Placebo|Randomized subjects will receive orally once daily dose of placebo matching AZD5718 oral suspension on Day 1 (SAD) and MAD form Days 3 to 10. On Day 2, no dose will be given. These procedures will be repeated in all cohorts.
88880285|NCT03400254|Experimental|Phase II: Arm A|Patients will receive HCQ, 600 mg BID, for 24 weeks.
89437486|NCT03807817|Active Comparator|Placebo Alcohol|
89190271|NCT06049927|Experimental|Experimental Group of quadrivalent influenza vaccine(0.25ml)|1100 subjects phase III will receive two doses of quadrivalent influenza vaccine(0.25ml) according to the immunization schedule of day 0,28
88880286|NCT03400254|Experimental|Phase II: Arm B|Patients will receive HCQ, 600 mg BID, for 24 weeks and GED x 2 weeks administered weekly, as an intravenous dose of 150 mg.
88880287|NCT03400254|Experimental|Phase II: Arm C|Patients will receive HCQ, 600 mg BID, for 24 weeks and GED x 6 weeks administered weekly, as an intravenous dose of 150 mg.
88880288|NCT03400254|Experimental|Phase II: Arm D|Patients will receive HCQ, 600 mg BID, for 24 weeks and GED x 12 weeks administered weekly, as an intravenous dose of 150 mg.
88880289|NCT03400254|Experimental|Phase Ib Arm|Patients will receive HCQ, 600 mg BID, and GED, administered weekly as an intravenous dose of 150 mg, for 6 weeks.
88880290|NCT03400020|Experimental|Ascorbic acid|Ascorbic acid 1000 mg in normal saline IV 2 hours before the operation and thereafter 500 mg in normal saline IV daily for three days.
88880291|NCT03400020|Placebo Comparator|Normal saline|Normal saline IV infusion 2 hours before the operation and for three days after operation.
88880292|NCT03408444|Experimental|EMO-114|Test Lens 1
88880293|NCT03408444|Experimental|EMO-116|Test Lens 2
88880294|NCT03408444|Experimental|EMO-118|Test Lens 3
88880295|NCT03408444|Active Comparator|EMO-117|Test Lens 4
88880296|NCT03401190|Experimental|Low Dose Group|Phase 1: Cohorts 1 & 2 will consist of 4 female and 4 male patients enrolled concurrently who will be randomized 3:1 to receive CM4620-IE plus standard of care versus standard of care alone. Planned doses for patients who are randomized to receive CM4620-IE are 1.0 mg/kg on Days 1 and 1.4 mg/kg on Days 2-4.
88880297|NCT03401190|Experimental|High Dose Group|Phase 2: Cohorts 3 & 4 will consist of 8 female and 8 male patients enrolled concurrently who will be randomized 3:1 to receive CM4620-IE plus standard of care versus standard of care alone. Planned doses for patients who are randomized to receive CM4620-IE are 2.08 mg/kg of CM4620-IE on Days 1 and 2, and 1.6 mg/kg on Days 3 and 4.
88880298|NCT03401190|No Intervention|Standard of Care|For all cohorts, patients will be randomized 3:1 to CM4620-IE plus standard of care versus standard of care alone.
88880299|NCT03406728|Active Comparator|PDSAFEX GROUP|Parkinson's Disease Sensory Attention Focused Exercise (PDSAFEX) is an exercise intervention developed in light of research which focuses on utilizing sensory integration and proprioception to improve balance. This intervention will be administered to one group of my participants. The protocol will be followed and led by trained volunteers.
88880300|NCT03406728|Active Comparator|CONTROL GROUP|The control group in this study will be asked to maintain their daily lifestyle as closely as possible for the 12-week duration of the study.
89190272|NCT06049927|Experimental|Experimental Group of quadrivalent influenza vaccine(0.5ml)|1100 subjects phase III will receive two doses of quadrivalent influenza vaccine(0.5ml) according to the immunization schedule of day 0,28
89190273|NCT06049927|Active Comparator|Control Group of trivalent influenza vaccine(BV)|550 subjects phase III will receive two doses of trivalent influenza vaccine(BV) according to the immunization schedule of day 0,28.
88880301|NCT03406728|Experimental|VIRTUAL REALITY GROUP|Virtual reality intervention will be assigned to this group. They will complete activities aimed at improving their dynamic balance. These activities are specifically developed based on previous literature and geared towards mirroring day to day activities/scenarios that individuals with PD may come into contact with.
88880302|NCT03403218|Experimental|case group|BESTest, mini-BESTest, Berg scale and FES (falls efficacy scale) (in Spanish version is administrated in case group.
88880303|NCT03400956|Experimental|Vilaprisan (A1)|Vilaprisan in treatment period 1 for 12 weeks and in treatment period 2 for 12 weeks, separated by 1 bleeding episode.
88880304|NCT03400956|Experimental|Placebo+Vilaprisan (B1)|Placebo in treatment period 1 for 12 weeks, and vilaprisan in treatment period 2 for 12 weeks, separated by 1 bleeding episode.
89190274|NCT06049927|Active Comparator|Control Group of trivalent influenza vaccine(BY)|550 subjects phase III will receive two doses of trivalent influenza vaccine(BY) according to the immunization schedule of day 0,28.
89404400|NCT05208788||renal transplant patients - group 2|Renal transplant recipients with stable renal function at inclusion, facing a pre-defined event during the course of the study. Pre-defined events are Acute Rejection (AR), viral transplant-associated infection (e.g. BKV), bacterial infection (febrile urinary tract infection (fUTI)), calcineurin-inhibitor (CNI) toxicity, and acute tubular necrosis (ATN).
89404401|NCT05208788||Patients with Chronic Kidney Disease Stage IV and V (CKD IV-V) - group 3|Patients with CKD IV-V (and maintained urine output, without renal replacement therapy and without pre-defined events).
89404402|NCT05208788||Healthy controls|Healthy children serve as control group
89404403|NCT03017079|Experimental|semi-solidification with nutrient|"semi-solidification with nutrient:after infusion of semi-solid agent, enteral nutrition is applied less than 60 mins.~Intervention: Other: bolus Intermittent enteral feeding"
89404404|NCT03017079|Placebo Comparator|Standard enteral nutrition|"After infusion of Sterile Water for Injection,bolus Intermittent enteral feeding via the nasogastric tube is applied less than 60 mins.~Intervention: Other: Standard enteral feeding"
89404405|NCT05048134|Experimental|Treatment group A|
89190275|NCT06047951|Experimental|SRS group|Participants in the SRS group will receive the intervention described earlier, consisting of a Gamma Knife radiosurgery, and undergo the same follow-up exams (radiological and clinical) as participants of the control group.
89404406|NCT05048134|Experimental|Treatment group B|
88880305|NCT03400956|Experimental|Vilaprisan+Placebo (B2)|Vilaprisan in treatment period 1 for 12 weeks, and placebo in treatment period 2 for 12 weeks, separated by 1 bleeding episode.
88880306|NCT00012012|Experimental|Radiation therapy plus cisplatin|Patients receive extended field external beam radiation therapy (RT) to the para-aortic region and pelvis, intracavitary brachytherapy with concurrent weekly cisplatin.
88880307|NCT00012012|Experimental|Radiation therapy plus cisplatin and amifostine|Patients receive extended field external beam radiation therapy (RT) to the para-aortic region and pelvis, intracavitary brachytherapy with concurrent weekly cisplatin and amifostine trihydrate.
88880308|NCT00010374|Experimental|NeuRx DPS|Laparoscopic implantation of 4 NeuRx DPS electrodes and subsequent pacing using the DPS system.
88880309|NCT02249520|Other|PET-MR imaging on Biograph mMR scanner|Research PET-MR imaging on Biograph mMR scanner will be conducted immediately following administration of FDG for clinically approved scan. No additional radioisotope will be administered for the research scan.
88880310|NCT02249520|Other|MR-only imaging on Biograph mMR scanner|Participants will undergo research MR-only imaging on Biograph mMR scanner.
88880311|NCT02249520|Other|MR imaging on the Siemens Vida 3T MR scanner|Participants will undergo research MR imaging on the Siemens MR scanner
89190276|NCT06047951|No Intervention|Control group|The medical care will consist of observation for any element that may indicate an increased risk of rupture, like aneurysm growth or instability in shape.
89404407|NCT05048134|Experimental|Treatment group C|
89404408|NCT05048134|Experimental|Treatment group D|
89404409|NCT05048134|Experimental|Treatment group E|
89404410|NCT04438928|Experimental|Healthy pregnant women - Supplement|"Supplementation with micronutrients plus docosahexaenoic acid (DHA) preparation (Multimicronutrients and docosahexaenoic acid (MMS) soft gel capsules) during 2nd and 3rd trimesters of pregnancy.~Subgroup: Healthy pregnant women with Caesarean section [A subset of subjects (approximately 10 subjects per study arm) undergoing elective Caesarean section (for reasons independent from the study)]"
89404411|NCT04438928|Other|Healthy pregnant women - Non-Supplement|"Control study group~Subgroup: Healthy pregnant women with Caesarean section [A subset of subjects (approximately 10 subjects per study arm) undergoing elective Caesarean section (for reasons independent from the study)]"
89404412|NCT03667677|Experimental|Group 1|Tandospirone + Amlodipine
89404413|NCT03667677|Experimental|Group 2|Tandospirone placebo + Amlodipine
89404414|NCT03667677|Experimental|Group 3|Tandospirone + Amlodipine placebo
89404415|NCT03667677|Placebo Comparator|Group 4|Tandospirone placebo + Amlodipine placebo
88880312|NCT02240082|Experimental|Web-based COPing with Shiftwork Program|Participants in this condition will use the web-based COPing with Shiftwork web-based program for three months
88880313|NCT02240082|No Intervention|Wait List Control|Participants in the wait list control group will not receive any intervention during the study period, but will have access to any program offered by the police department.
88880314|NCT02240160|Experimental|Sativex: acidic oral pH|Four sprays of Sativex taken within two minutes of pH measurement immediately following oral pre-treatment with Coca-Cola (30 mL held in the mouth for 45-60 seconds then spat out, repeated three times).
88880315|NCT02240160|Experimental|Sativex: neutral oral pH|Four sprays of Sativex taken within two minutes of pH measurement immediately following oral pre-treatment with tap water (30 mL held in the mouth for 45-60 seconds then spat out, repeated three times).
89404416|NCT04437472||CareSignal|-Participants will undergo a single training session on how to use the CareSignal software no more than 4 weeks before starting standard of care therapy. After the training session, patients will be encouraged by the treatment team to complete the baseline symptom report once they receive the questions via SMS prior to starting any therapy and to complete the weekly reports during therapy and in follow up.
89437487|NCT03807817|Active Comparator|No Alcohol|
89530993|NCT04497701|Active Comparator|rhG-CSF group|Patients received subcutaneous injection of rhG-CSF 24~72 hours after the end of chemotherapy, 100µg/kg/d, and stop using it until the ANC value exceeds the lowest value for 2 consecutive days> 0.5×10^9/L.
89530994|NCT02496065|Experimental|BLZ-100|
89404417|NCT04392856|Experimental|Unified Protocol Transdiagnostic Treatment Emotional Disorders|"An adaptation of the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (UP) to women in a homeless situation will be implemented in public shelters setting in Madrid, Spain.~The UP adaptation is an intervention based protocol for emotional disorders, consisted of 12 treatment sessions of one and a half hours of duration each, at a rate of one per week."
89404418|NCT04392856|Other|Waitlist Control condition|The participants assigned to the waitlist control condition will not immediately receive the intervention. They will wait for 3 months, which is the duration of the intervention in the experimental group. After that time, they will be offered the same psychological treatment as those assigned to the UP (experimental condition).
89404419|NCT00818480|Experimental|1. YM155|
89404420|NCT04176718|Experimental|Daratumumab,Carfilzomib, Pomalidomide and Dexamethasone|"Patients who meet eligibility criteria for the study will subsequently be enrolled for treatment.~Participants will receive daratumumab, carfilzomib, pomalidomide, and dexamethasone on a 28 day schedule.~Daratumumab will be given according to cycle and dosage determined by protocol.~Carfilzomib will be given at 56 mg/m2 on days 1, 8, 15 (except for C1D1 where it is 20 mg/m2)~Pomalidomide will be given daily on days 1-21.~Dexamethasone will be given weekly, split over two days."
89404421|NCT03134534|Other|VATS group|Surgical procedure: VATS lobectomy
89404422|NCT03134534|Other|RATS group|Surgical procedure: RATS lobectomy
89404423|NCT04154020|Experimental|Tenotomy|Patients allocated to this arm receive tenotomy treatment of affected toes, and standard care including offloading treatment
88880316|NCT02240160|Experimental|Sativex: alkaline oral pH|Four sprays of Sativex taken within two minutes of pH measurement immediately following oral pre-treatment with milk of magnesia (30 mL held in the mouth for 45-60 seconds then spat out, repeated three times).
88880317|NCT02240238|Experimental|NC-6004 and Gemcitabine|
88880318|NCT02240316||Follicular NHL Cohort|
88880319|NCT02240316||DLBCL Cohort|
88880320|NCT02240550|Active Comparator|ProFlor Hernia Repair System|A 3-D hernia mesh
88880321|NCT02240550|Active Comparator|Lichtenstein Hernia Repair|Using flat polypropylene mesh
88880322|NCT02240784||Acute Hepatic Porphyria|
89404424|NCT04154020|No Intervention|standard care|Patient who are randomized to this arm receive standard care including offloading treatment
89404425|NCT02880371|Experimental|Phase 1b/Part A|Patients in Part A will receive escalating doses of single-agent ARRY-382 in combination with 2 mg/kg pembrolizumab.
89404426|NCT02880371|Experimental|Phase 2|Patients in Phase 2 will receive the MTD/RP2D dose of ARRY-382 determined during Part A in combination with 200mg pembrolizumab.
89404427|NCT00813956|Experimental|1|standard chemotherapy plus BSI-201
89404428|NCT03667209|Experimental|Traditional exercise and pain neuroscience education|Will include exercises of the neck and scapular regions using traditional methods and pain neuroscience education
88880323|NCT02240940|Experimental|Parachute Implant|Appropriate patients meeting inclusion / exclusion will be implanted with the Parachute device after screening with transthoracic echocardiography (TTE) and cardiac CT or MRI.
88880324|NCT02241096|Experimental|Lidocaine|IV lidocaine bolus of 1.5mg/kg over 10 minutes followed by a 1mg/kg/hr IV lidocaine infusion.
88880325|NCT02241174|Experimental|Sodium Hypochlorite|The 0.005% sodium hypochlorite solutions will be prepared from the commercially available Clorox® at 6% solution. 0.83ml of the 6% sodium hypochlorite solution will be taken and incorporated to a-100ml absolute distilled water.
89404429|NCT03667209|Active Comparator|Suspension exercise and pain neuroscience education|Will include suspension exercises of the neck and scapular regions using traditional methods and pain education.
89404430|NCT01002248|Experimental|Perifosine added to combination|"Perifosine added to the combination of Bortezomib and Dexamethasone. Perifosine is is supplied as a film-coated tablet containing 50 mg of active ingredient. Perifosine will be administered orally on an outpatient basis throughout the study. Daily administration will be one 50 mg tablet.~The first dose of perifosine should be taken on the same day that bortezomib and dexamethasone are administered (Cycle 1 Day 1)."
89404431|NCT01002248|Placebo Comparator|Perifosine Placebo added to combination|Perifosine placebo added to the combination of Bortezomib and Dexamethasone. The placebo for perifosine is provided in 256 mg white to off-white, round, biconvex film-coated tablets to permit a blinded trial with perifosine 50 mg film coated tablets. Placebo will be administered orally on an outpatient basis throughout the study. Daily administration will be one perifosine placebo tablet. The first dose of placebo should be taken on the same day that bortezomib and dexamethasone are administered (Cycle 1 Day 1).
89404432|NCT02837029|Experimental|Treatment (yttrium Y 90 glass microspheres, nivolumab)|Patients receive yttrium Y 90 glass microspheres IA. Approximately 4 weeks after yttrium Y 90 glass microspheres treatment, patients receive nivolumab IV over 30-60 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88880326|NCT02241174|Placebo Comparator|Placebo|100ml distilled water will be used as a placebo and will be stored on amber bottles identical with the treatment group
88880327|NCT02241252|Other|iPhone ECG QT recording|iPhone ECG
88880328|NCT02241330|Placebo Comparator|Control|Control wheat used for meal, level of zinc is usual
88880329|NCT02241330|Active Comparator|fortification|Fortification Wheat is fortified before testmeal administration. Zinc level is comparable to WHO recommendation
88880330|NCT02241330|Active Comparator|Biofortified|Biofortification Biofortified wheat is used for testmeal administration. Zinc concentration is around 30% higher than control
88880331|NCT02241564||Malignancy post transplantation|
88880332|NCT02241642|Experimental|Treatment|VIVASURE CLOSURE DEVICE™
88880333|NCT02241798|Experimental|Pre-oxygenation first|"st, 3rd, 5th, etc seizure: continuous 'pre-oxygenation' up to 4L O2 nasal prongs, as tolerated~nd, 4th, 6th, etc seizure: Standard practice (O2 only in post-ictal period)."
88880334|NCT02241798|Experimental|Standard practice first|"st, 3rd, 5th, etc seizure: Standard practice (O2 only in post-ictal period).~nd, 4th, 6th, etc seizure: continuous 'pre-oxygenation' up to 4L O2 nasal prongs, as tolerated"
89404433|NCT04130932|No Intervention|Normal flooring|standard office flooring
89404434|NCT04130932|Experimental|Ergonomic flooring|Ergonomically designed flooring
88880335|NCT02241876|Placebo Comparator|Placebo|The patients will be treated with placebo as follows: 15 mL (0 mg of drug), once a day, during 7 days in each cycle (2 days before chemotherapy with cisplatin, on the day of chemotherapy and more 4 days after chemotherapy).
88880336|NCT02241876|Experimental|N-Acetylcysteine|The patients will be treated with n-acetylcysteine as follows: 15 mL (600mg of drug), once a day, during 7 days in each cycle (2 days before chemotherapy with cisplatin, on the day of chemotherapy and more 4 days after chemotherapy).
88880337|NCT02241954||Expansion Thoracoplasty|The rib prosthesis is lengthened periodically to correct the concavity of the deformity, expanding the volume of the hypoplastic thorax and improving associated spinal deformity. This device has been FDA approved by a Humanitarian Device Exemption and is described as a Vertical Expandable Prosthetic Titanium Rib (VEPTR). An updated version of the VEPTR, the VEPTR II, may be used instead depending on the physician's preference and the patient's anatomy. The VEPTR II device has greater size range and modularity of implants than the original VEPTR.
88880338|NCT02242032|Experimental|P-321|P-321 Ophthalmic Solution
88880339|NCT02242032|Placebo Comparator|P-321 Ophthalmic Solution Placebo|P-321 Ophthalmic Solution Placebo
88880340|NCT02242344|Experimental|telmisartan - low dose|
88880341|NCT02242344|Experimental|telmisartan - high dose|
88880342|NCT02242344|Placebo Comparator|Placebo|
88880343|NCT02242422||transobturator tape|
88880344|NCT02242500|Experimental|Coronally advanced flap + Mucograft|coronally advanced flap associated with a porcine collagen matrix graft as a subepithelial graft
88880345|NCT02242500|Other|Coronally advanced flap|Coronally advanced flap procedure alone
88880346|NCT02242656|Experimental|Group 1|Assigned to receive Treatment A (Period 1), Treatment B (Period 2), Treatment C (Period 3)
88880347|NCT02242656|Experimental|Group 2|Assigned to receive Treatment B (Period 1), Treatment A (Period 2), Treatment C (Period 3)
88880348|NCT02242812|Experimental|Telmisartan|MICARDIS®
88880349|NCT02242812|Active Comparator|Metoprolol succinate|BELOC ZOK®
88880350|NCT02242890|Other|Contraception Information Packet|Everyone in the study will receive the intervention, which is an information packet designed to facilitate conversations among peers about intrauterine contraception.
89190277|NCT06027905|Experimental|Remote Blood Pressure Monitoring and Social Intervention|Participants are enrolled in a remote blood pressure monitoring program and social intervention composed of remote outreach from a team of community health worker, pharmacist, nurse, and social worker for 12 weeks.
89535593|NCT03076125|Experimental|SCORRE group|Stroke risk factor brochure, stroke champions video, counseling on accuracy of perceived stroke risk and strategies to reduce stroke risk, weekly motivational health behavior tips (for physical activity, diet, or smoking cessation) text messages for 8 weeks.
89190278|NCT06019325|Experimental|Study Group|After endotracheal intubation, patients will be positioned in lateral decubitus position. A linear ultrasound probe will be placed at the edge of scapula at the level of T5-T6. Under sterile conditions, the landmark points (rhomboid major muscle, 5th and 6th ribs, and intercostal muscles) will be observed and a block needle will be directed to the interfacial plane between rhomboid major muscle and intercostal muscle. RIB will be performed by injecting 30 ml of bupivacaine 0.25%.
89190279|NCT06019325|No Intervention|Control Group|No block procedure will be performed in this group.
89190280|NCT06018467|Experimental|Dasatinib plus Quercetin (DQ)|Study participants will receive a combination of 100 mg/d dasatinib (oral) for two consecutive days and 1.250 mg/d quercetin (oral) for three consecutive days followed by 25 days without treatment, with treatment being repeated every 4 weeks for a total of 20 weeks (i.e., 5 times)
89190281|NCT06018467|Experimental|Nicotinamide Riboside (NR)|The participants will receive treatment with 1g Nicotinamide Riboside (oral) daily for 20 weeks
89190282|NCT06018467|No Intervention|Control|The participants in the Control group, will not receive any treatment for 20 weeks.
89190283|NCT06018311|Experimental|Exercising Together|Dyads perform partnered exercise over 1 hour, 3 days per week in a supervised, group setting remotely for 3 months.
89190284|NCT06010836|No Intervention|Control|Group getting standard treatment without script guided intervention in the preoperative period
89190285|NCT06010836|Experimental|Script guided intervention|Group getting script guided intervention during the preoperative conversation
89190286|NCT06004349||Participants with known or suspected autoinflammatory diseases|Participants with known or suspected autoinflammatory diseases (i.e., Probands)
89190287|NCT06004349||Family member|Family member, either by blood or marriage, to an individual enrolled or about to be enrolled in the study with known or suspected autoinflammatory disease.
89190288|NCT06004349||Healthy control|
89190289|NCT05997368||young group|Participants aged 18-39
89190290|NCT05997368||middle-aged group|Participants aged 40-56
89190291|NCT05997368||elderly group|Participants aged 57-79
89190292|NCT05992896|Experimental|Liposomal Bupivacaine Group|Subjects will receive an injection of liposomal bupivacaine during clinically indicated lower extremity revascularization surgery.
89190293|NCT05992896|Placebo Comparator|Placebo Group|Subjects will receive an injection of placebo during clinically indicated lower extremity revascularization surgery.
89190294|NCT05953207|Experimental|Medical hypnosis (HYP)|3 medical hypnosis interventions
89190295|NCT05953207|Active Comparator|Standard Of Care (SOC)|3 standard of care quality and sleep safety interventions
89190296|NCT05937386|Experimental|1|AGMB-129 and MDZ
89190297|NCT05922865|Experimental|KNEESUP smart knee assistive device + KNEESUP care APP|The participants with KNEESUP smart knee assistive device and KNEESUP care APP do exercise training at home.
89535594|NCT03076125|Sham Comparator|Attention Control Group|Sexual health education brochure and Safe in the City video, weekly sexual health tips text messages for 8 weeks.
89535595|NCT02490605|Experimental|occlusal plate group|"The sample group will receive an occlusal plate with criteria for occlusal stability (simultaneous, bilateral contacts with an absence of interference in the canine and anterior guides). The occlusal plate will be made from Vacuum Form acetate with a thickness of 1.5 mm; the simultaneous, bilateral, occlusal contacts and the canine and anterior guides will be obtained by way of autopolymerizable, acrylic resin with the mandible in a centric relationship."
89536681|NCT02473835|Experimental|Calorie Restriction|Participants reduced calorie intake by 50 % for a period of 3 consecutive days - the target calorie intake for each participant will be determined by a period of energy balance (diet and activity) monitoring.
89190298|NCT05922865|Active Comparator|KNEESUP care APP|The participants with KNEESUP care APP do exercise training at home.
89190299|NCT05922865|Placebo Comparator|Health consultation|The participants with healthy consultation do aerobic training at home.
89190300|NCT05920798|Experimental|Treatment (apheresis, FRalphaDC, pembrolizumab)|Patients undergo apheresis for multi-epitope folate receptor alpha-loaded dendritic cell vaccine manufacturing on study. Patients then receive multi-epitope folate receptor alpha-loaded dendritic cell vaccine ID and pembrolizumab IV on study. Patients also undergo CT and/or MRI as well as blood sample collection throughout the trial. Patients undergo biopsy on study.
89190301|NCT05907980|Experimental|Part A: Dose-escalation part of Phase Ia|Patients will receive ROSE12 as a IV infusion at escalated doses.
89190302|NCT05907980|Experimental|Part B: Biopsy part of Phase Ia|Serial biopsy will be conducted with patients who will receive ROSE12 as a IV infusion at escalated doses.
89190303|NCT05907980|Experimental|Part C: Dose-escalation part of Phase Ib|Patients will receive ROSE12 and atezolizumab as a IV infusion at escalated doses.
89190304|NCT05907980|Experimental|Part D: Biopsy part of Phase Ib|Serial biopsy will be conducted with patients who will receive ROSE12 and atezolizumab as a IV infusion at escalated doses.
89190305|NCT05907980|Experimental|Part E: Expansion part of Phase Ib in patients with selected solid tumors|Patients will receive ROSE12 and atezolizumab as a IV infusion at the recommended dose.
89190306|NCT05906615|Other|Intravenous lidocaine|Monitored intravenous lidocaine infusion for patients with CP and pancreatic cancer is already current practice in the participating centers. Patients undergo treatment in the recovery unit of the anesthesiology department, for early detection of possible, although highly unlikely adverse events such as anaphylactic reactions, arrhythmias or hypotension. At the recovery unit continuous monitoring is possible and treatment of the above mentioned side effects can be easily provided. Continuous monitoring includes a 3-lead ECG, saturation, and blood pressure control every 15 minutes.
89190307|NCT05889013||Nasal Nitric Oxide|Participants who are referred by his/her clinician for nasal NO testing and meet the inclusion and exclusion criteria will undergo testing. Clinical information regarding prior diagnostic testing will be collected at time of enrollment. Participants that have a confirmed diagnosis of PCD by genetics or ciliary biopsy at time of study entry
89190308|NCT05884853|Experimental|ASD group|autistic adolescents with their caregiver
89190309|NCT05884853|Sham Comparator|Control group|healthy control without their caregiver
89190310|NCT05880355|Experimental|Dapansutrile|Subjects randomized to receive oral dapnsutrile
89404435|NCT03668301||Group CPB-T2DM|Patients with diabetes mellitus undergoing cardiac surgery with cardiopulmonary bypass
89404436|NCT03668301||Group OPCAB-T2DM|Patients with diabetes mellitus undergoing cardiac surgery without cardiopulmonary bypass
89404437|NCT03668301||Group CPB-C|Control patients undergoing cardiac surgery with cardiopulmonary bypass
89404438|NCT03668301||Group OPCAB-C|Control patients undergoing cardiac surgery without cardiopulmonary bypass
89404439|NCT04097236|Active Comparator|45° semirecumbent position|
89404440|NCT04097236|Active Comparator|No elevation of the upper section of the bed|
89404441|NCT03667131|Experimental|Enalapril Maleate|Enalapril Maleate 5 mg every 12 hrs for 90 days.
89404442|NCT03667131|Experimental|Placebo|Substance that lacks in itself therapeutic action.
89404443|NCT04532710|Placebo Comparator|Placebo low dose|Application of 2 placebo eye drops once daily for 8 days.
89404444|NCT04532710|Active Comparator|Tacrosolv low dose|Application of 1 Tacrosolv eye drop once daily for 8 days.
89404445|NCT04532710|Placebo Comparator|Placebo high dose|Application of 1 placebo eye drop once daily for 8 days.
89404446|NCT04532710|Active Comparator|Tacrosolv high dose|Application of 2 Tacrosolv eye drops once daily for 8 days.
89404447|NCT05174000|Experimental|Sequence 1:Test Euthyrox®, then Reference Euthyrox®, then Test Euthyrox®, then Reference Euthyrox®|Participants will receive single oral dose of Test Euthyrox® on in treatment period 1, followed by single oral dose of Reference Euthyrox® in treatment period 2, followed by single oral dose of Test Euthyrox® in treatment period 3, followed by single oral dose of Reference Euthyrox in treatment period 4. Participants will remain resident until Day 4 for each treatment period and there will be a washout period of 53 days between each treatment period.
89404448|NCT05174000|Experimental|Sequence 2:Reference Euthyrox®, then Test Euthyrox®, then Reference Euthyrox®, then Test Euthyrox®|Participants will receive single oral dose of Reference Euthyrox® in treatment period 1, followed by single oral dose of Test Euthyrox® in treatment period 2, followed by single oral dose of Reference Euthyrox® in treatment period 3, followed by single oral dose of Test Euthyrox® in treatment period 4. Participants will remain resident until Day 4 for each treatment period and there will be a washout period of 53 days between each treatment period.
89404449|NCT03666585|Active Comparator|mobile application actuated rehabilitation exercise guidance|
89190311|NCT05880355|Placebo Comparator|Control|Subjects randomized to receive oral placebo
88880351|NCT02243124|Active Comparator|Group 1|cenersen IV infusion 0.3 mg/kg/day (0.1 mg/kg/h x 3 h x 4 days) for 6 cycles Administration of study drug will be over 4 consecutive days at the outset of each 28 day cycle for a total of 6 cycles for each patient. Dexamethasone 20 mg po weekly can be added after week 16 if stable disease but no Hematologic Improvement (HI) is observed.
88880352|NCT02243124|Active Comparator|Group 2|cenersen IV infusion 0.6 mg/kg/day (0.2 mg/kg/h x 3 h x 4 days) for 6 cycles Administration of study drug will be over 4 consecutive days at the outset of each 28 day cycle for a total of 6 cycles for each patient. Dexamethasone 20 mg po weekly can be added after week 16 if stable disease but no HI is observed.
88880353|NCT02243124|Active Comparator|Group 3|cenersen IV infusion 1.2 mg/kg/day (0.4 mg/kg/h x 3 h x 4 days) for 6 cycles Administration of study drug will be over 4 consecutive days at the outset of each 28 day cycle for a total of 6 cycles for each patient. Dexamethasone 20 mg po weekly can be added after week 16 if stable disease but no HI is observed.
88880354|NCT02243436|Experimental|BV-ESHAP|"- 3 cycles every 21 days:~Brentuximab Vedotin, on day 1 (BV will be administered at three different doses 0.9mg/kg, 1.2mg/kg, 1.8mg/kg)~Etoposide 40 mg/m2/day, on days 1 to 4~Soludomerin (methylprednisolone) 250 mg/day, on days 1 to 4~Cisplatin 25 mg/m2/day, on days 1 to 4~Ara C (cytarabine) 2 g/m2, on day 5~- A fourth dose of BV will be given 21 days after the third BV dose during the evaluation of response before the transplant.~- Autologous peripheral blood stem cell transplant~- A fifth dose of BV (1.8mg/kg) will be given on between day 28 and 35 post-transplant, followed by two additional doses (1.8mg/kg) every 3 weeks, to complete a total of 7 BV infusions."
88880355|NCT02243514||Resistant hypertension|
88880356|NCT02243514||Essential hypertension|
89190312|NCT05879367|Experimental|Eflornithine Dose Level 1 + Temozolomide|
89190313|NCT05879367|Experimental|Eflornithine Dose Level 2 + Temozolomide|
89190314|NCT05879367|Experimental|Eflornithine Dose Level -1 + Temozolomide|
89190315|NCT05863507|Experimental|grape group|The participant of this group will received a lyophilized grape powder
89190316|NCT05863507|Placebo Comparator|placebo group|The participant of this group will received a lyophilized powder similar to the grape one
89190317|NCT05853367|Experimental|MK-0472|Participants receive MK-0472 capsule up to 300 mg orally once daily (QD) until disease progression or withdrawal/discontinuation.
89190318|NCT05853367|Experimental|MK-0472 + Pembrolizumab|Participants receive MK-0472 capsule up to 300 mg orally QD until disease progression or withdrawal/discontinuation plus pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 cycles (up to approximately 2 years).
89190319|NCT05849493|Experimental|IU-ICBT|10 week program of internet delivered cognitive behavior therapy with written support by licensed clinical psychologist. Based on the Intolerance of uncertainty model of worry.
89190320|NCT05849493|Experimental|Meta-ICBT|10 week program of internet delivered cognitive behavior therapy with written support by licensed clinical psychologist. Based on the Metacognitive model of worry.
89190321|NCT05847439|Experimental|[14C]BMS-986419|
89190322|NCT05846022|Experimental|Dry needling|Dry needling involves the insertion of solid monofilament needles into tender points in tight muscle bands for therapeutic purposes.
89404450|NCT03666585|Active Comparator|routine rehabilitation exercise guidance|
89437488|NCT03797690|Experimental|Percutaneous needle aponeurotomy|It consists in cutting the fibrotic cord due to the disease and responsible for the flexion contracture, with a needle under local anesthesia. The procedure can be repeated as required during the same session. One to three sessions with at least one-week interval are usually sufficient and will be allowed. It will be performed in outpatient setting by a senior physician experienced in the procedure. End of treatment will be considered as the last session of needle aponeurotomy.
89530995|NCT02495675|No Intervention|No flow|Subjects will be spontaneously breathing in room air with no flow.
89404451|NCT05024656|Experimental|AmnioExcel Plus Amniotic Membrane + Standard of Care|"AmnioExcel Plus is a human placental-based tissue consisting of dehydrated, tri-layer Placental (Amnion/Chorion/Amnion) Allograft Membrane (T-PAM) layers. T-PAM is a minimally manipulated placental membrane product made from tissues donated by pre-screened mothers during planned C-sections and is intended for use as a wound covering in the homologous use for the repair, reconstruction and replacement of skin at the direction of a physician. AmnioExcel Plus contains Human Cellular and Tissue Based Products (HCT/P) as defined by US FDA 21 CFR Part 1271.~Standard of care includes the following:~Coban™~Conforming gauze~Optifoam® non-adhesive dressing~Xtrasorb® for highly exudated wounds~Cotton Gauze~Normal saline (liquid or gel)~Non-adhering dressings~Steristrips~Offloading boot, as appropriate"
89404452|NCT05024656|Active Comparator|Standard of Care|"Coban™~Conforming gauze~Optifoam® non-adhesive dressing~Xtrasorb® for highly exudated wounds~Cotton Gauze~Normal saline (liquid or gel)~Steristrips~Offloading boot, as appropriate"
89404453|NCT05764187|Experimental|Ceramic orthodontic brackets|Patients bonded with ceramic brackets for orthodontic treatment
89404454|NCT05764187|Active Comparator|Metal orthodontic brackets|Patients bonded with metal brackets for orthodontic treatment
89404455|NCT05019352|Experimental|CRRT with cytokine adsorption|Patients will be treated with CRRT and extracorporeal hemoadsorption for 72 hours
88880357|NCT02243514||Chronic heart failure|
88880358|NCT02243514||Control|
88880359|NCT02243670|Experimental|AiCure monitoring and intervention|Participants will use the AiCure app to monitor ingestion of all prescribed doses of Zubsolv®.
88880360|NCT02243748|Active Comparator|Phase I (usual care)|Participants receive usual care. This phase will aid in identifying usual care patterns in each site and provide an audit of system utilization as well as finalization of the educational materials for Phase II.
88880361|NCT02243748|Experimental|Phase II (individualized palliative care)|Participants receive individualized palliative care comprised of tailored educational sessions designed for each patient and FCG that have been modified based on patterns observed in Phase I. The first patient teaching session will cover physical and psychological areas and the second will cover social and spiritual areas. These sessions will be completed within 2 weeks of accrual. A third teaching session is held with the FCG alone to give the FCG the opportunity to discuss their perspectives and focus on their needs. Patients will be asked to identify topics they want included and which if any should be omitted which provides for tailoring of the content to the patient's needs and preferences.
89190323|NCT05846022|Sham Comparator|Sham needling|"Shallow penetration of a solid monofilament needle into the skin alone with the in and out plunging movement of the needle simulated with the needle's guide tube."
89404456|NCT05019352|Experimental|CRRT without cytokine adsorption|Patients will be treated with CRRT without extracorporeal hemoadsorption for 72 hours
88880362|NCT02243826|Experimental|N20|One group will inhale N2O for the 5 minutes before the puncture and during the rest of the procedure.
88880363|NCT02243826|Other|compressed air|The second group will inhale compressed air during the same period of time
89404457|NCT05019352|No Intervention|no CRRT, no cytokine adsorption|Patients will not receive CRRT, nor extracorporeal hemoadsorption. CRRT will only be initiated in case of severe electrolyte disorders or unmanageable fluid overload
89404458|NCT01377155|Other|Insulin determir|
89404459|NCT04976374|Active Comparator|Group A|Patients of group A will start dexmedetomidine (precedex 100 ug lmL, Hospira) infusion 0.4 ug {Kg}h after bolus of 0.5 ug 1 kg intravenously over 10 min
89404460|NCT04976374|Placebo Comparator|Group B|Group B will recive a bolus of saline then saline infusion identical to group A
89404461|NCT04473560||Catheter-directed thrombectomy group|Patients with acute pulmonary embolism treated with catheter-directed thrombectomy along with anticoagulation therapy
89404462|NCT04473560||No catheter-directed thrombectomy group|Patients with acute pulmonary embolism treated with anticoagulation therapy alone
88880364|NCT02244060|Experimental|Direct comparison|The Direct comparison against vignette (DCV) questionnaire asks subjects to estimate their own vision against vignette situations.Priming effect from vignette is designed in the arm of DCV.
88880365|NCT02244060|No Intervention|Indirect comparison|The Indirect comparison against vignette (ICV) questionnaire asks self-assessed vision and single evaluation of vignettes.
88880366|NCT02244138||Adolescent CDSS|Implementation clinic site for CDDS
88880367|NCT02244216||Chronic Obstructive Respiratory Tract Disease|
88880368|NCT02244294|Experimental|FLOMAX®|
88880369|NCT02244294|Placebo Comparator|Placebo|
88880370|NCT02244372|Experimental|Cordyceps sinensis mycelium culture extract 0.76 g|Cordyceps sinensis mycelium culture extract 0.76 g
88880371|NCT02244372|Experimental|Cordyceps sinensis mycelium culture extract 1.15 g|Cordyceps sinensis mycelium culture extract 1.15 g
88880372|NCT02244372|Placebo Comparator|Placebo|Placebo
88880373|NCT02244528|Experimental|Treatment|sildenafil treatment
88880374|NCT02244684||Pregnant women|
88880375|NCT02245074|Other|Acute exacerbation|Cell profiles Analysis after sputum induction in infants with Acute exacerbation
88880376|NCT02245074|Other|Uncontrolled asthma|Cell profiles Analysis after sputum induction in infants with Uncontrolled asthma
88880377|NCT02245074|Other|controlled asthma|Cell profiles Analysis after sputum induction in infants controlled asthma
88880378|NCT02245386||Group 1|(40 women after normal vaginal delivery) submitted to transperineal pelvic floor ultrasound 48-72 hours postpartum.
89404463|NCT03984058|Other|Study Arm 1|All enrolled participants will have participants' PAP usage monitored by Fusion Health using the ResMed AirView Remote Monitoring system. Fusion Health will provide individual care for each participant by monitoring daily PAP usage by all study participants. This assessment ensures routine follow-up of PAP adherence during the study. The responsibility for patient care during the study, however, will fall on clinical site staff with any needed assistance by the Fusion Health staff. An intervention will be required when PAP adherence decreases or if any other issues are identified that require a face-to-face visit.
89404464|NCT00809510|Experimental|1|
89404465|NCT03856684|Active Comparator|Self-sampling kit sent at home|Sending of a vaginal self-sampling kit at home
89190324|NCT05825092|Active Comparator|AndroGel® 1.62%|"AndroGel® will be applied daily to the upper arms/shoulders. AndroGel® will be administered within 24 hours after inclusion for a period of 28 days or until hospital discharge.~For patients discharged from ICU before day 28, AndroGel® will be administered in hospital wards to complete the 28 days of treatment or until hospital discharge"
89190325|NCT05825092|Placebo Comparator|Placebo gel will be the same gel without testosterone|Placebo gel will be applied daily to the upper arms/shoulders. Placebo gel will be administered within 24 hours after inclusion for a period of 28 days or until hospital discharge. For patients discharged from ICU before day 28, Placebo gel will be administered in hospital wards to complete the 28 days of treatment or until hospital discharge
89404466|NCT03856684|Experimental|Self-sampling kit sent at home + SMS reminder|"Sending of a vaginal self-sampling kit at home + a SMS reminder is sent if the woman do not (in 2 months) :~perform a pap smear~or send her vaginal self-sample to the laboratory~or contact the screening center to inform to an exclusion reason"
89004341|NCT04887688|Experimental|Group A: Wound treated using exciflex|Intervention treated wounds in Group A participants will be covered using the exciflex bandage which will be activated to deliver ES using a 10% duty cycle, i.e. ES will be active for 1 minute out of every 10 minutes. ES will be delivered for up to 10 weeks or until the wound is healed for 3 days. The exciflex bandage will be changed when indicated clinically or every 5 days, whichever is sooner. At each bandage change, wound status monitored as described above, specifically a 3D digital image and wound swabs will be obtained. The exciflex power/control module will then be transferred to a new sterile flexible substrate and the exciflex bandage reapplied to the wound.
89404467|NCT03856684|Experimental|"Letter offering a self-sampling kit on request+ SMS reminder"|"Sending of letter offering a vaginal self-sampling kit. Women can ask for this kit on line, on our website or by calling us.~If they do ask for the kit, one kit is sending to their home.~For these women, a SMS reminder is sent if the woman do not (in 2 months) :~perform a pap smear~or send her vaginal self-sample to the laboratory~or contact the screening center to inform to an exclusion reason"
89404468|NCT03856684|Experimental|"SMS offering a self-sampling kit on request+ SMS reminder"|"Sending of SMS offering a vaginal self-sampling kit. Women can ask for this kit on line, on our website or by calling us.~If they do ask for the kit, one kit is sending to their home.~For these women, a SMS reminder is sent if the woman do not (in 2 months) :~perform a pap smear~or send her vaginal self-sample to the laboratory~or contact the screening center to inform to an exclusion reason"
89404469|NCT00894530|Experimental|1|
89404470|NCT00894530|Placebo Comparator|2|
89404471|NCT01377077|Experimental|epidermal 1mm grafting|Epidermal skin biopsies of 1mm diameter
89404472|NCT01377077|Experimental|dermal 1mm grafting|dermal skinbiopsies of 1mm diameter
89404473|NCT01377077|Experimental|dermal 1,5mm grafting|dermal skinbiopsies of 1,5mm diameter
89404474|NCT01377077|Active Comparator|epidermal 1,5mm grafting|epidermal skinbiopsies of 1,5mm diameter
89404475|NCT04093336|Active Comparator|MSCs group|The people in this group will receive intravenous MSCs 2 x 10^6/kg as a single dose and standardized treatment of acute ischemic stroke.
89404476|NCT04093336|Placebo Comparator|control group|The people in this group will receive placebo and standardized treatment of acute ischemic stroke.
89404477|NCT05552534|Experimental|Intervention group|
89404478|NCT05552534|No Intervention|Control group|
89404479|NCT01376999|Experimental|Step Down|Step Down: We begin the COS (controlled ovarian stimulation) with 150 IU of FSH-r until 7th day of stimulation. This day we make an adjustment reducing the dose if necessary.
89404480|NCT01376999|Active Comparator|Step Up|Step up: We begin the COS (controlled ovarian stimulation) with 75 IU of FSH-r until 7th day of stimulation.This day we make an adjustment increasing the dose if necessary.
89404481|NCT03010527|Placebo Comparator|Placebo|Subjects with a PASI90 response at Week 12 and receiving Placebo in PS0010 entering PS0011 will receive Placebo.
89404482|NCT03010527|Experimental|Bimekizumab dosing regimen 1|"Subjects with a PASI90 response at Week 12 receiving dosing regimen 1 in PS0010 entering PS0011 will receive the same dosing regimen.~Subjects who do not achieve PASI90 response at Week 12 receiving dosing regimen 1 in PS0010 will be assigned to a higher dosing regimen."
89404483|NCT03010527|Experimental|Bimekizumab dosing regimen 2|"Subjects with a PASI90 response at Week 12 receiving dosing regimen 2 in PS0010 entering PS0011 will receive the same dosing regimen.~Subjects who do not achieve PASI90 response at Week 12 receiving dosing regimen 2 in PS0010 will be assigned to a higher dosing regimen."
89404484|NCT03010527|Experimental|Bimekizumab dosing regimen 3|Subjects that were initially randomized to bimekizumab dosage regimen 3, 4 and 5 in PS0010 will receive bimekizumab dosing regimen 3.
89404485|NCT05763095|Experimental|the MIED+TAU group|Intervention description: provide standard audio instructions for mindfulness exercises, introduce the nature and law of anxiety, depression and other emotions, the source of anxiety, depression and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems.
89404486|NCT05763095|No Intervention|the TAU-only group|
89404487|NCT00892970|Experimental|1|
89404488|NCT00892970|Placebo Comparator|2|
89404489|NCT05340257|Experimental|Participants with CAP and ABRS|
89404490|NCT03759808|Experimental|Persistent Post-Concussion Symptoms|Concussed participants with persistent post-concussion symptoms (PPCS) who receive the psychological intervention.
89404491|NCT03667521||non-nerve-sparing laparaoscopic sacrocolpopexy.|
89404492|NCT03667521||nerve-sparing laparaoscopic sacrocolpopexy.|
89404493|NCT02201381|Experimental|Metabolic Treatment|"Subjects will take the following treatments and have their data collected from their medical records every 3 months.~Oral atorvastatin up to 80mg uid, for study duration.~Oral metformin up to 1000mg uid, increased to bid if tolerated after 2 weeks, for study duration.~Oral doxycycline 100mg uid, for study duration.~Oral Mebendazole 100mg uid, for study duration."
89190326|NCT05824702|Experimental|Experimental: Peer education and network support|The intervention sessions will consist of 6 group sessions including 1) Introduction to Peer Educator role and peer Communication skills, 2) HIV and drug treatments, 3) using a decision balance tool with network members for drug treatment, 4) Promoting HIV prevention and medical care & using text messages as peer educators for promoting MAT and HIV prevention and care, 5) Preventing and responding to relapse, and 6) HIV care retention and medication adherence.
89199075|NCT02543775|Experimental|Sentinel lymph node mapping|Patients who consent to the study will have preoperative and intraoperative SLN mapping performed. This will include injection of a radioisotope (Technetium 99) into the cervix and imaging (SPECT/CT) at Nuclear Medicine in the morning prior to surgery in an effort to identify the lymph node basin containing the sentinel nodes. Intraoperatively, blue dye will also be injected into the cervix to aid in location of the sentinel nodes.
89404494|NCT00803114|Experimental|Epidural Morphine|2.5 mg dose of epidural morphine given within one hour following vaginal delivery
89404495|NCT00803114|Placebo Comparator|Placebo|5 ml of epidural preservative-free saline given within one hour following vaginal delivery
89404496|NCT05519384|Experimental|JK500 cell injection|"They were divided into three dose groups: 10^6, 5x10^6 and 3x10^7 JK500 cells injection /kg/ time, three times a week, a total of 6 times.~According to the principle of dose escalation, 3 patients were assigned to each dose group. After completing the treatment of 3 patients in each dose group, the Safety Review Committee (SRC) discussed whether to enter the next dose group."
89404497|NCT03489382|No Intervention|Control|Emergency Departments providing usual care, which includes assessment in hospital followed by placement on a wait list for psychiatric services and access to regional community resources for suicide prevention.
89404498|NCT03489382|Experimental|Smartphone Assisted PST|Emergency Departments providing the option to refer men who self-harm to a service that will deliver smartphone-assisted problem solving therapy.
89404499|NCT00799292|No Intervention|No injection|Patients did not receive an injection at cervix prior to beginning the procedure
89190327|NCT05824702|Active Comparator|comparison: Standard of care of health education|The comparison condition will include 5 group sessions focused on: 1) retention in MAT by addressing the myths about MAT; 2) information to MAT clients on finding local MAT and other health services in areas where they migrate; 3) importance of HIV prevention (including PreP) and HIV treatment including adherence to HIV; 4) harm reduction, safe drug use, overdose prevention and first aid in case of overdose; 5) addressing Hepatitis C, chronic conditions and mental health issues by emphasizing the importance of timely addressing these health problems and providing information on available local and national services.
89404500|NCT00799292|Experimental|Injection of vasopressin|Patients will be randomized to receive 20cc of dilute vasopressin (20units in 50cc normal saline)injected at cervix at beginning of the hysterectomy
89190328|NCT05820568|Experimental|Treatment|Patients receiving ICBT-IU
89190329|NCT05819749|Experimental|DH-Spanish Intervention|Behavioral treatment by a diabetes wellness coach.
89190330|NCT05818709|Experimental|HAC 22L|Participants will be randomized to receive HAC 22L on Day 1. Participants will have the opportunity to receive optional touch-up and optional repeat treatment of HAC 22L during the follow-up period.
89190331|NCT05818709|Other|Control Group|Participants can opt to receive HAC 22L after a control period of 6 months. Participants will have the opportunity to receive an optional touch-up treatment and will be followed for an additional 6 months period.
89190332|NCT05805397|Experimental|Motivation Skills Training (MST)|MST is a weekly group-based skills training intervention that aims to improve knowledge about one's level and sources of motivation, the ability to monitor and regulate (understand and manage) motivation so that one can better initiate and sustain goal-directed behavior
89190333|NCT05805397|Active Comparator|Healthy Behaviors Control Group|HBC is a weekly group-based intervention that provides psychoeducation and skills training to help individuals improve physical health
89190334|NCT05802615|Experimental|PARITY|Participants will take part in the Protective Assets Reinforced with Integrated care and TechnologY (PARITY) program which is community-based doula support, community resources, and a mobile technology platform that reinforces individual strengths through positive messaging and by promoting wellness (sleep, physical activity, nutrition, prenatal care adherence) in Black pregnant women.
89190335|NCT05802615|Placebo Comparator|Control|Participants will obtain prenatal care from their usual care provider and a handout on healthy pregnancy.
89190336|NCT05795101|Experimental|HER2 Positive|"Participants will be enrolled into one of two cohorts: HER2 positive IBC (cohort 1) and HER2 low IBC (cohort 2).~HER2-positive determined locally by the current ASCO/CAP guidelines~Participants will receive trastuzumab deruxtecan plus durvalumab for eight cycles prior to surgery. (Cycle Length is 21 days)~After surgery, Participants will receive therapy per physician's choice and to reflect current standard of care."
89190337|NCT05795101|Experimental|HER2-Low|"Participants will be enrolled into one of two cohorts: HER2 positive IBC (cohort 1) and HER2 low IBC (cohort 2)~HER2-low tumor expression (IHC 2+/ISH-, IHC 1+/ISH-, or IHC 1+/ISH untested)~Participants will receive trastuzumab deruxtecan plus durvalumab for eight cycles prior to surgery (Cycle Length is 21 days)~After surgery, Participants will receive therapy per physician's choice and to reflect current standard of care."
89190338|NCT05794789|No Intervention|PA education and planning condition|This group will receive sessions and information-based booklet and series of worksheets that provide a tangible knowledge translation product for the family. The material will consist of Canada's PA guidelines recommending 60 minutes of MVPA a day and a breakdown of ways for the parent to help their child achieve this PA, outlining three main domains of parental support (encouragement, logistical support, and PA together). The material also contains information about the benefits of PA for the child and how to plan for family PA. The material specifically includes a brainstorming exercise for parents where they list physical activities they think their children have found fun in the past. The investigators will provide this material as prompts/suggestions. This list helps create the template for PA planning by contextualizing what the parents would like to do with their kids. An additional two sessions will include education and planning material related to family healthy eating.
88880379|NCT02245386||Group 2|(40 women after urgent cesarean section) submitted to transperineal pelvic floor ultrasound 48-72 hours postpartum.
89199076|NCT00762294||644-001|Women treated for breast cancer who will be starting Arimidex or Femara
89199077|NCT00758472||Hip Resurfacing|
89199078|NCT00886275|Experimental|Dexmedetomidine|
89199079|NCT00886275|Active Comparator|Midazolam|
89199080|NCT00886275|Experimental|Dexmedetomidine, Midazolam|Combination
89404501|NCT00794924|Experimental|Probiotics, VSL#3|Acutely hospitalized elderly patients in a geriatric orthopedic rehabilitation department received commercially available probiotics (VSL#3) for 45 days.
89404502|NCT00794924|Placebo Comparator|Placebo|Acutely hospitalized elderly patients in a geriatric orthopedic rehabilitation department received placebo sachets for 45 days.
89404503|NCT02914275|Experimental|Seqirus QIV Cohort A|Seqirus Quadrivalent Inactivated Influenza Vaccine - Subjects 6 months through 35 months of age
89404504|NCT02914275|Experimental|Seqirus QIV Cohort B|Seqirus Quadrivalent Inactivated Influenza Vaccine - Subjects 36 months through 59 months of age
89404505|NCT02914275|Active Comparator|Comparator QIV Cohort A|Comparator Quadrivalent Inactivated Influenza Vaccine - Subjects 6 months through 35 months of age
88880380|NCT02245386||Group 3|(40 women after elective cesarean section) submitted to transperineal pelvic floor ultrasound 48-72 hours postpartum.
88880381|NCT02245464||Patients with essential hypertension|
88880382|NCT02245542||BPH patients|
89404506|NCT02914275|Active Comparator|Comparator QIV Cohort B|Comparator Quadrivalent Inactivated Influenza Vaccine - Subjects 36 months through 59 months of age
89404507|NCT05359978|Experimental|cards|participants received 2 days at week during 30 minutes
89404508|NCT05359978|Experimental|significance activities|participants received 2 days a week during 30 minutes
89404509|NCT01094795||Patients initiating abatacept|
89404510|NCT01094795||Patients receiving other biologic disease-modifying drugs|
89404511|NCT01094795||Patients with early rheumatoid arthritis (RA)|
88880383|NCT02245698|Experimental|Stem Cell|Bone marrow mononuclear cells
89404512|NCT01094795||Patients with prevalent RA identified by hospitalization|
88880384|NCT02245776|Experimental|Stem Cell|Bone marrow mononuclear cell transplantation
89404513|NCT01094795||General population|
89404514|NCT01941875|No Intervention|No Luteal Support|Control group: No luteal phase support or medication will be used
88880385|NCT02246244|Experimental|Escitalopram|10 mg once per day
88880386|NCT02246244|Placebo Comparator|Placebo|
89404515|NCT01941875|Experimental|Luteal Vaginal Progesterone|Experiment group: Vaginal progesterone for luteal support beginning the first day after IUI
89404516|NCT03667287|Experimental|Full-thickness skin graft|Repair of parastomal hernia with full-thickness skin graft, placed intraperitoneally, as reinforcement.
89404517|NCT03667287|Active Comparator|Synthethic mesh|Repair of parastomal hernia with best available conventional method, using synthetic mesh material as reinforcement
88880387|NCT02246322|Experimental|25G needle|All consecutive patients that will be referred for solid masses to be aspirated will be randomized to be targeted in the 25G needle arm (A), or in the 22G needle arm (B).
89404518|NCT03666429|Active Comparator|Bulb suction|Patients in this arm will be given bulb suction to treat nasal congestion. This group will contain participants who have used bulb suction in the past.
88880388|NCT02246322|Experimental|22G needle|All consecutive patients that will be referred for solid masses to be aspirated will be randomized to be targeted in the 25G needle arm (A), or in the 22G needle arm (B).
88880389|NCT02246400|Active Comparator|Delayed Intervention|Usual care for first three months. Initiation of the eCMP after the 3-month time point.
88880390|NCT02246400|Experimental|Immediate Intervention|Initiation of the eCMP immediately upon completion of baseline data collection and randomization
88880391|NCT02246556|Active Comparator|Patching therapy|Patching treatment followed by crossover to dichoptic virtual reality video game treatment arm using Diplopia (TM) software developed for the Oculus Rift (R) game system.
89199081|NCT02543619|Active Comparator|Gow-Gates injection|An injection technique for infra alveolar nerve anesthesia
89199082|NCT02543619|Active Comparator|Infra alveolar nerve block injection|An injection technique for infra alveolar nerve anesthesia
88880392|NCT02246556|Active Comparator|Dioptic (non-dichoptic) therapy|Dioptic (non-dichoptic) therapy followed by crossover to dichoptic virtual reality video game treatment arm using Diplopia (TM) software developed for the Oculus Rift (R) game system.
88880393|NCT02246556|Experimental|Dichoptic therapy|Dichoptic virtual reality video game treatment using Diplopia (TM) software developed for the Oculus Rift (R) game system.
89199083|NCT00886353|Active Comparator|APN01|Healthy volunteers will receive APN01
89199084|NCT00886353|Placebo Comparator|Placebo|Physiological saline administrated i.v.
89199085|NCT02543463|Other|With Navigation system|Large diameter head with Trident X3 insert with Navigation system
89404519|NCT03666429|Experimental|NoseFrida|Patients in this arm will be given the NoseFrida to treat nasal congestion. This group will contain participants who will trial the NoseFrida in the emergency department.
89404520|NCT03775408||FAST Patients|Patients at Sunnybrook Health Sciences Centre with femur fractures that will undergo a femoral antegrade intramedullary nailing procedure.
89404521|NCT01814657|Placebo Comparator|Normal Saline|Conscious sedation and sterile normal saline (placebo) paracervical block
89404522|NCT01814657|Active Comparator|Lidocaine|Conscious sedation and Lidocaine hydrochloride 1% solution paracervical block
89404523|NCT03666975|Experimental|LIV 30 Hz, 0.4 g|LIV 30 Hz, 0.4 g Low intensity vibration to short leg 3x / week x 10 wks
89404524|NCT03666975|Experimental|LIV 30 Hz, 1.0 g|LIV 30 Hz, 1.0 g Low intensity vibration to short leg 3x/week x 10 wks
89404525|NCT03666117||Study group|children and adolescents with type 1 diabetes
89404526|NCT00792116|Experimental|Gum Chewing|
89404527|NCT00792116|No Intervention|Non-gum chewing|
89404528|NCT04050033|Experimental|Treatment Arm|Enrolled subjects will undergo up to 3 successive bi-weekly (every 2 weeks) treatments (Tx.1, Tx.2 and Tx.3).
89404529|NCT01773395|Active Comparator|GVAX|"GVAX vaccine~Participants in the GVAX vaccine arm will undergo a conditioning regimen with busulfan and fludarabine prior to allogeneic hematopoietic stem cell transplant. Immediately after allogeneic hematopoietic stem cell transplant participants will start tacrolimus and methotrexate to prevent GVHD. GVAX arm participants meeting criteria to begin vaccinations will be administered the GVAX vaccine at established study time points."
89404530|NCT01773395|Placebo Comparator|Placebo|"Placebo vaccine~Participants in the Placebo vaccine arm will undergo a conditioning regimen with busulfan and fludarabine prior to allogeneic hematopoietic stem cell transplant. Immediately after allogeneic hematopoietic stem cell transplant participants will start tacrolimus and methotrexate to prevent GVHD. Placebo vaccine arm participants meeting criteria to begin vaccinations will be administered the placebo vaccine at established study time points."
89404531|NCT04437394||Study group|Study group was performed on 30 patients who were diagnosed with ankylosing spondylitis using modified New York criterion.
89404532|NCT04437394||Control group|Control group was performed on 30 participants who were healthy.
89404533|NCT01000922|Experimental|Regular Human Insulin|Single injection
89404534|NCT01000922|Experimental|Lispro|Single injection
89404535|NCT01000922|Experimental|VIAject|Single injection
89404536|NCT01000922|Experimental|VIAject 50%|Single injection
89404537|NCT01000922|Experimental|VIAject/Insulin glargine|Single injection
89404538|NCT01000922|Experimental|Insulin Glargine/VIAject|Single injection
89404539|NCT03666039|Experimental|Sensorimotor training|The participants will receive a tablet-based app for at home training that contains sensorimotor components.
89404540|NCT03666039|Active Comparator|Control training|The participants will receive a tablet-based app for at home training that contains relaxing components.
89404541|NCT04727606|Experimental|Open label|The study provides for a single group, which will be its own control (pre/post intervention study). Participants in the study will receive Oral Urea (Ure-Na) treatment at a dose of 30 grams per day (2 x 15 gram pouches per day) for 1 month
89404542|NCT03716908||P51S+ group|"Group 1 affected subjects (P51S+) Family member P51S mutation carrier~interventions/ Questionnaire (DHI, OS, EQ-D5-5L, ABC) Pure Tone audiometry VNG vHIT c- and o-VEMP"
88880394|NCT02246712|Active Comparator|Control group|Patients received a single oral dose of 100 mg racemic tramadol. Serial blood samples were collected up to 24 h after administration of the drug for pharmacokinetic study and for the analysis of noradrenaline in plasma. Pain was rated on a visual analog pain scale at the same time as blood sampling. CYP2D6 phenotype was evaluated using metoprolol as probe drug. CYP3A phenotype was evaluated using midazolam. Patients were genotyped for the single nucleotide polymorphism (SNP) 516G>T in CYP2B6 gene (CYP2B6 genotype).
89404543|NCT03716908||P51S- group (healthy control)|"Group 2: healthy control Family member P51S non-carrier~interventions: Questionnaire (DHI, OS, EQ-D5-5L, ABC) Pure Tone audiometry VNG vHIT c- and o-VEMP"
89404544|NCT03671434|Experimental|RPC Researchers|Researchers who are assigned to the experimental group that is eligible to receive the full RPC intervention
89404545|NCT03671434|Experimental|RPC Congressional Offices|Congressional offices that are assigned to the experimental group that is eligible to receive the full RPC intervention
88880395|NCT02246712|Experimental|T2DM group|"Patients received a single oral dose of 100 mg racemic tramadol. Serial blood samples were collected up to 24 h after administration of the drug for pharmacokinetic study and for the analysis of noradrenaline in plasma. Pain was rated on a visual analog pain scale at the same time as blood sampling. CYP2D6 phenotype was evaluated using metoprolol as probe drug. CYP3A phenotype was evaluated using midazolam. Patients were genotyped for SNP 516G>T in CYP2B6 gene (CYP2B6 genotype).~The diagnosis of type 2 DM was performed according to the American Diabetes Association (2010)."
88880396|NCT02246712|Experimental|T1DM group|"Patients received a single oral dose of 100 mg racemic tramadol. Serial blood samples were collected up to 24 h after administration of the drug for pharmacokinetic study and for the analysis of noradrenaline in plasma. Pain was rated on a visual analog pain scale at the same time as blood sampling. CYP2D6 phenotype was evaluated using metoprolol as probe drug. CYP3A phenotype was evaluated using midazolam. Patients were genotyped for SNP 516G>T in CYP2B6 gene (CYP2B6 genotype).~The diagnosis of type 1 DM was performed according to the American Diabetes Association (2010)."
88880397|NCT02246790|Active Comparator|Biatrial radiofrequency ablation and CABG|Biatrial radiofrequency ablation during CABG
89404546|NCT03671434|Active Comparator|Control Researchers|Researchers who are assigned to an Active Comparator control group that is enrolled in a light-touch intervention
89404547|NCT03671434|No Intervention|Control Congressional Offices|Congressional offices that are assigned to the control group that receives no intervention
88880398|NCT02246790|Active Comparator|Left atrial radiofrequency ablation and CABG|Left atrial radiofrequency ablation during CABG
88880399|NCT02246868|Experimental|Optivate®|Optivate® (Human Coagulation Factor VIII)
88880400|NCT02246946|Experimental|Positive Airway Pressure group|The patients allocated to this group will undergo bronchial hygiene treatments administered with a high-frequency oscillator for 5 sets of 10 repetitions, lung expansion exercises using flow oriented incentive spirometry for 5 sets of 20 repetitions and walking for 100 meters (i.e., the same treatment that will be administered to the Conventional Chest Physiotherapy group). Additionally, this group will receive positive airway pressure breathing with 15 mmHg by a device via a rubber facial mask for 30 minutes in a sitting position.
88880401|NCT02246946|Active Comparator|Conventional Chest Physiotherapy group|"In the sitting position, the patients allocated to this group will undergo bronchial hygiene treatments administered with a high-frequency oscillator for 5 sets of 10 repetitions, lung expansion exercises using flow oriented incentive spirometry for 5 sets of 20 repetitions and positive airway pressure breathing with 4 mmHg via a rubber facial mask for 5 minutes in a sitting position. These patients will also walk for 100 meters.~The use of positive pressure breathing with 4 mmHg has no therapeutic value, but will help keep the blinding of assessors by the presence of the equipment in the room and mark the patient's skin."
89404548|NCT03666195|Active Comparator|Group A|complete dentures will be fabricated using poly methyl methacrylate resin denture base material modified with 5%wt titanium dioxide nanoparticles.
89404549|NCT03666195|No Intervention|Group B|complete dentures will be fabricated with poly methyl methacrylate resin denture base material.
89404550|NCT00889382|Experimental|Phase 1 Arm A|Intermittent OSI-906 Once Daily (QD) on Days 1 - 3, 8 - 10, and 15 - 17 with paclitaxel on Days 1, 8, and 15 (except Treatment Period 1 (TP 1); in TP 1 OSI-906 on Days 1 - 3, 8 - 10, 15 - 17, and 22 - 24 with paclitaxel on Days 8, 15, and 22)
89404551|NCT00889382|Experimental|Phase 1 Arm B1|Continuous OSI-906 Twice Daily (BID) (Days 1 - 21) with paclitaxel dosing on Days 1, 8, and 15;(except TP 1; in TP 1 OSI-906 on Days 1 - 3, 8 - 10, 15 - 17, and 22 - 24 with paclitaxel on Days 8, 15 and 22)
89404552|NCT00889382|Experimental|Phase 1 Arm B2|Continuous OSI-906 BID (Days 1 - 21) with paclitaxel dosing on Days 1, 8, and 15 (except TP 1; in TP 1 OSI-906 on Days 1 - 3, 8 - 10, 5 - 17, and 22 - 24 with paclitaxel on Days 8, 15, and 22); (additional PK sampling on Days 9 or 13 0r 14 for TP 1)
89404553|NCT00889382|Experimental|Phase 1 Arm B3|Continuous OSI-906 BID (Days 1 - 21) with paclitaxel dosing on Days 1, 8, and 15 with no separation in OSI-906 and paclitaxel dosing (except TP 1; in TP 1 continuous OSI-906 dosing 2 hours prior to the initiation of paclitaxel infusion on Day 8 only, with paclitaxel on Days 8, 15, and 22, and additional PK sampling on Day 9 or 13 or 14)
89404554|NCT00889382|Experimental|Phase 2 Arm A|Intermittent OSI-906 QD on Days 1 - 3, 8 - 10, and 15 - 17 with paclitaxel on Days 1, 8, and 15
89404555|NCT00889382|Experimental|Phase 2 Arm B|Continuous OSI-906 BID from Day 1 onwards with paclitaxel on Days 1, 8, and 15
89404556|NCT00889382|Experimental|Phase 2 Arm C|Paclitaxel on Days 1, 8, and 15
88880402|NCT02246946|Placebo Comparator|Control group|"The patients allocated to this group will receive positive airway pressure breathing with 4 mmHg (without therapeutic value) via a rubber facial mask for 30 minutes in a sitting position.~The use of positive pressure breathing with 4 mmHg has no therapeutic value, but will help keep the blinding of assessors by the presence of the complete kit of equipment in the room."
88880403|NCT02247102|Experimental|Isomaltulose|Dosage of 1 g/ kg body weight (rounded up to the nearest 0.5 kg)
88880404|NCT02247102|Active Comparator|Sucrose|Dosage of 1 g/ kg body weight (rounded up to the nearest 0.5 kg)
88880405|NCT02247180|Experimental|Cognitive Rehabilitation|cognitive rehabilitation for 12 weeks
88880406|NCT02247180|Active Comparator|Cognitive Training|standardized cognitive training in the domesticity
88880407|NCT02247258|Active Comparator|Systematic azathioprine group|Patients randomized to the systematic azathioprine group received 2.0-2.5 mg/kg azathioprine within 14 days from surgery and throughout 102 weeks.
88880408|NCT02247258|Active Comparator|Endoscopy-driven azathioprine group|Patients randomized to the endoscopy-driven azathioprine group received no Crohn's disease specific treatment for 26 weeks postoperatively. A first ileocolonoscopy was performed at week 26. In case of endoscopic recurrence (Rutgeerts' score i2 or higher), azathioprine was introduced at a dose of 2.0-2.5 mg/kg until week 102. If not, an ileocolonoscopy was repeated at week 52, and azathioprine started in case of endoscopic recurrence. If no endoscopic recurrence was observed, no Crohn's disease-specific treatment was given until week 102.
88880409|NCT02247414|Experimental|Warfarin with dipyridamole|From postoperative day 3, patients will receive dipyridamole 25mg tid for three months along with subcutaneous Low Molecular Weight Heparin Calcium injection for first five days and Warfarin 2.5mg qd with titration of dose to maintain a target INR of 2-3. Intially the INR will be monitored twice weekly with gradual escalation of dose to achieve target INR. After achieving the target INR, this is to be repeated every 4 weeks. The Doppler Ultra Sonography screening will be done every 3 months to assess the occurrence of portal vein thrombus, but the medications will be continue for one year irrespective of the occurrence of portal vein thrombus.
88880410|NCT02247414|Active Comparator|Aspirin with dipyridamole|From postoperative day 3, patients will receive oral dipyridamole 25mg tid for three months along with subcutaneous injection of Low Molecular Weight Heparin (4100 IU) for first five days and Aspirin Enterie Ccoated Tablets 100mg qd for one year.
88880411|NCT02247492||Orsiro|
88880412|NCT02247570|Experimental|Vestibular Rehabilitation|Vestibular Rehabilitation
88880413|NCT02247648|Experimental|treatment|treatment: tramadol group
89404557|NCT00889382|Experimental|Phase 2 Arm C Roll-over|Continuous OSI-906 BID from Day 1 onwards
88880414|NCT02247648|Placebo Comparator|control|control: placebo group
88880415|NCT02247882|Experimental|Patient Education|Health Education.
88880416|NCT02247882|Active Comparator|Aquatic Physical Therapy|Protocol of aquatic physical therapy exercises.
88880417|NCT02248038|Active Comparator|open surgery|Conventional procedure
88880418|NCT02248038|Experimental|laparoscopic surgery|Minimum invasive procedure
89199086|NCT02543463|Other|Without Navigation system|Large diameter head with Trident X3 insert with conventional instrumentation
88880419|NCT02248116|Experimental|Alzheimer|
88880420|NCT02248194|Experimental|"Group 1Tactile electrosurgical ablation"|Endometrial ablation will be done by Tactile electrosurgical ablation probe.
88880421|NCT02248194|Active Comparator|"Group 2 Hysteroscopic endometrial ablation"|Hysteroscopic endometrial ablation will be done by trans-cervical resection of endometrium.
88880422|NCT02248272|Experimental|Polycystic Ovary Syndrome|40 women with PCOS followed one of two isocaloric weight maintenance diets (isocaloric diet with 3 meals or isocaloric diet with 6 meals), tailored to individual energy needs, with the same macronutrient composition (40% carbohydrates, 25% protein, 35% fat). The energy and carbohydrate contribution for the 3 meals' diet was 20% at breakfast, 50% at lunch, 30% at dinner, whereas for the 6 meals' diet was 20% at breakfast, 10% at morning snack, 30% at lunch, 10% at afternoon snack, 20% at dinner, 10% at before bedtime snack. Each intervention lasted 12 weeks and there was no wash out period.
89004342|NCT04887688|No Intervention|Group B: Wound treated using standard of care|Control treated wounds in Group B participants will be covered with a standard of care hydrogel dressing such as Restore (Hollister Inc) together with Tegaderm . The SoC dressing will be used for up to 10 weeks or until the wound is healed for 3 days. The SoC bandage will be changed when indicated clinically or every 5 days, whichever is sooner. At each bandage change, wound status monitored as described above, specifically a 3D digital image and wound swabs will be obtained. A fresh sterile SoC bandage will then be reapplied to the wound.
89199087|NCT04017897|Experimental|Experimental|
89199088|NCT02543541|Active Comparator|Standard Supportive Care|
89199089|NCT02543541|Experimental|Structured Supportive Care|
89404558|NCT00489827|Active Comparator|Intravenous glutamate|Intravenous infusion of 0.125 M glutamic acid solution at a rate of 1.65 ml/hour and kg body weight beginning with institution of anesthesia and stopping 2 hours after unclamping of aorta in patients operated for unstable coronary artery disease.
89404559|NCT00489827|Placebo Comparator|Saline infusion|Intravenous infusion of saline at a rate of 1.65 ml/hour and kg body weight beginning with institution of anesthesia and stopping 2 hours after unclamping of aorta in patients operated for unstable coronary artery disease.
89404560|NCT03629314|Experimental|Educational Pamphlet arm|Educational Pamphlet will be provided to all participants to review, questionnaire will be provided to complete before and after review of the pamphlets
89404561|NCT04052607|Experimental|Dydrogesterone Suppression|Dydrogesterone 30 mg on stimulation day 5 till the trigger day to prevent luteinizing hormone (LH) surge. The stimulation is with 150-300 IU FSH/HMG starting on cycle day 2 and adjusted according to the AFC and AMH.
89404562|NCT04052607|Experimental|Dydrogesterone Suppression with minimal stimulation|Dydrogesterone 30 mg on stimulation day 5 till the trigger day to prevent LH surge. The stimulation is with clomifene citrate 50 mg three times daily with150 IU FSH starting on cycle day 2 and continued every other day and adjusted according to the AFC and AMH.
89404563|NCT04052607|Active Comparator|Antagonist Suppression|cetrorelix acetate 0.25 started on stimulation day 6 till the trigger day to prevent LH surge. The stimulation is with150-300 IU FSH starting on cycle day 2 and continued daily and adjusted according to the AFC and AMH.
89404564|NCT00888914|Active Comparator|Dose A|RT001 Dose A; Active Comparator
89404565|NCT00888914|Active Comparator|Dose B|RT001 Dose B; Active Comparator
89404566|NCT00888914|Active Comparator|Dose C|RT001 Dose C; Active Comparator
89404567|NCT00888914|Active Comparator|Dose D|RT001 Dose D; Active Comparator
89404568|NCT00888914|Placebo Comparator|Dose E|RT001 Dose E; Vehicle Comparator
89404569|NCT03423550||Participants who are suspected with TB|
89404570|NCT05160064||Patients Treated with Loncastuximab Tesirine|Patients with B-cell lymphomas and other diagnoses who have been treated with loncastuximab tesirine will have their medical chart data entered into the registry.
89404571|NCT05135936|Experimental|Hyperthermia Group|For the study, the method of passive whole-body hyperthermia is used. The IRATHERM®1000 system (Von Ardenne Institute for Applied Medical Research/Dresden) is used, in which the entire body is heated to a core body temperature above the physiological 37°C. The aim is to achieve a core body temperature of 38.5°C within the framework of mild whole-body hyperthermia. After this warm-up phase, a temperature plateau phase of about 60 minutes follows, in which an attempt is made to maintain the core body temperature of 38.5°C. In the temperature plateau phase, a slight increase in the body core temperature is usually observed. The total time required for a session is given as 1.5 to 2 hours, but this depends on the individual constitution and daily condition of the patient and can be subject to fluctuations.
89404572|NCT05135936|Sham Comparator|Sham-Group|"Within the patient information, privacy policy, etc., there is talk of gentle hyperthermia and classic, mild hyperthermia. This serves to introduce the sham intervention as a control group compared to the patient. Lighting conditions, procedures, instructions and explanations are indistinguishable. Within the application, patients of the sham group will receive a hyperthermia application almost without overheating. In order to achieve this, the patients will be positioned on the IRATHERM®1000 in accordance with the Von Ardenne Institute's regulations. Due to the insulating blanket and the natural device and body heat, the patients of the sham group experience a gentle warmth, which is not the same as regular whole-body hyperthermia and an increase in the body core temperature of about 1.5 °C. In the sham setting, the core body temperature increases by about 0.3 to 0.4 °C within a 55-minute session."
89404573|NCT04059003||Sensitivity group|100 patients will be assigned into sensitivity group according to the actual situation of them.
88880423|NCT02248272|Experimental|Impaired Glucose Tolerance|35 individuals with Impaired Glucose Tolerance (IGT) followed one of two isocaloric weight maintenance diets (isocaloric diet with 3 meals or isocaloric diet with 6 meals), tailored to individual energy needs, with the same macronutrient composition (45% carbohydrates, 20% protein, 35% fat). The energy and carbohydrate contribution for the 3 meals' diet was 20% at breakfast, 50% at lunch, 30% at dinner, whereas for the 6 meals' diet was 20% at breakfast, 10% at morning snack, 30% at lunch, 10% at afternoon snack, 20% at dinner, 10% at before bedtime snack. Each intervention lasted 12 weeks and there was no wash out period.
88880424|NCT02248272|Experimental|Type 2 Diabetes|12 individuals diagnosed with type 2 diabetes followed one of two isocaloric weight maintenance diets (isocaloric diet with 3 meals or isocaloric diet with 6 meals), tailored to individual energy needs, with the same macronutrient composition (45% carbohydrates, 20% protein, 35% fat). The energy and carbohydrate contribution for the 3 meals' diet was 20% at breakfast, 50% at lunch, 30% at dinner, whereas for the 6 meals' diet was 20% at breakfast, 10% at morning snack, 30% at lunch, 10% at afternoon snack, 20% at dinner, 10% at before bedtime snack. Each intervention lasted 12 weeks and there was no wash out period.
88880425|NCT02248350|Experimental|Exercise Group|8-weeks of supervised and home based exercise intervention, 3 times a week, 50-minutes a session for a total of 150/minutes a week
88880426|NCT02248350|Active Comparator|Stretching Control group|Informational booklet containing stretching exercises (20-minutes a day)
89004343|NCT04885634|Active Comparator|Intervention group|Semaglutide 2.4 mg subcutaneously once weekly in addition to standard AF care with lifestyle and risk factor management focusing on cardiovascular risk reduction
89004344|NCT04885634|Placebo Comparator|Control group|Placebo treatment with volume-matched placebo s.c. once weekly in addition to standard AF care with lifestyle and risk factor management focusing on cardiovascular risk reduction
89404574|NCT04059003||Drug resistance group|100 patients will be assigned into drug resistance according to the actual situation of them.
89404575|NCT05160701|No Intervention|Usual Care|Usual Care: no intervention elements.
89404576|NCT05160701|Active Comparator|Existing Medherent|Group using the Medherent Device with no added intervention components.
89404577|NCT05160701|Experimental|New Medherent|Group using Medherent Device with added interventional components.
89404578|NCT05375188|Experimental|Group D|Dexmedetomidine was given as an infusion of 0.4 μg/kg/h from induction of anesthesia for 24 hours.
89404579|NCT05375188|Placebo Comparator|Group C|Equal volume of normal saline.
89404580|NCT05113589|Experimental|PBM TREATMENT|REAL PBM TREATMENT
89404581|NCT05113589|Placebo Comparator|PLACEBO PBM|PLACEBO PBM TREATMENT
89404582|NCT04058535|Experimental|ALT-L9|Intravitreal injection of ALT-L9 50 ul, every 4 weeks
89404583|NCT04058535|Active Comparator|Eylea|Intravitreal injection of Eylea 50 ul, every 4 weeks
89404584|NCT05375110|Experimental|NoYA™ Radiofrequency Interatrial Shunt System|Eligible patients will be enrolled and undergo radiofrequency ablation of the interatrial procedure with the NoYA™ Radiofrequency Interatrial Shunt System (Noya Medtech).
89404585|NCT00994292|Experimental|1. YM150 Dose V, twice daily|
89404586|NCT00994292|Experimental|2. YM150 Dose W, once daily|
89404587|NCT00994292|Experimental|3. YM150 Dose X, twice daily|
89404588|NCT00994292|Experimental|4. YM150 Dose Y, once daily|
88880427|NCT02248428|Experimental|BiCTd regimen|"Induction and consolidation therapy: BiCTd regimen for 8 cycles. Patients received Clarithromycin 500 mg orally on days 1-28,thalidomide 100-200mg orally on days d1-28, dexamethasone 40mg orally on days on 1,8,15,22, and cyclophosphamide 300mg/m^2 intravenously on day 1-3. Cycles were repeated every 28 days.~Maintenance therapy:CP regimen (cyclophosphamide 200 mg orally on days 1-14 and prednisone 30mg twice daily orally on days 1-7,repeated every 28 days) until disease progression.~If efficacy <PR after 4 cycles of induction or disease progression at anytime，patients will be quitted."
88880428|NCT02248428|Active Comparator|CTd regimen|"Induction and consolidation therapy: CTd regimen for 8 cycles. Patients received thalidomide 100-200mg orally on days d1-28, dexamethasone 40 mg orally on days on 1,8,15,22, and cyclophosphamide 300 mg/m^2 intravenously on day 1-3. Cycles were repeated every 28 days.~Maintenance therapy:CP regimen (cyclophosphamide 200 mg orally on days 1-14 and prednisone 30mg twice daily orally on days 1-7,28 Days per Cycle) until disease progression.~If efficacy <PR after 4 cycles of induction or disease progression at anytime，patients will be quitted.~If no further reduction in the serum and urine M protein in the next cycle，patients may cross over to BiCTd regimen."
88880429|NCT02248506|Other|Clotrimazole|Clotrimazole 500 mg
88880430|NCT02248584|Experimental|Vitamin E, C and Zinc|Capsule containing vitamin C (50 mg; CVS Quality, USA), vitamin E (60 mg; Nature´s Bounty, USA), and zinc (40 mg; CVS Quality, USA) per day for 60 days.
88880431|NCT02248584|Placebo Comparator|Placebo|Capsule containing only lactose
88880432|NCT02248896||Hypertensive patients|Hypertensive patients or patients treated with antihypertensive drugs with linked GPRD and hospital episodes statistics database (HES) data
88880433|NCT02249130|Experimental|Treatment of HIV- infected patients|14 days treatment with tipranavir, ritonavir, then 46 weeks of triple- treatment with delavirdine, zidovudine and lamivudine (stavudine for patients intolerant of zidovudine)
88880434|NCT02249208|Active Comparator|Tc+blue dye|Sentinel Lymph Node (SLN) identification and resection using the standard technique of sub-areolar injection of technetium-99m (Tc-99m) and sub-areolar injection of vital blue dye before surgery.
88880435|NCT02249208|Experimental|Tc+SPIO|Sentinel Lymph Node (SLN) identification and resection using isotope technique of sub-areolar injection of technetium-99m (Tc-99m) and the magnetic technique with the sub-areolar injection of SPIO (Sienna+®), before surgery.
88880436|NCT02249208|Experimental|SPIO alone|Sentinel Lymph Node (SLN) identification and resection using the magnetic technique with the sub-areolar injection of SPIO (Sienna+®) before surgery.
88880437|NCT02249286|Experimental|Child Centered Nutrition Counseling|The intervention comprises child-centered nutrition counseling for caretakers and support for 'developed' gardens and improved backyard poultry production.
88880438|NCT02249286|No Intervention|No intervention|
88880439|NCT02249364|Active Comparator|Control|Standard care without hypnosis session followed by closed-loop administration of propofol for anesthesia induction
88880440|NCT02249364|Experimental|Hypnosis|Hypnosis session followed by closed-loop administration of propofol for anesthesia induction
88880441|NCT02249442|Experimental|Scheme A, mild hepatic subjects|multi-dose
88880442|NCT02249442|Experimental|Scheme B, moderate hepatic subjects|single dose
89199090|NCT02542137|Experimental|Radiotherapy and Thymalfasin arm|Patients with metastatic lesions of small cell lung cancer receiving 3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin.
89404589|NCT00994292|Experimental|5. YM150 Dose Y, twice daily|
88880443|NCT02249598|Experimental|Univeristy of Sheffield|lactamica
88880444|NCT02249598|Placebo Comparator|Hallam University|Phosphate Buffered Saline (PBS)
88880445|NCT02249676|Experimental|Autologous mesenchymal stem cells group|"Generated clinical-grade MSC 10 mg chlorpheniramine Po.;100 mg hydrocortisone iv.;10 mg metoclopramide im.;30 min before administration of the cells .~MSC a day-case 2·0×106 cells/kg i.v. 15min Infused normal saline 500 Ml over 4 h i.v."
88880446|NCT02249676|Placebo Comparator|Control group|Patients with progressive and refractory NMO treated with regular methods
89404590|NCT00994292|Experimental|6. YM150 Dose Z, once daily|
89404591|NCT00994292|Placebo Comparator|7. Placebo|
89404592|NCT05387915|Experimental|Treatment (reduced dose radiation therapy)|Patients who are ctHPVDNA negative after surgery undergo reduced dose radiation therapy for 3 weeks (15 treatments). Patients who are ctHPVDNA positive after surgery undergo standard of care radiation therapy.
89404593|NCT02604433|Experimental|Luspatercept (ACE-536) plus Best Supportive Care (BSC)|Luspatercept, subcutaneous(ly) (SC) once every 21 days
89404594|NCT02604433|Placebo Comparator|Placebo plus Best Supportive Care (BSC)|normal saline solution subcutaneous(ly) (SC) once every 21 days
89404595|NCT04306744|Experimental|Vorso PROTECT System- ON|The subject will use the Vorso PROTECT System daily. This experimental group will have the stimulation turned on for all of the daily sessions.
89404596|NCT04306744|Sham Comparator|Sham Arm|The subject will use the Vorso PROTECT System daily. This experimental group will have the stimulation turned off for all of the daily sessions.
89404597|NCT03630419|Experimental|Mito-Food Plan and Cellular Repair|Mito-Food Plan with adjunctive Cellular Repair Therapy
89404598|NCT03665961||Central obesity|Cases with central obesity as defined by waist circumference cut-offs ≥ 90 cm in men and ≥ 80 cm in women for Asians
89404599|NCT03665961||No central obesity|Controls with no central obesity
88880447|NCT02249754|Active Comparator|Routine health education|Routine health education alone
88880448|NCT02249754|Experimental|Nutrition education package|Nutrition education package and routine health education
88880449|NCT02249988|Experimental|Group 1 - ABX203 therapeutic Hepatitis B vaccine treatment arm|ABX203 therapeutic vaccine in addition to NUCs background therapy
88880450|NCT02249988|No Intervention|Group 2 - Control arm|NUCs background therapy only
89404600|NCT03264508|Experimental|Heat therapy|Hot water immersion 3-4x per week for 8-10 weeks
88880451|NCT02244762|Experimental|Mild Renal Impairment|20 mg HC-ER
88880452|NCT02244762|Experimental|Moderate Renal Impairment|20 mg HC-ER
88880453|NCT02244762|Experimental|Severe Renal Impairment|20 mg HC-ER
89199091|NCT00886431|Experimental|Vitrification|The embryos of patients allocated to this arm will be cryopreserved by vitrification.
89199092|NCT00886431|No Intervention|Slow cooling|The embryos of patients allocated to this arm will be cryopreserved by the slow cooling method, which is the standard method (=no intervention)
88880454|NCT02242734|Experimental|Mild Hepatic Impairment|20 mg HC-ER
88880455|NCT02242734|Experimental|Moderate Hepatic Impairment|20 mg HC-ER
88880456|NCT02242734|Experimental|No Hepatic Impairment|20 mg HC-ER
88880457|NCT02240862||Carotid Artery Disease|Patients undergoing carotid artery stenting for high grade carotid artery stenosis with or without neurologic symptoms and with or without a high risk for carotid endarterectomy.
88880458|NCT02244606|Experimental|SCY-078 500 mg|A single loading dose of SCY-078 1000-mg orally on the first day, followed by SCY-078 500-mg orally once-daily on subsequent days.
88880459|NCT02244606|Experimental|SCY-078 750 mg|A single loading dose of SCY-078 1250-mg orally on the first day, followed by SCY-078 750-mg orally once-daily on subsequent days.
89404601|NCT03264508|Sham Comparator|Thermoneutral water immersion|Thermoneutral water immersion 3-4x per week for 8-10 weeks
89404602|NCT05762939|Experimental|Chatbot|Intervention using a pre-release version of Fido (https://fido.aid.pl), Polish AI-based therapy chatbot.
89404603|NCT05762939|Active Comparator|Control (book)|Intervention using self-help materials - chapters from a popular book on cognitive therapy, including worksheets.
88880460|NCT02244606|Active Comparator|Standard-of-care|Oral fluconazole 400 mg daily (with a loading dose of 800 mg on the first day) or IV micafungin 100 mg daily.
88880461|NCT02245308|Experimental|ART|Participants assigned to this treatment arm will receive a tele-health intervention that combines guideline-based cognitive-behavioral counseling for smoking cessation, a tele-medicine clinic for access to smoking cessation aids, and an intensive behavioral therapy for smoking cessation called mobile contingency management.
88880462|NCT02245308|Active Comparator|Control Group|Participants assigned to this active control arm will be referred to VA Specialty Smoking Cessation Clinic for standard-of-care treatment, which may include group counseling, individual counseling, self-help materials, and smoking cessation aids.
88880463|NCT02243358|Experimental|Neoadjuvant Chemo-Radiotherapy and Resection|2 cycles - FOLFOX6 (1 month) Gemcitabine/RT (5-6 weeks) Rest period 2 weeks Re-staging evaluation (CT scan to be done during the 2 weeks of rest) Surgery (To be performed no later than 6 weeks after completion of chemo-radiation)
88880464|NCT00550134||1, Non Cancer group|A noncancer control group (N=35), frequency matched on age (< 50 and ≥ 50) and education (less than college or some college and above) will also be recruited and evaluated with the same neuropsychological test battery on a schedule that matches the inter-test interval of the patients.
88880465|NCT00550134||2 Breast Cancer Patients Scheduled for chemotherapy|We will recruit patients with localized breast cancer undergoing adjuvant chemotherapy for the first time and will test the effects of chemotherapy will be given a battery of neuropsychological tests and an MRI evaluation prior to beginning chemotherapy and approximately one month (plus/minus 4 weeks) following completion of treatment.
88880466|NCT00550134||3 Breast Cancer Patients Not Scheduled for Chemotherapy|We will recruit patients with localized breast cancer not undergoing adjuvant chemotherapy.
88880467|NCT00559962|Placebo Comparator|1|Placebo
88880468|NCT00559962|Active Comparator|2|2.5 mg AEGR-733
88880469|NCT00559962|Active Comparator|3|5 mg AEGR-733
88880470|NCT00559962|Active Comparator|4|7.5 mg AEGR-733
88880471|NCT00559962|Active Comparator|5|10 mg AEGR-733
88880472|NCT00559962|Active Comparator|6|5 mg AEGR-733 + 20 mg atorvastatin
89199093|NCT00886509|Experimental|Collateral promotion; PCI after 6 months|First pegGCSF or placebo; PCI after 6 months
88880473|NCT00559962|Active Comparator|7|5 mg AEGR-733 + 145 mg fenofibrate
88880474|NCT00559962|Active Comparator|8|5 mg AEGR-733 + 10 mg ezetimibe
88880475|NCT00559104|Active Comparator|Irradiation in conditioning|total-body irradiation, etoposide, cyclophosphamide, infusion of peripheral blood stem cells, granulocyte-colony stimulating factor (G-CSF), autologous hematologic stem cell transplantation, peripheral blood stem cell transplantation
89404604|NCT03665883|Active Comparator|Diathermy preferred|Monopolar energy is the preferred dissection approach in this group of patients undergo TEP. Total time of activation of monopolar machine will recorded by specially designed device
89404605|NCT03665883|Active Comparator|Blunt dissection preferred|Blunt dissection is the preferred dissection approach in this group of patients undergo TEP. Use of monopolar energy for haemostasis is still allowed upon surgeons' decision. Total time of activation of monopolar machine will recorded by specially designed device
89404606|NCT00992732|Experimental|HQK-1004 + Valganciclovir|
89404607|NCT02659150|Other|Open-Label tocilizumab|tocilizumab will be given to rheumatoid arthritis patients at a dose of 162 mg subcutaneously a week
89404608|NCT00884234|Experimental|1|RT001 (Botulinum Toxin Type A Topical Gel)
89404609|NCT00884234|Placebo Comparator|2|Vehicle Control
89404610|NCT03006393|Experimental|Infliximab|Participants randomized to the infliximab group will receive one infusion of infliximab at 5mg/kg body weight.
88880476|NCT00559104|Active Comparator|Carmustine in conditioning|Carmustine, etoposide, cyclophosphamide, infusion of peripheral blood stem cells, granulocyte-colony stimulating factor (G-CSF), autologous hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
88880477|NCT00558636|Experimental|Sorafenib + Paclitaxel + Carboplatin|Chemotherapy plus Multi Kinase Inhibitor: Sorafenib Group - Sorafenib (Nexavar, BAY43-9006), [400 mg, (2 tablets x 200 mg each) orally, twice daily] on Study Days 2-19 and paclitaxel (175 mg/m^2, intravenous (IV), over 2.5 to 4 hours) and carboplatin (area under the curve (AUC) =5, IV for 15 to 60 minutes) on Study Day 1. The cycle duration will be 21 days.
88880478|NCT00558636|Placebo Comparator|Placebo + Paclitaxel + Carboplatin|Chemotherapy + Placebo: Placebo Group - Placebo (2 tablets twice daily, orally) on Study Days 2-19 and paclitaxel (175 mg/m^2 IV, over 2.5 to 4 hours) and carboplatin (AUC=5 IV, for 15 to 60 minutes) on Study Day 1. The cycle duration will be 21 days
88880479|NCT00558558|Other|Fermented Soy Supplement|4 oz Haelan orally twice daily for 8 weeks
88880480|NCT00557622|Experimental|paroxetine|Drug 2 (20 mg/day or placebo) will be administered once daily after supper for the first two weeks after the run-in phase. If the investigator/subinvestigator judges that a sufficient response is achieved, Drug 2 will be continued for the remaining period. If a sufficient response is not achieved with Drug 2 but treatment is well tolerated, the dose will be titrated to one step higher level until a sufficient response is achieved [i.e., Drug 3 (30 mg/day or placebo) → Drug 4 (40 mg/day or placebo) → Drug 5 (50 m/day or placebo)] at intervals of at least two weeks by once daily administration after supper. Once a sufficient response is achieved, that dose will be continued.
88880481|NCT00557622|Placebo Comparator|placebo|placebo
88880482|NCT00557466|Experimental|indacaterol 62.5 μg|Indacaterol 62.5 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.
89190339|NCT05794789|Experimental|Identity formation condition|This group will receive the same content as the education+planning comparison condition but with two additional coaching sessions. The session will include short overviews of the benefits of PA as a family, brainstorming how a family can each assist each other in PA, and an activity for developing a family PA action plan. Behavior change techniques that align with these approaches and are included in the coaching session include identity salience, identity similarity, as well as identity fit and contrast. This will be supplemented by an organization of fun family PA roles for all members (e.g., activity planner, goal setter, supporter, etc.) to instill involvement as well as items (creation of a family PA t-shirt, family PA photos and display, etc.) to instill distinctiveness, which is a central feature of a social identity.
89190340|NCT05767970|Experimental|Integrated Stress Toolbox for Healthcare Providers (ISTH)|A 12-week synchronous and app-based well-being training that involves weekly 2-hour sessions for weeks 1-8 and at week 12, along with 12-weeks of app-based content delivered through a special version of the Healthy Minds Program app.
89190341|NCT05767970|No Intervention|Wait-list control|The wait-list control group will continue with business as usual and receive the ISTH after the last data collection point.
88880483|NCT00557466|Experimental|indacaterol 125 μg|Indacaterol 125 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.
88880484|NCT00557466|Experimental|Indacaterol 250 μg|Indacaterol 250 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.
88880485|NCT00557466|Experimental|indacaterol 500 μg|Indacaterol 500 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.
88880486|NCT00557466|Active Comparator|formoterol|Formoterol 12 μg delivered by the AEROLIZER® device twice a day and placebo to indacaterol (placebo TWISTHALER® device) once a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.
88880487|NCT00557466|Placebo Comparator|placebo|Placebo to indacaterol (placebo TWISTHALER® device) once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.
88880488|NCT00557310|Experimental|Teriparatide|20 micrograms (mcg) teriparatide subcutaneous injection per day for 18 months, with possibility to continue for 24 months
89190342|NCT05765578||Moderna-Only Vaccine/Booster Series (MMMM Group)|Individuals who previously received Moderna COVID-19 vaccines in both primary series and first booster and a bivalent booster against Omicron BA.4/5 as the second booster dose (Moderna mRNA1273.222).
88880489|NCT00555438|Experimental|1|patients with renal impairment who received Fondaparinux 1.5 mg/l after major orthopaedic surgery
89004345|NCT04882579|Experimental|PoCUS group|Patients allocated to the PoCUS investigation arm will receive an ultrasound investigation resulting in either confirmation or dismissal of pulmonary embolism suspicion or requiring CTPA or VQ
89004346|NCT04882579|No Intervention|Control group|Patients allocated to the control group will continue with CTPA or VQ without PoCUS investigation
89190343|NCT05765578||Pfizer-Only Vaccine/Booster Series (PPPP Group)|Individuals who previously received Pfizer COVID-19 vaccines in both primary series and first booster and a bivalent booster against Omicron BA.4/5 as the second booster dose (Pfizer-BNT 162b2 bivalent booster).
89190344|NCT05765578||Moderna mRNA COVID-19 updated vaccine (XBB.1.5): Comparison Group|Individuals who received Moderna 2023 updated COVID-19 vaccine (XBB.1.5).
89190345|NCT05765578||Pfizer-BioNTech COVID-19 updated vaccine (XBB.1.5): Reference Group|Individuals who received Pfizer 2023 updated COVID-19 vaccine (XBB.1.5).
89190346|NCT05732740|Experimental|Treatment|Participants will participant in 9 weekly group-based sessions
89199094|NCT00886509|Experimental|Collateral promotion after PCI at baseline|Collateral promotion with pegGCSF after PCI at baseline
89404611|NCT03006393|Placebo Comparator|Placebo|Participants randomized to the placebo group will receive one placebo infusion.
89404612|NCT03028480||Subjects with Bronchial asthma|Subjects with a refractory asthma whose symptoms are inadequately controlled despite receiving standard asthma medications will be enrolled
89404613|NCT00991172|Placebo Comparator|placebo injection|
89404614|NCT00991172|Experimental|active|subcutaneous injection of REGN475
89404615|NCT00991172|Experimental|active 2|subcutaneous injection of REGN475
89404616|NCT05762861|No Intervention|Usual follow up|Group 1: To keep follow-up in their usual family practice/ pulmonology consultations
89404617|NCT05762861|Experimental|Home telemonitoring|Group 2: To keep follow-up in their usual family practice/ pulmonology consultations and associate an interactive home telemonitoring system managed by the researchers.
89404618|NCT02950012|Experimental|OPTI-BIOME™ Bacillus subtilis MB40|
89404619|NCT02950012|Placebo Comparator|Placebo|
89404620|NCT01383109|Experimental|Pyronaridine|All subjects will receive a single dose of Pyronaridine
89404621|NCT02903992|Other|All patients recruited|All patients who are enrolled in study with at least one Fried criteria will have a Dual-energy X-ray absorptiometry (DXA) to measure lean muscle mass adjusted for body mass index. As part of the usual care in the Frailty Clinic patients will also have a clinical examination, a standard biological sample (requiring 15 ml of blood); an evaluation of the cognitive and functional performances, of their medico-economic situation and lifestyle.
89404622|NCT04966871|Experimental|Group A (PfSPZ Vaccine; PfSPZ Challenge 7G8)|"14 volunteers will receive 3 doses of 9 x 10^5 PfSPZ Vaccine on days 1, 8, 29.~Controlled human malaria infection (CHMI) with PfSPZ Challenge (7G8) will be administered on day 14 by DVI injection."
89404623|NCT04966871|Experimental|Group B (PfSPZ Vaccine; PfSPZ Challenge 7G8)|"14 volunteers will receive 9 x 10^5 PfSPZ Vaccine on days 1, 8, 29.~Controlled human malaria infection (CHMI) with PfSPZ Challenge (7G8) will be administered on day 42 by DVI injection."
89404624|NCT04966871|Experimental|Group C (PfSPZ Vaccine; PfSPZ Challenge 7G8)|"14 volunteers will receive 9 x 10^5 PfSPZ Vaccine on days 1, 8, 29.~Controlled human malaria infection (CHMI) with PfSPZ Challenge (7G8) will be administered on day 70 by DVI injection."
89404625|NCT04966871|Placebo Comparator|Group A controls (Saline; PfSPZ Challenge 7G8)|"4 volunteers will receive Normal Saline (NS) as placebo on days 1, 8, 29.~Controlled human malaria infection (CHMI) with PfSPZ Challenge (7G8) will be administered on day 14 by DVI injection."
89404626|NCT04966871|Placebo Comparator|Group B controls (Saline; PfSPZ Challenge 7G8)|"4 volunteers will receive Normal Saline (NS) as placebo on days 1, 8, 29.~Controlled human malaria infection (CHMI) with PfSPZ Challenge (7G8) will be administered on day 42 by DVI injection."
89404627|NCT04966871|Placebo Comparator|Group C controls (Saline; PfSPZ Challenge 7G8)|"4 volunteers will receive Normal Saline (NS) as placebo on days 1, 8, 29.~Controlled human malaria infection (CHMI) with PfSPZ Challenge (7G8) will be administered on day 70 by DVI injection."
89404628|NCT00882440|Placebo Comparator|1|Placebo
88880490|NCT00553644|Experimental|Treatment (bortezomib, lenalidomide)|Patients receive induction therapy comprising bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11 and lenalidomide PO QD on days 1-14. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Patients achieving a complete or partial response as best response after completion of induction therapy receive maintenance therapy comprising bortezomib IV on days 1 and 8 and lenalidomide PO QD on days 1-14. Treatment repeats every 21 days for up to 6 years in the absence of disease progression or unacceptable toxicity.
88880491|NCT00553332|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive oral selumetinib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88880492|NCT00552240|Active Comparator|NVP 200mg bis indie (BID)|after receiving nevirapine (NVP) 200 mg quaue die (QD) for 2 weeks, pt titrated to NVP 200 mg bis in die (BID) combined with emtricitabine 200 mg QD/ tenofovir DF 300 mg QD (fixed dose combination Truvada) for 48 weeks
88880493|NCT00552240|Active Comparator|Atazanavir 300 mg QD/ritonavir 100 mg QD|patients to receive atazanavir 300 mg QD boosted with ritonavir 100 mg QD combined with emtricitabine 200 mg QD/ tenofovir DF 300 mg QD (fixed dose combination Truvada) for 48 weeks
88880494|NCT00552084|Experimental|Fish Oil|4 grams fish oil daily for 24 weeks
89404629|NCT00882440|Experimental|2|Losartan 10 mg
89404630|NCT00882440|Experimental|3|Losartan 25 mg
89404631|NCT00882440|Experimental|4|Losartan 50 mg
89404632|NCT00882440|Experimental|5|Losartan 100 mg
88880495|NCT00552084|Placebo Comparator|Placebo|corn oil taken daily for 24 weeks
89404633|NCT00882440|Experimental|6|Losartan 150 mg
89404634|NCT00882440|Active Comparator|7|Enalapril 20 mg
89404635|NCT02864290|Experimental|Dose Escalation of ASP1235 (AGS62P1) Schedule A|Subjects will receive ASP1235 (AGS62P1) as an intravenous infusion once every three weeks (Q3W) to determine the maximum tolerated dose (MTD) or recommended Phase 2 dose. A cycle is 21 days.
89404636|NCT02864290|Experimental|Dose Escalation of ASP1235 (AGS62P1) Schedule B|Subjects will receive ASP1235 (AGS62P1) as an intravenous infusion every other week of a 4-week cycle (Q2W) to determine the maximum tolerated dose (MTD) or recommended Phase 2 dose. A cycle is 28 days.
89404637|NCT02864290|Experimental|Dose Expansion of ASP1235 (AGS62P1) Schedule A|Once the maximum tolerated dose (MTD) or recommended Phase 2 dose has been determined, an expansion cohort of up to 25 subjects may be enrolled. Subjects will receive ASP1235 (AGS62P1) as an intravenous infusion once every three weeks (Q3W).
89199095|NCT00886665|Placebo Comparator|Placebo|
89199096|NCT00886665|Experimental|JWHGWT|
89404638|NCT02864290|Experimental|Dose Expansion of ASP1235 (AGS62P1) Schedule B|Once the maximum tolerated dose (MTD) or recommended Phase 2 dose has been determined, an expansion cohort of up to 25 subjects may be enrolled. Subjects will receive ASP1235 (AGS62P1) as an intravenous infusion every other week of a 4-week cycle (Q2W).
89404639|NCT02864290|Experimental|Dose Escalation of ASP1235 (AGS62P1) Schedule C|Subjects will receive ASP1235 (AGS62P1) as an intravenous infusion once weekly for three weeks of a 4-week cycle to determine the MTD or recommended Phase 2 dose. A cycle is 28 days.
89530996|NCT02495675|Experimental|Conventional flow via nasal prongs|Subjects will be breathing with nasal prongs delivering 5 L/min of air (inspired fraction of oxygen: 0.21)
88880496|NCT00550836|Active Comparator|Arm A: GE|Patients receive 1000 mg/m^2 gemcitabine hydrochloride IV on days 1, 8, and 15; and 100 mg oral erlotinib hydrochloride on days 1-28. Treatment repeats every 28 days for 2 courses. Patients achieving a complete response (CR) after 2 courses receive 2 additional courses of treatment; patients achieving a partial response (PR) receive retreatment as above. Patients achieving a CR after 4 courses of treatment receive erlotinib hydrochloride until the first disease progression. After the first progression, patients are retreated with gemcitabine hydrochloride and erlotinib hydrochloride until second progression.
88880497|NCT00550836|Experimental|Arm B: PGE|Patients receive 1000 mg/m^2 gemcitabine hydrochloride IV on days 1, 8, and 15; 100 mg oral erlotinib hydrochloride on days 1 - 28; and 4.0 mg/kg panitumumab IV on days 1 and 15. Treatment repeats every 28 days for 2 courses. Patients achieving a CR after 2 courses receive 2 additional courses of treatment; patients achieving a PR receive retreatment as above. Patients achieving a CR after 4 courses of treatment receive erlotinib hydrochloride and panitumumab until the first disease progression. After the first progression, patients are retreated with gemcitabine hydrochloride, erlotinib hydrochloride, and panitumumab until second progression.
88880498|NCT00550680|Experimental|Mircera in Renal Anemia|Participants with chronic renal anemia who have been previously treated with erythropoiesis-stimulating agent (ESA) therapy will receive IV Mircera every 4 weeks for a total of 24 weeks in this single-arm study. The first dose of 120, 200, or 360 mcg will be determined by the dose of ESA received prior to administration of study treatment. Subsequent doses will be adjusted to maintain Hb concentrations within target of 10.5 and 12.5 grams per deciliter (g/dL).
88880499|NCT00559650|Placebo Comparator|Arm 1|
89404640|NCT02864290|Experimental|Dose Expansion of ASP1235 (AGS62P1) Schedule C|Once the MTD or recommended Phase 2 dose has been determined, an expansion cohort of up to 25 subjects may be enrolled. Subjects will receive ASP1235 (AGS62P1) as an intravenous infusion once weekly for three weeks pf a 4-week cycle.
88880500|NCT00559650|Experimental|Arm 2|
88880501|NCT00554190|Experimental|1|AdvaCoat compared to Merogel Injectable Bioresorbable Nasal Dressing
89404641|NCT05214391|Experimental|Intervention ( zanubrutinib)|30 enrolled patients are picked up to take zanubrutinib at the indicated dose.
89404642|NCT00880490|Experimental|1|Inhaled PT005 2.4 mcg
89404643|NCT00880490|Experimental|2|Inhaled PT005 4.8 mcg
88880502|NCT00554190|Active Comparator|2|Merogel Injectable Bioresorbable Nasal Dressing compared to AdvaCoat
88880503|NCT00556374|Experimental|Denosumab|Participants received 60 mg denosumab subcutaneous injection once every 6 months. All participants continued to receive an approved non-steroidal aromatase inhibitor therapy.
88880504|NCT00556374|Placebo Comparator|Placebo|Participants received placebo subcutaneous injection once every 6 months. All participants continued to receive an approved non-steroidal aromatase inhibitor therapy.
88880505|NCT00556374|Experimental|SubStudy: Zoledronic Acid|Eligible participants who completed the open-label phase could be enrolled into the zoledronic acid substudy and randomized to receive a single 5 mg intravenous dose of zoledronic acid 8 months after the last open-label dose of denosumab.
88880506|NCT00556374|Other|Substudy: Standard of Care|Eligible participants who completed the open-label phase could be enrolled into the zoledronic acid substudy and randomized to receive standard of care 8 months after the last open-label dose of denosumab.
88880507|NCT03029910|Experimental|Cryotherapy and eccentric exercise|
88880508|NCT03029910|Experimental|Vibration and eccentric exercise|
88880509|NCT03029910|No Intervention|Control|
88880510|NCT03029754|Experimental|Passive leg raise|Participant's legs will be raised with a bolster prior to IV insertion.
88880511|NCT03029754|No Intervention|No leg raise|Participants will lie flat prior to IV insertion.
89190347|NCT05722769|Experimental|CSTOP Now! Child Sex Trafficking Stops with You|For this RCT, our research team has created CSTOP Now! online, interactive learning management system training. This CSTOP Now! online training will be offer to middle school staff in Kentucky counties randomized to this experimental intervention arm. This training seeks to provide middle school staff with information and resources to identify, intervene in, and prevent child sex trafficking (CST). This training will provide middle school staff with the knowledge, skills, and efficacy to intervene with children at risk of or experiencing CST. This training will also provide staff with skills to disrupt harmful attitudes or misinformation about CST.
89190348|NCT05722769|Active Comparator|Prevent Child Abuse Kentucky Online Training|The Kentucky State Police, in association with Prevent Child Abuse Kentucky, have developed training videos designed to identify child sex trafficking. For middle school staff in counties randomized to the active comparator, we offer these video as online training. Prevent Child Abuse Kentucky has consented to this use of their child sex trafficking identification training videos.
89190349|NCT05719350|Experimental|Experimental Group|Tele-rehabilitation exercises for the knee joint to reduce pain
88880512|NCT00555204|Experimental|A|
89190350|NCT05719350|Active Comparator|Control Group|Exercises in presence for the knee joint to decrease pain
89404644|NCT00880490|Experimental|3|Inhaled PT005 9.6 mcg
89404645|NCT00880490|Placebo Comparator|4|Inhaled Placebo
89404646|NCT00880490|Active Comparator|5|Formoterol Fumarate 12 mcg (Foradil Aerolizer)
88880513|NCT00555204|Experimental|B|
89404647|NCT05214157|Experimental|group A|interventional group, final two operative steps applied
89404648|NCT05214157|No Intervention|group B|control group
88880514|NCT00555204|Experimental|C|
88880515|NCT00555204|Experimental|D|
88880516|NCT00555204|Experimental|E|
88880517|NCT00555204|Experimental|F|
88880518|NCT00555204|Placebo Comparator|G|
88880519|NCT03029676|Experimental|Group B|spinal anesthesia premedication with benzodiazepine and opioid
88880520|NCT03029676|Active Comparator|Group K|spinal anesthesia premedication with opioid
88880521|NCT03029520|Active Comparator|pain iRoot SP sealer Vital Pulp|Evaluation of Postoperative pain after root canal obturation with iRoot SP sealer (Innovative BioCeramix Inc., Vancouver, Canada) with patients who has (mandibular premolar/molar) vital pulp.
89404649|NCT04957433||Cohort A|Patients new to The Lung Health Check (TLHC) pilot who are attending their first lung health check
89530997|NCT02495675|Experimental|High flow nasal cannulas 20 L/min|Subjects will be breathing with high flow nasal cannulas delivering 20 L/min with an inspired fraction of oxygen of 0.21.
89190351|NCT05714007|Experimental|Treatment group|"Iron to be administered as intravenous ferric derisomaltose:~Where Hb (hemoglobin) ≥100 g/L, dosage according to body weight is as follows:~Body weight <50 kg: 500mg; Body weight 50 to <70 kg: 1000 mg; Body weight ≥70 kg: 1500 mg.~Where Hb <100 g/L, dosage according to body weight is as follows:~Body weight <50 kg: 500mg; Body weight 50 to <70 kg: 1500mg; Body weight ≥70 kg: 2000 mg.~The maximial dose should not exceed 20mg/kg body weight, rounded off to the nearest 100mg"
88880522|NCT03029520|Active Comparator|pain iRoot SP sealer Devital pulp|Evaluation of Postoperative pain after root canal obturation with iRoot SP sealer (Innovative BioCeramix Inc., Vancouver, Canada) with patients who has (mandibular premolar/molar) devital pulp.
89190352|NCT05714007|Active Comparator|Control group|"Iron to be administered as oral ferrous succinate:~1 tablet (100 mg) tid (three times daily), starting on the first postoperative day and continuing for 4 weeks."
89199097|NCT02543385|Active Comparator|SKET|Intravenous S+ketamine 0.25 mg/kg (i.v. bolus) at the beginning and 0.25 mg/kg (i.v. bolus) 20 minutes before extubation along with remifentanil according to Minto model and propofol infusion according to Schnider model through target control infusion pump.
89199098|NCT02543385|Placebo Comparator|PLACEBO|Intravenous normal saline (as placebo, with similar volume) at the beginning and 20 minutes before extubation along with remifentanil according to Minto model and propofol according to Schnider model through target control infusion pump.
89199099|NCT00884481||Natalizumab|Participants with MS treated with Tysabri over 12 months
89404650|NCT04957433||Cohort B (Nodule Suveillance)|Patients who have already undergone one lung health check as part of the TLHC programme, and are now being followed up at 3 months (B1), 12 months (B2) or other (BX) due to an indeterminate finding (e.g. lung nodule)
89404651|NCT04957433||Cohort C (Incident Scan)|Patients who are already part of TLHC attending for routine 'incident' round follow-up scanning (usually at approximately 24 months)
89404652|NCT04957433||Cohort D|Participants with interstitial lung abnormalities (ILAs) identified as part of TLHC, who are referred to the interstitial lung disease (ILD) unit at Royal Brompton Hospital.
88880523|NCT03029520|Active Comparator|pain AHPlus Vital pulp|Evaluation of Postoperative pain after root canal obturation with AH Plus sealer (Dentsply Maillefer, Ballaigues, Switzerland) with patients who has (mandibular premolar/molar) vital pulp.
88880524|NCT03029520|Active Comparator|pain AHPlus Devital Pulp|Evaluation of Postoperative pain after root canal obturation with AH Plus sealer (Dentsply Maillefer, Ballaigues, Switzerland) with patients who has (mandibular premolar/molar) devital pulp.
88880525|NCT03029130|Experimental|Catheter Extension|Patients in this arm will have a foley catheter re-passed, to remain in situ for an additional 14 days, after which time the catheter will be removed and the patient discharged to return for follow up exam at 3 months postop.
88880526|NCT03029130|No Intervention|Discharge|Patients in this arm will be discharged, to return for follow up exam at 3 months postop.
88880527|NCT03029052|No Intervention|Control group|Medical and pharmaceutical management (at admission, during hospitalization and at discharge) will follow standard healthcare procedures of the department.
88880528|NCT03029052|Experimental|Reconciliation group|Standard healthcare procedures and pharmacist's involvement
88880529|NCT04279548|Active Comparator|On DBS|Patients in the on mode DBS
88880530|NCT04279548|Sham Comparator|Off DBS|Patients in the off mode DBS
88880531|NCT04270032||malignant group|women with malignant lesions confirmed by pathology
88880532|NCT04270032||benign group|women with benign lesions confirmed by pathology or stable in follow-up > 2 years
89404653|NCT04284124|Active Comparator|Erector Spinae block|Done unilaterally with the patient in the prone position about 20 min before induction of general anesthesia. Skin is prepared by 10% povidone iodine. An ultrasound machine with a large bandwidth, multifrequency convex probe (1-8 MHz) will be used for block performance. A 22G, 50-mm, at the T4 level of the spine using an in-plane approach. Probe is placed 2-3 cm laterally to the spine using a sagittal approach. Once the erector spinae muscle and the transverse processes is identified, the needle will be inserted deep into the muscle. The needle will be directed from a cranial to a caudal direction. Following confirmation of the correct position of the needle tip with administration of 0.5-1 ml of local anesthetic, 20 ml of 0.25% bupivacaine will be administered for block performance. Distribution of local anesthetic will be observed in both cranial and caudal directions.
89437489|NCT03797690|Active Comparator|Open surgery with limited aponeurectomy|It consists in excision of the fibrotic aponeurosis.It will be performed by hand surgeons under loco-regional anaesthesia during a short hospitalization (1 day stay). Post-operative cares are necessary (analgesics, splint, nursing, physiotherapy). End of surgical treatment will be considered as the removal of the stitches (two weeks after the surgical treatment).
88880533|NCT04270032||normal group|women have normal images with follow up > 2 years
88880534|NCT04277910|Active Comparator|MT2004|MT2004 oral capsules treated group
88880535|NCT04277910|Placebo Comparator|Placebo|Placebo oral capsules treated group
88880536|NCT04275570|Active Comparator|Motivational Interview.|Repeated motivational interview during prenatal care visits
88880537|NCT04275570|No Intervention|Usual intervention|Usual intervention
88880538|NCT04278846|Experimental|DepoFoam bupivacaine|local anesthetic
88880539|NCT04278846|Active Comparator|Bupivacaine hydrochloride (HCl)|local anesthetic
88880540|NCT04277988||Crossed leg position|Patients in this group will be randomly allocated to sit in crossed leg position first.Ultrasonography will be performed in this position to measure the best visualized length of posterior longitudinal ligament, ligamentum flavum and interlaminar distance at L3-4 lumbar level as by Operator 1 . These measurements will be recorded by Operator 2 using intrinsic caliper software.Operator 1 will not be told the measurements.
88880541|NCT04277988||Standard Sitting position|Patients in this group will be randomly allocated to sit in standard position first.Ultrasonography will be performed in this position to measure the best visualized length of posterior longitudinal ligament, ligamentum flavum and interlaminar distance at L3-4 lumbar level as by Operator 1 . These measurements will be recorded by Operator 2 using intrinsic caliper software.Operator 1 will not be told the measurements.
88880542|NCT03838770|Experimental|Active|
88880543|NCT03838770|Placebo Comparator|Sham|
88880544|NCT03839550|Experimental|Apatinib Mesylate +SHR-1210|Experimental arm: Apatinib mesylate +PD-1 antibody SHR-1210 for adjuvant therapy of HCC with high incidence of tumor recurrence after hepatic resection
88880545|NCT03839550|Active Comparator|Hepatic Arterial Infusion(HAI)|Active Comparator arm: HAI for adjuvant therapy of HCC with high incidence of tumor recurrence after hepatic resection
88880546|NCT03839160|Active Comparator|SAPB group. Group S|In this group, serratus anterior plane block (SAPB) was performed before extubation with injection of 30 ml of 0.25% bupivacaine hydrochloride followed by 0.1ml/kg/hr of 0.12% bupivacaine hydrochloride. In addition to SAPB, intravenous patient-controlled-analgesia morphine was used. Morphine solution was prepared at a concentration of 0.5 mg/mL with the device programmed to 2 mg of bolus dose and 10 min of locking time.
88880547|NCT03839160|Placebo Comparator|Control group. Group C|In this group, intravenous patient-controlled-analgesia morphine was used. Morphine solution was prepared at a concentration of 0.5 mg/mL with the device programmed to 2 mg of bolus dose and 10 min of locking time.
88880548|NCT03839238|Experimental|Meniscus Injured patients|hESC Derived MSC Like Cell
88880549|NCT03838926|Experimental|Trichostatin A|
88880550|NCT03839004|Experimental|Intervention group|200 woman with single spontaneous pregnancies who recieve, as well as traditional obstetrical care, yoga classes, myndfulness classes, coaching, nutrition counselling and osteopathic treatment
89404654|NCT04284124|Active Comparator|PECS type II block|Done unilaterally, patient is put in the supine position with ipsilateral arm abducted and externally rotated with elbow flexed 90 degrees. High frequency probe is put in the ipsilateral clavipectoral triangle between the clavicle medially and above and the shoulder joint laterally. The pectoralis major and minor and the plane between them are identified guided by pulsating thoracoacromial artery or its pectoral branch. Needle is advanced in plane targeting the space where the artery is located, 2ml of normal saline is injected to confirm the location. Then, 10 ml of bupivacaine 0.25% is injected. Probe is moved laterally and caudally towards the anterior axillary fold parallel to the deltopectoral groove till the serratus muscle slips appear underneath the pec minor attached to the underlying ribs. Targeting the plane between pec minor and serratus at the level of the third rib, 2 ml of normal saline is injected for confirmation of the needle tip then 20 ml of bupivacaine 0.25%.
88880551|NCT03839004|No Intervention|Controls|200 woman with single spontaneous pregnancies recieving traditional obstetrical care
88880552|NCT03838380|No Intervention|conventional management group|The conventional management group received standard GDM management and could freely use the smartphone healthcare application.
89404655|NCT03628963|Experimental|Concerto+ (Intervention group)|Patients with two or more targeted chronic diseases (diabetes, hypertension, dyslipidemia) and who had three or more visits in the last 12 months will use Concerto+ application during 6 months.
88880553|NCT03838380|Experimental|mobile management group|The mobile management group received mobile healthcare services through smartphone application specifically developed for this trial including tailored mobile coaching.
89404656|NCT03628963|No Intervention|Usual care (Control group)|Patients with two or more targeted chronic diseases (diabetes, hypertension, dyslipidemia) and who had three or more visits in the last 12 months will not use the application Concerto+ but receive usual care from FMG.
89404657|NCT03665727|Experimental|Mindfulness|15 minute mindfulness session
89404658|NCT03665727|Experimental|Suggestion|15 minute therapeutic suggestion session
89404659|NCT03665727|Active Comparator|Psychoeducation|15 minute psychoeducation session
89404660|NCT03665727|No Intervention|Usual Care|The usual care comparison group was comprised of patients who underwent total joint arthroplasty of the hip or knee at the same academic medical center during the study period but who did not attend Joint Academy.
89404661|NCT04215640|Experimental|MIFI group|Patients in the MIFI group receive standard radiofrequency ablation procedure for the supraventricular tachycardia using microfidelity (MIFI) catheter.
89404662|NCT04215640|Active Comparator|Control|Patients in the control group receive standard radiofrequency ablation procedure for the supraventricular tachycardia using conventional ablation catheter (Blazer II).
88880554|NCT03838614|Experimental|RAS-MPT group|Rhythmical auditory stimulation gait training and muscle power training group
88880555|NCT03838614|Experimental|RAS group|Rhythmical auditory stimulation gait training group
88880556|NCT03838614|Experimental|MPT group|Muscle power training group
88880557|NCT03838614|Other|Control group|Usual care group
88880558|NCT03838224|Experimental|Dry needling|Participants allocated in this group will receive a single session of dry needling of the obliquus capitis inferior. Prior to the intervention, participants will receive information about the procedure and will be free to withdraw. The needle was shown to the participant before the intervention. Participants will be requested to lie in prone on the plinth. Participants' skin will be sterilized with antiseptic spray for the skin. The therapist will clean his hands and use sterilized gloves.
88880559|NCT03838224|Sham Comparator|sham needling|Sham needling has shown to be a valid control method in dry needling research. The procedure in the sham group will be the same as the experimental group to guarantee the participants' blinding. Prior to the intervention, participants will receive information about the procedure and will be free to withdraw. The sham needle (same appearance/material as the true needle) was shown to the participant before the intervention to guarantee the blinding.
88880560|NCT03838302||Transvaginal retrieval|Transvaginal retrieval via a posterior colpotomy for removing tissue by laparoscopic surgery with uterus preservation
88880561|NCT03838302||Transabdominal retrieval|Transabdominal retrieval via trocar for removing tissue by laparoscopic surgery with uterus preservation
88880562|NCT03837834|Experimental|4 MIN X 4 MIN HIIT of FES-LCE|4 min of high-intensity phase intersperses with 4 min of low-intensity phase for a total of 5 bouts.
89190353|NCT05713838|Experimental|Durvalumab + Chemoradiotherapy|"Core Treatment:~D1: Durvalumab (1500 mg, IV) PLUS FLOT (50 mg/m² docetaxel, 85 mg/m² oxaliplatin, 200 mg/m² calcium folinate and 2600 mg/m² 5-FU 24h)~D15: FLOT (50 mg/m² docetaxel, 85 mg/m² oxaliplatin, 200 mg/m² calcium folinate and 2600 mg/m² 5-FU 24h),~D29: Durvalumab (1500 mg, IV) PLUS mFOLFOX (85 mg/m² oxaliplatin, 200 mg/m² calcium folinate, 400 mg/m² 5-FU bolus and 1600 mg/m² 5-FU 48h) PLUS 50 Gy radiotherapy~5 weeks with 5 days a week radiotherapy (25 daily fractions, 2.0 Gy = ∑50Gy)~D43: mFOLFOX (85 mg/m² oxaliplatin, 200 mg/m² calcium folinate, 400 mg/m² 5-FU bolus, 1600 mg/m² 5-FU 48h) (radiation cont.)~D57: Durvalumab (1500 mg, IV) PLUS mFOLFOX (85 mg/m² oxaliplatin, 200 mg/m² calcium folinate, 400 mg/m² 5-FU bolus and 1600 mg/m² 5-FU 48h) (radiation cont.)~Maintenance Phase Durvalumab monotherapy max. 12 cycles à 4 weeks:~Durvalumab (1500 mg, IV, Q4W) D1"
89404663|NCT05214079|Active Comparator|1 , Left paratracheal pressure|50 male
88880563|NCT03837834|Experimental|2 MIN X 2 MIN HIIT of FES-LCE|2 min of high-intensity phase intersperses with 2 min of low-intensity phase for a total of 10 bouts.
89404664|NCT05214079|Active Comparator|2, Left paratracheal pressure|50 female
89404665|NCT03628807||Retrospective 1|Retrospective Bare Metal Stent Cohort that received TIPS from 01/01/1996 to 12/31/2003.
89404666|NCT03628807||Retrospective 2|Retrospective Covered Stent Cohort that received TIPS from 01/01/2004 to 12/31/2012.
89404667|NCT03628807||Prospective|Prospective cohort that received TIPS from 01/01/2013 onwards
89404668|NCT02926144|Experimental|Laryngoscope with video|Use of the video-laryngoscope McGrath Mac with use of the video feature
88880564|NCT03837210|Experimental|Test Drug|This group is treated with Herbal formulation.
88880565|NCT03837210|Active Comparator|Control Drug|This group is treated with Quintuple therapy
88880566|NCT03837288|No Intervention|Vaginal progesterone only|continue on vaginal progesterone only
88880567|NCT03837288|Experimental|Cervical cerclage plus vaginal progesterone|cerclage with vaginal progesterone.
89404669|NCT02926144|Active Comparator|Laryngoscope without video|Use of the video-laryngoscope McGrath Mac without use of the video feature
89404670|NCT03630341|Experimental|study group|This group will receive oral clomiphene citrate 50 mg tablet, two times per day from the third day of the cycle until the seventh day of the cycle plus oral carnitine 1g tablet, three times per day from the third day until the day of the pregnancy test.
89404671|NCT03630341|Active Comparator|control group|This group will receive oral clomiphene citrate 50 mg tablet, two times per day from the third day of the cycle until the seventh day of the cycle plus oral placebo tablet, three times per day from the third day until the day of the pregnancy test.
89404672|NCT02632396|Experimental|Treatment (ixazomib, rituximab)|Beginning between 70-180 days after stem cell transplant, patients receive ixazomib PO on days 1, 8, and 15, and rituximab IV (or SC after first dose if deemed appropriate) on day 1 of courses 1, 3, 5, 7, and 9. Treatment repeats every 28 days for up to 10 courses in the absence of disease progression or unacceptable toxicity.
89190354|NCT05712512||Infant siblings of children with autism spectrum disorder|
89404673|NCT01376843||Health care workers|health care workers who performed TST or Quantiferon-TB Gold In tube assay before
89404674|NCT01872169|Other|Disordered eating screening questionnaire|
89404675|NCT04078516||Type 1 diabetes and painful neuropathy|No interventions. A series of observationel/expirimental methods for detecting and grading neuropathy will be applied.
88880568|NCT03837366|Experimental|Activity Tracker with Health Coaching|Participants assigned to this condition will receive a Fitbit activity tracker to use for 3 months. Also, they will be asked to come in for a visit approximately one week following baseline assessments. Using the principles of Motivational Interviewing and Habit Formation, participants will discuss their perceived benefits and barriers of becoming more physically active with a member of the research team. They will also be encouraged to set a goal related to using their Fitbit to increase their physical activity. Lastly, they will be given information regarding habit formation and encouraged to identify one or more cues that regularly occur in their daily life to check their Fitbit data as a prompt to engage in physical activity.
88880569|NCT03837366|Active Comparator|Activity Tracker alone|Participants assigned to this condition will use their Fitbit on their own for the duration of 3- month intervention, similar to the experience of participants buying the device off-the-shelf.
88880570|NCT03837054|Other|Breast cancer patients with external polychemotherapy|
88880571|NCT03836742||HF RCA|Cardiovascular surgery patients treated with hemofiltration with regional citrate anticoagulation
88880572|NCT03836898|Experimental|Implantation phakic intraocular lens|Presbyopic posterior chamber phakic intraocular lens IPCL implanted to the participants eye
88880573|NCT03836118||IUI|all the IUI with controlled ovarian stimulation cycles in an academic tertiary ART center between January 1997 and December 2017
88880574|NCT03836274|Experimental|Experimental|Patients established on an oral nutritional supplement (ONS), requiring nutritional supplementation of at least 300kcal/day will be changed onto an equivalent prescription of AYMES 'MONACO' for a period of 9 days.
88880575|NCT03835962|Experimental|Intervention Arm|All participants will be asked to attend one experimental session. During the session, participants will listen one auditory stimulus sequence including sounds and words while EEG activity is recorded using the NeuroCatch Platform™ device.
89190355|NCT05712187|Experimental|ALTO-100|Participants will receive ALTO-100 tablet twice daily, from Day 1 to Day 42 in double blind (DB) treatment period. Eligible participants who will enter the open label (OL) treatment period will receive ALTO-100 tablet twice daily from OL baseline until the end of OL period/early termination visit (Up to 7 weeks).
89404676|NCT04078516||Type 1 diabetes and non-painful neuropathy|No interventions. A series of observationel/expirimental methods for detecting and grading neuropathy will be applied.
89404677|NCT04078516||Type 1 diabetes and no neuropathy|No interventions. A series of observationel/expirimental methods for detecting and grading neuropathy will be applied.
88880576|NCT03835806|Active Comparator|Elastikon - traditional|The participant will be randomized to a treatment arm according to their racing bib number. Even bib numbers will be in the Elastikon treatment arm. The researcher will evaluate the blister and treat according to treatment arm with the following blister treatment device intervention: the blister will be prepped per routine, drained, covered with paper tape, sprayed with adhesive spray and then covered with Elastikon.
88880577|NCT03835806|Experimental|Rocktape - novel|The participant will be randomized to a treatment arm according to their racing bib number. Odd bib numbers will be in the Rocktape treatment arm. The researcher will evaluate the blister and treat according to treatment arm with the following blister treatment device intervention: the blister will be prepped per routine, drained, covered with paper tape and then covered with Rocktape
88880578|NCT03835572|Experimental|CircaHealth|The CircaHealth group will receive access to an online educational module on circadian rhythms and health as their intervention. Every week for six weeks, these participants will receive a new module that contains videos, quizzes, behavioral modification checklists, and journal prompts.
89404678|NCT04078516||Matched controls without diabetes|No interventions. A series of observationel/expirimental methods for detecting and grading neuropathy will be applied.
89404679|NCT05473754||Experimental Group|Families, teachers, and clinicians use SUPER digital platform in addition to usual rehabilitative and educative interventions.
89404680|NCT05473754||Control Group|Families, teachers, and clinicians perform usual rehabilitative and educative interventions.
89404681|NCT05208229||Patients with mCRPC enrolled in the Tumor Institute of Romagna (IRST) 185.03 Lu-PSMA protocol|Patients with mCRPC enrolled in the IRST 185.03 Lu-PSMA study, performing baseline CT and WB-MRI examinations and at least one CT and WB-MRI re-evaluation.
89404682|NCT05207995|Experimental|Patients with Type 1 Diabetes Mellitus receiving standard treatment and Tolerogenic Dendritic Cells|Group 1: Patients with Type 1 Diabetes Mellitus receiving standard treatment and Tolerogenic Dendritic Cells
88880579|NCT03835572|Active Comparator|Sleep hygiene materials|The control group will receive publicly available materials about sleep hygiene from the National Sleep Foundation and/or the American Academy of Sleep Medicine every week for six weeks as their intervention.
88880580|NCT03835494|Experimental|Fallot patients|Fallot patients
88880581|NCT03835494|Experimental|healthy controls|healthy volunteers
88880582|NCT03835104|Active Comparator|CRP in all|"All children will undergo a CRP point-of-care test using a fingerprick of blood and producing a result within 4 minutes using the Afinion 2 (Abbott).~There will be only 1 test at study entry"
88880583|NCT03835104|Experimental|CRP in high risk children only|"Children who are positive on a clinical prediction rule for serious infections in children will undergo CRP point-of-care test using a fingerprick of blood and producing a result within 4 minutes using the Afinion 2 (Abbott).~There will be only 1 test at study entry"
88880584|NCT03834636|Active Comparator|Nanoparticulated composite - self-etch|
88880585|NCT03834636|Active Comparator|Nanoparticulated composite - total-etch|
88880586|NCT03834636|Active Comparator|Nanohybrid composite - self-etch|
88880587|NCT03834636|Active Comparator|Nanohybrid composite - total-etch|
88880588|NCT03834480|Experimental|• Steroid Group (S)|
89190356|NCT05712187|Placebo Comparator|Placebo DB|Participants will receive matching placebo tablet twice daily, from Day 1 to Day 42 in double blind (DB) treatment period.
89404683|NCT05207995|Active Comparator|Patients with Type 1 Diabetes Mellitus receiving standard treatment|Group 2: Patients with Type 1 Diabetes Mellitus receiving standard treatment
88880589|NCT03834480|Experimental|• Platelet rich plasma Group (PRP)|
88880590|NCT03834558|No Intervention|Control Group|They will follow their daily routine without added exercise
88880591|NCT03834558|Experimental|Intervention Group|They will perform the mixed exercise program
88880592|NCT03834324|Experimental|intervention|FES
88880593|NCT03834012|Experimental|Beclomethasone 800 µg per day|Intervention: Drug: Beclomethasone 800 ug per day Daily dose of Beclomethasone 800 ug 4 inhalations 100 μg ex-valve 2 times a day for 6 weeks
88880594|NCT03834012|Active Comparator|Beclomethasone 640 µg per day|Intervention: Drug: Beclomethasone 640 µg per day 4 inhalations 80 μg ex-actuator 2 times a day for 6 weeks
88880595|NCT03834012|Placebo Comparator|Placebo|Intervention: Drug: placebo 4 inhalations 2 times a day for 6 weeks
88880596|NCT03834012|Experimental|Beclomethasone 400 µg per day|Intervention: Drug: Beclomethasone 400 µg per day Daily dose of Beclomethasone 400 µg 2 inhalations 100 μg ex-valve 2 times a day for 6 weeks Intervention: Drug: Placebo 2 inhalations 2 times a day for 6 weeks
88880597|NCT03834090|Experimental|rESWT|the group receiving rESWT
89437490|NCT03795220|Active Comparator|Vaginal progesterone + transfer 6. day|Lutinus + blastocyst warming and transfer 6 days after hCG trigger
88880598|NCT03834090|Active Comparator|supervised exercises|the group receiving supervised exercises
88880599|NCT03833466|Experimental|metformin and chemotherapy|
88880600|NCT03833388|Experimental|TOP1630 Ophthalmic Solution|
88880601|NCT03833388|Placebo Comparator|Placebo to TOP1630 Ophthalmic Solution|
88880602|NCT03832608||Older adults and Sarcopenia|Older adults with and without Sarcopenia living in Valencia Province.
88880603|NCT03830658|Experimental|Structured Intervention on Self-care with AVF|The structured intervention designed for this study was a multimethod approach with the purpose of capturing the learning styles of most patients through the use of written, listening and visual learning (10). Structured Intervention on Self-care with AVF (SISC-AVF) has been designed taking into account the structure of care to the person with AVF developed by Sousa (11). The SISC-AVF had the purpose of identifying the signs/symptoms or situations jeopardizing AVF working and includes both a theoretical and a practical part.
88880604|NCT03830658|Active Comparator|Usual-Care Control|Educational training was given during HD sessions. The dialysis nurse provided information about arteriovenous fistula care and trained the patient when he/she felt it was required. The dialysis units had no documentation concerning the educational training given to patients and the moment to provide such information was not defined, either.
88880605|NCT03830424||Control group|Healthy term newborns without pain relief during pain stimulus (intramuscular K vitamin administration and heel lancing for blood spot examination).
88880606|NCT03830424||Sucrose group|Healthy term newborns with oral application of sucrose during pain stimulus (intramuscular K vitamin administration and heel lancing for blood spot examination).
88880607|NCT03830424||Mother milk group|Healthy term newborns with oral application of mother milk during pain stimulus (intramuscular K vitamin administration and heel lancing for blood spot examination).
89437491|NCT03795220|Active Comparator|Vaginal progesterone + transfer 7. day|Lutinus + blastocyst warming and transfer 7 days after hCG trigger
89437492|NCT03795220|Active Comparator|No progesterone + transfer 6. day|No Lutinus + blastocyst warming and transfer 6 days after hCG trigger
89404684|NCT05102422||1-Propofol|"Induction and maintenance of general anesthesia using the intravenous anesthetic.~Every patient received an intravenous bolus of 0,2 μg.kg-1 sufentanil, and the propofol (P) infusion was started using target-controlled infusion (TCI - Schnider's pharmacokinetic/pharmacodynamic data set); targeting the effect-concentration of 3 µg.ml-1. The effect concentration was gradually increased by 1µg.ml-1 every 2 to 3 minutes until loss of consciousness occurred. 0.1 mg.kg-1 of iv cisatracurium was given to prepare definitive intubation. The P effect-concentration were increased of 1 µg.ml-1 until test laryngoscope was successful and oro-tracheal intubation was performed.~The effect concentration of propofol is reduced to 3 to 4 µg.ml-1 while awaiting the surgical incision. It is then left to the discretion of the anesthetist to add either an iv bolus of sufentanil (0.1 μg.kg-1) and/or an iv bolus of cisatracurium (0.1 mg.kg-1) only if necessary, in the clinical judgment of the practitioner."
89190357|NCT05711290|Experimental|Oxygen Nanobubble First|"In this arm, the oxygen nanobubbles will be provided as a drink first. The oxygen nanobubbles mixture will be mixed with water and oxygenated. This will be provided as a one-time 200ml drink 10 minutes before the start of the 6 minute walk test.~In this arm, the placebo will be provided as the second drink. This will be provided after atleast 2 hours after the first 6 minute walk test is completed. The placebo mixture will be mixed with water and oxygenated. This will be provided as a one-time 200ml drink 10 minutes before the start of the 6 minute walk test."
89404685|NCT05102422||2-Sevoflurane|"Induction and maintenance of general anesthesia using the inhaled anesthetic sevoflurane.~Every patient received an intravenous (iv) bolus of 0,2 μg.kg-1 sufentanil, then sevoflurane (S) is started at one minimal alveolar concentration (2% in 50% oxygen) during mask assisted ventilation. The S concentration is gradually incremented by 2% until the LOC when the mask ventilation became fully assisted. 0.1 mg.kg-1 of iv cisatracurium was given to prepare definitive intubation. The S end-tidal concentration were increased of 1% until the test laryngoscope was successful and oro-tracheal intubation was performed. The end-tidal concentration of sevoflurane is reduced to one MAC while awaiting the surgical incision.~After surgical incision, it is left to the discretion of the anesthetist to add either an iv bolus of sufentanil (0.1 μg.kg-1) and/or an iv bolus of cisatracurium (0.1 mg.kg-1) only if necessary, in the clinical judgment of the practitioner."
89404686|NCT03005067|Experimental|Carbomer 980 (1146A)|Participants will be administered test product (nasal spray) containing carbomer 980 gel. Three actuations per nostril per dose will be applied, each actuation will be 140µL (microliters) i.e. equivalent to 140mg.
89404687|NCT03005067|Placebo Comparator|Placebo|Participants will be administered reference product (nasal spray) containing vehicle without carbomer 980. Three actuations of placebo nasal spray per nostril per dose; each actuation will be 140µL.
89404688|NCT01088789|Other|Cohort 1|"Arm A: Vaccine only. Arm B receives vaccine as well as a single dose of intravenous cyclophosphamide. Arm C: In addition to Vaccine Cohort 3 receives a daily dose of metronomic cyclophosphamide orally.~Only patients from the J0810 study are eligible.~Closed to enrollment."
89004347|NCT04876846|Experimental|Interventional/Observational|The Gen 3 device will be positioned on the maternal abdomen to measure light scattering and absorption for a period of about 10-20 minutes. A second measurement may be obtained for a total of up to 40 minutes. Subject's end their participation in the study after that time period.
89004348|NCT04874285|No Intervention|control group|Women with risk factors for abortion, treated with progesterone
89004349|NCT04874285|Experimental|study group|Women with risk factors for abortion, treated with progesterone and a dietary supplement containing hyaluronic acid, alpha-lipoic acid, vitamin D and vitamin B6
89004350|NCT04862221|Experimental|High-dose methylprednisolone|Intravenous methylprednisolone at an initial dose of 10 mg/kg/day for 3 days, 5 mg/kg/day on day 4.
89004351|NCT04862221|Experimental|Equine anti-thymocyte globulin|Intravenous equine anti-thymocyte globulin at a dose of 40 mg/kg/day for 4 days.
89404689|NCT01088789|Other|Cohort 2|"Cohort 2 receives vaccine as well as a single dose of intravenous cyclophosphamide. Vaccine-naïve cohort.~Closed to enrollment."
89404690|NCT01088789|Other|Cohort 3|"Cohort 3 receives vaccine as well as a single dose of intravenous cyclophosphamide.~Only participants from J1568 study are eligible."
89404691|NCT01088789|Other|Cohort 4|"Cohort 4 receives vaccine as well as a single dose of intravenous cyclophosphamide.~Only participants from J15237 study are eligible."
89404692|NCT01088789|Other|Cohort 5|"Cohort 5 receives vaccine as well as a single dose of intravenous cyclophosphamide.~Only participants from J1766 study are eligible."
89404693|NCT01618279||Tryptase|Patients with clinical manifestations have been discovered and documented symptoms of coronary heart
89404694|NCT00979004|Experimental|ICA-105665|
89404695|NCT05207839|Placebo Comparator|Milk powder without GOS|
89404696|NCT05207839|Active Comparator|Milk powder with GOS|
89404697|NCT00788528|Experimental|Arm A|1600 mg S-2367 (velneperit)
89004352|NCT04862221|Placebo Comparator|Supportive care|Supportive care will be administered as determined by the clinical team at participating clinical sites in accordance with their local practices and standards.
89004353|NCT04859699|No Intervention|Control Group|This arm will include schools and the enrolled families assigned as the control group, who will not receive the COVID-19 health education comic books and video intervention.
89004354|NCT04859699|Active Comparator|COVID-19 Comic Books and Videos|This arm will include schools that are randomized to receive the health education with comic books and videos focused on the benefits of preventive measures for COVID-19.
89004355|NCT04855760|Experimental|REL-1017 25 mg|Participants will take 1 tablet of REL-1017 25 mg, orally, per day in addition to their ongoing antidepressant (ADT).
89004356|NCT04854434|Experimental|Arm A: Selinexor 80 mg|Participants received a single dose of selinexor 80 mg (4 tablets of 20 mg) orally QW on Day 1 of each week of a 42-day cycle (i.e., on Days 1, 8, 15, 22, 29, and 36 of each 42-day cycle) until PD, intolerable toxicity, or withdrawal from the study (maximum exposure: 33 weeks).
89004357|NCT04854434|Experimental|Arm B: Selinexor 80 mg and Pembrolizumab 400 mg|Participants received a single dose of selinexor 80 mg (4 tablets of 20 mg) orally QW on Day 1 of each week of a 42-day cycle (i.e., on Days 1, 8, 15, 22, 29, and 36 of each 42-day cycle) in combination with pembrolizumab 400 mg IV once every 6 weeks of each 42-day cycle until PD, intolerable toxicity, or withdrawal from the study (maximum exposure: 30 weeks).
89004358|NCT04854434|Active Comparator|Arm C: Standard of care (SOC)|Participants received combination of trifluridine and tipiracil 35 mg/m^2/dose tablets orally BID (maximum 80 mg per dose) as SOC on Days 1 through 5 and Days 8 through 12 of each 28-day cycle until PD, intolerable toxicity, or withdrawal from the study (maximum exposure: 11 weeks).
89004359|NCT04851535|Experimental|Jaktinib 100mg Bid|Jaktinib twice daily for 6 consecutive 28-day cycles, orally, empty stomach
89004360|NCT04848090|Other|Neonate WGS Testing|Neonate subjects who are eligible and whose parents consent to study will undergo blood sampling which will be sent for whole genome sequencing and bioinformatics analysis, filtering first a targeted panel of 1722 genes most likely to cause genetic disorders in the first year of life, and then with a whole exome filter if no obvious diagnosis is determined using the 1722 gene panel filter.
89004361|NCT04829201||Obstructive sleep apnea (OSA)|OSA patients who are eligible for either functional septorhinoplasty or oropharyngeal/orthognathic surgery
89004362|NCT04819464|Experimental|Group A: Participants with mild hepatic impairment|Participants with mild hepatic impairment (Child-Pugh Score of 5 to 6).
89004363|NCT04819464|Experimental|Group B: Participants with moderate hepatic impairment|Participants with moderate hepatic impairment (Child-Pugh Score of 7 to 9).
89004364|NCT04819464|Experimental|Group C:Healthy participants|Healthy participants will be matched to the participants with hepatic impairment based on age and body weight.
89404698|NCT05331274|Experimental|exercise group|Only DYMK exercise training will be applied to the exercise group.
89404699|NCT05331274|Experimental|pain training group|In the pain training group, pain training will be applied in addition to the DYMK exercise training.
89404700|NCT03665259|Active Comparator|Pure oxygen group|The patients receive 100% oxygen therapy during the induction phase of induction
89404701|NCT03665259|Experimental|Lower oxygen group|The patients received 60% oxygen therapy during the induction phase of induction
89404702|NCT05213767|Experimental|TQB2916 injection|2.5mg/ quaque die (QD) was used as the initial dose, 21 days as a treatment cycle. The drug is administered on the first day of each cycle until the disease progresses or the investigator judges that it is not suitable for subject to continue to take medicine.
89404703|NCT03533517|Experimental|AccuCinch® Ventricular Restoration System|
89404704|NCT01166737|No Intervention|Control Arm - Chemotherapy only|Chemotherapy for platinum-sensitive Ovarian Cancer can be selected on investigators choice
89404705|NCT01166737|Experimental|Procedure/Surgery|Maximum effort cytoreductive surgery
89404706|NCT00785954|Experimental|A1: KAI-9803|
89404707|NCT00785954|Experimental|A2: KAI-9803|
89190358|NCT05711290|Placebo Comparator|Placebo First|"In this arm, the placebo will be provided as a drink first. The placebo mixture will be mixed with water and oxygenated. This will be provided as a one-time 200ml drink 10 minutes before the start of the 6 minute walk test.~In this arm, the oxygen nanobubbles will be provided as the second drink. This will be provided after atleast 2 hours after the first 6 minute walk test is completed. The oxygen nanobubbles mixture will be mixed with water and oxygenated. This will be provided as a one-time 200ml drink 10 minutes before the start of the 6 minute walk test."
89404708|NCT00785954|Experimental|A3: KAI-9803|
89404709|NCT00785954|Placebo Comparator|A4: Placebo|
89404710|NCT05102032|Active Comparator|Conventional approach|Conventional approach to laparoscopic hysterectomy
89404711|NCT05102032|Experimental|Mini-invasive approach|Mini-invasive approach to laparoscopic hysterectomy
88880608|NCT03830346|Experimental|Experimental|In the experimental group, instrument-assisted soft tissue mobilization techniques and post-isometric horizontal adduction stretches were performed. The technique lasted 20 seconds in a parallel direction and 20 seconds in a perpendicular direction on the posterior shoulder and scapula muscles. While the dominant hand was used to hold the instrument, the other hand was used to tighten the skin medially to ensure an even area of treatment.
88880609|NCT03830346|Experimental|Control|Control group only underwent soft tissue mobilization. With the subject in the supine position, passively adducting the arm horizontally until the first motion barrier and performing active horizontal abduction for 5 seconds at 25% of force. The arm was then taken to the new motion barrier, repeating this process three times.
88880610|NCT03830112|Experimental|Pilates exercise with Theraband|"24 exercise sessions, 3x weekly (on alternate days).~11 Pilates-based exercises with Theraband® (blue color) from week one to four. (hundred,roll up, one leg circle,rolling like a ball,single leg stretch, double leg stretch,single straight leg stretch, double straight leg lower lift, criss-cross, spine stretch, corkscrew).~12 Pilates-based exercises with Theraband® (blue color) from week five to eight.~(saw, rest position, shoulder bridge, side, kick, front ad back, up and down, teaser, swimming, leg pull front, mermaid, seal, push up).~Every participant will perform three isometric repetitions of 30 seconds per exercise, with 10 seconds recovery between repetitions and 30 seconds rest between each exercise."
88880611|NCT03830112|Active Comparator|Pilates exercise|"24 exercise sessions, 3x weekly (on alternate days).~11 Pilates-based mat exercises from week one to four. (hundred,roll up, one leg circle,rolling like a ball,single leg stretch, double leg stretch,single straight leg stretch, double straight leg lower lift, criss-cross, spine stretch, corkscrew).~12 Pilates-based mat exercises from week five to eight. (saw, rest position, shoulder bridge, side, kick, front ad back, up and down, teaser, swimming, leg pull front, mermaid, seal, push up).~Every participant will perform three isometric repetitions of 30 seconds per exercise, with 10 seconds recovery between repetitions and 30 seconds rest between each exercise."
88880612|NCT03830034|Experimental|Amino Acid chelated iron tab 15 mg group|Contain 75 pregnant women will recommended to take ferrotrone(iron chelated amino acid containing 15mg elemental iron) prepared by egyptian pharmaceutical company (nerhadou) once daily (a dose recommended by the company of the product).
88880613|NCT03830034|Active Comparator|Ferrous Fumarate tab 350 mg( 115 mg elemental iron) group|Contain 75 pregnant women will recommended to take ferrous fumarate e.g. Hema-caps (ferrous fumarate 350 mg with elemental iron 115mg) prepared by another egyptian pharmaceutical company (Amoun pharmaceutical company) once daily but in sever cases of iron deficiency anemia (Hb<9g/dl) this dose can be doubled as recommended by the company of the product.
88880614|NCT03837132||Advanced pancreatic cancers|Newly diagnosed patients with advanced pancreatic cancer
89404712|NCT03665181||without modification of dose and without bismuth mask|The cranial CT imaging presrcibed in usual care will be performed without modification of dose and without bismuth mask
88880615|NCT03831360|Experimental|Hatha Yoga|12 weeks of hatha yoga
88880616|NCT03831360|Experimental|Group CBT|12 weeks of group CBT
88880617|NCT03838068|Active Comparator|Mineral trioxide aggegate|white mineral trioxide aggregate (MTA) calcium silicate-based cement
88880618|NCT03838068|Experimental|Biodentine|calcium silicate-based cement that consists of tricalcium silicate, dicalcium silicate, calcium carbonate, calcium oxide, zirconium oxide, and CH.
88880619|NCT03836508|Active Comparator|Medium cut-off|Medium cut-off dialyzers will be used in this group containing 26 randomized patients for three months. At the end of the third month with crossover, this groups of patients will start using high-flux dialyzers.
88880620|NCT03836508|Active Comparator|High-flux|High-flux dialyzers will be used in this group containing 26 randomized patients for three months. At the end of the third month with crossover, this groups of patients will start using medium cut-off dialyzers.
88880621|NCT03832530|Experimental|HIV-uninfected women|"A sample of 150 women, aged 18-35, likely to be fertile based on reproductive health history, with reported personal or partner desire to have a child in the next year and who self-reports having a relationship with a partner she reports as HIV-infected or likely to be HIV-infected (e.g. taking medicine daily, goes to clinic routinely, has HIV-infected partners, he has implied that he is sick but has not disclosed). All women are offered comprehensive safe conception counseling -- this is the intervention -- inclusive of daily oral TDF/FTC as PrEP."
88880622|NCT03832296|Experimental|Weight-Loss Maintenance|Weight Loss Maintenance Intervention
89404713|NCT03665181||with modification of dose and with bismuth mask|e cranial CT imaging presrcibed in usual care will be performed with modification of dose and with bismuth mask
89404714|NCT03665181||without modification of dose and with bismuth mask|e cranial CT imaging presrcibed in usual care will be performed without modification of dose and with bismuth mask
89404715|NCT03665181||with modification of dose and without bismuth mask|e cranial CT imaging presrcibed in usual care will be performed with modification of dose and without bismuth mask
89404716|NCT05101954|Experimental|Group A|
89404717|NCT05101954|Active Comparator|Group B|
89437493|NCT03795220|Active Comparator|No progesterone + transfer 7. day|No Lutinus + blastocyst warming and transfer 7 days after hCG trigger
89530998|NCT02495675|Experimental|High flow nasal cannulas 40 L/min|Subjects will be breathing with high flow nasal cannulas delivering 40 L/min with an inspired fraction of oxygen of 0.21.
89404718|NCT04765475|Experimental|MotivationaI Interviewing Group|Participants in this study group will receive a brief, culturally appropriate, and age-tailored motivational interviewing (MI) intervention targeting facilitators and barriers to appropriate testing, isolation, and care-seeking among young adults and elders. This group will also receive supportive services. Participants will be provided with referrals to needed medical, mental, or behavioral health care and a hygiene kit containing basic hygiene supplies. Additionally, participants will be provided with information on COVID-19 and nearby testing locations. This will include basic information about COVID-19, mask-wearing, how to prevent the spread in the home and managing stress during COVID-19.
88880623|NCT03832296|Active Comparator|Health Education (Attention Control)|Health Education Intervention
89404719|NCT04765475|Experimental|COVID-19 Symptom Monitoring System Group|Participants in this study group will receive daily COVID-19 symptom (CS) text-based monitoring system to prompt more rapid testing at the onset of symptoms. This group will also receive supportive services. Participants will be provided with referrals to needed medical, mental or behavioral health care and a hygiene kit containing basic hygiene supplies. Additionally, participants will be provided with information on COVID-19 and nearby testing locations. This will include basic information about COVID-19, mask-wearing, how to prevent the spread in the home and managing stress during COVID-19.
89404720|NCT04765475|Experimental|MotivationaI Interviewing and COVID-19 Symptom Monitoring System Group|Participants in this group will receive both motivational interviewing and daily COVID-19 symptom (CS) text-based monitoring system. This group will also receive supportive services. Participants will be provided with referrals to needed medical, mental or behavioral health care and a hygiene kit containing basic hygiene supplies. Additionally, participants will be provided with information on COVID-19 and nearby testing locations. This will include basic information about COVID-19, mask-wearing, how to prevent the spread in the home and managing stress during COVID-19.
89404721|NCT04765475|Other|Control Group|Participants in this group will only receive supportive services. Participants will be provided with referrals to needed medical, mental or behavioral health care and a hygiene kit containing basic hygiene supplies. Additionally, participants will be provided with information on COVID-19 and nearby testing locations. This will include basic information about COVID-19, mask wearing, how to prevent the spread in the home and managing stress during COVID-19
89404722|NCT00875108|Experimental|VIAject™|Single injection
89437494|NCT03794349|Active Comparator|Regimen A (chemotherapy, dinutuximab, sargramostim)|Patients receive temozolomide PO, via NG, or G tube on days 1-5, irinotecan hydrochloride IV over 90 minutes on days 1-5, dinutuximab IV over 10-20 hours on days 2-5, and sargramostim SC or IV over 2 hours on days 6-12 of a 21-day cycle. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
88880624|NCT05447208|Experimental|Treatment group|GH is supplemented during ovarian stimulation
88880625|NCT05447208|Active Comparator|Control group|GH is not supplemented during ovarian stimulation.
88880626|NCT05447442||Study group|Patients with anemia will be checked whether they would be assessed by protocol.
89404723|NCT04044209|Experimental|Patients receiving nivolumab and ivosidenib|"Patients who meet eligibility criteria will initiate therapy with the IDH1 inhibitor ivosidenib (AG-120) that will be administered orally on a continuous basis at the dose of 500 mg/day starting at day 1 of each cycle. A cycle will be defined as a 28-day period.~On Cycle 2 day 1 the patient will receive nivolumab 480mg once. This will be repeated on Day 1 of every subsequent cycle. Patient will be treated until progression, transplant or unacceptable toxicity. The patient will be continually monitored on therapy and will undergo scheduled response assessments to evaluate response."
88880627|NCT05444556|Experimental|Imlunestrant + Repaglinide|Repaglinide administered orally alone on day 1 followed by imlunestrant administered orally in combination with repaglinide orally on day 3.
88880628|NCT05444556|Experimental|Imlunestrant + Omeprazole & Dextromethorphan|Omeprazole administered in combination with dextromethorphan orally on day 1 followed by imlunestrant administered orally in combination with omeprazole and dextromethorphan orally on day 3.
88880629|NCT05444556|Experimental|Imlunestrant + Quinidine|"Imlunestrant administered orally on day 1 followed by quinidine alone orally on day 15 to 17.~On day 18, imlunestrant administered orally in combination with quinidine followed by quinidine administered orally on day 19 to 24."
88880630|NCT05444556|Experimental|Imlunestrant + Rosuvastatin & Digoxin|Rosuvastatin administered in combination with digoxin administered orally on day 1 followed by imlunestrant administered orally in combination with rosuvastatin and digoxin orally on day 10.
88880631|NCT05444400|Experimental|Strengthening of lower limbs|The participants of this group will carry out their training following the protocol described. The participants work with strength of lower limbs.
88880632|NCT05444400|Active Comparator|Conventional protocol|The participants of this group will carry out their rehabilitation following the conventional protocol.
89404724|NCT00874796|Experimental|GS-9450 10 mg/day|GS-9450 taken as one 10 mg capsule by mouth once daily
88880633|NCT05443542|Experimental|Virtual Reality Group|Group 1 will play a VR game using an Oculus Quest 2 in a home setting
89190359|NCT05705544|Active Comparator|ILLUMISITE™ Platform (EMN bronchoscopy)|Participants in the ILLUMISITE™ Platform arm will undergo a diagnostic bronchoscopy with the ILLUMISITE™ Platform (EMN) machine.
88880634|NCT05443542|Active Comparator|Active control group|The control group will be given a pamphlet containing exercises affecting working memory, attention and processing speed to be performed in a home setting
88880635|NCT05442294|Experimental|Juego de Llaves group|"This group will receive the prevention program during the academic year in school hours. The prevention program is called Juego de Llaves.~The main goal of this program is to prevent substance use and engagement in other addictive behaviors. It is intended to be delivered by teachers in a six to twelve session format through different modules that cover the following areas: emotional regulation, cognitive strategies, social interaction, free time, education on drugs and life values"
89404725|NCT00874796|Experimental|GS-9450 40 mg/day|GS-9450 taken as one 40 mg capsule by mouth once daily
88880636|NCT05442294|No Intervention|Control group|The control group will receive the usual teaching activities regarding substance use prevention.
88880637|NCT05441904|Experimental|PXL770 500 and 750 mg|Each subject received 1 dose of PXL770 at 500 mg and 1 dose at 750 mg
89404726|NCT00874796|Placebo Comparator|Placebo|Placebo taken as one placebo capsule by mouth once daily
89404727|NCT05100784||Sperm with normal spermogramm and more than 10 millions spermatozoids|Normal spermogramm : concentration ≥15 million / ml or total count> 39 million, progressive mobility ≥32% or total mobility ≥40%
89404728|NCT02658448|Experimental|GTx-024 3 mg|GTx-024 softgel capsules will be administered once daily to a total dose of 3 mg for up to 12 weeks.
89404729|NCT00872300|Experimental|1|
89530999|NCT02495675|Experimental|High flow nasal cannulas 60 L/min|Subjects will be breathing with high flow nasal cannulas delivering 60 L/min with an inspired fraction of oxygen of 0.21.
89190360|NCT05705544|Active Comparator|Ion™ Endoluminal System (SSCB bronchoscopy)|Participants in the Ion™ Endoluminal System arm will undergo a diagnostic bronchoscopy with the Ion™ Endoluminal System (SSCB) machine.
89404730|NCT05208853|Experimental|Anti CD30 CAR T cells|"Patients receive anti CD30 CAR-T cells on day 0 after lymphodepleting treatment.~Route of administration: Intravenous injection.~Lymphodepletion conditioning:~Lymphodepletion will be conducted several days prior to anti CD30 CAR-T cells infusion."
89404731|NCT00977522|Experimental|PF-03463275|
89404732|NCT00977522|Placebo Comparator|Placebo|
89404733|NCT05324176|Active Comparator|Gillian-Barre|Patients will be examined in the supine position. diaphragmatic thickness will is measured on both sides during a deep breath in inspiration and during expiration.
89404734|NCT05324176|Active Comparator|Myasthenia Gravis|Patients will be examined in the supine position. diaphragmatic thickness will is measured on both sides during a deep breath in inspiration and during expiration.
89404735|NCT05324176|Active Comparator|control|Patients hospitalized with neurological disorders without affection of the respiratory system.
89404736|NCT01561651|Experimental|Left Atrial Appendage Occlusion Group|Surgeon will close the left atrial appendage using a suture and/or a surgical stapler or a regulatory approved atrial appendage closure device during the patient's cardiac surgery procedure.
88880638|NCT05441436||Allogeneic hematopoietic stem cell transplantation|Patients in waiting list for and after allogeneic hematopoietic stem cell transplantation.
88880639|NCT05441436||Solid organ transplantation|Patients in waiting list for and after solid organ transplantation.
88880640|NCT05441358||Patients undergoing open heart surgery|"Subjects scheduled for elective cardiothoracic surgery requiring a sternotomy.~Coronary artery bypass grafting (CABG)~Combined CABG and valve surgery~On-pump double or triple valve procedures~Aortic surgery or redo surgery~Off pump CABG as part of a hybrid revascularization approach"
88880641|NCT05440578||olaparib plus bevacizumab treatment group|olaparib plus bevacizumab maintenance therapy in clinical practice and will be conducted in patients with tBRCAwt newly diagnosed high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete response or partial response) to platinum-based chemotherapy following the standard of care from Aug 2018 up to Dec 2020 (the time range could be extended in order to recruit enough eligible subjects as required) at tertiary-referral university hospitals and main cancer centers in China.
89190361|NCT05685212||Group Hypotension.|patients who developed hypotension defined as a decrease in systolic arterial pressure more than 20% of the baseline
88880642|NCT05446662|No Intervention|control group|After randomization, the patients in the control group will be given pre- and post-operative nursing care without any intervention.
88880643|NCT05446662|Experimental|case group|Patients in the case group after randomization will choose one or more of the music therapy, aromatherapy, progressive relaxation exercises and massage therapies according to their health care needs.
89190362|NCT05685212||Group Normotension|patients who did not experience a hypotensive event.
89190363|NCT05669859|Experimental|Telerehabilitation Group|It consists of postoperative patients included in the rehabilitation program consisting of approximately one hour of exercise training to be conducted via remote online video-conference (WhatApp Messenger app) for eight weeks, with 2 sessions per week.
89404737|NCT01561651|No Intervention|No Left Atrial Appendage Occlusion Group|Surgeon will not close the left atrial appendage during the patient's cardiac surgery procedure. Patient will be treated as per best medical practice for stroke prevention in atrial fibrillation. Treatment will be decided by the patient's primary care physician.
89404738|NCT00870818|Experimental|Double-blind Herold Regimen|Patients who had been assigned to Herold Regimen in Segment 2 of Study CP-MGA031-01 were enrolled to gather additional safety and efficacy data.
88880644|NCT05448690||Non-combined approach (Single or Staged)|Patients underwent transnasal approach or craniotomy approach; Patients underwent an initial surgery and a sencond staged surgery several months after the initial surgery
88880645|NCT05448690||Combined approach|Patients underwent a combined approach using transnasal approach and craniotomy approach simultaneously
89404739|NCT00870818|Experimental|Double-blind 33.3% Herold Regimen|Patients who had been assigned to 33.3% Herold Regimen in Segment 2 of Study CP-MGA031-01 were enrolled to gather additional safety and efficacy data.
89404740|NCT00870818|Experimental|Double-blind Curtailed Herold Regimen|Patients who had been assigned to Curtailed Herold Regimen in Segment 2 of Study CP-MGA031-01 were enrolled to gather additional safety and efficacy data.
89404741|NCT00870818|Placebo Comparator|Double-blind Placebo|Patients who had been assigned to Placebo in Segment 2 of Study CP-MGA031-01 were enrolled to gather additional safety and efficacy data.
89404742|NCT00870818|Experimental|Open-label Herold Regimen|Patients who had been assigned to Herold Regimen in Segment 1 of Study CP-MGA031-01 were enrolled to gather additional safety and efficacy data.
89404743|NCT03817463||Patients with T2DM|
89404744|NCT05101642|Experimental|Guided Creeping Technique (GCT)|Novel minimally invasive guided creeping technique
89404745|NCT05207683||patients with pulmonary hypertension|patients who are more than 18 years old , diagnosed with pulmonary hypertension by echocardiography
89404746|NCT05100550|Experimental|Intervention|"This group will receive~Health education regarding nutrition in pregnancy (including the importance of micronutrients, recognizing malnutrition, practicing breastfeeding)~Screening of Low birth weight risk~Zinc Supplementation 20 mg/daily from gestation week for 12 weeks, followed by 12 weeks of supplementation on the third day postpartum."
89404747|NCT05100550|Active Comparator|Control|Standard antenatal care for third trimester will be applied without supplementation of zinc
89404748|NCT00970424|Placebo Comparator|1|placebo, oral tablet administered once daily on background of pioglitazone
88880646|NCT01689402||Intracerebral Hemorrhage Patients|Patients admitted with acute intracerebral hemorrhage within 72 hours after symptom onset.Patients are included in the study for MRI studies
89404749|NCT00970424|Experimental|2|dutogliptin, oral tablet administered once daily on background of pioglitazone
89404750|NCT03075761|Experimental|Intervention|Participants randomized to the intervention arm will receive a Fitbit, formal 30-minute education session on post-thrombotic syndrome (PTS) and benefits of increased physical activity. An individualized activity prescription will be provided and participants will be asked to maintain the target level of activity for 12 weeks after determining their habitual activity in the first 4 weeks.
89404751|NCT03075761|Active Comparator|Control|Participants randomized to the control arm will receive a formal 30-minute education session on post-thrombotic syndrome (PTS) and the benefits of increased physical activity. Their physical activity will be self-reported in an activity log and by the Gordin activity questionnaire over the 16-week intervention period.
88880647|NCT01689480||FSHD training|Only the patients who have participated to the FSHD1 study (NCT01116570) can be included in this study.
89404752|NCT05106790|No Intervention|Standard care arm|The first group will be on standard care as usually being practiced in hospitals.
89404753|NCT05106790|Active Comparator|Ed-counseling arm|The second group will receive monthly educational support ( booklets) with peer counseling sessions in addition to standard care.
89404754|NCT05106790|Active Comparator|mHealth|The third group will receive daily written and voice reminders, and once weekly an education-led video in addition to standard care.
89404755|NCT05106790|Active Comparator|Combined arm|The fourth group will receive educational support (booklets)and counseling sessions every month, daily written and voice reminders, and once weekly an education-led video in addition to standard care.
89404756|NCT03000075|Placebo Comparator|Placebo (Part A)|Participants randomized to receive double-blind (DB) placebo for risankizumab by subcutaneous (SC) injection at Weeks 0 and 4 (Part A).
89404757|NCT03000075|Experimental|Risankizumab 75 mg (Part A)|Participants randomized to receive double-blind (DB) risankizumab 75 mg by subcutaneous (SC) injection at Weeks 0 and 4 (Part A).
89404758|NCT03000075|Experimental|Risankizumab 150 mg (Part A)|Participants randomized to receive double-blind (DB) risankizumab 150 mg by subcutaneous (SC) injection at Weeks 0 and 4 (Part A).
89404759|NCT03883516|Placebo Comparator|No pre-briefing prior to the simulation training|No pre-briefing prior to the simulation training
88880648|NCT01689558|Experimental|Recombine Endostatin|Induction chemotherapy:docetaxel 75mg/m2 iv in day 1 +Cisplatin 80mg/m2 iv in day 1 +human endostatin 7.5mg/m2 iv in day 8-21 and three weeks repeat and total two cycles Synchronous chemotherapy: cisplatin 80 mg/m2 points d1-2, 21days for a cycle, 2 cycles, the same day in radiation therapy. Synchronous chemotherapy in chemotherapy day one recombinant human vascular endothelial inhibin 7.5 mg/M2 / d, 1-14 days, a total of one period of treatment
88880649|NCT01689870|Experimental|Phase 1 Cohort 1|Ipilimumab will be administered at 3 mg/kg i.v. over 90 minutes every 3 weeks for a total of 4 doses, starting on Day 1. Anti-OX40 will be administered at 0.1 mg/kg over 60 minutes only in the first week on Days 1, 3 and 5.
88880650|NCT01689870|Experimental|Phase 1 Cohort 2|Ipilimumab will be administered at 3 mg/kg i.v. over 90 minutes every 3 weeks for a total of 4 doses, starting on Day 1. Anti-OX40 will be administered at 0.2 mg/kg over 60 minutes only in the first week on Days 1, 3 and 5.
89004365|NCT04794335||Patients undergoing resection of intestine for therapeutic purposes|Tissue will be accepted from all eligible donors who consent to having their intestine removed for therapeutic purposes. This tissue would normally be disposed of as medical waste, used for research purposes. The tissue will be studied in the lab in a series of experiments involving GABA agonists and antagonists. Each GABA agonist and/or agonists/antagonist combination will be studied on intestine tissue randomly assigned to one of four groups defined by patient sex (m/f) and the application of inflammatory mediators (+/-). Thus, four groups are needed per GABA agonist and agonist/antagonist combination and seven agonist/antagonist combinations will be tested for a total of 28 experimental groups. But all of these groups will be generated from all patients recruited for the study.
89404760|NCT03883516|Active Comparator|Pre-briefing with the current SE treatment guidelines|pre-briefing with the current SE treatment Guidelines published by the American Epilepsy Society
89404761|NCT03883516|Active Comparator|pre- briefing with consolidated SE treatment guideline|"pre-briefing with the consolidated one page SE treatment guideline"
89404762|NCT00869726|Experimental|Dirucotide|
89404763|NCT00869726|Placebo Comparator|Placebo|
89404764|NCT05213065|Experimental|Treatment Arm|The participants randomized into this arm will receive the SPG block with 0.5% bupivacaine.
89004366|NCT04790253|Active Comparator|PCI followed by brain MR surveillance|"Prophylactic cranial irradiation will be delivered at the dose of 25 Gy in 10 fractions to the whole brain.~Patients must have a brain MRI performed within 28 days before randomisation and at 3, 6, 9, 12, 18 and 24 months.~Extracranial imaging is recommended and will be performed per institutional standards at the discretion of the treating physician."
89004367|NCT04790253|No Intervention|MRI Active Surveillance|Patients must have a brain MRI performed within 28 days before randomisation and at 3, 6, 9, 12, 18 and 24 month. Clinical evaluation will be performed every 3 months.
89004368|NCT04785989||Group A: Healthy volunteers|Healthy volunteers are defined as people without a history of cancer
89004369|NCT04785989||Group B subset-1: Treatment naïve CLL(Chronic Lymphocytic Leukemia) patients with low disease burden|Participants with low disease burden CLL (Chronic Lymphocytic Leukemia) defined as confined to Rai stage 0.
89004370|NCT04785989||Group B subset-2: Treatment naïve CLL patients with low disease burden|Participants with low disease burden CLL (Chronic Lymphocytic Leukemia) defined as confined to Rai stage 0.
89004371|NCT04785989||Group C:Treatment naïve CLL patients with high systemic disease burden|Treatment naïve CLL patients with high systemic disease burden
89004372|NCT04784663|Experimental|Message Exposure|Participants exposed to 4 study videos over a one-month period and complete telephone-based assessments at baseline, 1- and 2-month follow up. Study videos are delivered by study's mobile app downloaded to participants' own Smartphone.
89004373|NCT04784663|Placebo Comparator|Wait List Control|While wait-listed, participants will receive one push notification each week thanking them for participation, informing them that they will receive messages in the near future or reminding them of the length of the study. Telephone-based assessments are completed at baseline, 1- and 2-month follow up. Push notifications are delivered by study's mobile app downloaded to participants' own Smartphone.
89004374|NCT04758117||Participants Receiving Upadacitinib|Participants receiving Upadacitinib for psoriatic arthritis (PsA).
89004375|NCT04739826||flumatinib|flumatinib 600mg QD, fasting administration
89004376|NCT04739826||nilotinib|nilotinib 300mg BID, fasting administration
89404765|NCT05213065|Placebo Comparator|Placebo Arm|The participants randomized into this arm will receive the SPG block with saline.
89404766|NCT03846076|Experimental|Internet-delivered CBT|10 weeks of CBT delivered via the Internet.
88813497|NCT03407924|Experimental|Intervention aerobic exercise (AER)|Participants with traumatic brain injury (TBI) that are enrolled in a comprehensive rehabilitation program (R) will be engaged in an aerobic exercise program (AER). These participants will also receive standard rehabilitation which includes exercise within the physical therapy session. Given that the duration of the rehabilitative program is variable the period of AER training will be no less than 4 weeks and will not exceed 30 weeks. Activity levels will be monitored.
89404767|NCT04423471||Group 1|Psoriasis patients who will receive systemic treatment (mainly methotrexate)
89004377|NCT04730583|Active Comparator|Kybella Injection|
89004378|NCT04730583|Active Comparator|1064nm laser|
89004379|NCT04730583|Active Comparator|755nm laser|
89004380|NCT04728451|Active Comparator|Full-Time Spectacle Wear|Parents are asked to encourage their child to wear the spectacles full-time (all waking hours). A study staff member works closely with families throughout the child's participation to provide support and encouragement and to make suggestions on methods parents can use to maximize spectacle wear.
89004381|NCT04728451|Active Comparator|Ad-Lib Spectacle Wear|Parents are asked to encourage their child to wear the spectacles as much as possible for the initial 30 days after dispensing, and thereafter to continue to offer the spectacles to the child but not force the child to wear them if they resist or refuse. Limited support for parents is provided with regard to maximizing spectacle wear.
89004382|NCT04713046|Experimental|Allogeneic bone marrow transplant|non-myeloablative allogeneic bone marrow transplant (BMT) from a haploidentical relative after vaccination with a therapeutic HPV vaccine series.
89404768|NCT04423471||Group 2|Psoriasis patients who will receive a biological treatment
89404769|NCT04423471||Group 3|Patients with major depression who will receive an antidepressant treatment
89404770|NCT03834532|Experimental|Intervention|Participants randomized to the intervention group will receive a breast reconstruction decision aid. Participants will be provided instructions on how to access and navigate the decision aid. Participants will access the decision aid through a website link that is emailed to them or on a tablet at the study site.
89404771|NCT03834532|Active Comparator|Control|Participants randomized to the control group will receive two website pages on healthy living with breast cancer from an educational website. Participants will be provided instructions on how to access and navigate the website pages. Participants will access the website pages through a link that is emailed to them or on a tablet at the study site.
89404772|NCT03665649|Other|CD133+ human donors|CD133+ cells isolation
89404773|NCT04610450|Experimental|RCI-BE-10|Robot assisted cochlear implant surgery.
89404774|NCT03664635|Experimental|Phase I - Safety Dose Level|In phase I three (3) + 3 patients will be treated with 1x10^5 MB-CART20.1 cells per kg body weight administered intravenously as single dose in the preceding safety dose level
89404775|NCT03664635|Experimental|Phase I - Dose Level 1|In phase I six (6) + 3 patients will be treated with 1x10^6 MB-CART20.1 cells per kg body weight administered intravenously as single dose in the dose level 1
89404776|NCT03664635|Experimental|Phase I - Dose Level 2|In phase I six (6) + 3 patients will be treated with 3x10^6 MB-CART20.1 cells per kg body weight administered intravenously as single dose in the dose level 2
89404777|NCT03664635|Experimental|Phase II|The number of additional patients who will be treated with MB-CART20.1 cells in Phase II is depending on the number of evaluable patients treated with the maximum tolerated dose (MTD) level and the results in Part I
89404778|NCT04414033|Experimental|research group|
89404779|NCT04406545||healthy volunteers|skin laser Doppler perfusion monitoring before and after local thermal hyperemia
89004383|NCT04713046|Experimental|CD8-depleted donor lymphocyte infusion (DLI) per dose escalation scheme|CD8-depleted donor lymphocyte infusion per dose escalation scheme from a haploidentical relative after vaccination with a therapeutic HPV vaccine series.
89004384|NCT04692831|Experimental|HER2-positive malignancy|Participants will have a diagnosis of HER2-positive malignancy
89004385|NCT04692831|Experimental|HER2-low malignancy|Participants will have a diagnosis of HER2-low malignancy
89404780|NCT04406545||cardiovascular disease and COVID-19 infection|skin laser Doppler perfusion monitoring before and after local thermal hyperemia
89404781|NCT04406545||cardiovascular disease without COVID-19 infection|skin laser Doppler perfusion monitoring before and after local thermal hyperemia
89404782|NCT00969722|Experimental|ARM I|Intravenous MAb-3F8 plus Subcutaneous Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)
89404783|NCT00969722|Active Comparator|ARM II|Oral 13-cis-Retinoic Acid (RA) plus Subcutaneous Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)
89404784|NCT03665571||Conventional Activation method|NK cell was incubated with either K562 cells
89404785|NCT03665571||Receptor specific activation method|NK cell was incubated with P815-ULBP1+CD48 cells that trigger NK cell synergy via NKG2D and 2B4
89004386|NCT04677387|Placebo Comparator|Prescribe to Prevent Naloxone Training Module|This a 55-minute online module that covers basic information about naloxone that is relevant to community pharmacists.
89004387|NCT04677387|Experimental|Nalox-Comm|This is a newly developed 30-60 minute online module focused on teaching pharmacists how to overcome naloxone communication barriers.
89004388|NCT04677114|Experimental|Outpatient Parenteral Antibiotic Therapy (OPAT)|Patients with opioid use disorder (OUD) and severe, injection-related infections (SIRI) will be treated with buprenorphine and be discharged with outpatient parenteral antibiotic therapy (OPAT).
89004389|NCT04677114|Active Comparator|Treatment as Usual (TAU)|Patients with OUD and severe, injection-related infections (SIRI) will receive usual care.
89004390|NCT04657575|No Intervention|ASTI|ECT guided with ASTi 2-4 min
89004391|NCT04657575|Active Comparator|Narcotrend|ECT guided with ECT
89004392|NCT04619225|Experimental|TetraGraph monitoring|Subject scheduled to undergo an elective surgical procedure will have TetraGraph device lead placement on either hand at a discretion of the anesthesiologist
89004393|NCT04614337|Experimental|LUM-201 (0.8 mg/kg/day)|
89004394|NCT04614337|Experimental|LUM-201 (1.6 mg/kg/day)|
89004395|NCT04614337|Experimental|LUM-201 (3.2 mg/kg/day)|
89004396|NCT04614337|Active Comparator|rhGH (34 µg/kg/day)|
89404786|NCT05099614|Experimental|Healthy adults|Healthy adults will receive 1.2 mg of naloxone hydrochloride injection solution, administered once via a wearable auto-injector, West Pharma SmartDose Generation I system. The respiratory sensing system under study is used to detect slowed breathing for the purpose of triggering the administration of the naloxone.
89404787|NCT00968942|Active Comparator|Dose A|RT001
89404788|NCT00968942|Placebo Comparator|Dose B|Placebo
89404789|NCT02418689|Experimental|NOV120101 (Poziotinib)|Single arm study with NOV120101(poziotinib) 12 mg PO once daily for 2 weeks followed by a 1-week drug-free interval
89404790|NCT05207371|Experimental|GAIA-102 alone|GAIA-102: 1 vial (2 x 10^8 cells) / dose at a fixed dose, 1 to 3 doses / week for 3 consecutive weeks.
89404791|NCT05207371|Experimental|GAIA-102 with Pembrolizumab|"GAIA-102: 1 vial (2 x 10^8 cells) / dose at a fixed dose, 1 to 3 doses / week for 3 consecutive weeks.~Pembrolizumab：200 mg Administer on Day 1."
89404792|NCT05212987|Experimental|Dose Escalation and Expansion|FCN-098 will be given orally in ascending doses in patients with advanced solid tumor , until the maximum tolerated dose or recommended dose is reached.
89404793|NCT03234790|Active Comparator|Filtered Air Exposure|Exposure for 4 hours to filtered air
89404794|NCT03234790|Experimental|Diesel Exhaust Exposure|Volunteers exposed to different concentrations of diesel exhaust
89404795|NCT00869336|Experimental|Luliconazole Cream 1% - 2 wks|Daily treatment with Luliconazole Cream 1% for 2 weeks
89404796|NCT00869336|Experimental|Luliconazole Cream 1% - 4 wks|Daily treatment with Luliconazole Cream 1% for 4 weeks
89404797|NCT00869336|Placebo Comparator|Placebo Comparator - 2 wks|Daily treatment with Vehicle Cream for 2 weeks
88880651|NCT01689870|Experimental|Phase 1 Cohort 3|Ipilimumab will be administered at 3 mg/kg i.v. over 90 minutes every 3 weeks for a total of 4 doses, starting on Day 1. Anti-OX40 will be administered at 0.4 mg/kg over 60 minutes only in the first week on Days 1, 3 and 5.
88880652|NCT01689870|Experimental|Phase 2 Cohort 4|Ipilimumab will be administered at 3 mg/kg i.v. over 90 minutes every 3 weeks for a total of 4 doses, starting on Day 1. Anti-OX40 will be administered i.v. at the Phase 1 Maximum Tolerated Dose over 60 minutes only in the first week on Days 1, 3 and 5.
88880653|NCT01689948|Experimental|Home rehabilitation therapy|12 weekly sessions of Home rehabilitation therapy
88880654|NCT01689012|Experimental|Facial Exercise|
88880655|NCT05768828||Migraine|Patients suffering from migraine based on ICHD-3 criteria
88880656|NCT05768828||Controls|Patients free of headaches or not suffering from headaches with a frequency that exceeds 1x/year
88880657|NCT05768750|Experimental|Control followed by intervention phase|"All participants will participate in 2 phases : control phase (12-week usual care) followed by an intervention phase (12-week home-based rehabilitation program).~The rehabilitation program consists of three domains of exercises divided by levels of difficulty: sitting balance (16 levels), standing balance (21 levels) and sit-to-stand transfer (12 levels), including 67 exercises. Each individualized home-based rehabilitation program will include 3 to 6 exercises, for a total duration of 15 to 20 minutes."
89190364|NCT05669859|No Intervention|Control Group|It consists of patients who are called for control by the physician periodically for radiological evaluation and physical examination in the post-surgical period, and who are not included in any rehabilitation program as in routine post-surgical practice.
89190365|NCT05655520|Experimental|Cohort 1 (Direct Rollover)|Participants from studies 718-CIH-201 (NCT05107128)/202 (NCT05358821) who will sign the informed consent for study 718-CIH-301 ≤7 days after the last day of the corresponding parent study. Participants will receive Sage-718 from Day 1 up to Day 365.
88880658|NCT05768724|Experimental|İntervention group|METAbolic Syndrome REduction in NAvarra (RESMENA) diet was applied to adolescents with PCOS
88880659|NCT05768724|Experimental|conrol group|American Heart Association (AHA) guidelines based diet was applied to adolescents with PCOS
88880660|NCT05768685||Cases|Right-handed women diagnosed with obesity will be consecutively recruited during their rehabilitative treatment at the Istituto Auxologico Italiano, IRCCS, San Giuseppe Hospital (Italy). Concurrent neurological, neurodevelopmental (e.g., autism), motor, somatosensory and/or psychiatric disorders will be exclusion criteria, as well as the evidence of any skin-related condition possibly affecting sensitivity on the participants' forearm (e.g., eczema, scars)
89404798|NCT00869336|Placebo Comparator|Placebo Comparator - 4 wks|Daily treatment with Vehicle Cream for 4 weeks
89404799|NCT05212675|Other|short daily dialysis|7 days 2hours dialysis
88880661|NCT05768685||Controls|Age-matched, right-handed, healthy women (i.e., with no history of eating disorders) will be recruited outside the hospital through personal contacts of the researchers and word-of-mouth.
89404800|NCT05212675|No Intervention|conventional dialysis|3 times weekly 4hours dialysis
89404801|NCT05090410|Experimental|Filgotinib monotherapy|The administration of filgotinib 200mg/day switched from MTX ± other csDMARDs throughout the study period.
89404802|NCT05090410|Active Comparator|Tocilizumab monotherapy|The administration of subcutaneous tocilizumab 162mg/biweekly switched from MTX ± other csDMARDs throughout the study period.
88880662|NCT05768672||Cases|Right-handed Individuals diagnosed with obesity will be recruited at the beginning of a rehabilitative treatment at the Istituto Auxologico Italiano, IRCCS, San Giuseppe Hospital (Italy).
88880663|NCT05768672||Controls|Age-matched, right-handed, individuals with a healthy weight recruited outside the hospital through personal contacts of the researchers and word-of-mouth
89404803|NCT02371889|Experimental|Topiramate + Medical Management|Topiramate 200 mg/day orally in two divided doses. Dose will be titrated upward over a six-week period, maintained for 6 weeks, then tapered over 6 days + Medical Management sessions for 15-25 minutes per study visit
88880664|NCT05768659||Cases|Participants affected by obesity (the level of body mass index (BMI) higher or equal to 30).
88880665|NCT05768659||Controls|Not-hospitalized participants with a healthy weight
89004397|NCT04613635|Experimental|Stratafix|
89404804|NCT02371889|Placebo Comparator|Placebo Pill + Medical Management|Inactive placebo with dosing schedule matched to intervention group + Medical Management sessions for 15-25 minutes per study visit
89404805|NCT00867698|Experimental|AST-120 (6g)|2 grams TID
89404806|NCT00867698|Placebo Comparator|Placebo A|2 grams TID
89404807|NCT00867698|Experimental|AST-120 (12g)|4 grams TID
89404808|NCT00867698|Placebo Comparator|Placebo B|4 grams TID
89404809|NCT05099458|Experimental|Hepatitis B|
89404810|NCT05207215|Active Comparator|Group A: Video Conferencing|Video conferencing is a 2-way interactive session that is enabled using telecommunication networks and the internet. The investigators will be working with 3rd party provider to create the video conferencing platform. Subjects can login to do SAFE exercises while physiotherapists monitor remotely. Subjects will complete two sessions per week (1hour for each session) for 12 weeks.
89531000|NCT02495753|Experimental|Abdominal and Vaginal Cleansing|In the treatment arm, the vagina will be cleansed prior to usual abdominal cleansing before cesarean section.
88880666|NCT05768646||ALS patients|
88880667|NCT05768646||Healthy controls|
88880668|NCT05768633||Cases|Individuals diagnosed with obstructive sleep apnea (OSA) syndrome recruited at the beginning of rehabilitative treatment at the Istituto Auxologico Italiano, IRCCS, San Giuseppe Hospital (Italy).
88880669|NCT05768633||Controls|Age-matched healthy individuals recruited outside the hospital through personal contacts of the researchers and word-of-mouth.
88880670|NCT05768581|Experimental|Concurrent Training|Experimental: home-based concurrent training composed by strength and aerobic exercises within the same training session
88880671|NCT05768581|Experimental|Strength Training|Experimental: home-based resistance training mode
88880672|NCT05768581|Experimental|Aerobic Training|Experimental: home-based endurance training mode
88880673|NCT05768568|Active Comparator|Group I|Manual Toothbrush.
88880674|NCT05768568|Active Comparator|Group II|Powered Toothbrush
88880675|NCT05768542|Active Comparator|Takotsubo Control|Patients with Takotsubo receiving betablockade
88880676|NCT05768542|Placebo Comparator|Takotsubo Intervention|Patients with Takotsubo receiving placebo
88880677|NCT05768542|No Intervention|Control|Control subjects
88880678|NCT05768503|Experimental|Chidamide + Sintilimab + Bevacizumab Group|The treatment option for the chidamide + sintilimab + bevacizumab is 200 mg of sintilimab IV Drip Q3W, 30 mg of chidamide PO BIW, and bevacizumab 7.5 mg/kg IV Drip Q3W until loss of clinical benefit or development of intolerable toxicity (whichever occurs first), with a maximum treatment duration of 2 years.
88880679|NCT05768503|Active Comparator|FOLFIRI + Bevacizumab Group|The treatment option for the standard second-line FOLFIRI + bevacizumab therapy group is bevacizumab 5 mg/kg IV Drip Q2W, irinotecan 180 mg/m2 IV Drip Q2W, calcium folinate 400 mg/m2 IV Q2W or calcium levofolinate 200 mg/m2 IV Drip Q2W, 5-fluorouracil 400 mg/m2 IV +2400 mg/m2 CIV (infusion 46-48 hr) Q2W until loss of clinical benefit or development of intolerable toxicity (whichever occurs first), with a maximum treatment duration of 2 years.
88880680|NCT05768490|Experimental|early intervention group of brain radiotherapy|the brain radiotherapy started within 1 month of almonertinib the brain radiotherapy here specifically refers to stereotactic radiotherapy
88880681|NCT05768490|Active Comparator|late intervention group of brain radiotherapy|Brain radiotherapy was given within 3 months after brain progression during almonertinib treatment
88880682|NCT05768464|Experimental|study group|"Drug: Toripalimab 240mg, intravenously every 3 weeks~Drug: Axitinib 5 mg orraly twice daily"
88880683|NCT05768451||benign|
88880684|NCT05768451||malignant|
88880685|NCT05768438|Experimental|Mulligan with upper limb movement|"This study arm will receive following therapy~.) Mulligan with upper limb movement."
88880686|NCT05768438|Experimental|Mckenzie exercises with neural mobilizations|"This study arm will receive following therapy~.) McKenzie exercises with neural mobilizations"
88880687|NCT05768412||All patients|All patients undergoing Radial Artery Access requiring interventional radiology.
88880688|NCT05768308|Experimental|Internet CBT-UP intervention (iCBT-UP)|Patricipants in the experimental group will receive online cbt intervention for students with adjustment disorder (iCBT-UP).
88880689|NCT05768308|Active Comparator|Internet Progressive Muscle Realxation Training (iPMR)|Participants from the active control group will receive progressive muscle relaxation training (iPMR).
88880690|NCT05768308|No Intervention|Waiting List|Participants from the waiting list condition will receive access to the choosen intervention after 6-weeks waiting period.
88880691|NCT05768243|Experimental|Treated with hyaluronic acid + SRP|After scaling and root planing, hyaluronic acid (GENGIGEL®) will be applied in the following forms (one ml of 0.8% HA was injected subgingivally once every four weeks), topically (0.2 ml of 0.8% HA applied by the patient twice daily for the following 14 days after the subgingival application).
88880692|NCT05768243|Experimental|Treated with red i-PRF + SRP|The red i-PRF will be injected into the pocket at the point of interdental space after SRP. Moreover, to control bleeding due to the needle tip after the procedure, a saline-soaked sponge will be placed between the lip and the gingiva and removed after 15 minutes. A total of four sessions of i-PRF will be administered to patients at a ten-day interval.
88880693|NCT05768243|No Intervention|Scaling and root planing only|no adjunctive treatment will be done to scaling and root planing
88880694|NCT05768230|Experimental|treatment group A|intravenously injected levosimendan 12.5mg with 5% glucose injection 50ml configuration at 2ml/h for 24h
88880695|NCT05768230|Placebo Comparator|treatment group B|treatment group B: control group with 5% glucose injection 2ml/h for 24h
88880696|NCT05768204|Experimental|Experimental group|Prednisolone, oral, 2 mg/kg.d (maximum dose 60 mg/day), two or three times a day , 5 days.
88880697|NCT05768204|Placebo Comparator|Placebo group|The same amount of placebo was taken orally as the trial for 5 days
88880698|NCT05768152|Experimental|Repeated low-level red-light (RLRL) therapy|single vision spectacles & RLRL
89190366|NCT05655520|Experimental|Cohort 2 (Gap Rollover)|Participants from studies 718-CIH-201 (NCT05107128)/202 (NCT05358821) who will sign the informed consent for study 718-CIH-301 after a gap of >7 days after the last day of the corresponding parent study. Participants will receive Sage-718 from Day 1 up to Day 365.
89531001|NCT02495753|Active Comparator|Abdominal Cleansing Alone|In the control arm, abdominal cleansing will be performed per routine with no vaginal cleansing.
89531002|NCT02495597||Subject-Group|Patients suffering from doctors diagnosed bronchiolitis obliterans
89531003|NCT02495597||Control Group|age- and sex matched to subject-group
89531004|NCT03341897|Experimental|Surgical varicocelectomy|
88880699|NCT05768126|Experimental|Rivastigmine|Rivastigmine, transdermal administration with a dosage of 4.6 and 9.6mg. The patches will be administered daily. The duration will equate to the duration of ECT treatment (that will be clinically determined)
88880700|NCT05768126|Sham Comparator|Sham|Non-active patches will be administered daily. The duration will equate to the duration of ECT treatment (that will be clinically determined)
88880701|NCT05768113||Covixyl-V ELAH|No formal sample size calculation was performed. A total of 30 patients were enrolled and considered as sufficient sample size to compare the estimates of tests treatment with reference treatment
88880702|NCT05768113||Placebo|No formal sample size calculation was performed. A total of 30 patients were enrolled and considered as sufficient sample size to compare the estimates of tests treatment with reference treatment. This one is Placebo
88880703|NCT05768074||Therapists|20 therapists who were already trained will participate in a qualitative interview to gather perceptions and experiences of the therapists about the process of learning and practicing specific CIFFTA competencies from the therapy training platform (time 1 interview) and later, about their unique experiences related to implementation of the Evidenced Based Treatment (EBT), delivery of competencies learned, and the application of EBT in a real-world context (time 2).
88880704|NCT05768074||Agency leaders|16 agency leaders from the main study will participate in qualitative interviews to 2) gain a deeper understanding from leaders of their experiences in facilitating EBTs at their agencies, the identification of barriers that can be addressed by the organizational readiness work (time 1), and later regarding their agencies experience with the platform, consultation process, perceived cost-benefit, and agency readiness (at time 2).
88880705|NCT05768022|Experimental|Cura kinesio-taping|100 subjects (females and males) will receive kinesio taping from origin to insertion on the superficial muscles of Quadriceps femoris (VM,VL, RF).
89004398|NCT04613635|Active Comparator|Vicryl|
89404811|NCT05207215|Active Comparator|Group B: Gamification|Gamification refers to exercise-driven gaming, where games are developed with specifications/parameters that incorporate exercise movements. Currently, the investigators have an ongoing pilot study on game-assisted rehabilitation at SGH Physiotherapy Outpatient clinic and the exercise games are developed by an external company. The investigators will engage an external company to develop exercise games based on the exercises used in SAFE programme. Each game will have different difficulty levels to provide progressive training for subjects
89404812|NCT05207215|Active Comparator|Group C: Self Guided|Subjects in the self-guided exercise programme will be instructed to do SAFE exercises at least twice a week for an hour each by themselves.
89190367|NCT05655520|Experimental|Cohort 3 (De Novo)|Participants who were not previously included in any SAGE-718 clinical study. Participants will receive Sage-718 from Day 1 up to Day 365.
88880706|NCT05768022|Placebo Comparator|Placebo|100 subjects (females and males) will receive placebo kinesio-taping across quadriceps.
88880707|NCT05767983|Experimental|Fat-free milk|Treatment
88880708|NCT05767983|Experimental|Fat-free yogurt|Treatment
88880709|NCT05767983|Experimental|Low-fat cheese|Treatment
88880710|NCT05767983|Experimental|Fruit juice|Treatment
88880711|NCT05767983|Experimental|Snack skipping|Treatment
88880712|NCT05767957|Active Comparator|Control group|
88880713|NCT05767957|Experimental|Intervention group|
88880714|NCT05767879|Experimental|Neo adjuvant BRAF/MEK inhibition in pN1c Melanoma|"Neo adjuvant BRAF/MEK inhibition (encorafenib/binimetinib).~Patients receive encorafenib 450 mg once daily for a period of 8 weeks. Patients receive 45 mg binimetinib twice daily for a period of 8 weeks. After the neo-adjuvant therapie, patients will receive encorafenib 450 mg once daily fand binimetinib 45mg twice daily for 44 weeks."
89190368|NCT05651295|Active Comparator|Personalized Condition|Participants will learn one of three emotion regulation skills (i.e., cognitive restructuring, opposite to emotion action, mindfulness) that is their personal strength, based on pre-Baseline emotion regulation capacities. They will watch an interactive video, created for the current study, in which they are taught the skill that is their personal strength. They will also be asked to complete a survey during the video in which they will input their own examples to practice the skill and to ensure attention to and comprehension of the material.
88880715|NCT05767853||SARS-Cov-2pos pneumonia with moderate/severe lung manifestations with clinical worsening|(PaO2/FiO2<200)
88880716|NCT05767853||SARS-Cov-2pos pneumonia with moderate/severe lung manifestations with clinical improvement|(PaO2/FiO2>200)
88880717|NCT05767827|Active Comparator|Group R|0.35% ropivacaine 20ml, 1.5% lidocaine with adrenaline 10ml = 30 ml
88880718|NCT05767827|Experimental|Group RD|0.35% ropivacaine and 1mcg/ kg dexmedetomidine (20 ml), 1.5% lidocaine with adrenaline (10ml) = 30 ml
88880719|NCT01689792|Active Comparator|CitraFleet|Administration of CitraFleet
88880720|NCT01689792|Experimental|MOVIPREP|Administration of MOVIPREP
88880721|NCT05767814||PsO patients at risk of PsA development|
88880722|NCT05767814||naive to treatment PsA|
88880723|NCT05767814||TNF-inhibitor resistant PsA|
88880724|NCT05767814||IL-17-inhibitor resistant PsA|
88880725|NCT05767814||TNF-inhibitor induced remission PsA|
88880726|NCT05767814||IL-17-inhibitor induced remission PsA|
88880727|NCT05767814||c-DMARDs resistant PsA|
88880728|NCT05767814||c-DMARDs resistant RA|
88880729|NCT05767801||RA patients in sustained clinical and ultrasound remission not changing treatment|
88880730|NCT05767801||RA patients in sustained clinical and ultrasound remission changing treatment|
88880731|NCT05767788|Experimental|Movement with Mobilization (MWM)|Active movement with passive mobilization gliding force
88880732|NCT05767788|Sham Comparator|Sham Movement with Mobilization (Sham MWM)|Active movement with passive light touch gliding force
88880733|NCT05767775||RA patients with BMI≥ 25 eligible to Tofacitinib|
88880734|NCT05767775||RA patients with BMI<25 eligible to Tofacitinib|
88880735|NCT05767723|Active Comparator|Acetylsalicylic acid + ticagrelor OR Acetylsalicylic acid + prasugrel|"Subjects randomized to Dual Antiplatelet Therapy Control Group will be treated with a regimen of acetylsalicylic acid combined with ticagrelor or prasugrel for 12 months.~Acetylsalicylic acid (100 mg/day) + ticagrelor (90 mg twice daily) Or Acetylsalicylic acid (100 mg/day) + prasugrel (10 mg once daily)"
88880736|NCT05767723|Experimental|Ticagrelor alone or prasugrel alone|"All subjects randomized to Monotherapy Group will have acetylsalicylic acid discontinued immediately after randomization.~Subjects randomized to Monotherapy Group will be treated with ticagrelor (90 mg twice daily) or prasugrel alone (10 mg once daily) for 12 months.~Ticagrelor alone (90 mg twice daily) Or Prasugrel alone (10 mg once daily)"
88880737|NCT05767710|Experimental|AI telerehabilitation - Tai Chi|All sessions were conducted online, with participants practicing along with Tai Chi videos while the AI guided the movements throughout the session. A remote rehabilitation program was installed in patients' homes by study team members. Participants who do not know how to use a computer were assisted by their family members.
89404813|NCT05207215|Placebo Comparator|Group D: Self Guided|Subjects in the self-guided exercise programme will be instructed to do SAFE exercises at least twice a week for an hour each by themselves.
88880738|NCT05767710|Active Comparator|general telerehabilitation - Tai Chi|All sessions were conducted in an online format, with participants practicing along with Tai Chi videos while the professional Tai Chi instructors supervised and guided the movements throughout the session. A computer connected to a high-resolution webcam was used to establish real-time remote visual communication between the rehabilitation unit and the patient's home via Tencent conferencing software (Meeting/Tencent).
88880739|NCT05767710|Active Comparator|traditional rehabilitation - Tai Chi|All sessions were conducted offline and implemented by professional Tai Chi instructors. The audio from the video used for the other two groups was utilized to assist the practice of participants in traditional rehabilitation - Tai Chi group.
88880740|NCT05767710|Experimental|AI telerehabilitation - Yi Jin Jing|All sessions were conducted online, with participants practicing along with Yi Jin Jing videos while the AI guided the movements throughout the session. A remote rehabilitation program was installed in patients' homes by study team members. Participants who do not know how to use a computer were assisted by their family members.
88880741|NCT05767710|Active Comparator|general telerehabilitation - Yi Jin Jing|All sessions were conducted in an online format, with participants practicing along with Yi Jin Jing videos while the professional Yi Jin Jing instructors supervised and guided the movements throughout the session. A computer connected to a high-resolution webcam was used to establish real-time remote visual communication between the rehabilitation unit and the patient's home via Tencent conferencing software (Meeting/Tencent).
88880742|NCT05767710|Active Comparator|traditional rehabilitation - Yi Jin Jing|All sessions were conducted offline and implemented by professional Yi Jin Jing instructors. The audio from the video used for the other two groups was utilized to assist the practice of participants in traditional rehabilitation - Yi Jin Jing group.
88880743|NCT05767710|Experimental|AI telerehabilitation - Ba Duan Jin|All sessions were conducted online, with participants practicing along with Ba Duan Jin videos while the AI guided the movements throughout the session. A remote rehabilitation program was installed in patients' homes by study team members. Participants who do not know how to use a computer were assisted by their family members.
88880744|NCT05767710|Active Comparator|general telerehabilitation - Ba Duan Jin|All sessions were conducted in an online format, with participants practicing along with Ba Duan Jin videos while the professional Ba Duan Jin instructors supervised and guided the movements throughout the session. A computer connected to a high-resolution webcam was used to establish real-time remote visual communication between the rehabilitation unit and the patient's home via Tencent conferencing software (Meeting/Tencent).
88880745|NCT05767710|Active Comparator|traditional rehabilitation - Ba Duan Jin|All sessions were conducted offline and implemented by professional Ba Duan Jin instructors. The audio from the video used for the other two groups was utilized to assist the practice of participants in traditional rehabilitation - Ba Duan Jin group.
89404814|NCT05099302|Experimental|cartoon group|In the research, the group whose fear was tried to be reduced by watching cartoons
89404815|NCT05099302|No Intervention|control group|The group whose change in the process was monitored without any intervention in the research
89190369|NCT05651295|Active Comparator|Standardized Condition|Participants will learn all three ER skills: cognitive restructuring, opposite to emotion action, and mindfulness. Participants will be asked to watch three interactive videos that cover each skill to provide an analogue to clinical practice in which clinicians must choose whether to provide greater breadth or depth of skill coverage. These videos will be presented in a randomized order and will include the same surveys for attention and comprehension used in the Personalized Condition.
89004399|NCT04601155||AlloSure Group|Patients will have quarterly AlloSure cfDNA testing (every 3 months) and DSA as part of their post-transplant surveillance for a period of 5 years. For the quarterly AlloSure tests, approximately 20 mL of blood will be obtained in Streck Cell-Free DNA BCT tubes and shipped to CareDx, Inc. (Brisbane, CA) to analyze the presence of donor-derived cell-free DNA.
89004400|NCT04601155||Control Group|The control group was never followed with AlloSure as part of their post-transplant follow-up care. Matched control data will originate from UNOS SRTR data.
89404816|NCT00860288|Experimental|Vildagliptin Dose 1|
89004401|NCT04593121|Experimental|Cohort 1A|Participants will receive Dose 1 of BIIB107 or placebo subcutaneous (SC) on Day 1.
89004402|NCT04593121|Experimental|Cohort 2A|Participants will receive Dose 2 of BIIB107 or placebo SC on Day 1.
89004403|NCT04593121|Experimental|Cohort 3A|Participants will receive Dose 3 of BIIB107 or placebo SC on Day 1.
89004404|NCT04593121|Experimental|Cohort 4A|Participants will receive Dose 4 of BIIB107 or placebo SC on Day 1.
89404817|NCT00860288|Experimental|Vildagliptin Dose 2|
89404818|NCT00860288|Placebo Comparator|Placebo|
89404819|NCT00860288|Active Comparator|Sitagliptin|
89404820|NCT03941275||Subjects undergoing bi-plane fluoroscopy|
89404821|NCT05099224|Experimental|Experimental group receiving mindfulness meditation|The ABC standardized version of mindfulness meditation was used, which includes 5 30-minute weekly sessions of mindfulness meditation. An additional 3-hour educational workshop about the rationale and procedures of intervention was provided before the actual training sessions. The intervention was supervised by PI is an experienced practitioner who received stress-management training at the Psychology Department at Kent State University The participants were asked to sit upright in a comfortable position, place their feet on the floor, and quietly observe and reflect on internal and external stimuli such as breathing, thought, feeling, physical sensation, and sound, without reactions, judgments, or evaluations.
88880746|NCT05767632|Active Comparator|R reference (first dose)|Reference drugs (Vesicare & Betmiga)
88880747|NCT05767632|Experimental|T test|Test drug (Mirfenacin MR)
88880748|NCT05767632|Active Comparator|R reference (second dose)|Reference drugs (Vesicare & Betmiga)
88880749|NCT05767593||Depressed Adults|Adults with a current diagnosis of Major Depressive Episode
88880750|NCT05767593||Healthy Controls|Adults without a current or past diagnosis of Major Depressive Episode
88880751|NCT05767580||alzehimer demantia geriatric|It is a group of individuals over the age of 65, diagnosed with Alzheimer's dementia, able to walk independently, have no communication problems, and volunteer to participate in the research.
88880752|NCT05767580||healty geriatric|This is a group of healthy geriatric individuals over the age of 65 who have not been diagnosed with Alzheimer's dementia, can walk independently, have no communication problems, and volunteered to participate in the study.
88880753|NCT05767541|Experimental|Pilates group|The Pilates technique consists of a series of low-impact exercises that build strength and flexibility throughout the body. All exercises performed 3 days in a week, 3 visits per week total of 9 sessions. In first week participants will perform 1 set of each exercise with 10 repetitions. In second week 2 sets of each exercise with 12 repetitions and in the third week both groups will perform 3 sets of each exercise with 15 repetitions with a rest interval of 2-3 minutes between sets.
88880754|NCT05767541|Active Comparator|Resistance group|Resistance exercises are anaerobic physical exercises, uses low number of repetitions with adjustable intensity contribute to hypertrophy of the muscle fibers and increase in muscle strength. All exercises performed 3 days in a week, 3 visits per week total of 9 sessions. In first week participants will perform 1 set of each exercise with 10 repetitions. In second week 2 sets of each exercise with 12 repetitions and in the third week both groups will perform 3 sets of each exercise with 15 repetitions with a rest interval of 2-3 minutes between sets.
89404822|NCT05099224|No Intervention|Control group|Each of the control group subgroups had 10 participants. The participants were instructed to sit with their eyes closed and relax during the intervention sessions, in order to control for the nonspecific effects of trainer interaction, social interaction, attention, environment, time, and closed eyes. The timings of the control group interventions were similar to those of the experimental groups, whereby if a given experimental group intervention lasted for 30 minutes, the control group participants would be asked to sit with their eyes closed and relax for 30 minutes also.
89404823|NCT03630029|Other|Administer a dose 12mgFeS/9mg SnPP|12 healthy volunteers will be administered a single dose of 12 mg Iron Sucrose and 9 mg of Stannous Protoporphyrin and followed for seven days.
89404824|NCT03630029|Other|Administer a dose 60mgFeS/45 mg SnPP|12 healthy volunteers will be administered a single dose of 60 mg of Iron Sucrose and 45 mg of Stannous Protoporphyrin and followed for seven days.
89404825|NCT03630029|Other|Administer a dose 120mgFeS/90mg SnPP|12 healthy volunteers will be administered a single dose of 120 mg of Iron Sucrose and 90 mg of Stannous Protoporphyrin and followed for seven days.
89531005|NCT02495519|Experimental|imatinib|Imatinib 400 mg/day until disease progression
88880755|NCT05767528||Case Group|Participants who were diagnosed as MIBC and plan to receive neoadjuvant therapy before the surgery, above 18 years of age, regardless of gender
88880756|NCT05767476||Newborns with hypoxic-ischemic encephalopathy treated with therapeutic hypothermia|
88880757|NCT05767450|Experimental|Treated|Probiotic name: Vivomixx® Form: powder Dosage: 4,4g/sachet with 450 billion of lactobacilli and bifidobacteria in a base of maltose Frequency: 1 sachet/day for children <10 year old or 2 sachets/day for children >10 year old Duration: 90 days
89404826|NCT03630029|Other|Administer a dose 180mgFeS/135mg SnPP|12 healthy volunteers will be administered a single dose of 180 mg and 135 mg of Stannous Protoporphyrin and followed for seven days.
89404827|NCT03630029|Other|Administer a dose of FeS/SnPP CKD Arm|12 subjects with stage 3 or 4 CKD will be administered a single dose of Iron Sucrose and Stannous Protoporphyrin selected from the highest dose from the prior arm that evidences the best safety profile. The subjects will be followed for seven days.
89404828|NCT03072875|Experimental|CAMS-RAS|In this single-arm study design, all enrolled patient participants are asked to provide feedback on the CAMS-RAS prototype as it is developed for this study. Feedback will be gathered via survey measure and interview.
89190370|NCT05628675|Experimental|Intervention|"Single-session 90-minute psychoeducational group (Baby CHAT) delivered antenatally."
89404829|NCT05212597|Active Comparator|Sacubitril-Valsartan Group|Participant start Sacubitril/Valsartan tablet 50mg twice a day and uptitrate to 100mg twice a day. Participants take the maximum dose considering blood pressure for a total of 48 weeks.
88880758|NCT05767450|Placebo Comparator|Untreated|Product name: Placebo Form: powder Dosage: 4,4g/sachet containing maltose Frequency: 1 sachet/day for children <10 year old or 2 sachets/day for children >10 year old Duration: 90 days
88880759|NCT05767385|Experimental|Single Arm|Maternal Hyperoxia (MH) will be administered to pregnant patients after their standard of care fetal echocardiogram has been performed at their scheduled fetal cardiology visit at ³28 weeks gestation. The evaluation at ³28 weeks was chosen since gestational age impacts both the cardiovascular and cerebrovascular response to MH.31 The evaluation will extend the duration of the visit by approximately 30 minutes but additional evaluations or visits for the study will not be required.
89190371|NCT05621096|Experimental|Single arm|Subjects will receive 4 gray (Gy) radiation in 2 fractions in the bridging period following lymphocyte pheresis, prior to lymphodepleting chemotherapy and chimeric antigen receptor (CAR) T-cell infusion. Post CAR T-cell infusion radiation therapy will be allowed as determined by study investigator but prespecified at time of radiation oncology consultation.
89190372|NCT05611957|Experimental|LY3437943 (Control)|LY3437943 administered subcutaneous (SC) to participants with normal renal function
89190373|NCT05611957|Experimental|LY3437943 (Severe Renal Impairment)|LY3437943 administered SC to participants with severe renal impairment
89190374|NCT05611957|Experimental|LY3437943 (End-Stage Renal Disease)|LY3437943 administered SC to participants with end-stage renal disease
89190375|NCT05601024|Experimental|Experimental Group|"After obtaining permission from the participants, patients will be called by phone and questions will be asked about Rosenberg Self-Esteem Scale, sociodemographic characteristics, City of Hope Quality of Life Ostomy.~Participants in this group will receive a 4 week of laughter therapy. Laughter therapy will be conducted on whatsapp.~After laughter therapy (after 1 month): Patients will be called again by phone to ask questions about the Rosenberg Self-Esteem Scale and City of Hope Quality of Life Ostomy.~After 3 month: Patients will be called again by phone to ask questions about the Rosenberg Self-Esteem Scale and City of Hope Quality of Life Ostomy."
89190376|NCT05601024|No Intervention|Control Group|"After obtaining permission from the participants, patients will be called by phone and questions will be asked about Rosenberg Self-Esteem Scale, sociodemographic characteristics, City of Hope Quality of Life Ostomy.~After 2 weeks: Patients will be called by phone and asked if they have any complaints about their disease.~After 1 month: Patients will be called again by phone to ask questions about the Rosenberg Self-Esteem Scale and City of Hope Quality of Life Ostomy.~After 3 month: Patients will be called again by phone to ask questions about the Rosenberg Self-Esteem Scale and City of Hope Quality of Life Ostomy."
89190377|NCT05592132|Experimental|Intervention|Patients randomized in this arm will have the virtual reality headset associated to the standard care
88880760|NCT05767320|Active Comparator|open approach for perforated pectic ulcer|repair of perforated peptic ulcer by open technique (exploration)
88880761|NCT05767320|Active Comparator|lap. approach for perforated peptic ulcer|repair of perforated peptic ulcer by laparoscopy
89190378|NCT05592132|No Intervention|Standard care|patients randomized in this arm will have standard care.
89404830|NCT05212597|Placebo Comparator|Amlodipine-Losartan group|Participant start amlodipine/losartan 25/2.5mg once a day and uptitrate to 5/100mg once a day. Participants take the maximum dose considering blood pressure for a total of 48 weeks.
89404831|NCT02450812||Radium-223-dichloride (Xofigo, BAY88-8223)|patients with mCRPC with symptomatic bone metastases
89404832|NCT03629717|Experimental|Denosumab|An ultrasound-guided core needle breast biopsy will be performed on day 1 prior to the intervention. A single dose of subcutaneous denosumab 60mg will be administered immediately after the core biopsy on day 1. This will take place on an outpatient basis. Repeat core-needle biopsy will take place on Day 60 (+/-10 days). Blood samples will also be collected at the time of core-needle biopsy to allow for biomarker assay. Gene expression analyses will be done using NanoString nCounter gene expression system.
89404833|NCT05212519||25-hydroxyvitamin D3≥30 ng/ml|the patients were categorized as having vitamin D sufficiency if its concentrationis ≥30 ng/m
89404834|NCT05212519||25-hydroxyvitamin D3< 30 ng/ml|insufficiency if levels are <30 but ≥20 ng/ml, deficiency when levels are <20 but ≥10 ng/ml and severe deficiency with levels <10 ng/ml
89404835|NCT04473404|Experimental|Probiotic - low dose|Powdered probiotic with a carrier.
89404836|NCT04473404|Experimental|Probiotic - high dose|Powdered probiotic with a carrier.
89404837|NCT04473404|Placebo Comparator|Placebo|Carrier only.
89404838|NCT04250077|Experimental|CRAFT-A|"Participants assigned to the CRAFT-A will have access to a 12-module on-line CRAFT intervention and asked to complete one module weekly for 12 weeks. Modules introduce CRAFT concepts and provide workbooks to assist participants in learning and applying the concepts. The modules include: 1)Introduction to CRAFT; 2) Communication Training; 3) Functional Analysis of Drug Using; 4) Positive Reinforcement; 5) Withdrawing Reinforcement; 6) Allowing Natural Consequences; 7) Problem-solving; 8) Life Enrichment; 9) Suggesting Treatment; 10) Recovery and Relapse; 11) Relationship; and 12) Recap of Skills.~CRAFT-A participants also attend a weekly 60-minute online group sessions facilitated by a CRAFT-certified coach. During weekly group sessions concepts are briefly reviewed, questions are answered, and skills are practiced through role-plays of common situations."
89190379|NCT05581212|No Intervention|Standard of Care (Control phase)|In the current standard of care in Thailand, at time of diagnosis and tuberculosis (TB) treatment initiation, TB patients are being advised to tell their household (HH) contacts to consult at the TB clinic for screening and provision of either curative or preventive treatment - according to the screening outcome.
89190380|NCT05581212|Experimental|Tuberculosis Case-Finding, Treatment and Prevention Public Health Pack (Intervention phase)|"In the selected provinces, individuals (≥18 years) with newly detected bacteriologically confirmed pulmonary Tuberculosis (index TB case) will be sensitized on the importance of HH contact investigation for detection and prevention of TB and stigma reduction.~Index TB cases will be asked to enumerate all persons living in their HH for ≥1 month at the date of TB diagnostic (contact list), and provide their name/age/sex and relationship with the index case.~Screening will be offered to each HH contact, using screening invitation cards that will be provided to the index TB case, to be handed over to each HH contact (or caregiver for children <13 years old).~Urban and Village Health Volunteers (U/VHV),will visit the HH to enhance awareness of the importance of screening for TB case-finding and prevention and facilitate liaison with the hospital.~If active tuberculosis has been formally excluded, they will be eligible to receive the Tuberculosis Preventive Treatment (TPT)."
89404839|NCT04250077|Experimental|CRAFT-C|"Participants assigned to the CRAFT-C groups will have access to a 12-module on-line CRAFT intervention and asked to complete one module weekly for 12 weeks. Modules introduce CRAFT concepts and provide workbooks to assist participants in learning and applying the concepts. The modules include: 1) Introduction to CRAFT; 2) Communication Training; 3) Functional Analysis of Drug Using; 4) Positive Reinforcement; 5) Withdrawing Reinforcement; 6) Allowing Natural Consequences; 7) Problem-solving; 8) Life Enrichment; 9) Suggesting Treatment; 10) Recovery and Relapse; 11) Relationship; and 12) Recap of Skills.~CRAFT-C participants attend a weekly 60-minute individualized on-on-one coaching session with a CRAFT certified coach. During weekly individual sessions concepts are briefly reviewed, questions are answered, and skills are practiced through role-plays of common situations. One-on-one sessions involve role-plays that are tailored to the participants' specific circumstances"
89404840|NCT04250077|Active Comparator|PEER|"Participants assigned to the PEER group will participate in an online peer support forum with other CSOs.~Members of the forum post questions or comments to weekly peer-led discussions and receive responses and feedback from other CSO forum members. Members typically express concerns regarding their IP's wellbeing and ask other members to share any strategies they have employed when dealing with their IPs. Interactions typically, are based either in 12-Step strategies members have learned (usually through Al-Anon or Nar-Anon Family Groups or Family Training Workshops provided by treatment programs) or in CRAFT skills learned (usually from treatment programs or other We The Village members). A staff member from We The Village monitors forum interactions to ensure members are interacting respectfully. This individual also will report any adverse or severe adverse events that members mention online."
89004405|NCT04593121|Experimental|Cohort 7A|Participants will receive Dose 5 of BIIB107 or placebo SC on Day 1.
89004406|NCT04593121|Experimental|Cohort 5A|Participants will receive Dose 5 of BIIB107 or placebo intravenous (IV) on Day 1.
89004407|NCT04593121|Experimental|Cohort 8A|Participants will receive Dose 6 of BIIB107 or placebo SC on Day 1.
89190381|NCT05577559|Active Comparator|Superficial cervical group|patients will receive bilateral ultrasound guided intermediate cervical plexus block using 15 ml of bupivacaine 0.25% for each side.
89404841|NCT00781742|Experimental|1|100 mg iv once per dosing day
89404842|NCT00781742|Experimental|2|150 mg iv once per dosing day
89404843|NCT00781742|Placebo Comparator|3|
89404844|NCT03538223|Experimental|"Radioterapy+Melomics-Health Listening"|"The musical content is composed by an algorithm (named Melomics-Health) with the purpose of acting psychologically and physiologically on the person: the music follows a constant, melodic trend with a reduced musical density; time is unchanged and there are no significant dynamic and tonal variations. Patients will undergo to music listening for 15 minutes (5 tracks lasting 3 minutes each) before radiotherapy session. Appropriate earphones will be used in order to focus their attention on the musical-sound component and to isolate themselves from the external context."
89190382|NCT05577559|Active Comparator|Erector spinae group|patients will receive bilateral ultrasound guided cervical erector spinae plane block using 15 ml of bupivacaine 0.25% for each side at the level of C6.
89190383|NCT05555875|Experimental|IntelliCare with Automated Motivational Messaging and Coach Support|IntelliCare Plus mobile application intervention with two engagement strategies, automated motivational messaging and coach support.
89190384|NCT05555875|Experimental|IntelliCare with Automated Motivational Messaging|IntelliCare Plus mobile application intervention with one engagement strategy, automated motivational messaging.
89190385|NCT05555875|Experimental|IntelliCare with Coach Support|IntelliCare Plus mobile application intervention with one engagement strategy, coach support.
89190386|NCT05555875|Active Comparator|IntelliCare Alone|IntelliCare Plus mobile application intervention with no additional engagement strategy applied.
89190387|NCT05534022|Experimental|Test myopia control lenses (BSL)|Myopia control spectacle lenses (test lenses) will be given to subjects throughout the 24 months trial.
89190388|NCT05531812|Experimental|G2R with individual coaching|
89190389|NCT05531812|Experimental|G2R with group coaching|
89404845|NCT03538223|Experimental|Radiotherapy+Individualized Listening|The musical content is based on the patient's preferred music (chosen by patients with the support of the music therapist) with the purpose of acting psychologically and physiologically on the person. Patients will undergo to music listening for 15 minutes before radiotherapy session. Appropriate earphones will be used in order to focus their attention on the musical-sound component and to isolate themselves from the external context.
88813498|NCT03407924|Active Comparator|rehabilitation (R)|Participants with traumatic brain injury that are enrolled in a comprehensive rehabilitation program. These participants will receive standard rehabilitation. Given that the duration of the rehabilitative program is variable the duration of participation will be no less than 4 weeks and will not exceed 30 weeks. Activity levels will be monitored.
89190390|NCT05531812|No Intervention|Control|
89190391|NCT05521113||Home Rehabilitation Monitoring System|Subjects will complete a home pulmonary rehabilitation program while using a home rehabilitation monitoring system and completing health coaching calls.
89404846|NCT03538223|Other|Radiotherapy+No Music Listening|Patients will undergo the standard treatment (radiotherapy) without music support.
89404847|NCT04474340|Experimental|CCP patients|"Patient has to fulfil the inclusion/exclusion criteria of the ward or the ICU~Valid consent.~Request the CCP from the central blood bank (200-250 ml/dose - can be repeated again in 12 hours) this is through the local hospital blood bank.~How to transfuse CCP:~Dose required is 200-250 ml/hr (one dose, can be repeated in 12 hrs), max total 500ml.~Premedication prior to administration of CCP (Acetaminophen, diphenhydramine,steriods) or according to hospital guidelines."
89404848|NCT04474340|No Intervention|Control|Standard COVID-19 treatment.
89404849|NCT05108350|Experimental|HR20033 FDC 5/500 mg|
88813499|NCT03407924|No Intervention|control (C)|Healthy volunteers' responsiveness to exercise and activity levels will be determined to detect TBI effects.
88813500|NCT03834896|Experimental|Experimental|Patients with dysphagia requiring Stage 1, 2 or 3 thickened fluids as determined by Speech and Language Therapist and who are expected to require provision of Stage 1, 2 or 3 thickened fluids for at least 2 further weeks.
88813501|NCT03835208|Experimental|Low-morning-carbohydrate|"Low morning intake and high evening intake of carbohydrates. This means a distribution of carbohydrate as follows:~10% morning, 40% lunch, 50% dinner. The overall recommendations for macro- and micronutrient intake for GDM patients will be met."
89190392|NCT05515198|Experimental|Arm 1|Patient Education
89190393|NCT05515198|Experimental|Arm 2|Patient Education + Nurse Navigation
89190394|NCT05515198|Experimental|Arm 3|Patient Education + Nurse Navigation + ChatBot
89404850|NCT05108350|Experimental|SHR3824 5mg + Metformin 500 mg XR|
89404851|NCT05108350|Experimental|HR20033 FDC 5/1000 mg|
89190395|NCT05513560|Experimental|IBUDILAST|Participants will receive 20 mg dose (2 pills) twice per day taken by mouth.
89190396|NCT05513560|Experimental|PENTOXIFYLLINE|Participants will receive a 400mg dose (1 pill) 3 times per day taken by mouth.
89190397|NCT05513560|Placebo Comparator|PLACEBO|Participants will receive 2 placebo pills twice per day taken by mouth OR 1 placebo pill 3 times a day taken by mouth.
89404852|NCT05108350|Experimental|SHR3824 5 mg + Metformin 1000 mg XR|
89404853|NCT05108272|Active Comparator|Silicone Sheeting|After explaining and taking consent from the patient about the intervention, pre intervention assessment will be made. Silicone gel sheet (Rystoraº) will be used at scar wound for 16 hours every day for 3 months. After 3 months post intervention assessment will be made.
89404854|NCT05108272|Experimental|Microneedling|After explaining and taking consent from the patient about the intervention, pre- intervention assessment will be made. Derma pen (Dr.Pen auto Microneedle system Ultima-A6) with 36 needles per cm2 will be used with adjustable depth of 0.5mm to 2mm. Micro-needling will be performed in 3 axis,1st in vertical, then horizontal and then oblique direction to the point of uniform petechial bleed. Four sessions at 3 weekly intervals will be performed. Final assessment will be made after 3 months of first intervention
89404855|NCT04596449|Experimental|healthy volunteers|
89404856|NCT00859430|Experimental|Levetiracetam|Levetiracetam 1000 mg Tablet (test) dosed in first period followed by Keppra® 1000 mg Tablet (reference) dosed in second period
89404857|NCT00859430|Active Comparator|Keppra®|Keppra® 1000 mg Tablet (reference) dosed in first period followed by Levetiracetam 1000 mg Tablet (test) dosed in second period
89404858|NCT04240483|Experimental|Intracutaneous sterile water injections (ISWI) group|
88880762|NCT05767281||Children 3 years old|Epidemiological examination of children according to the WHO 2013 methodology, including only an examination of the oral cavity.
88880763|NCT05767281||Children 5-6 years old|Epidemiological examination of children according to the WHO 2013 methodology, including only an examination of the oral cavity.
88880764|NCT05767281||Children 7 years old|Epidemiological survey of adolescents according to the WHO 2013 methodology, including only an examination of the oral cavity.
88880765|NCT05767281||Children 12 years old|Epidemiological survey of adolescents according to the WHO 2013 methodology, including an examination of the oral cavity and a questionnaire.
88880766|NCT05767281||Teenagers 15 years old|Epidemiological survey of adolescents according to the WHO 2013 methodology, including an examination of the oral cavity and a questionnaire.
88880767|NCT05767281||Teenagers 18 years old|Epidemiological survey of adolescents according to the WHO 2013 methodology, including an examination of the oral cavity and a questionnaire.
88880768|NCT05767268||treated with Lokomat|Patients perform a rehabilitation treatment of 15 or 20 sessions with lokomat + 15 or 20 sessions of physiotherapy in 3 or 4 weeks as defined by the clinician. During two or three sessions they wear a wearable device Empatica E4 that measure their electrocardiographic (ECG) activity and electrodermal activity (EDA). They also have a baseline acquisition of these signals in their room at hospital.
88880769|NCT05767255|Active Comparator|basal group bolus|"Insulin Glargine required on an in-hospital basis~Insulin Aspart required on an in-hospital basis"
88880770|NCT05767255|Experimental|insulin degludec + liraglutide ( ideglira)|16 Units once a day
88880771|NCT05767242||MEDEA BabyLab Cohort|
88880772|NCT05767229|Experimental|Carvedilol for 1.5 hrs|Carvedilol 0.2 mg/kg for 1.52 hrs
88880773|NCT05767216|Other|Down syndrome children|Two pairs of twins discordant for Down syndrome and 1 children with mosaic Down syndrome will be recruited. Blood, skin and feces samples will be specifically collected for the purpose of the study.
88880774|NCT05767203|Experimental|Patients with Down syndrome or other Intellectual deficiency of genetic origin|Patients with Down syndrome or with other intellectual deficiency of genetic origin followed at the outpatients clinic of the Institut Jérôme Lejeune.
89404859|NCT04240483|Sham Comparator|Intracutaneous dry injections (IDI) group|
88880775|NCT05767164|No Intervention|Preoperative|
88880776|NCT05767164|Experimental|postoperative (3 months)|
88880777|NCT05767164|Experimental|postoperative (6 months)|
88880778|NCT05767164|Experimental|postoperative (1 year)|
89404860|NCT05212285||Early-stage NSCLC with sarcopenia|Patients diagnosed with NSCLC meeting Stage IA-IIIA as well as sarcopenia by the enrollment
89404861|NCT05212285||Early-stage NSCLC without sarcopenia|Patients diagnosed with NSCLC meeting Stage IA-IIIA but without sarcopenia by the enrollment
89404862|NCT00959114|Experimental|ALV003|ALV003 is an orally administered mixture of two recombinant proteases (cysteine endoprotease B-isoform 2 and prolyl endopeptidase) engineered to degrade gluten into non-immunogenic fragments, by targeting the glutamine and proline residues common in gluten.
89404863|NCT00959114|Placebo Comparator|Placebo comparator|Excipients for ALV003 absent the experimental compounds
89404864|NCT00857090|Experimental|1|Drug
89404865|NCT00857090|Placebo Comparator|2|Vehicle
89404866|NCT04182919|Experimental|Arm 1|Phlai 2 capsules (compound D 8 mg) od evening after meal x 4 weeks
89404867|NCT04182919|Experimental|Arm 2|Phlai 1 capsules (compound D 4 mg) and placebo 1 capsule od evening after meal x 4 weeks
89404868|NCT04182919|Placebo Comparator|Arm 3|Placebo 2 capsules od evening after meal x 4 weeks
89404869|NCT00856934|No Intervention|Control|Wounds covered with standard dressings: three layers of paraffin gauze, standard bandages, elastic bandage.
89404870|NCT00856934|Experimental|PRP|PRP sprayed onto the wound bed with Calcium Choride. Wounds covered with same standard dressings used in control group.
89404871|NCT00856934|Experimental|PRP+K|Keratinocytes suspended in PRP sprayed onto the wound bed with Calcium Choride. Wounds covered with same standard dressings used in control group.
89404872|NCT05212051|Experimental|JS005 150 mg|30 patients will be enrolled in this arm.
89404873|NCT05212051|Placebo Comparator|Placebo 150 mg|10 patients will be enrolled in this arm.
89004408|NCT04593121|Experimental|Cohort 1B|Participants will receive multiple doses of BIIB107 or placebo SC on approximately 4 dosing days.
89004409|NCT04593121|Experimental|Cohort 2B|Participants will receive multiple doses of BIIB107 or placebo SC on approximately 4 dosing days.
89190398|NCT05502913|Experimental|standard of care (SoC) (IO±CTX) + FMT|"Subjects assigned to Arm 1 will be required to swallow FMT capsules in a regimen of ten capsules in the morning and ten capsules in the afternoon on day 1 of the first (chemo-)immunotherapy cycle, and then every three weeks.~abbreviation: Immuno-Oncology (IO) Chemotherapy (CTX)"
89190399|NCT05502913|No Intervention|standard-of-care treatment|Subjects will receive standard-of-care treatment only.
89404874|NCT05212051|Experimental|JS005 300 mg|30 patients will be enrolled in this arm.
89190400|NCT05497401|Experimental|treatment|
89190401|NCT05497401|Placebo Comparator|control|
89404875|NCT05212051|Placebo Comparator|Placebo 300 mg|10 patients will be enrolled in this arm.
89404876|NCT05212051|Experimental|JS005 450 mg|30 patients will be enrolled in this arm.
89404877|NCT05212051|Placebo Comparator|Placebo 450|10 patients will be enrolled in this arm.
89404878|NCT00855764|Experimental|Paclitaxel|
89404879|NCT00959036|Experimental|Treatment Group 1|ATN-103 10 mg every 4 weeks until week 12
89404880|NCT00959036|Experimental|Treatment Group 2|ATN-103 10 mg every 8 weeks until week 12
89404881|NCT00959036|Experimental|Treatment Group 3|ATN-103 30 mg every 4 weeks until week 12
89404882|NCT00959036|Experimental|Treatment Group 4|ATN-103 80 mg every 4 weeks until week 12
89404883|NCT00959036|Experimental|Treatment Group 5|ATN-103 80 mg every 8 weeks until week 12
89404884|NCT00959036|Placebo Comparator|Treatment Group 6|Placebo every 4 weeks
89404885|NCT04129723|Experimental|Perianal Crohn's patient|Stopping biological therapy
89404886|NCT03628729|Experimental|Embrace™ WetBond™ Pit & Fissure Sealant.|pits and fissures will be sealed with bioactive pits-and-fissure sealant
89404887|NCT03628729|Active Comparator|Seal-Rite™ Pit & Fissure Sealant, Pulpdent Corportation, USA|Pits and fissures will be sealed by fluoride releasing resin based pits and fissures sealant
89404888|NCT03619759||Sugammadex|Patients who used sugammadex Sugammadex 1 vial (200mg) intravenous, at the end surgery, before extubation
89404889|NCT03619759||Non-sugammadex|Patients who didn't use sugammadex Pyridostigmine 15~20mg intravenous, at the end of surgery, before extubation
89404890|NCT04474262|Active Comparator|Albumin with placebo|Group A will be given albumin 8g/l of ascitic tap along with placebo for 7 days. Standard albumin therapy will continue (40gm/week)
89404891|NCT04474262|Experimental|Albumin with Midodrine|GROUP B will be given midodrine 7.5 mg to 10 mg tds (keeping the target MAP above 70 mmhg)for 7 days plus albumin same as in other group.
89404892|NCT05211817|Experimental|Complex Intervention with Carnosine|Obese middle aged individuals will be subjected to 3 month complex lifestyle intervention including exercise (3 times per week) nutritional (weekly consultation) and psychological (monthly) interventions combined with oral administration of carnosine in dose 2g per day.
89404893|NCT05211817|Experimental|Complex Intervention with placebo|Obese middle aged individuals will be subjected to 3 month complex lifestyle intervention including exercise (3 times per week) nutritional (weekly consultation) and psychological (monthly) interventions combined with oral administration of identically looking placebo.
88880779|NCT05767138||Bamako Participants|301 male and female participants. Teenagers and adults. Living in two urban regions of Bamako.
89404894|NCT05211817|Experimental|Without complex intervention with carnosine|Obese middle aged individuals will be subjected to standard clinical procedure without lifestyle interventions. Oral administration of carnosine in dose 2g per day will be provided.
88880780|NCT05767125|Experimental|APRV Group|Patients with moderate-to-severe ARDS were supported with APRV.
89404895|NCT05211817|No Intervention|Without complex intervention with placebo|Obese middle aged individuals will be subjected to standard clinical procedure without lifestyle interventions. Oral administration of identically looking placebo will be provided.
88880781|NCT05767125|Active Comparator|LTV Group|Patients with moderate-to-severe ARDS were supported with LTV.
89404896|NCT04418648|Experimental|Toripalimab Consolidation|Patients in experimental group will receive toripalimab consolidation (240 mg) via iv infusion Q3W.
88880782|NCT05767112|Active Comparator|HMB-Ca in water|Investigate whether the pharmacological form of HMB has any impact on its bioavailability and pharmacokinetic profile.
88880783|NCT05767112|Experimental|HMB-Ca in capsules|Avaliate AUC of HMB-Calcium form supplementation.
88880784|NCT05767112|Experimental|HMB-FA|Avaliate AUC of HMB-free acid form supplementation.
88880785|NCT05767099||Patient undergoing general anesthesia with videolaryngoscopy intubation|Patient undergoing general anesthesia with intubation We will explore clinical airway parameters and external ultrasound parameters of the airway.
88880786|NCT05767060|Experimental|BAT7104 Injection 0.1 mg/kg|frequency: Q2W
88880787|NCT05767060|Experimental|BAT7104 Injection 0.3 mg/kg|frequency: Q2W
88880788|NCT05767060|Experimental|BAT7104 Injection 1 mg/kg|frequency: Q2W
88880789|NCT05767060|Experimental|BAT7104 Injection 3 mg/kg|frequency: Q2W
88880790|NCT05767060|Experimental|BAT7104 Injection 10 mg/kg|frequency: Q2W
88880791|NCT05767060|Experimental|BAT7104 Injection 20 mg/kg|frequency: Q2W
88880792|NCT05767060|Experimental|BAT7104 Injection 40 mg/kg|frequency: Q2W
88880793|NCT05765968|Experimental|Double Stimulation Protocol|Double stimulations were performed during the follicular and luteal phases in the same cycle by rFSH&hmg.
88880794|NCT05765968|Active Comparator|Antagonist Stimulation Protocol|The classical antagonist protocol were performed by rFSH,hmg and antagonist.
88880795|NCT05765955|Active Comparator|POLB 001 30 mg|
88880796|NCT05765955|Active Comparator|POLB 001 70 mg|
88880797|NCT05765955|Active Comparator|POLB 001 150 mg|
88880798|NCT05765955|Placebo Comparator|Placebo|
88880799|NCT05764031|Experimental|Clinical pilates group|The clinical pilates group received a total of 40 min of exercise training, including 5 min of warm-up exercises, 30 min of clinical pilates exercises and 5 min of cooldown exercises. Clinical Pilates training was performed as group sessions under the supervision of a physiotherapist Exercise training was provided to the clinical pilates group 2 days a week over a period of 8 weeks.
88880800|NCT05764031|Experimental|Aerobic exercise group|The aerobic exercise group received a total of 40 min of aerobic exercise training, including 5 min of warm-up exercises, 30 min of aerobic cycling exercise and 5 min of cooldown exercises. Aerobic exercises were performed individually under the supervision of a physiotherapist. Aerobic exercises were performed using an upright bike (HS-1200; Hattrick-Pro, Istanbul, Turkey). The exercises were planned as moderate-intensity exercises, at 60-70% of the maximum heart rate (MHR). Exercise training was provided to the aerobic exercise group 2 days a week over a period of 8 weeks.
88880801|NCT05761691|Experimental|Children treated for Early childhood caries under general anesthesia (DGA)|GA group (Study group) the dental treatment was provided as a day care surgery under general anasthesia for healthy child patients.
89404897|NCT04418648|No Intervention|Observation|Patients in this group will receive observation.
89404898|NCT03628183|Active Comparator|Hydrolysate Infant Formula 1|Ready to feed infant formula in can
89404899|NCT03628183|Experimental|Hydrolysate Infant Formula 2|Ready to feed infant formula in bottle
89404900|NCT00781118|Experimental|Treatment|The Treatment arm has alerting enabled in their device during the 6-month randomization period. Treatment arm patients also have alerting enabled in the post-randomization period. Once a patient arrives at the ER, the standard of care triage process for MI is followed and that is outside of the ALERTS Study protocol. With Amendment the Treatment arm was re-defined as an ALARMS_ON group which included A) Control patients after the randomization period and until database lock (4/1/2014); and, b) Treatment patients both during the randomization period and after the randomization period until database lock (4/1/2014).
89404901|NCT00781118|Other|Control|The Control arm has alerting disabled in their device during the 6-month randomization period. Control arm patients also have alerting enabled in the post-randomization period. Once a patient arrives at the ER, the standard of care triage process for MI is followed and that is outside of the ALERTS Study protocol. With Amendment the Control arm was re-defined as an ALARMS_OFF group which included A) Control patients during the randomization period when the Guardian did not have alarms enabled.
89404902|NCT05211583||subfertile women|Subfertile women with regular menses (menstrual cycle length range from 21 to 35 days) will be examined by transvaginal ultrasonography at menstruation, before the anticipated date of ovulation and after ovulation. Serum hormone levels will be measured at menstruation, before ovulation and after ovulation with a serial manner.
89404903|NCT04031599|Active Comparator|Carbohydrate counting|Rapid acting insulin analogue with carbohydrate counting
89404904|NCT04031599|Active Comparator|Simplified qualitative meal size estimation|Rapid acting insulin analogue with simplified qualitative meal size estimation
89190402|NCT05497024||Surveys|Participants may answer questions that are sensitive in nature.
89190403|NCT05497024||Interviews|The interview may occur over phone, web conferencing, or in-person.
88880802|NCT05761691|Experimental|Children treated for Early childhood caries under Local anesthesia (LA)|LA goup (control group) the average number of dental visits was required to finish the treatment plan in local anasthesia group around five to six visits.
88880803|NCT05761262||PATIENTS WITH SMA TYPE I|
88880804|NCT05761262||PATIENTS WITH SMA TYPE II|
89190404|NCT05486312|Experimental|Single arm|Single arm acceptability and feasibility of CT-155.
89404905|NCT00954590|Experimental|Dimebon (latrepirdine)|Dimebon, 20 mg orally three times daily
89404906|NCT00954590|Placebo Comparator|Placebo|Placebo orally three times daily
89404907|NCT02913105|Experimental|LMB763|Oral dose once daily for 12 weeks (84 days)
88880805|NCT05761262||PATIENTS WITH SMA TYPE III|
89190405|NCT05481502|Experimental|Patients receiving advanced therapy medicinal products|
88880806|NCT05759741|Experimental|MIYAIRI 588 group|4 tablets of MIYAIRI 588 were inserted into distal ileostomy once a week for 6 months.
88880807|NCT05759741|No Intervention|control group|The anastomosis stoma was followed up monthly in the outpatient department
88880808|NCT05759065|Experimental|Tele-Brief Behavioral Treatment for Insomnia|
88880809|NCT05759065|Active Comparator|Tele-Cognitive-Behavioral Therapy for Insomnia|
88880810|NCT05757804||Non-disease controls|
89190406|NCT05476224||A history of asymptomatic/mildly symptomatic SARS-CoV2 infection|Participant with asymptomatic or mild symptomatic SARS CoV2 infection that did not require hospitalization at least 6 months prior to study inclusion
89190407|NCT05476224||A history of symptomatic SARS-CoV2 infection hospitalized at the CHU of Dijon outside the ICU|participant with symptomatic SARS CoV2 infection requiring conventional hospitalization at least 6 months prior to study inclusion
89190408|NCT05476224||A history of symptomatic SARS-CoV2 infection hospitalized in the ICU|participant with a symptomatic SARS CoV2 infection requiring an ICU hospitalization at least 6 months prior to study inclusion
89190409|NCT05476224||No history of SARS-CoV2 infection matched on sex and age|participant with no evidence of SARS CoV2 infection and negative SARS-CoV2 serology
89190410|NCT05432258|Experimental|Bulk-fill composite resin|Bulk-fill Ormocer composite resin restorations on the mandibular first molars applied in layers of 4 mm depth
89190411|NCT05432258|Active Comparator|Nano-fill composite resin|Nano-fill composite resin restorations on the mandibular first molars were applied in layers of 2 mm depth
89190412|NCT05427539|Experimental|TEST/CONTROL|Eligible subjects that are habitual contact lens wearers will be randomized into the (test/control) sequence and wear two different study lens designs (test and control designs) one at a time bilaterally over 2 wear periods.
89190413|NCT05427539|Experimental|CONTROL/TEST|Eligible subjects that are habitual contact lens wearers will be randomized into the (control/test) sequence and wear two different study lens designs (test and control designs) one at a time bilaterally over 2 wear periods.
89190414|NCT05417581|Experimental|All patients|a sample of adipose tissue will be collected during the scheduled surgery
89404908|NCT02913105|Placebo Comparator|Placebo|Oral dose once daily for 12 weeks (84 days)
89404909|NCT04724759|Experimental|Opioid-free Anesthesia|Patients in this arm will not receiving opioids but the total intravenous anesthetic during surgery. Patients in this group will receive an infusion of lidocaine, ketamine, or dexmedetomidine supplemented with other intravenous analgesics and intravenous and inhaled anesthetics.
89404910|NCT04724759|No Intervention|Standard Anesthesia|Patients in this arm will undergo the standard of care and receive opioids as part of their anesthetic regimen.
88880811|NCT05757804||PD patients|
88880812|NCT05757804||DLB patients|
88880813|NCT05757804||MSA patients|
88880814|NCT05757427|Experimental|All patients will have an MBI scan with Wavelia #2 in addition to standard reference imaging.|Patients with an investigator assessed discrete breast abnormality of size >1cm and who attend the symptomatic breast unit for assessment as per standard of care protocol will be considered for participation in this clinical investigation.
88880815|NCT05753267|Active Comparator|Control Group|Mesalamine group will receive 1 g mesalamine three times daily for 6 months
88880816|NCT05753267|Active Comparator|Fenofibrate group|Fenofibrate group will receive 1 g mesalamine three times daily plus Fenofibrate (160 mg/day) for 6 months
88880817|NCT05751343|Experimental|TACE-HAIC plus atezolizumab-bevacizumab|transartery chemoembolization and hepatic artery infusion of FOLFOX, simultaneously followed by intravenous of 1200mg atezolizumab plus bevacizumab (15mg/kg)
88880818|NCT05750914|Experimental|Treatment Arm|Broadband light treatment using in-motion protocol
88880819|NCT05737134|Experimental|MA_PESAN APPLICATION|"The content of MA_PESAN includes an understanding of children, children's rights, sexual understanding, the definition of CSA, forms of CSA, the prevalence of CSA, the impact of CSA, risk factors for the occurrence of CSA, the importance of communication with children, who are the perpetrators/predators of CSA, efforts to prevent CSA. The material is presented in the form of text, images, stop motion videos about the prevention of CSA and videos of the jargon TANGKIS, songs about permissible and unacceptable touches, TikTok about permissible and prohibited touches, and discussion columns. The MA_PESAN intervention was carried out for 9 days."
88880820|NCT05737134|No Intervention|common information from the school|The control group was given intervention according to the procedure at each elementary school. However, information was provided regarding preventing child sexual violence under the procedures usually carried out in each elementary school. The time spent was the same as the intervention group.
88880821|NCT05736900|Other|Patients with COVID-19|Patients admitted as in-patients with SARS-CoV-2 Infection
88880822|NCT05708417|Experimental|Weight neutral intervention|"The intervention is based on the concept of Acceptance and Commitment Therapy (ACT) and is conducted by specially trained physiotherapist and a dietician. The intervention in SDOI has the predominantly focus on each individual reflection and realization and is built upon ACT' six core processes. Specific focus on teach participant with different narrative and background and on coaching and back-and-forth dialogue with physiotherapist and dietician. The program is based on up to 13 times attendance within the 12 months intervention period. Part 1: Three to five individual coaching, Part 2: six group sessions and Part 3: one or two individual coaching.~Compliance to the intervention is classified as 'good' if the participants participate for a minimum four out of six group sessions, a minimum three out of five initial individual coaching and a minimum one out of two individual coaching post intervention."
88880823|NCT05708417|Placebo Comparator|Reference group|The reference group will not receive the intervention in the study and only participate in the test/data collection. The reference group will established consisting of participants participating in the SDOI program but, who of some reasons have refused participating in the lifestyle program. In case of insufficient recruitment of participants to the reference group, individuals meeting inclusion criteria such as age and BMI will be recruited via advertising in local newspapers and social media.
88880824|NCT05700227|Experimental|Daily Adaptive External Beam Radiation Therapy|Daily adaptive radiation therapy delivered with Varian Ethos treatment system
88880825|NCT05683275|Experimental|IASTM|"In addition to the home exercise program application, IASTM application will be made for 4 weeks. IASTM will be applied to the affected extremity twice a week for 4 weeks, in total 8 sessions. Participants will be asked to sit comfortably in a chair with back support. IASTM will be applied to the wrist extensor muscles of the participants for 90 seconds in the position where the muscle is tense, with a frequency of 60 beats per minute (Cheatham et al., 2019). The instruments will be applied to the soft tissue at 30º-60º angles, using vaseline as an intermediate, with a multidirectional stroking movement."
88880826|NCT05683275|Experimental|ESWT|ESWT will be applied to the affected elbow two days a week for 4 weeks, a total of 8 sessions, each session 2000 shock 10 Hz frequency, 2.5 bar intensity point and circumferential application. Ultrasound gel will be used as an intermediate in the application. No anesthetic substance will be used before and after the application. Cold applications will be recommended for those who have pain after the application.
89011549|NCT04528888|Active Comparator|LMWH group|The treatments will be initiated as soon as possible after randomization (maximum allowed starting time 12h after randomization). Patients in this group will be administered enoxaparin at standard prophylactic dose (i.e., 4000 UI once day, increased to 6000 UI once day for patients weighting more than 90 kg). The treatment with enoxaparin will be initiated as soon as possible after randomization (maximum allowed starting time 12h after randomization). The treatment will be administered subcutaneously, daily up to ICU discharge. After ICU discharge it may be continued or interrupted in the destination ward up to clinical judgement of the attending physician.
89190415|NCT05412953|Experimental|Supportive care (tonation breathing techniques, questionnaire)|Patients participate in tonation breathing techniques twice daily (or more if pain occurs) for 2 weeks. Patients also complete questionnaire at baseline and at 2 weeks.
89190416|NCT05412082|Experimental|SMART TNT Plan I|"Participants will initiate therapy with neoadjuvant chemotherapy of either six (6) 14-day cycles of 5-fluorouracil + leucovorin + oxaliplatin (FOLFOX) or four (4) 21-day cycles of capecitabine+oxaliplatin (CAPOX). Participants will then receive chemo-radiation therapy according to Plan I as follows:~Plan I (5 weeks):~MRI-guided pelvic IMRT to the Planning Tumor Volume (PTV) at a dose of 50 Grays (gy) delivered in 25 fractions (fx) over 5 weeks.~Concurrent chemotherapy beginning on Day 1 of RT either:~5-FU delivered 5 or 7 days per week.~Capecitabine (Xeloda) delivered 5 days per week.~After completing Plan I, participants achieving complete Clinical Response (cCR) after completing Plan I chemo-radiation will forgo the Plan II boost and continue to follow-up. Participants not achieving cCR will begin Plan II, one week after completing Plan I."
89404911|NCT00771446|Experimental|ELAD (plus Standard of Care)|Treatment with ELAD in addition to standard of care therapy Standard of care therapy defines uniform treatment for ascites, esophageal varices, dietary recommendations, etc.
89190417|NCT05412082|Experimental|SMART TNT Plan II|"Plan II boost RT (1 week): For participants not achieving cCR after chemo-radiation. Participants will receive MRI-guided accelerated radiation therapy (ART) boost to the primary tumor.~Participants achieving a cCR will continue to follow-up. Participants still showing residual tumor will undergo standard of care treatment including surgery and adjuvant chemotherapy per institutional guidelines during follow-up."
88880827|NCT05683275|Experimental|Home Exercise|Static stretching and eccentric strengthening exercises specific to the forearm muscles will be taught and they will be asked to perform 2 sets (morning-lunch-evening) 10 repetitions per day, 5 days a week, for 4 weeks. For strengthening exercises, all patients will be asked to use green (medium resistance) elastic bands, hold them in a tense position for 10 seconds, let them back passively, and rest for 1 minute between sets. In the stretching exercise, they will be asked to stay in the most tense position for 30-45 seconds and rest for 30 seconds between stretching. In case of a painful situation, they will be asked to be informed about their information.
88880828|NCT05679752|Active Comparator|control group|massage therapy will be given to this group of participants
88880829|NCT05679752|Experimental|experimental group|Facial PNFtechnique will be given to this group of participants
89404912|NCT00771446|Other|Standard of Care (Control)|Standard of care treatment Standard of care for acute liver failure patients including medications and treatments typically given to these patients (Pentoxifylline, corticosteroids, abdominal paracentesis, nutritional therapy, etc., if indicated)
89404913|NCT05186467|Active Comparator|Intraperitoneal magnesium sulfate (IP) group|They will receive 100 ml normal saline infused over 10 min immediately before the induction of anesthesia and then continuous infusion of 500 ml normal saline intraoperatively then an intraperitoneal wash of 100 ml normal saline containing 30 mg/kg MgSO4 at the end of laparoscopy.
88880830|NCT05677568||Prospective|"Prospective patients are identified prior to undergoing the Carillon procedure and are only enrolled after being successfully implanted with the Carillon device (prior to hospital discharge). Prospective patients will have applicable medical history and details of the Carillon implant procedure collected from medical records. After the patient is discharged, the patient's primary care specialist (cardiologist) and clinical investigation site staff will coordinate follow-up evaluations. Patients will be evaluated at one (1), six (6), twelve (12) months per standard of care and with annual contact for an additional four (4) years, for a total of five (5) years to assess long-term safety of the Carillon implant."
88880831|NCT05677568||Retrospective/Prospective|"Retrospective/Prospective patients are implanted with the Carillon device and are currently being followed-up per standard of care. These patients will have applicable data collected from their medical records, including medical history, data about the Carillon procedure and follow-up visit data done since receiving the Carillon implant. They will be evaluated prospectively per standard of care follow-up through five (5) years post-implant to assess long-term safety of the Carillon implant."
89190418|NCT05402943||Intervention Group|The group which interventions applied during study.
89404914|NCT05186467|Active Comparator|Intravenous magnesium sulfate (IV) group|They will receive 100 ml normal saline containing MgSO4 30 mg/kg infused over 10 min immediately before the induction of anesthesia and then continuous infusion of 500 ml normal saline containing MgSO4 (8mg/kg) intraoperatively then intraperitoneal wash using 100 ml normal saline at the end of laparoscopy.
89404915|NCT00771134|Experimental|Lu AA39959|
88880832|NCT05668663|Experimental|Elderly patients|"Only one group of patients will be constituted. It will be composed of 453 patients aged more than 75 years old and hospitalized in a geriatric acute care unit.~If the patient consent to participate in the study, a 4-mL blood sample will be collected concomitantly with a general laboratory evaluation that will be performed when the patient enters the unit.~No other sample will be taken., and tThe participation of the patient to the study will end after the result of the test or after the end of the vitamin C supplementation. A telephone call is organized to follow up on any adverse effectswith this blood sample collection.~No further visit is organised."
89190419|NCT05402943||Control Group|None intervention applied.
89190420|NCT05386017||Young adults who were included in the PRALIMAPINES trial as adolescents|The population is all young adults who were included in the PRALIMAPINES trial as adolescents (n=1419); we estimated 852 young adults participated in the follow-up visit (T3). This visit was proposed to investigate long-term social, economic, educational/professional and health (in particular weight) trajectories in adolescents in the PRALIMAP-INÈS intervention
89190421|NCT05384080||Participants With IBD|Participants diagnosed with moderately to severely active IBD (UC or CD) who are currently ongoing vedolizumab IV induction treatment in accordance with the current Summary of Product Characteristics (SmPC) and National Drug Program (NDP) at baseline or receiving vedolizumab ongoing or maintenance IV treatment with the option to switch to vedolizumab SC treatment, will be observed prospectively for 24 months.
89404916|NCT00771134|Placebo Comparator|Placebo|
89404917|NCT00771134|Active Comparator|Quetiapine|
89190422|NCT05320835|Experimental|Experimental|behavioral training with 6 sessions
89190423|NCT05320835|Active Comparator|comparison|Attention control
88880833|NCT05668208|Experimental|extraperitoneal surgery group - TEP inguinal hernia repair|The external sheath of the rectus muscle was seen by passing through the skin and subcutaneous tissue with a mini incision made from the umbilicus edge. A 10 mm trocar was placed in the preperitoneal area and CO2 insufflation was performed. The pressure was set to 14 mmHg. Two more 5 mm trocars were inserted between the umbilicus and the sympisis pubis under the laparoscope. The preperitoneal inguinal area was dissected with a laparoscopic dissector and grasper. The hernia sac was released. A 10x15 cm prolene mesh was spread and fixed to cover the femoral, direct and indirect hernia areas. The trocars were removed by evacuating the CO2 gas. The skin was closed and the operation was terminated.
88880834|NCT05668208|Active Comparator|transperitoneal surgery group - laparoscopic cholecystectomy|With a mini incision made under the umbilicus, the abdomen was entered with a 10 mm trocar. Pneumoperitoneum was created with CO2 gas. Intra-abdominal pressure was set to 14 mmHg. Under the guidance of the laparoscope, one 10 mm trocar from the subxiphoid area and two more 5 mm trocars from the subcostal area were inserted. The cystic artery and cystic duct were clipped and cut by exposing the Callot triangle. Then the gallbladder was separated from the liver bed and taken out of the abdomen. The CO2 in the abdomen was evacuated and the trocars were removed. The fascia defect and skin were closed and the operation was terminated.
88880835|NCT05655442|Experimental|early APM|early APM within 3 and 6 month knee pain symptoms
88880836|NCT05655442|Active Comparator|delayed APM|delayed APM within 6 and 12 month knee pain symptoms
89190424|NCT05307068||Grade B-C stage III-IV periodontitis group|"Grade B: Moderate Moderate bone loss is observed compared to biofilm and % Root Bone Loss/age 0.25 to 1.0 is determined as grade B.~Stage III: Severe Consisted of individuals with interdental AL ≥5 mm, radiographic bone lose extending to middle or apical third of the root, PD≥6 mm and tooth loss due to periodontitis of ≤4.~Grade C: Rapid Rapid bone loss is observed compared to biofilm and % Root Bone Loss/age >1.0 is determined as grade C.~Stage IV:Advanced Consisted of individuals with interdental AL ≥5 mm, radiographic bone lose extending to middle or apical third of the root, PD≥6 mm and tooth loss due to periodontitis of ≥5. Need for complex rehabilition due to: Masticatory dysfunction, Secondary occlusal trauma(tooth mobility degree ≥2) Severe ridge defect,Bite collapse, drifting, flaring. Less than 20 remaining teeth (10 opposing pairs)"
89190425|NCT05307068||Healthy control group|Consisted of individuals with clinically healthy gingiva on an intact periodontium who had a BOP score less than 10% and PD≤3mm, showed no attachment loss or radiographic bone loss.
89190426|NCT05302154|Active Comparator|Standard treatment group|Dental treatment is carried out with tell-show-do technique as a behavioural guidance technique.
89190427|NCT05302154|Experimental|Cartoon movie- passive distraction group|Dental treatment is carried out with showing cartoon movie as a passive distraction during the treatment.
89190428|NCT05302154|Experimental|VR-active distraction group|The active distraction group is treated while wearing the VR headset and interacting with the designed application.
88880837|NCT05655429|Experimental|physical therapy|Physical therapy mainly include aerobic exercises and resistance exercise, flexibility exercises about 150 minutes for ≥2 d/week for 6 months.
88880838|NCT05655429|Active Comparator|arthroscopic partial meniscectomy|The torn meniscus and unstable part were removed with arthroscopic instruments.
88880839|NCT05647681|Active Comparator|"topic analgesic Douloff"|"Patients receive a tpic analgesic douloff in association with an oral treatment placebo"
88880840|NCT05647681|Active Comparator|oral paracetamol|Patients receive oral paracetamol in association with a topic placebo
88880841|NCT05644314|Experimental|Patients with vertebral atherosclerotic stenosis requiring stent implantation|"Referring to the 2015 Chinese Guidelines for Endovascular Interventional Treatment of Ischemic Cerebrovascular Disease, the 2015 Symptomatic Atherosclerotic Sclerotic vertebral artery initiation stenosis: Chinese expert consensus and Subclavian/extracranial vertebral artery stenosis: Chinese expert consensus in 2019 and other guidelines and expert consensus for the diagnosis of symptomatic vertebral artery atherosclerotic stenosis ≥ 50% and non-symptomatic vertebral artery atherosclerotic stenosis ≥ 70% in patients."
88880842|NCT05644171|Other|Patients with motor complete chronic spinal cord injury|
88880843|NCT05644145|Experimental|Yellow fever seropositive vaccinated pediatric population in Argentina|Yellow fever seropositive pediatric population in Argentina after receiving the YF vaccine at 12-23 months of age.
88880844|NCT05642858|Experimental|Intervention Arm|The intervention arm will receive education about HIV and heart disease risk via mobile phone text messages for up to 6 months. They will receive the text messages 3-5 times per week. The messages will include information about HIV and risk of heart disease and information about how to reduce heart disease risk. The intervention arm will also receive brief monthly surveys via a digital research platform.
88880845|NCT05642858|No Intervention|Control Arm|The control arm will not receive the educational text messages. They will receive brief monthly surveys via a digital research platform.
88880846|NCT05642416|Active Comparator|Continuous Infusion|Will receive a continuous infusion of pain medication (0.2% ropivacaine at a rate of 10mL per hour- 5mL per side per hour) via erector spinae plane (ESP) catheter for their postoperative pain following median sternotomy incision.
88880847|NCT05642416|Experimental|Intermittent Bolus|Will receive intermittent boluses of pain medication (30mL bolus of 0.2% ropivacaine every three hours) via erector spinae plane (ESP) catheter for their postoperative pain following median sternotomy incision.
88880848|NCT05636826|Active Comparator|atherolive-drug|In each study population, the patient will be assigned to one of two treatments (atherolive ) using a computer-generated randomization list (1: 1 allocation). The investigator who has the randomization code is not involved in other study procedures and does not interact with participants. The study drug (atherolive) will be prescribed at a dose of 400 mg, once a day for 3 months.
88880849|NCT05636826|Placebo Comparator|atherolive-placebo|In each study population, the patient will be assigned to one of two treatments (placebo ) using a computer-generated randomization list (1: 1 allocation). The investigator who has the randomization code is not involved in other study procedures and does not interact with participants. The study drug (atherolive-placebo) will be prescribed at a dose of 400 mg, once a day for 3 months.
88880850|NCT05632263||EHMRGscore|validation of the EHMRG score for hospitalized patients with acute heart failure in the emergency department
88880851|NCT05631028|Experimental|Group A|Dexmedetomidine pretreatment dose was 0. The effective dose of remimazolam tosilate inhibiting cardiovascular response during double-lumen tracheal intubation in elderly patients (age > 65 years) and young patients (18 < age <65 years) was explored respectively, without the use of dexmedetomidine. The starting dose of Remimazolam tosilate for Injection (36mg per bottle, powder, HengRui medicine, China) was 0.25 mg / kg, and the adjusted unit dose was 0.01mg.
88880852|NCT05631028|Experimental|Group B|Dexmedetomidine hydrochloride injection (200ug per bottle, HengRui medicine, China) was diluted to 50ml and the pretreatment dose was 0.5μg/kg at first 10 mins.The starting dose of Remimazolam tosilate for Injection (36mg per bottle, powder, HengRui medicine, China) was 0.15 mg / kg, and the adjusted unit dose was 0.01mg.
88880853|NCT05631028|Experimental|Group C|Dexmedetomidine hydrochloride injection (200ug per bottle, HengRui medicine, China) was diluted to 50ml and the pretreatment dose was 1μg/kg at first 10 mins.The starting dose of Remimazolam tosilate for Injection (36mg per bottle, powder, HengRui medicine, China) was 0.1 mg / kg, and the adjusted unit dose was 0.01mg.
88880854|NCT05625685|Experimental|Quitbuddy|Participants will be assigned to use a smartphone app (QuitBuddy) that will automatically guide NRT treatment delivery through the integration of ecological momentary assessments (EMA) and GPS into personalized relapse prevention algorithms.
88880855|NCT05625685|Active Comparator|Control|Control is intended to approximate the real-world experience where Participants will use The National Cancer Institute's smartphone app (QuitGuide) and will self-manage NRT treatment delivery based on written instructions.
88880856|NCT05623228|Experimental|Therapy Group A|"Therapy Group A Intervention: Pharmacotherapy in combination with the Integrated Psychological Therapy and Metacognitive Training will be implemented.~5 individuals with schizophrenia"
88880857|NCT05623228|Experimental|Therapy Group B|"Therapy Group B Intervention: Pharmacotherapy in combination with the Integrated Psychological Therapy and Metacognitive Training will be implemented.~2 individuals with schizophrenia"
88880858|NCT05623228|Experimental|Therapy Group C|Therapy Group C Intervention: Pharmacotherapy in combination with the Integrated Psychological Therapy and Metacognitive Training will be implemented.
89404918|NCT00768482|Experimental|Probuphine|Patients are first inducted on SL BPN, and then switched to 4 Probuphine implants
88880859|NCT05623228|Experimental|Therapy Group D|Therapy Group D Intervention: Pharmacotherapy in combination with the Integrated Psychological Therapy and Metacognitive Training will be implemented.
88880860|NCT05623228|Experimental|Therapy Group E|Therapy Group E Intervention: Pharmacotherapy in combination with the Integrated Psychological Therapy and Metacognitive Training will be implemented.
88880861|NCT05623228|Experimental|Therapy Group F|Therapy Group F Intervention: Pharmacotherapy in combination with the Integrated Psychological Therapy and Metacognitive Training will be implemented.
88880862|NCT05623228|Experimental|Therapy Group G|Therapy Group G Intervention: Pharmacotherapy in combination with the Integrated Psychological Therapy and Metacognitive Training will be implemented.
88880863|NCT05623228|Experimental|Therapy Group H|Therapy Group H Intervention: Pharmacotherapy in combination with the Integrated Psychological Therapy and Metacognitive Training will be implemented.
88880864|NCT05622877|Placebo Comparator|Placebo Group|Basic treatment according to the 2014 Chinese Guidelines for Secondary Prevention of Ischemic Stroke/Transient Ischemic Attack and placebo granules (6g/ bag, one bag each time, twice a day after meals);
88880865|NCT05622877|Experimental|Qushi Formula Group|Basic treatment according to the 2014 Chinese Guidelines for Secondary Prevention of Ischemic Stroke/Transient Ischemic Attack and Qushi Formula granules (6g/ bag, one bag each time, twice a day after meals);
88880866|NCT05622877|Experimental|Zhu's Wenban Formula Group|Basic treatment according to the 2014 Chinese Guidelines for Secondary Prevention of Ischemic Stroke/Transient Ischemic Attack and Zhu's Wenban Formula granules (6g/ bag, one bag each time, twice a day after meals);
88880867|NCT05605704|Active Comparator|atherolive|In each study population, the patient will be assigned to one of two treatments (atherolive or placebo) using a computer-generated randomization list (1: 1 allocation). The investigator who has the randomization code is not involved in other study procedures and does not interact with participants. The study drug (atherol) will be prescribed at a dose of 400 mg, once a day for 3 months. The placebo will be prescribed identically.
88880868|NCT05605704|Placebo Comparator|placebo atherolive|In each study population, the patient will be assigned to one of two treatments (atherolive or placebo) using a computer-generated randomization list (1: 1 allocation). The investigator who has the randomization code is not involved in other study procedures and does not interact with participants. The study drug (atherol) will be prescribed at a dose of 400 mg, once a day for 3 months. The placebo will be prescribed identically.
88880869|NCT05604599|Active Comparator|Intranasal dexmedetomidine group|30 patients will receive 1µg/kg dexmedetomidine diluted in 10ml 0.9% saline intranasally preoperative administered to each naris as drops 45 -60 min before the operation +infusion saline.
88880870|NCT05604599|Active Comparator|Intravenous dexmedetomidine group|30 patients will receive a dose of dexmedetomidine 1 µg/kg diluted in 10ml 0.9% saline infused over 45- 60 min before induction of anesthesia + intranasal saline.
88880871|NCT05594511|Experimental|Experimental Group (muscle-energy technique)|Mandibular muscle energy technique: In the supine position, the patient will open the mouth and perform isometric contractions for closure controlled by the physiotherapist. Passively, the physiotherapist will increase the range of mandibular opening. The technique consists of performing 3 sets, with 3 isometric contractions in each set of 3 seconds each. At the end of each set, the physiotherapist will passively try to gain mouth opening in order to continue the rest of the sets. At the end of all sets, gently return to the resting position.
88880872|NCT05594511|Sham Comparator|Control Group (sham technique)|Sham technique: In the supine position, the physiotherapist will place his hands under the patient's skull with the fingertips in contact with the suboccipital musculature for 5 minutes, without applying pressure or therapeutic intent. The objective is to provide a stimulus as similar as possible to the original Suboccipital Inhibition Technique, but without force of movement. The patient will keep the eyes closed for the duration of the technique.
88880873|NCT05576220|Experimental|Intervention group|Subjects being treated for a cancer diagnosis with a plan for outpatient transplant or CAR-T therapy
88880874|NCT05576220|No Intervention|Control Group|Retrospective data from the control group comprised of 105 patients directly preceding the intervention group who are underwent stem cell transplant or CAR-T therapy. Such control group information will be obtained via a research data request. Only de-identified data will be obtained for these subjects.
88880875|NCT05572840|Experimental|Training and activities|"The training program consists of two modules. The 1st module consists of a theoretical lecture (PowerPoint presentation) and an activity (application of hygienic handwashing by the researcher) explaining what to do for hygienic handwashing. The 2nd module consists of the theoretical explanation (PowerPoint presentation) in which the correct mask usage is explained and the activity (the make your own mask activity by painting the masks)."
88880876|NCT05543837|Experimental|Capsaicin .66μMol/ml|Group receiving .66μMol/ml
88880877|NCT05543837|Experimental|Capsaicin .99μMol/ml|Group receiving .99μMol/ml
89404919|NCT00766688|Experimental|25 mg/day AVE5530|
89404920|NCT00766688|Experimental|50 mg/day AVE5530|
89404921|NCT00766688|Placebo Comparator|Placebo|
89404922|NCT00840866|Experimental|1|
89404923|NCT00840866|Active Comparator|2|
88880878|NCT05534867|Experimental|Mandala coloring group|Mandala painting will be applied to pregnant women who have anxiety related to pregnancy.
88880879|NCT05534867|No Intervention|Control group|Participants in this group will consist of people who do not routinely do any practice on their own to reduce anxiety symptoms.
89404924|NCT05106556|Active Comparator|Control Group|"Patients in this group will receive conventional chest physiotherapy, two times a day, 5 days a week for 8 weeks. After the training given by the physiotherapist one exercise session will be supervised in a clinic per week, other sessions will be performed at home.~Maximal inspiratory mouth pressure measurements will be measured once a week to eliminate the effect of learning, however the training intensity will remain at the lowest intensity of the device for 8 weeks and will not be increased."
89404925|NCT05106556|Experimental|Inspiratory Muscle Training (IMT) Group|"In addition to conventional chest physiotherapy programme, patients in this group will also receive inspiratory muscle training at %30 of the maximal inspiratory mouth pressure (MIP) value of at least five days a week, for 15 minutes twice days, for 8 weeks at home. One exercise session will be supervised in a clinic per week, other sessions will be performed at home.~Maximal inspiratory mouth pressure measurements will be measured once a week. The training intensity will be increased weekly. At this rate it is 30% of the maximal inspiratory pressure value."
88880880|NCT05514561||Patients with chronic lower gastrointestinal symptoms|We enroll adults older than 18 years with chronic lower GI symptoms for more than 1 month and are scheduled for a colonoscopy. The lower GI symptoms consist of any of the followings; lower abdominal pain, constipation, diarrhea, rectal bleeding, change in stool caliber, and abdominal bloating.
89404926|NCT00840632|Experimental|Trandolapril|Trandolapril 4 mg Tablet (test) dosed in first period followed by Mavik® 4 mg Tablet (reference) dosed in second period
89404927|NCT00840632|Active Comparator|Mavik®|Mavik® 4 mg Tablet (reference) dosed in first period followed by Trandolapril 4 mg Tablet (test) dosed in second period
89404928|NCT00840476|Experimental|Meloxicam|Meloxicam 15 mg Tablet (test) dosed in first period followed by Mobic® 15 mg Tablet (reference) dosed in second period
89404929|NCT00840476|Active Comparator|Mobic®|Mobic® 15 mg Tablet (reference) dosed in first period followed by Meloxicam 15 mg Tablet (test) dosed in second period
89404930|NCT03665103|Experimental|Laser-assisted ICSI|
88880881|NCT05512000|Experimental|Contrast A|Feedback vs no feedback with massed trials
88880882|NCT05512000|Experimental|Contrast B|Feedback vs no feedback with spaced trials
88880883|NCT05512000|Experimental|Contrast C|Spaced vs massed trials without feedback
88880884|NCT05512000|Experimental|Contrast D|Spaced vs massed trials with feedback
88880885|NCT05497999|Experimental|Treatment Group|With Black and White Subgroups
88880886|NCT05497999|Active Comparator|Control Group|With Black and White Subgroups
88880887|NCT05496647|Experimental|Virtual Reality (VR)|Virtual Reality Application (VR) VR group patients will be shown VR videos that include landscapes such as nature and the sea, giving people a feeling of comfort and peace, and making them feel like they are inside. During the surgical procedure, VR videos will be watched for an average of 20 minutes with X-brand VR glasses. In the research, similar studies will be examined and 360o VR video, which is a licensed product with atmospheric music background, containing relaxing nature images and nature sounds will be used.
88880888|NCT05496647|Experimental|Music Therapy|"Music Therapy Application During the surgical procedure, an mp3 player, and music therapy CDs of uşşak and Hüseyni will be used. (Oline will also create a list from music platforms (fizzy-Spotify, etc.)) Before starting the procedure, the patients will be asked about their music preferences and the music will be played to the patients (20 minutes) during the procedure in line with their preferences. Headphones provided by the researcher will be used for patients with headphones, and for patients without headphones.~The music authorities used (hüseyni and uşşak) will be provided and used by order, by obtaining the necessary permissions from the official site of TÜMATA."
88880889|NCT05496647|Experimental|Stress Ball Application|"Stress Ball Application A sufficient number of stress balls will be provided by the investigator for each patient to use separately before starting the study. Before starting the day-to-day gynecological surgery, patients in the stress ball group will be given a round, colored, medium-hard, compressible Knaftmed ball made of high-quality silicone. To avoid implying that the procedure is inherently stressful, it will be referred to as a squeezing ball when instructing patients about stress ball application.~During the surgical procedure, it will be said that he can squeeze the stress ball as often as he wants for about 20-25 minutes and the stress ball will be given to each patient."
88880890|NCT05496647|Experimental|Control|During the process; Women in the control group will not undergo any intervention other than routine surgery.
88880891|NCT05486026|Active Comparator|Duloxetine tablet|Patient in the first group (case) will receive duloxetine tablet 30mg for two weeks then titrated up to duloxetine 30mg BID. Patients will be instructed to take the medication with meals for 13 weeks .
89404931|NCT03665103|No Intervention|conventional ICSI|
89404932|NCT03665025|Experimental|immediate implant placement with xenograft|Immediate implant placement with the use of xenograft as grafting material
88880892|NCT05486026|Active Comparator|NSAID(non steroidal anti inflammatory)|patient in the second group will receive NSAID(non-steroidal anti inflammatory) drugs for 13 weeks
88880893|NCT05463549|Experimental|Informative video|The research group will be exposed to an informative instructional film before the procedure.
88880894|NCT05463549|No Intervention|No video|The control group will undergo amniocentesis with information given as accepted by standard-of-care.
88880895|NCT05449587||Primary /Revision Augmentation Cohort|Patients that underwent primary and/or revision augmentation from 3 years or more postoperatively.
88880896|NCT05445596|Experimental|FCT Evaluation|This study uses single case experimental design in which participants will serve as their own control. Each participant will receive the treatment (functional communication training) and will participate in comparison conditions to evaluate the effects of the treatment. We will evaluate the effects of functional communication training during three treatment phases: initial implementation, schedule thinning, and generalization.
88880897|NCT05438654|Other|Cohort of patients presenting to emergency department with abdominal right upper quadrant pain|This study is a single arm study analyzing a prospective population of patients presenting at the emergency department complaining of non-traumatic right upper quadrant abdominal pain. The analysis of the diagnostic approach will take place before and after the intervention on a same patient. The intervention is the use of Point of Care Ultrasound bedside.
89404933|NCT03665025|Experimental|immediate implant using mixed allograft and xenograft|Immediate implant placement with using mixture of allograft and xenograft material
89404934|NCT00765830|Experimental|1|50mg qd vildagliptin
89404935|NCT00765830|Placebo Comparator|2|Placebo
88880898|NCT05438251|Experimental|Diabetic Foot Ulcers (TEXAS 3A, 3B)|"Name: Fespixon Cream~Dosage form: Topical cream, 15 g ointment per tube~Active ingredients: 1.25% extracts of Plectranthus amboinicus (PA-F4, 0.25%) and Centella asiatica (S1, 1%)~Dose(s): Apply 1 cc per 5 cm^2 ulcer size (approximately 2 mm in thickness)~Dosing schedule: Apply twice a day~Duration: up to 12 weeks"
88880899|NCT05432570|Active Comparator|Group A - Muscle Relaxants Used|Muscle Relaxants Used
88880900|NCT05432570|Active Comparator|Group B - No Muscle Relaxants|No Muscle Relaxants
88880901|NCT05390645|Experimental|MFA-370|MFA-370 once daily for up to 8 x 21 days.
88880902|NCT05384964||Nurses|
89404936|NCT03664947|Experimental|exercise|The exergaming training programs have included recent daily living activities in games. In our study we have planned the Nintendo Wii Fit Plus Game Console in the therapy training.
88880903|NCT05366582|Active Comparator|Group Macintosh Laryngoscope (ML)|Macintosh laryngoscope is used for intubation after anesthesia induction
88880904|NCT05366582|Active Comparator|Group Video Laryngoscope (VL)|Video laryngoscope is used for intubation after anesthesia induction
88880905|NCT05352386|Other|Patients with familial hypercholesterolemia, early treated|
88880906|NCT05352386|Other|Patients without familial hypercholesterolemia, late treated|
88880907|NCT05352386|Other|Healthy individuals|
88880908|NCT05333926|Experimental|MHNA-001|
88880909|NCT05332067|Experimental|Omalizumab|Single dose of omalizumab at the start of a viral upper respiratory infection as defined by onset of (or substantial worsening of) rhinorrhea, nasal congestion or sneezing (single or multiple symptoms) during the fall outcome season (defined as the 90-day period beginning on each child's return to school)
88880910|NCT05332067|Placebo Comparator|Placebo for omalizumab|Single dose of placebo for omalizumab at the start of a viral upper respiratory infection as defined by onset of (or substantial worsening of) rhinorrhea, nasal congestion or sneezing (single or multiple symptoms) during the fall outcome season (defined as the 90-day period beginning on each child's return to school)
88880911|NCT05323890|Experimental|Tislelizumab arm|Radiotherapy: PTV 41.4Gy in 23 Fractions，5 days per week; Chemotherapy: Paclitaxel (Albumin bound) (100mg/m2) and Cisplatin (75 mg/m2) for 5 weeks, concurrent with radiotherapy; Immunotherapy: Tislelizumab (200mg per 3 weeks)
88880912|NCT05323318||Neuropsychological Sequelae|Post-COVID-19 symptomatic patients with neuropsychological sequelae
88880913|NCT05323318||Without Neuropsychological Sequelae|Post-COVID-19 symptomatic patients Without neuropsychological sequelae
88880914|NCT05312554|Experimental|Intervention arm|Patients with cryptogenic stroke complicated with patent foramen ovale,and passed the screening and signed the informed consent form
88880915|NCT05312437|Experimental|Interruptive Best Practice Advisory - CDS Intervention|"Adults at Elevated Predicted Risk (>=2% predicted risk, based on our study, DOI: 10.1001/jamanetworkopen.2021.1428) at visit registration (aka check-in) will be randomized to either Interruptive Alert or Passive Prompt CDS interventions.~In the Interruptive Alert, the physician who next opens that patient's chart will be prompted to review a BPA describing the patient's risk and asking the physician to choose from the BPA options (see Interventions).~The BPA will need to be dismissed to the Epic Storyboard or completed as above to continue clinical workflow."
88880916|NCT05312437|Active Comparator|Passive Storyboard Prompt - CDS Intervention|"Adult patients in the highest predicted risk tier (>=2% predicted risk, based on our research study, DOI: 10.1001/jamanetworkopen.2021.1428) at the time of visit registration (aka check-in) will be randomized to either the Interruptive Alert or Passive Prompt CDS intervention arms.~In the Passive Prompt arm, the physician who next opens the patients' charts after check-in (e.g., Chart Review) will see a Storyboard icon for Elevated Suicide Risk on the left side of the screen. Hovering over this icon will bring up a window with the BPA information in a view identical to the Interruptive Alert arm. Clicking on the window will bring up the BPA with full functionality as in the Interruptive Alert arm."
88880917|NCT05308199|Experimental|experimental|thoracic manipulation group
88880918|NCT05308199|Active Comparator|control|MET group
88880919|NCT05303233|Experimental|TIBIAL group|All patients allocated to the TIBIAL group will receive an adductor canal block with 20ml of ropivacaine 0.75% and a selective tibial nerve block with 5 ml of ropivacaine 0.75% prior to surgery,
88880920|NCT05303233|Active Comparator|IPACK group|All patients allocated to the IPACK group will receive an adductor canal block with 20ml of ropivacaine 0.75% and an IPACK with 20ml of ropivacaine 0.2% prior to surgery.
88880921|NCT05301179|Experimental|RDA Lacto-Vegetarian/Vegan|Subjects will receive diets containing the RDA for protein from Lacto-vegetarian and Vegan sources in different periods during the protocol.
88880922|NCT05301179|Experimental|Higher than RDA Lacto-Vegetarian/Vegan|Subjects will receive diets containing more than the RDA for protein from Lacto-vegetarian and Vegan sources in different periods during the protocol.
88880923|NCT05295992|Experimental|Daily Adaptive External Beam Radiation Therapy|Daily adaptive radiation therapy delivered with Varian Ethos treatment system.
89404937|NCT03664947|No Intervention|control|No exercise training applied for the control group.
89404938|NCT03664869|Active Comparator|Group A|"BCG instillation therapy with induction period of six weekly instillations of BCG followed by maintenance period of ten monthly instillations of BCG~Dosage of Bacillus of Calmette-Guerin (BCG) is dependent on the preferred brand of BCG by the participating institution. Either 2 x 10^8 - 3 x 10^9 for BCG-MEDAC, 2-8 x 10^8 colony forming unit for OncoTICE or, 81mg for ImmuCYST and TheraCys. The investigators will nominate which BCG brand is used."
89404939|NCT03664869|Experimental|Group B|"Sequential BCG and EMDA mitomycin C treatment with nine weekly instillations of BCG, BCG, EMDA-MMC x3 followed by nine monthly instillations of EMDA-MMC, EMDA-MMC, BCG x3~Dosage of Bacillus of Calmette-Guerin (BCG) is dependent on the preferred brand of BCG by the participating institution. Either 2 x 10^8 - 3 x 10^9 for BCG-MEDAC, 2-8 x 10^8 colony forming unit for OncoTICE or, 81mg for ImmuCYST and TheraCys. The investigators will nominate which BCG brand is used.~Mitomycin C dosage is 40 mg of MMC with 960 mg of excipient sodium chloride dissolved in 100 ml sterile water"
88880924|NCT05293223|Experimental|Group A|One dose Sputnik V + one dose Ad5-nCoV
88880925|NCT05293223|No Intervention|Group B|Samples stored at the immunology lab of the Buenos Aires University Medical School, corresponding to individuals vaccinated with 2 doses of Sputnik V.
89404940|NCT03961009|Experimental|Kedrion IVIG 10%|Participants received intravenous infusion of Kedrion IVIG 10% at a dose of 200 to 800 milligrams per kilogram (mg/kg) body weight on every 21 or 28 days for period of 48 weeks.
88880926|NCT05284019|Experimental|Eptinezumab|Participants will receive eptinezumab via intravenous (IV) infusion on Day 0 and Day 84.
89404941|NCT00953420|Experimental|Chemotherapy and Immunotherapy|"Docetaxel 60 mg/m2 IV on Day 1~Carboplatin with target AUC of 5 (mg/ml x min) on Day 1~Dexamethasone 5 mg/m2/dose (max of 8 mg/dose) po q hs on Day 0, and q am and hs on Day 1~After cycle 1, subsequent cycles of chemotherapy may start once ANC > 1000 and platelets > 100,000 post nadir~Up to an additional 2 cycles of chemotherapy, given per the above schedule, may be given if the EBV-specific cytotoxic T lymphocytes product is not available after the initial 4 cycles"
88880927|NCT05284019|Experimental|Anti-CGRP injectables|Participants are free to select treatment from one of 3 calcitonin gene-related peptide (CGRP) inhibitors: erenumab, fremanezumab, or galcanezumab. CGRP inhibitors will be administered via subcutaneous (SC) injection on Day 0 and then, per product label.
89404942|NCT01602562|Experimental|VACV (256U87; valaciclovir hydrochloride)|Adult patients (16-65 years): A VACV tablet (containing 500mg of valaciclovir) is orally given twice daily. Pediatric patients (1-16 years): VACV granules are orally given at a dose of 25 mg/kg b.w. twice daily. The maximum dose per treatment is limited to 500 mg. Pediatric patients weighing 40 kg or over may be orally given a VACV tablet (containing 500 mg of valaciclovir) twice daily.
89404943|NCT00765518|Experimental|Ixmyelocel-T|The treatment arm of the study will receive injections of the study cellular product.
89404944|NCT00765518|Other|Standard of Care|Standard of care therapy only.
89404945|NCT03498105||Emergency Department (ED)|"450-500 participants who will;~self present to the Emergency Department (ED) will chest pain~be brought in by ambulance to ED with acute chest pain~be referred from Primary care or Urgent care centre with cardiac sounding chest pain"
89404946|NCT03498105||Community Cardiology Service (CCS)|This study group will consist of between 80-100 participants who self present to the Community Cardiology Service (CCS) in Milton Keynes primary care surgery
88880928|NCT05284019|Experimental|Onabotulinumtoxin-A|Onabotulinumtoxin-A will be administered via intramuscular (IM) injection on Day 0 and Day 84.
88880929|NCT05263336|Active Comparator|Intervention|Intraoperative verdye green iv administration to visualize blood supply to the anastomosis
88880930|NCT05263336|No Intervention|Control|No administration of verdye green intraoperatively
88880931|NCT05250804|Experimental|Experimental|All registered participants in the intervention group, will receive the intramuscular injection with Helfer Skin Tap Technique.
88880932|NCT05250804|No Intervention|No intervention|All registered participants in the intervention group, will receive the intramuscular injection with Routine Technique. Routine Technique involved inserting the injection intra muscularly at 90 degree angle into Dorso gluteal muscles without tapping after cleaning with alcohol swab.
89190429|NCT05293951|Experimental|Mirror Therapy + Cross Education|"Cross Education: Experimental participants will perform resisted task-specific upper limb exercises. During the exercises, participants will pull a resistance cord with their non-affected arm, Mirror Therapy: Participants will complete the exercises while looking at its reflection in a mirror covering their affected arm.~Training duration & frequency: 20-30 minutes, 5/week for 4 weeks = total 20 sessions."
89404947|NCT03498105||Participants with stable angina|This study group will consist of 450-500 participants with stable angina who have been referred for Stress Echocardiography.
89404948|NCT03498105||Elective Coronary Angioplasty|This study group will consist of between 50-100 participants who will have been referred for elective coronary angioplasty
89404949|NCT03498105||Cardio-toxic Chemotherapy|Consecutive patients being initiated on any of the following medication deemed as cardio toxic and requiring cardiac function will be approached to be recruited into the study.
89404950|NCT03498105||Invasive Coronary Angiography|The dynamics and performance characteristics of the CEB during acute coronary occlusion in patients undergoing invasive coronary angiography.
88880933|NCT05249270||Safe and Sound Protocol Participants|Parents of children receiving the Safe and Sound Protocol (a clinical auditory therapy provided outside of the study) will complete questionnaires to assess sensory behaviors prior to therapy initiation (baseline), 1 week after therapy conclusion, and 4 weeks after therapy conclusion. The SSP typically consists of 1 hour of listening per day, for 5 consecutive days. If modifications of the typical dosage are implemented due to client needs, they will be documented by parents in the 1 week post therapy questionnaire.
88880934|NCT05244980|Experimental|MAD Cohorts 1-4 TDM-105795 topical solution|Multiple dose administration of TDM-105795 Topical Solution, 0.0025% or 0.005% or 0.01% or 0.02%
89404951|NCT04367636|Active Comparator|Active Comparator: PSE + OCAT-sham|Psycho-education video + an active placebo training, consisting of 10 sessions of ±15 minutes each (during an intervention period of two weeks), will be administered. The training task is an undirected scrambled sentences task with online contingent feedback.
88880935|NCT05244980|Placebo Comparator|Placebo for TDM-105795 topical solution|Multiple dose administration of Placebo forTDM-105795 Topical Solution
88880936|NCT05236933||Neuropathic|Individuals who report pain that is categorized as neuropathic will be assigned to this group.
88880937|NCT05236933||Nociceptive|Individuals who report pain that is categorized as nociceptive will be assigned to this group.
89404952|NCT04367636|Experimental|Experimental: PSE + OCAT|Psycho-education video + an attention training, consisting of 10 sessions of ±15 minutes each (during an intervention period of two weeks), will be administered. The training task is a positively directed scrambled sentences task with online contingent feedback.
89404953|NCT01945775|Experimental|talazoparib|Patient will be randomized 2:1 to receive talazoparib oral capsules (1.0 mg) once daily for 21 continuous days
89404954|NCT01945775|Active Comparator|Physician's-Choice|Capecitabine, Eribulin, Gemcitabine or Vinorelbine
88880938|NCT05232604|Experimental|Aerobic exercise group (AE)|The session training will be divided into a warm-up, main exercise period, and cool-down, with a total duration of 60 minutes (guided by a PT). The training will be performed on a cycle ergometer, three times per week for 12 weeks. The duration of the main AE will be between 30-45 minutes and the intensity will be based on the maximal heart rate (HRmax), heart rate reserve (HRR), and the Borg Rating of Perceived Exertion Scale (Borg Scale), which will be monitored. The intensity of the AE program will be progressively increased according to each patient's response and tolerance but will be standardized as much as possible: 1) first two weeks, low to moderate intensity (60% HRmax or 9-11 on the Borg scale); 2) 2-6 weeks, moderate-intensity (55-70% HRmax or 12-14 on the Borg scale), and 3) last 6 weeks, high intensity interval training (HIT) (75-90% HRmax or 15-17 on the Borg scale; 4 min*4 times HIT followed by 3 min of 70%HRmax in between) will be targeted per literature endorsements.
89190430|NCT05293951|Active Comparator|Mirror Therapy Alone|"Mirror Therapy: Control participants will perform non-resisted task-specific upper limb exercises. Participants will complete the exercises while looking at its reflection in a mirror covering their affected arm.~Training duration & frequency: 20-30 minutes, 5/week for 4 weeks = total 20 sessions."
89190431|NCT05286034|Experimental|Intervention group|Women randomized to this group will be sent screening reminder letters to perform HPV self-sampling test, with access to a decision aid tool tailored to those with low education levels. This tool will be available via Chatbot platforms.
89404955|NCT00839930|Experimental|Cilostazol (test)|Cilostazol 50 mg Tablet (test) dosed in first period followed by Pletal® 50 mg Tablet (reference) dosed in second period
88880939|NCT05232604|Active Comparator|Neck motor control exercise group|The treatment will consist of a 12-week progressive exercise program targeted to the neck flexor and extensor muscles supervised by a physical therapist (PT). This exercise protocol has been successfully tested in subjects with NP. Low load craniocervical exercises (nodding) will be performed at early stages (first 6 weeks) guided by visual feedback from a pressure unit. Higher-load neck exercises will be performed at later stages (last 6 weeks). During the first month, subjects will receive 30-45 min of MCTF three times per week, in the second month twice per week, and in the third month once per week. This duration of treatment is commonly used in clinical settings and has proven to be sufficient to improve muscle function, clinical, and brain outcomes.
88880940|NCT05228366|Experimental|Heel warming with mild thermofor group|Heel warming will be applied to the newborns in the ıntervention group 1 with a thermofor containing 34-37C warm water for 5 minutes before the heel blood collection procedure. During the procedure, the general condition of the newborn and the changes in his skin will be observed closely. Heel blood collection will be performed by following the standard procedure steps that are routinely applied in the service.
88880941|NCT05228366|Experimental|Heel warming with hot thermofor group|Heel warming will be applied to the newborns in the ıntervention group 2 with a thermofor containing 38-40C warm water for 5 minutes before the heel blood collection procedure. During the procedure, the general condition of the newborn and the changes in his skin will be observed closely. Heel blood collection will be performed by following the standard procedure steps that are routinely applied in the service.
88880942|NCT05228366|Other|Ineffective heel warming with thermofor group|Ineffective heel warming will be applied to the newborns in the control group with a thermofor containing 28C warm water for 5 minutes before the heel blood collection procedure. During the procedure, the general condition of the newborn and the changes in his skin will be observed closely. Heel blood collection will be performed by following the standard procedure steps that are routinely applied in the service.
88880943|NCT05222581|Experimental|Prototypes of Breast Shield and Freedom Double Electric Breast Pump|Prototypes of breast shield and Freedom Double Electric Breast Pump
88880944|NCT05217342|Experimental|PVP-Guided|Peripheral venous pressure guided therapy arm
88880945|NCT05217342|Active Comparator|Control|Standard medical therapy arm
88880946|NCT05211245|Experimental|Pulse mode|Pulsed mode of US results in nonthermal effect i.e., micro massage like which lead to segmental analgesia due to decreased central & peripheral sensitization. The non-thermal effect of US can be explain by frequency resonance theory which states that the proteins in these structures absorbs mechanical energy thus altering the structure & function, finally resulting in stimulation of phagocytosis, increase number of free radicals, increase cell membrane permeability, cellular proliferation &acceleration of fibrinolysis
89190432|NCT05286034|No Intervention|Control group|Women randomized to this group will be sent screening reminder letters to perform HPV self-sampling test (Standard care)
88880947|NCT05211245|Active Comparator|Continous mode|Thermal effect which is a result of continuous mode of US therapy causes transient increase in the flexibility of collagenous structures including ligaments, tendons & joint capsules, thus leading to decrease in the pain & muscle spasm, stiffness of the joint & temporary increase in the blood flow.
88880948|NCT05194618|Experimental|Valerian/Lavender arm|Participants in this arm will receive actives products : 420 mg per tablet of Valerian root extract and 40 mg per tablet of essential oil of Lavender
89404956|NCT00839930|Active Comparator|Pletal® (reference)|Pletal® 50 mg Tablet (reference) dosed in first period followed by Cilostazol 50 mg Tablet (test) dosed in second period.
88880949|NCT05194618|Placebo Comparator|Placebo arm|Participants in this arm will receive placebo (no active product)
88880950|NCT05172947|Active Comparator|Resveratrol|Interventional group, participants in this group are receiving Resveratrol 500mg capsule once daily for 3 months.
88880951|NCT05172947|Placebo Comparator|Placebo|"Non-interventional group, participants are receiving only Placebo once daily for 3 months.~Placebo formulated as capsule match the color and size of the active comparator,"
88880952|NCT05172947|Other|Resveratrol plus Pharmaceutical care|Interventional group, participants in this group are receiving Resveratrol 500mg capsule once daily for 3 months with pharmaceutical care.
88880953|NCT05172947|Other|Placebo with pharmaceutical care|Interventional group, participants are receiving placebo along with pharmaceutical care for 3 months.
88880954|NCT05170607||PV associated atrial fibrillation|
88880955|NCT05170607||non-PV associated arrhythmic focuses|
88880956|NCT05170607||Healthy volunteers|
88880957|NCT05151367|Experimental|Text message reminders|Text message reminders
88880958|NCT05151367|No Intervention|Usual Care|No reminders
88880959|NCT05127902||adolescent idiopathic scoliosis group|Female subjects aged 10 to 16 will be recruited if they are diagnosed with AIS by standard standing long X-ray examinations, with Cobb angle larger or equal to 15°, without prior treatment for their AIS and been cleared for physical activity by their doctors. Subjects were excluded if they had (i) Cobb angle larger or equal to 40°, (ii) scoliosis with any known aetiologies such as congenital, neuromuscular, metabolic, and skeletal dysplasia, (iii) known endocrine and connective tissue abnormalities, (iv) known heart condition or other diseases that could affect the safety of exercise, (v) eating disorders or gastrointestinal malabsorption disorders, and (vi) currently taking medications that affecting their bone or muscle metabolism. All subjects will be recruited in the community.
88880960|NCT05127902||Control group|Ten healthy female subjects with matched for age, height and weight will be recruited as control.
88880961|NCT05122832||The study Group|Population of Kazakhstan
88880962|NCT05121415||Experimental group:|patients with hemorrhagic stroke complicating severe pre-eclampsia in pregnancy
88880963|NCT05121415||Control group|patients without hemorrhagic stroke complicating severe pre-eclampsia in pregnancy
88880964|NCT05118997|Experimental|Treatment Arm #1|IRRAflow with manual tPA administration followed by Active Fluid Exchange
88880965|NCT05118997|Experimental|Treatment Arm #2|IRRAflow with continuous infusion of tPA combined with Active Fluid Exchange
88880966|NCT05118997|Active Comparator|Treatment Arm #3|Standard EVD with manual tPA administration
88880967|NCT05095181||Experimental group:|patients with liver cirrhosis
88880968|NCT05095181||Control group|patients without liver cirrhosis
88880969|NCT05095155||Experimental group:|children with B-cell leukemia and lymphoma of Kazakhstani nationality
88880970|NCT05095155||Control group|children without B-cell leukemia and lymphoma of Kazakhstani nationality
88880971|NCT05095142||Experimental group:|patients with idiopathic osteoarthritis of the knee
88880972|NCT05095142||Control group|patients without idiopathic osteoarthritis of the knee
88880973|NCT05095129||Experimental group:|patients with idiopathic scoliosis
88880974|NCT05095129||Control group|patients without idiopathic scoliosis
88880975|NCT05090644||Experimental group:|Patients with schizophrenia
89404957|NCT05108038|Experimental|A|Period 1: CKD-382 Period 2: D860 Period 3: D027
89404958|NCT05108038|Experimental|B|Period 1: CKD-382 Period 2: D027 Period 3: D860
89404959|NCT05108038|Experimental|C|Period 1: D860 Period 2: D027 Period 3: CKD-382
88880976|NCT05090644||Control group|Patients without schizophrenia
88880977|NCT05090631||Experimental group:|Patients with atopic dermatitis
88880978|NCT05090631||Control group|Patients without atopic dermatitis
88880979|NCT05090618||Experimental group:|Patients with Heart Attack
88880980|NCT05090618||Control group|Patients without Heart Attack
88880981|NCT05090605||Experimental group:|Patients with breast cancer
88880982|NCT05090605||Control group|Patients without breast cancer
88880983|NCT05090436|Experimental|Schroth Exercise|The Schroth Method is a nonsurgical option for scoliosis treatment. It uses exercises customized for each patient to return the curved spine to a more natural position. The goal of Schroth exercises is to de-rotate, elongate and stabilize the spine in a three-dimensional plane. it will be applied 3 session per week for 3 months.
88880984|NCT05090436|Experimental|Functional Electrical Stimulation|30 minutes of Functional Electrical Stimulation (FES) three times a week for 3 months. Two electrodes were attached on the lateral parts of the convex side of the body, and two others on the erector spinae muscles. FES (CU-FS1; Novastim, Korea) was set at a frequency of 35 Hz, with a 250-μs pulse width. Electrical stimulation lasted for 6 seconds, followed by a 6-second rest.
88880985|NCT05088512||Experimental group:|Patients with bronchial asthma
88880986|NCT05088512||Control group|Patients without bronchial asthma
88880987|NCT05088499||Experimental group:|Patients with epilepsy
88880988|NCT05088499||Control group|Patients without epilepsy
88880989|NCT05088486||Experimental group:|Patients with arterial hypertension
88880990|NCT05088486||Control group|Patients without arterial hypertension
88880991|NCT05078827|Active Comparator|Comparator Arm|Reference Product (B): Fluorouracil 5% Topical Cream of Mylan Pharmaceuticals Inc., Morgantown, WV 26505 U.S.A.
88880992|NCT05078827|Experimental|Arms and Interventions|Test Product (A): Fluorouracil Cream, 5% of Encube Ethicals Pvt. Ltd., India
88880993|NCT05078827|Placebo Comparator|Placebo Arm|Placebo Product (C): Test vehicle cream for fluorouracil 5% of Encube Ethicals Pvt. Ltd., India
88880994|NCT05076981||Pure Natural Cycle|"Transvaginal ultrasound (TVUS) on day 2/3 of cycle + hormones FSH, LH, E2, P4 (IVF1)~TVUS day 9-10 of cycle to identify dominant follicle.~Blood test for IVF1 every 24h until identification of the LH surge.~The LH surge will be diagnosed when the concentration rises by 180% above the latest serum value available in that patient and continued to rise thereafter (Fatemi et al, 2010).~Once the LH rise is detected, blood test for IVF1 to be performed after 2h, and then every 12h after LH rise for 2 days.~During luteal phase, IVF1 day 7 after LH rise and day 14 after LH rise."
89404960|NCT05108038|Experimental|D|Period 1: D860 Period 2: CKD-382 Period 3: D027
88880995|NCT05076981||Modified Natural Cycle|"Transvaginal ultrasound (TVUS) on day 2/3 of cycle + hormones FSH, LH, E2, P4 (IVF1)~TVUS day 9-10 of cycle to identify dominant follicle.~Once the dominant follicle reaches 17mm or above, a bolus of 6500 rhCG (Ovitrelle, Merck-Serono) will be administered subcutaneously. IVF1 to be performed just before the rhCG-administration.~IVF1 2h after rhCG.~IVF1 every 12h for 2 days after rhCG.~During luteal phase, IVF1 day 7 after rhCG and day 14 after rhCG."
88880996|NCT05076422|Experimental|BI 3006337 treatment group|BI 3006337
88880997|NCT05076422|Placebo Comparator|Placebo group|Placebo
88880998|NCT05074979|Other|control group|While other groups continue their exercise program for 6 weeks, this group will only be informed after COVID 19.
88880999|NCT05074979|Experimental|home exercise program group|this group will implement COVID 19 home exercise program.
88881000|NCT05074979|Experimental|telerehabilitation group|this group will implement COVID 19 telerehabilitation program.
88881001|NCT05065164|Experimental|dnosumab|Desuzumab 60 mg subcutaneously /6 months, twice a year
88881002|NCT05065164|Placebo Comparator|placebo control|Placebo subcutaneous injection /6 months, twice a year
88881003|NCT05062122||vibration group|Vibration applied group in addition to conventional physiotherapy
88881004|NCT05062122||kinesiology tape group|The group in which kinesiology tape was applied in addition to conventional physiotherapy
88881005|NCT05062122||control group|Group receiving only conventional physiotherapy
88881006|NCT05057819|Experimental|Empagliflozin first, Placebo second|Oral empagliflozin 25 mg daily in the morning for 20 days, followed by oral placebo (daily in the morning) for 20 days after a wash-out period of 2-6 weeks
88881007|NCT05057819|Placebo Comparator|Placebo first, Empagliflozin second|Oral placebo (daily in the morning) for 20 days, followed by oral empagliflozin 25 mg daily in the morning for 20 days after a wash-out period of 2-6 weeks
88881008|NCT05046834|Experimental|cold application Group|a cold gel pack will be wrapped in gauze and placed directly on the skin in an area with a radius of about 5 cm to cover the chest tube. The cold gel package will remain on the skin surface for about 20 minutes.
88881009|NCT05046834|Experimental|Cold Application Group with Thermometer|10 of cold application. After a minute, the skin temperature will be measured with an infrared thermometer if the temperature has dropped below 13.6 o C, the procedure will be terminated. If the skin temperature has not decreased below 13.6 0 C, the application will be continued, the application will be terminated when the temperature drops below the specified temperature.
89404961|NCT05108038|Experimental|E|Period 1: D027 Period 2: D860 Period 3: CKD-382
88881010|NCT05046834|No Intervention|control Group|standard pain procedure.
88881011|NCT05038826||trial 1|Immune checkpoints + chemotherapy vs. chemotherapy + placebo
88881012|NCT05038826||trial 2|Immune checkpoints + chemotherapy vs. chemotherapy + placebo
88881013|NCT05038826||trial 3|RNA-polymerase-II inhibitor
89190433|NCT05273918|Experimental|Therapy cognitivo-comportmental|"Each child will participate in a structured cognitive behavioral therapy program entitled better manage your anger and frustration. 15 workshops is planned."
88881014|NCT05038826||trial 4|Tyrosine kinases inhibitor
88881015|NCT05038826||trial 5|Tyrosine kinases inhibitor
88881016|NCT05038826||trial 6|Immune checkpoints + chemotherapy vs. chemotherapy + placebo
88881017|NCT05035693|Experimental|PMCF MOVE-C|PMCF MOVE®_C is a single arm observational study with 170 patients.
89190434|NCT05273918|Active Comparator|Body mediation|Each child will participate in sports, artistic or fun activities involving the body (physical, emotional and communicative dimensions)
89190435|NCT05257772|Active Comparator|Optimum Right Ventricular Pacing On|AV Delay Optimised RV Pacing. Subjects will remain in this arm for 3 months before being crossed-over.
89404962|NCT05108038|Experimental|F|Period 1: D027 Period 2: CKD-382 Period 3: D860
89404963|NCT05051332|Experimental|CartiLife®|Extracellular matrix-associated autologous chondrocytes comprise CartiLife®, composed as pellets (1.1 to 1.8 mm in diameter) in suspension. One pre-filled syringe is implanted per 1 cm^3 of defect volume, and fibrin adhesive is applied to fix pellets in place through minimal arthrotomy.
89404964|NCT05051332|Active Comparator|Microfracture Surgery|Microfracture surgery, performed by arthroscopy after the joint is cleaned of calcified cartilage, will be conducted using an awl or drill to create tiny fractures in the subchondral bone plate.
89404965|NCT03875365||POPE Patients|Patients who underwent POPE for end-stage achalasia, a sigmoid esophagus, or a redundant conduit that has been used to replace the esophagus.
88881018|NCT05029375|Experimental|immediate parental involvement|Parental involvement in training is parallel to children's training
88881019|NCT05029375|Experimental|delayed parental involvement|Parental involvement in training will be given at the end of the children's training
88881020|NCT05027074|Experimental|MK-2060 Low Dose|MK-2060 low dose administered via intravenous (IV) infusion as a loading dose: Every other day (QOD) during week 1 (3 administrations), then once a week (QW) after week 1
88881021|NCT05027074|Experimental|MK-2060 High Dose|MK-2060 high dose administered via IV infusion as a loading dose: QOD during week 1 (3 administrations), then QW after week 1
88881022|NCT05027074|Placebo Comparator|Placebo|Placebo (normal saline) administered via IV infusion as a loading dose: QOD during week 1 (3 administrations), then once a week after week 1
88881023|NCT05024487|Experimental|Experimental group|The correlation between blood pressure level, dermal resistance level, and subjective symptoms caused by triggered AD below the level of the lesion will be performed in a group of SCI people.
89190436|NCT05257772|No Intervention|Optimum Right Ventricular Pacing Off|Subjects will remain in this arm for 3 months before being crossed-over. The pacemaker will be programmed to minimum ventricular pacing & dynamic AV delay will be programmed off.
88881024|NCT05022095||SCI Patients with ongoing spasticity|SCI Patients that are either seen in clinical routine due to fillings or controls of their intrathecal injection pumps or stationary patients will be informed about the project, they are granted with enough time to decide whether they want participate or not. After giving Informed Consent they will be administered a set of questionnaires including SCI-SETde, PSFS (adapted to german), SCIM-SR in german as well as self-evaluation of spasticity severity and intensity. The SCI-SETde will be filled in again one week later to evaluate test-retest reliability. Overall, the burden for the patients is kept at minimum. There are no expected risks or harm to the patients.
88881025|NCT05017142||Patient population|Children, adolescents and adults diagnosed with an IBrainD before age 18, who are born, treated or living in Switzerland
88881026|NCT05004389||Acute Stroke|Persons ≥ 18 years of age with acute (≤ 7 days) ischemic or intracerebral hemorrhagic stroke.
89404966|NCT00838136|Experimental|Lamotrigine|Lamotrigine 2 x 25 mg Chewable Tablet (test) dosed in first period followed by Lamictal® 2 x 25 mg Chewable Tablet (reference) dosed in second period
89404967|NCT00838136|Active Comparator|Lamictal®|Lamictal® 2 x 25 mg Chewable Tablet (reference) dosed in first period followed by Lamotrigine 2 x 25 mg Chewable Tablet (test) dosed in second period
89404968|NCT00944294|Other|binodenoson then adenosine|binodenoson (experimental); adenosine (active comparator)
88881027|NCT04981821|Experimental|GO-EXCAP|GO-EXCAP Mobile App involves the use of a mobile app delivery platform to deliver an exercise program [Exercise for Cancer Patients (EXCAP©®)]. EXCAP©®) is a progressive walking and resistance exercise program
88881028|NCT04981821|Active Comparator|Behavioral Placebo Control|Participants will meet with an oncology nurse (for approximately 60 min) to review the NCI booklet Chemotherapy and You: Support for People With Cancer, which includes facts about chemotherapy and its side effects. They will be provided with NCI online resources to review at home.
89404969|NCT00944294|Other|adenosine then binodenoson|adenosine (active comparator); binodenoson (experimental)
89404970|NCT00758966|Experimental|NF (Naltrexone+Fluoxetine)|Naltrexone SR 32 mg and fluoxetine 60 mg
89404971|NCT00758966|Active Comparator|Fluoxetine|Fluoxetine 60 mg
89404972|NCT00758966|Active Comparator|Naltrexone|Naltrexone SR 32 mg
88881031|NCT04962165|Experimental|Experimental group|The group of SCI people will use a mandibular advancement device for treatment of obstructive sleep apnea.
88881032|NCT04947033|Experimental|TJ210001 Injection|Single Arm Dose expansion
89404973|NCT03750877|Active Comparator|median approach|Spinal anesthesia will be performed with a conventional median approach
88881033|NCT04934124|Experimental|Cohort 1: 0.03 mg ITI-333 or placebo|
88881034|NCT04934124|Experimental|Cohort 2: 0.09 mg ITI-333 or placebo|
88881035|NCT04934124|Experimental|Cohort 3: 0.25 mg ITI-333 or placebo|
89404974|NCT03750877|Active Comparator|paramedian approach|Spinal anesthesia will be applied with a paramedian approach.
88881036|NCT04934124|Experimental|Cohort 4: 0.75 mg ITI-333 or placebo|
88881037|NCT04934124|Experimental|Cohort 5: 2.25 mg ITI-333 or placebo|
88881038|NCT04934124|Experimental|Cohort 6: 6.75 mg ITI-333 or placebo|
89190437|NCT05254730|Experimental|micro-macroelectrodes|Patients will be implanted with usually the novel intracerebral micro-macroelectrodes (instead of the regular clinical macroelectrodes). The primary and secondary outcomes will then be assessed.
88881039|NCT04924010|Active Comparator|Cognitive Behavioural Therapy (CBT)|Cognitive behavioural therapy (CBT) is a talking therapy that can help patients manage problems by changing the way they think and behave. It's most commonly used to treat anxiety, depression and chronic pain conditions.
88881040|NCT04924010|Placebo Comparator|Education and Mindfulness|Education and mindfulness therapy refers to lessons on techniques to calm the mind and body - can reduce the negative effects of stress
89404975|NCT05107804|Experimental|Exercise with caloric-restriction|"Exercise: Participants engaged in supervised exercise training sessions (to expend ~20% of baseline energy needs) in Noll Laboratory; 4 times per week.~Diet: Participants consumed meals in the General Clinical Research Center metabolic kitchen that reduced dietary intake 20-35% of baseline energy needs. Diet composition was 55% carbohydrates, 30% fat, and 15% protein."
89404976|NCT05107804|Active Comparator|Light Conditioning (reference group)|"Exercise: Participants engaged in supervised exercise training sessions (to expend ~10% of baseline energy needs) in Noll Laboratory; 1-2 times per week.~Diet: Participants consumed meals in the General Clinical Research Center metabolic kitchen that had calories sufficient to maintain body weight and additional calories to remain in energy balance. Diet composition was 55% carbohydrates, 30% fat, and 15% protein."
89404977|NCT04336124|Experimental|CVM-1118 ER|Dose escalation (escalation from 400, 600, 800 to 1200 mg of CVM-1118 ER Capsule)
89404978|NCT03734497|Active Comparator|Group Control|"will receive 2 ml/kg Ringer's lactate Lafleks® during anesthesia"
89404979|NCT03734497|Experimental|Group Preloading|"will receive 10 ml/kg Ringer's lactate Lafleks® fluid preloading"
89404980|NCT03734497|Experimental|Group Carotis FTc|"will receive 500 ml Ringer's lactate Lafleks® if the patient is fluid responder"
89404981|NCT04841122|Active Comparator|Camera observation|Camera observation
88881041|NCT04905979|Experimental|AD113|Two oral capsules administered before bed
88881042|NCT04905979|Experimental|Atomoxetine|Two oral capsules administered before bed
89404982|NCT04841122|No Intervention|No camera observation|No intervention
89404983|NCT00941486|Experimental|FST-100 Ophthalmic Suspension|FST-100 (PVP-I 0.4% and dexamethasone 0.1%)
89404984|NCT00941486|Placebo Comparator|Vehicle|
89404985|NCT04836364||Pediatric Cohort|Parents of children ages 2 to 15 years old will provide data using the APICHS.
89404986|NCT00937352|Active Comparator|Bapineuzumab 0.5 mg/kg|0.5 mg/kg
89404987|NCT00937352|Active Comparator|Bapineuzumab 1.0 mg/kg|1.0 mg/kg
89404988|NCT01566175|Experimental|Neovasc coronary sinus reducer|open label: Neovasc coronary sinus reducer
89404989|NCT03072719|Experimental|Dentifrice containing stannous fluoride|Toothpaste
89404990|NCT03072719|Active Comparator|Dentifrice containing Sodium Monofluorophosphate|Toothpaste
89404991|NCT04665700|Experimental|BI 764198 Single dose part|
89404992|NCT04665700|Experimental|BI 764198 Multiple dose low|
89404993|NCT04665700|Placebo Comparator|Placebo|
89404994|NCT04665700|Experimental|BI 764198 Multiple dose medium|
89404995|NCT04665700|Experimental|BI 764198 Multiple dose high|
89404996|NCT05107414||Journey II Bi-Cruciate Stabilized|Participants who have been implanted with a Smith & Nephew Journey II BCS TKA
89404997|NCT05107414||Journey II Cruciate Retaining|Participants who have been implanted with a Smith & Nephew Journey II CR TKA
89404998|NCT05107414||Journey II Bi-Cruciate Retaining|Participants who have been implanted with a Smith & Nephew Journey II BCR TKA
88881043|NCT04889859|Active Comparator|long RL group|long Roux limb Roux-en-Y reconstruction
88881044|NCT04889859|Experimental|long BPL group|long biliopancreatic limb Roux-en-Y reconstruction
88881045|NCT04885400|Experimental|iJobs|All the participants will be included in the program.
88881046|NCT04870827||Affected Subjects|Subjects diagnosed with moderate- severe psoriasis
88881047|NCT04870827||Healthy Controls|Females and males 18 years of age or older
88881048|NCT04860765||TPVR|Subjects with a dysfunctional RVOT conduit or previously implanted surgical valve in the pulmonic position will undergo transcatheter pulmonary valve replacement (TPVR).
88881049|NCT04854512|Experimental|Investigational Arm (Metformin DR plus metformin IR placebo)|Group A will receive 1800 mg Metformin DR qAM + placebo for 1500 mg metformin IR in divided doses (2×placebo for metformin IR 500 mg qAM and 1×placebo for metformin IR 500 mg qPM).
88881050|NCT04854512|Placebo Comparator|Placebo Arm (Metformin DR placebo plus metformin IR placebo)|Group B will receive placebo for 1800 mg Metformin DR qAM + placebo for 1500 mg metformin IR in divided doses (2× placebo for metformin IR 500 mg qAM and 1×placebo for metformin IR 500 mg qPM).
88881051|NCT04854512|Active Comparator|Active Control Arm (Metformin DR placebo plus metformin IR)|Group C will receive placebo for 1800 mg Metformin DR qAM + 1500 mg metformin IR in divided doses (2× metformin IR 500 mg qAM and 1× metformin IR 500 mg qPM).
88881052|NCT04804072|Experimental|Integrated health services delivered in the mobile unit and peer navigation|Participants in the intervention arm will be provided integrated health services delivered in the mobile unit and peer navigation for 26 weeks.
89404999|NCT04594265|Experimental|Ketone Monoester|Weight-adjusted dose of 3-OHB Monoester (KetoneAID KE4, Virginia, US) 0.5 g/kg (max 50 g)
89405000|NCT04594265|Placebo Comparator|Placebo Treatment|Maltodextrin-based placebo (Science In Sport, UK) in isocaloric dose to the experimental arm.
89405001|NCT04594265|Active Comparator|Ketone Monoester in presence of low-dose insulin clamp|Same as experimental arm, but in the presence of a low-dose insulin clamp to suppress free fatty acid metabolism
89405002|NCT05107258||Subjects Symptomatic for COVID-19|"Subjects must present with 1 or more of the following signs or symptoms:~Fever~Cough~Shortness of Breath~Difficulty Breathing~Muscle Pain~Headache~Sore Throat~Chills~New Loss of Taste or Smell~Congestion~Runny Nose~Diarrhea~Nausea or vomiting 2. Subjects must have experienced symptom onset within the previous 10 days"
89405003|NCT05106400|Other|ZTlido (Lidocaine Topical System) 1.8%|
89405004|NCT05106400|Other|Salonpas (Lidocaine Patch 4%)|
89405005|NCT05106400|Other|Aspercreme (Lidocaine Patch 4%)|
89405006|NCT05106400|Other|IcyHot (Lidocaine 4% + Menthol 1% Patch)|
89405007|NCT01433315|Experimental|sleep restriction|restricted sleep during the experimental period
89405008|NCT01433315|No Intervention|normal sleep|normal sleep during the experimental period
89405009|NCT00754988|Placebo Comparator|Placebo|Once daily oral administration of placebo (matching sitagliptin). Once weekly sc injection of placebo (matching taspoglutide). Continued treatment with metformin at prescribed doses.
89405010|NCT00754988|Active Comparator|Sitagliptin|Once daily oral administration of 100 mg of sitagliptin. Once weekly sc injection of placebo (matching taspoglutide). Continued treatment with metformin at prescribed doses.
89405011|NCT00754988|Experimental|Taspoglutide 10 mg|Once weekly subcutaneous (sc) injection of 10 mg of taspoglutide. Once daily oral administration of placebo (matching sitagliptin). Continued treatment with metformin at prescribed doses.
89405012|NCT00754988|Experimental|Taspoglutide up-titrated to 20 mg|Once weekly sc injection of 10 mg of taspoglutide for the first 4 weeks, then up-titrated to once weekly sc injection of 20 mg of taspoglutide from week 5 onwards. Once daily oral administration of placebo (matching sitagliptin). Continued treatment with metformin at prescribed doses.
89405013|NCT05107102||patients with LVR(left ventricular remodeling)|
89405014|NCT05107102||patients without LVR(left ventricular remodeling)|
89405015|NCT01416935|Active Comparator|No Amiodarone|Patient will be randomized not to receive to Amiodarone post Cox-Maze procedure unless indicated.
89405016|NCT01416935|No Intervention|Amiodarone|Patients randomized to receive Amiodarone post Cox-Maze procedure which is our current standard of care.
89405017|NCT05106322||Liver transplants|Whole liver transplants proposed for organ harvesting from brain-dead donors and assigned by the Biomedicine Agency.
89405018|NCT03547843|Experimental|Educational intervention|Patients randomized to the intervention group will start with a group-based educational program immediately after the randomization.
89405019|NCT03547843|Active Comparator|Waiting list|Participants randomized to the waiting list control group receive no educational intervention for the duration of the 10 weeks. During this period participants can receive standard treatment, consisting of diagnostic treatment with medication.
89535596|NCT02490605|Active Comparator|therapeutic exercises|The control group will only receive orientation to do physiotherapeutic exercises seeking to correctly position the mandible in the resting position (maxillar teeth should be approximately 2 mm away from the mandibular teeth) while the tip of the tongue is positioned and accommodated on the roof of the mouth over the incisive papilla on the hard palate (without touching the teeth). The exercise will consist of repeatedly opening the mouth with the tongue cleaving to the roof of the mouth, 3 times per day, each period consisting of 3 sets with 15 repetitions.
88881053|NCT04804072|Active Comparator|Peer navigation to connect them to health services available at community-based agencies|Participants in the active control arm will be provided 26 weeks of peer navigation to connect them to health services available at community-based agencies.
88881054|NCT04798365|Experimental|Intervention group|The main components of the intervention are 1) two sessions of voluntary continuing medical education on the urinary tract infection program in each LTCF for physicians and nursing staff, 2) distribution of educations materials such as written guidelines on antibiotic prescribing including a smart phone friendly version, 3) implementation of the project homepage as a platform to distribute guidelines and educational videos and to enable physicians to ask questions which will be answered by an infectious disease physician.
89405020|NCT05106166|Experimental|Experimental group: occupational therapy program + the usual special education program (USEP)|"The practitioner used the less-to-more orientation to get the child to respond to the offer of joint attention. For example, if the child did not respond to the joint attention offer within 5-10 seconds, practitioner first directed the child, used exaggerated gestures, gave a moving hint if he still did not respond, and physically slowly directed the child's head towards the target if he still did not respond. In addition, the practitioner gave a verbal command (practitioner said: look at how his arms are waving, pointing to the toy, now look at me). When the child looked at the toy and reacted, he again gave enthusiastic and activity-appropriate feedback (e.g. he tickled the child, saying, Isn't it weird, is there ever such a long arm?). The child's interest and leadership in the activities were followed, including what the child did and said. Positive feedback was then provided."
89405021|NCT05106166|Active Comparator|Control group: the usual special education program (USEP)|The USEP studied was including gross motor skills, communication skills, preschool preparation skills, and self-care skills. The control group of the study consisted of children attending the USEP.
88881055|NCT04798365|No Intervention|Control group|No intervention until end of the stuy.
89405022|NCT05107024|Active Comparator|Traditional balloon dilation group|The optimal size of the semi-compliant balloon (balloon to vessel ratio 1.0) was determined by the surgeon according to angiography, and sufficient predilation was performed to achieve residual stenosis. 30% vascular anatomy criteria, and then a 1:1 DCB was selected for drug release
89405023|NCT05107024|Experimental|RFR-guided step by step balloon dilation group|Balloon dilation start with 2.0mm compliant balloon. After 8atm pressure expansion, the RFR value was measured. If RFR≥0.93, the pre-expansion was stopped. Otherwise, RFR value is measured after pressure expansion of 16atm, if RFR value is still less than 0.93, then a 2.5mm compliant or non-compliant balloon was used to expand the pressure of 8ATM, and the balloon diameter and expansion pressure were continuously increased until RFR≥0.93. Then a DCB with the same diameter as the pre-expanded balloon was selected for drug release.
89405024|NCT03529981|Active Comparator|Stress incidents without TVS|a fraction of physiological detected stress incidents will not trigger TVS
89405025|NCT03529981|Experimental|TVS in response to participant initiation or stress detection|The majority of detected stress incidents will trigger TVS. Participants can also trigger TVS voluntarily
89405026|NCT05012566|Experimental|Hyaluronic Acid filler and Botulinum Toxin group|"Hyaluronic Acid filler:~Juvederm Volbella: it will be used in the softer soft tissue, beacuse its reology is the softest~Juvederm Volift: it will be used in malar area, because its reology is intermediate between the three products~Juvederm Voluma: il will be used unstructured area bacause it has the best rheologic characteristics in the reintegration of loss of tissue.~The differents products are going to use in different areas, depending on the area of the paralysis.~Botulinum Toxin:~Vistabex (50U/vial): it is going to be used in the controlateral area of the paralysed face, in order to relax muscle hyper-tonicity.~Dosage and administration steps will be selected according to the clinical situation."
89405027|NCT05012566|No Intervention|Control group|The control group will undergo at the same examinations of the treated group but it will not be subjected to any treatment.
89405028|NCT05202665|Experimental|Flouride Varnish applications (non-invasive approaches)|ClinproTM White Varnish 22600 ppm, 3M ESPE was applied in line with the manufacturer's recommendation to non-cavitated proximal caries lesion.
89405029|NCT05202665|Experimental|Resin Infiltration (micro-invasive approaches)|ICON DMG was applied in line with the manufacturer's recommendation to non-cavitated proximal caries lesion.
89405030|NCT04268342|No Intervention|Standard care|When clinical services are in the standard case phase of the study, all cases of gonorrhoea infection diagnosed at those services will be managed according to current standard of care management guidelines i.e. all cases of gonorrhoea infection will be treated with ceftriaxone by injection plus oral azithromycin tablets as first line therapy, regardless of whether the treatment is given at the initial clinic or the return clinic visit.
89405031|NCT04268342|Active Comparator|Implementation|When clinical services are assigned to the implementation phase, first line treatment for gonorrhoea infection for patients treated at their first clinic visit will remain the same as it is currently: ceftriaxone by injection plus oral azithromycin tablets. However, patients who are not treated presumptively will be treated at their return visit on the basis of the drug resistance test results. Patients with gonorrhoea infection that is shown to be susceptible to ciprofloxacin will be treated with oral ciprofloxacin therapy when they return for review at clinical services in the implementation phase. Patients with gonorrhoea infection that is not susceptible to ciprofloxacin or with an indeterminate ciprofloxacin result will be treated with ceftriaxone by injection.
89405032|NCT01567813||Regimen Initiators|Any male health plan member who receives at least one dose of GARDASIL™
89405033|NCT01567813||Regimen Completers|Regimen Initiators who complete the 3-dose vaccination regimen within 12 months
88881056|NCT04795089||Patients|Patients with iNPH and shunt surgery.
88881057|NCT04795089||Healthy individuals|Healthy controls with similar gender and age distribution as the patients.
88881058|NCT04778670|Active Comparator|Standard of Care|Standard of Care means all examinations will receive a flagging decision by: first reader and second reader radiologist as usual. However, in this paired design all participants will belong to both arms.
88881059|NCT04778670|Experimental|AI CAD combination|AI CAD combination in the primary end-point means the combination of the flagging decision of the first reader and AI CAD; in the secondary end-points it means any combination of AI alone, or AI in combination with first, second and both readers.
89405034|NCT01567813||Autoimmune cohort|Regimen Initiators who were members of the health plan during the 12-month period prior to their first dose of GARDASIL™
89405035|NCT05106010||Usual Activity|Participants continued with usual activity, not participating in any yoga intervention for 12 weeks
89405036|NCT05106010||Balance Flow Yoga|Community hatha yoga flow class, 75 minutes duration, twice per week for 12 weeks
89405037|NCT04473638||Arthroscopic|Deltoid Arthroscopic Repair in Ankle Fractures
89405038|NCT05210647||conventional laparoscopy surgery|Conventional laparoscopy surgery for colon and rectal disease.
89405039|NCT05210647||robot assisted surgery|robotic assisted surgery for colon and rectal disease.
89405040|NCT05106868|Experimental|acupuncture|5 sessions of acupuncture per week for 4 weeks. In each session, acupuncture will be applied bilaterally on acupoints. We will use transcutaneous electric acupoints stimulation (HANS; Han's acupoints nerve stimulator, HANS-200, Nanjing, China) to stimulate the acupoints. Each session will last 30 minutes.
88881060|NCT04774445|Experimental|Intervention Group|Individuals randomized to this arm will receive immediate access to the Interactive Health Communication Application.
88881061|NCT04774445|No Intervention|Usual Care Group|Individuals randomized to this arm will receive the standard clinical practice.
88881062|NCT04772651|Experimental|Mediterranean Diet and dietary coaching|Patients receive 3 Mediterranean meals a day for 4 weeks and dietary coaching sessions (á 50 minutes once a week for 4 weeks)
88881063|NCT04772651|Placebo Comparator|Diet as usual and psychoeducation for depression|Patients receive normal hospital diet with 3 meals a day for 4 weeks and psychoeducation sessions (á 50 minutes once a week for 4 weeks)
88881064|NCT04759144|Active Comparator|Faster insulin aspart with hybrid closed-loop insulin delivery|"Unsupervised home use of hybrid closed-loop insulin delivery with faster insulin aspart for 8 weeks.~Intervention: Use of faster insulin aspart with hybrid closed-loop insulin delivery"
88881065|NCT04759144|Active Comparator|Standard insulin aspart with hybrid closed-loop insulin delivery|"Unsupervised home use of hybrid closed-loop insulin delivery with standard insulin aspart for 8 weeks.~Intervention: Use of standard insulin aspart with hybrid closed-loop insulin delivery"
88881066|NCT04757701||General dentists and dental hygienists in North Carolina|This objective will be met by administering a quantitative survey to active and licensed NC dentists and dental hygienists.
88881067|NCT04757701||Directors of Service-Learning Centers and their partnering FQHCs|This objective will be met by conducting qualitative assessments with ECU's SoDM's CSLCs and their partnering community clinic/FQHCs. The investigators will interview the Directors of the eight existing CSLCs and focus groups with clinical staff at each CSLC. In collaboration with the Directors of the CSLCs, the investigators will identify key stakeholders in the co-located/partnering medical clinics, and conduct interviews with the administrators and focus groups with medical clinic staff.
89405041|NCT05106868|Sham Comparator|sham acupuncture|5 sessions of sham acupuncture per week for 4 weeks. In each session, acupuncture will be applied bilaterally on non-acupoints. We will use transcutaneous electric acupoints stimulation (HANS; Han's acupoints nerve stimulator, HANS-200, Nanjing, China) to stimulate the non-acupoints. Each session will last 30 minutes.
89405042|NCT05106868|No Intervention|waiting-list|
89405043|NCT05764577||Surgical intervention|Participants who underwent secondary DIEP flap breast reconstruction
89405044|NCT04438772|Experimental|LPEC|
89405045|NCT04438772|Sham Comparator|Sham procedure|
89405046|NCT04560634||Normal Diastolic Function|Diastolic Function within normal values (defined in terms of E wave and A wave velocity and Deceleration Time according to the American Society of Echocardiography and the European Association of Echocardiography)
88881068|NCT04737200|Experimental|Nighttime cycled enteral feeds first|Patients will start nighttime cycled enteral feeds first for 12 hours. Following a 24-hour washout period, patients will then start daytime cycled enteral feeds for 12 hours.
88881069|NCT04737200|Experimental|Daytime cycled enteral feeds first|Patients will start daytime cycled enteral feeds first for 12 hours. Following a 24-hour washout period, patients will then start nighttime cycled enteral feeds for 12 hours.
88881070|NCT04734847|Active Comparator|High-frequency rTMS|"Intensity: rTMS treatment intensity determined using resting motor threshold (RMT). Treatment will be delivered at 80% of the RMT.~Site of Stimulation: Region of supplementary motor area (SMA) that regulates pelvic floor muscle activity. This target is defined in Montreal Neurological Institute (MNI) Coordinates of X=-2, Y=-16, and Z=68 mm.~Frequency: 10 Hz.~Duration: 20 Trains, 10 second duration, 50 second inter-train interval.~Total number of pulses per session: 2000.~Total number of session: 5 (one session per day for 5 consecutive days)."
88881071|NCT04734847|Sham Comparator|Sham rTMS|"Identical to the High-frequency rTMS arm except delivered with an inert sham stimulation coil."
88881072|NCT04731870||Nurses/Doctors|Covid-19 vaccine confidence and recommendation practices of nurses/doctors
88881073|NCT04731870||Minority populations living in rural south|Covid-19 vaccine confidence and uptake of key at-risk subgroups and tailored Covid-10 vaccine messaging for at-risk subgroups.
88881074|NCT04724031||One cohort|women with advanced epithelial ovarian cancer who received PARP inhibitors at any line of treatment
88881075|NCT04679376|Experimental|Group 1: Atorvastatin Treatment|Subjects who have a histology-proved NASH with fibrosis stage 2 or higher will receive atorvastatin for 96 weeks
89405047|NCT04560634||Impaired Diastolic Function|Diastolic Function with pseudonormal pattern or impaired values (defined in terms of E wave and A wave velocity and Deceleration Time according to the American Society of Echocardiography and the European Association of Echocardiography)
89405048|NCT00927914|Experimental|Ranirestat 80 mg|Two 80 mg Ranirestat tablets, given orally, once daily, preferably in the morning with or without a light breakfast, for upto 24 months.
89405049|NCT00927914|Experimental|Ranirestat 40 mg|One 40 mg tablet of Ranirestat and a matching placebo, given orally, once daily, preferably in the morning with or without a light breakfast, for upto 24 months.
89405050|NCT00927914|Placebo Comparator|Placebo|Two placebo tablets, given orally, once daily, preferably in the morning with or without a light breakfast, for upto 24 months.
89405051|NCT04438616|Active Comparator|dome magnetic attachment|"A crestal incision is made using No. 15 c blade extending over the crest of anterior mandible and a full mucoperiosteum flaps elevated to provide access to the alveolar ridge for implant installed.~Full sequential drilling under copious saline irrigation will be made as indicated by the company guide lines. insertion of two implant in each group by the contra angle handpiece with special adaptor~We connect magnetic attachment(dome) for each groups on complete denture by pick up procedure at day of implant installation"
89405052|NCT04438616|Active Comparator|flat magnetic attachment|"A crestal incision is made using No. 15 c blade extending over the crest of anterior mandible and a full mucoperiosteum flaps elevated to provide access to the alveolar ridge for implant installed.~Full sequential drilling under copious saline irrigation will be made as indicated by the company guide lines. insertion of two implant in each group by the contra angle handpiece with special adaptor~We connect magnetic attachment(flat) for each groups on complete denture by pick up procedure at day of implant installation"
89405053|NCT05764499||Children|Patients under the age of 18
89405054|NCT05764499||Adults|Patients 18 years old and above
88881076|NCT04679376|Placebo Comparator|Group 2: Placebo|Subjects who have a histology-proved NASH with fibrosis stage 2 or higher will receive a placebo for 96 weeks
88881077|NCT04678999|Experimental|Tai Chi|The intervention will delivered via a secure Zoom video platform. One of two Tai Chi instructors will teach each of the classes. Tai Chi instructors will be selected prior to study start on the basis of familiarity with our previous Tai Chi protocols and experience working with OA patients.
88881078|NCT04678999|Experimental|Wellness Education|At each session, a variety of health professionals will provide a didactic lesson on a topic relating to knee OA. An informational brochure on knee OA education is presented to all participants during the first session. Each session will last 60 minutes including a 10-minute instructor-led program of stretching or flexibility exercises via a zoom platform.
89405055|NCT05261464|Active Comparator|Metoprolol protocol|"Metoprolol tartrate 50 mg will be given if patient's HR is more than 60 bpm.~Monitor BP and heart rate HR every 15 minute to assess targeted HR and side effects until patient's is sent to CCTA.~If patient can not reach targeted HR (less than 60 bpm) at 30 minutes, then second dose of 50-mg metoprolol will be given.~If patient can not reach targeted HR at next 30 minutes, then third dose of 50-mg metoprolol will be given.~If patient can not reach targeted HR at next 30 minutes, then fourth dose of 50-mg metoprolol will be given.~If patient's HR reach targeted HR for 15 minutes apart for 2 times or received total dose of 200 mg metoprolol tartrate, then total time will be recorded and patient will proceed to CCTA.~If patient can not reach targeted HR according to protocol, cardiac imaging specialist will decide whether to give further medication for HR control or proceed to CCTA. Cardiac imaging specialist may be able to consult dispensary."
89531006|NCT02495207|No Intervention|Conventional Surgery|No intervention in this arm. The patients are going to undergo normal surgical intervention. Conventional surgery will be performed to extract the impacted third molars.
89531007|NCT02495207|Experimental|Piezosurgery|Patients here will undergo a piezosurgery to extract their third molars on both sides.
88881079|NCT04677959|Experimental|Digital System (DS)|DS group participants utilizing the eMDPI DS, including inhaler, smart device application (App), DHP (Cloud solution), and dashboard
88881080|NCT04677959|Active Comparator|Standard of Care (SoC) Group|SoC group participants will be treated with their standard of care medications
89405056|NCT05261464|Experimental|Ivabradine protocol|"Ivabradine 5 mg will be given if patient's HR is more than 60 bpm.~Monitor BP and heart rate HR every 15 minute to assess targeted HR and side effects until patient's is sent to CCTA.~If patient can not reach targeted HR (less than 60 bpm) at 30 minutes, then second dose of 5-mg Ivabradine will be given.~If patient can not reach targeted HR at next 30 minutes, then third dose of 5-mg Ivabradine will be given.~If patient can not reach targeted HR at next 30 minutes, then placebo will be given.~If patient's HR reach targeted HR for 15 minutes apart for 2 times or received total dose of 15 mg ivabradine with 1 dose of placebo, then total time will be recorded and patient will proceed to CCTA.~If patient can not reach targeted HR according to protocol, cardiac imaging specialist will decide whether to give further medication for HR control or proceed to CCTA. Cardiac imaging specialist may be able to consult dispensary."
89437495|NCT03794349|Experimental|Regimen B (eflornithine, chemotherapy, dinutuximab)|Patients receive eflornithine PO, via NG, or G tube on days -6 to 7 and days 15-21 of cycle 1 and days 1-7 and 15-21 of subsequent cycles, temozolomide PO, via NG, or G tube on days 1-5, irinotecan hydrochloride IV over 90 minutes on days 1-5, dinutuximab IV over 10-20 hours on days 2-5, and sargramostim SC or IV over 2 hours on days 6-12. Treatment duration is 28 days for cycle 1 and then every 21 days in subsequent cycles for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
89437496|NCT03793140|Experimental|CPI-613|CPI-613 IV induction (Days 1-5 for first 2 Cycles [14-day cycles]), followed by CPI-613 IV maintenance (Days 1-5 for all Cycles thereafter [21-day cycles].
88881081|NCT04671043|Experimental|CAF+lowCHO|A drink containing caffeine and 10 g rapid-acting carbohydrate (glucose) dissolved in 200 mL of tap water
88881082|NCT04671043|Active Comparator|10g CHO|A drink containing 10 g rapid-acting carbohydrate (glucose) dissolved in 200 mL of tap water
88881083|NCT04671043|Placebo Comparator|placebo|A drink containing an artificial sweetener (aspartame) dissolved in 200 mL of tap water
89190438|NCT05236790|Experimental|Artificial intelligence for real-time detection and monitoring of colorectal polyps|Colonoscopies will be performed according to the standard of care. Patients will undergo colonoscopies using CAD-eye (CADe and CADx) and Scale-eye. All optically diagnosed (CADx) polyps will be removed and sent to the CHUM pathology laboratory for histopathological evaluation according to institutional standards. CADx will be combined with human input for final diagnosis.
88881084|NCT04656899|Active Comparator|Pillsy arm|Participants in the Pillsy arm will receive a prescription for buprenorphine-naloxone with an ''active'' Pillsy smart cap that will continuously collect data on pill bottle openings, missed doses, text messages sent, automated phone calls made. A participant who misses an entire day of buprenorphine-naloxone will automatically receive a survey about cravings and risk of relapse.
88881085|NCT04656899|No Intervention|Service as usual arm|Participants in the Service As Usual arm will receive a prescription for buprenorphine-naloxone with an ''inactive'' Pillsy smart cap that will track openings but will not provide reminders or any other messaging. They will receive a basic application that can deploy patient satisfaction surveys.
88881086|NCT04645342|Experimental|Baylis Versacross RF wire|Device: Baylis Versacross radiofrequency wire
88881087|NCT04645342|Active Comparator|Baylis RF Needle|Device: conventional Baylis radiofrequency needle
88881088|NCT04642586|Experimental|Hypertensive participants|diagnosed HTA within 5 years, treated or confirmed by Ambulatory Blood Pressure Measure;
88881089|NCT04642586|Experimental|Normotensive participants|absence of HTA confirmed by Ambulatory Blood Pressure Measure
89405057|NCT05261464|Experimental|Diltiazem protocol|"Diltiazem immediate release (IR) 30 mg will be given if patient's HR is more than 60 bpm.~Monitor BP and heart rate HR every 15 minute to assess targeted HR and side effects until patient's is sent to CCTA.~If patient can not reach targeted HR (less than 60 bpm) at 30 minutes, then second dose of 30-mg diltiazem will be given.~If patient can not reach targeted HR at next 30 minutes, then third dose of 30-mg diltiazem will be given.~If patient can not reach targeted HR at next 30 minutes, then fourth dose of 30-mg diltiazem will be given.~If patient's HR reach targeted HR for 15 minutes apart for 2 times or received total dose of 120 mg 30-mg diltiazem IR, then total time will be recorded and patient will proceed to CCTA.~If patient can not reach targeted HR according to protocol, cardiac imaging specialist will decide whether to give further medication for HR control or proceed to CCTA. Cardiac imaging specialist may be able to consult dispensary."
89405058|NCT04438694|Active Comparator|STANDARD OF COARE|Receiving SOC
89405059|NCT04438694|Experimental|STANDARD CP DOSE Adm (Two infusions)|Two infusions 48 hours apart
89405060|NCT05210491|Experimental|The observation of eyelid positioning and EEG pulses from the eyelid on increasing brightness|In a dimly lit room the participant will place their chin on the slit lamp We will use t he optimal background illumination used for Humphrey and Goldman visual fields which is 31.5 apostilbs (10Lux 9 They will look into the video camera placed 50cm away, which will have a dimmable remote control ring light fitted around it. The part icipant will have a reference measure taped to the headrest and three electrodes placed around the right eye. One active electrode place on the lower lid and one reference electrode towards the temporal margin and one earth electrode placed on the forehead The brightness of the ring light will be increased via the dimmer switch whilst simultaneously recording the lux with the LED light meter. The participant will be advised t o close their eyes if the brightness becomes uncomfortable and this will be repea ted three times.
89405061|NCT05105932||EIT group|patients went through EIT detection
89405062|NCT05105932||CTPA group|patients went through CTPA detection
88881090|NCT04637035|Experimental|Supportive Oncology Care at Home|"Participants will receive the Supportive Oncology Care at Home program for 14 days following their discharge from the hospital.~The Supportive Oncology Care at Home intervention consists of three key components:~Daily monitoring of patient-reported symptoms, vital signs, and body weight.~Medically Home care based on algorithmic changes in patients' daily symptoms, vital signs, and body weight.~Structured communication with the oncology team regarding care delivered to ensure continuity of care."
88881091|NCT04633590|Experimental|home-based exergaming|The home-based exergame intervention will take place in an unsupervised place of the participant's choosing. Participants will be provided with all of the equipment (including a television if required) and receive instructions on how to use the system. Participants will be provided with a stepped training plan with exergame session durations of 19 minutes (4x 3-minutes 45-seconds of exercise interspersed with 1 minute of rest) in weeks 1 and 2; 24-minutes (4x 5-minutes of exercise interspersed with 1 minute of rest) in week 3 and 4; and 30-minutes (5x 5-minutes of exercise interspersed with 1 minute of rest) in week 5 and 6. Sessions will be set at a vigorous intensity (≥80% heart rate maximum) and participants will be provided with individualised heart rate zones to achieve in line with heart rate maximum determined during a maximal exercise test in Visit 2. Participants will be asked to train 3 times per week.
88881092|NCT04618198|No Intervention|Diagnosis dependent / conventional dose anti-TB therapy|"Standard care per admitting team including ceftriaxone x 7 days~If subsequent TB test positive, then WHO recommended weight-based anti-TB therapy x 28 days"
88881093|NCT04618198|Experimental|Immediate anti-TB therapy/conventional dose anti-TB therapy|Standard care per admitting team including ceftriaxone x 7 days plus immediate empiric WHO recommended weight-based dose anti-TB therapy x 28 days
88881094|NCT04618198|Experimental|Diagnosis dependent/sepsis specific dose anti-TB therapy|"Standard care per admitting team including ceftriaxone x 7 days~If subsequent TB test positive, then sepsis specific dose anti-TB therapy x 28 days"
88881095|NCT04618198|Experimental|Immediate anti-TB therapy/sepsis specific dose anti-TB therapy|Standard care per admitting team including ceftriaxone x 7 days plus immediate empiric sepsis specific dose anti-TB therapy x 28 days
88881096|NCT04617925|Experimental|belantamab mafodotin|Belantamab mafodotin will be administered as an IV infusion at a dose of 2.5 mg/kg every six weeks until progression of disease, unacceptable toxicity or subsequent therapy, for a maximum of eight doses (approximately 12 months), according to the response adapted modifications
88881097|NCT04612920|Experimental|Study Group|Participants will receive ibuprofen 800mg every eight hours and acetaminophen 1000mg every eight hours, given at the same time, along with oxycodone five mg every six hours PRN for breakthrough pain.
88881098|NCT04612920|No Intervention|Standard Group|Participants will receive current OU standard of care therapy which includes ibuprofen 800mg every eight hours as needed (PRN), acetaminophen 1000mg every eight hours PRN, and oxycodone five mg every six hours PRN.
88881099|NCT04581135||COVID-19 Lung|COVID-19 survivors in Switzerland
89405063|NCT05379998|Experimental|Group A(neural mobilization)|sciatic nerve mobilization(sliding technique)
89405064|NCT05379998|Experimental|Group B(PNF hold relax)|PNF hold relax technique of Hamstring muscle
89405065|NCT04461730||Parkinson disease|
88881100|NCT04570293|Experimental|The LMP group|The LMP group will receive lidocaine patches (active patches) measuring 10 cm x 14 cm contains 700 mg lidocaine (5% w/w).
89405066|NCT04461730||essential tremor|
89405067|NCT04461730||dystonia|
89405068|NCT04461730||OCD|
89405069|NCT04461730||healthy volunteers|
89405070|NCT02928887|Experimental|Blue light|Exposure to high illuminance (1000 lux), blue spectrum (480nm) light for the 24 hour photoperiod prior to surgery and for the 24 hour photoperiod immediately after surgery
89190439|NCT05236790|No Intervention|Real time polyp detection using a standard colonoscopy without CAD eye|Real time polyp detection using a standard colonoscopy without CAD eye and without CADe. Patients will undergo a standard colonoscopy. Polyp size measurement will be assessed visually (phase 1 and 2) or with instruments such as snare or forceps (phase 3 or later) and polyp classification will be done by CADx without further input by the endoscopist. All optically diagnosed polyps will be removed and sent to the CHUM pathology laboratory for histopathological evaluation according to institutional standards.
88881101|NCT04570293|Placebo Comparator|The control group|The control group will receive vehicle patches that are identical to the active patch, except for the absence of lidocaine, without any optical differences.
88881102|NCT04565275|Experimental|ICP-192|"Dose Escalation Phase ICP-192~Dose Expansion Phase ICP-192"
88881103|NCT04543045||Stage 1|20 patients will be interviewed once, which will be approximately 60 minutes in duration. The interviews will be audio recorded.
88881104|NCT04543045||Stage 2|Five patients who participated in stage 1 will take part in a cognitive interview, which will be approximately 60 minutes in duration.The interviews will be audio recorded.
88881105|NCT04527016|Experimental|Microbiota and eosinophils phenotype based therapy|The children will be treated with different protocol(Fluticasone propionate (FP),Azithromycin,or FP+Azithromycin) according to their Blood eosinophils level and airway microbiota pattern for 3 months and follow up for 1 year.
88881106|NCT04527016|Active Comparator|Clinical guidelines based therapy|The children will be treated as directed by their paediatrician, the clinical practice is based on the guideline for the diagnosis and optimal management of asthma in children of China 2016 (FP or montelukast for 3 months，or intermittent budesonide inhalation suspension during wheezing episode) and follow up for 1 year.
88881107|NCT04511442||Bariatric surgery|Women with obesity, with a bariatric surgery
88881108|NCT04511442||Control|Women with obesity, without a bariatric surgery
88881109|NCT04507815|Experimental|Active tDCS|Participants will receive 10 sessions of cognitive training concurrent with transcranial direct current stimulation (anode over left frontal cortex, cathode over right frontal cortex; 2 mAmps for 20 minutes).
88881110|NCT04507815|Sham Comparator|Sham tDCS|Participants will receive 10 sessions of cognitive training concurrent with sham tDCS. For sham tDCS, electrodes are placed at the same locations as for active tDCS, but current is ramped up for the initial 30 secs, then immediately ramped back down. This ramp up/down method is done at the end of the stimulation period, as well. This method mimics the physical sensation of stimulation typically encountered at the very beginning and end of the intervention period.
89190440|NCT05228860|Experimental|Food and Lifestyle Intervention Group|The Food and Lifestyle Intervention Group will receive weekly household deliveries of healthy food as well as a lifestyle intervention (called Vida Sana) that will be delivered via Zoom and facilitated by a trained bilingual/bicultural health coach.
89190441|NCT05228860|Experimental|Waitlist Control Group|The waitlist control will continue usual care with no intervention for 6 months. To balance rigor with ethical considerations, they will receive the healthy food box deliveries after a 6 month waiting period.
88881111|NCT04501120|Experimental|APG2575 single agent|APG-2575 orally once daily starting from 200mg and will be increased in subsequent cohorts to 400mg, 600mg, 800mg, to determine the MTD/RP2D.
88881112|NCT04501120|Experimental|APG2575+reduced-dose HHT|APG-2575 MTD/RP2D-1 and MTD/RP2D combines with reduced-dose HHT in R/R AML, MPAL, BPDCN, CMML.
89405071|NCT02928887|No Intervention|Ambient light|Exposure to ambient, white fluorescent light
89405072|NCT05210335|No Intervention|Observational part|This part covers the list for comprehensive medication use at admission, medication reconciliation and medication review at preoperative surgical ward, postoperative intensive care, postoperative surgical ward and discharge made by clinical pharmacist. The identification and classification of drug related problems was made at each ward according to PCNE classification system. The expert panel (2 surgeon, 2 nurse, 1 pharmacist) scored all the drug related problems as a part of the risk analysis model development. Patients quality of life, nutritional status, cognitive functions and frailty status also recorder at admission, discharge and 1 month after surgery.
89405073|NCT05210335|Experimental|Interventional part|This part covers the list for comprehensive medication use at admission, medication reconciliation and medication review at preoperative surgical ward, postoperative intensive care, postoperative surgical ward and discharge made by clinical pharmacist. Clinical pharmacist made recommendation about drug related problems regarding solutions, record intervention type and problem status differently from observational part. As a component of the risk analysis model the affect of clinical pharmacist was shown clearly. Patients quality of life, nutritional status, cognitive functions and frailty status also recorder at admission, discharge and 1 month after surgery.
89405074|NCT00835796|Experimental|Finasteride|Finasteride 5 mg Tablet (test) dosed in first period followed by Proscar® 5 mg Tablet (reference) dosed in second period
89405075|NCT00835796|Active Comparator|Proscar®|Proscar® 5 mg Tablet (reference) dosed in first period followed by Finasteride 5 mg Tablet (test) dosed in second period
88881113|NCT04501120|Experimental|APG2575+ standard-dose HHT|APG-2575 MTD/RP2D-1 and MTD/RP2D combines with standard-dose HHT in R/R AML, MPAL, BPDCN, CMML.
89190442|NCT05214664|Experimental|Guiding device for inferior alveolar nerve block|"The system consists of a reusable angulator with a tube, a reusable plunger, and a single-use syringe body.~These three components are combined with a single-use needle and an anesthetic cartridge to create the ready-to-use EZ-Block® device."
88881114|NCT04501120|Experimental|APG2575+ AZA|APG-2575 MTD/RP2D-1 and MTD/RP2D combines with AZA in R/R AML, MPAL, BPDCN, CMML.
88881115|NCT04501120|Experimental|APG2575+ AZA(HR-MDS.)|APG-2575 MTD/RP2D-1 and MTD/RP2D combines with AZA in HR-MDS.
88881116|NCT04501120|Experimental|APG2575+ AZA(Naïve AML.)|APG-2575 MTD/RP2D-1 and MTD/RP2D combines with AZA in treatment naïve AML.
89405076|NCT05106712|Experimental|Vitamin D3|Participants will be treated with oral vitamin D3 4000IU capsules per day for around 12 weeks
89405077|NCT05106712|Active Comparator|"Ovulation-inducing drug Clomiphene citrate"|"Participants will be treated with oral Clomiphene citrate using its respective Stair-step dosage protocol as follow: 50 mg, 100 mg, and 150 mg, once daily for 5 days, in the 1st, 2nd, and 3rd cycle, respectively."
89405078|NCT05106712|Active Comparator|"Ovulation-inducing drug Letrozole"|"Participants will be treated with oral Letrozole using its respective Stair-step dosage protocol as follow: 5 mg, 5 mg, and 7.5 mg, once daily for 5 days, in the 1st, 2nd, and 3rd cycle, respectively, respectively."
88881117|NCT04477317|Experimental|Experimental|4% Articaine Hydrochloride with 1:100,000 Adrenaline (Alexadricaine, Alexandria Co., Egypt).
88881118|NCT04477317|Active Comparator|Control|2% Mepivacaine Hydrochloride with 1:20,000 Levonordefrin (Mepicaine-L, Alexandria Co., Egypt)
88881119|NCT04434196|Experimental|CC-99282 + obinutuzumab|Escalating doses of CC-99282 administered orally once daily on intermittent schedules with obinutuzumab IV infusion 1000 mg up to 2 years in Part A. CC-99282 administered orally once daily at MTD or alternative tolerating dosing schedule with obinutuzumab IV infusion 1000 mg up to 2 years in Part B.
88881120|NCT04426461|Experimental|Behavioral activation|
88881121|NCT04426461|Experimental|Exposure-based therapy|
88881122|NCT04426461|Active Comparator|Supportive therapy|
88881123|NCT04415931|Experimental|Local infiltration analgesia group|This group of patients will receive local infiltration analgesia
88881124|NCT04415931|Active Comparator|Interscalene block group|This group of patients will receive interscalene block
88881125|NCT04410380|Experimental|Electronic tablet|Spanish-speaking parents receive electronic tablet and teaching about use
88881126|NCT04395781||Control cases|Children who suspected COVID-19 cases but tested negative for COVID-19
88881127|NCT04395781||Confirmed cases|Children who tested positive for COVID-19
89405079|NCT05106712|Placebo Comparator|Placebo|PCOS-Vitamin D-deficient infertile women in the control (Placebo) group will be treated with equal amount of placebo tablets per day for the same duration.
89405080|NCT00835718|Experimental|Stage I, Arm 1|MK0594 5 mg/day
89405081|NCT00835718|Placebo Comparator|Stage I, Arm 2|Placebo
88881128|NCT04395430|Active Comparator|Information Group|Subjects randomized to the Information Group will receive standard care and age appropriate reading books.
88881129|NCT04395430|Experimental|Intervention Group|Subjects randomized to the Intervention Group will receive standard care plus invitation to participate in the online KKH Sports Singapore programme.
88881130|NCT04333875||TAVR/SAVR|Patients with critical aortic stenosis as defined by an AVA <0.6 cm2 or a transvalvular mean gradient of >60 mmHg or a history of cardiac decompensation during the previous 3 months or clinical symptoms on minimal exertion (NYHA III) will be allocated to transcatheter aortic valve replacement or surgical aortic valve replacement.
88881131|NCT04333875||Deferred Intervention|Patients with severe but not critical aortic Stenosis will undergo deferred intervention.
88881132|NCT04330638|Placebo Comparator|Usual Care|
88881133|NCT04330638|Active Comparator|Anakinra|
88881134|NCT04330638|Active Comparator|Siltuximab|
88881135|NCT04330638|Active Comparator|Anakinra + Siltuximab|
88881136|NCT04330638|Active Comparator|Tocilizumab|
89405082|NCT00835718|Experimental|Stage II, Arm 2|MK0594 1 mg/day
89405083|NCT00835718|Experimental|Stage II, Arm 3|MK0594 1 mg/week
89405084|NCT00835718|Placebo Comparator|Stage II, Arm 4|Placebo
89405085|NCT05463185|Experimental|stretching exercises|Stretching exercise along with manual lymph drainage
89405086|NCT05463185|Experimental|soft tissue mobilization|soft tissue mobilization along with manual lymph drainage
88881137|NCT04330638|Active Comparator|Anakinra + Tocilizumab|
88881138|NCT04325321|Other|Stress reactivity|Stress reactivity test
88881139|NCT04322006|Experimental|TJ004309 injection Monotherapy or Combination with Toripalimab|TJ004309 will be dose escalated in a 3+3 design in Monotherapy or combination with Toripalimab
89190443|NCT05214664|Active Comparator|Conventional freehand technique for providing anesthesia|"The injection site is located in the middle of the triangle with an upper base formed, during maximum mouth opening, outside by the mandibular ramus, inside by the mesial pterygoid muscle and above by the lateral pterygoid muscle.~The needle is inserted up to the bone contact (about 20mm) while the body of the syringe is directed towards the contralateral premolars or molars.~Use of a disposable carpule syringe with aspiration. Use of a 35mm long needle with a 0.5mm diameter. Use of an articaine anesthesia carpule with adrenaline 1/200000."
89405087|NCT05105698|Experimental|fasting conditions|A: A fixed dose combination of gemigliptin and dapagliflozin 50/10 mg film-coated tablet orally administered once without food (fasting conditions)
89405088|NCT05105698|Experimental|fed conditions|B: A fixed dose combination of gemigliptin and dapagliflozin 50/10 mg film-coated tablet orally administered once with food (fed conditions)
89405089|NCT00835640|Experimental|1|
89190444|NCT05214573||Aims 1, 2B, and 3 Groups|De-identified administrative claims with linked laboratory results, electronic health record (EHR), and mortality data from the OptumLabs Data Warehouse (OLDW) and Medicare fee-for-service data (Medicare parts A, B, D) will be utilized to identify adults (≥21 years) with T2D (established using validated Healthcare Effectiveness Data and Information Set criteria) who first filled any study drug GLP-1RA, SGLT2i, DPP-4i, or SU between 1/1/2014-12/31/2021.
89405090|NCT00835640|Active Comparator|2|
89405091|NCT05098678|Experimental|Zinc gluconate|zinc gluconate tablet daily (120 mg each tablet containing 30 mg elemental zinc)
89405092|NCT05098678|Placebo Comparator|Control|Placebo (microcrystalline cellulose): 1 tablet (120 mg each)
89405093|NCT00752570|Placebo Comparator|2|AMG 386 placebo QW, FOLFIRI Q2W
88881140|NCT04315610|Experimental|Access to mobile application|This application will help parents to recognize symptoms of reduced health status in their infant, provide decision-making support, increase their communication skills with health professionals, and provide easier access to quality assured information. At first login, the diagnosis, treatment, and contacts in the health service are registered to provide parents with personalized information that is adapted to their infant's needs. Under the guidance of healthcare personnel at the Neonatal Intensive Care Department (NICD) at Oslo University Hospital (OUH), parents are trained to assess their infant's condition, regarding circulation, breathing, eating habits, well-being, and more. In addition, before discharge, a baseline assessment of the infant's condition is stored in the application.
88881141|NCT04315610|Active Comparator|Treatment as usual|This group receives traditional oral and written information about their child's heart defect and further follow-up.
88881142|NCT04304131|Experimental|Colorectal cancer|Confirmed colorectal cancer under colonoscopy
88881143|NCT04304131|Experimental|Colon polyp|Confirmed colorectal polyp under colonoscopy
88881144|NCT04304131|Active Comparator|Healthy|Confirmed no cancer nor polyp under colonoscopy
88881145|NCT04298879|Experimental|IBI376|IBI376 will be administered orally at a dose of 20 mg once daily for 8 weeks followed by 2.5 mg once daily.
88881146|NCT04298554|Experimental|CBD Oil|CBD PURE CBD OIL 20mg/1ml concentration - 1 ml (20mg) qd PO, hold under tongue for 1 minute and swallow daily
88881147|NCT04298554|Placebo Comparator|Placebo (hemp oil)|CBD PURE Hemp Oil- 1 ml qd PO, hold under tongue for 1 minute and swallow daily
88881148|NCT04297020||Pre-menopausal BCS + ET|Pre-menopausal Breast Cancer Survivor (BCS) who have undergone Endocrine Therapy (ET)
88881149|NCT04297020||Post-menopausal BCS + ET|Post-menopausal Breast Cancer Survivor (BCS) who have undergone Endocrine Therapy (ET)
88881150|NCT04297020||Pre-menopausal Healthy Control|Pre-menopausal healthy control group
88881151|NCT04297020||Post-menopausal Healthy Control|Post-menopausal healthy control group
88881152|NCT04280601|Other|Low vitamin level at baseline|At specific time points we will measure vitamin D status (baseline and 12-months) and re-enforcing vitamin D supplementation in those with insufficient or deficient vitamin D levels. More specifically, we will ask patients with insufficient or deficient vitamin D levels at enrollment to increase vitamin D intake by 1,000 IU units (to a maximum of 2,000 IU if the patient is already on vitamin D supplementation) for the 12 month period.
88881153|NCT04271501|No Intervention|Control|Area without surgical intervention. Ultraviolet Lamp (UVB)
88881154|NCT04271501|Active Comparator|Melanocyte-Keratinocyte Transplantation|Autologous skin cell suspension prepared by laboratory based melanocyte-keratinocyte transplantation procedure technique applied to a surgically prepared area of depigmentation
88881155|NCT04271501|Experimental|RECELL 1:5|Regenerative epidermal suspension diluted 1:5 applied to a surgically prepared area of depigmentation
89405094|NCT00752570|Active Comparator|1|Arm 1 : AMG 386 10 mg/kg QW, FOLFIRI Q2W
89405095|NCT05083000|Experimental|Topotecan|"Subject will receive Topotecan as a single dose or 2 consecutive doses given via intravenous (IV). The starting dose level of Topotecan is 0.25mg. Subsequent dose levels will be 2 doses of 0.25mg, a single dose of 0.5mg and then 2 doses of 0.5mg.~Standard of care treatments for COVID-19 will be given together if available as per the following protocol:~IV Dexamethasone 6mg once daily for at least 5 days and not more than 10 days.~IV Remdesivir 200mg loading dose on day 1 followed by 100mg once daily for 4 days."
88881156|NCT04271501|Experimental|RECELL 1:10|Regenerative epidermal suspension diluted 1:10 applied to a surgically prepared area of depigmentation
88881157|NCT04271501|Experimental|RECELL 1:20|Regenerative epidermal suspension diluted 1:20 applied to a surgically prepared area of depigmentation
88881158|NCT04264013|Placebo Comparator|Exercise|Exercise
88881159|NCT04264013|Active Comparator|Exercise + Diet|Exercise + eggs
88881160|NCT04263064|Active Comparator|High Volume-Low Concentration without Clonidine|The control for this study will be a High Volume-Low Concentration (1.5cc/kg of 0.15% ropivacaine and 5mcg/cc epinephrine).
89190445|NCT05214573||Aim 2A Group|Adults with Type 2 diabetes treated with one or more of the study medications (GLP-1RA, SGLT2i, DPP-4i, or SU) and not treated with insulin who receive medical care at Mayo Clinic Rochester, Mayo Clinic Health System in Minnesota or Wisconsin, or Emory University/Grady Hospital.
89190446|NCT05211271|Experimental|Intervention Arm|Treatment of cervical neoplasia by thermal ablation
89437497|NCT03792919|Experimental|Cessation of NAs treatment|Chronic hepatitis B patients who meet the criteria to stop the current anti-HBV Neucleos(t)ides treatment will stop their NAs at the baseline of the clinical trial.
89531008|NCT02499341|Active Comparator|Tramadol|Intraoperative administration of a bolus dose of tramadol and continuous intravenous infusion of tramadol for up to 48 h postoperatively.
88881161|NCT04263064|Experimental|High Volume-Low Concentration with clonidine|The study intervention will be High Volume-Low Concentration with clonidine (1.5cc/kg of 0.15% ropivacaine, with 1mcg/cc of clonidine and 5mcg/cc epinephrine).
88881162|NCT04261751||Nurses|Nurses will be taking the Clinician Questionnaire electronically.
89190447|NCT05205668|Experimental|F-652 Dosage Level 1|IL-22 fusion protein administered intravenously
89405096|NCT05764421|Experimental|intervention groups|"The experimental group received a uniform exercise - cognitive intervention at a community health centre or a geriatric activity station. The intervention lasted for a total of 12 weeks at a frequency of once every fortnight, with each intervention lasting 60-90 minutes. At the end of the intervention, the participants were followed up by the researchers for a total of 12 weeks, at a frequency of once every fortnight.~The intervention consisted of physical-motor activities as well as integrated cognitive training."
89405097|NCT05764421|No Intervention|control group|Participants in the control group did not undergo any intervention and kept their old lifestyle unchanged. The control group was asked to avoid cognitive training and exercise training beyond the routine throughout the investigation.
89405098|NCT00752258|Experimental|1|Mentor Purified Toxin Botulinum Toxin Type A
89405099|NCT02942017|Placebo Comparator|Placebo|Participants received an infusion rate equivalent to the 90 micrograms per kilogram per hour (μg/kg/h) group.
89405100|NCT02942017|Experimental|SAGE-547 90 μg/kg/h|Participants received a 4-hour dose titration period of 30 μg/kg/h (0 to 4 hours), then 60 μg/kg/h (4 to 24 hours), then 90 μg/kg/h (24 to 52 hours), followed by a taper to 60 μg/kg/h (52 to 56 hours), and 30 μg/kg/h (56 to 60 hours).
89405101|NCT04447781|Experimental|Group 1 (Part A)|"Number of Subjects: 20 subjects~ID Injection of INO-4800 1mg/dose + EP using CELLECTRA® 2000 (dosing at Day 0 and Week 4)"
89405102|NCT04447781|Experimental|Group 2 (Part A)|"Number of Subjects: 20 subjects~ID Injection of INO-4800 2mg/dose + EP using CELLECTRA® 2000 (dosing at Day 0 and Week 4)"
89405103|NCT04447781|Experimental|Group 3 (Part B)|"Number of Subjects: 90 subjects~ID Injection of INO-4800 1mg or 2mg/dose + EP using CELLECTRA® 2000 (dosing at Day 0 and Week 4)"
89405104|NCT04447781|Placebo Comparator|Group 4 (Part B, Placebo)|"Number of Subjects: 30 subjects~ID Injection of Placebo (SSC) 1mg or 2mg/dose + EP using CELLECTRA® 2000 (dosing at Day 0 and Week 4)"
88881163|NCT04258449||Case|Participants must have suspected or confirmed upper genital tract cancer (uterine, tubal and ovarian) and must be scheduled to undergo surgery for tumor removal.
88881164|NCT04249466||Patient with cystic fibrosis|
88881165|NCT04248764|Experimental|Foam roller group|Participants will perform a 100 fall-bounces (5 sets x 20 reps, with two minutes of rest) from a 50 cm high box as the fatigue protocol. All participants will use a five-minute bicycle ergometer to warm up prior to the. Following the fatigue protocol, foam roler will be applied to the participants' quadriceps femoris muscles in a prone position for five minutes.
88881166|NCT04248764|Experimental|Massage group|Participants will perform a 100 fall-bounces (5 sets x 20 reps, with two minutes of rest) from a 50 cm high box as the fatigue protocol. All participants will use a five-minute bicycle ergometer to warm up prior to the. Following the fatigue protocol, sports massage will be applied on the quadriceps femoris muscles for five minutes.
89190448|NCT05205668|Placebo Comparator|Placebo|Placebo administered intravenously
89190449|NCT05205668|Experimental|F-652 Dosage Level 2|IL-22 fusion protein administered intravenously
89190450|NCT05204641|Active Comparator|Fecal microbiota transplant|"Pretreatment with rifaximin 3x 400 mg PO for 7 days Fecal Microbiota Transfer from healthy donor during colonoscopy. Assessments in clinical scales: 30 days, 90 days and 12 months: Unified Parkinson Disease Rating Scale, Constipation Assessment Scale, Parkinson Disease Questionnaire-39, Non- Motor Symptoms Questionnaire, Gastrointestinal Dysfunction Scale for Parkinson Disease.~Assessment of levodopa/benserazide 200+50 mg tablet before and 30 days after intervention: 20,40, 60, 90, 120, 150, 180 and 240 min since intervention"
89405105|NCT00835484|Experimental|1|
89405106|NCT00835484|Active Comparator|2|
89405107|NCT04442555|Experimental|3-Hydroxybutyrate treatment|HVMN Ketone Ester 0,5 g / kg
89405108|NCT04442555|Placebo Comparator|Placebo Treatment|Maltodextrin-base isocaloric placebo
89405109|NCT05105464|Experimental|Dose Escalation Cohort|Six dose levels will be tested. The dose-limiting toxicity (DLT) will be assessed from the first administration of SYHA1815 to the end of the first cycle (28 days).
89405110|NCT05105464|Experimental|cohort Expansion Cohort|Once the expected effective dose is determined, four expansion cohorts will be started to further evaluate the safety, clinical activity and PK profile of SYHA1815.
89405111|NCT05202431|Experimental|Adherence|Participants received training, telefollow-up and daily text messages for 6 months.
89405112|NCT05202431|No Intervention|Standart care|The standard follow-up applied in the dispensary for this group was performed.
89405113|NCT04999618|Active Comparator|Group with Haemoblock (A)|
89405114|NCT04999618|Placebo Comparator|Group without Haemoblock (B)|
89405115|NCT00835406|Experimental|Alendronate Sodium First|70 mg Alendronate Sodium Tablets test product dosed in first period followed by 70 mg Fosamax® Tablets reference product dosed in second period
89405116|NCT00835406|Active Comparator|Fosamax® First|70 mg Fosamax® Tablets reference product dosed in first period followed by 70 mg Alendronate Sodium Tablets test product dosed in second period.
89405117|NCT04973098|Experimental|5 dose levels each with or without lymphocyte clearance were tentatively determined.|CT0181 Cells were transfused after lymphocyte clearance with fludarabine and cyclophosphamide or without lymphocyte clearance.
89190451|NCT05204641|Placebo Comparator|Autotransplant of patients microbiota|"Pretreatment with rifaximin 3x 400 mg PO for 7 days Autotransplant of patients own microbiota collected in screening period during colonoscopy.~Assessments in clinical scales: 30 days, 90 days and 12 months: Unified Parkinson Disease Rating Scale, Constipation Assessment Scale, Parkinson Disease Questionnaire-39, Non- Motor Symptoms Questionnaire, Gastrointestinal Dysfunction Scale for Parkinson Disease.~Assessment of levodopa/benserazide 200+50 mg tablet before and 30 days after intervention: 20,40, 60, 90, 120, 150, 180 and 240 min since intervention"
89405118|NCT05202275|Experimental|OPA regimen|All patients were given orally olanzapine 10mg once on d1-5; intravenously palonosetron 0.25mg once on d1; aprepitant 125 mg once on d1, then 80mg once on d2-5.
89405119|NCT00749216|Experimental|QW|IV infusion of 400mg once each week for 2 months
89405120|NCT00749216|Experimental|Q4W|IV infusion of 400mg once every four weeks for 2 months
89190452|NCT05186974|Experimental|Sacituzumab Govitecan-hziy (SG) + Pembrolizumab (Cohort A)|Participants assigned to Cohorts A according to tumor proportion score (TPS) status will receive SG 10 mg/kg on Days 1 and 8 of a 21-day cycle + pembrolizumab 200 mg on Day 1 of a 21-day cycle.
89190453|NCT05186974|Experimental|SG + Pembrolizumab (Cohort B)|Participants assigned to Cohorts B according to TPS status will receive SG 10 mg/kg on Days 1 and 8 of a 21-day cycle + pembrolizumab 200 mg on Day 1 of a 21-day cycle.
89190454|NCT05186974|Experimental|SG + Pembrolizumab + Carboplatin Safety Run-in|Participants will receive SG (de-escalating dose levels: 10.0 mg/kg, 7.5 mg/kg, or 5.0 mg/kg) on Days 1 and 8 of a 21-day cycle + pembrolizumab 200 mg on Day 1 of a 21-day cycle + carboplatin area under the concentration versus time curve (AUC)5 on Day 1 of a 21-day cycle.
89190455|NCT05186974|Experimental|SG + Pembrolizumab + Cisplatin Safety Run-in (Optional)|Participants will receive SG (either 10 mg/kg or 7.5 mg/kg) on Days 1 and 8 of a 21-day cycle + pembrolizumab 200 mg on Day 1 of a 21-day cycle + cisplatin 75 mg/m^2 on Day 1 of a 21-day cycle.
89190456|NCT05186974|Experimental|SG + Pembrolizumab + Carboplatin or Cisplatin (Cohort C)|Participants assigned to Cohort C according to disease status will receive SG RP2D as determined during the safety run-in cohorts on Days 1 and 8 of a 21-day cycle + pembrolizumab 200 mg on Day 1 of a 21-day cycle + carboplatin AUC5 or cisplatin 75 mg/m^2 as determined during the safety run-in cohorts on Day 1 of a 21-day cycle.
89405121|NCT00749216|Experimental|Q8W|IV infusion of 400mg once every eight weeks for 2 months
89405122|NCT05104684|Experimental|group A:Chest Physical Therapy|Patients in group A will receive CPT program daily for three weeks before HSCT (hospital stay for allogeneic-HCT). The program consists of postural drainage, diaphragmatic breathing exercises, coughing, huffing, percussion, shaking, and exercise training using an incentive spirometer in addition to routine medical treatment. The total duration of each CPT session ranged from 45-60 minutes according to patient tolerance. The choice of airway clearance method that will be applied depends on two factors; patient preference and the individual response of the patient to treatment.
89405123|NCT05104684|Active Comparator|Control group (B):Routine medical treatment|patients in group B will receive routine medical treatment
89405124|NCT00748124|Experimental|PleuraSeal Sealant Device|
89405125|NCT00748124|Other|Control|
89405126|NCT05201963|No Intervention|Group 1 control group|Control group will recive only IV Opioids
89405127|NCT05201963|Experimental|Group 2 ((Serratus Anterior Plane Block SAPB))|Patients will receive Ultrasound guided Serratus Anterior Plane Block with injection of 30 ml levobupivacaine 0.25%
89405128|NCT05201963|Experimental|Group 3 ((Erector Spinae Plane Block ESB))|Patients will receive Ultrasound guided erector spinae plane block with injection of 30 ml levobupivacaine 0.25%.
89405129|NCT04911400|Experimental|Upper-lower clear plastic retainers + Class III elastics|Upper-lower clear plastic retainers + Class III elastics
89405130|NCT04911400|Active Comparator|Upper-lower clear plastic retainers|Upper-lower clear plastic retainers
89531009|NCT02499341|Active Comparator|Ketamine|Intraoperative administration of a bolus dose of ketamine and continuous intravenous infusion of ketamine for up to 48 h postoperatively.
89405131|NCT05201573||Subjects historically treated with DIAM|Subjects randomized to the DIAM arm and treated with the DIAM™ Spinal Stabilization System in the IDE study OR randomized to the Control arm and crossed over to receive treatment with the DIAM™ Spinal Stabilization System in the IDE study
89405132|NCT05462327|Experimental|Low Fresh Gas Flow in Prone Position|Low fresh gas flow (0,5 L/min during maintenance)
89405133|NCT05462327|Active Comparator|Normal Fresh Gas Flow in Prone Position|Normal flow (2 L/min) in general anesthesia.
89405134|NCT00744926|Placebo Comparator|placebo|
89405135|NCT00744926|Experimental|taspoglutide 10mg sc|
89405136|NCT00744926|Experimental|taspoglutide 10mg/20mg sc|
89405137|NCT03840772|Experimental|Eribulin|"Eribulin will be administered at the dose of 1.23 mg/m², intravenously over 2-5 min on day 1 and day 8 of every 21 day cycle.~Study treatment will be administered until evidence of progression or unacceptable toxicity, patient's own willingness, non-compliance or according to clinical investigator's decision."
89405138|NCT03838744|Active Comparator|Standard arm: Trabectedin in monotherapy|Trabectedin in monotherapy at the dose 1.5 or 1.3 mg/m2 (according institutional practice) given as intravenous infusion at day 1 every 3 weeks (21 days cycle)
89405139|NCT03838744|Experimental|Experimental arm: Trabectedin + Olaparib|Trabectedin at the dose 1.1mg/m2 given as intravenous infusion at day 1 every 3 weeks (21 days cycle) plus Olaparib per os at the dose of 150 mg twice a day
89405140|NCT05327348|Experimental|Parenteral Ascorbic Acid|Intravenous ascorbic acid 1 gram 8 hourly (3 grams per day) for 7 days
88881167|NCT04248764|No Intervention|Control group|Participants will perform a 100 fall-bounces (5 sets x 20 reps, with two minutes of rest) from a 50 cm high box as the fatigue protocol. All participants will use a five-minute bicycle ergometer to warm up prior to the. Following the fatigue protocol, the participants will rest in the long sitting position for 5 minutes.
88881168|NCT04231669|No Intervention|Control: bolstered care|Female adolescents in the bolstered care will receive services/education as usual in their respective schools. The usual care will be bolstered by providing school notebooks and lunch in the control arm (bolstered care will also be provided to treatment arm). Primary school education is universal and free in Ghana. Yet notebooks and lunch are costly expenses for families that create a barrier to school attendance. Hence, these will be provided to participants in all study schools.
88881169|NCT04231669|Experimental|Anzansi Family Program|In addition to bolstered care, participants(adolescent girls and caregivers) in this arm will receive the ANZANSI that combines Family Economic Empowerment (EE) with Multiple Family Groups (MFG).
88881170|NCT04228107|Experimental|Cohort|"Participants will be enrolled in medication use monitoring. Their medication use patterns will be available to themselves and their guardians via a smartphone application, and to their asthma care providers via a portal. There will be no interventions to change medication use patterns. A portion of them will be asked to participate in a semistructured interview during which they will be asked questions about their perception of their asthma, health beliefs regarding medication use, and what they feel would be the most helpful to get them to take their asthma medicines.~Additionally a small group of healthcare providers will be asked to participate in a focus group to collect qualitative data on medication use barriers and facilitators"
88881171|NCT04210778|Experimental|CRAFT (Cognitive Training and Functional Treatment)|Over 12 weeks this group will be instructed to complete 3 weekly sessions of Computerized Cognitive Training, in addition to a weekly 1 hour remote CO- OP (Meta cognitive strategy training) session. Each participant will set three occupational goals that will be the focus of the CO -OP treatment
89190457|NCT05186974|Experimental|SG + Pembrolizumab + Carboplatin or Cisplatin (Cohort D)|Participants assigned to Cohort D according to disease status will receive SG RP2D as determined during the safety run-in cohorts on Days 1 and 8 of a 21-day cycle + pembrolizumab 200 mg on Day 1 of a 21-day cycle + carboplatin AUC5 or cisplatin 75 mg/m^2 as determined during the safety run-in cohorts on Day 1 of a 21-day cycle.
89405141|NCT05327348|Placebo Comparator|0.9% Normal Saline|Intravenous 0.9% normal saline 10 mL 8 hourly for 7 days
89405142|NCT05201417|No Intervention|control group A|patients continue their usual HIV management no intervention
89405143|NCT05201417|Other|intervention group B|patients continue their usual HIV management, patients will benefit from an adapted physical activity program for 12 weeks
89437498|NCT03792919|Active Comparator|Keep on current NAs treatment|Chronic hepatitis B patients who meet the criteria to stop anti-HBV Neucleos(t)ides treatment will choose to keep on their current NAs treatment from the baseline of the clinical trial.
89437499|NCT03789162||Confirmed CRC with Residual Lesion|A diagnosis of CRC confirmed with a tissue biopsy or a colorectal lesion at least 1 cm in size suspicious for adenoma (including sessile serrated adenoma) or CRC on a pre-enrollment colonoscopy.
89437500|NCT03786926|Experimental|Treatment|All patients take HMPL-689 taken daily
89190458|NCT05186974|Experimental|SG + Pembrolizumab + Cisplatin (Cohort E)|Participants assigned to Cohort E will receive SG RP2D, as determined following safety review of Cohorts C and D, on Days 1 and 8 of a 21-day cycle + pembrolizumab 200 mg on Day 1 of a 21-day cycle + cisplatin 75 mg/ m^2 on Day 1 of a 21-day cycle.
89190459|NCT05182840|Experimental|Treatment period: Empagliflozin + BI 690517|
89190460|NCT05182840|Experimental|Treatment period: Empagliflozin + Placebo to BI 690517|
89190461|NCT05182840|Experimental|Treatment period: Placebo to Empagliflozin + BI 690517|
89190462|NCT05182840|Placebo Comparator|Treatment period: Placebo to Empagliflozin + Placebo to BI 690517|
89190463|NCT05146908||Patients in intensive care|Ventilated intubated patients for whom enteral nutrition is planned
89190464|NCT05144945|Experimental|Group 1: Quadrivalent Recombinant Influenza Vaccine (RIV4)|Participants received a single intramuscular (IM) injection of 0.5 milliliters (mL) RIV4 on Day 1.
89190465|NCT05144945|Active Comparator|Group 2: Quadrivalent-inactivated Influenza Vaccine (IIV4)|Participants received a single IM injection of 0.5 mL IIV4 on Day 1.
89190466|NCT05141370|Experimental|hand-held femtosecond laser|Anterior capsulorhexis will be performed with a hand-held femtosecond laser named CATSYS.
89190467|NCT05139303|Experimental|MAD therapy|
89190468|NCT05135767|Active Comparator|Alcohol Use Disorder Only|Individuals in the Alcohol Use Disorder Only arm will meet criteria for alcohol use disorder but will not show evidence of advanced alcohol-associated liver disease. Both arms receive the same brief motivational intervention with personalized feedback.
89190469|NCT05135767|Active Comparator|Alcohol Associated Liver Disease + Alcohol Use Disorder|Individuals in the Alcohol Associated Liver Disease + Alcohol Use Disorder arm will meet criteria for alcohol use disorder and also show evidence of advanced alcohol-associated liver disease. Both arms receive the same brief motivational intervention with personalized feedback.
89190470|NCT05135351|Experimental|Treatment|resistant starch
89190471|NCT05135351|Placebo Comparator|Placebo|maltodextrin
89190472|NCT05126485|Experimental|Randomizing Control and Biofeedback Phases|"The gait training and data collection procedure is split into two phases: a control phase and a biofeedback phase. The order of these phases is randomized across participants to reduce the probability of systematic error due participants warming-up or fatiguing between trials. Each phase consists of a pre-test, gait retraining session, and one or more post-tests."
89190473|NCT05123027|Experimental|Peer Intervention to Link Overdose Survivors to Treatment (PILOT) Peer|
89190474|NCT05123027|Active Comparator|Treatment As Usual Peer|
89190475|NCT05119621|Experimental|TENS application|TENS application will be applied to the experimental group before mobilization after abdominal surgery. TENS will be applied for an average of 40 minutes.
89190476|NCT05119621|No Intervention|Standard pain management|The control group will receive standard pain treatment without any intervention. The group will not receive any other intervention.
89190477|NCT05117489|Experimental|Cohort 1 - 150 mg of miricorilant for 24 weeks|Patients who meet the entry criteria for study CORT-118335-861 will be enrolled to receive miricorilant as a steady dose of 150 mg once daily, for 24 weeks.
89190478|NCT05117489|Experimental|Cohort 2 - 150 mg of miricorilant for 12 weeks|Patients who meet the entry criteria for study CORT-118335-861 will be enrolled to receive miricorilant as a steady dose of 150 mg once daily, for 12 weeks.
89190479|NCT05117489|Experimental|Cohort 3 - 100 mg daily miricorilant for 2 weeks, followed by 100 mg every MWF for 10 weeks|Patients who meet the entry criteria for study CORT-118335-861 will be enrolled to receive miricorilant as a steady dose of 100 mg once daily for 2 weeks, followed by 100 mg of miricorilant every Monday, Wednesday and Friday for 10 weeks.
89190480|NCT05117489|Experimental|Cohort 4 - 100 mg daily miricorilant for 2 weeks, followed by 100 mg every MF for 10 weeks|Patients who meet the entry criteria for study CORT-118335-861 will be enrolled to receive miricorilant as a steady dose of 100 mg once daily, for 2 weeks, followed by 100 mg of miricorilant every Monday and Friday for 10 weeks.
89405144|NCT04695106|Experimental|Study population|"In the study group (both STEMI and NSTE-ACS), aspirin will be discontinued, and ticagrelor will be started at a loading dose of 180 mg, irrespective of timing and dosing of clopidogrel, and continued at a maintenance dose of 90 mg twice daily for 1 month, followed by 60 mg twice daily up to 12 months.~Dabigatran will be used as a standard-of-care. Lower dose dabigatran (110 mg twice daily) will be used in patients ≥80 years of age and will be considered in patients (i) 75-80 years of age, (ii) with creatinine clearance 30-50 ml/min, (iii) at high risk of bleeding (HAS-BLED ≥ 3), (iv) at high-risk of gastrointestinal bleeding (with esophagitis, gastritis, gastroesophageal reflux disease), and (v) treated with verapamil, in accordance with the guidelines."
89405145|NCT04695106|Active Comparator|Control group|"In the control group, aspirin and clopidogrel will be continued depending on the diagnosis (STEMI or NSTE-ACS) and bleeding risk. In patients with STEMI, aspirin will be discontinued after 1-6 months, according to a balance between the estimated risk of recurrent coronary events and bleeding. In patients at high bleeding risk aspirin will be discontinued after 1 month. Subsequently, all patients will be treated with clopidogrel and dabigatran up to 12 months. In the NSTE-ACS group, aspirin will be used up to 1 week (in-hospital period), extendable up to one month in patients at high ischaemic risk. Dual therapy will be continued up to 12 months with the possibility of shortening for patients at high bleeding risk.~Dabigatran will be used as a standard-of-care (as above)."
89405146|NCT05104372|Experimental|Intervention|"Intervention Group HSNIG started within 5 days of symptom onset Number of times HSNIG should be done: As many times as needed (but not more than 12 times/day) PLUS~Standard personal, household hygiene and social distancing advice:~http://www.covid.gov.pk/prevention"
89405147|NCT05104372|Placebo Comparator|Control|"Control Group~Standard personal, household hygiene and social distancing advice:~http://www.covid.gov.pk/prevention"
89405148|NCT04032665||Stable coronary and peripheral artery disease (CAD/PAD)|Stable CAD/PAD patients with previous percutaneous coronary intervention and drug eluting stent-implantation treated with dual antiplatelet therapy (ASA+clopidogrel)
89405149|NCT04032665||Acute coronary artery disease (ACS)|Patients with troponin-positive ACS (NSTEMI/STEMI) with planned percutaneous coronary intervention and drug eluting stent-implantation treated with P2Y12 inhibitor (ticagrelor) and ASA
89405150|NCT04516720||Primary Nervous System Tumors arm|"The information letter will be delivered by the investigator physician to the patients to inform them on the study, its implementation and their complete freedom to participate or not.~Clinical Data and Questionnaires:~For the retrospective part~Patient identification based on data from the Medical Information Department (DIM) of the ICM;~Verification of the eligibility criteria;~Inclusion of patients in a coded form in BDD-NO;~Implementation of the database with the data already collected (as an coded EXCEL file) in specific studies (some patients are included in several of these studies): study of diffuse low grade gliomas, study on anaplastic gliomas, study on the place of Bevacizumab in high-grade gliomas, clinical database created~Collection of clinical data from each patient's medical record~For the prospective part~Inclusion of patients in a coded form in BDD-NO;~Collection of clinical data from each patient's medical record."
89190481|NCT05117489|Experimental|Cohort 5 - 100 mg of miricorilant every MWF for 12 weeks|Patients who meet the entry criteria for study CORT-118335-861 will be enrolled to receive miricorilant of 100 mg every Monday, Wednesday and Friday for 12 weeks.
88881172|NCT04210778|Active Comparator|Computerized Cognitive Training|This group will be instructed to complete 3 weekly sessions of Computerized Cognitive Training
88881173|NCT04210778|No Intervention|Treatment As Usual|This group will receive no intervention
88881174|NCT04208048||FLXfit 15|The FLXfit 15 device will then be placed into the space between the low backbones, using specific medical instruments, where the damaged disc was removed.
88881175|NCT04194541|Experimental|Treatment Group|Participants will be provided a kit containing 3 dressings: Cutimed Sorbact Hydroactive B, Cutimed Siltec, and Sorbion Sana multi-star. Participant can use their dressing of choice and can change their dressings as needed for 6 consecutive weeks.
88881176|NCT04190706|Experimental|bioactive components fortified food products|
88881177|NCT04190706|Placebo Comparator|control food products|
88881180|NCT04153396|Experimental|The Treatment Group|The local infiltration solution in the treatment group will consist of betamethasone and ropivacaine.
88881181|NCT04153396|Active Comparator|The Control group|The local infiltration solution in the control group will consist of ropivacaine.
88881182|NCT04148521|Experimental|Behavioral Health - Virtual Patient Navigation|All patients who meet eligibility criteria at sites where the virtual patient navigation behavioral health program is offered will be considered exposed to the intervention.
89190482|NCT05117489|Experimental|Cohort 6 - 100 mg of miricorilant every MF for 12 weeks|Patients who meet the entry criteria for study CORT-118335-861 will be enrolled to receive miricorilant of 100 mg every Monday and Friday for 12 weeks.
88881183|NCT04148521|No Intervention|Usual care Behavioral Health|All patients who meet eligibility criteria at sites where the virtual patient navigator behavioral health program is not offered will be considered exposed to usual care.
88881184|NCT04131309|Experimental|Daratumumab|"Daratumumab monotherapy 16 mg/kg intravenous infusion (iv) or 1800 mg subcutaneous injection (sc) weekly for Cycles 1-2, every 2 weeks for Cycles 3-6 and every 4 weeks thereafter.~Subjects who do not achieve either a hematologic VGPR or better, OR a hematologic PR with a major organ response by Cycle 4 Day 1 may receive, in addition to daratumumab, bortezomib (for a maximum of 6 cycles) and low dose dexamethasone."
89190483|NCT05117489|Experimental|Cohort 7 - 50 mg of miricorilant daily for 12 weeks|Patients who meet the entry criteria for study CORT-118335-861 will be enrolled to receive miricorilant as a steady dose of 50 mg once daily, for 12 weeks.
89190484|NCT05117489|Experimental|Cohort 8 - 100 mg of miricorilant daily for 12 weeks|Patients who meet the entry criteria for study CORT-118335-861 will be enrolled to receive miricorilant as a steady dose of 100 mg once daily, for 12 weeks.
89405151|NCT05201261||Ultrasound-guided group|Adult patients with American Society of Anesthesiologists physical status I/II/III scheduled to undergo elective Lower limb surgery under spinal anesthesia were considered for eligibility.
89405152|NCT03629639|Experimental|Metformin|the distributed subjects will be orally administered Metformin 500mg bid lasting for 12 weeks.
88881185|NCT04119778|Experimental|Aerobic Exercise|The exercise intervention will last 16 weeks, comprised of home-based exercise with weekly telephone counselling to encourage participants to continue to exercise, supplemented with 8 supervised exercise sessions (2 sessions per month). Each session will last for an hour. The supervised exercise sessions will be provided by professional exercise specialists twice in the first week in each month throughout the intervention period, an hour each time. Exercise trainers will lead the classes. Each class will include both aerobic exercise and resistance exercise. They are encouraged to do aerobic exercise for at least 150 min weekly at a moderate intensity level, as well as perform resistance exercises alternate day. Participants are also provided an exercise diary, containing details of their weekly prescribed exercises and the scales they have to refer to.
88881186|NCT04119778|Experimental|Tai chi|Our tai-chi classes will be based on a 16-form tai-chi exercise set. The classes will run twice a week for 16 weeks with each session lasting approximately 60 minutes. Classes will be taught by an experienced tai-chi master, who will explain the theory behind tai-chi and the principles of the techniques. The supervised session includes a warm up, self-massage and a guided run through of the movements, breathing techniques, and relaxation in tai-chi. The tai-chi master will guide participants to practice the tai-chi they learn in the classes at home each day. Upon completion of the 16 weeks course, participants will be encouraged to continue their tai-chi practice, given guidance on local services and programmes they may join if they wish to.
89405153|NCT03629639|Placebo Comparator|Placebo|the distributed subjects will be orally administered Metformin-like placebo 500mg bid lasting for 12 weeks.
88881187|NCT04119778|No Intervention|Self Management Group|Participants randomised to the control group shall receive written information on health levels of physical activity, which they can participate in at home (self-management) and continue to receive their usual care, participants will be followed up with an assessment at 16 weeks and one year. At the end of the evaluation stage of the study, survivors in the control group will be invited to take part in an intervention of their choice.
88881188|NCT04108767||Health students enrolled in the 3rd year at the University Cla|Health students enrolled in the 3rd year at the University Claude Bernard Lyon 1, aged over 18 years.
89405154|NCT03577288|Experimental|Experiment 1 A, B - Level of realism of EVR|Participants (50 children and 50 young adults for part A, and 50 other children and 50 other young adults) will be exposed to virtual experience having different level of realism. In one condition the realism will be high (very close to the real word) and in the second condition the realism will be low (comparable to cartoon). The stimuli of interest included in virtual experience will be of three emotional categories : negative, positive and neutral.
89405155|NCT03577288|Experimental|Experiment 2 - Presence and size of avatar|"Participants (50 children and 100 young adults) will be exposed to virtual experiences in which in one condition they will be part of the virtual environment in a body of an avatar and in another condition the avatar will not be present.~Children will be exposed to only one of the two possible situations: with an avatar or without an avatar for the entire experience. Adults will be exposed to only one of the four possible situations: with standard size avatar, with giant avatar, with tiny avatar, or without avatar."
89405156|NCT03577288|Experimental|Experiment 3 - Interaction in virtual experience|Participants (50 children and 50 young adults) will be submitted to two conditions of virtual experience, one condition in which it is possible to interact with the stimuli presented in the virtual environment and another condition in which it is not possible to interact. In addition, the stimuli of interest will be of one of three emotional categories : negative, positive and neutral. Thus participants will be exposed to six short virtual experiences.
88881189|NCT04078594|Experimental|Experimental wards|Active sepsis e-alert
88881190|NCT04078594|No Intervention|Contol wards|"Masked sepsis e-alert.~The wards will have masked sepsis e-alert."
88881191|NCT04077970|Experimental|Intrauterine flushing follicular fluid|Women underwent intrauterine flushing with follicular fluid plus granulosa cells
88881192|NCT04077970|No Intervention|Without intrauterine flushing with follicular fluid|Women without intrauterine flushing with follicular fluid
89190485|NCT05117489|Experimental|Cohort 9 - 30 mg of miricorilant daily for 12 weeks|Patients who meet the entry criteria for study CORT-118335-861 will be enrolled to receive miricorilant as a steady dose of 30 mg once daily, for 12 weeks.
89405157|NCT03577288|Experimental|Experiment 4 - Animate/Inanimate nature of interactive objects|Participants (30 children and 30 young adults) will be exposed to the virtual experience during which they will be able to interact in one condition with animated (e.g., dog, bird) stimuli and in another condition with inanimate (e.g., book, jacket) stimuli. The animate and inanimate stimuli of interest will be of three emotional categories : negative, positive and neutral.
89405158|NCT05210023|Experimental|Nutrigenetic Diet Group|Participants randomly included in this group will receive nutrigenetic menus, i.e., considering the genotypes of the 11 variants analyzed.
89405159|NCT05210023|Experimental|Conventional Diet Group|Participants randomly included in this group will receive menus prepared following the international conventional guidelines set out by the WHO, AHA and Official Mexican Standards (NOM) for the treatment of obesity and dyslipidemia.
89405160|NCT00835172|Experimental|Glimepiride|Glimepiride 4 mg Tablet (test) dosed in first period followed by Amaryl® 4 mg Tablet (reference) dosed in second period
89190486|NCT05117489|Experimental|Cohort 10 - 200 mg of miricorilant once a week for 12 weeks|Patients who meet the entry criteria for study CORT-118335-861 will be enrolled to receive miricorilant as a steady dose of 200 mg once weekly, for 12 weeks.
89405161|NCT00835172|Active Comparator|Amaryl®|Amaryl® 4 mg Tablet (reference) dosed in first period followed by Glimepiride 4 mg Tablet (test) dosed in second period
89405162|NCT04941755|Experimental|Sequence AB|
89405163|NCT04941755|Experimental|Sequence BA|
89437501|NCT03785600|Experimental|Morning Bright Light Therapy|Morning bright light: Sitting in front of a lightbox for 60 minutes every morning within 90 minutes of waking up.
88881193|NCT04067427|Active Comparator|Mental training|AF ablation followed by 3 months of a daily app-based mental training for 10 to 15 minutes per session. AF 6 questionnaire will be answered weekly via the Mental-AF webpage.
88881194|NCT04067427|No Intervention|Control|AF ablation without subsequent mental training. AF 6 questionnaire will be answered weekly via the Mental-AF webpage.
88881195|NCT04056221|Experimental|acupuncture|Acupuncture at the selected points.
88881196|NCT04056221|Sham Comparator|Sham acupuncture|Similar appearance to conventional acupuncture, however, without needles skin penetration.
88881197|NCT04040959|Experimental|Nicotinamide Riboside|Each nicotinamide riboside capsule contains 250 mg of nicotinamide riboside chloride mixed with microcrystalline cellulose. Dosage: 500 mg by mouth twice a day for 3 months.
88881198|NCT04040959|Placebo Comparator|Placebo|Matched placebo capsules.
89190487|NCT05117489|Experimental|Cohort 11 - 150 mg of miricorilant twice weekly for 12 weeks|Patients who meet the entry criteria for study CORT-118335-861 will be enrolled to receive miricorilant as a steady dose of 150 mg twice weekly for 12 weeks.
89190488|NCT05116722|Experimental|Shoulder Pacemaker Treatment|The patients will be treated using the pacemaker for 15 - 30 minutes at 3-months, 6-months and 12-months during physical therapy.
89190489|NCT05064332|Experimental|OC only|Subjects will receive a single dose of an oral contraceptive during the first period of the study
89190490|NCT05064332|Experimental|PF-06650833 + OC|Subjects will receive PF-06650833 every day for 11 days and a single dose of an oral contraceptive on day 10.
89190491|NCT05057780|Experimental|Intervention Curriculum|The intervention course consisted of 3 hour-long sessions on communication delivered over a 4-month period. It differed from the control course in subject matter and pedagogy. Subject matter focused on specific skills used in communication: reflective listening, responding to emotion, and providing information within a broad range of communication scenarios. In terms of pedagogy, the intervention course was interactive with a focus on skills practice, communication drills, and improvisation to engage learners. The sessions consisted of fifteen minutes of lecture and 45 minutes of skills practice.
89190492|NCT05057780|Active Comparator|Control (Standard) Curriculum|The control course consisted of three hour-long didactic lectures on delivering bad news, discussing prognosis, and talking to patients about pain. The majority of time in these lectures was spent on didactic material. Little, if any, time was spent practicing skills or on interactive skill building. The three parts of the course were delivered over a 4-month period.
89190493|NCT05055141|Experimental|Care to Share Poster|"The intervention was an 18x18 poster board with a large blank surface for patients to share information about who they are as people and what is important to them. The Care to Share poster was co-designed with ten medicine inpatients during pilot testing. The goal of the poster was to equip Caregivers with humanizing information about their patients, thereby provoking more genuine empathetic interactions. Based on input from pilot testing, the researcher wrote on the poster for the patient to ensure ease of completion and legibility. The posters were displayed on the wall behind patients' beds, so Caregivers entering the room could easily see the information when facing the patient."
89190494|NCT05055141|No Intervention|Control|Study participants hospitalized on the two control units had no Care to Share poster.
89190495|NCT05051345|Experimental|Goal 1 (Wellness app)|Participants download and use the Wellness app onto their smartphones. Participants also receive information on the services provided for pregnant women and smoking cessation.
89190496|NCT05051345|Experimental|Goal 2 (counseling, Wellness app, self-help)|Participants receive telephone counseling sessions over 30-45 minutes for a minimum of 6 sessions in the prenatal period and about 4-6 postpartum period. Participants who start counseling after birth, may receive 6-8 sessions up to 4 months postpartum. Participants may also use the Pregnancy and Wellness smartphone app that provides wellness messages, smoking cessation information, relapse prevention tips, and tips to create a smoke-free home. Participants also receive tobacco cessation self-help materials including National Partnership for Smoke Free Families and Forever Free Baby and Me.
89190497|NCT05051345|Experimental|Goal 3 (Smoke-free Homes)|Participants receive the Smoke-Free Homes kit providing guidance for how to talk with household members and visitors about not smoking inside the home. Participants may also receive 3 separate Smoke-Free Homes mailings over 6 weeks, and a coaching call from a Baby Steps for Health counselor to help follow the steps described in the mailed materials in order to set up a smoke-free home.
89190498|NCT05051345|Experimental|Goal 4 (counseling)|Non-pregnant participants receive telephone counseling sessions over 30 minutes for 6-8 sessions over a 3 month period.
89190499|NCT05036330||Observational (evaluation, examination, questionnaire)|Patients undergo speech and swallow evaluation by speech pathologist or study staff member and examination of TEP and laryngectomy stoma. Patients also complete questionnaires over 30 minutes about use the ProvoxLife HME system, symptoms, ability to communicate, exercise and physical activity levels, and quality of life at baseline and 3 months post-ProvoxLife.
89190500|NCT05027308|Experimental|Teduglutide 0.05 milligram per kilogram (mg/kg)|Participants will receive teduglutide 0.05 mg/kg (0.025 mg/kg for participants with moderate or greater renal impairment) subcutaneous (SC) injection once daily for 24 weeks followed by no treatment period for 4 weeks. The maximum duration of treatment is approximately 18 months.
89190501|NCT05022823|Active Comparator|Standard of Care|Group A (Control). Home decongestive exercise regimen + daytime use of a compression sleeve (12 hours per day)
89190502|NCT05022823|Experimental|DPRE + compression sleeve during exercise|Group B. Decongestive Progressive Resistance Exercise + compression sleeve use during exercise + daytime use of a compression sleeve (12 hours per day)
89531010|NCT02499185|Experimental|Nephro Check Test|We take urine samples and analyse the level of [TIMP-2]●[IGFBP-7] using the NephroCheck Test to diagnose AKI
88881199|NCT04035031|Experimental|Forxiga first, placebo second|Forxiga followed by placebo
88881200|NCT04035031|Experimental|Placebo first, Forxiga second|Placebo followed by forxiga
88881201|NCT04018638|Experimental|Adults with TKR Perform Home Exercise Program|Participants that have a total knee replacement will complete a home-based exercise program
88881202|NCT04018638|No Intervention|Healthy Controls Only|Participants that have no history of knee joint dysfunction will serve as age-matched uninjured controls
89405164|NCT05093218|Experimental|branch chain amino acid|• Branch chain amino acid at a dose of approxiametely 0.35g/kg will be supplemented in two divided doses group for a period of 12 weeks.For the sake of administration, it will be prescribed as per the following weight band categories: <5kg 2 gm 5-10kg 4 gm 10-20kg 8 gm 20-40kg 12 gm 40-60kg 24 gm
89405165|NCT05093218|Placebo Comparator|placebo|Placebo will have the similar colour, taste and consistency. Both groups will be given the same dose.
89405166|NCT05209945|Experimental|Vibration|Vibration (WBV, heel, and tendon vibration) was applied to participants
89405167|NCT04921735||Elderly|patients aged 80 years or older
89405168|NCT04921735||young|patients aged 18-40 years
89405169|NCT01676116|Experimental|Insulin degludec/liraglutide + OADs|
89405170|NCT01676116|Active Comparator|Liraglutide or exenatide + OADs|
89405171|NCT04930796|Experimental|VER-01 following overnight fast (Day 1) and a high-fat breakfast (Day 4)|The PK profile of VER-01 is investigated after oral intake of a single dose VER-01 (corresponding to 10 mg THC) in the morning after a 10-hour fasting period on day 1, and 30 minutes after the intake of a standardised high-fat breakfast has been started on day 4 (Group 1).
88881203|NCT04006392|Experimental|Erchonia FX-635|The Erchonia FX-635 is administered to the foot 12 times over 6 weeks (2 times each week) for 15 minutes per foot.
88881204|NCT04006392|Sham Comparator|Placebo Laser|Noise and appearance of output is the same but no active therapy applied. Treatment administration procedure is the same as with the experimental arm.
88881205|NCT04000568||Study Population|All the infants enrolled in the study will receive 1 h of NAVA-NIV and 1h PC-NIV in a cross-over study design
88881206|NCT03997617|Other|Personalized Functional Profiling|
88881207|NCT03959423|Experimental|Subjects 7-75 years of age|Subjects who have been diagnosed with type 1 diabetes
88881208|NCT03907462|Experimental|Treatment One|Participants assigned to the SMART 2.0 with technology and personal health coaching treatment group (i.e., treatment one) will receive the following: 1) consumer-level wearable and scale with a corresponding app, 2) daily text messages related to physical activity, diet, sleep and weight loss/maintenance, 3) access to SMART 2.0 social media pages and content through an online group with 6 to 12 participants total, and 4) technology-mediated, real-time individual health coaching. Participants will receive 1 to 2 text messages on a daily basis; be asked to use their wearable on a daily basis and self-weigh using the scale at least once per week; be asked to interact with their online group via social media as frequently as possible; and speak with their health coach at a predetermined session schedule.
88881209|NCT03907462|Experimental|Treatment Two|Participants assigned to the SMART 2.0 technology alone treatment group (i.e., treatment two) will receive the following: 1) consumer-level wearable and scale with a corresponding app, 2) daily text messages related to physical activity, diet, sleep and weight loss/maintenance, and 3) access to SMART 2.0 social media pages and content through an online group with 6 to 12 participants total. Participants will receive 1 to 2 text messages on a daily basis; be asked to use their wearable on a daily basis and self-weigh using the scale at least once per week; and be asked to interact with their online group via social media as frequently as possible.
88881210|NCT03907462|No Intervention|Control|Participants assigned to the control group will receive a consumer-level wearable and scale with a corresponding app to use at their discretion.
88881211|NCT03900910|Experimental|Gastric cancer prevention|13C-urea breath test and anti-H. pylori treatment for those who are tested positive.
89405172|NCT04930796|Experimental|VER-01 following a high-fat breakfast (Day 1) and overnight fast (Day 4)|The PK profile of VER-01 is investigated after oral intake of a single dose VER-01 (corresponding to 10 mg THC) in the morning 30 minutes after the intake of a standardised high-fat breakfast has been started on day 1 and after a 10-hour fasting period on day 4 (Group 2).
89405173|NCT04888286||patients who underwent mismatched allogeneic transplantation|Pediatric and adult patients who underwent mismatched allogeneic transplantation, from January 2014 to June 2017.
89405174|NCT05200793|Active Comparator|Metformin arm (control group)|Patients will receive Metformin (1500 mg orally/day) for 12 weeks .
89405175|NCT05200793|Active Comparator|Empagliflozin arm|Patients will receive Empagliflozin (25 mg orally/day) for 12 weeks.
88881212|NCT03900910|Experimental|The acceptability and applicability of the mass screening program|Our short-term outcome is the acceptability and feasibility of this screening program, which will be evaluated by answering whether the screening quality indicators can reach the minimal requirements.
89405176|NCT05200793|Active Comparator|Linagliptin arm|Patients will receive Linagliptin (10 mg orally/day) for 12 weeks
89405177|NCT00917306|Experimental|PEP005 gel|PEP005 gel, 0.05% administered once daily for 2 consecutive days
89405178|NCT05191303|Experimental|Intervention group|In addition to standard usual care of breastfeeding counseling, the intervention group will have an opportunity to access the mobile application breastfeeding counseling from weeks 18 of pregnancy, continuing for up to 6 months after childbirth.
89405179|NCT05191303|No Intervention|Control group|"The control group receives the standard usual care of breastfeeding counseling in maternity care and in hospital from weeks 18 of pregnancy, continuing for up to 6 months after childbirth.~The standard usual care of breastfeeding follows the 10 steps of the Baby Friendly Hospital Initiative programme and Finnish Institute for Health and Welfare recommendation."
89405180|NCT03453502|No Intervention|Before-intervention phase|All the very low birth weight (VLBW) and extremely low birth weight (ELBW) infants who were admitted from January 2017 to December 2017 to the NICUs of different hospitals.
89405181|NCT03453502|Experimental|Intervention phase|All the VLBW and ELBW infants who were admitted from January 2018 to December 2018 to the NICUs.During this phase,multiple intervention bundles of quality improvement will be implemented.
89405182|NCT03453502|Experimental|Sustainability intervention phase|All the VLBW and ELBW infants who were admitted from January 2019 to December 2019to the NICUs.In the Sustainability intervention phase,multiple intervention bundles of quality improvement will be continuous implemented.
89405183|NCT02264899|Experimental|Alzheimer's disease and related disorders|
89405184|NCT05763485|Active Comparator|Anti reflux mucosal ablation (ARMA)|Patients randomized into the intervention arm receive ARMA and a follow up control after 2, 4, 6 and 12 months. PPI treatment is stopped after 2 months until the end of the study or worsening of symptoms. Esophagogastroduodenoscopy, manometry and pH metry is performed after 4 months.
89405185|NCT05763485|Sham Comparator|Sham procedure|Patients randomized into the sham procedure arm receive a esophagogastroduodenoscopy in the same setting as if ARMA would be performed. Patients in the Control group receive follow up controls after 2 and 4 months and after unblinding after 4 months are allowed to perform a crossover to receive ARMA. PPI treatment is stopped 2 months after the initial sham procedure until the end of the study or worsening of symptoms. If the patients receive ARMA as a crossover reevaluation is performed 2, 4, 6 and 12 months after the actual ARMA procedure.
89405186|NCT03383224|Experimental|Genotype-guided (A allele carriers)|CHRNA5 rs16969968 genotype will be determined. Genotype-guided therapy will be given (A allele carriers will be given pharmacologic therapy (nicotine replacement therapy --NRT; nicotine patch used according to FDA labelling).)
89405187|NCT03383224|Experimental|Genotype-guided (GG homozygotes)|CHRNA5 rs16969968 genotype will be determined. Genotype-guided therapy will be given (GG homozygotes will be given smoking cessation counseling)
89405188|NCT03383224|Active Comparator|Standard (non-genotype guided) - NRT|1/2 of patients in this arm will be given nicotine replacement therapy (NRT; nicotine patch used according to FDA labeling) but this will NOT be based on the patient's genotype. Note that both nicotine replacement therapy and counseling are accepted treatments for smoking cessation in patients with coronary artery disease.
88881213|NCT03879304|Experimental|Multimodal physiotherapy program with RV|The RV intervention group receives a tele multimodal physiotherapy program with tradicional exercises of physiotherapy like stretching, aerobic, training through videos and gamification with VR glasses.
88881214|NCT03879304|Active Comparator|Traditional physiotherapy program|Traditional intervention group receives assistance of a program of physiotherapy traditional without virtual reality glasses.
89405189|NCT03383224|Active Comparator|Standard (non-genotype guided)- counseling|1/2 of patients in this arm will be given smoking cessation counseling but this will NOT be based on the patient's genotype. Note that both nicotine replacement therapy and counseling are accepted treatments for smoking cessation in patients with coronary artery disease.
89531011|NCT02499185|Active Comparator|serum creatinine measurement|"This is the Golden standard to diagnose AKI"
88881215|NCT03869957|Experimental|Intervention group|We will use ~0.8-0.9 g/kg/day of Clinoleic® (80% olive oil/20 soybean oil) + 0.2-0.1 g/kg/day [Omegaven® ](100% fish oil), to cover the proposed amount of n-3 PUFAs for 7 days. The infusion rate should not exceed 0.5 ml Omegaven® / kg body weight / hour = 0.05 g fish oil / kg body weight / hour. The intervention group will return to PN without n-3 PUFA after 7 days.
88881216|NCT03869957|No Intervention|Control group|Will be administering ~1.0 g/kg/d the lipid emulsion Clinoleic® (80% olive oil/20 soybean oil) without n-3 PUFAs.
88881217|NCT03852147|Active Comparator|Control group|hemodynamic management of patients is done according to usual practices by maintenance of blood pressure by norepinephrine as well as optimization of SV by vascular filling and use of dobutamine if necessary.
88881218|NCT03852147|Experimental|Experimental group|perioperative hemodynamic management is based on an algorithm that includes RQ measurement and includes volume expansion, norepinephrine, FiO2 enhancement, RBC transfusion and dobutamine.
88881219|NCT03844607|Experimental|Active tDCS|Participants will receive 5 sessions of cognitive training concurrent with transcranial direct current stimulation (anode over left frontal cortex, cathode over right frontal cortex; 2 mAmps for 20 minutes).
88881220|NCT03844607|Sham Comparator|Sham tDCS|Participants will receive 5 sessions of cognitive training concurrent with sham tDCS. For sham tDCS, electrodes are placed at the same locations as for active tDCS, but current is ramped up for the initial 30 secs, then immediately ramped back down. This method mimics the initial physical sensation of stimulation, but there is no active current for the remainder of the session.
88881221|NCT03801837|Active Comparator|Macadamia Nut Diet|This group will have their habitual diet supplemented with appropriate portion of Macadamia Nuts (15% of daily calories or 30-45 grams based on Kcal requirement of the individual)
88881222|NCT03801837|Placebo Comparator|Control Diet|This group will continue with their Habitual Diet
88881223|NCT03790150||Mechanically Ventilated Patients|All patients admitted to the critical care unit and require mechanical ventilation
88881224|NCT03786783|Experimental|Treatment(chemotherapy, dinutuximab, sargramostim, ASCT, EBRT)|See Detailed Description
89405190|NCT02021695||Group I: Non-diabetic controls|"Group I: Non-diabetic controls Good overall health without history of Type II diabetes. Normal fasting glucose level (<100 mg/dL) and HbA1C < 5.7%~Also:~Must provide informed consent~Males or Females aged 30 years or older to minimize the potential confounding of other forms of diabetes mellitus~In patients with diabetes, no concomitant diseases except for micro- and macrovascular complications of diabetes (nephropathy, retinopathy, peripheral arterial disease, coronary artery disease, neuropathy) or symptoms of the metabolic syndrome (hypertension, dyslipidemia and obesity)~Not taking any chronic medications (except of the diabetes and cardiovascular related drugs)."
89405191|NCT02021695||Group II: Diabetic with HbA1C<7%|"Group II:~HbA1C<7%~Also:~Must provide informed consent~Males or Females aged 30 years or older to minimize the potential confounding of other forms of diabetes mellitus~In patients with diabetes, no concomitant diseases except for micro- and macrovascular complications of diabetes (nephropathy, retinopathy, peripheral arterial disease, coronary artery disease, neuropathy) or symptoms of the metabolic syndrome (hypertension, dyslipidemia and obesity)~Not taking any chronic medications (except of the diabetes and cardiovascular related drugs)."
89405192|NCT02021695||Group III: Good controlled diabetics with 7 % <HbA1C < 10%|"Group III Good controlled diabetics with 7 % <HbA1C < 10%~Also:~Must provide informed consent~Males or Females aged 30 years or older to minimize the potential confounding of other forms of diabetes mellitus~In patients with diabetes, no concomitant diseases except for micro- and macrovascular complications of diabetes (nephropathy, retinopathy, peripheral arterial disease, coronary artery disease, neuropathy) or symptoms of the metabolic syndrome (hypertension, dyslipidemia and obesity)~Not taking any chronic medications (except of the diabetes and cardiovascular related drugs)."
89437502|NCT03785600|Sham Comparator|Negative Ion Generator|Negative ion generator: Sitting in front of a modified negative ion generator for 60 min every morning within 90 minutes of waking up.
88881225|NCT03785587|Experimental|Gel, 15%|Sofpironium Bromide Gel, 15%, applied once daily to each axilla for 24 weeks
88881226|NCT03761680|Experimental|MEDPass Group|Allocation of ONS in the MEDPass mode
89190503|NCT05022823|Experimental|DPRE + AC garment during exercise|Group C. Decongestive Progressive Resistance Exercise + Adjustable Compression (AC) garment use during exercise + daytime use of a compression sleeve (12 hours per day).
89190504|NCT04997681|Experimental|Exercise Intervention Training and Cognitive Intervention Training|Combined Aerobic Exercise and Resistance Training (AE + RT) + Cognitive Training (NeuropeakTM)
89190505|NCT04997681|Active Comparator|Exercise Intervention Training and Control Cognitive Training|Combined Aerobic Exercise and Resistance Training (AE + RT) + Control Cognitive Training of Website Searching and Video Watching (WS+V)
89405193|NCT02021695||Group IV: Poorly controlled diabetics with HbA1C > 10%.|"Group IV:~Poorly controlled diabetics with HbA1C > 10%.~Also:~Must provide informed consent~Males or Females aged 30 years or older to minimize the potential confounding of other forms of diabetes mellitus~In patients with diabetes, no concomitant diseases except for micro- and macrovascular complications of diabetes (nephropathy, retinopathy, peripheral arterial disease, coronary artery disease, neuropathy) or symptoms of the metabolic syndrome (hypertension, dyslipidemia and obesity)~Not taking any chronic medications (except of the diabetes and cardiovascular related drugs)."
89405194|NCT05200637|Active Comparator|Orsiro|Two-stent DK-crush technique with Orsiro
89405195|NCT05200637|Active Comparator|Xience|Two-stent DK-crush technique with Xience
89190506|NCT04997681|Active Comparator|Control Exercise Training and Cognitive Intervention Training|Control Balance and Toning Exercise Training (BAT) + Cognitive Training (NeuropeakTM)
89190507|NCT04997681|Placebo Comparator|Control Exercise Training and Control Cognitive Training|Control Balance and Toning Exercise Training (BAT) + Control Cognitive Training of Website Searching and Video Watching (WS+V)
89405196|NCT05200637|Other|Single stent|Provisional one-stent strategy with any drug-eluting stent
89405197|NCT05200169|Experimental|14C-AB1010|Oral solution of 14C radiolabelled AB1010 (200 mg per subject)
89405198|NCT00740480||Surgical|Adult population (ages 18-65) with clinically significant nasal septum deviation.
88881227|NCT03761680|Active Comparator|Control Group|Patients receive ONS between meals or at their request as usual
88881228|NCT03720080||670G/OpenAPS|Participants with Type 1 Diabetes wearing a Medtornic Minimed 670G hybrid closed loop system in parallel with a non-insulin injecting, self-constructed OpenAPS system.
88881229|NCT03661073|Experimental|Stroke|The investigator will include patients with stroke (either hemorrhagic or ischemic) with or without neglect in the experimental group.
88881230|NCT03661073|Sham Comparator|Healthy subjects|The investigator will include healthy subjects aged-matched to participants of the experimental group in the control group.
89405199|NCT03219658|Experimental|Parenting education sessions|Receive 10 weeks of group parenting education sessions with 2-4 public health nurse home visits.
89405200|NCT03219658|No Intervention|Control|Attend one-on-one check-ins with the interdisciplinary team at STOMP; wait-listed control group.
89405201|NCT05762081|Experimental|Intervention Group|Individuals who have undergone wiping bathing with disposable wipes
89405202|NCT05762081|Sham Comparator|Control Group|Individualswho have undergone bathing with a traditional bath
89405203|NCT04699357|Active Comparator|Group 1|0.01% atropine
89405204|NCT04699357|Experimental|Group 2|0.04% atropine
89405205|NCT04699357|Experimental|Group 3|0.1% atropine
89405206|NCT00737516|Experimental|single arm|HPC, Cord Blood
89405207|NCT04651387|Experimental|Intervention group|"In addition to the routine standard treatments for COVID-19, in the intervention group, combined use of HOO capsules and HOO oropharyngeal and nasal spray will be administered"
89405208|NCT04651387|No Intervention|Control group|For the control group, the placebo will be not considered and they will follow the routine standard treatments for COVID-19.
89405209|NCT05198531|Experimental|TQB2858 Injection combining with other drugs|"Combination 1 is TQB2858 Injection and Anlotinib Hydrochloride Capsules. Combination 2 is TQB2858 Injection, Gemcitabine Hydrochloride Injection and Cisplatin Injection for 4-6 cycles of induction chemotherapy, then using TQB2858 Injection and Anlotinib Hydrochloride Capsules for maintenance treatment.~Combination 3 is TQB2858 Injection, Gemcitabine Hydrochloride Injection, Cisplatin Injection and Anlotinib Hydrochloride Capsules for 4-6 cycles of induction chemotherapy, then using TQB2858 Injection and Anlotinib Hydrochloride Capsules for maintenance treatment."
89405210|NCT02986516|Experimental|Randomized Cohort|Participants who will decided to undergo to randomization, will receive surgical treatment or definitive radiotherapy according with randomization assignment
89405211|NCT02986516|Active Comparator|Prospective Cohort|Participants who will not decide to be randomized, will received the surgical or definite radiotherapy treatment according to their choice
89405212|NCT03628651||HCC Surveillance|Approximately 1400 HCC surveillance subjects (controls) will be enrolled.
88881231|NCT03654833|Experimental|MiST1 Rucaparib|BRCA1/BAP1 negative mesothelioma; 600mg twice daily (BID) every 28 days.
88881232|NCT03654833|Experimental|MiST2 Abemaciclib|p16INK4A negative mesothelioma; 200mg orally twice daily every 28 days.
88881233|NCT03654833|Experimental|MiST3 Pembrolizumab & Bemcentinib|"No specific biomarker requirement: Pembrolizumab 200mg IV infusion on Day 1 only:~Bemcentinib loading dose of 400mg on days 1-3, on day 4 on-wards 200mg daily every 21-days."
88881234|NCT03654833|Experimental|MiST4 Atezolizumab & Bevacizumab|PDL1 expression positive mesothelioma: Atezolizumab 1200 milligrams via intravenous nfusion; Bevacizumab 15 milligrams per kilogram via IV infusion both on Days 1 every 21-days.
88881235|NCT03654833|Experimental|MiST 5 Dostarlimab and Niraparib|Platinum sensitive mesothelioma: Niraparib 200-300mg daily every 21 days; Dostarlimab 500mg on day 1 of each 21 day cycle for 4 cycles, then 1000mg on day 1 of each 42 day cycle.
88881236|NCT03653455|Experimental|Pre- and post-operative discussion group|Patients will discuss with their care provider their health outcomes before and at 6-months after their surgery. In addition, patients will receive email reminders to complete their forms, if they haven't done so.
88881237|NCT03653455|Experimental|Incentivised group|Patients will receive up to $30 in amazon gift cards as an incentive if they complete their forms before surgery, as well as at 6-months and 1-year after surgery. In addition, patients will receive email reminders to complete their forms, if they haven't done so.
88881238|NCT03653455|Experimental|Control group|Patients will only receive email reminders to complete their forms, if they haven't done so.
88881239|NCT03520751|Experimental|Dose (8.87e11 vg/kg)|Three patients age 18-35 will receive intramuscular injection of recombinant AAV1 carrying a human NFT3 gene under the control of the tMCK promoter (scAAV1.tMCK.NTF3) distributed bilaterally between both limbs at a dose of 8.87e11 vg/kg.
89405213|NCT03628651||HCC|Approximately 700 subjects with untreated clinically diagnosed HCC will be enrolled.
89405214|NCT02743520|Experimental|Cardiac event monitor|Participants will under go evaluation with a two week cardiac event monitor.
89405215|NCT05186207||observation group|those who need clinical intervention before or after pregnancy, the experts shall formulate a personalized treatment plan according to the international guidelines. Researchers wouldn't interfere with the expert diagnosis and treatment process. And they should be confirmed intrauterine pregnancy within the study period.
88881242|NCT03432494|Experimental|Transcaval access and closure with the transcaval closure device (TCD) test article.|All participants undergo transcaval access for transcatheter aortic valve replacement (TAVR) followed by implantation of the transcaval closure device (TCD).
88881243|NCT03426904|Experimental|Neoadjuvant FOLFOX|4 cycles of FOLFOX (Folinic acid, fluorouracil and oxaliplatin) neoadjuvant followed by surgery and 8 cycles of FOLFOX
89405216|NCT05186207||control group|those who need not clinical intervention before or after pregnancy, pregnancy was prepared under the clinical and health care guidance provided by experts, and intrauterine pregnancy was confirmed within the study period.
89405217|NCT05176613|Experimental|HF-rTMS and ML|High frequency Repetitive Transcranial Magnetic Stimulation and Motor Learning(Experimental group)
89405218|NCT05176613|Sham Comparator|Sham-rTMS and ML|Sham Repetitive Transcranial Magnetic Stimulation and Motor Learning
88881244|NCT03426904|Active Comparator|Conventional adjuvant FOLFOX|surgery followed by 12 cycles of FOLFOX
88881245|NCT03420482|Experimental|Fecal Microbiota Transplant (FMT) oral capsules|Subjects will receive 15 oral capsules of FMT on days 1, 2, 7, 14, and 21.
88881246|NCT03420482|Placebo Comparator|Placebo capsules|Subjects will receive placebo capsules on the same schedule as the experimental arm (days 1, 2, 7, 14, and 21).
89405219|NCT04473170|Experimental|Group A|Autologous Non-Hematopoietic Peripheral Blood Stem Cells (NHPBSC) therapy as add-on COVID-19 standard care.
89405220|NCT04473170|Active Comparator|Group B|COVID-19 Standard care.
89405221|NCT02872948||70 euploïdes foeti samples|"Patients with foetus euploïde (no sick)"
89405222|NCT02872948||30 trisomies 21 samples|"Patients with foetus reached(affected) by trisomy 21 (sick)"
89531012|NCT02495285||Gelofusine 4%|Children age ≤ 12 years
88881247|NCT03375827|Experimental|Survey QOL|"Study participants will be provided with the Individualized Goals of Care Discussion Guide (IGCDG) consisting of a brief pamphlet and the IGCDG questionnaire.~Participants will be asked to complete the IGCDG questionnaire prior to their next visit.~Participants will also complete an 8-week follow-up survey after the clinic visit to evaluate the impact on patient satisfaction with care, communication, and care received."
88881248|NCT03362372|Experimental|INTERVENTION GROUP: MEDITERRANEAN DIET COUNSELING|During 2 years a nutritional intervention will be carried out to increase adherence to DiMet based on: annual visit of personalized nutritional education, a telephone contact for intervention reinforcement and computer access to a nutrition blog
88881249|NCT03362372|No Intervention|CONTROL GROUP: WITHOUT CHANGES IN DIET|The participants of health centers will carry out the same 5 visits (3 individual visits and 2 phone calls), although no changes are induced in their usual diet and they will not be offered access to the nutritional blog.
88881250|NCT03361072|Experimental|Milk allergy|Milk oral immunotherapy intervention for milk allergy
89405223|NCT01869829||Pediatric Invasive Candidiasis|Pediatric patients (age > 120 days and < 18 years) with documented proven or probable invasive candidiasis
88881251|NCT03361072|Experimental|Peanut allergy|Peanut oral immunotherapy intervention for peanut allergy
88881252|NCT03361072|Experimental|Egg allergy|Egg oral immunotherapy intervention for egg allergy
88881253|NCT03303963||Rifampicin resistant and susceptible patients|Study 1: Patients detected positive by the GeneXpert Mycobacterium tuberculosis/Rifampicin (susceptible and resistant to rifampicin)
88881254|NCT03303963||Rifampicin resistant patients|Study 2: Follow up of the rifampicin resistant patients included in the study 1 during their treatment
88881255|NCT03302611|Experimental|Surf Therapy|Participants receive a physical activity-based intervention, which in this arm is surf therapy. Each service member is paired with a surf instructor who typically works with them each week for the length of the program.
88881256|NCT03302611|Active Comparator|Hike Therapy|Participants receive a physical activity-based intervention, which in this arm is hike therapy. During hike therapy, service members may hike together or at a self-selected pace.
89405224|NCT02683018|Active Comparator|Smoked Cannabis High CBD/low THC|Participants will visit the Marijuana Research Laboratory 3-5 weekdays per week for 4 weeks to be administered 1-2 Smoked Cannabis High CBD/low THC cigarettes (15.76% CBD; 3.11% THC) over the course of a 2-3 hour session.
89405225|NCT02683018|Placebo Comparator|Smoked Placebo Cannabis Low CBD/low THC|Participants will visit the Marijuana Research Laboratory 3-5 weekdays per week for 4 weeks to be administered 1-2 cannabis cigarettes (0.01% THC; 0.00% CBD) over the course of a 2-3 hour session.
89405226|NCT04472624|Experimental|Fasting arm|Participants will be fasting during 72 hours
88881257|NCT03292315|Experimental|Semaglutide 1MG Injection [Ozempic]|20 subjects will be randomized to receive once weekly injection of Semaglutide (Ozempic1mg) for 26 weeks.
88881258|NCT03292315|Other|No Intervention|10 subjects will be randomized to receive no intervention for 26 weeks.
88881259|NCT03287830|Experimental|Intervention|Text message influenza vaccine reminders
88881260|NCT03287830|No Intervention|Usual care|"Season 2017-18: Usual care has no text message~Season 2018-19: Usual care includes on text message with a link to American Academy of Pediatrics parenting information page. The purpose is to provide those randomized to usual care with tangible benefit that is not related to the study."
89405227|NCT04472624|Experimental|Diet arm|Participants will be using ketogenic diet for 14 days
89405228|NCT03982576|Experimental|CS Relapse Prevention|"Participants will receive 4 group sessions of a novel culturally specific, CBT-based intervention. They will also receive Path2Quit, a newly developed video-text program, which delivers 6 weeks of CS video messages (1-2 times/day) and provides 24/7 access to messages pulled from 3 keywords (HELP1, JONES, SLIP). Notably, CS relapse prevention will incorporate surface and deep structure elements,17 including race-matched interventionists, religion/spirituality, discussion of race-related stress, traditional values (e.g., collectivism), culturally specific recipes, etc.~All participants will receive 4 weeks of nicotine replacement therapy (NRT; transdermal nicotine patches or nicotine gum)."
88881261|NCT03287778|Active Comparator|Pyridoxine|Pyridoxine will be administered in dosages of 200 mg with a maximum dose of 400 mg.
88881262|NCT03287778|Placebo Comparator|Placebo|Matching placebos will be administered for each active drug.
88881263|NCT03273413|Placebo Comparator|Placebo|Participants will receive inactive 40 mg tablets of placebo everyday for 6 weeks. If well tolerated, participants will continue taking inactive 40 mg dose of placebo everyday for 2 years.
88881264|NCT03273413|Active Comparator|Pravastatin|Participants will receive 40 mg tablets of pravastatin everyday for 6 weeks. If well tolerated, participants will continue taking 40 mg dose of pravastatin everyday for 2 years.
89531013|NCT02495285||Gelaspan 4%|Children age ≤ 12 years
88881265|NCT03266484|Active Comparator|Probiotic Mixture|"Participants who are meeting the inclusion criteria will be randomized to either the probiotic mixture or an identical placebo.~The probiotics sachets will be taken twice a day for 12 weeks."
88881266|NCT03266484|Placebo Comparator|Placebo|"Participants who are meeting the inclusion criteria will be randomized to either the probiotic mixture or an identical placebo~The identical placebo sachets will be taken twice a day for 12 weeks."
88881267|NCT03242824|Experimental|18F-DOPA PET|Patients will receive 18FDOPA-PET for radiation treatment planning
88881268|NCT03233750|Experimental|Stress Inoculation Training|"Phase 1: Conceptualization / Educational Phase (60 minutes) Provision of preparatory information, to allow the participants to form accurate expectations regarding the stress environment and stress reactions.~Phase 2: Skill Acquisition and Rehearsal (60 minutes) Development and practice of cognitive restructuring techniques and relaxing training to reduce anxiety and enhance the individual's capacity to respond effectively to stressful situations, in low stress conditions.~Phase 3: Application of Coping Skills (180 minutes) Coping skills are applied in increasingly stressful conditions that approximate the real-world stressor environment."
89437503|NCT03785106|Experimental|1HP|4-week daily regimen of weight-based RPT and INH, plus pyridoxine (vitamin B6)
88881269|NCT03233750|Active Comparator|Crisis Resource Management Training|The CRM training targets the non-technical skills (e.g. behavioural and cognitive skills) required for effective teamwork during crisis situations. It focuses on communication, teamwork, situational awareness and leadership
88881270|NCT03227458|Active Comparator|Exercise and DHEA|1 study pill containing 50 mg of DHEA daily for 36 weeks and supervised bone-loading exercise on 3 days per week for 36 weeks.
88881271|NCT03227458|Active Comparator|Exercise and Placebo|1 study pill containing placebo daily for 36 weeks and supervised bone-loading exercise on 3 days per week for 36 weeks.
88881272|NCT03227458|Active Comparator|DHEA only|1 study pill containing 50 mg of DHEA daily for 36 weeks
88881273|NCT03181633|Experimental|ACH-0144471|All participants will receive ACH-0144471 during the treatment period.
89437504|NCT03785106|Active Comparator|3HP|12-weekly INH/RPT regimen, plus pyridoxine (vitamin B6)
89437505|NCT03783078|Experimental|Pembrolizumab|Pembrolizumab (MK-3475) 200 mg (adult participants) or 2 mg/kg (up to 200 mg; pediatric participants) on Day 1 of each 3-week cycle (Q3W) intravenous (IV), for up to 35 administrations (approximately 2 years)
89405229|NCT03982576|Active Comparator|Standard Relapse Prevention|"Participants will receive 4 group sessions of a standard relapse prevention program, publicly available at smokefree.gov. Participants will also receive SmokefreeTXT, the NCI's 6-week fully automated text-based cessation program that is free to U.S. subscribers, and is available on smokefree.gov. Users can text one of 3 keywords (MOOD, CRAVE, or SLIP) to receive a relevant message from the system 24/7.~All participants will receive 4 weeks of nicotine replacement therapy (NRT; transdermal nicotine patches or nicotine gum)."
89405230|NCT05081518|Experimental|Sequence 1: Lu AG06466-Placebo|Participants will receive Lu AG06466 capsules once daily (QD) at a low dose for 4 days (Days 1 to 4), medium dose for 4 days (Days 5 to 8), and high dose for 21 days (Days 9 to 29) in treatment period 1. Participants will receive matching placebo capsules from Day 1 to Day 29 in treatment period 2. Each treatment period will be separated by a washout period of 7 to 11 days.
89405231|NCT05081518|Experimental|Sequence 2: Placebo-Lu AG06466|Participants will receive matching placebo capsules QD from Day 1 to Day 29 in treatment period 1. Participants will receive Lu AG06466 capsules QD at a low dose for 4 days (Days 1 to 4), medium dose for 4 days (Days 5 to 8), and high dose for 21 days (Days 9 to 29) in treatment period 2. Each treatment period will be separated by a washout period of 7 to 11 days.
89405232|NCT05127005|Experimental|Trapeziectomy|Trapeziectomy
89405233|NCT05127005|Sham Comparator|Sham surgery|Sham surgery
88881274|NCT03141983|Active Comparator|Anakinra|"Anakinra (Kineret®) is a therapeutic agent that blocks the effects of IL-1 alpha and IL-1 beta by competitively binding to the interleukin-1 type I receptor (IL-1RI). Anakinra is a recombinant, non-glycosylated form of the naturally occurring human interleukin-1 receptor antagonist (IL-1Ra).~Anakinra will be supplied in pre-filled syringes as a sterile, clear, colorless-to-white, preservative free solution. Each syringe will contain 100 mg in 0.67 ml solution (pH 6.5) containing disodium EDTA (0.12 mg), sodium chloride (5.48 mg), sodium citrate (1.29 mg), and polysorbate 80 (0.70 mg) in Water for Injection, USP."
89405234|NCT05127005|Other|Non-randomized observational arm|Non-randomized observational arm (trapeziectomy, not blinded)
88881275|NCT03141983|Placebo Comparator|Placebo|Saline (0.9%) will be used as the placebo, supplied in pre-filled syringes as a sterile, clear, colorless-to-white, preservative free solution.
88881276|NCT03122223|Active Comparator|ALVAC-HIV + 100mcg Protein/MF59 + Placebo|50 participants will receive 1 mL ALVAC-HIV injection in the left deltoid on Months 0, 1, 3, and 6. They will receive 0.5 mL100 mcg Protein/MF59 and 0.75 mL placebo injection in the right deltoid on Months 3 and 6.
88881277|NCT03122223|Active Comparator|ALVAC-HIV + 100mcg Protein/AS01(B) + Placebo|50 participants will receive 1 mL ALVAC-HIV injection in the left deltoid on Months 0, 1, 3, and 6. They will receive 0.75 mL100 mcg Protein/AS01(B) and 0.5 mL placebo injection in the right deltoid on Months 3 and 6.
88881278|NCT03122223|Active Comparator|ALVAC-HIV + 20mcg Protein/AS01(B) + Placebo|50 participants will receive 1 mL ALVAC-HIV injection in the left deltoid on Months 0, 1, 3, and 6. They will receive 0.75 mL 20 mcg Protein/AS01(B) and 0.5 mL placebo injection in the right deltoid on Months 3 and 6.
88881279|NCT03122223|Placebo Comparator|Placebo|10 participants will receive 1 mL of the placebo injection in the left deltoid on Months 0, 1, 3, and 6. They will receive 0.5 mL of the placebo injection and 0.75 mL of a separate placebo injection in the right deltoid on Months 3 and 6.
88881280|NCT03077087|Experimental|Single-stage Integra|"Composed of a porous collagen-chondroitin 6-sulfate fibrillary mat covered with a thin sheet of silastic, it serves to cover wound beds of freshly excised burns and allow for the infiltration of fibroblasts, capillaries, and macrophages, essentially creating a neodermis while also acting as a barrier against infection and a blockade against heat and moisture loss"
88881281|NCT03074539|Active Comparator|Pulmonary Endarteriectomy - PEA|"CTEPH treatment via PEA. This arm includes patients who will receive Pulmonary Endarteriectomy (PEA) according to local CTEPH board recommendation. A standardized polygraphy will be conducted before the PEA - intervention, to obtain information concerning Sleep Disorder Breathing. 6 months after the PEA surgery another polygraphy will be accomplished and the results compared with the first polygraphy and the other arms.~If Sleep Disorder Breathing remains, a personalized recommendation on further specific therapy (e.g. nocturnal continuous positive airway pressure ventilation) will be made."
88881282|NCT03074539|Active Comparator|Balloon Pulmonary Angioplasty - BPA|"CTEPH treatment via BPA. Patients who are suitable for Balloon Pulmonary Angioplasty (BPA) according to the recommendation of the local CTEPH board (e.g. patients not suitable for Pulmonary Endarteriectomy). A standardized polygraphy will be conducted before the first BPA intervention, to gain information about possible sleep-disordered breathing. 6 months after the first BPA intervention another polygraphy will be accomplished and the results compared with the first polygraphy and the other arms.~If Sleep Disorder Breathing remains, a personalized recommendation on further specific therapy (e.g. nocturnal continuous positive airway pressure ventilation) will be made."
89405235|NCT00798265|Experimental|1|.5 mL dose injected IM at 0, 2 and 6 months (+/- 2 weeks) and knowledge survey at week 0
89405236|NCT00798265|Experimental|2|.5 mL dose injected IM at 0, 2 and 6 months (+/- 2 weeks) and knowledge survey at week 0
89405237|NCT00798265|Active Comparator|3|.5 mL dose injected IM at 0, 2 and 6 months (+/- 2 weeks) and knowledge survey at week 0
89405238|NCT04882124|Experimental|CSJ117 8mg|Intervention: Drug: CSJ117
89405239|NCT04882124|Experimental|CSJ117 4mg|Intervention: Drug: CSJ117
89405240|NCT04882124|Placebo Comparator|CSJ117 Placebo|Intervention: Drug: Placebo
89405241|NCT03976960|Experimental|Biological collection|"For all the patients include in the study :~samples of blood samples collected before or after surgery but also samples in paraffin-embedded tissue sections.~In parallel to this biological collection, standardized clinical data will be entered into a database"
89405242|NCT03628573|Other|Intermittent Theta burst stimulation.|Procedure: repetitive transcranial magnetic stimulation (iTBS) to the left Dorsolateral Prefrontal Cortex; 3 sessions per day, for 20 days.
89405243|NCT05125913||COVID-19 group|Patients with CKD stage 3-5, on dialysis or kidney transplanted patients with confirmed SARS-CoV-2 infection by reverse transcriptase polymerase chain reaction (RT-PCR), at minimum 2 weeks after the confirmed test.
89405244|NCT05125913||non-COVID-19 group|CKD stage 3-5, dialysis or kidney transplantation matched patients without confirmed SARS-CoV-2 infection
89405245|NCT04472780|Experimental|HBOT Group|will benefit from HBOT
88881283|NCT03074539|Active Comparator|Medical Treatment|"CTEPH treatment via Medical Treatment. Patients who are inoperable (not suitable for Pulmonary Endarteriectomy) and not eligible for BPA according to the recommendation of the local CTEPH board will get medical treatment with Riociguat. The treatment will be assigned according to the currently valid guidelines (2015 European Respiratory Society / European Society of Cardiology guidelines on the diagnosis and treatment of pulmonary hypertension). A standardized polygraphy will be conducted before the medical treatment starts, another polygraphy will be conducted after 6 months of treatment if Riociguat. The results will be compared with the first polygraphy and the other arms.~If Sleep Disorder Breathing remains, a personalized recommendation on further specific therapy (e.g. nocturnal continuous positive airway pressure ventilation) will be made."
89190508|NCT04990349|Experimental|Extracorporeal normoxemia|"After randomization, extracorporeal normoxemia is targeted by setting the ECMO membrane oxygen fraction (FmO2) at 60%.~The objective is to maintain oxygen partial pressure measured on the arterial cannula (PO2 postoxygenator) between 100 and 150 mmHg.~PO2 postoxygenator is monitored at least twice a day by the nurse.~If PO2 postoxygenator is less than 100 mmHg or more than 150 mmHg, FmO2 is modified by 10% and PO2 postoxygenator is monitored 10 minutes after.~Ventilator's setting at let to the clinician's discretion. However, PaO2 on right radial artery will be monitored to ensure that is more that 80 mmHg.~Intervention will be applied for 7 days after randomization."
88881284|NCT03030131|Experimental|Durvalumab|durvalumab 750 mg IV J1, J15, J29
88881285|NCT03011021|Experimental|UCB-Treg plus Liraglutide|Subjects will receive a single infusion of ex vivo expanded umbilical cord blood derived Treg product (2 x 10^6). Dose escalation of liraglutide up to 1.2 mg will be started 3 days after Treg infusion only if no severe side effects showed. Subjects continue to receive the reached liraglutide dose once daily for 6 months thereafter. Insulin will be continued as a routine therapy.
88881286|NCT03011021|Active Comparator|UCB-Treg|Subjects will receive a single infusion of ex vivo expanded Treg product (2 x 10^6). Insulin will be continued as a routine therapy.
88881287|NCT03011021|Active Comparator|Liraglutide|Patients will be subjected to a dose escalation of liraglutide up to 1.2 mg, then continue to receive the reached liraglutide dose once daily for 6 months thereafter. Insulin will be continued as routine therapy.
88881288|NCT03011021|Active Comparator|Insulin|Patients will receive insulin injection as a routine therapy.
89190509|NCT04990349|Active Comparator|Extracorporeal hyperoxemia|"After randomization, extracorporeal hyperoxemia is targeted by setting the ECMO membrane oxygen fraction (FmO2) at 100%.~The objective is to maintain PO2 postoxygenator higher than 300 mmHg.~PO2 postoxygenator is monitored at least twice a day by the nurse.~If PO2 postoxygenator is less than 300 mmHg, membrane change should be discussed.~Ventilator's setting at let to the clinician's discretion. However, PaO2 on right radial artery will be monitored to ensure that is more that 80 mmHg.~Intervention will be applied for 7 days after randomization."
89190510|NCT04987216|Experimental|PODEYE TORIC IOL Implantation experimental|Mono- or bilateral implantation of toric intraocular lenses PODEYE TORIC
89190511|NCT04978948||Myasthénie|Blood samples will be collected
89190512|NCT04978948||Myopathie inflammatoire (Myosite)|Blood samples will be collected
89190513|NCT04978948||Neuropathie autoimmune|Blood samples will be collected
89405246|NCT04472780|No Intervention|Control group|will benefit from the conventional treatment
89405247|NCT03768622||surgery for femoral neck fracture|patients with proximal femoral fracture (type: femoral neck fracture) with surgical procedure: partial hip arthroplasty
88881289|NCT02995252||Group 1: Hepatitis C infection|Participants with chronic hepatitis C infection; includes both hepatitis C mono infected and hepatitis C-HIV coinfected. Participants will attend study visits for research blood draws (once a year with optional additional visits), and a one-time optional knowledge questionnaire. No drugs will be given to this group.
88881290|NCT02995252||Group 2: Hepatitis B infection|"Participants with chronic hepatitis B: includes patients with hepatitis B with and without hepatitis C and/or HIV. Participants will attend study visits for research blood draws (once a year with optional additional visits), and a one-time optional knowledge questionnaire. Participants who are already taking hepatitis B treatment are eligible.~Hepatitis B treatment sub-study: In this treatment sub-study, participants with hepatitis B monoinfection will receive tenofovir alafenamide (TAF) pill once a day for 2 years with study visits every 3 months. Liver transient elastography will be reviewed or obtained. In addition, approximately 40 participants will be invited to undergo optional liver biopsies at the start, end of year 1 and end of year 2 of the sub-study."
88881291|NCT02970513|Experimental|patients operated on for colorectal cancer|
88881292|NCT02932826|Experimental|Treg Treatment + Insulin|subjects will be treated with Umbilical Cord Blood Regulatory T cells Therapy and insulin according to routine clinical practice at the discretion of the treating physician
89190514|NCT04978948||Néphropathies autoimmunes|Blood samples will be collected
89190515|NCT04978948||Hépatite auto-immune|Blood samples will be collected
89190516|NCT04978948||Pancréatite auto-immune|Blood samples will be collected
89190517|NCT04978948||Purpura Thrombopénique Immunologique|Blood samples will be collected
89190518|NCT04978948||Dermatose bulleuse|Blood samples will be collected
89190519|NCT04978948||Thyroïdite autoimmune|Blood samples will be collected
89190520|NCT04978948||Sclérose en plaque|Blood samples will be collected
89190521|NCT04978948||Sclérose latérale amyotrophique|Blood samples will be collected
89190522|NCT04978948||Polyarthrite Rhumatoïde|Blood samples will be collected
89190523|NCT04978948||Spondylarthrite axiale|Blood samples will be collected
89190524|NCT04978948||controls|Patients without autoimune desease* Blood samples will be collected
89190525|NCT04978948||Lichen plan buccal auto-immun (LPB)|Blood samples will be collected
89190526|NCT04978948||"lichen plan buccal allo-immun liée à une GvHD ( Graft versus Host Disease )"|Blood samples will be collected
89190527|NCT04978948||Lupus érythémateux systémique|Blood samples will be collected
89190528|NCT04978948||Sclérodermie|Blood samples will be collected
89405248|NCT03768622||surgery for pertrochanteric femoral fractures|patients with proximal femoral fracture (type:pertrochanteric femoral fractures) with surgical procedure: intramedullary nail type Gamma® Nail or similar
89405249|NCT04472546|Other|Control subject group|"Divided in 5 subgroups :~A': associated to acne of the face subgroup~B' : associated to atopic dermatitis of the upper limb subgroup~C' : associated to vulgar plaque psoriasis subgroup~D' : associated to telangiectasic erythrocouperosis papule of the face (rosacea) subgroup~E' : associated to seborrheic dermatitis of scalp subgroup"
88881293|NCT02932826|Active Comparator|Insulin|subjects will be treated with insulin according to routine clinical practice at the discretion of the treating physician
88881294|NCT02874131|Experimental|Behavioral Activation + CPT|Behavioral Activation, an evidence-based treatment for depression, is combined with Cognitive Processing Therapy (CPT), an evidence-based treatment for PTSD, to address symptoms of PTSD and comorbid MDD.
88881295|NCT02874131|Active Comparator|Cognitive Processing Therapy|CPT is an evidence-based treatment for PTSD that has also been shown to reduce depression symptoms.
89405250|NCT04472546|Other|Subject group with dermatitis|"Divided in 5 subgroups :~A : acne of the face subgroup~B : Atopic dermatitis of the upper limb subgroup~C : Vulgar plaque psoriasis subgroup~D : Telangiectasic erythrocouperosis papule of the face (rosacea) subgroup~E : Seborrheic dermatitis of scalp subgroup"
89405251|NCT02675842|Active Comparator|Smoked Cannabis High CBD/low THC|Participants will visit the research laboratory 3-5 days a week over 6 weeks to be administered 1-2 Cannabis cigarettes (15.76% CBD; 3.11% -9-THC) over the course of 2-3 hours.
88881296|NCT02853604|Placebo Comparator|Placebo|Participants with locally advanced cervical cancer at higher risk for recurrence (HRLACC) received ADXS11-001 matching placebo by intravenous infusion for approximately 60 minutes every 3 weeks for 3 doses (Weeks 1, 4 and 7) and thereafter, every 8 weeks for 5 doses (Weeks 15, 23, 31, 39, and 47) during treatment phase or until disease recurrence. Participants received a 7-day course placebo matching to either trimethoprim/sulfamethoxazole or ampicillin starting 72 hours post treatment in prime and maintenance phase.
89190529|NCT04976088|Experimental|Group A Test|Test product: treated once a day (morning) with the medicated plaster containing 140 mg Diclofenac Sodium for seven days Diclofenac Sodium 140 mg medicated plaster
88881297|NCT02853604|Experimental|ADXS11-001|Participants with HRLACC received ADXS11-001 at a dose of 1x10^9 colony forming units (CFU) by intravenous infusion for approximately 60 minutes every 3 weeks for 3 doses (Weeks 1, 4 and 7) and thereafter, every 8 weeks for 5 doses (Weeks 15, 23, 31, 39, and 47) during treatment phase or until disease recurrence. Participants received a 7-day course of either trimethoprim/sulfamethoxazole or ampicillin starting 72 hours post treatment in prime and maintenance phase.
88881298|NCT02843191|Active Comparator|Adjuvant chemotherapy|After neoadjuvant chemoradiotherapy, patients will receive surgery followed by eight cycles of chemotherapy.
88881299|NCT02843191|Experimental|Consolidation chemotherapy|After neoadjuvant chemoradiotherapy, patients will receive three cycles of chemotherapy. Thereafter, they will receive surgery followed by five cycles of chemotherapy.
88881300|NCT02817360|Experimental|Intensive therapy|RAS-antagonist and beta-blocker up-to maximal dosages as permitted and tolerated and following national guidelines.
88881301|NCT02817360|Other|Conventional therapy|No RAS-antagonist and beta-blocker or at stable dose as per study entrance. Changes in RAS-antagonist or beta-blocker therapy are not allowed in the control group during the study phase.
88881302|NCT02811250|Experimental|Stereotactic radiotherapy 4 x 8 Gy|Patient receive 4 stereotactic radiotherapy sessions with a dose of 8 Gy
89190530|NCT04976088|Active Comparator|Group B Reference|Reference product: treated once a day (morning) with the medicated plaster containing DIEP 180 mg, Flector® for seven days Diclofenac epolamine (DIEP) 180 mg medicated plaster, Flector®
88881303|NCT02811250|Experimental|Stereotactic radiotherapy 5 x 8 Gy|Patient receive 5 stereotactic radiotherapy sessions with a dose of 8 Gy
88881304|NCT02811250|Experimental|Stereotactic radiotherapy 4 x 10 Gy|Patient receive 4 stereotactic radiotherapy sessions with a dose of 10 Gy
88881305|NCT02811250|Experimental|Stereotactic radiotherapy 4 x 12 Gy|Patient receive 4 stereotactic radiotherapy sessions with a dose of 12 Gy
88881306|NCT02799706|Active Comparator|GnRH agonist + radiation therapy (RT)|"As the study investigates the effect of a drug given concomitantly to radiotherapy, all patients will be treated with the same treatment technique and target dose. The preferred treatment technique is intensity modulated radiotherapy (IMRT) + A GnRH-agonist will be given for the duration selected for each patient.~A non-steroidal anti-androgen (e. g. flutamide, bicalutamide) will be given orally one week before the first injection of the GnRH agonist and will be continued for no longer than 8 weeks to protect against flare.~Dose may vary due to availability of different brand names and pharmaceutical forms The start of antiandrogen must be registered as day 1 of treatment in the GnRH agonist arm."
88881307|NCT02799706|Experimental|GnRH antagonist + radiation therapy (RT)|"As the study investigates the effect of two drugs given concomitantly to radiotherapy, all patients will be treated with the same treatment technique and target dose. The preferred treatment technique is intensity modulated radiotherapy (IMRT) +a GnRH antagonist will be given for a predefined duration of 18, 24, or 36 months as per institution policy.~Each institution has to adhere to the chosen duration of treatment for all patients throughout the study"
88881308|NCT02770599||IBD multidisciplinary team model (MDT)|IBD multidisciplinary team model including IBD nurse
88881309|NCT02770599||IBD conventionally follow up model (CF)|IBD patient treated by doctors with specialist qualifications, assistant doctors, general practitioner or scarcity of follow-up-service.
89190531|NCT04976088|Placebo Comparator|Group C Placebo|Placebo: treated once a day (morning) with the placebo plaster for seven days
89405252|NCT02675842|Placebo Comparator|Smoked Placebo Cannabis Low CBD/low THC|Participants will visit the research laboratory 3-5 days a week over 6 weeks to be administered 1-2 Cannabis cigarettes Cannabis (0.0% CBD/ 0.01% -9-THC) over the course of 2-3 hours.
89405253|NCT05116553|Active Comparator|SDT (MI)|This group will receive standard 2 SDT (Self Determination Theory) psychological interviews.
88881310|NCT02759458|Experimental|Healicoil|Patients that met the inclusion criteria who were randomly selected to receive the Healicoil anchor for their rotator cuff repair.
88881311|NCT02759458|Active Comparator|Twinfix|Patients that met the inclusion criteria who were randomly selected to not receive the Healicoil anchor for their rotator cuff repair.
88881312|NCT02689778|Experimental|Pirfenidone|Oral pirfenidone 600 mg with breakfast and 1200 mg with dinner for 12 months.
88881313|NCT02689778|Placebo Comparator|Placebo|Oral placebo with breakfast and with dinner for 12 months.
88881314|NCT02678377|Active Comparator|OnabotulinumtoxinA injections|100 units of OnabotulinumtoxinA (Botox®) injected into the detrusor (large muscle of the bladder) at the time of sling surgery.
89190532|NCT04920318|Experimental|active TDCS|During intervention excitatory/anodal tDCS will be administered alongside speech-language therapy 5 days a week for 2 weeks. The exact location of the stimulation and electrode configuration will be targeted individually based on the optimal site identified in fMRI. TDCS will be administered with NeurConn1 Channel DC- Stimulator Plus (neuroCare Group, München, Germany) according to established guidelines and procedures. The active tDCS will be delivered for 20 minutes using sponge electrodes with a 30-s ramp-up and ramp-down period
89190533|NCT04920318|Sham Comparator|sham TDCS|The sham will be administered alongside speech-language therapy 5 days a week for 2 weeks. For sham, stimulation will be ramped up and then down to 0 milliamperes (mA) in the first minute of stimulation. The sham parameters were chosen based on previous reports that the perceived sensations on the skin, such as tingling, fade out in the first 30 s of tDCS
89190534|NCT04912323|Experimental|MAGNITUDE® Scaffold|Subject with up to three study lesions treated by implanting a maximum of 3 R3 Vascular MAGNITUDE® Bioresorbable Drug-Eluting Scaffolds
89190535|NCT04866719|Experimental|PODEYE TORIC IOL Implantation experimental|Mono- or bilateral implantation of toric intraocular lenses PODEYE TORIC
89190536|NCT04799535||Observational (ultrasound)|"AIM 1: Participants undergo a breast ultrasound over 15 minutes.~AIM 2: Participants undergo breast ultrasounds over 15 minutes before starting the chemotherapy, 2 months after start of chemotherapy, and after the completion of chemotherapy before surgery. Participants may also undergo breast ultrasounds at 2 weeks after start of chemotherapy and 1 month after start of chemotherapy.~AIM 3: Patients with suspicious breast masses or known breast cancer who are scheduled for axillary lymph node biopsy undergo ultrasound over 15 minutes at the same visit of the breast mass study."
89190537|NCT04771481|Experimental|metoclopramide|Metoclopramide 10mg with normal saline up to 10 ml IV slowly push in 5minutes.
89190538|NCT04771481|Placebo Comparator|placebo|Normal saline 10 ml IV slowly push in 5 minutes.
88881315|NCT02678377|Sham Comparator|Saline injections|100 units of saline injected into the detrusor (large muscle of the bladder) at the time of sling surgery.
88881316|NCT02659384|Experimental|Bevacizumab|Bevacizumab monotherapy treatment in arm 1 will be discontinued upon RECIST documented progression or upon treatment withdrawal, whichever occurs first. Patients will cross-over to the combination of bevacizumab and atezolizumab upon progression as long as they meet cross-over criteria.
88881317|NCT02659384|Experimental|atezolizumab + bevacizumab + placebo|The randomized treatment regimen (atezolizumab + bevacizumab + placebo) will be continued until treatment failure or upon treatment withdrawal, whichever occurs first. Patients then go off protocol treatment and further treatment is left to the investigator's decision.
88881318|NCT02659384|Experimental|atezolizumab + bevacizumab + acetylsalicylic acid|The randomized treatment regimen (atezolizumab + bevacizumab + acetylsalicylic acid) will be continued until treatment failure or upon treatment withdrawal, whichever occurs first. Patients then go off protocol treatment and further treatment is left to the investigator's decision.
89190539|NCT04757038|Experimental|Hyalodisc injection|"• Group 1: One single X-ray-guided intradiscal injection (25 gauge) of 8 mg/mL of HYALODISC combined with PEP. The investigator will use one syringe for each involved disc, up to a maximum of three discs.~The injection will be administered at V1 baseline (day 0). Any physical activity (e.g. jogging, tennis, weightlifting, prolonged upright position) in the 48 hours following the injection should be avoided. Both groups (Group 1 and Group 2) will be treated with PEP according to a standardized protocol."
89190540|NCT04757038|No Intervention|Physical exercise program (PEP)|Group 2: PEP alone
89190541|NCT04720196|Experimental|Active repetitive transcranial magnetic stimulation|10 hertz (Hz) rTMS will be administered over the primary motor area. Therapy will include 5 daily sessions (on consecutive week days). In every sessions 1500 magnetic pulses of 90% of the resting motor threshold intensity will be elicited.
89190542|NCT04720196|Sham Comparator|Sham repetitive transcranial magnetic stimulation|Sham stimulation will mimic the active one except that the stimulating coil will be held perpendicularly to the scalp, which assures similar impression as the active stimulation but prevents that significant magnetic field will reach brain tissue.
89190543|NCT04651582|Experimental|Cognitive Training|20 hours of computerized brain exercises
89190544|NCT04651582|Active Comparator|Cognitively Stimulating Activities|20 hours of computerized brain exercises
89405254|NCT05116553|Experimental|SDT (MI) + CA|This group will receive standard 2 SDT (Self Determination Theory) psychological interviews; moreover they will use an APP with a CA (Conversational Agent), an Artificial Intelligence.
88881319|NCT02659306|Experimental|Metformin|Assessment will be done at the baseline, during and after 12 week of metformin use.
88881320|NCT02632552|Experimental|Technology-assisted care transition arm|In-patient virtual nurse on-screen touchscreen and outpatient virtual nurse follow-up by texting
89190545|NCT04650893|Placebo Comparator|Control|no steroid or non steroidal anti-inflammatory
89190546|NCT04650893|Active Comparator|Ketorolac|one time dose of 30mg of IV Ketorolac at time of closure
88881321|NCT02632552|Active Comparator|Active attention control|In-patient brief animated power-point style didactic onscreen tutorial covering the core pillars of care transitions and brief outpatient texting
89190547|NCT04650893|Active Comparator|dexamethasone|one time dose of 10mg of IV dexamethasone at the time of closure
89190548|NCT04622423||PDAC liver-MTS|Adult patients with clinical /radiological diagnosis/suspicious of PDAC metastatic to the liver, with subsequent cytological/histological confirmation (stage IV disease, AJCC) from liver resection/metastasectomy or core liver biopsy.
89190549|NCT04622423||CRC liver-MTS|Adult patients with histologically or cytologically confirmed diagnosis of CRC metastatic to the liver with indication to surgical resection (upfront or after neoadjuvant therapy).
89190550|NCT04622423||Primary non-MTS PDAC|Adult patients with clinical/radiological diagnosis of primary non-metastatic PDAC, candidates for surgical resection with radical intent of the primary tumor (upfront surgery or after neoadjuvant therapy). These patients will be monitored for early diagnosis of metachronous hepatic PDAC MTS by follow up testing.
89190551|NCT04622423||Healthy volunteers|Negative control for the clinical study.
89190552|NCT04611152|Experimental|KSI-301 (Arm A)|Intravitreal injection of KSI-301 (5 mg) once every 4 weeks for 3 monthly doses followed by an individualized dosing regimen (every 8 to 24 weeks) via intravitreal injection from Week 16 to Week 100.
89190553|NCT04611152|Active Comparator|Aflibercept (Arm B)|Intravitreal injection of aflibercept (2 mg) once every 4 weeks for 5 monthly doses followed by aflibercept (2 mg) once every 8 weeks via intravitreal injection from Week 24 to 100.
89190554|NCT04604041||Relapsing-remmitting MS group treated with corticosteroids|"Clinical testing~Neurophysiological examination (TMS, EMNG)~Psychomotor examination~Neuropsychological evaluation~Flow cytometry~ELISA"
88881322|NCT02598271||Low SCr|Patients with a serum creatinine below or equal to 1.3mg/dL
88881323|NCT02598271||High SCr|Patients with a serum creatinine above to 1.3mg/dL
89190555|NCT04604041||Relapsing-remmitting MS group treated with immunomodulation|1. Clinical testing 2. Neurophysiological examination (TMS, EMNG) 4. Neuropsychological evaluation 5. Flow cytometry
89190556|NCT04604041||Healthy control group|5. Flow cytometry
89405255|NCT05187247|Experimental|VR group|"Women assigned to the VR group will use the virtual reality technology throughout the insertion procedure"
89405256|NCT05187247|No Intervention|control group|control group for the intervention group
89405257|NCT04528108|Experimental|ZYZQ Group|ZYZQ group is the experimental group which is treated with kidney-tonifying and tune up Chong-Ren hemostasis Chinese medicine for 3 months.
89437506|NCT03781921||BN|Females with a current diagnosis of Bulimia Nervosa between 18 and 50 years old
88881324|NCT02591147|Active Comparator|Silver Diamine Fluoride 38%|Group 1 (SDF 38%) will receive the application of silver diammine fluoride (38% SDF solution) in addition to 5% sodium fluoride varnish to each approximal carious lesion (scores RA1,RA2,RA3) in a posterior tooth (premolar or molar) that is in contact with an adjacent tooth, using super floss, for a duration of 3 minutes under rubber dam isolation.
88881325|NCT02591147|Placebo Comparator|Placebo (Sterile water)|Group 2 Placebo (control) will receive the application of sterile water (placebo) in addition to 5% sodium fluoride varnish to each approximal carious lesion (scores RA1,RA2,RA3) in a posterior tooth (premolar or molar) that is in contact with an adjacent tooth, using super floss, for a duration of 3 minutes under rubber dam isolation.
88881326|NCT02588872|Active Comparator|Hyaluronic Acid (HA)|Hyaluronic acid administered as an intra-articular injection under ultrasound guidance as a series of three weekly injections to the affected knee. 3 weekly injections are of ultra high molecular weight hyaluronan (16mg) in a 2mL injection.
88881327|NCT02588872|Experimental|Platelet-rich Plasma (PRP)|Platelet-rich plasma administered as an intra-articular injection under ultrasound guidance as a series of three weekly injections to the affected knee. 3 weekly injections are of leukocyte poor, buffer/additive free, singe spin, platelet-rich plasma averaging 4mL in volume.
89190557|NCT04603937|Experimental|KSI-301 (Arm A)|Intravitreal injection of KSI-301 (5 mg) once every 4 weeks for 3 monthly doses followed by an individualized dosing regimen (every 8 to 24 weeks) via intravitreal injection from Week 16 to Week 100.
89405258|NCT04528108|Active Comparator|GXN Group|GXN group is the active Comparator group which is treated with Gong Xue Ning capsules for 3 months
89190558|NCT04603937|Active Comparator|Aflibercept (Arm B)|Intravitreal injection of aflibercept (2 mg) once every 4 weeks for 5 monthly doses followed by aflibercept (2 mg) once every 8 weeks via intravitreal injection from Week 24 to 100.
89405259|NCT03699878||patients undergoing robotic esophagectomy|Patients 20 years or older who undergo robotic esophagectomy
89405260|NCT04602559|Experimental|MOBIDERM Panty group|"MOBIDERM Panty group :~All patients will wear the Panty MOBIDERM device for 12 weeks, day and night recommended. A removable pad is also recommended to be worn additionnaly to the panty."
89405261|NCT03701776|Experimental|Aerobic Training|Participants will be given a stationary exercise bike for home use. They will be instructed to use the exercise bike five times a week for thirty-minute sessions. The exercise intensity prescription will be based on the subject's VO2max determined on pre-test day. The exercise program will start at 60% of intensity per session, and then will be increased by steps of 5% intensity every 2 sessions until participants reach 30 minutes of training at 80% intensity. Participants will be contacted weekly by e-mail or phone to answer any questions about the exercise protocol and will be instructed to log each training session. Subjects will record duration of exercise, perceived exertion, average heart rate, maximum heart rate, and distance.
89405262|NCT03701776|Active Comparator|Balance Training|A physical therapist will tailor a home balance training program for each participant based on pre-training capabilities. Subjects will be asked to perform exercises five times a week for thirty-minute sessions. Both dynamic and static exercises will be performed in sitting and standing positions. Exercises will start with stabilizing in a challenging static position and progress to dynamic arm and leg movements in the same or modified position. Participants will be contacted weekly by e-mail or phone to answer any questions about the exercise protocol and will be required to log their exercise effort in terms of frequency and level of balance challenge. Individuals will be instructed to perform more difficult exercises if balance challenge scores are low.
89405263|NCT05216731|Experimental|Bypass group|Under general anesthesia: Use of the best vascular substitute (inverted saphenous vein or vascular prosthesis).
89405264|NCT05216731|Active Comparator|Endovascular procedure group|Under local or general anesthesia: Performing a balloon angioplasty completed by preferred stent deployment or drug-coated balloon angioplasty.
89405265|NCT04436614|Experimental|Aloe Vera and Crocus|50 patients Aloe Vera and Crocus (saffron) 1L, 1 bottle per 15 days. Dietary Supplement: Aloe Vera and Crocus (saffron) in a glass bottle Intervention: Dietary Supplement: Aloe Vera and Crocus (saffron) in a glass bottle 1L, per 15 days.
89405266|NCT04436614|Placebo Comparator|Aloe Vera|50 patients Aloe Vera (simple) in a glass bottle 1L, 1 bottle per 15 days. Dietary Supplement: Aloe Vera (simple) in a glass bottle Intervention: Dietary Supplement: Aloe Vera (simple) in a glass bottle in a glass bottle 1L, per 15 days.
89405267|NCT04436614|Other|Mediterranean Diet|50 patients Mediterranean dietary protocol Intervention:mediterranean diet
89405268|NCT04299503|Active Comparator|Crisaborole|ointment applied topically in the morning and in the evening
89405269|NCT04299503|Placebo Comparator|Placebo|ointment applied topically in the morning and in the evening
89437507|NCT03781921||Controls|Females with no current or past diagnosis of any eating disorder; between 18 and 50 years old
88881328|NCT02448485||Aortic Valve Intervention|Consecutive symptomatic patients who underwent aortic valve intervention (SAVR or TAVI) for the treatment of severe AS since 2010
88881329|NCT02448485||Conservative Treatment|Asymptomatic patients with aortic stenosis followed conservatively at our department
88881330|NCT02387203|Experimental|PrevPac|"Study intervention: PrevPac (Prevacid, Amoxicillin, Clarithromycin)twice daily x 14 days for 2 courses (preoperative and post-operative).~All eligible patients with a PMP diagnosis, undergoing CRS/HIPEC treatment, who consent to study participation will have a urea breath test prior to the first course of PrevPac.~After surgery, when tolerated, each patient will take a second course of PrevPac. Patients will be seen for follow-up as clinically indicated until year 5."
88881331|NCT02387203|No Intervention|PMP Historical Control|The historical control group will consist of all PMP patients who did not receive perioperative antibiotic treatment.
88881332|NCT02381353|Active Comparator|Plain bupivacaine|Intraoperative injection of local anesthetic agent, standard of care
88881333|NCT02381353|Experimental|Exparel (sustained release bupivacaine)|Intraoperative injection of local anesthetic agent, long acting agent
88881334|NCT02310061|Placebo Comparator|Control arm|Standard protocol of fluid management in hemodialysis
89190559|NCT04602975|Experimental|Adults cohort 1 vaccinees|Eligible subjects (adults - 18 to 50 yr-old) will be randomized to receive 3 intramuscular (IM) injections with the 10μg OS adjuvanted dose (or matching placebo), at a ratio of 3:1.
89190560|NCT04602975|Placebo Comparator|Adults cohort 1 placebo recipients|Eligible subjects (adults - 18 to 50 yr-old) will be randomized to receive 3 IM injections with the adjuvanted matching placebo.
88881335|NCT02310061|Experimental|Active arm|Extra-vascular lung water measurements by ultrasound (LW-US)
89190561|NCT04602975|Experimental|Children cohort 2 vaccinees|Eligible subjects (Children 2 to 5 yr-old) will be randomized to receive 3 IM injections of the 10 μg OS dose with Alhydrogel (or matching placebo) at a ratio of 3:1.
89190562|NCT04602975|Placebo Comparator|Children cohort 2 placebo recipients|Eligible subjects (Children 2 to 5 yr-old) will be randomized to receive 3 IM injections of the matching placebo with Alhydrogel.
89190563|NCT04602975|Experimental|Infants cohort 3A vaccinees (-)|Eligible subjects (9 mo-old +/- 1mo infants) will be randomized to receive 3 IM injections of the not adjuvanted 2 μg dose (or of matching placebo), at a ratio of 4:1.
89190564|NCT04602975|Placebo Comparator|Infants cohort 3A placebo recipients (-)|Eligible subjects (9 mo-old +/- 1mo infants) will be randomized to receive 3 IM injections of the not adjuvanted matching placebo.
89190565|NCT04602975|Experimental|Infants cohort 3A vaccinees (+)|Eligible subjects (9 mo-old +/- 1mo infants) will be randomized to receive 3 IM injections of the adjuvanted 2 μg dose (or of matching placebo), at a ratio of 4:1.
89190566|NCT04602975|Placebo Comparator|Infants cohort 3A placebo recipients (+)|Eligible subjects (9 mo-old +/- 1mo infants) will be randomized to receive 3 IM injections of the adjuvanted matching placebo.
88881336|NCT02305537|Experimental|Treatment (Cognitive-Behavioral Therapy)|Participants in the McLean Anxiety Mastery Program
88881337|NCT02305537|No Intervention|Waitlist|Participants on the waitlist for the McLean Anxiety Mastery Program
89190567|NCT04602975|Experimental|Infants cohort 3B vaccinees (-)|Eligible subjects (9 mo-old +/- 1mo infants) will be randomized to receive 3 IM injections of the not adjuvanted 10 μg dose (or of matching placebo), at a ratio of 4:1.
89190568|NCT04602975|Placebo Comparator|Infants cohort 3B placebo recipients (-)|Eligible subjects (9 mo-old +/- 1mo infants) will be randomized to receive 3 IM injections of the not adjuvanted matching placebo.
89405270|NCT05033470|Experimental|Dabir Surface Mattress Overlay System|Eligible patients are treated with a mattress overlay system and standard of care (debridement, proper moisture balance, reduction of bacterial burden and nutritional counseling). Subjects will be seen weekly for 4 weeks. Patients who respond to the offloading device, may use the overlay for an additional 12 weeks with monthly follow-up visits in the clinic or their home. Subjects undergo study procedures on a weekly basis.
89405271|NCT05178433|Experimental|Experimental group|Use baby moisturizers in addition to basic skin care and protection during phototherapy.
89405272|NCT05178433|No Intervention|control group|Only basic skin care and protection during phototherapy.
88881338|NCT02296307||DOvEE Participants|"All symptomatic women who are eligible for participation in the DOvEE trial receive the same interventions:~Blood test: CA-125 biomarker at day 1 and week 6-8. Second Test: Transvaginal Ultrasound at day 1. Follow-up Phone Call: Confirms continuing health 6 months after last visit."
89405273|NCT04251689|Experimental|intervention|mannitol 20 gram plus 0.9% normal saline 100 ml one hour after cisplatin
89405274|NCT04251689|Placebo Comparator|placebo|0.9% normal saline 100 ml one hour after cisplatin
89405275|NCT05164393|Experimental|AVX001 1%|Application of AVX001 1% gel to treatment field once daily
89190569|NCT04602975|Experimental|Infants cohort 3B vaccinees (+)|Eligible subjects (9 mo-old +/- 1mo infants) will be randomized to receive 3 IM injections of the adjuvanted 10 μg dose (or of matching placebo), at a ratio of 4:1.
88881339|NCT02288676||Case Group|Participants must have suspected or confirmed upper genital tract cancer (uterine, tubal and ovarian) and must be scheduled to undergo surgery for tumor removal.
89190570|NCT04602975|Placebo Comparator|Infants cohort 3B placebo recipients (+)|Eligible subjects (9 mo-old +/- 1mo infants) will be randomized to receive 3 IM injections of the adjuvanted matching placebo.
89405276|NCT05164393|Experimental|AVX001 3%|Application of AVX001 3% gel to treatment field once daily.
89405277|NCT05164393|Placebo Comparator|AVX001 Vehicle|Application of AVX001 vehicle gel to treatment field once daily
89405278|NCT04232423|Experimental|OLN 0-5-10|Placebo tablet in chemotherapy cycle 1, olanzapine 5 mg tablet in chemotherapy cycle 2, and olanzapine 10 mg tablet in chemotherapy cycle 3
89405279|NCT04232423|Experimental|OLN 5-10-0|Olanzapine 5 mg tablet in chemotherapy cycle 1, olanzapine 10 mg tablet in chemotherapy cycle 2, and placebo tablet in chemotherapy cycle 3
88881340|NCT02288676||Control Group|Participants must not be under investigation for any pre-cancerous or cancerous lesions of the genital tract, and must be scheduled for a hysterectomy, bilateral salpingectomy with/without bilateral oopherectomy for presumed benign condition.
88881341|NCT02079714||Questionnaire|All STREAM Study participants will be complete a series of computer adaptive testing (CAT) questions covering all core and exploratory domains, once written informed consent is obtained. Administration of these surveys will follow completion of all other follow-up activities related to the main METRC study in which they were originally enrolled. Identical surveys will be repeated at the 6 month study visit. At the final 12 month study visit, participants will complete the CAT survey for the six core domains, and will also complete a randomly assigned subset of items from the total item bank across these six core domains. At any visit, if the CAT cannot be administered, respondents will instead complete paper surveys of the short form for each domain.
88881342|NCT01992653|Experimental|Polatuzumab Vedotin (1.4mg) + G-CHP|Dose Escalation: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with G-CHP.
88881343|NCT01992653|Experimental|Polatuzumab Vedotin (1.0mg) + R-CHP|Dose Escalation: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with R-CHP.
88881344|NCT01992653|Experimental|Polatuzumab Vedotin (1.8mg) + G-CHP|Dose Escalation: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with G-CHP.
88881345|NCT01992653|Experimental|Polatuzumab Vedotin (1.4mg) + R-CHP|Dose Escalation: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with R-CHP.
89190571|NCT04600934|Active Comparator|Standard POBA (plain old balloon angioplasty)|The first 50 patients will be pre-treated with standard POBA
89405280|NCT04232423|Experimental|OLN 10-0-5|Olanzapine10 tablet in chemotherapy cycle 1, placebo tablet in chemotherapy cycle 2, and olanzapine 5 mg tablet in chemotherapy cycle 3
89405281|NCT04436770|Active Comparator|Control Group|Standard physiotherapy and OT
89405282|NCT04436770|Experimental|Experimental|Virtual Reality Therapy and OT
89405283|NCT05104294||mild Primary Open Angle Glaucoma group (Group I)|28 eyes of 16 patients with mild primary open angle glaucoma as group I.
89405284|NCT05104294||moderate to severe Primary Open Angle Glaucoma group (Group II)|44 eyes of 24 patients with moderate to severe primary open angle glaucoma as group II.
89405285|NCT05104294||Control Group|80 eyes of 40 healthy subjects as control group.
89405286|NCT04367467||Individuals with solid tumors receiving PARPi|"Kidney function will be assessed by serum creatinine, serum cystatin C, and urine creatinine clearance calculation for patients who opt-in to 24 hour urine collection.~These laboratory measures will be completed by patients at the following time points:~Timepoint A: Baseline (prior to PARP inhibitor initiation, at the time of standard of care clinical testing)~Timepoint B: On-treatment (within 3-9 weeks of PARP inhibitor initiation, at the time of standard of care clinical testing)~Timepoint C: Post-treatment (within 4 weeks of PARP inhibitor discontinuation, only for those patients with clinically significant changes in GFR based on serum creatinine, cystatin C, or 24 hour urinalysis at Timepoint B"
89405287|NCT04178993|Placebo Comparator|Placebo Comparator: Placebo|Subjects will be maintained on oral placebo. Subjects will be maintained on placebo and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.
89405288|NCT04178993|Active Comparator|Active Comparator: Duloxetine|Subjects will be maintained on oral duloxetine. Subjects will be maintained on duloxetine and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during duloxetine maintenance. Placebo will be administered acutely during duloxetine maintenance.
89405289|NCT04795804|Placebo Comparator|Placebo|11.43 g (3 x 3.81 g) maltodextrin the day before the clinical investigation day
89405290|NCT04795804|Active Comparator|Human milk-like oligosaccharide alone|12 g (3 x 4 g) of the human milk-like oligosaccharide the day before the clinical investigation day
88881346|NCT01992653|Experimental|Polatuzumab Vedotin (1.8mg) + R-CHP|Dose Escalation: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with R-CHP.
88881347|NCT01992653|Experimental|Polatuzumab Vedotin (2.4mg) + R-CHP|Dose Escalation: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with R-CHP.
88881348|NCT01992653|Experimental|Expansion: Polatuzumab Vedotin (1.8mg) + R-CHP|Dose Expansion: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with R-CHP.
88881349|NCT01992653|Experimental|Expansion: Polatuzumab Vedotin (1.8mg) + G-CHP|Dose Expansion: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with G-CHP.
89190572|NCT04600934|Experimental|Shockwave|The second 50 patients will be treated primarily with Shockwave
88881350|NCT01924247|Other|Interventional Arm|Interventional Arm
88881351|NCT01924247|Other|Control Arm|Control Arm: Standard treatment by family physician
88881352|NCT01881659||Women attending cervical screening|Women aged 30-64 years who signed informed consent and comply with inclusion and exclusion criteria.
88881353|NCT01850303|Other|Surveillance|
88881354|NCT01850303|Experimental|Maintenance|Pemetrexed for non squamous NSCLC Gemcitabine for squamous NSCLC
88881355|NCT01763671|Active Comparator|Docetaxel|
88881356|NCT01763671|Experimental|Paclitaxel - Bevacizumab|
88881357|NCT01696435|Active Comparator|Vitamin D + fish oil placebo|"Vitamin D3 (cholecalciferol), 2000 IU per day~Fish oil placebo"
88881358|NCT01696435|Active Comparator|Vitamin D placebo + fish oil|"Vitamin D placebo~Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])"
89190573|NCT04595890|Experimental|Intervention Group|Injection of Bone Marrow Concentrate (BMC)
89190574|NCT04595890|Placebo Comparator|Control Group|Injection of saline
89190575|NCT04551547|Experimental|Experimental Vaccine-low dosage|low dosage inactivated SARS-CoV-2 vaccine
89190576|NCT04551547|Experimental|Experimental Vaccine-medium dosage|medium dosage inactivated SARS-CoV-2 vaccine
89190577|NCT04551547|Placebo Comparator|Placebo|No active ingredient in the placebo
89190578|NCT04539236|Experimental|Luspatercept + Lenalidomide Group|"Phase 1B: Luspatercept will be administered at starting dose 1.0 mg/kg and can be titrated to 1.33 and 1.75 mg/kg dependent on participant response. Lenalidomide will be administered in a dose escalation design between 3 cohorts to determine MTD (2.5 mg, 5 mg and 10 mg daily dose on a 21-day cycle). MTD will be defined as the dose level with 0 or 1 DLT out of 6 participants. MTD will be declared as the RP2D for the Phase II portion of the study.~Phase II: Luspatercept will be administered at 1.0 mg/kg and can be titrated to 1.33 and 1.75 mg/kg dependent on participant response. Lenalidomide will be administered with the RP2D daily for 21 days on a 21 day cycle.~Treatment with combination of Lenalidomide and Luspatercept will continue as long as a participant is deriving clinical benefit, in the opinion of the treating physician, for up to 5 years or until disease progression or treatment intolerance."
89190579|NCT04509102|Active Comparator|Active|Subjects randomized to Adderall will take an tablet/capsule by mouth daily.
89190580|NCT04509102|Placebo Comparator|Placebo|Subjects randomized to placebo will take an identical-appearing tablet/capsule and, in order to maintain blinding, will also take one tablet by mouth daily. The placebo substance will be sugar.
88881359|NCT01696435|Active Comparator|Vitamin D placebo + fish oil placebo|"Vitamin D placebo~Fish oil placebo"
88881360|NCT01696435|Active Comparator|Vitamin D + fish oil|"Vitamin D3 (cholecalciferol), 2000 IU per day~Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])"
88881361|NCT01681264|Active Comparator|Morphine:Placebo|
88881362|NCT01681264|Active Comparator|Morphine:Guanfacine 1mg|
88881363|NCT01681264|Active Comparator|Morphine:Guanfacine 2mg|
88881364|NCT01681264|Active Comparator|Placebo:Guanfacine 2mg|
88881365|NCT01681264|Placebo Comparator|Placebo:Placebo|
88881366|NCT01654276|Experimental|Febuxostat|Adult patients (age > 21 years) with gout and hyperuricemia (serum uric acid > 7.0 mg/dl in men and >6.0 mg/dl in women) requiring uric acid lowering therapy.
88881367|NCT01527591|Other|vaccine|pneumococcal conjugated vaccine
88881368|NCT01399658|Experimental|Image-Guided Brachytherapy|Image-guided brachytherapy
88881369|NCT01296113|Experimental|A|
88881370|NCT01199692||Age|
88881371|NCT01199692||Gender|
88881372|NCT01199692||Ethnicity|
88881373|NCT01199692||Body Mass Distribution|
88881374|NCT01199692||Dietary Habits|
88881375|NCT01199692||Exercise Habits|
88881376|NCT01199692||Medication Requirements|
88881377|NCT01199692||Disease State Burden|
88881378|NCT00690196|Experimental|1|Tai Chi Chih
88881379|NCT00690196|Active Comparator|2|Cognitive Behavioral Therapy
89190581|NCT04502186|Experimental|Raising Our Spirits Together Intervention|
89190582|NCT04502186|Other|Enhanced Control Condition|
89190583|NCT04470518|Active Comparator|Intervention: Diagnostic algorithm|diagnostic algorithm including a standardised clinical assessment, a Point-of-care C-reactive protein test, and safety netting advice
89405291|NCT04795804|Experimental|Human milk-like oligosaccharide and resistant starch|12 g (3 x 4 g) of the human milk-like oligosaccharide and 7.5g resistant starch (3 x 2.5 g) the day before the clinical investigation day
89405292|NCT04436848||PD patients positive for LRRK2 G2385R|
89405293|NCT04436848||PD patients negative for LRRK2 G2385R|
88881380|NCT00590122|Experimental|Randomization Group b|Parcopa at equivalent dosage to subjects current stable dose
88881381|NCT00590122|Active Comparator|Randomization Group a|Carbidopa-levodopa (Sinemet)at subjects current stable dose
88881382|NCT00309192|Experimental|1|Triamcinolone acetonide + Grid Laser
89190584|NCT04470518|No Intervention|Usual care|"In the control arm, patients will receive 'usual care' left at the discretion of the treating physician.~Apart from the general training session for all participating physicians they have attended prior to recruitment and randomization, physicians in the control arm will not receive additional tools.~They are expected (but not forced) to follow the Belgian guidelines (as described in BAPCOC National guidelines and the RIZIV consensus meeting Rational use of antibiotics in children)."
88881383|NCT00309192|Sham Comparator|2|Sham procedure + Grid laser
88881384|NCT00110591|Placebo Comparator|Placebo|Intravenous placebo for PRO 140
88881385|NCT00110591|Experimental|PRO 140 dose 1|0.1 mg/kg PRO 140 by intravenous infusion
88881386|NCT00110591|Experimental|PRO 140 dose 2|0.5 mg/kg PRO 140 by intravenous infusion
88881387|NCT00110591|Experimental|PRO 140 dose 3|2.0 mg/kg PRO 140 by intravenous infusion
89190585|NCT04428060|Experimental|PERSEUS CPR|Patients will be resuscitated according to the PERSEUS protocol
89190586|NCT04428060|Active Comparator|CONTROL|Patients will be resuscitated according to current Advanced Life Support guidelines
89190587|NCT04409340||Training cohort|"All patients enrolled will undergo:~Magnetic Resonance Viscoelastography~Quantitative ultrasound (QUS)"
89190588|NCT04409340||Validation cohort|"All patients enrolled will undergo:~• Quantitative ultrasound (QUS)"
89190589|NCT04367922|Experimental|Positive emotion skills invervention|Participants will go through a 6-week positive emotion skills course where 1 new skill opens each week.
89190590|NCT04294745|Experimental|Group A|Buccal infiltration of 4% Articaine
89190591|NCT04294745|Active Comparator|Group B|Inferior alveolar nerve block of 4% Articaine
89190592|NCT04283734|Experimental|Intervention group|Long/diffuse coronary lesion should be evaluated and guided by iFR pullback with Syncvision software to achieve a final iFR of 0.90
88881388|NCT00110591|Experimental|PRO 140 dose 4|5.0 mg/kg PRO 140 by intravenous infusion
88881389|NCT01689246|Experimental|TRx0237 250 mg/day|
89190593|NCT04283734|No Intervention|Control group|Long/diffuse coronary lesion should be treated guided by angiography
89190594|NCT04278001|Other|Ambulatory blood pressure measurement|Dual 24-hour ABPM with both the SOMNOtouch NIBP and a validated oscillometric 24-hour ABPM-device (SPACELABS 90217 / 90207).
89190595|NCT04256317|Experimental|Phase 1, Stage A (Dose Escalation)|In Cycle 1 (28 days per cycle), single dose oral azacitidine will be administered, followed by subcutaneous (SC) azacitidine, ASTX030 and oral cedazuridine on a specific dosing schedule; in Cycle 2, oral ASTX030 (cedazuridine + azacitidine) will be administered
89190596|NCT04256317|Experimental|Phase 1, Stage B (Dose Expansion)|Oral cedazuridine + azacitidine will be administered separately at the recommended dose for expansion (RDE)
89190597|NCT04256317|Experimental|Phase 2, Sequence A|Oral ASTX030 (cedazuridine + azacitidine) will be administered in Cycle 1, followed by SC azacitidine in Cycle 2; all participants will receive ASTX030 in subsequent cycles (Cycles ≥3)
89190598|NCT04256317|Experimental|Phase 2, Sequence B|SC azacitidine will be administered in Cycle 1, followed by oral cedazuridine + azacitidine tablets/capsules in Cycle 2; all participants will receive ASTX030 in subsequent cycles (Cycles ≥3)
89190599|NCT04256317|Experimental|Phase 3, Sequence A|Participants will receive ASTX030 in Cycle 1, followed by SC azacitidine in Cycle 2; all participants will receive ASTX030 in subsequent cycles (Cycles ≥3)
89190600|NCT04256317|Experimental|Phase 3, Sequence B|Participants will receive SC azacitidine in Cycle 1 followed by ASTX030 in Cycle 2; all participants will receive ASTX030 in subsequent cycles (Cycles ≥3)
88881390|NCT01689246|Placebo Comparator|Placebo|
88881391|NCT01689246|Experimental|TRx0237 150 mg/day|
89190601|NCT04249492|Experimental|IOL implantation experimental|Experimental arm: Enhanced depth of focus (EDOF) intraocular lens.
88881392|NCT01685268|Experimental|Part A, Regimen 1|AT13387 given as a 1-hr IV infusion at a starting dose of 220 mg/m2 once weekly for 3 weeks in a 4-week cycle, in combination with abiraterone acetate 1000 mg by mouth (PO) daily (QD) and prednisone or prednisolone 5 mg PO twice daily.
89535597|NCT03318107|Experimental|Transvaginal probe (Photoacoustic + ultrasound imaging)|"A transvaginal imaging probe using ultrasound and photoacoustic imaging will be inserted into the vagina and will use different frequencies of lights to create images~This will occur before the first standard of care treatment, mid-treatment, end of treatment, and approximately 3 months after the end of treatment for a total of 4 imaging time points"
88881393|NCT01685268|Experimental|Part A, Regimen 2|At13387 administered as a 1-hr IV infusion at a starting dose of 120 mg/m2 on Day 1 and Day 2 weekly for 3 weeks in a 4-week cycle, in combination with abiraterone acetate 1000 mg by mouth (PO) daily (QD) and prednisone or prednisolone 5 mg PO twice daily.
88881394|NCT01683786|Experimental|Pegintron + Riba for 36 wks in total|Pegylated IFN-α2b at 1.5 µg/kg of body weight/week and ribavirin 800~1400 mg/day for 24 weeks (36 weeks in total HCV treatment)
88881395|NCT01683786|Active Comparator|Pegintron + Riba for 48 wks in total|Pegylated IFN-α2b at 1.5 µg/kg of body weight/week and ribavirin 800~1400 mg/day for 36 weeks (48 weeks in total HCV treatment)
88881396|NCT01684956|Experimental|Intradermal first|Intradermal injection experiment first, followed by subcutaneous injection experiment
88881397|NCT01684956|Experimental|Subcutaneous first|Subcutaneous injection experiment first, followed by intradermal injection experiment
88881398|NCT01683084|Active Comparator|Telmisartan|One 40mg telmisartan pill given once daily for 24 months
88881399|NCT01683084|Placebo Comparator|Placebo|One 40mg placebo pill given once daily for 24 months
88881400|NCT04823442|Active Comparator|Study A|Metabolic PET study with mirabegron
88881401|NCT04823442|Experimental|Study B|Metabolic PET study with mirabegron and bisoprolol
88881402|NCT04820244||No intervention|Otherwise healthy human volunteers, 16-55 years old, with a confirmed genetic diagnosis of Usher Syndrome type 2 or non-syndromal USH2A related retinitis pigmentosa
88881403|NCT04825470|Experimental|Liver Transplantation|
88881404|NCT04821648|Experimental|Dosage group A|"Dosage group A will consist of 6 subjects, 1:1:1 (A1:A2:A3 below):~A1: 0.04 mg/injection; A2: 0.075 mg/injection; A3: 0.15 mg/injection Two subjects will be dosed in the area scheduled for resection with 5 injections of the lowest of the 3 RJV001 test article strengths (i.e., 0.04 mg/injection); the two subjects will also be dosed with a single injection of vehicle in the area scheduled for resection for a total of 6 injections. At the conclusion of a given test article dose group, if tolerated, enrollment will continue to the next higher dose after approval to advance based upon an interim safety review. This same process will be repeated for the 0.075 mg/injection dose with 2 additional subjects. Assuming the interim safety review for the mid dose (i.e., 0.075 mg/injection) is deemed acceptable, the 2 final subjects will be treated with the high dose (0.15 mg/injection)."
88881405|NCT04821648|Experimental|Dosage group B|"Dosage group B will consist of 3 subjects (if only 1 dose from Dosage group A is well tolerated) or 6 subjects (if 2 doses from Dosage group A are well tolerated), randomized 1:1 (B1:B2 below).~B1: RJV001 Solution for Injection, Dose 1 B2: RJV001 Solution for Injection, Dose 2 Subjects will be dosed with 1 RJV001 test article (i.e., one of the 2 highest concentrations of RJV001 doses that were well tolerated in Dosage group A, referred to as Dose 1 and Dose 2). Up to 13 injections (12 active and 1 vehicle) will be administered in an open label manner in the area scheduled for resection. If tolerated, enrollment will continue to Dosage group C after approval to advance based upon an interim safety review."
88881406|NCT04821648|Experimental|Dosage group C|"Dosage group C will consist of 3 subjects (if only 1 dose from dosage group B is well tolerated) or 6 subjects (if 2 doses from Dosage group B are well tolerated), randomized 1:1 (C1:C2 below).~C1: RJV001 Solution for Injection, Dose 1~C2: RJV001 Solution for Injection, Dose 2 Subjects will be dosed with 1 RJV001 test article (i.e., one of the 2 highest concentrations of RJV001 doses that were well tolerated in Cohort B, referred to as Dose 1 and Dose 2). Up to 31 injections (30 active and 1 vehicle) will be administered in an open-label manner in the area scheduled for resection."
88881407|NCT04821414||trial group|anakinra canakinumab
89190602|NCT04249492|Active Comparator|IOL implantation active comparator|Comparator arm: Monofocal intraocular lens.
89190603|NCT04249245||Parkinson Patients|"These patients are Hospitalized or consult in the participating hospitals of the Pointe à Pitre (Guadeloupe), or at the Pitié-Salpêtrière hospital (Paris).~They were diagnosed Idiopathic PD (Parkinson Disease). The diagnosis is made according to the MDS criteria described in Postuma and al. 2015."
89190604|NCT04249245||Control Subjects|"They are Spouse of Parkinson Patients group , with an age difference <5 years compared to the patient concerned.~If the Spouse can't be included, a corresponding control subject could be recruited in the consultation with an age difference <5 years compared to the patient concerned, in respecting the final gender ratio of the PD group."
89190605|NCT04229680|Experimental|High Salt|Subjects will be counseled to consume a diet with 2,300 mg/d sodium which they will supplement with pills containing salt to achieve an intake of 6,900 mg/d sodium.
89190606|NCT04229680|Placebo Comparator|Recommended Salt|Subjects will be counseled to consume a diet with 2,300 mg/d sodium which they will supplement with placebo pills.
89190607|NCT04228380||Inclusion|Inclusion criteria: The cohort is made up of adult patients over 65 years of age, admitted to an intensive care unit in Sweden, for other reason than postoperative care or simple monitoring.
89190608|NCT04228380||Exclusion|Exclusion criteria: Declined consent to participate.
89190609|NCT04221594||CAD detection/risk assessment|Patients with angina referred for the assessment of CAD will undergo imaging studies to develop tools to fuse coronary anatomic data obtained from CCTA with dPET data to non-invasively measure absolute MBF, MFR and RFR along vessels centerlines and across coronary lesions.
89190610|NCT04217447|Active Comparator|Experimental group|Patients intaking full-dose OAC + ASA 100mg od
89190611|NCT04217447|Placebo Comparator|Control group|Patients intaking full-dose OAC + Placebo of ASA 100mg od
89190612|NCT04210349|Experimental|Group A: 6 to 35 months, previously unvaccinated, step 1|Participants will receive two injections of SP Shz QIV 0.5 mL at Day 0 and Day 28
89405294|NCT04436848||Non-PD controls negative for LRRK2 G2385R|
89405295|NCT05104216|Experimental|Experimental Group|Subjects receive a third dose of inactivated COVID-19 vaccine
89405296|NCT04671472|Experimental|Aceneuramic acid tablets|Aceneuramic acid tablets 6 g/day, divided 3 times a day for 48 weeks
88881408|NCT04821414||control group|conventional treatment
89405297|NCT04671472|Placebo Comparator|Aceneuramic acid placebo tablets|Matching placebo 3 times a day for 48 weeks
89190613|NCT04210349|Experimental|Group 1: 6 to 35 months, step 2|Participants will receive one injection of SP Shz QIV 0.25 mL or SP Shz QIV 0.5 mL at Day 0 or SP Shz TIV1 0.25 mL or SP Shz TIV2 0.25 mL at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.
89190614|NCT04210349|Experimental|Group 2: 3 to 8 years, step 2|Participants will receive one injection of SP Shz QIV 0.5 mL or SP Shz QIV 0.5 mL or SP Shz TIV1 0.5 mL or SP Shz TIV2 0.5 mL at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.
89190615|NCT04210349|Experimental|Group 3: 9 to 17 years, step 2|Participants will receive one injection of SP Shz QIV 0.5 mL or SP Shz TIV1 0.5 mL or SP Shz TIV2 0.5 mL at Day 0.
88881409|NCT04829682|Experimental|ACT for Life|ACT for Life + Treatment as Usual
88881410|NCT04829682|Active Comparator|Present Centered Therapy|Present Centered Therapy + Treatment as Usual
89190616|NCT04210349|Experimental|Group 4: 18 to 60 years, step 2|Participants will receive one injection of SP Shz QIV 0.5 mL or SP Shz TIV1 0.5 mL or SP Shz TIV2 0.5 mL at Day 0.
89190617|NCT04210349|Experimental|Group 5: >=61 years|Participants will receive one injection of SP Shz QIV 0.5 mL or SP Shz TIV1 0.5 mL or SP Shz TIV2 0.5 mL at Day 0.
88881411|NCT02270892|Active Comparator|Group A|Left side Ulthera treatment
88881412|NCT02270892|Active Comparator|Group B|Right side Ulthera treatment
89190618|NCT04203901|Experimental|Combination Arm|CMN-001 dosing (1x10^7 DC/dose) is initiated at Visit 2 during 1st line therapy and through 2nd line therapy. CMN-001 is administered as 1 dose every 3 weeks for 3 doses (Induction phase), followed by maintenance doses, 1 every 4 weeks for 7 doses (Maintenance phase), followed by booster doses, 1 dose every 12 weeks (Booster phase). 1st line therapy, Nivolumab (3mg/kg) + Ipilimumab (1 mg/kg) will be administered at 3 week intervals for 4 administrations starting at visit 1. Followed by Nivolumab (3 mg/kg) administration every 4 weeks until progression. After progression, 2nd line therapy with lenvatinib (18mg/day) + everolimus (5mg/day) until discontinuation criteria are met.
89405298|NCT04436536|Experimental|training with random speed changes|Walking training on treadmill with random speed changes, that is, random sequence of several different walking speeds
89405299|NCT04436536|Active Comparator|training with blocked speed changes|Walking training on treadmill with blocked speed changes, that is a steady progression of faster walking speed.
89405300|NCT04086017|Experimental|Reiki teaching|Reiki Master will perform the teaching and attunement process for Level 1 Reiki and teach the caregiver(s) how to complete a simple 10-minute Reiki session with the patient and a 10-minute self-Reiki session for the caregiver(s). The Reiki Master will explain that Reiki sessions can be given whenever the patient and caregiver feel it is appropriate, but sessions should be at minimum twice per 24-hour period for at least 10 minutes with at least two hours between sessions. Reiki sessions may be more frequent than twice per day and/or longer than 10 minutes. Self-Reiki sessions should be performed daily for at least 10 minutes but maybe more frequent and/or longer in length. Each family caregiver will receive a copy of the book. The patient and caregiver will wear a Holter monitor continuously for 48 hours beginning when the caregiver(s) are trained in Reiki to measure HRV, a valid measure for stress.
88881413|NCT01384396|Experimental|KW-3357|
88881414|NCT01384409|Experimental|KW-3357|
88881415|NCT01384422|Experimental|GLPG0634 100 mg bid oral capsules|
89405301|NCT04086017|No Intervention|Usual care|Patients and caregivers will complete all measures expected of the intervention cohort including daily symptom checklist for 10 days. The patient and caregiver will wear a Holter monitor for the first 48 hours of study participation to measure heart rate variability (HRV), a valid measure for stress. The patient and/or caregiver may opt out of the Holter monitor if requested and still participate in the rest of the study.
89535598|NCT04485403|Experimental|Ibuprofen|Depending on body weight, patients will be divided into two groups. Women with a body weight <70 kg will be taking a daily dose of 800 mg ibuprofen orally. Women ≥ 70 kg will take a dose of 1200 mg ibuprofen orally. Before and after 3 weeks of treatment, all subjects will have a full hormonal, biochemical and clinical profile.
88881416|NCT01384422|Experimental|GLPG0634 200 mg qd oral capsules|
88881417|NCT01384422|Placebo Comparator|Placebo oral capsules|
88881418|NCT01384435|Experimental|KPS-0373, lowest dose|
88881419|NCT01384435|Experimental|KPS-0373, 2nd lowest dose|
88881420|NCT01384435|Experimental|KPS-0373, 2nd highest dose|
88881421|NCT01384435|Experimental|KPS-0373, highest dose|
88881422|NCT01384435|Placebo Comparator|Placebo|
88881423|NCT01384448|Experimental|Initial Stress Echocardiography|
88881424|NCT01384448|Experimental|Initial Coronary CT Angiography|
88881425|NCT01384461||Cohort|
88881426|NCT01384474||CRM training of surgical teams|CRM : Crew resource Management
88881427|NCT01384474||No CRM training of surgical teams|CRM : Crew resource Management
89190619|NCT04203901|Active Comparator|Standard Treatment|1st line therapy, Nivolumab (3mg/kg) + Ipilimumab (1 mg/kg) will be administered at 3 week intervals for 4 administrations starting at visit 1. Followed by Nivolumab (3 mg/kg) administration every 4 weeks until progression. After progression 2nd line therapy with lenvatinib (18mg/day) + everolimus (5mg/day) until discontinuation criteria are met.
88881428|NCT01384487||Normal Eyes|Eyes without disease
88881429|NCT01384487||Eyes with Glaucoma|
88881430|NCT01384487||Eyes with Retinal Disease|
88881431|NCT01384487||Eyes with Corneal Disease|Including post keratorefractive surgery
88881432|NCT01384500|Experimental|Saline in tube cuff|Use of sterile saline to inflate tracheal tube cuff
89190620|NCT04198766|Experimental|Part 1 INBRX-106 Escalation|INBRX-106 will be escalated in subjects with locally advanced or metastatic solid tumors.
89190621|NCT04198766|Experimental|Part 3 INBRX-106 Escalation in Combination with Pembrolizumab|INBRX-106 will be escalated, in combination with pembrolizumab, in subjects with locally advanced or metastatic solid tumors.
89190622|NCT04198766|Experimental|Part 4 INBRX-106 Expansion in Combination with Pembrolizumab|Subjects with melanoma (any type), head and neck squamous cell carcinoma (non-nasopharyngeal), nasopharyngeal carcinoma, MSI-high, TMB-high or MMR-deficient tumors, will be treated with INBRX-106 in combination with 200mg pembrolizumab IV every 3 weeks.
89190623|NCT04198766|Active Comparator|Part 4 Pembrolizumab Expansion Arm, Randomized|Subjects with non-small cell lung cancer will be treated with 200 mg pembrolizumab IV every 3 weeks
89190624|NCT04198766|Experimental|Part 4 INBRX-106 Expansion in Combination with Pembrolizumab in NSCLC, Randomized|Subjects with non-small cell lung cancer will be treated with alternating every 6 weeks dosing of INBRX-106 0.3 mg/kg Q6W and 400 mg pembrolizumab IV
89190625|NCT04198766|Experimental|Part 4 INBRX-106 Expansion in Combination with Pembrolizumab in NSCLC; Randomized|Subjects with non-small cell lung cancer will be given a 0.3 mg/kg priming dose of INBRX-106 in cycle 1, followed by 0.1 mg/kg INBRX-106 and 200 mg pembrolizumab IV every 3 weeks in subsequent cycles
89190626|NCT04198766|Experimental|Part 2 INBRX-106 Escalation in NSCLC|Subjects with non-small cell carcinoma relapsed or refractory to prior checkpoint inhibitor (CPI) therapy will be treated with INBRX-106
89190627|NCT04198766|Experimental|Part 2 INBRX-106 Escalation in Various Solid Tumor Types|Subjects with melanoma (any type), head and neck squamous cell carcinoma, renal cell carcinoma, urothelial carcinoma or MSI/TMB-high tumors that are relapsed or refractory to prior checkpoint inhibitor (CPI) therapy will be treated with INBRX-106
88881433|NCT01384500|No Intervention|Air in tube cuff|No intervention (control) - patient cohort, using air to inflate tracheal tube cuff.
88881434|NCT01384526||history of hormone therapy|
88881435|NCT01384526||no history of hormone therapy|
88881436|NCT01384552|Active Comparator|Normal Weight, Unrestrained - Standard|Each participant is of normal weight (BMI: 18.5-24.9 kg/m2) and is classified as an unrestrained eater (scoring less than or equal to 12 on the Three Factor Eating Questionnaire - Cognitive Restraint Scale).
88881437|NCT01384552|Active Comparator|Normal Weight, Restrained - Single Serving|Each participant is of normal weight (BMI: 18.5-24.9 kg/m2) and is classified as a restrained eater (scoring greater than 12 on the Three Factor Eating Questionnaire - Cognitive Restraint Scale).
88881438|NCT01384552|Active Comparator|Normal Weight, Restrained - Standard|Each participant is of normal weight (BMI: 18.5-24.9 kg/m2) and is classified as a restrained eater (scoring greater than 12 on the Three Factor Eating Questionnaire - Cognitive Restraint Scale).
88881439|NCT01384552|Active Comparator|Overweight, Unrestrained - Single Serving|Each participant is overweight (BMI: 25-39.9 kg/m2) and is classified as an unrestrained eater (scoring less than or equal to 12 on the Three Factor Eating Questionnaire - Cognitive Restraint Scale).
88881440|NCT01384552|Active Comparator|Overweight, Unrestrained - Standard|Each participant is overweight (BMI: 25-39.9 kg/m2) and is classified as an unrestrained eater (scoring less than or equal to 12 on the Three Factor Eating Questionnaire - Cognitive Restraint Scale).
88881441|NCT01384552|Active Comparator|Overweight, Restrained - Single Serving|Each participant is overweight (BMI: 25-39.9 kg/m2) and is classified as a restrained eater (scoring greater than 12 on the Three Factor Eating Questionnaire - Cognitive Restraint Scale).
88881442|NCT01384552|Active Comparator|Overweight, Restrained - Standard|Each participant is overweight (BMI: 25-39.9 kg/m2) and is classified as a restrained eater (scoring greater than 12 on the Three Factor Eating Questionnaire - Cognitive Restraint Scale).
89405302|NCT04570618|Sham Comparator|Standard of Care|Subjects are monitored for potential development of sepsis according to the local established clinical management guidelines.
88881443|NCT01384552|Active Comparator|Normal Weight, Unrestrained - Single Serving|Each participant is of normal weight (BMI: 18.5-24.9 kg/m2) and is classified as an unrestrained eater (scoring less than or equal to 12 on the Three Factor Eating Questionnaire - Cognitive Restraint Scale).
88881444|NCT01384565|Active Comparator|G-CSF+EPO|
88881445|NCT01384565|Placebo Comparator|Placebo|
88881446|NCT01384578|Experimental|pentoxiphylline and Vitamin E|
88881447|NCT01384578|Active Comparator|Vitamin E|
88881448|NCT01384617|Experimental|Roux-en-Y anastomosis of the pancreatic stump|end-to-side pancreaticojejunostomy into a retrocolic Roux-en-Y reconstruction. The pancreaticojejunostomy anastomosis is performed in duct-to-mucosa.
88881449|NCT01384617|Active Comparator|Stapling closure of the pancreatic stump|Echelon 60 with a gold cartridge provide provides precise and uniform wide compression throughout the entire 60mm length with compressible thickness to 1.8mm, which can attach two triple-staggered rows of titanium staples.
88881450|NCT01384643|Experimental|Propofol group|
88881451|NCT01384643|Placebo Comparator|Control group|
88881452|NCT01384656|Experimental|GIK group|
88881453|NCT01384656|Placebo Comparator|Control group|
88881454|NCT01384669||Group 1|papillary thyroid microcarcinoma without lymph node metastasis
88881455|NCT01384669||Group 2|papillary thyroid microcarcinoma with lateral lymph node metastasis
88881456|NCT01384682|No Intervention|No change|continue their current cART regimen
88881457|NCT01384682|Active Comparator|Replace N(t)RTI drugs with Maraviroc|Replace N(t)RTI drugs with MVC at a dose of 150mg bid (MVC 300mg bid can be used at the discretion of the Investigator if the PI/r is fosamprenavir/r) and continue the PI/r
88881458|NCT01384682|Active Comparator|Replace PI/r drugs with Maraviroc|Replace PI/r drugs with MVC at a dose of 300mg bid and continue 2N(t)RTI.
89190628|NCT04198766|Experimental|Part 4 INBRX-106 Expansion with Pembrolizumab in Uveal Melanoma|Subjects with ocular (uveal) melanoma who are relapsed or refractory to checkpoint inhibitor (CPI) therapy will be treated with INBRX-106 and 200 mg pembrolizumab IV every 3 weeks
89190629|NCT04198766|Experimental|Part 4 INBRX-106 Expansion with Pembrolizumab in MSI-high, TMB-high or MMR-deficient tumors|Subjects with solid tumors that have confirmed MSI-high, TMB-high or MMR-deficient states who are relapsed or refractory to checkpoint inhibitor (CPI) therapy will be treated with INBRX-106 and 200 mg pembrolizumab IV every 3 weeks
88881459|NCT01384695|Experimental|Fluorescein|Confocal imaging using contrast agent fluorescein
88881460|NCT01384695|Experimental|Proflavine hemisulfate|confocal imaging using contrast agent proflavine
88881461|NCT01384708|Experimental|treatment|imaging with proflavine
88881462|NCT01384747|Experimental|Fimasartan|Initial dose will be started with 60mg per day. At 4 week follow-up after the procedure, dose titration upto 120 mg per day will be made if the patient is not hypotensive.
88881463|NCT01384747|Placebo Comparator|Placebo|Initial dose will be started with 60mg per day. At 4 week follow-up after the procedure, dose titration upto 120 mg per day will be made if the patient is not hypotensive.
88881464|NCT01384812|Placebo Comparator|Isoton sodium chloride|
88881465|NCT01384812|Active Comparator|Prostin E2 (dinoprostone)|
88881466|NCT01384825||MS|Subjects with Multiple Sclerosis
88881467|NCT01384825||HC|Healthy Controls
88881468|NCT01384825||OND|"Subjects with Other Neurodegenerative Diseases, including both other non-inflammatory neurodegenerative diseases (OND) and other inflammatory neurodegenerative diseases (ONDi)"
88881469|NCT01384838|Other|Counseling|Patients are to receive identical counseling for ideal nutritional, lifestyle, physical activity.
88881470|NCT01384838|Experimental|Controlled physical activity|"All patients are to receive identical counseling for ideal nutritional, lifestyle, physical activity.~Patients randomized to Arm 2 will additionally undergo a controlled and observed program of physical activity for a period of 6 months. Thereafter the patients are expected to adhere to a comparable, unobserved exercise program at home."
89405303|NCT04570618|Experimental|Standard of Care + AlgoDx Sepsis Prediction Algorithm|Subjects are monitored for potential development of sepsis according to the local established clinical management guidelines, and sepsis prediction algorithm alerts are unblinded to clinical staff.
89405304|NCT03008980||Community GI Group|Diagnostic Test
89405305|NCT03008980||Academic GI Group|Diagnostic Test
89405306|NCT03008980||Academic Esophageal Dysplasia and Cancer|Diagnostic Test
89405307|NCT03008980||Community Barrett's Esophagus Screening|Diagnostic Test
89405308|NCT03008980||Community Esophageal Dysplasia|Diagnostic Test
89405309|NCT03008980||Post-Ablation BE and Esophagus Dysplasia|Diagnostic Test
89405310|NCT03008980||GERD, BE, and Esophageal Dysplasia|Diagnostic Test
89405311|NCT04660708|Experimental|Pregnant women|"Physical assessment for women 20-34 weeks gestation including evaluating pain, back and hip range of motion, strength of hip and abdominal muscles, diastasis recti, and strength, amount of scar tissue from previous pregnancies / deliveries, level of muscle overactivity, and the extent of any prolapse of pelvic floor muscles.~Treatment: internal and external myofascial release of the pelvic floor muscles, pelvic floor stretching, and instruction diaphragmatic breathing and exercises for postpartum recovery to perform at home. Exercises include: Pelvic floor stretching: happy baby stretch, deep squat, butterfly stretch; Belly breathing; transverse abdominis contraction, transverse abdominis march, bridge, shoulder blade; Instruction and education on perineal massage and posture."
89405312|NCT03001557|Experimental|Lemborexant 2.5 milligrams (mg)|Participants will take one lemborexant 2.5 mg tablet and one lemborexant-matched placebo tablet orally each night for 28 consecutive nights immediately (i.e., within 5 minutes) before the time the participant intends to try to sleep.
89405313|NCT03001557|Experimental|Lemborexant 5 mg|Participants will take one lemborexant 5 mg tablet and one lemborexant-matched placebo tablet orally each night for 28 consecutive nights immediately (i.e., within 5 minutes) before the time the participant intends to try to sleep.
88881471|NCT01384851|Experimental|Next Generation Emulsion|Next Generation Emulsion Multi-Dose Eye Drop (9963X) is a sterile, buffered, aqueous and emulsion topical ophthalmic product formulated for the relief of ocular surface irritation and symptoms of dryness. The Next Generation Emulsion 9963X formulation is an oil-in-water aqueous emulsion intended to replenish deficient aqueous and lipid components and stabilising the tear film.
88881472|NCT01384851|Active Comparator|Refresh Dry Eye Therapy|A preserved multi-dose formulation for use in treating dry eye symptomatology. The key ingredients are Castor oil, Polysorbate 80, Carbomer 1342 and Glycerin. Refresh Dry Eye Therapy® Lubricant Eye Drops contains emulsified castor oil, which enhances the natural oily superficial tear layer on the ocular surface. By stabilizing and supplementing the lipid layer, castor oil may retard evaporation of surface moisture.
88881473|NCT01384851|Active Comparator|Refresh Contacts|Solution contains carboxymethylcellulose sodium (carmellose), sodium chloride, boric acid, sodium borate, potassium chloride, calcium chloride, magnesium chloride, Purite®, sodium hydroxide, and purified water. This product is registered as a CE Mark medical device. Refresh Contacts Comfort drops providing soothing relief from tired, dry eyes. Although intended for contact lens wearers, the primary indication is for relief of dry eyes as is being studied in this investigation.
88881474|NCT01384864|Experimental|treatment|fluorescent imaging with proflavine
88881475|NCT01384890|Experimental|VMAT with CBCT|Volumetric modulated arc therapy (VMAT) with cone-beam computed tomography position (CBCT) verification
88881476|NCT01384890|Active Comparator|VMAT with kV-ray|Volumetric modulation arc therapy (VMAT) with kV-ray position verification
88881477|NCT01384903|Experimental|KW-3357|
88881478|NCT01384903|Active Comparator|Plasma-derived antithrombin|
88881479|NCT01384916|Experimental|Yoga|
88881480|NCT01384916|Active Comparator|Health education|
88881481|NCT01384929||ICU patients|All patients present in the ICU on the selected days
88881482|NCT01384942|Experimental|Meaning-Based Bereavement Group|
88881483|NCT01384942|Active Comparator|Conventional Bereavement Group|
88881484|NCT01384955||exercise|subjects diagnosed and treated in the Centre of Corrective and Compensatory Gymnastics in Bielsko - Biala, Poland, between 1983 and 1994, with scoliosis - specific exercise program
89190630|NCT04197648|Experimental|Exercise group|24 week, supervised exercise program at the PPMC (pavillon de prevention des maladies cardiaques). 3x/week. Blood pressure response evaluated during every session.
88881485|NCT01384955||control|age and condition - matched subjects, who were diagnosed at the same time, in the same clinic, and by the same physician, and prescribed the same method of physiotherapy, but did not start the exercise treatment
88881486|NCT01384968|Experimental|Beetroot juice|beetroot juice (170 mL, 8 mmol nitrate)
88881487|NCT01384968|Placebo Comparator|Nitrate-depleted beetroot juice|140 mL ...0 nitrate. Beetroot juice
88881488|NCT01384981|Active Comparator|pulmonary rehabilitation with NIV|Patients receiving nocturnal non-invasiv Ventilation during a 3-week pulmonary Rehabilitation program.
88881489|NCT01384981|Sham Comparator|pulmonary rehabilitation without NIV|Patients receiving no nocturnal non-invasiv Ventilation during a 3-week pulmonary Rehabilitation program.
89190631|NCT04197648|No Intervention|Control goup|No exercise program. Continuation of the daily life activities. Consultation with a kinesiologist at baseline, 3 months and 6 months for advice on physical activities and lifestyle habits.
89190632|NCT04196777|Experimental|Intervention|We will randomly select 3 intervention sites from the top quartile of all VHA sites, as ranked by the frequency of excessive post-procedural antimicrobial use after the 3 urologic procedures of interest. We will provide feedback both at baseline and at regular intervals to the 3 intervention sites. Data on hospital-level excessive post-procedural antimicrobial use specific to urologic patients (primary outcome) will be shared at baseline with the intervention sites. Updated data will be sent electronically to urology providers and the antimicrobial stewardship team at the intervention site every other month via electronic mail. These data will include an anonymous comparison to all other VHA hospitals.
89190633|NCT04171700|Experimental|Rucaparib|"Eligible participants will be enrolled in either Cohort A or Cohort B.~Cohort A: Up to 200 participants with deleterious mutations in BRCA1, BRCA2, PALB2, RAD51C or RAD51D.~Cohort B (Exploratory): Up to 20 participants with deleterious mutations in BARD1, BRIP1, FANCA, NBN, RAD51 or RAD51B."
89190634|NCT04168684|Experimental|Attachment and Biobehavioral Catch-up (ABC)|10 sessions that focused on parental nurturance, and sensitivity
89190635|NCT04168684|Active Comparator|Developmental Education for Families (DEF)|10 sessions that focused on cognitive development
89405314|NCT03001557|Experimental|Lemborexant 10 mg|Participants will take one lemborexant 10 mg tablet and one lemborexant-matched placebo tablet orally each night for 28 consecutive nights immediately (i.e., within 5 minutes) before the time the participant intends to try to sleep.
88881490|NCT01384994|Experimental|FOLFOX + Panitumumab|
88881491|NCT01384994|Active Comparator|FOLFOX|
89190636|NCT04128137|Experimental|fludrocortisone|FLUCORTAC® 50 μg (tablet breackable). One tablet during the first week. Then 2 tablets during the second week. Then 3 tablets during the third week and finally 4 tablets during the 4th week. Maximum of 200μg/day.
89190637|NCT04128137|Placebo Comparator|Placebo|placebo of flucortac and same diagram of administration
88881492|NCT01385020|Experimental|Gemfibrozil & red yeast rice (LipoCol)|The effect of gemfibrozil on the pharmacokinetics of red yeast rice capsule (LipoCol) after administering single-dose combination in healthy subjects
88881493|NCT01385046|Experimental|physical activity and nutrition|
88881494|NCT01385072|Experimental|Double matched sibling transplantation|"Patients with poor risk active acute leukemia and who have 2 matched sibling donors can be included. Patients' conditioning may be myeloablative or non-myeloablative. Both matched donors will be mobilized with G-CSF and their peripheral blood stem cells will be collected on day 0.Equal numbers of CD34+ cells from both donors will be transfused to the patient.~Patients will be followed for engraftment kinetics, chimerism, GVHD rate, severity and response to treatment, relapse rates, DFS and OS."
88881495|NCT01385085||No natural sunlight|one group works in a basement with no natural sunlight
88881496|NCT01385085||Low level of Natural Sunlight|the second group work in offices with unopenable windows.
88881497|NCT01385085||High level of Natural Sunlight|The third group works outdoors.
88881498|NCT01385111|Active Comparator|Arm A|EBUS centered
88881499|NCT01385111|Experimental|Arm B|EUS centered
88881500|NCT01385124|Experimental|Oral Cannabidiol|Oral Cannabidiol 10 mg twice daily will be given from conditioning starting day and until day +30 after allogeneic transplantation. Dose can be doubled every 7 days if no significant side effects documented.
88881501|NCT01385215|Placebo Comparator|Placebo|
88881502|NCT01385215|Placebo Comparator|Nasal Aerosol Immunization|
88881503|NCT01385215|Placebo Comparator|Nasal Droplet Immunization|
88881504|NCT01385215|Placebo Comparator|Intramuscular Immunization|
88881505|NCT01385228|Experimental|"Dose Level Xa"|once daily pazopanib for Days 1-21 in combination with docetaxel given IV on Day 1 and prednisone daily. Pegfilgrastim (Neulasta) every 21 days on Day 2, 3 or 4 of each cycle.
89405315|NCT03001557|Experimental|Lemborexant 15 mg|Participants will take one lemborexant 5 mg tablet and one lemborexant 10 mg tablet orally each night for 28 consecutive nights immediately (i.e., within 5 minutes) before the time the participant intends to try to sleep.
89405316|NCT03001557|Placebo Comparator|Lemborexant-matched placebo|Participants will take two lemborexant-matched placebo tablets orally each night for 28 consecutive nights immediately (i.e., within 5 minutes) before the time the participant intends to try to sleep.
89405317|NCT03587480|Other|TME+LLND group|Total Mesorectal Excision plus Lateral Lymph Node Dissection for low rectal cancer with regional lymph node metastasis.
89405318|NCT03587480|Other|TME+nCRT group|Total Mesorectal Excision After Neoadjuvant Chemo-radiotherapy for low rectal cancer with regional lymph node metastasis.
89405319|NCT03776669|Active Comparator|LSG alone|"Intervention: laparoscopic sleeve gastrectomy alone.~LSG will be performed laparoscopically via a 5-port technique. The greater omentum is dissected by using the 5-mm laparoscopic LigaSure or Harmonic from 4 cm proximal to the pyloric ring to the angle of His. Sleeve calibration is done by a 36-French bougie inserted along the lesser curvature. Then the stomach is transected with sequential firings of linear green, gold, and blue 60 mm staplers starting about 4 cm proximal to the pylorus and ending approximately 2 cm distal to the left of the esophagus. The staple-line of the remnant gastric tube is oversewn with 3-0 V-Loc to prevent leakage and hemorrhage."
88881506|NCT01385228|Experimental|"Dose Level Xb"|once daily oral administration of pazopanib for Days 3-19 in combination with docetaxel given intravenous administration on Day 1 and prednisone daily. Pegfilgrastim (Neulasta) every 21 days on Day 2, 3 or 4 of each cycle.
88881507|NCT01385241|Experimental|Received video intervention|The group of women who received an Ipod Touch with the video loaded onto it and told to view it at least once a week for the first 4 weeks, and as often as desired in weeks 5-12.
88881508|NCT01385241|No Intervention|Did not receive video|This group does not receive the video intervention during the study period, and will complete surveys at baseline, 30 days and 90 days for comparison to the intervention group.
88881509|NCT01385254||siblings and mothers of Very Low Birth Weight infants|50 older siblings (closest in age) and mothers of very low birthweight (VLBW) infants, born at <33 weeks gestation and <1500 grams at birth
88881510|NCT01385254||siblings and mothers of healthy infants|50 siblings (closest in age) and mothers of healthy, full-term infants (between 38-42 weeks gestation and lacking medical conditions that require a hospital stay past the mother's discharge date)
88881511|NCT01385267||Diamniotic twin gestations|
88881512|NCT01385319|Active Comparator|bare metal stent|
88881513|NCT01385319|Experimental|Endeavor sprint stent|
88881514|NCT01385332|Active Comparator|Early luteal phase -COH-|We perform an standard antagonist protocol beginning the second day of the menstrual cycle compared with an antagonist protocol beginning in the early luteal phase.
88881515|NCT01385332|Active Comparator|Late folicular phase - COH -|We perform an standard antagonist protocol beginning the second day of the menstrual cycle compared with an antagonist protocol beginning in the late follicular phase.
88881516|NCT01385345|Active Comparator|Vitamin D3 high dose|200,000 units (time 0) followed by (100,000 units) at months 1.5, 3 and 5. Participants will also have daily 1,000 units per day to mirror the control arm and maintain double blinding.
88881517|NCT01385345|Placebo Comparator|Vitamin D3|Participants will have a placebo liquid (to mirror the active arm high dose Vitamin D3) and also have daily 1,000 units Vitamin D3.
88881518|NCT01385358|Experimental|Thoracoscopically Assisted Surgical Ablation|This arm will have an index thoracoscopically assisted surgical ablation.
88881519|NCT01385358|Active Comparator|Catheter Ablation|This is an active comparator arm where study subjects will undergo conventional catheter ablation.
88881520|NCT01385384|Other|NeuRx|
88881521|NCT01385397|Experimental|Preceptorship and virtual community|
88881522|NCT01385410|Active Comparator|CPS, cell phone based peer support|Cell phone base peer mother support for continued exclusive breastfeeding
88881523|NCT01385410|Active Comparator|PSG, group meeting based peer support|Group based peer Cell phone base peer mother support for continued exclusive breastfeeding
88881524|NCT01385410|No Intervention|Control|Current standard of care and support (national health system)
88881525|NCT01385423|Experimental|IL-15 Patients with AML|Adults with Refractory or Relapsed Acute Myelogenous Leukemia (AML) treated with preparative regimen and Intravenous Recombinant Human IL-15 (rhIL-15)
88881526|NCT01385436||HPV HSIL cervical carcinoma|
88881527|NCT01385449|Experimental|interscalene block|interscalene block
88881528|NCT01385449|Experimental|interscalene catheter|interscalene catheter
88881529|NCT01385475|Experimental|Control|
88881530|NCT01385488|Experimental|self-monitoring|participants will use bioelectrical impedance to self-monitor arm volume at home
88881531|NCT01385488|No Intervention|completion of forms|participants will complete self-report forms
88881532|NCT01385501|No Intervention|routine care|
88881533|NCT01385501|Experimental|Educational intervention group|
88881534|NCT01385514||company A-Training Base No.1|
88881535|NCT01385514||company A-Training Base No.2|
88881536|NCT01385514||company A-Training Base No.3|
88881537|NCT01385527|Experimental|Weekly Internet survey w medication|Weekly survey via email plus topical triamcinolone
89190638|NCT04112355||6 months of age|"Visit 1~This visit will take about 15 minutes and will be at the time of the next scheduled clinical vaccinations. Study procedures at this visit include :~Draw a blood sample based on age groups below~Provided a temperature diary to fill out for the next week Visit 2~This visit will take about 15 minutes and will be approximately 7 days after the first visit. Study procedures at this visit include :~Draw a blood sample based on age groups below~Collect temperature diary if not already mailed in"
89190639|NCT04112355||12 months of age|"Visit 1~This visit will take about 15 minutes and will be at the time of the next scheduled clinical vaccinations. Study procedures at this visit include :~Draw a blood sample based on age groups below~Provide a temperature diary to fill out for the next week Visit 2~This visit will take about 15 minutes and will be approximately 7 days after the first visit. Study procedures at this visit include :~Draw a blood sample based on age groups below~Collect temperature diary if not already mailed in"
89190640|NCT04112355||5 years of age|"Visit 1~This visit will take about 15 minutes and will be at the time of the next scheduled clinical vaccinations. Study procedures at this visit include :~Draw a blood sample based on age groups below~Provide a temperature diary to fill out for the next week Visit 2~This visit will take about 15 minutes and will be approximately 7 days after the first visit. Study procedures at this visit include :~Draw a blood sample based on age groups below~Collect temperature diary if not already mailed in"
89190641|NCT04096066|Experimental|KRd (Experimental Arm)|"Carfilzomib (K):~20 mg/m2 IV on day 1 of cycle 1;~56 mg/m2 IV on days 8 and 15 in cycle 1;~56 mg/m2 IV on days 1, 8 and 15 in cycles 2-12;~56 mg/m2 on days 1 and 15 from cycle 13 and onwards.~Lenalidomide (R):~- 25 mg orally on days 1-21 of each cycle.~Dexamethasone (d):~- 40 mg orally on days 1, 8, 15 and 22 of each cycle. Each cycle is a 28-day cycle.~Until PD or intolerance. Only patients that achieve at least a VGPR within the first year of treatment and in sustained MRD negativity (MRD negative at least at 10-5 after 1 and 2 years of therapy) will stop carfilzomib after 2 years of treatment, and will continue with lenalidomide and dexamethasone administration."
89190642|NCT04096066|Active Comparator|Rd (Control Arm)|"Lenalidomide (R):~-25 mg orally on days 1-21 of each cycle.~Dexamethasone (d):~-40 mg orally on days 1, 8, 15 and 22 of each cycle. Each cycle is a 28-day cycles.~Until PD or intolerance."
89190643|NCT04057352|Other|Citadel Embolization Device|The Citadel Embolization Device is intended to endovascularly obstruct or occlude blood flow in intracranial aneurysms.
89190644|NCT04037787|No Intervention|Usual care|Perioperative care for colorectal cancer cancer is managed according to current hospital clinical practice.
89190645|NCT04037787|Experimental|ERAS protocol|Perioperative care for colorectal cancer surgery is managed according to ERAS protocol.
89190646|NCT04022590|Experimental|E-clothes|The participants with E-clothes do aerobic training at home
88881538|NCT01385527|Active Comparator|Topical triamcinolone only|Standard of care
88881539|NCT01385540||Task-based fMRI|
88881540|NCT01385553|Active Comparator|Individual Drug Counseling|
88881541|NCT01385553|Experimental|Fathers for Change|
88881542|NCT01385605||female patients|ICSI treatment because of male subfertility
88881543|NCT01385618||high responder|females with >15 follicles or E2>3000 after treatment with gonadotropins
88881544|NCT01385618||low responder|patients with <3 follicles or no response to treatment with gonadotropins
88881545|NCT01385618||control|females with an indication for treatment because of male subfertility
88881546|NCT01385631|Placebo Comparator|Atorvastatin plus Placebo|50/100 patients are randomized to Atorvastatin 80 mg per day plus placebo.
88881547|NCT01385631|Experimental|Atorvastatin plus Ezetimibe|100 patients with ST elevation myocardial infarction are randomized 1:1 to either placebo or Ezetimibe 10 mg per day in addition to treatment with Atorvastatin 80 mg in both arms.
88881548|NCT01385657|Experimental|Placebo|Placebo (for Dupilumab) as a single subcutaneous (SC) injection on Day 1, 8, 15, and 22
88881549|NCT01385657|Experimental|Dupilumab 150 mg|Dupilumab 150 mg as a single SC injection on Day 1, 8, 15, and 22
88881550|NCT01385657|Experimental|Dupilumab 300 mg|Dupilumab 300 mg as a single SC injection on Day 1, 8, 15, and 22
88881551|NCT01385683|Active Comparator|Arm A|Dabigatran then dabigatran and clarithromycin
88881552|NCT01385683|Active Comparator|Arm B|Clarithromycin and dabigatran and dabigatran
88881553|NCT01385709||Sertraline|Therefore, patients who are already taking psychotropic medications, and therefore are currently in treatment for a psychiatric illness, will be recruited. The specific psychiatric diagnoses anticipated in the subject pool include the conditions that sertraline is indicated to treat, including Bipolar Affective Disorders, Cyclothymic Disorder, Schizoaffective Disorder, Major Depressive Disorder, Dysthymic Disorder, Obsessive-Compulsive Disorder, Panic Disorder, Posttraumatic Stress Disorder, Premenstrual Dysphoric Disorder, and Social Anxiety Disorder. Patients must be female, between the ages of 18-40, taking either sertraline on a daily basis for at least one week. Exclusion criteria include 1) currently pregnant or breastfeeding, 2) concurrent use of any form of hormonal birth control, including oral contraceptive pills, Norplant or Depo-provera, 3) hepatic or renal disease, 4) irregular menstrual cycles.
88881554|NCT01385709||Lithium|Therefore, patients who are already taking psychotropic medications, and therefore are currently in treatment for a psychiatric illness, will be recruited. The specific psychiatric diagnoses anticipated in the subject pool include the conditions that lithium is indicated to treat, including Bipolar Affective Disorders, Cyclothymic Disorder, Schizoaffective Disorder, Major Depressive Disorder, Dysthymic Disorder, Obsessive-Compulsive Disorder, Panic Disorder, Posttraumatic Stress Disorder, Premenstrual Dysphoric Disorder, and Social Anxiety Disorder. Patients must be female, between the ages of 18-40, taking lithium on a daily basis for at least one week. Exclusion criteria include 1) currently pregnant or breastfeeding, 2) concurrent use of any form of hormonal birth control, including oral contraceptive pills, Norplant or Depo-provera, 3) hepatic or renal disease, 4) irregular menstrual cycles.
88881555|NCT01385735|Placebo Comparator|Placebo|Placebo 1 Tbl per day, 12 week (84 days) duration
88881556|NCT01385735|Active Comparator|Rasagiline|Azilect Group: Dose: 1 mg per day, 12 week (84 days) duration
88881557|NCT01385761||Laryngeal Mask airway (LMA)|children weighing 20 to 30 kg
88881558|NCT01385761||Intubating Laryngeal Airway (ILA-SP)|Children weighing 20-30 kg
88881559|NCT01385774|Active Comparator|Intervention group: Angioplasty|Angioplasty with or without stent of the iliac artery
88881560|NCT01385774|Active Comparator|Control: Supervised Exercise Therapy|Supervised exercise therapy by a physiotherapist
88881561|NCT01385800|Placebo Comparator|Placebo|Intradermal injection, 1 x 8 administrations 2 weeks apart
88881562|NCT01385800|Experimental|ToleroMune Grass Dose 1|Intradermal injection 1 x 8 administrations 2 weeks apart
88881563|NCT01385800|Experimental|ToleroMune Grass Dose 2|Intradermal injection 1 x 8 administrations 2 weeks apart
89190647|NCT04022590|Active Comparator|Home exercise|The participants with healthy consultation do aerobic training at home.
89190648|NCT04018391|Experimental|Stepped care for non-adherence and depression|Participants will be randomized approximately two weeks post-baseline. Those randomized to the experimental condition will receive the Intervention and Stepped Care Treatment Protocol
89190649|NCT04018391|Active Comparator|Enhanced Usual Care|Participants will be randomized two weeks post-baseline. Those randomized to the control condition will receive Enhanced Usual Care.
89190650|NCT04016870|Active Comparator|New Device|New pacemakers will be sourced from pacemaker manufacturers.
89190651|NCT04016870|Experimental|Reconditioned Device|Donated devices are inspected according to specific protocols that evaluate physical and electrical (battery longevity) suitability for future use. Devices deemed to be acceptable are shipped to a third-party vendor (NEScientific) for disassembly, cleaning and re-sterilization.
89190652|NCT03990610|Experimental|Treatment (vascularized lymph node transfer)|Patients undergo vascularized lymph node transfer during standard of care breast reconstructive surgery.
89190653|NCT03976258||HIV-infected adults actively using heroin|HIV-infected adults on antiretroviral therapy who are currently using heroin at least 1 month with a cumulative duration of at least 12 months in the past.
89190654|NCT03976258||HIV-infected adults never having used heroin|HIV-infected adults on antiretroviral therapy matched to HIV-infected adults actively using heroin by age, sex and CD4+ count.
89190655|NCT03976258||HIV-infected adults initiating buprenorphine/naloxone|HIV-infected adults on antiretroviral therapy who are currently using heroin at least 1 month with a cumulative duration of at least 12 months in the past initiating medication assisted treatment (MAT) for opioid use disorder with buprenorphine/naloxone.
88881564|NCT01385800|Experimental|ToleroMune Grass Dose 3|Intradermal injection 1 x 8 administrations 2 weeks apart
88881565|NCT01385813||Pregnant women who develop preeclampsia|pregnant women who develop preeclampsia (n =43) compared to pregnant women fulfilling a normotensive pregnancy (n= 86).
88881566|NCT01385826|Experimental|adalimumab|Anti-tumor necrosis factor alpha monoclonal antibody
88881567|NCT01385826|Placebo Comparator|placebo|placebo
88881568|NCT01385839|Experimental|alopecia areata|pts will have one area (or ½ of a large area) treated by hair transplant and another (or the other ½) treated by simple irritation with a large gauge sterile hypodermic needle
88881569|NCT01385852|Active Comparator|Longitudinal U/S - low fluidic|ASPIRATION FLOW RATE - 25 CC/MIN, BOTTLE HEIGHT - 90 CMS, LONGITUDINAL ULTRASOUND
88881570|NCT01385852|Active Comparator|Torsional U/S - low fluidic|ASPIRATION FLOW RATE - 25 CC/MIN, BOTTLE HEIGHT - 90 CMS, TORSIONAL ULTRASOUND
88881571|NCT01385852|Active Comparator|Longitudinal U/S - high fluidic|ASPIRATION FLOW RATE - 40 CC/MIN, BOTTLE HEIGHT - 110 CMS, LONGITUDINAL ULTRASOUND
88881572|NCT01385865|Experimental|Mulberry leaf extract|
88881573|NCT01385865|Placebo Comparator|Placebo|
88881574|NCT01385878|Active Comparator|Phacoemulsification with 1.8mm incision|Microcoaxial phacoemulsification was performed using a 1.8mm clear corneal incision
88881575|NCT01385878|Active Comparator|Phacoemulsification with 2.2mm incisi|Microcoaxial phacoemulsificaiton will be performed through 2.2mm incision
88881576|NCT01385891|Experimental|children with advanced leukemia|
88881577|NCT01385930|Experimental|Lifestyle counseling|Lifestyle counseling
89405320|NCT03776669|Experimental|LSG + HHR|"Intervention: concomitant laparoscopic sleeve gastrectomy + hiatal hernia repair.~The surgical detail of LSG is the same as described in LSG alone arm, and the surgical detail of HHR is described as below.~The hiatus is approached from the right side of the EGJ, through the lesser omentum. The hiatal defect is repaired by 1-0 Surgilon interruptedly, and then a commercialized U-shaped Biodesign Hiatal Hernia Graft is placed to the EGJ to cover the posterior side but spare the anterior side of the hiatus. Care must be taken to avoid direct contact of mesh to the esophagus to avoid any unnecessary complication. After the mesh is appropriately placed and oriented, 2 ml of TISSEEL solution for sealant is applied all over the mesh for fixation."
88881578|NCT01385930|No Intervention|Control group|Control group
88881579|NCT01385943||Skin Cancer|Patients from dermatology practices throughout Europe that have a skin lesion or tumor requiring a biopsy for diagnosis.
89405321|NCT05112094|Experimental|peripheral magnetic stimulation|peripheral magnetic stimulation (50-80% output, 20-40Hz, pulse duration 3-5 seconds, for 15 minutes) + physical therapy (shoulder range of motion exercise and stretching 30-40 minutes per day)
89405322|NCT05112094|Placebo Comparator|physical therapy only|regular physical therapy (shoulder range of motion exercise and stretching 30-40 minutes per day)
89405323|NCT04003220||MyeloDysplastic Syndrome|platelets <150 G/l and diagnosis of myelodysplasia according to the WHO classification (abnormal bone marrow features).
89405324|NCT04003220||Idiopathic Chronic Thrombocytopenia of Unknown Significance|Acquired thrombocytopenia lasting>6 months, without feature of dysimmunity (antiplatelet Ab, or anti nuclear Ab, anti ENA Ab, ANCA, anti-CCP Ab, cryoglobulinemia), normal bone marrow examination, absence of other thrombocytopenia in the family. All ICTUS patients included in the study will thus have a bone marrow aspiration.
89405325|NCT04003220||Immune Thrombocytopenic Purpura|Diagnosis of Immune Thrombocytopenic Purpura (ITP) is made according to the international ITP consensus (diagnostic criteria of Rodeghiero){Provan, 2010 #18}, knowing that a presumptive diagnosis of ITP is made when the history, physical examination, complete blood count, and examination of the peripheral blood smears do not suggest other etiologies for the thrombocytopenia
89405326|NCT04003220||healthy volunteers undergoing cardiac surgery|patients with normal blood counts undergoing cardiovascular surgery for valve replacement, or healthy bone-marrow donors
89405327|NCT03134612|Active Comparator|Ondansetron|Ondansetron 8mg (2mg/cc) was given intravenously via a 20 G vein canula
89405328|NCT03134612|Active Comparator|Lidocain|Lidocain 40mg (20mg/cc + 2cc of normal saline) was given intravenously via a 20 G vein canula
88881580|NCT01385956|Experimental|SOM 230 LAR and Gemcitabine|"Combination Therapy: Dose escalation of SOM 230 LAR and standard treatment with gemcitabine. Treatment will be administered on an outpatient basis. Gemcitabine is administered by IV infusion. The dose should be based on the patient's actual baseline body weight; the dose will be recalculated if there is a weight change of > 10% from baseline. The dose of gemcitabine will be given over 30 minutes, weekly every 3 weeks followed by 1 week rest period.~SOM 230 LAR will be administered as an intramuscular dose determined by the dosing schema, every month."
88881581|NCT01385969||Standard Practice|
88881582|NCT01385969||Syringe recoil|
88881583|NCT01385969||Pressure Transducer|
88881584|NCT01385982|Other|Actionable Test Results|"Creating standardized policies and procedures around actionable test results (ATR) management, and implementing them network-wide:~Defining the levels of severity and urgency for clinically significant test results~Network-wide policy for test result follow-up by the responsible providers, documentation and escalation processes to assure timely communication.~Standardized policies for the time frames and nature of communication of test result alerts.~Establish criteria for appropriate ATR management by the responsible provider.~Feedback performance including provider, practice and service report cards"
88881585|NCT01386021||Prior recipients of allografts for CABG|
89405329|NCT05203757|Experimental|Conventional CT-arthrogram + CBCT arthrogram|"Conventional CT-arthrogram + CBCT arthrogram (CBCT in the minutes following the conventional CT arthrogram).~Routine care (arthroCT) and CBCT of ankle."
89405330|NCT05112016||TME for rectal cancer|Patients with rectal cancer treated by TME (laparoscopic TME, transanal TME, robotic TME, open TME)
89405331|NCT00831662|Placebo Comparator|Arm 2|
89405332|NCT00831662|Experimental|Arm 1|
88881586|NCT01386034|Experimental|Citrulline/Placebo|
88881587|NCT01386034|Experimental|Placebo/Citrulline|
88881588|NCT01386047|Experimental|iCPR randomized providers|The physician population for the proposed study will comprise primary care providers (physicians, internal medicine residents, or licensed nurse practitioners; practicing in the outpatient primary care clinics at Mount Sinai Medical Center. The iCPR tool will automatically trigger for providers randomized into the iCPR intervention arm when they initiated an encounter for a patient that meets the criteria for possible evaluation of Strep Pharyngitis or Pneumonia.
88881589|NCT01386047|No Intervention|Control providers|The physician population for the proposed study will comprise primary care providers (physicians, internal medicine residents, or licensed nurse practitioners; practicing in the outpatient primary care clinics at Mount Sinai Medical Center. These providers will conduct visits for Strep Pharyngitis and Pneumonia in their manner (usual care).
88881590|NCT01386060|Experimental|Mindfulness Meditation Training|Participants receive the 6-week meditation training intervention between the 1st and 2nd study visits.
88881591|NCT01386060|No Intervention|Waitlist Control|Participants receive no intervention between the 1st and 2nd study visits. They receive the training between the 2nd and 3rd study visits only.
89437508|NCT03781648|Other|WL withdrawal method|Active Comparator: WL was used on withdrawal. During the insertion phase, air pump was turned off to avoid inadvertent insufflations. Water exchange with infusion pump was used to open the lumen and simultaneous suction of infused water to allow passage of the scope in clear water. Withdrawal phase done using air insufflation.
88881592|NCT01386073|Active Comparator|FreshKote|
88881593|NCT01386073|Placebo Comparator|Systane|
88881594|NCT01386086|Experimental|Aripiprazole|aripiprazole used adjunctively to antidepressants in patients with resistant postpartum depression
88881595|NCT01386099|Experimental|PSN821|
88881596|NCT01386099|Placebo Comparator|Placebo|
88881597|NCT01386112|Experimental|EUR-1100 1.5 mg|
88881598|NCT01386112|Experimental|EUR-1100 3.0 mg|
89190656|NCT03976258||HIV-uninfected adults initiating buprenorphine/naloxone|HIV-uninfected adults who are currently using heroin at least 1 month with a cumulative duration of at least 12 months in the past initiating medication assisted treatment (MAT) for opioid use disorder with buprenorphine/naloxone.
88881599|NCT01386112|Placebo Comparator|placebo|
88881600|NCT01386138|Experimental|RBT+WHIC|Participants met in groups for 2 hours thrice weekly (M/W/F). During the first hour, the counselor facilitated discussion of 1 of the 12 RBT module topics, repeated three times during the course of the 12-week intervention (as in RBT). A patient-led group served the purpose of mutual support during the second hour. The counselor facilitated but did not have direct discussion in these latter groups. The four WHC modules were incorporated into the RBT sessions.
88881601|NCT01386138|Active Comparator|Psycho-education|Participants met in groups for 2 hours thrice weekly (M/W/F). During the first hour, the counselor facilitated discussion of 1 of the 12 RBT module topics, repeated three times during the course of the 12-week intervention (as in RBT). A patient-led group served the purpose of mutual support during the second hour. The counselor facilitated but did not have direct discussion in these latter groups.
88881602|NCT01386151|Active Comparator|Study drug|Keratinocyte growth factor (KGF) will be administered intravenously in a 'collapsed dose' regime of 180ug/kg on day 0 and day 11.
88881603|NCT01386151|Placebo Comparator|Placebo|Saline will be used as a placebo comparator
88881604|NCT01386164|Experimental|Gardasil®|
88881605|NCT01386164|Experimental|Cervarix®|
89190657|NCT03976258||HIV-infected adults initiating methadone|HIV-infected adults on antiretroviral therapy who are currently using heroin at least 1 month with a cumulative duration of at least 12 months in the past initiating medication assisted treatment (MAT) for opioid use disorder with methadone
89190658|NCT03976258||HIV-infected adults initiating Vivitrol|HIV-infected adults on antiretroviral therapy who are currently using heroin at least 1 month with a cumulative duration of at least 12 months in the past initiating medication assisted treatment (MAT) for opioid use disorder with Vivitrol.
89190659|NCT03976258||HIV-uninfected adults initiating methadone|HIV-uninfected adults who are currently using heroin at least 1 month with a cumulative duration of at least 12 months in the past initiating medication assisted treatment (MAT) for opioid use disorder with methadone.
89190660|NCT03976258||HIV-uninfected adults initiating Vivitrol|HIV-uninfected adults who are currently using heroin at least 1 month with a cumulative duration of at least 12 months in the past initiating medication assisted treatment (MAT) for opioid use disorder with Vivitrol.
89190661|NCT03909165|Experimental|Part A. Sugammadex 2 mg/kg|Single intravenous (IV) bolus of sugammadex at 2 mg/kg
89190662|NCT03909165|Experimental|Part A. Sugammadex 4 mg/kg|Single IV bolus of sugammadex at 4 mg/kg.
88881606|NCT01386177|Experimental|doxazosin, MDMA, placebo|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but two (actually 4) treatment conditions in the same subject.
88881607|NCT01386190|Experimental|Exercise Group|Caregivers will be taught progressive exercises to use with their infants from hospital discharge to 1 year of age.
88881608|NCT01386190|Active Comparator|Control|Both the control and the intervention groups will be guided in implementing structured social interaction.In the control group, the structured interaction will consist of predominantly social activities such as the caregiver reading or singing to the baby. The duration of the structured activities for both groups will be the same.
89190663|NCT03909165|Experimental|Part B. Sugammadex 2 mg/kg|Single IV bolus of sugammadex at 2 mg/kg.
88881609|NCT01386203||Lung Cancer|
88881610|NCT01386203||Lung Cancer after therapy|
88881611|NCT01386203||COPD controls|
88881612|NCT01386216|Experimental|Bone Marrow Cell Concentrate|Bone Marrow Cell Concentrate Prepared Using the Magellan System
88881613|NCT01386229|Active Comparator|Ketamine|
88881614|NCT01386229|Active Comparator|Etomidate|
88881615|NCT01386242|Experimental|The first group|Recombinant anti-tumor and anti-virus protein for injection, twice per week
88881616|NCT01386242|Experimental|The second group|Recombinant anti-tumor and anti-virus protein for injection, three times per week
88881617|NCT01386242|Placebo Comparator|Placebo group|Saline Injection, three times per week
88881618|NCT01386242|Experimental|The third group|High dose of recombinant anti-tumor and anti-virus protein for injection, three times per week
88881619|NCT01386255|Active Comparator|baclofen|Baclofen suspension
88881620|NCT01386255|Placebo Comparator|placebo|Identical palcebo suspension
89190664|NCT03909165|Experimental|Part B. Sugammadex 4 mg/kg|Single IV bolus of sugammadex at 4 mg/kg.
88881621|NCT01386268||Group 1|
88881622|NCT01386281||Group 1|Drug (incl. Placebo)
88881623|NCT01386294|Experimental|Tenofovir 1% vaginal gel|Participants will be required to insert a single dose of assigned gel intravaginally up to 12 hours before coitus and a second dose within 12 hours after coitus but no more than 2 applications within a 24 hour period.
88881624|NCT01386294|Placebo Comparator|Universal placebo gel|Participants will be required to insert a single dose of assigned gel intravaginally up to 12 hours before coitus and a second dose within 12 hours after coitus but no more than 2 applications within a 24 hour period.
88881625|NCT01386320|Active Comparator|Ultrasound guided ankle block|Subjects in this arm will be given an ultrasound guided ankle block prior to foot surgery.
88881626|NCT01386320|Active Comparator|Medial forefoot block|Subjects in this arm will be given a nerve-stimulator guided forefoot block prior to anaesthesia and forefoot surgery
88881627|NCT01386333|Experimental|Oxytocin 24IU|Oxytocin 24 IU administered intranasally twice daily for 1 week
88881628|NCT01386333|Experimental|Oxytocin 48 IU|48 IU of intranasal oxytocin administered twice daily for 1 week
89190665|NCT03909165|Active Comparator|Part B. Neostigmine|Single IV bolus containing neostigmine (50 μg/kg; up to 5 mg maximum dose) in combination with either glycopyrrolate (10 μg/kg) or atropine sulfate (20 μg/kg).
88881629|NCT01386333|Experimental|72 IU oxytocin|72 IU of intranasal oxytocin administered twice daily for 1 week
88881630|NCT01386333|Placebo Comparator|Saline nasal spray|
88881631|NCT01386346|Experimental|All subjects|"Azacitidine Dose level -1: 50 mg/m2 subcutaneous injection on Day 1-3 of a 21 day cycle. Repeat for a total of 3 cycles. Dose level 1: 75 mg/m2 subcutaneous injection on Day 1-3 of a 21 day cycle. Repeat for a total of 3 cycles. Dose level 2: 75 mg/m2 subcutaneous injection on Day 1-5 of a 21 day cycle. Repeat for a total of 3 cycles.~Oxaliplatin on Day 1 130mg/m2 Epirubicin on Day 1 50mg/m2 Capecitabine 625 mg/m2"
88881632|NCT01386372|Experimental|Tolvaptan|
88881633|NCT01386372|Active Comparator|standard therapy|
88881634|NCT01386411||Women with Breast Cancer|The proposed investigation is a prospective cohort study. Women with newly diagnosed breast cancer will decide whether to undergo BRCA testing either before or after completion of local surgical treatment.
88881635|NCT01386541|Active Comparator|BYK324677|"Dose group I: total daily dose 2 mg (1 mg BID or 2 mg SID)~Dose group II: total daily dose 4 mg (2 mg BID or 4 mg SID)~Dose group III: total daily dose 6 mg (3 mg BID or 6 mg SID)~In each dose group 12 subjects (8 subjects BYK324677, 4 subjects placebo) are planned.~Within each dose group, the subjects will be randomised to either BYK324677 or placebo at a ratio of 2:1.~Within each verum group, the subjects will be randomised to one of the 2 treatment sequences (BID/SID or SID/BID, ratio 1:1) and treated in a cross-over manner."
88881636|NCT01386541|Placebo Comparator|Placebo|
88881637|NCT01386567|Experimental|Androxal|Androxal (enclomiphene citrate)12.5 mg or 25 mg
88881638|NCT01386567|Active Comparator|Testim (topical testosterone)|
88881639|NCT01386580|Experimental|2B3-101 Single Agent Dose Escalation|Patients in single agent dose escalation arm will receive a single IV dose of 2B3-101 on day 1 of each cycle. In order to minimize the risk of infusion reactions 5% of the total dose of 2B3-101 (in mg) should be infused slowly over the first 30 minutes. If tolerated, the infusion may then be completed over the next hour for a total infusion time of 90 minutes.
88881640|NCT01386580|Experimental|2B3-101 in combination with trastuzumab|HER2+ breast cancer patients with brain metastases will receive a single IV dose of 2B3-101 on day 1 of each cycle. In order to minimize the risk of infusion reactions 5% of the total dose of 2B3-101 (in mg) should be infused slowly over the first 30 minutes. As long as 2B3-101 is well tolerated, the remaining 95% of the infusion could thereafter be administered over the next 60 min, resulting in a total infusion time of 90 minutes. The infusion of trastuzumab will then follow 30 minutes after the completion of the 2B3-101 infusion.
88881641|NCT01386580|Experimental|2B3-101 solid tumor expansion|Patients in the breast, Small Cell Lung Cancer and melanoma dose expansion arms will receive a single IV dose of 2B3-101 on day 1 of each cycle. In order to minimize the risk of infusion reactions 5% of the total dose of 2B3-101 (in mg) should be infused slowly over the first 30 minutes. If tolerated, the infusion may then be completed over the next hour for a total infusion time of 90 minutes.
88881642|NCT01386580|Experimental|2B3-101 glioma expansion|Patients in the single agent glioma dose expansion arm will receive a single IV dose of 2B3-101 on day 1 of each cycle. In order to minimize the risk of infusion reactions 5% of the total dose of 2B3-101 (in mg) should be infused slowly over the first 30 minutes. If tolerated, the infusion may then be completed over the next hour for a total infusion time of 90 minutes.
88881643|NCT01386593|Other|(A) Baseline|
88881644|NCT01386593|Other|(B) Inhibition|
88881645|NCT01386593|Other|(C) Induction|
88881646|NCT01386658|Experimental|Icatibant|Single dose of icatibant 0.4 mg/kg subcutaneous(SC) up to a maximal dose of 30 mg
88881647|NCT01386671|Experimental|Metformin glycinate|Metformin glycinate is a new biguanide, for this study the dose administrated will be 1050.6 mg OD for a month, and 1050.6 mg BID for 11 moths.
88881648|NCT01386671|Active Comparator|Metformin Hydrochloride|Metformin Hydrochloride is the biguanide most used, for this study the dose administrated will be 850 mg OD for a month, and 850 mg BID for 11 months.
88881649|NCT01386684||Patients with Prostate Cancer|Patients with prostate cancer who were receiving treatment with leuprolide acetate (Lupron).
89190666|NCT03876808|Experimental|Convective pre-warming|Undergo convective warming during the preoperative preparations, completed for a minimum of 60 minutes prior to entering the operating room
89190667|NCT03876808|No Intervention|Standard of care|Undergo standard of care, which includes providing each patient with blankets and sheets, as well as more blankets on patient request.
89536682|NCT03108755|Experimental|ASP7713 Single Ascending Dose|Successive cohorts of 8 non-Japanese participants (6 ASP7713/ 2 Placebo / 1-7 cohorts) will be started on a fixed single dose of ASP7713 or matching Placebo. The first two participants will receive either ASP7713 or matching placebo. If no safety issues are observed in the first 24 hours in the first two participants, then the remaining six participants will be dosed. Safety, tolerability and available Pharmacokinetic data from proceeding cohorts will be assessed for dose escalation.
89190669|NCT03844828|Experimental|POD FT IOL Implantation experimental|Mono- or bilateral implantation of trifocal toric intraocular lenses POD FT and POD F.
89190670|NCT03808454|Experimental|Platelet rich plasma (PRP)|PRP injection only
89190671|NCT03808454|Experimental|PRP+Rehabilitation|PRP injection combined with rehabilitation
89190672|NCT03808454|Active Comparator|Rehabilitation|Rehabilitation treatment only
89190673|NCT03784443|Active Comparator|Iluvien Arm|Participants assigned to the Iluvien treatment arm will receive Iluvien 0.19 MG Drug Implant to the study eye under aseptic condition at baseline visit with monthly Ranibizumab Injection [Lucentis] for first three visits followed by monthly Ranibizumab Injection [Lucentis] PRN.
89190674|NCT03784443|Sham Comparator|Control Arm|To maintain double-masking, participants assigned to the control arm will receive Sham Intravitreal Injection at the baseline visit with monthly Ranibizumab Injection [Lucentis] for first three visits followed by monthly Ranibizumab Injection [Lucentis] PRN.
89190675|NCT03777709|Experimental|Intervention|The FAITH! App intervention includes a 10-week core series of multimedia education modules with a LS7 focus and other features including interactive self-quizzes, self-monitoring (diet/physical activity), and social networking. Participants will follow a weekly schedule of each module concentrating on each LS7 component. Personalized messages will be delivered to each participant 3-4 times weekly over the intervention phase through the app dashboard, text message, or email. The sharing board will be moderated weekly to foster discussion on behavior change influences and participant successes/challenges to healthy lifestyle. Participants will maintain app access for the duration of the study.
89190676|NCT03777709|No Intervention|Delayed Intervention/Control|"The delayed intervention group will not receive additional materials while under the control time point (intervention group within intervention/maintenance phases)."
89190677|NCT03768336|Active Comparator|Waitlist Control|"The 3RP-AYA will be delivered in weekly sessions over the course of approximately 8 weeks, for a total of 8 sessions~Mini relaxation practice~Weekly goal check-ins~RR-practice"
89190678|NCT03768336|Experimental|3RP Group Sessions|"The 3RP-AYA will be delivered in weekly sessions over the course of approximately 8 weeks, for a total of 8 sessions~Mini relaxation practice~Weekly goal check-ins~RR-practice"
89190679|NCT03742141|Experimental|Intraoperative Video Laryngoscopy|Participants undergoing neck procedures
89190680|NCT03687060|Other|Organization Level|
89190681|NCT03687060|Other|Provider Level|
89190682|NCT03687060|Other|Patient Level|
89190683|NCT03663777|Experimental|Isometric Handgrip Training|Experimental group will perform home-based bilaterall handgrip exercise and will be recommended to increase daily physical activity levels.
89190684|NCT03663777|Other|Control group|Control gorup will be recommended to increase daily physical activity level
89190685|NCT03583073|Active Comparator|Standard Care/Baseline Control|Standard care is the typical process of referral to mental health services for Juvenile Justice (JJ) youth who screen positive for mental heath concerns at intake. For this study, baseline control participants will be referred to the Coordinated Specialty Care (CSC) clinic due to their endorsement of psychosis-spectrum symptoms.
88881650|NCT01386723||Discontinuation of eltrombopag|ITP subjects who have discontinued the use of eltrombopag
89405333|NCT05111938|Active Comparator|Arm A: Standard Care followed by F3A-App|The first portion of Arm A is a Standard Care (SC) office visit. Changes over time in Arm A represent a typical delivery channel in which a physician provides brief education and then encourages use of the F3A-App program. The SC intervention included a brief, structured office visit designed to replicate what would typically occur in a follow-up visit in an allergy clinic, and include provision standardized educational handouts available from the Food Allergy Research & Education (FARE) website. The second phase of Arm A is use of the F3A-App.
89405334|NCT05111938|Active Comparator|Arm B: F3A-App followed by Standard Care|"The first portion of Arm B is the use of the F3A-App for 2 weeks. Changes over time in Arm B represent an alternative delivery channel in which families use the F3A-App on their own and then have a follow-up office visit after using the self-guided program. The second phase of Arm B is the standard care office visit.~F3A-App efficacy vs. SC is evaluated after the first intervention period on primary outcomes."
89405335|NCT04365985|Placebo Comparator|Placebo|Placebo by mouth 1 time per day for patients with stage I or stage 2A COVID-19
89405336|NCT04365985|Experimental|Naltrexone|Naltrexone 4.5 mg by mouth 1 time per day for patients with stage I or stage 2A COVID-19.
89405337|NCT04365985|Experimental|Ketamine|Ketamine IV infusion (0.15 mg/kg based on total body weight for maximum 20 mg every 6 hours) for patients with stage 2B or stage 3 COVID-19; may be increased to 0.3 mg/kg based on total body weight for a maximum of 30 mg every 6 hours if needed. Patients entering this arm from the placebo or naltrexone arms remain on those medications as well.
89405338|NCT00830336|Experimental|Azithromycin (test)|Azithromycin for Oral Suspension 200 mg/5 mL (test) dosed in first period followed by Zithromax® Oral Suspension 200 mg/5 mL (reference) dosed in second period
89405339|NCT00830336|Active Comparator|Zithromax® (reference)|Zithromax® for Oral Suspension 200 mg/5 mL (reference) dosed in first period followed by Azithromycin for Oral Suspension 200 mg/5 mL (test) dosed in second period
89405340|NCT05111704|Experimental|Balance Body Tape|Three-week treatment with Balance Body Tape (BBT).
89405341|NCT05111704|No Intervention|Control group|Control group receiving no intervention.
89190686|NCT03583073|Experimental|Enhanced Referral/Linkage to Care|"The experimental condition will include a psychoeducational and motivational enhancement protocol completed at the JJS intake appointment, paired with a warm hand-off referral to the CSC for evaluation and initiation of mental health services."
89190687|NCT03531814|Experimental|1/Intervention|Questionnaires and use of the medication event monitoring system (MEMS)
89190688|NCT03512223|Experimental|Group A (IV dexamethasone)|Perineural (30ml of 0.75% ropivacaine + 0.5 ml normal saline) and IV (9.0 ml normal saline + 1 ml of 10 mg/ml Dexamethasone)
89405342|NCT04316689|Experimental|S-588210 (S-488210 + S-488211)|Participants will receive subcutaneous injections once a week for 4 weeks and then a biweekly extension treatment for 8 weeks. Each treatment will consist of 1 subcutaneous injection of 1 mL of S- 488210 and 1 subcutaneous injection of 1 mL of S-488211 containing 1 mg each of the 5 peptides.
88881651|NCT01386736|Active Comparator|Vitamin D|Subjects will randomly be assigned to Vitamin D drops versus placebo drops.
88881652|NCT01386736|Placebo Comparator|Placebo|Subjects will randomly be assigned to Vitamin D drops versus placebo drops.
88881653|NCT01386749|No Intervention|Control|
88881654|NCT01386749|Experimental|Treatment|receive 6 months LMHFV
88881655|NCT01386762|Experimental|Exercise intervention|6 months of intense multimodal training.
88881656|NCT01386775||HED Affected Males|
88881657|NCT01386775||Controls|
88881658|NCT01386801||People with Diabetes Mellitus Type II|500 subjects will have T2D
88881659|NCT01386801||Healthy|500 persons who do not have T2D, hypertension or hypercholesterol
88881660|NCT01386827|Active Comparator|A) primary immunization with MB-JEV|Volunteers immunized with MB-JEV
88881661|NCT01386827|Active Comparator|Primary and booster MBJEV vaccinations|Booster immunization with MB-JEV of vaccinees primed with MB-JEV
89405343|NCT05111470|Experimental|kayak polo players|Having a level of expertise greater than or equal to the national level 4
88881662|NCT01386827|Active Comparator|C) primary immunizations with Ixiaro|Primary immunization with Ixiaro 2 dose
88881663|NCT01386827|Active Comparator|S) Ixiaro booster to MBJEV primed|Actual study group:Booster immunization with Ixiaro to those primed previously with MB-JEV
88881664|NCT01386840|No Intervention|Severe Pneumonia - Hospital Management|"Those randomized to hospital management will be monitored by health personnel for at least 48 hours for clinical deterioration and parameters like temperature, Respiratory rate, Lower chest indrawing, Pulse rate, Clinical deterioration, Other signs eg. comorbid conditions, Assessment of adherence, Adverse event.~Mothers, whose children are discharged after 48 hours, will be counseled to continue with oral treatment prescribed for a period of 7 days and will be advised to return to healthcare facility at their scheduled times and any time during the study period if there is clinical deterioration. The symptoms and signs of clinical deterioration will be discussed with the mother as described in the patient discharge counselling checklist. Mothers will be given a study patient data card"
88881665|NCT01386840|Experimental|Severe Pneumonia - Home Management|"For those randomized to home management, first dose will be administered by the mother/caretaker under supervision at health facility. The health personnel will assess the parameters like temperature, Respiratory rate, Lower chest indrawing, Pulse rate, clinical deterioration, Other signs eg. co-morbid conditions, Assessment of adherence, Adverse event when they visit the home after 24 hours, 72 hours and on day 8th.~Mothers will be advised to return to the healthcare facility at their scheduled times and any time during the study period if there is clinical deterioration. The symptoms and signs of clinical deterioration will be discussed with the mother as described in the patient discharge counselling checklist. Mothers will be given a study patient data card with contact Numbers."
88881666|NCT01386853|Experimental|Pitavastatin|
88881667|NCT01386853|Active Comparator|Atorvastatin|
88881668|NCT01386866|Experimental|A|
88881669|NCT01386879|Experimental|TaperGuard Evac ETT|Trachea will be intubated with Mallinckrodt™TaperGuard™ Evac Endotracheal Tube with a suction port to facilitate removal of secretions from the region of the trachea below the vocal cords and above the inflated ETT cuff
88881670|NCT01386879|Experimental|Teleflex ISIS ETT|Trachea will be intubated with Teleflex ISIS HVT Cuffed Tracheal Tube with Subglottic Secretion suction port to facilitate removal of secretions from the region of the trachea below the vocal cords and above the inflated ETT cuff
88881671|NCT01386879|Active Comparator|Standard ETT|Control group of patients will be intubated with a standard ETT without a suction port above the cuff (The Mallinckrodt Intermediate Hi-Lo Endotracheal Tube)
88881672|NCT01386892||Healthy Volunteer|Healthy Volunteer without lung disease
89190689|NCT03512223|Experimental|Group B (IV + perineural dexamethasone)|(IV + perineural dexamethasone): Perineural (30ml of 0.75% ropivacaine + 0.5 ml of 10 mg/ml Dexamethasone) and IV (9.5 ml normal saline + 0.5 ml of 10 mg/ml Dexamethasone)
89190690|NCT03512223|No Intervention|Group C (control with no adjuvant dexamethasone)|Perineural (30ml of 0.75 ropivacaine + 0.5 ml normal saline) and IV (10 ml normal saline)
89190691|NCT03502668|Experimental|Phase 1 Stage A|3 cohorts of 6 subjects each in a schedule in 28-day cycles of ASTX727 LD
89190692|NCT03502668|Experimental|Phase 1 Stage B|3 cohorts of 10 subjects each in 28-day cycles of ASTX727 LD
89190693|NCT03502668|Experimental|Phase 2|80 additional subjects randomized in a 1:1 ratio studying two different doses
89190694|NCT03481075|Experimental|Rigid and Elastic registration softwares|
89190695|NCT03474458|Experimental|Experimental intervention|doxycycline (100 mg bid)
89190696|NCT03474458|Active Comparator|Control intervention|Standard of care therapy
89190697|NCT03452319|Experimental|Pretraining|Increased physical activity daily Daily strength training Daily inspiratory and expiratory muscle training Standard care during hospital stay and continued training after discharge.
89190698|NCT03452319|Active Comparator|Usual care treatment|Standard care including preoperative information and postoperative breathing exercises and mobilization during hospital stay.
89190699|NCT03386500|Other|Concurrent Radiation Therapy, 5FU, Mitomycin and BMX-001|One arm includes all enrolled patients.
89190700|NCT03369405||Periodontally healthy patients|Patients that have no history of periodontal treatment and that have been scheduled for routine prophylaxis appointments in the predoctoral clinics at the School of Dental Medicine, University at Buffalo.
89190701|NCT03369405||Periodontitis, group 1|Patients that have been referred from the pre-doctoral dental clinics to the Postgraduate Periodontics clinic for advanced periodontal disease. Clinical attachment loss, pain, mobility, bleeding, suppuration, and probing depths > 4 mm more likely to be prevalent.
89190702|NCT03369405||Periodontitis, group 2|Patients referred to a faculty practice periodontist over the course of his clinical career due to chronic periodontitis that could not be treated by the referring general dentist. Clinical attachment loss, pain, mobility, bleeding, suppuration, and probing depths > 4 mm more likely to be prevalent.
89190704|NCT03266874||Patients who received the G7 BiSpherical Cup|Subject in need of a THA who met the inclusion/exclusion criteria and received the G7 BiSpherical cup.
89190705|NCT03226418|Experimental|Group I|"INTENSIVE INDUCTION THERAPY: Patients receive cytarabine intravenously (IV) on days 1-7 and idarubicin over 10-15 minutes on days 1-3 (7+3), or liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1, 3 and 5. Gemtuzumab or midostaurin are added to 7+3 as per the standard of care. Treatment continues for 1 course in the absence of unacceptable toxicity.~INTENSIVE CONSOLIDATION THERAPY: Patients who go into remission, receive cytarabine IV over 1-3 hours twice daily (BID) on days 1, 3, and 5. Treatment repeats every 4 weeks for 2-4 courses in the absence of disease progression or unacceptable toxicity. Patients treated with liposome-encapsulated daunorubicin-cytarabine receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1 and 3. Treatment repeats every 5-8 weeks for 2 courses in the absence of disease progression, unacceptable toxicity."
89190706|NCT03226418|Experimental|Group II|"LOW-INTENSITY: Patients receive venetoclax in combination with azacitidine or decitabine or other standard of care low-intensity therapy such as azacitidine or decitabine alone or in combination with FLT3 inhibitor such as midostaurin, low-dose cytarabine in combination with glasdegib.~Venetoclax dose varies depending on drug interaction with antifungal agents. Given daily continuous for >= 3 months orally. Glasdegib dose is 100 mg oral daily.~Decitabine IV over 1-3 hours daily for 5-10 days. Treatment repeats every 4-5 weeks for >= 3 courses in the absence of disease progression, unacceptable toxicity or receipt of allogeneic stem cell transplant. Azacitidine IV infusion over 10 to 40 minutes days 1 -7. Treatment repeats every 4-5 weeks for >= 3 courses in the absence of disease progression, unacceptable toxicity or receipt of allogeneic stem cell transplant."
89190707|NCT03169010||Idiopathic Pulmonary Artery Hypertension|Investigators will conduct laboratory biomarker analysis and genetic analysis to identify pathogenesis or factors related to idiopathic pulmonary artery hypertension (PAH).
89190708|NCT03169010||Hereditary PAH|Investigators will conduct laboratory biomarker analysis and genetic analysis to identify pathogenesis or factors related to hereditary PAH.
88881673|NCT01386918|Experimental|Low frequency left (LFL) sided rTMS|LFL rTMS was administered at an intensity of 115% resting motor threshold at 1HZ for 20 minutes. The treatment targeted the left temporoparietal cortex (TPC).
88881674|NCT01386918|Experimental|Priming stimulation|Priming stimulation was administered as follows: 10 minutes of 6 Hz at 90% resting motor threshold (RMT) administered to the left temporoparietal cortex followed by 10 minutes of 1 Hz stimulation at 115% RMT.
88881675|NCT01386918|Sham Comparator|Sham Control|Sham stimulation was applied with identical parameters to those for the LFL condition but with the coil angled at 90 degrees off the scalp in a single wing tilt position.
89405344|NCT03567551||Women w/ Preeclampsia w/o Visual Disturbances or Headache|Preeclampsia Without either Visual Disturbances or Headaches Blood Pressure: >Systolic 160 or Diastolic 110
89405345|NCT03567551||Women w/ Preeclampsia w/ Visual Disturbances or Headaches|Preeclampsia With either Visual Disturbances or Headaches Blood Pressure: >Systolic 160 or Diastolic 110
89405346|NCT03567551||Women w/o Preeclampsia|Normal Pregnancy Blood Pressure: <140/90
89405347|NCT00830258|Experimental|Pravastatin|Pravastatin 80 mg Tablet (test) dosed in first period followed by Pravachol® 80 mg Tablet (reference) dosed in second period
89405348|NCT00830258|Active Comparator|Pravachol®|Pravachol® 80 mg Tablet (reference) dosed in first period followed by Pravastatin 80 mg Tablet (test) dosed in second period
89405349|NCT05111158||50 eyes of 25 SLE patients with renal affection (Lupus nephritis).|mfERG
89405350|NCT05111158||50 eyes of 25 SLE patients without renal affection|mfERG
89405351|NCT03664479|Experimental|classical electrical stimulation protocol|"apply 4 channel electrical stimulation device with protocol 1.~It will simultaneously stimulate suprahyoid, thyrohyoid and sternothyroid m with 4 channel electrical stimulation device.~during apply the device, we evaluate the manometry and videofluoroscopic swallowing study for evaluation of deglutition function."
89405352|NCT03664479|Experimental|revised sequential activation protocol|"apply 4 channel electrical stimulation device with protocol 2~Is a revised sequential activation protocol, it sequentially stimulate bilateral suprahyoid m (channel 1), pharyngeal constrictors (ch 2), thyrohyoid m (ch 3), sternothyroid m (ch 4) with 4 channel electrical stimulation device.~during apply the synchronized electrical stimulation device, we will evaluate the parameters same as group 1."
89004410|NCT04589689|Experimental|Intervention Group|The intervention group will participated in the The Insul-In This Together intervention, which consists of 6 weekly 30-minute online family sessions to discuss topics related to diabetes distress and parent-teen communication. Sessions include structured education, discussions, and skill-building activities related to parental involvement, parental monitoring, and parent-adolescent conflict. The intervention will be conducted by the PI or clinically trained research staff via Zoom. Online surveys, and glucose monitoring data will be captured at baseline and 3,6 and 12-month follow-ups. Brief surveys will also be conducted at 2-, 4-, and 6-week follow-ups (after every 2 sessions for the intervention group and later the control group). Participants will be asked to provide A1C test results that will be collected via chart review or from participants sharing their test results at baseline, 6-month, and 12-month follow-up.
89405353|NCT00724334|Experimental|1|
89004411|NCT04589689|Experimental|Waitlisted Control Group|The waitlisted control group will receive the same intervention as the intervention group, but at the 6-month follow-up mark. The intervention will be conducted by the PI or clinically trained research staff via Zoom. Online surveys, and glucose monitoring data will be captured at baseline and 3,6 and 12-month follow-ups. Brief surveys will also be conducted at 2-, 4-, and 6-week from baseline. Participants will be asked to provide A1C test results that will be collected via chart review or from participants sharing their test results at baseline, 6-month, and 12-month follow-up.
89004412|NCT04585737|Experimental|Treatment group 1|Treatment Group 1 (n=148): FDC of DTG/3TC (50mg/300mg) administered orally, once daily (QD), without regard to food.
89405354|NCT03664401|Experimental|Kerecis Oral™|The Fish Skin Graft will be is cut to shape of wound bed and placed directly on the appropriate prepared recipient wound bed. The Fish skin graft has the smooth side down and the scaly side facing out. The graft will be sutured in place at either coronal end with resorbable sutures and may be secured apically if needed. A surgical dressing (Coe-Pak® ) will be placed over the graft if needed.
89405355|NCT03664401|Active Comparator|Autogenous Free Gingival Graft|"The recipient bed will be prepared at the appropriate sequential time as described. The graft will be harvested from the same side that the Free Gingival Graft is to be placed. A measurement will be made to determine the size of the donor tissue needed to be placed at the recipient site. Local anesthetic will be administered. The donor tissue will be harvested using the usual techniques. The width will be 5 mm and the length will match the predetermined measurement. The graft will be thinned as is usual practice.~The harvested palatal graft will be centered on the study tooth and placed on the appropriately prepared recipient wound bed. The graft will be sutured with resorbable sutures on the mesial and distal aspects of the tooth. A surgical dressing (Coe-Pak® ) will be placed over the graft if needed."
89405356|NCT05110768|Experimental|FPC 20 mg Fe IV by infusion over 12 hours every other day|Patients in the FPC arm will receive FPC 20 mg Fe IV by infusion over 12 hours every other day (qOD), for a total duration of up to 12 weeks plus a one-week follow-up after the last study drug treatment.For patients whose duration of therapy is >10 hours, patients will receive a 12-hour infusion of FPC.
89405357|NCT05110768|Placebo Comparator|Placebo|Patients in the placebo arms will receive IV placebo on the same schedule for 12 weeks. All patients are eligible to receive Rescue conventional IV iron if criteria are met and the patient's principal physician agrees.
89405358|NCT05215483|Experimental|Customised advice + LFT available at home|"Respondents will see an altered testing advice in text and picture in which they are allowed to use LFT with corona related symptoms.~Respondents will informed in writing that they don't currently have any LFT available at home."
89405359|NCT05215483|Experimental|Customised advice + No LFT available at home|"Respondents will see an altered testing advice in text and picture in which they are allowed to use LFT with corona related symptoms.~Respondents will informed in writing that they don't currently have any LFT available at home."
89405360|NCT05215483|Experimental|Regular advice + LFT available at home|"Respondents will see the regular testing advice in text and picture with the current governmental advice to visit a test facility with corona related symptoms.~Respondents will informed in writing that they don't currently have any LFT available at home."
89405361|NCT05215483|Active Comparator|Regular advice + No LFT available at home|"Respondents will see the regular testing advice in text and picture with the current governmental advice to visit a test facility with corona related symptoms.~Respondents will informed in writing that they don't currently have any LFT available at home."
89405362|NCT00830102|Active Comparator|1|"Period 1 Treatment Regimen A: FlutiForm 100/10 ug~Period 2 Treatment Regimen B: FlutiForm 250/10 ug~Period 3 Treatment Regimen C: Flixotide Evohaler 250 ug + Foradil Aerolizer 12 ug~Period 4 Treatment Regimen D: Flixotide Evohaler 250 ug"
89190709|NCT03169010||Hereditary Hemorrhagic Telangiectasia|Investigators will conduct laboratory biomarker analysis and genetic analysis to identify pathogenesis or factors related to hereditary hemorrhagic telangiectasia associated PAH.
89405363|NCT00830102|Active Comparator|2|"Period 1 Treatment Regimen D: Flixotide Evohaler 250 ug~Period 2 Treatment Regimen C: Flixotide Evohaler 250 ug + Foradil Aerolizer 12 ug~Period 3 Treatment Regimen B: FlutiForm 250/10 ug~Period 4 Treatment Regimen A: FlutiForm 100/10 ug"
89405364|NCT00830102|Active Comparator|3|"Period 1 Treatment Regimen B: FlutiForm 250/10 ug~Period 2 Treatment Regimen A: FlutiForm 100/10 ug~Period 3 Treatment Regimen F: Placebo~Period 4 Treatment Regimen E: Foradil Aerolizer 12 ug"
89405365|NCT00830102|Active Comparator|4|"Period 1 Treatment Regimen E: Foradil Aerolizer 12 ug~Period 2 Treatment Regimen F: Placebo~Period 3 Treatment Regimen A: FlutiForm 100/10 ug~Period 4 Treatment Regimen B: FlutiForm 250/10 ug"
89405366|NCT00830102|Active Comparator|5|"Period 1 Treatment Regimen C: Flixotide Evohaler 250 ug + Foradil Aerolizer 12 ug~Period 2 Treatment Regimen D: Flixotide Evohaler 250 ug~Period 3 Treatment Regimen E: Foradil Aerolizer 12 ug~Period 4 Treatment Regimen F: Placebo"
89004413|NCT04585737|Active Comparator|Treatment group 2|Treatment Group 2 (n=74): Stay on baseline regimen consisting of FDC of B/F/TAF (50mg/200mg/ 25mg) (taken as prescribed) without regard to food.
89004414|NCT04543253||Standard of care CS|Patients undergoing curative surgery for any type of CS who will be followed through standard of care after surgery
89004415|NCT04543253||MUSE intervention CS|Patients undergoing curative surgery for any type of CS who will be introduced to and provided MUSE for use after surgery
89004416|NCT04537299|Experimental|Treatment Group|Subjects will receive treatment drug (Fisetin)
89405367|NCT00830102|Active Comparator|6|"Period 1 Treatment Regimen F: Placebo~Period 2 Treatment Regimen E: Foradil Aerolizer 12 ug~Period 3 Treatment Regimen D: Flixotide Evohaler 250 ug~Period 4 Treatment Regimen C: Flixotide Evohaler 250 ug + Foradil Aerolizer 12 ug"
89405368|NCT03665415|Other|Formative|This stage represents an initial formative phase to implement the NDGame Squad intervention with small samples of youth in order to make any modifications necessary before embarking on the full pilot in both sites in the next phase. Three (n=3) participants from the school site only will participate in an initial 4-week Game Squad intervention in the first formative phase. Participant feedback including barriers to engagement and suggestions for improvements will be obtained via parent/caregiver and child interviews post-intervention.
89405369|NCT03665415|Experimental|Pilot Intervention|Participants in the pilot intervention arm will receive either 10 or 14 weeks of the NDGameSquad intervention. School site participants will receive 10 weeks during the school year, followed by another 4 weeks during summer vacation. Clinic site participants will receive 10 weeks only.
89405370|NCT03665415|Other|Pilot Waitlist Control|Participants at both sites randomized to the waitlist control arm will be asked to maintain current physical activity levels during the first 10-week period. They will then be provided the intervention equipment and training. School site control arm participants will then participate in a 4-week, unsupported summer NDGame Squad intervention. Clinic site control arm participants will not be required to participate in the NDGameSquad intervention.
89405371|NCT03349775|Active Comparator|Metformin|Metformin: 500mg twice daily for 1 week, followed by 1g twice daily for a total of 3 months.
89405372|NCT03349775|Placebo Comparator|Placebo|Placebo: 500 mgh twice daily for 1 week, followed by 1g twice daily for a total of 3 months.
89405373|NCT00830024|Experimental|Alprazolam (test)|Alprazolam 3 mg ER Tablet (test) dosed in first period followed by Xanax XR® 3 mg Tablet (reference) dosed in second period
89405374|NCT00830024|Active Comparator|Xanax XR®|Xanax XR® 3 mg Tablet (test) dosed in first period followed by Alprazolam 3 mg ER Tablet (test) dosed in second period
89405375|NCT04053933||Patients treated with ESA|
89405376|NCT04053933||Patients treated with 5'azacitidin|
88881676|NCT01386931||Cytopathologist present during EUS-FNA|"Patients assigned to the on-site cytopathologist arm will have the cytopathologist dictate the number of FNA passes performed by the endosonographer. This number will be based on the adequacy of specimen and the ability to provide a preliminary diagnosis.~After EUS-FNA is performed all slides will be sent to the pathology department. The slides will be sent for review regardless of which arm the patient is randomized into, and they will be reviewed by experienced cytopathologists for the purpose of determining the final diagnoses."
88881677|NCT01386931||Cytopathologist absent during EUS-FNA|"In the absence of an on-site cytopathologist, the endosonographer will perform a predetermined number of 7 passes (standard of care in the absence of an on-site cytopathologist).~After EUS-FNA is performed all slides will be sent to the pathology department. The slides will be sent for review regardless of which arm the patient is randomized into, and they will be reviewed by experienced cytopathologists for the purpose of determining the final diagnoses."
88881678|NCT01386957||Study group|children aged 6 months - 18 years, diagnosed with an initial episode of INS occurring from the first of July 2011 to the 31st of june 2013.
88881679|NCT01386996|Experimental|Charcoal and Budesonide/formoterol Easyhaler|
88881680|NCT01386996|Active Comparator|Charcoal and Symbicort Turbuhaler|
88881681|NCT01386996|Experimental|Budesonide/formoterol Easyhaler|
88881682|NCT01386996|Active Comparator|Symbicort Turbuhaler|
88881683|NCT01387048|Experimental|Skinoren gel 15 %, topical|primary treatment 12 weeks with Skinoren gel®, followed by maintenance therapy with Skinoren gel® for another 24 weeks,
88881684|NCT01387048|Active Comparator|Differin Gel 0.1%|primary 12 weeks therapy with Differin gel®, followed by maintenance therapy with Differin gel® for another 24 weeks.
89405377|NCT04053933||Patients treated with deferoxamine|
89405378|NCT04053933||Patients treated with deferasirox|
89405379|NCT04053933||Patients treated with transfusion only|
89405380|NCT04053933||Patients treated with lenalidomide|
89405381|NCT04053933||Patients treated with intensive chemotherapy|
89405382|NCT04810780|Experimental|1st arm|Wearing the Duo infusion set for up to 1 month or up to 4 infusion set failures.
88881685|NCT01387048|Experimental|Skinoren|primary 12 weeks therapy with Skinoren gel®, followed by observation only for another 24 weeks,
88881686|NCT01387061|Experimental|hepatic resection|
88881687|NCT01387087|Experimental|Group A|Lowest dose, all males, fasting
88881688|NCT01387087|Experimental|Group B|Second lowest dose, all males, fasting
88881689|NCT01387087|Experimental|Group C|Third lowest dose, all males, fasting
88881690|NCT01387087|Experimental|Group D|Middle dose, all males, fasting
88881691|NCT01387087|Experimental|Group E|Third lowest dose, all females, fasting
88881692|NCT01387087|Experimental|Group F|Third highest dose, all males, fasting then fed
88881693|NCT01387087|Experimental|Group G|Second highest dose, all males, fasting
88881694|NCT01387087|Experimental|Group H|Highest dose, all males, fasting
89405383|NCT05203211||Men who have undergone icsi from ejaculated semen|
89405384|NCT05203211||Men who have undergone icsi from testicular sperm|
89405385|NCT05215249|No Intervention|Standard of Care|Patient will receive conventional tubeless anesthesia
89405386|NCT05215249|Experimental|High Flow Oxygen Delivery|Patient will receive Transnasal humidified high-flow oxygen delivery (Optiflow)
89405387|NCT00829868|Experimental|Zaleplon|Zaleplon 10 mg Capsule (test) dosed in first period followed by Sonata® 10 mg Capsule (reference) dosed in second period
89405388|NCT00829868|Active Comparator|Sonata®|Sonata® 10 mg Capsule (reference) dosed in first period followed by Zaleplon 10 mg Capsule (test) dosed in second period
89405389|NCT05215015|Experimental|Anti-CD33/CLL1 CAR-NK Cells|The administration of CAR-NK cells will be performed on day 1 and day 3 of each cycle (28 days). The first administration dose in the first cycle is 2.0×10^9 cells. If no adverse events were observed, the second administration dose in the first cycle would be 3.0×10^9 cells, and each administration dose in the second cycle and thereafter would be 3.0×10^9 cells.
89405390|NCT05110066|Active Comparator|BPA group|Balloon pulmonary angioplasty. Typically 4-8 sessions are needed to treat the patient. The specific pre-planning protocol, choice of wires and balloons, the number of vessels treated per session, and the decision that no further BPA sessions are needed is at the discretion of the treating physician.
88881695|NCT01387087|Experimental|Group I|Second highest dose, all females, fasting
88881696|NCT01387087|Placebo Comparator|Placebo Group A|all male, fasting
88881697|NCT01387087|Placebo Comparator|Placebo Group B|all male, fasting then fed
89405391|NCT05110066|Active Comparator|PEA group|Patients randomized to PEA will undergo surgery within 4 months after randomization and optional run-in phase. Distality of the dissection plane is at the discretion of the operating physicians.
88881698|NCT01387087|Placebo Comparator|Placebo Group C|all female, fasting
88881699|NCT01387100|Experimental|Physical Therapist/Occupational Therapist Intervention|This group will be assigned a physical therapist or occupational therapist to meet with followed by 2 phone consultations.
88881700|NCT01387100|No Intervention|Control|This is the control group. This group will not receive the vocational rehabilitation intervention from an occupational or physical therapist. They will receive written information regarding job accommodations and disability advocacy.
88881701|NCT01387126|Experimental|Novel fibre supplement|The full dose of the study intervention is 15 grams per day.
88881702|NCT01387126|No Intervention|Weight management program|
88881703|NCT01387152||Very low dose stress test protocol|Patients admitted to New York Presbyterian Hospital (NYPH)-Columbia University Medical Center with chest pain but normal or nondiagnostic electrocardiograms and at least 3 negative troponins taken 4 or more hours apart, and undergo exercise or pharmacologic stress testing using a very low dose (<6 mCi) of Tc99m tetrofosmin or sestamibi with imaging performed using acquisitions with an Alcyone camera.
88881704|NCT01387165||Patients|males and females between 18 and 75 years of age who been diagnosed with T2DM as defined by the American Diabetes Association
88881705|NCT01387191||Subjects prescribed epoprostenol|Subjects with pulmonary arterial hypertension prescribed epoprostenol injection during study period
88881706|NCT01387204|Experimental|Single-Dose, 2 mg [14C]GSK1120212|A single 2 mg (2 mg/10mL) oral dose of [14C]GSK1120212 containing approximately 79 μCi of radioactivity will be delivered as a solution.
88881707|NCT01387217|Experimental|Part A|Part A will be used to confirm the prediction of GSK2018682 PK, assess its effects on lymphocytes, and monitor its safety profile in a single cohort (Cohort 1). Cohort 1 will consist of 4 subjects and explore 4 doses of GSK2018682 in 4 study sessions. In each session, three subjects will receive GSK2018682 and one subject will receive placebo. Thus, when the cohort completes, each subject will receive placebo and 3 doses of GSK2018682.
88881708|NCT01387217|Experimental|Part B|Part B will explore doses to refine the dose-response curve of GSK2018682 on lymphocyte suppression, as allowed by stopping criteria, in 1 or 2 cohorts of up to 15 subjects (Cohort 2 and Cohort 3). In Part B, up to six single ascending doses of GSK2018682 and one dose of placebo will be investigated in up to 8 sessions.
89405392|NCT05214703|Experimental|cold therapy|Pain scores were measured with a visual analog scale (VAS) before the port catheter was removed from the patients in the experimental group. Before the port catheters were removed, cold application with an ice pack was applied to the patients whose first visual analog scale measurement was made by the researchers. The cold application was terminated an average of 15 minutes after the body temperature decreased by 1 °C.
89405393|NCT05214703|No Intervention|no intervention|The patients in the control group did not receive any intervention before and after port catheter removal.
88881709|NCT01387243||60 mg Orlistat|Purchased by consumer
89405394|NCT00721760|Experimental|Semuloparin|"Semuloparin sodium 20 mg (10 mg if Severe Renal Impairment [SRI]) once daily for 7-10 days with an initial dose given 8 hours after surgery~Placebo for Enoxaparin sodium prior to surgery according to local standard for Enoxaparin and 12 hours after surgery to maintain the blind"
89405395|NCT00721760|Active Comparator|Enoxaparin|"Enoxaparin sodium 40 mg (20 mg if Severe Renal Impairment [SRI]) once daily for 7-10 days with an initial dose given prior to or 12 hours after surgery according to local standard for Enoxaparin sodium~Placebo for Semuloparin sodium 8 hours after surgery to maintain the blind"
89405396|NCT05109832|Experimental|14C-IMP4297|In this study, one 100 mg dose of 14C IMP4297 Oral Suspension, 100 mg (100 μCi).
89405397|NCT04943068|Experimental|Bremelanotide|Bremelanotide (BMT) subcutaneously (SC) via auto-injector for 8-weeks double-Blind period
89405398|NCT04943068|Placebo Comparator|Placebo|Placebo subcutaneously (SC) via auto-injector for 4-weeks single-Blind period and for 8-weeks double-Blind period
89405399|NCT03628105|Experimental|CR Before Exposure|Participants in this arm will receive 15 minutes of CR (preparation) before engaging in exposure and will complete the 15-minute questionnaire filler task after exposure.
89405400|NCT03628105|Experimental|CR After Exposure|Participants in this arm will complete the 15-minute questionnaire filler task before exposure and receive 15 minutes of CR (consolidation) after engaging in exposure.
89405401|NCT04780282|Experimental|Scapular Stabilization Group|In the study, Adalar Water Sports Club (AWSK) takes places with its A team players; 15 players aged from 16-25 as the scapular stabilization group. The players in the scapular stabilization group will be applied scapular stabilization exercises for 8 weeks, 3 days a week in company with a physiotherapist. As stabilization exercises for the players; 1)Squatting while sliding a towel on the wall, 2)Wall push-ups with one leg extension, 3)Cross squat, 4)Pulling elastic band while squatting on one leg, 5)Double-leg squatting
89405402|NCT04780282|No Intervention|Control group|No Intevention
89405403|NCT03628027|Experimental|Treatment Algorithm|The treatment algorithm arm will be the experimental arm in which GPs use the computerised decision support tool to guide their prescribing of antidepressants.
89405404|NCT03628027|No Intervention|Treatment-as-usual|The treatment-as-usual arm will comprise GPs prescribing antidepressants and providing care as they typically would.
89405405|NCT00829790|Experimental|1|Doxycycline Monohydrate
89405406|NCT00829790|Active Comparator|2|Vibramycin Monohydrate®
89405407|NCT03207815|Experimental|Filgotinib|Participants will receive filgotinib 200 milligrams (mg) once daily for up to 52 weeks along with a standardized prednisone burst of 60 milligrams per day (mg/day) at Day 1/Baseline followed by a protocol-defined mandatory taper schedule up to Week 15.
88881710|NCT01387256|Other|mifepristone+misoprostol|200 mg mifepristone + 800 mcg buccal misoprostol
89190710|NCT03169010||Pulmonary Veno-Occlusive Disease (PVOD)|Investigators will conduct laboratory biomarker analysis and genetic analysis to identify pathogenesis or factors related to PVOD.
89190711|NCT03169010||Pulmonary Capillary Hemangiomatosis|Investigators will conduct laboratory biomarker analysis and genetic analysis to identify pathogenesis or factors related to pulmonary capillary hemangiomatosis associated PAH
89405408|NCT03207815|Placebo Comparator|Placebo|Participants will receive placebo to match filgotinib once daily for up to 52 weeks along with a standardized prednisone burst of 60 mg/day at Day 1/Baseline followed by a protocol-defined mandatory taper schedule up to Week 15.
89405409|NCT05110534|Experimental|Intervention group|Received two additional preventive oral hygiene appointments; one week before the general anaesthesia treatment and one week after the general anaesthesia.
89405410|NCT05110534|No Intervention|Control group|Received only standard prevention, without two additional preventive oral hygiene appointments before and after the general anaesthesia.
89405411|NCT02911935|Active Comparator|Oral azithromycin|Oral Azithromycin
89405412|NCT02911935|Placebo Comparator|Placebo|Oral Placebo
89405413|NCT05193487|Active Comparator|inferior alveolar nerve block|Conventional inferior alvoelar nerve block anaesthesia will be given using a traditional metal syringe
88881711|NCT01387256|Experimental|buccal misoprostol|2 doses of 800 mcg buccal misoprostol
88881712|NCT01387308|Experimental|A|Fostamatinib 50 mg tablet x 2 (Phase 3 batch)
88881713|NCT01387308|Sham Comparator|B|Fostamatinib 50 mg tablet x 3 (Phase 3 batch)
88881714|NCT01387308|Experimental|C|Fostamatinib 100 mg tablet (new formulation)
88881715|NCT01387308|Experimental|D|Fostamatinib 150 mg tablet (new formulation)
88881716|NCT01387308|Experimental|E|Fostamatinib 50 mg tablet x 2 (Phase 3 batch)
88881717|NCT01387321|Experimental|BYL719|
88881718|NCT01387334|Experimental|Resistance Exercise Training Program|
88881719|NCT01387360|Experimental|Supracor|Study arm will consist of patients who have undergone previous cataract surgery with implantation of a monofocal IOL. The Supracor procedure will be performed on the non-dominant pseudophakic eye of these patients.
88881720|NCT01387373|Experimental|chemotherapy|
88881721|NCT01387399|Experimental|Cisplatin as HIPEC|Phase I dose escalating study of cisplatin administered intraoperatively as hyperthermic intraperitoneal chemoperfusion
88881722|NCT01387412||Genital warts|Those with and without ano-genital warts
88881723|NCT01387425|Active Comparator|varenicline|varenicline 1 mg BID. The duration of active treatment will be 12 weeks.
89405414|NCT05193487|Experimental|intra-osseous mandibular anaesthesia|Computerized intraosseous anesthesia administration using the Quick Sleeper 5TM system (Dental Hi TecTM, Cholet, France)
89405415|NCT04294108||Patients underwent VATS lobectomy|All consecutive patients scheduled for video-assisted thoracoscopic surgery lobectomy.
89405416|NCT03479762||Liraglutide|Patients in the CPRD primary care database who have been prescribed liraglutide after the UK launch of Saxenda® (and have no liraglutide prescriptions in the previous 12 months)
89405417|NCT05100394|Experimental|Experimental Group|High Power laser therapy was provided.
89405418|NCT05100394|Active Comparator|Control Group|Conventional physiotherapy was applied including moist heat packs, US, and eccentric hamstring exercises.
89405419|NCT03391635|Experimental|Electroacupuncture|"The treatment consists of 3 times a week for 8 weeks.Huatuo Brand needles (0.30×50mm or 0.30×70mm) and the SDZ-V EA apparatus (Suzhou Medical Appliance) will be used for ST25, SP14 and ST37.After acupuncture，the needle handle will be connected with the electrode in the electroacupuncture instrument.~The parameters of the electric acupuncture apparatus：Dilatational wave，the frequency is 2/10Hz，the electric current intensity is 0.1mA-1.0mA."
89405420|NCT03391635|Active Comparator|TranscutaneousElectricNerveStimulation|"The treatment consists of 3 times a week for 8 weeks.Huatuo Brand electrode patch (50mm×50mm) and the SDZ-V EA apparatus (Suzhou Medical Appliance) will be used for ST25, SP14 and ST37.~The parameters of the electric acupuncture apparatus：Dilatational wave，the frequency is 2/10Hz，the electric current intensity is 2mA-5mA."
89405421|NCT00829712|Experimental|1|
89405422|NCT00829712|Active Comparator|2|Focalin®
88881724|NCT01387425|Placebo Comparator|control group|
88881725|NCT01387477|Experimental|Lactate|infusion of 66 mmol of lactate
88881726|NCT01387477|Active Comparator|glucose|infusion of 33 mmol of glucose
88881727|NCT01387490|Experimental|Individualized Scheduled Telephone Support (ISTS)|ISTS is a telephone intervention that provides injury-related education, training in problem solving, and focused behavioral strategies for problems (e.g., anxiety, depression) that commonly co-occur with Mild Traumatic Brain Injury (MTBI). ISTS also includes access to usual care and web-based and printed educational material. The 12 phone calls included in ISTS will be administered over a 6-month period.
88881728|NCT01387490|Other|Usual Care (UC)|UC is the usual care provided to service members attending the Traumatic Brain Injury (TBI) Clinics at Madigan Army Medical Center and Womack Army Medical Center, plus web-based education and 12 mailings of educational materials over a 6-month period.
88881729|NCT01387503|Experimental|Group 1 - Transplant strategy|Patients randomized to Group 1 will be enlisted for liver transplantation and will undergo liver transplantation within 8 months unless oncological (i.e. extrahepatic disease) or medical (i.e. cardiac insufficiency) will occur
89405423|NCT04306211|Active Comparator|Facial mask|facial mask for oxygen delivery
89405424|NCT04306211|Experimental|SuperNO2VA|SuperNO2VA is CPAP device to deliver oxygen with nasal mask rather than with facial mask
89405425|NCT05079802|Experimental|Group 1|study group
89405426|NCT05079802|Other|Group 2|control group
88881730|NCT01387503|No Intervention|Group 2 - Non-transplant strategy|Patients randomized to Group 2 will continue to receive treatments according to their stage of disease, or will undergo only strict follow-up should a complete response after downstaging treatments have been achieved
88881731|NCT01387555|Experimental|Arm A|Patients on Arm A will receive 1 e9 pfu (plaque forming units) total dose of JX-594 (Vaccinia GM-CSF / TK-deactivated Virus) on each of six (6) treatments over 18 weeks.
88881732|NCT01387555|Other|Arm B|Patients on the control arm (Arm B) will have best supportive care over 18 weeks.
88881733|NCT01387568|Active Comparator|group L|Lidocaine group
88881734|NCT01387568|Placebo Comparator|group P|Placebo group
88881735|NCT01387633|Experimental|Educational intervention through telephone contact|Educational intervention for family members/caregivers of people with diabetes mellitus through telephone contact
88881736|NCT01387633|Active Comparator|Educational intervention group|Educational intervention group for people with diabetes through Diabetes Conversation Maps.
89004417|NCT04537299|Placebo Comparator|Placebo Group|Subjects will receive placebo
89004418|NCT04530799||IAPA+|Influenza patients who develop IAPA during ICU admission
89405427|NCT05187091|No Intervention|Standard IMRT|Standard IMRT with radical CRT/RT
89405428|NCT05187091|Experimental|Swallowing Sparing IMRT|Standard IMRT with radical CRT/RT with additional sparing of dysphagia-aspiration related structures & submandibular gland sparing by SWOAR-IMRT
89405429|NCT04473248|Experimental|Method 1- Nasopharyngeal Swab in transfer liquid|A nasopharyngeal swab will inoculate a proprietary solution which will be transferred to the Spartan COVID-19 System for analysis
89405430|NCT04473248|Experimental|Method 2- Dipping of specialized swab in VTM|A nasopharyngeal swab will inoculate VTM solution. A modified traditional Spartan Swab will be dipped into the inoculated VTM solution and then transferred to the Spartan COVID-19 System for analysis.
89190712|NCT03169010||Cavernous Transformation of Portal Vein|Investigators will conduct laboratory biomarker analysis and genetic analysis to identify pathogenesis or factors related to cavernous transformation of portal vein associated PAH
89405431|NCT04473248|Experimental|Method 3: Direct input of VTM|Using the VTM from Method 2, pipette 10uL of VTM, inoculated with sample, into the Spartan COVID-19 System for analysis.
88881737|NCT01387646|Other|Control Group|Participants in the control arm will be interviewed at baseline, be given a targeted physical exam including a STI/HIV screen, pap smear and contraception counseling and will receive abuse and enhanced clinical counseling
88881738|NCT01387659|Experimental|Transplant recipients|All subjects receive identical drug treatment
88881739|NCT01387711|Experimental|ingenol mebutate|PEP gel 0.05% once daily exposure
88881740|NCT01387750|Placebo Comparator|Mentholated Cream|
88881741|NCT01387750|Active Comparator|Mentholated Cream with OGT|
88881742|NCT01387776||study group|patients coming to clinique OVO in the 1st trimester of pregnancy to undergo prenatal screening
88881743|NCT01387802||Non-Biologic arm|Patients that have not responded to the current treatment with an NSAID (Nonsteroidal Anti-Inflammatory Drug) and/or non - biologic DMARD (Disease-Modifying Anti Rheumatic Drug) for peripheral joint involvement and switch to or addition of another NSAID /DMARDS
88881744|NCT01387802||Biologic arm|Patients that have not responded to the current treatment with non biologic DMARDS (Disease-Modifying Anti Rheumatic Drug) /NSAID (Nonsteroidal Anti-Inflammatory Drug) and switch to or addition of adalimumab
88881745|NCT01387828|Active Comparator|Laparoscopy|Includes all patient underwent intervention with a laparoscopic approach, even if converted to open surgery during intervention
88881746|NCT01387828|Active Comparator|Open surgery|Includes all the patients underwent intervention with a laparotomic approach; it does not include patient underwent laparoscopic approach and then converted in laparotomy.
88881747|NCT01387841|Experimental|Yoga group|Yoga intervention with standard antiemetic care
88881748|NCT01387841|Active Comparator|PMRT/Jacobsons Relaxation training|25 minutes of progressive muscle relaxation training will be given to this group with standard antiemetic care
88881749|NCT01387841|No Intervention|Standard antiemetic care|Standard antiemetic care only
88881750|NCT01387867|Experimental|Strength training|Strength training three times weekly, i.e.supervised strength training twice weekly and un-supervised strength training once weekly for 4 months.
89190713|NCT03169010||CTEPH|Investigators will conduct laboratory biomarker analysis and genetic analysis to identify pathogenesis or factors related to chronic thromboembolism pulmonary hypertension (CTEPH).
89190714|NCT03169010||Pulmonary Takaysu Arteritis|Investigators will conduct laboratory biomarker analysis and genetic analysis to identify pathogenesis or factors related to Pulmonary Takaysu Arteritis.
89190715|NCT03165136|Experimental|Hydroxychloroquine|The treatment will be orally administrated, at a daily dose of 400 mg of hydroxychloroquine . The treatment will be started before conception and will be stopped at the end of the tenth week of gestation or before in case of pregnancy loss.
88881751|NCT01387867|Experimental|Nordic Walking|Nordic walking three times weekly, i.e.Nordic walking twice weekly and un-supervised Nordic walking once weekly for 4 months.
88881752|NCT01387867|Active Comparator|Unsupervised home based exercise|The home based unsupervised exercise comprised exercises recommended by the Danish Arthritis Association.
88881753|NCT01387880|Experimental|Cetuximab, everolimus, irinotecan|
88881754|NCT01387880|Active Comparator|Cetuximab, everolimus and Irinotecan.|"Patients with metastatic colorectal cancer with KRAS mutant tumours are treated with cetuximab, everolimus and irinotecan.~Patients with KRAS wildtype colorectal cancer that have progressed on therapy with cetuximab and irinotecan are treated with cetuximab, irinotecan and everolimus."
88881755|NCT01387893|Experimental|Immediate & Delayed Instruction|Male patients with mild to moderate lower urinary tract symptoms will alternately be assigned to either immediate intervention or delayed intervention groups. Statistical assessments will be performed to establish comparability of baseline characteristics in the two groups.
88881756|NCT01387906|Experimental|Topical bimatoprost for eyebrows|Topical bimatoprost will be applied to areas of the eyebrow that have diminished eyebrows (hypotrichosis).
88881757|NCT01387919|Experimental|1|healthy young and lean men
88881758|NCT01387945|No Intervention|HBPM only|
89405432|NCT04473248|Experimental|Method 4: Collection of nasal sample.|Using a modified tip of the Spartan swab, a nasal sample will be taken from the patient and directly placed into the Spartan COVID-19 System for analysis.
88881759|NCT01387945|Experimental|HBPM+website+patient navigator|
88881760|NCT01387958|Experimental|LCQ908|
88881761|NCT01387958|Placebo Comparator|Placebo|
88881762|NCT01387971||ocular surface disorders|various ocular surface disorders
88881763|NCT01387984||Type 2 diabetes mellitus|
88881764|NCT01387997|Experimental|1|
88881765|NCT01388010|Experimental|1 = Test product|Arm 1 - Intervention 1 (probiotics)
88881766|NCT01388010|Other|2 = Control product|Arm 2 - Intervention 2 (control)
89405433|NCT05203055|Experimental|monotherapy group|Peginterferon alpha-2b injection is given subcutaneously at a dosage of 180μg/w for 48 consecutive weeks. Patients will stop the treatment whenever HBsAg is eliminated, and those without HBsAg elimination after 48 dosages will enter the group of best treatment. The patients will be followed up for another 24 weeks after treatment.
89405434|NCT05203055|Experimental|continuous combination therapy group|Peginterferon alpha-2b injection is given subcutaneously at a dosage of 180μg/w for 48 consecutive weeks, plus continuous oral NA. Patients will stop the treatment whenever HBsAg is eliminated, and those without HBsAg elimination after 48 dosages will enter the group of best treatment. The patients will be followed up for another 24 weeks after treatment.
89405435|NCT05203055|Experimental|pulse combination therapy group|Peginterferon alpha-2b injection is given subcutaneously at a dosage of 180μg/w for 8 consecutive weeks and cessation for 4 weeks,plus continuous oral NA. Patients will discontinue the treatment at any time if they are recovery, and those without HBsAg elimination after 48 dosages will enter the group of best treatment.The patients will be followed up for another 24 weeks after treatment.
89405436|NCT05108662|Active Comparator|HOLEP|Patients with a prostate volume greater than 80 g
89405437|NCT05108662|Active Comparator|TURP|Patients with a prostate volume less than 80 g
88881767|NCT01388023|Active Comparator|smellx|test group- SmellX palatal patch with the herbal formula
89405438|NCT05186155||premature baby without ROP (Group 0)|ROP: retinopathy of prematurity
89405439|NCT05186155||ROP without treatment (Group 1)|ROP: retinopathy of prematurity
88881768|NCT01388023|Placebo Comparator|smellx palatal patch|negative control group- SmellX palatal patch with out the herbal formula
88881769|NCT01388023|Active Comparator|chlorhexidine|poositive control group-mouth wash with chlorhexidine 0.125%
88881770|NCT01388023|Active Comparator|listerine|listerine mouth wash
88881771|NCT01388036|Experimental|esmolol infusion|infusion of esmolol during rest and exercise
88881772|NCT01388049|Experimental|virus detection|
88881773|NCT01388062|Experimental|virus detection|
88881774|NCT01388075|Experimental|Rifampicin|Consecutive treatments with rifampicin and placebo
88881775|NCT01388088|Active Comparator|Spironolactone|Increases the level of potassium
88881776|NCT01388088|Active Comparator|Amiloride|Increases the level of potassium
88881777|NCT01388088|Placebo Comparator|Placebo|
88881778|NCT01388101|Experimental|LECT2 detection|single-arm study: Electrosensing antibody probing system(e-AB sensor)
88881779|NCT01388114|Experimental|Electrosensing antibody probing system (e- Ab sensing)|
88881780|NCT01388140||psychiatric inpatients, regardless of clinical diagnoses|
89004419|NCT04530799||IAPA-|Influenza patients admitted to the ICU not developing IAPA
89405440|NCT05186155||ROP with laser photocoagulation treatment (Group 2)|ROP: retinopathy of prematurity
89405441|NCT05186155||ROP with anti-VEGF treatment (Group 3)|ROP: retinopathy of prematurity anti-VEGF: anti-Vascular Endothelial Growth Factor
88881781|NCT01388153|Experimental|Arm 1|
88881782|NCT01388153|Experimental|Arm 2|
88881783|NCT01388153|Active Comparator|Arm 3|
88881784|NCT01388179|Active Comparator|Real rTMS treatment|low-frequency rTMS to the left DLPFC (Dorsa-Lateral Pre-Frontal Cortex) prior to high-frequency deep rTMS to the FFA (Fusi-Form Area) through the STS(Superior Temporal Sulcus).
88881785|NCT01388179|Sham Comparator|Sham rTMS treatment|Sham coil which simulate the real coil action
88881786|NCT01388192||Receiving pancreaticoduodenectomy|
88881787|NCT01388205|Experimental|Family-based Intervention Arm|
88881788|NCT01388205|No Intervention|Control|
88881789|NCT01388218||Arm 1 - Daily+Clinical|Order of assessment: Daily PRO + Clinical visit PRO
88881790|NCT01388218||Arm 2 - Clinical+Daily|Order of assessment: Clinical visit PRO + Daily PRO
88881791|NCT01388231|Active Comparator|Manualized CBT Group|The present group is comprised of clinical practitioners performing cognitive-behavioral therapy (CBT) on social phobic patients after receiving structured clinical training on the treatment of social phobia based on the Clark and Wells (1995) model.
88881792|NCT01388231|Active Comparator|CBT Group -Treatment as Usual|The present group is comprised of clinical practitioners performing cognitive-behavioral therapy (CBT) on social phobic patients, while receiving no structured training in the treatment of social phobia.
88881793|NCT01388257|Experimental|Surgery|Seton drain removal is associated with proctological surgery.
88881794|NCT01388257|Other|Simple seton drain removal|
88881795|NCT01388270|Active Comparator|Evodial|a pre-heparin-coated hemodialysis filter
88881796|NCT01388270|No Intervention|170 H|Conventional filter
88881797|NCT01388296||Morbidly obese patients|BMI 40-50 k/m2
88881798|NCT01388296||Morbidly obese|BMI 50-60 k/m2
88881799|NCT01388296||Morbidly obeses|BMI 60-70 k/m2
88881800|NCT01388309||Cohort|
88881801|NCT01388322|Experimental|Enoxaparin|Subcutaneous administration of one dose daily of enoxaparin
88881802|NCT01388322|No Intervention|expectant management|Usual management
88881803|NCT01388348|Experimental|"Dynamic Urine Vibration Holter"|"each subject will undergo intervention for the diagnosis of bladder outlet obstruction first using the Dynamic Urine Vibration Holter and then urodynamically by pressure flow study"
88881804|NCT01388374|No Intervention|General Practitioners Care|Usual medical care provided by a general practitioner at the Primary Out of Hours Emergency Service.
89405442|NCT05186155||ROP with laser photocoagulation + anti-VEGF treatment (Group 4)|ROP: retinopathy of prematurity anti-VEGF: anti-Vascular Endothelial Growth Factor
89405443|NCT05186155||Fullterm baby (Group 5)|Fullterm baby
89405444|NCT03899636|Experimental|IRE|
89405445|NCT03899636|Active Comparator|Control|
89405446|NCT05184751||50 years and over|patients who underwent colonoscopic examination aged 50 years and over
89190716|NCT03165136|Placebo Comparator|Placebo|A similar placebo will be orally administrated every day.
89405447|NCT05184751||under 50 years|patients who underwent colonoscopic examination aged under 50 years
88881805|NCT01388374|Experimental|Nurse Practitioners Care|Medical care provided by the Nurse Practitioner at the Primary Out of Hours Emergency Service.
89405448|NCT03773380|Experimental|Feasibility|50 patients will be recruited to take part in this feasibility study. They will all undergo this Breathe Anew Program post-surgery. Breathe Anew consists of radiological surveillance, physical rehabilitation using a Fitbit, mindfulness therapy, and referral for symptom management specialists when needed.
89405449|NCT03457766|Experimental|Patients with skin lesions|Using HIFU in identification of safety margins of lesions clinically apparent locally malignant, or malignant
89405450|NCT05168371|Experimental|CBT-O|Women randomized to this arm will receive access to the eight modules of Cognitive-Behavioural Therapy-Online (CBT-O). Participants will meet weekly via Zoom with treatment navigators during the 8-12 weeks that it takes to complete the program.
89405451|NCT05168371|Experimental|MBT-O|Women randomized to this arm will receive access to the eight modules of Mindfulness-Based Therapy-Online (MBT-O). Participants will meet weekly via Zoom with treatment navigators during the 8-12 weeks that it takes to complete the program.
89405452|NCT05168371|No Intervention|Wait-List Control|Participants who are randomized to the wait-list group will complete two baseline online questionnaire/assessment batteries before being randomized to one of the active treatment groups. Participants will be randomized into one of the active treatment groups after a 10 week waiting period.
89405453|NCT04237181|Other|Acute diarrhoea or colitis presumed to be of infectious origin|
88881806|NCT01388400|Experimental|Conventional intervention for upper limb reaching|Reaching or holding cones, cups, etc. in all planes with and without gravity or loading
88881807|NCT01388400|Experimental|VR treatment|The Virtual Reality (VR) therapy group received the treatment in the GestureTek VR environment which focused on reaching movements of the affected upper limb using virtual games and a virtual supermarket.
88881808|NCT01388413|Experimental|Weekly Oral Cyclic Antibiotic programme|
88881809|NCT01388413|No Intervention|Classic care|
88881810|NCT01388426|Experimental|7eye( Panoptx)™ Moisture chamber glasses|7eye( Panoptx)™
88881811|NCT01388439||Oseltamivir exposure|One infant in the Neonatal Intensive Care Unit (NICU) at St. Louis Children's Hospital experienced respiratory decompensation and tested positive for influenza virus type A by fluorescent antibody stain performed on a nasopharyngeal swab. This infant received treatment doses of oseltamivir. Subsequently, 27 other infants received oseltamivir prophylaxis for exposure to influenza virus type A. Exposed infants were those who shared a primary medical team, nursing care, respiratory therapist, physical therapist, or occupational therapist with the influenza A positive infant. Prophylaxis was deemed necessary by the attending neonatologist after consultation with the Infectious Diseases Division of the Department of Pediatrics at the Washington University School of Medicine.
88881812|NCT01388452|Experimental|Point of Care HIV RNA PCR|Patients randomized to this arm will be followed prospectively from the time of clinical evaluation in the hospital until 12 months after returning for outpatient care at the KCH HIV clinic. The counselor will collect infant blood for point of care RNA PCR testing, number the sample, and transport it to the central laboratory for processing. Patients determined to be HIV-uninfected or HIV-exposed uninfected will not continue in the study beyond virologic test result disclosure, which will occur as an inpatient at KCH for this arm. If the patient does not return for outpatient care for three months after hospitalization then the patient's participation in the study will end.
89405454|NCT05157139|No Intervention|Control|Patients receiving only standard care
89405455|NCT05157139|Active Comparator|Intervention (low dose)|Two capsules twice daily for 3 days then one capsule twice daily for 2 days
89405456|NCT05157139|Active Comparator|Intervention (high dose)|two capsules three times daily for 3 days, followed by one capsule three times daily for 4 days
89405457|NCT03687346||High Risk Group|Parental history of eating pathology
89405458|NCT03687346||Low Risk Group|No parental history of eating pathology
89405459|NCT03386942|Experimental|Farletuzumab Ecteribulin|"Part 1 (Dose-escalation): The initial dose level of farletuzumab ecteribulin will be 0.3 milligrams per kilogram (mg/kg) every 3 weeks in the first cohort with 1 participant for dose-limiting toxicity (DLT) evaluation. DLTs will be evaluated in successive dose level cohorts with a single participant until a drug-related Grade 2 or higher toxicity is observed. If such a toxicity is observed, the cohort will be expanded to enroll a total of 3 participants.~Part 2 (Treatment Phase): farletuzumab ecteribulin will be administered every 3 weeks during the treatment phase at the dose determined in Part 1 until participants meet any of the criteria for discontinuation. Criteria for discontinuation include: withdrawal of consent, major protocol violations, unable to continue due to adverse events, pregnancy, progressive disease, Investigator decision, or infusion reactions."
89405460|NCT04527094||AI_PRF|Adults patients undergoing general anesthesia
89405461|NCT05136937|Experimental|Oncolytic virus injection(RT-01) for patients with advanced solid tumors|"Intratumoral administration of RT-01 as single agent for patients with advanced solid tumors.The injection dose of RT-01 was determined by the lesion size:~mL for lesion length <1.5 cm;~mL for lesion length between 1.5 cm and 2.5 cm;~mL for lesion length between 2.5 cm and 5.0 cm;~mL for lesion length between >5 cm"
89405462|NCT05015569|Active Comparator|Patient Gown + COVR garment|Patients will receive the standard of care patient gown and a COVR garment. Patients undergoing unilateral lower extremity surgery will receive a half short. Patients undergoing upper extremity or spine surgery will receive the brief (bilateral) style COVR garment.
89405463|NCT05015569|Active Comparator|Patient Gown|Patient will receive the standard of care patient gown only without undergarments.
89405464|NCT04910230|Experimental|nicotinamide plus usual care|
89405465|NCT04910230|No Intervention|usual care|
89405466|NCT03069989|Experimental|Cohort 1 GSK3008348|Participants will receive a single nebulized dose of GSK3008348 during each of 2 planned dosing periods and up to 3 microdose administrations of [18F]-FBA-A20FMDV2 for the PET scanning in period 2.
88881813|NCT01388452|No Intervention|Standard of Care|"Patients randomized to this arm will be followed prospectively from the time of clinical evaluation in the hospital until 12 months after returning for outpatient care at the KCH HIV clinic. The counselor will collect infant blood for dried blood spot DNA PCR testing, number the sample, and transport it to the central laboratory for processing. If the patient is PD positive then the patient will be offered ART initiation prior to hospital discharge.~Patients determined to be HIV-uninfected or HIV-exposed uninfected will not continue in the study beyond virologic test result disclosure, which will occur as an outpatient at KCH for this arm. If the patient does not return for outpatient care for three months after hospitalization then the patient's participation in the study will end."
89405467|NCT03069989|Placebo Comparator|Cohort 1 Placebo|Participants will receive a single nebulized dose of placebo during each of 2 planned dosing periods and up to 3 microdose of [18F]-FBA-A20FMDV2 for the PET scanning in period 2.
89405468|NCT03069989|Experimental|Cohort 2 GSK3008348|Participants will receive a single nebulized dose of GSK3008348 during each of 2 planned dosing periods and up to 3 microdose administrations of [18F]-FBA-A20FMDV2 for the PET scanning in period 2.
89405469|NCT03069989|Placebo Comparator|Cohort 2 Placebo|Participants will receive a single nebulized dose of placebo during each of 2 planned dosing periods and up to 3 microdose of [18F]-FBA-A20FMDV2 for the PET scanning in period 2.
89405470|NCT04894474|Experimental|BI 767551 inhalation and placebo intravenous infusion|
89405471|NCT04894474|Experimental|BI 767551 intravenous infusion and placebo inhalation|
89405472|NCT04894474|Placebo Comparator|Placebo inhalation and placebo intravenous infusion|
88881814|NCT01388465|Experimental|Mobile phone text message Intervention|Daily assessments with feedback about (1) filling prescription and (2) number of doses taken
89405473|NCT03438682||Essure Hysteroscopic Sterilization|Women who have undergone Essure hysteroscopic sterilization
89405474|NCT03438682||Laparoscopic Sterilization|Women who have undergone laparoscopic sterilization
89405475|NCT03438682||Intrauterine device (IUD) placement|Women who have undergone IUD placement
89405476|NCT03619915||Greater dependence|
89405477|NCT03619915||Less dependence|
89405478|NCT03619915||Independent|
89405479|NCT05202977|Experimental|SinocrownTM Transcatheter Aortic Valve Replacement System|The experimental apparatus consisted of artificial aortic valve, transporter and grip-loading system.
89405480|NCT04995094|Experimental|Imprime PGG + Pembrolizumab (Investigational ARM)|Imprime PGG + Pembrolizumab (Investigational ARM)
89405481|NCT04995094|Active Comparator|Pembrolizumab (Control ARM)|Pembrolizumab (Control ARM)
89405482|NCT04924387|Experimental|Experimental Group (EXP group)|The experimental group (EXP Group) is going to follow a programme of stabilisation through specific therapeutic exercises of the lumbopelvic centre. Two weekly sessions will be programmed for 12 weeks, making a total of 24 sessions. Each sesión will have a duration of 60 minutes, the first 5 minutes for a warm-up and the last 10 for a cool-down phase of active stretching. All patients will start learning how to activate the abdominal muscles in the first training session. The exercise progression will be adapted according to the capacity of each patient, considering their pain levels. The exercices will be made in 1 to 3 series of among 8 and 15 repetitions and the isometric contractions for 5 to 10 seconds. The rests between series will be of 30 seconds, and between exercies of 2-3 minutes.
89405483|NCT04924387|Active Comparator|Experimental Group and Manual Therapy (MT Group)|Additionally to the core exercises previously exposed in Group EXP, Group MT will lay on the stretcher first, where the physiotherapist will work on a manual therapy thrust. The patient will receive an impulse technique in lateral decubitus position, with high velocity and low range on both sides.
89405484|NCT04924387|Active Comparator|Experimental Group and Kinesio Tape (KT Group)|"The experimental group plus kinesio tape (KT Group) will go previously through physiotherapy, where a kinesio tape band will be applied (kinesio tape Nondolens 5cm x 5cm black color), in Y technique, by applying the KT base in neutral position of the lumbar spine without any tension on the tape."
89405485|NCT05202821|Active Comparator|group of 20 participants receiving fluoride varnish|*Group (I): patients will receive Fluoride varnish ttt.
89405486|NCT05202821|Experimental|group of 20 participants receiving PR-G Barrier coat|*Group (II): patients will receive PR-G Barrier coat
89405487|NCT05202821|Active Comparator|group of 20 participants receiving MI Paste (CPP-ACP)|*Group (III): Patients will receive MI Paste (CPP-ACP)
89405488|NCT04958902|Experimental|RESTORE intervention|Participants who screen eligible and consent will receive RESTORE with guidance.
89405489|NCT02951416||Idiopathic Pulmonary Fibrosis (IPF)|"IPF diagnosis according to the guidelines of 2011 (AJRCCM 2011; 183:788). For patients diagnosed prior to 2011, the criteria of the consensus statement 2000 apply (AJRCCM 2000;161:646).~Patient registry (observation and biomaterial sampling)."
89405490|NCT02951416||Non-specific interstitial pneumonia|"Non-specific interstitial pneumonia (NSIP) based on the histopathological demonstration of an NSIP pattern.~Patient registry (observation and biomaterial sampling)."
88881815|NCT01388465|No Intervention|Control|No TM queries or feedback
88881816|NCT01388504|Experimental|sodium nitrite|
88881817|NCT01388504|Placebo Comparator|placebo|sterile solution containing 0.9%w/v sodium chloride in 5ml water injected intravenously over a period of 2½ - 5 minutes
89405491|NCT02951416||Cryptogenic organising pneumonia (COP)|"COP characterised histologically by an organising pneumonia with intraluminal organising fibrosis in the alveolar ducts and alveolar spaces.~Patient registry (observation and biomaterial sampling)."
89405492|NCT02951416||Acute interstitial pneumonia (AIP)|"Histological pattern of diffuse alveolar damage (DAD), characterised by hyaline membranes, alveolar oedema and a marked interstitial and alveolar inflammatory reaction.~Patient registry (observation and biomaterial sampling)."
89405493|NCT02951416||Lymphoid interstitial pneumonia (LIP)|"Histological pattern of LIP primary or secondary (e.g. rheumatoid arthritis, Sjögren's syndrome, pernicious anaemia, chronic active hepatitis, systemic lupus erythematosus (SLE), primary biliary cirrhosis, myasthenia gravis, severe immune deficiency syndromes (AIDS)).~Patient registry (observation and biomaterial sampling)."
88881818|NCT01388517|Active Comparator|Calcitriol|Repigmentation treatment for the relief of hypopigmented pityriasis alba lesions
89405494|NCT02951416||respiratory bronchiolitis-ILD (RB-ILD)|Histological pattern of RB-ILD or typical clinical and radiological findings. Patient registry (observation and biomaterial sampling).
89405495|NCT02951416||Desquamative Interstitial Pneumonia|"Histological pattern of Desquamative Interstitial Pneumonia (DIP). The picture is similar to RB-ILD, but the distribution pattern is much more homogeneous and does not even have the bronchiolocentric distribution.~Patient registry (observation and biomaterial sampling)."
89405496|NCT02951416||Hypersensitivity Pneumonitis|"Hypersensitivity Pneumonitis (HP) characterized by exposure to inhaled organic antigens and development of antibodies. Typical clinical and radiological findings, lymphocytosis in bronchoalveolar lavage (BAL) or histology showing HP granulomas.~Patient registry (observation and biomaterial sampling)."
89405497|NCT02951416||Sarcoidosis|"Histological pattern with sarcoid granulomas or typical clinical and radiological findings with a lymphocytosis in BAL.~Patient registry (observation and biomaterial sampling)."
89405498|NCT02951416||Lung Cancer|"Histological confirmation of Lung Cancer. Patients will be included as control group.~Patient registry (observation and biomaterial sampling)."
89405499|NCT02951416||Chronic Obstructive Pulmonary Disease|"Obstructive spirometry and physical history suggesting Chronic Obstructive Pulmonary Disease (COPD). Patients will be included as control group.~Patient registry (observation and biomaterial sampling)."
89405500|NCT02951416||Pulmonary Hypertension|"Pulmonary Hypertension (PH) diagnosed through right heart catheterisation. Patients will be included as control group.~Patient registry (observation and biomaterial sampling)."
88881819|NCT01388517|Active Comparator|Tacrolimus|Treatment for the relief of hypopigmented pityriasis alba lesions
88881820|NCT01388517|Placebo Comparator|Petrolatum|Petrolatum treatment for the relief of hypopigmented pityriasis alba lesions
88881821|NCT01388556|Experimental|Tango|Twice weekly tango dance classes for 12 months.
88881822|NCT01388556|No Intervention|Control Group|
88881823|NCT01388582|Active Comparator|Combined oral contraceptive|10 women will receive COC during breastfeeding
88881824|NCT01388582|Active Comparator|Levonorgestrel intrauterine system|10 women will receive a LNG-IUS during breastfeeding
88881825|NCT01388582|Active Comparator|Implanon|10 women will receive Implanon during breastfeeding
88881826|NCT01388582|Active Comparator|TCu380A intrauterine device|10 women will receive a TCu380A intrauterine device as non hormonal contraceptive during breastfeeding
88881827|NCT01388595|Active Comparator|Fluticasone Proprionate|The participants will be randomised and at each study visit, will receive a single inhaler which can either be active or placebo.
88881828|NCT01388595|Active Comparator|Salmeterol|The participants will be randomised and at each study visit, will receive a single inhaler which can either be active or placebo.
89190717|NCT03141437|Active Comparator|Arm I (standard of care)|Participants receive standard of care including education materials about fertility preservation from the Livestrong organization and a referral for fertility preservation, if requested.
89405501|NCT02951416||Sleep Apnea|"Sleep Apnea diagnosed by polysomnography. Patients will be included as control group.~Patient registry (observation and biomaterial sampling)."
89405502|NCT02951416||Asthma|"Asthma diagnosed by positive bronchoprovocation test and typical history or bronchoreversibility in the lung function measurement or through peak flow measurement. Patients will be included as control group.~Patient registry (observation and biomaterial sampling)."
89405503|NCT02951416||Control/Health Individuals|Healthy volunteers not suffering from any lung disease as control group. Patient registry (observation and biomaterial sampling).
88881829|NCT01388595|Placebo Comparator|placebo|The participants will be randomised and at each study visit, will receive a single inhaler which can either be active or placebo.
88881830|NCT01388608||RA patients receiving etanercept|Patients with active rheumatoid arthritis (RA) who are eligible to a treatment with etanercept.
88881831|NCT01388621|Experimental|Experimental arm (A):|"Caelyx 30 mg/m² d1 Carboplatin AUC 5 d1 Panitumumab 6 mg/kg/KG d1 + 15 q4w until progressive disease or for a max. of 6 cycles~OR~Gemcitabine 1000 mg/m² d1 + 8 Carboplatin AUC 4 d1 Panitumumab 9 mg/kg/KG d1 q3w until progressive disease or for a max. of 6 cycles~The backbone chemotherapy (Caelyx or Gemcitabine-based) is specified by the investigator before randomization of a patient."
88881832|NCT01388621|Active Comparator|Standard arm (B):|"Caelyx 30 mg/m² d1 Carboplatin AUC 5 d1 q4w until progressive disease or for a max. of 6 cycles~OR~Gemcitabine 1000 mg/m² d1 + 8 Carboplatin AUC 4 d1 q3w until progressive disease or for a max. of 6 cycles~The backbone chemotherapy (Caelyx or Gemcitabine-based) is specified by the investigator before randomization of a patient."
88881833|NCT01388634||Study cohort|Patients with prolonged length of hospital stay (>5 days) or readmission after ventral hernia repair
88881834|NCT01388634||control group|Patients without prolonged length of hospital stay (>5 days) or readmission after ventral hernia repair
88881835|NCT01388660|Experimental|Cloas|A tablet containing 75 mg of Clopidogrel and 100 mg of Aspirin
88881836|NCT01388660|Active Comparator|Plavix/Astrix|Simultaneous Administration of Plavix (75 mg of Clopidogrel) and Astrix (100 mg of Aspirin)
89405504|NCT05201651|Experimental|Creatine|Participants will orally consume creatine (20 grams in 4×5-gram servings for seven days), followed by 3-g/day during training days.
89405505|NCT05201651|Placebo Comparator|Placebo|Participants will orally consume maltodextrin placebo (20 grams in 4×5-gram servings for seven days), followed by 3-g/day during training days.
89405506|NCT04826731||Incentive Spirometer Group|"Patients who would use an incentive spirometer, in addition to standard care provided to COVID-19 patients, will be categorized under Incentive Spirometer Group."
89405507|NCT04826731||Standard Care Group|"Patients who did not use an incentive spirometer despite being suggested to do so will be categorized under Standard Care Group."
89405508|NCT04853914|Experimental|HIFU intervention|Patients will benefit of an HIFU treatment of their Benign Prostatic Hyperplasia.
89405509|NCT04231409|Active Comparator|WaveWriter Settings|WaveWriter Programming
89405510|NCT04231409|Active Comparator|Conventional Settings|Conventional Programming
89405511|NCT04684810||Treatment Group|Participants seeking treatment completed longitudinal data
89405512|NCT02698163|Active Comparator|Gutta Percha|For all the patients in the control arm of the study, standard treatment of care procedures will be given. Root canal therapy will be given according to the vertical obturation technique. The root canals will be filled with standard root canal filler material: gutta percha at the apical third up to and including the coronal third. The tooth will be restored with a crown for posterior teeth, or a composite filling for anterior teeth.
89405513|NCT02698163|Experimental|Nanodiamond reinforced Gutta Percha|For all the patients in the treatment arm of the study, standard treatment of care procedures will be given. Root canal therapy will be given according to the vertical obturation technique. The difference between the two arms will be the root canal filler material used. The root canals for the treatment arm of the study will be filled with gutta percha at the apical third, Nanodiamond gutta percha (NDGP) in the middle third, and again with gutta percha at the coronal third. The tooth will be restored with a crown for posterior teeth, or a composite filling for anterior teeth.
89405514|NCT04680676|Experimental|BI 730357 - low dose|
89405515|NCT04680676|Experimental|BI 730357 - medium dose|
89405516|NCT04680676|Experimental|BI 730357 - high dose|
89405517|NCT04680676|Placebo Comparator|Placebo|
89004420|NCT04503499|Experimental|Study Group|The group to which the manuel therapy will be applied.
89190718|NCT03141437|Experimental|Arm II (standard of care, decision-making website)|Participants receive standard of care as in Arm I. Participants also use the decision-making the website.
89190719|NCT03115086||Existing User|Patients who have been using Cholbam for at least 30 days
89190720|NCT03115086||New User|First-time initiators of Cholbam
89190721|NCT03106701|Experimental|Ablation|Radiofrequency epicardial ablation
89190722|NCT03089268||Group 1|"Individuals scheduled for colonoscopy at Hospital Universitari i Politècnic La Fe, participating in the Valencian CRC screening program, will be recruited.~Polypectomy or biopsy will be performed if necessary (following current guidelines).~Specific molecular analysis of serrated lesions and CRC will be carried out."
89190723|NCT03073785|Active Comparator|Arm A (chemotherapy, radiation therapy)|Patients undergo hypofractionated stereotactic body radiation therapy in 5 fractions on days 1-5. Patients receive fluorouracil IV over 24 hours on day 1 weekly for 4 weeks or capecitabine PO every 12 hours starting the evening before day 1 of radiation therapy for 4 weeks as per standard of care. Patients then undergo surgery 6-8 weeks after completion of radiation therapy.
89190724|NCT03073785|Experimental|Arm B (zoledronic acid, chemotherapy, radiation therapy)|Patients receive zoledronic acid IV over no less than 15 minutes 1 week prior to radiation therapy. Patients undergo hypofractionated stereotactic body radiation therapy and receive treatment with fluorouracil IV or capecitabine PO as in Arm A. Patients then undergo surgery 6-8 weeks after completion of radiation therapy.
89190725|NCT03066648|Experimental|Decitabine and PDR001|Decitabine in combination with PDR001
89190726|NCT03066648|Experimental|Decitabine and MBG453|Decitabine in combination with MBG453
89190727|NCT03066648|Experimental|Decitabine, PDR001 and MBG453|Decitabine in combination with PDR001 and MBG453
89190728|NCT03066648|Experimental|MBG453|MBG453 alone
89190729|NCT03066648|Experimental|MBG453 and PDR001|MBG453 in combination with PDR001
89405518|NCT04631731|Experimental|Single agent PD-1/L1 inhibitor|
89405519|NCT04631731|Experimental|PD-1/L1 inhibitor + CTLA-4 inhibitor|
89405520|NCT04631731|Experimental|Platinum-based chemotherapy + PD-1/L1 inhibitor|
89405521|NCT04631731|Experimental|PD-1/L1 inhibitor + tyrosine kinase inhibitor|
89405522|NCT04631731|Experimental|PD-1/L1 inhibitor + VEGF inhibitor|
89405523|NCT02941276|Experimental|Group A|Active electrostimulator device (intra-oral active second generation Saliwell GenNarino) (Saliwell Ltd., Harutzim, Israel)
89405524|NCT02941276|Sham Comparator|Group B|Sham electrostimulator device (intra-oral sham second generation Saliwell GenNarino) (Saliwell Ltd., Harutzim, Israel)
89004421|NCT04503499|No Intervention|Control Group|The control group where only the evaluations will be made.
89004422|NCT04494542|Experimental|Sustained Low Efficiency Dialysis|Sustained Low Efficiency Dialysis
89004423|NCT04494542|Active Comparator|Continuous Renal Replacement Therapy|continuous renal replacement therapy
89405525|NCT03817190|Experimental|2g Oral DS107|2g DS107 (4 DS107 capsules) administered once-daily for 16 weeks
89405526|NCT03817190|Placebo Comparator|Placebo|Placebo (4 placebo capsules) orally administered once-daily for 16 weeks
89405527|NCT04771624||Patients|Subjects who have been Covid positive by RT-PCR at least 60 days ago and not having any symptoms of Covid-19 at the moment
89405528|NCT04771624||Healthy|Subjects who do not have any general medical, neurological or psychiatric disorder
89405529|NCT04615936|Experimental|Methylene Blue-Photodisinfection|The Health-Canada approved Steriwave system (Ondine Biomedical, BC) will be used to deliver the Methylene Blue-Photodisinfection (MB-PDF) to the anterior nares.
89405530|NCT04887415|Experimental|Respiratory strength training|Enrolled cardiac surgical patients will undergo 4 weeks of preoperative respiratory strength training using two respiratory strength training devices.
89405531|NCT04544254|Active Comparator|Bilateral transversus thoracis muscle plane block|Regional block will be performed after induction of anesthesia by anesthesiologist on duty who is not part of investigators for this study. The block will be performed in between intercostal space 4 and 5, lateral from sternum, with ultrasound guided
89405532|NCT04544254|Placebo Comparator|Control|Needle will be put in the superficial skin on the same area as transversus thoracis muscle plane block area without any drugs injected into the injection area
89405533|NCT01569971||Adolescents|Adolescents with SCD (all genotypes) age 12 years old up to 18 years old and currently receiving services through the St. Jude Children's Research Hospital Sickle Cell Disease Transition Program.
89405534|NCT01569971||Caregivers|Caregiver of an adolescent with SCD who has resided with the adolescent for at least two years prior.
89405535|NCT01569971||Young Adults|Young adults with SCD (all genotypes) age equal to 18 years up to and equal to 30 years of age who have transitioned to adult care.
89405536|NCT04489498||Children with stiff cerebral palsy|Children with stiff cerebral palsy, aged 1 to 13 years
89405537|NCT04489498||Normal children|Normal children, aged 1 to 13 years
89405538|NCT05175833|Experimental|Oral probiotics|oral gel containing Streptococcus salivarius K12 (2 billion live bacilli) and Lactobacillus brevis CD2 (4 billion live bacilli). During the trial, the oral gel was applied in the mouth every 8 hours for 7 days
89405539|NCT05175833|Placebo Comparator|Oral placebo|oral gel containing placebo. During the trial, the oral gel was applied in the mouth every 8 hours for 7 days
89405540|NCT04799392|Experimental|Persons tested with investigational device following PCR test|Persons tested with investigational device who previously tested positive or negative for COVID-19 with an emergency use authorized or FDA cleared COVID-19 test
89405541|NCT04799392|Experimental|Persons tested with investigational device following vaccination|Persons tested with investigational device who previously were vaccinated for COVID-19 with an emergency use authorized or FDA cleared COVID-19 vaccine
89405542|NCT04507321|Experimental|GSK3640254 tablet + [14C]-GSK3640254 IV/[14C] oral suspension|Participants will receive a single oral dose of GSK3640254 200 milligram (mg) (2×100 mg) tablets with a moderate fat meal. Participants will then be administered a 100 microgram (mcg) dose (approximately 3.7 kilobecquerel; 100 nano Curie) of [14C]-GSK3640254 as an IV infusion for 1 hour on Day 1 in treatment Period 1, On Day 1 in treatment Period 2, participants will receive a single oral dose of 85 mg (approximately 3.15 megabecquerel; 85 micro Curie) [14C]-GSK3640254 administered as an oral suspension with a moderate fat meal. A wash out period of at least 13 days will be maintained between oral doses of treatment periods.
89405543|NCT03797222|Experimental|Vitamin E Supplementation|Daily oral supplementation with Vitamin E (alpha-tocopherol) for 2 weeks.
89405544|NCT04725760|Experimental|Single Group Assisgnment|
89405545|NCT04118231|Experimental|Dry needling|
89405546|NCT04118231|No Intervention|Control group|
89004424|NCT04494451|Experimental|Vitamin C + Standard Medical Treatment|vitamin C (25 mg/kg or max. 1.5 gram every 6 hourly) for maximum 5 days along with iv antibiotics as per institutional protocol along with iv antibiotics
89004425|NCT04494451|Active Comparator|Standard Medical Treatment|iv antibiotics alone
89004426|NCT04491292||Observational (questionnaire)|Participants complete 2 online questionnaires over 10 minutes each at baseline and at 3 months after the pandemic ends.
89405547|NCT04783324|Experimental|Experimental Group|Pregnant women in the intervention group will use the e-mobile health application developed by the researcher.
89405548|NCT04783324|No Intervention|Control Group|Pregnant women in the control group will not be intervened and standard care will be applied.
89405549|NCT02742818|Other|Upper body blanket, Bair Hugger|Patients undergoing EVAR and LEA will use this type of warming blanket.
89004427|NCT04468126|Active Comparator|standard oxygen group|In order to maintain SpO2 between 92 and 96%
89405550|NCT02742818|Other|Underbody blanket, Bair Hugger|Patients undergoing EVAR and LEA will use this type of warming blanket.
89405551|NCT04708990|Experimental|DELP|Delipid Extracorporeal Lipoprotein filter from Plasma (DELP) is a non-pharmacological therapy for acute stroke, which is approved by China Food and Drug Administration
89004428|NCT04468126|Experimental|high-flow nasal cannula oxygen group|At least 50 L/min adjusted in order to maintain SpO2 between 92 and 96 %
89004429|NCT04421170|Experimental|Intervention Group|Participants from the intervention group will receive CBT based smoking cessation. It provides both mandatory information of evidence-based and guideline-based smoking cessation interventions, and optional information about quitting benefits, tips for quitting et al. The app will be available for the participants in the intervention group until 26-week post-quit date follow-up. After this period, the app will automatically stop the data collection, but they can continue to use it if they want. As the participants progressed through the study, smoking cessation related information will be gradually reduced until 12 weeks after quit date, and follow-up messages will be sent at 16, 20 and 26 weeks after quit date. Participants from intervention group can also seek for help at any time by text or WeChat, or make a phone call.
89190730|NCT03066648|Experimental|Azacitidine and MBG453|Azacitidine in combination with MBG453
89405552|NCT04708990|No Intervention|control group|
89405553|NCT04876105||Acute-subacute group|According to the duration of low back pain, it is classified as acute pain if it lasts less than a month, subacute pain if it lasts for 1-3 months.
89405554|NCT04876105||Chronic group|According to the duration of low back pain, it is classified as chronic pain if it lasts for more than 3 months.
89405555|NCT03069365|Experimental|GLE/PIB for 8 weeks|HCV genotype 1,2,4-6 non-cirrhotic, treatment-naive or treatment-experienced; genotype 3 non-cirrhotic, treatment-naïve participants treated with glecaprevir/pibrentasvir (GLE/PIB): three 100 mg/40 mg co-formulated tablets once daily with food for 8 weeks
89405556|NCT03069365|Experimental|GLE/PIB for 12 weeks|HCV genotype 1,2,4-6 compensated cirrhosis, treatment-naive or treatment-experienced; genotype 3 compensated cirrhosis, treatment- naïve participants treated with glecaprevir/pibrentasvir (GLE/PIB): three 100 mg/40 mg co-formulated tablets once daily with food for 12 weeks
89405557|NCT03069365|Experimental|GLE/PIB for 16 weeks|HCV genotype 3 non-cirrhotic or with compensated cirrhosis, treatment-experienced participants treated with glecaprevir/pibrentasvir (GLE/PIB): three 100 mg/40 mg co-formulated tablets once daily with food for 16 weeks
89405558|NCT04480411|Experimental|COVID-19 Patients|Patients that are admitted to the hospital with COVID 19.
88881837|NCT01388673|Experimental|ACE Stapler procedure|ACE Stapler procedure for the treatment of dilated post-surgical gastric anatomy
88881838|NCT01388686||INABBRA|Participating intensive care units of hospitals in the INABBRA alliance.
89190731|NCT02877394|Experimental|Squatting Assist Device|The Squatty Potty is a 7 inch tall stool to assist subjects in maintaining a squatting position while using a toilet. While sitting on the toilet, the subject supports her feet on the Squatty Potty.
89190732|NCT02877394|Sham Comparator|Sham Squatting Assist Device|This stool will be 2 inches tall and be similar in appearance to the Squatty Potty. While sitting on the toilet, the subject supports her feet on the 2 inch high stool.
89405559|NCT04471675|Experimental|Experimental: solid tumors|Albumin-bound docetaxel by intravenous infusion.Patients receive albumin-bound docetaxel once every three weeks (a Cycle), starting at a dose of 50mg/m2.
89405560|NCT00716534|Experimental|A|12.5 mg ABT-869 + Carboplatin/Paclitaxel
89405561|NCT00716534|Experimental|B|7.5 mg ABT-869 + Carboplatin/Paclitaxel
89405562|NCT00716534|Placebo Comparator|C|Placebo (7.5 mg or 12.5 mg) + Carboplatin/Paclitaxel
88813502|NCT03835208|Experimental|High-morning-carbohydrate|"High morning intake and low evening intake of carbohydrates.~This means a distribution of carbohydrate as follows:~50% morning, 40% lunch, 10% dinner. The overall recommendations for macro- and micronutrient intake for GDM patients will be met."
88813503|NCT04377230|Experimental|Biliopancreatic limb 60cm|Roux-en- Y gastric bypass will be performed with a biliopancreatic limb length of 60cm.
88813504|NCT04377230|Active Comparator|Biliopancreatic limb 100cm|Roux-en- Y gastric bypass will be performed with a biliopancreatic limb length of 100cm.
88813505|NCT03407846|Active Comparator|Total laparscopic hystrectomy|
88813506|NCT03407846|Experimental|Total abdominal hystrectomy|
88813507|NCT01728662|Experimental|ELVR Procedure|A single subsegmental AeriSeal System treatment consists of the administration of 10 mL Foam Sealant administered through a standard fiberoptic bronchoscope via an administration syringe and bronchoscopic catheter into the target area of damaged lung
88813508|NCT01728740|Experimental|Acarbose/Metformin FDC|Day 0: oral sucrose load (75 g sucrose dissolved in 225 mL water) without Acarbose/Metformin FDC; Day 1: oral sucrose load plus single dose of 1 tablet Acarbose/Metformin FDC (containing 50 mg Acarbose and 500 mg Metformin)
88813509|NCT01728740|Active Comparator|Acarbose+Metformin|Day 0: oral sucrose load (75 g sucrose dissolved in 225 mL water) without loose combination of Acarbose and Metformin; Day 1: oral sucrose load plus single dose of 1 tablet each of a loose combination of Acarbose 50 mg and Metformin 500 mg
88813510|NCT01728740|Active Comparator|Acarbose|Day 0: oral sucrose load (75 g sucrose dissolved in 225 mL water) without comedication; Day 1: oral sucrose load plus single dose of 1 tablet Acarbose 50 mg
88813511|NCT01728740|Active Comparator|Metformin|Day 0: oral sucrose load (75 g sucrose dissolved in 225 mL water) without comedication; Day 1: oral sucrose load plus single dose of 1 tablet Metformin 500 mg
88813512|NCT01728818|Experimental|Arm A|
88813513|NCT01728818|Active Comparator|Arm B|
88813514|NCT04377542|Active Comparator|LIFT|Ligation of intersphincteric fistula tract
88813515|NCT04377542|Active Comparator|Parks|Modified Parks technique
88813516|NCT04377542|Active Comparator|Seton|Two-stage seton placement
88813517|NCT01728896|Experimental|Patient-controlled oral refeeding|Patients will be allowed to drink and eat hospital food freely as tolerated.
88813518|NCT01728896|No Intervention|Conventional management|
88813519|NCT03407690||PIN2 study participants|All those giving swabs for the study
88813520|NCT03835832||HIV-infected participants who receive TST test|0.1 ml of tuberculin purified protein derivative will be intra-dermally inoculated on the forearm of the HIV-infected participants. They will learn how to interpret the results of the TST test. When they return to the clinic, the nurse will also interpret the results of the TST test. The results from the participants will be compared to the nurses' interpretation. We will assess the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of the innovative method.
88813521|NCT01576055|Experimental|TIGRIS Vascular Stent|GORE TIGRIS Vascular Stent
88813522|NCT01576055|Active Comparator|BARD LifeStent|BARD LifeStent
88813523|NCT01728974|Experimental|Pharyngeal topical anesthesia|Pharyngeal topical anesthesia will be performed using 4% lidocaine spray
89190733|NCT02796313|Experimental|Intervention Group|Participants in the intervention group will receive tailored advice on adopting a low-sodium DASH diet, comprising nutritional education and ongoing guidance for purchasing heart-healthy foods, plus a weekly $35 credit for groceries.
88881839|NCT01388699||migraine group|female migraineurs with aura
88881840|NCT01388699||control group|healthy women without headache syndrome
88881841|NCT01388712|Placebo Comparator|Placebo|
88881842|NCT01388712|Active Comparator|Probiotics|Lactobacillus reuteri DSM 17938
88881843|NCT01388725||SIRS|(1) temperature > 38oC or < 36oC; (2) pulse rate > 90 beats/min; (3) ventilation rate > 20 breaths/min or hyperventilation with a partial pressure of arterial carbon dioxide (PaCO2) < 32 mmHg; (4) white blood cell (WBC) count >1 2,000μL-1 or < 4000 μL-1 , or > 10% immature cells.
88881844|NCT01388725||Sepsis|SIRS + infection
88881845|NCT01388738|Active Comparator|cerebrolysin|IV
88881846|NCT01388738|Active Comparator|L-Alpha glycerylphosphorylcholine|IV
88881847|NCT01388738|Active Comparator|citicoline|IV and per os
88881848|NCT01388751|No Intervention|no night splinting|
88881849|NCT01388751|Active Comparator|night splinting|Night Splinting for 4 weeks after removal of initial cast
88881850|NCT01388764|Experimental|L-arginine|
88881851|NCT01388829|Experimental|formulation comparison|formulation comparison
88881852|NCT01388842|Placebo Comparator|Placebo|Controls will receive small pulses of placebo study drug via the INOpulse delivery system. Oxygen saturation will be maintained above 94% by adding oxygen to inspired gas via a loose fitting mask when necessary.
88881853|NCT01388842|Experimental|inhaled nitric oxide|Subjects randomized to the intervention arm will receive a dose equivalent to 80 ppm iNO in air using an INOpulse delivery system for 24 hours per day for a minimum of two days and until clinical improvement (coma recovery), death or a maximum of 5 days. Oxygen saturation will be maintained above 94% by adding oxygen to inspired gas via a loose fitting mask when necessary.
88881854|NCT01388855|Experimental|Cholecalciferol|Patients were given two cholecalciferol tablets (10,000 IU each) daily for 30 days.
88881855|NCT01388855|Placebo Comparator|Placebo|Patients were given two cholecalciferol placebo tablets daily for 30 days.
88881856|NCT01388868|Active Comparator|TOF count guided group|adjustment of neuromuscular blocking agent infusion dose every 15 minute as guided by No. of response to TOF stimulation
88881857|NCT01388868|Experimental|T1/T0 guided group|adjustment of neuromuscular blocking agent infusion dose every 15 minute as guided by T1 twitch height as compared with control (T0)
88881858|NCT01388868|Experimental|T2/ T0 guided group|adjustment of neuromuscular blocking agent infusion dose every 15 minute as guided by T2 twitch height as compared with baseline (T0)
88881859|NCT01388881|Experimental|Music Education|Music education classes take place three times a week, 50 minutes each. These interventional classrooms will make available keyboard and blockflute.
88881860|NCT01388881|No Intervention|Non-intervention|In this arm, children will be not encourage practicing musical activities and will not have musical classes.
88881861|NCT01388959|Experimental|Single arm|
88881862|NCT01389037|Experimental|Health Literacy-focused Self-help|
88881863|NCT01389037|Placebo Comparator|Delayed intervention control|
88881864|NCT01389063|Active Comparator|Arm A|HAART of subjects in arm A will be intensified with maraviroc during week 1-8.
88881865|NCT01389063|Active Comparator|Arm B|HAART of subjects enrolled in arm B will be intensified with maraviroc during week 9-16
88881866|NCT01389115||Liver Cirrhosis|Patient with liver cirrhosis undergoing liver transplant
88881867|NCT01389115||Liver donors|Subjects eligible for organ explant
88881868|NCT01389115||Healthy controls|
88881869|NCT01389141||mid-reproductive age|
89405563|NCT01024829|Other|Whole tumor boost|Patients in this arm will receive radiotherapy (66Gy) in 24 fractions of 2.75 Gy with an integrated boost to the primary tumor as a whole
88881870|NCT01389141||late reproductive age-1|
88881871|NCT01389141||late reproductive age-2|
88881872|NCT01389154|Experimental|Patients recommended for a lung biopsy.|Patients with a positive diagnosis of a peripheral, less than 3.0 centimeter lung lesion, recommended for bronchoscopic biopsy are eligible to be consented into the study.
89190734|NCT02796313|Active Comparator|Control Group|Participants in the control group will receive printed educational materials with general information about low-salt diets plus a weekly $35 credit for groceries.
88881873|NCT01389167|Experimental|Vivitrol + BDRC|
88881874|NCT01389167|Experimental|Vivitrol + Medical Management|
88881875|NCT01389167|Experimental|Naltrexone (oral)+BDRC|
88881876|NCT01389167|Experimental|Naltrexone (oral) + Medical Management|
88881877|NCT01389180|Experimental|BDRC|
88881878|NCT01389180|Experimental|EC|
88881879|NCT01389180|Other|TAU|
88881880|NCT01389193|Experimental|Ibudilast|
88881881|NCT01389193|Placebo Comparator|Placebo|
88881882|NCT01389206||Standard of care|Observational study to improve the management of PAH patients through an evidence-based approach aimed at achieving optimal WHO functional class (FC) treated with Tracleer, Ventavis, Veletri, Opsumit and/or Uptravi.
88881883|NCT01389219|No Intervention|Control|Control arm
88881884|NCT01389219|Other|Intervention clusters|Focus is to increase the number of visits by LHWs to the newborn baby and to ensure that this visit occurs within 48-72 hours of birth. The purpose of this visit was the provision of postpartum maternal and immediate newborn care, including postpartum visit, maternal nutrition supplementation, cord care, eye care, Kangaroo Care, delayed bathing, colostrum administration and linkages to immunization services), complications/illness management through stabilization/referral of cases.
88881885|NCT01389271||Group 1|
88881886|NCT01389297|Active Comparator|Face-to-face SMART Recovery meetings|Participants in this arm will be asked to attend face-to-face SMART Recovery meetings.
88881887|NCT01389297|Experimental|Overcoming Addictions web app|Participants in this condition will use the Overcoming Addictions web application and not attend face-to-face SMART Recovery meetings.
88881888|NCT01389297|Experimental|Web app + meetings|Participants in this condition will be asked to use both the Overcoming Addictions web application and attend face-to-face SMART Recovery meetings.
88881889|NCT01389310||HIV-infected children <18 yrs old - exposed to Atazanavir|
88881890|NCT01389336||Add-on Ayurveda - Group|In the Āyurveda add-on-group 20 patients will receive individualized treatment according to the Āyurveda diagnosis which may include manual treatments, massages, dietary advice, specific consideration of selected food items, āyurvedic lifestyle & yoga posture advice and daily self-applied massage on top of standard care.
88881891|NCT01389336||Standard Care|20 Patients will receive the individually adjusted complex conventional standard care according to the current AWMF-guidelines including physiotherapy, occupational therapy, specific pain therapy and psychotherapy.
88881892|NCT01389349|Experimental|Acupuncture|
88881893|NCT01389349|Sham Comparator|Sham Control|
88881894|NCT01389362|Active Comparator|Chinese Herbal Medicine|2 sachets of Chinese Herbal Medicine to be taken daily
88881895|NCT01389362|Placebo Comparator|Placebo arm|2 sachets to be taken daily
88881896|NCT01389375|Experimental|FemoSeal®|Device: FemoSeal®
88881897|NCT01389375|Experimental|ExoSeal®|Device: ExoSeal®
88881898|NCT01389375|Active Comparator|Manual compression|Other: Manual compression
88881899|NCT01389388|Experimental|Rosuvastatin intervention|Patients > 70 years will be given Rosuvastatin of 5 mg a day, uptitering the dose until the LDL level of 1.6-1.8 mmol/l has been reached. Patient <70 years, strat on Rosuvastatin 20 mg a day, uptitered to 40 mg a day, with the LDL of 1.6-1.8 mmol/l. -1.8 mmol/l. The objective is that all the participants should have reached a LDL level of 1.6-1.8 mmol/l 3 months after the start of the study. The participants will remain on Rosuvastatin medication for a total of 18 months.
88881900|NCT01389401||reflux laryngitis group pre-treatment|adults with clinical suspicion of Reflux Laryngitis confirmed by 24-hour double probe esophageal monitoring who have not made use of any treatment in the past 15 days.
88881901|NCT01389401||study group - post treatment|adults with reflux laryngitis after 16 weeks of treatment with proton pump inhibitor (omeprazole 40 mg twice a day)and dietary/lifestyle changes that present improvement in symptoms and video laryngoscopic signs of chronic laryngitis
88881902|NCT01389401||control group|healthy controls paired by gender and age that do not present symptoms and videolaryngoscopic signs suggestive of reflux laryngitis
88881903|NCT01389414|Experimental|Arm A- p-Gemox|"Panitumumab will be administered by intravenous (IV) infusion at a dose of 6 mg/kg once Q2W.~GEMOX chemotherapy will be administered after the administration of panitumumab once Q2W.~Gemcitabine 1000mg/sqm will be administered by intravenous infusion as 1-hour infusion on day 1 of each cycle. Oxaliplatin 100mg/sqm will be administered by intravenous infusion as 2-hour infusion on day 2 of each cycle."
88881904|NCT01389414|Active Comparator|Arm B-GEMOX|Gemcitabine 1000mg/sqm will be administered by intravenous infusion as 1-hour infusion on day 1 of each cycle. Oxaliplatin 100mg/sqm will be administered by intravenous infusion as 2-hour infusion on day 2 of each cycle.
88881905|NCT01389427|Experimental|Torisel 15 mg|Chemotherapy (R-CHOP, R-DHA or R-FC) associated to Torisel 15 mg
88881906|NCT01389427|Experimental|Torisel 25 mg|Chemotherapy (R-CHOP, R-DHA or R-FC) associated to Torisel 25 mg
88881907|NCT01389427|Experimental|Torisel 50 mg|Chemotherapy (R-CHOP, R-DHA or R-FC) associated to Torisel 50 mg
88881908|NCT01389427|Experimental|Torisel 75 mg|Chemotherapy (R-CHOP, R-DHA or R-FC) associated to Torisel 75 mg
89190735|NCT02795104|Experimental|Arm I (TIDVD)|Educational Intervention via DVD: In this arm of the intervention participants watch a tailored interactive DVD program and answer questions posed by the DVD program.
88881909|NCT01389440|Experimental|Gemcitabine, Erlotinib and radiotherapy|Gemcitabine + Erlotinib follow by Gemcitabine + Erlotinib + radiotherapy
88881910|NCT01389453|Active Comparator|stem cell transplatation|All experimental group patients accept a treatment course stem cell transplantation, including one time stem cell transplantation through intravenous injection way at the 10-21th day of cerebral hemorrhage, and the 7-14th day of cerebral infarction incidence; the second time transplantation through lumbar puncture way at the 7th day after the First time transplantation.
88881911|NCT01389453|No Intervention|control|The control group gives injection through intravenous and lumbar puncture ways separately in the corresponding time, but the transplantation matter is physiological saline not the stem cell.
88881912|NCT01389466|Experimental|MG1109 - Step 1|
88881913|NCT01389466|Placebo Comparator|Normal Saline - Step 1|
88881914|NCT01389466|Experimental|MG1109 - Step 2|
88881915|NCT01389479|Experimental|Fluviral Group|
88881916|NCT01389479|Active Comparator|Fluzone Group|
88881917|NCT01389492|Other|frozen meat|250 g of frozen meat meal for 4 days
88881918|NCT01389492|Other|frozen meat and wine|250 g of frozen meat and red wine for 4 days
88881919|NCT01389492|Other|fresh meat|250 g of fresh meat meal
88881920|NCT01389492|Other|fresh meat and wine|250 g of fresh meat meal
88881921|NCT01389505|Active Comparator|Panretinal photocoagulation|Group 1: Panretinal photocoagulation treatment (PRP) at month-0 that can be repeated after month-3.
88881922|NCT01389505|Experimental|Bevacizumab + Panretinal Photocoagulation (PRP)|Group 2: Bevacizumab intravitreous injections plus PRP
88881923|NCT01389518|Active Comparator|Paracetamol,Chlorpheniramin,Phenylephrin|
88881924|NCT01389518|Placebo Comparator|Placebo|
88881925|NCT01389531|Other|Stents|All recruited patients will be receiving a stent during a rigid bronchoscopy procedure.
88881926|NCT01389544|Experimental|Single Arm|
88881927|NCT01389570|Experimental|Acupressure wrist band|The group receiving acupressure wrist band
88881928|NCT01389583|Experimental|AUY922|AUY922
89190736|NCT02795104|Experimental|Arm II (TIDVD, PN)|Educational Intervention-DVD & Telephone based Navigation: In this arm of the intervention participants watch a TIDVD and are called by a patient navigator.
89190737|NCT02795104|Experimental|Arm III (UC)|Educational Intervention via brochure: In this arm of the intervention participants receive brochures that explain and provide information and encouragement for cancer screening.
89405564|NCT01024829|Other|Boost 50% SUV area|Patients in this arm receive radiotherapy (66Gy) in 24 fractions of 2.75Gy with an integrated boost to the 50% SUVmax area of the primary tumor (of the pre-treatment FDG-PET-CT scan)
89405565|NCT04623736|Experimental|quitSTART|
88881929|NCT01389609|Experimental|A|Doxazosin 4 mg Japanese marketed IR tablet as a single oral dose under fasted conditions
89405566|NCT03360500|Experimental|EXERCISE PROTOCOL + CRYOTHERAPY|Patients with knee osteoarthritis, both sexes, with age between 40 and 75
89405567|NCT03360500|Experimental|EXERCISE PROTOCOL|Patients with knee osteoarthritis, both sexes, with age between 40 and 75
89405568|NCT03360500|Placebo Comparator|EXERCISE PROTOCOL + PLACEBO|Patients with knee osteoarthritis, both sexes, with age between 40 and 75
89405569|NCT03627949|Experimental|Intervention group 1|Students in the intervention group 1 received first 4-week treatment on physical activity followed by 4-week treatment on healthy dietary behaviour.
89405570|NCT03627949|Experimental|Intervention group 2|Students in the intervention group 2 received first 4-week treatment on healthy dietary behaviour followed by 4-week treatment on physical activity.
89405571|NCT03627949|No Intervention|Control group|Students in the control group were not provided with any supportive treatments on physical activity or healthy dietary behaviour.
89405572|NCT04554706|Experimental|a JITAI interactive narrative condition (Narrative JITAI)|This arm is an exploratory condition, which tested whether story-based JITAI would be an effective way to deal with rumination.
89405573|NCT04554706|Experimental|a JITIAI non-interactive condition|This arm uses the regular JITAI ( mobile phone delivered) intervention to provide treatment for ruminative thoughts.
89405574|NCT04554706|No Intervention|a wait-list control condition|Participants in this arm will be put on a waitlist without receiving active treatment upon the end of the study.
89405575|NCT05761067|Experimental|Percutaneous Coronary Intervention (PCI)|Patients will be revascularized by PCI
89405576|NCT05761067|No Intervention|Coronary artery bypass grafting (CABG)|Patients will be revascularized by CABG
88881930|NCT01389609|Experimental|B|Doxazosin 4 mg ODT with water as a single oral dose under fasted conditions
88881931|NCT01389609|Experimental|C|Doxazosin 4 mg ODT without water as a single oral dose under fasted conditions
88881932|NCT01389622|Experimental|Arm 1: NADA points and digital pressure|Arm 1: NADA points and digital pressure with urge.
89405577|NCT02283398|Experimental|with RIPC|RIPC will be induced with three cycles of inflation of a blood-pressure cuff on the left arm to 200 mm Hg for 5 min, followed by 5 min of reperfusion while cuff deflated
89405578|NCT02283398|Sham Comparator|without RIPC|the cuff will be placed around the left arm without being inflated
89190738|NCT02766465|Experimental|Donor Arm|"Donor Arm patients will undergo hematopoietic cell transplant. Patients with a matched unrelated donor will receive a bone marrow transplant (unless PBSC graft is pre-approved per section 2.5.1 using a preparative regimen with Busulfan, Fludarabine and rabbit ATG. Patients with an HLA-identical sibling donor can receive a transplant using one of three regimens:~A. Busulfan, Fludarabine, and rabbit ATG using a bone marrow graft (preferred regimen) B. Alemtuzumab/TBI 300 cGy using a peripheral blood graft C. Alemtuzumab, fludarabine, melphalan using a bone marrow graft"
89190739|NCT02766465|Active Comparator|No-Donor Arm|No-donor arm patients will continue with standard of care per their SCD physician.
89405579|NCT03981731|Experimental|Cardiac coherence|
89405580|NCT02283476|Experimental|Endostar continuous intravenous infusion|Endostar continuous intravenous infusion in combination with Gemcitabine and Cisplatin
89405581|NCT02283476|Active Comparator|Endostar routine intravenous infusion|Endostar routine intravenous infusion in combination with Gemcitabine and Cisplatin
89190740|NCT02749422|Active Comparator|Healthy Subjects|
89190741|NCT02749422|Experimental|Temporal Lobe Epilepsy Patients|
89190742|NCT02743455|Active Comparator|Group 1|Subjects will receive 1.0x10^8 TCID50 of MVA-BN as two doses subcutaneously on Day 1 and Day 29. N=15
89190743|NCT02743455|Experimental|Group 2|Subjects will receive 1.0x10^8 TCID50 of MVA-BN-YF as two doses intramuscularly on Day 1 and Day 29. N=15
89405582|NCT04054570||Adaptive servo-ventilation patients|All patients under adaptive servo-ventilation in the Geneva Lake area and details of the specifics indications, population treated and venitator settings
89405583|NCT04054570||Barometric and Volumetric patients|All patients under barometric and volumetric ventilation in the Geneva Lake area and details of the specifics indications, population treated and venitator settings
89405584|NCT05156879|Experimental|Aspirin|Aspirin Enteric-coated Tablets，75mg/day，24 weeks
89405585|NCT05156879|Active Comparator|Drospirenone ethinyl estradiol|Drospirenone ethinyl estradiol，one tablet/day for 21 consecutive days, 28 days as a cycle of use，24 weeks
89405586|NCT02283554|Placebo Comparator|ARM1- open flap debridement (OFD)|open flap debridement done for 30 subjects. After debridement, Metformin or PRF was not added into the intrabony defect.
89405587|NCT02283554|Experimental|ARM2- open flap debridement plus PRF(Platelet rich fibrin)|"After open flap debridement, PRF( Platelet rich fibrin) was added into the intrabony defect.~No. of subjects= 30"
89405588|NCT02283554|Experimental|ARM3- open flap debridement plus 1%Metformin|After open flap debridement, 1% metformin was added into the intrabony defect No. of subjects= 30
89405589|NCT02283554|Experimental|ARM4- open flap debridement plus PRF plus metformin|"After open flap debridement, PRF and 1% metformin was added into the intrabony defect.~No. of subject- 30"
89405590|NCT03957070|Experimental|Liver Incyte|Patients with successfully treated HCV, or NASH Healthy volunteers with no history of liver disease. Patients and Volunteers will be scanned with FibroScan and Liver Incyte.
88881933|NCT01389622|Experimental|Arm 2: random points + digital pressure with urge|Arm 2 (20 participants): random points + digital pressure with urge
88881934|NCT01389622|No Intervention|Arm 3 (20 participants): NO acupressure, only advice + support|
88881935|NCT01389635||Abdominoplasty patients|All patients who underwent abdominoplasty at our institution without concurrent operations
89190744|NCT02743455|Experimental|Group 3|Subjects will receive 1.0x10^8 TCID50 of MVA-BN-YF + ISA 720 as two doses intramuscularly on Day 1 and Day 29. N=15
88881936|NCT01389648|Experimental|Pre Operative|Pre operative chest physiotherapy treatment
88881937|NCT01389648|No Intervention|usual care|
88881938|NCT01389661|Experimental|MSV treatment|MSV treatment: Mesenchymal stem cells from bone marrow expanded by GMP-compliant procedure in IBGM cell production unit in autologous plasma scaffold and implanted in maxillary bone cavities after cyst removal
88881939|NCT01389674|Experimental|2D-strain echo|After myocard vitality diagnostics with MRI follows a stress echocardiography to determine the LV volumes and EF. The received Data are compare with the MRI-Data(reference)to identify the ideal strain-parameters and Cut-Off-Result for an intraprocedural vitality diagnostic of the different films (endocardial, myocardial and epicardial).
88881940|NCT01389687|Experimental|Study Group|
88881941|NCT01389713|Active Comparator|High doses|Administration of high doses of gonadotrophins to stimulate ovarian follicular growth
88881942|NCT01389713|Experimental|Clomid|Administration of Clomiphene Citrate to obtain ovarian follicular growth
88881943|NCT01389726|Experimental|Behavioral Parenting Training|Triple-P Parenting Training Program (group level)
88881944|NCT01389726|Experimental|Cognitive Behavioral Therapy|CBT group-level intervention (Designed by Larry Thompson & Dolores Gallagher Thompson)
88881945|NCT01389726|Active Comparator|Psychosocial-Informational Support|Standard of Care informational support group
88881946|NCT01389739|Experimental|Exposed to the intervention|Patients in the intervention arm will be exposed to a multi-faceted intervention to improve continuity of care; the intervention includes 4 components: 1) systematic appointments with FP at 3-month interval during the study period; 2) transmission to FP of a standardized comprehensive summary before each appointment; 3)systematic transmission to the oncology team of patients' information resulting from FP visits; 4) development of a priority access to FP for cancer patients
88881947|NCT01389739|No Intervention|Usual care|
88881948|NCT01389778|Experimental|Metformin|Subjects treated with metformin.
88881949|NCT01389791|No Intervention|Roc|Patients in this group receive neither MgSO4 nor priming dose of rocuronium.
88881950|NCT01389791|Active Comparator|priming|patients in this group receive 0.06mg/kg of rocuronium before 0.54mg/kg of rocuronium.
88881951|NCT01389791|Experimental|Mg&priming|Patients in this group receive MgSO4 50mg/kg and 0.06mg/kg of rocuronium before administration of 0.54mg/kg of rocuronium.
89190745|NCT02743455|Experimental|Group 4|Subjects will receive 1.0x10^8 TCID50 of MVA-BN-YF + ISA 720 as a single dose intramuscularly on Day 1 and matching placebo on Day 29. N=15
89190746|NCT02743455|Active Comparator|Group 5|Subjects will receive = / > 4.74 log10 PFU of YF-Vax as a single dose subcutaneously on Day 1 and matching placebo on Day 29. N=15
89190747|NCT02743455|Experimental|Group 6|Subjects with prior receipt of MVA-BN will receive 1.0x10^8 TCID50 of MVA-BN-YF as two doses intramuscularly on Day 1 and Day 29. N=15
89190748|NCT02716753|Experimental|Seminal plasma|Half of the amount of seminal plasma received after preparation of the spermatozoa used for IVF will be deposited around the external cervical opening
89190749|NCT02716753|Placebo Comparator|Physiological NaCL solution|An amount of physiological NaCL solution equal to half of the amount of seminal plasma received after preparation of the spermatozoa used for IVF will be deposited around the external cervical opening
89190750|NCT02675244|Active Comparator|MVS Alone|Participants will undergo mitral valve surgery alone.
89190751|NCT02675244|Active Comparator|MVS + TV Annuloplasty|Patients will undergo mitral valve surgery and tricuspid valve annuloplasty.
89190752|NCT02553447|Experimental|Arm I (high-dose cholecalciferol)|Patients receive high-dose cholecalciferol PO daily for 3 years in the absence of disease progression or unacceptable toxicity.
89190753|NCT02553447|Experimental|Arm II (low-dose cholecalciferol)|Patients receive low-dose cholecalciferol PO daily for 3 years in the absence of disease progression or unacceptable toxicity.
89190754|NCT02553447|No Intervention|Arm III (control)|Patients receive no intervention.
89190755|NCT02424188|Experimental|TRIUMPH intervention|Group and individual smoking cessation and weight management counseling, pharmacotherapy with varenicline or bupropion and nicotine replacement therapy, group exercise, and text messaging support
89190756|NCT02424188|No Intervention|Treatment as Usual|referral to quit line
89190757|NCT02351791|Experimental|Patch 1, 3 and 5|"Patch 1, Patch 3 and Patch 5 applied on peristomal skin. Patch 1 - Patch 6 applied on healthy abdominal skin~Measurements of skin at three locations of each patch: Center and under adhesive."
89190758|NCT02351791|Experimental|Patch 2, 4 and 6|Patch 2, Patch 4 and Patch 6 applied on peristomal skin. Patch 1- Patch 6 applied on healthy abdominal skin Measurements of skin at three locations of each patch: Center and under adhesive.
89190759|NCT02306174|Experimental|Cognitive Rehabilitation and Exposure-based Class for Compulsi|"Cognitive training is to improve thinking by learning new skills and strategies. The class begins with cognitive training to increase ability to carry out the skills learned later in treatment.~Exposure therapy for discarding and acquiring helps to improve ability to make choices about possessions and learn to tolerate anxiety. Participants will face making difficult choices about items and potentially letting them go. Through repeated exposure to decisions about discarding and acquiring, distress about letting go or making choices about items will decrease over time."
88881952|NCT01389791|Active Comparator|MgSO4|Patients in this group receive intravenous MgSO4 before administration of rocuronium.
88881953|NCT01389804||Pediatric Solid Organ Transplant|Parents of pediatric solid organ transplant recipients
88881954|NCT01389830||Older Latinos With Cancer|Monthly Telephone Survey of Cohort with stage III or greater of breast, colorectal, or prostate cancer up until 12 months.
89190760|NCT02020707|Experimental|Treatment (AB-complex)|Patients receive nab-paclitaxel/bevacizumab-complex IV over 30-60 minutes on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patient may receive paclitaxel if supply of nab-paclitaxel is exhausted.
89190761|NCT01814358|Experimental|Whey protein|Subjects on this arm will receive whey protein
88881955|NCT01389830||Older Latinos Without Cancer|Single Telephone Survey of Cohort without a history of cancer.
88881956|NCT01389843||All consecutive hospitalized adult patients|"All consecutive hospitalized adult patients who have 1 and (2 and/or 3)~Symptom and/or sign of heart failure~Lung congestion~Objective finding of LV systolic dysfunction (LVEF), or structural heart disease."
88881957|NCT01389869|Experimental|Tears|Emotional tears of female volunteers while watching sad video clips
88881958|NCT01389869|Placebo Comparator|Saline|Saline collected after being trickled down women's skin below eyes like tears
88881959|NCT01389869|Placebo Comparator|Fasting|Their own overnight fasting plasma of male volunteers
88881960|NCT01389869|Experimental|Prandial|Their own postprandial plasma of male volunteers
88881961|NCT01389895|Active Comparator|AMG 557|All will receive AMG 557 on Day 1, Day 8, Day 15, Day 29, Day 43, Day 57, Day 71, Day 85, and Day 99.
88881962|NCT01389895|Placebo Comparator|AMG 557 Placebo|All will receive placebo on Day 1, Day 8, Day 15, Day 29, Day 43, Day 57, Day 71, Day 85, and Day 99.
89405591|NCT03629405|No Intervention|A - Negative control (untreated) for product C|On the forearms four test areas were located, which were labeled from A-D. Test area A contralateral to product C
89405592|NCT03629405|No Intervention|B - Negative control (untreated) for product D|On the forearms four test areas were located, which were labeled from A-D. Test area B contralateral to product D
88881963|NCT01389908|Experimental|schizophrenia|schizophrenia or schizoaffective patients
88881964|NCT01389921|Experimental|healthy testpersons|Electroencephalography recording during electrical stimulation of different locations of the lower urinary tract as well as during electrical and heat stimulation at the tibial and pudendal nerve and S3 dermatome.
88881965|NCT01389921|Experimental|patients with non-neurogenic OAB|Electroencephalography recording during electrical stimulation of different locations of the lower urinary tract as well as during electrical and heat stimulation at the tibial and pudendal nerve and S3 dermatome.
88881966|NCT01389921|Other|patients with neurogenic OAB|Electroencephalography recording during electrical stimulation of different locations of the lower urinary tract as well as during electrical and heat stimulation at the tibial and pudendal nerve and S3 dermatome
88881967|NCT01389947||Extracorporeal circulation|Patients who have coronary artery bypass graft performed under extracorporeal circulation
88881968|NCT01389947||Heart beating group|Patients who have a coronary artery bypass graft without extracorporeal circulation
88881969|NCT01389986|Experimental|Gum chewing|Gum chewing (30 minutes in duration each time, 4 times/days at the usual time of meal, until the first flatus) in addition to conventional postoperative feeding schedule
88881970|NCT01389986|No Intervention|Conventional|Conventional postoperative feeding schedule
88881971|NCT01389999||Chronic back pain patients|Patients who have had back pain for at least three months.
88881972|NCT01390012|Active Comparator|Dexamethasone oral|
88881973|NCT01390012|Active Comparator|Dexamethasone intravenous|
88881974|NCT01390025|Experimental|TCN-032|
88881975|NCT01390025|Placebo Comparator|Placebo|
88881976|NCT01390051|Active Comparator|Innohep|Tinzaparin 4500 I.U. sub cutaneous once daily until gestational week 37
88881977|NCT01390051|No Intervention|no treatment|
88881978|NCT01390103||Assessment following the hip injection|Assessment to evaluate the effect of the hip injection on biomechanics.
88881979|NCT01390116|Placebo Comparator|Sugar pill|looks like and is given in the same way as the experimental treatment but contains no active ingredient
88881980|NCT01390116|Experimental|AGE|Encapsulated aged garlic extract, 4 capsules per day, 2.56 g/day
88881981|NCT01390129|Experimental|Control|
88881982|NCT01390129|Active Comparator|Remote ischemic preconditioning|
88881983|NCT01390142|Experimental|Control|
89405593|NCT03629405|Experimental|C - Cosmetic Product WO 3741 with pH 4|On the forearms four test areas were located, which were labeled from A-D. Test area C on the same arm like product D.
89405594|NCT03629405|Experimental|D - Cosmetic Product WO 4081-1 with pH 5.8|On the forearms four test areas were located, which were labeled from A-D.
89405595|NCT00641732|Experimental|TAK-442 40 mg QD|
89405596|NCT00641732|Experimental|TAK-442 80 mg QD|
88881984|NCT01390142|Active Comparator|RIPer|Remote ischemic preconditioning
88881985|NCT01390142|Active Comparator|RIPer + IPost|Remote ischemic preconditioning and Local ischemic postconditioning
89190762|NCT01814358|Active Comparator|Gelatin protein|Subjects on this arm will consume gelatin protein
89190763|NCT01814358|No Intervention|Control arm|Subjects on this arm will receive no intervention
89190764|NCT01714271|Experimental|Home environs-based lifestyle counseling|Home environs-based lifestyle counseling Involves Spanish-speaking community health workers interacting with intervention subjects in home visits and phone calls - 12 contacts overall. The counseling focuses on promoting subject adherence to the Dietary Guidelines for Americans (DGA) and the Physical Activity Guidelines for Americans (PAGA) with special attention devoted to changing the home environment to make it optimally supportive of the lifestyle choices consistent with the DGA and PAGA. Study participants will also be provided 4 group education sessions that will be devoted to improving subject adherence to the DGA and PAGA.
89190765|NCT01714271|Experimental|Cancer early detection|Cancer Early Detection Spanish-speaking health educators will interact with study participants via a home visit and four telephone calls. The focus of the health education will be on practical strategies to detect cancer early to help prevent death from cancer. Cancer sites of interest will be: breast, cervical, skin, colon, prostate and testicular cancers. In addition, study participants will be provided two group education classes that will focus on the basics of the cancer process and why early detection and intervention can be life-saving.
89190766|NCT01683877|Experimental|FloSeal group|After laparoscopic ovarian cystectomy, hemostasis will be performed using FloSeal (1 vial of FloSeal 5mL per unilateral ovarian cystectomy)
89190767|NCT01683877|Active Comparator|Electrocautery group|After laparoscopic ovarian cystectomy, hemostasis will be performed using electrocautery
89190768|NCT01632436|Experimental|Stage 1 -Moderate Hepatic Impairment|Pixantrone
89190769|NCT01632436|Experimental|Stage 2 - Severe Hepatic Impairment|Pixantrone
89190770|NCT01594047|No Intervention|zero/morphine|Patient received a standard balance anaesthesia and morphine for post operative pain.
89190771|NCT01594047|Experimental|ketamine/morphine|Ketamine infusion scheme: 5mcg/Kg/min from induction od anaesthesia for 10 min, than 2,5mcg/Kg/min for 20 min and than 2 mcg/Kg/min to the end of surgery.
89190772|NCT01594047|Experimental|zero/metadone|Methadone PCA
89190773|NCT01594047|Experimental|ketamine/methadone|"Ketamine infusion scheme: 5mcg/Kg/min from induction od anaesthesia for 10 min, than 2,5mcg/Kg/min for 20 min and than 2 mcg/Kg/min to the end of surgery.~Methadone administered by a PCA system (dose 2 mg, lock-out 12min.)."
89190774|NCT01532609|Experimental|Intervention|Intervention group service providers received four training sessions (plus reunion sessions) on MMT protocol, reducing stigma and its impact, maintaining positive interactions with clients, and motivational interviewing skills. The participating providers are required to conduct three individual motivational sessions with their clients upon completion of the intervention sessions.
89190775|NCT01532609|No Intervention|Standard care|No additional training or service is provided for standard care group service providers or clients.
89190776|NCT01519349|Experimental|Cohort 1|Low Dose: 2E11 vg/kg of rAAV1.CMV.huFollistatin344 administered via intramuscular injection unilaterally to single quadriceps muscle (n=3, sIBM only)
89405597|NCT00641732|Experimental|TAK-442 10 mg BID|
89405598|NCT00641732|Experimental|TAK-442 20 mg BID|
89405599|NCT00641732|Experimental|TAK-442 40 mg BID|
89405600|NCT00641732|Experimental|TAK-442 80 mg BID|
89405601|NCT00641732|Active Comparator|Enoxaparin 30 mg BID|
89405602|NCT03845842|Active Comparator|Control (volitional help sheet)|"Participants read a brief statement designed to encourage them to reduce their cannabis use (We want you to plan to reduce your cannabis use). Participants are presented with a table with two columns and twenty rows. Twenty 'high risk' situations (temptations) are presented in the left hand column and 20 appropriate responses (processes of change) are presented in the right hand column (see Armitage, 2008). Participants are told that identifying situations in which they were tempted to use cannabis and identifying ways to overcome those temptations had been shown to help people change their behaviour and are asked to tick critical situations/appropriate responses that might be useful to them."
89405603|NCT03845842|Experimental|Intervention (volitional help sheet)|"Participants read a brief statement designed to encourage them to reduce their cannabis use (We want you to plan to reduce your cannabis use). Participants are presented with a table with two columns and twenty rows. Twenty 'high risk' situations (temptations) are presented in the left hand column and 20 appropriate responses (processes of change) are presented in the right hand column (see Armitage, 2008). Participants are told that identifying situations in which they were tempted to use cannabis and identifying ways to overcome those temptations had been shown to help people change their behaviour. Implementation intentions are formed by linking critical situations with appropriate responses by choosing an appropriate response from a drop down menu for each critical situation."
89405604|NCT03770494|Experimental|LY3405105|LY3405105 administered orally.
88881986|NCT01390155||1|Patients undergoing temporary myocardial ischemia produced by a one-minute balloon occlusion of the proximal left anterior descending coronary artery.
88881987|NCT01390155||2|Patients undergoing temporary myocardial ischemia produced by a one-minute balloon occlusion of the proximal left circumflex artery.
89190777|NCT01519349|Experimental|Cohort 2|Mid Dose: 3E11 vg/kg per quadriceps of rAAV1.CMV.huFollistatin344 administered via intramuscular injection bilaterally to both quadriceps muscles (n=6; 3 sIBM and 3 BMD)
89190778|NCT01519349|Experimental|Cohort 3|Low Dose: 6E11 vg/kg per quadriceps of rAAV1.CMV.huFollistatin344 administered via intramuscular injection bilaterally to both quadriceps muscles (n=6; 3 sIBM and 3 BMD)
89190779|NCT01496313|Active Comparator|300mg vandetanib|
89190780|NCT01496313|Active Comparator|150mg vandetanib|
89405605|NCT00790829|Experimental|A, B|Group B received a seven-milligram transdermal patch and Group A received a placebo patch.
89405606|NCT00640484|Experimental|A|CHF 4226 (carmoterol) 2 μg once a day, in the morning
89405607|NCT00640484|Experimental|B|CHF 4226 (carmoterol) 4 μg once a day, in the morning
89405608|NCT00640484|Placebo Comparator|C|placebo once a day, in the morning
89405609|NCT00640484|Active Comparator|D|salmeterol 50 μg twice daily, in the morning and in the evening
89405610|NCT04382248|Experimental|Interventional Group|An app for tracking medications, receiving personal coaching and educational material
89405611|NCT04382248|Active Comparator|Control Group|An app for tracking medications
89405612|NCT03949361||Patients starting glucocorticoids|Patients starting a glucocorticoid therapy measuring primary and secondary endpoints before and after at least 4 weeks of treatment.
89405613|NCT03949361||Patients stopping glucocorticoids|Patients stopping a glucocorticoid therapy measuring primary and secondary endpoints before weaning off glucocorticoids and after a period of at least 3 months.
89405614|NCT03065933|Experimental|clonidine as an antimanic agent|Subjects with Bipolar Disorder, Mania receive an extended-release form of clonidine on the second day of this 3-day study. Rating scales, record of sleep, and a questionnaire of adverse effects is recorded on each of the three days.
89405615|NCT00630656|Experimental|1|Talactoferrin alfa
89405616|NCT00630656|Placebo Comparator|2|Placebo
88881988|NCT01390155||3|Patients undergoing temporary myocardial ischemia produced by a one-minute occlusion of the proximal right coronary artery.
88881989|NCT01390155||4|Patients undergoing temporary myocardial ischemia produced by a one-minute occlusion of the target vessel.
89405617|NCT04256629|Experimental|Treatment ABC|Subjects will receive a single dose of all 3 treatments (A, B, and C) in a crossover design with wash-out periods of at least 7 days between each study dose administration.
88881990|NCT01390168|Experimental|tailored internet-administrated CBT|Behavioral: tailored internet-administrated CBT
89190781|NCT01298323|Active Comparator|Vandetanib Control|Control - treatment 300mg vandetanib opel label
89190782|NCT01298323|Experimental|Experimental|Experimental - treatment 300mg vandetanib opel label
88881991|NCT01390168|Active Comparator|waitlist|waitlist
88881992|NCT01390207|Experimental|16mm follicles|
89190783|NCT01268579|Experimental|ribavirin|This will be a single institution non-randomized study for patients with tonsil and/or base of tongue squamous cell cancer. This is a pilot study to obtain pharmacodynamic data regarding the effects of ribavirin on tonsil squamous cell cancer.
89190784|NCT01200082||Healthy Controls|Male or female, age 19-65, no apparent signs of hepatobiliary diseases
89190785|NCT01200082||Patients with hepatobiliary diseases|Male or female, age 19-65, visiting the UNMC hepatology clinic for treatment from hepatobiliary diseases
88881993|NCT01390285|Experimental|TENS|
88881994|NCT01390285|Sham Comparator|Sham TENS|
88881995|NCT01390311|Active Comparator|Control Cohort|"Pre-DLI Salvage Chemotherapy (at the discretion of the treating physician)~DLI will be administered 2 +/- 1 weeks after pre-DLI chemotherapy. The minimum CD3+ cell counts in DLI product should be 1 x 107 cells/kg for sibling and ~1 x 106/kg for match unrelated donors based on recipient weight~No Azacitidine will be given"
89190786|NCT01165632|Experimental|Arm I|Beginning at no more than 1 week before biopsy or resection, patients undergo fluorine F 18 fluorodopa-labeled PET/CT scan and pre-operative MRI. Patients then undergo stereotactic craniotomy. Some patients may also undergo radiation therapy.
89405618|NCT04256629|Experimental|Treatment BCA|Subjects will receive a single dose of all 3 treatments (B, C, and A) in a crossover design with wash-out periods of at least 7 days between each study dose administration.
89405619|NCT04256629|Experimental|Treatment CAB|Subjects will receive a single dose of all 3 treatments (C, A, and B) in a crossover design with wash-out periods of at least 7 days between each study dose administration.
89405620|NCT04256629|Experimental|Treatment ACB|Subjects will receive a single dose of all 3 treatments (A, C, and B) in a crossover design with wash-out periods of at least 7 days between each study dose administration.
89405621|NCT04256629|Experimental|Treatment BAC|Subjects will receive a single dose of all 3 treatments (B, A, and C) in a crossover design with wash-out periods of at least 7 days between each study dose administration.
89405622|NCT04256629|Experimental|Treatment CBA|Subjects will receive a single dose of all 3 treatments (C, B and A) in a crossover design with wash-out periods of at least 7 days between each study dose administration.
89405623|NCT04225936|Experimental|Group A: Mild Hepatic Impairment|Part 1
89405624|NCT04225936|Experimental|Group B: Moderate Hepatic Impairment|Part 1
89405625|NCT04225936|Experimental|Group C: Severe Hepatic Impairment|Part 2
89405626|NCT04225936|Experimental|Group D: Normal Hepatic function (control group)|Part 1
89405627|NCT04225936|Experimental|Group E: Normal Hepatic Function (optional, control group)|Part 2
89405628|NCT05206721|Experimental|Intervention group|
89405629|NCT05206721|No Intervention|Control group|
89004430|NCT04421170|No Intervention|Control group|Participants from the control group will only receive information of thanking them for being in the study and reminding them of the time until their free month at the end of follow up. In order to measure the outcomes between two groups, continuous smoking abstinence, point prevalence of abstinence, how many cigarettes per day during the last week if they are still smoking will be checked at week 1, 2, 3, 4, 8, 12, 16, 20 and 26 points after quit date by ePRO software. Biochemically verified continuously abstinence will also be checked if they have reported continuous smoking abstinence at week 26 points after quit date.
89004431|NCT04419558|Experimental|Pamrevlumab|"Treatment phase: Pamrevlumab 30 mg/kg administered by IV infusion, every 3 weeks, for a total of up to 17 infusions over 48 weeks.~Open-label extension phase: Pamrevlumab 30 mg/kg administered by intravenous infusion, every 3 weeks for up to 48 weeks"
89004432|NCT04419558|Experimental|Placebo|Pamrevlumab-matching placebo administered by IV infusion every 3 weeks for a total of up to 17 infusions over 48 weeks
89190787|NCT01056523|Experimental|Ribavirin-Cytarabine arabinoside|Ribavirin will be given orally bid according to a dose escalation scheme daily for 28 days of a 28 day cycle Cytarabine arabinoside will be given 20 mg sc bid days 1 to 10 of a 28 day cycle
89190788|NCT00579878|Active Comparator|Leflunomide alone vs combination therapy|Group A: Leflunomide alone
89190789|NCT00579878|Active Comparator|Methotrexate-Sulfasalazine-Hydroxychloroquine|Methotrexate, Sulfasalazine, Hydroxychloroquine.
89190790|NCT00579878|Active Comparator|Leflunomide-Sulfasalazine-Hydroxychloroquine|Leflunomide-Sulfasalazine-Hydroxychloroquine
89190791|NCT00554788|Experimental|Treatment (chemotherapy, radiotherapy, autologous SCI)|"INDUCTION: Patients receive vincristine IV; cisplatin IV; cyclophosphamide IV; and G-CSF SC beginning on day 3 and continuing until blood counts recover.~CONSOLIDATION (stage 4a or 4b disease only): Patients receive carboplatin IV; thiotepa IV; and etoposide IV.~AUTOLOGOUS STEM CELL INFUSION (stage 4a or 4b disease only): Patients undergo autologous stem cell infusion on day 0 and receive G-CSF SC beginning on day 1 and continuing until blood counts recover.~RADIOTHERAPY: Patients with stage 2 or 3 disease (orbital and/or regional involvement) undergo radiotherapy to sites that were initially involved beginning within 42 days after the start of course 4 of induction chemotherapy. Patients with stage 4a or 4b disease undergo radiotherapy to sites initially involved based on response beginning approximately 42 days after autologous stem cell infusion."
89190792|NCT00431288|Experimental|DASH intervention|The DASH diet used in this intervention was slightly modified from the original version of the DASH diet for adults to more closely conform to the unique nutritional needs of adolescents. Details of the intervention have been published (Couch, SC et al. J Pediatrics 2008; 152: 494-501)
89190793|NCT00431288|Other|Routine Care|Routine care did not deviate from the nutrition counseling that was routinely given to all new patients at the Cincinnati Children's Hypertension Clinic. Details of routine care have been published (Couch, SC et al. J Pediatrics 2008; 152: 494-501)
89190794|NCT00410761|No Intervention|1|Placebo vandetanib
89190795|NCT00410761|Experimental|2|Vandetanib
89190796|NCT00138216|Experimental|Oral Irinotecan, temozolomide and vincristine sulfate|see detailed description
89190797|NCT03548103|Experimental|Green Tea Extract|Green Tea Extract 500 mg per capsule
89405630|NCT04183270||Patients|Non-valvular atrial fibrillation (NVAF) patients who will start treatment with a non-VKA oral anticoagulants (NOAC).
89405631|NCT04183270||Physicians|Treating physicians for NVAF patients.
89405632|NCT05206019|Experimental|cohort 1: Albuvirtide|Single dose of 320 mg by intervenous drop infusion for 45 min
89405633|NCT05206019|Experimental|cohort 2: Albuvirtide|Single dose of 320 mg by intervenous injection for 0.5 min
89405634|NCT05206019|Experimental|cohort 3: Albuvirtide|Single dose of 320 mg by intervenous injection for 3 min
89405635|NCT00696332|Experimental|Talampanel 50mg|50mg Talampanel 3 times per day
88881996|NCT01390311|Experimental|Cohort 1 (Starting Dose)|"Pre-DLI Salvage Chemotherapy (at the discretion of the treating physician)~DLI will be administered 2 +/- 1 weeks after pre-DLI chemotherapy. The minimum CD3+ cell counts in DLI product should be 1 x 107 cells/kg for sibling and ~1 x 106/kg for match unrelated donors based on recipient weight~Azacitidine 45 mg/m2 IV on Days 4, 6, 8, and 10 post-DLI."
88881997|NCT01390311|Experimental|Cohort 2|"Pre-DLI Salvage Chemotherapy (at the discretion of the treating physician)~DLI will be administered 2 +/- 1 weeks after pre-DLI chemotherapy. The minimum CD3+ cell counts in DLI product should be 1 x 107 cells/kg for sibling and ~1 x 106/kg for match unrelated donors based on recipient weight~Azacitidine 75 mg/m2 IV on Days 4, 6, 8, and 10 post-DLI."
88881998|NCT01390324|Experimental|Fixed-dose combination of naratriptan+naproxen|Fixed-dose combination of naratriptan+naproxen
88881999|NCT01390324|Active Comparator|Naratriptan|Naratriptan
88882000|NCT01390324|Active Comparator|Naproxen|Naproxen
89405636|NCT00696332|Experimental|Talampanel 25mg|25mg Talampanel 3 times per day
89405637|NCT00696332|Placebo Comparator|Placebo|placebo 3 times per day
88882001|NCT01390337|Experimental|AC220|
88882002|NCT01390350|Placebo Comparator|Placebo|
88882003|NCT01390350|Experimental|Canakinumab|
88882004|NCT01390363|No Intervention|control|This study arm will receive usual clinical care, but no specific intervention will be made to inform the parent or adolescent that the adolescents is overdue for a routine vaccine.
88882005|NCT01390363|Experimental|Parent Only Group|Parent Only Phone Call
89190798|NCT03548103|Placebo Comparator|Placebo|Identical Placebo capsule
88882006|NCT01390363|Experimental|Parent and Adolescent Group|Parent and Adolescent Phone Call
88882007|NCT01390376|Experimental|BE 1|DAAOI-1 1g
88882008|NCT01390376|Experimental|BE 2|DAAOI-1 2g
88882009|NCT01390376|Placebo Comparator|starch pill|
88882010|NCT01390454|Experimental|Tennis elbow patients|These patients have tennis elbow, according to stated inclusion criteria.
88882011|NCT01390454|Active Comparator|Healthy volunteers|Healthy volunteers are selected and paired according to age, sex, socio-professional category and left- or right-handedness.
88882012|NCT01390480|Placebo Comparator|Placebo|peanut oil
88882013|NCT01390480|Active Comparator|Vitamin D (Oleovit®)|cholecalciferol
88882014|NCT01390493|Experimental|neurofeedback, alpha power|
89405638|NCT04163926|Experimental|Intervention group - Post op follow up by trained optometrist|Intervention group will have cataract follow up conducted by a trained optometrist 4-6 weeks after surgery in community clinic
89405639|NCT04163926|Active Comparator|Usual care group - Consultant led post op follow up|Follow-up at 4-6 weeks after surgery led by consultant ophthalmologist
89405640|NCT05125523|Experimental|Sirolimus for Injection (Albumin Bound)|"Stage 1：Multiple doses of Sirolimus for Injection (Albumin Bound) will be administered intravenously.~Stage 2：RP2D of Sirolimus for Injection (Albumin Bound) as determined during stage 1 will be administered intravenously."
89405641|NCT00625664|Experimental|1|
89405642|NCT00625664|Active Comparator|2|
89405643|NCT03628495|Experimental|SSCP + SPMS|
89405644|NCT03628495|Active Comparator|PG|
89405645|NCT04762264|Active Comparator|Short term post inguinal hernia repair with ProFlor|MRI of the pelvic area in patients who underwent inguinal hernia repair with ProFlor from 1 to 3 months before to assess tissue incorporation into the 3D scaffold
89405646|NCT04762264|Active Comparator|Mid term post inguinal hernia repair with ProFlor|MRI of the pelvic area in patients who underwent inguinal hernia repair with ProFlor from 4 to 7 months before to assess tissue incorporation into the 3D scaffold
89405647|NCT04762264|Active Comparator|Long term post inguinal hernia repair with ProFlor|MRI of the pelvic area in patients who underwent inguinal hernia repair with ProFlor after 8 months and beyond to assess tissue incorporation into the 3D scaffold
89405648|NCT04498858||Patient|
88882015|NCT01390506|Active Comparator|Sodium-selenite infusion|Di-sodium-selenite-pentahydrate (Na 2SeO3.5H2O) in 0,9% sodium chloride is administered intravenously at a does of 3000µg on day 0, 2000µg on day 1 and 2 and at a dose of 1000µg per day on day 3-6.
88882016|NCT01390506|Placebo Comparator|Placebo|0.9% sodium chloride
88882017|NCT01390519||Afinitor|Afinitor
88882018|NCT01390558||Persons with Down Syndrome who use orthotics|Orthotic users
88882019|NCT01390558||Persons with Down Syndrome who do not use orthotics|Non orthotic users
88882020|NCT01390636||ED-DMT1 and ED/only|Eating Disorder and Type 1 Diabetes and only an Eating Disorder
88882021|NCT01390662|Active Comparator|Vitamin D3|one tablet of vitamin D3 (70µg) per day for 24 weeks.
88882022|NCT01390662|Placebo Comparator|placebo|one tablet of sugar pill per day for 24 weeks.
88882023|NCT01390688||Type 2 Diabetes|80 individuals with type 2 Diabetes, confirmed by an OGTT, age 40-65 years, BMI > 18.5 kg/m2 fatsing plasma glucose < 12 mmol/l
88882024|NCT01390688||Impaired glucose tolerance|40 individuals with impaired glucose tolerance. age 40 -65 years, BMI > 18. 5 kg/m2
88882025|NCT01390688||Normal glucose tolerance|80 Individuals without type 2 diabetes Age 40-65 years, BMI >18.5 kg/m2.
88882026|NCT01390701|Experimental|transcutaneous electr. nerve stimulation|
88882027|NCT01390701|Active Comparator|felodipin|
88882028|NCT01390714|Experimental|1|
88882029|NCT01390714|Experimental|2|
88882030|NCT01390727|Placebo Comparator|Listen music|After randomization, the patients allocated in this arm will be instructed to listen to calm music for 15 minutes per day during 8 weeks
88882031|NCT01390727|Active Comparator|Device-guided breathing|After randomization, the patients allocated in this arm will be instructed to use a device-guided breathing, for 15 minutes per day during 8 weeks, with the aim to reduce the respiratory frequency to less than 10 breaths/min
88882032|NCT01390740||Echocardiography|patients with echocardiography
88882033|NCT01390753|No Intervention|Preterm formula|
88882034|NCT01390753|Active Comparator|Donor milk + preterm formula|Human milk from a donor bank
88882035|NCT01390753|No Intervention|Breastfeeding + formula|
88882036|NCT01390753|No Intervention|Breasfeeding|
89190799|NCT03542760||Primary Treated Group|Subjects who are administered methylene blue for treatment of acquired methemoglobinemia that is symptomatic (eg, exhibiting sleepiness, cyanosis, dizziness, etc) or with measured methemoglobin levels > 30%.
89190800|NCT03542760||Secondary Treated Group|Subjects who are administered methylene blue for treatment of acquired methemoglobinemia with measured methemoglobin levels ≤ 30 and lack of clinical symptoms
89405649|NCT05062655|Experimental|Drug reconciliation|Drug reconciliation and transmission to pharmacist
89405650|NCT05062655|No Intervention|standard|
88882037|NCT01390766||Subjects prescribed azathioprine tablet|Subjects prescribed azathioprine tablet during study period after the liver transplantation
88882038|NCT01390792||Subjects prescribed zanamivir|Subjects prescribed zanamivir during study period
88882039|NCT01390805||Subjects with recurrent genital herpes|
88882040|NCT01390831|Experimental|Catheter, Renal Denervation, Ablation|Catheter-based renal denervation and maintenance of anti-hypertensive medications
88882041|NCT01390831|No Intervention|anti-hypertensive medications|Maintenance of anti-hypertensive medications
88882042|NCT01390883||Patients prescribed fondaparinux|Patients undergoing abdominal surgery in urology, obstetrics and gynecology departments prescribed fondaparinux during study period
88882043|NCT01390896||Patients prescribed fondaparinux|Patients undergoing general surgery of the lower limb at high risk for venous thromboembolism
88882044|NCT01390922||Subjects prescribed botulinum injection|Subjects prescribed botulinum injection
88882045|NCT01390935||systolic heart failure|EF under 45%
88882046|NCT01390974||Patients treated for ACS|ACS patients who recently underwent stent PCI, who are stable and eligible for prasugrel or clopidogrel therapy.
88882047|NCT01391039|Experimental|Contrast perfusion and elastography arm|Intravenous injection of microbubble contrast agent and elastography
88882048|NCT01391052|Active Comparator|Norethindrone acetate pretreatment|This arm will receive two cycles of norethindrone acetate before LVN IUS insertion.
88882049|NCT01391052|Other|No pretreatment|LVN IUS is placed without norethindrone acetate pretreatment.
88882050|NCT01391065|Other|1|The study arm will undergo baseline multifunctional PET and MRI scans, before brachytherapy and at follow up
88882051|NCT01391078|Experimental|Sensimed Triggerfish|
88882052|NCT01391078|Active Comparator|Goldmann Applanation Tonometry/Perkins Tonometry|
88882053|NCT01391091|Active Comparator|Patients without history of migraine|Incidence and prevalence of migraine episodes in the post-ablation period
88882054|NCT01391091|Active Comparator|Patients with history of migraine|Incidence and prevalence of migraine episodes in the post-ablation period
88882055|NCT01391104|Experimental|Sildenalfil|Patients will be assigned to sildenafil (20 mg tid) or placebo per os for 28 days in a randomized, double-blind manner. After a four-week wash-out period, patients will then be crossed over to the alternate therapy for the next 28 days.
88882056|NCT01391104|Placebo Comparator|Sugar Pill|Patients will be assigned to sildenafil (20 mg tid) or placebo per os for 28 days in a randomized, double-blind manner. After a four-week wash-out period, patients will then be crossed over to the alternate therapy for the next 28 days.
89190801|NCT03513653||Acute heart failure|Patients hospitalized for acute heart failure and underwent echocardiography with speckle-tracking imaging
89405651|NCT03585322|Experimental|APG-1387 for Injection|APG-1387 will be explored sequentially using a escalation scheme at the dose escalation phase.
89405652|NCT02947165|Experimental|NIS793|
89405653|NCT02947165|Experimental|NIS793 + PDR001|
89405654|NCT02280746|Experimental|A - gluten challenge group|Gluten challenge group - recommended daily intake of at least one normal meal containing gluten such as bread, pita, pasta, biscuits.
89405655|NCT02280746|No Intervention|B - gluten-free diet|Continuation of GFD.
88882057|NCT01391117|Experimental|010|TMC649128 panel 4 arm 2: 10 participants receive PegIFN a-2a/RBV in combination with TMC649128 administered q12h or q24h for 14 days. Actual dose and dose regimen (12h or 24h) is to be selected based on panels 1 2 and 3.
89405656|NCT02283632|Experimental|Jejunal Diversion|all subjects who receive jejunal diversion surgery
89405657|NCT03528382|Experimental|period I group|
89405658|NCT03528382|Experimental|period II group|
89405659|NCT03528382|Experimental|period III group|
89405660|NCT04739839||Inception cohort, former pupils in different schools in Western Zealand|1327 former Western Zealand pupils (originally 1389). Aged 14-15 in 1997. This is the first follow up on this cohort.
89405661|NCT03629093||Long-time anesthesia exposure|Infants receive general anesthetics longer than 3 hours in total.
89405662|NCT03629093||Short-time anesthesia exposure|Infants receive general anesthetics shorter than 3 hours in total.
89405663|NCT02283710|Experimental|Pentoxifylline + lifestyle modification|Pentoxifylline for 6 months plus obtaining ideal body weight by calorie restriction diet and programmed physical activity.
89405664|NCT02283710|Experimental|Lifestyle modification|Obtaining ideal body weight by calorie restriction diet and programmed physical activity.
89405665|NCT04739293|Experimental|ON 123300|ON 123300 capsules at increasing doses per cohort, starting at 40 mg
89405666|NCT04425304|Active Comparator|Group counseling|
89405667|NCT04425304|Experimental|Group counseling + persuasive ICT support|
89405668|NCT04425304|Active Comparator|Intensive group counseling|
88882058|NCT01391117|Experimental|001|TMC649128. panel 1: 8 participants receive a q24h regimen at 1000 mg of TMC649128.
89004433|NCT04397458|Sham Comparator|Sham Control|20 milliliters (mL) 0.9% saline on each side
89405669|NCT04425304|Experimental|Intensive group counseling + persuasive ICT support|
89405670|NCT00506792|Experimental|1|QAU145
89405671|NCT00506792|Placebo Comparator|2|Placebo
88882059|NCT01391117|Placebo Comparator|002|placebo. panel 1: 2 participants receive placebo at a q24h regimen.
88882060|NCT01391117|Experimental|003|TMC649128. panel 2 arm 1: 8 participants receive a q12h regimen of TMC649128 at a selected dose based on results of panel 1.
88882061|NCT01391117|Placebo Comparator|004|placebo. panel 2 arm 1: 2 participants receive placebo at a q12h regimen.
88882062|NCT01391117|Experimental|005|TMC649128. panel 2 arm 2: 8 participants receive a q24h regimen TMC649128 at a dose based on results of panel 1.
88882063|NCT01391117|Placebo Comparator|006|placebo. panel 2 arm 2: 2 participants receive placebo at a q24h regimen.
89405672|NCT03507010|Experimental|Radiotherapy|Patients assigned to the Radiotherapy group are treated with electrons and will receive a total dose of 30 Gy.
89405673|NCT03507010|Placebo Comparator|Sham Radiotherapy|Patients assigned to the sham-radiotherapy group will not actually receive radiation. For these patients the radiation is simulated.
89405674|NCT05043311|Experimental|Experimental: 20 µg dose, 18-59 years of age (phase 1/2)|
89405675|NCT05043311|Experimental|Experimental: 20 µg dose, ≥60 years of age (phase 1/2)|
89405676|NCT05043311|Experimental|Experimental: 40 µg dose, 18-59 years of age (phase 1/2)|
89405677|NCT05043311|Experimental|Experimental: 40 µg dose, ≥60 years of age (phase 1/2)|
89405678|NCT05043311|Placebo Comparator|Placebo Comparator: Placebo, 18-59 years of age (phase 1/2)|
89405679|NCT05043311|Placebo Comparator|Placebo Comparator: Placebo, ≥60 years of age (phase 1/2)|
89405680|NCT03258164|Experimental|ASC|
89405681|NCT03258164|Active Comparator|Control|
89405682|NCT03943342|Experimental|Treatment (venetoclax, ibrutinib)|"OBSERVATION COHORT: Patients who are taking ibrutinib enter observation cohort and undergo screening every 3 months for development for genetic mutations. If mutations develop, patients undergo increased screening for development of clinical disease progression. Patients who develop clinical disease progression with or without mutations enter the Intervention cohort.~INTERVENTION COHORT: Patients receive venetoclax PO daily and ibrutinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who achieve MRD negative CR after 12 or 24 cycles continue receiving ibrutinib PO QD on days 1-28 in the absence of disease progression or unacceptable toxicity."
89405683|NCT02280824|Experimental|A|Transcaval acesss for transcatheter aortic valve replacement in patients with no good options for aortic access
89405684|NCT01415323||Acutely admitted psychiatric in-patients|
89405685|NCT01569893|No Intervention|Control group|Usual care: treatment as usual
89405686|NCT01569893|Experimental|Self-monitoring for patients with Dibetes mellitus type 2|Self-monitoring for patients with Dibetes mellitus type 2
89405687|NCT03837964|Experimental|Treatment T|Fed
89405688|NCT03837964|Experimental|Treatment R|Fasted
89405689|NCT00694928|Experimental|1|clindamycin phosphate/butoconazole nitrate
89405690|NCT00694928|Active Comparator|2|butoconazole nitrate
89405691|NCT04424368|Experimental|The remote monitoring system|A group of patients, who had myocardial infraction and who has a very high risk of developing an unfavorable prognosis, which are followed up in the local outpatient department according to existing clinical recommendations and using remote monitoring system.
89405692|NCT04424368|No Intervention|Clinical recommendations|A group of patients, who had myocardial infraction and who has a very high risk of developing an unfavorable prognosis, which are followed up in the local outpatient department according to existing clinical recommendations.
89405693|NCT03737591||Healthy individuals|Healthy individuals
89405694|NCT03737591||Patients with Colorectal cancer|Stage I-IV colorectal cancer patients
89405695|NCT03737591||Patients with Colorectal Adenomas|Patients with Colorectal Adenomas
89405696|NCT04758754|Experimental|Single leg knee extension training (SLKE)|Active 8-week training involving lower limbs. SLKE participants will be involved in a 8-week aerobic training protocol involving the knee extensor muscles. The training will be held on an Anderson and Saltin ergometer, 3 times per week, with a single session duration of 33.3 min. Total weekly duration: 100 min.
88882064|NCT01391117|Experimental|007|TMC649128 panel 3: 8 participants receive TMC649128. Actual dose and dose regimen (q12h or q24h) to be selected based on the results of the panels 1 and 2.
89405697|NCT04758754|Active Comparator|Passive static stretching training (PST)|Passive 8-week training involving lower limbs. PST participants will be involved in a 8-week passive static training training involving the knee extensor muscles. The training will have a frequency of 5 times per week, with a single duration of 20 min. Total weekly duration: 100 min
89405698|NCT04758754|No Intervention|Control (CTRL)|CTRL will not receive any intervention.
89405699|NCT00694382|Experimental|Semuloparin|Semuloparin sodium 20 mg once daily until change in chemotherapy regimen
89405700|NCT00694382|Placebo Comparator|Placebo|Placebo (for semuloparin) once daily until change in chemotherapy regimen
89405701|NCT05116228|Active Comparator|500mg RTX Group|Patients in this group will receive 1x500mg (500mg RTX group) RTX (Mabthera) at baseline (time-point of their upcoming semi-annual infusion) and at months 6, 12, 18 and 24
88882065|NCT01391117|Placebo Comparator|008|placebo. panel 3: 2 participants receive placebo. Actual dose and dose regimen (q12h or q24h) to be selected based on the results of the panels 1 and 2.
88882066|NCT01391117|Placebo Comparator|009|placebo panel 4 arm 1: 10 participants receive PegIFN a-2a/RBV in combination with placebo administered q12h or q24h for 14 days. Actual dose and dose regimen (12h or 24h) is to be selected based on panels 1 2 and 3.
88882067|NCT01391156|Experimental|Minoxidil|
88882068|NCT01391156|Active Comparator|MinoxidilFinasteride|
88882069|NCT01391169|Active Comparator|1sup group|enforcement of the anastomoses with seromuscular flap
88882070|NCT01391169|Placebo Comparator|2nd group|primary anastomosis without enforcement
89405702|NCT05116228|Active Comparator|1000mg RTX group|Patients in this group will receive 1x1000mg RTX (Mabthera) at baseline (time-point of their upcoming semi-annual infusion) and at months 6, 12, 18 and 24
88921974|NCT06003543|Experimental|Virtual Reality|virtual glasses will be applied
88921975|NCT06003543|No Intervention|Control|no application will be made
89405703|NCT05205395||Women with stress incontinence|Women with urodynamic stress incontinence (USI) scheduled for mid-urethral sling surgery in the urogynecological department of a tertiary referral center were recruited.
89405704|NCT05116150|Active Comparator|Randomized double blind grape seed extract design|Grape see extract
89405705|NCT05116150|Placebo Comparator|Randomized double blind placebo design|Placebo
89405706|NCT01346293|Experimental|Study Group 1|Participants will receive concomitantly a dose of DTap-IPV, a dose of M-M-R®II, and a dose of VARIVAX® vaccine on Day 0
89405707|NCT01346293|Experimental|Study Group 2|Participants will receive concomitantly a dose of DAPTACEL®, a dose of IPOL®, a dose of M-M-R®II, and a dose of VARIVAX® vaccines on Day 0
89405708|NCT01346293|Experimental|Study Group 3|Participants will receive concomitantly a dose of DTap-IPV with or without a dose of M-M-R®II and a dose of VARIVAX® on Day 0
89405709|NCT01346293|Experimental|Study Group 4|Participants will receive concomitantly a dose of DAPTACEL® vaccine, a dose of IPOL® vaccine with or without a dose of M-M-R®II and a dose of VARIVAX® vaccines on Day 0
89405710|NCT04989101|Active Comparator|Nigelle Group|The candidate must take one capsule / day of nigella 5 for 21 days (1 bottle). Follow-up should be done weekly for 1 month.
89405711|NCT04989101|No Intervention|Placebo Group|Follow-up should be done weekly for 1 month.
89405712|NCT04200664||Siderosis (iSS) group|participants with a known diagnosis of infratentorial superficial siderosis (defined using standardised radiological criteria) confirmed by a consultant neurologist with expertise in this condition at University College London Hospitals National Health Service (NHS) Foundation Trust
89405713|NCT04200664||Age-related hearing loss (ARHL) group|participants with age-related hearing loss (as identified from participant's clinical history and examination, with hearing thresholds confirmed on a pure-tone audiogram)
89405714|NCT04200664||Control group|participants with no known or previously reported hearing loss (as identified from participant's clinical history and examination, with hearing thresholds confirmed on a pure-tone audiogram)
89405715|NCT04940351|Experimental|GROUP - A: PIEZOCISION GROUP|This group will receive piezocision using piezotome inbetween the roots of mandibular anteriors after the placement of initial arch wire.
89405716|NCT04940351|Experimental|GROUP- B: MICRO-OSTEOPERFORATION GROUP|This group will receive Micro-Osteoperforation using orthodontic mini-implants and mini-implant screw driver after the placement of initial arch wire.
89405717|NCT05115916|No Intervention|Standard of Care|This group will receive standard FIT mailer protocol (includes mailed FIT kit plus standardized messaging via EHR portal)
89405718|NCT05115916|Experimental|MyChart Message|This group will receive a message via EHR portal informing them about the incoming FIT Kit
89405719|NCT05115448|Other|Bevel Up|In the patients who participated in the study, cannulation was applied to the fistula with the needle direction antegrade and the needle pointing upwards for the first 6 sessions, and the needle direction antegrade and the needle tip facing down for the next 6 sessions. The cannulation procedure was performed by the same nurse for each patient who participated in the study.
89405720|NCT05115448|Other|Bevel Down|In the patients who participated in the study, cannulation was applied to the fistula with the needle direction antegrade and the needle pointing downwards for the next 6 sessions. The cannulation procedure was performed by the same nurse for each patient who participated in the study.
89405721|NCT00136903|Active Comparator|Prochymal® - 2 Million cells/kg|Participants will receive Prochymal® consisting of 2 million hMSCs/kg actual body weight, intravenously (IV) on Days 1 and 4 along with daily standard of care which includes methylprednisolone 2 milligrams (mg)/kg IV or prednisone 2.5 mg/kg orally. Participants will also continue cyclosporine, tacrolimus, and/or mycophenolate mofetil (MMF) at full therapeutic doses.
89405722|NCT00136903|Active Comparator|Prochymal® - 8 Million cells/kg|Participants will receive Prochymal® consisting of 8 million hMSCs/kg actual body weight IV on Days 1 and 4 along with daily standard of care which includes methylprednisolone 2 mg/kg IV or prednisone 2.5 mg/kg orally. Participants will also continue cyclosporine, tacrolimus, and/or mycophenolate mofetil (MMF) at full therapeutic doses.
89405723|NCT04917029|Active Comparator|Active:Group A|Group A: receive 40 ml bupivacaine 0.25% +5 ml placebo in FICB perineurally in generally anaesthetized patients with intravenous infusion of 0.5 µg/kg/h of Dexmedetomidine.
89405724|NCT04917029|Active Comparator|(Group B|Group B: receive FICB with dexmedetomidine 80µg diluted in 5 ml normal saline and 40 ml bupivacaine 0.25% added perineurally in generally anaesthetized patients without dexmedetomidine infusion.
89405725|NCT04189510|Experimental|Artificial Pancreas (AP) Insulin Group|
89405726|NCT04189510|Active Comparator|Multiple Daily Injections (MDI) Insulin Group|
89405727|NCT04098952|Active Comparator|Group 1: Manual Therapy|The treatment techniques used will be: ischemic compression in the trigger point of the masseter and soft-tissue release technique over the temporal region.
89405728|NCT04098952|Experimental|Group 2: Interferential massage plus Manual Therapy|In addition to the treatment techniques applied to the other group, an electric massage will be performed with interferential currents at the level of the cervical region.
89405729|NCT03654131|Active Comparator|MWA|Percutaneous ultrasound-guided MWA or open surgery MWA. The patient is fully anesthetized during the treatment.
89405730|NCT03654131|Active Comparator|SBRT|3 fractions of 15 Gy (in total 45 Gy), 3 fractions per week. The dose is prescribed to the PTV encompassing 67% isodose. The SBRT plan is normalized such that the mean dose to the GTV is 100% = 67.5 Gy.
89405731|NCT00500084|Experimental|Liprotamase|Liprotamase is a fixed combination of lipase (32,500 units), protease (25,000 units) and amylase (3,750 units) administered orally with each of three meals and two snacks daily for 12 months
89004434|NCT04397458|Experimental|Quadratus Lumborum Block|20 mL solution with 0.25% bupivacaine (50 milligrams (mg)) and 3mg preservative-free dexamethasone on each side
89004435|NCT04390425|No Intervention|Control - Standard pneumatic tourniquet pressure|This group receives the standard pneumatic tourniquet pressure during surgery like they would during standard of care.
89004436|NCT04390425|Experimental|Experimental - Limb occlusion pressure|This group receives a slightly lower tourniquet pressure than they would during standard of care. This lowered limb occlusion pressure is determined by the tourniquet device.
89405732|NCT03471520|Experimental|Earplugs and eye masks|
89405733|NCT03060902|Experimental|Dialectical Behavior Therapy Skills|Dialectical Behavior Therapy SKills; 2.5 hour group session/week; 1 year
89405734|NCT03060902|No Intervention|Family Services as Usual|Mothers will continue with services they are receiving in the community
89405735|NCT03632759|Experimental|Liraglutide|Participants will receive subcutaneous (SC) liraglutide for 8 weeks
89405736|NCT03632759|Experimental|Golimumab|Participants will receive subcutaneous (SC) golimumab for 8 weeks
89405737|NCT03047083||IC eligible AML patients with FLT3 mutation|Newly diagnosed AML patients
89405738|NCT03047083||IC ineligible patients with FLT3 mutation|Newly diagnosed AML patients
89405739|NCT03047083||AML patients after R/R with FLT3 mutation|R/R are relapse/refractory patients
89405740|NCT03047083||IC eligible patients without FLT3 mutation|Newly diagnosed AML patients
89405741|NCT03047083||IC ineligible patients without FLT3 mutation|Newly diagnosed AML patients
88813524|NCT01729052|Experimental|Acupuncture and standard treatment|"Acupuncture at Neiguan (Pericardium-6) bilaterally with Seirin needles no 3 (0.20x15 mm) to a depth of approximately 7 mm will be performed on the children immediately after induction of anaesthesia and removed before they are fully awake.~Standard treatment: general anaesthesia"
88813525|NCT01729052|No Intervention|Standard treatment|General anaesthesia
88813526|NCT01729130||Group 1 Pancreas/kidney transplant|Group 1 of patients with End Stage Renal Disease (ESRD) and Diabetes Mellitis who will receive a pancreas and kidney transplant. An adipose tissue biopsy and blood samples are collected at time of transplant surgery. A repeat adipose tissue needle biopsy and blood samples are collected between 3-12 months post transplant.
88813527|NCT01729130||Group 2 DM with kidney transplant|Group 2 are patient with DM and ESRD and who will receive only a kidney transplant.
88813528|NCT01729130||Group 3 No DM and kidney transplant|Group 3 will be patients who do not have DM but do have the diagnosis of ESRD and will receive only a kidney transplant.
88813529|NCT03407378|Experimental|Assessments ON regular PD treatment|IPT803 Questionnaires Motor assessments on regular PD treatment Optional pharmacogenetic assessments Optional Blood-Oxygen-level Dependent Functional-MRI
88813530|NCT03407378|Experimental|Assessments OFF regular PD treatment|IPT803 Questionnaires Motor assessments before taking regular PD treatment Optional pharmacogenetic assessments Optional Blood-Oxygen-level Dependent Functional-MRI
88882071|NCT01391182|Active Comparator|EACA arm|In order to obtain sufficient power, a total of 120 patients will be studied, 60 in each group. The surgeon performing the case, their staff, the anesthesiologist, nurse anesthetist and the patient will be blinded to whether the patient received EACA or placebo. Pharmacy will prepare the EACA dose or the saline. Serum hemoglobin levels with be drawn preoperatively and on post operative days one, two, and three. The first dose will be given in the operating room prior to incision (within 30 minutes of the incision). The second dose will be given four hours after the first dose. Two doses are given due to the short half-life of EACA. The timing of administration of EACA will be recorded.
88882072|NCT01391182|Placebo Comparator|Placebo arm|In order to obtain sufficient power, a total of 120 patients will be studied, 60 in each group. The surgeon performing the case, their staff, the anesthesiologist, nurse anesthetist and the patient will be blinded to whether the patient received EACA or placebo. Pharmacy will prepare the EACA dose or the saline. Serum hemoglobin levels with be drawn preoperatively and on post operative days one, two, and three. The first dose will be given in the operating room prior to incision (within 30 minutes of the incision). The second dose will be given four hours after the first dose. Two doses are given due to the short half-life of EACA. The timing of administration of EACA will be recorded.
88882073|NCT01391195|Experimental|Laser therapy and aerobic capacity|Effects of low level laser therapy on aerobic capacity of young women submitted to endurance training
88882074|NCT01391208|No Intervention|peptide application|
88882075|NCT01391221|Experimental|Duloxetine treatment|Subjects with major depression will be entered into the trial and treated with open label duloxetine
88882076|NCT01391247||healthy age machted controls|
88882077|NCT01391247||normal tension glaucoma patients|
88882078|NCT01391247||primary open angle glaucoma patients|
88882079|NCT01391260|Experimental|Radiotherapy Combined With Gefitinib|
88882080|NCT01391338|Experimental|Lowest dose ASP3652 twice daily|
88882081|NCT01391338|Experimental|Low dose ASP3652 twice daily|
88882082|NCT01391338|Experimental|Medium dose ASP3652 twice daily|
89190802|NCT03496792|Experimental|Tilt + external pressure|"Tilt + external pressure on legs performed in both BP elevated with standing and BP maintained with standing groups."
88882083|NCT01391338|Experimental|High dose ASP3652 once daily|
88882084|NCT01391338|Experimental|High dose ASP3652 twice daily|
88882085|NCT01391338|Placebo Comparator|Placebo|
88882086|NCT01391351|Other|Taxol and carboplatin|blood samples in patients receiving Taxol and carboplatin chemotherapy
88882087|NCT01391351|Other|Taxol, carboplatin and avastin|blood samples in patients receiving Taxol, carboplatin chemotherapy with avastin
88882088|NCT01391377|Active Comparator|Niacin / Laropiprant|
88882089|NCT01391377|Placebo Comparator|Sugar Pill (Placebo)|
88882090|NCT01391390|Experimental|Melatonin, antioxidant, oxidative stress|Melatonin is an active treatment for TD.
88882091|NCT01391390|Placebo Comparator|Placebo|Placebo look like the active drug, and same dose.
88882092|NCT01391403|Experimental|Artemisinin, anti-toxoplasma|Artemisinin
88882093|NCT01391403|Placebo Comparator|Placebo|Placebo looks like the active drug, with the same dose.
88882094|NCT01391416||CKD stage 3-4|CKD stage 3-4 from Thai SEEK study
89190803|NCT03496792|Placebo Comparator|Tilt + no external pressure|"Tilt + no external pressure performed in both BP elevated with standing and BP maintained with standing groups."
88882095|NCT01391416||hyperhomocysteine group|CKD stage 3-4 from Thai SEEK study
88882096|NCT01391429|Experimental|Video decision support tool|Video decision support tool for goals-of-care options
88882097|NCT01391429|No Intervention|Verbal description|Standard verbal description of goals-of-care options provided by an inpatient palliative care team
88882099|NCT01391455|No Intervention|Spermatic Cord in contact with mesh|Where the spermatic cord has been allowed to remain in contact with the mesh.
88882100|NCT01391455|Experimental|Spermatic Cord is isolated from the mesh|The inguinal ligament is interposed between the cord and the mesh and then repaired. This isolates the cord from the mesh and the splinting function of the overlying inguinal ligament.
88882101|NCT01391481|Experimental|Perfluorocarbon|
88882102|NCT01391481|Placebo Comparator|Sterile Water for Injection|
88882103|NCT01389934|Placebo Comparator|Control|Women of this group be infused saline 2 ml / h for 48h.
88882104|NCT01389934|Experimental|levo-bupicaine|Women of this group will be infused L-bupivacaine 0.50% 2 ml / h for 48h.
88882105|NCT01391494|Experimental|160Eu/0.5ml in adults|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 12 adults aged 18-49 years old on day 0, 14.
88882106|NCT01391494|Experimental|320Eu/0.5ml in adults|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 12 adults aged 18-49 years old on day 0, 14.
88921976|NCT06003049|Active Comparator|Treatment Arm|OnabotulinumtoxinA
89190804|NCT03496792|Experimental|Limb occlusion + negative pressure|"Limb occlusion + negative pressure performed in both BP elevated with standing and BP maintained with standing groups."
88882107|NCT01391494|Experimental|640Eu/0.5ml in adults|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 12 adults aged 18-49 years old on day 0, 14.
88882108|NCT01391494|Experimental|1280Eu/0.5ml (without adjuvant) in adults|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 12 adults aged 18-49 years old on day 0, 14.
88882109|NCT01391494|Placebo Comparator|0Eu/0.5ml in adults|0Eu/0.5ml placebo in 24 adults aged 18-49 years old on day 0, 14.
88921977|NCT06003049|Placebo Comparator|Placebo Arm|Normal saline
89190805|NCT03496792|Placebo Comparator|Limb occlusion + no negative pressure|"Limb occlusion + no negative pressure performed in both BP elevated with standing and BP maintained with standing groups."
89190806|NCT03487224||Hoarding Disorder|Adults diagnosed with Hoarding Disorder
89190807|NCT03487224||Healthy Controls|Adults without mental illness
89405742|NCT03047083||AML patients after R/R without FLT3 mutation|R/R are relapse/refractory patients
89405743|NCT00498914|Experimental|1|
89405744|NCT02953093|Other|Acarbose first|Participants will take acarbose three times daily for 10 weeks (titration over 4 weeks, maintenance 6 weeks). After a two week washout, participants will take placebo three times daily for a total of 10 weeks (titration over 4 weeks, maintenance 6 weeks).
89190808|NCT03477292|Experimental|Long duration of antibiotics|14 days of Colistin
89190809|NCT03477292|Active Comparator|Short duration of antibiotics|7 days of Colistin
89190810|NCT03471650|Experimental|18F-DCFPyL Injection|A bolus of ~9 mCi (333 MBq) of 18F-DCFPyL will be injected by slow IV push.
89190811|NCT03465540|Experimental|Part 1A: AMG 397 Dose Escalation|This arm includes subjects with multiple myeloma (MM) or non-Hodgkin's lymphoma (NHL).
89190812|NCT03465540|Experimental|Part 1B: AMG 397 Dose Escalation|This arm includes subjects with acute myeloid leukemia (AML).
89190813|NCT03465540|Experimental|Part 2A: AMG 397 Monotherapy|This arm includes subjects with AML or myelodysplastic syndrome (MDS).
89405745|NCT02953093|Other|Placebo first|Participants will take placebo three times daily for 10 weeks (titration over 4 weeks, maintenance 6 weeks). After a two week washout, participants will take acarbose three times daily for a total of 10 weeks (titration over 4 weeks, maintenance 6 weeks).
88813531|NCT03407300|Active Comparator|Docetaxel|Stage III-IV NSCLC patients who failed first-line chemotherapy will be treated with Docetaxel alone.
88813532|NCT03407300|Active Comparator|Docetaxel plus XH1|Stage III-IV NSCLC patients who failed first-line chemotherapy will be treated with Docetaxel plus Chinese traditional medicine XH1.
88813533|NCT01729286|Active Comparator|PriMatrix Moist Wound Therapy|sharp debridement, Primatrix, a dressing regimen that maintains a moist wound healing environment, and offloading
88813534|NCT01729286|Other|Standard of Care Moist Wound Therapy|sharp debridement, a dressing regimen that maintains a moist wound healing environment, and offloading
88813535|NCT01729364|Experimental|crystalloid|crystalloid fluid administration, Ringer-acetat 20ml/kg under 30 minutes
88813536|NCT01729364|Experimental|colloid|colloidal fluids administration, HES 6% (130/0,4) 7ml/kg under 30 minutes
88813537|NCT01722968|Active Comparator|Arm A|Arm A and feasibility phase: Bevacizumab 15mg/kg administered iv every 3 weeks in combination with paclitaxel 80mg/m2 iv weekly.
88813538|NCT01722968|Active Comparator|Arm B|Arm B: Paclitaxel 80mg/m2 iv weekly.
88813539|NCT03407222|Active Comparator|Intervention group|Intervention group receives weekly text messages which encourage the increment of daily step count
88813540|NCT03407222|No Intervention|Control group|Control group does not receive text message
88813541|NCT01723046|Experimental|Training with the device|Training with new upper limb robot assisted therapy device
88813542|NCT01723046|No Intervention|Control group|The control group is treated with conventional therapy.
88813543|NCT01729442|Other|Patients referred for first-line prostate HIFU ablation|10 patients
88813544|NCT01729442|Other|Patients referred for first-line HIFU hemi-ablation|10 patients
88813545|NCT01729442|Other|Patients referred for salvage HIFU after radiotherapy|10 patients
89190814|NCT03465540|Experimental|Part 2B: AMG 397 Monotherapy|This arm includes subjects with AML in Japan only.
88882110|NCT01391494|Experimental|160Eu/0.5ml in children|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 12 children aged 3-11 years old on day 0, 14.
88882111|NCT01391494|Experimental|320Eu/0.5ml in children|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 12 children aged 3-11 years old on day 0, 14.
89190815|NCT03465540|Experimental|Part 2C: AMG 397 Monotherapy|This arm includes subjects with MM.
89190816|NCT03465540|Experimental|Part 3A: AMG 397 + Azacitidine Combotherapy|This arm includes subjects MDS.
89190817|NCT03465540|Experimental|Part 3B: AMG 397+ Azacitidine Combotherapy|This arm includes subjects AML.
89190818|NCT03465540|Experimental|Part 3C: AMG 397+ Dexamethasone Combotherapy|This arm includes subjects MM.
89190819|NCT03462316|Experimental|NY-ESO-1 TCR Specific T cell Therapy|NY-ESO-1 TCR specific T cells are prepared by lentiviral infection. Seven days before TCR-T cell reinfusion, the subjects received low-dose cyclophosphamide (15mg/kg/d x 3 days) and low-dose fludarabine (15mg/m2/d x 3 days) lymphocyte clearance. Four days later, TCR-T cells were transfused back (1 x 109-5 x 1010 was administered once or in stages). Then interleukin (IL)-2 subcutaneous injections (250,000 IU/twice/day) will be subcutaneously administered for 14 days concomitantly to each subject within 15-30 minutes after cell reinfusion. If the first three patients had no severe bone marrow suppression side effects (CTCAE was above grade 3) on low-dose lymphocyte clearance therapy, the dosage of cyclophosphamide (20 mg/kg/d x 3 days) and fludarabine (25 mg/m2/d x 3 days) could be increased for follow-up patients.
89190820|NCT03420404|Experimental|Collaborative care with TCM physicians|TCM physician involved collaborative care model (TCMCMC): The intervention arm will involve the TCM physician in the management of patients with AxSpA in addition to the usual rheumatological care.
89190821|NCT03420404|No Intervention|Usual care only|The attending rheumatologist will prescribe a variety of treatment inclusive of medications such as non-steroidal anti-inflammatory drugs and physiotherapy.
89190822|NCT03397108||Women with IBD|This group is composed of breastfeeding women aged over 18 years and in their first 4-month postpartum period, who are diagnosed with Crohn's disease or Ulcerative Colitis.
89190823|NCT03397108||Healthy breastfeeding women|This group is composed of healthy breastfeeding women aged over 18 years and in their first 4-month postpartum period.
89190824|NCT03368547|Experimental|Diagnostic (68Ga-PSMA-11, PET/CT)|Patients receive 68Ga-PSMA-11 IV and undergo PET/CT scan over 20-50 minutes on day 1.
89190825|NCT03338309||iFR-guied strategy group|1,200 patients with suspected ischemic heart disease including stable angina, or acute coronary syndrome including unstable angina, non ST-segment elevation MI, or ST-segment elevation MI with non-culprit stenosis who underwent iFR measurement and enrolled at 5 centers in Republic of Korea.
88813546|NCT03406910||Seventh day Adventist adults|Seventh day Adventist adults recruited from the USA and Canada. Approximately 65% female and 35% male. Composed of participants with different dietary patterns and a wide variation in egg and meat intake ranging from non-consumptive to daily consumption.
88813547|NCT01729520|Experimental|Knee extension strength training|
88813548|NCT01729676||Group A|Degarelix or gonadotrophin releasing hormone (GnRH) agonist for treatment of prostate cancer according to physicians current practice
88813549|NCT04379180||Treatment(bosentan, sildenafil and tadalafil)|
88813550|NCT03406754||Ezera LaMarpeh rehabilitation programs|Participation in a rehabilitation program for 8 weeks
88813551|NCT01576523|Experimental|Low, then medium, C1-esterase inhibitor dose|
88813552|NCT01576523|Experimental|Medium, then low, C1-esterase inhibitor dose|
88813553|NCT01576523|Experimental|Medium, then high, C1-esterase inhibitor dose|
88813554|NCT01576523|Experimental|Low, then high, C1-esterase inhibitor dose|
88813555|NCT01576523|Experimental|High, then low, C1-esterase inhibitor dose|
88813556|NCT01576523|Experimental|High, then medium, C1-esterase inhibitor dose|
88813557|NCT01723124|Experimental|Molecular Breast Imaging|Molecular Breast Imaging (MBI) utilizes small high resolution gamma camera detectors in a dual-detector configuration to image the breast following the administration of a radiopharmaceutical that accumulates preferentially in breast tumors.
88813558|NCT03406676|Experimental|Methylene blue|2mg / Kg of methylene blue in volume of 50ml is administrated I.V before anesthesia induction.
88813559|NCT03406676|No Intervention|saline|50ml of saline is administrated I.V before anesthesia induction.
88813560|NCT03007667||Colorectal cancer patients|Colorectal cancer patients
88813561|NCT03406598||Patients in shock|Analysis of sublingual microcirculation by nurses in ICU patients in shock to predict needs for fluid challenge, vasopressors or transfusion.
88813562|NCT04378946|Experimental|Experimental - Error Augmented feedback (Restricted area)|Error augmented feedback. Random targets always INSIDE of workspace area.
88813563|NCT04378946|Active Comparator|Control - General feedback (Full area)|General feedback about task success. Random target INSIDE or OUTSIDE of workspace area.
88813564|NCT03001739|Experimental|Intensive BP control (<120mmHg)|Urapidil Hydrochloride Injection (100-400ug/min) or other antihypertensive agents to decrease the BP to < 120 mm Hg
88813565|NCT03001739|Active Comparator|Conventional BP control (120-140mmHg)|Urapidil Hydrochloride Injection (100-400ug/min) or other antihypertensive agents to decrease the BP to 120-140 mm Hg
88813566|NCT03001583|Experimental|Education Program with cooking lessons|Structured education program of mediterranean diet and lifestyle changes with cooking lessons delivered in monthly visits for an induction phase of 6 months, with an extension period of up to two years.
88813567|NCT03001583|Active Comparator|Education without cooking|Structured education program of mediterranean diet and lifestyle changes WITHOUT cooking lessons delivered in monthly visits for an induction phase of 6 months, with an extension period of up to two years.
88813568|NCT01729832|Experimental|Supportive care (image-guided breast reconstruction)|Patients undergo DIEP flap breast reconstruction using the StealthStation navigation system.
88882112|NCT01391494|Experimental|640Eu/0.5ml in children|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 12 children aged 3-11 years old on day 0, 14.
89405746|NCT04518280|Experimental|Group A|The patients will receive short-course radiotherapy (25Gy/5Fx), followed by 6 cycles of CAPOX and PD-1 antibody. TME surgery is scheduled after TNT while a W&W option can be applied to patients achieving cCR.
88882113|NCT01391494|Experimental|1280Eu/0.5ml (without adjuvant) in children|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 12 children aged 3-11 years old on day 0, 14.
88882114|NCT01391494|Placebo Comparator|0Eu/0.5ml in children|0Eu/0.5ml placebo in 24 children aged 3-11 years old on day 0, 14.
88882115|NCT01391494|Experimental|160Eu/0.5ml in infants|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 24 infants aged 6-35 months old on day 0, 28.
88882116|NCT01391494|Experimental|320Eu/0.5ml in infants|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 24 infants aged 6-35 months old on day 0, 28.
88882117|NCT01391494|Experimental|640Eu/0.5ml in infants|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 24 infants aged 6-35 months old on day 0, 28.
88882118|NCT01391494|Experimental|1280Eu/0.5ml (without adjuvant) in infants|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 24 infants aged 6-35 months old on day 0, 28.
88882119|NCT01391494|Placebo Comparator|0Eu/0.5ml in infants|0Eu/0.5ml placebo in 48 infants aged 6-35 months old on day 0, 28.
88882120|NCT01391520|Experimental|CRMD001-Deferiprone|CRMD001 represents unique formulations of Deferiprone. Subjects will be given one (900 mg) immediate release and two (900 mg) extended release tablets 1-3 hours prior to angiography and then every 12 hours for a total of 8 days
88882121|NCT01391520|Placebo Comparator|Placebo|3 placebo tablets matching the appearance of the experimental treatment arm (CRMD001) will be given every 12 hours for a total of 8 days, beginning 1-3 hours prior to angiography
89190826|NCT03336931||High-risk childhood cancers|Expected survival < 30%
89190827|NCT03319407|Other|Observation|All participants will be monitored with EPAD system
89190828|NCT03270150|Experimental|BTL-899 Therapy Arm|BTL-899 therapy, 3 therapies
89190829|NCT03262155||ECMO / ECLS|Patients hospitalized for ARDS or Cardiogenic shock with ECMO / ECLS
89190830|NCT03262155||No ECMO / ECLS|Patients hospitalized for ARDS or Cardiogenic shock without ECMO / ECLS
88882122|NCT01391533|Experimental|Dose Escalation|Dose escalation phase: The starting dose of SAR125844 will be 50 mg/m^2 up to 960 mg/m^2
89190831|NCT03217227||Healthy Volunteer|"Healthy Volunteers will undergo the following study procedures:~Cardiovascular Magnetic Resonance Imaging with Exercise Bike~Blood Sampling~Activity and Lifestyle Questionnaires~Fat Mass Measurement"
88882123|NCT01391572|Experimental|A|After esophagectomy, patients in Arm A will receive Large field radiation (tumor bed + ENI (elective nodal irradiation)) + Sequential chemotherapy
88882124|NCT01391572|Active Comparator|B|After esophagectomy, patients in Arm B will receive small field radiation (tumor bed only) + Sequential chemotherapy
88882125|NCT01391585|Experimental|text message recipients|Patients will be recruited to receive text messages
89190832|NCT03217227||Patients with Stable Angina|"Patients will undergo the following study procedures:~Cardiovascular Magnetic Resonance Imaging with Exercise Bike~Blood Sampling~Cardiac Catheterization~Activity, Lifestyle and Medication Compliance Questionnaires~Fat Mass Measurement~Retinal Photography (Optional)~I123 MIBG scan (Optional)"
89190833|NCT03209414||Stable coronary artery disease|Patients with stable effort angina wil be enrolled. Based on coronary angiography, heart team will decide on medical, percutaneous angioplasty, or bypass grafting.
88882126|NCT01391598|Active Comparator|Lidocaine|After completion of the inclusion criteria all patients receive a dose of amitriptyline 12.5 mg in the first week, and 25 mg in the eight subsequent weeks, orally, once daily at night. At lidocaine group 20 pacients will receive lidocaine at a dose of 4 mg / kg, not exceeding a dose of 240 mg diluted in 125ml of solution 0.9% saline.The solutions will be infused in 1 hour once a week in the four weeks following the start of the study..:Patients may use as additional analgesics up to 4g/day acetaminophen, and if necessary, they can use tramadol, recording the dose
89004437|NCT04387162|Experimental|Immediate|Participants will enter treatment after one week baseline
89190834|NCT03209414||Unstable coronary artery disease|Patients with unstable angina wil be enrolled. Based on coronary angiography, heart team will decide on medical, percutaneous angioplasty, or bypass grafting.
89190835|NCT03209414||Non-ST elevation myocardial infarction|Patients with non-ST elevation myocardial infarction wil be enrolled. Based on coronary angiography, heart team will decide on medical, percutaneous angioplasty, or bypass grafting.
89405747|NCT04518280|Experimental|Group B|The patients will firstly receive 2 cycles of CAPOX and PD-1 antibody, then receive short-course radiotherapy (25Gy/5Fx), followed by 4 cycles of CAPOX and PD-1 antibody. TME surgery is scheduled after TNT while a W&W option can be applied to patients achieving cCR.
89405748|NCT04892771||Experimental group|Patients who have honored two consultations per year for two years.
89190836|NCT03209414||ST-elevation myocardial infarction|Patients with ST elevation myocardial infarction wil be enrolled. In majority of patients primary percutaneous coronary intervention will be performed. Based on coronary angiography, heart team will decide on further medical treatment, percutaneous angioplasty, or bypass grafting.
89405749|NCT04892771||Control group|Patients who have not honored two consultations per year for two years.
89405750|NCT02283866|Experimental|Administering desflurane according to the patient's BIS value|The anesthesiologist administers the volatile anesthetic desflurane to set the patient's BIS value at 50 during balanced anesthesia, and titrate the remifentanil dose to set the patient's systolic arterial blood pressure between 100-140mmHg.
89405751|NCT02283866|Experimental|Administering desflurane at 1 MAC|The anesthesiologist administers the volatile anesthetic desflurane at 1 MAC during balanced anesthesia, and titrate the remifentanil dose to set the patient's systolic arterial blood pressure between 100-140mmHg.
89405752|NCT03502187|Active Comparator|Primary Care Management (PCM)|Non-specific LBP, where the cause for the pain cannot be determined, accounts for ninety percent of LBP cases.(Koes, et al, 2006) Reducing pain and continuing daily activity to prevent deconditioning are the primary therapy goals of PCM. Traditional PCM treatment of LBP will include advice/information on self-care options, over-the-counter analgesics, heat application, and remaining active.(Chou, et al., 2007; Koes, et al, 2010) Despite evidence that physical activity is effective, limiting activity remains common; individuals cite pain or re-injury fear as a limiting factor.( Lethem, et al., 1983; Poirandeau, et al., 2006; Steenstra, et al., 2016)
88882127|NCT01391598|Placebo Comparator|Saline|After completion of the inclusion criteria all patients receive a dose of amitriptyline 12.5 mg in the first week, and 25 mg in the eight subsequent weeks, orally, once daily at night. At saline group 20 pacients will receive 125ml of solution 0.9% saline.The solutions will be infused in 1 hour once a week in the four weeks following the start of the study. Patients may use as additional analgesics up to 4g/day acetaminophen, and if necessary, they can use tramadol, recording the dose
89405753|NCT03502187|Experimental|NeuromuscularElectricalStimulation(NMES)|Rehabilitation requires activation of deep stabilizing muscle groups in the lumbopelvic region. Traditional exercises specific for these muscles are hard to teach with poor compliance. NMES is effective in stimulating these muscles, (Porcari, et al., 2005; Glaser, et al., 2001) resulting in enhanced activation, and improved performance. (Coghlan, et al., 2011) NMES devices are programmed to exercise core muscles through a series of stimulated muscle contractions. Concurrent muscle stimulation of the abdominal wall and lumbar paraspinal area has been shown to be most effective to maximally activate deep lumbar stabilizers in LBP patients. (Baek, et al., 2016) NMES provides as much pain relief as transcutaneous electric nerve stimulation (TENS) in LBP subjects. (Moore SR, Shurman J, 1997)
89405754|NCT03502187|Experimental|Progressive Exercise Plan (PEP)|The literature suggests that this intervention may be of benefit in military personnel with subacute LBP. (Chou, et al., 2007;Marshall PW, Murphy BA, 2006) Meta-analysis showed evidence that graded-activity exercise improved patient outcomes in subacute LBP; however, evidence for other exercise programs were inconsistent. (Hayden, et al., 2005) A strengthening program involving the trunk and abdomen muscles showed clinical reductions in low back pain and disability with high adherence. (Kendall, et al., 2015) Systematic reviews were unable to support any one type of exercise over another. The use of pain-relieving modalities combined with muscle strengthening, such as home-based electrotherapy or progressive exercise, could reduce pain and improve function more rapidly.
88882128|NCT01391624|Experimental|Omega 3|The group was treated with omega 3 fatty acids for 2 months.
88882129|NCT01391624|Placebo Comparator|Placebo|The group received paraffin with dye in order to mimic the visual aspects of omega 3 fatty acid capsules.
89190837|NCT03185455|No Intervention|Standard of Care|Those randomized to the standard protocol for blood pressure monitoring will be scheduled for an office based nursing blood pressure visits 4-6 days postpartum. Care at this visit is based on a physician derived algorithm.
89405755|NCT03058705|Experimental|Hexaminolevinulate HCL with Near Infrared Fluorescence (NIRF)|During the transurethral resection of the bladder procedure, the bladder will initially be examined in a systematic meridian fashion. Suspicious tumors identified by white light only, NIRF only, and both will be identified. If intense fluorescence is observed in the initial patient(s) at 10 min, dwell duration will be reduced to 5 min for the next patient(s); if abundant fluorescence is detected there as well, dwell duration will be shortened again to 2.5 min. At least three patients will be studied at each duration to document intense fluorescence before proceeding to shorter instillation durations in subsequent patients.
89405756|NCT04517110|Experimental|Pregabalin + Usual Care|300 mg pregabalin taken orally within 2 hours before surgery and 75 mg pregabalin taken orally twice daily after surgery beginning after successful extubation (day after surgery or later) until discharge or 5 days, whichever comes first. Participants will also receive standard pain management.
89405757|NCT04517110|Placebo Comparator|Placebo + Usual Care|Placebo taken orally within 2 hours before surgery and placebo taken orally twice daily after surgery beginning after successful extubation (day after surgery or later) until discharge or 5 days, whichever comes first. Participants will also receive standard pain management.
89405758|NCT00498212|Experimental|1018 ISS-HBsAg-Single|Single dose (3000 µg 1018 ISS + 20 µg rHBsAg)
89405759|NCT00498212|Experimental|1018 ISS-HBsAg-Double|Double dose (6000 µg 1018 ISS + 40 µg rHBsAg)
89405760|NCT02798263|Experimental|Group I kinesiotherapy|Treated with standard therapeutic exercise, pre-defined, based on stretching the neck muscles, shoulder girdle and upper limb exercises for ADM lasting 30 minutes
88882130|NCT01391637||HuCNS-SC transplanted subjects in the lead-in phase|Subjects who had HuCNS-SC transplant in the lead-in phase study CL-N01-PMD
88882131|NCT01391650|Experimental|biomechanic of the knee|
88882132|NCT01391676||Trabeculectomy|glaucoma patients undergoing trabeculectomy with mitomycin c 0,02%
88882133|NCT01391689|Experimental|Arm I (antineoplastic therapy)|Patients receive diindolylmethane (BioResponse) PO BID for approximately 18 months.
88882134|NCT01391689|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID for approximately 18 months.
89405761|NCT02798263|Experimental|: Group II Acupuncture|Treated with 30 minutes of classical acupuncture using predefined points
89405762|NCT02798263|Experimental|Group III Stiper|They will be used the same acupuncture points of the group II, but using the needles in place Stiper®
89405763|NCT02280980|Experimental|Combined rehabilitation protocol|The usual rehabilitation protocol in the physiotherapy department is supplemented with a three weeks home protocol of oculomotor and gaze stability exercises.
89405764|NCT02280980|No Intervention|Usual rehabilitation protocol|The usual rehabilitation protocol in the physiotherapy department for patients after stroke.
89405765|NCT04882553|Experimental|Incremental inspiratory effort|"Every participant will be subjected to a stepwise incremental inspiratory effort:~Ventilated~Baseline spontaneous breathing with deep anesthesia (minimal alveolar concentration 1.5)~Spontaneous breathing with PEEP 10 and deep anesthesia (minimal alveolar concentration 1.5)~Spontaneous breathing with PEEP 0 and deep anesthesia (minimal alveolar concentration 1.5)~Spontaneous breathing with PEEP 0 and moderate anesthesia (minimal alveolar concentration 1.0)~Spontaneous breathing with PEEP 0 and moderate anesthesia (minimal alveolar concentration 1.0) and added inspiratory threshold of +7cmH2O~Spontaneous breathing with PEEP 0 and moderate anesthesia (minimal alveolar concentration 1.0) and added inspiratory threshold of +15cmH2O"
89405766|NCT02281058|Experimental|intervention group|Ten subjects recruited to self-administer abatacept 125mg injected subcutaneously weekly for 24 weeks to determine the impact it has on their vitiligo skin lesions.
89405767|NCT05760911|Experimental|Outdoor activities motivating group|Wear a smartwatch and receive Mini Program reminders and encouragement for outdoor activities. The required outdoor time is at least 2 hours from Monday to Friday and more than 2 hours on weekends.
89405768|NCT05760911|No Intervention|Outdoor activities monitoring group|Outdoor activities are monitored with smartwatches.
89405769|NCT01568723||Radiofrequency ablation|participants with barrett's esophagus with high grade dysplasia who undergo radiofrequency ablation (RFA)
89405770|NCT02784262|Experimental|botox injection|"Preoperative medication: Paracetamol 1,5g oral, diclofenac 50mg (evt ibuprofen 600mg) oral and/or diazepam 5-10 mg oral.~Skin and tissue inside the projected injection canal will be infiltrated with 5-10ml Marcain-Adrenalin (5mg/ml + 5microg/ml) for local anaesthesia.~Localization will be confirmed with help of navigation before the medication will be given. Intravascular injection will be prevented by control of aspiration."
89405771|NCT03049202||Never-smoker COPD participants|COPD patients with mild-to-moderate COPD (GOLD I-II) that have never smoked. Definition of never-smoker: Lifetime consumption of <100 cigarettes. No cigarettes the past 2 years.
89405772|NCT03049202||Ex-smoker COPD participants|COPD patients with mild-to-moderate COPD (GOLD I-II) that stopped smoking. Definition of smoking: > 10 pack years. Definition of ex-smoker: > 2 years since smoke cessation.
89405773|NCT03049202||Current-smoker COPD participants|COPD patients with mild-to-moderate COPD (GOLD I-II) that are currently smoking. Definition of smoking: > 10 pack years. Definition of current-smoker: > 10/cigarettes/dat the past 6 months.
89405774|NCT03049202||Current-smoker healthy controls|Current-smokers that are otherwise healthy, with normal lung function. Definition of smoking: > 10 pack years. Definition of current-smoker: > 10/cigarettes/dat the past 6 months.
89405775|NCT03049202||Never-smoker healthy controls|Healthy participants that have never smoked. Definition of never-smoker: Lifetime consumption of <100 cigarettes. No cigarettes the past 2 years.
89405776|NCT05205317|Experimental|vaginal repair + metformin|CSD patients were treated with vaginal repair of CSD in combination with metformin (Boke, 500 mg, Wanhui Shuanghe, Beijing, China) as an oral medicine (abbreviated as VR + metformin). In the group of VR + metformin, the patients start oral metformin from one month before the operation to 6 months after the operation. The dose is 500mg twice a day. The detailed procedure of VR has been described in investigators' previous study.
89405777|NCT05205317|Active Comparator|vaginal repair|The procedure of vaginal repair of CSD was shown as following. The bladder was dissected away carefully from the uterus toward the abdominal cavity until the peritoneum was reached. The CSD tissue was cut to the normal healthy muscle after the abdominal cavity had been entered, and the lower uterine segments had been completely exposed. A double layer of 1-0 absorbable interrupted sutures was used to close the incisions.
88882135|NCT01391702||Labouring woman with epidural in situ|Any healthy English-speaking pregnant woman in labour who has received an epidural for pain relief
88882136|NCT01391715|Active Comparator|Double dose rabeprazole|Rabeprazole 20m bid per day will be given for 2 weeks
88882137|NCT01391715|Placebo Comparator|standard dose rabeprazole|rabeprazole 20mg per day will bi given for 2 weeks
88882138|NCT01391728|Active Comparator|Lifestyle counseling|
88882139|NCT01391728|No Intervention|Control|
88882140|NCT01391741|Experimental|Walking with visual cues|Walking with visual cues for 30 minutes, 4 times a week for 4 weeks
88882141|NCT01391741|Active Comparator|Walking without visual cues|Walking without visual cues, but verbal encouragement twice a week to take longer steps, for 30 minutes, 4 times a week for 4 weeks.
88882142|NCT01391754|Experimental|SafeCare with Coached Implementation|Home-based services with the SafeCare model, implemented with in vivo provider coaching as quality control
88882143|NCT01391754|Experimental|SafeCare without Coaching|Home-based services using the SafeCare model, implemented without in vivo coached implementation quality control
88882144|NCT01391754|Experimental|Services As Usual with Coaching|Usual home based services, with in vivo coached implementation quality control
88882145|NCT01391754|Active Comparator|Services As Usual Without Coaching|Usual home based services without in vivo coached quality control
88882146|NCT01391767||NuOss XC|Bone grafting material used in this group will be NuOss XC.
88882147|NCT01391767||NuOss Particulate|Bone grafting material used in this group will be NuOss Particulate.
88882148|NCT01391780||Group 1|Patients with stress urinary incontinence
88882149|NCT01391780||Group 2|Patients with urgency urinary incontinence.
88882150|NCT01391806||Breast cancer|Patients selected for breast-conserving surgery based on conventional radiological methods, following the criteria recommended by the Norwegian Breast Cancer Group
88882151|NCT01391845|Experimental|UPA, 300UI FSH|patients on COS with 300UI FSHu/GnRH Antagonist protocol and ulipristal acetate use
88882152|NCT01391845|Placebo Comparator|No UPA, 300FSH|patients on COS with 300UI FSHu/GnRH Antagonist protocol and without ulipristal acetate use
89405778|NCT04087330|Experimental|Group 1 Experimental group|Stretching, facilitation exercises with whole body vibration
89405779|NCT04087330|Active Comparator|Group 2 Control group|Stretching and facilitation exercises
89405780|NCT04471298|Active Comparator|Active dosage group 1|Qishenyiqi dripping pills, 3.12g, oral, three times a day
89004438|NCT04387162|Experimental|Delayed|Participants will enter treatment after two week baseline
89004439|NCT04383743|Experimental|Treatment (pembrolizumab, aMVAC)|Patients receive pembrolizumab IV over 30 minutes on day 1 of weeks 0, 3, and 6 and methotrexate IV, vinblastine IV, doxorubicin IV, and cisplatin IV on day 1 of weeks 0, 2, 4, and 6 in the absence of disease progression or unacceptable toxicity. Patients also receive pegfilgrastim SC on day 1 or 2 of weeks 0, 2, 4, and 6 in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care radical cystectomy.
89405781|NCT04471298|Active Comparator|Active dosage group 2|Qishenyiqi dripping pills, 4.68g, oral, three times a day
89405782|NCT04471298|Active Comparator|Active dosage group 3|Qishenyiqi dripping pills, 6.24g, oral, three times a day
89405783|NCT04471298|Placebo Comparator|Control dosage group 1|Qishenyiqi dripping pills placebo, 3.12g, oral, three times a day
89004440|NCT04370002||No Intervention|This is an observational study. There is no active treatment that is examined.
89004441|NCT04366531|No Intervention|Monitoring/Treatment as usual|Veterans will not receive any study related interventions.
89405784|NCT04471298|Placebo Comparator|Control dosage group 2|Qishenyiqi dripping pills placebo, 4.68g, oral, three times a day
89004442|NCT04366531|Active Comparator|Reentry Program|Veterans will receive the START-VET reentry program
89004443|NCT04360434|Experimental|NI006|Dose escalation in up to 6 dose cohorts. Subjects will be administered a single dose of NI006 in the SAD, multiple doses of NI006 in the MAD and OLE phases.
89405785|NCT04471298|Placebo Comparator|Control dosage group 3|Qishenyiqi dripping pills placebo, 6.24g, oral, three times a day
89405786|NCT05205239|Experimental|Systemic sclerosis|
89405787|NCT00691964|Experimental|A|
89405788|NCT00691964|Active Comparator|B|
89405789|NCT00691964|Placebo Comparator|C|
89405790|NCT03474887||DIGI-Throat|Patients choosing to seek primary care through an online consultation with chief complaint sore throat.
89405791|NCT03474887||DIGI-Resp|Patients choosing to seek primary care through an online consultation with chief complaint cough/common cold/influenza.
89405792|NCT03474887||DIGI-Dysuria|Patients choosing to seek primary care through an online consultation with chief complaint dysuria.
89405793|NCT03474887||PHYSI-Throat+CONTROL-Throat|"Patients choosing to seek primary care through physical consultation with chief complaint sore throat.~+ Patients seeking primary care prior to implementation of online consultations, with a chief complaint of sore throat."
89004444|NCT04360434|Placebo Comparator|Placebo|"Subjects will be administered a single dose of placebo in the SAD phase and multiple doses of placebo in the MAD phase.~In the OLE phase, all subjects will be administered multiple doses of NI006."
89004445|NCT04337853|Experimental|Intervention group|N=6
89004446|NCT04337853|Active Comparator|Control group|N=7
89004447|NCT04332874|Experimental|Participants with Sarcoma|Advanced/metastatic extremity sarcoma eligible for pembrolizumab and isolated limb infusion (ILI)
89004448|NCT04331522||Antibiotics|Children aged 0-18 years investigated for allergy to antibiotics
89004449|NCT04331522||Milk|Children aged 0-18 years investigated for allergy to milk
89004450|NCT04331522||Egg|Children aged 0-18 years investigated for allergy to egg
89004451|NCT04331522||Peanut|Children aged 0-18 years investigated for allergy to peanut
89405794|NCT03474887||PHYSI-Resp+CONTROL-Resp|"Patients choosing to seek primary care through physical consultation with chief complaint cough/common cold/influenza.~+ Patients seeking primary care prior to implementation of online consultations, with a chief complaint of cough/common cold/influenza."
89004452|NCT04331522||Hazelnut|Children aged 0-18 years investigated for allergy to hazelnut
89004453|NCT04331522||Sesame|Children aged 0-18 years investigated for allergy to sesame
89405795|NCT03474887||PHYSI-Dysuria+CONTROL-Dysuria|"Patients choosing to seek primary care through physical consultation with chief complaint dysuria~+ Patients seeking primary care prior to implementation of online consultations, with a chief complaint of dysuria."
89405796|NCT05761457|Experimental|Treatment group|Patients receive cryopreserved autologous platelet transfusion
89405797|NCT04522180|Experimental|IONIS-GHR-LRx Dose 1|Single dose of IONIS-GHR-LRx Dose 1 will be administered by SC injection once every month for 73 weeks with a booster dose administered on Day 15 (Week 3).
89405798|NCT04522180|Experimental|IONIS-GHR-LRx Dose 2|Single dose of IONIS-GHR-LRx Dose 2 will be administered by SC injection once every month for 73 weeks with a booster dose administered on Day 15 (Week 3).
89405799|NCT04522180|Experimental|IONIS-GHR-LRx Dose 3|Single dose of IONIS-GHR-LRx Dose 3 will be administered by SC injection once every month for 73 weeks with a booster dose administered on Day 15 (Week 3).
89405800|NCT02281214|Experimental|blood sample, biopsy|
89405801|NCT04520854|Experimental|2-week Telehealth Protocol|Participants randomized to this arm will receive 5 live-video sessions. The first 2 live-video sessions will occur during the first week, last 20 minutes each and separated by 48-72 hours. The last 3 live-video sessions will occur during the second week, last 30-minutes each and separated by 24-48 hours.
89405802|NCT04520854|Active Comparator|2-week Usual Care|The usual care group will be used to reflect the current care provided to patients after discharged from the emergency department for an ankle sprain.
89405803|NCT05756075||Parkinson's Disease|
89405804|NCT05756075||COPD|
89405805|NCT02281292|Experimental|LKA651 (Part 1)|LKA651 ophthalmic solution in 1 of 5 concentrations, administered as a single IVT injection in the study eye
89405806|NCT02281292|Placebo Comparator|Sham injection (Part 1)|Sham injection in the study eye
89405807|NCT02281292|Experimental|LKA651 and Lucentis (Part 2)|LKA651 ophthalmic solution in 1 of 3 concentrations, administered as a single IVT injection in the study eye, followed by ranibizumab ophthalmic solution, 0.5 mg injection in the same eye 30 minutes later
89405808|NCT02281292|Placebo Comparator|Sham injection and Lucentis (Part 2)|Sham injection in the study eye, followed by ranibizumab ophthalmic solution, 0.5 mg injection in the same eye 30 minutes later
89405809|NCT04044742|Experimental|Resiniferatoxin|12.5 ug of Resiniferatoxin in 5 mL volume is administered as a one-time dose, intra-articularly
89405810|NCT04044742|Placebo Comparator|Placebo|Placebo formulation in 5 mL volume administered intra-articularly
89405811|NCT00690716|Experimental|1|Nasal CO2
89405812|NCT00690716|Placebo Comparator|2|Inactive Placebo
88882153|NCT01391845|Experimental|UPA, FSH 225|patients on COS with 225UI FSHu/GnRH Antagonist protocol and ulipristal acetate use
89405813|NCT03942484|Experimental|Treatment Group|Treatment with the investigational device - rPMS
89405814|NCT05205083|Experimental|Investigational vaccine group|Recombinant novel coronavirus vaccine (CHO cells) injection, Intramuscular injection of deltoid muscle of upper arm of 25μg/0.5ml/person dose.
88882154|NCT01391845|Placebo Comparator|no UPA, FSH225|patients on COS with 225UI FSHu/GnRH Antagonist protocol and without ulipristal acetate use
89405815|NCT02998671|Experimental|Group 1: CJM112 high dose|CJM112 high dose in treatment period 1; CJM112 high dose in extension period 2
88882155|NCT01391871||PRO-Kinetic DES|Patients receiving PRO-Kinetic drug-eluting stent
88882156|NCT01391871||Endeavor Resolute DES|Patient receiving Endeavor Resolute zotarolimus-eluting stent
89405816|NCT02998671|Experimental|Group 2: CJM112 low dose|CJM112 low dose in treatment period 1; CJM112 low dose in extension period 2
88882157|NCT01391884||Dialysis, Non-diabetic|Hemodialysis
88882158|NCT01391884||Healthy control|
88882159|NCT01391897||in- and out-patient psychotherapy patients|All included patients are highly selected in- and outpatients in a department of psychosomatic medicine (Germany) undergoing high dose psychotherapy (e.g. group therapy, creative therapy, cbt and psychodynamic psychotherapy).
88882160|NCT01391910||post endoscopic sinus surgery for chronic rhinosinusitis|Patients who have undergone functional endoscopic sinus surgery for treatment of chronic rhinosinusitis and completed a pre-surgery SNOT-20
88882161|NCT01391936|Other|Tension Band Wiring|Patients in this arm will receive the tension band wiring technique for fixation of their olecranon fracture.
88882162|NCT01391936|Other|Plate fixation|Patients in this arm will receive plate and screw fixation of their olecranon fracture.
88882163|NCT01391975|Experimental|Surveillance and proactive intervention|
88882164|NCT01391975|No Intervention|Control and reactive intervention|
89405817|NCT02998671|Placebo Comparator|Group 3: Placebo, CJM112 low dose or high dose|Placebo in treatment period 1; CJM112 low dose or CJM112 high dose in extension period 2
88882165|NCT01392001||Cohort|
88882166|NCT01392014|Active Comparator|dihydroartemisinin-piperaquine|
88882167|NCT01392014|Active Comparator|Dihydroartemisininpiperaquine primaquine|
88882168|NCT01392040||Patients in oral anticoagulant therapy|Patients taking oral anticoagulant therapy
88882169|NCT01392066||Breast cancer patients and their partners|Patients with breast cancer and their cohabiting partners/spouses
88921978|NCT05998655|Experimental|experimental group|In the research, tele-nursing practices and counseling based on the theory of technological competence will be provided to the experimental group.
88921979|NCT05998655|No Intervention|control group|No attempt will be made on individuals in the control group during the research process
89004454|NCT04331522||Wheat|Children aged 0-18 years investigated for allergy to wheat
89405818|NCT00688766|Experimental|IPI-504|retaspimycin hydrochloride (IPI-504) plus best supportive care
89405819|NCT00688766|Placebo Comparator|Placebo|Placebo plus best supportive care
89405820|NCT03390725|Experimental|A Healthy School Start Plus intervention|The intervention consists of 4 components given to all participants in the experimental group: 1) A health information brochure regarding child's health; 2) Motivational Interviewing with the parents by the school nurse concerning the child; 3) classroom activities for the children with home assignments; and 4) a web-based self-test of type-2 diabetes risk by parents with recommendation to contact primary health care in case of elevated risk.
89405821|NCT03390725|Active Comparator|Control|Treatment as usual in school health services plus the health information brochure regarding child's health (component 1 of the intervention)
89405822|NCT05204771||Normal foetus|All pregnant women reffered for 3rd trimester routine ultrasound examination without any fetal abnormality
89405823|NCT05112328|Experimental|Intervention|Exocrine Pacancreatic enzyme(Norzyme Capsule 40000 capsules) after meals 3 times a day
89405824|NCT05112328|Placebo Comparator|Control|Placebo after meals 3 times a day
89405825|NCT00684944|Active Comparator|1|30mg tid TRx0014
89405826|NCT00684944|Active Comparator|2|60mg tid TRx0014
89405827|NCT04515537||conventional therapy plus AFA|Patient using conventional therapy plus Extract of the Cyanophyta Aphanizomenon Flos-aquae (AFA), for a period of 6 months
89405828|NCT04515537||conventional therapy plus SVF|Patient using conventional therapy plus aplication of stroma vascular fraction (SVF) from the adipose tissue, evaluted for period of 6 months
89405829|NCT04515537||conventional therapy plus SVF and AFA|Patient using conventional therapy plus aplication of stroma vascular fraction (SVF) from the adipose tissue plus Extract of the Cyanophyta Aphanizomenon Flos-aquae (AFA), for a period of 6 months
89405830|NCT00492596|Experimental|device|insertion of balloon system
89405831|NCT00492596|Sham Comparator|sham|cystoscopy with sham system
89405832|NCT03663699|Experimental|Exergaming|24 week access to the exergaming platform PlayPulse
89405833|NCT03663699|No Intervention|Control|Asked to continue with their normal daily routine
89405834|NCT04202146|Experimental|Contingency Management + Motivational Interviewing|Participants will complete a seven-day combined CM with two sessions of brief Motivation Interviewing (MI) followed by standardized individual drug counseling.
89405835|NCT02660827|Experimental|Hybrid closed loop|All subjects will be wearing the MMT-670G insulin pump, using it with the closed loop algorithm
89405836|NCT03664557|Experimental|ER Reboa TM Catheter|During cardiac arrest occlusion of descending aorta to redistribute CPR-generated blood flow to brain and coronaries
89405837|NCT00491738|Experimental|1|
89405838|NCT00491738|Placebo Comparator|2|
89405839|NCT03664323||Group 1 Sequential strategy|Patients for whom anti-PD-1 therapy was stopped with the introduction of a new treatment line (19 patients, 63%).
89405840|NCT03664323||Group 2 Concomitant strategy|Patients for whom a combination of CT with anti-PD-1 therapy was initiated (11 patients, 37 %).
89405841|NCT05114200||patient|erector spinae plane block applied patients
89405842|NCT02281370|Experimental|SEQUENCE D0, D1, D2|Participants will receive treatment D0 in treatment period 1, D1 in treatment period 2 and D2 in treatment period 3 (one treatment per period). Where D0=eltrombopag 50 milligram (mg), D1= cyclosporine 200 mg + eltrombopag 50 mg, and D2= cyclosporine 600 mg + eltrombopag 50 mg. Treatment periods will be separated by washout periods of 3-10 days
89405843|NCT02281370|Experimental|SEQUENCE D1, D0, D2|Participants will receive treatment D1 in treatment period 1, D0 in treatment period 2 and D2 in treatment period 3 (one treatment per period). Where D0=eltrombopag 50 mg, D1= cyclosporine 200 mg + eltrombopag 50 mg, and D2= cyclosporine 600 mg + eltrombopag 50 mg. Treatment periods will be separated by washout periods of 3-10 days
89405844|NCT02281370|Experimental|SEQUENCE D1, D2, D0|Participants will receive treatment D1 in treatment period 1, D2 in treatment period 2 and D0 in treatment period 3 (one treatment per period). Where D0=eltrombopag 50 mg, D1= cyclosporine 200 mg + eltrombopag 50 mg, and D2= cyclosporine 600 mg + eltrombopag 50 mg. Treatment periods will be separated by washout periods of 3-10 days
89405845|NCT05114122|Experimental|Vonlay lithium disilicate ceramic restorations|Vonlay is a hybrid of an onlay with an extended buccal veneer surface for use in bicuspid regions where there is mostly enamel to bond to. The vonlay is less invasive, more readily repairable, less technique-sensitive to attain adequate bonding, and will leave sounder tooth structure remaining if further treatment is required in the future
89405846|NCT05114122|Active Comparator|Onlay lithium disilicate ceramic restorations|Onlays are used to restore large areas of decay and also used to replace old restorations, whether they are defective amalgam fillings, old cast-gold onlays, or fabricated from some other material
89405847|NCT03664245||experimental group|Critically ill patients receiving empirical antibiotic therapy for suspected or confirmed infections at the Intensive Care Unit
89405848|NCT00680342|Placebo Comparator|1|Placebo (lactose pill)
89405849|NCT00680342|Experimental|2|700mg of Legalon (silymarin) three times daily
88882170|NCT01392079|Experimental|Alemtuzumab|"30 mg alemtuzumab will be administered subcutaneously 3 times weekly for 4 weeks (total of 12 doses of 30 mg alemtuzumab) with premedication (as needed) and infection prophylaxis; combined with oral dexamethasone 40 mg total dose for 4 days every 2 weeks; evaluation at end of cycle (i.e. after 12 doses of 30 mg alemtuzumab).~If CR is documented after week 4 (12 doses of 30 mg alemtuzumab) or 8 (24 doses of 30 mg alemtuzumab), maintenance treatment with alemtuzumab or withdrawal from the study and stem cell transplantation will be instituted at this time point.~After a maximum of three 4-week cycles (total of 36 doses of 30 mg alemtuzumab, in case of interruptions this may take longer than 12 weeks), maintenance treatment with alemtuzumab or withdrawal from the study and stem cell transplantation will be instituted. Maintenance treatment with alemtuzumab will continue for a maximum of two years, with evaluation every three months, unless there is PD."
88882171|NCT01392105|Active Comparator|Mesenchymal stem cell treatment group|
89004455|NCT04331522||walnut|Children aged 0-18 years investigated for allergy to walnut
89405850|NCT00680342|Experimental|3|420mg Legalon (silymarin) three times daily
89405851|NCT03664167|Experimental|intervention|intensive weight loss diet, with Cambridge weightplan products, and visits to a dietician.
89405852|NCT03664167|No Intervention|control|usual care
89405853|NCT05114044|Experimental|Core stability group|Patients were performed therapy 5 times a week for 45 min over a period of 3 weeks. The therapy session takes 45 min; 15 min of the session was core stability training, remaining 30 min were conventional therapy.
89405854|NCT05114044|Active Comparator|Conventional therapy group|Patients were performed therapy 5 times a week for 45 min over a period of 3 weeks. The therapy session takes 45 min of conventional therapy.
89405855|NCT00617552|Placebo Comparator|1|
89405856|NCT00617552|Experimental|2|
89405857|NCT00617552|Experimental|3|
89405858|NCT00617552|Experimental|4|
89405859|NCT00617552|Experimental|5|
89405860|NCT00617552|Experimental|6|
89405861|NCT00617552|Experimental|7|
89405862|NCT00617552|Experimental|8|
89405863|NCT05113888|Experimental|Qizhi Weitong granules high-dose group|interventions：Qizhi Weitong granules Specification: 5.0g/bag，the drug content is equivalent to 2 bags of Qizhi Weitong granules (2.5g/ bag commercially available).
89405864|NCT05113888|Experimental|Qizhi Weitong granules low-dose group|interventions：Qizhi Weitong granules Specification: 5.0g/bag，the drug content is equivalent to 1 bag of Qizhi Weitong granules (2.5g/ bag commercially available).
89405865|NCT05113888|Placebo Comparator|The control group|interventions：Qizhi Weitong granules placebo Specification: 5.0g/bag，Does not contain effective crude drug ingredients.
89405866|NCT03663621||Initial survey and interview (Aim 2)|Participants in Aim 2 will be asked to complete an initial 15-minute survey and 20-30 minute semi-structured interview. The purpose of this study is to learn the best ways to support healthful behaviors and weight loss prior to pregnancy. Researchers are also interested in what motivates or prevents women of reproductive age from engaging in a structured weight loss program.
89405867|NCT03663621||Formal weight loss program (Aim 3)|Participants in Aim 3 have expressed interest in referral to the Mass General Weight Center. The purpose of this study is to learn what motivates or prevents women of reproductive age from engaging in a structured weight loss program. Researchers will ask for no more than a half hour of participant's time to complete a 5- minute interview following Orientation at the Weight Center and another 10-minute interview after a participant has participated in a program offered at the Weight Center.
89405868|NCT05113654||IPF|Patients with idiopathic pulmonary fibrosis
89405869|NCT05113654||COPD|Patients with chronic obstructive pulmonary disease
89405870|NCT05113654||Healthy|Healthy controls
89405871|NCT04057365|Experimental|DKN 01 and Nivolumab Safety Run in|"DKN-01 will be administered intravenously on day 1 and day 15 of each 28 day cycle~Nivolumab will be administered intravenously on day 1 and day 15 of each 28 day cycle"
89405872|NCT04057365|Experimental|DKN 01 and Nivolumab|"DKN-01 will be administered intravenously on day 1 and day 15 of each 28 day cycle~Nivolumab will be administered intravenously on day 1 and day 15 of each 28 day cycle"
89405873|NCT00616148|Placebo Comparator|Placebo|
89405874|NCT00616148|Experimental|YKP3089|
89405875|NCT05113576||patient|patients with DLBCL
89405876|NCT02283944|Experimental|TMS electrochemotherapy|Combined TMS (transcranial magnetic stimulation) and Temozolomide chemotherapy.
89405877|NCT03622827|Experimental|Chemoradiotherapy + Endostar|"Chemoradiotherapy with Endostar：~Chemoradiotherapy: pelvic radiotherapy with concurrent chemotherapy that consisted of cisplatin (75 mg/m2, day 1-3) and 5-fluorouracil (5-FU; 1000mg/m2/day,civ, day 1-4) for 2 cycles every 3 weeks.~Endostar: recombinant human endostatin (15mg/m2/d, civ, d1-7) is given 3 days before the chemotherapy every 3 weeks, total of two cycles during chemoradiotherapy course."
89405878|NCT00486512|Experimental|Active Treatment (calcitriol+ASA+CaCO3)|Daily dose of 0.5 mg calcitriol (1a -25-dihydroxycholecalciferol, Rocaltrol; Roche, Basel, Switzerland), 75 mg acetylsalicylic acid (ASA), and 1250 mg calcium carbonate (CaCO3). The daily dose was administered as 1 capsule containing 0.5 mg calcitriol (Rocaltrol; Roche) and 2 tablets containing a 37.5-mg ASA core with a 625-mg calcium carbonate shell (tablet-in-tablet) that was made expressly for this study. Patients should take 1 capsule and 2 tablets daily, together or separately. Timing of the intake is not important; study medication can be taken with or without food. The daily dose should not be exceeded. Before randomization, patients were given the placebo and followed up for a 3-week run-in period. Only patients who showed a placebo medication compliance rate of at least 80% were eligible for randomization. The primary outcome was the proportion of patients with recurrence of any adenomas as detected by colonoscopy after 3 years of treatment.
89405879|NCT00486512|Placebo Comparator|Placebo to calcitriol+ASA+CaCO3|Daily dose of matching placebo to 0.5 mg calcitriol, 75 mg acetylsalicylic acid (ASA), and 1250 mg calcium carbonate (CaCO3). Patients should take 1 capsule and 2 tablets of placebo daily, together or separately. Timing of the intake is not important; study medication can be taken with or without food. The daily dose should not be exceeded. Before randomization, patients were given the placebo and followed up for a 3-week run-in period. Only patients who showed a placebo medication compliance rate of at least 80% were eligible for randomization. The primary outcome was the proportion of patients with recurrence of any adenomas as detected by colonoscopy after 3 years of treatment.
88921980|NCT05997420|Experimental|Sepsis Transition and Recovery (STAR) program|Virtual sepsis navigation delivered across the peri-hospital discharge interval
89405880|NCT04057989||Battlefield Injury with ketamine treatment|Patients who received ketamine infusions to treat pain from January 2007 to December 2013.
89405881|NCT04093882||Cognitive normal|Individuals who do not show clinical or neuropsychological deficits.
88882172|NCT01392105|Placebo Comparator|Control group|All patients were required to have successful revascularization of an infarct-related artery on coronary angiography at the time of randomization. All patients received aspirin (300 mg loading dose, then 100 mg daily) and clopidogrel (600 mg loading dose, then 75 mg daily) with optimal medical therapy according to the American College of Cardiology (ACC)/ American Heart Association (AHA) guidelines for treatment of ST-segment elevation myocardial infarction (STEMI)
88882173|NCT01392131|Active Comparator|Oncoxin will be administered orally|20 patients will receive syrup Oncoxin 25 ml bd and capsule Oncoxin 1 cap bd for 24 weeks
89405882|NCT04093882||Mild cognitive impairment|Individuals who show deficits in neuropsychological test procedures but who do not exhibit substantial problems in daily life. Those individuals are part of the DELCODE cohort and were initially recruited in a memory clinic.
89405883|NCT04093882||Dementia due to Alzheimer's disease|Individuals diagnosed with dementia due to Alzheimer's disease by relying on anamnesis, neuropsychological test results, results of MRI and biomarkers found in the cerebrospinal fluid. Those individuals are part of the DELCODE cohort and were initially recruited in a memory clinic.
89405884|NCT03687580|Experimental|B-Cure Laser Pro|Subjects from the B-Cure Laser Pro group will receive standard care and in addition will self-treat at home daily with the B-Cure device.
89405885|NCT03687580|Sham Comparator|Sham laser|Subjects from the Sham laser group will receive standard care and in addition will self-treat at home daily with the sham B-Cure device.
89405886|NCT00486200|Active Comparator|1|Oral administration of active comparator
89405887|NCT00486200|Placebo Comparator|2|Oral administration of placebo
89405888|NCT00486200|Experimental|3|Dosing regimen 1
89405889|NCT00486200|Experimental|4|Dosing regimen 2
89405890|NCT00486200|Experimental|5|Dosing regimen 3
89405891|NCT00486200|Experimental|6|Dosing regimen 4
89405892|NCT02284022||Brain Computer Interface|Patients will test the brain computer interface system
89405893|NCT04079062|Experimental|ONO-4685 (PartA, D)|
89405894|NCT04079062|Placebo Comparator|Placebo (PartA, D)|
88882174|NCT01392131|Active Comparator|Supportive treatment|20 patients with hepatocellular carcinoma will receive supportive treatment only
88882175|NCT01392144||Nitric Oxide Breath Analysis|Nitric Oxide Breath Test + Questionnaires
89405895|NCT04079062|Experimental|KLH+placebo (Part B)|
89405896|NCT04079062|Experimental|KLH+ONO-4685 (PartC)|
89405897|NCT04079062|Experimental|KLH+placebo (PartC)|
89405898|NCT02936050|Other|Intervention|"Experimental: Addition of diagnostic ultrasound performed by nurses at the outpatient heart failure clinic. Interpretation by specialist per telemedicine.~No Control arm"
89405899|NCT00481520|Experimental|1|
89405900|NCT00481520|Placebo Comparator|2|
89405901|NCT05206526|Experimental|Dragon Boat|12 weeks of training, defined by a precise progressive, structured and supervised program divided into 3 weekly sessions of one hour / one hour and a half preparatory to the Dragon Boat activity.
89405902|NCT05206526|Active Comparator|Control|12 weeks of home-based training, without supervision, to perform 3 time per week composed by ten total body exercise.
89405903|NCT05113420||Per os+topical solution(1)|
89405904|NCT05113420||Per os+topical solution(2)|
89405905|NCT05113420||Per os only|
89405906|NCT05113420||Topical solution only|
89405907|NCT00479492|Experimental|1|
89405908|NCT00479492|Experimental|2|
89405909|NCT00479492|Experimental|3|
89405910|NCT00479492|Placebo Comparator|4|
89405911|NCT05112796|Experimental|VST technique|
89405912|NCT05112796|Active Comparator|PET technique|
89405913|NCT05112718|Experimental|Platelet Rich Plasma|The patients who receive PRP injections
89405914|NCT05112718|Sham Comparator|Normal Saline|The patients who receive normal saline
89405915|NCT00479258|Experimental|Inhaled insulin (Exubera)|
89405916|NCT00479258|Active Comparator|Subcutaneous Insulin (subject's prescribed)|
89405917|NCT05112562|Experimental|Computerized attentional bias modification training|
89405918|NCT05112562|Placebo Comparator|Placebo attention control training|
89405919|NCT00612170|Experimental|3|
89405920|NCT00612170|Sham Comparator|4|
89405921|NCT00612170|Experimental|1|
89405922|NCT00612170|Experimental|2|
89405923|NCT05104996|Experimental|Intervention Group|In the first interview, the patients were met and their consent for participation in the study was obtained. Afterwards, The Patient Descriptive Characteristics Form, ESCA and CAPS forms were filled. After this, patients were given discharge training and patient counseling service was provided by telephone for two months after discharge. At the end of two months, the ESCA and CAPS forms were filled again.
89405924|NCT05104996|No Intervention|Control Group|In the first interview, the patients were interviewed and their consent was obtained to participate in the study. Then, the Patient Descriptive Characteristics Form, ESCA and CAPS forms were filled. After this, the patients did not undergo any intervention for two months. At the end of two months, the ESCA and CAPS forms were filled again and a copy of the guideline was submitted.
89405925|NCT05099146|Experimental|pictorial|brushing technique taught by using pictures
89405926|NCT05099146|Experimental|video|brushing technique taught by showing video
89405927|NCT05099146|Experimental|control|only oral hygiene instructions provided
89405928|NCT01069419||Cimzia|All patients will be treated with Cimzia according to normal clinical practice for the prescribing physician and as defined by the SmPC
89405929|NCT00612014|Placebo Comparator|1|
89405930|NCT00612014|Experimental|2|40 micrograms/kg
89405931|NCT00612014|Experimental|3|80 micrograms/kg
88882176|NCT01392157|Active Comparator|copper intrauterine device|100 women will be allocated to receive a TCu380A intrauterine device
88882177|NCT01392157|Active Comparator|LNG-releasing intrauterine system|100 women were allocated to receive a LNG-IUS
89405932|NCT00612014|Experimental|4|160 micrograms/kg
89405933|NCT00612014|Experimental|5|320 microgram/kg
89405934|NCT00612014|Experimental|6|600 microgram/kg
89437509|NCT03781648|Experimental|NBI withdrawal method|Experimental: NBI was used on withdrawal. During the insertion phase, air pump was turned off to avoid inadvertent insufflations. Water exchange with infusion pump was used to open the lumen and simultaneous suction of infused water to allow passage of the scope in clear water. Withdrawal phase done using air insufflation.
89437510|NCT03779867|Experimental|Arm I (acute exercise)|Participants undergo a moderate-intensity acute exercise bout over 45 minutes.
89405935|NCT05098288|Experimental|App + Unified Protocol Arm|"Participants at this condition will be daily monitored by the app (Multicentre Pain Monitor) while they are administered a self-applied online transdiagnostic intervention (Unified protocol) for their emotional disorders. Alarms will be generated in the face of certain pre-set undesired events.~Therapists will receive pre-set clinical alarms in real time in the presence of relevant clinical events previously determined by the clinical staff (e.g., clinical worsening or no improvement of functionality, mood or psychological mechanisms worked in therapy). This information will be used to make clinical decisions in a short period of time (e.g., call the patient, or send additional therapeutic material by mail or through the app (momentary ecological intervention), or for its implementation during the course of psychological therapy in order to make the therapy more efficient, safe, personalized and adapted to the needs of the patient"
88882178|NCT01392157|Active Comparator|ENG-releasing implant|100 women will receive an LNG-IUS
88882179|NCT01392209|Experimental|Bevacizumab & Stereotactic Radiotherapy|This will be a multicenter (MSKCC and UCSF) phase I dose escalation study to determine the maximum tolerated dose (MTD) of hypofractionated stereotactic radiotherapy when administered in combination with a fixed dose of bevacizumab.
89004456|NCT04331522||cashew|Children aged 0-18 years investigated for allergy to cashew
89405936|NCT05068336||desflurane|Anesthesia maintenance of the first group will be provided with desflurane, one of the inhalation anesthetics we routinely use. Before and after the operation, blood will be taken from the patients, and the blood will be centrifuged to evaluate the heparan sulfate and syndecan levels.
89405937|NCT05068336||sevoflurane|Anesthesia maintenance of the first group will be provided with sevoflurane, one of the inhalation anesthetics we routinely use. Before and after the operation, blood will be taken from the patients, and the blood will be centrifuged to evaluate the heparan sulfate and syndecan levels.
89405938|NCT00607256|Experimental|Open Label|
89405939|NCT02774590|Experimental|Timolol to split face for 8 weeks|All 24 subjects will receive study drug and everyone will be randomized to which side of the face is treated with study drug first (right half-face versus left half-face). After 8 weeks of split-face treatment every night before bed, the subjects will be instructed to start treating both sides for another 8 weeks. Up to 30 subjects may be enrolled to ensure a target sample size of 24 (12 acne cases, 12 rosacea cases). This is an exploratory study. No part of this protocol will be considered routine care.
89405940|NCT00606476|Active Comparator|1|0.15 mg/kg active bapineuzumab
89405941|NCT00606476|Active Comparator|2|0.5 mg/kg active bapineuzumab
89405942|NCT00606476|Active Comparator|3|1.0 mg/kg active bapineuzmab
89535599|NCT02490059|Active Comparator|Standard size bronchoscopy|ll procedures were started using SB with an external diameter of 5.0-6.0 mm with a biopsy channel of 2.2-2.8 mm (models Olympus BF-30 and BF-1T160, Olympus, Tokyo, Japan). If during SB the lesion was endoscopically visible the bronchoscopy was continued as standard diagnostic procedure and the patients were excluded from the analysis. Only if no tumour was visible during complete inspection of the bronchial tree using the SB, a participant was randomised by opening a numbered sealed opaque envelope. Randomisation was performed using sequentially numbered (1-40) sealed opaque envelopes (block randomisation: block size 4). For subjects allocated to the SB group, the examination was immediately continued with the same SB bronchoscope.
89535600|NCT02490059|Experimental|Ultrahin bronchoscopy|For subjects randomised to UB, the instrument was changed immediately to an Olympus BF-XP 40 ultrathin bronchoscope with an outer diameter of 2.8 mm and a working channel 1.2 mm during the same bronchoscopy session.
89535601|NCT03073239||ALS epidemiological characterization|epidemiological characterization
89535602|NCT03073239||Genetic findings in ALS patients|genética characterization
89535603|NCT03220867|Experimental|Treatment Sequence: AB|Participants in cohort 1 (fasting) and cohort 2 (fed) will receive 1 milligram (mg) risperidone administered as Xian Risperdal (test) 1*1 mg oral tablet (Treatment A) on Day 1 in Period 1 followed by 1 mg risperidone administered as Gurabo Risperdal (reference) 1*1 mg oral tablet (Treatment B) on Day 1 in period 2. There will be a washout period of at least 10 days between treatments.
88921981|NCT05997420|Active Comparator|Usual Care|Standard of care received through each facility for patients hospitalized with sepsis. Aspects of usual care will be determined by treating clinicians independent of trial assignment.
88921982|NCT05995925||Patients with planned ICU admission|Patients with preoperative planned ICU admission
89405943|NCT02419456|Experimental|MK-2048A Intravaginal Ring (IVR) (Low Dose)|The MK-2048A IVR (Low Dose) will be inserted during the enrollment visit (Day 0), and it will be removed on Day 28.
89405944|NCT02419456|Experimental|MK-2048A IVR (Original Dose)|The MK-2048A IVR (Original Dose) will be inserted during the enrollment visit (Day 0), and it will be removed on Day 28.
89405945|NCT01069341|Other|Treatment|All subjects enrolled received treatment with identical dosage of Ranibizumab
89405946|NCT00676832|Placebo Comparator|Group 1|
89405947|NCT00676832|Experimental|Group 2|
89405948|NCT00676832|Experimental|Group 3|
89405949|NCT00676832|Experimental|Group 4|
89405950|NCT00676832|Experimental|Group 5|
89405951|NCT04057443|Experimental|Intervention group|Patients in the intervention group will follow the standard treatment and follow-uo according to the clinical protocol of the institution and will participate in an intervention program with physical exercise and nutritional support during the period in which they are receiving oncological treatment or for a maximum period of 6 months.
89405952|NCT04057443|Active Comparator|Control group|The patients of the control group will follow the standard treatment and follow-up according to the clinical protocol of the institution.
89405953|NCT04057521|Experimental|CHECK Program|Participants were offered enrollment into CHECK care coordination services.
89405954|NCT04057521|Active Comparator|Comparison Group|Participants were not offered enrollment into CHECK.
89405955|NCT01909414|Experimental|Arm A: GEO-D03 DNA and MVA/HIV62B vaccines|At study entry and Week 8, participants will receive the GEO-D03 DNA vaccine administered as 1 mL intramuscularly (IM) in either deltoid. At Weeks 16 and 24, they will receive the MVA/HIV62B vaccine administered as 1 mL IM in either deltoid.
89405956|NCT01909414|Placebo Comparator|Arm B: Placebo for GEO-D03 and MVA/HIV62B|At study entry and Week 8, participants will receive the placebo for GEO-D03 DNA vaccine administered as 1 mL IM in either deltoid. At Weeks 16 and 24, they will receive the placebo for MVA/HIV62B vaccine administered as 1 mL IM in either deltoid.
89405957|NCT00467402|Experimental|1|
89405958|NCT00467402|Experimental|2|
89405959|NCT00467402|Placebo Comparator|3|
89405960|NCT02996097|Experimental|CO2 ablative laser plus intralesional triamcinolone acetonide|A topical eutectic mixture of local anesthetics (EMLA) cream or tetracaine 7%/lidocaine 23% will be applied to the both treatment sites and after sufficient anesthesia is attained, one keloid will be treated with the fractional CO2 laser using standard protocol as practiced in our clinics followed by intralesional triamcinolone acetonide. One lesion would be treated with fractional CO2 ablative laser followed with intralesional triamcinolone acetonide at 4 weeks intervals
89405961|NCT02996097|Active Comparator|Intralesional triamcinolone acetonide alone|A topical EMLA cream or tetracaine 7%/lidocaine 23% will be applied to the both treatment sites and after sufficient anesthesia is attained, one keloid will be treated with the fractional CO2 laser using standard protocol as practiced in our clinics followed by intralesional triamcinolone acetonide. The other chosen lesion would be treated with intralesional triamcinolone acetonide alone at 4 week intervals.
89437511|NCT03779867|Active Comparator|Arm II (rest)|Participants rest by sitting for 45 minutes.
89437512|NCT03761108|Experimental|Linvoseltamab - Phase 1|"Phase 1 has two parts. Part 1, consists of REGN5458/linvoseltamab intravenous (IV) dose escalation and Part 2, consists of subcutaneous (SC) administration.~Note: subcutaneous (SC) administration is not applicable for US."
89437513|NCT03761108|Experimental|Linvoseltamab - Phase 2 - Cohort 1|Low Dose of REGN5458/linvoseltamab IV monotherapy.
89437514|NCT03761108|Experimental|Linvoseltamab - Phase 2 - Cohort 2|High Dose of REGN5458/linvoseltamab IV monotherapy.
89405962|NCT04054713|Active Comparator|Chromoendoscopy with acetic acid and targeted biopsies|Acetic acid is prepared at a concentration of 2.5%, after initial cleaning is done, it will be applied with a 7 French spray catheter, starting the proximal application performing a uniform application on the area of intestinal metaplasia an then will be timed for mucous visualization in search of areas of loss of acetowhitening, in case of finding such area will be registered the time in which there was loss of acetowhitening, the distance at which it is located from the upper dental arch in addition to the esophageal face on which the area is located, subsequently evaluation of the glandular pattern is performed only by classifying as normal (glands evenly distributed with normal or abnormal crypt density (compact crypts with increased density; focal irregularity or disorganized crypts; absence of a cryptic pattern), once this evaluation has been carried out, biopsies are directed to these areas to be sent to the pathology service.
89405963|NCT04054713|Active Comparator|Seattle protocol|Take random biopsies by quadrants every 2 centimeters biopsy of the intestinal metaplasia areas 1cm above the esophagogastric junction begins, taking tissue every 2cm from the 4 quadrants, separating the biopsies in different bottles based on the length in which they were taken, to later be sent to the pathology service.
88921983|NCT05995925||Patients with unplanned ICU admission|Patients with preoperative unplanned ICU admission
89405964|NCT03314181|Experimental|Arm A, Part 1a: VenDd Dose Escalation|Venetoclax (Ven) various doses administered orally, once daily (QD) in combination with daratumumab (D) (1800 mg subcutaneous injection (preferred) or 16 mg/kg intravenous [IV]) administered in accordance with prescribing information and dexamethasone (d) (oral or IV) 40 mg weekly (or 20 mg weekly, if necessary, as described in the protocol).
89405965|NCT03314181|Experimental|Arm B, Part 1b: VenDd Dose Expansion|Venetoclax at a dose determined by the dose-escalation phase, administered orally QD in combination with daratumumab (1800 mg subcutaneous injection (preferred) or 16 mg/kg IV) administered in accordance with prescribing information and dexamethasone (oral or IV) 40 mg weekly (or 20 mg weekly, if necessary, as described in the protocol).
89405966|NCT03314181|Experimental|Arm D, Part 2a: VenDVd Dose Escalation|Venetoclax at various doses administered orally QD in combination with daratumumab (1800 mg subcutaneous injection (preferred) or 16 mg/kg IV) administered in accordance with prescribing information, bortezomib (1.3 mg/m2 subcutaneous injection [preferred] or IV) Cycles 1-8, Days 1, 4, 8 and 11), and dexamethasone (oral or IV) 20 mg Cycles 1 - 3, Days 1, 2, 4, 5, 8, 9, 11,12 and 15; 20 mg Cycles 4-8, Days 1,2,4,5,8,9,11 and 12; 40 mg weekly (or 20 mg weekly, if necessary as described in the protocol) Cycle 9+.
89405967|NCT03314181|Experimental|Arm E, Part 2b: VenDVd Dose Expansion|Venetoclax at dose determined by the dose-escalation phase, administered orally QD in combination with daratumumab (1800 mg subcutaneous injection (preferred) or 16 mg/kg IV) administered in accordance with prescribing information, bortezomib (1.3 mg/m2 subcutaneous injection) Cycles 1-8, Days 1, 4, 8 and 11, and dexamethasone (oral or IV) 20 mg Cycles 1 - 3, Days 1, 2, 4, 5, 8, 9, 11,12 and 15; 20 mg Cycles 4-8, Days 1,2,4,5,8,9,11 and 12; 40 mg weekly (or 20 mg weekly, if necessary as described in the protocol) Cycle 9+.
89405968|NCT03314181|Experimental|Arm F: VenDd Dose Expansion|Venetoclax at a pre-determined dose, administered orally QD in combination with daratumumab (1800 mg subcutaneous injection (preferred) or 16 mg/kg IV) administered in accordance with prescribing information and dexamethasone (oral or IV) 40 mg weekly (or 20 mg weekly, if necessary, as described in the protocol).
89405969|NCT03314181|Experimental|Arm G: VenDd Dose Expansion|Venetoclax at a pre-determined dose, administered orally QD in combination with daratumumab (1800 mg subcutaneous injection (preferred) or 16 mg/kg IV) administered in accordance with prescribing information and dexamethasone (oral or IV) 40 mg weekly (or 20 mg weekly, if necessary, as described in the protocol).
89405970|NCT03314181|Active Comparator|Arm H: DVd Dose|Daratumumab (1800 mg subcutaneous injection (preferred) or 16 mg/kg IV) administered in accordance with prescribing information, bortezomib (1.3 mg/m2 subcutaneous injection) Cycles 1-8: Days 1, 4, 8 and 11, and dexamethasone (oral or IV) 20 mg on Cycles 1 - 3: Days 1, 2, 4, 5, 8, 9, 11,12 and 15; 40 mg weekly (or 20 mg weekly, if necessary as described in the protocol) on Cycles 4-8: Days 1,2,4,5,8,9,11 and 12; 20 mg monthly for Cycles 9+: Day 1
89535604|NCT03220867|Experimental|Treatment Sequence: BA|Participants in cohort 1 (fasting) and cohort 2 (fed) will receive Treatment B on Day 1 in period 1 followed by Treatment A on Day 1 in period 2. There will be a washout period of at least 10 days between treatments.
89535605|NCT02490137|Experimental|Game Players|Participants that will play video game
89535606|NCT02490137|No Intervention|Control|No video game experience
88921984|NCT05994612|Experimental|Cognitive Therapy for Suicide Prevention + Services as Usual|10 sessions of Cognitive Therapy for Suicide Prevention (CTSP) provided over 6 months, with 9 optional booster sessions + services as usual (SAU) received by the community.
89535607|NCT03073473||Concordant with GPS Cancer Test|Patients with advanced cancer who undergo GPS Cancer testing whose therapy matches the recommendations from the NantHealth GPS Cancer Test.
88921985|NCT05994612|Active Comparator|Services as Usual|Services as Usual involves utilizing Strengths-Based Outreach and Advocacy to link youth to community services for a period of 6 months.
88921986|NCT05991544|Experimental|Experimental|Training and Follow-up According to the Neuman Systems Model
88921987|NCT05991544|No Intervention|Control|only procedure will be applied
89405971|NCT03133832|Experimental|The cure rate between the two treatment|Compare the cure rate between the Chinese-made praziquantel and companion tablet at one dose of 40 mg/kg
89405972|NCT03133832|Experimental|The amount of eggs produced|Compare the amount of eggs produced between the Chinese-made praziquantel and companion tablet at one dose of 40 mg/kg
89405973|NCT03133832|Experimental|The economic benefit|Compare the economic benefit between the Chinese-made praziquantel and companion tablet at one dose of 40 mg/kg
89004457|NCT04331522||Pistachio|Children aged 0-18 years investigated for allergy to pistachio
89405974|NCT00603668|Experimental|milatuzumab|different doses of hLL1
88882180|NCT01392222||patients who have had surgery or have scheduled surgery|In this exploratory study we will conduct focus groups and individual interviews with two population segments according to the established methodology of Krueger and Casey [13] and Morgan [14]. We will conduct 4-6 focus groups, two to three within each population segment, to evaluate the process of decision-making to manage papillary microcarcinoma, factors that influenced decision-making, understanding of risk for recurrence and other negative outcomes due to thyroid cancer, information needed to make informed decisions, and what could influence thyroid cancer patients who have had surgery or have scheduled to have surgery to remove their papillary microcarcinomas to consider active surveillance. Individual interviews will be offered and conducted as needed for those patients who are unable to attend a focus group due to scheduling conflicts or other reasons.
88882181|NCT01392222||who chose to not have immediate surgery|In this exploratory study we will conduct focus groups with two population segments according to the established methodology of Krueger and Casey [13] and Morgan [14]. We will conduct 4-6 focus groups, two to three within each population segment, to evaluate the process of decision-making to manage papillary microcarcinoma, factors that influenced decision-making, understanding of risk for recurrence and other negative outcomes due to thyroid cancer, information needed to make informed decisions, and what could influence thyroid cancer patients who have had surgery or have scheduled to have surgery to remove their papillary microcarcinomas to consider active surveillance. Individual interviews will be offered and conducted as needed for those patients who are unable to attend a focus group due to scheduling conflicts or other reasons.
88882182|NCT01392235|Experimental|Drug: Famitinib|
88882183|NCT01392274||pCLE|This trial will study only one group which will receive a standard ERCP procedure followed by pCLE
89405975|NCT03663309||study group|"Children and adolescents aged 2-17 years, reported to be on gluten free diet for at least a year, diagnosed with celiac disease~Children and adolescents aged 2-17 years that are reported to be noncompliant with gluten free diet, diagnosed with celiac disease for at least 1 year."
89405976|NCT03663309||control group|Healthy controls aged 2-17 years old matched for age and sex.
89405977|NCT05011240|Experimental|Paediatric Autism Communication Therapy (PACT) Intervention plus Community Assistance as Usual|Participants will receive 12 sessions over 5 months of Paediatric Autism Communication Therapy (PACT).
89405978|NCT05011240|Active Comparator|Community support as usual plus psychoeducation (Control)|Participants in the Control group will receive psycho-educational support via monthly sessions led by researchers with experience in child development. In each session, a presentation will be delivered to provide parents with information about child development and environmental factors that contribute to healthy child development, including sensitive parenting styles, frequent positive social interactions between parents and children and cognitive stimulation. The presentations will be followed by group discussions. Children will also continue to receive Community Assistance as Usual via their normal early education centers. These centers offer daily activities designed to promote children's learning, autonomy, movement, integration and socialization. Children attend their educational center five days per week between the hours of 8am and 5pm.
89405979|NCT03663465|Experimental|Hawthorn and SGAs|SGAs has a dose of 3-20 gm/day, Hawthorn at a dose of 3 gm/day for six months.
89405980|NCT03663465|Active Comparator|Hawthorn|Hawthorn at a dose of 3 gm/day for six months.
89405981|NCT00461006|Experimental|Aleglitazar|
88882184|NCT01392287|Experimental|Memantine hydrochloride|Older individuals with DSM IV TR Major Depression, with persistent symptoms of depression despite at least 8 weeks of treatment with standard pharmacotherapy, will be referred for a study of memantine hydrochloride augmentation. Healthy control subjects follow similar study schedule for baseline and endpoint but do not receive memantine hydrochloride.
88882185|NCT01392313|Experimental|Carnitine|Participants will be given Creatinine supplements
89004458|NCT04331522||Almond|Children aged 0-18 years investigated for allergy to almond
89004459|NCT04331522||Soy|Children aged 0-18 years investigated for allergy to soy
89004460|NCT04331522||Fish|Children aged 0-18 years investigated for allergy to fish
89405982|NCT00461006|Active Comparator|Actos|
88882186|NCT01392313|Placebo Comparator|Placebo|participants will be given creatinine placebo
89190838|NCT03185455|Experimental|Remote (text based) surveillance|Those randomized to remote surveillance will be provided with electronic blood pressure monitors prior to discharge and instructed on their use. Every day, for two weeks post-discharge, patients will receive a standard text message in the morning from a HIPAA compliant automated monitoring system reminding them to text their blood pressure. They will be asked to send in one blood pressure a day at minimum. They may be asked to send in more depending on the blood pressure result and clinical algorithm. This system will provide timely responses to patient texts and create a physician derived response to elevated blood pressures based on a programmed algorithm. Additionally, for blood pressures that reach a dangerous threshold, a clinical provider will be alerted per the algorithm and contact the patient for further evaluation.
89190839|NCT03182075|Experimental|Active Training|OCD and hoarding disorder participants will receive active emotional reactivity training (14 sessions) via computer.
88882187|NCT01392339|Experimental|CPAP|CPAP - Continuous Positive Airway Pressure, gold standard treatment to Obstructive Sleep Apnea
88882188|NCT01392352|Experimental|Pazopanib|Patients will receive 800mg (2 X 400mg tablets) of pazopanib, to be administered once daily orally for 12 weeks or until development of hypertension (defined as VHyp), whichever occurs first.
88882189|NCT01392365||Crohn' disease|The group of patients whose final diagnosis is Crohn's disease
88882190|NCT01392365||Intestinal tuberculosis|The group of patients whose final diagnosis is intestinal tuberculosis
88882191|NCT01392391|Experimental|Exercise|Task-oriented exercise training (aerobic, strength, and balance exercises)
88882192|NCT01392391|Active Comparator|Stroke Care|"Best Medical Care in Jamaica adapted from the American Stroke Association Get with the Guidelines."
88882193|NCT01392430|No Intervention|Arm A|Continuation of prophylaxis of opportunistic infections
88882194|NCT01392430|Experimental|Arm B|Discontinuation of opportunistic infections
89190840|NCT03182075|Sham Comparator|Passive Training|OCD and hoarding disorder participants will receive passive computerized training (14 sessions) via computer.
88882195|NCT01392456|Active Comparator|Retentive Anchor Group|23 fully edentulous patients will receive Retentive Anchors (Institute Straumann AG, Basel Switzerland)as retention system for the two implant overdenture.
88882196|NCT01392456|Active Comparator|Magnet Group|23 fully edentulous patients will receive Magnets (Institute Straumann AG, Basel Switzerland)as retention system for the two implant overdenture.
88882197|NCT01392456|Active Comparator|Locator Group|23 fully edentulous patients will receive Locator (Institute Straumann AG, Basel Switzerland)as retention system for the two implant overdenture.
89190841|NCT03177044|Experimental|Behavioural treatment|2 to 6 sessions of bowel behavioural training with a pelvic floor physiotherapist
89190842|NCT03152903|Experimental|VPM1002 (Recombinant BCG vaccine)|
89190843|NCT03152903|Placebo Comparator|Placebo|
89190844|NCT03152890|Experimental|Study group|The study group receives a linear mixed effects model-proposed dose of insulin when hyperglycemia is noticed after reperfusion of liver graft.
89190845|NCT03148600|Active Comparator|Intervention arm|Pelvic floor and bowel behavioural training programme provided by physiotherapists over 2- 6 sessions within the 6 months following ileostomy closure for patients with an ileo-anal pouch
89190846|NCT03148600|Placebo Comparator|Standard arm|Standard post-operative nursing and medical care provided in hospital clinic
88882198|NCT01392482||treatment with antipsychotics|40 LHU covering about 18 millions inhabitants distributed all over Italy with a coverage of nearly 100% of Italian regions. All subjects will be included in the analysis who have received treatment with antipsychotics (typical and / or atypical) between January 1, 2009 and June 30, 2010 and diagnosed with schizophrenia and / or Bipolar Disorder.
88882199|NCT01392521|Experimental|Arm 1|
88882200|NCT01392534||Group 1|
88882201|NCT01392586|Experimental|Upfront surgery|Upfront surgery followed by systemic treatment
88882202|NCT01392586|Other|Systemic therapy|Systemic therapy possibly followed by local treatment of the breast tumor
88882203|NCT01392599|Experimental|Surgery|Patients with CRPS Type II
88882204|NCT01392612|Other|Erythropoietin|all subjects received epo iv.
88882205|NCT01392638|Placebo Comparator|sugar pill|Intervention: sugar pill
88882206|NCT01392638|Active Comparator|sildenafil|Intervention: sildenafil citrate
88882207|NCT01392651||Women with urinary stress incontinence|
88882208|NCT01392690|No Intervention|Waiting list control - no intervention|No intervention. After the post-test they were offered the prevention program.
88882209|NCT01392690|Experimental|Dominique's handy tricks|Children assisted to 10 workshops where they learned exercises to control their stress and anxiety.
89190847|NCT03141255|No Intervention|Control Group|Patients will receive only standard of care treatment for cardiogenic shock.
89190848|NCT03141255|Experimental|Therapeutic Hypothermia|Patients will be cooled to between 32°C and 34°C using the IVTM™ System and the Quattro® Catheter in addition to receiving standard of care treatment for cardiogenic shock.
89190849|NCT03062085||High myopic cataract group|Cataract patients with high myopia.
89190850|NCT03062085||Age-related cataract group|Age-related cataract patients.
89190851|NCT03062085||Ametropic cataract group|Cataract patients with ametropia.
89190852|NCT03055897|Experimental|iLux 2020 System|Meibomian gland treatment (Day 0) according to instructions for use (IFU)/User Manual
89190853|NCT03055832|Experimental|iLux 2020 System|Meibomian gland treatment (Day 0) according to instructions for use (IFU)/User Manual
89190854|NCT03055832|Active Comparator|LipiFlow Thermal Pulsation System|Meibomian gland treatment (Day 0) according to instructions for use (IFU)/User Manual
89190855|NCT03052595||SM|Patients with newly diagnosed multiple sclerosis undergo Oral glucose tolerance test to measure glucose and insulin concentrations after oral glucose load Patients undergo testing of autonomous nervous system function and testing of cognitive function (Stroop test)
89190856|NCT03052595||Control|Age, sex, Body Mass Index (BMI) matched healthy subjects undergo Oral glucose tolerance test to measure glucose and insulin concentrations after oral glucose load Healthy controls undergo testing of autonomous nervous system function and testing of cognitive function (Stroop test)
89190857|NCT03048877|Experimental|Apatinib|Apatinib Mesylate Tablets
89405983|NCT02452840||NVAMD Patients with PDA|NVAMD Patients with PDA
89190858|NCT03048877|Placebo Comparator|Placebo|Placebo Tablets
89405984|NCT04161430|Experimental|DRBP108|Phase A (Weeks 1-24): DBPR108 100mg + placebo matching Sitagliptin 100 mg; Phase B (Weeks 25-52): DBPR108 100 mg
88882210|NCT01392716|Experimental|Single arm|
88882211|NCT01392729||Cohort|
89405985|NCT04161430|Active Comparator|Sitagliptin|Phase A (Weeks 1-24): Placebo matching DBPR108 100 mg + Sitagliptin 100 mg; Phase B (Weeks 25-52): DBPR108 100 mg
89405986|NCT04161430|Placebo Comparator|Placebo|Phase A (Weeks 1-24): Placebo matching DBPR108 100 mg + placebo matching Sitagliptin 100 mg; Phase B (Weeks 25-52): DBPR108 100 mg
89405987|NCT03663153||SEMA4C high value follow-up group|Postoperative SEMA4C value is higher than 5.00 ng/ml.
89405988|NCT03663153||SEMA4C low value follow-up group|Postoperative SEMA4C value is lower than 5.00 ng/ml.
89405989|NCT02203474|Experimental|Tiotropium HFA BAI 5 mcg|1 inhalation from each of 3 inhalers containing either Tiotropium HFA BAI 5 mcg or placebo daily
88882212|NCT01392755|Experimental|1|
89405990|NCT02203474|Experimental|Tiotropium HFA BAI 10 mcg|1 inhalation from each of 3 inhalers containing either Tiotropium HFA BAI 5 mcg or placebo daily
89405991|NCT02203474|Experimental|Tiotropium HFA BAI 15 mcg|1 inhalation from each of 3 inhalers containing either Tiotropium HFA BAI 5 mcg or placebo daily
88882213|NCT01392755|Experimental|2|
88882214|NCT01392768|Experimental|Levetiracetam|
89405992|NCT02203474|Active Comparator|SPIRIVA HandiHaler|2 inhalations from one 18 mcg capsule daily
89405993|NCT02203474|Placebo Comparator|Placebo|1 inhalation from each of 3 inhalers containing either Tiotropium HFA BAI 5 mcg or placebo daily
89405994|NCT04053699||Patients undergoing treatment with a VWF-containing product|Patients with type 3, type 2 (except 2N), or severe type 1 VWD undergoing routine on-demand treatment with a VWF-containing product over a period of 6 months
89405995|NCT02281604||0.2/1.2 microliter filter|Use of 0.2/1.2 microliter filters for intravenous drug administration
89405996|NCT02281604||5 mircroliter filter|Use of 5 microliter filters for intravenous drug administration
89405997|NCT00672386|Experimental|001|JNJ16269110 5 mg twice daily for 12 weeks
89405998|NCT00672386|Experimental|002|JNJ16269110 10 mg twice daily for 12 weeks
88882215|NCT01392768|Placebo Comparator|Placebo|
88882216|NCT01392781||normoweight PCOS patients|
88882217|NCT01392781||normoweight controls|
88882218|NCT01392781||overweight plus obese PCOS patients|
88882219|NCT01392781||overwqeight plus obese controls|
89405999|NCT00672386|Experimental|003|JNJ16269110 15 mg twice daily for 12 weeks
89406000|NCT00672386|Placebo Comparator|004|Placebo twice daily for 12 weeks
89406001|NCT04056897|Experimental|BCD-132, 125 mg|72 patients
89406002|NCT04056897|Experimental|BCD-132, 500 mg|72 patients
89406003|NCT04056897|Active Comparator|Teriflunomide|72 patients
88882220|NCT01392794|Experimental|orally-disintegrating (OD) tablet precedence group|
88882221|NCT01392794|Experimental|conventional tablet precedence group|
88882222|NCT01392807|Experimental|Group 1|Normal hepatic function, 25 mg NKTR-118 administered orally
88882223|NCT01392807|Experimental|Group 2|Mild hepatic impairment, 25 mg NKTR-118 administered orally
88882224|NCT01392807|Experimental|Group 3|Moderate hepatic impairment, 25 mg NKTR-118 administered orally
88882225|NCT01392820|Experimental|TC-5214|
88882226|NCT01392820|Placebo Comparator|Placebo|
88882227|NCT01392833|Active Comparator|steroids|intravenous methylprednisolone 1 g for three consecutive days at the beginning of months 1, 3 and 5, and oral prednisone 0.5 mg/kg every other day for six months followed by oral prednisone 0.2 mg/kg every other day for a further six months.
89004461|NCT04331522||Shellfish|Children aged 0-18 years investigated for allergy to shellfish
89406004|NCT04056897|Placebo Comparator|Placebo|54 patients
89406005|NCT04436302|Experimental|Intervention|Dividat senso exergame device
89406006|NCT04436302|Active Comparator|Control|Listening to music
89406007|NCT02281682|Active Comparator|Imiquimod|three times a week once daily during 4 consecutive weeks. Prior to treatment: curettage
89406008|NCT02281682|Active Comparator|5-Fluorouracil|during 4 (consecutive) weeks twice daily. Prior to treatment: curettage
89406009|NCT02281682|Active Comparator|Ingenol mebutate 0.015%|during 3 (consecutive) days once daily. Prior to treatment: curettage
89406010|NCT02281682|Active Comparator|MAL-PDT|methylaminolevulinate photodynamic therapy; one session. Prior to treatment: curettage
89406011|NCT04057053|Experimental|Netarsudil use|Patient eye undergoes cataract surgery + DWEK, immediately after surgery Netarsudil 0.02% ophthalmic 1 drop daily is used in the operative eye until corneal clearance is documented.
89406012|NCT04057053|Active Comparator|Standard of care + possible rescue drop|Patient eye undergoes cataract surgery + DWEK, no Netarsudil is used after surgery, if cornea is not cleared in time for first eye Netarsudil 0.02% ophthalmic 1 drop dailyadded daily as possible rescue drop and time to corneal clearance is documented
89406013|NCT04589338|Experimental|Endurance training group|
89406014|NCT04589338|Experimental|Resistance training group|
89406015|NCT04589338|No Intervention|Control group|
89406016|NCT04056975|Experimental|single arm|A-319 dosage: 0.05, 0.15, 0.03, 0.06, 0.12, 0.18, 0.24 μg/kg
89406017|NCT02281916|Experimental|P28GST treatment|P28GST as a parasite enzyme
89406018|NCT03663075|Experimental|Group 1|This group will receive the intervention Group information (GI).
89406019|NCT03663075|Experimental|Group 2|This group will receive the intervention Group information (GI) followed by Structured person-centered support (PCS)
89406020|NCT03663075|Experimental|Group 3|This group will receive the intervention Structured person-centered support (PCS)
89406021|NCT03663075|No Intervention|Group 4|This is a control group.
89190859|NCT03032575|Other|sample size 100|Study Design: This is a prospective observational cohort of Thai MSM who initiated ART at the time of AHI, defined as the first 30 days after HIV acquisition (Fiebig stages 1 through 5). Volunteers will be examined at baseline to determine the prevalence of HPV infection and HSIL at HIV diagnosis. They will then be followed longitudinally for new incidence of HPV and HSIL, as well as progression or regression of existing lesions.
89190860|NCT02951351|Active Comparator|Standard procedure + Culture|Patients will undergo the standard injection protocol. A conjunctival culture will then be obtained followed by the application of povidone-iodine to the eyelashes and eyelid margins. Patients will be randomized to receive 5% povidone-iodine drop to the conjunctival surface followed by conjunctival culture then re-application of 5% povidone-iodine drop to the conjunctival surface. Injection will then proceed.
89406022|NCT04963504|Experimental|Rest-to-exercise|
89406023|NCT04963504|Experimental|Sitting-to-supine|
89406024|NCT02284100|Experimental|animal assisted therapy group|the dog was present during post-operative awakening (2 hours after surgery)
89406025|NCT02284100|No Intervention|standard group|children had standard post-operative medical care
88882228|NCT01392833|Experimental|steroids plus azathioprine|intravenous methylprednisolone 1 g for three consecutive days at the beginning of months 1, 3 and 5, and oral prednisone 0.5 mg/kg every other day plus azathioprine 1.5 mg/kg/day for six months followed by oral prednisone 0.2 mg/kg every other day plus azathioprine 50 mg/day for a further six months.
88882229|NCT01392846||Resolute Integrity|Patients receiving Resolute-Integrity stent
88882230|NCT01392872|Other|sclerosis|
88882231|NCT01392898|Experimental|liraglutide|
89406026|NCT03662763|Placebo Comparator|Placebo|
88882232|NCT01392898|Active Comparator|insulin|
89406027|NCT03662763|Experimental|Extended-release Guanfacine Hydrochloride (SPD503)|
89406028|NCT02141932|Experimental|Bed-side pocket-size ultrasound|All participants will be examined bed-side by pocket size ultrasound for the assessment of the carotid arteries and the heart. All participants will then be examined by reference imaging in specific ultrasound laboratories and when appropriate computer tomography or magnetic resonance imaging.
89406029|NCT00458978|Experimental|Treatment (enzyme inhibitor)|Patients receive oral cediranib maleate once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
89406030|NCT04514224||Healthy Start Program 1|Community Partner with HRSA-funded Healthy Start designation and services a patient population with over 50% identifying African American and/or Black
89406031|NCT04514224||Community Health Center 1|Community Partner with Community Health Center or Federally Qualified Community Health Center designation and services a client population with over 50% identifying African American and/or Black
89406032|NCT04514224||Healthy Start Program 2|Community Partner with HRSA-funded Healthy Start designation and services a patient population with over 50% identifying African American and/or Black
89406033|NCT04514224||Community Health Center 2|Community Partner with Community Health Center or Federally Qualified Community Health Center designation and services a client population with over 50% identifying African American and/or Black
89406034|NCT04514224||Healthy Start Program 3|Community Partner with HRSA-funded Healthy Start designation and services a patient population with over 50% identifying African American and/or Black
89406035|NCT04514224||Community Health Center 3|Community Partner with Community Health Center or Federally Qualified Community Health Center designation and services a client population with over 50% identifying African American and/or Black
89406036|NCT04514224||Healthy Start Program 4|Community Partner with HRSA-funded Healthy Start designation and services a patient population with over 50% identifying African American and/or Black
89406037|NCT04514224||Community Health Center 4|Community Partner with Community Health Center or Federally Qualified Community Health Center designation and services a client population with over 50% identifying African American and/or Black
89406038|NCT04514224||Healthy Start Program 5|Community Partner with HRSA-funded Healthy Start designation and services a patient population with over 50% identifying African American and/or Black
89406039|NCT04514224||Healthy Start Program 6|Community Partner with HRSA-funded Healthy Start designation and services a patient population with over 50% identifying African American and/or Black
89406040|NCT00458276|Experimental|1|Tezosentan
89406041|NCT00458276|Placebo Comparator|2|Placebo
89406042|NCT03661749|Experimental|Clean catch|women in this group will collect urine for PR/CR using a clean catch technique
89406043|NCT03661749|Placebo Comparator|Non-clean catch|women in this group will not employ clean catch technique
89535608|NCT03073473||Discordant with GPS Cancer Test|Patients with advanced cancer who undergo GPS Cancer testing whose therapy does not match the recommendations from the NantHealth GPS Cancer Test.
88882233|NCT01392911|Active Comparator|10 mg/kg rifampicin|7 Days monotherapy with 10 mg/kg rifampicin followed by 7 days standard TB treatment, i.e. Rifafour® e275 once daily including the standard dose of rifampicin.
88882234|NCT01392911|Experimental|20 mg/kg Rifampicin|7 Days monotherapy with 20 mg/kg rifampicin followed by 7 days combination therapy consisting of 20 mg/kg rifampicin plus the standard doses of isoniazid, ethambutol and pyrazinamide.
88882235|NCT01392911|Experimental|25 mg/kg Rifampicin|7 Days monotherapy with 25 mg/kg rifampicin followed by 7 days combination therapy consisting of 25 mg/kg rifampicin plus the standard doses of isoniazid, ethambutol and pyrazinamide.
88882236|NCT01392911|Experimental|30 mg/kg Rifampicin|7 Days monotherapy with 30 mg/kg rifampicin followed by 7 days combination therapy consisting of 30 mg/kg rifampicin plus the standard doses of isoniazid, ethambutol and pyrazinamide.
88882237|NCT01392911|Experimental|35 mg/kg Rifampicin|7 Days monotherapy with 35 mg/kg rifampicin followed by 7 days combination therapy consisting of 35 mg/kg rifampicin plus the standard doses of isoniazid, ethambutol and pyrazinamide.
88882238|NCT01392911|Experimental|40 mg/kg Rifampicin|7 Days monotherapy with 40 mg/kg rifampicin followed by 7 days combination therapy consisting of 40 mg/kg rifampicin plus the standard doses of isoniazid, ethambutol and pyrazinamide.
88882239|NCT01392911|Experimental|45 mg/kg Rifampicin|7 Days monotherapy with 45 mg/kg rifampicin followed by 7 days combination therapy consisting of 45mg/kg rifampicin plus the standard doses of isoniazid, ethambutol and pyrazinamide.
88882240|NCT01392911|Experimental|50 mg/kg rifampicin|7 Days monotherapy with 50 mg/kg rifampicin followed by 7 days combination therapy consisting of 50 mg/kg rifampicin plus the standard doses of isoniazid, ethambutol and pyrazinamide.
88882241|NCT01392911|Experimental|55 mg/kg Rifampicin|7 Days monotherapy with 55 mg/kg rifampicin followed by 7 days combination therapy consisting of 55 mg/kg rifampicin plus the standard doses of isoniazid, ethambutol and pyrazinamide.
88882242|NCT01392924|Experimental|SAR245408|single cohort: SAR245408 administered once daily
88882243|NCT01392937|Active Comparator|All-in-One Light multipurpose|Used All in One light multipurpose with one of five different lens brands: Air Optix Aqua(Ciba Vision Inc.), PureVision (Bausch + Lomb Inc.), Biofinity (CooperVision Inc.), Acuvue Advance and Acuvue 2 (both Johnson & Johnson).
88882244|NCT01392937|Active Comparator|Aquify care|Use Aquify care with one of five different lens brands: Air Optix Aqua(Ciba Vision Inc.), PureVision (Bausch + Lomb Inc.), Biofinity (CooperVision Inc.), Acuvue Advance and Acuvue 2 (both Johnson & Johnson).
89406044|NCT04520074|No Intervention|Follow-up|No interevention
89406045|NCT04520074|Experimental|three steps chemotherapy|Cyclophosphamide 400mg（250mg/m2）+Etoposide 100mg (70mg/m2)d1-d3 iv 4w/6cycles , followed by Carboplatin (AUC=5)+Cyclophosphamide 600mg(400mg/m2)d1-d2 iv 8w/6cycles.
89406046|NCT03661671|Experimental|LCI+white light|Using white light firstly to observe from cardia to duodenum and then switch LCI model to observe from antrum to cardia
89406047|NCT03661671|No Intervention|White light|Using white light only.
89406048|NCT00600782|Experimental|Group A|These subjects were further stratified into 3 groups according to the size of their PPD skin test reactions
89406049|NCT05118958|Experimental|Part 1 - Period 1 - Prototype 1 600 mg (single dose fasted)|600 mg (2 x 300 mg) KVD824 prototype 1 modified-release tablet dosed orally in fasted state as a single dose
89406050|NCT05118958|Experimental|Part 1 - Period 3 - Prototype 2 600 mg (single dose fasted)|600 mg (2 x 300 mg) KVD824 prototype 2 modified-release tablet dosed orally in fasted state as a single dose
89406051|NCT05118958|Experimental|Part 1 - Period 4 - Prototype 1 900 mg (single dose fasted)|900 mg (3 x 300 mg) KVD824 prototype 1 modified-release tablet dosed orally in fasted state as a single dose
89406052|NCT05118958|Experimental|Part 1 - Period 5 - Prototype 1 600 mg and Prototype 3 300 mg (single dose fasted)|600 mg (2 x 300 mg) KVD824 prototype 1 modified-release tablet plus 300 mg (1 x 300 mg) Prototype 3 dosed orally in fasted state as a single dose
89535609|NCT03073473||CNA controls without testing|Retrospective patients in the COTA database matched by similar characteristics (CNA matched).
89004462|NCT04331522||Poppy seed|Children aged 0-18 years investigated for allergy to poppy seed
88882245|NCT01392950|Active Comparator|Air Optix Aqua|Compare safety and efficacy using OptiFree Replenish solution
89004463|NCT04262856|Experimental|Arm 1 (zimberelimab monotherapy)|Participants will receive zimberelimab as an intravenous (IV) infusion.
88882246|NCT01392950|Active Comparator|Clariti|Compare safety and efficacy of the lens using OptiFree Replenish solution
88882247|NCT01392976|Experimental|CO-1.01 Formulation B|
88882248|NCT01392976|Active Comparator|CO-1.01 Formulation A|
88882249|NCT01393002||INABBRA|Participating hospitals in the INABBRA alliance.
88882250|NCT01393015|Experimental|FreeO2 system|FreeO2 is a new system that automatically adjusts the oxygen flow delivered to patients in closed-loop based on the SpO2 signal. This system is intended to maintain SpO2 in a predefined target and to adapt oxygen flow to patient's needs.
88882251|NCT01393015|Active Comparator|Rotameter (flowmeter)|A rotameter is a device that measures the flow rate of liquid or gas in a closed tube.
88882252|NCT01393028|Experimental|Cardiac CT|Cardiac CT (CT calcium and/or CT angiography), followed by stress testing, invasive angiography or neither depending on the CT scan result
88882253|NCT01393028|Other|Standard care|Standard diagnostic management, including stress testing and/or invasive angiography
88882254|NCT01393041|Other|Angio-Seal VIP|
88882255|NCT01393067|Active Comparator|study group NEPS|implantation of multiple non-expandable plastic stents
88882256|NCT01393067|Active Comparator|group cSEMS|implantation of a self-expandable metal stent (cSEMS)
88882257|NCT01393080|Experimental|Nimotuzumab and TP regimen|"TP Regimen ：Paclitaxel Liposome,135mg/m2,d1;Carbopatin（AUC=5） d2, 3 weeks/cycle, for 4 cycles.~Nimotuzumab : 200mg/w, weekly, for 6 weeks; Consolidation treatment， 200mg every 2 weeks, until the end of 4 cycles of chemotherapy or the disease progression."
88882258|NCT01393080|Placebo Comparator|TP Regimen|TP Regimen：Paclitaxel Liposome,135mg/m2,d1;Carbopatin（AUC=5） d2, 3 weeks/cycle, for 4 cycles.
88882259|NCT01393093|Active Comparator|TACE -oil|embolization agent:Iodinated Oil or /and gelatin sponge Iodinated Oil （5-30ml）with Epirubicin （30-40mg/m2） or and gelatin sponge
88882260|NCT01393093|Experimental|TACE-KMG ( routine dose Chemo)|embolization agent:KMG microsphere( 150-450µm,0.2-2g) with routine dose Epirubicin （30-40mg/m2）
88882261|NCT01393093|Experimental|TACE-KMG( low dose Chemo )|embolization agent:KMG microsphere( 150-450µm,0.2-2g) with low dose Epirubicin （5-10mg/m2）
88882262|NCT01393093|Experimental|TACE-KMG(withou chemo)|embolization agent:KMG microsphere( 150-450µm,0.2-2g)
88882263|NCT01393119|Experimental|3000mg GTx-758 daily|loading dose 3000mg GTx-758 daily + maintenance dose of 1000mg
88882264|NCT01393119|Experimental|3000 mg GTx-758 daily|loading dose of 3000mg GTx-758 daily + maintenance dose of 2000mg GTx-758 daily
88882265|NCT01393119|Experimental|1500 mg GTx-758 BID|Loading dose of 1500 mg GTx-758 BID + maintenance dose of 1000mg GTx-758 daily
88882266|NCT01393119|Experimental|1500mg GTx-758 BID|loading dose of 1500mg of GTx-758 BID + maintenance dose of 2000mg GTx-758 daily
88882267|NCT01391988|Active Comparator|Electric Scalpel Mastectomy|Radical mastectomy with electric scalpel
88882268|NCT01391988|Experimental|Harmonic scalpel mastectomy|Radical Mastectomy with harmonic scalpel
88882269|NCT01393145|Experimental|Group 1|
88882270|NCT01393145|Active Comparator|Group 2|
88882271|NCT01393184|Experimental|Radiotherapy + Nimotuzumab|"Radiotherapy (RT) Technique: IMRT, Rapid Arc, Tomotherapy Total dose: GTV 70 Gy & CTV 60 Gy/33F~Nimotuzumab (Nimo) weekly Nimo (200 mg) × 8, started 1 w before RT"
89406053|NCT05118958|Experimental|Part 1 - Period 6 - Prototype 1 900 mg (single dose fed)|900 mg (3 x 300 mg) KVD824 prototype 1 modified-release tablet dosed orally in fed state as a single dose
88882272|NCT01393184|Active Comparator|Radiotherapy (RT)|Radiotherapy (RT) Technique: IMRT, Rapid Arc, Tomotherapy Total dose: GTV 70 Gy & CTV 60 Gy/33F
88882273|NCT01393197|Active Comparator|TACE -oil|embolization agent:Iodinated Oil or /and gelatin sponge Iodinated Oil （5-30ml）with Epirubicin （30-40mg/m2） or and gelatin sponge
88882274|NCT01393197|Experimental|TACE-KMG ( routine dose Chemo)|embolization agent:KMG microsphere( 150-450µm,0.2-2g) with routine dose Epirubicin （30-40mg/m2）
88882275|NCT01393197|Experimental|TACE-KMG( low dose Chemo )|embolization agent:KMG microsphere( 150-450µm,0.2-2g) with low dose Epirubicin （5-10mg/m2）
88882276|NCT01393197|Experimental|TACE-KMG(without chemo)|embolization agent:KMG microsphere( 150-450µm,0.2-2g)
88882277|NCT01393210|Active Comparator|low-calorie diet|Intervention was low-calorie diet only for 12 weeks.
88882278|NCT01393210|Active Comparator|low calorie diet plus beta-glucan|Intervention was low-calorie diet plus BETA-GlLUCAN 1.3D-1.6D 500 mg daily for 12 weeks.
88882279|NCT01393223|Active Comparator|LP-08 80mg|4 weekly intravesical administration of LP-08 80mg
88882280|NCT01393223|Active Comparator|LP-08 20mg|4 weekly intravesical administration of LP-08 20mg
89004464|NCT04262856|Experimental|Arm 2 (domvanalimab and zimberelimab combination therapy)|Participants will receive domvanalimab IV in combination with zimberelimab IV infusion.
89406054|NCT05118958|Experimental|Part 3 - KVD824 Prototype 1 600 mg (multiple dose fed)|600 mg (2 x 300 mg) KVD824 prototype 1 modified-release tablet dosed orally twice daily in fed state for 13 days with a single dose on day 14.
89406055|NCT05118958|Placebo Comparator|Part 3 - Placebo to KVD824 Prototype 1 600 mg (multiple dose fed)|Placebo to 600 mg KVD824 prototype 1 modified-release tablet dosed orally twice daily in fed state for 13 days with a single dose on day 14.
89406056|NCT05118958|Experimental|Part 3 - KVD824 Prototype 1 900 mg (multiple dose fed)|900 mg (3 x 300 mg) KVD824 prototype 1 modified-release tablet dosed orally twice daily in fed state for 13 days with a single dose on day 14.
89406057|NCT05118958|Placebo Comparator|Part 3 - Placebo to KVD824 Prototype 1 900 mg (multiple dose fed)|Placebo to 900 mg KVD824 prototype 1 modified-release tablet dosed orally twice daily in fed state for 13 days with a single dose on day 14.
89535610|NCT03205345|Active Comparator|Emricasan (25 mg)|Emricasan 25 mg
89406058|NCT05118958|Experimental|Part 3 - KVD824 Prototype 1 900 mg (multiple dose fasted)|900 mg (3 x 300 mg) KVD824 prototype 1 modified-release tablet dosed orally twice daily in fasted state for 13 days with a single dose on day 14.
89406059|NCT05118958|Placebo Comparator|Part 3 - Placebo to KVD824 Prototype 1 900 mg (multiple dose fasted)|Placebo to 900 mg KVD824 prototype 1 modified-release tablet dosed orally twice daily in fasted state for 13 days with a single dose on day 14.
89406060|NCT05118958|Active Comparator|Part 1 - Period 2 - KVD824 IR Capsule 600 mg (single dose fasted)|600 mg (2 x 300 mg) KVD824 immediate release Capsule dosed orally in fasted state as a single dose
89406061|NCT00672074|Active Comparator|1 Ipamorelin|
89406062|NCT00672074|Placebo Comparator|2 Placebo|
89406063|NCT03662451|Active Comparator|Robotic single-site hysterectomy|Robotic single-site hysterectomy is performed in this arm
88882281|NCT01393223|Placebo Comparator|Normal Saline|Four weekly normal saline intravesical administration
88882282|NCT01393236||patients|patient characteristics are specified in H-2-2010-011
88882283|NCT01393236||controls|age matched to patients described in protocol H-2-2010-011
88882284|NCT01393249||ALL, Asparaginase, pancreatitis|Patients that have been scanned and have had blood tests
88882285|NCT01393275|Active Comparator|Rehabilitation intervention group|The group is performing a strength endurance training intervention in addition with rehabilitation exercise intervention.
88882286|NCT01393275|Placebo Comparator|Placebo rehabilitation|The group is performing a strength endurance training intervention in addition with placebo rehabilitation exercise intervention.
88882287|NCT01393288|Placebo Comparator|Ondansetron|
88882288|NCT01393288|Placebo Comparator|Lorazepam|
88882289|NCT01393288|Placebo Comparator|Aprepitant|
88882290|NCT01393327|Experimental|Respiratory and exercise therapy|Early after PEA postoperative three-week inpatient rehabilitation and subsequent continuing of the training at home for 12 weeks.
88882291|NCT01393340|Placebo Comparator|Placebo|
88882292|NCT01393340|Active Comparator|Omalizumab|
88882293|NCT01393353|Sham Comparator|Computer game|Nintendo Wii
88882294|NCT01393353|Experimental|Cognitive Training with Cogniplus|CogniPlus
88882295|NCT01393366|Other|Without AMA|Patient will be follow only like usual practice
88882296|NCT01393366|Other|With AMA|Patient will be follow like usual practice, plus 'Telephone Intervention' every week with a nurse to evaluate physical conditions.
88882297|NCT01393418||Subjects undergoing cardiac surgery|
88882298|NCT01392196|Other|Single arm|Renal Denervation
88882299|NCT01393431||EBC pH|Observational study
88882300|NCT01393470||Cohort A (Trial Cohort, Vaccinated during HPV-008)|"Cohort A subjects were previously enrolled in the HPV-008 study, and have received at least 1 dose of the HPV vaccine.~Cohort A subjects have provided written informed consent prior to enrolment to allow retrieval of biospecimens for HPV DNA testing and confirmation of diagnosis.~Subjects who provided written informed consent prior to enrolment for the use of their personal identifier for linkage purposes to Finnish Registries."
88882301|NCT01393470||Cohort B1 + B2|"Cohort B1 subjects were previously enrolled in the HPV-008 study and received at least 1 dose of HPV vaccine as cross-over vaccination at the end of the HPV-008 study.~Cohort B1 subjects have provided written informed consent prior to enrolment to allow retrieval of biospecimens for HPV DNA testing and confirmation of diagnosis.~Subjects who provided written informed consent prior to enrolment for the use of their personal identifier for linkage purposes to Finnish Registries.~Cohort B2 (Trial Cohort, Non-Vaccinated)"
89406064|NCT03662451|Active Comparator|Robotic multi-site hysterectomy|Robotic multi-site hysterectomy is performed in this arm
89406065|NCT05118880|Experimental|İntervention group|the children enrolled in the Peer Bullying Counseling Program based on the Interpersonal Relationship Model
89406066|NCT05118880|No Intervention|control group|
89406067|NCT04056507||ITP group|On frozen spleens of already splenectomized adult ITP patients.
89406068|NCT04056507||Control group|On frozen control spleens from patients who had a splenectomy at the Bordeaux University Hospital following a road accident.
89406069|NCT00455156|Experimental|150/15 NES/EE CVR|150 mg of Nestorone and 15 mg of ethinyl estradiol (150/15 NES/EE CVR), administered via vaginal ring, used on a 21/7 days in/out schedule for no more than one year.
89406070|NCT05118646|Experimental|Microcirculation-oriented resuscitation group|The microcirculation-oriented resuscitation group will evaluate the organ perfusion level and adjust the hemodynamic therapy according to the sublingual microcirculation parameters (PPV > 68%).
89406071|NCT05118646|Other|Control group|The standard treatment group will adjust the shock management scheme through systemic hemodynamic parameters.
89406072|NCT03661593|Experimental|Cataract guideline|In this patients we follow cataract guideline and correct the patients ametropia during the cataract surgery
89535611|NCT03205345|Active Comparator|Emricasan (5 mg)|Emricasan 5mg
88921988|NCT05990803|Experimental|Study treatment|Participants received BL-B01D1, SI-B003 or BL-B01D1 + SI-B003 therapy in the first cycle (3 weeks). Participants who had a clinical benefit could receive additional cycles of additional treatment. Administration will be discontinued because of disease progression or intolerable toxicity or for other reasons.
89406073|NCT03661593|No Intervention|Standard refraction|The patients gets an IOL ensuring his preoperatively refraction
89406074|NCT04513834|Experimental|Multi-faceted intervention|Patient education material on PPI deprescribing will be sent to the patients and their general practitioner (GP) will receive an educational outreach visit by a Delegue d'Assurance Maladie (DAM, healthcare representative )
89406075|NCT04513834|Active Comparator|Educational outreach visit to GPs|GP will receive the educational outreach visit by a DAM (healthcare representative). Their patients will not receive any patient education material.
89406076|NCT04513834|No Intervention|Control|Neither the patients nor their GP will receive any information.
89406077|NCT03661515|Experimental|Fludarabine-Idarubicine-Cytarabine- Selinexor|"fludarabine 30 mg/m2/day intravenously on days 1 to 4, idarubicin 10 mg/m2/day intravenously on days 1 to 3, cytarabine 2 g/m2/day intravenously on days 1 to 4, G-CSF 300 mcg/m2/day subcutaneously from days -1 to 5. This schedule will be combined with oral selinexor (KPT-330) for three weeks at days and dose according to escalation level:~Level -1: Selinexor 40 mg/day, once weekly~Level 1: Selinexor 60 mg/day, once weekly~Level 2: Selinexor 80 mg/day, once weekly~Level 3: Selinexor 100 mg/day, once weekly"
89406078|NCT02284256|Experimental|Fibrocaps|"Human fibrinogen and thrombin powder. Single application during surgery~Other Names:~Raplixa~PRO-0601~Fibrin sealant~Device: Gelatin sponge. Single application during surgery~Other Name: Spongostan"
89406079|NCT02284256|Active Comparator|TachoSil|Human fibrinogen and thrombin powder. Single application during surgery
89406080|NCT01624480|Experimental|Armodafinil 50 mg|In period 1, patients will receive a single 50-mg dose of armodafinil on day 1. In period 2, patients will receive a single 50-mg dose daily on days 1 through 42.
89406081|NCT01624480|Experimental|Armodafinil 100 mg|In period 1, patients will receive a single 100 mg dose of armodafinil on day 1. In period 2, patients will receive a single 50-mg dose on day 1 then daily 100-mg doses on days 2 through 42.
89406082|NCT01624480|Experimental|Armodafinil 150 mg|In period 1, patients will receive a single 150-mg dose of armodafinil on day 1. In period 2, patients will receive a single 50-mg dose on day 1, 100-mg doses on days 2 and 3, then daily 150-mg doses on days 4 through 42.
89406083|NCT00670592|Other|HCD122|
88882302|NCT01393470||Cohort C (Referent Cohort, Non-Vaccinated)|"Cohort C subjects have not participated in the HPV-008 study but have been enrolled in the Referent Cohort.~Cohort C subjects have not received any HPV vaccination (neither Cervarix, nor Gardasil, nor any experimental HPV vaccine).~Cohort C subjects are partially matched to HPV-008 in terms of the geographical recruitment area.~Subjects who provided written informed consent prior to enrolment for the use of their personal identifier for linkage purposes to Finnish Registries."
88882303|NCT01393496|Experimental|"liberal transfusion triggers"|"liberal guidelines for red blood cell transfusions"
88882304|NCT01393496|Active Comparator|"restrictive transfusion triggers"|"restrictive guidelines for red blood cell transfusions"
88882305|NCT01393548|Experimental|brompheniramine + phenylephrine|Fixed dose combination of brompheniramine + phenylephrine
88882306|NCT01393548|Active Comparator|brompheniramine + pseudoephedrine|Fixed dose combination of brompheniramine + pseudoephedrine
88882307|NCT01393561|Experimental|Group 1|Fixed dose combination of brompheniramine + phenylephrine.
88882308|NCT01393561|Placebo Comparator|Group 2|Placebo
88882309|NCT01393574|Experimental|Melatonin treatment|Treatment with Melatonin before sleep for 1 month - 3 mg for body weight <40kg, 6mg for body weight >40kg
88882310|NCT01393574|Active Comparator|Stimulants treatment|Treatment with Methylphenidate with a formulary and dose as decided by the treating neurologist, for 1 month.
88882311|NCT01393587|Experimental|Experimental|
88882312|NCT01393652|Experimental|Cohort 1: Experimental intervention: PF-05105679 or placebo|Cohort 1
88882313|NCT01393652|Experimental|Cohort 2: Experimental intervention: PF-05105679 or placebo|Cohort 2
88882314|NCT01393652|Active Comparator|Cohort 3: Experimental intervention PF-05105679 or placebo and|Cohort 3
88882315|NCT01393665|Placebo Comparator|Placebo|
88882316|NCT01393665|Experimental|PENNEL capsule|1cap or 2cap T.I.D
88882317|NCT01393678|Experimental|PENNEL|2cap T.I.D
89406084|NCT05115682|Experimental|Morning First|Participants will complete a single bout of exercise at 09:00, and after at least a one-week washout perform another exercise bout at 16:00.
89406085|NCT05115682|Experimental|Afternoon First|Participants will complete a single bout of exercise at 16:00, and after at least a one-week washout perform another exercise bout at 09:00.
89406086|NCT02992899|Experimental|Vagal Nerve Stimulation|Participants randomized to this arm will receive stimulation of the vagus nerve in conjunction with stress exposure.
89406087|NCT02992899|Sham Comparator|Sham Stimulation|Participants randomized to this arm will receive sham stimulation of the vagus nerve in conjunction with stress exposure.
89406088|NCT02281994|Active Comparator|Active PEMF|Active device emits Pulsed Electromagnetic Field (PEMF)
89406089|NCT02281994|Placebo Comparator|Control/no PEMF|control/placebo device does not emit Pulsed Electromagnetic Field (PEMF)
89406090|NCT04472390||Tapering|TNF-α inhibitors
89406091|NCT04472390||Discontinuing|TNF-α inhibitors
89406092|NCT00448058|Experimental|GSK372475|flexible-dose design from GSK372475 1.0 mg/day to GSK372475 2.0 mg/day
89406093|NCT00448058|Active Comparator|Venlafaxine|Flexible- dose design from Venlafaxine XR 75 mg/day to Venlafaxine XR 225 mg/day
89406094|NCT00448058|Placebo Comparator|placebo|
89406095|NCT01081210||Ultrasound screening|Patients admitted to Department of medicine at local hospital. Randomized inclusion, informed consent obtained.
89406096|NCT03662373||carbon ions radiation therapy|the group of patients treated with carbon ion radiation therapy, affected by one of the four pathologies foreseen in inclusion criteria
89406097|NCT03662373||protons radiation therapy|the group of patients treated with proton radiation therapy, affected by one of the four pathologies foreseen in inclusion criteria
89406098|NCT02282072|Active Comparator|Deep Brain Stimulation|Stimulator is ON
89406099|NCT02282072|Sham Comparator|Placebo|Stimulator is OFF
89535612|NCT03205345|Placebo Comparator|Placebo|Matching placebo
89406100|NCT01602484|Experimental|Splint Pack|Group of post-op patients who have splint applied from prepared Plaster-of-Paris splint pack
89406101|NCT01602484|Active Comparator|Bulk Supplies|Group of post-op patients who have splint applied from bulk supplies
89406102|NCT04441736|Active Comparator|High flow nasal cannula|A device og high flow nasal cannula giving 60 litres / min
89406103|NCT04441736|Placebo Comparator|Conventional oxygen|Nasal cannula giving oxygen up to 10 litres / minute
89406104|NCT05118100||Protect Bond|Restoration placed using Clearfil Protect Bond adhesive (Kuraray Noritake, Osaka, Japan) , which contains the antibacterial monomer MDPB (12-Methacryloyloxydodecylpyridiniumbromide)
89406105|NCT05118100||SE Bond|Restoration placed using Clearfil SEBond adhesive (Kuraray Noritake, Osaka, Japan)
89406106|NCT03662529|Experimental|Mind Freedom Plan therapy sessions|The Four-Session Mind Freedom Plan (MFP) is cognitive behavioral therapy (CBT)-based, client-centered, manualized individual therapy that functions as part of intensive outpatient substance abuse treatment. The MFP model is based on efficacious brief interventions, with content and format driven from military veteran feedback. The four 60-minute MFP sessions were one-on-one private consultations with a therapist that were focused on identifying and changing unhealthy thinking and behavioral patterns as core elements of CBT, but with an emphasis on problem-solving, coping skills, goal setting, and psychosocial functioning. At each session, structured worksheets were utilized and homework was assigned to facilitate this CBT-based skill building.
89406107|NCT03662529|Active Comparator|Treatment as usual therapy|The four 50-minute TAU sessions were one-on-one individual therapy sessions. Therapy was mostly supportive therapy with an emphasis problem solving on increasing veteran motivation. A discussion of the antecedents to relapse would take place if a relapse occurred and coping skills were discussed and reviewed. Veterans were also connected with community-level psychosocial supports as appropriate.
89406108|NCT04900870||Neck pain|Diagnostic Test: A self-administered questionnaire A self-administered questionnaire will be used to screen VAS scores, bournemouth neck questionnaire, demographic information and for temporomandibular pain Diagnostic Criteria for Temporomandibular Disorders: Assessment Instruments Axis I TMD Pain Screener, Symptom questionnaire and Axis II PHQ-4, Oral Behaviors Checklist .
89406109|NCT04900870||Neck pain with temeporomandibular pain|Diagnostic Test: A self-administered questionnaire A self-administered questionnaire will be used to screen VAS scores, bournemouth neck questionnaire, demographic information and for temporomandibular pain Diagnostic Criteria for Temporomandibular Disorders: Assessment Instruments Axis I TMD Pain Screener, Symptom questionnaire, Clinical Examination Form, Axis II Pain Drawing Graded Chronic Pain (version 2), JFLS-8 ,PHQ-4 Oral Behaviors Checklist.
89406110|NCT00447980|Experimental|1 NT-501 implant|High Dose
89406111|NCT00447980|Experimental|2 NT-501 implant|Low Dose
89406112|NCT02284334||Low GI-High GI|"Two study visits are separate by around one month.~For this arm, test meal (Visit 1): low-glycemic index; test meal (Visit 2): high-glycemic index"
89406113|NCT02284334||High GI-Low GI|"Two study visits are separate by around one month.~For this arm, test meal (Visit 1): high-glycemic index; test meal (Visit 2): low-glycemic index"
89406114|NCT05116696||Chronic limb-threatening ischemia (CLTI) group|All CLTI patients presenting with wound, ischemia, foot infection (WIfI) stage IV disease consecutively treated at one institution
89406115|NCT05116696||Colorectal liver metastases (CRLM) group|All CRLM patients presenting with wound, ischemia, foot infection (WIfI) with stage IV disease consecutively treated at one institution
89406116|NCT02284412|Active Comparator|neostigmine|Neostigmine will be dosed as 60 μg/kg, and glycopyrrolate 12 μg/kg (commercially available 5:1 co-formulation), as a single iv bolus administered over 10sec, for reversal of rocuronium-induced moderate neuromuscular blockade.
89406117|NCT02284412|Experimental|Sugammadex|Sugammadex will be dosed 15 mg/kg, as a single iv bolus administered over 10sec, for reversal of rocuronium-induced moderate neuromuscular blockade.
89406118|NCT02284412|Placebo Comparator|Water for injection|Water will be dosed arbitrarily as a 1 mL single iv bolus administered over 10sec.
89406119|NCT02284490|Experimental|Treatment Arm|Pemetrexed 900 mg/m² every 21 days until disease progression.
89406120|NCT00583154|Experimental|1|BLI-801 Dose 1
89406121|NCT00583154|Experimental|2|BLI-801 Dose 2
89406122|NCT00583154|Experimental|3|BLI-801 Dose 3
88882318|NCT01393678|Active Comparator|NISSEL|"NISSEL~BDD (biphenylmethyl dicarboxylate) ................25mg~2cap T.I.D"
89406123|NCT00583154|Experimental|4|BLI-801 Dose 4
89406124|NCT02207218||NovoEight®|
88882319|NCT01393691|Experimental|CBT with parent combined play|This is a CBT adaptation designed for preschool children, which includes multiple standard cognitive-behavioral techniques, namely psycho-education, problem solving via play, gradual exposure and reinforcement management.
88882320|NCT01393691|Active Comparator|Triadic expressive play therapy|Based on expressive play therapy guidelines, children and their parents will express themes concerning bedtime routines and fears via play.
89406125|NCT02273570|Active Comparator|control|Control group: standard care. The iPTH target in this group is 300-540 pg/ml
89406126|NCT02273570|Experimental|Optimal CKD-MBD control|Optimal CKD-MBD control: in this group the PTH target is150-300 pg/ml to be achieved with a therapeutic algorithm
89406127|NCT01676818|Experimental|Eribulin mesylate|Eribulin mesylate 1.4 mg/m2 IV bolus over 2-5 minutes on days 1 and 8 every 21 days in the absence of disease progression or unacceptable toxicity.
89406128|NCT02282150|Other|Conventional vs modified hydrocortisone;|5 weeks of conventional hydrocortisone followed by 16 weeks of modified-release hydrocortisone (Plenadren)
88882321|NCT01393769|Experimental|Melphalan|Intra-arterial chemotherapy with melphalan, via direct administration by catheterization of the ophthalmic artery. Dosage range from 3 to 5 mg, depending of patient's weight and estimated tumour volume: a)3 mg for patients under 10 kg and tumour volume size under 1,5 cm3; b)5 mg for patients over 10 kg and tumour volume over 1,5 cm3; c)4 mg in all other situations(tumour volume over 1,5 cm3 in patients under 10 kg or tumour volume under 1,5 cm3 in patients over 10 kg).
88882322|NCT01393782|Active Comparator|Angiotensin|The angiotensin arm will receive angiotensin II acetate at an initial dose of 20ng/kg/min, titratable during the study (6 hours) for MAP goals as outlined in the protocol.
88882323|NCT01393782|Placebo Comparator|Control|Control patients will receive placebo intravenously equal in duration, color and volume to the intervention arm's angiotensin II.
88882324|NCT01393808|Experimental|Paricalcitol|
88882325|NCT01393808|Placebo Comparator|placebo|
88882326|NCT01393834|Experimental|Delayed cord clamping|Delayed cord clamping for 30 seconds
88882327|NCT01393834|Experimental|Milking of the cord|Milking of the cord 4 times in 10 seconds
88882328|NCT01393834|No Intervention|Immediate cord clamping|Immediate cord clamping after delivery
88882329|NCT01393860||Aliskiren|Diabetic nephropathy
88882330|NCT01393873||Bariatric surgery pts with Type 2 DM|Primary bariatric surgery pts with Type 2 DM
88882331|NCT01393886|Experimental|Laparoscopic Greater Curvature Plication|Only one treatment arm
88882332|NCT01393912|Other|Stratum A Patients|The patients are newly diagnosed Diffuse Intrinsic Pontine Glioma patients. Patients may take crenolanib as an intact tablet or crushed in apple sauce/juice. Currently accruing to dose level 3 (170 mg/m^2).
88882333|NCT01393912|Other|Stratum B Patients|The patients are recurrent, refractory or progressive high-grade glioma including Diffuse Intrinsic Pontine Glioma patients. Patients may take crenolanib as an intact tablet or crushed in apple sauce/juice. Currently accruing to dose level 4 (220 mg/m^2).
88882334|NCT01393925|Experimental|parecoxib, normal saline|
88882335|NCT01393938|Other|Mullerian Duct Anomaly|
88882336|NCT01393951|Experimental|sc dose 1|subcutaneous (sc) vaccination of ASP7374 dose-1
88882337|NCT01393951|Experimental|sc dose 2|subcutaneous vaccination of ASP7374 dose-2
88882338|NCT01393951|Experimental|im dose 3|intramuscular (im) vaccination of ASP7374 dose-3
88882339|NCT01393977|No Intervention|control|Outpatient in hospital
88882340|NCT01393977|Active Comparator|rehabilitation|interventions: rehabilitation
88882341|NCT01393977|Experimental|Stem Cell Transplantation|interventions: stem cell transplantation
88882342|NCT01394029||deferasirox|
88882343|NCT01394042|No Intervention|No intervention|All consenting patients will be imaged with the Proxiscan and data compared with MRI, ProstaScint and biopsy data
89406129|NCT01354210|No Intervention|Standard of care only|The SOC for ART adherence consists of viewing a 20-minute animated tutorial which explains the importance of adherence to antiretroviral medication. It is specifically designed for viewers who have no science background and is appropriate for adolescents and young adults.
89406130|NCT01354210|Experimental|Intervention|This study will test a tailored, personalized SMS Text Message Reminder intervention to improve adherence to ART among non-adherent YLH. Participants will use their own cell phones for receipt of the intervention. Participants will have the option to choose a tailored personalized message that may be changed as requested throughout the study period (six months). Taking advantage of the Intelecare technology, participants will be asked to send a text message response indicating that that have successfully (or not) taken their meds per schedule. No identifying patient information will be included in the SMS text to protect patient confidentiality.
89406131|NCT00583076|Experimental|1|AST-120, 2grams, three times daily
89406132|NCT05122468|Active Comparator|CAF group|"Coronally advanced flap in combination with a connective tissue graft.~According to the technique(Zucchelli & De Sanctis 2000), this procedure consists of a rotated papilla, envelope flap. Intrasulcular incisions will be performed involving all the experimental units and at least one tooth mesial and distal to the experimental teeth. From the centre of rotation the incisions will be traced in a corono-apical direction toward the mesial and toward the distal extension of the flap.~After the accurate initial incisions, the flap will be raised full thickness apical to the mucogingival junction (MGJ), exposing 1 to 2 mm of bone at the base of the recession/dehiscence defects.~A linear mesio-distal incision will then be performed to cut the periosteum, releasing any muscular tension and allow a passive coronal positioning of the flap to cover the CEJ."
89437515|NCT03761108|Experimental|Linvoseltamab - Phase 2 - Cohort 3|"Anti-interleukin (IL)-6 receptor (R) prophylactic therapy followed by high dose of IV dose of REGN5458 monotherapy.~Note: Cohort 3 is not applicable for US."
88882344|NCT01394055|Active Comparator|RM-131|
88882345|NCT01394055|Placebo Comparator|Placebo|
88882346|NCT01394094|Experimental|Gum Chewing|Gum chewing (30 minutes in duration each time, 4 times/days at the usual time of meal, until the first flatus) in addition to conventional postoperative feeding schedule
88882347|NCT01394094|No Intervention|Conventional|Conventional postoperative feeding schedule
88882348|NCT01394107||Pregnant|"50 pregnant women with physiological ongoing pregnancy and undergoing planned caesarean section, without known coagulation disorders, will be included in to the study.~Inclusion criteria: pregnant women undergoing planned caesarean section, 39th-40th week of pregnancy, age 18-40 years, informed consent."
88882349|NCT01394107||Control|50 healthy women in fertility age (18-40 years) undergoing elective surgery for other than oncology or inflammatory indication, without known risk factors for coagulation disorders, not using hormonal contraception, informed consent.
88882350|NCT01394120|Experimental|Tarteted Therapy|
88882351|NCT01394120|Active Comparator|Standard Chemotherapy|
88882352|NCT01394133||HIV+ Female|HIV infected women between 21-40 years of age, not receiving oral contraceptives.
89437516|NCT03757689|Experimental|Neoadjuvant Pembrolizumab|Subjects will receive one dose of pembrolizumab 200 mg. Approximately 3 weeks after the initial dose of pembrolizumab, subjects will undergo wide excision and sentinel lymph node (SLN) biopsy. Post-operatively, subjects will receive up to 1 year of adjuvant pembrolizumab 200 mg every 3 weeks.
88882353|NCT01394146|Experimental|Subjects with healthy kidney function|
88882354|NCT01394224|Experimental|Levetiracetam IV Infusion (1500 mg)|
88882355|NCT01394224|Experimental|Levetiracetam tablets (1500 mg)|
88882356|NCT01394237||Operated by laparoscopic sacrocolpopexy|Patients operated at our institution by laparoscopic sacrocolpopexy between 2003 and 2007
88882357|NCT01394289|Experimental|Biological/Vaccine: Lolium allergen extract|Four concentrations of Lolium perenne allergen extract, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. This test will be referred to as the Titrated Skin Prick test.
88882358|NCT01394328||Persons with Dementia|Persons with Dementia are identified by the Modified Blessed Dementia Rating Scale and the IQCODE
89437517|NCT03755128||Pregnant women and their offspring from current pregnancy|
89535613|NCT03318029|Placebo Comparator|Placebo UK trial|Placebo and living in the UK
88882359|NCT01394341|Active Comparator|T2D, Dialysis, Liraglutide|Daily liraglutide treatment Chronic dialysis treatment
88882360|NCT01394341|Placebo Comparator|T2D, Dialysis, Placebo|Daily placebo Chronic dialysis treatment
88882361|NCT01394341|Active Comparator|T2D, Normal kidney function, Liraglutide|Daily Liraglutide treatment Normal kidney function
88882362|NCT01394341|Placebo Comparator|T2D, Normal kidney function, Placebo|Daily placebo treatment Normal kidney function
88882363|NCT01394354|Experimental|1|"Vorinostat. To determine the MTD, dose escalation for Vorinostat will be conducted following the 3 + 3 design The first cohort of 3 patients will be given 100mg/d on days 1-4, 8-11, 15-18. The second cohort of 3 new patients will be treated with Vorinostat 200mg/d. The third cohort will be given Vorinostat 300mg/d. Cycles will be repeated every 28 days. Maximum treatment cycles: 6. Bortezomib will be administered intravenously (i.v.) 1.3mg/m2 BSA an days 1, 8, 15.~Doxorubicin will be administered i.v. with a total dose of 18mg/m2 BSA per cycle (9mg/m2 BSA, d1 and 8).~Dexamethasone will be administered per os (p.o.) with 40mg (first cycle) or 20mg (all other cycles) on d1, 8, 15, and 22."
88882364|NCT01394367|Experimental|Respiratory and exercise therapy|Randomized, prospective, controlled, blinded study of three-week inpatient rehabilitation and subsequent continuing of the training at home for 12 weeks. The control group received conventional rehabilitation without a specific training program. After 15 weeks training is also offered to patients in the control group.
88882365|NCT01394367|No Intervention|respiratory and exercise therapy|
89406133|NCT05122468|Experimental|Tunnel group|"Tunnel technique in combination with a connective tissue graft.~When tunnelling procedures are applied, this technique consists of a supra-periosteal bed under a pedicle flap without any external incisions (Zabalegui et al. 1999). Afterwards, a connective tissue graft is placed and secured through the tunnel, covering the adjacent exposed roots.~To create a tunnel at the buccal aspect of the gingiva, sulcular partial-thickness incisions are made by means of a micro-blade through each recession area, extending the split-thickness beyond the mucogingival junction (MGJ). The partial dissection plane is then extended laterally through the papillae between the treated teeth without separating them. This incision must also be extended 3 to 5 mm mesial and distal from the lateral teeth to allow space for the connective tissue graft."
89406134|NCT05122312|Other|Totally removed smear layer|Smear layer is completely removed by etchant of phosphoric acid
89406135|NCT05122312|Other|Partially removed smear layer|Smear layer is partially removed by etchant of phosphoric acid
89406136|NCT00579020|Experimental|Moxidex|Moxifloxacin/dexamethasone phosphate ophthalmic solution, one drop in cul-de-sac and 4 drops on closed lids of study eye(s), four times a day, for seven days
89406137|NCT00579020|Active Comparator|Moxifloxacin|Moxifloxacin ophthalmic solution 0.5%, one drop in cul-de-sac and 4 drops on closed lids of study eye(s), four times a day, for seven days
89406138|NCT00579020|Active Comparator|Dexamethasone|Dexamethasone phosphate solution, 0.1%, one drop in cul-de-sac and 4 drops on closed lids of study eye(s), four times a day, for seven days
89406139|NCT04530604|Experimental|Defibrotide|
88882366|NCT01394380|Experimental|artificially sweetened beverages|subjects will be required to consume only artificially-sweetened sodas, water, tea or coffee
88882367|NCT01394380|No Intervention|regular sodas|subjects will continue their usual consumption of sweetened sodas
89406140|NCT04471142|Experimental|Group A|Intervention group with preventive application of compressive bandages in addition to suction drain (routine adopted at the institution).
88882368|NCT01394393|Experimental|ECT|Experiential-Cognitive Therapy for Obesity
89406141|NCT04471142|No Intervention|Group B|Group control. The patient will follow the institution's routine with only the suction drain.
88882369|NCT01394393|Active Comparator|BCT|Cognitive behavioral treatment program
88882370|NCT01394393|Sham Comparator|NT|Nutritional groups In this condition (NT) the participants enter only 5 weekly nutritional groups held by dietitians.
88882371|NCT01394406|Experimental|Ketamine group|
88882372|NCT01394406|Placebo Comparator|Saline group|
88882373|NCT01394419|Experimental|NAC group|N-acetylcysteine
89406142|NCT04169698|No Intervention|Control group|Participants will receive daily supplements of calcium (1000 mg), vitamin D (800 IU or more) and calcitriol (0.25 micro gram).
89406143|NCT04169698|Experimental|Denosumab group|Participants will receive a single 60 mg subcutaneous dose of denosumab (Prolia) every 6 months for 12 months plus daily supplements of calcium (1000 mg), vitamin D (800 IU or more) and calcitriol (0.25 micro gram).
89406144|NCT04169698|Experimental|Alendronate group|Participants will receive an oral alendronate at a dose of 70 mg once every week for up to 12 months plus daily supplements of calcium (1000 mg), vitamin D (800 IU or more) and calcitriol (0.25 micro gram).
89406145|NCT04470752|Placebo Comparator|Placebo|InOrpha solution/ml, three times daily with meals for the Treatment period, 7 or 30 days.
89406146|NCT04470752|Experimental|Capsaicin|InOrpha solution plus 1 mcg Capsaicin/ml, three times daily with meals for the Treatment period of 7 or 30 days.
89406147|NCT02273804|Experimental|topiramate|pill
89406148|NCT02273804|Placebo Comparator|placebo|Sugar pill
89406149|NCT04142944|Experimental|Dexcom G6 with predictive hypo alert|
89406150|NCT04142944|Active Comparator|Dexcom G6 without predictive hypo alert|
89406151|NCT00578474|Experimental|Moxidex|Moxidex otic solution
89406152|NCT00578474|Active Comparator|FLOXIN|Ofloxacin otic solution
89406153|NCT03909490|Active Comparator|Control|
89406154|NCT03909490|Experimental|intervention- tool|
88882374|NCT01394419|Placebo Comparator|Placebo group|Saline
88882375|NCT01394432|Active Comparator|Group 1 (PCI+SC implantation)|Endocardial Stem cells implantation with Noga system
88882376|NCT01394432|Placebo Comparator|Group 2 (PCI+Placebo)|Placebo
88882377|NCT01394445|Active Comparator|Physostigmine|
88882378|NCT01394445|Placebo Comparator|Placebo|
89406155|NCT00577148|Experimental|Rimonabant|Rimonabant 20 mg once daily.
89406156|NCT00577148|Placebo Comparator|Placebo|Placebo (for Rimonabant) once daily.
89406157|NCT03700918|Experimental|DaVingiTR System Single Arm|single-arm, open label, multi-center study.
89406158|NCT05203796|Experimental|Experimental group: Dry eye disease patients (n=12)|"Patient needs to visit site at least 7 times(Screening, Baseline, wk1, wk2, wk3, wk4, wk5). From baseline visit, patients wear our clinical trial device 30mins per day for 5wks(2Hz stimulation). All other procedures during clinical trial the are the same.~Intervention: Device: Transcutaneous pulsed electrical stimulation"
88882379|NCT01394458|Experimental|30 % ethanol/ 4 % sodium citrate group|For patients randomized to the 30% ethanol /4 % sodium citrate group, the lock solution will be provided in pre-filled syringes for single use only. After each dialysis session, the locking solution will be instilled into both catheter lumens, the lumens clamped and caps tightly secured to the hubs. Any remaining 30% ethanol/4% sodium citrate solution in each syringe will be discarded. The locking solution will be withdrawn from the catheter lumens before the next dialysis session.
89406159|NCT05203796|Sham Comparator|Comparison group: Dry eye disease patients (n=12)|"Patient needs to visit site at least 7 times(Screening, Baseline, wk1, wk2, wk3, wk4, wk5). From baseline visit, patients wear our clinical trial device 30mins per day for 5wks(sham stimulation). All other procedures during clinical trial the are the same.~Intervention: Device: Sham device"
89406160|NCT03673228|Experimental|Intervention Group|"Participants randomized to the Intervention Arm will receive counseling that includes:~A Visit prior to discharge~Follow up calls after discharge~Text Messaging Support~Caregiver Support"
89406161|NCT03673228|Active Comparator|Standard treatment|Patients will receive current usual care.
89406162|NCT00664664|Experimental|1|APD125 20 mg
89406163|NCT00664664|Experimental|2|APD125 40 mg
89406164|NCT00664664|Placebo Comparator|3|Matching Placebo
89406165|NCT05122234|Experimental|Secretome - mesenchymal stem cell group (n = 20)|This group will be given secretome - mesenchymal stem cell and COVID-19 standard therapy
88882380|NCT01394458|Experimental|Heparin 1000 U/ml|For patients randomized to the heparin group, the heparin will be provided in 10 ml glass vials. Two, 3 ml syringes will be used to draw up the required volume of heparin to fill each lumen. A separate syringe will be used to fill each catheter lumen. The necessary volume should match the lumen volume with no overfill. The locking solution will be instilled into both catheter lumens, the lumens clamped and caps tightly secured to the hubs. The locking solution will be withdrawn from the catheter lumens before the next dialysis session.
89406166|NCT05122234|Placebo Comparator|Control ( n= 20)|This group will be given placebo and COVID-19 standard therapy
88882381|NCT01394471|Experimental|oxytocin|Twice daily treatment of oxytocin will be administered by subjects
88882382|NCT01394471|Placebo Comparator|Control spray|Self administration twice daily of intranasal spray that does not contain oxytocin
88882383|NCT01394484|Experimental|Arm 1|Four servings of dairy foods per day for 42 days, followed by washout for 42 days, followed by dietary supplements for 42 days
88882384|NCT01394484|Experimental|Arm 2|Dietary Supplements for 42 days, followed by washout for 42 days, followed by 4 servings of dairy foods for 42 days.
88882385|NCT01394497|Experimental|NAC procurement protocol|The allocated organ, in addition to the standard procedure, was treated with a systemic NAC infusion before initiating the liver harvesting procedure, and a loco-regional infusion into the portal vein before cross-clamping.
88882386|NCT01394497|No Intervention|Standard procurement procedure|Allocated organ was treated according to the centre's standard procurement procedure: a modified double perfusion technique, where donor livers are gravity-perfused in situ via the aorta and portal vein with Celsior solution at 4 °C. After hepatectomy, donor livers were further perfused at the back-table with Celsior solution and then stored in conventional bags containing the same solution at 4 °C until transplantation.
88882387|NCT01394536|Sham Comparator|1|"Sham device - an EAS band placed over the P6 acupoint that will be turned off (inactive)."
88882388|NCT01394536|Active Comparator|2|The second arm will use the ReliefBand (Aeromedix, Jackson, WY), an FDA-approved, reusable, battery-operated electroacustimulation device.
88882389|NCT01394549||Cardiology|The study includes all patients hospitalized for acute coronary syndrome during the week selected and who agreed to participate in the study.
88882390|NCT01394562|Experimental|Ferinject (ferric carboxymaltose)|
88882391|NCT01394562|Other|Standard of Care|Standard of care. IV iron is not permitted
88882392|NCT01394575|Experimental|IMRT-SIB|
88882393|NCT01394588||Cardiac Surgery Patients|Competent Adult Patients going for elective cardiac surgery.
88882394|NCT01394653|Experimental|orally-disintegrating (OD) tablet precedence group|
88882395|NCT01394653|Experimental|conventional tablet precedence group|
88882396|NCT01394666||CP-CML patients who have failed Imatinib 400 mg daily|
88882397|NCT01394679|Active Comparator|18-F-FDG Imaging Agent|18 F FDG followed by PET/CT imaging
88882398|NCT01394679|Experimental|99m Tc-EC-DG imaging agent|99m Tc-EC-DG injection followed by SPECT/CT imaging (target of 20-30 mCi of Tc)and < 1 mg EC-DG
88882399|NCT01394731|Experimental|Paracetamol 1|
88882400|NCT01394731|Experimental|Paraceatmol 2|
88882401|NCT01394731|Active Comparator|Meperidine|
88882402|NCT01394770|Experimental|Aliskiren|
88882403|NCT01394770|Active Comparator|Amlodipine|
88882404|NCT01394783|Other|Classic laryngoscope|Phase 1 and 2: Endotracheal intubation using the classic laryngoscope with Miller blade 0 or 1 according to weight of infant.
88882405|NCT01394783|Other|Videolaryngoscope|Phase 1: Endotracheal intubation using the videolaryngoscope with blade 0 or 1 according to weight of infant. videolaryngoscope will be used to proceed to endotracheal intubation indirectly with the use of the video monitor for guidance. Phase 2: Endotracheal intubation using the classic laryngoscope with Miller blade 0 or 1 according to weight of infant.
88882406|NCT01394796|Active Comparator|Epigallocatechin-3-gallate (EGCG)|EGCG normally works as a dietary supplement. EGCG administration in Down syndrome patients will result in an improvement of their cognitive performance.A a daily oral dose containing 9 mg/kg (range 6.9-12.7) of EGCG is given during three months.
88882407|NCT01394796|Placebo Comparator|Placebo|No active substance is given.
88882408|NCT01394809|Experimental|Mental Practice|During motor imagery practice a person imagines performing a movement with all its sensory consequences without actually moving. In this study the therapists follow a motor imagery guideline designed for rehabilitation of movement performance. The guideline offers therapists structure and a strategy to deliver subject-specific imagery, and is based on principles of motor learning.
88882409|NCT01394809|Experimental|Mirror Therapy|Mirror therapy is thought to work by using vision of the intact or good arm to replace or drive proprioception in the affected arm, and so normalise the afferent segment of the movement process.
88882410|NCT01394809|Active Comparator|Relaxation training|The control group will receive therapy as usual. Currently, this means that patients are immobilized during first 3-4 weeks. The control group will receive additional relaxation training during this period to achieve the same total amount of time the therapist spends with the patients of the experimental groups.
88882411|NCT01394822||Ultrasound results reported|
88882412|NCT01394822||Ultrasound results NOT reported|
88882413|NCT01394835|Experimental|Alpha -1 Antitrypsin|
88882414|NCT01394848|Active Comparator|Genous stent group|Genous stent (Endothelial progenitor cell capture stent) insertion in elderly patients with stable coronary artery disease
88882415|NCT01394848|Active Comparator|Xience stent group|Xience Prime V stent (everolimus eluting stent) insertion in elderly patients with stable coronary artery disease
88882416|NCT01394848|Active Comparator|Atorvastatin 20mg group|
88882417|NCT01394848|Active Comparator|Atorvastatin 80mg group|
88882418|NCT01394861|Experimental|ESD using MASTER Slave Robotic System|
88882419|NCT01394874|Experimental|Telephone-linked Communication (TLC)|This group will receive the computer-based telephone counseling.
89406167|NCT00439634|Placebo Comparator|Placebo|
89406168|NCT00439634|Experimental|AVE1625 dose level 1|
89406169|NCT00439634|Experimental|AVE1625 dose level 2|
89406170|NCT00439634|Experimental|AVE1625 dose level 3|
88882420|NCT01394874|No Intervention|Control|This is the control group. They will receive the exercise class, however, they will not receive the telephone counseling.
89406171|NCT03161626||Moderate to Severe Factor X Deficiency|
89406172|NCT02282306|Other|TTIP-PRO|"Patients who have experienced an OOD in the past 8 months will be eligible to receive TTIP-PRO. A letter about the study will be sent to those patients. Interested patients will call the UC Health staff working on this study. The intervention entails administering the Personal Opioid-Overdose Risk Survey and the Opioid Overdose and Treatment Awareness Survey to the patient. The TTIP-PRO computer program uses the information to generate the Personal Feedback Report, which is used by the Peer Interventionist to provide the intervention. The TTIP-PRO computer program also creates the Personal Risk Factors Report which is mailed to the participant with some other helpful information."
89406173|NCT02277236||Younger Veterans|Male Veterans, 45-64.9 years of age. (Exposures include DXA scanning and CT imaging.)
89406174|NCT02277236||Young-Old Veterans|Male Veterans, 65-84.9 years of age. (Exposures include DXA scanning and CT imaging.)
89406175|NCT05116306|Experimental|hyaluronic acid group|study group
89406176|NCT05116306|Other|propylene glycol group|control group
89406177|NCT00570986|Placebo Comparator|1|Arm #1 is used for entire study. At week 12, arm is rerandomized.
89406178|NCT00570986|Active Comparator|2|Arm #2 is used for entire study. At week 12, arm is rerandomized.
89406179|NCT00570986|Active Comparator|3|Arm #3 is not used for weeks 0-11. At week 12, arm is rerandomized.
89406180|NCT00570752|Active Comparator|Placebo + background low to moderate dose statin|Placebo + background low to moderate dose statin Tablets, Oral, 0 mg, once daily, for 12 weeks
89406181|NCT00570752|Experimental|BMS-582949 + Background low to moderate dose statin|BMS-582949 + Background low to moderate dose statin Tablets, Oral, 100 mg, once daily for 12 weeks
89406182|NCT00570752|Active Comparator|Atorvastatin|Atorvastatin Tablets, oral, 80 mg once daily for 12 weeks
89406183|NCT00569972|Experimental|15 mg PD 0200390|
89406184|NCT00569972|Experimental|30 mg PD 0200390|
88882421|NCT01394887|Active Comparator|metformin group|this group received 850 mg metformin twice daily, along with recommended diet and exercise
88882422|NCT01394887|Placebo Comparator|placebo group|This group received 850 mg of placebo twice daily, along with a recommended regimen of diet and exercise
88882423|NCT01394913|Experimental|Reumatocept 25mg|50mg each week for 30 weeks
88882424|NCT01394913|Active Comparator|Enbrel 25mg|50mg each week for 30 weeks
88882425|NCT01394965|No Intervention|ECG Mapping|
89406185|NCT00569972|Experimental|45 mg PD 0200390|
89406186|NCT00569972|Experimental|60 mg PD 0200390|
89406187|NCT00569972|Experimental|Placebo PD 0200390|
89406188|NCT05106946|Experimental|ThisCART22 cells injections|In this study, allogeneic anti-CD22 CAR T Cells(ThisCART22 cells) is used to treat patients with refractory or relapsed CD22 positive B cell malignancies.
89406189|NCT04250740|Experimental|Coffee A|
89535614|NCT03318029|Active Comparator|Vitamin D UK trial|Vitamin D supplementation and living in the UK
88882426|NCT01395069|Active Comparator|Nepafenac 0.1%|
88882427|NCT01395069|Active Comparator|Ketorolac 0.5%|
88882428|NCT01395069|Placebo Comparator|Placebo|
88882429|NCT01395095|Experimental|OPTICARE-A|Starts 2 weeks after ending standard cardiac rehabilitation (CR) and is based on five phonebased coaching sessions at 6 weeks intervals up to 6 months. Each coaching session includes 5 stages: (1) Asking questions to establish patient's knowledge, attitude and beliefs about their risk factors; (2) Explanation and rationale; (3) Assertiveness training; (4) Goal setting; (5) Reassessment.
88882430|NCT01395095|Active Comparator|OPTICARE-B|Standard CR according to the guidelines consisting of (a) 2 times a week exercise program of 1.5 hours during 12 weeks, (b) upon request of the patient: participation in multifactorial lifestyle and risk factor sessions (medical information, dietary advises and emotional advises, information about risk factors, smoking cessation program and stress management sessions)
88921989|NCT05989802|Experimental|Evaluation of various novel TB triage and diagnostic tests|The investigators will conduct evaluation of novel TB triage and diagnostic tests in a cohort of children with presumed TB. The investigators aim to enroll 250 participants per year at each of three enrollment sites for evaluation of various novel TB triage and diagnostic tests and 30 health workers to assess test usability. Novel test evaluations will be conducted on a rolling basis as new tests ready for field evaluation are identified.
88921990|NCT05989412|No Intervention|Control arm|a control arm where the investigators will only measure the quality of life using the EQ-5D questionnaire. This measurement will be performed at the same time as both screening arms.
89406190|NCT04250740|Experimental|Coffee B|
89406191|NCT04250740|Experimental|Coffee C|
89406192|NCT00565760|Experimental|1|
89406193|NCT00565760|Placebo Comparator|2|
89406194|NCT05121610||CABG group|CABG group
89406195|NCT05121610||HCR group|HCR group
89406196|NCT05121610||PCI group|PCI group
89406197|NCT02282384|Experimental|oseltamivir|75 mg oseltamivir orally twice daily for 5 days within 72 hours of symptom onset
89406198|NCT02282384|Placebo Comparator|Placebo|75mg placebo calcium carbonate pills taken twice daily for five days within 72 hours of symptom onset and will be identical in appearance to oseltamivir
89406199|NCT02989389|Experimental|LY3323795 (Part A)|Participants received escalating doses of 0.3 mg (milligrams), 1 mg, 3 mg, 10 mg, 30 mg and 100 mg of LY3323795 orally.
89406200|NCT02989389|Placebo Comparator|Placebo (Part A)|Participants received placebo identical to LY3323795 orally.
89406201|NCT02989389|Experimental|LY3323795 (Part B)|Participants received 6 mg, 20 mg and 80 mg of LY3323795 orally.
89406202|NCT02989389|Placebo Comparator|Placebo (Part B)|Participants received placebo identical to LY3323795 orally.
89406203|NCT02989389|Experimental|LY3323795 (Part C)|Part C was not initiated due to a Lilly internal strategy decision.
89406204|NCT02989389|Experimental|LY3323795 + Itraconazole (Part C)|Part C was not initiated due to a Lilly internal strategy decision.
89406205|NCT00436670|Experimental|AMG 317 75 mg|75 subjects
89406206|NCT00436670|Placebo Comparator|Placebo Arm|75 subjects
89406207|NCT00436670|Experimental|AMG 317 300 mg|75 subjects
89406208|NCT00436670|Experimental|AMG 317 150 mg|75 subjects
89406209|NCT02284646|Experimental|Personalized physical training|9-week personalized physical training program (ergometric bicycle)
89406210|NCT02284646|No Intervention|Information about physical activity|2 sessions of information on physical activity
89406211|NCT04055337|Experimental|Flap Sliding|"noninvasive flap sliding technique for managing flap striae following laser in situ keratomileusis (LASIK)."
89406212|NCT03187509|Experimental|Weight-Based Torsemide Group|Subjects will be randomized to complete a weight-based torsemide dosing regimen for their outpatient heart failure management. These subjects will prescribed a specified dose of torsemide on discharge from the hospital and subsequently have a phone encounter with a physician three times a week where their dose of torsemide will be titrated based on an algorithm which factors in current symptoms and weight. Study subjects will have a final follow-up appointment at the completion of the study to evaluate current symptoms, weight and perform blood work to assess kidney function, electrolytes and brain natriuretic peptide levels.
89406213|NCT03187509|Active Comparator|Standard Outpatient Management Group|Subjects will be randomized to standard outpatient heart failure management where they will be prescribed a fixed daily dose of a loop diuretic upon discharge from the hospital and have a follow-up appointment within one week of discharge. All medications including loop diuretic type, dose and frequency will be managed at the discretion of the patient's primary care physician or cardiologist. Study subjects will have a final follow-up appointment at the completion of the study to evaluate current symptoms, weight and perform blood work to assess kidney function, electrolytes and brain natriuretic peptide levels.
88921991|NCT05989412|Experimental|Standard referral|a screening arm with standard participant referral for diagnosis at the general practitioner's office (after 1 positive test score on the PHQ-9 questionnaire or suicidal ideation).
88921992|NCT05989412|Experimental|Limited referral|a screening arm with limited participant referral for diagnosis at the general practitioner's office (after three consecutive positive test scores on the PHQ-9 questionnaire or suicidal ideation).
89406214|NCT05121532|Active Comparator|non segmental vitiligo|serum analysis
89406215|NCT05121532|Active Comparator|normal volunteer|serum analysis
89406216|NCT00430508|Experimental|4|olmesartan medoxomil (OM) /hydrochlorothiazide (HCTZ) Tablet 40mg/0mg + 20mg/12.5mg matching placebo tablet once daily for 8 weeks
89406217|NCT00430508|Experimental|1|olmesartan medoxomil (OM) /hydrochlorothiazide (HCTZ) tablets 40mg/25mg + 20mg/12.5mg matching placebo tablet once daily for 8 weeks
89406218|NCT00430508|Experimental|3|olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets 20mg/12.5mg + 40mg/0mg matching placebo tablet once daily for 8 weeks
89406219|NCT00430508|Experimental|2|olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets 40mg/12.5mg + 20mg/12.5mg matching placebo tablet once daily for 8 weeks
89406220|NCT03660735||Male Factor Subfertility|Participant is undergoing first or second cycle of IVF and ICSI for male factor subfertility
89406221|NCT03660735||Recurrent Implantation Failure|Participant is undergoing an IVF cycle to treat subfertility with a history of Recurrent Implantation Failure (RIF).
89406222|NCT03660735||Female Subfertility|Participant is undergoing an IVF cycle to treat at least 1 year of subfertility
89406223|NCT04221880|Active Comparator|Group ESPB|Ultrasound-guided erector spinae plane block with 20 ml %0.25 bupivacaine and Saline iv. bolus and infusion (same volume as Group Lidocaine)
89406224|NCT04221880|Active Comparator|Group Lidocaine|1.5 mg / kg lidocaine iv. bolus and, 1.5mg / kg / h lidocaine iv. infusion and, Ultrasound-guided erector spinae plane block with 20 ml saline
89406225|NCT04221880|Sham Comparator|Group Control|Ultrasound-guided erector spinae plane block with 20 ml saline and, Saline iv. bolus and infusion (same volume as Group Lidocaine)
89406226|NCT04055415|Experimental|Intervention group|The MSCs of 1×10*6/kg will be given in Central venous catheterization for injection at a total 100 ml . Once every week#a total of two times. The Conventional drug therapy（expectorant，bronchodilator） is used.
89406227|NCT04055415|Other|Control group|The Conventional drug therapy（expectorant，bronchodilator） is used with the control group
89406228|NCT05218759|Experimental|arm A|Progressive disease (PD) after anlotinib administration
89406229|NCT05218759|Experimental|arm B|Stable disease (SD) after anlotinib administration
89406230|NCT01922752|Experimental|CEP-37440|
89406231|NCT03662217|Experimental|Algorithm-based diet|Subjects randomized to this arm will receive personally tailored dietary recommendations based on their predicted glycemic responses according to the study algorithm.
89406232|NCT03662217|Other|ADA- based diet|Subjects randomized to this arm will receive nutritional recommendations according to the standard American dietary approach for treating diabetes
89406233|NCT03661359|Experimental|Social Determinants of Health|Intervention will be the Social Determinants of Health Referrals.
88882431|NCT01395095|Experimental|OPTICARE-C|(a) standard CR consisting of 2 times a week exercise program of 1.5 hours during 12 weeks. (b) (mandatory) participation in multifactorial lifestyle and risk factor sessions: i.e. 4 sessions of 2 hours each (medical information, dietary advises, risk factors and emotional advises). If applicable, patients will participate in smoking cessation, dietary and stress management programs . (c) Individual sessions and a personalized home-based program to promote an active life style upon instruction of a physiotherapist and physical activity counselor during and after completion of rehabilitation. Activity monitors will be used to provide feedback. (d) Additional compulsory supervised multifactorial lifestyle and risk management training sessions of each 2 hours provided at 4, 6 and 12 months.
88882432|NCT01395108|Placebo Comparator|Placebo|Placebo
88882433|NCT01395108|Active Comparator|Nemonoxacin 125mg|Nemonoxacin 125mg
88882434|NCT01395108|Active Comparator|Nemonoxacin 250mg|Nemonoxacin 250mg
88882435|NCT01395108|Active Comparator|Nemonoxacin 500mg|Nemonoxacin 500mg
88882436|NCT01395108|Active Comparator|Nemonoxacin 750mg|Nemonoxacin 750mg
88882437|NCT01395108|Active Comparator|Nemonoxacin 1000mg|Nemonoxacin 1000mg
88882438|NCT01395121|Experimental|nilotinib|nilotinib 400mgs oral tablets
88882439|NCT01395134|No Intervention|Visualization of the EBSLN and RLN|Visual inspection of the nerves.
88882440|NCT01395134|Experimental|Neuromonitoring of the EBSLN and RLN|Electrical stimulation and monitoring of the nerves' function.
88882441|NCT01393262||Healthy Escort|
88882442|NCT01393262||Hand Service patient|
88882443|NCT01395147|Experimental|Lu AA21004 group|
89406234|NCT00427856|Experimental|Obatoclax mesylate 40mg|40 mg over 3 hrs q/weekly for 12 weeks, 4 weeks combo with rituximab, another 8 weeks single-agent obatoclax
88882444|NCT01395160||Adult ADHD|
88882445|NCT01395160||Bipolar Disorder|
89190861|NCT02951351|Experimental|Proparacaine + Culture|Patients will undergo the standard injection protocol. A conjunctival culture will then be obtained followed by the application of povidone-iodine to the eyelashes and eyelid margins. Patients will undergo application of another drop of topical anesthetic followed by conjunctival culture. After the culture, this group of patients will have 5% povidone iodine applied to the conjunctival surface. Intravitreal injection will then proceed.
89406235|NCT00427856|Experimental|Obatoclax mesylate 60mg|60 mg obatoclax mesylate over 24 hours, q/weekly for 12 weeks, 4 weeks combo with rituximab, another 8 weeks single-agent obatoclax
88882446|NCT01395160||Healthy control|
88882447|NCT01395173|Placebo Comparator|Control|Subject will undergo standard colonoscopy.
88882448|NCT01395173|Active Comparator|Position change|Subject will under go standard colonoscopy, but also with position changes during colonoscope withdrawal.
88882449|NCT01395186|Other|varicocelectomy|varicocelectomy for patients complaining of pain
88882450|NCT01395199|Placebo Comparator|Starch pill|Placebo
88882451|NCT01395199|Experimental|Amlodipine|Amlodipine 5mg QD
88882452|NCT01395212||Cardiac stem cell therapy 5 years ago|
88882453|NCT01395225||All Patients|There will be no separate cohorts in this study. All patients will have their specimens processed by conventional means and by the study method. The conventional means will be the control for the study method.
88882454|NCT01395238|No Intervention|Wait-List Group|
89406236|NCT00427154|Active Comparator|A|
89406237|NCT00427154|Active Comparator|B|
89406238|NCT03627871|Experimental|Trending majority norm|Participants receive information about exercise-related norms that apply to the majority of the population and are told this norm has been increasing recently.
89406239|NCT03627871|Experimental|Non-trending majority norm|Participants receive information about exercise-related norms that apply to the majority of the population but are not told about recent trends.
89406240|NCT03627871|Experimental|Trending minority norm|Participants receive information about exercise-related norms that apply to a minority of the population and are told this norm has been increasing recently
89406241|NCT03627871|Experimental|Non-trending minority norm|Participants receive information about exercise-related norms that apply to a minority of the population but are not told about recent trends.
89406242|NCT03627871|Experimental|Control|Participants receive information about exercise unrelated to social norms or recent trends.
89406243|NCT02988219|Active Comparator|General anesthesia (G)|Holter ECG monitor General anesthesia Open kidney cancer surgery
89406244|NCT02988219|Experimental|Combined general/epidural (G/E)|Holter ECG monitor Epidural anesthesia General anesthesia Open kidney cancer surgery
89406245|NCT05120674|Active Comparator|CPT+CBT-I (usual care)|Veterans in this group completed the inpatient unit's existing Cognitive Processing Therapy (CPT) group based protocol. Furthermore, veterans in this group will also complete the inpatient unit's existing Cognitive Behavioral Therapy for Insomnia (CBT-I) group based protocol.
89406246|NCT05120674|Active Comparator|CPT+ CBT-I + ERRT|Veterans in this group completed the CPT and CBT-I protocols augmented by the ERRT. ERRT therapy focuses on treating the posttrauma nightmares and does these via sleep hygiene, nightmare rescription, and exposure.
89190862|NCT02940925|Experimental|Drug: Taxol,cisplatin and capecitabine|"Taxol, cisplatin and capecitabine as induction chemotherapy (IC) combined with cisplatin concurrent chemoradiotherapy with intensity modulated radiation therapy |(CCRT)."
89406247|NCT05120674|Experimental|CPT+ CBT-I + ERRT + NAP|Veterans in this group will complete the CPT+CBT-I+ERRT protocol augmented by auditory stimulation (NAP). Exposure stimulation includes playing a rhythmic tone at 40-60hz (commonly referred to as pink noise) throughout the ERRT session and during the presleep exposure portion of ERRT. During the ERRT session, the tone will be played softly so as not to interfere with the session and will be played throughout the entire session. Before sleep, the veteran will play the 40-60hz tone via their smartphone while they read their rescripted nightmare. During sleep, the 40-60hz tone will be delivered during slow-wave-sleep (SWS) by the DREEM device (DREEM, 2013).
89406248|NCT01346059|Placebo Comparator|Saline|The saline arm will receive normal saline through the catheter as a placebo.
89406249|NCT01346059|Experimental|Vancomycin|The vancomycin arm will receive vancomycin solution through the catheter.
89190863|NCT02940925|Active Comparator|Drug: Cisplatin and 5-Fluorouracil|Cisplatin and 5-Fluorouracil as induction chemotherapy combined with cisplatin concurrent chemoradiotherapy with intensity modulated radiation therapy.
88882455|NCT01395238|Experimental|Parenting Group|Experimental Condition. Group-based, 8 weekly sessions/2 hours per week.
88882456|NCT01395251|Other|Prednisolone|Patients with suspicious of rheumatoid arthritis will undergo a prednisolone test with 20 mg per day for 3 days after 2 days of therapy with paracetamol 500 mg twice for 2 days.
88882457|NCT01395264||Episodic Migraine.|
89406250|NCT03661281|Experimental|Simulated Thumb Arthrodesis|Subjects will have their thumb immobilized in 2 prefabricated wrist splints to simulate 2 different fusion positions tested: one splint to simulate the MCP fusion and one to represent the IP fusion. Patients will complete hand function tests in each of the splints to evaluate hand function.
89406251|NCT03202030|Experimental|IDR|Immediate dentoalveolar restoration conducted with bone removed from the tuber
89406252|NCT03202030|Active Comparator|Bio-oss|Bovine demineralized bone (Bio-oss Collagen) applied on the buccal resorption of the immediate implant
89406253|NCT02284724|Experimental|Needling|Insertion of solid mono-filament needle into lumbar multifidus muscle at both sides of L4/5 segment
89406254|NCT02284724|Other|Sham|The plastic tube containing the mono-filament needle will be pressed into the skin over the lumbar multifidus muscle at both sides of L4/5 segment - without insertion through the skin
89406255|NCT05204069|Experimental|Three-dimensional screening for visual disorders using the RetinoMax Device|Instillation of cyclopentolate of 3 drops of cyclopentolate at T0',T5' and t10' with to induce a certain level of cycloplegia and evaluate manifest refraction at t45' using the RetinoMax Device.
88882458|NCT01395264||menstrual migraine|
89406256|NCT05204069|Active Comparator|Non-standardized device for usual vision disorders|Screening device for usual vision disorders, performed by the school doctor during the usual prevention visit, with the tools used in the school doctor's current practice, non-standardized, according to his preference
88882459|NCT01395264||Cluster Headache patients|
88882460|NCT01395264||control (non-headache group)|
88882461|NCT01395290|Experimental|cholecalciferol|cholecalciferol 20.000 IU per week
88882462|NCT01395303||myocardial infarction|subjects with myocardial infarction in the Tromsø study end point registry
88882463|NCT01395303||type 2 diabetes|subjects with type 2 diabetes in the Tromsø study end point registry
88882464|NCT01395303||stroke|subjects with stroke in the Tromsø study end point registry
88882465|NCT01395303||fracture|subjects with fracture in the Tromsø study end point registry
88882466|NCT01395303||cancer|subjects with cancer in the Tromsø study end point registry
88882467|NCT01395303||death|subjects registered as dead in the Tromsø study end point registry
89406257|NCT03661203||Qualitative cohort|The cohort consists of MSM with late HIV diagnosis. The person from this cohort will participate to round table called also focus group or individual interview.
89406258|NCT03661203||Quantitative cohort|MSM community will be invited to participate to an online self questionnaire established from the information gathered from the previous cohort.
88882468|NCT01395303||aortic stenosis|subjects with aortic stenosis in the Tromsø study end point registry
88882469|NCT01395303||control group|randomly selected controls from the Tromsø study
88882470|NCT01395342|No Intervention|blood pressure and heart rate data|
88882471|NCT01395355|Experimental|Linking Individuals Being Emotionally Real (LIBER8)|Participants will attend a 8-12 week, 1-2 hours long intervention comprised of cognitive behavior and dialectical behavior therapy techniques.
89406259|NCT04548973|Experimental|Esketamine Group|At the beginning of the operation, 0.25mg/kg ketamine was administered intravenously, and normal saline was diluted to 2mL to assist sedation and analgesia
89406260|NCT04548973|Placebo Comparator|Control Group|At the beginning of the operation, 2ml normal saline was given intravenously
89406261|NCT02277938||Amantadine|Lung cancer patients being prescribed chemotherapy
89406262|NCT04056585|Experimental|Brachial plexus block with intermittent pneumatic compression|Hand and forearm surgery is performed after axillary brachial plexus block with intermittent pneumatic compression for 3 minutes.
89406263|NCT04056585|Placebo Comparator|Brachial plexus block|Hand and forearm surgery is performed after axillary brachial plexus block only.
89406264|NCT05120518||Pediatric patients with cancer and non-cancer tumor types|Pediatric patients with cancer and non-cancer tumor types (solid, liquid, neuro-oncology and stem cell)
89406265|NCT04710875|Active Comparator|Na-lactate|Iv infusion of sodium D/L lactate
89406266|NCT04710875|Placebo Comparator|Sodium chloride|Iv infusion of Sodium chloride
88882472|NCT01395355|Active Comparator|Weight Management Control|Participants will attend a 8-12 week, 1-2 hours long intervention comprised of behavioral weight management techniques.
88882473|NCT01395381|Placebo Comparator|Placebo|
88882474|NCT01395381|Experimental|Albendazole|
88882475|NCT01395407|Experimental|Cohort A|"Cohort A: resection cavity volume up to 4.2 cc (corresponds to 0 - 2 cm diameter).~Dose level Cohort A (Gy)~21~23~25"
88882476|NCT01395407|Experimental|Cohort B|"Cohort B: resection cavity volume > 4.2 cc and ≤ 14.1 cc (2 - 3 cm diameter).~Dose level Cohort B (Gy)~18~20~22"
88882477|NCT01395407|Experimental|Cohort C|"Cohort C: resection cavity volume > 14.1 cc and ≤ 35 cc (3 - 4 cm diameter).~Dose level Cohort C (Gy)~15~17~19"
88882478|NCT01395420|Experimental|1|CAZ104 (2000mg Ceftazidime/500mg Avibactam)
88882479|NCT01395420|Experimental|2|CAZ104 (3000mg Ceftazidime/1000mg Avibactam)
88882480|NCT01395433|Active Comparator|Treatment A|Conventional escitalopram
88882481|NCT01395433|Experimental|Treatment B|Escitalopram test treatment B
88882482|NCT01395433|Experimental|Treatment C|Escitalopram test treatment C
88882483|NCT01395446||prolonged neutropenic patients|patients that will undergo treatment for a hematological malignancy expected to result in grade 4 neutropenia of prolonged duration
88882484|NCT01395459|No Intervention|control|Care as usual is given.
89406267|NCT04055805||Fondazione Policlinico Universitario A. Gemelli, Roma|Polo Scienze della Salute della Donna e del Bambino
89406268|NCT04055805||Università degli Studi di Pavia|
89406269|NCT04055805||"Università di Napoli Federico II"|
89406270|NCT04055805||Università degli Studi di Siena|
89406271|NCT04055805||Azienda Ospedaliero-Universitaria Careggi Firenze|
89406272|NCT04055805||Fondazione Policlinico Universitario A. Gemelli Roma|U.O.C Chirurgia Senologica
89406273|NCT04055805||Istituto Nazionale dei Tumori di Napoli Fondazione G.Pascale|
89406274|NCT00415142|Experimental|Saredutant 100 mg|Saredudant100 mg once daily for a maximum of 32 weeks
89406275|NCT00415142|Active Comparator|Escitalopram 10 mg|Escitalopram 10 mg once daily for a maximum of 32 weeks
89406276|NCT00415142|Placebo Comparator|Placebo|Placebo once daily for one week during screening phase and a maximum of 8 weeks during the acute phase
89406277|NCT04904926||Older Individuals|
89190864|NCT02915705|Experimental|Burosumab|Burosumab 0.8 mg/kg starting dose, administered Q2W by SC injection during the Treatment Period (up to Week 64). During the Treatment Extension Period (Week 64 to Week 140), participants continued to receive a starting dose of SC burosumab 0.8 mg/kg Q2W. Participants in Japan and Korea did not enter the Treatment Extension Period.
89406278|NCT04904926||Healthy young to middle aged Individuals|
88882485|NCT01395459|Experimental|IVR only|The participants in this study arm receive calls from an Interactive Voice Response (IVR) call system, to remind them that they are in need of breast, cervical and colon cancer screening, as applicable.
88921993|NCT05988515|Experimental|CONCURRENT treatment order|"5 speech lessons with a human speech-language clinician: 1 time per week for 5 weeks.~15 speech lessons with an AI clinician (supervised by the caregiver), 3 times per week DURING the same 5 weeks as the human clinician sessions."
89406279|NCT03661125|Experimental|Saracatinib or placebo|In the first arm of the study, participants will be randomised into either the group that receives Saracatinib (study drug) or the Placebo.
89406280|NCT03661125|Experimental|Placebo or Saracatinib (Cross-over)|The groups will now cross over i.e. the group that had the study drug in the first arm will get the placebo in the second arm and the group that had the placebo in the first arm will have the study drug in the second arm.
89406281|NCT00413114|Experimental|Obatoclax Mesylate|Obatoclax Mesylate 30mg
89406282|NCT03660579|No Intervention|HIIT-CON|No intervention: Control
89406283|NCT03660579|Experimental|HIIT-AB Group|"Intake:~330ml (women) or 2x300 ml (men) of beer with 5.4% alcohol. The beverage intakes will be programmed from Monday to Friday.~Training:~The volume in HIIT 40-65 min/week at high intensity. HIIT with short intervals. Frequency two times/week. Load variation. Gradual progression to control the exercise dose. Periodization divided in: familiarization phase, phase I, phase II. Sessions. The participants will performed 8 weight-bearing exercises (in circuit form) 2 times/set with an active rest (walking at 6 RPE scale) as many times at as defined. The HIIT intensity will controlled by RPE (0-10 RPE scale).~All sessions will be started with a dynamic standardized warm-up, including several muscle activation exercises, and will be ended with a cooling-down protocol."
89535615|NCT03318029|Placebo Comparator|Placebo Brazil Trial|Placebo and living in the Brazil
89535616|NCT03318029|Active Comparator|Vitamin D Brazil Trial|Vitamin D supplementation and living in Brazil
88882486|NCT01395459|Experimental|IVR+PCC|The participants in this study arm receive calls from an Interactive Voice Response (IVR) call system, to remind them that they are in need of breast, cervical and colon cancer screening, as applicable. Furthermore, if remained unscreened, these participants receive person to person follow up telephone calls from a prevention care coordinator (PCC) to address barriers.
89190865|NCT02915705|Active Comparator|Active Control|Multiple daily doses of oral phosphate and one or more daily doses of active vitamin D therapy, titrated and individualized by the investigator based on published recommendations during the Treatment Period (up to Week 64). During the Treatment Extension Period (Week 64 to Week 140), participants crossed over to receive a starting dose of SC burosumab 0.8 mg/kg Q2W. Participants in Japan and Korea did not enter the Treatment Extension Period.
88882487|NCT01395472|Experimental|TBI - Experimental Sample|TBI patients will be submitted to two acute physical exercise protocols in a cycloergometer with one weak of interval (until voluntary exhaustion and 30 minutes in ventilatory threshold I)
88882488|NCT01395472|Active Comparator|Healthy Controls|healthy volunteers will be submitted to two acute physical exercise protocols in a cycloergometer with one weak of interval (until voluntary exhaustion and 30 minutes in ventilatory threshold I)
88882489|NCT01395472|Active Comparator|TBI Controls|Patients will be submitted to a protocol of stretching for 30 minutes
88882490|NCT01395485|Experimental|Cohort 2|Adolescents - Ages 13 to <17
89190866|NCT02891278|Experimental|Sertraline with cytosine arabinoside|"All subjects will receive the following:~Induction phase~Sertraline, twice daily at one of the pre-defined dose levels~Cytosine arabinoside, on days 1 and 10~Consolidation phase~Patients who achieve complete remission (CR) or complete remission with incomplete count recovery (CRi) and are eligible for allogeneic stem cell transplantation will receive one of the following:~Allogeneic SCT and off study~Repeat cycle of oral sertraline and cytosine arabinoside IV infusion~Maintenance phase with sertraline for cycles of 28 days in length"
89190867|NCT02843308|Experimental|Immediate Treatment|Facilitated group therapy with behavioral practice; 18 weeks
89190868|NCT02843308|Experimental|Delayed Treatment|Facilitated group therapy with behavioral practice; 18 weeks (after a 18-20 week delay)
89190869|NCT02843308|No Intervention|Healthy Control|This group is matched to the immediate treatment group on age and gender. They do not receive an active treatment.
89190870|NCT02807181|Active Comparator|Chemotherapy (Cisplatin-Gemcitabine)|Cisplatin 25mg/m2 in 1000ml 0.9% saline given over 1 hour followed by 500 ml 0.9% saline over 30 minutes, followed by Gemcitabine 1000 mg/m2 in 250-500 ml 0.9% saline over 30 minutes by intravenous infusions on days 1, and 8 of a 21-day cycle.
89190871|NCT02807181|Experimental|Radiation: SIRT + chemotherapy (Cisplatin-Gemcitabine)|A single treatment of hepatic arterial injection of SIR-Spheres Y-90 resin microspheres (SIRT) followed 14-16 days later by systemic chemotherapy (ABC-02 CIS-GEM protocol) with an intention to treat with 8 cycles of cisplatin + gemcitabine, or until progression, toxicity or patient choice. Treatment may be continued beyond 8 cycles in the absence of significant disease progression, at the treating clinicians' discretion.
89190872|NCT02768870|Experimental|Harpoon Medical Device|This is a prospective, single arm, nonrandomised, multi-center EU study to demonstrate the performance and safety of the Harpoon Medical device in patients with degenerative MR.
89190873|NCT02750618|Experimental|Burosumab Q2W|Burosumab subcutaneous (SC) injections every 2 weeks (Q2W) for a total of 160 weeks.
89190874|NCT02616432|Experimental|Tomosynthesis + FFDM|Women enrolled to DBT Arm will undergo manufacturer-defined DBT
89190875|NCT02616432|No Intervention|FFDM - Standard of Care for Screening|Women enrolled to the FFDM Arm will undergo bilateral digital mammogram with standard CC and MLO views acquired
89190876|NCT02537431|Experimental|Open-Label Burosumab Q4W|1.0 mg/kg burosumab monthly (Q4W), calculated based on baseline weight and up to a maximum dose of 90 mg.
89190877|NCT02526160|Experimental|Burosumab 1 mg/kg|Burosumab 1 mg/kg administered subcutaneously (SC) every 4 weeks, for the duration of the study.
89190878|NCT02526160|Placebo Comparator|Placebo|Placebo administered SC every 4 weeks through Week 24, followed by burosumab 1 mg/kg, for the duration of the study.
89190879|NCT02454543|Other|Radical prostatectomy and BST|BST plus radical prostatectomy with ext. lymphadenectomy
89190880|NCT02454543|Other|Best Systemic Therapy (BST)|e.g. Androgen deprivation therapy, chemotherapy, others
89190881|NCT02430740|Other|control group|standard care recFSH
89190882|NCT02430740|Experimental|study group|modified dosage of recFSH for controlled ovarian stimulation based on AMH, BMI and AFC
89190883|NCT02366494||Androgen blockade|Androgen DeprivationTherapy or Complete Androgen Blockade
89190884|NCT02366494||Hormonal Therapy and Chemotherapy|Hormonal therapy, novel oral hormonal therapy (abiraterone/apalutamide/enzalutamide) and chemotherapy (docetaxel)
89190885|NCT02333136||IVRS studied|subjects will be monitored for changes in hematocrit based on results of in vivo raman spectroscopy scatter
89190886|NCT02257229||Surgical|Corrective Surgery only
89190887|NCT02257229||Non-Surgical|Correction with casting, braces, Physical therapy, other non-surgical methods
89190888|NCT02257229||Non-surgical + surgical|Correction with casting, braces, Physical therapy, other non-surgical methods subsequently followed by Corrective Surgery
89190889|NCT02208271||Control|pre-operative total hip patients with no existing total hip implant
89190890|NCT02208271||Metal on polyethylene|patients who have a failed metal on polyethylene total hip implant and are presenting for revision surgery
89190891|NCT02208271||Metal on Metal|patients who have a failed metal on metal total hip implant and are presenting for revision surgery
89190892|NCT02169518||Diabetes Arm|Patients with Type 1 and Type 2 diabetes
89190893|NCT02169518||Bariatric Arm|Obese patients scheduled for bariatric surgery
89190894|NCT02163577|Experimental|Burosumab Q2W|Burosumab subcutaneous (SC) injections every 2 weeks (Q2W). Dose was determined by the participant's weight and prescribed dose by their study doctor.
89190895|NCT02163577|Experimental|Burosumab Q4W Then Q2W|Burosumab SC injections every 4 weeks (Q4W). Dose was determined by the participant's weight and prescribed dose by their study doctor. Participants in Q4W were to switch to Q2W beginning with Week 64 dosing.
89535617|NCT03076281|Experimental|Arm A (metformin hydrochloride)|Patients receive metformin hydrochloride PO daily on days 1-3 and twice daily starting on day 4 to the day prior to surgery in the absence of disease progression or unacceptable toxicity
89406284|NCT03660579|Experimental|HIIT-NAB Group|"Intake:~330 ml (women) or 2x300 ml (men) of beer without alcohol (0.0%). The beverage intakes will be programmed from Monday to Friday.~Training:~The volume in HIIT 40-65 min/week at high intensity. HIIT with short intervals. Frequency two times/week. Load variation. Gradual progression to control the exercise dose. Periodization divided in: familiarization phase, phase I, phase II. Sessions. The participants will performed 8 weight-bearing exercises (in circuit form) 2 times/set with an active rest (walking at 6 RPE scale) as many times at as defined. The HIIT intensity will controlled by RPE (0-10 RPE scale).~All sessions will be started with a dynamic standardized warm-up, including several muscle activation exercises, and will be ended with a cooling-down protocol."
89406285|NCT03660579|Experimental|HIIT-SW Group|"Intake:~330 ml (women) or 2x300 ml (men) of sparkling water. The beverage intakes will be programmed from Monday to Friday.~Training:~The volume in HIIT 40-65 min/week at high intensity. HIIT with short intervals. Frequency two times/week. Load variation. Gradual progression to control the exercise dose. Periodization divided in: familiarization phase, phase I, phase II. Sessions. The participants will performed 8 weight-bearing exercises (in circuit form) 2 times/set with an active rest (walking at 6 RPE scale) as many times at as defined. The HIIT intensity will controlled by RPE (0-10 RPE scale).~All sessions will be started with a dynamic standardized warm-up, including several muscle activation exercises, and will be ended with a cooling-down protocol."
89406286|NCT03660579|Experimental|HIIT-ASW Group|"Intake:~330 ml (women) or 2x300 ml (men) of sparkling water with 5.4% alcohol.The beverage intakes will be programmed from Monday to Friday.~Training:~The volume in HIIT 40-65 min/week at high intensity. HIIT with short intervals. Frequency two times/week. Load variation. Gradual progression to control the exercise dose. Periodization divided in: familiarization phase, phase I, phase II. Sessions. The participants will performed 8 weight-bearing exercises (in circuit form) 2 times/set with an active rest (walking at 6 RPE scale) as many times at as defined. The HIIT intensity will controlled by RPE (0-10 RPE scale).~All sessions will be started with a dynamic standardized warm-up, including several muscle activation exercises, and will be ended with a cooling-down protocol."
89406287|NCT01318915|Experimental|Induction (Rituximab and ATG)|Study participants will undergo induction with rituximab and ATG and an initial maintenance therapy with tacrolimus, mycophenolate mofetil (MMF) and sirolimus. MMF will be discontinued on day 12. Participants will be evaluated for eligibility for tacrolimus withdrawal which must be initiated between weeks 26 and 38. Tacrolimus withdrawal must be completed in no fewer than 4 weeks and no more than 8 weeks. Then after at least 26 weeks on sirolimus monotherapy, participants will be evaluated for eligibility for sirolimus withdrawal which must be initiated between weeks 56 and 88. Sirolimus withdrawal must be completed in no fewer than 12 weeks and no more than 26 weeks.
89406288|NCT04508842|Experimental|CD19/CD22-Dual-STAR-T|CD19/CD22-Dual-STAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of Dual-STAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 500mg/m2 for 3 days and take a rest for 2 days before infusion. Dual-STAR-T cells will be intravenously infused with a escalated dose of 6E5、1E6、2E6、3E6 cells/kg.
89406289|NCT04688177||smokers|cigarette smokers male 20 ≤ age ≤ 45 years old female 20 ≤ age ≤ 55 years old
89406290|NCT04688177||never smokers|age and gender-matched non-smokers
89406291|NCT02278796|Experimental|BeEAM|Chemotherapy regimen consisting of bendamustine intravenously on days -7 and -6 at 200 mg/m2; cytarabine, 400 mg/m2 intravenously daily from day -5 to day-2; etoposide, 200 mg/m2 intravenously daily from day -5 to day -2; and melphalan, 140 mg/m2 intravenously on day -1 before reinfusion of autologous stem cells
89535618|NCT03076281|Experimental|Arm B (doxycycline)|Patients receive doxycycline PO every 12 hours on days 1 to the day prior to surgery in the absence of disease progression or unacceptable toxicity.
88882491|NCT01395485|Experimental|Cohort 1|Adolescents - Ages 12 to <13
88882492|NCT01395485|Experimental|Cohort 4|Adults - Ages 18 to <=50
88882493|NCT01395485|Experimental|Cohort 3|Adolescents - Ages 17 to <18
88882494|NCT01395498||fiberoptic bronchoscopy|patients undergoing fiberoptic bronchoscopy who are not immunocompromized and in whom an opportunistic infection is not suspected.
88882495|NCT01395511|Experimental|Acupuncture|"About ten acupuncture points are selected from the following points to be used. Local Acupoints : SI14, SI15, BL10, BL12, BL13, BL14, TE15, GB20, SI9~Distal Acupoints :~Upper extremities: LU6, LU7, LU9, LI11, HT3, SI2, SI3, SI5, SI7, PC4, PC6, TE5~Lower extremities: SP3, SP4, BL59, BL60, BL61, BL62, BL66, KI3, KI4,KI6, KI7, GB40, GB41, LR4~All Acupuncture points were prepared with 70% alcohol pads, and disposable stainless steel needles were used. Most of acupuncture were inserted vertically 1~1.5cm in depth until patient can feel De-Qi. (No more additional stimulation)"
88882496|NCT01395511|No Intervention|Waiting list group|"No Intervention Comparator~The waiting-list group did not receive acupuncture treatment and participants were permitted to receive usual care including physical therapy and exercise and were not permitted to take analgesics and antiphlogistics during the periods."
88882497|NCT01395563|Experimental|1|pancreatic cancer patients
88882498|NCT01395563|Experimental|2|pancreatic cancer patients
88882499|NCT01395589|Active Comparator|Injectable + oral vitamin D|Children with moderate-to-severe asthma exacerbations and vitamin D levels < 25 ng/mL.
88882500|NCT01395589|Active Comparator|Oral-only Vitamin D|Children with moderate-to-severe asthma exacerbations and vitamin D levels < 25 ng/mL.
88882501|NCT01395602|Placebo Comparator|placebo|placebo pill
88882502|NCT01395602|Active Comparator|cabergoline|cabergoline pill
88882503|NCT01395615||Cohort|
88882504|NCT01395654|Experimental|Standard rechallenge, Slow rechallenge|
88882505|NCT01395667|Experimental|Bevacizumab + CCRT followed by surgery|Bevacizumab 5 mg/kg every 2 weeks + radiotherapy 45~55 Gy/25 fractions, followed by total mesorectal excision
88882506|NCT01395680||cancer adolescent|
88882507|NCT01395693|Experimental|Salt Lake mask system|
88882508|NCT01395706|Experimental|ICG flourescence technique|This is an uncontrolled, non-randomised, open-label, monocenter clinical trial. A total of n=125 subjects will participate in this clinical trial. No clinical trial participant will be allowed to be included in this trial more than once.
88882509|NCT01395719|No Intervention|Non remote ischemic conditionin(non-rIC)|Patients receiving kidney transplantation from a deceased donor. This group does not receive remote ischemic conditioning, but has a tourniquet on the leg (not inflated).
89406292|NCT02278796|Active Comparator|BEAM|Chemotherapy regimen with carmustine (BCNU) 300 mg/m2 on day -6, cytarabine, 400 mg/m2 intravenously daily from day -5 to day-2; etoposide, 200 mg/m2 intravenously daily from day -5 to day -2; and melphalan, 140 mg/m2 intravenously on day -1 before reinfusion of autologous stem cells
89406293|NCT02987205|Experimental|Revanesse Ultra|Revanesse Ultra in the NLF on one side of the face
88882510|NCT01395719|Experimental|Remote ischemic conditioning (rIC)|Patients receiving kidney transplantation from a deceased donor. This group receives remote ischemic conditioning by inflating a tourniquet on the leg during surgery, before reperfusion of the kidney.
89406294|NCT02987205|Active Comparator|Restylane|Restylane injection in the NLF on the other side of the face to optimal correction
89406295|NCT00411242|Experimental|1|
89406296|NCT00411242|Experimental|2|
89406297|NCT00411242|Placebo Comparator|3|
88882511|NCT01395732|Experimental|1|
88882512|NCT01395745|Experimental|blisibimod weekly dose|
88882513|NCT01395745|Placebo Comparator|Placebo|
88882514|NCT01395771|Experimental|Phone call|New cases and old cases will be randomly categorized into two groups,respectively,one is phone call intervention group, the other is no phone call intervention group.
88882515|NCT01395836||Treatment|"The treatment group will be medically managed based on data obtained from monthly transmissions of the implanted Cardiac Monitor."
88882516|NCT01395836||Control Group|"The control group will be managed in the usual standard of care with physicians blinded to their ICM data."
88882517|NCT01395849||Patients prescribed fluticasone and salmeterol|Patients with asthma prescribed fluticasone and salmeterol during study period
88882518|NCT01395862||Patients prescribed fluticasone and salmeterol|Patients with asthma prescribed fluticasone and salmeterol for long-term use during study period
88882519|NCT01395875||COPD patients with moderate exacerbations|COPD patients with COPD-related using ICD-9 codes physician office/outpatient visit with a dispensing for oral corticosteroid (OCS) or antibiotic (ABX) within 5 days of the visit (Phy+Rx)
88882520|NCT01395927|Experimental|001|Canagliflozin Type=1 unit=mg number=300 form=tablet. Single dose of one 300-mg tablet on Day 1 and Day 10,Rifampin Type=2 unit=mg number=300 Form=capsule route=oral use. Two 300-mg capsules once daily on days Days 4 through 12.
88882521|NCT01395940|Experimental|KLH-2109, lower dose|
88882522|NCT01395940|Experimental|KLH-2109, higher dose|
88882523|NCT01395953|Active Comparator|Buspirone|
88882524|NCT01395953|Placebo Comparator|Placebo|
88882525|NCT01395979|Experimental|Cognitive Processing Therapy for Sexual Risk (CPT-SR)|The CPT-SR condition will be comprised of 10 individual therapy sessions fully integrating sexual risk reduction counseling into cognitive therapy for sexual abuse-related trauma.
88882526|NCT01395979|Active Comparator|Time-Matched Control (TMC)|The TMC will be comprised of sexual risk reduction counseling/education and supportive psychotherapy.
89406298|NCT04530643|Experimental|HY209 0.3%|multiple dose of HY209 0.3% gel
88882527|NCT01395992|Experimental|Asenapine 5 mg|Participants who were randomized to asenapine 5 mg twice per day (BID) during the P05691 study will be assigned to receive asenapine 5 mg BID on this extension study. Participant who were randomized to placebo during the P05691 study will be assigned to receive asenapine 5 mg BID on this extension trial.
88882528|NCT01395992|Experimental|Asenapine 10 mg|Participants who were randomized to asenapine 10 mg BID during the P05691 study will be assigned to receive asenapine 10 mg BID on this extension study.
88882529|NCT01396031|Experimental|Excercise|Cardiovascular exercise Standing Hip Abduction Step-up/Step-down Wall Slide Sit-to-Stand Activity / Exercise Diary 3 times per week x ~1 month
88882530|NCT01396109|Active Comparator|Group I|Intervention: Procedure: TVH and GYNECARE PROSIMA* Pelvic Floor Repair System
88882531|NCT01396109|Active Comparator|Group II|Intervention: Procedure: TVH and Modified Pelvic Floor Reconstruction Surgery with Mesh
88882532|NCT01396122|Experimental|PROSIMA group|Reconstructive surgeries with GYNECARE PROSIMA* were performed in all patients.
88882533|NCT01396135|Experimental|Single dosing|Single doses of CP-601,927 (1, 2 or 3 mg) or placebo
88882534|NCT01396135|Experimental|Multiple dosing|Multiple doses of CP-601,927 (2 mg BID, 4mg/day) or placebo
88882535|NCT01396174|Active Comparator|Standard Online Support Group|
88882536|NCT01396174|Experimental|Prosocial Online Support Group|
88882537|NCT01396200|Experimental|Hydroxychloroquine (Cohort B)|Infusional cyclophosphamide 300mg/m2/day for 4 days IV and dexamethasone 40mg/day orally or IV for 4 days on days 1 through 4. Hydroxychloroquine oral will be given on days 5 through 28 of cycle 1 and every day of all subsequent cycles (to be given with milk or food at approximately the same time each day)
89406299|NCT04530643|Experimental|HY209 0.5%|multiple dose of HY209 0.5% gel
89406300|NCT04530643|Placebo Comparator|Placebo|multiple dose of Placebo
89406301|NCT03238053|Active Comparator|Menopausal Laser|20 women with vaginal laser treatment
89406302|NCT03238053|Sham Comparator|Menopausal sham|20 women with probe, no active laser ray
88882538|NCT01396200|Experimental|Rapamycin (Cohort A)|Infusional cyclophosphamide 300 mg/m2/day for 4 days IV and dexamethasone 40 mg/day orally or IV for 4 days on days 3 through 6. Rapamycin oral loading dose will be given on day 1 followed by an oral daily dose for an additional 5 days (days 2 through 6) to be given on an empty stomach at approximately the same time each day suggested 11 am)This dosing schedule is the same for all cycles.
88882539|NCT01396252|Experimental|Arm1: BMS-820836|Panels 1-4 are fixed dose panels (0.5, 1, 1 and 2 mg respectively), Panels 5-7 are titration dose panels (initiated at 1 mg and dose escalated to the target dose of 2 mg)
88882540|NCT01396252|Placebo Comparator|Arm 2: Placebo matching BMS-820836|Panels 1-4 are fixed dose panels (0.5, 1, 1 and 2 mg respectively), Panels 5-7 are titration dose panels (initiated at 1 mg and dose escalated to the target dose of 2 mg)
88882541|NCT01396291|Experimental|Asenapine|All study participants will first receive open-label asenapine and placebo for 12 to 16 weeks before being randomized. After randomization, participants will receive asenapine or placebo (this is the double-blind period) for up to 26 weeks.
89406303|NCT03238053|Active Comparator|breast cancer laser|20 women with breast cancer with vaginal laser treatment
89406304|NCT03238053|Sham Comparator|breast cancer sham|20 women with breast cancer with vaginal probe, no active laser rays
89406305|NCT03238053|Active Comparator|endometrial cancer laser|20 women with endometrial cancer with vaginal laser treatment
89406306|NCT03238053|Sham Comparator|endometrial cancer sham|20 women with endometrial cancer with vaginal probe, no active laser rays
89406307|NCT03238053|Active Comparator|overactive bladder laser|20 women with overactive bladder with vaginal laser treatment
89406308|NCT03238053|Sham Comparator|Overactive bladder sham|20 women with overactive bladder with vaginal probe, no active laser rays
89406309|NCT05230420|Experimental|Clamping|This arm will undergo chest drain clamping after a certain criteria has been met. Four hours post clamping a chest x-ray will be made, and the presence of pneumothorax will be assessed. The chest drain will be removed only in the absence of pneumothorax, if pneumothorax persists patients will stay attached to the underwater seal
89406310|NCT05230420|Active Comparator|Urine bag|The second arm will be attached to a urine bag, and bag inflation will be measured after a certain criteria has been met. bag inflation will be assessed four hours after its attachment. Bag inflation indicates the persistence of an air leak, thus the absence of bag inflation indicates the removal of the chest drain
89406311|NCT03134066||Treatment-resistant depression patients|Subjects with TRD who have been deemed appropriate for (and have decided to receive) clinical, non-research ketamine treatment at the ketamine clinic at Massachusetts General Hospital. As this is an assessment-only observational study, no treatment assignment or randomization procedures will be used.
89406312|NCT03622671|Active Comparator|Skeletonized LIMA|In patients in this arm the left internal mammary artery will be skeletonized without opening of the left pleural cavity during CABG.
89406313|NCT03622671|Active Comparator|Pedicled LIMA|In patients in this arm the left internal mammary artery will be harvested as a pedicled graft with wide opening of left pleural cavity.
89406314|NCT05230264||Men|Elective AAA Repair
89406315|NCT05230264||Women|Elective AAA Repair
89004465|NCT04262856|Experimental|Arm 3 (domvanalimab, etrumadenant, and zimberelimab combination therapy)|Participants will receive oral etrumadenant in combination with domvanalimab IV and zimberelimab IV infusion
89406316|NCT02279810||Medical students, medical staff|Survey about Knowledge, Attitude and Practice About Organ Transplantation
89004466|NCT04262141|Experimental|IMG-7289 in ET and PV Patients|"Oral daily dose of 0.6 mg/kg/day IMG-7289 will be administered:~The initial pilot period will enroll 8 participants to receive oral daily dose of IMG-7829 for 24 weeks, iteratively as long as there is clinical benefit in the absence of excess toxicity.~The second stage group will enroll an additional 16 participants to receive IMG-7829 for over 2 years, iteratively as long as there is clinical benefit in the absence of toxicity."
89406317|NCT01658293|Experimental|thermal stimulation|The experimental group receiving heat and cold-water stimulation, 30 minutes a session, five sessions a week for six weeks.
89406318|NCT01658293|Active Comparator|control group|The control group receiving the similar intensity of ergometer exercise as the experimental group.
89406319|NCT05230108|No Intervention|Phase 1 (F1): retrospective control.|Phase 1, retrospective, will include all patients who attended the ED from January 2018 to December 2022.
89406320|NCT05230108|Experimental|Phase (F2): prospective intervention of Advanced Triage|Phase 2, prospective, where advanced triage based on advanced practice nurse will be implemented. Will include patients from January 2023 to December 2024.
89406321|NCT00402428|Active Comparator|1|180 mcg PEG-IFNx2a every 1 week (48 doses) + Ribavirin 1000 or 1200 mg/day
89406322|NCT00402428|Experimental|2|900 mcg alb-IFN every 2 weeks (24 doses)+ Ribavirin 1000 or 1200 mg/day
89406323|NCT00402428|Experimental|3|1200 mcg alb-IFN every 2 weeks (24 doses)+ Ribavirin 1000 or 1200 mg/day
89406324|NCT05120206|Active Comparator|Cigarette smokers with periodontitis|Periodontal therapy in cigarette smokers
89406325|NCT05120206|Active Comparator|Non-smokers with periodontitis|Periodontal therapy in non-smokers
89190896|NCT02157610|Experimental|Standard Treatment (ST)|Participants receive free self-help materials mailed at baseline, 6, and 12 months. Participants receive a referral to the Oklahoma Quitline. Participants receive a 12-week supply of the nicotine patch and lozenge. Nicotine patch regime based on participant's self-reported smoking rate. REDCap will be used to collect all questionnaires data over the phone. Questionnaires done at baseline to randomize, then at 3, 6, 12, and 18 months. Saliva test performed at 3, 6, 12, and 18 months.
89406326|NCT05120050||Patients with confirmed Lung cancer|
89406327|NCT03953599|Experimental|CD19-STAR-T cells|CD19-STAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of STAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest for 2 days before infusion.
89406328|NCT03660267|Experimental|coffee group|caffeine coffee
89406329|NCT03660267|Experimental|decaffeinete coffee group|decaffeinete coffee group
89406330|NCT03660267|Experimental|water group|
89406331|NCT03950245|Other|Gastric bypass operated patients|Four test days in a randomized, patient-blinded, cross-over design
89406332|NCT03950245|Other|Sleeve gastrectomy operated patients|Four test days in a randomized, patient-blinded cross-over, design
89406333|NCT03950245|Other|Un-operated controls|Four test days in a randomized, patient-blinded cross-over, design
89406334|NCT03660111|Other|spirometry|single spirometry: only a routine diagnostic test
89406335|NCT05208515|Other|stardard group|wowen who need emergency cesarean section will be send to the general operating center.
89406336|NCT05208515|Experimental|new group|women who need emergency cesarean section will be send to the obstetric operating center
89406337|NCT04211818|Experimental|Patients|
89406338|NCT03660033|Experimental|With ECG|These teams will have access to ECG monitoring (intervention) during the scenario
89406339|NCT03660033|No Intervention|Without ECG|These teams will NOT have access to ECG monitoring during the scenario
89406340|NCT00401570|Experimental|Cohort 1|Volociximab (10 mg/kg every other week (qowk)) and Gemcitabine
89406341|NCT00401570|Experimental|Cohort 2|Volociximab (15 mg/kg weekly (qwk)) and Gemcitabine
88882542|NCT01396291|Placebo Comparator|Placebo|All study participants will first receive open-label asenapine and placebo for 12 to 16 weeks before being randomized. After randomization, participants will receive asenapine or placebo (this is the double-blind period) for up to 26 weeks.
89190897|NCT02157610|Experimental|Motivation + Problem Solving (MAPS)|Participants receive free self-help materials mailed at baseline, 6, and 12 months. Participants receive a referral to the Oklahoma Quitline.Participants receive a 12-week supply of the nicotine patch and lozenge. Nicotine patch regime based on participant's self-reported smoking rate. REDCap will be used to collect all questionnaires data over the phone. Questionnaires done at baseline to randomize, then at 3, 6, 12, and 18 months. Saliva test performed at 3, 6, 12, and 18 months. 6 telephone counseling sessions performed over 12 months. Sessions performed at baseline, 3, 6, 12, and 18 months. Sessions digitally recorded.
89190898|NCT02078869|Active Comparator|intramuscular Progesterone in oil|50mg of intramuscular Progesterone injection will be administered once daily for 6 days including the day of embryo transfer
89190899|NCT02078869|Active Comparator|vaginal progesterone suppositories|200mg of progesterone suppositories will be administered 3 times a day for 6 days including the day of embryo transfer
89190900|NCT02031913||HBV without FL|Chronic hepatitis B without steatosis
89190901|NCT02031913||HBV with FL|Chronic hepatitis B patients with steatosis
89190902|NCT01994057||sensitive group; resistant group|"sensitive patients were defined as patients reached CR or PR after first month administration,SD after first three months administration.~resistant patients were defined as patients reached PD after first month administration and first three months administration"
89190903|NCT01946815|Experimental|Atorvastatin|Atorvastatin (Lipitor) will be prescribed with 20mg,40mg,or 80mg by the unit of 28 tablets upon the result of lipid profile. Besides Clinical and lab test, follow-up CAG, IVUS(optional) and FFR will be performed in 12 months.
89190904|NCT01943318||Alcohol|"Alcoholic Liver Cirrhosis~Participants will undergo liver biopsy. Participants will undergo hepatic venous pressure gradient measurement."
89190905|NCT01943318||Hepatitis B virus|Hepatitis B virus (HBV) Liver Cirrhosis
89190906|NCT01943318||Hepatitis C virus|Hepatitis C virus (HCV) Liver Cirrhosis
89190907|NCT01943318||Autoimmune|Autoimmune Cirrhosis
89190908|NCT01943318||Biliary|Primary or secondary biliary cirrhosis
89190909|NCT01943318||Toxic|Medication related cirrhosis
89190910|NCT01943318||Others|Hepatic venous pressure gradient (HVPG) measurement
89190911|NCT01937156|Experimental|SP-01|
89190912|NCT01937156|Active Comparator|Granisetron Hydrochloride Tablet|
89190913|NCT01805804|Placebo Comparator|Placebo|Placebo pills to match valsartan tablets administered once daily
89190914|NCT01805804|Experimental|valsartan 80mg daily|Valsartan 80mg tablet once daily
89190915|NCT01805804|Experimental|valsartan 160mg daily|Valsartan 160mg tablet once daily
89190916|NCT01718873|Experimental|bevacizumab before chemotherapy|Bevacizumab administered 4 days before each cycle of chemotherapy containing oxaliplatin (mFOLFOX-6 / mOXXEL)
89190917|NCT01718873|Active Comparator|bevacizumab with chemotherapy|Bevacizumab administered on the first day of each cycle of chemotherapy containing oxaliplatin (mFOLFOX-6 / mOXXEL)
89190918|NCT01511250|Experimental|Part I: TDV 21 to 45 Years (yrs)|TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose). TDV comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4 containing 2*10^4 plaque forming units (PFU), 5*10^4 PFU, 1*10^5 PFU, and 3*10^5 PFU respectively, total virus per dose: 4.7*10^5 PFU.
88882543|NCT01396304|Experimental|Restore Calcium Alginate Dressing Silver|Restore Calcium Alginate Dressing Silver under compression wrap
88882544|NCT01396304|Active Comparator|Aquacel Ag Wound Dressing|Aquacel Ag Wound Dressing under compression wrap
88882545|NCT01396330|Other|Stress|
88882546|NCT01396343||Pediatric MS Case|Demographic and Medical History Questionnaire, Environmental Exposure Questionnaire, Food Frequency Questionnaire, Blood Sample Collection
88882547|NCT01396343||Pediatric Control|Demographic and Medical History Questionnaire, Environmental Exposure Questionnaire, Food Frequency Questionnaire, Blood Sample Collection
88882548|NCT01396356||ablation procedure|
88882549|NCT01396369|Active Comparator|Birth control|
88882550|NCT01396369|Experimental|Birth control plus Brevail|
88882551|NCT01396460||bariatric patients|Bariatric post operative patients were compared with morbid obese population
88882552|NCT01396460||control group|morbid obese population
88882553|NCT01396473|No Intervention|control|
88882554|NCT01396473|Experimental|Policy and Environmental Change|
88882555|NCT01396499|Experimental|BKM120|Oral BKM120 starting dose 80 mg once daily.
88882556|NCT01396564|Active Comparator|Metformin|Randomized patients are given 850 mg of metformin daily, increased to 1700 mg after 12 weeks. Adherence is evaluated and after the first phase, the arm is opened. Fasting plasma glucose concentration, body weight, and blood pressure, fasting plasma lipids (total cholesterol, triglyceride, HDL cholesterol, and LDL cholesterol), HbA1c are measured during the initial and final week of treatment. Dietary adherence is reinforced.
89190919|NCT01511250|Placebo Comparator|Part I: Placebo 21 to 45 yrs|TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).
89190920|NCT01511250|Experimental|Part I: TDV 12 to 20 yrs|TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose). TDV comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4 containing 2*10^4 PFU, 5*10^4 PFU, 1*10^5 PFU, and 3*10^5 PFU respectively, total virus per dose: 4.7*10^5 PFU.
89190921|NCT01511250|Placebo Comparator|Part I: Placebo 12 to 20 yrs|TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).
89190922|NCT01511250|Experimental|Part I: TDV 6 to 11 yrs|TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose). TDV comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4 containing 2*10^4 PFU, 5*10^4 PFU, 1*10^5 PFU, and 3*10^5 PFU respectively, total virus per dose: 4.7*10^5 PFU.
89190923|NCT01511250|Placebo Comparator|Part I: Placebo 6 to 11 yrs|TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).
89406342|NCT02284958|Active Comparator|Standard/Control group|Each participant will receive a one-off individualized educational session regarding the management of chronic low back pain with a Physical Therapist: includes a physical examination, standardized advice & provision of the 'Back Book'.
89406343|NCT02284958|Experimental|Walking group|Each participant will receive a one-off educational session as per standard/control group followed by a 12 week graded, individually tailored, pedometer driven walking programme given by a Physical Therapist. Participants will be monitored each week and provided with encouragement and advice to increase the number of steps taken each day.
89406344|NCT05193565|Experimental|RaparoBell Tablet|RaparoBell Tablet
89406345|NCT05193565|Active Comparator|Mycophenolate Mofetil Tablet/Capsule|Myrept Tablet/Capsule
89406346|NCT03214887|Experimental|RV-P1501-4|Gel-like product with 10 thousand BMMNCs in each ml of 1% hyaluronan (HA) solution
89406347|NCT03214887|Experimental|RV-P1501-5|Gel-like product with 100 thousand BMMNCs in each ml of 1% hyaluronan (HA) solution
89406348|NCT03214887|Experimental|RV-P1501-6|Gel-like product with 1 million BMMNCs in each ml of 1% hyaluronan (HA) solution
89406349|NCT05189587|Experimental|TES group|Intervention: Device (transcranial electrical stimulation, TES)
89406350|NCT05189587|Sham Comparator|sham TES group|Intervention: Device (transcranial electrical stimulation, TES)
89406351|NCT05189587|No Intervention|Control group|Intervention: none
89406352|NCT04471922|Experimental|Anaprazole Sodium enteric-coated tablet|"Multiple ascendinng dose, anaprazole 60mg QD(60mg QD group), 80mg QD(80mg QD group), 100mg QD(100mg QD group) , 7 days, fasting oral administration.~"
89406353|NCT04471922|Placebo Comparator|Placebo|Multiple dose, 1 tablet QD (60mg QD,80mg QD and 100mg QD group), 7 days, fasting oral administration.
89406354|NCT04471922|Active Comparator|Active controlled (rabeprazole)|Multiple dose, rabeprazole 20mg QD (60mg QD,80mg QD and 100mg QD group), 7 days, fasting oral administration.
89406355|NCT04368364|Active Comparator|Group 1 (Control group)|
88882557|NCT01396564|Active Comparator|Pioglitazone|Randomized patients are given 15 mg of pioglitazone daily, increased to 60 mg after 12 weeks. Adherence is evaluated and after the first phase, the arm is opened. Fasting plasma glucose concentration, body weight, and blood pressure, fasting plasma lipids (total cholesterol, triglyceride, HDL cholesterol, and LDL cholesterol), HbA1c are measured during the initial and final week of treatment. Dietary adherence is reinforced.
88882558|NCT01396577|Active Comparator|3 x 2-mg perampanel|
88882559|NCT01396577|Active Comparator|6mg perampanel|
88882560|NCT01396590|Active Comparator|6 x 2 mg perampanel|
88882561|NCT01396590|Active Comparator|12 mg Perampanel|
88882562|NCT01396616|Experimental|Single Arm|The enrolled subject will be implanted with Toric IOL manufactured by AuroLab
89406356|NCT04368364|Experimental|Group 2(Bupivacaine hydrochloride group)|
89406357|NCT04368364|Experimental|Group 3 (ropivacaine hydrochloride group)|
89406358|NCT02285036|Experimental|A newly PPV23|The treatment pneumococcal vaccine was developed by Yunnan Walvax Biotech Co., Ltd (Walvax) China, is a sterile, liquid vaccine for intramuscular or subcutaneous injection. It consists of a mixture of highly purified capsular polysaccharides from the 23 most prevalent or invasive pneumococcal types of Streptococcus pneumoniae, including the six serotypes that most frequently cause invasive drug-resistant pneumococcal infections among children and adults in China. The dose of vaccine is an individual with a 0.5ml dose contains 23 kinds of pneumococcal polysaccharide serotypes each 25μg, and does not contain any preservatives. Vaccination of single dose of either treatment vaccine or control vaccine intramuscularly was performed in a ratio of 1:1.
89406359|NCT02285036|Active Comparator|PNEUMOVAX 23|PNEUMOVAX 23 is an established US-licensed vaccine and manufactured by the Merck Research Laboratories. Each 0.5 mL dose of vaccine contains 25μg of each polysaccharide type in isotonic saline solution containing 0.25% phenol as a preservative.Vaccination of single dose of either treatment vaccine or control vaccine intramuscularly was performed in a ratio of 1:1.
89406360|NCT03659877|Experimental|Heart failure patients|Patients will be required to perform a number of physical activity tasks such as laying down, sitting and walking. During these activities, acceleration, oxygen consumption, rating of perceived exertion and heart rate will be recorded.
89406361|NCT05180851|Experimental|Safety and efficacy of recombinant L-IFN adenovirus injection in relapsed/refractory solid tumors|"1.Only 1 lesion: If the tumor volume is less than or equal to 10 cm3, the whole tumor is injected radially and evenly.~If the tumor volume was >10 cm3, the tumor was evenly divided into five quadrants and injected into one quadrant at a time.~2. If there are 2 or more lesions, the most manageable tumor injection is selected; 3. Priority should be given to the body surface metastases that meet the evaluation criteria for tumor efficacy.~4. According to patients' conditions (e.g., patients with thorax and ascites), the investigator and the research group and cooperative units jointly explored other drug administration approaches (e.g., bladder infusion, thorax and abdominal cavity administration)"
89406362|NCT00543374|Placebo Comparator|Placebo|Placebo
88882563|NCT01396629||single group|the intra ocular lenses will be loaded in the cartridge.
89190924|NCT01511250|Experimental|Part I: TDV 1.5 to 5 yrs|TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose). TDV comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4 containing 2*10^4 PFU, 5*10^4 PFU, 1*10^5 PFU, and 3*10^5 PFU respectively, total virus per dose: 4.7*10^5 PFU.
89406363|NCT00543374|Active Comparator|PROCHYMAL Low dose|Low dose (total of 600 million cells)
89406364|NCT00543374|Active Comparator|PROCHYMAL High dose|High dose (total of 1200 cells)
89406365|NCT04056195|Experimental|SKI-O-703 200 mg|2 capsules of 100 mg SKI-O-703 BID (twice a day) 12 hours apart + 2 capsules of placebo during 12 weeks
88882564|NCT01396642|Experimental|Topical Emollient|Neonates in this group will receive topical emollient application with coconut oil twice a day till 28th day of life
88882565|NCT01396642|No Intervention|Routine Skin Care|Neonates in this group will receive routine skin care as per unit protocol
88882566|NCT01396655|Experimental|docetaxel + doxorubicin|The chemotherapeutic regimen consisted of docetaxel (75 mg/m2) and doxorubicin (50 mg/m2) by intravenous infusion every 3 weeks.
88882567|NCT01396694||all|All patients requiring arthroscopy or arthroplasty
88882568|NCT01396707|Experimental|Herceptin+XELOX|
88882569|NCT01396720|Active Comparator|fluvoxamine|
89190925|NCT01511250|Placebo Comparator|Part I: Placebo 1.5 to 5 yrs|TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).
89190926|NCT01511250|Experimental|Part II: TDV 1.5 to 11 yrs|TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose). TDV comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4 containing 2*10^4 PFU, 5*10^4 PFU, 1*10^5 PFU, and 3*10^5 PFU respectively, total virus per dose: 4.7*10^5 PFU.
89406366|NCT04056195|Experimental|SKI-O-703 400 mg|4 capsules of 100 mg SKI-O-703 + 0 capsules of placebo during 12 weeks
89406367|NCT04056195|Placebo Comparator|Placebo|4 capsules of placebo during 12 weeks
89190927|NCT01511250|Placebo Comparator|Part II: Placebo 1.5 to 11 yrs|TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).
89190928|NCT01424566|Experimental|Nabiximols|Nabiximols was self-administered by participants as a 100 microliter (μL) oromucosal spray in the morning and evening, up to a maximum of 10 sprays per day for 2 or 7 weeks. Nabiximols oromucosal spray contained delta-9-tetrahydrocannabinol (THC) (27 milligrams [mg]/milliliter [mL]):cannabidiol (CBD) (25 mg/mL), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%)flavoring. Each 100 μL actuation delivered 2.7 mg THC and 2.5 mg CBD.
89190929|NCT01424566|Placebo Comparator|Placebo (GA-0034)|Placebo was self-administered by participants as a 100 μL oromucosal spray in the morning and evening, up to a maximum of 10 sprays per day for 5 weeks. Placebo oromucosal spray contained ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring and colorings.
89190930|NCT01367561|Experimental|Arm 1|
89190931|NCT01367561|Experimental|Arm 2|
89190932|NCT01367561|Placebo Comparator|Arm 3|
89190933|NCT01361607|Experimental|Nabiximols|Nabiximols was self-administered by participants as a 100 microliter (μL) oromucosal spray in the morning and evening, up to a maximum of 10 sprays per day for 5 weeks. Nabiximols oromucosal spray contained delta-9-tetrahydrocannabinol (THC) (27 milligram [mg]/milliliter [mL]):cannabidiol (CBD) (25 mg/mL), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring. Each 100 μL actuation delivered 2.7 mg THC and 2.5 mg CBD.
89190934|NCT01361607|Placebo Comparator|Placebo (GA-0034)|Placebo was self-administered by participants as a 100 μL oromucosal spray in the morning and evening, up to a maximum of 10 sprays per day for 5 weeks. Placebo oromucosal spray contained ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring and colorings.
89190935|NCT01337089|Experimental|Non-comparative, open-label Nabiximols|Nabiximols was self-administered by participants as a 100 microliter (μL) oromucosal spray, in the morning and evening, up to a maximum of 10 sprays per day for 6 months. Nabiximols oromucosal spray contained delta-9-tetrahydrocannabinol (THC) (27 milligrams [mg]/milliliter [mL]):cannabidiol (CBD) (25 mg/mL), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring. Each 100 μL actuation delivered 2.7 mg THC and 2.5 mg CBD.
89190936|NCT01276587|Experimental|Single arm|
89406368|NCT02926937|Experimental|Sotagliflozin 400 mg|Following a 2-week run-in period, participants were randomized to Sotagliflozin 400 milligrams (mg) administered as two 200 mg tablets, once daily (QD), before the first meal of the day in the double-blind treatment period for up to 26 weeks.
89406369|NCT02926937|Experimental|Sotagliflozin 200 mg|Following a 2-week run-in period, participants were randomized to Sotagliflozin 200 mg administered as 1 Sotagliflozin tablet and 1 matching placebo tablet, QD, before the first meal of the day in the double-blind treatment period for up to 26 weeks.
89406370|NCT02926937|Placebo Comparator|Placebo|Following a 2-week run-in period, participants were randomized to matching placebo to sotagliflozin administered as 2 tablets, QD, before the first meal of the day in the double-blind treatment period for up to 26 weeks.
89406371|NCT05174533||with schizophrenia|"with schizophrenia group : patients aged 40 and more with schizophrenia"
89406372|NCT05229796|Active Comparator|Fasting state|
89406373|NCT05229796|Active Comparator|Fed state|
89406374|NCT04426981|Experimental|Intervention arm|Consenting patients will be enrolled into a Behavioral Activation treatment arm. Behavioral activation is a behavioral treatment that focuses on helping participants engage in more rewarding and enjoyable activities.
89406375|NCT03627481|Experimental|AERD patients|Patients managed with Endoscopic sinus surgery for treatment of AERD.
89406376|NCT00151892|Experimental|SPD476|Mesalazine
89406377|NCT00151892|Active Comparator|Asacol|
89406378|NCT05093491||Stroke patients|Ultrasonographic measurements were performed of the bilateral diaphragm and abdominal muscle thickness and thickening ratio of stroke patients. Spirometry evaluation was performed by another investigator. Diagnostic Test: Bilaterally diaphragm and abdominal muscle thickness and thickening ratio with ultrasonography
89406379|NCT05093491||Healthy individuals|Ultrasonographic measurements were performed of dominant side diaphragm and abdominal muscle thickness and thickening ratio. Spirometry evaluation was performed by another investigator. Diagnostic Test: Dominant side diaphragm and abdominal muscle thickness and thickening ratio with ultrasonography
89406380|NCT04914091||Patients with diffuse large B-cell lymphoma treated with CART-cells|
89406381|NCT02740127|Experimental|Caudal Nerve Block + General Anesthesia Group|"Participants receive a caudal nerve block (CNB) prior to surgery and receive general anesthesia during surgery.~Study staff calls participant about 3 days after surgery."
89406382|NCT02740127|Active Comparator|General Anesthesia Alone Group|"Participants receive general anesthesia (GA) during surgery without a caudal nerve block.~Study staff calls participant about 3 days after surgery."
89406383|NCT05119504|Experimental|Acceptance-based|This 90-minute one-on-one intervention will provide psychoeducation and experiential training on the use of acceptance-based strategies for physical activity.
89406384|NCT05119504|Sham Comparator|Multi Health Behavior|This 90-minute one-on-one intervention will provide psychoeducation on physical activity as one of several interconnected health behaviors.
89406385|NCT05119426|Experimental|Vi-TT|Single dose of Vi-TT to children 9 months to <16 years of age
88882570|NCT01396720|Active Comparator|citalopharm|
89406386|NCT04590833|Experimental|Aerobic exercise group|
88882571|NCT01396733|Active Comparator|Low dose group|Patients who will receive 600 mg/day alpha-lipoic acid
89406387|NCT04590833|Placebo Comparator|Attention control group|
89406388|NCT04539431||Retrospective|The cases with glioma will be identified in the databases of hospital, the material will be preliminarily evaluated in order to see if there is sufficient tissue left for analysis.
89406389|NCT04539431||Prospective|A blood sample for molecular analyses will be collected in all the cases, CSF samples will be taken only if recommended by the normal surgical routine.
89406390|NCT04472234|Other|BPA level|BPA (Bisfenol A) in urine, blood and follicle fluid samples
89406391|NCT04450498|Experimental|Walvax MPV ACYW® vaccine group|
89406392|NCT04450498|Active Comparator|Sanofi Pasteur Menactra® vaccine group|
88882572|NCT01396733|Active Comparator|High dose group|Patients who will receive 1,200 mg/day alpha-lipoic acid
88882573|NCT01396746||People with Post Stroke Conditions|(a) having acquired stroke at least 1 year before testing. (b) Chronic weakness and/or spasticity of the affected side. (c) Independent stair-climbers (with hand-rail). (d) With cognitive level sufficient to comprehend instructions. (e) age range between 40-69. (f) Use of walking aid is permitted as long as the participant is able to walk on a treadmill with hand-rail. (g) No heart failure or other medical conditions that preclude participation in the study.
88882574|NCT01396759|Experimental|bubble CPAP|Children will receive bubble CPAP Bubble-CPAP, which requires a source of gas flow (typically 6-8 L/ minute in a neonate), an air-oxygen blender, a humidifier and a T-piece. The expiratory arm is inserted in a bottle of water and the level of CPAP delivered is equivalent to the length of the expiratory tubing that remains under water. Robust equipment is now available at a fraction of the cost of mechanical ventilators. Bubble-CPAP has potential advantages over the mechanical ventilation, such as lower cost, ease of application by nursing staff, lower risk of complications, and has been proposed as an inexpensive method of delivering CPAP in developing countries.
89406393|NCT00654992|Active Comparator|EPO group|
89406394|NCT00654992|Placebo Comparator|Placebo group|
89406395|NCT05208203||stroke patients|acute ischemic stroke patients including all treatments.
89406396|NCT02282462|Experimental|Reg pressure, Active suction (Dig)|Regulated pleural pressure with active suction
89406397|NCT02282462|Experimental|Reg pressure, Passive drainage (Dig)|Regulated pleural pressure with passive drainage
89406398|NCT02282462|Experimental|Unreg pressure, Active suction (Trad)|Unregulated pleural pressure with active suction
89406399|NCT02282462|Experimental|Unreg pressure, Passive drainage (Trad)|Unregulated pleural pressure with passive drainage
89406400|NCT05207969|No Intervention|Control Arm|Cystoscopy procedure will be done based on cystoscopy protocol. During scope procedure patient will not giving instruction to urinate during the procedure.
89406401|NCT05207969|Experimental|Experimental Arm|Cystoscopy procedure will be done based on cystoscopy protocol. During scope procedure, patient will be ask to urinate and this will lead to contraction of urinary bladder and relaxation of external urethral sphincter. Scope will then pass through external urethral sphinter and go to the urinary bladder
89406402|NCT03055195|Experimental|Mepolizumab|Eligible subjects will receive mepolizumab 100 mg subcutaneously every 4 weeks on Day 1, Week 4, Week 8, and Week 12
89406403|NCT03055195|Placebo Comparator|Placebo|Eligible subjects will receive matching placebo subcutaneously every 4 weeks on Day 1, Week 4, Week 8, and Week 12
89406404|NCT02282540|Experimental|Iodixanol to the Eustachian tube|Iodixanol contrast medium diluted with NaCl to 20% into the tympanostomy tube while the patient lies on his / her back with the head slightly turned to the opposite side. After 10 minutes the CT examination will be conducted using 200 mA and 120 kV.
89406405|NCT02921919|Experimental|Talazoparib|
89535619|NCT03076281|Experimental|Arm C (metformin hydrochloride, doxycycline)|Patients receive metformin hydrochloride PO daily on days 1-3 and twice daily starting on day 4 to the day prior to surgery and doxycycline PO every 12 hours on days 1to the day prior to surgery in the absence of disease progression or unacceptable toxicity.
89406406|NCT02737553|Active Comparator|enclosed morcellation|"In this group, after extirpation of the myoma from the uterus and repair of the uterine defect, the myoma will be removed from the abdomen with an enclosed laparoscopic electromechanical morcellation as described in the literature by Akdemir et al with using surgical glove (Akdemir A et. al, Innovative technique for enclosed morcellation using a surgical glove. Obstet Gynecol. 2015 May;125(5):1145-9.~doi: 10.1097/AOG.0000000000000823.)."
89406407|NCT02737553|Active Comparator|vaginal morcellation|In this group, after extirpation of myoma from uterus and repair of the uterine defect, myoma will be removed through the vagina with posterior colpotomy. In this group myoma will also be removed in a enclosed fashion with using endo bag.
89406408|NCT00393068|Experimental|Treatment|"Prior to surgery study treatment will be given over a 6 weeks (Days 1-42) period. Beginning Day 1 and continuing through Day 35 patients will receive a continuous infusion of 5-FU by vein. A small portable pump will be used to administer this drug into a tube that has been surgically inserted into the patient's vein. On Day 1 and 22 patients will also receive the drugs paclitaxel, carboplatin and bevacizumab by vein. Erlotinib is given by mouth beginning on Day 1 and continuing through Day 45. Patients will receive radiation therapy daily, Monday through Friday, beginning Day 1-35 (approximately 5 weeks).~Surgery will be performed approximately 12-14 weeks after beginning this combined treatment."
89406409|NCT03659643||Retrospective MCI cohort|EEG with SPR analysis of the group from the study 2011-2013 is evaluated in relation to the status of current cognitive impairment
89406410|NCT03659643||Prospective MCI cohort|New individuals diagnosed with MCI. EEG with SPR analysis is performed during the diagnostic work-up and evaluated in relation to changes in cognitive status during the following two years.
89406411|NCT03658863|Active Comparator|Endoscopy first|Endoscopic ultrasound is used to evaluate bile ducts. If stones in extrahepatic bile ducts are seen ERCP and stone evacuation is performed during the same anaesthesia. Laparoscopic cholecystectomy is performed after endoscopic procedures in two days.
89406412|NCT03658863|Active Comparator|Cholecystectomy first|Laparoscopic cholecystectomy with intraoperative cholangiography is performed. If stones are found postoperative ERCP with stone evacuation is applied (during cholecystectomy if common bile duct is completely blocked or as soon as possible).
89406413|NCT02280278|Experimental|CIK group|Stage III Colon Cancer patients after radical operation and adjuvant chemotherapy will receive 8 cycles of CIK therapy in this group.
89406414|NCT02280278|Active Comparator|Control group|Stage III Colon Cancer patients will only receive radical operation and adjuvant chemotherapy.
89406415|NCT02280434|Active Comparator|CBP-307|Participants will receive a single dose or once daily dose of CBP-307 for 28 days.
89406416|NCT02280434|Placebo Comparator|Placebo|Participants will receive a single dose or once daily dose of matching placebo for 28 days.
89406417|NCT02285348|Other|Ataxia Telangiectasia|20 patients with clinically and/or genetically diagnosed Ataxia telangiectasia will get a lumbar puncture
88813569|NCT03007277|Experimental|PANJO Intervention|201 nulliparous women will be recruited within the PMI public services. Nurses/Midwives will propose to enroll in the PANJO group, which consist in receiving 6 to 12 home visits by a home visitor trained by the PANJO team The visits will consist on 45 to 90-minutes interventions aiming at supporting the family in the everyday challenges they may encounter, and to support the development of qualitative parent-child relationships.
88813570|NCT03007277|Active Comparator|Service as usual|246 nulliparous women will be recruited within several maternity wards. They will recieve the services they may request from (a) the maternities, (b) the maternal and child protection services (PMI, usually 1 or 2 home visit without any standards) or any other service available. They will be provided with the address and telephone of the closest maternity ward.
88813571|NCT01729988|Experimental|Carotid body excision|Patients undergoing the carotid body excision to test the hypothesis that carotid body excision is sufficient to attain target blood pressure.
89406418|NCT02285348|Other|Healthy Control|20 patients without inflammation, infection or any other pathology of the CNS, in that a lumbar puncture is indicated for either diagnostic or therapeutic reason (i.e. for the exclusion of a meningitis, subarachnoid hemorrhage or in therapeutic liquor drain in idiopathic intracranial hypertension)
89406419|NCT00391196|Placebo Comparator|Placebo|
89406420|NCT00391196|Experimental|CP-945,598|
89406421|NCT00391196|Experimental|CP-945,598 Treatment B|Subjects receive CP-945,598 plus non-pharmacological weight loss program.
89406422|NCT04879459||Intervention Group IG|"The IG is constituted of participants, naïve to ultrasound use. Participants undergo a web-based video learning about gallbladder evaluation using CUS on day 0 (same video as in CG). Participants undertake 3 times a one-day CUS course consisting in 2 practical sessions of 10 times 10 minutes on 10 healthy volunteers on day 0, day 7 and day 10. One practical session takes place before lunchtime, the second one after lunchtime.~Participants of IG don't have any contact with CG during study days. An evaluation is organized on day 60 to evaluate primary and secondary endpoints."
88813572|NCT03002129|Other|fluid challenge|
89406423|NCT04879459||Control Group CG|"The CG is constituted of participants, naïve to ultrasound use. Participants undergo a web-based video learning about gallbladder evaluation using CUS on day 0. Participants of CG undertake 2 practical CUS sessions of 10 times 10 minutes on 10 volunteers, at least 50% of them suffering from gallstones on day 0, day 7 and day 10. One session takes place before lunchtime, the second one after lunchtime.~Participants of CG don't have any contact with IG during study days. An evaluation is organized on day 60 to evaluate primary and secondary endpoints."
89406424|NCT04861831|Experimental|Immediate PCS Intervention|After the pre-intervention clinical assessments, immediate (within one week) begin with the PCS exercise program (75-minute group class, twice weekly for 12 weeks; home practice of exercises recommended but not required). Post-intervention clinical assessments within one week after the last intervention class, followed by a 12-week follow-up period (continuation of exercise program at home recommended but not required). Final clinical assessments within one week after the 12-week follow-up period.
89406425|NCT04861831|Experimental|Delayed PCS Intervention|During the 12 weeks that the Immediate Intervention (II) group participates in the PCS intervention, the Delayed Intervention (DI) group waits (there is no control intervention) and serves as a control arm comparison for the II group during this time. After the 12 weeks, the DI group will undergo a second pre-intervention assessment to document any change in baseline measures that may have occurred in those 12 weeks. No significant changes are expected. The DI group then begins the same exercise intervention (75-minute group class, twice weekly for 12 weeks; home practice of exercises recommended but not required) that the II group underwent, given by the same instructors. Post-intervention clinical assessments, 12-week follow-up period, and final clinical assessments after the follow-up period as described for the II group. After the trial, pooled data from both groups will provide results on the overall changes in outcome measures post- versus pre-intervention.
89406426|NCT02285426||suspected lungcancer|"Patients will undergo a bronchoscopy with the Pentax EB1990i HD-bronchoscope investigating the entire bronchial tree. The HD+ bronchoscopy needs to be performed in a standardized way using 3 different imaging modes:~HD+bronchoscopy~HD+bronchoscopy + i-Scan 1~HD+bronchoscopy + i-Scan 2"
89406427|NCT02250144|Experimental|Morpho-specific foot orthoses|"Morpho-specific thermo-molded foot orthoses are designed according to the patient's morphotype.~Orthoses are custom-molded from different materials such as BIOFLUX resin, Covercuir MF, EVA300/60, EVA400/70, PE255/55, ABSORB Dur and CAPITON PU."
89406428|NCT02250144|Placebo Comparator|Placebo foot orthoses|The placebo foot orthoses will be made with the same principle of molding and with the same materials as for the experimental group. The only difference is that they involve no active corrective insert element : they will be made without morphotype correction.
89406429|NCT02282618||heart failure with HTEA|Heart failure patients are treated with the world-wide accepted medicine, plus HTEA for 4 weeks.
89406430|NCT02282618||heart failure with medicine|Heart failure patients are treated with the world-wide accepted medicine.
89406431|NCT02910219|Experimental|Crofelemer|Patients on the treatment arm will take one tablet of crofelemer twice a day (each tablet is 125 mg), to be swallowed whole without chewing or crushing, during cycles 1-2 of chemotherapy with THP or TCHP. Patient will be monitored off crofelemer during cycle 3 of chemotherapy.
89406432|NCT02910219|No Intervention|Control|Patients on the control arm will be on the study for cycles 1-3 of THP or TCHP. Patients on the control arm will not receive crofelemer at any time on this study.
89406433|NCT02250222|Experimental|Part 1: LGD-6972 15 mg|15 mg LGD-6972 administered once daily (QD) for 14 days.
89406434|NCT02250222|Placebo Comparator|Part 1: Placebo (Captisol ®)|Placebo administered once daily (QD) for 14 days.
89406435|NCT02250222|Experimental|Part 2: LGD-6972 5 mg|5 mg LGD-6972 administered orally QD for 14 days.
89406436|NCT02250222|Experimental|Part 2: LGD-6972 10 mg|10 mg LGD-6972 administered orally QD for 14 days.
89190937|NCT01217580|Experimental|20 ml per side of 0.5% ropivacaine|Ultrasound guided TAP blocks will be performed once patient is in the recovery area. Patients will be placed on their back with their hands resting comfortably above their head. Using an ultrasound guided technique, the ultrasound probe will be positioned on abdominal until the three lateral abdominal wall muscles and TAP are clearly imaged. A two or four inch, 20 gauge needle will be advanced using an in-plane technique. After visual confirmation that the needle tip is in the TAP, 1 ml of preservative free 0.9% sodium chloride will be injected to reconfirm correct placement in the TAP. Then 20 ml of 0.5% ropivacaine will be injected. The procedure will be repeated on the other side.
89406437|NCT02250222|Experimental|Part 2: LGD-6972 15 mg|15 mg LGD-6972 administered orally QD for 14 days.
89190938|NCT01217580|Placebo Comparator|20 ml per side of 0.9% sodium chloride|Ultrasound guided TAP blocks will be performed once patient is in the recovery area. Patients will be placed on their back with their hands resting comfortably above their head. Using an ultrasound guided technique, the ultrasound probe will be positioned on abdominal until the three lateral abdominal wall muscles and TAP are clearly imaged. A two or four inch, 20 gauge needle will be advanced using an in-plane technique. After visual confirmation that the needle tip is in the TAP, 1 ml of preservative free 0.9% sodium chloride will be injected to reconfirm correct placement in the TAP. Then 20 ml of 0.9% preservative free sodium chloride will be injected. The procedure will be repeated on the other side.
89190939|NCT01033812||Index Recruiter|Young African American or Latina women who served as index recruiters in ATN 067 and members of their female friendship network members who tested HIV positive based on HIV screening and a confirmatory test result that was conducted in ATN 067.
89190940|NCT01033812||Male Sexual Partners|Any male partner who engaged in at least one episode of oral, vaginal or anal sex during the course of their lifetime with an 084 index recruiter.
89190941|NCT00981396|Active Comparator|CBT|Cognitive Behavioral Therapy
89004467|NCT04232085|Experimental|PID/IDS|"Alemtuzumab IV infusion over 2 hours on days -14, -13, and -12. Day -14 3 mg followed by 10 mg. Day -13 15 mg (or 10 mg if <10 kg). Day -12 20 mg (or 10 mg if <10 kg).~Fludarabine 30 mg/m2/day IV infusion over 2 hours on days -6 to -2. Melphalan 70 mg/m2/day IV infusion over 30-60 minutes on days -3 and -2. (Or may be given as a single infusion of 140 mg/m2/day on day -2.) Total body irradiation: 200 cGy will be administered in a single fraction on day -1.~Bone Marrow will be harvested and infused on day 0. Post-transplantation Cyclophosphamide 50mg/kg will be given on D+3 post-transplant (within 60-72 hr of marrow infusion) and on D+4 post-transplant.~Tacrolimus begins on day 5, at least 24 hours after completion of posttransplantation Cy at 0.015mg/kg IBW/dose IV over 4 hours every 12 hours.~Mycophenolic acid mofetil (MMF) begins on day 5 at a dose of 15 mg/kg PO TID (based upon actual body weight) with the maximum total daily dose not to exceed 3 grams (1 g PO TID)."
89004468|NCT04232085|Experimental|IBMFS|"Alemtuzumab IV infusion over 2 hours on days -14, -13, and -12. Day -14 3 mg followed by 10 mg. Day -13 15 mg (or 10 mg if <10 kg). Day -12 20 mg (or 10 mg if <10 kg).~Fludarabine 30 mg/m2/day IV infusion over 2 hours on days -6 to -2. Melphalan 70 mg/m2/day IV infusion over 30-60 minutes on days -3 and -2. (Or may be given as a single infusion of 140 mg/m2/day on day -2.) Bone Marrow will be harvested and infused on day 0. Post-transplantation Cyclophosphamide 50mg/kg will be given on D+3 post-transplant (within 60-72 hr of marrow infusion) and on D+4 post-transplant.~Tacrolimus begins on day 5, at least 24 hours after completion of posttransplantation Cy at 0.015mg/kg IBW/dose IV over 4 hours every 12 hours.~Mycophenolic acid mofetil (MMF) begins on day 5 at a dose of 15 mg/kg PO TID (based upon actual body weight) with the maximum total daily dose not to exceed 3 grams (1 g PO TID)."
89004469|NCT04195568|Experimental|Surpass Evolve Flow Diverter System|This is a prospective single arm study in which all subjects who present for flow diverter implantation, provide informed consent, and meet inclusion/exclusion criteria may receive treatment (Surpass Evolve Flow Diverter).
89004470|NCT04158895||Patients enrolled in differentiated service delivery models|
89004471|NCT04158895||Patients not enrolled in DSD models|
89004472|NCT04158882||Patients enrolled in differentiated service delivery models|
89004473|NCT04158882||Patients not enrolled in DSD models|
89004474|NCT04137757|Experimental|Lower Body Negative Pressure (LBNP)|Participants complete mental tasks and imaging while undergoing lower body negative pressure (LBNP).
89004475|NCT04137757|Sham Comparator|Sham Pressure|Participants complete mental tasks and imaging with pressure noise but no pressure.
89004476|NCT04131647|Active Comparator|Weight Maintenance|Heart Healthy nutrition, walking, resistance band exercise
89004477|NCT04131647|Experimental|Weight Maintenance + Intermittent Fasting|Heart Healthy nutrition, walking, resistance band exercise and intermittent fasting (2 small meals per day) one day per week for 24 weeks.
89004478|NCT04119648|Experimental|CAMS-4Kids|Participants will receive up to 10 sessions of CAMS-4Kids
89004479|NCT04109209|Active Comparator|Usual Care Group|"60 Participants will be randomized to receive usual care for caregivers of patients with malignant brain tumors~Caregivers randomized to the usual care arm will be referred to the brain tumor clinic social worker or other appropriate cancer center resources upon request from the caregiver, patient or clinician~Complete 3 questionnaires: Baseline, 11 weeks, 16 weeks"
89004480|NCT04109209|Experimental|Psychosocial Intervention Group|"60 Participants of caregivers of patients with malignant brain tumors will be randomized into the psychosocial intervention arm~Caregivers assigned to the intervention arm will receive usual care and the psychosocial intervention. The intervention entails six one-on-one sessions with an interventionist (psychologist or social worker)~Complete 3 questionnaires: Baseline, 11 weeks, 16 weeks"
89004481|NCT04086368|Active Comparator|The Synthes Pediatric LCP Plate System|Open osteotomy and osteofixation with the pediatric LCP hip plate
89190942|NCT00981396|Experimental|EFT|Emotional Freedom Techniques, a novel but efficacious stress-reduction technique
89406438|NCT02250222|Placebo Comparator|Part 2: Placebo (Captisol ®)|Placebo administered orally QD for 14 days.
89406439|NCT00530114|Placebo Comparator|Placebo|1.0 g TID orally 3.0 g TID orally 4.0 g TID orally 5.0 g TID orally
89004482|NCT04086368|Experimental|The adolescent Lateral Femoral Nail|Percutaneous osteotomy and intramedullary nailing
89004483|NCT04076657|Experimental|Brock String|Participants will receive instruction on Brock String therapy after first clinic visit (<48 hours post) injury, and will complete home therapy exercise twice daily
89004484|NCT04076657|Active Comparator|Standard of Care|Participants will receive standard of care (i.e., no Brock String therapy within the first week post injury) but will be informed they will receive any therapy deemed necessary at follow up visit 7-10 days post injury, consistent with standard of care
89004485|NCT04061135|Experimental|Treatment|Parkinson's Disease Patients receiving DBS electrodes
89004486|NCT04061135|No Intervention|Control|Control subjects will be non-Parkinson's Disease patients with essential tremor
89004487|NCT04057300|Experimental|Ticagrelor 90mg|Ticagrelor: 180 mg loading dose followed by 90 mg BID. Aspirin: 325 loading dose followed by 81 mg daily.
89004488|NCT04057300|Active Comparator|Clopidogrel 75mg|Clopidogrel: 300 mg loading dose followed by 75 mg daily. Aspirin: 325 loading dose followed by 81 mg daily.
89004489|NCT04056468|Experimental|Moderate HI (Child-Pugh B): Mobocertinib 40 mg|Mobocertinib 40 milligram (mg), capsule, orally, a single dose on Day 1.
89004490|NCT04056468|Experimental|Severe HI (Child-Pugh C): Mobocertinib 40 mg|Mobocertinib 40 mg, capsule, orally, a single dose on Day 1.
89004491|NCT04056468|Experimental|Normal Hepatic Function: Mobocertinib 40 mg|Mobocertinib 40 mg, capsule, orally, a single dose on Day 1.
89004492|NCT04055376|Experimental|Daily exposure to active stimulation|Subjects in this arm will receive daily exposure to active stimulation
89190943|NCT00802646|Experimental|1|When it is time for the epidural catheter, the mother will receive 2.5 mcg fentanyl spinally and then a bag of preservative-free normal saline will be administered through the epidural pump. When additional pain medication is requested, the mother will receive a known combined spinal epidural solution.
89190944|NCT00802646|Active Comparator|2|When it is time for the epidural catheter, the mother will receive 2.5 mcg fentanyl spinally and then a bag of combined spinal epidural anesthetic through the epidural pump. When additional pain medication is requested, the mother will receive a known combined spinal epidural solution.
89190945|NCT00473707|Active Comparator|1|Active management of the third stage of labor- oxytocin infusion after delivery of fetus, gentle cord traction, and fundal massage
88882575|NCT01396759|Experimental|High flow air/ oxygen mix|High flow air/ oxygen mix is useful in reducing the indication of mechanical ventilation (4); however, there is a lack of randomized studies comparing it with bubble CPAP or with standard flow O2 supplementation by nasal prongs. High flow air/oxygen mix uses flows of 2 litre per kg per minute of blended air / oxygen mix, usually with a low fraction of inspired oxygen (say 25-40%).
88882576|NCT01396759|Active Comparator|Standard O2 supplementation by nasal prongs|Standard O2 supplementation by nasal prongs @ 0.5-2.0 litre per minute
89406440|NCT00530114|Experimental|AMG 223|1.0 g TID orally 3.0 g TID orally 4.0 g TID orally 5.0 g TID orally
89406441|NCT04769401|Experimental|Normal Progesterone group|Progesterone level ≥ 10 ng/mL on ET day.
88882577|NCT01396772|Experimental|PREPARE education program|This is a 6-month program that consists of monthly nutrition and physical activity education sessions (2 hours per session) and includes interactive hands-on activities to help you gain knowledge and skills to make positive lifestyle choices. It is a pilot study to test the effectiveness of this type of health-care program in individuals with prediabetes.
88882578|NCT01396772|Other|Control arm|Individuals self-selecting the control arm receive the current standard of care for prediabetes, which is a one-time 2-hour group education session. In addition, the individuals are asked to provide some information at baseline and 6 months and 1 year later. The information collected will include a record of dietary and physical activity habits and whether or not they have developed Type 2 diabetes.
88882579|NCT01396798||Children with an acute illness|Children aged 1 month to 16 years of age, which attend the A&E department of UZLeuven with an acute illness episode of maximum 5 days.
88882580|NCT01396824||Heart failure|Heart failure patients attending a HF clinic with depressed LVEF (< 45%) or ≥ 1 hospital admission due to HF decompensation.
88882581|NCT01396850||Psychotic Group|
88882582|NCT01396850||Anxiety|
88882583|NCT01396850||Depressed|
88882584|NCT01396850||Control Group|
88882585|NCT01396863|Active Comparator|First treatment HDF|The patient will receive treatment with pre-dilution hemodiafiltration during the first examination day. During the second examination day the patient will receive treatment with low flux hemodialysis.
88882586|NCT01396863|Active Comparator|First treatment HD|The patient will receive treatment with low flux hemodialysis during the first examination day. During the second examination day the patient will receive treatment with pre-dilution hemodiafiltration.
88882587|NCT01396876|Active Comparator|Clown|A clown is present during venipuncture
88882588|NCT01396876|No Intervention|No clown|
88882589|NCT01396889|Experimental|Echinacea|0.5ml daily for children 1-2 years old and 2ml daily for children2-5 years old for 3 months
88882590|NCT01396889|Placebo Comparator|Placebo|Placebo
88882591|NCT01396902|Active Comparator|Standard of care|
88882592|NCT01396902|Experimental|Text Messaging|
88882593|NCT01396915||High or Normal Dietary Protein Intake|
88882594|NCT01396928||"J pouch"|"Anastomosis coloanal wiht j pouch reservoir"
88882595|NCT01396928||Transverse coloplasty pouch|Coloanal anastomosis with transverse coloplasty pouch reservoir
88882596|NCT01396941|Experimental|sleep restriction|The investigators will compare the effects of sleep restriction vs. normal sleep in healthy volunteers, using a randomized crossover study design. Each subject will undergo a period of normal sleep and a period of sleep restriction, separated by a 1-month washout period. Subjects will be randomized to receive either sleep restriction first (later followed by normal sleep) or normal sleep first (later followed by sleep restriction).
88882597|NCT01396980||dialysis patients|dialysis patients, stabil, dialysis dependancy for more than 3 months, with adequate access
88882598|NCT01396993||iTOP|Patients undergoing immediate techniques for oncoplastic surgery (level I only parenchmyl rotation and breast undermining as well as level II using complex reduction plastics for nipple-areola-complex movings) and patients with mastectomy and immediate reconstruction
88882599|NCT01396993||BCT|patients undergoing conservative breast surgery
88882600|NCT01397006|Experimental|Pregabalin|
88882601|NCT01397006|Placebo Comparator|Placebo|
88882602|NCT01397019|Experimental|FOLFIRINOX|
88882603|NCT01397032|Experimental|Attention Bias Modification (ABM)|Attention training via repeated trials of a dot-probe task intended to direct attention away from threat stimuli.
88882604|NCT01397032|Placebo Comparator|Placebo|Attention training via repeated trials of a dot-probe task not intended to change threat-related attention patterns.
88882605|NCT01397045|Active Comparator|Video-assisted lung segmentectomy|Patients undergoing VATS segmentectomy
88882606|NCT01397045|Other|Mini thoracotomy|Patients undergoing lung segmentectomy through a mini thoracotomy
88882607|NCT01397097|Experimental|Arm 1|
88882608|NCT01397097|Active Comparator|Arm 2|
88882609|NCT01397123|Experimental|Lifestyle counseling|
88882610|NCT01397149|Experimental|Eltrombopag|In phase II, patients will be randomized (2:1 eltrombopag : placebo) to receive either eltrombopag or placebo to explore the efficacy and confirm the safety of the identified eltrombopag dose from Phase I.
88882611|NCT01397149|Placebo Comparator|Film coated tablet|
88882612|NCT01397175|Active Comparator|Biolimus-eluting stent|Biomatrix stent, Biosensors, USA Biomatrix Flex stent, Biosensors, USA
88882613|NCT01397175|Active Comparator|Everolimus-eluting stent|Xience Prime stent, Abbott, USA Xience V stent, Abbott, USA
88882614|NCT01397175|Active Comparator|Zotarolimus-eluting stent|Endeavor resolute, Medtronic, USA Endeavor resolute integrity, Medtronic, USA
88882615|NCT01397188|Experimental|PiCCO group|Intervention: Device: Picco- thermodilution catheter
89406442|NCT04769401|Active Comparator|Low Progesterone group|Progesterone level <10 ng/mL on ET day.
89406443|NCT02280512||elderly with fractures|patients more than 65 years old accepting surgeries for lower extremities fracture
89406444|NCT02250378|Experimental|Treatment (stereotactic radiosurgery, wedge resection)|Patients undergo stereotactic radiosurgery every other day for 3 or 5 fractions (depending on the size tumor and proximity to the chest wall). Within 4-6 weeks after completion of stereotactic radiosurgery, patients undergo wedge resection.
89406445|NCT02282696|Experimental|cancer patients|Questionnaire, focus group participation
89406446|NCT03056157|Experimental|Adaptive Disclosure for Moral Injury and Loss|Ad-MIL is a 12-session treatment designed to address shame and guilt and to develop compassion for the self and the other. At the outset of AD-MIL, the investigators ask Veterans to enlist a family member or friend to provide support and to reinforce their plan for adaptive, purposeful functioning moving forward. The sessions that follow homework assignments involve a discussion to reinforce positive steps taken and identifying obstacles to completion (e.g., self-defeating beliefs). There is a special emphasis on discussing self-handicapping, namely feeling unworthy of getting better or living a good life. The goal is not only for Veterans to develop a sense of mastery in accomplishing tasks and to experience the benefits of the activities, but also to work on overcoming feelings of unworthiness.
89406447|NCT03056157|Active Comparator|Present Centered Therapy|PCT is a manualized evidenced-based PTSD treatment used in several large-scale PTSD trials. It incorporates the essential therapeutic elements common to different types of psychotherapies, including supportive empathic listening and unconditional positive regard. The therapist plays an active role, but does not impart any systematic training. The focus is to create an understanding of how the symptoms of PTSD are related to day-to-day difficulties and to help patients develop new, more adaptive responses to these stressors with a problem-focused and problem-solving approach. In prior trials, PCT showed equivalent change to active therapies at the last follow-up. The VA offers PCT as an evidence-based therapy for PTSD.
89190946|NCT00473707|Other|2|Expectant management of the third stage of labor
89406448|NCT02280590|Experimental|Cresnon®|Rosuvastatin 10mg, tablet, q.d.
89406449|NCT02280590|Active Comparator|Crestor®|Rosuvastatin 10mg, tablet, q.d.
89406450|NCT02090244|No Intervention|Control|Standard care postoperatively.
89190947|NCT00279500|Experimental|single arm study|Argus 16 Retinal Stimulation System-single arm study.
89190948|NCT00114530|Experimental|mHSCT|Myeloablative Hematopoietic Stem Cell Transplant (mHSCT) Participants will first have hematopoietic stem cells removed from their blood. They then will receive high doses of chemotherapy and radiation to eliminate their developed and presumably abnormal immune system, followed by autologous stem cell transplantation to reintroduce the purified stem cells to re-establish their immune system.
89406451|NCT02090244|Experimental|Teriparatide|One injection daily for 4 weeks
89406452|NCT02282774|Experimental|SB|receive subtenon block of 4mL of 2% lidocaine and 0.5% bupivacaine (50:50) mixture
89406453|NCT02282774|Sham Comparator|C|receive subtenon block of 4mL saline
89406454|NCT02090322|Experimental|Bevacizumab|"The treatment for Retinopathy of prematurity is Intravitreal bevacizumab. We want to compare two dosages (0.500 and 0.625mg) and demonstrate that 0.500mg there isn't lower in efficacy than 0.625mg.~When the baby have the diagnosis or Retinopathy of prematurity we are going to inyect the eye that have te problem, then we are going to explore until this illness disappear. It is only one intervention"
89406455|NCT02282852|Experimental|Wireless Capsule Endoscopy|Wireless capsule endoscopy is the investigation modality of choice for suspected diseases of the small bowel. A small pill-sized capsule contianing a camera is swallowed by the patient. The procedure is safe and non-invasive. Normally, the pill camera travels through the gut an exits the bowel via natural means. In a small number of cases the capsule is maintained. If the capsule is still in the stomach, mobilisation is encouraged followed by an intramuscular pro-kinetic injection if this fails.
89406456|NCT02282852|Active Comparator|Magnetically steerable capsule endoscopy|A handheld magnet (manufactured by Intromedic Ltd.) has been developed to allow some control of the pill camera (that contains a small amount of magnetic material) in the upper GI tract. We propose that this could be used, alongside positional changes, to expedite capsule transit through the stomach thus improving completion rates and avoiding the risks of unnecessary medication.
89406457|NCT02095782|Experimental|chemotherapy and erlotinib|Intercalated combination of chemotherapy and erlotinib in 1st line setting for patients with advanced stage non-small-cell lung cancer with low abundant activating EGFR mutation
89406458|NCT03659487|Active Comparator|Nissen|Surgery of GERD with 360 degrees total fundoplication
89406459|NCT03659487|Active Comparator|Toupét|Surgery of GERD with 270 degrees partial fundoplication
89406460|NCT02280668|Active Comparator|Control Group|Will perform the eccentric muscle damage exercise and will not perform any icing interventions post damage. These participants will be the control group.
88882616|NCT01397188|Sham Comparator|sham group|No PiCCO Intervention
88882617|NCT01397214|Experimental|Megace F|Megace F oral suspension
88882618|NCT01397214|Active Comparator|Megace OS|Megace acetate oral suspension
88882619|NCT01397240|Experimental|Albis|Drug: Albis Tab 2 tab, twice a day
88882620|NCT01397240|Placebo Comparator|Placebo|Placebo 2 tab, twice a day
88882621|NCT01397266|Active Comparator|Active TMS|active rTMS delivered to the left dorsolateral prefrontal cortex
88882622|NCT01397266|Placebo Comparator|Placebo TMS|PLACEBO rTMS delivered to the left dorsolateral prefrontal cortex
88882623|NCT01397305|Experimental|Modufolin and Pemetrexed|Modufolin ( [6R] 5,10-methylenetetrahydrofolate) and Pemetrexed
88882624|NCT01397318||Experimental Group|
88882625|NCT01397318||Control Group|
88882626|NCT01397331|Active Comparator|Inhalational anesthesia|Group of patients undergoing the surgery under anesthesia based on inhalational anesthetic
88882627|NCT01397331|Active Comparator|TIVA|Group of patients undergoing the surgery under total intravenous anesthesia
88882628|NCT01397357||suspected Myocardial Ischemia|Patient with diagnosis of suspected coronary artery disease (CAD) or recurrent ischemic symptoms assessed by under-effort angina symptoms and/or cardiac conventional stress test, and the presence of at least two risk factors.
88882629|NCT01397370|Experimental|GLPG0492 oral solution|Multiple ascending doses once daily for 14 days, starting from 5 mg/day
88882630|NCT01397370|Placebo Comparator|Placebo oral solution|Once daily dosing for 14 days
88882631|NCT01397383||Vitamin D deficiency|Patients with low serum vitamin D (25-hydroxy vitamin D < 32 ng/ml)
88882632|NCT01397383||Control group|Patients with normal serum vitamin D level (serum 25-hydroxy vitamin D > 32 ng/ml)
88882633|NCT01397396|Experimental|Inspiratory Muscle Training|Inspiratory Muscle Training
88882634|NCT01397396|Placebo Comparator|Sham IMT|Sham Inspiratory Muscle Training
88882635|NCT01397435||Gaucher|We will enroll 15 children who have a confirmed diagnosis of Gaucher disease.
88882636|NCT01397435||Healthy volunteers|We will enroll 15 age and gender matched controls.
88882637|NCT01397474|No Intervention|Control|The fluid management algorithm of the control group is based on the standard care procedure of our ICU as recommended in guidelines: the patient's fluid status is assessed by performing a fluid challenge with a bolus of 250 ml colloids. When the patients is fluid responsive (i.e. showing an increase in stroke volume > 10% ) he will receive an additional bolus of 250 ml of colloids. After each fluid challenge, patients will be revaluated for fluid responsiveness to access need of further fluid administration.
88882638|NCT01397474|Experimental|PPTFM|"The fluid management algorithm of the intervention group uses identical therapy (i.e. fluids) yet targeted at different endpoints (i.e. peripheral perfusion parameters). After evaluation of peripheral perfusion, only patients with a bad peripheral perfusion (i.e. 3 out of 4 criteria considered as bad) will receive a fluid challenge, the same way as in the standard care procedure (i.e. bolus of 250 ml of fluid). After each fluid challenge, patients will be re-evaluated for peripheral perfusion to access further need in fluid challenges. To ensure that no hypovolemia will occur in the intervention group, fluid will be administered irrespectively of peripheral perfusion parameters, if cardiac index falls below a value of 2,5 L/min/m2."
89190949|NCT00114530|Experimental|cyclophosphamide|"Cyclophosphamide (CY) Participants will receive high doses of intravenous cyclophosphamide. The dose being used in this study is about 50% higher than that commonly used by most physicians to treat many other autoimmune diseases.~Administration of 12 monthly pulses of high-dose intravenous cyclophosphamide (an initial dose of 500 mg/m^2, followed by 11 doses of 750 mg/m^2)."
89190950|NCT00107744|Active Comparator|Soy protein-milk protein-carbohydrate|Participants received 40 grams of soy protein daily for 8 weeks, 40 grams of milk protein daily for 8 weeks, and 40 grams of carbohydrate daily for 8 weeks.
89190951|NCT00107744|Active Comparator|Milk protein-carbohydrate-soy protein|Participants received 40 grams of milk protein daily for 8 weeks, 40 grams of carbohydrate daily for 8 weeks, and 40 grams of soy protein daily for 8 weeks.
89190952|NCT00107744|Active Comparator|Carbohydrate-soy protein-milk protein|Participants received 40 grams of complex carbohydrate daily for 8 weeks, 40 grams of soy protein daily for 8 weeks, and 40 grams of milk protein daily for 8 weeks.
89190953|NCT00845338|Experimental|Arm 1|
89190954|NCT00855634|Active Comparator|1|"COHORT 1 (minimal metastatic disease):~Arm 1 (intervention): resection of the primary tumor, followed by resection of the liver metastasis/metastases~Arm 2 (control): exploration and/or gastroenterostomy and/or hepaticojejunostomy/choledochojejunostomy"
89190955|NCT00855634|Active Comparator|2|"COHORT 2 (venous infiltration):~Arm 1 (intervention): resection of the primary tumor with resection of the portal vein (and/or superior mesenteric vein/splenic vein (SMV/SV)~Arm 2 (control): resection of the primary tumor with dissection of the portal vein (and/or superior mesenteric vein/splenic vein (SMV/SV) plus tumor masses adjacent to these veins; no venous resection"
89190956|NCT00923962|Active Comparator|Type 2 Diabetes patients|
89190957|NCT00923962|Active Comparator|Healthy|
89190958|NCT00923962|Active Comparator|Artherosclerosis|
89190959|NCT00711438|Experimental|FT|Breathlessness Intervention Service (BIS)
89190960|NCT00711438|Active Comparator|WL|Best supportive care
89190961|NCT02575092|Active Comparator|Group A, without hypertension|The patients who will not be taken the drugs of antihypertension and antihomocysteine.
89190962|NCT02575092|Experimental|Group B, hypertension|The hypertensive patients with their plasma Hcy levels <10 umol/L will be taken the drugs of antihypertension(Enalapril Maleate Tablets,as the program-based antihypertension)
89190963|NCT02575092|Experimental|Group C,hypertension and hyperhomocysteinemia|The hypertensive patients with their plasma Hcy levels ≥10 umol/L will be taken the drugs of antihypertension and antihomocysteine( Enalapril Maleate and Folic Acid Tablets,as the program-based antihypertension)
89190964|NCT00851578|Experimental|WATCHMAN|non-valvular atrial fibrillation patients contraindicated to warfarin
89190965|NCT04097470|Active Comparator|Arm A: Decitabine|"Cycles 1-3: Decitabine 10-day; depending on day +28 bone marrow (BM) blasts after the previous cycle, next cycle consists of either 5-day (BM blasts < 5%) or 10-day (BM blasts ≥5%) decitabine. Cycles 4 and beyond: 5-day decitabine (in cycles of 4-8 weeks); continuation of these cycles until progression.~Dosage for Decitabine 20 mg/m2 i.v."
88882639|NCT05269290|Experimental|Ingavirin®, syrup, 30 mg/5 ml|Ingavirin®, syrup, 30 mg/5 ml will be administered on top of standard therapy
88882640|NCT05269290|Placebo Comparator|Placebo|Placebo will be administered on top of standard therapy
88882641|NCT05268952|Experimental|GEP-NET and lung-NET patients|Liquid biopsies and scans
89406461|NCT02280668|Experimental|Icing Protocol 1|Will perform the eccentric muscle damage exercise and will begin the icing intervention immediately after the muscle damage. The icing protocol will be icing the elbow flexor muscles for 10 minutes with a cold pack followed by 10 minutes with no icing and another 10 minutes of elbow flexor muscle icing. The participants will perform this protocol every day at approximately the same time for the duration of the study.
88882642|NCT05268913||Women with BRCA1/2 genes|
88882643|NCT05268913||Women with breast cancer|
89406462|NCT02280668|Experimental|Icing Protocol 2|Will perform the eccentric muscle damage exercise and will begin the icing intervention 6 hours post muscle damage. The icing protocol will be icing the elbow flexor muscles for 10 minutes with a cold pack followed by 10 minutes with no icing and another 10 minutes of elbow flexor muscle icing. The participants will perform this protocol every day at approximately the same time for the duration of the study.
89406463|NCT02094378|Experimental|Esketamine-Placebo|Participants assigned to treatment sequence 1 will receive 84 mg esketamine intranasally on Day 1 of Period 1 and then receive placebo intranasally on Day 1 in Period 2. Periods 1 and 2 will be separated by 7 days.
89406464|NCT02094378|Placebo Comparator|Placebo-Esketamine|Participants assigned to treatment sequence 2 will receive placebo intranasally on Day 1 of Period 1 and then receive 84 mg esketamine intranasally on Day 1 in Period 2. Periods 1 and 2 will be separated by 7 days.
89406465|NCT03659409|Experimental|Mindfulness Based Intervention|4 weekly 2-hour sessions. Participants will be introduced, taught and guided in practice of mindfulness-based interventions that are focused on their (1) breath, (2) senses, (3) body and bodily movements, (4) feelings of empathy and compassion.
89406466|NCT03659409|Other|Treatment Waitlist Group|Participants will receive no intervention, except for a baseline follow-up at the start and again at the end of the first phase. 2 months after the end of the first intervention phase, participants in this group will receive the same mindfulness-based intervention for 4 weeks.
89406467|NCT02285660|Other|Routine CT scan plus 4D PET-CT scan|
89406468|NCT02285660|Other|Routine CT scan|
89406469|NCT02095860|Experimental|Treatment A: DCV 3DAA FDC fasted state|DCV 3 Direct Acting Antiviral (DAA) Fixed Dose Combination (FDC) tablet by mouth once on specified days in fasted state
89406470|NCT02095860|Experimental|Treatment B: DCV 3DAA FDC with high-fat meal|DCV 3DAA FDC tablet by mouth once on specified days with high-fat meal
89406471|NCT02095860|Experimental|Treatment C: DCV 3DAA FDC with light meal|DCV 3DAA FDC tablet by mouth once on specified days with light meal
89406472|NCT02285738|Active Comparator|Aspirin+Asprin/Simvastatin+Observation (ASO)|Aspirin 81mg/day for 4 weeks followed by 2-week washout, followed by 4 weeks of Aspirin 81mg/day with daily dose of Simvastatin with a 2-week washout period, ending with 4 weeks of observation
89406473|NCT02285738|Experimental|Aspirin+Observation+Asprin/Simvastatin (AOS)|Aspirin 81mg/day for 4 weeks followed by 2-week washout, followed by 4 weeks of observation with 2-week washout, ending with Aspirin 81mg/day with daily dose of Simvastatin
89406474|NCT02285738|Experimental|Aspirin/Simvastatin+Observation+Asprin (SOA)|Aspirin 81mg/day for 4 weeks with daily dose of Simvastatin followed by 2-week washout, followed by 4 weeks of observation with 2-week washout, ending with Aspirin 81mg/day
89406475|NCT02285738|Experimental|Aspirin/Simvastatin+Asprin+Observation (SAO)|Aspirin 81mg/day for 4 weeks with daily dose of Simvastatin followed by 2-week washout, followed by 4 weeks of Aspirin 81mg/day and a 2-week washout, ending with observation for 4 weeks.
89406476|NCT02285738|Experimental|Observation+Aspirin/Simvastatin+Asprin (OSA)|Observation for 4 weeks with 2-week washout, followed by Aspirin 81mg/day for 4 weeks with daily dose of Simvastatin followed by 2-week washout, ending with Aspirin 81mg/day for 4 weeks.
89406477|NCT02285738|Experimental|Observation+Aspirin+Asprin/Simvastatin (OAS)|Observation for 4 weeks with 2-week washout, followed by Aspirin 81mg/day for 4 weeks followed by 2-week washout, ending with Aspirin 81mg/day for 4 weeks with daily dose of Simvastatin.
88882644|NCT05268913||Women with obesity|
88882645|NCT05268900|Placebo Comparator|Volume control ventilation group|Patients' lungs will be ventilated with volume control ventilation mode
88882646|NCT05268900|Active Comparator|Pressure control ventilation-volume guaranteed group|patients' lungs will be ventilated with Pressure control ventilation-volume guaranteed mode
88882647|NCT05268861|Experimental|Training with EA feedback|Subjects will undergo training with the EA-VR game that includes a 15 degree elbow flexion error.
88882648|NCT05268861|Sham Comparator|Training without EA feedback|Subjects will undergo training with the EA-VR game that does not include EA feedback.
88882649|NCT05268848|Experimental|Termography PRE|Foot thermography before lining test
88882650|NCT05268848|Experimental|Termography POST|Foot thermography after wearing 2 types of liner for three hours (one on each foot)
88882651|NCT05268848|Active Comparator|Thermographic comparations|Thermographic comparations between PRE and POST measurements
89406478|NCT03556410|Placebo Comparator|sleep|Subject will undergo 5 days of shortened sleep and then 2 days of ad libitum sleep.
88882652|NCT05268835|Active Comparator|Clindamycin 150mg|Patients receiving 150mg of clindamycin (Dalacin C, Pfizer) after surgery every 8 hours
88882653|NCT05268835|Active Comparator|Clindamycin 300mg|Patients receiving 300mg of clindamycin after surgery every 8 hours
88882654|NCT05268835|Active Comparator|Clindamycin 600mg|Patients receiving 600mg of clindamycin after surgery every 12 hours
88882655|NCT05268770||Tinnitus patients with good hearing|
88882656|NCT05268770||Healthy controls with good hearing|
88882657|NCT05268718|Experimental|Nanogel photothermal therapy|After the subjects were enrolled in the study, the eyes were coated with Au-Ag-Cu2O nano-gel once (the concentration was 26.4μg/mL, the dosage was suitable to cover the ulcer surface evenly, and the dosage was recorded). Combined with mdl-n-808-10w near-infrared laser (China changchun new industry photoelectric technology) combined with photothermal therapy (laser wavelength 808 nm, power 1.5W/cm2, temperature controlled at 40℃, lasting 10min)
89406479|NCT03556410|Experimental|sleep+exercise|Subject will undergo 5 days of shortened sleep but also have 45 min of moderate exercise/day and then 2 days of ad libitum sleep
89406480|NCT00650702|Experimental|1|Low Latanoprost-PPDS
89406481|NCT00650702|Experimental|2|Medium Latanoprost-PPDS
89406482|NCT00650702|Experimental|3|High Latanoprost-PPDS
89406483|NCT02090400|Other|Bazedoxifene & Calcium/Vit D|Bazedoxifene 20mg oral once a day and calcium 500mg and 400 IU vitamin D (OSTINE)
89406484|NCT02090400|Other|Calcium/Vit D|Calcium 500mg and 400 IU vitamin D (OSTINE )daily.
89406485|NCT04471610|No Intervention|Control group|Group A: Patients allocated to the control group will undergo the measurements at inclusion and discharge visit. The control group conduces to compare the NT-proBNP and HF medication changes under therapy monitoring with serial NT-proBNP measurements to the NT-proBNP and HF medication changes with sign and symptom guided HF therapy. The diagnostic and therapeutic decisions in the control Group and in the Intervention group will be based on the current 2016 ESC guidelines on the diagnosis and therapy of HF as established at the KSBL Liestal. At discharge, the same measurements as at the inclusion visit will be repeated in all patients to monitor the effects associated with the participation in this trial.
89406486|NCT04471610|Experimental|POC-available group|Group B:Patients allocated to the intervention group (POC-available group) will undergo serial measurements of NT-pro BNP, potassium, sodium, and creatinine every second business day. The blood collection (10 ml of Lithium Heparin blood) for these tests will be done in the morning together with the regularly blood collection. The study team does the the analysis on the study devices. The result of the test will be provided directly to the responsible physician. Treatment changes are at the discretion of the responsible physician. The physician will be alerted by a phone call of a study member if the NT-proBNP hasn't decreased by 10% or more between two measurements. But no specific recommendations with regards to therapy will be provided by the investigator or his team. However, diagnostic and therapeutic decisions will be based on the current 2016 ESC guidelines on the diagnosis and therapy of HF as established at the KSBL Liestal.
89406487|NCT02090478|Sham Comparator|No change in dietary sugar levels|Group met with a dietician as often as the control group to discuss diet, but the dietician gave them advice geared toward no change in dietary sugar levels
89406488|NCT02090478|Experimental|Low sugar group|Subjects met with a dietician who discussed diet records. After the first month (baseline, regular diet), the dietician made suggestions geared toward reducing calories from simple sugars by 40%. This will be achieved by replacing sugar calories with complex carbohydrates and fats, while maintaining energy balance (same number of calories as the baseline month).
89406489|NCT03134846|Experimental|Phase 1: 10mg Cetuximab-IRDye800CW|Three patients will receive 10mg Cetuximab-IRDye800cv I.V. four days prior to surgery.
89406490|NCT03134846|Experimental|Phase 1: 25mg Cetuximab-IRDye800CW|Patients will receive 25mg Cetuximab-IRDye800cv I.V. four days prior to surgery.
89406491|NCT03134846|Experimental|Phase 1: 50 mg Cetuximab-IRDye800CW|Patients will receive 50mg Cetuximab-IRDye800cv I.V. four days prior to surgery.
89406492|NCT03134846|Experimental|Phase 1: 75mg cetuximab + 15 mg Cetuximab-IRDye800CW|Patients will receive 75mg cetuximab + 15 mg Cetuximab-IRDye800CW I.V. four days prior to surgery.
89406493|NCT03134846|Experimental|Phase 1: 75mg cetuximab + 25 mg Cetuximab-IRDye800CW|Patients will receive 75mg cetuximab + 25 mg Cetuximab-IRDye800CW I.V. four days prior to surgery.
89406494|NCT03134846|Experimental|After having established the optimal cetuximab-IRDye800CW dose|After having established the optimal cetuximab-IRDye800CW dose we will extent the study by including up to 70 patients for this specific dose (as determined in phase 1).
89406495|NCT02094456|Experimental|Endoscopic clipping of diverticula|Endoscopic clipping of diverticula Follow-up colonoscopy
89406496|NCT04471688||patients|Preoperative patients needing transfusions
89406497|NCT01068717|Other|Saxagliptin, 2.5 mg + Metformin, 500 mg (fasted state)|Single oral doses of saxagliptin, 2.5 mg, and metformin, 500 mg, administered together as tablets in the fasted state
89406498|NCT01068717|Other|Saxagliptin, 2.5 mg/Metformin, 500 mg FDC (fasted state)|Single oral dose of a 2.5-mg saxagliptin/500-mg metformin fixed-dose combination (FDC) tablet administered in the fasted state
88882658|NCT05268718|Active Comparator|Voriconazole eye drops|Voliconazole eye drops (once in half an hour) were also used in the control group.
89406499|NCT01068717|Other|Saxagliptin, 2.5 mg + Metformin, 500 mg (fed state)|Single oral doses of saxagliptin, 2.5 mg, and metformin, 500 mg, administered together as tablets in the fed state
89406500|NCT01068717|Other|Saxagliptin, 2.5 mg/Metformin, 500 mg FDC (fed state)|Single oral dose of saxagliptin, 2.5 mg/metformin, 500 mg, FDC tablet administered in the fed state
89406501|NCT02095938|Experimental|Solian|Amisulpride (Solian) will be orally administered once or twice daily after meal intake for 8 weeks. Patients initially will receive a low dose of amisulpride (200-400mg/day). The dosage may be adjusted to between 400 and 800mg/day according to the clinical decision by treating physician
89406502|NCT04471376|Active Comparator|Sugammadex group|
88882659|NCT05268718|Placebo Comparator|Normal saline|Normal saline eye drops (once in half an hour) were also used in the control group.
89406503|NCT04471376|No Intervention|control group|
88882660|NCT05268692|Active Comparator|GS|gemcitabine plus S-1
88882661|NCT05268692|Active Comparator|GnP|gemcitabine plus nab-paclitaxel
88882662|NCT05268627|Active Comparator|Endoscopic Ultrasound Guided Gastric Botulinum Toxin Injections|
88882663|NCT05268627|Active Comparator|liraglutide|
88882664|NCT05268536|Active Comparator|resistance exercise|Participants will perform Squat walking with resistance band, Butt blaster, Mussel with resistance band, Hip extension with resistance band, and Ankle dorsiflexion exercises with resistance band. All the participants will perform exercise for 6 weeks, 2 days a week for approximately 30-45 (including warm-up and cool-down).
89406504|NCT02094690|Active Comparator|Device Hyperboloid|"5 min of bilateral mastication alternated with the device hyperboloid The exercises should begin one day before the onset of Radiotherapy (RT) and kept until the end of RT.~Repeated 4x a day (after breakfast, lunch, dinner and before going to bed)."
89406505|NCT02094690|Active Comparator|Device Therabite|"10 repetitions holding the device Therabite for 30 seconds~5 min of bilateral mastication alternated with the device hyperboloid The exercises should begin one day before the onset of Radiotherapy and kept until the end of RT.~Repeated 4x a day (after breakfast, lunch, dinner and before going to bed)."
89406506|NCT02094690|No Intervention|Control|The control group (GEC) will not receive any of the protocols tested in the study, but together with the other groups, will receive the regular treatment offered by the institution, which is made up of guidance and advice given by the hospital´s nursing team about the radiotherapy treatment. Currently, patients do not receive any information as far as trismus is concerned.
89406507|NCT02285894|Experimental|Inspiratory hold|Mechanical inspiratory pressure held for 10 seconds at a time.
89406508|NCT02285972|Placebo Comparator|saline|
89406509|NCT02285972|Active Comparator|dexketoprofen|
89406510|NCT02285972|Active Comparator|tenoxicam|
89406511|NCT02096016||Human Papilloma Virus test|"Patients treated with surgery alone for uterine cervical neoplasms attending surveillance at Dept. of Obstetrics and Gynecology, Oncogynecological unit, Aarhus University Hospital from 01.01.14 From 01.01.15 patients will be recruited from Oncogynecologic units at Aalborg University Hospital and Rigshospitalet. Recruitment of patients from these institutions has not been successful and has been closed.~It is expected due to political decisions that the cervical cancer patients from the uptake area of Aalborg University Hospital will be treated at Aarhus University Hospital and they will then be eligible for the study"
89406512|NCT03134300|Active Comparator|Low SES|
89406513|NCT03134300|Placebo Comparator|Normal/high SES|
88882665|NCT05268536|Active Comparator|core stabilization exercise|Patients will perform Plank, Bird dog, Double leg lifts, Prone cobra, Oblique twists exercises under the supervision of experienced Physiotherapist. All the participants will perform exercise for 6 weeks, 2 days a week for approximately 30-45 (including warm-up and cool-down).
88882666|NCT05268523|Experimental|Education and Strategies Intervention Group|Participants will use a videoconferencing system to participate in the Education and Strategies Intervention composed of 1 session per week (1.5 hrs/session) over the course of 8 weeks.
88882667|NCT05268523|Active Comparator|Mindfulness Skills Intervention Group|Participants will use a videoconferencing system to participate in the Mindfulness Skills Intervention composed of 1 session per week (1.5 hrs/session) over the course of 8 weeks.
88882668|NCT05268523|No Intervention|No-Treatment Control Group|Participants adhere to the standard of care (no study treatment) for 8 weeks.
89406514|NCT02096094|Experimental|Chlorhexidine bath|This arm is composed with 27 healthy volunteers which will perform full body bath with wipes impregnated with 2% chlorhexidine and with shampoo with 0.15% chlorhexidine.
89406515|NCT02096094|Placebo Comparator|Control bath|This arm is composed with 27 healthy volunteers which will perform full body bath with wipes and shampoo without chlorhexidine.
89406516|NCT02921763||Dydrogesterone|Dydrogesterone 20 mg (4 tablets) per day should be orally administered in 2 divided doses (in the morning and evening). It should be administered for 21 days; dosage starts on the 5th day of each menstrual cycle until 25th day. The administration period will be from the start of Duphaston treatment (cycle 1) to cycle 4.
89406517|NCT02286362||Cohort|
89406518|NCT02094768|Experimental|Reduced Fat Milk|20 oz. reduced fat (2%) milk per day
89406519|NCT02094768|Experimental|Sugar Sweetened Soda|24oz. soda per day
88882669|NCT05268484|Experimental|TBI Intervention Group|Participants will participate in 16 anticipatory postural adjustments (APA) and compensatory postural adjustments (CPA) training sessions using the Neurocom Balance Platform. Each session will last for 1 hour. During the APA portion, a visual cue on the front screen in the form of a countdown timer showing the remaining seconds to the onset of the upcoming perturbation. This information will allow an opportunity for the participant to adjust their posture to handle the upcoming perturbation in the best possible way and also train them to anticipate upcoming disturbances and execute corrective motor outputs. This will ensure the generation of APA in a consistent and repetitive manner. In CPA, after a 5 second pause, the platform will oscillate at 1 Hz, with a constant amplitude, in the anterior-posterior direction for 50 seconds, followed by an additional 5 second quiet period. The participant will wear a safety harness at all times and a spotter will be present at all times.
89406520|NCT03658473|Active Comparator|Treatment A|Administration of 550 mg naproxen 2x daily + 300 mg rebamipide 2x daily + 20 mg rabeprazole 1x daily over 7 days.
88882670|NCT05268484|No Intervention|TBI Control Group|No intervention is provided
89406521|NCT03658473|Active Comparator|Treatment B|Administration of 550 mg naproxen 2x daily + 300 mg rebamipide placebo 2x daily + 20 mg rabeprazole 1x daily over 7 days.
89406522|NCT03658473|Active Comparator|Treatment C|Administration of 550 mg naproxen 2x daily + 300 mg rebamipide 2x daily + 20 mg rabeprazole placebo 1x daily over 7 days.
89406523|NCT03658473|Placebo Comparator|Treatment D|Administration of 550 mg naproxen 2x daily + 300 mg rebamipide placebo 2x daily + 20 mg rabeprazole placebo 1x daily over 7 days.
89406524|NCT02096250|Experimental|NaFeEDTA|NaFeEDTA
89406525|NCT02096250|Experimental|Ferrous fumarate|Ferrous fumarate
89406526|NCT02096250|Experimental|NaFeEDTA + ferrous fumarate|NaFeEDTA + ferrous fumarate
89406527|NCT02286050|Experimental|CF Nursing Intervention|
89406528|NCT03659331|Experimental|unexplained elevation of liver enzymes|patients over the age of 18 referred for unexplained elevation of liver enzymes and carry a single mutation in the ATP7B gene. After a washout period of 3 months these patients will be re-checked for liver enzymes and if high will receive zinc therapy at a dose of 300 mg / day for 6 months, after which the liver enzymes will be checked again.
89406529|NCT02094846|Active Comparator|Voice messages|This group receive voice messages to reinforce given information about diet, physical activity, glycemic index
89406530|NCT02094846|Placebo Comparator|Messages|This group received voice messages with fun facts.
89406531|NCT02286128||Non-diabetic controls|Age-matched non-diabetic subjects
89406532|NCT02286128||Type 2 diabetes|Type 2 diabetes with metformin monotherapy failure
89406533|NCT02096328|Experimental|POL7080, Anti-pseudomonal antibiotics|POL7080 daily co-administered with standard of care treatment
89406534|NCT02283008|No Intervention|Standard care|This arm will receive standard care which involves informal education on how to use metered dose inhalers
89406535|NCT02283008|Active Comparator|Structured education|This arm will receive structured education on the use of inhalers. At 6 weeks post education inhaler technique will be re-assessed. Participants who fail to achieve a set level of competence may be chosen for semi structured interview.
89406536|NCT01318135|Active Comparator|Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID|
89406537|NCT01318135|Active Comparator|Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID|
89406538|NCT01318135|Active Comparator|Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID|
89406539|NCT01318135|Active Comparator|Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID|
89406540|NCT02922153|Experimental|Cryoanalgesia + Standard of Care (SOC)|Cryoanalgesia in Conjunction with Standard of Care. Up to 5 sessions of cryoanalgesia for 120 seconds per session.
89406541|NCT02922153|Active Comparator|Standard of Care|Institutional SOC for pain management will be followed. The use of local post-operative pain management techniques (i.e., intercostal, peri-vertebral, or any other acceptable method) is permitted for both treatment groups up to 24 hours post-operatively according to institutional standard of care.
89406542|NCT02283086|No Intervention|Control|
88882671|NCT05268484|No Intervention|Healthy Control|No intervention is provided
89406543|NCT02283086|Experimental|Intervention|The intervention consisted of quarterly performance feedback reports sent via e-mail.
89406544|NCT03555630||Post-cesarean preeclampsia|
89406545|NCT03555630||Post spontaneous vaginal delivery preeclampsia|
89406546|NCT02286440|Experimental|GeneSight guided treatment|GeneSight guided group will have their research psychiatrist make treatment recommendations based on test results
88882672|NCT05268354|Experimental|Training group|6-week neuromuscular training program
88882673|NCT05268354|No Intervention|Control group|
89406547|NCT02286440|Active Comparator|Treatment as usual group|Treatment as usual group will have treatment recommendations based on clinical judgment
89406548|NCT02094924|Experimental|Sequence 1|Participants in this arm will receive treatment A in period 1 and treatment B in period 2. Subjects will receive a single reference FDC tablet of 16mg candesartan cilexetil/12.5mg HCTZ as Treatment A administered orally with 240mL of water and a single 16mg candesartan cilexetil/12.5mg HCTZ FDC tablet (GSK587323) as Treatment B.
89406549|NCT02094924|Experimental|Sequence 2|Participants in this arm will receive treatment B in period 1 and treatment A in period 2. Subjects will receive a single reference FDC tablet of 16mg candesartan cilexetil/12.5mg HCTZ as Treatment A administered orally with 240mL of water and a single 16mg candesartan cilexetil/12.5mg HCTZ FDC tablet (GSK587323) as Treatment B.
89406550|NCT02286206|Experimental|Clozapine bid|"Participants have been taking clozapine once daily and have reached steady-state prior to the start of this study.~Intervention: Days 1-14"
89406551|NCT03578731||Consilium-APP|Patients with oncological, medical treatment for breast cancer, colon cancer, prostate cancer, lung cancer or hematological malignancies.
89406552|NCT02096406|Other|ACE/ARB Continuation|ACE/ARB will be continued up to and including the morning of surgery.
89406553|NCT02096406|Other|ACE/ARB withdrawal|ACE/ARB will be discontinued medication 48 hours prior to surgery
89406554|NCT00387686|Experimental|A|1.0 mg/mL rhBMP-2/CPM + surgical fixation
89406555|NCT00387686|Experimental|B|2.0 mg/mL rhBMP-2/CPM + surgical fixation
89406556|NCT00387686|Active Comparator|C|Buffer/CPM + surgical fixation Intervention
89406557|NCT00387686|Other|D|Standard of Care: Surgical fixation intervention
89406558|NCT03659253|Experimental|Oral Fluid Based Self Testing|All study participants that received intervention and meet inclusion criteria intervention that will be offered OFT
89406559|NCT03659253|No Intervention|Control Group|All HIV Patients in the clinic that not received any intervention
89406560|NCT03659253|Experimental|Simplified ART Initiation|All study participants that received intervention and meet inclusion criteria intervention that will be offered SAI
89406561|NCT03659253|Experimental|CBO AND BROTHEL-BASED ART SERVICE|All patients coming to brothel or Community Based Organization services will be offered to get tested and received ART
89406562|NCT03659253|Experimental|SMS Reminder|"All patients that recently found HIV Positive HIV Naive offered to get SMS Reminder"
89406563|NCT03659253|Experimental|Motivational Interviewing|PWID in Jakarta and Bandung that recently found HIV Positive or lost to follow up ARV offered MI intervention
89406564|NCT02096484|Experimental|Metacognitive Therapy|Individuals randomly assigned to the metacognitive therapy group will undergo group metacognitive therapy for generalized anxiety disorder.. Individuals will undergo 8 sessions of group therapy lasting approximately 90 minutes.
89406565|NCT02096484|Experimental|Mindfulness Meditation Therapy|Individuals randomly assigned to the mindfulness meditation therapy group will undergo group mindfulness meditation therapy for generalized anxiety disorder. Individuals will undergo 8 sessions of group therapy lasting approximately 90 minutes.
89406566|NCT03515317|Experimental|LoRETA Z-score NF group|BrainMaster Discovery 24E (BrainMaster Technologies, Inc.) combined with Neuroguide software (Applied Neuroscience, Inc.) to conduct both LoRETA Z-score NF. A total treatment dosage of 600 minutes is needed.
89406567|NCT03515317|Experimental|theta/beta NF group|BrainMaster Discovery 24E (BrainMaster Technologies, Inc.) combined with Neuroguide software (Applied Neuroscience, Inc.) to conduct both theta/beta NF. A total treatment dosage of 600 minutes is needed.
89406568|NCT03515317|No Intervention|control group|The control group involves no NF training. The control group will be designed to parallel the cognitive tasks to control for practice effects due to repeated testing (pre- and post- assessments) and the time effect on cognitive function recovery (spontaneous recovery of cognition).
89406569|NCT02286284|Experimental|Apheresis arm|Apheresis for extracorporal removal of sFlt-1
89406570|NCT03104283|Experimental|Apatinib Group|take apatinib orally (500mg/d or 250mg/d, once a day, continuously )
89406571|NCT03659175||male elderly with SIBO|"male elderly who was diagnosed as SIBO via 'lactulose breath test' (LBT). At the same time, they meet the following criteria:~no use of antibiotics in the past 1 month.~no use of prokinetic drugs and probiotics in the past 1 week.~without these diseases: active inflammation, cardiac insufficiency, respiratory insufficiency, hepatic insufficiency, renal insufficiency, cirrhosis, thyroid diseases, Crohn disease, ulcerative colitis, hepatobiliary and pancreatic disease."
89406572|NCT03659175||male elderly without SIBO|"male elderly without SIBO after 'lactulose breath test'. At the same time, they meet the following criteria:~no use of antibiotics in the past 1 month.~no use of prokinetic drugs and probiotics in the past 1 week.~without these diseases: active inflammation, cardiac insufficiency, respiratory insufficiency, hepatic insufficiency, renal insufficiency, cirrhosis, thyroid diseases, Crohn disease, ulcerative colitis, hepatobiliary and pancreatic disease."
89406573|NCT03556644|Other|Single arm study|70 patients with coronary artery disease will have CTCA imaging and 3 vessel intravascular imaging with NIRS-IVUS during percutaneous coronary intervention and the obtained imaging data will be used to assess the efficacy of CTCA in detecting plaque morphology and shear stress distribution.
89406574|NCT03077061|Active Comparator|Control - Open flap debridement|The surgical procedure includes flap elevation, debridement of the peri-implant defect and decontamination of the implant surfaces using saline for irrigation. Flaps are replaced in their original position and carefully sutured. Patients are provided with post-surgical information and thereafter called in for regular follow-up visits.
88882674|NCT05268068|Experimental|Dose A of Risankizumab for Subcutaneous (SC) Injection|Participants will receive SC injections of risankizumab at dose A and then followed for 140 days.
88882675|NCT05268068|Experimental|Dose B of Risankizumab for Subcutaneous (SC) Injection|Participants will receive SC injections of risankizumab at dose B and then followed for 140 days.
88882676|NCT05268068|Experimental|Dose C of Risankizumab for Intravenous (IV) Infusion|Participants will receive IV infusion of risankizumab at dose C and then followed for 140 days.
88882677|NCT05267977|Active Comparator|cephalosporin|cephalosporin
88882678|NCT05267977|Active Comparator|cephalosporin and aminoglycoside|the combination of cephalosporin and aminoglycoside.
88882679|NCT05267964|Active Comparator|Epping resection arthroplasty|During the Epping resection-suspension arthroplasty the trapeziectomy is performed, the flexor carpi radialis tendon is divided into two parts and one of these is stripped and cut proximally. To prevent shortening of the first ray with following loss of strength, this tendon strip is pulled through a drill hole in the base of the 1st metacarpal from ulnar palmar to radial dorsal. The rest of the tendon strip is sutured to a roll replacing the os trapezium.
88882680|NCT05267964|Active Comparator|CMC I prosthesis group|During implantation of the prosthesis the CMC joint is opened and 3 mm of the metacarpal base as well as osteophytes are resected. Following the release of the trapezium the first metacarpal and the trapezium are prepared for the prosthesis by broaching and drilling. After the test-implants have shown satisfying joint tension and anatomic conditions, the HA coated stem and cup are pressfit inserted in the appropriate size followed by the modular head.
88882681|NCT05246891||Rehabilitation nursing intervention|Functional respiratory rehabilitation exercise plan. Motor exercise plan. Cardiorespiratory optimization. Early diagnosis of potential problems associated.
88882682|NCT05246891||Rehabilitation nursing not intervention|General nursing care
88882683|NCT05246748|Experimental|Intervention group|The intervention group was given a breastfeeding education program based on the HCT for six face to face sessionconducted in parallel with asynchronous distance education sessions in prenatal period and continued with web based sessions and telephone support in postnatal period.
88882684|NCT05246748|Active Comparator|Control group|The control group received solely standard education program for one sessions in prenatal period.
88882685|NCT05238090|Other|Control group|Static stretching of the extensor carpi radialis brevis and eccentric strengthening of the wrist extensor musculature
88882686|NCT05238090|Experimental|Experimental|Passive and active analytical stretching exercises described by Neiger and Simons , applying them to the muscle chain involved in lateral epicondylitis described by Busquet
89190966|NCT04097470|Experimental|Arm B: Decitabine and Midostaurin|"Cycle 1:Decitabine; 10-day schedule (start day +1) + midostaurin (start day +11). Midostaurin is given until 2 days before start next cycle of decitabine. Cycles 2-3: Decitabine 5 or 10-day schedule; depending on day +28 bone marrow blasts of the previous cycle, next cycle consist of either 5-day (BM blasts < 5%) or 10-day (BM blasts ≥5%) decitabine + midostaurin (daily, starting the day after the last dose of decitabine (i.e. day +6 or +11). Midostaurin is given until 2 days before start next cycle. Cycles 4 and beyond: 5-day decitabine (in cycles of 4-8 weeks) followed by midostaurin starting at day +6 until two days before start of next cycle of decitabine; continuation of these cycles until progression. Midostaurin is given until 2 days before start next cycle of decitabine.~Dosage for Decitabine 20 mg/m2 i.v.~Dosage for Midostaurin 50 mg b.i.d."
89190967|NCT02575014|Experimental|Preoperative HBOT|25 out of 50 patients will receive 2 preoperative hyperbaric oxygen therapy treatments, one the day before their operation, the other within 5 hours preceding their operation. The participants will be treated with up to 2.4 ATA O2, for a maximum of 90 minutes each day with or without air breaks, as deemed necessary by the investigator. Day 0 will be the first day of their HBOT treatment, Day 1 will be the day of their operation and second/final HBOT treatment.
89190968|NCT02575014|No Intervention|No HBOT|25 out of 50 patients will not receive preoperative hyperbaric oxygen therapy. Day 1 will be the day of the operation.
88882687|NCT05207696||Platelet-rich fibrin (PRF)|A total of 28 sites from 12 patients who underwent papilla reconstruction with PRF placed with semilunar incision in the maxillary anterior region were included in PRF group. ( Data of 12 patients were included in the study.)
88882688|NCT05207696||Connective tissue graft (CTG)|A total of 27 sites from 8 patients who underwent papilla reconstruction with CTG placed with semilunar incision in the maxillary anterior region were included in CTG group. (Data of 8 patients were included in the study.)
89190969|NCT04041934|Experimental|cohorte 1|Tryptophan (Trp) / Large neutral amino acids (Lnaa) ratio = 0.11
89190970|NCT04041934|Experimental|cohorte 2|Tryptophan (Trp) / Large neutral amino acids (Lnaa) ratio = 0.07
89190971|NCT04041934|Experimental|cohort 3|Tryptophan (Trp) / Large neutral amino acids (Lnaa) ratio = 0.04
89190972|NCT02573142|Active Comparator|Education-only|Subjects in the education-only control will receive standard of care clinical treatment in the Duke Healthy Lifestyles clinic and educational materials describing community-based resources for physical activity and how to access them.
89190973|NCT02573142|Experimental|Bull City Fit Intervention|Subjects in the Bull City Fit intervention will receive standard of care clinical treatment in the Duke Healthy Lifestyles clinic and unlimited access to a community-based wellness program that includes physical fitness activities and cooking classes.
89190974|NCT00845494|Other|medication history education|Four hospital unit nurses asked to participate in the study. Two nursing units will receive the cognitive behavioral intervention.
89190975|NCT00711672||1|Medical Oncologists treating patients with metastatic colorectal cancer
89190976|NCT00711672||2|Patients with metastatic colorectal cancer receiving re-staging CT scans
89190977|NCT00855790|Active Comparator|RJ3 Biopsy Forcep|use of RJ3 Biopsy forcep for the polypectomy
89190978|NCT00855790|Active Comparator|RJ4 Biopsey Forcep|Use of RJ$ biopsy forcep for polypectomy
89406575|NCT03077061|Experimental|Test - Bone replacement graft|The surgical procedure is identical to the control procedure with the exception of the application of the bone replacement graft. Following decontamination, Bio-Oss Collagen® is placed into the peri-implant bony defect. Flaps are carefully sutured and patients are provided with the same information and follow-up as patients in the control group.
89406576|NCT03556566|Experimental|V3-OVA treatment arm|Oral once daily pill of tableted vaccine (V3-OVA) containing ovarian cancer antigens administered for 3 months in 20 volunteers with ovarian cancer
88882689|NCT05186558|Experimental|penpulimab, lenalidomide, rituximab, gemcitabine and oxaliplatin（Penpulimab-R2-GemOx)）|penpulimab: 200 mg q2w, iv, drip R2-GemOx: lenalidomide 10 mg，po; Rituximab 375mg/m2, iv, drip; Gemcitabine 1000mg, po; Oxaliplatin 100mg/m2, iv, drip;
88882690|NCT05175456|Experimental|Bedjet arm|All participants will complete a baseline study period of 4 weeks and then will be provided the Bedjet system.
88882691|NCT05113810|Experimental|First Arm (Hydroxychloroquine sulfate, 5 days)|Participants will receive continued standard of care therapy (SOC) for COVID-19 together with 2 ml HCQ01 (12.5 mg/ml) twice a day for 5 consecutive days.
88882692|NCT05113810|Active Comparator|Second Arm (Continued Standard of Care (SOC) Therapy)|Participants will receive continued standard of care therapy for COVID-19
88882693|NCT05101135|Experimental|JT-001|Drug: JT-001
88882694|NCT05101135|Placebo Comparator|JT-001 Placebo|Drug: JT-001 Placebo
88882695|NCT05092698|Active Comparator|Vit_D_suppl|Patients will receive 60,000 IU of cholecalciferol dissolved in 45 ml herbal oil orally or via feeding tube weekly followed by 5,000 IU of cholecalciferol (two drops) daily until discharge or death.
88882696|NCT05092698|Placebo Comparator|Vit_D_placebo|Patients will receive 45 ml of herbal oil orally or via feeding tube followed by 45 ml of herbal oil weekly followed by two drops of herbal oil daily until discharge or death.
89190979|NCT04042090|Experimental|Intervention group: use of therapeutic virtual reality|Intervention group: use of virtual reality intervention at home over a period of 28 days (with a maximum of 35 days) at least ten minutes a day (excluding day 1, in which the participants should do the entire education module of 25 minutes) and in addition, when participants feel the need. Meanwhile, participant is placed on the waiting list to receive normal chronic pain treatment.
89190980|NCT04042090|No Intervention|Control group: no use of therapeutic virtual reality|Control group: no intervention, patient is waiting to receive normal chronic pain treatment.
88882697|NCT05051254|Experimental|Respiratory muscle impairment|Minor patients with primary or secondary impairment of respiratory muscles and followed at Necker Hospital
88882698|NCT05009355|Experimental|experimental|A Group: Consisted of 20 patients who were treated with scaling and root planing in conjunction with 2g antioxidant Vit (C)
88882699|NCT05009355|No Intervention|Control|A Group: consisted of 20 patients who were treated with scaling and root planing.
88882700|NCT05003661|Experimental|Mother's voice|Neonates receive the intervention that recording of mother's voice of reading children's book. And the pain of high-risk newborns was measured with the Heartbeat, Respiration, SPO2 and Neonatal Infant Pain Scale (NIPS) in three minutes before the heel puncture, during the puncture, and the first, fifth and tenth minutes after the puncture.
88882701|NCT05003661|Experimental|Father's voice|Neonates receive the intervention that recording of father's voice of reading children's book. And the pain of high-risk newborns was measured with the Heartbeat, Respiration, SPO2 and Neonatal Infant Pain Scale (NIPS) in three minutes before the heel puncture, during the puncture, and the first, fifth and tenth minutes after the puncture.
88882702|NCT05003661|No Intervention|control group|When the infants undergoing heel puncture procedure, the control group were under routine care. And the pain of high-risk newborns was measured with the Heartbeat, Respiration, SPO2 and Neonatal Infant Pain Scale (NIPS) in three minutes before the heel puncture, during the puncture, and the first, fifth and tenth minutes after the puncture.
88882703|NCT04986449|Experimental|Intervention group|All families will receive the culinary and nutritional intervention. Changes before-after will be assessed regarding culinary skills, knowledge and attitudes of families on cooking with plant-based foods
88882704|NCT04981587|Experimental|Intervention group|This is the group that receives strength exercise in addition to usual treatment
88882705|NCT04981587|Other|Control group|This is the group that only receives usual treatment
88882706|NCT04980807||CMT Patients|Individuals with Charcot-Marie-Tooth Disease Types 1 and 2.
88882707|NCT04980807||Healthy Controls|Healthy age-matched volunteers
88882708|NCT04980014||NesinaAct® Tablet|Participants with a diagnosis of Type 2 Diabetes who took NesinaAct® tablet, a fixed dose combination of alogliptin along with pioglitazone, as prescribed by the physician, are observed in this study.
88882709|NCT04975204|Experimental|TQB3909 Tablets|Take 100-1200mg once a day; Oral administration on an empty stomach, 28 days as a cycle.
88882710|NCT04954807|Active Comparator|Human Milk Fortifier|human milk fortifier which contains protein, lipid, carbohydrate and micronutrients
88882711|NCT04954807|Placebo Comparator|placebo|Placebo is made of polysaccharides (0.9 g/1 g placebo) and maltose (0.1 g/1 g placebo) and minerals.
88921994|NCT05988515|Experimental|SEQUENTIAL treatment order|"5 speech lessons with a human speech-language clinician: 1 time per week for 5 weeks.~15 speech lessons with an AI clinician (supervised by the caregiver), 3 times per week for the 5 weeks AFTER the human clinician sessions end."
89190981|NCT04069650||None-malnutrition|normal nutritionnal status
89190982|NCT04069650||Malnutrition|"weight loss was superior to 5% in the past month;~a weight loss was superior to 10% in the past 6 months;~a BMI was inferior to 18,5 kg/m² (if age inferior to 70 years old) or inferior to 21 kg/m² (if age superior to > 70 years old) - a serum albumin level inferior to 30g/L (if age inferior to 70 years old) or inferior to <35g/L (if age superior to 70 years old)."
89190983|NCT00851734|Experimental|LX214 0.02%|LX214 ophthalmic solution 0.02%
88921995|NCT05986591|Experimental|Treatment A: 18 mcg of Test Product (tiotropium bromide inhalation powder)|
89190984|NCT00851734|Experimental|LX214 0.2%|
89190985|NCT00851734|Placebo Comparator|placebo|placebo
89190986|NCT00716040|Experimental|Intervention|The intervention group will be submitted to four social-psychological individual sessions with a pre-trained health professional.
89190987|NCT00716040|Other|Control|The control group will be submitted to the usual care of the health service.
89190988|NCT04019028|Experimental|Navigated low frequency rTMS|"Application of 1Hz low frequency repetitive transcranial magnetic stimulation to the primary motor area of the dominant hemisphere using a navigation system.~Using the BrainSight instrument, a navigation system, the TMS coil position can be fixed on the point precise target area based on the subject's MRI image."
89190989|NCT04019028|Experimental|only low frequency rTMS(not using Navigation System)|"Application of low frequency repetitive transcranial magnetic stimulation to the primary motor area of the dominant hemisphere not using a navigation system.~TMS coil is fixed on the target area based on MEP hotspot."
89190990|NCT04019028|Sham Comparator|Navigated Sham rTMS|"Application of repetitive transcranial magnetic stimulation with sham mode(no stimulation) to the primary motor area of the dominant hemisphere using a navigation system.~Using the BrainSight instrument, a navigation system, the TMS coil position can be fixed on the point precise target area based on the subject's MRI image.~Sham stimulation is stimulated by the same frequency, intensity and time as the actual stimulus in such a way that the 8-shaped coil is placed at a 90 degree angle to the scalp in the same manner as rTMS and sounds are heard but the magnetic stimulus is not transmitted to the cerebrum"
89190991|NCT00845572|Experimental|Consta Club|
89190992|NCT00851812|Other|Arm 1|Usual Care: Standard care monitoring
89406577|NCT00523328|Experimental|BG9924|dosage administered as per Biogen-idec protocol
89190993|NCT00851812|Experimental|Arm 2|Progressive walking and resistance exercise treatment
89406578|NCT02920983|Active Comparator|somofilcon A|Subjects are randomized to wear somofilcon A for one week during the cross over study.
89406579|NCT02920983|Active Comparator|nelfilcon A II 2|Subjects are randomized to wear nelfilcon A II 2 for one week during the cross over study.
89190994|NCT00711906|Experimental|1|HIV-negative women taking CTX as chemoprophylaxis
89406580|NCT02920983|Active Comparator|omafilcon A ll 2|Subjects are randomized to wear omafilcon A ll 2 for one week during the cross over study.
89406581|NCT00523250|Experimental|AR-102 0.003% Ophthalmic Solution|q.d. ocular
89406582|NCT00523250|Experimental|AR-102 0.005% Ophthalmic Solution|q.d. ocular
88882712|NCT04944745|Experimental|Myofascial release (MFR)|The pectoral MFR will be completed by an experienced registered massage therapist (RMT). They will stand on the participant's right side slightly rotated to the left facing towards the participant's left hip and apply a cross-hand MFR technique to the superficial pectoral fascia on the right side. The therapist will begin by placing the distal region of the anterior palm of the anchoring hand (therapist's right hand) on the right edge of the anterior sternum at the level of the 3rd to the 6th ribs on the skin and the draping over the pectoral fascia. They will then apply a gentle posterior pressure to hold the fascia in place. The forearm of the mobilizing hand (RMT's left hand) will be directed to the right shoulder wit hate right forearm crossing over the left and the contact of are of the mobilizing hand will be the skin superficial to the pectoral fascia and insertion of pectorals major on the anterior aspect of the humerus. This will be held for four minutes.
88882713|NCT04944745|Sham Comparator|Soft-touch Control (CON)|This control treatment will be set up the same way in regards to the RMT's hand placement, except no pressure will be applied. The RMT's hands will simply be resting over the contact points. This treatment will also be held for four minutes.
88882714|NCT04856436||Pregnant women with exposure to benzodiazepines|Women who gave birth during 2011-2018, were aged 20-45 years and were filled at least one benzodiazepine prescription during the first trimester (first 90 days of pregnancy).
89190995|NCT00711906|Active Comparator|2|HIV-negative women taking SP as IPT
89190996|NCT00711906|Experimental|3|HIV-positive women (CD4> 200) taking CTX as chemoprophylaxis
89190997|NCT00711906|Active Comparator|4|HIV-positive women (CD4 > 200) taking SP as IPT
89190998|NCT00851968|Active Comparator|Pringle's Maneuver|Patients with HCC received Pringle's Maneuver in hepatectomy.
89190999|NCT00851968|Experimental|Hemihepatic vascular Clamping|Patients with HCC received Hemihepatic vascular Clamping in hepatectomy
89406583|NCT00523250|Experimental|AR-102 0.01% Ophthalmic Solution|q.d. ocular
89406584|NCT00523250|Experimental|AR-102 0.03% Ophthalmic Solution|q.d. ocular
89406585|NCT00523250|Experimental|AR-102 Vehicle Ophthalmic Solution|q.d. ocular
89406586|NCT02095080|Experimental|Leucine intake|Dietary supplement: Leucine intake
89406587|NCT02654002|Experimental|Cohort 1: Cilofexor 10 mg|Participants in fasted state will receive cilofexor 10 mg or placebo once on Day 1 followed by a 5-day washout period then receive cilofexor 10 mg or placebo once daily from Day 7 to Day 20.
89406588|NCT02654002|Experimental|Cohort 2: Cilofexor 30 mg|Participants in fasted state will receive cilofexor 30 mg or placebo once on Day 1 followed by a 5-day washout period then receive cilofexor 30 mg or placebo once daily from Day 7 to Day 20.
89406589|NCT02654002|Experimental|Cohort 3: Cilofexor 100 mg|Participants in fasted state will receive cilofexor 100 mg or placebo once on Day 1 followed by a 5-day washout period then receive cilofexor 100 mg or placebo once daily from Day 7 to Day 20.
89406590|NCT02654002|Experimental|Cohort 4: Cilofexor 300 mg|Participants in fasted state will receive cilofexor 300 mg or placebo once on Day 1 followed by a 5-day washout period then receive cilofexor 300 mg or placebo once daily from Day 7 to Day 20.
88882715|NCT04856436||Pregnant women without exposure to benzodiazepines|Women who gave birth during 2011-2018, were aged 20-45 years and did not fill a benzodiazepine prescription during the 3 months before the pregnancy onset through the end of the first trimester
88882716|NCT04685902||Adult patients with tracheostomy|Adult patients who currently have a tracheostomy and receive an order for one-way speaking valve trial
88882717|NCT04641091||Study group 1|"Multispectral Optoacoustic Tomography (MSOT) and B-Mode Ultrasound of the Musculus triceps surae of the affected leg in PAD patients or one leg in healthy volunteers (total 1 site)~physical assessment: Color-Coded Duplex Sonography / treadmill examination to determine actual walking distance / Ankle-Brachial Index / defined walking distance of 150 meters under medical supervision"
88882718|NCT04641091||Study group 2|"Multispectral Optoacoustic Tomography (MSOT) and B-Mode Ultrasound of the Musculus triceps surae of the affected leg in PAD patients or one leg in healthy volunteers (total 1 site)~physical assessment: Color-Coded Duplex Sonography / treadmill examination to determine actual walking distance / Ankle-Brachial Index / defined walking distance of 150 meters under medical supervision"
88882719|NCT04600674|Experimental|delayed cord clamping|DCC performed at 60 sec after birth
88882720|NCT04600674|Experimental|early cord clamping|ECC performed at 15 sec after birth
88882721|NCT04598087|Experimental|Prehabilitation|- Tailored exercise prescription involving aerobic and resistance training, supported by a clinical exercise physiologist.
88882722|NCT04593784|Experimental|Cohort 1|Subjects receive 60 mg edoxaban orally once daily in the morning on Days 1 to 4. On Day 4, approximately 3 hours after administering edoxaban, study drug (ciraparantag or placebo) will be intravenously administered.
88882723|NCT04593784|Experimental|Cohort 2|Subjects receive 10 mg apixaban orally every 12 hours on Days 1 to 3, with a final dose in the morning on Day 4. On Day 4, approximately 4 hours after administering apixaban, study drug (ciraparantag or placebo) will be intravenously administered.
88882724|NCT04593784|Experimental|Cohort 3|Subjects receive 20 mg rivaroxaban orally once daily in the morning on Days 1 to 4. On Day 4, approximately 4 hours after administering rivaroxaban, study drug (ciraparantag or placebo) will be intravenously administered.
88882725|NCT04576910|Experimental|"Group A(Sabin IPV+ bOPV+ bOPV+Sabin IPV)"|Give the 4th doses of polio vaccine with Sabin IPV for participants in the Group 1 of preliminary study (NCT03147560).
88882726|NCT04576910|Experimental|"Group B(Sabin IPV+ Sabin IPV+ bOPV+bOPV)"|Give the 4th doses of polio vaccine with bOPV for participants in the Group 2 of preliminary study (NCT03147560) after randomization.
88882727|NCT04576910|Experimental|"Group C(Sabin IPV+ Sabin IPV+ bOPV+Sabin IPV)"|Give the 4th doses of polio vaccine with Sabin IPV for participants in the Group 2 of preliminary study (NCT03147560) after randomization.
88882728|NCT04576910|Experimental|"Group D(Sabin IPV+ Sabin IPV+ Sabin IPV+bOPV)"|Give the 4th doses of polio vaccine with bOPV for participants in the Group 3 of preliminary study (NCT03147560) after randomization.
88882729|NCT04576910|Experimental|"Group E(Sabin IPV+ Sabin IPV+ Sabin IPV+Sabin IPV)"|Give the 4th doses of polio vaccine with Sabin IPV for participants in the Group 3 of preliminary study (NCT03147560) after randomization.
88882730|NCT04503603|Experimental|Lanadelumab 300 mg|Participants will receive single dose of lanadelumab 300 mg intravenous (IV) infusion on Day 1 followed by second dose on Day 4.
88882731|NCT04503603|Placebo Comparator|Placebo|Participant will receive single dose of lanadelumab matching placebo (normal saline) IV infusion on Day 1 followed by second dose on Day 4.
88882732|NCT04500366|Active Comparator|Socialization|Participants randomized to the socialization arm will receive once-weekly phone calls from medical student volunteers for a total of 12-weeks (n=35). This program pairs health professional student volunteers with older adults in the community to provide social comfort while heightened physical distancing measures are in place during the current COVID-19 pandemic. Attendance and duration of the phone calls will be logged.
88882733|NCT04500366|Experimental|Multi-Modal Frailty Rehabilitation|Multi-modal frailty rehabilitation will involve virtual care including 1x/week socialization, 2x/week exercise (small group physiotherapy live-streamed sessions), nutrition (virtual consult), and medication support (virtual pharmacist consult) all through a videoconferencing system.
89191000|NCT00851968|Experimental|portal vein occlusion|Patients with HCC received portal vein occlusion in hepatectomy
89191001|NCT04018950|Experimental|ETX2514 and 14C-ETX2514|Participants will receive a single intravenous infusion of 1 gram non-labeled ETX2514 and 1 microCurie (µCi) of 14C-ETX2514 in normal saline, administered as a 3-hour infusion.
89191002|NCT00845806||Arabic Speakers|All subjects must be male native arabic speakers who can read and speak english.
88882734|NCT04466540|Experimental|Hydroxychloroquine (HCQ)|HCQ group participants will receive a dose of 400mg twice daily (BID) in the first day, and a dose of 400 mg once daily (OD) from the second day of treatment, in a total of 7 days.
89191003|NCT00709410|Experimental|1|This is a single arm study. All consenting, eligible participants will receive the oral cholera vaccine.
89191004|NCT02545972|Experimental|Once a day tacrolimus|Tacrolimus extended release will be given at an initial once daily dose equivalent to the total daily dose of the twice a day Tacrolimus formulation.
89191005|NCT02574780|Experimental|Grupo I TFC|Women with lymphedema , perform complex physical therapy with manual lymphatic drainage, compression bandaging and exercises linfomiocinéticos.
89191006|NCT02574780|Experimental|Grupo II TFC X PFM|Standard treatment for lymphedema perform complex physical therapy associated with a muscular strength protocol.Muscle-building arm with load
89191007|NCT00852046|Experimental|1. Low dose dexmedetomidine|Dexmedetomidine 0.2 mcg/kg/hr added to fentanyl & propofol.
89406591|NCT02654002|Experimental|Cohort 5: Cilofexor 100 mg|Participants in fed state will receive cilofexor 100 mg or placebo once with food on Day 1 followed by a 5-day washout period then receive cilofexor 100 mg or placebo tablet, orally, once daily with food from Day 7 to Day 20.
89406592|NCT02654002|Experimental|Cohort 6: Cilofexor 50 mg|Participants in fed state will receive cilofexor 50 mg or placebo twice with food on Day 1 followed by a 5-day washout period then receive cilofexor 50 mg or placebo twice daily from Day 7 to Day 20.
89406593|NCT02654002|Experimental|Cohort 7: Cilofexor 15 mg|Participants in fed state will receive cilofexor 15 mg or placebo twice with food on Day 1 followed by a 5-day washout period then receive cilofexor 15 mg or placebo twice daily from Day 7 to Day 20.
89406594|NCT02654002|Experimental|Cohort 8: Cilofexor 10 mg|Participants in fed state will receive cilofexor 10 mg or placebo once with food on Day 1 followed by a 5-day washout period then receive cilofexor 10 mg or placebo once daily from Day 7 to Day 20.
89406595|NCT02654002|Experimental|Cohort 9: Cilofexor|Participants will receive cilofexor up to 300 mg or placebo once daily in the evening on empty stomach.
89406596|NCT02654002|Experimental|Cohort 10: Cilofexor|Participants will receive cilofexor up to 300 mg or placebo once daily in the evening on empty stomach.
89406597|NCT02286596||heparin-induced extracorporeal LDL precipitation|Lipid apheresis treatment for 3 hours
89406598|NCT02286596||dextran sulfate adsorption|Lipid apheresis treatment for 3 hours
88882735|NCT04466540|Placebo Comparator|Placebo|The placebo group will follow the same regimen of administration
88882736|NCT04454918|Experimental|TAK-906 50 mg + [14C]-TAK-906 100 mcg + [14C]-TAK-906 50 mg|TAK-906 50 mg, capsule, orally, once on Day 1, followed by [14C]-TAK-906 100 micrograms (μg) [approximately 1 microcurie (μCi)], IV infusion, once on Day 1 of Treatment Period 1, followed by a Washout Period of 7 days, further followed by [14C]-TAK-906 50 mg (approximately 100 μCi), solution, orally, once on Day 1 of Treatment Period 2.
88882737|NCT06105541|Experimental|2 Weeks Sham tAN followed by 2 Weeks Active tAN|Participants will be randomized to receive 2 weeks of at-home, self-administered sham Transcutaneous Auricular Neurostimulation (tAN), followed by 2 weeks of at-home, self-administered active Transcutaneous Auricular Neurostimulation (tAN).
88882738|NCT06105541|Experimental|Four Weeks of Active Transcutaneous Auricular Neurostimulation|Participants will be randomized to receive 2 weeks of at-home, self-administered active Transcutaneous Auricular Neurostimulation (tAN), followed by 2 additional weeks of at-home, self-administered active Transcutaneous Auricular Neurostimulation (tAN)
88882739|NCT06105515|Experimental|Interventional arm|The group that will receive the active treatment
88921996|NCT05986591|Active Comparator|Treatment B: 18 mcg of Reference Product (Spiriva)|
89406599|NCT02098824|Active Comparator|Galantamine|Single administration of capsule containing 16 mg Galantamine
89406600|NCT02098824|Placebo Comparator|Placebo|Single oral administration of capsule containing placebo
89406601|NCT02098824|Active Comparator|Methylphenidate|Single administration of capsule containing 10 mg Methylphenidate
89406602|NCT03659097|Experimental|Periodontally accelerated osteogenic orthodontics|Patients in this group will undergo orthodontic treatment plus periodontally accelerated osteogenic orthodontics in order to induce tooth movement.
89406603|NCT03659097|No Intervention|Traditional orthodontics|Patients in this group will undergo traditional orthodontics without any surgical interventions
89406604|NCT02098902|Experimental|Smart Moms Intervention|This arm will receive the Smart Moms intervention immediately following randomization.
89406605|NCT02098902|No Intervention|Waitlist control group|This arm will receive a modified version of the Smart Moms intervention after the 6-month assessment.
88921997|NCT05986591|Placebo Comparator|Placebo|
89406606|NCT03658317|Active Comparator|cases|laboratory tests including (random blood glucose , serum urea and creatinine , lipogram , serum uric acid , HbA1c , urine analysis , 24 hours urinary proteins ) abdominal ultrasonography dupplex on the renal vessels
89406607|NCT03658317|Active Comparator|controls|laboratory tests including (random blood glucose , serum urea and creatinine , lipogram , serum uric acid , HbA1c , urine analysis , 24 hours urinary proteins ) abdominal ultrasonography dupplex on the renal vessels
89406608|NCT02286752|Active Comparator|neostigmine|
89406609|NCT02286752|Active Comparator|sugammadex|
89406610|NCT02096562|Placebo Comparator|B - No compression stockings|normal therapy - no compression stockings
89406611|NCT02096562|Active Comparator|A - Use of compression stockings|Patients use compression stockings for 10 days after surgery
89406612|NCT05103592||Primary osteoprosis patients|patients older than 18 years with primary osteoporosis diagnosed by dxa scan . tartrate- resistant acid phosphatase 5b level will be measured.
89406613|NCT05103592||Rheumatoid arthritis patients|"patients older than 18 years with primary osteoporosis diagnosed by dxa scan and rhumatoid arthritis.~tartrate- resistant acid phosphatase 5b level will be measured."
89406614|NCT05103592||Ankylosing spondylitis patients|"patients older than 18 years with primary osteoporosis diagnosed by dxa scan and ankylosing spondylitis.~tartrate- resistant acid phosphatase 5b level will be measured."
89406615|NCT05103592||Control group|patients older than 18 years not complaining of any bone disease tartrate- resistant acid phosphatase 5b level will be measured.
89406616|NCT03659019||ventilatory paralysis|dependence on mechanical ventilatory support
88882740|NCT06105502||Psychotherapy students|The participating psychotherapy students will come from the following courses at the Center for Psychotherapy Education and Research: the psychotherapist program (six semesters), the specialist training for psychologists in adult psychiatry (six semesters), the basic training in evidence-based psychotherapeutic methods (three semesters), and the basic training in psychotherapy for residents in child, adolescent, and adult psychiatry (two semesters).
89406617|NCT03659019||central hypoventilation|documented permanent or nocturnal hypoventilation
89406618|NCT02095236|Experimental|experimental|Radioopaque fiducial markers or electro-magnetic transponders will be implanted into or in close proximity of the tumor. During a radiotherapy treatment session image and/or signal acquisition will be performed by ultrasound, computed tomography, magnetic resonance imaging or by specialized signal detectors The data will help to characterize tumor and organ motion during one treatment session which may in fact have impact on dose distribution
89406619|NCT03658941|Experimental|No dural tenting sutures|No dural tenting techniques
89406620|NCT03658941|Active Comparator|Dural tenting sutures|Dural tenting techniques
89406621|NCT02283164|Experimental|Treatment|Hazardous materials online education and study feedback
89406622|NCT02283164|Active Comparator|Control then treatment|Hazardous materials online education and study feedback
89406623|NCT02095314|Experimental|Pentavalen|Pentabio Vaccine One dose corresponds to 0.5ml The vaccine shall be given intramuscularly
88882741|NCT06105489|Experimental|Tunnel flap design|Participants will undergo a lateral sinus lift procedure in which a single vertical anterior incision will be made at least 10 mm mesially to the expected outline of the bony window.
89406624|NCT00517868|Other|Crossover|Placebo Treatment on Visit 1 followed by URG101 Treatment on Visit 2
89406625|NCT00517868|Other|Crossover 2|URG101 Treatment on Visit 1 followed by Placebo Treatment on Visit 2
89406626|NCT02098980|Active Comparator|Dietary Supplement: Vitamin D|Vitamin D supplement 4000 IU/day for 6 months
88882742|NCT06105489|Active Comparator|Trapezioidal flap design|Participants will undergo a lateral sinus lift procedure. The incision will be made horizontally on the top of the alveolar ridge, with two additional releasing incisions in the mesial and distal regions.
88921998|NCT05984147|Experimental|AUR108, 50mg to 300mg|Currently, planned dose levels are 50,90,150,220,300 mg will be administered in 3+/4- regimen.
89406627|NCT02098980|Placebo Comparator|Placebo|Placebo for 6 months
89406628|NCT05228938|Experimental|Study group: vNOTES|Elective bilateral salpingectomy or Salpingo-oophorectomy by vaginal Natural Orifice Transluminal Endoscopic Surgery approach
88921999|NCT05978102|Experimental|STI-7349 alone|Dose escalation and dose expansion for STI-7349 alone,to determine the RP2D and to evaluate the preliminary antitumor activity of STI-7349 in specific solid tumor patients.
89004493|NCT04055376|Sham Comparator|Daily exposure to control stimulation|Subjects in this arm will receive daily exposure to control stimulation
89406629|NCT05228938|Other|Control group: Laparoscopic|Elective bilateral salpingectomy or Salpingo-oophorectomy by conventional laparoscopy
89406630|NCT03658239|Experimental|Experimental|"Subjects will undergo 4-5 visits total over the course of 6 months. There will be 3-4 visits that will be done at the Flaum Eye Institute. During these sessions the subject will be measured with a stationary topographer (GALILEI G4), with a rotatable topography measurement (Oculus Topographer) and a Tonometer. The subject's heart rate and blood pressure will also be measured (using a commercially available blood pressure and heart rate meter).~The GALILEI measurement will only be done once. The rest of the measurements will be done up to 4 times. Once at the start of the study session then, after the subject has been inverted using a commercially available inversion table to first 135 degrees, then 150 degrees and finally to 165 degrees.~The blood pressure and heart rate will be monitored to ensure subject safety.~There will also be one visit at the Massachusetts General Hospital. The visit will be 2 hours and will involve a Brillouin Microscopy measurement."
89406631|NCT00517790|Experimental|ABT-869 0.25 mg/kg|Approximately half of the subjects were randomized to receive the high dose
89406632|NCT00517790|Experimental|ABT-869 0.10 mg/kg|Approximately half of the subjects were randomized to receive the Low Dose
89406633|NCT02799693||Recurrent VT failing RF ablation|Patients undergoing intramural needle catheter ablation of recurrent monomorphic ventricular tachycardia who have failed prior attempted radiofrequency catheter ablation.
89406634|NCT02095392|Experimental|P1000/Ca0|
89406635|NCT02095392|Experimental|P1000/Ca500|
89406636|NCT02095392|Experimental|P1000/Ca1000|
89406637|NCT02095392|Placebo Comparator|Placebo|
89406638|NCT00123968|Experimental|1A|Participants will receive a low dose of the adenovirus-vectored HIV vaccine or placebo at study entry
89406639|NCT00123968|Experimental|1B|Participants will receive a higher dose of the adenovirus-vectored HIV vaccine or placebo at study entry
89406640|NCT00123968|Experimental|1C|Participants will receive the DNA plasmid vaccine or placebo at study entry and Days 28 and 56. They will also receive either a low dose of the adenovirus-vectored HIV vaccine or placebo at Day 168.
89406641|NCT00123968|Experimental|1D|Participants will receive the DNA plasmid vaccine or placebo at study entry and Days 28 and 56. They will also receive either a higher dose of the adenovirus-vectored HIV vaccine or placebo at Day 168.
88882743|NCT06105437|Other|BE-EMPOWERed program|The BE-EMPOWERed program entails a group program for older people, workshops for healthcare professionals and a 6-steps implementation plan for primary care areas. The group program for older people is based on the main principles of the Australian multifactorial falls prevention program 'Stepping On'. The workshops for healthcare professionals focus on the multifactorial falls prevention approach, reimbursement of healthcare costs, referrals to other healthcare professionals and motivational interviewing. The Implementation plan consists of 6-steps: 1. enable support, 2. map baseline situation, 3. define objectives and priorities, 4. plan implementation, 5. implementation and 6. evaluation, adjust and work towards sustainability. Last, to support the primary care areas, implementation facilitators were trained.
88882744|NCT06105424|Experimental|Smokers|Someone who exclusively smokes 10 - 20 combustible filtered cigarettes per day (CPD) 83 - 100 mm in length, non-menthol or menthol, for at least 3 years prior to Screening.
88882745|NCT06105424|Experimental|Moist Snuff Consumers|Someone who exclusively consumes ≥ 1 can of moist snuff per week for at least 6 months prior to Screening.
88882746|NCT06105424|Experimental|Vapers|"Someone who exclusively uses a nicotine-containing cig-a-like and/or tank system daily for at least 3 months prior to Screening."
88882747|NCT06105424|Experimental|Non-Tobacco Consumers|Someone who has used no tobacco or nicotine-containing products for at least the past 5 years prior to Screening and do not plan to use any tobacco or nicotine-containing products throughout the study.
88882748|NCT06105398||Study group|Patients between the ages of 40-75 who had rotator cuff repair at least one year ago at the Orthopedics and Traumatology Clinic of Pamukkale University
88882749|NCT06105398||Control group|healthy adults between the ages of 40-75
88882750|NCT06105385|Experimental|First|Suboccipital Myofascial Release Technique will be applied to this group first. After the intervention in this group is completed, the transition to the other crossover group will be made.
88882751|NCT06105385|Experimental|Second|"Once the intervention to the first group is completed, the second intervention Suboccipital Myofascial Release Technique will be applied to this group."
88882752|NCT06105333||NIRS Group|Preterm neonates less than 32 weeks gestation were randomly assigned to standard care plus cerebral oxygen saturation monitoring with a dedicated treatment guideline (NIRS-group) during immediate transition (first 15 minutes after birth) and resuscitation.
88882753|NCT06105333||Standard Care Group|Preterm neonates less than 32 weeks gestation were randomly assigned to standard care (control-group) with routine monitoring during immediate transition (first 15 minutes after birth) and resuscitation.
88882754|NCT06105320|Active Comparator|1: LCHF-HCLF|"LCHF (12 weeks) followed by HCLF (12 weeks) with immediate contrast (no wash-out period)"
88882755|NCT06105320|Active Comparator|2: HCLF-LCHF|"HCLF (12 weeks) followed by LCHF (12 weeks) with immediate contrast (no wash-out period)"
88882756|NCT06105294|Experimental|time-restricted eating|Post-baseline, participants will be asked to restrict their eating to a 10-hour window.
88882757|NCT06105281|No Intervention|Control group|The participants that only get the standard care in the pain clinic.
88882758|NCT06105281|Experimental|The consultation with a pain specialist nurse|When the participant receives a consultation with the pain specialist nurse ,there will be assessed if the patient knows what the procedure involves and what they can expect of it. To meet de expectations of the patient the nurse will explain the procedure and what they can expect. Further there will be an short education about what pain is and the physiology of chronic pain. Because chronic pain has a lot of influencing factors the nurse will explain the main factors.
88882759|NCT06105255|Experimental|Multipledose D-1553 on PK of single dose midazolam, caffeine, rosuvastatin, furosemide, digoxin|To evaluate the effects of multiple-dose D-1553 tablets on pharmacokinetics (PK) of single-dose midazolam, caffeine, rosuvastatin, furosemide, and digoxin in healthy male subjects.
88882760|NCT06105255|Experimental|Evaluate the effects of multiple-dose itraconazole on PK of single-dose D-1553|To evaluate the effects of multiple-dose itraconazole on PK of single-dose D-1553 tablets in healthy male subjects.
88882761|NCT06105255|Experimental|Evaluate the effects of multiple-dose omeprazole on PK of single-dose D-1553|To evaluate the effects of multiple-dose omeprazole on PK of single-dose D-1553 tablets in healthy male subjects.
88882762|NCT06105242||Retrospective Cohort Aim 1|Aims 1 and 2 are retrospective and will be conducted with the same dataset, just at two different time points (at diagnosis of CTEPH and after PTE surgery). For simplicity, aims 1 and 2 will be combined into one section throughout the protocol.
88882763|NCT06105242||Retrospective Cohort Aim 2|Aims 1 and 2 are retrospective and will be conducted with the same dataset, just at two different time points (at diagnosis of CTEPH and after PTE surgery). For simplicity, aims 1 and 2 will be combined into one section throughout the protocol.
88882764|NCT06105242||Prospective Cohort Aim 3|Aim 3 is prospective and will enroll a distinct set of patients from Aim 1 and 2.
88882765|NCT06105229||Acute kidney injury|Patients with AKI who meet KDIGO criteria
89406642|NCT00123968|Experimental|2A|Participants will receive the DNA plasmid vaccine at study entry and Days 28 and 56. They will also receive a low dose of the adenovirus-vectored HIV vaccine at Day 168.
88882766|NCT06105229||Healthy controls|Healthy people without other underlying medical conditions
89191008|NCT00852046|Experimental|2. High dose dexmedetomidine|Dexmedetomidine 0.6 mcg/kg/hr added to fentanyl & propofol.
89406643|NCT00123968|Experimental|2B|Participants will receive the DNA plasmid vaccine placebo at study entry and Days 28 and 56. They will also receive a the adenovirus-vectored HIV vaccine placebo at Day 168.
88882767|NCT06105203|Other|RATME|In RaTME groups, the low anterior resection and TME was finished with the assistance of robot (da Vinci Xi surgical system)
89191009|NCT00852046|Placebo Comparator|3. Placebo|Placebo added to fentanyl & propofol.
89191010|NCT00845884|Experimental|AVDCF|Drug: Docetaxel, Cisplatin, Capecitabine, Bevacizumab
89191011|NCT02574936|Other|modified Karydakis,surgical technique|a new surgical technique(modified Karydakis) to be compared with standard Karydakis
89191012|NCT00923806|Experimental|Gene Therapy Treatment|
89406644|NCT03556254|Experimental|Genotypic resistance guided therapy|In the absence of 23S rRNA mutation, clarithromycin based sequential therapy will be given. In the presence of 23S rRAN mutation but the absence of gyrase A mutation, levofloxacin based sequential therapy will be given. In the presence of both 23S rRNA and gyrase A mutations or if genotyping fails, bismuth quadruple therapy will be given.
89406645|NCT03556254|Active Comparator|Susceptibility testing guided therapy|Tailored therapy according to the minimum inhibitory concentration result (susceptibility testing, E-test)
89406646|NCT04350658||TAVR|all comers study including all transfemoral or transcarotid TAVR procédures. direct implantation is the default strategy usually used in our enter as in may centers
89406647|NCT03774264||Xiaflex group|"Patients will be evaluated in our urology clinic at baseline for possible inclusion in our study. All patients at baseline evaluation will be evaluated for duration of symptoms, relationship stability, IIEF and PDQ. All patients will obtain a penile Doppler ultrasound with the aid of a vasoactive substance by a specially trained technician. During this visit, plaque measurements will be taken: location of plaque, distance of plaque from the tip of the penis, degree of curvature measured by goniometer.~Ultrasound characteristics will be documented: Type (Type 1: The plaque appears as a thickening of the tunica albuginea without acoustic shadowing. Type 2: A moderately calcified plaque with a typical ultrasound shadow. Type 3: A severely calcified plaque with typical ultrasound shadowing) and Grade of calcification (grade 1 (<0.3 cm), grade 2 (>0.3 cm, <1.5 cm), grade 3 (>1.5 cm; or ≥ 2 plaques >1.0 cm). Sample data sheet attached as appendix 2."
89406648|NCT00117884|Experimental|1|
89406649|NCT00117884|Experimental|2|
89406650|NCT00117884|Experimental|3|
89406651|NCT00117884|Experimental|4|
89406652|NCT00117884|Experimental|5|
89406653|NCT00117884|Experimental|6|
89406654|NCT00117884|Experimental|7|
89406655|NCT00117884|Experimental|8|
89406656|NCT00117884|Experimental|9|
89191013|NCT00848068|Other|OD (Right Eye)|FID 114657 or OPTIVE
89191014|NCT00848068|Other|OS (Left eye)|FID 114657 or OPTIVE
89191015|NCT00711984|Active Comparator|1|Renal artery stenting and Best medical treatment
89191016|NCT00711984|Active Comparator|2|Best medical treatment alone
89191017|NCT00856102|Experimental|Exercise|
89191018|NCT00856102|No Intervention|Control|
89191019|NCT00718536|Experimental|1|Addition of raltegravir 800 mg QD to HAART
89191020|NCT00856258|Placebo Comparator|Cohort 1|Cohort 1 completed.
89191021|NCT00856258|Placebo Comparator|Cohort 2|Cohort 2 not studied
89191022|NCT00856258|Placebo Comparator|Cohort 3|Cohort 3 not studied
89406657|NCT00117884|Experimental|10|
89406658|NCT00117884|Experimental|11|
89406659|NCT05228782|Experimental|HOW RU Intervention delivered by telephone|Group Phone will receive the HOW RU? intervention over the telephone.
89406660|NCT05228782|Experimental|HOW RU Intervention delivered by video-call|Group Video will receive the HOW RU? intervention delivered over video-call using the aTouch Away platform.
89406661|NCT05228782|No Intervention|Wait-list Control Group|Control groups will be offered standard care through their referring service (i.e. their routine clinical follow-up). The control group will be offered HOW RU? telephone support outside of the main trial after their primary outcome assessment at 12 weeks
89406662|NCT02095470|Experimental|videolaryngoscope group|video laryngoscopy was done for them
89406663|NCT02095470|Placebo Comparator|traditional laryngoscope|comparison to active group with routine laryngoscope
89406664|NCT04088656|Experimental|Hypertension Systems Analysis and Improvement|Eight (8) health facilities will receive the Systems Analysis and Improvement Approach (SAIA-HTN) intervention to optimize hypertension screening and management for people living with HIV/AIDS.
89406665|NCT04088656|No Intervention|Control|Eight (8) health facilities will not receive the Systems Analysis and Improvement Approach (SAIA-HTN) intervention to optimize hypertension screening and management for people living with HIV/AIDS.
88882768|NCT06105203|Other|LATME|In LaTME groups, the low anterior resection and mesorectal excision procedures was completed under laparoscopy.
88882769|NCT06105164|Active Comparator|Active cerebellar rTMS|Cerebellar targeted iTBS
88882770|NCT06105164|Sham Comparator|Sham cerebellar rTMS|Cerebellar targeted sham iTBS
88882771|NCT06105112|Experimental|Hyaluronic acid|Minimally invasive surgical technique with a combined approach using hyaluronic acid gel and a bone xenograft.
88882772|NCT06105112|Active Comparator|Enamel matrix derivatives|Minimally invasive surgical technique with a combined approach using enamel matrix derivatives gel and a bone xenograft.
88882773|NCT06105099|Active Comparator|Children with anterior oral cleft speech characteristics|To investigate the best speech therapy approach for children with anterior oral cleft speech characteristics, we will provide three different interventions.
88882774|NCT06105099|Experimental|Children with posterior oral cleft speech characteristics|To investigate the best speech therapy approach for children with potserior oral cleft speech characteristics, we will provide three different interventions.
88882775|NCT06105099|Experimental|Children with non-oral cleft speech characteristics|To investigate the best speech therapy approach for children with non-oral cleft speech characteristics, we will provide three different interventions.
88882776|NCT06105086|Experimental|medical doctors and clinical laboratory managers|Semi-structured interviews
88882777|NCT06104995|Experimental|Interventional Educational video on back beliefs|Participants receive an educational video on back beliefs and its contributing factors.
88882778|NCT06104995|Experimental|Control Video Education|Participants receive a neutral video about the back (e.g. anatomy of the back).
88882779|NCT06104982|Experimental|SiFES group|The investigators applied FES to the abdominal muscles of the SiFES group bilaterally, using 2 units of NeuroTrac MyoPlus Pro single-channel electromyography biofeedback electrotherapy devices. The investigators conducted electrical stimulation for a total of 10 minutes per session, with 5 minutes dedicated to bilateral rectus abdominis (RA) and 5 minutes to bilateral obliques externus (OE), obliques internus (OI), and transversus abdominis (TA) muscles three days a week, a period of four weeks. The investigators triggered the initial contraction of the abdominal muscles by instructing the patient to slightly flex their head before the application of electrical stimulation. During this process, the contraction was detected by the surface EMG present in the FES device, and the abdominal muscles were stimulated with electrical impulses.
88882780|NCT06104982|Active Comparator|Control group (TE group)|The investigators administered isometric strengthening to the TE groups, three days a week, with three sets per session, a period of four weeks.
88882781|NCT06104969||Diabetic Foot Ulcer|Adult individuals with at least one diabetic foot ulcer who meet inclusion/exclusion criteria
88882782|NCT06104943||Index patients|All individuals who had had at least one plasma Triglyceride measurement between 1st January 2000 and 31st December 2021 at Karolinska University Laboratory or Unilabs AB in Stockholm County in Sweden.
88882783|NCT06104943||First degree relatives to index patients|Parents and the siblings to the index patients by interlinkage of personal identification numbers via the Swedish Multi-Generation register.
88882784|NCT06104839|Experimental|NXC736|
88882785|NCT06104839|Placebo Comparator|Placebo|
89191023|NCT00856258|Placebo Comparator|Cohort 4|Cohort 4 not studied
89406666|NCT03556176|Active Comparator|5-HTTLPR or BDNF polymorphisms|
88882786|NCT06104813||URASSM volunteer deaf men|Volunteer deaf men recruited at Nancy's URASSM Deaf Care Unit (Unité régionale d'accueil et de soins des sourds et malentendants), for individual interviews.
88882787|NCT06104800|Experimental|Red meat diet|Calorie-restricted diet with macronutrient distribution: 1.5 g/kg of ideal body weight in protein (including red meat), 50% carbohydrates, and 25-30% fats.
88882788|NCT06104800|Active Comparator|Red meat free diet|Calorie-restricted diet with macronutrient distribution: 1.5 g/kg of ideal body weight in protein (excluding red meat), 50% carbohydrates, and 25-30% fats
88882789|NCT06104774|Experimental|Tai Chi group|After recruitment, participants will receive Tai Chi Exercise teaching. In the acupressure group, participants will receive acupressure treatment.
88882790|NCT06104774|No Intervention|Control group|conventional treatment
88882791|NCT06104761|Experimental|Release Group|Release of tight muscles in upper crossed syndrome
88882792|NCT06104761|Other|Control group|strength exercises and stretching for upper crossed syndrome
88882793|NCT06104709||LUAD patients undergoing cryoablation|No interventions.
88882794|NCT06104696||Non-frail|Group of patients which will meet the criteria for non-frail according to the result of functional examination.
88882795|NCT06104696||Pre-frail|Group of patients which will meet the criteria for pre-frail according to the result of functional examination.
88882796|NCT06104696||Frail|Group of patients which will meet the criteria for frail according to the result of functional examination.
88882797|NCT06104644||Moderate-to-severe plaque psoriasis|
89191024|NCT00716118||1|IVF patients.
89406667|NCT03556176|Active Comparator|Control ( without 5-HTTLPR or BDNF polymorphisms )|
89406668|NCT00372944|Active Comparator|1|Xeloda
89406669|NCT00372944|Experimental|2|AZD6244
89406670|NCT05228704|Experimental|activities in the Botanical Garden or Urban|experiment group is activities in the Botanical Garden, and the control group is activities in urban
89406671|NCT05228704|Other|Cross-over design|The participants are randomized divided into in two groups following by the experiment which is designed by two consecutive times at one week intervals, and the experimental activities and the control activities are staggered.
89406672|NCT02099136|Experimental|Group I (placebo)|Patients receive placebo PO BID for 14 days.
89406673|NCT02099136|Experimental|Group II (low-dose celecoxib)|Patients receive low-dose celecoxib PO BID for 14 days.
88882798|NCT06104631|Experimental|BK003|Dietary Supplement: BK003 The product is a combination of chitin-glucan and micronutrients. The dose of chitin-glucan is 3 g/day. The product is provided as sachets containing powder to be dissolved in a glass of water (about 250 ml) and taken orally.
88882799|NCT06104631|Placebo Comparator|Placebo|Dietary Supplement: BK003 placebo The placebo product has the same composition in excipient, same form and same posology as BK003.
88882800|NCT06104488|Experimental|Dose Level -1|If 0 of 3-6 or no more than 1 of 6 evaluable participants experience a DLT, then the dose will be escalated to Dose Level 2 and the same approach will be repeated. If 2 or more DLTs are observed on Dose Level 1 in 2-6 subjects, then further enrollment to Dose Level 1 will stop, the dose will be de-escalated to Dose Level -1 and the same approach will be repeated. The MTD will be the highest dose with <2 DLTs in 6 patients.
89406674|NCT02099136|Experimental|Group III (higher dose celecoxib BID)|Patients receive higher dose celecoxib PO BID for 14 days.
89406675|NCT02099136|Experimental|Group IV (higher dose celecoxib QD)|Patients receive same dose of celecoxib PO as Group III QD for 14 days.
89406676|NCT02099136|Experimental|Group V (high-dose celecoxib)|Patients receive high-dose celecoxib PO QD for 14 days.
89406677|NCT00117650|Active Comparator|Low Dose|2 x 10^9 vp (viral particles)
89406678|NCT00117650|Active Comparator|Middle Dose|2 x 10^10 vp
89406679|NCT00117650|Active Comparator|High Dose|2 x 10^11 vp
89406680|NCT00117650|Placebo Comparator|Placebo|(PBS + 10% sucrose + 0.02% polysorbate 80)
89406681|NCT02099214|Experimental|Patients with HFE hereditary haemochromatosis|"The patients (40) will undergo a medical examination in order to analyse their medical history, cardiovascular parameters and check inclusion and non-inclusion criterions.~Then will be performed :~An electrocardiogram~Blood tests : iron and cardiac markers (serum iron, serum transferrin, transferrin saturation, serum ferritin, NT-proBNP), beta-hCG if needed, serum bank~A 3Tesla cardiac MRI repeated twice (in order to respect the reproducibility criterion)~A 3Tesla abdominal MRI~An echocardiography at rest."
89406682|NCT02099214|Experimental|Healthy volunteers|"The healthy volunteers (10 men and 10 women) will undergo :~A urinary pregnancy test (if applicable)~A 3Tesla cardiac MRI repeated twice (in order to respect the reproducibility criterion)~An echocardiography at rest."
89406683|NCT03324958|Experimental|Virtual Reality Helmet|Patients will use a virtual reality helmet during brachytherapy applicator's setting up. The use of virtual reality helmet has already been assessed during oncologic treatments, and seems to reduce pain and anxiety. The use of virtual reality helmet has never been assessed to reduce the pain or anxiety associated with brachytherapy applicators' setting up.
89406684|NCT03324958|Active Comparator|No Virtual Reality Helmet|Patient wont use virtual reality helmet during brachytherapy applicator setting up, as in current practice.
89406685|NCT02095548|Experimental|SM04690, 0.03mg/2mL|Single, intra-articular injection of SM04690, 0.03mg/2mL
89406686|NCT02095548|Experimental|SM04690, 0.07mg/2mL|Single, intra-articular injection of SM04690, 0.07mg/2mL
89406687|NCT02095548|Experimental|SM04690, 0.23mg/2mL|Single, intra-articular injection of SM04690, 0.23mg/2mL
88813573|NCT03406364|Experimental|MG005|Cohort 1 :3 × 250 mgMG005+1 × 200 mgSorafenib[8:00 AM (±2 hours)] Cohort 2 :6 × 250 mgMG005+1 × 200 mgSorafenib[8:00 AM (±2 hours)] Cohort 3 :3 × 250 mgMG005+1 × 200 mgSorafenib; 3 × 250 mgMG005+1 × 200 mgSorafenib[8:00 AM (±2 hours); 8:00 PM (±2 hours)]
89004494|NCT04042922|Experimental|Exposure to active stimulation for 30 - 60 min|Subjects in this arm will receive 30 - 60 minutes of active stimulation
89406688|NCT02095548|Placebo Comparator|Placebo|Single, intra-articular injection of placebo
89406689|NCT00113438|Experimental|45 mg/m2 Combretastatin A-4 Phosphate|
89406690|NCT00113438|Experimental|60 mg/m2 Combretastatin A-4 Phosphate|
89406691|NCT04087408|No Intervention|control group|"Ovarian stimulation will be initiated from the day 2 of the menstrual cycle using gonadotropins 150-450 IU~doses will be adjusted according to ovarian response. Once the leading follicle will reach a size of 14 mm, co-treatment with a GnRH antagonist will initiated and continued up until at least three follicles reached a size of 17-18 mm.~Trigger will be done using HCG followed by OPU 36 h later.~Retrieved oocytes will be fertilized by ICSI.~LPS, using micronized P (400 mg/day) vaginally beginning on the day of oocyte retrieval.~6 - Blood sampling will be performed for progesterone 7 days after OPU.~7-Quantative BHCG will be performed 14 days after OPU."
89406692|NCT04087408|Active Comparator|study group|"Ovarian stimulation will be initiated from the day 2 of the menstrual cycle using gonadotropins 150-450 IU~doses will be adjusted according to ovarian response. Once the leading follicle will reach a size of 14 mm, co-treatment with a GnRH antagonist will initiated and continued up until at least three follicles reached a size of 17-18 mm.~Trigger will be done using HCG followed by OPU 36 h later.~Retrieved oocytes will be fertilized by ICSI.~LPS, using micronized P (400 mg/day) vaginally beginning on the day of oocyte retrieval.~GnRH agonist 0.1 mg will be given 6 days after OPU.~Blood sampling will be performed for progesterone within 24 h following the GnRH agonist 0.1 mg~Quantative BHCG will be performed 14 days after OPU."
89406693|NCT02099292|Experimental|Rituximab and DexaBEAM|Rituximab and DexaBEAM
88813574|NCT03001661|Active Comparator|Propess|Control intervention: Propess® (dinoprostone) Slow release vaginal drug delivery system (Prostaglandin E2).
88813575|NCT03001661|Experimental|Dilapan-S|Experimental intervention: DILAPAN-S® A synthetic osmotic cervical dilator for insertion into the cervical canal, using as many rods as necessary.
88813576|NCT01723358|Experimental|Neuromuscular electrical stimulation (NMES)|
88813577|NCT03007199||AGNES Controls|AGNES controls are individuals with a first acute ST-elevation myocardial infarction but without ventricular fibrillation.
88813578|NCT03007199||AGNES cases|AGNES cases have ECG- registered ventricular fibrillation occurring before reperfusion therapy for an acute and first ST-elevation myocardial infarction.
88813579|NCT01723436|No Intervention|DLST Only|Surrogates will complete the Stroop test then answer the hypothetical life sustaining therapy (LST)
88813580|NCT01723436|Experimental|Contemplate only|Surrogates will contemplate each of the 3 scenarios but not make any decisions, then complete the Stroop test and answer the hypothetical LST question
88813581|NCT01723436|Experimental|Decide with advice|Surrogates will make decisions on 4 scenarios with physician advice, then complete the Stroop test and answer the hypothetical LST question. Within this arm, surrogates will receive two positive recommendations (i.e. to go ahead with the intervention) and two negative recommendations (i.e. to decline the intervention). These positive and negative recommendations will be randomly assigned upon study enrollment. With four hypothetical scenarios, there are six possible options for recommendation variations.
88813582|NCT01723436|Experimental|Decide without advice|Surrogates will make decisions on 4 scenarios without physician advice, then complete the Stroop test and the hypothetical LST question.
88813583|NCT03006965||Hemophilia A patients|"Group of patients in prophylactic treatment with Advate® (octocog alfa) or Adynovi® (rurioctocog alfa pegol), or patients using already myPKFit®.~Patients will be given a dose of octocog alfa or rurioctocog alfa pegol according to usual clinical practice, and two blood samples will be taken in case of octocog alfa: one sample will be extracted 3-4h postdose (+/- 30 minutes), and the second sample will be extracted 24-32h postdose (+/- 60 minutes). In case of rurioctocog alfa pegol, the first sample is taken in the same conditions than octocog alfa, and the second sample will be extracted 48h postdose (+/- 120 minutes), and other sample post 72h(+/- 120 minutes) optional."
88813584|NCT03406208|Experimental|Stress and Symptom Management Program 1|The Stress and Symptom Management Program 1 (SMP1) introduces and reinforces stress and symptom management skills. The program consists of 8 weekly sessions (90 minutes each), delivered through live videoconferencing.
88813585|NCT03406208|Experimental|Stress and Symptom Management Program 2|The Stress and Symptom Management Program 2 (SMP2) introduces and reinforces stress and symptom management skills. The program consists of 8 weekly sessions (90 minutes each), delivered through live videoconferencing.
88813586|NCT01577537|Experimental|VivaGel|
88813587|NCT01577537|Placebo Comparator|HEC Placebo|
88813588|NCT04379102||IUD patients|80 patients who matched the inclusion criteria and received IUDs
88813589|NCT02469246|Experimental|F/TAF (Double-Blind)|"F/TAF + ABC/3TC placebo + allowed 3rd antiretroviral (ARV) agent for 96 weeks~After Week 96, participants will continue to take their blinded study drug and attend visits every 12 weeks until treatment assignments have been unblinded."
89406694|NCT02283242|Experimental|Galantamine|"8 mg of Galantamine for 4 weeks~16 mg Galantamine for 8 weeks"
89406695|NCT02283242|Placebo Comparator|Placebo|"8 mg of placebo for 4 weeks~16 mg placebo for 8 weeks"
89406696|NCT02283320|Experimental|BIND-014 (Docetaxel Nanoparticles for Injectable Suspension)|
89406697|NCT05228392|Experimental|lullaby group|For two weeks and 30 minutes every day at home, the lullaby group (LG) only listened to the lullaby record selected by the researcher
89406698|NCT05228392|Experimental|multi music group|For two weeks and 30 minutes every day at home, the multi-music group (MG) listened to self-selected music from different records presented to them by the researcher.
89406699|NCT05228392|No Intervention|control group|The control group (CG) only received routine care. This group do not listened to music.
89406700|NCT02099448||Elective Cardiac Catheterization|
89406701|NCT05228236|Experimental|Plant based protein|
89406702|NCT05228236|Experimental|Whey Protein|
89406703|NCT03556098|Active Comparator|GIP|Infusion of Glucose-dependent insulinotropic peptide
89406704|NCT03556098|Active Comparator|GIP[3-30]|Infusion of GIP[3-30]
88882801|NCT06104488|Experimental|Dose Level 1|If 0 of 3-6 or no more than 1 of 6 evaluable participants experience a DLT, then the dose will be escalated to Dose Level 2 and the same approach will be repeated. If 2 or more DLTs are observed on Dose Level 1 in 2-6 subjects, then further enrollment to Dose Level 1 will stop, the dose will be de-escalated to Dose Level -1 and the same approach will be repeated. The MTD will be the highest dose with <2 DLTs in 6 patients.
89406705|NCT03556098|Placebo Comparator|Saline|Infusion of saline
89406706|NCT02096640|Active Comparator|Percutaneous dilatation tracheostomy: Smiths Medical|Type of surgical teqnique for tracheostomy: Percutaneous dilatation tracheostomy. The set for the tracheostomy is bought from Smiths Medical TM.
89406707|NCT02096640|Active Comparator|Open surgery tracheostomy|Type of surgical teqnique for tracheostomy: Open surgical tracheostomy
88882802|NCT06104488|Experimental|Dose Level 2|If 0 of 3-6 or no more than 1 of 6 evaluable participants experience a DLT, then the dose will be escalated to Dose Level 2 and the same approach will be repeated. If 2 or more DLTs are observed on Dose Level 1 in 2-6 subjects, then further enrollment to Dose Level 1 will stop, the dose will be de-escalated to Dose Level -1 and the same approach will be repeated. The MTD will be the highest dose with <2 DLTs in 6 patients.
88882803|NCT06104475|Experimental|CT scan intervention|
88882804|NCT06104423|Active Comparator|Nebivolol 5 mg|Single dose Phase (4 weeks): patients will be treated with Nebivolol 5 mg. Combination Phase (12 weeks): uncontrolled patients will be treated with the extemporaneous combination of Nebivolol 5 mg and Ramipril 2.5 mg for 4 weeks. Ramipril 2.5 mg will switched to Ramipril 5 mg in uncontrolled patients for further 4 weeks while controlled patients will continue with Nebivolol 5 mg/Ramipril 2.5 mg therapy. After 8 weeks Ramipril 5 mg will be switched to Ramipril 10 mg in the uncontrolled patients as well as Ramipril 2.5 mg will be switched to Ramipril 5 mg. Controlled patients will continue same therapy.
89004495|NCT04042922|Sham Comparator|Exposure to control stimulation for 30 - 60 min|Subjects in this arm will receive 30 - 60 minutes of control stimulation
89191025|NCT02572674|Other|experimental arm|Experimental follow up : Neuropsychological assessment at 6 month and genetic samples
89191026|NCT00712062|Experimental|Pemetrexed|500 mg/m2 given as an injection into a vein over 10 minutes once every 21 days until progression or unacceptable toxicity.
89406708|NCT02286986|Other|Cannabidiol|open label administration
89406709|NCT04995874|Experimental|Intervention|KOKOPlus protein and micronutrient powder , a complementary food supplement containing soya powder, sugar and oil along with the essential amino acid lysine and a micronutrient mix was formulated. Two weeks' supply of KOKOPlus sachets will be given to intervention arm participants every fortnight for 6 months to be mixed into any cereal, soup, stew, or other food given to the children.
89406710|NCT04995874|No Intervention|Control|This arm will receive no supplement and no placebo for the duration of the study.,
89406711|NCT02095626|Experimental|AP301|Treatment group
89406712|NCT02095626|Placebo Comparator|Saline solution|
89406713|NCT02287064|Experimental|Intravenous Immune Globulin (IVIG)|
89406714|NCT02095704|Experimental|paracetamol oral solution|dosage form: paracetamol oral solution;dosage:15.6ml(containing 500 mg of the active ingredient);frequency:single dose
89406715|NCT02095704|Experimental|paracetamol tablet|dosage form: paracetamol tablet;dosage: 500 mg;frequency:single dose
89406716|NCT02287142|Active Comparator|Interscalene|Single-shot Interscalene Nerve Block with ropivacaine 0.5%
89406717|NCT02287142|Active Comparator|Supraclavicular|Single-shot Supraclavicular Nerve Block with ropivacaine 0.5%
89406718|NCT02287142|Active Comparator|Suprascapular|Single-shot Suprascapular Nerve Block with ropivacaine 0.5%
89406719|NCT03178630||Patients with autoimmune liver disease|"Patients with autoimmune liver disease~Patients (6-23 y.o.) with established clinical diagnosis of AIH or suspected diagnosis of AIH based on elevated serum AST or ALT, elevated IgG level >1.1 ULN, elevated titer of autoantibodies, including ANA, SMA, LKM, LC-1 or SLA, which is consistent with the simplified criteria for the diagnosis of AIH in children will be enrolled.~Patients (6-23 y.o.) with established clinical diagnosis of PSC or Suspected diagnosis of PSC supported by abnormal cholangiogram (ERCP or MRCP) or elevated GGT>1.5 ULN and dilated bile ducts by liver ultrasound will be enrolled."
89406720|NCT02102412|Experimental|single arm|single arm patients underwent colonoscopy with aer-o-scope followed by conventional colonoscopy to assess if any mucosal damage occurred with the experimental device.
89406721|NCT04820140||muscle strengthening program|All patients will be receiving a muscle strengthening program consisting in both a training against resistance and an endurance training by elliptical bike during an observational period of 12 weeks for each treatment. Each training program will be preceded by a 4-week period of lymphatic drainage in order to improve neuromuscular sensitivity.
89406722|NCT02096796||persons without arm pump|
89406723|NCT02096796||persons with arm pump|
89406724|NCT02287220||Newborn Infants|0-12 months old Male or female Any ethnicity
89406725|NCT01675492|Experimental|wave-front guided LASIK|
89004496|NCT03984682|Experimental|Experimental group|Patients will benefit from regular care + Joint Crisis Plan
89004497|NCT03984682|No Intervention|Control group|Patients will benefit from regular care
89004498|NCT03975400|No Intervention|Pre-Campaign|Investigators will measure the duration of untreated psychosis and rates of referrals to OnTrackNY programs throughout New York States prior to campaign initiation.
89004499|NCT03975400|Active Comparator|Active Campaign|Investigators will measure the duration of untreated psychosis and rates of referrals to OnTrackNY programs throughout New York States during the active campaign initiation.
89004500|NCT03932903|Experimental|Contextually-tailored Mobile Messages for Adherence|All participants will be micro-randomized to receive contextually-tailored mobile messages designed to promote their oral chemotherapy adherence, with a 60% probability of receiving a contextually-tailored message each day.
89004501|NCT03932903|No Intervention|No messages|All participants will also be micro-randomized to not receive messages on some days of the intervention (~40% of the time).
89004502|NCT03929250|Experimental|2g CAW Dose|2g of Centella asiatica water extract in a standardized product.
89004503|NCT03929250|Experimental|4g CAW Dose|4g of Centella asiatica water extract in a standardized product.
89004504|NCT03905941|Experimental|Metformin then oral combined hormonal contraceptives|Subjects will take metformin 2000 mg/day for the first 6 months, followed by 6 months of oral combined hormonal contraceptive (OCs) with a combination of ethinyl estradiol 20 mcg/norethindrone acetate 1 mg.
89004505|NCT03905941|Active Comparator|Oral combined hormonal contraceptives then metformin|Subjects will take oral combined hormonal contraceptive (OCs) with a combination of ethinyl estradiol 20 mcg/norethindrone acetate 1 mg for the first 6 months, followed by 6 months of metformin 2000 mg/day.
89004506|NCT03905603|Experimental|ACTH (Cosyntropin), rhCG (Ovidrel)|ACTH (Cosyntropin) administered 250 mcg IV; rhCG (Ovidrel) administered 250 mcg IV
89004507|NCT03904524|Experimental|SET-to-MEET|This is a single arm, open trial that will be conducted in parallel in 3 separate ICUs. Each site will receive the SET-to-MEET intervention.
89004508|NCT03799653||Nurses|All subjects are registered nurses in Xiamen, China
89004509|NCT03797014|Experimental|B/F/TAF|Treatment group (1-arm study)
89004510|NCT03796273|Experimental|Arm I (ketoconazole)|Patients receive ketoconazole PO QD on days 1-4 before standard surgery in the absence of disease progression or unacceptable toxicity.
89004511|NCT03796273|Active Comparator|Arm II (standard surgery)|Patients undergo standard surgery.
89004512|NCT03782207||Cohort 1 (UC LOT2+later lines[LOT2+] & platinum eligible LOT1)|"Participants diagnosed with locally advanced or metastatic Urothelial Cancer previously treated with platinum-containing chemotherapy.~Enrollment is closed."
89004513|NCT03782207||Cohort 2 (NSCLC LOT2 plus later lines [LOT2+])|"Participants diagnosed with Locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) after prior chemotherapy. Participants with epidermal growth factor receptor (EGFR) activating mutations or anaplastic lymphoma kinase (ALK)-positive tumor mutations should also have received targeted therapy.~Enrollment closed."
89004514|NCT03782207||Cohort 3 (NSCLC LOT1 plus EGFR+/ALK+ LOT2+)|"EMA: Participants diagnosed with locally advanced/metastatic non-squamous NSCLC not previously treated. Participants with EGFR-activating mutations or ALK-positive tumor mutations should have received at least one line of targeted therapy.~FDA: for the treatment of adult participants with metastatic NSCLC who have disease progression during or following platinum-containing chemotherapy. Participants with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for NSCLC harboring these aberrations prior to receiving TECENTRIQ.~Enrollment is closed."
89004515|NCT03782207||Cohort 4 (ES-SCLC LOT1)|"Participants diagnosed with extensive stage (ES) small cell lung cancer (SCLC) not previously treated.~Enrollment is closed."
89004516|NCT03782207||Cohort 5 (NSCLC LOT1)|Participants diagnosed with metastatic Non-Small Cell Lung cancer with high PD-L1 expression, previously untreated.
89004517|NCT03782207||Cohort 6 (HCC LOT1)|Participants diagnosed with unresectable locally advanced or metastatic hepatocellular carcinoma previously untreated with systemic therapy.
89004518|NCT03777215|Experimental|Angiotensin-(1-7)|Subjects will receive intravenous infusion of three ascending doses of angiotensin-(1-7). The doses are: 2, 4, and 8 ng/kg/min. Each dose will be maintained for 10 minutes, with the highest dose maintained for an additional 90 minutes. The total infusion period is 120 minutes.
89004519|NCT03777215|Placebo Comparator|Placebo|Subjects will receive intravenous infusion of saline that is matched in volume to the angiotensin-(1-7). The total infusion period is 120 minutes.
89004520|NCT03775954||1) Fetal Congenital Heart Disease|Pregnancy with major fetal congenital heart disease, after 20 weeks gestation, and as neonate following delivery. Two fetal magnetocardiograms (fMCG) and 1 neonatal electrocardiogram (nECG) will be obtained and heart rate, rhythm, and conduction patterns will be compared.
89004521|NCT03775954||2) History of fetal demise (Stillbirth)|Pregnancy with a history of an unexplained fetal demise (stillbirth at 20 -40 weeks gestation) during any prior pregnancy. Two fetal magnetocardiograms (fMCG) and 1 neonatal electrocardiogram (nECG) will be obtained and heart rate, rhythm, and conduction patterns will be compared.
89004522|NCT03775954||3) Fetal hydrops, immune or non-immune|Pregnancy with fetal hydrops, immune or non-immune, at or after 20 weeks gestation. Two fetal magnetocardiograms (fMCG) and 1 neonatal electrocardiogram (nECG) will be obtained and heart rate, rhythm, and conduction patterns will be compared.
89004523|NCT03775954||4) Fetal gastroschisis|Pregnancy with fetal gastroschisis, at or after 20 weeks gestation. Two fetal magnetocardiograms (fMCG) and 1 neonatal electrocardiogram (nECG) will be obtained and heart rate, rhythm, and conduction patterns will be compared.
89004524|NCT03775954||5) Twin pregnancy, monochorionic|Twin pregnancy, monochorionic, with or without twin-twin transfusion syndrome, at or after 20 weeks gestation. Two fetal magnetocardiograms (fMCG) and 1 neonatal electrocardiogram (fMCG) will be obtained and heart rate, rhythm, and conduction patterns will be compared.
89004525|NCT03738579|Active Comparator|Control Group|After standard of care debridement and irrigation (using normal saline), Mepilex foam dressing will be used. Foam dressing will be used throughout the study, including for mid-week dressing changes.
89406726|NCT02250690|Experimental|experimental group - tDCS|The tDCS intervention occur at 10 sessions of intervention where electrodes are connected to head specifically in supplementary motor area placed at 2 cm in front of vertex. The clinical stimulator (NeuroConn, Germany) provided the direct current using two silicon-sponge electrodes with a surface area of 35 cm2 (5 × 7cm) embedded in a saline-soaked solution. Immediately after 13 minutes of tDCS application, patient was submitted to gait training three times a week during 4 weeks with visuals cues. The patients were asked to walk along at a 7 meters rubber carpet to at different speed, forward and backward gait, side walk during thirty minutes with three intervals of two minutes. The patient may be at on state of drug administration and the training is applied by another physiotherapist.
89406727|NCT02250690|Sham Comparator|Control group (tDCS sham)|The sham character is ensured by the stimulation time, once the device is programmed to turn off 30 seconds after the beginning of stimulation. The current is switched in ascending ramp mode for 10 seconds until 2 mili ampere and a descending ramp similar also for 10 seconds will be used until the end of stimulation. The sham stimulation is commonly perceived by the patient as the actual treatment and all procedures for the application of the technique should be similar to those adopted for the active stimulation. Immediately after tDCS stimulation, the gait training consisting of a protocol based on sensory cues for 30 minutes is administered three times a week for four weeks. Sham stimulation will be held for 30 seconds in order to mimic the perceived lowering effect of ramp current.
89406728|NCT02099604|Experimental|Vitamin D|Vitamin D + Pegylated Interferon Alpha 2b + Ribavirin
89406729|NCT02099604|No Intervention|Standard of Care|Pegylated Interferon Alpha 2b + Ribavirin
89191027|NCT00848146|Experimental|NOTES-Assisted Lap Chole|These patients will undergo an experimental surgical procedure that uses a combination of laparoscopic instruments (i.e., inserted through the skin into the abdominal cavity) and flexible endoscopic instruments (i.e., inserted through the mouth).
89406730|NCT03075046|Experimental|blue LED 405 nm in vulvovaginal candidiasis|It will be applied the a 405 nm blue LED in a closed room by a physiotherapist for 30 minutes. The apparatus shall be supported on a tripod, statically, externally, 5 cm away from the vulva and vagina region, with the patient naked, in gynecological stretcher and lithotomy position. The protocol will consist of only one session. This part of the study will see if there is fungicidal effect of the blue led 405 nm
88882805|NCT06104423|Active Comparator|Ramipril 2.5/5/10 mg|Single dose Phase (4 weeks): patients will be treated with Ramipril 2.5 mg. Combination Phase (12 weeks): uncontrolled patients will be treated with the extemporaneous combination of Nebivolol 5 mg and Ramipril 2.5 mg for 4 weeks. Ramipril 2.5 mg will switched to Ramipril 5 mg in uncontrolled patients for further 4 weeks while controlled patients will continue with Nebivolol 5 mg/Ramipril 2.5 mg therapy. After 8 weeks Ramipril 5 mg will be switched to Ramipril 10 mg in the uncontrolled patients as well as Ramipril 2.5 mg will be switched to Ramipril 5 mg. Controlled patients will continue same therapy.
88882806|NCT06104384||Adult chronic pain patients|Adult chronic pain patients who received pain management
88882807|NCT06104267|Experimental|Medical Tai Chi Exercise Group|
88882808|NCT06104241|Experimental|BGT007 Cell Injection|"This is an exploratory study of single-arm, open, modified 3+3 dose escalation. The BGT007 cell therapy group received five progressively increased dose levels (5.0× 10^7 cells,1.0 ×10^8 cells, 3.0× 10^8 cells,1.0 × 10^9 cells,3.0 ×10^9 cells) of BGT007 cells. Each subject was observed for at least 4 weeks after cell transfusion (DLT observation period). The first two dose groups (5.0×10^7 cells and 1.0×10^8 cells) included 1 subject each, and the other three dose groups were followed by conventional 3+3 dose increments."
88882809|NCT06104215|Experimental|BGT007H Cell Injection|"This is an exploratory study of single-arm, open, modified 3+3 dose escalation. The BGT007H cell therapy group received five progressively increased dose levels (2.0× 10^8,5.0 ×10^8, 1.0× 10^9,3.0 × 10^9,6.0 ×10^9) of BGT007H cells. Each subject was observed for at least 4 weeks after cell transfusion (DLT observation period). The first two dose groups (2.0×10^8 cells and 5.0×10^8 cells) included 1 subject each, and the other three dose groups were followed by conventional 3+3 dose increments."
88882810|NCT06104150|Experimental|Intervallic submaximal test|Intervallic exercise test
88882811|NCT06104137|Experimental|MOOC group|If a patient chooses to take part and is randomly allocated to the MOOC group, a member of research team will issue them with details of how to access the course. Three to six weeks later the research team will contact them to test their recall over the phone of some important information about bariatric surgery. At six week's after the procedure, the research team will send them a copy of the SDM Q9 questionnaire to complete and send back. This is a questionnaire that asks about satisfaction with the shared decision making process.
88882812|NCT06104137|Active Comparator|non MOOC group|If a patient is randomly allocated to the non MOOC group, they will also receive a recall test and a questionnaire after the consultant appointment in order to compare the two groups.
88882813|NCT06104111|Experimental|Vitamin D3 (cholecalciferol)|1000 IU vitamin D3 (cholecalciferol)/kg body mass will be taken in form of individual number of pills (4000 IU each, e.g. 20 pills for a person of 80 kg) in the morning together with a breakfast at days 0, 28 and 56
88882814|NCT06104085|Experimental|99mTc-MY6349 SPECT/CT|Inject 99mTc-MY6349 and then perform SPECT/CT scan.
88882815|NCT06104072|Placebo Comparator|Control group (GA)|control group (GA) and study group (GB). Patients in (GA) will be treated by a designed physiotherapy program consisted of aerobic exercise on treadmill, stretching exercise, Proprioceptive neuromuscular facilitation (PNF) techniques, Graduated active exercises, gait training, Reciprocal and weight shifting exercises in addition to sham computerized cognitive training.
88882816|NCT06104072|Experimental|Study group (GB)|Patients in (GB) will be treated by computer-based cognitive training in addition to the same physiotherapy program as GA.
88882817|NCT06104059|Active Comparator|Nociception level index (NOL™)|The nociception level index NOL will be used in order to quide intraopertaive analgesia.
88882818|NCT06104059|Active Comparator|Standard of care|Intraoperative analgesia will be based on common practice, i.e. changes in hemodynamic parameters.
88882819|NCT06104033||Hybrid strategy|The patient undergoes percutaneous coronary intervention with drug-coated balloons and drug-eluting stents or drug-coated balloons only in the coronary artery lesion.
88882820|NCT06104033||DES only|The patient undergoes percutaneous coronary intervention with drug-eluting stents only in the coronary artery lesion.
88882821|NCT06104007||Genoss® DCB|Patients with coronary in-stent restenosis (ISR) who underwent percutaneous coronary intervention using the Genoss® DCB
89191028|NCT02545816|Other|study group|Patients (age ≥ 18 years) admitted to the ICU with an acute neurological insult which will be sedated/ventilated (Glasgow Coma Scale (GCS) ≤ 8).
89406731|NCT03075046|Experimental|blue LED 405 nm in healthy women|It will be applied the a 405 nm blue LED in a closed room by a physiotherapist for 30 minutes. The apparatus shall be supported on a tripod, statically, externally, 5 cm away from the vulva and vagina region, with the patient naked, in gynecological stretcher and lithotomy position. The protocol will consist of only one session.This part of the study will see the security and the effects of the blue led 405 nm in healthy vaginal microflora
89406732|NCT03075046|No Intervention|Sociodemographic data of women with vulvovaginal candidiasis|The women will answer some questions of the anamnesis as: Age, weight, height, form of intimate hygiene, and others to evaluate possible correlations of these data with the presence of vulvovaginal candidiasis
89406733|NCT02099760||STD testing (GC/Ct/trich)|
89406734|NCT04751110|Other|block group|ultrasound guided rhomboid intercostal block will performed
89406735|NCT02099916|Active Comparator|gonadotropins plus DHEA|Patients in this group will be stimulated according to a short stimulation protocol with gonadotropins and GnRH antagonists. Prior to the stimulation will be treated with DHEA 25 mg PO tid for 12 weeks.
89406736|NCT02099916|Active Comparator|Gonadotropins|Patients in this group will be stimulated according to a short stimulation protocol with gonadotropins and GnRH antagonists.
89191029|NCT00712140|Active Comparator|Arm I|Patients receive trastuzumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for up to 12 months in the absence of disease progression or unacceptable toxicity. All patients also receive standard chemotherapy regimens as per local institutional protocols either concurrently with or sequentially to trastuzumab.
89406737|NCT02102646|Active Comparator|Triptorelin|Triptorelin 22,5mg/24th week intramuscularly
89406738|NCT02102646|Active Comparator|orchiectomy|Androgen deprivation therapy by bilateral subcapsular orchiectomy
89406739|NCT00366704|Experimental|A|
89406740|NCT00366704|Active Comparator|B|
89406741|NCT03924622|Experimental|Group 1: Mepilex on Litter + AE Mattress + 30 degree backrest|Intervention: Mepilex
89406742|NCT03924622|No Intervention|Group 2: Without Mepilex on Litter + AE mattress + backrest|Intervention: Control (no Mepilex)
89406743|NCT03924622|Experimental|Group 3: Mepilex on VSB on AE mattress|Intervention: Mepilex
89406744|NCT03924622|No Intervention|Group 4: Without Mepilex on VSB on AE mattress|Intervention: Control (no Mepilex)
89406745|NCT03924622|Experimental|Group 5 Prolonged Field Care (PFC) - LiquiCell on Talon litter|Intervention: LiquiCell mat
89406746|NCT03924622|No Intervention|Group 6: PFC Without LiquiCell on Talon Litter|Intervention: Control (no LiquiCell)
89406747|NCT02099994|Experimental|A - AM|Ad35-GRIN 5 x 10^10 vp IM at week 0, MVA.HIVconsv 2 x 10^8 pfu IM at week 8.
89406748|NCT02099994|Experimental|B - DDDAM|pSG2.HIVconsv DNA 4 mg or saline placebo at weeks 0, 4 and 8. Ad35-GRIN 5 x 10^10 vp or saline placebo at week 12. MVA.HIVconsv 2 x 10^8 pfu or saline placebo at week 20.
89406749|NCT02099994|Experimental|C - DeDeDeAM|"Electroporated pSG2.HIVconsv 4 mg or electroporated saline placebo at weeks 0, 4 and 8.~Ad35-GRIN 5 x 10^10 vp or saline placebo at week 12. MVA.HIVconsv 2 x 10^8 pfu or saline placebo at week 20."
89406750|NCT02097186|Experimental|Remote ischaemic preconditioning|Remote ischaemic preconditioning will be performed in the same manner as several previous trials. Immediately after induction of anaesthesia, a standard, CE-approved blood pressure cuff will be placed around one arm of the patient. It will then be inflated to a pressure of 200mmHg for 5 minutes. For patients with a systolic blood pressure >185mmHg, the cuff will be inflated to at least 15mmHg above the patient's systolic blood pressure. The cuff will then be deflated and the arm allowed reperfuse for 5 minutes. This will be repeated so that each patient receives a total of 4 ischaemia-reperfusion cycles. In all other respects, the procedure and peri-operative care will follow the routine practices of the surgeons and anaesthetists involved.
89406751|NCT02097186|No Intervention|Control to remote preconditioning group|Patients randomised to this group will receive routine pre-operative, peri-operative and post operative care.
89406752|NCT05725850|Experimental|EG (Experimental A. Oleracea extract gel)|The EG group received the application of experimental gel of A. Oleracea extract for post tooth bleaching sensitivity.
89406753|NCT05725850|Placebo Comparator|GP (Gel placebo)|The GP group received the application of a placebo gel.
89406754|NCT02097264|Experimental|NNC0109-0012|
89406755|NCT02097264|Active Comparator|Adalimumab|
89406756|NCT03530618|Experimental|Flexible tip straight guidewire|
89406757|NCT03530618|Experimental|J-tip guidewire|
89406758|NCT02097342|Experimental|Linagliptin|Tablet Linagliptin (5mg) per oral, once daily will be given to 10 patients for 6 months
89406759|NCT02097342|Placebo Comparator|Placebo|Tablet Placebo per oral, once daily will be given to 10 patients for 6 months
89406760|NCT02097342|Active Comparator|Voglibose|Tablet Voglibose (0.2mg) per oral, thrice daily (with meals) will be given to 10 patients for 6 months
89406761|NCT03530540|Experimental|Intervention|Active shockwaves
89406762|NCT03530540|Placebo Comparator|Placebo|Placebo shockwaves
89406763|NCT04294498|Experimental|Durvalumab|Durvalumab
89406764|NCT02260518|Experimental|Lifestyle Intervention|The intervention will focus on women gaining the recommended amount of weight, increasing physical activity to 150 minutes per week, and meeting healthy eating guidelines.
89406765|NCT02260518|Other|Standard Care|Women in the standard care group will attend their regularly scheduled obstetric (OB) visits with their prenatal care providers and will receive monthly mailings and matched number of podcasts.
89406766|NCT04288648||SUI group|Examination will include an abdominal ultrasound assessment of pelvic floor muscle in supine, sitting, standing and squatting. The Height of the bladder base will be measured during rest period and maximal contraction.
89406767|NCT04288648||control group|Examination will include an abdominal ultrasound assessment of pelvic floor muscle in supine, sitting, standing and squatting. The Height of the bladder base will be measured during rest period and maximal contraction.
89406768|NCT02102958|Experimental|Experimental|DSME with Nonvisual Foot Examination
89406769|NCT02102958|Active Comparator|Comparison|DSME with Usual Foot Examination Instruction
89406770|NCT02097498|No Intervention|Simulation only|One group will be randomized to receive simulation training similar to that required for certification. Paramedics in this group will then complete a second simulation scenario
89406771|NCT02097498|Experimental|Directed feedback|One group will review their baseline simulation scenario with a member of the research staff while providing specific feedback for errors made during the first simulation. Paramedics in this group will then complete a second simulation scenario.
88882822|NCT06103981||Group A|About 88 patients having pneumonia and developed acute liver injury That need observation of the outcome and hospital stay to evaluate acute liver injury impact
88882823|NCT06103981||Group B|About 88 patients having pneumonia but did not develop acute liver injury that need observation of the outcome and hospital stay
88882824|NCT06103903||Children aged 6-13 years|Children aged 6-13 years with a chronic skin visible disease
88882825|NCT06103903||Adolescents aged 14-17 years|Adolescents aged 14-17 years years with a chronic skin visible disease
88882826|NCT06103903||Adult patients|Adult patients aged 18 years and more with a chronic skin visible disease
88882827|NCT06103903||Parents of children aged 6 years and more|Parents of children aged 6 years and more with a chronic skin visible disease
88882828|NCT06103825|Experimental|Strengths of solriamfetol (JZP-110) strengths: 37.5 mg，75 mg, 150 mg|"subject will first enter a 2-week Titration Phase, during which the initial dose will be 37.5mg. The dose will be increased from 37.5mg QD to 75mg QD after 3 days, and then to 150mg QD at the first day of the second week if well-tolerated. subjects will then enter the 10-week Maintenance Phase on 150mg QD if well-tolerated.~If a subject tolerability issues after titration up to 150mg at the second week, the dose can be reduced to 75mg QD following instructions of the investigators. This subject will then enter the 10-week Maintenance Phase on 75mg QD.~If a subject experiences tolerability issues after titration up to 75mg at the first week, the dose can be reduced to 37.5mg QD following instructions of the investigators. The dose will be increased to 75mg QD again at the first day of the second week. Subject will then enter the 10-week Maintenance Phase on 75mg QD if well-tolerated.~All subjects should be maintained on either 75mg QD or 150mg QD during the Maintenance Phase."
88882829|NCT06103825|Placebo Comparator|matching Placebo|
88882830|NCT06103812||Hyalo4 Skin Gel|
89004526|NCT03738579|Active Comparator|Antibacterial Control|After standard of care debridement and irrigation (using normal saline), Mepilex AG foam dressing will be used. This dressing will be used throughout the study, including for mid-week dressing changes.
89406772|NCT02097498|Experimental|Basic Videolaryngoscopy|One group will review a series of instructional videos related to common airway management errors. Paramedics in this group will then complete a second simulation scenario.
89406773|NCT02097576|Active Comparator|NeilMed Saline Sinus Rinse|Saline nasal rinses will be performed using a NeilMed® Sinus Rinse 240 ml bottle and one NeilMed® packet containing sodium chloride/sodium bicarbonate at a concentration to make an isotonic solution when mixed with distilled or previously boiled water.
89406774|NCT02097576|Active Comparator|Saline mixed with Manuka Honey|Saline mixed with MH nasal rinses participants will be instructed how to mix a rounded teaspoon of MH (Wedderspoon® 100% Raw Manuka Honey Active 16+) with 4-6 oz of lukewarm distilled or previously boiled water, to add along with distilled or previously boiled water and the NeilMed® Sinus Rinse packet to the rinse bottle to a final volume of 240 ml. Participants will be instructed to rinse slowly with the MH/saline rinse mixture to maximize contact time with the MH/saline mixture.
89406775|NCT02097654|Experimental|SENATOR|Physicians attending multi-morbid older patients i.e. with 3 or more chronic medical conditions receive a SENATOR software-generated report with advice details on potentially inappropriate pharmacotherapy and/or potentially inappropriate prescribing omissions.
89406776|NCT02097654|No Intervention|Control|Standard pharmaceutical care as per local practice.
89406777|NCT03530462||patient with first-line and second-line|patients who received intravenous second-line immunotherapy (steroids, intravenous immunoglobulin, plasmapheresis),in addition to first-line immunotherapy (rituximab, cyclophosphamide)
89406778|NCT03530462||patients with first-line only|patients who received first-line immunotherapy (steroids, intravenous immunoglobulin, plasmapheresis)only
89406779|NCT03530462||healthy control|healthy individuals without a history of psychiatric or neurologic disease
89406780|NCT02250456||Turner syndrome patients and vascular abnormalities|
89406781|NCT04044664|Placebo Comparator|Placebo|
89406782|NCT04044664|Experimental|NYX-783 Low Dose (10 mg QD)|
89406783|NCT04044664|Experimental|NYX-783 High Dose (50 mg QD)|
89406784|NCT03555474|Experimental|Theta burst stimulation & Physiotherapy|"Patients were given theta burst stimulation (intermittent TBS (iTBS) to the affected hemisphere and continuous TBS (cTBS) to the unaffected hemisphere) along with physiotherapy. TBS was delivered for 3 times in a week for 4 weeks.The stimulation was given with an intensity of 60% of RMT. The iTBS protocol of 10 bursts of high-frequency stimulation (3 pulses at 50 Hz) was applied at 5 Hz every 10 second for a total of 600 pulses.~Continuous TBS (inhibitory) was delivered to the unaffected hemisphere at the hot-spot with an intensity of 60% of RMT, 3 pulses at 50 Hz, repeated every 200 ms for a total of 600 pluses."
89406785|NCT03555474|Experimental|Functional stimulation & Physiotherapy|"Patients in the functional electrical stimulation (FES) group received the electrical stimulation with electrodes positioned according to pattern 3 [Grasp/Flexion/Extension, PATT (pattern movement)] of the FES (F) mode of the instrument. The electrodes were connected to a stimulator controller unit that delivers alternating current at a frequency of 35 Hz and a pulse width of 200 µs, intensity 10~50 mA.~The FES group stimulation session was given for 30 minutes for each day 3 times in a week (alternate days) for 4 weeks and it was concurrently synchronized with the physiotherapy."
89406786|NCT03555474|Active Comparator|Physiotherapy|"The following different physiotherapy regimens were followed for all the patients in the study.~Passive/Active Range of Motion (ROM); Weight bearing and supportive reaction; Reaching activities; Grasping, holding and release; Upper extremity activities of daily living (ADL). Physiotherapy intervention was given to all the patients 5 days per week for 1 month. In addition, all patients continued to receive in-home physiotherapy 1 to 2 times per week by a home physiotherapist who was guided by the research physiotherapist."
89406787|NCT02100306|Experimental|Patients|"Patients will receive:~Auditory Feedback 100% Auditory Feedback 50% alternate"
89406788|NCT05202184||Percutaneous thermal ablation of small HCC|Percutaneous thermal ablation of small HCC
89406789|NCT02103036|Experimental|Core Stability Exercises|"Core Stability Exercises:~20 sessions, distributed daily, from Monday to Friday. The first 5 sessions are common in all patients in the study, and involves the application of infrared light (IR) (10 minutes) and TENS (20 minutes) to treat acute pain. From session number 6 to session 20, the patients will receive IR + TENS 2 days a week, and the other 3 days IR+TENS+Core Stability Exercises (25-30 minutes)."
89406790|NCT02103036|Experimental|Traditional Back School|"Traditional Back School:~20 sessions, distributed daily, from Monday to Friday. The first 5 sessions are common in all patients in the study, and involves the application of infrared light (IR) (10 minutes) and TENS (20 minutes) to treat acute pain. From session number 6 to session 20, the patients will receive IR + TENS 2 days a week, and the other 3 days IR+TENS+Traditional Back School (25-30 minutes)."
89406791|NCT02100384|Active Comparator|Ultrasonics|Ultrasonic instrumentation for peri-implant maintenance
89406792|NCT02100384|Active Comparator|Scalers|Titanium Scalers instrumentation for peri-implant maintenance
89406793|NCT03922126|Experimental|Listos peer intervention|Listos intervention (peer counseling, PrEP information, and HIV/STI testing kits)
89406794|NCT03922126|Active Comparator|Peer only group|Peer only group (peer counseling, PrEP information)
89406795|NCT02103192|Experimental|Control plus low level nutrient fortification|Control plus low level nutrient fortification
89406796|NCT02103192|Experimental|Control plus increasing level nutrient fortification|Control plus increasing level nutrient fortification
89406797|NCT02103192|Placebo Comparator|Caffeine-free, carbonated soft drink|Caffeine-free, carbonated soft drink
89406798|NCT03555864||Obese|Patients need two intravenous access with infra red
89406799|NCT02097810|Experimental|Entrectinib (RXDX-101)|Oral entrectinib (RXDX-101)
89406800|NCT04153552|Other|Study Participants who Suffer from Heartburn or indigestion|Subjects who meet the inclusion/exclusion criteria for the trial will be invited to participate in the trial. Subjects will be asked to sign a consent and complete screening survey. At the onset on an episode of the subject will start a symptom diary and completed and rate the symptoms using a 4-point Likert scale for each symptom. The participant will take 2 capsules per indigestion and heartburn episode. With a max of 6 capsules per day. • After taking the test product, the participant will complete a 4-point Likert scale assessment for each symptom at 15 minutes, 30 minutes, and 1 hour after taking the test product.
89406801|NCT01918930|Experimental|MGA271|MGA271 (administered in main study CP-MGA271-01)
89191030|NCT00712140|Experimental|Arm II|Patients receive trastuzumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for up to 6 months in the absence of disease progression or unacceptable toxicity. All patients also receive standard chemotherapy regimens as per local institutional protocols either concurrently with or sequentially to trastuzumab.
89191031|NCT02546206|Experimental|Probiotic Yoghurt|Probiotic yoghurt consumption
89191032|NCT02546206|Placebo Comparator|Natural Yoghurt|Natural yoghurt consumption
89191033|NCT02545738|Experimental|Liraglutide|Liraglutide s.c. up-escalated to 1.8 mg/day for 12 weeks.
89191034|NCT02545738|Placebo Comparator|Placebo|Placebo s.c. for 12 weeks.
89191035|NCT00712218|Active Comparator|A|
89406802|NCT03555162|Other|Tool Use|The fMRI experimental conditions in this arm will allow us to study the activity of the brain when using tools. Here only the fMRI experimental session is necessary. Tasks proposed to the participants within the fMRI scanner will be related to tool use. They will have to solve mechanical problems, to judge the appropriateness of hand postures for using tools, and to judge if tools presented share the same context of use, the same functional goals, the same hand postures for using them.These experimental conditions related to the BOLD measures given by the fMRI technique will allow us to draw hypotheses on the neurocognitive mechanisms at work when we use tools.
89536683|NCT03108755|Placebo Comparator|Placebo Single Ascending Dose|Successive cohorts of 8 non-Japanese participants (6 ASP7713/ 2 Placebo / 1-7 cohorts) will each be started on a single fixed dose of ASP7713 or matching Placebo. The first two participants will receive either ASP7713 or matching placebo. If no safety issues are observed in the first 24 hours in the first two participants, then the remaining six participants will be dosed. Safety, tolerability and available Pharmacokinetic data from proceeding cohorts will be assessed for dose escalation.
88882831|NCT06103799|Experimental|IMB model-based continuity of care|"Intervention through the IMB model-based continuity of care was focused on three aspects:~Information intervention: (a) instructing patients to follow the official account of the dental implant department and introducing the instructions to use the application, (b) regularly updating the educational content and disseminating detailed knowledge about the prevention and treatment of oral diseases, especially for peri-implantitis.~Motivation intervention: (a) providing an online platform for patients to interact with nurses and doctors, where they can obtain professional answers. (b) assessing the risk factors related to peri-implantitis and diabetes and developing appropriate interventions~Behavioral skills intervention: (a) providing feedback on the correct use of tools and implants and cleaning of the overdentures by observing the cleaning videos that the patients were required to upload."
88922000|NCT05978102|Experimental|STl-7349 in combination with Pembrolizumab|Dose escalation and dose expansion for STI-7349 in combination with Pembrolizumab,to determine the RP2D of STI-7349 in combination with Pembrolizumab and to evaluate the preliminary antitumor activity in specific solid tumor patients.
89406803|NCT03555162|Other|Tool Evolution|The fMRI experimental conditions in this arm will allow us to study the activity of the brain when we improve tools. Here the fMRI experimental session will be complemented by a cognitive psychology experiment, where participants will be given a tool to improve. Tasks proposed to the participants within the fMRI scanner will be related to cognitive functions that could be implicated in improving tools : creativity, technical reasinoning, logic, empathy. The BOLD measures realted to these experimental condfitions will be related to the ability of the participant to improve a tool, through General Linear Modeling.
89406804|NCT05179798|Experimental|Mobile app|Lifestyle modification, insulin therapy if needed, utilization of a mobile app with personalized recommendations.
89406805|NCT05179798|No Intervention|Standard of care|Lifestyle modification, insulin therapy if needed; conventional care without a mobile app.
89406806|NCT02100462|Experimental|Chlorthalidone 12.5 mg|Chlorthalidone 12.5 mg by mouth once daily for 2 weeks
89406807|NCT02100462|Experimental|Hydrochlorothiazide 25 mg|Hydrochlorothiazide 25 mg by mouth once daily for 2 weeks
89406808|NCT02100462|Active Comparator|Aspirin 81 mg|Aspirin 81 mg by mouth once daily for 2 weeks
89406809|NCT00150176|Experimental|asenapine|
89406810|NCT00150176|Placebo Comparator|placebo|
89406811|NCT02100540|Placebo Comparator|I placebo capsule|I placebo capsule
89406812|NCT02100540|Experimental|II RDC 0.3mg capsule|II RDC 0.3mg capsule
89406813|NCT02100540|Experimental|III RDC 0.6mg capsule|III RDC 0.6mg capsule
89406814|NCT02100618|Experimental|HPV Group 1|Subjects who were aged 9-14 years at study entry and received two doses of the HPV-16/18 vaccine according to a 0,6-months schedule in the study HPV-048 PRI (NCT00541970).
89406815|NCT02100618|Active Comparator|HPV Group 2|Subjects who were aged 15-25 years at study entry and received three doses of the HPV 16/18 vaccine according to a 0,1,6-months schedule in the study HPV-048 PRI (NCT00541970).
89406816|NCT05201768||INDIVIDUALS WITH ALZHEIMER|balance and gait will be evaluated survey questions will be asked
89406817|NCT05201768||HEALTHY INDIVIDUALS|balance and gait will be evaluated survey questions will be asked
89406818|NCT04435912|No Intervention|PS alone group|Patients received only Protamine Sulfate for reversal of Heparin
89406819|NCT04435912|Experimental|PS and HC group|Patients received Hydrocortisone pre-treatment then Protamine Sulfate for the reversal of Heparine
89406820|NCT02100774||healthy male adults|no added micronutrient, tomato puree, lutein supplement, vitamin E supplement, vitamin D supplement
89406821|NCT02287298||2006 TO 2010 PATIENTS|PATIENTS TREATED WITH TRIPLE COMBINATION THERAPY
89406822|NCT02287298||CURRENT PATIENTS|PATIENTS TREATED WITH TRIPLE COMBINATION THERAPY AND ADDITION OF 20 MG OF ORAL ZEAXANTHIN
89406823|NCT02100852|Experimental|TGR-1202 + Obinutuzumab + Chlorambucil|TGR-1202 is an oral daily dose with obinutuzumab at a fixed IV infusion and chlorambucil as an oral dose on specified days.
89406824|NCT02985879|Placebo Comparator|Placebo|0.9% Sodium Chloride Injection/Solution for Infusion; intravenous infusions at Day 1, Day 15, and Day 29, then every 28 days for 52 weeks
89406825|NCT02985879|Experimental|ABBV-8E12 2000 mg|Intravenous infusions at Day 1, Day 15, and Day 29, then every 28 days for 52 weeks; 300 mg/15 mL (participants in countries other than Japan or Spain); 1000 mg/10 mL (for participants in Japan or Spain)
89191036|NCT00712218|Experimental|B|
89191037|NCT00848224|Experimental|2|
89406826|NCT02985879|Experimental|ABBV-8E12 4000 mg|Intravenous infusions at Day 1, Day 15, and Day 29, then every 28 days for 52 weeks; 300 mg/15 mL (participants in countries other than Japan or Spain); 1000 mg/10 mL (for participants in Japan or Spain)
89406827|NCT02103426|Experimental|Part 1: ASP0113 CMV-seropositive healthy cohort|5 mg single dose IM injection
89406828|NCT02103426|Experimental|Part 1: ASP0113 CMV-seronegative healthy cohort|5 mg single dose IM injection
89191038|NCT00848302|Experimental|L-arginine|Assess the effects of regional L-arginine supplementation in patients with chronic lower extremity occlusive disease undergoing angiography
89406829|NCT02103426|Placebo Comparator|Part 1: Placebo CMV-seropositive healthy cohort|single dose IM injection
89406830|NCT02103426|Placebo Comparator|Part 1: Placebo CMV-seronegative healthy cohort|single dose IM injection
89406831|NCT02103426|Experimental|Part 2: ASP0113 CMV-seropositive healthy cohort|4 IM injections of ASP0113
89406832|NCT02103426|Experimental|Part 2: ASP0113 CMV-seronegative healthy cohort|4 IM injections of ASP0113
89406833|NCT02103426|Experimental|Part 2: ASP0113 CMV-seronegative dialysis cohort|4 IM injections of ASP0113
89406834|NCT02103426|Placebo Comparator|Part 2: Placebo CMV-seropositive healthy cohort|4 placebo IM injections
89406835|NCT02103426|Placebo Comparator|Part 2: Placebo CMV-seronegative healthy cohort|4 placebo IM injections
89406836|NCT02103426|Placebo Comparator|Part 2: Placebo CMV-seronegative dialysis cohort|4 placebo IM injections
89406837|NCT05039320|Experimental|Group 1 - probiotic|"The use of Streptococcus salivarius K12 containing tablets (Bactoblis, registration number: AM.01.06.01.003.Е.000024.07.18; 20.07.18, MEDICO DOMUS, d.d.o.; 18116, Nis, Serbia)) once a day for 4 weeks (before bedtime after evening brushing).~Ingredients: basic active ingredient - Streptococcus salivarius K12 (≥1×109 CFU in 1 tablet), excipients - fructose (sweetener), maltodextrin, silicon dioxide, magnesium stearate (vegetable), strawberry flavouring."
89406838|NCT05039320|Placebo Comparator|Group 2 - placebo|"The use of placebo tablets once a day for 4 weeks (before bedtime after evening brushing).~Ingredients: fructose (sweetener), maltodextrin, silicon dioxide, magnesium stearate (vegetable), flavouring (strawberry)."
89406839|NCT05718518|Experimental|ASC11 tablets|"Part 1: Subjects will receive ASC11 tablets on single ascending doses with proposed dose levels of ASC11 tablets: 100mg (cohort 1), 200 mg (cohort 2), 400mg (cohort 3) and 800 mg (cohort 4).~Part 2: Subjects will receive ASC11tablets 100 to 300 mg (including 3 cohorts) and ASC11 tablets 300 mg(cohort 4) twice daily (BID) for 5 consecutive days and receive a single dose in the early morning of Day 6.~Part 3: Subjects will be randomized to receive ASC11 tablets two single 200 mg or 300 mg doses (fed or fasted)"
89406840|NCT05718518|Experimental|RTV tablets|"Part 1: Subjects will receive RTV tablets on 100 mg (cohort 1-4). Part 2: Subjects will receive RTV tablets 100 mg (including 3 cohorts) twice daily (BID) for 5 consecutive days and receive a single dose in the early morning of Day 6.~Part 3: Subjects will be randomized to receive two single 100 mg doses (fed or fasted)"
89406841|NCT05718518|Placebo Comparator|Placebo|Part 1 and 2: Subjects will be randomized to receive placebo
89406842|NCT02103504|Other|DePuy Attune TKA|DePuy Attune posterior stabilized fixed bearing total knee replacement
89406843|NCT04253782|Experimental|Team Intervention Arm|Recovery coaches and trained health educators will team together and meet with participants (remotely/electronically and/or by phone or in person, when appropriate) at least twice and for a maximum of 7 times. This includes access to mediation, trained mental healthcare providers, and educational resources.
89406844|NCT02287454|Experimental|Cognitive remediation program: REHACOP|Cognitive rehabilitation program (REHACOP) including intervention in: attention, memory, processing speed, language, executive functioning and social cognition during 3 months, 3 times per week
89406845|NCT02287454|No Intervention|Control group|No intervention was administered.
89406846|NCT05716958||Cancer group|Interpreted as BI-RADS 0 (Assessment Incomplete), BI-RADS 3 (Probably Benign), 4 (Suspicious) or 5 (Highly Suggestive of Malignancy) with a visible suspicious lesion for breast cancer on the DBT exam and confirmed as a cancer (malignant) through the subsequent biopsy conducted within following 1 year of the DBT exam.
89406847|NCT05716958||Non-Cancer group|"Negative Cases~▪ Interpreted as BI-RADS 0 (Assessment Incomplete) or BI-RADS 1 (Negative) with no cancers on the DBT exam and confirmed as BI-RADS 1 (Negative) on the further diagnostic imaging (e.g., MMG, DBT, MRI, CT and Ultrasound) taken at least after 1 year of the DBT exam.~Benign Cases~Interpreted as BI-RADS 0 (Assessment Incomplete) or BI-RADS 2 (Benign) with a visible lesion on the DBT exam and confirmed as BI-RADS 2 (Benign) on the further diagnostic imaging (e.g., MMG, DBT, MRI, CT and Ultrasound) taken at least after 1 year of the DBT exam without a further breast biopsy.~Or for the biopsy-proven benign exams, interpreted as BI-RADS 0 (Assessment Incomplete), BI-RADS 3 (Probably Benign), 4 (Suspicious) or 5 (Highly Suggestive of Malignancy) with a visible suspicious lesion for breast cancer on the DBT exam but confirmed as benign through subsequent biopsy conducted within following 1 year of the DBT exam."
89406848|NCT04249648||Patients with new diagnosis of heart failure with reduced ejection fraction|Patients with new diagnosis of heart failure with reduced ejection fraction who will be started on renin-angiotensin-aldosterone system inhibitors or in whom there is a plan to increase renin-angiotensin-aldosterone system inhibitors (if already taking prior to diagnosis of heart failure).
89406849|NCT04249648||Patients with hyperkalaemia|Hospitalised patients and patients attending emergency department who have at least 1 blood test with a potassium level of ≥5.5 mmol/l.
89406850|NCT04249648||Healthcare professionals managing patients with hyperkalaemia|Healthcare professionals (doctors, pharmacists, non-medical prescribers) who manage patients with hyperkalaemia and/or heart failure and hyperkalaemia.
88882832|NCT06103799|No Intervention|routine health education|For the control group, standard care was provided in the form of routine health education regarding various topics, such as proper brushing techniques, use of an oral irrigator, and other auxiliary tools. The patients were followed-up via telephonic interviews to monitor their condition, including usage of the implant and lifestyle changes; the interviews were conducted at 2 weeks, 1 month, 3 months, and 6 months after treatment. Data were collected about oral health, blood glucose control, lifestyle habits, and comorbidities by using the compliance questionnaire. Appropriated health education was provided if there were any concerns such as gingival swelling, plaque accumulation, and elevated blood glucose levels.
88882833|NCT06103773|Experimental|SAD-TollB-001 50mg Dosage groups|drug：TollB-001 tablets（50mg，single-dose, on the first day）
88882834|NCT06103773|Experimental|SAD-TollB-001 100mg Dosage groups|drug：TollB-001 tablets （100mg，single-dose, on the first day）
88882835|NCT06103773|Experimental|SAD-TollB-001 200mg Dosage groups|drug：TollB-001 tablets （200mg，single-dose, on the first day）
88882836|NCT06103773|Experimental|SAD-TollB-001 400mg Dosage groups|drug：TollB-001 tablets （400mg，single-dose, on the first day）
88882837|NCT06103773|Experimental|SAD-TollB-001 800mg Dosage groups|drug：TollB-001 tablets （800mg，single-dose, on the first day）
88882838|NCT06103773|Experimental|SAD-TollB-001 1000mg Dosage groups|drug：TollB-001 tablets （1000mg，single-dose, on the first day）
88882839|NCT06103773|Experimental|MAD- TollB-001 100mg Dosage groups|drug：TollB-001 tablets （100mg，Multiple-dose, once per day for 5 days）
88882840|NCT06103773|Experimental|MAD- TollB-001 200mg Dosage groups|drug：TollB-001 tablets （200mg，Multiple-dose, once per day for 5 days）
88882841|NCT06103773|Experimental|MAD-TollB-001 400mg Dosage groups|drug：TollB-001 tablets （400mg，Multiple-dose, once per day for 5 days）
88882842|NCT06103773|Experimental|MAD-TollB-001 800mg Dosage groups|drug：TollB-001 tablets （800mg，Multiple-dose, once per day for 5 days）
88882843|NCT06103773|Experimental|FE-Low Dosage groups|drug：TollB-001 tablets（Subjects in the fasting-fed sequence group will be administered with TollB-001 under fasting condition in the first period and under fed condition in the second period; subject in the fed-fasting sequence group will be administered with TollB-001 under fed condition in the first period and under fasting condition in the second period. The two periods of cross-administration will have a washout period of 5-10 days）
89406851|NCT05716178|Experimental|Maternal health education|participants in the intervention group will receive behavioral change communication on maternal health from trained religious leaders. The local religious leaders from each clustered kebele will be recruited based on religious educational status (educational status greater than or equal to diploma), acceptance by their followers and popularity, in collaboration with religious organization leaders, health extension workers, and kebele leaders. Then after the potential religious leaders are recruited, the two days training will be given for them. Recruited religious leaders are expected to give training on the topics (maternal health) for four sessions to promote healthy maternal behaviors for the members of their religion. After training sessions, every participant will receive a copy of the visual materials (posters) containing the key messages for promoting prenatal health behaviors.
89406852|NCT05716178|No Intervention|Usual or routine care|The control group in this study will be on the existing routine maternal service without a provision of religious leaders' training intervention. In this arm, there will be no intervention by the researchers, rather baseline and end line data will be collected.
89406853|NCT02103582|Placebo Comparator|control|Participants who are randomized to the 'control arm' will be asked to maintain their current daily activities for 12 weeks. They will also be required to visit the study site 3 times per week for 12 weeks to view videos on different wellness topics. Control participants will have anthropometric measurements of weight, height, hip size and waist size taken at the beginning of the study, 6 weeks, and at 12 weeks. Control participants will also have a fitness test on a treadmill, full body scan, blood pressure, heart rate and questionnaires given at the beginning of the study, 6 weeks and at 12 weeks.
89406854|NCT02103582|Experimental|intervention|Participants who are randomized to the 'intervention arm' will be asked to come to the study site to exercise 3 days per week for 12 weeks. The exercise duration will increase over time from 75 minutes per week to 150 minutes per week. Intervention participants will have anthropometric measurements of weight, height, hip size and waist size taken at the beginning of the study, 6 weeks, and at 12 weeks. Intervention participants will also have a fitness test on a treadmill, full body scan, blood pressure, heart rate and questionnaires given at the beginning of the study, 6 weeks and at 12 weeks.
89406855|NCT00052598|Experimental|Treatment (adoptive immunotherapy)|Patients receive allogeneic CD8+ PR3-specific CTLs IV over 1-2 hours on days 0, 7, 14, 28, and 49 and aldesleukin SC twice daily on days 28-41 and 49-63 in the absence of unacceptable toxicity.
89406856|NCT05037994|Placebo Comparator|Control Group (C Group)|Patients will receive continuous US suprascapular nerve block only.
89406857|NCT05037994|Experimental|Gabapentin Group (G Group)|Patients will receive continuous US suprascapular nerve block with oral gabapentin 300 mg once daily at bed time.
89406858|NCT03555084|Experimental|Device: Extension of Phonak Virto B-Titanium|The extension of Phonak Virto B-Titanium will be fitted to the participants individual Hearing loss.
89406859|NCT03555084|Active Comparator|Device: Phonak Virto B-Titanium|The Phonak Virto B-Titanium will be fitted to the participants individual Hearing loss.
89406860|NCT03658161|Experimental|CASCADE|Oncology providers will receive the CASCADE coaching intervention.
89406861|NCT00052520|Experimental|Treatment|See Detailed Description
89406862|NCT02098044||Professional footballers|Retired professional footballers
89406863|NCT02098044||Control Population|members of the general public recruited from the east midlands region
89406864|NCT05036434|Experimental|Treatment arm|Pembrolizumab 200mg q 3wks IV / Lenvatinib 20mg daily once PO q 3wks
89191039|NCT02572596|Experimental|rhTPO treatment group|Subject will receive chemotherapy with intermediate-dose CTX 2.5/m2 for 2 days. 10 ug/kg/d of G-CSFwas administered from the WBC was lower than 1×10^9/L following bejing of chemotherapy or no later than day 7after chemotherapy. G-CSF was subcutaneously administered once daily until the stem cell collection was completed. rhTPO was administered 15 000 U/d once daily by subcutaneous injection from day 5-7 after chemotherapy and until the stem cell collection was completed.
89191040|NCT02572596|Active Comparator|non- rhTPO treatment group|Subject will receive chemotherapy with intermediate-dose CTX 2.5/m2 for 2 days. 10 ug/kg/d of G-CSF was administered from the WBC was lower than 1×10^9/L following bejing of chemotherapy or no later than day 7after chemotherapy. G-CSF was subcutaneously administered once daily until the stem cell collection was completed.
89406865|NCT02098122||Tetraplegia|
89406866|NCT02098122||Paraplegia|
89406867|NCT05035186|Experimental|Group 1|Clarithromycin based
89191041|NCT00718614|Other|1|Patients with long standing IDDM (>10 years) and no diabetic retinopathy
89406868|NCT05035186|Experimental|Group 2|Levofloxacin based
89406869|NCT01067469|Experimental|Standard Dose Bevacizumab|Bevacizumab 10 mg/kg by vein (IV) over 90 minutes on Days 1, 15, and 29 of 6 week cycle.
89406870|NCT01067469|Experimental|Low Dose Bevacizumab + Lomustine|Bevacizumab 5 mg/kg IV over 90 minutes on Day 1 and 22 (every 3 weeks) of 6 week cycle. Lomustine starting dose of 75 mg/m2 administered orally at sleep time on Day 3 of every 6 week cycle.
89406871|NCT02098200|Experimental|Percutaneous treatment of TR by TriCinch|Percutaneous treatment of Tricuspid Regurgitation with TriCinch System
89406872|NCT02287532|Experimental|DIABEO software alone|Patient will have an introductory training session in the use of DIABEO by the investigating physician an will return for an on site consultation at 6 mounths (optional), 12 mounths and 24 mounths
89191042|NCT00718614|Other|2|Patients with long standing IDDM (>10 years) and mild non-proliferative diabetic retinopathy
89191043|NCT00718614|Other|3|Patients with long standing IDDM (>10 years) and moderate to severe non-proliferative diabetic retinopathy
89191044|NCT00718614|Other|4|healthy volunteers, matched for age and sex
89191045|NCT04069728|Other|Standard clinic appointment|Patients who undergo a routine clinic outpatient appointment using standard explanation of their fistula with words, diagrams and MRI images, as per Consultant preference
89406873|NCT02287532|Experimental|DIABEO+paramedical telemonitoring|"Patient will have an on site introductory training session in the use of DIABEO, by his/her telemedicine nurse from his/her region. The nurse will then follow up the patient according to a delegated tasks protocol written by the investigating physician with the nurse. Patient will be asked to return to see the investigator at 6 mounths (optional), 12 mounths and 24 mounths"
89406874|NCT02287532|No Intervention|Usual Follow up|Patient will continue his/her usual follow up and return to see the investigator at 6 mounths (optional) and at the one year end of follow up for the study
89406875|NCT02103660|Active Comparator|Depo-Medroxyprogesterone Acetate|Half of women will be randomized to receive Depo-Medroxyprogesterone Acetate injections every 13 weeks
89406876|NCT02103660|Active Comparator|Progestin Implant (Jadelle)|Half of women will be randomized to receive progestin implant.
89406877|NCT03658005||Study cohort|"Adult (>18 years, <90 years) patients admitted and treated for acute myocardial infarction, and whose treatment includes ticagrelor in association with aspirin.~Blood samples will be taken at 3 timepoints between two doses of ticagrelor (taken at 12 hours interval)."
89406878|NCT04704232|Active Comparator|ACD440|Subjects are simultaneously exposed to topical administration of ACD440 in a crossover design in separate locations from the placebo exposure.
89406879|NCT04704232|Placebo Comparator|Placebo|Subjects are simultaneously exposed to topical administration of placebo in a crossover design in separate locations from the ACD440 exposure.
89406880|NCT02098356|Experimental|Low bicarbonate|Low bicarbonate hemodialysis - 30 mEq/L dialysate bicarbonate
89406881|NCT03363256|Experimental|TAU+TES-NAV|Standard outpatient addiction treatment plus Therapeutic Education System adapted for AI/AN
89406882|NCT03363256|Active Comparator|TAU|Standard outpatient addiction treatment
89406883|NCT02101086|Experimental|Autologous Cord Blood Transfusion|Autologous cord blood transfusion 10 mL per kg for anemia
89406884|NCT02101086|Active Comparator|Allogeneic blood transfusion|Allogeneic blood transfusion 10 mL per kg for anemia
89406885|NCT00358982|Experimental|1|
89406886|NCT02101164|Active Comparator|Treatment Group A|1 dose of denosumab every 4 weeks for 2 doses, followed by 1 dose of pamidronate every 4 weeks for 2 doses.
89406887|NCT02101164|Active Comparator|Treatment Group B|1 dose of pamidronate every 4 weeks for 2 doses, followed by 1 dose of denosumab every 4 weeks for 2 doses.
89406888|NCT03657927|Active Comparator|C-MAC Videolaryngoscope|Morbidly obese patients intubated with C-MAC Videolaryngoscope
89406889|NCT03657927|Active Comparator|McGrath MAC Videolaryngoscope|Morbidly obese patients intubated with McGrath MAC Videolaryngoscope
89406890|NCT02098434|Experimental|Montreal Imaging Stress Task|Math task to induce stress response
89406891|NCT03223480|Experimental|EUS-guided gastrojejunostomy|"The procedures would be performed under conscious sedation or monitored anesthesia by a therapeutic gastroscope. The endoscope would be used to reach the site of obstruction. The stricture would be cannulated with a 0.025 or 0.035 guide-wire. The double balloon occluder would then be inserted on guidewire beyond the duodenal-jejunal flexure and the two balloons of the occluder would be inflated. A segment of duodenum/jejunum would then be occluded and saline would be injected. A linear echoendoscope would then be inserted into the stomach to guide insertion of the gastrojejunostomy stent."
89406892|NCT02103738||Arm 1 (Monthly)|0.5 mg intravitreal injections of Ranibizumab monthly for the duration of the study.
89406893|NCT02103738||Arm 2 (Treat and Extend)|Three consecutive months of 0.5 mg Ranibizumab intravitreal injections (Day 1, Month 1, and Month 2). Monthly injections will continue until evidence of disease stability is observed. Specifically, monthly treatment will continue until visual acuity is deemed stable as indicated by a gain in visual acuity of ≤ 3 ETDRS letters from the prior month, no clinical evidence of lesion growth, fluid or blood, and no intraretinal or subretinal fluid on OCT. When this is achieved, the intervals between each subsequent injection will be extended by 2 weeks (intervals of 6 weeks, 8 weeks, 10 weeks, to a maximum of 12 weeks) until clinical or diagnostic evidence of disease instability is observed based on OCT findings and/or BCVA ETDRS.
89406894|NCT02985021|Experimental|Treatment (docetaxel, carboplatin)|"Docetaxel 60 mg/m2 will be administered on Day 1 of each 21-day cycle. Carboplatin Area Under the Curve (AUC) 5 will be administered on Day 1 of each 21-day cycle.~Docetaxel and carboplatin should be administered per institutional guidelines. Treatment will be repeated until disease progression or unacceptable toxicity."
89406895|NCT03902704|Experimental|Cleverscope|Cleverscope is a new videolaryngoscope used for tracheal intubation. in this group we use this device to intubate participants.
89406896|NCT03902704|Active Comparator|Laryngoscope / Videolaryngoscope C-MAC® Storz|in this group we use a standart comercial device for intubation (laryngoscope or C-MAC) to intubate participants
89406897|NCT05714540|Placebo Comparator|Control group|The patients will receive 20 ml 0.9% saline soaked pharyngeal pack inserted in the posterior pharyngeal wall after induction of anesthesia and endotracheal intubation .
88882844|NCT06103773|Experimental|FE-High Dosage groups|drug：TollB-001 tablets Subjects in the fasting-fed sequence group will be administered with TollB-001 under fasting condition in the first period and under fed condition in the second period; subject in the fed-fasting sequence group will be administered with TollB-001 under fed condition in thefirst period and under fasting condition in the second period. The two periods of cross-administration will have a washout period of 5-10 days）
88882845|NCT06103747|Experimental|First group of healthy volunteers|The first group of healthy volunteers, defined by randomization
88882846|NCT06103747|Active Comparator|Second group of healthy volunteers|The second group of healthy volunteers, defined by randomization
88882847|NCT06103695|Other|Vtama|open label Vtama
88882848|NCT06103669|Experimental|Ablative local therapy|Stereotactic ablative radiotherapy (SABR) or interventional radiology (IR) ablation therapy
88882849|NCT06103578||Non-smoker periodontitis|
88882850|NCT06103578||Smoker periodontitis|
88882851|NCT06103578||Control|
88882852|NCT06103565|Other|Active clinical decision support tool for pharmacists|In this single arm, pilot feasibility study, pharmacists with be exposed to a clinical decision support tool to facilitate monitoring adherence to GDMT for patients with heart failure with reduced ejection fraction
88882853|NCT06103188|Placebo Comparator|Placebo|A 5mg vitamin B12 pill
88882854|NCT06103188|Active Comparator|Diazepam|A 5mg diazepam pill
88882855|NCT06103188|Experimental|Melatonin|A 5mg melatonin pill
88882856|NCT06103006|Experimental|Telerehabilitation Group|Participants in this group will receive telerehabilitation exercises.
88882857|NCT06102408||Patients with only one etiological workup|patients who underwent only one set of exams for etiological investigations of uveitis
88882858|NCT06102408||Patients without diagnostic modification subsequently to the second etiological workup|Patients who underwent a second etiological workup, independently of the results of the fist line investigations, and whose diagnosis was not modified by the second line investigations.
88882859|NCT06102408||Patients with diagnostic modification subsequently to the second etiological workup|Patients who underwent a second etiological workup, independently of the results of the fist line investigations, and whose diagnosis was modified by the second line investigations.
88882860|NCT06101979||Fortiva Tissue Matrix|
88882861|NCT06100497|Experimental|Stage IVB cohort|patients must undergo evaluation after receiving 2 cycles of PD-1 (pembrolizumab, 200mg, IV, Q3W) combined with platinum-based (cisplatin: 75 mg/m2, IV, Q3W) and albumin paclitaxel (260mg/m2, IV, Q3W) treatment (Arm 1 may receive a third cycle of treatment based on tumor regression). if achieving CR/PR on imaging, suitable for surgical treatment, not suitable for surgery or SD/PD patients, subsequent synchronous chemoradiotherapy or synchronous chemoradiotherapy combined with PD-1 (pembrolizumab) treatment (total of no more than 17 cycles).
88882862|NCT06100497|Experimental|Stage III-IVA cohort|patients with stage III and IVA (T3NxM0, T4aNxM0) receive PD-1 (pembrolizumab, 200mg, IV, Q3W) combined with platinum-based chemotherapy (cisplatin: 75 mg/m2, IV, Q3W) and albumin-bound paclitaxel (260mg/m2, IV, Q3W) for 2 cycles. Patients who undergo surgery within 2 weeks based on pathological results are given PD-1 monotherapy maintenance treatment or low-dose radiotherapy followed by PD-1 monotherapy maintenance treatment if they achieve pathological complete response (pCR). Non-pCR patients with positive surgical margins or extracapsular extension after surgery receive PD-1 maintenance treatment after concurrent chemoradiotherapy (up to a maximum of 17 cycles). Patients without high-risk factors receive PD-1 maintenance treatment after radiotherapy (up to a maximum of 17 cycles).
88882863|NCT06097442||Participants with Long-COVID Using Apollo|Participants with long-COVID symptoms who have consented to be part of this study will use an Apollo device according to a suggested schedule pre-set within their Apollo app, which participants can alter as they see fit.
88882864|NCT06097195|No Intervention|Usual Care|Participant has usual care
88882865|NCT06097195|Other|Usual Care + BioEP|Participant has usual care + BioEP algorithm on their EEG
89406898|NCT05714540|Active Comparator|ketamine group|The patients will receive ketamine soaked 50 mg ketamine in 20 ml normal saline soaked pharyngeal pack inserted in the posterior pharyngeal wall after induction of anesthesia and ETT insertion
89406899|NCT05714540|Active Comparator|Magnesium group|The patients will receive 20 mg/kg magnesium sulfate soaked pharyngeal pack inserted in the posterior pharyngeal wall after induction of anesthesia and ETT
89191046|NCT04069728|Experimental|Clinic appointment with 3D model|Patients who undergo a routine clinic outpatient appointment using a 3D printed model to assist explanation of their fistula
89406900|NCT02101242||Orthopedic surgery of the shoulder|Near-infrared spectroscopy (NIRS) can detect fluctuation of regional cerebral oxygen saturation during change from supine position to beach chair position.
89406901|NCT02101242||Gynecological, urological or general surgery|Near-infrared spectroscopy (NIRS) can detect fluctuation of regional cerebral oxygen saturation during change from supine position to Trendelenburg position.
89406902|NCT02101242||Cardiac surgery|Near-infrared spectroscopy (NIRS) can detect fluctuation of regional cerebral oxygen saturation in patients undergoing cardiac surgery with cardiopulmonary bypass (heart-lung machine).
89406903|NCT04385667|Active Comparator|levonorgestrel intrauterine system (LNG-IUD)|"levonorgestrel intrauterine system (LNG-IUD) applied.~Follow up endometrial sampling will be scheduled for all study patients in 3 months manner for at least one year. Specimens will be reviewed by single expert pathologist.~Patients with persistent atypical hyperplasia in specimens done after 6 months of start of therapy will be considered resistant to therapy and hysterectomy will be done.~Primary and secondary outcome data will be collected in tables with the other demographic data. All will be processed in tables for statistical analysis."
89406904|NCT04385667|Active Comparator|Megestrol acetate (MA)|"Megesterol arm will receive 160 mg daily~Follow up endometrial sampling will be scheduled for all study patients in 3 months manner for at least one year. Specimens will be reviewed by single expert pathologist.~Patients with persistent atypical hyperplasia in specimens done after 6 months of start of therapy will be considered resistant to therapy and hysterectomy will be done.~Primary and secondary outcome data will be collected in tables with the other demographic data. All will be processed in tables for statistical analysis."
89406905|NCT02103894|Experimental|[18F]T807 ([18F]MNI-777)|At the [18F]MNI-777 PET imaging visit, subjects will be injected with no more than 10 mCi (370 MBq) of [18F]MNI-777).
89406906|NCT04441346||patients with recent hemodialysis(less than 6 month|
89406907|NCT04441346||patients on hemodialysis more than 6 months and l|
89406908|NCT04441346||patients on hemodialysis more than 5 years|
89406909|NCT03657615|Active Comparator|Control|Hearing Aid Fitting Patients with hearing loss but no tinnitus paired by age and hearing loss degree Hearing aided fitted PET image acquisition before and after 6 months og Hearing aid usage.
89406910|NCT03657615|Experimental|Tinnitus|Hearing Aid Fitting Patients with tinnitus and hearing loss associated Hearing aided fitted PET image acquisition before and after 6 months og Hearing aid usage.
89406911|NCT04413136|Experimental|Web-ORLA|"Administered 90 minutes a day, six days a week ( i.e. nine hours of computer treatment per week) for a total of six weeks.~The participant is presented with 3-5 word (level 1) or 8-10 word (level 2) sentences, depending upon the severity of the aphasia. Each sentence is chosen by the software program at random from a group of 150 sentences. The participant is instructed to look, listen, and point to words spoken by the virtual therapist, read highlighted words aloud, and then read the sentence aloud, both chorally with the virtual therapist and independently."
89406912|NCT04413136|Placebo Comparator|Control|"Administered 90 minutes a day, six days a week ( i.e. nine hours of computer treatment per week) for a total of six weeks.~A commercially available game, Bejeweled 2, by PopCap. Participants use loaned 13-in laptop computers to access the Bejeweled interface, which displays an 8 X 8 grid of gems of varying shapes and colors. The objective is to match three gems of the same color and shape to score points and advance to more difficult levels."
89406913|NCT02101320|No Intervention|Group 1|Patients with a resection of the lesions according to the procedure SNOLL without the use of TReCam.
89191047|NCT00712374|Experimental|Intervention|Children 3 months to 10 years old will receive a treatment dose of SP+AQ on three occasions during the malaria transmission season, delivered by the local health post
89406914|NCT02101320|Experimental|Group 2|Patients with a resection of the lesions according to the procedure SNOLL with the use of TReCam.
89406915|NCT04441424|Experimental|Convalescent plasma group|21 critically-ill COVID-19 patients were given convalescent plasma: 400 ml of convalescent plasma from COVID-19 recovered subjects. The plasma infusion lasts for one hour.
89406916|NCT04441424|Other|Control group|"This group is 28 critically-ill COVID-19 patients who are at the same disease stage to those of experimental group that were treated with conventional therapy without taking convalescent plasma.~The conventional therapy: 400 mg once PO Hydroxychloroquine/day with 250mg once PO Azithromycin."
89406917|NCT03657537|Experimental|Hyperketonemia - Placebo|Participants are randomly assigned to initially receive ketone infusion and then saline infusion
89406918|NCT03657537|Experimental|Placebo - Hyperketonemia|Participants are randomly assigned to initially receive saline infusion and then ketone infusion
89406919|NCT02103972|Placebo Comparator|Maltodextrin|Maltodextrin
89406920|NCT02103972|Active Comparator|GM080|GM080
89531014|NCT02495363||PECS block in additions to general anesthesia|"As standard analgesic protocol participants undergoing mastectomy surgeries under general anesthesia will have an addition of Pectoral Block regional anesthesia.~Following obtaining written informed consent, ultrasound guided PECS Block will be performed by identifying the thoracic muscles, in addition to general anesthesia Following the identification, the investigator will inject the anesthetic solution which will contain the conventional 25 cc of Bupivacaine 0.25-0.5% ."
89191048|NCT02573220|Experimental|Treatment (FOLFIRI and cetuximab)|Patients receive irinotecan hydrochloride IV over 1-2 hours, fluorouracil IV continuously over 46 hours, and leucovorin calcium IV on days 1 and 15. Patients also receive cetuximab IV over 2 hours on days 3 and 15 of course 1 and days 1 and 15 of all subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89406921|NCT04470362|Placebo Comparator|Control group|The control group will receive an isokinetic strengthening program for the quadriceps muscles. Twenty-four strengthening session will be performed using an isokinetic device. The exercise program begins with 60% of the mean peak torque, and the patient reaches this intensity by auditory biofeedback. An increasing dose program will be used in the first 5 sessions (1 set to 5 sets), and a dose of 6 sets will be applied from the sixth to twenty-fourth sessions, with the density rising from 60% to 80% of the mean peak torque according to the patient tolerance. Each set consisted of 5 repetitions of concentric (Con/Ecc) contraction in angular velocities of 30°/second and 120°/second for extensors. This program accomplished significant results in increasing quadriceps power and strength.
89406922|NCT04470362|Experimental|Study group|"Participants in the study group will perform the same exercise parameters used in the control group but in a different manner.~The isokinetic exercise will be done with a closed eye to improve the proprioception function. This exercise will be performed for 6 sets.~Additional training will be performed by the application of three vibrators above and on both sides of the knee joint to improve the function of the Pacinian and Meissner corpuscles which is one of the included receptors in the sensation of the fatigue."
89406923|NCT04607356|Active Comparator|Evidence-informed care|Standardized, evidence based rehabilitation program for lateral epicondylalgia to include: discussion of ergonomics, home exercise program performance, use of any prescribed splint or brace, forearm and shoulder stretches, soft tissue mobilization, and performance of standard resistance exercises.
89406924|NCT04607356|Experimental|Evidence-informed care + Blood Flow Restriction (BFR)|Standardized, evidence based rehabilitation program for lateral epicondylalgia to include: discussion of ergonomics, home exercise program performance, use of any prescribed splint or brace, forearm and shoulder stretches, soft tissue mobilization, and performance of standard resistance exercises with the addition of BFR while performing resistive exercises.
89406925|NCT03530228|Experimental|Treatment A: Tegoprazan (C1)|Tegoprazan QD, oral administration
89406926|NCT03530228|Experimental|Treatment B: Tegoprazan (C1)|Tegoprazan QD, oral administration
89406927|NCT03530228|Experimental|Treatment C: Tegoprazan (C1)|Tegoprazan BID, oral administration
89406928|NCT03530228|Experimental|Group 1: Tegoprazan (C2)|Tegoprazan QD, oral administration, for 7 days
89406929|NCT03530228|Experimental|Group 2: Tegoprazan (C2)|Tegoprazan QD, oral administration, for 7 days
89406930|NCT03530228|Active Comparator|Group 3: Esomeprazole (C2)|Esomeprazole QD, oral administration, for 7 days
89406931|NCT03530228|Experimental|Tegoprazan (C3)|Tegoprazan QD, oral administration
89406932|NCT03554928||Cocaine Dependent|Individuals with cocaine dependence
89406933|NCT03554928||Not Cocaine Dependent|Individuals without cocaine dependence
89406934|NCT01066923|Experimental|Daily ASA, Active cool, Acute ASA|Two weeks of daily aspirin therapy prior to exercise, active cooling following exercise, aspirin immediately post exercise
89406935|NCT01066923|Experimental|Daily ASA, Active cool, Acute placebo|Two weeks of daily aspirin therapy prior to exercise, active cooling following exercise, placebo immediately post exercise
89406936|NCT01066923|Experimental|Daily ASA, Passive cool, Acute ASA|Two weeks of daily aspirin therapy prior to exercise, passive cooling following exercise, aspirin immediately post exercise
89406937|NCT01066923|Experimental|Daily ASA, Passive cool, Acute placebo|Two weeks of daily aspirin therapy prior to exercise, passive cooling following exercise, placebo immediately post exercise
88813590|NCT02469246|Active Comparator|ABC/3TC (Double-Blind)|"ABC/3TC + F/TAF placebo + allowed 3rd ARV agent for 96 weeks~After Week 96, participants will continue to take their blinded study drug and attend visits every 12 weeks until treatment assignments have been unblinded."
88813591|NCT02469246|Experimental|Open-Label F/TAF|After the unblinding visit, in countries where F/TAF FDC is not commercially available, participants (except in certain countries such as the UK) will be given the option to receive open-label F/TAF (200/10 mg or 200/25 mg) FDC and attend study visits every 12 weeks until it becomes commercially available, or until Gilead terminates the study in that country.
88813592|NCT03001427|Experimental|Structured center-based lifestyle intervention|The Structured center-based Lifestyle Intervention (C-LIFE) will include individualized plans for the DASH diet, weight management, and aerobic exercise.
88813593|NCT03001427|Experimental|Standard education and physician advice|The Medical Management with Standardized Education and Physician Advice (SEPA) will consist of encouragement to achieve an ideal body weight and engage in exercise as part of routine counseling in primary care, but no special program will be delivered to enhance the participants' ability to comply with these recommendations.
88813594|NCT01723202|Experimental|Arm A: GSK2118436|Patients receive dabrafenib orally 2 twice a day on days 1-28. Patients with disease progression may cross over to arm II.
89406938|NCT01066923|Experimental|Daily placebo, active cool, Acute ASA|Two weeks of daily placebo prior to exercise, active cooling following exercise, aspirin immediately post exercise
89406939|NCT01066923|Experimental|Daily placebo, active cool, Acute placebo|Two weeks of daily placebo prior to exercise, active cooling following exercise, placebo immediately post exercise
89406940|NCT01066923|Experimental|Daily placebo, Passive cool, Acute ASA|Two weeks of daily placebo prior to exercise, passive cooling following exercise, aspirin immediately post exercise
89191049|NCT00712452|Other|1|systemic lupus erythematosus
89406941|NCT01066923|Placebo Comparator|Daily placebo, Passive cool, Acute placebo|Two weeks of daily placebo prior to exercise, passive cooling following exercise, placebo immediately post exercise
89406942|NCT03530150|Active Comparator|Pirfenidone 600 mg|Burn patients randomly allocated to this group will receive pirfenidone 600 mg orally once per day for 21 days additionally to the coverage of the wound with non-adherent gauzes and bandages. The aforementioned coverings will be changed every 3 or 4 days until a complete re-epithelization is achieved.
89406943|NCT03530150|No Intervention|Usual Care|Burn patients randomly allocated to this group will only be treated by the usual care of our hospital which consists in covering the wound with non-adherent gauzes and bandages. These covering will be changed every 3 or 4 days until a complete re-epithelization is achieved.
89406944|NCT02098590|Experimental|NF54 CPS-immunization challenged by NF135.C10|Subjects will receive CPS-immunization by bites from 3 x 15 NF54 P. falciparum infected mosquitoes under chloroquine prophylaxis. After stopping chloroquine subjects will receive a heterologous malaria challenge infection by exposure to the bites of 5 NF135.C10 P. falciparum infected mosquitoes. Subjects will be treated with Malarone if they develop a malaria infection or on day 28 after challenge infection.
89406945|NCT02098590|Experimental|NF54 CPS-immunization challenged by NF166.C8|Subjects will receive CPS-immunization by bites from 3 x 15 NF54 P. falciparum infected mosquitoes under chloroquine prophylaxis. After stopping chloroquine subjects will receive a heterologous malaria challenge infection by exposure to the bites of 5 NF166.C8 P. falciparum infected mosquitoes. Subjects will be treated with Malarone if they develop a malaria infection or on day 28 after challenge infection.
89406946|NCT02098590|Other|NF54 CPS-immunization challenged by NF54|[Negative control group, to assess effectiveness of CPS-immunization.] Subjects will receive CPS-immunization by bites from 3 x 15 NF54 P. falciparum infected mosquitoes under chloroquine prophylaxis. After stopping chloroquine subjects will receive a homologous malaria challenge infection by exposure to the bites of 5 NF54 P. falciparum infected mosquitoes. Subjects will be treated with Malarone if they develop a malaria infection or on day 28 after challenge infection.
89406947|NCT02098590|Other|Control group challenged by NF135.C10|[Control group] Subjects will receive bites from 3 x 15 uninfected mosquitoes under chloroquine prophylaxis. After stopping chloroquine subjects will receive a malaria challenge infection by exposure to the bites of NF135.C10 P. falciparum infected mosquitoes. Subjects will be treated with Malarone if they develop a malaria infection or on day 28 after challenge infection.
89406948|NCT02098590|Other|Control group challenged by NF166.C8|[Control group] Subjects will receive bites from 3 x 15 uninfected mosquitoes under chloroquine prophylaxis. After stopping chloroquine subjects will receive a malaria challenge infection by exposure to the bites of NF166.C8 P. falciparum infected mosquitoes. Subjects will be treated with Malarone if they develop a malaria infection or on day 28 after challenge infection.
89531015|NCT03121079|Experimental|Interferon alpha group|The patients in arm will be receive interferon alpha injection (3 million U/time)twice a week, as the intervention since the third month after HLA-identical transplantation.
88813595|NCT01723202|Experimental|Arm B: GSK2118436 and GSK1120212|Patients receive dabrafenib orally twice a day and trametinib orally once a day on days 1-28.
88813596|NCT01723202|Other|Correlative Studies|Tumor pharmacodynamics (PD) evaluation,BRAF mutation quantification in circulating plasma DNA,Tumor mutation screening/Mechanisms of Drug Resistance,Predictive Markers of Response (Archival Tumor Block),Pharmacokinetics(PK,Pharmacogenetics (PGx)
88813597|NCT01578317|Experimental|AS03 adjuvanted|Adminsitered day 1, booster at Day 21
88813598|NCT01578317|Experimental|unadjuvanted|Administer day 1 and booster at Day 21
88813599|NCT03406130|Active Comparator|Insignia orthodontic treatment|
88813600|NCT03406130|Experimental|Piezocision-assisted Insignia orthodontic treatment|
88813601|NCT03830216|Experimental|Treatment Arm|Study subjects will administer prandial insulin to manage their diabetes using a connected insulin pen and smartphone app with integrated dose calculator.
88813602|NCT03830216|Sham Comparator|Control Arm|Study subjects will administer prandial insulin to manage their diabetes using an inactive connected insulin pen without smartphone app.
88813603|NCT01726946|Experimental|VX-135 High Dose with ribavirin|12 weeks of a high dose of VX-135 in combination with ribavirin
88882868|NCT06096584|Experimental|Group TIPS|patients will receive double level subsartorial block and suprasartorial LA injection at the level of the distal FT after induction of general anesthesia (GA)
88882869|NCT06096584|Active Comparator|Group Dual|patients will receive double level subsartorial canal block after induction of GA
88882870|NCT06094075|Experimental|DSI-based training group|This group will perform resistance exercises based in their DSI values.
88882871|NCT06094075|Active Comparator|Normal training group|This group will perform a normal, typical resistance exercise program
88882872|NCT06092411|Experimental|CBT for Depression + Bright Light Therapy (CBTD+BLT)|N = 54
88882873|NCT06092411|Active Comparator|CBT for Depression + Placebo Light (CBTD-BLT)|N = 54
88882874|NCT06092411|No Intervention|Waitlist Control (WL)|N = 54
88882875|NCT06090071|Active Comparator|Phyto A+ Brightening Treatment|Phyto A+ Brightening Treatment is a serum comprised of a soothing botanical blend matched with a keratolytic (3% azeleic acid), 2.5% niacinamide, a brightening compound (2 % α-arbutin), and botanical extracts. Product will be topically applied to the assigned side of the face, either left or right side, at Day 0, Day 14, Day 28, Day 42, Day 70, and Day 98.
88882876|NCT06090071|Placebo Comparator|Placebo Moisturizer|Placebo Moisturizer will be topically applied to the assigned side of the face, either left or right side, at Day 0, Day 14, Day 28, Day 42, Day 70, and Day 98.
88882877|NCT06089057|Experimental|Power training and monitored physical activity|This is a 16-week power-training and physical activity-focused intervention that contains in-center and at-home components and motivational coaching. Participants will meet 2-3 times per week for the in-center power training. Participants will also be asked to wear accelerometers at home in order for their physical activity frequency to be measured.
88882878|NCT06089057|Active Comparator|Attention control|This will be the attention control arm that will involve receipt of a physical activity education booklet, use of an accelerometer, and weekly check-in calls. No power training or motivational coaching will be delivered.
88882879|NCT06088563|Active Comparator|Morning injection|EFLUELDA influenza vaccine injection between 07:00 am and 09:00 am.
88882880|NCT06088563|Active Comparator|Evening injection|EFLUELDA influenza vaccine injection between 07:00 pm and 09:00 pm.
88882881|NCT06087991||Quantitative Interviews|Any Castleview patient who participates in this model will be emailed both the Patient Satisfaction Questionnaire Short Form (PSQ 18) and the Government Performance and Results Act surveys after hospital discharge, six months, and at discharge for buprenorphine.
88882882|NCT06087991||Qualitative Interviews|Qualitative interviews among providers, stakeholders and community members associated with Castleview Hospital will be conducted after the model has been deployed. The qualitative interviews will come from The Consolidated Framework for Implementation Research (CFIR) which is a validated tool that was developed that was developed to evaluate implementation studies.
88882883|NCT06087484|Experimental|MIED-I group|Provide standard audio instructions for mindfulness exercises, introduce the nature and law of anxiety, depression and other emotions, the source of anxiety, depression and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and sleep problems.
88882884|NCT06087484|No Intervention|Waitlist control group|
88882885|NCT06086717|Active Comparator|Group A|Kinesio Taping Group
88882886|NCT06086717|Active Comparator|Group B|Dry Needling Group
88882887|NCT06085885||Cochlear implant recipients|This study involves no clinical interventions beyond cochlear implantation that will be already available to participants as part of their routine care pathway. Participants will undergo routine pre- and post-operative assessments as part of usual care.
88882888|NCT06085534|Experimental|LNK01001 Dose A|Participants were randomized to receive LNK01001 capsule dose A BID orally for 12 weeks in Period 1. At Week 13, participants were re-randomized to LNK01001 dose A or B capsule BID orally for 12 weeks in Period 2.
88882889|NCT06085534|Experimental|LNK01001 Dose B|Participants were randomized to receive LNK01001 capsule dose B BID orally for 12 weeks in Period 1. At Week 13, participants were re-randomized to LNK01001 capsule dose A or B BID orally for 12 weeks in Period 2.
88882890|NCT06085534|Placebo Comparator|placebo|Participants were randomized to receive a placebo capsule twice a day (BID) orally for 12 weeks in Period 1. At Week 13 participants were re-randomized to receive LNK01001 capsule dose A or B BID orally for 12 weeks in Period 2.
88882891|NCT06085521|Experimental|LNK01001 Dose A|Participants will receive LNK01001capsule Dose A BID orally for 12 weeks.
88882892|NCT06085521|Experimental|LNK01001 Dose B|Participants will receive LNK01001capsule Dose B BID orally for 12 weeks.
88882893|NCT06085521|Placebo Comparator|placebo|Participants will receive a Placebo capsule BID orally for 12 weeks.
88882894|NCT06074055|Other|Programmed FET Protocol|Patients in this arm of the study will proceed with another programmed FET protocol which involves taking exogenous estrogen by mouth to stimulate the uterine lining to grow and develop. Once the lining has reached ≥ 7 mm and an endometrial pattern of type 1 or type 2, intramuscular progesterone in oil (50mg/ml daily) will be started at 8am on the morning that progesterone is initiated and continued per routine.
89191050|NCT00712452|Other|2|breast cancer
89004527|NCT03738579|Experimental|Next Science Group|Standard of care debridement will be performed as well as irrigation using TorrentX Wound Wash,then BlastX Wound gel will be applied to the wound before covering treatment site with Mepilex foam dressing (no AG component). BlastX will re-applied again mid-week during mid-week dressing change.
89406949|NCT02098590|Other|Control group challenged by NF54|[Control group] Subjects will receive bites from 3 x 15 uninfected mosquitoes under chloroquine prophylaxis. After stopping chloroquine subjects will receive a malaria challenge infection by exposure to the bites of NF54 P. falciparum infected mosquitoes. Subjects will be treated with Malarone if they develop a malaria infection or on day 28 after challenge infection.
89406950|NCT04216264|Other|Response|
89406951|NCT04216264|Other|Non-response|
89406952|NCT03657381|Experimental|F520 0.2mg/kg single-dose|F520 0.2mg/kg single-dose
89406953|NCT03657381|Experimental|F520 1.0mg/kg single-dose|F520 1.0mg/kg single-dose
89406954|NCT03657381|Experimental|F520 3.0mg/kg single-dose|F520 3.0mg/kg single-dose
88813604|NCT01726946|Experimental|VX-135 Low Dose with ribavirin|12 weeks of a low dose of VX-135 in combination with ribavirin
89004528|NCT03726554|Experimental|Comp. Rev. Porous Augmented Glenoid|Subjects with a grossly deficient rotator cuff in need of a reverse shoulder arthroplasty who met the inclusion/exclusion criteria and received the Comprehensive Reverse Porous Augmented Glenoid.
89004529|NCT03726554|Experimental|Comp. Rev. Mini Humeral Tray|Subjects with a grossly deficient rotator cuff in need of a reverse shoulder arthroplasty who met the inclusion/exclusion criteria and received the Comprehensive Reverse Mini Humeral Tray
89004530|NCT03713294|Experimental|Treatment (dexamethasone, elotuzumab, pomalidomide)|Patients receive dexamethasone IV on days 1, 8, 15, and 22 of cycles 1-2 and IV on day 1 and PO on days 8, 15, and 22 of subsequent cycles and elotuzumab IV on days 1, 8, 15, and 22 of cycles 1-2 and day 1 of subsequent cycles. Patients also receive pomalidomide PO on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89004531|NCT03691220|Experimental|Telemetric Intervention Arm|Adolescent with MLVI>2 to receive the telemetric intervention.
89191051|NCT00712452|Other|3|Hodgkin disease
89406955|NCT03657381|Experimental|F520 200mg/times single-dose|F520 200mg/times single-dose
89406956|NCT03657381|Experimental|F520 10mg/kg single-dose|F520 10mg/kg single-dose
89406957|NCT03657381|Experimental|F520 1mg/kg multiple dosing, every 2 weeks|F520 1mg/kg every 2 weeks
89406958|NCT03657381|Experimental|F520 3mg/kg multiple dosing, every 2 weeks|F520 3mg/kg every 2 weeks
89406959|NCT03657381|Experimental|F520 200mg/times multiple dosing, every 2 weeks|F520 200mg/times every 2 weeks
89406960|NCT03657381|Experimental|F520 10mg/kg multiple dosing, every 2 weeks|F520 10mg/kg every 2 weeks
89535620|NCT03317951|Experimental|Novel integrated care concept (NICC)|The care center is at the heart of the NICC structure. It will be available 24/7. It is the core platform to share information for all NICC patients in the care process and serves as integration point between the professional groups. The care center is utilizing the NICC platform for care coordination and patient monitoring. The NICC platform enables patient management from the distance and allows treating physicians to observe and follow the health status of patients daily. Using the NICC tablet, patients provide information from home about their health status. They will receive feedback about their therapy, measurements and reminders and motivation to follow care plans. The communication allows for a regular evaluation of the patient's situation, a review of the therapy and coordination of necessary adjustments with care providers. The general intervention rules are based on the current European Society of Cardiology (ESC) guidelines for treating AF, HF and TRH patients.
89004532|NCT03691220|No Intervention|Standard of Care Arm|Adolescent with MLVI>2 to receive standard of care.
89004533|NCT03605342|Active Comparator|Buprenorphine + CPT-C|Buprenorphine induction and stabilization for all participants (x1 week). Participants will be started at a dose of 2mg/0.5 mg BUP/NLX and this dose will be increased as needed for stabilization of opioid withdrawal symptoms up to 24 mg per day, then CPT-C for 12 weeks.
89191052|NCT04070274|Experimental|New surgery platform for calcaneal surgery|"The lateral position surgical platform for calcaneus surgery is designed with a bottom board, mats in front and at back of calf and thigh, and two sizes of cover plates, using tunnel principle according to physiological curve of lower limbs."
89191053|NCT04070274|Experimental|Traditional lateral platform|"The traditional lateral position makes the surgery platform bread-shaped arch surface by using medical mats and putting lower limbs superimpose on each other"
89406961|NCT03657381|Experimental|F520 3mg/kg multiple dosing, every 3 weeks|F520 3mg/kg every 3 weeks
89406962|NCT03657381|Experimental|F520 200mg/times multiple dosing, every 3 weeks|F520 200mg/times every 3 weeks
89406963|NCT02250846|Experimental|arm a|EGFR exon 19 mutation with EGFR-TKI
89406964|NCT02250846|Experimental|arm b|EGFR exon 21 mutation with EGFR-TKI
89406965|NCT02656797|Experimental|AM-B|Topical Amphotericin-B 0.4% liposomal gel
89406966|NCT02656797|Placebo Comparator|Placebo|Placebo gel preparation
89406967|NCT02101398|Experimental|F7A|Anodal electrode set on the left Broca's area and cathodal electrode set on its right homologue. Active stimulation.
89406968|NCT02101398|Experimental|F7C|Cathodal electrode set on the left Broca's area and anodal electrode set on its right homologue. Active stimulation.
89406969|NCT02101398|Experimental|T5A|Anodal electrode set on the left Wernicke's area and cathodal electrode set on its right homologue. Active stimulation.
89406970|NCT02101398|Experimental|T5C|Cathodal electrode set on the left Wernicke's area and anodal electrode set on its right homologue. Active stimulation.
89406971|NCT02101398|Sham Comparator|Sham|Electrodes set on the left Broca's area and its right homologue or electrodes set on the left Wernicke's area and its right homologue, but no stimulation will be delivered.
89406972|NCT04443244|Experimental|Botulinum Toxin Type A(Botulax®) 24Units|Botulinum Toxin Type A (Botulax®) 24Units total dose administered intramuscularly to the bilateral masseter muscles.
89406973|NCT04443244|Experimental|Botulinum Toxin Type A(Botulax®) 48Units|Botulinum Toxin Type A (Botulax®) 48Units total dose administered intramuscularly to the bilateral masseter muscles.
89406974|NCT04443244|Experimental|Botulinum Toxin Type A(Botulax®) 72Units|Botulinum Toxin Type A (Botulax®) 72Units total dose administered intramuscularly to the bilateral masseter muscles.
89406975|NCT04443244|Experimental|Botulinum Toxin Type A(Botulax®) 96Units|Botulinum Toxin Type A (Botulax®) 96Units total dose administered intramuscularly to the bilateral masseter muscles.
89406976|NCT04443244|Placebo Comparator|Placebo(Normal Saline)|Placebo(Normal saline) administered intramuscularly to the bilateral masseter muscles.
89406977|NCT04383327|Experimental|ParentCorps-Professional Development (PD)|"n = 6 Schools in Kampala, Uganda (Urban) - 90 Teachers, 6 PTAs, 330 Parent-Child Pairs~+ n = 6 Schools in Hoima, Uganda (Rural) - 90 Teachers, 6 PTAs, 330 Parent-Child Pairs"
89406978|NCT04383327|Experimental|ParentCorps-Professional Development (PD) + T-Wellness|"n = 6 Schools in Kampala, Uganda (Urban) - 90 Teachers, 6 PTAs, 330 Parent-Child Pairs~+ n = 6 Schools in Hoima, Uganda (Rural) - 90 Teachers, 6 PTAs, 330 Parent-Child Pairs"
89406979|NCT04383327|No Intervention|Control|"n = 6 Schools in Kampala, Uganda (Urban) - 90 Teachers, 6 PTAs, 330 Parent-Child Pairs~+ n = 6 Schools in Hoima, Uganda (Rural) - 90 Teachers, 6 PTAs, 330 Parent-Child Pairs"
89406980|NCT02101476|Active Comparator|Percocet|Oxycodone/APAP (acetaminophen)
89406981|NCT02101476|Active Comparator|Xartemis|
89406982|NCT02104128|Experimental|Depressed patient given bupropion|All depressed patients will be given open label bupropion
88882895|NCT06074055|Other|Modified Natural FET Protocol|Following development of at least one dominant follicle and endometrial proliferation ≥ 7 mm during cycle monitoring, patient will undergo administration of human chorionic gonadotropin (hCG) trigger shot followed by initiation of vaginal progesterone administration in accordance with institutional protocols.
88882896|NCT06071845|Experimental|Known or Suspected Barrett's Esophagus (Case Arm)|Investigators will follow Cytosponge Cell Collection Kit Instructions for Use to administer and retrieve the Cytosponge device.c. After the sponge is retrieved, it will then be placed in a vial of cell preservative solution (PN DD-13631, Exact Sciences, Madison, WI) and shipped to the Exact Sciences laboratory for further processing and subsequent analysis.
88882897|NCT06071845|Active Comparator|No Known Barrett's Esophagus (Control Arm)|Participants will undergo a diagnostic clinically indicated sedated endoscopy with standard endoscopic equipment.
88882898|NCT06067516||Group CRT-R|If the CRT measured at T1 decreased equal to or more than 25% compared to the CRT measured at T0
88882899|NCT06067516||Group CRT-NR|If the CRT measured at T1 decreased by less than 25% compared to the CRT measured at T0
89406983|NCT02104128|No Intervention|Control pts given no intervention|Control participants will be assessed at the same time points as the depressed group, but will be given no drug
89406984|NCT02919267|Other|Intra-pulmonary pressure determination|A pressure tubing catheter will be connected to the luerlock adaptor of the bronchial blocker (BB) or to the adaptor located on the side of the occluding system mounted at the extremity of the double lumen tube (DLT). The catheter will then be connected to a differential pressure transducer (AD Instruments, Colorado Springs, CO, USA), allowing direct visualisation of the bronchial pressures. Along with intra-bronchial pressure, esophageal pressure will also be measured to eliminate the pressure generated by the positive pressure of the ventilated lung (Adult esophageal balloon catheter, Cooper Surgical, Trumbull, CT, USA). Intra-bronchial pressures will be measured at end-inspiration and end-expiration.
89531016|NCT03120845|Experimental|Post operative Pain in one visit RCT|One visit RCT Ibuprofen for Post operative pain. Take 400 mg every 6 hours, a week after.
89531017|NCT03120845|Experimental|Post operative pain in two-visits RCT|Two visits RCT Ibuprofen for Post operative pain. Take 400 mg every 6-8 hours, a week after.
89531018|NCT02495441||Dribbling group|Any woman who presents with alleged leakage of amniotic fluid. They will under go rapid Immunoassay Tests for the Detection of PROM
89531019|NCT02495129|Experimental|VAY736 lower dose|12 evaluable patients will be enrolled and randomized (at a ratio of 1:1) to receive either a lower dose or a higher dose of the study drug (VAY736)
89531020|NCT02495129|Experimental|VA736 higher dose|12 evaluable patients will be enrolled and randomized (at a ratio of 1:1) to receive either a lower dose or a higher dose of the study drug (VAY736)
89531021|NCT02495051||single group-study|
89406985|NCT02919267|Other|Volume determination|A one-liter bag (Roxon, Etobicoke, ON, Canada) will be filled precisely with 300 mL of air with the use of a calibrated syringe of 3 liters (Hans Rudolph inc, Shawnee, Kansas, United States), through a three-way valve (Hans Rudolph inc, Shawnee, Kansas, United States). Following the filling of the bag, it will be connected to the non-ventilated lumen of the double lumen tube (DLT) or to the bronchial blocker (BB) through the three-way connector. At the end of the observation period, the collector bag will be connected to the calibrated syringe and will emptied from its residual volume.
89406986|NCT04809610|Experimental|Intervention group: Internet attachment-based compassion therapy (iABCT).|The iABCT is a self-applied program based on the attachment theory and the use of compassion meditations. It is composed of 8 modules that have been reformulated to be completely self-applied and include text, images, illustrations, videos, audio with guided meditations, exercises, and homework. Downloadable PDF files will be made available so that users can review them offline. Each module has been optimized to have a duration of 60 and 90 minutes approximately. The entire intervention is estimated to be completed in eight weeks.
89406987|NCT04809610|No Intervention|Control group: Waiting list control group.|Participants in this condition will be informed that they will have access to the intervention at 3 months (after the intervention group).
89406988|NCT03555318|Experimental|Geriatrician + Cardiologist|Patients randomized to a combined ambulatory follow up with a cardiologist and a geriatrician.
89406989|NCT03555318|Active Comparator|Cardiologist|Patients randomized to usual care (ambulatory follow up with a cardiologist).
89406990|NCT04778566||Cologuard Study Group|Within 60 days of their already scheduled screening colonoscopy, participants will provide a stool sample to be tested by a Cologuard screening test kit. Participants will also complete surveys prior to their colonoscopy as well as post colonoscopy.
89406991|NCT02101632|Experimental|Bee Venom|Bee Venom Ointment 0,0005%
89406992|NCT02101632|Placebo Comparator|Vaseline|Vaseline ointment
89406993|NCT04434274||Group A, MPFF-group|MPFF [Detralex®, Servier, France] 1,000 mg OD for 30 days in the postoperative period.
89406994|NCT04434274||Group B|No venoactive drug prescribed in the postoperative period.
89406995|NCT02101710|Experimental|Elantan SR 60 mg fed|Elantan SR 60 mg is orally administered on Day 1 of treatment period 1 for Fed group 2 and on Day 1 of treatment period 2 for Fed group 1.
89406996|NCT02101710|Experimental|Imdur SR 60 mg fed|Imdur SR 60 mg is orally administered on Day 1 of treatment period 1 for Fed group 1 and on Day 1 of treatment period 2 for Fed group 2.
89406997|NCT02101710|Experimental|Elantan SR 60 mg fasted|Elantan SR 60 mg is orally administered on Day 1 of treatment period 1 for Fasted group 2 and on Day 1 of treatment period 2 for Fasted group 1.
88882900|NCT06066905|Experimental|chidamide and azacitidine|
88882901|NCT06049576|Active Comparator|Arm 1 (nivolumab and ipilimumab)|Patients receive nivolumab IV over 30 minutes on day 1 and ipilimumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 3 weeks for cycles 1-4. Beginning cycle 5, patients receive nivolumab over 30 minutes on day 1 of each cycle. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Patients also undergo blood and stool sample collection and undergo CT and/or bone scan and/or MRI on trial.
88882902|NCT06049576|Experimental|Arm 2 (nivolumab, ipilimumab, camu camu)|Patients receive nivolumab IV over 30 minutes on day, ipilimumab IV over 30 minutes on day 1, and camu camu PO QD continuously with each cycle. Cycles repeat every 3 weeks for cycles 1-4. Beginning cycle 5, patients receive nivolumab over 30 minutes on day 1, and camu camu PO QD of each cycle. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Patients also undergo blood and stool sample collection and undergo CT and/or bone scan and/or MRI on trial.
88882903|NCT06044896|Experimental|Supine Positioning|The participant will be in the supine position.
88882904|NCT06044896|Experimental|Body Lateral Positioning|The participant will be in the body lateral position at 30 degrees.
88882905|NCT06044623|Experimental|Lower initial dose of CDK 4/6-inhibitor (vulnerable/frail patient cohort)|-1 level dose reduction as initial dose of either one of the CDK 4/6-inhibitors: Palbociclib 100 mg x 1 for 21 days with 7 days off; or Ribociclib 400 mg x 1 for 21 days with 7 days off; or Abemaciclib 100 mg x 2 daily added to endocrine therapy.
88882906|NCT06044623|Active Comparator|Full initial dose of CDK 4/6-inhibitor (vulnerable/frail patient cohort)|Full initial dose of either one of the CDK 4/6-inhibitors: Palbociclib 125 mg x 1 for 21 days with 7 days off; or Ribociclib 600 mg x 1 for 21 days with 7 days off; or Abemaciclib 150 mg x 2 daily) added to physician's choice endocrine therapy.
88882907|NCT06044623|Other|Full initial dose of CDK 4/6-inhibitor (fit patient cohort)|Full initial dose of either one of the CDK 4/6-inhibitors: Palbociclib 125 mg x 1 for 21 days with 7 days off; or Ribociclib 600 mg x 1 for 21 days with 7 days off; or Abemaciclib 150 mg x 2 daily) added to physician's choice endocrine therapy.
88882908|NCT06044142|Experimental|Group A: Oral Mucositis|Group A will be submitted to photodynamic therapy (Curcumin and red laser, λ450 nm) with 142 J/cm2, 100mW. The number of points will be calculated based on the size of lesion (1 laser shot per cm2 of lesion). The intervention will be repeated daily until cure of the oral mucositis was attained.
89406998|NCT02101710|Experimental|Imdur SR 60 mg fasted|Imdur SR 60 mg is orally administered on Day 1 of treatment period 1 for Fasted group 1 and on Day 1 of treatment period 2 for Fasted group 2.
89406999|NCT02098668||Normal, pathological cycle, infertility|healthy women PCOS Endometriosis hyperprolactinemia fertility treatment
89407000|NCT03529994||Enrollment|
89407001|NCT03878368|Experimental|Intervention|32 participants with moderate osteoarthritis will eat soup with the active ingredient once-a-day for 4 days-a-week for 3 months.
89407002|NCT03878368|Active Comparator|Control|32 participants with moderate osteoarthritis will eat soup without the active ingredient once-a-day for 4 days-a-week for 3 months.
89407003|NCT03529916||CVD subjects|CVD will be defined as >50% stenosis of one or more coronary arteries as assessed by coronary angiography.
89407004|NCT03529916||healthy controls|healthy controls defined as not having stenosis of coronary arteries as assessed by coronary angiography.
89407005|NCT01368900|Experimental|Ulthera System Treatment|Ulthera treatment to the upper face.
89407006|NCT04383808|Experimental|Arm-1|20 participants will be recruited, inject with radiopharmaceutical, and imaged on the 3T PETMR with PET insert.
89407007|NCT04383808|Experimental|Arm-2|20 participants will be recruited from other imaging studies that have been already injected (pre-injected) with a radiopharmaceutical. These subjects wont receive an additional injection of radiopharmaceutical.
89407008|NCT02910063|Experimental|Blinatumomab|Blinatumomab is administered as a continuous intravenous infusion (CIVI). A single cycle of blinatumomab is continuous infusion with step dosing of 9 µg/day x 7 days, 28 µg/day x 7 days, and 112 µg/days until the end of the cycle.
88882909|NCT06044142|Placebo Comparator|Group B: Oral Mucositis|Group B (control group) will be submitted to low level (LL) laser therapy (λ660 nm) with 1J energy per point at 100mW power output for 10 seconds on daily basis until the lesion is clinically cured. The light will be applied perpendicular to the lesion on a continuous mode. The number of points will be calculated similarly as mentioned for patients included in Group A.
89407009|NCT03554694|Experimental|Start with prebiotics|Half of the participants start with prebiotics, followed by a testing period. After a wash-out period they will continue with placebo followed by a testing period.
89407010|NCT03554694|Experimental|Start with placebo|Half of the participants start with placebo, followed by a testing period. After a wash-out period they will continue with prebiotics followed by a testing period.
89407011|NCT04441762|Active Comparator|intravenous|30 mg intravenous ketorolac in 10 ml syringe + 1 mL Normal Saline 9% using an intranasal device (0.5 ml in each nostril).
89407012|NCT04441762|Experimental|Intranasal|30 mg intranasal ketorolac in 1 ml intranasal device (0.5 ml in each nostril) + 10 ml Intravenous Normal Saline 9%.
89407013|NCT02104284|Other|Normal controls, methacholine positive|methacholine and mannitol bronchial challenge tests: Positive methacholine challenge tests in normal controls
89407014|NCT02104284|Other|Normal controls, mannitol|methacholine and mannitol bronchial challenge tests: Positive mannitol challenge tests in normal controls.
89407015|NCT02104284|Active Comparator|Asthma, Methacholine|methacholine and mannitol bronchial challenge tests: Positive methacholine challenge tests in asthmatics
88882910|NCT06043986||Bed bay A|"Time from nurse call system activated by the novel nurse call system to initial response time T1 and time to complete task T2.~Reason for nurse call system activated: Toilet/Pain/Medication/ /Need a nurse/Other"
88882911|NCT06043986||Bed bay B|Time from nurse call system activated by standard system to initial response timeT1 and time to complete task T2.
88882912|NCT06043011||Chronic Lymphocytic Leukemia (CLL)|Patients with CLL receiving systemic treatment (physician's choice)
88882913|NCT06043011||Diffuse Large B-cell Lymphoma (DLBCL)|Patients with DLBCL receiving systemic treatment (physician's choice)
88882914|NCT06043011||Follicular Lymphoma (FL)|Patients with FL receiving systemic treatment (physician's choice)
88882915|NCT06043011||Mantle Cell Lymphoma (MCL)|Patients with MCL receiving systemic treatment (physician's choice)
88882916|NCT06043011||Marginal Zone Lymphoma (MZL)|Patients with MZL receiving systemic treatment (physician's choice)
88882917|NCT06043011||Waldenström's macroglobulinemia (WM)|Patients with WM receiving systemic treatment (physician's choice)
88882918|NCT06038487|Experimental|Test - IL ( Immediate Loading)|The maxillary denture will be immediately connected to the implants on the day of the surgery
89407016|NCT02104284|Active Comparator|Asthma, Mannitol|methacholine and mannitol bronchial challenge tests: Positive mannitol challenge tests in asthmatics
88882919|NCT06038487|Active Comparator|Control - DL ( Delayed Loading)|At the time of surgery, the cover screw will be seated on the implants and the flap will be sutured for a submerged healing. After 3 months of healing the implants will be exposed and connected to the prosthesis following the same prosthetic protocol as the test group.
88882920|NCT06037876|Experimental|IVM (200 µg/kg) + ALB (400 mg)|A single tablet of albendazole (400mg) plus 200 µg/kg of ivermectin, provided as single oral dose.
88882921|NCT06037876|Active Comparator|ALB (400mg)|A single tablet of albendazole (400mg), provided as single oral dose.
88882922|NCT06037590|Experimental|Test 1 - Levodopa Cyclops™ 45 mg|1 pre-filled single-use Levodopa Cyclops™ (= 45 mg levodopa)
88882923|NCT06037590|Experimental|Test 2 - Levodopa Cyclops™ 90 mg|2 pre-filled single-use Levodopa Cyclops™ devices (= 90 mg levodopa)
88882924|NCT06037590|Experimental|Test 3 - Levodopa Cyclops™ 135 mg|3 pre-filled single-use Levodopa Cyclops™ devices (= 135 mg levodopa)
88882925|NCT06037590|Active Comparator|Reference - Inbrija® 84 mg|2 Inbrija® capsules (42 mg levodopa per capsule) from the Arcus® dry powder inhaler
88882926|NCT06032247|Experimental|Unilateral strength training|Resistance training three times per week for 8-weeks on one leg at a time per exercise.
88882927|NCT06032247|Active Comparator|Bilateral strength training|Resistance training three times per week for 8-weeks on both legs at a time per exercise.
88882928|NCT06028802||Visible lesion|Patients where an ischaemic lesion is visible on non-enhanced CT acquired at baseline.
89407017|NCT00337532|Active Comparator|paclitaxel-cisplatin combination regimen|
89407018|NCT02106234|Active Comparator|Control: NO prophylactic iv hydration|"Control group:~Patients having been referred for an elective procedure involving intravascular iodinated contrast material administration and for intravenous prophylactic hydration according to current guidelines (but only those patients with an eGFR ≥30ml/min/1.73m2) will NOT receive the standard intravenous prophylactic hydration treatment with normal saline prescribed."
89407019|NCT02106234|No Intervention|Standard care: prophylactic iv hydration|"Standard care group:~Patients having been referred for an elective procedure involving intravascular iodinated contrast material administration and for intravenous prophylactic hydration according to current guidelines (but only those patients with an eGFR ≥30ml/min/1.73m2) will receive the standard intravenous prophylactic hydration treatment with normal saline as prescribed."
89407020|NCT04433260||Cases|Doctors, nurses and other healthcares ≥ 18 years of age in direct contact with patients potentially infected with COVID-19
89407021|NCT04433260||Internal Control|Healthcare /NHS Administrative staff who are working in the hospital, but not directly in contact with patients potentially infected with COVID-19.
89407022|NCT04433260||Population Control|Non-healthcare/non-NHS academic staff who are not working in the environment where patient exposure is expected.
89407023|NCT04433260||Follow-up cases|Doctors, nurses and other healthcare workers ≥ 18 years of age in direct contact with patients potentially infected with COVID-19 consenting to receive follow-up surveys (n ~ 400)
89407024|NCT04433260||Follow-up controls|Healthcare Administrative staff who are working in the hospital, not at risk of work-related exposure to patients potentially infected with COVID-19 (n~80)
89407025|NCT04453683|Active Comparator|Group I ( Air Q)|nsertion of proper size Air-Q. ILA
89407026|NCT04453683|Active Comparator|Group II (ILMA)|nsertion of proper size ILMA
89407027|NCT02101866|Experimental|Vapendavir 300 mg tablet|Vapendavir 300 mg tablet single dose with up to 7 day washout period followed by two vapendavir 132 mg capsules single dose
89407028|NCT02101866|Experimental|Two Vapendavir 132 mg capsules|Two Vapendavir 132 mg capsules single dose with up to 7 day washout period followed by Vapendavir 300 mg tablet single dose
89407029|NCT02625441|Experimental|Short anti-HER2 treatment|Pertuzumab 840 mg, i.v., then 420 mg i.v., 3-weekly for 3 cycles; Trastuzumab 8 mg/kg, i.v., then 6 mg/kg, 3-weekly for 3 cycles; Docetaxel 75 mg/m2, i.v., 3-weekly for 3 cycles
89407030|NCT02625441|Active Comparator|Standard anti-HER2 treatment|Trastuzumab 8 mg/kg, i.v., then 6 mg/kg, 3-weekly for 3 cycles; Docetaxel 75 mg/m2, i.v., 3-weekly for 3 cycles; Trastuzumab 6 mg/kg, i.v., 3-weekly for for a total duration of one year
89407031|NCT02104362|Other|exclusive single-fraction irradiation|
89407032|NCT04303468|Experimental|GABA|GABA is a nutrient commonly present in our diet in for example tomatoes and potatoes. It is also commercially sold as dietary supplement. A dose of 500 mg, 3 times daily is used
89407033|NCT04303468|Placebo Comparator|Placebo|The placebo consists of capsules containing powdered cellulose.
88882929|NCT06028802||Non-visible lesion|Patients where an ischaemic lesion is not visible on non-enhanced CT acquired at baseline.
88882930|NCT06026436|Experimental|CKD patients|
88882931|NCT06017882||Group A : Usual sleep *2 ; Deprivation *2|V1->V3 id. V4 : Usual sleep and test series (easy; difficult; difficult) V5 : Usual sleep and test series (difficult; easy; easy) V6 : Sleep deprivation and test series (easy; easy; difficult) V7 : Sleep deprivation and test series (difficult; difficult; easy)
88882932|NCT06017882||Group B : Usual sleep ; Deprivation; Deprivation ; Usual sleep|V1->V3 id. V4 : Usual sleep and test series ( difficult; difficult ; easy) V5 : Sleep deprivation and test series (easy; difficult; difficult) V6 : Sleep deprivation and test series (difficult; easy; easy) V7 : Usual sleep and test series (easy ; easy ; difficult)
89407034|NCT03555240||Patient with Rheumatoid Arthritis|Patient with Rheumatoid Arthritis living in the Emilia Romagna Italian region whom samples will be collected for the Biobank creation and Pharmacogenetic analysis
88882933|NCT06017882||Group C : Deprivation; Usual sleep ; Deprivation ; Usual sleep|V1->V3 id. V4 : Sleep deprivation and test series (easy; easy; difficult) V5 : Usual sleep and test series (difficult; difficult; easy) V6 : Sleep deprivation and test series (easy; difficult; difficult) V7 : Usual and test series (difficult; easy; easy)
88882934|NCT06017882||Group D : Deprivation ; Deprivation ; Usual sleep ; Usual sleep|V1->V3 id. V4 : Sleep deprivation and test series (difficult; easy; easy) V5 : Sleep deprivation and test series (easy; difficult; easy) V6 : Usual sleep and test series ( difficult; easy ; easy) V7 : Usual sleep and test series (easy ; difficult; difficult)
88882935|NCT06011798|Active Comparator|Anti-VEGF control arm|Prior to randomization, participants will receive 3 IVT injections of aflibercept over 4-week intervals. Upon randomization, participants will receive 2 mg aflibercept (50 μl of 40 μg/μl solution) IVT on Day 1, Weeks 8, and 16. A sham procedure will also be administered on Day 1.
88882936|NCT06011798|Experimental|foselutoclax arm|Prior to randomization, participants will receive 3 IVT injections of aflibercept over 4-week intervals. Upon randomization, participants will receive 10 μg foselutoclax (50 μl of 0.2 μg/μl solution) IVT on Day 1 and Weeks 8 and 16. 2 mg aflibercept (50 μl of 40 μg/μl solution) will also be administered on Day 1.
88882937|NCT06011291|Experimental|Arm A: SYH2051 monotherapy dose escalation in advanced solid tumors (Phase Ia)|
88882938|NCT06011291|Experimental|Arm B: SYH2051+RT dose escalation in locally advanced head and neck cancer (Phase Ib)|
88882939|NCT06011291|Experimental|Arm C: SYH2051+RT dose expansion in locally advanced head and neck cancer (Phase Ic)|
88882940|NCT06008613|Experimental|Intervention|Electromagnetic guidance and tracking as an adjunct to and confirmed by fluoroscopic imaging to be used with Cook Zenith Flex AAA Endovascular Graft.
88882941|NCT06008158|Experimental|Supportive care (APBI)|Patients undergo APBI QD on consecutive business days for 5 treatments.
88882942|NCT05988710|Experimental|Buccal Buprenorphine 300mcg and oral Placebo|In randomized order (crossover) across 5 laboratory sessions approximately 5 days apart, participants will receive: 1) Buccal buprenorphine 300 mcg and oral placebo, 2) Buccal buprenorphine 600 mcg and oral placebo, 3) Buccal buprenorphine 900 mg and oral placebo, 4) oral immediate-release oxycodone 10mg and oral placebo, or 5) buccal placebo and oral placebo.
88922006|NCT05972174|Experimental|Part A Group 1 Vaccine: mRNA-1018 for H5N8 Dose Level 1|Participants will receive mRNA-1018 for H5N8 at dose level 1 by intramuscular (IM) injection on Day 1 and Day 22.
89407037|NCT03657225|Active Comparator|Mini CPB (ECCO, Sorin, Italy)|Utilization of the mini CPB circuit (Extra Corporeal Circuit Optimized; Phisio, Sorin Group, Italy)
89407038|NCT03657225|Placebo Comparator|Conventional|Use of conventional CPB circuit
89004534|NCT03605342|Active Comparator|Buprenorphine + IDC|Buprenorphine induction and stabilization for all participants (x1 week). Participants will be started at a dose of 2mg/0.5 mg BUP/NLX and this dose will be increased as needed for stabilization of opioid withdrawal symptoms up to 24 mg per day, then IDC for 12 weeks
89004535|NCT03604289|Experimental|Angiotensin-(1-7)|Participants receive intravenous angiotensin-(1-7) at one study visit for 100 minutes total. Angiotensin-(1-7) will be given in escalating doses of 2ng/kg/min, 4ng/kg/min, and 8ng/kg/min. Each of these doses will be infused for 10 minutes. Following the dose escalation, angiotensin-(1-7) will be given at 8ng/kg/min for an additional 70 minutes. Infusion rates will be calculated for each patient based on body mass.
89004536|NCT03604289|Placebo Comparator|Saline|Participants receive intravenous saline at one study visit for 100 minutes total. The volume of saline will match the volume of angiotensin-(1-7) infused. Infusion rates will be calculated for each patient based on body mass. Saline will be given in escalating doses for 10 minutes each and then held for 70 minutes at the highest dose.
89004537|NCT03596450|Experimental|Semaglutide|Participants will receive semaglutide subcutaneously (s.c.) in addition to metformin monotherapy as treatment intensification in the course of routine clinical practice. Participants will be followed for 2 years, regardless of changes in antidiabetic treatment over the course of the study.
89407039|NCT03554538|Experimental|Web app exercises|An evidence based exercise program for the shoulder pain. Web application with multimedia animations with the tailored exercise program for each patient in this group.
89407040|NCT03554538|Active Comparator|Exercises|An evidence based exercise program for the shoulder pain.
89407041|NCT04469738|Experimental|SCS off|
89407042|NCT04469738|Experimental|SCS on|
89407043|NCT04281004|Active Comparator|Amniotic Fluid (AFED)|
89407044|NCT04281004|Placebo Comparator|Saline Solution|
89407045|NCT03656991|Experimental|0 month group|Receive the bicycle intervention at 0 months after enrollment.
89407046|NCT03656991|Experimental|2 month group|Receive the bicycle intervention at 2 months after enrollment.
89407047|NCT03656991|Experimental|4 month group|Receive the bicycle intervention at 4 months after enrollment.
89004538|NCT03596450|Active Comparator|Standard of care|Participants will receive standard of care in addition to metformin monotherapy as treatment intensification in the course of routine clinical practice. Participants will be followed for 2 years, regardless of changes in antidiabetic treatment over the course of the study.
89407048|NCT03656991|Experimental|6 month group|Receive the bicycle intervention at 6 months after enrollment.
89407049|NCT02106312|Other|Radiation|Dose reduction of preoperative radiotherapy in MLS from 50 Gy to 36 GY.
89407050|NCT04469816|Experimental|Behavioral: Family Check-Up 4 Health|Families will receive the FCU4Health program 3 times annually in a health maintenance model. The FCU4Health coordinator reviews the assessment results with the parents, using motivational interviewing strategies to create a tailored plan to address family needs. This plan may include referrals to community resources or parenting modules that focus on family management.
89407051|NCT04469816|Experimental|Control-Services as Usual|"Families will continue with their medical standard of care and referrals for services as appropriate from the healthcare staff in their respective FQHCs or primary healthcare clinics.~Families will receive brochures about the community programs to which families in the FCU4Health arm are referred."
89407052|NCT03841864|Other|Grade 1 Vein Visualization|Visual vein classification grade described as excellent Visualization. Objective vein criteria to be included in this group are vein raised above skin and wider than 1mm. Initial IV placement will be traditional attempt but subsequent attempts will be provider discretion for traditional vs ultrasound guided placement
89407053|NCT03841864|Other|Grade 2A Vein Visualization|Veins that don't fit grade 1 or 2b classification (see respective group descriptions). This groups visual vein classification is described as fair visualization. Initial IV placement will be traditional attempt but subsequent attempts will be provider discretion for traditional vs ultrasound guided placement
89407054|NCT03841864|Other|Grade 2b Vein Visualization|Only faint vein shadow appearance described as poor visualization. Initial IV placement attempt will be ultrasound guided
89407055|NCT03841864|Other|Grade 3 Vein Visualization|No vein visualization. Initial IV placement attempt will be ultrasound guided
89407056|NCT02361801|Active Comparator|Liberal dobutamine group|All patients will receive dobutamine at the cardiopulmonary bypass weaning
89407057|NCT02361801|Active Comparator|Restrictive dobutamine group|Patients will only receive dobutamine if they present clinical signs of cardiogenic shock
89407058|NCT02104440|Experimental|Patients with cytopenia after allo-HSCT|Patients with cytopenia after allo-HSCT
89407059|NCT04469972|Experimental|Implementation in the intervention group|This group of elderly were subjected to a pursed-lip breathing exercise (using a windmill toy), a diaphragmatic breathing exercise and a coughing exercise three times a week (Mondays, Tuesdays and Thursdays) for 12 weeks in groups of 5-6 individuals (2 groups of 6 persons, and 4 groups of 5 persons: 6 groups in total) between 10:00 and 15:30, at the same time of the day for each group in 30-minute sessions. All breathing exercises were taught to the elderly individuals on the first day of implementation and demonstrated again prior to practice by the researcher throughout the implementation phase.
89407060|NCT04469972|No Intervention|Implementation in the control group|None of the elderly in the control group were subjected to breathing exercises. They continued their daily lives as normal.
89407061|NCT03965728|Experimental|BAY1830839 arm|Period 1: Dose 1, Dose 2, Dose 3, Dose 4, Dose 5 and Dose 6, single dose. Period 2: Dose 1, Dose 2 and Dose 3, once daily over 10 days. Dose 4 and Dose 5, twice daily over 10 days. Dose 6, single dose on Day 1, three times daily (TID) for 9 days (Days 2-10).
89407062|NCT03965728|Placebo Comparator|Placebo arm|Placebo tablets matching BAY1830839
89407063|NCT02104518||G6PD testing|Blood samples will be tested for G6PD activity levels
89407064|NCT00337454|Experimental|A1|
89407065|NCT00337454|Experimental|A2|
89407066|NCT00337454|Experimental|A3|
89407067|NCT00337454|Experimental|B1|
89407068|NCT00337454|Experimental|B2|
89407069|NCT00337454|Experimental|B3|
88882943|NCT05988710|Experimental|Buccal Buprenorphine 600mcg and oral Placebo|In randomized order (crossover) across 5 laboratory sessions approximately 5 days apart, participants will receive: 1) Buccal buprenorphine 300 mcg and oral placebo, 2) Buccal buprenorphine 600 mcg and oral placebo, 3) Buccal buprenorphine 900 mg and oral placebo, 4) oral immediate-release oxycodone 10mg and oral placebo, or 5) buccal placebo and oral placebo.
88882944|NCT05988710|Experimental|Buccal Buprenorphine 900mcg and oral Placebo|In randomized order (crossover) across 5 laboratory sessions approximately 5 days apart, participants will receive: 1) Buccal buprenorphine 300 mcg and oral placebo, 2) Buccal buprenorphine 600 mcg and oral placebo, 3) Buccal buprenorphine 900 mg and oral placebo, 4) oral immediate-release oxycodone 10mg and oral placebo, or 5) buccal placebo and oral placebo.
88882945|NCT05988710|Active Comparator|Oral immediate release oxycodone 10mg and buccal placebo|In randomized order (crossover) across 5 laboratory sessions approximately 5 days apart, participants will receive: 1) Buccal buprenorphine 300 mcg and oral placebo, 2) Buccal buprenorphine 600 mcg and oral placebo, 3) Buccal buprenorphine 900 mg and oral placebo, 4) oral immediate-release oxycodone 10mg and oral placebo, or 5) buccal placebo and oral placebo.
88882946|NCT05988710|Placebo Comparator|Oral placebo and buccal placebo|In randomized order (crossover) across 5 laboratory sessions approximately 5 days apart, participants will receive: 1) Buccal buprenorphine 300 mcg and oral placebo, 2) Buccal buprenorphine 600 mcg and oral placebo, 3) Buccal buprenorphine 900 mg and oral placebo, 4) oral immediate-release oxycodone 10mg and oral placebo, or 5) buccal placebo and oral placebo.
88882947|NCT05969808|Active Comparator|control group|"The control group will participate in regular activities and routines typically provided to children with developmental delays. These activities may include general playtime, basic gross motor activities, and free play with toys for 3 times a week for 45mins for 12 weeks. The control group will not receive any specific intervention targeted at improving visual motor integration, manual dexterity, or intra-limb coordination.~Experimental group"
88882948|NCT05969808|Active Comparator|experimental group|The Experimental group will receive the baseline treatment as Control group. Adaptive Physical Activities will perform for to improve Visual Motor Integration 3 times a week for 45mins for 12 weeks. Pre and post assessment will be performed by using box and boll test, box and block test, Discrete Vertical Finger Tapping Test (DVFTT), discrete horizontal finger tapping test and discrete vertical tapping test with ball.
88882949|NCT05965258||Optimize mGDMT|NICM patients referred for mGDMT optimization
88882950|NCT05965258||MitraClip and mGDMT|NICM patients who are fully medically optimized with significant FMR at the time of the baseline CMR and are referred for Mitraclip treatment
88882951|NCT05944770|Active Comparator|Intervention arm|Subjects in the treatment arm will use a DIY portable air cleaner made by attaching a highly effective furnace filter (MERV 13) and carbon absorbent to a box fan.
89407070|NCT02909907|Experimental|150 units of abobotulinumtoxinA|150 units of abobotulinumtoxinA in flexor compartment of dominant arm (75 units in flexor carpi radialis [FCR] and 75 units in flexor carpi ulnaris [FCU]) along with placebo in extensor carpi radialis (ECR) and extensor carpi ulnaris (ECU)
88882952|NCT05944770|Sham Comparator|Control arm|Subjects in the control arm will use a DIY portable air cleaner with a sham filter. All subjects will receive education on air quality, wildfire smoke, and health.
88882953|NCT05936970||Adults diagnosed with RA|Adults diagnosed with RA and with inadequate response or intolerance to at least one bDMARD or tsDMARD and who are planning to initiate a new bDMARD +/- csDMARD or tsDMARD +/- csDMARD treatment
88882954|NCT05936255|Experimental|Give to Others Module|A brief, talk therapy protocol that targets negative interpersonal beliefs (i.e., perceived social disconnection, burdensomeness) using cognitive-behavioral strategies.
88882955|NCT05916885|Experimental|experimental group|an experimental group receiving short-intensity modified CIMT and conventional therapy
88882956|NCT05916885|Active Comparator|control group|a control group receiving conventional therapy alone.
88882957|NCT05916872|Experimental|experimental group|patients in this group will receive contract relax exercises along with EMS
88882958|NCT05916872|Active Comparator|control group|patients in groups B will receive conventional therapy.
89407071|NCT02909907|Experimental|75 units of abobotulinumtoxinA|75 units of abobotulinumtoxinA in FCR and FCU and 25 units in ECR and ECU
88882959|NCT05915247|Placebo Comparator|Placebo (Part 1)|Corresponding volumes of placebo solution according to the dosing cohort administered as a s.c. injection.
89407072|NCT03962842|Experimental|Pilates group|This group is the experimental group. The intervention program consisted on performance Pilates method exercise program during the sessions of Physical Education.
89407073|NCT03962842|No Intervention|Control group|Adolescents assigned to the CG did not receive any structured exercise programme; they just attended their usual Physical Education sessions.
89407074|NCT02104596|Experimental|Xylitol injection|Intraarticular injection of Xylitol
89407075|NCT02104596|Placebo Comparator|Control|
89407076|NCT02106468|Active Comparator|prednisone 50 mg tablet|This group included 15 patients who received prednisone (Delta-cortene Fort®, Lepetit, Carmano, Melano, Italy) at 40mg /day (8 tablets/day in divided dose , 4 tablet at morning and 4 at evening) for 6 weeks then 20mg/day for 2 week then to 10 mg/day for 2 week, and finally to 5 mg /day for the last 2 weeks.
89407077|NCT02106468|Active Comparator|Omega-3 capsules 1000 mg|This group included 15 patients who received Omega-3 soft gelatin capsules 1000 mg (Super Omega; Technopharma, Cairo, Egypt). The patients received instruction to take one capsule three times daily for 3 months.
89407078|NCT03956446|Active Comparator|Doxycycline, Doxy®|Beside symptomatic therapy, patients will receive oral doxycycline 100 mg (Doxy®) twice daily. Patients will answer a questionnaire asking about the presence and frequency of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
89407079|NCT03956446|Other|No antibiotics|Patients will receive symptomatic therapy (paracetamol, Lekadol®, granisetron, Kytril®, metamizol, Analgin®, parenteral hydration with saline). Patients will answer a questionnaire asking about the presence and frequency of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
89407080|NCT03956446|Other|Healthy controls|Patients will be asked to refer a spouse to serve as a control. If unmarried they will be asked to refer a family member or a friend of +/- 5 years to serve as a control. Control subjects will be asked to answer a questionnaire asking about the presence and frequency of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
89407081|NCT03529682|Experimental|Circuit Training Group|Circuit exercise training will be given to the experimental group participants during 10 weeks, 60 minutes in a day and 3 times a week.
89407082|NCT03529682|Other|Control Group|The control group participants will continue to their own previous physiotherapy approaches as the same as minimum 3 times a week and total 3 hours.
89407083|NCT02106624|Experimental|High Nitrogen|In this arm, daily nitrogen supply is as much as 2.5-3.0 g per kilogram (lean mass weight)
89407084|NCT02106624|Active Comparator|conventional nitrogen|In this arm, daily nitrogen supply is 1.2-1.5g per kilogram (lean mass weight) as recommended by ESPEN guideline
89407085|NCT02250768|Experimental|GM-CSF|Injected oocytes were cultured in GM-CSF supplemented media until day of transfer
89407086|NCT00325364|Experimental|1|
89407087|NCT00325364|Active Comparator|2|
89407088|NCT02102178|Experimental|Group 1 (Intensive occupational therapy)|"All patients received pharmacological treatment for pain in accordance with the World Health Organization (WHO)'s analgesic ladder and occupational therapy follow-up, with guidance regarding activities of daily living (ADLs).~They also carried out therapeutic activities such as embroidery onto gauze (tapestry), weaving a scarf on a nail frame and playing dominos."
89407089|NCT02102178|Active Comparator|Group 2 (Regular occupation therapy)|All patients received pharmacological treatment for pain in according to WHO's analgesic ladder and only guidance regarding ADLs from the occupational therapist.
89407090|NCT02651194|Experimental|ABT-493/ABT-530|ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 12 weeks.
89407091|NCT02104674|Placebo Comparator|Placebo|
89407092|NCT02104674|Active Comparator|Singulair (montelukast)|
89407093|NCT02104674|Experimental|lebrikizumab|
89407094|NCT03529604||Oral Cancer group|Patients with pathohistologically diagnosed T1 conventional oral squamous cell carcinoma. The investigators will collect saliva from the mouth floor (saliva sampling), measure SCCA1, SCCA2 and TROP2 using ELISA tests and measure Ap4A levels using HPLC.
89407095|NCT03529604||PMOD group|Patients with clinically diagnosed leukoplakia, erythroplakia and oral lichen planus. The investigators will collect saliva from the mouth floor (saliva sampling), measure SCCA1, SCCA2 and TROP2 using ELISA tests and measure Ap4A levels using HPLC.
89407096|NCT03529604||Control|Age and sex matched subjects. The investigators will collect saliva from the mouth floor (saliva sampling), measure SCCA1, SCCA2 and TROP2 using ELISA tests and measure Ap4A levels using HPLC.
89407097|NCT01917604|Experimental|open exposure and control|● surgically uncover the canine tooth and bone removal exposing the largest diameter of the ectopic canine crown make a window in the palatal soft tissue and bond bracket after 10 days
89407098|NCT01917604|Experimental|closed exposure and control|raising a flap in the area of impacted canine,bonding an attachment and resuturing the flap
89407099|NCT01903330|Experimental|(ERC1671/GM-CSF/Cyclophosphamide)+bevacizumab/bevacizumab biosimilar|"ERC1671 and GM-CSF will be intradermally administered, while cyclophosphamide is orally administered. GM-CSF dose is 500mcg fixed dose and cyclophosphamide dose is 50 mg/day. Bevacizumab or approved bevacizumab biosimilars are administered as standard of care at 10 mg/kg every 2 weeks.~The treatment will be repeated every 28 days until progression of disease or intolerance."
89407100|NCT01903330|Placebo Comparator|(Placebo Injection/Placebo Pill) +Bevacizumab/bevacizumab biosimilar|"The control group will have the same study schedule except that the patients will be receiving the Oral Control on the Cyclophosphamide treatment days and the Injectable control on the GM-CSF + ERC1671 treatment days. The control group will receive bevacizumab or approved bevacizumab biosimilar just as the active treatment group above.~The treatment will be repeated every 28 days until progression of disease or intolerance."
89407101|NCT03529526|Experimental|KN046|
89407102|NCT02102256|Experimental|Experimental|Device Implantation
89407103|NCT02106702|Active Comparator|FAP counseling|Control arm utilizing the standard of care: access to services provided by the Forensic AIDS Project for up to 90 days after release
89407104|NCT02106702|Experimental|Navigator enhanced case-management|Experimental arm: access to Navigator enhanced case-management services for one year after release
89407105|NCT03869632|Experimental|YL-13027|YL-13027 tablets will be given daily for 28 days in 28-day cycles until there appears evidence of progressive disease, intolerable toxicity, or the subject discontinues from the study treatment for other reasons.
89407106|NCT02104908|Experimental|paravertebral nerve|Injection with 20ml 0.5% ropivacaine at lumbar plexus(level L3-4) , 10ml 0.5%ropivacaine at sacral plexus and 10ml 0.5%ropivacaine at paravertebral nerve(level L1)
89407107|NCT02104908|Other|lumbar and sacral plexus block|a lumbar and sacral plexus block(LS) group with 20ml 0.5% ropivacaine at lumbar plexus(level L3-4) and 10ml 0.5%ropivacaine at sacral plexus;
89407108|NCT04366648|Experimental|50mg/m2|Starting dose, administered once only
89407109|NCT04366648|Experimental|75mg/m2|Second dose level, administered at least twice, first two cycles of drug delivery accompanied with PK analyses.
89407110|NCT04366648|Experimental|100mg/m2|Third dose level, administered at least twice, first two cycles of drug delivery accompanied with PK analyses.
89407111|NCT04366648|Experimental|125mg/m2|Forth dose level, administered at least twice, first two cycles of drug delivery accompanied with PK analyses.
89407112|NCT04366648|Experimental|150mg/m2|Fifth dose level, administered at least twice, first two cycles of drug delivery accompanied with PK analyses.
89407113|NCT04366648|Experimental|180mg/m2|Sixth dose level, administered at least twice, first two cycles of drug delivery accompanied with PK analyses.
89407114|NCT04366648|Active Comparator|175mg/m2|CPT-11, given every 14 days, first 2 cycles of drug delivery will accompanied with PK test,
89407115|NCT02106780|Experimental|1: ASP1707|
89407116|NCT02907177|Experimental|Ponesimod|Ponesimod
89407117|NCT02907177|Placebo Comparator|Placebo|Placebo
89407118|NCT04353310|Experimental|Curcumin|
89407119|NCT04353310|Placebo Comparator|Placebo|
89407120|NCT02102334||Unilateral osteoarthritis|Patients operated with a total hip replacement due to unilateral osteoarthritis of the hip. Radiographic measurements of the postoperative radiographs.
89407121|NCT02105064|Active Comparator|Active rTMS|rTMS over Supplementary Motor Area, 1hz, no pauses, 20 minutes per sessions. Total: 20 sessions.
89407122|NCT02105064|Sham Comparator|Sham|Sham stimulation, 20 minutes per session, total 20 sessions
89407123|NCT02652442|Experimental|Centrifugation Parameters|Three experiments were performed to identify optimal centrifugation parameters: (1) distance off-axis (3.5 vs 7 cm); (2) duration (1 min vs 3 mins); (3) schedule (daily vs biweekly). The comparisons were all within subjects; i.e., each subject was tested systematically for each centrifugation parameter under both conditions. The change in the outcome measure SVV (from pre- to post-off-axis rotation) for each condition (e.g., 3.5 vs 7 cm) within a parameter was compared.
89407124|NCT03554460|Experimental|dual-limb NIV|A maximal cycle exercise test with the participants assisted by BiPAP (Servo i, Maquet, Siemens) receiving 10 cmH2O pressure support in addition to oxygen therapy. During the test, breathing pattern, inspiratory flow of the inhalation limb and expiratory flow of the exhalation limb, fractional concentration of inspired CO2 (FiCO2) of the inspiratory line was measured for each breath were recorded.
89407125|NCT02105142|Active Comparator|Computer Decision Support|ADHD Module of the Child Health Improvement through Computer Automation (CHICA) system Designed to facilitate physician adherence to clinical care guidelines for ADHD identification and chronic care management
89407126|NCT02105142|Active Comparator|ADHD Group visits|Parents and children attend separate but concurrently run group visits every three months; groups are facilitated by general pediatricians
89407127|NCT02105142|Active Comparator|ADHD Group Visits plus Online Discussion Portal|Parents and children attend separate but concurrently run group visits every three months; groups are facilitated by general pediatricians. Online discussion portal access granted to parent participants and will allow parents to communicate with each other in between in-person group visits
89407128|NCT03803566|Experimental|Faster|This group will comprise participants who complete the grooved pegboard test at baseline with a time of less than 71 seconds. One half of the members in this group will perform the two interventions in the order of pegboard practice and then force control practice, whereas the other half of the group will perform the two practice interventions in the opposite order.
89407129|NCT03803566|Experimental|Slower|This group will comprise participants who complete the grooved pegboard test at baseline with a time of greater than 70 seconds. One half of the members in this group will perform the two interventions in the order of pegboard practice and then force control practice, whereas the other half of the group will perform the two practice interventions in the opposite order.
89407130|NCT02250924|Placebo Comparator|Placebo|Subjects will wear a silicone bracelet for 30 minutes 3 times daily at 8 am, 12 pm and 4 pm.
89407131|NCT02250924|Sham Comparator|Sugar-less Gum|Subjects will chew one stick of sugar-less gum for 30 minutes 3 times daily at 8 am, 12 pm and 4 pm.
89407132|NCT02250924|Experimental|Caffeinated Gum|Subjects will chew one stick of caffeinated gum (100mg caffeine per stick) for 30 minutes 3 times daily at 8 am, 12 pm and 4 pm.
89407133|NCT03645148|Experimental|iNeo-Vac-P01|"Personal Cancer Vaccine: iNeo-Vac-P01 (peptides)+ GM-CSF;~Peptides: 4 x 100 mcg per peptide given on days 1, 4, 8, 15, 22, 78, and 162 for a total of 7 doses;~GM-CSF: 4 x 40 mcg (total dose 160 mcg) given on days 1, 4, 8, 15, 22, 78, and 162 for a total of 7 doses"
89407134|NCT02251002||Control|no history of TBI or neurologic disorder
89407135|NCT02251002||mTBI|documented past mild to moderate TBI
89407136|NCT02287766||Control|Men and women ages 21-85 lacking any medical diagnosis (as defined in the protocol) of one or more of the following cancer, coronary artery disease or heart attack, renal failure or dialysis, hepatitis, Multiple Sclerosis, or any autoimmune disorder.
89407137|NCT02287766||Metabolic Syndrome Diagnosis Group|Men and women ages 21-85 with at least of at least three of the following (as defined in the protocol) : Elevated waist circumference, elevated triglycerides, reduced HDL cholesterol, elevated blood pressure, elevated fasting glucose.
89407138|NCT04142164|Active Comparator|MacInfo presentation|Patient will get access to an online version of the MacInfo presentation
89407139|NCT04142164|Placebo Comparator|Placebo presentation|Patient will get access to an online version of a placebo presentation
89407140|NCT02251080||Internet-based Survey|Assessments completed over the 2-month study will include: disease severity as measured by DSM-V classification and by several validated measures including the ADHD Rating Scale IV with adult prompts, and Clinical Global Impressions, severity and improvement scales; adherence measures (MEMS® and pill counts); validated medication satisfaction measure (the Treatment Satisfaction Questionnaire for Medication); and quality of life measured using the validated WHO Quality of Life Brief measure (WHOQOL-BREF); and responses to a weekly Internet-based questionnaire of adherence and disease severity.
89407141|NCT02251080||Standard-of-Care|Assessments completed over the 2-month study will include: disease severity as measured by DSM-V classification and by several validated measures including the ADHD Rating Scale IV with adult prompts, and Clinical Global Impressions, severity and improvement scales; adherence measures (MEMS® and pill counts); validated medication satisfaction measure (the Treatment Satisfaction Questionnaire for Medication); and quality of life measured using the validated WHO Quality of Life Brief measure (WHOQOL-BREF);
89407142|NCT05725538|Experimental|COVIDReApp Group|The intervention group will complete a program of exercise guided by a m-health system (COVIDReApp) for 24 weeks.
89407143|NCT05725538|Active Comparator|Control Group|The comparator group will complete a program of exercise in a traditional way (exercises will be provided in paper format) for 24 weeks.
89004539|NCT03581604|Other|Patients labeled as penicillin allergic|Patients labeled as penicillin allergic will be allergologically investigated to confirm/exclude the diagnosis. Allergy work-up will be performed. Blood samples will be obtained.Questionnaire to evaluate the effectiveness of the intervention.
89004540|NCT03579875|Experimental|Treatment Plan 1: TBI 300 with Thymic Shielding, CY, FLU, MP|"Given to:~Patients with an unrelated donor or HLA mismatched related donor, regardless of disease type OR~Patients with an HLA- identical sibling donor recipient and MDS or acute leukemia"
89004541|NCT03579875|Experimental|Treatment Plan 2: CY, FLU and MP|"Given to:~• HLA-identical sibling donor recipients with aplastic anemia"
89004542|NCT03579875|Experimental|Treatment Plan 3: BU, Cy, FLU, MP and Rituximab|"Given to:~Patients with an unrelated donor or HLA mismatched related donor, regardless of disease type who cannot tolerate TBI~Patients with an HLA- identical sibling donor recipient and MDS or acute leukemia who cannot tolerate TBI~Per treating physician preference"
89004543|NCT03570606||HA Paste in Spine|"Evaluation of HA Paste in spinal fusion procedures~o Spinal cage filling"
89407144|NCT04082728|Active Comparator|Metamizole|Patients in the experimental group will be instructed to take metamizole 1000 mg orally three times a day for four days, ibuprofen 600 mg orally three times a day for four days and 1000 mg paracetamol orally four times a day during the entire study period.
89407145|NCT04082728|Placebo Comparator|Placebo|Patients in the experimental group will be instructed to take a placebo orally three times a day for four days, ibuprofen 600 mg orally three times a day for four days and 1000 mg paracetamol orally four times a day during the entire study period.
89407146|NCT02109978||Responders|Patients with Type 2 diabetes that have been taking a second- or third-line glucose-lowering treatment (Sulphonylurea, DPP-4 inhibitors, GLP-1R agonists, SGLT2 inhibitors, Glitazone or insulin) for at least 4 months.
89407147|NCT02109978||Progressors|Patients with Type 2 diabetes that progressed to requiring insulin treatment ≤10 years from diagnosis or have had no requirement for insulin treatment >10 years from diagnosis.
89004544|NCT03570606||HA Paste in long bone & extremities|"Evaluation of HA Paste in long bone and extremity group:~Filling bone defects after cyst removal~Filling distal radius fractures~Filling defects such as tibial plateau fractures~Filling defects created by osteotomy procedures"
89004545|NCT03570606||Granulated Paste in Spine|"Evaluation of Granulated Paste in spinal fusion procedures~o Spinal cage filling"
89407148|NCT02906709|Experimental|Omarigliptin 25 mg|Omarigliptin 25 mg once weekly for 52 weeks (Phase A and B)
89407149|NCT02906709|Experimental|Placebo→Omarigliptin 25 mg|Placebo to Omarigliptin once weekly for 16 weeks (Phase A) switching to Omarigliptin 25 mg once weekly for 36 weeks (Phase B)
89407150|NCT00321308|Active Comparator|B|Standard of care chemotherapy
89407151|NCT00321308|Experimental|A|Standard of care chemotherapy plus experimental intervention (PF-3512676)
89004546|NCT03570606||Granulated Paste in long bone & extremities|"Evaluation of Granulated Paste in long bone and extremity group:~Filling bone defects after cyst removal~Filling distal radius fractures~Filling defects such as tibial plateau fractures~Filling defects created by osteotomy procedures"
89004547|NCT03570606||Granules in Spine|"Evaluation of Granules in spinal fusion procedures~o Spinal cage filling"
89004548|NCT03570606||Granules in long bone & extremities|"Evaluation of Granules in long bone and extremity group:~Filling bone defects after cyst removal~Filling distal radius fractures~Filling defects such as tibial plateau fractures~Filling defects created by osteotomy procedures"
89004549|NCT03570606||Block in long bone & extremities|"Evaluation of Blocks in long bone and extremity group:~o High tibial osteotomies with fixation"
89004550|NCT03451799|Experimental|Ketogenic diet+radiation+temozolomide|Ketogenic diet in combination with standard-of-care radiation and standard-of-care temozolomide
89004551|NCT03451149|Experimental|Intervention|Undergo transjugular intrahepatic portosystemic shunt creation using a radiofrequency wire (Powerwire) in lieu of a trocar needle to cut through liver parenchyma
89004552|NCT03405753|Active Comparator|Aroia|
89004553|NCT03405753|Placebo Comparator|Placebo|
89004554|NCT03405480|Experimental|Rehabilitation|Physiotherapist-supervised outpatient rehabilitation program 2 times a week for a total of 8 weeks.
89004555|NCT03405480|No Intervention|No rehabilitation|Patients will receive usual care, including information pamphlets with information on the disease and the general importance of exercise.
89004556|NCT03396874|Experimental|Patient participants|PET/CT imaging
89004557|NCT03389620|Active Comparator|Transforaminal Cervical Epidural Corticosteroid Injections|
89004558|NCT03389620|Experimental|Lateralized Interlaminar Epidural Corticosteroid Injections|
89004559|NCT03364582||Men-observed dietary pattern|Health Professionals Follow-up Study: a prospective cohort of male health professionals
89004560|NCT03364582||Women-observed dietary pattern|Nurses' Health Study: a prospective cohort of female registered nurses
89004561|NCT03347565||Adolescents with an Eating Disorder|Females between the ages of 14-17 currently diagnosed with an eating disorder (including ARFID, Anorexia Nervosa, Bulimia Nervosa, OSFED)
89004562|NCT03347565||Healthy Controls|Females between the ages of 14-17 with no psychiatric conditions
89004563|NCT03303846|Experimental|Treatment (breast MRI, biopsy)|Participants undergo standard of care high risk breast cancer screening MRIs at baseline and follow-up and blood sample collection at baseline. Participants also undergo collection of breast tissue samples at any breast biopsy or breast surgery.
89004564|NCT03300817|Experimental|Prevention (MUC1 peptide-Poly-ICLC vaccine)|Patients receive MUC1 peptide-Poly-ICLC vaccine SC at weeks 0, 2, and 10.
89004565|NCT03264664|Experimental|E7386 BID|E7386 will be administered as a single agent orally, initially twice daily (BID) continuously in 28 days treatment cycle. The dose will be escalated in cohorts of participants subject to safety data and the absence of DLTs. Based on the emerging data after completion of Dose Escalation Part, identifying MTD or RP2D, or after a decision is made to evaluate more than one potential RP2D level, a Dose Expansion Part will be initiated. Participants will continue to receive study treatment in extension phase until disease progression, development of unacceptable toxicity, withdrawal of consent, or termination of the study program.
89004566|NCT03260712|Experimental|CisGem + pembrolizumab|Patients will be enrolled in the experimental arm and will receive CisGem [25mg/m2 cisplatin + 1000mg/m2 gemcitabine, on days 1 and 8 of a 21 day cycle] plus 200 mg pembrolizumab (fixed dose) on day 1 of a 21 day cycle.
89004567|NCT03255915|Experimental|Arm 1|Arm 1 will receive the Tenofovir Disoproxil Fumarate (TDF)-Emtricitabine (FTC) pod-IVR for Stage 2 followed by the placebo pod-IVR during Stage 3.
89004568|NCT03255915|Experimental|Arm 2|Arm 2 will receive the placebo pod-IVR for Stage 2 followed by the Tenofovir Disoproxil Fumarate (TDF)-Emtricitabine (FTC) pod-IVR during Stage 3.
89004569|NCT03235245|Active Comparator|ARM A: Nivolumab + Ipilimumab|nivolumab 3 mg/kg q3w + ipilimumab 1 mg/kg q3w for 4 injections followed by nivolumab 480 mg IV q4w until completion of 2 years total treatment or progression. Then treatment will be left at the investigator choice and continued until the 2nd progression.
89191054|NCT00718848||1|These are patients treated with conventional hemodialysis (4 hours/session, 3 sessions/week) who convert to incentre nocturnal hemodialysis (8 hours/session, 3 sessions/week).
89191055|NCT00718848||2|These are patients treated with conventional hemodialysis (4 hours/session, 3 session/week) who elect to remain on this dialysis schedule and agree to the study-related investigations at baseline and one year thereafter.
89191056|NCT00618982|Experimental|Sorafenib (Nexavar, BAY43-9006)|Intrapatient dose escalation of sorafenib from 400 mg orally twice daily (bid) for the first cycle, 600 mg bid for the second cycle and 800 mg bid until disease progression, unacceptable toxicity or withdrawal of consent. Dose reductions due to toxicities were allowed.
88882960|NCT05915247|Active Comparator|HER-096 (Part 1)|Single ascending doses of HER-096 up to six dosing cohorts administered as a s.c. injection.
89407152|NCT02110056|Experimental|training + tDCS|Combination of intensive training of visual-spatial abilities (LOCATO task) with transcranial direct current stimulation (tDCS)
89407153|NCT02110056|Sham Comparator|training + sham stimulation|Combination of intensive training of visual-spatial abilities (LOCATO task) with sham stimulation
89407154|NCT03943732|No Intervention|control|Respiratory samples are treated according to routine laboratory testing : culture, immuno assays
89407155|NCT03943732|Experimental|Intervention|Respiratory samples are treated according to routine laboratory testing : culture, immuno assays AND molecular testing (FilmArray PNEU) of the endotracheal aspirate sample 24 hours a day.
89407156|NCT02110134|Experimental|Revlite Laser System with Topical|Revlite Laser System for the Treatment of Melasma and hydroquinone skin care regimen
89407157|NCT02110134|Active Comparator|Topical|Hydroquinone skin care regimen
89407158|NCT03532646|Other|group 1: RYGB|All patients who underwent RYGB and were readmitted to upper endoscopy are getting observed
89407159|NCT03532646|Other|group 2:MGB/OAGB|All patients who underwent MGB/OAGB and were readmitted to upper endoscopy are getting observed
89407160|NCT02110290||Children with Physical Disabilities|This group includes children 8-18 years old participating in an adapted ski/snowboarding program with any type of physical disability, including cerebral palsy, traumatic brain injury, spinal cord injury, and amputation.
89407161|NCT04108546|Experimental|massage-electroacupuncture|Electroacupuncture will be applied throughout the back of the body, upper limbs and ears.Massage will follow the same paths of acupuncture points respectively
89407162|NCT04108546|Active Comparator|Epidural analgesia|Epidural analgesia will be applied using ropivacaine 0.2%, 5-7% ml and Fentanyl 25 mcg
89407163|NCT03529214|Other|Implemented Health Facility|"Health facility that has piloted the Team Birth Project"
89407164|NCT02105220||Obese|"We will enroll patients with BMI≥40 kg/m2 to describe the impact of obesity on chest wall compliance and respiratory mechanics.~Respiratory mechanics assessment: We will assess respiratory mechanics through different end expiratory pressure settings and recording airway and esophageal pressure tracings."
89407165|NCT02105220||Intraabdominal Hypertension|"We will enroll patients with IAP≥12 mmHg to describe the impact of intraabdominal hypertension on chest wall compliance and respiratory mechanics.~Respiratory mechanics assessment: We will assess respiratory mechanics through different end expiratory pressure settings and recording airway and esophageal pressure tracings."
88882961|NCT05915247|Active Comparator|HER-096 (Part 2)|A single dose of HER-096 will be administered as a s.c. injection.
89407166|NCT03877822|Experimental|Habitual activity and 2 days bed rest|Participants will undergo 2 days of habitual activity and 2 days bed rest
89407167|NCT02110446|Experimental|SS-1|SS-1 is composed of the powder of Gan-Lu-Yin, Sang-Ju-Yin and Xuefu-Zhuyu-Decoction with the ratio of 2:1:1. Patients take 6 gram of experiment medicine three times per day.
89407168|NCT02110446|Placebo Comparator|Placebo|The placebo is composed of corn starch, pigment and minimal dose of 1% SS-1. Patients take 6 gram of experiment medicine three times per day.
89407169|NCT03847168|Experimental|KN026|Patient will be intravenously administrated with one dose of KN026. Dosing interval may be adjusted during the study based on emerging data from this trial and/or from other trial.
89407170|NCT02110524|Experimental|CVI Drug Coated Balloon|
88882962|NCT05902546|Experimental|High intensity interval training (group A)|30 Diabetic patients (Type 2 Diabetes Mellitus) will receive high intensity interval training
89407171|NCT02908347|Experimental|MP1032|"Test Product:~100 mg MP1032 (= 2 capsules a 50 mg) are provided orally twice daily for 42 days"
89407172|NCT02908347|Experimental|Placebo|"Placebo to MP1032:~2 capsules of Placebo are provided orally twice daily for 42 days"
88882963|NCT05902546|Experimental|moderate intensity aerobic exercise (group B)|30 Diabetic patients (Type 2 Diabetes Mellitus) will receive moderate intensity aerobic exercise
88882964|NCT05888662|Experimental|Endo-epicardial ablation|
88882965|NCT05888662|Active Comparator|endocardial ablation only|
88882966|NCT05882357|Experimental|Part A|Participants will receive ELX/TEZ/IVA in the morning and IVA in the evening.
89407173|NCT02110602|Experimental|Initial Diet - high in amino acid levels|"Visit 1 (Day 1): Screening Visit~Visit 2 (14-21 days after Visit 1): Begin high amino acid diet~Visit 3 (4 days after Visit 2): Completion of high amino acid diet~Visit 4 (3 days after Visit 3): Begin low amino acid diet~Visit 5 (4 days after Visit 4): Completion of low amino acid diet, completion of study"
89407174|NCT02110602|Experimental|Initial Diet - low in amino acid levels|"Visit 1 (Day 1): Screening Visit~Visit 2 (14-21 days after Visit 1): Begin low amino acid diet~Visit 3 (4 days after Visit 2): Completion of low amino acid diet~Visit 4 (3 days after Visit 3): Begin high amino acid diet~Visit 5 (4 days after Visit 4): Completion of high amino acid diet, completion of study"
89407175|NCT02107170|Experimental|Sevoflurane & remifentanil|sevoflurane at 0.5 to 1.5 minimum alveolar concentrations plus remifentanil (0.1 - 0.5 µg/kg/min) during the surgery.
89407176|NCT02107170|Active Comparator|propofol & remifentanil|propofol (50 - 150 µg/kg/min) plus remifentanil (0.1 - 0.5 µg/kg/min) during the surgery.
88882967|NCT05882357|Experimental|Part B|Participants will receive ELX/TEZ/IVA in the morning and IVA in the evening with the dose(s) to be based on the outcome of Part A.
88882968|NCT05879653|Experimental|MK-3475 and ASG-22CE With Radiation Therapy|
88882969|NCT05878288|Other|Cemiplimab|Cemiplimab 350 mg intravenously every 3 weeks for up to 12 weeks (up to 4 doses), or until unacceptable toxicity, disease progression, or withdrawal of consent.
89407177|NCT03622281|Experimental|Colonoscopists who received quality intervention|
89407178|NCT03622281|No Intervention|Colonoscopists who did not received quality intervention|
89407179|NCT00313196|No Intervention|1|
88882970|NCT05877586|Experimental|Caregivers using CLARE app|Caregiver participants in the study
89407180|NCT00313196|Experimental|2|
89407181|NCT02107248|Active Comparator|Sleep position: supine|Subjects will be instructed to sleep in a supine position during the first eight weeks after a total hip replacement following a posterolateral surgical approach
89407182|NCT02107248|Experimental|Sleep position: no restrictions|Patients do not have any restrictions in sleeping position during the first eight weeks after a total hip replacement following a posterolateral surgical approach
89004570|NCT03235245|Experimental|ARM B: Encorafenib + Binimetinib + Nivolumab + Ipilimumab|encorafenib 450 mg QD + binimetinib 45 mg BID orally for 12 weeks followed, after a week of pause, by nivolumab 3 mg/kg q3w + ipilimumab 1 mg/kg q3w for 4 injections, followed by nivolumab 480 mg IV q4w until completion of 2 years total treatment or progression. Then patients will be rechallenged with encorafenib 450 mg QD + binimetinib 45 mg BID orally continuously until the 2nd progression.
89004571|NCT03222492|Experimental|Cohort 1: 0.6 mg/kg brentuximab vedotin|"This is the first of three ascending dose cohorts. Participants in this cohort will receive 0.6 mg/kg brentuximab vedotin (to a maximum dose 60 mg) every 3 weeks from week 0 (initial dose) to week 21, a total of 8 treatments. Brentuximab vedotin will be administered as an intravenous infusion over 30 minutes.~Cohort 1 Randomization schedule: N=6 assigned to brentuximab vedotin: N=2 assigned to placebo."
89004572|NCT03222492|Placebo Comparator|Cohort 1: placebo|"0.6 mg/kg placebo (to a maximum dose 60 mg). Participants in this cohort will receive 0.6 mg/kg placebo every 3 weeks from week 0 (initial dose) to week 21, a total of 8 treatments. Placebo will be administered as an intravenous infusion over 30 minutes.~Cohort 1 Randomization schedule: N=6 assigned to brentuximab vedotin: N=2 assigned to placebo."
89004573|NCT03222492|Experimental|Cohort 2: 1.2 mg/kg brentuximab vedotin|"This is the second of three ascending dose cohorts. Participants in this cohort will receive 1.2 mg/kg brentuximab vedotin (to a maximum dose 60 mg) every 3 weeks from week 0 (initial dose) to week 21, a total of 8 treatments. Brentuximab vedotin will be administered as an intravenous infusion over 30 minutes.~Cohort 2 Randomization schedule: N=6 assigned to brentuximab vedotin: N=2 assigned to placebo."
89191057|NCT02544880|Experimental|Tadalafil plus Vaccine Group (Phase I)|The first 6 participants will be enrolled in the open label Phase I portion of the study and will receive Tadalafil, Anti-mucin 1 (MUC1) Vaccine and the Anti-Influenza Vaccine for 5 courses. A standard of care (SOC) tumor removal surgery will be completed after the completion of Course 1. Course 2 will resume 5-8 weeks after completion of SOC tumor removal surgery.
89191058|NCT02544880|Experimental|Tadalafil plus Vaccine Group (Phase II)|After completion of the Phase I portion of the study, new participants will be enrolled for the randomized, placebo-controlled Phase II. Participants randomized in this group will receive Tadalafil, Anti-MUC1 Vaccine and the Anti-Influenza Vaccine for 5 courses. A standard of care (SOC) tumor removal surgery will be completed after the completion of Course 1. Course 2 will resume 5-8 weeks after completion of SOC tumor removal surgery.
89191059|NCT02544880|Experimental|Tadalafil plus Vaccine Placebo Group (Phase II)|After completion of the Phase I portion of the study, new participants will be enrolled for the randomized, placebo-controlled Phase II. Participants randomized in this group will receive Tadalafil, placebo for the Anti-MUC1 Vaccine and placebo for the Anti-Influenza Vaccine for 5 courses. A standard of care (SOC) tumor removal surgery will be completed after the completion of Course 1. Course 2 will resume 5-8 weeks after completion of SOC tumor removal surgery.
89191060|NCT02544880|Experimental|Tadalafil Placebo plus Vaccine Group (Phase II)|After completion of the Phase I portion of the study, new participants will be enrolled for the randomized, placebo-controlled Phase II. Participants randomized in this group will receive placebo for Tadalafil, the Anti-MUC1 Vaccine and the Anti-Influenza Vaccine for 5 courses. A standard of care (SOC) tumor removal surgery will be completed after the completion of Course 1. Course 2 will resume 5-8 weeks after completion of SOC tumor removal surgery.
89191061|NCT02544880|Other|Control Group|For eligible participants who opt out of receiving study intervention. Participants in this group will receive SOC treatment only.
89191062|NCT00718926||Sjogren|Sjogren syndrome with dry eye
89191063|NCT00718926||non-Sjogren|dry eye without Sjogren syndrome
89191064|NCT00718926||Short-BUT|Dry eye by shortened tear break up time
89004574|NCT03222492|Placebo Comparator|Cohort 2: placebo|"1.2 mg/kg placebo (to a maximum dose 60 mg). Participants in this cohort will receive 1.2 mg/kg placebo every 3 weeks from week 0 (initial dose) to week 21, a total of 8 treatments. Placebo will be administered as an intravenous infusion over 30 minutes.~Cohort 2 Randomization schedule: N=6 assigned to brentuximab vedotin: N=2 assigned to placebo."
89191065|NCT00718926||control|normal patients
89191066|NCT04068870|Experimental|Contraceptive management program|
89191067|NCT04068870|No Intervention|Usual care|
89191068|NCT00719004|Experimental|Normals|Normal volunteers having Ultrasound scan of foot.
89191069|NCT00856648||Group 1|SCI
89191070|NCT00856648||Group 2|Able-bodied
89191071|NCT00719082||AARP Community|Members of AARP Geriatric Community
89191072|NCT00856804|Experimental|1|thalidomide added to peg-interferon + ribavirina
89191073|NCT00712608|Active Comparator|1|Marketed cow's milk-based formula
89191074|NCT00712608|Experimental|2|Cow's milk based formula with prebiotics, different level of fatty acids and fat and a different calcium source
89191075|NCT00712608|Experimental|3|Cow's milk based formula with prebiotic, different level of fatty acids and fat and a different calcium source
89191076|NCT00856882|Experimental|soy protein and isoflavones|
89191077|NCT00856882|Experimental|milk protein and isoflavones|
89191078|NCT00856882|Placebo Comparator|milk protein only|
89191079|NCT00712686|Active Comparator|A1|
89191080|NCT00712686|Active Comparator|B1|
89407183|NCT02983305|Experimental|Retinal Dystrophy|Subjects with retinal dystrophy will have their visual field, gait and self-reported mobility tested at baseline. Subjects will then be fit with a head-mounted display and undergo a brief training with the investigators to learn about use of the device. After a 2 week period of in-home adaptation to the device, their visual field, gait and self-reported mobility will be retested.
89407184|NCT02983305|Experimental|Healthy Age-Matched Controls|Age-matched control subjects without eye disease will have their visual field, gait and self-reported mobility tested at baseline. Control subjects will then be fit with a head-mounted display and undergo a brief training with the investigators to learn about use of the device. After a 2 week period of in-home adaptation to the device, their visual field, gait and self-reported mobility will be retested.
89407185|NCT02110680|Active Comparator|TENS 1|TENS at posterior tibial nerve area
89407186|NCT02110680|Sham Comparator|TENS 2|TENS at shoulder area
89407187|NCT03532568|Experimental|CKD-aP patients|skin biopsy for Klotho and fibroblast growth factor 23 levels in skin tissue and their response to narrow band ultraviolet B
89407188|NCT03532568|Experimental|CKD patients without pruritis|skin biopsy for Klotho and fibroblast growth factor 23 levels in skin tissue
89407189|NCT03532568|Experimental|normal healthy participants|skin biopsy for Klotho and fibroblast growth factor 23 levels in skin tissue
89407190|NCT03656679|Active Comparator|Pectoralis Blockade(PECs)|Participants undergo pectoralis nerve block (PEC II) will received anesthesia between the pectoralis major and minor in the chest while lying flat.
89407191|NCT03656679|Active Comparator|Paravertebral Blockade (PVB)|Participants undergoing paravertebral nerve block (PVB) consisting of receiving anesthesia in the back while sitting upright.
89407192|NCT02110836|Active Comparator|Glucose ingestion|Glucose ingestion during exercise at a rate of 1.8 g/min.
89407193|NCT02110836|Experimental|Sucrose ingestion|Sucrose ingestion during exercise at a rate of 1.8 g/min.
89407194|NCT02110914|Experimental|Coaching|10 coaching sessions over a period of 6 - 9 months. The intervention is life coaching based on principles of the co-active coaching model.
89407195|NCT02110914|No Intervention|Control|Standard care
89407196|NCT02107326|Experimental|Webdia Software use|Use of Webdia Software during 3 months by the patient. Monthly review of blood glucose values by the medical team and automatic adjustment of insulin doses by the team.
89407197|NCT02107326|No Intervention|Observation|No use of the software. No intervention.
89407198|NCT03663166|Experimental|Radiation and Chemotherapy|Thoracic Radiotherapy with cytotoxic platinum based chemotherapy with cytotoxic platinum based chemotherapy including cisplatin and etoposide, carboplatin and paclitaxel or cisplatin and pemetrexed (for patients with non-squamous histology) and Ipilimumab.
88882971|NCT05876273|Experimental|NAP first, then UMPC|Participants will use the Neural Net Artificial Pancreas (NAP) algorithm for 18 hours. Then switch to the University of Virginia Model-Predictive Control (UMPC) for 18 hours.
88882972|NCT05876273|Experimental|UMPC first, then NAP|Participants will use the UMPC for 18 hours, then switch to NAP for 18 hours.
89407199|NCT03663166|Experimental|Nivolumab|Nivolumab 480 mg (30 minute IV infusion) after completion of radiation and chemotherapy for up to 12 cycles until progression.
89407200|NCT02107404|Experimental|DCVAC/PCa Arm|Dendritic Cells DCVAC/PCA Experimental therapy
88882973|NCT05874713|Experimental|Arm A|Eligible subjects who have been randomized to receive aH5N8c on Day 1, Day 22 and Day 202
88882974|NCT05874713|Experimental|Arm B|Eligible subjects who have been randomized to receive aH5N8c on Day 1, aH5N6c on Day 22, and aH5N8c on Day 202
88882975|NCT05874713|Experimental|Arm C|Eligible subjects who have been randomized to receive aH5N6c on Day 1 and aH5N8c on Day 22 and Day 202
88882976|NCT05864950||Young Adults|Young Adults between 20-40 years of age.
88882977|NCT05864950||Middle-Aged Adults|Middle-Aged Adults between 55-69 years of age.
89407201|NCT02107404|No Intervention|Standard Therapy|No Intervention
89407202|NCT03524404|Experimental|Diabetes Prevention Program (DPP)|Live stream the first six sessions of the Diabetes Prevention Program (DPP) curriculum to Senior Planet on a weekly basis, The webinars will be about 1 hour long, led by a certified DPP educator, and live-streamed to the senior center. Participants will have weekly weigh-ins and meet with a research assistant led focus group following two out of the six sessions to discuss program acceptability.
89407203|NCT03529136|Experimental|MSC group 1|Procedure:UC-MSC infusion via peripheral vein. Four times of MSC infusion (1.5x10E6 cells/kg body weight) via peripheral vein will be given to the group 1(once every 4 days).
89407204|NCT03529136|Experimental|MSC group 2|Procedure:UC-MSC infusion via peripheral vein. Two times of MSC infusion (1.5x10E6 cells/kg body weight) via peripheral vein will be given to the group 2(once every 7 days).
89407205|NCT03529136|Experimental|Control group|Control group with standard medical care. UC-MSC infusion could be considering in this group after 24 weeks' followed-up.
89407206|NCT03554304|Experimental|WCK 5222|WCK 5222 IV solution administered as either a 30- or 60-minute IV infusion)
89407207|NCT03554304|Placebo Comparator|Placebo (IV placebo matched toWCK 5222IV solution)|placebo capsule matched to moxifloxacin overencapsulated tablet IV placebo matched to WCK 5222 IV solution
88882978|NCT05864001|Experimental|Intervention|Immediate access to the digital coaching intervention
88882979|NCT05864001|No Intervention|Control|Delayed access to the digital coaching intervention, six months
88882980|NCT05859152|Experimental|ZP Bound Sperm Selection Oocyte Cohort|This is half of the patient's mature oocytes that will be inseminated via the ICSI procedure with sperm that has bound to the ZP of an immature oocyte.
88882981|NCT05859152|Other|Routine Care: Embryologist Selected Sperm Oocyte Cohort|This is half of the patient's mature oocytes that will be inseminated via the ICSI procedure per routine with sperm that is subjectively selected by the embryologist (based on morphology and mobility characteristics). This is the current standard of care for ICSI.
88922007|NCT05972174|Experimental|Part A Group 1 Vaccine: mRNA-1018 for H5N8 Dose Level 2|Participants will receive mRNA-1018 for H5N8 at dose level 2 by IM injection on Day 1 and Day 22.
89407208|NCT03554304|Active Comparator|Moxifloxacin 400-mg|positive control
89407209|NCT03244852||OCD Patients with Deep Brain Stimulators|Patients with deep brain stimulation for intractable obsessive compulsive disorder (OCD)
89407210|NCT02107716|Experimental|Bicarbonate|Each participant will receive two lidocaine injections on the abdomen with different pH
89407211|NCT02110992|Experimental|Docetaxel + Stereotactic Radiation|Docetaxel 15mg/m2 IV weekly for 3 weeks. SBRT 25-40 Gy in 5 fractions given twice weekly with each treatment separated by > 48 hours.
89407212|NCT03306394|Experimental|S95005|Film-coated tablet containing 15 mg of trifluridine and 7.065 mg of tipiracil hydrochloride, or 20 mg of trifluridine and 9.42 mg of tipiracil hydrochloride, taken orally twice a day at the dose of 35 mg/m²/dose. The treatment is given until progression of disease, unacceptable toxicity, investigator decision, patient refusal or until market authorization or reimbursement has been granted by the relevant Authority of the country where that patient is treated or until trifluridine / tipiracil is available by a doctor's prescription or can be accessed from another source or Sponsor decision.
89407213|NCT02287844|Experimental|XOS group|Subjects consumed 6.64 g of a XOS-enriched compound derived from wheat arabinoxylans (5 g of XOS) everyday for 4 weeks.
89407214|NCT02287844|Experimental|INU-XOS group|Subjects consumed 6.64 g of a mixture containing inulin-type fructans, XOS and maltodextrins (3 g of inulin and 1 g of XOS) everyday for 4 weeks.
89407215|NCT02287844|Active Comparator|Placebo|Subjects consumed 6.64 g of wheat maltodextrins everyday for 4 weeks.
89407216|NCT02105376|Experimental|Trigeminal Nerve Stimulation (TNS)|"TNS active group~TNS will be applied by the external simulator EMS400. The stimulation will be conducted at a frequency of 120 Hz with pulse duration of 200 microseconds. The current intensity will be individually established and should be equivalent to a slight feeling of not painful paresthesia (approximately 0.5-2mA). The stimulus generates a pulse and asymmetric biphasic waveform. Electrodes (25cm2) will be placed on the forehead just above the supraorbital foramen bilaterally."
89407217|NCT02105376|Placebo Comparator|Sham|"TNS sham~The placebo intervention will consist of an initial stimulation until a mild paresthesia is achieved, and then turn off the machine after 60 seconds, after which period there is a tendency of reduction natural feeling secondary to skin sensitization paresthesia."
89407218|NCT02111070|Experimental|ILYANG Inactivated split influenza vaccine|IL-YANG FLU Vaccine Vial INJ 0.5mL by intramuscular injection
89407219|NCT02983227|Experimental|GDC-0853 (200mg BID) Cohort 1|Participants received GDC-0853 orally twice daily (BID) for 52 weeks, after completing 12 weeks in Cohort 1 of Study GA29350. Cohort 1 participants in GA29350 were enrolled with moderate to severe active Rheumatoid Arthritis (RA) and an inadequate response to previous methotrexate (MTX) therapy and then randomized to 12 weeks of GDC-0853 (50 mg daily, 150 mg daily, or 200 mg BID), adalimumab, or placebo.
89407220|NCT02983227|Experimental|GDC-0853 (200mg BID) Cohort 2|Participants received GDC-0853 orally twice daily (BID) for 52 weeks, after completing 12 weeks in Cohort 2 of Study GA29350. Cohort 2 participants in GA29350 were enrolled with moderate to severe active Rheumatoid Arthritis (RA) and an inadequate response to one or two tumor necrosis factor (TNF) inhibitors and methotrexate (MTX) therapy, and then randomized to 12 weeks of GDC-0853 (200 mg BID) or placebo.
89407221|NCT02107794|Active Comparator|Decision Aid|Observation of clinical encounter using the decision aid, via video, audio or written notes.
89407222|NCT02107794|No Intervention|Usual Care|Observations in clinical encounters, either video, audio, or observational notes.
89407223|NCT00311090|Experimental|Idrabiotaparinux|"Idrabiotaparinux sodium , 3.0 mg, once-weekly for 6 months.~In avidin sub-study, participants receive on Day 183, avidin 100 mg or placebo (for avidin) (4 hours after Idrabiotaparinux administration)"
89407224|NCT00311090|Active Comparator|Idraparinux|"Idraparinux sodium, 2.5 mg, once-weekly for 6 months~In avidin sub-study, participants receive on Day 183, placebo (for avidin) (4 hours after Idrabiotaparinux administration)"
89407225|NCT02105532|Active Comparator|Restrictive Transfusion Policy|Participants allocated to this group will be eligible for transfusion once their Hb level is ≤ 8 g/dL after presentation to hospital. The objective for the attending clinician is to maintain the Hb level between 8.1-10 g/dL for the duration of hospital stay.
89407226|NCT02105532|Active Comparator|Liberal Transfusion Policy|Participants allocated to this group will be eligible for transfusion once their Hb level is ≤ 10 g/dL after presentation to hospital. The objective for the attending clinician is to maintain the Hb level between 10.1-12 g/dL for the duration of hospital stay.
88922008|NCT05972174|Experimental|Part A Group 1 Vaccine: mRNA-1018 for H5N8 Dose Level 3|Participants will receive mRNA-1018 for H5N8 at dose level 3 by IM injection on Day 1 and Day 22.
89407227|NCT05622188||Healthy participants|Age of the participants is between 18-40 years, females and males equally distributed
89407228|NCT03554070|Experimental|Infravesical Obstruction|Patients with infravesical obstruction due to BPH (IPSS > 20, Qmax < 10), who underwent Thulium Fiber Laser Enucleation of the Prostate.
89407229|NCT03553992|Experimental|The Put It Out Project (POP-6):|a culturally tailored intervention developed for sexual and gender minority (SGM) young adults on Facebook
89407230|NCT03553992|Experimental|Tobacco Status Project (TSP-6):|the original TSP intervention (non-tailored) delivered to groups of only SGM participants on Facebook
89407231|NCT03815734|No Intervention|control group|Non intervention group
89407232|NCT03815734|Experimental|intervention group|motor imagery group
89407233|NCT02105610|Experimental|volatile anesthetics (desflurane, isoflurane, sevoflurane)|
89407234|NCT02105610|Active Comparator|total intravenous anesthesia|
89407235|NCT02254941||Active comparator: Chemotherapy|Metastatic colon cancer and first line treatment with conventional chemotherapy without monoclonal antibody.
88882982|NCT05845541|Experimental|Technology Supported Meditation|Patient's randomized to the treatment arm will receive technology-based meditation therapy at least three times per week for a minimum of 10 minutes per session. They will participate in sessions throughout the length of their inpatient stay via the iom2 device and the interactive meditation software. Signals from the iom2 are then sent to an App on a phone, tablet or personal computer that generates biofeedback information and allows patients to adjust their breathing based on the feedback. The interactive Meditation programs teach specific breathing, mindfulness and relaxation techniques to increase a person's heart rate variability (HRV). Doing so provides the participant with instantaneous awareness of their nervous system state, which helps them to learn to directly influence their HRV.
88882983|NCT05845541|Active Comparator|Standard Treatment|Patients at St. John's Rehab undergoing rehabilitation are supported by an interprofessional team - including physiatrists, nurses, occupational therapists, speech language pathologists, physical therapists, social workers and psychiatrists. During their inpatient stay, patients receive a wide range of rehabilitation services aimed at addressing their physical, emotional and cognitive care needs. Length of stay for inpatient services ranges between 2 to 12 weeks.
88882984|NCT05838183||OSA group|Sleep detection was performed in OSA patients，And according to the severity of the analysis, obtain the corresponding biological specimens, the relevant detection
88882985|NCT05838183||Interstitial lung disease group|Bronchoscopy was performed to obtain alveolar lavage fluid in ILD patients and lung tissue was obtained for ROSE and NGS in appropriate patients
88882986|NCT05835856|Experimental|NAO robot group|
88882987|NCT05835856|Experimental|Google Nest Hub (2e generation) group|
88882988|NCT05835856|Experimental|Gatebox group|
88882989|NCT05835856|Experimental|CelesTE robot group|
88882990|NCT05835856|Other|Control group|
88882991|NCT05831046|Experimental|Study Arm|Patients who undergo use of the software prior to being re-evaluated by a physician
88882992|NCT05831046|No Intervention|Healthy Control|Patients undergo care without using the software
88882993|NCT05816330|Experimental|Arm 1: 900 mg of L9LS SC|Participants will receive 900 mg of L9LS SC.
88882994|NCT05816330|Placebo Comparator|Arm 2: Placebo (normal saline) SC|Participants will receive placebo of Normal Saline for comparison.
88882995|NCT05802927|Other|Experimental: Diabetes-specific formula|
88882996|NCT05802927|Other|Experimental: Breakfast 1 Noodle Soup|
89407236|NCT02254941||Experimental: Chemotherapy plus mAb|Metastatic colon cancer and first line treatment with conventional chemotherapy plus monoclonal antibody
89407237|NCT02107872|Experimental|dosing cohort 1|Patients will receive REGN1500 or placebo in dosing cohort 1
89407238|NCT02107872|Experimental|dosing cohort 2|Patients will receive REGN1500 or placebo in dosing cohort 2
88882997|NCT05802927|Other|Experimental: Breakfast 2 Glutinous rice|
88882998|NCT05784194|Experimental|Intervention for correct discharge medication list|Identification of potential errors in medication list before discharge, information and actions to delete errors before discharge in collaboration between pharmacist (PhD student, patient and physician) on top of standard care
88882999|NCT05784194|No Intervention|Standard care|Standard care
88883000|NCT05775809||Patients with major depressive disorder|We collect data of patients with major depressive disorder at different point (baseline, 2nd weekend±7days, 6th weekend±14days, 8th weekend±14days, 12th weekend±14days, Week 14-104 Every 4 weekends ± 14 days).
88883001|NCT05770804|Experimental|Intervention group|Face to face group
88883002|NCT05770804|No Intervention|Control Group|Control Group
88883003|NCT05759221|Experimental|Peripheral airway biopsy arm|All patients with clinical and radiological suspicion of sarcoidosis will be submitted to biopsy of peripheral airways (> 6th branching generation).
88883004|NCT05727059|Experimental|HR-PCI patients|Patients undergoing non-emergent, high-risk percutaneous coronary interventions
88883005|NCT05711420|Experimental|Gamification method group|"The group to be trained by gamification method; A gamification application was made every week. Points are given in the table prepared for those who are successful in weekly participation in gamification, coming to the lesson with their homework done, participating in the discussions in the lesson, and in the evaluation at the end of the lesson. Every week, the winner was given a gift. At the end of the lesson, the points in the headings of Leaderboard, Badge and Status, which are the elements of the gamification method, were added weekly. And in the last week, a meeting was held with the students according to all scores and a post-test was applied."
88883006|NCT05711420|Experimental|Flipped learning group|"Before the study, videos were found each week that lecture on the relevant subject, videos were shot on the subject, and the videos were transferred to the students via a platform. At the end of each video, they were told to complete the homework on the subject and come to the lesson.~In the lesson, the lesson was processed with activities according to the videos."
88883007|NCT05711420|No Intervention|Control group|Lessons were taught with traditional learning method.
88883008|NCT05703113|Experimental|Group trained with Web 2.0 tools|Group trained with Web 2.0 tools: Web 2.0 tools were used both while making presentations to the students and at the time of evaluation. Wordaart, google form, padlet, canva, bubbl.us were used in the presentation as Web 2.0 tools. For reviews kahoot, Socrative, Bamboozle, Mentimeter and Who Wants To Be A Millionaire? application is used.
89407239|NCT02107872|Experimental|dosing cohort 3|Patients will receive REGN1500 or placebo in dosing cohort 3
89407240|NCT02107872|Experimental|dosing cohort 4|Patients will receive REGN1500 or placebo in dosing cohort 4
89407241|NCT02107872|Experimental|dosing cohort 5|Patients will receive REGN1500 or placebo in dosing cohort 5
89407242|NCT02111148|Active Comparator|urea and creatinine|urea and creatinine detected in vaginal fluid wash after injecting of 5 ml saline intavaginally
89407243|NCT02111148|Active Comparator|Nitrazine|Biochemical description of Nitrazine in the vaginal wash
89407244|NCT02111148|Active Comparator|saline|5ml saline will be injected in vagina of each patient in both groups within 24 hours of membrane rupture.
89407245|NCT02111226|Active Comparator|Passive SMS Group|Passive SMS messages focused on lifestyle adjustment
89407246|NCT02111226|Experimental|Active SMS Group|Active SMS messages based on hypertension clinical practice guidelines including rational for taking antihypertensive medication and reminders to see the health care practioner if BP is above target.
89407247|NCT02905149|Experimental|Serrato|Standard anesthesia+serratus plane block.
89407248|NCT02905149|Placebo Comparator|Control|Standard anesthesia
89407249|NCT02105844||Atrial Fibrillation|Cohort Study on patients with atrial fibrillation in Switzerland
89407250|NCT03553680|Experimental|Emotion-Focused CBT|Ten CBT sessions with a therapist.
89407251|NCT03553680|No Intervention|Wait List|Three visits for assessments only over the same time period of the Experimental Arm.
89407252|NCT03656913|Experimental|Study Group|Patients will receive both the clinically indicated and extremely low dose CT exams
89407253|NCT02790606|Experimental|Covera(TM) Vascular Covered Stent|Placement of the Covera Vascular Covered Stent following percutaneous transluminal angioplasty (PTA)
89407254|NCT03656523||Acute Coronary Syndrome|Patients with Aute coronary syndrome trated with Percutaneous Coronary Intervention plus Stent implantation and Atrial Fibrillation
89407255|NCT03528980||Bariatric surgery|
89407256|NCT03528980||standard nutritional management|
89407257|NCT02105922|Active Comparator|Heavy Resistance Training|Heavy Resistance Training of the lower extremities three times weekly in combination with two daily 20g whey protein and 10g carbohydrate supplementations for 3 months.
89407258|NCT02105922|Experimental|Light Intensity Training|Home-based Light Intensity Training of the lower extremities three-five times weekly in combination with two daily 20g whey protein and 10g carbohydrate supplementations for 3 months.
89407259|NCT02105922|Active Comparator|Protein Whey|Two daily 20g whey protein and 10g carbohydrate supplementations for 3 months.
89407260|NCT03077620|Experimental|Poor sleep group treatment 1|10mg Suvorexant tablet h.s. for two consecutive nights
89407261|NCT03077620|Placebo Comparator|Poor sleep group control|Participant will receive placebo for two consecutive nights and sleep as normal under the same controlled conditions in a clinical research unit.
89407262|NCT03077620|Placebo Comparator|Good sleep group|Participant will receive placebo for two consecutive nights and sleep as normal under the same controlled conditions in a clinical research unit.
89407263|NCT03077620|Experimental|Poor sleep group treatment 2|20mg Suvorexant tablet h.s. for two consecutive nights
89407264|NCT03656445|Active Comparator|Group A - Tranexamic Acid|1 dose of IV TXA (15mg/kg) in 100-ml normal saline, 10 minutes before incision, administered during the induction of the anesthesia
89407265|NCT03656445|Active Comparator|Group B - Tranexamic Acid|1 dose of IV TXA (15mg/kg) in 100-ml normal saline, 10 minutes before incision and an additional dose of IV TXA (15mg/kg) in 100-ml normal saline 3 hours after skin incision
89407266|NCT03656445|Active Comparator|Group C - Tranexamic Acid|1 dose of IV TXA (15mg/kg) in 100-ml normal saline, before incision and two additional doses of IV TXA (15mg/kg) in 100-ml normal saline 3 and 6 hours after skin incision respectively
89407267|NCT02111304|Active Comparator|Part A (Adults)|In Part A, approximately 170 adult patients with severe dehydrating diarrhea due to cholera will be enrolled and randomized 1:1 to receive iOWH032 500 mg or placebo TID for up to 3 days
88883009|NCT05703113|No Intervention|Control Group|Lessons were taught with traditional learning method.
88883010|NCT05692635|Experimental|Surveillance MRI of the Brain|Brain MRI will be performed as scheduled for up to 14 months or until detection of a brain metastasis, whichever occurs first.
88883011|NCT05686122|Experimental|PainPac|4 behavioral cancer pain intervention sessions delivered by mobile application. Patient-focused intervention. PainPac uses Social Cognitive Theory to promote behaviors to improve pain, self-efficacy for pain management, and pain-related quality of life indices. It also uses real-time data to personalize the intervention and messaging to participants. The app also has interactive components to improve coping skills engagement.
88883012|NCT05686122|No Intervention|PCST-Video|4 behavioral cancer pain intervention sessions delivered by videoconferencing by a pain therapist in the medical center to the patient in their natural environment (e.g., home). Sessions will be scheduled weekly for 45-60 min and mimic in person sessions. PCST-Video session content is matches the PainPac skills modules. PCST-Video participants will complete assessments at the same intervals as PainPac participants.
88883013|NCT05673005|Experimental|MED3000 topical gel treatment|All qualified enrolled patients will receive treatment with MED3000 topical gel on demand through the 12-week follow-up visits.
88883014|NCT05645523|Experimental|Indocyanine green (ICG)|Participants will receive Indocyanine green intraoperatively.
88883015|NCT05635032||IPF|Patients with Idiophatic Pulmonary Fibrosis (IPF), serving as a prototype of a progressive fibroproliferative disorder.
88883016|NCT05635032||Progressive Pulmonary Fibrosis (non-IPF)|Patients with non-IPF interstitial lung diseases, presenting a progressive fibrosing phenotype, or acute exacerbations.
88883017|NCT05635032||Non-Progressive Pulmonary Fibrosis (non-IPF)|Patients with fibrotic non-IPF interstitial lung diseases that are stable during a minimum follow-up of 24 months.
88883018|NCT05621733||ruxolitinib|Patients currently receiving or going to receive Jakavi® treatment according to locally approved label
88883019|NCT05619991|Experimental|Group watching video|For the Educational Video, a scenario appropriate for the age group, about the preparation for the surgery, the operating room environment and the post-operative process will be created by the researchers. Expert opinion will be taken for the suitability of the scenario.
88883020|NCT05619991|Other|Scheduled training group|For the Planned Education, a power point presentation will be prepared by the researchers, appropriate for the age group, about the preparation for the surgery, the operating room environment and the post-operative process, and the patients will be trained before the surgery.
89191081|NCT04041856|Active Comparator|EKC patients|Povidone-iodine 2% eye drop will be prescribed four times a day All patients will learn how to improve the hygiene level in order to reduce transmission
89191082|NCT04041856|No Intervention|Control group|All patients will undergo observational treatments including artificial tear drop and improving hygiene level
89191083|NCT02572518||2 doses of yellow fever vaccine|30 days,1-5 years and 6 years or more after last dose
89191084|NCT00856960|Active Comparator|1|Aliskiren 600 mg
89191085|NCT00856960|Active Comparator|2|Aliskiren 150 mg
89191086|NCT00856960|Active Comparator|3|Losartan 100 mg
89191087|NCT00856960|Placebo Comparator|4|Placebo
89191088|NCT00848380||1|Patients with hypertension and hyperlipidemia and other CV risk factors
89191089|NCT00712764|Active Comparator|1|
89191090|NCT00712764|Placebo Comparator|2|
89191091|NCT00848458|Experimental|Azelaic Acid Iontophoresis|
89191092|NCT00848458|Active Comparator|Azelaic acid topical|
89191093|NCT00578786|Experimental|Ambrisentan|2.5, 5 or 10 mg ambrisentan
89191094|NCT00424255|Experimental|Lapatinib+Chemoradiation|"Adjuvant concurrent chemoradiotherapy plus lapatinib 1500 mg once daily for 6 to 7 weeks, followed by lapatinib 1500 mg once daily for one year.~Chemoradiotherapy=total dose of 66Gy over 6-7 weeks plus cisplatin 100mg/m2 on days 1,2 and 43 of the course of radiotherapy. Lapatinib is also given at 1500 mg once daily for 3-7 days prior to the start of chemoradiotherapy."
89191095|NCT00424255|Placebo Comparator|Placebo+Chemoradiation|"Adjuvant concurrent chemoradiotherapy plus placebo once daily for 6 to 7 weeks, followed by placebo once daily for one year.~Chemoradiotherapy = total dose of 66Gy over 6-7 weeks plus cisplatin 100mg/m2 on days 1,2 and 43 of the course of treatment. Placebo is also given once daily for 3-7 days prior to the start of chemoradiotherapy."
89191096|NCT00852358|Experimental|intrathecal laronidase|The Experimental treatment group will receive study assessments and intrathecal laronidase (1.74 mg laronidase) treatments every 1-3 months beginning at start of study.
89191097|NCT00852358|Other|Control Group|During the first 11 months, the control group will receive study assessments but will be unblinded with no intrathecal treatment or placebo administered. Beginning at month 12, the control group will receive intrathecal laronidase (1.74 mg) treatment every 3 months (months 12, 15, 18, and 21).
89191098|NCT02574156|Experimental|Conventional Group|Patients randomized for Conventional Group will receive insulin infusion of regular insulin (100 UI) in 100 mL of saline in continuous infusion pump for maintenance of blood glucose between 140 mg/dl and 180 mg/dl.
89191099|NCT02574156|Experimental|Moderate Group|Patients randomized for ModerateGroup will receive insulin infusion of regular insulin (100 UI) in 100 mL of saline in continuous infusion pump for maintenance of blood glucose between 100 mg/dl and 130 mg/dl.
89191100|NCT00848692|Experimental|1|Rituximab
89191101|NCT00848692|Placebo Comparator|2|Placebo (saline)
89191102|NCT00712842||1|Patients with non or mild non-proliferative diabetic retinopathy
89191103|NCT00712842||2|Healthy control subjects
89191104|NCT00712998||1|Twenty subjects receiving health check program without X-ray computed tomography examination will be included as the control group.
89191105|NCT00712998||2|Twenty subjects receiving health check program including X-ray computed tomography examination of lung will be included as the treatment group-1.
89191106|NCT00712998||3|Twenty subjects receiving health check program including X-ray computed tomography examination of heart will be included as the treatment group-2.
88813605|NCT02469168|Experimental|ReCell|Allocation of treatments (Recell vs Control) to the INTEGRA™ Meshed Bilayer Wound Matrix (MBWM). Each patient serves as their own control. Their study treatment area will be divided into Area A and Area B. Investigational treatment will be randomly allocated to either Area A or Area B
89191107|NCT00848770|Active Comparator|1, 140 to 160 mmHg|Esmolol, NPS or NOR
89191108|NCT00848770|Active Comparator|2, 161 to 180 mmHg|Esmolol, NPS or NOR
89191109|NCT00848770|Active Comparator|3, 181 to 200 mmHg|Esmolol, NPS or NOR
89191110|NCT04070118||patients with previous cesarean section|presenting to the emergency department with pain, previous cesarean section; Patients measured niche thickness before operation
89191111|NCT00717704|Experimental|1|All participants will receive ixabepilone by vein once every three weeks as well as dasatinib by mouth once daily. All participants will receive the study drugs at a baseline dose. If the side effects are minimal and tolerable, the next cycle of study drugs will be given at same dosage. If side effects are intolerable, then the dose will be lowered.
89191112|NCT00713076|Experimental|1|Polyquaternium-preserved Multi-purpose solution
89191113|NCT00713154|Placebo Comparator|1|Placebo group
89191114|NCT00713154|Active Comparator|2|Control Group
89407268|NCT02111304|Active Comparator|Part B (Pediatric)|"Following completion of Part A, the data and safety monitoring board (DSMB) will review the unblinded data to assess safety and efficacy and conduct a futility analysis prior to proceeding to Part B.~Following the DSMB recommendation of dose and dosing schedule for pediatric patients, Part B will be initiated. Approximately 156 pediatric patients with severe dehydrating diarrhea due to cholera will be enrolled and randomized 1:1 to receive iOWH032 or placebo at the recommended dose and dosing regimen."
89407269|NCT01903486|Other|Prednisone|Prednisone (study medication) at a dose of 40mg for 1 week, then 30mg for 1 week, then 20mg for 1 week, then 10mg for 1 week, and then stop the medication.
89407270|NCT03656289|Experimental|Etonogestrel Contraceptive|Etonogestrel contraceptive implant; consists of a single, radiopaque, rod-shaped implant, containing 68 mg etonogestrel, pre-loaded in the needle of a disposable applicator. The implant must be removed no later than by the end of the third year.
89407271|NCT02106000||Arm 1: Non-pregnant females|Inhalation profiles will be recorded for non-pregnant females
89407272|NCT02106000||Arm 2: Pregnant females|Inhalation profiles will be recorded for the women in the 3rd stage of labour
89407273|NCT02106078|Active Comparator|Level 1|Moderated discussion board only
89407274|NCT02106078|Active Comparator|Level 2|Moderated discussion board plus psychoeducation
89407275|NCT02106078|Active Comparator|Level 3|Moderated discussion board plus psychoeducation plus interactive psychosocial tools
89407276|NCT01883817|Placebo Comparator|Placebo|Corn/soy oil placebo capsules that are similar in shape and color to the DHA capsules given over 10 weeks
89407277|NCT01883817|Experimental|DHA Omega-3|Long-chain omega-3 fatty acid docosahexaenoic acid (DHA) at 1,200 mg/day, 600 mg twice daily for 10 weeks
89407278|NCT00599170|Experimental|Arm 1|Rituximab 375 mg/m2 iv on day 1 q 15 days just prior to CHOP, beginning with cycle 1.
89407279|NCT05128240|Placebo Comparator|Placebo|4x1g corn oil capsules
89407280|NCT05128240|Experimental|Ceto 10|4x1g capsules containing containing broad spectrum marine oil from north atlantic fish
89407281|NCT03656211||Patients with UAVM|"All patients who have been diagnosed with UAVM (symptomatic or non-symptomatic) between January 1, 2000 and March 30, 2017, and confirmed by an imaging examination.~Telephone interview"
89407282|NCT04256434|Experimental|Dinabuphine sebacate|Each subject in cohort 1 will receive 150 mg Dinalbuphine sebacate (75 mg/mL x 2 mL) intramuscularly.
89407283|NCT04256434|Active Comparator|Nalbuphine HCl|Each subject in cohort 2 will receive 20 mg Nalbuphine (20 mg x 1 mL) intramuscularly.
89407284|NCT03553602|Experimental|HDR Brachytherapy + EBRT + STAD|"Day 1: HDR Brachytherapy implant: 2 fractions of 12 Gy to prostate/ proximal SV.~EBRT: 50.4 Gy in 28 fractions to the pelvic lymph nodes +/- para-aortic nodes, with SIB up to 70 Gy to the PET positive lesions.~6 months hormonal therapy(LHRH agonist and antiandrogen [until the end of radiotherapy])"
89407285|NCT03655977|Experimental|Cervical cancer patients|This pilot study includes 25 women with histologically proven advanced stage primary cervical cancer (FIGO stages ≥IB2-IVA), planned for treatment with radio-chemotherapy.
88883021|NCT05619991|No Intervention|Control group|Before the operation, the fear and vital signs of the children in the sample will be evaluated. In the postoperative period, the pain, fear and vital signs of the children in the control group will be recorded and a questionnaire examining the satisfaction status will be applied.
89407286|NCT02588326|Active Comparator|MFF 1, then MFF 2|Mometasone furoate drug formulation (MFF) 1 will be administered by suspension-based nasal spray. After a wash out period then Mometasone furoate drug formulation (MFF) 2 will be administered by suspension-based nasal spray. All formulations will be a 200 mcg single dose.
89407287|NCT02588326|Active Comparator|MFF 2, then MFF 1|Mometasone furoate drug formulation (MFF) 2 will be administered by suspension-based nasal spray. After a wash out period then Mometasone furoate drug formulation (MFF) 1 will be administered by suspension-based nasal spray. All formulations will be a 200 mcg single dose.
88883022|NCT05619874|Experimental|HIFCT-S|For sessions 7 to 14, a concentrated circuit divided into four blocks of three exercises will be carried out, with a duration of 40 seconds per exercise with no rest between them. A rest of 120 seconds will be given at the end of each block, and a rest of the same time at the end of the first set. Two sets will be executed, which will result in a total time of 30 minutes including rest. For sessions 15 to 30, four blocks of two exercises will be performed, with a duration of 60 seconds per exercise, with no rest between them. The rest between blocks will be 120 seconds. Two sets will be performed, for a total time of 30 minutes including breaks. The exercises will be performed at speeds between 35 and 75 bpm. The intensity will be between 80% - 90% (8-9 RPE).
89191115|NCT00620074|Experimental|combination 2|anidulafungin plus voriconazole
89191116|NCT00620074|Experimental|combination 1|anidulafungin plus voriconazole
89191117|NCT01033435||chronic Hemodialysis patients, treated in our unit.|
89407288|NCT02113722|Active Comparator|Left cardiac sympathetic denervation|Left cardiac sympathetic denervation
89407289|NCT02113722|Placebo Comparator|Standard of care|Continuing medical therapy
89407290|NCT03655509|Other|ACTH stimulation test|
89407291|NCT04182802||eosinophilic asthma|
89407292|NCT02111460|Experimental|Radiotherapy|Systemic Chemotherapy Combined with Loco-regional Radiotherapy
89407293|NCT02111460|Active Comparator|Chemotherapy|Chemotherapy alone without Loco-regional Radiotherapy
89407294|NCT02111538||Amyloidosis|Consecutive adult patients affected by systemic immunoglobulin light-chain (AL) amyloidosis
89407295|NCT02982213|No Intervention|No companion present|No companion is present during the placement of the epidural catheter.
89407296|NCT02982213|Active Comparator|Companion present|A companion will be present during the placement of the epidural catheter.
89407297|NCT05403424||Group 1: Pregnant women with pelvic girdle pain|This group will consist of pregnant women diagnosed with pelvic girdle pain.
89407298|NCT05403424||Group 2: Pregnant women without pelvic girdle pain|This group will consist of pregnant women who do not have pelvic girdle pain.
89407299|NCT05403424||Group 3: Non-pregnant women|This group will consist of non-pregnant women.
89407300|NCT02111616|Active Comparator|Standard of Care (SCP)|Patient will attend a transition visit at the conclusion of cancer treatment. Patient will receive an individualized cancer survivorship care plan based on their cancer type and treatment.
89407301|NCT02111616|Experimental|Intervention Arm (SCP + PCP visit)|"Patient will attend a transition visit at the conclusion of cancer treatment. Patient will receive an individualized cancer survivorship care plan based on their cancer type and treatment.~SCP plus Coordinated PCP Visit: Care coordinators will schedule patient appointment with PCP within 4 weeks of treatment."
89407302|NCT03655431|Experimental|Telerehabilitation|Physical therapists will develop an individualized program lasting 12 weeks depending on the needs of a given patient. Veterans will be seen 1 day/week via clinical video teleconferencing (CVT) for treatment. The rehabilitation protocol will last approximately 30 minutes with activities that are individualized to meet the participant's needs (range of motion, balance, strengthening, endurance, and functional activities). Patients assigned to telerehabilitation will utilize the VITAL rehab unit with Jintronix exercise package. Exercises, progression and rest periods will be administered and adjusted remotely by the physical therapist using a web-based clinical portal.
89407303|NCT02111694|Experimental|Clear versus Opaque Bottle|This is a within-subject study; all infants will be exposed to both conditions. Order of presentation will be counterbalanced across infants.
89407304|NCT03655353|Experimental|ABY-PET|68Ga-ABY-025 is used as tracer for PET scan
89407305|NCT02649634|Experimental|Motivational Interviewing|Two 45-60 minute motivational interviewing sessions focusing on exploring and resolving ambivalence towards change.
88883023|NCT05619874|Active Comparator|HIFCT-P|"For sessions 7 to 14, a concentrated circuit divided into two blocks of six exercises will be carried out, with a duration of 60 seconds per exercise with no rest between them. A rest of 120 seconds will be given at the end of each block, and a rest of the same time at the end of the first set. Two sets will be executed, which will result in a total time of 30 minutes including rest.~For sessions 15 to 30, five blocks of two exercises will be performed, with a duration of 120 seconds per exercise, with no rest between them. The rest between blocks will be 120 seconds. The total time per block is four minutes, for a total time of 30 minutes including breaks. The exercises will be performed at speeds between 35 and 75 bpm. The intensity will be between 80% - 90% (8-9 RPE)."
88883024|NCT05605379||Responders (with CCR at 1 year)|
88883025|NCT05605379||No responders (without CCR at 1 year)|
88883026|NCT05597878|Active Comparator|Opioid Control Cohort|Participants will receive standard general anesthesia and receive local anesthesia medication (bupivacaine) during surgery per the investigator's surgical protocol. AFTER surgery participants will be administered oxycodone and acetaminophen.
88883027|NCT05597878|Active Comparator|Experimental Non-Opioid Cohort|Participants will receive standard general anesthesia and receive local anesthesia medication (bupivacaine) during surgery per the investigator's surgical protocol. BEFORE and AFTER surgery participants will be administered Ketamine; DURING surgery Ketorolac and acetaminophen.
88883028|NCT05594589|Experimental|Lemborexant 5 mg (LEM5)|Participants will receive one LEM5 tablet, orally, once daily for 30 nights (Day 1 up to Day 30) on each night approximately 5 minutes before participants intend to try to sleep.
88883029|NCT05594589|Experimental|Lemborexant 10 mg (LEM10)|Participants will receive one lemborexant 10 mg (LEM10) tablet, orally, once daily for 30 nights (Day 1 up to Day 30) on each night approximately 5 minutes before participants intend to try to sleep.
89407306|NCT02649634|Active Comparator|Attention Control|Two 45-60 minute semi-structured interviews, acting as a pseudo-intervention, ascertaining information relevant to health history, weight history, diet history, as well as dietary and physical activity habits.
89407307|NCT02107950|Experimental|DCVAC/OvCa in parallel with chemotherapy|Combination therapy with DCVAC/OvCa and Standard of Care
89407308|NCT02107950|Active Comparator|Standard of Care|Standard of Care carboplatin and gemcitabine
89407309|NCT03655275|Active Comparator|Group(A): PRP|PRP prolotherapy injections with 2.5ml of PRP at an interval of 2 weeks. Intraticular and pericapsular
89407310|NCT03655275|Active Comparator|Group (B): saline|Saline prolotherapy injections with 2.5ml of saline at an interval of 2 weeks.intrarticular and pericapsular
89407311|NCT02108106|Experimental|AG-348|Single oral dose of AG-348
89407312|NCT02108106|Placebo Comparator|Placebo|Single oral dose of placebo
89407313|NCT03655041|Experimental|Beta-Alanine|6.4 g/day of beta-alanine for 24 weeks
89407314|NCT03655041|Placebo Comparator|Placebo|6.4 g/day of maltodextrin for 24 weeks
89407315|NCT02108184|Experimental|Sequential therapy 10 days|1.(pantoprazole 40 mg + amoxicillin 1.0 g bid) for the first 5 days, subsequently (pantoprazole 40 mg + clarithromycin 500 mg + metronidazole 500 mg bid) for the next 5 days
89407316|NCT02108184|Active Comparator|Sequential therapy 14 days|(pantoprazole 40 mg + amoxicillin 1.0 g bid) for the first 7days, subsequently (pantoprazole 40 mg + clarithromycin 500 mg + metronidazole 500 mg bid) for the next 7 days
89407317|NCT02108184|Active Comparator|Concomitant therapy 10 days|(pantoprazole 40 mg + amoxicillin 1.0 g + clarithromycin 500 mg + metronidazole 500 mg bid) for 10 days
89407318|NCT02108184|Active Comparator|Concomitant therapy 14 days|(pantoprazole 40 mg +amoxicillin 1.0 g + clarithromycin 500 mg + metronidazole 500 mg bid) for 14 days
89407319|NCT03654963|No Intervention|Control|Patients of the control group will not receive the best possible medication history with medication reconciliation at admission. The standard physician-acquired medication history will be performed as usual.
89407320|NCT03654963|Experimental|Medication reconciliation|The pharmacy assistant will obtain the best possible medication history by compiling a comprehensive list of the medications the patient is taking. To confirm the accuracy of the history, the pharmacy assistant will use at least two sources of information, one of which being, when possible, the interview with the patient and/or family members. The clinical pharmacist will reconcile the best possible medication history with prescribed medicines and, to resolve unclear or ambiguous discrepancies between the two lists and/or to propose any adaptations of the pharmacotherapy, the clinical pharmacist will refer to the medical doctor. The medical doctor will decide potential changes in pharmacotherapy and communicate them to the patient.
89407321|NCT02113800|Experimental|Single Arm|"Patients receive Everolimus orally, 10 mg/day.~The end of study will be performed when tumor progression has been observed for 28 patients. Patients who are still under treatment at that time may continue with chemotherapy at the discretion of the investigator, but will be excluded from the study."
89407322|NCT03622203||Real life patients|Patients who are often offered a Biofreedom in real life, that is those with active cancer or needing major surgery or on OAT (Oral Anticoagulation)
89407323|NCT03622203||Difficult coronary lesions|Patients with bifurcation and multivessel disease, that is those with an increased risk of ST
89407324|NCT03622203||STEMI|Patients with STEMI
89407325|NCT02108340|Experimental|Microwave radiometry|Patients diagnosed with acute appendicitis will undergo a measurement of the temperature of the appendix with the use of microwave radiometry in a room temperature of 20 -24 degrees celsius.
89407326|NCT05405062|Active Comparator|Carboxytherapy|Six carboxytherapy sessions with an interval of 2 weeks. Five ccs will be injected at each point with a depth of 7mm. Between each point and the other is 5 cm.
89004575|NCT03222492|Experimental|Cohort 3: 1.8 mg/kg brentuximab vedotin|"This is the third/last of three ascending dose cohorts. Participants in this cohort will receive 1.8 mg/kg brentuximab vedotin (to a maximum dose 60 mg) every 3 weeks from week 0 (initial dose) to week 21, a total of 8 treatments. Brentuximab vedotin will be administered as an intravenous infusion over 30 minutes.~Cohort 3 Randomization schedule: N=6 assigned to brentuximab vedotin: N=2 assigned to placebo."
89004576|NCT03222492|Placebo Comparator|Cohort 3: placebo|"1.8 mg/kg placebo (to a maximum dose 60 mg). Participants in this cohort will receive 1.8 mg/kg placebo every 3 weeks from week 0 (initial dose) to week 21, a total of 8 treatments. Placebo will be administered as an intravenous infusion over 30 minutes.~Cohort 3 Randomization schedule: N=6 assigned to brentuximab vedotin: N=2 assigned to placebo."
89004577|NCT03156790|Experimental|Spectrila®|recombinant L-Asparaginase
89191118|NCT01033435||chronic Hemodialysis patients , No intervention|chronic Hemodialysis patients, treated in our unit.
89407327|NCT05405062|Active Comparator|Short pulsed 1064 nm Nd-YAG laser combined with subcision|Twenty-five joules/cm2, 2.2Hz combined with subcision with an interval of 1 month.
89407328|NCT01066143|Experimental|Seroquel XR|
89407329|NCT02108418|Experimental|TG-2349 as the original formulation|400 mg, 2 syringes
89407330|NCT02108418|Experimental|TG-2349 as a new capsule formulation|400 mg, 4 capsules
89407331|NCT05404984|Experimental|Dry cupping with core stabilization exercises|On 12 patients, dry cupping will be performed by using a disposable manual cupping set including a hand suction pump and plastic cups of different sizes. These cups will be placed over the points GB 30, Huantiao, BL-28 Pangguangshu, BL-54 ZHIBIAN and EM-Yaoyan. After dry cupping session core stabilization exercises will be added.
89407332|NCT05404984|Active Comparator|Core stabilization exercises|12 patients will be asked to perform core stabilization exercises where the local stabilizers of the lumbopelvic region will be targeted to ensure segmental control in different positions such as supine, crook-lying, side-lying, prone, four-point kneeling, sitting, and standing.
89407333|NCT03654339|Experimental|experimental group|"Group A-15 patients were allocated to the microsurgical group for root coverage. following scaling and root planning, the laterally repositioned flap was done using the microsurgical approach~Group B-15 Patients were allocated to the conventional group for root coverage following scaling and root planning, the laterally repositioned flap was done using the macrosurgical approach"
89407334|NCT02251470|Experimental|HBE Wii (EG)|Participants receive an introduction of using the Nintendo Wii by an individual mentoring for over 6 weeks (a total of 6 sessions á 60 minutes). During the following 6 weeks the participants perform the balance exercise program (wii-fit balances games) at home (instruction: min. 3 times a week for each 30 minutes).
89407335|NCT02251470|Active Comparator|HBE Control (CG)|Participants receive an introduction for conventional/traditional balance exercise by an individual mentoring for over 6 weeks (a total of 6 sessions á 60 minutes). During the following 6 weeks the participants perform the balance exercise program (exercises in standing and walking) at home (instruction: min. 3 times a week for each 30 minutes).
89407336|NCT05404828||OSAS|All adult patients consulting the pneumology department for possible OSAS with >1x/night nocturia
89407337|NCT05404828||Insomnia|All adult patients consulting the center for integrative medicine for insomnia with >1x/night nocturia
89407338|NCT05404828||Urological|All adult patients consulting the urology department with >1x/night nocturia
89004578|NCT03097783|Experimental|Restylane Perlane Lidocaine|Single injection and optional touch up injection with Restylane Perlane Lidocaine in Midface
89407339|NCT03654495|Experimental|Exergame Training|Routine (standard) therapy given based on conventional current-best-evidence Rehabilitation. In addition training on Medical Device (MD): Dividat Senso, DIV-SENSO-H, Dividat GmbH, Software development: ISO 62304:2016; designed to train different aspects of executive functions (EFs; divided attention, working memory, inhibition, and shifting) and physical functions through Virtual Reality video game training.
89407340|NCT03654495|Active Comparator|Usual Care Training|Routine (standard) therapy given based on conventional current-best-evidence Rehabilitation.
89407341|NCT02108574|Placebo Comparator|Placebo Filter|Placebo device
89407342|NCT02108574|Active Comparator|Rhinix Nasal Filter|Actual Rhinix Nasal Filter
89004579|NCT03097783|No Intervention|No intervention arm|No treatment
89004580|NCT03088059|Experimental|Patient Cohort B1|Patients who are p16 negative and have an EGFR amplification/mutation or PTEN high or HER2 mutation/amplification will be randomized between afatinib or the standard of care (Methotrexate, Paclitaxel, Docetaxel, Carboplatin, 5-Fluorouracil, Bleomycine, Gemcitabine, Mitomycine or Best supportive care).
89004581|NCT03088059|Experimental|Patient Cohort B2|Patients who are p16 negative and cetuximab naïve will be randomized between afatinib or the standard of care (Methotrexate, Paclitaxel, Docetaxel, Carboplatin, 5-Fluorouracil, Bleomycine, Gemcitabine, Mitomycine or Best supportive care)
89004582|NCT03088059|Experimental|Patient Cohort B3|Patients who are p16 negative and have an amplification of CCND1 will be randomized between palbociclib or the standard of care (Methotrexate, Paclitaxel, Docetaxel, Carboplatin, 5-Fluorouracil, Bleomycine, Gemcitabine, Mitomycine or Best supportive care)
89004583|NCT03088059|Experimental|Patient Cohort B4|Patients who are p16 negative and 'platinum sensitive' SCCHN will receive niraparib
89191119|NCT04069130|Experimental|BIA 5|single oral dose of 400 mg as an oral capsule
89407343|NCT02111928||NovaTears®|
89407344|NCT02112006|Experimental|distal injection|0.5% bupivacaine injected in the forearm
89407345|NCT02112006|Active Comparator|proximal injection|20-30ml of 0.5% bupivacaine
89407346|NCT02521324|Experimental|Immediate treatment (IT)|Subjects from this group will perform 2 weeks of DGB with the DGB2 system immediately after 1 week of baseline monitoring. All subjects will answer questionnaires pertaining to their sleep quality.
89407347|NCT02521324|Active Comparator|Wait list control (WLC)|The subjects from the WLC group will do the same (answer questionnaires and perform 2 weeks of DGB with the DGB2 system) at a 1 week delay.
89407348|NCT02980107|Active Comparator|PLS|The control group will receive PLS: text format with simple explanation of the survey topic main findings and is intended for lay audience.
89407349|NCT02980107|Experimental|Infographics|Infographics format of a Cochrane systematic review summary represents the experimental intervention in the trial, where the results are presented with text and pictures.
89407350|NCT02108730||non-focal congenital hyperinsulinism|13 children and one adult with non-focal congenital hyperinsulinism
89407351|NCT02114112|Experimental|Group A-NCPAP Cycling group|Infants in Group A were cycled between NCPAP and nasal prongs. For the first 12 hours, infants received 10 hours of NCPAP and 2 hours of 1 litre per minute of nasal prongs (NP). For the next 12 hours, infants received 8 hours of NCPAP and 4 hours of NP. In the subsequent 24 hours, infants alternated between 6 hours of NCPAP and 6 hours of NP. In the last 24 hours of intervention they alternated between 4 hours of NCPAP and 8 hours of NP.
89407352|NCT02114112|Active Comparator|Group B-Continuous NCPAP|Infants randomized to group B received continuous NCPAP at a CPAP distending pressure of 4 cm of water for 72 hours. Both the groups after 72 hours of intervention were weaned to 1litre per minute NP. During the intervention period all infants were scored using the ACoRN respiratory score on a 12 hourly basis.
89407353|NCT02251158|Experimental|TPV/r with food|Tipranavir/Ritonavir paediatric/oral solution
89407354|NCT02251158|Experimental|TPV/r|Tipranavir/Ritonavir paediatric/oral solution
89407355|NCT02251158|Active Comparator|TPV/r capsules|
89407356|NCT02652130|Experimental|Safety population|All participants who were enrolled and had received at least 1 dose of remestemcel-L in Study MSB-GVHD001.
89407357|NCT03553914|Experimental|12 mg/m^2 dose group|Subjects will receive PLM60 at 12 mg/m^2 dose.
89407358|NCT03553914|Experimental|16 mg/m^2 dose group|Subjects will receive PLM60 at 16 mg/m^2 dose.
88883030|NCT05594589|Placebo Comparator|Placebo (PBO)|Participants will receive one lemborexant-matched PBO tablet, orally, once daily for 30 nights (Day 1 to Day 30) on each night approximately 5 minutes before participants intend to try to sleep.
88883031|NCT05591846|Experimental|Face-to-face training|Face-to-face training group: In the study, the trainings were given face to face in a meeting room suitable for individuals. Documents were explained and animations and interviews were watched.
88883032|NCT05591846|Experimental|web-based training|web-based training Group:In the study, trainings were given to individuals through the website established. Training videos, animations, interviews and documents have been added to the website.
88883033|NCT05591846|No Intervention|Control group|Control group: No application has been made.
89407359|NCT03553914|Experimental|20 mg/m^2 dose group|Subjects will receive PLM60 at 20 mg/m^2 dose.
88883034|NCT05589701||Stereotactic Radiotherapy (SBRT)|Standard of care stereotactic radiotherapy.
89407360|NCT02114190|Experimental|Adolescent Mindful Eating Group|Adolescents will participate in a 8 week mindful eating programs tailored for adolescents.
88883035|NCT05589701||Conventional Radiotherapy (CRT)|Standard of care conventional radiotherapy.
88883036|NCT05584657|Experimental|Sulopenem etzadroxil/probenecid|Sulopenem etzadroxil/probenecid 500 mg/500 mg PO twice daily for 5 days
88883037|NCT05584657|Active Comparator|Amoxicillin/clavulanate|Amoxicillin/clavulanate PO twice daily for 5 days
88883038|NCT05580770|Experimental|Phase 1 Dose Escalation Cohorts Ranging in Dose|Participants with an oncogenic mutation or other genomic aberration of the MAPK pathway
89407361|NCT02114190|Experimental|Parent Intergrated Group|This intervention incorporates a family systems perspective into mindful eating interventions for adolescents. This intervention will consist of 11 sessions in an 8 week period, with sessions 2,7, and 11 incorporating family sessions. The purpose of the family sessions are to increase overall family motivation for behavior change, involve family members in identifying specific targets of change and establishing agreed upon strategies.
89407362|NCT05404750||Providers|Individuals providing service or care to PLWH or people who use drugs at high risk for HIV acquisition working at our study sites in one of the following positions: front desk/patient engagement, social worker, nurse, medical assistant, advanced practice provider, or physician.
89407363|NCT05404750||Patients|PWLH with current or lifetime substance use who receive care at one of our study sites.
89191120|NCT00713232||test construction|university student living in Taiwan for more than 5 years No known neurological, psychiatric or speech language disorders
89191121|NCT00713232||normative data|normal subjects 20-80 y/o Living in Taiwan for at least 5 years No know neurological, psychiatric and speech-language disorders
89407364|NCT02112084|No Intervention|Usual Care|Usual care participants do not receive an intervention.
89407365|NCT02112084|Experimental|Individualized DPM|Individualized DPM
89407366|NCT05404516|Experimental|Sorafenib|"Induction cycle(s):~IA3+7. Patients will receive sorafenib 400 mg BID on days 8-21.~Consolidation Cycle 1:~IA3+3. Patients will receive sorafenib 400 mg BID on days 1-21.~Consolidation Cycles 2-4:~MDAC. Patients will receive sorafenib 400 mg BID on days 1-21.~Maintenance therapy:~Single agent sorafenib 400 mg BID for one year."
89407367|NCT05404516|Active Comparator|Standard therapy|"Induction cycle(s):~IA3+7.~Consolidation Cycle 1:~IA3+3.~Consolidation Cycles 2-4:~MDAC."
89407368|NCT02114346|Experimental|Atorvastatin|Patients in the atorvastatin group receive 80 mg atorvastatin (2 x atorvastatin 40 mg tablets) once daily from 24 hours before to 48 hours after administration of contrast material.
89407369|NCT02114346|Placebo Comparator|Placebo|Patients in the placebo group receive 2 placebo tablets once daily from 24 hours before to 48 hours after administration of contrast material.
89407370|NCT02112162|Experimental|Diagnostic (FDG PET/MRI, gene expression)|FDG PET/MRI at baseline and at 2-4 weeks before surgery (after neoadjuvant chemoradiation). Tissue samples for gene expression at baseline and during surgery
89407371|NCT02108808|Active Comparator|Prasugrel or Clopidogrel|Prasugrel 60mg or Clopidogrel 600mg loading dose, as clinically indicated
89407372|NCT02108808|Experimental|Ticagrelor|Ticagrelor 180mg loading dose
89407373|NCT02108886|Experimental|Montelukast|Intervention group
89407374|NCT02108886|Placebo Comparator|Placebo|Placebo
89407375|NCT05392816|Other|Study group 1. Texturized fava protein meal and beef protein meal|Participants recruited to study group 1 will be served a meal with fava bean protein (B) and beef protein (A), each meal twice which in total brings four meals on four consecutive days as fasting breakfast. Meals are served in the order BBAA
89407376|NCT05392816|Other|Study group 2. Texturized fava protein meal and cod protein meal|Participants recruited to study group 1 will be served a meal with fava bean protein (B) and cod protein (A), each meal twice which in total brings four meals on four consecutive days as fasting breakfast. Meals are served in the order BBAA
89407377|NCT02114424|Active Comparator|Positional vibrator belt|Positional belt to avoid supine sleep.
89407378|NCT02114424|No Intervention|No Night balance|the first 2 months without Night Balance
88813606|NCT02469168|Active Comparator|Control|Allocation of treatments (Recell vs Control) to the INTEGRA™ Meshed Bilayer Wound Matrix (MBWM). Each patient serves as their own control. Their study treatment area will be divided into Area A and Area B. Investigational treatment will be randomly allocated to either Area A or Area B
88813607|NCT01723592|Placebo Comparator|Placebo|30 participants in this group receive a oral lactose placebo
88813608|NCT01723592|Active Comparator|Probiotics|"30 participants in this group receiving oral probiotic capsules for 7 days twice daily containing four lyophilised Lactobacillus strains belonging to the species:~L.rhamnosus/ LbV96 (DSM 22560)~L.jensenii /LbV 116 (DSM 22567)~L.crispatus/ Lbv88 (DSM 22566)~L.gasseri /LbV 150N (DSM 22583)"
88813609|NCT01723670|Experimental|CHF 5074 1x|oral tablet, multidose
88813610|NCT01723670|Experimental|CHF 5074 2x|oral tablet, multidose
88813611|NCT01723670|Placebo Comparator|Placebo|placebo, oral tablet, multidose
88813612|NCT01723748|Active Comparator|surgery treated|"10 patients with well-controlled acromegaly for at least 6 months after surgery alone.~Stimulated with genotropin"
88813613|NCT01723748|Active Comparator|SA treated|10 patients with well-controlled acromegaly for at least 6 months after SA treatment Stimulated with genotropin
88813614|NCT01720160|Experimental|Device|1) BAROSTIM NEO System and 2) standard of care medical management therapy for heart failure (American Heart Association [AHA] / American College of Cardiology [ACC] guidelines), including drugs (determined by the patient's physician). Drug types include: Loop Diuretics, Thiazide Diuretics, Potassium-sparing Diuretics, Sequential Nephron Blockade, ACE Inhibitors, ARBs, ARNI, Aldosterone Antagonists, Beta Blockers and Hydralazine and Isosorbide Dinitrate.
88813615|NCT01720160|Active Comparator|Medical Management|Standard of care medical management therapy for heart failure (American Heart Association [AHA] / American College of Cardiology [ACC] guidelines), including drugs (determined by the patient's physician). Drug types include: Loop Diuretics, Thiazide Diuretics, Potassium-sparing Diuretics, Sequential Nephron Blockade, ACE Inhibitors, ARBs, ARNI, Aldosterone Antagonists, Beta Blockers and Hydralazine and Isosorbide Dinitrate.
88813616|NCT03405896|Experimental|Normal subjects|
88813617|NCT02469090|Experimental|APL-130277|APL-130277 sublingual thin film (10 mg, 15 mg, 20 mg, 25 mg, 30 mg and 35 mg)
88813618|NCT02469090|Placebo Comparator|Placebo|Matching placebo for APL-130277 sublingual thin film (10 mg, 15 mg, 20 mg, 25 mg, 30 mg and 35 mg)
88813619|NCT02496000|Placebo Comparator|Placebo Comparator|three identical capsules containing placebo
88813620|NCT02496000|Experimental|ORMD-0801 Dose 1|three identical capsules, as follows: capsule #1: one half of Dose 1 capsule #2: one half of Dose 1 capsule #3: placebo
88813621|NCT02496000|Experimental|ORMD-0801 Dose 2 = 1.5 * Dose 1|three identical capsules, as follows: capsule #1, 2, and 3: one half of Dose 1
88813622|NCT02468934|Experimental|Peripheral Nerve Stimulation|All study subjects will have up to 2 Smartpatch Leads placed in their leg that underwent total knee replacement, will use the SPRINT Peripheral Nerve Stimulation (PNS) System, and will receive electrical stimulation.
88813623|NCT02517528|Experimental|ABT-450/r/ABT-267 + ABT-333 + Ribavirin|ABT-450/r/ABT-267 once daily + ABT-333 twice daily + weight-based RBV divided twice daily for 12 weeks
88813624|NCT02495844|Experimental|UCB0942|UCB0942/UCB0942
88813625|NCT02495844|Placebo Comparator|Placebo|Placebo/UCB0942 (after 2-week inpatient period, placebo subjects will receive the experimental medicine, UCB0942).
88813626|NCT02468778|Experimental|HeartMate PHP (Roll-in)|Participants who receive a HeartMate PHP device without randomisation will be included in this arm
88813627|NCT02468778|Experimental|HeartMate PHP (Randomised)|Participants who receive a HeartMate PHP device after randomisation will be included in this arm
89407379|NCT02114502|Experimental|Carfilzomib/SAHA + Gem/Bu/Mel + Auto Stem Cell Transplant SCT|Busulfan test dose of 32 mg/m2 by vein on Day -10 if inpatient, on Day -12 if outpatient, then AUC of 4,000 microMol.min on Days -8 to -5. Palifermin 60 microgram/kg by vein on Days -12 to -10 and Days 0, +1 and +2. SAHA 1,000 mg by mouth on Days -8 to -3. Gemcitabine loading dose of 75 mg/m2 followed by continuous infusion of the remaining dose of 1875 mg/m2 by vein on Days -8 and -3. Carfilzomib 27 mg/m2 by vein on Days -7 and -6, then on Days -2 and -1. SAHA 1,000 mg by mouth on Days -7 to -3. Melphalan 60 mg/m2 by vein on Days -3 and -2. Stem cell transplant on Day 0. Dexamethasone 8 mg by vein twice a day from Day -9 PM to Day -2 PM. Caphosol oral rinses 30 mL four times a day from Day -9 until discharge. Oral glutamine 15 g four times a day, swished, gargled and spit on Day -9 until discharge. Pyridoxine 100 mg by vein or mouth three times a day from Day -1.
89407380|NCT02979639|Experimental|GSK1437173A Group|Subjects ≥ 50 years of age who will receive two doses of the GSK1437173A vaccine (first dose given at Month 0 and second dose given 2 months later) in this study.
88883039|NCT05580770|Experimental|Phase 2 Dose Expansion A|Participants with cutaneous melanoma harboring NRAS mutations
88883040|NCT05580770|Experimental|Phase 2 Dose Expansion B|Participants with NSCLC harboring KRAS mutations
88883041|NCT05580770|Experimental|Phase 2 Dose Expansion C|Participants with NSCLC or cutaneous melanoma harboring BRAF Class II or Class III mutation or BRAF Fusion mutation
88883042|NCT05568615|Experimental|MT-1186 orally|Subjects receive the edaravone oral suspension orally once daily for 10 days out of a 14-day period, followed by a 14-day drug-free period.
88883043|NCT05547425|Experimental|Blur obfuscation|Blurring is applied to objects and people in the background of images.
88883044|NCT05547425|Experimental|Edge obfuscation|Objects and people in the background of images are replaced with an outline of the object.
88883045|NCT05547425|Experimental|Cartoon obfuscation|Blurring is applied to objects and people in the background of images and the wearer's face is concealed with cartoon faces.
88883046|NCT05547425|Experimental|Raw images|No editing is performed on images.
88883047|NCT05529511||Phase 1 - Preoperative|"Interviews to be completed with approximately 12 participants at three time points:~Prior to anterior cruciate ligament surgery~3-month after anterior cruciate ligament surgery~12-months anterior cruciate ligament surgery"
88883048|NCT05529511||Phase 2 - Nominal Group Technique panel|Consensus meeting with up to 12 participants (clinicians, patients and stakeholders) to develop the prehabilitation intervention
88883049|NCT05509634|Experimental|Treatment group A|HR20013 for injection + simulant of fosaprepitant dimeglumine for injection + simulant of palonosetron hydrochloride injection + dexamethasone
89191122|NCT03909542||Ileostomy Closure|Patients who have undergone an ileostomy closure procedure.
89191123|NCT04042012|Experimental|Eccentric group|The dancers of this group wil perform a soleus eccentric exercise
88883050|NCT05509634|Active Comparator|Treatment group B|simulant of HR20013 for injection + fosaprepitant dimeglumine for injection + palonosetron hydrochloride injection + dexamethasone + simulant of dexamethasone
88883051|NCT05505760|Experimental|Appointment Reminder Model|This is the current MomConnect WhatsApp model (control). Mothers receive weekly conversation starter messages reminding them about their upcoming clinic appointments, providing more comprehensive and relevant maternal health information only after mothers respond to the appointment reminder.
88883052|NCT05505760|Experimental|Relevant Content Model (WhatsApp)|"Mothers receive weekly conversation starter messages on WhatsApp, which carry both clinic appointment reminders along with some maternal and infant health information relevant to their pregnancy/postpartum stage. In addition, a list of frequently asked questions (FAQs) relevant to the week of pregnancy the mother is in are provided so that mothers can engage further with maternal health information topics relevant to them."
89004584|NCT03088059|Experimental|Patient Cohort B5|Patients whith oropharyngeal cancer and which are p16 positive will receive niraparib
89004585|NCT03088059|Experimental|Patient Cohort I1|Patients who are anti-PD(L)1-naïeve or resistant (primary or secondary resistance) will receive IPH2201 antibody (monalizumab).
89191124|NCT04042012|Experimental|PNE group|"The dancers of this group will receive a PNE treatment, consisting of the application of galvanic current, by ultrasound.~The approach will be performed with a transverse axis with a needle orientation that will depend on the location of the target tissue. The parameters will be 3 mA, 3 seconds, 3 impacts (3: 3: 3). The periodicity will be 1day/7day/21day"
89407381|NCT02109120||carotid endarterectomy (CEA)|CEA patients with vein blood collection
89407382|NCT02114580|Experimental|Aerobic exercise|
89407383|NCT02114580|Active Comparator|stretching exercise|
89407384|NCT01674634|Experimental|XIAFLEX / XIAPEX|AA4500 (collagenase clostridium histolyticum)
89407385|NCT02109198|Experimental|Active CN-NINM PoNS|Active CN-NINM PoNS - Active cranial-nerve non-invasive neuromodulation (CN-NINM) using the Portable Neuromodulation Stimulator (PoNS) and balance/gait rehabilitation with physical therapy
89004586|NCT03088059|Experimental|Patient Cohort I2|Patient who are PD(L)1 pretreated will be randomized between monalizumab + durvalumab or the standard of care (Methotrexate, Paclitaxel, Docetaxel, Carboplatin, 5-Fluorouracil, Bleomycine, Gemcitabine, Mitomycine or Best supportive care)
89004587|NCT03088059|Experimental|Patient Cohort I3|Patient who are progressing prior PD(L)1 after having received at least 2 months of anti-PD(L)-1 will receive INCAGN01876.
89004588|NCT03048279||Multiple Endocrine Neoplasia Syndromes: MEN1/MEN2|Consented individuals will be interviewed by phone and/or mail to obtain medical history specific to their diagnosis of either MEN1 or MEN2.
89407386|NCT02109198|Placebo Comparator|Sham PoNS CN-NINM|Sham CN-NINM PoNS - Sham cranial-nerve non-invasive neuromodulation (CN-NINM) using the Portable Neuromodulation Stimulator (PoNS) and balance/gait rehabilitation with physical therapy
89407387|NCT03654027|Experimental|Anlotinib Plus Docetaxel|Anlotinib (12mg QD PO d1-14, 21 days per cycle) and Docetaxel (75mg/m2 IV d1)
89407388|NCT03654027|Active Comparator|Docetaxel|Docetaxel (75mg/m2 IV d1)
89407389|NCT03005964|Experimental|AM001 Cream, 7.5%|A white to off-white Cream free from any foreign particles
89407390|NCT03005964|Placebo Comparator|Vehicle Cream|A white to off-white Cream free from any foreign particles.
89407391|NCT02112240|Experimental|Surgery with pre- and intra-op imaging|Subjects will have a preoperative flexible sigmoidoscopy where they will receive an endoscopic injection of 99mTc-sulfur colloid (up to 0.5 mCi) and 3 to 5 cc of circumferential endoscopic injections of Spot. A SPECT/CT will be performed prior to surgery to identify lymph nodes in the rectum. Subjects will proceed to their standard surgery. Intraoperative mobile gamma camera imaging of the rectum will occur before and after resection in attempt to identify sentinel lymph nodes.
89407392|NCT03455842|Experimental|BCD-089 weekly|
89407393|NCT03455842|Experimental|BCD-089 biweekly|
89407394|NCT03455842|Placebo Comparator|Placebo|
89407395|NCT02979249|Experimental|Oral Iron|standard dose of iron pills
89407396|NCT05404438|Experimental|intervention group|single arm study
89407397|NCT02112396|Experimental|Immediate Intervention|Subjects receive 12 sessions of Community Reinforcement and Family Training (CRAFT) immediately after study inclusion
89407398|NCT02112396|Other|Waiting list group|Waiting list group members receive the Community Reinforcement and Family Training CRAFT intervention after the first follow-up (3 months post study inclusion)
89407399|NCT02114658|Experimental|Arm 1|Sorafenib 400 mg bid continuous dose
89407400|NCT05126602|Experimental|High Dose Vitamin D3|A chewing tablet of 5000 IU of vitamin D3 is given twice daily, orally in the morning and evening for two weeks
89004589|NCT03048279||Close Relatives of Registered MDACC MEN Patients|Participants will be asked to complete a health and family history questionnaire. This questionnaire process may be completed by phone or mail.
89004590|NCT03003130|Experimental|Restylane Defyne|Single injection and optional touch up injection with Restylane Defyne in NLF
88813628|NCT02468778|Active Comparator|Any Abiomed Impella® (Randomised)|Participants who receive any Abiomed Impella® Device approved for use in high-risk PCI after randomisation will be included in this arm
89004591|NCT03003130|Active Comparator|Restylane|Single injection and optional touch up injection with Restylane in NLF
89004592|NCT02994069|Experimental|Every 3 Weeks Cisplatin + XRT|Every 3 Weeks Cisplatin + XRT
89004593|NCT02994069|Experimental|Weekly Cisplatin + XRT|Weekly Cisplatin + XRT
89004594|NCT02989844|Experimental|N-803|
89191125|NCT04042012|Experimental|Combined group|The dancers of this group will receive a combined treatment and will be carried out in the same way as the other two groups.
89191126|NCT00719238|Experimental|1|
89191127|NCT00719238|Active Comparator|2|
89407401|NCT05126602|Active Comparator|Low Dose Vitamin D3|A chewing tablet of 1000 IU of vitamin D3 is given once daily, orally in the morning for two weeks
89407402|NCT02114736|Experimental|Rectus femoris tenotomy|Surgical release of the proximal tendon of the rectus femoris
89407403|NCT02114736|Active Comparator|Botulinum toxin in the rectus femoris muscle|Botulinum toxin (200U Botox) injection in the rectus femoris muscle
89407404|NCT02109276|Active Comparator|Spheric Sensar(R) 3-piece IOL|This group of patients with Fuchs endothelial dystrophy and cataract will undergo cataract extraction and be randomized to receive a Spheric Sensar(R) 3-piece IOL
89407405|NCT02109276|Experimental|Aspheric Tecnis(R) 3-piece IOL|This group of patients with Fuchs endothelial dystrophy and cataract will undergo cataract extraction and be randomized to receive an Aspheric Tecnis(R) 3-piece IOL
89407406|NCT02114970|Other|Focus Group- paper and tablet consent|Participation in a focus group of other older adults, lasting 120 minutes. Participants will answer semi-structured questions in a group format, describing their impressions of both a prototype tablet-delivered and a paper consent.
89407407|NCT02114970|Active Comparator|Randomized- paper consent|Participants will review a mock paper consent form with a study clinician, and complete a series of questionnaires assessing their comprehension of material covered and general experience with the paper informed consent form.
89407408|NCT02114970|Active Comparator|Randomized- Tablet-delivered consent|Participants will review a mock tablet-delivered consent form with a study clinician, and complete a series of questionnaires assessing their comprehension of material covered and general experience with the tablet-delivered informed consent.
89407409|NCT05126368|Experimental|Eyhance toric II|The Eyhance toric II intraocular lens will be implanted in one of the patients eyes during cataract surgery
89407410|NCT02251392|Experimental|Chamomila recutita Gel|Experimental Group 1 - patients will apply the gel since the begging of radiodermatitis, three times a day. The dose is being determined in a Phase II study that is being conducted. Topical application of gel is going to occur concomitantly to the initiation of radiodermatitis and will be follow up until the cure of it.
89407411|NCT02251392|Experimental|Chamomila recutita Infuse 2,5%|Experimental Group 2 - patients will apply the infuse since the begging of radiodermatitis, three times a day. The dose of 2,5% was determined before in a Phase II study. Radiodermatitis grade and intensity is going to be evaluated. Topical application of the infuse is going to occur concomitantly to the initiation of radiodermatitis and will be follow up until the cure of it.
89191128|NCT02571296|Active Comparator|group A|"subjects will recieve twice daily tablets of 100 mg of oral Micronized Progesterone from (14-18 weeks) until 36 weeks or delivery.~Subjects: 106 cases Name: Oral micron ized progesterone Form: oral tablets Dosage: one tablet Frequency: every 12 hours Duration: 14-36 weeks gestational age."
89407412|NCT02251392|Active Comparator|Urea cream based|Control Group - usual care to treat radiodermatitis, patients will apply the infuse since the begging of radiodermatitis, three times a day. Radiodermatitis grade and intensity is going to be evaluated. Topical application of urea is going to occur concomitantly to the initiation of radiodermatitis and will be follow up until the cure of it.
89407413|NCT05126212||Patients|Patients admitted to the Hospi'Senior room
89407414|NCT05126212||Informal caregivers|Informal caregivers of patients admitted to the Hospi'Senior room
89407415|NCT05126212||Caregivers|Caregivers who have worked in the Hospi'Senior room
89407416|NCT02112474|Experimental|Spinal Cord Stimulation Group 1|9 days of spinal cord stimulation at 30 Hertz and perceptible paraesthesias
89407417|NCT02112474|Experimental|Spinal Cord Stimulation Group 2|9 days of spinal cord stimulation with 1000 Hertz and sub-perception paraesthesias
89407418|NCT02112552|Experimental|Treatment (paclitaxel, carboplatin, radiotherapy)|"CHEMOTHERAPY: Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15 and carboplatin IP on day 1. Treatment repeats every 21 days for up to 6 courses (weeks 1-18) in the absence of disease progression or unacceptable toxicity.~RADIATION: At provider discretion, patients may undergo 3D conformal or IMRT 5 days a week for 5 weeks (weeks 19-23)."
89407419|NCT02976519|Experimental|BI 443651|
89407420|NCT02976519|Placebo Comparator|Placebo|
89407421|NCT05124028|Experimental|Orelabrutinib|Orelabrutinib 50mg po qd 6 weeks
89407422|NCT02109354|Active Comparator|HIV Regimen + Tetanus and HBV Vaccines|Participants will receive a tetanus vaccine injection (tetanus toxoid vaccine), followed by 2 injection of an experimental canarypox HIV vaccine (ALVAC-HIV; months 1, 2), than 2 injection of a protein HIV vaccine boost (AIDSVAX B/E; months 4, 7), followed by a hepatitis B vaccine series (months 7.5, 8.5, 13)
89407423|NCT02109354|Active Comparator|HIV Vaccine Regimen|Participants will receive a placebo for tetanus vaccine by injection (placebo tetanus toxoid vaccine), followed by 2 injection of an experimental canarypox HIV vaccine (ALVAC-HIV; months 1, 2), than 2 injection of a protein HIV vaccine boost (AIDSVAX B/E; months 4, 7), followed by a placebo for hepatitis B vaccine series (months 7.5, 8.5, 13)
89407424|NCT02109354|Placebo Comparator|Tetanus and HBV Vaccines|Participants will receive a tetanus vaccine injection (tetanus toxoid vaccine), followed by 2 injection of a placebo for the experimental canarypox HIV vaccine (placebo for ALVAC-HIV; months 1, 2), than 2 injection of a placebo protein HIV vaccine boost (placebo for AIDSVAX B/E; months 4, 7), followed by a hepatitis B vaccine series (months 7.5, 8.5, 13)
89407425|NCT04565353|No Intervention|Holdout control|Participants will only receive the standard appointment reminders from their providers.
89004595|NCT02948842|Experimental|Treatment Group|Patients will undergo instillation of local anesthesia (20 mL of 2% urethral lidocaine jelly), the patient will undergo cystoscopy, transurethral injection (via a 70 cm 4.8 Fr flexible cystoscopic needle with a 23 gauge needle tip manufactured by Laborie®, Ontario, Canada) of 0.08ml of XIAFLEX® (0.58 mg of XIAFLEX® mixed with 0.39 mL of sterile diluent) in a single location within the stricture, chased by an additional 0.25 mL of reconstituted XIAFLEX® to allow for clearance of the original 0.08 mL of reconstituted XIAFLEX® from the transurethral syringe into the urethral stricture.
89191129|NCT02571296|Placebo Comparator|Group B|"subjects will receive placebo twice daily from (14-18 weeks) until 36 weeks or delivery.~Subjects: 106 cases Name: placebo Form: oral tablets Dosage: one tablet Frequency: every 12 hours Duration: 14-36 weeks gestational age."
89191130|NCT00857038|Experimental|1|Doxycycline 100mg daily
89191131|NCT00857038|Placebo Comparator|2|Placebo
89407426|NCT04565353|Experimental|Default Reservations Opt-Out Condition|"The day before their scheduled appointment, participants receive a text reading: A flu shot has been reserved for you to receive at your appointment tomorrow. Reply Y if you want this shot held for you, N if you don't. The text will include a picture of a vial that says Your Flu Shot on it."
89407427|NCT04565353|Experimental|Default Reservations Opt-In Condition|"The day before their scheduled appointment, participants receive a text reading: Reply Y if you would like to receive a flu shot at your appointment tomorrow, N if not. The text will include a picture of vial with no text on it."
89407428|NCT04565353|Experimental|Intergroup Competition Treatment Condition|"Three days before their scheduled appointment, participants will receive a text message with information about how much your region lagged behind another region in flu shot rate last year (your region and another region will depend on the study site and include realistic flu shot rates based on historical CDC data). Participants will receive a reminder message on the day of the appointment."
89407429|NCT04565353|Experimental|Intergroup Competition Control Condition|"Three days before their scheduled appointment, participants will receive a text message with information about how much your region lagged behind the target flu shot rate of 70% last year (your region will depend on the study site and include realistic flu shot rates based on historical CDC data). Participants will receive a reminder message on the day of the appointment."
89407430|NCT04565353|Experimental|Flu Shot for You Symbolic Condition|Three days before their scheduled appointment, participants will receive a text message encouraging them to get a flu shot. They will also be told that they have the opportunity to dedicate getting the flu shot to someone by texting back the initials of an individual. Participants will receive a reminder message on the day of the appointment.
89407431|NCT04565353|Experimental|Flu Shot for You Herd Immunity Condition|Three days before their scheduled appointment, participants will receive a text message encouraging them to get a flu shot. They will also be told that they have the opportunity of getting the flu shot to protect a vulnerable loved one by texting back the initials of an individual. Participants will receive a reminder message on the day of the appointment.
89407432|NCT04565353|Experimental|Flu Shot for You Control Condition|Three days before their scheduled appointment, participants will receive a text message encouraging them to get a flu shot. They will also receive a reminder message on the day of the appointment. They will not receive any further information, nor will they be asked to respond with initials of an individual.
88883053|NCT05505760|Experimental|Relevant Content Model (SMS)|Mothers receive twice weekly conversation starter messages of 160 characters each per SMS, which carry both clinic appointment reminders as well as maternal and infant health information, relevant to their stage of pregnancy or the age of their baby. Mothers can access the list of frequently asked questions relevant to their week of pregnancy via USSD.
88883054|NCT05505760|Experimental|Relevant Content + Browsable Content Model|This is a combination of the Relevant Content and Browsable Content Models on WhatsApp (RCM+BCM), including appointment reminders, clinical information, a browsable menu and prompts to relevant stage-based topics. Mothers receive weekly conversation starter messages.
88883055|NCT05503095||patients who develop cardiac rupture following acute myocardial infarction|
88883056|NCT05503095||patients with acute ST-elevation myocardial infarction not complicated by cardiac rupture|
88883057|NCT05489718|Experimental|treated with different doses of single intravitreal inmection of IBI324|
88883058|NCT05489718|Experimental|treated with different doses of multiple intravitreal inmection of IBI324|
88883059|NCT05475925|Experimental|Part A Dose Escalation 1 mg/kg of DR-01|Subjects in this arm will initially receive 1 mg/kg at either the Primary regimen (bi-weekly dosing for fist month), Secondary regimen (doses at Days 1, 8, 15, 29 during first month), or Tertiary regimen (dosing days 1-5, 15, 29 during first month), followed by monthly dosing (up to 6 mg/kg) thereafter for up to 25 cycles total.
88883060|NCT05475925|Experimental|Part A Dose Escalation 3 mg/kg of DR-01|Subjects in this arm will initially receive 3 mg/kg at either the Primary regimen (bi-weekly dosing for fist month), Secondary regimen (doses at Days 1, 8, 15, 29 during first month), or Tertiary regimen (dosing days 1-5, 15, 29 during first month), followed by monthly dosing (up to 10 mg/kg) thereafter for up to 25 cycles total.
88883061|NCT05475925|Experimental|Part A Dose Escalation 6 mg/kg of DR-01|Subjects in this arm will initially receive 6 mg/kg at either the Primary regimen (bi-weekly dosing for fist month), Secondary regimen (doses at Days 1, 8, 15, 29 during first month), or Tertiary regimen (dosing days 1-5, 15, 29 during first month), followed by monthly dosing (up to 10 mg/kg) thereafter for up to 25 cycles total.
88883062|NCT05475925|Experimental|Part A Dose Escalation 10 mg/kg of DR-01|Subjects in this arm will initially receive 10 mg/kg at either the Primary regimen (bi-weekly dosing for fist month), Secondary regimen (doses at Days 1, 8, 15, 29 during first month), or Tertiary regimen (dosing days 1-5, 15, 29 during first month), followed by monthly dosing (up to 10 mg/kg) thereafter for up to 25 cycles total.
88883063|NCT05475925|Experimental|Part A Dose De-escalation 0.3 to <1 mg/kg of DR-01|This cohort would only be triggered should a DLT occur at Dose Level 1 or if recommended by the Safety Review Committee. Subjects in this arm would initially receive 0.3 to <1 mg/kg at either the Primary regimen (bi-weekly dosing for fist month), Secondary regimen (doses at Days 1, 8, 15, 29 during first month), or Tertiary regimen (dosing days 1-5, 15, 29 during first month), followed by monthly dosing (up to 3 mg/kg) thereafter for up to 25 cycles total.
88883064|NCT05475925|Experimental|Part B Dose Expansion (Cohort B1) Optimized Dose/Regimen of DR-01|Subjects in this arm will receive the pharmacologically optimized dose/regimen for LGL leukemia subjects determined in Part A. Depending on the selected dose/regimen, subjects will receive target dose at either the Primary regimen (bi-weekly dosing for fist month), Secondary regimen (doses at Days 1, 8, 15, 29 during first month), or Tertiary regimen (dosing days 1-5, 15, 29 during first month), followed by monthly dosing thereafter for up to 25 doses total.
88883065|NCT05475925|Experimental|Part B Dose Expansion (Cohort B2) Optimized Dose/Regimen of DR-01|Subjects in this arm will receive the pharmacologically optimized dose/regimen for cytotoxic lymphoma subjects determined in Part A. Depending on the selected dose/regimen, subjects will receive target dose at either the Primary regimen (bi-weekly dosing for fist month), Secondary regimen (doses at Days 1, 8, 15, 29 during first month), or Tertiary regimen (dosing days 1-5, 15, 29 during first month), followed by monthly dosing thereafter for up to 25 doses total.
89407433|NCT04565353|Experimental|Prosocial Condition|The day before their scheduled appointment, participants will receive a message describing the pro-social benefits of getting a flu shot, and a reminder to ask for their flu shot. The described pro-social benefits will vary whether they emphasize the COVID-19 pandemic (e.g., protecting loved ones from the risk of hospital-acquired COVID-19 infection) or not (e.g., protecting loved ones from serious complications from the flu). Participants will also receive a reminder message on the day of the appointment.
88883066|NCT05469464|Experimental|Orismilast modified release tablets 20 mg BID|Oral, twice daily morning and evening
88883067|NCT05469464|Experimental|Orismilast modified release tablets 30 mg BID|Oral, twice daily morning and evening
88883068|NCT05469464|Experimental|Orismilast modified release tablets 40 mg BID|Oral, twice daily morning and evening
89191132|NCT00719316|Experimental|Group 1|Patients receive Aliskiren 300mg for 6 weeks
89191133|NCT00719316|No Intervention|Group 2|4 weeks no antihypertensive medication
89407434|NCT04565353|Experimental|Self-Oriented Condition|The day before their scheduled appointment, participants will receive a message describing the self-oriented benefits of getting a flu shot, and a reminder to ask for their flu shot. The described self-oriented benefits will vary whether they emphasize the COVID-19 pandemic (e.g., protecting oneself from the risk of hospital-acquired COVID-19 infection) or not (e.g., protecting oneself from serious complications from the flu).
89407435|NCT04565353|Experimental|Information Vivid Condition|Three days before their scheduled appointment, participants will receive a message inviting them to watch a 2-minute wellness video and answer some related questions, as well as encouragement to get the flu shot. In this condition, the video will contain vivid information about getting the flu. Participants will also receive a reminder message the day before the appointment.
89407436|NCT04565353|Experimental|Information Basic Condition|Three days before their scheduled appointment, participants will receive a message inviting them to watch a 2-minute wellness video and answer some related questions, as well as encouragement to get the flu shot. In this condition, the video will contain basic information about getting the flu. Participants will also receive a reminder message the day before the appointment.
89407437|NCT04565353|Experimental|Information Control Condition|Three days before their scheduled appointment, participants will receive a message inviting them to watch a 2-minute wellness video and answer some related questions, as well as encouragement to get the flu shot. In this condition, the video will contain information about exercising. Participants will also receive a reminder message the day before the appointment.
88883069|NCT05469464|Placebo Comparator|Placebo tablets BID|Oral, twice daily morning and evening
88883070|NCT05464498|Experimental|MD-Tissue Medical Device|Group A which, alongside physiotherapy (eccentric strengthening protocol) will receive MD-Tissue Collagen Medical Device.
88883071|NCT05464498|Other|Eccentric strengthening protocol|Group B who will only perform physiotherapy (eccentric strengthening protocol).
88883072|NCT05438225|Experimental|Automated Text Message Reminder|Participants will receive automated reminder text instructing them to discuss hearing issues with their PCPs, and to request a referral to audiology or otolaryngology if they have hearing loss.
88883073|NCT05438225|No Intervention|Control Group|
89191134|NCT00720200|Experimental|1|
89407438|NCT04565353|Experimental|Sharing Humor Condition|The day before their scheduled appointment, participants will receive a text message encouraging them to get the flu shot. The message will include a joke about the flu and will encourage participants to share the joke with nurses, doctors, or pharmacists.
89407439|NCT04565353|Experimental|No Humor Condition|The day before their scheduled appointment, participants will receive a text message encouraging them to get the flu shot.
89407440|NCT04565353|Experimental|Healthy Habits Easy Health Behavior Condition|The day before their scheduled appointment, participants will be asked if they have completed a series of easy health behaviors (e.g., whether they walked 500 feet yesterday, at least two serving of fruits and vegetables in the last week, and slept at least 6 hours the previous night). They will then be encouraged to get a flu shot at their appointment.
89407441|NCT04565353|Experimental|Healthy Habits Difficult Health Behavior Condition|The day before their scheduled appointment, participants will be asked if they have completed a series of difficult health behaviors (e.g., whether they walked 3 miles yesterday, ate 4-6 servings of fruits and vegetables yesterday, and slept at least 9 hours the previous night). They will then be encouraged to get a flu shot at their appointment.
88883074|NCT05432167|Experimental|Low dose CIN-107|Patients will take oral tablets of CIN-107 for 26 weeks. The dose strength may be titrated within 6 weeks.
88883075|NCT05432167|Experimental|High dose CIN-107|Patients will take oral tablets of CIN-107 for 26 weeks. The dose strength may be titrated within 6 weeks.
88883076|NCT05432167|Placebo Comparator|Placebo|Patients will take oral tablets of Placebo for 26 weeks. The dose strength may be titrated within 6 weeks.
88883077|NCT05430230|Experimental|Cross-over Treatment: Initial treatment with naproxen|There will be a 4 period cross-over: 2 weeks of treatment with IP, followed by 2 weeks of washout, and this repeated 3 more times. Treatment will be such that all participants will receive 2 treatment periods with naproxen and 2 treatment periods with placebo. The order of treatment will be randomized and the treatment allocation and IP will be blinded.
88883078|NCT05430230|Experimental|Cross-over Treatment: Initial treatment with placebo|There will be a 4 period cross-over: 2 weeks of treatment with IP, followed by 2 weeks of washout, and this repeated 3 more times. Treatment will be such that all participants will receive 2 treatment periods with naproxen and 2 treatment periods with placebo. The order of treatment will be randomized and the treatment allocation and IP will be blinded.
88883079|NCT05405569||Group 1|Manikin laying on the ground and rescuer kneeled on the floor
88883080|NCT05405569||Group 2|Manikin laying on a bed at the level of the rescuer knees and rescuer standing on the side of the bed
89191135|NCT00720200|Active Comparator|2|
89191136|NCT03926988|Other|Intervention|NeVa Stent Retriever
89191137|NCT00857116|Active Comparator|Albendazole|Albendazole 400mg per os once daily for three consecutive days
89191138|NCT00857116|Placebo Comparator|Placebo|Placebo 400mg per os for three consecutive days
89407442|NCT04565353|Experimental|Healthy Habits Control Condition|The day before their scheduled appointment, participants will receive a text message encouraging them to get a flu shot.
89407443|NCT04565353|Experimental|Just-In-Time Reminders 24-Hour Condition|Seventy-two hours before their appointment, participants will receive a text message alerting them to the availability of the flu vaccine at their upcoming appointment. Participants will be told they'll receive a reminder, which they can opt-out from receiving. The text message reminder will be sent 24 hours before their appointment.
89407444|NCT04565353|Experimental|Just-In-Time Reminders 15-Minute Condition|Just-In-Time Reminders 15-Minute Condition: Seventy-two hours before their appointment, participants will receive a text message alerting them to the availability of the flu vaccine at their upcoming appointment. Participants will be told they'll receive a reminder, which they can opt-out from receiving. The text message reminder will be sent 15 minutes before their appointment.
89407445|NCT02975973|Experimental|2.5mA|Active stimulation group will receive 20 minutes of 2.5 mA transcranial direct current stimulation.
89407446|NCT02975973|Experimental|2.0mA|Active stimulation group will receive 20 minutes of 2.0 mA transcranial direct current stimulation.
89407447|NCT02975973|Experimental|1.5mA|Active stimulation group will receive 20 minutes of 1.5 mA transcranial direct current stimulation.
89407448|NCT02975973|Sham Comparator|0mA|This will be an active sham involving transcranial direct current stimulation, though stimulation will be brief (15 msec) and have low current (0.11 mA) pulses every 550 ms.
89407449|NCT02109510|Experimental|Nonintubated sedation anesthesia|nonintubated single port thoracoscopic bullectomy using local anesthesia under sedation Drug: Dexmedetomidine IV loading dose of 1ug/kg for 10 minutes and maintain dosage of 0.3-1 ug/kg/hr, ketamine IV 2-4 mg/kg/hr and intercostal nerve block with 2% lidocaine 2cc Device: facial O2 Mask
89407450|NCT02109510|Active Comparator|Intubated general anesthesia|intubated single port thoracoscopic bullectomy under general anesthesia Drug: propofol 2mg/kg IV , rocuronium 0.6mg/kg IV,1.2-2.4% sevoflurane, N20 50% 02 at fresh gas flow of 4L/min Device: double lumen endotracheal tube intubation
89407451|NCT02109588|No Intervention|Control|Sedentary pregnant women
89407452|NCT02109588|Experimental|Exercise group|"Supervised physical conditioning program of three 55-60 minute sessions per week during whole pregnancy (from week 9 to 38). Each session consists of 25-30 minutes of cardiovascular exercise,10 minutes of specific exercises (strength and balance exercises), and 10 minutes of pelvic floor muscles training~Aerobic activity was prescribed at light to moderate intensity, aiming for 55-60% of heart rate reserve. All subjects wore a heart rate (HR) monitor (Polar FT7) during the training sessions to ensure that exercise intensity was light to moderate"
89407453|NCT05404126|No Intervention|Control (Group 1)|Only assessments and scales will be applied to the participants in Group 1 at the beginning of the study and at the end of 12 weeks.
89407454|NCT05404126|Experimental|Conventional Exercise Balance (Group 2)|Group 2 will be included in the exercise program twice a week for 40 minutes for 12 weeks.
89407455|NCT05404126|Experimental|Dual Task-Oriented Stroboscopic Visual Training Group (Group 3)|Group 3 will be included in the exercise program twice a week for 40 minutes for 12 weeks. Trainings are planned with one-on-one therapist.
89407456|NCT05404126|No Intervention|Healthy Control Group (Group 4)|Only assessments and scales will be applied to the participants in Group 4 at the beginning of the study and at the end of 12 weeks.
89407457|NCT04470895||Usual falling patients|"a group enrolling the patients who completed the inclusive criteria and have had at least one fall in the last 12 months in addition to the possible fall causing the index fracture.~These patients must answer positively the following question Have you fallen in the last 12 months, regardless of the current fracture?"
89407458|NCT04470895||Unusual falling patients|"a group enrolling the patients who also completed the inclusive criteria, but are defined as unsual falling patients. These patients must answer negatively the following question: Have you fallen in the last 12 months, regardless of the current fracture?"
89407459|NCT03553368|Experimental|Step 1: Healthy volunteers|"Experimental intervention:~MRI data will be acquired with the use of HF-NIV (HF-NIV-MR).~Control intervention:~MRI data will be acquired without the use of HF-NIV, as a reference (MR)."
89407460|NCT03553368|Experimental|Step 2: Patients (arm A)|"Experimental intervention:~MRI data will be acquired with the use of HF-NIV (HF-NIV-MR).~Control intervention:~MRI data will also be acquired without the use of HF-NIV, as a reference (MR). The clinically prescribed CT will be the gold standard."
89407461|NCT03553368|Experimental|Step 2: Patients (arm B)|"Experimental intervention:~PET/CT data will be acquired with the use of HF-NIV (HF-NIV-PET). MRI data will be acquired with the use of HF-NIV (HF-NIV-MR). PET/CT data will be acquired in inspiratory breath hold without the use of HF-NIV (PET/CT breath hold).~Control intervention:~Data from the clinically indicated PET/CT acquisition will be used as reference.~MRI data will also be acquired without the use of HF-NIV, as a reference (MR). Histological data will be used when available."
89407462|NCT03553368|Experimental|Step 1 bis: Healthy volunteers|"Experimental intervention:~MRI data will be acquired with the use of CPAP (CPAP-MR).~Control intervention:~MRI data will be acquired without the use of CPAP, as a reference (MR)."
89407463|NCT02818972|Experimental|RelayPro|Endovascular treatment with the investigational device.
89407464|NCT04466995|Experimental|laparoscopic gynecologic surgery|25 laparoscopic surgery to endotracheal cuff pressure 5., 15., 30., 45. min will be measured, values will be recorded
89407465|NCT04466995|Other|laparotomic gynecologic surgery|25 laparotomic surgery to endotracheal cuff pressure 5., 15., 30., 45. min will be measured, values will be recorded
89407466|NCT02115126|Active Comparator|LMP2A-loaded conventional DC vaccine|Epstein-Barr virus (EBV) derived tumor antigen, LMP2 loaded DC vaccine
89407467|NCT02115126|Experimental|LMP2A-loaded DC vaccine + DUK-CPG-001|Epstein-Barr virus (EBV) derived tumor antigen, LMP2 loaded DC vaccine co-administered with a Toll-like receptor 9 (TLR9) ligand, DUK-CPG-001
89407468|NCT03627793|Active Comparator|High load non-frail|Non-frail participants who will receive resistance training at 70% of their maximal strength
89407469|NCT03627793|Active Comparator|low load non-frail|Non-frail participants who will receive resistance training at 30% of their maximal strength
89407470|NCT03627793|Experimental|high load frail|Frail participants who will receive resistance training at 70% of their maximal strength
89407471|NCT03627793|Experimental|low load frail|Frail participants who will receive resistance training at 30% of their maximal strength
89407472|NCT02109666||RA patients treated with Abatacept|RA patients are treated with Abatacept IV according Summary of Product Characteristics (SmPC) in Europe and Product Monograph in Canada
89407473|NCT03208855|Experimental|CBT-I|Participants will receive 8 1-hour sessions of group Cognitive Behavioral Therapy for insomnia as part of their intensive outpatient treatment of substance use recovery
89407474|NCT03208855|No Intervention|Treatment as Usual|Participants will receive treatment as usual for substance abuse treatment as part of their intensive outpatient treatment of substance use recovery
89407475|NCT02109822||CF patients with pulmonary exacerbations|Patients with CF who are hospitalized with a pulmonary exacerbation treated with intravenous antibiotics.
89407476|NCT03167281|No Intervention|tPA and DNase|10mg of t-PA and 5 mg of DNase in a 30 mL solution of water/saline administered via chest tube over three days twice daily 24-48 hours after chest tube placed.
89407477|NCT03167281|Experimental|Early tPA and DNase|10mg of t-PA and 5 mg of DNase in a 30 mL solution of water/saline administered via chest tube over three days twice daily with initial administration occurring at chest tube placement.
89407478|NCT02760004|Experimental|Prism Intervention|PRogram In Support of Moms (PRISM)
89407479|NCT02760004|Experimental|Enhanced Usual Care|Enhanced Usual Care group (Access to MCPAP for Moms)
89407480|NCT02109900||Serum Progesteron Levels|
89407481|NCT04408417|Experimental|Harnessing Sequence A|Participants will harness their child into the 2 different child safety seats in the following order: control, prototype, prototype, control.
89407482|NCT04408417|Experimental|Harnessing Sequence B|Participants will harness their child into the 2 different child safety seats in the following order: prototype, control, control, prototype.
89407483|NCT04408417|Experimental|Harnessing Sequence C|Participants will harness their child into the 2 different child safety seats in the following order: control, control, prototype, prototype.
89407484|NCT04408417|Experimental|Harnessing Sequence D|Participants will harness their child into the 2 different child safety seats in the following order: prototype, prototype, control, control.
89407485|NCT02112630|Experimental|Group 1 - Response Guided Therapy|"Treatment naive and documented relapsers : Subjects who have never been previously treated with P-IFN +/- ribavirin therapy and those who have documented relapse after P-IFN +/- ribavirin therapy.~Subjects in group 1 will receive P-IFN alfa 2a or P-IFN alfa 2b and ribavirin for a 4 week lead-in followed by the addition of boceprevir. Based on the patient's HCV-RNA levels at Treatment Week (TW) 8, TW12 and TW24 treatment with be continued for a total duration of 28 to 48 weeks.Subjects will be followed through treatment and up to 24 weeks post treatment."
89407486|NCT02112630|Experimental|Group 2 - Fixed Duration Therapy|"Partial/Null Responders /Undefined Previous Response, Compensated cirrhosis: Subjects who have compensated cirrhosis, and/or were previously treated with P-IFN +/- ribavirin without SVR (including partial responders, null responders, and those previously treated without adequate documentation of response).~Subjects in Group 2 will all be assigned to fixed duration therapy.Patients will be treated with P-IFN alfa 2a or P-IFN alfa 2b and ribavirin for a 4 week lead-in followed by the addition of boceprevir for a total of 48 weeks of therapy. Subjects will be followed through treatment and up to 24 weeks post treatment."
89407487|NCT04873375|Experimental|Cemiplimab|After inclusion, all patients will be treated with Cemiplimab 350mg intravenously every three weeks
89407488|NCT02112708|Experimental|Rational-Emotive-Behavioral Therapy|A social worker held eight 30 minutes sessions fortnightly of Rational-Emotive-Behavioral Therapy. First session is informative about the type of treatment to be performed. The next sessions work events, thoughts and feelings with the goal of changing the dysfunctional thoughts by other more rational ones, measured by scales.
88883081|NCT05405569||Group 3|Manikin laying on a higher bed and rescuer standing on a step stool on the side of the bed (the manikin should be at the level of rescuers knees)
89407489|NCT02112708|Active Comparator|Control Group|The control group (GC) will take the usual medical care for dysthimia, according with up-dated guidelines.
89407490|NCT05125666|Experimental|Dual Task Training|
88883082|NCT05405569||Group 4|Manikin laying on a bed and rescuer kneeled on the bed, on the side of the manikin.
89407491|NCT05125666|Active Comparator|Ordinary Physical Therapy for Ataxia|
89407492|NCT02112786|Active Comparator|Intermittent then Continuous|This group will be set to intermittent stimulation first, then after the wash out period they will be switched to continuous stimulation.
89407493|NCT02112786|Active Comparator|Continuous Then Intermitent|This group will be set to continuous stimulation first, then switch to intermittent after the wash out time period.
89407494|NCT05123950||Cohort 1|Participants diagnosed with R/M SCCHN between 01-Jan-2014 and 31-Dec-2016
88883083|NCT05400655|Experimental|Part 1: Children age 5-10: 5 mg/kg of L9LS|Enrolled individuals will receive 5 mg/kg of L9LS via SC injection.
88883084|NCT05400655|Placebo Comparator|Part 1: Children age 5-10: Placebo|1/4 of children age 5-10 will receive placebo of Normal Saline for comparison.
88883085|NCT05400655|Experimental|Part 1: Children age 5-59 months: 5 mg/kg of L9LS|
88883086|NCT05400655|Experimental|Part 1: Children age 5-10 years: 10 mg/kg of L9LS|
88883087|NCT05400655|Experimental|Part 1: Children age 5-10 years: 20 mg/kg of L9LS|
89407495|NCT05123950||Cohort 1- Augment|Participants newly initiating 1L treatment for R/M SCCHN between 01-Jun-2017 and 01-Jun-2018
89407496|NCT05125588|Experimental|Treatment A|"Reumoxicam® 15 mg tablets (PJSC Farmak, Ukraine)"
89407497|NCT05125588|Active Comparator|Treatment B|"Movalis 15 mg tablets (Boehringer Ingelheim Ellas A.E., Greece)"
89407498|NCT02115204|Experimental|EC-Doc|4 cycles epirubicin + docetaxel (90/600) i.v., q = 3 weeks, followed by 4 cycles docetaxel (100) i.v., q = 3 weeks
89407499|NCT02115204|Active Comparator|CMF/CEF|6 cycles cyclophosphamide, methotrexate, 5-fluorouracil (CMF) (600/40/600) i.v., day 1 + 8, q = 4 weeks or 6 cycles cyclophosphamide, epirubicin, 5-fluorouracil (CEF) (500/100/500) i.v., day 1, q = 3 weeks
89407500|NCT02115360|Active Comparator|Calcitonin|Under full aseptic conditions, the epidural space was identified at the L 2-3 or L 3-4 lumbar interspace using the loss-of-resistance to saline technique using 16-gauge Tuohy needle. A test-dose of 3 mL of a 2% solution of lidocaine with adrenaline (1:200,000) will be given to exclude subarachnoid or intravenous catheter placement. An injection of a2 ml hyperbaric bupivacaine will be injected into the subarachnoid space through 25 gauge spinal needle, then 15ml 0.5% bupivacaine, 100 micrograms of fentanyl and 100 iu of calcitonin will be injected epidurally in Bupivacain-Calcitonin-fentanyl (BC) Group,
89407501|NCT02115360|Active Comparator|fentanyl|Under full aseptic conditions, the epidural space was identified at the L 2-3 or L 3-4 lumbar interspace using the loss-of-resistance to saline technique using 16-gauge Tuohy needle. A test-dose of 3 mL of a 2% solution of lidocaine with adrenaline (1:200,000) will be given to exclude subarachnoid or intravenous catheter placement. An injection of a2 ml hyperbaric bupivacaine will be injected into the subarachnoid space through 25 gauge spinal needle, then 15ml 0.5% bupivacaine, 100 micrograms of fentanyl and 1ml normal saline will be injected epidurally in Bupivacain- fentanyl (BF) Group, then a 16G Portex catheter was inserted for post- operative analgesia.
89407502|NCT01362322|Experimental|BOOSTRIX NEW GROUP|Subjects, aged 10 to 15 years, received one dose of Boostrix™ vaccine administered using a new syringe presentation (prefilled syringes from a different manufacturer) in the deltoid of the non-dominant arm, at Day 0.
89407503|NCT01362322|Active Comparator|BOOSTRIX PREV GROUP|Subjects, aged 10 to 15 years, received one dose of Boostrix™ vaccine administered using a previous syringe presentation (single dose vial or a prefilled disposable syringe without a needle) in the deltoid of the non-dominant arm, at Day 0.
89407504|NCT02112942|Experimental|Group A|Healthy subjects, sequential dose escalation, IDX21459 capsules or Matching Placebo capsules, once daily, up to 7 days
89407505|NCT02112942|Experimental|Group B|HCV subjects genotype 1, IDX21459 capsules, once for 1 day
89407506|NCT02112942|Experimental|Group C|HCV subjects genotype 1, IDX21459 capsules or Matching Placebo capsules, once daily, for 7 days
89407507|NCT02113020|Experimental|TAK-233|Oral administration
89407508|NCT02113020|Placebo Comparator|Placebo|Oral administration
89407509|NCT02115438||Occupational Stress|
89407510|NCT03553290|Sham Comparator|control|Mechanical debridement alone
89191139|NCT00717782|Experimental|1|"Patients were injected with 0·6 ml of a solution containing 30 units botulinum toxin A (Botox; Allergan, Ireland).~A 27-G needle was used to give two injections of equal volume (0·3 ml) into the internal anal sphincter, one on each side of the anterior midline of the sphincter."
89191140|NCT00717782|Placebo Comparator|2|"Patients in the placebo group received a 0·6-ml injection of saline.~A27-G needle was used to give two injections of equal volume (0·3 ml) into the internal anal sphincter, one on each side of the anterior midline of the sphincter."
89191141|NCT00719394|Experimental|GSI 136|
89407511|NCT03553290|Active Comparator|lower-level laser Therapy|"Mechanical debridement with lower-level laser therapy~Device: A.R.C. FOX Laser-FOX Q-810nm Mechanical debridement with lower-level laser therapy"
89407512|NCT02432404|Active Comparator|Cyclic NuvaRing CVR Use|CVR use for 3 weeks, remove for 1 week, then replace
89407513|NCT02432404|Experimental|Continuous NuvaRing CVR Use|CVR use for 4 weeks, then replace
89191142|NCT00719394|Placebo Comparator|placebo|
89191143|NCT00857194||Group 2|Chronic, stable spinal cord injury
89191144|NCT03909828||Parkinson's disease patients|patients with Idiopathic Parkinsonism
89191145|NCT00857350||HIV+, opiod dependent|
89407514|NCT02115516|Experimental|Stage A: Grp A1 - 3,200 PfSPZ Challenge|Group A1 (PfSPZ Challenge) (n=9) receives three injections of 3,200 PfSPZ Challenge intravenous (IV) at 4-week intervals. Immunizations are given under a standard chemoprophylactic regimen with chloroquine. Two days before the first PfSPZ Challenge injection volunteers receive one oral dose of 10 mg/kg CQ base. On Day 5 volunteers will receive 5 mg/kg CQ base. Subsequently, volunteers will receive 5 mg/kg CQ base in weekly intervals for a total of ten doses. Eight weeks after the last immunization, volunteers will undergo homologous CHMI with 3,200 PfSPZ Challenge IV. Early unblinding for this group may be done on Week 19, if required. All groups in Stage A are scheduled to be unblinded on Week 27.
89407515|NCT02115516|Experimental|Stage A: Grp A2 - 12,800 PfSPZ Challenge|Group A2 (PfSPZ Challenge) (n=9) starts when Group A1 receives the second immunization. Group A2 receives three injections of 12,800 PfSPZ Challenge IV at 4-week intervals. Immunizations are given under a standard chemoprophylactic regimen with chloroquine. Two days before the first PfSPZ Challenge injection volunteers receive one oral dose of 10 mg/kg CQ base. On Day 5 volunteers will receive 5 mg/kg CQ base. Subsequently, volunteers will receive 5 mg/kg CQ base in weekly intervals for a total of ten doses. Eight weeks after the last immunization, volunteers will undergo homologous CHMI with 3,200 PfSPZ Challenge IV. Early unblinding for this group may be done on Week 23, if required. All groups in Stage A are scheduled to be unblinded on Week 27.
89407516|NCT02115516|Experimental|Stage A: Grp A3 - 51,200 PfSPZ Challenge|Group A3 (PfSPZ Challenge) (n=9) starts when Group A2 receives the second immunization. Group A3 receives three injections of 51,200 PfSPZ Challenge IV at 4-week intervals. Immunizations are given under a standard chemoprophylactic regimen with chloroquine. Two days before the first PfSPZ Challenge injection volunteers receive one oral dose of 10 mg/kg CQ base. On Day 5 volunteers will receive 5 mg/kg CQ base. Subsequently, volunteers will receive 5 mg/kg CQ base in weekly intervals for a total of ten doses. Eight weeks after the last immunization, volunteers will undergo homologous CHMI with 3,200 PfSPZ Challenge IV. This group is scheduled to be unblinded with all other groups in Stage A Week on 27.
89407517|NCT02115516|Placebo Comparator|Stage A: Grp A1 - 0.9% Sodium Chloride|Group A1 (placebo) (n=5) receives three injections of 0.9% Sodium chloride IV at 4 week intervals. Placebo injections are given under a standard chemoprophylactic regimen with chloroquine. Two days before the first placebo injection volunteers receive one oral dose of 10 mg/kg CQ base. On Day 5 volunteers will receive 5 mg/kg CQ base. Subsequently, volunteers will receive 5 mg/kg CQ base in weekly intervals for a total of ten doses. Eight weeks after the last placebo injection, volunteers will undergo homologous CHMI with 3,200 PfSPZ Challenge IV. Early unblinding for this group may be done on Week 19, if required. All groups in Stage A are scheduled to be unblinded on Week 27.
89531022|NCT02498795|Active Comparator|Group of Dry Needling|"They will receive a treatment of dry needling with ultrasound scan together with a treatment in which they will realize eccentric exercise's program that the patient will have to realize in his domicile.~The needle will get in the relevant zone of treatment. The punction will be realized using the technique of entry - Hong's rapid exit. Three punction will realize in the disabled zone of 3 seconds of duration."
89531023|NCT02498795|Active Comparator|Group of electrolysis|"They will receive a treatment of Intratissue Percutaneous Electrolysis with ultrasound scan together with a treatment in which they will realize eccentric exercise's program that the patient will have to realize in his domicile.~The needle will get in the relevant zone of treatment. An intensity of 3 milliampere will be in use, during 3 seconds and one will repeat 3 times."
89531024|NCT02498795|Placebo Comparator|Control Group|They will receive a treatment of punction placebo with ultrasound scan together with a treatment in the one that will realize eccentric exercise's program that the patient will have to realize in his domicile.
89531025|NCT02494895|Experimental|Ticagrelor monotherapy|Ticagrelor monotherapy at 3 months after PCI
88883088|NCT05400655|Experimental|Part 1: Children age 5-59 months: 10 mg/kg of L9LS|
88883089|NCT05400655|Experimental|Part 1: Children age 5-59 months: 20 mg/kg of L9LS|
88883090|NCT05400655|Placebo Comparator|Part 1: Children age 5-59 months: Placebo|1/4 of subjects age 5-59 months will receive placebo of Normal Saline for comparison.
88883091|NCT05400655|Experimental|Part 2: Children age 5-17 months: 1 dose L9LS at 10-19 mg/kg|Subjects age 5-17 months will receive 1 dose of L9LS via SC injection.
88883092|NCT05400655|Experimental|Part 2: Children age 5-17 months: 2 doses L9LS at 10-19 mg/kg|Subjects age 5-17 months will receive 1 dose of L9LS and a second dose at 6 months via SC injection.
88883093|NCT05400655|Placebo Comparator|Part 2: Children age 5-17 months: Placebo|1/3 of subjects age 5-17 months will receive placebo of normal saline for comparison.
88883094|NCT05400655|Experimental|Part 2: Children age 18-59 months: 1 dose L9LS at 10-19 mg/kg|Subjects age 18-59 months will receive 1 dose L9LS via SC injection.
88883095|NCT05400655|Experimental|Part 2: Children age 18-59 months: 2 doses L9LS at 10-19 mg/kg|Subjects age 18-59 months will receive 1 dose L9LS, followed by a second dose at 6 months via SC injection.
88883096|NCT05400655|Placebo Comparator|Part 2: Children age 18-59 months: Placebo|1/3 of subjects age 18-59 months will receive placebo of normal saline for comparison.
88883097|NCT05397912||Women undergoing euploid, single frozen embryo transfer|Women age 18yo-45yo undergoing euploid, single, frozen embryo transfer with sonographically normal appearing uterus without uterine factor infertility
88883098|NCT05390398|Experimental|Intervention group|The intervention group follows a six-month personalized lifestyle program to increase adherence to the World Cancer Research Fund cancer prevention guidelines on healthy nutrition, physical activity and healthy weight.
88883099|NCT05390398|No Intervention|Wait-list usual care group|The wait-list usual care group follows usual care and usual activities. Participants receive a lifestyle program after the intervention period of six months: this includes two personalized behavioural coaching sessions and any material that the intervention group also received.
88883100|NCT05383079|Experimental|Radium-223 and Lutetium-177 PSMA-I&T|In this single-arm study, patients will receive 7.4 GBq of 177Lu-PSMA-I&T on Day 1 of every 6 week Cycle. Radium-223 will be administered concurrently every 6 weeks. The dose of Radium-223 will vary in dose-escalation. Up to 6 Cycles will be given.
88883101|NCT05381155|Experimental|Immediate Treatment|Participants in the immediate treatment group will receive the single-session behavioral intervention on day 15.
88883102|NCT05381155|Other|Waitlist|Participants in the waitlist control group will receive the single-session behavioral intervention on day 30.
88883103|NCT05370820|Experimental|Cesarean Delivery|
88883104|NCT05370820|Experimental|Vaginal Delivery|
88883105|NCT05370820|Experimental|Morbidly Obese|
88883106|NCT05370820|No Intervention|No TXA|
88883107|NCT05367544|Experimental|Health Education & Peer Coaching|Participants will have access to online health education materials and will also be matched with a community health worker who will offer support through peer coaching
88883108|NCT05367544|Active Comparator|Health Education Only|Participants will have access to online health education materials but will not receive individualized peer support
89407518|NCT02115516|Placebo Comparator|Stage A: Grp A2 - 0.9% Sodium Chloride|Group A2 (placebo) (n=5) starts when Group A1 receives the second immunization. Group A2 receives three injections of 0.9% Sodium chloride IV at 4 week intervals. Placebo injections are given under a standard chemoprophylactic regimen with chloroquine. Two days before the first placebo injection volunteers receive one oral dose of 10 mg/kg CQ base. On Day 5 volunteers will receive 5 mg/kg CQ base. Subsequently, volunteers will receive 5 mg/kg CQ base in weekly intervals for a total of ten doses. Eight weeks after the last placebo injection, volunteers will undergo homologous CHMI with 3,200 PfSPZ Challenge IV. Early unblinding for this group may be done on Week 23, if required. All groups in Stage A are scheduled to be unblinded on Week 27.
88883109|NCT05341011|Experimental|Treatment (TX) Group|The TX group received 14 weeks of the PEERS® intervention immediately following a baseline assessment,
88883110|NCT05341011|Experimental|Delayed Treatment Control (DTC) Group|The DTC group received the same intervention after a 14-week waiting period. Parents and teens attended concurrent sessions held in separate rooms.
88883111|NCT05329220|Experimental|ABNCoV2 100μg single dose|ABNCoV2 100μg single dose
88883112|NCT05329220|Active Comparator|Comirnaty|Comirnaty
88883113|NCT05328258|Experimental|Arm A: Triptorelin|"Triptorelin given intramuscularly once every month or every third month during gonadotoxic chemotherapy treatment.~The dose is ether 11.25 mg triptorelin given for subjects having at least 3 months gonadotoxic treatment, OR 3.75 mg for subjects during one-month of gonadotoxic treatment"
89407519|NCT02115516|Placebo Comparator|Stage A: Grp A3 - 0.9% Sodium Chloride|Group A3 (placebo) (n=5) starts when Group A2 receives the second immunization. Group A3 receives three injections of 0.9% Sodium chloride IV at 4 week intervals. Placebo injections are given under a standard chemoprophylactic regimen with chloroquine. Two days before the first placebo injection volunteers receive one oral dose of 10 mg/kg CQ base. On Day 5 volunteers will receive 5 mg/kg CQ base. Subsequently, volunteers will receive 5 mg/kg CQ base in weekly intervals for a total of ten doses. Eight weeks after the last placebo injection, volunteers will undergo homologous CHMI with 3,200 PfSPZ Challenge IV. This group is scheduled to be unblinded with all other groups in Stage A on Week 27.
89407520|NCT02115516|Experimental|Stage B: Grp B1 - 51,200 PfSPZ Challenge|Group B1 (n=5) will receive the optimal PfSPZ Challenge immunizing dose from the dose-escalation phase (Stage A; 51,200 PfSPZ Challenge (NF54)), using the same standard chemoprophylactic regimen with CQ (10 mg/kg CQ base loading dose, followed by weekly dosing with 5 mg/kg CQ base), but for five instead of ten weeks. Group B1 will receive 3 injections of 51,200 PfSPZ Challenge (NF54) on days 0, 14 and 28. All volunteers in Group B1 will undergo homologous CHMI with PfSPZ Challenge 10 weeks after the last immunization.
89407521|NCT02115516|Placebo Comparator|Stage B: Group B1 - 0.9% Sodium Chloride|Group B1 (placebo) (n=2) will receive three injections of 0.9% Sodium Chloride on days 0, 14 and 28. This group will follow the the same standard chemoprophylactic regimen with CQ (10 mg/kg CQ base loading dose, followed by weekly dosing with 5 mg/kg CQ base), but for five instead of ten weeks. All volunteers in Group B1 will undergo homologous CHMI with PfSPZ Challenge 10 weeks after the last immunization.
89531026|NCT02494895|Active Comparator|Ticagrelor with Aspirin|Ticagrelor with Aspirin DAPT(Dual Anti-platelet Treatment)
89531027|NCT02498873|Active Comparator|Linear Periodization|Linear Periodization Running (Crossover Design)
89531028|NCT02498873|Active Comparator|Non Linear Periodization|Non Linear Periodization Running (Crossover Design)
88883114|NCT05328258|Placebo Comparator|Arm B: Placebo|"Placebo, 0.9% sodium chloride, given intramuscularly once every month or every third month during gonadotoxic chemotherapy treatment.~The dose will be provided both as one injection compensating for 3 months' effect and one injection compensating for 1 month' effect to maintain the study blind."
88883115|NCT05311969|Experimental|groups/cohort|participants will perform the various neuropsychological tests provided for in the protocol
88883116|NCT05301322|Experimental|Coadministration Group|RSVpreF and SIIV followed by placebo a month later
88883117|NCT05301322|Experimental|Sequential Administration Group|Placebo and SIIV followed by RSVpreF a month later
88883118|NCT05265026|Experimental|Exercise Intervention Arm|Three high intensity interval exercise sessions per week of 40 minutes duration per session. Exercise will be performed on ergometerbikes.
88883119|NCT05265026|No Intervention|No Intervention|No lifestyle changes
88883120|NCT05256537|Experimental|Open Arm|Omission of the drug mycophenolate mofetil
88883121|NCT05253573|Experimental|Automated Treatment|AT consists of all SC components plus a fully automated smartphone-based JITAI that involves proactive, interactive, and personalized messages, images, or videos in Lao.
88883122|NCT05253573|Active Comparator|Standard Care|"SC consists of brief advice to quit smoking delivered by research staff, self-help written materials (the WHO's A guide for tobacco users to quit that we have translated to and validated in Lao), and a 2-week supply of NRT (transdermal patches)."
88883123|NCT05252845|Experimental|R21/Matrix-M + DHA-PIP+PQ|The R21/Matrix-M vaccine (IM injection) + co-formulated Dihydroartemisinin/Piperaquine tablets + one single low dose of Primaquine
88883124|NCT05252845|Experimental|R21/Matrix-M only|The R21/Matrix-M vaccine (IM injection) only
88883125|NCT05252845|Active Comparator|DHA-PIP+PQ only|Co-formulated Dihydroartemisinin/Piperaquine tablets + one single low dose of Primaquine
88883126|NCT05242380|Experimental|Kettlebell Exercise|8-week, 3-day/week supervised training will be applied to the participants in this group. After the initial assessment, patients in this group will receive a one-session education on the pathophysiology of PAH, the benefits of physical activity, and energy conservation techniques during activities of daily living. Pharmacological treatment of patients in this group will be continued.
88922009|NCT05972174|Experimental|Part A Group 1 Vaccine: mRNA-1018 for H5 Only Dose Level 1|Participants will receive mRNA-1018 for H5 only at dose level 1 by IM injection on Day 1 and Day 22.
89407522|NCT02115516|Experimental|Stage B: Grp B2 - 51,200 PfSPZ Challenge|Group B2 (n=5) will receive 3 injections of 51,200 PfSPZ Challenge on days 0, 14 and 28, using same std chemoprophylactic regimen with CQ (10 mg/kg CQ base loading dose, followed by weekly dosing with 5 mg/kg CQ base), for 5 instead of 10 wks. But Group B2 will receive extended-release azithromycin (ER-AZ, 2g) on the day of 1st PfSPZ Challenge and monitored for parasitemia by quantitative real time polymerase reaction (qPCR). In case that all CQ+ER-AZ treated volunteers are parasite-free until Day 11 following first PfSPZ Challenge injection, it will indicate that ER-AZ effectively killed the parasites in the liver prior to development of parasitemia. With demonstration of the effectiveness of ER-AZ, the 2nd and 3rd immunizations will be done under ER-AZ alone, otherwise CQ prophylaxis will continue and ER-AZ will not be administered for the 2nd and 3rd injections. Group B2 will undergo homologous CHMI with PfSPZ Challenge, 10 weeks after the last immunization.
89407523|NCT02115516|Placebo Comparator|Stage B: Group B2 - 0.9% Sodium Chloride|Group B2 (placebo) (n=2) will receive three injections of 0.9% Sodium Chloride on days 0, 14 and 28, using the same standard chemoprophylactic regimen with CQ (10 mg/kg CQ base loading dose, followed by weekly dosing with 5 mg/kg CQ base), for 5 instead of 10 wks. But Group B2 will receive ER-AZ, 2g on the day of 1st placebo injection and monitored for parasitemia by qPCR. In case that all CQ+ER-AZ treated volunteers are parasite-free until Day 11 following 1st injection, it will indicate that ER-AZ effectively killed the parasites in the liver prior to the development of parasitemia. With demonstration of the effectiveness of ER-AZ, the 2nd and 3rd immunizations will be done under ER-AZ alone, otherwise CQ prophylaxis will be continued and ER-AZ will not be administered for 2nd and 3rd injections. Group B2 will undergo homologous CHMI with PfSPZ Challenge 10 weeks after last immunization.
89407524|NCT02115516|Experimental|Stage B: Grp B3 - 51,200 PfSPZ Challenge|Group B3 (n=9) volunteers will receive CQ and PfSPZ Challenge simultaneously every five days with one additional dose of CQ five days after the third PfSPZ Challenge injection. A 10 mg/kg CQ base loading dose is given at the time of first PfSPZ Challenge inoculation, followed by 5 mg/kg CQ base on the day of second and third inoculation and five days after the last PfSPZ Challenge inoculation. Group B3 will undergo homologous CHMI with PfSPZ Challenge 10 weeks after the last immunization.
89407525|NCT02115516|Placebo Comparator|Stage B: Group B3 - 0.9% Sodium Chloride|Group B3 (placebo) (n=2) volunteers will receive CQ and 0.9% Sodium Chloride simultaneously every five days with one additional dose of CQ five days after the third placebo injection. A 10 mg/kg CQ base loading dose is given at the time of first placebo injection, followed by 5 mg/kg CQ base on the day of second and third injections and five days after the last placebo injection. Group B3 will undergo homologous CHMI with PfSPZ Challenge 10 weeks after the last immunization.
89407526|NCT02192788|Experimental|SBRT|Stereotactic Body Radiation Therapy for Oligometastases (SBRT)
89407527|NCT02113098|Experimental|Treadmill, ankle load|The experimental group will perform gait training on a treadmill with added load to the non-paretic lower limb
89407528|NCT02113098|Active Comparator|Treadmill|The control group (active comparator) will perform gait training on a treadmill
89407529|NCT02113176|Experimental|Minocycline|"200 mg IV/placebo~Followed by 100 mg IV BID x 7days~Followed by 200 mg tablet QD x 14days"
89407530|NCT02113176|Placebo Comparator|Placebo|200 mg IV/placebo
89407531|NCT01831570|Other|symptomatic and radiographic hand osteoarthritis|Patients above 35-years old with symptomatic and radiographic hand osteoarthritis
89407532|NCT02113254|Experimental|Healthy volunteer|
89407533|NCT01755208|Experimental|Diagnostic (light-scattering spectroscopy)|Patients undergo light-scattering spectroscopy of the breast in addition to standard of care as it relates to screening for breast cancer or treatment of breast cancer.
89407534|NCT02118870|Active Comparator|DAPT 360 days|Treatment 360 days DAPT
89407535|NCT02118870|Active Comparator|DAPT 90 days|Treatment 90 days DAPT
89407536|NCT05125432|Experimental|Acupuncture group|Acupuncture group Patients with breast cancer who experienced AIA were assessed by the Brief Pain Inventory (BPI)scale and McMasters College Osteoarthritis Index Score (WOMAC). Patients who met the criteria for inclusion would receive regular acupuncture treatment. The location of acupuncture is based on the principles of acupuncture treatment in Traditional Chinese medicine. Patients with high scores and obvious pain received standardized acupuncture treatment, and standard acupuncture points and most painful joint (up to 3) specific point. Meanwhile, blood samples of patients were collected, and SNP related to AIA was screened through SNP typing technology.
89407537|NCT05123638|Experimental|Virtual reality cycling exercise|These patient participants will receive 1 session of unsupervised stationary cycling exercise with the SYNCSENSE VR-technology every weekday of participation and be allowed up to 30min of voluntary exercise pr. session.
89407538|NCT05123638|Active Comparator|Conventional cycling exercise|These patient participants will receive 1 session of unsupervised stationary cycling exercise on every weekday of participation and be allowed up to 30min of voluntary exercise pr. session.
89407539|NCT02118948|Experimental|Abuse-focused intervention|Participants attend 5 weekly, 2-hour intervention sessions focused on the psychological consequences of abuse, current sexual risk behavior, and the link between the two.
89004596|NCT02834884||RP-1828 IMMUcan|"The goal is to generate broad molecular and cellular profiling data of the tumour and its microenvironment from cancer patients integrated with clinical data, to understand how the immune system and tumours interact, and the impact of current therapeutic interventions.~Tumor types: Thorax, Head and Neck, Breast, Gastrointestinal, Genito Urinary"
89191146|NCT00717938|Other|A|Standard chemotherapy treatment for patients with small cell lung cancer. Chemotherapy regimen contains a platinum drug and a topoisomerase inhibitor. Numbers of cycles 4-6 according to local variants.Used drugs=cisplatinum or carboplatin and e.g.etoposide.
89407540|NCT02118948|Active Comparator|Sexual behavior-focused intervention|Participants attend 5 weekly, 2-hour intervention sessions focused on current sexual risk behavior.
89407541|NCT05125120|Other|Attention Deficit and Hyperactivity Disorder|Attention Deficit and Hyperactivity Disorder (CO-OP Group) Attention Deficit and Hyperactivity Disorder (Control Group)
89407542|NCT03552666|Experimental|Vitafusion Extra Strength Vitamin D3 Gummy|A single oral dose of gummy vitamin D3 to monitor Vitamin D blood levels
89407543|NCT03552666|Active Comparator|Nature Made Vitamin D3 Tablet|A single oral dose of tablet vitamin D3 to monitor Vitamin D blood levels
89407544|NCT05123404|Experimental|intervention arm|Patients will undergo MRI followed by TURBT
89407545|NCT02115594|Experimental|Fulvestrant + Entinostat|Arm A: Fulvestrant (500 mg on C1D1, C1D15, C2D1, and on Day 1 of each subsequent cycle) plus entinostat (5 mg PO once weekly)
89407546|NCT02115594|Active Comparator|Fulvestrant + Placebo|Arm B: Fulvestrant (500 mg on C1D1, C1D15, C2D1, and on Day 1 of each subsequent cycle) plus placebo (5 mg PO once weekly)
89407547|NCT05125042|Experimental|group A|Amiodarone hydrochloride tablet + acupoint catgut embedding of Neiguan and Zusanli
89407548|NCT05125042|Active Comparator|group B|Amiodarone hydrochloride tablet
89407549|NCT02115672|Experimental|BL-8040|Patients with chronic phase CML on Imatinib therapy (400 mg/day) achieving less than an optimal response will be treated with sc injections of BL-8040, while continuing Imatinib. The first part of the study will include escalating dose groups. Up to 4 dose levels will be investigated starting at dose level 1. Patients will be accrued in a conventional 3+3 design. Applying this study design, the first cohort of 3 patients will be treated at dose level 1 (0.5 mg/kg) on Day 1, 15, 29 and 43. Patients will continue taking Imatinib 400 mg/day throughout the study. Dose escalation will continue until the maximal tolerated dose (MTD) is established and protocol specific stopping rules for toxicity are met. If no MTD is reached, dose escalation will continue up to dose level 4 (1.25 mg/kg).
89407550|NCT05124964||1|Patients with newly diagnosed primary intracranial germ cell tumors are scheduled for subsequent anti-tumor therapy.
89407551|NCT02119182||Comprehensive Assessment with MRI|"In-Person Outcome Assessment at 2 weeks, 6 months, and 12 months.~Phone Outcome Assessment at 3 months.~3T Magnetic Resonance Imaging (MRI) at 2 weeks and 6 months.~Blood Draw for Plasma, DNA, Serum, RNA at baseline, in hospital (if applicable), 2 weeks, and 6 months (DNA at baseline only)."
88883127|NCT05242380|No Intervention|Control|Any intervention will not be performed. After the initial assessment, patients in this group will receive a one-session education on the pathophysiology of PAH, the benefits of physical activity, and energy conservation techniques during activities of daily living. Pharmacological treatment of patients in this group will be continued.
88883128|NCT05201898|Placebo Comparator|usual medical management|with regular doctor visits every 3 months
88883129|NCT05201898|Experimental|usual medical management+individual dietary consultation|with regular doctor visits every 3 months and dietitian visits every 3 months until meeting dietary recommendation or reaching 3 years limit
88883130|NCT05201898|Experimental|usual medical management+individual dietary consultation+ daily tea drinking|with regular doctor visits every 3 months, dietitian visits every 3 months until meeting dietary recommendation or reaching 3 years limit, and daily tea drinking
88883131|NCT05179954|Other|Control group|Healthy control group
88883132|NCT05179954|Active Comparator|T1D group|T1D group
88883133|NCT05166785|Active Comparator|In-person Diabetes Prevention Program (DPP)|Participants randomized to the in-person DPP intervention for 12 months
88883134|NCT05166785|Active Comparator|DPP program Tailored for Older Adults and delivered via Telehealth (DPP-TOAT arm)|Participants randomized to the DPP program Tailored for Older Adults and delivered via Telehealth (DPP-TOAT arm) intervention for 12 months.
89407552|NCT02119182||Comprehensive Assessment without MRI|"In-Person Outcome Assessment at 2 weeks, 6 months, and 12 months.~Phone Outcome Assessment at 3 months.~Blood Draw for Plasma, DNA, Serum, RNA at baseline, in hospital (if applicable), 2 weeks, and 6 months (DNA at baseline only)."
89407553|NCT02119182||Brief Assessment|• Telephone outcome assessment at 2 weeks, 3 months, 6 months, and 12 months.
89407554|NCT01341574|Experimental|Early phase, experimental|Neglect patients, randomized in the experimental group (Prism adaptation, optical shift of 10 degrees) in the early phase after stroke.
89407555|NCT01341574|Experimental|Delayed phase, experimental|Neglect patients, randomized in the experimental group (Prism adaptation, optical shift of 10 degrees) in the delayed phase after stroke.
89407556|NCT01341574|Placebo Comparator|Early phase, placebo|Neglect patients, randomized in the placebo group (Prism adaptation, optical shift of 0 degrees) in the early phase after stroke.
89407557|NCT01341574|Placebo Comparator|Delayed phase, placebo|Neglect patients, randomized in the placebo group (Prism adaptation, optical shift of 0 degrees) in the delayed phase after stroke.
89407558|NCT01341574|Experimental|Delayed phase postural, experimental|Neglect patients, randomized in the experimental group (Prism adaptation, optical shift of 10 degrees) in the delayed phase after stroke. In this group, postural aspects are taken into account.
89407559|NCT03622125||1|Patients who apply anti-scorpion venom serum Birmex at the discretion of the attending physician were given vital signs.
89407560|NCT03622125||2|Patients who apply anti-scorpion venom serum Alacramyn at the discretion of the attending physician were given vital signs.
89407561|NCT02113332|Experimental|Liraglutide|Liraglutide injected once per day for 24 weeks. Dose is 1,8 mg or highest tolerable dose.
89407562|NCT02113332|Placebo Comparator|Placebo|Placebo injected once per day for 24 weeks. Dose is 1,8 or highest tolerable dose.
89407563|NCT03653949|Experimental|High Intensity Interval Training|The subjects will participate of an educational intervention and a High Intensity Interval Training.
89407564|NCT03653949|Active Comparator|Control Group|The subjects will participate of an educational intervention.
89407565|NCT05130112|Experimental|HFNC then NC|High flow nasal cannula for 10 min (Period 1) and nasal cannula for 10 min (Period 2) after a 4-week washout period
89407566|NCT05130112|Experimental|NC then HFNC|Nasal cannula for 10 min (Period 1) and high flow nasal cannula for 10 min (Period 2) after a 4-week washout period
89407567|NCT02115906||Acromegalic patients|Acromegalic patients before and after initiation of individual therapy will be investigated by 1H/31P magnetic resonance spectroscopy, thyroid sonography and oral glucose tolerance testing
88883135|NCT05154058|Active Comparator|Control: electrocautery|Primary patients with Osteoarthritis (OA) undergoing Total Knee arthroplasty (TKA) will be randomly assigned into either the control or investigational group. The control arm of the study will undergo medial sub periosteal release with electrocautery.
88883136|NCT05154058|Active Comparator|Investigational: sharp dissection.|Primary patients with OA undergoing TKA will be randomly assigned into either the control or investigational group. The investigational arm will undergo medial sub periosteal release using sharp dissection.
88883137|NCT05140551|Experimental|COMPASS|This is a single arm study. We are investigating COMPASS digital CBT.
88883138|NCT05129098|Experimental|Left Bundle Branch Pacing|Implantation of a left bundle branch lead via sheath, to perform left bundle branch pacing
88883139|NCT05129098|Active Comparator|Conventional Right Venticular Pacing|The ventricular lead will be implanted in the right ventricle in the conventional way
88883140|NCT05082649|Experimental|Telerehabilitation|Remotely (with video) progressive spinal stabilization exercises.
88883141|NCT05082649|Active Comparator|Face to Face Exercises|Face to face (in clinic) progressive spinal stabilization exercises.
88883142|NCT05073809||Group 1|Proven or highly suspected head and neck tumour undergoing routine clinical staging of their neck LN status
88883143|NCT05073809||Group 2|Proven or suspected oral cavity cancer, amenable to intraoral examination
88883144|NCT05066347|No Intervention|Usual care|Patients randomized to usual care will receive all care as prescribed by the discharging physician and there will be no study specific interventions. The current usual care varies from no outpatient monitoring to short-term Holter monitoring (24 hours to 72 hours).
88883145|NCT05066347|Experimental|Prolonged 24/7 live outpatient cardiac rhythm monitoring|Patients randomized to the intervention arm will receive 24/7 live cardiac rhythm monitoring for 15 days. If a patient is randomized to the intervention arm and was prescribed outpatient cardiac monitoring such as Holter monitor, this will be replaced by the 24/7 live monitoring and will be applied either prior or within 24 hours of discharge from the ED.
88883146|NCT05062343|Active Comparator|Dilapan-S|After randomization, the patient will have Dilapan-S placed via sterile speculum exam with placement of 3-5 rods. The rods will remain in place until expelled or up to 24 hours or until the scheduled return to labor and delivery. At presentation to labor and delivery, the rods will be confirmed expelled or will be removed and a blinded examiner will complete a sterile cervical exam. At that point the primary health care providers will manage further labor per their standard practice.
88883147|NCT05062343|Active Comparator|Cook Catheter|After randomization, the patient will have the Cook catheter placed via sterile vaginal or speculum exam with the uterine component of the balloon inflated to maximum 60mL. The balloon will remain in place until expelled or up to 24 hours or until the scheduled return to labor and delivery. At presentation to labor and delivery, the Cook catheter will be confirmed expelled or will be removed and a blinded examiner will complete a sterile cervical exam. At that point the primary health care providers will manage further labor per their standard practice.
88883148|NCT05048212|Experimental|Nivolumab|by vein every 3 weeks for 4 doses
88883149|NCT05048212|Experimental|Ipilimumab|by vein over 30 minutes every 3 weeks for 4 doses
88883150|NCT05048212|Experimental|Cabozantinib|tablets by mouth 1 time every day.
88883151|NCT05025280||hearing loss|According to the audiological test results, individuals with a pure tone average of more than 25 dB in the better ear and with less than 10 dB difference between the air-bone conduction thresholds
89407568|NCT02115906||Healthy control subjects|Age and Body mass index matched control subjects will be investigated by 1H/31P magnetic resonance spectroscopy and oral glucose tolerance testing
89407569|NCT05129956|Experimental|therapy group|
89407570|NCT02119338|Experimental|5-ala preoperatively|A dose of 5-ala will be taken by mouth approximately 3 hours before going to surgery.
89407571|NCT02918877|Experimental|Inhaled Anesthesia|Patients in the inhaled anesthesia arm will be given sevoflurane anesthesia maintenance for the duration of the procedure including cardiopulmonary bypass.
88883152|NCT05025280||normal hearing|According to the audiological test results, individuals with a pure tone average of 25 dB or less in both ears and with less than 10 dB difference between the air-bone conduction thresholds
88883153|NCT05020821|Active Comparator|Single-shot superior trunk block with intravenous dexmedetomidine|participants receiving single-shot superior trunk block with intravenous dexmedetomidine
88883154|NCT05020821|Experimental|Continuous superior trunk block|participants receiving continuous superior trunk block
88883155|NCT05010265||Use of advanced neurotechnologies to detect consciousness and predict recovery|Treating clinicians, family members (caregivers) and patients recovering from a diagnosis of coma, vegetative state, or minimally conscious state minus (i.e. minimally conscious state without language function)
88883156|NCT05007873|Experimental|Treatment (dasatinib, decitabine and cedazuridine)|"Patients receive dasatinib PO QD on days 1-28. Beginning cycle 4, patients also receive decitabine and cedazuridine PO QD on days 1-3. Cycles repeat every 28 days for up to 3 years in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive dasatinib PO QD on days 1-28. Cycles repeat every 28 days for up to 12 years in the absence of disease progression or unacceptable toxicity."
88883157|NCT05005910|Experimental|Vonoprazan|Vonoprazan 20 mg oral every 12 hours (total 72 hours) then vonoprazan 20 mg oral once daily for 28 days
88883158|NCT05005910|Active Comparator|PPIs|PPIs IV infusion for 72 hours then oral PPIs twice per day for 28 days
88883159|NCT05004285|Other|MRI / [F-18]Florastamin|MRI and [F-18]Florastamin PET/CT are performed for each subject.
88883160|NCT04957992|Active Comparator|Control Feeding Group|Milk based product
88883161|NCT04957992|Experimental|Experimental Feeding Group|Milk based product with oligosaccharides
88883162|NCT04957992|Other|Human Milk Reference Group|Human Milk
88883163|NCT04956575|Experimental|Phase 1/2: mRNA-1010 Dose Level A|Participants will receive mRNA-1010 at dose level A by intramuscular (IM) injection on Day 1.
88883164|NCT04956575|Experimental|Phase 1/2: mRNA-1010 Dose Level B|Participants will receive mRNA-1010 at dose level B by IM injection on Day 1.
88883165|NCT04956575|Experimental|Phase 1/2: mRNA-1010 Dose Level C|Participants will receive mRNA-1010 at dose level C by IM injection on Day 1.
88883166|NCT04956575|Experimental|Phase 1/2: Placebo|Participants will receive placebo matching to mRNA-1010 by IM injection on Day 1.
88883167|NCT04956575|Active Comparator|Phase 2 NH: Active Comparator Dose Level A|Participants will receive active comparator at dose level A by IM injection on Day 1.
88883168|NCT04956575|Experimental|Phase 2 NH: mRNA-1010 Dose Level D|Participants will receive mRNA-1010 at dose level D by IM injection on Day 1.
88883169|NCT04956575|Experimental|Phase 2 NH: mRNA-1010 Dose Level A|Participants will receive mRNA-1010 at dose level A by IM injection on Day 1.
88883170|NCT04956575|Experimental|Phase 2 NH: mRNA-1010 Dose Level B|Participants will receive mRNA-1010 at dose level B by IM injection on Day 1.
88883171|NCT04956575|Active Comparator|Phase 2 Extension: Active Comparator Dose Level A|Participants will receive active comparator at dose level A by IM injection on Day 1.
88883172|NCT04956575|Experimental|Phase 2 Extension: mRNA-1010 Dose Level D|Participants will receive mRNA-1010 at dose level D by IM injection on Day 1.
88883173|NCT04956575|Experimental|Phase 2 Extension: mRNA-1010 Dose Level E|Participants will receive mRNA-1010 at dose level E by IM injection on Day 1.
88883174|NCT04956575|Experimental|Phase 2 Extension: mRNA-1010 Dose Level F|Participants will receive mRNA-1010 at dose level F by IM injection on Day 1.
88883175|NCT04949087|Experimental|Corticosteroid Injection Group|80mg Depo-Medrol and 8cc Lidocaine ultrasound-guided intra-articular injection
88883176|NCT04949087|Active Comparator|Platelet-Rich Plasma Injection Group|15cc blood draw in Arthrex Autologous Conditioned Plasma (ACP) kit and processed per manufacturer instructions Ultrasound-guided intra-articular injection of isolated PRP
88883177|NCT04948294|Experimental|Channeled group|Group of patients using a channeled blade for videolaryngoscopy
88883178|NCT04948294|Active Comparator|Non-channeled group|Group of patients using a non-channeled blade (standard type) for videolaryngoscopy
88883179|NCT04942379|Experimental|Asthma Link|Site providers will be trained to efficiently discuss school-supervised medication administration with families and school nurses. Providers identify children with poorly controlled asthma and poor medication adherence and offer enrollment in Asthma Link to provide school-supervised asthma therapy. Ongoing communication occurs between the pediatric practice, school nurse and families through electronic medical record messaging and phone communication. Data will be collected at baseline (study entry) and at 3-, 6-and 12-month follow-up.
88883180|NCT04942379|Active Comparator|Enhanced Usual Care|Sites will receive pediatric pulmonologist-delivered training and a workbook for pediatric practices to provide to patients on behavioral strategies to help promote asthma medication adherence. Providers identify children with poorly controlled asthma and poor medication adherence and offer enrollment to this Enhanced Usual Care condition of study (receipt of workbook). Data will also be collected at baseline (study entry) and at 3-, 6-and 12-month follow-up.
88883181|NCT04925414|Experimental|oxygenotherapy|
88883182|NCT04925414|Placebo Comparator|placebo air aerosol|
88883183|NCT04920708|Experimental|Palbociclib + Fulvestrant + Ipatasertib (Interventional arm)|Where high ctDNA is detected in screening, patients to be randomised on a 1:1 basis to interventional arm or comparison arm. Patients randomised to interventional arm receive Palbociclib + Fulvestrant + Ipatasertib. n = 87.
88883184|NCT04920708|Active Comparator|Palbociclib + Fulvestrant (Comparison arm)|Where high ctDNA is detected in screening, patients to be randomised on a 1:1 basis to interventional arm or comparison arm. Patients randomised to Comparison arm receive Palbociclib + Fulvestrant. n = 87.
88883185|NCT04920708|Active Comparator|Standard of Care (No ctDNA observational arm)|Where no ctDNA is detected in screening, patients to be allocated to the observational arm and receive standard of care (Abemaciclib / Ribociclib / Palbociclib + fulvestrant). n = 50.
88883186|NCT04920708|Active Comparator|Standard of Care (Low ctDNA observational arm)|Where low ctDNA is detected in screening, patients to be allocated to the observational arm and receive standard of care (Abemaciclib / Ribociclib / Palbociclib + fulvestrant). n = 100.
88883187|NCT04904796|Experimental|Constraint-induced Movement Therapy With Home-based Hand-arm Bimanual Intensive Therapy|Children in experimental group will receive 2-hour clinic-based CIMT sessions, 5 days/week for 3 weeks (30 hours), and 2-hour home-based HABIT sessions, 3 days/week for 5 weeks (30 hours).
88883188|NCT04904796|Active Comparator|Constraint-induced Movement Therapy only|Children in experimental group will receive 2-hour clinic-based CIMT sessions, 5 days/week for 3 weeks (30 hours).
88883189|NCT04895111||Patients with suspected sarcoidosis|Consecutive patients with clinical and radiological (CT scan +/- PET) suspect of sarcoidosis
88883190|NCT04889274|Experimental|Part A: Male healthy volunteers|
88883191|NCT04889274|Experimental|Part A: Female healthy volunteers|
88883192|NCT04889274|Active Comparator|Part B: Nitrate-rich beetroot juice|Dietary Supplement: Concentrate beetroot Juice (70 ml) containing ~5mmol of inorganic nitrate
88883193|NCT04889274|Placebo Comparator|Part B: Nitrate-deplete beetroot juice|Dietary Supplement: Concentrate beetroot Juice (70 ml) which is nitrate-depleted
89407572|NCT02918877|Active Comparator|Intravenous Anesthesia|Patients in the intravenous anesthesia arm will be given total intravenous anesthesia with propofol for the duration of the procedure including cardiopulmonary bypass.
89407573|NCT02116062|Other|Amniotic membrane transplantation|
89407574|NCT02116062|Other|Pterygium surgery|
89407575|NCT02116062|Other|Penetrating keratoplasty|
89407576|NCT03653871|Experimental|Intervention|Performing arts instruction delivered 1 hour/week for 8 weeks.
89407577|NCT03653871|No Intervention|Wait List Control|Control group. Performing arts instruction delivered upon completion of control period.
89407578|NCT05129800||PRP 1|This is the group of patients who were injected with 5 ml of PRP prepared using a tube from a company 1
89407579|NCT05129800||PRP 2|This is the group of patients who were injected with 5 ml of PRP prepared using a tube from a company 2
89407580|NCT05129800||Mesotherapy 1|This is the group of patients who were injected with mesotherapy from a company 1
89407581|NCT05129800||Mesotherapy 2|This is the group of patients who were injected with mesotherapy from a company 2
89407582|NCT03653793|Experimental|LivRelief Varicose Veins Cream|"Intervention:~All subjects were provided with an adequate supply of the Natural Health Product LivRelief Varicose Veins cream for 6 weeks of at home use."
89407583|NCT05129488|Experimental|Biotrue ONEday lenses with an alternate packaging solution (EPG03)|
89407584|NCT05129488|Active Comparator|Biotrue ONEday lenses|
89407585|NCT03652857|Experimental|Apatinib Combined With Vinorelbine|Apatinib Combined With Vinorelbine Used for Driver Gene Mutation Negative Third-line and Third-line Post Progression Advanced Non-small Cell Lung Cancer
89407586|NCT02113488||Control: P|Patients who did attend a scheduled appointment at the Clinical Medicine Outpatient care system at the Italian Hospital of Buenos Aires (HIBA)
89407587|NCT02113488||Case: A|Patients who did not attend (A) a scheduled appointment at the Clinical Medicine Outpatient care system at the Italian Hospital of Buenos Aires (HIBA)
89407588|NCT02113488||Control: C|Patients who cancelled (C) a scheduled appointment at the Clinical Medicine Outpatient care system at the Italian Hospital of Buenos Aires (HIBA)
89407589|NCT05129410|Experimental|A single-arm open-label pilot observational study|Patients were received prednisone(0.5mg-1mg/kg/day) and a combination with MMF (1.5g-2.0g/d).
89407590|NCT02113566|Placebo Comparator|Placebo|2 capsules identical to comparator, 3 times daily on Day 1 and Day 2. On Day 3 only one dose will be taken. The intervention is Acetaminophen 1000mg.
89407591|NCT02113566|Active Comparator|Ibuprofen|2oomg capsules (400 mg per dose), 3 times daily on Day 1 and Day 2. On Day 3 only one dose will be taken. The intervention is Acetaminophen 1000mg.
89407592|NCT03652779|Experimental|Tecarfarin 10mg|
89407593|NCT03652779|Experimental|Tecarfarin 20mg|
89407594|NCT03652779|Experimental|Tecarfarin 30mg|
89407595|NCT03652779|Experimental|Tecarfarin 40mg|
89407596|NCT02113644||Overweight or obese children|Overweight or obese children according to the International Obesity Task Force (IOTF) criteria following the lifestyle intervention in the Centre for Overweight Adolescent and Children's Healthcare
89407597|NCT02113644||Lean children|Lean children according to the International Obesity Task Force (IOTF) criteria admitted at de pediatric ward for a planned surgery, for example the correction of floppy ears
88922010|NCT05972174|Experimental|Part A Group 1 Vaccine: mRNA-1018 for H5 Only Dose Level 2|Participants will receive mRNA-1018 for H5 only at dose level 2 by IM injection on Day 1 and Day 22.
89407598|NCT05124730|Experimental|Treatment A|Metformin 500 mg Prolonged Release Tablets (JSC Farmak, Ukraine)
89407599|NCT05124730|Active Comparator|Treatment B|Glucophage® XR 500 mg prolonged release tablets (Merck Serono Ltd, UK)
89407600|NCT02251626|Experimental|Coenzyme Q10 (ubiquinol)|Coenzyme Q10 (ubiquinol) group will be given 1,800 mg coenzyme Q10 (ubiquinol) per day
89407601|NCT02251626|Placebo Comparator|Placebo for CoQ10 (ubiquinol)|Placebo group will be given placebo only
89407602|NCT02116218|Experimental|acupuncture|Experimental group would receive acupuncture at specific acupoints for 15 minutes.
89407603|NCT02116218|Sham Comparator|seed|Control group would receive another intervention that we would put Vaccaria seeds near the acupoints but without acupressure for the same period.
89407604|NCT02119572|Experimental|peer support|Patients are divided into small groups and assigned with peer leaders for twelve months according to their residence. Besides the same training and follow-ups as the control arm, patients from intervention groups are suggested and encouraged to take part in the group activities with the peer leaders per month. And if possible, casual activities (such as phone call, chatting, short message; physical exercise, group member family visiting，going to supermarket together, etc.)are also recommended
89407605|NCT02119572|Active Comparator|usual education|Patients attend the usual self-management education and communicate with the professionals every two months, getting the information on diabetes diet, exercise, glucose monitor, etc. besides that the group members should attend three follow ups at baseline,6 and 12 months.
89407606|NCT02122926|Experimental|Intensive discharge intervention|"The intervention is a multi-modal program consisting of the following:~Inpatient protocol for adjusting the discharge diabetes regimen;~Nurse practitioner discharge advocate to schedule follow-up appointments, prepare an after-hospital care plan, and patient education and counseling;~Inpatient pharmacist counseling (identifying and addressing previous barriers to medication adherence, performing enhanced medication reconciliation, and patient education);~Visiting nurse intervention after discharge;~Follow-up in a post-discharge clinic with the NP discharge advocate and pharmacist /certified diabetes educator within 3 days of discharge;~Telemonitoring of POC glucose levels to the study CDE, patient's PCP, or endocrinologist as appropriate; and~Follow-up with PCP or endocrinologist within 1 week of discharge."
89407607|NCT02122926|No Intervention|Usual Care|Patients in the control arm of this study receive usual care.
89407608|NCT02123004|Experimental|Ticagrelor|"Investigational product/Dosage form and strength/Manufacturer:~ticagrelor/tablet /90mg/AstraZeneca 180mg loading dose for one day ,then 90mg per day for 4 weeks"
89407609|NCT02123004|Active Comparator|Clopidogrel|"Investigational product/Dosage form and strength/Manufacturer:~clopidogrel/tablet /75mg/Sanofi 300mg loading dose for one day ,then 75mg per day for 4 weeks"
89407610|NCT02116296|Other|LIfestyle counseling|
89531029|NCT02498717|Active Comparator|RICE (control)|Standard of Care procedures including ice and elevation.
89407611|NCT02123082|Other|Single-Lumen Ureteroscope|Subjects enrolled in this study arm will have their procedure performed using the single lumen ureteroscopes. This scope is currently employed in clinical practice, including at UC Irvine Medical Center.
89407612|NCT02123082|Experimental|Dual Lumen Ureteroscope|Subjects enrolled in this study arm will have their procedure performed using the dual lumen ureteroscopes. This scope is currently employed in clinical practice, including at UC Irvine Medical Center.
89407613|NCT01674712|Experimental|Fenofibrate/simvastatin 145/20 mg|
89407614|NCT01674712|Active Comparator|Simvastatin 20 mg|
89407615|NCT01674712|Active Comparator|Fenofibrate 145 mg|
89407616|NCT01674712|Experimental|Fenofibrate/simvastatin 145/40 mg|
89407617|NCT01674712|Active Comparator|Simvastatin 40 mg|
89407618|NCT02119728|Active Comparator|Arm I (standard of care surgery)|Patients undergo standard of care surgery on day 1.
89407619|NCT02119728|Experimental|Arm II (HPPH, photodynamic therapy)|Patients receive HPPH IV over 1 hour on day 0. Approximately 24 hours later, patients undergo photodynamic therapy on day 1.
89407620|NCT01368432|Placebo Comparator|Placebo|Daily for 12 weeks
89407621|NCT01368432|Experimental|Escitalopram|Escitalopram 10 mg or 20 mg daily for 12 weeks
89407622|NCT05122858|Experimental|EUS guided biliary drainage|
89407623|NCT05122858|Active Comparator|ERCP (Endoscopic Retrograde Cholangiopancreatography|
89407624|NCT05122780|Active Comparator|"Precision medicine approach"|"Comprehensive diagnostic work-up with:~Coronary angiography and ventriculography in all patients~OCT at the time of coronary angiography in the cath-lab.~Acetylcholine provocative test (to assess the presence of coronary vasospasm) at the time of coronary angiography in the cath-lab.~TE-Echo and/or CE-Echo (if distal/microvascular embolization is suspected)~Blood sampling for circulating biomarkers and miRNA expression profile~Trans-thoracic echocardiography in all patients during the index hospitalization~CMR in all cases during the index hospitalization.~Targeted pharmacological treatment specific for the underlying cause:~DAPT ± stent implantation (if required), statins, beta-blockers, ACEi/ARB (in case of evidence of plaque rupture/erosion)~CCB and/or nitrates (in case of documentation of coronary vasospasm)~Anticoagulation (in case of coronary embolism)."
89407625|NCT05122780|Other|"Standard approach"|"Routine diagnostic work-up with:~Coronary angiography and ventriculography~Transthoracic echocardiography in all patients during the index hospitalization~CMR with contrast media only if clinically indicated (i.e. to exclude myocarditis or takotsubo syndrome)~Standard medical treatment with:~DAPT in all patients~Beta-blockers (if indicated by the clinical context, i.e. documentation of left ventricular ejection fraction <50%, tachycardia).~High intensity statins in all patients~ACEi/ARB (if clinically indicated)."
89407626|NCT01063881|Experimental|Dapoxetine|Starting dose is one 30-mg tablet taken approximately 1-3 hours prior to sexual activity may be increased after 4 weeks to 60mg taken for 12 weeks. The maximum recommended dosing frequency is once every 24 hours.
89407627|NCT02116374||HIV-1 patients|
89407628|NCT02116452|No Intervention|Breast Milk|Breast FED newborns
89407629|NCT02116452|Placebo Comparator|Standard Formula|Standard Formula FED newborns
88883194|NCT04843683|Experimental|Stereotactic ablative radiotherapy (SBRT) Arm|Stereotactic ablative radiotherapy (SBRT) is a type of radiation treatment that delivers precise, high dose radiation to targeted areas. In this study, a single treatment of SBRT will be delivered to the abnormal area of a participant's heart that is causing dangerous heart rate and rhythm changes (arrhythmia).
88883195|NCT04843683|No Intervention|Observational Arm|Potential participants who are eligible to be included in the study, but who choose not to have the SBRT procedure, can still receive standard medical treatment alone and be followed up with study visits and questionnaires.
88883196|NCT04832698||Observational (survey administration)|Participants complete a survey over 10 minutes before and after completing training and using the Mentice endovascular simulator device.
88922011|NCT05972174|Experimental|Part A Group 1 Vaccine: mRNA-1018 for H5 Only Dose Level 3|Participants will receive mRNA-1018 for H5 only at dose level 3 by IM injection on Day 1 and Day 22.
88922012|NCT05972174|Experimental|Part A Group 2 Vaccine: mRNA-1018 for H7N9 Dose Level 1|Participants will receive mRNA-1018 for H7N9 at dose level 1 by IM injection on Day 1 and Day 22.
89407630|NCT02116452|Active Comparator|Supplemented Formula|GOS/PDX Formula FED newborns
89407631|NCT02119806|Active Comparator|Benzodiazepine group|"Premedication 0.02mg/kg-0.1mg/kg of Benzodiazepine ;~Maintenance 0.8 minimum alveolar concentration of inhaled anesthetic (MAC) and 10-30mcg/kg of fentanyl;~Postoperative 10-100mcg/kg/min of propofol"
89407632|NCT02119806|Active Comparator|Non-benzodiazepine group|"Premedication 0-50mg of propofol and/or 0-250mcg of fentanyl;~Maintenance 0.8 minimum alveolar concentration of inhaled anesthetic (MAC) and 10-30mcg/kg of fentanyl;~Postoperative 10-100mcg/kg/min of propofol"
89407633|NCT05124496||Comparison to Rt-PCR|
89407634|NCT04054245|Experimental|Treatment (LOXL2 inhibitor PAT-1251)|Patients receive LOXL2 inhibitor PAT-1251 PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89407635|NCT05062408||cases|Patients treated with direct-acting antivirals.
89407636|NCT02119884|Experimental|Terlipressin group|Patients receive terlipressin 2 mg IV bolus
89407637|NCT02119884|Active Comparator|High Dose Octreotide group|Patients receive Octreotide 50 μg/h with an initial bolus of 100 μg
89407638|NCT03653559|Experimental|"Home meals condition"|The recommendation consists of menus with examples of breakfast, lunch and dinner based on typical preparations plus a prescription of the number of portions of the food groups that provides 1200 kcal with a distribution of 50-60% carbohydrates, 15-20% protein and < 30% lipids.
89407639|NCT03653559|Active Comparator|"Healthy meals condition"|"The recommendation consists of the educative graphic tool Eatwell plate plus a prescription of the same number of portions of the food groups for a isocaloric diet with the same macronutrient distribution as the home meals condition."
89407640|NCT05109910|Active Comparator|Radical prostatectomy with an extended pelvic lymph node dissection|According to the standard of care, patients in this arm will receive a radical prostatectomy with a standard bilateral ePLND. This includes the removal of lymph nodes within the obturator fossa and bilateral to the external iliac artery, internal iliac artery and common iliac artery up to the ureteral-vessel crossing.
89407641|NCT05109910|No Intervention|Radical prostatectomy without an extended pelvic lymph node dissection|Patients in this arm will undergo a radical prostatectomy without a bilateral extended pelvic lymph node dissection. In case of intraoperatively found suspicious lymph nodes, a lymphadenectomy is performed. According to the intention to treat principle, patients with intraoperatively removed lymph nodes remain included in the study.
89407642|NCT02123160|Experimental|Child Parent Psychotherapy (CPP)|Following Time 1 (pre-treatment) assessment, mother-child patient dyads will be randomly assigned to either Child Parent Psychotherapy (CPP) treatment or control (usual treatment) group. CPP treatment will be conducted by a CPP study clinician over approximately six months (24 weekly sessions). CPP includes developmental guidance and fostering affect regulation , continuity in daily living, reciprocity between mother and child, and helping the mother and child understand themselves and each other in the context of the maternal psychiatric functioning and/or familial exposure to trauma.
89407643|NCT02123160|Active Comparator|Usual Treatment|Following Time 1 (pre-treatment) assessment, mother-child patient dyads randomized to the control group will be referred for usual treatment via referral to therapists in the community and at Columbia University Medical Center, for psychoeducation, counseling/ therapy for maternal depressive symptoms, and child behavioral/ emotional difficulties. Additionally, control patient dyads will be monitored through regular contact with the study research assistant. If the research assistant detects worsening of depressive symptoms or the presentation of new symptoms, a licensed study clinician will follow up to assess mother/ child's psychiatric functioning and make necessary referrals to alternative treatments or arrange an emergency evaluation, if needed.
89407644|NCT05104918|Experimental|Vorscot Arm|Vortioxetine 10 mg
89407645|NCT05104918|Active Comparator|Vanlafexine Arm|Venlafaxine 75 mg
89407646|NCT02123238|Other|Control|standard of care positioning (0 degree)
89407647|NCT02123238|Other|30 degree|30 degree bed positioning
89407648|NCT02123238|Other|60 degree|60 degree bed positioning
89407649|NCT03653403|Experimental|IDP-126 Gel|Component A
89407650|NCT03653403|Active Comparator|Control Gel|Gel
89407651|NCT05089942|Experimental|Recombinant Human Insulin Patch ZJSRM2021|health subjects or diabetic patients receive recombinant human insulin patch ZJSRM2021
89407652|NCT05089942|Placebo Comparator|Placebo|health subjects receive patch
88883197|NCT04815577||CHD group|The CHD group is made up of the children included in the first study. From these 496 children with CHD, children with a second CPET more than one year from the first referral CPET were included. If several CPETs were performed in the follow-up, we retain the most distant CPET from the first, excluding the CPETs that were performed after a cardiopulmonary rehabilitation program implemented in the region in 2018. The group corresponding to the first CPET was called. Among the initial 496 children, if patients had not had a second CPET, the cause was indicated. As a reminder, the patients included in the initial study were aged 5-18 years old and they were referred by their paediatric cardiologists to one of the two CPET laboratories after their annual medical check-up. The anatomical and clinical classification of congenital heart diseases was used to define the type of malformation. The demographic, clinical, echocardiographic data were collected during the first CPET.
88883198|NCT04815577||Controle|The controle Group consisted of children referred for nonsevere functional symptom linked to exercise (murmur, palpitations or dyspnea) or for a medical sports certificate. We included controlled children from 2015 to 2020 period who will be added to the controlled patients of the initial study. These patients only had one CPET.
88883199|NCT04812015|Other|Dose Group 1|
88883200|NCT04812015|Other|Dose Group 2|
88883201|NCT04812015|Other|Dose Group 3|
88883202|NCT04812015|Other|Dose Group 4|
88883203|NCT04812015|Other|Dose Group 5|
88883204|NCT04812015|Other|Dose Group 6|
88883205|NCT04811040|Experimental|Primary Cohorts: Lenacapavir (LEN), Teropavimab, Zinlirvimab Dose C|Participants will begin treatment by receiving LEN Dose A + LEN Dose B + teropavimab + zinlirvimab Dose C followed by LEN Dose A on the next day. The last treatment regimen will include LEN Dose B + teropavimab + zinlirvimab Dose C.
88883206|NCT04811040|Experimental|Primary Cohorts: LEN, Teropavimab, Zinlirvimab Dose D|Participants will begin treatment by receiving LEN Dose A + LEN Dose B + teropavimab + zinlirvimab Dose D followed by LEN Dose A on the next day. The last treatment regimen will include LEN Dose B + teropavimab + zinlirvimab Dose D.
88883207|NCT04811040|Experimental|Optional Cohorts: Lenacapavir (LEN), Teropavimab, Zinlirvimab Dose C|Optional cohort included participants from primary cohort who could not qualify for primary cohort at the study start. Participants in optional cohort will begin treatment by receiving LEN Dose A + LEN Dose B + teropavimab + zinlirvimab Dose C followed by LEN Dose A on the next day. The last treatment regimen will include LEN Dose B + teropavimab + zinlirvimab Dose C.
89407653|NCT04055181|Active Comparator|rTMS in schizophrenia patients|In active rTMS, 10 Hz stimulations over left DLPFC occurred at a power of 110% of motor threshold (MT) for 27-s intervals with 20s inter-train interval. 20 minutes were administered each day (Monday-Friday) for 4 consecutive weeks
89407654|NCT04055181|Sham Comparator|rTMS in schizophrenia Controls|In sham rTMS, all procedures were identical to 10Hz Schizophrenia group except they were the non-magnetized steel cylinders, instead of cylindrical magnets, that were rotated.
89407655|NCT04055181|Active Comparator|rTMS in major depressive disorders patients|In active rTMS, 10 Hz stimulations over left DLPFC occurred at a power of 110% of MT for 27-s intervals with 20s inter-train interval. 20 minutes were administered each day (Monday-Friday) for 4 consecutive weeks
89407656|NCT04055181|Sham Comparator|rTMS in major depressive disorders controls|In sham rTMS, all procedures were identical to 10Hz depression group except they were the non-magnetized steel cylinders, instead of cylindrical magnets, that were rotated.
89407657|NCT04055259|Experimental|mobile Health and Wellness Coaching|
89407658|NCT04055259|Active Comparator|Usual Care|
89407659|NCT04941508|Experimental|Mother's recorded voice|Children will be exposed to the mother's voice.
89407660|NCT04941508|Experimental|Dexmedetomidine IV|Children will be given dexmedetomidine injection.
89407661|NCT04941508|Placebo Comparator|Saline placebo IV|Children will be given normal saline.
89407662|NCT03552510|Active Comparator|Initial OPAMM|"At the start of the study, infants will receive mother's milk (to the maximum of 0.2 ml) to the oro-pharyngeal pouch, tongue and cheeks every 3 hours (5 minutes before time of feeding), and the remaining amount will be given by regular gavage feeding for 24 hours.~Then, infants will receive regular gavage feeding only for the next 24 hours."
89407663|NCT03552510|Active Comparator|Initial Gavage|"At the start of the study, infants will receive regular gavage feeding only for 24 hours.~Then, infants will receive mother's milk (to the maximum of 0.2 ml ) by dropper to the oro-pharyngeal pouch, tongue and cheeks every 3 hours (5 minutes before time of feeding), and the remaining amount will be given by regular gavage feeding for the next 24 hours."
89407664|NCT04934254||Newborn Nurses|
89407665|NCT01062555|Active Comparator|Phase I Arm 1|CSA and MMF
89407666|NCT01062555|Active Comparator|Phase I Arm 2|FK and MMF
89407667|NCT01062555|Active Comparator|Phase II Arm 1|Low CNI and MMF
89407668|NCT01062555|Active Comparator|Phase II Arm 2|Rapa and MMF
88883208|NCT04811040|Experimental|Optional Cohorts: LEN, Teropavimab, Zinlirvimab Dose D|Optional cohort included participants screened for primary cohort but could not qualify for primary cohort at the study start. Participants in optional cohort will begin treatment by receiving LEN Dose A + LEN Dose B + teropavimab + zinlirvimab Dose D followed by LEN Dose A on the next day. The last treatment regimen will include LEN Dose B + teropavimab + zinlirvimab Dose D.
88883209|NCT04808479|Experimental|UC imFREE Smartphone application intervention|The imFREE condition is a 32-week tailored, interactive text messaging intervention targeting buprenorphine treatment retention and adherence as well as opioid use and associated health consequences. Following a face-to-face CBT session with a clinician, participants receive CBT skills training via daily text messaging, with content themes around relapse prevention, adherence behaviors, and personalized plans to overcome risk factors for treatment discontinuation.
88883210|NCT04808479|Active Comparator|Health Education and pamphlet|The mHealth condition will provide participants with a manualized health psychoeducation session of equivalent duration to the face-to-face CBT session delivered to imFREE participants. Content focuses on various dimensions of health and well-being. Subsequent to this session participants will receive an informational pamphlet regarding BUP and the importance of adherence. the mHealth component of the intervention comprises text reminders for scheduled MM appointments.
89407669|NCT02119962|Experimental|Working memory training|
89407670|NCT02119962|Placebo Comparator|Placebo training|
89407671|NCT05128864|Active Comparator|HTO and Fulkerson|High Tibial Osteotomy with Antero-medialisation of Tibial Tubercle
89407672|NCT05128864|Sham Comparator|HTO|Descending Hight Tibial Osteotomy
89407673|NCT03652701|Experimental|Hair Up|
89407674|NCT03652701|Placebo Comparator|Placebo|
89407675|NCT05128708|Active Comparator|open right hemicolectomy|participants diagnosed as operable right sided colon cancer were enrolled in this study and did open combined medial and caudal resection procedure
89407676|NCT05128708|Active Comparator|laparoscopic right hemicolectomy|participants diagnosed as operable right sided colon cancer were enrolled in this study and did laparoscopic combined medial and caudal resection procedure
89407677|NCT03622047|Experimental|dexmedetomidine ropivacaine|Observing 0.5 μ g / ml dexmedetomidine + 0.1 % ropivacaine with 2 hours after fetal delivery, and the patients leave the delivery room without abnormality.
89407678|NCT03622047|Experimental|sufentanil ropivacaine|compare the analgesic effects of dexmedetomidine or sufentanil combined with ropivacaine in epidural labor.
89407679|NCT03622047|Experimental|No analgesia labor|Observing with 2 hours after fetal delivery, and the patients leave the delivery room without abnormality.
89407680|NCT05128552|Experimental|Study group|Twenty-five patients who received traditional chest physiotherapy and LVR technique for 30-45 minutes for successive 4 Days after extubation
89407681|NCT05128552|Active Comparator|Control group|Twenty-five patients who received only traditional chest physiotherapy for 30 minutes at least for successive 4 Days after extubation
89407682|NCT05073562|Experimental|Nutrition+ Intervention|This group will receive a structured nutrition education package provided by Community Health Assistants (CHAs) based on a handbook on nutrition education developed by UNICEF with collaboration from the Liberia Ministry of Health. The structured nutrition education package will focus on four key areas: causes and prevention of anemia, healthy eating and food choices, hand washing, and physical exercise. Participants in the intervention group will also receive IFA supplementation on a weekly basis for the duration of the study, and a one-time oral deworming treatment (mebendazole), which will be administered once at the beginning of the study.
89407683|NCT05073562|Active Comparator|Control group - standard services only|This group will receive only the current package of basic nutrition services provided at the health facility and at community level by health workers and CHAs, respectively.
89407684|NCT01064817|Experimental|PRM-151|PRM-151 (recombinant human serum amyloid P, recombinant human pentraxin 2)
89407685|NCT01064817|Placebo Comparator|Placebo|Placebo
89407686|NCT01368276|Active Comparator|GM-CSF|Granulocyte macrophage colony-stimulating factor (GM-CSF) was administered at a dose of 125 μg/m²/day subcutaneously for 14 consecutive days followed by 14 days of rest, in 28-day treatment cycles for up to 12 months or until a complete response, occurrence of an unacceptable toxicity, death or another criterion for withdrawal from treatment was met. Participants who demonstrated a partial response after being on treatment for 12 months could continue to be treated until disease progression or another treatment discontinuation criterion was met.
89407687|NCT01368276|Experimental|Talimogene Laherparepvec|Talimogene laherparepvec was administered at a concentration of 10⁸ plaque forming units (PFU)/mL injected into 1 or more skin or subcutaneous tumors on Days 1 and 15 of each 28-day cycle for up to 12 months or until a complete response, occurrence of an unacceptable toxicity, death or another criterion for withdrawal from treatment was met. Participants who demonstrated a partial response after being on treatment for 12 months could continue to be treated until disease progression or another treatment discontinuation criterion was met.
89407688|NCT05009524|Experimental|iPACES (interactive Physical and Cognitive Exercise System)|"iPACES (interactive Physical and Cognitive Exercise System) involves a pedal-to-play neuro-exergame in which physical and mental exercise are combined in an interactive way. In this condition a person will pedal to control forward motion in a tablet-based game, such as when pedaling along a virtual path and steering to different assigned errand locations."
89407689|NCT05009524|Active Comparator|PACE (physical and cognitive exercise)|"PACE (Physical and Cognitive Exercise) involves a pedal-while-play experience in which physical and mental exercise are combined in a simultaneous, but not fully interactive way. In this condition a person will pedal while also separately steering in a tablet-based game, such as when pedaling while automatically progressing along a virtual path to different assigned errand locations."
89407690|NCT01064739|Experimental|Study Diet +/- fava beans|Participants underwent testing while on a methylxanthine-free diet providing 150 mEq sodium and 75 mEq potassium per day. The study involved a longitudinal design where the participants served as their own controls. Subjects consumed the standard fixed sodium diet on study day one. On study day two, participants ate 100 g of puréed fava beans and pods with study diet at breakfast (0800hr) and lunch (1200hr).
89407691|NCT02116686||Heart failure patients with sleep apnea syndrom|For heart failure patients, a standard nocturnal in-home ventilatory polygraphic recordings were performed using an Embla device (Embla®, Broomfield, USA) and scored according to the America Academy of Sleep Medicine (AASM) recommendations (RemLogic® software, Broomfield, USA).
89407692|NCT02116842|Experimental|0.075% bupivacaine|Consenting patients randomised to receive 0.075% bupivacaine and 40 µg fentanyl.
89407693|NCT02116842|Experimental|0.1% bupivacaine|Consenting patients randomised to receive 0.1% bupivacaine and 40 µg fentanyl.
89407694|NCT03652623|Experimental|TDF/FTC and cs-HT|Transgender youth will simultaneously take TDF/FTC and cs-HT. TW will take oral estradiol +/- spironolactone and TM will take subcutaneous testosterone. In order to ensure adherence to TDF/FTC, daily DOT procedures will be employed.
89407695|NCT02120118|Experimental|Radiation; Hyperthermia; Chemotherapy|Patients will be treated with radiotherapy with 50Gy/22fx/6 weeks, plus hyperthermia 42℃ ± 0.5℃ for 40 minutes within 2hr after irradiation, once a week since the 1st week of radiation for a total of 6 times. The regimen of concurrent chemotherapy will cisplatin 30mg/m2 and taxotere 20mg/m2 per week for 6 weekly cycles.
89407696|NCT04054089|Experimental|A|B/F/TAF
89407697|NCT04054089|Active Comparator|B|DTG+3TC
89407698|NCT02120196|Experimental|rifaximin|Arm 1: 109 patients will be treated with 1200 mg of rifaximin daily for 6 months.
89407699|NCT02120196|Active Comparator|norfloxacin|Arm 2: 109 patients will be treated with 400 mg of norfloxacin daily for 6 months.
89407700|NCT05001802|Active Comparator|transverse quadratus lumborum block|The patients will receive the transmuscular quadratus lumborum block before surgery using the transverse scan, in-plain, posterior to anterior approach. 0.6ml/kg 0.375% ropivacaine is injected when the correct needle location is confirmed.
89407701|NCT05001802|Experimental|longitudinal quadratus lumborum block|The patients will receive the transmuscular quadratus lumborum block before surgery using the paramedic sagittal longitudinal scan, in-plain, caudal-cephalic approach.0.6ml/kg 0.375% ropivacaine is injected when the correct needle location is confirmed.
89407702|NCT02120274|No Intervention|Control|Pegylated Interferon-Alfa plus ribavirin for 48 weeks
89407703|NCT02120274|Experimental|Vitamins|Pegylated Interferon-Alfa plus ribavirin for 48 weeks together oral vitamin D 2,000 IU qd throughout, irrespective of baseline vitamin D level. Intramuscular vitamin B12 5000 UI will be given weekly in the first 12 weeks followed by a monthly injection until the end of therapy.
89004597|NCT02834884||RP-1759 AYA/TYA (CLOSED for recruitment since December 2021)|"The pilot study will be focusing on young adults (12 to 29 years old) with rare cancer to understand better the biology of the tumor in this specific population, and compare it to children and adults with similar disease, as well as to improve the inclusion of young adults into clinical trials.~Tumor type: CNS"
89407704|NCT02402842|Experimental|DCF regimen|docetaxel 75 mg/m2 day, Cisplatin75 mg/m2 and 5Fluorouracil at 750 mg/m2/day for 5 days
89407705|NCT02123316|Active Comparator|Pangramin Plus D. pteronyssinus|Pangramin Plus D. pteronyssinus 100% for subcutaneous injection
89407706|NCT02123316|Placebo Comparator|Placebo|Placebo for subcutaneous injection
89407707|NCT03652935|Experimental|Mindfulness Based Stress Reduction|The Mindfulness Based Stress Reduction (MBSR) program consists of an 8-week (2.5 hr/wk) program with a 6-hour silent mindful practice retreat after the fifth week. A licensed clinical psychologist, certified as an MBSR instructor, will provide instruction to all groups. Mindfulness will be taught using breath awareness, sitting and walking meditation, and mindful yoga. Participants will be given a standardized session-by-session program workbook containing weekly objectives and assignments, as well as two practice recordings and the book, Full Catastrophe Living (Kabat-Zinn, J, 1990).
89531030|NCT02498717|Experimental|Cryocompression (experimental)|treatment using the GameReady cryotherapy system
89407708|NCT03652935|Active Comparator|Health Education Series|The active comparator condition consists of an 8-week educational series, administered in group-format, and matched in duration and frequency to the MBSR program. Session topics include: 1) Understanding Breast Cancer and Risks for Breast Cancer, 2) Breast Cancer Treatment, 3) Communicating Effectively with your Health Care Providers; Keeping your Medical Records, 4) Genetic Testing and Cancer, 5) Nutrition and Cancer, (6) Cooking Demonstration, 7) Bone Health, and 8) Image and Cancer (American Cancer Society - Look Good, Feel Better). The program content and objectives were reviewed by four content experts (oncology clinicians) and two breast cancer survivors.
89407709|NCT02123394|Placebo Comparator|Placebo|The patients allocated to the Placebo group will be treated with detuned pulsed ultrasound for 5 minutes and detuned short wave diathermy in pulsed mode for 25 minutes. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week).
89407710|NCT02123394|Experimental|McKenzie method|The patients of the McKenzie group will be treated according to the principles of the method and the choice of therapeutic intervention will be guided by the physical examination findings and classification. Patients will also receive written instructions from the Treat Your Own Back book and will be asked to perform home exercises based on the principles of McKenzie method. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week).
89535621|NCT03317951|Active Comparator|Standard care|Patients will be treated according to current practice as described in the guidelines of the European Society of Cardiology (ESC). For AF, this has been provided by Kirchhof et al. (2016 Eur Heart J). HF treatment will follow the 2016 ESC guideline for HF (Ponikowski et al., 2016 Eur Heart J), and TRH will be treated according to the ESC treatment guideline for arterial hypertension (Mancia et al., 2013 Eur Heart J).
89535622|NCT03317873|Experimental|wild type AA (CC)|All participants with the wild type genotype AA (CC) will be allocated to this group
89407711|NCT04054479|Experimental|Penehyclidine|Patients in this arm will receive penehyclidine after anesthesia intubation.
89407712|NCT04054479|Placebo Comparator|Normal Saline|Patients in this arm will receive normal saline after anesthesia intubation.
89407713|NCT02116920||VIA Positive|Those patients having acetowhite lesion over cervix on visual inspection after application of acetic acid
89407714|NCT01061775|Experimental|Exenatide|5mcg of exenatide will be given twice a day for 4 weeks and increased to 10 mcg twice a day for 20 weeks.
89407715|NCT02123628|Active Comparator|antibiotic therapy|"patients are treated with a 6 week-duration of antibiotic therapy :~Rifampin IP and PO twice daily, 10mg/kg /12H~Levofloxacin IV and PO 500-750mg once daily~Doxycycline PO 200mg once daily~Trimethoprim- sulfamethoxazole IV and PO 800/160mg thrice daily~Fusidic acid PO 500mg twice daily~Linezolid IV and PO 600mg twice daily~Ciprofloxacin IV and PO 750to 1000mg/12h~Cefotaxime IV 100mg/kg in three IV infusions daily~Ceftriaxone IV,intramuscularly or subcutaneously 2g once daily~Cefepime IV ou intra-muscularly 2g /8-12h"
89407716|NCT02123628|Active Comparator|12 week-duration of antibiotic therapy|"patients are treated with a 12 week-duration of antibiotic therapy :~Rifampin IP and PO twice daily, 10mg/kg /12H~Levofloxacin IV and PO 500-750mg once daily~Doxycycline PO 200mg once daily~Trimethoprim- sulfamethoxazole IV and PO 800/160mg thrice daily~Fusidic acid PO 500mg twice daily~Linezolid IV and PO 600mg twice daily~Ciprofloxacin IV and PO 750to 1000mg/12h~Cefotaxime IV 100mg/kg in three IV infusions daily~Ceftriaxone IV,intramuscularly or subcutaneously 2g once daily~Cefepime IV ou intra-muscularly 2g /8-12h"
89407717|NCT02651116|Experimental|Dextromethorphan Hydrobromide|15 mg/ 10 mL: 10 mL of Dextromethorphan Hydrobromide
88883214|NCT04796896|Experimental|mRNA-1273|"Part 1: Participants will receive 2 IM injections of mRNA-1273 at doses pre-specified for this study, on Days 1 and 29. Participants will be offered an optional BD of mRNA-1273 lower than the dose chosen for primary series, ≥6 months after Dose 2. After protocol amendment (PA) 9, participants who have not yet received a BD will be offered a BD with mRNA-1273.214.~Part 2: Participants will receive 2 IM injections of mRNA-1273 at dose selected from Part 1 on Days 1 and 29. Participants (6 to <12 year) will be offered an optional BD of mRNA-1273 lower than the dose chosen for primary series, ≥6 months after Dose 2. After PA 9, participants who have not yet received a BD will be offered a BD with mRNA-1273.214.~Part 3: Participants will receive 2 IM injections of mRNA-1273 on Days 1 and 29 as primary series then 1 IM injection as Dose 3, on Day 149 ≥3 months and ≤5 months after receipt of Dose 2 of primary series. All 3 injections will be administered at lower dose than that of Part 1."
88883215|NCT04796896|Placebo Comparator|Placebo|Part 2 only: Participants will receive 2 IM injections of mRNA-1273-matching placebo on Day 1 and Day 29. Participants (6 to <12 year old) will be offered an optional BD of mRNA-1273 at a dose lower than the dose that was chosen for the primary series for this age group, at least 6 months post-cross-over Dose 2. After PA 9, participants who have not yet received a BD will be offered a BD with mRNA-1273.214.
88883216|NCT04789720|Experimental|SyMon-SAYS Intervention (Group A)|Group A participants will receive the SyMon-SAYS intervention every week for 16 weeks.
88883217|NCT04789720|Other|SyMon-SAYS Waitlist Control (Group B)|The waitlist control group participants (Group B) will receive their usual care during weeks 1-8 and will receive the SyMon-SAYS intervention every week during weeks 9-16.
89407718|NCT02651116|Placebo Comparator|Placebo|10 mL of Placebo
89437518|NCT03732820|Experimental|olaparib plus abiraterone|"Olaparib is available as a film-coated tablet containing 100 milligrams (mg) or 150 milligrams (mg) of olaparib. Subjects will be administered olaparib orally at a dose of 300 milligrams (mg) twice daily (bid). The initial dosage of 300 milligrams (mg) twice daily will be composed of 2 x 150 milligrams (mg) tablets per dose. The 100 milligrams (mg) and 150 milligrams (mg) tablets will be used to manage dose reductions during the study.~Abiraterone acetate with prednisone or prednisolone will be sourced locally as commercially available materials. Subjects will be administered abiraterone orally at a dose of 1000 milligrams (mg) once daily, in combination with prednisone or prednisolone 5 milligrams (mg) administered orally twice daily."
89535623|NCT03317873|Experimental|mutation VV (TT)|All participants with the mutation genotype VV (TT) will be allocated to this group
89535624|NCT04992897||REN-Medication combinations|"all evaluable treatments.~'Treatment' defined as a REN treatment of at least 20 minutes (the nominal duration is 45 minutes).~'Evaluable treatment' defined as a treatment in which pain levels were reported at baseline and post 2 hours."
89407719|NCT03552042|Experimental|Counterclockwise Program|"Subjects will participate in an 6-day Counterclockwise Retreat in a retrofitted physical environment circa 1989, which helps the participant psychologically return to a time before diagnosis to re-experience their younger self. Groups will be composed of 10-12 participants plus 3 research assistants/facilitators. Participants will live during the week as if they were in 1989, talking about 1989 events as if they were in the present, and avoiding talking about post-1989 events. Everybody will be invited to participate in conversations and discussions about 1989 in the present tense (presente). Furniture, posters, music, television, newspapers, and technological instruments will all reflect what was available in 1989. Participants will be told not merely to reminisce about this earlier era, but to inhabit life in that era, making a psychological leap to be the person they were at the end of the 1980s."
89407720|NCT03552042|Active Comparator|Active control group|Participants in the active control group will follow the same agenda of the Counterclockwise Program group, without the constant reference to 1989. The intervention will take place in the same location of the Counterclockwise Program, without any specific change. Activities will mirror the ones of Counterclockwise Program, but participants will not live as if they were younger. The agenda will be the same, but no mention to 1989 will be done. All discussion activities will refer to present days (e.g., instead of discussing the open of the Berlin Wall, they can discuss Brexit or Trump presidency).
89407721|NCT03552042|No Intervention|No-treatment control group|Non-treated participants will be assessed with the same timeline followed by the other groups. Participants will receive three coupons, for each assessment after the baseline (at T2, T3, and T4) for a two-night break in a location of their choice (among a selection of commercial services).
89407722|NCT02120430|Active Comparator|Early administration of the video|Video delivered at one month of child's life
89407723|NCT02120430|Experimental|Late administration of the video|Video delivered at seven months of child's life
89407724|NCT01061385|Experimental|ReShape Intragastric Balloon|Patients receiving the ReShape Intragastric Balloon
89407725|NCT01061385|Other|Control Arm|Weight loss using behavior modification (diet and exercise counseling) alone
89407726|NCT03652467|Experimental|Deferoxamine|Patients are treated with deferoxamine and conventional TACE.
89191147|NCT00717938|Experimental|B|Standard chemotherapy treatment for patients with small cell lung cancer. Chemotherapy regimen contains a platinum drug and a topoisomerase inhibitor. Numbers of cycles 4-6 according to local variants. Used drugs=cisplatinum or carboplatin and e.g.etoposide. In addition to this, subjects will receive daily subcutaneous injections of enoxaparin during chemotherapy treatment.
89191148|NCT04068558|Experimental|VNI-NAVA/sNIPPV|Ventilation of the child non-invasive ventilation (VNI) NAVA then sNIPPV
89407727|NCT03652467|Active Comparator|Conventional TACE|Patients are treated with conventional TACE.
89407728|NCT00292292|Experimental|Kineflex Lumbar Artificial Disc|Treatment arm
89407729|NCT00292292|Active Comparator|Charite|
89407730|NCT02120508|Experimental|1 Hz rTMS, real|1 Hz rTMS over unaffected hemisphere for 15 minutes
89407731|NCT02120508|Sham Comparator|1Hz rTMS, sham|1Hz sham rTMS, over unaffected hemisphere for 15 minutes
89407732|NCT02120586|No Intervention|Control group|Usual care
89407733|NCT02120586|Experimental|Respiratory training group|"Participants will breathe against a load ≥ 50% of their baseline MIP, after which loads will increase according to the participant's tolerance across the remaining training period, using a Borg scale rating of 4 to 6 on perceived exertion as an indicator of adequate training intensity.~Intervention: Inspiratory Muscle training (12-weeks)"
89407734|NCT02120586|Experimental|Peripheral training group|"Participants will load ≥ 50% of their maximum muscle force (Kg), after which load will increase according to the participant's tolerance across the remaining training period, using a Borg scale rating of 4 to 6 on perceived exertion as an indicator of adequate training intensity.~Intervention: Peripheral muscle training (12-weeks)"
89531031|NCT02498639|Active Comparator|BAV without pacing|Patients undergo percutaneous balloon aortic valvuloplasty (BAV) without previous insertion of a temporary pacemaker lead in the right ventricle. Stabilization of the balloon during inflation is done without rapid pacing.
89535625|NCT04992897||Consistent efficacy|"all users that performed at least 2 evaluable treatments. In order to isolate the effect of REN treatments, this dataset considered only treatments where REN was used as a standalone treatment.~'Treatment' defined as a REN treatment of at least 20 minutes (the nominal duration is 45 minutes).~'Evaluable treatment' defined as a treatment in which pain levels were reported at baseline and post 2 hours."
88813629|NCT04963842|No Intervention|Conventional phase (use of conventional food packaging material)|During the conventional phase, participants are asked to maintain their usual habits for 5 days.
88813630|NCT04963842|Experimental|Intervention phase (use of bio-plastic and no plastic food packaging material)|During the 5-day long intervention period, all participants will be asked to: i) refrain from packaged (cans, plastic, paper) ready to consume foods, and foods from take away/delivery/fast food and ii) use the bio-based food packaging material to package their food.
88813631|NCT01727336|Experimental|Dalantercept 0.9 mg/kg plus axitinib|Subcutaneous (SC) injection of dalantercept 0.9 mg/kg once every 3 weeks and oral axitinib 5 mg BID for continuous dosing.
88813632|NCT01727336|Placebo Comparator|Placebo plus axitinib|Subcutaneous injection of normal saline once every 3 weeks and oral axitinib 5 mg BID for continuous dosing
88813633|NCT01727336|Experimental|Dalantercept 0.6 mg/kg|Part 1 dose escalation arm 0.6 mg/kg dalantercept once every 3 weeks
89191149|NCT04068558|Experimental|sNIPPV/VNI-NAVA|Ventilation of the child sNIPPV then non-invasive ventilation (VNI) NAVA
89191150|NCT04068090||Patients with CIPN|Patients with peripheral neuropathy after treatment with taxanes
89535626|NCT04992897||Treatment intensity distribution|"all treatments.~'Treatment' defined as a REN treatment of at least 20 minutes (the nominal duration is 45 minutes)."
89191151|NCT04068090||Patients without CIPN|Patients treated with taxanes and don't develop will be enrolled to this cohort and matched to a specified subject with neurotoxicity based on age, tumor stage, chemotherapy regimen or total taxane dosage
89191152|NCT00857428|Experimental|1|Oxymorphone ER 40 mg tablets Sandoz
89407735|NCT05725148|Experimental|Participants whose SBP and DBP meet the ISO 81060-2:2018 requirements|Each set of blood pressure tests is performed simultaneously. A cuff is worn on the right (or left) arm to check the blood pressure by auscultation, while 'CART-I plus' is worn on the finger of the opposite arm to check the blood pressure. At this time, the blood pressure test using an auscultation method is performed by two investigators simultaneously, and the blood pressure test using 'CART-I plus' is performed by the participants themselves
89407736|NCT02117154||HbA1c, 6-day Professional CGM|6-day Continuous Glucose Monitoring System (Medtronic iPro2 Professional CGM) will be deployed on a same patient for 3 times, which is one month apart
89407737|NCT03528824|Experimental|Fenugreek wraps|Daily application of fenugreek wraps for 1/2-2 hours per day, 4 weeks application
89407738|NCT03528824|Active Comparator|Diclofenac gel|Daily application of diclofenac gel, 4 weeks application
89407739|NCT03528824|No Intervention|Usual care|no specific intervention
89407740|NCT03553056|Experimental|Intervention|NZ Step Away app
89407741|NCT03553056|Active Comparator|Control|Modified NZ Step Away app
89407742|NCT00289640|Experimental|1|
89407743|NCT00289640|Experimental|2|
89407744|NCT00289640|Experimental|3|
89407745|NCT03552432|Experimental|Alirocumab therapy group|start with alirocumab 75mg per 2weeks and rosuvastatin 10mg per day
89407746|NCT03552432|No Intervention|standard statin therapy group|start with only rosuvastatin 10mg per day
89407747|NCT05006170|Experimental|6 to below 10 kg weight band|Children with perinatal HIV infection whose weight from 6 kg to below 10 kg
89407748|NCT05006170|Experimental|10 to below 14 kg weight band|Children with perinatal HIV infection whose weight from 10 kg to below 14 kg
89407749|NCT05006170|Experimental|14 to below 20 kg weight band|Children with perinatal HIV infection whose weight from 14 kg to below 20 kg
89407750|NCT02117232|Experimental|Visualization balloon|"Colonoscopy performed with the use of Visualization balloon"
89191153|NCT00857428|Active Comparator|2|Opana ER 40 mg tablets Eon Pharmaceuticals
89407751|NCT02117232|Active Comparator|Traditional CO2-insufflation colonoscopy|"Traditional colonoscopy performed with CO2 insufflation without Visualization balloon"
89407752|NCT03765632|Experimental|Gene Therapy|Infusion of autologous cryopreserved EFS-ADA LV CD34+ cells
89407753|NCT02973477|Experimental|Group A: Dapagliflozin/Glimepiride|Participants will take open-label dapagliflozin 5 mg daily for 4 weeks and escalate the dose gradually up to dapagliflozin 10 mg daily as needed based on their glucose monitoring for a total of 12 weeks on dapagliflozin. Patients will then begin a 2 week washout period where they are not taking any study drugs. After the washout period, participants will receive open-label glimepiride 2 mg daily for 4 weeks and escalate the dose gradually up to glimepiride 4 mg daily (no more than 4 mg daily) as needed based on their glucose monitoring for a total of 12 weeks on glimepiride.
89407754|NCT02973477|Experimental|Group B: Glimepiride/Dapagliflozin|Participants will take open-label glimepiride 2 mg daily for 4 weeks and escalate the dose gradually up to glimepiride 4 mg daily (no more than 4 mg daily) as needed based on their glucose monitoring for a total of 12 weeks on glimepiride. Patients will then begin a 2 week washout period where they are not taking any study drugs. After the washout period, participants will receive open-label dapagliflozin 5 mg daily for 4 weeks and escalate the dose gradually up to dapagliflozin 10 mg daily as needed based on their glucose monitoring for a total of 12 weeks on dapagliflozin.
89407755|NCT04558450|Other|Group 1|Patients with confirmed infection by SARS-Cov-2, requiring a hospitalization in intensive care unit
89407756|NCT04558450|Other|Group 2|Patients with confirmed infection by SARS-Cov-2, requiring a hospitalization in a medicine unit
89407757|NCT04558450|Other|Group 3|Patients with confirmed infection by SARS-Cov-2, not requiring hospitalization
89407758|NCT04558450|Other|Group 4|4) individuals having performed a test for SARS-Cov-2 infection, but resulted to be negative
88813634|NCT01727336|Experimental|Dalantercept 0.9 mg/kg|Part 1 dose escalation arm 0.9 mg/kg dalantercept once every 3 weeks
89407759|NCT02117388|Experimental|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy is designed to identify incorrect ideas about sleep, challenge their validity, and replace them with correct information. This therapy tries to reduce worry, anxiety, and fear that one won't sleep by providing accurate information about sleep.
89407760|NCT02117388|Experimental|Sleep Restriction|Sleep Restriction therapy will limit the time participants spend in bed in order to make sure they are sleepy enough to fall asleep quickly.
88813635|NCT01727336|Experimental|Dalantercept 1.2 mg/kg|Part 1 dose escalation arm 1.2 mg/kg dalantercept once every 3 weeks
88813636|NCT01727336|Experimental|Dalantercept 1.5 mg/kg|Part 1 dose escalation arm 1.5 mg/kg dalantercept once every 3 weeks
88813637|NCT01578707|Active Comparator|Ofatumumab (Arm A)|An anti-CD20 monoclonal antibody
88813638|NCT01578707|Experimental|ibrutinib (Arm B)|A Bruton Tyrosine Kinase Inhibitor
88813639|NCT03835442|Active Comparator|baclofen arm|baclofen 10mg tid for 4 weeks
88813640|NCT03835442|Placebo Comparator|placebos arm|placebo tid for 4 weeks
88813641|NCT02466516|Experimental|SEL 6 mg|Selonsertib (SEL) 6 mg for 24 weeks.
89407761|NCT02117388|Experimental|Combined Therapy Treatment for Insomnia|Combined Therapy involves combining Sleep Restriction and Cognitive Therapy so that the two therapies reinforce each other.
89407762|NCT03528746|Experimental|Isometric exercise|Participants will complete isometric quadriceps exercise
89407763|NCT03528746|Active Comparator|Isotonic exercise|Participants will complete dynamic leg extension
89407764|NCT04918888||Overall study population|All new oncologic patients of the outpatient-clinic of the department of radiooncology
89407765|NCT04918888||First dose received (Subpopulation 1)|Patients, who received one or two doses of SARS-CoV-2 vaccine prior to radiotherapy
89407766|NCT04918888||Vaccination during therapy (Subpopulation 2)|Patients, who will receive at least one dose of SARS-CoV-2 vaccine during or up to 6 weeks after radiotherapy
89407767|NCT03552354|Experimental|Argatroban combined with antiplatelet|
89535627|NCT04992897||Safety|all reported treatment/device-related adverse events (AEs) within the time period.
89407768|NCT03531944|Experimental|Community pharmacist-involved care|Community pharmacist-involved collaborative care in the management of type 2 diabetes mellitus
89407769|NCT03531944|Placebo Comparator|Usual care|Usual care with physician and as needed referral to nurses
89407770|NCT04847362|Experimental|Experimental|The mothers in this group will be given telehealth training for 4 weeks.
89407771|NCT04847362|No Intervention|Control|Mothers in this group will not be given telehealth education, they will receive care within the scope of routine care.
89407772|NCT02288000|Active Comparator|Memantine|Memantine will be administered OS as of 10 mg- capsule one per day in the morning over 15 days.
89407773|NCT02288000|Placebo Comparator|Placebo|The placebo will be presented as capsule comparable to memantine
89407774|NCT02788656|Experimental|Group A|Group A will receive sacubitril/valsartan + placebo for weeks 1-12. and then sacubitril/valsartan only for weeks 13-32. All subjects in Group A will also receive longitudinal pulmonary artery pressure monitoring using a previously placed implantable hemodynamic monitor (CardioMEMS device).
89407775|NCT02788656|Active Comparator|Group B|"Group B will receive an Angiotensin-Converting Enzyme Inhibitor (ACEi) or Angiotensin II Type 1 Receptor Blocker (ARB) + placebo for weeks 1-6 (depending on previous background therapy) and then switch to sacubitril/valsartan + placebo for weeks 7-12.~Group B will then receive sacubitril/valsartan only for weeks 13-32. All subjects in Group B will also receive longitudinal pulmonary artery pressure monitoring using a previously placed implantable hemodynamic monitor (CardioMEMS device)."
89407776|NCT03531866|Experimental|Intervention Version A|Youth will be asked to complete a version of DigiKnowIt News that includes investigations, comics, and spotlight videos that focus on four topic areas related to participating in clincial trials. Version A will include an additional topic area.
89407777|NCT03531866|Experimental|Intervention Version B|Youth will be asked to complete a version of DigiKnowIt News that includes investigations, comics, and spotlight videos that focus on four topic areas related to participating in clincial trials. Version B will include an additional topic area (different than in Version A).
89407778|NCT03531866|No Intervention|Wait-List Control|Youth will not have access to DigiKnowIt News until after the post-test timepoint.
89407779|NCT03652311|Experimental|TNM Device Group|In this arm participants will receive 5 sessions of twice daily treatments of 15 minutes of caloric vestibular stimulation (CVS) using the ThermoNeuroModulation TNM Device. In addition, participants will continue with the standard therapy that they are receiving.
89407780|NCT03652311|Sham Comparator|Sham CVS Group|In this arm participants will receive 5 sessions of twice daily sessions of 15 minutes of sham stimulation with the ThermoNeuroModulation TNM Device. The ThermoNeuroModulation TNM device will be fitted and turned on in a random paradigm that has no demonstrated efficacy. Participants will continue with the standard therapy that they are receiving.
89407781|NCT00284804|Experimental|MDX-060 plus standard of care|MDX-060 in combination with gemcitabine
89407782|NCT00284804|Active Comparator|Standard of care|Gemcitabine
89407783|NCT05258110|Experimental|Reference (R): midazolam alone|First treatment period
89407784|NCT05258110|Experimental|Test (T): midazolam + BI 425809|Second treatment period
89407785|NCT03652233|Experimental|Afatinib and Nivolumab|
89407786|NCT02123784||Rotator cuff tear|Patients which demonstrate a full-thickness tear of the rotator cuff tendon and meet the inclusion criteria.
89407787|NCT02123862||Prostate Cancer|
88922013|NCT05972174|Experimental|Part A Group 2 Vaccine: mRNA-1018 for H7N9 Dose Level 2|Participants will receive mRNA-1018 for H7N9 at dose level 2 by IM injection on Day 1 and Day 22.
88922014|NCT05972174|Experimental|Part A Group 2 Vaccine: mRNA-1018 for H7N9 Dose Level 3|Participants will receive mRNA-1018 for H7N9 at dose level 3 by IM injection on Day 1 and Day 22.
89407788|NCT02123862||Breast Cancer|
89407789|NCT02123862||Colorectal Cancer|
89407790|NCT02123862||Solid Tumor|
89407791|NCT02123862||Benign Condition|
89407792|NCT03652155||Orthognathic Surgery Patients|The study cohort will be patients undergoing orthognathic surgery for correction of an existing dentofacial deformity.
89407793|NCT03621969|Experimental|Group 1|"Group 1 will receive:~Medical History and Brief Physical Exam~Diagnostic Assessments~Patient Instruction and use of RePlay Device~two weeks of RePlay device therapy twice per week at REACT (weeks 1-2), followed by re-assessment,~then will rest for 2 weeks (weeks 3-4),~then will take the RePlay devices and tablets home for two weeks (weeks 5-6) for daily RePlay device therapy, followed by re-assessment."
89407794|NCT03621969|Experimental|Group 2|"Group 2 will receive:~Medical History and Brief Physical Exam~Diagnostic Assessments~Patient Instruction and use of RePlay Device~two weeks of RePlay device therapy daily at home (they will take the RePlay devices and tablets home) (weeks 1-2), followed by re-assessment,~then will rest for 2 weeks (weeks 3-4),~then will receive two weeks of RePlay device therapy twice per week at REACT (weeks 5-6), and then will undergo re-assessment."
89407795|NCT02117466|Other|Standard dose cetuximab|Uptake of 89Zr-cetuximab: continue standard dose (500mg/m2 bsa) (standard care)
89535628|NCT02452255|Active Comparator|Fenofibrate|Fenofibrate by mouth given daily throughout hospitalization for up to 12 months
89535629|NCT02452255|Active Comparator|Fenofibrate and Propranolol|Fenofibrate and Propranolol by mouth given throughout hospitalization for up to 12 months
89535630|NCT02452255|Placebo Comparator|Placebo|Placebo by mouth given daily throughout hospitalization for up to 12 months.
89535631|NCT02452255|Active Comparator|Propranolol|Propranolol by mouth given throughout hospitalization for up to 12 months
89535632|NCT04492787|Experimental|Changkang Granules|Changkang Granules
89191154|NCT04069494||patients|People diagnosed with advanced lung cancer and scheduled to receive palliative RT will be invited to participate between 1st July 2019 and 31st January 2020.
89191155|NCT04069494||care giver|Patients' family caregivers will also be invited to participate
89191156|NCT04018768||Ibuprofen + Percocet|
89191157|NCT04018768||Percocet|
89191158|NCT00719784|Experimental|1|All patients recruited will have VRI recordings done. There is no comparative arm.
89191159|NCT00848848|Active Comparator|1|
89191160|NCT00848848|Active Comparator|2|
89191161|NCT00848848|Active Comparator|3|
89191162|NCT00848848|Active Comparator|4|
89191163|NCT00848848|Active Comparator|5|
89191164|NCT00848848|Active Comparator|6|
89191165|NCT00848848|Active Comparator|7|
89191166|NCT00848848|Active Comparator|8|
89191167|NCT00848848|Active Comparator|9|
89191168|NCT00848848|Active Comparator|10|
89191169|NCT02573922|Experimental|Oxycodone-naloxone|Oxycodone-naloxone prolonged release tablet twice a day
89191170|NCT02573922|Active Comparator|Oxycodone|Oxycodone prolonged release tablet twice a day
89191171|NCT00718016||ALS|Subjects having either definite or probable ALS by El Escorial Criteria.
89407796|NCT02117466|Experimental|Dose escalation cetuximab|No 89Zr-cetuximab uptake: dose escalation in a 3x3 cohort design (with maximal 50% dose increase each cohort; with a maximum of 2000 mg/m2 bsa every two weeks)
88813642|NCT02466516|Experimental|SEL 18 mg|SEL 18 mg for 24 weeks.
88813643|NCT02466516|Experimental|SEL 6 mg+SIM 125 mg|SEL 6 mg plus SIM 125 mg for 24 weeks.
88813644|NCT02466516|Experimental|SEL 18 mg+SIM 125 mg|SEL 18 mg plus SIM 125 mg for 24 weeks.
88813645|NCT02466516|Experimental|SIM 125 mg|SIM 125 mg for 24 weeks.
88813646|NCT04377464||COVID-19 Survivors|Patients following-up at the PWH outpatient clinics will be enrolled for further evaluation via telephone follow-up at one, three, and six months after hospital discharge. SF12, EQ-5D-5L and work status standardized quantitative assessments of quality of life will be implemented via telephone follow-up at these time-points.
88813647|NCT01722656|Other|Aflibercept|All subjects will receive aflibercept
88813648|NCT03405584|Experimental|Bismuth Plus Dual Therapy|Esomeprazole 40mg bid, Amoxicillin 1.0g tid and Bismuth Potassium Citrate 600mg bid for 14 days.
88813649|NCT03405584|Active Comparator|Dual Therapy|Esomeprazole 40mg bid and Amoxicillin 1.0g tid for 14 days.
88813650|NCT03007043||Normal responders|Normal response following IVF
88813651|NCT03007043||Suboptimal responders|Suboptimal response following IVF
89191172|NCT00852436|Active Comparator|1|Pregabalin capsules in 75 mg, administered orally one (or two, or four) capsule(s), twice daily. Dosing increment from 150, 300, to 600mg/day at weekly intervals.
89191173|NCT00852436|Placebo Comparator|2|Placebo capsules in 75 mg, administered orally one (or two, or four) capsule(s), twice daily. Dosing increment from 150, 300, to 600mg/day at weekly intervals.
89191174|NCT02574000||Single group baseline and follow-up|"Single group of adult stroke patients assessed using ShoulderQ shoulder pain questionnaire and Clinical shoulder examination at two time-points:~Baseline: within 72 hours post-stroke Follow-up: at 8-10 weeks post-stroke"
89191175|NCT04068350||Single arm|The evaluation at 3 months of the postoperative pain will be carried out without the information collected in preoperative and immediate postoperative.
89191176|NCT02573844|Active Comparator|A: Proklama ( 1 sachet/ day)|"15 patients belonging to group A will receive drug A (Proklama: 1 sachet/ day). The treatment will be administred starting from visit 3 for a 2 weeks- treatment's period.~After a 2 weeks wash out's period, patients belonging to group A, starting from visit 5, will receive drug B ( Placebo: 1 sachet/day)."
89407797|NCT02123940|Experimental|nasal humidified high flow therapy|Prospective randomized clinical multicentric study on ICU comparing a treatment strategy (nasal humidified high flow therapy and Noninvasive Ventilation) in patients with high-risk of postextubation distress in ICU based on a Lung Ultrasound Score VERSUS standard strategy
89191177|NCT02573844|Placebo Comparator|B: Placebo ( 1 sachet/ day)|"15 patients belonging to group B will receive drug B (Placebo: 1 sachet/ day). The treatment will be administred starting from visit 3 for a 2 weeks- treatment's period.~After a 2 weeks wash out's period, patients belonging to group B, starting from visit 5, will receive drug A ( Proklama: 1 sachet/day)."
89407798|NCT02123940|Other|standard strategy|Prospective randomized clinical multicentric study on ICU comparing a treatment strategy (nasal humidified high flow therapy and Noninvasive Ventilation) in patients with high-risk of postextubation distress in ICU based on a Lung Ultrasound Score VERSUS standard strategy
89407799|NCT02117622||Patients with diabetes mellitus requiring insulin therapy|
89407800|NCT04529902||Tumor necrosis factor inhibitors|Reference group
89407801|NCT04529902||Abatacept|Exposure group
89407802|NCT00283868||Telemedicine|Patients randomized to this group were evaluated using the digital observation camera and DICOM evaluations for telemedicine
89407803|NCT00283868||Telephone|Patients randomized to this group were evaluated using telephone only and no use of the digital observation camera or DICOM
89407804|NCT02117778|Active Comparator|Interscalene|Continuous Interscalene Nerve Block
89407805|NCT02117778|Active Comparator|Supraclavicular|Continuous Supraclavicular Nerve Block
89407806|NCT02117778|Active Comparator|Suprascapular|Continuous Suprascapular Nerve Block
89407807|NCT04696900|Other|Exercise training|14 participants will absolve a prescribed exercise training for 12 months.
89407808|NCT02120742|Experimental|Social Norming|"The first group will receive SMS message reminders framed as social norming (ie Most of your peers wear helmets)."
89407809|NCT02120742|Experimental|Fear Appeal|"The second group will receive SMS message reminders framed as fear appeals (ie Not wearing your helmet increases your chance of dying in an accident)."
89407810|NCT02120742|Placebo Comparator|Control|The third group will act as the control and receive texts that relate to general road safety, but not helmet use.
89407811|NCT02120820|Active Comparator|Multisensory environment|Multisensory environment (MSE): 30 minutes/session, twice a week for 10 weeks
89407812|NCT02120820|Active Comparator|Massage therapy|Massage therapy (MT): 15 minutes/session, twice a week for 10 weeks
89407813|NCT02120820|Other|Control group|Control group: usual care for 10 weeks, with attention and interactions with the caregivers only.
89407814|NCT02120820|Active Comparator|Massage in multisensory environment|Participants receive 15 minutes massage therapy in multisensory environment (MT-MSE), twice a week for 10 weeks.
89407815|NCT02288078|Active Comparator|Treatment group|"Treatment with regorafenib (160 mg/day, oral administration, 3 weeks on therapy followed by 1 week off therapy), test drug capsule (dexamethasone 2 mg) and proton pump inhibitors (PPIs) will be started within 14 days of enrollment. The protocol treatment period is 4 weeks.~Follow-up treatment for the underlying disease after the 4-week protocol treatment is not specified. The physician in charge will decide whether or not to continue treatment with regorafenib. For the prevention of fatigue/malaise, dexamethasone 2 mg can be used.~General condition, blood pressure, Patient Reported Outcome, clinical findings, hematology/blood chemistry, coagulation and fibrinolysis system, urinalysis, medicatiob check, adverse event, thyroid function test, brain MRI, Contrast-enhanced torso CT"
89407816|NCT02288078|Placebo Comparator|Placebo group|"Treatment with regorafenib (160 mg/day, oral administration, 3 weeks on therapy followed by 1 week off therapy), placebo capsule (lactose) and proton pump inhibitors (PPIs) will be started within 14 days of enrollment. The protocol treatment period is 4 weeks.~Follow-up treatment for the underlying disease after the 4-week protocol treatment is not specified. The physician in charge will decide whether or not to continue treatment with regorafenib. For the prevention of fatigue/malaise, dexamethasone 2 mg can be used.~General condition, blood pressure, Patient Reported Outcome, clinical findings, hematology/blood chemistry, coagulation and fibrinolysis system, urinalysis, medication check, adverse event, thyroid function test, brain MRI, Contrast-enhanced torso CT"
89407817|NCT02117856|Active Comparator|1 implant|"Participants receive the following:~1 implant placed surgically in the mandibular midline; Soft reline of the existing complete lower denture; 2.25mm ball patrix placed on 1 healed implant; and Reline with 1 retentive matrix in the lower denture."
89407818|NCT02117856|Active Comparator|2 implants|"Participants receive the following:~2 implants placed surgically in the mandibular canine sites; Soft reline of the existing complete lower denture; 2.25mm ball patrices placed on 2 healed implants; and Reline with 2 retentive matrices in the lower denture."
89407819|NCT03531554|Experimental|ketone ester drink|Oral intake of ketone ester drink muscle biopsy exercise muscle biopsy Magnetic Resonance imaging
89407820|NCT03531554|Placebo Comparator|carbohydrate drink|Oral intake of isocaloric carbohydrate drinkmuscle biopsy exercise muscle biopsy Magnetic Resonance imaging
89407821|NCT02120976|Experimental|Dose 1 JTT-252 or Placebo|Tablets, single dose in fasted condition
89407822|NCT02120976|Experimental|Dose 2 JTT-252 or Placebo|Tablets, single dose in fasted condition
89407823|NCT02120976|Experimental|Dose 3 JTT-252 or Placebo|Tablets, single dose in fasted condition
89407824|NCT02120976|Experimental|Dose 4 JTT-252 or Placebo|Tablets, single dose in fasted condition
89407825|NCT02120976|Experimental|Dose 5 JTT-252 or Placebo|Tablets, single dose in fasted condition
89407826|NCT02120976|Experimental|Dose 6 JTT-252 or Placebo|Tablets, single dose in fasted condition
88813652|NCT04935840|Experimental|FertyBiotic Pregnancy|Participants received FertyBiotic Pregnancy one capsule a day
89407827|NCT02120976|Experimental|Dose 7 JTT-252 or Placebo|Tablets, single dose in fasted condition
89407828|NCT02120976|Experimental|Dose 8 JTT-252|Tablets, single dose in fed condition
89407829|NCT02120976|Experimental|Dose 9 JTT-252|Tablets, single dose in fasted condition
89407830|NCT04346524||microbiome sampling|pregnant women with type 1 diabetes
89407831|NCT02288234||Vibativ|This is an observational study for patients who were already prescribed Vibativ.
89407832|NCT03531398|Experimental|High fat meal|Muffin containing 30g fat
89407833|NCT03531398|Experimental|Medium fat meal|Muffin containing 20g fat
89407834|NCT04654312|Experimental|Intervention|Intake of HCT 25 mg, 1 tablet/d for 15 days
89191178|NCT02545894|No Intervention|BASELINE TESTING|Language and cognitive assessments conducted
89191179|NCT02545894|Experimental|Treatment|"Intervention given:~visual tracking pressing a button every time a picture is seen on the screen~playing dominoes and snap~pressing a button every time a specific picture is seen on the screen~Pressing a button every time a specific sound is heard~Matching objects to a picture~Matching gestures to objects~Matching two connected objects~Sorting objects by categories~Matching sounds to objects~Complete the category and odd on out with objects~Choosing target objects by pointing~Choosing objects to complete the category by pointing"
89191180|NCT02545894|No Intervention|Post intervention|Repeated testing
89191181|NCT03910920||Cystic fibrosis patients with PA|All the children with acute or chronic Pseudomonas aeruginosa infection and followed-up in our cystic fibrosis center will be included in this study.
89191182|NCT00424177|Experimental|eltrombopag|
89191183|NCT04068116|Experimental|Postconditioning in primary percutaneous coronary intervention|Patients presenting with ST-elevation myocardial infarction will undergo primary per-cutaneous coronary intervention with post-conditioning by making 4 cycles of repeated occlusion & re-perfusion 30-second each by inflation/deflation of an appropriately sized PTCA (per-cutaneous trans-luminal coronary angioplasty) balloon
89191184|NCT04068116|Active Comparator|Primary percutaneous coronary intervention|Patients presenting with ST-elevation myocardial infarction will undergo primary per-cutaneous coronary intervention without post-conditioning
89191185|NCT00716430|Active Comparator|QI|Quality Improvement Centres
89191186|NCT00716430|No Intervention|Non-QI|No Quality Improvement Programme
89191187|NCT00720512|Active Comparator|Arm I|Patients receive either irinotecan hydrochloride over 1 hour or oxaliplatin over 1 hour on day 1. Patients also receive leucovorin calcium IV over 2 hours and fluorouracil IV over 46 hours continuously beginning on day 1. Treatment repeats every 2 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.
89191188|NCT00720512|Experimental|Arm II|Patients receive combination chemotherapy as in arm I and bevacizumab IV on day 1. Treatment repeats every 2 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.
89191189|NCT04069286|Experimental|Treated Group|in which dry Aroeira extract (Schinus terebinthifolius raddi, 640mg / tablet) will be administered + amoxicillin 500mg 2 tablets + clarithromycin, 500mg 1 tablet given twice daily (12/12 hours).
89191190|NCT04069286|Active Comparator|Control Group|in which 1 tablet of 20mg of omeprazole will be administered + amoxicillin 2 tablets of 500mg + clarithromycin, 1 tablet of 500mg administered twice daily (12/12 hours).
89191191|NCT00716508|Active Comparator|A|Repair with suture anchors: The insertion points for the three suture anchors will be marked with electrocautery. The anchors will be placed approximately 2 mm from the articulate surface; placing them too superficially may increased the joint reactive force and lead to abnormal patella femora joint mechanics. Pilot holes will be drilled with a 3.2-mm drill bit parallel to the patella, avoiding penetration of the articular surface. Three Suture anchors (Arthrex, Naples FL) will be threaded with two No. 5 Fiberwire (Arthrex, Naples FL) sutures and will be inserted and deployed in the pilot holes in the usual manner.
89407835|NCT04654312|Placebo Comparator|Placebo|Intake of Placebo, 1 tablet/d for 15 days
89535633|NCT04492787|Placebo Comparator|Changkang Placebo Granules|Changkang Placebo Granules
88883218|NCT04777305|Experimental|Aerobic exercise training|"The aerobic exercise training group, weeks 5-8 after surgery: this training will consist of 30 min. of walking, 3 times per week at an intensity of 60-70% of peak VO2 or RPE 6-7 on the Borg scale.~Weeks 9-26 after surgery: this training will consist of 60 minutes of exercise, 3 times per week at an intensity of 65-80% of peak VO2 or RPE 6-8 on the Borg scale. The aerobic exercises will consist of a treadmill or outside walking or running, stationary cycling or elliptical trainer in continuous and interval training."
88883219|NCT04777305|Experimental|Resistance exercise training|Resistance exercise training group, weeks 5-8 after surgery: this training will consist of 5-10 minutes of warmup, followed by 6-8 multi-joint exercises for major muscle groups, comprising 2 sets of 10 to 25 repetitions at 40% of the one-repetition maximum (1-RM) for each exercise. The intensity will increase on weeks 9-26 after surgery to 8-10 multi-joint exercises of 3-4 sets of 10 to 25 repetitions. For this training participants will use free-weights and body weight exercises.
88883220|NCT04777305|Experimental|Combination exercise training|"The combination exercise training will consist of a combined aerobic and resistance exercise training sessions three times weekly. At weeks 5-8 after surgery the sessions will include 5-10 minutes of warmup, followed by 3-4 multi-joint exercises for major muscle groups, comprising 2 sets of 10 to 25 repetitions at 40% of the one-repetition maximum (1-RM) for each exercise. Afterwards the aerobic part of the training will consist of 10-15 minutes of aerobic exercises (treadmill or outside walking or running, stationary cycling or outdoors or elliptical trainer) at 60-70% of peak VO2 or RPE 6-7 at Borg scale.~The intensity will increase on weeks 9-26 after surgery to 4-5 multi-joint exercises of 3-4 sets of 10 to 25 repetitions and 30 minutes of aerobic exercises at 65-80% of peak VO2 or RPE 6-8 at Borg scale."
88883221|NCT04777305|No Intervention|The control group|The control group will receive routine health care without exercise supervision (clinical and nutritional follow up).
89191192|NCT00716508|Active Comparator|B|Repair with transpatellar tunnels: We will make a small horizontal trough at the inferior pole of the patella. Multiple, braided Krackow sutures will then be placed through the substance of the tendon using no. 5 Fiberwire (Arthrex, Naples FL) suture. Three to four drill holes will then be made through the patella. Using a suture passer, the sutures will then be brought from distal to proximal and tied over the superior pole. The knee will be flexed to 45 degrees. The tendon will be repaired adjacent to the articular surface and not to the anterior surface of the patella.
89191193|NCT04069442||cDC-1 positive|cDC-1 positive patients according to RNAseq and in situ analysis
89191194|NCT04069442||cDC-1 negative|cDC-1 negative patients according to RNAseq and in situ analysis
89191195|NCT00713466||1|all third year medical students entering their pediatric clerkship at the Medical College of Wisconsin
89191196|NCT03992846|Experimental|Linzagolix 75 mg|
89191197|NCT03992846|Experimental|Linzagolix 200 mg + Add-back (E2 1 mg / NETA 0.5 mg)|
89191198|NCT03992846|Placebo Comparator|Placebo|
89191199|NCT00713622|Active Comparator|1|
89191200|NCT00713622|Active Comparator|2|
89191201|NCT00719940|Experimental|1|Cognitive behavioral therapy
89191202|NCT00719940|Placebo Comparator|2|Waiting group
89191203|NCT00720018|Experimental|Period 1|NP101 Patch
89191204|NCT00720018|Experimental|Period 2|NP101 Patch
89191205|NCT00720018|Experimental|Period 3|NP101 Patch
89191206|NCT00720018|Experimental|Period 4|NP101 Patch
89191207|NCT00720018|Experimental|Period 5|NP101 Patch
89191208|NCT00716664|Experimental|1|The experimental group receives the intervention in addition to normal optimal care
89191209|NCT00716664|Active Comparator|2|The active comparator, or control group, receives normal optimal care only
89191210|NCT00618826|Experimental|Treatment Period|Treatment will be administered once every 2 weeks. One cycle of therapy will consist of 14 days. Paclitaxel is administered first after appropriate premedications. Gemcitabine is administered second and Avastin is administered after chemotherapy, all given on day 1 of each cycle.
89191211|NCT00718250|Experimental|cohort 1|AML Cell Vaccine alone
89191212|NCT00718250|Experimental|cohort 2|Donor leukocytes alone
89191213|NCT00718250|Experimental|cohort 3|AML cell vaccine and Donor Leukocyte Infusion (1x107/kg)
89191214|NCT00718250|Experimental|cohort 4|AML cell vaccine and Donor Leukocyte Infusion (1x108/kg)
89191215|NCT00720174|Experimental|Treatment (cixutumumab and doxorubicin hydrochloride)|Patients receive cixutumumab IV over 1 hour on days 1, 8, and 15 and doxorubicin hydrochloride IV continuously over 44-52 hours beginning on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with stable or responding disease may continue to receive cixutumumab in the absence of disease progression or unacceptable toxicity.
89191216|NCT04041544|Active Comparator|SN1011|5 Cohort for Part A:25mg once a day,50mg once a day, 100mg once a day, 150mg once a day, 200mg once a day 4 Cohort for Part B : 50mg once a day, 100mg once a day, 200mg once a day, 100mg twice a day
89191217|NCT04041544|Placebo Comparator|SN1011 placebo|5 Cohort for Part A:25mg once a day,50mg once a day, 100mg once a day, 150mg once a day, 200mg once a day 4 Cohort for Part B : 50mg once a day, 100mg once a day, 200mg once a day, 100mg twice a day
89191218|NCT00722930|Experimental|1. Consolidation with Y90 Ibritumomab Tiuxetan|1. Consolidation with Y90 Ibritumomab Tiuxetan
89191219|NCT00713778|Experimental|1|Laparoscopic ovarian cystectomy using bipolar
89191220|NCT00713778|Experimental|2|Laparoscopic ovarian cystectomy using ultrasonic scalpel
89191221|NCT00713778|Active Comparator|3|Laparotomic ovarian cystectomy using suture
89191222|NCT00849004|Active Comparator|Gel vs. Sheet|One group will act to compare the effectiveness between silicone gel and silicone sheet.
89191223|NCT00849004|Active Comparator|sheet vs. paper tape|The second group between silicone sheet and paper tape.
89191224|NCT00849004|Active Comparator|gel vs. paper tape|One group will act to compare the effectiveness between silicone gel and paper tape.
89407836|NCT02973087|Experimental|All Study Participants|Participants will receive prophylaxis with rVWF in two cohorts: on-demand (OD) cohort (previously treated with OD) and pdVWF switch cohort (participants switching from prophylactic treatment with pdVWF).
88883222|NCT04774471||Women with breast lesions|Women with an identified breast lesion have a non-invasive non-contrast MRI scan prior to biopsy.
88883223|NCT04736004||Athletes with COVID-19|
88883224|NCT04736004||Athletes without COVID-19 (control)|
88883225|NCT04732065|Experimental|Arm A: ONC206 for participants with diffuse midline gliomas + prior therapy|Patients receive ONC206 orally (PO) up to six times per week. Cycles repeat every 28 days for up to 12 months in the absence of disease progression or unacceptable toxicity.
89191225|NCT03834740|Experimental|Cohort 1: last dose 1 to 3 hours prior to resection|"Three to fourteen patients will receive ribociclib and everolimus orally-administered in 5 daily doses with the last dose being administered at one of 3 intervals before brain tumor resection:~• Cohort 1: last ribociclib+everolimus dose 1 to 3 hours prior to craniotomy for tumor resection"
89191226|NCT03834740|Experimental|Cohort 2: last dose 7 to 9 hours prior to resection|"Three to fourteen patients will receive ribociclib and everolimus orally-administered in 5 daily doses with the last dose being administered at one of 3 intervals before brain tumor resection:~• Cohort 2: last ribociclib+everolimus dose 7 to 9 hours prior to craniotomy for tumor resection"
89191227|NCT03834740|Experimental|Cohort 3: last dose 23 to 25 hours prior to resection|"Three to fourteen patients will receive ribociclib and everolimus orally-administered in 5 daily doses with the last dose being administered at one of 3 intervals before brain tumor resection:~• Cohort 3: last ribociclib+everolimus dose 23 to 25 hours prior to craniotomy for tumor resection"
89191228|NCT00716898||1|"A. Patients with pathologically or cytologically confirmed diagnosis of advanced solid malignancy.~B. Venous thromboembolism: Deep vein thrombosis (DVT) confirmed by Doppler ultrasound, or pulmonary embolism confirmed by lung ventilation perfusion scan, or computerized tomography.~C. Treatment with therapeutic dose of low molecular weight heparin. D. No major surgery during the last month before investigation. E. No evidence of major infectious disease. F. Serum creatinine level < 1.5 mg/dl. G. Informed consent"
89191229|NCT00716898||2|"A. Patients with unstable angina pectoris/ atypical chest pain, with no evidence of acute myocardial infarction.~B. Treatment with therapeutic dose of low molecular weight heparin. C. No evidence of VTE. D. No major surgery during the last month before investigation. E. No evidence of major infectious disease. F. No history of malignancy. G. Serum creatinine level < 1.5 mg/dl. H. Informed consent"
89191230|NCT00713856|Active Comparator|1|
89191231|NCT00713856|Active Comparator|2|
89191232|NCT02545582||Therapy|Heart failure patients implanted with the VITARIA system
89191233|NCT00713934|Experimental|1|
89191234|NCT00713934|Experimental|2|
89191235|NCT00849160|Experimental|Darunavir/r|
89191236|NCT00714012||1 Visualization users|End users of the domain specific visualizations.
89191237|NCT03909230||Day 2 post ovulation|Ultrasound of the endometrium, Endometrial fluid sample, Blood sample
89191238|NCT03909230||Day 4 post ovulation|Ultrasound of the endometrium, Endometrial fluid sample, Blood sample
89191239|NCT00857974|No Intervention|Usual Care|No physical activity intervention will be prescribed for the Usual Care Arm.
89191240|NCT00857974|Active Comparator|Physical Activity|
89191241|NCT00720252|Experimental|A|
89191242|NCT00720590|Experimental|1|Participants will receive treatment with atazanavir and placebo lopinavir/ritonavir.
89191243|NCT00720590|Experimental|2|Participants will receive treatment with lopinavir/ritonavir and placebo atazanavir.
89191244|NCT00720590|Placebo Comparator|3|Participants will receive treatment with placebos for both drugs.
89191245|NCT00852514|Experimental|Monthly BIA|monthly BIA to monitor fluid status
89191246|NCT00718406|Active Comparator|A|A=metoprolol
89191247|NCT00718406|Active Comparator|B|B=metoprolol plus morphine
89191248|NCT02572206|Other|PET/SPECT and MRI scans|"PET/SPECT scan will be used to evaluate the utility of mGluR5 binding as a biomarker of the CNTNAP2 mutation and related mTOR kinase pathway dysregulation.~30 minute structural MRI will be obtained to permit co-registration of PET images."
89191249|NCT05374070|Active Comparator|Streptococcus salivarius K12|Streptococcus salivarius K12 (Dose 1: 1 Billion colony forming units /g)
89191250|NCT05374070|Active Comparator|Streptococcus salivarius K12 with a prebiotic included|Streptococcus salivarius K12 (Dose 1: 1 Billion colony forming units /g)
89191251|NCT05374070|Active Comparator|Streptococcus salivarius M18|Streptococcus salivarius M18 (Dose 1: 1 Billion colony forming units /g)
89191252|NCT05374070|Active Comparator|Streptococcus salivarius M18 with a prebiotic included|Streptococcus salivarius M18 (Dose 1: 1 Billion colony forming units /g)
89191253|NCT00720408|Experimental|Prograf-XL + MMF|
89191254|NCT00720408|Active Comparator|Prograf + MMF|
89191255|NCT00852670|Experimental|A|
89191256|NCT00852670|Placebo Comparator|B|
89191257|NCT00717210|Active Comparator|A|Conventional Radiotherapy
89191258|NCT00717210|Experimental|B1/2|1:1 randomization between temozolomide and procarbazine/lomustine/vincristine (PCV)
89191259|NCT00849394||1|Shortened infusions of bevacizumab
89191260|NCT00720486|Experimental|1|Participants will receive Juvenile Justice Anger Management for Girls plus treatment as usual.
89191261|NCT00720486|Active Comparator|2|Participants will receive treatment as usual.
89191262|NCT00858286|Experimental|Stable dosing with SERETIDE, short acting B-2agonist as needed|Regular treatment with SERETIDE in a stable dosing with short acting beta-2 agonists as needed
89191263|NCT00858286|Experimental|Maintenance treatment with SYMBICORT and SYMBICORT as needed|Maintenance treatment with SYMBICORT and using the same inhaler with SYMBICORT as needed
89191264|NCT04018378|Experimental|RT|"period 1: HGP1604 1mg (reference drug, R) will be administered once orally.~period 2: HIP1502 1mg (test drug, T) will be administered once orally after 14 days of the washout period."
89407837|NCT05284656|Experimental|folic acid Group|20 patients will receive folic acid 500 µg per day with their standard therapy for 6 months.
89407838|NCT05284656|Experimental|Pentoxifylline Group|20 patients will receive Pentoxifylline ( TRENTAL® Tablets, 400 mg) twice daily with their standard therapy for 6 months.
89004598|NCT02834884||RP-1843 Arcagen (CLOSED for recruitment since November 2022)|"This is a collaborative project between EORTC and EURACAN to perform molecular characterisation of rare cancers patients, using Foundation Medicine tests. The goal of this project is to get a better understanding of the genomic landscape of rare cancers and potentially help define possibilities for targeted treatments/clinical trials for this population.~Tumor types: all 10 EURACAN domains"
89004599|NCT02834884||RP-1920 BioRadon|"The primary objective is to assess the correlation between the molecular profiles of NSCLC patients and indoor radon concentration, measured with an alpha-particle detector (a standardized and validated way of measuring indoor radon).~Tumor type: Thorax"
89407839|NCT05284656|Experimental|folic acid and pentoxifylline Group|20 patients will receive combination therapy of folic acid5 mg per day and pentoxifylline ( TRENTAL® Tablets, 400 mg) twice daily with their standard therapy for 6 months
89407840|NCT05284656|No Intervention|control group|20 patients will receive their standard therapy only.
89407841|NCT04287088|No Intervention|Control|After IMPROD bpMRI all men undergo prostate biopsies. In men with Likert scores of 1-2, TRUS guided systematic biopsies are performed. In men with Likert 3-5 score, in addition to systematic biopsies, two targeted biopsies are taken from each lesion (up to two lesions).
89407842|NCT04287088|Experimental|Intervention|After IMPROD bpMRI prostate biopsies are performed according to shared decision-making by the treating urologist and the patient. If biopsies are to be performed, in men with IMPROD bpMRI likert scores of 1-2, 12-core systematic TRUS guided biopsies are performed and in men with Likert 3-5 score lesions systematic biopsies are performed and two targeted biopsies are taken from each lesion (up to two lesions). If biopsies are not performed, men are referred for a PSA follow-up.
89004600|NCT02782468|Experimental|Arm 1, Cohort 1: Pevonedistat 25 mg/m^2|Pevonedistat, 25 milligram per square meter (mg/m^2), 60-minute infusion, intravenously, on Days 1, 3 and 5, followed by a rest period of 16 days, in 21-day treatment cycles.
89004601|NCT02782468|Experimental|Arm 1, Cohort 2: Pevonedistat 44 mg/m^2|Pevonedistat, 44 mg/m^2, 60-minute infusion, intravenously, on Days 1, 3, and 5, followed by a rest period of 16 days, in 21-day treatment cycles.
89004602|NCT02782468|Experimental|Arm 2, Cohort 1: Pevonedistat 10 mg/m^2+ Azacitidine 75 mg/m^2|Pevonedistat 10 mg/m^2, 60-minute infusion, intravenously, on Days 1, 3, and 5 and azacitidine 75 mg/m^2, on Days 1 to 5, and Days 8 and 9, intravenously or subcutaneously, followed by a rest period of 19 days, in 28-day treatment cycles.
89004603|NCT02782468|Experimental|Arm 2, Cohort 2: Pevonedistat 20 mg/m^2+ Azacitidine 75 mg/m^2|Pevonedistat 20 mg/m^2, 60-minute infusion, intravenously, on Days 1, 3, and 5 and azacitidine 75 mg/m^2, on Days 1 to 5, and Days 8 and 9, intravenously or subcutaneously, followed by a rest period of 19 days, in 28-day treatment cycles.
89004604|NCT02779244|Experimental|Early Weight Bearing + Cam boot|
89004605|NCT02779244|Active Comparator|Standard Treatment Cam boot|
89191265|NCT04018378|Experimental|TR|"period 1: HIP1502 1mg (test drug, T) will be administered once orally.~period 2: HGP1604 1mg (reference drug, R) will be administered once orally after 14 days of the washout period."
89407843|NCT02288390|Active Comparator|Miswak (Sewak)|Miswak (sewak) oral care applied 4 hourly for oral care in mechanically ventilated patients.
89407844|NCT02288390|Active Comparator|Chlorhexidine/ toothbrush|Chlorhexidine 0.12 % plus toothbrushing oral care applied 4 hourly for oral care in mechanically ventilated patients.
89407845|NCT02124174|Experimental|Vidaza and Valproic Acid|Vidaza and Valproic Acid
88883226|NCT04732065|Experimental|Arm B: ONC206 + radiation therapy for newly diagnosed participants|Patients undergo standard of care radiation therapy daily 5 days a week and receive ONC206 PO up to six times per week. Cycles repeat every 28 days for up to 12 months in the absence of disease progression or unacceptable toxicity.
88883227|NCT04732065|Experimental|Arm C: ONC206 + radiation therapy, DMGs with evidence of first progression but previously untreated|Patients undergo standard of care radiation therapy daily 5 days a week and receive ONC206 PO up to six times per week. Cycles repeat every 28 days for up to 12 months in the absence of disease progression or unacceptable toxicity.
89407846|NCT00277238|Experimental|CPG10101 (0.2) + pegylated inteferon + ribavirin|
89407847|NCT00277238|Experimental|CPG10101 (0.5) + pegylated inteferon + ribavirin|
89407848|NCT00277238|Active Comparator|Pegylated interferon + ribavirin|
89407849|NCT00277238|Experimental|CPG10101 + pegylated interferon + ribavirin (rollover)|
89407850|NCT02124252|No Intervention|Control|Women will be offered HPV testing within the health facilities in the communities randomized to this arm. Women who test HPV positive will be referred to care at the sub-district and district hospitals (current standard of care).
89407851|NCT02124252|Active Comparator|Standard Intervention|Women will be offered HPV-based cervical cancer screening followed by standard linkage to care for women who test positive (to subdistrict or district hospitals).
89407852|NCT02124252|Active Comparator|Enhanced Intervention|Women will be offered HPV-based cervical cancer screening followed by enhanced linkage to care using the strategies determined in partnership with the key stakeholders in the communities.
89407853|NCT03956368|Experimental|Treatment Group|Randomised on the day of admission to receive oral Atorvastatin 20mg daily for 8 weeks.
89407854|NCT03956368|Placebo Comparator|Control Group|Randomised on the day of admission to receive placebo 20mg daily for 8 weeks.
89407855|NCT02124330|Experimental|montmorillonite 5 g|5g Montmorillonite + 15 g protein (ratio 1:3)
89407856|NCT02124330|Experimental|Montmorillonite 3 g|3g Montmorillonite + 15 g protein (ratio 1:5)
89407857|NCT02124330|Experimental|Montmorillonite 1 g|1g Montmorillonite + 15 g protein (ratio 1:15)
89407858|NCT02124330|No Intervention|Control|A control goup will intake 15 g of protein alone
89407859|NCT02118090|Experimental|Chloroquine|Patients treat with chloroquine sulfate (NIVAQUINE) 10 mg/kg/day - 3 days
89407860|NCT02118090|Active Comparator|DHA-PP|Patient treat with DHA 40 mg and PP 320 mg, (Duo-Cotecxin®) The approximate total adult dose is 2-4 mg/kg for DHA and 20mg/kg for PP
88883228|NCT04732065|Experimental|Arm D: ONC206 Therapy, Primary malignant CNS tumors with progression|Patients receive ONC206 PO once a day (QD) up to six times per week. Cycles repeat every 28 days for up to 12 months in the absence of disease progression or unacceptable toxicity.
88883229|NCT04723862|Experimental|Spironolactone|Prior to the first or second admission (randomly determined), participants will be pretreated for 2 weeks with spironolactone (50 mg twice daily).
88883230|NCT04723862|Placebo Comparator|Placebo|Prior to the first or the second admission (randomly determined), participants will be pretreated for 2 weeks with placebo (twice daily).
88883231|NCT04720105|Experimental|Participants with plaque type psoriasis|Participants with plaque type psoriasis to be treated with Duobrii® (halobetasol propionate 0.01%/tazarotene 0.045% lotion) to be applied thinly once a day on the affected areas of hands and/or feet.
88883232|NCT04693234|Other|Tislelizumab and Ociperlimab (BGB-A1217) Combination (Cohort 1)|Participants will receive tislelizumab 200 milligrams (mg) on Day 1 followed by the administration of ociperlimab (BGB-A1217) 900 mg of each 21-day cycle.
88883233|NCT04693234|Other|Tislelizumab Monotherapy (Cohort 2)|Tislelizumab 200 mg will be administered on Day 1 of each 21-day cycle
88883234|NCT04664179|Experimental|Arm A: Treatment without lymphodepletion chemotherapy|"C7R-EBVSTs~Group B will be activated if only limited expansion and clinical efficacy is observed in Group A"
88883235|NCT04664179|Experimental|Arm B: Treatment with lymphodepletion chemotherapy|C7R-EBVSTs with lymphodepletion chemotherapy
89407861|NCT03621891||healthy individuals|Orally and systemically healthy individuals who has no hypo-functional teeth, hyper-occlusion or occlusal trauma
89407862|NCT03621891||periodontitis patients|Systemically healthy individuals who has chronic periodontitis but no hypo-functional teeth, hyper-occlusion or occlusal trauma
89407863|NCT03621891||healthy-occlusal trauma|Orally and systemically healthy individuals who has occlusal trauma caused by bruxism
89407864|NCT03621891||periodontitis-occlusal trauma|Systemically healthy individuals who has both chronic periodontitis and occlusal trauma caused by bruxism
89407865|NCT04539184|Experimental|Motion Style Acupuncture treatment|Motion Style Acupuncture treatment (2-3 times/week, 2 weeks)
89407866|NCT04539184|Active Comparator|Acupuncture treatment|Acupuncture treatment (2-3 times/week, 2 weeks)
89407867|NCT03551808|Active Comparator|installation of Ketorolac Tromethamine Eye Drop|
89407868|NCT03551808|No Intervention|not receiving placebo|
89407869|NCT04053543|Experimental|150mg CXA-10|Once daily dosing of 150mg CXA-10 in the morning
89407870|NCT04229914|Other|stroke patients|Assessment
89407871|NCT02124408|Experimental|Intervention group|Personalized Behavioral Intervention
89407872|NCT02124408|No Intervention|Control group|
89407873|NCT04202458|Experimental|intra-arterial tenecteplase administration|Intra-arterial administration of 4mg tenecteplase is given after microcatheter navigation through the clot. Intra-arterial administration of tenecteplase (0.4 mg/min) continuously is given after the first attempt of thrombectomy device pass for 30 minutes, and then followed by DSA
89407874|NCT00273650|Active Comparator|A|Methyl-B12
89407875|NCT00273650|Placebo Comparator|B|Saline placebo
89407876|NCT04053777||NIV group|Patients receiving non-invasive ventilation in the hospital or at home
89407877|NCT02121288|Experimental|Ticagrelor|oral ticagrelor 90 mg (yellow) tablet
89407878|NCT02121288|Active Comparator|Clopidogrel|oral clopidogrel 75 mg (pink) tablet
89407879|NCT03552900|Active Comparator|App 1 Study group (7cups)|"Participants assigned to this group will be assigned a behavioral intervention, the mobile app (7cups) which allows participants access to direct online social support via the app."
89407880|NCT03552900|Active Comparator|App 2 Study Group (Bliss|"Participants assigned to this group will be assigned to a behavioral intervention, the mobile app ( Bliss ) which provides participants an informational app about mental health resources at Harvard."
89407881|NCT04501042||Obese patients tissue proved NASH|age >20，morbid obesity who will receive bariatric surgery, tissue proved NASH
89407882|NCT04501042||Obese patients tissue proved NAFL|age >20，morbid obesity who will receive bariatric surgery, tissue proved NAFL
89407883|NCT04501042||NASH (before bariatric surgery)|age >20，morbid obesity receiving bariatric surgery and was proved NASH histologically. Data collected before bariatric surgery.
89407884|NCT04501042||NASH (after bariatric surgery)|age >20，morbid obesity receiving bariatric surgery and was proved NASH histologically. Data collected after bariatric surgery.
89407885|NCT05724680|Experimental|Treatment group|"cognitive behavior therapy~one session per week~six to eight session"
89407886|NCT05724680|Other|Wait list control group|"waitlist control group~offer CBT after completing data collection."
89407887|NCT01525329|Experimental|Solid Organ Transplant with AKs|Patients who have undergone kidney or liver transplant within 2 years and have at least 4 premalignant skin lesions on the face, ears, scalp, forearms and/or dorsal hands. Patients will serve as their own control, and one side of the body will be randomized to either 5-FU plus PDT, and the other will receive PDT alone.
89407888|NCT01525329|Active Comparator|Actinic Keratoses|Patients with at least 4 actinic keratoses on the face, ears, scalp, forearms and/or dorsal hands. Patients will serve as their own control, and one side of the body will be randomized to either 5-FU plus PDT, and the other will receive PDT alone.
89407889|NCT02121366|Experimental|Insulinoma|Patients with Insulinomas will received EUS-guided ethanol ablation therapy
89407890|NCT03914014|Active Comparator|intervention|connective tissue manipulation
89407891|NCT03914014|Placebo Comparator|placebo ultrasound|placebo ultrasound
89407892|NCT03914014|No Intervention|control|control group
89191266|NCT00858520||Smoking controls|Smokers without lung cancer and without COPD
89407893|NCT04382313|Placebo Comparator|the adequate hydration group guided by Vigileo|The hydration speed is adjusted according to SVV or SV by Vigileo
89407894|NCT04382313|No Intervention|the control group|The routine hydration regimen is adopted, perioperative saline ≤500 ml hydration
89407895|NCT03133754|Experimental|DP-PEEP|recruitment maneuver + individualized PEEP
89407896|NCT03133754|Active Comparator|RM-5|recruitment maneuver + fixed standard PEEP
89407897|NCT02121444||Cohort 1|Multiple Sclerosis patients who are treated with Betaferon and who are using the Betaconnect auto-injector
89407898|NCT04413526||radiofrequency-assisted liver resection|radiofrequency-assisted liver resection for intractable liver cancer
89407899|NCT04413526||TACE(transcatheter arterial chemoembolization)|temporary TACE for intractable liver cancer
89407900|NCT04413526||radiofrequency ablation plus TACE|radiofrequency ablation plus TACE for intractable liver cancer
89407901|NCT00271544|Experimental|4196 Lead|Non-randomized study.
89407902|NCT04383028|Experimental|MELD-assisted SEEG trajectory planning|Following routine clinical planning, the MELD algorithm will be run on the enrolled patient's scans. Up to 3 extra electrodes may be used to target lesion clusters identified by the algorithm such that the investigators will record from the top 3 clusters, with the aim of improving the rate of identification of a focal seizure onset zone in patients undergoing SEEG.
89407903|NCT02124486|Active Comparator|Dietetic Intervention|Participants randomised to the dietetic arm will be given vouchers at baseline, 3, 6 and 9 months that exempt them from paying for consecutive and specified weeks of their local Weight Watchers diet programme.
89191267|NCT00858520||COPD patients|Smokers with COPD but without lung cancer
89191268|NCT00858520||Lung cancer patients|smokers - never smokers with lung cancer
89407904|NCT02124486|Experimental|Bariatric surgery|Patients randomised to the bariatric surgery arm will be referred to the bariatric surgery pathway and, if judged suitable according to the bariatric surgery clinic's screening processes, undergo bariatric surgery.
89407905|NCT02124486|No Intervention|Matched obese control group|To evaluate the baseline difference in ICP between IIH patients and a matched obese control cohort we will recruit 20 obese but otherwise healthy participants who will undergo the same baseline visit as the main trial participants and then exit the study.
89407906|NCT02124486|No Intervention|MRI Test run|5 patients will undergo double baseline MR scans to validate the novel MR sequences being used in the main trial.
89407907|NCT02118168||No treatment|"All patients that participated to the therapeutic phase II trial of the Tat vaccine ISS T-002 and that received at least 3 immunizations and reached 48-weeks of follow-up."
89407908|NCT03868540|Experimental|BI 1291583|
89407909|NCT03868540|Placebo Comparator|Placebo|
89407910|NCT03318874|Experimental|Blephasteam|Heat delivery device, to be used according to guidelines from manufacturer.
89407911|NCT03318874|Active Comparator|THERA°PEARL Eye Mask|Heat delivery device, to be used according to guidelines from manufacturer.
89407912|NCT03551652||Young patients|Patients aged 18 - 50 years
89407913|NCT03551652||Geriatric patients|Patients aged ≥ 80 years
89407914|NCT05724524||Profile 2|People living with HIV with immune activation profile 2: inflammatory profile - high level of sTNFRI
89407915|NCT05724524||Other profiles|People living with HIV with immune activation profiles1 + 3-5: T8, NK, T4 and monocyte profiles
89407916|NCT03615976|Active Comparator|group A|group A with patellofemoral pain resistant to medical and physiotherapy assessment by pre operative knee score HIGH TIBIAL osteotomy will be done for all patients with arthroscopic patellar denervation will be done
89407917|NCT03615976|Active Comparator|GROUP B|operative group B with patellofemoral pain resistant to medical and physiotherapy assessment by pre operative knee score HIGH TIBIAL osteotomy will be done without arthroscopic patellar denervation
89407918|NCT02118246|Experimental|Dry Needling|The taut band of trigger point in vastus lateralis muscle; localized between the thumb and index finger, was needled forward and backward repeatedly until there were no more local twitch response
89407919|NCT02118246|Experimental|Kinesio Tape|Y technique with 25% tension on the tails was applied. Direction of the technique was insertion to origin of the muscle and zone of the trigger point was placed at the center of Y strip.
89407920|NCT00263042|Experimental|Rimonabant|Rimonabant 20 mg once daily
89004606|NCT02664181|Experimental|Oral THU/decitabine + Nivolumab|Oral THU ~10 mg/kg, followed by oral decitabine ~0.2 mg/kg 60 minutes after the THU, twice weekly on consecutive days. This drug combination is administered with Nivolumab 3mg/kg IV Q2 weeks until progression
89407921|NCT00263042|Placebo Comparator|Placebo|Placebo (for Rimonabant) once daily.
89407922|NCT05055934|Experimental|SHR-1314 injection|
89407923|NCT05055934|Placebo Comparator|placebo|
89407924|NCT02251782||Epi proColon Group|Subjects assigned to the Epi proColon Group will be offered the Epi proColon test for colorectal cancer screening.
89407925|NCT02251782||FIT Group|Subjects in the FIT Group will be offered a fecal immunochemical test (FIT test) for colorectal cancer screening.
89407926|NCT02251782||Usual Care Group|For the purpose of comparison to usual care, participating health systems will build an anonymized group of patients meeting study eligibility criteria, who do not participate in the study. This group will serve as a passive control and their CRC screening activity will be monitored via Medical Record.
89407927|NCT03218410|Active Comparator|surgical pulmonary embolectomy|
89407928|NCT03218410|Active Comparator|catheter-directed thrombolysis|
89407929|NCT03528590|Active Comparator|size 3 i-gel®|size 3 i-gel supraglottic airway device in anesthetized, paralyzed female patients weighing 50 to 60 kilograms who undergo breast surgery.
89407930|NCT03528590|Experimental|size 4 i-gel®|size 4 i-gel supraglottic airway device in anesthetized, paralyzed female patients weighing 50 to 60 kilograms who undergo breast surgery.
89407931|NCT03552744|Experimental|Intervention group|
89407932|NCT03552744|No Intervention|Control group|
88883236|NCT04649177|Other|study group|There is only one study group in this study. All subjects will receive the OCT scanning and PROSE lens fitting.
88883237|NCT04620824||Trial Participants|"Overall Description of Trial Participants: The spleen organ samples included in this project will be from patients undergoing elective surgery for a lesion in the pancreas in the HPB Unit of the Leicester General Hospital. No change in the surgical procedure or recruiting results from this study and the use of the samples.~Inclusion Criteria: The samples included in this project will be from patients undergoing elective surgery in the HPB Unit of the Leicester General Hospital. The criteria for inclusion of spleen samples from radical surgery are adult age and presence of splenic tissue in the discarded material after hepato-pancreato-biliary surgery.~Exclusion Criteria: The main exclusion criterion is acute invasive bacterial and viral infection, but these patients are automatically excluded from major surgery. Vulnerable groups will not be recruited."
89004607|NCT02664181|Active Comparator|Nivolumab|Nivolumab 3mg/kg IV Q2 weeks until progression; This is the standard of care for patients with NSCLC who have progressed on prior chemotherapy.
89407933|NCT05002192||ELP_ONLY|Patients who were diagnosed with community-acquired pneumonia and were treated with Eucalyptol, Limonene and Pinene Enteric Soft Capsules, not treated with other oral mucolytics.
89407934|NCT05002192||EXP_ONLY|Patients diagnosed with community-acquired pneumonia and treated with an oral mucolytic drug other than Eucalyptol, Limonene and Pinene Enteric Soft Capsules.
89407935|NCT05002192||ELP+AMB|Patients diagnosed with community-acquired pneumonia and treated with Eucalyptol, Limonene and Pinene Enteric Soft Capsules and ambroxol injection.
89407936|NCT05002192||EXP+AMB|Patients diagnosed with community-acquired pneumonia and treated with oral mucolytics and ambroxol injection other than Eucalyptol, Limonene and Pinene Enteric Soft Capsules.
89407937|NCT05002192||AMB_ONLY|Patients diagnosed with community-acquired pneumonia and treated with ambroxol injection alone.
89407938|NCT03528434|Experimental|Zinc|Dietary Supplement: Zinc 10mg dispersible zinc sulfate tablet
89407939|NCT03528434|Placebo Comparator|Placebo|Dispersible tablet with inert ingredients, identical to zinc in appearance
89407940|NCT02121600|Other|Docetaxel|Patients who will be receiving Docetaxel as cancer treatment will be assigned to Arm 1. All patients in this cohort will have a [F-18]-FCH PET scan with full body MRI scan
89407941|NCT02121600|Other|Abiraterone|Patients who will be receiving Abiraterone as cancer treatment will be assigned to Arm 2. All patients in this cohort will have a [F-18]-FCH PET scan with full body MRI scan.
89531032|NCT02498639|Active Comparator|BAV with pacing|Patients undergo percutaneous balloon aortic valvuloplasty (BAV) after previous insertion of a temporary pacemaker lead in the right ventricle. Stabilization of the balloon during inflation is done under rapid pacing.
89407942|NCT02288468|Experimental|STN|"Deep Brain Stimulation of Nucleus subthalamicus with Vercise™ Deep Brain Stimulation System.~The STN will be typically reached with the most distal contacts of the DBS electrode (8 contact). Imaging studies (postop helical CT and re-fusion to planning MRI data) will allow for the identification of contacts located in the STN. We expect the STN to be typically covered by contacts 1-4 of the Vercise™ DBS lead. Typically, only the most superficial contacts (3,4) will be activated after a monopolar review of each contact. In this monopolar review the therapeutic widths of each contact will be tested for its effectiveness in tremor reduction, reduction of rigidity and bradykinesia. Typical settings will be: Frequency 130-180 Hz, pulse width 60-90 us, Amplitude 1-7 mA."
89407943|NCT02288468|Experimental|Vim/DRT|"Deep Brain Stimulation of Ventral intermediate nucleus with Vercise™ Deep Brain Stimulation System.~The thalamic target (Vim/DRT) will be typically reached with the proximal contacts. Imaging studies (postop helical CT and re-fusion to planning MRI data) will allow for the identification of contacts located the thalamic target. We expect the thalamic target to be typically covered by contacts 5-8 of the Vercise™ DBS lead. We will perform a monopolar review of each contact. In this monopolar review the therapeutic widths of each contact will be tested for its effectiveness in tremor reduction and the occurrence of side effects (typically capsular e.g. facial contraction). Typical settings will be: Frequency 130-180 Hz, pulse width 60-90 us, Amplitude 1-7 mA."
89407944|NCT02288468|Experimental|STN+Vim/DRT|"Combined Deep Brain Stimulation of Nucleus subthalamicus and Ventral intermediate nucleus with Vercise™ Deep Brain Stimulation System.~STN+Vim/DRT stimulation is essentially a combination of the previously described procedure."
89407945|NCT02121678|Experimental|Run-in - Aerobic - Resistance|"Week -12 to 0: Run-in period with no training~Week 0 to 12: Aerobic training on ergometer bicycle~Week 12 to 24: Resistance training with dumbbells"
89407946|NCT02121678|Experimental|Run-in - Resistance - Aerobic|"Week -12 to 0: Run-in period with no training~Week 0 to 12: Resistance training with dumbbells~Week 12 to 24: Aerobic training on ergometer bicycle"
89407947|NCT04973020|Experimental|Treatment group|
89407948|NCT02118324|Experimental|Exercise treatment|Participants will be instructed to use the exergaming program at home for 30 mins, 3-5 times per week.
89407949|NCT02118324|No Intervention|Control group|No intervention is provided.
89407950|NCT05724446|Experimental|Clobetasol propionate|One drop of Clobetasol propionate ophthalmic nanoemulsion, 0.05% will be administered of the study eye QID beginning the day after surgery (Day 1) for 14 days followed by a tapering period of 14 days.
89407951|NCT05724446|Active Comparator|Prednisolone acetate|One drop of Prednisolone ophthalmic suspension, 1% will be administered of the study eye QID beginning the day after surgery (Day 1) for 14 days followed by a tapering period of 14 days.
88883238|NCT04594278|Experimental|Mindfulness Based Intervention|A remotely delivered closed group mindfulness-based intervention using Microsoft Teams Meeting will be performed, consisting of 12-16 participants (Maximum 10 groups) and one professional with a background in mindfulness coaching . Three professionals will be coaching 2-3 groups each. The curriculum entails weekly sessions (1 hour) over a 4-week period.
88883239|NCT04585542|Experimental|Polyethylene glycol 3350 (MiraLax)|"Participants will be randomized to one of four study arms. They will receive one dose of the study drug.~One study arm is the nonspecific laxative MiraLax (one dose of 17g). Since constipation can contribute to hyperkalemia, this arm will study the effect of treating constipation instead of direct cation exchange for potassium in the gut."
88883240|NCT04585542|Experimental|Sodium polystyrene sulfonate (Kayexalate)|"Participants will be randomized to one of four study arms. They will receive one dose of the study drug.~The potassium binder drugs of interest include sodium polystyrene sulfonate (one dose of 30g), patiromer (one dose of 25.2g), and sodium zirconium cyclosilicate (one dose of 15g)."
88883241|NCT04585542|Experimental|Patiromer (Veltassa)|"Participants will be randomized to one of four study arms. They will receive one dose of the study drug.~The potassium binder drugs of interest include sodium polystyrene sulfonate (one dose of 30g), patiromer (one dose of 25.2g), and sodium zirconium cyclosilicate (one dose of 15g)."
88922015|NCT05972174|Experimental|Part A Group 2 Vaccine: mRNA-1018 for H7 Only Dose Level 1|Participants will receive mRNA-1018 for H7 only at dose level 1 by IM injection on Day 1 and Day 22.
89407952|NCT03177772||LTC Facility 1|Pre-loss Grief Support Group offered in long-term care facility for dementia family caregivers anticipating the death of their care recipient within next 6 month. Two hour sessions for 10 weeks include psychoeducation, motivational interviewing, cognitive behavioral and exposure approaches. Supportive others, selected by participants are included in two sessions.
89407953|NCT03177772||LTC Facility 2|Pre-loss Grief Support Group offered in long-term care facility for dementia family caregivers anticipating the death of their care recipient within next 6 month. Two hour sessions for 10 weeks include psychoeducation, motivational interviewing, cognitive behavioral and exposure approaches. Supportive others, selected by participants are included in two sessions.
89407954|NCT03177772||LTC Facility 3|Pre-loss Grief Support Group offered in long-term care facility for dementia family caregivers anticipating the death of their care recipient within next 6 month. Two hour sessions for 10 weeks include psychoeducation, motivational interviewing, cognitive behavioral and exposure approaches. Supportive others, selected by participants are included in two sessions.
89407955|NCT02124642|Active Comparator|Folic acid, 400 mcg/day|A daily 400 microgram (mcg) dose of folic acid will be taken orally, along with the recommended intake for pregnancy of other vitamins, minerals and docosahexaenoic acid (DHA), beginning at enrollment until delivery. The 400 mcg dose approximates the current Recommended Dietary Allowance (RDA) for pregnant women of 600 mcg Dietary Folate Equivalents (400 mcg folic acid ≈ 600 mcg DFEs; conversion factor based on higher bioavailability of folic acid is: 1 mcg folic acid = 1.7 mcg DFE).
89531033|NCT02494739|Experimental|Yogurt enriched with polyphenols|Two yogurts (400g) enriched with polyphenols (10mg/100g yogurt) per day, for two weeks.
89407956|NCT02124642|Experimental|Folic acid, 800 mcg/day|A daily 800 microgram (mcg) dose of folic acid will be taken orally, along with the recommended intake for pregnancy of other vitamins, minerals and docosahexaenoic acid (DHA), beginning at enrollment until delivery. The 800 microgram dose, which is considerably higher than the current RDA, represents an amount commonly found in over-the-counter prenatal vitamin formulations.
89407957|NCT00262106|Placebo Comparator|Placebo|placebo
89407958|NCT00262106|Active Comparator|PRO 2000/5 Gel 0.5%|PRO 2000/5 Gel 0.5%
89407959|NCT03094234|Active Comparator|8mm-TIPS|Patients in this group would underwent TIPS placement with 8mm-diameter ePTFE-covered stents.
89407960|NCT03094234|Active Comparator|EVL plus propranolol|Patients in this group would underwent sequential endoscopic variceal ligation and propranolol treatment.
89407961|NCT02118402|Active Comparator|Fortified maize porridge (MNP)|The MNP contains 400 µg Vitamin A, 5 µg Vitamin D, 5 mg Tocopherol Equivalent, 0.5 mg Thiamine, 0.5 mg Riboflavin, 0.5 mg Vitamin B6 , 90 µg Folic Acid, 6 mg Niacin, 0.9 µg Vitamin B12, 30 mg Vitamin C, 0.56 mg Copper, 90 µg Iodine, 17 µg Selenium, 4.1 mg Zinc, 190 Phytase-units, maltodextrin carrier (added up to 11g)
89407962|NCT02118402|Active Comparator|Fortified maize porridge (MNP+Fe)|The MNP contains 400 µg Vitamin A, 5 µg Vitamin D, 5 mg Tocopherol Equivalent, 0.5 mg Thiamine, 0.5 mg Riboflavin, 0.5 mg Vitamin B6 , 90 µg Folic Acid, 6 mg Niacin, 0.9 µg Vitamin B12, 30 mg Vitamin C, 0.56 mg Copper, 90 µg Iodine, 17 µg Selenium, 4.1 mg Zinc, 190 Phytase-units, plus 2.5 mg Fe as ferrous fumarate and 2.5 mg Fe as NaFeEDTA, maltodextrin carrier (added up to 11g)
89407963|NCT02118402|Active Comparator|Fortified maize porridge (MNP+Fe+GOS)|The MNP contains 400 µg Vitamin A, 5 µg Vitamin D, 5 mg Tocopherol Equivalent, 0.5 mg Thiamine, 0.5 mg Riboflavin, 0.5 mg Vitamin B6 , 90 µg Folic Acid, 6 mg Niacin, 0.9 µg Vitamin B12, 30 mg Vitamin C, 0.56 mg Copper, 90 µg Iodine, 17 µg Selenium, 4.1 mg Zinc, 190 Phytase-units, 2.5 mg Fe as ferrous fumarate and 2.5 mg Fe as NaFeEDTA plus 7.5 g of galactooligosaccharides given as 10.5 g GOS-75, maltodextrin carrier (added up to 11g)
89407964|NCT00260156|Experimental|vildagliptin|
89407965|NCT00260156|Placebo Comparator|Placebo|
89407966|NCT04367103|Active Comparator|NEP group|Norepinephrine infusion of 0.025 µg/kg/min and 6 µg bolus will be used if BP is reduced 20 % below baseline.
89407967|NCT04367103|Placebo Comparator|PHE group|Phenylephrine will be started at 25µg/min immediately after the intrathecal local anaesthetic injection and titrated according to blood pressure and pulse rate.
89407968|NCT01950130|Experimental|IABP group|Preoperative IABP insertion
89407969|NCT01950130|No Intervention|Control group|Preoperative conservative treatment
89407970|NCT02118480|Experimental|cognitive remediation program: REHACOP|Cognitive rehabilitation program (REHACOP) including intervention in: attention, memory, processing speed, language, executive functioning and social cognition during 3 months, 3 times per week
89407971|NCT02118480|Active Comparator|Occupational Therapy|The activities included drawing, reading the daily news and constructing using different materials (such as paper or wood) during 3 months, 3 times per week.
89407972|NCT00260078|Experimental|D|TDF and EFV or NVP throughout study
89191269|NCT05373524|Active Comparator|the rheopheresis group|Rheopheresis is performed using an automated monitor in a double-filtration cascade. Plasma purify from of high molecular weight proteins through a secondary filter is then returned to the patient. This technique is performed in tandem with a hemodialysis monitor.
89407973|NCT00260078|Experimental|E|TDF and DRV with or without EFV throughout study
89191270|NCT05373524|Placebo Comparator|the shamapheresis group|Shamapheresis is performed with the same automated monitor (Plasauto, HemaT company). Extracted plasma is not treated through the secondary filter (Rheofilter) and return to the patient. This technique is performed in tandem with a hemodialysis monitor.
89191271|NCT00849550|Experimental|XELOX-A-Ev|
89407974|NCT00260078|Experimental|F|TDF and ATV and RTV with or without EFV throughout study
89407975|NCT03034564|Active Comparator|1|Active group started 100 mg TID, increased by 100 mg per interval (i.e. 100 TID) every 2 days till on 600 TID, or until intolerable dose is achieved at which time the next highest dose will be maintained (increments of 100 TID will be used).
89407976|NCT03034564|Placebo Comparator|2|Dosing regimen identical to active group
89407977|NCT03651921|No Intervention|Usual care|Usual follow-up care offered in the breast centers after primary treatment by breast care team (e. g. breast care nurses, gynaecologist, oncologist, psychologist).
89407978|NCT03651921|Experimental|Usual care and CTS-BC-CH|CTS-BC-CH as 7 weekly group session à 2.5 - 3 hours.
89407979|NCT05342532|Active Comparator|High Dose Dual Therapy|This regimen includes a 14-day course of amoxicillin 1 g three times daily and omeprazole 40 mg three times daily.
89407980|NCT05342532|Active Comparator|Standard triple therapy|This regimen includes a 14-day course of clarithromycin 500 mg twice daily, omeprazole 40 mg twice daily, and amoxicillin 1g twice daily.
89407981|NCT03651843||Healthy subjects|
89407982|NCT04469114|Experimental|Tofacitinib|Tofacitinib 10mg twice daily for 14 days or until hospital discharge
89407983|NCT04469114|Placebo Comparator|Placebo|Placebo twice daily for 14 days or until hospital discharge
89407984|NCT02118558|Experimental|Negative Pressure Wound Therapy (NPWT)|
89407985|NCT02118558|Active Comparator|standard prophylactic therapy|
89407986|NCT02400567|Active Comparator|Chemotherapy|3 cycles of FEC 100 followed by 3 cycles of Docetaxel Drugs: Fluorouracile, Epirubicine, Cyclophosphamide, Docetaxel
89407987|NCT02400567|Experimental|Letrozole Palbociclib|Drugs: letrozole + palbociclib combination
89407988|NCT02124720|Experimental|Mobile application|Use of the iSTIM mobile application 2 to 4 times per week over approximately 8 to 16 weeks
89407989|NCT02288546||Vegans|Vegans' data are compared with those of sex-and age-matched non vegetarians
89407990|NCT02288546||Non-vegans|Non-vegans are age and sex-matched controls
89407991|NCT02118636||Aromatase inhibitor therapy|Subjects who are starting treatment with any of the three aromatase inhibitor (AI) medications
89407992|NCT05724368||Group 1|Patients with gastrointestinal symptoms and positive only for Blastocystis.
89407993|NCT05724368||Group 2|Patients with gastrointestinal symptoms and Blastocystis free.
89407994|NCT05724368||Group 3|Healthy volunteers with neither gastrointestinal symptoms nor parasitological infections.
89407995|NCT02868112|Experimental|Transdisciplinary Intervention|"Patients randomized to the Transdisciplinary Intervention will undergo evaluation with a board-certified geriatric clinician, who will tailor their care based on the results of a brief geriatric screening tool.~-Investigators will test a two-visit Transdisciplinary Intervention with the first visit occurring within four weeks of enrollment and the second visit four weeks after the initial visit."
88922016|NCT05972174|Experimental|Part A Group 2 Vaccine: mRNA-1018 for H7 Only Dose Level 2|Participants will receive mRNA-1018 for H7 only at dose level 2 by IM injection on Day 1 and Day 22.
89191272|NCT04018976|Experimental|Heat and Vacuum|AVACEN 100 applies heat and vacuum to hand
88813653|NCT04935840|Placebo Comparator|Control|Participants received 400 mcg of folic acid once a day
88813654|NCT03834662|Experimental|Dose Level 1: 180 mg/m2 of AVID200|Intravenous infusion of AVID200 over 1 hour administered every three weeks. Starting dose for dose escalation.
88813655|NCT03834662|Experimental|Dose Level 2: 550 mg/m2 of AVID200|Intravenous infusion of AVID200 over 1 hour administered every three weeks.
88813656|NCT03834662|Experimental|Dose Level 3: 1100 mg/m2|Intravenous infusion of AVID200 over 1.5 hours administered every three weeks.
88813657|NCT03007121|Experimental|Morphine intrathecal|An intrathecal administration of preservative-free morphine 0.3 mg in 3 ml NS prepared in a sterile ampoules by a hospital pharmacy will be performed before induction of anaesthesia in a sitting position between L2 and L3 - L4/L5 vertebrae. Standard general anaesthesia will be performed. After surgery, the patients will have the possibility to use PCA device with morphine, bolus dose 1 mg, lock-out interval 5 min for 3 days at a surgical ICU.
89407996|NCT02868112|Active Comparator|Usual Care|Participants receiving Usual Oncology Care will not meet routinely with geriatric clinicians, though they may receive a geriatrics consult at their request or at the discretion of their treating team.
89407997|NCT03551574||Macular involving retinal detachment|Patients with retinal detachments that have developed PVR when the macula has been involved
89407998|NCT03531242|Experimental|Cohort A: Initial Non-responders to VEE TC-83 vaccinations|Venezuelan Equine Encephalomyelitis (VEE) Vaccine, Inactivated, Dried, C-84, TSI-GSD 205, Lot 7, Run 1, to be administered as dose(s) of 0.5 mL given subcutaneously in the upper outer aspect of the triceps area.
89531034|NCT02494739|Placebo Comparator|Yogurt not enriched with polyphenols|Two yogurts (400g) not enriched with polyphenols per day, for two weeks.
89531035|NCT02494661|Experimental|Healthy Cart and Stress Mangement Videos|Healthy Cart and Stress Management Videos: Participants receive two nutritional intervention videos: active comparator and managing stress while food shopping.
89407999|NCT03531242|Experimental|Cohort B: Responders to TC-83 or previous C-84 vaccinations|"Subjects who showed an initial immune response ≥ 1:20 to TC-83 and whose titer decreased over time or who rollover from a previous VEE C-84 protocol will receive a single 0.5 mL booster dose of C-84 vaccine.~Subjects who were initial non-responders (< 1:20) to TC-83 will be given subcutaneous 0.5 mL injections on Days 0, 28-35, and 56-63"
88883242|NCT04585542|Experimental|Sodium zirconium cyclosilicate (Lokelma)|"Participants will be randomized to one of four study arms. They will receive one dose of the study drug.~The potassium binder drugs of interest include sodium polystyrene sulfonate (one dose of 30g), patiromer (one dose of 25.2g), and sodium zirconium cyclosilicate (one dose of 15g)."
89408000|NCT04937920|Active Comparator|DBI-002 probiotic gel|Topical application of DBI-002 probiotic gel on skin affected with tinea versicolor
89408001|NCT04937920|Placebo Comparator|Aqueous gel|Topical application of aqueous gel on skin affected with tinea versicolor
89408002|NCT04936360||Patient Group|Patients with non-progressive non-neurodegenerative acquired brain damage, who were over 18 years of age, who could establish voluntary social communication will be included in the study.
89408003|NCT04936360||Caregivers Group|Caregivers over the age of 18, who took care of the patient for at least 1 month, and who did not have premorbid medical or psychological problems will be included in the study.
89408004|NCT04468646|Placebo Comparator|Placebo|matching placebo drug
89408005|NCT04468646|Experimental|NK-1R antagonist group|80 mg daily
89408006|NCT00962884|Experimental|ITD breathing device|Breathing through the Res-Q-Gard ITD device from Advanced Circulatory Systems Inc.
89191273|NCT04018976|Active Comparator|Heat Only|AVACEN 100 applies heat only
89191274|NCT04018976|Sham Comparator|Sham|AVACEN 100 applies neither heat nor vacuum
89408007|NCT00962884|Sham Comparator|Sham Device|Breathing device similar to active Res-Q-Gard device but with one-way resistance valve removed.
89408008|NCT02802124|Experimental|carbon-ion radiotherapy for tumor away from GI|For tumor location which is away from gastrointestine (the distance is more than 1 cm). We use carbon-ion radiotherapy for the treatment of hepatocellular carcinoma. Four dose levels [55 Gray equivalent (GyE)/10 fractions (Fx), 60GyE/10Fx, 65GyE/10Fx, 70GyE/10Fx] are planned within the Phase I part.
88883243|NCT04585334|Experimental|Arm A Tricortin|Tricortin 1000 by intramuscular route
89408009|NCT02802124|Experimental|carbon-ion radiotherapy for tumor adjacent to GI|"For tumor location which is adjacent to gastrointestine (less than 1 cm).We use carbon-ion radiotherapy for the treatment of hepatocellular carcinoma.~Three dose levels (carbon 60GyE/15Fx, carbon 67.5GyE/15Fx, carbon 75GyE/15Fx) are planned within the Phase I part."
89408010|NCT00228176|Experimental|Rimonabant|Rimonabant 20 mg once daily
89408011|NCT00228176|Placebo Comparator|Placebo|Placebo (for Rimonabant) once daily.
89408012|NCT02984943|Experimental|Hyperbaric Oxygen|Hyperbaric Oxygen
89408013|NCT03528356|Placebo Comparator|Regular diet|
89408014|NCT03528356|Experimental|White diet|
89408015|NCT05131984||Multiple Sclerosis patients on Ocrelizumab at Brigham and Women's Hospital|All MS patients at the Brigham MS Center who have been diagnosed with relapsing remitting multiple sclerosis (RRMS) or primary progressive multiple sclerosis (PPMS), ages 18 or older, on Ocrelizumab for at least one year and have received at least 3 treatments (two loading treatments of 300mg each, and one full dose treatment of 600 mg), who have been followed at these institutions for clinical care and brain and/or spinal cord MRI, and who have received Ocrelizumab infusions at these institutions for the duration of the study period.
89408016|NCT05131984||Multiple Sclerosis patients on Ocrelizumab at Boston Medical Center|All MS patients at the Boston Medical Center MS Clinic who have been diagnosed with RRMS or PPMS, ages 18 or older, on Ocrelizumab for at least one year and have received at least 3 treatments (two loading treatments of 300mg each, and one full dose treatment of 600 mg), who have been followed at these institutions for clinical care and brain and/or spinal cord MRI, and who have received Ocrelizumab infusions at these institutions for the duration of the study period.
89408017|NCT05724290|Experimental|immunohistochemistry|Thirty-eight patients with confirmed nasal polyps (20 with primary CRSwNP and allergic rhinitis (AR) and 18 with CRSWNP) and 20 patients with chronic hypertrophic rhinitis were included. The nasal polyps and mucosal specimens of all patients were collected and analyzed by immunohistochemistry
89408018|NCT05724290|Experimental|WestBlot|Thirty-eight patients with confirmed nasal polyps (20 with primary CRSwNP and allergic rhinitis (AR) and 18 with CRSWNP) and 20 patients with chronic hypertrophic rhinitis were included. The nasal polyps and mucosal specimens of all patients were collected and analyzed by Western Blot.
89408019|NCT04874662|Active Comparator|Investigational NAM/B6|"2 VCaps® capsules daily (commercial vegetarian capsules made of Hydroxy Propyl Methyl Cellulose, a polymer of cellulose)~Dosage per capsule: 357mg of nicotinamide, 9.5mg of pyridoxine and 195mg of microcrystalline cellulose~Form:The VCaps® Size 00 will be used. They have a volume of 0.95 ml for 23.3 mm length and a diameter of 8.51 mm head / 8.16 mm body.daily of NAM/B6~Frequency and duration: 2 capsules daily for 9 days"
89408020|NCT04874662|Placebo Comparator|Placebo control group|"2 capsules daily of microcrystalline cellulose excipient (337mg per capsule)~Frequency and duration: 2 capsules daily for 9 days"
88883244|NCT04585334|Active Comparator|Arm B Itami|Itami Diclofenac sodium medicated plaster by topical application
88883245|NCT04585334|Placebo Comparator|Arm C Placebo|Placebo
89191275|NCT00858598||Pro Osteon|All patients in this pilot study will receive pro osteon as a bone void filler and will be enrolled according to the same inclusion / exclusion criteria.
88883246|NCT04573309|Experimental|ALXN1840|Participants will be administered ALXN1840 at a dose of 15 milligrams (mg)/day on Day 1 through Day 28 and then increased to 30 mg/day on Day 29 through Day 39
88883247|NCT04554693|Experimental|Metronidazole|Metronidazole
88883248|NCT04554693|Placebo Comparator|Placebo|Halal and Kosher certified gelatin placebo capsules
89408021|NCT03133442|No Intervention|Baseline Nights|No vestibular stimulation is applied. However, the sound of the moving bed will be played back to the participant at the right sound intensity level.
89408022|NCT03133442|Experimental|Movement Nights|Vestibular stimulation, in the form of gentle rocking movements, is provided using the Somnomat V4 rocking bed. Stimulation is provided for the entire 7 hours of the night from lights off to lights on. The stimulation frequency is in the range of 0.1-0.3 Hz, with an amplitude in the range of 0.05 to 0.1m
89408023|NCT01308190|Active Comparator|Chemoradiotherapy+TEM|Preoperative chemotherapy: capecitabine 825 mg/m2 every 12 hours orally, plus Radiotherapy (50.4 Gy). After 6-8 weeks, transanal endoscopic microsurgery (TEM)is done
89408024|NCT01308190|Other|Total Mesorectal Excision|Standard surgical treatment of T2 , T3s, N0, M0 rectal cancer
89408025|NCT02787408|Experimental|EW Tricuspid Transcatheter Repair System|Edwards (EW) Tricuspid Transcatheter Repair System
89408026|NCT00226772|Experimental|OMS103HP irrigation solution|Drug
89408027|NCT00226772|Placebo Comparator|vehicle irrigation solution|Vehicle
89408028|NCT01210768|Active Comparator|EC|Cyclophosphamide,600 mg/m2 q3wk and Epirubicin,90 mg/m2 q3wk
89408029|NCT01210768|Experimental|LC|liposomal doxorubicin, 37.5 mg/m2 q3wk, and Cyclophosphamide,600 mg/m2 q3wk
89408030|NCT02971605|Experimental|Psilocybin|Participants will be administered a 25 mg/70 kg dose of psilocybin
89408031|NCT02288624|Placebo Comparator|Control|Water control (240 ml)
89408032|NCT02288624|Experimental|Orange Juice|Orange juice, 240 ml. Commercial orange juice
89408033|NCT02288624|Experimental|Whole orange|Whole orange, 240 ml. Whole orange, blended to include all edible orange material.
89408034|NCT02288624|Experimental|processed orange juice|Processed orange juice, 240 ml. Experimental orange juice processing
89408035|NCT02251860||Participants with Rheumatoid Arthritis|Participants with active rheumatoid arthritis who are prescribed tocilizumab treatment according to the marketing authorization by their physician will be followed under routine conditions over an observation period of up to 2 years if baseline and disease characteristics data are available.
89408036|NCT03651999||dream workshop|After consultation with the pediatric surgeon or the anesthesiologist, parents and children are invited to meet the nurse anesthetist, in a room dedicated to this purpose and specially designed to accommodate children; they will find a playmobil model, photographs of the patient circuit as well as different games or activities that can be performed during induction; The nurse anesthetist explains the hospitalization process and will help them to choose a pleasant dream, a perfume adapted to their taste, a distraction adapted to their age (animated book, soap bubbles, favorite song ...); the child will be able to customize his mask and choose the blanket he wants to take along; the most recalcitrant or special sites (autism, long-term hospitalization) will be able to be accompanied by a parent during sleep
89408037|NCT03651999||control|"No dream workshop"
88883249|NCT04511845|Experimental|Dose escalation cohort of SPYK04|Patients will receive SPYK04 at escalated dose.
89408038|NCT03054337|Experimental|Vadadustat, Dose 1|Daily oral dose
88883250|NCT04511845|Experimental|Expansion part in NSCLC, ovarian cancer and other solid tumors|Patients will receive SPYK04 at the recommended dose.
88883251|NCT04507568|Experimental|Person-Centered Model-of-Care|Patients randomized to the person-centered model-of-care will have a 30 minute education session with a radiation therapist in addition to the standard of care, radiation therapy procedures.
89408039|NCT03054337|Experimental|Vadadustat, Dose 2|Daily oral dose
89408040|NCT03054337|Experimental|Vadadustat, Dose 3|Daily oral dose
89408041|NCT03054337|Placebo Comparator|Placebo|Daily oral dose
89408042|NCT02288780||Control|BPH patients with normal diastolic function
89408043|NCT02288780||Diastolic dysfunction|BPH patients with preoperative diastolic dysfunction
89408044|NCT02124876||Transtibial amputees|
89408045|NCT05134324|Experimental|active rTMS|Participants recevied 1 Hz low frequency repetetive TMS during 20 minutes and a total of 1200 stimuli for 15 sessions. The patient received robotic therapy for upper extremity just after each active TMS sessions
88883252|NCT04507568|Other|Standard Model-of-Care|Patients randomized to the standard model of care will be treated as per standard of care.
88883253|NCT04488198|No Intervention|Control group|20 CIBD patients do not receive acupuncture or placebo-acupuncture.
88883254|NCT04488198|Active Comparator|Acupuncture group|20 CIBD patients receive 8 sessions of acupuncture therapy with 0,3 x 30mm needles (asia-med special number 16).
89408046|NCT05134324|Sham Comparator|sham rTMS|Participants recevied sham TMS during 20 minutes and a total of 1200 sham stimuli for 15 sessions with sham coil. The patient received robotic therapy for upper extremity just after each sham TMS sessions
88883255|NCT04488198|Placebo Comparator|Placebo group|20 CIBD patients receive 8 sessions of sham acupuncture with placebo-needles 0,3 x 30mm (Streitberger).
88883256|NCT04475523|Experimental|CI-8993 dose escalation|Patients will be administered CI-8993 intravenously at a planned infusion rate over 2 hours at planned step-doses and subsequent full doses. The planned schedule of administration is every 2 weeks. The MTD of full doses of CI-8993 will be determined based on the occurrence of DLTs 28 days from the first full dose. Eligible patients may receive CI-8993 at the dose and schedule, according to their assigned cohorts, until disease progression or unacceptable toxicity.
89408047|NCT05134324|Experimental|active tDCS|Participants recevied 2 mA anodal transcranial direct current stimulation 20 minutes for 15 sessions. The patient received robotic therapy for upper extremity just after each active tDCS sessions
89408048|NCT05134324|Sham Comparator|sham tDCS|Participants recevied sham stimulation. The patient received robotic therapy for upper extremity just after each sham tDCS sessions
89408049|NCT02124954|Experimental|Digoxin with/without TA-8995|Digoxin with/without TA-8995
89408050|NCT02124954|Experimental|Midazolam with/without TA-8995|Midazolam with/without TA-8995
89408051|NCT04440800||Study participants|All patients will receive the intervention
89408052|NCT04928794|Other|Peripheral Nerve Block with 2 Techniques|
89408053|NCT03768180||Patient with infective endocarditis|All patients diagnosed with infective endocarditis after TAVR
89408054|NCT04441112|Experimental|Ketorolac Intraarticular Hip Injection|Patients will receive an intraarticular hip injection with ketorolac.
89408055|NCT04441112|Active Comparator|Triamcinolone Intraarticular Hip Injection|Patients will receive an intraarticular hip injection with triamcinolone.
89408056|NCT04441112|Experimental|Ketorolac Intraarticular Knee Injection|Patients will receive an intraarticular knee injection with ketorolac.
89408057|NCT04441112|Active Comparator|Triamcinolone Intraarticular Knee Injection|Patients will receive an intraarticular knee injection with triamcinolone.
89408058|NCT05131906|Experimental|People with Parkinson's disease on medication who freeze|We will be testing each of the 15 participants both with and without the removeable lasers on their shoes.
89191276|NCT05373368|Experimental|home residents|multi purpose activities were performed for home residents
89191277|NCT05373368|Experimental|nursing home residents|multi purpose activities were performed for nursing home residents
89408059|NCT02125032|Active Comparator|Transcranial pulsed electromagnetic fields (T-PEMF)|One group receives 8 weeks of active T-PEMF treatment and another group receives 8 weeks of placebo T-PEMF. Both treatments to be performed 30 minutes once a day.
89408060|NCT02125032|Placebo Comparator|Trancranial electromagnetic pulsed fields (T-PEMF)|8 weeks of T-PEMF treatment placebo.
89408061|NCT04440878|Experimental|Static stretching|Static stretching will be administered to the hamstring muscles in the first group.
89408062|NCT04440878|Experimental|Mulligan TSLR technique|The Mulligan TSLR technique will be administered on the same muscle in the second group.
89408063|NCT05134168|Active Comparator|LIFT|Patients underwent LIFT proecdure
88883257|NCT04474925|Active Comparator|Surgical Resection followed by SRS (Non-Experimental)|Surgical Resection followed by SRS within 3 weeks of surgery date.
88883258|NCT04474925|Experimental|SRS followed by Surgical Resection (Experimental)|SRS followed by surgery within 1 week of radiotherapy end date.
89191278|NCT03816488|Experimental|Metformin|Self-administered metformin (patient's usual dose) taken 2 hours prior to surgery
89191279|NCT03816488|Experimental|Salsalate|Self-administered salsalate taken 2 hours prior to surgery
89408064|NCT05134168|Active Comparator|LIFT+bone marrow mononuclear cell injection|Patients underwent LIFT with bone marrow mononuclear cell injection
88883259|NCT04446312|Experimental|BLI4900|Experimental bowel preparation solution for oral ingestion
88883260|NCT04446312|Active Comparator|FDA Approved Control|FDA approved bowel preparation solution for oral ingestion
89191280|NCT03816488|No Intervention|Placebo|Self-administered placebo taken 2 hours prior to surgery
89191281|NCT00858676|Active Comparator|Acarbose|
89191282|NCT00720668||1|patient with hepatocellular carcinoma after radiofrequency ablation
89191283|NCT00858754|Experimental|Group 1 Active Drug|Methylnaltrexone
89408065|NCT04440956|Experimental|Intervention|"200MBq of 64Cu-MeCOSar-Octreotate (64Cu-SARTATE) given as a single bolus intravenous injection."
89408066|NCT02121990|Experimental|Cisplatin, Paclitaxel, bevacizumab & olaparib|All treatments will be given in the outpatient setting. A cycle is 21 days. The sequence of infusions on Day 1 will be IV paclitaxel (135 mg/m2), then IV bevacizumab (15 mg/kg, beginning Cycle 2). On Day 2 patients will receive IP cisplatin (75 mg/m2). Patients will be given twice-daily treatment with oral olaparib in cycles 1-6 for 7 consecutive days, starting on Day 2 (Days 2-8). IP paclitaxel (60 mg/m2) will be given on Day 8. Sequential cohorts of 3 patients will receive escalating doses of olaparib (50mg BID, 100mg BID, 200mg BID).
89408067|NCT05724056|Experimental|Idroflog®|Patients randomized in this group will be treated with Sodium Hyaluronate 2 mg/ml and Hydrocortisone 10 μg/ml.
89408068|NCT05724056|Active Comparator|Sodium Hyaluronate 0.18% (Vismed®)|Patients randomized in this group will be treated with Sodium Hyaluronate 0.18%.
89408069|NCT05131360|Placebo Comparator|Introduction Only|This is the control; participants only partake in one day's worth of the introduction or foundational mindfulness activities on the HMI app.
89408070|NCT05131360|Experimental|Purpose Only|Participants partake in the introduction or foundational mindfulness for one day and then perform purpose-based mindfulness techniques for 5 days on the HMI app.
89408071|NCT05131360|Experimental|Connection Only|Participants partake in the introduction or foundational mindfulness for one day and then perform connection-based mindfulness techniques for 5 days on the HMI app.
89408072|NCT05131360|Experimental|Connection and Purpose|Participants partake in the introduction or foundational mindfulness for one day and then perform connection and purpose-based mindfulness techniques for 5 days on the HMI app.
89408073|NCT05131360|Experimental|Awareness Only|Participants partake in the introduction or foundational mindfulness for one day and then perform awareness-based mindfulness techniques for 5 days on the HMI app.
89408074|NCT05131360|Experimental|Awareness and Purpose|Participants partake in the introduction or foundational mindfulness for one day and then perform awareness and connection-based mindfulness techniques for 5 days on the HMI app.
89408075|NCT05131360|Experimental|Awareness, Purpose, and Connection|Participants partake in the introduction or foundational mindfulness for one day and then perform connection, awareness, and purpose-based mindfulness techniques for 5 days on the HMI app.
89408076|NCT05131360|Experimental|Awareness and Connection|Participants partake in the introduction or foundational mindfulness for one day and then perform awareness and connection-based mindfulness techniques for 5 days on the HMI app.
89408077|NCT02126904||IVR group|
89408078|NCT02609737|Experimental|68Ga-DOTA-JR11 and 177Lu-DOTA-JR11|Pts get a PET/CT study with approx.150-200 MBq of 68Ga-DOTA-JR11. Lesions with focal radiotracer uptake not explained by physiologic sstr2 expression will be interpreted as metastatic disease. If 68Ga-DOTA-JR11 uptake by metastases with a diameter of more than 2 cm is less than the physiologic radiotracer uptake by the liver, no further imaging & therapy will be performed as part of the study, as it is unlikely that pts with this low radiotracer uptake will benefit from PRRT (2). All other pts will undergo a dosimetric study with 1850 MBq (less than 100 μg peptide) of 177Lu-DOTA-JR11. Results of the dosimetry study, will determine the balance of activity of 177Lu-DOTA-JR11 that can be administered without exceeding the radiation dose limits. This activity will be split into 2 equal amounts to be delivered in 2 cycles, approximately 3 months apart. After each therapy cycle, pts will be followed clinically for 3 months.
89408079|NCT05723978||Selective extended dissection (SED) group|
89408080|NCT05723978||Standard dissection (SD) group|
89408081|NCT01060059||exenatide|The targeted population consists of adult patients with type 2 Diabetes Mellitus unable to achieve the desired level of glycemic control while using oral anti-hyperglycemic agents and who initiate treatment with exenatide.
89408082|NCT01060059||basal insulin|The targeted population consists of adult patients with type 2 Diabetes Mellitus unable to achieve the desired level of glycemic control while using oral anti-hyperglycemic agents and who initiate treatment with basal insulin.
89408083|NCT02122068|Experimental|Mentalizing Imagery Therapy|Meditation and mindfulness 4 week program
89408084|NCT02122068|Active Comparator|Relaxation cd|Listening to a relaxation cd
89408085|NCT04329481|Active Comparator|mycodigest supplement|"Mycodigest is a dietary supplement which consists of traditional medicinal mushrooms, as essences and grounded powder. These include Shiitake, Maitake, Trametes Coriolus Versicolor, Agaricus.~Compliance to treatment will be considered as taking 80% of supplement/placebo treatment, and will be monitored by telephone calls and emails to patients during the study phase, and by counting the pills which were not taken at the end of the trial.~Treatment with Mycodigest supplement will initiate with 2 pills/day for 7 days, and gradually rise to 4 pills/day for 7 days, 6 pills/day for 42 days. Thus, the full dose of the treatment will be administered for 6 weeks."
89408086|NCT04329481|Placebo Comparator|placebo|"will be be identical in size, shape and color to Mycodigest Treatment with Mycodigest placebo will initiate with 2 pills/day for 7 days, and gradually rise to 4 pills/day for 7 days, 6 pills/day for 42 days. Thus, the full dose of the treatment will be administered for 6 weeks."
89408087|NCT02252094|Active Comparator|Conventional lung protective ventilation|Lung protective ventilation (6ml/kg predicted body weight). All other interventions per intensive care unit standardised ARDS management protocol
89408088|NCT02252094|Experimental|Ultra-protective ventilation|Ultra-protective ventilation (</= 3ml/kg predicted body weight) targeting plateau pressure of </= 25 cmH2O, supported by Prismalung. All other intervention per intensive care unit standardised ARDS management protocol
89408089|NCT04846816|Experimental|SQIN-01|The drug and device combination is called SQIN-01. SQIN-01 is a combination of SQIN-Infusor and SQIN-Furosemide Investigational pump (SQIN-Infusor, medical device) intended for subcutaneous infusion of investigational product, SQINFurosemide.
89408090|NCT05134090||Percutaneous laparoscopy|Laparoscopy with percutaneous grasp (2.9 mm).
89408091|NCT05134090||Conventional laparoscopy|Conventional laparoscopy with conventional laparoscopic trocars (10 or 5 mm).
88883261|NCT04439409||Patients with Cluster Headache (CH)|Patients with Cluster Headache (CH) will be included. They will have a Holter electrocardiogram during 7 days.
89408092|NCT04318015|Experimental|High-risk Treatment|Hydroxychloroquine 200mg per day for 60 days.
89408093|NCT04318015|Placebo Comparator|High-risk Placebo|Placebo tablet per day for 60 days.
89408094|NCT04318015|Experimental|Low-risk Treatment|Hydroxychloroquine 200mg per day for 60 days
89408095|NCT04318015|Placebo Comparator|Low-risk Placebo|Placebo tablet per day for 60 days.
89408096|NCT02127060|Experimental|Vitamin C|in postoperative time, vitamin C administered orally with other pain analgesics.
89408097|NCT02127060|Placebo Comparator|Placebo drug|in postoperative time, vitamin C do not administered.
89408098|NCT02288858|Active Comparator|Test product|Viviscal Oral Supplement Tablets (as 512mg coated red-brown tablets in unbranded blister packs)
89191284|NCT00858754|Placebo Comparator|Group 2 Non-Active Drug|Placebo
89408099|NCT02288858|Placebo Comparator|Placebo|Placebo Tablets (as 512 coated red-brown tablets in unbranded blister packs)
89408100|NCT00790803|Other|Pegaptanib (Macugen)|Open label, non randomized, interventional controlled injection of 0.3mg of Pegaptanib (Macugen) every 6weeks with max of 5 injections over 30weeks.
89408101|NCT02125188|Experimental|Desmopressin|Desmopressin 3ug/kg in saline 100ml ivdrip before surgery
89408102|NCT02125188|Placebo Comparator|saline|saline 100ml ivdrip before surgery
89408103|NCT05131126|Experimental|Patient requiring anterior abutment surgery by Latarjet method|
89408104|NCT05131126|Active Comparator|Healthy volunteers|
89408105|NCT02288936|Experimental|Enzalutamide|Enzalutamide 160 mg/day
89531036|NCT02494661|Active Comparator|Healthy Cart Video|Healthy Cart Video: Participants receive one nutritional video intervention on how to shop for healthy foods using My Plate Guidelines.
88883262|NCT04410406|Active Comparator|IA (Ivermectin + Albendazole)|Participants will receive one oral dose of Ivermectin (IVM) 200 µg/kg + Albendazole (ABZ) 400 mg (IA) annually for 24 months.
89191285|NCT00723164|Active Comparator|FM|Premedication consisting of fentanyl 0.6 ug/kg and midazolam 9 ug/kg (FM), five minutes before tidal volume sevoflurane 8% induction with 6 L/min O2.
89531037|NCT02494427|Experimental|1|CAD/CAM manufactured fixed unitary dental prostheses
89531038|NCT02494427|Active Comparator|2|Conventionally manufactured unitary dental prostheses
89531039|NCT03341819|Active Comparator|Retained Urinary Catheter|
89408106|NCT05131048|Active Comparator|Conventional group|"Patients will be given thermal therapy with the hot pack for 20 minutes followed by Conventional physiotherapy will consist of a set of exercises. The exercise components willl be chosen based on previous studies (Deyle 2000) and will comprises of~stretches of lower limb muscles (gastrocnemius, soleus and hamstring)~isometric quadriceps work~straight leg raising~Joint mobilization includes anteroposterior (AP) glide of the tibia on the femur~the patella glides in all directions Subjects will participate in a 45-minute physical therapy session, on alternate days weekly for 6 weeks, in our centre under the close surveillance of a physical therapist. A total of 24 sessions will be given to this group."
89408107|NCT05131048|Experimental|interventional group|"Patients in this group will perform home-based hip Strengthening exercises to strengthen hip abductor and adductor muscles. Six different home-based exercises will be taught. This group will have 3 sessions in 1st week in the hospital under the supervision of a trained physiotherapist just to teach them and ensure that patients are doing exercises correctly on their own. After that, patients will perform exercises 5 days at home and 1 session at the hospital per week. The therapist will be trained to deliver different exercises and adjust the intensity of exercise accordingly advise the participants to complete 10 repetitions of every exercise at home96.~Abduction in side-lying~Abduction in standing~Standing wall isometric hip abduction~Hip Adduction in side-lying~Hip abduction in a standing position~Towel press"
89408108|NCT02125344|Experimental|PM(Cb)|"PM(Cb):~paclitaxel 80mg/m² 18 times weekly simultaneously with NPLD (Myocet®)20mg/m² 18 times weekly simultaneously with carboplatin AUC 1.5 18 times weekly (only in patients with TNBC) Patients with HER2-positive disease will receive trastuzumab 6 (8) mg/kg every 3 weeks and pertuzumab 420 (840) mg every 3 weeks simultaneously to all cycles."
89408109|NCT02125344|Active Comparator|ETC|"ETC:~epirubicin 150mg/m² every 2 weeks for 3 cycles followed by paclitaxel 225 mg/m² every 2 weeks for 3 cycles followed cyclophosphamide 2000 mg/m² every 2 weeks for 3 cycles. Patients with HER2-positive disease will receive trastuzumab 6 (8) mg/kg every 3 weeks and pertuzumab 420 (840) mg every 3 weeks simultaneously to all T and C cycles."
89004608|NCT02651480|Experimental|Vegan Group|Participants in the intervention group will follow a low-fat, plant-based diet for 14 weeks, and will attend nutrition classes in the form of a weekly support group.
89004609|NCT02651480|Active Comparator|Control Group|The control group will follow an unrestricted diet with no instruction.
89408110|NCT03651609|Experimental|UNE at HUA_HUA release|Patients with UNE under the HUA randomly distributed for simple decompression of the ulnar nerve. Patients will also receive pictured recommendations with descriptions, which limb positions should be avoided. Control neurological examination will be performed every 3 months and identical protocol as at the time of diagnostic evaluation at 1 year follow-up.
89408111|NCT03651609|Active Comparator|UNE at HUA_conservative treatment|Patients with UNE under the HUA randomly distributed for conservative treatment. Patients will receive pictured recommendations with descriptions, which limb positions should be avoided. In order to prevent deterioration in conservatively treated group of patients with UNE at HUA control neurological examination will be performed every 3 months. Criteria for surgical HUA release will be clinical deterioration or lack of clinical improvement after 12 months. Prior to surgical HUA release and at 1 year follow-up identical protocol as at the time of diagnostic evaluation will be performed.
89408112|NCT03651609|Experimental|UNE at RTC_HUA release|Patients with UNE in the RTC groove randomly distributed for simple decompression of the ulnar nerve. Patients will also receive pictured recommendations with descriptions, which limb positions should be avoided. At 1 year follow-up identical protocol as at the time of diagnostic evaluation will be performed.
89408113|NCT03651609|Active Comparator|UNE at RTC_conservative treatment|Patients with UNE in the RTC groove randomly distributed for conservative treatment. Patients will receive pictured recommendations with descriptions, which limb positions should be avoided. At 1 year follow-up identical protocol as at the time of diagnostic evaluation will be performed.
89408114|NCT05468840|Experimental|Intravenous ketamine infusion|Participants in the intervention group will receive 0.5mg/kg of 1mg/mL intravenous ketamine (50 mg maximum) over 40 minutes.
89408115|NCT05468840|Placebo Comparator|Intravenous normal saline infusion|Participants in the control group will receive 0.5mL/kg intravenous normal saline (50 ml maximum) over 40 minutes.
89408116|NCT03651375|Experimental|Sequential chemoradiotherapy|1xAI (doxorubicin 75 mg/sqm and ifosfamide 10 g/sqm) + 5x5 Gy radiotherapy + 2xAI + surgery
89408117|NCT02122224|Experimental|Group 1|"Groups will rotate through each of the 3 intervention breakfasts as well as the usual breakfast supplied at the preschool for a total of 4 weeks."
89531040|NCT03341819|Experimental|Non-retained Urinary Catheter|
89004610|NCT02605785|Experimental|Tau PET Scan, F-18 AV 1451|All subjects will received a Tau PET scan.
89004611|NCT02600884|Experimental|Families Talking Together Plus (FTT+HPV)|Parents in the experimental group will attend a 1-hour intervention session, receive program materials to use with youth at home, and receive 2 booster phone calls post-intervention. Content of the experimental intervention includes parent-child sexual health communication and HPV vaccination navigation.
89004612|NCT02600884|Active Comparator|Brief motivational interviewing (BMI)|Parents in the brief motivational interviewing (BMI) group will attend a 1-hour intervention session, receive program materials to use with youth at home, and receive 2 booster phone calls post-intervention. Content of the control intervention includes obesity prevention strategies using motivational interviewing.
89004613|NCT02595866|Experimental|Treatment (pembrolizumab and cART)|Patients receive pembrolizumab IV over 30 minutes on day 1. Patients continue receiving their recommended combination antiretroviral therapy PO QD. Cycles repeat every 21 days for up to 2 years or 35 doses in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or PET/CT and blood sample collection throughout the trial. Patients may also undergo biopsies during screening and on study.
89408118|NCT02122224|Experimental|Group 2|"Groups will rotate through each of the 3 intervention breakfasts as well as the usual breakfast supplied at the preschool for a total of 4 weeks."
89408119|NCT02122224|Experimental|Group 3|"Groups will rotate through each of the 3 intervention breakfasts as well as the usual breakfast supplied at the preschool for a total of 4 weeks."
89408120|NCT02122224|Experimental|Group 4|"Groups will rotate through each of the 3 intervention breakfasts as well as the usual breakfast supplied at the preschool for a total of 4 weeks."
89408121|NCT05723900|Experimental|Castor oil|Castor oil applied to one side of the selected primary canine
89408122|NCT05723900|Experimental|Formocresol|Formocresol applied to other side
89408123|NCT03970291|Experimental|Nociceptive-Level (NOL)|Analgesic component of anesthesia (fentanyl) will be guided using NOL
89408124|NCT03970291|No Intervention|Standard Clinical Care (SCC)|Standard Clinical Care guided fentanyl administration
89408125|NCT03651297|Experimental|Younger Adults|First group will include 20 young adults with no history of falls or fear of falling. They will complete both interventions: Balance Training with Fall-Arrest Harness and Balance Training with Adjustable Harness.
89408126|NCT03651297|Experimental|Older adults|Second group will include 20 older adults with a self-reported history of falls or fear of falling. They will complete both interventions: Balance Training with Fall-Arrest Harness and Balance Training with Adjustable Harness.
89408127|NCT02122302|Experimental|Web-based health assessment|
89408128|NCT02127138|Experimental|ATP technique|This arm plan to enroll 158 subjects，Sirolimus-eluting Drug stent implantation via Active transfer of Plaque technique in the treatment of unprotected distal left main bifurcation lesions.In the ATP technique treatment of bifurcation lesions, by the balloon pre-dilation in the target side branch, the plaque will be actively transferred from side branch to main vessel. Subsequently, the plaque will be fixed by the expansive stent in main vessel. A stent with stent/artery ratio of 1.1:1 is inflated in MV. Rewire to SB is also left at operator's discretion. FKBI or stent in SB is recommended if there is at least one of following: residual stenosis>70%, >type B dissection and TIMI flow<3.
89408129|NCT02127138|Active Comparator|Provisional T stenting technique|This arm plan to enroll 158 subjects.Sirolimus-eluting Drug stent implantation via Provisional T Stenting technique in the treatment of unprotected distal left main bifurcation lesions.Provisional T stenting technique is the typic step-T stenting. In brief, two wires are advanced to distal MV and SB. Pre dilation is left at operator's discretion, however, pre dilating SB is not encouraged. Kissing balloon inflation before stenting MV is left at operator's discretion. A stent with stent/artery ratio of 1.1:1 is inflated in MV. Rewire to SB is also left at operator's discretion. FKBI is recommended if there is at least one of following: residual stenosis>70%, >type B dissection and TIMI flow<3.
89408130|NCT03651531|Active Comparator|insulin|
89408131|NCT03651531|Active Comparator|insulin and metformin|
89408132|NCT02648932|Other|Haplo-Cord Search|If subject meets the inclusion criteria and consents, will undergo a haplo-cord transplant.
89408133|NCT02648932|Other|Matched Unrelated Donor Search (MUD)|If subject meets the inclusion criteria and consents, will undergo a MUD transplant.
89408134|NCT03627637|Experimental|Experimental: Soy nuts|
89408135|NCT03627637|No Intervention|Control - no soy nuts|
89408136|NCT02127216|No Intervention|Standard of Care Group - A|The control group
88883263|NCT04410406|Active Comparator|MoxA (Moxidectin + Albendazole)|Participants will receive one oral dose of Mox 8 mg + ABZ 400 mg. Participants who are Mf positive at 24 months will be retreated with MoxA at the same dosage.
88883264|NCT04410406|Active Comparator|IDA (Ivermectin + Diethylcarbamazine + Albendazole)|Participants will receive one oral dose of IVM 200 µg/kg + Diethylcarbamazine (DEC) 6mg/kg + ABZ 400 mg. Participants who are Mf positive at 24 months will be retreated with IDA at the same dosage.
88883265|NCT04410406|Active Comparator|MoxDA (Moxidectin + Diethylcarbamazine + Albendazole)|Participants will receive one oral dose of Mox 8 mg + DEC 6mg/kg + ABZ 400 mg. Participants who are Mf positive at 24 months will be retreated with MoxDA at the same dosage.
88883266|NCT04403074||Chronic Pancreatitis Patients|Patients that have Chronic Pancreatitis and the current treatment with Celiac Plexus Blocks (CPB) are providing minimal relief of pain (CPB provide less than one month of pain relief). These patient will then receive a Celiac Plexus Neurolysis.
88883267|NCT04359888||MCET Group|Multi-Component Exercise Training (MCET) Group
88883268|NCT04359888||BRT Group|Balanced Reach Training Group
88883269|NCT04350125|Experimental|Platelet Rich Plasma Treatment|Male subjects diagnosed with Erectile Dysfunction (ED) will receive platelet rich plasma injections.
88883270|NCT04342546|Experimental|Toxicity test|"For all patients, the NovaGray RILA Breast® test will be performed between day -30 and until the first day of radiotherapy (before the start of this one) and then 12 months after the end of radiotherapy and in the case of neoadjuvant chemotherapy, between day -30 and until the first day of chemotherapy (before any injection) and in the case of adjuvant chemotherapy, between day -30 and until the first day of chemotherapy (before any injection).~The test consists of a blood sample of 2x4 mL"
89191286|NCT00723164|Placebo Comparator|NaCl|A 2.5 ml NaCL placebo (NaCl) IV, five minutes before tidal volume sevoflurane 8% induction with 6 L/min O2.
89408137|NCT02127216|Active Comparator|MOSES - Group B|Individual patients using application and pedometer without healthcare provider support
89408138|NCT02127216|Active Comparator|MOSES - Group C|Individual patients using application and pedometer with healthcare provider support
89408139|NCT02127216|Active Comparator|MOSES - Group D|Peer patient teams using application and pedometer without healthcare provider support
89408140|NCT02127216|Active Comparator|MOSES - Group E|Peer patient teams using application and pedometer with healthcare provider support
89408141|NCT03133520|No Intervention|Standard oxygen group|This patient groups will receive only routine oxygen therapy. Routine oxygen therapy involves administering low-to-medium oxygen flows through a nasal cannula or mask to achieve SpO2≥95%.
88813698|NCT02494596|Experimental|RhuMab 2C4 + Capecitabine 1250 mg/m^2 (Level 3)|Participants will receive a single 1250-mg/m^2 dose of PO capecitabine on Day -7 for pretreatment assessment. Capecitabine will then be administered on Days 1 to 14 of each 3-week cycle at a dose of 1250 mg/m^2 twice daily, and rhuMab 2C4 will be given on Day 1 of each 3-week cycle as a fixed-dose 1050-mg IV infusion. The incidence of DLTs will be used to guide intrapatient dose modification, as well as subsequent enrollment.
88813699|NCT02494596|Experimental|RhuMab 2C4 + Capecitabine 825 mg/m^2 (Level 1)|Participants will receive a single 825-mg/m^2 dose of PO capecitabine on Day -7 for pretreatment assessment. Capecitabine will then be administered on Days 1 to 14 of each 3-week cycle at a dose of 825 mg/m^2 twice daily, and rhuMab 2C4 will be given on Day 1 of each 3-week cycle as a fixed-dose 1050-mg IV infusion. The incidence of DLTs will be used to guide intrapatient dose modification, as well as subsequent enrollment.
88813700|NCT01581437|Other|64 pole basket catheter|all patients participating undergo mapping using the 64 pole basket catheter to assess for Atypical areas of drivers that may cause atrial fibrillation
89191287|NCT00849628||1|Constipation
89191288|NCT00849706||Study group|Medical staff personal, doctors and nurses, working night shifts.
89191289|NCT00858910|Experimental|EG1: embedded MI|"Experimental group 1:~Participants receive motor imagery (MI) training included in 45min physiotherapy, 3 times per week for 2 weeks."
89191290|NCT00858910|Experimental|EG2: added MI|"Experimental group 2:~Participants receive a 15 minutes motor imagery (MI) training added to a 30 min physiotherapy session, 3 times a week for two weeks."
89191291|NCT00858910|Placebo Comparator|CG|"Control group:~Participants receive a 15 min control intervention added to their 30 min physiotherapy session, 3 times a week for two weeks."
89191292|NCT03436238||MINSS cohort|"Adult patients >= 50 years old undergoing elective, major, abdominal surgery requiring at least one overnight stay in hospital.~Major abdominal surgery is defined as those classified as major OR major/complex by the Surgical Outcome Risk Tool (SORT) (www.sortsurgery.com)."
89191293|NCT00852826|Sham Comparator|1|Standard axillary lymphadenectomy
89191294|NCT00852826|Experimental|2|Three patches of collagen sponge coated with human coagulation factors (TachoSil®, Nycomed Pharma, AS) were perpendicularly placed at the end of lymphadenectomy on the axillary neurovascular bundle, thoracodorsal pedicle, and costal wall, covering the axillary walls
89191295|NCT02545426|Active Comparator|Calcium dialysate 2.5mEq/L|Dialysis with low calcium concentration
89191296|NCT02545426|Active Comparator|Calcium dialysate 3.5mEq/L|Dialysis with high calcium concentration
89191297|NCT00720824|Active Comparator|1|Ethyl chloride spray, plastic arm gripper, vibrating instrument, hypnotic suggestions
89191298|NCT00720824|Placebo Comparator|2|Office routine
89191299|NCT00859066||Control Group|"First year University of Michigan Radiology residents will take call as scheduled without a buddy call experience.~(Enrollment completed for the control group)"
89191300|NCT00859066||Experimental Group|2009 class of first year Radiology residents who will be assigned two 5 hour shifts working side by side with a more senior resident (who has experience taking call).
89191301|NCT05373134|Experimental|Pentoxifylline|400mg OD x 1 week, 400mg BD x 1 week then increased to 400mg TDS and continued
89191302|NCT05373134|Placebo Comparator|Placebo|Placebo will be given in a same manner as experimental drug
89191303|NCT00723320|No Intervention|P+N|placebo without lifestyle intervention
89191304|NCT00723320|Experimental|D+N|Atorvastatin 10mg/d
89191305|NCT00723320|Experimental|P+A|lifestyle intervention without Atorvastatin
89191306|NCT00723320|Experimental|D+A|lifestyle intervention and Atorvastatin 10mg/d
89191307|NCT00578448|Active Comparator|A|"10mg/kg~6 doses (Day 1, 5, week 2, 4, 8 and 12) for 12 weeks"
89191308|NCT00578448|Active Comparator|B|"5mg/kg~33 doses (every 4 weeks) for 144 weeks"
89191309|NCT05373056|Active Comparator|Group 1- Control group|They will performer the conventional exercise program por epicondylar muscles.
89191310|NCT05373056|Experimental|Group 2 - Experimental group|The experimental group will perform the conventional exercise program and also a scapular exercise program.
89191311|NCT05372978|Experimental|Cash|Participants will receive a one-time unconditional cash transfer of $8,500 CAD.
89191312|NCT05372978|No Intervention|Control|Participants will not receive a cash transfer.
89191313|NCT02571764|Experimental|Nutritional Oats Cookie|
89191314|NCT02572128|Experimental|Study 1|Iron fortified rice hot or cold extruded.
89191315|NCT02572128|Experimental|Study 2|Iron and zinc fortified rice hot extruded or coated.
89191316|NCT02572050|Experimental|Robotic Distal Gastrectomy with D2 LND|Robotic Distal Gastrectomy (RDG) with D2 LND for patient with stage II or III gastric cancer The primary efficacy endpoint of number of dissected lymph nodes in the N2 area (which is #7, #8a, #9, #11p and #12a according to the JRSSGC) after oncologic resection for clinical stage II or III gastric adenocarcinoma.assessment.
89191317|NCT04070430|Active Comparator|2 weeks of partial weight bearing on crutches|post-operative patient reported outcome (PRO) scores will be collected 6 weeks, 6 months, 12 months, and 24 months post-operatively
88813701|NCT03405428|Other|All patients|
88813702|NCT02494206|Experimental|QBX258 (VAK694 3mg/kg and QAX576 6mg/kg)|This will be a single arm, open label design pilot study, aiming to test the efficacy of QBX258, a combination of two fully human monoclonal antibodies that neutralize the biologic activity of interleukin 4 and interleukin 13 (IL4/IL13), for the treatment of stage I or II breast cancer related upper extremity lymphedema (BCRL).
89191318|NCT04070430|Active Comparator|4 weeks of partial weight bearing on crutches|post-operative patient reported outcome (PRO) scores will be collected 6 weeks, 6 months, 12 months, and 24 months post-operatively
89191319|NCT00578318|Experimental|Motivational Interviewing Active|Patients received a stepped progression of talk based treatment utilizing Motivational Interviewing as the basis.
88813703|NCT01724294||Cohort|
88813704|NCT01582139|Experimental|Experimental Condition: (Heart-Rate Informed SSM+HMM)|An experimental condition involving an exercise session where the Safety Supervision Module + Hyperglycemic Mitigation Module (SSM+HMM) is informed about heart rate
88813705|NCT01582139|No Intervention|Control Condition (SSM+HMM)|A control condition involving an exercise session where the Safety Supervision Module + Hyperglycemic Mitigation Module (SSM+HMM) is not informed about heart rate.
89531041|NCT03341741|Experimental|Tobramycin powder / Colistin|TOBI®Podhaler 2 x 112 mg daily for 2 x 28 days (on/off); and Colistin solution 2 x daily 1 Mega continuously for 112 days
89191320|NCT00578318|Active Comparator|Delayed Control|Patients received Treatment as usual (TAU) (i.e. no specific intervention and supportive check-ins from the study staff)
88883271|NCT04323189|Other|Crossover AB|Subjects in arm A will first receive placebo daily for 7 days in the first intervention followed by sitagliptin 100mg/d for 7 days in the crossover intervention.
88883272|NCT04323189|Other|Crossover BA|Subjects in arm B will first receive sitagliptin 100mg/d for 7 days in the first intervention followed by placebo for 7 days in the crossover intervention.
88883273|NCT04287985|Placebo Comparator|Placebo|Placebo (0.9% NaCl) will be administered IV
88883274|NCT04287985|Experimental|Low Dose - VIS649|Low dose of VIS649 administered IV
88883275|NCT04287985|Experimental|Medium Dose - VIS649|Medium dose of VIS649 administered IV
88883276|NCT04287985|Experimental|High Dose - VIS649|High dose of VIS649 administered IV
88883277|NCT04268914|No Intervention|Standard of Care (No VR) Randomization|In the standard of care treatment condition, participants will receive the standard CHLA treatment protocol for IV placement and induction of anesthesia. Current standard of care practices at CHLA for outpatient surgery induction will include the following steps. Children may receive midazolam, parental presence during induction and any other intervention or medication chosen by the HCP. The research team will have no input to the decision regarding the use of any therapy.
88883278|NCT04268914|Experimental|VR Randomization|When a child is assigned to the VR condition s/he will have the added component of VR distraction during pre-surgical preparation. Children in the VR condition will interact with an immersive 3D virtual environment presented via a HMD (head-mounted display), a helmet with computer screens for each eye. This study will use two HMDs at two possible time points: (1) Prior to and during IV placement, participants will play using the Oculus Go; (2) Prior to and during anesthesia induction, participants will play using the Mira Prism.
88883279|NCT04268901|No Intervention|Standard of Care (No VR) Randomization|In the standard of care treatment condition, participants will receive the standard CHLA treatment protocol for the medical procedure.
89191321|NCT00714090|Active Comparator|A|Double active comparator : venlafaxine (150 mg/day) and rTMS (5 times/week)
89191322|NCT00714090|Experimental|B|active rTMS (5 times/week) and sham venlafaxine (150 mg/day)
89191323|NCT00714090|Sham Comparator|C|sham rTMS (5 times/week) and active venlafaxine (150 mg/day)
89191324|NCT04067024|Active Comparator|Local anesthesia by the surgeon (LAS)|Local infiltration (ropivacaine 3,75 mg/ml) by surgeon
89191325|NCT04067024|Experimental|Regional anesthesia group (LRA):|By ultrasound, a pecs block I associated with a supraclavicular nerf block is performed. (Ropivacaine 3,75 mg/ml)
88883280|NCT04268901|Experimental|VR Randomization|Children in the VR condition will undergo the invasive procedure while distracted by interaction with an immersive virtual environment (VE) presented via a head mounted display (HMD). The intervention group will receive standard CHLA treatment with VR distraction.
89191326|NCT00722748||Genebank|By creating a genebank from patient's blood donations we will ultimately be able to define genes for various cardiovascular conditions.
89408142|NCT03133520|Experimental|High flow oxygen therapy group|This patients group will receive high flow oxygen therapy. High flow nasal oxygen therapy is a focus of growing attention as an alternative to standard oxygen therapy. By providing warmed and humidified gas, it allows the delivery of higher flow rates [of up to 60 L/min] via nasal cannula devices, with fraction of inspired oxygen(FiO2) values of nearly 100%.
89408143|NCT05130736|Experimental|Robot|Patients treated using a rehabilitation robot
88883281|NCT04221724|Experimental|Intervention Group|Multicomponent physical exercise intervention
88883282|NCT04220866|Experimental|Ulevostinag+Pembrolizumab|Participants receive ulevostinag 540 ug via intratumoral (IT) injection on Day 1 of every week for two 3-week cycles (Cycles 1-2), then on Day 1 of each 3-week cycle for up 33 cycles (Cycles 3-35), for a total of 35 cycles PLUS pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 cycles. The total duration of treatment is up to approximately 2 years.
88883283|NCT04220866|Active Comparator|Pembrolizumab|Participants receive pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for up to 35 cycles. The total duration of treatment is up to approximately 2 years.
88883284|NCT04197297|Other|CT and MRI Scans|Each patient will undergo a 3T MRI scan as well as a dynamic contrast-enhanced CT scan within one week prior to the start of treatment. Patients will also undergo a research 3T MRI scan and research dynamic contrast-enhanced CT scan at the one week post radiotherapy mark. An MRI scan during their 3 month post-treatment follow up visits will take place as per routine standard of care.
88883285|NCT04179136|Active Comparator|High enterolactone producer's (intervention)|lignan capsules contain 300 mg flaxseed (SDG) extract
88883286|NCT04179136|Placebo Comparator|High enterolactone producer's (Control)|Placebo treatment matching intervention
88883287|NCT04179136|Active Comparator|Low enterolactone producer's (intervention)|lignan capsules contain 300 mg flaxseed (SDG) extract
88883288|NCT04179136|Placebo Comparator|Low enterolactone producer's (Control)|Placebo treatment matching intervention
88883289|NCT04170946|Experimental|Talazoparib in Combination with Low Dose RT|Patients will start on talazoparib on day 1 of study intervention, and will continue to orally take talazoparib until the last day of RT (until day 20-23). Patient will start low dose RT on day 6-9, and will continue for 10 fractions throughout 2 weeks. Talazoparib dose levels will start at 0.5mg daily and increase to 1mg if dose limiting toxicites are not observed. Toxicities include renal impairment and other treatment related toxicities Grade ≥3. Patients will be monitored weekly during study treatment, and followed up at 3 weeks, and every 3 months after for 1 year.
89408144|NCT05130736|Active Comparator|Control|Patients receiving traditional rehabilitation treatment (robot used only as assessment tool)
89408145|NCT02122458|Active Comparator|Immediate Hearing Aid Treatment: Blast-exposed Only|This group consisted of blast-exposed Veterans with auditory complaints but normal audiometric test results. These Veterans were negative for significant PTSD. They were fitted with open-fit hearing aids that provided mild high-frequency amplification and were monitored for 6 months.
89531042|NCT03341741|Active Comparator|Colistin|Colistin solution 2 x daily 1 Mega continuously for at least 30 days
88883290|NCT04170283|Experimental|Zanubrutinib (BGB-3111)|All participants to receive open-label zanubrutinib
88883291|NCT04170283|Experimental|Zanubrutinib in combination with Tislelizumab|Participants to receive the combination as in the parent study (Australia Only)
88883292|NCT04160052|Experimental|Treatment (venetoclax, azacitidine)|Patients receive venetoclax orally PO QD on days 1-7 or 1-14 and azacitidine SC or IV over 15 minutes on days 1-5. Cycles repeat every 4-8 weeks in the absence of disease progression or unacceptable toxicity.
88883293|NCT04149574|Experimental|Arm A: nivolumab + Bacillus Calmette-Guérin (BCG)|
88883294|NCT04149574|Placebo Comparator|Arm B: placebo +BCG|
88883295|NCT04121325||Gastroparesis patients with abdominal pain|Patients with gastroparesis who have had an Enterra device in place for at least two months who continue to have moderate to severe abdominal pain.
88883296|NCT04115384|Experimental|Insulin (Novolin-R)|Regular insulin (Novolin-R) 20 IU/IN (0.1ml/10 units IN in each nostril) BID
88883297|NCT04113733||Crohn's Disease|This group consists of patients with a diagnosis of Crohn's disease undergoing colonoscopy for clinical care. Samples including tissue biopsy, blood and stool will be collected one time. In addition, patient information that may include questionnaires and medical record review will be collected.
88883298|NCT04113733||Control|This group will include patients undergoing screening colonoscopy as part of standard of care. Samples including tissue biopsy, blood and stool will be collected one time. In addition, patient information that may include questionnaires and medical record review will be collected.
88883299|NCT04113733||Cooperative Human Tissue Network|This group will consist of non-IBD patients and Crohn's disease patients participating in the Cooperative Human Tissue Network (CHTN). The CHTN will be utilized to obtain surgical specimens from these patients. The patients will be screened and consented via the CHTN protocol. No additional samples in the form of blood or stool will be collected. Associated clinical data will be collected through medical record review.
88883300|NCT04075149|Experimental|Spironolactone|16 weeks without medication, then 16 weeks with medication, then 12 months without medication; spironolactone 50 mg tablets: 50-100 mg orally twice daily (1.7-3.3 mg/kg/24 hr)
88883301|NCT04060199|Experimental|Viltolarsen|Patients amenable to exon 53 skipping will receive viltolarsen intravenous (IV) infusions, weekly, at 80 mg/kg for up to 48 weeks.
88883302|NCT04060199|Placebo Comparator|Placebo|Patients amenable to exon 53 skipping will receive placebo intravenous (IV) infusions, weekly, for up to 48 weeks.
88922017|NCT05972174|Experimental|Part A Group 2 Vaccine: mRNA-1018 for H7 Only Dose Level 3|Participants will receive mRNA-1018 for H7 only at dose level 3 by IM injection on Day 1 and Day 22.
88883303|NCT04028570|Experimental|Radiation|This study involves a 3+3 design. The starting cohort (n=3) will receive a neoadjuvant Background dose to the affected hemithorax (starting at 0 cGy) as well as concomitant Boost dose (of at least 2100 cGy) to a part of the gross tumour volume (GTV). The radiation will be delivered over 3 alternate days over 5-7 calendar days followed by macroscopically complete extensive pleural resection (either extra-pleural pneumonectomy or extended pleurectomy decortication, at the surgeon's discretion) after 7 to 14 days. If no dose limiting toxicities (DLTs) seen, then the Background RT dose will be increased by 600 cGy (up to 1800 cGy) and the cohort (n=3) for the next dose level will be accrued. If only 1 DLT seen, then an additional 3 patients will be treated on this dose level. If 2 or more DLTs seen at any given dose level, then the previous dose level will be defined as the maximum tolerated dose (MTD). Patients will be stratified by type of resection.
89408146|NCT02122458|Active Comparator|Immediate Hearing Aid Treatment: Blast-exposed with PTSD|This group consisted of blast-exposed Veterans with auditory complaints but normal audiometric test results. These Veterans were comorbid for significant PTSD. They were fitted with open-fit hearing aids that provided mild high-frequency amplification and were monitored for 6 months.
88883304|NCT04025554|Experimental|1/Active treatment|Patients with MS will be assigned to the same intervention
88883305|NCT04025372|Experimental|Bicalutamide+GnRH Agonist+Radiation Therapy|"Bicalutamide is administered orally on a daily basis~GnRH Agonist as prescribed~Radiation therapy is administered starting 4-16 weeks after ADT"
88883306|NCT04025372|Experimental|Darolutamide+Radiation Therapy|"Darolutamide is administered orally twice daily~Radiation therapy is administered starting 4-16 weeks after Darolutamide"
88883307|NCT04019002|Experimental|Cohort 1: Newly Diagnosed- Standard Treatment|"This arm is for patients with histologically proven newly diagnosed glioblastoma who will undergo standard treatment with radiation therapy (RT) and temozolomide (TMZ).~Patients will receive two injections of hyperpolarized 13C pyruvate for research imaging performed prior to standard imaging on the same day. Research imaging occurs at two time points: before receiving standard treatment with RT/TMZ and at the first post-radiation follow-up scan (8 weeks later)."
88883308|NCT04019002|Experimental|Cohort 2: Recurrent- Standard Surgical Resection|"This arm is for patients with histologically proven recurrent suspected glioblastoma who will receive surgical resection for the recurrence.~Patients will receive one injection of hyperpolarized 13C pyruvate for research imaging performed prior to standard imaging on the same day. Research imaging occurs at one time point: before surgery."
88883309|NCT04019002|Experimental|Cohort 3: Recurrent- Standard Treatment|"This arm is for patients with histologically proven recurrent suspected glioblastoma who will undergo standard treatment for the recurrence.~Patients will receive two injections of hyperpolarized 13C pyruvate for research imaging performed prior to standard imaging on the same day. Research imaging occurs at three time points: prior to treatment (baseline), approximately 7-14 days after the initiation of treatment, and 6-8 weeks after the initiation of treatment."
88883310|NCT04017351|Experimental|Subjects with virtual assistance|Subjects receiving current standard of care for a surgical procedure within the department of plastic surgery will have access to artificial intelligence virtual assistance (AIVA)
88883311|NCT04017351|No Intervention|Subjects without virtual assistance|Subjects receiving current standard of care for a surgical procedure within the department of plastic surgery
89191327|NCT00717444|Experimental|1|contingency management for abstinence plus 12-step facilitation therapy and contingency management for completing healthy activities
89191328|NCT00717444|Experimental|2|contingency management for abstinence plus 12-step facilitation therapy
89191329|NCT05364710|Experimental|Group A|Crossover study: Participants will be consuming placebo on a clinic day at least 1 week prior to a clinic day where he/she will consume the active intervention.
89191330|NCT05364710|Experimental|Group B|Crossover study: Participants will be consuming the active intervention on a clinic day at least 1 week prior to a clinic day where he/she will consume placebo.
89191331|NCT00618748|Experimental|Pre-Olanzapine|Participants who received olanzapine 5-20 mg/day in Study HGMP (NCT#00510146), received olanzapine 5-20 mg/day, orally for 24 weeks.
89191332|NCT00618748|Experimental|Pre-Placebo|Participants who received placebo in acute phase of Study HGMP (NCT#00510146), received olanzapine 5-20 mg/day, orally for 24 weeks.
89408147|NCT02122458|Active Comparator|Delayed Hearing Aid Treatment: Blast-exposed Only|This group consisted of blast-exposed Veterans with auditory complaints but normal audiometric test results. These Veterans were negative for significant PTSD. They were fitted with hearing aids after a 6-month delay. Their performance was monitored 6-months pre-fitting and for the 6 months after the fitting.
89191333|NCT00618748|Experimental|New Olanzapine|Participants who did not participate in Study HGMP (NCT#00510146), received olanzapine 5-20 mg/day, orally for 48 weeks.
89191334|NCT04067544|Other|Acupuncture Treatment|All patients receive 10 acupuncture treatments over the course of 8 weeks.
89191335|NCT00723476|Active Comparator|A|Participants will receive three 60- to 90-minute health education control sessions.
89004614|NCT02563769|Experimental|Clavulanic Acid (CLAV) 250mg; CLAV 500mg then Placebo (PBO)|Clavulanic acid OR Placebo to be given in combination with intravenous cocaine; Day #2: Clavulanic Acid 250 mg (low dose); Day #3: Clavulanic Acid 500 mg; Day #4: Placebo
89191336|NCT00723476|Experimental|B|Participants will receive three 60- to 90-minute Family Centered Advanced Care Planning sessions.
89191337|NCT00720642||PSAP|This is the population of patients in whom surgical intervention could possibly be avoided. These patients will be those in whom all imaging evidence (mammographic or sonographic) was removed during the Intact BLES procedure, and in whom a definitive diagnosis of ADH could be made using the pathology assessment criteria outlined in the protocol.
89191338|NCT00720642||NPSAP|Patients with a pathology diagnosis of ADH in whom all imaging evidence (mammographic or sonographic) of the target lesion was NOT removed OR in whom a definitive diagnosis of ADH COULD NOT be made by implementing the pathology criteria for evaluation outlined in the protocol AND patients with a diagnosis of DCIS will undergo open surgical excision and will be analyzed separately from the PSAP group.
89408148|NCT02122458|No Intervention|Non-treatment Diagnostic Testing: Normal|This group consisted of Veterans who completed the same pre-treatment diagnostic testing as the three treatment groups but were not enrolled in the hearing aid treatment protocol. This group included neurotypical Veterans with normal hearing and were negative for blast-exposure and PTSD.
89408149|NCT02122458|No Intervention|Non-Treatment Diagnostic Testing: Blast-exposed Only|This group consisted of Veterans who completed the same pre-treatment diagnostic testing as the three treatment groups but were not enrolled in the hearing aid treatment protocol. This group consisted of blast-exposed Veterans with auditory complaints but normal audiometric test results. They were negative for significant PTSD.
89408150|NCT02122458|No Intervention|Non-treatment Diagnostic Testing: Blast-exposed with PTSD|This group consisted of Veterans who completed the same pre-treatment diagnostic testing as the three treatment groups but were not enrolled in the hearing aid treatment protocol. This group consisted of blast-exposed Veterans with auditory complaints but normal audiometric test results. These Veterans were comorbid for significant PTSD.
89408151|NCT02122458|No Intervention|Non-treatment Diagnostic Testing: PTSD Only|This group consisted of Veterans who completed the same pre-treatment diagnostic testing as the three treatment groups but were not enrolled in the hearing aid treatment protocol. This group was negative for blast-exposure and hearing loss but positive for significant PTSD.
89408152|NCT04468724|Experimental|IMMEDIATE|People who are included in the Immediate Arm receive the Makasi intervention right away or in a six-week time if they are not available on the spot
89408153|NCT04468724|Other|DIFFERED|People who are included in the Differed Arm receive the Makasi intervention three months after inclusion
89408154|NCT02903511|Experimental|Metformin|Participants will receive metformin 500 mg tablets, starting with 1 tab twice a day. The dose will be increased by 500 mg every 2 weeks up to 1000 mg by mouth twice a day, as tolerated, for 12 months.
89408155|NCT02903511|Placebo Comparator|Placebo|Participants will receive placebo 500 mg tablets, starting with 1 tab twice a day. The dose will be increased by 500 mg every 2 weeks up to 1000 mg by mouth twice a day, as tolerated, for 12 months.
89408156|NCT05133778|Experimental|Sweet orange and pomegranate extract|Supplementation
89191339|NCT00852904||NCS Vanguard cohort|Women of child bearing potential, children born to women enrolled in the study, the children s biological and/or social fathers, and primary caregivers (if other than parent)
88883321|NCT04002882||Subjects with Cystic Fibrosis|n=60 patients with CF ages 16-30
88883322|NCT04002882||Healthy Controls|n=30 healthy controls matched to participants with CF for age, sex, BMI, and race.
89408157|NCT05133778|Placebo Comparator|Maltodextrin|Supplementation
88883323|NCT03994770|Other|STR|Older people who have suffered a stroke
88883324|NCT03951259|Experimental|SM934 10mg|SM934 10mg（1 tablet）+Placebo（4 tablets）p.o. qd in combination with steroids
88883325|NCT03951259|Experimental|SM934 30mg|SM934 10mg（3 tablet）+ Placebo（2 tablets）p.o. qd in combination with steroids
88883326|NCT03951259|Experimental|SM934 50mg|SM934 10mg（5 tablet）p.o. qd in combination with steroids
88883327|NCT03951259|Placebo Comparator|Placebo|Placebo（5 tablets）p.o. qd in combination with steroids
88883328|NCT03949660|Experimental|Epidural stimulation for blood pressure without stand|To assess whether epidural stimulation, used for regulating blood pressure without standing, is neuromodulatory for bowel motility after motor complete SCI
88883329|NCT03949660|Experimental|Epidural stimulation for blood pressure with stand|To assess whether epidural stimulation, used for regulating blood pressure with standing, is neuromodulatory for bowel motility after motor complete SCI
88883330|NCT03949660|Experimental|Epidural stimulation for trunk and core without stand|To assess whether epidural stimulation, used for activating the trunk and core musculature without standing, is neuromodulatory for bowel evacuation after motor complete SCI
88883331|NCT03949660|Experimental|Epidural stimulation for trunk and core with stand|To assess whether epidural stimulation, used for activating the trunk and core musculature with standing, is neuromodulatory for bowel evacuation after motor complete SCI
88883332|NCT03948061|Experimental|Cherry juice followed by placebo|Sweet cherry juice concentrate will be consumed twice daily for 6 weeks, followed by consumption of placebo beverage twice daily for 6 weeks.
88883333|NCT03948061|Experimental|Placebo beverage followed by cherry juice|Placebo beverage will be consumed twice daily for 6 weeks, followed by consumption of sweet cherry juice concentrate twice daily for 6 weeks.
88883334|NCT03939767||wAMD patients|Patients with a diagnosis of wAMD and naïve to any treatment in the study eye will be enrolled after the decision by treating physician for IVT aflibercept therapy according to the local label.
88883335|NCT03918382|No Intervention|Control group|First phase. 97 participants. This group will continue standard procedure regarding side effect registration and handling. When the 97 patients have been included and have finished their radiotherapy the second phase will be initiated.
88883336|NCT03918382|Experimental|PRO group|Second phase. 194 participants. This group will be assigned to the intervention which is weekly electronic Patient-Reported Outcomes. Patients report the symptoms (PRO) on a tablet before each weekly control visit. The clinician will use the patients PRO answers as part of the consultation. The PRO symptoms consist of head and neck relevant items fra PRO-CTCAE™ (Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events) and EORTC (European Organisation for Research and Treatment of Cancer) item library.
88883337|NCT03916302||Complicated outcome|"The patients meet at least one of the following criteria:~systolic blood pressure < 90 mmHg for at least 15 minutes~need for catecholamine administration because of persistant arterial hypotension or shock~need for mechanical ventilation~need for cardiopulmonary resuscitation~bleeding classified according to the International Society on Thrombosis and Haemostasis classification (major bleeding and non-major clinically relevant bleeding)."
88883338|NCT03916302||Non-complicated outcome|"The patients meet none of the following criteria:~systolic blood pressure < 90 mmHg for at least 15 minutes~need for catecholamine administration because of persistant arterial hypotension or shock~need for mechanical ventilation~need for cardiopulmonary resuscitation~bleeding classified according to the International Society on Thrombosis and Haemostasis classification (major bleeding and non-major clinically relevant bleeding)."
89191340|NCT00717600|Experimental|1|Oral probiotics
89191341|NCT00721058|Other|1|
89191342|NCT00850018|Experimental|1|Participants will receive monthly blood transfusions.
88883339|NCT03914820|Experimental|Experimental|ARM A: Prophylactic surgery plus HIPEC CO2 performed with mitomycin
88883340|NCT03914820|Active Comparator|Comparator|ARM B: Standard surgey without HIPEC CO2 The arm B is with standard surgery without HIPEC CO2
88883341|NCT03895359|Active Comparator|Transarterial Chemoembolization (TACE)|Transarterial Chemoembolization (TACE)
88883342|NCT03895359|Active Comparator|TACE Plus Stereotactic Body Radiation Therapy (SBRT)|Stereotactic Body Radiation Therapy (SBRT)
88883343|NCT03891966|Active Comparator|Splint|
88883344|NCT03891966|Active Comparator|Soft Dressing|
88883345|NCT03859427|Active Comparator|Carfilzomib once-weekly|Carfilzomib, lenalidomide, dexamethasone (KRd) regimen using once-weekly carfilzomib 56 mg/m2
88883346|NCT03859427|Active Comparator|Carfilzomib twice-weekly|Carfilzomib, lenalidomide, dexamethasone (KRd) regimen using twice-weekly carfilzomib 27 mg/m2
88883347|NCT03824938|Experimental|Aspirin|Aspirin 650 mg capsule by mouth, single dose
88883348|NCT03824938|Active Comparator|Acetaminophen|Acetaminophen 650 mg capsule by mouth, single dose
88883349|NCT03824938|Placebo Comparator|Placebo|Placebo 650 mg capsule by mouth, single dose
88883350|NCT03766425|Experimental|Aflibercept|Aflibercept applied intraoperatively as a subconjunctival injection at a dose of 0.05 ml (40 mg / ml) and one week after the operation at the same dose, also subconjunctival.
88883351|NCT03766425|Active Comparator|Mitomycin|Mitomycin applied during a surgery at a concentration of 0.3mg / ml for 3 min. on a soaked sponge.
88883352|NCT03638167|Experimental|ARM A (Tumor Cavity Infusion)|Patients with supratentorial tumors for which CAR T cells will be delivered into the tumor resection cavity
88883353|NCT03638167|Experimental|ARM B (Ventricular System Infusion)|Patients with either infratentorial tumors or leptomeningeal tumors for which the CAR T cells will be delivered into the fourth ventricle or lateral ventricle, respectively
88883354|NCT03636373|Experimental|Etanercept|Subjects will be administered etanercept 50 mg subcutaneously and a placebo intramuscularly
88883355|NCT03636373|Active Comparator|Triamcinolone acetonide|Subjects will be administered triamcinolone acetonide 40 mg intramuscularly and a placebo subcutaneously
88883356|NCT03560310|Experimental|Dual antiplatelet therapy|Ticagrelor 90 mg twice daily and ASA 75-100 mg daily for 12 months
88883357|NCT03560310|Active Comparator|Acetylsalicylic acid|ASA 75-160 mg daily for 12 months
88883358|NCT03470675|Placebo Comparator|Epidural saline + IV saline|Sterile saline via the epidural catheter. Sterile saline via intravenous catheter.
88883359|NCT03470675|Active Comparator|Epidural morphine 3 mg + IV saline|3 milligrams morphine via the epidural catheter. Sterile saline via intravenous catheter.
88883360|NCT03470675|Active Comparator|Epidural morphine 3 mg + IV ketamine 0.3 mg/kg|3 milligrams morphine via the epidural catheter. Ketamine 0.3 milligrams per kilogram via intravenous catheter.
88883361|NCT03456063|Experimental|Arm A: Atezolizumab + platinum-based chemotherapy|"Neoadjuvant treatment will consist of 4 cycles; atezolizumab + platinum-based chemotherapy~Platinum-based chemotherapy may include:~carboplatin + pemetrexed~carboplatin + nab-paclitaxel~cisplatin + pemetrexed~cisplatin + gemcitabine~Post-operative adjuvant treatment will consist of 16-cycles of atezolizumab"
88883362|NCT03456063|Placebo Comparator|Arm B: Placebo + platinum-based chemotherapy|"Neoadjuvant treatment will consist of 4 cycles; placebo + platinum-based chemotherapy~Platinum-based chemotherapy may include:~carboplatin + pemetrexed~carboplatin + nab-paclitaxel~cisplatin + pemetrexed~cisplatin + gemcitabine~Participants will receive best supportive care and monitoring after surgery"
89191343|NCT00850018|Active Comparator|2|Participants will receive usual care.
89408158|NCT05325528|Experimental|study group|patients in this arm will be treated with Tislelizumab in Combination with Oxaliplatin and Tegafur
89408159|NCT00147290|Experimental|BiV|ATP therapies are delivered in both the ventricles
88883363|NCT03448796|Active Comparator|HTO-group|Group receives opening wedge high tibial osteotomy with Tomofix -plate. Operative intervention is followed by supervised physiotherapeutic rehabilitation.
88883364|NCT03448796|Active Comparator|FT -group|Group receives only supervised physiotherapeutic rehabilitation.
89408160|NCT00147290|Active Comparator|RV|ATP delivered only in the right ventricle
89408161|NCT05133466||Northern pattern|Mothers recruited from Beijing
89408162|NCT05133466||East coastal pattern|Mothers recruited from Wuxi
89408163|NCT05133466||South-western pattern|Mothers recruited from Chengdu
89408164|NCT02125422|Experimental|Cefaly tDCS|"Cathodal Cefaly tDCS is delivered over the visual cortex at 2 mA of intensity, for 20 minutes, for 5 consecutive days in 9 HV. The anode is placed over the left DLPFC.~2 mA anodal tDCS is delivered over the visual cortex, for 20 minutes, for 5 consecutive days in 9 HV"
88883365|NCT03418818|Experimental|Arm A|Participants will complete FAZA PET/MRI scan and radiation therapy before surgery.
88883366|NCT03418818|Experimental|Arm B|Participants will receive pimonidazole prior to surgery. Participants in Arm B also have the option to complete a FAZA PET/MRI scan prior to surgery.
88883367|NCT03417284|Experimental|Group 1 (melphalan hydrochloride, HSCT, filgrastim)|"PREPARATIVE REGIMEN: Participants receive melphalan hydrochloride IV over 30-60 minutes on day -2.~TRANSPLANT: Participants in both groups undergo donor stem cell transplantation IV on day 0 over 30-60 minutes.~POST-TRANSPLANT: Participants in both groups receive filgrastim-sndz SC QD starting on day 5 and continuing in the absence of disease progression, unacceptable toxicity, or until evidence of an ANC of 0.5 x 10^9/L."
88883368|NCT03417284|Experimental|Group 2 (melphalan hydrochloride, HSCT, filgrastim)|"PREPARATIVE REGIMEN: Participants receive melphalan hydrochloride IV over 8-9 hours on day -2.~TRANSPLANT: Participants in both groups undergo donor stem cell transplantation IV on day 0 over 30-60 minutes.~POST-TRANSPLANT: Participants in both groups receive filgrastim-sndz SC QD starting on day 5 and continuing in the absence of disease progression, unacceptable toxicity, or until evidence of an ANC of 0.5 x 10^9/L."
88883369|NCT03383133|Experimental|SULT Allosteric Inhibition|A single, therapeutic dose of acetaminophen (1.0 g)) or dehydroepiandrosterone (75 mg) is taken orally (with 375 ml of water) either alone or simultaneously with a single, oral, therapeutic dose of mefenamic acid (0.75 g).
88883370|NCT03281369|Active Comparator|1L-Control: mFOLFOX6 (Gastric Cancer)|Participants in the 1L Gastric Cancer Control arm will receive modified FOLFOX6 (mFOLFOX6) treatment consisting of 5-fluorouracil (5-FU), leucovorin (folinic acid), and oxaliplatin. Participants who progressed on treatment may have the option of receiving Atezolizumab + Cobimetinib treatment, provided they meet the eligibility criteria. No longer enrolling participants as of June 2018.
88883371|NCT03281369|Experimental|1L-A: mFOLFOX6 + Atezo + Cobi (Gastric Cancer)|Participants in the 1L-A Gastric Cancer arm will receive mFOLFOX6 treatment consisting of 5-FU, leucovorin and oxaliplatin in combination with atezolizumab plus cobimetinib. No longer enrolling participants as of June 2018.
88883372|NCT03281369|Experimental|1L-A2: Atezo+mFOLFOX6 followed by Atezo+Cobi (Gastric Cancer)|Participants in the 1L-A2 Gastric Cancer arm will receive mFOLFOX6 treatment consisting of 5-FU, leucovorin and oxaliplatin in combination with atezolizumab during cycles 1 and 2 followed by atezolizumab plus cobimetinib during cycles 3 and beyond. No longer enrolling participants as of June 2018.
88883373|NCT03281369|Active Comparator|2L-Control: Ramucirumab + Paclitaxel (Gastric Cancer)|Participants in the 2L Gastric Cancer Control arm received ramucirumab plus paclitaxel. Participants who progressed on treatment had the option of receiving Atezolizumab + Cobimetinib treatment, provided they met the eligibility criteria. Enrollment completed as of October 2019.
88883374|NCT03281369|Experimental|2L-1: Atezo + Cobi (Gastric Cancer)|Participants in the 2L-1 Gastric Cancer arm received atezolizumab in combination with cobimetinib. Enrollment completed as of October 2019.
89004615|NCT02563769|Experimental|CLAV 250mg; PBO; then CLAV 500mg|Clavulanic acid OR Placebo to be given in combination with intravenous cocaine; Day #2: Clavulanic Acid 250 mg (low dose); Day #3: Placebo; Day #4: Clavulanic Acid 500 mg
89004616|NCT02563769|Experimental|PBO; CLAV 250mg; then CLAV 500mg|Clavulanic acid OR Placebo to be given in combination with intravenous cocaine; Day #2: Placebo; Day #3: Clavulanic Acid 250 mg (low dose); Day #4: Clavulanic Acid 500 mg
89408165|NCT02125500|Experimental|Sofosbuvir/Ledipasvir|"Non-cirrhotic patients will receive SOF/LDV Fixed Dose Combination (FDC) for 12 weeks.~Cirrhotic patients will receive SOF/LDV Fixed Dose Combination (FDC) for 24 weeks."
89408166|NCT03531008||Treatment-resistant focal epilepsy|Individuals with treatment-resistant focal epilepsy
89408167|NCT05130502|Experimental|Foam roller|Individuals perform Foam roller on bilateral legs and the muscles include Quadriceps, hamstring and gastrocnemius and soleus with a dynamic warm up program The investigators conduct the test for 2 sets and 60 seconds with 30 seconds rest period per muscle
89408168|NCT05130502|Active Comparator|Kinesiotape|Individuals perform Kinesiotape on bilateral legs and the muscles include Quadriceps, hamstring and gastrocnemius and soleus with a dynamic warm up program The investigators conduct the kinesiotape per muscle and will wait for 45 minutes for bring out the effects.
89408169|NCT02125578|Experimental|BIIB017 (PEGylated Interferon Beta-1a)|Varying doses (63 mcg up to 188 mcg) of BIIB017 will be administered SC every other week for a total of 6 weeks.
89408170|NCT02125578|Experimental|BIIB017 (PEGylated Interferon Beta-1a) and Placebo|Varying doses (63 mcg up to 188 mcg) of BIIB017 will be administered SC every 4 weeks for a total of 6 weeks. To ensure blinding, each subject will receive placebo every other week.
89408171|NCT02125578|Placebo Comparator|Placebo|Placebo dose will be administered SC every other week for a total of 6 weeks.
89408172|NCT05723744|Experimental|CS6BP , ECG holter and Blood pressure measurements|The investigational device sensors tracings will be compared to the arrhythmia documented in all patients.
89408173|NCT05723666|Experimental|Group watching video with virtual reality glasses|A nature video will be watched with virtual reality glasses.
89408174|NCT05723666|No Intervention|Group not watching video with virtual reality glasses|Virtual reality glasses will not be watched. An intervention will not be applied.
89408175|NCT02122536|Active Comparator|Xeomin right side; Xeomin to left side of face|Patients were randomized as to which side of the face was treated with Xeomin.
89408176|NCT02122536|Active Comparator|Botox right side; Botox to left side|Patients were randomized as to which side of the face was treated with Botox.
88883375|NCT03281369|Experimental|2L-2: Atezo + PEGPH20 (Gastric Cancer)|Participants in the 2L-2 Gastric Cancer arm received atezolizumab in combination with PEGylated recombinant human hyaluronidase (PEGPH20). Participants who progressed on treatment had the option of receiving Atezolizumab + Cobimetinib treatment, provided they met the eligibility criteria. Enrollment completed as of October 2019.
88883376|NCT03281369|Experimental|2L-3: Atezo + BL-8040 (Gastric Cancer)|Participants in the 2L-3 Gastric Cancer arm received atezolizumab in combination with BL-8040. Participants who progressed on treatment had the option of receiving Atezolizumab + Cobimetinib treatment, provided they met the eligibility criteria. Enrollment completed as of October 2019.
88883377|NCT03281369|Experimental|2L-4: Atezo + Linagliptin (Gastric Cancer)|Participants in the 2L-4 Gastric Cancer arm received atezolizumab in combination with linagliptin. Participants who progressed on treatment had the option of receiving Atezolizumab + Cobimetinib treatment, provided they met the eligibility criteria. Enrollment completed as of October 2019.
88883378|NCT03281369|Experimental|1L-1:Atezo+Tiragolumab+Cisplatin+5FU(Esophageal Cancer Cohort)|Participants in the 1L-1 Esophageal Cancer arm will receive atezolizumab in combination with tiragolumab and chemotherapy.
88883379|NCT03281369|Experimental|1L-2: Atezo+Cisplatin+5-FU (Esophageal Cancer Cohort)|Participants in the 1L-2 Esophageal Cancer arm will receive atezolizumab in combination with chemotherapy.
88883380|NCT03281369|Active Comparator|1L-Control: Cisplatin+5-FU (Esophageal Cancer Cohort)|Participants in the 1L-Control Eophageal Cancer arm will receive chemotherapy.
88883381|NCT03281369|Experimental|1L-3: Atezo+Tiragolumab (Esophageal Cancer Cohort)|Participants in the 1L-3 Esophageal Cancer arm will receive atezolizumab + tiragolumab treatment. Participants from the cisplatin + 5-FU esophageal cancer cohort arm may be permitted to enroll in this arm if they progress after receiving chemotherapy.
88883382|NCT03263130||COPD, Emphysema, Asthma-COPD Overlap|Based on clinical, pathologic, laboratory, physiologic and radiologic differences, patient groups can be described.
88883383|NCT03262974||CML patients with MMR|CYP3A5*3 , CYP2C8*3 , ABCG2 421 C>A and SLC22A1 1222A > G SNPs on the plasma level by HPLC-UV and molecular response of imatinib by PCR
88883384|NCT03262974||CML patients without MMR|CYP3A5*3 , CYP2C8*3 , ABCG2 421 C>A and SLC22A1 1222A > G SNPs on the plasma level by HPLC-UV and molecular response of imatinib by PCR
88883385|NCT03016871|Experimental|Cohort A (nivolumab, etoposide, ifosfamide, carboplatin)|Patients receive nivolumab IV over 30 minutes on day 1. Cycles repeat every 14 days for 6 weeks in the absence of disease progression or unacceptable toxicity. Patients with CR or PR receive nivolumab for an additional 6 weeks. Patients with only SD after 6-week nivolumab treatment receive nivolumab for an additional 6 weeks or receive nivolumab IV over 30 minutes on day 1, etoposide IV on days 1-3, ifosfamide IV continuously over 24 hours on day 2, and carboplatin IV on day 2 every 21 days for 6 weeks per physician/investigator's discretion. Patients with PD after 6-week nivolumab treatment or patients with PR, SD, or PD after 12-week nivolumab treatment receive nivolumab IV over 30 minutes on day 1, etoposide IV on days 1-3, ifosfamide IV continuously over 24 hours on day 2, and carboplatin IV on day 2. Treatment repeats every 21 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.
88883386|NCT03016871|Experimental|Cohort B (nivolumab, etoposide, ifosfamide, carboplatin)|Patients receive nivolumab IV over 30 minutes on cycle 1 (cycle 1 is 14 days), day 1 in the absence of disease progression or unacceptable toxicity. Beginning in cycle 2, patients receive nivolumab IV over 30 minutes on day 1, etoposide IV on days 1-3, ifosfamide IV continuously over 24 hours on day 2, and carboplatin IV on day 2. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
88883387|NCT03004443|Experimental|Infliximab|Participants will be randomized to receive one intravenous (IV) infusion of infliximab.
88883388|NCT03004443|Placebo Comparator|Placebo|Participants will be randomized to receive one intravenous (IV) infusion of placebo.
88883389|NCT02869841|Active Comparator|Continuous rectus sheath analgesia|Local anesthetic continuous infusion with infusion pumps
88883390|NCT02869841|Active Comparator|Bolus rectus sheath analgesia|Bolus administration of local anesthetic
88883391|NCT02869841|Active Comparator|Single dose rectus sheath analgesia|single dose administration of local anesthetic
88883392|NCT02869841|Placebo Comparator|Placebo|no rectus sheath analgesia
89408177|NCT03835039||HIE|Infants with a diagnosis of HIE
89408178|NCT00144014|Experimental|V10153, 1.0 mg/kg|Single acute intravenous bolus dose
88883393|NCT02861755|Experimental|Arm 1|The MARIGOLD positive emotions course plus a blend of enhancements to include: 5-minutes of weekly facilitator contact, online discussion board, or gamification through virtual flower badges.
88883394|NCT02861755|Experimental|Arm 2|Emotion reporting control condition. Reporting daily emotions for the same duration of the online emotions course.
88883395|NCT02798029|Experimental|Treatment (FFSRT)|Patients undergo FFSRT daily over 30 minutes for 3-5 days.
88883396|NCT02793492|Experimental|Misago® RX Self-expanding Stent|Eligible participants will undergo stent implantation with the Misago® RX Self-expanding Stent
88883397|NCT02701699|Experimental|18-F-FAZA Scan|All patients enrolled in this study will receive a FAZA PET Scan prior to their first radiation therapy fraction
88883398|NCT02629692|Experimental|Vodobatinib (K0706) capsules|
88883399|NCT02596490|Experimental|Phase 1: Couple-Based Mindfulness Disclosure Group|"Phase 1:~Couples participate in 2 guided meditation sessions. During the sessions, participants do deep breathing and visualization exercises then asked to review the exercises. Participants also asked for feedback about the instructions. Participants complete a written review about the program and a questionnaire about their general health and well-being. Each session will last about 60-90 minutes."
89191344|NCT00721370|Experimental|1|Patients imaged using ICG:HSA and NIR imaging system
89408179|NCT00144014|Experimental|V10153, 2.5 mg/kg|Single acute intravenous bolus dose
89408180|NCT00144014|Experimental|V10153, 5.0 mg/kg|Single acute intravenous bolus dose
89408181|NCT00144014|Experimental|V10153, 7.5 mg/kg|Single acute intravenous bolus dose
89408182|NCT00144014|Experimental|V10153, 10 mg/kg|Single acute intravenous bolus dose
89408183|NCT04573114||Stroke subjects|
89408184|NCT04573114||Healthy|
89408185|NCT03551184|Active Comparator|Endotoxin|Endotoxin 0.6 ng/kg body weight injection
88883400|NCT02596490|Experimental|Phase 2: Couple-Based Mindfulness Disclosure Group|"Phase 2:~Participants complete 12 questionnaires before first meditation and discussion session. Questionnaires ask about participant's health, mood, level of fatigue, sleeping habits, relationship, and their quality of life. It should take about 45 minutes to complete these questionnaires. After completing the last session, about 4 weeks later, participants complete the same questionnaires again. Participants also complete a program review.~Couples participate in 4 guided meditation sessions with a trained meditation instructor. Participants do deep breathing and visualization exercises. All meditation and discussion sessions videotaped.~Participants continue daily meditation practice and some other short exercises at home."
88883401|NCT02596490|Experimental|Phase 3: Couple-Based Mindfulness Disclosure Group|"Participant completes 13 questionnaires before first mediation session, after last session, and again 3 months later. Questionnaires ask about participant's health, any symptoms they may be having, mood, level of fatigue, sleeping habits, their relationship, and their quality of life. Partners complete 12 questionnaires about their health, mood, level of fatigue, sleeping habits, their relationship, and their quality of life. It should take about 45 minutes to complete these questionnaires.~Participant and partner attend meditation class with a trained meditation instructor each week for 4 weeks. Each session will last about 60 minutes total. Meditation and discussion sessions videotaped."
88883402|NCT02596490|Experimental|Phase 3: Cancer-Related Discussion Program Group|"Participant completes 13 questionnaires before first mediation session, after last session, and again 3 months later. Questionnaires ask about participant's health, any symptoms they may be having, mood, level of fatigue, sleeping habits, their relationship, and their quality of life. Partners complete 12 questionnaires about their health, mood, level of fatigue, sleeping habits, their relationship, and their quality of life. It should take about 45 minutes to complete these questionnaires.~Participant and partner take part in a discussion program, 1 discussion session each week for 4 weeks with a trained interventionist. These are one-on-one sessions. Issues discussed for couples coping with cancer. Each session will last about 60 minutes."
88883403|NCT02596490|Other|Phase 3: Attention Control (AC) Group|Participant completes 13 questionnaires at baseline and again 3 months later. Questionnaires ask about participant's health, any symptoms they may be having, mood, level of fatigue, sleeping habits, their relationship, and their quality of life. Partners complete 12 questionnaires about their health, mood, level of fatigue, sleeping habits, their relationship, and their quality of life. It should take about 45 minutes to complete these questionnaires.
88883404|NCT02402920|Experimental|Part A (LS-SCLC, pembrolizumab, chemoradiotherapy)|Patients receive pembrolizumab IV over 30 minutes on day 1 and undergo radiation therapy BID 5 days a week for 3 weeks. Patients also receive cisplatin IV over 2 hours or carboplatin IV over 30 minutes and etoposide IV over 4 hours on days 1, 2, and 3. Treatment repeats every 3 weeks for 16 courses (1 course for radiation therapy, 4 courses for chemotherapy) in the absence of disease progression or unacceptable toxicity. Patients who achieve systemic disease control and do not exhibit severe (grade > 3) pembrolizumab related toxicity during/after completion of 16 courses may receive 16 additional courses of pembrolizumab in the absence of disease progression or unacceptable toxicity.
88883405|NCT02402920|Experimental|Part B (ES-SCLC, pembrolizumab, radiation therapy)|Beginning after the completion of chemotherapy, patients receive pembrolizumab IV over 30 minutes on day 1 and undergo radiation therapy BID 5 days a week for 3 weeks. Treatment repeats every 3 weeks for 16 courses (1 course for radiation therapy) in the absence of disease progression or unacceptable toxicity.
88883406|NCT02315521||Group 1|Fetuses with LUTO before 18 weeks
88883407|NCT02315521||Group 2|Fetuses with LUTO between 18 and 30 weeks
88883408|NCT02315521||Group 3|Fetuses with LUTO between 30 and 34 weeks
88883409|NCT02315521||Group 4|Fetuses with LUTO after 34 weeks
89191345|NCT03566160|Experimental|Cryobiopsy probe as a tool for biopsy|Cryobiopsy probe, administered to study participants.Testing the efficacy of a novel cryobiopsy probe in acquiring tissue samples.
89191346|NCT04067102|Experimental|Nab-paclitaxel Based Regimens|
89191347|NCT04067102|Active Comparator|Paclitaxel Based Regimens|
89408186|NCT03551184|Placebo Comparator|Placebo|Saline injection
89408187|NCT03528200|Other|Dyna Embo|Contrast dye injected through the IV in their arm which helps to see the blood in the arteries using x-ray pictures
89408188|NCT02125656|No Intervention|Regular Sleep|A single night of regular sleep
89408189|NCT02125656|No Intervention|Sleep Deprivation|A single night of sleep deprivation
89408190|NCT02125656|Experimental|HIIT + Regular Sleep|2 weeks of HIIT and after a single night of regular sleep.
89408191|NCT02125656|Experimental|HIIT + Sleep Deprivation|2 weeks of HIIT and after a single night of sleep deprivation
88883410|NCT02277028|Experimental|Bilateral Priming|"Bilateral priming a priming technique which is non-invasive and free of side effects. The technique described in this study uses bilateral, symmetrical, rhythmic movement bilateral priming and its purpose is to ready the motor cortex for functional limb training. A rocker is used so that the less affected limb can drive the affected one in symmetrical wrist flexion and extension.~There are 2 parts to this behavioral intervention. Bilateral priming and task specific training Dosage: 15 minutes of bilateral priming per day 3/days per week for 5/wks. Also 45 minutes of task specific training is delivered 3/days per week for 5/wks. The total of 30 hours of a combination of bilateral priming and task specific training can be completed within 6 weeks.~Dosage frequency 2 times per day. Dosage type: Research participant must perform activities with hands as directed by an occupational therapist"
88883411|NCT02277028|Active Comparator|Health Education|"The group with no priming will receive stroke related health education via a website from the American Heart Association (15 minutes). They will use their affected hand (as they are able) This will be followed by 45 minutes of the same task specific arm training protocol described in the bilateral priming group. This group will follow the same schedule as experimental.~There are 2 parts to this behavioral intervention. Computerized health education training and task specific training Dosage: 15 minutes of health education per day 3/days per week for 5/wks. Also 45 minutes of task specific training is delivered 3/days per week for 5/wks. A total of 30 hours of a combination of computerized stroke health education and task specific training can be completed within 6 weeks.~Dosage frequency 2 times per day. Dosage type: Research participant must perform computerized health education activities with hands as well as task specific training directed by an occupational therapist"
88883412|NCT02273375|Experimental|MEDI4736|MEDI4736 by intravenous infusion. Treatment from Day 1 for a maximum of 12 months or study drug withdrawal if this occurs earlier.
89408192|NCT03830359|Experimental|T2769|T2769 Ophthalmic solution patients treated with 1 drop in each eye 3 to 6 times daily
89408193|NCT04551820||Regular Hours|These subjects have undergone a cholecystectomy during regular hours at the Institution.
89408194|NCT04551820||After Hours|These subjects have undergone a cholecystectomy during after hours at the Institution.
89408195|NCT02127294|Experimental|Transcatheter closure group|Migraine patients with patent foreman ovale (PFO)，who meet the criteria and agree to conduct closure of patent foramen ovale will be selected to this group.
89408196|NCT02127294|No Intervention|Contrast group|Migraine patients with PFO，who meet the criteria but don't agree to conduct closure of patent foramen ovale will be selected to this group.
89408197|NCT04328506|Experimental|T-R cohort under fasted state|Subjects will be administered with one single dose of CM082 tablet (test product) under fasted state, after a wash period of 5 days, the subjects will be administered with one single dose of CM082 tablet (reference product) under fasted state.
88883413|NCT02273375|Placebo Comparator|Placebo|PLACEBO by intravenous infusion. Treatment from Day 1 for a maximum of 12 months or study drug withdrawal if this occurs earlier
88883414|NCT02266212|Active Comparator|Smoke|Fagerstrom test for nicotine dependence
88883415|NCT02266212|Active Comparator|Pain|pain during post-operation Day1 to Day4
88883416|NCT02266212|Active Comparator|Morphine|Morphine consumption during post-operation Day1 to Day4
88883417|NCT02117063|Experimental|Go Girls! Fitness Support Group|
88883418|NCT02113202|Experimental|Tracer dose: 4.5 mg|Patients receive three days before the fluorescence endoscopy procedure (with the near infrared fluorescence endoscopy platform) 4.5 mg of the fluorescent tracer bevacizumab-IRDye800CW.
89191348|NCT00859144|Experimental|BART|Participants will complete the Becoming a Responsible Teen (BART) program.
89408198|NCT04328506|Experimental|R-T cohort under fasted state|Subjects will be administered with one single dose of CM082 tablet (reference product) under fasted state, after a wash period of 5 days,the subjects will be administered with one single dose of CM082 tablet (test product) under fasted state.
89408199|NCT04328506|Experimental|T-R cohort after meal|Subjects will be administered with one single dose of CM082 tablet (test product) after meal, after a wash period of 5 days,the subjects will be administered with one single dose of CM082 tablet (reference product) after meal.
89408200|NCT04328506|Experimental|R-T cohort after meal|Subjects will be administered with one single dose of CM082 tablet (reference product) after meal, after a wash period of 14 days,the subjects will be administered with one single dose of CM082 tablet (test product) after meal
89408201|NCT02127450||Case: NS-CARB positive|Patient with a clinical sample positive for a NS-CARB Enterobacteriaceae
89408202|NCT02127450||Control 1: non-NS-CARB positive|Patient with clinical sample positive for a non-NS-CARB Enterobacteriaceae
89408203|NCT02127450||Control 2 : negative sample|Patient having had clinical sample(s) being stayed negative since the beginning of his admission and up to 3 days after the detection of the case
89408204|NCT03530930|Experimental|Comarum Palustre|Patients taking Comarum Palustre together with conventional treatment for osteoarthritis
89408205|NCT02125812|Placebo Comparator|scaling and root planing|scaling and root planing
89408206|NCT02125812|Experimental|scaling and systemic moxifloxacin|scaling and root planing combined with systemic moxifloxacin
89408207|NCT05120908||Mexican Women|Mexican, premenopausal women ages 18-50.
89408208|NCT05120908||Filipina Women|Filipina, premenopausal women ages 18-50.
89408209|NCT01473199|Experimental|BioPoly RS Implant|BioPoly RS Implant
89408210|NCT02125890|Experimental|Tranexamic Acid|We will be administering Tranexamic Acid in patients with ruptured abdominal aortic aneurysms to determine if this has an effect on primary outcome measures as significant bleeding, blood transfusion requirements.
89408211|NCT03530774|Experimental|Egg while protein supplement|25 g of powdered egg white protein supplement daily for 6 months. Total of 20.6 g of protein in 25 g of supplement.
89408212|NCT03530774|Placebo Comparator|Maltodextrin supplement|25 g of powdered maltodextrin supplement daily for 6 months. Total 23.5 g of carbohydrate in 25 g of supplement.
89408213|NCT05132764|Experimental|MOPs group|Orthodontic treatment will be started in all subjects using fixed preadusted edgewise appliance (0.022-in MBT prescription, Ortho Organizers, Inc. USA).Local anesthesia will be given in lower arch .Two points for screw insertion will be demarcated on buccal mucosa, in each interdental segment using a calibrated periodontal probe. Orthodontic miniscrew (AbsoAnchor, Korea) of 1.3 mm diameter will be used for MOPs to the depth of 2-3 mm into the buccal cortical bone. An endodontic rubber stopper will be set for required / optimal depth on miniscrew and MOPs will be performed. After the intervention, the patients will be instructed for maintaining good oral hygiene and to take analgesics, such as acetaminophen, only if necessary.
89408214|NCT05132764|No Intervention|Control group|Orthodontic treatment will be started in all subjects using fixed preadusted edgewise appliance (0.022-in MBT prescription, Ortho Organizers, Inc. USA).The control group will receive no MOPs at the alignment stage.
89408215|NCT03551418|Experimental|Repetitive video watching|Repetitively watching a video of an adult with Down Syndrome washing his hands
89408216|NCT05287984|Experimental|ZFCR regimen|Patients aged 65 years or younger who can tolerate FCR： Patients in this group will receive zanubrutinib monotherapy for 12 months, then receive 4 cycles of zanubrutinib, fludarabine, cyclophosphamide and rituximab(ZFCR). Efficacy evaluation and MRD test of peripheral blood and bone marrow were performed at the 17th cycle after 16 cycles to obtain study end point data. Patients with CR/CRi and MRD negative could stop taking zanubrutinib, and other patients could stop taking zanubrutinib or continue treatment. Follow-up and efficacy assessment were conducted every three months.
88883419|NCT02113202|Experimental|Tracer dose: 10 mg|Patients receive three days before the fluorescence endoscopy procedure (with the near infrared fluorescence endoscopy platform) 10 mg of the fluorescent tracer bevacizumab-IRDye800CW.
88883420|NCT02113202|Experimental|Tracer dose: 25 mg|Patients receive three days before the fluorescence endoscopy procedure (with the near infrared fluorescence endoscopy platform) 25 mg of the fluorescent tracer bevacizumab-IRDye800CW.
88883421|NCT01999062|Experimental|IMRT + CT + MR scan|
88883422|NCT01811043|Experimental|Guided Meditation|Guided meditation is played via headphones during biopsy
88883423|NCT01811043|Active Comparator|Music|Music is played via headphones during biopsy
88883424|NCT01811043|Placebo Comparator|Supportive Dialogue|Supportive dialogue is provided during biopsy by the radiologist performing the procedure
88883425|NCT01803542|Experimental|SBRT|High dose of radiation will be used to treat tumours.
88883426|NCT01781468|Experimental|Arm I|Patients receive 150 mg armodafinil orally every day in the morning for 8 weeks.
88883427|NCT01781468|Placebo Comparator|Arm II|Patients receive placebo orally every day in the morning for 8 weeks.
88883428|NCT01781468|Experimental|Arm III|Patients receive 250 mg armodafinil orally every day in the morning for 8 weeks.
88883429|NCT01709045||Patients scheduled for CEA|All patients who are scheduled for carotid endarterectomy (CEA)
88883430|NCT01545141|No Intervention|Surgery only|Surgical resection only, performed as standard of care for the disease
88883431|NCT01545141|Experimental|Chemokin Modulatory Regimen (5 MU/m2)|"Chemokine Modulatory Regimen monday through Friday prior to surgery:~400 mg celecoxib for 5 days IFN by intravenous infusion (IV) (Phase 1 dose escalation of 5 MU/m2) for 5 days Rintatolimod 200 mg by IV infusion for 5 days"
89408217|NCT05287984|Experimental|ZBR regimen|For patients older than 65 years or who cannot tolerate FCR regimens: Patients in this group will receive zanubrutinib monotherapy for 12 months, then receive 4 cycles of bendamostine and rituximab(BR). Efficacy evaluation and MRD test of peripheral blood and bone marrow were performed at the 17th cycle after 16 cycles to obtain study end point data. Patients with CR/CRi and MRD negative could stop taking zanubrutinib and other patients could stop taking zanubrutinib or continue treatment.
88883432|NCT01545141|Experimental|Chemokin Modulatory Regimen (10 MU/m2)|"Chemokine Modulatory Regimen monday through Friday prior to surgery:~400 mg celecoxib for 5 days IFN by intravenous infusion (IV) (Phase 1 dose escalation of 10 MU/m2) for 5 days Rintatolimod 200 mg by IV infusion for 5 days"
88883433|NCT01545141|Experimental|Chemokin Modulatory Regimen (20 MU/m2)|"Chemokine Modulatory Regimen monday through Friday prior to surgery:~400 mg celecoxib for 5 days IFN by intravenous infusion (IV) (Phase 1 dose escalation of 20 MU/m2) for 5 days Rintatolimod 200 mg by IV infusion for 5 days"
88883434|NCT01500798|Placebo Comparator|Placebo|
88883435|NCT01500798|Experimental|Bardoxolone methyl|
88883436|NCT01428895|Active Comparator|Surgery Alone|
88883437|NCT01428895|Active Comparator|Surgery + Radiation Therapy|
88883438|NCT01422759|Experimental|spironolactone|12 weeks spironolactone with pre- and post-intervention dexamethasone, and ACTH to perform standardized adrenal stimulation testing; dexamethasone and rhCG to perform standardized ovarian stimulation testing
88883439|NCT01421797|Experimental|Dexamethasone, Cortrosyn|Dexamethasone given 1 mg PO Cortrosyn given single IV bolus 0f 0.25 mg
88883440|NCT01404741|Active Comparator|5-azacytidine treatment until progress|5-azacytidine until progress
88883441|NCT01404741|Experimental|allogeneic stem cell transplantation|after 4 cycles 5-azacytidine and if donor available: allogeneic stem cell transplantation after reduced intensity conditioning
88883442|NCT01335022|Experimental|Cardiovascular Disease Education|6 lectures on cardiovascular disease were given over a 2 month time period
88883443|NCT00957450||1|"Impact of organ motion~Characterize the impact of normal organ motion in the pelvic on tumour movement, during treatment. This will be assessed in patients with pelvic cancer."
88883444|NCT00944528|Experimental|Single dose radiosurgery: Dose Level 1|A single 15 Gy dose of radiation given in radiosurgery technique about 10 days before lumpectomy.
88883445|NCT00944528|Experimental|Single dose radiosurgery: Dose Level 2|A single 18 Gy dose of radiation given in radiosurgery technique about 10 days before lumpectomy.
88883446|NCT00944528|Experimental|Single dose radiosurgery: Dose Level 3|A single 21 Gy dose of radiation given in radiosurgery technique about 10 days before lumpectomy.
88883447|NCT00937248|Experimental|Interventional|Patient randomized to be immobilized using a prone pillow and simple ankle fixation device with a CVID.
88883448|NCT00937248|Active Comparator|Standard Arm|Patient randomized to be immobilized using a prone pillow and simple ankle fixation device without a CVID
88883449|NCT00881660|Experimental|Fetal Endotracheal Occlusion|Placement and retrieval of the GoldBAL4 or GoldBal2 Detachable balloon using the plug/unplug method, using BALTACCIDBPE100 Delivery Catheter.
88883450|NCT00857662|Experimental|Onyx|
88883451|NCT00857662|Active Comparator|TRUFILL|
88883452|NCT00777998|Experimental|A|Auto-Allo Tandem Stem cell Transplantation plus maintenance therapy with Thalidomide and DLI
88883453|NCT00777998|Active Comparator|B|Auto-Auto Tandem stem cell Transplantation plus maintenance therapy with Thalidomide
88883454|NCT00188539|Experimental|Pre-treatment tumour oxygen measurements (under anesthesia)|
88883455|NCT04453449||No sedation|Patients who will undergo the diagnostic lumbar medial branch blocks without sedation (control group).
88883456|NCT04453449||Sedation|Patients who will undergo the diagnostic lumbar medial branch blocks with midazolam sedation (treatment group).
88883457|NCT04366336|Experimental|Blood Flow Restriction Training|"Blood flow restriction training (BFRT) uses a specialized tourniquet system to restrict arterial inflow and venous outflow to the limb during low-load resistance exercise.~BFRT involves placing the pressure cuff before the start of therapeutic exercises.~Therapeutic exercise, including but not limited to: movement re-education, balance, and functional strength training; Manual Physical Therapy including but not limited to passive range of motion (therapist will move your knee without your help), joint mobilization, soft-tissue mobilization and static stretching"
88883458|NCT04366336|Active Comparator|Standard Physical Therapy|Subjects will receive American College of Sports Medicine guided-strength training Therapeutic exercise, including but not limited to: movement re-education, balance, and functional strength training; and Manual Physical Therapy including but not limited to passive range of motion (therapist will move your knee without your help), joint mobilization, soft-tissue mobilization and static stretching
88883459|NCT04364867|Experimental|Exparel|Single shot Exparel 10cc (133mg) mixed with 10cc of 0.5% Bupivicaine
88883460|NCT04364867|Active Comparator|Pain pump|Subject will receive an interscalene block with Ropivicaine 0.5% (20cc), and then a pain pump attached in the PACU infusing at 4cc/hr. The patient will go home with that device until it runs out.
88883461|NCT04347343|Experimental|COMBO|Neuromuscular Electrical Stimulation and Blood Flow Restriction (COMBO) in addition to standard postoperative rehabilitation.
88883462|NCT04340739||Cohort 1 (8 Patients)|A wireframe mock-up of the GEMINI platform will be usability tested by 8 chronic pain patients from whom feedback will be collected by completing a virtual semi-structured interview. Outcomes: Quantitative Testing Data from Usability Testing Prompt. Qualitative data collected as feedback from semi-structured interview using the Usability Test Moderator Guide.
89408218|NCT05132608|Experimental|Social Media|social media based health education program developed using Health belief model
89408219|NCT05132608|No Intervention|Usual care|physical assessment of maternal and foetal wellbeing, screening, treatment, and receiving preventive measures
89408220|NCT02122614|Experimental|Experimental group|
88883463|NCT04340739||Cohort 2 (16 Patients)|"A live version of GEMINI will be beta-tested by 16 chronic pain patients through completing a faux medical group visit (MGV). This will include things like exploring the education topics available, interacting with the other participating patients, and interacting with a medical provider posing as the faux group's health care provider, all in order to robustly test the system in a live environment. Outcomes: Quantitative Testing/User Experience Data from Usability Testing Prompt, System Usability Scale, Perceived Feature Usefulness Scale, and the Technology Acceptance Model Based Survey. Qualitative data collected as feedback from semi-structured interview using the Usability Test Moderator Guide."
88883464|NCT04340739||Cohort A (8 Healthcare Providers)|Eight healthcare providers will be divided into pairs, and these pairs will each conduct a faux medical group visit (MGV) with faux patients (staff will pose as patients). They will be asked to complete the faux session as if it were actual patients of theirs, conduct pre- and post-session tasks, and provide usability feedback on the platform. Outcomes: Quantitative Testing/User Experience Data from Usability Testing Prompt, System Usability Scale, Perceived Feature Usefulness Scale, and the Technology Acceptance Model Based Survey. Qualitative data collected as feedback from semi-structured interview using the Usability Test Moderator Guide.
88883465|NCT04333888|Experimental|Treatment|
88883466|NCT04333888|No Intervention|Control|
88883467|NCT04283071||Patient|Progressive MS patients administered clinical examination measures including EDSS, nine-hole PEG test, patient reported outcomes measures and kinematic assessment of upper limb function
88883468|NCT04283071||Control|Healthy volunteers administered nine-hole PEG test and kinematic assessment of upper limb function
88883469|NCT04233814|Sham Comparator|Placebo|Matching placebo is a micronized lactose powder administered by inhalation through a dry powder inhaler (DPI)
88883470|NCT04233814|Experimental|SAD Cohort 1|LTI-03 20 mg delivered qd x 1 day via DPI
88883471|NCT04233814|Experimental|SAD Cohort 2|LTI-03 40 mg delivered qd x 1 day via DPI
88883472|NCT04233814|Experimental|SAD Cohort 3|LTI-03 80 mg delivered qd x 1 day via DPI
88883473|NCT04233814|Experimental|MAD Cohort 1|LTI-03 dose at 20mg once daily x 14 days via DPI
88883474|NCT04233814|Experimental|MAD Cohort 2|LTI-03 dose at 40mg once daily x 14 days via DPI
88883475|NCT04233814|Experimental|MAD Cohort 3|LTI-03 dose at 2.5 mg once daily x 14 days via DPI
88883476|NCT04233814|Experimental|MAD Cohort 4|LTI-03 dose at 5 mg once daily x 14 days via DPI
88883477|NCT04233814|Experimental|MAD Cohort 5|LTI-03 dose at 5 mg twice daily x 14 days via DPI
88883478|NCT04232059|Active Comparator|Group 1: hyperventilation|• Group 1: hyperventilation (ETco2 25-30 mm Hg) for 20 minutes that will start immediately after skin incision followed by normoventilation (ETco2 31-35 mm Hg) for another 20 minutes.
88883479|NCT04232059|Active Comparator|Group 2: normoventilation|• Group 2: normoventilation (ETco2 31-35 mm Hg) for 20 minutes immediately after skin incision followed by hyperventilation (ETco2 25-30 mm Hg) for another 20 minutes.
88883480|NCT04212286|Experimental|Diagnostic CEUS and EOB-MRI|Patients with high risk of HCC having suspicious lesions with Diameters ≤ 2cm will receive CEUS and EOB-MRI examinations.
88883481|NCT04023162|Experimental|Biomedical (Physiotherapy) group|Therapy Exercise and Back School; 8 sessions during 4 weeks (2 times a week), with one session lasting 60 min.
89191349|NCT00859144|Experimental|Reducing the Risk|Participants will complete the Reducing the Risk program.
89191350|NCT00859144|Active Comparator|Be Proud Be Responsible|Participants will complete the Be Proud! Be Responsible! program.
89191351|NCT04067154|Experimental|ALPE-TAC|ARDS patients on mechanical ventilation. Measurement of CT scan at PEEP of 5, 20 and 45 cm H2O to evaluate potential for recruitment and measurement of gas exchange by model-based method and FiO2 titration at PEEP of 5 and 20 cm H2O
89408221|NCT02122614|Active Comparator|Control group|
89408222|NCT05285800|Experimental|Saddle group|After administration of 12mg of 0.5 % Hyperbaric Bupivacaine intrathecally, Patient is advised to remain in Sitting position for the next 5minutes and then take supine position
88883482|NCT04023162|Experimental|Biopsychosocial (Graded Activity) group|Operant Conditioning implement in Physiotherapy, Therapy Exercises and Back School; 8 sessions during 4 weeks (2 times a week), with one session lasting 60 min.
89408223|NCT05285800|Active Comparator|Spinal group|After administration of 12mg of 0.5% Hyperbaric Bupivacaine intrathecally, Patient is advised to take Supine position immediately.
89408224|NCT02122692|Experimental|Lu AE58054 30 mg + itraconazole 200 mg|
89408225|NCT03627247|Experimental|Cognitive Behavioral Stress Management|Women randomized to CBSM participated in an eight-week prenatal course called SMART Moms (Stress Management and Relaxation Training for Moms) aimed at teaching coping and relaxation skills that address stressors and daily challenges experienced during pregnancy and motherhood.
89408226|NCT03627247|No Intervention|Attention Control Group|"Women randomized to the AC group participated in an eight-week program where they received printed materials (offered in Spanish and English) by mail once per week, on common prenatal health information topics (e.g., common discomforts of pregnancy, labor and delivery) chosen from the March of Dimes Foundation's Becoming a Mom handouts (March of Dimes, 2011). Women in this group were contacted once per week by phone by a research staff member to make sure that they received their mailed prenatal health information and to see if they had any questions."
89408227|NCT05285722|Other|dental anxiety group|"Children,~Aged 5-15 years~Having dental anxiety but not having negative experiences during dental treatment in childhood or adolescence~Without any systemical and mental diasabilities~Who volunteered to participate in the study and whose parental consent was obtained."
88883483|NCT04023162|No Intervention|Usual care|Usual care and written instructions on Therapy Exercise and Back School for self-care.
88883484|NCT04002388|Experimental|Activity Monitor Group|This arm will receive a FitBit and will be asked to wear this for one year
88883485|NCT04002388|Active Comparator|Usual Care Group|The usual care group will NOT receive a FitBit
88883486|NCT03993821|Experimental|Burosumab|Burosumab, which is FDA-approved for X-linked hypophosphatemic rickets, will be given monthly, for a total of 12 months and titrated to achieve a target fasting serum phosphorus level within normal range for age. The chosen starting dose of burosumab will be 0.3 mg/kg given SQ Q4W. The maximum dose allowed in this protocol is 2.0 mg/kg. Burosumab will be administered via subcutaneous (SC) route.
88883487|NCT03964545|Experimental|EFP neurofeedback|Ten sessions of EFP neurofeedback training. EEG is picked up with scalp electrodes, processed in real-time and returned to patients. One session lasts 30 min.
88883488|NCT03964545|No Intervention|Treatment as usual|Like patients from the treatment arm, these patients are on current residential treatment.
88883489|NCT03871751|Experimental|Safe and Sound Protocol|All child participants will participate in 1 pre-intervention assessment and 1 post-intervention assessment. The auditory intervention (i.e., Safe and Sound Protocol, SSP) will last for 1 hour per day, for 5 consecutive days.
88883490|NCT03735849|No Intervention|Pre-treatment|Biopsy collected but was not randomized to any treatment group
88883491|NCT03735849|Experimental|Group 1: VRC07-523LS|Participants will receive 10 mg/kg of VRC07-523LS at Weeks 0, 16, and 32.
88883492|NCT03735849|Experimental|Group 2: VRC07-523LS|Participants will receive 30 mg/kg of VRC07-523LS at Weeks 0, 16, and 32.
88883493|NCT03691857|Other|Acute non-traumatic dyspnea patients|Patients with acute non-traumatic dyspnea managed in the emergency department to assess the diagnostic accuracy of an ultrasound algorithm (EMERALD-US) dedicated to emergencies using lung, cardiac and vascular ultrasound for the 3 main dyspnea causes (heart failure, pneumonia and obstructive pulmonary disease exacerbation)
88883494|NCT03663361|Experimental|SMART Intervention|"The SMART intervention will utilize the elements of the Standard of Care intervention, and will also include Sensorimotor Improvements and other specific additions that will focus on sensory inputs, motor outputs, and integration of the sensory and motor pathways."
88883495|NCT03663361|Active Comparator|Standard of Care Intervention|The Standard of Care intervention will include restoration of ankle joint range of motion, strength and functional movement.
88922018|NCT05972174|Experimental|Part B Group 1 Vaccine: mRNA-1018 for H5 Only-CG Dose Level 1|Participants will receive mRNA-1018 for H5 Only-CG at dose level 1 by IM injection on Day 1 and Day 22.
89191352|NCT05311202|Experimental|low-volume moderate-intensity group|Participants will attend the trainer-supervised resistance exercise program for 30 minutes
89191353|NCT05311202|Experimental|moderate-volume moderate-intensity group|Participants will attend the trainer-supervised resistance exercise program for 40 minutes
89191354|NCT05311202|Experimental|high-volume moderate-intensity group|Participants will attend the trainer-supervised resistance exercise program for 50 minutes
89191355|NCT05311202|Experimental|moderate-volume low-intensity group|Participants will attend the trainer-supervised resistance exercise program for 45 minutes
89191356|NCT05311202|Experimental|Control group|Reading for 40 minutes
89191357|NCT00859300||1|500 patients with ventricular fibrillation at the acute phase of myocardial infarct
89191358|NCT00859300||2|500 patients without ventricular fibrillation at the acute phase of myocardial infarct.
89408228|NCT02122848|Experimental|Bilevel|The intervention will be performed using BiLevel ventilation mode with EPAP=10 cmH2O and a IPAP which manages 6-8ml/kg tidal volume.
89408229|NCT05707039|Experimental|Open chain kinetic exercises|In open chain exercises extremities are free to move and there is no weight bearing. Subjects performed group of exercises, 3sets of 10 repetitions for each exercise after warm-up and stretching exercises The open kinetic chain exercise program consisted of 1) maximal static quadriceps muscle contractions
88883496|NCT03572621|Experimental|Experimental group|Patients in the experimental group are offered to participate in a 6-session therapeutic education program on sexuality, ranging from 15 days before surgery to approximately 3 months after. This in addition to the current care by the teams of care about sexual rehabilitation (information and medication prescriptions).
88883497|NCT03572621|Sham Comparator|Control group|Patient without therapeutic education.
88883498|NCT03572621|Other|Partner|Patient's partner.
88883499|NCT03552393|Experimental|Mircera|Mircera will be administered subcutaneously once every 4 weeks
88883500|NCT03524170|Experimental|Treatment (M7824, radiation therapy)|Patients receive M7824 IV over 1 hour every 14 days. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Beginning within 3 days after second dose of M7824, patients undergo radiation therapy QD for 5-10 days depending on the site of disease in the absence of disease progression or unacceptable toxicity.
88883501|NCT03490331|Experimental|Genetically corrected cultured epidermal autograft|"The surgery will be carried out in 2 stages, the first aims at taking biopsy to isolate epidermal cells including stem cells. The biopsy will be processed in a laboratory of a regenerative medicine manufacturing site where they will be corrected, expanded and prepared as final sheets to be implanted.~In the second surgery, genetically corrected cultured epidermal autograft (Hologene17) will be implanted into the selected area. The specialist surgeon will either use a local or general anaesthetic for the implant operation. The treated area will be immobilized for some days after this operation. Antibiotics and anti-inflammatory drugs will be administered (if necessary) to prevent infections and to minimise swelling."
88883502|NCT03336983|Other|LHRH-A + Enzalutamide|Prostate cancer patients with hormone sensitive metastatic bone disease will be treated with LHRH-A + Enzalutamide until patient's progression, consent withdrawal or unacceptable toxicity
88883503|NCT03336983|Experimental|LHRH-A + Enzalutamide + Zoledronic Acid|Prostate cancer patients with hormone sensitive metastatic bone disease will be treated with LHRH-A + Enzalutamide + Zoledronic Acid until patient's progression, consent withdrawal or unacceptable toxicity
88883504|NCT03333382|Active Comparator|Plastic Biliary Stent|Subjects with anastomotic bile leaks following orthotopic liver transplant (OLT) will have a temporary plastic biliary stent placed across the site of the leak during retrograde cholangiopancreatography (ERCP).
88883505|NCT03333382|Active Comparator|FCSEMS|Subjects with anastomotic bile leaks following orthotopic liver transplant (OLT) will have a temporary fully covered self-expanding metal stent (FCSEMS) placed across the site of the leak during retrograde cholangiopancreatography (ERCP).
88883506|NCT03283813|Active Comparator|Active group - Zinc and Myo-inositol|This arm will receive a supplementation with Zinc and Myo-inositol once a day.
88883507|NCT03283813|Placebo Comparator|Placebo group|This arm will receive a supplementation with a same product equal to the active product but without Zinc and Myo-inositol inside.
88883508|NCT03283657|Experimental|DiRECT|DiRECT consists of the following components that will be delivered by medical assistants before patients' routinely scheduled office visits: 1) a prediabetes decision aid focused on type 2 diabetes (T2D) risk and treatment options for preventing T2D; 2) a 'think aloud' exercise; and 3) formulating a preliminary treatment plan for T2D prevention.
88883509|NCT03283657|Active Comparator|Usual Care (UC)|Participants randomized to standard care will receive routine medical care without the medical assistant delivered DiRECT intervention.
89191359|NCT05659290|Experimental|Arm A|Efficacy of Fruquintinib alternating Bevacizumab plus Capecitabine as maintenance therapy after first-line treatment
89191360|NCT05659290|Active Comparator|Arm B|Efficacy of Bevacizumab plus Capecitabine as maintenance therapy after first-line treatment
88883510|NCT03262519||Patients at UCSD Sleep Medicine Clinic|Patients referred for sleep testing (either home sleep testing or in-lab full polysomnography) will be approached for participation.
88883511|NCT03245827|Active Comparator|Obese males with hypogonadism-active|Subjects will be randomized to receive clomiphene capsules
88883512|NCT03245827|Placebo Comparator|Obese males with hypogonadism-placebo|Subjects will be randomized to receive placebo capsules
88883513|NCT03245827|No Intervention|Obese males with normal testosterone|comparison group
88883514|NCT03245827|No Intervention|lean males with normal testosterone|comparison group
88883515|NCT03169231|Experimental|Study Group A|Single peripheral IV infusion of 25 million Longeveron Mesenchymal Stem Cells (LMSCs)
88883516|NCT03169231|Experimental|Study Group B|Single peripheral IV infusion of 50 million Longeveron Mesenchymal Stem Cells (LMSCs)
88883517|NCT03169231|Experimental|Study Group C|Single peripheral IV infusion of 100 million Longeveron Mesenchymal Stem Cells (LMSCs)
88883518|NCT03169231|Experimental|Study Group D|Single peripheral IV infusion of 200 million Longeveron Mesenchymal Stem Cells (LMSCs)
88883519|NCT03169231|Placebo Comparator|Study Group E|Single peripheral IV infusion of placebo.
88883520|NCT03129321|Experimental|Test|Econazole Nitrate Cream, 1%, topical, sufficient amount to cover all affected areas on the feet once daily for 28 days
88883521|NCT03129321|Active Comparator|Reference Standard|Econazole Nitrate Cream, 1%, topical, sufficient amount to cover all affected areas on the feet once daily for 28 days
88883522|NCT03129321|Placebo Comparator|Placebo|Placebo Cream, topical, sufficient amount to cover all affected areas on the feet once daily for 28 days
88883523|NCT03107611|Experimental|Test|Pimecrolimus Cream, 1%, topical, thin layer applied to all affected skin areas twice daily for 14 days
88883524|NCT03107611|Active Comparator|Reference Standard|Pimecrolimus Cream, 1%, topical, thin layer applied to all affected skin areas twice daily for 14 days
88883525|NCT03107611|Placebo Comparator|Placebo|Placebo cream, topical, thin layer applied to all affected skin areas twice daily for 14 days
88883526|NCT02988544|Experimental|Artificial shrinkage (AS) group|The Artificial shrinkage group where blastocoelic cavity is artificially reduced by a laser pulse prior to transfer
88883527|NCT02988544|No Intervention|Control group|No intervention on blastocoelic
88883528|NCT02880774|Experimental|Mandibular Nonspecific mobilization|GA: Mandibular Nonspecific mobilization on the region of the face with presence of TMD.
89408230|NCT05707039|Experimental|Closed Chain Kinetic Exercises|In closed kinetic chain exercises extremities are fixed and weight bearing is done. Subjects performed group of exercises, 3sets with 10 repetitions for each exercise after warm up and stretching exercises. The closed kinetic chain exercise program consisted of 1) seated leg presses, 2) one-third knee bends on one leg and on both legs, 3) stationary bicycling, 4) rowing-machine exercises, 5) step-up and step-down exercises. Each exercise in the closed kinetic chain protocol was performed dynamically with a 3-second rest between repetitions.
89408231|NCT04270786|Experimental|Early de-escalation|In the experiment arm, empirical antibiotics will be stopped and levofloxacin prophylaxis will be resumed in case of afebrile after 72 hours.
89408232|NCT04270786|Other|Standard|In the control group, empirical antibiotics will be continue until recovery of neutropenia or at least 7 days as standard clinical practice.
89408233|NCT05132530|Experimental|Intervention Gruop|"Experimental: İntervention Group~Yoga practice will be practiced 2 days a week for 10 weeks."
89408234|NCT05132530|No Intervention|Control Group|no intervention
88883529|NCT02880774|Placebo Comparator|ultrasound detuned|Group B: Used ultrasound equipment detuned on the region of the face with presence of TMD.
88883530|NCT02801136|Experimental|ReACT for PNES|ReACT consists of 8 weekly sessions of therapy focused on teaching adolescents to regain control of their body through managing thoughts and behaviors that reinforce the PNES and return to previous activities. It teaches parents how to respond to PNES in a manner that encourages the adolescents to regain control of their body. The PNES is explained as behaviors learned through classical and operant conditioning .
88883531|NCT02801136|Active Comparator|Supportive Therapy|The supportive therapy treatment consists of 8 weekly sessions of therapy focused on discussing daily difficulties and/or stressors they experience and identifying stress triggers for PNES. The PNES is explained as physical manifestations of psychological stress.
88883532|NCT02801136|No Intervention|Healthy Control|Healthy controls are matched to patients with PNES based on age (+ or - 1 year), gender, race and family income. They come to one laboratory visit to complete initial visit questionnaires and computer tasks.
88883533|NCT02798588|Experimental|Comatose patients in ICU|
88883534|NCT02720016|Experimental|CBCT-Home Based (CBCT-HB)|Couples in CBCT-HB will receive 8 sessions of standardized Cognitive-Behavioral Conjoint Therapy (CBCT), a manualized couple-based intervention for PTSD designed to simultaneously reduce PTSD and enhance relationship and functioning. The psychotherapy is administered over 8 to 15 weeks to the Veterans home via home-based clinical video teleconferencing (CVT).
88883535|NCT02720016|Active Comparator|CBCT-Office Based (CBCT-OB)|Couples in CBCT-OB will receive 8 sessions of standardized Cognitive-Behavioral Conjoint Therapy (CBCT), a manualized couple-based intervention for PTSD designed to simultaneously reduce PTSD and enhance relationship and functioning. The psychotherapy is administered over 8 to 15 weeks in-person in the therapist's office.
88883536|NCT02720016|Active Comparator|PTSD Family Education (PFE)|Couples in the PFE condition will receive 8 sessions of standardized PTSD Family Education, a manualized psychoeducational program designed to help couples learn more about posttraumatic stress disorder and related difficulties. This psychotherapy is administered over 8 to 15 weeks and is delivered in-person in the therapist's office.
89408235|NCT02126046|Other|Hi-HSC-CBT|
89408236|NCT05132452||adults living in the community|Healthy community dwelling participants, aged 20 year old and above, without dysphagia.
89408237|NCT02127606|Experimental|Vibration with tilt-table standing|Participants in this arm will undergo alternating side-to-side, whole body vibration while standing on a tilt table for multiple treatments for a total of approximately 14 minutes for 3 sessions over 3 different days
88883537|NCT02607956|Experimental|B/F/TAF|B/F/TAF + DTG + F/TAF placebo administered without regard to food for at least 144 weeks.
88883538|NCT02607956|Active Comparator|DTG + F/TAF|DTG + F/TAF+ B/F/TAF placebo administered without regard to food for at least 144 weeks.
88883539|NCT02607956|Experimental|Open-label Phase B/F/TAF from B/F/TAF|After Week 144, participants will continue to take their blinded study drug and attend visits every 12 weeks until the End of Blinded Treatment Visit. Following the End of Blinded Treatment Visit, participants will be given the option to receive open-label (OL) B/F/TAF for 96 weeks. After the Week 96 OL Visit, participants in a country where B/F/TAF is not commercially available will be given the option to continue OL B/F/TAF until the product becomes accessible through an access program or until Gilead elects to discontinue the study in that country, whichever occurs first.
89408238|NCT05284630|Active Comparator|Experimental Group|Exercise follow up with mobile application in patients with chronic neck pain five sessions a week for 4 weeks
89408239|NCT05284630|Active Comparator|Control Group|Home based exercise follow up him/herself in patients with chronic neck pain five sessions a week for 4 weeks
88883540|NCT02607956|Experimental|Open-label Phase B/F/TAF from DTG + F/TAF|After Week 144, participants will continue to take their blinded study drug and attend visits every 12 weeks until the End of Blinded Treatment Visit. Following the End of Blinded Treatment Visit, participants will be given the option to receive OL B/F/TAF for 96 weeks. After the Week 96 OL Visit, participants in a country where B/F/TAF is not commercially available will be given the option to continue OL B/F/TAF until the product becomes accessible through an access program or until Gilead elects to discontinue the study in that country, whichever occurs first.
89408240|NCT02126124|Active Comparator|Active dTMS Treatment|Brainsway Deep TMS Treatment
89408241|NCT02126124|Sham Comparator|Sham Treatment|Brainsway Sham Treatment
89531043|NCT02498327|Placebo Comparator|Gelatine Capsules|Gelatine capsules containing only inactive ingredients (starch amyral white, di-calcium phosphate DC and magnesium stearate fine), will be taken once per day, in the morning after breakfast, for 30 days. These capsules will be of identical appearance to the experimental comparator.
89408242|NCT05284474|No Intervention|Control|"Small fetuses will be classified into 5 severity stages and managed as follows:~SGA: Estimated fetal weight (EFW) between p3 and p10 with normal Dopplers. Ultrasound/2 weeks, elective vaginal delivery at ≥39-40 weeks.~Stage I: EFW ≤p3 p or EFW p3-10 + UA PI >p95 and/or UtA PI >p95, and, at ≥32 weeks, CPR and/or MCA PI <p5, in 2 occasions >12 hours apart. Ultrasound weekly, elective vaginal delivery at ≥37 weeks.~Stage II: AEDF UA in 2 occasions >12 hours apart. Ultrasound every 48-72h, elective Cesarean delivery at ≥34 weeks. Fetal lung maturation at ≥ 33 weeks.~Stage III: DV PI > p95 (or absent DV a wave) or reversed end-diastolic UA >50% of cycles, in both cases in two occasions > 6 hours apart. Ultrasound every 24-48h, elective Cesarean delivery at ≥30 weeks. Fetal lung maturation at ≥ 28 weeks.~Stage IV: reversed DV a wave in two occasions > 6 hours apart. Elective Cesarean delivery at ≥26 weeks. Fetal lung maturation at ≥ 25+5 weeks."
88883541|NCT02564523|Experimental|Group 1|Participants will receive Ad26.ZEBOV, MVA-BN-Filo (Day 1/Day 29) or placebo (Day 1/Day 29) followed by a subset of participants who received Ad26.ZEBOV and MVA-BN-Filo (at selected sites) will receive Ad26.ZEBOV as third vaccination and who received placebo will receive placebo as third vaccination (at least 1 year post prime vaccination).
88883542|NCT02564523|Experimental|Group 2|Participants will receive Ad26.ZEBOV, MVA-BN-Filo (Day 1/Day 57) or placebo (Day 1/Day 57) followed by a subset of participants who received Ad26.ZEBOV and MVA-BN-Filo (at selected sites) will receive Ad26.ZEBOV as third vaccination and who received placebo will receive placebo as third vaccination (at least 1 year post prime vaccination).
88883543|NCT02564523|Experimental|Group 3|Participants will receive Ad26.ZEBOV, MVA-BN-Filo (Day 1/Day 85) or placebo (Day 1/Day 85)
88883544|NCT02560961|Experimental|Kinesio Taping protocol - Group A|Kinesio Taping (Kinesio Tex Gold®; color: black) will be applied by an experienced, duly trained researcher. The technique described by Kase [1] for activation of the triceps surae on the dominant leg will be employed, with the volunteer in the prone position, maintaining the dominant leg off the cot with hip extension, knee extension and ankle dorsiflexion to maintain the triceps surae in a stretched position. The tape will be applied in a Y shape beginning with the origin of the muscle (femur condyles) without tension (Anchor I), passing over the belly of the muscle (therapeutic region) with 15 to 20% tension and ending near the posterior surface of the heel (Anchor II) without tension.
88883545|NCT02560961|Placebo Comparator|Placebo Taping - Group B|Standard white bandaging tape will be applied by the same researcher who placed the tape in Group A. The technique described by Kase [1] for activation of the triceps surae on the dominant leg will be employed, with the volunteer in the prone position, maintaining the dominant leg off the cot with hip extension, knee extension and ankle dorsiflexion to maintain the triceps surae in a stretched position. The tape will be applied in a Y shape beginning with the origin of the muscle (femur condyles) and ending near the posterior surface of the heel.
88883546|NCT02499666||Asymptomatic|Patients with known chronic total occlusion who are undergoing percutaneous coronary intervention wtih balloon angioplasty and coronary stent placement who are currently asymptomatic (without any chest pain or anginal equivalent) but have decreased exercise capacity or are easily fatigued. Patients will also be on dual antiplatelet therapy with aspirin and a second agent such as clopidogrel.
88883547|NCT02499666||Symptomatic|Patients with known chronic total occlusion who are undergoing percutaneous coronary intervention with balloon angioplasty and coronary stent placement who are currently symptomatic with chest pain or anginal equivalent.. Patients will also be on dual antiplatelet therapy with aspirin and a second agent such as clopidogrel.
88883548|NCT02474017|Experimental|MGR001|MGR001 (FP/Salmeterol) (250/50 µg) twice daily (BID)
88883549|NCT02094716|Experimental|Permethrin Foam 4%/ Permethrin Foam 4%|First treatment with Permethrin Foam 4% with potential to re-treat with Permethrin Foam 4%, if necessary.
88883550|NCT02094716|Experimental|Permethrin Foam 5%/ Permethrin Foam 5%|First treatment with Permethrin Foam 5% with potential to re-treat with Permethrin Foam 5%, if necessary.
88883551|NCT02094716|Placebo Comparator|Vehicle Foam / Permethrin Foam 4%|First treatment with Vehicle with potential to re-treat with Permethrin Foam 4%, if necessary.
88883552|NCT02094716|Placebo Comparator|Vehicle / Permethrin Foam 5%|First treatment with Vehicle with potential to re-treat with Permethrin Foam 5%, if necessary.
88883553|NCT01868139|Experimental|Cryotherapy|Liquid nitrogen spray cryotherapy with the truFreeze device
88883554|NCT01762605|Experimental|Supportive Care|No casting or splinting, supportive care only by parents
88883555|NCT01762605|Active Comparator|Cast|Casting for 4 weeks
88883556|NCT01620658|Active Comparator|standard cap|Interventionalist wear a standard fabric cap during fluoroscopy guided interventions.
88883557|NCT01620658|Experimental|0.3mm XPF cap|Interventionalist wear a XPF 0.3mm lead equivalent cap during fluoroscopy guided interventions.
88883558|NCT01620658|Experimental|0.5mm XPF cap|Interventionalist wear a XPF 0.5mm lead equivalent cap during fluoroscopy guided interventions.
88883559|NCT01460810|Experimental|1000CsK Silicon Oil Tamponade|In 20 patients, a standard three-port vitrectomy will be performed. Following a standard air-fluid exchange, the eye will be filled with Silikon-1000 silicone oil in standard fashion. At a subsequent surgery, a standard two-port pars plana vitrectomy will be performed to remove the silicone oil and replace it with saline. The removed silicone oil will be tested onsite for traces of radiation.
88883560|NCT01447628|Active Comparator|Ferinject or CosmoFer followed by Placebo|"IV iron formulation used in Europe - Ferinject - given over 15 minutes~IV iron formulation used in China - CosmoFer - over a period of 4 to 6 hours~IV Iron given at Week 0, Placebo (saline) given at Week 12."
88883561|NCT01447628|Placebo Comparator|Placebo followed by Ferinject or CosmoFer|"Placebo comparator~Placebo (saline) given at Week 0, IV Iron given at Week 12."
88883562|NCT01072084||Patients with food allergy|
88883563|NCT01072084||Healthy subjects|
88883564|NCT00744484|Experimental|B1|B1 - training in water
88883565|NCT00744484|Experimental|S1|S1 - training on land
89191361|NCT00852982|Experimental|Exercise|Five hours of Nordic walking per week, during four months
89191362|NCT00852982|No Intervention|Control|Control group asked not to alter lifestyle during study
89191363|NCT02571504|Experimental|Immediate cognitive training group|Plasticity-based Adaptive Cognitive Remediation (PACR) is an 8 week training to improve executive functions (e.g., working memory, flexibility, cognitive control) as well as attention. Participants in the immediate cognitive training group will receive the PACR intervention shortly after enrollment.
89191364|NCT02571504|Experimental|Waitlist control group|Participants in the waitlist control group will receive a brochure with 8 simple tips for better brain health around the time of enrollment. They will begin the Plasticity-based Adaptive Cognitive Remediation (PACR) intervention within 8 weeks of the initial enrollment.
89191365|NCT05304494||Severe Breathlessness|Breathlessness requiring admission or supplementary oxygen
89191366|NCT05304494||Moderate Breathlessness|Breathlessness requiring medical intervention < 24 hours without meeting the criteria for severe breathlessness
89408243|NCT05284474|Experimental|Study|"Doppler protocol (as in controls) + sFlt-1/PlGF ratio cutoffs will be incorporated as follows:~<38: Ultrasound biweekly in stage I FGR and every three weeks in SGA. In both cases delivery at ≥39-40 weeks.~38-85: In stage I FGR and SGA ultrasound weekly. Delivery at ≥37 weeks.~>85: In stage I FGR and SGA ultrasound every 72h-96h. Delivery at ≥37 weeks.~>110: In stage I FGR and SGA ultrasound every 48h-72h. Delivery at ≥36 weeks. If concurrent preeclampsia, delivery at ≥34+0 weeks.~>201: Ultrasound every 48-72h, delivery at ≥34+0 weeks. If concurrent preeclampsia, delivery at ≥32+0 weeks.~>655: Ultrasound every 48-72h, delivery at ≥32+0 weeks. If concurrent preeclampsia, delivery at ≥30+0 weeks.~>1000: In cases with concurrent PE, delivery at ≥28+0 weeks."
89408244|NCT05223361|Active Comparator|Hydroxy ethyl starch (HES)|Six percent hydroxy ethyl starch 130/0.4 additive to ringer lactate as priming solution during CPB
89408245|NCT05223361|Active Comparator|Ringer lactate (RL)|Ringer lactate as priming solution during CPB
88883566|NCT00667329|Experimental|2CdA + Cyclophosphamide + Rituximab|2CdA 1.5 mg/m^2 subcutaneous injection three times daily x 7 days. Cyclophosphamide 40 mg/m^2 PO twice daily x 7 days. Rituximab 375 mg/m^2 IV once weekly x 4 weeks.
88883567|NCT00515853|Experimental|Biofeedback|Received feedback
88883568|NCT00515853|No Intervention|No biofeedback|Did not received feedback
88883569|NCT00492167|Experimental|Beta-Glucan and Monoclonal Antibody 3F8|"This is a dose-escalation study of beta-glucan. Patients receive oral beta-glucan once daily on days -4 to 12 and monoclonal antibody 3F8 IV over 30-90 minutes on days 1-5 and 8-12. Treatment repeats every 4 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity and with a human antimouse antibody (HAMA) titer < 1,000 U/mL.~Cohorts of 3-6 patients receive escalating doses of beta-glucan until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.~Patients undergo urine, bone marrow, and blood sample collection periodically for biological studies. Samples are analyzed for antibody-dependent cellular cytotoxicity, complement-mediated cytotoxicity, and serum HAMA response via immunohistochemistry.~After completion of study treatment, patients are followed periodica"
88883570|NCT00003458|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
88883571|NCT05274724|Active Comparator|Standard institutional protocol, without teleconsultation.|standard will be met according to the current institutional protocol, which does not include teleconsultation. Therefore, the call will be interrupted after guidance from the telemedicine on duty.
88883572|NCT05274724|Active Comparator|Teleconsultation during the ambulance journey to the place of care.|"teleconsultation will receive a video call using the free WhatsApp application, made by one of the emergency workers of the Telemedicine Center, using an institutional smartphone. The teleconsultation can be done directly to the patient and/or with the companion who made the call. The telemedicine on-duty officer will then assess the condition during the time the ambulance travels. The ambulance team will contact the Telemedicine Center and inform the on-call person when the ambulance geolocation application informs 2 minutes of estimated time of arrival at the place of care. At this point, the on-call doctor will interrupt the teleconsultation and pass the information on to the ambulance team. The video call will be turned off upon arrival of the ambulance team."
88883573|NCT05274685|Experimental|covid positive with acute kidney injury receiving early renal replacement|
88883574|NCT05274685|Experimental|covid positive with acute kidney injury under conservative management|
88883575|NCT05274568|Experimental|[18F]UCB-2897|"Administration of Investigational Agent:~Study center personnel will administer [18F]UCB-2897 as an IV injection. Prior to PET imaging, participants will have an IV catheter (for radiopharmaceutical administration) inserted according to standard clinical practice. Each participant will receive a single injection of [18F]UCB-2897. [18F]UCB-2897 will be injected IV at a dose of not more than 10 mCi, with a maximum mass dose of 10 μg and maximum volume of 10 mL. The injection will be followed by a 10 mL saline flush. Qualified study staff will accompany participants during PET imaging procedures."
88883576|NCT05274490||copd patients with covid infection|
88883577|NCT05274490||non-copd patients with covid infection|
88883578|NCT05274438|Experimental|JS001+Imatinib Mesylate|Imatinib: 400mg qd po. Toripalimab: 240mg q3w ivgtt. The longest cumulative use period of the two drugs was 2 years.
88883579|NCT05274386|Other|Averaging time 4to6 s|The SpO2 averaging time will be set to 4to6 s for the next 12 hours. All elements of care will be as routinely used, except the changing of the averaging time setting.
88883580|NCT05274386|Other|Averaging time 10 s|The SpO2 averaging time will be set to 10 s for the next 12 hours. All elements of care will be as routinely used, except the changing of the averaging time setting.
88883581|NCT05274386|Other|Averaging time 16 s|The SpO2 averaging time will be set to 16 s for the next 12 hours. All elements of care will be as routinely used, except the changing of the averaging time setting.
88883582|NCT05274360|Experimental|Experimental Group|Mobile evidence-based aphasia therapy
89408246|NCT05132218||Ensatinib for treated patients with ALK-positive advanced non-small cell lung cancer|Ensatinib 225mg QD Until the disease progresses or intolerance
89408247|NCT05405816|Other|after laparoscopic sleeve gastrectomy|Patients who underwent laparoscopic sleeve gastrectomy surgery
89408248|NCT05405816|No Intervention|before laparoscopic sleeve gastrectomy surgery|obese patient preparing for laparoscopic sleeve gastrectomy surgery
89408249|NCT05609695||Immunotherapy group|Treatment based on immunotherapy.
89408250|NCT05624515|Experimental|dry needling group|Subjects undergoing dry needling of the angularis scapulae muscle
89408251|NCT05624515|Experimental|ischaemic compression group|Subjects undergoing ischaemic compression of the angularis scapulae muscle
89408252|NCT04246060||Cohort 1|Patients on extended release cysteamine treatment at study enrollment
89408253|NCT04246060||Cohort 2|Patients switching from immediate release cysteamine to extended release cysteamine during the study
89408254|NCT04246060||Cohort 3|Patients remaining on immediate release cysteamine treatment
89408255|NCT05599633|Experimental|Intervention Arm|Subjects who are randomised to Intervention Arm will be taking a drink containing 25g of Sarawak sago starch in 200mL of plain water. The subjects will take the drink twice daily i.e., within 30 minutes before lunch and dinner. On top of that, they will be counselled on diet recommendations for diabetes by a study dietitian at Visit 1 or baseline.
89408256|NCT05599633|Placebo Comparator|Control Arm|Subjects who are randomised to Control Arm will be taking a drink containing 25g of corn starch in 200mL of water. The subjects will take the starch suspension twice daily i.e., within 30 minutes before lunch and dinner. On top of that, they will be counselled on diet recommendation for diabetes by a study dietitian at Visit 1 or baseline.
88883583|NCT05274360|Active Comparator|Control Group|Conventional aphasia therapy
88883584|NCT05274256|Other|patients with missing teeth in maxillary aesthetic zone|
89408257|NCT01368042||Chronic Kidney Disease, Secondary Hyperpathyroidism|All eligible participants treated with paricalcitol iv according to the approved Summary of Product Characteristics (SmPC)
88883585|NCT05274191|Experimental|A single arm, open-label Phase II clinical study.|"All subjects enrolled will receive the following treatment：Pyrotinib±standard treatment.~Pyrotinib 400 mg/ D (once a day, at the same time each day) until the progression of disease; Chemotherapy regimens follow the programme cycle recommended by the guidelines or as determined by the investigator.~The dosage can be adjusted according to the protocol according to the adverse reactions of subjects. Subjects will continue to take medication until completion of the prescribed course of treatment, disease progression, toxicity intolerance, withdrawal of Informed Consent Form, or termination in the investigator's judgment."
88883586|NCT05274139|Experimental|FTD regimen|FTD regimen(fotemustine, temozolomide and dexamethasone),fotemustine 100mg/m2 d1 ivgtt, temozolomide 150mg/m2 d1-5 po,dexamethasone 40mg d1-5 ivgtt.Continued use to the end of chemotherapy .Every 28 days for one cycle and four cycles are required. Efficacy was evaluated every two cycles.
88883587|NCT05274139|Experimental|HD-MTX-Ara-C regimen|high-does metrotrexate 3.5g/m2 d1 ivgtt 6h,cytarabine 1g/m2 bid d2-3.Continued use to the end of chemotherapy .Every 21 days for one cycle and four cycles are required. Efficacy was evaluated every two cycles.
88883588|NCT05274113|Active Comparator|Group 1: Block with Ropivacaine + Dexamethasone|Before surgery an ultrasound guided supraclavicular block with ropivacaine and 4 mg of dexamethasone will be administered
89408258|NCT05132062||Patients with CA-AKI occurrence|Occurrence of CA-AKI as defined by the Acute Kidney Injury Network definition
89408259|NCT05132062||Patients without CA-AKI occurrence|No occurrence of CA-AKI as defined by the Acute Kidney Injury Network definition
89408260|NCT04141852|Experimental|AVF surgery with device|
89408261|NCT04141852|No Intervention|AVF surgery conventional|
89408262|NCT05283460|Experimental|mandala|As in the case of previous studies, to prevent confusion and make the mandala drawing process easier, a few videos describing what a mandala is were shown to the patients, and information was provided. Next, each patient was given a set of felt-tip pens (in 24 different colors) and ready-to-use mandala papers, and they were asked to complete the mandala activity. The patients were given empty mandala books with enough pages for them to draw mandalas every day, they were asked to perform the mandala activity regularly in a time interval of their own choice every day, and whether they performed the activity was checked daily without them noticing (so that they would not have the feeling of being checked on or inspected).
89408263|NCT05283460|No Intervention|control group|The Life Satisfaction Scale was administered to patients in the control group at the first encounter (pre-test) and three weeks after the first encounter (post-test). Although the pre- and post-test treatment protocols were the same for both intervention and control groups, the only difference between their treament was the mandala activity, which was not applied to those in the control group. Patients in the control group continued their routine lives at home for three weeks. After the application, the mandala activity was applied to all patients who wanted it.
88883589|NCT05274113|Active Comparator|Group 2: Ropivacaine Block + IV Dexamethasone|Before surgery an ultrasound guided supraclavicular block with ropivacaine will be administered and patients will receive dexamethasone intravenously
88883590|NCT05274100|Experimental|Group 1: Risankizumab Dose A|Participants will receive risankizumab dose A.
88883591|NCT05274100|Experimental|Group 2: Risankizumab Dose B|Participants will receive risankizumab dose B.
88883592|NCT05274100|Experimental|Group 3: Risankizumab Dose C|Participants will receive risankizumab dose C.
88883593|NCT05274100|Experimental|Group 4: Risankizumab Dose D|Participants will receive risankizumab dose D.
88883594|NCT05274100|Experimental|Group 5: Risankizumab Dose D|Participants will receive risankizumab dose D.
89408264|NCT05129176|Experimental|levofloxacin-tetracycline-containing quadruple group|patients in levofloxacin-tetracycline-containing quadruple group will receive vonoprazan fumarate 20mg po bid, tetracycline 500mg po qid , bismuth potassium citrate(Lizhudele) 220mg po bid, and levofloxacin 500mg po qd for 14d
89408265|NCT05129176|Active Comparator|metronidazole-tetracycline-containing quadruple group|patients in metronidazole-tetracycline-containing quadruple group will receive vonoprazan fumarate 20mg po bid, tetracycline 500mg po qid , bismuth potassium citrate(Lizhudele) 220mg po bid, and metronidazole 400mg po qid for 14d
89408266|NCT02127684|Active Comparator|Standard Dosing Group|Standard Dosing Group will receive intravitreal injections of 0.3mg. ranibizumab at baseline, week 4 and 8 )sham injections at week 2 and 6). After week 8 retreatment will be given monthly if edema is greater than 290um or ETDRS visual acuity score <83
89408267|NCT02127684|Experimental|Frequent dosing group|Frequent dosing subjects will be evaluated and treated every two weeks through week 8 with intravitreal injection of 0.3mg ranibizumab. Subjects will then be evaluated monthly through week 24 and will receive treatment with ranibiumab based on residual edema and visual acuity
89408268|NCT05706571|No Intervention|control grup (skill laboratory)|The control group of the study: The control group of the study; Students will be formed from students whose school number has a single last digit. The experimental 1 group and control group of experimental 2 groups of the study consist of the same group. Before the theoretical lecture of the pediatric patient end-of-life care module of nursing students teaching with augmented reality and the Benner model, students will be pre-tested. After the pre-test, students are taught on a virtual case in the last hours and days of life; Theoretical lecture will be given by the researcher in the form of a PowerPoint presentation, which will last 60 minutes, using question-answer, discussion, and commentary methods. A final test will be given at the end of the course.
89408269|NCT05706571|Experimental|experimental group1 (Benner model)|Experiment 1 Group of the Research With the Benner model, it is planned to create the pediatric end-of-life care module for nursing students in the Fall Term of the 2023-2024 Academic Year, with an estimated 140 students enrolled in the Istanbul Medipol University Faculty of Health Sciences Nursing Department Child Health and Diseases Nursing Course. The enrolled students will form the novice nurse group according to the Benner model of the research. A pre-test will be done before the theoretical lesson is given to the novice nurse group of the research.
89408270|NCT05706571|Experimental|experimental group2 (augmented reality mobile application)|Application of the Research to the Experimental Group 2 Experiment 2 group of the research; In the Fall Term of the 2023-2024 Academic Year, an estimated 140 students will be enrolled in the Istanbul Medipol University Health Sciences Faculty Nursing Department Child Health and Diseases Nursing Course. The 3rd group of the study will be pre-tested before the theoretical lecture of the Pediatric Patient End-of-Life Care Module with the augmented reality method and Benner model. At the end of the pre-test, students will be given a theoretical lecture.
89408271|NCT02126202|No Intervention|Conservative therapy|Optimized medical therapy
89408272|NCT02126202|Experimental|Invasive therapy|Coronary angiography and revascularization if feasible
89408273|NCT04066816|Experimental|Walnut Consumption|After screening, participants will avoid foods high in ellagic acid. These foods include pomegranates, hazelnuts, pistachios, strawberries, raspberries, blackberries, oak-aged wines, spirits, and walnuts (besides the ones given by researchers); a complete list will be provided to the subjects. Participants will then return to research facility and provide urine and stool samples, as well as a set of 3-day dietary records. Then, they will start to consume 2 ounces of walnuts per day for 21 days with their usual diet. At the end, they will collect another urine and stool sample as well as another set of dietary records, and then come in for the scheduled colonoscopy where they will be asked to provide biopsy specimens. That completes the intervention and participation in the study.
88883595|NCT05274087|Experimental|Group 1|Participants will receive Regimen A (15-minute autoinjector (AI) warm-up time) in Period 1, Regimen B (30-minute AI warm-up time) in Period 2 followed by Regimen C (45-minute AI warm-up time) in Period 3.
88883596|NCT05274087|Experimental|Group 2|Participants will receive Regimen B in Period 1, Regimen C in Period 2 followed by Regimen A in Period 3.
88883597|NCT05274087|Experimental|Group 3|Participants will receive Regimen C in Period 1, Regimen A in Period 2 followed by Regimen B in Period 3.
88883598|NCT05273957|Experimental|Case Manager|Patients are followed up by a case manager
88883599|NCT05273957|Active Comparator|Standard-of-care|Patients are followed up only by the neurologist
88883600|NCT05273944|Active Comparator|Reference product-R|Caelyx® (Janssen-Cilag International NV); 20 mg/10 mL (50 mg/m2 dose). As this is a crossover study, subjects receiving the Reference Product (Caelyx®) in Cycle 1, will receive the Test Product (Lipodox®) in Cycle 2. Cycle is defined as 28-42 days (RT).
88883601|NCT05273944|Experimental|Test Product-T|Lipodox® (Sun Pharmaceutical Industries Ltd.); 20 mg/10 mL (50 mg/m2 dose). As this is a crossover study, subjects receiving the Test Product (Lipodox®) in Cycle 1, will receive the Reference Product (Caelyx®) in Cycle 2. Cycle is defined as 28-42 days (TR).
88883602|NCT05273866|Experimental|Virtual reality|Virtual reality video application
88883603|NCT05273866|No Intervention|control group|control group
88883604|NCT05273853|Other|Patients with high risk of hypernasality|In 1958, Gibb indicated an incidence of hypernasality (escape of air from nose as in patients with cleft palate) postadenoidectomy in approximately 1of 2000 cases. Closure pattern of velopharyngeal valve in children is veloadenoidal rather than velopharyngeal closure. Adenoid tissue is vital to velopharyngeal closure in children and its removal necessitates a change in the closure pattern of velopharyngeal valving. These changes are easily overcome if there is no anatomic abnormality
89191367|NCT05304494||Mild Breathlessness|Breathlessness not requiring any medical intervention within 24 hours other than a dose change in the individuals pre-established pharmacological treatment plan
89191368|NCT00859378|Active Comparator|1 - cemented|Patients are treated with a cemented semiendoprosthesis
89191369|NCT00859378|Active Comparator|2 - non-cemented|Patients are treated with a non-cemented semiendoprosthesis
89191370|NCT00717678|Experimental|Prograf-XL + MMF|
89191371|NCT00717678|Active Comparator|Prograf + MMF|
89191372|NCT05050682|Experimental|PF-07304814|PF-07304814 is an anti-viral, formulated for intravenous delivery
89535634|NCT04992741|Experimental|Experimental|Health Belief Model Based Motivational Interview Group The application will be made by the researcher who has been trained in motivational interviewing techniques. Motivational interviews based on Health Belief Model will be made by telephone to mothers who have daughters studying in high school. There will be 3 interviews with mothers based on the benefits, barriers, sensitivity and severity perception structures of the Health Belief Model regarding HPV infection and vaccination, and each interview will last 15-20 minutes. One week after each interview, the questionnaire/scale forms will be sent via whatsapp and applied.
89535635|NCT04992741|No Intervention|other|The control group will remain subject to the routine process without any intervention.
89191373|NCT00853138|Experimental|CBT|Cognitive-behavioral therapy delivered via the internet in eight treatment modules for children (education, stress and negative emotions, deep breathing and relaxation, distraction, cognitive skills, sleep hygiene and lifestyle, staying active, relapse prevention) and eight treatment modules for parents (education, stress and negative emotions, operant strategies I, operant strategies II, modeling, sleep hygiene and lifestyle, communication, relapse prevention).
89191374|NCT00853138|No Intervention|SMC|The standard medical care wait-list control group continued with the treatment recommendations proscribed by their pain care team.
89191375|NCT04067466|Experimental|Fiber product|Fiber product: Inulin, maltodextrin, gum guar, plum powder
89191376|NCT04067466|Placebo Comparator|Control product|Maltodextrin, plum powder
89191377|NCT02571842|Experimental|Rituximab|"Drug: Rituximab~•Rituximab 375 mg/m2 on treatment month 1, 2, 3, 4~Other Name: Mabthera"
89191378|NCT02571842|Active Comparator|ACEI/ARB plus corticosteroids|"Drug: ACEI/ARB~An ACEI and /or ARBs will be used to achieve proteinuria reduction and a blood pressure goal of <130/80 mmHg. Patients not attaining the target blood pressure with an ACEI or ARB alone should be treated with the combination of ACEI + ARB~Corticosteroids will be used as prednisolone 0.5 mg/kg/day with gradually taper off in 6-8 weeks to 5mg/day daily~Other Name: Enalapril, Lorsartan, Prednisolone"
89191379|NCT02546284|Experimental|Single Agent lenzilumab|Dose levels: lenzilumab IV infusion once monthly for a 28 day dosing cycle (with extra dose on Day 15 during cycle). Three (3) to Six (6) subjects will be enrolled into planned escalating cohorts of 200 mg, 400 mg or 600 mg lenzilumab.
89191380|NCT02572830|Experimental|Delayed Bilateral Eye Movements|Delayed Bilateral Eye Movements after reactivation of fear-memory.
89191381|NCT02572830|Active Comparator|Undelayed Bilateral Eye Movements|Undelayed Bilateral Eye Movements after reactivation of fear-memory.
89191382|NCT00859690||Sleep Disorder - Sleep Apnea|Subjects determined by a clinically indicated overnight sleep study (Nocturnal Polysomnography) to have Obstructive Sleep Apnea (OSA).
89191383|NCT00859690||Sleep Disorder - Not Sleep Apnea|Subjects determined by a clinically indicated overnight sleep study (Nocturnal Polysomnography) to have a sleep disorder other than Obstructive Sleep Apnea (OSA).
89191384|NCT00720954|Other|A|CT guided pleural needle biopsy
89191385|NCT00720954|Other|B|Thoracoscopy
89191386|NCT02570828|Experimental|Thermal imaging|All subjects in the study will have thermal images of the chest taken using the FLIR ONE attachment to an iPhone.
89191387|NCT00853216|Experimental|A|Oxycodone hydrochloride tablet 30 mg
89191388|NCT00853216|Active Comparator|B|Roxicodone™ tablet 30 mg
89191389|NCT02571062|Experimental|experimental formulation|crossover design
89191390|NCT02571062|Experimental|final formulation|crossover design
89191391|NCT00859768|Experimental|Intervention group 1|Pre-test measures are assessed. The patient receives the SIPP twice during their RT period. The first time is before the first consultation with the radiotherapist and the second time is before the last consultation at the end of the RT period. At both time points, the SIPP is handed over to the radiotherapist at the start of the consultation. The radiotherapist screens the scores of the SIPP to get an overview of potential psychosocial problems and patient's needs of psychosocial care. Follow-up measures are directly after first consultation (T2) and at three (T3) and twelve months (T4) after first measurement.
89191392|NCT00859768|Experimental|Intervention group 2|No pre-test measures are assessed. The patient receives the SIPP twice during their RT period. The first time is before the first consultation with the radiotherapist and the second time is before the last consultation at the end of the RT period. At both time points, the SIPP is handed over to the radiotherapist at the start of the consultation. The radiotherapist screens the scores of the SIPP to get an overview of potential psychosocial problems and patient's needs of psychosocial care. Follow-up measures are directly after first consultation (T2) and at three (T3) and twelve months (T4) after first measurement.
89191393|NCT00859768|No Intervention|Control group 1|Pre-test measures are assessed. Enhanced usual care. Follow-up measures are directly after first consultation (T2) and at three (T3) and twelve months (T4) after first measurement.
89191394|NCT00859768|No Intervention|Control group 2|No pre-test measures are assessed. Enhanced usual care. Follow-up measures are directly after first consultation (T2) and at three (T3) and twelve months (T4) after first measurement.
89191395|NCT04961528|Experimental|Terlipressin|"Dosage: 1 mg /5 ml Pharmaceutical form: solution for infusion Posology: 1 mg /8 hours Treatment duration: 5 days~Method and route of administration: inhalation using the same jet nebulizers (INT'AIR Medical RN 300) in all Investigating centers"
88883605|NCT05273801|No Intervention|Clinician Arm (period 1) - behavior prior to HR intervention|The investigators will monitor baseline behavior of providers in regards to sessions and how frequently heart rate (HR), rating of perceived exertion (RPE) and intensity is monitored and subsequent sessions are performed/modified through observation.
88883606|NCT05273801|Active Comparator|Clinician arm (period 2) & Patient arm (control - HR monitor, no feedback)|Participants will receive 1 week of HR monitoring in their group sessions where visual feedback is not provided during group session. The investigators will monitor overall HR response, mean HR and time in target HR zone, RPE and clinician behavior to HR monitor on patient during these sessions.
88883607|NCT05273801|Experimental|Clinician arm (period 3) & Patient arm (active - HR monitor, with feedback)|The same participants will receive 1 week of HR monitoring with visual feedback during group sessions. The investigators will monitor overall HR response, mean time HR and time in target zone, RPE, and clinician behavior to HR monitoring with visual feedback.
88883608|NCT05273528|Experimental|V-01-351/V-01D bivalence vaccine|
88883609|NCT05273424||no groups|A cohort of CKD patients on hemodialysis
88883610|NCT05273398|Experimental|Treatment|Single arm of treatment
88883611|NCT05273372|Experimental|Oxaloacetate|500 mg anhydrous enol-oxaloacetate in hypromellose capsules (veggie caps). 2 capsules with breakfast and 2 capsules with lunch (1,000 mg BID) for 90 days.
88883612|NCT05273372|Placebo Comparator|Placebo|500 mg white rice flour in hypromellose capsules (veggie caps). 2 capsules with breakfast and 2 capsules with lunch (1,000 mg BID) for 90 days.
88883613|NCT05273333|Other|Ultra-gyn®|ovule
88883614|NCT05273294|Experimental|Ultrasound group|Anesthesiologist will convenient color ultrasound high frequency 12MHZ array probe perpendicular to the neck, by the glottal down, until the thyroid isthmus, and ring cartilage level, ring cartilage level diameter by ultrasound, to avoid the effect of inspiration and breath on airway diameter, measurement timing should choose after anesthesia induction, mask pressure gas 1min, suspended pressure ventilation for 5s, ultrasonic measurement time is not more than 10s.Repeated measurements were averaged three times, and the maximum outer diameter of the catheter was selected, that is, the maximum outer diameter was selected closest to the measured value.
88883615|NCT05273294|No Intervention|Control group|tracheal catheter models are usually selected through traditional experience, according to the age formula in Clinical Anesthesiology, People's Health Press (i. e., 2.5 for preterm infants, 3.5 at 1-6 months, 4.0 at 6-12 months).
88883616|NCT05273229|Experimental|Virtual Gait and Physical Exercise|"Virtual Gait and Physical Exercise Virtual Gait The subject will be stand up with a standing opposite a mirror (from the waist up) and a screen (from the waist down) where a video of treadmill gait of a person will be projected.~Physical Exercise Specific gait exercise was conducted."
88883617|NCT05273229|Sham Comparator|Documental projection and Physical Exercise|"Physical Exercise Specific gait exercise was conducted.~Documental projection The subject will be stand up with a standing opposite a mirror (from the waist up) and a screen (from the waist down) where video without any type of animal or human movement was showed."
88883618|NCT05273229|Experimental|Virtual Gait|only the virtual gait program will be carried out, detailed in Arm I.
88883619|NCT05273229|Sham Comparator|Virtual Gait Sham|Documental projection The subject will be stand up with a standing opposite a mirror (from the waist up) and a screen (from the waist down) where video without any type of animal or human movement was showed.
88883620|NCT05273073|Active Comparator|Probiotics group|83 participants received probiotics for 12-week
88883621|NCT05273073|Placebo Comparator|Placebo group|83 participants received placebo for 12-week
89535636|NCT03205033|Active Comparator|Melatonin|Melatonin 20 mg Oral Capsules, once a day at bedtime
88922019|NCT05972174|Experimental|Part B Group 1 Vaccine: mRNA-1018 for H5 Only-CG Dose Level 2|Participants will receive mRNA-1018 for H5 Only-CG at dose level 2 by IM injection on Day 1 and Day 22.
89191396|NCT04961528|Experimental|Tranexamic Acid|"Dosage : 500 mg /5 ml Pharmaceutical form: solution for infusion Posology (and adjustments based on toxicity) : 500 mg/ 8 hours Treatment duration: 5 days~Method and route of administration: inhalation using the same jet nebulizers (INT'AIR Medical RN 300) in all Investigating centers."
89535637|NCT03205033|Placebo Comparator|Placebo|Placebo Oral Capsules, once a day at bedtime
89535638|NCT02490215||ARDS, non-ARDS|patients with ARDS and patients without ARDS
88883623|NCT05272982||Successful weaning group|Criteria of weaning included resolution of the primary cause of intubation, adequate cough without excessive tracheobronchial secretions, PaO2 > 60 mmHg with positive end-expiratory pressure ≤ 8 cmH2O, fraction of inspired oxygen ≤ 0.4, respiratory rate < 30 per minute, appropriate pH for patients' baseline respiratory status, and stable cardiovascular status.
88883624|NCT05272982||Failed weaning group|Weaning failure will be defined as a patient need for reintubation or noninvasive ventilation within 48 h after extubation due to the presence of one or more of the following criteria: altered mental status tachypnea (respiratory rate more than 35 breaths per minute), oxygen saturation less than 90% or PaO2 less than 60 mmHg on a fraction of inspired oxygen of 40%, an apparent increase in accessory respiratory muscle activity, evident facial signs of respiratory distress and hemodynamic instability (Heart rate >140 b/min, systolic blood pressure >180 or < 90mmHg )
89408274|NCT02126280||Subclinical atherosclerosis|In vitro estimation of individual reactivity of monocytes in study participants with asymptomatic atherosclerotic plaques found in carotid arteries by ultrasound examination
89408275|NCT02126280||Healthy subjects|In vitro estimation of individual reactivity of monocytes in study participants without ultrasound signs of subclinical carotid atherosclerosis
89408276|NCT02126280||Diffuse intimal thickening|In vitro estimation of individual reactivity of monocytes in study participants with diffuse intima-media thickening of carotid arteries found at ultrasound examination
89408277|NCT02127762|Experimental|Mindfulness Based Stress Reduction|Participants assigned to this group will be enrolled in an Mindfulness-Based Stress Reduction (MBSR) program following medical treatment optimization. The MBSR program will be composed of eight weekly 2.5 hour sessions and one 6 hour session midway through the course.
89408278|NCT02127762|No Intervention|Wait-listed Control Group|Participants assigned to this group after medical treatment optimization will act as wait-list controls for the MBSR group. They will be enrolled in the MBSR workshop 3 months after the corresponding intervention group completes the program.
89408279|NCT02126358|Placebo Comparator|Gemigliptin|only Gemiglitpin (Gemiglitpin/Rosuvastatin FDC:Placebo , Rosuvastatin :Placebo)
89408280|NCT02126358|Placebo Comparator|Rosuvastatin|only Rosuvastatin (Gemiglitpin/Rosuvastatin FDC:Placebo , gemigliptin :Placebo)
89408281|NCT02126358|Experimental|FDC|Gemigliptin & Rosuvastatin (Gemiglitpin only:Placebo ,Rosuvastatin only:Placebo)
89408282|NCT02127840|Experimental|Synacthen|Synacthen infusion during adrenal venous sampling
88883625|NCT05272904|Active Comparator|Conventional closure method|Following mastectomy, skin is closed using subcutaneous sutures followed by intracutaneous running suture. Depending on the surgeons discretion a vacuum closed suction drain was placed beneath the skin flaps.
88883626|NCT05272904|Experimental|Quilting|The implemented intervention is the quilting suture technique. The subcutaneous tissue is sutured to the pectoralis muscle placing multiple rows of running sutures. The suture starts at either end of the scar, running back and forth, creating rows of quilting stiches. The rows are placed transversely from the cranial to the caudal end of the wound with 2-3 cm between them, totalling some three to ﬁve rows for the cranial ﬂap. The caudal ﬂap is quilted with 2-3 rows in a caudal to cranial fashion. A subcutaneous suture followed by a intracutaneous running suture is used to close the skin. No wound drain is placed.
88883627|NCT05272839|Experimental|Hypoglycemic food group|The patient will choose 2 food products clinically validated against diabetes, at the same dosage and the same mode of preparation as in the reference clinical trials. This will be done additionally to healthcare advice and standard medication if any.
88883628|NCT05272839|Placebo Comparator|Control group|The control group will receive only dietary advice and standard medication if any.
88883629|NCT05272540||Day case surgery|Adult patients who are operated on as outpatients in day surgery. Treatment and care follow clinical routine. Weighing on a scales measuring bioelectrical impedance data before and after the surgery is added.
88883630|NCT05272540||In patient surgery|Adult patients who are operated on as inpatients in hospital care. Treatment and care follow clinical routine. Weighing on a scales measuring bioelectrical impedance data before the surgery and every morning during hospital stay is added.
88883631|NCT05272449|Experimental|Evaluation of a disposable sound sensor for recording respiration during sleep|PneaVoX sensor, CIDELEC
88883632|NCT05272436|Experimental|Patients IVR for Upper Limb Motor Impairment Rehabilitation in children and at home trial|"For the purpose of the trial, patients had their usual OT/PT appointments but were asked to use the IVR games to do the prescribed home exercises. Before consenting to participate, each patient was offered a 5-10 minute experience of the game to familiarise themselves with how it worked and to check for problems. Written and verbal consents were taken from parents and children.~The pre-trial PedsQL was administered in the initial OT/PT appointment. Children were then asked to use the IVR system for approximately 15 minutes twice a day. Trial participation lasted three weeks during the prescribed treatment weeks.~Following the at-home trial, patients and parents returned the equipment to the clinic in the final appointment and the SUS and the post-trial Peds QL were administrated by OT/PT in person. In addition, they participated in semi-structured interviews as described above."
88922020|NCT05972174|Experimental|Part B Group 1 Vaccine: mRNA-1018 for H5 Only-CG Dose Level 3|Participants will receive mRNA-1018 for H5 Only-CG at dose level 3 by IM injection on Day 1 and Day 22.
89408283|NCT02127840|No Intervention|Without Synacthen|Adrenal venous sampling without Synacthen
89408284|NCT05066074|Experimental|Distal Radial Access|Distal Radial (Anatomical Snuffbox) Vascular Access prior to catheterization
89408285|NCT05066074|Active Comparator|Proximal Radial Access|Proximal Radial Vascular Access prior to catheterization
89408286|NCT02126436|Active Comparator|Acupuncture|"Eight treatments of acupuncture will be given to participants twice weekly over four weeks. A combination of body and auricular acupuncture will be given and treatment will be pragmatic.~In addition the group will receive usual care (including physiotherapy, occupational therapy, medical intervention and any other intervention as deemed appropriate by clinical staff)."
89408287|NCT02126436|Other|Usual care|The group will receive usual care (including physiotherapy, occupational therapy, medical intervention and any other intervention as deemed appropriate by clinical staff).
89408288|NCT02131116|Experimental|IMT|Integrated Metacognitive Therapy
89408289|NCT02131116|No Intervention|TAU|No intervention group/Treatment as Usual
89535639|NCT03205267|Experimental|Bosutinib|Drug: Bosulif 100 mg or 500 mg tablets step in dosing scheme
89408290|NCT05031442|Other|low waist arm (investigational product RH1 first)|Investigational product RH1 (low waist) will be used for 5 consecutive days at the start before switching to the control product (low waist) for 5 days after cross-over.
89408291|NCT05031442|Other|high waist arm (Investigational product RC2 first)|Investigational product RC2 (high waist) to be used for 5 consecutive days at the start before switching to the control product (high waist) for 5 days after cross-over.
88883633|NCT05272436|Other|Occupational Therapist perceptions of the effectiveness of the IVR|"She recruited the patients, gave out devices, administered the outcome measures and provided us with feedback about their experience with the VR game.~At the end of the trial, an interview (10 minutes) with the OT was conducted by a research nurse."
89408292|NCT05031442|Other|low waist arm (Control product first)|Control product (low waist) to be used for 5 consecutive days at the start before switching to the investigational product RH1 for 5 days after cross-over.
89408293|NCT05031442|Other|high waist (Control product first)|Control product (high waist) to be used for 5 consecutive days at the start before switching to the investigational product RC2 for 5 days after cross-over.
88883634|NCT05272410||cases|Patients colonized or infected with CPE
89408294|NCT03527888|Other|Anlotinib|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
89408295|NCT02131194|Experimental|Lenstatin|Lenstatin (2) capsules orally per day for (6) months
89408296|NCT02131194|Placebo Comparator|Sugar Pill|Placebo manufactured to mimic Lenstatin (2) capsules orally per day for (6) months
89408297|NCT04820920|Experimental|LTP+CaCBT|The LTP+CaCBT intervention will consist of 10 (mother-child pairs) participants per sub-group in online group sessions (approx. 60 minutes each) and will deliver one session every fortnight for 12 sessions.
89408298|NCT04820920|Active Comparator|Psychoeducation|This is a form of psychoeducation involving basic discussions around mother-child relationships, childcare, child nursing related activities and general maternal discussions. The psychoeducation would last approximately 60 minutes each for 12 sessions (10 participants per sub-group). One session would be delivered every fortnight for 12 sessions.
89408299|NCT02127918||ESES treated with clobazam|The patients that will participate in the protocol will be those that are administered for clinical reasons oral clobazam.
89408300|NCT00127634|Experimental|1|
88883635|NCT05272410||controls|Patients not colonized or infected with CPE
89191397|NCT04961528|Placebo Comparator|Normal Saline Placebo|"Dose : normal saline solution (NaCl 0.9%) Pharmaceutical form : solution for infusion Posology : 5ml / 8 hours Treatment duration: 5 days~Method and route of administration: inhalation using the same jet nebulizers (INT'AIR Medical RN 300) in all Investigating centers."
89408301|NCT00127634|Active Comparator|2|
89408302|NCT03550638|Experimental|group A|Coil system(Ton-bridgeMT)
89408303|NCT03550638|Active Comparator|group B|Axium Detachable Coil(Medtronic)
89408304|NCT04730050|Experimental|Drug: TT-01025-CL|TT-01025-CL
89408305|NCT04730050|Placebo Comparator|Drug: Placebo|Placebo of TT-01025-CL
89408306|NCT03550560||EUS-Guided drainage|Cancer patients in terminal phase with refractory malignant ascites
88883636|NCT05272371|Experimental|Intervention arm|Chemoimmunotherapy arm.
88883637|NCT05272358||strategy 1: sarcoma MDTB before surgery and initial management in the NETSARC network|Patients who had a sarcoma-specialized multidisciplinary tumour board (MDTB) before the initial surgery and complete initial management (including surgery) in the network (also including patients who had a sarcoma-specialized MDTB after the initial surgery and complete initial management in the network) (strategy 1)
88883638|NCT05272358||strategy 2: sarcoma MDTB before surgery and initial management outside the NETSARC network|Patients who had a sarcoma-specialized MDTB before the initial surgery and initial management (including surgery) outside the network (strategy 2)
88883639|NCT05272358||strategy 3: sarcoma MDTB after surgery and initial management outside the NETSARC network|Patients who had initial management (including surgery) outside the network and a sarcoma-specialized MDTB after initial surgery (strategy 3)
88883640|NCT05272358||strategy 4: No sarcoma MDTB and initial management outside the NETSARC network|Patients who had an initial management (including surgery) outside the network, without sarcoma-specialized MDTB neither before nor after the initial surgery (strategy 4).
88883641|NCT05272215||Patient group|"Pre-BaS: Patients administered for BaS, Department of Endocrinology either Odense University Hospital, Odense, Denmark or Hospital of Southwest Jutland, Esbjerg, Denmark~Post-BaS: (3, 6, 12 months postoperatively, then yearly) Department of Surgery, Southwest Jutland, Esbjerg, Denmark~Pre-BC: Patients administered for BC, Department of Plastic Surgery, Odense University Hospital, Odense, Denmark or Department of Plastic Surgery, Southwest Jutland, Esbjerg, Denmark.~Post-BC: (3, 6, 12 months postoperatively, then yearly), department of Plastic Surgery, Odense University Hospital; Hospital of Southwest Jutland, Esbjerg.~Normative group: Reference scores of the general population from an international sample of 10 countries and country specific scores. This study sample is submitted for publication elsewhere."
89408307|NCT03528122|Experimental|Recurrent opened macular hole|Pars plana vitrectomy with internal limiting membrane peel if not peeled in the first surgery and application of amniotic membrane graft
89408308|NCT02126514|Experimental|AZD3293|7 subjects will receive AZD3293
89408309|NCT04720222|Experimental|TENA-PROTO1|Investigational device. Early prototype
89408310|NCT02126592||PCOS cohort|Women with PCOS
89408311|NCT02126592||Control cohort|Women without PCOS
88883642|NCT05272189|Experimental|Experiment|All participants are tested in all conditions of this experiment.
88883643|NCT05272163|Experimental|Main Experiment|This is a single arm study where all participants are tested on 1-2 hours of visual search.
88813706|NCT01048502|Experimental|Fenofibrate (Tricor) (145 mg/day)|Participants will be given 1 fenofibrate (Tricor) 145mg and 4 fish oil placebos - supplies of study drug will be provided to last 8 weeks.
88883644|NCT05272124|Experimental|Hip Abductor Strengthening|This group received quadriceps and hip abductor strengthening along with patellar mobilization and stretching exercises.
88883645|NCT05272124|Active Comparator|Traditional Physical Therapy|This group received quadriceps strengthening along with patellar mobilization and stretching exercises.
88883646|NCT05272020|Other|TAVI|Cardiopulmonary exercise testing, 6 minute walking test, QOL assessment
88883647|NCT05272020|Other|AVR|Cardiopulmonary exercise testing, 6 minute walking test, QOL assessment, Myocardial + aortic valve biopsy
89191398|NCT00721032|Experimental|1|Magnetic resonance imaging (MRI)-guided ablation of ventricular tachycardia.
89191399|NCT00721032|Active Comparator|2|Anti-arrhythmic group.
88813707|NCT01048502|Placebo Comparator|Placebo|Participants will be given 5 placebo pills (4 fish oil placebo and 1 fenofibrate placebo) - supplies of study drug will be provided to last 8 weeks.
88813708|NCT01048502|Experimental|Lovaza (900 mg/day)|Participants will be given 1 Lovaza capsule, 3 Fish oil placebo capsules, and 1 Fenofibrate placebo - supplies of study drug will be provided to last 8 weeks.
88813709|NCT01048502|Experimental|Lovaza (3,600 mg/day)|Participants will be given 4 Lovaza capsules and 1 Fenofibrate placebo - supplies of study drug will be provided to last 8 weeks.
88813710|NCT02465034|Active Comparator|Subcortical stroke|Subjects with subcortical stroke in the chronic phase of recovery with mild-moderate impairment of arm function will undergo noninvasive targeting of cortical locations by stereotactic neuronavigation using Transcranial Magnetic Stimulation (TMS), median nerve stimulation and arm motor function assessments. A paired associative stimulation (PAS) protocol using noninvasive stimulation will also be used which will be one of the following, a traditional or a corticocortical or a sham paired associative stimulation protocol. The subjects will also undergo median nerve stimulation.
88813711|NCT02465034|Active Comparator|Healthy Control|Healthy individuals will undergo noninvasive targeting of cortical locations by stereotactic neuronavigation using Transcranial Magnetic Stimulation (TMS), median nerve stimulation and arm motor function assessments. A paired associative stimulation (PAS) protocol using noninvasive stimulation will also be used which will be one of the following, a traditional or a corticocortical or a sham paired associative stimulation protocol.
88813712|NCT03001037||Group A - Low Back Pain|"Group A:~Subject provides written authorization and/or consent per institution and geographical requirements~Subjects in Group A with a predominant complaint of Low back pain, with a minimum daily average VAS ≥ 30/100~Subjects in Group A are intended to be assessed with ViMove based on standard of care~Subject is willing to participate in follow-ups at 3, 6, 12 months post initial assessment~Observational study, no intervention"
88813713|NCT03001037||Group B - Without Low Back Pain|"Subject is without current low back pain~Subject does not have a history of low back pain lasting longer than 3 months in the past 12 months~Subject is willing to follow up 3 months post initial assessment~Observational study, no intervention"
88813714|NCT00918866|Experimental|Low Pulmonary Arterial Pressure|Subjects with pulmonary arterial pressure (PAP) of < or = to 35 mmHg.
88883648|NCT05271968|No Intervention|Control|Standard Care : The classic treatment recommended is the prescription of an oral drug, Ivermectin to be taken two times at one or 2 weeks interval. And recommendations on the need to change the clothes and the linen of the bedding the following day after taking the drug, washing them at more than 50° as well as all the clothes three days before are explained. The first course of oral treatment is swallowed at the BOPC, while the second course is given to be swallowed one week later.
88883649|NCT05271968|Experimental|Intervention|Patients in this interventional arm will come back to BOPC the following day after intake the treatment (D1 and D8) to take a shower and to receive again new clothes
88883650|NCT05271942|Experimental|Tilt and Tumble|"The patients of this group will undergo cataract surgery using the Tilt and Tumble technique."
88883651|NCT05271942|Active Comparator|Divide and Conquer|"The patients of this group will undergo cataract surgery using the Divide and Conquer technique."
88883652|NCT05271877||Pregnant women|Pregnant women, regardless of the gestational age.
88883653|NCT05271838|Experimental|High protein diet|High protein diet (2/g/kg/day)
88883654|NCT05271838|No Intervention|Standard Nutritional care|Standard nutritional care.
88883655|NCT05271838|Experimental|Magnesium|Magnesium oral supplementation
88883656|NCT05271838|No Intervention|Standard: No magnesium supplementation|No supplementation
88883657|NCT05271812||Mothers|All women delivered in the recruitment center
88883658|NCT05271812||Staff|All staff working in the labor and delivery areas of the recruiting center.
88883659|NCT05271786||Tracheostomized patients|Patients who underwent percutaneous tracheostomy performed for any reason
88883660|NCT05271695||The patients with type 2 diabetes|"Patients with a diagnosis of Type 2 Diabetes Mellitus and HbA1c ≤ 7%~Patients using or not using oral antidiabetic drugs~Patients who inject insulin once or twice a day or repeated insulin injections"
88883661|NCT05271695||The healthy controls|"Patients diagnosed with Type I Diabetes Mellitus,~Patients with HbA1c > 7%~Those with gestational diabetes,~Breastfeeding diabetics,~Patients with renal dysfunction,~Patients with acute and chronic infection status"
88883662|NCT05271539|Active Comparator|The first group, Lucentis alone group|The first group received 3 monthly intravitreal injections of 0.5 mg in 0.05 mL ranibizumab alone (Lucentis, by Novartis), aspirated from vial through 5-micron sterile filter needle (19-gauge × 1-1/2 inch), with a 1-mL syringe and injected through a 30-gauge × ½ inch sterile injection needle.
88883663|NCT05271539|Active Comparator|The second group, Lucentis dexamethasone group|The second group received monthly intravitreal injections of the same dose of ranibizumab combined with 0.4 mg in 0.1 ml dexamethasone (Dexamethasone sodium phosphate, Amriya Pharmaceuticals, Cairo, Egypt) in a separate 1ml syringe with 27- gauge × ½ inch sterile injection needle, followed by 2 Intravitreal ranibizumab, 1 month apart (with dexamethasone if follow up OCT shows less than 10% improvement from baseline i.e., PRN).
88883664|NCT05271500|Active Comparator|group(1)|40 post covid 19 patients will receive laser acupuncture
88883665|NCT05271500|Placebo Comparator|group(2)|40 post covid patients will receive placebo laser acupuncture in which laser will be off
88883666|NCT05271487|Experimental|Multi-Step Botanical Skin Care Regimen|The patient will be provided with and instructed to use a cleanser, toner, oil control cream, exfoliating facial scrub, clay mask, acne spot treatment, and body scrub for the duration of the study.
88883667|NCT05271461|Active Comparator|Circulatory exercises group .|Circulatory exercises.
88883668|NCT05271461|Experimental|LLLT group .|Low level laser Therapy + circulatory exercises.
88883669|NCT05271422|Experimental|Experimental Group|Dry eye disease patients (n=12)
88883670|NCT05271422|Sham Comparator|Control Group|Dry eye disease patients (n=12)
88883671|NCT05271396||Temporomandibular Joint Dysfunction Group|Being diagnosed with Temporomandibular Joint Dysfunction
88883672|NCT05271396||Healthy-matched Group|Being healthy according to WHO criteria
88883673|NCT05271370|Experimental|PRO 140 350 mg|PRO 140 350mg weekly SQ injection.
89191400|NCT00859846|Experimental|Long Axis arterial line placement|Twenty four patients will undergo arterial line placements using long axis arterial line placement under ultrasound.
88883674|NCT05271370|Experimental|PRO 140 525 mg|PRO 140 525mg weekly SQ injection.
88883675|NCT05271370|Experimental|PRO 140 700 mg|PRO 140 700mg weekly SQ injection.
89191401|NCT00859846|Experimental|Short Axis arterial line placement|Twenty four patients will undergo arterial line placements using short axis arterial line placement under ultrasound.
88883676|NCT05271253|Active Comparator|Group (C)|caudal group, where caudal anaesthesia was given using 1 mL/kg dose of 0.25% bupivacaine without epinephrine.
88883677|NCT05271253|Active Comparator|Group (D)|Dexmedetomidine (D) group, where Dex. (Precedex, hospira, Egypt) 0.8 μg/kg was given intravenously over 10 min as a loading dose, and then infused at a rate of 0.4 μg/kg/h
88883678|NCT05271253|Placebo Comparator|Group (P)|Placebo (P) group, where normal saline instead of Dex was given in volume (ml) and rate (ml/h) calculated related to the patient's body weight.
88883679|NCT05271227||Cardiogenic Shock Patients|"Cardiac output and Carotid Blood flow is measured before & after PLR test, then percent change is calculated were increase in cardiac output with 10 % or more is considered volume responder.~Measurements can be repeated as needed, and fluid resuscitation continues until no further response to passive leg raising is noted."
88883680|NCT05271201|Experimental|mild intensity group|Received mild intensity treadmill training according to Martti Karvonen's formula.
88883681|NCT05271201|Experimental|moderate intensity group|Received moderate intensity treadmill training according to Martti Karvonen's formula.
88883682|NCT05271188|Active Comparator|Group 1 who will receive IPACK block|This group of patients will receive IPACK block immediately before spinal anaesthesia then follow up for 24 hrs to register first pain sensation and analgesic requirements
88883683|NCT05271188|Active Comparator|Group 2 who will receive adductor canal block|This group of patients will receive adductor canal block immediately before spinal anaesthesia then follow up for 24 hrs to register first pain sensation and analgesic requirements
88883684|NCT05271149|Other|Control group|conventional physical therapy based on neurodevelopmental techniques, This program will be given for 1 hour, 3 days a week for 12 weeks
89191402|NCT00859846|Active Comparator|Palpation arterial line placement|Twenty four patients will undergo arterial line placements using Traditional palpation arterial line placement.
89408312|NCT02127996|Placebo Comparator|Normal Saline|Infusion of Normal Saline during Percutaneous Coronary Intervention
89408313|NCT02127996|Experimental|GLP-1|Infusion of GLP-1 (7-36) amide during elective percutaneous coronary intervention
89408314|NCT03551106||Web based learning module|Laboratory prescriptions made by postgraduate students who were enrolled to follow the web based modules
88883685|NCT05271149|Experimental|study group|conventional physical therapy and orthosis (Thera togs) : the child will wear the orthosis for twelve weeks, from 8 to 10 hours a day, during daily-life activities. The child's guardian (mother) will be trained and will receive a DVD recording, with a step-by-step demonstration on the fitting of TheraTogs® in the child. Markings were made in TheraTogs® to facilitate and improve fitting. All necessary support will be offered, with weekly monitoring in person to control the fitting of the orthosis, as well as for possible questions or clarifications.in addition to conventional physical therapy as the control group
88883686|NCT05271136|Active Comparator|Cell 1: Anti-aging Serum|"Dosage form: Anti-aging Serum~Frequency of Dosage: two times daily. Subjects are asked to apply 2 pumps of the Anti-aging Serum.~Study Duration: 7 days"
88883687|NCT05271136|Active Comparator|Cell 2: Anti-aging Serum and Facial Moisturizer|"Dosage form: Anti-aging Serum and Facial Moisturizer~Frequency of Dosage: two times daily. Subjects are asked to apply 2 pumps of the Anti-aging Serum, and then 2 pumps of the Facial Moisturizer to the global face.~Study Duration: 7 days"
88883688|NCT05271123||Study group|Children were evaluated using spirometer to assess forced expiratory volume at first second and peak expiratory flow and gross motor function classification system to assess the functional level.
88883689|NCT05271110|Experimental|Treatment cohort|Adult patients (ECOG 0-1) with a resectable (or previously resected) PDAC and either synchronous or metachronous liver metastases are the target population of this study.
88883690|NCT05271058|Sham Comparator|Control group 1|23 eyes that did not receive any intraoperative steroids
88883691|NCT05271058|Active Comparator|Dexamethasone group 2|23 eyes that received intracameral dexamethasone
88883692|NCT05271058|Active Comparator|Triamcinolone (TA) group 3|23 eyes that received intracameral triamcinolone (TA)
88883693|NCT05271045|Experimental|fortified canola oil with vitamins A and D and γ-oryzanol|daily intake of fortified canola oil (385 IU vitamin D/ 30g & 154 IU vitamin A/30 g & 2130 ppm γ-oryzanol/30g)
88883694|NCT05271045|Active Comparator|fortified canola oil with vitamins A and D|daily intake of fortified canola oil (385 IU vitamin D/ 30g & 154 IU vitamin A/30 g)
88883695|NCT05271045|Placebo Comparator|fortified sunflower oil with vitamins A and D|daily intake of fortified sunflower oil (385 IU vitamin D/ 30g & 154 IU vitamin A/30 g)
88883696|NCT05270954|Active Comparator|Group 1 (Phase 1)|All volunteers randomized to Group 1 will be administered the Betuvax-CoV-2 drug according to the following scheme: 20 μg + 5 μg, twice, within a 28-day period.
88883697|NCT05270954|Active Comparator|Group 2 (Phase 1)|All volunteers randomized to Group 2 will be administered the Betuvax-CoV-2 drug according to the following scheme: 20 μg + 20 μg, twice, within a 28-day period.
88883698|NCT05270954|Active Comparator|Group 3 (Phase 2)|All volunteers randomized to Group 3 will be administered the Betuvax-CoV-2 drug according to the following scheme: 20 μg + 5 μg, twice, within a 28-day period.
88883699|NCT05270954|Active Comparator|Group 4 (Phase 2)|All volunteers randomized to Group 4 will be administered the Betuvax-CoV-2 drug according to the following scheme: 20 μg + 20 μg, twice, within a 28-day period.
89408315|NCT00126776|Active Comparator|1|CAse/self management for COPD
88883700|NCT05270954|Placebo Comparator|Group 5 (Phase 2)|Volunteers randomized to Group 5 will be administered a placebo reference drug (0.9% aqueous sodium chloride solution), twice, within a 28-day period.
88883701|NCT05270941|Active Comparator|Control Groups|"Control groups. This clinical trial was designed as a split-mouth, randomized, controlled clinical trial. Bilateral gingival recession defects were randomly assigned to the test (CAF+T-PRF) or control (CAF+SCTG) groups after initially evaluating the clinical parameters and randomized by coin flip method.~Intervention: Procedure: Control groups"
88883702|NCT05270941|Experimental|Test Group|"Test groups. This clinical trial was designed as a split-mouth, randomized, controlled clinical trial. Bilateral gingival recession defects were randomly assigned to the test (CAF+T-PRF) or control (CAF+SCTG) groups after initially evaluating the clinical parameters and randomized by coin flip method.~Intervention: Procedure: Control groups Intervention: Procedure: test groups"
88883703|NCT05270915|Experimental|Family supportive EOLC|The intervention 'family supportive EOLC' was developed based on the international guidelines of family-centered care (25) with additional aspects of care and support. The investigators designed a separated single-bedded EOLC room for the infant and parents. Other family members, such as grandparents or siblings, were allowed to visit the infant and parents. The design of the room included the option for parents to stay comfortably on a sofa to relax and to play soothing music. Parents were encouraged to stay as long as they want and participate in basic care including physical contact with their infant. The nurses supported the parents in creating commemorative items such as a 'Yuan man' box with photos, baby handprint cards, footprint cards, a lock of hair and other precious memory items. A psychologist, in collaboration with our NICU, and a neonatologist supported the parents by individual interviews.
89408316|NCT00126776|Other|2|usual care
89408317|NCT02131350|Experimental|Ranibizumab with Photocoagulation|
89408318|NCT02128308|Experimental|Levofloxacin and Streptomycin added|Levofloxacin and Streptomycin added : Cycloserine(CS) 250mg bid, P-aminosalicylic acid(PAS) 2 pack bid, Prothionamide(PTH) 250mg (125mg x 2 tab) bid, Pyrazinamide(PZA) 1500mg (500mg x 3 tab) qd, Levofloxacin 750mg (500mg x 1.5 tab) qd, Streptomycin 1g IM qd
89408319|NCT02128308|Experimental|Moxifloxacin and Kanamycin added|Cycloserine(CS) 250mg bid, P-aminosalicylic acid(PAS) 2 pack bid, Prothionamide(PTH) 250mg (125mg x 2 tab) bid, Pyrazinamide(PZA) 1500mg (500mg x 3 tab) qd, Moxifloxacin 400mg (400mg x 1 tab) qd, Kanamycin 1g IM qd
89408320|NCT02131506|Experimental|Lapatinib, Caelyx|"Lapatinib is given at escalating doses orally and continuously on days 1-21.~Caelyx is administered at escalating doses in a 60-minute i.v. infusion on day 1."
89535640|NCT03076905|Experimental|IV drug|AUC0-t of single intravenous dose of F901318
89191403|NCT00723866|Experimental|1|BtxA+mCIMT (combination group)
89191404|NCT00723866|Placebo Comparator|2|BtxA+ conventional rehabilitation (control group)
89191405|NCT04069182|Other|Behavioral Activation Therapy|Psychological intervention
89191406|NCT00850252|Experimental|Lifeline blood vessel|
89191407|NCT00853294|Active Comparator|B|Tussionex® Pennkinetic® Extended Release Oral Suspension
89191408|NCT00853294|Experimental|A|Chlorpheniramine polistirex equivalent to 8 mg of chlorpheniramine maleate and hydrocodone polistirex equivalent to 10 mg of hydrocodone bitartrate capsule
89191409|NCT00717834|Experimental|Cohort 1, Treatment Arm 1|Randomization of a total of approx. 200 subjects to one of four treatment arms at 1:1:1:1 ratio to receive 1.25 µg of the RRV Vaccine with/without adjuvant (Al(OH)3), or 2.5 µg of the RRV Vaccine with/without adjuvant (Al(OH)3). Cohort 1 is subdivided into Cohort 1a (n = 60, i.e. 15 subjects per dose/adjuvantation combination) to receive the first vaccination on Day 0, with Day 7 safety data being reviewed by a Data Monitoring Committee and, following DMC recommendation, to receive the second vaccination at Day 21; Cohort 1b (n=140, i.e. 35 subjects per dose/adjuvantation combination) is to be vaccinated twice 21 days apart upon availability of DMC recommendation. Booster vaccination to follow 180 days after first vaccination.
89191410|NCT00717834|Experimental|Cohort 1, Treatment Arm 2|Same as Cohort 1, Treatment Arm 1
89191411|NCT00717834|Experimental|Cohort 1, Treatment Arm 3|Same as Cohort 1, Treatment Arm 1
89191412|NCT00717834|Experimental|Cohort 1, Treatment Arm 4|Same as Cohort 1, Treatment Arm 1
89191413|NCT00717834|Experimental|Cohort 2, Treatment Arm 1|Randomization of a total of approx. 100 subjects to one of two treatment arms at 1:1 ratio to receive 5 µg of the RRV Vaccine with/without adjuvant (Al(OH)3). Vaccinations take place upon review of Cohort 1a Day 7 safety data by DMC and recommendation to proceed. Booster vaccination to follow 180 days after first vaccination.
89191414|NCT00717834|Experimental|Cohort 2, Treatment Arm 2|Same as Cohort 2, Treatment Arm 1
89191415|NCT00717834|Experimental|Cohort 3, Treatment Arm 1|Randomization of a total of approx. 100 subjects to one of two treatment arms at 1:1 ratio to receive 10 µg of the RRV Vaccine with/without adjuvant (Al(OH)3). Vaccinations take place upon review of Cohort 1b and Cohort 2 Day 7 safety data by DMC and recommendation to proceed. Booster vaccination to follow 180 days after first vaccination.
89191416|NCT00717834|Experimental|Cohort 3, Treatment Arm 2|Same as Cohort 3, Treatment Arm 1
89191417|NCT00658359|Active Comparator|Treatment Arm 1|Treatment Arm 1 will also receive standard of care medications
89191418|NCT00658359|Experimental|Treatment Arm 2|Treatment Arm 2 will also receive standard of care medications
89191419|NCT00658359|Experimental|Treatment Arm 3|Treatment Arm 3 will also receive standard of care medications
89191420|NCT00860002||1|Ultramini laparotomy (UMLT) myomectomy (UMLT-M) versus laparoscopic myomectomy (LM)
89191421|NCT00860002||2|Laparoscopically aided myomectomy (LAM) versus LM
89191422|NCT00860002||3|LAM versus UMLT-M
89191423|NCT00860002||4|Mini laparotomy myomectomy (ML-M) versus UMLT-M
89191424|NCT00860002||5|Laparoscopic uterine artery occlusion with blockage of anastomosis between the uterine and ovarian vessels (LUVO) versus laparoscopic uterine artery occlusion without blockage of anastomosis between the uterine and ovarian vessels (LUAO)
89191425|NCT00860002||6|LUVO+LAM versus LUAO+LAM
89191426|NCT00860002||7|LUVO+LM versus LUAO+LM
89191427|NCT00860002||8|LUVO+UMLT-M versus LUAO+UMLT-M
89191428|NCT00860002||9|LUVO versus UMLT-UVO
89191429|NCT00860002||10|UMLT-UVO versus UMLT-UAO
89408321|NCT01674010|Experimental|Lamotrigine or Valproic acid + ELND005|Lamotrigine or valproic acid plus ELND005 film coated tablets, 500mg BID for up to 48 weeks
89408322|NCT01674010|Placebo Comparator|Lamotrigine or Valproic acid + placebo|Lamotrigine or valproic acid plus matched placebo BID for up to 48 weeks
89191430|NCT00860002||11|LUAO versus UMLT-UAO
89191431|NCT00860002||12|UMLT-UVO+UMLT-M versus UMLT-UAO+UMLT-M
89191432|NCT00860002||13|LUVO versus LM
89191433|NCT00860002||14|LUVO versus LAM
89191434|NCT00860002||15|LUVO versus LUAO+LM
89191435|NCT00860002||16|LUVO versus LUAO+UMLT-M
89191436|NCT00860002||17|LUVO versus LUAO+LAM
89191437|NCT00721266|Experimental|1|
89191438|NCT00853450|Experimental|1|AZD6482 on top of ASA
89191439|NCT00853450|Active Comparator|2|Clopidogrel on top of ASA
89191440|NCT04066790|Experimental|Pyrotinib in combination with nab-paclitaxel|Prior to surgery: pyrotinib and nab-paclitaxel for 4 cycles (1 cycle = 21 days). After surgery/chemotherapy with epirubicin and cyclophosphamide (EC): trastuzumab up to 1 year total.
89191441|NCT04066790|Active Comparator|Trastuzumab in combination with nab-paclitaxel|Prior to surgery: trastuzumab and nab-paclitaxel for 4 cycles (1 cycle = 21 days). After surgery/chemotherapy with epirubicin and cyclophosphamide (EC): trastuzumab up to 1 year total.
89191442|NCT03477552|Experimental|Accuvein V400 device|In the Accuvein group, the nurse uses the Accuvein device to identify the veins before any puncture to infuse the patient and then proceeds as usual, under illumination of the device.
89191443|NCT03477552|Active Comparator|Routine procedure|In the control group, the nurse proceeds as usual to infuse the patient (visual identification in the light of the chamber and palpation)
89191444|NCT00860080|Experimental|PXL01|Four Subjects per cohort will receive 10, 20, or 40 mg PXL01 respectively.
89191445|NCT00860080|Placebo Comparator|Placebo|One subject per cohort will receive 10, 20, or 40 mg Placebo respectively.
89191446|NCT00722904||1|patients undergoing routine post-intervention surveillance of aortic coarctation
89191447|NCT00722904||2|Healthy volunteers
89191448|NCT00721604||1|patients with mean arterial pressure lower than 65 mmHg
89191449|NCT00850330||Hospitalized patients|Patients elder than 65 years old hospitalized for any reason.
89191450|NCT02571192|Experimental|Experimental Drug|single oral dose radiolabelled 50mg of SHP626
89191451|NCT00724022|Other|A|Standard: Advagraf, CellCept, Decortin H + 2x Simulect Day 0 + 4
89191452|NCT00724022|Experimental|B|Steroidfree: Advagraf, Cellcept, Decortin H until Day 8, 2x Simulect Day 0 + 4
89191453|NCT00724022|Experimental|C|Steroidfree: Advagraf, Cellcept, Decortin H until Day 8, 3 x Thymoglobulin
89535641|NCT02452099|Other|5% DMSO|
89535642|NCT02452099|Other|7.5% DMSO|
89535643|NCT02452099|Other|10% DMSO|
89535644|NCT03076671|No Intervention|Standard of Care|Patients to get usual care from their established neurology care team that is enrolled in the study.
88883704|NCT05270915|Active Comparator|The standard EOLC|The standard EOLC included the international guidance of palliative care and EOLC in neonatology (21-23). In China, parents are often the decision-makers of their infant's treatment and the NICU clinicians usually respect the parent's decision (24). After parents have decided to withdraw treatment, standard EOLC is initiated and includes monitoring of vital signs and withholding or withdrawing rescue procedures such as intubation and intravenous infusion. Unnecessary lines are removed and pain management is provided by analgesia. Comfort care is provided by nurses including basic care such as skin care and oral care. After the infant died, the NICU physician informs the parents by phone.
88883705|NCT05270889|Experimental|Tislelizumab+Zanidatamab|
88883706|NCT05270824|Experimental|radical surgery after neoadjuvant immunotherapy (albumin Paclitaxel + Seggio + PD-1 inhibitor)|After randomization, patients received radical surgery after the neoadjuvant immunotherapy (albumin Paclitaxel + Seggio + PD-1 inhibitor)
88883707|NCT05270824|Active Comparator|radical surgery after neoadjuvant chemotherapy (albumin Paclitaxel + Seggio)|After randomization, patients received radical surgery after neoadjuvant chemotherapy (albumin Paclitaxel + Seggio)
88883708|NCT05270772|Experimental|CAR-T-19 Cells|The patients with CD19+ relapse or refractory B-ALL will receive a single infusion of autologous CAR-T-19 cells, with the escalated dose ranging from 0.5×10^6/kg to 5.0×10^6/kg CAR+ cells.
88883709|NCT05270720|Experimental|experimental group|This arm will evaluate the safety of administering a total dendritic cell dose of 5x106. A total of 3 to 6 patients will be enrolled. If this dose is associated with unacceptable side effects, as detailed in the study protocol, no further patients will be enrolled at this dose.
88883710|NCT05270681|Experimental|Individuals with HD|Participants with a confirmed diagnosis of Huntington's disease
88883711|NCT05270681|Experimental|Care Partners|Participants' care partners
88883712|NCT05270642|Experimental|HCC patients guided by Plan for Microwave Thermal Field|The plan for HCC patients undergoing microwave ablation would be refer to Plan for Microwave Thermal Field system
88883713|NCT05270629||Lower limb lymphedema patients|This was a retrospective cohort propensity score-matched study. Patients with lower limb lymphedema were enrolled.
88883714|NCT05270616|Experimental|robotic surgery group|minimally invasive lung surgery using the Davinci robotic system to assist.
88883715|NCT05270616|Active Comparator|uniport surgery group|VATS minimally invasive lung surgery under the uniportal status.
88883716|NCT05270616|Active Comparator|multiple- port surgery group|VATS minimally invasive lung surgery under the multiple- port status.
88883717|NCT05270590||group A|periareolar approach
88883718|NCT05270590||group B|submamary approach
88883719|NCT05270577|Experimental|Prehabilitation|Prehabilitation with physical exercise, psychological support, nutritional support and smoking/alchohol stop
88883720|NCT05270577|Active Comparator|Standard care|Standard preoperative recomendations
88883721|NCT05270564|Active Comparator|Drain|Surgical drains used as routine
88883722|NCT05270564|Experimental|No drain|No surgical drain used
88883723|NCT05270551|Active Comparator|Group 1|Without augmentation
88883724|NCT05270551|Active Comparator|Group 2|With augmentation
88883725|NCT05270538|Active Comparator|comparison of clinical and gasometric parameters between the study group and the control group|"To carry out the study, we defined a control group and a study group distributing them between the two groups. The control group will perform the exercise, without using a mask, while the study group will perform the exercise using Masks Zero Mask Sewing Virus Bac-Off Lupo® for the duration of the exercise.~The exercise consisted of 15 minutes of treadmill without inclination interspersing every 2 minutes at speeds 10 Km/h and 12 Km/h, being by definition of a dynamic aerobic exercise of intensity 4 of 5 in the Borg scale- classification of the intensity of physical exercise. Physical activity was performed in water deprivation and fasting at least 30 minutes before the start of activated."
88883726|NCT05270486||Group A|group A undergoing TELD (transforaminal endoscopic lumbar discectomy) with electromagnetic navigation system
88883727|NCT05270486||Group B|group B undergoing TELD with X-ray fluoroscopy (gold standard)
88883728|NCT05270447|Experimental|Total laparoscopic hysterectomy (TLH) Connetive tissue massage group|Connective tissue massage+ routine care+ advising
88883729|NCT05270447|Other|Total laparoscopic hysterectomy (TLH) control group|routine care+ advising
88883730|NCT05270447|Experimental|Total abdominal hysterectomy (TAH) Connetive tissue massage group|Connective tissue massage+ routine care+ advising
88883731|NCT05270447|Other|Total abdominal hysterectomy (TAH) control group|routine care+ advising
88883732|NCT05270434|Experimental|Endoscopic group <12h|The patients received intravenous analgesia (flurbiprofen and remifentanil) before the ESWL (Compact Delta II; Dornier Med Tech, Wessling, Germany). After the last ESWL session, the patients are treated with following ERCP within 12h. ERCP was performed under conscious sedation with intramuscular administration of diazepam 2.5-5.0 mg and pethidine 25-50 mg. If necessary, endoscopic sphincterotomy was performed. A dilating bougie or balloon will be used to dilate the stenosis after sphincterotomy. Standard techniques (i.e., extraction basket, extraction balloon, or both) will be used for stone removal. A pancreatic duct stent for drainage and nasopancreatic catheters will be inserted for temporary drainage if necessary.
89191454|NCT00850408|Experimental|Real rTMS|Real rTMS - subjects receiving real repetitive TMS - 1Hz over unaffected hemisphere
89191455|NCT00850408|Sham Comparator|Sham rTMS|Sham rTMS
89191456|NCT00721344|Experimental|1|
89535645|NCT03076671|Experimental|Standard of Care plus Palliative Care|Patients to get usual care, augmented by palliative care, provided by their established neurology care team that is affiliated with the study, with additional support provided by the University of Colorado Denver Neurology Palliative Care team.
89408323|NCT02131740|Experimental|Eye rubbing intervention|eye rubbing performed for 1 minute in horizontal direction, clockwise rest for 5 seconds eye rubbing for a further 1 minute
89408324|NCT02131740|Active Comparator|No eye rubbing|no eye rubbing - comparator
89408325|NCT03551340||Traditional methods|Patients, who consulted for gastro-intestinal symptoms between July 2016 and May 2017, and were investigated by traditional methods (stool microscopy and/or culture).
88813715|NCT00918866|Experimental|Elevated Pulmonary Arterial Pressure|Subjects with a PAP of > or = to 35 mmHg.
88813716|NCT02516982||Screening - Scrolling layout|"Participants will be asked to complete a survey consisting of three sections using an iPad Air tablet:~Section 1: Demographic information survey~Section 2: Whooley questions~Section 3: Edinburgh Postnatal Depression Scale~All questions will be presented on a single screen. This means that participants will have to scroll vertically in order to answer all the questions."
89191457|NCT00721344|Experimental|2|
89191458|NCT00721344|Experimental|3|
89408326|NCT03551340||Gastro-intestinal panel by PCR|Patients, who consulted for gastro-intestinal symptoms between July 2017 and May 2018,and were investigated by a gastro-intestinal panel by PCR
89408327|NCT02252328|Experimental|Simvastatine|Group of patients receiving simvastatin 80mg once daily in addition to standard care
89408328|NCT02252328|Placebo Comparator|Placebo|Group of patients receiving placebo once daily in addition to standard care
89408329|NCT05392400|Active Comparator|Control|"Currently, the standard of care for Cesarean section patients includes covering the closed incision with a sterile bandage to reduce the chance of infection, and approximately 48 hours of post-op hospitalization and wound surveillance. The control group will receive post-operative wound dressings consistent with the current standard of care."
89408330|NCT05392400|Experimental|Experimental|Patients randomized to the Experimental group will receive treatment with Steri3x immediately following closure of the Cesarean section incision. Participants in the experimental group will receive approximately 48 hours of post-op hospitalization and wound surveillance.
88813717|NCT02516982||Screening - Paging layout|"Participants will be asked to complete a survey consisting of three sections using an iPad Air tablet:~Section 1: Demographic information survey~Section 2: Whooley questions~Section 3: Edinburgh Postnatal Depression Scale~Only one question will be presented at any given time. This means that participants will have to navigate through multiple pages in order to answer all the questions."
88813718|NCT02516982||Retrospective plus momentary assessment|Participants in this group will be asked to download and install an app onto their own smartphones. After that, they will be asked to complete a sampling protocol consisting of 6 consecutive days, once a month for 6 months. During the 6 assessment days, participants will be required to complete the Edinburgh Postnatal Depression Scale, 5 momentary questions on a 5-point pictorial scale, and 2 contextual questions.
88813719|NCT02516982||Retrospective assessment|Participants in this group will be asked to download and install an app onto their own smartphones. After that, they will be asked to complete a sampling protocol consisting of one day a month for 6 months. The assessment days will consist of a single administration of the Edinburgh Postnatal Depression Scale.
88813720|NCT01583543|Experimental|Olaparib|400mg PO BID Continuous
88813721|NCT01724372|Experimental|Antidepressant|Fluoxetine
88813722|NCT01724372|Active Comparator|Antipsychotic|Aripiprazole
88813723|NCT00919100|Other|Standard Care|venipuncture with vapocoolant spray offered
88813724|NCT00919100|Experimental|Buzzy|Vibrating device with cold pack held to arm with tourniquet proximal to venipuncture site, optional distraction cards.
88813725|NCT03405350|Active Comparator|Study Group|The treatment included a comprehensive therapy: redon-sulfide baths, partial mud baths, kinesiotherapy, terrain therapy, dry massage, laser therapy, low-frequency magnetic field, ultrasonotherapy, cryotherapy, electrotherapy, light therapy. On the day of admission to the SPA the patients were subjected to subjective and objective examination. Laboratory tests (lipids profile, CRP, smear blood morphology, TAS- total antioxidative potential, the concentration of endorphins and serotonin, bilirubin, uric acid, albumin) were performed before treatment on day 5 and after 18 days. In addition, before and after treatment, standard scales were used to assess pain intensity: VAS scale and anxiety and depression levels - HADS scale.
88813726|NCT03405350|No Intervention|Control Group|On the day of admission to the SPA the patients were subjected to subjective and objective examination. Laboratory tests (lipids profile, CRP, smear blood morphology, TAS- total antioxidative potential, the concentration of endorphins and serotonin, bilirubin, uric acid, albumin) were performed before treatment on day 5 and after 18 days. In addition, before and after treatment, standard scales were used to assess pain intensity: VAS scale and anxiety and depression levels - HADS scale.
88883733|NCT05270434|Active Comparator|Endoscopic group 12-36h|The patients received intravenous analgesia (flurbiprofen and remifentanil) before the ESWL (Compact Delta II; Dornier Med Tech, Wessling, Germany). After the last ESWL session, the patients are treated with following ERCP within 12-36h. ERCP was performed under conscious sedation with intramuscular administration of diazepam 2.5-5.0 mg and pethidine 25-50 mg. If necessary, endoscopic sphincterotomy was performed. A dilating bougie or balloon will be used to dilate the stenosis after sphincterotomy. Standard techniques (i.e., extraction basket, extraction balloon, or both) will be used for stone removal. A pancreatic duct stent for drainage and nasopancreatic catheters will be inserted for temporary drainage if necessary.
88883734|NCT05270434|Active Comparator|Endoscopic group >36h|The patients received intravenous analgesia (flurbiprofen and remifentanil) before the ESWL (Compact Delta II; Dornier Med Tech, Wessling, Germany). The time scale between the last ESWL session and following ERCP is greater than 36h. ERCP was performed under conscious sedation with intramuscular administration of diazepam 2.5-5.0 mg and pethidine 25-50 mg. If necessary, endoscopic sphincterotomy was performed. A dilating bougie or balloon will be used to dilate the stenosis after sphincterotomy. Standard techniques (i.e., extraction basket, extraction balloon, or both) will be used for stone removal. A pancreatic duct stent for drainage and nasopancreatic catheters will be inserted for temporary drainage if necessary.
88883735|NCT05270421|Experimental|Intervention Group|"40 mg of furosemide IV + IV midazolam + 1000 ml of normal saline 30 minutes before ESWL~+ Standard ESWL"
88883736|NCT05270421|Active Comparator|Control Group|"IV midazolam + 1000 ml of normal saline 30 minutes before ESWL~+ Standard ESWL"
88883737|NCT05270343|Experimental|Vitamin D|In 99 subjects of 3-18yr with newly-onset T1D, oral administration of 140IU/kg qd of cholecalciferol will be given until the serum 25(OH)D3 was maintained at the upper limit of normal range(50-80 ng/ml[125-200 nmol/L], ≤100 ng/ml[≤250 nmol/L]) for the loading peroid. And then oral administration of 70IU/kg qd of cholecalciferol for the maintenance period, meanwhile combined with intensive Insulin therapy for 12 months.
88883738|NCT05270343|No Intervention|Insulin|In 99 subjects of 3-18yr with newly-onset T1D, only intensive insulin therapy will be given for 12 months.
88883739|NCT05270252|No Intervention|Control group|no intervention
88883740|NCT05270252|Experimental|Intervention group|Interdisciplinary educational intervention with a combination of active educational methods.
88883741|NCT05270226|Experimental|Group A|After being randomly allocated, group A participants had first evaluation (out of 3, pre-intervention) and immidiatlly recived Metacognitive ADHD Telehealth intervention for Work-performance Enhancement (Work-MATE).
88883742|NCT05270226|Experimental|Group B|After being randomly allocated, group B participants had first evaluation (out of 4), then waiting-phase of 10-11 weeks, and after second evaluation (pre-intervention) start Work-MATE intervention process.
88883743|NCT05270187|Experimental|Scanning Gorup|"Patients in this group will receive facial massage, facial expression exercises and a Multiwave Locked System Laser with energy density 10 J/cm2. Laser will scan the affected side after calculating the distance and the total energy delivered to the one side of the face.~The average treatment area is 50 cm2. The energy density was 10 J/cm2 with a total energy of 500 J and the treatment time is approximately 15 minutes. The laser probe will be away from the eye region. Both patients and therapist wear a laser googles."
88883744|NCT05270187|Experimental|Point laser Group|Patients in this group will received facial massage, facial expression exercises and laser at predetermined eight points on the affected side of the facial muscles. the hand piece is positioned perpendicular to 8 points which is located on the superficial roots of the facial nerve of the affected side. Each point will receive an energy density of 10 J/point with total energy delivered to the patient during one session of 80 joules. The time of application 90 sec/point. laser is calibrated by the manufacture company before the starting the experiment and periodically during the sessions. The laser probe will be away from the eye region. Both patients and therapist wear a laser googles.
88883745|NCT05270187|Placebo Comparator|Control Group|patients in this group will receive only facial massage, facial expression exercises and placebo laser. Facial expression exercises include active graduated strengthening exercises in front of a mirror (active assisted, freedom, and resisted), proprioceptive neuromuscular facilitation exercises for facial muscles, and resisted exercises for neck muscles. Participants are taught to perform massage and exercises correctly by the physiotherapist. All treatment groups are given instruction to repeat the massage and exercises two times a day for at least 6 weeks. The patient or one of his/her family members will confirm that the participant carries out the massage and exercises at home.
88883746|NCT05270161|Experimental|Test Group 1 (T1)|Multiple gingival recessions in the anterior region of the mandible treated with the tunnel technique.
88883747|NCT05270161|Experimental|Test Group 2 (T2)|Isolate gingival recessions in the anterior region of the mandible treated with the laterally closed tunnel technique.
88883748|NCT05270161|Active Comparator|Control Group 1 (C1)|Multiple gingival recessions in the anterior region of the mandible will be treated using the free gingival graft technique.
89191459|NCT00721344|Experimental|4|
89191460|NCT00721682||Case|The CASE group will be composed of children for whom the medical team will have chosen to carry out a sign of alert of ill-treatment during his hospitalization and with no plausible cause of traumatism
89191461|NCT00721682||control|The Control group will be composed of children, consulting with the emergency care for traumatism, not having a sign of alarm and having a plausible cause of traumatism.
89191462|NCT00717990|Experimental|1|XELIRI/Avastin
89191463|NCT00853528|Experimental|Single-fraction radiosurgery; 16 Gray|Subjects able to achieve the spinal cord dose constraints for single-fraction SRS stereotactic radiosurgery Radiation: stereotactic radiotherapy at 16 Gray Questionnaire administration diffusion tensor imaging functional magnetic resonance imaging
89408331|NCT05388968||Nuchal translucency with no genetic abnormalities|Pregnant women between 11 and 14 weeks with a fetus showing a nuchal translucency > 3.5 mm and no genetic abnormalities with array CGH.
89408332|NCT05388968||Nuchal translucency with genetic abnormalities|Pregnant women between 11 and 14 weeks with a fetus showing a nuchal translucency > 3.5 mm and a genetic abnormalities at array CGH.
89408333|NCT05388968||Genetic abnormalities|Pregnant women between 11 and 14 weeks with a fetus showing a nuchal translucency < 3.5 mm and a suspicion of genetic abnormalities
89408334|NCT02135952|Active Comparator|SRP+MTZ+AMX|Scaling and root planing (SRP) + metronidazole (MTZ; 400 mg thrice a day [TID] for 14 days) + amoxicillin (AMX; 500 mg TID for 14 days)
88883749|NCT05270161|Active Comparator|Control Group 2 (C2)|Isolate gingival recessions in the anterior region of the mandible will be treated using the free gingival graft technique.
88883750|NCT05270161|Experimental|Gel Group (G)|The donor area on the palate will be treated using hyaluronic acid gel and green tea applied by the participant 3 times a day for 7 days.
89408335|NCT02135952|Placebo Comparator|SRP+placebo|Scaling and root planing + placebo
89408336|NCT04656964|Experimental|Remimazolam Tosilate group|Patients received remimazolam tosilate to maintain sufficient sedation (sufficient sedation as judged by MOAA/S ≤ 4 for 3 consecutive measurements) during endoscopy procedure. And patients were slowly injected of 0.4 ug/kg of remifentanil for 1 min during the examination.When the analgesia was insufficient, Remifentanil can be added 5-10 ug each time according to the situation.
89408337|NCT04656964|Active Comparator|Midazolam group|Patients received midazolam to maintain sufficient sedation (sufficient sedation as judged by MOAA/S ≤ 4 for 3 consecutive measurements) during endoscopy procedure. And patients were slowly injected of 0.4 ug/kg of remifentanil for 1 min during the examination.When the analgesia was insufficient, Remifentanil can be added 5-10 ug each time according to the situation.
88883751|NCT05270161|Active Comparator|Clot Group (CO)|No material will be placed in the donor area, only the clot will be kept in position by means of sutures.
89408338|NCT02136030|Experimental|Lipo-AB|
89408339|NCT02136030|Active Comparator|Amphotericin B|
89408340|NCT02136108|Experimental|OPENtext|OPENtext will target cognitive, affective, and behavioral strategies through a single, brief in-person assessment, followed by 12 weeks of theoretically-informed text messages, a core set of information organized in a 'frequently asked questions' structure, interactive peer support, static resources on key patient-identified topics, and a library of peer stories accessible throughout the study period.
89408341|NCT02136108|Active Comparator|OPENnav|Peer Navigation is currently offered to some individuals in this Medicaid population but not all. Peer navigators interact with patients by phone/text and at home visits. Efforts focus on drivers of a patient's ED use, and may include providing or identifying patient support, improving health literacy, assisting with transportation vouchers, health education, family support, accessing housing services, and orienting to other community support services.
89408342|NCT02131818|Experimental|Amoxicillin|The patient will be received amoxicillin 500 mg 2 capsules orally bid pc for 5 days
89408343|NCT02131818|Placebo Comparator|Placebo|The patient will be received placebo 2 capsules orally bid pc for 5 days
88883752|NCT05270135|Other|ASAP Intervention|This is a pilot study of the ASAP intervention pharmacies to explore the preliminary impact of intervention components: the CEU training, coaching from research staff, ASAP materials and tracking for the sale of syringes. Staff of each enrolled pharmacy will complete surveys.
88883753|NCT05270070||Digital Booking|Patients bookings done through digital booking system.
88883754|NCT05270070||Traditional Booking|Patients bookings done through traditional booking like telephone or secure email.
88883755|NCT05270018|Experimental|Bacterial Lysate group|Oral / gastric administration of bacterial lysate once a day on an empty stomach, 14.0mg each time for at least 5 days
88883756|NCT05270018|Placebo Comparator|Control group|Oral / gastric administration of normal saline once a day, 14.0ml each time
88883757|NCT05270005||Asymptomatic carotid artery stenosis|Patients with an asymptomatic carotid artery stenosis, defined by 30% to 69% narrowing of the carotid artery according to conventional duplex measurements in the absence of ipsilateral retinal or cerebral ischemia in the preceding 6 months.
89408344|NCT05171920|Experimental|Auxora|
89408345|NCT05171920|Placebo Comparator|Placebo|
88883758|NCT05269979|Experimental|Intervention (the Vislanda district)|435 women living in Vislanda responded to a detailed survey and participated in physical exercise and received lifestyle advice on diet, smoking, walking and outdoor activities. Recommendations to use calcium and Vitamin D and do exercise at home by written instructions. Home visit by rehab team when needed. Group training with a physiotherapist. Gymnastics group and walking group. Walking aides and instructions of anti-slip protection. Home environment risk reduction was offered.
89408346|NCT04467398||Tuohy needle group|The participants who undergo the trigeminal nerve block using 22 guage Tuohy needle.
89408347|NCT04467398||Quincke needle group|The participants who undergo the trigeminal nerve block using 22 guage Quincke needle.
89408348|NCT02131896|Experimental|Mediterranean Diet|Mediterranean Diet
89408349|NCT02131896|Active Comparator|Regular nutritional instructions|Regular nutritional instructions
89408350|NCT04636138|Experimental|Single arm|
89408351|NCT03525626|Experimental|Online Mindfulness-based Tic Reduction|
89408352|NCT02128386||Renal sympathetic denervation|Olmesartan 40 mg once daily + Amlodipine 5 or 10 mg once daily + Hydrochlorothiazide 25 mg one daily plus renal sympathetic denervation
89408353|NCT02128386||Intensified antihypertensive treatment|Olmesartan 40 mg once daily + Amlodipine 5 or 10 mg once daily + Hydrochlorothiazide 25 mg one daily plus second-line antihypertensive agents (e.g. mineralocorticoid receptor antagonists or alpha-1-blockers)
89408354|NCT04605796|Experimental|Single Arm|"Experimental group:~Toripalimab combined with Bevacizumab"
89408355|NCT02252640|Active Comparator|Group 1|Week 0: RTS,S/AS01B (50mcg of RTS,S and standard adult dose of AS01), Week 4: RTS,S/AS01B (50mcg of RTS,S and standard adult dose of AS01), Week 8: RTS,S/AS01B (50mcg of RTS,S and standard adult dose of AS01), Week 11: Controlled Human Malaria Infection (CHMI), Week 31-39: Repeat CHMI of sterilely protected volunteers.
89408356|NCT02252640|Active Comparator|Group 2|Week 0: RTS,S/AS01B (50mcg of RTS,S and standard adult dose of AS01), Week 4: RTS,S/AS01B (50mcg of RTS,S and standard adult dose of AS01), Week 8: RTS,S/AS01B (10mcg of RTS,S and 1/5 of the standard dose of AS01), Week 11: Controlled Human Malaria Infection (CHMI), Week 31-39: Repeat CHMI of sterilely protected volunteers.
89408357|NCT02252640|Active Comparator|Group 3|Week 0: RTS,S/AS01B (50mcg of RTS,S and standard adult dose of AS01) & ChAd63 ME-TRAP (5 x 10^10 vp), Week 4: RTS,S/AS01B (50mcg of RTS,S and standard adult dose of AS01) & MVA ME-TRAP (2 x 10^8 pfu), Week 8: RTS,S/AS01B (50mcg of RTS,S and standard adult dose of AS01) & MVA ME-TRAP (2 x 10^8 pfu), Week 11: Controlled Human Malaria Infection (CHMI), Week 31-39: Repeat CHMI of sterilely protected volunteers.
89408358|NCT02252640|Active Comparator|Group 4|Week 0: RTS,S/AS01B (50mcg of RTS,S and standard adult dose of AS01) & ChAd63 ME-TRAP (5 x 10^10 vp), Week 4: RTS,S/AS01B (50mcg of RTS,S and standard adult dose of AS01) & MVA ME-TRAP (2 x 10^8 pfu), Week 8: RTS,S/AS01B (10mcg of RTS,S and 1/5 of the standard dose of AS01) & MVA ME-TRAP (2 x 10^8 pfu), Week 11: Controlled Human Malaria Infection (CHMI), Week 31-39: Repeat CHMI of sterilely protected volunteers.
89408359|NCT02252640|No Intervention|Group 5|Week 11: Controlled Human Malaria Infection
89191464|NCT00853528|Experimental|Hypo-fractionated radiosurgery; 21 Gray|Subjects unable to achieve the spinal cord dose constraints for single-fraction radiosurgery (SRS), based on tumor location and expected tolerance dose to the adjacent normal tissue, will be offered hypo-fractionated SRS (3 fractions) Radiation: stereotactic radiotherapy Questionnaire administration diffusion tensor imaging functional magnetic resonance imaging hypo-fractionated radiation therapy at 21 Gray
88883759|NCT05269979|No Intervention|Control (the Tingsryd/Emmaboda districts)|415 women living in Tingsryd and 395 women living in Emmaboda responded to the same detailed survey as the 435 women living in Vislanda.
89408360|NCT02252640|No Intervention|Group 6|Week 31-39: Controlled Human Malaria Infection
88883760|NCT05269940|Experimental|ZX-101A Dose Level A|ZX-101A administered orally at level A once daily
88883761|NCT05269940|Experimental|ZX-101A Dose Level B|ZX-101A administered orally at level B once daily
88883762|NCT05269940|Experimental|ZX-101A Dose Level C|ZX-101A administered orally at level C once daily
88883763|NCT05269940|Experimental|ZX-101A Dose Level D|ZX-101A administered orally at level D once daily
88883764|NCT05269940|Experimental|ZX-101A Dose Level E|ZX-101A administered orally at level E once daily
88883765|NCT05269927|Experimental|TD (typically developing) infants|Typically developing infants, infants without familiar risk for ASD or LD.
88883766|NCT05269927|Experimental|HR (high risk) for LD infants|Infants at high risk for language disorders
88883767|NCT05269927|Experimental|HR for ASD infants|Infants at high risk for autism spectrum disorder
88883768|NCT05269914|Experimental|Autologous anti-CD19 CAR-T cell injection|with 1.00×106 CAR+T cells/kg, 3.00×106 CAR+T cells /kg and 9.00×106 CAR+T cells/kg
89191465|NCT00853528|Experimental|Single-fraction radiosurgery; 18 Gray|Subjects able to achieve the spinal cord dose constraints for single-fraction SRS stereotactic radiosurgery Radiation: stereotactic radiotherapy at 18 Gray Questionnaire administration diffusion tensor imaging functional magnetic resonance imaging
89191466|NCT00853528|Experimental|Single-fraction radiosurgery; 20 Gray|Subjects able to achieve the spinal cord dose constraints for single-fraction SRS stereotactic radiosurgery Radiation: stereotactic radiotherapy at 20 Gray Questionnaire administration diffusion tensor imaging functional magnetic resonance imaging
89408361|NCT04534660|Experimental|Nasolabial Fold|"SMI-01 is an injectable device comprising silk particles distributed in a hydrogel carrier. The intervention will be administed once, at the Day 1 visit. An optional touch-up treatment is allowed at the Day 30 visit.~The study treatment facial areas are the Right and Left nasolabial fold. The Treating Investigator will inject SMI-01 into the mid to deep dermis for correction of moderate to severe wrinkle and folds. The Treating Investigator will determine the appropriate volume of SMI-01 to be injected during initial and touch-up treatment(s)."
89531044|NCT02498327|Experimental|Venavine Intensive®|Gelatine capsules containing the active ingredients of: 360 mg Red Vine Leaf extract, 60 mg of Horse Chestnut extract, 35 mg of Butcher's Broom extract and 3,2 mg of Vitamin B6 as well as the inactive ingredients of starch amyral white, di-calcium phosphate DC and magnesium stearate, will be taken once per day, in the morning after breakfast, for 30 days.
88883769|NCT05269719||Digital nerve injury, surgical treatment, isolated injury|Patient over the age of 18 with an isolated injury to a digital nerve.
88883770|NCT05269719||Digital nerve injury, surgical treatment, concomittant flexor tendon injury|Patient over the age of 18 with an injury to a digital nerve and a concomittant flexor tendon injury.
88883771|NCT05269693|Experimental|the Brief Hope Intervention group|The BHI consisted of 4 one-on-one sessions: 2 (1 hr) face- to-face sessions, and 2 (30 min) telephone follow-up sessions in-between.
88883772|NCT05269693|No Intervention|wait-listed control group|Usual community care
88883773|NCT05269654|Experimental|injectable poly-L-lactic acid|One side of the subject's hips will be treated with injectable poly-L-lactic acid (PLLA, Sculptra® Aesthetic; Galderma Laboratories; Fort Worth, TX).
88883774|NCT05269654|Sham Comparator|Normal Saline|One side of the subject's hips will be treated with injectable normal saline
88883775|NCT05269641|Experimental|Almonds|Daily consumption of almonds.
88883776|NCT05269641|Placebo Comparator|Control Snack|Daily non-nut snack will be consumed.
88883777|NCT05269524|Experimental|Treatment|Therapist-guided internet treatment.
88883778|NCT05269524|Active Comparator|Attention control|Non-directive supportive contact via email.
88883779|NCT05269485|Experimental|High-dose hypofraction Arm|Irradiation of 60-68Gy/15-17f is administered followed by one-year immunotherapy maintenance.
88883780|NCT05269485|Experimental|Low-dose hypofraction Arm|Irradiation of 48Gy/12f is administered followed by one-year immunotherapy maintenance.
88883781|NCT05269420|Experimental|SAS-J|single anastomosis sleeve Jejunal Bypass as a revisional bariatric procedure after restrictive bariatric procedures
89408362|NCT04534660|Experimental|Cheek Augmentation|"SMI-01 is an injectable device comprising silk particles distributed in a hydrogel carrier. The intervention will be administed once, at the Day 1 visit. An optional touch-up treatment is allowed at the Day 30 visit.~The midface constitutes the area of the face below the eyes and between the nose and the left or right ear. The study treatment facial areas are the Right and Left cheeks. The Treating Investigator will inject SMI-01 deeply (subcutaneous and/or supraperiosteal plane) for cheek augmentation to correct age-related volume deficiency in the midface, i.e., zygomaticomalar region, anteromedial cheek, and/or submalar region"
89408363|NCT01345669|Experimental|Afatinib (BIBW 2992)|Once daily
89408364|NCT01345669|Placebo Comparator|Placebo|Once daily
89408365|NCT05334212|Experimental|Evaluation of usefulness|To evaluate usefulness of Surgical Theater's Patient Engagement 360VR platform in helping align patient expectations and improve patient satisfaction and understanding in spinal surgery consults.
89408366|NCT02136186|No Intervention|Standard of care|patients will receive standard of care discharge instructions
89408367|NCT02136186|Active Comparator|Philips Telehealth|patients will be discharged with a telemonitoring device for 30 days
89408368|NCT05144464|Experimental|Quadrivalent influenza vaccine|Subjects received 2 doses of 0.5 mL of quadrivalent influenza vaccine, 4 weeks apart. Each 0.5-ml dose contained 15 μg of hemagglutinin per strain.
89408369|NCT02128464|Active Comparator|Standard knee cutting guides|Standard cutting guides use traditional instrumentation to determine knee implant positions. During surgery, a rod is placed in the leg bone and the cutting guide is attached to that rod.
89408370|NCT02128464|Active Comparator|Patient specific cutting guides|Patient specific cutting guides are custom-made for each patient based on Magnetic Resonance Imaging (MRI). Before surgery, MRI of the knee is done and used to create a cutting guide that is formed to the exact shape of the knee. The patient specific cutting guides have platforms that can be attached to the bone, so the rod does not need to be placed in the leg bone.
89408371|NCT02136264|Active Comparator|PCFA interventional dietary counselling|personalized categorical food avoidance dietary counselling
89408372|NCT02136264|Sham Comparator|conventional DASH diet counselling|"DASH = conventional dietary approach to stop hypertension"
89408373|NCT04466774|Experimental|Dip Home-Based Dipstick Analyzer|Each participant will test their urine sample using the HBDA. device
89408374|NCT04552418|Experimental|Potato-based dietary starch supplement|Patients undergoing cancer treatment with dual immune checkpoint inhibitors (ICI) will receive potato-based dietary starch supplements.
89408375|NCT02136342|Experimental|chlorogenic acid|
89408376|NCT05222503|Active Comparator|Control group: Medial off-loader brace and home exercise program|The subject will receive a traditional medial off-loader brace and a take-home, self-guided exercise program. The subject will be instructed how to wear the brace. The subject will be instructed to incrementally increase wear time of the brace in the first week to get accustomed to the brace to reach a minimum of 6 hours per day after the first week.
89408377|NCT05222503|Experimental|2. Intervention group: Medial off-loader brace with OPUM Digital Knee and Remote Patient Monitoring|"The same off-loader brace as above but with the ODK sensor will be provided. The subject will be instructed how to wear the brace and sensor. The patient will be instructed to incrementally increase wear time in the first week to get accustomed to the brace to reach a minimum of 6 hours per day after the first week. Using the sensor they will be able to keep track of their exercise frequency, range of motion (ROM), and kinematics in the OPUM app on their mobile phone. Education/resources will also be provided to the subjects via modules in the mobile app. The subjects will be instructed how to use the app as well.~Patients data will be monitored remotely for 20mins per patient per month in the sensor group. Programs will be updated as necessary based on data."
89408378|NCT05222347||Comparison of biochemical parameters of OLT drinkers|Compared biochemical parameters of OLT smokers and nonsmokers
88883782|NCT05269342|Experimental|the nurse-led counseling and after intervention exercise|"The NUCAI aims to help patients manage themselves physically and psychologically by giving support, education, and exercise tracking.~The participants in the control group were care as usual.Intervention group were the nurse-led counseling and after intervention exercise (NUCAI), in patients with HNC."
89408379|NCT05222347||Comparison of biochemical parameters of OLT nondrinkers|Compared biochemical parameters of OLT smokers and nonsmokers
89408380|NCT02260596||Cohort Population|Pediatric SOT/HSCT recipients
89408381|NCT02128620|No Intervention|Control Group|Users randomized to the www.sjekkdeg.no A version, consisting en the educative web app, not including the Game-Based Appointment System
89408382|NCT02128620|Experimental|Intervention Group|Users randomized to the www.sjekkdeg.no B version, consisting in the web app www.sjekkdeg.no including the Game-Based Appointment System
89408383|NCT05521867|Active Comparator|Endoscopic balloon dilation|Confirmed Crohn's disease with gastro-duodenal or ileo-colonic short (<3 cm) strictures (both de novo and anastomotic) without prior history of endoscopic stricture therapy
88883783|NCT05269329|Experimental|XC8, film-coated tablets, 20 mg/day|
88883784|NCT05269329|Experimental|XC8, film-coated tablets, 40 mg/day|
88883785|NCT05269329|Experimental|XC8, film-coated tablets, 80 mg/day|
88883786|NCT05269329|Placebo Comparator|Placebo|
88883787|NCT05262673|Experimental|CART/CTL/DCvac cells to treat B-ALL|
89408384|NCT05521867|Active Comparator|Endoscopic stricturotomy with or without stricturoplasty|Confirmed Crohn's disease with gastro-duodenal or ileo-colonic short (<3 cm) strictures (both de novo and anastomotic) without prior history of endoscopic stricture therapy
89408385|NCT03550482|Experimental|Oncoxin®|
89408386|NCT03550482|No Intervention|Control|
89408387|NCT03550326||general anesthesia|Patients who undergo general anesthesia and are intubated or inserted airway device will be enrolled. researchers will follow the induction and intubation period and record all the complications due to airway management.
89531045|NCT04494581||Pregnant and postpartum women|Pregnant and postpartum women over 18, meeting inclusion and exclusion criteria.
89531046|NCT04494581||healthcare workers|Health professionals over 18, working in maternity wards included.
89531047|NCT02498561|Active Comparator|obese-chronic periodontitis patients|GCF, plasma and GCF samples were taken before and after nonsurgical periodontal therapy
88883788|NCT05254392|No Intervention|Usual Care|Participants in the UC arm received the usual/conventional care offered by the hospitals which included: hospital visits on appointment or a sick day, consultations with the physicians, prescription of drugs and routine laboratory tests, review of diagnosis and medications, refilling of prescriptions by patients and referral.
88883789|NCT05254392|Experimental|Pharmacists' Intervention|Participants in the PI arm received routine usual care plus pharmacists' interventions for 12 months. The PI arm received usual care plus face-to-face education on CKD, hypertension as a co-morbidity and its management, and antihypertensive medication adherence at baseline (group education), 6 months and 12 months (individualized according to each patient's needs), CKD patient educational infographic leaflet at baseline, a calibrated sphygmomanometer digital BP monitor (Chidalex®) for HSMBM, a BP logbook at baseline for the recording of BP values daily and hands-on training on BP self-measurement. Also, antihypertensive medication adherence and HSMBM reminder cell phone text messages were sent biweekly throughout the trial period, while phone-in inquiries from the participants and phone-out reinforcement interventions were utilized throughout the trial period
88883790|NCT05253625|Experimental|lullaby mother|The participant will listen to a lullaby recorded with his mothers voice.
88883791|NCT05253625|Experimental|lullaby female|The participant will listen to a lullaby recorded with a foreign female voice.
88883792|NCT05253625|No Intervention|no lullaby|The participant will not listen to a lullaby.
88883793|NCT05252897|Active Comparator|Endoscopic step-up approach|"After endoscopic drainage of WON, patients will be reassessed 72 hours after the procedure. If there is no clinical improvement 72 hours after drain placement, a CECT is performed to check the adequacy of the drainage. Irrigation of the WON via a nasocystic drain or endoscopic irrigation (step 1) is performed in case of inadequate drainage. If a nasocystic drain is inserted, 500ml of normal saline, twice a day will be used to irrigate the WON. If endoscopic irrigation is performed, only irrigation with normal saline without necrosectomy is allowed.~Patients are again evaluated 72 hours after step 1. In case of improvement, treatment is conservative; otherwise step 2 will be initiated, which is endoscopic necrosectomy. Further endoscopic necrosectomy will be performed until there is clinical improvement."
88883794|NCT05252897|Active Comparator|Direct endoscopic necrosectomy approach|Patients in the DEN group will undergo an immediate endoscopic necrosectomy after LAMS placement and balloon dilatation. A 10Fr 5cm double pigtail plastic stent will be inserted within the LAMS after necrosectomy. Patients will be assessed in 72 hours after the procedure. If there is no clinical improvement, a CECT is performed to check the adequacy of the drainage. DEN will be repeated in case of inadequate drainage. Patients will be reassessed every 72 hours and DEN repeated until there is clinical improvement. Subsequently, necrosectomy is performed weekly until a reassessment CECT at 3 weeks.
88883795|NCT05252468|Experimental|TaffiX™|TaffiX™ is a Nasal powder personal spray that blocks viruses particles from entering the nasal cells.
88883796|NCT05252468|Placebo Comparator|Lactose powder|Lactose nasal powder will be used as a placebo. It has an identical appearance as TaffiX™ (white powder in an identical bottle).
88883797|NCT05250739|Experimental|Strength training|Participants completed 16 training sessions of strength training during eight weeks.
88883798|NCT05250739|Experimental|Neuromuscular training|Participants completed 16 training sessions of neuromuscular training during eight weeks.
88883799|NCT05250739|No Intervention|Control group|The Control group received no intervention.
88883800|NCT05250583|Experimental|LV-Visio-AMTRIX|Sutureless amniotic membrane supported by a biological ring.
88883801|NCT05250193|Experimental|DK ScoreTM Coronary Scoring Balloon (DK Score)|DK ScoreTM Coronary Scoring Balloon Manufactured by DK Medical Technolgy CO.,LTD
88883802|NCT05250193|Active Comparator|Non-Slip Element Coronary Dilatation Catheter (NSE)|Non-Slip Element Coronary Dilatation Catheter Manufactured by GOODMAN CO.,LTD
88883803|NCT05250141|Experimental|Levodopa and Carbidopa Test Product|Participants will receive one tablet of the test formulation containing Levodopa and Carbidopa 250 mg/ 25 mg. The tablet will be taken with water and in a fasting condition.
88883804|NCT05250141|Experimental|Levodopa and Carbidopa Referent Product|Participants will receive one tablet of the marketed reference containing Levodopa and Carbidopa 250 mg/ 25 mg. The tablet will be taken with water and in a fasting condition.
88883805|NCT05254769|Experimental|Neurofeedback Intervention in children with Autism Spectrum Disorder|Neurofeedback therapy will be provided to 35 children with Autism Spectrum Disorder 30 sessions each and cognitive domains will be assessed before and after intervention.
89408388|NCT01673854|Experimental|Vemurafenib, 960 mg + Ipilimumab, 10 mg/kg|Participants received vemurafenib, 960 mg, twice daily for 6 weeks (Vem1 Phase). After a washout period of 3-10 days, patients received ipilimumab, 10 mg/kg, every 3 weeks for a maximum of 4 doses. At Week 24, participants received ipilimumab, 10 mg/kg, every 12 weeks until disease progression or unacceptable toxicity. Patients who did not progress or have unacceptable toxicity in the Vem1 Phase were retreated with vemurafenib (Vem 2 Phase) at the last dose level identified at the end of the Vem1 Phase until disease progression or unacceptable toxicity.
88883806|NCT05248724|Experimental|Intervention,|Patients allocated to the intervention group received a periarticular infiltration with a solution containing 200 mg of ropivacaine hydrochloride (10mg/ml Kabi Fresenius Kabi Norway AS),150 mg if the patient weight was below 65kg, 5 mg of morphine hydrochloride (10mg/ml Braun Medical SA Spain), 30 mg of ketorolac tromethamine (Normon Spain), 300 micrograms of adrenaline (epinephrine Braun Medical SA Spain), and saline 0.9% till reaching 50 ml of volume
88883807|NCT05248724|Placebo Comparator|placebo|Participants in the placebo group received a periarticular infiltration of 50 ml of saline 0.9%.
88883808|NCT05237310|Active Comparator|Standard Colonoscopy followed by CAD-EYE|Subjects will undergo standard colonoscopy immediately followed by CAD-EYE colonoscopy (both procedures performed by the same endoscopist in the same sedation session).
88883809|NCT05237310|Active Comparator|CAD-EYE followed by Standard Colonoscopy|Subjects will undergo CAD-EYE colonoscopy immediately followed by standard colonoscopy (both procedures performed by the same endoscopist in the same sedation session).
88883810|NCT05237310|Active Comparator|Standard Colonoscopy followed by combined CAD-EYE and G-EYE colonoscopy|Subjects will undergo standard colonoscopy immediately followed by combined CAD-EYE and G-EYE colonoscopy (both procedures performed by the same endoscopist in the same sedation session).
88883811|NCT05237310|Active Comparator|Combined CAD-EYE and G-EYE colonoscopy followed by Standard Colonoscopy|Subjects will undergo combined CAD-EYE and G-EYE colonoscopy immediately followed by standard colonoscopy (both procedures performed by the same endoscopist in the same sedation session).
88883812|NCT05235893|Experimental|Reflexology Group|The newborns who have applied Reflexology to soles three minutes before and during 5-7 minutes of painful procedure by a physiotherapist, certificated in reflexology.
88883813|NCT05235893|Active Comparator|Sucrose Group|The newborns who were given one ml of a single-use 24% concentration of sucrose solution in the form of ready to use preparations
88883814|NCT05235893|Active Comparator|Kangaroo Care Group|The newborns who were placed on the mother's lap for 3-5 minutes before the painful intervention and kangaroo care was applied
88883815|NCT05235893|Active Comparator|Music Group|"Newborns who were exposed to the recorded Deep Sleep track from Bedtime Mozart: Classical Lullabies for Babies music"
88883816|NCT05235893|No Intervention|Control Group|Control arm
89408389|NCT05514301|Experimental|Sensitivity of Polydeep vs high experienced endoscopists for colorectal polyp detection|Both diagnostic interventions will be performed in all patients: High definition colonoscopy and Polydeep system.
89408390|NCT03550248|Other|Intervention group|Participants will receive the intervention - Healthy Together (HT).
89408391|NCT02136654|Experimental|Culturally tailored diabetes program|"Culturally tailored diabetes program~culturally tailored diabetes education~lifestyle counselling~medication adherence counseling~peer supporter~communication training~family member involvement"
88883817|NCT05232006|Experimental|Niraparib|PARP-inhibitor, Niraparib Dosage : starting 300 mg/day for patients with body weight ≥77kg and platelet counts ≥ 150 000/µl or 200 mg when body weight inferior to 77kg and/or platelet counts ≤ 150 000/µl and > 100 000/µl Pharmaceutical form : 100 mg capsules Posology : single dose daily Route of administration : oral Administration procedures : oral, daily single dose Duration of treatment : 12 cycles of 28 days each
89408392|NCT02136654|No Intervention|Usual Care|Usual Care includes continuing to visit primary care physician for ongoing diabetes management Printed diabetes education materials.
89408393|NCT03525470|Experimental|Water|Subjects consumed water
89408394|NCT03525470|Experimental|No water|Subjects did not consume water
88883818|NCT05225051|Experimental|presymptomatic HD individuals with UHDRS motor ≤ 5 (Mutated Huntingtin)|presymptomatic HD individuals with UHDRS motor ≤ 5 (Mutated Huntingtin)
88883819|NCT05225051|Experimental|symptomatic HD individuals with motor UHDRS > 5 (Mutated Huntingtin)|symptomatic HD individuals with motor UHDRS > 5 (Mutated Huntingtin)
88883820|NCT05225051|Experimental|human control cell lines, Unmutated Huntingtin|human control cell lines, Unmutated Huntingtin
88883821|NCT05224583||Simultaneous Liver-Kidney Transplant patients population at MDMC|Consecutive SLK transplant recipients who were transplanted at MDMC over a 6-year period (2015 to 2020).
88883822|NCT05224297||breast|
88883823|NCT05224297||thorax|
88883824|NCT05224297||skin|
88883825|NCT05224297||abdomen|
88883826|NCT05224297||skull|
88883827|NCT05224297||head and neck|
88883828|NCT05224297||pelvis male|
88883829|NCT05224297||pelvis female|
89408395|NCT02804152|Other|CBT for Chronic Pain|single arm open-label design
89408396|NCT03549702|Active Comparator|Povidone irrigation Group|Includes the 100 women who will undergo elective caesarian section with subcutaneous tissue irrigation with Povidone iodine 1% solution.
89408397|NCT03549702|No Intervention|Control Group|Includes the 100 women who will undergo elective caesarian section without subcutaneous tissue irrigation with Povidone iodine 1% solution.
88883830|NCT05224297||extremities|
88883831|NCT05224193||Paediatric Patients with Inflammatory Bowel Disease|
88883832|NCT05214885||the ccRCC patient group|The age and gender of patients are not limited. The patient was preliminarily diagnosed as renal carcinoma by imaging examination and finally diagnosed as clear cell renal cell carcinoma by pathology.
88883833|NCT05214885||the healthy control group|The age and sex of the healthy control group were matched with that of ccRCC patient group. There was no tumor in the kidney or other parts of the body, and no tumor in the blood system. The healthy control group did not have any renal benign diseases, such as kidney stones, diabetic nephropathy, inflammation, and uremia. There are no inflammatory diseases in other parts of the body. The functions of the liver, kidney, and heart were normal.
88883834|NCT05214885||the benign kidney disease group|The age and sex of this group were matched with that of ccRCC patient group. The patient did not have any tumor but had one of the benign kidney diseases, such as kidney stones, diabetic nephropathy, inflammation, and uremia. The functions of the liver and heart were normal.
88883835|NCT05211362|Experimental|Sticky Bone and Repeated Injectable PRF (iPRF)|The surgical treatment phase was initiated only if the subjects had a full-mouth dental plaque score of less than one and a test site plaque score of 0. Following mucoperiosteal flap reflection for one tooth on either side of the defect, all granulation tissue was removed from the defects by means of Gracey 7/8 metal curettes, and root surfaces were scaled and planed using hand and ultrasonic instruments, then the defect was filled with xenograft mixed with IPRF, Finally, the flap was replaced and closed with crossed horizontal and vertical internal mattress sutures.
88883836|NCT05211362|Active Comparator|bone substitute|The surgical treatment phase was initiated only if the subjects had a full-mouth dental plaque score of less than one and a test site plaque score of 0. Following mucoperiosteal flap reflection for one tooth on either side of the defect, all granulation tissue was removed from the defects by means of Gracey 7/8 metal curettes, and root surfaces were scaled and planed using hand and ultrasonic instruments, bone graft substitute was heavily condensed into the intra bony defects. The flap was replaced and closed with crossed horizontal and vertical internal mattress sutures.
88883837|NCT05203978||Virtual reality colonoscopy|using virtual reality with glasses and sound no anaesthesia
88883838|NCT05203978||General anaesthesia colonoscopy|gold standard
89531048|NCT02498561|Placebo Comparator|obese-periodontally healthy controls|GCF, plasma and GCF samples were taken at baseline after oral hygiene instructions
88883839|NCT05202899|Experimental|Sugammadex Group|rocuronium-induced general anesthesia，use of sugammadex antagonism
88883840|NCT05202899|No Intervention|Control Group|general anesthesia without rocuronium
88883841|NCT05191537|Experimental|spinal mobilization with arm movement|conventional treatment and of spinal mobilization with arm movement
88883842|NCT05191537|Active Comparator|positional SNAGs|conventional treatment and positional SNAGs
88883843|NCT05186922|Experimental|CM326 55 mg, once every two weeks (Q2W)|55mg for 6 doses, every 2 weeks, subcutaneous (SC)
88883844|NCT05186922|Experimental|CM326 110 mg, once every two weeks (Q2W)|110mg for 6 doses, every 2 weeks, subcutaneous (SC)
88883845|NCT05186922|Experimental|CM326 110 mg, once every four weeks (Q4W)|110mg for 3 doses, every 4 weeks, subcutaneous (SC)
88883846|NCT05186922|Experimental|CM326 220 mg, once every two weeks (Q2W)|220mg for 6 doses, every 2 weeks, subcutaneous (SC)
88883847|NCT05186922|Experimental|CM326 220 mg, once every four weeks (Q4W)|220mg for 3 doses, every 4 weeks, subcutaneous (SC)
88883848|NCT05186922|Placebo Comparator|Placebo|Placebo for 6 doses, every 2 weeks, subcutaneous (SC) and placebo for 3 doses, every 4 weeks, subcutaneous (SC)
88883849|NCT05182827|Experimental|Euthymic patients with history of suicide attempt (suicide attempters)|Currently euthymic patients with at least one lifetime major depressive episode and a history of suicide attempts
88883850|NCT05182827|Experimental|Euthymic patients without any history of suicide attempt (affective controls)|Currently euthymic patients with at least one lifetime major depressive episode and with no history of suicide attempts
88883851|NCT05182346|Experimental|Acupressure of classical acupoints|Acupressure is applied on four acupoints: Pressure was applied to large intestine 10 (LI10) (large intestine meridians): It is located on the dorsal radial side of the forearm, 2 Cun below the transverse cubital crease. Hegu (large intestine meridians, LI 4): It is in the middle of the 2nd metacarpal bone on the radial side. TE5 (Triple energizer): It is located 2 cun proximal to the dorsal wrist crease between the radius and the ulna. SI3 (small intestine meridians): It is located at the ulnar end of the distal palmar crease proximal to the 5th metacarpal phalangeal joint. These acupoints are commonly used in the treatment of cervical myofascial pain syndrome.
88883852|NCT05182346|Experimental|Ischemic compression release of myofascial trigger points|Ischemic compression was gradually applied pressure to the trigger point with your thumb. The patient will likely feel referred pain in a question mark pattern (along the back of the neck, around the side of the head, and then a focused pain right behind the eye). Keep in communication with the patient, checking to ensure that in staying within the limits of his pain tolerance. Hold this technique for approximately 20 seconds to 1 minute, patient tells you that pain has diminished, or until feels the muscle fibers begin to relax under your pressure. Once feel this release, gradually release pressure. All identified trigger points will be treated. Then apply a few effleurage strokes to flush out the area and follow up with a passive stretch to the muscle.
88883853|NCT05175911||premature infants|premature infants less than 31 weeks of gestation or weighting less than 1300 g
88883854|NCT05173142|Experimental|dose escalation phase of HMPL-453 monotherapy or combination therapy|HMPL-453 monotherapy or combination therapy
88883855|NCT05173142|Experimental|indication specific dose expansion phase of HMPL-453 combination therapy|HMPL-453 combined with chemotherapy or anti-PD-1 antibody, in patients with IHCC, G/GEJ, or UC harboring specific FGFR gene alterations
88883856|NCT05167929|Experimental|Intervention Group|
88883857|NCT05167929|Experimental|Intervention PLUS Group|
88883858|NCT05167929|Active Comparator|Comparison Group|
88883859|NCT05167435|Experimental|Group A (Intervention)|"Myofascial release (Following Cross-hand release techniques of myofascial release in a manner of 2 minutes approach:~Cross-Hand Release of Back [For Thoracolumbar Fascia] Cross-Hand Release of the Lumbosacral Junction [L5-S1] Cross-Hand Release of Lateral low back area [for quadratus lumborum]) will be provided with conventional therapy including stretching exercises (Stretching of Latissimus Dorsi [10 seconds hold, 10 reps, 2 sets], Quadratus Lumborum Stretching [10 seconds hold, 3 reps, 1 set bilaterally], Lower Back Stretching [10 seconds hold, 10 reps, 2 sets], Hamstring Stretching [10 seconds hold, 10 reps, 2 sets bilaterally], Tensor Fasciae Latae Stretching [10 sec hold, 10 reps, 2 sets bilaterally] with duration rest will be of thirty seconds after five minutes) and Thermotherapy will be given for 20 minutes"
88883860|NCT05167435|Active Comparator|Group B (Control)|Posterior-anterior glide: Grade 1-4 [depending on tolerance] (120 oscillations per minute x 3 sets, Duration of rest between each set: 30 seconds) will be provided with the same conventional therapy as in Group A (Intervention)
88883861|NCT05165875|Other|Randomized: Steroid injection|1ml injection of a mixture of 0.5ml triamcinolone acetonide (50mg/5ml) and 0.5ml 1% lignoacaine is given intra-thecally into the first extensor compartment.
88883862|NCT05165875|Other|Randomized: Splint|a long thumb spica thermoplastic splint (wrist neutral, 30º CMCJ flexion, 30º thumb abduction, IPJ free) will be customized and intermittent active range of motion exercises will be taught for 4 weeks
88883863|NCT05163860||Youth|TGGD youth age 12-17 will answer a survey regarding demographics (gender identity, sex assigned at birth, age, religion, degree of religiosity, degree of family religiosity, degree of conservatism/liberalism, degree of family conservatism/liberalism, ethnicity), age at which they revealed their gender identity, family gender environment (FGE), eating disorder risk (ADO-BED, previous Eating Disorder diagnosis), food insecurity (HVS), perceived support of healthy eating and physical activity (SheL), risk taking behavior (ARQ), adequacy of physical activity (PACE+), bodyweight (BMI, BMI%ile, %mBMI), and previously diagnosed psychiatric and neurodevelopmental disorders
88883864|NCT05163860||Young Adults|TGGD young adults age 18-25 will answer a survey regarding demographics (gender identity, sex assigned at birth, country of residence, ethnicity, age, religion, degree of religiosity, degree of family religiosity, degree of conservatism/liberalism), age at which they revealed their gender identity, family gender environment (FGE), eating disorder risk (SCOFF, ADO-BED, previous ED diagnosis), food insecurity (HVS), perceived support of healthy eating and physical activity (SheL), risk taking behavior (RRBQ), bodyweight (BMI), malnutrition risk (MST), and previously diagnosed psychiatric and neurodevelopmental disorders.
89408398|NCT02136732|Experimental|Active self-management intervention|Participants will receive home visits and phone calls from a registered nurse and social worker. The registered nurse and social worker will provide participants one on one coaching, education, support and referrals to community resources to help them manage their chronic conditions.
88883865|NCT05163860||Parents|Parents of TGGD youth will answer a survey with information regarding demographics (religion, degree of religiosity, degree of conservatism/liberalism, country of residence, ethnicity, gender identity, sex assigned at birth, sexual orientation, education, marital status, household size, income), anxiety (GAD-7), depression (PHQ-9), family gender environment (FGE), food insecurity (HVS), height and bodyweight (BMI).
88883866|NCT05163457||aged of 75 and more living at home|"aged of 75 and more living at home group: patients aged of 75 and more living at home"
88883867|NCT05162313|Other|all patients undergoing tracheal intubation procedure|"In current practice, the endotracheal intubation procedure includes the systematic use of the capnometer, which is immediately connected to the tube after its insertion by direct laringoscopy. Confirmation of the correct tube positioning is established by color change of the capnometer from violet to yellow. Then, the colorimetric capnometer is usually removed before connecting the endotracheal tube to the flow-sensor of the ventilator.~For the purpose of our study, after the tube insertion the care provider will connect in line both the capnometer and the ventilator flow-sensor to the tracheal tube."
88883868|NCT05162118|Experimental|Single Arm|"Intratumoral injection of VG161 - 1.5*10^8 on D1 + Nivolumab on D8, D22~Intratumoral injection of VG161 - 1.0*10^8 on D1, D2 + Nivolumab on D8, D22~Intratumoral injection of VG161 - 1.0*10^8 on D1, D2, D3 + Nivolumab on D8, D22"
88883869|NCT05159310|Other|Cast|Patients presenting with DRF will be screened by the attending consultant. The temporary backslab will be removed, X-rays will be obtained, and the attending consultant will discuss the treatment options. Patients who are planned for non-operative treatment and meet the inclusion criteria will be eligible for the study. The purpose and details of the study will be explained and informed consent will then be taken by the research coordinator (RC). The participants will then be randomized (using a block-randomization method) to either treatment by splint or cast. A research assistant will facilitate the randomisation process so that the RC and the treating physician remain blinded to treatment allocation.
88883870|NCT05159310|Other|Splint|Patients presenting with DRF will be screened by the attending consultant. The temporary backslab will be removed, X-rays will be obtained, and the attending consultant will discuss the treatment options. Patients who are planned for non-operative treatment and meet the inclusion criteria will be eligible for the study. The purpose and details of the study will be explained and informed consent will then be taken by the research coordinator (RC). The participants will then be randomized (using a block-randomization method) to either treatment by splint or cast. A research assistant will facilitate the randomisation process so that the RC and the treating physician remain blinded to treatment allocation.
88883871|NCT05158556|Experimental|myofascial release technique|Myofascial Release Technique will be applied with forearm/ ulnar border of palm. deep pressure will be applied and glided medially towards the thoraco-lumbar region.ins
88883872|NCT05158556|Experimental|Instrument Assisted Soft Tissue Mobilization|instrument assisted soft tissue mobilization is done via M2T Blade. it is a multifunctional instrument consisting of many planes and is very effective in treating pain and spasm. Its efficacy is proven over soft tissues that it releases fascial tightness.
88883873|NCT05155917|Experimental|basal insulin and insulin pump|Subjects in the intervention group received insulin glargine sc (0.25 U/kg body weight) within 6 h of initiation of iv insulin infusion, as close to initiation of iv insulin as possible.
88883874|NCT05155917|No Intervention|insulin pump|Patients in the control group did not receive placebo injections.
88883875|NCT05153291|Experimental|Bachmann's bundle area pacing|Lead placement in Bachmann's bundle area
88883876|NCT05153291|Active Comparator|Right atrial appendage pacing|Lead placement in the right atrial appendage
88883877|NCT05150041|Active Comparator|iPRo2 only (Control group)|- The Control group will go through target lifestyle coaching including diet and exercise and they will undergo 24 weeks of follow-up period.
88883878|NCT05150041|Experimental|iPRo2 + RT-CGM 1 week treatment (Treatment group 1)|Treatment group 1 will go through target lifestyle coaching including diet and exercise and will have 1 session of RT-CGM after which they will undergo 24 weeks of follow-up period.
88883879|NCT05150041|Experimental|iPRo2 + RT-CGM 1 week on /3 weeks off (2cycles) (Treatment 2)|- Treatment group 2 will go through target life coaching including diet and exercise and will have 2 sessions(CGM 1week, 12week after measuring HbA1c) of RT-CGM after which they will undergo 24 weeks of follow-up period.
88883880|NCT05139940||Pilot Group to calibrate the operating points for AI algorithms (Estimated Enrollment up to 500)|"Diagnostic Test: TB AI algorithm performance in detecting active TB.~Diagnostic Test: TB diagnosis from sputum and urine (Smear microscopy, Xpert MTB RIF/ultra, Lipoarabinomannan (LAM) and mycobacterial culture)~Diagnostic Test: Abnormal/Normal AI algorithm to detect abnormal/normal CXRs.~Diagnostic Test: Radiologist evaluation of CXRs for active TB, abnormal/normal.~Diagnostic Test: Labs: Hemoglobin level, HIV status, CD4 count."
89408399|NCT02136732|Active Comparator|Attention control phone calls|Participants will receive an initial visit and then a phone call every other month from a social services aide who can provide information about community resources that might be helpful.
89408400|NCT03550950|Experimental|Single Ascending Dose (SAD) IV Cohort|Participants will receive single intravenous (IV) dose of JNJ-64232025 or placebo in Cohorts 1 to 6 on Day 1.
89408401|NCT03550950|Experimental|Subcutaneous (SC) Cohort|Participants will receive single dose of JNJ-64232025 or placebo as SC injection.
89408402|NCT01343407|Experimental|MK-1029 60 mg|Part 2 - Participants will receive 5 days of double-blind, once-daily MK-1029 60 mg followed by a 21-day washout in Period 2, 3, or 4 in a crossover design
89408403|NCT01343407|Experimental|MK-1029 500 mg|Part 2 - Participants will receive 5 days of double-blind, once-daily MK-1029 60 mg followed by a 21-day washout in Period 2, 3, or 4 in a crossover design
89408404|NCT01343407|Placebo Comparator|Placebo|Part II - Participants will receive 5 days of double-blind, once-daily MK-1029 60 mg followed by a 21-day washout in Period 2, 3, or 4 in a crossover design
89408405|NCT02529904|Experimental|MF59 - ATIV|"All child participants will receive 2 doses of the MF59-ATIV, with the doses separated by 28 days.~Adult participants will receive one dose of MF59-ATIV."
89408406|NCT01367886|Other|Fesoterodine|Females with overactive bladder symptoms will be given Fesoterodine 4 mg. daily for six weeks.
89408407|NCT04442594|Experimental|personalized video|Each subject of the reminiscence group will have two personalised virtual surroundings (after data being collected from team and/or families).
88883881|NCT05139940||Main Cross Sectional Group (Estimated Enrollment 1932 minus the volume in pilot)|"Diagnostic Test: TB AI algorithm performance in detecting active TB.~Diagnostic Test: TB diagnosis from sputum and urine (Smear microscopy, Xpert MTB RIF/ultra, Lipoarabinomannan (LAM) and mycobacterial culture)~Diagnostic Test: Abnormal/Normal AI algorithm to detect abnormal/normal CXRs.~Diagnostic Test: Radiologist evaluation of CXRs for active TB, abnormal/normal.~Diagnostic Test: Labs: Hemoglobin level, HIV status, CD4 count."
88883882|NCT05138029|Experimental|Anti-VEGF treatment group|Visual acuity and center thickness of the macula
89408408|NCT04442594|Active Comparator|generic vidéo|The subjects of the control group will be exposed to two generic virtual settings (beach, mountain etc.)
89408409|NCT05706415||patients with solid lesions of pancreas|
89408410|NCT02128698|Experimental|Protein and computer-assisted exercise|Patient group which takes daily protein supplements and is advised to do exercise 4 times per week by using Nintendo Wii Balance Board and Wii Fit Plus Software during 6 months after bariatric surgery.
89408411|NCT02128698|Placebo Comparator|Placebo and computer-assisted exercise|Patient group which takes daily control product and is advised to do exercise 4 times per week by using Nintendo Wii Balance Board and Wii Fit Plus Software during 6 months after bariatric surgery.
89408412|NCT02128698|Active Comparator|Protein and usual exercise|Patient group which takes daily protein supplements and is advised to do exercise 4 times per week by using written exercise instructions during 6 months after bariatric surgery.
89408413|NCT02128698|Active Comparator|Placebo and usual exercise|Patient group which takes daily control product and is advised to do exercise 4 times per week by using written exercise instructions during 6 months after bariatric surgery.
89408414|NCT04060420|Experimental|Comprehensive sexual and reproductive health services|In clusters randomised to the Yathu Yathu intervention, the comprehensive, community-based and peer-led intervention is being delivered. In addition to delivery of sexual and reproductive health services through community-based hubs, the intervention includes the Yathu Yathu prevention points cards, with which adolescents and young people can accrue points for accessing services at the Yathu Yathu hub and local health facility, and redeem rewards using these points.
89408415|NCT04060420|No Intervention|Standard of care|In the comparison arm, adolescents and young people will have access to sexual and reproductive health services at the local health facility. They will also have a Yathu Yathu prevention points card, with which they can accrue points for accessing sexual and reproductive health services at the local health facility and redeem rewards using these points.
88883883|NCT05138029|Experimental|Inner limiting membrane stripping group|Visual acuity and center thickness of the macula
88883884|NCT05138029|Experimental|Glucocorticoid treatment group|Visual acuity and center thickness of the macula
88883885|NCT05135039|Experimental|Lifestyle interventions + Canagliflozin|Subjects were instructed on diet and exercise and advised to make lifestyle changes while they were given daily oral doses of canagliflozin 100mg.
88883886|NCT05135039|Placebo Comparator|Lifestyle interventions + Placebo|Subjects were instructed on diet and exercise and advised to make lifestyle changes while they were given daily oral doses of placebo 100mg.
88883887|NCT05128591|Experimental|Arm A-Rivaroxaban|Period 1 : Reference Drug(AD-1091) Period 2 : Test Drug(AD-109)
88883888|NCT05128591|Experimental|Arm B-Rivaroxaban|Period 1 : Test Drug(AD-109) Period 2 : Reference Drug(AD-1091
88883889|NCT05123560||women attending first-trimester ultrasound|All women attending their first-trimester ultrasound and meeting the inclusion criteria will be invited to participate
88883890|NCT05121701|Active Comparator|Videolaryngoscopy|The patients were intubated with the C-MAC PM-Karl Storz Video laryngoscope.
88883891|NCT05121701|Active Comparator|Laryngoscopy|The patients were intubated with the Macintosh laryngoscope.
88883892|NCT05111327|Experimental|Intervention|Students in the interventional groups will receive structured simulation guideline
88883893|NCT05111327|No Intervention|Control|Students in the control groups will receive standard treatment.
88883894|NCT05109806|Experimental|Experimental group|Problem prevention therapy will be given as per intervention. a group of parents will be included for a group session for narration of their problems in relevance to health related quality of life .After the assessment the next session the solution to these problems would be given to them.
88883895|NCT05109806|Other|control group|for this group only a general education regarding disease will be conducted and no further interventions will be provide to them .
88883896|NCT05096052|Experimental|ProLectin M|Active chewable tablets containing galectin inhibitor complex carbohydrate
88883897|NCT05096052|Placebo Comparator|PLACEBO|Placebo chewable tablets not containing galectin inhibitor complex carbohydrate
88883898|NCT05093595|No Intervention|Group A|The tracheal tube was routinely fixed with a teeth pad and adhesive tape (3M).
88883899|NCT05093595|Experimental|Group B|The tracheal tube was fixed by the trans-nasal Silicone Foley Catheter (SFC) and adhesive tape.
88883900|NCT05088928|Experimental|Interventional Arm|Ecru (Apixaban )Tablets
88883901|NCT05088928|Active Comparator|Comparator/control|Rivascot (Rivaroxaban)
88883902|NCT05078762|Experimental|iVR|The intervention group will train on a bronchoscopy simulator in an iVR environment with Virtual Reality Goggles (HTC IVE Pro Eye, HTC corporation, Taiwan) while using the bronchoscopy simulator.
88883903|NCT05078762|No Intervention|Non iVR|The control group will train on a bronchoscopy simulator without VR goggles.
88883904|NCT05075122|Experimental|Vaccination arm|Pembrolizumab flat dose iv every 3 weeks + UV1 vaccination (UV1 plus GM-CSF/Sargramostim as adjuvant per vaccination)
88883905|NCT05075122|Other|Calibration arm|Pembrolizumab flat dose iv every 3 weeks
88883906|NCT05067439|Other|Period 1|In Period 1, all the participants will receive single doses of the probe drugs, including caffeine 100 mg, efavirenz 50 mg and omeprazole 10 mg, together on Day 1.
88883907|NCT05067439|Other|Period 2|In Period 2, participants will receive abrocitinib 200 mg once daily (QD) on Day 1-10, single dose of omeprazole on Day 2 and single dose of probe drugs together on Day 8.
88883908|NCT05064176|Experimental|Reconstructive lymphatic surgery|"The intervention treatment is reconstructive lymphatic surgery and consists of the application of lymphovenous anastomosis (LVA), lymph node transfer (LNT) or a combination of both. The choice of reconstructive technique(s) is determined by the surgeon and is based on the algorithm for reconstructive lymphatic surgery of lymphoedema.~Additionally, all patients receive usual care (i.e. maintenance decongestive lymphatic therapy)"
88883909|NCT05064176|Active Comparator|No surgery|All patients receive usual care (i.e. maintenance decongestive lymphatic therapy)
88883910|NCT05064137|Experimental|Curodont Repair® ( monomeric self - assembling peptide P11-4 )|Self assembling peptide P11-4 as Curodont Repair® can remineralize WSLs in a deeper manner than fluoride by guided enamel regeneration by forming a three-dimensional matrix within the subsurface body of an initial carious lesion to which calcium and phosphate ions found in natural saliva can bind and build de novo hydroxyapatite crystals.
88883911|NCT05064137|Experimental|Clinpro white varnish® ( Tricalcium Phosphate Fluoride Varnish, 5% F- )|Tri-calcium phosphate can be hydrolyzed rapidly to form calcium hydroxyapatite (HAp). The processes of hydrolysis and formation of HAp are accelerated by the presence of NaF ions as in case of Clinpro white varnish®. Moreover, the HAp formed by such hydrolysis tends to have a greater uptake of fluoride than conventional HAp.
88883912|NCT05064137|Active Comparator|Voco-profluorid® fluoride varnish (5% sodium fluoride)|Fluoride varnish is the gold standard for treating WSLs.
88883913|NCT05059743|Experimental|[14C]-Larotinib|Patients will receive single dose of [14C]-Larotinib (Suspension, 350mg/100μCi).
88883914|NCT05057364|Experimental|Heart Smart Group|Receives Heart Smart Intervention
88883915|NCT05055986||CBCT Dicom files of patients|CBCT Dicom files of patients will be used for measurements of mandibular bone volume by open-source software.
88883916|NCT05052528|Experimental|Dose level 1 (fludarabine, cyclophosphamide, CD19 CAR T)|Patients receive fludarabine phosphate IV over 30 minutes daily and cyclophosphamide IV over 60 minutes daily on days -5 to -3. Patients also receive CD19 CAR T cells IV on day 0.
88883917|NCT05052528|Experimental|Dose level 2 (rituximab, fludarabine, cyclophosphamide, CAR T)|Patients receive rituximab IV on day -5, fludarabine phosphate IV over 30 minutes daily on days -5 to -3, and cyclophosphamide IV over 60 minutes on days -5 to -3. Patients also receive CD19 CAR T cells IV on day 0.
88883918|NCT05052528|Experimental|Dose level 3 (fludarabine, cyclophosphamide, CD19 CAR T)|Patients receive fludarabine phosphate IV over 30 minutes daily on days -3 to -5 and cyclophosphamide IV over 60 minutes daily on day -5. Patients also receive CD19 CAR T cells IV on day 0.
88883919|NCT05052528|Experimental|Dose level 4 (rituximab, fludarabine, cyclophosphamide, CAR T)|Patients receive rituximab IV on day -5, fludarabine phosphate IV over 30 minutes daily on days -5 to -3, and cyclophosphamide IV over 60 minutes on day -5. Patients also receive CD19 CAR T cells IV on day 0.
88883920|NCT05052528|Experimental|Dose level 5 (fludarabine, cyclophosphamide, CD19 CAR T)|Patients receive fludarabine phosphate IV over 30 minutes daily on days -5 to -1 and cyclophosphamide IV over 60 minutes daily on days -5 and -4. Patients also receive CD19 CAR T cells IV on day 0.
88883921|NCT05052528|Experimental|Dose level 6 (rituximab, fludarabine, cyclophosphamide, CAR T)|Patients receive rituximab IV on day -5, fludarabine phosphate IV over 30 minutes daily on days -5 to -1, and cyclophosphamide IV over 60 minutes on days -5 and -4. Patients also receive CD19 CAR T cells IV on day 0.
88883922|NCT05051150|Active Comparator|epinephrine 0.03 mcg|
88883923|NCT05051150|Active Comparator|epinephrine 0.05 mcg|
88883924|NCT05051150|Active Comparator|epinephrine 0.07 mcg|
88883925|NCT05045313|Experimental|The DDI of DBPR108 and Warfarin Sodium Tablets|Subjects will receive a single dose of Warfarin sodium 5 mg on Day 1, then take DBPR108 100 mg once-daily on Day 15 through Day 26 and a single dose of Warfarin sodium 5 mg on Day 19.
88883926|NCT05045313|Experimental|The DDI of DBPR108 and Digoxin Tablets|Subjects will receive a single dose of Digoxin 0.25 mg on Day 1, then take DBPR108 100 mg once-daily on Day 6 through Day 15 and a single dose of Digoxin 0.25 mg on Day 10.
88883927|NCT05045313|Experimental|The DDI of DBPR108 and Probenecid Tablets|Subjects will receive a single dose of DBPR108 100 mg on Day 1, then take Probenecid 500 mg twice-daily on Day 5 through Day 9 and a single dose of DBPR108 100 mg on Day 7.
88883928|NCT05044572|Experimental|Open chain kinetic exercises|
88883929|NCT05044572|Experimental|Forward head posture correction exercises|
89191467|NCT00853528|Experimental|Hypo-fractionated radiosurgery; 24 Gray|Subjects unable to achieve the spinal cord dose constraints for single-fraction radiosurgery (SRS), based on tumor location and expected tolerance dose to the adjacent normal tissue, will be offered hypo-fractionated SRS (3 fractions) Radiation: stereotactic radiotherapy Questionnaire administration diffusion tensor imaging functional magnetic resonance imaging hypo-fractionated radiation therapy at 24 Gray
89191468|NCT00853528|Experimental|Hypo-fractionated radiosurgery; 27 Gray|Subjects unable to achieve the spinal cord dose constraints for single-fraction radiosurgery (SRS), based on tumor location and expected tolerance dose to the adjacent normal tissue, will be offered hypo-fractionated SRS (3 fractions) Radiation: stereotactic radiotherapy Questionnaire administration diffusion tensor imaging functional magnetic resonance imaging hypo-fractionated radiation therapy at 27 Gray
89191469|NCT00721422|Experimental|Group 1-Normal|
89191470|NCT00721422|Experimental|Group 2-Mild|
88883930|NCT05044156||Case group|vaginal candidiasis
88883931|NCT05044156||Control group|healty women
88883932|NCT05032872|Experimental|Social Exergame Treatment Group|The treatment group will wear a Fitbit step counter for 8 weeks. In addition, participants will use the full version of the Go&Grow fitness app for 6 weeks.
88883933|NCT05032872|Active Comparator|Control Group|The control group will wear a Fitbit step counter for 8 weeks. In addition, participants will use the Go&Grow fitness app without the social features for 6 weeks.
88883934|NCT05007561|Experimental|Naltrexone|50mg naltrexone HCL once daily for seven days by mouth
88883935|NCT05007561|Placebo Comparator|placebo|sugar pill once daily for seven days by mouth
89191471|NCT00721422|Experimental|Group 3-Moderate|
89191472|NCT00721422|Experimental|Group 4-Severe|
89191473|NCT04878302|Experimental|Experimental: Taming Tics Together Protocol|"Families will participate in the 5-day telehealth-based intensive intervention and will receive three treatment formats which will provide CBIT and co-occurring diagnosis treatment:~Child/teen-only groups~Individual one-to-one sessions~Parent/caregiver-only groups"
89191474|NCT04878302|No Intervention|1-Month Waitlist Control|Families in the 1-month waitlist control group will participate in the initial intake assessment, then receive no treatment for a 1-month period. Following the 1-month period, families will participate in an assessment, then will be offered a place in a Taming Tics Together group
89191475|NCT00722982||1|
88883936|NCT04983394|Experimental|Virtual Realty|Participants will play a motion-controlled video game with Microsoft XBox One Kinect for 30 minutes, three days a week, for 8 weeks and lower and upper extremity stretching, strengthening and endurance exercises
88883937|NCT04983394|Active Comparator|Conventional|Participants will do aerobic exercises for 30 minutes, three days a week, for 8 weeks and lower and upper extremity stretching, strengthening and endurance
89191476|NCT00722982||2|
89191477|NCT02572986|Experimental|Permethrin cream 5%|Manufactured by Dr. Reddy's Laboratories, Ltd
89191478|NCT02572986|Active Comparator|Elimite™ Cream (permethrin) 5%|Manufactured by Prestium Pharma, Inc
89191479|NCT00853684|Experimental|oxaliplatin, capecitabine plus endostar|
89191480|NCT00853918|Experimental|$20 Cash|
89191481|NCT00853918|Experimental|$50 Cash|
89191482|NCT00853918|Experimental|$50 Check|
89191483|NCT00853918|Experimental|$100 Check|
89191484|NCT02570360|Active Comparator|exercise|Participants will engage in their outpatient treatment program as-usual, but additionally complete 30mins of moderately intense aerobic exercise 3 times per week for 6 weeks. They will complete 6 weeks of treatment, totaling 18 sessions with exercise.
89191485|NCT02570360|Placebo Comparator|treatment-as-usual|Participants will engage in their outpatient treatment program as-usual,but additionally complete 6 weekly, hour-long visits to complete questionnaires. They will complete 6 weeks of treatment (6 sessions total).
89191486|NCT00723060|Active Comparator|1|escitalopram high dose group
89191487|NCT00723060|Active Comparator|2|escitalopram conventional group
89191488|NCT00860236|Active Comparator|Psycoeducation/counseling|
88883938|NCT04981002|Active Comparator|Adult patients with orthopedic complaints - telemedicine self exam before face-to-face evaluation|First care will be performed via telemedicine with a clinical physician, guiding self-examination guided by telemedicine. After the remote consultation, a face-to-face evaluation will be performed with an orthopedist, according to institutional protocol.
88883939|NCT04981002|Active Comparator|Adult patients with orthopedic complaints - only face-to-face evaluation|Face-to-face care with an orthopedist, according to institutional protocol.
88883940|NCT04970914|Experimental|Anlotinib+Penpulimab|
88883941|NCT04965402|Experimental|Panel 1: Dose 1|
88883942|NCT04965402|Experimental|Panel 2: Dose 2|
88883943|NCT04965402|Placebo Comparator|Placebo|
88883944|NCT04961801|Experimental|Acalabrutinib in combination with tacrolimus and methotrexate|"Phase I: To determine the maximum tolerated dose (MTD) of Acalabrutinib in combination with tacrolimus and methotrexate for Phase II.~Phase II: To determine if acalabrutinib in combination with tacrolimus and methotrexate is safe and effective in reducing acute GVHD rate."
88883945|NCT04954131|Experimental|SCB-2019 vaccine|Investigational SCB-2019 vaccine contains 30 μg of SCB-2019 antigen, and 1.5 mg CpG 1018 and 0.75 mg Alhydrogel as adjuvants, in each 0.5 mL dose
88883946|NCT04954131|Placebo Comparator|Placebo|Saline solution (0.9%)
88883947|NCT04938388|Active Comparator|Oral Semaglutide (OS) with Enhanced Lifestyle Care (organic vegetables)|"Participants will start at a 3 mg dose of OS. If this minimum dose is not tolerated, the participant will be withdrawn from the study. After 4 weeks, the OS dose will be adjusted to 7 mg. After a further 4 weeks of study and thereafter, the OS dose will be adjusted at the study physician's discretion to 14 mg. At each study visit, the current dose of OS will be maintained, unless participants report moderate-to-severe nausea or vomiting for 3 or more days in the week before the scheduled visit. If participants report moderate-to-severe nausea or vomiting, the OS dose will be maintained or decreased at the study physician's discretion.~Participants will be instructed to swallow the OS tablet whole (not crushed, cut or chewed) in the morning, in a fasted state, with up to 120 mL of plain water, at least 30 minutes before any other food, beverage, or oral medication."
88883948|NCT04938388|Placebo Comparator|Oral Semaglutide (OS) Placebo with Enhanced Lifestyle Care (organic vegetables)|"Participants will start at a 3 mg dose of OS matched Placebo. If this minimum dose is not tolerated, the participant will be withdrawn from the study. After 4 weeks, the Placebo will be adjusted to 7 mg. After a further 4 weeks of study and thereafter, the Placebo will be adjusted at the study physician's discretion to 14 mg. At each study visit, the current dose of Placebo will be maintained, unless participants report moderate-to-severe nausea or vomiting for 3 or more days in the week before the scheduled visit. If participants report moderate-to-severe nausea or vomiting, the Placebo will be maintained or decreased at the study physician's discretion.~Participants will be instructed to swallow the matched OS Placebo whole (not crushed, cut or chewed) in the morning, in a fasted state, with up to 120 mL of plain water, at least 30 minutes before any other food, beverage, or oral medication."
88883949|NCT04935723|Experimental|EFFECT OF REIKIN ON ANXIETY, FEAR, PAIN AND LIFE FINDINGS OF ABDOMINAL SURGERY PATIENTS|According to randomization, the patients in the reiki/sham reiki group were taken to a quiet single room and reiki/sham reiki was applied for approximately 25-30 minutes. will be applied. Reiki application will be applied by a researcher who has Reiki I and Reiki II level training.
88883950|NCT04935723|Placebo Comparator|EFFECT OF SHAM REIKIN ON ANXIETY, FEAR, PAIN AND LIFE FINDINGS OF ABDOMINAL SURGERY PATIENTS|According to randomization, the patients in the sham reiki group were taken to a quiet single room and sham reiki was applied for approximately 25-30 minutes. will be applied. Sham Reiki will be applied by a health professional who has not received Reiki training.
88883951|NCT04935723|No Intervention|ANXIETY, FEAR PAIN LEVELS AND LIFE FINDINGS OF ABDOMINAL SURGERY PATIENTS|The control group will be given routine post-operative care without any intervention and the data collection tools will be applied at the same time as the experimental group, twice at 30-minute intervals.
88883952|NCT04935008|Experimental|Effect of recruitment maneuver on intracranial pressure|A recruitment maneuver will be performed in patients with decreased oxygen saturation due to atelectasis by applying 30 cm H2O positive pressure support for 30 seconds. The effect of the recruitment maneuver on intracranial pressure will be investigated by measuring the optic nerve sheath diameter with the help of ultrasonography before and after the recruitment maneuver.
89191489|NCT00860236|Active Comparator|Cognitive behavioural therapy|
89191490|NCT04069416||Group I|175 patients who fall within the Milan criteria.
89191491|NCT04069416||Group II|36 patients who fall within up-to-7 criteria
89191492|NCT04069416||Group III|30 patients beyond up-to-7 criteria and will be termed beyond all criteria (BAC).
89191493|NCT00860392|Experimental|1|Biomarker evaluation
89191494|NCT02571816|Experimental|ASP2215: Subjects with mild hepatic impairment|Subjects with Child Pugh classification score of 5-6 (mild)
89191495|NCT02571816|Experimental|ASP2215: Subjects with moderate hepatic impairment|Subjects with Child Pugh classification score of 7-9 (moderate)
88883953|NCT04931264|Experimental|YuWell YE660D and mercury sphygmomanometer|Blood Pressure Measurement with the YuWell YE660D Electronic Sphygmomanometer (YuWell YE660D) and with Desk Mercury Sphygmomanometer.
88883954|NCT04910932|Experimental|Breathing Exercises group|Breathing exercises will be applied via teleconference by a physiotherapist 1 day a week. Individuals will perform exercises by themselves at their homes on the remaining 6 days of the week. Exercise program will be applied for 4 weeks. Individuals will also be informed about COVID-19 for once at baseline.
88883955|NCT04910932|Other|Control group|Individuals will be informed about COVID-19 for once at baseline.
88883956|NCT04909372|No Intervention|No labelling|Food products without any label in the virtual supermarket.
89408416|NCT05706337|Active Comparator|propofol group|According to grouping，patients were premeditated with injection of Propofol 1-2mg / kg IV . If BIS is ≤ 60, Tracheal intubation was facilitated with cisatracurium 0.2mg/kg a IV and sufentanil 0.3 μ g / kg IV. if BIS is >60, propofol 0.5mg/kg was titrated intravenously, with an interval of more than 1min until the BIS is ≤ 60，and intubation was performed after cisatracurium and sufentanil injected .General anesthesia was maintained with Propofol and remifentanil.
88883957|NCT04909372|Experimental|Environmental labelling|Food products with an environmental label in the virtual supermarket.
88883958|NCT04908826|Active Comparator|Group A (standard cholangiography during surgery)|All patients will undergo laparoscopic cholecystectomy. In this group standard cholangiography will be performed during surgery. Standard cholangiography will be performed with selective catheterization of the cystic duct and infusion of a radiolucent substance (non-ionic low osmotic iodine). The category includes drugs such as iohexol, iopamidol, iopromide, ioversol, iobitriol, iomeprol and iodixanol. In our study we will use Xenetix (iobitriol) and perform cholangiography with C-ARM recording.
88883959|NCT04908826|Active Comparator|Group B (cholangiography with iv administration of icg prior to surgery)|All patients will undergo laparoscopic cholecystectomy. In this group intravenous fluorescent cholangiography with indocyanine green will be given at a dose of 0.3 mg / mL / Kg 6 (six) hours before the start of surgery.The bile duct system will be recorded with a special camera (Karl Storz NIR / ICG).
89408417|NCT05706337|Experimental|ciprofol group|According to grouping，patients were premeditated with injection of ciprofol 0.2-0.5mg/kg IV. If BIS is ≤ 60, Tracheal intubation was facilitated with cisatracurium 0.2mg/kg a IV and sufentanil 0.3 μ g / kg IV. if BIS is >60, ciprofol 0.1mg/kg was titrated intravenously, with an interval of more than 1min until the BIS is ≤ 60，and intubation was performed after cisatracurium and sufentanil injected .General anesthesia was maintained with Propofol and remifentanil in both groups.
88883960|NCT04908826|Active Comparator|Group C (cholangiography with direct administration of icg to the bile duct system during surgery)|All patients will undergo laparoscopic cholecystectomy. In the third group intraoperative cholangiography will be performed with direct administration of indocyanine green at a dose of 0.03 mg / ml / Kg to the bile duct cyst.
88883961|NCT04897425|Experimental|Mindful SensoriMotor Therapy Enhanced with Brain Modulation|"The participant can choose between one, two, or five interventions per week depending on their availability.~Steps of each intervention:~Pain Evaluation: Numeric Rating Scale (NRS)~Functional Assessments (1st, 5th, 10th, and last sessions)~Preparation:~Locate participant in a comfortable position for training (comfortable chair, about a meter distance to the screen, pleasant arm position)~Placement of the surface electrodes~Positioning of the feedback wearable device over the affected body part~Placement of the brain modulation cap~Treatment modalities:~Motor training~Sensory training~Sensorimotor training~Assessments~Step 4 is repeated for different phantom movements, initially one at a time, progressing to several joints simultaneously. A treatment session lasts 2 hours."
88883962|NCT04894786|Experimental|Mulligan Internal Rotation Mobilization|Mulligan Internal Rotation Mobilization & Sleeper Stretch
88883963|NCT04894786|Active Comparator|Post Isometric Relaxation Technique|Post Isometric Relaxation Technique and Sleeper Stretch
88883964|NCT04886817|No Intervention|Control|The control group participants in this study will not receive any intervention as is the current standard of clinical care for excess sugary drink consumption. They will receive monthly check-in reminders from research staff to promote engagement and retention and will participate in data collection visits at baseline, 3 and 6 months.
89191496|NCT02571816|Experimental|ASP2215: Subjects with normal hepatic function|Healthy subjects that match with respect to age, sex and body mass index (BMI)
89191497|NCT00850798|Experimental|1|Fasting plasma glucose (mg/dL) 90 to 130 Glycated hemoglobin (%) 6.0 to 7.0
89191498|NCT00850798|Active Comparator|2|Fasting plasma glucose (mg/dL) 90 to 180 Glycated hemoglobin (%) 7.0 to 9.0
89191499|NCT02572908|Active Comparator|Fermented wheat bread for 7 days|Long sourdough fermentation
89408418|NCT01613560|Experimental|PEPI：2-4 group-A|
89408419|NCT01613560|Active Comparator|PEPI：2-4 group-B|
88883965|NCT04886817|Experimental|Intervention|"Intervention group participants will receive a 6-month behavioral intervention with the following components:~A water promotion toolkit that includes water bottles, water flavor infusers, stickers to decorate bottles, and a children's book about water consumption, as well as instructions for other intervention components (how to view video, download app, and prepare for calls)~A 5-minute educational video that introduces parents to healthy drink choices for the family.~Ready, Set Gulp! A smartphone application for families that will help all family members track their beverage intake, find out how much water and sugar they are consuming, set goals, compete for points, answer quiz questions and create new recipes for flavor infused water.~A series of 14 interactive voice response phone calls to parents over 6 months that educate parents on topics relevant to improving family drink choices."
88883966|NCT04886284|Experimental|Ertapenem|Ertapenem 1g IV daily infused over 2 hours x 5 days
88883967|NCT04886284|Placebo Comparator|Placebo|Saline placebo infused daily over 2 hours x 5 days
88883968|NCT04876703|Experimental|Excite group (Group A)|The experimental group (Group A) will receive standard motor retraining of the affected upper extremity in addition to functional electrical stimulation provided by means of Xcite system 4 days per week for 30 minutes for two weeks.
88883969|NCT04876703|Active Comparator|Standard motor training group (Group B)|The control group (Group B) will receive standard motor retraining of the upper extremity.
88883970|NCT04871815|Experimental|Treatment of COVID19 Long Haulers with sodium pyruvate nasal spray|This is a single arm, open label study. All subjects will be provided a log for monitoring symptoms associated with Long COVID and asked to record symptom severity using a likert scale for one week. All subjects will then use N115 sodium pyruvate nasal spray 3x daily for an additional week and continue to log their symptoms.
88883971|NCT04867018||Orthopaedic Trauma, Pediatrics and Joint Patients|Patients will have an additional 9ml of blood drawn during their normal course of care for this study up to 4 times. Intraoperatively, we will request a tissue sample of the debrided injured muscle from the area where the surgeon is operating. There will be no additional tissue sample taken during the surgery, but what is removed in the normal course of the operation will be used for analysis in our study.
88883972|NCT04867018||Healthy Volunteer|Blood will be taken from healthy, nonpregnant adults who weigh at least 110 pounds. All volunteers will have a single blood draw of 100ml at the time of consent.
88883973|NCT04860271|Active Comparator|Filiform Needle|Respondent are health workers that is having mild to moderate anxiety symptoms, with Hamilton Anxiety Scale less than 25. This arm will receive 6 acupuncture treatment within 2 weeks, and will be taken outcome measurements 4 times, that is before the first treatment, after the third treatment, after the sixth treatment and at 2 weeks after the sixth treatment.
88883974|NCT04860271|Active Comparator|Press Needle|Respondent are health workers that is having mild to moderate anxiety symptoms, with Hamilton Anxiety Scale less than 25. This arm will receive 3 acupuncture treatment within 2 weeks, and will be taken outcome measurements 4 times, that is before the first needle placement, after replacing the first sets of needles, after removing the third sets of needles and at 2 weeks after removing the third sets of needle.
88883975|NCT04857099||Macular edema|
88883976|NCT04856696|Experimental|combined non-invasive PGT-A & PGT-A|Infertility women who underwent both non-invasive PGT-A and PGT-A
88883977|NCT04856696|Experimental|non-invasive PGT-A|Infertility women who underwent non-invasive PGT-A only
88883978|NCT04856696|Active Comparator|PGT-A|Infertility women who underwent PGT-A only
88883979|NCT04853459|Experimental|Retention|After Border modeling by traditional and light cure. Amount of force required to dislodge.
88883980|NCT04853459|Experimental|Vestibular depth measurement|Casts By using Ney Surveyor
88883981|NCT04851847|Experimental|MatrixflexTM resorbable collagen membrane|Experimental arm using the Matrixflex Resorbable Collagen Membrane for treatment of periodontal intrabony defects
88883982|NCT04851847|Active Comparator|control group membrane|Control arm using the Comparator Xenograft Resorbable Collagen Membrane or treatment of periodontal intrabony defects
88883983|NCT04837534|Experimental|Counseling group|In this group after the children have been examined, treatment plan and follow up schedule been advised by a pediatric ophthalmologist, parents/guardians along with the child will receive counseling from a trained counselor as per the set counseling protocol in every follow-up visits and will also be provided with the disease-specific information leaflets as an additional information material before the child is discharged from the department.
89191500|NCT02572908|Placebo Comparator|Yeast baked wheat bread for 7 days|Regular toast bread
89191501|NCT02572908|Other|Run-in|Gluten-free diet for 7 days before entering either bread period
89191502|NCT02571140|Active Comparator|Active Comparator|Subcutaneous injection of Teriparatide
89191503|NCT02571140|Experimental|Oral PTH (1-34)|Oral administration of pill with API with different optimizations
88883984|NCT04837534|Experimental|SMS and phone call reminder group:|In this group after the children have been examined, treatment plan and the follow-up schedule been advised, they will be discharged from the department but later they will receive reminders through short messaging text (SMS) and phone calls as per the set protocol
88883985|NCT04837534|No Intervention|Routine standard care group|In this group, the children will undergo ocular examination, and treatment plan. They will be discharged from the department and advised accordingly including a routine follow-up schedule as per hospital protocol.
88883986|NCT04835402|Experimental|Intervention|Day 1: Pembrolizumab 400mg Day 10: Irreversible electroporation Day 42/84/126/168: Pembrolizumab 400mg
88883987|NCT04834648|Experimental|Structured Counseling|"Structured Counseling, which includes A. Counseling is done by a trained counselor~B. Telephonic Follow up:~C. Development of Fast Track system at the Base Hospital. D. Provide Health Education Material to all Diabetic Patients. E. Referral communication and feedback between referring and referral facility."
88883988|NCT04834648|No Intervention|Control Arm|General Counseling, which included saying you need to visit the hospital and you have involvement in the eyes due to diabetes, providing a health education leaflet.
88883989|NCT04817579|Active Comparator|Conventional visual shade matching|Patients requiring single crown in the esthetic zone treated with Conventional visual shade matching (Ivoclar Classic shade guide)
88883990|NCT04817579|Experimental|Spectrophotometer|Patients requiring single crown in the esthetic zone treated with Spectrophotometer (Vita Easy Shade)
88883991|NCT04817579|Experimental|Digital photography combined with eLABor_aid shade analyzing software.|Patients requiring single crown in the esthetic zone treated with Digital photography combined with eLABor_aid shade analyzing software.
88883992|NCT04805255||Hypofractionated Stereotactic Radiotherapy (HF-SRT)|"A prospective cohort study addressing both neurocognitive outcome measures and oncological endpoints will be carried out for treating newly-diagnosed brain oligometastases with a pre-defined course of hypofractionated stereotactic radiotherapy (HF-SRT) in cancer patients with a fair/satisfactory performance status.~Either a limited number of brain metastases or oligometastatic brain disease refers to that the number of brain metastatic lesions (both post-resected and intact) at enrollment should be limited to three or fewer and that the greatest diameter of any metastatic lesion (either a tumor bed post-surgical resection or an intact brain metastasis) should be no more than 4 cm."
88883993|NCT04800718|Experimental|Door-to-door screening|Intervention includes door-to-door screening and awareness generation in 8-12 villages surrounding the Vision Centres
88883994|NCT04800718|No Intervention|Routine awareness activities,Control Arm|The control arm VC will continue its routine awareness activities & health talk sessions in the community.
88883995|NCT04800276|Experimental|APA with consideration of ischemia localization|
88883996|NCT04800276|Experimental|APA without consideration of ischemia localization|
88883997|NCT04791813||Exposure group|group of surgically treated unilateral cleft lip and palate Egyptian children aged 9_12years
88883998|NCT04791813||Control group|group of healthy Egyptian children aged 9_12years
88883999|NCT04783376|Active Comparator|Arm 1 (usual treatment)|intervention A
88884000|NCT04783376|Active Comparator|Arm 2(splitted bolus dose, fast-acting insulin only)|intervention B
89191504|NCT00854074|No Intervention|2|Subject will be observed until recovery of normal GI function
89191505|NCT00854074|Experimental|1|Spinal neurostimulation
88884001|NCT04783376|Active Comparator|Arm 3 (splitted bolus dose, fast acting insulin before the meal and regular insulin after the meal)|intervention C
88884002|NCT04783285|Experimental|Intervention Group|Participants who meet the inclusion criteria will be randomly assigned to the intervention group receiving CS or to a control group receiving treatment as usual. Participants in the intervention group will participate in two CS sessions per week for 16 weeks besides their treatment as usual. The sessions will be based on the existing protocol.
88884003|NCT04783285|No Intervention|Control Group|Participants assigned to the control group will maintain their usual treatment: social interaction activities, stimulation of personal skills, and any prescribed psychotic-specific medication.
88884004|NCT04772560|Experimental|Toric, Then Sphere|Participants who received Toric contact lenses first and spherical lenses after 10 days
88884005|NCT04772560|Experimental|Sphere, Then Toric|Participants who received Spherical contact lenses first and Toric lenses after 10 days
88884006|NCT04768829|Active Comparator|Placebo group|Nystatin ear drops formulations prepared as intervention except for the addition of Moringa prepared using biodegradable polymers in aseptic condition and tested for sensitivity
88884007|NCT04768829|Experimental|Moringa group|Moringa ear drops prepared using biodegradable polymers in aseptic condition and tested for sensitivity
88884008|NCT04760912|Experimental|Experimental group general anesthesia without rocuronium|30 patient ASA classification 1-2 for general anesthesia. Standard anesthesia monitoring. After induction with Propofol and Sufentanil ( doses adjusted according to weight and age) anesthesia was maintained with sevorane. Muscle strength measured on three occasions with Yamar dinamometar for hand grip strength, before induciran to anesthesia and immediate after Salingeru from anesthesia, then again measured in first 24 hours.
88884009|NCT04760912|Active Comparator|Active comparator: general anesthesia with rocuronium|30 patient ASA classification 1-2 for general anesthesia. Standard anesthesia monitoring with train-of-four (TOF). After induction with Propofol and Sufentanil (doses adjusted according to weight and age) and rocuronium 0,6 mg per kg, anesthesia maintained with sevorane. Muscle strength neasured with Yamar dinamometar for hand grip strength before induction to anesthesia and immediate after awakening from anesthesia, then again measured in first 24 hours.
89191506|NCT04068324|No Intervention|8 hours fasting group|Routine preoperative fasting group undergoes 8 hours of fasting before the operation.
88813727|NCT01584479||Low Risk Experimental Group|"1 visit - Low Risk~~1200 subjects~- Low Risk Experimental Group = 1 visit intervention, no history of periodontitis, non-smoker, non-diabetic, IL-1 genotype (-)"
88884010|NCT04758208||Healthy CALIPER Participants|Healthy community children and adolescents recruited through the CALIPER initiative as well as healthy children and adolescents recruited from outpatient clinics at the Hospital for Sick Children through the CALIPER initiative. Blood samples from these participants will be tested on the Mindray BC-6800Plus device to measure hematology parameters and establish reference intervals.
88884011|NCT04738448|Experimental|Art Therapy Group|
88884012|NCT04738201|Active Comparator|Control group|Thumb orthosis at night. Daily exercises program during 4 weeks grouped in 3 sets of 10 repetitions in absence of pain. Exercises will consisted of active - resistive exercises for the first dorsal interosseous (FDI) muscle, manual distraction of the CMC joint and relaxation of the adductor thumb muscle.
88884013|NCT04738201|Experimental|Experimental group|The experimental group will also carried out a proprioceptive exercise program divided in three phases of 2 weeks per phase.
88884014|NCT04734613|Experimental|Tai Chi intervention|Tai Chi exercise intervention provided twice a week for one hour for 12 weeks
88884015|NCT04734613|Active Comparator|self management|self management program provided 6 sessions (one hour per session) for 12 weeks
88884016|NCT04732481||interventional group|passive leg lift test
88884017|NCT04732481||control group|no intervention (SOC)
88884018|NCT04729816|Experimental|Dietary Intervention|All participants will stay weight stable while undergoing 5 phases of a dietary intervention that lasts 62 days.
88884019|NCT04717401|Experimental|Strain-counterstrain Group A|Strain Counterstrain (SCS) is a passive positional technique which aims to relieve musculoskeletal pain and dysfunction by indirect manipulation .
88884020|NCT04717401|Experimental|Muscle Energy Technique Group B|MET is a gentle manual therapy for the restricted mobility of the spine and extremities and is an active procedure in which the corrective force is regulated by the patient, not the clinician. This technique requires the patient to perform voluntary muscle contractions of varying intensity, in a specific direction, while the clinician uses a counter-force that does not allow movement to occur The physiological mechanism underlying SCS is unknown though. It has hypothesized that muscle tone inhibition occurs by stimulation of the target muscle's Golgi tendon organ by physical approximation of muscle origin and insertion.
88884021|NCT04715516|Experimental|alcohol brief intervention + lifestyle health promotion|"The intervention arm will receive 4 minutes of alcohol brief intervention, and 3 minutes of lifestyle health promotion (physical activity; maintaining a healthy weight), to increase knowledge of how to improve women's health and reduce breast cancer risk. Alcohol and lifestyle information will be delivered by way of an animation on an iPad. Participant responses to questions about current alcohol use will branch to personalised feedback consistent with level of alcohol consumption (i.e. drinking within or above current Australian Alcohol Guidelines).~Take-home pamphlets - a pamphlet summarising the alcohol information presented during the animation, and a pamphlet on nutrition to maintain a healthy weight, will be provided."
88884022|NCT04715516|Other|lifestyle health promotion, not inclusive of alcohol information|"The control arm will receive 3 minutes of lifestyle health promotion (physical activity; maintaining a healthy weight) to increase knowledge of how to improve women's health and reduce breast cancer risk, not inclusive of alcohol information. Lifestyle information will be delivered by way of an animation on an iPad.~Take-home pamphlet - a pamphlet on nutrition to maintain a healthy weight will be provided."
88884023|NCT04712604|Experimental|MSOS Group|The participants in this group will receive the MSOS Intervention for 4 consecutive weeks.
88884024|NCT04706767|Experimental|Effect of Co-administration Lidocaine and Dexmedetomidine on Quality of Recovery|
88884025|NCT04706767|Experimental|Effect of Dexmedetomidine infusion on Quality of Recovery|
88884026|NCT04706767|Experimental|Effect of Lidocaine infusion on Quality of Recovery|
88884027|NCT04706767|Experimental|Effect of saline infusion on Quality of Recovery|
88884028|NCT04706468|Experimental|40 mg TG-1000|Participants received 40 mg of TG-1000 and 40 mg of placebo orally on Day 1 and 40 mg of placebo on Day 3.
88884029|NCT04706468|Experimental|80 mg TG-1000|Participants received 80 mg of TG-1000 orally on Day 1 and 40 mg of placebo on Day 3.
88884030|NCT04706468|Experimental|40 mg TG-1000+40 mg TG-1000|Participants received 40 mg of TG-1000 and 40 mg of placebo orally on Day 1 and 40 mg of TG-1000 on Day 3.
88884031|NCT04706468|Placebo Comparator|Placebo|Participants received 80 mg of placebo orally on Day 1 and 40 mg of placebo on Day 3.
88884032|NCT04705298|Placebo Comparator|Placebo|Maltodextrin 4 grams daily for ≤ age 6; or 8 grams daily for >6 years
88884033|NCT04705298|Experimental|Prebiotic|Oligofructose-enriched inulin 4 grams daily for ≤ age 6; or 8 grams daily for >6 years
88884034|NCT04700215|Active Comparator|Group 01 Effectiveness of BiPAP in reducing post CABG pulmonary complications|Bilevel positive airway pressure device after every 6 hours
88884035|NCT04700215|Active Comparator|Group 02 Effectiveness of IS in reducing post CABG pulmonary complications|Incentive spirometry for 15 minutes after every 4 hours
88884036|NCT04699656|Experimental|Plazomicin Injection|plazomicin (30-minute IV infusion at 2.5 mg/kg) single dose given before IHD and single dose given after IHD
89408420|NCT01613560|Active Comparator|PEPI：0-1group|
88813728|NCT01584479||Low risk Control Group|"2 visits - Low Risk~~1200 subjects~- Low risk Control Group = 2 visit intervention, no history of periodontitis, non-smoker, non-diabetic, IL-1 genotype (-)"
88813729|NCT01584479||High Risk Experimental Group|"1 visit - High Risk~~800 subjects High Risk Experimental Group = 1 visit intervention, one or more of the following risk factors: history of periodontitis, smoker or diabetic, IL-1 genotype (+)"
89535646|NCT03076671|Experimental|Clinicians|Clinicians enrolled in the study will receive an 8-hour supportive and palliative care training, followed by monthly coaching and the availability of telemedicine visits for enrolled patients with the university neuro-palliative care team. The unit of randomization is the time when they receive training. Four to five clinical practices will receive training every 6 months during years 2 and 3, at which time all of their enrolled patients will be switched from usual care to the intervention arm.
89535647|NCT03317717|Experimental|botulinum toxin 2U|
88884037|NCT04698304||Group A：TASC C lesion group|Multiple stenoses or occlusions totaling >15cm or recurrent stenoses or occlusions that need treatment after endovascular interventions (300 cases)
89535648|NCT03317717|Experimental|botulinum toxin 5U|
89191507|NCT04068324|Experimental|Clear liquid group|"30 pediatric patients drink 3ml/kg 1 hour before the surgery. Although clear liquid suggests any drinks that do not contain any solid ingredients, but in this study we define clear liquid as water."
89191508|NCT04068324|Experimental|Carbohydrate containing liquid group|"Other 30 pediatric patients drink 3ml/kg of carbohydrate containing fluid 1 hour before the surgery. The product name we have is NoNPO from NewCare (South Korean company). This fluid does not contain any solid ingredients, so consuming the fluid does not exceed Nil per Os time needed before the surgery."
89191509|NCT02570204|Experimental|Self-assessment of abortion outcome|Patients enrolled in the study will self-assess the outcomes of their medical abortion with the aid of a multi-level pregnancy test (MLPT) which they will perform at home.
89191510|NCT00721656|Placebo Comparator|Placebo|
89191511|NCT00721656|Experimental|KLS-0611|
89191512|NCT04066712|Experimental|A: Normal (control) renal function|
89535649|NCT03317717|Experimental|botulinum toxin 10U|
89535650|NCT03317717|Experimental|botulinum toxin 20U|
89191513|NCT04066712|Experimental|B: Mild impairment renal function|
89191514|NCT04066712|Experimental|C: Moderate impairment renal function|
89191515|NCT04066712|Experimental|D: Severe impairment renal function|
89535651|NCT03317717|Experimental|botulinum toxin 30U|
89535652|NCT03220789|Experimental|Biologic drilling drilling at low speed|Procedure/Surgery: Drilling at low speed
89535653|NCT03220789|Active Comparator|conventional drilling drilling at convention|Procedure/Surgery: Drilling at conventional or high speed
89191516|NCT00723216|Active Comparator|1|Enoxaparin
89191517|NCT00723216|Other|2|Intermittent Pneumatic Compression (IPC)
89191518|NCT00619918|Experimental|1|3% saline
89191519|NCT00619918|Placebo Comparator|2|Normal saline
89191520|NCT00724178|Experimental|A|Oral cholecalciferol (100,000 IU) administered orally every 60 days plus calcium carbonate (1 gram)given daily
89191521|NCT00724178|Placebo Comparator|B|Double placebo
89191522|NCT02571270|Active Comparator|Active lifestyle|Active lifestyle involves nutritional education, physical activity and active recreation.
89191523|NCT02571270|Active Comparator|Lifestyle counseling|Lifestyle counseling helps patients to have better self-care.
89535654|NCT03317639|Experimental|an intervention arm|Hospitals in the intervention arm will receive a multi-components intervention based on the Behaviour Change Wheel model
89191524|NCT02571270|Active Comparator|secondary prevention|Secondary prevention it is essential to prevent a new unfavorable event.
89408421|NCT02132208||Trauma|Severe trauma patients admitted in the resuscitation room of our emergency department.
89191525|NCT02571270|Active Comparator|survival|The survival of patients with heart failure may increase with exercise training.
89408422|NCT03854578|Experimental|BI 1358894|
89408423|NCT03854578|Experimental|Citalopram|
89408424|NCT03854578|Experimental|Placebo matching BI 1358894|
89408425|NCT03550014|Active Comparator|Low Back Only|Participants randomized to the Low Back Only arm will receive physical therapy as directed by the treating physical therapist targeting the lower back.
89408426|NCT03550014|Active Comparator|Low Back+Hip|Participants randomized to the Low Back+Hip arm will receive physical therapy as directed by the treating physical therapist targeting the lower back. In addition to that treatment, participants will received hands-on and exercise physical therapy interventions directed at the hip(s).
89408427|NCT03038594|Experimental|Growth Hormone|Daily subcutaneous injections of 0.05 mg/kg/day of Growth Hormone [somatropin, Genotropin, Pfizer, New York, NY] will be administered, from one week prior to discharge until 9 months post-burn.
89408428|NCT03038594|Placebo Comparator|0.09% saline solution|Daily subcutaneous injections of 0.09% of saline solution will be administered, from one week prior to discharge until 9 months post-burn.
89408429|NCT05222035|Experimental|G-CSF+Camrelizumab|
89408430|NCT05222035|Active Comparator|Camrelizumab|
88884038|NCT04698304||Group B：TASC D lesion with common femoral artery involved|Chronic total occlusions >20cm with common femoral artery involved (100 cases)
88884039|NCT04698304||Group C：TASC D lesion with proximal popliteal artery involved|Chronic total occlusions >20cm with proximal popliteal artery involved (300 cases)
88884040|NCT04698304||Group D：TASC D lesion with distal popliteal artery involved|Chronic total occlusions >20cm with distal popliteal artery involved (200 cases)
88884041|NCT04698304||Group E：TASC D lesion with popliteal artery and proximal trifurcation vessels involved|Chronic total occlusion of popliteal artery (P1-3 segment) with proximal trifurcation vessels involved (100 cases)
88884042|NCT04693364||Observational (questionnaire, 3D breast model, discussion)|Patients complete questionnaire over 5 minutes about difficulties in making decision about breast cancer treatment, then participate in a consultation with regular care doctor and study doctor/study staff using the 3D breast model. Patients then complete questionnaires over 5-10 minutes about their opinions on the breast model and different breast surgical treatment options available.
88884043|NCT04690686|Experimental|LW-02 device immunopheresis combined with atezolizumab|LW-02 column immunopheresis treatments ~3x/week for 16 weeks plus atezolizumab 1200 milligrams (mg) q3w until disease progression or loss of clinical benefit, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurs first [N=8]
89191526|NCT04800536|Experimental|Cardiovascular effects of rapidly declining plasma glucose|A combined hyperglycaemic and euglycaemic clamp with a rapidly declining plasma glucose (>0.15 mmol/l/min). Plasma glucose will be measured every 5 minute and cardiovascular effects of the plasma glucose decline rate will be assessed using Holter-ECG, echocardiography, thrombelastography and blood sampling.
89191527|NCT04800536|Experimental|Cardiovascular effects of slowly declining plasma glucose|A combined hyperglycaemic and euglycaemic clamp with slowly declining plasma glucose (<0.085 mmol/l/min). A combined hyperglycaemic and euglycaemic clamp with a slowly declining plasma glucose (>0.15 mmol/l/min). Plasma glucose will be measured every 5 minute and cardiovascular effects of the plasma glucose decline rate will be assessed using Holter-ECG, echocardiography, thrombelastography and blood sampling.
89408431|NCT02136888|Experimental|Group A|"Ponesimod will be administered orally, once daily for 22 days starting on Day 2, and will comprise the following multiple-dose up-titration: 3 days of 10 mg (Days 2 to 4), 3 days of 20 mg (Days 5 to 7), 5 days of 40 mg (Days 8 to 12), 3 days of 60 mg (Days 13 to 15), 3 days of 80 mg (Days 16 to 18), and 5 days of 100 mg (19 to 23).~Placebo matched for ponesimod will be given on Day -1. Placebo tablets matched for moxifloxacin will be administered on Days 1 and 24."
89408432|NCT02136888|Experimental|Group B|Placebo matched for ponesimod will be administered orally, once daily on Day -1 and on Day 2 through Day 23. In half of Group B subjects, 400 mg moxifloxacin will be administered orally on Day 1 and a matching placebo tablet on Day 24. In the other half of Group B subjects, a matching placebo tablet will be administered on Day 1 and 400 mg moxifloxacin on Day 24.
89408433|NCT04465994||primary repair|Patients with acute achilles tendon ruptures who received the treatment of primary repair.
89408434|NCT04465994||gastrocnemius turn-down flaps|Patients with acute achilles tendon ruptures who received the treatment of gastrocnemius turn-down flaps.
88884044|NCT04690686|Experimental|LW-02 device immunopheresis combined with weekly paclitaxel|LW-02 column immunopheresis treatments ~3x/week for 16 weeks plus paclitaxel 80 mg/m2 /week × 6 followed by 2 weeks rest until disease progression, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurs first. [N=8]
89191528|NCT02546050|Experimental|Metformin|18 weeks study with intervention during week 6 to 12: the intervention consist of 500 mg of metformin once daily for week 7, then 500 mg twice daily week 8, 1000 mg + 500 mg daily week 9 and 1000 mg + 1000 mg daily for weeks 10-12.
89191529|NCT00721812|Other|Part A|Single dose escalation
89191530|NCT00721812|Other|Part B|14 day repeat dose escalation
89408435|NCT05488951|Experimental|Otago Exercise Program Plus Usual Care|The Otago Exercise Program will be led by a physical therapist in a group setting (5-7 participants/exercise class). The exercise will be 20 min of walking and 30 min of strength and balance exercises 3x/week for 6 months. The physical therapist will select suitable exercises for each participant, such that the exercise is individualized and progressive. Participants will also receive usual care from health care providers (e.g., specialist and local doctor visits, community nurse visits, paid care provider visits, hospitalizations as required, and any ongoing treatment for any illness and/or their comorbidities).
89408436|NCT05488951|No Intervention|Usual Care Only|Usual care will consist of routine care from their health care providers (e.g., specialist and local doctor visits, community nurse visits, paid care provider visits, hospitalizations as required, and any ongoing treatment for any illness and/or their comorbidities).
89408437|NCT02128776|Active Comparator|Usual Care|Usual care provided in the offices of private pediatricians or our general pediatrics clinic staffed by faculty-supervised residents.
89408438|NCT02128776|Active Comparator|Comprehensive care medical home|Comprehensive care provided in our High-Risk Children's Clinic as a medical home augmented by measures to prevent serious illness
89408439|NCT03527342||Dilated Cardiomyopathy|
89408440|NCT03527342||Myocarditis|
89408441|NCT03527342||Sarcoidosis Heart|
89408442|NCT03527342||Giant Cell Myocarditis|
89408443|NCT03527342||Amyloidosis Heart|
89408444|NCT03527342||Hypertrophic Cardiomyopathies|
89408445|NCT03527342||Left Ventricular Myocardial Noncompaction Cardiomyopathy|
89408446|NCT03527342||Arrhythmogenic Right Ventricular Cardiomyopathies|
89408447|NCT02132286|Experimental|Quetiapine -XR (extended release)|Quetiapine-XR (extended release) 150-300mg- treatment in MDD patients with S/Lg alleles in MDD
88884045|NCT04690686|Experimental|LW-02 device immunopheresis|LW-02 column immunopheresis treatments ~3x/week for 16 weeks alone until disease progression, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurs first. [N=8]
88884046|NCT04685369||Active smokers with wet AMD|
88884047|NCT04682977|Experimental|IPROACTIF|12 weekly sessions. First two sessions focus on comprehensive assessment of physical and executive functioning, assessment of home safety and accessibility, assessment of ADL/IADL competence and performance in context; information in these areas is used by the interventionist to collaboratively identify three patient-centered goals. Goal planning is followed by 10 treatment sessions. Treatment sessions focus on chronic disease education, problem solving issues related to disease management by modifying daily routines, recommendations for embedding physical activity in everyday tasks, and environmental modifications or activity adaptations to increase ADL/IADL independence.
88884048|NCT04682977|Other|Usual care|Participants in the control group will receive usual services which might include primary care and prescription medications for chronic disease management.
88884049|NCT04682626|Experimental|VD3 group|"Dietary Supplement: Soft gelatin capsules each contain 50 000 IU VD3 (cholecalciferol) equivalents to 1.25 mg once weekly for 8 weeks.~."
88884050|NCT04682626|No Intervention|Control group|none has been administered
88884051|NCT04665622|Other|Fronto-temporal Dementia|10 subjects
89191531|NCT00721812|Other|Part C|Fixed dose food effect
89191532|NCT04800224|Placebo Comparator|Placebo|Patients in the Placebo group will receive an identical number of capsules containing 900 mg / day of placebo (3 capsules of 100 mg each, divided into 3 daily doses); for 10 days.
89191533|NCT04800224|Active Comparator|Propolis|Participants in the Propolis group will receive propolis EPP-AF at a dose of 900 mg / day (3 capsules of 100 mg each, divided into 3 daily doses); for 10 days.
88884052|NCT04665622|Other|Alzheimer's Dementia|20 subjects
89408448|NCT02132286|Active Comparator|Citalopram|Citalopram 10-20 mgm/day treatment for 8 weeks in MDD with S/Lg alleles
89408449|NCT02132364|Other|optimised follow-up|optimised follow-up will be done by nursing personnel associated with a caregiving member of his social circle.
89408450|NCT02132364|No Intervention|typical follow-up|no intervention
89408451|NCT03627169||MATRx plus/PSG group|Healthy individuals, individuals suspected of having OSA, and individuals with a previous diagnosis of OSA will spend a single night in a sleep laboratory and undergo a standard polysomnogram simultaneously with a Level III sleep study using the MATRx plus device. There is no interventional aspect to the study.
89408452|NCT01673698|Active Comparator|ReShape Duo Balloon|ReShape Duo Balloon
89408453|NCT01673698|Sham Comparator|Sham Comparator|Sham Comparator
89408454|NCT05706103|Experimental|Specific skilled motor training|13 weeks of treatment, with 18 supervised treatment sessions in combination with an individualized home-exercise program. This group will first receive low-load training (i.e. at 25-30% of the individual's repetition maximum, sessions 1-9) followed by high-load training (i.e. at 40-60% of the individual's one repetition maximum, sessions 10-18).
89408455|NCT05706103|Active Comparator|General extension training|13 weeks of treatment, with 18 supervised treatment sessions in combination with an individualized home-exercise program. This group will first receive low-load training (i.e. at 25-30% of the individual's repetition maximum, sessions 1-9) followed by high-load training (i.e. at 40-60% of the individual's one repetition maximum, sessions 10-18).
89408456|NCT02136966|Experimental|Programme|"Distribution of Micronutrients powders (MNP)~Intensive counseling on Infant and Young Child Nutrition~Cooking demonstrations"
89408457|NCT02136966|No Intervention|Controle|"Usual Infant growth monitoring and promotion activities~No distribution of micronutrients powders~No Intensive counseling~No cooking demonstrations"
89408458|NCT05225090|Other|Smartphone App Intervention|Cancer patients taking at least one oral anti-cancer drug or oral medication to manage a chronic condition in conjunction with any cancer treatment will receive messages through the Medisafe App.
89408459|NCT02128854|Experimental|Tablets Intervention|Individuals randomized to this arm will receive: 1) peripheral devices for monitoring blood glucose, blood pressure, and weight; 2) 8 weekly tablet-delivered education and skills training sessions; 3) two booster sessions delivered via tablet-based videoconferencing at 3 and 6 months.
89408460|NCT02128854|No Intervention|Usual Care|Apart from study visits, individuals randomized to the Usual Care group will receive usual care for diabetes management as provided by their primary care physician. The provider will be responsible for determining changes in the treatment regimen and determining the timing of follow-up visits for diabetes care. Between scheduled office encounters, contact will be initiated by the individual.
89408461|NCT03522818|Active Comparator|Normal|Group will use the alarm as provided by the manufacture.
89408462|NCT03522818|Experimental|Manual trigger|Group will use the same model but will be instructed to manually trigger the alarm 1-2 hours after the child falls asleep.
88884053|NCT04665622|Other|Parkinson's Disease|20 subjects
88884054|NCT04665622|Other|Healthy volunteers|20 subjects
88884055|NCT04656236|Experimental|Intervention|3 hours of continuously intravenous infusion of 3-hydroxybutyrate.
89004617|NCT02513407|Experimental|Group I (EML)|Participants complete an assessment on knowledge, attitudes, and behaviors at baseline and attend 2 weekday sessions comprised of interactive education segment that is culturally responsive, and based on the community EML program, and topics including: nutrition guideline, nutrition label reading, comparison shopping/grocery store tour, recipe modification and healthy food preparation, eating healthy on a budget, and making healthy choices outside the home (e.g., restaurants) and physical activity over 1 hour led by CHE, a physical activity conducted by Duarte Fitness Centers instructors over 30 minutes, and cooking/taste test demonstration co-led by the CHE and local chef over 30 minutes over 12 weeks. Participants are also prescribed and encouraged to participate in 3 days a week exercise classes (for > 30 minutes) including salsa, Zumba and other aerobic exercises that are provided at Duarte Fitness Center.
89004618|NCT02513407|Active Comparator|Group II (control)|Participants receive a fitness tracker to track their physical activity and be wait listed to receive the intervention during month 10-12.
89004619|NCT02454140|Experimental|Cohort 1|SBRT 40 Gy in 5 fractions
89004620|NCT02454140|Experimental|Cohort 2|SBRT 45 Gy in 5 fractions (starting dose level)
89004621|NCT02454140|Experimental|Cohort 3|SBRT 50 Gy in 5 fractions
89004622|NCT02454140|Experimental|Cohort 4|SBRT 55 Gy in 5 fractions
89004623|NCT02454140|Experimental|Cohort 5|SBRT 60 Gy in 5 fractions
89004624|NCT02420717|Experimental|Cohort A (ruxolitinib phosphate)|Patients receive ruxolitinib phosphate PO BID. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89004625|NCT02420717|Experimental|Cohort B (dasatinib)|Patients receive dasatinib PO QD. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89004626|NCT02420717|Experimental|Phase 1|Patients Receive ruxolitinib Phosphate PO BID. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89004627|NCT02267330||Standard of care, Exposure recording|Patient will undergo fracture surgery as per standard of care, and will have radiation exposure recording.
89531049|NCT02498561|Active Comparator|normal weight-CP patients|GCF, plasma and GCF samples were taken before and after nonsurgical periodontal therapy
88884056|NCT04656236|Placebo Comparator|Control|3 hours of continuously intravenous infusion of saline (NaCl).
89004628|NCT02257138|Experimental|Treatment (ruxolitinib phosphate, decitabine) Ph1|Patients receive ruxolitinib phosphate PO BID on days 1-28 and decitabine IV on days 1-5. Treatment repeats every 4-6 weeks for up to 24 courses in the absence of disease progression or unacceptable toxicity.
89004629|NCT02257138|Experimental|Treatment (ruxolitinib phosphate, decitabine) Ph2|Patients receive 50mg ruxolitinib phosphate PO BID on days 1-28 and decitabine IV on days 1-5. Treatment repeats every 4-6 weeks for up to 24 courses in the absence of disease progression or unacceptable toxicity.
89004630|NCT02228889|Experimental|Strattice|Abdominal wall reconstruction with Strattice Assess pain intensity at last office visit preoperatively Assess pain interference at last office visit preoperatively Assess physical functioning at last office visit preoperatively Assess patient quality of life at last office visit preoperatively Assess patient pain intensity postoperatively Assess pain interference postoperatively Assess physical functioning postoperatively Assess quality of life postoperatively Assess hernia recurrence at 30 days postoperatively Assess bulge at 30 days postoperatively Assess Surgical Site Occurrences at 30 days postoperatively Assess hernia recurrence at 1 year postoperatively Assess bulge at 1 year postoperatively Assess Surgical Site Occurrences at 1 year postoperatively Assess overall complications at 30 days postoperatively Assess overall complications at 1 year postoperatively
89191534|NCT00718068|Experimental|Continuous|This group will receive potassium chloride by continuous infusion on a sliding-scale system based on serum potassium level.
89191535|NCT00718068|Active Comparator|Intermittent|This arm will form the control group and receive potassium chloride by intermittent infusion as per conventional management
89191536|NCT00718146|Experimental|Group 1|Age 16 to 60 years
89191537|NCT00718146|Experimental|Group 2|Age over 60 years
89191538|NCT00860626|Experimental|1|At the twelfth week of interferon α treatment, HBV DNA is detectable(>1000 copies/ml), or HBeAg is still positive. And nucleoside analogue is added for 12 weeks.
89531050|NCT02498561|Placebo Comparator|normal weight-PH controls|GCF, plasma and GCF samples were taken at baseline after oral hygiene instructions
89531051|NCT01597245|Experimental|80 mg ixekizumab Dosing Regimen 1|Administered by two 80 mg subcutaneous (SC) injections at Week 0, then one 80 mg SC injection per Dosing Regimen 1 until Week 12. At Week 12, ixekizumab responders are re-randomized to placebo, Dosing Regimen 2 or Dosing Regimen 3. Ixekizumab non-responders are assigned to Dosing Regimen 2.
88884057|NCT04647513|Experimental|Art Filler Fine Lines (forehead)|Injection of Art Filler Fine Lines in Forehead wrinkles
88884058|NCT04647513|Experimental|Art Filler Fine Lines (upper lip)|Injection of Art Filler Fine Lines in upper lip wrinkles
88884059|NCT04647513|Experimental|Art Filler Fine Lines (cheek folds)|Injection of Art Filler Fine Lines in cheek folds
88884060|NCT04647513|Experimental|Art Filler Fine Lines (crow's feet)|Injection of Art Filler Fine Lines in crow's feet
88884061|NCT04647513|Experimental|Art Filler Universal (lips volume)|Injection of Art Filler Universal in lips
88884062|NCT04647513|Experimental|Art Filler Universal (nasolabial folds)|Injection of Art Filler Universal in nasolabial folds
88884063|NCT04647513|Experimental|Art Filler Lips (lips volume)|Injection of Art Filler Lips in lips
89408463|NCT05706025|Experimental|Enterotracker|The EnteroTracker® is a capsule device that includes an absorbent string. The trailing end of the string is taped to the cheek and the capsule is swallowed with 8-12 ounces of water. The capsule dislodges the string as it travels to the proximal small intestine. The capsule continues through the remainder of the GI tract, leaving a string in the esophagus, stomach, and duodenum. Following a 60-minute dwell time, the string is removed via the subjects' mouth and processed for analysis. Subjects will be coached to ease any potential anxieties and answer any questions. A preparatory video can be used for education if desired.
89408464|NCT03525236|Experimental|Taste of 5 flavors|"Each patient will taste 5 products, in sequential-monadic test, randomized, one by one.~Patients will take few sips of each study product, ideally in isolation (avoid influence of other patients)~For each product tasted the subjects will be asked to answer a questionnaire including 1 question on the palatability of the product using a 10-point hedonic scale and a more detailed organoleptic evaluation of the product.~Between product tastings, participants will have a 10 minutes break to rinse their mouth and fill in a questionnaire assessing sensory changes"
89408465|NCT02137044|Experimental|Collaborative Care (CC)|Collaborative care (CC) is a systematic and integrated approach to improving the delivery and utilization of effective treatments for chronic pain and depression. The care was delivered through an interdisciplinary team, organized around a CC manager (CCM) who guided the patient through various aspects of care during the 16-week treatment phase. The team also included the patient's MS physician and the CC Supervisors, a group of clinicians who were experts of the study domain . The CCM offered all subjects care management, collaborative medical management, and psychosocial treatment appropriate to their problem area (i.e., pain, depression, or both) described below. If the patient had both pain and depression, he or she received care management and collaborative medical management for both.
89408466|NCT02137044|No Intervention|Usual Care|Subjects assigned to usual care were informed by the CCM of their depressive and pain symptoms and that they should consult with their MS or primary care provider about possible care for these conditions. Study personnel did not make any further attempts to influence usual care participants' depression or pain management unless a psychiatric emergency arose (e.g., suicidal ideation was detected at baseline or any of the outcome assessments).
89408467|NCT05032846|Experimental|Ultrasound Guided Laparoscopic Ovarian Cystectomy|During surgical resection of the ovarian cyst, a clinician with experience of ultrasound and laparoscopy will perform an ultrasound scan during surgery to resect cyst tissue only and preserve healthy ovarian tissue.
89408468|NCT05032846|Active Comparator|Laparoscopic Ovarian Cystectomy|A laparoscopic ovarian cystectomy will be performed without ultrasound guidance. This is currently standard clinical practice.
88884064|NCT04647513|Experimental|Art Filler Lips (very deep nasolabial folds)|Injection of Art Filler Lips in very deep nasolabial folds
89408469|NCT03548246|Placebo Comparator|Placebo|Daily placebo, plus usual maintenance treatment with hydrocortisone and fludrocortisone.
88884065|NCT04645576|Other|Midface zone|Injection in the mid-facial areas (split-face). One side of the subject's face will receive Art Filler Volume according to the randomization table, whereas the other side will receive Juvéderm Voluma injections in a blinded manner for the subjects (single blinded).
89408470|NCT03548246|Experimental|Abiraterone acetate|Abiraterone acetate administered daily in dose determined in Phase 1, plus usual maintenance treatment with hydrocortisone and fludrocortisone..
89408471|NCT02129010||Subarachnoid hemorrhage with and without Terson syndrome|Patients with aneurysmatic subarachnoid hemorrhage with and without Terson syndrome
89408472|NCT05705869|No Intervention|Routine care arm|Patients in this arm will undergo routine diabetes care. They will be managed and followed up as per routine clinical care. They will be remotely monitored for heart failure events electronically. Quality of life questionnaires (Kansas City Cardiomyopathy Questionnaire-12 and EQ-5D) will be collected.
89437519|NCT03732820|Placebo Comparator|placebo plus abiraterone|"Placebo to match olaparib is available as a film-coated tablet in 100 milligrams (mg) or 150 milligrams (mg). Subjects will be administered placebo orally at a dose of 300 milligrams (mg) twice daily (bid). The initial dosage of 300 milligrams (mg) twice daily will be composed of 2 x 150 milligrams (mg) tablets per dose. The 100 milligrams (mg) and 150 milligrams (mg) tablets will be used to manage dose reductions during the study.~Abiraterone acetate with prednisone or prednisolone will be sourced locally as commercially available materials. Subjects will be administered abiraterone orally at a dose of 1000 milligrams (mg) once daily, in combination with prednisone or prednisolone 5 milligrams (mg) administered orally twice daily."
89437520|NCT03729453||Intraoperative Pancreatoscopy|All subjects will undergo the intraoperative pancreatoscopy with SpyGlass procedure.
88884066|NCT04645576|Other|Temple|Injection in the temples (split-face). One side of the subject's face will receive Art Filler Volume according to the randomization table, whereas the other side will receive Juvéderm Voluma injections in a blinded manner for the subjects (single blinded).
88884067|NCT04645576|Other|Jaw-line|Injection in the jaw-line areas (split-face). One side of the subject's face will receive Art Filler Volume according to the randomization table, whereas the other side will receive Juvéderm Voluma injections in a blinded manner for the subjects (single blinded).
88884068|NCT04645576|Experimental|Chin|The chin will only receive one injection of Art Filler Volume.
88884069|NCT04623372|Experimental|suture|
88884070|NCT04623372|Experimental|Directed wound healing|
88884071|NCT04621682|Active Comparator|Non technical skills and check list|10 hours of training in non-technical skills and checklists in high Fidelity simulation
88884072|NCT04621682|Active Comparator|check list|Control: 10 hours of standard training with checklists in high Fidelity simulation
88884073|NCT04616846|No Intervention|Control cohort|
88884074|NCT04616846|Experimental|Infected cohort|
88884075|NCT04614597||Three-dose schedule for Sabin IPV|Subjects already vaccinated Sabin IPV at 2, 3, and 4 months of age, collected two blood samples and laboratory test results were available.
88884076|NCT04614597||Two-dose schedule for Sabin IPV|Subjects already vaccinated Sabin IPV at 4 and 8-11 months of age, collected two blood samples and laboratory test results were available.
88884077|NCT04614142|Experimental|Experimental: Glecaprevir/pibrentasvir for HCV+ kidney transplant recipient|"Glecaprevir (100mg) / pibrentasvir (40mg) (fixed dose combination) treatment for Hepatitis C virus (HCV)-naive recipients who receive a kidney transplant from a deceased, HCV-infected donor.~Subject will receive first dose on day 3 (+/- 2 days) post-kideny transplantation and continue daily for 8 weeks."
89408473|NCT05705869|Experimental|Investigational arm|"Patients in this arm will have a blood sample taken to measure N-terminal prohormone of B-type natriuretic peptide (NT-proBNP).~In addition to this, routine blood samples, an ECG, body measurements, patient reported outcomes and observations will be recorded.~Further blood and urine samples will be collected and stored within Glasgow University storage facilities for future measurement of relevant biomarkers and for use in future ethically approved research.~Patients with an elevated NT-proBNP (≥125 pg/mL) will undergo a full cart-based transthoracic echocardiogram along with a clinical examination for signs of HF and a HF symptom assessment. Patients will then also undergo a handheld echocardiogram with a CE-marked handheld point of care EchoNous Kosmos echocardiogram device.~Patients who are classified as having heart failure (HFrEF, HFmrEF, or HFpEF) will be managed according to the latest version of European Society of Cardiology guidelines."
89408474|NCT03529786||Retrospective|An observational medical records review study (data collected retrospectively) in subjects with the severe form of MPS II.
89408475|NCT02132442|Experimental|Vitamin D supplementation|Ergocalciferol 50,000 IU per week for 6 weeks, then bi-weekly for 6 mo
89408476|NCT02132442|Placebo Comparator|Placebo|Placebo capsules, on capsule per week for 6 weeks, then bi-weekly for 6 mo.
89408477|NCT05010148|Placebo Comparator|Placebo|Patients will be administered D5 water intravenously at the same infusion rate (ml/hr) as the intervention group for 48 hours after major spinal surgery.
89408478|NCT05010148|Experimental|Intervention-Intravenous Lidocaine Infusion|Will be administered intravenous lidocaine at 1.33mg/kg/hr (adjusted body weight) for 48 hours following major spinal surgery.
89408479|NCT03550872|No Intervention|Control Group|Patients in the group who are continuously guided as the activities of daily living normally avoiding participation in any regular program of physical exercise does not proceed from the study.
89408480|NCT03550872|Experimental|Training Group|the patients randomized to the physical training group will undergo the supervised physical training program
89408481|NCT03525158|Other|Baseline phase ('A') and Intervention phase ('B')|"Baseline phase ('A'): Measurements collected in a pen-and-paper diary four times a day (morning, afternoon, evening and night) over one week for the primary outcome (occurrence of intrusive memories of trauma). Individual baseline phases will be used as control periods.~Intervention phase ('B'): A one-session intervention with a researcher including a simple cognitive task (a memory cue, 10 minutes time gap and ca. 20 minutes of Tetris game-play) followed by instructions to engage in the task self-guided over the subsequent week. Measurements collected in a pen-and-paper diary four times a day over one week following the intervention for the primary outcome (occurrence of intrusive memories of trauma)."
89408482|NCT05007028|Experimental|Nitrous Oxide|Active Drug: EMONO (Equimolar Mixture of Oxygen and Nitrous Oxide)
88884078|NCT04613739|Experimental|Insurance navigation|The intervention group will be offered access to AAFA's insurance chat bot and navigation services. Navigation will be provided through AAFA's existing online patient community platform that provides assistance with clinical, educational and financial questions and includes secure, personal messaging capabilities that will be supplemented with telephonic outreach.
89408483|NCT05007028|Placebo Comparator|Medical air|Control Drug: Medical air : 78% N2 / 22% O2
89408484|NCT03549936|Active Comparator|Low lactose formula|"If infant is not breast feeding and parents plan to formula feed, following written informed consent, infant is randomized to receive low lactose formula which arrives from milk lab labeled as formula A or formula B."
89408485|NCT03549936|Active Comparator|Regular formula|"If infant is not breast feeding and parents plan to formula feed, following written informed consent, infant is randomized to receive regular formula which arrives from milk lab labeled as formula A or formula B"
89408486|NCT05381935|Experimental|Part 1 dose escalation|ES014 doses will be escalated in patients with advanced solid tumors with approximately 30 subjects.
89408487|NCT05381935|Experimental|Part 2 dose expansion|Part 2 of the study will consist of 3 expansion cohorts for pancreatic ductal adenocarcinoma (Cohort 2A), NSCLC (Cohort 2B), and colorectal adenocarcinoma (Cohort 2C) with 10 subjects per expansion cohort respectively at the recommended optimal biological dose determined in Part 1 dose escalation.
88884079|NCT04613739|No Intervention|Wait-list controls|Control subjects will be offered the chat bot after completion of data collection for the intervention group (after completion of the four-month follow-up surveys)
88884080|NCT04609124||Intervention group:|Patients (n=35) fasting for 8 hours and received 10 mg metoclopramide intravenously diluted in 10 mL saline 0.9%.
88884081|NCT04609124||Control group:|Patients (n=35) fasting for 8 hours and received intravenous 10 mL saline 0.9% as placebo
88884082|NCT04605172||Lockdown Group|newborn born prematurely during confinement (1st March - 1st June 2020)
88884083|NCT04605172||Control group|newborn born prematurely in comparative years over the same period (1st March - 1st June from 2015 to 2019)
88884084|NCT04604691|Experimental|Blinatumomab Treatment|
88884085|NCT04580381||Standard Interval Dosing (SID)|Patients continuing Natalizumab treatment with standard interval dosing defined as > 11 infusions per year
88884086|NCT04580381||Extended Interval Dosing (EID)|Patients switching to extended interval dosing defined as ≤ 10 infusions per year
88884087|NCT04575792||C group|C group: control group, children who do not practice oral habits.
89408488|NCT04467632|Experimental|Patients affected with idiopathic Parkinson Disease|
89408489|NCT05138146|Experimental|experimental group|609A combined with doxorubicin hydrochloride
89408490|NCT02252952|Experimental|Sugar Sweetened Beverages|Any beverage from a range of caffeine free, sugar sweetened drinks. One serving =12oz. Two servings will be consumed daily as part of a structured, weight maintenance diet for 6 months.
89408491|NCT02252952|Experimental|Diet Beverage|Any beverage from a range of caffeine free drinks sweetened with non-caloric sweetener. One serving =12oz. Two servings will be consumed daily as part of a structured, weight maintenance diet for 6 months.
88884088|NCT04575792||E group|E group: exposed group, children who practicing oral habits.
88884089|NCT04561154|Experimental|patient hospitalized between march 1 and june 30, 2020|patient hospitalized between march 1 and june 30, 2020
88884090|NCT04548245||Term|
88884091|NCT04548245||Preterm|
89191539|NCT00860626|Active Comparator|2|At the twelfth week of interferon α treatment, HBV DNA is detectable (>1000 copies/ml), or HBeAg is still positive. But no nucleoside analogue is added.
89408492|NCT02252952|Active Comparator|Water|12 oz of water. Two servings will be consumed daily as part of a structured, weight maintenance diet for 6 months.
89408493|NCT05221957|Experimental|Iron(III)isomaltoside 1000|Anemic patients receiving treatment with iron(III)isomaltoside
89408494|NCT05221957|No Intervention|Historical comparison|Anemic patients without receiving treatment prior to surgery. Historical comparison.
89408495|NCT05221957|No Intervention|Concurrent comparison|Non-anemic patients not receiving treatment with iron(III)isomaltoside prior to surgery
89408496|NCT02934854||Observation|Patients with the Creatine Deficiency Syndromes or high-grade suspicion for the Creatine Deficiency Syndromes
89408497|NCT05221879|No Intervention|Patients with target factor 10a levels|Patients with target factor 10a levels continued to recieve the standard Enoxaparin dose of 40 mg SC daily.
89408498|NCT05221879|Other|Patients with sub-therapuetic factor 10a levels|In patients with sub-therapuetic factor 10a levels we increased the Enoxaparin dose to 60 mg SC daily.
89408499|NCT03450772|Experimental|Creon® 25000 then Creon® 10000|Pancreatic enzyme
89408500|NCT03450772|Active Comparator|Creon® 10000 then Creon® 25000|Pancreatic enzyme
89408501|NCT04083196|Experimental|experiment group|According to the 0, 2, and 6 months immunization program, intramuscular injection of the upper arm deltoid muscle, 3 doses of the experiment vaccine
89408502|NCT04083196|Placebo Comparator|placebo group|According to the 0, 2, and 6 months immunization program, intramuscular injection of the upper arm deltoid muscle, 3 doses of the placebo
89408503|NCT02129088|Experimental|Cohort 1|Participants will receive esketamine 14 milligram (mg) as intranasal spray into each nostril on Day 1.
89408504|NCT02129088|Experimental|Cohort 2|All participants will receive esketamine 14 mg as intranasal spray into each nostril on Day 1 of Period 1 as Treatment A and esketamine 14 mg as intranasal spray followed by intranasal administration of placebo solution after 5 and 10 minutes of esketamine administration into each nostril on Day 1 of Period 2 as Treatment B in a fixed sequence.
89408505|NCT05280080|Active Comparator|Regular Task|Knee extensions.
89408506|NCT05280080|Experimental|Dual Task|Knee extensions while also doing a self-regulated mathematical dual-task.
89408507|NCT05221801|Active Comparator|angle 5 + 1ml water|The measurement would be done in seat inclination angles of 5 degrees with 1 ml water intake.
88884092|NCT04542564|Experimental|telemedicine group|The HT app (HealthCap) allows patients to record their home BP measurements (HBPM) and can automatically provide mean BP values from the previous 7 or 30 days. 1-2 week prior to a scheduled physician, HealthCap and a research assistant will remind patients to take dual BP readings both in the morning and evening for 1 week for doctors' management. The mean values of the 7-day home BP will be checked before the index consultation. If the home BP control was optimal (i.e. ≤135/85 mmHg), other important parameters will be checked automatically by a questionnaire in the app: (i) if they have good drug compliance and if they experienced any side effects,(ii) if they have symptoms suggestive of target organ damages such as chest pain or hemiplegia, and (iii) if they have any problem(s) that need to consult a physician. If no complaints are identified, the patient can collect medications directly from the clinic and the physician appointment will be deferred for 3 months
89191540|NCT00860626|Active Comparator|3|At the twelfth week of interferon α treatment, HBV DNA is undetectable (<1000 copies/ml), or HBeAg is negative. And interferon is continued for another 9 months.
89191541|NCT00724256|Experimental|1|
89191542|NCT00724256|Active Comparator|2|
89191543|NCT04041466|Experimental|Atrial fibrillation (AF)|Patients diagnosed with AF during reference ECG
89191544|NCT04041466|Experimental|Sinus Rhythm (SR)|Patients diagnosed with SR during reference ECG
89408508|NCT05221801|Active Comparator|angle 5 + 5 ml water|The measurement would be done in seat inclination angles of 5 degrees with 5 ml water intake.
89408509|NCT05221801|Active Comparator|angle 5 + 5 ml pudding|The measurement would be done in seat inclination angles of 5 degrees with 5 ml pudding intake.
89408510|NCT05221801|Active Comparator|angle 15 + 1ml water|The measurement would be done in seat inclination angles of 15 degrees with 1 ml water intake.
89408511|NCT05221801|Active Comparator|angle 15 + 5 ml water|The measurement would be done in seat inclination angles of 15 degrees with 5 ml water intake.
89408512|NCT05221801|Active Comparator|angle 15 + 5 ml pudding|The measurement would be done in seat inclination angles of 15 degrees with 5 ml pudding intake.
89408513|NCT05221801|Active Comparator|angle 30 + 1ml water|The measurement would be done in seat inclination angles of 30 degrees with 1 ml water intake.
89408514|NCT05221801|Active Comparator|angle 30 + 5 ml water|The measurement would be done in seat inclination angles of 30 degrees with 5 ml water intake.
89408515|NCT05221801|Active Comparator|angle 30 + 5 ml pudding|The measurement would be done in seat inclination angles of 30 degrees with 5 ml pudding intake.
89408516|NCT05221801|Active Comparator|angle 45 + 1ml water|The measurement would be done in seat inclination angles of 45 degrees with 1 ml water intake.
89408517|NCT05221801|Active Comparator|angle 45 + 5 ml water|The measurement would be done in seat inclination angles of 45 degrees with 5 ml water intake.
89408518|NCT05221801|Active Comparator|angle 45 + 5 ml pudding|The measurement would be done in seat inclination angles of 45 degrees with 5 ml pudding intake.
89408519|NCT05137756||Amyoplasia|patient with diagnosis of Amyoplasia
89408520|NCT05137756||Distal arthrogryposis|patient with diagnosis of Distal arthrogryposis
89408521|NCT02137200|Active Comparator|Delayed pushing|
89408522|NCT02137200|Experimental|Immediate pushing|
89408523|NCT05277584||Patients with hyponatremia|
88884093|NCT04542564|Placebo Comparator|usual care|Patients in the usual care group will be asked to refrain from downloading or using any health care apps related to HT
88884094|NCT04537884|Experimental|Treatment with UBX1325|UBX1325, single intravitreal injection, ascending dose
88884095|NCT04535349|Other|No cardiac ATTR amyloidosis|"Cardiac echocardiography at baseline and whole-body & CZT bone tracer imaging (SPECT).~day 3 - day 10 : second whole-body & CZT bone tracer imaging (SPECT), test-retest Bone tracer imaging Perugini 0 : no cardiac TTR amyloidosis No further follow-up."
88884096|NCT04535349|Other|Cardiac ATTR amyloidosis, no treatment with tafamidis planned|"Cardiac echocardiography at baseline and whole-body & CZT bone tracer imaging (SPECT).~day 3 - day 10 : second whole-body & CZT bone tracer imaging (SPECT), test-retest Bone tracer imaging demonstrating cardiac ATTR amyloidosis but no treament with tafamidis planned.~Cardiac echocardiography at 3 months and whole-body & CZT bone tracer SPECT and cardiac echocardiography at 6 months"
88884097|NCT04535349|Other|Cardiac ATTR amyloidosis, treatment with tafamidis planned|"Cardiac echocardiography at baseline and whole-body & CZT bone tracer imaging (SPECT).~day 3 - day 10 : second whole-body & CZT bone tracer imaging (SPECT), test-retest Bone tracer imaging demonstrating cardiac ATTR amyloidosis. Start of the treament with tafamidis.~Cardiac echocardiography at 3 months and whole-body & CZT bone tracer SPECT and cardiac echocardiography at 6 months"
88884098|NCT04534686|Experimental|CogXergaming|CogXergaming based cognitive-motor balance training will be delivered to group A using the commercially available Wii-Fit Nintendo and a mouse in conjunction with cognitive training. All participants will undergo 18 sessions of training in a tapering manner for six weeks with 60-90 minutes of training per session, i.e., 3 sessions each week till the 6th week. Each session will be divided into 3 sub-sessions, where each sub-session will consist of playing 4 to 6 games in conjunction with cognitive task. All the games will be performed using a Wii-Fit balance board in front of a TV screen.
88884099|NCT04534686|Experimental|Matter of Balance Training|Participants in group B will undergo matter of balance training for 8 weeks (one session a week for 2 hours/day).
88884100|NCT04526925|Active Comparator|standard CPET|Standard CPET will be performed without in-line filter
88884101|NCT04526925|Experimental|standard CPET with in-line filter|An in-line filter will be placed on the mouthpiece during standard CPET
88884102|NCT04496245|Active Comparator|Wait-list control|One capsule OM85 (7.0 mg) will be given daily for 3 months, commencing in Month 3, with 3 months follow-up off treatment.
88884103|NCT04496245|Experimental|Initial treatment wtih OM85|One capsule OM85 (7.0 mg) will be given daily for 3 months, commencing on day 0, with 3 months follow-up off treatment.
88884104|NCT04492410|Experimental|Experimental arm|screening using a rapid serological test with a drop of blood from a finger prick.
88884105|NCT04476745|Experimental|Experimental: VD3 group|Dietary Supplement: Dietary Supplement: Vitamin D3 Dietary Supplement: Vitamin D3 (50,000) IU / week for 8 weeks Other Names: cholecalciferol,
88884106|NCT04476745|No Intervention|Control group|Control group No intervention was given
88884107|NCT04471545|Experimental|Interventional group|Intervention arm: PECS II block with ropivacaine
88884108|NCT04471545|Placebo Comparator|Control group|Control arm: PECS II block with placebo (saline)
88884109|NCT04469140||Cohort 1 'IMPACT Cohort'|Subjects with intermediate AMD in both eyes, and at least one eye with a drusen volume in the central 3 mm circle centered on the fovea of at least 0.02mm3 in the absence of GA or nGA as diagnosed with OCT en face imaging OR subjects with AMD (early or intermediate) diagnosed in one eye and exudative AMD diagnosed in the fellow eye will undergo SS-OCT imaging every 3 months for 2 years
88884110|NCT04469140||Cohort 2 'SWAGGER Cohort'|Subjects with GA or nGA secondary to AMD that is at least the size of a large druse (125 microns in diameter; 0.05 mm2) and no greater than 7 disc areas (17 mm2) in at least one eye will undergo SS-OCT imaging every 3 months for 2 years
88884111|NCT04469140||Cohort 3|Subjects with GA enrolled in another trial
88884112|NCT04468971|Placebo Comparator|Arm 1|Excipient
88884113|NCT04468971|Experimental|Arm 2|CK0802: 1x10^8 cells
88884114|NCT04468971|Experimental|Arm 3|CK0802: 3x10^8 cells
88884115|NCT04458805|Experimental|NX-13 250mg|Dose escalation in Part A will be conducted in 5 cohorts (Cohorts 1 to 5). Seven participants will be enrolled in each cohort and randomized to receive either NX-13 or placebo (ratio 5:2). NX-13 will be administered to Cohort 1 participants at the starting dose of 250 mg and increased in each new cohort. Five nominal dose levels in the range of 250 to 4000 mg have been selected for evaluation in Part A. The starting dose level in Part B will be determined by the SRC based on safety and tolerability data obtained in Part A. A dose level will only be evaluated in Part B if determined to be safe and tolerable in Part A. It is anticipated that 3 dose levels will be evaluated in Part B in a total of 3 cohorts (Cohorts 6 to 8). Seven participants will be enrolled in each cohort and will be randomized to receive a single oral dose of either NX-13 or placebo (ratio 5:2), once daily for seven days. NX-13 dose levels to be evaluated in Part B will be in the range of 500 to 4000 mg.
89191545|NCT04041466|Experimental|Other Arrythmia|Patients diagnosed with an arrhythmia other than AF during the reference ECG
89437521|NCT03727152|Other|generic single tablet regimen of tenofovir alafenamide/e|HIV infected adults currently on protease inhibitor/ritonavir will switch to use generic single tablet regimen of tenofovir alafenamide/emtricitibine/dolutegravir to see if the single tablet can continue to suppress viral replication and be used as a maintenance regimen
89535655|NCT03317639|No Intervention|a control arm|hospitals in the control arm will receive no intervention and maintain existing care
88884116|NCT04458805|Placebo Comparator|Placebo|Dose escalation in Part A will be conducted in 5 cohorts (Cohorts 1 to 5). Seven participants will be enrolled in each cohort and randomized to receive either NX-13 or placebo (ratio 5:2). NX-13 will be administered to Cohort 1 participants at the starting dose of 250 mg and increased in each new cohort. Five nominal dose levels in the range of 250 to 4000 mg have been selected for evaluation in Part A. The starting dose level in Part B will be determined by the SRC based on safety and tolerability data obtained in Part A. A dose level will only be evaluated in Part B if determined to be safe and tolerable in Part A. It is anticipated that 3 dose levels will be evaluated in Part B in a total of 3 cohorts (Cohorts 6 to 8). Seven participants will be enrolled in each cohort and will be randomized to receive a single oral dose of either NX-13 or placebo (ratio 5:2), once daily for seven days. NX-13 dose levels to be evaluated in Part B will be in the range of 500 to 4000 mg.
88884117|NCT04458753|Experimental|Lumbar focused + knee focused exercise group|Will receive strengthening of back , abdominal, and quadriceps muscles, and stretching if calf and Hamstring muscles
88884118|NCT04458753|Active Comparator|Knee focused exercise group|Will receive strengthening of quadriceps and stretching of calf and Hamstring muscles
88884119|NCT04458441|Active Comparator|warm skin desenfection group|Povidion iodine will be used as a skin cleanser. povidion iodine will be heated sterile to 38 degrees with a ben-mari method and its temperature will be controlled by degrees. When it reaches the appropriate degree, the skin cleaning of the baby will be done sterile.
88884120|NCT04458441|No Intervention|cold skin desenfection group|Povidion iodine will be used as a skin cleanser. povidion iodine will be used in the skin cleaning of the baby without any heating procedure.
88884121|NCT04450888|Other|Model A|Total cardiovascular disease (CVD)-free life expectancy gain in one's remaining life.
88884122|NCT04450888|Other|Model B|Average CVD-free life expectancy gain per year.
88884123|NCT04450888|Other|Model C|Total CVD-free life expectancy loss that can be reclaimed in one's remaining life.
88884124|NCT04450888|Other|Model D|Average CVD-free life expectancy loss that can be reclaimed per year.
88884125|NCT04433390|Experimental|Naloxegol group|naloxégol tablet by oral route
88884126|NCT04433390|Placebo Comparator|Placebo group|inert tablet by oral route
88884127|NCT04432272|Experimental|Group A|Hospitalized COVID-19 patients ages ≥18 years with respiratory symptoms, requiring >6 L of oxygen to maintain oxygen saturation >92%. Patient may not require intubation, and may be admitted for no longer than 14 days.
88884128|NCT04432272|Experimental|Group B|Hospitalized COVID-19 patients ages ≥18 years requiring intubation.
88884129|NCT04408222||Awake Proning|COVID-19 patients with hypoxemic respiratory failure with awake prone positioning, as tolerated, up to 24 hours daily.
88884130|NCT04407806|Active Comparator|Continuous Pulse Oximetry Monitoring of Oxygen Saturation|Continuous pulse oximetry to measure oxygen saturation
88884131|NCT04407806|Active Comparator|Intermittent Pulse Oximetry Monitoring of Oxygen Saturation|Intermittent pulse oximetry to measure oxygen saturation, measured every 4 hours
89191546|NCT04067934|Experimental|Jumping exercise|High-impact exercise intervention: 3 sessions per week for four weeks Each session will consist of three jumping-based exercises, performed for three sets of various repetitions, following a progressive protocol with increasing volume/intensity.
89191547|NCT00860704|Active Comparator|Ringerlactate lean|fluidtherapy with crystalloids in lean patients
89191548|NCT00860704|Active Comparator|Ringerlactate overweight|fluidtherapy with crystalloids in overweight patients
89191549|NCT00860704|Active Comparator|Ringerlactate obese|fluidtherapy with crystalloids in obese patients
89191550|NCT04742660|Placebo Comparator|group R|Participants are administered a dose of 0.3mg of ramosetron (conventional antiemetics) intravenously followed by continuous infusion of 120mL normal saline at a rate of 10mL/min.
89191551|NCT04742660|Active Comparator|group G|participants are administered a dose of 0.3mg of ramosetron followed by continuous infusion of mixture of 20mL glycyrrhizin and 100mL normal saline (total 120mL) at a rate of 10mL/min.
89191552|NCT00860782|Experimental|Annual Parent Intervention (API) Group|Participants in this group will receive the parent educational support intervention once a year for 2 years.
88884132|NCT04399746|Experimental|Combination|Ivermectin (6mg once daily in day 0,1,7 and 8) plus Azithromycin (500mg once daily for 4 days) plus Cholecalciferol (400 IU twice daily for 30 days).
88884133|NCT04399746|No Intervention|Control|No intervention
88884134|NCT04391608|Active Comparator|Tenofovir Alafenamide|Tenofovir Alafenamide 25 mg/day
88884135|NCT04391608|No Intervention|TDF dose reduction|TDF dose reduction
88884136|NCT04383756|Experimental|Donor Blood|Between 2-4 units of donor leukoreduced whole blood (each unit will contain up to 350mL) transfused as needed in Liver transplantation participants
88884137|NCT04383756|Active Comparator|Banked Blood|Standard of Care - Up to 350mL Allogenic banked component blood transfusion in a 1:1:1 manner (packed red blood cells : plasma : platelets) transfused as needed in Liver transplantation participants
88884138|NCT04368299|Experimental|Telemedicine|Telemedicine group will receive scheduled follow-ups via videoconferencing.
89191553|NCT00860782|Experimental|Quarterly Parent Intervention (QPI) Group|Participants in this group will receive the parent educational support intervention quarterly (4 times a year) for 2 years.
89191554|NCT04069260|Experimental|ELX-02|Eukaryotic ribosomal selective glycoside (ERSG)
88884139|NCT04368299|Active Comparator|Standard care|Standard care group patients will continue conventional standard in-person outpatient care.
88884140|NCT04368091||All-comers, real-world registry|Subjects requiring infrainguinal revascularization with the Xtreme Touch - Neo (Magic Touch PTA)
88884141|NCT04362436|Experimental|TheraSpheres Selective Internal Radiation Therapy (SIRT)|Radiation therapy
88884142|NCT04331379|Experimental|Nasal Elevator|
88884143|NCT04331379|Active Comparator|Taping Alone|
88884144|NCT04329715|Experimental|Expedited instructions|
88884145|NCT04329715|Active Comparator|Restricted instructions|
89191555|NCT04734938|No Intervention|Habitual Diet|All volunteers will participate in this arm, continuing this habitual diet for 1 week
89191556|NCT04734938|Experimental|100% Huel|All volunteers will participate in this arm of the study and consumer 100% Huel as their food for 4 weeks
88884146|NCT04328090|Experimental|CDSS-Antimicrobial stewardship|Computer-based, multicomponent intervention targeting on reduction of perioperative antimicrobial use will be delivered to teams in the intervention arm.
88884147|NCT04328090|No Intervention|Standard of care|Teams in the control arm will continue with usual standard clinical care.
88884148|NCT04324021|Active Comparator|Emapalumab|Emapalumab i.v. infusion every 3rd day for a total 5 infusions. Day 1: 6mg/kg. Days 4, 7, 10 and 13: 3 mg/kg
88884149|NCT04324021|Active Comparator|Anakinra|Anakinra i.v. infusion four times daily for 15 days. 400 mg/day in total, divided into 4 doses given every 6 hours
88884150|NCT04324021|No Intervention|Standard of care|Standard of care according to local practice
88884151|NCT04320797||Active lupus nephritis|Patients with proliferative lupus nephritis (Class III and IV)
88884152|NCT04320797||Control|Patients with systemic lupus erythematodes without lupus nephritis or lupus nephritis I, II or VI
88884153|NCT04318821|Experimental|LA group|The subjects in the experimental group will receive 0.375 J of energy at each of the following acupoints: LI4 (Hegu, B3), PC6 (Neiguan, B3), ST25 (Tianshu, B3), ST36 (Zusanli, B2), CV4 (Guanyuan), CV12 (Zhongwan, B3).
89191557|NCT02571894|No Intervention|Observational arm|Participants randomized to observational arm will receive standard oncological followup and care.
89437522|NCT03725878|Experimental|Interventional|Standard tertiary interventions of birth defects; Additional preconception health care; Additional health care procedures during and after pregnancy.
88884154|NCT04318821|Sham Comparator|Control group|The subjects in the control group will receive sham LA treatment, without any laser output (no stimulation) at the same acupoints used in experimental group.
88884155|NCT04318808|Experimental|LA group|The subjects in the experimental group will receive 0.375 J of energy at each of the following acupoints: LI4 (Hegu, B3), LI11 (Quchi, B2), PC6 (Neiguan, B3), ST36 (Zusanli, B2), ST37 (Shangjuxu, B2), ST39 (Xiajuxu, B2), SP4 (Gongsun, B3) , SP9 (Yinlingquan, B2).
88884156|NCT04318808|Sham Comparator|Control group|The subjects in the control group will receive sham LA treatment, without any laser output (no stimulation) at the same acupoints used in experimental group.
88884157|NCT04311437|Experimental|Self-acupressure group|The subjects in experimental group will undergo additional self-acupressure therapy in addition to Valsalva and Toynbee maneuvers before the first HBOT. The acupoints used are TE17 (Yifeng, 翳風), TE21 (Ermen, 耳門), SI19 (Tinggong, 聽宮), GB2 (Tinghui, 聽會).
88884158|NCT04311437|Placebo Comparator|Control group|The subjects in control group will receive Valsalva and Toynbee maneuvers alone.
88884159|NCT04310956|Experimental|Y-Knot group|Patients use Y-Knot all-suture anchor
88884160|NCT04310956|Active Comparator|Biocomposite suture anchor|Patients use Biocomposite suture anchor
88884161|NCT04309513|Active Comparator|Step Counter to motivate physical activity|Participants will be encouraged to work up to achieving at least 10,000 steps a day, higher if possible and reasonable, as measured by a wearable device.
88884162|NCT04309513|Experimental|PAI score to motivate physical activity|Participants will be encouraged to work up to and maintain the highest PAI score possible, with 100 being the ideal, as measured by a wearable device.
88884163|NCT04300738|Other|Patients undergoing CT scann for CCS determination|
88884164|NCT04265365|Experimental|rTMS+rPMS_iTBS_R|In this group, they received intermittent theta burst stimulation(iTBS) on affected hemisphere after following iTBS at radial nerve on affected hand.
88884165|NCT04265365|Experimental|rTMS+rPMS_cTBS_R|In this group, they received intermittent theta burst stimulation on affected hemisphere after following continuous theta burst stimulation(cTBS) at radial nerve on affected hand.
88884166|NCT04265365|Sham Comparator|rTMS +sham-rPMS|In this group, they received iTBS on affected hemisphere after following sham TBS stimulation at radial nerve on affected hand.
88884167|NCT04265365|Experimental|rTMS+rPMS_iTBS_M/U|In this group, they received iTBS on affected hemisphere after following iTBS at median/ulnar nerve on affected hand.
88884168|NCT04265365|Experimental|rTMS+rPMS_cTBS_M/U|In this group, they received iTBS on affected hemisphere after following cTBS at median/ulnar nerve on affected hand.
89191558|NCT02571894|Experimental|Intervention arm|Intervention arm receives standard oncological followup and care + subclinical cardiotoxicity surveillance and treatment.
88884169|NCT04265365|Sham Comparator|sham-rTMS+sham-rPMS|In this group, they received iTBS on affected hemisphere after following sham TBS stimulation at median/ulnar nerve on affected hand.
88884170|NCT04265365|Experimental|rTMS + optimal-rPMS|In this group, patient received iTBS on affected hemisphere after following optimal repetitive peripheral magnetic stimulation(rPMS) on affected hand.
88884171|NCT04265365|Experimental|rTMS+ sham-rPMS|In this group, patient received iTBS on affected hemisphere after following sham repetitive peripheral magnetic stimulation on affected hand.
88884172|NCT04265365|Sham Comparator|sham-rTMS+optimal-rPMS|In this group, patient received sham iTBS on affected hemisphere after following optimal repetitive peripheral magnetic stimulation on affected hand.
88884173|NCT04261153|Other|cognitive stimulation|3 cognitive stimulation sessions in total from the HAPPYNeuron® software, approximately 20 minutes each and spread over several days
89408524|NCT03404362|Active Comparator|MRgFUS|"The treatment process begins with the physician acquiring a set of MR images, identifying target volume(s) of tissue to ablate, and then drawing the treatment contours.~The therapy planning software computes the type and number of sonications required to treat the defined region while minimizing total treatment time. MR images taken during the sonication provide a diagnostic quality image of the target tissue and a quantitative, real-time temperature map overlay to confirm the therapeutic effect of the treatment"
89408525|NCT03404362|Active Comparator|EBRT|Patient would undergo single fraction of external beam radiation to a dose of 8Gy or a session of 10 fractions of external beam radiations at 3Gy per fraction for two weeks.
89408526|NCT05274932|Active Comparator|Placebo|Knee extensions with 30% 1RM and no occlusion pressure.
88884174|NCT04260945|Experimental|CD19/CD20 Dual-CAR-T cells|CD19/CD20 Dual-CAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of CAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest for 2 days before infusion.
89408527|NCT05274932|Experimental|BFR at 40% AOP|Knee extensions with 30% 1RM and BFR at 40% AOP.
88884175|NCT04260932|Experimental|CD19/CD20 Dual-CAR-T cells|CD19/CD20 Dual-CAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of CAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest for at least 2 days before infusion.
88884176|NCT04251078||Myelodysplastic Syndromes - Progression cohort|According to the literature (Greenberg et al, Blood. 2012), around 5-15% are expected to progress to high/very high-risk MDS subtype or to acute myeloid leukemia (AML). According to the total cohort of patients, it is expected that 20 of them would comprise this group and will be studied by targeted deep sequencing.
88884177|NCT04251078||Myelodysplastic Syndromes - Non Progression cohort|20 patients without progression will be analyzed by targeted deep sequencing in order to find out if there are any differences in the mutational spectrum compared with those disease progression cases.
88884178|NCT04246008|Experimental|Neuromuscular training group|This group will receive a 60-min neuromuscular training sessions twice a week, for 10 weeks until the completion of twenty sessions
88884179|NCT04246008|Active Comparator|Conventional training group|This group will receive a 60-min convencional cardiac rehabiliation session twice a week, for 10 weeks until the completion of twenty sessions
88884180|NCT04238845|Active Comparator|SMC + Vitamin A alone|Children under SMC Coverage, receiving AQSP and Vitamin A supplementation alone
88884181|NCT04238845|Experimental|SMC+ Vitamin A + Plumpy'Doz|Children under SMC Coverage, receiving AQSP + Vitamin A plus Plumpy'Doz supplementation
88884182|NCT04238845|Experimental|SMC+ Vitamin A + Zinc|Children under SMC Coverage, receiving AQSP + Vitamin A plus Zinc supplementation
88884183|NCT04232202|Experimental|Laser|After extraction, Er:YAG and Nd:YAG lasers used for degranulation, disinfection, deepithelialization, clot stabilization and photobiomodulation.
88884184|NCT04232202|Active Comparator|Control|Standard extraction procedure.
88884185|NCT04228822|Experimental|Low carb diet intervention group|Low carbohydrate diet defined as 25-35% of total energy intake
88884186|NCT04228822|No Intervention|Control|Standard diet defined as 45-65% total energy intake
88884187|NCT04223037|Active Comparator|Day 0，7 immunization shedule|Japanese Encephalitis Vaccine produced by Institute of Medical Biology, Chinese Academy of Medical Sciences (IMBCAMS) and Japanese Encephalitis Vaccine produced by Liaoning Chenda CO.,LTD Dosage form: 0.5mL/vial Two Dose injection with 7 days interval
88884188|NCT04223037|Experimental|Day 0，28 immunization shedule|Japanese Encephalitis Vaccine produced by IMBCAMS Dosage form: 0.5mL/vial Two Dose injection with 28 days interval
88884189|NCT04213365|Other|cognitive stimulation and adapted physical activity|12 weeks of cognitive stimulation sessions coupled with APA (Adapted Physical Activity) sessions.
88884190|NCT04211753|Experimental|Treatment as usual plus mobile app|Those who will receive naturalistic treatment in outpatient setting and also the mobile app
88884191|NCT04211753|Active Comparator|Treatment as usual|Those who will receive naturalistic treatment in outpatient setting but not the mobile app
88884192|NCT04210661|Active Comparator|classic prediction software|test with classic precition software
88884193|NCT04210661|Experimental|prediction software with spell checker|test with prediction software with spell checker
89408528|NCT05274932|Experimental|BFR at 80% AOP|Knee extensions with 30% 1RM and BFR at 80% AOP.
89408529|NCT02786004|Experimental|Full Field Digital Mammography|2-dimensional breast imaging
89408530|NCT02786004|Experimental|Digital Breast Tomosynthesis|3-dimensional breast imaging
89408531|NCT05137522|Experimental|Assigned Interventions|Chidamide combines with VP-16 and methylprednisolone
89408532|NCT05271890|Experimental|Immediate periodontal treatment|Subjects assigned to this group were receiving non-surgical periodontal treatment as well as oral hygiene instructions immediately after their inclusion. All subjects were undergone full periodontal and rheumatologic clinical examinations both at baseline and 90 days after the completion of the treatment. Blood collection for the analysis of the serum concentration of CRP, ESR, Fibrinogen, IL-6 and TNF-α was also performed at baseline and 90 days after periodontal treatment.
89191559|NCT01089296|Other|Individually customized physiotherapy|The intervention involves handling the infant and changing its position. It focuses on improving symmetry, muscle balance and movement in infants. The parent who is with the infant during the admission period will carry out the daily intervention after being taught by the physiotherapist.
89191560|NCT01089296|No Intervention|Control|Ordinary follow up in the Neonatal Intensive Care Unit (NICU).
89191561|NCT04041388|Other|Tooth tipping|
89408533|NCT05271890|No Intervention|Delayed periodontal treatment|Subjects assigned to this group were receiving non-surgical periodontal treatment 90 days after baseline evaluation. All subjects were undergone full periodontal and rheumatologic clinical examinations both at baseline and 90 days after. Blood collection for the analysis of the serum concentration of CRP, ESR, Fibrinogen, IL-6 and TNF-α was also performed at baseline and 90 days after.
89408534|NCT02129166|Placebo Comparator|Dasatinib|In this group, subjects will take dasatinib only. Dose regimen: dasatinib 20 mg single oral dose
89408535|NCT02129166|Active Comparator|Dasatinib+Imatinib|"In this group, subjects will take imatinib prior to dasatinib administration.~Dose regimen: Imatinib: 400 mg single oral dose Dasatinib: 20 mg single oral dose"
89408536|NCT02858830|Other|Group 1: Healthy Subject|Healthy Subject (Control) will undergo assessments before and after ingesting a high fat mixed meal.
89408537|NCT02858830|Other|Group 2: FPL Subject|FPL Subject will undergo assessments before and after ingesting a high fat mixed meal.
89408538|NCT02137278|Active Comparator|Stop/reduce vasoactive drugs|Discontinuation of any vasoactive therapy or reduction of vasoactive drug therapies as much as possible according to clinical judgment
89408539|NCT02137278|Experimental|Vasoactive drug therapy|Continue current vasoactive therapy
88884194|NCT04209621|Other|Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma|Duvelisib with ibrutinib will be administered for the first six 28-day (± 7) cycles followed by duvelisib alone until disease progression or intolerance. Duvelisib is an orally administered at 15 mg twice a day (dose level 1) or 25 mg twice day (dose level 2). Subjects will continue the same dose of ibrutinib prior to study enrollment for the first six 28-day cycles. Ibrutinib is an orally administered and provided as 140 mg white opaque capsules or tablets in 4 strengths: 140 mg, 280 mg, 420 mg, and 560 mg.
89408540|NCT05137444|Experimental|low-dose LYB001 in participants aged 18-59 years|25μg/0.5ml/Vial. Intramuscular injection (IM) at upper arm deltoid on day 0, 28, 56.
89408541|NCT05137444|Experimental|high-dose LYB001 in participants aged 18-59 years|50μg/0.5ml/Vial. Intramuscular injection (IM) at upper arm deltoid on day 0, 28, 56.
88884195|NCT04207983|Experimental|Treatment Arm A (Re-administration)|Two administrations of EYS606 (135μg pEYS606/90 μL). The frequency between the two administrations will be determined by the DSMB upon completion of the Part I safety cohorts.
89408542|NCT05137444|Placebo Comparator|placebo in participants aged 18-59 years|intramuscular injection (IM) at upper arm deltoid on day 0, 28, 56.
89408543|NCT05137444|Experimental|low-dose LYB001 in participants aged over 60 years|25μg/0.5ml/Vial. Intramuscular injection (IM) at upper arm deltoid on day 0, 28, 56.
88884196|NCT04207983|Experimental|Treatment Arm B (Single administration)|One administration of EYS606 (135μg pEYS606/90 μL) at the baseline visit (V1).
88884197|NCT04186663|Experimental|Advantage Arrest|38% silver diamine fluoride, topical, 1 drop, single application
88884198|NCT04180267|No Intervention|Control Group|Subject assigned to Control Group will not receive LMHFV
88884199|NCT04180267|Active Comparator|LMHFV group|Subject assigned to LMHFV group will receive LMHFV (35Hz, 0.3g, 20min/day, at least 3 times/week) for half year.
89408544|NCT05137444|Experimental|high-dose LYB001 in participants aged over 60 years|50μg/0.5ml/Vial. Intramuscular injection (IM) at upper arm deltoid on day 0, 28, 56.
89408545|NCT05137444|Placebo Comparator|placebo in participants aged over 60 years|intramuscular injection (IM) at upper arm deltoid on day 0, 28, 56.
89408546|NCT05137444|Experimental|LYB001 in participants aged over 18 years|intramuscular injection (IM) at upper arm deltoid on day 0, 28, 56.
88884200|NCT04179734|Experimental|Intervention|Bremelanotide 1.75 mg - prefilled subcutaneous autoinjector containing 1.75 mg Bremelanotide in a 0.3 mL solution volume.
88884201|NCT04179734|Placebo Comparator|Placebo|1.75 mg equivalent - prefilled subcutaneous autoinjector containing Bremelanotide formulation without the active ingredient in a 0.3 mL solution volume.
88884202|NCT04176302|Active Comparator|Parkinson Holter|The neurologists in the study will receive information from the Parkinson Holter (device being studied)
88884203|NCT04176302|Active Comparator|Parkinson's diary|The neurologists in the study will receive information from a motor fluctuations diary
88884204|NCT04176302|Placebo Comparator|Traditional clinical practice|The neurologists in the study will receive no additional information other than what is obtained during the visit
88884205|NCT04158219|Experimental|Treatment|Behavioral activation for health and depression (BA-HD)
88884206|NCT04156217|Experimental|EBV-TCR-T cells|Patients with EBV emias or EBV positive PTLD will be enrolled, and donor derived EBV-TCR-T(HLA-A*1101\0201\2402) cells will be intravenously infused with a escalated dose of 0.1-1×106 EBV-TCR-T cells. The EBV DNA copies and EBV-TCR-T cell proliferation will be monitored in the scheduled time (day 0, day 4, day 7, day 10, day 14, day 28).
88884207|NCT04155853|Active Comparator|Interposition Arthroplasty|Fascia lata interposition arthroplasty for the treatment of thumb carpometacarpal joint osteoarthritis
88884208|NCT04155853|Active Comparator|Hematoma and Distraction Arthroplasty|Hematoma and Distraction Arthroplasty for the treatment of thumb carpometacarpal joint osteoarthritis
88884209|NCT04155437|Experimental|Intervention|A&T intervention areas: intensified maternal nutrition behavior change interventions during antenatal care delivered through government health facilities.
88884210|NCT04155437|No Intervention|Control|Comparison areas: standard antenatal care services delivered at government health facilities.
88884211|NCT04154423|Active Comparator|Glow! Group Prenatal Care|Group prenatal care with wrap around services.
88884212|NCT04154423|Active Comparator|Individual Prenatal Care- CPSP|Individual prenatal care with supplemental services covered by CPSP.
89191562|NCT00854152|Experimental|1|
89191563|NCT00721890|Experimental|1|
89408547|NCT05705635|Experimental|Docetaxel for Injection (Albumin-bound)|Docetaxel for Injection (Albumin-bound) will be administrated by intravenous infusion once every 3 weeks.
89408548|NCT05705635|Active Comparator|Taxotere|Taxotere will be administrated by intravenous infusion once every 3 weeks.
89408549|NCT04467320|Experimental|Intervention Group|Receiving the Teaching Recovery Techniques intervention (delivered online).
89408550|NCT04467320|Active Comparator|Care-As-Usual Group|Receiving care-as-usual.
89408551|NCT00085774|Experimental|Albuterol HFA BOI|
89408552|NCT00085774|Experimental|Albuterol HFA MDI|
89408553|NCT00085774|Placebo Comparator|Placebo|
89408554|NCT05193968|Other|Experimental: Healthy Women Volunteers|Hot Flash frequency will be assessed in the study subjects during a screening period. Participants can then chose to participate 1 or 2 study visits- Protocol 1: Microvascular function and/or Protocol 2: Autonomic function
89408555|NCT02137356|Experimental|treatment arm|standard dose pelvic radiation therapy, standard dose capecitabine, dose-escalated selinexor treatment
89437523|NCT03725878|Active Comparator|Control|Standard tertiary interventions of birth defects; Additional health care procedures during and after pregnancy.
89408556|NCT05137288|Active Comparator|patients receiving intrathecal atropine|Patient received intrathecal hyperbaric bupivacaine ( 10 mg ) ( 2 ml 0.5% ) with morphine 250mic and atropine sulphate 100 micwith total volume = 2.5 ml .
89408557|NCT05137288|Active Comparator|patients receiving preoperative intravenous ondasetron|Patient received intrathecal hyperbaric bupivacaine ( 10 mg ) ( 2 ml 0.5% with 0.5 ml normal saline with morphine 250 mic ) with total volume = 2.5 ml with giving 4 mg IV ondansetron before anesthesia ( patients with body weight more than 80 Kg may need additional 4 mg IV ) .
89408558|NCT04467476|Active Comparator|tDCS (anodal)|tDCS: 20 minutes, 2mA, over the motor cortex representation of lower limbs.
89408559|NCT04467476|Sham Comparator|tDCS (sham)|tDCS: 20 minutes (but 30s ON), 2mA, over the motor cortex representation of lower limbs.
89408560|NCT04467242||COPD patients|COPD patients with severe emphysema and right heart dysfunction
89408561|NCT05135182|Experimental|furazolidone-tetracycline-containing quadruple|patients in furazolidone-tetracycline-containing quadruple group will receive vonoprazan fumarate 20mg po bid, tetracycline 500mg po qid , bismuth potassium citrate(Lizhudele) 220mg po bid, and furazolidone 100mg po bid for 14d
89408562|NCT05135182|Active Comparator|metronidazole-tetracycline-containing quadruple group|patients in metronidazole-tetracycline-containing quadruple group will receive vonoprazan fumarate 20mg po bid,tetracycline 500mg po qid , bismuth potassium citrate(Lizhudele) 220mg po bid, and metronidazole 400mg po qid for 14d.
89408563|NCT02137434|Placebo Comparator|Low calcium fatty meal|Fatty meal consisting of biscuit, butter and drink made of albumin and sugar containing 40 mg of calcium, 600 kcal, with approximately 10% of energy from protein, 53% from fat, and 37% from carbohydrates.
89408564|NCT02137434|Experimental|High dietary calcium fatty meal|Fatty meal consisting of biscuit, butter and drink made of skimmed milk containing 540 mg of dietary calcium, 600 kcal, with approximately 10% of energy from protein, 53% from fat, and 37% from carbohydrates.
89408565|NCT02137434|Experimental|High supplementary calcium fatty meal|Fatty meal consisting of biscuit, butter and drink made of albumin and sugar containing 540 mg of supplementary calcium from calcium carbonate, 600 kcal, with approximately 10% of energy from protein, 53% from fat, and 37% from carbohydrates.
89408566|NCT02137590|Experimental|Spanish Black Radish|Spanish Black Radish product
89408567|NCT03051607|Experimental|Tozadenant|120 mg twice daily. At Week 2 or thereafter doses of 60 mg BID and 120 mg BID will be permitted.
89408568|NCT02137668|Experimental|Oral Vancomycin|Every participant with PSC or BA will received the same Arm of Oral Vancomycin
89408569|NCT02137746|Experimental|DCVAC/PCa Arm|Dendritic Cells DCVAC/PCa Experimental therapy
89408570|NCT04962568|Experimental|NHF-NIV|Subjects will start with NHF. If all measurements are done, subjects will change to NIV. Same measurements will done.
89408571|NCT04962568|Experimental|NIV-NHF|Subjects will start with NHF. If all measurements are done, subjects will change to NIV. Same measurements will done.
89408572|NCT05291767|Experimental|Diet: high fat meal|Participants will consume either a high fat or a high carbohydrate meal.
89408573|NCT05291767|Experimental|Exercise: medium intensity exercise|After consuming the meal, participants will either exercise at moderate intensity for 30 minutes or rest.
89408574|NCT04956406|Experimental|MIAKTR|MIAKTR is an acronym that defines Motivational Interviewing for Adult Kidney Transplant Recipients
89408575|NCT04956406|Active Comparator|Control Group|routine care
88884213|NCT04154371|Experimental|Single-arm or non-randomized trial|Six post-stroke patients, in the chronic recovery stage, will receive a treatment in which motor execution is promoted by virtual and augmented reality using serious gaming controlled by myoelectric pattern recognition. The aim of this treatment is to improve upper limb functionality.
88884214|NCT04152824|Experimental|Leader Intervention|Leaders in the intervention group will go through the Resilience-Supportive Leadership Training (RESULT)
88884215|NCT04152824|No Intervention|Control Group|Leaders in the control group will be usual practice
88884216|NCT04131959|Experimental|Pharmacodynamic population|Single arm
88884217|NCT04121559|Experimental|Intervention|A&T intervention areas: adolescent-nutrition-focused behavior change interventions delivered through government primary schools and communities
89408576|NCT03522428|Active Comparator|Receiving treatment|Adding vitamin B12 at a dose of 5 μg / 100 days, custom folic acid therapy and iron supplements
89408577|NCT03522428|No Intervention|Control group|Standard prenatal care (custom folic acid therapy and iron supplements)
89408578|NCT05575999|Other|Bupivacaine Alone|This is the control group of patients receiving 20 cc of 0.5% bupivacaine (Bupivacaine HCL 100 mg [5mg/ml] alone. The dose and number of doses of the medicines will be adjusted as per discretion of the operator.
89408579|NCT05575999|Experimental|Bupivacaine-Ketorolac-Ketamine (BKK) Combination|This is the intervention group of patients receiving 20 cc combination of BKK (Bupivacaine HCl 60 mg [3 mg/mL], Ketorolac Tromethamine 24 mg [1.2mg/mL], Ketamine HCl 24 mg [1.2 mg/mL]).The dose and number of doses of the medicines will be adjusted as per discretion of the operator.
89408580|NCT02132988|Experimental|OPT-822/OPT-821|
89408581|NCT04449484|Experimental|MEDI1341|3 doses given at 4 week intervals
89408582|NCT04449484|Placebo Comparator|Placebo|3 doses given at 4 week intervals
88884218|NCT04121559|No Intervention|Control|Comparison areas: standard activities at government primary schools
88884219|NCT04112654|Active Comparator|Conventional laparoscopy|Laparoscopy realized at the conventional pressure (12-15 mmHg) using conventional insufflator.
88884220|NCT04112654|Experimental|Low pressure laparoscopy|Laparoscopy realized at low pressure (6-8mmHg) using pressure-controlled insufflator AirSeal®
88884221|NCT04098406|Placebo Comparator|Placebo|The matched placebo to be used in this study will consist of water, sodium bicarbonate, and food coloring to match volume and color of the experimental treatment
88884222|NCT04098406|Experimental|30 mg CNM-Au8|30mg suspension of clean-surfaced, faceted, gold nanocrystals in 60ml of sodium bicarbonate buffered water
89408583|NCT01062399|Experimental|Ph I: RT + TMZ + RAD001 2.5 mg/day|Radiation therapy (RT), concurrent temozolomide (TMZ), and concurrent RAD001 2.5 mg/day followed by post-radiation temozolomide and post-radiation RAD001 10 mg/day.
89408584|NCT01062399|Experimental|Ph I: RT + TMZ + RAD001 5 mg/day|Radiation therapy, concurrent temozolomide, and concurrent RAD001 5 mg/day followed by post-radiation temozolomide and post-radiation RAD001 10 mg/day.
89408585|NCT01062399|Experimental|Ph I: RT + TMZ + RAD001 10 mg/day|Radiation therapy, concurrent temozolomide, and concurrent RAD001 10 mg/day followed by post-radiation temozolomide and post-radiation RAD001 10 mg/day.
89408586|NCT01062399|Active Comparator|Ph II: RT + TMZ|Radiation therapy and concurrent temozolomide followed by post-radiation temozolomide
89408587|NCT01062399|Experimental|Ph II: RT + TMZ + RAD001|Radiation therapy, concurrent temozolomide, and concurrent RAD001 10 mg/day followed by post-radiation temozolomide and post-radiation RAD001 10 mg/day.
89408588|NCT02133144|Experimental|High fat diet|Intervention: overeating high fat diet (1000 extra calories per day) for 3 weeks
89408589|NCT02133144|Experimental|High carbohydrate diet|Intervention: overeating high carbohydrate diet (1000 extra calories per day) for 3 weeks
89408590|NCT05136508|Experimental|TIVA|In the TIVA group, anesthesia was induced with TCI of propofol (Ce of 4.0-4.5 μg/ml) and remifentanil (Ce of 4.0 ng/ml). Anesthesia was maintained with TCI of propofol and remifentanil. Anesthesia depth was adjusted to maintain a PSI of 25-50.
89004631|NCT02228889|Experimental|XenMatrix|Abdominal wall reconstruction with XenMatrix Assess pain intensity at last office visit preoperatively Assess pain interference at last office visit preoperatively Assess physical functioning at last office visit preoperatively Assess patient quality of life at last office visit preoperatively Assess patient pain intensity postoperatively Assess pain interference postoperatively Assess physical functioning postoperatively Assess quality of life postoperatively Assess hernia recurrence at 30 days postoperatively Assess bulge at 30 days postoperatively Assess Surgical Site Occurrences at 30 days postoperatively Assess hernia recurrence at 1 year postoperatively Assess bulge at 1 year postoperatively Assess Surgical Site Occurrences at 1 year postoperatively Assess overall complications at 30 days postoperatively Assess overall complications at 1 year postoperatively
89191564|NCT01005914|Experimental|Group 1|"Drug:cyclophosphamide Day 1- 3: 300 m g/m2 IV over 2-3 hours every 12 hours for 6 doses plus mesna 600 mg/ m2 /day continuous infusion Days 1-3~Drug:cytarabine Day 2 & 3: 3g/m2 IV over 2 hours q12 X 4~Drug:dexamethasone Day 1-4; 11-14: 40 mg daily~Drug:doxorubicin hydrochloride Day 4: 50 mg/m2 IV over 2 hours~Drug:imatinib mesylate 600 mg/day~Drug:methotrexate Day 1: 1g/ m2 (200 mg/ m2load IV over 2 hours plus 800 mg/ m2 over 22 hours as an infusion~Drug: methylprednisolone Day 1-3: 50mg IV BID~Drug: pegaspargase Day 3/Day4: 2,500 IU/ m2 IV~Drug: vincristine sulfate Day 4 & 11: 2 mg IV"
89408591|NCT05136508|Active Comparator|Inhalation|In the volatile group, anesthesia was induced with an intravenous bolus of propofol 1.0-1.5 mg/kg and TCI of remifentanil (effect-site concentration [Ce] of 4.0 ng/ml). Anesthesia was maintained with sevoflurane (0.8-1 age-adjusted minimum alveolar concentration) and TCI of remifentanil
89408592|NCT02133222|Experimental|Metastatic (stage IV) melanoma|
89408593|NCT05221567|Active Comparator|High intensity high dosage inpatient short-term psychodynamic psychotherapy (affect phobia therapy)|APT and VITA psychotherapy was carried out in accordance with treatment manuals. In addition to weekly individual sessions the inpatient program at both groups contained two 75 min group sessions each week. In addition, VITA had shorter group meetings each morning (15 minutes). Patients in both treatments participated in two physical exercise sessions per week, weekly psycho-educational lectures and art-therapy groups, and both groups finish each week with end of the week status groups. On average, patients in both treatments received seven sessions of therapeutic activity each week. All treatment components, with the exception of the physical exercises, adhered to the APT or VITA treatments, and thus the two intensive treatments were similar in dose but different in content. Medication was managed by psychiatrists, aiming to optimize the psychotropic medication regime, typically by reducing medication use.
89408594|NCT05221567|Other|Treatment-as-usual|TAU through public services locally, either outpatient treatment from a psychologist/psychiatrist and/or treatment/support from their local general practitioner.
89408595|NCT05221567|Active Comparator|High intensity high dosage inpatient short-term psychodynamic psychotherapy (VITA)|APT and VITA psychotherapy was carried out in accordance with treatment manuals. In addition to weekly individual sessions the inpatient program at both groups contained two 75 min group sessions each week. In addition, VITA had shorter group meetings each morning (15 minutes). Patients in both treatments participated in two physical exercise sessions per week, weekly psycho-educational lectures and art-therapy groups, and both groups finish each week with end of the week status groups. On average, patients in both treatments received seven sessions of therapeutic activity each week. All treatment components, with the exception of the physical exercises, adhered to the APT or VITA treatments, and thus the two intensive treatments were similar in dose but different in content. Medication was managed by psychiatrists, aiming to optimize the psychotropic medication regime, typically by reducing medication use.
89408596|NCT05132140|Experimental|normal healthy group|Adaptive optics system: this system controls the optical quality of the eye at the peripheral visual field temporarily.
89408597|NCT02129322|Active Comparator|Sorafenib|Leading 4 cycles: S-1 + Oxaliplatin Q3W + Sorafenib daily Sequential : Sorafenib maintenance
89408598|NCT02129322|Experimental|S-1 and Sorafenib|Leading 4 cycles: S-1 + Oxaliplatin Q3W + Sorafenib daily Sequential : 4 cycles of S-1 + Sorafenib maintenance
89408599|NCT05221489|Experimental|lullaby group|For two weeks and 30 minutes every day at home, the lullaby group (LG) only listened to the lullaby record selected by the researcher.
88813730|NCT01584479||High Risk Control Group|"2 visits - High Risk~~800 subjects High Risk Control Group = 2 visit intervention, one or more of the following risk factors: history of periodontitis, smoker or diabetic, IL-1 genotype (+)"
88813731|NCT02464410|Experimental|Motivational Intervention|The intervention session combines elements of motivational enhancement (ME) and cognitive behavioral therapy (CBT) and uses the structure of ME brief interventions. The motivational session is overlaid on the VA long-term opioid therapy informed consent process.
89191565|NCT00854230|Experimental|1|Naltrexone
89191566|NCT00854230|Placebo Comparator|2|
89408600|NCT05221489|Experimental|mix music group|For two weeks and 30 minutes every day at home, the multi-music group (MG) listened to self-selected music from different records presented to them by the researcher.
89408601|NCT05221489|No Intervention|control group|The control group (CG) only received routine care.
89408602|NCT05136274|Active Comparator|Medical treatment|By administering a single intramuscular dose of 50mg / m2 / Sc of Methotrexate.
89408603|NCT05136274|Active Comparator|Surgical treatment|Will be performed by laparoscopy or laparotomy, using the Linear Salpingostomy technique.
89408604|NCT05221411|Experimental|Mycofenolate Mofetil|Patients in the mycophenolate mofetil (MMF) arm will receive MMF for a total of 12 months (if tolerated)
89408605|NCT05221411|Experimental|Tacrolimus (Envarsus)|Patients in the tacrolimus (TAC) arm will receive treatment with meltdose TAC for a total of 12 months (if tolerated)
89408606|NCT02133300|Experimental|electrical stimulation|Compex 3 professional NMES for 60' per day
89408607|NCT02133300|No Intervention|control|
89408608|NCT05306002|Other|Antioxidant therapy|The patient will get a nutritional personalized treatment with the following characteristics: hypocaloric diet, rich in micronutrients related with DNA reparation and polyphenols, with the next distribution: 45% carbohydrates, 30% lipids, 25% protein, <10% saturated fats, >10% unsaturated fats, based on the recommendations of the American Institute for Cancer Research (AICR).
89408609|NCT03650517||Robotic Right Colectomy with ICA|"Robot-assisted surgery (RAS), allows many types of complex MIS procedures using robotic systems to aid in surgical procedures providing more precision, flexibility and control than is possible with other MIS techniques.~Intracorporeal anastomosis: when the anastomosis is performed inside the abdominal cavity with a laparoscopic or robotic technique. A Pfannenstiel incision will be done exclusively for specimen extraction."
89408610|NCT03650517||Robotic Right Colectomy with ECA|"Robot-assisted surgery (RAS), allows many types of complex MIS procedures using robotic systems to aid in surgical procedures providing more precision, flexibility and control than is possible with other MIS techniques.~Extracorporeal anastomosis: when the anastomosis is performed by pulling out the bowel through a laparotomy wherever that laparotomy is performed."
89408611|NCT03650517||Laparoscopic Right Colectomy with ICA|"Laparoscopic surgery, also called minimally invasive surgery (MIS), or keyhole surgery, is a surgical technique in which operations are performed far from their location through small incisions (usually 0.5-1.5 cm) elsewhere in the body.~Intracorporeal anastomosis: when the anastomosis is performed inside the abdominal cavity with a laparoscopic or robotic technique. A Pfannenstiel incision will be done exclusively for specimen extraction."
89408612|NCT03650517||Laparoscopic Right Colectomy with ECA|"Laparoscopic surgery, also called minimally invasive surgery (MIS), or keyhole surgery, is a surgical technique in which operations are performed far from their location through small incisions (usually 0.5-1.5 cm) elsewhere in the body.~Extracorporeal anastomosis: when the anastomosis is performed by pulling out the bowel through a laparotomy wherever that laparotomy is performed."
89408613|NCT03766620||Tube Fed Participants|Individuals with diabetes and malnutrition receiving tube feed as sole source nutrition.
88884223|NCT04095104|Experimental|Phentermine & Topiramate|"Phentermine- Formulation: 8mg scored tablet, Dosage/Frequency/Duration:~4mg x 7d then 8mg x 7d then 12mg x 7d then 16mg x 63d, taken once every morning~+~Immediate release topiramate- Formulation: 25mg tablet, Dosage/Frequency/Duration: 25mg x 7d then 50mg x 7d then 75mg x 7d then 100mg x 63d then 50mg x 7 days then 25mg x 7d, taken once every morning~+~Standard of Care (multidisciplinary postoperative bariatric surgery clinic visits)"
89408614|NCT05705557||Patients undergoing laparotomic (open) liver resection|
89408615|NCT02137902|Experimental|Tobacco/Physical Activity Intervention|Includes a psychosocial component that utilizes a counselor-facing computer-assisted intervention with tailored counseling feedback focused on increasing intrinsic motivation, goal setting for tobacco and physical activity, adherence with nicotine replacement therapy, and self-monitoring with a pedometer-based walking program. The intervention will provide 12 weeks of nicotine replacement therapy for participants.
89408616|NCT02137902|Experimental|Diet plus BP/CHOL Intervention|Consists of a psychosocial component that includes counselor-facing computer-assisted intervention with tailored counseling feedback focused on increasing intrinsic motivation, goal setting for managing hypertension and hypercholesterolemia, and adherence with antihypertensives and statins with supportive dietary changes. The intervention provides a cookbook of heart healthy regional recipes and medication bag for storing medications.
89408617|NCT05135962|Active Comparator|RME (rapid expansion)|"Intervention orthodontic - maxillary expansion:~maxillary expansion with RME expander anchored on second deciduous molars. Activation: 1/turn day. RME was kept on teeth as a passive retainer and removed after one year from its application."
89408618|NCT05135962|Experimental|Leaf expander 450g (slow expansion)|Intervention orthodontic - maxillary expansion: maxillary expansion with Leaf Expander appliance anchored on second deciduous molars Activation: The leaves are preactivated in the laboratory to deliver 3mm of expansion. Reactivation is performed in the office by 10 quarter-turns of the screw per month until expansion has been completed. After active expansion, the Leaf Expander was kept on teeth as a passive retainer and removed after one year from its application.
89408619|NCT05135962|Experimental|Leaf self-expander 450g (slow expansion)|"Intervention orthodontic - maxillary expansion: maxillary expansion with Leaf self Expander appliance anchored on second deciduous molars.~Activation: self activation (preactivated). After active expansion the Leaf self expander was kept on teeth as a passive retainer and removed after one year from its application"
89408620|NCT05135962|Experimental|Leaf expander 900g (slow expansion)|"Intervention orthodontic - maxillary expansion: maxillary expansion with Leaf Leaf Expander appliance anchored on second deciduous molars.~Activation: The leaves are preactivated in the laboratory to deliver 3mm of expansion. Reactivation is performed in the office by 15 quarter-turns of the screw per month until expansion has been completed. After active expansion the Leaf Expander was kept on teeth as a passive retainer and removed after one year from its application."
89408621|NCT05135962|Experimental|Leaf self-expander 900g (slow expansion)|"Intervention orthodontic - maxillary expansion: maxillary expansion with Leaf self Expander appliance anchored on second deciduous molars.~Activation: self activation (preactivated). After active expansion the Leaf self expander was kept on teeth as a passive retainer and removed after one year from its application"
89408622|NCT05221333|Other|Healthy participants|Up to 25ml of saline administered through OBI
89191567|NCT04067076||Students of IEMS of Mexico City|Students currently enrolled in the academic year 2019-2020 from the 24 IEMS centers of Mexico City
88884224|NCT04095104|Placebo Comparator|Placebo Drugs|"Placebo Phentermine- Formulation: 8mg scored tablet, Dosage/Frequency/Duration: 4mg x 7d then 8mg x 7d then 12mg x 7d then 16mg x 63d, taken once every morning~+~Placebo Immediate release topiramate- Formulation: 25mg tablet, Dosage/Frequency/Duration: 25mg x 7d then 50mg x 7d then 75mg x 7d then 100mg x 63d then 50mg x 7 days then 25mg x 7d, taken once every morning~+~Standard of Care (multidisciplinary postoperative bariatric surgery clinic visits)"
89408623|NCT05565703|Experimental|Intervention Group|This group is randomly selected from the Acute care for elders unit and receives a one hour intervention with the PARO robotic seal two days in a row during their hospital stay.
89408624|NCT05565703|Active Comparator|Attention Control Group|This group is randomly selected from the Acute Care for Elders unit and receives a one hour visit from the Researcher or research assistant two days in a row.
89408625|NCT04346914|Experimental|Combined treatment group|recombinant anti-PD-L1 monoclonal antibody injection combined with carboplatin and etoposide ZKAB001 ,5 mg/kg, d1，q3w； carboplatin，5 AUC，d1，q3w； etoposide，100mg/m2，d1~3，q3w
89408626|NCT02129400|Experimental|10min Xenon 15%, FiO2 75%|10 minutes of 15 % xenon-inhalation (with 75 % FiO2)
89408627|NCT02129400|Experimental|10min Xenon 30%, FiO2 60%|10 minutes of 30 % xenon-inhalation (with 60 % FiO2)
89408628|NCT02129400|Experimental|30min Xenon 15%, FiO2 75%|30 minutes of 15 % xenon-inhalation (with 75 % FiO2)
89408629|NCT02129400|Experimental|30min Xenon 30%, FiO2 60%|30 minutes of 30 % xenon-inhalation (with 60 % FiO2)
89408630|NCT02129400|Experimental|45min Xenon 15%, FiO2 75%|45 minutes of 15 % xenon-inhalation (with 75 % FiO2)
89408631|NCT02129400|Experimental|45min Xenon 30%, FiO2 60%|45 minutes of 30 % xenon-inhalation (with 60 % FiO2)
89408632|NCT02129400|Experimental|90min Xenon 15%, FiO2 75%|90 minutes of 15 % xenon-inhalation (with 75 % FiO2)
88884225|NCT04091113||Participants with Hereditary Angioedema|Participants older than 18 years that are clinically diagnosed with Hereditary Angioedema type 1/2 and experienced ≥4 HAE attacks within last 12 month before the enrollment
89408633|NCT02129400|Experimental|90min Xenon 30%, FiO2 60%|90 minutes of 30 % xenon-inhalation (with 60 % FiO2)
89408634|NCT02129400|Placebo Comparator|10min air medicinalis, FiO2 75%|10 minutes of air medicinalis (with 75 % FiO2)
89408635|NCT02129400|Placebo Comparator|10min air medicinalis, FiO2 60%|10 minutes of air medicinalis inhalation (with 60 % FiO2)
89408636|NCT02129400|Placebo Comparator|30min air medicinalis, FiO2 75%|30 minutes of air medicinalis inhalation (with 75 % FiO2)
89408637|NCT02129400|Placebo Comparator|30min air medicinalis, FiO2 60%|30 minutes of air medicinalis inhalation (with 60 % FiO2)
88884226|NCT04086966|Experimental|Metastatic Prostate Cancer Arm|[68Ga]PSMA-11 PET/MRI or PET/CT for guiding the radiation treatment plan in patients with known or suspected locally metastatic prostate cancer
88884227|NCT04084990|Experimental|aPAP|Nightly use of aPAP when sleeping through the date of delivery
88884228|NCT04084990|No Intervention|No aPAP|No use of aPAP (standard of care)
89408638|NCT02129400|Placebo Comparator|45min air medicinalis, FiO2 75%|45 minutes of air medicinalis inhalation (with 75 % FiO2)
88884229|NCT04067622|Other|Exersides restraints first|Patients in this arm will wear the novel Exersides restraint during hours 1-4 on Day 1, then switched to soft wrist restrains during hours 5-8. On Day 2, patients in this arm will will wear soft wrist restraints during hours 1-4, and Exersides during hours 5-8. They will then wear Exersides during study days 3-6.
89408639|NCT02129400|Placebo Comparator|45min air medicinalis, FiO2 60%|45 minutes of air medicinalis inhalation (with 60 % FiO2)
89408640|NCT02129400|Placebo Comparator|90min air medicinalis, FiO2 75%|90 minutes of air medicinalis inhalation (with 75 % FiO2)
89408641|NCT02129400|Placebo Comparator|90min air medicinalis, FiO2 60%|90 minutes of air medicinalis inhalation (with 60 % FiO2)
89408642|NCT05135884||Cohort|
89408643|NCT05704465|Other|Reiki Therapy|Reiki is a biofield therapy technique based on energy healing.
88884230|NCT04067622|Other|Traditional restraints first|Patients in this arm will wear soft wrist restraints during hours 1-4 on Day 1; they will then be switched to the novel Exersides restraint during hours 5-8. On Day 2, patients in this arm will will wear Exersides during hours 1-4, and soft wrist restraints during hours 5-8. They will then wear soft wrist restraints during study days 3-6.
88884231|NCT04067284|Active Comparator|Education|Nutrition education on dietary diversity.
88884232|NCT04067284|Experimental|Yogurt|A combination of similar education plus daily supplementation of homemade yogurt
88884233|NCT04067284|Active Comparator|Control|Control group.
88884234|NCT04061564|Active Comparator|Active transcutaneous vagal nerve stimulation|The participant will be administered vagal nerve stimulation to each ear (20 minutes in total)
88884235|NCT04061564|Sham Comparator|Sham transcutaneous vagal nerve stimulation|The participant will be administered sham stimulation to each ear (20 minutes in total)
88884236|NCT04045405|Experimental|CDR132L|
88884237|NCT04045405|Placebo Comparator|Saline|
89408644|NCT05704465|Other|Qi-gong Therapy|Qigong technique is a type of mind-body meditative exercise developed in traditional Chinese medicine more than 5000 years ago.
89408645|NCT05305768|Active Comparator|OLD (4 U per 0.1 mL)|Participants will receive a total Xeomin dose of 20U using a 4U per 0.1mL concentration divided into 5 intramuscular injections performed once.
89408646|NCT05305768|Active Comparator|COLD (4 U per 0.05 mL group)|Participants will receive a total Xeomin dose of 20U using a 4U per 0.05mL concentration divided into 5 intramuscular injections performed once.
89408647|NCT05245981|Experimental|BRI.MAG 2|Patients presenting with dislocated isolated or combined fracture of the medialis malleolus are eligible to receive the investigational device.
89408648|NCT02133378|Experimental|Hemopatch|Use of Hemopatch on bleeding spot
89408649|NCT02133378|Sham Comparator|Control|Traditional techniques hemostasis (dry or wet gauze compression or similar)
89408650|NCT05135416|Active Comparator|chewing gum Group|"Questions related to surgery and bowel function found in the Participant Information Form it will be filled in. The chewing gum group data will be followed up with the Follow-up Form- Chewing Gum Group . Women who make up the gum group, based on the time of arrival in the room 2. per hour, 4. and 6 o'clock. they'll chew gum an hour. Chewing gum based on knowledge of the literature its duration will be limited to 15 minutes, and a new gum will be introduced with each chewing. To all women the same brand will be given unsweetened chewing gum, which is easy to chew, does not contain sorbitol and xylitol. Sorbitol GIS problems in the case of ingestion of gums containing it, while gums containing xylitol are more in order not to ignore the decongestant risk of diarrhea when consumed, sugar-free chewing gum was preferred."
89408651|NCT05135416|Active Comparator|Control group|"Questions related to surgery and bowel function found in the Participant Information Form it will be filled in. The control group data were followed up with the Follow-up Form-Control Group will be. Of the women who made up the control group, it was not until the bowel sounds were first heard that bowel sounds will be listened to by the service nurse december 2 hours intervals. The patient has gas-stool by querying the output, it will be saved. Application of analgesics to pain levelsin the case of Visual Analog Scale (Visual Analog Scale -Vas) within 15 minutes it will be evaluated with. After the end of the researcher's 8-hour shift, the time of gas extraction and defecation is estimated since it cannot be done, women can set the time of gas extraction and defecation as time/date; they'll record it. Assessment of pain level, first 8. After the time of 16 and 24. in the hours will be made."
89191568|NCT00861016|Experimental|1|The patients with mild to moderate essential hypertension
89408652|NCT03550716|Active Comparator|mTESE|Patients randomized to mTESE
89408653|NCT03550716|Active Comparator|TESA|Patients randomized to TESA
89408654|NCT05305690||Penetrating cerebrovascular injury, managed nonoperatively|PCVI from penetrating trauma without upfront operation
89408655|NCT05305690||Penetrating cerebrovascular injury, managed operatively|
89408656|NCT03525080|Experimental|PET Arm|
89191569|NCT02571582||Patients died|"All patients underwent extensive evaluation:~- Body composition, Diabetes; dyslipidemia, hemoconcentration, hypertension, exercise capacity: 6-Minute Walk test procedure, renal function, inflammatory markers, cause and place of death, time tracking concentrator, quality of life and pulmonary Function."
89191570|NCT02571582||living patients|"All patients underwent extensive evaluation:~- Body composition, Diabetes; dyslipidemia, hemoconcentration, hypertension, exercise capacity: 6-Minute Walk test procedure, renal function, inflammatory markers, cause and place of death, time tracking concentrator, quality of life and pulmonary Function."
89408657|NCT04171622|Experimental|Treatment (pembrolizumab, lenvatinib)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for up to 35 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive lenvatinib PO daily on days 1-21. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
89408658|NCT05234580|Experimental|PA9159 10 μg|Fifty subjects will be randomly assigned to receive 10 μg of PA9159 Nasal Spray for 14 days. Subjects will be administered two vials of drug (spray bottle A and spray bottle B) once daily in the morning, one spray each in the left and right nostril, in the order of first spray A and then spray B. Spray Bottle A: 5 μg/spray; Spray Bottle B: 0 μg/spray.
88884238|NCT04044729|Active Comparator|Cannabidiol|"Drug: Cannabidiol An oral dose of Cannabidiol (CBD) will be given once a day for five day with pain ratings taken before and after each dose every day.~Other Names:~CBD"
88884239|NCT04044729|Placebo Comparator|Placebo|"Drug: Placebos An oral placebo will be given once a day for five day with pain ratings taken before and after each dose every day.~Other Names:~placebo"
88884240|NCT04008082||Lenvatinib|Lenvatinib capsules 12 milligram (mg) for participants with body weight greater than or equal to (>=) 60 kilograms (kg) or 8 mg for participants with body weight less than (<) 60 kg, orally, once daily as per routine clinical practice.
88884241|NCT03997526||3C Patch treatment|Medicare beneficiaries with diabetes and hard-to-heal non-healing ulcers of the foot will receive usual care (i.e., care consistent with the IWGDF guidance on use of interventions to enhance the healing of chronic ulcers of the foot in diabetes) supplemented by the application of the 3C Patch (A platelet-rich plasma gel patch comprised of distinct fibrin, platelet, and leukocyte substantially parallel layers, prepared without the use of any added reagents through a two-step centrifugation process)
88884242|NCT03995589|Experimental|Walking Group|
88884243|NCT03995589|Active Comparator|Control|
88884244|NCT03979547|Experimental|Exercise intervention|The exercise program will be similar to the Exercise in All ChemoTherapy (ENACT) study which combines in-person and home-based strength training and aerobic exercise five days a week.
88884245|NCT03979547|No Intervention|Standard of Care|Subjects are instructed to maintain their current activity level.
88884246|NCT03979534|Experimental|Diet group|"Diet follow-up to personalize a low-protein diet for each patient. All patients following a low protein diet one month or more compose the diet group."
88884247|NCT03979534|No Intervention|Control group|Patients who accepted to take part of the study but refused the low protein diet and patients who discontinued the diet on the first month compose the control group.
88884248|NCT03978000|Active Comparator|IBP-9414|
89191571|NCT04018144||Group-1|Healthy individuals
88884249|NCT03978000|Placebo Comparator|Placebo|
88884250|NCT03977779|Experimental|Prophylactic biodegradable pancreatic stent placement|
88884251|NCT03974243|Experimental|treatment group|"In this arm, patients would be given the regimen composed of Chiauranib and Chidamide orally.~Intervention: Drug: Chiauranib and Chidamide"
89191572|NCT04018144||Group-2|Periodontitis patients-stage 3-grade B
89191573|NCT04018144||Group-3|Periodontitis patients-stage 3-grade C
89191574|NCT00718380|Experimental|Group 1|Dose escalation from Open label 0.05 to 0.25 mg/kg once a day dosing for 21 days
89191575|NCT00718380|Experimental|Group 2|Open label 0.10 mg/kg once a day dosing after safety evolution of Group 1
89191576|NCT00718380|Experimental|Group 3|Open label 0.20 mg/kg once a day dosing after safety evolution of Group 2
89191577|NCT00718380|Experimental|Group 4|Open label 0.25 mg/kg once a day dosing after safety evolution of Group 3
89408659|NCT05234580|Experimental|PA9159 20 μg|Fifty subjects will be randomly assigned to receive 20 μg of PA9159 Nasal Spray for 14 days. Subjects will be administered two vials of drug (spray bottle A and spray bottle B) once daily in the morning, one spray each in the left and right nostril, in the order of first spray A and then spray B. Spray Bottle A: 0 μg/spray; Spray Bottle B: 10 μg/spray.
89191578|NCT02553291|Experimental|SystemCHANGE|Subjects will participate in SystemCHANGE behavioral intervention focusing on diet and exercise. This six-session intervention focuses on system redesign of an individual's interpersonal environment and daily routines using small self-designed experiments to increase healthy behavior.
89191579|NCT02553291|Active Comparator|Control|Subjects randomized to the control group will receive an usual care condition and pamphlets on diet and exercise from the U.S. Department of Agriculture and the American Heart Association (AHA)
89408660|NCT05234580|Experimental|PA9159 40 μg|Fifty subjects will be randomly assigned to receive 40 μg of PA9159 Nasal Spray for 14 days. Subjects will be administered two vials of drug (spray bottle A and spray bottle B) once daily in the morning, one spray each in the left and right nostril, in the order of first spray A and then spray B. Spray Bottle A: 10 μg/spray; Spray Bottle B: 10 μg/spray.
89408661|NCT05234580|Placebo Comparator|Placebo|Fifty subjects will be randomly assigned to receive placebo Nasal Spray without active of PA9159 for 14 days. Subjects will be administered two vials of drug (spray bottle A and spray bottle B) once daily in the morning, one spray each in the left and right nostril, in the order of first spray A and then spray B. Spray Bottle A: 0 μg/spray; Spray Bottle B: 0 μg/spray.
89408662|NCT05305222|Experimental|Japanese Participants Receiving Risankizumab|Participants will receive single dose of risankizumab.
89408663|NCT05305222|Experimental|Japanese Participants Receiving Placebo|Participants will receive single dose of placebo.
89408664|NCT05305222|Experimental|Caucasian Participants Receiving Risankizumab|Participants will receive single dose of risankizumab.
89408665|NCT05305222|Experimental|Caucasian Participants Receiving Placebo|Participants will receive single dose of placebo.
88884252|NCT03970109|Active Comparator|ANS-6637 - 200mg|200 mg ANS-6637 (given as 2 x 100 mg tablet) once a day
89408666|NCT03522272|Experimental|Ultrasonic cleaning with cetylpyridinium chloride|Mechanical cleaning of the RPD with a soft toothbrush and liquid detergent, and ultrasonic cleaning (frequency 42kHz) (for 7 minutes 30 seconds) of the denture with 0.07% cetylpyridinium chloride mouthrinse
89408667|NCT03522272|Active Comparator|Ultrasonic cleaning with water|Mechanical cleaning of the RPD with a soft toothbrush and liquid detergent, and ultrasonic cleaning (frequency 42kHz) (for 7 minutes 30 seconds) of the denture with distilled water
89408668|NCT03522272|Active Comparator|Conventional denture hygiene|Mechanical cleaning of the RPD with a soft toothbrush and liquid detergent (Control group)
89408669|NCT02138058|Placebo Comparator|Placebo|a 12 week placebo matching tablets plus 4 sessions of a manualized cognitive restructuring intervention
89408670|NCT02138058|Experimental|topiramate|a 12 week topiramate flexible dose administration plus 4 sessions of a manualized cognitive restructuring intervention
88884253|NCT03970109|Active Comparator|ANS-6637 - 600mg|600 mg ANS-6637 (given as 2 x 300 mg tablet) once a day
88884254|NCT03970109|Placebo Comparator|Matched Placebo|2 placebo tablets once a day
88884255|NCT03967925|Active Comparator|Belimumab|Weekly 200mg SC injections of belimumab for 12 months
88884256|NCT03967925|Placebo Comparator|Belimumab placebo|Weekly SC injections of belimumab placebo for 12 months
89408671|NCT05187403|Experimental|Laquinimod - Single Ascending Doses|One single dose of laquinimod eye-drops. There are up to four planned dose levels.
89408672|NCT05187403|Placebo Comparator|Placebo - Single Ascending Doses|One single dose of placebo eye-drops.
89408673|NCT05187403|Experimental|Laquinimod - Multiple Ascending Doses|Eye-drops administered once daily for 14-21 days. There are up to two planned dose levels. The first dose level will be defined in the SAD-part of the study.
88884257|NCT03954743|Experimental|HRV PCV-free Liq Group|Subjects aged 6 to 12 weeks at the time of first vaccination, who received two doses of oral live-attenuated human rotavirus (HRV) porcine circovirus (PCV)-free vaccine in liquid formulation, one at Day 1 and one at Month 1 or Month 2, according to the immunization schedule for rotavirus (RV) vaccine administration in participating countries. PCV-free implies no detection of PCV-1 and PCV-2 according to the limit of detection of the tests used.
88884258|NCT03954743|Active Comparator|HRV Lyo group|Subjects aged 6 to 12 weeks at the time of first vaccination, who received two doses of oral live-attenuated human rotavirus (HRV) vaccine in lyophilized formulation, one at Day 1 and one at Month 1 or Month 2, according to the immunization schedule for rotavirus (RV) vaccine administration in participating countries.
88884259|NCT03952663|Experimental|Group I|inferior alveolar nerve lateralization for dental implant placement ,and platelet rich fibrin membrane is placed around the nerve.
88884260|NCT03952663|Active Comparator|Group II|inferior alveolar nerve lateralization for dental implant placement without placement of platelet rich fibrin membrane around the nerve.
88884261|NCT03925584|Experimental|Music Therapy|Implement standardized nurse-led music therapy for neonates post congenital heart surgery who are admitted to the cardiac intensive care unit.
88884262|NCT03915327|Experimental|Intravenous iron group|Enrolled subjects would receive intravenous iron isomaltose anhydride within 24 hours of the subject's inclusion.
88884263|NCT03915327|No Intervention|Control group|Clinical management, including surgical procedures, anesthesia, and perioperative management, are performed in accordance with standard clinical practice.
88884264|NCT03911830|Experimental|Exercise followed cold water immersion|Exercise program on cycloergometer and its submerged recovery
88884265|NCT03895710||Sleep-deprived group|i. Self-reported time in bed (period from bedtime to get-up time) during school days of <8 hours per day ii. Self-perceived insufficient sleep during school days
89408674|NCT05187403|Placebo Comparator|Placebo - Multiple Ascending Doses|Eye-drops administered once daily for 14-21 days.
88884266|NCT03895710||Normal sleep group|i. Self-reported time in bed during school days of >=8 hours per day ii. Self-perceived sufficient sleep during school days
89408675|NCT02129634|Active Comparator|CB-PTA arm|After successful crossing of the trial lesion, a conventional angioplasty balloon with a diameter matching the trial vessel is advanced over the guidewire and is inflated at the trial lesion site, according to the normal practice of the operator. Comparisons of pre- and post-angioplasty percentage stenosis will be made in the same angiographic projection(s).
89408676|NCT02129634|Experimental|DEB-PTA arm|After successful crossing of the trial lesion, angioplasty with a conventional angioplasty balloon is performed before DEB-PTA. This is because the paclitaxel coating may be scrapped off the balloon if the DEB is used to cross the trial lesion. A conventional angioplasty balloon with a diameter matching the trial vessel is advanced over the guidewire and is inflated at the trial lesion site, according to the normal practice of the operator. A DEB with a diameter matching the trial vessel and lesion length is then advanced over the 0.018 inch guidewire and inflated at the trial lesion site for 60 seconds. If the lesion length is longer than the length of the balloon, a second inflation with another DEB will be required. The maximal total lesion length of the treated lesions will not exceed 20cm. Comparisons of pre- and post-angioplasty percentage stenosis will be made in the same angiographic projection(s).
89408677|NCT05174455|Experimental|Treatment (Niraparib)|Patients receive niraparib PO QD. Cycles repeat every 28 days for 15 months in the absence of disease progression or unacceptable toxicity.
89408678|NCT04142606||Control Group (Group 1)|Having prenatal ultrasound screening without detected abnormality
89408679|NCT04142606||Non Optimal Ultrasound Scan Group (Group 2)|Having an ultrasound examination without abnormality detected but in whom ultrasound examination is not optimal (poor technical conditions, multiple pregnancies, obese patients)
89408680|NCT04142606||Malformation Group (Group 3)|Standardized prenatal screening with ultrasound examination finding an isolated anomaly that does not currently constitute a commonly accepted indication of fetal MRI
89408681|NCT04142606||TOP Group (Group 4)|A medical termination of pregnancy, (TOP), in addition to a fetopathological examination (virtopsy)
88884267|NCT03883594|Experimental|TASC Intervention|All participants receive Step 1 of the intervention. Participants who have adherence below or at 68% will step up to Step 2 or Step 3 after the third or fourth month in the study.
88884268|NCT03880565|Experimental|ECMO Facilitated Resuscitation|Regardless of whether return of spontaneous circulation (ROSC) has been achieved and with on-going mechanical CPR, patients will enter the Cardiac Catheterization Laboratory (CCL) for expeditious VAECMO initiation, if required, followed by coronary angiography and percutaneous coronary intervention (PCI) when appropriate.
88884269|NCT03880565|Other|Standard ACLS Resuscitation|Patients with refractory VF/VT OHCA will be treated with ACLS resuscitation for at least 15 minutes after arrival in the emergency department (ED), or up to 60 minutes from 911 call, after which the physician (MD) can continue resuscitation efforts until ROSC is achieved or futility has been reached based on their clinical judgment. If the patient has not achieved ROSC during the times mentioned above, the ED MD can declare death when he or she believes that ACLS is futile. If ROSC is present upon arrival or has been achieved anytime during resuscitation in the ED, the patient will be taken to the cardiac catheterization laboratory (CCL) for coronary angiography and PCI, and potential VA ECMO or other circulatory support device initiation, as clinically indicated.
88884270|NCT03876652|Experimental|DDD-CLS|Patients with a pacemaker programmed in DDD-CLS mode
88884271|NCT03876652|Active Comparator|DDD-R|Patients with a pacemaker programmed in DDD-R mode
88884272|NCT03876080|Experimental|Dry needling|Dry needling intervention to the gastrocnemius muscle trigger point
88884273|NCT03876080|Sham Comparator|Sham needling|Sham dry needling intervention to the gastrocnemius muscle trigger point
88884274|NCT03874988|Experimental|Portion-Controlled Meals|Participants will receive prepackaged food, delivered biweekly to their home over the course of 13 weeks, with costs covered by the grant. Depending on their calorie goals, participants will drink and eat a mix of shakes and entrees each day, plus up to five fruits and vegetables. HMR entrees and shakes are formulated to provide recommended levels of macronutrients, vitamins, sodium, fat, cholesterol and fiber and fortified to meet at least 100% of the recommended daily allowance for essential vitamins and minerals.
88884275|NCT03874988|Experimental|Enhanced Self-Monitoring|Participants will be encouraged to self-monitor 4 specific behaviors daily: 1) measuring their food; 2) measuring their physical activity; 3) recording their food, drink, and physical activity; and 4) monitoring their weight. To achieve this aim, participants will attend a single group-based educational session at baseline during which they will be provided the self-monitoring equipment (scale and Garmin vivofit) and receive training about how to use the Lilypad scale and smartphone food tracking app.
89408682|NCT04335604|Experimental|JPI-547|
89408683|NCT05063084|Experimental|OHD (HFNO)|High flow nasal oxygen
89408684|NCT05063084|Other|Control|Classic pre-oxygenation with facemask
89408685|NCT02138292|Experimental|Trametinib (2mg)/Digoxin (0.25mg)|"Trametinib (2mg) will be administered orally on a daily basis.~Digoxin (0.25mg) will be administered orally on a daily basis.~On a 8-week cycle, duration of treatment can last from 8 to 104 weeks."
89408686|NCT04468100|Experimental|Tigerase®|Dornase alfa
89408687|NCT04468100|Active Comparator|Pulmozyme®|Dornase alfa
89408688|NCT02138370||stage II and III colorectal cancer|
89408689|NCT01317277|Experimental|Personalized Reminder Texting (iTAB) + Psychoeducation|Participants in the individualized Texting for Adherence Building (iTAB) arm will receive daily text messaging reminders for antiretroviral medication adherence. These text messages will be targeted to the specific schedule and needs of the individual. Participants will also receive a one-time psychoeducational intervention reviewing the importance of adherence to anti-HIV medications.
89408690|NCT01317277|Active Comparator|Psychoeducation (CTRL)|Participants will receive a one-time psychoeducational intervention reviewing the importance of adherence to anti-HIV medications. They will also receive daily text messages to evaluate mood and methamphetamine use, but these messages will not remind participants about medication adherence.
89408691|NCT05135338||answer 1|a senior emergency physician on interpretation of chest x-ray and blinded to the final diagnosis .
89004632|NCT02188368|Experimental|A: POM 4mg+Steroids+(CFZ, BTZ, CY or CLA)|"POM 4 mg PO days 1-21 Steroids at the same dose and on the same days as the patient's lenalidomide-containing treatment (it varies for each subject).~BTZ (bortezomib) at the same dose and on the same days as the patient's lenalidomide-containing treatment (it varies for each subject).~CFZ (carfilzomib) at the same dose and on the same days as the patient's lenalidomide-containing treatment (it varies for each subject).~CLA (clarithromycin) at the same dose and on the same days as the patient's lenalidomide-containing treatment (it varies for each subject).~CY (cyclophosphamide) at the same dose and on the same days as the patient's lenalidomide-containing treatment (it varies for each subject)."
89408692|NCT05135338||answer 2|a resident or an intern interpretation of chest x-ray and blinded to the final diagnosis
89408693|NCT04467788|Active Comparator|Computer-aided session|Training on ergonomic principles in dentistry will be given to the participants through Computer-Aided sessions, including explaining videos on proper postures in dental practice .
89408694|NCT04467788|Active Comparator|Clinical Simulation Session|Training on ergonomic principles in dentistry will be given to the participants through clinical simulation sessions showing the proper postures in dental practice.
89408695|NCT02133456||SIBP's vaccine|SIBP's vaccine group is the population injected with this vaccine.
89408696|NCT03526952|Experimental|Intervention Group|Couples in this group will receive the Internet-Delivered Intervention for Sexual Re-Adjustment
89408697|NCT03526952|Active Comparator|Educational Comparison Group|Couples in this group will receive only written educational material about sexuality and intimacy with an ostomy.
89408698|NCT03626935|Experimental|3D-printed customized guide plate|3D-printed customized guide plate will be used to guide the Kirschner wires in ankle arthrodesis.
89408699|NCT05134870|Experimental|TeleXercise intervention|TeleXercise intervention will be delivered via exergaming-based animation videos combined with or without cognitive exercises by a health coach. Participants will need a computer/tablet/smart phone for the study. The health coach will launch the exercise application on their computer and share their screen with the participants. They have to mimic the exercises shown to them. The intervention will have 12 sessions for 4 weeks, each session for 1.5 hours, including warm-ups and cool-down. Warm-up and cool down are for 20 minutes. A wearable device provided will measure the heart rate and physical activity during the training. Participants are provided with a set of balance exercises which includes non-interactive balance games (stepping forward, backward, sideways), Tai-Chi, Weight shifting (to right leg, left leg and practice distributing equal weights on both the legs), Aerobic (stepping in place), dance, strength, and stretching
89408700|NCT02133612|Experimental|single arm paclitaxel and cisplatin|
89408701|NCT03522194||Sevoflurane|Anesthesia maintenance
89408702|NCT03522194||Propofol|Anesthesia maintenance
89408703|NCT05304988||Developing and testing of EFT|It aims to develop a patient-based assessment tool by our research members for adolescents with cancer in Hong Kong.
89408704|NCT02260752||Medical|Patients who receive medical therapy only for treatment of their uterine fibroids
89408705|NCT02260752||Procedure|Patients who have a hysterectomy, myomectomy, uterine arterial embolization, endometrial ablation, radiofrequency ablation, or magnetic resonance guided focused ultrasound to treat their UF.
89408706|NCT04820686|Experimental|VBR + AB-729 + SOC NrtI|Participants with cHBV received VBR + AB-729 + SOC NrtI for 48 weeks followed by 48 weeks in follow-up.
89408707|NCT04820686|Other|VBR + SOC NrtI|Participants with cHBV received VBR + SOC NrtI for 48 weeks followed by 48 weeks in follow-up. This treatment was used as a reference regimen.
89408708|NCT04820686|Other|AB-729 + SOC NrtI|Participants with cHBV received AB-729 + SOC NrtI for 48 weeks followed by 48 weeks in follow-up. This treatment was used as a reference regimen.
89408709|NCT02260830|Experimental|Treatment Period A|1 reference treatment (2 mg Lu AF11167 immediate release hard capsule) + 5 different test prototype formulations of Lu AF11167
89408710|NCT02260830|Experimental|Treatment Period B|Food interaction and multiple dosing of Lu AF11167
89408711|NCT02260908|Active Comparator|Early initiation of thromboprophylaxis|Early initiation of thromboprophylaxis with Enoxaparin between 36-48 hours post-injury until day 5, followed by standard of care (DVT prophylaxis with Enoxaparin) starting on post-injury day 6.
89408712|NCT02260908|Placebo Comparator|Late initiation of thromboprophylaxis|Initiation of placebo (normal saline) 36-48 hours post-injury until day 5, followed by standard of care (DVT prophylaxis with Enoxaparin) starting on post-injury day 6.
89408713|NCT02740478||Volunteers|20 volunteer subjects, no selection criteria
89408714|NCT02969655|Experimental|Daprodustat|Subjects will receive oral daprodustat once daily and intravenous (IV) darbepoetin alfa placebo once weekly for 52 weeks
89408715|NCT02969655|Active Comparator|Darbepoetin alfa|Subjects will receive IV darbepoetin alfa once weekly and oral daprodustat placebo once daily for 52 weeks
89408716|NCT02129712|Placebo Comparator|Non-adaptive cognitive training|Non-adaptive cognitive training
89408717|NCT02129712|Experimental|Adaptive cognitive triaining|Adaptive cognitive training
89408718|NCT04489420|Experimental|Intravenous IV ( Recurrent and Surgical ) GBM|Cohort 1A ( recurrent GBM) will receive CYNK-001 at a dose of 1.2 x 10^9 cells intravenous ( IV) on Days 0, 7, and 14 and will include up to 6 subjects. The subjects will be followed for a 42 day DLT period from the initial CYNK-001 infusion (or 28 days after the last dose). No other treatment interventions are planned between the last day of CYNK-001. In the event of DLTs, Cohort 1C ( recurrent GBM dose-De escalation) will receive CYNK-001 at a dose of 600 x 10^6 cells (IV) on Days 0, 7, 14, and will include up to 6 subjects who will be followed for a 42-day DLT period from the initial CYNK-001 infusion (or 28 days after the last dose. Cohort 1B (surgical cohort) will receive CYNK-001 at the maximum safe dose (MSD) (either 1.2x10^9 cells or 600x10^6 cells) (IV) at Days 0, 7, 14, and will include up to 6 subjects. The tumor resection surgery will be performed after the last CYNK-001 infusion during the DLT period.
89004633|NCT02188368|Experimental|B: POM 3mg+PLD with or without steroids|"POM 3 mg PO days 1-21 Steroids (if the patient had received them) at the same dose and on the same days as the patient's lenalidomide-containing treatment (it varies for each subject).~PLD at the same dose and on the same days as the patient's lenalidomide-containing treatment (it varies for each subject)."
89408719|NCT04489420|Experimental|Intratumoral IT ( Recurrent and Surgical ) GBM)|The cohort 2A or cohort 2C (recurrent GBM) IT route of administration can be started only after the safety results were acceptable from the completion of cohort 1A or Cohort 1C (IV route of administration). The Treatment Period for the IT cohorts will begin with having the Ommaya catheter placement per institutional policy, which is planned to occur within one week prior to the CYNK-001 administration on Day 0. Cohort 2A will be treated with CYNK-001 IT at 200 x 10^6 ± 50 x 10^6 cells IT on Day 0, 7 and 14 includes up to 6 recurrent GBM subjects Cohort 2C ( dose de-escalation) will be treated with CYNK-001 200 x 106 ± 50 x 106 cells IT on Day 0, and Day 7 ( only two days dosing) and include up to 6 recurrent GBM subjects. Cohort 2B ( the surgical IT cohort) will be treated with CYNK-001 at the maximum safe dose ( MSD) (either 200 x 10^6 ± 50 x 10^6 cells on Days 0, 7 and 14 or at 200 x 10^6 ±50x10^6 cells on Days 0 and 7) and include up to 6 surgical GBM subjects
89408720|NCT02138526|Active Comparator|fasted|Intake of pazopanib in agreement with drug label - fasted state
89408721|NCT02138526|Experimental|Continental breakfast|Intake of a reduced equivalent pazopanib dose with a continental breakfast
89004634|NCT02188368|Experimental|C: POM MTD + other drugs|"Phase 1:~POM at escalating doses of 2 mg (Cycle 1), 3 mg (Cycle 2) or 4 mg (Cycle 3+) All other agents at the same dose and on the same days as the patients were receiving them in the lenalidomide-containing regimen they had failed~Phase 2:~POM at the MTD All other agents, at the same dose and on the same days as phase 1"
89004635|NCT02074839|Experimental|AG-120|AG-120 administered continuously as a single agent dosed orally every day of a 28-day cycle.
89004636|NCT01970306|Experimental|Surgical intervention|Patients will undergo standard resection and gastrointestinal anastomosis and will then have reinforcement of the anastomosis with MatriStem PSM. Patients undergoing esophagectomy, PG or TG will be evaluated with one routine postoperative contrast swallow study at post-operative day #4-10.
89004637|NCT01962636|Experimental|Umbilical Cord Blood Transplant|The myeloablative preparative regimen will consist of cyclophosphamide (CY), fludarabine (FLU) and fractionated total body irradiation (TBI)followed by umbilical cord blood transplant. Immunosuppressive Cyclosporine and Mycophenylate Mofetil (MMF) will be administered pre- and post UCBT.
89004638|NCT01795313|Experimental|HLA-A2 restricted tumor antigen vaccine|This is a single-arm study of a HLA-A2 restricted tumor antigen peptide vaccine, administered in conjunction with imiquimod
89004639|NCT01709292|Experimental|Vemurafenib - (Presurgery)|All Groups: Vemurafenib 960 mg by mouth 2 times a day for 56 days prior to surgery (patients not planned for surgical resection will have a core biopsy at day 56 +/- 7 days).
89004640|NCT01709292|Experimental|Vemurafenib (Post Surgery) - Group A|Vemurafenib 960 mg by mouth two times a day 2 weeks post-surgery, or if patients have not sufficiently recovered at that point, as soon as their condition permits. Patients in Group A restaged 8 weeks after resuming drug. If patients in Group A demonstrate either stable or regressing disease, they will continue on vemurafenib with restaging occurring every 8 weeks until no longer benefitting from the drug.
89408722|NCT03526796|Experimental|Hyperbaric oxygen therapy|Patients who recieve hyperbaric oxygen therapy will be maintained at 2.4 ATA with 100% oxygen for 90 min and then decompressed back to 1 ATA. The treatment duration is 4 weeks and extends to 6 weeks if necessary.
89408723|NCT04488874|Experimental|Sodium Lactate|Intravenous Molar Sodium Lactate is administered during the first surgical incision. The dose is 2.5mL/kg.
89408724|NCT04488874|Active Comparator|Mannitol 20%|Intravenous mannitol 20% is administered during the first surgical incision. The dose is 5mL/kg (1g/kg).
89408725|NCT02129790|Experimental|Mentalization-Based Therapy|Up to 21 individual MBT-A sessions plus 9 monthly family sessions. MBT-A will include psychoeducation and coping strategies.
89408726|NCT05304754|Active Comparator|KIR mismatch aloreactive NK donor cells|Three patients from each cohort will receive NK aloreactive cells from a KIR mismatch donor
89408727|NCT05304754|Experimental|NK cells stimulated ex vivo with IL-15 from KIR match donor|Three patients in each cohort will receive ex vivo stimulated NK cells with IL-15 from a KIR match donor.
89408728|NCT01317199|Experimental|Phase 1: Dose-escalation of Muscadine Plus Grape Skin Extract|Muscadine Plus Grape Skin Extract (MPX): Phase I Dose-escalation starts at 500mg daily for 1 cycle (28 days), then increased to 1000mg for 2nd cycle, then increased to 2000mg daily for 3rd cycle, then increased to 3000mg daily for 4th cycle, then increased to maximum dose of 4000mg daily for final cycle. Pills given by mouth once daily for 28 days per cycle.
89408729|NCT01317199|Placebo Comparator|Phase 2: Placebo control|Randomly-assigned participants receive 8 capsules once daily of placebo composed of pulverized rice for up to 12 cycles (28 days per cycle).
89408730|NCT01317199|Experimental|Phase 2: Low-dose MPX|Randomly-assigned participants receive low-dose (500mg) MPX
89408731|NCT01317199|Experimental|Phase 2: High-dose MPX|Randomly-assigned participants receive high-dose (4000mg) MPX
89408732|NCT02138682||l-123 Ioflupane|Study group includes those clinically diagnosed with Parkinson disease who are aged 75 and older who have agreed to donate brain tissue at time of death and are able to participate in the imaging scan process.
89004641|NCT01709292|No Intervention|Post Surgery - Group B|Post Surgery - Group B: Patients discontinue vemurafenib after surgery but will be restaged with CT neck 8 weeks after surgery.
89408733|NCT03651219|Experimental|experimental group|Patients use Apatinib Mesylate tablets combined with Irinotecan.
89408734|NCT03651219|Active Comparator|controlled group|Patients use Irinotecan
89408735|NCT02648698|Experimental|Antibiotic group|This group received antibiotic therapy
89408736|NCT02648698|No Intervention|Control group|This group did not receive antibiotic therapy
89408737|NCT05032417|Active Comparator|EBNPG knowledge-focused training (knowledge-only group)|The knowledge-focused training includes didactic information about the content of the EBNPG related to nutrition care for individuals on dialysis. This training contains information that is typically shared with RDNs when an EBNPG is released, and in this instance, includes a free webinar developed by the Academy and NKF that provides an overview of EBNPGs, as well as a presentation of the specific EBNPG developed.
89408738|NCT05032417|Experimental|EBNPG knowledge-focused training plus an implementation toolkit (comprehensive group)|The comprehensive training includes the knowledge-focused training, plus access to the EBNPG virtual implementation toolkit. Due to the depth and breadth of the CKD EBNPG, which includes over 70 recommendations, consensus building discussions were conducted with key stakeholders, such as leadership from national dialysis companies and the Evidence Analysis Center guideline developers, to select five recommendations for patients on dialysis as the primary implementation focus for this project.
89408739|NCT02133690|Experimental|Vaccine Arm|3 doses, 4 weeks apart, of Live Attenuated Pentavalent (G1-G2-G3-G4-G9) Human X Bovine Reassortant Rotavirus Vaccine (BRV-PV), at a dosage of ≥ Log10^5.6 fluorescent focus units (FFU)/Serotype/Dose in 2.5 ml of buffered diluent
89408740|NCT02133690|Placebo Comparator|Placebo group|3 doses, 4 weeks apart, of Lyophilized minimal essential medium (MEM) + excipients reconstituted in 2.5 ml of buffered diluents
89408741|NCT03627559||Pancreaticoduodenectomy patients|All patients undergoing pancreaticoduodenectomy receive a microdialysis catheter before skin closure and will be monitored postoperatively for lactate, pyruvate, glucose and glycerol in the microdialysate at certain timepoints
89191580|NCT04683068|Active Comparator|First-person gain-framed self-referred messages|"This group receives a message in which the main character is a man who speaks in first-person. The character is a man with a sister with a BRCA germline mutation. After this common introduction, the content of the messages becomes different.~Group 1 receives a self-referred narrative message in which the protagonist explains that he has decided to have a genetic test to discover BRCA germline mutation. He then explains the reasons why this decision is important to himself (e.g., implementing preventive behaviors) and what are the possible benefits for the individual."
89408742|NCT02129868|Experimental|Closed-loop on day 1 of CGM sensor life|Glucose level is controlled by the automated closed-loop glucose control system on day 1 after CGM sensor insertion.
89408743|NCT02129868|Active Comparator|Closed-loop on day 3 of CGM sensor life|Glucose level is controlled by the automated closed-loop glucose control system on day 3 or 4 after CGM sensor insertion.
89408744|NCT03524846|Active Comparator|Ascorbic acid 300 mg|Ascorbic acid 300 mg was administered intravenously for 5 minutes after each dialysis session, three times per week for 12 weeks.
89408745|NCT03524846|Active Comparator|Ascorbic acid 600 mg|Ascorbic acid 600 mg was administered intravenously for 5 minutes after each dialysis session, three times per week for 12 weeks.
89408746|NCT03524846|Placebo Comparator|Placebo|Normal saline was administered intravenously for 5 minutes after each dialysis session, three times per week for 12 weeks.
88884276|NCT03874988|Experimental|GLB-SCI|The content and delivery format of the developed GLB SCI lifestyle intervention program is subject to change based on guidance of the SCI Consumer Group. Therefore, this section provides a general description of the GLB AIM (lifestyle intervention program adapted for impaired mobility). The content of the GLB AIM core meetings include a mix of in-person (4) and telephone (9) sessions. The initial meeting is conducted in person, with one in-person sessions delivered each month, and the intervening weeks delivered by telephone. To achieve weight loss, participants will be encouraged to follow daily calorie and fat gram goals to achieve a .5 to 1 pound weight loss over the 13 weeks. Participants will also be encouraged to gradually increase their physical activity to ultimately achieve 150 weekly minutes.
88884277|NCT03874988|Experimental|GLB-SCI+|The final multicomponent GLB SCI+ will include combining specific intervention strategies identified from the previous 3 interventions as effective and usable. If all 3 strategies yield evidence in support of being included, the combined intervention would encompass (1) providing prepackaged foods for a specified period of time to facilitate greater initial weight loss, (2) encouraging enhanced self-monitoring of food, physical activity, and weight using devices and apps along with social support, and (3) delivering the further adapted GLB SCI in a group-based format to teach skills helpful in making lifestyle changes.
88884278|NCT03873467|Experimental|GLB Weight-Loss Intervention|The GLB program, adapted for individuals with stroke, will be delivered to participants over a 12-month period, divided into 22 in-person or virtual, group sessions. The intervention promotes 5-7% weight-loss by reducing calories and increasing exercise (150 minutes of moderate physical activity per week).
88884279|NCT03873467|Other|Wait-List Control|The wait-list control group will receive no intervention for 6 months after enrollment. After the 6 month control period, the wait-list control group will receive the GLB Intervention.
88884280|NCT03867643||Hepatitis B vaccine booster|Children with anti-HBs at a level of<10mIU/mL or [10,100) mIU/mL before booster.
88884281|NCT03867643||Observation|Children with anti-HBs at a level of >100mIU/mL or [10,100) mIU/mL before booster.
88884282|NCT03858621|Experimental|fentanyl NOL guided|A bolus of 2 mcg/kg IV Fentanyl will be given at the induction of the anesthesia. A bolus of 0,5 - 1 mcg/kg IV Fentanyl will be given at the time of incision and during surgery following a predeterminate NOL index + heart rate + mean arterial blood pressure variations.
88884283|NCT03858621|No Intervention|fentanyl standard analgesia|A bolus of 2 mcg/kg IV Fentanyl will be given at the induction of the anesthesia. A bolus of 0,5 - 1 mcg/kg IV Fentanyl will be given at the time of incision and during surgery following the heart rate and mean arterial blood pressure variations.
88884284|NCT03857984|Experimental|Erythrocyte Fatty-Acid Status|Erythrocyte Fatty-Acid Status Profiling of HD patients are studied before and after a single HD using LC-MS / MS
89408747|NCT02138760|No Intervention|MRI guided cognitive fusion biopsy|Men in this arm will undergo MRI followed by systematic biopsy and then additional cognitive (freehand) biopsies of MRI suspicious targets
89408748|NCT02138760|Experimental|UroNav fusion biopsy|Men in this arm will undergo MRI followed by systematic biopsy and then additional UroNav fusion biopsy of MRI suspicious targets
89408749|NCT05134558|Experimental|Xenon-enhanced Ventilation CT-guided Radiotherapy|Patients will be receiving Xenon-enhanced Ventilation CT-guided Radiotherapy for functional lung avoidance. The doses for the tumors, lungs, and organs at risk will be examined and evaluated.
89408750|NCT05220553|Experimental|Prosthesis|Participants will be given the PROLIMB II prosthesis to trial in our lab and in their daily lives
89408751|NCT02129946|Active Comparator|Resistant Starch Bagels|Bagels made from high-resistant starch flour (provides 24g resistant starch per day)
89408752|NCT02129946|Placebo Comparator|Control Bagels|Bagels made from wheat flour
89408753|NCT04916236|Experimental|Phase I - Dose-escalation|This is a single-center open-label phase I dose-finding study (3+3 classical design) evaluating the RP2D of RMC-4630 in combination with LY3214996. Based on the safety, tolerability, and PK and PD data from the dose-finding stage of the study, a RP2D will be defined for the expansion phase.
89408754|NCT04916236|Experimental|Phase Ib|The phase Ib expansion cohort study is intended to further characterize the safety, tolerability and PK/PD of the selected dose of RMC-4630 in combination with LY3214996 in patients with advanced KRASm PDAC. Furthermore, it will explore the clinical activity of RMC-4630 in combination with LY3214996 in patients with advanced KRASm PDAC.
89408755|NCT02970669|Active Comparator|Enalapril|"Double blind treatment epoch: Patients randomized to this arm received 1 tablet of enalapril and 1 tablet of matching placebo sacubitril/valsartan twice daily for 8 weeks. All Patients began the study on Dose Level 1 (i.e. 2.5 mg enalapril BID). Patients may have been sequentially up-titrated to achieve desired dose of Dose Level 3 (i.e. 10 mg enalapril BID). Patients not tolerating dose escalation could have been titrated down to next lower dose level.~Open-label treatment epoch: All patients entering this epoch (8 weeks) were given sacubitril/valsartan 49/51 mg BID (Dose Level 2) unless they completed the double-blind treatment epoch on enalapril Dose Level 1. Instead, these patients entered open-label epoch on Dose Level 1 of sacubitril/valsartan. Patients may have been sequentially up-titrated to achieve desired dose of Dose Level 3 of sacubitril/valsartan. Patients not tolerating dose escalation could have been titrated down to next lower dose level."
89408756|NCT02970669|Experimental|Sacubitril/Valsartan|"Double blind treatment epoch: Patients randomized to this arm received 1 tablet of sacubitril/valsartan and 1 tablet of matching placebo enalapril twice daily for 8 weeks. All Patients began the study on Dose Level 1 (i.e. 24/26 mg sacubitril/valsartan BID). Patients may have sequentially been up-titrated to achieve desired dose of Dose Level 3 (i.e. 97/103 mg sacubitril/valsartan BID). Patients not tolerating dose escalation could have been titrated down to next lower dose level.~Open-label treatment epoch: All patients entering this epoch (8 weeks) were given sacubitril/valsartan 49/51 mg BID (Dose Level 2) unless they completed the double-blind treatment epoch on Dose Level 1. Instead, these patients entered open-label epoch on Dose Level 1. Patients may sequentially have been up-titrated to achieve desired dose of Dose Level 3. Patients not tolerating dose escalation could have been titrated down to next lower dose level."
89408757|NCT02133846|Experimental|TPI-287 low dose|2 mg/m2 of TPI-287 administered as a 1-hour intravenous infusion once every 3 weeks for 9 weeks (for a total of 4 infusions)
89408758|NCT02133846|Experimental|TPI-287 moderate dose|6.3 mg/m2 of TPI-287 administered as a 1-hour intravenous infusion once every 3 weeks for 9 weeks (for a total of 4 infusions).
89408759|NCT02133846|Experimental|TPI-287 high dose|20 mg/m2 of TPI-287 administered as a 1-hour intravenous infusion once every 3 weeks for 9 weeks (for a total of 4 infusions)
89408760|NCT02133846|Placebo Comparator|Placebo|0.9% sodium chloride as a 1-hour intravenous infusion once every 3 weeks for 9 weeks (for a total of 4 infusions)
89408761|NCT05220007|Experimental|Glaucomatous arm|Mild stage glaucomatous patients age more than 18 years old, a history of uneventful phacoemulsification with MIOL implantation at least 1 month before participation, distant best-corrected visual acuity (BCVA) equal to or better than 20/30, near BCVA at least Jaeger 2.
88884285|NCT03857074|Experimental|Open Label, Green Light Exposure|This is a single-center, open label, pilot feasibility study. Patients with epilepsy will be exposed to a narrow band of green light at low intensities (1-10 cd/m2). The investigators will record 30 minutes of scalp EEG prior to the light exposure and 30 minutes of scalp EEG recording post-light exposure. The number of epileptic spikes per minute at baseline will be compared to epileptic spike count per minute post-treatment, to determine whether green light exposure effectively decreases the number of epileptic spikes, in patients with ≥1 epileptic spike per minute at baseline.
88884286|NCT03815370|Placebo Comparator|Usual Care|"The current approach for temporary coverage of abdomen is called vacuum assisted techniques (VAT). This technique requires the use of vacuum-assisted drainage to remove blood or watery fluid from a wound or operative site."
88884287|NCT03815370|Experimental|Device: ABRO™Binder Arm|Intervention is the usual care (listed above) plus a novel new abdominal binder device called ABRO™
88884288|NCT03799588|Experimental|Biphasic Chest Cuirass Arm|This is the only arm in the study and all patients will receive negative pressure ventilation via the biphasic chest cuirass.
88884289|NCT03795883||Participants with atrial fibrillation|Patients with atrial fibrillation admitted for standard pulmonary vein ablation.
88884290|NCT03795883||Participants without atrial fibrillation|Patients without atrial fibrillation admitted for standard left sided supra ventricular tachycardia ablation or patients admitted to mitral clip procedure.
88884291|NCT03788993|Experimental|Blue-depleted evening light condition|
88884292|NCT03788993|Active Comparator|Normal light condition|
88884293|NCT03788421|Active Comparator|Study group|Women undergoing elective bilateral salpingectomy during cesarean section with LIGASURE.
88884294|NCT03788421|Active Comparator|Control group|Women undergoing elective bilateral salpingectomy during cesarean section with traditional step by step clamping and suturing.
88884295|NCT03782792|Experimental|Spesolimab|
88884296|NCT03782792|Experimental|Placebo|
88884297|NCT03762161|Experimental|Intervention TAS-102|
89408762|NCT05220007|Active Comparator|Non-glaucomatous arm|Pseudophakic participants without glaucoma, age more than 18 years old, a history of uneventful phacoemulsification with MIOL implantation at least 1 month before participation, distant best-corrected visual acuity (BCVA) equal to or better than 20/30, near BCVA at least Jaeger 2.
89408763|NCT02252484|Experimental|Weight loss intervention Group|Participants will receive tailor weight loss program. Participants will complete 8-weeks of the weight loss intervention prior to having their prostatectomy (weight loss phase). Program includes individual weight coaching, tailored diet and exercise plan, weight coaching and tracking of daily activities. Sessions will be held weekly during the weight loss phase. The groups will be facilitated by a registered dietitian with genitourinary (GU) oncology experience.
89408764|NCT02252484|Active Comparator|Comparison Group|All patients who are unwilling or not ready to engage in a weight loss program will be offered entry into the comparison group arm.
89408765|NCT03651453|Active Comparator|Standard Care|Participants will receive standard information about harm reduction as available at the drug treatment centers.
89408766|NCT03651453|Experimental|Decision aid|Participants in this arm will receive the adapted decision aid for PrEP.
89004642|NCT01709292|Experimental|Vemurafenib - Group C|Patients not scheduled for surgical resection undergo a CT scan and core biopsy at day 56, Vemurafenib 960 mg by mouth twice a day unless there is evidence of progressive disease on day 56 CT scan. Patients evaluated for resectability after each CT scan is performed. If scheduled for resection, patient continues vemurafenib until surgery and follows same treatment schema as patients in Groups A and B.
89004643|NCT01574274|Active Comparator|SC-PEG (Arm A)|Patients in this arm were randomized to receive IV Calaspargase Pegol (SC-PEG) 2500 IU/m2, administered as a single dose during induction and for 30 weeks post-induction. In the post-induction phases, IV SC-PEG was administered every 3 weeks (for a total of 10 post-induction doses). Protocol therapy was comprised of 5 phases: Induction, Consolidation I, CNS, Consolidation II, and Continuation, and varied based off risk classification.
89004644|NCT01574274|Active Comparator|Oncaspar (Arm B)|Patients in this arm were randomized to receive IV Oncaspar 2500 IU/m2, administered as a single dose during induction and for 30 weeks post-induction. In the post-induction phases, IV Oncaspar was administered every 2 weeks (for a total of 15 post-induction doses). Protocol therapy was comprised of 5 phases: Induction, Consolidation I, CNS, Consolidation II, and Continuation, and varied based off risk classification.
89004645|NCT01375140|Experimental|Ruxolitinib + Lenalidomide|Ruxolitinib 15 mg orally twice daily continuously + Lenalidomide orally 5 mg/day on days 1-21, followed by 7 days of no therapy (28-day cycle). Prednisone will be added for patients who have not responded after 3 cycles of therapy. Prednisone 30 mg by mouth a day during cycle 4, 15 mg/day during cycle 5, and 15 mg every other day during cycle 6, and then it will be discontinued.
89004646|NCT01208675||Mild cognitive impairment|550 patients with mild cognitive impairment or subjective cognitive symptoms at baseline.
89004647|NCT01208675||Healthy elderly subjects|650 elderly subjects, who are cognitively healthy at baseline.
89004648|NCT01144507||Group A|Approximately 60 subjects with a heterogeneous echo pattern of the liver on abdominal ultrasound (HTG US).
89004649|NCT01144507||Group B|Approximately 680 subjects with a normal echo pattern on abdominal ultrasound (NL US). Of these subjects, approximately 110 will be matched 1:1 with Group A participants and followed for the duration of the study. The remaining unmatched subjects will not be followed beyond their initial visit.
89004650|NCT01144507||Group C|An estimated 30 subjects with cirrhosis pattern on abdominal ultrasound. These subjects will be followed in the study.
89004651|NCT01144507||Group D|An estimated 30 subjects with diffusely homogeneous echogenic pattern at screening ultrasound will be followed in the study.
89004652|NCT01130077|Experimental|HLA Restricted glioma antigen peptides plus Poly ICLC|All subjects will receive vaccine plus Poly ICLC will receive 9 injections ( once every 3 weeks)
89004653|NCT01104220|No Intervention|Lean, metabolically normal|Subjects with body mass index 18.5 - 24.9 kg/m² and normal fasting blood glucose and oral glucose tolerance and liver fat.
89004654|NCT01104220|No Intervention|Obese, metabolically normal|Subjects with body mass index ≥30.0 kg/m² and normal fasting blood glucose and oral glucose tolerance and liver fat.
89004655|NCT01104220|No Intervention|Obese, metabolically abnormal|Subjects with body mass index ≥30.0 kg/m² and impaired fasting or oral glucose tolerance and increased liver fat.
89408767|NCT05219773|Other|Clinic vs Home spirometry|The collection of medical history and demographic data Spirometry testing in both the clinic and home setting. The measurement of height and weight. The evaluation of the perception of home spirometry via a survey.
89408768|NCT02134002|Experimental|Disulfiram|disulfiram 250 mg/day
89408769|NCT02134002|Placebo Comparator|Placebo|Placebo
89408770|NCT03650361|Experimental|Test Product|Adapalene Gel 0.3% manufactured by Aleor Dermaceuticals Limited, applied for 84 days
89004656|NCT01104220|Experimental|Obese, scheduled for bariatric surgery|Subjects with a body mass index ≥35.0 kg/m² undergoing bariatric surgery
89004657|NCT01104220|No Intervention|Obese, scheduled for gallbladder surgery|Subjects with a body mass index ≥35.0 kg/m² undergoing gallbladder surgery
89004658|NCT01104220|No Intervention|Lean, scheduled for inguinal hernia, hysterectomy or myomectomy surgery|Subjects with body mass index 18.5 - 24.9 kg/m² and normal fasting blood glucose and oral glucose tolerance and liver fat.
89408771|NCT03650361|Active Comparator|Reference Product|Adapalene Gel 0.3%, , applied for 84 days
89408772|NCT03650361|Placebo Comparator|Placebo Control|Vehicle of the test product, applied for 84 days
89408773|NCT02138994|Active Comparator|Triple Antibiotic Ointment Neosporin|Daily direct application to the wound, covered with conventional dressing. Dressing should be changed daily or as directed by the health care provider.
89408774|NCT02138994|Experimental|Next Science Wound Gel|Daily direct application to the wound, covered with a conventional non-alginate dressing. Dressing should be changed daily or as directed by the health care provider.
89408775|NCT05219461|Experimental|Group A rhEGF 10mcg/mL|"single dose of rhEGF 10mcg/mL eye drop or single dose of placebo~*single dose means daily dose (administration twice daily)"
89408776|NCT05219461|Experimental|Group B rhEGF 50mcg/mL|"single dose of rhEGF 50mcg/mL eye drop or single dose of placebo~*single dose means daily dose (administration twice daily)"
89408777|NCT05219461|Experimental|Group C rhEGF 100mcg/mL|"single dose of rhEGF 100mcg/mL eye drop or single dose of placebo~*single dose means daily dose (administration twice daily)"
89408778|NCT05219461|Experimental|Group D rhEGF 10mcg/mL|multiple dose of rhEGF 10mcg/mL eye drop or multiple dose of placebo
89408779|NCT05219461|Experimental|Group E rhEGF 50mcg/mL|multiple dose of rhEGF 50mcg/mL eye drop or multiple dose of placebo
89408780|NCT05219461|Experimental|Group F rhEGF 100mcg/mL|multiple dose of rhEGF 100mcg/mL eye drop or multiple dose of placebo
89408781|NCT04771234|Experimental|Treatment group|The intervention consists of a self-guided digital tool to guide participants with chronic insomnia through sleep restriction and stimulus control procedures.
89408782|NCT03549546|Other|Patients undergoing lung cancer surgery|Patients undergoing lung cancer surgery will be included. Blood samples will be collected.
89408783|NCT04761796||Professional flight members|
89408784|NCT02130102||Users of ModuLAAr|A group of volunteers (aged 60+), living in assisted living homes, will be provided with module based technical solutions to improve their independency and quality of life.
89408785|NCT02253186|Experimental|Group I|Patients wear, for 90 days, the experimental Auto-Adjustable MOBIDERM® Armsleeve during night-time and a usual custom-made compressive armsleeve during Day-time.
89408786|NCT02253186|No Intervention|Group II|Patients wear, for 30 days, only a usual custom-made compressive armsleeve during Day-time and no garment during night-time. Then, for the next 60 days, patients wear the experimental Auto-Adjustable MOBIDERM® Armsleeve during night-time and a usual custom-made compressive armsleeve during Day-time.
89408787|NCT05303818|Experimental|post-operative patients with colonic cancer|Patients will receive Rivaroxaban 10mg/daily for 28 days after surgery. Only one arm.
89408788|NCT03766230||peribulbar anesthesia1|Time interval between two eyes' cataract surgery is or less than 14 days and using peribulbar anesthesia
89004659|NCT01063647|Experimental|1|Treosulfan: 10 g/m² i.v. on 3 consecutive days (day -6 to -4)
89408789|NCT03766230||topical anesthesia1|Time interval between two eyes' cataract surgery is or less than 14 days and using topical anesthesia
89408790|NCT03766230||peribulbar anesthesia2|Time interval between two eyes' cataract surgery is from 15 to 21 days and using peribulbar anesthesia
89004660|NCT01063647|Experimental|2|Treosulfan:12 g/m² i.v. on 3 consecutive days (day -6 to -4)
89408791|NCT03766230||topical anesthesia2|Time interval between two eyes' cataract surgery is from 15 to 21 days and using topical anesthesia
89408792|NCT03766230||peribulbar anesthesia3|Time interval between two eyes' cataract surgery is from 22 to 28 days and using peribulbar anesthesia
89004661|NCT01063647|Experimental|3|Treosulfan: 14 g/m² i.v. on 3 consecutive days (day -6 to -4)
89004662|NCT00779974||s/p Total Shoulder Arthroplasty|The subject population for this study consists of adult patients with a primary diagnosis of osteoarthritis who have had a total shoulder arthroplasty preformed by the PI between September 2003 through December 2007.
89004663|NCT00625586|Experimental|RAV12 plus gemcitabine|
89408793|NCT03766230||topical anesthesia3|Time interval between two eyes' cataract surgery is from 22 to 28 days and using topical anesthesia
89408794|NCT03766230||peribulbar anesthesia4|Time interval between two eyes' cataract surgery is from 29 to 60 days and using peribulbar anesthesia
89408795|NCT03766230||topical anesthesia4|Time interval between two eyes' cataract surgery is from 29 to 60 days and using topical anesthesia
89408796|NCT03766230||peribulbar anesthesia5|Time interval between two eyes' cataract surgery is from 61 to 90 days and using peribulbar anesthesia
89408797|NCT03766230||topical anesthesia5|Time interval between two eyes' cataract surgery is from 61 to 90 days and using topical anesthesia
89408798|NCT05024149|Experimental|Healthy group|Subjects in this group will not undergo acupuncture intervention. For participants in the healthy control group, the IRT examination of the measurement sites will last for 3 minutes, with one thermal image taken every 10s. In the Healthy group, there will be two visits, and the first visit will be considered as the screening stage (i.e., demographic data recording, medical history taking, physical examination report review and recording on the day of enrollment) and the second visit will be considered as the detection stage (i.e., the day of enrollment). At the second visit, the subjects received the Self-rating depression scale (SDS), HAMD, and then the infrared thermographic images to be acquired.
89408799|NCT05024149|Experimental|MDD electroacupuncture intervention group|
89408800|NCT05024149|Experimental|MDD waiting-list group|In this study, we used a waiting list control group. During the 4 weeks follow-up period, participants from the MDD waiting-list group had no contact with participants from the MDD EA intervention group and no access to the EA intervention. After the 4 weeks follow-up period, patients in the waiting list group received access to the EA intervention.
89408801|NCT02134080|Active Comparator|PF-04457845|PF-04457845 will be administered orally at 4mg daily for four weeks.
89408802|NCT02134080|Placebo Comparator|Placebo|Placebo (sugar pill) will be administered orally at 4mg daily for four weeks.
89408803|NCT05303740||Anlotinib|
89408804|NCT02130180||ED T1DM and hyperglycemia without criteria for DKA|
89408805|NCT02130180||Well controlled T1DM|
89408806|NCT02130180||ED DKA|
89408807|NCT02139072||CoaguChek XS|INR measured by CoaguChek XS in patients with APL at visit 1 and visit 2, in addition to routine measure by standard lab draw
89408808|NCT02139072||Standard Lab Draw|INR measured by standard lab draw at visit 1 and visit 2 for non-APL patients, in addition to routine measurement by CoaguChek XS
89408809|NCT02139150|Experimental|Serial FLT PET Imaging|"Patients will receive a target injection of up to 10 mCi of FLT. Optionally, dynamic PET imaging over a chosen index lesion (based on size and/or high FDG-avidity on preceding CT and/or FDG PET/CT scans done for clinical purpose such as staging), may be performed. Otherwise, static PET images are obtained at approximately 60 min (+15 min) post FLT injection. In general this body scan will cover at least the region from skull base to the upper thigh for extracranial malignancies; depending on the specific location, extremities maybe also be scanned (e.g., extremity sarcoma), or the scan may be restricted to the brain (e.g. glioma)."
89408810|NCT02130336|Experimental|Aerobic interval training|"Frequency: Exercise 3 times a week. Twice under supervision and home exercise once a week.~Duration: Totally 40 minutes in one session. Intensity: 10-minute warm-up and 5-minute cool-down at 40% maximal heart rate (HRmax), participants and exercise 4-minute high-intensity training at 85-90% HRmax and 4 times separated by 3-minute active recovery at 70% HRmax.~Type: Using treadmill while under supervision."
89408811|NCT02130336|Experimental|Continuous moderate-intensity exercise|"Frequency: 5 times a week. Twice under supervision and home exercise 3 times a week.~Duration: Totally 45 minutes per session. Intensity: 10-minute warm-up at 40% maximal heart rate (HRmax), 30-minute moderate intensity exercise at 50-70% HRmax and 5-minute cool-down at 40% HRmax Type: Using treadmill under supervision."
89408812|NCT02130336|No Intervention|Control group|Subjects in control group will receive general exercise knowledge and counseling.
89408813|NCT02902965|Experimental|Ibrutinib+ Bortezomib+ Dexamethasone|
89408814|NCT02134158|Experimental|sham and then anodal|visit 2 sham stimulation (120 seconds) and visit 3 anodal stimulation (30 minutes)
89408815|NCT02134158|Experimental|anodal and then sham|visit 2 anodal stimulation (30 minutes) and visit 3 sham stimulation (120 seconds)
89408816|NCT02130414|Active Comparator|Sandimmun® IV|Sandimmun® IV 2mg/kg as a 24 hour infusion (2mg/kg/day)
89408817|NCT02130414|Experimental|CyCol® capsules|CyCol®: 75 mg OD & BID for 7 days
89408818|NCT02130414|Experimental|CyCol® capsules 37.5 mg|CyCol®: 37.5 mg OD or BID for 7 days
89408819|NCT02130414|Experimental|CyCol® capsules, 150 mg|CyCol®: 150 mg OD or BID for 7 days
89408820|NCT03651141|Experimental|Neurodynamic Sliding|neurodynamic sliding consists of 2 movements; 1) movement 1 involves sitting on the edge of the treatment table the bringing their neck to their chest along with bending their knee and pointing their ankle to the ground. Movement 2 is performed by facing their head towards the ceiling and straightening their knee while pointing their ankle towards their nose. Subjects will alternate these 2 active movements for 60s and repeated 5 times, with rest period of 15s between sets.
89531052|NCT01597245|Experimental|80 mg ixekizumab Dosing Regimen 2|Administered by two 80 mg SC injections at Week 0, then one 80 mg SC injection per Dosing Regimen 2 until Week 12. At Week 12, ixekizumab responders are re-randomized to placebo, Dosing Regimen 2 or Dosing Regimen 3. Ixekizumab non-responders are assigned to Dosing Regimen 2.
88884298|NCT03758170|Experimental|High dose Dexamethasone|An intravenous bolus dose of Dexamethasone 1 mg/kg bodyweight administered preoperatively before surgery.
88884299|NCT03758170|Active Comparator|Medium dose Dexamethasone|An intravenous bolus dose of Dexamethasone 0,3 mg/kg bodyweight administered preoperatively before surgery.
88884300|NCT03752762|No Intervention|Standard Care|Participants will receive standard health care services provided by the Health Secretary
88884301|NCT03752762|Experimental|SPOON behavioral change strategy+SQ-LNS|Participants will receive SQ-LNS supplement from 6-24 months and a behavioral change to promote adequate infant and young child feeding practices and the use of SQ-LNS will be delivered to mothers or caregivers. The behavioral change strategy includes individual home-visits and group sessions. SQ-LNS consists of a 20g nutrient supplement package to be consumed daily from 6-24 of age. SQ-LNS formulation does not include sugar.
88884302|NCT03746756|Experimental|SBIRT as Usual|The follow-up team will (a) contact participants within 24-48 hours to collect additional locator information and mailing a schedule card for the next interview, (b) receipt information in a management information system (MIS), (c) assign each case to a follow-up case tracker, (d) verify locator data, (e) conduct outreach for unverified cases and discussing them at weekly meetings, (f) mail thank-you cards to participants and collaterals, (g) schedule follow-up appointments, (h) mail 3 and 6 week post-enrollment flyers, (i) implement returned-mail procedures, (j) call participants 6 weeks before appointment to confirm date and location (phone vs. research office), (k) conduct outreach for unconfirmed cases and review them at weekly meetings, (l) complete follow-up interviews and scheduling next appointments, and (m) implement a no-show protocol.
88884303|NCT03746756|Experimental|SBIRT + RMC-PC|Patients will receive SBIRT plus the RMC protocol. The Linkage Manager (LM) will: 1) provide personalized feedback to participants about the status of their condition based on responses from the Global Appraisal of Individual Needs Quick version 3 (GAIN-Q3), 2) help participants resolve ambivalence about their dependence and moving them toward a commitment to change by accessing additional care, 3) address existing barriers to treatment, 4) schedule an assessment, and 5) facilitate reentry and engagement. The LM will stay in contact 2-3 times per week for two weeks to ensure that individuals both initiate and remain engaged in treatment.
88884304|NCT03740035||Prostate Cancer Patients|Prostate cancer patients that who have been actively receiving care through Wake Forest Baptist Comprehensive Cancer Center and/or satellite clinics over the past two-year period will be using an eHealth for Sedentary Behavior.
88884305|NCT03739034|Experimental|Lifestyle Medicine|Patients presenting for lifestyle medicine treatment to prevent, arrest or reverse chronic lifestyle related diseases.
88884306|NCT03736954|Experimental|ICU doulas intervention|specially trained ICU doulas will provide critically ill intubated patients with early psychological support on a daily basis
88884307|NCT03733119|Experimental|Akt/ERK inhibitor ONC201|Participants receive Akt/ERK inhibitor ONC201 PO on days 3, 10, and 17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89191581|NCT04683068|Experimental|First-person gain-framed family-referred messages|"This group receives a message in which the main character is a man who speaks in first-person. The character is a man with a sister with a BRCA germline mutation. After this common introduction, the content of the messages becomes different.~Group 2 receives a family-referred narrative message in which the frame is similar to the previous message, but the character this time explains what are that the benefits for his family and why his decision to have a genetic test is important to them."
89191582|NCT00851032||Molecular Profiling Analyses|Participants seen in the Department of Investigational Cancer Therapeutics at MD Anderson Cancer Center in Houston, Texas
89191583|NCT00718458||ALS|Subjects having either definite or probable ALS by El Escorial Criteria.
89191584|NCT00718458||Non-ALS|Subjects not having either definite or probable ALS by El Escorial Criteria.
89191585|NCT05632250|Other|ConvaFoam dressings|All participants wounds will be assessed and allocated a dressing based upon the investigator's clinical judgement. They will receive either ConvaFoam Border, Silicone or Non-Adhesive for up to 12 weeks as part of their standard of care
89191586|NCT00807105|Experimental|depressive patients|patients suffering from deppresion
89191587|NCT00854386|Active Comparator|1|liberal fluid administration group
89191588|NCT00854386|Experimental|2|Restrictive fluid administration group
89191589|NCT00804219|Experimental|TBE low responder|
89191590|NCT00804219|Experimental|FSME responder|
89191591|NCT00804219|Experimental|hepatitis B non-responder|
89191592|NCT00723684|Placebo Comparator|Placebo group|This group will receive no real EEG-Neurofeedback.
89191593|NCT00723684|Experimental|NF group|This group will receive real EEG-Neurofeedback
89191594|NCT00721838||1|Surgery group
89191595|NCT00721838||2|Control - Lifestyle modification program
89191596|NCT00798291|Placebo Comparator|Ad lib diet/placebo|Ad lib diet and control product placebo
88884308|NCT03733119|Experimental|Akt/ERK inhibitor ONC201, methionine-restricted diet|Participants receive Akt/ERK inhibitor ONC201 PO on days 3, 10, and 17. Participants also receive methionine-restricted diet PO on days 1-5, 8-12, and 15-19. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
88884309|NCT03724669|Placebo Comparator|waiting list|
88884310|NCT03724669|Experimental|Benzodiazepines and Z-drugs knowledge|
88884311|NCT03719183||Acute Myeloid Leukemia (AML) group|"Patients who are diagnosed as Acute Myeloid Leukemia based on peripheral blood, bone marrow aspiration and immunophenotyping and fulfill WHO criteria for diagnosis.~Fluorescent in Situ Hybridization (FISH) Panels for AML, Multiplex FISH (M-FISH) and Conventional Cytogenetics Studies will be performed for AML patients."
88884312|NCT03717935|Experimental|Essential Amino Acid (EAA) Supplement|4 weeks: Essential Amino Acid Supplement- 15g 2/day
88884313|NCT03717935|Placebo Comparator|Placebo|4 weeks: Placebo- 15g 2/day
88884314|NCT03715751|Active Comparator|ASV|Patients in this arm will have the ventilator adjusted per results of recent arterial blood gas. Esophageal balloon placement will be confirmed. Study team will measure several tidal breaths, end-expiratory and end-inspiratory ventilator holds. Then PEEP will be adjusted to achieve desired end-expiratory transpulmonary pressures, Fraction of Inspired Oxygen (FiO2) adjusted as needed to achieve SpO2>95%, and Tidal Volume (Vt) adjusted to 6cc/kg (IBW). Respiratory Rate (RR) will be adjusted to target the same minute ventilation achieved prior to any change in Vt. Patients will then be switched to ASV mode. The percentage minute volume (%minVol) will be adjusted to target the same minute ventilation as was achieved before the change. Settings will be maintained for approximately 1-2 hours, after which breath hold measurements will be repeated and another blood gas drawn.
88884315|NCT03715751|Active Comparator|Lung Protective Ventilation|Patients in this arm will have the ventilator adjusted per results of recent arterial blood gas. Esophageal balloon placement will be confirmed. Study team will measure several tidal breaths, end-expiratory and end-inspiratory ventilator holds. Then PEEP will be adjusted to achieve desired end-expiratory transpulmonary pressures, Fraction of Inspired Oxygen (FiO2) adjusted as needed to achieve SpO2>95%, and Tidal Volume (Vt) adjusted to 6cc/kg (IBW). Respiratory Rate (RR) will be adjusted (while leaving the Vt at 6cc/kg) to achieve the same minute ventilation. Patients will then be maintained on their current lung protective ventilation settings for approximately 1-2 hours, after which breath hold measurements will be repeated and another blood gas drawn.
88884316|NCT03709368|Experimental|RANAS|Hardware CLTS+PHAST RANAS (contextualized)
88884317|NCT03709368|Experimental|Mini-RANAS|Hardware CLTS+PHAST mini-RANAS (norms)
88884318|NCT03709368|Active Comparator|Control|Hardware CLTS+PHAST Placebo
88884319|NCT03705338||Electroencephalography|Electroencephalography (EEG) for induction and emergence in pediatric patients under general anesthesia with propofol.
88884320|NCT03704285||Propofol|Severe burn adult under general anesthesia with propofol + remifentanil evaluation of propofol effect using BIS
89191597|NCT00798291|Experimental|Ad lib diet/AN 777|Ad lib diet and AN 777
89191598|NCT00798291|Active Comparator|Ad lib diet/placebo/exercise|Diet ad lib; exercise; and placebo
89191599|NCT00798291|Experimental|Ad lib diet/ AN 777/ exercise|Diet ad lib; AN 777; exercise
89191600|NCT03650088|Experimental|Weight Loss Intervention|Behavioral weight loss program with digital tools including smartphone app for dietary self-monitoring using a 'traffic light' approach, physical activity tracker, smart scale, and blood glucose monitoring plus with weekly consultation (in person or phone) with an interventionist for behavioral lessons and supports.
88884321|NCT03696537|Experimental|Fludarabine + Total Marrow Irradiation|
88884322|NCT03688243||Cohort 1 'IMPACT Cohort'|Subjects with intermediate AMD in both eyes, and at least one eye with a drusen volume in the central 3 mm circle centered on the fovea of at least 0.02mm3 in the absence of GA or nGA as diagnosed with OCT en face imaging OR subjects with AMD (early or intermediate) diagnosed in one eye and exudative AMD diagnosed in the fellow eye will undergo SS-OCT imaging every 3 months for 2 years
89191601|NCT00721916|Experimental|1|SOL(The combination therapy of S-1, Leucovorin, and Oxaliplatin)
89191602|NCT00721916|Active Comparator|2|mFOLFOX6(The combination therapy of 5-FU, l-LV and Oxaliplatin)
89191603|NCT02552901|Experimental|LFT Dye Detection Monitor|
89191604|NCT02552901|Active Comparator|Serial Blood Draws|
89191605|NCT00861172|Experimental|1|
89191606|NCT00721994||1|IDE subjects who received the Cormet Hip Resurfacing device
89191607|NCT04068714||Endovascular repair|Observational retrospective cohort of patients consecutively submitted to elective abdominal aortic aneurysm surgery repair at a tertiary academic referral center from south Europe, between January 2009 and December 2015 through endovascular repair. The exclusion criteria were non-elective cases, aortic intervention due to diagnosis other than infrarenal AAA and complex aortic aneurysms such as juxta-renal, thoraco-abdominal or thoracic aneurysms.
89191608|NCT04068714||Open repair|Observational retrospective cohort of patients consecutively submitted to elective abdominal aortic aneurysm surgery repair at a tertiary academic referral center from south Europe, between January 2009 and December 2015 through open repair. The exclusion criteria were non-elective cases, aortic intervention due to diagnosis other than infrarenal AAA and complex aortic aneurysms such as juxta-renal, thoraco-abdominal or thoracic aneurysms.
89191609|NCT00861250|Experimental|Vel/Dex|
89191610|NCT00807183|Placebo Comparator|Tx1|Inactive air filter
89191611|NCT00807183|Experimental|Tx2|New EPA-certified woodstove
89191612|NCT00807183|Experimental|Tx3|Active air filter
89191613|NCT00722150|Active Comparator|Arm 1|"Oral Artesunate (standard dose)"
89191614|NCT00722150|Active Comparator|Arm 2|"Oral Artesunate (ARC1 dose)"
89191615|NCT00722150|Experimental|Arm 3|"Oral Artesunate (experimental high dose)"
89191616|NCT02571738|Active Comparator|CHAM|Cryopreserved Human Amniotic Membrane
89191617|NCT02571738|Placebo Comparator|Control|Standard of Care
89191618|NCT00861094|Experimental|FOLFOX and radiotherapy|Oxaliplatin (85mg/m2); Folinic Acid (200mg/m2); 5-FU (400mg/m2-Bolus and 1600mg/m2 over 46h)- once every two weeks for six cycles
89191619|NCT00861094|Experimental|5-FU / cisplatin and radiotherapy|5-FU (100mg/m2); Cisplatin (75mg/m2)
89191620|NCT02554149||stem anteversion|a hip lateral radiograph and CT scan were taken to measure stem anteversion
89191621|NCT00722228|Experimental|Autologous or Allogeneic tumor cells|Intervention: 5 vaccine doses, 3 weeks apart, injected subcutaneously.
89191622|NCT04019106|Experimental|Dosing Level 1|0.0625 mg/kg Budesonide in bovine lipid extract surfactant (BLES)
89191623|NCT04019106|Experimental|Dosing Level 2|0.125 mg/kg Budesonide in bovine lipid extract surfactant (BLES)
89191624|NCT04019106|Experimental|Dosing Level 3|0.25 mg/kg Budesonide in bovine lipid extract surfactant (BLES)
89191625|NCT02571608|Active Comparator|Metformin|Metformin, dosage same as the patient's regular dosage
89191626|NCT02571608|Placebo Comparator|Placebo|Placebo
89191627|NCT00865072|Experimental|A|Metformin HCl 750 mg Extender Release tablets, single dose
89191628|NCT00865072|Active Comparator|B|GLUCOPHAGE® XR 750 mg tablets, single dose
89191629|NCT00798447|Experimental|lipid emulsion with n-3 FA|
89191630|NCT00798447|Active Comparator|lipid emulsion without n-3 FA|
89191631|NCT02571660|Active Comparator|conventional treatment|GINA treatment fot asthma +vit.D low supplementation dose
89191632|NCT02571660|Experimental|conventional treatment + vitamin D3|GINA treatment fot asthma +vit.D high supplementation dose
89191633|NCT00722306|Experimental|A425|A425 Treated
89191634|NCT00722384|Experimental|1|0.1 mg bevasiranib in the study eye
89191635|NCT00722384|Experimental|2|0.33 mg bevasiranib in the study eye,
89191636|NCT00722384|Experimental|3|1.0 mg bevasiranib in the study eye
89191637|NCT00722384|Experimental|4|1.5 mg bevasiranib in the study eye
89191638|NCT00722384|Experimental|5|3.0 mg bevasiranib in the study eye.
89191639|NCT00804375|Experimental|2PX|Pain medication
89191640|NCT00804375|Placebo Comparator|placebo|placebo
89191641|NCT04067700|Other|Coronary perfusion PET/CT patients|
89191642|NCT00865228|Experimental|Lapaquistat Acetate 100 mg QD (morning)|
89191643|NCT00865228|Experimental|Lapaquistat Acetate 100 mg QD (evening)|
89191644|NCT00865228|Experimental|Lapaquistat Acetate 50 mg BID|
89191645|NCT00865228|Placebo Comparator|Placebo BID|
89191646|NCT00724412|Active Comparator|Systane|Systane
89191647|NCT00724412|Active Comparator|Optive|Optive
89191648|NCT00722202|Active Comparator|ERB-257|7 IV single doses of ERB-257 will be given to 6 healthy subjects per group - 1, 4, 15, 45, 90, 180, and 300 mg
89191649|NCT00722202|Placebo Comparator|placebo|2 placebo subjects per group
89191650|NCT00723762||1|Resident of Hattie Larlham long-term care facility receiving VPA
89191651|NCT00723762||2|Control AED patients will be recruited based on similar AED regimens excluding VPA, length of time on AED (number of months to >1 year), age, and gender; one control patient per VPA patient.
89191652|NCT00723762||3|Control non-AED patients will be recruited based on age and gender; one control patient per VPA patient.
89191653|NCT00861328|Experimental|A|Treatment of escalating doses of ON 01910.Na in combination with irinotecan
89191654|NCT00861328|Experimental|B|Treatment of escalating doses of ON 01910.Na in combination with oxaliplatin
89191655|NCT00722462|Experimental|1|Active acupuncture
89191656|NCT00722462|Sham Comparator|2|Sham Acupuncture- acupuncture at neutral points
89191657|NCT00722462|No Intervention|3|Embryo transfer with no acupuncture
89191658|NCT02570880|Experimental|Bread sample vs. glucose solution|glycemic index
89191659|NCT00724646||1|Habilitation assistants
89191660|NCT00724646||2|Parents/ legal guardians
89191661|NCT00618514|Active Comparator|1|Bright Tip Laser Fiber - FDA-cleared study device
89408821|NCT03651141|Experimental|Myofascial Decompression|For the group receiving the cupping treatment, the subject will lay on their stomach and their affected hamstring will be exposed. Cocoa butter will be applied to the hamstring prior to the application of the cups. 5 cups will be placed along the hamstring and calf muscles. Using a handheld suction pump, each cup will be pumped so that skin fills up half of the cup. The cups will stay in place for five minutes and the clinician will instruct the subject to perform 5 repetitions of active quad sets and 5 repetitions of ankle pumps .
89408822|NCT03651141|Sham Comparator|Diathermy|The control group will receive a sham heat (diathermy treatment). The subjects will be asked to sit and relax for five minutes and the machine will not be turned on with a timer timing the treatment.
88884323|NCT03688243||Cohort 2 'SWAGGER Cohort'|Subjects with GA or nGA secondary to AMD that is at least the size of a large druse (125 microns in diameter; 0.05 mm2) and no greater than 7 disc areas (17 mm2) in at least one eye will undergo SS-OCT imaging every 3 months for 2 years
88884324|NCT03688243||Cohort 3|Subjects with GA enrolled in another trial
89408823|NCT02130648||Prenatal diagnosis|Prenatal diagnosis witch A sampling of blood de 14 ml
88884325|NCT03682250||Patients with type 1 diabetes with a high cardiovascular risk|
88884326|NCT03663829||Participants RA who have received a TNFi|
88884327|NCT03663829||Participants with RA who have received abatacept|
88884328|NCT03662672|Experimental|Rib-raising Intervention|We will do daily rib raising and lumbar release from the 5th thoracic vertebra to the 2nd lumbar vertebra for 2 minutes per side for rib raising and 2 minutes for lumbar release.
88884329|NCT03662672|Sham Comparator|Sham Intervention|We will do daily sham intervention from the 5th thoracic vertebra to the 2nd lumbar vertebra where we place our hands under the ribs for 2 minutes per side and under the lumbar area for 2 minutes without applying any pressure (or applying pressure into the bed).
88884330|NCT03661996|Experimental|Breg Cooling Control Group|Subject receives 2% lidocaine and CNTX-4975-05 with cooling device Breg ice water pump.
89408824|NCT02139462|Experimental|Standard training|Therapists will receive standard training in FBT.
89408825|NCT02139462|Experimental|Novel training|Therapists will receive a novel, more efficient training in FBT
89408826|NCT02902809|Experimental|Open-label study to evaluate safety|A fixed 300 mg dose every 2 weeks (Q2W) of tralokinumab administered subcutaneously in subjects with inadequately controlled asthma on medium to high-dose of inhaled corticosteroid plus long-acting β2-agonist.
88884331|NCT03661996|Experimental|Gel Pack Cooling Group|Subject receives 2% lidocaine and CNTX-4975-05 with cooling device Elasto-Gel.
88884332|NCT03661996|Experimental|Shortened Gel Pack Cooling Group|Subject receives 2% lidocaine and CNTX-4975-05 with cooling device Elasto-Gel.
88884333|NCT03661996|Experimental|Single Needle Injection Gel Pack Cooling Group - 2% Lidocaine|Subject receives 2% lidocaine and CNTX-4975-05 with cooling device Elasto-Gel.
88884334|NCT03661996|Experimental|Single Needle Injection Gel Pack Cooling Group - 1% Lidocaine|Subject receives 1% lidocaine and CNTX-4975-05 with cooling device Elasto-Gel.
88884335|NCT03645759|Experimental|I'm Whole|This arm will receive 6 behavioral health treatment sessions that focus on stroke self-management, psychological distress and social re-integration. Treatments will occur weekly. They will also receive 3 assessments at 0, 6, and 12 weeks.
88884336|NCT03645759|Active Comparator|Education + usual care|This arm will only receive the standard usual care for stroke self-management provided by the Michael E. Debakey VA Medical facility and will receive 6 brief health education calls unrelated to stroke or psychological distress.
88884337|NCT03639064|Experimental|CanniMed® Oil 1:20 formulation|∆9-THC: 1.0 mg/mL; CBD: 20.0 mg/mL
89408827|NCT01362244|Experimental|Treatment Periods 1-8|Part A comprises eight outpatient visits (Visits 1 - 8). For six of these visits, subjects will receive a dose of either 750 mg mepolizumab or placebo. Dosing occurs in four week intervals. Assessment for entry into Part B will take place at the last visit in Part A (Visit 8). Subjects not eligible for Part B will have study exit procedures performed and be discontinued.
89408828|NCT01362244|Other|Run In period|10-14 day run in period to assess the patients suitability for entry into Part A of the trial.
89535656|NCT03220555|Experimental|Buzzy® device|Just before the vaccination or venipuncture the device will be applied on the selected site during 30 seconds and then it will be moved 5 cm above the selected site to make the injection or the puncture. The child will choose if he wants to use the cooling system.
88884338|NCT03639064|Experimental|CanniMed® Oil 10:10 formulation|∆9-THC: 9.8 mg/mL; CBD: 9.9 mg/mL
88884339|NCT03639064|Experimental|CanniMed® Oil 18:0 formulation|∆9-THC: 18.3 mg/mL; CBD: 0.2 mg/mL
88884340|NCT03633461|Active Comparator|OC-02 (simpinicline) spray spray, 11.1 mg/ml|OC-02 (simpinicline) nasal spray, 11.1 mg/ml
88884341|NCT03633461|Placebo Comparator|Placebo|Placebo (vehicle) nasal spray
89535657|NCT03220555|Active Comparator|EMLAPATCH (lidocaine, prilocaine)|The patch will be applied during 1 hour to 1 hour and half before the vaccination or venipuncture, on the selected site. After 1 hour to 1 hour and half, it will be removed and the injection or the puncture will be made on the selected site.
88884342|NCT03628560|Experimental|RespirAct Step-Wise Normocapnia desaturation sequence|Reduction in oxygen saturation 100 to 70% in approximate 5% steps.
88884343|NCT03628560|Experimental|RespirAct Slope Normocapnia desaturation sequence|Reduction in oxygen saturation 100 to 70% as gradual slope.
88884344|NCT03628560|Experimental|RespirAct Step-Wise Hypocapnia desaturation sequence|Reduction in oxygen saturation 100 to 70% in approximate 5% steps.
88884345|NCT03628560|Experimental|RespirAct Slope Hypocapnia desaturation sequence|Reduction in oxygen saturation 100 to 70% as gradual slope.
88884346|NCT03628560|Active Comparator|ROBD Step-Wise desaturation sequence|ROBD = Reduced Oxygen Breathing Device. Reduction in oxygen saturation 100 to 70% in approximate 5% steps. This represents the standard type of desaturation sequence for pulse oximeter accuracy testing.
88884347|NCT03622658|Placebo Comparator|Placebo|Placebo solution administered by subcutaneous injection on 4 occasions over 10 weeks
88884348|NCT03622658|Experimental|Namilumab|Namilumab (150 mg) administered by subcutaneous injection on 4 occasions over 10 weeks
89191662|NCT00618514|Active Comparator|2|Standard bare tip Laser Fiber - Any commercially available laser device (the control)
89191663|NCT04067804|No Intervention|Usual Care|Standard school disciplinary practices.
89408829|NCT01362244|No Intervention|Treatment periods 9-13|Subjects eligible for Part B will attend the clinic for up to 5 more outpatient visits (Visits 9 - 13) for assessments. Visits occur every four weeks. There is no dosing in Part B. At the point when each subject meets Study Exit criteria, study exit procedures will be performed and the subject will exit the study.
89408830|NCT02134470|Experimental|Testosterone|Chemical testing of saliva is an objective method to quantify steroid hormones. Recent studies indicate that salivary testosterone is significantly higher than in other body fluids. Therefore, saliva may serve as pre-screening parameter to select suspicious cases for further target evaluation. The aim of the present project is to detect administered testosterone in saliva and compare these levels to those in blood and urine. Therefore, each participant represents its own control.
89408831|NCT02130726|Experimental|Minimally-invasive Gastrectomy|Patients allocated to the 'Minimally-invasive Gastrectomy' group will undergo minimally-invasive/laparoscopic total gastrectomy. If, during surgery, laparoscopic resection does not seem feasible, the procedure may be converted to an open one.
89408832|NCT02130726|Active Comparator|Open Gastrectomy|Patients allocated to the 'Open Gastrectomy' group will receive total resection of the stomach via laparotomy. This group is considered the control group
89408833|NCT04076319|Other|CAPABLE|CAPABLE Intervention
89408834|NCT05202067|Experimental|pharmaceutical education|The patients assigned to the intervention group will receive from the research pharmacist, a didactic talk (of at least 10 and up to 20 minutes), where they will be provided information about type 2 diabetes mellitus and Systemic Arterial Hypertension, causes of the disease and consequences of poor control, on its pharmacological treatments, changes in lifestyle and diet. In addition, the patient will be given an updated list of their prescribed medications on a wallet card.
89408835|NCT05202067|No Intervention|control|Patients assigned to the control group will receive only standard care, represented by regular consultation with their prescribing physician.
89408836|NCT03649737|Experimental|Supportive care (exercise)|Participants attend supervised group exercises classes twice per week during weeks 1-6 and once per week during weeks 7-12. Participants also attend home-based unsupervised exercise sessions via an instructional DVD once per weeks over for 30 minutes during weeks 1-6 and twice per week during weeks 7-12.
89408837|NCT02134626|Experimental|Simvastatin|Arm 1: Simvastatin 40mg / pill, one pill once a day for three months
89408838|NCT02134626|Placebo Comparator|Placebo pill|Arm 2: Placebo one pill once a day for three months
89408839|NCT05199883|Experimental|TI.VA group|The titration of Propofol and Remifentanil levels will be guided by TI.VA algorithm in the time between skin incision and completion of surgical resection.
89408840|NCT02134704|Experimental|Scoliosis Group|
89408841|NCT02134704|Experimental|Healthy Volunteers Group|
89408842|NCT02969187|Experimental|Experimental|Patients at our Bariatric Surgery Center of Excellence fulfilling NIH criteria for bariatric surgery and planned operation of laparoscopic Roux-en Y gastric bypass (LRYGB) or laparoscopic sleeve gastrectomy (LSG) as primary bariatric procedure randomized to receive 20 ml of 1.3% Exparel + 30 ml of 0.5% Bupivacaine + 150 ml of Saline
89408843|NCT02969187|Active Comparator|Control|Patients at our Bariatric Surgery Center of Excellence fulfilling NIH criteria for bariatric surgery and planned operation of laparoscopic Roux-en Y gastric bypass (LRYGB) or laparoscopic sleeve gastrectomy (LSG) as primary bariatric procedure randomized to receive 60ml of 0.5% Bupivacaine + 140 ml of Saline.
89408844|NCT05220475|Experimental|fc-SEMS with anchoring plastic stent|fully covered self-expanable metal stent with an external anchoring plastic stent
89408845|NCT05220475|Active Comparator|uc-SEMS|uncovered self-expandable metal stent
89408846|NCT02134860|Active Comparator|Isocaloric diet|3 daily meals
89408847|NCT02134860|Active Comparator|Alternate daily fasting|One meal (25% of caloric need) every second day and four meals (175% of caloric need) every second day
89408848|NCT03650985|Experimental|TOCTD|Pregnancy women with complicated twin diseases, who are able to withstand risks of intrauterine treatments and informed consent, will be involved. Fetoscope technique will be administered in suitable patients.
89408849|NCT02139618|Experimental|Methyl Aminolevulinate (MAL)|1 gram of Topical Methyl Aminolevulinate (MAL) applied to the whole face 30 minutes before sun exposure for 2 hours (3 sessions , 2 to 4 weeks apart)
89408850|NCT02139618|Placebo Comparator|Placebo|1 gram of placebo cream applied to the whole face 30 minutes before sun exposure for 2 hours (3 sessions , 2 to 4 weeks apart)
89408851|NCT04850287|Placebo Comparator|Control|
89408852|NCT04850287|Experimental|Intervention|
89408853|NCT04850287|Experimental|Optimal|
89408854|NCT05285085||Secondary prevention|Individuals with previous myocardial infarction and/or stroke
89408855|NCT05285085||Primary prevention|Individuals with hypertension, diabetes and/or dyslipidemia
89408856|NCT05285085||Unknown diagnosis|Individuals without a previous myocardial infarction and/or stroke or a diagnosis of hypertension, diabetes and/or dyslipidemia
89408857|NCT02139696||MS patients initiating fingolimod|Patients will be imaged using PET and MRI at baseline, and twice during treatment.
89408858|NCT05057416|Experimental|High Intensity Interval Training (HIIT) Protocol|Participants in the HIIT group will start with a 2.5-minute warm-up at about 30% VO2 max. The participants will then complete 3 running bouts at 80-90% VO2 max. Each running bout will be separated by 2 minutes of active rest where the participants will walk at 50% VO2 max. The total exercise time of this protocol will be 15 minutes. Finally, the participants will finish with a 2.5 min cool-down where they will walk at a light intensity of 30% VO2 max, for a total exercise duration of 20 minutes.
89408859|NCT05057416|Experimental|Sprint Interval Training (SIT) Protocol|Participants in the Sprint Interval Training group will perform a 2.5-minute warm up at a VO2 max of 30%. Next, the participants will perform 6 all-out sprints at 150-200% of VO2 max, separated by 2-minute active rests at 50% VO2 max. The total exercise time of the SIT protocol is about 14 minutes. Finally, the participants will perform a walking cool-down of 3.5 minutes at 30% VO2 max, for a total exercise duration of 20 minutes.
89531053|NCT01597245|Experimental|80 mg ixekizumab Dosing Regimen 3|Dosing Regimen 3 is not used until Week 12. At Week 12, ixekizumab responders re-randomized to this arm will receive Dosing Regimen 3.
89531054|NCT01597245|Active Comparator|50 mg etanercept|Administered by one 50 mg SC injection twice weekly starting at Week 0 up to Week 12. At Week 12, etanercept responders are assigned to placebo, and nonresponders to Dosing Regimen 2.
89408860|NCT05057416|Experimental|Moderate Intensity Continuous Training (MICT)Protocol|Participants in the Moderate Intensity Continuous Training group will first be warming up for 2.5 minutes at a VO2 max of 30%. After the warm up, participants will be running for 15 minutes at 45-60% of VO2 max. Finally, the participants will perform a 2.5-minute cool-down at 30% VO2 max, for a total exercise duration of 20 minutes.
89408861|NCT04850209|Other|Control group|Patients in this group will receive clarithromycin based bismuth-containing quadruple therapy, Vonoprazan fumarate 20 mg, colloidal bismuth pectin capsule 200 mg , amoxicillin 1000 mg and clarithromycin 500 mg, twice daily, 14 days.Patients will receive oral and written education
89408862|NCT04850209|Experimental|Wechat group|Patients in this group will receive clarithromycin based bismuth-containing quadruple therapy, Vonoprazan fumarate 20 mg, colloidal bismuth pectin capsule 200 mg ,amoxicillin 1000 mg and clarithromycin 500 mg, twice daily, 14 days.Patients will receive oral and written education. And patients will be invited into a Wechat group to obtain interactive education through question and answer,which is provided by medical professionals.
89408863|NCT02139774||Active Survelliance|Men age 65 and older who are undergoing active surveillance as primary treatment for their prostate cancer.
89408864|NCT02139774||Radiation|Men age 65 and older who are undergoing radiation only as primary treatment for their prostate cancer.
89408865|NCT02139774||Endocrine Therapy|Men age 65 and older who are undergoing endocrine therapy as primary treatment for their prostate cancer.
89408866|NCT02139774||Surgery|Men age 65 and older who are undergoing surgery as primary treatment for their prostate cancer.
89408867|NCT03650205|Active Comparator|Ivabradine|Patients will receive ivabradine just before anthracycline chemotherapy, 5 mg per oral twice daily, until one month after the last chemotherapy session.
89408868|NCT03650205|Placebo Comparator|Placebo|Patients will receive placebo just before anthracycline chemotherapy, one capsule per oral twice daily, until one month after the last chemotherapy session.
89408869|NCT05698459|Experimental|OH2|Administration：intratumoral injection Frequency：once every 3 weeks
89408870|NCT02139930|Active Comparator|Normal Nicotine Control Group|These subjects will smoke normal nicotine content Spectrum brand cigarettes for 20 weeks.
89408871|NCT02139930|Experimental|Immediate Nicotine Reduction Group|This group will immediately be switched to smoking very low nicotine content (VLNC) Spectrum brand cigarettes. They will smoke these cigarettes for 20 weeks.
89408872|NCT02139930|Experimental|Gradual Nicotine Reduction Group|This group will smoke progressively lower nicotine content Spectrum brand cigarettes for a period of one month each until they end up smoking the same VLNC cigarettes as the immediate reduction group.
88884349|NCT03621475|Experimental|Novel restraint first, then traditional restraint|Participants will be randomized to wear the novel arm restraint bilaterally for 4 hours on study day #1, followed by traditional soft bilateral wrist restraints for 4 hours. Then, on study day #2, they will wear both kinds of restraints in the opposite order.
89408873|NCT05285163|Experimental|palliative care education|The patients in the intervention group were presented palliative care training in addition to their usual care. The training period lasts at least 45 minutes. After the training, patients were given the book 'Palliative Care in Heart Failure'. In this training, patients were informed about heart failure and pharmacological and non-pharmacological methods for symptoms such as dyspnea, pain, constipation, depression, edema, tiredness, nausea. The patients were followed up by telephone at the first, third, and sixth months after discharge. The patient's symptoms and quality of life were re-evaluated in telephone follow-up. During the follow-up period, the patient's training related to symptoms was repeated. The patients were referred to the physician for the symptoms and problems which they experienced in the house.
89408874|NCT05285163|No Intervention|usual care|Firstly, the usual care provided to patients was described. It was determined that patients were not given regular and comprehensive training on heart failure, and no training was given on palliative care. Written educational material was not given to the patients. Patients were not followed up after discharge. Palliative care was not discussed with patients and their relatives. Also, they were not asked about their preferences. In usual care, Heart failure patients received medical treatment for their symptoms during hospitalization.
89408877|NCT02140008|Experimental|I-gel group|
88884350|NCT03621475|Experimental|Traditional restraint first, then novel restraint|Participants will be randomized to wear traditional soft bilateral wrist restraints for 4 hours on study day #1, followed by the novel arm restraint bilaterally for 4 hours. Then, on study day #2, they will wear both kinds of restraints in the opposite order.
88884351|NCT03620968|No Intervention|Group 1|Control, no intervention
88884352|NCT03620968|Experimental|Group 2|Intervention before surgery (cognitive training)
88884353|NCT03620968|Experimental|Group 3|Intervention Before and after surgery (cognitive training)
89408878|NCT02140008|Active Comparator|Air-Q group|
89408879|NCT04590118|Experimental|Experimental: it-hMSC|Single intravenous infusion of 0.5×10^6, 1×10^6, 2×10^6 it-hMSC/kg
89408880|NCT04590118|Placebo Comparator|Placebo-controlled: Placebo|Single intravenous infusion of 1 ml/kg placebo
89408881|NCT02603042||Observation|Patients with Hypophosphatasia disease or high-grade suspicion for Hypophosphatasia disease
89408882|NCT04810351||Younger 1|young patients ( 18-69 years old) with oral or rectal fever > 37°8 or tympanic fever > 37°2 or CRP > 30 mg/dl during more than one week but less than three weeks of hospital with appropriate intelligent standard inpatient or outpatient workup to rule out usual causes of fever
88884354|NCT03615521|Experimental|Repeated Contraction Exercise Group|Repeated Contractions Exercise Group, Hotpack apply for knee 20 minute, Ultrasound is a termal ajan which use for 10 minute and Repeated Stretch (Repeated Contractions) exercise. Repeated Contractions exercise is type of Proprioceptive Neuromusculer Facilititation Exercise. 3 session for 6 weeks.
88884355|NCT03615521|Experimental|Combine Exercise Group|"Combination of Isotonics Exercise Group, Hotpack apply for knee 20 minute, Ultrasound is a termal ajan which use for 10 minute Combination of Isotonics Exercise. Combination of Isotonics Exercise is type of PNF. Combined concentric, eccentric, and stabilizing contractions of one group of muscles (agonists) without relaxation.~3 Session for 6 weeks."
88884356|NCT03615521|Experimental|Standart Exercise Therapy|"Classic Physiotherapy: Hotpack, Ultrasound, Standart exercise program to improve Quadriceps, Hamstring and hip muscle strength.~3 session for 6 weeks."
88884357|NCT03600142|No Intervention|Standard of Care (SoC)|Participants randomized to the control condition will receive the standard HIV counseling protocol in the clinic, which is administered by clinic nurses. According to the Tanzania PMTCT guidelines, HIV pre-test counseling should provide education about HIV and prepare a woman (and her partner, if present) for HIV testing. For anyone who tests positive for HIV, counseling should help the woman/couple to accept an HIV test result and discuss implications for treatment.
88884358|NCT03600142|Experimental|SoC + stigma counseling (Maisha)|Participants randomized to the intervention condition will receive the SoC counseling plus Maisha, a brief, scalable, theory-based counseling intervention that addresses HIV stigma at entry into antenatal care. Maisha involves a video delivered to all women prior to HIV testing, and, if a woman tests positive for HIV, two counseling sessions. If a male partner is present with the women, he may also be enrolled and participate in the first two counseling sessions together with the woman.
88884359|NCT03526510|Active Comparator|Standard Fractionation|Using 2 sequential IMRT plans, the pelvic lymph nodes and prostate will initially be treated to 46 Gy in 23 fractions, followed by a subsequent boost to the prostate to a total dose of 78 Gy.
88884360|NCT03526510|Experimental|Hypofractionation|Using a one phase IMRT plan, the pelvic lymph nodes will be treated to a dose of 48 Gy in 25 fractions, while the prostate will be treated to a dose of 68 Gy in 25 fractions concomitantly (simulataneous integrated boost).
88884361|NCT03517098|Experimental|The ERAS group|Patients will be treated with the ERAS pathway
88884362|NCT03517098|Other|The non-ERAS group|Patients undergoing THA or TKA will receive conventional care.
88884363|NCT03499314|Experimental|RS-tDCS Stimulation|20 times 20 minute stimulation session supervised by a study technician through a videoconferencing platform, VSee
88884364|NCT03499314|Placebo Comparator|Sham Stimulation|20 ×20-minute sessions sham tDCS
88884365|NCT03496597||Patients|type 1 diabetes patients
88884366|NCT03496597||Healthy controls|non diabetic control subjects of the same age
88884367|NCT03496597||Dyslipidemic controls|non-diabetic control participants with familial dyslipidemia
88884368|NCT03478215|Experimental|Mesenchymal Stromal Stem Cells Infusion|"Intervention: Mesenchymal stromal stem cells infusion. This is the active investigational intervention, administered intravenously at surgery and day 4 post-transplant in a dose-escalation fashion beginning as 1x10^6 cells for the first dose group, 2x10^6 cells for the second dose group, or 3x10^6 cells for the last dose group. The infusion set-up will be covered to mask the group assignment.~Participants will also receive BASILIXIMAB (Simulect, for all subjects at a standard dose, 20mg reconstituted with normal saline or 5% dextrose) on the day of surgery and day 3 or 4 post-transplant administered by a member of the anesthesia team; TACROLIMUS (Prograf for maintenance therapy), MYCOPHENOLATE MOFETIL (Cellcept for maintenance therapy), and CORTICOSTEROIDS as routine care."
88884369|NCT03478215|Placebo Comparator|Placebo Infusion|Placebo: A normal saline infusion. This is the placebo intervention to occur at surgery and day 4 post-transplant. The infusion set-up will be covered to mask the group assignment. Participants will also receive BASILIXIMAB (Simulect, for all subjects at a standard dose, 20mg reconstituted with normal saline or 5% dextrose) on the day of surgery and day 3 or 4 post-transplant administered by a member of the anesthesia team; TACROLIMUS (Prograf for maintenance therapy), MYCOPHENOLATE MOFETIL (Cellcept for maintenance therapy), and CORTICOSTEROIDS as routine care.
89408883|NCT04810351||Older 1|old patients ( > 70 years old) with oral or rectal fever > 37°8 or tympanic fever > 37°2 or CRP > 30 mg/dl during more than one week but less than three weeks out of hospital with appropriate intelligent standard inpatient or outpatient workup to rule out usual causes of fever
88884370|NCT03477084||Long Term Care Facilities|Spread of ESBL-producing E. coli and K. pneumoniae among the residents of Long Term Care Facilities.
88884371|NCT03477084||Households|Household transmission of ESBL-producing bacteria after hospital discharge of a patient carrying ESBL-producing E. coli or K. pneumoniae.
88884372|NCT03468556|Experimental|test drug|2 tabs of SNP-610
88884373|NCT03468556|Placebo Comparator|placebo|2 tabs of placebo
88884374|NCT03465384|Active Comparator|Comet in group format|The standard format of the intervention that is well established in primary and specialized care in Sweden. Parents receive the education/training in small groups led by two group leaders.
89408884|NCT04810351||Young 2|young patients (18-69 years old) with oral or rectal fever > 37°8 or tympanic fever > 37°2 or CRP > 30 mg/dl during more than 3 weeks with appropriate intelligent standard inpatient or outpatient workup to rule out usual causes of fever.
89408885|NCT04810351||Older 2|old patients ( > 70 years old) with oral or rectal fever fever > 37°8 or tympanic fever > 37°2 or CRP > 30 mg/dl during 3 weeks with appropriate intelligent standard inpatient or outpatient workup to rule out usual causes of fever13 .
89535658|NCT05004597|Experimental|infants longitudinally received three dimensional photo|A series of 3D craniofacial photos were captured using a 3dMDHead System (3dMD, Atlanta, GA, USA) within 7 days before or after the age of 1, 2, 4, 6, 9, and 12 months
88884375|NCT03465384|Experimental|Internet-based Comet|The same content as the group format of Comet, but delivered mainly as online self-help.
88884376|NCT03416088|Experimental|Beverage consumption|Drink 300ml red wine (alcohol concentration:12.5%), 300ml coffee (caffeine concentration 72 mg), or 300ml water.
88884377|NCT03416088|Experimental|Daily reading|Reading paper books, playing video games with mobile phones, or non-reading.
88884378|NCT03416088|Experimental|Body motion|Exercise and body postural changes.
88884379|NCT03410394||registry of endocrine tumors|"Patients who undergo thyroid surgical procedures. This registry was declared at the commission national informatique et libertés (CNIL) with the number R2015-22.~Patients who undergo parathyroid surgical procedures. This registry was declared at the commission national informatique et libertés (CNIL) with the number R2015-23~Patients who undergo adrenal surgical procedures. This registry was declared at the commission national informatique et libertés (CNIL) with the number R2015-24~Patients who undergo pancreatic and digestive surgical procedures. This registry was declared at the commission national informatique et libertés (CNIL) with the number R2015-26"
88884380|NCT03410355|Experimental|BMAC/PRP Injection Group|This group will receive an injection of BMAC/PRP for treatment of OA
88884381|NCT03410355|Active Comparator|Cortisone Injection Group|This group will receive an injection of cortisone for treatment of OA
88884382|NCT03399617|Active Comparator|Standard Care+MNPs|Participants will receive standard health care services provided by the Ministry of Health, including micronutrient powders (MNPs). Children 6 months old will receive 1 gram of powdered micronutrients for 60 days every 6 months until 24 months of age.
88884383|NCT03399617|Experimental|SPOON behavioral change strategy+SQ-LNS|Participants will receive Small Quantity Lipid-based Supplements (SQ-LNS) from 6-24 months and a behavioral change to promote adequate infant and young child feeding practices and the use of SQ-LNS will be delivered to mothers or caregivers. The behavioral change strategy includes individual home-visits, group sessions, and community mobilization activities. SQ-LNS consists of a 20g nutrient supplement package to be consumed daily from 6-24 of age. SQ-LNS formulation does not include sugar.
88884384|NCT03399617|Experimental|SPOON behavioral change strategy+MNPs|Participants will receive micronutrient powders (MNPs) from 6-24 months and a behavioral change to promote adequate infant and young child feeding practices and the use of MNPs will be delivered to mothers or caregivers. The behavioral change strategy includes individual home-visits, group sessions, and community mobilization activities.
88884385|NCT03395366|Active Comparator|Group 1|Multifaceted Educational / Cognitive Behavioral Intervention
88884386|NCT03395366|No Intervention|Group 2|Standard of Care + Dialysis Education without the Cognitive Behavioral component
88884387|NCT03386162|Experimental|Experimental arm (Arm A3)|fulvestrant (500 mg intramuscular [as two 5 mL injections] every 28 days ± 3 days, with an additional injection on 15 after the first administration + Alpelisib (300 mg by mouth once daily, in a 21-day cycle). Premenopausal women will receive LH-RH analogs in addition every 28 days ± 3 days.
88884388|NCT03386162|Active Comparator|Control arm (Arm B3)|maintenance chemotherapy, meaning the same chemotherapy regimen used during the first 6-8 cycles (investigator's choice) or no antineoplastic treatment in case of toxicity after 4 full cycles.
88884389|NCT03373071|Experimental|CD19-CART01|Following the lymphodepleting treatment, with patients will be treated with 0.5 to 3.0 x 10⁶/kg CD19 Chimeric Antigen Receptor (CAR) positive T cells as a single dose
88884390|NCT03369431|Other|Vivomixx, then placebo|This group starts with Vivomixx probiotic for the first 12 weeks then crosses over to have the placebo after a 4-week washout.
88884391|NCT03369431|Other|Placebo, then Vivomixx|This group starts with the placebo for the first 12 weeks then crosses over to have Vivomixx probiotic after a 4-week washout.
88884392|NCT03360214|Other|Active PEMF + Treatment PIB|Participants will receive an active device (Pulsed Electromagnetic Field (PEMF) Device) and active drug (Bupivacaine Hydrochloride or Ropivacaine HCl).
88884393|NCT03360214|Other|Active PEMF + Sham PIB|Participants will receive an active device (Pulsed Electromagnetic Field (PEMF) Device) and placebo drug.
88884394|NCT03360214|Other|Sham PEMF + Treatment PIB|Participants will receive a placebo device and active drug (Bupivacaine Hydrochloride or Ropivacaine HCl).
88884395|NCT03360214|Other|Sham PEMF + Sham PIB|Participants will receive placebo drug and placebo device.
88884396|NCT03359239|Experimental|PGV 001 with Atezolizumab|Atezolizumab: programmed death-ligand 1 PGV001:personalized cancer vaccine PGV 001 - vaccine Poly ICLC- adjuvant The product is prepared within the Icahn School of Medicine at Mount Sinai (ISMMS) . The product consists of two independent preparations of patient specific long peptides mixed with poly-ICLC.
88884397|NCT03350594|Active Comparator|Systemic Family Therapy|"SyFT involves the patient, the parents, and siblings over the age of 6 living at home. Therapists do not manage the issues relating to AN, which are taken on by referent psychiatrist who can be called on in case of any concern. Without denying personal suffering and its intra-psychic and meta-psychological impact, or the somatic and biological aspect of the pathology, the emphasis is on interactions around the symptom.~There will be free exchanges along the lines between therapist and family, within the family and between therapists.~Session is possible with sibling alone or the parents alone or in inter-generational mode (other family relatives)"
88884398|NCT03350594|Experimental|Multiple Family Therapy|"Each session will involve 5 families of patients suffering from AN including the parents and non-systematically the siblings. There will be exchanges in groups and mediation via different exercises involving different sub-groups according to the theme: complete families, patients on their own for problems specific to them, or  cross-parenting  exercises whereby parents adopt another patient for the duration of the exercise. This organization enables mutual support and social propping, favoring the emergence of family resources. Direct exchanges between families (between parents, siblings, or mixes) with and between therapists are also sought."
88884399|NCT03336866|Placebo Comparator|Placebo|Normal saline
88884400|NCT03336866|Experimental|IXT-m200|Single 6 or 20 mg/kg intravenous dose of IXT-m200
88884401|NCT03336411|Active Comparator|mHealth|
88884402|NCT03336411|Experimental|Personalized mHealth|
88884403|NCT03335345|Other|maximum gastric void|stopping enteral feeding at least 6 hours before extubation. Suction in the gastric tube (if its size permits) continuously for 6 hours before extubation.
88884404|NCT03335345|Other|maintaining calorie intake|maintaining enteral caloric intake at the same rate. No aspiration in the gastric tube
88884405|NCT03332173|Experimental|Zanubrutinib|Zanubrutinib 160 mg orally twice daily with or without food until progressive disease or intolerable toxicity
88884406|NCT03328676|Experimental|"Avidekel  cannabis oil 20:1 CBD:THC"|The cannabis oil will be mad out of extract from the Avidekel strain and olive oil. Avidekel oil containing Δ9-Tetra-Hydrocannabinol (Δ9-THC) and Cannabidiol (CBD) in a 1:20 ratio and at a concentration of 30% CBD and 1.5% Δ9-THC. Each Avidekel oil drop is approximately 0.04 ml in volume containing about 12 mg CBD and 0.6 mg Δ9-THC.
88884407|NCT03328676|Placebo Comparator|placebo oil|Patients in the control group will receive placebo.
88884408|NCT03324711|Other|Elderly patient (65 and more)|Ederly patients seen in geriatric day hospital, from creole culture.
88884409|NCT03322293|Active Comparator|A. Conventional arm|"This is considered the standard of care arm for photodynamic therapy for the treatment of actinic keratosis. This treatment arm includes: Acetone preparation, ALA topical application, 1 hour incubation, 16 minutes 40 seconds (16:40) BLU-U exposure, application of sunscreen.~Drug intervention: Aminolevulinic acid HCl (ALA) topical solution 20% Device: BLU-U blue light phototherapy illuminator"
88884410|NCT03322293|Experimental|B. Combination arm|"This treatment arm combines standard of care BLU-U exposure and daylight exposure. This treatment arm includes: Acetone preparation, ALA topical application, 15 minute incubation, 16:40 BLU-U exposure, application of sunscreen, 45 minute daylight exposure.~Drug intervention: Aminolevulinic acid HCl (ALA) topical solution 20% Device: BLU-U blue light phototherapy illuminator"
88884411|NCT03322293|Experimental|C. Daylight arm|"This is the experimental arm. This treatment arm includes: Acetone preparation, ALA topical application, 15 minute incubation, application of sunscreen, 1 hour daylight exposure.~Drug intervention: Aminolevulinic acid HCl (ALA) topical solution 20% Device: none"
89408886|NCT03549390|Experimental|Yoga|The yoga session will be held in a room where lighting, temperature and music can be regulated. The session will be led by a trained instructor and involve a combination of body postures, breathing techniques and meditation. There will be a series of progressive breath centred yoga poses named Sun Salutations A & B for participants to complete, which have been chosen based on PPI and current relevant yoga practices. Sun Salutations A & B will be completed in a continuous sequence and aim to be completed with one breath per pose, but can be modified based on participant ability.
89408887|NCT03549390|Experimental|Continuous exercise|The exercise will be 30 minutes of treadmill walking. During the initial stages of walking, participants will gradually be taken up to a speed that registers between 10 and 12 on the Borg Rating of Perceived Exertion (RPE) Scale, up to a maximum of 4.0 km/h. This speed will be fixed for the entire exercise period. This exercise intensity has been chosen as it is the exercise intensity matched to light-moderate physical activity.
88884412|NCT03322033|Experimental|Type A Dissection|High risk subjects with ascending thoracic aortic pathologies including type A aortic dissection who are suitable for endovascular repair
88884413|NCT03315039|Experimental|Liposomal annamycin|2-hour intravenous infusion liposomal annamycin daily for 3 consecutive days followed by 18 days off study drug (i.e., one treatment cycle = 21 days).
88884414|NCT03308045|Experimental|pEYS606|Cohort 1 (pEYS606 lower dose); Cohort 2 (pEYS606 intermediate dose); Cohort 3 (pEYS606 higher dose); Extension Cohort (pEYS606 maximum tolerated dose)
88884415|NCT03295773||Symptomatic stroke patient|Patients who are found signal void in a relevant intracranial internal carotid artery or middle cerebral artery (stenosis >60%) will proceed to a 3-Dimensional rotational angiography (3DRA) at baseline and in 12 months. All recruited patients will receive dual antiplatelet agents for 4 weeks, followed by aspirin alone. The investigator or neurologists shall regularly review the patients and treat the conventional cardiovascular risk factors based on four pre-specified goals, for example, LDL <1.8, HbA1c <6.0, blood pressure <140/90 and no smoking. The morphologic changes of the cerebral plaques with the intensity of the risk factor control in pre and post will be correlated.
88884416|NCT03291652||Symptomatic stroke patient|"DSA and 3DRA will be performed with access through a 4F sheath at the right femoral artery. Angiograms of intracranial arteries will be obtained by contrast injection at internal carotid artery and vertebral artery ostium from a 4F H1 catheter. Each injection will contain 10ml of iopaminro 300 diluted in 1:1 with normal saline. Each angiographic run will capture a complete series of images from the arterial phase to the end of the venous phase. A 3-dimensional rotational angiogram (a scan time of 4 seconds with 120 images) will be obtained for evaluation of plaque morphology.~2. The access site will be closely observed for hemostasis after the procedure. The neurological status and renal function will be monitored.~Diagnosis procedure: DSA/3DRA"
88884417|NCT03291652||Asymptomatic stroke patient|"DSA and 3DRA will be performed with access through a 4F sheath at the right femoral artery. Angiograms of intracranial arteries will be obtained by contrast injection at internal carotid artery and vertebral artery ostium from a 4F H1 catheter. Each injection will contain 10ml of iopaminro 300 diluted in 1:1 with normal saline. Each angiographic run will capture a complete series of images from the arterial phase to the end of the venous phase. A 3-dimensional rotational angiogram (a scan time of 4 seconds with 120 images) will be obtained for evaluation of plaque morphology.~2. The access site will be closely observed for hemostasis after the procedure. The neurological status and renal function will be monitored.~Diagnosis procedure: DSA/3DRA"
88884418|NCT03276533|Experimental|Intravenous saline, dexmedetomidine and lidocaine|
88884419|NCT03276533|Experimental|Intravenous saline, dexmedetomidine, lidocaine and combination|
88884420|NCT03276533|Experimental|Intravenous saline,dexmedetomidine plus lidocaine|
88884421|NCT03276533|Experimental|Intravenous saline, dexmedetomidine combined with lidocaine|
89408888|NCT03549390|No Intervention|Control|Participants will remain sitting throughout the test period whilst undertaking typical sedentary behaviours such as watching TV, using a computer, reading and writing. Walking and standing will be restricted.
89408889|NCT03649425||hydroxyapatite coated pins|Patients submitted to surgical treatment with external fixators using pins coated with hydroxyapatite.
89408890|NCT03649425||uncoated steel pins|Patients submitted to surgical treatment with external fixators using uncoated steel pins.
89408891|NCT03650907|Experimental|Group exercise program by coach|
88884422|NCT03258996|Experimental|Modified vestibular incision subperiosteal tunnel access|Test group: Coverage of Class III multiples gingival recessions with the application of Modified vestibular incision subperiosteal tunnel access technique and a connective tissue graft from the palate.
88884423|NCT03258996|Active Comparator|Coronally advanced flap|Control group: Coverage of Class III multiples gingival recessions with the application of Coronally advanced flap and a connective tissue graft from the palate.
89408892|NCT03650907|Sham Comparator|Self exercise|
89408893|NCT02130804|Experimental|Salsalate|Salsalate (4 g/day)
89408894|NCT02130804|Placebo Comparator|Placebo|Placebo (4 g/day)
88884424|NCT03254394|Placebo Comparator|Placebo + FOLFOX|"Intravenous infusion of D5W solution over a 130 minute period.~FOLFOX:~Oxaliplatin 85mg/m2 IV over 2h, Leucovorin 400 mg/m2 IV over 2h, 5-FU 400mg/m2 IV bolus, followed by a 1200mg/m2/day continuous infusion for 2 days."
88884425|NCT03254394|Active Comparator|Lidocaine + FOLFOX|"Intravenous infusion of lidocaine hydrochloride solution in D5W over a 130 minute period.~FOLFOX:~Oxaliplatin 85mg/m2 IV over 2h, Leucovorin 400 mg/m2 IV over 2h, 5-FU 400mg/m2 IV bolus, followed by a 1200mg/m2/day continuous infusion for 2 days."
89408895|NCT03650751||stroke patients；neurologic impairment|It provides nursing staff with a unified reference standard for nursing observation indicators and sets monitoring and warning values according to the score, which is helpful to improve the timeliness and accuracy of nursing observation for patients with cerebral apoplexy.
89408896|NCT05303272|Experimental|Abatacept|Subject received subcutaneous administration of abatacept 125 mg once every week through the 52 week double blind period.
89408897|NCT05303272|Active Comparator|Mycophenolate mofetil|Subject received subcutaneous administration of matching placebo of abatacept once a weeks through the 24 week double blind period. A washout period of MMF for 4 weeks (24 th-28th week) is used to ensure data integrity. Subsequently,subject were administered subcutaneous administration of abatacept 125 mg once every week through the 28-52 week open label period.
89408898|NCT02131038||Ectoin group|Ectoin Allergy Nasal Spray
89408899|NCT02131038||Cromolyn group|Cromolyn sodium
89408900|NCT02140086|Experimental|Buteyko based Remedial Breathing Therapy|Buteyko based Remedial Breathing Therapy
88884426|NCT03253809|Experimental|Coronary Sinus Branch Pacing|"After cannulation, pacing impulses will be delivered via a Biotronik Vision Guidewire to 3 sites (apical, mid ventricular, and basal) within each coronary sinus branch receiving venous blood from the anterior, lateral and posterior regions of the ventricle.~ECG signals will be saved digitally for analysis"
88884427|NCT03252314||Subjects with ruptured aneurysms|
89408901|NCT02140086|No Intervention|Waiting List|Training in the course of the study
89408902|NCT03549312|Experimental|Switch to Genvoya Followed By HCV Therapy Then Start Biktarvy|Oral Genvoya 150/150/200/10 mg & Epclusa 400/100 mg once daily. Once completed HCV therapy, switch anti-retroviral treatment to Oral Biktarvy 50/200/25 mg.
89004664|NCT00400946|Active Comparator|Intramuscular native E coli L-asparaginase (IM-EC)|Patients in this arm were randomized to intramuscular native E coli L-asparaginase 25 000 IU/m2 weekly for 30 doses. Protocol therapy was comprised of 5 phases: Induction, Consolidation I, CNS, Consolidation II, Continuation and varied dependent on risk classification. Patients who achieved complete remission after induction were eligible for post-induction asparaginase randomization. Further details are provided in the study description section.
89004665|NCT00400946|Experimental|Intravenous PEG-asparaginase (IV-PEG)|Patients in this arm were randomized to intravenous PEG-asparaginase 2500 IU/m2 every 2 weeks for 15 doses. Protocol therapy was comprised of 5 phases: Induction, Consolidation I, CNS, Consolidation II, Continuation and varied dependent on risk classification. Patients who achieved complete remission after induction were eligible for post-induction asparaginase randomization. Further details are provided in the study description section.
89408903|NCT04573036|Experimental|HRS4800 tablets cohort 1|Part 1 - HRS4800 Single Ascending Dose
89004666|NCT00123305|Experimental|1|
89004667|NCT00123305|Experimental|2|
89004668|NCT00123305|Experimental|3|
89004669|NCT00123305|Placebo Comparator|4|
89408904|NCT04573036|Experimental|HRS4800 tablets cohort 2|Part 1 - HRS4800 Single Ascending Dose
89004670|NCT00221247|Active Comparator|Group 1|Intensely administered (5 times per week for 12wk) physical therapy, occupational therapy, and hydrotherapy with acupuncture
89004671|NCT00221247|No Intervention|Group 2|Intensely administered (5 times per week for 12wk) physical therapy, occupational therapy, and hydrotherapy without acupuncture
89004672|NCT00214266|Experimental|Campath-1H Induction Therapy Combined With CellCept® Therapy|Campath-1H Induction Therapy Combined With CellCept® Therapy
89004673|NCT00221325|Experimental|Rituximab Plus MTX|
89004674|NCT00123500|Active Comparator|1|Worksite Intervention
89004675|NCT00123500|Placebo Comparator|2|Control Group
89004676|NCT00214305|Experimental|Range of Motion Therapy Program|The program involves exercises and maneuvers that include voluntary maximal movements of the tongue, pitch range exercises, head lifting (Shaker exercise), resistance to laryngeal excursion (Mendelsohn Maneuver), breath holding after swallow and cough, thermal-tactile stimulation (ice), suck-swallow, optimal posturing, and dietary changes.
89004677|NCT00214305|Placebo Comparator|Postural Sensory Therapy Program|The program involves all of the above, except that range of motion exercises (voluntary maximal movements of the tongue, pitch range exercises, head lifting, resistance to laryngeal excursion, breath holding after swallow and cough) are not performed.
89004678|NCT00221442|Active Comparator|zonisamide|zonegran (zonisamide)
89004679|NCT00221442|Placebo Comparator|Sugar pill|fake pill
89004680|NCT00123578|Experimental|Lorazepam|Lorazepam for the treatment of mild GHB withdrawal.
89408905|NCT04573036|Experimental|HRS4800 tablets cohort 3|Part 1 - HRS4800 Single Ascending Dose
89408906|NCT04573036|Experimental|HRS4800 tablets cohort 4|Part 1 - HRS4800 Single Ascending Dose
89408907|NCT04573036|Experimental|HRS4800 tablets cohort 5|Part 2 - HRS4800 Food Effect
89004681|NCT00123578|Active Comparator|Pentobarbital|Pentobarbital for the treatment of mild GHB withdrawal.
89004682|NCT02962752|Experimental|Blackadder Juice|Cold pressed Blackadder blackcurrant juice. Standardised at 500mg of polyphenols per 60kg of body weight
89004683|NCT02962752|Placebo Comparator|Placebo|Sugar, flavour and volume matched placebo control drink.
89004684|NCT00123617|Experimental|Phase III cardiac rehabilitation|Phase III group-based cardiac rehabilitation classes, weekly
89004685|NCT00123617|No Intervention|Monitoring|Normal daily living, no extra visits to study centre
89408908|NCT04573036|Placebo Comparator|Placebo tablets|
89408909|NCT03524768||patients presenting with Chagas cardiomyopathy|Evaluation of systemic microvascular reactivity using laser speckle contrast imaging Evaluation of skin capillary density using video-capillaroscopy
89408910|NCT03524768||control group|Evaluation of systemic microvascular reactivity using laser speckle contrast imaging Evaluation of skin capillary density using video-capillaroscopy
89408911|NCT03649269|Experimental|PC-300 tea|Patients that received the Eryngium heterophyllum + Amphipterygium adstringens tea, one cup half an hour before eating.
89408912|NCT03649269|Active Comparator|Bezafibrate|Patients that received fibrate (bezafibrate) 200 mg/day.
89004686|NCT00123656|Active Comparator|1|fluticasone
89004687|NCT00123656|Active Comparator|2|esomeprazole
89004688|NCT00221715|Experimental|1|bypass by autologous saphenous vein
89004689|NCT00221715|Active Comparator|2|bypass by dacron or PTFE Prosthesis
89004690|NCT02963207|Experimental|Modified Sano's Classification|Modified Sano's Classification as described by Singh et al. 2013
89004691|NCT02963207|Active Comparator|NICE classification|NBI International Colorectal Endoscopic Classification as described by Hewett et al. 2012
89004692|NCT00214773||Observational|No intervention. This is an observational program.
89004693|NCT00221793|Experimental|1|Deep Brain Stimulation of the Subthalamic Nucleus
89004694|NCT00221793|Active Comparator|2|Later Deep Brain Stimulation of the Subthalamic Nucleus
89004695|NCT02962440|Experimental|Somapacitan|
89004696|NCT00409487|Experimental|1|8 weeks of Valsartant treatment, 4 weeks of washout, 8 weeks of CPAP and 8 weeks of Valsartant plus CPAP treatments
89004697|NCT00409487|Experimental|2|8 weeks of CPAP , 4 weeks of washout, 8 weeks of Valsartant treatment and 8 weeks of Valsartant plus CPAP treatments
89004698|NCT00412698|Experimental|1|
89004699|NCT00412698|Placebo Comparator|2|
89004700|NCT00123929|Active Comparator|1|doxorubicin
89408913|NCT04758520|Experimental|Experimental|"Six subjects are involved in a single session of upper limb robotic-assisted therapy lasting about 3 hours and including:~passive mobilization of patient's upper arm along elementary shoulder movements:shoulder flexion/extension, adduction/ abduction in the frontal plane, horizontal adduction/ abduction, intra/extrarotation (Passive Mode);~passive mobilization of patient's upper arm along complex trajectories recorded from manual mobilization of the therapist (Learn&Replay Mode);~active mobilization, performed by the patient during rehabilitative functional tasks, relying only on gravity and friction compensations and tuneable assistance from the exoskeleton (Transparency Mode)."
89408914|NCT02134938|Experimental|Konjac Glucomannan|650g KJM-G
89408915|NCT02134938|Experimental|Half Control/Half Konjac Glucomannan|325g KJM-G
88884428|NCT03247205|Experimental|HipERS|A trained physical therapist will visit each participant for a 1-hour session 3 times a week for the initial 2 weeks, and then 2 times a week for 4 weeks (total 14 hours over 6 weeks).
88884429|NCT03227081|No Intervention|Sleep|Sleep
88884430|NCT03227081|Experimental|Sleep Deprivation|Sleep Deprivation
88884431|NCT03203876|Experimental|Part One Combination Therapy|Lirilumab and Nivolumab
88884432|NCT03203876|Experimental|Part 2 Combination Therapy|Lirilumab, Nivolumab and Ipilimumab
88884433|NCT03191240|Experimental|Vasopressins|Additional vasopressin 40 IU intravenous injection for 2 times
88884434|NCT03191240|Placebo Comparator|Normal saline|Additional normal saline intravenous injection for 2 times
88884435|NCT03180294|Experimental|Bupropion 150 mg|One Bupropion 150 mg XL capsule by mouth (PO) in a.m. daily for one week; one Bupropion 150 mg XL capsule and one placebo capsule daily for 8 weeks; one placebo capsule daily for one 1 week (titration off).
88884436|NCT03180294|Experimental|Bupropion 300 mg|One Bupropion 150 mg XL capsule PO in a.m. daily for one week; two Bupropion 150 mg XL capsules PO in a.m. daily for 8 weeks (300 mg target dose); one Bupropion 150 mg XL capsule PO in a.m. daily for 1 week (titration off)
88884437|NCT03180294|Placebo Comparator|Placebo|One placebo capsule PO in a.m. daily for 1 week; two placebo capsules PO in a.m. daily for 8 weeks; one placebo capsule PO in a.m. daily for 1 week (titration off)
88884438|NCT03147222|Experimental|Fracture Care at Home|A trained FFC coach will visit each caregiver and fracture participant in the home for a 1-2 hour session once a week for 8 weeks.
88884439|NCT03122743||Ancillary-Correlative (collection of samples, questionnaires)|Patients undergo collection of serum samples for epinephrine and cortisol levels at baseline and 4 clinical visits. Patients also receive the Self-Perceived Stress questionnaire and the Distress Thermometer questionnaire to measure perceived stress.
88884440|NCT03111030|Experimental|ProacTive SCI|Individualized physical activity coaching sessions
88884441|NCT03111030|No Intervention|Wait-list control|Standard care, receiving physical activity coaching sessions after completing post-testing
89535659|NCT02489669|No Intervention|LVEDP-guided group|Patients allocated to the LVEDP-guided group will continue to receive intravenous 0.9% sodium chloride, according to the protocol suggested in the POSEIDON trial (that is, 5 mL/kg/hr for LVEDP ≤12 mmHg; 3 mL/kg/hr for 13-18 mmHg; and 1.5 mL/kg/h for >18 mmHg). The fluid rate will be eventually modified at the start of the procedure in case of discordance between non-invasive and invasive LVEDP pressure estimate, being the invasive value considered as gold-standard. The fluid rate will continued during the procedure, and for 4 hours post-procedure.
88884442|NCT03098797|Experimental|Experimental: Elamipretide|Patients will be randomized to receive 12 weeks of elamipretide in one of the two treatment periods. All subjects will receive 12 weeks of elamipretide and 12 weeks of placebo.
88884443|NCT03098797|Placebo Comparator|Placebo|Patients will be randomized to receive 12 weeks of placebo in one of the two treatment periods. All subjects will receive 12 weeks of placebo and 12 weeks of elamipretide.
88884444|NCT03096067|Active Comparator|Heavy slow resistance group|Heavy slow resistance training. Three times weekly for 12 weeks.
88884445|NCT03096067|Experimental|Moderate slow resistance group|Moderate slow resistance training. Three times weekly for 12 weeks.
88884446|NCT03095313|Experimental|18F-NaF PET and CT scanning|18F-NaF PET-CT scan (at Baseline visit only) Contrast-enhanced CT Scan (at Baseline and Year 2 only) with possible beta-blocker and nitroglycerin, if medically safe.
88884447|NCT03090295|Experimental|Palpation and Accuro|The placement site for the spinal anesthesia will be identified using both palpation and Accuro.
89004701|NCT00123929|Other|2|docetaxel
88884448|NCT03071601|Experimental|Topical anesthesia|Topical anesthesia using a cream containing 2.5% Lidocaine and 2.5% Prilocaine applied for at least 30 minutes before laceration repair.
88884449|NCT03071601|Experimental|Subcutaneous injection anesthesia|Local anesthesia by a subcutaneous injection of a solution containing 1% Lidocaine and 0.005 mg/mL Epinephrine in the minutes before laceration repair.
88884450|NCT03061903|Experimental|Prevena|Subjects will receive PREVENA after surgery.
88884451|NCT03061903|Active Comparator|Aquacel|Subjects will receive AQUACEL Ag after surgery.
88884452|NCT03061643|Experimental|Docetaxel PLUS ADT|receive docetaxel 40 mg/m2 IV every 2 weeks plus ADT
88884453|NCT03061630|Experimental|gemcitabine|cisplatin 60 mg/m2 on day 1 and gemcitabine 1000 mg/m2 on days 1, 8 and 15. On day 1
88884454|NCT03055390|Placebo Comparator|Control|They received two ml of normal saline intravenously as a placebo
88884455|NCT03055390|Active Comparator|20 mg hyoscine butylbromide|They received (20mg) hyoscine butylbromide (one ml HBB+ one ml saline) intravenously
88884456|NCT03055390|Active Comparator|40 mg hyoscine butylbromide|They received (40mg) hyoscine butylbromide (one ml HBB+ one ml saline) intravenously
88884457|NCT03039140|Experimental|Supportive care (CR program)|Patients participate in a CR program consisting of 1-hour CR intervention sessions, based on a personalized exercise prescription, 3 times per week for 14 weeks (a total of 36 sessions). Components of the exercise prescription includes intensity, mode, duration, and frequency. Intensity of exercise is guided by the results of a graded exercise stress test, RPE, heart rate, and symptoms, such as chest pain/angina or shortness of breath. If exercise is well-tolerated during CR sessions, patients are encouraged to supplement their exercise program at home, increasing their exercise frequency to up to 5 times per week. Patients may attend weekly educational sessions offered by the Phase 2 CR program which covers topics such as stress management, smoking cessation, nutrition, and weight loss.
88884458|NCT03033056||Anxiety Clinic Patients|Adult males and females being treated at the anxiety disorders clinic at the University of Minnesota predominantly for clinical anxiety.
88884459|NCT03033056||Healthy Comparisons|Sex, age, and socioeconomically matched healthy controls
88884460|NCT03015142||New image-guidance software|Patients in this group had spine surgery with new image-guidance software application.
89004702|NCT00475033|Experimental|1|
89004703|NCT00475033|Active Comparator|2|
89004704|NCT00412776|Experimental|1|Proxinium plus Best Supportive Care
89004705|NCT00412776|No Intervention|2|Best Supportive Care
88884461|NCT03012672|Experimental|Arm I (higher-dose)|"INDUCTION: Patients receive G-CSF SC on days 0-5, higher dose cladribine IV over 2 hours on days 1-5, higher dose cytarabine IV over 2 hours on days 1-5, and higher dose mitoxantrone IV over 60 minutes on days 1-3. Treatment repeats every 6 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Patients who achieve CR/CRi with up to 2 courses of Induction receive G-CSF, cladribine, and cytarabine as in Induction. Courses repeat every 6 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity."
88884462|NCT03012672|Experimental|Arm II (lower-dose)|"INDUCTION: Patients receive G-CSF SC on days 0-5, lower dose cladribine IV over 2 hours on days 1-5, lower dose cytarabine IV over 1 hour on days 1-5, and lower dose mitoxantrone IV over 60 minutes on days 1-3. Treatment repeats every 6 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Patients who achieve CR/CRi with up to 6 courses of Induction receive G-CSF, cladribine, and cytarabine as in Induction. Courses repeat every 6 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity."
88884463|NCT03011775|Experimental|Pioglitazone + Standard Care|20 patients who received standard medical therapy complex: isosorbide dinitrate 10-20 mg 2 times a day, acetylsalicylic acid 75 mg 1 time a day, bisoprolol 2.5 mg 1 time a day, rosuvastatin 20 mg 1 time a day, ramipril 5 mg 1 time a day. Patients also received recommendations on diet and lifestyle changes. Included pioglitazone 15 mg 1 time per day in the morning for 6 months.
88884464|NCT03011775|Other|Standard Care|23 patients who received standard medical therapy complex: isosorbide dinitrate 10-20 mg 2 times a day, acetylsalicylic acid 75 mg 1 time a day, bisoprolol 2.5 mg 1 time a day, rosuvastatin 20 mg 1 time a day, ramipril 5 mg 1 time a day. Patients also received recommendations on diet and lifestyle changes.
88884465|NCT03011346|Active Comparator|Symetis ACURATE neo/TF transfemoral TAVI system|Symetis ACURATE neo/TF transfemoral TAVI system: self-expandable transcatheter aortic bioprosthesis, support frame made of nitinol, supra-annular processed trileaflet porcine pericardial valve and an outer skirt to mitigate paravalvular regurgitation (manufactured by Symetis SA, Ecublens, Switzerland)
88884466|NCT03011346|Active Comparator|Edwards Sapien 3 Transcatheter Heart Valve|Edwards SAPIEN 3 Transcatheter Heart Valve system: balloon-expandable transcatheter aortic bioprosthesis, support frame made of cobalt-chromium, three leaflets constructed of processed bovine pericardial tissue and an outer polyethylene terephthalate (PET) sealing cuff to mitigate paravalvular regurgitation (manufactured by Edwards Lifesciences, Inc., Irvine, California, USA)
88884467|NCT03007485|No Intervention|Standard of Care|Standard pulmonary rehabilitation
88884468|NCT03007485|Experimental|Intervention|Telehealth delivered pulmonary rehabilitation
88884469|NCT02998476|Experimental|Group A Parsaclisib (no prior BTK inhibitor)|Parsaclisib in subjects who were not previously treated with a BTK inhibitor.
89191664|NCT04067804|Experimental|Dynamic Adaptation Process|Using the Dynamic Adaptation Process, specialist coordinators will convene and lead Implementation Resource Teams (IRTs). With the assistance of expert trainers and coaches, the coordinator-led IRTs will then engage in an iterative process of assessment and planning to build school capacity and implement restorative practices to reduce adverse student outcomes related to discipline.
88884470|NCT02998476|Experimental|Group B Parsaclisib (prior BTK inhibitor)|Parsaclisib in subjects who were previously treated with a BTK inhibitor.
88884471|NCT02960997|Experimental|Sirolimus, then Placebo|Participants will receive Sirolimus, 2% topical ointment for 12 weeks followed by placebo to match sirolimus for 12 weeks.
88884472|NCT02960997|Placebo Comparator|Placebo, then Sirolimus|Participants will receive placebo to match sirolimus for 12 weeks followed by Sirolimus, 2% topical ointment for 12 weeks.
88884473|NCT02951104|Experimental|USCOM|
88884474|NCT02947217|Experimental|Influenza Vaccine|O.5 mL single dose influenza vaccine suspension administered intramuscularly
88884475|NCT02947217|Placebo Comparator|Saline Injection|O.5 ml of sterile Saline administered intramuscularly
88884476|NCT02924480|Active Comparator|Lidocaine Study Group|Intravenous Lidocaine for Cystectomy Procedures: During the surgery, the lidocaine infusion group will receive the lidocaine bolus (1.5mg/kg bolus followed by a 2mg/kg/h infusion) 30 minutes prior to skin incision and the infusion will continue until 60 minutes after skin closure.
88884477|NCT02924480|Placebo Comparator|Placebo Study Group|Intravenous Saline for Cystectomy Procedures: During the surgery, patients will be randomized to the control group and receive a normal saline bolus 30 minutes prior to skin incision and the infusion will continue until 60 minutes after skin closure.
88884478|NCT02924064|Experimental|Teneligliptin 20mg|Teneligliptin (20mg once daily) for 24 weeks in combination with metformin
88884479|NCT02924064|Placebo Comparator|Placebo|Placebo for 24 weeks in combination with metformin
88884480|NCT02916706|Experimental|Teneligliptin 20mg|Teneligliptin (20mg once daily) for 24 weeks
89408916|NCT02134938|No Intervention|Control|0g KJM-G
89408917|NCT04750408|Active Comparator|Oxygen use|Patients will use standard oxygen via face mask of nasal prongs as usual care.
88884481|NCT02916706|Placebo Comparator|Placebo|Placebo for 24 weeks
89408918|NCT04750408|Experimental|NHF use|Patients will use NHF instead of oxygen. Oxygen will be supplemented via the NHF flow.
89408919|NCT03649893|No Intervention|Control Group|The control group will use conventional siiting-desk office.
89408920|NCT03649893|Experimental|Active Office Group|The experimental group will use active offfice, including sit-to-stand desk, bike desk, seddle chair and active breask.
89408921|NCT05185609||Healthy volunteers|Healthy volunteers aged 18-to 65
89408922|NCT05185609||Asymptomatic patients with quiescent IBD|Asymptomatic patients with IBD in remission.
89408923|NCT05185609||Symptomatic patients with quiescent UC|Symptomatic patients with UC in remission
89408924|NCT05185609||Symptomatic patients with quiescent CD with anorectal involvement|Symptomatic patients with CD with distal involvement of the colon or perianal disease
89408925|NCT02135172|Experimental|Sitting|During the sitting treatment condition, walking and standing will be restricted. Participants will be in a designated room with access to a computer, books/magazines throughout the day. Participants will have a cannula fitted and the first of the half-hourly blood samples will be taken (time point: -1hr). Participants will then be asked to sit quietly for 60 minutes to achieve a steady state. Following this, participants will have another blood sample taken and then be provided with a standardised mixed meal breakfast (09:00am) (time point: 0h). Blood sampling will continue at 30 minutes intervals for 3 hours following breakfast. A second, lunch meal (12:00pm), will be then be consumed over 15 minutes. Blood sampling will then continue at 30 minute intervals for 3 hours following lunch.
89408926|NCT02135172|Experimental|Standing|This is the same as the sitting condition, but participants will be asked to break their sitting time by standing close to their chair for 5 minutes, after 15 and 45 minutes of each hour following breakfast. The standing protocol will be repeated after lunch. Individuals will be asked to stand in the same position with no further instructions provided. In total, individuals will accumulate 12 bouts (60 minutes) of standing throughout the test period.
89408927|NCT02135172|Experimental|Walking|This is identical to the standing condition, but the breaks in sitting time will be punctuated with 5 minute bouts of light-intensity treadmill walking (equivalent to around 4.0km•h-1) rather than standing. In total, individuals will accumulate 12 bouts (60 minutes) of light-intensity activity throughout the test period. The light-intensity walking activity undertaken here replicates the low-grade ambulatory activity associated with everyday life.
89408928|NCT03649191|Other|Intervention ACP Group|The BABEL Approach to Advance Care Planning in Nursing Homes
89408929|NCT03649191|Other|Control ACP Group|Control group Advance Care Planning
89191665|NCT00854542|Active Comparator|TCSCT|
89191666|NCT00854542|Placebo Comparator|Usual Care|
89408930|NCT02135250|Experimental|placebo|the placebo is not drug
89408931|NCT02135250|Experimental|Xinkeshu tablet|4 Xinkeshu tablets are given three times per day
89408932|NCT05182723|Active Comparator|oXiris|Monotoring of extracorporeal Method for Removing Mediators of Systemic Inflammation of oXiris will be performed for 24 hours
89408933|NCT05182723|Experimental|oXiris in combination with Jafron HA330|"Extracorporeal Method for Removing Mediators of Systemic Inflammation oXiris in combination with Jafron HA330 will be performed for 4 hours.~If SOFA is more or equally 4 , CRP is more than 100 ng/ml;, the IL6 value is increased by 5 or more times after 12 hours of procedure Jafron HA330 will be reconnected and performed for 4 hours.~Monitoring of whole procedure will be performed for 24 hours."
89408934|NCT05373446|Experimental|SSD8432 300mg|SSD8432 300mg in combination with ritonavir 100mg
89408935|NCT05373446|Experimental|SSD8432 750mg|SSD8432 750mg in combination with ritonavir 100mg
89408936|NCT05373446|Placebo Comparator|SSD8432 placebo|SSD8432 placebo in combination with ritonavir placebo
88884482|NCT02895789||spinal muscular atrophy|ambulatory children and adults ages between 8 and 55 years old by the time of enrollment with laboratory documentation of homozygous deletion of SMN1 exon 7
88884483|NCT02895789||mitochondrial myopathy|ambulatory children and adults ages between 8 and 55 years old by the time of enrollment with genetic confirmation or evidence from muscle biopsy confirming the diagnosis
88884484|NCT02895789||control|The healthy control group will be age and gender-matched to the SMA and mitochondrial myopathy groups as best as possible.
88884485|NCT02889900|Experimental|combination of cediranib and olaparib|Open label
88884486|NCT02882022|Experimental|CPAP|All participants will be included in this arm, and CPAP will be administered using a full face mask at incrementally increasing pressures. This will occur during a single session lasting no more than one hour.
88884487|NCT02879942||Case cohort|Patients with pregnancies complicated by placental insufficiency (preeclampsia and/or intrauterine growth restriction) will be included in this cohort.
88884488|NCT02879942||Control cohort|Patients with pregnancies not complicated by placental insufficiency (preeclampsia and/or intrauterine growth restriction) will be included in this cohort.
88884489|NCT02873819|Experimental|GL-0817|Subjects in active treatment will be vaccinated with GL-0817 with the adjuvants Poly-ICLC (Hiltonol®) and GM-CSF (Sargramostim, Leukine®) 3 times at 3-week intervals followed by 7 doses at 3-month intervals beginning at Week 18. Patients will receive IV Cyclophosphamide 1 day prior to the first 3 vaccinations.
88884490|NCT02873819|Placebo Comparator|Placebo|Subjects in placebo arm will receive placebo to cyclophosphamide (normal saline solution) followed by Poly-ICLC/GM-CSF/placebo vaccine injections on the same schedule as the GL-0817 cohort.
88884491|NCT02866695|Other|Open label treatment|All patients will be treated with ingenol mebutate gel 0.015%. There is no placebo or comparator for this study. The investigator will identify the patient's treatment area at Baseline, and provide a detailed application instruction sheet. The first dose will be applied in clinic under the supervision of the investigator.
88884492|NCT02862964||identify L4-5|Level marked as L4-5 using Accuro and palpation
88884493|NCT02834793|Experimental|Perampanel up to 8 mg/day|"During the Randomization Phase, participants will receive perampanel at a starting dose of 2 milligrams per day (mg/day). Thereafter, the dose will be increased to a maximum target dose of 8 mg/day according to individual tolerability and efficacy for up to 18 weeks. Participants who enter into Extension A will continue to receive perampanel at the dose last received during randomization phase. Participants can be titrated up to 12 mg/day (at 2-week intervals) per the investigator's discretion.~Participants who continue in Extension B will continue to receive perampanel at the dose last received at the end of Extension A."
88884494|NCT02834793|Placebo Comparator|Matching placebo|"During the Randomization Phase, participants will receive matching placebo for up to 18 weeks.~During the Extension A, participants who received placebo during the Randomization Phase will begin treatment with perampanel in a blinded manner in double-blind Conversion Period, starting at 2 mg/day and then up-titrated to a maximum target dose of 8 mg/day according to individual tolerability and efficacy. After the Conversion Period, participants can be titrated up to 12 mg/day (at 2-week intervals) per the investigator's discretion."
88884495|NCT02810457|Experimental|FKB238 / paclitaxel / carboplatin|"Drug: FKB238:~15 mg/kg IV infusion on Day 1 of each 21-day cycle.~Drug: Paclitaxel:~200 mg/m2 IV infusion on Day 1 of each 21-day cycle for at least 4 and no more than 6 cycles.~Drug: Carboplatin:~Area Under Curve (AUC) = 6.0 IV infusion on Day 1 of each 21-day cycle for at least 4 and no more than 6 cycles."
88884496|NCT02810457|Active Comparator|Avastin / paclitaxel / carboplatin|"Drug: Avastin:~15 mg/kg IV infusion on Day 1 of each 21-day cycle.~Drug: Paclitaxel:~200 mg/m2 IV infusion on Day 1 of each 21-day cycle for at least 4 and no more than 6 cycles.~Drug: Carboplatin:~AUC = 6.0 IV infusion on Day 1 of each 21-day cycle for at least 4 and no more than 6 cycles."
88884497|NCT02797093||HIV suppressed individuals|HIV suppressed individuals on chronic ART, suboptimal adherence and exposure, measured through TFV-DP in DBS.
88884498|NCT02745535|Experimental|SOF/VEL/VOX|Fixed dose combination of SOF/VEL/VOX (Sofosbuvir 400mg/Velpatasvir 100mg/ Voxilaprevir 100mg) dosed once daily for 12 weeks.
88884499|NCT02730312|Experimental|XmAb14045|Biological/Vaccine: XmAb14045 Administered IV weekly up to 8 weeks
88884500|NCT02729701|Experimental|Duavee|Participants will be asked to take Duavee for 6 months while on the study.
88884501|NCT02723305||Testosterone Naive|Boys with Klinefelter syndrome age 12-17 who are Tanner 3, 4, or 5. No exogenous testosterone exposure in the past 5 years
88884502|NCT02723305||Testosterone exposed|"Boys with Klinefelter syndrome age 12-17 who are Tanner 3, 4, or 5.~+topical testosterone treatment for >1 year"
88884503|NCT02684253|Experimental|Nivolumab 3mg/kg IV every 2 weeks|Nivolumab 3mg/kg IV every 2 weeks
88884504|NCT02684253|Experimental|Stereotactic Body Radiotherapy & Nivolumab|"Image Guided, Stereotactic Body Radiotherapy (27 Gy over 3 fractions given every other day) to a single lesion to start by study day 14 (study day 1 is day of first dose of Nivolumab).~Nivolumab 3mg/kg IV starting day 1 and then every 2 weeks thereafter. Treatment with Nivolumab will continue until progression or unacceptable toxicity."
89536684|NCT03108755|Experimental|ASP7713 Multiple Ascending Dose (Adults: 18-55 years)|Successive cohorts of 16 participants consisting of 8 non-Japanese and 8 Japanese (12 ASP7713/ 4 Placebo /1-3 cohorts) will each be started on a fixed multiple dose of ASP7713 or matching Placebo twice or three times daily for 14 days. Safety, tolerability and available Pharmacokinetic data from proceeding cohorts will be assessed for dose escalation.
88884505|NCT02683356|Active Comparator|OCT-guided PCI|OCT before and after Stent implantation
88884506|NCT02683356|Active Comparator|Angiography-guided PCI|OCT after Stent implantation
88884507|NCT02681406|No Intervention|Treatment as Usual|Participants randomized to this condition will continue their schedules and treatments as they had been and just come in to see research staff for research visits.
88884508|NCT02681406|Experimental|Telephone Monitoring and Counseling|TMC - participants receive brief (20 minute) telephone counseling once weekly, then biweekly, etc for 12 months.
88884509|NCT02681406|Experimental|ACHESS|Participants are signed up for an addiction based smart phone application that connects them in an anonymous fashion to a social network of other people in the study who are also struggling with alcohol addiction and sober living.
88884510|NCT02681406|Experimental|TMC + ACHESS|Participants in this arm receive both interventions - the telephone counseling plus the ACHESS phone application.
88884511|NCT02666794|Active Comparator|Puncture epidural|Women in labor the epidural group will receive epidural bupivacaine with vasoconstrictor 0.125% 10 ml plus 20 micrograms sufentanil, followed by the placement of the epidural catheter
88884512|NCT02666794|Active Comparator|Puncture combined spinal-epidural|The mothers of the combined spinal-epidural analgesia group will receive intrathecal hyperbaric bupivacaine solution 0.5% 2.5 mg plus 5.0 micrograms of sufentanil and plus 60 micrograms of morphine, followed by placement of an epidural catheter to the catheter through technical needle
89191667|NCT00722540|Experimental|A|
88884513|NCT02656550|Experimental|Uterine Transplant|Women will undergo uterine transplantation after IVF. Donor uterus will be from either a living donor or cadaveric.
88884514|NCT02655055|Experimental|Intervention|high frequency voluntary apheresis blood donation (i.e. 20 - 26 donations in one year period)
88884515|NCT02655055|No Intervention|Control|no voluntary (or paid) apheresis blood donation (whole blood donation allowed during one year period)
88884516|NCT02625090|Experimental|UCB0942|"UCB0942 400 mg bid or a tapered UCB0942 dose of 200 mg bid.~The Investigator will be allowed to increase or decrease the dose of UCB0942 to optimize tolerability and seizure control for each subject. Increases or decreases to the dose of UCB0942 should be made in steps not exceeding 200 mg/day per week; an exception is Taper Week 1 where a step of 800 mg/day to 500 mg/day is allowed. A faster decrease of the dose than 200 mg/day per week is allowed when it is clinically appropriate in the Investigator's medical judgment. Daily UCB0942 doses during this study may be 100 mg (50 mg bid), 200 mg (100 mg bid), 400 mg (200 mg bid), 600 mg (300 mg bid), or 800 mg (400 mg bid); intermediate doses will not be allowed except for tapering and titration unless agreed by the UCB Study Physician or PRA Medical Monitor. The dose of UCB0942 must always be administered as bid morning and evening doses, approximately 12 hours apart."
88884517|NCT02619552||Anti-TNF (Remicade, Humira or Cimzia) for luminal CD|All participants are required to undergo study visits at baseline, 2 months, and 6 months in addition to any other routine visits. Sexual function, body image, disease activity, quality of life, and depression scores will be measured at baseline and at each study visit during the 6-month study.
88884518|NCT02619552||Anti-TNF (Remicade, Humira or Cimzia)for perianal CD|All participants are required to undergo study visits at baseline, 2 months, and 6 months in addition to any other routine visits. Sexual function, body image, disease activity, quality of life, and depression scores will be measured at baseline and at each study visit during the 6-month study.
89408937|NCT03649113|Experimental|sclerotherapy arm|Patients with symptomatic liver hemangioma undergoing sclerotherapy (percutaneous injection) with 45 units of Bleomycin once during the procedure
88884519|NCT02619552||Steroid (Prednisone or budesonide) for luminal CD|All participants are required to undergo study visits at baseline, 2 months, and 6 months in addition to any other routine visits. Sexual function, body image, disease activity, quality of life, and depression scores will be measured at baseline and at each study visit during the 6-month study.
88884520|NCT02612038|Experimental|Expiratory resistance|Generic expiratory resistance will be added to the patient's respiratory circuit
88884521|NCT02612038|Sham Comparator|Sham expiratory resistance|Sham resistance will be added to the patient's respiratory circuit
88884522|NCT02598492||Imputation of SF to PF|Patients required invasive mechanical ventilation within 6 hours after intubation
89408938|NCT05169541||Recurrent pregnancy loss after spontaneous conception|Minimum three consecutive losses from pregnancies achieved after spontaneous conception
88884523|NCT02573376|Other|Sofosbuvir/Ledipasvir with Directly Observed Therapy (DOT)|Participants randomized to vDOT will be provided a smart phone with cellular service and will be pre-programmed with the mobile phone-based video application and contact information for study personnel.
88884524|NCT02573376|Other|Sofosbuvir/Ledipasvir with Wirelessly Observed Therapy (WOT)|Participants on WOT will be provided the Wisepill portable medication dispenser.
88884525|NCT02566018||experimental intervention|A greater degree of initial displacement is tolerated to allow for conservative, non-operative treatment in more simple fracture patterns. Two-part fractures with marked displacement including two part patterns with a non-displaced greater or minor tuberosity fracture (formally three part fractures) are treated with a proximal humerus nail; and displaced three and four part fractures are primarily managed with a reverse total shoulder arthroplasty. Proximal Humeral Internal Locking System (PHILOS)-plates are only used exceptionally in this group of patients.
88884526|NCT02566018||control intervention|"Since May 2013 we have changed our treatment algorithm for the treatment of fractures of the humeral head in the elderly. Before this change in algorithm we used PHILOS plates extensively and rarely Inverse Shoulder prostheses.~In general all proximal humerus fractures were operated except minimally or undisplaced."
88884527|NCT02563691|Experimental|Stereotactic radiotherapy|Stereotactic radiotherapy will be delivered to the prostate (if not previously treated) and to all metastatic tumours.
88884528|NCT02556450|Experimental|Spironolacton Group|Spironolacton Sandoz given 25mg daily oral use
89536685|NCT03108755|Placebo Comparator|Placebo Multiple Ascending Dose (Adults: 18-55 years)|Successive cohorts of 16 participants consisting of 8 non-Japanese and 8 Japanese (12 ASP7713/ 4 Placebo /1-3 cohorts) will each be started on a fixed multiple dose of ASP7713 or matching Placebo twice or three times daily for 14 days. Safety, tolerability and available Pharmacokinetic data from proceeding cohorts will be assessed for dose escalation.
88884529|NCT02556450|No Intervention|Control group|Only background treatment
89004706|NCT00474994|Experimental|Group A|Vascular connective tissue neoplasms, leiomyosarcoma, dermatofibrosarcoma protuberans (DFSP), desmoid tumors. Sunitinib 37.5 mg daily continuously; one cycle is 28 days. Restaging: after every 2 cycles until after 6 cycles, when restaging will be decreased to once every 3 cycles.
89191668|NCT00722540|Experimental|B|
89191669|NCT00722540|Experimental|C|
89191670|NCT00722540|Experimental|D|
89191671|NCT00722540|Experimental|E|
89191672|NCT00861406|Experimental|Group 1|Pegylated Interferon alfa-2b (Once week x 4 weeks) + GP-100 Peptide
89191673|NCT00861406|Experimental|Group 2|Pegylated Interferon alfa-2b (Once week x 8 weeks) + GP-100 Peptide
89191674|NCT00861406|Experimental|Group 3|Pegylated Interferon alfa-2b (Once week x 12 weeks) + GP-100 Peptide
89191675|NCT00861484|Experimental|GSK958108 3 mg|Experimental
89191676|NCT00861484|Placebo Comparator|Placebo of GSK958108|Placebo
89408939|NCT05169541||Recurrent pregnancy loss after assisted reproductive treatment|Minimum three consecutive losses from pregnancies achieved after assisted reproductive treatment (ART), which includes in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), and frozen embryo transfer (FER).
89536686|NCT03108755|Experimental|ASP7713 Multiple Ascending Dose (Elderly: 65 years or older)|Dosing of the non-Japanese elderly cohort will commence after having established the safety and tolerability of corresponding dose in adults male and female participants.
89408940|NCT05169541||Recurrent implantation failure|Minimum three consecutive embryo transfers (ET) of good quality embryos with no hCG production. The patient must not have experienced any clinical pregnancies (i.e. evidence of pregnancy on an US or by histopathological examination) after IVF or spontaneous conception. Biochemical pregnancies after spontaneous conception, which terminated before evidence of a gestational sac on an ultrasonic scan (US) could be visualized and before the series of RIF occurred, are accepted.
89408941|NCT04734028||PTRG-DES registry|After DES implantation, CAD patients were treated with DAPT with clopidogrel and aspirin. During hospitalization, their platelet function, genotype and inflammation biomarker were evaluated.
89408942|NCT02135328|Experimental|Radio Story|Participants listen to a radio story about a family's' success with preventing or managing type 2 diabetes through diet and physical activity; the focus was for the entire family to implement healthful lifestyle behaviors so the children can learn as well.
89408943|NCT02135328|Active Comparator|Audio brochure|Participants received an audio version of a standard brochure about type 2 diabetes prevention and management.
89408944|NCT05285397|Experimental|Liraglutide|drug starts 6 weeks post-operative until 6 months SC injection dose starting 0.6 mg/day and weekly up titrated until 3.0 mg/day
89408945|NCT05285397|No Intervention|Control|Patients with no weight loss drug intervention after bariatric surgery
89408946|NCT05579496||Infants Hospitalized in the NICU|Infants born between 28 0/7 weeks 32 6/7 weeks gestational age, who are within 6 weeks postnatal age, and their caregiver and/or health professional will be recruited for qualitative interview.
89191677|NCT04018742||Patients with an abscess|Patient diagnosed with a cerebral abscess at admission; and to benefit from an abscess puncture as part of routine care.
89408947|NCT05302882|Experimental|Experimental Group|Myofascial release was applied to the experimental group
89408948|NCT05302882|Active Comparator|Control Group|Classical massage was applied to the control group
89408949|NCT03526640|Experimental|Plug Arm|Participants randomized for plug arm will be treated with a plug after CT guided is conducted.
89408950|NCT03526640|No Intervention|Non Plug arm|No Intervention, i.a. CT guided biopsy without plug.
89408951|NCT03050359|Experimental|TAK-438 20 mg|H. pylori negative (HP -) participants: TAK-438 20 mg, tablets, orally, once daily (QD) and lansoprazole placebo-matching capsules, orally, QD for up to 6 weeks. H. pylori positive (HP +) participants: TAK-438 20 mg, tablets, orally, twice daily (BID) and lansoprazole placebo-matching capsules, orally, BID for first 2 weeks along with Bismuth-Containing Quadruple Therapy followed byTAK-438 20 mg, tablets, orally, QD and lansoprazole placebo-matching capsules, orally, QD for up to 4 weeks.
89408952|NCT03050359|Experimental|Lansoprazole 30 mg|H. pylori negative (HP -) participants: lansoprazole 30 mg, capsules, orally, QD and TAK-438 placebo-matching tablets, orally, QD for up to 6 weeks. HP + participants: lansoprazole 30 mg, capsules, orally, BID and TAK-438 placebo-matching tablets, orally, BID for first 2 weeks along with Bismuth-Containing Quadruple Therapy followed by lansoprazole 30 mg, capsules, orally, QD and TAK-438 placebo-matching tablets, orally, BID for up to 4 weeks.
89408953|NCT03648957|Experimental|Behavioral intervention|Usual stroke service care plus additional lifestyle counselling focusing on smoking cessation, physical activity, and adherence to preventive medication. Regular follow-up sessions (3-4 weeks intervals). Physical activity is monitors by an activity tracker.
89408954|NCT03648957|Active Comparator|Usual care|Usual stroke service care; including computed tomography brain scan, neurological evaluation, and relevant cardiological/vascular evaluation (48-72 hour telemetry, echocardiography, carotic ultrasound imaging). At discharge all patients will receive written and verbal encouragement to a healthy lifestyle.
89408955|NCT05302726|Active Comparator|Oral estrogen|oral estrogen (2 mg/24 hours)
89408956|NCT05302726|Active Comparator|Transdermal estrogen|Transdermal estrogen (100ug/24 hours)
89408957|NCT05302726|No Intervention|No treatment|Estrogen pause
89408958|NCT03648801||Hypertention, Dyslipidemia|NA (Observation study)
89408959|NCT04721236|Experimental|Single|hyperimmune plasma with titre 1:80 or more
89408960|NCT02135406|Experimental|Multiple Myeloma Patients|Adult subjects (18 years or older) with multiple myeloma and with poor prognosis by virtue of having relapsed/progressive disease within one year of first autologous stem cell transplantation.
89408961|NCT03648411||Shwegyin|Shwehyin is a Township in Bago Region. We will use the comparison between the two sentinel sites by the name of Shwegyin and Pinlebu. We will compare the prevalence of asymptomatic infection between these two sites. Then proportion of the drug resistance molecular markers will be compared.
89408962|NCT03648411||Pinlebu|Pinlebu is a township in Sagaing Region. We will use the comparison between the two sentinel sites by the name of Shwegyin and Pinlebu. We will compare the prevalence of asymptomatic infection between these two sites. Then proportion of the drug resistance molecular markers will be compared.
89408963|NCT04549402|Experimental|Mirror Therapy group|The intervention will consist of the visualization of movement through the Mirror Therapy VR® application, broadcast on a mobile device and visualized with virtual reality glasses. The knee extension and ankle dorsiflexion movements (quadriceps and sural triceps), together with the elbow flexion (elbow flexors) will be the movements to be performed, based on their functional need (walking and feeding, respectively).
89408964|NCT04549402|Active Comparator|Video group|The intervention will consist of the visualization of movement through the reproduction of an immersive 360º video broadcast on a mobile device and viewed with virtual reality glasses. Knee extension and ankle dorsiflexion movements (quadriceps and sural triceps), together with elbow flexion (elbow flexors) will be the movements to be performed, based on their functional need (ambulation and feeding, respectively).
89408965|NCT04549402|No Intervention|Control group|Patients included in the control group will not receive any physiotherapy intervention. They will continue with their routine prior to the beginning of the study.
89408966|NCT02298686||Observation|Patients with Sanfilippo Type A-B-C-D disease or high-grade suspicion for Sanfilippo Type A-B-C-D disease
89191678|NCT00865384|Experimental|A|Mirtazapine 15 mg tablets, single dose
89191679|NCT00865384|Active Comparator|B|REMERON® 15 mg tablets, single dose
89191680|NCT00724724|Experimental|1|Butylphthalide Soft Capsules + Aspirin
89191681|NCT00724724|Active Comparator|2|Aspirin
89191682|NCT00865462|Experimental|A|Abrika Bupropion 150 mg XL Tablet, single dose
89004707|NCT00474994|Experimental|Group B|High grade undifferentiated pleomorphic sarcoma (includes the older designation malignant fibrous histiocytoma [MFH]) and other non-GIST connective tissue tumors; may include carcinosarcomas.Sunitinib 37.5 mg daily continuously; one cycle is 28 days. Restaging: after every 2 cycles until after 6 cycles, when restaging will be decreased to once every 3 cycles.
89004708|NCT00474994|Experimental|Group C|Chordomas. Sunitinib 37.5 mg daily continuously; one cycle is 28 days. Restaging: after every 2 cycles until after 6 cycles, when restaging will be decreased to once every 3 cycles.
89004709|NCT00192140|Active Comparator|1|FluMist
89004710|NCT00474955|Experimental|Peginterferon Alpha-2a|Eligible participants will be administered peginterferon alpha-2a [Pegasys] (40 kilo Dalton), 180 micrograms as a subcutaneous injection, once in a week, for 48 weeks. Participants with a calculated glomerular filtration rate of <15 milliliter /minute will be administered a reduced dose of 135 mcg as a subcutaneous injection, once in a week, for 48 weeks.
89004711|NCT00124046|Active Comparator|Surgical|
89004712|NCT00124046|Active Comparator|Medical Treatment|
89004713|NCT00215046|Experimental|Drug|no randomization, all patients receive experimental drugs
89004714|NCT00192179|Experimental|CAIV-T|The total volume of 0.2 ml was administered intranasally with a spray applicator (approximately 0.1 mL into each nostril).
89004715|NCT00192179|Placebo Comparator|Placebo|The total volume of 0.2 ml was administered intranasally with a spray applicator (approximately 0.1 mL into each nostril).
89004716|NCT00474487|Experimental|Novartis MenACWY Vaccine (19 to 55 Years)|Novartis meningococcal ACWY conjugate vaccine administered to subjects 19 years to 55 years
89004717|NCT00474487|Active Comparator|Licensed polysaccharide vaccine|Licensed meningococcal ACWY polysaccharide vaccine
89004718|NCT00474487|Active Comparator|Licensed Conjugate Vaccine|Licensed meningococcal ACWY polysaccharide-protein conjugate vaccine
89004719|NCT00474487|Experimental|Novartis MenACWY Vaccine (56 to 65 Years)|Novartis meningococcal ACWY conjugate vaccine administered to subjects 56 years to 65 years
89004720|NCT00124124|Experimental|1|KLH and peptide pulsed DCs
89004721|NCT00124124|Experimental|2|KLH, peptides plus Montanide
89004722|NCT00474253|Experimental|Rocuronium + Sugammadex|Participants were to receive a single bolus dose of 1.2 mg/kg rocuronium. Three minutes after the start of the rocuronium administration, they were to receive a single bolus dose of 16.0 mg/kg sugammadex.
89004723|NCT00474253|Active Comparator|Succinylcholine|Participants were to receive a single bolus dose of 1.0 mg/kg succinylcholine and allowed to recovery spontaneously from neuromuscular blockade.
89004724|NCT00474058|Experimental|Rotigotine|Rotigotine transdermal patch
89004725|NCT00474058|Placebo Comparator|Placebo|Placebo transdermal patch
89004726|NCT00192218|Experimental|1|FluMist
89004727|NCT02277574|Experimental|Crossover Group 1|Subjects assigned to this arm will receive 1 of 3 escalating doses of AMP-110 once a week for 4 weeks followed by 4 weekly doses of placebo
89004728|NCT02277574|Experimental|Crossover Group 2|Subjects assigned to this arm will receive 4 weekly doses of placebo followed by 1 of 3 escalating doses of AMP-110 once a week for 4 week
89004729|NCT02277613|Experimental|AMI MultiStem cells|AMI MultiStem cells is a cell therapy medicinal product originating from adherent stem cells taken from the bone marrow of a non-related donor and expanded ex vivo.
89004730|NCT02277613|Sham Comparator|Sham|Sham procedure using Micro-Infusion Catheter in coronary artery without injection.
89004731|NCT02277652|Experimental|Scenario 1: Uninterrupted chest compressions|Endotracheal intubation (ETI) during pediatric manikin with uninterrupted chest compressions. Chest compression was performed using LUCAS-2 (Physio-Control, USA).
89004732|NCT02277652|Experimental|Scenario 2: Neutral position|ETI performed in neutral mannikin head position
89408967|NCT02253264|Experimental|Intrathecal rituximab|25 mg of rituximab will be administered intrathecally by direct infusion over 10 minutes at two time points, two weeks apart.
89004733|NCT02277652|Experimental|Scenario 3: Sniffing position|ETI performed in sniffing mannikin head position
89004734|NCT02277652|Experimental|Scenario 4: Pharyngeal swelling|ETI performed during mannikin pharyngeal swelling scenario
89004735|NCT02277652|Experimental|Scenario 5: Swollen tongue|ETI performed during mannikin swollen tongue scenario
89004736|NCT02277652|Experimental|Scenario 6: Immobilized cervical spine|ETI performed during mannikin immobilized cervical spine scenario
89191683|NCT00865462|Active Comparator|B|Wellbutrin XL® 150 mg Tablet, single dose
89408968|NCT03648333|Experimental|Lodivixx tab. 5/160mg|S-amlodipine nicotinate (5mg as S-amlodipine), valsartan 160mg
89004737|NCT02277730|Experimental|vasopressor delivery automated system|vasopressor delivery automated system administering phenylephrine and ephedrine using a 2 step algorithm vasopressor delivery technique
89004738|NCT02277730|Active Comparator|manual vasopressor delivery|manual bolus delivering phenylephrine and ephedrine using a 2 step algorithm vasopressor delivery technique
89004739|NCT00124202|Placebo Comparator|a fatty meal vs normal saline|Approximately one hour before ERCP procedure, patient will have a fatty meal in the study group and normal saline in control group
89004740|NCT04571437|Active Comparator|Chemo endocrine treatment (A)|Letrozole 2.5mg PO daily + Capecitabine 500mg/m2 bid PO continously
89004741|NCT04571437|Active Comparator|Endocrine treatment only (B)|Letrozole 2.5mg PO daily
89004742|NCT00473824|Experimental|Civacir Treated|Hepatitis C Immune Globulin Intravenous (Human) 5% [Civacir], 18 infusions total, per schedule, of Civacir 300 or 400 mg/kg of body weight, with standard post-transplant site specific routine immunosuppressant therapy .
89004743|NCT00473824|No Intervention|Observational Control|Observation on standard post-transplant site specific routine immunosuppressant therapy without infusions of Hepatitis C Immune Globulin Intravenous (Human) 5% [Civacir].
89004744|NCT00192335|Active Comparator|1|CAIVT-The total volume of 0.2 mL will be administered intranasally with a spray applicator (approximately 0.1 mL into each nostril).
89004745|NCT00192335|Active Comparator|2|FluMist- The total volume of 0.5 mL will be administered intranasally with a spray applicator (approximately 0.25 mL into each nostril).
89004746|NCT00124280|Experimental|previously treated with chemotherapy only|patients previously treated with chemotherapy only (at most 2 prior regimens one of which must have been platinum-based) and no EGFRI
89408969|NCT03648333|Active Comparator|Exforge tab. 10/160mg|amlodipine besylate (10mg as amlodipine), valsartan 160mg
89408970|NCT03626779|Other|immediate placment and loading with prf|Immediat placment and loading with prf
89408971|NCT03626779|No Intervention|immediate implant placment and loading|Immediate implant placment and loading without prf
89408972|NCT02252796|Experimental|Sub-group 1|HySBst to be delivered during week 1 with Chemo-radiation to be delivered weeks 2-7
89408973|NCT02252796|Experimental|Sub-group 2|Chemo-radiation to be delivered weeks 1-6 and HySBst to be delivered week 7
89408974|NCT05285007|Experimental|Primary Intervention Group|The experimental group will receive two interventions to increase dorsiflexion range of motion.
89408975|NCT05285007|Active Comparator|Minimal Intervention Group|The minimal intervention group will read and infographic and complete 5 minutes of treadmill walking.
89408976|NCT03524690|Active Comparator|SUSOPS Balance|Volunteers provided sufficient food to maintain energy balance.
89408977|NCT03524690|Experimental|SUSOPS Negative Balance|Volunteers provided insufficient food to maintain energy balance resulting in negative energy balance.
89408978|NCT04721197|Experimental|Intervention|30-day egg vouchers, in addition to the standard of care.
89408979|NCT04721197|Active Comparator|Control group|Standard of care.
89408980|NCT03648177|Active Comparator|Treatment as Usual|"Active Comparator: (n=15) Treatment as Usual~The treatment as usual or control group refers to the standard of care that patients receive for their chronic pain which allows patients to discuss chronic pain with their providers at their discretion. Although highly variable, providers can recommend and prescribe pharmacologic, non-pharmacologic approaches for pain. This study will not interfere in any way with usual care. No additional treatment will be provided to participants allocated to the control group."
89408981|NCT03648177|Experimental|IPGT|"Experimental: IPGT (n=15) Integrated Psychosocial Group Treatment~IPGT consists of 6 weekly group sessions of motivational interviewing and behavioral change, self-management, and pain education focused on appropriate adherence to treatment and resisting urges to misuse prescription medications. The intervention also entails an education session on knowledge pertaining to overdose education and naloxone distribution. Topics covered in IPGT include: Pacing and goal setting, negative thinking, coping with stress and anxiety, sleep enhancement techniques, managing set-backs, and chronic pain and your life."
89408982|NCT02785770|Experimental|PF-04447943 low dose|25 mg of PF-04447943
89408983|NCT02785770|Experimental|PF-04447943 high dose|100 mg of PF-04447943
89408984|NCT02785770|Placebo Comparator|Placebo|Matching placebo for PF-04447943
89408985|NCT02785770|Active Comparator|Moxifloxacin|400 mg of moxifloxacin
89408986|NCT03650595|Experimental|Single arm prospective clinical trial|This is a single arm study where patients with low-intermediate risk MR visible locally confined prostate cancer will be treated with focal laser ablation under MRI guidance in the magnet. Following treatment, the patients will be assessed by MRI and Biopsy at 6 months and at 2 years, with PSA assessment at regular intervals during the time
89408987|NCT05302648|Experimental|Human Derived anti-BCMA CAR-T Injection|Single administration：1.0×10^6 CAR+T, 3.0×10^6 CAR+T, 6.0×10^6 CAR+T
89408988|NCT03648099|Experimental|Labor Dance and music groups|"Labor Dance; The pregnant women performed labor dance when the cervical dilatation reached 4-5 cm. The dance was performed in the company of music played through headphones.~The pregnant women listened to music for 30 minutes when the cervical dilatation reached 4-5 cm. They took any position they wanted while listening to music."
89408989|NCT03648099|No Intervention|Control group|The control group: No intervention was made to relieve the labor pain and reduce the fear of childbirth in the control group of the study. They were administered routine hospital applications.
89408990|NCT05302258||Obesity|BMI of 95 th percentile or more
89408991|NCT05302258||Normal weight|BMI of 85 th percentile or less
89408992|NCT04522492|Experimental|internet CBT|Internet delivered cognitive behavioral therapy, thru 2 booster sessions. Each session will last 50 minutes. Fist session will involve: psychoeducation about the symptoms, evaluation of the skin picking habit, reinforcement of the habit reversal strategies. After 1 week, the second session will be applied, consisting of: strategies to cope with anxiety (breathing and muscle relaxation techniques) and to cope with depressive status (cognitive restructuring techniques).
88884530|NCT02539225|Experimental|S-1/Oxaliplatin + Ramucirumab|"(Part A) Ramucirumab intravenously (IV) on day 1 and day 8 along with S-1 by mouth (PO) on days 1-14 and oxaliplatin IV on day 1 of each 21 day cycle. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met then move to Part B.~(Part B) Ramucirumab IV on day 1 and day 15 along with paclitaxel IV on day 1, 8, and 15 of each 28 day cycle. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met."
89004747|NCT00124280|Experimental|previously treated with chemotherapy + small|patients previously treated with chemotherapy (at most 2 prior regimens one of which must have been platinum-based) and with one small molecule EGFRI
89004748|NCT04727294||MGUS, SMM, MM Patients or their Caregivers|"Eligible participants will be asked to create a free patient profile on the HealthTree Cure Hub (www.healthtree.org) or use their existing patient profile.~The creation of a HealthTree Cure Hub patient profile will serve as a screen for eligibility.~Patients will complete a one-time questionnaire found on the HealthTree Cure Hub. Telephone assistance can be provided as needed. The questionnaire will take 20-30 minutes to complete."
89004749|NCT00215319|Experimental|TSM Cage|Lumbar I/F with cage and pedicle screws
89408993|NCT04522492|Active Comparator|Quality of life promotion|The therapist will send to the patient 2 videos with strategies to improve quality of life during the pandemia (1 video about social support and one video about sleep hygiene). After 1 week, the therapist will send to the patient another 2 videos with strategies do improve quality of life (dietary guidance and guidance on physical activity)
89408994|NCT05284929||Patients with pemphigus|
89408995|NCT05284929||Healthy controls|
89408996|NCT04660123|Experimental|Quadruple therapy with colloidal bismuth pectin granules|colloidal bismuth pectin granules 150 mg, Selection of 2 antibiotics and 1 proton pump inhibitor based on China's fifth national consensus report on the management of H. pylori infection.All medication is taken orally, twice a day.
89408997|NCT03526406|Experimental|CP9700|400 mg CP9700 along with modified cellulose (MCC), magnesium stearate, silica (sillicon dioxide), Gelatin, FD&C Red No. 40, titanium dioxide, sodium lauryl sulfate, glycerin, brilliant blue FCF consumed with breakfast in a 1 capsule per day regimen.
89408998|NCT03526406|Placebo Comparator|Matched Placebo|Maltodextrin along with modified cellulose (MCC), magnesium stearate, silica (sillicon dioxide), Gelatin, FD&C Red No. 40, titanium dioxide, sodium lauryl sulfate, glycerin, brilliant blue FCF consumed with breakfast in a 1 capsule per day regimen.
88884531|NCT02539225|Active Comparator|S-1/Oxaliplatin + Placebo|"(Part A) Placebo IV on day 1 and day 8 along with S-1 PO on days 1-14 and oxaliplatin IV on day 1 of each 21 day cycle. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met then move to Part B.~(Part B) Ramucirumab IV on day 1 and day 15 along with paclitaxel IV on day 1, 8, and 15 of each 28 day cycle. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met."
88884532|NCT02535650|Experimental|tipifarnib|Tipifarnib will be administered at a starting dose of 900 mg, po, bid on days 1-7 and 15-21 of 28-day treatment cycles.
88884533|NCT02526017|Experimental|Phase 1a Monotherapy Dose Escalation|Cabiralizumab administered at 2 mg/kg every 2 weeks (Q2W), 4 mg/kg Q2W and 6 mg/kg Q2W in participants with any solid tumor.
88884534|NCT02526017|Experimental|Phase 1a Combination Therapy Dose Escalation|Nivolumab 3 mg/kg Q2W + cabiralizumab at the following doses: 1 mg/kg, 2 mg/kg, 4 mg/kg, and 6 mg/kg Q2W. Also nivolumab 3 mg/kg + cabiralizumab 4 mg/kg every 3 weeks (Q3W). Participants with any solid tumor.
88884535|NCT02526017|Experimental|Phase 1b Combination Therapy Dose Expansion|The expansion phase would use the recommended dose determined in Phase 1a: cabiralizumab 4 mg/kg + nivolumab 3 mg/kg Q2W. Participants are enrolled for the following advanced cancer types: non-small cell lung cancer (anti-programmed cell death 1 [PD1] targeted drug naïve), non-small cell lung cancer (prior treatment with anti-PD-1), pancreatic cancer, ovarian cancer, renal cell cancer, glioblastoma, and melanoma.
88884536|NCT02516657|Experimental|Liraglutide 0.6 mg|Liraglutide 0.6 mg daily injection x 7 days
88884537|NCT02479919|Experimental|TBS-MPC|Intervention with Magstim® Active TBS aiming Medial Prefrontal Cortex in 18 patients with schizophrenia
88884538|NCT02479919|Active Comparator|TBS-CPDLF|Intervention with Magstim® Active TBS aiming Dorsolateral Prefrontal Cortex in 18 patients with schizophrenia
88884539|NCT02479919|Sham Comparator|TBS-Sham|Intervention with Magstim® Sham TBS in 25 patients with schizophrenia
88884540|NCT02459067|Experimental|ImmuniCell®|Subjects will receive 6 cycles of ImmuniCell®, one infusion over an hour, at two-week intervals. During Stage 1, intra-patient dose escalation to achieve a total dose of 30 x 109 γδ T cells.
88884541|NCT02427581|Experimental|Arm 1 - personlized synthetic long peptide vaccine|"Each subject will receive a single synthetic long peptide vaccine on Days 1, 4, 8, 15, 22, 50, and 78.~The first five injections must take place within +/- 1 day window and the remaining injections must take place within a +/- 2 week window.~The synthetic long vaccine is reconstituted in up to four pools (A, B, C, and D). At each vaccination time point, each of the up to four pools will be administered to one of the four limbs (A - Right Arm, B - Left Arm, C - Right Leg, and D - Left Leg) by subcutaneous (SC) injection. Alternative anatomical locations for patients who are status post complete axillary or inguinal lymph node dissection or other contraindications that prevent injections to a particular extremity are the left and right midriff, respectively. The same pool should be administered to the same limb across doses."
88884542|NCT02423525|Experimental|Afatinib|Afatinib tablets are taken by mouth. Dose Level 1: 80 mg every 4 days Dose Level 2: 120 mg every 4 days Dose Level 3: 180 mg every 4 days Dose Level 4: 280 mg every 7 days
88884543|NCT02417415|Experimental|Local Heat Stress|Passive heat-stress using a commercial heating pad applied over the abdomen and part of the torso
88884544|NCT02417415|Sham Comparator|Control (Non-heating)|Commercial heating pad applied over the abdomen and part of the torso but turned off
88884545|NCT02369653|Experimental|Apixaban|"Children aged 1 to <18 years weighing 6 to <35 kg randomized to apixaban will receive a fixed dose apixaban based on body weight tier twice a day for approximately 28 days.~Children aged 1 to <18 years weighing ≥ 35 kg will receive 2.5 mg of apixaban twice a day for approximately 28 days. Subjects ≥ 5 years may be administered either 2.5-mg, 0.5-mg tablets or oral solution apixaban. Subjects < 5years and < 35 kg may be administered 0.5-mg tablets only"
88884546|NCT02369653|Placebo Comparator|No systemic anticoagulant prophylaxis|No systemic anticoagulant prophylaxis
88884547|NCT02356861|Active Comparator|Real, Active LED Treatment Series|These participants will first receive a series of 12, sham LED treatments, At 1 week post completion of the Sham LED treatment series, participants in this group receive a series of 12 real LED treatments from the helmet housing LEDs that deliver photons of light in the infrared range.
88884548|NCT02356861|Sham Comparator|Sham LED Treatment Series|These participants will first receive an initial series of 12 sham LED treatments from the helmet containing the sham LEDs.
88884549|NCT02353221||Subjects|Entry criteria include being at least 18 years old at screening visit, being able to understand the information given to them and to give written informed consent, willingness to comply with the requirements of the data collection, absence of a diagnose of autoimmune disease or inflammatory arthritis, and absence of a previous treatment with any disease modifying anti-rheumatic drug (DMARD). We will exclude patients that are pregnant or intend to become pregnant during the time of follow up.
88884550|NCT02353221||Controls|Healthy control subjects will be recruited based on similar criteria as study subjects. Our effort will be to include age and gender matched control subjects in the registry. We will be also aiming to match environmental characteristics (i.e. partners living in same location as registry subject or in a radius of 10 miles for at least one year previous to the date of evaluation) or genetic background (i.e. by asking the participation of first-degree relatives)
89408999|NCT02965833|Other|CCP, then HMPS|3% hydrogen peroxide solution with HydraGlyde® Moisture Matrix contact lens solution in Period 1, followed by subject's habitual multi-purpose contact lens solution (HMPS) in Period 2. Each product used daily per packaging instructions with subject's habitual contact lenses for approximately 30 cleaning and disinfection cycles.
89409000|NCT02965833|Other|HMPS, then CCP|Subject's habitual multi-purpose contact lens solution in Period 1, followed by 3% hydrogen peroxide solution with HydraGlyde® Moisture Matrix contact lens solution in Period 2. Each product used daily per packaging instructions with subject's habitual contact lenses for approximately 30 cleaning and disinfection cycles.
89004750|NCT00192413|Experimental|Cold-adapted influenza vaccine trivalent (CAIV-T)|A single 0.2 mL dose of 10^7 fluorescent focus units was administered intranasally.
89409001|NCT04647019|Experimental|Blueberry powder|
89409002|NCT04647019|Experimental|Placebo powder|
89409003|NCT05302024|Experimental|Iguratimod treatment|Iguratimod is given at a dose of 25 mg bid for 12 weeks.
89409004|NCT04252339|Experimental|RLY-1971 - Dose Escalation/Expansion|"Dose Escalation: Oral dose of RLY-1971 until Maximum Tolerated Dose (MTD), and Recommended Phase 2 dose (RP2D) are identified~Dose Expansion: Oral dose of RLY-1971 once Maximum Tolerated Dose (MTD), and Recommended Phase 2 Dose (RP2D) are identified."
89409005|NCT04467944||NS Group|Patients without pre-existing degeneration at L3/4 segment will be classified into control group (NS group).
89409006|NCT04467944||D Group|Patients with pre-existing disc factors (Pfirrmann grade≥3, Hiz or vacuum sign) at L3/4 segment will be classified into group D.
89409007|NCT04467944||C Group|Patients with pre-existing canal stenosis factors (cerebrospinal fluid occlusion≥1) at L3/4 segment will be classified into group C.
89409008|NCT03647631||Patients affected to porocarcinoma|
89409009|NCT03647631||patients affected to porocarcinoma in our centre|
89409010|NCT03900442|Experimental|PTX-100|IV infusion over 60 minutes on days 1 to 5 of a 14-day cycle for 4 cycles
89409011|NCT03648723||Diabetic nephropathy|Diabetic nephropathy is defined by macroalbuminuria that is, a urinary albumin excretion of more than 300 mg in a 24-hour collection or macroalbuminuria and abnormal renal function as represented by an abnormality in serum creatinine, or glomerular filtration rate(GFR)
89409012|NCT03648723||Non-diabetic nephropathy|This group consisted of diagnosis with nephropathy without diabetes mellitus.
89409013|NCT05579418|Active Comparator|Interventional Arm|Patient that qualify for the trial will be randomized for receiving the PCSK9i injection in addition to the standard medical therapy.
89409014|NCT05579418|No Intervention|Control Arm|Patient will only receive the standard medical therapy, No PCSK9i
89409015|NCT05301868|Experimental|Multidomain intervention|The participants in the intervention arm will receive all five components of the intervention: (1) monitoring and management of metabolic and vascular risk factors; (2) cognitive training; (3) physical exercise; (4) nutritional guidance; and (5) motivational training via none-face-to-face tablet PC application (app).
89409016|NCT02968173|Experimental|Children at High Risk of severe RSV Infection|A single IM injection every 30 days beginning at Day 0 for a total of 3-5 injections determined by when in the RSV season a participant was enrolled.
89409017|NCT02785458|No Intervention|Usual Care|Subjects will receive the current standard of care.
89409018|NCT02785458|Experimental|EMC2 Strategy|Subjects will receive the EMC2 Strategy. See description of strategy below.
89409019|NCT02140320|Experimental|Single dose (healthy volunteers)|
89409020|NCT02140320|Experimental|14 day repeat dose (healthy volunteers)|
89409021|NCT02140320|Experimental|14 day repeat dose (asthma patients)|
89409022|NCT02140320|Experimental|28 day repeat dose (healthy volunteers)|
89409023|NCT04867694|No Intervention|Control|The control group receiving the standards of care and the usual activities of the partners without additional support from the IRAM project for the implementation of the PASIM. This includes the usual Community Management of Acute Malnutrition (CMAM) program. This group will also continue to benefit from the BCC and screening services already existing in their areas.
89409024|NCT04867694|Experimental|Intervention|"The PASIM is delivered by the care groups. Each beneficiary is visited at home at least once a month (up to once a week if possible).~The package of activities includes :~Behavior change communication (all children in care groups)~Monthly delivery of a nutritional supplement: limited to [6-11] months old children diagnosed as non-wasted (green MUAC) or for [6-59] months old for 6 months after discharge from the national CMAM program.~Monthly delivery of a water purification input: limited to households with [6-11] months old children or with [6-59] months old children under CMAM treatment and for 6 months after discharge.~Delivery of micronutrient powders to [12-23] months old children.~Screening and referral for [6-59] months old children, formative supervision of MUAC measurement in families."
89409025|NCT04329598|Experimental|Whole-Body Electromyostimulation Group|Whole-Body Electromyostimulation group includes exercises with electric stimulation. Whole-Body Electromyostimulation group will have 45 minutes of exercises which are specific exercises for Lumbar Disc Herniation.
89409026|NCT04329598|Experimental|Exercise Group|Exercise group includes exercises without electric stimulation. Exercise group will have 45 minutes of exercises which are specific exercises for Lumbar Disc Herniation.
89409027|NCT02135562|Experimental|Supportive Care (PSMF)|Participants will take part in a Protein-Sparing Modified Fast (PSMF) Intervention for weight loss. Participants will undergo a dietary intervention high in protein for 6 weeks or until they have loss 15% of their body weight. This intervention will be followed by weight maintenance in which participants reintroduce non-starchy vegetables to their diet. At this time participants will also receive informational material and dietary education which teaches participants how to read nutrition labels and calculate carbohydrate loads in foods. Participants are given the Obesity and Weight-Loss Quality of Life Questionnaire to survey the impact of the intervention
89409028|NCT04854746|Active Comparator|Cohort 1 Low Dose Active|VXA-GI.1-NN tableted vaccine group, 2 doses (Day 1 and Day 29) at 1x10Log10
89409029|NCT04854746|Active Comparator|Cohort 3 High Dose Active|VXA-GI.1 tableted vaccine group, 2 doses (Day 1 and Day 29) at 1x10Log11
89409030|NCT04854746|Placebo Comparator|Cohort 1 Low Dose Placebo|Placebo tablets matching in number and appearance to active vaccine doses.
89004751|NCT00192413|Active Comparator|Trivalent Inactivated Vaccine (TIV)|A single dose was administered by intramuscular injection.
89004752|NCT00192491|Active Comparator|2|FluMist
89004753|NCT00192491|Placebo Comparator|3|Placebo
89004754|NCT00192491|Active Comparator|1|FluMist with other solution
89409031|NCT04854746|Placebo Comparator|Cohort 3 High Dose Placebo|Placebo tablets matching in number and appearance to active vaccine doses.
89004755|NCT00222066|Experimental|1|Fetal ovarian cyst aspiration performed as soon as possible
89004756|NCT00222066|No Intervention|2|Expectative
89004757|NCT00192569|Experimental|Treated|Subjects will be treated for 24 weeks with PEG-IFN (HIV coinfected subjects will received RBV)
89409032|NCT04854746|Active Comparator|Cohort 2 Medium Dose Active|VXA-GI.1 tableted vaccine group, 2 doses (Day 1 and Day 29) at 3x10Log10
89409033|NCT04854746|Placebo Comparator|Cohort 2 Medium Dose Placebo|Placebo tablets matching in number and appearance to active vaccine doses.
89409034|NCT03647865|Experimental|Patients need genioplasty|
89409035|NCT05118841|Experimental|ZX-4081 Dose Level 1|Starting dose (SD) of ZX-4081 administered orally twice daily (BID) in a 28-day cycle
89409036|NCT05118841|Experimental|ZX-4081 Dose Level 2|2-times the SD of ZX-4081 administered orally BID in a 28-day cycle
89409037|NCT05118841|Experimental|ZX-4081 Dose Level 3|4-times the SD of ZX-4081 administered orally BID in a 28-day cycle
89409038|NCT05118841|Experimental|ZX-4081 Dose Level 4|6-times the SD of ZX-4081 administered orally BID in a 28-day cycle
89409039|NCT05118841|Experimental|ZX-4081 Dose Level 5|8-times the SD of ZX-4081 administered orally BID in a 28-day cycle
89409040|NCT05118841|Experimental|ZX-4081 Dose Level 6|10-times the SD of ZX-4081 administered orally BID in a 28-day cycle
89409041|NCT05118841|Experimental|ZX-4081 Expansion Dose Level|Recommended Phase 2 Dose (RP2D) (to be determined) of ZX-4081 administered orally BID in a 28-day cycle
89409042|NCT04255342|Active Comparator|Group 1|Group 1: 3 months post-ARP-SG and dental implant placement using Azento® with an Astra Tech Implant® EV implant and immediate implant provisionalization using Azento®. At 3 months post-DIP&P, a definitive all-ceramic crown, fabricated using a digital workflow (CoreFile), will be placed
89409043|NCT04255342|Active Comparator|Group 2|Group 2: at 6 months post-ARP-SG and dental implant placement using Azento® with an Astra Tech Implant® EV implant and immediate implant provisionalization using Azento®. At 3 months post-DIP&P, a definitive all-ceramic crown, fabricated using a digital workflow (CoreFile), will be placed.
89409044|NCT04255342|Active Comparator|Group 3|Group 3: 9 months post-ARP-SG and dental implant placement using Azento® with an Astra Tech Implant® EV implant and immediate implant provisionalization using Azento®. At 3 months post-DIP&P, a definitive all-ceramic crown, fabricated using a digital workflow (CoreFile), will be placed
88884551|NCT02333708||GCA group|
88884552|NCT02333708||Inflammatory syndrome (without GCA) group|
89409045|NCT03646929|Other|healthy individuals and patients with multiple sclerosis|MEP in healthy individuals and patients with multiple sclerosis are measured using standard facilitation technique
89409046|NCT03646929|Other|patients with multiple sclerosis|MEP in patients with multiple sclerosis are measured using modified facilitation technique
89409047|NCT04052919|Experimental|Cardiac dysfunction in adolescents with type 1 diabetes|"to identify specific parameters related to glucoregulation which correlate with cardiac function and structure in adolescent with T1DM.~In T1DM, exercise training to have beneficial effects on HbA1c levels, cardiovascular risk profile.~To evaluate the association between cardiac function/structure and cardiopulmonary exercise capacity in adolescent T1DM patients (in the perspective of their physical activity behavior). This study thus may provide greater insights in the etiology and consequences of a disturbed cardiac function/structure in adolescents with T1DM."
89409048|NCT02135640|Experimental|denosumab 60 mg|solution
89409049|NCT02135640|Experimental|denosumab 120 mg|solution
89409050|NCT02135640|Placebo Comparator|placebo|solution
89409051|NCT02784834|Experimental|Dimethyl fumarate (DMF)|"Cohort 1: dimethyl fumarate 120 mg PO BID (approximately 12 hours apart) for 2 x 28 day cycles.~Cohort 2: dimethyl fumarate 120 mg PO BID (approximately 12 hours apart) for 1 week, then escalating to the assigned dose of (240mg PO BID for the remainder of 2 x 28 day cycles.~Cohort 3: dimethyl fumarate 120 mg PO BID for 1 week, then escalate to the dose of 360mg PO BID for the remainder of 2 x 28 day cycles."
89409052|NCT03862274||CLN2 Natural History Control Group|Patients that have a TPP1 enzyme deficiency and/or confirmed molecular diagnosis of pathogenic variants in the TPP1 gene are eligible to participate if they are untreated or not receiving cerliponase alfa.
89409053|NCT03862274||CLN2 Treatment Group|Patients that have a TPP1 enzyme deficiency and/or confirmed molecular diagnosis of pathogenic variants in the TPP1 gene are eligible to participate if they are receiving cerliponase alfa.
89409054|NCT04564495|Experimental|Live zoom exercise classes|Participants will engage in a live zoom exercise session. Participants will undergo 45 minutes of aerobic exercise intervention, three times a week, for a period of 12 weeks. Exercise will include repetitive bouts of high intensity exercises with intermittent periods of rest or active recovery. circuit of moves like 'jabs', 'hooks' etc, and a strength and endurance class that promotes postural awareness.
89409055|NCT04564495|Active Comparator|Recorded zoom exercise classes|Participants will undergo 45 minutes of aerobic exercise intervention, three times a week, for a period of 12 weeks, using a pre-recorded class that they can do according to their own schedule. Exercise will include repetitive bouts of high intensity exercises with intermittent periods of rest or active recovery. circuit of moves like 'jabs', 'hooks' etc, and a strength and endurance class that promotes postural awareness.
89409056|NCT02140398|Experimental|Currettage|Endometrial Currettage (endometrial scrapping) will be performed at the time of laparoscopic ovarian drilling
89409057|NCT02140398|No Intervention|Nothing|No endometrial curettage at time of Laparoscopic ovarian drilling
89409058|NCT04467710||Success of LCBDE|Patients with a fully laparoscopic surgical treatment of common bile duct stones
88884553|NCT02333708||Without inflammatory syndrome and without GCA group|
88884554|NCT02307877||Fingolimod|Subjects currently taking Fingolimod for a minimum of 2 years
88884555|NCT02307877||glatiramer acetate|Subjects currently taking glatiramer acetate for a minimum of 2 years
88922021|NCT05971537|Active Comparator|intervention arm|"in addition to the appropriate IP antibiotics, an antibiotic-lock will be prepared by the same antibiotics. We will follow the suggested data used in hemodialysis catheter for the concentration of different antibiotics to prepare the locking solution The resulting locking solution will be instilled precisely to fill up the Tenckhoff catheter and the transfer set once a day. Prior to that, the existing PD solution is drained out first. As such, a dry abdomen is maintained during antibiotic-lock dwelling in the Tenckhoff catheter. This is to ensure the antibiotic-lock solution can be maintained within the catheter lumen for a prolonged period of time After a 6-hour dwell, the antibiotic-lock is drained out and usual PD schedule is resumed. Such a daily application of antibiotic lock shall last until the course of IP antibiotics is completed."
88884556|NCT02293109|Experimental|Treatment (carfilzomib and hyper-CVAD)|Patients receive carfilzomib IV over 30 minutes on days 0, 1, 7, and 8. Patients also receive hyper-CVAD comprising cyclophosphamide IV over 2 hours every 12 hours for 6 doses beginning on day 1, vincristine sulfate IV on days 4 and 11, doxorubicin hydrochloride IV over 2-24 hours on day 4, and dexamethasone PO on days 1-4 and 11-14 (courses 1 and 3) and methotrexate IV over 24 hours on day 1, cytarabine IV over 2 hours every 12 hours for 4 doses starting on day 2, leucovorin calcium IV or PO every 6 hours beginning 36 hours after the start of methotrexate infusion, and methylprednisolone IV every 12 hours for 6 doses beginning on day 1 (courses 2 and 4). Patients with CD20 positive disease also receive rituximab twice daily on days 1 and 11 of courses 1 and 3 and days 1 and 8 of courses 2 and 4. Treatment repeats every 3-4 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
88884557|NCT02284568|Placebo Comparator|Placebo|once daily oral dose
88884558|NCT02284568|Experimental|Laquinimod 0.6 mg|1 capsule containing 0.6 mg laquinimod and 2 capsules containing placebo were administered orally once daily for at least 48 weeks.
88884559|NCT02284568|Experimental|Laquinimod 1.5 mg|3 capsules containing 0.5 mg laquinimod were administered orally once daily for at least 48 weeks. However this arm was discontinued as of 01 January 2016 and no participants reached the 48 week timeframe.
88884560|NCT02228525|Experimental|selinexor (KPT-330)|Patients with myelodysplastic syndromes who are refractory to hypomethylating agents (decitabine or 5-azacytidine) will receive oral selinexor at a starting dose of 60 mg twice weekly for 2 weeks, followed by 1 week of no therapy. Dose reductions are permitted for patients who are benefiting from selinexor but have poor tolerance. After discontinuation from treatment, patients will be followed by the study staff for survival status approximately every three months.
88884561|NCT02195986|Experimental|Estradiol Vaginal Cream|Estradiol Vaginal Cream, 0.01%, administered once daily for 7 days.
88884562|NCT02195986|Active Comparator|Estrace® 0.01% cream|Estrace® 0.01% vaginal cream, administered once daily for 7 days.
88884563|NCT02195986|Placebo Comparator|Placebo Vaginal Cream|Placebo Vaginal Cream, administered once daily for 7 days.
88884564|NCT02078206|Experimental|Neurocognitive stimulation|Intervention of experimental group consists in a neurocognitive stimulation treatment. Using kinect technology, patient can interact with a virtual environment where different cognitive tasks have to be resolved.
88884565|NCT02078206|No Intervention|Treatment as usual|
88884566|NCT02061319|Experimental|Nordic Walking Group|Participants in the Nordic walking group will be provided with walking poles (GymstickTM Nordic Walking Poles, Gymstick International OY, Lahti, Finland) for the duration of the study. They will attend on-site exercise classes twice weekly for 12 weeks. The on-site exercise training classes will be one hour in length and include the following components: a 15 minute chair warm-up that excludes resistance exercises; 10-15 minutes of walking with Nordic walking poles for the first 3 weeks, progressing to 30 minutes of continuous walking with poles for the remaining 9 weeks; and 15 minutes of cool down exercises. Participants will be instructed to take the walking poles home and perform 200-400 minutes of Nordic walking per week for 12 weeks
88884567|NCT02061319|No Intervention|Standard Exercise Therapy|Individuals assigned to standard exercise therapy will attend on-site exercise classes twice weekly for 12 weeks. Each on-site class will be one hour in duration and consist of: a 15-minute chair-based warm-up that includes 6-8 upper and lower body resistance training exercises using either hand-held weights or therabands at an intensity of 50-60% of 1- RM with the patient completing one set of 10-12 repetitions progressing to 15 repetitions before increasing the intensity by 5-10%; 10-15 minutes of walking for the first 3 weeks, progressing to 30 minutes of continuous walking for the remaining 9 weeks; and 15 minutes of cool down exercises. A strength training program will be provided to participants and they will be encouraged to do one additional strength training session at home. Participants will also be instructed to complete additional walking sessions at home so that they can accumulate a total of 200-400 minutes of exercise per week.
88884568|NCT02027948|Experimental|nutritional management|The proposed study will be a prospective feasibility study of a nutritional management algorithm with risk-based guidelines in older adults (n=50) with newly diagnosed locally advanced esophageal cancer receiving preoperative or definitive chemoradiotherapy with an induction chemotherapy approach. Eligible patients must be age ≥ 65 years old. While all patients with esophageal cancer may benefit from this intervention, we wish to target the most vulnerable population (older patients who are at highest risk of malnutrition) in this pilot study.
88884569|NCT02013297|Experimental|SBRT treatment|According to the site to irradiate and to local constraints, SBRT consist in 1 to 8 fractions of 5 to 18 Gy
88884570|NCT02000635||Leptospirosis|Patient with a diagnosis of leptospirosis confirmed by PCR in the five first day
88884571|NCT01987973|Active Comparator|Partial Repair / Debridement|"Subjects in this arm of the study will receive the intervention Partial Rotator Cuff Repair. This is the control group."
88884572|NCT01987973|Experimental|Allograft Reconstruction|"Subjects in this arm of the study will receive the intervention Partial Rotator Cuff Repair with Allograft Augmentation"
88884573|NCT01982630|Experimental|Part 1: MK-8521 64/120 μg/day|Type 2 diabetes mellitus (T2DM) participants received once daily subcutaneous MK-8521 starting at 64 μg on Days 1 to 7 and escalated to 120 μg on Days 8 to 14.
88884574|NCT01982630|Experimental|Part 1: MK-8521 34/72 μg/day|T2DM participants received once daily subcutaneous MK-8521 starting at 34 μg on Days 1 to 7 and escalated to 72 μg on Days 8 to 14.
89409059|NCT04467710||Failure of LCBDE|Patients with a laparoscopic cholecystectomy but an endoscopic treatment of common bile duct stone with an ERCP performed intra, per or postoperatively
88884575|NCT01982630|Active Comparator|Part 1: Liraglutide 0.6/1.2/1.8 mg/day|T2DM participants received once daily subcutaneous liraglutide starting at 0.6 mg on Day 1 and 2, escalated to 1.2 mg on Days 3 to 7, and escalated to 1.8 mg on Days 8 to 14.
88884576|NCT01982630|Placebo Comparator|Part 1: Placebo for MK-8521|T2DM participants received once daily subcutaneous placebo for MK-8521 for 14 days.
88884577|NCT01982630|Experimental|Part 2: MK-8521 64/120/180/240/300 µg/day-T2DM|T2DM participants received once daily subcutaneous MK-8521 titrated to 300 µg starting at 64 µg and increasing to 120 µg on Day 8, 180 µg on Day 15, 240 µg on Day 20, and 300 µg on Day 25. The total number of dosing days was 29.
89409060|NCT05284695||TAP + RB|transversus abdominis plane block and rectus sheath block
89409061|NCT05284695||ESPB|Erector spinae plane block
89409062|NCT05284695||EOI|External oblique intercostal block
89004758|NCT00192569|No Intervention|Untreated|Subjects will be followed for natural history of newly acquired HCV
89004759|NCT00192608|Experimental|saquinavir at baseline|patients receiving NRTIs + saquinavir + ritonavir 1000/100 mg BID at entry switch from 200 mg SQV capsules to 500 mg SQV tablets following PK at day 0. After PK at day 8 NRTIs ceased and regimen changed to ATV/SQV/RTV 300/1500/100 QD using 500 mg SQV formulation and continued to week 48
89004760|NCT00192608|Experimental|other boosted PI at baseline|Patients receiving NRTIs + PI/RTV randomised at baseline to receive ATV/SQVRTV 300/1500/100 QD using 500 mg SQV formulation or ATV/SQV/RTV 300/1600/100 QD using 200 mg formulation. Following PK at day 7, SQV formulation switched with second PK assessment at day 15. Patients then receive ATV/SQV/RTV 300/1500/100 QD to week 48.
89004761|NCT00215514|Experimental|ECF followed by 5-FU/RT followed by ECF|
89004762|NCT00222144|Experimental|1|Gleevec and Taxotere
89004763|NCT00411957|Active Comparator|1|ATV/r 300/100 mg
89004764|NCT00411957|Active Comparator|2|ATV/r 200/100 mg OD
89004765|NCT00411996|Other|1|IDV/r 600/100 mg + rifampicin
89004766|NCT00222261|Active Comparator|1, aspirin|Aspirin 160 mg
89004767|NCT00222261|Active Comparator|2, clopidogrel|Clopidogrel 75 mg
89004768|NCT00193154|Experimental|OSI-774 & bevacizumab|OSI-774 (Tarceva) 150mb PO, days 1-28; bevacizumab (Avastin) 10mg/kg, IV infusion, days 1 and 15; Regimen will be repeated every 28 days.
89004769|NCT00222417||Myringoplasty|Patients subject to myringoplasty for tympanic membrane perforations.
89004770|NCT00222417||Otosclerosis|Patients subject to stapes surgery
89004771|NCT00222534|Experimental|Acetazolamide|Acetazolamide 250 mg Three times a day for five days
89004772|NCT00222534|Placebo Comparator|Placebo|Placebo, one tablet Three times a day for five days
89004773|NCT00124319||1|Incoming cadets at the U.S. Naval, Air Force, or Military Academies
89004774|NCT00215826|Active Comparator|1|650 IU
89004775|NCT00215826|Active Comparator|2|1300 IU
89004776|NCT00215904|Placebo Comparator|1|
89004777|NCT00215904|Experimental|2|
89004778|NCT00215982|Experimental|Combination Therapy|Capecitabine in Combination with Irinotecan and Oxaliplatin
89004779|NCT00216021|Experimental|Single Group Assignment|Capecitabine + Oxaliplatin
89004780|NCT00216138|Active Comparator|1|Docetaxel + Capecitabine
89004781|NCT00409604|Experimental|1|Standard PCI procedure + pacing post conditioning
89004782|NCT00409604|No Intervention|2|Standard PCI procedure
89004783|NCT00216216|Active Comparator|1|Pemetrexed for patients with chemosensitive and chemoresistant relapsed small cell lung cancer.
89004784|NCT00473746|Experimental|Phase I Dose Escalation|
89004785|NCT00473746|Experimental|Phase II Dose Treatment|
89004786|NCT00473668|Experimental|TRITANRIX-HEPB/HIBERIX KFT. GROUP|Subjects, male or female, aged 6 to 8 weeks received 3 doses of Tritanrix™-HepB/Hiberix™ Kft. vaccine, administered intramuscularly in the anterolateral thigh at 6, 10 and 14 weeks of age.
89004787|NCT00473668|Active Comparator|TRITANRIX-HEPB/HIBERIX LD GROUP|Subjects, male or female, aged 6 to 8 weeks received 3 doses of Tritanrix™-HepB/Hiberix™ low-dose (LD) formulation vaccine, administered intramuscularly in the anterolateral thigh at 6, 10 and 14 weeks of age.
89004788|NCT00473668|Active Comparator|TRITANRIX-HEPB/HIBERIX HD GROUP|Subjects, male or female, aged 6 to 8 weeks received 3 doses of Tritanrix™-HepB/Hiberix™ high-dose (HD) formulation vaccine, administered intramuscularly in the anterolateral thigh at 6, 10 and 14 weeks of age.
89004789|NCT04722497||Physicians and nurses|All physicians, nurses, involved in a cesarean births are included in the cohort.
89191684|NCT04130204|Experimental|Active|DYV700, 10mL 3 times per day for 7 days Colchicine 1.2mg plus 0.6 mg 1 hour later at onset of flare (SOC)
89004790|NCT04722497||Patients undergoing cesarean births|All patients undergoing cesarean births
89004791|NCT00409721|Experimental|Memantine Low Dose|
89004792|NCT00409721|Experimental|Memantine High Dose|
89004793|NCT00473590|Experimental|Bortezomib + bevacizumab|Participants received bortezomib 1.3 mg/m^2 administered as a 3- to 5-second bolus intravenous injection on Days 1, 4, 8, and 11 of a 21-day cycle for a maximum of eight cycles and bevacizumab 15 mg/kg administered by intravenous infusion on the first day of each 21-day cycle during the blinded treatment phase. After completion of 8 cycles, participants could continue to receive bevacizumab as monotherapy until disease progression.
89004794|NCT00473590|Active Comparator|Bortezomib + placebo|Participants received bortezomib 1.3 mg/m^2 administered as a 3- to 5-second bolus intravenous injection on Days 1, 4, 8, and 11 of a 21-day cycle for a maximum of eight cycles and placebo intravenous infusion on the first day of each 21-day cycle during the blinded treatment phase. At the completion of the 8-cycle treatment phase, participants entered the observation phase until disease progression.
89004795|NCT00124787|Experimental|Dimenhydrinate|dimenhydrinate PO x 4 doses
89004796|NCT00124787|Placebo Comparator|Placebo|placebo PO x 4 doses
89004797|NCT00206232|Active Comparator|Spironolactone|Randomized, double-blind, placebo controlled trial evaluating the safety and efficacy of spironolactone 25mg daily for 6 months.
89004798|NCT00206232|Placebo Comparator|Placebo|Randomized, double-blind, placebo controlled trial evaluating the safety and efficacy of spironolactone 25mg daily for 6 months.
89004799|NCT00223353||Lower Limb Amputee|
89004800|NCT00223353||Amputee and Normals and Clinical Case Study|"Amputee:~Lower limb below/above knee amputee~Normals:~Health adult~Clinical Case Study:~Individual case studies"
89004801|NCT00193739|Active Comparator|NACT followed by surgery|3 cycles of neoadjuvant chemotherapy (NACT) (Inj.Paclitaxel +Inj.Carboplatin) followed by surgery (radical abdominal hysterectomy Class III , bilateral pelvic lymphadenectomy & lower para aortic lymph node sampling)
89004802|NCT00193739|Active Comparator|Concurrent chemoradiotherapy|Radiation therapy will be administered to whole pelvis followed by intracavitary brachytherapy. Patients will be given chemotherapy (Inj.Cisplatin) concurrently with external beam radiotherapy.
89004803|NCT00193778|Experimental|Loco Regional Treatment Arm (LRT)|Surgery for breast cancer. (MRM/BCT)
89191685|NCT04130204|Placebo Comparator|Placebo|Placebo, 10mL 3 times per day for 7 days Colchicine 1.2mg plus 0.6 mg 1 hour later at onset of flare (SOC)
89191686|NCT00723918|Active Comparator|1|methadone plus SAB placebo
89191687|NCT00723918|Experimental|2|methadone plus active SAB
89191688|NCT00723918|Placebo Comparator|3|methadone placebo plus SAB placebo
88884578|NCT01982630|Active Comparator|Part 2: Liraglutide 0.6/1.2/1.8 mg/day-T2DM|T2DM participants received once daily subcutaneous liraglutide titrated to 1.8 mg starting at 0.6 mg and increasing to 1.2 mg on Day 8, and 1.8 mg on Day 15. The total number of dosing days was 29.
89191689|NCT00722618|Active Comparator|Intervention|Written materials, telephone based education
89191690|NCT00722618|Other|Comparison|Written materials
88884579|NCT01982630|Placebo Comparator|Part 2: Placebo for MK-8521-T2DM|T2DM participants received once daily subcutaneous placebo for MK-8521 for 29 days.
88884580|NCT01982630|Experimental|Part 2: MK-8521 64/120 µg/day-Non-Diabetic Overweight/Obese|Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 titrated to 120 µg starting at 64 µg and increasing to 120 µg on Day 8. The total number of dosing days was 14.
88884581|NCT01951469|Experimental|Gefitinib and Pemetrexed/platinum|Gefitinib 250mg is Taken Orally on day 1-28,combined Pemetrexed (D1)+cisplatin (D1-3) chemotherapy or Pemetrexed (D1)+nedaplatin (D1) chemotherapy, every 28 days
88884582|NCT01951469|Active Comparator|Gefitinib mono-therapy|Gefitinib 250mg is Taken Orally everyday
88884583|NCT01940809|Experimental|Arm A1 (ipilimumab, dabrafenib, trametinib)|Patients receive dabrafenib PO BID and trametinib PO QD for 25 days. Patients then receive ipilimumab IV over 90 minutes. Treatment with ipilimumab repeats every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
88884584|NCT01940809|Experimental|Arm A2 (dabrafenib, trametinib, nivolumab, ipilimumab)|Patients receive dabrafenib PO BID and trametinib PO QD for 25 days followed by nivolumab IV over 60 minutes and ipilimumab IV over 90 minutes every 3 weeks for 4 doses, followed by nivolumab monotherapy IV every 2 weeks continuously for up to 42 courses.
88884585|NCT01940809|Experimental|Arm B1 (ipilimumab, trametinib)|Patients receive trametinib PO QD for 25 days. Patients then receive ipilimumab IV over 90 minutes. Treatment with ipilimumab repeats every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
88884586|NCT01940809|Experimental|Arm B2 (trametinib, nivolumab, ipilimumab)|Patients receive trametinib PO QD for 25 days followed by nivolumab IV over 60 minutes and ipilimumab IV over 90 minutes every 3 weeks for 4 doses, followed by nivolumab monotherapy IV every 2 weeks continuously for up to 42 courses.
88884587|NCT01940809|Experimental|Arm C1 (ipilimumab, dabrafenib)|Patients receive dabrafenib PO BID for 25 days. Patients then receive ipilimumab IV over 90 minutes. Treatment with ipilimumab repeats every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
88884588|NCT01940809|Experimental|Arm C2 (dabrafenib, nivolumab, ipilimumab)|Patients receive dabrafenib PO BID for 25 days followed by nivolumab IV over 60 minutes and ipilimumab IV over 90 minutes every 3 weeks for 4 doses, followed by nivolumab monotherapy IV every 2 weeks continuously for up to 42 courses.
88884589|NCT01940809|Experimental|Arm D1 (ipilimumab)|Patients receive ipilimumab IV over 90 minutes Treatment repeats every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
88884590|NCT01940809|Experimental|Arm D2 (nivolumab, ipilimumab)|Patients receive nivolumab IV over 60 minutes and ipilimumab IV over 90 minutes every 3 weeks for 4 doses, followed by nivolumab monotherapy IV every 2 weeks continuously for up to 42 courses
89191691|NCT05373888||Main|Enterostomy patients, including colostomates, ileostomates or jejunostomates.
89191692|NCT00865540|Experimental|prednisolone acetate 1%|one drop every 8h two days before surgery
89191693|NCT00865540|Experimental|ketorolac tromethamine 0.4%|one drop every 8h two days before surgery
89191694|NCT00865540|Experimental|nepafenac 0.1%|one drop every 8h two days before surgery
89191695|NCT00865540|Placebo Comparator|placebo|one drop every 8h two days before surgery
88884591|NCT01937247|Placebo Comparator|Standard process|The control group is placebo group and this is our standard practice. Patients will be induced in the operating room and at the end of surgery will be reversed with neostigmine 50µg/kg and glycopyrrolate 10µg/kg. Once extubated and rolled out of the room, the house keeper team will start cleaning the operating room
88884592|NCT01937247|Active Comparator|Redesigned process|Patients will be inducted in the induction room. At the end of surgery and after placement of the surgical dressing, the registered nurse will call in the house keeper to start cleaning of the OR (parallel processing) before the patient exits the room. The patient will be reversed with sugammadex 4mg/kg IV
88884593|NCT01879228|Experimental|Sitagliptin|The dose of sitagliptin (Januvia®) 100 mg tablet will be taken orally each morning for 6 months.
88884594|NCT01879228|Placebo Comparator|Placebo|Placebo tablet will be taken orally each morning for 6 months.
88884595|NCT01813370||Pts with prostate cancer|Patients who have progressed or hit their 36 month post treatment date between the closure of TAX3503 and the activation of this TAX3503 Registry protocol will be permitted on the study to capture their date of progression or their 36 month post treatment progression free date.
88884596|NCT01779557|Experimental|Huaren peritoneal dialysate|Huaren Peritoneal dialysate CAPD 3-5 times/d
88884597|NCT01779557|Active Comparator|Baxter Peritoneal Dialysate|Baxter Peritoneal dialysate CAPD 3-5 times/d
88884598|NCT01750619||Mucosal tumors of the colon|Patients who received endoscopic treatment for noninvasive mucosal tumors of the colon.
88884599|NCT01750619||Nonampullary tumors of the duodenum|Patients who received endoscopic treatment for noninvasive mucosal tumors of the duodenum.
88884600|NCT01750619||Ampullary tumors|Patients who received endoscopic treatment for noninvasive ampullary tumors.
89191696|NCT00723996||Group 1|Women receiving a CRC-related questionnaire and a CRC educational video.
89191697|NCT00723996||Group 2|Women who receive only a CRC-related questionnaire.
89191698|NCT00723996||Group 3|Women who receive neither questionnaire nor educational video.
89191699|NCT04066556||Acute ischemic stroke patients|Acute ischemic stroke patients who received intravenous (IV) thrombolysis and/or intra-arterial (IA) recanalization treatment
89191700|NCT00865618|Experimental|1|Eplerenone 50mg Tablets
89191701|NCT00865618|Active Comparator|2|INSPRA 50mg Tablets
89191702|NCT02570594|Other|healthy volunteers|
89191703|NCT00722280|Experimental|Hand Transplantation|Described above
89191704|NCT00655629|Experimental|Vardenafil ODT (STAXYN, BAY38-9456)|Vardenafil 10 mg orodispersible tablet (ODT) taken on demand (PRN), approximately one hour before start of sexual activity, no more than one dose per day.
89409063|NCT04468022|Active Comparator|Toric Trifocal IOL|Twenty patients (20) underwent Toric Trifocal IOL surgery (first group)
89409064|NCT04468022|Active Comparator|Toric Trifocal IOL RELEX SMILE|Twenty patients (20) underwent Toric Trifocal IOL and RELEX SMILE surgery (second group)
89409065|NCT02140476|Experimental|Thyroid Goiter|Benign thyroid disease with a nodule equal or lesser than 4 cm in diameter of any gender or ethnical origin. Half of these patients will undergo either bipolar or conventional thyroidectomy.
89409066|NCT02140476|Active Comparator|Papillary Thyroid Cancer|Patients of any gender or ethnical origin with papillary thyroid cancer no greater than 4 cm in diameter. Half of these patients will undergo either bipolar or conventional thyroidectomy.
89409067|NCT03133364|Active Comparator|Sensory optimized meals|"Intervention group is receiving:~Popular dishes selected from hospital and meal service menus optimized by sensory experts. Optimization is done with respect to taste, texture and appereance and on nutritional composition of the meals with focus on protein content."
89409068|NCT03133364|Placebo Comparator|Control|"Control group is receiving:~Popular dishes selected from hospital and meal service menus, NOT optimized by sensory experts."
89409069|NCT02966223|Experimental|MRI and HIDA scan|
89409070|NCT04157179|Active Comparator|Healthy Controls|
89409071|NCT04157179|Active Comparator|Extracorporeal Membrane Oxygenation survivors|
89409072|NCT04157179|Active Comparator|Sickle Cell Anemia participants|
89409073|NCT02253342|Experimental|WCK 2349|Subjects will receive oral doses of WCK 2349 administered twice-daily for five days starting on Day 1
89409074|NCT03844022||McArdle disease|Glycogen storage disease
88884601|NCT01738009|Experimental|Induction of flow limitation|Flow limitation will be induced by sustained reductions in continuous positive airway pressure during sleep
88884602|NCT01729754|Experimental|Tildrakizumab 200 mg|Participants receive tildrakizumab 200 mg subcutaneously (SC) on Weeks 0, 4, 16, 28, 40 and 52 and, optionally, every 12 weeks thereafter until Week 244, plus etanercept placebo (PBO) twice weekly until Week 12 and once weekly from Week 12 to Week 28.
88884603|NCT01729754|Experimental|Tildrakizumab 100 mg|Participants receive tildrakizumab 100 mg SC on Weeks 0, 4, 16, 28, 40 and 52 and, optionally, every 12 weeks thereafter until Week 244, plus etanercept placebo twice weekly until Week 12 and once weekly from Week 12 to Week 28.
88884604|NCT01729754|Placebo Comparator|Placebo|Participants receive matching placebo to tildrakizumab SC on Weeks 0 and 4 plus etanercept placebo twice weekly up to Week 12 and once weekly from Week 12 to Week 28. Participants will be re-randomized 1:1 at Week 12 to receive tildrakizumab 200 mg or tildrakizumab 100 mg on Weeks 12, 16, 28, 40 and 52 and, optionally, every 12 weeks thereafter until Week 244.
89409075|NCT03844022||Healty controls|Age and gender matched
89409076|NCT02252874|Placebo Comparator|Control Group|Receive leisure activities (e.g. reading, web-surfing, playing chess/ Mahjong) Twenty hours (2-3 sessions per week, 1.5 hours per session)
88884605|NCT01729754|Active Comparator|Etanercept 50 mg|Participants receive matching placebo to tildrakizumab SC on Weeks 0 and 4 and etanercept 50 mg twice weekly up to Week 12 and once weekly from Week 12 to Week 28. Participants who don't achieve PASI-75, receive tildrakizumab 200 mg after Week 28 (Weeks 32, 36 and 48) and, optionally, every 12 weeks thereafter until Week 244.
88884606|NCT01658683|Experimental|Exercise Facilitator Intervention|The intervention employs small group counseling teleconferences (5),personal telephone contacts (3) and community Heart Wise Exercise program demonstrations.
88884607|NCT01658683|No Intervention|Usual Care|Usual care for cardiac rehab graduates provided by the University of Ottawa Heart Institute Minto Prevention & Rehabilitation Centre and the Cardiovascular Rehabilitation and Prevention Centre at the University Health Network.
88884608|NCT01622998|Active Comparator|Standard transdermal NRT group (UC)|10 week standard transdermal nicotine replacement therapy patch protocol
88884609|NCT01622998|Experimental|Titrated transdermal NRT group (EXP)|10 week titrated transdermal nicotine replacement therapy patch dose regimen based on smoking history with the option to increase dose, if withdrawal symptoms are unmanageable.
88884610|NCT01599741|Experimental|ClarityIQ|Low-dose DSA (83% reducation compared to normal dose) with novel X-ray imaging technology.
88884611|NCT01599741|Active Comparator|AlluraXper|Normal dose DSA with conventional X-ray imaging technology.
89409077|NCT02252874|Active Comparator|Intervention Group 1|Receive slow motion Nintendo Wii video games Twenty hours ( 2-3 sessions per week, 1.5 hours per session)
89409078|NCT02252874|Active Comparator|Intervention Group 2|Receive fast motion Nintendo Wii video games (e.g. shooting game) Twenty hours ( 2-3 sessions per week, 1.5 hours per session)
89409079|NCT05284461|Placebo Comparator|Mechanized parallel abutments|Implants were immediately covered with this type of abutments after insertion. This is the most common procedure. It would be the gold standard
89409080|NCT05284461|Experimental|Anodized parallel abutments|Implants were immediately covered with this kind of abutments after insertion. Only the surface treatment varies to the gold standard
88884612|NCT01597583|Experimental|Use of MobileMedMinder|
88884613|NCT01597583|No Intervention|Usual care|
88884614|NCT01595620|Active Comparator|THC 0.01 mg/kg|
88884615|NCT01595620|Placebo Comparator|Placebo|
88884616|NCT01595620|Active Comparator|THC 0.03 mg/kg|
88884617|NCT01593852|Active Comparator|Regular X-ray dose settings|For patients in this group x-ray images are acquired with regular dose settings of the x-ray system and regular image processing
88884618|NCT01593852|Experimental|Reduced X-ray dose settings|For patients in this group x-ray images are acquired with reduced dose settings of the x-ray system and advanced image processing
88884619|NCT01591629|Placebo Comparator|Placebo and Placebo|
89409081|NCT05284461|Experimental|Mechanized convergent abutments|Implants were immediately covered with this kind of abutments after insertion. Only the geometry of the emergence profile varies with regards to the gold standard
89409082|NCT05284461|Experimental|Anodized convergent abutments|Implants were immediately covered with this kind of abutments after insertion. Both the surface treatment and the geometry vary with regards to the gold standard
89409083|NCT04802096|Experimental|Inspiratory muscle training combined pulmonary rehabilitation|
89409084|NCT04802096|Sham Comparator|Sham inspiratory muscle training combined pulmonary rehabilitation|
89409085|NCT00495508|Active Comparator|Quinine|
89409086|NCT00495508|Active Comparator|Arthemeter lumefantrine|
89409087|NCT02135718||Group 1|Subjects will use the ELLIPTA inhaler once daily for 5 to 9 days during the first period followed by the MDI inhaler twice daily for 5 to 9 days during the second period.
89409088|NCT02135718||Group 2|Subjects will use the MDI inhaler twice daily for 5 to 9 days during the first period followed by the ELLIPTA inhaler once daily for 5 to 9 days during the second period.
89409089|NCT03646851|Experimental|COPD|COPD patients GOLD stage III and IV
89409090|NCT04793828|Experimental|Intervention (velibra)|Arm consisting of participants who receive velibra, an internet-based cognitive behavioral therapy program.
89409091|NCT03549156|Active Comparator|C-RUSF|Control/Standard RUSF
89409092|NCT03549156|Active Comparator|HIPRO RUSF|New RUSF product
89409093|NCT04052451|Experimental|Major Depression Disorder|MET-2 will be given to subjects with major depression disorder and its effect on mood will be measured
89409094|NCT04052451|Experimental|Generalized Anxiety Disorder|MET-2 will be given to subjects with generalized anxiety disorder and its effect on mood will be measured
89409095|NCT03526328||DCLK1 post BE treatment|Effects of EMR and RFA on the expression of putative stem cell biomarkers and correlate them with serum/plasma protein expression and disease progression and/or recurrence (Barrett's esophagus/ esophageal adenocarcinoma)
89409096|NCT03549078|Experimental|Intervention|Participants will complete an initial assessment within 2 weeks prior to starting the course or during the first class. The course will include 10 sessions conducted on a weekly basis. Following completion of the course, participants will again complete another assessment during the last class or within 2 weeks of course completion. Participants may be invited to complete assessments at 3- and 6-months following course completion.
89409097|NCT05284851|Experimental|Experimental group 1|Healthy people in experimental group will receive a dose of Live Attenuated Influenza Vaccine (non freeze- dried)
89409098|NCT05284851|Active Comparator|Positive control group|Healthy people in Positive control group will receive a dose of Live Attenuated Influenza Vaccine ( freeze- dried)
89409099|NCT05284851|Placebo Comparator|Placebo group|Healthy people in placebo group will receive a dose of placebo
89409100|NCT01457456||Observation|Patients with Morquio disease
89409101|NCT03783884|Active Comparator|Treatment|Subject receives Lungpacer Catheter for transvenous phrenic nerve stimulation to deliver Diaphragm Pacing Therapy Sessions. DPT sessions are 6 sets of 10, delivered twice daily, for a total of 120 stimulation reps per day, plus standard of care for weaning from mechanical ventilation.
89409102|NCT03783884|No Intervention|Control|Subject does not receive Lungpacer Catheter or DPT. Subject receives only Standard of care for weaning from mechanical ventilation.
89409103|NCT03049735|Experimental|Relugolix plus E2/NETA (Group A)|Relugolix co-administered with E2/NETA for 24 weeks.
89409104|NCT03049735|Experimental|Relugolix plus Delayed E2/NETA (Group B)|Relugolix co-administered with E2/NETA placebo for 12 weeks, followed by relugolix co-administered with E2/NETA for 12 weeks.
89409105|NCT03049735|Placebo Comparator|Placebo (Group C)|Relugolix placebo co-administered with E2/NETA placebo for 24 weeks.
89409106|NCT05579028||Study|Patients of the group received supplemental nutritional support with Nutridrink ONS 200 ml, 2 bottles (400 ml) daily for 28 days from the date of inclusion. In a hospital setting, additional nutritional support will be added to the patient's standard hospital diet. After being discharged from the hospital, the patient will receive at his disposal the required amount of Nutridrink ONS 200 ml in amount of 400 ml per day and will take it in addition to his usual and habitual diet. The Nutridrink ONS 200 ml is recommended to be taken between main meals.
89409107|NCT05579028||Control|Patients of the group received a standard hospital diet, and upon discharge from the hospital - their usual habitual diet.
89004804|NCT00193778|Active Comparator|No Loco-regional Treatment Arm|No surgery for Breast cancer
88884620|NCT01591629|Experimental|Active Naloxone and Placebo|
88884621|NCT01591629|Placebo Comparator|Placebo and Active Delta-9-THC|
88884622|NCT01591629|Experimental|Active Naloxone and Active Delta-9-THC|
88884623|NCT01515306|Experimental|Part A: ramucirumab (IMC-1121B) and paclitaxel|Experimental: Part A: ramucirumab (IMC-1121B) and paclitaxel Cycle 1: paclitaxel administered on Day 1 of 2-week cycle. Cycle 2 and beyond : ramucirumab (IMC-1121B) administered on Day 1 and Day 15, paclitaxel administered on Day 1, Day 8 and Day 15 of 4-week cycle.
89191705|NCT00655629|Placebo Comparator|Placebo|Matching placebo tablet taken on demand (PRN), approximately one hour before start of sexual activity, no more than one dose per day.
89191706|NCT00865696|Experimental|A|Mirtazapine 15 mg tablets, single dose
89191707|NCT00865696|Active Comparator|B|REMERON® 15 mg tablets, single dose
89409108|NCT03957447||patients exhibiting skin wounds|Within the framework of Taabo HDSS Cross-sectional community and health services surveys are performed before wound management intervention (main study and substudy 1) is implemented (baseline) and are continued at 6 monthly intervals thereafter. Surveys are done door-to-door. All patients with skin lesions (broken skin barrier) are enrolled, lesions are documented with help of a questionnaire and photographic documentation.
89409109|NCT03957447||patients identified in the survey and willing to participate|Each patient with a wound will be enrolled. Presumptive clinical diagnosis and empirical treatment, as well wound assessment, will be recorded at enrollment and at each follow-up visit. Additional laboratory testing done within the framework of the local health system will also be recorded.
89409110|NCT03957447||patients exhibiting Buruli ulcers < 2cm|Buruli ulcer patients fulfilling inclusion criteria will be offered thermotherapy instead of standard antibiotic treatment. Heat treatment is applied for 42 days plus a safety margin of up to 14 days, if ulcer margins have not fully collapsed and/or induration has not fully subsided. Treatment terminates earlier, if a lesion is completely closed. Thermotherapy will be applied with heat packs twice daily.
89409111|NCT02135796||Sepsis/Septic Shock|Individuals who are admitted to the Intensive Care Unit (ICU) with an infection called Sepsis or Septic Shock. This group will receive transthoracic echocardiography as part of the study.
89409112|NCT03646695|Experimental|ILM flap|vitrectomy with ILM flap transposition and gas-tamponade will be performed
89409113|NCT03646695|Active Comparator|ILM peeling|vitrectomy with ILM peeling and gas-tamponade will be performed
89409114|NCT03522116||No intervention|
89409115|NCT03548844|Experimental|local excision group|Pathologically verified ypT0-1cN0 rectal cancer patients after local excision are randomized to observation (local excision group)
89409116|NCT03548844|Active Comparator|total mesorectal excision group|Pathologically verified ypT0-1cN0 rectal cancer patients after local excision are randomized to complementary rectal excision (local excision group)
89409117|NCT04785638|Experimental|INL-001 (bupivacaine hydrochloride) implant|INL-001 (bupivacaine hydrochloride) implant
89409118|NCT05578794|Experimental|Valsalva Straining (Control Group)|The straining techniques for the groups were explained by the researcher in line with the process steps in the latent phase. Valsalva straining is supported in 2nd stage of labor. Duration of delivery, perineal trauma status and Apgar Scores were evaluated.
89409119|NCT05578794|Experimental|Spontaneous Straining|The straining techniques for the groups were explained by the researcher in line with the process steps in the latent phase. Spontaneous straining is supported in 2nd stage of labor. Duration of delivery, perineal trauma status and Apgar Scores were evaluated.
89409120|NCT05578794|Experimental|Natural Straining|The straining techniques for the groups were explained by the researcher in line with the process steps in the latent phase. Duration of delivery, perineal trauma status and Apgar Scores were evaluated.
89409121|NCT04762472|Active Comparator|Montelukast|Montelukast 10mg daily (tablet) orally x 26 weeks
89409122|NCT04762472|Placebo Comparator|Montelukast-matched placebo|Placebo (Montelukast identical) tablet 1 daily orally x 26 weeks
89409123|NCT03647397|Experimental|PECO|All pediatric patients admitted for respiratory distress will have the intervention of Photo Electrochemical Oxidation (PECO) for Air Purification.
89409124|NCT01295944|Experimental|1/Carboplatin and Bevacizumab for Recurrent Ependymoma|The total duration of treatment will be 6 cycles. After cycle 6, carboplatin should be discontinued, but bevacizumab may be continued at the discretion of the treating physician.
89409125|NCT03547440||type 1 diabetes mellitus|Children with type 1 diabetes mellitus, usually not obese, with diabetic ketoacidosis. They could be with or without stationary metabolic profile. They are recruited at the onset of the T1DM into the Torino and Novara Pediatric Hospitals and then they are divided in relation to the ethnicity.
89409126|NCT03547440||Control healthy|Healthy children without relevant metabolic or systemic co-morbility. They are recruited from orthopedy department of the Torino and Novara Pediatric hospitals and then they are divided in relation to the ethnicity
89409127|NCT03647319|Experimental|Anodal Dual-mode stimulation|"10Hz of rTMS was applied over the left DLPFC for 10 minutes with simultaneous application of anodal tDCS on the right DLPFC.~Each participant's 2-back verbal/nonverbal working memory task and variety cognitive function test are assessed and their resting-state fMRI data at three times: prior to stimulation (pre-stimulation), immediately after stimulation (post-stimulation) and 2 months after stimulation (f/u) are acquired."
88884624|NCT01515306|Experimental|Part B: ramucirumab (IMC-1121B) and paclitaxel|"Cycle 1: ramucirumab (IMC-1121B) administered as monotherapy on Day 1 of 3-week cycle.~Cycle 2 and beyond: ramucirumab (IMC-1121B) administered on Day 1 and Day 15, paclitaxel administered on Day 1, Day 8 and Day 15 of 4- week cycle.~*After Cycle 1 (mandatory pharmacokinetic phase) is completed, participants may continue to receive ramucirumab (IMC-1121B) monotherapy or combination therapy with paclitaxel as described in Part A."
88884625|NCT01515098|Experimental|Blueberry Group|37 grams of dehydrated blueberries daily for 6 months
88884626|NCT01515098|Placebo Comparator|Placebo Group|37 grams of dextrose powder daily for 6 months
89409128|NCT03647319|Experimental|Cathodal Dual-mode stimulation|"10Hz of rTMS was applied over the left DLPFC for 10 minutes with simultaneous application of cathodal tDCS on the right DLPFC.~Each participant's 2-back verbal/nonverbal working memory task and variety cognitive function test are assessed and their resting-state fMRI data at three times: prior to stimulation (pre-stimulation), immediately after stimulation (post-stimulation) and 2 months after stimulation (f/u) are acquired."
89536687|NCT03108755|Placebo Comparator|Placebo Multiple Ascending Dose (Elderly: 65 years or older)|Dosing of the non-Japanese elderly cohort will commence after having established the safety and tolerability of corresponding dose in adults male and female participants.
88884627|NCT01515098|No Intervention|Reference Group|No intervention
88884628|NCT01513187|Experimental|Pazopanib + interferon|"Five levels of pazopanib in different doses: 400, 600 and 800 mg / day and interferon alfa 2-A 3, 6 and 9 MIU three times a week, in cycles of 28 days.~Treatment will continue until disease progression, unacceptable toxicity, non-compliance or withdrawal of consent by the patient"
88884629|NCT01433965|Experimental|Phase I Dose Escalation|Subjects are given a single dose of the drug while they are observed and tested for a period of time. If they do not exhibit any adverse side effects the dose is escalated, and a new group of subjects is then given a higher dose.
88884630|NCT01431157|Active Comparator|Nasal oxygen|Nocturnal nasal oxygen
88884631|NCT01431157|Placebo Comparator|No nasal oxygen|
88884632|NCT01423851|Experimental|Intervention: Drug: NS-018|In Phase 1 part, subjects were treated with oral NS-018 at a dose of 75 - 400 mg once daily or 100 - 400 mg twice daily. In Phase 2 part, subjects were treated with oral NS-018 at a dose of 300 mg once daily.
88884633|NCT01360593|Other|Gem, Xeloda, SBRT|
88884634|NCT01354977|Experimental|Resveratrol|Each participant will receive a 28 days' supply of resveratrol capsules on day 0.
89004805|NCT00206388|Experimental|Zolendric acid with Cyclophosphamide|Zometa will be administered intravenously every 28 days beginning on day 0. Cyclophosphamide will be administered daily without interruption (unless toxicity supervenes) beginning day 0. Each course of therapy will be 28 days. On day 0 of each cycle, cyclophosphamide should be given first, followed by Zometa with a separation between the two drugs of at least one hour. All patients are required to take calcium and Vitamin D supplementation for the duration of study participation.
89409129|NCT03647319|Active Comparator|Single sham stimulation|"10Hz of rTMS was applied over the left DLPFC for 10 minutes with simultaneous application of tDCS with sham mode (no stimulation) on the right DLPFC.~Each participant's 2-back verbal/nonverbal working memory task and variety cognitive function test are assessed and their resting-state fMRI data at three times: prior to stimulation (pre-stimulation), immediately after stimulation (post-stimulation) and 2 months after stimulation (f/u) are acquired."
89409130|NCT04742348|Placebo Comparator|Control, Placebo|Similar looking tablet(s) to active drug will be administered in a single dose to those who are randomly assigned to this group.
89409131|NCT04742348|Experimental|Active Drug, Carbidopa + Levodopa|Single dose of immediate release carbidopa-levodopa (50mg/500mg).
89004806|NCT00193856|Active Comparator|A|LH-RH analogue for 5 months prior to and during first month of radiation treatment (total 6 mths)
89004807|NCT00193856|Active Comparator|B|LH-RH analogue for 5 months prior to and during first month of radiation treatment (total 6 months) + bisphosphonate therapy.
89004808|NCT00193856|Experimental|C|LH-RH analogue as for arm A, but continued for further 12 months (total 18 months)
89004809|NCT00193856|Experimental|D|LH-RH analogue as for arm A, but continued for further 12 months (total 18 months) + bisphosphonate therapy.
89004810|NCT00193895|Active Comparator|Radiotherapy alone|Radiotherapy alone (60Gy or 66Gy in 30-33 fractions 5-5/week)
89004811|NCT00193895|Experimental|Radiotherapy plus chemotherapy|Radiotherapy plus chemotherapy (Radiotherapy 60Gy or 66Gy in 30-33 fractions 5/week + Carboplatin (AUC 2) intravenously weekly)
89004812|NCT00223587|Experimental|A|1 week of treatment discontinuation
89004813|NCT00193934||1|Cervical Cancer Patients
89004814|NCT00223626|Experimental|Topiramate|
89004815|NCT00223626|Placebo Comparator|Placebo|
89004816|NCT00223743|Experimental|Zonisamide|Zonisamide administration and tremor assessment to assess efficacy in reducing essential tremor
89004817|NCT00411177|Active Comparator|Post-dilution on-line hemodiafiltration|Post-dilution on-line hemodiafiltration
89004818|NCT00411177|Other|High-flux hemodialysis|High-flux hemodialysis
89191708|NCT05373732|Experimental|Transcendental Meditation|The Transcendental Meditation (TM) technique is described as a simple, natural technique that is practiced twice a day for 20 minutes while sitting comfortably with eyes closed. There are no required changes in lifestyle, beliefs or philosophy. Instruction in the TM technique involves a seven-step course over five sessions (90-minute meetings).
89004819|NCT00193973|Active Comparator|1|
89004820|NCT00223782|Other|1|
89004821|NCT00411879|Placebo Comparator|Control Group|Patients with refractory cardiac arrest (as defined in methods) treated according to the latest guidelines for resuscitation and receiving placebo instead of vasopressin and corticosteroids
89004822|NCT00411879|Experimental|Study Group|Patients with refractory cardiac arrest treated with combined vasopressin, epinephrine, and methylprednisolone during resuscitation. Patients receive stress-dose hydrocortisone for postresuscitation shock
89004823|NCT00125216|Other|Arm 1|Single subject design - participant receives three administrations of the same treatment
89004824|NCT00223860|Other|1|
89004825|NCT00125255|Experimental|S-Caine Peel|
89004826|NCT00125255|Placebo Comparator|Placebo Peel|
89004827|NCT00223899|Experimental|A|IL-2-encoding plasmid formulated in phosphate-buffered saline at 0.5 mg/mL, 1.5 mg/mL, and 5.0 mg/mL (VCL-IM01) intratumorally injected and followed by electroporation with Inovio MedPulser® 1.0 cm array with needles up to 3 cm long (one 6-pulse cycle per tumor).
89004828|NCT00223938|Active Comparator|1|Oral Iron
89004829|NCT00223938|Experimental|2|sodium ferric gluconate
89004830|NCT00223938|Experimental|3|sodium ferric gluconate
89004831|NCT00206466|Active Comparator|One|Taxotere
89004832|NCT00224094|Experimental|Sequence A|Oral ERT then transdermal ERT
89004833|NCT00224094|Experimental|Sequence B|Transdermal ERT then oral ERT
89004834|NCT00206544|Active Comparator|1|Tamoxifen 40 mg daily
89004835|NCT00206544|Active Comparator|2|Progesterone 20 mg daily
89004836|NCT00206544|Placebo Comparator|3|Placebo daily
89004837|NCT00125450|Experimental|A|Chest Physiotherapy with Forced Expiratory Technique
89004838|NCT00125450|Active Comparator|B|Aspiration
89004839|NCT00206583|Experimental|EV/DNG (Qlaira, BAY86-5027)|Estradiolvalerate (EV)/Dienogest (DNG) Tablet p.o. (oral)
89004840|NCT00224211||I|Stable premature infants
89004841|NCT00206622|Active Comparator|Arm 1|
89004842|NCT00206622|Active Comparator|Arm 2|
89004843|NCT00206622|Placebo Comparator|Arm 3|
89004844|NCT00194402|Active Comparator|1|Atorvastatin 10 mg for 12 weeks followed by Slo-Niacin (titrated from 500 to 1500 mg over 8 weeks) taken with atorvastatin 10 mg for an additional 12 weeks
89004845|NCT00194402|Active Comparator|2|Slo-Niacin (titrated from 500 to 1500 mg over 8 weeks) for 12 weeks followed by atorvastatin 10 mg taken with Slo-Niacin 1500 mg for an additional 12 weeks
89409132|NCT03548766|Experimental|Healthy Subjects|Six healthy subjects will receive an ABT (Autologous Blood Transfusion)
89409133|NCT03548766|Experimental|Anemic Patients|Six patients with anemia will receive a HBT (Homologous Blood Transfusion)
89409134|NCT05284773|Experimental|intervention + standard of care|Caretakers of children 6-59 months old living in communities assigned to the intervention arm will be trained to detect malnutrition using MUAC on their children weekly. Caretakers living in communities assigned to the intervention will also receive usual standard of care.
89409135|NCT05284773|No Intervention|standard of care|Caretakers of children 6-59 months living in communities assigned to the standard of care arm will receive usual acute malnutrition screening. This includes biannual community-based screening by community health workers as well as weekly malnutrition days led by the Centre de Sante et Promotion Sociale (CSPS).
89409136|NCT04731584||AVC|Patients hospitalized for TM after a proximal ischemic stroke of the middle cerebral artery and whose reperfusion is satisfactory (TICI 2b, 2c and 3). Additional blood sample will be taken during usual treatment the day of the stroke.
89191709|NCT05373732|Active Comparator|Health Education|The health education (HE) intervention provided behavioral instructions for CVD risk factor prevention . This group received written materials, structured presentations, didactic instructions and group support for modifying the major cardiovascular risk factors including salt restriction, weight reduction, aerobic exercise, alcohol and smoking cessation.
89409137|NCT04731584||Control|Population of control patients, consisting of patients admitted on an outpatient basis for a diagnostic cerebral arteriography.
89409138|NCT02140632|Experimental|Local steroid injection|"The local injection of steroid is performed by the same investigator after the randomization. Using a sterile technique, 20mg methylprednisolone acetate premixed with lidnocaine is injected using a 25-gauge x 5/8 needle. The needle is inserted medially to the palmaris longus tendon at the distal palmar crease in the wrist at an angle of 45-degree to the forearm. The steroid is injected at approximately 1cm below the skin. The needle will be repositioned if there is any resistance to injection, or any pain or paraesthesia in the median nerve territory."
89409139|NCT02140632|Active Comparator|Wrist splinting|After randomization, the hands of the patients in the splinting group are splinted in neutral position with standard cotton-polyester splint. Patients are encouraged to use the splints during nighttime whenever possible for one month.
89409140|NCT05536375|Other|Healthy volunteers|
88884635|NCT01334606|Experimental|Nano: 4mm x 32G Pen Needle|Subjects will use the 4mm x 32G pen needle for all self-administered pen injections of diabetes medications during the assigned three week study period.
88884636|NCT01334606|Experimental|Short: 8mm x 31G Pen Needle|Subjects will use the 8 mm x 31G pen needle for all self-administered pen injections of diabetes medications during the assigned three week study period.
89409141|NCT02965599|Experimental|GSK3117391|Subjects will receive GSK3117391 (Dose A) for 28 days.
89409142|NCT02965599|Placebo Comparator|Placebo|Subjects will receive placebo for 28 days.
88884637|NCT01317875|Experimental|Stratum -1|Participants with baseline Platelet counts of 75-99 x10^9/L
88884638|NCT01317875|Experimental|Stratum -2|Participants with baseline Platelet counts of 50-74 x10^9/L
89409143|NCT03524456|Experimental|Home blood pressure monitoring|
89409144|NCT03524456|No Intervention|Usual monitoring|
89409145|NCT05517577|Experimental|Intervention group|An integrated Community-based package of interventions An integrated intervention consisting of behaviourchange communication, and male involvement will be delivered to pregnant women in their third trimester. They will receive 2 prenatal and five home visits. each visit will last 40-60 minutes. After delivery mother-newborn pairs will be followed up until six weeks.
89409146|NCT05517577|No Intervention|Control group|First, we selected two districts that have similar characteristics and are adjacent to each other. Both districts have a total of 72 kebeles (the smallest administrative unit), 36 in each district. Then, we chose 20, 10 from each district, kebeles on the boundary of the two districts to act as a buffer zone, to prevent information contamination between the intervention and control clusters. Finally, 26 kebeles in the Dedo district will be assigned to the intervention group while 26 kebeles in the Seka Chekorsa district are assigned to control clusters. Allocation concealment will not be done for study participants, as they would certainly know if they are in the intervention group or not. However, data collectors will be blinded to the allocation assignment by not being informed about it, not being part of the trial implementers, and not being inhabitants of any of the kebeles. Moreover, data analysts will be blinded to group allocation.
89409147|NCT04631848||ULTRASCORE™ Focused Force PTA Balloon|
89409148|NCT05578404|Placebo Comparator|Control Group|50 patients will receive the standard conventional therapy in addition to a placebo for 4 months.
89409149|NCT05578404|Active Comparator|Vit D Group|50 patients were given the standard conventional therapy plus cholecalciferol. Cholecalciferol was given as a high oral loading dose of 300,000 IU followed by a daily oral dose of 800 IU for 4 months.
89409150|NCT03646539|Experimental|Smartphone use + treatment as usual|Participants will receive treatment as usual and use the smartphone app for the management of mood.
89409151|NCT03646539|Active Comparator|Treatment as usual|Participants will receive treatment as usual.
88884639|NCT01226732|Experimental|Dose Level 1|Hsp90 Inhibitor AUY922: 22mg/m2 IV days 1, 8, and 15 of 21-day cycles Capecitabine: 1000mg/m2 PO BID d 1-14 of 21-day cycles
88884640|NCT01226732|Experimental|Dose Level 2|Hsp90 Inhibitor AUY922: 28mg/m2 IV days 1, 8, and 15 of 21-day cycles Capecitabine: 1000mg/m2 PO BID d 1-14 of 21-day cycles
88884641|NCT01226732|Experimental|Dose Level 3|Hsp90 Inhibitor AUY922: 40mg/m2 IV days 1, 8, and 15 of 21-day cycles Capecitabine: 1000mg/m2 PO BID d 1-14 of 21-day cycles
88884642|NCT01226732|Experimental|Dose Level 4|Hsp90 Inhibitor AUY922: 55mg/m2 IV days 1, 8, and 15 of 21-day cycles Capecitabine: 1000mg/m2 PO BID d 1-14 of 21-day cycles
88884643|NCT01226732|Experimental|Dose Level 5|Hsp90 Inhibitor AUY922: 70mg/m2 IV days 1, 8, and 15 of 21-day cycles Capecitabine: 1000mg/m2 PO BID d 1-14 of 21-day cycles
88884644|NCT01226732|Experimental|Dose Level 6|Hsp90 Inhibitor AUY922: 70mg/m2 IV days 1, 8, and 15 of 21-day cycles Capecitabine: 1250mg/m2 PO BID d 1-14 of 21-day cycles
88884645|NCT01194362||45 specimens collected from BAV patients|
88884646|NCT01194362||45 specimens collected from TAV patients|
88884647|NCT01194362||15 specimens collected from CABG pts|
89409152|NCT03521960|Active Comparator|Buspirone oral capsule|Buspirone (15 milligrams) administered orally three times per day
89409153|NCT03521960|Placebo Comparator|Placebo oral capsule|Placebo administered orally three times per day
89409154|NCT03548922||Pectus carinatum|Demographic data (age, sex), pressure of correction, Tanner stage, Risser stage, Haller index, pectus carinatum protrusion measurements of patients with pectus carinatum will be recorded and association of them with pressure of correction will be investigated.
89409155|NCT04616170|Active Comparator|Usual care|Patients in this arm will be randomized to the routine positioning instructions given at the time of crowning of the fetal vertex during vaginal delivery.
89409156|NCT04616170|Experimental|Hip extension|Patients in this arm will be randomized to hip extension at the time of crowning of the fetal vertex during vaginal delivery.
89409157|NCT03524300|Experimental|Robotic Assisted Total Gastrectomy|Robotic Assisted Total Gastrectomy will be performed for the treatment of patients assigned to this group.
89409158|NCT03524300|Active Comparator|Laparoscopic Assisted Total Gastrectomy|Laparoscopic Assisted Total Gastrectomy will be performed for the treatment of patients assigned to this group.
89409159|NCT02898597|Experimental|Video|Video-call delivered cognitive behavioral therapy
89409160|NCT02898597|Active Comparator|Voice|Voice-call delivered cognitive behavioral therapy
89409161|NCT05479578|Experimental|Treatment (cyclophosphamide, dexamethasone)|Patients receive cyclophosphamide PO QD and dexamethasone PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89409162|NCT01306604||Observation|Patients from the first day of life with Niemann Pick Type C syndrome NPC1/NPC2 or profound suspicion for Niemann Pick Type C syndrome NPC1/NPC2 disease
89409163|NCT04482088|Experimental|OTC & OTEE|Every participant will receive 10 weeks of occupational therapy in a clinic environment (OTC) followed by 10 weeks of occupational therapy in an equine environment
89409164|NCT03521882||Stroke Symptom Participants|
89409165|NCT03521882||Healthy Controls|
89409166|NCT02899377|Experimental|Group A: Health subjects|During Visit 1, these subjects will undergo the following: An MRI of the salivary glands with one-time intravenous (IV) bolus injection of 0.1 mmol/kg of gadoterate meglumine and receive one-time IV bolus injection of 500 megabecquerels (MBq) of 11C MET followed by a PET/CT (dynamic scan of the salivary glands followed by head to hip static scan)
89409167|NCT02899377|Experimental|Group B: pSS subjects|During Visit 1, subjects with pSS will undergo the following: An MRI of the salivary glands with IV bolus injection of <=0.1 mmol/kg of gadoterate meglumine and receive one-time IV bolus injections: 500 MBq of 11C-MET (PET/CT: as for Group A) and 200 MBq of 18F-FDG followed by a PET/CT (static head to hip scan)
89409168|NCT05578248||Collegiate Athletes|Group designated for collegiate athletes; see protocol for treatment plan
89409169|NCT05578248||Pre-collegiate Athletes|Group designated for pre-collegiate, or high school-age, athletes; see protocol for treatment plan
89409170|NCT04052217|Other|Control Ring|"Normal intercourse with very thin (less than 0.5cm) ring randomised to either 3, 4 or 5 episodes of intercourse (Phase A)"
89409171|NCT04052217|Experimental|"1 RIng"|"Intercourse wearing a 1 ring. Randomised to either 3, 4, or 5 episodes of intercourse (Phase B)"
89409172|NCT04052217|Experimental|"1.5 Ring"|"Intercourse wearing a 1.5 ring randomised to either 3, 4, or 5 episodes of intercourse (Phase C)"
89409173|NCT04052217|Experimental|"2 Ring"|"Intercourse with a 2 ring randomised to either 3, 4, or 5 episodes of intercourse (Phase D)"
89409174|NCT04467164|Experimental|Exhalatory-gated tVNS|exhalatory-gated tVNS on the left auricle
89409175|NCT04467164|Active Comparator|Inhalatory-gated tVNS|inhalatory-gated tVNS on the left auricle
89409176|NCT04853628|Experimental|Alerta Alcohol|The EC-1 receives Alerta Alcohol, which consists of session 1 or baseline, two sessions in three scenarios: at home, celebrations, and public places, and two follow-up evaluations. The adolescents are provided with answers related to their views of each scenario; this information is used to provide highly specific feedback regarding their knowledge, risk perception, self-esteem, attitude, social influence (modelling, norms and social pressure), self-efficacy and action plans. In addition, four booster sessions are given at home to reinforce the contents of the three scenarios. Evaluations take place after six and twelve months.
89409177|NCT04853628|Experimental|Alerta Alcohol 2.0|The EC-2 receives an improved version of Alerta Alcohol (Alerta Alcohol 2.0) using animated videos and new gamification strategies. Evaluations take place after six and twelve months.
89409178|NCT04853628|No Intervention|Control condition|The CC just completes the baseline and the evaluation questionnaires and then they are allowed to receive the intervention as well (as a waiting list). Evaluations take place after six and twelve months from baseline.
89409179|NCT04052763||High-risk ACS patients|High-risk ACS patients admitted to the emergency departement witch chest pain.
89409180|NCT03521726|Other|Intraluminal Amoxicillin eradication|20 Patients receive intraluminal Amoxicillin eradication of H. pylori.
89409181|NCT03521726|Other|Rabeprazole, Amoxicillin dual therapy|Patients fail to achieve intraluminal eradication of H. pylori will be assigned to the oral antibiotic rescue therapies with high dose dual therapy (Rabeprazole and Amoxicillin) for 14 days.
89409182|NCT03647241|Experimental|Self-Ligating Brackets|Patients will be treated using self-ligating brackets to achieve proper alignment of teeth
89409183|NCT03647241|Experimental|Self-Ligating Brackets with Corticotomy|Patients will be treated using self-ligating brackets with corticotomy (alveolar cortical cuts) in order to accelerate orthodontic treatment.
89409184|NCT03647241|Active Comparator|Traditionally-Ligated Brackets|Patients in this group will be treated using traditionally-ligated brackets to achieve proper alignment of teeth
89409185|NCT03524222|Experimental|Home Hospitalization|Patients will return home after triage, diagnosis, and the beginning of treatment in the emergency department with a set of specialized patient-tailored services (listed above). On discharge and 30 days after discharge, they will be interviewed regarding their hospitalization and health.
89531055|NCT01597245|Placebo Comparator|Placebo for ixekizumab|Placebo for ixekizumab administered by two SC injections at Week 0, then one SC injection per Dosing Regimen 1 until Week 12. At Week 12, placebo responders are assigned to placebo, and nonresponders to Dosing Regimen 2. Placebo for etanercept administered by one SC injection twice weekly starting at Week 0 up to Week 12 was used to blind etanercept injections for Dosing Regimen 1, Dosing Regimen 2, and Placebo Comparator groups.
89409186|NCT03548610|Experimental|Nanofat-seeded biological scaffold on surgical defect|Nanofat is obtained via lipoaspiration of 10cc of fat from abdomen under moderate local tumescent anesthesia w/ saline. Cannula access point is anesthetized by local lidocaine infiltration. Lipoaspirate is processed into nanofat using the Tonnard method, after 3-minute decantation. Aspiration is performed using a multihole 3mm cannula. Wound margin + bed is treated w/ topical & local injections of nanofat, then covered w/ a biological scaffold, the inferior surface of which is soaked in nanofat; scaffold is fixed w/ external dressings or resorbable sutures; external covering includes polyurethane film & 3 layers of dressings. Topical application creates a fine <1mm nanofat layer. Scaffold (Puracol Plus) is left in place to integrate w/ surrounding skin, while external dressings changed at 7 & 15 days. Lipoaspirate donor site needs mild to moderate compression for 24 hours & suture removal (if not absorbed) at 7 days.
89409187|NCT03548610|No Intervention|Standard of Care dressings|Immediately after surgical resection, each patient will be treated following the SOC, therefore with a local skin flap, rather than with a skin graft, based on surgeon assessment. Sutures, and moulage, if present, will be removed at 7 days and patient instructed to apply a daily silicone cream and sunscreen for 2 months.
89409188|NCT03621579|Other|the RNFLT and CMT|the retinal nerve fiber layer (RNFLT) and macular thickness (CMT)
89409189|NCT04781946|Experimental|Treatment Arm|Endoscopic pneumatic balloon dilation (PBD), gastric peroral endoscopic myotomy (G-POEM) and Roux-en-Y gastric bypass (RYGB) will be used for the management of post-LSG GSS using a predefined treatment algorithm.
89409190|NCT04302064|Experimental|Eplontersen|Single dose on Day 1 or multiple doses (every 4 weeks for 12 weeks) of Eplontersen administered SC.
89409191|NCT04302064|Placebo Comparator|Placebo|Single dose on Day 1 or multiple doses (every 4 weeks for 12 weeks) of Eplontersen-matching placebo administered SC.
88884648|NCT01003496|Active Comparator|Treatment as Usual (TAU)|
88884649|NCT01003496|Experimental|TAU + Long-Term Recovery Management (LTRM)|
88884650|NCT00962988|Experimental|Cost-Free Group|
89191710|NCT02545114|Other|Tolvaptan|Intervention arm. Open label, no control group
88884651|NCT00962988|Other|Prescription Only Group|
88884652|NCT00949312||Stage II unresected Colon Cancer|
88884653|NCT00883597||Controls|Patients with ileostomy.
88884654|NCT00883597||Standard Sepsis Treatment|Patients with ileostomy and sepsis
88884655|NCT00828308|Experimental|Ixabepilone|"Ixabepilone, 16 mg/m2 or 20mg/m2, weekly x 3, in 4 week cycles, x 4 cycles.~Prostatectomy 2-8 weeks after completion ***this was standard of care and not a part of the study***"
89409192|NCT03645993||Early-Onset Alzheimer's disease|Patients ages 45-60 with Early-Onset Alzheimer's disease
89409193|NCT03645993||Negative Control|Family members of patients with Early-Onset Alzheimer's disease who have consented to the study.
88884656|NCT00824252||Spousal Support|Questionnaire for Head and Neck Cancer Patients + Spouses
88884657|NCT00768820|Experimental|1|
88884658|NCT00691223||Experimental|Individuals with Goltz syndrome and their first degree relatives.
88884659|NCT00678730|Active Comparator|1|"Very low dose (0.005 mg/kg = 0.35 mg in a 70kg individual) THC, dissolved in ethanol. This dose is roughly equivalent to smoking 1/10th of a marijuana cigarette, or joint.~Low dose (0.025 mg/kg = 1.75 mg in a 70kg individual) THC, dissolved in ethanol. This dose is roughly equivalent to smoking 1/2 of a marijuana cigarette, or joint.~Medium dose (0.05 mg/kg = 3.5 mg in a 70 kg individual) THC, dissolved in ethanol. This dose is roughly equivalent to smoking 1 marijuana cigarette, or joint."
88884660|NCT00678730|Placebo Comparator|2|small amount of ethanol, (quarter teaspoon), with no THC
88884661|NCT00654264|Other|1|Patients will have water immersion on first day and sitting in a tub without water on the second day.
88884662|NCT00654264|Other|2|Patients will sit in a tub without water on the first day and have water immersion on the second day.
88884663|NCT00600015|Experimental|Combination Therapy|Erlotinib + Sorafenib
88884664|NCT00600015|Placebo Comparator|Placebo|Erlotinib + Placebo
88884665|NCT00500071|Experimental|1|
88884666|NCT00447122|Experimental|treatment 1|Gemcitabine 1000mg/m2 with lapatinib 1000mg/d weekly x 3 weeks
88884667|NCT00447122|Experimental|treatment 2|Gemcitabine 1000mg/m2 with lapatinib 1500mg/d weekly X 3 weeks
88884668|NCT00447122|Experimental|treatment 3|gemcitabine 1000 mg/m2 and oxaliplatin 100 mg/m2 on days 1 and 14 of a 28-day cycle with lapatinib 1000 mg/d
88884669|NCT00447122|Experimental|treatment 4|gemcitabine 1000 mg/m2 and oxaliplatin 100 mg/m2 on days 1 and 14 of a 28-day cycle with lapatinib 1500 mg/d
88884670|NCT00430040|Experimental|carvedilol|carvedilol
88884671|NCT00430040|Active Comparator|lisinopril|lisinopril
88922022|NCT05971537|Other|control arm|"In the control arm, appropriate IP antibiotics are to be continued. The dosage and duration of antibiotics will fully follow the recommendation from the latest International Society for Peritoneal Dialysis (ISPD) peritonitis guidelines~*For the subjects in the control arm who reach the defined primary end-point, they will automatically undergo crossover to the intervention arm to receive standard IP antibiotics together with the intra-catheter antibiotic-lock. They will be followed for another 6 months subsequently."
89409194|NCT03524144|Other|adult patients with Crohn's disease|All adult patients(18 years old or older) with Crohn's disease underwent gastroscopy; patients with diagnosed and treated Crohn's disease had gastroscopy performed during the re-examination, and patients diagnosed with Crohn's disease for the first time had gastroscopy performed during the initial consultation.
89409195|NCT03548376|Experimental|One-group intervention|Hippotherapy sessions were delivered once a week for 30 minutes, during 6 months.
89409196|NCT04291690|No Intervention|Control Group|Usual clinical care as prescribed by their treating clinicians; which may or may not include physiotherapy, geriatric consultation, nutritional consultation and supplementation, and treatment of anemia.
89409197|NCT04291690|Experimental|Intervention Group|Multi-component intervention in addition to usual care; which may include - in a targeted fashion - physical training for those with physical weakness, cognitive stimulation for those with cognitive impairment, oral nutritional supplementation for those with malnutrition, and intravenous iron replacement therapy for those with iron deficiency anemia.
89409198|NCT04466696||t4 colorectal cancer treated with ERAS protocol|prospective from January 2016 to May 2020
89409199|NCT04466696||t4 colorectal cancer treated with standards of care|retrospective from January 2010 to December 2015
89409200|NCT03546426|Experimental|study treatment|Pembrolizumab in combination with Autologous dendritic cells and Interleukin-2
89409201|NCT03525938|Active Comparator|TAP group|
89409202|NCT03525938|Sham Comparator|SHAM group|
89409203|NCT01316887|Experimental|GSK573719/GW642444|125/25 mcg once-daily
89004846|NCT00473512|Experimental|Abiraterone acetate|Abiraterone acetate 250 mg up to a maximum of 2000 mg capsules will be given orally daily for 28-day treatment period to determine the MTD in Phase 1 of the study. Participants will receive MTD of abiraterone acetate for 12 cycles (28 day each) in Phase 2 of the study. Dexamethasone 0.5 mg will be given orally (If participants have disease progression) daily up to 12 cycles.
89004847|NCT00206661|Experimental|Arm 1|
89409204|NCT01316887|Experimental|GSK573719|125 mcg once-daily
89409205|NCT01316887|Placebo Comparator|Placebo|inactive
89409206|NCT02897349|Experimental|linagliptin|
89004848|NCT00206661|Experimental|Arm 2|
89004849|NCT00194441|Experimental|1|Highly visible continually updating color coded bar computer display of cerebral perfusion pressure.
89004850|NCT00194441|Placebo Comparator|2|Bedside computer display with a blank screen except for a message indicating that the program is running.
89004851|NCT00473434|Experimental|001|Paliperidone3mg or 6mg or 9mg or 12mg once daily for 52 weeks
89004852|NCT00125567|Experimental|1|Stalevo (levodopa/carbidopa/entacapone)
89004853|NCT00125567|Active Comparator|2|Levodopa/carbidopa
89004854|NCT00473083|Experimental|Arm 1: Prophylactic Treatment|Participants will receive prophylactic treatment with minocycline 100 mg orally twice-daily for at least 4 weeks on the initiation of erlotinib therapy. If rash occurs during the 4 week period of minocycline prophylaxis, the minocycline prophylaxis will continue and additional treatment by grade of rash will be according to the Treatment Arm 2 schedule. If rash occurs after the completion of the 4 week prophylaxis period, treatment by grade of rash will be according to the Treatment Arm 2 schedule.
89409207|NCT02897349|Placebo Comparator|Placebo|
89409208|NCT03525782|Experimental|CAR-T|Anti-MUC1 CAR-T cells will be prepared ex vivo and infused back to the patients.
89409209|NCT03525782|Experimental|CAR-T combining PD-1 knockout|Anti-MUC1 CAR-T cells and PD-1 knockout Engineered T cells will be prepared ex vivo and infused back to the patients.
89409210|NCT03525782|Experimental|PD-1 knockout|PD-1 knockout Engineered T cells will be prepared ex vivo and infused back to the patients.
89409211|NCT03525782|Active Comparator|PD-1 mAb|Patients will be treated with a FDA approved monoclonal antibody for an identical course of treatment. This group will serve as PD-1 antibody treated group.
89409212|NCT03525782|Placebo Comparator|Sham Control|Patient's T cells will be separate without genetic or engineered modification ex vivo and infused back to the patients.
89409213|NCT03103048|Active Comparator|Group 1|The tests will be performed in thirty days, session with lasting 15 minutes each, when all volunteers will be submitted in four measure tests: 1- Without bandages (start); 2 - With placebo; 3 - With bandage; 4 - With tensioned bandage.
89409214|NCT03103048|Placebo Comparator|Group 2|The tests will be performed in thirty days, session with lasting 15 minutes each, when all volunteers will be submitted in four measure tests: 1- Without bandages; 2 - With placebo (start); 3 - With bandage; 4 - With tensioned bandage.
89409215|NCT03103048|Active Comparator|Group 3|The tests will be performed in thirty days, session with lasting 15 minutes each, when all volunteers will be submitted in four measure tests: 1- Without bandages; 2 - With placebo; 3 - With bandage (start); 4 - With tensioned bandage.
89409216|NCT03103048|Active Comparator|Group 4|The tests will be performed in thirty days, session with lasting 15 minutes each, when all volunteers will be submitted in four measure tests: 1- Without bandages; 2 - With placebo; 3 - With bandage; 4 - With tensioned bandage (start).
89409217|NCT01003262|Experimental|Emergency Department Observation|The EDOSP will consist of cardiac enzyme testing, 12-24 hours of cardiac monitoring, and echocardiogram testing by explicit criteria
89409218|NCT01003262|Active Comparator|Unstructured, inpatient evaluation|
89409219|NCT04282408|Experimental|Treatment|Group treated with 3D printed brace
89536688|NCT04430855|Experimental|Upadacitinib 30 mg|Participants will receive 30 mg upadacitinib orally once a day for 12 weeks (Period 1) followed by 30 mg upadacitinib orally once a day for 36 weeks (Period 2).
89409220|NCT03362710|Experimental|PAD patients|"Patients referred for an arterial doppler assessment of lower limbs will be included.~Intervention is a series of examination, followed by the measurement of the ABI and an arterial echo-doppler of the lower limbs +/- transcutaneous oxygen pressure measurements in case of suspected critical limb ischemia.~A technician will perform the evaluation with simplified tools blinded to the results of vascular specialised investigations"
89409221|NCT03645291|Active Comparator|Skin test with local extract|Skin prick test and intradermal test with local stinging insect allergen extracts that develop in Immunological division of Siriraj hospital, mahidol University
89409222|NCT03645291|Sham Comparator|Skin test with commercial extract|Skin prick test and intradermal test with commercial stinging insect allergen extracts that order from ALK company
89409223|NCT03134378|Experimental|14 days triple therapy|Rabeprazole Clarithromycin Amoxicillin
89409224|NCT03134378|Placebo Comparator|10 days triple therapy|Rabeprazole Clarithromycin Amoxicillin
89409225|NCT03645837|Experimental|10 minutes|Compression clamp release start after 10 minutes
88884672|NCT00382252|Experimental|18F-FDG PET/CT + RFA|"18F-FDG PET/CT: I.V. injection of 5 to 15 mCi (185 to 555 MBq) of 18F-FDG. Capture time of 60 to 90 minutes. Acquisition of images: A whole body CT scan with normal breathing will be performed for attenuation correction with 5mm thick slices. A whole body PET acquisition of 6 or 7 steps will be done from the upper third of the thighs to the base of the skull. PETC/CT performed at inclusion, 1 month et 3 months after RFA.~RFA: Treatment procedure: the location under scanner allows to place the electrode in the center of the tumor. The treatment then lasts 15 to 20 minutes.~CT scanner: The CT examination will be performed in spiral acquisition without or after injection of contrast medium (70 ml at 2 or 3 ml/sec). On a 16-slice scanner, the examination is performed with 1.25 mm slices every 0.9. Constants generally used 120kV, 350 mA. Ct scanner performed at inclusion, 48H post-RFA, 1 month, 3 months, 6, 9 and 12 months after RFA."
88884673|NCT00290251|Active Comparator|ulipristal acetate -20 mg|20 mg daily dose ulipristal acetate for three menstrual cycles or up to 102 days
89191711|NCT02570568|Active Comparator|Conventional Venepuncture|Veins will be identified by a combination of visualization and palpation. Once a suitable vein is localized, a tourniquet is applied (Braun® International, USA). The area of the skin to be cannulated is disinfected with an alcohol wipe (Webcol®, Covidien®, USA). For the setting of IV cannulation, a standardized 23G IV cannula is used (Introcan Safety®, Braun®, USA). Normal saline (PosiFlush® 3ml, BD®, USA) will be used for flushing the cannula after successful cannulation. For blood taking, a syringe (Terumo®, Philippines) ranging from 2ml to 20ml and a 23G needle (Venofix®, Braun®, USA) will be used. All instruments needed for venepuncture, including 4 IV cannula or 4 needles should be by the patient's bedside prior to the start of each venepuncture.
89191712|NCT02570568|Experimental|Veinlite|Placing Veinlite onto the skin will cause the outlines of the veins to show up. Once a suitable vein is localized, a tourniquet is applied (Braun® International, USA). The area of the skin to be cannulated is disinfected with an alcohol wipe (Webcol®, Covidien®, USA). For the setting of IV cannulation, a standardized 23G IV cannula is used (Introcan Safety®, Braun®, USA). Normal saline (PosiFlush® 3ml, BD®, USA) will be used for flushing the cannula after successful cannulation. For blood taking, a syringe (Terumo®, Philippines) ranging from 2ml to 20ml and a 23G needle (Venofix®, Braun®, USA) will be used. All instruments needed for venepuncture, including 4 IV cannula or 4 needles should be by the patient's bedside prior to the start of each venepuncture.
89409226|NCT03645837|Experimental|20 minutes|Compression clamp release start after 20 minutes
89409227|NCT03645837|Active Comparator|30 minutes|Compression clamp release start after 30 minutes
89409228|NCT05434104|Experimental|Lactoferrin intervention group|Women will be given bovine lactoferrin 300mg vaginal pessaries to insert every evening for the first 21 days of the study [25].
89409229|NCT05434104|Active Comparator|Usual care control - standard oral antibiotics/antifungals|Control women with BV will be given oral metronidazole 400mg twice daily for five days (and routine advice about avoiding alcohol). Control women with candida will be given a fluconazole 150mg capsule to take orally the same day.
88884674|NCT00290251|Active Comparator|ulipristal acetate - 10 mg|10 mg daily dose ulipristal acetate for three menstrual cycles or up to 102 days
88884675|NCT00290251|Placebo Comparator|Placebo|Placebo taken daily for three menstrual cycles or up to 102 days
88884676|NCT00290251|No Intervention|Pre-ulipristal acetate 10 mg|Subjects were studied during one baseline cycle without any intervention before entering ulipristal acetate 10 mg arm
88884677|NCT00290251|No Intervention|Pre-ulipristal acetate 20 mg|Subjects were studied during one baseline cycle without any intervention before entering ulipristal acetate 20 mg arm
88884678|NCT00290251|No Intervention|Pre-placebo|Subjects were studied during one baseline cycle without any intervention before entering placebo arm
88884679|NCT00066963|No Intervention|Counseling Only|Counseling Only
88884680|NCT00066963|Experimental|FV every 12mo for 24mo + Counsel|Preventive fluoride varnish every 12mo for 24mo plus Counseling
88884681|NCT00066963|Experimental|FV every 6mo for 24mo + Counseling|Preventive fluoride varnish every 6mo for 24mo plus Counseling
88884682|NCT01397487|Other|one single arm|All patients are included to complete a biopsy of half part of the embryos
89409230|NCT03699748|Experimental|Intervention Group Arm|"Patients randomized into the intervention will be assigned a lay health worker who will contact the patient to begin the intervention. The intervention includes: education on early advance care planning, documenting goals of care, assessing symptoms, and coordinating community services (such as home health, home visits, and home hospice).~The intervention arm will also receive usual care as provided by Unite Here Health and their local oncologists."
89409231|NCT03699748|Active Comparator|Control Group Arm|The control group arm will receive usual care as provided by Unite Here Health and their local oncologists.
88884683|NCT01397500|Active Comparator|Genotropin|"6 months Genotropin (open treatment)~Daily dose:~Male < 45 years: 0,4 mg; ≥ 45 years: 0,2 mg Female < 45 years: 0,5 mg; ≥ 45 years: 0,3 mg Starting with half of the dose for the first 4 weeks."
88884684|NCT01397500|Active Comparator|Testosterone undecannoate|18 weeks testosterone undecanoate/placebo (double-blind treatment) 1000 mg/4 ml at baseline and after 6 weeks
88884685|NCT01397500|No Intervention|control group|No Intervention.
88884686|NCT01397513|Active Comparator|Aspirin 75mg|
88884687|NCT01397513|Active Comparator|Aspirin 320mg|
89409232|NCT03524066|Experimental|Inhaled + Bronchoscopy|One-time Inhalation of Salbutamol 200 µg, Salmeterol 50µg and Fluticasone 500µg. During two bronchoscopic procedures two pre-specified lung tissue sites (middle lobe and lingula) will be sampled. Bronchoadsorption sample, bronchial brushing, mucosal biopsy, and bronchoalveolar lavage (BAL) samples will be taken from each site.
89409233|NCT03524066|Experimental|Systemic + Bronchoscopy|One-time Salbutamol (8 mg) and Propranolol (40mg) administered orally. During two bronchoscopic procedures two pre-specified lung tissue sites (middle lobe and lingula) will be sampled. Bronchoadsorption sample, bronchial brushing, mucosal biopsy, and BAL samples will be taken from each site.
88884688|NCT01397539|Experimental|BIIB037|A single dose of BIIB037 by intravenous infusion.
88884689|NCT01397539|Placebo Comparator|Placebo|A single dose of placebo matching BIIB037 by intravenous infusion.
88884690|NCT01397565|Active Comparator|Laparoscopic cholecystectomy|Patients in this arm will undergo conventional laparoscopic cholecystectomy
88884691|NCT01397565|Experimental|Minilaparoscopic cholecystectomy|Patients in this arm will undergo laparoscopic cholecystectomy using minilaparoscopic instruments
88884692|NCT01397604|No Intervention|Saline Placebo|"The trial will consist of a total of 32 people. An over-enrollment of about 10% (3 volunteers) will be permitted.~Each cohort will be recruited in sequence. Cohort I will include 16 subjects that will receive a subcutaneous injection, randomized equally so that 5 individuals will receive GLA-AF (2µg), 5 individuals will receive GLA-SE, 3 individuals will receive saline placebo and 3 individuals will receive SE vehicle. Cohort II will include 16 subjects that will receive intramuscular injections, randomized equally into 5 GLA-AF (2µg) subjects, 5 GLA-SE (2µg) subjects, 3 saline placebo subjects and 3 SE vehicle control subjects."
88884693|NCT01397604|Placebo Comparator|SE Vehicle|"The trial will consist of a total of 32 people. An over-enrollment of about 10% (3 volunteers) will be permitted.~Each cohort will be recruited in sequence. Cohort I will include 16 subjects that will receive a subcutaneous injection, randomized equally so that 5 individuals will receive GLA-AF (2µg), 5 individuals will receive GLA-SE, 3 individuals will receive saline placebo and 3 individuals will receive SE vehicle. Cohort II will include 16 subjects that will receive intramuscular injections, randomized equally into 5 GLA-AF (2µg) subjects, 5 GLA-SE (2µg) subjects, 3 saline placebo subjects and 3 SE vehicle control subjects.~The SE (squalene) vehicle contains the oil emulsion in which the GLA-SE is solubilized."
88884694|NCT01397604|Active Comparator|GLA-AF|"The trial will consist of a total of 32 people. An over-enrollment of about 10% (3 volunteers) will be permitted.~Each cohort will be recruited in sequence. Cohort I will include 16 subjects that will receive a subcutaneous injection, randomized equally so that 5 individuals will receive GLA-AF (2µg), 5 individuals will receive GLA-SE, 3 individuals will receive saline placebo and 3 individuals will receive SE vehicle. Cohort II will include 16 subjects that will receive intramuscular injections, randomized equally into 5 GLA-AF (2µg) subjects, 5 GLA-SE (2µg) subjects, 3 saline placebo subjects and 3 SE vehicle control subjects.~GLA-AF contains the study drug in an aqueous solution."
88884695|NCT01397604|Active Comparator|GLA-SE|"The trial will consist of a total of 32 people. An over-enrollment of about 10% (3 volunteers) will be permitted.~Each cohort will be recruited in sequence. Cohort I will include 16 subjects that will receive a subcutaneous injection, randomized equally so that 5 individuals will receive GLA-AF (2µg), 5 individuals will receive GLA-SE, 3 individuals will receive saline placebo and 3 individuals will receive SE vehicle. Cohort II will include 16 subjects that will receive intramuscular injections, randomized equally into 5 GLA-AF (2µg) subjects, 5 GLA-SE (2µg) subjects, 3 saline placebo subjects and 3 SE vehicle control subjects.~GLA-SE contains the study drug in a squalene oil emulsion."
88884696|NCT01397630|Experimental|Accelerated Oxytocin Titration|
89409234|NCT03903861|Experimental|Glucose alone|Participants will complete a glycogen depleting bout of exercise followed by the provision of glucose-alone over 4 hours of recovery before a subsequent bout of exercise.
89409235|NCT03903861|Experimental|Galactose alone|Participants will complete a glycogen depleting bout of exercise followed by the provision of galactose-alone over 4 hours of recovery before a subsequent bout of exercise.
88884697|NCT01397630|Active Comparator|Gradual Oxytocin Titration|
88884698|NCT01397643|Other|Non-operative|Patients in the non-operative arm will be managed conservatively using a sling, or an above elbow lightweight cast if problems with pain, for 10-14 days post injury. Patients will then be allowed to mobilise as able.
88884699|NCT01397643|Other|Operative|Patients in this arm will be managed operatively for their olecranon fracture using either tension band wiring or plate fixation.
88884700|NCT01397708|Experimental|INXN-1001 in combination with INXN-2001|Intratumoral injections of INXN-2001 (Ad-RTS-hIL-12) at a constant dose in combination with inter-cohort escalating doses of INXN-1001 (activator ligand).
88884701|NCT01397734|Experimental|Cohort 1|Patients who are receiving Imatinib as part of their standard of care therapy for CML.
88884702|NCT01397734|Experimental|Cohort 2|Patients who are receiving Dasatinib as part of their standard of care therapy for CML.
88884703|NCT01397734|Experimental|Cohort 3|Patients who are receiving Nilotinib as part of their standard of care therapy for CML.
89409236|NCT03903861|Experimental|Glucose and galactose|Participants will complete a glycogen depleting bout of exercise followed by the provision of glucose and galactose over 4 hours of recovery before a subsequent bout of exercise.
89409237|NCT05063305|Experimental|Male Probiotic|• Participants will be instructed to take 1 capsule per day for the following 90 days. If a participant misses a day, they should resume taking 1 capsule per day the next day. The capsule should not be crushed or chewed. The capsule may be taken with or without food per participant preference. The participant should consistently take the capsule at a similar time each day (example: always take it in the morning or evening)
89409238|NCT05063305|Placebo Comparator|Male Placebo|• Participants will be instructed to take 1 capsule per day for the following 90 days. If a participant misses a day, they should resume taking 1 capsule per day the next day. The capsule should not be crushed or chewed. The capsule may be taken with or without food per participant preference. The participant should consistently take the capsule at a similar time each day (example: always take it in the morning or evening)
89409239|NCT05063305|Experimental|Female Probiotic|• Participants will be instructed to take 1 capsule per day for the following 90 days. If a participant misses a day, they should resume taking 1 capsule per day the next day. The capsule should not be crushed or chewed. The capsule may be taken with or without food per participant preference. The participant should consistently take the capsule at a similar time each day (example: always take it in the morning or evening)
89409240|NCT05063305|Placebo Comparator|Female Placebo|• Participants will be instructed to take 1 capsule per day for the following 90 days. If a participant misses a day, they should resume taking 1 capsule per day the next day. The capsule should not be crushed or chewed. The capsule may be taken with or without food per participant preference. The participant should consistently take the capsule at a similar time each day (example: always take it in the morning or evening)
89409241|NCT04052529|Experimental|Intervention|Participants are instructed to use a popular dietary self-monitoring application on their smartphone for one month.
89409242|NCT04052529|No Intervention|Control|Participants are not asked to use the smartphone application.
88884704|NCT01397773||Hemodialysis group|Patients on chronic hemodialysis program
88884705|NCT01397773||Peritoneal dialysis group|Patients on chronic peritoneal dialysis program
88884706|NCT01397773||Pre-dialysis group|Patients with chronic kidney disease stage-4
88884707|NCT01397773||Control group|Healthy subjects
88884708|NCT01397799|Experimental|Treatment|Subjects will be enrolled into a 28-day dose-escalation study. If no DLT's are observed during the first 28 days, subjects are eligible to continue treatment in the Extension Phase and can remain on treatment until toxicity occurs or until disease progression.
88884709|NCT01397812||1|"Subjects will comprise of patients who are the recipients of a heart transplant within the previous 12 months and are scheduled for a routine endomyocardial biopsy.~Subjects will provide breath samples for the Heartsbreath test using the BreathScanner 1.0. Optionally subjects will provide breath samples using the BreathLink point of care system."
88884710|NCT01397838|Experimental|Pro-Bone|
88884711|NCT01397903||Group 1|"Inpatients and outpatients diagnosed with major depressive disorder as per the DSM-IV criteria who had poor disease control during antidepressant treatment and have completed 4 weeks of add-on drug therapy at enrolment in the study.~The percentage of patients with CGI-I score ≤ 2 at study Visit (4 weeks after the commencement of add-on treatment)."
88884712|NCT01397942|Experimental|Diet intervention - Ancient vegatables|A healthy Nordic diet with high content of bitter strong tasting vegetables and cabbages.
88884713|NCT01397942|No Intervention|Control Nordic diet|A diet habitually consumed in the Nordic countries
88884714|NCT01397942|Experimental|Diet intervention - Modern Vegetables|A healthy Nordic diet with high content of sweet and mild tasting vegetables and cabbages.
88884715|NCT01397955||Group 1|Drug (incl. Placebo)
89409243|NCT03446794||patients with NVAF and ESCKD on HD|
88884716|NCT01397981|Experimental|Walking modification|Changing kinematics for walking
88884717|NCT01397994|Active Comparator|Nicorandil test arm|Nicorandil is given with atenolol therapy.
88884718|NCT01397994|Active Comparator|Atenolol control arm|Atenolol 50 mg OD is given.
88884719|NCT01398007|No Intervention|Conventional syringe|Conventional syringe
88884720|NCT01398007|Experimental|Camouflage syringe|The camouflage syringe is divided into three parts: head, body and tail. Head consists of bristles to apply topical anesthesia. The body holds the normally used conventional syringe and presents with a slot to check the aspiration results. The tail hides the conventional syringe loaded with the local anesthetic solution. This syringe is made up of cold-cure acrylic with a colorful toy-like look.
88884721|NCT01398020|Active Comparator|Standard bowel prep|Subject will receive standard bowel prep prior to colonoscopy.
88884722|NCT01398020|Experimental|2L Bi-Peglyte|Subjects will be asked to take 2L Bi-Peglyte + 15mg bisacodyl for bowel prep the day before colonoscopy.
89409244|NCT04515121|Experimental|HD-tCES & lower limb rehabilitation|The experiment group will receive HD-tCES combined with lower limb rehabilitation of affected side.
88884723|NCT01398033|Active Comparator|Drug-coated balloon|"pre-dilatation of the target lesion with a non-coated balloon.~treatment of the target lesion with the paclitaxel-coated balloon"
88884724|NCT01398033|Placebo Comparator|non-coated balloon|Treatment of the target lesion with plain balloon angioplasty.
88884725|NCT01398046|Active Comparator|Dasatinib|
88884726|NCT01398046|Experimental|Dasatinib plus Rabeprazole|
88884727|NCT01398046|Experimental|Dasatinib plus Rabeprazole AND Betaine Hydrochloride|
88884728|NCT01398072|Active Comparator|Moxifloxacin|
88884729|NCT01398072|Active Comparator|Azithromycin|
88884730|NCT01398072|Active Comparator|Doxycycline|
88884731|NCT01398072|Placebo Comparator|Placebo|
89409245|NCT04515121|Sham Comparator|Sham HD-tCES & lower limb rehabilitation|The sham control group will receive sham HD-tCES combined with lower limb rehabilitation of affected side.
89409246|NCT03523910|Experimental|Patient|A research MRI scan with exercise will be obtained in conjunction with standard of care cardiopulmonary testing.
88884732|NCT01398098|Experimental|COLOKIT®|
88884733|NCT01398111|Active Comparator|Treatment R2|
88884734|NCT01398111|Active Comparator|Treatment R1|
88884735|NCT01398111|Placebo Comparator|Placebo|
88884736|NCT01398111|Experimental|Treatment T|
88884737|NCT01398137||Ragweed allergic subjects|
89409247|NCT03525704|Experimental|Saline Solution Enriched|Saline Solution enriched with electrolytes and PH balanced to mimic normal tears
89409248|NCT03525704|Active Comparator|Saline Rinse Solution|Saline Solution .9% NaCL
89409249|NCT03047551|Active Comparator|Transabdominal Sonography|"Subjects will receive transabdominal sonography using a standard ultrasound device to determine medical abortion eligibility.~A transabdominal ultrasound is used to look at the pelvic organs. Gel is placed on your abdomen. Then a small, handheld unit called a transducer is gently moved around to view the pelvic organs. The transducer sound waves make a picture on the TV screen."
88884738|NCT01398150|Placebo Comparator|Sweetened Beverage|looks like and is given in the same way as the experimental treatment but contains no active ingredient
88884739|NCT01398150|Experimental|Cranberry Beverage|15 ounce bottle of cranberry beverage consumed daily for 70 days
88884740|NCT01398163|Experimental|1 = Tested product|
88884741|NCT01398163|Active Comparator|2 = Control product|
88884742|NCT01398163|No Intervention|3 = No product|
88884743|NCT01398189|Experimental|clozapine|patients with refractory schizophrenia or schizoaffective disorder
88884744|NCT01398202|Active Comparator|Vitamin D3 (20 microgram/day)|
88884745|NCT01398202|Active Comparator|25-hydroxyvitamin D (7 microgram/day)|
88884746|NCT01398202|Active Comparator|25-hydroxyvitamin D3 (20 micogram/day)|
88884747|NCT01398202|Placebo Comparator|Placebo|
88884748|NCT01398215||transvaginal NOTES|
88884749|NCT01398228|Other|Group 1|Group 1 will receive quality improvement initiatives first, after 6 months of baseline initiation.
88884750|NCT01398228|Other|Group 2|Group 2 will receive quality improvement initiatives second, after 6 months of the intervention initiation for Group 1.
88884751|NCT01398228|Other|Group 3|Group 3 will receive quality improvement initiatives third, after 6 months of the intervention initiation for Group 2.
88884752|NCT01398228|Other|Group 4|Group 4 will receive quality improvement initiatives forth, after 6 months of the intervention initiation for Group 3.
88884753|NCT01398241|Experimental|Active|
88884754|NCT01398241|Placebo Comparator|Placebo|
88884755|NCT01398254|Other|TRA|Transradial Access
88884756|NCT01398254|Other|TFA|Transfemoral Access
88884757|NCT01398267|Experimental|1|
88884758|NCT01398267|Placebo Comparator|2|
88884759|NCT01398293|Experimental|A|
88884760|NCT01398293|Experimental|B|
88884761|NCT01398293|Active Comparator|C|
88884762|NCT01398293|Placebo Comparator|D|
88884763|NCT01398306||Group A|Patients with clear cell renal cell carcinoma with metastases.
88884764|NCT01398306||Group B|Patients with low grade neuro-endocrine tumours with metastases.
88884765|NCT01398345|Active Comparator|Exercise and Respiratory Training|
88884766|NCT01398371|Active Comparator|Stable digoxin therapy|Participants need to have been receiving digoxin therapy for at least 3 months at a dose that results in digoxin plasma levels of 0.4-0.8 on 2 consecutive blood tests (at least 1 weeks apart) prior to randomisation. The dose of digoxin must remain stable for at least 2 weeks prior to randomisation.
88884767|NCT01398371|Experimental|Digoxin withdrawal|Participants will receive a placebo for 4 weeks.
88884768|NCT01398384|Active Comparator|Nitric Oxide|nitric oxide for inhalation
88884769|NCT01398384|Placebo Comparator|Placebo|inhalation gas
88884770|NCT01398423|Active Comparator|Active control|Losartan potassium (50 mg) plus placebo to match alpha lipoic acid (600 mg)
88884771|NCT01398423|Experimental|INV-144|INV-144 is a combination drug product consisting of losartan potassium (50mg) and alpha lipoic acid (600 mg)
89409250|NCT03047551|Active Comparator|Transvaginal Sonography|"Subjects will receive transvaginal sonography using a standard ultrasound device to determine medical abortion eligibility.~Transvaginal ultrasound is an examination of the female pelvis and urogenital tract (kidneys and bladder). It differs from an abdominal ultrasound as it looks at the pelvic organs from inside the vagina."
88884772|NCT01398436|Experimental|Catheter tip in right atrium|In this group a central venous catheter will be advanced for its entire length unless arrhythmias develop.Catheter position will be controlled by transesophageal echocardiography and/or by chest radiography.
88884773|NCT01398436|No Intervention|Catheter tip in superior vena cava|In this group a central venous catheter will be inserted for 15 cm in accordance with standard practice. Catheter position will be controlled by transesophageal echocardiography and/or by chest radiography
88884774|NCT01398449|Experimental|B|After esophagectomy, patients in Arm B will receive adjuvant chemotherapy, followed by elective nodal irradiation (ENI)
88884775|NCT01398449|Active Comparator|A|After esophagectomy, patients in Arm A will receive adjuvant chemotherapy only
88884776|NCT01398462|Experimental|CWP232291|
88884777|NCT01398488|Active Comparator|Conventional Patient education|Conventional Patient education by health care professionals.
88884778|NCT01398488|Experimental|Patient education via Tablet computer|Patient education after lung transplantation via Tablet computers. An electronic patient questionnaire via tablet computer will be collected in addition.
88884779|NCT01398501|Experimental|Post-SCT Sorafenib|Sorafenib will be given as maintenance therapy after allo HCT to patients with FLT3-ITD AML.
88884780|NCT01398527|No Intervention|LTC Osteoporosis Toolkit Only|Homes will receive the LTC osteoporosis toolkit only and will be required to attend an online webinar to outline the toolkit contents.
88884781|NCT01398527|Active Comparator|Educ sessions & LTC Osteoporosis toolkit|LTC homes will receive the LTC osteoporosis toolkit, on line webinar. Three educational sessions lead by an osteoporosis expert will also take place, 1 on-site visit and 2 webinars.
88884782|NCT01398540|Experimental|elderly|subjects are at least 60 years old (with no upper age limit), receiving 2 immunisations with IXIARO
88884783|NCT01398540|Experimental|young|subjects 18 to 40 years old, receiving 2 immunisations with IXIARO
88884784|NCT01398553|Experimental|Armeo Spring|
88884785|NCT01398553|Active Comparator|conventional physiotherapy|
88884786|NCT01398579|Active Comparator|Group A|Group A: WLE followed by AFI followed by NBI followed by pCLE.
88884787|NCT01398579|Active Comparator|Group B|Group B: WLE followed by NBI followed by AFI followed by pCLE.
88884788|NCT01398592|Experimental|Vildagliptin|Experimental
88884789|NCT01398592|Active Comparator|Sitagliptin|Active comparator (drug)
88884790|NCT01398605|Experimental|moderate exercise training|
88884791|NCT01398605|Experimental|intensive exercise training|
88884792|NCT01398605|No Intervention|Control|
88884793|NCT01398618|Experimental|4M-RMP|adult household contacts with latent tuberculosis infection receiving 4-month rifampicin preventive therapy
88884794|NCT01398618|Active Comparator|9M-INH|adult household contact with latent tuberculosis infection receiving 9-month isoniazid preventive therapy
88884795|NCT01398631||Study Group|All included patients presented with chest pain at the emergency room within the inclusion period.
88884796|NCT01398644|Active Comparator|Phlebotomy -intervention phlebotomy|Patients are treated with phlebotomy if ferritin level >50 ug/l
88884797|NCT01398644|Experimental|Erythrocytapheresis|Patients are treated with erythrocytapheresis if serum ferritin level >50ug/l
88884798|NCT01398657|Experimental|Adjuvant Androgen-Deprivation Therapy|Cryotherapy with Short-term Adjuvant Androgen-Deprivation Therapy
88884799|NCT01398657|No Intervention|No adjuvant therapy|Cryotherapy without any adjuvant therapy
88884800|NCT01398670|Experimental|Lispro arm|Lispro and Lispro Mix 75/25 /Lispro Mix 50/50
88884801|NCT01398670|Active Comparator|Humalog® arm|Humalog® and Humalog® Mix75/25 / Humalog® Mix50/50
88884802|NCT01398696|Active Comparator|Patient Information Leaflets|Patient Information Leaflets (PIL) is given to the patient during consultation
88884803|NCT01398696|Placebo Comparator|usual consultation without PIL|no particular intervention during consultation for the patient.
88884804|NCT01398709|Active Comparator|Slow rewarming strategy|Slow rewarming strategy (0.24 degrees C/min)
88884805|NCT01398709|Active Comparator|Fast rewarming strategy|Fast rewarming strategy (0.5 degrees C/min)
88884806|NCT01398722|Active Comparator|Intensive insulin therapy|Intensive insulin therapy(Blood glucose target: 110-150 mg/dL)
88884807|NCT01398722|Active Comparator|Conventional insulin therapy|Conventional insulin therapy(Blood glucose target: 150-180 mg/dl)
88884808|NCT01398748|Active Comparator|Intranasal GSH 100mg/ml|Study participant will be provided with monthly supply of study medication and will be asked to intake 100mg/ml of intranasal glutathione (n=15) An amount of 1ml with a frequency 3x per days and duration of 12 weeks with a dosage of 2100mg
88884809|NCT01398748|Active Comparator|Intranasal glutathione 200mg/ml|Study participant will be provided with monthly supply of study medication and will be asked to intake 200/ml of intranasal glutathione (n=15) An amount of 1ml with a frequency 3x per days and duration of 12 weeks with a dosage of 4200mg
88884810|NCT01398748|Placebo Comparator|Saline intranasal delivery|Study participant will be provided with monthly supply of study medication and will be asked to intake Intranasal saline delivery (n=15) An amount of 1ml with a frequency 3x per day with a duration of 12 weeks
88884811|NCT01398748|No Intervention|Watchful waiting|No intervention, watchful waiting only (n=4)
88884812|NCT01398761|Experimental|Intervention|nurses, residents, PAs, and attendings from the two pilot services
88884813|NCT01398878|No Intervention|Traditional work schedule|Residents in the intensive care unit perform overnight shifts in excess of 24 hrs every fourth night
88884814|NCT01398878|Active Comparator|Intervention work schedule|Residents in the Intensive Care Unit perform shifts less than 16 hours in length and have at least 8 hours off between shifts
88884815|NCT01398891|Experimental|Positive Psychology Exercises|
88884816|NCT01398904||Body dysmorphic disorder (BDD) Participants|Participants must be 18 years or older with a primary diagnosis of body dysmorphic disorder (BDD), a BDD Yale-Brown Obsessive Compulsive Scale (BDDY-BOCS) score of >20, and a primary facial/head concern. Participants must have the ability to provide informed consent and understand study staff.
88884817|NCT01398904||Healthy Controls|Males and females 18 years of age or older with ability to provide informed consent and understand study staff.
88884818|NCT01398917|Active Comparator|short-term stenting|one 10 Fr Plastic endoprosthesis or 2 7 Fr plastic endoprosthesis inserted through dominant stricture(s), to be extracted after 1-2 weeks
88884819|NCT01398917|Active Comparator|balloon dilatation|4 cm 6 mm biliary dilatation balloon to be inflated for 2 minutes in dominant stricture(s)
88884820|NCT01398930|Active Comparator|Group I was treated with etoricoxib|
88884821|NCT01398930|Active Comparator|Group II was treated with acupuncture and etoricoxib|
88884822|NCT01398930|Sham Comparator|Group III was treated with sham acupuncture and etoricoxib.|
88884823|NCT01398969|Experimental|Fresh FMT|Participants in this arm will receive Fresh FMT via rectal administration. They will be followed for 13 weeks to assess the cure or recurrence of CDI. All other procedures between the two arms will be identical.
88884824|NCT01398969|Experimental|Frozen-and-Thawed FMT|Participants in this arm will receive Frozen-and-Thawed FMT via rectal administration. They will be followed 13 weeks to assess the cure or recurrence of CDI. All other procedures between the two arms will be identical.
88884825|NCT01398995|Experimental|90 minutes|Basal insulin infusion reduced to 50% of normal 90 minutes prior to exercise
88884826|NCT01398995|Experimental|60 minutes|Basal insulin infusion reduced to 50% of normal 60 minutes prior to exercise
88884827|NCT01398995|Experimental|30 minutes|Basal insulin infusion reduced to normal 30 minutes prior to exercise
88884828|NCT01398995|Experimental|Start|Basal insulin infusion reduced to 50% of normal at the start of exercise
88884829|NCT01399021|Other|Flat Davol drain|both arms will have flat davol drains placed at the end of the parotidectomy surgery
88884830|NCT01399034||MicroRNA study|Obese group (+ periodontitis group) Non-obese group (+ periodontitis group)
88884831|NCT01399034||DNA methylation study|Periodontitis group Healthy periodontium group
88884832|NCT01399073||Patients with Neglect|
88884833|NCT01399073||Patients with Hemianopsia|
88884834|NCT01399073||Healthy age-matched controls|
88884835|NCT01399086||Fulvestrant|
88884836|NCT01399112|Experimental|Electronic Decision Support System|The Electronic Decision Support System (EDSS) is a 5-module computer program aimed to assess, motivate, educate, solicit preferences, and provide feedback and referrals for people with severe mental illness. The program provides: a) a personalized assessment of the individual's smoking, b) information to improve knowledge of smoking risks and treatment benefits, c) interactive exercises to personalize the impact of smoking, improve attitudes about quitting, and increase self-efficacy for seeking smoking cessation treatment, and d) a video patient vignette to develop social norms for smoking cessation treatment and increase self-efficacy. Usability testing among people with severe mental illness established that the system was comprehensible, easy to use, and took 30-90 minutes to complete.
88884837|NCT01399112|Active Comparator|thetruth.com website|"Participants who are assigned to use the web-based thetruth.com website will be asked to navigate through the website as they wish. The home page of thetruth.com site has links to access video games, fact sheets, and videos that highlight negative aspects of cigarettes or tobacco companies. Thetruth.com website is not structured and participants can utilize whatever aspects of the website they wish and in any order they wish to view them.~Individuals will use the computer with a research staff member present who can provide assistance if needed. The sections of the two programs website that are used and the time spend on each portion of the program will be recorded. Participants who use TheTruth.com will be given a referral for assistance in quitting smoking if requested."
89409251|NCT02964741|Active Comparator|Migraine Patients Active Group|"Episodic migraine patients will be randomized (Taves method) to receive high-definition transcranial direct current stimulation (HD-tDCS*) as 20 minute sessions, once daily for 10 days (M-F for 2 weeks).~*Active Comparator"
89409252|NCT02964741|Sham Comparator|Migraine Patients Sham Group|"Episodic migraine patients will be randomized (Taves method) to receive high-definition transcranial direct current stimulation (HD-tDCS*) as 30-second administrations at the beginning and end of each 20 minute session, once daily for 10 days (M-F for 2 weeks).~*Sham Comparator"
89409253|NCT02964741|No Intervention|Healthy Control Group|"Healthy Volunteers will be asked to undergo baseline assessments only (including imaging, but no brain stimulation).~Healthy volunteer data (n </= 10) may be used from a prior study (NINDS-K23062946 project [IRBMED #HUM00027383; Dr. Alexandre DaSilva, Principal Investigator]). Consent to use data for a future study was obtained in the informed consent document at the time of participation."
88884838|NCT01399151|Experimental|Vitamin D - Treatment 1|400 IU/day Vitamin D
88884839|NCT01399151|Experimental|Vitamin D- Treatment 2|2,000 IU/day Vitamin D
88884840|NCT01399151|Experimental|Vitamin D- Treatment 3|5,000 IU/day Vitamin D
88884841|NCT01399164|Experimental|Fortified Bread|A single serving of 14C-B12 fortified bread
88884842|NCT01399203||percutaneous coronary intervention|The investigators reviewed all consecutive patients who were undergoing percutaneous coronary intervention
88884843|NCT01399216|Experimental|Fucoidan supplement|
88884844|NCT01399216|Placebo Comparator|Placebo|
88884845|NCT01399242|Active Comparator|Certican, prednisona, EC-MPS|Twenty patients will be selected at 16 weeks of renal transplantation to convert a immunosuppression to certican,prednisone and myfortic. The allocation will be done randomly to provide similar epidemiological characteristics with respect to gender, age, renal function and co morbidities in the two groups. The informed consent will obtained after an interview involving the researcher and patient when the protocol will be explained.A protocol renal biopsy will be performed at the end of the study, 12 months after transplantation
89409254|NCT05577780||internal fixation|
89409255|NCT05577780||arthroplasty|
89409256|NCT03523832|Active Comparator|Group 1|celecoxib 400mg and pregabaline 150mg 1 hour before operation
89409257|NCT03523832|Active Comparator|Group 2|celecoxib 200mg and pregabaline 75mg twice daily started from 3 days before operation
89409258|NCT03523832|Placebo Comparator|Group 3|No treatment given
89409259|NCT05577624|Experimental|AMG 510 + Rifampin|
89409260|NCT03294694|Experimental|Ribociclib and PDR001 (Cohort A)|"The treatment regimen is defined as ribociclib + PDR001.~Treatment will be administered on an outpatient basis.~The study will use a 3 + 3 dose escalation design to determine the MTD/RP2D.~Three to six evaluable patients will be enrolled in each cohort in the dose escalation phase.~Once the RP2D of the combination of ribociclib + PDR001 is determined, there will be an expansion cohort.~Cohort A expansion will assess the combination of ribociclib + PDR001 in 12 patients with metastatic ovarian cancer."
89409261|NCT03294694|Experimental|Ribociclib, PDR001 and Fulvestrant (Cohort B)|"The treatment regimen is defined as ribociclib + PDR001 + fulvestrant .~Treatment will be administered on an outpatient basis.~There will be a safety run-in using the MTD/RP2D of ribociclib + PDR001 from Cohort A with the addition of fulvestrant in an initial 6-12 patients.~Once the safety of the combination of ribociclib + PDR001 + fulvestrant is established, there will be an expansion cohort.~Cohort B expansion will assess the combination of ribociclib + PDR001 + fulvestrant in 24 patients with hormone receptor-positive metastatic breast cancer (HR+ MBC)."
89409262|NCT03523754|Other|Misoprostol only|This group will receive Intravaginal Misoprostol only.
89409263|NCT03523754|Other|Isosorbide Mononitrate & Misoprostol|This group will reveive intravaginal Isosorbide Mononitrate & Misoprostol.
89409264|NCT04727034|Active Comparator|Control group|Propofol（1.5mg/kg）
89409265|NCT04727034|Experimental|Test group 1（Remimazolam tosylate 0.15mg/kg）|Remimazolam tosylate 0.15mg/kg
88884846|NCT01399242|No Intervention|Tacrolimus,Prednisona, EC-MPS|Twenty patients will be selected at 16 weeks of renal transplant to continue use EC-MPS,Tacrolimus and Prednisone. The allocation will be done randomly to provide similar epidemiological characteristics with respect to gender, age, renal function and co morbidities in the two groups. The informed consent will obtained after an interview involving the researcher and patient when the protocol will be explained.A protocol renal biopsy will be performed at the end of the study, 12 months after transplantation
88884847|NCT01399255|Experimental|Listro™ Arm|Insulin Lispro (Listro™); 100 U/mL, DispoPen 3.0 mL.
88884848|NCT01399255|Active Comparator|Humalog® Arm|Insulin Lispro (Humalog®; 100 U/mL), Humalog® Kwik Pen™ 3.0 mL.
88884849|NCT01399281||Biologics alone or methotrexate alone|This group mainly refer to children with polyarticular course JIA treated with methotrexate ± biologics,
88884850|NCT01399281||Biologics and MTX|JIA treated with a combination of biologic and MTX (including any other add on therapy e.g. cyclosporine, leflunomide etc). This group mainly refer to children with polyarticular course JIA treated with MTX ± biologics
89409266|NCT04727034|Experimental|Test group 2（Remimazolam tosylate 0.2mg/kg）|Remimazolam tosylate 0.2mg/kg
89409267|NCT03523676||Group A|sepsis patients who did not develop atrial fibrillation during ICU stay
89409268|NCT03523676||Group B|sepsis patients with newly developed atrial fibrillation during ICU stay
89409269|NCT03644511||Patients with HCC|Treated with Nexavar and/or Stivarga as ≥ 2nd-line systemic treatment
89409270|NCT03290560|Experimental|Recombinant human tissue kallikrein|A single IV infusion of 1 microgram/kg followed by 8 subcutaneous injections of 3 microgram/kg occurring every 72 hours.
89409271|NCT03290560|Placebo Comparator|Placebo|A single IV infusion of 1 microgram/kg followed by 8 subcutaneous injections of 3 microgram/kg occurring every 72 hours.
89409272|NCT03523598|Placebo Comparator|Placebo gel + Normal Toothpaste|The patient will receive the application of placebo gel on vestibular surface teeth, for 10 minutes and will use the normal toothpaste (Colgate).
89409273|NCT03523598|Experimental|Placebo Gel + Potassium Nitrate Toothpaste|The patient will receive the application of placebo gel on vestibular surface teeth, for 10 minutes and will use the Potassium nitrate toothpaste (Sensodyne).
89409274|NCT03523598|Experimental|Potassium Nitrate Gel + Normal Toothpaste|The patient will receive the application of 5% Potassium nitrategel on vestibular surface teeth, for 10 minutes and will use the normal toothpaste (Colgate).
89409275|NCT01316419||Patients with essential hypertension|
89409276|NCT03547362|Experimental|Casein|Single oral administration
89409277|NCT03547362|Experimental|Dairy protein blend 1|single oral administration
89409278|NCT03547362|Experimental|Whey protein|Single oral administration
89409279|NCT03547362|Experimental|Dairy protein blend 2|Single oral administration
89409280|NCT03547362|Experimental|Dairy protein blend 3|Single oral administration
88884851|NCT01399281||NSAIDs and/or steroid injections alone|This group refers to children with mostly oligoarticular persistent course who are usually NOT treated with second line agents and have a more benign course.
88884852|NCT01399307|Other|Elective Liposuction|
89191713|NCT02570568|Experimental|Pen-torch Transillumination|The tips of the pen torches are pressed onto the skin, causing the silhouette of the vein to show up. Once a suitable vein is localized, a tourniquet is applied (Braun® International, USA). The area of the skin to be cannulated is disinfected with an alcohol wipe (Webcol®, Covidien®, USA). For the setting of IV cannulation, a standardized 23G IV cannula is used (Introcan Safety®, Braun®, USA). Normal saline (PosiFlush® 3ml, BD®, USA) will be used for flushing the cannula after successful cannulation. For blood taking, a syringe (Terumo®, Philippines) ranging from 2ml to 20ml and a 23G needle (Venofix®, Braun®, USA) will be used. All instruments needed for venepuncture, including 4 IV cannula or 4 needles should be by the patient's bedside prior to the start of each venepuncture.
89191714|NCT00861562|Active Comparator|Imescard pills/Placebo crossover|Patients received Imescard water smartweed composed pills during the first intervention period and placebo during the second, after a 10-day washout period.
89191715|NCT00861562|Active Comparator|Placebo/Imescard pills crossover|Patients received placebo during the first intervention period and Imescard water smartweed composed pills during the second, after a 10-day washout period.
89191716|NCT00724880|Experimental|1|Clopidogrel is stopped 5 days prior to surgery
89191717|NCT00724880|Experimental|2|Clopidogrel is stopped 3 days prior to surgery
89191718|NCT00724880|Experimental|3|Clopidogrel is stopped 0 days prior to surgery
89191719|NCT02571348|Active Comparator|4 weeks and 8 weeks|Micro-osteoperforation will be done on either side of the maxilla at 4 weeks interval and the contralateral site will be the control. In mandible, micro-osteoperforation will be done every 8 weeks and the contralateral site will serve as the control
89191720|NCT02571348|Active Comparator|8 weeks and 12 weeks|Micro-osteoperforation will be done on either side of the maxilla at 8 weeks interval and the contralateral site will be the control. In mandible, micro-osteoperforation will be done every 12 weeks and the contralateral site will serve as the control
89191721|NCT02571348|Active Comparator|12 weeks and 4 weeks|Micro-osteoperforation will be done on either side of the maxilla at 12 weeks interval and the contralateral site will be the control. In mandible, micro-osteoperforation will be done every 4 weeks and the contralateral site will serve as the control
89191722|NCT00854698|Experimental|Group with MVA|
89191723|NCT00854698|Other|group without MVA|
89191724|NCT00804453|Active Comparator|1|Standard blood line
89191725|NCT00804453|Experimental|2|Cartridge blood line
89191726|NCT00724074|Experimental|S|Patients receive the On-Q local continuous wound infusion system intra-operatively and use it for up to three days post-operatively.
89191727|NCT00724074|Active Comparator|C|Usual care - post operative pain medications as per the knee arthroplasty care map.
89191728|NCT00854776|Active Comparator|1|Upper GI tract symptoms are evaluated. Patients are asked to report to gastroenterologist if they have persistent ulcer symptoms and to report to the emergency room if they have evidence of GI bleeding or ulcer complications (melena, hematemesis, or sudden onset of severe epigastric pain). Endoscopy will be undergone to document any gastroduodenal ulcers with or without ulcer complications. If the hemoglobin level has decreased by 2g/dL or more, or stool check shows occult blood at each visit, endoscopy will be undergone to check the presence of gastroduodenal ulcers with or without bleeding. Patients without persistent ulcer symptoms or without evidence of ulcer complications will be invited to undergone scheduled endoscopy at the 3-month end of follow-up in each subjective.
89191729|NCT00854776|Placebo Comparator|2|Upper GI tract symptoms are evaluated at each visit. Patients are asked to report to gastroenterologist if they have persistent ulcer symptoms and to report to the emergency room if they have evidence of GI bleeding or ulcer complications (melena, hematemesis, or sudden onset of severe epigastric pain). Endoscopy will be undergone to document any gastroduodenal ulcers with or without ulcer complications. An ulcer is defined as a circumscribed mucosal break at least 3 mm in diameter. If the hemoglobin level has decreased by 2g/dL or more, or stool check shows occult blood at each visit, endoscopy will be undergone to check the presence of gastroduodenal ulcers with or without bleeding. Patients without persistent ulcer symptoms or without evidence of ulcer complications will be invited to undergone scheduled endoscopy at the 3-month end of follow-up in each subjective.
89191730|NCT00798525|Active Comparator|PR1|Patients treated with Argatroban (Argatra®), a direct thrombin inhibitor
89191731|NCT00798525|Active Comparator|PR2|Patients treated with Lepirudin (Refludan®), a direct thrombin inhibitor
89191732|NCT02571374|Experimental|symbiotic group|Symbiotic group
89191733|NCT02571374|Placebo Comparator|placebo group|placebo group
89191734|NCT00861640|Experimental|Intravenous Omeprazole|100 cases of Intravenous Omeprazole
89191735|NCT00861640|Experimental|Oral Rabeprazole|100 cases of oral rabeprazole
89191736|NCT00724230||Arm 1|Overall study population.
89191737|NCT04066322||system treatment|Patients continue to receive standard system treatment, including SSA, targeted therapy and chemotherapy.
89191738|NCT04066322||system treatment and Surgery|Patients receive synchronous resection of primary tumor and metastasis after system treatment. and treatment after surgery is based on the clinical decision.
89191739|NCT00861718|Experimental|AZD7268|
88884853|NCT01399320|Experimental|cyanoacrylate dressing,excesion|we excise the sinus tip then apply cyanoacrylate dressing and watch for healing
88884854|NCT01399333|Active Comparator|Group 1|full liquid diet utilizing meal replacements with PDCAAS of 1.0
89191740|NCT00861718|Placebo Comparator|Placebo|
89191741|NCT00865774|Experimental|1|Arm number 1 focuses on the traditional quantity frequency model.
89191742|NCT00865774|Experimental|2|Arm number 2 targets subjective drunkenness.
88884855|NCT01399333|Active Comparator|Group 2|full liquid diet utilizing protein supplements with PDCAAS of 0.5-0.99
89191743|NCT00865852|Experimental|A|Metformin HCl 750 mg Extender Release tablets, single dose
89409281|NCT03547362|Experimental|Dairy protein blend 4|Single oral administration
89536689|NCT04430855|Experimental|Placebo followed by Upadacitinib 15 mg|Participants will receive matching placebo orally once a day for 12 weeks (Period 1) followed by 15 mg upadacitinib orally once a day for 36 weeks (Period 2).
88884856|NCT01399333|Active Comparator|Group 3|full liquid diet utilizing protein supplement with a PDCAAS less than 0.5
88884857|NCT01399346|Experimental|1 bolus of insulin aspart 18 IU|Subcutaneous administration of insulin aspart as one bolus of 18 IU at one injection site.
88884858|NCT01399346|Experimental|9 bolus of insulin aspart a 2 IU|Subcutaneous administration of insulin aspart as 9 separately and simultaneously applied bolus of 2 IU at 9 separate injection sites
88884859|NCT01399359||Women who decide not to take a SERM|Women participate in the counseling session, questionnaire 1, and questionnaire 2, and the online questionnaire.
88884860|NCT01399359||Women who decide to take a SERM|Women participate in the counseling session, questionnaire 1 and questionnaire 2.
88884861|NCT01399450|Experimental|paliperidone add on|paliperidone add on
88884862|NCT01399463|Experimental|DEB + BMS|Paclitaxel drug-eluting balloon (DEB) dilatation and bare metal stenting
88884863|NCT01399463|Active Comparator|Stenting with commonly used Drug Eluting Stents (DES)|
88884864|NCT01399476|Experimental|Endoscopic Myotomy|
88884865|NCT01399489|Experimental|Exercise training|Individuals randomized to this arm get 48 sessions of personal training in a state of the art fitness facility
88884866|NCT01399489|No Intervention|Control|Individuals in the control arm are expected to continue to live normally, following their doctor's advice but not engage in any formal exercise training.
88884867|NCT01399502|Active Comparator|Self-help advice|Each email will contain a self-help strategy for coping with depressive symptoms. The email will contain information about why the strategy will be effective, tips for implementing the strategy and overcoming barriers, and how to set a goal to implement the strategy. Strategies are based on previous research published by the trial co-ordinators.
88884868|NCT01399502|Placebo Comparator|Depression information|Each email will contain different information about depression, such as symptoms, risk factors, prevalence.
88884869|NCT01399515|Active Comparator|Valproic acid|
88884870|NCT01399515|No Intervention|Control|
88884871|NCT01399528||Beaumont Hospital, Dublin, Ireland|
88884872|NCT01399528||St. James' Hospital, Dublin, Ireland|
88884873|NCT01399528||Hôpital Erasme, Brussels, Belgium|
88884874|NCT01399528||Duke Medical Centre, North Carolina, USA|
88884875|NCT01399528||The Institute of Neurology/University College London, UK|
88884876|NCT01399541||Under and over 65 years|
88884877|NCT01399554|No Intervention|Assessment Only|
88884878|NCT01399554|Experimental|Weekly Exercise Counseling Intervention|
88884879|NCT01399567|Experimental|Algorithm|The NH pain management algorithm is a series of decision-making tools that begins with regular, comprehensive pain assessment matched to residents' cognitive status and proceed through analgesic therapy appropriate to the character, severity, and pattern of pain. The algorithm is coupled with intense diffusion strategies (e.g., education, consultation, boosters) to increase adoption of these evidence-based practices
88884880|NCT01399567|Active Comparator|Control|Control sites received staff education for pain assessment and management comprised of four one-hour classes
88884881|NCT01399606|Experimental|BF2.649|
88884882|NCT01399632|Experimental|High Fat and Low Carbohydrate Diet|
88884883|NCT01399632|Experimental|Low Fat and High Carbohydrate Diet|
88884884|NCT01399645|Experimental|Liraglutide-Metformin|"Liraglutide (Victoza, Novo Nordisk) at a dose of 0.6 - 1.8 mg subcutaneous per day until the end of the study.~All subjects will be given metformin with a starting dose of 500 mg in one tablet twice daily given before or during meals for the duration of the study."
88884885|NCT01399645|Experimental|Insulin-Metformin|"Insulin glargine (Lantus, Sanofi-Aventis) with an initial bedtime starting dose of 10 IU. The patients will be taught to increase their insulin dose by 1 unit each day until achieving an FPG ≤ 7.0 mmol/L.~All subjects will be given metformin with a starting dose of 500 mg in one tablet twice daily given before or during meals for the duration of the study."
88884886|NCT01399749|Experimental|Autologous ASC implantation|Treatment with autologous ASC
88884887|NCT01399749|Active Comparator|Autologous Chondrocytes implantation|Treatment with autologous chondrocytes
88884888|NCT01399762||mechanical recanalization|Patients with acute stroke being treated with endovascular devices for mechanical recanalization (no restriction to specific endovascular devices)
88884889|NCT01399775|Experimental|immediate implantation|Immediately after tooth extraction, dental implant is inserted.
88884890|NCT01399775|Other|Delayed implantation|Four months after extraction, Dental implant is inserted.
88884891|NCT01399814|Active Comparator|standard fluid regimen group|perioperative fluid treatment
88884892|NCT01399814|Experimental|restricted fluid regimen group|perioperative fluid treatment
88884893|NCT01399840|Experimental|Arm 1: BMN 673|Arm 1 will enroll patients with either AML or MDS
88884894|NCT01399840|Experimental|Arm 2: BMN 673|Arm 2 will enroll patients with either CLL or MCL
88884895|NCT01399853|Experimental|160U /0.5ml in children (from 12 to 36 months old)|inactivated vaccine(vero cell) against EV71 of 160U /0.5ml in 120 children aged 12-36 months old on day0,28
88884896|NCT01399853|Experimental|320U /0.5ml in children (from 12 to 36 months old)|inactivated vaccine(vero cell) against EV71 of 320U /0.5ml in 120 children aged 12-36 months old on day0,28
88884897|NCT01399853|Experimental|640U /0.5ml in children (from 12 to 36 months old)|inactivated vaccine(vero cell) against EV71 of 640U /0.5ml in 120 children aged 12-36 months old on day0,28
88884898|NCT01399853|Experimental|(without adjuvant) 640U /0.5ml in children (12-36months)|inactivated vaccine(vero cell) against EV71 of (without adjuvant) 640U /0.5ml in 120 children aged 12-36 months old on day0,28
88884899|NCT01399853|Experimental|160U /0.5ml in infants (from 6 to 11 months old)|inactivated vaccine(vero cell) against EV71 of 160U /0.5ml in 120 infants aged 6-11 months old on day0,28
88884900|NCT01399853|Experimental|320U /0.5ml in infants (from 6 to 11 months old)|inactivated vaccine(vero cell) against EV71 of 320U /0.5ml in 120 infants aged 6-11 months old on day0,28
88922024|NCT05969145|Experimental|hot-cold application|This group will be given a hot cold application to the bladder
89409282|NCT04465682|Experimental|Dip Home-Based Dipstick Analyzer|The Dip Home-Based Dipstick Analyzer is a prescription, in-vitro diagnostic, home use device, which qualitatively and semi-quantitatively measures 10 urine analytes. The device combines a urine stick kit with an easy to use smartphone application using an image recognition algorithm. Results of the experimental HBDA device will be compared to the results of the predicate device tested by a professional user
89409283|NCT03243448||The general public|people between 20-85 years old, without sympathetic hyperactivity disease
89409284|NCT03243448||Sympathetic hyperactivity diseases|Sympathetic hyperactivity diseases included: hypertension, heart failure atherosclerotic diseases, arrhythmias, cardiomyopathy, pulmonary hypertension, chronic obstructive pulmonary disease, sleep apnea, pulmonary embolism, hepatitis, liver cirrhosis, hepatopulmonary syndrome, hepatorenal syndrome, renal failure, nephritis, irritable bowel syndrome.
89409285|NCT02290262|Experimental|Comprehensive phase one rehabilitation|Patients allocated to the experimental group receive a rehabilitation programme consisting of physical exercise and psycho-education plus usual care.
89409286|NCT02290262|No Intervention|Usual care|The control group will receive usual care alone.
89409287|NCT04258150|Experimental|Experimental|SBRT of 15 Gy will be given on day 1 of the first cycle. Nivolumab 6 mg/kg (up to 480 mg maximum) will be given on day 1 (± 3 days) of each 14-day treatment cycle until the progression of disease or maximum of 48 weeks, discontinuation due to toxicity, withdrawal of consent. Ipilimumab 1 mg/kg will be given on day 1 (± 3 days) twice in total every 6 weeks. Nivolumab will be administered as an IV infusion over 60 (± 5) minutes and then, after a 30 minutes rest period, ipilimumab will be administered as an IV infusion over 30 (± 5) minutes. Tocilizumab 8 mg/kg is given IV on day 1 (± 3 days) over 1-hour, repeated every 4 weeks. Tocilizumab infusion over 30 minutes is allowed after 5. infusion in the absence of infusion related events.
89409288|NCT02964039|Experimental|Error reduction|"Participants will complete a 12-week training program, in which they practice walking on a treadmill for 30-minutes during twice-weekly training sessions. During these sessions, participants will interface with a custom-built force-field able to exert mediolateral forces on the legs, which will be in error reduction mode. This training period will be followed by a 12-week follow-up period. Five assessment sessions will be interspersed throughout this total 24-week period."
89409289|NCT02964039|Experimental|Error augmentation|"Participants will complete a 12-week training program, in which they practice walking on a treadmill for 30-minutes during twice-weekly training sessions. During these sessions, participants will interface with a custom-built force-field able to exert mediolateral forces on the legs, which will be in error augmentation mode. This training period will be followed by a 12-week follow-up period. Five assessment sessions will be interspersed throughout this total 24-week period."
89409290|NCT02964039|Sham Comparator|Activity matched control|"Participants will complete a 12-week training program, in which they practice walking on a treadmill for 30-minutes during twice-weekly training sessions. During these sessions, participants will interface with a custom-built force-field able to exert mediolateral forces on the legs, which will be in transparent mode. This training period will be followed by a 12-week follow-up period. Five assessment sessions will be interspersed throughout this total 24-week period."
89409291|NCT03217708||Children without OSA|Children for AT due to chronic tonsillitis without OSA.
89409292|NCT03217708||Children with OSA|Children with OSA for AT as determined by PSG
89409293|NCT02290418|Active Comparator|Roux-en-Y Gastric Bypass|Laparoscopic Roux-en-Y Gastric Bypass and routine care.
88884901|NCT01399853|Experimental|640U /0.5ml in infants (from 6 to 11 months old)|inactivated vaccine(vero cell) against EV71 of 640U /0.5ml in 120 infants aged 6-11 months old on day0,28
88884902|NCT01399853|Experimental|(without adjuvant) 640U /0.5ml in infants (from 6 to 11 months|inactivated vaccine(vero cell) against EV71 of (without adjuvant) 640U /0.5ml in 120 infants aged 6-11 months old on day0,28
88884903|NCT01399853|Placebo Comparator|0/0.5ml placebo in children (from 12 to 36 months old)|0/0.5ml placebo in 120 children aged 12-36 months old on day0,28
88884904|NCT01399853|Placebo Comparator|0/0.5ml placebo in infants (from 6 to 11 months old)|0/0.5ml placebo in 120 infants aged 6-11 months old on day0,28
88884905|NCT01399879||Healthy Volunteers|
88884906|NCT01399931||Early-stage Hodgkin Lymphoma Patients|Early-stage Hodgkin Lymphoma (HL) patients presenting bulky nodal lesions treated with ABVD and consolidation radiotherapy
88884907|NCT01399957||pwMS prescribed dalfampridine-ER|Anyone prescribed D-ER per usual clinical care was recruited into this observational study. All those willing to participate were consented and observed pre-drug and for a 14week period with two follow-up visits scheduled at 12 and 18months.
88884908|NCT01399970|Other|Outpatient Consultation Arm (OCA)|Conventional in Office Care
88884909|NCT01399970|Experimental|Mobile Teleconsultation Arm (MTA)|Mobile Teledermatology Care
88884910|NCT01399983||pulmonary hypertension|patients with pulmonary hypertension and with exercise-induced pulmonary hypertension take part
88884911|NCT01400009|Placebo Comparator|Placebo|Subjects in this group will receive a placebo tablet (Lactose 100 mg) for the duration of the study
88884912|NCT01400009|Active Comparator|Vitamin D|Subjects in this arm will receive a dose of 50,000 IU of vitamin D3, followed by weekly doses of 10,000 IU of vitamin D3
88884913|NCT01400022|Active Comparator|Cortisone|
88884914|NCT01400022|Experimental|UVA1 phototherapy|
89191744|NCT00865852|Active Comparator|B|GLUCOPHAGE® XR 750 mg tablets, single dose
89191745|NCT02571114|Active Comparator|Control 1|white bread - 25 g available carbohydrate
89409294|NCT02290418|Active Comparator|Omega-Loop Gastric Bypass|Laparoscopic Omega-Loop Gastric Bypass and routine care.
89409295|NCT04227730||group A|group A (+ve GBS) 300 pregnant of gestational age 35-37 weeks were screened by a group B streptococcal (GBS) conventional PCR assay. Patients who were followed till delivery without prolonged rupture of membrane were eligible to enter the study and details with regard to labor and delivery were recorded. Infant data were also recorded.
89409296|NCT04227730||group B|group B (-ve GBS) 300 pregnant of gestational age 35-37 weeks were screened by a group B streptococcal (GBS) conventional PCR assay. Patients who were followed till delivery without prolonged rupture of membrane were eligible to enter the study and details with regard to labor and delivery were recorded. Infant data were also recorded.
89409297|NCT02290496|Experimental|CBT for Insomnia (CBT-I)|Cognitive behavior therapy to improve sleep and depression.
89409298|NCT02290496|Placebo Comparator|Sleep Hygiene (SH)|Attention control placebo comprising sleep hygiene therapy
89409299|NCT03548298|Experimental|GERD without hiatal hernia|Participants with GERD without hernia hiatal will receive ARAT
88884915|NCT01400035||test group, control group|"Test group: Patients will be given cytidine diphosphate choline 0.4-0.5g, aspirin 75-100mg or Clopidogrel 75mg, intravenous infusion of Cavinton 30mg once a day.~Control group: Patients will be given cytidine diphosphate choline 0.4-0.5g, aspirin 75-100mg or Clopidogrel 75mg once a day."
88884916|NCT01400048|Active Comparator|Aloe vera effervescent tablet (AVH200)|
88884917|NCT01400048|Placebo Comparator|Placebo|
88884918|NCT01400061||normal|body mass index: 19-24
88884919|NCT01400061||overweight|body mass index: 25-29
88884920|NCT01400061||obesity|body mass index: 30-40
88884921|NCT01400061||modbid obes|body mass index: over 40
88884922|NCT01400074|Active Comparator|Nilotinib|400 mg twice daily
88884923|NCT01400074|Active Comparator|Imatinib|400 mg twice daily
88884924|NCT01400087|Active Comparator|Cap-attached Colonoscopy|
88884925|NCT01400087|Placebo Comparator|Regular colonoscopy|
88884926|NCT01400100|Experimental|Octreotide|Study patients receive after randomization a single shot of 5 mL 500 µg Octreotide in the gastroduodenal artery at the time of its transection.
88884927|NCT01400100|Placebo Comparator|Control|Control patients receive after randomization a single shot of 5 mL 0,9% NaCL solution in the gastroduodenal artery at the time of its transection.
88884928|NCT01400152|Active Comparator|Passive warming with additional active warming|
88884929|NCT01400152|No Intervention|Passive warming|
88884930|NCT01400165|Active Comparator|Desyrel/Teva-Trazodone|Both drugs will be given at the dose of 150 mg. A washout period (corresponding to 10 half-life of the active compound) will be respected after receiving each medication.
88884931|NCT01400165|Active Comparator|Visken/Teva-Pindolol|Both drugs will be given at the dose of 10 mg. A washout period (corresponding to 10 half-life of the active compound) will be respected after receiving each medication
88884932|NCT01400165|Active Comparator|Seroquel/Teva-Quetiapine|Both drugs will be given at the dose of 100 mg. A washout period (corresponding to 10 half-life of the active compound) will be respected after receiving each medication
88884933|NCT01400191|Active Comparator|Homozygote wildtype OCT1|
88884934|NCT01400191|Active Comparator|Heterozygote OCT1|
88884935|NCT01400191|Active Comparator|Homozygote OCT1 variant|
88884936|NCT01400204||MDMA|poly drug users that used MDMA at New Years Eve
88884937|NCT01400204||Other Drugs|poly drug users that used drugs at New Years Eve, but not MDMA
88884938|NCT01400204||Alcohol|poly drug users that used no drugs at New Years Eve, but did consume alcohol
88884939|NCT01400217||IPDI EF HFA-BDP|Patients initiating inhaled corticosteroid therapy as extra-fine HFA-BDP MDI at the index date
88884940|NCT01400217||IPDI SP HFA-BDP|Patients initiating inhaled corticosteroid therapy as standard particle HFA-BDP MDI at the index date
88884941|NCT01400217||IPDA SP HFA-BDP|Patients increased inhaled corticosteroid therapy as standard particle HFA-BDP MDI at the index date
88884942|NCT01400217||IPDA EF HFA-BDP|Patients increased inhaled corticosteroid therapy as extra fine particle HFA-BDP MDI at the index date
88884943|NCT01400217||IPDS SP HFA-BDP|Patients increased inhaled corticosteroid therapy as standard particle HFA-BDP MDI at the index date
88884944|NCT01400217||IPDS EF HFA-BDP|Patients increased inhaled corticosteroid therapy as extrafine particle HFA-BDP MDI at the index date
88884945|NCT01400230||CCTA-IVUS-FFR|Patients suspected ischemic heart disease by the symptom and CCTA and undergone IVUS and FFR in the Cath Lab with CAG enrolled consecutively.
88884946|NCT01400282|Other|Sequence 1|Conventional stimulation (2 weeks)- High frequeny stimulation (2 weeks)- Conventional stimulation (2 weeks)and sham stimulation (2 weeks)
88884947|NCT01400282|Other|Sequence 2|Conventional stimulation (2 weeks)- sham stimulation (2weeks) - Conventional stimulation (2 weeks) - high frequeny stimulation (2 weeks)
89191746|NCT02571114|Active Comparator|Control 2|white bread - 25 g available carbohydrate
89409300|NCT03644433|Placebo Comparator|Single layer|Single layer closure
89191747|NCT02571114|Sham Comparator|Frozen Yogurt|unflavoured frozen yogurt - 25 g available carbohydrate
88884948|NCT01400295||coronary angiography|The investigators reviewed all consecutive patients who were undergoing coronary angiography
88884949|NCT01400308|Active Comparator|Chlorhexidine + Mupirocin|"Will be treated with the protocol described in the Consensus document and GEIH-SEIMC SEMPSPH Version 31/10/07, as shown listed in Table 4. It is a protocol of 5 days (nasal mupirocin and chlorhexidine, potentially plus systemic antibiotics and 7 days)."
88884950|NCT01400308|Experimental|Prontoderm|Will be treated with the protocol established for Prontoderm® for five days and eventually plus systemic antibiotics.
88884951|NCT01400321||Distal region|Patients with loss of tooth in the premolar and molar region of the atrophied mandible
88884952|NCT01400321||aesthetic zone|Patients with loss of tooth within the aesthetic zone (canine to canine)
88884953|NCT01400334||Ischemic Cardiomyopathy|Subjects with ischemic cardiomyopathy [pre-enrollment left ventricular ejection fraction ≤0.35, with coronary artery disease documented by cardiac catheterization, a history of definite myocardial infarction, or reversible ischemia on nuclear imaging] who are considered eligible to receive an implantable cardiac defibrillator for the primary prevention of sudden cardiac death.
88884954|NCT01400360|Active Comparator|invasive|After proof of perfusion relevant CVS in interventional therapy should be performed as best possible combination from TBA and intraarterial vasodilators additional to the conventional treatment.
88884955|NCT01400360|No Intervention|conventional|After proof of perfusion relevant CVS only conventional treatment should be performed (no intraarterial therapy).
88884956|NCT01400373|No Intervention|Control|Patients in the control group standard advanced cardiac life support care. Patients that achieve return of spontaneous circulation will be treated with hypothermia according to current guidelines upon arrival at the intensive care unit.
88884957|NCT01400373|Experimental|Intervention|Intra-arrest trans-nasal cooling with RhinoChill will be initiated during advanced cardiac life support. In patients achieving return of spontaneous circulation, trans-nasal cooling will continue until systemic cooling is started at the intensive care unit.
89409301|NCT03644433|Active Comparator|Double layer with resection|Double layer closure after resection uterine scar
89409302|NCT02289014|No Intervention|Wait-list control group|Wait-list control group
89191748|NCT02571114|Experimental|Saskatoon Berry Frozen Yogurt|frozen yogurt containing powder prepared from Saskatoon berries - 25 g available carbohydrate
89191749|NCT00725114|Active Comparator|Tetrodotoxin|
89191750|NCT00725114|Placebo Comparator|Sugar injection|
89409303|NCT02289014|Experimental|Active treatment group|online stress Management program
88884958|NCT01400386|Experimental|Soluble coffee 1|
88884959|NCT01400386|Experimental|Soluble coffee 2|
89191751|NCT02545192|Experimental|Active LFMS treatment|20 minutes of active Low Field Magnetic Stimulation using the LFMS device.
89191752|NCT02545192|Sham Comparator|Sham LFMS treatment|20 minutes of sham Low Field Magnetic Stimulation using the LFMS device.
89409304|NCT05577078||TEER|Patients with tricuspid valve regurgitation eligible for transcatheter edge-to-edge repair (TEER)
88884960|NCT01400386|Experimental|Soluble coffee 3|
88884961|NCT01400386|Experimental|Soluble coffee 4|
89191753|NCT00724542|No Intervention|Control|Placebo with lifestyle intervention
88884962|NCT01400438|Experimental|patients group with Herceptin|Patients beginning Herceptin in adjuvant after chemotherapy
88884963|NCT01400438|Active Comparator|Control group|patient not beginning Herceptin after chemotherapy : control group
88884964|NCT01400490|Placebo Comparator|Olive Oil 6 grams/day|
88884965|NCT01400490|Active Comparator|DHA 1800 mg/day|
88884966|NCT01400490|Active Comparator|EPA 1800 mg/day|
88884967|NCT01400490|Active Comparator|Fish Oil with EPA 1800 mg/day and DHA 1200 mg/day|
88884968|NCT01400542||OSAS +|Patient with obstructive sleep apnea syndrome (OSAS)detected at the inclusion visit by a polysomnography
88884969|NCT01400542||OSAS -|Patient without obstructive sleep apnea syndrome (OSAS)detected at the inclusion visit by a polysomnography
88884970|NCT01400555|Experimental|001|Cohort 1 Docetaxel 60 mg/m2 administered once every 3 weeks + abiraterone acetate 500 mg/day + prednisone 10 mg/day
88884971|NCT01400555|Experimental|002|Cohort 2 Docetaxel 75 mg/m2 administered once every 3 weeks + abiraterone acetate 500 mg/day + prednisone 10 mg/day
88884972|NCT01400555|Experimental|003|Cohort 3 Docetaxel 75 mg/m2 administered once every 3 weeks + abiraterone acetate 1000 mg/day + prednisone 10 mg/day
88884973|NCT01400555|Experimental|004|Cohort 4 Docetaxel 75 mg/m2 administered once every 3 weeks + abiraterone acetate 750 mg/day + prednisone 10 mg/day
88884974|NCT01400568|Experimental|LPS challenge and fluticasone propionate|In case LPS induced airway inflammation is reproducible, the effect of a single high dose of inhaled fluticasone propionate will be assessed after a 4-week wash-out period.
88922025|NCT05969145|No Intervention|control group|Routine clinical functioning will be applied to this group
89191754|NCT00724542|Experimental|Drug|Voglibose tablets with lifestyle intervention
89191755|NCT00724620|Experimental|Early Responders (ER)|All patients will receive peginterferon alfa-2b 1.5 ug/kg administered subcutaneously (SC) once weekly in combination with ribavirin (800-1200 mg/day) administered orally (PO) for a minimum period of 12 weeks. Patients who have responded to therapy at Treatment Week 12 (ie, who are Early Responders defined by HCV-RNA[-] at Treatment Week 12) will continue the combined treatment for a total of 48 weeks and will complete 24 weeks of follow up to determine the Sustained Viral Response (SVR).
89409305|NCT02289170|Experimental|Heating and cooling combination therapy|The patients in this group received heating and cooling combination therapy by a certified Korean Medicine Doctor with more than 6 years of oriental medicine college education and 2 years of clinical experience. Doctor press 8 acupuncture points which is treated in LBP patients and select the most painful 2 acupuncture points. Device's probe is attached to the acupuncture points in 15 minutes. Probe's temperature is changed 5 cycles from maximum 45℃ to minimum 15℃.
89536690|NCT04378907|Active Comparator|Cigarette Smokers: 0 mg/ml nicotine concentration|"ECIG Lab Session, 30 watts, 0 mg/ml nicotine concentration~During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout."
89409306|NCT02289170|Sham Comparator|Sham heating and cooling therapy|The patients in this group received sham heating and cooling combination therapy in same conditions of treatment group except the temperature. Before the treatment begin, caregiver measure the patient's skin temperature. Then probe's temperature is changed 5 cycles from 1℃ over the skin temperature to 1℃ under the skin temperature.
89409307|NCT02854696|Experimental|Islet graft|Patients who receive islet graft Intervention : Procedure/Surgery
89409308|NCT02854696|Active Comparator|Best medical care|Patients who continue their optimal medical treatment (insulin pump therapy coupled with real time continuous glucose monitoring) Intervention : insulin treatment
89409309|NCT02289248|Experimental|Ketamine/CBT Group|Subjects will undergo 2 week course of 4 intravenous infusions of ketamine (given twice weekly for two weeks) in combination with twice weekly cognitive behavioral therapy for a total of 8 weeks.
89409310|NCT05348304|No Intervention|Control|Hypocaloric diet
89409311|NCT05348304|Experimental|EUDIAMET|Hypocaloric diet plus a supplementation with myo-inositol and D-chiro-inositol in the 40:1 ratio, Gymnema sylvestre, alpha-lactalbumin and zinc
89409312|NCT02253420|Experimental|Copanlisib with and without concomitant Itraconazole (Arm A)|"To evaluate the effect of Itraconazole on the pharmacokinetics of Copanlisib (BAY80-6946) and safety in patients with advanced solid tumor. Cycle 1 of the study will be conducted in 2 parts: Part 1 and part 2:~Part 1 of Cycle 1: 6 patients will be enrolled and will receive 12 mg of copanlisib on Day 1 and Day 15. Itraconazole 200 mg will be administered twice a day on Day 12 and then once daily from Days 13 to 21.~Part 2 of Cycle 1: 20 patients will be enrolled and receive copanlisib doses of either 12 mg, 30 mg or 60 mg on Days 1 and 15 with the same dose administered on both days. Copanlisib dose for Part 2 will be based on safety and copanlisib pharmacokinetics in Part 1. Itraconazole 200 mg will be administered twice a day on Day 12 and then once daily from Days 13 to 21.~Cycle 2 and subsequent cycles: All patients will receive copanlisib doses of 60 mg on Days 1, 8 and 15."
89409313|NCT02253420|Experimental|Copanlisib with and without concomitant Rifampin (Arm B)|"To evaluate the effect of Rifampin on the pharmacokinetics of Copanlisib (BAY 80-6946) and safety in patients with advanced solid tumor or non-Hodgkin's lymphoma in Cycle 1. Approximately 30 subjects will receive 60mg of copanlisib on Cycle 1 Day 1 and Cycle 1 Day 15. Rifampin will be administered once a day from Cycle 1 Day 10 to Day 21. Holter monitoring will be performed on Cycle 1 Day -1 and Cycle 1 Day 1 to evaluate the effect of copanlisib on the QT/QTc assessment.~Cycle 2 and subsequent cycles, all patients will receive copanlisib dose of 60 mg on Days 1, 8 and 15. Holter monitoring will be performed on Cycle 3 Day 1 and Cycle 6 Day 1."
89409314|NCT04483180|Placebo Comparator|Control|Beverage containing a sucrose solution. Same aspect and flavor than the experimental beverages. About 1/4 of participants will start with this beverage first.
89409315|NCT04483180|Experimental|Sucralose / acesulfame K|Beverage containing a blend of sweeteners based on sucralose and acesulfame K. Same aspect and flavour than the control beverage. About 1/4 of participants will start with this beverage first.
89409316|NCT04483180|Experimental|Stevia rebaudioside A / thaumatin|Beverage containing a blend of sweeteners based on stevia rebaudioside A and thaumatin. Same aspect and flavour than the control beverage. About 1/4 of participants will start with this beverage first.
89409317|NCT04483180|Experimental|Mogroside V / stevia rebaudioside M|Beverage containing a blend of sweeteners based on mogroside V and stevia rebaudioside M. Same aspect and flavour than the control beverage. About 1/4 of participants will start with this beverage first.
89409318|NCT01566396|Experimental|A3F|A3F, Fractional RF treatment
89409319|NCT02289404|Experimental|NVP-1203(fed then fasting)|Subjects will receive a oral dose of NVP-1203 under fed conditions in period 1, then subjects will receive a oral dose of NVP-1203 under fasting conditions in period 2
89409320|NCT02289404|Experimental|NVP-1203(fasting then fed)|Subjects will receive a oral dose of NVP-1203 under fasting conditions in period 1, then subjects will receive a oral dose of NVP-1203 under fed conditions in period 2
88884975|NCT01400581|Experimental|Collaborative Care [CC] Intervention|The CC intervention will consist of offering subjects: 1) an in-depth baseline assessment, 2) frequent (weekly first, then monthly) visits with a nurse care manager, 3) alcohol dependence medications prescribed by a Nurse Practitioner. An interdisciplinary CC team will supervise nurse care managers weekly.
88884976|NCT01400581|No Intervention|Usual Care|Observational
88884977|NCT01400607|Active Comparator|Neocartilage Implant|Neocartilage Implant surgically implanted and affixed to subchondral bone using commercial fibrin during mini-open knee arthrotomy.
88884978|NCT01400607|Other|Microfracture|Standard of care cartilage repair technique.
89409321|NCT05576766|Active Comparator|Routine care group|Perioperative management according to routine care.
89409322|NCT05576766|Experimental|ERAS group|Perioperative management according to the Enhanced Recovery after Surgery (ERAS) pathway.
89409323|NCT04171804|Active Comparator|Active|Left anodal/right anodal transcranial direct current stimulation over the dorsolateral prefrontal cortex
88884979|NCT01400620|Experimental|Active oral rinse|Oral rinse containing botanical extracts
88884980|NCT01400620|Placebo Comparator|Placebo rinse|
88884981|NCT01400633||001|decitabine injection decitabine intravenous injection 20mg/m2 once a day for 5 consecutive days every 4 weeks
88884982|NCT01400646|Experimental|Rivaroxaban + Warfarin Concomitant Therapy Phase|Rivaroxaban monotherapy 20 mg/day for 5 days followed by Rivaroxaban 20 mg/day + Warfarin. 10 mg/day for >= 2 to <= 4 days concomitant therapy, then Warfarin monotherapy 0-15 mg/day for 4 days (Treatment Period 1). A 14-day washout period will separate Treatment Periods 1 and 2.
88884983|NCT01400646|Experimental|Warfarin Monotherapy Phase|Warfarin monotherapy 10 mg/day for >=2 to <=4 days, then Warfarin 0-15 mg/day for 4 days (Treatment Period 2). A 14-day washout period will separate Treatment Periods 1 and 2.
89409324|NCT04171804|Sham Comparator|Sham|Sham transcranial direct current stimulation over the dorsolateral prefrontal cortex
89409325|NCT03521648||PAE|Men with BPH - LUTS BPE who have opted for PAE and have consented to take part in the Register Study.
89409326|NCT03521648||TURP|Men with BPH - LUTS BPE who have opted for TURP and have consented to take part in the Register Study.
88884984|NCT01400659|Active Comparator|CARB Counting|For CARB counting, insulin dose will be calculated according to the carbohydrate content of the test meal (1 carb unit = 10 g carbohydrate). The insulin-to-carbohydrate ratio will be applied according to the current individual therapy of the patient.
88884985|NCT01400659|Active Comparator|CFP counting|For CFP counting, insulin dose will be calculated according the carbohydrate content (1 carb unit = 10 g carbohydrate) as well as fat/protein content (1 FPU = 100 kcal from fat and protein) of the meal. The insulin-to-carbohydrate ratio will be applied according to the current individual therapy of the patient. The insulin-to-FPU ratio is the same as the insulin to carb ratio.
89409327|NCT03521648||Other|Men with BPH - LUTS BPE who have opted for other treatment options (e.g., holmium laser enucleation of the prostate, open prostatectomy, thulium laser vaporization, resection or enucleation, transurethral incision of the prostate) and have consented to take part in the Register Study.
89409328|NCT02253732|Experimental|'3 months exercise intervention program'|all participants will be subjected to 3 months supervised exercise intervention programme
89409329|NCT02028364|Experimental|Everolimus given in conjunction with exemestane|Everolimus 10mg orally daily given in conjunction with exemestane 25mg orally daily until disease progression or treatment discontinuation for any other reasons.
89409330|NCT03547284|Active Comparator|81 patients,group 1|81 women will receive 1 stick of sugarless gum for 15 minutes every 2 hours after surgery .
89409331|NCT03547284|No Intervention|81 patients,group 2|81 patients will have traditional management(oral intake of clear fluids after hearing of first intestinal sounds or passage of flatus and regular diet after passage of stool)
89409332|NCT02290652||Prospective|Prospective - Factors affecting sexual function pre-THR
89409333|NCT02290652||Retrospective|Retrospective- Factors affecting sexual function post-THR
88884986|NCT01400672|Experimental|DIPG Patients Receiving Vaccine|Patients with diffuse intrinsic pontine glioma (DIPG) receiving radiation therapy, Tumor Lysate Vaccine (dose of 4 x 10^6 cells divided into 2 doses then every 4 weeks for up to 1 year) and Imiquimod (5% Aldara cream at a total dose of 12.5 mg) topically at each site prior to and 24 hours after vaccination.
88884987|NCT01400711|Active Comparator|ERAS patients|Patients planned to undergoing major intrabdominal surgery, following the ERAS perioperative care.
88884988|NCT01400711|Active Comparator|Control patients|Patients planned to undergo major intrabdominal surgery, following the conventional perioperative care.
88884989|NCT01400724|Experimental|Inofolic NRT|
88884990|NCT01400737|Experimental|ibuprofen|The patients in the control group were given 3 doses of an orange starch suspension as placebo that looked like ibuprofen.
88884991|NCT01400750|Active Comparator|Ciproxin-inhaled Colistin|oral ciprofloxacin (30mg/kg/day) plus inhaled colistimethate sodium (Colistineb® 2x2 mill U daily) for 3 months
88884992|NCT01400750|Active Comparator|Tobramycine for inhalation (TIS)|tobramycin inhalation solution (TOBI® 2x300 mg) for 28 days
88884993|NCT01400789|Experimental|ListroMix 50/50®|Insulin Lispro/ insulin Lispro protamine ( ListroMix 50/50®; 100 U/mL), DispoPen 3.0 mL.
88884994|NCT01400789|Active Comparator|Humalog Mix50/50®|Insulin Lispro/ insulin Lispro protamine (Humalog Mix50/50® ; 100 U/mL), Humalog Mix 50/50® Kwik PenTM 3.0 mL.
88884995|NCT01400802|Experimental|Listro Mix75/25®|Insulin Lispro/ insulin Lispro protamine (Listro Mix75/25®; 100 U/mL), DispoPen 3.0 mL.
88884996|NCT01400802|Active Comparator|Humalog Mix75/25®|Insulin Lispro/ insulin Lispro protamine (Humalog® Mix75/25TM; 100 U/mL), Humalog Mix 75/25® Kwik PenTM 3.0 mL.
88884997|NCT01400828|Experimental|Bilastine|Intervention: Drug: Bilastine
88884998|NCT01400828|Active Comparator|Desloratadine|Intervention: Drug: Desloratadine
88884999|NCT01400828|Placebo Comparator|Placebo|Intervention: Drug: Placebo
88885000|NCT01400854||Effentora®|Single group prospective treatment cohort
88885001|NCT01399996|Placebo Comparator|Yogurt smoothie without probiotic.|
88885002|NCT01399996|Experimental|Probiotic added post fermentation.|
88885003|NCT01399996|Experimental|Probiotic added pre-fermentation.|
88885004|NCT01399996|Experimental|A capsule containing the probiotic.|
88885005|NCT01400867|Experimental|Ceftaroline fosamil|
88885006|NCT01400867|Active Comparator|Comparators|Vancomycin +/- Aztreonam Cefazolin +/- Aztreonam
88885007|NCT01400945|Experimental|S-Pantoprazole|Experimental drug: AGSPT201 Tab. (contain S-Patoprazole) Active comparator: Pantoloc Tab. (contain pantoprazole)
88885008|NCT01401036|Active Comparator|Nobori|subjects receiving Biolimus A9 eluting stent implantation
88885009|NCT01401036|Sham Comparator|Uncoated stents|subjects receiving uncoated stent implantation
88885010|NCT01401075|Active Comparator|doxifluridine|oral chemotherapy with the 5-FU prodrug doxifluridine
88885011|NCT01401075|Experimental|doxifluridine + mistletoe extract|oral chemotherapy with the 5-FU prodrug doxifluridine + mistletoe extract as subcutaneous injection
89409334|NCT02897115|Experimental|Treat-to-Target (T2T)|Participants initially received treatment with any non-steroidal anti-inflammatory drug (NSAID) at full anti-inflammatory dose for 4 weeks. After 4 weeks, if the Ankylosing Spondylitis Disease Activity Score (ASDAS) was ≥ 2.1 or treatment with NSAID 1 was not tolerated, treatment was changed to a second NSAID at full anti-inflammatory dose for 4 weeks. If ASDAS was ≥ 2.1 after 4 weeks of NSAID 2 or treatment with the chosen NSAID was not tolerated, , participants were switched to receive a combination of NSAID and adalimumab 40 mg every other week for up to 48 weeks.
89409335|NCT02897115|Active Comparator|Standard of Care (SOC)|Participants received treatment as prescribed by their physician according to the local standard of care.
89409336|NCT05576688|Experimental|Alzheimer's disease|People with Alzheimer's disease who were diagnosed with Alzheimer's disease according to NINCDS/ARDRA diagnostic criteria by a neurologist and whose cognitive level was between 18-23 points according to Mini Mental State Examination.
89409337|NCT05576688|No Intervention|Healthy older adults|33 healthy older adults with matching ages and gender.
89409338|NCT02290730|Experimental|Kinesio tape|Kinesio tape on lower trapezius
89409339|NCT02290730|No Intervention|Control|No intervention
89409340|NCT03062878||Breast Cancer/Lymphoma Patient|Breast cancer or lymphoma patients currently undergoing anthracycline-based chemotherapy treatment. Patients are eligible if they have completed at least 1 cycle of chemotherapy. Free of known clinical cardiovascular disease.
89409341|NCT03062878||Breast Cancer/Lymphoma Survivor|Individuals with history of breast cancer or lymphoma (1-5 years removed from last date of chemotherapy) who have a treatment history of anthracycline-based chemotherapy. Free of known clinical cardiovascular disease.
89409342|NCT03062878||Control|Individuals with no history of caner or chemotherapy. Free of known clinical cardiovascular disease
89409343|NCT02290808|Experimental|Theory-based group|The theory-based intervention group will receive strategies based on the Theory of Planned Behaviour to help increase physical activity among couples. Parents will receive materials on how to work together.
89409344|NCT02290808|No Intervention|Information group|The information group will serve as the control group and will receive informational materials on the benefits of physical activity.
89409345|NCT03818373|Other|Patients with univentricular congenital heart disease|Patients 8 years old or more with functionally univentricular congenital heart disease
89409346|NCT01452802||HM II (HeartMate II LVAD)|Subjects who elect to, and receive HM II LVAD therapy at baseline
89409347|NCT01452802||OMM (Optimal Medical Management)|Subjects who elect to remain on optimal medical management
89409348|NCT02289482|Experimental|GSK2838232 Part A: Single Dose Escalation|During Part A, subjects will receive GSK2838232/ placebo (3:1) in 4-period (period 1: GSK2838232 200mg, period 2: GSK2838232 500mg), single dose escalation design. Subjects randomized to placebo will receive placebo in all four periods. Following completion of Period 2 PK assessments at 96hr post-dose, subjects will begin daily dosing of RTV 100mg (period 3: GSK2838232 20 mg + RTV 100 mg, period 4: GSK2838232 50 mg + RTV 100 mg) for a total of 26 days.
89409349|NCT02289482|Experimental|GSK2838232 Part B: Single Dose, 3-Period Crossover, Relative B|During Part B, subjects will receive GSK2838232/ placebo, in an open-label, unbalanced, 3-period, cross-over design; subjects will be randomized (1:1) to each sequence. The relative bioavailability of single 100 mg doses of powder in a bottle (PIB) Active Pharmaceutical Ingredient (API) of GSK2838232 versus PIB Spray-Dried Dispersion (SDD) will be assessed (Period 1: SDD GSK2838232 100 mg vs GSK2838232 API 100 mg; period 2: GSK2838232 API 100 mg Vs SDD GSK2838232 100 mg ). A single dose of GSK2838232 will be co-administered on the 10th day of RTV dosing (period 3:GSK2838232 10 mg + RTV 100 mg); RTV dosing will continue for an additional 4 days (total of 14 days).
89409350|NCT03645213|Experimental|Virtual Reality (VR)|Children were asked which cartoon they wanted to watch and it was prepared. The cartoons began to be shown a minute before venipuncture and lasted about 4 minutes. The procedure and reason were explained to the child before each step of the venipuncture process such as apply a tourniquet, insert and remove the needle. The parent stopped on the left side of the child's. The display was a head-mounted VR box in the VR group.
89409351|NCT03645213|Experimental|Non- Virtual Reality (VR)|Children were asked which cartoon they wanted to watch and it was prepared. The cartoons began to be shown a minute before venipuncture and lasted about 4 minutes. The procedure and reason were explained to the child before each step of the venipuncture process such as apply a tourniquet, insert and remove the needle. The parent stopped on the left side of the child's. The display was a computer tablet in the non-VR group. The computer tablet was the 10 centimeters far from the child.
89409352|NCT03645213|No Intervention|Control|There was no additional intervention in the control group. Venipuncture procedures was the same other groups. The procedure and reason were explained to the child before each step of the venipuncture process such as apply a tourniquet, insert and remove the needle. The parent stopped on the left side of the child's.
89409353|NCT03645135|No Intervention|Control|Patients in the control group will be asked to complete a demographics survey and assess their perceived involvement in care after their visit
89409354|NCT03645135|Experimental|Goal elicitation|Patients in the intervention group will be asked to list 2 goals for their visit. They will also be asked to complete a demographics survey and access their perceived involvement in care after their visit.
89409355|NCT02921230|Experimental|ELUVIA Stent Implantation|Peripheral stenting
89409356|NCT02921230|Active Comparator|control Bare Metal Stent Implantation|Peripheral stenting
89409357|NCT04600128|Active Comparator|Dairy-based Greek yogurt|Plain dairy-based Greek yogurt
89409358|NCT04600128|Active Comparator|Dairy-based cheddar cheese|Mild dairy-based cheddar cheese
88885012|NCT01401088|Experimental|Artificial drainage implant|Aurolab Artificial Drainage Implant (AADI) on intraocular pressure reduction will be implanted in patients with refractory glaucoma.
88885013|NCT01401114||Group 1|Drug (incl. Placebo)
89409359|NCT04600128|Active Comparator|Plant-based Greek yogurt|Plain plant-based Greek yogurt
89409360|NCT04600128|Active Comparator|Plant-based cheese|Medium cheddar plant-based cheese
89409361|NCT02289638|Experimental|Intubation without chest compressions|Endotracheal intubation of pediatric mannikin during resuscitation without chest compressions.
89409362|NCT02289638|Experimental|Intubation with uninterrupted chest compressions|Endotracheal intubation of pediatric mannikin during resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
89409363|NCT05575986|Experimental|Observation group|Herombopag Olamine Tablets
88885014|NCT01401127||Type 1 Diabetes|Participants with type 1 Diabetes running their insulin pump at 70% of usual basal rate
88885015|NCT01401127||Participants without diabetes|Participants without diabetes or evidence of impaired glucose regulation
88885016|NCT01401140|Active Comparator|St Thomas|
88885017|NCT01401140|Experimental|Custodiol|
88885018|NCT01401179|Active Comparator|cefazolin|
88885019|NCT01401179|Active Comparator|cefazolin plus erythromycin|cefazolin, erythromycin
88885020|NCT01401179|Active Comparator|cefazolin plus clarithromycin|
88885021|NCT01401192|Experimental|TS positive cohort & Gem/Cis Tx arm|Among TS expression positive patients, some will be randomized to Gem/cis therapy
88885022|NCT01401192|Active Comparator|TS+ cohort & Pem/Cis arm|Among patients with TS+, randomised to Pem/cis chemotherapy
88885023|NCT01401192|Active Comparator|TS negative cohort & Pem/Cis Tx arm|Among patients with TS-, some will be randomised to Pem/cis Tx arm
89409364|NCT02896569|Experimental|Topical combination therapy|Application of human bone marrow stem cell derived growth factor and cytokines serum followed by a botanical lipid-based occlusive immediately post-radio-frequency treatment of the face
89409365|NCT02896569|No Intervention|Standard of care|No topical therapies for 24 hours post-radio-frequency treatment of the face
89409366|NCT02290964|No Intervention|Control group|After general anesthesia is applied, surgery is performed. Whenever transfusion is indicated, the patients will received allogenic blood transfusion
89409367|NCT02290964|Active Comparator|ANH group|After general anesthesia is applied, blood from patients in this group were withdrawn. the volume of blood withdrawn was determined based on Gross equation. The blood obtained was then stored in the operating room at temperature between 23 - 25 Celsius degree, and given back to the patient whenever transfusion is indicated.
89409368|NCT04599036|Experimental|Feasibility|To explore if the feasibility of adding an EMG controlled device to the acute rehabilitation for stroke subjects with severe arm deficit.
89409369|NCT04066270||study group|"candidates for cochlear implantation 18 years or older, who are eligible for implantation for the indication of bilateral severe hearing loss or single sided deafness.~clinical audiometric and vestibular investigations, CT and MR imaging of petrous bone"
89409370|NCT04066270||control group|"Symptomatic DFNA9 patients carrying the p.P51S mutation in COCH, presenting the radiologic semicircular canal lesion(s) on CT and/or MR.~clinical audiometric and vestibular investigations, CT and MR imaging of petrous bone"
89409371|NCT04030195|Experimental|Dose Level 1 of PBCAR20A CAR T cells|"1 x 10^6 chimeric antigen receptor (CAR) T cells per kg body weight.~In this study, PBCAR20A, allogeneic anti-cluster of differentiation (CD20) CAR T Cells, is used to treat patients with relapsed or refractory (r/r) CD20+ Non-Hodgkin Lymphoma (NHL) or r/r Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL).~Route of Administration: Intravenous infusion (IV)~Lymphodepletion Conditioning: Lymphodepletion will be conducted several days prior to PBCAR20A infusion. A combination of fludarabine and cyclophosphamide will be used for lymphodepletion."
89409372|NCT04030195|Experimental|Dose Level 2 of PBCAR20A CAR T cells|240 x 10^6 CAR T cells (flat dose)
89409373|NCT04030195|Experimental|Dose Level 3 of PBCAR20A CAR T cells|480 x 10^6 CAR T cells (flat dose)
89409374|NCT02253966|Active Comparator|Methylprednisoloneacetate|"Administration of:~1 ml methylprednisoloneacetate 40 mg/ml 5 ml lidocaine 20 mg/ml 4 ml sodium chloride 9 mg/ml as a single intraarticular injection 7 days prior to surgery."
89409375|NCT02253966|Placebo Comparator|Sodium chloride|"Administration of:~5 ml lidocaine 20 mg/ml 5 ml sodium chloride 9 mg/ml as a singe intraarticular injection 7 days prior to surgery."
89409376|NCT03644979|Experimental|Skydiving|Tandem skydiving
88885024|NCT01401192|Experimental|TS negative cohort & Gem/Cis Tx arm|Among patients with TS-, some will be randomised to Gem/Cis Tx arm
88885025|NCT01401205||shoulder arthroscopic surgery group|the patients who undergo the elective shoulder arthroscopic surgery of rotator cuff repair
88885026|NCT01401218||thoracic aortic surgery group|patients who underwent thoracic aortic surgery
88885027|NCT01401231|Experimental|Behavioral Activation|Behavioral activation psychotherapy
88885028|NCT01401231|Placebo Comparator|Usual Care|Continued care as usual
89409377|NCT03644979|No Intervention|Negative control|No skydiving
89409378|NCT02291042|Experimental|Suppository|Patients will receive a single antispasmodic muscarinic suppository after induction of anesthesia but before insertion of urological scope for surgery. The suppository is composed of Belladonna (16.2 mg) and Opium (30 mg) in a water soluble base manufactured as Belladonna and Opium Supprettes.
89409379|NCT02291042|No Intervention|Control|Patients will be provided with routine care.
89409380|NCT01673620|Experimental|Montelukast 10 mg/loratadine 10 mg|Montelukast 10 mg/loratadine 10 mg combination tablet administered orally once daily for 2 weeks
89409381|NCT01673620|Placebo Comparator|Placebo|Matching placebo tablet administered orally once daily for 2 weeks
89409382|NCT03547206|Experimental|RPh201 Cohort A|A 26-week schedule consisting of twice-weekly subcutaneous administration of 400 μL of the Investigational Medical Product (IMP) (20 mg RPh201).
89409383|NCT03547206|Placebo Comparator|Placebo Cohort A|A 26-week schedule consisting of twice-weekly subcutaneous administration of 400 μL of the vehicle control.
89409384|NCT03547206|Experimental|RPh201 Cohort B|A 12-week schedule consisting of four-times-per-week subcutaneous administration of 400 μL of the Investigational Medical Product (IMP) (20 mg RPh201).
88885029|NCT01401270|No Intervention|Treatment Group A|Standard Care
88885030|NCT01401270|Experimental|Treatment Group B|100% probability of winning a prize with each draw and has 3 prize categories
88885031|NCT01401270|Experimental|Treatment Group C|31% probability of winning and has 3 prize categories
88885032|NCT01401270|Experimental|Treatment Group D|100% probability of winning and has 7 prize categories
88885033|NCT01401270|Experimental|Treatment Group E|31% probability of winning and has 7 prize categories
88885034|NCT01401270|Experimental|Treatment Group F|usual prize contingency management with a 50% probability of winning from 3 prize categories
88885035|NCT01401296|Active Comparator|Wait-list group|Subjects receive access to deprexis after eight weeks
88885036|NCT01401296|Experimental|Deprexis|Web-based intervention deprexis consists of ten online modules (plus one introductory and one summary module) representing different psychotherapeutic strategies with a strong focus on evidence-based cognitive-behavioral techniques (e.g. interpersonal skills). Each module lasts approximately 10-60 minutes (e.g. depending on the user´s reading speed). Modules are sequential and organized as simulated dialogues. Each module refers and builds upon previous one. The program is delivered at no cost to participants.
88885037|NCT01401335|Other|Trauma counseling|
88885038|NCT01401374||Vitiligo Patients|patients with vitiligo vulgaris
88885039|NCT01401374||Controls|Individuals without vitiligo vulgaris
89409385|NCT03547206|Placebo Comparator|Placebo Cohort B|A 12-week schedule consisting of four-times-per-week subcutaneous administration of 400 μL of the vehicle control.
89409386|NCT02291120|Active Comparator|MTA|ProRoot® MTA is a root canal repair material that is a unique improvement over other materials used for root canal repair. Made up of fine hydrophilic particles that set in the presence of water, ProRoot® MTA seals off all pathways between the root canal system and surrounding tissues, significantly reducing bacterial migration. Its excellent compatibility with the dentinal wall allows for a predictable clinical healing response.
88885040|NCT01401387|Active Comparator|Standard treatment|Treatment with pancreatic enzymes after clinical sings and symptoms of steatorrhea and 10% decrease of weight at time of randomisation.
88885041|NCT01401387|Active Comparator|Preventive treatment|Patients will be prescribed with pancreatic enzymes immediately after diagnosis with pancreatic cancer, regardless of the presence of steatorrhea
88885042|NCT01401400||(Peg) interferon|Patients who are treated for at least 12 weeks with (peg-)interferon for chronic hepatitis B
88885043|NCT01401413|Placebo Comparator|1|placebo control nightly
88885044|NCT01401413|Active Comparator|2|8 mg ramelteon nightly
88885045|NCT01401426|Active Comparator|Single incision laparoscopic vertical sleeve gastrectomy|Active Comparator Patients in this group will undergo laparoscopic vertical sleeve gastrectomy through a single periumbilical incision.
88885046|NCT01401426|Active Comparator|Five port laparoscopic vertical sleeve gastrectomy|Patients in this group will undergo conventional laparoscopic vertical sleeve gastrectomy using 5 small incisions.
88885047|NCT01401491|Active Comparator|clozapine + fluvoxamine|
88885048|NCT01401491|Placebo Comparator|clozapine + placebo|
88885049|NCT01401504|Experimental|ASP3026|
88885050|NCT01401569|Active Comparator|Control|All subjects (intervention and control groups) participate in a smoking cessation program composed of a pharmacological treatment (including nicotine replacement therapy or varenicline) and counseling.
88885051|NCT01401569|Experimental|physical activity program|Experimental group subjects were required to attend 2 supervised exercise sessions and 2 counseling sessions during Week 1 and Week 2. Supervised exercise and counseling sessions are realized successively. For Week 3 to 8, participants were required to attend 1 supervised exercise session and 1 counseling session plus 1 home exercise session.
88885052|NCT01401608||Treatment|Ablation of VT/PVCs using a magnetic RF ablation catheter
88885053|NCT01401621|Experimental|Scratch-Off Test Name Condition|The name of the test the recipient needs is hidden behind a scratchoff on the reminder
88885054|NCT01401621|Experimental|Scratch-Off Call to Action Condition|The recipient will be prompted to scratch-off the paper in order to find out how to follow the recommendation that the test be received.
88885055|NCT01401621|Experimental|Control Condition|A control condition with no scratch-off element.
88885056|NCT01401634|Other|Intravenous Fluids|Intravenous fluids for patients with hyperglycemia is part of the standard protocol in our department
88885057|NCT01401634|Experimental|Oral Fluids|
88885058|NCT01401660||Group A|Subjects who do not currently have low back pain.
88885059|NCT01401660||Group B|Subjects who have low back pain at the time of the study, and who are currently being treated or have been previously treated for their low back pain and do not wish to receive further treatment for their pain.
88885060|NCT01401660||Group C|Subjects who have low back pain at the time of the study, and wish to receive physical therapy to reduce their low back pain.
88885061|NCT01401712|Experimental|Paravertebral catheter (ON-Q® Pain Relief System)|
88885062|NCT01401712|Active Comparator|Thoracic epidural catheter|
88885063|NCT01401725|Experimental|Hamilton General Hospital|
88885064|NCT01401725|Active Comparator|Juravinski Hospital|
88885065|NCT01401725|Other|St. Joseph's Hospital|
88885066|NCT01401751|Other|Single Arm|non-randomized, uncontrolled, feasibility study
88885067|NCT01401764|Other|Platform II, PASS, ARG 100|
88885068|NCT01401777||Control, No PercuNav|Patient having procedure without PercuNav Guidance information
88885069|NCT01401777||PercuNav aided procedure|Biopsy procedure aided with use of PercuNav
88885070|NCT01401790|Experimental|Telehomecare|3 month use of a new telehomecare program
88885071|NCT01401790|Active Comparator|Control|3 month regular education program and follow up at the Diabetes Clinic
88885072|NCT01401803|Other|Dysport|Dysport injections into the glabella and orbicularis oculi muscles with dose based on muscle mass.
88885073|NCT01401816|Experimental|Intervention Group|Subjects in this group will receive a prescription for emergency contraception and then text-messages (on Day 1, 3 and 5 after enrollment) to their personal cell phone with a reminder to fill their prescription.
88885074|NCT01401816|No Intervention|Control Group|Subjects in this group will receive a only a prescription for emergency contraception and no reminder text messages.
88885075|NCT01401829|Experimental|75 weekly minutes walking|12-week physical activity intervention group with a goal of 75 minutes of moderate intensity exercise (walking) per week
88885076|NCT01401829|Experimental|150 weekly minutes walking|12 week physical activity intervention group with a goal of 150 minutes of moderate intensity exercise (walking) per week
88885077|NCT01401829|Active Comparator|Stretching and Flexibility exercise|Stretching/Flexibility exercise
88885078|NCT01401855||In Vivo Probe Prediction|
88885079|NCT01401855||Cytology Results|
88885080|NCT01401868|Experimental|single arm|dose escalation
88885081|NCT01401881||Post STEMI|The study population will consist of adult patients with acute STEMI and primary PCI with clear identification of symptoms onset, willing to participate in the research protocol and not having any of the exclusion criteria. Patient screening will take place after the primary PCI in the cardiac catheterization laboratory or in the coronary care unit. Participation will be offered to all those who meet eligibility criteria.
88885082|NCT01401920||patients undergoing open heart surgery|small infant or children patients undergoing open heart surgery
88885083|NCT01401933|Experimental|Linifanib|
88885084|NCT01401946|Active Comparator|soy isoflavones|
88885085|NCT01401946|Placebo Comparator|Placebo|
88885086|NCT01402024|Experimental|Aprepitant|It is an double blind randomized placebo controlled trial with age group of 5-18 years and weight between 15-65 kg, who will receive highly emetogenic chemotherapy. Patient who will meet the inclusion criteria will be randomly enrolled in either of the two arm-aprepitant arm and control arm. The patient on aprepitant arm will receive the study drug (aprepitant)along with standard anti-emetic therapy (as per the dosages mentioned in the protocol).
89409387|NCT02291120|Experimental|MedCem Portland Cement (PC)|MedCem PC is an excellent capping material for cariology on permanent teeth (direct and indirect capping) and in milk tooth endodontics (milk tooth amputation). Is characterized by excellent colour stability and neutrality and does not contain any additional ingredients
89409388|NCT05284149|Active Comparator|H.S. Supplement|Patients taking Hirsutella Sinensis Nutrient Supplements
89409389|NCT05284149|Placebo Comparator|Placebo|Patients taking placebo
89409390|NCT04037956|Experimental|Tubeless NOSES|Patients receive Tubeless NOSES.
89409391|NCT04037956|Active Comparator|traditional laparoscopic|Patients receive traditional laparoscopic radical resection.
89409392|NCT04671355|Experimental|Trimbow|Pressurized metered dose inhaler
89409393|NCT04671355|Active Comparator|Relvar|Dry powder inhaler
89409394|NCT03987542||Exposed|Patients who had their asparaginase treatment truncated or had no asparaginase enzyme activity.
89409395|NCT03987542||Unexposed|Patients who did not have their asparaginase treatment truncated and had measurable asparaginase enzyme activity
89409396|NCT03644901||Patients whose blood type is A|Applying nonsurgical periodontal treatment (scaling and root planning).
89409397|NCT03644901||Patients whose blood type is B|Applying nonsurgical periodontal treatment (scaling and root planning).
89409398|NCT03644901||Patients whose blood type is AB|Applying nonsurgical periodontal treatment (scaling and root planning).
88885087|NCT01402024|Placebo Comparator|Control|It is an double blind randomized placebo controlled trial with age group of 5-18 years and weight between 15-65 kg, who will receive highly emetogenic chemotherapy. Patient who will meet the inclusion criteria will be randomly enrolled in either of the two arm-aprepitant arm and control arm. The patient on the control arm will receive the placebo along with standard anti-emetic therapy (as per the dosages mentioned in the protocol).
88885088|NCT01402037|Other|NDP 12-39 y|In newly diagnosed patients a hyperglycemic clamp tests will be performed within 4 weeks after diagnosis and 6, 12, 18 and 24 months later in 40 patients. The clamp will not be carried out in participants who became Cpeptide negative (defined as AUC C-peptide ≤ 0.03 nmol/L x min.) at a previous visit. HbA1c will be determined at the day of the clamp and glycemic variability during 5 days starting immediately after the clamp procedure. Insulin requirements and severe hypoglycemia (defined as an episode in which a patient required the assistance of another person and which was associated with a blood level of < 50 mg/dL or prompt recovery following intravenous glucose, glucagon or oral carbohydrate) will be recorded
88885089|NCT01402037|Other|NDP 5-12 y|Ten childhood-onset patients (under age 12) will be tested for 5 days with CGM (without clamp) and their glycemic variability compared with that of 10 patients aged 12-17 years at diagnosis.
89409399|NCT03644901||Patients whose blood type is O|Applying nonsurgical periodontal treatment (scaling and root planning).
89409400|NCT04034212|Experimental|Singing for Lung Health group|Once weekly attendance at a Singing for Lung Health group for 12 weeks.
89409401|NCT04034212|No Intervention|Usual Care group|Usual care group, participants given advice on physical activity while continuing with usual care.
89409402|NCT03521492|Experimental|caries group|
89409403|NCT03521492|Experimental|free caries group|
89409404|NCT03765879|Experimental|Verum VGAIT Group|Participants in this group will receive verum (real) acupuncture and verum video-guided acupuncture imagery treatment (VGAIT).
89409405|NCT03765879|Placebo Comparator|Sham VGAIT Group|Participants in this group will receive sham acupuncture and sham VGAIT.
89409406|NCT04644991|Experimental|Kinesiotape|Experimental group consisting of transfemoral amputees who kinesiology tape will be applied
89409407|NCT04644991|Sham Comparator|ShamKinesiotape|The placebo group of transfemoral amputees who shame kinesiology tape will be applied
89409408|NCT03521414|Active Comparator|Group I=13-15 mildly injured|"Patients were divided into 3 groups according to the Glasgow Coma Scores calculated before surgery. use of anesthetic agent were recorded during bispectral index (BIS) monitoring and anesthesia application. we used sevoflurane drug intraoperative.~Group I (n=15)=13-15 mildly injured"
89409409|NCT03521414|Active Comparator|Group 2 =9-12 moderately damaged|"Patients were divided into 3 groups according to the Glasgow Coma Scores calculated before surgery.use of anesthetic agent were recorded during bispectral index (BIS) monitoring and anesthesia application. we used sevoflurane drug intraoperative.~Group 2 (n=15)=9-12 moderately damaged"
89409410|NCT03521414|Active Comparator|Group 3=3-8 severely damaged.|"Patients were divided into 3 groups according to the Glasgow Coma Scores calculated before surgery. use of anesthetic agent were recorded during bispectral index (BIS) monitoring and anesthesia application. we used sevoflurane drug intraoperative.~Group 3 (n=15)=3-8 severely damaged."
89409411|NCT00432094|Experimental|2 Transplants/1 Transplant (Overall)|"2 Transplants: Patients with Germ Cell Tumors (GCT) treated with a second tandem autologous stem cell transplant (AuSCT) with non-cross-resistant conditioning regimens.~1 Transplants:Patients with Germ cell tumors who receive one transplant only."
89409412|NCT04562779|Experimental|XR Naltrexone|Participants will receive a single dose of extended-release, injectable naltrexone prior to hospital discharge, in addition to enhanced linkage to follow-up addiction care.
89409413|NCT04562779|Experimental|IV Ketamine|Participants will receive a single dose of intravenous ketamine (0.5mg/kg over 40 minutes) prior to hospital discharge, in addition to enhanced linkage to follow-up addiction care.
89409414|NCT04562779|Active Comparator|Linkage|Participants will receive no single-dose addiction medication prior to hospital discharge, but will receive enhanced linkage to follow-up addiction care.
89409415|NCT05218200|Experimental|experimental group|In addition to the routine care in the hospital, the patient will be given deep breathing and coughing exercises.
88885090|NCT01402037|Other|FDR 12-39 y|In first degree relatives of type 1 diabetes patients a hyperglycemic clamp tests will be performed at inclusion and 6, 12, 18 and 24 months later in 40 high-risk first-degree relatives (see previous definition) with a non-diabetic OGTT performed 1 to 2 weeks before the clamp procedure. An OGTT result suggestive of diabetes will be confirmed and the relative will be offered participation in the patient arm of the study. HbA1c will be determined at the day of the OGTT and glycemic variability during the 5 days preceding the OGTT procedure.
88885091|NCT01402037|Other|FDR 5-12 y|"Ten high-risk first-degree relatives (see criteria) aged 5 to 12 years will also be tested for CGM and their results correlated with beta-cell function derived from a mini-clamp procedure (first 10 min. C-peptide release in hyperglycemic clamp) and results (CGM and first clamp phase) from relatives aged 12-17 years."
88885092|NCT01402076|Experimental|Steady State PK Group|
88885093|NCT01402076|Experimental|No steady state PK|
88885094|NCT01402154||All study patients|All patients included according to stated inclusion and exclusion criteria.
89191756|NCT00724620|Experimental|Slow Responders (SR): Decrease in viral load >=2 log|All patients will receive peginterferon alfa-2b 1.5 ug/kg administered subcutaneously (SC) once weekly in combination with ribavirin (800-1200 mg/day) administered orally (PO) for a minimum period of 12 weeks. Patients who have a slow response to therapy at Treatment Week 12 (ie, Slow Responders who are not HCV-RNA[-] at Treatment Week 12 but decrease >=2 log) will continue the combined treatment for a total of 72 weeks and will complete 24 weeks of follow up to determine the Sustained Viral Response (SVR).
89191757|NCT00724620|Experimental|Nonresponders (NR): Decrease in viral load <2 log|All patients will receive peginterferon alfa-2b 1.5 ug/kg administered subcutaneously (SC) once weekly in combination with ribavirin (800-1200 mg/day) administered orally (PO) for a minimum period of 12 weeks. Patients who have not responded to therapy at Treatment Week 12 (ie, Nonresponders who are not HCV-RNA[-] at Week 12 of Treatment and/or have a decrease in viral load <2 log) will stop treatment at Treatment Week 12.
88885095|NCT01402167|Experimental|Kyphoplasty|Patients randomized to this arm will be treated via balloon kyphoplasty.
89191758|NCT00866008|Experimental|1|Conventional regimen with a daily dose of 225 IU recombinant FSH and GnRH agonist long protocol co-treatment.
89191759|NCT00866008|Experimental|2|Mild ovarian stimulation regimen using the endogenous FSH production by starting treatment on day 5 of the menstrual cycle with 150 IU / d recFSH with GnRH antagonist co treatment starting on day 6. As soon as two follicles reach 12 mm, treatment is continued with 200 IU / d rec hCG.
89191760|NCT00722514|Experimental|IG|Patient education
89191761|NCT00722514|Other|CG|without patient education
89191762|NCT02571426|Active Comparator|Propofol|Continuous infusion during surgery. Individual dosage.
88885096|NCT01402167|Active Comparator|Vertebroplasty|Patients randomized to this arm will be treated via vertebroplasty.
88885097|NCT01402180|Experimental|A|Patients randomized in Arm A will receive chemoradiation and weekly Nimotuzumab for 6 weeks concurrent with radiation
88885098|NCT01402180|Active Comparator|B|Patients randomized in Arm B will receive chemoradiation only
89409416|NCT05218200|No Intervention|Control group|There will be no intervention other than routine nursing care practices in the hospital.
88885099|NCT01402193|Active Comparator|Study Arm|"Investigational treatment: Arimidex commenced before and continued during radiotherapy.~Interventions:~Drug: Pre-radiotherapy commencement of Arimidex Radiation: Radiotherapy"
88885100|NCT01402193|Active Comparator|Control Arm|"Standard Treatment: Arimidex delayed until 2 weeks after radiotherapy~Interventions:~Radiation: Radiotherapy Drug: Post radiotherapy commencement of Arimidex"
89191763|NCT02571426|Active Comparator|sevoflurane|Inhalational anesthetic during surgery. Individual dosage
89191764|NCT00861796|Experimental|1|
89191765|NCT00861796|Placebo Comparator|2|
89191766|NCT00722670|Experimental|Woman-focused (WF)|Woman-focused intervention (Women's CoOp)
89191767|NCT00722670|Active Comparator|Treatment as Usual (TAU)|TAU (substance abuse treatment only)
89409417|NCT03751761|Experimental|durvalumab, tremelimumab, paclitaxel|
89409418|NCT03523130||HIV-infected|
89191768|NCT00854854|No Intervention|Control|"Oxaliplatin infusion (100mg/m2) on days 1 and 15 (every 2 weeks)~5-FU bolus + infusions (400 mg/m2) on days 1, 2, 15 and 16~LV infusions (200 mg/m2) on days 1, 2, 15 and 16"
89191769|NCT00854854|Active Comparator|Active|"Infusion of TKCell(autologous activated lymphocyte) over 2x10^9 cells, IV route, 7 times~and chemotherapy schedule"
89191770|NCT05373030|Experimental|Recombinant adenovirus type-5-vectored COVID-19 vaccine|
89191771|NCT05373030|Active Comparator|Inactivated COVID-19 vaccine|
89191772|NCT00854932|Experimental|PCT group|In the PCT group, if infection is considered to be unlikely or possible, antibiotic therapy is discontinued when two consecutive PCT values are within the normal range.Antibiotic therapy can be continued despite fulfilled criteria at the discretion of the attending physician. These divesions from the stopping rules will be reported for further analysis.
89191773|NCT00854932|No Intervention|Standard group|The duration of antibiotic treatment in the standard group is based on the attending physician's assessment of the risk of classification: infection unlikely for 36-72 hours, infection possible for 5-7 days, infection probable of proven for 7-21 days depending on clinical course, laboratory values and positive cultures.
89191774|NCT02570802|Other|ultrasound of peripheral nerves|Ultrasonographic examination
89409419|NCT03523130||non-HIV-infected|
89531056|NCT03341585|Experimental|Expiration Lente Prolongée|In this controlled trial with intra-subject design infants will be studied using multichannel intraluminal impedance pH (pH-MII) monitoring , during which they receive one 20 min session of 'Expiration Lente Prolongée (ELPr)' . The number of reflux episodes (RE) is the outcome measure. The results obtained during and 20 min after the intervention will be compared to a period of 20 min before treatment ( control ).
89409420|NCT03044197|Experimental|MRI/ultrasound transperineal prostate biopsy|In arm A, all patients with positive mpMRI evidence of lesions suspicious for PCa, i.e. PI RADS ≥ 3 will be submitted to transperineal mpMRI-targeted prostate biopsy (arm A MRI+). The gland and the regions of interest will be contoured, and the prostate contour will be fused in real time with the TRUS image. Biopsies will be performed via a transperineal approach in the operating room. The patient will be placed in dorsal lithotomy position. mpMRI-targeted biopsies will be performed on regions of interest, and three to six cores will be obtained for biopsy from each lesion and is standard of care according to START criteria for targeted biopsy. In cases of negative mpMRI results i.e. PI RADS<3, arm A patients will undergo TRUS-guided transrectal 12-core prostate biopsy (arm A MRI-) as described in arm B.
89409421|NCT03044197|Active Comparator|transrectal ultrasound-guided prostate biopsy|TRUS-guided transrectal prostate biopsy will be performed using a disposable 18-gauge biopsy gun with a specimen size of 18-22 mm (Bard Medical, Covington, GA, USA). The 12 cores will be obtained from 12 separate anatomical regions of the prostate which is standard practice in performing TRUS-guided transrectal prostate biopsy: left medial apex, left lateral apex, left medial midgland, left lateral midgland, left medial base, left lateral base, right medial apex, right lateral apex, right medial midgland, right lateral midgland, right medial base and right lateral base.
89409422|NCT02291276||Female cancer patients with ascites|Primary epithelial ovarian female cancer patients with ascites (> 500 ml ascites in the preoperative sonographic examination)
89409423|NCT02291276||Female cancer patients aged > 70 years|"Primary epithelial ovarian female cancer patients aged > 70 years with at least one of the following secondary diagnoses:~Status Post stent placement due to coronary heart disease respectively Status Post-myocardial infarction~existing arterial Hypertension for more than 5 years~chronic heart failure (New York Heart Association (NYHA) class II-III)~peripheral arterial disease"
89409424|NCT05202990|Experimental|Fecal Microbiota Transplantation by Stool capsules|Patients receiving fecal microbiota transplantation from a healthy donor in 3 times after inclusion and randomisation (Month 0 - Month 1 - Month 2) using frozen stool capsules
89409425|NCT05202990|Experimental|Fecal Microbiota Transplantation by enema|Patients receiving fecal microbiota transplantation from a healthy donor in 3 times after inclusion and randomisation (Month 0 - Month 1 - Month 2) using frozen stool enemas.
89409426|NCT02291354|Placebo Comparator|FMT + Placebo|Patients allocated to control group will receive standard FMT, followed by placebo for 12 weeks.
89409427|NCT02291354|Experimental|FMT + Pectin|Patients allocated to experiment group will receive standard FMT, followed by 24g pectin each day for 12 weeks.
89409428|NCT03644823|Experimental|PDL1-inhibitor and radiotherapy|PDL1-inhibitor (Atezolizumab) and Radiotherapy (6 Gy x 3)
89409429|NCT00072358|Experimental|patients have refractory bone marrow disease|This phase II trial of the anti-GD2 murine IgG3 monoclonal antibody 3F8 combined with granulocyte-macrophage colony stimulating factor (GM-CSF) will assess response of minimal residual disease (MRD) in patients with high-risk neuroblastoma (NB) and help establish the optimal way to use GM-CSF.
89409430|NCT00072358|Experimental|patients have no evidence of disease|This phase II trial of the anti-GD2 murine IgG3 monoclonal antibody 3F8 combined with granulocyte-macrophage colony stimulating factor (GM-CSF) will assess response of minimal residual disease (MRD) in patients with high-risk neuroblastoma (NB) and help establish the optimal way to use GM-CSF.
89409431|NCT03644745|Experimental|VM @ Home Usability|We will pilot our customer engagement and physical exercise system in the homes of up to 20 participants for 3 months. Participants will interact with the system on their own computers, smart phones, and/or televisions and wear an activity tracker throughout the study. Interactions include physical exercise, system usage, and video conferencing.
89409432|NCT03546114||Patients referring to an osteopathic clinic - CMO, Milan|Adults, age>18 years, first visit at osteopathic clinic (Centro di Medicina Osteopatica)
89409433|NCT02289794|Active Comparator|E.coli bioconjugate vaccine|E.coli bioconjugate vaccine in saline buffer
89409434|NCT02289794|Placebo Comparator|Placebo|Saline buffer
89409435|NCT03644355|Experimental|Diet and Nutrition Education|Lifestyle counseling plus nutrition education and counseling and protein sparing modified fast diet plus supplementation of vitamins and minerals, followed by a balanced, hypo-caloric diet and nutrition education provided by a registered dietician
88885101|NCT01402206|Other|Structured patient visits|Participants in the intervention group visit their general practitioner at baseline and 4, 8, and 12 weeks. At each visit, participants complete MADRS-s for the assessment of depression severity and discuss the results with their GP in a patient-centered consultation.
88885102|NCT01402206|Other|Treatment as usual|The control group receives treatment as usual by general practitioner (no intervention).
89409436|NCT03644355|Active Comparator|Exercise Instruction|Lifestyle counseling plus moderate intensity, progressive exercise prescription including cardio-pulmonary, strength and flexibility exercise tailored to the individual needs of each participant.
89409437|NCT03644355|Active Comparator|Combined Diet and Exercise|Lifestyle counseling plus dietary intervention including nutrition education and counseling and a protein sparing modified fast diet and nutrition education combined with the exercise intervention including a moderate intensity, progressive exercise prescription including cardio-pulmonary, strength and flexibility exercise tailored to the individual needs of each participant.
89409438|NCT03644355|No Intervention|Control|Delayed intervention (waiting list) group receives no intervention for 12 weeks followed by the Diet plus Exercise intervention.
88885103|NCT01402219|Active Comparator|Iopamiro-370|
88885104|NCT01402219|Active Comparator|Visipaque 320|
88885105|NCT01402232||coronary angiography|We recruit all consecutive patients who were undergoing coronary angiography or percutaneous coronary intervention.
88885106|NCT01402245|No Intervention|Pneumonia group|Patients with Pnc pneumonia
88885107|NCT01402245|Active Comparator|PPV Group|Volunteers immunized with Pnc polysaccharide vaccine
88885108|NCT01402245|Active Comparator|PCV Group|Volunteers immunized with Pnc conjugate vaccine
88885109|NCT01402297|Experimental|COPD patients|Thirteen nonsmoking patients, suffering from GOLD II and GOLD III stage participated in the study (mean age 57 years (range 42-79), 9 men, 4 women). COPD was diagnosed based on GOLD 2009 criteria. All the participants were diagnosed at Department of Clinical Physiology, Medical university of Lodz.
89409439|NCT03521336|Experimental|Umbilical Cord Mesenchymal Stem Cells|Intrathecal Transplantation of Umbilical Cord Mesenchymal Stem Cells, 1*10^6 cells/kg, once a month for 4 months
89409440|NCT03521336|Placebo Comparator|Control|Placebo: Sham operation, 10ml saline, once a month for 4 months
89409441|NCT03104920|Experimental|ERAS program|We give an ERAS pathway, which comprises of optimized management of diet, mobilization, analgesia and GI function recovery for patients with HCC.
89409442|NCT03104920|Active Comparator|Traditional treatment|We give routine clinic practices for the treatment of HCC.
89409443|NCT03645447|Experimental|Taste test|Participants will be presented with a series of tastants of 4 different modalities (sweet, salt, sour, bitter) of 9 different concentrations in pseudo-random order. The threshold at which each participant reliably identifies the taste is determined for each tastant. Mood Questionnaires will be used to determine whether a participant is clinically depressed.
89409444|NCT02289872|Experimental|Scenario A|The control scenario, where neither chest compression nor cervical stabilization was applied during intubation.
89409445|NCT02289872|Experimental|Scenario B|The chest compression scenario, where continuous chest compression was applied using chest compression system LUCAS-2 (Physio-Control, Redmond, WA, USA). Chest compression was provided at a rate of 100 min-1 to a depth of 5-6 cm during all intubation procedures.
89409446|NCT02289872|Experimental|Scenario C|The chest compression with cervical stabilization scenario, where both chest compression using Lucas-2 and cervical stabilization were applied. A correctly fitting standard cervical immobilization collar (StifNeck Select, Laerdal, Stavanger, Norway) was applied to the manikin's neck to prevent movement of the cervical spine.
89409447|NCT03104998|Other|coenzyme Q10|Dose of 200 mg of CoQ10 taken daily by mouth from day 1 till 26 weeks
89409448|NCT04572984|Experimental|EBUS-TBNA-TBMCB|endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) was followed by endobronchial ultrasound-guided transbronchial mediastinal cryobiopsy (EBUS-TBMCB)
89409449|NCT04572984|No Intervention|EBUS-TBNA|endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) was performed
89409450|NCT04545138|Experimental|cognitive training during treadmill training group|Cognitive training combine treadmill training is an intervention that can challenge participants by practicing different tasks simultaneously.
89409451|NCT04545138|Active Comparator|treadmill training group|Treadmill training as an active control.
89409452|NCT04543032|Experimental|study group|the patients in this group will receive sensorimotor training for 6 weeks in addition to medical care.
89409453|NCT04543032|No Intervention|control group|the patients in this group will receive medical care only.
89409454|NCT03990766|Experimental|Theophylline saline irrigation|Theophylline 12 mg capsule contents dissolved into a sinus rinse bottle containing distilled or boiled tap water and USP Grade Sodium Chloride & Sodium Bicarbonate Mixture commercially prepared packets, delivered to the bilateral nasal cavities twice daily.
89409455|NCT03990766|Placebo Comparator|Placebo saline irrigation|Identical-appearing lactose monohydrate capsule contents dissolved into a sinus rinse bottle containing distilled or boiled tap water and USP Grade Sodium Chloride & Sodium Bicarbonate Mixture commercially prepared packets, delivered to the bilateral nasal cavities twice daily.
89409456|NCT02294162|Experimental|0.5 mg/kg body weight Ketamin|Patients allocated to this arm will receive an iv dose of 0.5 mg/kg body weight ketamine.
89409457|NCT02294162|Placebo Comparator|5 ml normal saline as placebo|Patients allocated to this arm will receive an iv dose of 5ml saline as placebo.
88885110|NCT01402310||Women attending antenatal clinic|Women attending antenatal clinic were consecutively enrolled at between 39+6 and 40+1 weeks of gestation.
88885111|NCT01402323|Other|early or late tooth extraction|
88885112|NCT01402336|Experimental|GnRH antagonist, SD #1 starting group|Start GnRH antagonist from stimulation day 1 during ovulation induction cycles
88885113|NCT01402336|Experimental|GnRH antagonist, SD #6 starting group|Start GnRH antagonist from stimulation day 6 during ovulation induction cycles
88885114|NCT01402336|Active Comparator|Conventional GnRH agonist long group|Conventional GnRH agonist long protocol
89409458|NCT05176158|Experimental|Morning dosage|Dexketoprofen pill at morning; Placebo at night
89409459|NCT05176158|Experimental|Night dosage|Placebo pill at morning; Dexketoprofen at night
89409460|NCT03522896|Placebo Comparator|control meal|glucose, fructose, sucrose, malic acid and citric acid in water
89409461|NCT03522896|Experimental|test meal 1|orange juice with added hesperidin (low dose)
89409462|NCT03522896|Experimental|test meal 2|orange juice with added hesperidin (high dose)
89409463|NCT03522896|Experimental|test meal 3|diluted orange juice with added hesperidin
89409464|NCT03104764|Active Comparator|Scalpel|Frenotomy performed with conventional scalpel
88885115|NCT01402362||Ethiopians participating in previous study, year 2000|
88885116|NCT01402388|Experimental|Lifestyle intervention group.|
88885117|NCT01402414|Active Comparator|NB-UVB|NB-UVB irradiations adapted to the NB-MED-UVB (70%) started and increased by 10-20% per session.
88885118|NCT01402414|Active Comparator|Bath-PUVA|Phototherapy with UVA irradiation following bathing in psoralen water
88885119|NCT01402414|Active Comparator|NB-UVB plus salt water baths|Balneophototherapy with NB-UVB and 3% Dead Sea salt water baths
88885120|NCT01402440|Experimental|AEB071|
88885121|NCT01402453|No Intervention|Control Subjects|Receive educational materials and a home BP monitor.
88885122|NCT01402453|Experimental|Intervention Subjects|Receive educational materials and a home BP monitor, as well as monetary incentives tied to amount of improvement in BP from baseline and a personalized intervention to internalize motivation for BP control. Monthly monetary incentives will cease after 6 months.
89409465|NCT03104764|Experimental|Er:YAG laser|Frenotomy performed with Er:YAG laser
89409466|NCT05575050|Active Comparator|Standard oral procedure|"Standard mouth cleaning protocol (without brushing) included:~Preparation of sterile catheter (12F lub 14F), suction of excess fluid from the oral cavity.~Using Sage Suction Swab (Toothette®), soaking in Perox-A-Mint Solution and cleaning with circular movements of each mucosal site for 10 seconds:~Right cheek mucosa and right upper quadrant~Left cheek mucosa and left upper quadrant~Left lower buccal quadrant~Right lower buccal quadrant~Moisturizing with Mouth Moisturizer /firma/ of oral cavity mucosa, tongue and lips.~Repeated suction of excess fluid from the oral cavity."
89409467|NCT05575050|Active Comparator|Extended oral procedure|"Extended mouth cleaning protocol (with brushing) included:~Preparation of sterile catheter (12F lub 14F), suction of excess fluid from the oral cavity.~Teeth brushing (each teeth quadrant for 30) using Sage Untreated Suction Toothbrush (SUST) connected to suction unit, moistured with sterile water.~Using Sage Untreated Suction Toothbrush (SUST) moisturised with sterile water and cleaning with circular movements of each mucosal site for 10 seconds:~Right cheek mucosa and right upper quadrant~Left cheek mucosa and left upper quadrant~Left lower buccal quadrant~Right lower buccal quadrant~Moisturizing with Mouth Moisturizer of oral cavity mucosa, tongue and lips.~Repeated suction of excess fluid from the oral cavity."
89409468|NCT04323163|Experimental|Yoga Group|Participants will be led through a beginner yoga course taught by a certified yoga instructor. Classes will meet three times a week for 60 minutes over the 6 month study duration. Sessions will focus on yoga postures, breathing, and meditative practices and may utilize mats, blocks, belts, and blankets.
89409469|NCT04323163|Experimental|Aerobic Group|Trained exercise instructors will lead participants through an aerobic group exercise class. Sessions will begin with a 15-20 minute aerobics class and increase in duration over the 6 months capping off at 40-minutes per session. The prescribed intensity will be 50-60% of the maximum heart rate reserve for weeks one to six and 60-75% for the remainder of the program.
89409470|NCT04323163|Active Comparator|Stretching Toning Group|Participants randomized to this group will meet three times a week for an hour-long structured group exercise session. This group will perform stretching and toning exercises using resistance bands, balance disks, and exercise mats.
89409471|NCT02294240|Experimental|Arm One|Energy dense biscuits will be provided throughout pregnancy after enrolment
89409472|NCT02294240|Placebo Comparator|Arm Two|Wheat Flour,oil, iron and folic acid will be provided fortnightly throughout pregnancy after enrolment
89409473|NCT04481724|Experimental|gamma-linolenic acid (GLA) supplementation|Sonova GLA safflower oil (840 mg GLA per day)
89409474|NCT04481724|Placebo Comparator|placebo control|1500 mg 'light' olive oil per day
89409475|NCT02298218|Experimental|Meloxicam|The intervention drug, meloxicam is safe medicine which is used to treat pain or inflammation caused by osteoarthritis or rheumatoid arthritis in adults and children who are at least 2 years old. It may also be used for purposes not listed in the medication guide. It will be taken once a daily with a dose of 0.125 mg/kg/day (high-dose group) or 0.06 mg/kg/day (low-dose group). After 6 months of medication, the maintenance will be decided by the comparison of liver stiffness score before and after the intervention.
89409476|NCT02298218|No Intervention|No intervention|During 6 months, without meloxicam, the maintenance will be decided by the comparison of liver stiffness score comparing the intervention group.
89409477|NCT03547830|Experimental|Plerixafor/G-CSF|Plerixafor/G-CSF for HSCT conditioning Myeloablative conditioning regimen with Plerixafor as addition agent before stem cell transplantation in CGD patients
89409478|NCT02920216|Experimental|eligible patient for a salvage surgery|
89409479|NCT03132662|Active Comparator|Very Low Calorie Diet|The first group will continue according to the standard bariatric preoperative protocol and will be assigned a VLCLD of 900 cal/day (Optifast ® 4 servings/day each containing: 225 cal + 0.35 g linolenic acid) for 2-3 weeks prior to surgery according to the surgeon's preferences.
89409480|NCT03132662|Experimental|Omega-3|The second group will be assigned to 3 gr. daily oral intake of Ω-3 PUFAs ((Oceano3 ® 1000 mg Krill Oil tabs (150 mg EPA + 90 mg DHA) 3 times a day) for 4 weeks with only regular dietary suggestions before surgery.
89409481|NCT03132662|No Intervention|No-treatment|The third group will not receive treatment for liver size reduction prior to surgery.
89409482|NCT05431933|Experimental|Safety group|Three doses of Eupolio will be administered at 6, 10 and 14 weeks of age. Only safety will be evaluated for this arm.
88885123|NCT01402466|Active Comparator|Standard Referral|Participants randomized to this arm will be referred to local HIV care resources
88885124|NCT01402466|Experimental|Project Bridge|Participants randomized to this arm will be given the Project Bridge intervention
88885125|NCT01402479|Active Comparator|ramipril|open label single arm trial
88885126|NCT01402505||Transvaginal NOTES sleeve gastrectomy|Transvaginal NOTES sleeve gastrectomy
88885127|NCT01402518||Per-oral endoscopic myotomy|
88885128|NCT01402557|Active Comparator|Telephone Support Only|These participants receive telephone support only during the weight maintenance phase.
88885129|NCT01402557|Experimental|Telehealth|These participants receive telehealth support (with Internet-enabled digital video recorders) during the weight maintenance phase. These participants also receive telephone support monthly.
88885130|NCT01402583||PEG IFN/Ribavirin|Subjects with Hepatitis C undergoing PEG IFN/Ribavirin treatment
88885131|NCT01402596|Active Comparator|Chloral hydrate|Children undergoing CT scanning will receive in this arm 50 mg per kg of rectal chloral hydrate.
88885132|NCT01402596|Active Comparator|Midazolam|Children undergoing CT scanning will receive in this arm 0,4 mg/kg of nasal midazolam.
88885133|NCT01402609|Placebo Comparator|Control group, usual care|Control group will receive usual care. This usual care typically involves paper-based handwritten discharge communications, with subsequent provision of a dictated discharge summary produced some time after hospital discharge, with unpredictable success of delivery, and with unstructured and sometimes haphazard content.
88885134|NCT01402609|Experimental|electronic discharge communication tool|Patients allocated to the experimental arm will receive a copy of the discharge summary that is generated by the electronic discharge communication tool. The same copy is shared with their healthcare providers using an electronic, web-based, communication platform that allows communication between acute-care and community -care physicians. The electronic discharge communication tool allows physicians to start generating the discharge summary from time of admission to hospital.
88885135|NCT01402622|Active Comparator|Control group|balanced anaesthesia with antiemetic prophylaxis
89409483|NCT05431933|Experimental|Immunogenicity group 1 (4 Eupolio including 1 boosting dose)|Three doses of Eupolio will be administered at 6, 10 and 14 weeks of age, and additional single dose of Eupolio will be administered one year after the three primary vaccinations.
89409484|NCT05431933|Experimental|Immunogenicity group 2 (3bOPV+2 Eupolio)|bOPV will be administered at 6, 10 and 14 weeks of age, and Eupolio will be administered at 14 and 40 weeks of age.
89409485|NCT03132818||Patients undergoing AMP with oocyte donation|
89409486|NCT03132818||Couples supported in AMP with sperm donation|
88885136|NCT01402622|Active Comparator|TIVA group|TIVA without antiemetic prophylaxis
88885137|NCT01402622|Active Comparator|TIVA-P group|TIVA with antiemetic prophylaxis
88885138|NCT01402635|Experimental|POCT lab|The patient group whose laboratory test perform by POCT chemistry analyzer.
88885139|NCT01402635|Active Comparator|central laboratory group(CLT)|The patients group whose laboratory test perform by central laboratory.
88885140|NCT01402648|Placebo Comparator|Dietary supplement|900 mg Maltodextrins
88885141|NCT01402648|Active Comparator|Eviendep (CM&D Pharma Limited, UK)|175 mg milk thistle (fruit dry extract, 70% in silymarin)+ 20 mg flaxseed (dry extract, 40% in secoisolariciresinoldiglucoside) + 750 mg non starch, insoluble and indigestible fiber (6% in lignin).
88885142|NCT01402674|Active Comparator|LPT|Subjects treated with phentermine for 2 years or more.
88885143|NCT01402674|No Intervention|APT|Patients treated with phentermine for 7 to 14 days.
88885144|NCT01402687||Mucositis Positive|Participants who developed severe mucositis
88885145|NCT01402687||Mucositis Negative|Participants who did not develop severe mucositis
88885146|NCT01402713|Experimental|GC1107-T5.0|Dosage: 0.5ml
88885147|NCT01402713|Experimental|GC1107-T7.5|Dosage: 0.5ml
88885148|NCT01402713|Active Comparator|TD_PUR INJ /SK Td vaccine|The name: step 1(phase 2)-SK Td vaccine step 2(phase 3)-TD_PUR INJ Dosage: 0.5ml
88885149|NCT01402726|Experimental|renal sympathetic modification|Renal artery ablation to modify sympathetic activity in patients with heart failure.
88885150|NCT01402726|No Intervention|Absolute medicine therapy|Maintenance of anti-heart failure medications only
88885151|NCT01402739|Experimental|PoC algorithm guided transfusions|experimental arm
88885152|NCT01402739|Active Comparator|standard of care transfusions|control arm
89191775|NCT00578292|Experimental|Bone Marrow or Stem Cell Infusion|"Mesna, Cyclophosphamide, Busulfan, Fludarabine, Campath 1H~Bone Marrow or Stem Cell infusion with pre-meds to take place on Day 0.~Bone marrow dose/stem cell dose: To ensure the probability for bone marrow engraftment, 4 x 10e8 nucleated cells/kg patient weight or 5 x 10e6/kg of CD34+ cells/kg patient weight if the product is mobilized peripheral blood, will be the target to be obtained from the unrelated donor."
88885153|NCT01402752|Experimental|All patients|All patients included in this study according to stated inclusion and exclusion criteria.
88885154|NCT01402765|Active Comparator|Group 1 (Summit first)|In Group 1 pressure measurements are first taken on the Summit mattress. The patient is then transferred to a Nimbus 3 mattress, and the measures are repeated.
88885155|NCT01402765|Active Comparator|Group 2 (Nimbus 3 first)|In Group 2 pressure measurements are first taken on the Nimbus 3 mattress. The patient is then transferred to a Summit mattress, and the measures are repeated.
88885156|NCT01402778||Cather fixation by tunneling and suture|
88885157|NCT01402778||Catheter fixation by adhesive tape|
88885158|NCT01402791||The study population|All patients included according to state inclusion and exclusion criteria.
88885159|NCT01402804||Stable CAD, ASA, NSAID|
88885160|NCT01402804||Stable CAD, ASA|
88885161|NCT01402830||001|Visual analogue scales (EVAs) This scale measures the pain intensity.
88885162|NCT01402843|Experimental|pitavastatin + valsartan|
88885163|NCT01402843|Placebo Comparator|pitavastatin + placebo|
88885164|NCT01402843|Placebo Comparator|valsartan + placebo|
88885165|NCT01402843|Placebo Comparator|placebo|
88885166|NCT01402856||Southern Lehigh HS, PA School District|This school will not receive the education, yet, will be surveyed, quizzed and observed at the same time.
88885167|NCT01402856||Bethlehem HS, PA Area School District|Freedom & Liberty HS's in Bethlehem, PA will serve as the study's control group.
88885168|NCT01402856||Phillipsburg HS, NJ Area School District|This school will not receive the education, yet, will be surveyed, quizzed and observed at the same time.
88885169|NCT01402882|Experimental|Tranexamic acid|
88885170|NCT01402882|Placebo Comparator|Placebo|(Sodium Chloride 0.9%)
88885171|NCT01402895|Active Comparator|Mobilizations|The physiotherapist will perform mobilizations to the L-spine and SI joints with the participant in a specific position.
88885172|NCT01402895|Active Comparator|Exercise|The physiotherapist will teach the participant how to tighten the transversus abdominus muscle. The participant will be asked to do a series of these exercises.
88885173|NCT01402921|Experimental|Elastic Medical Compressive Therapy|"V0322BC verum medical compressive therapy is a progressive compressive sock with:~ankle pressure: 10 mmHg~calf pressure : 23 mmHg"
88885174|NCT01402921|Placebo Comparator|Placebo|"V0322BC placebo medical compressive therapy is a progressive compressive sock with:~ankle pressure: <5 mmHg~calf pressure : <7 mmHg"
88885175|NCT01402934|Experimental|fluid infusion|
88885176|NCT01402960|Experimental|Active Anodal HD-tDCS|Subject will receive one 20-minute session of active anodal HD-tDCS.
88885177|NCT01402960|Experimental|Active Cathodal HD-tDCS|Subject will receive one 20-minute session of active cathodal HD-tDCS.
88885178|NCT01402960|Sham Comparator|Sham HD-tDCS|Subject will receive one sham session of HD-tDCS
88885179|NCT01402973|Experimental|High-AGE Diet|The high-AGE diet will be approximately four times higher in AGEs than the low-AGE diet.
88885180|NCT01402973|Experimental|Low-AGE Diet|The low-AGE diet will be approximately four times lower in AGEs than the high-AGE diet.
88885181|NCT01401244|Experimental|Norditropin®|
88885182|NCT01401244|Active Comparator|Genotropin®|
88885183|NCT01403025||Liraglutide|
88885184|NCT01403038|Experimental|Elagolix Dose Regimen 1|Elagolix Dose regimen 1 for 84 days
88885185|NCT01403038|Experimental|Elagolix Dose Regimen 2|Elagolix Dose Regimen 2 for 84 days
88885186|NCT01403038|Experimental|Elagolix Dose Regimen 3|Elagolix Dose Regimen 3 for 84 days
88885187|NCT01403038|Experimental|Elagolix Dose Regimen 4|"Elagolix Dose Regimen 4 for 84 days~Additional Dose Regimens may be added and will be administered for 84 days."
89191776|NCT00861874|Experimental|Treatment|
89191777|NCT03765242||Patient initiating warfarin|
89191778|NCT03765242||Patient initiating apixaban|
89191779|NCT05372874||Healthy voluntaries control group (Group 1)|
89191780|NCT05372874||sofosbuvir/daclatasvir treated group (group 2)|
89191781|NCT05372874||sofosbuvir /daclatasvir/ ribavirin treated group (group 3)|
89409487|NCT03132818||Couples supported in AMP intra torque|
89409488|NCT05692765|No Intervention|Control group|Adolescents in the control group were not exposed to the smartphone application and did not receive any advice to promote their F&V consumption, which may have affected their F&V consumption. Instead, they were only asked to complete the pre- and post-questionnaires.
89409489|NCT05692765|Experimental|Intervention group|Adolescents in the intervention group were divided into 11 smaller groups, each containing five participants to explain the application. The researcher provided a brief presentation about the health benefits and appropriate serving sizes of F&Vs and explained how to use the smartphone application. An instructional brochure was provided in Arabic to all adolescents in the intervention group. The research team was available to assist participants at any time during the study period. After choosing six goals (three for fruit and three for vegetables), the participants were required to mark the goal that they chose daily and were requested to adhere to their chosen goals until the end of the study. The intervention period was 6 weeks.
89409490|NCT02885896||Experimental period (active platform)|During the experimental period, the eligible calls will be transferred to the platform by SAMU regulator doctors, and callers will be subject to health advice by specially trained nurses. The nurse conduct the call by holding the conversation guide, giving advice for a home care, answering questions from the circle (caller, family,..) and ensuring the proper understanding of these tips. An information leaflet for the theme of the call will be sent in the days following the call to the caller of the experimental group having given their consent.
89409491|NCT02885896||Control period (inactive platform)|During the control periods, the call center will not be active, eligible calls can not receive advice from nurses, but will be subject to the usual care: the regulator doctor will treat the call as its current practice.
89409492|NCT03547752|Active Comparator|Effective movement group|Observation of a video of neck movement at 100% range of movement, and imagination of the same observed movement, feeling the realization of the movement but not developing it.
88885188|NCT01403038|Experimental|Elagolix Dose Regimen 5|Elagolix Dose Regimen 5 for 84 days
89409493|NCT03547752|Experimental|Ineffective movement group|Observation of a video of neck movement at 40% range of movement, and imagination of the same observed movement, feeling the realization of the movement but not developing it.
89409494|NCT04390945|Experimental|Camrelizumab Combined With Concurrent Radiotherapy and Chemotherapy|Camrelizumab (200mg Q2W, continuous medication until disease progression, intolerable toxicity, or withdrawal due to other reasons) Simultaneous radiotherapy (50-50.4Gy / 1.8-2Gy / 25-28F) Chemotherapy (Capecitabine, 625mg/m2, bid, oral, d1-5, qw, total 5 weeks).
89409495|NCT02291588|Experimental|AMG 811|AMG 811 administered as subcutaneous and intravenous doses
89409496|NCT02291588|Placebo Comparator|Placebo|No active drug
89409497|NCT03521258|Experimental|Human Amnion/Chorion Membrane + skin graft|Dehydrated Human Amnion/Chorion Membrane (dHACM) will be placed on wound at the initial debridement to promote granulation tissue at the wound bed. Approximately 5-7 days following debridement, wound will be assessed for suitability of split thickness skin grafting. If an adequate granulation tissue is present, skin grafting will be performed and assessed for take in 5 days.
89409498|NCT03521258|Active Comparator|Flap Reconstruction (Standard of Care)|A negative pressure wound dressing (NPWD) will be applied at the time of debridement until the wound is clean and adequate for flap reconstruction. Flap-based reconstruction is performed. Following flap reconstruction,patient will have 5 days of bed rest to allow proper healing and coverage of the wounds. If flaps are successful, patients starts a limb dangle protocol which gradually increases the dependent position and allows the flap to acclimate to new physiologic demands. Following dangle protocol patient will require inpatient physical and occupational therapy prior to discharge.
88885189|NCT01403038|Experimental|Elagolix Dose Regimen 6|Elagolix Dose Regimen 6 for 84 days
89409499|NCT03102814|Active Comparator|Current rehabilitation program|The control group will receive the rehabilitation program currently provided at each participating centre at the start of the study.
89409500|NCT03102814|Experimental|BRIDGE rehabilitation program|In intervention phase, the BRIDGE program will be added to the current program.
89409501|NCT04465890|Experimental|cohort1: Single dose ASC22 injection 0.3mg/kg|Single dose ASC22 Injection; Specification: 200mg/1ml/1bottle; Subcutaneous injection; once administration,0.3mg/kg dose of the drug once.
88885190|NCT01403038|Experimental|Elagolix Dose Regimen 7|Elagolix Dose Regimen 7 for 84 days
89191782|NCT02544646|Other|trabeculectomy|
89409502|NCT04465890|Experimental|cohort2:Single dose ASC22 injection 1.0mg/kg|Single dose ASC22 Injection; Specification: 200mg/1ml/1bottle; Subcutaneous injection; once administration,1.0mg/kg dose of the drug once.
89409503|NCT04465890|Experimental|cohort3:Single dose ASC22 injection 2.5mg/kg|Single dose ASC22 Injection; Specification: 200mg/1ml/1bottle; Subcutaneous injection; once administration,2.5mg/kg dose of the drug once.
89409504|NCT04465890|Experimental|cohort4: Multiple dose ASC22 injection 1.0mg/kg|Multiple dose ASC22 injection; Specification: 200mg/1ml/1bottle; Subcutaneously administered once every 2 weeks , 4 received 1.0mg/kg, up to 24 weeks
88885191|NCT01403077|Experimental|Scaffold Treatment|
88885192|NCT01403103|Experimental|Treatment (chemoprevention)|Patients receive cholecalciferol orally (PO) 7 days prior to scheduled surgery or endorectal ultrasound. Patients with sigmoid colon cancer or clinical stage I rectal cancer would proceed with surgical resection without preceding chemoradiation and will have a portion of normal colorectal mucosa and tumor tissue obtained for research purposes.
88885193|NCT01403129||Keratoconus-Suspect|A person who has or is suspected of having keratoconus. Will have either or both Artemis-2 exam and OCT exam.
88885194|NCT01403129||Keratoconus-Related|A person who is genetically related to someone with keratoconus. Will have either or both Artemis-2 exam and OCT exam.
88885195|NCT01403129||Age-Matched Normal|"A person who is approximately the same age as subjects who have been enrolled in the study.~Will have either or both Artemis-2 exam and OCT exam."
88885196|NCT01403155|Experimental|All subjects|All subjects will receive 0.9mg/mL of study vaccine (INO-3401 DNA plasmid vaccine) at Day o and Month 3.
89191783|NCT00725192|Active Comparator|1|Cognitive Processing Therapy
89191784|NCT00725192|Experimental|2|Hypnosis plus Cognitive Processing Therapy.
89409505|NCT04465890|Experimental|cohort5: Multiple dose ASC22 injection 2.5mg/kg|Multiple dose ASC22 injection; Specification: 200mg/1ml/1bottle; Subcutaneously administered once every 2 weeks , 4 received 2.5mg/kg, up to 24 weeks
89409506|NCT04465890|Placebo Comparator|cohort4: Placebo sodium chloride injection A|Placebo saline injection; Specification: 90mg/10ml/1 bottle; Subcutaneously administered every 2 weeks (Q2W, known as one drug administration cycle), duration: once every 2 weeks (Q2W), up to 12 weeks. Based on the weight of the patients, an equal dose of placebo was administered according to the incoming dose group (1.0mg/kg).
89409507|NCT04465890|Placebo Comparator|cohort5: Placebo sodium chloride injection B|Placebo saline injection; Specification: 90mg/10ml/1 bottle; Subcutaneously administered every 2 weeks (Q2W, known as one drug administration cycle), duration: once every 2 weeks (Q2W), up to 12 weeks. Based on the weight of the patients, an equal dose of placebo was administered according to the incoming dose group (2.5mg/kg).
89409508|NCT04465890|Experimental|cohort6: Multiple dose ASC22 injection 1.0mg/kg|Multiple dose ASC22 injection; Specification: 200mg/1ml/1bottle; Subcutaneously administered once every 2 weeks , 4 received 1.0mg/kg, up to 24 weeks
89409509|NCT04465890|Placebo Comparator|cohort6: Placebo sodium chloride injection A|Placebo saline injection; Specification: 90mg/10ml/1 bottle; Subcutaneously administered every 2 weeks (Q2W, known as one drug administration cycle), duration: once every 2 weeks (Q2W), up to 12 weeks. Based on the weight of the patients, an equal dose of placebo was administered according to the incoming dose group (1.0mg/kg).
89409510|NCT03521180||Subjects with Celiac Disease|"Group 1 will start the gluten challenge with 4 slices of white bread once daily for 3 days. Blood will be taken at pre-specified time points for up to 9 days following the start of gluten challenge for biomarker analyses.~Based on data from the first 5 subjects, the 2nd group of 5 subjects may: 1) not be needed if the objectives are met; 2) receive gluten at increased quantity (not to exceed 6 slices of bread once daily for 3 days) or have biomarker samples collected at adjusted time points; 3) same as the first 5 subjects; 4) reducing the duration of gluten free diet for a minimum of 3 months instead of 6 month for the Inclusion Criteria # 5;5) subjects may be re-enrolled once.~The same applies to the 3rd group of subjects. A notification will be provided to the clinical study site for detailed changes."
89409511|NCT03625843|Experimental|Mindfullness exercises|Participate in mindfulness exercises prior to urodynamic studies (UDS). As a participant, you will be guided through a mindfulness meditation exercise by a licensed professional. During this exercise you will be asked to focus your attention on your breathing, physical sensations, and thoughts. This exercise will last for approximately 10 minutes.
89409512|NCT03625843|No Intervention|Control|Sitting quietly in a room alone.
89409513|NCT03102502|Experimental|Enhanced External Counterpulsation|Patients receive a total of 35-36 hours of EECP treatment on top of guideline- driven standard medical therapy for coronary heart disease, 1-hour sessions every day over a 7-week period.
89409514|NCT03102502|Active Comparator|Control|Patients receive guideline- driven standard medical therapy for 7 weeks without Enhanced External Counterpulsation intervention.
88885197|NCT01403168|Experimental|osteopathy + conventional analgesic treatments|
88885198|NCT01403168|Placebo Comparator|conventional analgesic treatments|
88885199|NCT01403181||Chronic hepatitis C|"10 naïve genotype 1 chronic hepatitis C patients treated with PEG plus RBV (control arm)~20 naïve genotype 1 chronic hepatitis C patients treated with a response guided therapy consisting of Boceprevir in combination with PEG plus RBV (experimental arm)"
88885200|NCT01403207||knee osteoarthritis|Many musculoskeletal conditions are impacted by the chromosomal sex of the patient. While osteoarthritis (OA) is predominant in men younger than 50 years of age, after age 50 the condition is more prevalent in women, particularly post-menopause. This has implications for diagnosis and treatment of OA, as well as for joint replacement.
88885201|NCT01403220|Active Comparator|Group 1 (hemodiafiltration first)|This group of patients will alternate consecutive dialysis sequences between hemodiafiltration and hemofiltration, but starting with hemodiafiltration.
88885202|NCT01403220|Active Comparator|Group 2 (hemofiltration first)|This group of patients will alternate consecutive dialysis sequences between hemodiafiltration and hemofiltration, but starting with hemofiltration.
88885203|NCT01403233|Experimental|cogniVida™ 50 mg/day|
88885204|NCT01403233|Experimental|cogniVida™ 100 mg/day|
88885205|NCT01403233|Active Comparator|Rebaudioside-A 303.7 mg/day|
89191785|NCT04067856|Active Comparator|Bevacizumab|Intravitreal injection of 1.25mg/0.05cc bevacizumab
89409515|NCT02291666|Experimental|T2D patients with A1C ≤7.0|CRCHUM-MT cocktail; a single oral dose of the CRCHUM-MT cocktail will be administered; 100mg caffeine, 75mg bupropion, 150mg tolbutamide, 20mg omeprazole, 30mg dextromethorphan, 2mg midazolam and at night, one oral 250mg dose of chlorzoxazone will be taken separately.
89536691|NCT04378907|Experimental|Cigarette Smokers: 4 mg/ml nicotine concentration|"ECIG Lab Session, 30 watts, 6 mg/ml nicotine concentration~During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout."
88885206|NCT01403259|Experimental|S-1 plus oxaliplatin|S-1 60 mg BID at day 1-14 Oxaliplatin 100 mg/m2 at day 1 Frequence of cycles: every 3 weeks for 6 cycles
88885207|NCT01403272|Experimental|DermaTherapy® Linen group|The DermaTherapy® Linen group uses bed sheets and underpads made with DermaTherapy® fabric.
88885208|NCT01403298|Active Comparator|Adolescent Only Health Promotion|An individual adolescent-only health education program that focuses on risk behaviors related to HIV/AIDS, smoking, diet and exercise
88885209|NCT01403298|Experimental|Family-Based HIV prevention|This individual, family-based intervention provides sex and HIV/AIDS education as part of a family-based general health education program that focuses on safe decision-making and how to control emotions to stay safe and improve parenting skills.
88885210|NCT01403311|Experimental|ALA|5-Aminolevuline Acid (ALA)
88885211|NCT01403324|Other|TSH stimulation|rh TSH stimulation followed by thyroid hormon withdrawal
88885212|NCT01403337|Placebo Comparator|Control|Blood pressure cuff inflated in the right or left arm to 40-50 mmHg
89191786|NCT04067856|Active Comparator|Dexamethasone implant|Intravitreal injection of 0.7mg dexamethasone implant
89191787|NCT00570063|Placebo Comparator|1|PF-02545920 15 mg tablets taken twice a day by mouth for 21 days
89191788|NCT00570063|Placebo Comparator|2|Matching placebo tablets taken twice a day by mouth for 21 days
89191789|NCT05372796|Experimental|Control Group|participants were given home exercise (once a day for 5 weeks)
89409516|NCT02291666|Experimental|T2D patients with A1C>7.0|CRCHUM-MT cocktail; a single oral dose of the CRCHUM-MT cocktail will be administered; 100mg caffeine, 75mg bupropion, 150mg tolbutamide, 20mg omeprazole, 30mg dextromethorphan, 2mg midazolam and at night, one oral 250mg dose of chlorzoxazone will be taken separately.
89409517|NCT02291666|Active Comparator|Non T2D subjects|CRCHUM-MT cocktail; a single oral dose of the CRCHUM-MT cocktail will be administered; 100mg caffeine, 75mg bupropion, 150mg tolbutamide, 20mg omeprazole, 30mg dextromethorphan, 2mg midazolam and at night, one oral 250mg dose of chlorzoxazone will be taken separately.
89409518|NCT03102658|Experimental|Obese subjects 100mg|8 subjects with a BMI>40kg/m2 will receive 100mg Micafungin
89409519|NCT03102658|Active Comparator|Obese subjects 200mg|8 subjects with a BMI>40kg/m2 will receive 200mg Micafungin
89409520|NCT03102658|Active Comparator|non-obese subjects|8 non obese subjects with a BMI >18.5 and <25 kg/m2 will receive 100mg Micafungin
89409521|NCT03546036|Experimental|Weighted metal chain blanket|As experimental intervention, a weighted metal chain blanket of 8 kg was used during the night. Using a flexible dose protocol, participants who found the 8 kg blanket too heavy were allowed to change to a 6 kg weighted blanket (see below)
89409522|NCT03546036|Sham Comparator|Control plastic chain blanket|As sham comparator, light chain blankets were used, were plastic chains of the same shape and size as the metal chains in the weighted blanket were sewn in. The control blanket has a weight of 1535 grams. When checking the weight of standard blankets for sale in one of the largest stores in Stockholm, weight was ranging from 550 to 2389 grams (average 1332).
89409523|NCT02291744|Experimental|XELOX plus surgery|Eight cycles of XELOX chemotherapy plus surgery:Oxaliplatin 130mg/m2 ivgtt d1 and capecitabine 1000mg/m2,bid,po,d1-d14,every three weeks for a cycle. After 4 cycles, the patients are randomized to surgery group. Then the rest four cycles are administrated.
89409524|NCT02291744|Active Comparator|XELOX|Eight cycles of XELOX chemotherapy: Oxaliplatin 130mg/m2 ivgtt d1 and capecitabine 1000mg/m2,bid,po,d1-d14,every three weeks for a cycle
89409525|NCT02646748|Experimental|pembrolizumab + itacitinib|"Part 1a Group A will utilize an open-label 3+3 dose-escalation design based on observing each dose level for a period of 21 days.~Part 1b Group A-1 and Group A-2 will evaluate the MTD or PAD of itacitinib in combination with pembrolizumab in subjects with select solid tumors."
89409526|NCT02646748|Experimental|pembrolizumab + INCB050465|"Part 1a Group B will utilize an open-label 3+3 dose-escalation design based on observing each dose level for a period of 21 days.~Part 1b Group B-1 and Group B-2 will evaluate the MTD or PAD of INCB050465 in combination with pembrolizumab in subjects with select solid tumors.~Part 2 will evaluate the combination of INCB050465 in combination with pembrolizumab in subjects with small cell lung cancer, non-small lung cancer and urothelial cancer."
88885213|NCT01403337|Active Comparator|Preconditioning|The RIPC protocol will consist of three cycles of the following: 5-minute inflation of a blood pressure cuff around the right upper arm to 200 mmHg (or 20 above the systolic blood pressure if baseline BP > 200 mmHg) to allow for external compression of the brachial artery resulting in transient arm ischemia, followed by a 5-minute interval of cuff deflation to allow for reperfusion. The total duration of the protocol is 30 minutes equally divided between ischemia and reperfusion. The protocol is to be applied in the patient room the morning of the operation.
88885214|NCT01403363|Experimental|fentanyl patch|
88885215|NCT01403389|Experimental|Eculizumab|
89409527|NCT03547674|Active Comparator|barefoot|Gait analysis under 4 conditions (barefoot, shoes only, untuned AFO with shoes, tuned AFO with shoes) will be performed in a random order.
89409528|NCT03547674|Active Comparator|shoes only|Gait analysis under 4 conditions (barefoot, shoes only, untuned AFO with shoes, tuned AFO with shoes) will be performed in a random order.
88885216|NCT01403389|Placebo Comparator|0.9% Sodium Chloride|
89409529|NCT03547674|Active Comparator|untuned AFO with shoes|Gait analysis under 4 conditions (barefoot, shoes only, untuned AFO with shoes, tuned AFO with shoes) will be performed in a random order.
89409530|NCT03547674|Experimental|tuned AFO with shoes|Gait analysis under 4 conditions (barefoot, shoes only, untuned AFO with shoes, tuned AFO with shoes) will be performed in a random order.
89409531|NCT02298296||No treatment|
89409532|NCT03624985|Experimental|Intravenous Lidocaine Infusion|Patients will be randomly assigned to receive 1 mg/kg lidocaine bolus and intraoperative infusion of 2 mg/min.
89409533|NCT03624985|Placebo Comparator|Placebo Infusion|Patients will be randomly assigned to receive a 1mg/kg bolus of water with 5% dextrose and an intraoperative infusion of 2mg/min. of water with 5% dextrose.
88885217|NCT01403402||Congenital Muscle Disease|The congenital muscle diseases include congenital muscular dystrophy, congenital myopathy, congenital myasthenic syndrome and bridge into the limb girdle/late onset spectrum. For data collection and analysis, subtype specific reports will be generated. True incidence of the congenital muscle diseases is unknown.
88885218|NCT01403415|Experimental|Treatment (temsirolimus, combination chemotherapy)|Patients receive dexamethasone PO or IV on days 1-5 and 15-19; mitoxantrone hydrochloride IV over 30 minutes on days 1-2; temsirolimus IV over 30 minutes on days 1 and 8; vincristine sulfate IV on days 1, 8, 15, and 22; and pegaspargase IV over 1 hour on days 3 and 17. Some patients may also receive methotrexate IT up to 72 hours prior to or on day 1 and on day 8.
89191790|NCT05372796|Experimental|IASTM (instrument-assisted soft tissue mobilization)|IASTM was applied to the patients (M. Sternocleidomastoideus, M. Trapezius, M. Paraspinales and M. Levator Scapula) in the IASTM group twice a week for 5 weeks.
89409534|NCT03521024|Active Comparator|lithium disilicate crowns|lithium disilicate crowns are well documented in the literatures as successful restoration modality.
89409535|NCT03521024|Experimental|poly ether ketone ketone crowns|pekkton
89409536|NCT05178108|Other|healthy individuals|
89409537|NCT05431465|Experimental|Vita Ambria onlay|The onlays will be constructed from Zirconia reinforced Lithium disilicate (Vita Ambria) glass ceramic system.
89409538|NCT05431465|Active Comparator|IPS emax onlay|The onlays will be constructed from Lithium disilicate (IPS e-max press) glass ceramic system
88885219|NCT01403428|Experimental|NPPV plus standard of care|Noninvasive positive pressure ventilation (NPPV) plus standard of care in the management of children admitted to the hospital with status asthmaticus
88885220|NCT01403428|No Intervention|Standard of care|standard of care treatment in the management of children admitted to the hospital with status asthmaticus
88885221|NCT01403454|No Intervention|usual care|
88885222|NCT01403454|Active Comparator|Health Communication Application|
88885223|NCT01403467|Experimental|NIPPV|
88885224|NCT01403493|Active Comparator|Multidisciplinary patient education|A multidisciplinary (nurse, gastroenterologist, dietician, physiotherapist, psychologist) group education with six sessions for patients with IBS.
88885225|NCT01403493|Active Comparator|Nurse based patient education|A nurse based patient education with three sessions for patients with IBS.
88885226|NCT01403506|Active Comparator|N-Acetyl Cysteine|N-Acetyl Cysteine: receive N-Acetyl Cysteine in addition to standard treatment
88885227|NCT01403506|No Intervention|standard treatment|This group is without N-Acetyl Cysteine : just receives standard treatment
88885228|NCT01403519||Alzheimer's disease patients|Patients blood and CSF samples
88885229|NCT01403519||Control group|Blood and CSF samples
88885230|NCT01403519||FTD patients|Blood ad CSF samples
88885231|NCT01403532|Active Comparator|Traditional|
88885232|NCT01403532|Experimental|Sequential|
88885233|NCT01403532|Experimental|Sequential Plus|
88885234|NCT01403545|Experimental|Liposomal Curcumin|Single dose, dose escalation
88885235|NCT01403545|Placebo Comparator|5% Glucose|
88885236|NCT01403558|Experimental|Cognitive behavioral therapy|Ten weekly individual cognitive behavioral therapy sessions before bariatric surgery
88885237|NCT01403558|No Intervention|Control group|Usual preoperative care consisting of up to three voluntary sessions with nutritionist and physiotherapist before bariatric surgery
88885238|NCT01403571|Experimental|Salba supplement|30g/1000kal
88885239|NCT01403571|Placebo Comparator|Oat-bran based Control Supplement|36g/1000kcal
88885240|NCT01403597|Experimental|Treatment|The defined areas for treatment are the entire face or at least two facial sub areas (e.g., peri-orbital and peri oral) with the combination of two devices where a total of 5 treatments every 4 weeks will be administered
88885241|NCT01403623|Active Comparator|Resuscitation with plastic bag|Plastic bag will be used during and after resuscitation to assist with temperature regulation.
88885242|NCT01403623|Sham Comparator|Standard resuscitation- no plastic bag|Infant will be resuscitated per standard of care without being placed in a plastic bag for temperature regulation.
88885243|NCT01403649|Experimental|Increasing flu vaccination|Collect from billing records in the 10 intervention practice sites to test for an increase in the rate of receipt of ≥1 influenza vaccine during the post-intervention year compared to the pre-intervention year among children 6 months to 18 years during the season. The interventions include: 1. Develop practice-based intervention strategies (like use of reminder-recall of children due for influenza,2. Develop Private/public collaboration to increase flu vaccination between the intervention practices, their county public health department and visiting nursing associations, and 3. Implement both practice-based and private-public collaborative strategies in the intervention practices while monitoring only in the control practices
89536692|NCT04378907|Experimental|Cigarette Smokers: 15 mg/ml nicotine concentration|"ECIG Lab Session, 30 watts, 15 mg/ml nicotine concentration~During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout."
88885244|NCT01403649|Other|Usual care|Patients in control practices will continue to receive usual care with no change in practice regarding influenza immunization delivery.
88885245|NCT01403662|Experimental|Minocycline|
88885246|NCT01403675|Experimental|Ovarian autotransplantation|
88885247|NCT01403688||Random Fine Needle Aspiration (RPFNA)|RPFNA
88885248|NCT01403701|Experimental|Physical therapy|Standardized pelvic floor physical therapy
88885249|NCT01403701|No Intervention|routine care|Standard postoperative visits
88885250|NCT01403714|No Intervention|Medical Management|Patients may be randomized to medical management alone
88885251|NCT01403714|Active Comparator|Renal Artery Stenting|Those patients with recent heart failure exacerbations that cannot be attributed to poor left ventricular function and have a hemodynamically significant renal artery stenosis may be randomized to renal artery stenting
88885252|NCT01403727||Unassisted Biopsy - CONTROL GROUP|Routine biopsy needle placement and Physician blinded to needle location
88885253|NCT01403727||Assisted Biopsy - STUDY GROUP|The physician will be shown the PercuNav screen and will correct the desired approach path.
88885254|NCT01403740||Acquired haemophilia patients|
88885255|NCT01403753||Non-clinical sample of children|
88885256|NCT01403766||Pediatric post-kidney transplant|Patients having standard of care surviellance biopsies.
88885257|NCT01403779|Active Comparator|1-Hypofractionated IMRT|hypofractionated IMRT for right sided breast cancer
88885258|NCT01403779|Active Comparator|2-Normofractioated IMRT|normofractionated IMRT for left sided breast cancer
88885259|NCT01403792|Experimental|Up to 7mg P2G12|
88885260|NCT01403792|Experimental|Up to 14mg P2G12|
88885261|NCT01403792|Experimental|Up to 28mg P2G12|
88885262|NCT01403792|Placebo Comparator|Placebo (saline solution)|
88885263|NCT01403818|Experimental|Part 1|"Subjects will receive ASP1941 alone and ASP1941 + Mitiglinide calcium hydrate in different orders."
88885264|NCT01403818|Experimental|Part 2|"Subjects will receive Mitiglinide calcium hydrate alone and ASP1941 + Mitiglinide calcium hydrate in different orders."
88885265|NCT01403831|Experimental|Text messages|Patients randomized to this arm will receive daily text messages to their mobile phones consisting of educational materials, motivational materials, trivia questions, and challenges to engage in healthy lifestyle choices
88885266|NCT01403831|No Intervention|Control|
88885267|NCT01403844|Other|Skin Carotenoids|Skin carotenoids will be measured under conditions of depletion or repletion
88885268|NCT01403870||Low Back Pain Subjects|Subjects who have low back pain at the time of the study, and wish to receive physical therapy to reduce their low back pain.
88885269|NCT01403883|Active Comparator|Standard care|standard care of patient with psychological and enterostomal therapy clinic if necessary
88885270|NCT01403883|Experimental|Optimal care|Optimal care of patient with systematic and repeated psychological and enterostomal therapy follow up
89409539|NCT02294552|Experimental|Matched bone marrow graft|Days -8 through -4: Busulfan 1 mg/kg po qid x 4 days Days -3 through -2: Cyclophosphamide 50mg/kg/day iv x 2 days Or Days -7 through -2: Fludarabine 30 mg/m2/day iv x 6 days Days -4 through -3: Busulfan 1 mg/kg po qid x 2 days Day 0: Infusion of unmanipulated graft Day +3 and +4: Cyclophosphamide 50 mg/kg/day iv
88885271|NCT01403896|Active Comparator|Plerixafor Group|
88885272|NCT01403896|Experimental|Plerixafor + G-CSF group|
88885273|NCT01403909|Experimental|With compression|The patients randomized to this group will have intermittent pneumatic venous compression of the lower limbs during surgery.
88885274|NCT01403909|Active Comparator|Without compression|The patients randomized to this group will not have intermittent pneumatic venous compression of the lower limbs during surgery. (Standard care)
88885275|NCT01403922|Experimental|1|TC-5214
88885276|NCT01403922|Experimental|2|TC-5214 with placebo
88885277|NCT01403922|Experimental|3|TC-5214 with placebo
88885278|NCT01403922|Experimental|4|TC-5214
88885279|NCT01403948|Experimental|Patients with relapsed or refractory NHL|Adult patients with relapsed or refractory non-Hodgkin lymphoma of B cell origin after at least two prior treatments
88885280|NCT01403961||HbA1c > 7|Diabetic patients with HbA1c > 7
88885281|NCT01403961||HbA1c ≤ 7|Diabetic patients with HbA1c ≤ 7
88885282|NCT01403974|Experimental|Monotherapy|BI 836845 dose escalation, infusion, once every week, monotherapy
88885283|NCT01404000|Active Comparator|Iodinated Active Charcoal|Iodinated activated charcoal 3 gram daily in the morning for 56 days +- 2 days (=8 weeks)
88885284|NCT01404000|Placebo Comparator|non-iodinated activated charcoal|3g non-iodinated activated charcoal is given daily for 8 weeks
88885285|NCT01404013|Active Comparator|Montelukast|Monotherapy with Montelukast 10mg, take orally ,every night,for 8 weeks
88885286|NCT01404013|Active Comparator|ICS/LABA and Montelukast|Combination therapy with inhaled corticosteroid/β2 agonist 160/4.5ug,twice a day and Montelukast 10mg，take orally,every night for 8 weeks
88885287|NCT01404013|Active Comparator|ICS/LABA|Monotherapy with corticosteroid/β2 agonist 160/4.5ug,inhaled, twice a day, for 8 weeks
88885288|NCT01404026|Active Comparator|Active tDCS|Subjects will undergo 20 minutes of active tDCS stimulation.
88885289|NCT01404026|Sham Comparator|Sham tDCS|Subjects will undergo sham tDCS stimulation, where the current is only active for 30 seconds.
88885290|NCT01404052|Experimental|Active tDCS + transcranial ultrasound|Subjects will undergo 20 minutes active tDCS in conjunction with transcranial ultrasound measurements.
88885291|NCT01404052|Sham Comparator|Sham tDCS + transcranial ultrasound|Subjects will receive sham tDCS in conjunction with transcranial ultrasound measurements.
88885292|NCT01404065|Experimental|Active tDCS + visual illusion|Subjects will receive active tDCS while watching a visual illusion movie (legs walking on a treadmill). Stimulation will last for 20 minutes.
88885293|NCT01404065|Sham Comparator|Sham tDCS + visual illusion|Subjects will receive sham tDCS stimulation (30 seconds ramp up/ramp down) while watching a visual illusion movie (legs walking on a treadmill)
88885294|NCT01404065|Other|Healthy Subjects|Healthy subjects will receive both interventions (active and sham) in a randomized and counterbalanced order. Each stimulation session will be at least 1 week apart to prevent carry-over effects
88885295|NCT01404091|Experimental|Cohort 1: 40 milligram (mg) LY2940094|"40 mg LY2940094 was administered orally, one time only (it was originally expected that 100 mg LY2940094 would be administered).~If the receptor occupancy (RO) for a given dose is lower than 50%, (time to maximum concentration [tmax] or an optimal time window) then a higher dose will be administered to the next cohort whereas if the RO for a given dose is higher than 50%, then a lower dose will be administered to the next cohorts."
88885296|NCT01404091|Experimental|Cohort 2: 10 mg LY2940094|"The dose levels for subjects in Cohort 2 will be defined based on the results of the receptor occupancy (RO) data of previous cohort and the ongoing review of safety data. This dose was determined to be 10 mg, and was administered orally, one time only.~If the RO for a given dose is lower than 50%, (tmax or an optimal time window) then a higher dose will be administered to the next cohort whereas if the RO for a given dose is higher than 50%, then a lower dose will be administered to the next cohorts."
88885297|NCT01404091|Experimental|Cohort 3: 4 mg LY2940094|"The dose levels for subjects in Cohort 3 will be defined based on the results of the receptor occupancy (RO) data of previous cohort(s) and the ongoing review of safety data. This dose was determined to be 4 mg, and was administered orally, one time only.~If the RO for a given dose is lower than 50%, (tmax or an optimal time window) then a higher dose will be administered to the next cohort whereas if the RO for a given dose is higher than 50%, then a lower dose will be administered to the next cohorts."
88885298|NCT01404091|Experimental|Cohort 4: 20 mg LY2940094|"The dose levels for subjects in Cohort 4 will be defined based on the results of the receptor occupancy (RO) data of previous cohort(s) and the ongoing review of safety data. This dose was determined to be 20 mg, and was administered orally, one time only.~If the RO for a given dose is lower than 50%, (tmax or an optimal time window) then a higher dose will be administered to the next cohort whereas if the RO for a given dose is higher than 50%, then a lower dose will be administered to the next cohorts."
88885299|NCT01404104|Experimental|Temsirolimus (pre-surgery)|
88885300|NCT01404117|Experimental|Laquinimod 0.6|GA 20 mg/1mL or an IFN-B preparation + oral daily administration of laquinimod 0.6 mg
88885301|NCT01404117|Experimental|Laquinimod 1.2|GA 20 mg/1mL or an IFN-B preparation + oral daily administration of laquinimod 1.2 mg
89536693|NCT04378907|Experimental|Cigarette Smokers: 30 mg/ml nicotine concentration|"ECIG Lab Session, 30 watts, 30 mg/ml nicotine concentration~During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout."
89536694|NCT02471105|Experimental|Lumigan 0.01% + Saflutan 15 µg/ml|Bimatoprost 0.01 % Eye drops solution Topical use Once in the evening 3 months
89409540|NCT02294552|Experimental|Matched peripheral blood stem cells graft|Days -8 through -4: Busulfan 1 mg/kg po qid x 4 days Days -3 through -2: Cyclophosphamide 50mg/kg/day iv x 2 days Or Days -7 through -2: Fludarabine 30 mg/m2/day iv x 6 days Days -4 through -3: Busulfan 1 mg/kg po qid x 2 days Day 0: Infusion of unmanipulated graft Day +3 and +4: Cyclophosphamide 50 mg/kg/day iv Days +5 through +35: Mycophenolate mofetil 30 mg/kg/day, maximum 2 g/day, iv or po x 30 days Days +5 through +120: Tacrolimus 0.03 mg/kg/day with further correction by concentration
89409541|NCT02294552|Experimental|Mismatched peripheral blood stem cells or bone marrow graft|Days -8 through -4: Busulfan 1 mg/kg po qid x 4 days Days -3 through -2: Cyclophosphamide 50mg/kg/day iv x 2 days Or Days -7 through -2: Fludarabine 30 mg/m2/day iv x 6 days Days -4 through -3: Busulfan 1 mg/kg po qid x 2 days Day 0: Infusion of unmanipulated graft Day +3 and +4: Cyclophosphamide 50 mg/kg/day iv Days +5 through +35: Mycophenolate mofetil 45 mg/kg/day, maximum 3 g/day, iv or po x 30 days Days +5 through +120: Tacrolimus 0.03 mg/kg/day with further correction by concentration
89409542|NCT03514706|Experimental|Volume controlled ventilation|Group V: Patients will receive volume controlled mechanical ventilation. (Vt 7ml/kg ideal body weight).
89409543|NCT03514706|Experimental|Pressure controlled ventilation|Group P: Patients will receive pressure controlled mechanical ventilation. (to achieve Vt 7 ml/kg ideal body weight, Pmax 30 cmH2O)
89409544|NCT03940924|Experimental|High Intensity Interval Training (HIIT) + Resistance Training|Subjects perform three sessions of training during 12 weeks. Session are composed of 20min HIIT program : 60 cycles of speeding up for 8s and pedaling slowly for 12s. (Intensity between 85 and 90% HRmax) + a single set circuits including 10 exercises with a load of 8-12 repetition at around 80% of maximal repetition (1RM)
89409545|NCT03940924|No Intervention|Control Group|Subjects don't have training program. They keep their life style.
88885302|NCT01404117|Experimental|GA or IFN + Placebo|GA 20 mg/1mL or an IFN-B preparation + oral daily placebo
88885303|NCT01404130|Experimental|Isotretinoin therapy|0.5-1mg /kg titrated by clinical need and tolerance of each patient according to normal clinical practice
89409546|NCT05692531|Experimental|A Story Within A Story|This is a single event that will be evaluated using quasi-experimental design methods.
89409547|NCT02298374|Experimental|Homecare reablement|Receives comprehensive assessment and individualized follow-up according to a plan with short and longterm goals.
89409548|NCT02298374|Active Comparator|Usual care|Receives normal care
89409549|NCT03554551||Patients with Parkinsons disease|Disease duration > 4 years, Hoehn & Yahr stage 2-3, 50-85 years old
89409550|NCT03554551||Healthy controls|50-85 years
89409551|NCT03869944|Experimental|Intervention|Lamivudine Oral Solution
89409552|NCT05105178|Experimental|Orientation|Information of orientation (time, place, patient's own name) is repeatedly provided during emergence.
89409553|NCT05105178|Active Comparator|Name|As usual, patient is recovered from general anesthesia with his/her name called.
89409554|NCT02291900|Active Comparator|medial femoral condyle|Patients in this arm receive core decompression followed by free vascularized medial femoral condyle graft
88885304|NCT01404143|Active Comparator|Subscapularis Tenotomy|"This treatment group will undergo a technique that involves division of the tendon to gain access to the shoulder.~After the deltopectoral approach is completed, the subscapularis tendon will be tenotomized one centimeter medial to its insertion on the lesser tuberosity."
88885305|NCT01404143|Experimental|Subscapularis Peel|This treatment group will use a technique that involves elevation of the tendon off the bone in order to gain access to the shoulder.The subscapularis will be elevated from the lesser tuberosity.
89409555|NCT02291900|Active Comparator|core decompression|Patients in this arm receive core decompression followed by osseous autograft from the iliac crest
89409556|NCT05429905|Experimental|Cohort 1 (Dose-escalation)|Dose-finding and dose expansion cohort for intravenous autologous anti-CD22/CD19 CAR-T using a relapsed refractory B-ALL cohort.
89409557|NCT05429905|Experimental|Cohort 2 (High MRD)|Patients with B-ALL with high MRD after induction therapy or after consolidation therapy in replacement of stem cell transplant
89409558|NCT05429905|Experimental|Cohort 3 (Extramedullary ALL)|Patients with testicular or central nervous system B-ALL in replacement of radiation
89409559|NCT05692219|Experimental|Lifestyle medicine|The booklet-delivered multicomponent lifestyle medicine intervention includes six weekly sessions (i.e., participants are anticipated to access the intervention every day for 42 days) that are related to the following topics: (a) lifestyle psychoeducation, (b) exercise, (c) nutritional recommendations, (d) stress management, (e) sleep management, and (f) motivation and goal-setting techniques.
89409560|NCT05692219|Active Comparator|Cognitive behavioural therapy|The booklet-delivered self-help CBT includes six weekly sessions (i.e., participants are anticipated to access the intervention every day for 42 days) that are related to psychoeducation of depression, cognitive behavioural techniques( e.g. behavioral activation, cognitive restructuring), stress management, mindfulness, goal-setting, and/or positive psychology.
89409561|NCT05692219|No Intervention|Waitlist control|Participants in the waitlist control group will be asked to maintain their typical activities during the trial period, and they will be given the lifestyle medicine booklet or CBT booklet based on their preference following the completion of the 3-month follow-up assessment (Week 19).
89409562|NCT03514628|Experimental|Valsalva Assist Device (VAD)|Intervention is the use of Valsalva Assist Device (VAD) to deliver the Valsalva strain
89535660|NCT02489669|Experimental|Renalguard group|Patients enrolled in this group will be treated by hydration with 0.9% saline controlled by the RenalGuard system. On top of the 1.5-5.0 ml/kg/h that patients would have received over the previous hour (according to the non-invasive estimate LVEDP), an initial bolus of 250 ml will be administered. In case of LV ejection fraction ≤30% and/or LVEDP >18 mm Hg the bolus will 150 mL. Therefore, furosemide (0.25 mg/kg) will be administered in order to achieve the optimal urine flow rate (≥300 mL/h). The controlled hydration by the RenalGuard system will be continued during the procedure and for 4 hours following the procedure. Urine flow rate is monitored and maintained at the target value through the procedure and during the following 4 hours. Additional furosemide doses are allowed in case of decrease of the urine flow rate below the target value.
88885306|NCT01404156|Active Comparator|Neoadjuvant Chemotherapy|"NEOADJUVANT CHEMOTHERAPY (OPTION of CHEMO REGIMEN 1 or 2)~1) FLOT - Four x 14 day cycles FLOT preoperatively and 4 cycles postoperatively (within 4-10 weeks after surgery): 5-Fluorouracil 2600 mg/m², day 1 IV every 14 days Leucovorin 200 mg/m², day 1, IV., every 14 days Oxaliplatin 85 mg/m², day 1, IV, every 14 days Docetaxel 50mg/m2, day 1, IV, every 14 days~2) ECF / ECX - Three x 21-day cycles ECF preoperatively and 3 cycles postoperatively (within 4-10 weeks after surgery): Epirubicin (50 mg/m²,mg per square meter of body-surface area) by intravenous bolus on day 1 IV Cisplatin: 60 mg/m², mg per square meter intravenously with hydration on day 1 IV 5-Fluorouracil: 200 mg/m², mg per square meter daily for 21 days by continuous intravenous infusionIV infusion 5-FU may be substituted with Capecitabine (Xeloda) 625mg/m2 PO BID (ECX)"
88885307|NCT01404156|Experimental|Neoadjuvant Chemoradiation|"1) -carboplatin and paclitaxel given on days 1, 8, 15, 22 and 29~paclitaxel: 50 mg / m2 IV over 1 hour~carboplatin: dosed to an area under the curve of 2, by Calvert formula, as a 1 hour IV infusion Radiation Therapy Concurrent radiation therapy will begin within 24 hours of initiation of chemotherapy for patients randomized to chemoradiation treatment.~Dose specifications:~Phase 1: Total radiation prescription dose 45 Gy given in 25 fractions of 1.8 Gy per fraction, 5 fractions / week, one treatment / day, starting on the first day of first cycle of chemotherapy.~Phase 2: (GTV only) Boost is not mandatory and up to the discretion of radiation oncologist. Total radiation prescription dose 5.4 Gy given in 3 fractions of 1.8 Gy per fraction, 5 fractions / week, one treatment."
88885308|NCT01404169|Experimental|1|
88885309|NCT01404169|Placebo Comparator|2|
88885310|NCT01404182|Experimental|Influenza vaccination|Vaccination with a single dose of Fluval AB influenza vaccine (trivalent, seasonal, active ingredient content: 15 μg HA/0.5mL of seasonal H1N1, H3N2 and B influenza antigens each) and aluminium phosphate gel adjuvant.
88885311|NCT01404195|Experimental|Ensure Plus Advance, Supplement|Participating patients will be dispensed two bottles daily, one at breakfast and one in the evening, seven days a week.
88885312|NCT01404195|No Intervention|Control|without supplementation
88885313|NCT01404247|Experimental|OCT imaging in neonates|OCT imaging of all neonates, 38-42 weeks, enrolled in this study
88885314|NCT01404273|Experimental|Meditation/Relaxation Response Training|
88885315|NCT01404286|Experimental|physical exercise|Experimental group: physical exercise Control group: no physical exercise
88885316|NCT01404286|No Intervention|Control group|
88885317|NCT01404299|Experimental|Supplementary Group|
88885318|NCT01404299|No Intervention|Control Group|
88885319|NCT01404312|Experimental|RPT plus INH Regimen (Arm A)|Participants received RPT (dosage based on their weight), 300 mg of INH, and 25 mg or 50 mg of pyridoxine (vitamin B6) each day during Weeks 1 to 4. During Weeks 5 to 36, participants did not receive any study medications.
88885320|NCT01404312|Active Comparator|INH Regimen (Arm B)|Participants received 300 mg of INH and 25 mg or 50 mg of pyridoxine (vitamin B6) each day during Weeks 1 to 36.
88885321|NCT01404338|Active Comparator|Active Arm|1. Active arm/Target Lesion: Halobetasol 0.05% ointment applied under occlusion to be left in place for one week
88885322|NCT01404338|Placebo Comparator|Vehicle Arm|Vehicle arm/Comparator Lesion: Vehicle ointment applied under occlusion to be left in place for one week
88885323|NCT01404351|Experimental|PEAK PlasmaBlade|
88885324|NCT01404351|Active Comparator|Standard of Care|The Standard of Care arm will consist of the scalpel for the skin incision and traditional electrosurgery for subcutaneous dissection.
88885325|NCT01404364|Active Comparator|Intravitreal Triamcinolone|Patients with phthisis bulbi received 0,3ml intravitreal triamcinolone injection
88885326|NCT01404364|Active Comparator|Retrobulbar Chlorpromazine|Patients with refractory glaucoma and blind painful eye were submitted to 2,5mL Chlorpromazine retrobulbar injection
88885327|NCT01404377|Active Comparator|ropivacaine|treated group (ropivacaine infiltration)
88885328|NCT01404377|Placebo Comparator|placebo|placebo group : infiltration with saline solution
89409563|NCT03514628|Active Comparator|Standard Care|Intervention is the use of Standard technique to deliver Valsalva strain eg blowing on empty syringe
88885329|NCT01404390|Experimental|Arm 1|
88885330|NCT01404390|Experimental|Arm 2|
88885331|NCT01404403|Other|Stroke patients|
88885332|NCT01404442|Active Comparator|Ketamine|The ketamine group (groupK) received bupivacaine 10mg combined with 0.1 mg/kg ketamine preservative free intrathecally .
88885333|NCT01404442|Active Comparator|midazolam|The midazolam group (group M) received bupivacaine 10mg combined with0.02 mg/ kg midazolam intrathecally
88885334|NCT01404442|Placebo Comparator|placebo|The placebo group (group P) received bupivacaine 10mg combined with 0.5ml distilled water intrathecally .
88885335|NCT01404455|Other|Normal pulse pressure|pulse pressure <60mmHg
88885336|NCT01404455|Other|Wide pulse pressure|pulse pressure ≥60mmHg
88885337|NCT01404468|Active Comparator|pulsed|
88885338|NCT01404468|Sham Comparator|control|
88885339|NCT01404468|Active Comparator|continuous|
88885340|NCT01404481||Single use group|New catheter for each Clean Intermittent Self Catheterisation (CISC), then discard.
88885341|NCT01404481||Re use of catheters group|"Use same catheter for 1week- Cleaning with sunlight liquid soap, air dry or dry with lint free towel, store in a snap lock bag.~Discard catheter and snap lock bag at end of each week."
88885342|NCT01404507|Active Comparator|Intracoronary abciximab|Intracoronary injection of bolus abciximab
88885343|NCT01404507|Active Comparator|Aspiration thrombectomy|Aspiration thrombectomy
88885344|NCT01404507|Active Comparator|Both use|Both use of intracoronary injection of bolus abciximab and aspiration thrombectomy
89409564|NCT04435522|Experimental|Maraviroc Treatment|Maraviroc 300 mg Twice Daily
89409565|NCT03843970|Experimental|Levobupivacaine Hydrochloride 0,5%|The doses used of Levobupivacaine Hydrochloride 0.5% will be 6 mg and the dose of fentanyl 10 μg.
89409566|NCT03843970|Active Comparator|isobaric bupivacaine 0,5%|The doses used of isobaric bupivacaine will be 6 mg and the dose of fentanyl 10 μg.
89409567|NCT02298452|Other|Hearing aid|172 subjects with a mild hearing loss. 140 subjects with a moderate hearing loss. 70 subjects with a severe/ profound hearing loss.
89409568|NCT03645369|Experimental|Mechano-Analgesia|The first SC heparin injections were applied from the right abdominal region using ShotBlocker®.
89409569|NCT03645369|Experimental|Cold Application|The second SC heparin injections were applied from the left abdominal region with an ice pack
89409570|NCT03645369|No Intervention|Control|The second SC heparin injections were applied from the lower abdominal region without any additional application
89409571|NCT02294708|Experimental|supine|postoperative postures: patients in this arm are assigned to adopt supine position for 24 hours after the surgery
88885345|NCT01404520|Experimental|Exercise based multimodal intervention|The intervention is initiated early, during treatment (consolidation) in the intra-hospital setting and continues for two successive treatment series (12 weeks). The intervention is a three hour/wk supervised in-hospital programme of aerobic (stationary cycle) and functional muscle training, progressive relaxation training, nutrition supplement (protein and carbohydrate) immediately after training and health-promoting consultation combined with an unsupervised in-home walking and progressive relaxation programme
88885346|NCT01404520|No Intervention|Control Group|Control group receives usual care
88885347|NCT01404533|Experimental|Iron supplement without food|
88885348|NCT01404533|Experimental|Iron supplement with food|
89409572|NCT02294708|Experimental|temporal lateral|postoperative postures: patients in this arm are assigned to adopt temporal lateral position for 24 hours after the surgery
89409573|NCT04367298||Chronoprevention in hospital falls|Implementation of a hospital preventive measures program: adjusted to the identification of temporal patterns of falls and relative risk factors of falls.
88885349|NCT01404533|Experimental|Iron fortificant with food|
88885350|NCT01404546|Experimental|Cost Free Pharmacotherapy|Participants assigned to the CF group received a starter kit (4-week supply) of cost-free quit smoking medication (nicotine replacement therapy, bupropion, or varenicline) and a pre-printed prescription to be filled by the patient at the end of the 4-weeks.
88885351|NCT01404546|Active Comparator|Usual Care Group|Participants assigned to the prescription only usual care group received a prescription for smoking cessation pharmacotherapy to be filled at their own cost at their local community pharmacy.
89409574|NCT02291978|Experimental|ExAblate 2100 Treatment|The ExAblate 2100 system will be used in the MRgHIFU treatment of lower back pain arising from facet joint arthritis.
88885352|NCT01404598|Experimental|naproxcinod 750 mg bid|
88885353|NCT01404598|Experimental|naproxcinod 3000 mg od|
88885354|NCT01404598|Active Comparator|naproxen 500 mg bid|
89409575|NCT02807350|Experimental|Overminus Treatment|spectacles with full cycloplegic refraction plus 2.50 D overminus added to the sphere
88885355|NCT01404637|Experimental|Tamsulosin 0.4mg|
88885356|NCT01404637|Active Comparator|tamsulosin 0.2mg|
88885357|NCT01404663|Experimental|stem cell recipients|The 4-12 years old patients with cerebral palsy who undergone bone marrow derived CD133 transplantation
88885358|NCT01404676|Experimental|Vildagliptin + Metformin|Adding Vildagliptin to metformin users
88885359|NCT01404676|Active Comparator|Glimepiride + Metformin|Adding Glimepiride to metformin users
88885360|NCT01404689|Experimental|Midazolam-Meperidine-Dexmedetomidine|midazolam 0.06mg/kg IV bolus, meperidine 50mg IV bolus and dexmedetomidine 1μg/Kg•hr infusion (30% reduction of midazolam dose and 25mg of meperidine for patients 65 years of age or older)
88885361|NCT01404689|Sham Comparator|Midazolam-Meperidine|midazolam 0.06mg/kg IV bolus, meperidine 50mg IV bolus and placebo(saline) infusion(30% reduction of midazolam dose and 25mg of meperidine for patients 65 years of age or older)
88885362|NCT01404702|Experimental|Zoledronic Acid and Interleukin-2|
88885363|NCT01404715|Experimental|Metformin and Imatinib Co-Adminisdered|Subjects will be dosed with Metformin (1850 mg) in conjunction with imatinib (600mg).
88885364|NCT01404715|Experimental|Metformin Alone|Subjects will be dosed with Metformin alone (1850mg)
88885365|NCT01404728||Pelvic Malignancies|Women with Vaginal Stenosis
88885366|NCT01404767|Active Comparator|Metoprolol oral dose or Placebo infusion|
88885367|NCT01404767|Experimental|Esmolol infusion or Placebo oral dose|
88885368|NCT01404780|Experimental|The GlideScope (GVL)|
88885369|NCT01404780|Active Comparator|Macintosh direct laryngoscope (MDL)|
88885370|NCT01404793||Liver transplant recipient|
88885371|NCT01404806|Experimental|GSK1349572|
88885372|NCT01404819|Experimental|Experimental arm|Patients in this arm undergo anesthesia with Xenon.
88885373|NCT01404819|Active Comparator|Standard arm|Patients in this arm undergo standard anesthesia
88885374|NCT01404845|Active Comparator|B: patients with wet AMD in one eye.|group B: patients with wet AMD in one eye. In each group, A and B, half the patients will be randomized in a subgroup to Nutrof Total, and the other half in a subgroup to a food supplement not containing Lutein and Zeaxanthin.
88885375|NCT01404845|Active Comparator|A :patients without retinal pathology|"group A :patients without retinal pathology who underwent cataract surgery 1 month previously.~In each group, A and B, half the patients will be randomized in a subgroup to Nutrof Total, and the other half in a subgroup to a food supplement not containing Lutein and Zeaxanthin."
88885376|NCT01404858||Patients undergoing IVF|
88885377|NCT01404871|Active Comparator|Randomization to ECIT or CMI|Randomized trial of clomipramine or escitalopram
88885378|NCT01404871|Active Comparator|Open label Duloxetine|Open label trial of duloxetine
88885379|NCT01404884|Experimental|SUPRACOR|Treatment arm consisting of patients with history of myopia or myopic astigmatism who are also diagnosed with presbyopia.
88885380|NCT01404897|Experimental|Dietary Intervention: Control Diet|
89409576|NCT02807350|Active Comparator|Non-overminus Treatment|spectacles with full cycloplegic refraction without overminus
89409577|NCT03043651|Experimental|Oral treprostinil|Sustained-release tablets for TID administration
89409578|NCT04353024|Placebo Comparator|Placebo|Bolus of 0 mg DMT + perfusion of 0 mg/min DMT over 60 min, resulting in a total dose of 0 mg DMT.
89409579|NCT04353024|Experimental|Low dose|Intravenous bolus of 0 mg DMT + perfusion of 0.6 mg/min DMT over 90 min, resulting in a total dose of 54 mg DMT.
89409580|NCT04353024|Experimental|Low dose with bolus|Intravenous bolus of 15 mg DMT + perfusion of 0.6 mg/min DMT over 90 min, resulting in a total dose of 69 mg DMT.
88885381|NCT01404897|Experimental|Dietary Intervention: DASH-based diet|
88885382|NCT01404897|Experimental|Dietary Intervention: Modified DASH diet|
88885383|NCT01404910|Experimental|Apheresis|Apheresis using Liposorber LA-15 System
88885384|NCT01404962|Other|Group 1|
88885385|NCT01404975|Experimental|Paravertebral Block|Patients randomized to receive PVB will have a continuous thoracic paravertebral block using local anesthetic after trans-apical aortic valve replacement. The patient will be placed in lateral decubitus position and under aseptic conditions the skin entry points will be 2.5-3cm from the spinal processes of the vertebra at a level of the proposed surgical incision. A 17G Touhy needle will be inserted perpendicular to the skin until the transverse process is contacted. After negative aspiration test an initial bolus of 8ml of plain ropivacaine 0.5% will be administered. This will be followed by a continuous infusion of 0.2% ropivacaine at 10 mL/hr. For break through pain additional doses of ropivacaine will be administered as required.
88885386|NCT01404975|Active Comparator|Standard intravenous opioid analgesia|"Patient Controlled Analgesia (PCA) :~PCA: the patients who are randomized to PCA group will receive standard of care for this modality."
88885387|NCT01405014|Experimental|Relationship enhancement group|One group, all involved in the intervention
88885388|NCT01405040||EV1000 Observational Group|Patient must have an indwelling femoral arterial catheter and central venous catheter considered necessary for routine clinical monitoring; Patient, or legal guardian, will give consent prior to study enrollment and data capture; Patient must be at least 18 years old; Patient height and weight are available prior to study.
88885389|NCT01405079|Experimental|Gefitinib|Gefitinib 250 mg/day oral daily
88885390|NCT01405079|Active Comparator|Vinorelbine+Cisplatin|Vinorelbine 25 mg/m2 intravenous infusion on day 1 and day 8, Cisplatin 75 mg/m2 on day 1 for 4 cycles
88885391|NCT01405092|Placebo Comparator|Standard volume management|patients on this arm will receive usual care volume management during continuous renal replacement therapy
88885392|NCT01405092|Active Comparator|continuous volume management|use of Critline, Hemametrics USA, in conjunction with continuous renal replacment therapy to determine volume removal
88885393|NCT01405105||Patients with Flares of IBD|Active flare of Crohn's or UC
88885394|NCT01405105||Control Group|Patients with quiescent Crohn's disease or UC
88885395|NCT01405118|Experimental|Metformin/CP-690,550|
88885396|NCT01405131|Experimental|methylprednisolone suspension|
88885397|NCT01405131|Active Comparator|methylprednisolone tablets|
88885398|NCT01405144|Active Comparator|5% 5-fluoruracil cream|30 patients will use 5% 5-fluoruracil cream, twice a day, during 3 weeks, in one randomized forearm
88885399|NCT01405144|Active Comparator|5% 5-fluoruracil peeling|The same 30 patients will be submitted to 4 applications of 5% 5-fluoruracil superficial peeling in the other forearm
88885400|NCT01405157|Experimental|methylprednisolone suspension|
88885401|NCT01405157|Active Comparator|methylprednisolone tablets|
88885402|NCT01405170|Experimental|methylprednisolone suspension|
88885403|NCT01405170|Active Comparator|methylprednisolone tablets|
88885404|NCT01405183||Renal Cell Carcinoma patients|Newly diagnosed (within 6 months) renal cell carcinoma patients in who a biopsy or surgery will be performed
88885405|NCT01405183||Colorectal cancer patients|Newly diagnosed (6 months) colon cancer patients
88885406|NCT01405209||Atrial Fibrillation|Patients who develop atrial fibrillation
88885407|NCT01405209||Non Atrial FIbrillation|Patients without atrial fibrillation
88885408|NCT01405222||Acute COPD exacerbation|Patients admitted in to hospital with an acute exacerbation of COPD
89409581|NCT04353024|Experimental|High dose|Intravenous bolus of 0 mg DMT + perfusion of 1 mg/min DMT over 90 min, resulting in a total dose of 90 mg DMT.
89409582|NCT04353024|Experimental|High dose with bolus|Intravenous bolus of 25 mg DMT + perfusion of 1 mg/min DMT over 90 min, resulting in a total dose of 115 mg DMT.
88885409|NCT01405235|Active Comparator|Arm B: Cisplatin/Topotecane|Topotecan 0.75 mg/m2/d i.v. on Days 1- 3 in combination with Cisplatin 50 mg/m2 i.v. on Day 1, q 21 d
88885410|NCT01405235|Experimental|Arm A: Paclitaxel/Topotecan|Paclitaxel 70 mg/m2/d i.v. on Days 1, 8, and 15 in combination with Topotecan 1.75 mg/m2/d i.v. on Days 1, 8, and 15, q 28 d
88885411|NCT01405248|Experimental|Butylphthalide|Single center of the placebo control a double-blind randomized control study to evaluate Butylphthalide prevention stents restenosis effect
88885412|NCT01405248|Placebo Comparator|control|Placebo
88885413|NCT01405261|Experimental|NNC 0113-0987 (gastro)|
88885414|NCT01405261|Experimental|NNC 0113-987 (coated)|
88885415|NCT01405261|Experimental|NNC 0113-987 (i.v)|
88885416|NCT01405274|Experimental|Physiotherapy intervention|
88885417|NCT01405274|No Intervention|standard care|
88885418|NCT01405287|Experimental|Combo Stent|PTCA with Combo Stent
88885419|NCT01405287|Active Comparator|Everolimus Eluting Stent (EES)|PTCA with DES (Everolimus Eluting Stent: Xience V or Promus)
88885420|NCT01405300|Experimental|Peanut|
88885421|NCT01405300|Placebo Comparator|Control|
88885422|NCT01405326|Experimental|Adalimumab|Adalimumab treatment for 6 months
88885423|NCT01405326|Placebo Comparator|Pacebo|Corresponding placebo for active treatment group
88885424|NCT01405339|Experimental|Budesonide via MAD|The current standard of care at St. Paul's Sinus Centre is to administer budesonide via the Mucosal Atomization Device (MAD). Its believed that MAD is a better device than the standard nasal lavage (Budesonide diluted in saline and delivered via Nasal Irrigation Bottle)because its fine mist and higher concentration enhances absorption and improves bioavailability.
88885425|NCT01405339|Active Comparator|Budesonide via Sinus Rinse Bottle|Budesonide via Sinus Rinse Bottle is the most commonly used delivery method.
88885426|NCT01405352|Active Comparator|Non obese/ vitamin A|Non obese individuals with body mass index 18.5-24.9 kg/m2 who receive 25000 IU/day vitamin A for 4 months .
88885427|NCT01405352|Placebo Comparator|obese/ placebo|obese individuals with body mass index greator than 30 kg/m2 who receive 1 cap placebo per day for 4 months .
88885428|NCT01405352|Active Comparator|Obese/ vitamin A|obese individuals with body mass index greater than 30 kg/m2 who receive 25000 IU/day vitamin A for 4 months
88885429|NCT01405365|Experimental|Metronidazole|
88885430|NCT01405365|Placebo Comparator|Placebo|
88885431|NCT01405378|Experimental|Robot Therapy and Real Transcranial Direct Current Stimulation|This group will involve carrying out robot therapy and real transcranial Direct Current Stimulation (tDCS).
88885432|NCT01405378|Placebo Comparator|Robot Therapy and sham tDCS|Participants will be randomised to group 2 whereby they will carry out the same robot therapy programme however, receiving sham stimulation.
88885433|NCT01405391|Experimental|A|Patients will receive PM01183 on Days 1 and 8 q3wk (three weeks = one treatment cycle) as an i.v. infusion, starting at 3.0 mg/day, flat dose (FD), over a minimum total volume of 100 ml dilution (on 5% glucose or 0.9% sodium chloride) via a central catheter or over a minimum total volume of 250 ml via a peripheral line, over one hour (at a fixed rate) and through a pump device.
88885434|NCT01405404|No Intervention|No intervention control|Parents complete surveys only
88885435|NCT01405404|Experimental|parent training but no discount|parent enrolled in the parent training intervention but do not receive childcare discounts for attending
88885436|NCT01405404|Experimental|Parent training with discount|parents receive parent training and a childcare discount for attending
88885437|NCT01405417|Experimental|Peroral endoscopic myotomy|"Patients with achalasia who are designed to either have balloon dilatation or botulinum toxine injection, or to have surgical intervention (Heller myotomy) for therapy.~Peroral endoscopic myotomy: A forward-viewing upper endoscope is used with a transparent distal cap attachment. Carbon dioxide gas is necessary for insufflation during the procedures. An endoscopic knife is used to access the submucosa, dissect the submucosal tunnel and also to divide circular muscle bundles over a length of approximately 10cm, extending 2-3cm onto the cardia. A electrogenerator is used with spray coagulation mode. A coagulating forceps is used for hemostasis as needed. Closure of the mucosal entry site is performed using standard endoscopic clips."
88885438|NCT01405430|Experimental|Bevacizumab + blood samples|
88885439|NCT01405443||Basic training|Theory lecture esophagogastroduodenoscopy (EGD). One hour simulator training for EGD. 30 minutes supervised training. Supervised endoscopy. Theory lecture Colonoscopy. One hour simulator training for Colonoscopy. 30 minutes supervised training. Supervised endoscopy. Group will be followed up for 2 weeks training time.
88885440|NCT01405443||Intermediate training|Theory lecture EGD. Three hours simulator training for EGD. 60 minutes supervised training. Supervised endoscopy. Theory lecture Colonoscopy. Three hours simulator training for Colonoscopy. 60 minutes supervised training. Supervised endoscopy. Group will be followed up for 4 weeks training time.
88885441|NCT01405443||Extended training|Theory lecture EGD. Five hours simulator training for EGD. 90 minutes supervised training. Supervised endoscopy. Theory lecture Colonoscopy. Five hours simulator training for Colonoscopy. 90 minutes supervised training. Supervised endoscopy. Group will be followed up for 6 weeks training time.
88885442|NCT01405482|Active Comparator|Botulinum Toxin Type A injection|Double-blind, randomized, placebo-controlled trial evaluating changes in pain, paresthesias, and function in subjects with TOS before, at six weeks, and four months following injection of BTX-A into the scalene muscles and pectoralis minor muscle under EMG guidance.
88885443|NCT01405482|Placebo Comparator|Normal Saline|Double-blind, randomized, placebo-controlled trial evaluating changes in pain, paresthesias, and function in subjects with TOS before, at six weeks, and four months following injection of placebo into the scalene muscles under EMG guidance.
88885444|NCT01405495||PTSD group|Intervention 'MRI-based techniques (sMRI, fMRI, DTI, ASL)'
88885445|NCT01405495||Exposed without PTSD|Intervention 'MRI-based techniques (sMRI, fMRI, DTI, ASL)'
88885446|NCT01405495||Healthy Controls|Intervention 'MRI-based techniques (sMRI, fMRI, DTI, ASL)'
88885447|NCT01405534||Central venous catheter|All patients who require the placement of a central venous catheter
88885448|NCT01405573|Active Comparator|A: Best Supportive Care|best supportive care
88885449|NCT01405573|Experimental|B: Sorafenib 400 mg, twice a day + Best Supportive Care|sorafenib + best supportive care
88885450|NCT01405599|Experimental|Control|Healthy subjects
88885451|NCT01405599|Experimental|Severe hepatic impairment|CTP class C
88885452|NCT01405599|Experimental|Moderate hepatic impairment|CTP class B
88885453|NCT01405599|Experimental|Mild hepatic impairment|CTP class A
88885454|NCT01405612|Experimental|Midazolam|Those subjects to receive Treatment A will receive a single dose of midazolam on Day 1 and will be discharged from the study unit on Day 2, at least 30 hours after midazolam dosing.
88885455|NCT01405612|Experimental|Ulimorelin|Those subjects to receive Treatment B will receive once daily ulimorelin on Days 1 to 5. Midazolam will be administered on Day 5 with the last dose of ulimorelin and subjects will be discharged from the study unit on Day 6, at least 30 hours after midazolam dosing.
88885456|NCT01405625|Active Comparator|AAAAI Action Plan|Asthma Action Plan from the American Academy of Allergy, Asthma, and Immunology
88885457|NCT01405625|Experimental|Asthma pictogram written action plan|Cartoon/pictogram-based written action plan sheet
88885458|NCT01405638|Experimental|Motivational Interviewing|The use of a one-on-one motivational interviewing counseling intervention, 4 visits over 5 months, focusing on changes to behavior related to blood pressure control.
88885459|NCT01405638|Experimental|Patient Navigation|The use of a patient navigation intervention to guide participants through the process of getting screened for colorectal cancer.
88885460|NCT01405638|Experimental|PLUS|This group receives both the motivational interviewing intervention and the patient navigation intervention.
88885461|NCT01405651|Experimental|E|ONO-6950
88885462|NCT01405651|Placebo Comparator|P|Placebo
88885463|NCT01405664|No Intervention|Non-Weight Bearing x 6 weeks|
88885464|NCT01405664|Experimental|Immediate Weight-Bearing as Tolerated|
88885465|NCT01405677|Experimental|Epaxal 0.25 mL|Single intramuscular dose (M. deltoideus) given on Day 1 and at Month 6
88885466|NCT01405677|Active Comparator|Epaxal 0.5 mL|Single intramuscular dose (M. deltoideus) given on Day 1 and at Month 6
88885467|NCT01405677|Active Comparator|Havrix Junior|Single intramuscular dose (M. deltoideus) given on Day 1 and at Month 6
88885468|NCT01405703||percuataneous plate fixation|an approach with three small longitudinal incisions
88885469|NCT01405703||open plate fixation|large transverse incision
88885470|NCT01405716|Active Comparator|Behavioral-Mindfulness|Mindfulness Meditation
88885471|NCT01405716|Placebo Comparator|Behavioral-Health|Health Education Class
88885472|NCT01405755|Experimental|National Vaccine Program Plus Radio|Appropriate complementary feeding messages delivered using: (a) nurses during the 1st National Vaccination Week (NVW); and (b) radio.
88885473|NCT01405755|No Intervention|Comparison (no intervention)|No complementary feeding messages delivered.
88885474|NCT01405807|Experimental|Alemtuzumab - high dose (60mg)|Alemtuzumab 30mg will be administered on Day 1 and Day 2 at 0 and 6 months
88885475|NCT01405807|Experimental|Alemtuzumab - low dose (30mg)|Alemtuzumab 15mg will be administered on Day 1 and Day 2 at 0 and 6 months
88885476|NCT01405833|Experimental|BG00010 (Neublastin)|Participants may be randomized to escalating doses of BG00010
88885477|NCT01405833|Placebo Comparator|Placebo|Participants may be randomised to a matching placebo
88885478|NCT01405846|Other|Gefitinib|Single arm study
88885479|NCT01405859||TS controls|10
88885480|NCT01405859||Non TS Controls|11
88885481|NCT01405859||TS remission|0
88885482|NCT01405885|Experimental|Arm A - 0.9mg of INO-3605|
88885483|NCT01405885|Experimental|Arm B - 0.9mg of INO-3609|
88885484|NCT01405885|Experimental|Arm C- 0.9mg of INO-3401|
88885485|NCT01405885|Experimental|Arm D- 0.3mg of INO-3609|
88885486|NCT01405885|Experimental|Arm E - 0.45mg each INO-3605 , INO-3609|
88885487|NCT01405885|Experimental|Arm F - 0.3mg each of INO-3401,INO-3605,INO-3609|
88885488|NCT01405885|Experimental|Arm G - 0.9mg of INO-3609|
88885489|NCT01405885|Experimental|Arm H - 0.9mg of INO-3609|
88885490|NCT01405885|Active Comparator|Arm I - Seasonal influenza vaccine|
88885491|NCT01405885|Experimental|Arm J - 1.8mg of INO-3609|
88885492|NCT01405976|Active Comparator|1|NIV for severe OSA group
88885493|NCT01405976|Active Comparator|2|CPAP for severe OSA group
88885494|NCT01405976|Active Comparator|3|Life stile modification for severe OSA group
88885495|NCT01405976|Active Comparator|4|NIV for non-severe OSA group
88885496|NCT01405976|Active Comparator|5|Life stile modification for non-severe OSA group
89409583|NCT04465292|Experimental|Intervention|Participants will receive Tildrakizumab 100mg at Weeks 0, 4, 16; three doses; a 16-week treatment course and 24-week followup
89409584|NCT03638817|Experimental|Eltrombopag|
88885497|NCT01405989|Experimental|Treatment arm A|darexaban, wash-out, ketoconazole + darexaban
88885498|NCT01405989|Experimental|Treatment arm B|ketoconazole + darexaban, wash-out, darexaban
88885499|NCT01406002|Experimental|Treatment arm 1|darexaban, wash-out, rifampicin + darexaban
88885500|NCT01406028|No Intervention|Standard of Care|Standard of care includes discharge instructions from one of our IVF nurses regarding medications and timing of follow-up, at which point patients are told what day they need to return for their pregnancy test. Patients have access to phone numbers for their IVF nurses and physicians, as well as information about how to contact the social workers if additional support is needed. They also are provided the emergency phone numbers for after-hour calls to the fellow on call. However, during the time between the embryo transfer and the pregnancy test, the current standard of care is that contact between the patient and our team is patient-initiated.
88885501|NCT01406028|Active Comparator|Intervention phone calls|The intervention consisted of two phone calls from an IVF social worker during the time between embryo transfer and pregnancy test. The first phone call occurred between days 2-4 after transfer and the second phone call occurred between days 5 and 9 after embryo transfer. Standard language for introductions to phone calls and for voice mails was established prior to the start of the study.
88885502|NCT01406041||Diseases|1. Pituitary adenomas; 2. Craniopharyngioma; 3. Sellar germinoma; 4. Sellar tuberalis meningioma; 5. Hypophystis; 6. Sellar glioma; 7. Rathke's cleft cyst; 8. Hypothalamic hamartoma
88885503|NCT01406054|Experimental|neuromuscular training|subjects in this arm will be exposed to a neuromuscular warm-up before practices and games
88885504|NCT01406054|No Intervention|control|
88885505|NCT01406067|Experimental|Social Skills Training|
88885506|NCT01406067|Active Comparator|Play group|
88885507|NCT01406080|Active Comparator|Adapalene|Differin® gel 0.3% (adapalene Gel 0,3%)
88885508|NCT01406080|Active Comparator|Tretinoin|Tretinoin 0,05% emollient cream
88885509|NCT01406093||Candidemia patients|Patients with diagnosis of candidemia
88885510|NCT01406106|Experimental|Liquid yoghurt with plant stanol esters|"Dairy product in the form of liquid yoghurt, marketed in Spain, that contains 2 g per container of plant stanol esters: sitostanol and campestanol (AHA recommended dose - 1.5 to 3 g).~It also contains: proteins 1.8 g, carbohydrates 9.8 g, fat 1.4 g, plant stanol 2 g, vitamin B6 0.6 mg, folic acid 60 mg."
88885511|NCT01406106|Placebo Comparator|Yoghurt without plant stanol esters|Composition per container: proteins 1.8 g, carbohydrates 9.8 g, fat (except stanol) 1.4 g, plant stanol 2 g, vitamin B6 0.6 mg, folic acid 60 mg.
88885512|NCT01406119|Experimental|ABT-806 Arm|
88885513|NCT01406132|Experimental|ASP015K|
88885514|NCT01406145|Experimental|ASP0777 low dose|ASP0777 low dose for 6 weeks
88885515|NCT01406145|Experimental|ASP0777 low dose, then high dose|ASP0777 low dose for 1 week and ASP0777 high dose for 5 weeks
88885516|NCT01406145|Experimental|ASP0777 high dose|ASP0777 high dose for 6 weeks
88885517|NCT01406145|Placebo Comparator|Placebo|Placebo for 6 weeks
88885518|NCT01406158|Experimental|Treatment A|
88885519|NCT01406158|Experimental|Treatment B|
88885520|NCT01406158|Experimental|Treatment T|
88885521|NCT01406171|Experimental|Isavuconazole and Midazolam|Isavuconazole three times per day (TID) for 2 days followed by once a day (QD) for 9 days. Midazolam single doses on days 1 and 12
88885522|NCT01406210||Prospective Group|Those patients that will be consented and data collected prospectively
89409585|NCT02298530|Experimental|Combination of caffeine and theanine|250 mg caffeine + 200 mg theanine
89409586|NCT02298530|Placebo Comparator|Caffeine|250 mg caffeine
89409587|NCT03756402||Healthy Subjects|All subjects underwent protein loading test and IRRIV test on the same day. The renal resistive index (RRI) measurements were performed by one trained sonographer using a multi-frequency convex probe through a manual RRI calculations. The RRIs were measured on three interlobular arteries (superior, middle and inferior) in each kidney, and expressed as a mean value. RFR was measured using an oral protein loading test and was then defined as the difference between the highest CrCl obtained after the protein load and the baseline CrCl measured on rest conditions. Urinary creatinine and sCr were measured by the enzymatic method (IL testTM Instrumentation(R), Laboratory SpA, Milano, Italy) and by ILab650 (Instrumentation Laboratory, Werfen Group, Barcelona, Spain).
89409588|NCT04218877||Children with atopic dermatitis|Children 1-3 years old with atopic dermatitis
89409589|NCT04218877||Children without atopic dermatitis|
89409590|NCT04218877||Children with genetic predisposition|Children with genetic predisposition to atopic dermatitis, but without manifestations
89409591|NCT03634215||Multiple Trauma patients|
89409592|NCT02294864|Experimental|Pulsed Radiofrequency|Pulsed Radiofrequency This group will receive one dose of intra-articular PRF in the affected knee using previous literature standards. This includes standard blood pressure monitoring, sterile preparation, and needle insertion of the PRF probe directed at the site of maximal pain. The RFG-3C Plus radiofrequency generator will be activated at 42C, pulse width 10ms, and 2Hz frequency for 15 min.
89409593|NCT02294864|Active Comparator|Physical Therapy|This group will receive standard of care outpatient physical therapy weekly for 3-4 weeks with therapist instructions to reduce knee pain.
88885523|NCT01406210||Retrospective Group|Those charts that will be utilized to collect retrospective data, waiver of consent will be granted by the IRBs.
88885524|NCT01406236|Other|Transradial PCI|
88885525|NCT01406236|Other|Transfemoral PCI|
88885526|NCT01406249|Active Comparator|S-1,Cisplatin|
88885527|NCT01406249|Experimental|Capecitabine, Cisplatin|
88885528|NCT01406262|Active Comparator|Albiglutide + moxifloxacin placebo|Once weekly subcutaneous injection of albiglutide for 6 weeks plus oral tablet of moxifloxacin matching placebo on Days -1 and 40
88885529|NCT01406262|Active Comparator|Albiglutide matching placebo + moxifloxacin|Once weekly subcutaneous injection of albiglutide matching placebo for 6 weeks, given with oral 400mg moxifloxacin tablet on Day -1 and moxifloxacin matching placebo on Day 40, or weekly albiglutide matching placebo for 6 weeks plus oral moxifloxacin matching placebo on Day -1 then oral 400mg moxifloxacin on Day 40
88885530|NCT01406275||Pediatrics patients prescribed amoxicillin and clavulanate|Pediatrics patients prescribed amoxicillin and clavulanate for treatment of diseases other than otitis media during study period
88885531|NCT01406288||HUS epidemy in Bordeaux, E. coli of the O104H4 serotype|
88885532|NCT01406301||Patients with a discharge diagnosis of ACS (UA/NSTEMI or STEMI|Patients with a discharge diagnosis of ACS (UA/NSTEMI or STEMI)
88885533|NCT01406314|Experimental|Intervention|Intravenous infusion for approximately 48 hours followed by subcutaneous injection
88885534|NCT01406327||Subjects prescribed ambrisentan|Subjects with pulmonary arterial hypertension (PAH) prescribed ambrisentan during study period
88885535|NCT01406340|Experimental|Normal subjects and subjects with Stage 3/4 renal function|Subjects will receive 5mg GSK1278863 for 14 days.
88885536|NCT01406340|Experimental|Subjects with Stage 5 renal function|Subjects will receive 5mg GSK1278863 for 15 days.
88885537|NCT01406353|Active Comparator|Early Percutaneous Mitral Intervention|early elective percutaneous mitral commissurotomy within 3 months of enrollment
88885538|NCT01406353|No Intervention|Conventional Treatment|All patients in the conventional treatment group regularly visit their attending physicians at 3 monthly interval for maintenance of anticoagulation therapy or every year for annual re-evaluation. Patients who become symptomatic during follow-up are referred for percutaneous mitral commissurotomy or mitral valve surgery.
88885539|NCT01406366||Group 1|Group 1: 16 programs / 148 residents
88885540|NCT01406366||Group 2|Group 2: 16 programs / 142 residents
88885541|NCT01406379|Experimental|Prophylactic clip|Prophylactic clip
88885542|NCT01406379|Active Comparator|Detachable snare|Detachable snare
88885543|NCT01406392|Active Comparator|Sublingual Misoprostol 12,5mcg|Sublingual misoprostol or placebo tablete will be administered for each six hours until the maximum dose of 100mcg or eight tablets.
89531057|NCT03341429|Experimental|Treatment|"Daily subcutaneous injection of liraglutide 3.0 mg~Study dosing of liraglutide:~Week 1: 0.6 mg once daily Week 2: 1.2 mg once daily Week 3: 1.8 mg once daily Week 4: 2.4 mg once daily Week 5-24: 3.0 mg once daily~In addition to the daily injection of liraglutide/placebo, participants in both groups will be advised to cut down approximately 500 calories from their usual food intake and to achieve a minimum of 150 minutes per week of physical activity."
88885544|NCT01406392|Active Comparator|Vaginal Misoprostol 25 mcg|Vaginal misoprostol or placebo tablets will be administered for each six hours until the maximum dose of 200mcg or eight tablets. Each pacient will receve at the same time a sublingual placebo tablet and vaginal misoprostol or sublingual misoprostol and vaginal placebo tablet. It will depend of the randomization.
88885545|NCT01406405||PEEK cages|Patients will have fusion surgery performed using polyetheretherketone (PEEK) cages
88885546|NCT01406405||Allograft spacers|Patients will have fusion surgery performed using allograft spacers
88885547|NCT01406418|Experimental|Cohort 1: CR6261|2 mg/kg CR6261
88885548|NCT01406418|Placebo Comparator|Cohort 1: Placebo|5% dextrose in water
88885549|NCT01406418|Experimental|Cohort 2: CR6261|5 mg/kg CR6261
88885550|NCT01406418|Placebo Comparator|Cohort 2: Placebo|5% dextrose in water
88885551|NCT01406418|Experimental|Cohort 3: CR6261|15 mg/kg CR6261
88885552|NCT01406418|Placebo Comparator|Cohort 3: Placebo|5% dextrose in water
88885553|NCT01406418|Experimental|Cohort 4: CR6261|30 mg/kg CR6261
88885554|NCT01406418|Placebo Comparator|Cohort 4: Placebo|5% dextrose in water
88885555|NCT01406418|Experimental|Cohort 5: CR6261|50 mg/kg CR6261
88885556|NCT01406418|Placebo Comparator|Cohort 5: Placebo|5% dextrose in water
88885557|NCT01406418|Experimental|Cohort 6: CR6261|30 mg/kg CR6261
88885558|NCT01406418|Placebo Comparator|Cohort 6 Placebo|5% dextrose in water
88885559|NCT01406431|Active Comparator|Pitavastatin + Valsartan|Intervention: Drug: Pitavastatin, Valsartan
88885560|NCT01406431|Experimental|Livalo fixed combination drug|Intervention: Drug: Livalo® fixed combination drug
88885561|NCT01406470|Experimental|IVIG-SN™|Immune Globulin Intravenous (Human) 5% Liquid
88885562|NCT01406483|Other|CABG|
88885563|NCT01406496|Experimental|Timing of insulin administration|
88885564|NCT01406509|Experimental|children aged 2-5 years (1 dose)|group A, C polysaccharide meningococcal and type b haemophilus Influenzal Conjugate vaccines of 0.5ml/dose for a person in 20 children aged 2-5 years, on day 0
88885565|NCT01406509|Experimental|children aged 6-23months (2 doses)|group A, C polysaccharide meningococcal and type b haemophilus Influenzal Conjugate vaccines of 0.5ml/dose for a person in 20 children aged 6-23 months old, on day 0, 28
88885566|NCT01406522|Placebo Comparator|Oral placebo|Inactive treatment
88885567|NCT01406522|Experimental|Oral tacrine|Oral tacrine
88885568|NCT01406587|Experimental|PP4001 50 mg|
88885569|NCT01406587|Experimental|PP4001 100 mg|
88885570|NCT01406587|Experimental|PP4001 200 mg|
88885571|NCT01406587|Placebo Comparator|Placebo|
88885572|NCT01406600|Active Comparator|rhCG 250mcg|For final oocyte maturation triggering in ART, rhCG 250mcg will be administrated.
88885573|NCT01406600|Experimental|rhCG 500mcg|For final oocyte maturation triggering in ART, rhCG 500mcg will be administrated.
88885574|NCT01406613||Particpants of previous TRIO study|All participants to this study are being observed as a follow up to a previous study which involved 4 arms. All participants to this follow up study will be subject to identical study procedures.
88885575|NCT01406626|Experimental|Peer Navigation Intervention Arm|"Subjects will receive the following peer navigation services:~1) 10 Navigator meetings: Navigators will meet with participants in person to teach linkage/retention skills and knowledge~2a) 2 Navigator accompaniment sessions: the peer navigator will accompany participants to HIV care appointment. Before and after the appointment, participants and navigators will review linkage and retention skills/knowledge and things that make it hard or easy for him/her to get regular HIV care~2b) Optional peer navigator accompaniment sessions: If the participant requests, the peer navigator will provide accompaniment to supportive HIV care appointments (one per month max)~3) 14 peer navigator care calls: During these calls, navigators and participants will talk about any problems that could make it difficult to get regular HIV care."
88885576|NCT01406626|No Intervention|Usual Care|Participants assigned to the control arm will receive the transitional case management (TCM) services that are currently offered at the jail
88885577|NCT01406639|Experimental|Ranibizumab|Patients treated with topical ranibizumab.
88885578|NCT01406665||increased diabetes risk|the recruited group consists of persons with moderate to high risk for impaired glucose tolerance or diabetes
88885579|NCT01406704|No Intervention|Control|
88885580|NCT01406704|Experimental|Rosiglitazone|Rosiglitazone (8 mg/day)
88885581|NCT01406704|Experimental|alpha-lipoic acid|alpha-lipoic acid (1800 mg/day)
88885582|NCT01406704|Experimental|Rosiglitazone/alpha-lipoic acid|combination of Rosiglitazone (8 mg/day) and alpha-lipoic acid (1800 mg/day)
88885583|NCT01406730|Experimental|exercise|16 weeks of running exercise
88885584|NCT01406730|No Intervention|control|
89409594|NCT04084522|Placebo Comparator|Standard Treatment Group|In addition to standard pharmacological treatment, this group would receive a diet comprising of 35-40 kcal. The total distribution of the calories would be as 55-60% from carbohydrates, 20% from protein and 30% from fat, a fixed amount of 50g of oil would be given and the remaining amount of fat would be met by the invisible dietary fat. The source of visible dietary fat would be refined soyabean oil. This group would not receive any fat in the form of Desi ghee or butter or any nutritional supplement other than the prescribed diet. The diet would be explained to the patient by individual diet charts.
89531058|NCT03341429|Placebo Comparator|Control|"Daily subcutaneous injection of placebo; the same dosage regimen as treatment to be followed.~In addition to the daily injection of liraglutide/placebo, participants in both groups will be advised to cut down approximately 500 calories from their usual food intake and to achieve a minimum of 150 minutes per week of physical activity."
88885585|NCT01406743||EOS™ Acquisition|
88885586|NCT01406769|Experimental|Diagnostic (bioimpedance to measure lymphedema)|Patients undergo preoperative and postoperative lower-extremity lymphedema assessment comprising serial circumferential measurements, bioimpedance spectroscopy measurements, and clinical evaluation using the Stemmer sign. Patients undergo radical vulvectomy or radical local excision as prescribed by GOG-0244, and unilateral or bilateral inguinal or inguinal-femoral lymphadenectomy.
88885587|NCT01406808|Other|standard of care plus genetic information|
88885588|NCT01406808|No Intervention|usual standard of care without genetic information|
88885589|NCT01406821|Sham Comparator|Dry needling|Blood will be drawn, and tendon will be penetrated with dry needle. Nothing will be injected into the tendon.
88885590|NCT01406821|Experimental|Platelet-rich plasma (PRP)|Blood will be drawn, and platelet-rich plasma will be injected into the tendon.
88885591|NCT01406847|Experimental|Spinal Manipulation|High-velocity manual technique applied to the pelvis with the participant in supine
88885592|NCT01406847|Sham Comparator|Static Touch|Practitioner hands are placed on the lumbar spine with the participant in prone.
88885593|NCT01406847|Active Comparator|Spinal Mobilization|Oscillation of the third lumbar level performed with the participant in prone
88885594|NCT01406886|Experimental|Energy density|Low or high energy density meal
88885595|NCT01406899|No Intervention|Treatment as Usual|Standard treatment as usual (TAU) in the VA Connecticut Healthcare System substance abuse clinic consisting of individual and group therapy sessions and regular urine monitoring.
88885596|NCT01406899|Experimental|Computer-based treatment|Standard treatment as usual (TAU) plus coping skills computer program. In addition to the individual and group therapy sessions (TAU), individuals will work with a computerized program that teaches skills for stopping substance use and increasing coping skills twice weekly for 8 weeks.
88885597|NCT01406912|Active Comparator|Recreational Activity Arm|recreational activity includes playing cards, ominoes, jenga or a ball game.
88885598|NCT01406912|Experimental|Wii Gaming System Arm|Use of Wii gaming technology (e.g. commercially available games)
88885599|NCT01406925|Placebo Comparator|Control|Placebo control
88885600|NCT01406925|Experimental|Low dose NRL001|0.5% NRL001 cream
88885601|NCT01406925|Experimental|Intermediate dose NRL001|0.75% NRL001 cream
88885602|NCT01406925|Experimental|High dose NRL001|1.0% NRL001 cream
88885603|NCT01406951||SIRS|(1) temperature > 38oC or < 36oC; (2) pulse rate > 90 beats/min; (3) ventilation rate > 20 breaths/min or hyperventilation with a partial pressure of arterial carbon dioxide (PaCO2) < 32 mmHg; (4) white blood cell (WBC) count >1 2,000μL-1 or < 4000 μL-1 , or > 10% immature cells.
88885604|NCT01406951||sepsis|SIRS + infection
88885605|NCT01406951||VAP|(1) after 48-72h endotracheal intubation, X-ray film displays new or progressive infiltrating focus; (2)The patient is in two of the following conditions: a. fever (temperature >38 ℃ or higher than basal temperature; b. peripheral WBC count≥10×10∧9/L，or <4×10∧9/L; c. appearance or increase of purulent respiratory tract secretion. Besides the diagnostic norms above, it is suggested that lower respiratory tract secretions be collected under the bronchoscope and half-quantitative etiological culture be carried out through the medium of BALF samples (diagnostic threshold value:104cfu/mL ).
88885606|NCT01406964|Experimental|Arm A|Arm A performs a CAT test to study tubal factor causes
88885607|NCT01406964|Experimental|Arm B|In Arm B a histerosalpingography is performed.
88885608|NCT01407016|Experimental|1.0|
88885609|NCT01407042||mb-UKA|Patients with unicondylar osteoarthritis of the knee
89409595|NCT04084522|Active Comparator|Intervention Arm|In addition to standard pharmacological treatment, this group would receive a diet comprising of 35-40kcal and 1.2-1.5gm protein per kg ideal body weight per day. The total distribution of the calories would be as 55-60% from carbohydrates, 20% from protein and 30-35% from fat, a fixed amount of 50g of ghee would be given in 3 divided doses of 30 ml to be taken raw, 20 ml to be used for cooking and the remaining amount of fat would be met by the invisible dietary fat. The source of visible fat would be exclusively Desi ghee. This group would not receive any fat in the form of butter or any other oil or any other nutritional supplement other than the prescribed diet. The diet would be explained to the patient by individual diet charts.
88885610|NCT01407055|No Intervention|Standard Medical Care|Patients receive standard treatment protocol for Coronary Artery Bypass Graft Surgery
88885611|NCT01407055|Active Comparator|Attention Control Group|In addition to standard medical care patients receive a comparable amount of therapist´s attention (common and unspecific factors = supportive therapy) to the intervention group, without targeting patients' expectations.
89437524|NCT03720366|Experimental|Arm 1: Administration of enasidenib and Arm 1 probes|Part 1: Subjects will receive prescribed doses of Arm 1 probes on Day -1, followed by the first enasidenib dose on Day 1. Subjects will continue to take enasidenib once daily for 27 more days. On Day 28, subjects will receive the Arm 1 probes again together with the Day 28 dose of enasidenib. Part 2: the subjects continue to receive daily doses of enasidenib for the next 28 days (equivalent to a cycle). The subject will continue in subsequent cycles until the end of the study (28 months) or termination
88885612|NCT01407055|Experimental|Expectation Manipulation Intervention|In addition to standard medical care patients' expectations prior to surgery are targeted in a brief psycho-educational intervention.
88885613|NCT01407120|Experimental|Mother Program|11 session program focused on parenting skills
88885614|NCT01407120|Experimental|Mother Plus Child Program|11 session Mother Program focused on parenting skills plus 11 session Child program focused on child coping skills
89531059|NCT03342833|Active Comparator|Blood flow restriction|
89531060|NCT03342833|Sham Comparator|Usual training|
88885615|NCT01407120|No Intervention|Literature Control|Families received books on children's post-divorce adjustment
88885616|NCT01407133|Experimental|Active rTMS|"48 subjects will receive active temporal rTMS, applied with the following combined parameters:~intensity: 100% of resting motor threshold~stimulation frequency: low-frequency continuous stimulation (0.5 or 1 Hz) or high-frequency stimulation trains (4 or 12 Hz)~number of stimulations per session: 300, 900 or 1800 per session~number of sessions per week: spaced out / low density protocol (1 per week) or dense / high density protocol (5 per week)~total number of sessions for the whole intervention: short protocol (5 sessions) or long protocol (20 sessions)."
88885617|NCT01407133|Sham Comparator|Sham rTMS|16 subjects will receive sham rTMS, applied with the same combination of parameters as active rTMS, except for the number of stimulations per session (300 or 900)
88885618|NCT01407159||Thoracic Stentgraft plus E-XL|male and female patients with complicated type B aortic dissection involving the infra-diaphragmatic aorta treated with any thoracic stentgraft extended by the E-XL aortic stent
88885619|NCT01407159||Control group|"historical control group fulfilling the following criteria:~Age +/- 3 years~Sex matched~Same follow-up period"
88885620|NCT01407172||Symptomatic PAD|Patient with symptomatic PAD as defined by the presence of typical or atypical claudication symptoms or critical limb ischemia in conjunction with ABI <0.9.
88885621|NCT01407172||Patients without PAD|Patients without PAD as defined by ABI>0.9 and <1.3.
88885622|NCT01407172||Asymptomatic PAD|Patients with asymptomatic PAD as defined by ABI<0.9 but no symptoms.
89191791|NCT05372796|Experimental|OTES (Occipital Transcutenous Electric Stimulation)|Participants in the OTES group were treated with a Chattanooga direct Tens device (DJO UK Ltd, Guildford Surrey, United Kingdom) 3 times a week for 5 weeks. Four self-adhesive 40*40 mm sized electrodes were attached to the occipital region of the patients bilaterally, covering the occipital nerves. The current intensity was adjusted according to the patient. The current intensity started from 0 mA and the current intensity was increased one by one every 30 seconds, the patient was allowed to tolerate the current by giving current without muscle twitching or harmful stimulation. The current frequency was determined as 2/100 Hz. Square waves at 2 Hz were applied for 3 seconds followed by an automatic shift to 100 Hz for another 3 seconds.
89191792|NCT04042714|Experimental|TAS-102|Patients will receive TAS-102, Orally, BID for 5 days a week with 2 days rest for 14 days, followed by a 14-day rest treatment cycle. Treatment may continue until disease progresses, intolerable toxicity is developed, or if the patient becomes pregnant or dies.
89191793|NCT03401918|Experimental|Patients with recurrent pregnancy loss or unexplained infertility|"Patients with recurrent pregnancy loss or unexplained infertility will have an assessment of the uterine environment at the time of implantation, followed by testing of uterine endometrial gene expression using the ERA test and the uterine micro biome.~Those who have abnormal results (an abnormal microbiome or an abnormal ERA) will have the option to undergo treatment followed by retesting of the uterine environment. For an abnormal ERA suggesting a pre-receptive result, luteal phase vaginal progesterone supplementation will be offered prior to re-testing of the ERA. For an abnormal microbiome a combination of oral antibiotics and vaginal probiotics will be offered prior to re-testing the uterine microbiome."
89191794|NCT03401918|Experimental|Healthy Control Patients|Patients who have had a normal delivery and no history of infertility or recurrent pregnancy loss will have assessment of the uterine environment at the time of implantation.
89191795|NCT05227378|Experimental|neoantigen tumor vaccine|neoantigen tumor vaccine with or without PD-1/L1
89191796|NCT00866398||1 DES|Patients receiving drug-eluting stent
89191797|NCT00866398||2 BMS|Patients receiving bare metal stent
89191798|NCT02570646|Experimental|QA-DDS|Patients will receive exposure to the QA-DDS tool from their dental care practitioner.
89191799|NCT00725348|Experimental|A|R115866
89191800|NCT00724776|Experimental|1|Open-label treatment with albinterferon alfa 2b escalating single dose
89191801|NCT05325216|Experimental|POPRC group|pelvic-organ preserving radical cystectomy with orthotopic ileal neobladder
89191802|NCT05325216|Active Comparator|SRC group|standard radical cystectomy with orthotopic ileal neobladder
89191803|NCT00866632|Experimental|Group Cognitive Behavioural Therapy|
89191804|NCT00866632|Experimental|Telephone Cognitive Behavioural Therapy|
89191805|NCT00866632|No Intervention|Group Education|
89191806|NCT00866632|No Intervention|Telephone Education|
89191807|NCT00577772|Active Comparator|Healthy Participants|Healthy Participants will report for simultaneous lactulose hydrogen breath test (H_2BT) and SmartPill study after an overnight fast. They will swallow the SmartPill Capsule at the study site. After 4 hours, they will be allowed to leave the study site and consume their usual diet. They will return for removal of the data recorder 5 days later.
89191808|NCT00577772|Active Comparator|Symptomatic Participants|"Subjects with symptoms suggestive of small bowel bacterial overgrowth (SBBO) (e.g., diarrhea, bloating, abdominal discomfort) for at least 3 months will be divided into 2 groups based on the results of their previous testing for SBBO (5 SBBO positive patients, 5 SBBO negative patients).~The symptomatic participants will report for simultaneous lactulose hydrogen breath test (H_2BT) and SmartPill study after an overnight fast. They will swallow the SmartPill Capsule at the study site. After 4 hours, they will be allowed to leave the study site and consume their usual diet. They will return for removal of the data recorder 5 days later.~After the capsule has been demonstrated to be passed from the subject, the subjects with SBBO present will then enter into an open-label treatment using Rifaximin (400 mg PO TID) for 7 days."
89191809|NCT00578136|Active Comparator|1|1) One group will receive the rectus sheath block prior to Umbilical hernia repair.
89191810|NCT00578136|Active Comparator|2|2) The second group will receive local anesthetic infiltration of the surgical site at the end the umbilical hernia repair.
89191811|NCT00861952|Experimental|Neuragen|Ad lib use of Neuragen (a natural health product) applied topically 2-3 times per day in 2-3 drops per application
89191812|NCT00861952|Sham Comparator|Mineral oil|Mineral oil, scent and color matched to intervention
89191813|NCT04065698|Experimental|RV521|Three single 200 mg oral doses of RV521 administered on Day 1, Day 5 and Day 9 as either the drug in capsule (1 dosing occasion) or the dry powder blend dispersed in water (2 dosing occasions)
89191814|NCT00655551|Experimental|Lacosamide 200 mg cohort|Single loading dose of intravenous (iv) lacosamide 200 mg followed by 6.5 days of oral lacosamide 100 mg twice daily
89191815|NCT00655551|Experimental|Lacosamide 300 mg combined cohorts|Single loading dose of intravenous (iv) lacosamide 300 mg dose followed by 6.5 days of oral lacosamide 150 mg twice daily
89191816|NCT00655551|Experimental|Lacosamide 400 mg cohort|Single loading dose of intravenous (iv) lacosamide 400 mg followed by 6.5 days of oral lacosamide 200 mg twice daily
89409596|NCT03644589|Experimental|Treatment (pembrolizumab, cisplatin)|"Participants receive pembrolizumab and cisplatin once every 3 weeks for a total of 6 doses. Both drugs are given by vein (IV). Participants that are responding to the study treatment will continue to receive pembrolizumab alone beyond 6 cycles for up to 24 months until disease gets worse, having bad side effects, no longer wish to be in the study, or have become pregnant (whichever comes first).~Participants receive pembrolizumab over 30 minutes and cisplatin on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Participants without disease progression after 6 courses may continue on pembrolizumab IV on day 1 every 21 days for up to 24 months (or 35 courses) in the absence of disease progression or unacceptable toxicity."
89409597|NCT02298608|Experimental|Irreversible Electroporation|Percutaneous, CT guided, Irreversible Electroporation of renal mass
89409598|NCT03536143|Experimental|Topical beremagene geperpavec|HSV1-COL7A1 vector (KB103)
89409599|NCT03536143|Placebo Comparator|Placebo|Placebo
89409600|NCT03514550|Experimental|total intravenous anesthesia|Patients, scheduled for nephrectomy for kidney cancer will receive neuraxial epidural block and propofol for perioperative anesthesia
89409601|NCT03514550|Active Comparator|Volatile anesthesia|Patients, scheduled for nephrectomy for kidney cancer will receive neuraxial epidural block and sevoflurane for perioperative anesthesia
89409602|NCT02294942|Experimental|RANCAD 500mg|RANCAD 1 tab (500 mg) + Placebo 1 tab, twice daily.
89409603|NCT02294942|Experimental|RANCAD 1000mg|RANCAD 2 tabs (500 mg), twice daily
89409604|NCT02294942|Active Comparator|Placebo|2 tabs, twice daily
89409605|NCT01344759|Active Comparator|Propofol|
89409606|NCT01344759|Active Comparator|Dexmedetomidine|
89409607|NCT03520868||Coumadin|Coumadin patients with undergo standard procedure with monitoring of Anti-Factor Xa assay level before and during the procedure. Heparin bolus given will be based on 70 U/kg
89409608|NCT03520868||Dabigatran|Dabigatran patients with undergo standard procedure with monitoring of Anti-Factor Xa assay level before and during the procedure. Heparin bolus given will be based on 110 U/kg
89409609|NCT03520868||Rivaroxiban|Rivaroxiban patients with undergo standard procedure with monitoring of Anti-Factor Xa assay level before and during the procedure. Heparin bolus given will be based on 110 U/kg
88885623|NCT01407185|Experimental|Resistive Training|Subjects will be working at 30-60% of 1 RM. The therapist selects theraband that will produce muscle fatigue ~ 15 reps. Subjects should report that the exercise was somewhat light to somewhat hard 11 to 14 on RPE scale. Increase or decrease resistance until the desired RPE is obtained. Continues until momentary fatigue is evidenced. Fatigue is defined as the inability to move through the full ROM in a slow controlled fashion. Record the exercise performed, amount of resistance, and # of good quality reps performed before fatigue was reached. A single set will be done for each muscle group.
88885624|NCT01407211|Active Comparator|with Multiple Sclerosis/ vitamin A|Patients with Multiple Sclerosis confirmed Relapsing Remitting Type who receive 25000 IU/day vitamin A
88885625|NCT01407211|Placebo Comparator|with Multiple Sclerosis/ placebo|Patients with Multiple Sclerosis confirmed Relapsing Remitting Type who receive 1 cap of placebo/day
88885626|NCT01407224|Experimental|Only training|Training on Early Breastfeeding Practices to front line health workers
88885627|NCT01407224|Active Comparator|Training and supervision|Training as well as supervision by field supervisor for six months intervention
89409610|NCT03520868||Apixaban|Apixaban patients with undergo standard procedure with monitoring of Anti-Factor Xa assay level before and during the procedure. Heparin bolus given will be based on 10 U/kg
89409611|NCT05885386|Other|Pheochromocytoma or Paraganglioma patients|TMZ was administered orally at an initial daily dose of 150 mg/m2 per day for 5 days, every 28 days preoperatively. In patients with a good tolerance during the first cycle, the dose was increased to 200 mg/m2 per day for 5 days, every 28 days.
89409612|NCT05885360|Experimental|Istradefylline 20 and 40 mg|The study intervention will be to add 20 mg Istradefylline for 2 weeks, following which the dose will be increased to 40 mg daily for the remainder of the 24 weeks.
89409613|NCT05885308|Active Comparator|Group training|
89409614|NCT05885308|Experimental|Online training|
89409615|NCT05885295||Patient|Patient with stroke
89409616|NCT05885295||Controls|Age-matched controls
89409617|NCT05885269|Active Comparator|Group A applied Clobetasol Propionate 0.05%|Patient in group-A applied clobetasol propionate 0.05% twice daily for upto 03 months.
89409618|NCT05885269|Active Comparator|Group B applied topical Tacrolimus 0.1%|Group-B applied topical tacrolimus 0.1% twice daily for upto 3 months.
88885628|NCT01407224|No Intervention|Control|No intervention such as training or supervision
89409619|NCT05885256||Trauma Patients|Seeking all patients that meets trauma activation criteria for the amendment of our order set. The participants existing blood from the routine clinical care blood draws will be used to obtain samples.
89409620|NCT05885243|Experimental|ESWT|Group 1 (n:16) will be given once a week, total 5 sessions of ESWT+ home exercise program
89409621|NCT05885243|Experimental|customized insoles|Group 2 (n:16) will be given customized insoles+ home exercise program. Insoles will be used for 12 weeks.
89409622|NCT05885243|Experimental|combined ESWT and customized insoles|Group 3 (n:16) will be given once a week, total 5 sessions of ESWT+ home exercise program. Also, simultaneous insoles will be provided. Insoles will be used for 12 weeks.
89409623|NCT05885204||Sun Yat-sen Memorial Hospital|
89409624|NCT05885204||Renji Hospital, Shanghai Jiaotong University School of Medicine|
89191817|NCT00855088|Experimental|Darunavir, ritonavir, etravirine|Single arm trial looking at the pharmacokinetics of darunavir, ritonavir, etravirine in healthy volunteers.
89191818|NCT00725426|Experimental|1|Bosutinib
88885629|NCT01407237||HIV-infected Individuals|
88885630|NCT01407237||non-HIV-infected Individuals|
88885631|NCT01407289|Experimental|Insulin titration protocol|Patients in care at the Division of Endocrinology will be treated by enhanced version of published best paper based practice insulin titration protocol to control glycaemia in hospitalised patients with type 2 diabetes.
88885632|NCT01407289|No Intervention|Standard care|Patients in care of the Division of Cardiology will be treated using antihyperglycaemic therapy according to standard care.
88885633|NCT01407302||LMA group|patients undergoing general anesthesia with LMA insertion
89191819|NCT00730106||1|Patients with pre-defined alarm symptoms
89191820|NCT00730106||2|Patients without pre-defined alarm symptoms
89191821|NCT02553603|Placebo Comparator|Mild Cognitive Impairment, Placebo|Subjects aged 55 - 85 years, scored between 23- 26 on screening Mini Mental Status Exam, receiving placebo Growth Hormone Releasing Hormone (GHRH).
89191822|NCT02553603|Placebo Comparator|Non-cognitively impaired, Placebo|Subjects aged 55- 85 years, scored between 27-30 on screening Mini Mental Status Exam, receiving placebo Growth Hormone Releasing Hormone (GHRH).
89191823|NCT02553603|Experimental|Mild Cognitive Impairment, GHRH|Subjects aged 55 - 85 years, scored between 23- 26 on screening Mini Mental Status Exam, receiving active Growth Hormone Releasing Hormone (GHRH).
89191824|NCT02553603|Experimental|Non-cognitively impaired, GHRH|Subjects aged 55 - 85 years, scored between 27-30 on screening Mini Mental Status Exam, receiving active Growth Hormone Releasing Hormone (GHRH).
89191825|NCT00730184|Active Comparator|1|Participants receive potassium bicarbonate in dosage of 90 mmol/d. This compound has no other name.
89191826|NCT00730184|Placebo Comparator|2|Participants receive placebo as microcrystalline cellulose. This compound has no other name.
89191827|NCT00807339|Experimental|1|Phase I dose escalation
89191828|NCT03314766||IC-8 IOL|Patients previously implanted with an IC-8 IOL contralaterally or bilaterally under the protocol ACU-P14-029
89191829|NCT00730262|Experimental|Single-Arm|
88885634|NCT01407302||E-tube group|patients undergoing general anesthesia with e-tube
88885635|NCT01407315|Experimental|GlucoMenDay - Multiple sampling (A)|
88885636|NCT01407315|Experimental|GlucoMenDay - Meal/Insulin test (B)|
88885637|NCT01407341|Experimental|Supportive care (ChronOS)|Patients undergo placement of beta-tricalcium phosphate bone graft strips posterolaterally during surgery.
88885638|NCT01407393|Experimental|Glucosanol|Glucosanol
88885639|NCT01407393|Placebo Comparator|Placebo|Placebo
88885640|NCT01407406|Experimental|Chinese Subjects - low dose BIIB023 IV|
88885641|NCT01407406|Experimental|Chinese Subjects - high dose BIIB023 IV|
88885642|NCT01407406|Experimental|Japanese Subjects - low dose BIIB023 IV|
88885643|NCT01407406|Experimental|Japanese Subjects - high dose BIIB023 IV|
88885644|NCT01407406|Experimental|Causasian Subjects - low dose BIIB023 IV|
88885645|NCT01407406|Experimental|Caucasian Subjects - high dose BIIB023 IV|
88885646|NCT01407419|Experimental|Treat to Target Intervention Strategy|Subjects at sites randomized to this arm will be expected to return to the clinic for Monthly Assessments until low disease activity (LDA) defined as CDAI of 10 or less has been achieved. Providers are prompted to accelerate therapy (Treatment Acceleration) at each visit that CDAI is >10 (unless not felt to be medically appropriate or refused by the subject.) Accelerations are expected at least every 3 months, until/unless LDA has been achieved.
88885647|NCT01407419|No Intervention|Control Group Treated with Usual Care|Subjects in this arm will be expected to complete study visits with their rheumatologist/study doctor at Baseline, Month 3, Month 6, Month 9 and Month 12. Data collection will occur at each of those visits. Subjects and Providers will continue managing disease per usual practices and do not receive protocol prompts relative to visit frequency or acceleration of therapy, regardless of disease activity level (by CDAI)
88885648|NCT01407432|Experimental|Folic acid|tablets of 5 mg of folic acid
88885649|NCT01407432|Placebo Comparator|Placebo|Tablets of placebo of folic acid
88885650|NCT01407445|Placebo Comparator|Placebo|1 tablet of placebo/ oral/ 3 times a day for three months
89191830|NCT00862030||1|Study Cohort
89191831|NCT00804531|Experimental|Visipaque - Hydrocortancyl|Administration of two treatments for the experimental arm
89409625|NCT05885204||The Third Medical Centre of Chinese PLA General Hospital|
89004855|NCT00473083|Experimental|Arm 2: Reactive Treatment|"Pts will receive treatment at initiation of rash. Tx is dependent on grading of rash as follows:~Grade 1 or 2A: Topical clindamycin 2%, with hydrocortisone 1% in lotion base applied twice daily until resolution of rash by one grade~Grade 2B: Topical clindamycin 2%, with hydrocortisone 1% in lotion base applied 2x daily and oral minocycline 100mg 2x daily for a min. of 4 weeks and continuing thereafter, as required, until resolution of rash by 1 grade. Scalp lesions will be treated with a topical clindamycin 2%, triamcinolone acetonide 0.1% soln.~Grade 3: Pts will discontinue tx with erlotinib 150mg for 1 week and restart at 100mg once daily.~Tx with topical clindamycin 2%, with hydrocortisone 1% in lotion base applied 2x daily and oral minocycline 100mg 2x daily for a min. of 4 weeks and continuing thereafter, as required, until resolution of rash to Grade 1 or 2A. Scalp lesions will be treated with a topical clindamycin 2%, triamcinolone acetonide 0.1% soln."
89004856|NCT00473083|Experimental|Arm 3: No Treatment Unless Severe (Grade 3)|This is the control group. Patients will be treated only if grade 3 rash develops. For grade 3 rash, treatment will be in accordance with that of Grade 3 rash in Treatment Arm 2.
89004857|NCT00194480|Experimental|PegInterferon|Arm 1: 24 weeks of weekly injections of peginterferon Arm 2: control (no treatment)
89004858|NCT00125606|Active Comparator|conditioning therapy with 12 Gy TBI / cyclophosphamide 120|
89004859|NCT00125606|Experimental|conditioning therapy with 8 Gy TBI / fludarabine 120|
89004860|NCT00472420|Experimental|1|
89004861|NCT00194519|Active Comparator|Acyclovir|
89191832|NCT00804531|Placebo Comparator|Visipaque|Administration of only one treatment in intra discal of visipaque
89191833|NCT00725088|Experimental|1|exercise training group
89191834|NCT00725088|No Intervention|2|control group
89191835|NCT00807729|Active Comparator|ERCP|All ERCP's were performed by one of the authors (JPC), a fulltime faculty member and gastroenterology fellowship instructor in the presence and concurrence of the principal author/ surgeon (SJR). Patients randomized to ERCP/S + LC were scheduled to undergo the endoscopic procedure using fluoroscopy (OEC Diasonics 9400) in the endoscopy suite under moderate sedation (principally intravenous midazolam and meperidine) prior to the intended laparoscopy. Duodenal atony during ERCP was routinely achieved using intravenout glucagon. The laparoscopic cholecystectomy was subsequently performed as soon as technically feasible (i.e. following abdominal gas decompression) following the ERCP
89191836|NCT00807729|Active Comparator|Lap CBDE|LC + LCBDE was performed in a routine fashion by one fulltime faculty member (SJR) with fellowship training in laparoscopy. Cholangiograms were obtained fluoroscopically using the same make and model fluoroscope (OEC Diasonics 9400) as used in ERCP by antegrade contrast flushing through the cystic duct. All fluoroscopy was performed by the principal author (SJR) in the presence of and concurrence with the ERCP endoscopist (JPC). When stones were detected or suspected by cholangiography, transcystic exploration was undertaken by balloon or basket with associated balloon dilation of the sphincter of Oddi A completion cholangiogram was obtained to confirm that all stones were removed. Once the LCBDE was completed, the cystic duct was ligated and the gallbladder removed.
89191837|NCT00866866|Experimental|N-Acetyl Cysteine|
89191838|NCT00866866|Placebo Comparator|Placebo|
89191839|NCT00804765|Experimental|1|Therapeutic education
89191840|NCT00804765|Placebo Comparator|2|
89191841|NCT00855244|Other|BMT survivors|Diagnostic exams
89191842|NCT00312728|Experimental|bevacizumab|
89191843|NCT00866944|Experimental|1|Adecatumumab alone
89191844|NCT00866944|Experimental|2|FOLFOX 4 followed by Adecatumumab
89191845|NCT00866944|Active Comparator|3|FOLFOX 4 alone
89191846|NCT00922155|No Intervention|EBUS|After the PPLs been localized by endobronchial ultrasound(EBUS), patients in the EBUS group received transbronchial biopsy and bronchial washing at the bronchus located by EBUS.
89191847|NCT00922155|Active Comparator|EBUS-GS|After PPLs been localized by EBUS, the EBUS and guide sheath were then inserted to localize the lesion again. Transbronchial biopsy and brushing were done through the guide sheath after the probe been removed.
89004862|NCT00194519|Placebo Comparator|Placebo|
89004863|NCT00206700|Experimental|Arm 1|
89004864|NCT00125645|Experimental|Irbesartan|Tablet Irbesartan 150 mg once daily
89004865|NCT00125723|No Intervention|No Intervention|
89409626|NCT05885204||The First Affiliated Hospital of Nanchang University|
89409627|NCT05885204||Peking University Third Hospital|
89409628|NCT05885204||The Second Xiangya Hospital, Central South University|
89004866|NCT00125723|Other|Intervention|PI Discretion
89004867|NCT00224445|Experimental|Truvada + Ritonavir-boosted Atazanavir|All participants received Truvada plus ritonavir-boosted atazanavir
89409629|NCT05885204||Zhongda Hospital Southeast University|
89409630|NCT05885204||The First Hospital of Jilin University|
89409631|NCT05885204||Second Hospital of Dalian Medical University|
89409632|NCT05885204||Gansu Provincial Hospital|
89409633|NCT05885178||Endovascular therapy|Timely thrombectomy for acute ischemic stroke patients with large vessel occlusion by either stent retriever, thrombus aspiration, others, or combination methods.
89409634|NCT05885178||Best medical management|Patients enrolled in this group received the best medical management.
89409635|NCT05885165|Experimental|Supervised team-based exercise|In this arm, participants will receive guided training by an instructor in teams of 10 on the online platform Zoom.
89409636|NCT05885165|Active Comparator|Unsupervised exercise|In this arm, participants will perform the training individually with the exercises provided on the platform Exorlive, which is a one-way communication platform. However, the first two weeks (5 training sessions) will be conducted in teams of 10 participants with the presence of an instructor who will introduce, demonstrate, and supervise correct form and technique and ensure understanding of the exercise concept.
89409637|NCT05885126|Experimental|Intervention Group|Patients in the intervention group were allowed to paint mandala templates for 30 minutes during chemotherapy treatment after premedication. Before the application, the patients were informed by the practitioner and given a laptop table, mandala coloring books and crayons, they were asked to paint a mandala template of their choice. The ambient light and the position of the laptop table were adjusted appropriately during the intervention to help the participants move freely and eliminate the environmental stimulus. In addition, there was no communication between the patient and the practitioner during the application. The patients in the intervention group were given the materials necessary for painting medallions after the treatment, and they were asked to apply at home for at least 30 minutes the day after the treatment. The patients were supported by telephone to paint while they were at home.
88885651|NCT01407445|Active Comparator|Tribulus terrestris|1 tablet of 250mg/ oral/ 3 times a day for three months
88885652|NCT01407458|Active Comparator|Experimental Group|Children doing additional exercises with upper limbs in physical education class
89191848|NCT03907670||CML patients who will receive imatinib|Patients with chronic myeloid leukemia newly diagnosed, who will receive Tyrosine Kinase inhibitor treatment (imatinib)measure the fluctuations in the levels of sCTLA-4, TGFβ1, and PDMPs, and to clarify the clinical significance of these biomarkers during TKI therapy in patients with CML
89409638|NCT05885126|No Intervention|Control Group|Participants in the control group did not receive any intervention during or after treatment.
89409639|NCT05885100|Experimental|Obesity class 1|
89409640|NCT05885100|Experimental|Obesity class 2|
89409641|NCT05885100|Experimental|Obesity class 3|
89409642|NCT05885087|Experimental|Foley/Balloon catheter arm|Participants were assessed as having a favourable cervix using the modified Bishop score of equal to or more than 7. Three Foley balloon catheters attached side by side were inflated with 60mls each and a gentle traction of 250mls water applied.
89409643|NCT05885048||Cancer female participants|Fertility status before and after gonadotoxic treatment
89409644|NCT05885048||Cancer male participants|Fertility status before and after gonadotoxic treatment
88885653|NCT01407458|Active Comparator|Control Group|Children doing normal physical education exercises
88885654|NCT01407471|Experimental|Clobetasol + Spironolactone|0.05% clobetasol and 5% spironolactone
88885655|NCT01407471|Active Comparator|Clobetasol + Placebo|0.05% clobetasol + inert excipient
88885656|NCT01407471|Active Comparator|Placebo + Spironolactone|Inert excipient + 5% spironolactone
88885657|NCT01407471|Placebo Comparator|Placebo + placebo|Inert excipient
88885658|NCT01407484|Experimental|Treatment|Cortancyl (prednisone) 0,2 mg/kg/day for 3 weeks and 0,1mg/kg/day for 1 week
88885659|NCT01407484|Placebo Comparator|Placebo|Placebo
88885660|NCT01407497|Active Comparator|IA|600 µg i.d. (separate plasmids pools) of DNA priming at weeks 0, 4 and 12 108 pfu i.m. MVA boosting at weeks 24 and 36
88885661|NCT01407497|Placebo Comparator|IB|2 x 0.1 ml of saline solution i.d at weeks 0, 4 and 12 saline solution i.m at weeks 24 and 36
88885662|NCT01407497|Active Comparator|IIA|1200 µg i.d. (separate plasmids pools) of DNA priming at weeks 0, 4 and 12;108 pfu i.m. MVA boosting at weeks 24 and 36
88885663|NCT01407497|Placebo Comparator|IIB|2 x 0.2 ml of saline solution i.d at weeks 0, 4 and 12 ; saline solution i.m at weeks 24 and 36
88885664|NCT01407549|Experimental|Intervention group|The intervention group will participate in the Mindfulness Program consists of one 2-hour session each week for 6 consecutive weeks plus a half day retreat near the end of the intervention.
89409645|NCT05885035|Experimental|Treated with hyperdilute Calcium Hydroxylapatite (CaHA)|Subjects will have 3 treatment sessions at weeks 0, 4, and 8 and a final live assessment visit at week 14. Approximately two syringes of CaHA will be injected per side of the buttocks (at sites with cellulite dimpling) during each of the three treatment sessions.
89409646|NCT05884983||Screening cohort|30-69 years old healthy participants in Zhongshan
89409647|NCT05884970|Active Comparator|FEV1 >90%|Children with lung function FEV1 > 90%
89409648|NCT05884970|Active Comparator|FEV1 80-90%|Children with lung function FEV1 80-90%
89409649|NCT05884970|Active Comparator|FEV1 70-80%|Children with lung function FEV1 70-80%
89409650|NCT05884970|Active Comparator|FEV1 60-70%|Children with lung function FEV1 60-70%
89409651|NCT05884970|Active Comparator|FEV1 < 60%|Children with lung function FEV1 < 60%
89409652|NCT05884944|Experimental|Interventional Group- OMM- Muscle energy|For the OMM treatment group, an osteopathic manipulative treatment protocol will be applied to the lower extremities, specifically muscle energy technique (MET) to the hip, knee, and ankle bilaterally based on the protocol from Atlas of Osteopathic Techniques. The adductor, extensor, and flexor muscles of the hip joint will be treated, the extensors and flexors of the knee joint will be treated, and the plantar and dorsiflexion muscles of the ankle will be treated
88885665|NCT01407549|No Intervention|Control group|Participants in the control group will be assigned to a waiting list group. Participants will be told that they will be eligible for the intervention three months after the completion of a preliminary documentation of their symptoms and additional measures. Participants will complete the same battery of measures according to the same time table as participants in the intervention group.
88885666|NCT01407588|Experimental|Magnetic navigation|
88885667|NCT01407588|Experimental|Manual navigation|
88885668|NCT01407601|Experimental|45 µg MK-7|45 µg MK-7 daily over 6 weeks
88885669|NCT01407601|Experimental|135 µg MK-7|135 µg MK-7 daily over 6 weeks
88885670|NCT01407601|Experimental|360 µg MK-7|360 µg MK-7 daily over 6 weeks
88885671|NCT01407614|Active Comparator|external lumbar drainage|Within 96 hours of initial subarachnoid hemorrhage, patients were randomized for external lumbar drainage (ELD)of cerebrospinal fluid during a maximum of 7 days or standard treatment of subarachnoid hemorrhage without ELD
88885672|NCT01407614|No Intervention|No intervention|In this arm the patients received standard treatment following protocol for patients with subarachnoid hemorrhage
88885673|NCT01407640|Experimental|1|Allergy tests
88885674|NCT01407653|Experimental|virtual reality|
88885675|NCT01407653|Other|usual care|
88885676|NCT01407666|Experimental|Bilateral paravertebral blocks|Bilateral continuous paravertebral blocks for open liver resection
88885677|NCT01407666|No Intervention|epidural block|received thoracic epidural block for open liver resection
89409653|NCT05884944|Sham Comparator|Control Group- Sham- Light touch, not reaching restrictive barrier|Joint articulation without engaging joint barriers The sham group will serve as the control group and will receive a sham-control procedure as outlined in the paper by Wells, et al in which they will undergo voluntary ROM and then passive movement with the same joint movements without reaching their barrier and no isometric contraction (Wells et al. 1999) The proposed sham procedure will occupy the same amount of time as MET treatment.
89409654|NCT05884905|Experimental|short hydration|Normal saline (NSS) 500 ml infusion in 1 hour cisplatin in NSS 100 ml with 20% mannitol 100 ml infusion in 1 hour other chemotherapy infusion in 1 hour (if available) NSS 500 ml infusion in 1 hour, then NSS 500 ml infusion in 2 hours
89409655|NCT05884905|Other|conventional hydration|NSS 1000 ml infusion in 8 hour cisplatin in NSS 100 ml with 20% mannitol 100 ml infusion in 1 hour other chemotherapy infusion in 1 hour (if available) NSS 2000 ml infusion in 16 hour
89409656|NCT05884749|Experimental|P2C Intervention|Participants in this condition will receive the P2C model.
89409657|NCT05884749|Active Comparator|Care as Usual|Participants in this group will receive care as usual supports, and will be waitlisted to receive P2C model supports after 6 months.
89409658|NCT05884723|Experimental|Ketogenic Diet Arm|Participants in this group will be counselled by a registered dietician and then undergo a 4-week preoperative well formulated ketogenic diet. They will record all nutritional uptake during the diet using an app called Cronometer and provide weekly summary reports to the study team.
89409659|NCT05884723|No Intervention|Control Arm|Participants in this group will be counselled by a registered dietician and then undergo a 4-week standard of care diet, as recommended by Canada's Food Guide. They will record all nutritional uptake during the diet using an app called Cronometer and provide weekly summary reports to the study team.
89409660|NCT05884697|Experimental|K-Talk Intervention: Storytelling and AI Chatbot|After completing the pre-test survey, participants from all intervention groups will receive the written information. Subsequently, they will be randomly assigned to one of the intervention groups. The K-Talk group will receive a series of weekly storytelling videos, and access to the chatbot via the web-based platform KakaoTalk for 3 months.
89409661|NCT05884697|Experimental|Storytelling Intervention|After completing the pre-test survey, participants from all intervention groups will receive the written information. Subsequently, they will be randomly assigned to one of the intervention groups. The storytelling intervention group will only be exposed to periodic release of stories via email for 3 months.
89409662|NCT05884697|Experimental|K-Bot (AI Chatbot Intervention) Intervention|After completing the pre-test survey, participants from all intervention groups will receive the written information. Subsequently, they will be randomly assigned to one of the intervention groups. The K-Bot group will only interact with the chatbot via the web-based platform or KakaoTalk for 3 months.
89409663|NCT05884697|Active Comparator|Written Information|This group will only be exposed to written, didactic HPV education materials after the pre-test.
89409664|NCT05884632|Experimental|Treatment arm|Patients will be treated on the prostate bed with Ethos using daily-adaptive modality with the dose of 59 Gy in 20 daily fractions of 2.95 Gy
89409665|NCT05884606|Experimental|non-randomized, pilot study|"This study is a prospective, non-randomized, pilot study to test the impact of the Allurion Digital Behaviour Change Intervention in participants who have been treated with the Allurion Gastric Balloon System. The study consists of the following segments:~Screening and enrolment period (prior to or day of Allurion Gastric Balloon System treatment)~All participants will take part in the Allurion DBCI for 6 months following study enrolment~All participants will complete a 6-month follow-up assessment after completion of the Allurion DBCI"
89409666|NCT05884567|Experimental|experimental|neck isometric exercises will be administered at for 4 weeks and will be evaluuated at baseline, 2nd and after 4 weeks of interventions
89409667|NCT05884567|Active Comparator|control|cervical mobilization will be administered at for 4 weeks and will be evaluuated at baseline, 2nd and after 4 weeks of interventions
89409668|NCT05884502|Experimental|Combination therapy|combination of high-dose rosuvastatin and ezetimibe
89409669|NCT05884502|Active Comparator|Single therapy|high-dose rosuvastatin single administration group
89409670|NCT05884489|Experimental|Intervention group|
89409671|NCT05884463|Experimental|Experimental|Patients underwent both 18F-FDG PET/CT and 18F-FDG PET/CT scan
89409672|NCT05884450|Experimental|Experiment|In the experimental group, acupressure will be applied to the patients by the researchers twice a day, every day for two weeks, for 3 minutes to each point (Lu1, Lu10, P6).
89409673|NCT05884450|No Intervention|Control|No application will be made to the control group.
89409674|NCT05884411|Experimental|LBBAP|This arm will investigate improvement in cardiac function following placement of the LBBA pacing electrode in half the patients.
89409675|NCT05884411|Experimental|Cardiac MRI with devices|This arm will investigate the feasibility of cardiac MRI to be used to measure cardiac function in patients with cardiac devices.
89409676|NCT05884385|No Intervention|No intervention|Surgeons performing procedures under this condition will receive no intervention. They will perform the robotic procedure as they would normally on a day-to-day basis without any change. EMG and EEG monitoring will be performed by collecting data at the various predefined POIs.
89409677|NCT05884385|Experimental|Simulated exercises|When surgeons perform procedures under this condition they perform the initial theatre briefing prior to starting an operating list. They then perform 5 minutes of a preloaded simulated task on the robotic console. These tasks are designed to emulate fundamental skills required to perform robot-assisted laparoscopic surgery. They will then proceed to perform surgery as they normally do whilst undergoing EMG and EEG motoring, collecting data at the predefined POIs.
89531061|NCT04494659|Experimental|Single arm|single dose of Famitinib on Day 1, and co-administered with Rifampicin on Day 16
89535661|NCT03204877|Active Comparator|Melatonin|Four capsules of Melatonin 10 mg is administered orally every hours for four hours during the study day.
89409678|NCT05884385|Experimental|Mental Visualisation|"Mental training scripts based on the different surgical procedures performed by the different specialties were developed using the Mackay nodal model of mental practice(34). This involves breaking down a task into individual steps called nodal points with detailed instructions which also incorporate sensory cues to enhance the mental representation in the eye of participants' minds.~On the day of surgery, surgeons performing the procedure under this condition will consent to patients for their robotic procedure and then proceed to perform the initial theatre briefing prior to starting am operating list.~After this, surgeons will then perform 5 minutes of guided mental visualisation rather than self-produced imagery will be performed using the mental training scripts. They will then proceed to perform surgery as they normally do whilst undergoing EMG and EEG motoring, collecting data at the predefined POIs."
89409679|NCT05884281|Active Comparator|Intervention|
89409680|NCT05884281|Placebo Comparator|Control|
89409681|NCT05884268|Active Comparator|Laparoscopic Cholecystectomy|
89409682|NCT05884268|Placebo Comparator|Control|
89409683|NCT05884255|Experimental|Treatment group A|
89409684|NCT05884255|Active Comparator|Treatment group B|
89409685|NCT05884229|No Intervention|Standard opioid administration|
89409686|NCT05884229|Experimental|SPI-guided opioid administration|
89409687|NCT05884164|Active Comparator|Erector spinae group|Patients will receive erector spinae plane block after general anaesthesia .
89409688|NCT05884164|Active Comparator|Paravertebral block group|Patients will receive paravertebral plane block after general anaesthesia .
89409689|NCT05884151|Active Comparator|Intralesional tranexamic acid in the treatment of melasma|Group A 30 patients treated with Intradermal Tranexamic acid injection (4mg/ml) for preparation an insulin syringe was used with a volume of 1ml containing 0.04 ml of TXA and the reminder being normal saline to ensure 4mg preparation in each insulin syringe
89409690|NCT05884151|Active Comparator|Intrlesional platelets rich plasma in the treatment of melasma|Group B 30 patients prescribed with PRP (1ml) intra-dermally PRP was obtained manually by a two-step procedure using a centrifuge machine. First spin was performed at 1500 RPM for 10 minutes. Second spin was performed at 4000 RPM for 10 minutes. Thus, obtaining a two-part plasma. Upper two third was platelet poor plasma and was discarded. Lower one third was platelets rich plasma. Before injection applying 0.1 ml calcium chloride was added for each 1 ml of PRP to activate the platelets. PRP was injected 1 ml by using 30 G needle (insulin syringe) in each cm2 of melasma.
89409691|NCT05884112|Experimental|Narcolepsy (type1 +type 2) with depression|Stimulate with Double 70mm Alpha Coil figure of 8 stimulator (8-shaped stimulator) (Magstim Company, UK, high frequency magnetic stimulator with force power booster), each treatment will give subjects 1800 pulses, including 60 TBS Section stimulation, each section has 2 seconds of stimulation (30 pulses) and 8 seconds of interval, a total stimulation time of 10 minutes.
89409692|NCT05884112|Sham Comparator|Narcolepsy with depression|Sham-control
89409693|NCT05884047|Other|Virtual reality glasses|"In the research, Samsung Gear VR SM-R323 brand and model SG glasses provided by the researcher were used. Patients were offered four different options to watch as Forest of Serenity, Calm Place, Happy Place, Gala 360 Travel & Relax. Forest of Serenity is a nature video consisting of bird sounds, colorful trees and flowers, and a clear lake where fish can be seen swimming in it. Calm Place is a relaxing video where cycles are shown 24 hours a day, where a person finds himself by the lake in the forest in snowy, rainy sunny weather. In Happy Place, one finds himself in a virtual camp environment where natural events such as dynamically changing weather, day-night cycles, and falling stars are experienced. Gala 360 Travel & Relax is a Paris-Notre Dame museum tour video."
89409694|NCT05884047|Other|Scales|Spielberger State Anxiety Inventory Vital Signs Follow-up Form
89409695|NCT05884034|Experimental|Telerehabilitation group|Self-care educational program via telerehabilitation
89409696|NCT05884034|Active Comparator|Education group|Self-care educational program via informative booklet
89409697|NCT05883982|Experimental|I-PRF|Patients receiving I-PRF injections into temporomandibular joints.
89409698|NCT05883969|Active Comparator|Early intervention for infants|Early family-centered, individualized, goal-directed, intensive, and carried out within the home environment in a cross sectorial setting fortnightly contact shifting between at home visits and virtual meetings for 6 months after an interim diagnosis of CP or high risk of CP
89409699|NCT05883969|Other|Usual care|Standard care consists rehabilitation offered by the local hospital/community or other private initiatives when diagnosed with CP or high risk of CP. The approach, frequency, and location (at home or rehabilitation centers) is varied
89409700|NCT05883943|Experimental|Cook® Venous Valve System|
89531062|NCT03341351|Active Comparator|Instructional video|The modified beef tongue video group will be given an instructional video created using the modified beef tongue model to show anatomy and proper repair of the laceration.
89004868|NCT00194753|Experimental|1|Weekly doxorubicin (24 mg/m2 IV) with daily oral cyclophosphamide (60 mg/m2 PO) for 12 weeks with G-CSF support days 2 - 7 of each week followed by weekly paclitaxel (80 mg/m2 IV) for 12 weeks.
88885678|NCT01407679|Experimental|Alitretinoin|
88885679|NCT01407705||Control Group|"No diagnosis of cervical degenerative or traumatic disease~30 to 80 years of age~Ability of volunteers to tolerate 1 hr examination"
89004869|NCT00125879|Experimental|1|
89004870|NCT00125918|Placebo Comparator|1|Placebo
89004871|NCT00125918|Active Comparator|2|2.5 mg tadalafil
89004872|NCT00125918|Active Comparator|3|10 mg tadalafil
89004873|NCT00125918|Active Comparator|4|20 mg tadalafil
89409701|NCT05883917|Experimental|robot assisted gait training|Gait training using SUBAR® (Cretem, Korea) proceeded by adjusting parameters (gait speed, step length, and degree of knee flexion) according to the patient's leg length and gait function. The parameters were set to the maximum levels tolerated by the patient. The patients underwent 30 min of robot-assisted training using SUBAR® with 30 min of conventional physiotherapy, 5 days a week for 12 weeks.
88885680|NCT01407705||Disease (Non-healthy) Group|"Cervical Spinal Cord:~Clinical and Radiographic evidence of cervical spondylotic myelopathy~18 to 80 years of age~Safe and stable clinical scenario to undergo imaging~Awake, alert patient able to cooperate with physical examination~Give written informed consent prior to any testing under this protocol~Degenerative Disease Group:~Have signs or symptoms consistent with spinal cord injury.~Be diagnosed with cervical spondylosis (degenerative disease).~Traumatic Group:~• A spinal cord injury associated with a traumatic event."
89004874|NCT00125918|Active Comparator|5|40 mg tadalafil
89409702|NCT05883891||severe alcoholic hepatitis|Patients admitted with a clinical diagnosis of severe alcoholic hepatitis eligible to corticosteroid treatment. Prothrombin time at diagnosis was registered to evaluate wether it correlated with Lille score at day 7 and therefore response to standard medical treatment.
89409703|NCT05883878|No Intervention|Standard of Care|Participants will receive traditional lifestyle advices in order to reduce the risk.
89409704|NCT05883878|Experimental|Genetic testing - PRS|Participants will receive the information of the genetic cardiovascular risk (PRS) and personalized advices.
89409705|NCT05883878|Experimental|Digital intervention - app and wearable device|Participants will receive an app and a wearable device for the evaluation of various parameters.
89409706|NCT05883878|Experimental|Digital intervention and genetic testing - PRS|Participants will receive both app and wearable device and PRS information
89409707|NCT05883865||fenofibrate group|Women with TG level ≥10mM receive fenofibrate micronized capsule（200mg ，qd）or table（160mg ，qd）for at least 1 week during pregnancy.
89409708|NCT05883865||negative group|Pregnant women with TG level ≥10mM without fenofibrate treatment.
89409709|NCT05883839||Student Group|"Three scales (knowledge, attitude, self-efficacy) in the Sexual Healthcare Questionnaire will be applied to 2nd and 3rd year nursing students. The scales will be re-administered to at least 30 students within 4 weeks."
89409710|NCT05883813|Active Comparator|Group 1|suboccipital muscle release for 10 mins + 5 min general warm up exercises + 10 min hot pack + 10 min TENS + trapezius stretching with 3 sec hold and 5 reps
89409711|NCT05883813|Experimental|Group 2|suboccipital muscle release for 10 mins + SNAGS: 3 glides with 10 sec hold of each glide + 5 min general warm up exercises + 10 min hot pack + 10 min TENS + trapezius stretching with 10 sec hold and 5 reps
89409712|NCT05883761||HIV-positive DTG preconception|HIV status defined as a documented positive result in the perinatal and/or maternity register or other clinical source record. Preconception drug exposure determined using date of DTG initiation and LMP date or gestational age at delivery (if LMP not available). ART at conception is defined as maternal ART that started up to 8 weeks after the calculated LMP date, which would be up to 6 weeks after the estimated date of conception. As this is the group of interest, sample size target was determined as 10,000.
89409713|NCT05883761||HIV-negative|Women with the last HIV test result recorded during pregnancy or labor and delivery as negative.
89409714|NCT05883761||HIV-positive on non-DTG ARV preconception|HIV status defined as a documented positive result in the perinatal and/or maternity register or other clinical source record. Preconception drug exposure determined using date of ARV initiation (e.g., efavirenz) and LMP date or gestational age at delivery (if LMP not available). ART at conception is defined as maternal ART that started up to 8 weeks after the calculated LMP date, which would be up to 6 weeks after the estimated date of conception. Other groups to be included as informed by the data (e.g., HIV+ not on ART a conception, unknown ART at conception, etc).
89409715|NCT05883722|Experimental|RA group|The RA group received adjunctive right atrial ablation in addition to left side ablation.
89409716|NCT05883722|Active Comparator|Control group|The control group received left side ablation only.
89409717|NCT05883709||Cohort 1|Tafa combination therapy group, which could include Tafa combined with lenalidomide, Tafa combined with Lenalidomide plus BTK inhibitors, Tafa combined with Lenalidomide plus chemotherapy (including ADC)
89409718|NCT05883709||Cohort 2|Tafa combination therapy group followed by sequential CAR T or transplantation
89409719|NCT05883696||Descriptive patient group|The research nurse will fill in the documents in Swedish Palliative care guide (S-PCG) together with the patient.
89409720|NCT05883683||Colorectal Cancer|Colorectal cancer patients with advanced or recurrent tumors
89004875|NCT00224523|Experimental|Arm 1|
89191849|NCT03907670||CML patients who will receive nilotinib|Patients with chronic myeloid leukemia newly diagnosed, who will receive Tyrosine Kinase inhibitor treatment(nilotinib)measure the fluctuations in the levels of sCTLA-4, TGFβ1, and PDMPs, and to clarify the clinical significance of these biomarkers during TKI therapy in patients with CML
89409721|NCT05883670||Cohort 1|"The medication plan is determined by gynecological oncology or oncology physician. Select the treatment plan containing serplulimab (single drug and/or combination), the other anti-tumor treatment schemes without intervention.~The recommended dose of serplulimab is 300 mg IV, Day1 of each cycle. Apply the drug on the first day of each cycle until the disease progresses or intolerable toxicity occurs.The combined drugs is decided by the doctor.~In this non-interventive study, do not change or interfere with the current medical treatment of the recruited patients."
89409722|NCT05883657|Experimental|Condition 1 : Prototypes (816-v1) every weeks|Application on the brown spots of the face and the hands for the prototypes (816-v1) at D0, D7, D14, D21, D28, D35, D42, D49, D56, D63, D70 and D77.
89409723|NCT05883657|Experimental|Condition 2 : Prototypes (816-v1) every two weeks|Application on the brown spots of the face and the hands for the prototypes (816-v1) at D0, D14, D28, D42, D56 and D70.
89409724|NCT05883618||Radiologically confirmed traumatic spine injury|
89409725|NCT05883605|Other|one population of normotensive and hypertensive|treated and untreated normotensive and hypertensive patients
89409726|NCT05883592||Fabulous Thoracic Aortic Stent System|
89409727|NCT05883553|Experimental|Epithesis group|Participants receive an Elator device which was measured to the size of their phallus.
89535662|NCT03204877|Placebo Comparator|Placebo|Four capsules of placebo is administered orally every hours for four hours during the study day.
89409728|NCT05883553|Active Comparator|Prosthesis group|Participants receive a Zephyr ZSI 475 FTM internal erection prosthesis device as the current standard of care in our hospital. A healing phase of at least six weeks is respected.
89409729|NCT05883527||Health and Care Professionals|GP's, nurses, social workers, mental health professionals, support workers, Independent mental capacity advocates (IMCA), and other HCP's working in GP surgeries and integrated social care hubs. Safeguarding leads in GP surgeries, social care organisations and other relevant organisations. Professionals from third-sector organisations who have previous experience of safeguarding.
89409730|NCT05883527||People Living with Dementia|Who have been involved in the safeguarding process and have capacity to consent.
89409731|NCT05883527||Paid carers of people living with dementia|Who have been involved in the safeguarding process.
89409732|NCT05883527||Family members of people living with dementia|Who have been involved in the safeguarding process.
89409733|NCT05883514|Experimental|Intervention group|Group one (study group, 35 patients): received the Motivational interviewing intervention.
89409734|NCT05883514|No Intervention|Control group|Group two(the control group, 35 patients): will receive routine hospital care such as medication administration, assessment of vital signs, and hygienic care.
89409735|NCT05883501|Experimental|Group I|"Pregnant women will be given love cards containing positive affirmations that will be trained outside the classroom by asking the mother to practice alone once a day between waking up, before bed, or when relaxing.~The suggestions will be implanted using simple language, easy to understand, in detail, and straightforward. For example, From now, I know how to take care of myself in pregnancy and trust in my ability to birth my baby.~Love cards will be developed through literature studies and expert tests containing positive affirmations for pregnancy and childbirth."
89409736|NCT05883501|Experimental|Group 2|"The researcher will be used the heel of the hands, moving along the spine; using the palms moving hands with rocking movements from the top of the shoulder blade to the backbone; pressing fingertips, along both sides of the spine from the neck to the backbone and then stroking upward from the hip to the neck; stroking the shoulder muscles(trapezius); inching up the back, using fingertips placed on sides of spine, starting from the hipbone to the neck and then reversing the direction downward using fingertips in a raking fashion; massaging the lower back from the backbone across the waistline using the heel of the palm to make large circles; long gliding strokes from the hip up and over the shoulder (Nair ,. 2020 ; El-Hosary et al,. 2019).~Back massage will be done in four sessions each session takes 10 minutes and will be performed every week."
89409737|NCT05883475||Patients with shoulder pain|"Those who scored above 0 for shoulder pain on the Visual Analog Scale (VAS) were assigned to the group with shoulder pain"
89409738|NCT05883475||Patients without shoulder pain|"Those who scored 0 for shoulder pain on the Visual Analog Scale (VAS) were assigned to the group without shoulder pain"
89409739|NCT05883436|Other|Single Arm Observational|Cervical Interbody Cage
89004876|NCT00472303|Placebo Comparator|Matching Placebo after Tapentadol in Titration Phase|Oral Tapentadol 100 mg to 250 mg twice daily. Participants randomized to placebo in the maintenance phase received 100 mg tapentadol prolonged release twice daily for 3 days to taper them off the tapentadol dose they had received in the Titration Phase. From the 4th day (Day 18) all participants received matching placebo in the maintenance (i.e. randomized withdrawal) phase.
89004877|NCT00472303|Active Comparator|Morphine Controlled Release|Oral Morphine 40 mg to 100 mg twice daily. Capsule taken orally, twice daily, morning & evening with preferably 12 hours (not less than 6 hours) between doses. Maintenance phase: continuing on dose level established in titration phase.
89409740|NCT05883423|Experimental|FPCMP-Old Age group|The program mainly refers to Ha and Park (2020), and extends the development of the 12-week FPCMP-Old Age program, which combines sports and health integrated nursing management courses (nutrition, psychosocial, drug and other health management activities). Twice a week, 2 hours each time, 12 weeks, a total of 24 times, the execution period is scheduled to be from July to the end of September.
89004878|NCT00472303|Experimental|Tapentadol Prolonged Release|Oral Tapentadol 100 mg to 250 mg twice daily. Tablet taken orally, twice daily, morning & evening with preferably 12 hours (not less than 6 hours) between doses.
89409741|NCT05883423|No Intervention|usual group|Participate in the original health promotion activities of the community group
89409742|NCT05883397|Active Comparator|HBOT|Participants will be treated in a multiplace chamber (HAUX-Life-Support GmbH) for a total of 60 daily sessions, five days a week. Each session will consist of 90 minutes exposure to 100% oxygen at 2 ATA (atmospheres), with five-minute air brakes every 20 minutes.
89409743|NCT05883397|Active Comparator|HBOT + hippocampal training|"Participants will be treated in a multiplace chamber (HAUX-Life-Support GmbH) for a total of 60 daily sessions, five days a week. Each session will consist of 90 minutes exposure to 100% oxygen at 2 ATA, with five-minute air breaks every 20 minutes.~Hippocampal training: This will combine physical and cognitive training. Training will be given 3 times per week, prior to the next HBOT, and more than 20 hours after the last HBOT session."
89409744|NCT05881720|Experimental|Group 1 (N = 40)|Group 1 (N = 40) received sacubitril/valsartan (target dose, 100 mg twice daily) in addition to recommended therapy according to physician's judgment.
89409745|NCT05881720|Experimental|Group 2 (N = 40)|group 2 received valsartan (target dose, 80 mg twice daily) in addition to recommended therapy according to physician's judgment.
89409746|NCT05881564|Active Comparator|Blood prime for cardiopulmonary bypass|
89409747|NCT05881564|Active Comparator|clear prime for cardiopulmonary bypass|
89004879|NCT00471718|Experimental|Phase I/II: Chemotherapy ABT-751|"Phase I: Patients receive oral ABT-751 twice daily on days 1-7 and 15-21.~Phase II: Patients receive ABT-751 twice daily"
89004880|NCT00194870|Other|Digital EEG|Digital EEG
89004881|NCT00206934|Placebo Comparator|1|
89004882|NCT00206934|Placebo Comparator|2|
89004883|NCT00224640|Experimental|1|Iron chelating intervention
89535663|NCT03220399|Experimental|NVP-1603-1 (P)|"Drug: NVP-1603-1~1capsule, oral dosing"
89535664|NCT03220399|Experimental|NVP-1603-2(T)|"Drug: NVP-1603-2~1Tablet, oral dosing"
89409748|NCT05881096|Experimental|START (Startle Adjuvant Rehabilitation Therapy)|Participants in this group practice a functional reaching task with the START condition (startling acoustic stimuli applied during 33% of trials).
88885681|NCT01407744||Correlative studies|Archived tumor tissue samples are analyzed by laboratory biomarker analysis for cellular density, mitotic count, tumor cell invasion, hTERT expression, telomere dysfunction, 1q gain, 9p deletion, and genetic mutations by IHC, Affymetrix MIP arrays, and FISH. Results are then correlated with patient-outcome variables and known risk factors, namely gender, age at diagnosis, tumor location infratentorial vs. supratentorial), tumor grade (differentiated vs anaplastic), and extent of surgery as well as pathologic variables.
88885682|NCT01407783|Experimental|Problem Solving Tools|The home visitation nurse will teach and utilize the problem solving tools to help low-income depressed mothers. It is a brief treatment with the a non-pathologizing intervention being done in 4-8 sessions.
88885683|NCT01407783|No Intervention|Enhanced Referral|
88885684|NCT01407796|Experimental|Endotoxin and [18F](+/-)NOS|All volunteers in this study will receive endotoxin in a single segment of the lung to induce mild, self-limited inflammation. They will also be imaged before and after endotoxin instillation with the novel PET tracer F-18 (+/-) NOS
88885685|NCT01407809|Experimental|Intervention|
88885686|NCT01407822|Experimental|Erlotinib arm|In the neo-adjuvant treatment phase, erlotinib 150 mg/day taken orally for 6 weeks(42 days).In the post-surgery phase, erlotinib 150mg/day taken orally for 1 year or till disease progression or unacceptable toxicity.
88885687|NCT01407822|Active Comparator|Chemo arm|In the neo-adjuvant treatment phase, patient will receive gemcitabine 1250mg/m2 IV on day 1 and day 8, and cisplatin 75mg/m2 on day 1 of a 3-week schedule for 2 cycles. In the post-surgery phase, Gemcitabine 1250mg/m2 IV on day 1 and day 8, and cisplatin 75mg/m2 on day 1 of a 3-week schedule for 2 cycles or till disease progression or unacceptable toxicity.
88885688|NCT01407835|Experimental|1|"Dactylis glomerata allergen extract at 4 different concentrations~Positive control~Negative control"
88885689|NCT01407848|Experimental|Furosemide|1 mg/kg/Ed
88885690|NCT01407848|Active Comparator|Saline 0,9%|1ml/kg/Ed
88885691|NCT01407861|Active Comparator|Relaxation training|Patients participate in a relaxation training program under expert guidance at least three times a week over 12 weeks.
88885692|NCT01407861|Active Comparator|Aerobic endurance training|Patients participate in a moderate aerobic endurance training program under expert guidance three times a week over 12 weeks.
88885693|NCT01407887|Active Comparator|artesunate, amodiaquine methylene blue|two arms, open randomized controlled study in children with uncomplicated falciparum malaria in Burkina Faso. Intervention: artesunate (AS) - amodiaquine (AQ) - methylene blue (MB) control: artesunate (AS) - amodiaquine (AQ)
88885694|NCT01407887|No Intervention|artesunate amodiaquine|The control group will receive once daily a fixed dose AS-AQ over three days.
88885695|NCT01407900|Placebo Comparator|5% Dextrose in Water|Infusion of D5W
88885696|NCT01407900|Active Comparator|CD-NP|CD-NP as a four hour infusion at 10 ng/kg/min IV
88885697|NCT01407939||Children, Adults|3- to 15-year old children and their parent (adults
88885698|NCT01407965|Experimental|Ertapenem|"Free tissue kinetics of ertapenem in fatty tissue and intraperitoneal fluid in mg/L~Free and bound plasma concentration of ertapenem or meropenem in mg/L"
88885699|NCT01407965|Experimental|Meropenem|Free tissue kinetics of meropenem in fatty tissue and intraperitoneal fluid in mg/L up to 24 hours after administration. Free and bound plasma concentration of meropenem in mg/L.
88885700|NCT01407978|Active Comparator|Vaccination with Fluval AB Novo|"Vaccination with Fluval AB Novo trivalent influenza vaccine with 6 μg HA/0.5ml/strain active ingredient content and aluminium phosphate gel adjuvant.~Dose: 0.25 ml /total 3x3 μg HA/ in age group 3-12 years, 0.5 ml /total 3x6 μg HA/ in age group 12-18 years, single dose."
88885701|NCT01407978|Active Comparator|Vaccination with Fluval AB|"Vaccination with Fluval AB trivalent influenza vaccine with 15 μg HA/0.5ml/strain active ingredient content and aluminium phosphate gel adjuvant.~Dose: 0.25 ml /total 3x7.5 μg HA/ in age group 3-12 years, 0.5 ml /total 3x15 μg HA/ in age group 12-18 years, single dose."
88885702|NCT01407978|Experimental|Vaccination with Fluval P|"Vaccination with Fluval P monovalent influenza vaccine with 6 μg HA/0.5 ml active ingredient content and aluminium phosphate gel adjuvant.~Dose: 0.25 ml /total 3 μg HA/ in age group 3-12 years, and 0.5 ml /total 6 μg HA/ in age group 12-18 years, single dose."
88885703|NCT01407991|Experimental|Length or graph method|The graph method is based on the infants' length determined by measurement using a length board and plotted on a graph derived from a formula to determine the depth for tube insertion (graph method). The graph method has been tested in the pediatric population but not in infants under six months of age (Klazner, Luke and Scalso, 2002). Using a graph method might reduce some of the variability in placement. We propose to extend the Klazner, Luke and Scalso (2002) study in the infant population.
88885704|NCT01407991|Active Comparator|NEM method for NG/OG tube placement|Standard method- measure distance from the mouth to the ear and then the ear to mid abdomen and mark the tube to insert to that length. Nose to ear to mid-xiphoid-umbilicus (NEM).
88885705|NCT01408004|Experimental|Alternating regimen|In the experimental arm (Arm A) alternating treatment will consist of 8 weeks of Pazopanib 800 mg qd alternated by 8 weeks of Everolimus 10 mg qd until first progression(PD per RECIST 1.1)followed thereafter by Pazopanib (when PD after 8 weeks of Everolimus)or Everolimus (when PD after 8 weeks of Pazopanib) monotherapy until second progression.
88885706|NCT01408004|Active Comparator|Sequential treatment|The comparative arm (Arm B) will be the standard regimen of Pazopanib (800 mg qd continuously) until progression, followed thereafter by Everolimus (10 mg qd continuously) until progression.
88885707|NCT01408056|Experimental|Timolol 0.5% Gel Forming Solution (GFS)|Half of enrolled subjects will receive topical Timolol
89409749|NCT05881096|Sham Comparator|Control|Participants in this group will practice a functional reaching task without the START (Startle Adjuvant Rehabilitation Therapy) intervention
89409750|NCT05879016|Experimental|Group 1|Functional Correction Technique
89409751|NCT05879016|Experimental|Group 2|Fascia Correction Technique
89409752|NCT05879016|Experimental|Group 3|Star Taping Technique
89409753|NCT05879016|Sham Comparator|Group 4|I taping technique without tension
89409754|NCT05876884|Experimental|Hypothermic Neonates (90)|Any neonate who been identified as in need of thermal care defined as having a moderate hypothermic temperature (32.0 - 36.0°C) as the last temperature recorded in hospital chart, or during recruitment procedures will be placed on the Celsi Warmer mattress
88885708|NCT01408056|Active Comparator|Mupirocin 2% ointment|Half of enrolled subjects will receive Mupirocin
89409755|NCT05873725||Follitropin delta + hCG|Combination of follitropin delta and serial hCG injections at individualized doses, where dosing regimen was determined according to AMH and weight in women undergoing an IVF antagonist cycle
89409756|NCT05873725||Follitropin delta + HP-hMG|Combination of follitropin delta and highly-purified human menopausal gonadotropin (HP-hMG) where dosing regimen was determined according to AMH and weight in women undergoing an IVF antagonist cycle
89409757|NCT05873166|Experimental|Bilateral pressure release in Flexor Brevis Digitorum in subjects with latent trigger point|Bilateral pressure release in Flexor Brevis Digitorum in subjects with latent trigger point
89409758|NCT05873166|Sham Comparator|Bilateral non emission Laser in latent trigger points of the Flexor digitorum Brevis Muscle|
89409759|NCT05871398|Placebo Comparator|placebo group|
89409760|NCT05871398|Active Comparator|tegoprazan group|
89409761|NCT05864469|Experimental|12-week psychosocial dyadic intervention|The 12-week psychosocial dyadic intervention will comprise six weekly 60-min telephone-based sessions, followed by two weekly and two bi-weekly telephone follow-ups.
89409762|NCT05864469|No Intervention|Usual care|Participants in the control group will receive the usual care provided by the clinical team in the hospital
89409763|NCT05860530|Other|Test-reference|Administration order: The test olaparib tablets for 7 days, then the reference olaparib tablets for 7 days.
89409764|NCT05860530|Other|Reference-test|Administration order: The reference olaparib tablets for 7 days, then the test olaparib tablets for 7 days.
89409765|NCT05859451|No Intervention|Smokers|Participants subject to an orthopedic surgery (does not want to quit smoking conventional cigarettes) will continue smoking conventional cigarettes ad libitum for a period of 6 month post surgery
89409766|NCT05859451|Experimental|Smokers willing to switch to THS|Participants subject to an orthopedic surgery (currently smoking conventional cigarettes) will start to used THS ad libitum for a period of 6 month post surgery
89409767|NCT05859451|Active Comparator|Ex Smokers|Participants subject to an orthopedic surgery will not smoke cigarettes or use electronic nicotine deliver systems for a period of 6 month post surgery
89409768|NCT05858450||Same day|Pfizer-BioNTech mRNA bivalent COVID and flu on the same day
89409769|NCT05858450||COVID alone|Pfizer-BioNTech bivalent COVID only
89409770|NCT05858450||flu alone|influenza vaccine of any type only
89409771|NCT05849272|Experimental|Toludesvenlafaxine hydrochloride sustained-release tablets 80-160 mg group|orally once a day
88885709|NCT01408069|Experimental|MIGRANE|1 to 2 tablets ergotamine 1mg + caffeine 100mg + acetylsalicylic 350 mg + homatropine 1,2 mg
88885710|NCT01408069|Active Comparator|PARCEL|1 to 2 tablets(ergotamine 1mg + paracetamol 450 mg + caffeine 40 mg)
88885711|NCT01408095|Experimental|LY2608204|80 to 400 mg, Doses will be titrated to reach glycemic targets during the first 4 weeks. The starting dose level depends on the participant's HbA1c level measured at Screening. Administered orally, daily for 12 weeks
88885712|NCT01408095|Active Comparator|Glimepiride|1 to 6 mg, Doses will be titrated to reach glycemic targets during the first 4 weeks. Administered orally, daily for 12 weeks
89409772|NCT05839340|Experimental|Neurally Adjusted Ventilatory Assist|Infants will first be ventilated with NAVA for four hours. Following this, they will undergo a 20-minute stabilisation period prior to ventilating with assist control ventilation (ACV).
89409773|NCT05839340|Experimental|Assist Control Ventilation (ACV)|Infants will first be ventilated with ACV for four hours. Following this, they will undergo a 20-minute stabilisation period prior to ventilating with non-invasive neurally adjusted ventilatory assist.
88885713|NCT01408108|Active Comparator|Lightweight mesh repair|Laparoscopic hiatal repair with sub-lay partially absorbable lightweight mesh
88885714|NCT01408108|Active Comparator|Primary crural repair|Laparoscopic primary posterior crural repair
88885715|NCT01408121||African-American on clopidogrel|
88885716|NCT01408121||African-American on prasugrel|
88885717|NCT01408121||Caucasian on clopidogrel|
88885718|NCT01408121||Caucasian on prasugrel|
89409774|NCT05836675|Experimental|Experimental Intradialytic exercise|Aerobic, resistance and Kegel exercises
89409775|NCT05831241|Experimental|Ashwagandha|"KSM-66 Ashwagandha is the active ingredient in Waithania somifera, a medicinal plant in Indian medicine. Ashwagandha is known as an adaptogen, an herb in capsule form that protects the body from stress.~After enrollment in the study, 50% participants will be randomly assigned to take one capsule of KSM 66 Ashwagandha (300 mg) two times daily after breakfast and every night at bedtime with food, preferably 30 minutes before the anticipated sexual intercourse with a glass of water for 8 weeks."
89531063|NCT03341351|Active Comparator|Instructional workshop|The group randomized to the modified beef tongue instructional workshop will undergo an interactive workshop using the modified beef tongue model to show anatomy and proper repair of the laceration.
89409776|NCT05831241|Placebo Comparator|Placebo|"Placebo means that the capsules will not contain Ashwagandha but some other inactive substance. By using placebo, investigators will know whether the positive results are because of Ashwagandha or are because of psychological factors. For example, the subject may feel that her condition is improved because she is expecting the capsules to be helpful.~After enrollment in the study, 50% participants will be randomly assigned to take one capsule of placebo two times daily after breakfast and every night at bedtime with food, preferably 30 minutes before the anticipated sexual intercourse with a glass of water for 8 weeks."
89409777|NCT05830799|Experimental|Experimental: C21|C21, single dose, oral administration twice daily, for 15 days
89409778|NCT05827523|Experimental|HIPEC|Interval cytoreductive surgery with HIPEC
89409779|NCT05827523|No Intervention|No HIPEC|Interval cytoreductive surgery without HIPEC
89409780|NCT05826470|Experimental|Laser Ablation|TRANBERG® Transperineal Micro Ultrasound guided laser ablation of Prostate Cancer.
89409781|NCT05803928|Experimental|radiofrequency ablation + Lenvatinib +Sintilimab|"Experimental: radiofrequency ablation + Lenvatinib +Sintilimab Radiofrequency ablation: ultrasound-guided percutaneous radiofrequency ablation for recurrent hepatocellular carcinoma. After local anesthesia and intravenous sedation, the unipolar needle was gradually inserted into the lesion and placed at the deepest edge of the lesion. Ablation electrodes are unipolar needles with bare ends of 2 or 3cm (depending on tumor size).~Lenvatinib: (TBILI<2 times the upper limit of normal) about 3 to 7 days after treatment. The dosage and usage of the regimen were 8mg qd po (body weight < 60kg) or 12mg qd po (body weight ≥60kg).~Sintilimab: About 3 to 7 days after radiofrequency ablation, (TBILI<2 times the upper limit of normal). The dosage was 200mg with 100ml saline and intravenous infusion, every 3 weeks for a course of treatment. The longest course of treatment is 24 months."
89409782|NCT05803928|Active Comparator|radiofrequency ablation|Experimental group: radiofrequency ablation Radiofrequency ablation: ultrasound-guided percutaneous radiofrequency ablation for recurrent hepatocellular carcinoma. After local anesthesia and intravenous sedation, the unipolar needle was gradually inserted into the lesion and placed at the deepest edge of the lesion. Ablation electrodes are unipolar needles with bare ends of 2 or 3cm (depending on tumor size). The ablation power is 150W (range from 100 to 200W). In general, the average ablation time per lesion is about 12 minutes (ranging from 10 to 15 minutes).
89409783|NCT05799911|Experimental|Molecular hydrogen|Hydrogen-rich water supplied in 420-ml packages. 3 days before testing day - 3 packages per day, testing day - 6 packages, 15 packages in total.
88885719|NCT01408160|Experimental|Treatment (Combotox, cytarabine)|Patients receive high-dose cytarabine IV over 2-3 hours every 12 hours on days 1-3 and deglycosylated ricin A chain-conjugated anti-CD19/anti-CD22 immunotoxins IV over 4 hours on days 8, 10, and 12. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
88885720|NCT01408173|Experimental|NPC-11|"Loading Dose (Day 1): Caffeine citrate 20 mg/kg body weight will be administered intravenously using a syringe infusion pump over 30 minutes.~Maintenance Dose (Day 2～Day 10): After an interval 24 hours, caffeine citrate 5 mg/kg body weight will be administered intravenously (over 10 minutes) or orally if the patients will be able to receive oral administration once a day. The maintenance dose can be increased to a maximum 10 mg/kg caffeine citrate once a day if apnea persists."
88885721|NCT01408186|Active Comparator|Rabeprazole|Tablet 20mg daily for 12 months
88885722|NCT01408186|Active Comparator|Famotidine|Tablet 40mg daily for 12 months
88885723|NCT01408199|Experimental|Lenalidomide Group|
88885724|NCT01408212|Experimental|Acupuncture therapy|
88885725|NCT01408238|Experimental|1|"Secale cereale allergen extract at 4 different concentrations~Positive control~Negative control"
88885726|NCT01408264|Active Comparator|0.035 guidewire|conventional 0.035 guidewire
88885727|NCT01408264|Active Comparator|Olympus Visiglide 0.025 guidewire|Olympus Visiglide 0.025
88885728|NCT01408290|Experimental|FAB-6011|- One 0.5 mL injection of FAB-6011 trivalent influenza vaccine containing 6μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens (32 subjects aged 18-60 years /Group 2A/ and 32 subjects aged over 60 years /Group 2E/).
88885729|NCT01408290|Experimental|FAB-9011|- One 0.5 mL injection of FAB-9011 trivalent influenza vaccine containing 9μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens (32 subjects aged 18-60 years /Group 3A/ and 32 subjects aged over 60 years/Group 3E/).
88885730|NCT01408290|Experimental|FLUVALAB|- One 0.5 mL injection of FLUVAL AB trivalent influenza vaccine containing 15μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens (32 subjects aged 18-60 years /Group 4A/ and 32 subjects aged over 60 years/Group 4E/).
88885731|NCT01408290|Experimental|FAB-3511|- One 0.5 mL injection of FAB-3511 trivalent influenza vaccine containing 3.5μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens (32 subjects aged 18-60 years /Group 1A/ and 32 subjects aged over 60 years /Group 1E/).
89409784|NCT05799911|Placebo Comparator|Placebo|Tap water supplied in 420-ml packages. 3 days before testing day - 3 packages per day, testing day - 6 packages, 15 packages in total.
89409785|NCT05798091|Experimental|Supportive-expressive group therapy|An intervention is based on the evidence-based supportive-expressive approach that was designed by an interprofessional team from psychiatry, social work, physiatry and occupational therapy, along with patient advisors. This SEGT approach has been modified, in both content and process, to specifically address the needs of limb loss inpatients.
89409786|NCT05798091|Active Comparator|Treatment as usual|Standard care for impatiens with limb loss at St. John's Rehab - Sunnybrook Health Sciences Centre. Patients may be referred to social work and/or a psychiatrist to address their mental health needs. As well, members of the interprofessional team provide psycho-social supports where needed.
89409787|NCT05787054|Active Comparator|Single scan|Normal screening at 28-32 weeks as currently recommended
89409788|NCT05787054|Experimental|Longitudinal scan|Early and late ultrasound screening with a scan at 35-37 weeks to detect late iugr
89409789|NCT05776368|Experimental|Sub-study E1, arm 1, patients and tool motor training|patients undergo a 30 minutes tool motor training and two linguistic tasks (one before and one after).
88885732|NCT01408316|Experimental|Part 1 (Crystalline vs. Amorphous)|Volunteers in part 1 of the study will initially receive either crystalline PX-866 tablets or amorphous PX-866 capsules, then after seven days, the same volunteers will respectively cross-over to receive the alternate amorphous PX-866 capsules or crystalline PX-866 tablets.
89409790|NCT05776368|Experimental|Sub-study E1, arm 2, patients and hand motor training|patients undergo a 30 minutes hand motor training and two linguistic tasks (one before and one after).
89409791|NCT05776368|Experimental|Sub-study E1, arm 3, patients and no motor training (control group)|patients only undergo two linguistic tasks separated by a 30-minutes break (without motor activity (control group)).
89409792|NCT05776368|Experimental|Sub-study E1, arm 4, healthy volunteers and tool motor training|healthy volunteers undergo a 30 minutes tool motor training and two linguistic tasks (one before and one after).
89409793|NCT05776368|Experimental|Sub-study E1, arm 5, healthy volunteers and hand motor training|healthy volunteers undergo a 30 minutes hand motor training and two linguistic tasks (one before and one after).
89409794|NCT05776368|Experimental|Sub-study E1, arm 6, healthy volunteers and no motor training (control group)|healthy volunteers only undergo two linguistic tasks separated by a 30-minutes break (without motor activity (control group)).
88885733|NCT01408316|Experimental|Part 2 (Crystalline Food Effect)|Volunteers in part 2 of the study will receive two single dose treatments of PX-866 crystalline tablets initially administered in either fed or fasted state, then after at least seven days, the same volunteers will respectively cross-over to receive PX-866 tablets in the alternate fed or fasted state.
88885734|NCT01408342|Other|Rituximab, Alemtuzumab|
88885735|NCT01408355|Experimental|50 microgram PF-06273588 intravenous|Subjects will receive a single intravenous microdose of PF-06273588 in period one
88885736|NCT01408355|Experimental|50 microgram PF-06273588 oral|Subjects will receive a single oral microdose of PF-06273588 in period two
88885737|NCT01408368|Active Comparator|Bilateral subtotal thyroidectomy|
88885738|NCT01408368|Experimental|Total thyroidectomy|
89409795|NCT05776368|Experimental|Sub-study E2, arm 1, single case design|patients undergo 4 weeks of tool motor training according to an on/off design.
89409796|NCT05776368|Experimental|Sub-study E3, arm 1, patients and 4 week experimental sensorimotor protocol|patients undergo 4 weeks of tool motor training
89409797|NCT05776368|Experimental|Sub-study E3, arm 2, control group of patients|aphasic patients receiving the standard treatment as a control group
89409798|NCT05769062|Experimental|Single-digit pelvic exam|"Patients will have a pelvic floor muscle exam performed by their gynecologic radiation oncologist prior to treatment, at treatment mid-point (after 3 weeks of treatment), at the end of treatment (after 6 weeks of treatment), and at a follow-up visit 6 months after the end of treatment. Patients will also complete the Pelvic Floor Impact Questionnaire 7 (PFIQ-7), Pelvic Floor Disability Index (PFDI-20), and the EORTC QLQ-CX24 at these time points.~The patient will also undergo a standard of care MRI prior to starting treatment."
89409799|NCT05762692|Experimental|HFNO Group|Intra-operative oxygenation will be administered by the high-flow nasal oxygenation device. The flow rate is 2L/kg.(upper limit 30L/min)
88885739|NCT01408381|No Intervention|Control|No cell therapy
88885740|NCT01408381|Experimental|Low dose|Intraarterial Infusion of Autologous Bone Marrow Mononuclear Cells: 1 x 108
88885741|NCT01408381|Experimental|Intermediate dose|Intraarterial Infusion of Autologous Bone Marrow Mononuclear Cells: 5 x 108
89409800|NCT05748873|Experimental|Step 1 : SPVN06 dose 1|Participants will receive a single subretinal injection of SPVN06 Dose 1 on Day 0.
89409801|NCT05748873|Experimental|Step 1 : SPVN06 dose 2|Participants will receive a single subretinal injection of SPVN06 Dose 2 on Day 0
89409802|NCT05748873|Experimental|Step 1 : SPVN06 dose 3|Participants will receive a single subretinal injection of SPVN06 Dose 3 on Day 0
89409803|NCT05748873|Experimental|Step 2 : SPVN06 Dose Recommended 1|Participants will receive a single subretinal injection of SPVN06 recommended dose 1 on Day 0
89409804|NCT05748873|Experimental|Step 2 : SPVN06 Dose Recommended 2|Participants will receive a single subretinal injection of SPVN06 recommended dose 2 on Day 0
89409805|NCT05748873|No Intervention|Step 2 : Control group|
88885742|NCT01408381|Experimental|High dose|Intraarterial Infusion of Autologous Bone Marrow Mononuclear Cells: 1 x 109
88885743|NCT01408394|Active Comparator|100 mg immediate release form|This is the formulation currently in use
88885744|NCT01408394|Experimental|90 mg controlled release|This is the low dose of the controlled release form
88885745|NCT01408394|Experimental|180 mg controlled release form|This is the medium controlled release dose
88885746|NCT01408407|Active Comparator|Arm A: standard of care|Patients will be asked to apply Aveeno cream twice a day starting the day of their treatment until two weeks after the end of their treatment
89409806|NCT05731843|Experimental|BEM vs BEM + Ruzasvir n=16|
88885747|NCT01408407|Experimental|Arm B: standard of care plus Alkagin paste|Patients will apply Alkagin Paste to the treatment area everyday one week before starting radiotherapy, throughout treatment and for two weeks post treatment. They will also perform standard of care skin treatment.
88885748|NCT01408420|No Intervention|Standard blood pressure|Extracorporeal circulation during the surgery are conducted using standard blood pressure
88885749|NCT01408420|Active Comparator|MAP > 60 mmHg|A blood pressure of MAP > 60 mmHg is used during extracorporeal circulation. The higher MAP is maintained by using continuous intravenous administration of norepinephrine titrated to the appropriate dose for each patient.
88885750|NCT01408433|Other|Single Embryo Transfer|Patients will have a single, chromosomally normal embryo transferred.
88885751|NCT01408433|Other|Double Embryo Transfer|Patients will have two (2) untested embryos transferred.
88885752|NCT01408446|Active Comparator|Menthol|Interventions Drug: Menthol Arms: Group 1
88885753|NCT01408446|Placebo Comparator|Placebo|Interventions Drug: Placebo Arms: Group 2
88885754|NCT01408472|Experimental|NT-501 CNTF Implant|Patients will receive single NT-501 CNTF implant in one eye.
88885755|NCT01408498|No Intervention|Placebo Control|Control group who will not receive exogenous testosterone administration. Will act as a comparison group to the testosterone group.
88885756|NCT01408498|Experimental|Testosterone administration group|Experimental group that will receive a single 10 g dose of 1% testosterone topical gel.
88885757|NCT01408524|Active Comparator|Diltiazem|2.5 mg iv q 2-5 min for keeping SBP below 140 mmHg during the emergence
88885758|NCT01408524|Active Comparator|Labetalol|2.5 mg iv q 2-5 min for keeping SBP below 140 mmHg during the emergence
88885759|NCT01408550|Active Comparator|NPB-01|Active Comparator: 1 Intravenous immunoglobulin
89409807|NCT05731843|Experimental|Ruzasvir vs Ruzasvir + BEM n=16|
89409808|NCT05730387||mother and newborn dyads|We will recruit 6700 mother and newborn dyads from the two participating hospitals. We will continue to follow-up with all patients enrolled in the study until 6 weeks (42 days) post delivery.
89409809|NCT05699915|Other|Cancer patients with a solid tumour eligible for treatment with immune checkpoint inhibitors|Patients are treated as standard of care
89409810|NCT05683405|Experimental|Mechanical debridement|
89409811|NCT05683405|Experimental|Air polishing|
88885760|NCT01408550|Placebo Comparator|Placebo|Placebo Comparator: 2 Physiological saline
88885761|NCT01408589|Placebo Comparator|Sugar Pill|
88885762|NCT01408589|Experimental|Atomoxetine 40 mg|
88885763|NCT01408589|Experimental|Atomoxetine 60 mg|
88885764|NCT01408589|Experimental|Atomoxetine 80 mg|
88885765|NCT01408602|Experimental|MRC375 75 mg|MRC375 (enteric coated Tetracycline) 75 mg 3 times a day
88885766|NCT01408602|Experimental|MRC375 150mg|MRC375 (enteric coated Tetracycline) 150mg 3 times a day for 24 weeks.
89409812|NCT05676411|Active Comparator|Electrocautery-incision alone group|The skin inicsion will be made using electrocautery during shoulder replacement in patients assigned this group with no other preoperative treatment.
89409813|NCT05676411|Experimental|Electrocautery-incision and BPO group|Patients assigned in this group will undergo an application of topical benzoyl peroxide to the shoulder skin prior to shoulder replacement surgery in addition to their skin incision being made using electrocautery.
88885767|NCT01408602|Placebo Comparator|Placebo|Placebo
88885768|NCT01408654|Experimental|Peer Companionship|Behavioral intervention: Receipt of peer companionship provided by trained, supervised volunteer companions.
88885769|NCT01408654|No Intervention|Care-as-Usual|Care-as-Usual in Primary Care
88885770|NCT01408667|Placebo Comparator|Placebo|
88885771|NCT01408667|Active Comparator|TRC150094|
88885772|NCT01408680|Active Comparator|Coenzyme Q10 600 mg|
88885773|NCT01408680|Active Comparator|Coenzyme Q10 1200 mg|
89409814|NCT05652491||Control|Subjects who are not diagnosed with IBD
89409815|NCT05652491||IBD Patients|New onset, treatment-naive pediatric IBD patients
89409816|NCT05647369|Experimental|Experimental: Group 1|Experimental: Experimental group 1: patients, age 13-18, conventional brackets, Mastic mouthwash 15 patients, age 13-18,with conventional brackets,will get Mastic mouthwash
89409817|NCT05647369|Placebo Comparator|Control group: Group 2|Control group: Group 2 patients, age 13-18, conventional brackets, placebo mouthwash 15 patients, age 13-18,with conventional brackets,will get placebo mouthwash
89409818|NCT05633563|Active Comparator|Active Drug|Study participants receiving Trimetazidine
89409819|NCT05633563|Placebo Comparator|Placebo|Study participants receiving placebo (calcium)
88885774|NCT01408680|Placebo Comparator|Placebo|
88885775|NCT01408693|Active Comparator|Anterior minimal invasive approach, AMIS|AMIS in 95 randomized patients.
88885776|NCT01408693|Active Comparator|Trans-gluteal approach, CLAS|CLAS in 95 randomized patients.
88885777|NCT01408745|Experimental|Sternumfix|sternotomy closure with Sternumfix
88885778|NCT01408745|Active Comparator|Steel wire|sternotomy closure with steel wire
88885779|NCT01408758|Other|VCRT|This group will have 2 visits with a study physician in addition to using the VCRT.
88885780|NCT01408758|Other|no VCRT|This group will have 2 visits with study physician only, no VCRT.
88885781|NCT01408797|Experimental|Donor specific transfusion|Subjects with uremia will undergo donor specific transfusion before transplantation
88885782|NCT01408797|Experimental|Clonal deletion|
88885783|NCT01408797|Experimental|Drugs Added When Needed|
88885784|NCT01408810|Experimental|Infliximab|Infliximab 5 mg/Kg, I.V. at weeks 0, 2, 6 and every 8 weeks thereafter. The treatment should follow infliximab's Summary of Product Characteristics.
88885785|NCT01408823||Idiopathic Scoliosis|
88885786|NCT01408823||Non-idiopathic Scoliosis|
88885787|NCT01408836|Experimental|1|Plasma exchange x 7 over 14 days
88885788|NCT01408836|Active Comparator|2|Methyl prednisolone 1g x 3
88885789|NCT01408849|Experimental|Maytenus|Tea of Martens ilicifolia leaves
88885790|NCT01408849|Active Comparator|Omeprazole|Omeprazole as active comparator
88885791|NCT01408875|Experimental|Rehabilitation and EMS Group|Patient Heart Failure who follows physical training and sessions of electrical quadricipital myostimulation.
88885792|NCT01408875|No Intervention|Rehabilitation Group only|Patient Heart Failure who follows physical training
89409820|NCT05627271||ocrelizumab|patients prescribed with ocrelizumab
89409821|NCT05627271||natalizumab|Patients prescribed with natalizumab
89409822|NCT05627271||ofatumumab|Patients prescribed with ofatumumab
89409823|NCT05614960|Experimental|2.4μg vitamin B12|Participants need to consume 4 sheets (5g) of dried purple laver (Nori) daily for 4 weeks.
89409824|NCT05614960|Experimental|4μg vitamin B12|Participants need to consume 7 sheets (8g) of dried purple laver (Nori) daily for 4 weeks.
89409825|NCT05614960|No Intervention|Control|No intervention
89409826|NCT05611866|Experimental|Fecal Microbiota Transplantation|Recruited patients will receive Fecal Microbiota Transplantation
89409827|NCT05584176|Experimental|Subject 14-65+ years of age|Participants will have a nasopharyngeal swab sample collected by trained study site personnel for testing on a high sensitivity EUA SARS-CoV-2 RT-PCR assay to compare the result to the result of the Rapid SARS-CoV-2 Antigen Test. The participant will then self-collect or, if both are over 18, collect from another study participant an anterior nasal swab sample and test using the Rapid SARS-CoV-2 Antigen Test.
89409828|NCT05584176|Experimental|At least 30 children between 2 and 13 years of age|Participants 2-13 years of age will have a nasopharyngeal swab sample collected by trained study site personnel for testing on a high sensitivity EUA SARS-CoV-2 RT-PCR assay to compare the result to the result of the Rapid SARS-CoV-2 Antigen Test. The parent or legal guardian of the child will collect an anterior nasal swab sample from the child and perform the Rapid SARS-CoV-2 Antigen Test.
89409829|NCT05576337|Experimental|Strict vegetarians|Strict vegetarians women
89409830|NCT05576337|Experimental|non vegetarians|Non vegetarians women
89409831|NCT05571514|Experimental|Mother-of-pearl|"Patient randomized in the Mother-of-pearl group :~Mother of pearl supplementation: 2 capsules of 400mg = 800mg mother of pearl/day, equivalent to 320mg Ca/day~- Vitamin D: 50,000 IU/month (standard practice)"
89409832|NCT05571514|Active Comparator|Calcium carbonate|"Patient randomized in the Calcium carbonate control group :~Calcium carbonate supplementation: 2 capsules of 400mg= 800mg CaCO3/day, equivalent to 320mg Ca/day~- Vitamin D: 50,000 IU/month (standard practice)"
89409833|NCT05559372|Experimental|Nutrabolt C4 Energy Drink Carbonated|16 oz
89409834|NCT05559372|Active Comparator|Monster Energy Original|16 oz
89409835|NCT05559372|Placebo Comparator|Placebo|16 oz carbonated placebo
89409836|NCT05556720|Experimental|People living with Human Immunodeficiency Virus (HIV)|"Eligible participants living with HIV will be randomised 1:1:1 to receive a one or two doses of bivalent COVID-19 vaccine:~Moderna bivalent COVID-19 vaccine, SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.4-5 (elasomeran/davesomeran); 25 micrograms of imelasomeran that targets the Omicron variant BA.4-5, and 25 micrograms of elasomeran that targets the ancestral strain of SARSCoV-2.~Pfizer bivalent COVID-19 vaccine, COMIRNATY ORIGINAL/OMICRON BA.4-5 (tozinameran/famtozinameran); 15 µg of tozinameran and 15 µg of famtozinameran.~TBC"
89409837|NCT05556720|Experimental|Solid Organ Transplant recipients|"Eligible participants who have previously received at least one solid organ transplant, including kidney, pancreas, liver, heart, lung, or any combination of these organs at least 6 weeks prior and without episodes of severe rejection requiring T- or B-cell depleting agents in the prior 3 months, will be randomised 1:1:1 to receive a one or two doses of bivalent COVID-19 vaccine:~Moderna bivalent COVID-19 vaccine, SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.4-5 (elasomeran/davesomeran); 25 micrograms of imelasomeran that targets the Omicron variant BA.4-5, and 25 micrograms of elasomeran that targets the ancestral strain of SARSCoV-2.~Pfizer bivalent COVID-19 vaccine, COMIRNATY ORIGINAL/OMICRON BA.4-5 (tozinameran/famtozinameran); 15 µg of tozinameran and 15 µg of famtozinameran.~TBC"
89531064|NCT03341195|Active Comparator|1. One way SMS messages.|Parents/caregiver will receive one way educational/reminder/proactive SMS messages related to routine immunization once a week till 20 weeks of age.
88885793|NCT01408953|Experimental|bevacizumab for all patients|This is a single arm trial. All patients receive treatment with bevacizumab.
88885794|NCT01408966|Experimental|DarkChocolate|11 patients were randomized to receiving dark chocolate 0.55 g/kg of body weight (Lindt Excellence 85% Cocoa, Lindt & Sprüngli España) together with the test meal
88885795|NCT01408966|Placebo Comparator|White chocolate supplementation|11 patients received 0.63 g/kg white chocolate (Lindt Excellence Natural Vanilla, Lindt & Sprüngli España) in an iso-caloric and iso-volumetric proportion adjusted to body weight.
88885796|NCT01408979|Experimental|12 hours of magnesium sulfate|Patients in this group will have magnesium sulfate administered for 12 hours after delivery
88885797|NCT01408979|Active Comparator|24 hours of magnesium sulfate|Patients in this group will have magnesium sulfate administered for 24 hours after delivery
88885798|NCT01409005|Experimental|Gemcitabine plus UFTE|Gemcitabine plus UFTE chemotherapy (Single arm)
88885799|NCT01409018|Experimental|Itraconazole|
88885800|NCT01409044|Experimental|Music|Research participant listened to music
88885801|NCT01409057||No heart lung machine|Coronary-artery-disease
88885802|NCT01409057||Heart lung machine|Coronary artery disease
88885803|NCT01409070||Azacitidine|200 MDS patients taking Azacitidine will be assessed
88885804|NCT01409070||Decitabine|100 MDS patients taking Decitabine will be assessed
88885805|NCT01409083|Experimental|intravenous bicarbonate|Diluted sodium bicarbonate will be injected to s new IV catheter expecting a rise in end-tidal CO2
89409838|NCT05556720|Experimental|People with Haematological Neoplasms (CLL, NHL, MM)|"Undergoing chemotherapy, immunotherapy and/or targeted therapy, or completed in the last 2 years for chronic lymphocytic leukemia, multiple myeloma or non-Hodgkin lymphoma will be randomised 1:1:1 to receive a one or two doses of bivalent COVID-19 vaccine:~Moderna bivalent COVID-19 vaccine, SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.4-5 (elasomeran/davesomeran); 25 micrograms of imelasomeran that targets the Omicron variant BA.4-5, and 25 micrograms of elasomeran that targets the ancestral strain of SARSCoV-2.~Pfizer bivalent COVID-19 vaccine, COMIRNATY ORIGINAL/OMICRON BA.4-5 (tozinameran/famtozinameran); 15 µg of tozinameran and 15 µg of famtozinameran.~TBC"
89409839|NCT05555485|Sham Comparator|tAN stimulation - sham|Active or sham auricular stimulation will be conducted using the FDA-cleared tAN device (Sparrow®) manufactured by Spark Biomedical (Dallas, TX). The tAN devices are portable, wearable systems with two channels of stimulation (auricular vagus and auricular trigeminal). Two individual stimulation frequencies will be set: 15 Hz at cymba concha (Region1/Channel 1; vagal innervation) and 100 Hz adjacently anterior to the tragus (Region 2/Channel 2; trigeminal innervation). The pulse duration will be set at 250 µs for all participants. The stimulation intensities (mA) will be set at 1.0 and 1.4 (for Regions 1 and 2, respectively) based on values observed in previous clinical studies. If the participant states that the stimulation intensity is discomforting or unperceivable, the study personnel will gradually decrease/increase the intensity until a comfortable stimulation intensity is achieved.
89409840|NCT05555485|Active Comparator|tAN stimulation - active|Active or sham auricular stimulation will be conducted using the FDA-cleared tAN device (Sparrow®) manufactured by Spark Biomedical (Dallas, TX). The tAN devices are portable, wearable systems with two channels of stimulation (auricular vagus and auricular trigeminal). Two individual stimulation frequencies will be set: 15 Hz at cymba concha (Region1/Channel 1; vagal innervation) and 100 Hz adjacently anterior to the tragus (Region 2/Channel 2; trigeminal innervation). The pulse duration will be set at 250 µs for all participants. The stimulation intensities (mA) will be set at 1.0 and 1.4 (for Regions 1 and 2, respectively) based on values observed in previous clinical studies. If the participant states that the stimulation intensity is discomforting or unperceivable, the study personnel will gradually decrease/increase the intensity until a comfortable stimulation intensity is achieved
89409841|NCT05552378|Other|Single arm|
89409842|NCT05509309|Experimental|Experimental group|"In the experimental group, in-service training on autism, program quality, and APERS will be provided to participating staff. Furthermore, APERS-rating to assess the program quality for students with ASD/SCC will be conducted. Pertaining feedback on program areas of strength and improvement will be provided by the APERS-raters to the classroom teachers.~Subsequently, assigned coaches (already employed at the school as special educators or equivalent) will based on the APERS-ratings develop an action plan to improve program quality for students with ASD and SCC, in collaboration with classroom teachers. Subsequently, the coach will provide weekly or bi-weekly coaching to promote program quality during the course of two school semesters (approximately 8-9 months)."
89409843|NCT05509309|No Intervention|Comparison group|The classrooms in the comparison group will also be rated with the APERS, and feedback will provided to classroom teachers. However, no further support will be provided in transforming APERS-ratings with pertaining feedback into best practice.
89409844|NCT05498389|Experimental|Part 1 Dose Escalation (Phase Ib), Part 2 Dose Expansion (Phase II)|"In Part 1 dose escalation, patients will receive EMB-01 IV once weekly and osimertinib PO QD on days 1-28. The treatment cycle repeats every 28 days in the absence of disease progression or unacceptable toxicity. Dose escalation will continue until the maximum tolerated dose (MTD) or recommended phase II dose (RP2D) is reached, or all planned doses are administered.~In Part 2 dose expansion, patients will receive EMB-01 IV once weekly and osimertinib PO QD on days 1-28 at the recommended phase II dose (RP2D) regimen. The treatment cycle repeats every 28 days in the absence of disease progression or unacceptable toxicity."
89409845|NCT05467085|Experimental|LIFU in OCD group|"Each subject will receive 3 LIFU sessions epr week for two weeks (6 total image-guided treatments).~A total of 20 sonications will be administered to one side of the head, with a derated (based on FDA standard of 0.3 dB/cm-MHz) spatial-peak temporal-average intensity (i.e., Ispta) of approximately 720mW/cm2, each lasting 30 s, separated by 30 s pause intervals. Thus, total duration of sonication will be 10 minutes, the same as used in our study of VS LIFU in healthy subjects. Sonication will be administered within a 3T Siemens Prisma scanner. During sonication, we will use the 20-channel head coil as the 32-or 64-channel coil does not allow enough space to fit the transducer.~In summary, the entire sequence of 20 sonications, each lasting 30s, separated by 30s pause intervals, will be administered over 20 minutes for a total duration of sonication equal to 10 minutes."
89409846|NCT05462782|Experimental|Active TMS|Older healthy participants will be scanned with MRI and undergo memory task synchronized PAS with an active TMS in each visit with different stimulation localization and ISIs.
89191850|NCT03907670||CML patients who will receive dasatinib|Patients with chronic myeloid leukemia newly diagnosed, who will receive Tyrosine Kinase inhibitor treatment(dasatinib) measure the fluctuations in the levels of sCTLA-4, TGFβ1, and PDMPs, and to clarify the clinical significance of these biomarkers during TKI therapy in patients with CML
89409847|NCT05462782|Sham Comparator|Sham TMS|Older healthy participants will be scanned with MRI and undergo memory task synchronized PAS with a sham TMS coil in each visit with different ISIs application.
89409848|NCT05459363|Experimental|Varsity Athletes|Healthy adults recruited from the University of Kentucky varsity tennis programs.
89409849|NCT05458531||Patients with an inflammatory disease taking immune-suppressing medication|Aged 18 years and over, able to give consent, diagnosed with one of the above inflammatory conditions and currently treated with one of the following immune-suppressing treatments for six months or longer: methotrexate, azathioprine, 5-acetyl salicylates, sulfasalazine, mycophenolate mofetil, leflunomide or biologics.
89409850|NCT05458531||Healthcare professionals|Consultants, general practitioners (GPs), nurse specialists, practice nurses and pharmacists with experience of prescribing and monitoring long-term immune-suppressing treatments for the above inflammatory diseases
88885806|NCT01409083|Placebo Comparator|control|equal volume of normal saline will be randomely injected
89191851|NCT00798681|Experimental|1|Patients will receive RTU TPN with olive-oil as the primary source of lipids
89191852|NCT00798681|Active Comparator|2|CNF parenteral nutrition made with olive oil as the primary source of lipids
89191853|NCT00798681|Active Comparator|3|CNF parenteral nutrition made with LCT/MCT as the primary source of lipids
88885807|NCT01409122|Experimental|Part A Multiple Dose|Ascending multiple dose administration (every 8 hours, [Q8H]) of AIR001 or placebo for 16 consecutive doses
88885808|NCT01409122|Experimental|Part B Single Dose with Sildenafil|Single escalating doses of AIR001 or placebo (Q8H, Day 4-6) administered in combination with steady-state sildenafil administration (Q8H, Days 1-6)
88885809|NCT01409122|Experimental|Part C, administration of AIR001 to patients with PAH|Four doses of AIR001 will be administered via nebulization to patients with PAH.
88885810|NCT01409122|Experimental|Part D, device crossover study|PK, safety and tolerability of single doses of AIR001 administered in a randomized order with three different nebulizers.
88885811|NCT01409148|Other|I-124 Mu 11-1F4 sterile injection|Single arm study
88885812|NCT01409174|Experimental|Ipilimumab + Chemotherapy|Ipilimumab starting 1 mg/kg by vein (IV) Day 1 each cycle; Temozolomide 200 mg/m^2 orally Days 2-5 of Induction; Cisplatin 25 mg/m^2 IV for Days 2-4 of Induction; Interferon alfa-2b 5 million U/m2 subcutaneously on Days 1-5 of each cycle Induction + Consolidation; and Interleukin-2 9 million IU/m^2 IV as a continuous infusion on Days 2-5 of Induction + Consolidation.
88885813|NCT01409187|Experimental|Ipilimumab + Interferon + Interleukin-2|Ipilimumab starting dose 2 mg/kg intravenous (IV) day 1 only; IFN alfa-2b at 5 million U/m2 subcutaneously daily for 5 days starting day 1; IL-2 at 9 million IU/m^2 daily IV continuous infusion for 4 days on days 2-5.
88885814|NCT01409226|Experimental|MRI|
88885815|NCT01409252||Hemorrhagic stroke patients|
88885816|NCT01409265||No treatment|
88885817|NCT01409278|Experimental|Ropivacaine infiltration and infusion.|Ropivicaine infiltration followed by continuous ropivicaine infusion for 48 hours.
88885818|NCT01409278|Experimental|Ropivacaine and Saline|Ropivicaine infiltration followed by normal saline infusion.
88885819|NCT01409278|Placebo Comparator|Saline infiltration and infusion.|Normal saline infiltration followed by saline infusion.
88885820|NCT01409317|Experimental|Deep Transcranial Magnetic Stimulation|
88885821|NCT01409317|Active Comparator|Repetitive Transcranial Magnetic Stimulation|
88885822|NCT01409343|Experimental|TrasGEX|A total of 37 patients with advanced HER2-positive carcinomas and progressive disease.
88885823|NCT01409356|Experimental|Diet+Exercise|Program of weight loss through diet+exercise (=intervention)
88885824|NCT01409369|Experimental|1|
88885825|NCT01409369|Active Comparator|2|
88885826|NCT01409395|Experimental|Metformin|Subjects will be dosed with Metformin alone (850 mg)
88885827|NCT01409395|Experimental|Metformin and Nizatidine|Subjects will be dosed with metformin in conjunction with nizatidine
88885828|NCT01409408|Active Comparator|Aliskiren|
88885829|NCT01409408|Active Comparator|Amlodipine|
88885830|NCT01409421|Experimental|motivational interviewing|3 phone and 3 in person counseling support sessions with glaucoma educator
88885831|NCT01409421|Active Comparator|reminder calls|behavioral: three phone calls to remind patients to take their eye drops
88885832|NCT01409421|No Intervention|standard care|standard care for glaucoma
88885833|NCT01409447|Experimental|Biphasic osteochondral composite|feasibility study for the new medical device & technique
88885834|NCT01409460|Experimental|True Obturator Nerve Block|
88885835|NCT01409460|Sham Comparator|Sham Block|
88885836|NCT01409473|Experimental|Prostate SBRT|Prostate SBRT with concurrent boost to intraprostatic lesion (IPL) will be delivered in 5 fractions using intensity-modulated radiotherapy planning techniques.
88885837|NCT01409512||Women with OAB|Patients that will be diagnosed as having OAB syndrome by an urogynecologist based on their clinical symptoms (urinary urgency, with or without urinary urgency incontinence, urinary frequency or nocturia).
88885838|NCT01409525||cardiac surgery patients|
88885839|NCT01409538|Placebo Comparator|Placebo|Asymptomatic control participants receive Natural History and Placebo instructions in a within-subject design. There are no patients, or active agents in this study. It is not a Clinical Trial.
88885840|NCT01409538|Active Comparator|Control condition|"The control condition represents a no-intervention, repeated baseline control, since the active intervention in this study is placebo."
88885841|NCT01409551|Active Comparator|VATS hyperthermic pleural chemoperfusion|The patients undergo a VATS drainage of pleural effusion with adhesiolysis and complete mobilization of the lung, following by a 1 hour hyperthermic (40oC)chemoperfusion by means of a pump machine.
88885842|NCT01409551|Active Comparator|Bedside talc slurry pleurodesis|The patients undergo tube thoracostomy under local anesthesia. When the lung is fully expanded, talc slurry bed-side pleurodesis is performed.
88885843|NCT01409577||FFR|Patients with intermediate coronary stenosis Patients with successful fractional flow measurement Feasible > 9months clinical follow-up
88885844|NCT01409590|Other|Exercise and Diet program|All patients recruited in the study, participated in an homogeneous exercise program and diet.
88885845|NCT01409603|Experimental|Treatment arm A|darexaban, wash-out, naproxen, wash-out, combination therapy
88885846|NCT01409603|Experimental|Treatment arm B|darexaban, wash-out, combination therapy, wash-out, naproxen
88885847|NCT01409603|Experimental|Treatment arm C|naproxen, wash-out, darexaban, wash-out, combination therapy
88885848|NCT01409603|Experimental|Treatment arm D|naproxen, wash-out, combination therapy, wash-out, darexaban
88885849|NCT01409603|Experimental|Treatment arm E|combination therapy, wash-out, naproxen, wash-out, darexaban
88885850|NCT01409603|Experimental|Treatment arm F|combination therapy, wash-out, darexaban, wash-out, naproxen
88885851|NCT01409616|Experimental|Treatment arm A|ASA, wash-out (w.o.), ASA + darexaban
88885852|NCT01409616|Experimental|Treatment arm B|ASA + darexaban, w.o., ASA
88885853|NCT01409616|Experimental|Treatment arm C|ASA, w.o., darexaban (double dose) + ASA
88885854|NCT01409616|Experimental|Treatment arm D|darexaban (double dose) + ASA, w.o., ASA
88885855|NCT01409616|Experimental|Treatment arm E|ASA + clopidogrel, w.o., ASA + clopidogrel + darexaban
88885856|NCT01409616|Experimental|Treatment arm F|ASA + clopidogrel + darexaban, w.o., ASA + clopidogrel
88885857|NCT01409616|Experimental|Treatment arm G|ASA + clopidogrel, w.o., darexaban (double dose) + ASA + clopidogrel
89409851|NCT05438771|Active Comparator|Bicarbonate|"1.Correct method of brush Platelet value suitable for tooth brushing Feature of toothbrush (soft, nylon bristled, rounded tip, standard size) Fluoride toothpaste, its amount and use in dry brushes In toothbrush 45 degree, the contact of the bristles with the gums, 4 times contact with the inner, outer, chewing surface, tongue cleaning The benefits of correct brushing (preventing dental plaque and gingival recession, etc.) Importance of brushing teeth twice a day (breakfast and after dinner) Preparation of mouth wash Boiled and cooled water at 100°C Putting 5 measures of boiled and cooled water in a teacup with the 20 ml measuring cup provided.~Adding 1 teaspoon (6 g) of sodium bicarbonate to water Making a mouthwash Teaching how to gargle with 20 ml of bicarbonate 4 times a day at 6-hour intervals and being asked to spit it out without swallowing,"
89409852|NCT05438771|Experimental|Ankaferd Blood Stopper|"Correct method of brush Preparation of the mouthwash Boiled and cooled water at 100°C Putting 4 ml of water in the 5 ml measuring cup given to the patient Putting Ankaferd Blood Stopper on the remaining 1 ml portion of the 5 ml beaker Giving information about making and using mouthwash Use on an empty stomach 2 hours before meals in the morning and at least 2 hours after dinner After rinsing your mouth thoroughly with a mouthwash containing 5 ml of Ankaferd Blood Stopper prepared 2 times a day, you can swallow the solution in your mouth.~It is said that there is a solution-related discoloration in the mouth and teeth, but that it will return to its original state after tooth brushing."
89409853|NCT05437458||Persistent delirium|People with Parkinson's who have experienced persistent delirium (delirium lasting for ≥14 days) and will also be invited to interview.
89409854|NCT05437458||Non-persistent delirium|People with Parkinson's who have experienced non-persistent delirium (delirium lasting <14 days).
89409855|NCT05437458||No delirium (Control group)|People with Parkinson's who have never experienced delirium
89409856|NCT05437458||Carers for Qualitative Interview|Carers of people with Parkinson's who have consented to being interviewed.
89409857|NCT05434871|Experimental|Yoga Group|There will be a 45-minute yoga session 2 days a week for 8 weeks. Warm up with yoga-specific moves for 10 minutes (light stretching), yoga postures for 25 minutes and rest and meditate for the last ten minutes.
89409858|NCT05434871|Active Comparator|Control Group|The routine physiotherapy and rehabilitation program consists of strength, flexibility, balance, gait and coordination exercises 2 days a week for 8 weeks.
89409859|NCT05422261||Experimental Group|Children with Autism Spectrum Disorder and their parents
89409860|NCT05422261||Control Group|Health children and their parents
89409861|NCT05417568|Experimental|Healthy Participants|"Healthy participants will randomly receive either high (250mg) or low (40mg) oxalate diet for for four days, a ten day washout period on a self-selected diet, and finally the opposite diet from the first for the last four days."
89409862|NCT05417568|Experimental|Calcium Oxalate Kidney Stone|"Calcium oxalate kidney stone participants will randomly receive either high (250mg) or low (40mg) oxalate diet for for four days, a ten day washout period on a self-selected diet, and finally the opposite diet from the first for the last four days."
89409863|NCT05414513||Chronic Headache Group|Children with chronic headache
88885858|NCT01409616|Experimental|Treatment arm H|darexaban (double dose) + ASA + clopidogrel, w.o., ASA + clopidogrel
88885859|NCT01409642|Active Comparator|Individual Child CBT|12 sessions of individual child-focused cognitive behavior therapy with a parent component
88885860|NCT01409642|Experimental|Positive Family Interaction Therapy|12 sessions of standard individual child CBT plus six sessions of positive family interaction therapy (PFIT)
88885861|NCT01409655|Experimental|cognitive-behavioral therapy intervention|Reinforcement for medication-taking will be wired to debit cards that patients will be given to receive the payments. This contingent reinforcement of medication-taking will be coupled with twelve sessions of cognitive-behavioral therapy (CBT) conducted by phone, also assisted by the website which will generate CBT-related text messages, reminders and scheduling information from a menu of choices negotiated by the patient and therapist.
88885862|NCT01409668|Experimental|L. Amylovorus|
88885863|NCT01409668|Experimental|L. Fermentum|
88885864|NCT01409681||Observational Group|NSCLC subject undergoing bronchoscopy
88885865|NCT01409694|Active Comparator|Intervention|All participants start the treatment with memantine on the first day of the study and immediately start vitamin D supplementation.
88885866|NCT01409694|Placebo Comparator|Placebo|Participants in this arm start the treatment with memantine in the same way as the 'Intervention' group. They also immediately start Vitamin D placebo administered at the same pace.
88885867|NCT01409720|Experimental|A|patients in arm A carry out daily physical training consisting of three different isometric exercises under the guidance and supervision of a physiotherapist. Training starts day one (first radiotherapy session), 10 daily units of 30 min each are scheduled during radiotherapy. Patients are expected to continue training until 12 weeks post completion of radiotherapy at home.
88885868|NCT01409720|No Intervention|B|Patients in arm B (control group) receive 10 daily sessions of 15 min manual therapy (i.e. massage, etc) starting from day one of radiotherapy.
89409864|NCT05414513||Healthy Group|Children without pain
89409865|NCT05407688||ADHD group|Adolescents with ADHD
89409866|NCT05407688||Health group|Adolescents without ADHD
89409867|NCT05401461|Experimental|Intervention|Evening mobilisation delivered between 7pm and 9pm
89409868|NCT05401461|No Intervention|Control|Patients in the control arm will receive standard care which incorporates physiotherapy and mobilisation as appropriate between 8am and 5pm
89409869|NCT05400291||Renal Cell Carcinoma|patients undergoing radical nephrectomy because of renal clear cell carcinoma, tissue will be collected after the organ is removed.
89409870|NCT05400291||Muscle Invasive Bladder Cancer|patients underoing radical cystectomi because of muscle-invasive bladder cancer, tissue will be collected after the organ is removed.
88885869|NCT01409733|Experimental|Stage IV melanoma patients|
88885870|NCT01409746||twins|twin pairs
88885871|NCT01409759|Experimental|Perforator based interposion flap|In our concept the flap is designed based on a selected perforator and locally available, preferably normal skin adjacent to the burn scar contracture. The flap consists of skin and underlying subcutaneous tissue. Based on the pre-operative defined perforator, the required length and width and the available preferable normal skin, a design for the perforator flap is made.
88885872|NCT01409759|Other|Full thickness graft|
89409871|NCT05384379|Experimental|Treated Group|Intubated patients treated with inhaled BZ371B will receive a dose of 12 mg of BZ371B divided in two different nebulizations per day, for three cosnecutive days
89409872|NCT05382962|Experimental|Intervention: iCanCope Post-Op App|Adolescents randomized to the intervention group will receive the iCanCope PostOp app, in addition to usual care. Both groups will complete measures at pre-operative appointments following consent and randomization (6-8 weeks prior to surgery, T0), at 1-week pre-op (T1), 2-week post-op, (T2) and 4-week post-op (T3), and 12-week post-op (T4).
89409873|NCT05382962|No Intervention|Control: Usual Care|Adolescents randomized to the control group will receive usual care. Both groups will complete measures at pre-operative appointments following consent and randomization (6-8 weeks prior to surgery, T0), at 1-week pre-op (T1), 2-week post-op, (T2) and 4-week post-op (T3), and 12-week post-op (T4).
88885873|NCT01409499|Experimental|A, surgery|The patients in this group will receive palliative resection of HCC, then take sorafenib as remain therapy.
89409874|NCT05380284|Experimental|Experimental Group|Senior Driving Simulation Training
88885874|NCT01409499|Experimental|B, TACE|Patients in group B will receive transcatheter hepatic arterial chemoembolization, then take sorafenib as remain therapy.
89191854|NCT02821208||One cohorte : patient psychogenic nonepileptic seizures|The Psychogenic nonepileptic seizures (PNESs) are paroxysmal episodes type of abnormal movements, behavior modification or alteration of the contact-like seizures. These episodes are involuntary and underpinned by an unconscious psychological processes. In the International Classification of Disease-10 (ICD-10), they are classified as dissociative phenomena as conversing syndromes in the Manual of Diagnostic and Statistical Mental Disorders-IV (DSM-IV). The participants of the study only receive the usual care they would have if they were not included (no new/different intervention allocated in the study).
88885875|NCT01409499|Experimental|C, sorafenib|Patients in group C will receive monotherapy of sorafenib.
88885876|NCT01409785||LMA Supreme|
88885877|NCT01409785||LMA unique|
88885878|NCT01409824|No Intervention|without CDSS|This arm includes 6 health facilities in each partner country, where the clinical decision support system will not be implemented
88885879|NCT01409824|Experimental|with CDSS|This arm includes 6 health facilities in each partner country, where the clinical decision support system will be implemented, parallel to the performance based incentive package
88885880|NCT01409850|Active Comparator|Aqualizer|
88885881|NCT01409850|Active Comparator|Soft splint|elastic splint made of copolyester foil
88885882|NCT01409850|No Intervention|Counselling|
88885883|NCT01409876|Experimental|Brachytherapy|
88885884|NCT01409889|Active Comparator|Diabetes Prevetion Program|Individuals in this group will receive the Diabetes Prevention Program
89409875|NCT05380284|Other|Control Group|Ｗaiting-list
89409876|NCT05375604|Experimental|Experimental CDK-004|CDK-004 administered as a single agent intravenously (IV) on Days 1 and 15 of Cycles 1 and 2, on Day 1 of every Cycle.
89409877|NCT05368038||Newborn infants born at a ScreenPlus pilot hospital|Parents who give permission will have their infant's sample screened for the ScreenPlus panel. Infants who screen positive after multi-tiered testing will be referred to a ScreenPlus doctor for confirmatory testing and care coordination.
89191855|NCT00577824|Experimental|1|
89409878|NCT05357742|Experimental|Intervention Group|Participants randomized to the intervention group will receive the manualized study intervention delivered by a health educator via telephone weekly for 12-weeks, followed by three monthly booster sessions resulting in a total of 6 months intervention.
89409879|NCT05357742|Active Comparator|Control group|Participants randomized to the control group will receive the manualized study intervention delivered by a health educator via telephone weekly for 12-weeks, followed by three monthly booster sessions resulting in a total of 6 months intervention.
89535665|NCT03220399|Experimental|NVP-1603-1and NVP-1603-2 (P+T)|Drug: NVP-1603-1, 1capsule and NVP-1603-2, 1Tablet co-adminstration (oral dosing)
89535666|NCT02489747|Experimental|WBE group|wheat bran extract
88885885|NCT01409889|Active Comparator|Healthy Living Program|Individuals in this group will receive the Healthy Living Program
88885886|NCT01409980||Triphalangeal Thumb|A search will be performed using CPT code 26587 (reconstruction of a supernumerary digit) at both Primary Children's Hospital and Shriners to identify all patients who Dr. Wang and Hutchinson operated on with a delta phalanx.
88885887|NCT01410019|Experimental|1|Gene transfer
88885888|NCT01410032|Active Comparator|Plate fixation|Reconstruction plate
88885889|NCT01410032|Active Comparator|ESIN|ESIN (Elastic Stable Intramedullary Nailing)
88885890|NCT01410045|Experimental|Surgery|Ovariectomy
88885891|NCT01410071||sphincter of oddi dysfunction|endoscopic therapy vs conservative care
88885892|NCT01410136|Other|Chondrofix|Subjects with one or two confirmed knee articular cartilage lesion(s) each less than 8cm2, of the femoral condyle or trochlear groove
88885893|NCT01410149|Active Comparator|PAV|Proportional Assist Ventilation (PAV+ on PB840 ventilator)
88885894|NCT01410149|Active Comparator|PSV|Pressure Support Ventilation (PSV on PB840 ventilator)
88885895|NCT01410149|Active Comparator|ACV|Assist Control/ Pressure limited Ventilation (on PB840 ventilator)
88885896|NCT01410162|Active Comparator|Advagraf|
88885897|NCT01410162|Active Comparator|Prograf|
88885898|NCT01410175|Experimental|Conventional scalpel|Use of conventional scalpel to incise the skin and subcutaneous layer.
88885899|NCT01410175|No Intervention|Electric scalpel|Use of electric scalpel to incise the skin and subcutaneous layer.
88885900|NCT01410201|Experimental|PPV + MP + DEX|Patients will undergo pars plana vitrectomy, membrane peel, and concomitant Ozurdex implant (0.7 mg dose).
88885901|NCT01410201|Active Comparator|PPV + MP|Patients will undergo pars plana vitrectomy with membrane peel, without Ozurdex implant.
88885902|NCT01410214|Experimental|Erlotinib arm|In the adjuvant treatment phase, erlotinib 150 mg/day taken orally for 2 years or till disease progression or unacceptable toxicity.
89191856|NCT00577824|Experimental|2|
89191857|NCT00577824|Placebo Comparator|3|
89191858|NCT00867022||1|Women with gestational diabetes
89191859|NCT00867022||2|Pregnant women without gestational daibetes
89191860|NCT00867022||3|Women with gestational diabetes and hypertension
89191861|NCT00867022||4|Non pregnant women
89409880|NCT05338463|Experimental|Fespixon Cream|"A single arm of Fespixon Cream for DFU (TEXAS 1A, 2A) in dialysis patients~Test drug :~Name : Fespixon Cream~Dosage form: Topical cream, 15 g ointment per tube~Active ingredients: 1.25% extracts of Plectranthus amboinicus (PA-F4, 0.25%) and Centella asiatica (S1, 1%)~Dose(s): Apply 1 cc per 5 cm^2 ulcer size (not exceeding 2 mm in thickness)~Dosing schedule: Apply twice a day~Duration: up to 20 weeks"
89409881|NCT05328414|Placebo Comparator|Placebo group|
89409882|NCT05328414|Experimental|steroid based intranasal film|
89409883|NCT05316181|Experimental|HIPEC|Intraoperative Hyperthermic Intraperitoneal Chemotherapy (HIPEC) followed by physician-choice chemotherapy until disease progression.
89409884|NCT05316181|No Intervention|No HIPEC|Physician-choice chemotherapy from enrollment until disease progression.
89409885|NCT05298085|Experimental|OXYTOCIN nasal spray|intranasal administration of Oxytocin
89409886|NCT05298085|Placebo Comparator|PLACEBO|intranasal administration of placebo
89409887|NCT05291598|Active Comparator|Ketorolac group|Participants will receive the institution specific joint replacement pain protocol.
89409888|NCT05291598|Experimental|IV meloxicam group|Participants will be given IV meloxicam for pain management post total knee and hip arthroplasty.
89535667|NCT02489747|Placebo Comparator|Placebo group|placebo
88885903|NCT01410214|Active Comparator|Chemo arm|In the adjuvant treatment phase, patient will receive vinorelbine 25mg/m2 IV on day 1 and day 8, and cisplatin 25mg/m2 on day 1 and day 2 and day 3, of a 3-week schedule for 4 cycles or till disease progression or unacceptable toxicity.
88885904|NCT01410253|Experimental|Group 1|
88885905|NCT01410253|Experimental|Group 2|
88885906|NCT01410253|Experimental|Group 3|
88885907|NCT01410253|Placebo Comparator|Group 4|
88885908|NCT01410266|No Intervention|Standard of care|Standard of care includes a routine clinic visit two weeks after misoprostol administration. At the clinic visit, the woman undergoes a bimanual examination. In the event the woman fails to return for the follow-up visit, clinic procedure is followed for contacting her to determine abortion status and the need for further intervention, if any.
88885909|NCT01410266|Active Comparator|Alternative follow-up|At a clinic visit, before mifepristone administration, the woman completes a semi-quantitative pregnancy test. After mifepristone administration, she is provided with another pregnancy test and a checklist to be self-administered two weeks after she takes misoprostol. On an assigned date, the woman is contacted by phone by the clinic staff and asked to report on the results of both tests. The provider then confirms whether, based on the woman's responses, she should return for a follow-up visit.
88885910|NCT01410292|Experimental|meal D|low fiber and low GI
88885911|NCT01410292|Experimental|meal C|low Fiber and High GI
88885912|NCT01410292|Experimental|meal B|high Fiber and low GI
88885913|NCT01410292|Experimental|meal A|high fiber and high GI meal
88885914|NCT01410305||HIV+|HIV Positive children or young people between the ages of 8 and 25
88885915|NCT01410305||HIV Negative|HIV Negative matched controls by age and race
88885916|NCT01410331|Experimental|Cohort 1|Subjects will be randomized to receive either 4 mg of JVS-100 or placebo over 8 injections.
88885917|NCT01410331|Experimental|Cohort 2|Subjects will be randomized to receive either 8 mg of JVS-100 or placebo over 8 injections.
88885918|NCT01410331|Experimental|Cohort 3|Subjects will be randomized to receive either 8 mg of JVS-100 or placebo over 16 injections.
88885919|NCT01410331|Experimental|Cohort 4|Subjects will be randomized to receive either 16 mg of JVS-100 or placebo over 16 injections.
88885920|NCT01410370|Experimental|treatment|Radiotherapy plus Endostar
88885921|NCT01410370|Active Comparator|control|Radiotherapy
88885922|NCT01410383|Placebo Comparator|Placebo|
88885923|NCT01410383|Experimental|Eprotirome I|
88885924|NCT01410383|Experimental|Eprotirome II|
88885925|NCT01410422||COPD|COPD
88885926|NCT01410422||Bronchiectasis|Bronchiectasis
88885927|NCT01410435|Experimental|Treatment|
88885928|NCT01410461||Patients with painful bladder syndrome|Patients with diagnosis of PBS Will be offered to take part in the following study.
88885929|NCT01410487||Obese group|
89191862|NCT04046289||Low Calcium|low calcium milk of 180 ml, twice daily for 24 weeks
89409889|NCT05277779||control|non-obese （BMI<25kg/m2）controls without known endocrine diseases, cardiac disease, or other comorbidities, and with unremarkable imaging results.
89409890|NCT05277779||metabolically healthy obese|obese individuals having no more than one of the metabolic syndrome components (with exception of increased waist circumference) and without impaired glucose tolerance (defined as a 2-hour post loading glucose level of 7.7-11.1mmol/L )
89409891|NCT05277779||metabolically unhealthy obese|obese individuals with more than one metabolic syndrome components or impaired glucose tolerance
89409892|NCT05272709|Experimental|Cohort 1M (Monotherapy dose escalation cohort)|This cohort will recruit patients with solid tumours.
89409893|NCT05272709|Experimental|Cohort 2M: mCRPC (Monotherapy expansion cohort)|This cohort will recruit patients with mCRPC only.
89409894|NCT05272709|Experimental|Cohort 2M: MSI/MMR defective tumours (Monotherapy expansion cohort)|This cohort will recruit patients with MSI/MMR defective tumours only.
89409895|NCT05272709|Experimental|Cohort 2M: TNBC (Monotherapy expansion cohort)|This cohort will recruit patients with TNBC only.
89409896|NCT05267678||Pregnant women with history of recurrent miscarriage|
89409897|NCT05256368||Inpatients poststroke|Individuals post acute or subacute that that are inpatients at the Shirley Ryan AbilityLab ages 18-80
89409898|NCT05253261|Experimental|Odontogenic cyst treated by decompression with an appliance.|Cystostomy procedure is carried out with the same day delivery of a decompression appliance fabricated with a fully digital workflow. Enucleation of the cyst is carried out following decompression.
89409899|NCT05239026|Experimental|Advanced Training Group|This arm will receive a single session treadmill training session in which both cadence and treadmill speed are controlled.
89409900|NCT05239026|Experimental|Traditional Training Group|This arm will receive a single session treadmill training session in which only treadmill speed is controlled.
89409901|NCT05225480|Experimental|intervention arm|"The illness perception conversation will be delivered in one session during around 15 minutes. The conversation will be based on responses to the eight item Brief illness perception questionnaire and a rating of the most relevant item made by the patient on the same day.~The aim of the conversation will be to get an overview of the patient's illness perceptions concerning their knee OA and what is deemed the most maladaptive perceptions by the participant. Participants will be invited to elaborate on their thoughts concerning these perceptions.Although any maladaptive perceptions will be corrected if natural during the conversation, the conversation will not lead to any active attempts of changing illness perceptions. Rather, the conversation focusses on giving patients time and opportunity to express knee pain related perceptions and worries concerning their knee pain."
89409902|NCT05225480|Active Comparator|control arm|"The control conversation will be delivered in one session during around 15 minutes. In order to create two similar conversational settings where the only difference is the actual content of the conversations. The conversation will be based on responses to an eight item questionnaire concerning motivation for research participation and - similar to the illnes perception conversation - a rating of the most relevant item made by the patient.~The aim of the conversation will be to get an overview of the patient's motivation for research participation and let them elaborate on their thoughts concerning their motivation."
89409903|NCT05202379|Experimental|SAD cohort 1A|first dose level with 6 active and 2 placebo healthy participants
88885930|NCT01410513|Experimental|SAR245409 + rituximab|Subjects will receive oral SAR245409 twice daily continuously and weekly rituximab intravenously
89409904|NCT05202379|Experimental|SAD cohort 1B|second dose level with 6 active and 2 placebo healthy participants
88885931|NCT01410513|Experimental|SAR245409 + rituximab + bendamustine (iNHL, MCL)|Subjects will receive oral SAR245409 twice daily continuously and monthly bendamustine intravenously.
89409905|NCT05202379|Experimental|SAD cohort 1C|third dose level with 12 active and 2 placebo healthy participants; food-effect cohort
89409906|NCT05202379|Experimental|SAD cohort 1D|fourth dose level with 6 active and 2 placebo healthy participants
89409907|NCT05202379|Experimental|MAD cohort 2A|first dose level with 6 active and 2 placebo healthy participants dose x 14 days
89409908|NCT05202379|Experimental|MAD cohort 2B|second dose level with 6 active and 2 placebo healthy participants dose x 14 days
88885932|NCT01410513|Experimental|SAR245409 + rituximab+ bendamustine (CLL)|Subjects will receive oral SAR245409 twice daily continuously and monthly bendamustine and rituximab intravenously
89409909|NCT05202379|Experimental|MAD cohort 2C|third dose level with 6 active and 2 placebo healthy participants dose x 14 days
89409910|NCT05202379|Experimental|MAD cohort 2D|forth dose level with 6 active and 2 placebo healthy participants dose x 5 days
88885933|NCT01410526||VAC group|Patients with intra-abdominal sepsis treated with Vacuum Assisted Closure (VAC) system plus the dynamic sutures
88885934|NCT01410526||Control group|Patients suffering major abdominal surgery
88885935|NCT01410539|Experimental|Stent Thrombosis|Consecutive patients with stent thrombosis with stent strut assessment by OCT
88885936|NCT01410539|Active Comparator|Controls|Control subjects without stent thrombosis from the RHR OCT database
88885937|NCT01410578||systemic inflammatory response syndrome|(1) temperature > 38oC or < 36oC; (2) pulse rate > 90 beats/min; (3) ventilation rate > 20 breaths/min or hyperventilation with a partial pressure of arterial carbon dioxide (PaCO2) < 32 mmHg; (4) white blood cell (WBC) count >1 2,000μL-1 or < 4000 μL-1 , or > 10% immature cells.
88885938|NCT01410578||sepsis|SIRS + infection
89004884|NCT00471445|Experimental|ketamine/amitriptyline NP-H cream|Patients apply 4 grams amitriptyline (4%) and ketamine (2%) hydrochloride topical analgesic cream twice daily to areas of pain, numbness, or tingling in the hands and/or feet.
89004885|NCT00471445|Placebo Comparator|Placebo Cream|Patients apply a placebo cream twice daily to areas of pain, numbness, or tingling in the hands and/or feet.
89409911|NCT05202379|Experimental|MAD cohort 2E|forth dose level with 6 active and 2 placebo healthy participants dose x 5 days
89409912|NCT05202340||Prostate Cancer|Patients diagnosed with prostate cancer
89004886|NCT00207051|Experimental|1|
89409913|NCT05198375|Active Comparator|Control group (CG)|decision to administer exogenous surfactant when FiO2 >0.30 on nCPAP (pressure 6-8 cmH20) to maintain preductal SpO2 between 90 and 95%.
89004887|NCT00402467|Experimental|Arm 6|
89409914|NCT05198375|Experimental|LUS group (LUSG)|"decision to administer surfactant when LUS > 8 on nCPAP (pressure 6-8 cmH20) to maintain preductal SpO2 between 90 and 95%.~The LUS group will receive surfactant administration as rescue therapy in case of LUS < or = 8 but FiO2 > 0.30 on nCPAP (pressure 6-8 cmH20) to maintain preductal SpO2 between 90 and 95%."
89409915|NCT05190432|Experimental|Taxifolin/Dihydroquercetin|250mg/day Taxifolin (also known as Dihydroquercetin). One capsule in the morning for 8 weeks.
89409916|NCT05190432|Experimental|Ergothioneine|80mg/day Ergothioneine. One capsule in the morning for 8 weeks.
89409917|NCT05190432|Placebo Comparator|Control|One capsule in the morning for 8 weeks.
89409918|NCT05167318|Experimental|every 3-4 hour oral care|Infants will receive standardized oral care every 3-4 hours for 4 weeks
89409919|NCT05167318|No Intervention|every 12 hour oral care|Infants will receive standardized oral care every 12 hours for 4 weeks
88885939|NCT01410578||bacteremia|(1) The blood culture tested positive at least for the same pathogen;(2) The patient had at least one of the following symptoms: fever, shivering, or low blood pressure and showed signs of at least one of the following conditions: the blood culture tested positive at least twice for common skin flora from different sites; the blood culture tested positive only once for the skin flora listed above, the intravascular catheter culture tested positive for the same pathogen and the correct antibiotic treatment had been initiated for the patient; or a positive serology test consistent with other clinical laboratory test results and unrelated to infections at different sites.
88885940|NCT01410591|Active Comparator|10-mm covered stent group|Patients treated with 10-mm covered stent.
88885941|NCT01410591|Active Comparator|8-mm covered stent group|Patients treated with 8-mm covered stent.
89409920|NCT05161377|Active Comparator|Surgical management|
89409921|NCT05161377|Active Comparator|Endovascular management|
89409922|NCT05123131|Experimental|Isa-RVD|"Isatuximab (IV): 10 mg/kg on Days 1, 8, 15, 22, 29 in Cycle 1; from Cycle 2 onwards, it will be given on Days 1, 15, 29.~Bortezomib (SQ): 1.3 mg/m² on Days 1, 4, 8, 11, 22, 25, 29, and 32. Lenalidomide (PO): 25 mg/day (10 mg/day for patients with creatinine clearance [CrCl] ≥30 to <60 mL/min) from Day 1 to Day 14 and from Day 22 to Day 35 of each cycle.~Dexamethasone (IV on the days of Isatuximab and PO on other days):~20 mg/day on Days 1, 2, 4, 5, 8, 9, 11, 12, 15, 16, 22, 23, 25, 26, 29, 30, 32, and 33.~If patients are ≥75 years old, dexamethasone will be administered on Days 1, 4, 8, 11, 15, 16, 22, 25, 29 and 32."
89409923|NCT05108090|Other|Procedure/Surgery|Mohs micrographic surgery followed by sentinel lymph node biopsy
88885942|NCT01410617|Active Comparator|dialysis|the patients who undergo 3 sessions prophylactic hemodialysis
88885943|NCT01410617|No Intervention|control group|the patients who do not undergo hemodialysis
88885944|NCT01410630||FLT-PET/CT and FDG-PET/CT scan|Patients will have FLT-PET/CT and FDG-PET/CT scans performed 18-24 days after the second cycle of R-CHOP.
88885945|NCT01410643|Active Comparator|Reduced Carbohydrate|42% carbohydrate macronutrient modification
88885946|NCT01410643|Active Comparator|STandard Carbohydrate|60% carbohydrate macronutrient modification
88885947|NCT01410656|No Intervention|Standard PA Recommendation|Received the standard physical activity recommendation.
88885948|NCT01410656|Experimental|Telephone Implementation Intention|Behavioural Telephone Assisted Implementation Intention Intervention
88885949|NCT01410656|Experimental|Self-completed implementation intention|Self-administered implementation intention intervention.
88885950|NCT01410669|Experimental|Motivational Interviewing (MI)|
89004888|NCT00402467|Experimental|Arm 1|
89004889|NCT00402467|Experimental|Arm 2|
89004890|NCT00402467|Experimental|Arm 3|
89409924|NCT05101187|Active Comparator|Olorofim|Olorofim versus AmBisome followed by Standard of Care (SOC)
89409925|NCT05101187|Active Comparator|AmBisome|Olorofim versus AmBisome followed by Standard of Care (SOC)
89004891|NCT00402467|Experimental|Arm 4|
89004892|NCT00402467|Experimental|Arm 5|
89409926|NCT05073978||Case group|Case group with certain pregnancy outcome, e.g., miscarriage, stillbirth, preterm birth, and birth defects,gestational hypertension, gestational diabetes mellitus, etc.
89409927|NCT05073978||Control group|Control group without certain pregnancy outcome,e.g., miscarriage, stillbirth, preterm birth, and birth defects,gestational hypertension, gestational diabetes mellitus, etc.
89409928|NCT05065502|Active Comparator|Academic Detailing (AD) Only|One-on-one educational outreach to employees and providers.
89409929|NCT05065502|Experimental|AD + LEAP Combined|This arm combines use of AD plus the Learn. Engage. Act. Process (LEAP) program. LEAP is a 6-month quality improvement coaching program plus a 6-month monthly follow-up.
89409930|NCT05061472||COC|Pre-menopausal women with overweight or obesity who are newly initiating the combined oral contraceptive pill, Sprintec (norgestimate/ethinyl estradiol 0.25mg/35mcg)
89409931|NCT05061472||NHC|Pre-menopausal women with overweight or obesity who are using non-hormonal methods of birth control
89409932|NCT05051501|Experimental|Probiotics C2P/Placebo|Crossover design does not confine one group of patients strictly either to an intervention in question or a placebo. Each group will receive both placebo and probiotics in tandem, but in a reversed order.
89409933|NCT05051501|Experimental|Placebo/Probiotics C2P|Crossover design does not confine one group of patients strictly either to an intervention in question or a placebo. Each group will receive both placebo and probiotics in tandem, but in a reversed order.
89409934|NCT05027451|Experimental|IXT-m200|3 g of IXT-m200 given once by 30-min intravenous infusion
89409935|NCT05027451|Placebo Comparator|Placebo|Normal saline
89409936|NCT05024045|Experimental|LOXO-338 (Monotherapy)|LOXO-338 administered orally.
89409937|NCT05024045|Experimental|LOXO-338 + Pirtobrutinib (Combination)|LOXO-338 administered orally in combination with pirtobrutinib
89409938|NCT05019339|Experimental|Healthy HomeStyles|Six-week virtual, group nutrition education series using the HomeStyles-2 experimental curriculum administered through SNAP-Ed. This curriculum addresses factors affecting school-aged children's health and nutritional status: inadequate intake of fruits and vegetables, infrequent family meals, excessive consumption of sugar-sweetened beverages, large portion sizes, and irregular breakfast consumption.
89409939|NCT05019339|Active Comparator|Eat Healthy Be Active|Six-week virtual, group nutrition education series using the Eat Healthy Be Active attention control curriculum administered through SNAP-Ed. This curriculum addresses factors affecting overall health and nutritional status: limiting nutrients of concern (saturated fat, sodium, and added sugars), eating healthy while dining out, eating healthy on a budget, losing weight and keeping it off, understanding nutrition facts labels, and being physically active.
89409940|NCT05001958|Experimental|Action observation|
89409941|NCT05000047||All participants|All study participants who have bilateral earmold impressions completed using both a 3D ear scanner and the conventional procedure using silicone impression material.
88885951|NCT01410682|Experimental|0.12% Chlorhexidine Digluconate|Oral care included use of an oral gel containing chlorhexidine digluconate 0.12% as an active ingredient (chlorhexidine digluconate 0.12%; methylcellulose gel 2.12%, 25 g; gooseberry syrup, 4 drops; menthol solution 50%,3 drops; and distilled water, to 30 g).The gel is applied on a toothbrush, and the teeth are cleaned in quadrants; all teeth surfaces are cleaned (vestibular,lingual, occlusal, and incisal). After each quadrant was cleaned, 10 mL of water (dispensed via a syringe) is used to rinse the quadrant and continual aspiration is used to remove all the gel and debris. After all the teeth are cleaned, the ventral surface of the tongue is brushed with posteriorto- anterior movements.
89409942|NCT04996420|Experimental|Clearsight|hemodynamic monitoring and goal directed fluid therapy guided by clearsight
89409943|NCT04996420|Other|Control|hemodynamic monitoring blinded and silenced, no goal directed fluid therapy. Fluid therapy based on clinical evaluation and mean arterial pressure by non-invasive monitoring
89409944|NCT04974047|Experimental|Cohort A (Responder)|Participants with a decrease in positron emission tomography (PET) Standardized Uptake Value (SUV)max ≥ 35% will receive 3 cycles of tislelizumab (200 milligrams [mg]/cycle) plus 2 cycles of chemotherapy doublet (cisplatin + paclitaxel)
88885952|NCT01410682|Placebo Comparator|tothbrushing|This group received the same oral care that experimental group with the use of a similarly formulated gel without the antiseptic agent.The gel is applied on a toothbrush, and the teeth are cleaned in quadrants; all teeth surfaces are cleaned (vestibular, lingual, occlusal, and incisal). After each quadrant is cleaned, 10 mL of water (dispensed via a syringe) is used to rinse the quadrant and continual aspiration is used to remove all the gel and debris. After all the teeth are cleaned, the ventral surface of the tongue is brushed with posterior to anterior movements.
89409945|NCT04974047|Experimental|Cohort B (Non-responder)|Participants with a decrease in PET SUVmax < 35% will receive 3 cycles of tislelizumab (200 mg/cycle) plus 2 cycles of investigator-chosen chemotherapy doublet (paclitaxel + cisplatin or 5-fluorouracil + cisplatin) plus concurrent radiotherapy (40 grays/20 fractions).
89409946|NCT04920942|Experimental|Treatment group|Ivermectin 0.4mg/kg/day for 5 days + standard-of-care
89409947|NCT04920942|No Intervention|Control group|Standard-of-care only
89409948|NCT04911530||elderly patients (aged ≥ 65 years)|elderly patients undergo surgeries
89409949|NCT04875169|Experimental|Core Treatment Active Experimental: SHR0302 Dose#1|Drug: SHR0302 Oral tablets taken once daily (QD) for 16 weeks
88885953|NCT01410721|Experimental|Cognitive Rehabilitation Intervention|Baseline training and follow-up at two months and four months.
89004893|NCT00224718|Active Comparator|1|surgery - open repair
89409950|NCT04875169|Experimental|Core Treatment Active Experimental: SHR0302 Dose#2|Drug: SHR0302 Oral tablets taken once daily (QD) for 16 weeks
89409951|NCT04875169|Placebo Comparator|Core Treatment Placebo Comparator: Placebo|Drug: Placebo Oral tablets taken once daily (QD) for 16 weeks
89409952|NCT04875169|Experimental|Extension Treatment Active Experimental: SHR0302 Dose#1|Drug: SHR0302 Oral tablets taken once daily (QD) for 36 weeks
89409953|NCT04875169|Experimental|Extension Treatment Active Experimental: SHR0302 Dose#2|Drug: SHR0302 Oral tablets taken once daily (QD) for 36 weeks
89409954|NCT04873505|Experimental|Troches|25 persons take one probiotic troche after each meal.
89409955|NCT04873505|Placebo Comparator|Troches do not contain probiotics|25 persons take one troche that does not contain probiotics after each meal.
89531065|NCT03341195|Active Comparator|2. Two Way SMS messages|Parents/caregiver will receive two way (interactive) educational/reminder/proactive SMS messages related to routine immunization once a week till 20 weeks of age-parents will have the option to reply and receive more information related to immunization through text messages.
88885954|NCT01410721|Active Comparator|Cognitive Rehabilitation Control Arm|Baseline training and follow-up at two months and four months.
88885955|NCT01410734|Experimental|ICG|Patient will received IV injection of ICG intra-operatively. Surgeon will view bile ducts under fluorescence imaging mode to see if ICG helps to identify biliary ducts.
88885956|NCT01410747||tacrolimus group|Oral
88885957|NCT01410786|Active Comparator|Conventional Oxford instrumentation|Patients who receive an Oxford Partial Knee with Conventional instrumentation.
88885958|NCT01410786|Experimental|Signature Guides Oxford|Patients who receive an Oxford Partial Knee with Signature Custom Guides
88885959|NCT01410838|Placebo Comparator|Broth- NaCl|Sodium chloride containing broth matched for sodium content to the MSG broth
88885960|NCT01410838|Active Comparator|Broth- MSG|MSG containing broth with the same sodium content as the placebo comparator.
88885961|NCT01410851|Experimental|Pasta, tomato sauce & added chickpeas|The pulse treatments and control (pasta with tomato sauce) were made the day before the session and the recipe was calculated to provide 1500 kcal at each session. All meals had the same energy density (~77kcal/100g). Calories derived from pulses were consistent among all pulse treatments (44%). The pulse treatments and control all contained macaroni pasta and homemade tomato sauce.
88885962|NCT01410851|Experimental|Pasta, tomato sauce and added lentils|The pulse treatments and control (pasta with tomato sauce) were made the day before the session and the recipe was calculated to provide 1500 kcal at each session. All meals had the same energy density (~77kcal/100g). Calories derived from pulses were consistent among all pulse treatments (44%). The pulse treatments and control all contained macaroni pasta and homemade tomato sauce.
88885963|NCT01410851|Experimental|Pasta, tomato sauce and added navy beans|The pulse treatments and control (pasta with tomato sauce) were made the day before the session and the recipe was calculated to provide 1500 kcal at each session. All meals had the same energy density (~77kcal/100g). Calories derived from pulses were consistent among all pulse treatments (44%). The pulse treatments and control all contained macaroni pasta and homemade tomato sauce.
88885964|NCT01410851|Experimental|Pasta, tomato sauce with yellow peas|The pulse treatments and control (pasta with tomato sauce) were made the day before the session and the recipe was calculated to provide 1500 kcal at each session. All meals had the same energy density (~77kcal/100g). Calories derived from pulses were consistent among all pulse treatments (44%). The pulse treatments and control all contained macaroni pasta and homemade tomato sauce.
88885965|NCT01410851|Experimental|Pasta and tomato sauce|The pulse treatments and control (pasta with tomato sauce) were made the day before the session and the recipe was calculated to provide 1500 kcal at each session. All meals had the same energy density (~77kcal/100g). Calories derived from pulses were consistent among all pulse treatments (44%). The pulse treatments and control all contained macaroni pasta and homemade tomato sauce.
88885966|NCT01410864||DuraSeal Arm|Prospective enrollment of subjects who have received DuraSeal Exact Spinal Sealant System for treatment of an intentional or incidental dural tear during spine surgery.
88885967|NCT01410864||Control Arm|Subjects who have undergone a spinal procedure where techniques other than DuraSeal were administered for the treatment of either an intentional or incidental opening of the dura may be enrolled either prospectively or retrospectively (via medical record screening)
88885968|NCT01410877||Inhaler naive healthy volunteers|
88885969|NCT01410903|Experimental|TheraSorb Ig|
88885970|NCT01410955|Experimental|Probiotics|Patients receiving probiotics.
88885971|NCT01410955|Placebo Comparator|Placebo|Patients receiving placebo
88885972|NCT01410968|Experimental|Vaccination|vaccination with investigational Poly-ICLC & peptide-pulsed dendritic cells
88885973|NCT01410981||Multiple Myeloma subjects with bone marrow aspirate/biopsy|All patients seen at MUSC with a diagnosis of multiple myeloma or possible multiple myeloma who undergo bone marrow aspirate and biopsy will be approached for participation in this study.
88885974|NCT01411007||Smokers|Nicotine addicted smokers, smoking an average of at least 10 cigarettes per day.
88885975|NCT01411007||Non-Smokers|
88885976|NCT01411020|Experimental|Grupo 1|Doses of induction: propofol 4 mcg/ml and fentanyl 3 mcg/kg
88885977|NCT01411020|Experimental|Grupo 2|Dose of induction: propofol 4.5 mcg/ml and fentanyl 3 mcg/kg
88885978|NCT01411020|Experimental|Grupo 3|Doses of propofol: propofol 5 mcg/ml and fentanyl 3 mcg/kg
88885979|NCT01411020|Experimental|Grupo 4|Doses of induction: propofol 5.5 mcg/ml and fentanyl 3 mcg/kg
88885980|NCT01411020|Experimental|Grupo 5|Doses of induction: propofol 6 mcg/ml and fentanyl 3 mcg/kg
88885981|NCT01411020|Experimental|Grupo 6|Doses of induction: propofol 4 mcg/ml and fentanyl 5 mcg/kg
88885982|NCT01411020|Experimental|Grupo 7|Doses of induction: propofol 4.5 mcg/ml and fentanyl 5 mcg/kg
88885983|NCT01411020|Experimental|Grupo 8|Doses of induction: propofol 5 mcg/ml and fentanyl 5 mcg/kg
89536695|NCT02471105|Experimental|Saflutan 15 µg/ml + Lumigan 0.01%|Tafluprost Unit Dose Preservative Free 15microgram/ml Eye drops solution Topical use Once in the evening 3 months
88885984|NCT01411020|Experimental|Grupo 9|Doses of induction: propofol 5.5 mcg/ml and fentanyl 5 mcg/kg
88885985|NCT01411020|Experimental|Grupo 10|Doses of induction: propofol 6 mcg/ml and fentanyl 5 mcg/kg
88885986|NCT01411033||Newly diagnosed diabetes mellitus type 1|
88885987|NCT01411046||RA treated with prednisolone|Patients with RA treated with prednisolone, minimum 5 mg/day for minimum 6 months. Patients are grouped according to haplotype of 4 SNPs of the glucocorticoid recepror gene. Patients with or without these polymorphisms were invited to a Synacthen® test, but patients with a mixed hetero- and homozygote genotype were not. Adrenal function is evaluated with a Synacthen test.
88885988|NCT01411059|Experimental|yoga|32 weeks of yoga training
88885989|NCT01411072|Experimental|Gemcitabine|
88885990|NCT01411072|Experimental|5-fluorouracil|
88885991|NCT01411098|Experimental|Treatment (radiation therapy and chemotherapy)|Patients undergo 3D-CRT or IMRT 5 days a week for 8 weeks. Patients also receive cisplatin IV over 60 minutes on days 1, 8, 28, and 36 and etoposide IV over 60 minutes on days 1-5, and 28-32.
89004894|NCT00224718|Experimental|2|endovascular procedure
89004895|NCT00207129|Experimental|A|
89004896|NCT00207129|Experimental|B|
89004897|NCT00224757|Active Comparator|Aspirin|Ascal 100mg once daily
89004898|NCT00224757|Active Comparator|Coumarin derivates|Acenocoumarol or fenprocoumon
89004899|NCT04722159||Treatment resistent hypertensives, treated with renal denervation|Patients having undergone renal denervation and fulfilling the criteria for resistant hypertension according to the criteria as applied in the Swedish Registry for Renal Denervation (Office BP >140/90 despite treatment with at least three antihypertensive drugs) with a follow up period of at least 5 years.
89004900|NCT04722159||Treatment resistent hypertensives, conservatively treated|Patients fulfilling the criteria for resistant hypertension according to the criteria as applied in the Swedish Registry for Renal Denervation (Office BP >140/90 despite treatment with at least three antihypertensive drugs) with a follow up period of at least 5 years.
89004901|NCT00224835|Experimental|1|Mindfulness Based Stress Reduction Class
89004902|NCT00224835|Experimental|2|Cardiac Education Class
89004903|NCT00195104|Experimental|All Patients|Arsenic trioxide [TrisenoxTM Injection], 0.25mg/kg/dose administered intravenously over 1 to 4 hours
89004904|NCT00207285|Other|In Person Training|These firefighters received the sleep education and sleep disorders screening in person by one of our research staff.
89004905|NCT00207285|Other|Train the Trainer|These firefighters received the education and sleep disorder screening in person with someone taught by our research staff.
89004906|NCT00207285|Other|Online Group|These firefighters took the sleep disorder screening and education online.
89004907|NCT00195182||1. No intervention|This group received follow-up every 2-months for one year. Follow-up included questions about their blood pressure and how well they had been able to adhere to their medication goal.
89004908|NCT00195182||2. Experimental|This group received follow-up every 2-months for one year. Follow-up included questions about their blood pressure and how well they had been able to engage adhere to their medication goal. The intervention included receiving an additional educational workbook about using positive affect and self affirmation, as well as participating in using positive affect and self-affirmation to motivate behavior change, which in this case was to increase their physical activity level.
89004909|NCT00413127|Experimental|1|Lidocaine i.v
89004910|NCT00413127|Active Comparator|2|intraoperatively lidocaine epidural postoperatively lidocaine i.v.
89004911|NCT00413127|Active Comparator|3|intraoperatively lidocaine i.v. postoperatively lidocaine epidural
89004912|NCT00413127|Active Comparator|4|lidocaine epidural
89004913|NCT00413127|Placebo Comparator|5|placebo i.v.
89004914|NCT00207363|Experimental|Initial induction therapy|Receive Peg Intron 3.0mcg/kg/wk for 12 weeks followed by Peg Intron 1.5 mcg/kg/wk for 36 weeks
89004915|NCT00207363|Active Comparator|Standard of Care|Peg Inter 1.5mcg/kg/wk for 48 weeks
89004916|NCT00207402|Active Comparator|rosiglitazone|Treatment with rosiglitazone 4 mg twice a day for 3 months prior to and during the course of 48 weeks of treatment with interferon alfacon-1 15mcg/0.5ml SQ daily and weight-based ribavirin.
89004917|NCT00207402|No Intervention|No Avandia|Monitoring period without rosiglitazone for 3 months prior to 48 weeks of interferon alfacon-1 15mcg/0.5ml SQ daily and weight-based ribavirin
89004918|NCT00471328|Experimental|Nilotinib|400mg twice daily in core and extension phases of the study.
89004919|NCT00471328|Active Comparator|Control/cross-over to Nilotinib|"In core study phase, patients in this arm received Best Supportive Care (BSC) with or without imatinib or sunitinib at the last tolerated dose or at the investigator's choice until documented disease progression followed by cross-over to nilotinib arm.~Patients entering the extension study on this control arm were permitted to cross over to nilotinib arm only upon documented disease progression."
89004920|NCT00126308|Experimental|Immediate|poly-L-lactic acid injections
89004921|NCT00126308|Active Comparator|Delayed|poly-L-lactic acid injections
89004922|NCT00225069|Experimental|1|T2 sympathectomy
89004923|NCT00225069|Experimental|2|T2-T3 sympathectomy
89004924|NCT00207441|Experimental|Arthritis self management program|
89004925|NCT00207441|Experimental|Chronic Disease Self Management Program|
89004926|NCT00225186|Experimental|Arm 1|
89004927|NCT00225225|Active Comparator|fixed calorie (500 kcal) Reduction|
89004928|NCT00225225|Placebo Comparator|Control (no diet change)|
89004929|NCT00225264|Experimental|Pioglitazone QD|
89004930|NCT00225264|Active Comparator|Glimepiride QD|
89004931|NCT00202280|Placebo Comparator|Placebo pill|Placebo pill daily for 3 months
89004932|NCT00202280|Experimental|5mg folic acid, 0.4mg B12, 50mg B6|5mg folic acid, 0.4mg B12, 50mg B6 in one pill, daily for 3 months
89004933|NCT00470470|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive oral imatinib mesylate twice daily for up to 12 weeks in the absence of disease progression or unacceptable toxicity.
89004934|NCT00470275|Experimental|Cytarbine|Cytarabine IV every 12 hours days 1-5 of 21 day cycle. Response evaluation after 6 cycles of therapy.
89004935|NCT00225381||metabolic gas exchange and cardiac output|
89004936|NCT00225381||mass spectrometer and anaerobic metabolism|
89004937|NCT00225381||metaboic gas exchange and type of anesthesia induction|
89004938|NCT00225381||metabolic gas exchange and PEEP|
89004939|NCT00225381||metabolic gas exchange and trendelenburg position|
89004940|NCT00225381||Patients requiring tourniquet during surgery|Patients undergoing orthopaedic surgeries requiring tourniquet intervention. Oxygen consumption and CO2 production were measured before, during and after tourniquet release.
89004941|NCT00225381||Patients prone to metabolic acidosis|Oxygen consumption and CO2 measurements taken during long surgeries prone to metabolic acidosis.
89004942|NCT00195728|Experimental|hydrocodone/acetaminophen extended release|
89004943|NCT00470158|Experimental|combined iron and zinc|Iron and zinc together
89004944|NCT00470158|Experimental|Separate iron and zinc|Iron and zinc on separate days
89004945|NCT00470158|Experimental|iron alone|Iron
89004946|NCT00470158|Experimental|zinc alone|Zinc
89004947|NCT00470158|Placebo Comparator|placebo|
89004948|NCT00475540|Active Comparator|Prolift mesh|vaginal prolapse repair with mesh
88885992|NCT01411111|Active Comparator|Rosuvastatin foll by GSK2190915 30mg + rosuvastatin|Subjects will be orally administered rosuvastatin 10 mg/day for 7 days in treatment period 1. The subjects will then receive rosuvastatin 10 mg/day in combination with GSK2190915 30 mg/day for 7 days in treatment period 2A.
88885993|NCT01411111|Active Comparator|Rosuvastatin foll by GSK2190915 100mg + rosuvastatin|Subjects will be orally administered rosuvastatin 10 mg/day for 7 days in treatment period 1. The subjects will then receive rosuvastatin 10 mg/day in combination with GSK2190915 100 mg/day for 7 days in treatment period 2B.
88885994|NCT01411124|Experimental|Gabapentin Enacarbil|600 mg of Gabapentin Enacarbil
88885995|NCT01411124|Active Comparator|diphenhydramine|50 mg
88885996|NCT01411124|Placebo Comparator|placebo|placebo to match
88885997|NCT01411176|Active Comparator|Menthol|20 ml NPO-11
88885998|NCT01411176|Placebo Comparator|Placebo|20 ml NPO-11(Placebo)
88885999|NCT01411189|Other|Menthol|20 mL NPO-11
88886000|NCT01411202|Experimental|Doxycycline|Pleurx insertion with injection of 500mg of doxycycline in 50cc of normal saline.
88886001|NCT01411202|Placebo Comparator|Normal Saline|Pleurx insertion with placebo injection of 50cc of normal saline
88886002|NCT01411254|Experimental|1|
88886003|NCT01411254|Experimental|2|
88886004|NCT01411254|Sham Comparator|3|
88886005|NCT01411280|Placebo Comparator|Laboratory trial|Compare methylphenidate to placebo in an acute laboratory trial
88886006|NCT01411280|Experimental|Home/School trial|Low dose and moderate dose methylphenidate are compared to placebo in a home and school trial
88886007|NCT01411293|Experimental|Low-Fat Dairy|Participants will ingest 2 cups of low-fat milk on 1 occasion prior to measure postprandial changes in vascular function
88886008|NCT01411293|Active Comparator|Rice Milk|Participants will ingest 2 cups of rice milk on 1 ocassion prior to measuring postprandial vascular function
88886009|NCT01411306||Med/Surg ICU Inpatients, Intubated ≥ 48 hours|
88886010|NCT01411358|Experimental|AdimFlu-S 2011-2012|
88886011|NCT01411371|Experimental|Catheter Ablation|Catheter ablation of persistent atrial fibrillation to restore normal sinus rhythm.
88886012|NCT01411371|Active Comparator|Medical treatment alone|Patients are randomised to medical treatment alone for atrial fibrillation. Treatment will be as per current guidelines for persistent atrial fibrillation, with rate control as first line (using beta-blockers, calcium channel blockers and digoxin as indicated) and rhythm control as second line (using sotalol, dronedarone, or amiodarone as indicated). (Both groups will receive standard heart failure medication including angiotensin converting enzyme inhibitors, beta blockers, aldosterone antagonists, and diuretics as indicated).
88886013|NCT01411397|Active Comparator|mesh repair|MESH HERNIA REPAIR WHEN REqUIRE INTESTINAL RESECTION
89004949|NCT00475540|Active Comparator|Prolapse repair without mesh|vaginal prolapse repair without mesh
88886014|NCT01411397|Active Comparator|mesh repair without intestinal resection|mesh repair of strangulated hernia without resection
88886015|NCT01411410|Experimental|Copanlisib (BAY80-6946)|The treatment of consists of repetitive cycles, each over 4 weeks. It continues until disease progression or limiting toxicity. If paclitaxel is discontinued for toxicity, BAY80-6946 may continue at the discretion of the investigator if a clinical benefit (response or stable disease for 6 months) is noted.
88886016|NCT01411423||Group 1|
88886017|NCT01411436||Group 1|
88886018|NCT01411449||Group 1|
88886019|NCT01411462||VIBE-DEB|
88886020|NCT01411475||Bifurcation restenosis|Patients with either a main vessel or a side branch restenosis following succesful percutaneous coronary intervention
88886021|NCT01411514|Experimental|Prednisone|
88886022|NCT01411514|Placebo Comparator|Placebo|
88886023|NCT01411540|Experimental|Whole grain diet|Subjects will eat a whole grain based diet for eight weeks. Pre-and post-diet intervention testing will determine effects on body composition. Whole grain-based are will be compared to the refined grain based diet.
88886024|NCT01411540|Active Comparator|Refined grain diet|Subjects will eat a refined grain diet for 8 weeks matched with the whole grain arm for calorie and macro nutrient intake. Pre-and post-diet testing will determine effects on body composition.
88886025|NCT01411553|No Intervention|Reusable ECG leadwires-ICU|Current ECG leadwires will be used
88886026|NCT01411553|Active Comparator|Disposable ECG leadwires-ICU|Disposable ECG-LW
88886027|NCT01411566|Experimental|Treatment|
88886028|NCT01411566|Active Comparator|Control|
88886029|NCT01411579||Clinical Benefit|The patients responding to the chemotherapy, i.e. who show at least a non progressive disease
88886030|NCT01411579||Non responder|The patients non responding to the chemotherapy, i.e. who show a progressive disease
88886031|NCT01411605|Experimental|Exercise training|"12-week supervised exercise-training (ET) program consisting of two 60-min and one 120-min exercise sessions per week which focus mainly on aerobic exercises (cycling, treadmill, rower).~Initial aerobic exercise intensity is set at 60 % of HR peak and will reach 80 % at the end of the ET protocol."
88886032|NCT01411618|Experimental|free alcohol essential oil moutwash|
88886033|NCT01411618|Active Comparator|alcohol containing essential oil mouthwash|
88886034|NCT01411631|Active Comparator|Grape juice|Participants will drink 100% concord grape juice daily for 12 weeks
88886035|NCT01411631|Placebo Comparator|Placebo drink|Participants will drink the placebo for 12 weeks. The placebo will be equicaloric and matched on appearance, taste, volume and macronutrient composition to the grape juice drink.
88886036|NCT01411657|Experimental|NT-501 CNTF Implant|Patients will receive single NT-501 CNTF implant in one eye
88886037|NCT01411670|Experimental|Human protein C concentrate|
88886038|NCT01411670|Active Comparator|activated protein C|Continuous infusion of Activated Protein C
88886039|NCT01411670|Placebo Comparator|Placebo|Standard treatment
88886040|NCT01411683|Experimental|4 mini dental implants|Retention of an overdenture by means of 4 mini implants.
88886041|NCT01411683|Experimental|2 mini dental implants|Retention of an overdenture by means of 2 mini implants.
88886042|NCT01411683|Active Comparator|2 conventional dental implants|Retention of an overdenture by means of 2 conventional implants associated to ball attachments.
88886043|NCT01411709|Active Comparator|Vitano|
88886044|NCT01411709|No Intervention|Control|No tablets - control group
89409956|NCT04866342|Experimental|Servo control - Masimo oximetry technology (Oxygen Assist Module, IntellO2, Vapotherm)|"Automated control of oxygen. The oxygen saturation target range will be set to 90-95% (set to maintain an integral value of 93%) as per standard clinical practice.~Automated oxygen control can be overridden by manual adjustment of oxygen at any time if this is considered necessary to optimise control of oxygenation according to current clinical targets."
89409957|NCT04866342|Active Comparator|Servo control - Nellcor oximetry technology (Oxygen Assist Module, IntellO2, Vapotherm)|"Automated control of oxygen. The oxygen saturation target range will be set to 90-95% (set to maintain an integral value of 93%) as per standard clinical practice.~Automated oxygen control can be overridden by manual adjustment of oxygen at any time if this is considered necessary to optimise control of oxygenation according to current clinical targets."
89409958|NCT04844034|Active Comparator|Active treatment|High-EPA multinutrient supplement.
89409959|NCT04844034|Placebo Comparator|Placebo|Inert oil mix.
89409960|NCT04840134|Experimental|From Hardship to Hope: Financial Wellness Intervention|"From Hardship to Hope: A Peer-led intervention to reduce financial hardship and suicide risk~Over the course of this study, the investigators will develop and pilot a financial wellness intervention to work in tandem with clinical treatment. The intervention will support individuals experiencing financial hardship and suicide risk to address their financial difficulties (e.g., debt, inability to meet basic needs) by coaching them on financial management techniques, facilitating a financial wellness plan, and connecting them with community-based financial supports (e.g., free financial counseling). The intervention will be facilitated by trained peer specialists, who are individuals with lived experience of financial hardship and suicidal ideation or suicidal behaviors who are state certified peer specialists (having met formal training and experience requirements)."
89409961|NCT04821687|Experimental|Opicapone 50mg|
89409962|NCT04821687|Active Comparator|Levodopa 100mg|
89409963|NCT04810247|Experimental|Body Project intervention|
89409964|NCT04809402|Other|Telemonitoring|Subjects in the telemonitoring group will have post-operative follow-up measurements involving teleconsultations, remote eye exams and health questionnaires.
89409965|NCT04809402|No Intervention|Usual care|Subjects in the usual care group will receive regular post-operative care, mostly involving in-hospital consultations.
89409966|NCT04764344|Experimental|Haloperidol|2.5 mg of IV haloperidol diluted to a final concentration of 5 mL with 0.9% sodium chloride
89409967|NCT04764344|Active Comparator|Ondansetron|4 mg of IV ondansetron diluted to a final concentration of 5 mL with 0.9% sodium chloride
89409968|NCT04738981|Experimental|UC-MSC and anti-CD25 mAb|UC-MSC, iv, 1×10^6 cells/kg, once a week, for 4 weeks. Anti-CD25 mAb, iv, 20mg，twice in first week and once a week thereafter, 4 weeks. Other treatment would replace it according to clinical experience if aGVHD continue to progress within 3 weeks of treatment or patients are lack of response after 4 weeks of treatment. The treatment would be repeated in another 4 weeks if patients receive partial response after the first 4 weeks of treatment.
89409969|NCT04738981|Active Comparator|Anti-CD25 mAb|Anti-CD25 mAb, iv, 20mg，twice in first week and once a week thereafter, for 4 weeks. Other treatment would replace it according to clinical experience if aGVHD continue to progress within 3 weeks of treatment or patients are lack of response after 4 weeks of treatment. The treatment would be repeated in another 4 weeks if patients receive partial response after first 4 weeks of treatment.
89409970|NCT04709185|Experimental|AVS after 1mg DST|Patients divided into AVS after 1mg DST group need to oral 1mg dexamethasone the night before AVS
89409971|NCT04709185|Placebo Comparator|AVS after placebo|Patients divided into AVS after placebo group need to oral placebo the night before AVS
89409972|NCT04693156|Active Comparator|oblique subcostal tap block|ultrasound-guided right oblique subcostal TAP block with an anesthetic solution of %0.5 Bupivacaine 10ml + %1 Prilocaine 10ml + %0.9 NaCl (sodium chloride) 10ml and ultrasound-guided posterior TAP block with %0.9 NaCl 30ml
88886045|NCT01411722|Other|EADIWEANING|Patients mechanically ventilated for more than 48 hours during the weaning process.
88886046|NCT01411735|Active Comparator|Enalapril|2.5mg titrated up to 10mg- twice daily
89004950|NCT00472186|Experimental|1|Post-operative administration of Lansoprazole
89004951|NCT00472186|Placebo Comparator|2|Placebo
89409973|NCT04693156|Active Comparator|posterior tap block|ultrasound-guided right oblique subcostal TAP block with %0.9 NaCl 30ml and ultrasound-guided posterior TAP block with an anesthetic solution of %0.5 Bupivacaine 10ml + %1 Prilocaine 10ml + %0.9 NaCl 10ml
89004952|NCT00202358|Placebo Comparator|placebo|
88886047|NCT01411735|Placebo Comparator|placebo|2.5 mg titrate up to 10mg twice daily placebo comparator
88886048|NCT01411748|Experimental|S. boulardii|The patients in this group will be given 5 million unit/day S. boulardii until discharge.
88886049|NCT01411748|Active Comparator|nystatin|
88886050|NCT01411761|Experimental|Saccharomyces boulardii|study group
88886051|NCT01411761|Placebo Comparator|placebo|serum physiologic
88886052|NCT01411787|No Intervention|Control Group|Patient will continue normal activities. Ki-67 will be measured in the initial core biopsy and then again in the final pathologic specimen which is removed for definitive surgical intervention. Insulin resistance levels will be measured by obtaining insulin-like growth factor binding protein one and C-peptide levels just prior to initiation of neoadjuvant chemotherapy, and then again after the last chemotherapy dose. Body mass index, percent body fat, and improving fitness levels will also be measured.
89004953|NCT00202358|Experimental|atenolol|
89409974|NCT04693156|Active Comparator|dual tap block|ultrasound-guided right oblique subcostal TAP block with %0.5 Bupivacaine 10ml + %1 Prilocaine 10ml + %0.9 NaCl 10ml and ultrasound-guided posterior TAP block with an anesthetic solution of %0.5 Bupivacaine 10ml + %1 Prilocaine 10ml + %0.9 NaCl 10ml
89409975|NCT04677556|Other|Severe acute bronchiolitis|Infants under 6 months admitted in Pediatric Intensive Care Unit for a severe acute bronchiolitis needing NIV (modified Woof clinical asthma score (WCAS) >4 and/or hypercapnic acidosis (pH<7,3 and/or pCO2>50mmHg)
89409976|NCT04647682||One single group study|Patients aged 75 years and over Hospitalized in a French COVID-19 geriatric unit Positive COVID-19 infection made by Real-time Polymerase Chain Reaction COVID-19 or suspected on thoracic lesions on computerized tomography.
89409977|NCT04645979||Participants|Participants who used betamethasone plus loratadine to treat allergic rhinitis within the previous two months.
89409978|NCT04617496|Experimental|Combined speech and exercise intervention|Home-based exercise intervention with interactive automated speech response features that encourage a higher level of speech performance.
89409979|NCT04617496|Active Comparator|Control group|Health education
89409980|NCT04606030|Experimental|BioBridge treatment group|Vascularized Lymph Node Transplant surgery (VLNT) supplemented by BioBridge Collagen Matrix implantation
89409981|NCT04606030|Active Comparator|Control group|Vascularized Lymph Node Transplant surgery (VLNT) only
89409982|NCT04589273|Experimental|Alginate capsule|The participants of this arm will be give the alginate capsules
89409983|NCT04589273|Placebo Comparator|Placebo|The participants of this arm will be give the placebo capsules
89409984|NCT04578210|Experimental|Arm A: allogeneic T memory cells|patients will receive memory T cells
89409985|NCT04578210|Experimental|Arm B: allogeneic NK cells|patients will receive NK cells
89409986|NCT04553341|Experimental|Therepeutic|rTMS
89409987|NCT04549454|Experimental|Intervention App|Students in arm of the study will have a parent who has access to the following content in the parent app: (a) FITSTART+ PBI materials (personalized normative feedback quiz, information on college student drinking, and alcohol-specific advice for parents of first year students); (b) general advice for parents of college students (e.g., improving communication; reducing conflict); (c) information about university resources; and (d) a community section (parents can view other parent profiles, submit family photos, and view family photos submitted by other parents).
89409988|NCT04549454|Placebo Comparator|Control App|Students in this arm of the study will have a parent who has access to the following content in the parent app: (a) general advice for parents of college students (e.g., improving communication; reducing conflict); (b) information about university resources; and (c) a community section (parents can view other parent profiles, submit family photos, and view family photos submitted by other parents).
89409989|NCT04546451|Experimental|Music practice|Patients will receive Music Practice interventions of 45 minutes twice a week over 6 months, provided by a professional musician
89409990|NCT04546451|Experimental|Psychomotor therapy|Patients will receive Psychomotor interventions of 45 minutes twice a week over 6 months, provided by a professional psychomotor therapist
89409991|NCT04546451|No Intervention|Passive control group|Healthy passive controls will pass all measurements without any intervention. The control group participants must adhere to the same inclusion and exclusion criteria as the experimental groups, except for an MCI diagnosis. Control participants will be matched to the experimental groups for age, gender and education level.
89409992|NCT04533425||Patients with syncope|Patients who present to the ED with syncope
89409993|NCT04510532||Patients with Breast Cancer who use pyrotinib|The diagnosis of Breast Cancer was made based on the clinical classification criteria. The subjects were given pyrotinib as having HER2-positive breast cancer with no metastasis.
88886053|NCT01411787|Experimental|Exercise|"Five woman undergoing neoadjuvant chemotherapy for breast cancer will be randomized to an exercise protocol supervised by an experienced personal trainer. The exercise will be administered three times a week for the 4-6 months of neoadjuvant chemotherapy. The exercise protocol will consist of activities including walking/running up to a mile, calisthenics, and light weightlifting.~Ki-67 will be measured in the initial core biopsy specimen and then again in the final pathologic specimen which is removed for definitive surgical intervention. Insulin resistance levels will be measured by obtaining insulin-like growth factor binding protein one and C-peptide levels just prior to inititation of neoadjuvant chemotherapy and then again after the last chemotherapy dose in both arms. Body mass index, percent body fat, and improving fitness levels will also be measured."
88886054|NCT01411800|Experimental|Treatment A|500 mg LX1033, capsules administered two times per day orally
88886055|NCT01411800|Experimental|Treatment B|500 mg LX1033, tablets administered two times per day orally
88886056|NCT01411813||Alprazolam|Patients receiving Alprazolam.
88886057|NCT01411826|Active Comparator|Information|
88886058|NCT01411826|Experimental|Information + Narratives + Support group|
88886059|NCT01411865|Experimental|Intervention|
88886060|NCT01411865|Other|Control|
89409994|NCT04510532||Patients with Breast Cancer who use apatinib|The diagnosis of Breast Cancer was made based on the clinical classification criteria. The subjects were given apatinib as having HER2-negative breast cancer with no metastasis.
89536696|NCT03108989|Experimental|Sugammadex group|After the end of surgery, sugammadex of 2 mg/kg will be administered to reverse neuromuscular blockade.
88886061|NCT01411878|Experimental|Reducing the Risk|Students will be randomly assigned to participate in Reducing the Risk training
88886062|NCT01411878|Experimental|Love Notes|The second healthy relationships program for high-risk youth, Love Notes, was developed to educate participants about healthy relationships, including issues of decision-making, communication and conflict resolution, and overall safety, including the prevention of pregnancy and sexually transmitted disease (Pearson, 2009). Love Notes is a derivative of the Prevention and Relationship Enhancement Program (PREP; Stanley, Markman, & Jenkins, 2009), which is relationship marriage education program listed as an evidence-based practice (EBP) by SAMSHA (www.samhsa.gov).
88886063|NCT01411904|Experimental|MagProbe (TM)|"Patients whose bone marrow aspirates are exposed to the MagProbe and CD34 nanoparticles.~Leukemia patients~MagProbe (TM)~Diagnosed or suspected leukemia~Non-leukemia patients~MagProbe (TM)~Requiring bone marrow biopsy"
88886064|NCT01411930|Experimental|Olanzapine -> Aripiprazole|Crossover design. Order of agents is randomized. For this arm, the order will be IM olanzapine (1st clamp study) and IM aripiprazole (2nd clamp study).
88886065|NCT01411930|Experimental|Aripiprazole -> Olanzapine|Crossover design. Order of agents is randomized. For this arm, the order will be IM aripiprazole (1st clamp study) and IM olanzapine (2nd clamp study).
89409995|NCT04510532||Control group|The controls were healthy volunteers who have normal electrocardiographic and echocardiographic results and normal CMR findings
89409996|NCT04504331|Experimental|Cohort 1: Infigratinib (100mg) + Tamoxifen|In study part 1 (dose exploration), participants will receive up to infigratinib 100 mg. 100 mg of Infigratinib will be administered orally daily, 3 weeks on, 1 week off + 20 mg/day tamoxifen
89409997|NCT04504331|Experimental|Cohort 2: Infigratinib (125mg) + Tamoxifen|In study part 1 (dose exploration), participants will receive up to infigratinib 125 mg. 125 mg of Infigratinib will be administered orally daily, 3 weeks on, 1 week off + 20 mg/ day tamoxifen
89409998|NCT04504331|Experimental|Cohort 3: Infigratinib (75mg) + Tamoxifen|In study part 1 (dose exploration), participants will receive up to infigratinib 75 mg. 75 mg of Infigratinib will be administered orally daily, 3 weeks on, 1 week off + 20 mg/day tamoxifen
89409999|NCT04457102|Active Comparator|Arm N°1 - Standard treatment-Breast DIBH|Patients will be treated during spontaneous breath hold wich is considered as the gold-standard radiotherapy treatment for left breast cancer.
89410000|NCT04457102|Experimental|Arm N°2 - Interventional -Breast MANIV DIBH|Irradiation will take place during DIBH induced by MANIV (Bellavista 1000, IMTMedical®) with SL mode. Oxygen will be added (FiO2 60%) to safely and easily prolong the DIBH duration up to 30 seconds to allow the complete delivery of a treatment beam.
89410001|NCT04457102|Experimental|Arm N°3 - Interventional -Liver/Lung MANIV DIBH|Irradiation will take place during DIBH induced by the MANIV (Bellavista 1000, IMTMedical®) with SL mode. Oxygen will be added (FiO2 60%) to safely and easily prolong the DIBH duration up to 30 seconds to allow the complete delivery of a treatment beam [13]. Prior to treatment, a radio-opaque fiducial will be implanted in the tumor by an interventional radiologist, to facilitate the tumor position monitoring from onboard imaging. Residual tumor baseline shift and motion will thus be measured during beam delivery, and used to recompute the optimal safety margins that ensure an adequate dose coverage of at least 90% of tumors, according to literature recommendations [24]. We will also compare these safety margins computed under MANIV condition with those routinely applied in free-breathing condition to estimate the gain in terms of margin reduction.
89410002|NCT04457102|Experimental|Arm N°4 - Interventional -Liver/Lung MANIV VC|Patients will be ventilated by VC mode during their treatment. For each fraction, the treatment time, the number of reconstructions of the tracking model and the correlation errors of the model will be collected. The same information will be extracted from a matched retrospective cohort treated by tracking in spontaneous breathing.
89410003|NCT04457102|Other|Arm N°5 -Liver/Lung MANIV DIBH for PT|Data on tumor position and its residual motion from patients included in the arm n°3 will be used to compute the planned and in silico delivered dose distribution with PBS PT. The MIRO lab (UCLouvain - IREC) has developed comprehensive tools for simulating treatment delivery on patients CT images using the Monte Carlo dose engine MCsquare [25], coupled with log-file acquisitions [26]. In this way, we will be able to validate our approach in silico in collaboration with IBA, as a first step before conducting prospective trials for the clinical validation of this approach.
89410004|NCT04447911|Experimental|Empagliflozin|Empagliflozin (Jardiance)® 25mg per os once daily for 30 days
89410005|NCT04447911|Placebo Comparator|Placebo|Placebo (Lactose tablet) per os once daily for 30 days
89410006|NCT04443452||Prevalent Central Sensitisation|Participants with sensitisation that significantly deviates from the normal mean as assessed by Quantitative Sensory Testing
89191863|NCT04046289||Regular Calcium|regular calcium milk of 180 ml, twice daily for 24 weeks
89191864|NCT04046289||Probiotic 1|regular calcium milk of 180 ml + probiotic, twice daily for 24 weeks
88886066|NCT01411956|Experimental|Treatment Group|"This group viewed the intervention video, a 24-minute episode of the sitcom White Coats, deliberately scripted with the five health behavior theory constructs we are testing."
88886067|NCT01411956|Placebo Comparator|Control Group|The control group viewed a 25-minute video on an unrelated subject (depression).
88886068|NCT01411969||External nasal dilator, decongestion|
88886069|NCT01412008|No Intervention|botox diffusion|Each subject was given 3 injections in lateral gastrocnemius muscle:2 botox, 1 saline, each injection was 2.5mL. MRI of the lower leg was taken prior to injections and 2 months post for a comparison of diffusion properties.
88886070|NCT01412073|Active Comparator|oxytocin bolus|"5 IU bolus iv over 3 minutes after delivery of the baby Operative blood loss will be estimated in theatre based on the volume in the suction bottle and the weight of swabs used. We will record blood loss up until the time the woman will be discharged from the theatre recovery ward.~Hemoglobin level and haematocrit value will be done as follow:-~After admission of each case in the pre-operative period.~Immediately post- operative.~24 hours post- operative."
89191865|NCT04046289||Probiotic 2|regular calcium milk of 180 ml + probiotic, twice daily for 24 weeks
89191866|NCT02554071|Experimental|Pharmacist - Smoking Cessation Support'|Active Comparator Arm Receive smoking assessment Initial Smoking Cessation Counselling Smoking Cessation Prescription/Non-Prescription Product as required Follow-up Counselling
89191867|NCT00855322|Experimental|1|Gym group exercise intervention
88886071|NCT01412073|Active Comparator|oxytocin bolus & oxytocin infusion|5 IU oxytoxin bolus over 3 minutes and 30 IU oxytocin infusion in 500 ml 0.9% saline over 4 hours after delivery of the baby
88886072|NCT01412073|Active Comparator|misoprostol intrauterine|misoprostol 800 micrograms intrauterine, placed manually on the bottom of the uterine cavity after delivery of the placenta and cleaning of the cavity
88886073|NCT01412099|Experimental|Feedback report plus peer counseling|
88886074|NCT01412099|Experimental|Feedback report|
89004954|NCT00479713|Experimental|1|Arm 1: drug
89191868|NCT00855322|Experimental|2|Hydrotherapy group exercise intervention
89191869|NCT00855322|No Intervention|3|Control group
89191870|NCT00807807|Placebo Comparator|1|Participants will receive placebo folic acid.
89191871|NCT00807807|Experimental|2|Participants will receive 100 mcg of folic acid.
89191872|NCT00807807|Experimental|3|Participants will receive 400 mcg of folic acid.
89191873|NCT00807807|Experimental|4|Participants will receive 1000 mcg of folic acid.
89410007|NCT04443452||Non-prevalent Central Sensitisation|All other participants with sensitisation that is not significantly deviating from the normal mean as assessed by Quantitative Sensory Testing
89410008|NCT04384835||Mild to moderate asthma|low or medium dose of inhaled steroids according to GINA guidelines
89410009|NCT04384835||Severe asthma|criteria described by the ATS / ERS guidelines (for the recruitment of severe patients)
89191874|NCT00807807|Experimental|5|Participants will receive 2000 mcg of folic acid.
89410010|NCT04336215||Healthcare Workers|546 HCW with high intensity direct patient care from two RBHS-affiliated academic hospitals: Robert Wood Johnson University Hospital (New Brunswick, NJ) and University Hospital (Newark, NJ) and Rutgers School of Dental Medicine (Newark, NJ).
89410011|NCT04336215||Non-Healthcare Workers|283 non-healthcare workers (NHCW) from Rutgers faculty, postdoctoral students, students, other trainees, administrators, and staff who do not have patient contact.
88886075|NCT01412125||Patient|Voluntary Huntington patients symptomatic or asymptomatic, with a number of nucleotide expansion(CAG) ≥36 and who know their genetic status
89531066|NCT03341195|Active Comparator|3. One way automated calls.|Parents/caregiver will receive one way educational/reminder/proactive automated phone call related to routine immunization once a week till 20 weeks of age.
88886076|NCT01412125||Healthy subject|Voluntary controls with no family history of huntington's disease
88886077|NCT01412138||ARM 1|ENDOMETRIAL SAMPLE
89004955|NCT00479713|Active Comparator|2|Arm 2: active comparator
88886078|NCT01412203|No Intervention|Usual Practice|School continues with regular programming
88886079|NCT01412203|Experimental|Action Schools! BC|School adopts the AS!BC model
88886080|NCT01412216|Experimental|Fish Oil (Omega-3 Fatty Acids)|High-dose, short-duration dietary omega-3 fatty acids supplementation
88886081|NCT01412216|Placebo Comparator|Placebo|Placebo control
88886082|NCT01412242|Experimental|Extensive search for isolated calf DVT|As this is a prospective cohort study, for definition there is only 1 arm
88886083|NCT01412294|Experimental|Capecitabine, Cisplatin|
88886084|NCT01412307|Experimental|lenalidomide plus bendamustine|
88886085|NCT01412320|Experimental|Flavanol rich cocoa|
88886086|NCT01412320|Experimental|Flavanol poor|
89410012|NCT04313985|Active Comparator|Electrical Stimulation First, then Sham Stimulation|"Treat the patient's wound area:~Place self-adhesive, conductive electrode pads on either side of the wound on the skin where the pads are not placed in the open wound itself, but rather in the surrounding area with one pad on each side of the wound.~Connect the pads to the lead wire to the Avazzia device. Turn on the Avazzia device and change modes to the RSI mode. Increase power to maximum comfortable power level for the patient. If the patient cannot feel the output, then increase power to 250.~Instruct the patient to reduce the power level if it begins to feel too strong. (sometimes as the microstimulation is applied, the tissue will become more sensitive to the stimulation. In this case the power should be reduced for patient comfort.) Allow to run unattended for 15 minutes. Take a picture of the pad placement and display on the device to document location, power setting, and treatment mode while the treatment is running for the 15 minutes."
89410013|NCT04313985|Sham Comparator|Sham Electrical Stimulation First, then Electrical Stimulation|"Treat the patient's wound area:~Place self-adhesive, conductive electrode pads on either side of the wound on the skin where the pads are not placed in the open wound itself, but rather in the surrounding area with one pad on each side of the wound.~Connect the pads to the lead wire to the Avazzia device. Turn on the Avazzia device and change modes to the RSI mode. Increase power to maximum comfortable power level for the patient. If the patient cannot feel the output, then increase power to 250.~Instruct the patient to reduce the power level if it begins to feel too strong. (sometimes as the microstimulation is applied, the tissue will become more sensitive to the stimulation. In this case the power should be reduced for patient comfort.) Allow to run unattended for 15 minutes. Take a picture of the pad placement and display on the device to document location, power setting, and treatment mode while the treatment is running for the 15 minutes."
89410014|NCT04305782|Experimental|Release/Relock Socket - In Lab|The test socket will be operated by the participant in lab, following a structured protocol. This arm focuses on the order effects on the re-lock panel and pin mechanisms on limb volume.
89410015|NCT04305782|Experimental|Release/Relock Socket - Out of Lab|The test socket will be operated by the participant out of lab, with no structured protocol. This arm focuses on the effects of the re-lock panel and pin mechanisms on participant comfort.
89410016|NCT04305782|Experimental|Release/Relock Socket & Control|The test socket will be operated by the participant out of lab, with no structured protocol. This arm focuses on the comparing participant experience using the novel mechanism versus traditional socket mechanisms.
89410017|NCT04283578|Experimental|Oxytocin|intranasal administration of OT
89410018|NCT04283578|Placebo Comparator|Placebo|intranasal administration of placebo
89410019|NCT04274998|Experimental|AD/MCI or HC|Main Study: Subjects are diagnosed with Alzheimer's Disease (AD)/Mild Cognitive Imparment (MCI) or are healthy volunteers/controls (HC).
89410020|NCT04274998|Experimental|AD/MCI or HC with Genetic Polymorphism|Sub-Study: Subjects have a specific genetic polymorphism andare diagnosed with Alzheimer's Disease (AD)/Mild Cognitive Imparment (MCI) or are healthy volunteers/controls (HC).
89410021|NCT04271371||Prototype intervention|To be developed through Phase 1 and 2
88886087|NCT01412346|Active Comparator|Plant-based food and fish with salt restr.|The subjects consume plant based foods (fruits, berries, vegetables, whole grain) and fish in addition to a salt-restricted diet. Intake of salt is normal to high for 8 weeks and low for 8 weeks (subjects receive salt and placebo capsules in a crossover design).
88886088|NCT01412346|Placebo Comparator|Diet with salt restriction|The subjects follow a salt-restricted diet. Intake of salt is normal to high for 8 weeks and low for 8 weeks (subjects receive salt and placebo capsules in a crossover design).
88886089|NCT01412385|Experimental|Epoch 1 (intravenous pre-study treatment) + Epoch 2|Study Epoch 1 (13 weeks): treatment with KIOVIG (once every 3 or 4 weeks, dose as during pre-study period) + Study Epoch 2 (same for all subjects, 51 weeks): treatment with IGSC, 20% (every week, dose to be calculated on the basis of weekly equivalents)
88886090|NCT01412385|Experimental|Epoch 1 (subcutaneous pre-study treatment) + Epoch 2|Study Epoch 1 (12 weeks): treatment with SUBCUVIA (once every week or once every two weeks, dose as during pre-study period) + Study Epoch 2 (same for all subjects, 51 weeks): treatment with IGSC, 20% (every week, dose to be calculated on the basis of weekly equivalents)
88886091|NCT01412398||Group 1|Drug (incl. Placebo)
88886092|NCT01412411|Active Comparator|Nutrition Education plus Multiple Micronutrient Fortification|In this group along with the nutritional education, multiple micronutrient fortification was given in the form of Sprinkles
88886093|NCT01412411|Active Comparator|OIS plus Nutritional Eductaion|In this group, along with the nutritional education, Oral Iron Supplementation was given.
88886094|NCT01412411|Active Comparator|Nutrition Education Group|This is group was followed for the growth of the child and was given Nutritional Education to children's mothers.
88886095|NCT01412437|Experimental|Diet|12 participants will be randomized to diet. Phe levels will be followed by blood levels. A dietician will analyze diet for phe content and advise
88886096|NCT01412437|Experimental|sapropterin dihydrochloride|Intervention: 24 participants will be randomized to receive the drug 10 mg/kg per day. Responders and non responders will remain on drug for four months
88886097|NCT01412450|Experimental|nitinol stent|Protégé EverFlex stent
88886098|NCT01412463|Experimental|Protégé EverFlex+|Stenting with Protégé EverFlex+
88886099|NCT01412476||case group|Subjects with metabolic syndrome
89004956|NCT00202397|Placebo Comparator|2|placebo bid for 8 weeks
89004957|NCT00202397|Experimental|1|Riluzole, capsule-shaped 50 mg tablets bid for 8 weeks
89004958|NCT00479635|Experimental|TPI 287|
88886100|NCT01412476||control group|Healthy individuals
88886101|NCT01412489|Experimental|1|For each patient, the HYALOBARRIER Gel was introduced into the uterine cavity with the canula after hysteroscopic myomectomy procedure
88886102|NCT01412502||Brain death with organ donation|"Participants in this group are the nearest relatives (or person-of-trust) of a patient who has passed away within 3 days of admission to an intensive care unit. The cause of death includes brain death with multiple organ donation +/- tissues."
88886103|NCT01412502||Limitation/cessation of active treatment|"Participants in this group are the nearest relatives (or person-of-trust) of a patient who has passed away within 3 days of admission to an intensive care unit. The cause of death includes limitation/cessation of active treatment without brain death."
89410022|NCT04267302|Other|Baby Bouncer Group|Participants in the group will be receiving a baby bouncer for use from infant's birth up to 8 months after birth.
89410023|NCT04267302|Other|Baby Bouncer Group with Infant T-Shirt with LENA|A subsample of the participants in the baby bouncer group will also receive infant t-shirts with wearable audio recorders.
89410024|NCT04267302|Other|Baby Carrier Group|Participants in the group will be receiving a baby carrier for use from infant's birth up to 8 months after birth.
89410025|NCT04267302|Other|Baby Carrier Group with Infant T-Shirt with LENA|A subsample of the participants in the baby carrier group will also receive infant t-shirts with wearable audio recorders.
89410026|NCT04160130|Experimental|SAPIEN 3 or SAPIEN 3 Ultra|Edwards SAPIEN 3 THV system Model 9600 TFX (20, 23, 26 and 29 mm) or SAPIEN 3 Ultra THV system Model 9750 TFX (20, 23, 26) with the associated transfemoral delivery systems.
89410027|NCT04160130|Active Comparator|any surgical bioprosthetic aortic valve|Any commercially available surgical bioprosthetic valve
89410028|NCT04157062|Experimental|Study Group|Participants will receive a type of TMS called repetitive TMS (rTMS) wherein the magnetic pulses delivered will be close together in a rapid sequence. They will receive excitatory rTMS with a stimulation frequency of 10 Hz or higher.
89410029|NCT04143126|Experimental|Cognitive Enhancement Therapy|"This research treatment aims to help with problems in thinking, planning, and socialization. Participants begin with cognitive training using computer software programs. They also participate in a small social-cognitive group to learn about their condition and how to act wisely in social situations by developing the abilities needed to understand another person's perspective, evaluate social contexts, and be foresightful.~Time commitment: about 3½ hours per week; Location: Pittsburgh, PA only"
89410030|NCT04143126|Active Comparator|Enriched Supportive Therapy|"This research treatment uses individual supportive therapy to help patients learn about schizophrenia, manage their emotions and stress, improve their social skills, and cope with everyday problems. Participants will learn about the impact of stress on their lives, and how to identify their own early cues of distress and apply effective coping strategies.~Time commitment: about 2 hours per week; Location: Pittsburgh, PA only"
89410031|NCT04132544|Experimental|Intervention group|"a standardized gerontological evaluation (EGS) and a fall balance performed at home by a Gerontological Assessment Nurse~the proposal for a Proposal for a personalized intervention plan (PIP) to correct potentially reversible and modifiable factors~a close follow-up by the Gerontological Assessment Nurse for the implementation of the PIP throughout the follow-up period of 24 months (6 home visits and 5 telephone follow-ups)."
89410032|NCT04132544|Active Comparator|Comparison group - usual care|Usual Care with the provision of documentation on simple recommendations for the prevention of falls and aging well.
89410033|NCT04123873|Experimental|Group A|"Paracetamol 1000 mg + Ibuprofen 400 mg administered orally 1 hour before surgery and given with 6-hour intervals to a total of 4 times the first postoperative day.~Plus placebo (matching DXM) IV administered after induction of anaesthesia"
89410034|NCT04123873|Experimental|Group B|"Paracetamol 1000 mg and placebo (matching ibuprofen) orally 1 hour before surgery and given with 6-hour intervals to a total of 4 times the first postoperative day.~Plus DXM 24 mg IV after induction of anaesthesia"
89410035|NCT04123873|Experimental|Group C|"Placebo (matching paracetamol) + ibuprofen 400 mg orally 1 hour before surgery and given with 6-hour intervals to a total of 4 times the first postoperative day.~Plus DXM 24 mg IV after induction of anaesthesia"
89410036|NCT04123873|Experimental|Group D|"Paracetamol 1000 mg + ibuprofen 400 mg orally 1 hour before surgery and given with 6-hour intervals to a total of 4 times the first postoperative day.~Plus DXM 24 mg IV after induction of anaesthesia"
89410037|NCT04121585||SL-PLUS™ hydroxylapatite coated cement free hip stem|Total Hip Arthroplasty using the SL-PLUS™ hydroxylapatite coated cement free hip stem
89410038|NCT04117620||Patients|Patients from 7 to 17 years of age with vestibular deficiency.
89410039|NCT04117620||Controls|Subjects from 7 to 17 years of age without vestibular deficiency
89410040|NCT04110795||Cases|Atypical Femur fracture cases
89410041|NCT04110795||Control|matched to AFF cases by race, age, length of ART use
89410042|NCT04106362|Active Comparator|Arm I (radiation therapy, cisplatin)|Beginning on day 0, patients undergo radiation therapy over 6 weeks for a total of 35 fractions. Patients also receive cisplatin IV over 1-2 hours on days 0 and 21.
89410043|NCT04106362|Experimental|Arm II (cetuximab, radiation therapy, cisplatin)|Patients receive cetuximab IV over 120 minutes 5-7 days prior to start of radiation therapy and then IV over 60 minutes weekly on Monday or Tuesday for 7 weeks. Patients also undergo radiation therapy and receive cisplatin as in Arm I.
89410044|NCT04101188|Experimental|Moderate Potassium/Low Sodium|Subjects will be provided with a diet that is moderate in potassium and low in sodium.
89410045|NCT04101188|Experimental|Moderate Potassium/High Sodium|Subjects will be provided with a diet that is moderate in potassium and high in sodium.
89410046|NCT04101188|Experimental|High Potassium/High Sodium|Subjects will be provided with a diet that is high in both potassium and sodium.
89410047|NCT04100733|Active Comparator|Control|Study subjects will cohere to current clinical guidelines for follow-up regimes of HG NMIBC with flexible cystoscopy and cytology every four months for a period of two years.
89004959|NCT00478972|Experimental|Rimonabant|Rimonabant 20 mg once daily in addition to diet and exercise
89004960|NCT00478972|Placebo Comparator|Placebo|Placebo (for Rimonabant) once daily in addition to diet and exercise
89004961|NCT00477529|Experimental|ABI-008|
89004962|NCT00472693|Experimental|Bevacizumab and ABI-007 (Abraxane)|Bevacizumab and ABI-007 (Abraxane)
89004963|NCT00195845|Experimental|Double-Blind Galantamine vs Placebo|Double-Blinded, Placebo-Controlled Study of Galantamine to Improve Cognitive Dysfunction
89004964|NCT00195845|Placebo Comparator|Placebo Control Group|Placebo-Controlled Group
89004965|NCT00202436|Active Comparator|1|Phlebotomy
89004966|NCT00202436|Active Comparator|2|Erythrocytapheresis
89004967|NCT00195884|Experimental|Aerobic Group|Aerobic training is divided into three stages: the Starter phase (during the run-in period), the Progression phase, and the Maintenance phase. All aerobic activities are performed on a cycle ergometer, treadmill, elliptical exercise machine or stairclimber. Subjects are free to vary the machine(s) used from one visit to the next. Exercise intensity is standardized using Polar Heartminder heart rate monitors that display the subject's heart rate and emits a warming signal when heart rate is outside the prescribed training zone, thus guiding the subject in adjustment of the work load up or down to achieve the desired intensity.
89004968|NCT00195884|Experimental|Resistance Group|"Exercises are performed at weight machines arranged in a circuit. Throughout the resistance training program, subjects will alternate between the exercises of group A and group B below.~Group A: abdominal crunches, seated row (back), seated biceps curls, supine bench press (chest), leg press, shoulder press (shoulders and neck); leg extension (quadriceps)~Group B: abdominal crunches, lat pulldown (back), sitting chest press (chest), leg press, upright row (shoulders and neck), triceps pushdown, leg curls (hamstrings).~Subjects are instructed to exhale while lifting a weight and inhale while lowering it, in order to minimize blood pressure excursions. Warm-up and cooldown are the same as for aerobic training."
89004969|NCT00195884|Experimental|Combined Aerobic and Resistance Training|Combined aerobic and resistance training. This group will perform both aerobic and resistance training programs, as described above. The aerobic and resistance components are performed on the same days, in varying orders.
89004970|NCT00195884|No Intervention|Control Group|Members of this group are asked to revert to their pre-study activity levels for 5 months, at which point they begin the combined aerobic and resistance exercise program.
89004971|NCT00202475|Active Comparator|1|
89004972|NCT00202475|Active Comparator|2|
89410048|NCT04100733|Experimental|Intervention|Patients in the interventional arm will be followed at 4, 8, 16 and 20 months after inclusion with Xpert Bladder Cancer Monitor-test (and urinary cytology) instead of flexible cystoscopy.
89410049|NCT04079088|Placebo Comparator|Placebo|Participants will receive BIIB061-matched placebo, orally once daily in addition to IFN-β1 injection or glatiramer acetate for up to 72 weeks.
89004973|NCT00225576|No Intervention|1|Paper prescribing, 2005 and 2007
89004974|NCT00225576|Experimental|2|Paper prescribing 2005 vs. electronic prescribing 2007
89004975|NCT00207831|Experimental|Tegafur uracile + radiotherapy|
89004976|NCT00207831|Active Comparator|radiotherapy|
89004977|NCT00202670||1|SPECT
89004978|NCT00202670||2|dobutamine echocardiography
89191875|NCT05333406|Experimental|Dose group A (Low dose)|Participants will receive EN001 intravenously (IV) once on Day 0.
89410050|NCT04079088|Experimental|BIIB061 Dose 1|Participants will receive BIIB061 Dose 1 orally once daily in addition to IFN-β1 injection or glatiramer acetate for up to 72 weeks.
89410051|NCT04079088|Experimental|BIIB061 Dose 2|Participants will receive BIIB061 Dose 2 orally once daily in addition to IFN-β1 injection or glatiramer acetate for up to 72 weeks.
89004979|NCT00202709|Experimental|Thought Field Therapy (TFT)|Treatment with TFT, first one hour, then 1/2 hour.
89004980|NCT00202709|No Intervention|Wait list control|
89004981|NCT00196157|Experimental|1|linear lesions to ablate persistent atrial fibrillation
89004982|NCT00196157|Experimental|2|focal electrophysiologically guided ablations to treat persistent atrial fibrillation
89004983|NCT00202787|Experimental|1|FOLFOX-4+cetuximab
89004984|NCT00202787|Active Comparator|2|FOLFOX-4
89004985|NCT00202865|Experimental|1|
89410052|NCT04079088|Experimental|BIIB061 Dose 3|Participants will receive BIIB061 Dose 3 orally once daily in addition to IFN-β1 injection or glatiramer acetate for up to 72 weeks.
89004986|NCT00202865|Placebo Comparator|2|
89004987|NCT00226005|Active Comparator|Vatalanib|Administered orally, twice daily: after enrollment - first week 250 BID, second week 500 BID, then 750 BID thereafter.
89004988|NCT00196352|Experimental|1|
89004989|NCT00226044|No Intervention|Oral omeprazole|Standard of care: A single dose of 1 mg/kg orally administered omeprazole.
89004990|NCT00226044|Active Comparator|Rectal omeprazole|A single dose of 1 mg/kg rectally administered omeprazole.
89004991|NCT00202982|Active Comparator|glatiramer acetate 20 mg|glatiramer acetate 20 mg
89004992|NCT00202982|Active Comparator|glatiramer acetate 40 mg|glatiramer acetate 40 mg
89004993|NCT00207948||Therapeutic Dose Adjustment|To adjust the doses of medications to meet target therapeutic concentrations
89004994|NCT00196391|Experimental|1|
89004995|NCT00196391|Experimental|2|
89004996|NCT00196391|Experimental|3|
89004997|NCT00196391|Experimental|4|
89004998|NCT00196391|Experimental|5|
89004999|NCT00196391|Placebo Comparator|6|
89005000|NCT00203060|Experimental|A|Rasagiline treatment
89005001|NCT00203060|Placebo Comparator|B|placebo arm
89005002|NCT00203099|Active Comparator|Glatiramer Acetate, N-Acetylcysteine|
89191876|NCT05333406|Experimental|Dose group B (High dose)|Participants will receive EN001 intravenously (IV) once on Day 0.
89191877|NCT00867256|Experimental|Large Diameter Metal on Metal|
88886104|NCT01412502||Sudden death|"Participants in this group are the nearest relatives (or person-of-trust) of a patient who has passed away within 3 days of admission to an intensive care unit. The cause of death was sudden death of a previously healthy patient (no physical or mental limitations; MacCabe score = 0) within 3 days of admission to ICU without LATA nor brain death."
88886105|NCT01412515|Experimental|Everolimus|everolimus 10 mg per day
89410053|NCT04060030|Experimental|L-leucovorin calcium|The liquid form of leucovorin calcium will be dosed by weight, with a target dose of 1mg/kg/day, divided into two daily doses. This product may be taken alone or mixed with liquid. Participants randomized to this arm will receive active treatment for both 12-week phases of the study.
89410054|NCT04060030|Placebo Comparator|Placebo|The placebo will mimic the experimental treatment in flavor, odor, packaging, and dosing instructions. Participants randomized to this arm will receive placebo for the first 12 weeks of the study, then active treatment for the remaining 12 weeks.
89410055|NCT04033861|Experimental|rhBNP|rhBNP intra-coronary injection 1.5 ug/kg loading dose, with intravenous injection 0.0075-0.01 ug/kg/min persistent for 72 hour.
89410056|NCT04033861|Placebo Comparator|Control|saline intra-coronary injection 0.15ml/kg loading dose, with same intravenous injection speed for 72 hour after randomization.
89410057|NCT04012944|Experimental|Cordella™ Pulmonary Artery Sensor System|The Cordella PA Sensor System (CorPASS) is intended to measure, record, and transmit pulmonary artery pressure (PAP) data from NYHA Class III heart failure patients at home to clinicians for assessment and patient-centered heart failure management
89410058|NCT03990870|Experimental|Experimental Treatment|dCBGT + WASABI
88886106|NCT01412528|Other|Eight different allergens will be standardized in this study|
88886107|NCT01412567|Active Comparator|Vaccine+HBIG|
88886108|NCT01412567|Placebo Comparator|Vaccine+Placebo|
88886109|NCT01412580||observational followup|This was an observational follow-up to a larger study in which treatment group was given 20 mg of vitamin B1, 20 mg of vitamin B2, 25 mg of vitamin B6, 100 mg of niacin, 50 μg of vitamin B12, 500 mg of vitamin C, 30 mg of vitamin E, and 0.8 mg of folic acid
88886110|NCT01412593|Experimental|Stem cell transplant|
88886111|NCT01412593|No Intervention|Control|
88886112|NCT01412606|Experimental|Scrathcing|scratching of endometrium on day 21-26 of a spontaneous menstrual cycle
88886113|NCT01412606|Placebo Comparator|Control|Uterine sounding on day 21-26 of a spontaneous menstrual cycle
88886114|NCT01412632|Experimental|General vs deep sedation|General anesthesia: remifentanil and propofol Deep sedation: remifentanil, propofol and citanest
88886115|NCT01412645|Placebo Comparator|Placebo|
88886116|NCT01412645|Experimental|High-dose Resveratrol|
89410059|NCT03990870|Active Comparator|Active Comparator|dCBGT Only
89410060|NCT03986411|Other|Feasibility study of physiotherapy for UI in athletic women|A mixed methods study with 3 distinct but related phases to explore the feasibility of conducting an RCT of physiotherapy as management of urinary incontinence in athletic women
89410061|NCT03948893|Experimental|MORE|
89410062|NCT03948893|Active Comparator|CBT|
89410063|NCT03921333|Active Comparator|Low dose plant extract|300 mg
89410064|NCT03921333|Active Comparator|Middle dose plant extract|500 mg
89410065|NCT03921333|Active Comparator|High Dose plant extract|700 mg
89410066|NCT03921333|Placebo Comparator|Placebo control|Cellulose microcrystalline
89410067|NCT03913819||substance abuse group|Patients with voiding dysfunction secondary to substance abuse in a special clinic
88886117|NCT01412645|Experimental|Low-dose Resveratrol|
88886118|NCT01412658|Experimental|Milk Peptides|
88886119|NCT01412658|Placebo Comparator|Placebo|Participants ingested 6ml - 21ml (based on participants' weight) of clear, sugar-less liquid placebo mixed with 1/2 cup milk twice daily (once immediately after breakfast and once immediately after dinner). The supplements were prepared in liquid form and packaged in generic bottles for double blind administration. The placebo was a glycerol-based placebo matched for color, texture, and taste to the active supplement.
88886120|NCT01412671||Group 1|
88886121|NCT01412697|Experimental|Fruit and Vegetable Intake Behavioral Intervention|measure fruit and vegetable intake in rural youth based on specific behavioral intervention.
88886122|NCT01412697|No Intervention|Control Group|control group received the standard health information
88886123|NCT01412723|Active Comparator|Ferrous sulphate|Preschool children with depleted levels of iron enrolled in FAN Foundation of Medellin, which will be supplied with ferrous sulfate-fortified milk
88886124|NCT01412723|Experimental|Iron Amino acid chelate|Preschool children with depleted levels of iron enrolled in FAN Foundation of Medellin , which will be supplied with iron amino acid chelate-fortified milk
88886125|NCT01412736|Experimental|2mg|sterile lyophilized formulation, 2mg
88886126|NCT01412736|Experimental|20mg|sterile lyophilized formulation, 20mg
88886127|NCT01412736|Experimental|100mg|sterile lyophilized formulation, 100mg
88886128|NCT01412736|Placebo Comparator|Placebo|two SC administration on day 1
88886129|NCT01412749||eHNS Participant Registry|Participants diagnosed with head and neck cancer who are candidates for definitive surgical resection of the primary tumor and who are candidates for eHNS.
89191878|NCT02570438||Older surgical patients|older patients (≥ 65 years of age) presenting to Massachusetts General Hospital (MGH) or Newton-Wellesley Hospital (NWH) for elective noncardiac, non-neurological surgery requiring hospital admission
89410068|NCT03900273|Experimental|Novel measures of cognition and everyday function|"No Practice Effects (NPE) cognitive battery~Miami Computerized Functional Assessment Scale (CFAS)~Participants will receive three serial assessments of the NPE and CFAS over a one year period. Assessments will take place at baseline, week 12, and week 52."
89410069|NCT03900273|Active Comparator|Established measures of cognition and everyday function|"Preclinical Alzheimer's Cognitive Composite (PACC)~Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog)~Functional Assessment Questionnaire (FAQ).~Participants will receive three serial assessments of the PACC, ADAS-Cog and FAQ over a one year period.~Assessments will take place at baseline, week 12, and week 52."
89410070|NCT03819465|Experimental|A1|Durvalumab
88886130|NCT01412775|Experimental|Psychological stress and exhaustion|Twenty four male and female nurses from the cardiac intensive-care unit (CCU) of Meir Hospital, who consent to take part in the offered intervention program, will participate in the study. The participants will be randomly assigned to an experiment group of 12 participants and a control group of 12 participants.
89410071|NCT03819465|Experimental|A2|Durvalumab + danvatirsen
88886131|NCT01412788|Experimental|peri-areolar incision|Peri-areolar incision was used to carry out lumpectomy
88886132|NCT01412788|Active Comparator|traditional incision|traditional incision above tumor was used to carry out lumpectomy
88886133|NCT01412814|Experimental|Experimental|These patients will carry out the specified intervention of the study with the AposTherapy Biomechanical System in addition to the typical physical therapy regiment prescribed to them by their physician.
88886134|NCT01412814|Active Comparator|Control|The patients within this group will also carry out the typical physical therapy program for total knee replacement as prescribed by their physician. The patients will carry out a similar therapy program to the experimental group, but without the study intervention device (placebo walking shoe).
88886135|NCT01412827|Other|Comparison of radioisotope dosing|
88886136|NCT01412840|Experimental|Standard care and sterile water injections|The patients in the intervention group will be given standard treatment, i.e. intramuscular injection of 50 mg diclofenac. Patients in this group will also be given four subcutaneous injections of 0.5 ml sterile water at the same segmental level, i. e. the area in which the patient reports the pain.
88886137|NCT01412840|Placebo Comparator|Standard care and isotonic saline|The patients in this group will be given standard treatment, i.e. intramuscular injection of 50 mg diclofenac They will also be given four subcutaneous injections of isotonic saline at the same segmental level, i. e. the area in which the patient reports the pain.
88886138|NCT01412840|No Intervention|Standard care|The patients in this group will be given standard treatment, i.e. intramuscular injection of 50 mg diclofenac.
88886139|NCT01412853|Experimental|MR-spectroscopy|
88886140|NCT01412892|Experimental|Everolimus|RAD001: Everolimus
88886141|NCT01412931||1) Pregnant women with a single intrauterine pregnancy|50 women with uncomplicated pregnancies and no history of preterm birth.
88886142|NCT01412931||2) Pregnant women with a single intrauterine pregnancy|50 multiparous women with history of spontaneous preterm labor or preterm premature rupture of membranes (PPROM).
88886143|NCT01412931||3) Pregnant women with a single intrauterine pregnancy|20 women evaluated on the labor and delivery unit because they are deemed to be at high risk for preterm birth.
88886144|NCT01412996|Active Comparator|single ACCESS cholecystectomy|single ACCESS laparoscopic cholecystectomy
88886145|NCT01412996|Active Comparator|traditional|conventional laparoscopic cholecystectomy
88886146|NCT01413009||ICU patients|Adult patients admitted to the University of Nebraska Medical Center or the Nebraska Medical Center trauma critical care service.
88886147|NCT01413022|Active Comparator|Group A (FOLFIRINOX chemotherapy)|"Patients receive FOLFIRINOX chemotherapy comprising of:~oxaliplatin 85 mg/m2 IV on Day 1~irinotecan 180 mg/m2 IV on Day 1~leucovorin 400 mg/m2 IV on Day 1~5FU 400 mg/m2 bolus and 2400 mg/m2 CIVI over 46 hours beginning on Day 1~Treatment is repeated every 14 days for 6 cycles."
88886148|NCT01413022|Experimental|Group B (FOLFIRINOX and PF-04136309)|"Patients receive FOLFIRINOX chemotherapy comprising of:~oxaliplatin 85 mg/m2 IV on Day 1~irinotecan 180 mg/m2 IV on Day 1~leucovorin 400 mg/m2 IV on Day 1~5FU 400 mg/m2 bolus and 2400 mg/m2 CIVI over 46 hours beginning on Day 1~PF-04136309 500 mg PO BID on days 1-14~Treatment is repeated every 14 days for 6 cycles."
88886149|NCT01413035|Experimental|MSC and the oral hypoglycemic drugs|1.0E+6 MSC/kg, IV drop and repeat to apply in Day 90 if the effect of MSC is better. At the same time, patient continues to apply the former oral hypoglycemic drugs, such as Dimethylbiguanide, Glurenorm and Acarbose, et al. and regulates the dosage for 1 year.
88886150|NCT01413035|Experimental|MSC and insulins|1.0E+6 MSC/kg, IV drop and repeat to apply in Day 90 if the effect of MSC is better. At the same time, patient continues to apply the former insulins and regulates the dosage for 1 year.
88886151|NCT01413035|Experimental|MSC and the combination of drugs and insulins|1.0E+6 MSC/kg, IV drop and repeat to apply in Day 90 if the effect of MSC is better. At the same time, patient continues to apply the former combination of the oral hypoglycemic drugs and insulins and regulates the dosage for 1 year.
88886152|NCT01413048|Experimental|AGSCT101|
88886153|NCT01413048|Active Comparator|Carvedilol|
89410072|NCT03819465|Experimental|A3|Durvalumab + oleclumab
89410073|NCT03819465|Experimental|A4|MEDI5752
88886154|NCT01413061|Active Comparator|AlloStem Live Cellular Allograft|AlloStem is the combination of the Mesenchymal Stem Cells (MSC) derived from adipose with demineralized bone.
88886155|NCT01413061|Active Comparator|Control: Autologous Bone Marrow Aspirate|Autologous bone graft is recovered from the patient's own tibia or iliac crest, for transplantation in the subtalar joint.
88886156|NCT01413074|Active Comparator|ESRD patients receiving HD treatment|no investigational drug involved. Only oberseve therapy treatment
88886157|NCT01413074|Experimental|ESRD patients receiving PD treatment|no investigational drug involved. Only oberseve therapy treatment
88886158|NCT01413113|Experimental|Treatment (enzyme inhibitor and radioactive drug therapy)|Patients receive iodine I 131 IM QD 5 days a week in weeks 5-6. Patients also receive pazopanib hydrochloride PO QD beginning in week 1 and continuing for 8 weeks post-radioactive iodine therapy.
88886159|NCT01413126|Experimental|Peanut butter|42.5 g of Peanuts butter were added to a 75g available carbohydrate-matched breakfast meal
88886160|NCT01413126|Experimental|Whole peanut|42.5 g of whole peanuts were added to a 75g available carbohydrate-matched breakfast meal
88886161|NCT01413126|No Intervention|No peanuts (control)|
88886162|NCT01413139|Other|4F portfolio products from Biotronik|The devices under investigation are the 4F portfolio products from Biotronik: Astron pulsar / Astron Pulsar-18, Fortress, Passeo-18 and Cruiser-18.
88886163|NCT01413152|Experimental|0|
88886164|NCT01413243|Experimental|Drug: Trichuris suis ova|Experimental: Trichuris suis ova (TSO) 2500 eggs every 2 weeks for 12 months
89191879|NCT00805077|Experimental|1|mechanical ventilation with low tidal volume (5 ml/kg of ideal body weight) plus PEEP
89191880|NCT00805077|Other|2|tidal volume of 10 ml/kg of ideal body weight without PEEP
89191881|NCT00870298|Experimental|computerized alert|An automatic electronic stop of the tmp/sulfa or warfarin order whenever a resident or nurse practitioner places an order for tmp/sulfa with an already active warfarin order, or when ordering both simultaneously
89191882|NCT00870298|Other|2 Current practice|Current practice of the pharmacist recommending cessation of concurrent warfarin and tmp/sulfa orders
89191883|NCT00730340|Active Comparator|1|Patients will receive closure of the tonsillar fossae following tonsillectomy.
89191884|NCT00730340|Active Comparator|2|Patients will not receive closure to one or both tonsillar fossa following a tonsillectomy
89191885|NCT00805155||Cohort Group 1|Subjects number 1 to 20
89191886|NCT00805155||Cohort Group 2|Subjects number 21 to 50
89191887|NCT00805155||Cohort Group 3|Subject Numbers 51 to 80
89191888|NCT04016350|Experimental|Exercise Training with Inulin Propionate Ester|Study participants underwent 4 week supervised moderate intensity exercise training combined with Inulin Propionate Ester supplementation at doses of 10g / day.
89191889|NCT04016350|Experimental|Exercise Training with Placebo|Study participants underwent 4 week supervised moderate intensity exercise training combined with cellulose as placebo at doses of 10g / day.
89191890|NCT00725166||Young|Young men 19-25 years old
89191891|NCT00725166||Old|old men 70-76 years old, who participate in the PROOF study (NCT 00759304)
89191892|NCT02575742||Young women without chronic constipation|Healthy women without chronic constipation who are aged between 18-40 years
89191893|NCT02575742||Older women without chronic constipation|Healthy women without chronic constipation who are aged between 70-90 years
89191894|NCT02575742||Young women with chronic constipation|Women with symptoms of chronic constipation who are aged between 18-40 years
89191895|NCT02575742||Older women with chronic constipation|Women with symptoms of chronic constipation who are aged between 70-90 years
89191896|NCT00807963|Experimental|Stage 1: rHuPH20 plus ZA|Participants will receive one of several dose/concentrations of recombinant human hyaluronidase PH20 (rHuPH20) with zoledronic acid (ZA).
89191897|NCT00807963|Experimental|Stage 2: ZA|Participants will receive a dose/concentration of ZA administered without rHuPH20.
89191898|NCT00807963|Experimental|Stage 3: rHuPH20 plus ZA|Participants will receive one of several dose/concentrations of rHuPH20 with ZA.
89191899|NCT00807963|Experimental|Stage 4: ZA|Participants will receive an intravenous (IV) dose of 5 milligrams (mg) ZA.
89191900|NCT00807963|Experimental|Stage 4: ZA with rHuPH20|Participants will receive a subcutaneous (SC) dose of ZA with rHuPH20.
89191901|NCT05227066|Experimental|traditional physical therapy group|received traditional physical therapy protocol
89191902|NCT05227066|Experimental|lower extremity weights group|received the same traditional physical therapy in addition to lower extremity weights
89191903|NCT05210634|Placebo Comparator|Group 1: Placebo|Single oral administration of 4 ml of Placebo MCT oil
89191904|NCT05210634|Active Comparator|Group 2: 12.5 mg THCv (CHI-915)|Single oral administration of 12.5 mg THCv in MCT oil
89191905|NCT05210634|Active Comparator|Group 3: 25 mg THCv (CHI-915)|Single oral administration of 25 mg THCv in MCT oil
89191906|NCT05210634|Active Comparator|Group 4: 50 mg THCv (CHI-915)|Single oral administration of 50 mg THCv in MCT oil
89191907|NCT05210634|Active Comparator|Group 5: 100 mg THCv (CHI-915)|Single oral administration of 100 mg THCv in MCT oil
89191908|NCT05210634|Active Comparator|Group 6: 200 mg THCv (CHI-915)|Single oral administration of 200 mg THCv in MCT oil
89191909|NCT00730418|Experimental|doxazosin 4mg|doxazosin 4mg group
89191910|NCT00730418|Experimental|doxazosin 8mg|doxazosin 8mg group
89191911|NCT00805233|Experimental|1|Combination Ranibizumab intravitreal injection plus bromfenac ophthalmic drops
89191912|NCT00805233|Active Comparator|2|ranibizumab injection alone.
89191913|NCT03842566||20-29 Years Old|
89191914|NCT03842566||30-39 Years Old|
89191915|NCT03842566||40-49 Years Old|
89191916|NCT03842566||50-59 Years Old|
88886165|NCT01413243|Placebo Comparator|Placebo|Drug: Placebo, fluid every 2 weeks
88886166|NCT01413269|Experimental|hypofractionation radiotherapy|irradiation to the whole breast to a total dose of 43.5Gy,at 2.9Gy per fraction, 5 fractions a week, followed by tumor bed boost of 8.7Gy, at 2.9Gy per fraction 5 fractions a week.
88886167|NCT01413269|Active Comparator|conventional fractionation radiotherapy|irradiation to the whole breast to a total dose of 50Gy,at 2.0Gy per fraction, 5 fractions a week, followed by tumor bed boost of 10Gy, at 2.0Gy per fraction 5 fractions a week.
89191917|NCT03842566||60-69 Years Old|
89191918|NCT03842566||70-79 Years Old|
89191919|NCT00725244|Active Comparator|1|Bipolar Eletrocoagulation was performed with a high-frequency electrosurgical generator (ERBE® ICC 200 Eletromedizin, Tubingen, Germany), using Gold probe (Wilson- Cook®) with 7 Fr diameter and 300 cm length. The power setting was 50 W. Coagulation of each telangiectasia was achieved with the probes by applying light pressure directly on the telangiectasia.
89191920|NCT00725244|Active Comparator|2|"Argon Plasma Coagulation was delivered using a spray-painting technique, with short applications at 40 W power with a gas flow of 1.0l per minute. APC equipment was an argon delivery unit (ERBE® ICC 300) coupled a high frequency surgery unit (ERBE® ICC 200). Only the end-firing probe with 2.3 mm and 220 cm length was used. The probe was purged with argon, tested and passed though the endoscope until it extends approximately 1 cm from the tip. The probe was hold just above the mucosal surface and the contact was avoided. During the procedure periodic suction was made to prevent over-distention with gas and consequently patient discomfort."
89191921|NCT02569502|Experimental|Enfuvirtide|Participants will receive 180 milligrams (mg) of enfuvirtide adminstered twice daily as subcutaneous injections
89410074|NCT03819465|Experimental|B1|Durvalumab + Investigator's choice of chemotherapy
89410075|NCT03819465|Experimental|B2|Durvalumab + Investigator's choice of chemotherapy + danvatirsen
89410076|NCT03819465|Experimental|B3|Durvalumab + investigator's choice of chemotherapy + oleclumab
89410077|NCT03819465|Experimental|B4|MEDI5752
89410078|NCT03819465|Experimental|A5|AZD2936
89410079|NCT03819465|Experimental|B5|AZD2936 + chemotherapy
89410080|NCT03806764|No Intervention|Retrospective study|Medical records of 250 allo-HSCT recipients will be evaluated retrospectively to determine the incidence and clinical outcomes of CMV viremia post HSCT, including both the direct (CMV disease) and indirect (such as invasive fungal infection, other viral infections, bacterial infection) effects on clinical outcomes.
89410081|NCT03806764|Other|Prospective study|"120 recipients of allo-HSCT will be recruited into the prospective part of the study. Participants will be reviewed pre-transplant, 6, 12, 24 and 52 weeks following HSCT during routine clinical visits. clinical assessment will be made such as CMV viremia, transplant related complications and current medications.~Participants who are at high risk of CMV will have study blood sampling taken to assess immune functions"
89410082|NCT03705286|Active Comparator|PVC-ETT|Polyvinylchloride endotracheal tube
89410083|NCT03705286|Experimental|EVAC-PU-ETT|Continuous aspiration of subglottic secretions with polyurethane cuff endotracheal tube
89410084|NCT03679117|Experimental|Mindfulness Training|Phone-delivered mindfulness training
89410085|NCT03679117|No Intervention|Treatment as Usual|Prenatal care
89410086|NCT03637803|Experimental|MRx0518 with pembrolizumab|Subjects will receive IV infusion of pembrolizumab once every 3 weeks until disease progression, unacceptable AEs or withdrawal of consent up to a maximum of 35 cycles (approx. 2 years). Starting on the day of first pembrolizumab dose, subjects will take one capsule of MR0518 twice daily until the end of the treatment period.
89410087|NCT03630289|Experimental|Surgical tissue autograft: TPF flap/pericranial flap|Use of a pedicled autologous piece of tissue called the temporoparietal fascial (TPF) flap or pericranial flap into the resection cavity of newly diagnosed glioblastoma multiforme (GBM) patients
89410088|NCT03615794||Pregnant women with Mood Disorders|Pregnant women with a history or current diagnosis of Major Depressive Disorder or Bipolar Disorder
89410089|NCT03615794||Healthy controls|Pregnant women without a history or current diagnosis of a mood disorder.
89410090|NCT03567720|Experimental|TAVO-EP plus IV pembrolizumab|Intratumoral Tavokinogene Telseplasmid (tavo, pIL 12) plus Electroporation (ImmunoPulse) in Combination with Intravenous Pembrolizumab (Cohort enrollment completed)
89410091|NCT03567720|Experimental|TAVO-EP plus IV pembrolizumab with chemotherapy|Intratumoral Tavokinogene Telseplasmid (tavo, pIL 12) plus Electroporation (ImmunoPulse) in Combination with Intravenous Pembrolizumab along with treatment of an approved chemotherapy per standard of care (either nab-paclitaxel or gemcitabine plus carboplatin)
89410092|NCT03519256|Experimental|Nivolumab monotherapy|
89191922|NCT00798837|Other|IMAX|"There is only one arm in this study.~Each patient will undergo a course of intensity modulated external beam radiation therapy (IMRT) using RapidArc for optimization and delivery.~Doses of radiotherapy are as follows:~The prescription dose will be 73.7 Gy in 28 fractions.~A simultaneous intraprostatic maximal simultaneous boost will be given to as much of the CTV as possible without contravening OAR dose constraints."
89191923|NCT00725400|Active Comparator|1|Patients will receive a Cetuximab and Radiation Therapy.
89410093|NCT03519256|Experimental|Nivolumab + BCG|
89410094|NCT03519256|Experimental|Nivolumab + BMS-986205|
89191924|NCT00725400|Active Comparator|2|Patients will undergo Surgery before or after Radiation Therapy.
89191925|NCT00798915|Experimental|Normal Glucose Tolerance|Healthy individuals exhibiting plasma glucose levels less than 140mg/dl two hours after ingestion of 75-g of glucose.
89410095|NCT03519256|Experimental|Nivolumab + BMS-986205 + BCG|
89410096|NCT03507608|Experimental|flutamide|50mg flutamide prior to brachytherapy and prostatic biopsy
89410097|NCT03507608|Placebo Comparator|placebo|placebo prior to brachytherapy and prostatic biopsy
89410098|NCT03465579|Other|Cohort 1|Men with suspected clinically-significant PCa (CS-PCa) who are candidates for prostate biopsy or after first-round negative transrectal ultrasonography (TRUS) biopsy
89410099|NCT03465579|Other|Cohort 2|Men framed in Active Surveillance (PRIAS study), scheduled for PRIAS repeat biopsy.
89410100|NCT03465579|Other|Cohort 3a|Men with high-risk PCa (HR-PCa) prior to radical surgery.
89410101|NCT03465579|Other|Cohort 3b|Men diagnosed with CS-PCa prior to nerve-sparing prostate surgery (NSS).
89410102|NCT03458000|Active Comparator|Active Control|Video Capsule Endoscopy will be administered during ED, but video will not be read until after inpatient EGD. Subject will have hospital admission with an EGD conducted during hospital stay.
89410103|NCT03458000|Experimental|Experimental|Subject will have Video Capsule Endoscopy read during ED length of stay, disposition will be determined using Capsule Endoscopy Risk Assessment.
89410104|NCT03453528|Experimental|68Ga-PSMA|68Ga-PSMA
89410105|NCT03390413|Active Comparator|Robot|
89410106|NCT03390413|Experimental|Cryo|
89410107|NCT03388398||Mother-Infant Pairs|Mothers or caregivers (at least 16 years of age) and their infants who are 9 to 18 months of age at the time of their survey.
89410108|NCT03388398||Mothers or caregivers|Mothers or caregivers (at least 16 years of age) who are 19 to 36 months postpartum at the time of the survey.
89410109|NCT03388398||Healthcare staff|Healthcare staff (employed staff and volunteers at least 18 years of age) at all participating healthcare facilities.
88886168|NCT01413282|Active Comparator|Cardiac CT|Triage based on cardiac CT results.
88886169|NCT01413282|No Intervention|Standard Care|Standard diagnostic management according to the European guidelines.
88886170|NCT01413295|Experimental|Dendritic Cells Vaccine|Dendritic Cells Vaccine after 2 lines of chemotherapy
88886171|NCT01413295|Other|Supportive treatment|Supportive treatment after 2 lines of chemotherapy
88886172|NCT01413321||SHABI|Subacute hemiparetic ABI subjects group
88886173|NCT01413321||CHABI|Chronic hemiparetic ABI subjects group
88886174|NCT01413347|Active Comparator|pillow|confirmation of double-lumen tube position with a head on a pillow
88886175|NCT01413347|Experimental|neutral|confirmation of double-lumen tube position in neutral position of a head
88886176|NCT01413386|Experimental|Paclitaxel Eluting Covered Metal Stent|
88886177|NCT01413386|Active Comparator|Covered Metal Stent|
88886178|NCT01413412|Experimental|Hernia repair using full-thickness skin graft|25 patients
88886179|NCT01413412|Experimental|Hernia repair using Mesh|25 patients
88886180|NCT01413477|Active Comparator|Calcipotriol ointment|
88886181|NCT01413477|Active Comparator|Betamethasone dipropionate ointment|
88886182|NCT01413477|Active Comparator|Calcipotriol and betamethasone ointment|
88886183|NCT01413477|Placebo Comparator|Vaseline Petroleum Jelly|
88886184|NCT01413555|Experimental|Blood Culture QI Program|
89410110|NCT03388398||Providers|Health care providers (at least 18 years of age) at select participating healthcare facilities.
88886185|NCT01413568|Experimental|Donor (Phase I and Phase II)|"On Day 1 (and possibly Day 2) POL6326 IV Infusion with increasing dose levels in Phase I or with random dose assignment (from the 2 selected from Phase I) in phase II~Leukapheresis collection on Day 1 (and possibly Day 2)"
88886186|NCT01413568|Experimental|Recipient|Day 0 - PBSC transplant with stem cells mobilized with IV POL6326
88886187|NCT01413581|Experimental|rhBSSL|rhBSSL (recombinant human bile-salt-stimulated lipase)
88886188|NCT01413581|Placebo Comparator|Placebo|Placebo
88886189|NCT01413594|Experimental|HABIT|Hand-Arm Bimanual Intensive Therapy (HABIT)
88886190|NCT01413594|No Intervention|Ongoing usual and customary rehabilitation care|Subjects are tested over 6 months while receiving their ongoing usual and customary care schedule of physical and occupational therapy or following constraint-induced movement therapy received as usual and customary care independent of the study, and then are crossed-over to receive HABIT.
88886191|NCT01413607|Experimental|Quill knotless tissue-closure device|During partial nephrectomy participants in this group will receive the Quill Knotless Tissue-Closure device (Angiotech Pharmaceuticals) to close the central defect in their kidney.
88886192|NCT01413607|Active Comparator|2-0 absorbable vicryl suture|Participants in this group will be receiving traditional 2-0 vicryl sutures (Ethicon) during partial nephrectomy.
88886193|NCT01413620|Experimental|Vitamin E Treated|
88886194|NCT01413620|No Intervention|Untreated|
88886195|NCT01413633|Experimental|cholecystectomy|single incision laparoscopic cholecystectomy
88886196|NCT01413646|Experimental|Walnut Supplementation|Eight weeks with walnut supplementation to an ad lib diet
88886197|NCT01413646|Placebo Comparator|2|Eight weeks ad lib diet without walnut supplementation
88886198|NCT01413659|Experimental|Symbiotic|Symbiotic is a combination of prebiotics and probiotics that is designed to have synergistic or additive effects benefiting the host
88886199|NCT01413672||person with ostomy|Community dwelling subject with either colostomy or ileostomy and at least 3 months post-surgery.
88886200|NCT01413685|No Intervention|Tacrolimus|Determination of tacrolimus concentrations in whole blood and of calcineurin activities in lymphocytes at D8, D15, D21 (pharmacokinetics on 4 times samples), D28, M2 and M3 (residual measurement)
88886201|NCT01413698||Patient with chronic cough|
88886202|NCT01413711|Experimental|Vigabatrin|
88886203|NCT01413724||Surgical patients|PAtients who had surgery the previous day and are still hospitalized
88886204|NCT01413763|Active Comparator|Imiquimod cream|
88886205|NCT01413763|Placebo Comparator|Placebo cream|
88886206|NCT01413776|Experimental|Dietary supplement|Pregnant women in 37 villages.
88886207|NCT01413776|No Intervention|Control group|Pregnant women in 38 villages
88886208|NCT01413789|Experimental|Patients and healthy volunteers|Patients with healed full thickness burns and healthy volunteers will be included in the study
88886209|NCT01413828|Experimental|concurrent|trastuzumab was administered concurrently with any anthracycline-containing adjuvant regimen
88886210|NCT01413828|Active Comparator|sequential|trastuzumab was administered sequentially to any anthracycline-containing adjuvant regimen
88886211|NCT01413841|Active Comparator|Nasal oxygen|3 liter per minute
88886212|NCT01413841|Placebo Comparator|Nasal Air|3 l regular nasal air
88886213|NCT01413854|Active Comparator|diclofenac|
88886214|NCT01413854|Placebo Comparator|sugar pill|
88886215|NCT01413867|Experimental|EEA group|Group of patients with III degree hemorrhoids treated by EEA stapler
88886216|NCT01413867|Active Comparator|PPH group|group of patients with III degree hemorrhoids treated by PPH stapler
88886217|NCT01413893|Experimental|linifanib|
88886218|NCT01413906|Experimental|Arm 1: BMS-833923 (XL139)|
88886219|NCT01413945||Normal volunteers|Normal volunteers without Irritable bowel syndrome who are undergoing screening colonoscopy.
88886220|NCT01413945||Irritable bowel syndrome|Patients with Irritable bowel syndrome are undergoing colonoscopy as standard of care.
89410111|NCT03388398||Patients|Patients (at least 18 years of age) receiving care at select participating healthcare facilities.
89410112|NCT03375710|Experimental|Cordella™ Heart Failure System|Cordella™ Heart Failure System and implant of Cordella™ Pulmonary Artery Sensor System (CorPASS)
89410113|NCT03215927|Placebo Comparator|Placebo|Subcutaneous placebo injection weekly for 24 weeks.
89410114|NCT03215927|Experimental|Abatacept|Subcutaneous injection of abatacept 125 mg weekly for 24 weeks. 24 week optional follow up phase all subjects receive abatacept 125 mg weekly.
89535668|NCT03076437|Experimental|Anti-CD19-CAR transduced T cells|"Patients will receive a lymphodepleting preconditioning regimen followed by anti-CD19- CAR-transduced T cells.~Interventions:~Drug: Fludarabine Drug: Cyclophosphamide Biological: Anti-CD19-CAR transduced T cells"
89191926|NCT00798915|Experimental|Impaired Glucose Tolerance|Healthy individuals exhibiting plasma glucose levels between 140 and 199 mg/dl two hours after ingestion of 75-g of glucose.
89191927|NCT00798915|Experimental|Type 2 diabetes mellitus|Healthy individuals exhibiting plasma glucose levels greater than 150 mg/dL under fasting conditions OR greater than 199 mg/dl two hours after ingestion of 75-g of glucose.
89191928|NCT00730496|Experimental|1|the study group, 45 women
89191929|NCT00730496|No Intervention|2|the control group, 45 women
89191930|NCT00798993|Active Comparator|Structured exercise program|Participants will be randomised at 3 months into either this group or the comparator of usual exercise.
89191931|NCT00798993|Experimental|Vitamin D|Cholecalciferol 2000U per day will be given to all participants for the duration of the study
89191932|NCT00798993|Placebo Comparator|Usual exercise|Participants randomised to this arm, at 3 months, will continue on their usual exercise routine
89191933|NCT00867412||Conventional staging|Staging with CT, mediastinoscopy and bronchoscopy
89191934|NCT00867412||Conventional staging and PET/CT|Staging with CT, mediastinoscopy and bronchoscopy, and PET/CT performed prior to mediastinoscopy
89191935|NCT00725582|Experimental|A|
89191936|NCT00725582|Placebo Comparator|B|
89191937|NCT02953704||Myelofibrosis Cohort|Patients will be categorized as low-risk using Dynamic International Prognostic Scoring System (DIPSS) risk OR intermediate-1 risk by DIPSS by reason of age alone.
89191938|NCT02953704||Essential Thrombocythemia Cohort|Patients will be age ≥ 60 years OR have history of thromboembolic events OR currently receiving ET-directed therapy.
89191939|NCT00862108|Experimental|Methylphenidate|
89191940|NCT00725660||1|Pregnant women in second trimester that took the routine triple test, and are having an early routine detailed ultrasound examination.
89191941|NCT04041154|Experimental|Cognitive Fatigue|We will use a behavioral intervention. Participants will perform a cognitively demanding task, repeatedly, to induce cognitive fatigue.
89191942|NCT04041154|Experimental|Physical Fatigue|We will use a behavioral intervention. Participants will perform a physically demanding task (grip force exertion task), repeatedly, to induce cognitive fatigue.
89191943|NCT04041154|Experimental|Rewarding Stimuli|We will use a behavioral intervention. Reward-associated stimuli will be used to study how reward-induced changes in motivational state influence effort choices.
89191944|NCT00862264|Experimental|CHF 1535 pMDI|CHF 1535 HFA pMDI aerosol (100 µg/unit dose of beclomethasone dipropionate plus 6 µg of formoterol/unit dose
89191945|NCT00862264|Active Comparator|BDP pMDI|Beclomethasone dipropionate-CFC pMDI, 250 µg/unit dose
89191946|NCT02569424|Experimental|ventilated patients|Patient's position (Supine or Trendelenburg strict -20°)
89191947|NCT00870376||urodynamic studies|
89191948|NCT02844660|Experimental|EpiCord|Weekly application of EpiCord and standard of care (moist wound therapy and offloading)
89191949|NCT02844660|Active Comparator|Standard of Care|Weekly application of moist wound therapy and offloading
89191950|NCT00730574|No Intervention|B|The control group, marked B, gets only B12 vitamin 1mg/day treatment to comply with ethics regulations seeing as they do suffer from B12 deficiency .
89191951|NCT00730574|Experimental|A|The trial group which receives daily treatment of 1mg Vitamin B12 (sublingual tablets) combined with 5 mg Folic acid (tablets)
89535669|NCT03224845|Experimental|Cognitive behavioural skills training|
88886221|NCT01413984|Experimental|cognitive behavioral group treatment|Helping Women Recover/Beyond Trauma integrated substance abuse and trauma treatment group. (Dr. Covington)
89191952|NCT02570048||Experimental: Mutebutton intervention|This one armed trail will recruit participants who have been diagnosed with Tinnitus for a minimum of 6 months. Participants will use the Mutebutton device in their own home for 30 minutes every day for 12 weeks. The intervention requires sitting in a quiet space with the earphones on and the tongue tip placed on their tongue.
89191953|NCT00870532|Experimental|1|60 mg/week of vinorelbine + sorafenib
89191954|NCT00870532|Experimental|2|90 mg/week of vinorelbine + sorafenib
89191955|NCT00870532|Experimental|3|120 mg/week of vinorelbine + sorafenib
89191956|NCT02771496||Patients with OCD|Patients with diagnosis of OCD as confirmed by x-ray or MRI. Surveys collected from patients at 2 years, 5 years, 10 years, and 25 years.
89191957|NCT05121402|Experimental|Low dose TLL018,BID|Drug: TLL018 all subjects will receive TLL018 for 8 weeks
89191958|NCT05121402|Experimental|Middle dose TLL018,BID|Drug: TLL018 all subjects will receive TLL018 for 8 weeks
89191959|NCT05121402|Experimental|High dose TLL018,BID|Drug: TLL018 all subjects will receive TLL018 for 8 weeks
89191960|NCT05121402|Placebo Comparator|Placebo|Placebo twice daily for 8 weeks.
89191961|NCT00867724|Experimental|Aer-O-Scope Colonoscopy|Screening Colonoscopy
89191962|NCT02570516|Active Comparator|Indigo carmine colonoscopy|Colonoscopy using indigo carmine is performed in second place
89191963|NCT02570516|Experimental|NBI colonoscopy|Colonoscopy using NBI is performed in first place
89191964|NCT00730652|Experimental|MDX1411|An accelerated titration design (ATD) will be utilized and subjects will be assigned to a dose level in the order they enter the study.
89191965|NCT01951274|Experimental|0.25 mg VPD-737|0.25 mg of VPD-737 daily by mouth for 42 days
89191966|NCT01951274|Experimental|1 mg VPD-737|1 mg VPD-737 taken daily by mouth for 42 days
89191967|NCT01951274|Experimental|5 mg VPD-737|5 mg tablets of VPD-737 to be taken daily by mouth for 42 days
89536697|NCT03108989|Active Comparator|Neostigmine group|After the end of surgery, neostigmine will be administered to reverse neuromuscular blockade.
88886222|NCT01413984|No Intervention|comparison group|a comparison group of incarcerated women will receive the pre and post assessments with no interventions.
88886223|NCT01413997||Chronic Low Back Pain|
88886224|NCT01413997||No Low Back Pain|
89005003|NCT00208104|Experimental|Motivational Interview Condition|Trained nurses will interview the group using motivational interview counseling techniques. All sessions will be conducted with the aid of an adapted version of a standardized structured adherence counseling script. This script was specifically developed for use in medication adherence studies of HIV positive patients and has been provided for this trial.
89410115|NCT03076034|Experimental|Post-menopausal women|We will use the handheld Osteoprobe device to measure cortical bone reference point indentation properties.
89410116|NCT03076034|Experimental|Males over 50 years|We will recruit males to this second study arm, to use the handheld Osteoprobe device to measure cortical bone reference point indentation properties.
89005004|NCT00208104|No Intervention|Non-supportive Counseling|A non-supportive counseling session will consist of regular nurse-patient interaction.
89005005|NCT02962869|Experimental|BAY987517|All subjects are patched with the same product
89005006|NCT00203177|Experimental|Experimental 1|0.5 mg rasagiline mesylate oral once daily
89005007|NCT00203177|Experimental|Expermental 2|1.0 mg rasagiline mesylate oral once daily
89005008|NCT00226317|Experimental|Aripiprazole in depression treatment|
89005009|NCT00226356|Experimental|Supplements of L-methionine, betaine and folate|
89005010|NCT00226434|Experimental|1|
89005011|NCT00226434|Active Comparator|2|
89005012|NCT00410579||Patients treated in NSABP R-02, R-03, C-05, C-06 or C-07|Study population to be interviewed comprises patients who were treated at least 5 years ago for colon or rectal cancer in NSABP trials R-02, R-03, C-05, C-06 or C-07
89005013|NCT00208260|Active Comparator|A|FOLFIRI
89005014|NCT00208260|Active Comparator|B|FOLFOX-4
89005015|NCT00208260|Experimental|C|FOLFIRI-HD
89005016|NCT00208260|Experimental|D|FOLFOX-7
89005017|NCT00208260|Experimental|E|FOLFIRINOX
89005018|NCT00208299|Experimental|1|Regadenoson
89005019|NCT00208299|Active Comparator|2|Adenoscan
89005020|NCT00208338|Experimental|1|Rotator cuff repair with RESTORE Porcine Small Intestine Submucosa patch (RESTORE SIS Patch) reinforcement
89410117|NCT03009110|Experimental|Prophylactic NPWT|Women assigned to prophylactic NPWT will have the Prevena device applied and secured with fixation adhesion strips. The device will be monitored while the patient is in the hospital to confirm that it is functioning well. The device will be removed prior to discharge, typically on postoperative day 4, but longer for up to 7 days for patients who remain hospitalized.
89005021|NCT00208338|Active Comparator|2|Standard rotator cuff repair
89005022|NCT00413322|Experimental|Single-arm dose escalation|
89005023|NCT00196781|Experimental|the Information + Decision Aid group|
89005024|NCT00196781|Active Comparator|Information Only group|
89005025|NCT00413361|Placebo Comparator|A|placebo
89005026|NCT00413361|Experimental|B|versus hydroxychloroquine
89005027|NCT00196820|Experimental|A|Capecitabine 2000 mg/m2 orally day 1-14 q day 22 until progression, unacceptable toxicity, patient's request or withdrawal from study
89005028|NCT00208377|Other|DePuy ASR Hip System|A metal-on-metal bearing surface replacement system for use in resurfacing hip arthroplasty
89005029|NCT00410696|Active Comparator|Filgrastim|Filgrastim administration starting 1 day after autologous stem-cell reinfusion up to hemopoietic reconstitution (defined as more than 500/mm3 for 2 days)
89005030|NCT00410696|Experimental|Pegfilgrastim|Pegfilgrastim administered the day after autologous stem-cell reinfusion
89005031|NCT00409799|Experimental|1|Experimental - high dose
89005032|NCT00409799|Experimental|2|Experimental - low dose
89005033|NCT00409799|Active Comparator|3|Autograft
89005034|NCT00208416|Active Comparator|1|DePuy MI System
89005035|NCT00208416|Active Comparator|2|Conventional surgical technique
89005036|NCT00410735|Placebo Comparator|P|
89005037|NCT00410735|Experimental|E|
89005038|NCT00208455|Other|DePuy Proxima™ Hip|A short, anatomic, cementless femoral component for use in total hip arthroplasty
89005039|NCT00203372|Experimental|Bevacizumab 7.5 and TAC|one dose of Bevacizumab (7.5mg/kg) will be administered intravenously every 3 weeks followed by TAC.
89005040|NCT00203372|Placebo Comparator|Placebo 7.5 and TAC|Placebo7.5 will be administered intravenously every 3 weeks followed by TAC.
89005041|NCT00203372|Experimental|Bevacizumab 15 and TAC|one dose of Bevacizumab (15mg/kg) will be administered intravenously every 3 weeks followed by TAC.
89005042|NCT00203372|Placebo Comparator|Placebo 15 and TAC|Placebo 15mg/kg will be administered intravenously every 3 weeks followed by TAC.
89005043|NCT00196859|Active Comparator|A|Ibandronate 50 mg p.o. daily or 6 mg i.v., q4W, 2yrs
89005044|NCT00196859|Experimental|B|Ibandronate 50 mg p.o. daily or 6 mg i.v., q4W, 2yrs plus Capecitabine 2000 mg/m2 days 1-14 q d22 x6
89005045|NCT00208533|Other|1 Open Label|Open Label Aripiprazole
89005046|NCT00203450|Experimental|Zonegran|Zonegran
89410118|NCT03009110|Active Comparator|Standard Dressing|Women assigned to standard care will receive routine postoperative wound dressing consisting of layers of gauze and adhesive tap. The dressing will be removed after 24 - 48 hours.
89410119|NCT02999230|Active Comparator|Caries Free|Gums will be examined and caries assessment performed. On some visits Saliva and supragingival plaque will be collected. Study toothpaste will be assigned.
89410120|NCT02999230|Placebo Comparator|Caries Free- Placebo|Gums will be examined and caries assessment performed. On some visits Saliva and supragingival plaque will be collected. Marketed Toothpaste will be assigned.
89410121|NCT02999230|Active Comparator|Caries Active|Gums will be examined and caries assessment performed. On some visits Saliva and plaque will be collected. Study toothpaste will be assigned.
89410122|NCT02999230|Placebo Comparator|Caries Active- Placebo|Gums will be examined and caries assessment performed. On some visits Saliva and supragingival plaque will be collected. Marketed Toothpaste will be assigned.
89410123|NCT02941315|Experimental|with CMR confirmed etiology|Participants who were identified with cardiac magnetic resonance (CMR) in etiology were treated with drug including etiologic treatment,anti-myocardial remodeling.
89191968|NCT01951274|Placebo Comparator|Placebo|placebo tablets to be taken daily by mouth for 42 days
89191969|NCT00725556|Other|1|Speech therapy
89410124|NCT02941315|Placebo Comparator|etiology unconfirmed without acute HF|Participants who were not identified with cardiac magnetic resonance (CMR) in etiology and without acute hearts failure (HF) were treated with drug with anti-myocardial remodeling.
89410125|NCT02941315|Placebo Comparator|etiology unconfirmed with acute HF|Participants who were not identified with CMR in etiology but with acute hearts failure were treated with drug with anti-myocardial remodeling,anti-acute heart failure.
89410126|NCT02941315|Experimental|etiology confirmed with acute HF|Participants who were identified with CMR in etiology but with acute hearts failure were treated with drug with Etiological, anti-remodeling and symptom treatment.
89410127|NCT02920229|Experimental|68Ga- PSMA PET/CT|100-200 MBq of 68Ga-PSMA will be injected intravenously prior to perform the PET/CT
89410128|NCT02918721|Experimental|Restylane Lidocaine|Restylane Lidocaine will be injected into one side nasolabial fold on Day 1
89410129|NCT02918721|Active Comparator|Restylane|Restylane will be injected into the opposite side nasolabial fold on Day 1
89410130|NCT02884180|Active Comparator|Treatment A|Dexamethasone 24 mg i.v. after start of anaesthesia
89410131|NCT02884180|Placebo Comparator|Treatment B|Saline isotonic i.v. after start of anaesthesia
89410132|NCT02879682|Active Comparator|nTMS|presurgical motor mapping by nTMS and fusion with intraoperative neuronavigation
89191970|NCT03355794|Experimental|Dose level 1 (starting dose level) (participants </= 21yrs)|Ribociclib administered orally; daily on days 1-21 each 28 day cycle; dose calculation age dependent (>21 yrs of age 300mg daily (DIPG only); </=21 yrs of age 120 mg/m2/day) Everolimus administered orally; daily on days 1 - 28 each 28 day cycle; dose calculation age dependent (>21yrs 2.5mg/day (DIPG only); </=21yr 1.2 mg/m2/day) BSA >/=0.75m2
89410133|NCT02879682|Sham Comparator|non-nTMS|presurgical motor mapping by nTMS without access of the surgeon to these data
89410134|NCT02799602|Experimental|BAY1841788 /darolutamide (ODM-201)+standard ADT+Docetaxel|Co-administration of BAY 1841788 / darolutamide (ODM-201), standard ADT and docetaxel
89410135|NCT02799602|Placebo Comparator|Placebo + standard ADT + Docetaxel|Co-administration of Placebo matching BAY 1841788 / darolutamide (ODM-201) tablets, standard ADT and docetaxel
89410136|NCT02792166|Active Comparator|BPD-DS|BPD-DS involves creating a sleeve gastrectomy and creation of a Roux-en-Y bypass involving a Roux limb (150cm) which is anastomosed to the transected first-stage of the duodenum and a short common channel (100cm).
89410137|NCT02792166|Experimental|SADI-S|SADI-S involves creating a sleeve gastrectomy but simplifies the bypass part of the BPD-DS by a single anastomosis of a loop of jejunum at 250cm from the ileocecal valve (longer common channel) to the transected first-stage of the duodenum instead of the Roux-en-Y construct.
89410138|NCT02791854||Registry participant|This is a registry study, the same information is collected from all participants.
89410139|NCT02788903||Diabetes|During year 1 of the proposed project, the investigative team will identify a valid cohort of patients with type 2 diabetes using EHR data. The cohort of patients under study will be defined as all patients age 18 and older with an indication of type 2 diabetes during the proposed study time frame (2009-2019).
89410140|NCT02788903||Pre-Diabetes|The cohort of patients under study will be defined as patients age 18 and older who are at risk for the development of diabetes, based on being overweight. Patients seen at one of the six PaTH institutions will be included in the at-risk cohort if they have a BMI ≥ 25 kg/m2, based on most recent recorded weight and at least one recorded height.
89410141|NCT02770040|Active Comparator|Intensified Infliximab Induction|Infliximab 10mg/kg at Week 0 and Week 1
89410142|NCT02770040|Active Comparator|Accelerated Infliximab Induction|Infliximab 5mg/kg at Week 0, Week 1 and Week 3
89410143|NCT02770040|Active Comparator|Standard Infliximab Induction|Infliximab 5mg/kg at Week 0, Week 2 and Week 6
89410144|NCT02754297|Experimental|Personalized PRRT (P-PRRT)|"177Lu-Octreotate (LuTate) P-PRRT will be administered as follows:~Renal absorbed radiation dose will be prescribed for the 4-cycle induction course (23 Gy) and for each subsequent cycle (6 Gy), with a reduction in cases of impaired renal or bone marrow function, or significant toxicity from prior cycles.~The personalized activity to be administered at each cycle will be derived from renal dose per unit of injected activity that is predicted by patient characteristics or renal dose delivered during prior cycle(s).~Participants responding to the induction course of P-PRRT will be eligible to receive additional consolidation and/or maintenance cycles.~Participants with prior PRRT exposure outside the trial may receive less induction cycles, or only consolidation/maintenance cycle(s)."
89410145|NCT02747459|Experimental|SSS Intervention|Sensory Supported Swimming-eight, 30 minute lessons
89005047|NCT00203450|Placebo Comparator|Placebo|Placebo pill
89191971|NCT03355794|Experimental|Dose level 2 (participants </= 21yrs)|Ribociclib administered orally; daily on days 1-21 each 28 day cycle; 170 mg/m2/day Everolimus administered orally; daily on days 1 - 28 each 28 day cycle; 1.2 mg/m2/day BSA >/=0.45m2
89191972|NCT03355794|Experimental|Dose level 3 (participants </= 21yrs)|Ribociclib administered orally; daily on days 1-21 each 28 day cycle; 170 mg/m2/day Everolimus administered orally; daily on days 1 - 28 each 28 day cycle; 1.5 mg/m2/day BSA >/=0.45m2
89410146|NCT02472015|No Intervention|normal care|patients who will have normal care
88886225|NCT01414023|Experimental|CCT|Cognitive Control Training - Pace Auditory Serial Addition Task (PASAT;(Gronwall, 1977): A computer version of the PASAT will be used to measure sustained attention and working memory. Participants are asked to add serially presented numbers. Attention Control Intervention (Wells, 2000): This task involves training individuals to attend differentially to multiple auditory sources (e.g., by counting tones, discriminating the location of tones, and moving their attention between auditory sources for a prolonged period).
88886226|NCT01414023|Placebo Comparator|PVT|Peripheral Vision Task (PVT; C. Moore, personal communication): This task serves as a non-active control condition which does not target the brain regions influenced by the Wells and PASAT tasks. Participants focus on the placement of dots on a computer screen in this task while listening to a tone.
88886227|NCT01414049|Experimental|On-pump CABG|
88886228|NCT01414049|Experimental|Off-pump CABG|
88886229|NCT01414062|Active Comparator|Arm A|Participants receiving written dietary recommendations for breast cancer survivors (control arm)
88886230|NCT01414062|Experimental|Arm B|Participants attending Cocinar Para Su Salud Program held over a 12-week period
89410147|NCT02472015|Experimental|telemedicine|patients who will have telemedicine
89410148|NCT02306200||Aortic Disease|Patients with a diagnosis of any form of Aortic Disease
89410149|NCT02306200||Controls|Patients without a diagnosis of Aortic Disease
89410150|NCT02291705|Experimental|rectus sheath block|rectus sheath block
89410151|NCT02291705|Active Comparator|tramadol|tramadol control group
89410152|NCT02243709|Active Comparator|Mifepristone|mifepristone 600-mg/day for a week, in a stress-induced condition triggered by a single dose of 32.4-mg of yohimbine
89410153|NCT02243709|Placebo Comparator|Sugar pill|matching placebo/day for a week, in a stress-induced condition triggered by a single dose of 32.4-mg of yohimbine
89410154|NCT02192931|Active Comparator|Creatine monohydrate|5 grams of daily creatine monohydrate for 8 weeks
89410155|NCT02192931|Placebo Comparator|Placebo|5 g of placebo for 8 weeks
88886231|NCT01414088|Placebo Comparator|glucose|glucose 5 %
88886232|NCT01414088|Active Comparator|isotonic saline|isotonic saline 0.9 mg/ml
89410156|NCT02192931|No Intervention|Healthy Control|
89410157|NCT02012153|Experimental|Mesenchymal Stromal Cells|"A single intravenous infusion of ex-vivo expanded autologous MSCs will be performed in patients in addition to the living-donor kidney transplantation.~2x10 elevated to sxth power MSCs per kilogram body weight previously isolated from the same recipient will be infused intravenously the day before the kidney transplant procedure."
89410158|NCT01896011|Active Comparator|Teriparatide 20 mcg daily|Teriparatide (Forteo) 20 mcg daily by injection pen for 12-24 months
89410159|NCT01896011|Placebo Comparator|Placebo|Placebo injection pen identical to active drug injection pen
89410160|NCT01891396|Placebo Comparator|Saline|Single injection of 0.9% saline supplied as a 4 milliliter (mL) unit dose in a 5mL glass syringe
89410161|NCT01891396|Experimental|Hyaluronic Acid and TH (Cingal®)|Single injection of sodium hyaluronate with triamcinolone hexacetonide (TH) supplied as a 4 milliliter (mL) unit dose in a 5 mL glass syringe
89410162|NCT01891396|Active Comparator|Hyaluronic Acid (Monovisc®)|Single injection of sodium hyaluronate supplied as a 4 milliliter (mL) unit dose in a 5 mL glass syringe
89410163|NCT01747304||Screening population|Healthy post-menopausal women attending bone mineral density screening clinic with leg/hip/groin pain/discomfort/weakness an has been on anti-resorptive therapy for at least 5 years.
89410164|NCT01747304||Comparator Group|Control group from Toronto CaMOS cohort willing to participate.
89410165|NCT01747304||AFF group|participants in the AFF Cohort study at UHN
89410166|NCT01746225|Experimental|A: nab-Paclitaxel 150 mg/m2 days 1,15|"Arm A: Induction* nab-Paclitaxel 125 mg/m2 on days 1,8,15 every 28 days for 3 cycles followed by maintenance nab-Paclitaxel 150 mg/m2 administered on days 1, 15 of each 28-day cycle (total 300mg/m2 per cycle) until progression or unacceptable toxicity.~*Following Amendment 1, the dose in the induction phase dose in all three arms was reduced to 125 mg/m² from 150 mg/m²."
88886233|NCT01414088|Active Comparator|hypertonic saline|hypertonic saline 2.9 mg/ml
88886234|NCT01414101|Experimental|Group A|Dose 1 ISIS CRP Rx versus Placebo
88886235|NCT01414101|Experimental|Group B|Dose 2 ISIS CRP Rx versus Placebo
88886236|NCT01414101|Experimental|Group C|Dose 3 ISIS CRP Rx versus Placebo
88886237|NCT01414140||Group 1|
88886238|NCT01414218|Experimental|Humor as Way of Life Seminar|See description of study in previous section for further details.
88886239|NCT01414231|Active Comparator|Cytarabine low dose|This is the golden standard of AML treatment
88886240|NCT01414231|Active Comparator|Cytarabine intermediate dose|This is the OSHO internal arm
88886241|NCT01414283|Experimental|Arm 1|
88886242|NCT01414296|Experimental|Arm 1|
88886243|NCT01414309||Observational patients|Heart Failure patients with moderate to severe central sleep apnea
88886244|NCT01414322||Group 1: Patients ages 0 - 3|
88886245|NCT01414322||Group 2: Patients ages 3 - 7|
88886246|NCT01414322||Group 3: Patients ages 7 - 15|
88886247|NCT01414335|Placebo Comparator|placebo|
88886248|NCT01414335|Active Comparator|amino acid composition|
88886249|NCT01414348|Active Comparator|Conventional rehabilitation|In-home work on problems in daily living.
88886250|NCT01414348|Experimental|Novel rehabilitation approach|
88886251|NCT01414361||intermediate lesion|intermediate lesions evaluated by both IVUS and FFR
88886252|NCT01414374|Active Comparator|Iron|
88886253|NCT01414374|Experimental|Herbal|
88886254|NCT01414387|Active Comparator|Carotid filter|For this intervention group, patients will receive FDA-approved filter devices for cerebral embolic protection during carotid artery stenting intervention.
88886255|NCT01414387|Active Comparator|Carotid reversal of flow|For this intervention group, patients will receive reversal of flow with the FDA-approved Gore Neuroprotection System for cerebral protection during carotid artery stenting.
89410167|NCT01746225|Experimental|B: nab-Paclitaxel 100 mg/m2 days 1,8,15|"Arm B: Induction* nab-Paclitaxel 125 mg/m2 on days 1,8,15 every 28 days for 3 cycles followed by maintenance nab-Paclitaxel 100 mg/m2 administered on days 1, 8, 15 of each 28-day cycle (total 300mg/m2 per cycle) until progression or unacceptable toxicity.~*Following Amendment 1, the dose in the induction phase dose in all three arms was reduced to 125 mg/m² from 150 mg/m²."
89410168|NCT01746225|Experimental|C: nab-Paclitaxel 75 mg/m2 days 1,8,15,22|"Arm C: Induction* nab-Paclitaxel 125 mg/m2 on days 1,8,15 every 28 days for 3 cycles followed by maintenance nab-Paclitaxel 75 mg/m2 administered on days 1, 8, 15, 22 of each 28-day cycle (total 300mg/m2 per cycle) until progression or unacceptable toxicity.~*Following Amendment 1, the dose in the induction phase dose in all three arms was reduced to 125 mg/m² from 150 mg/m²."
89410169|NCT01730547|Active Comparator|Early treatment with mesenchymal stem cells|Patients receive a single intravenous dose of autologous bone marrow-derived MSCs followed by placebo at week 24. Fommow up at week 48
89410170|NCT01730547|Active Comparator|Delayed treatment with mesenchymal stem cells|Patients receive placebo for 24 weeks followed by autologous MSCs at week 24, with a follow-up visit at week 48.
89410171|NCT01716806|Experimental|Part A: Brentuximab Vedotin in HL Patients|
89410172|NCT01716806|Experimental|Part B: Brentuximab Vedotin + Dacarbazine in HL Patients|
89410173|NCT01716806|Experimental|Part C: Brentuximab Vedotin + Bendamustine in HL Patients|
89410174|NCT01716806|Experimental|Part D: Brentuximab Vedotin + Nivolumab in HL Patients|
88886256|NCT01414439||Congestive Heart Failure Patients|40 patients diagnosed with heart failure at levels III and IV, according to the classification of the NYHA will participate in the research. The researchers will randomly allocate the patients to the treatment group or the control group. The subjects in the treatment group will participate in Existential Group Therapy, while the subjects in the control group will not participate in the treatment until after the completion of the study. Psychological data will be collected in the form of a self-reported questionnaire completed by all participants prior to the beginning of the research and again upon completion of the final group session.
89410175|NCT01716806|Experimental|Part E: Brentuximab Vedotin in HL Patients|
89410176|NCT01716806|Experimental|Part F: Brentuximab Vedotin in PTCL Patients|
89410177|NCT01650545|Experimental|Liposomal Aerosol Cyclosporine|Arm 1) Aerosol liposomal cyclosporine Open label randomized trial using experimental inhalational therapy with liposomal aerosol cyclosporine in addition to standard immune suppression (tacrolimus , mycophenolate mofetil and prednisone) for 6 month duration at inhalational doses (5mg and 10 mg bid), to be defined by transplant type respectively (single, double lung transplant )
88886257|NCT01414452||STEMI patients|Patients with ST elevation myocardial infarction,lasting <12 hour, who were succesfully treated with primary PCI
88886258|NCT01414465|No Intervention|low caloric diet|10 health obese women (BMI 30 to 40 kg/m2)
88886259|NCT01414465|Experimental|Orlistat|10 obese women treated with Orlistat 120mg 3 times per day
88886260|NCT01414465|Sham Comparator|lifestyle counseling|Women with BMI < 30 kg/m2, no taking drug in study
88886261|NCT01414478|Active Comparator|High Protein Shake|Protein shake that contain 30 grams of protein in 11 fluid ounces.
88886262|NCT01414478|No Intervention|Ice Chips|Patients allowed consumption of ice chips only during labor.
88886263|NCT01414504|Active Comparator|Neonatal PCV + PPV 9 months|Group 1: Children receiving 7VPCV at 0-1-2 months of age and PPV at 9 months of age
89410178|NCT01650545|Active Comparator|Conventional oral immune suppression|"Arm 2) Standard immune suppression consisting of typical oral immune suppression for lung transplant recipients typically tacrolimus, mycophenolate mofetil and prednisone.~Conventrional oral immune suppression as standard of care thus consists of tacrolimus, mycophenolate mofetil prednisone rapamycin described in the subsequent section as well."
89410179|NCT01528189|Placebo Comparator|Standard glucose management|Arterial-blood glucose levels will be checked at induction of anesthesia and every 30 - 60 min thereafter with an StatStrip Xpress® (Nova Biomedical, MA, USA) ( A blood glucose level above 10 mmol/l will be treated with a 2U bolus of IV insulin (Humulin® R regular insulin, Eli Lilly and Company, Indianapolis, IN) followed by a 1 U/hour drip infusion adjusted according to a standard sliding scale
89410180|NCT01528189|Active Comparator|Hyperinsulinemic normoglycemic clamp|The blood glucose level will be checked prior to intubation. A 2U bolus of IV insulin will be given if blood glucose level is higher than 6 mmol/l, followed by an IV infusion of 2 U/kg/min (0.12 U/kg/hour). Dextrose 20% (D20W®) will be titrated to maintain blood glucose between 4 and 6 mmol/l. Blood glucose levels will be measured at 5-30 min intervals with a to ensure normoglycemia. At the end of surgery, the insulin infusion will be stopped, and the dextrose infusion weaned off in the post anesthesia care unit.
89410181|NCT01471522|Active Comparator|Invasive Strategy (INV)|Routine invasive strategy with cardiac catheterization followed by revascularization plus optimal medical therapy.
88886264|NCT01414504|Active Comparator|Infant PCV + PPV at 9 months|Group 2: Children receiving 7VPCV at 1-2-3 months of age and PPV at 9 months of age
88886265|NCT01414504|Active Comparator|No PCV + PPV at 9 months|Group 3: Children who only received PPV at 9 months of age
88886266|NCT01414504|Active Comparator|Control|Group 4: Children who have not received any previous pneumococcal vaccine
88886267|NCT01414517|Active Comparator|FOS|Prebiotic (FructoOligoSaccharide-FOS.
88886268|NCT01414517|Placebo Comparator|Placebo|Maltodextrin (non-prebiotic carbohydrate).
88886269|NCT01414530|Experimental|oral contraceptive|
88886270|NCT01414530|Active Comparator|NSAID|
88886271|NCT01414543|Other|providing information sheet|providing participants with information regarding the purpose of the research
88886272|NCT01414543|Other|Seeking consent|
88886273|NCT01414543|Other|Interview Participant|
88886274|NCT01414543|Other|Debrief|The Participants will be debriefed after the interview.
88886275|NCT01414556|Experimental|hyperglycemia|
88886276|NCT01414556|Experimental|fasting glycemia|
88886277|NCT01414556|Experimental|hypoglycemia|
88886278|NCT01414569|Active Comparator|8 mg dexamethasone|
88886279|NCT01414569|Placebo Comparator|Placebo, saline|
89410182|NCT01471522|Active Comparator|Conservative Strategy|Optimal medical therapy with cardiac catheterization and revascularization reserved for patients with acute coronary syndrome, ischemic heart failure, resuscitated cardiac arrest or refractory symptoms.
89410183|NCT01191008||Latan-timolol maleate fixed comb ophthalmic solution|
89410184|NCT01155232||Forteo (teriparatide)|postmenopausal women and men with osteoporosis Teriparatide is marketed as Forteo by Eli Lilly Teriparatide is not supplied (observational study)
89410185|NCT01155232||Forteo (teriparatide) in AFF|women who have experienced an atypical femur fracture (AFF) Teriparatide is not supplied (observational study)
89410186|NCT01060371||Spinocerebellar Ataxia 1|"If you decide to participate in this study, the following study procedures will be performed:~blood collection for DNA testing, analysis (genetic modifier study) and banking~Medical history~Physical exam~Scale for Assessment and Rating of Ataxia (SARA)~Timed measure of your hand dexterity and walking (25 ft)~Questionnaire about your daily living activities, your physical and mental quality of life and assessment of depression.~Disease stage estimation by the clinician.~Demographics and disease-related information (i.e. age, sex, race, age at disease onset, disease duration)~Review of your medical records"
88886280|NCT01414569|Experimental|40 mg dexamethasone|
88886281|NCT01414582|Experimental|Anodal tDCS and Motor Training|Participants will receive anodal tDCS over the primary motor cortex of the ipsilesional hemisphere. The following parameters will be used: stimulation intensity of 1mA for the first 20 minutes of motor training (9 consecutive sessions Monday-Friday).
88886282|NCT01414582|Sham Comparator|Sham tDCS and Motor Training|Participants will receive sham tDCS over the primary motor cortex of the ipsilesional hemisphere for the first 20 minutes of motor training (9 consecutive sessions Monday-Friday).
88886283|NCT01414595||Group 1|CALGB 140202 outlines the standard procedures for sample procurement. Samples to be used for this project have already been obtained and are currently banked at the CALGB Pathology Coordinating Office (PCO) and the Lung Cancer Tissue Bank at Brigham and Women's Hospital.
88886284|NCT01414608|Experimental|Arm I (cisplatin, radiation therapy, brachytherapy)|Patients receive cisplatin IV over 60-90 minutes on days 1, 8, 15, 22, and 29. Patients also undergo external-beam radiation therapy once daily, 5 days a week, for approximately 5 weeks. Patients then undergo high-dose rate, pulsed-dose rate, or low-dose rate intracavitary brachytherapy.
89191973|NCT03355794|Experimental|Dose level 1 (DIPG participants > 21yrs)|Ribociclib administered orally; daily on days 1-21 each 28 day cycle; 300mg daily Everolimus administered orally; daily on days 1 - 28 each 28 day cycle; 2.5mg/day
89191974|NCT01487174|Experimental|KD019|KD019 will be administered orally once daily at a dose of 300 mg. One dose reduction to 200 mg will be permitted.
89191975|NCT01487174|Active Comparator|Erlotinib|Erlotinib will be administered orally once daily at a dose of 150 mg. One dose reduction to 100 mg daily will be permitted.
89191976|NCT00725634|Experimental|AV-299 Dose Escalation Arm|AV-299 Administered by IV Infusion as Monotherapy in Advanced Solid Tumors, Lymphomas, or Multiple Myeloma
89191977|NCT00725634|Experimental|AV-299 in combination with erlotinib|AV-299 Administered by IV Infusion in Combination with Erlotinib (150 mg daily) in Advanced Solid Tumors
89191978|NCT01248806||Smokers or former smokers, Aged ≥ 50|Men and women current daily smokers or former smokers, Aged ≥ 50
89191979|NCT00617344|Experimental|CYD Dengue Vaccine 5555 Formulation|Participants received 3 doses of CYD dengue vaccine (5555 formulation); one each at 0 (vaccination 1), 6 (vaccination 2), and 12 (vaccination 3) months.
89191980|NCT00617344|Experimental|CYD Dengue Vaccine 5553 Formulation|Participants received 3 doses of CYD dengue vaccine (5553 formulation); one each at 0 (vaccination 1), 6 (vaccination 2), and 12 (vaccination 3) months.
89191981|NCT00617344|Experimental|CYD Dengue Vaccine 4444 Formulation|Participants received 3 doses of CYD dengue vaccine (4444 formulation); one each at 0 (vaccination 1), 6 (vaccination 2), and 12 (vaccination 3) months.
89410187|NCT01060371||Spinocerebellar Ataxia 2|"If you decide to participate in this study, the following study procedures will be performed:~blood collection for DNA testing, analysis (genetic modifier study) and banking~Medical history~Physical exam~Scale for Assessment and Rating of Ataxia (SARA)~Timed measure of your hand dexterity and walking (25 ft)~Questionnaire about your daily living activities, your physical and mental quality of life and assessment of depression.~Disease stage estimation by the clinician.~Demographics and disease-related information (i.e. age, sex, race, age at disease onset, disease duration)~Review of your medical records"
89410188|NCT01060371||Spinocerebellar Ataxia 3|"If you decide to participate in this study, the following study procedures will be performed:~blood collection for DNA testing, analysis (genetic modifier study) and banking~Medical history~Physical exam~Scale for Assessment and Rating of Ataxia (SARA)~Timed measure of your hand dexterity and walking (25 ft)~Questionnaire about your daily living activities, your physical and mental quality of life and assessment of depression.~Disease stage estimation by the clinician.~Demographics and disease-related information (i.e. age, sex, race, age at disease onset, disease duration)~Review of your medical records"
89410189|NCT01060371||Spinocerebellar Ataxia 6|"If you decide to participate in this study, the following study procedures will be performed:~blood collection for DNA testing, analysis (genetic modifier study) and banking~Medical history~Physical exam~Scale for Assessment and Rating of Ataxia (SARA)~Timed measure of your hand dexterity and walking (25 ft)~Questionnaire about your daily living activities, your physical and mental quality of life and assessment of depression.~Disease stage estimation by the clinician.~Demographics and disease-related information (i.e. age, sex, race, age at disease onset, disease duration)~Review of your medical records"
89410190|NCT00821587|Active Comparator|Tacrolimus|Tacrolimus
89410191|NCT00821587|Active Comparator|Cyclosporine|Cyclosporine
88886285|NCT01414608|Experimental|Arm II (cisplatin, radiation therapy, brachytherapy, chemo)|Patients receive cisplatin and undergo external-beam radiation and brachytherapy as in arm I. Beginning 4 weeks later, patients also receive adjuvant chemotherapy comprising paclitaxel IV over 3 hours and carboplatin IV over 1 hour on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
88886286|NCT01414621||CABG patients|atrial tissue samples from CABG patients
88886287|NCT01414647|Experimental|SRC|Strawberry, raspberry and cloudberry intervention for 8 weeks
88886288|NCT01414647|Experimental|BB|Bilberry intervention for 8 weeks
89410192|NCT00751829|Experimental|1|oral olmesartan medoxomil tablets 20 mg or 40 mg once daily for 24 weeks + oral hydrochlorothiazide tablets 12.5 or 25 mg once daily after 12 weeks, if needed to controll BP
89410193|NCT00751829|Active Comparator|2|oral nitrendipine tablets 10 or 20 mg taken twice daily for 24 weeks + oral hydrochlorothiazide tablets 12.5 or 25 mg once daily after 12 weeks, if needed to control BP
89410194|NCT00645801|Active Comparator|Ingested 4 tablets of lubiprostone in divided doses + 1 gallon of polyethylene glycol|"First dose of lubiprostone 24 micrograms or placebo was administered 2 nights before colonoscopy and subsequent doses at breakfast, lunch, and dinner on the day before the procedure. Patients were on a clear liquid diet on the day before the procedure and were instructed to initiate drinking PEG (immediately after the last dose of lubiprostone) at 6 PM the evening before the colonoscopy and continued drinking the solution until at least 2 bowel movements were clear yellow or green. All study patients were educated and instructed to observe for clear stool, which was defined as watery consistency without any solid fecal material or dark liquid stools. Patients were instructed to return the unused PEG solution on the day of colonoscopy. After completing the preparation but before colonoscopy, patients were also required to fill a questionnaire to assess the tolerability of tablets and solution."
89410195|NCT00645801|Placebo Comparator|Ingested 4 tablets of placebo in divided doses + 1 gallon of polyethylene glycol|"First dose of look alike placebo was administered 2 nights before colonoscopy and subsequent doses at breakfast, lunch, and dinner on the day before the procedure. Patients were on a clear liquid diet on the day before the procedure and were instructed to initiate drinking PEG (immediately after the last dose of lubiprostone) at 6 PM the evening before the colonoscopy and continued drinking the solution until at least 2 bowel movements were clear yellow or green. All study patients were educated and instructed to observe for clear stool, which was defined as watery consistency without any solid fecal material or dark liquid stools. Patients were instructed to return the unused PEG solution on the day of colonoscopy. After completing the preparation but before colonoscopy, patients were also required to fill a questionnaire to assess the tolerability of tablets and solution."
89410196|NCT00424099|Experimental|Group 1: Methylphenidate + NTI|Methylphenidate 5 mg (one capsule) orally every two hours as needed up to a maximum of 20 mg per day for a period of 14 days + Nursing Telephone Intervention (NTI). NTI calls from study nurse 3 times weekly to ask about side effects and other symptoms.
89410197|NCT00424099|Placebo Comparator|Group 2: Placebo + NTI|Placebo capsule orally as needed for 14 days + NTI, calls from study nurse 3 times weekly to ask about side effects and other symptoms.
89410198|NCT00424099|Experimental|Group 3: Methylphenidate + Non NTI|Methylphenidate 5 mg (one capsule) orally every two hours as needed up to a maximum of 20 mg per day for a period of 14 days + Non NTI, calls from research staff 3 times weekly.
89410199|NCT00424099|Experimental|Group 4: Placebo + Non NTI|Placebo capsules as needed with Non NTI, calls from research staff 3 times weekly.
89410200|NCT00176267|Experimental|1|
89410201|NCT03102346|Experimental|Home-based Cardiac Rehabilitation group|remote instructed exercise training at home
89410202|NCT03102346|No Intervention|routine group|no instructed exercise training
89410203|NCT02298764|Active Comparator|standard + 10 psychotherapeutic sessions|- standard back pain treatment plus 10 psychotherapeutic sessions, that will include the shock-trauma method 'Somatic Experiencing'.
89410204|NCT02298764|Active Comparator|Standard back pain treatment|Standard back pain treatment
89410205|NCT05428501||Person Living with Obesity (PLwO)|PLwO recruited via online platforms or face-to-face channels
89410206|NCT05428501||Health Care Professionals (HCPs)|HCPs treating people who have obesity
89410207|NCT03102112||Patients with glioma|Consecutive patients with privious MRI scans or symptoms that suggested a cerebral mass, not yet receive treatment.
89410208|NCT02292056|Experimental|Counseling Group|Participation in the study will be completed in a single session and will involve a pre-counseling questionnaire, followed by a pre-counseling quiz, individualized counseling session, post-counseling quiz and post-counseling questionnaire.
89191982|NCT02570724|Active Comparator|Blood Patch arm|Standard of care arm: injection of autologous blood approximately 40 mL of blood sample into the epidural space at a rate of 1 ml / about 5 seconds.
89410209|NCT03643731|Experimental|HeatTens|"After baseline measurements and during 4 weeks of follow up~Composition and dosing of the device:~HeatTens (HV-F311-E) 2 - 108 Hz (modulation), 100 microsec (pulse duration) for 30 minutes."
89410210|NCT03643731|No Intervention|Control group|No intervention
89410211|NCT03755544||Asthma patients|"Male or female patients with diagnosed asthma who have been using salmeterol/fluticasone propionate combination treatment for at least 3 months before the beginning of the study, and for whom the decision has already been made to switch to Salmeterol/fluticasone Easyhaler.~During the study, the Salmeterol/fluticasone Easyhaler will be used according to the local Summary of Product Characteristics (SmPC)."
89410212|NCT03755544||COPD patients|"Male or female patients with diagnosed COPD who have been using salmeterol/fluticasone propionate combination treatment for at least 3 months before the beginning of the study, and for whom the decision has already been made to switch to Salmeterol/fluticasone Easyhaler.~During the study, the Salmeterol/fluticasone Easyhaler will be used according to the local Summary of Product Characteristics (SmPC)."
89410213|NCT05431894|Experimental|Intervention Arm|Group received support from Laguna Coaches
89410214|NCT05431894|No Intervention|Control Arm|Group received no support from Laguna Coaches
89410215|NCT02298920|Experimental|Single Group|Open Label ADME Study
89410216|NCT05007366|Active Comparator|Real-time gait biofeedback (RTGBF)|The RTGBF regimen delivers biofeedback that cues a personalized target to normalize vertical ground reaction force (vGRF) of each limb.
89410217|NCT05007366|Sham Comparator|Sham real-time gait biofeedback (Sham RTGBF)|The Sham RTGBF regimen will receive biofeedback that cues their habitual step length determined during the accommodation period on the first session of treadmill walking.
89410218|NCT05691907|Experimental|Directional Preference Exercises|Directional Preference Exercises will be provided, also known as Mckenzie's extension exercises
88886289|NCT01414647|Experimental|C|Control diet with restricted berry consumption
89191983|NCT02570724|Active Comparator|"Drug: injection of HES  Voluven®  patch arm"|"Drug: injection of HES  Voluven®  into the epidural space of 15 to 30 ml at a rate of 1 ml / about 5 seconds"
89191984|NCT00725738|Experimental|A|"Stem Cell Transplantation Group: Between the fifth and seventh day post-primary angioplasty (PTCA) we extract the stem cell from iliac crest and during the same day the patient undergoes to a new cardiac catheterization in which we perform the intracoronary injection (about 1-2 million of CD34 cells) through the infarct related artery by a PTCA over-the-wire catheter."
89191985|NCT00862342|Experimental|Bevacizumab|Bevacizumab continuation plus chemotherapy in patients who have failed previous bevacizumab plus other chemotherapy
89191986|NCT00730808|Experimental|Test|Oral nutritional supplement: assignment according to consecutive random numbers.
89410219|NCT05691907|Experimental|Motor Control Exercises|Motor Control Exercises consisting of extension bias external limb loading protocol.
89410220|NCT03517748|Experimental|the investigational device: DM05|DM05 eye drops, multidose sterile emulsion, will be administered in the DM05 Arm at one to two drops instilled in each eye from 4 to 6 times per day during 84 days
89410221|NCT03517748|Active Comparator|The comparative device : Optive™|Optive™ eye drops, multidose sterile solution, will be administered in the Optive Arm at one to two drops instilled in each eye from 4 to 6 times per day during 84 days
89410222|NCT03104686|Active Comparator|Bread|Bread (50g available carbohydrate, 109 g) eaten with 500 mL of water
89410223|NCT03104686|Experimental|Short pasta (dry)|Cooked penne (142 g; 71 g uncooked) eaten with 500 mL of water
89410224|NCT03104686|Experimental|Long pasta (dry)|Cooked spaghetti (142 g; 71 g uncooked) eaten with 500 mL of water
89410225|NCT03104686|Active Comparator|Glucose|Glucose monohydrate (55 g) dissolved with 500 mL of water
89410226|NCT02253498|Experimental|Deep Brain Stimulation|Deep Brain Stimulation is on
89410227|NCT02253498|Sham Comparator|Sham Stimulation|placebo
88886290|NCT01414660||islet|type 1 diabetic patients undergoing islet transplantation
88886291|NCT01414660||liver|non diabetic patients undergoing a liver transplantation
88886292|NCT01414660||kidney|non diabetic patients undergoing a kidney transplantation
88886293|NCT01414673|Other|spontaneous LH|
88886294|NCT01414673|Experimental|HCG|
88886295|NCT01414686|Experimental|Immediate Treatment Group|
88886296|NCT01414686|No Intervention|Delayed Treatment Group|
88886297|NCT01414699|Active Comparator|One-Course, Variety|Participants will receive a snack in one course with a variety of fruit.
88886298|NCT01414699|Active Comparator|Two-Course, Variety|Participants will receive a snack in two courses with a variety of fruit.
88886299|NCT01414699|Active Comparator|One-course, Non-Variety|Participants will receive a snack in one course with no variety of fruit.
88886300|NCT01414699|Active Comparator|Two-Course, Non-Variety|Participants will receive a snack in two courses with no variety of fruit.
88886301|NCT01414712||prostate cancer patients|
88886302|NCT01414725|Experimental|Core Stability Training|
88886303|NCT01414725|Placebo Comparator|Relaxation|
88886304|NCT01414725|Active Comparator|Standard Physiotherapy Exercises|
88886305|NCT01414751|Active Comparator|Absolute risk reduction information|Patients belonging to this arm receive effectiveness information by means of absolute risk reduction when talking with their general practitioner concerning their cholesterol level and possible gain if starting therapy.
88886306|NCT01414751|Active Comparator|Prolongation of life information|Patients belonging to this arm receive effectiveness information by means of prolongation of life/life extension when talking with their general practitioner concerning their cholesterol level and possible gain if starting therapy.
88886307|NCT01414764|Active Comparator|Autologous conditioned plasma (ACP)|"10ml of patient's own venous blood is aspirated. The syringe is centrifuged in a proprietary closed unit (Arthrex Medical Company) for 5 minutes. The red blood cells will be discarded, and the supernatant containing ACP (with additional CaCl to activate the ACP and local anaesthetic) is injected into the tendon bone junction and adjacent area under ultrasound guidance. No adverse consequences are anticipated by using the Arthrex ACP injection.~First injection at approximately 10 days post-operatively~Second Injection at approximately 21 days post-operatively~Other Names:~Platelet rich plasma (PRP)"
88886308|NCT01414764|Placebo Comparator|Placebo|"10ml of patient's own venous blood is aspirated. The syringe is centrifuged in a proprietary closed unit (Arthrex Medical Company) for 5 minutes. The venous blood sample will be discarded and a placebo (saline + local anaesthetic) is injected to the surrounding tissue, but not into the tendon, under guided ultrasound.~First injection at approximately 10 days post-operatively~Second Injection at approximately 21 days post-operatively"
88886309|NCT01414790|Experimental|ADM group|29 patients (ADM group) had a total parotidectomy with a simultaneous ADM implantation
88886310|NCT01414790|No Intervention|control group|41 patients (control group) had a total parotidectomy alone
88886311|NCT01414803|Experimental|rosuvastatin/fenofibrate combination|rosuvastatin 10 mg/fenofibrate 160 mg per day
88886312|NCT01414803|Active Comparator|rosuvastatin monotherapy|rosuvastatin 10 mg per day
88886313|NCT01414816||Group 1|
88886314|NCT01414842|Active Comparator|Standard|Standard constant (no profiled) sodium dialysate used during endogenous hemodiafiltration
88886315|NCT01414842|Experimental|Automated profiled|Automate sodium profiling in endogenous hemodiafiltration
88886316|NCT01414881|Experimental|mipomersen|mipomersen 200mg subcutaneously (SC) once weekly
88886317|NCT01414881|Placebo Comparator|Placebo|Placebo administered subcutaneously (SC) once weekly
88886318|NCT01414894|Active Comparator|Normal Fluids & Normal Blood Pressure|Patients are treated with conventional fluid replacement (Normovolemia) and maintenance of blood pressure in a normal range (Conventional Blood Pressure).
88886319|NCT01414894|Active Comparator|Increased Fluids & Normal Blood Pressure|Patients are treated with fluids to achieve higher volume expansion (Hypervolemia) and maintenance of blood pressure in a normal range (Conventional Blood Pressure)
88886320|NCT01414894|Active Comparator|Normal Fluids & Higher Blood Pressure|Patients are treated with conventional fluid replacement (Normovolemia) and maintenance of blood pressure in a higher range (Augmented Blood Pressure).
88886321|NCT01414894|Active Comparator|Increased Fluids & Higher Blood Pressure|Patients are treated with fluids to achieve higher volume expansion (Hypervolemia) and maintenance of blood pressure in a higher range (Augmented Blood Pressure).
88886322|NCT01414907|Active Comparator|Health Promotion activities|
88886323|NCT01414907|No Intervention|No Intervention|
89005048|NCT00226668|Experimental|I|Patients will receive hCRf (XERECEPT) 2mg/day and dexamethasone 4 mg/day along with any open-label dexamethasone that they may be taking
89005049|NCT00226668|Placebo Comparator|II|Patients will receive placebo hCRF (XERECEPT) 2mg/day and dexamethasone 4 mg/day along with any open-label dexamethasone they may be taking
89005050|NCT00208611|Experimental|Open-Label Treatment|Levodopa-treated Parkinson's Disease subjects with vitamin B12 < 200 pg/ml given oral vitamin B12 supplement
89005051|NCT00203567|Active Comparator|Equetro|Equetro
89005052|NCT00226746|Experimental|Paclitaxel and Gemcitabine|"Radiation Therapy: 63.80 Gy (1.1 Gy twice a day X 58 fractions), Paclitaxel: 60 mg/m2 / week by 1- hour IV infusion on days 1, 8, 15, 22, 29, and 36.~Gemcitabine: 75 mg/m2 / week on days 1, 8, 15, 22, 29, and 36."
89005053|NCT00203606|Experimental|Active Treatment|Active Treatment with Pegylated Interferon Alfa 2a (Pegasys, Roche) and ribavirin
89005054|NCT00203606|No Intervention|Observation|Observation with no active treatment for Hepatitis C. Observation period is based on standard treatment duration based on genotype of Hepatitis C. Active treatment offered to participants at conclusion of observation. (Protocol Amendment #1, October 30, 2001. Ethics approval Jan 19, 2004).
89005055|NCT00203645|Experimental|Brief self-directed treatment|self-help workbook plus motivational telephone intervention
89005056|NCT00203645|Experimental|Self-directed plus telephone support|Self-help workbook, motivational telephone intervention plus telephone booster calls
89005057|NCT00203645|Active Comparator|Workbook only|Workbook only
89005058|NCT00203645|No Intervention|Waitlist|Six week waitlist
89005059|NCT02962791|Experimental|Stimulation of 3 ventricular sites|Cardiac resynchronization therapy implantation wil be done as usual, except the additional stimulation lead. Standard Echocardiography will be done at one year
89005060|NCT02962791|Active Comparator|Stimulation of 2 ventricular sites|Cardiac resynchronization therapy implantation wil be done as usual. Standard Echocardiography will be done at one year
89005061|NCT00208806||congenital heart patients with congestive heart failure|20 effected patients with congestive heart failure patients total 50 patients
89005062|NCT00208845||adult ED patients|
89005063|NCT00203879|Experimental|1|MAGE-3/Melan-A/gp100/NA17 Peptide-pulsed autologous PBMC, rhIL-12 with IL-2
89005064|NCT00203879|Experimental|2|MAGE-3/Melan-A/gp100/NA17 Peptide-pulsed autologous PBMC, rhIL-12 without IL-2
89005065|NCT00208923|Active Comparator|1|Chemotherapy-only conditioning regimen comprising busulfan (Bu), cyclophosphamide (Cy) and fludarabine (FLUDARA) followed by an allogeneic stem cell transplant.
89005066|NCT00203918||Prostate biopsies|Males undergoing prostate biopsies
89005067|NCT00208962|Active Comparator|1|
89005068|NCT00203957|Experimental|Group A|Patients who completed double-blind treatment studies 6002-US-013, 6002-US-013, 6002-US-018 immediately prior to entering this open-label trial and may have had an interuption of study drug of 14 days or less.
89005069|NCT00203957|Experimental|Group B|Patients who previously completed double-blind treatment studies 6002-US-013, 6002-US-018 or 6002-EU-007 or discontinued from open label study 6002-US-007 and have had an interuption of study drug greater than 14 days.
89005070|NCT00209001|Sham Comparator|Sham acupuncture therapy|Sham acupuncture therapy
89005071|NCT00209001|Active Comparator|Acupuncture|Acupuncture
89005072|NCT00209001|No Intervention|Observation|Observation
89005073|NCT00197444|Experimental|1|Chemoradiotherapy
89005074|NCT00227292|Placebo Comparator|A, 2, II|Placebo 10mg per day for the first week, then 20mg per day till the end of study.
89005075|NCT00227292|Experimental|A, 1|Escitalopram 10mg per day for the first week, then 20mg per day till the end of study.
89005076|NCT00197561|Active Comparator|Selenium|Selenium (200 ug as selenomethionine)
89005077|NCT00197561|Placebo Comparator|Placebo|Placebo
89005078|NCT00197678|Experimental|Multivitamins-Single RDA|Multivitamins at doses resembling a single daily Recommended Dietary Allowance (RDA)
89005079|NCT00197678|Active Comparator|Multivitamins-Multiples of RDA|Multivitamin supplements at multiples of the Recommended Dietary Allowance (RDA)
89005080|NCT00227487|Other|Stool collection, Carbohydrate administration, Questionnaires|"A stool sample will be obtained~A carbohydrate solution (lactulose plus rhamnose dissolved in tap water) will be administered during a clinically indicated endoscopic procedure.~Five questionnaires will be completed by parent/guardian"
89005081|NCT00197756||Vitamin A|Participants in the in the parent study who had been randomized to receive either Vitamin A alone or multivitamins including vitamin A.
89005082|NCT00197756||No Vitamin A|Participants in the parent study who were randomized to receive either multivitamins excluding vitamin A, or placebo.
89005083|NCT00197756||Multivitamins|Participants in the parent study who were randomized to receive multivitamins including vitamin A or multivitamins excluding vitamin A
89005084|NCT00197756||No Multivitamins|Participants from the parent study who had been randomized to vitamin A alone or placebo
89005085|NCT00227565|Experimental|pemetrexed + carboplatin + radiation|"Patients receive pemetrexed disodium IV over 10 minutes and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who develop progressive disease in the CNS only may receive whole-brain radiotherapy and then continue chemotherapy after completion of whole-brain radiotherapy for up to 6 courses.~After completion of study treatment, patients are followed every 3 months for 1 year and then every 6 months for 4 years."
89005086|NCT00204308|Experimental|combination tenofovir-emtricitabine|
89005087|NCT00204308|No Intervention|control arm|
89005088|NCT02963246|Experimental|Mindfulness group|Mindfulness intervention (12 months). Mindfulness based Cognitive Therapy is an evidence-based psychological program designed to help manage depressive and stress symptoms.
89005089|NCT02963246|No Intervention|Control Group|Treatment-as-usual control
89005090|NCT00227682|Experimental|Arsenic Trioxide|Arsenic Trioxide in Combination With Thalidomide, Dexamethasone, and Ascorbic Acid
89005091|NCT00230763|Experimental|Active|
89005092|NCT00230763|Other|Procedure|
89005093|NCT04721964|Experimental|Intervention|All 24 participants will daily consume 6 mg iron/kg body weight for 13 weeks to correct their anaemia and increase their iron stores.
89005094|NCT02962323|Experimental|Test|Torrent Pharmaceutical Ltd's Rosuvastatin Calcium Tablets 40 mg
89410228|NCT02298998||Intervention|The intervention group refers to surveillance based on the EAU guidelines.
89410229|NCT02298998||Control|The control group refers to surveillance based on the AUA guidelines.
89410230|NCT03104608|Active Comparator|Automatic Self Transcending Meditation|Participants in the ASTM group will undergo training in groups of 10 by certified teachers. Further, the following self-rated scales will be administered by a trained rater at the fourth ASTM session (week 0) as well as at weeks 4, 8, 12, and 24: Time Trade-off (TTO), Visual Function Questionnaire (VFQ-25), the Patient Health Questionnaire (PHQ-9), and Generalized Anxiety Disorder (GAD-7).
89410231|NCT03104608|Placebo Comparator|Treatment as Usual|Participants will continue to receive their treatment as usual. The following self-rated scales will be administered by a trained rater at weeks 0, 4, 8, 12 and 24: TTO, VFQ-25, PHQ-9, and GAD-7.
89410232|NCT03626155|Experimental|Seated Control|
89410233|NCT03626155|Experimental|Morning Exercise (walking)|
89410234|NCT03626155|Experimental|Afternoon Exercise (walking)|
89410235|NCT03626155|Experimental|Evening Exercise (walking)|
89410236|NCT04988880|Experimental|Relapsing multiple sclerosis group|Multiple sclerosis relapsing groups: each unit will provide a group of participant with relapsing multiple sclerosis
89410237|NCT04988880|Experimental|Progressive multiple sclerosis group|Multiple sclerosis progressive groups: each unit will provide a group of participants with progressive multiple sclerosis
89410238|NCT03104452||Pregnant Smokers|Participants are pregnant women who smoked in the six months prior to their pregnancy.
89410239|NCT02295098|Active Comparator|Thoracic epidural catheter|Thoracic epidurals work by delivering local anesthetics and narcotics to the epidural space, which then diffuse into the spinal nerve roots and block the transmission of pain from the chest wall to the spinal cord and brain.
89410240|NCT02295098|Active Comparator|Paracostal catheter|Paracostal catheters run along the outer surface of the chest wall and act by delivering local anesthetics to the intercostal nerves as traverse the lower border of the ribs.
89410241|NCT05431504|Experimental|Treatment group|Dalpiciclib in combination with endocrine therapy by physicians choice
89410242|NCT02292134|Experimental|earplug and sleep mask|
89410243|NCT02292134|No Intervention|control|
88886324|NCT01414946|Experimental|Glucose and amino acids|Perioperative nutrition with glucose and amino acids
88886325|NCT01414946|Active Comparator|Amino acids only|Perioperative nutrition with amino acids only
88886326|NCT01414972|Active Comparator|patients with atherosclerosis/ vitamin A|patients with angiographically confirmed CAD (defined as luminal stenosis ≥50% in at least one major coronary artery branch)who receive 25000 IU/day vitamin A
88886327|NCT01414972|Placebo Comparator|patients with atherosclerosis/ placebo|patients with angiographically confirmed CAD (defined as luminal stenosis ≥50% in at least one major coronary artery branch)who receive placebo
88886328|NCT01414972|Active Comparator|people without athrosclerosis/ vitamin a|people in whom significant (e.g. stenosis ≥ 50%) CAD is ruled out by coronary angiography, who receive 2500 Iu/day vitamin A
88886329|NCT01414985|Experimental|Group A|Group A consists of 2 subjects who received 9x10^11 molecules of AAVrh.10CUCLN2, the gene transfer vector carrying the CLN2 gene. This is equal to 900,000,000,000 molecules of the study drug. The drug will be administered only once in the study.
88886330|NCT01414985|Experimental|Group B|Group B will consist of 6 subjects who will receive 2.85x10^11 molecules of AAVrh.10CUCLN2, the gene transfer vector carrying the CLN2 gene. This is equal to 285,000,000,000 molecules of the drug. The drug will be administered only once in the study.
88886331|NCT01414998|Active Comparator|Stress Ball|This is the active comparator for study 1
88886332|NCT01414998|Experimental|De-nicotinised Cigarette|This will be the experimental arm for study 2
88886333|NCT01414998|Experimental|Nicotine-free Electronic Cigarette (1)|This will be the experimental arm for study 1
88886334|NCT01414998|Active Comparator|Nicotine-free Electronic Cigarette (2)|This will be the active comparator for study 2
88886335|NCT01415011|Experimental|Afatinib (BIBW 2992)|All patients will be given daily oral afatinib (BIBW 2992) administered every 28 days until disease progression/toxicity/clinician decision to stop. Starting dose is 40mg. 30mg and 20mg will be administered according to protocol dose modification requirements following toxicity.
89410244|NCT03626077|Active Comparator|group A|Group (A) physical therapy program for 60 minutes per session, three times a week for three consecutive months
89410245|NCT03626077|Active Comparator|group B|Group (B) E-Link Upper Limb Exerciser (augmented biofeedback training)for 60 minutes per session, three times a week for three consecutive months
89410246|NCT03626077|Experimental|group C|group (C) physical therapy program and E-Link Upper Limb Exerciser
89410247|NCT03520634|Experimental|PD-L1 PET imaging in melanoma patients|The main intervention of this study is a [18F]PD-L1 PET scan. In both phase one and phase two a scan sequence will be performed both at baseline and 6 weeks after initiation of nivolumab treatment. The PET scans will be combined with either a low dose or diagnostic CT scan of chest, abdomen and pelvis and a MRI of the brain. In phase two, a biopsy of at least one accessible lesion will be performed to analyze PD-L1 expression using immunohistochemical staining after each PET scan.
89410248|NCT03104530||Brown crabmeat consumers|Those habitually consuming 40 grams or more of brown crab meat each week.
89410249|NCT03104530||Control|Those consuming less than 40 grams of brown crabmeat a year, or no brown crabmeat.
89410250|NCT03514472|Active Comparator|Group A (Below 18 years)|Dried Moringa oleifera leaves (15g/recipe)
88886336|NCT01415037||Annular Array Ultrasound|Subject with possible or with known posterior vitreous detachment. Subjects with diabetic retinopathy will receive annular array ultrasound exam.
88886337|NCT01415050|Active Comparator|Alendronate|
88886338|NCT01415050|Active Comparator|Raloxifane|
89410251|NCT03514472|Active Comparator|Group B (Above 18)|Dried Moringa oleifera leaves (15g/recipe)
89410252|NCT03104140|Experimental|Ketamine group|This group of patients will receive: 1 mg/Kg ketamine + 0.5 ug/Kg fentanyl + 0.05 mg/Kg midazolam for induction of anesthesia. Endotracheal tube will be inserted aided by 1 mg/Kg succinyl choline. Patients will undergo surgical procedure to eliminate the source of sepsis e.g. abdominal exploration. Invasive blood pressure monitor will be connected to the patient through an arterial catheter. Electrical velocimetry (cardiometry) device will be connected to the patient to measure cardiac output, stroke volume, and systemic vascular resistance.
89410253|NCT03104140|Active Comparator|Thiopental group|2 mg/Kg thiopental + 0.5 ug/Kg fentanyl + 0.05 mg/Kg midazolam for induction of anesthesia. Endotracheal tube will be inserted aided by 1 mg/Kg succinyl choline. Patients will undergo surgical procedure to eliminate the source of sepsis e.g. abdominal exploration. Invasive blood pressure monitor will be connected to the patient through an arterial catheter. Electrical velocimetry (cardiometry) device will be connected to the patient to measure cardiac output, stroke volume, and systemic vascular resistance.
89410254|NCT05472883|Experimental|study arm|This arm consists of obese patients with type 2 diabetes who are scheduled for bariatric surgery.
89410255|NCT03514316|Active Comparator|Scalpel Gingivectomy|Patients treated with Scalpel Gingivectomy on the labial side of the anterior maxillary teeth
89410256|NCT03514316|Active Comparator|Laser Gingivectomy|Patients treated with Laser Gingivectomy on the labial side of the anterior maxillary teeth
89410257|NCT03514316|Active Comparator|Nonsurgical periodontal treatment|Patients treated with a full-mouth periodontal debridement
89410258|NCT02114242||Parkinson's disease patients|Patients suffering from Parkinson desease
89410259|NCT02114242||multiple system atrophy patients|"Patients suffering from probable multiple system atrophy according to clinical consensus criteria and age > 30"
89191987|NCT00730808|Placebo Comparator|Control|Assignment according to consecutive random numbers.
89410260|NCT02114242||progressive supranuclear palsy|Patients suffering from progressive supranuclear palsy and age > 40
89410261|NCT02253576|Experimental|inhaled 7% hypertonic saline|Three consecutive 4ml doses of 7% NaCl solution with salbutamol(0.15 mg/kg; 0.03 ml/kg of 0.5% salbutamol nebulizer solution) nebulized over a 1-hour period
89410262|NCT02253576|Active Comparator|inhaled nebulized normal saline|Three consecutive 4ml doses of 0.9 NaCl solution added to salbutamol(0.15 mg/kg; 0.03 ml/kg of 0.5% salbutamol nebulizer solution) nebulized over a 1-hour period
89410263|NCT03520478|Experimental|SHR3680|Participants will receive SHR3680 orally
89410264|NCT03520478|Active Comparator|bicalutamide|Participants will receive bicalutamide orally
89410265|NCT04412590|Experimental|Vermont Family Based Approach|"The VFBA group was offered a variety of supports and services to help them achieve and maintain wellness and address emotional behavioral challenges.~All families partnered with a Family Wellness Coach (FWC) to design and implement a comprehensive program of family health and wellness with an emphasis on nutrition, exercise, music training, mindfulness, decreasing screen time, and positive parenting.~Families with a child or parent experiencing significant emotional and behavioral problems were also partnered with Focused Family Coaches (FFCs) and Family Based Psychiatrists (FBPs). FFCs and FBPs respectively provided evidence-based psychotherapy and psychiatric care from the family perspective.~Families also were also offered health promotion programs, including music lessons for all family members, behavioral parent training, yoga and mindfulness training, and nutrition coaching."
89410266|NCT04412590|Active Comparator|Control|The Control Group received pediatric care as usual.
89410267|NCT05430880||"CRAC patients : ICU patients ventilated and shocked"|"Patient hospitalized in intensive care.~Patient sedated and mechanically ventilated in Volume Assisted Controlled mode.~Patient with hypotension (MAP <65 mmHg OR SAP <90 mmHg) AND / OR under continuous infusion of Norepinephrine / Dobutamine / Epinephrine~Patient equipped with a cardiac output measurement system by transpulmonary thermodilution (PICCO®) with a femoral arterial module; as well as a central venous route in the superior vena cava territory.~Inclusion after agreement of the patient or his trusted person after validation of the inclusion criteria and verification of the absence of exclusion criteria."
88886339|NCT01415063|Experimental|RFA|For RFA, we used a commercially available system with a 375-KHz computer-assisted radiofrequency generator (Elektrotom HiTT 106, Berchtold, Medizinelektronik, Germany) and an open-perfused electrode (Berchtold, Tuttlingen, Germany) of 15 cm (or 20 cm), 14 Ga, and a 15 mm (or 20 mm) active electrode tip with microbores.
88886340|NCT01415063|Experimental|TACE-RFA|TACE first, then RFA within 2 weeks
89005095|NCT02962323|Active Comparator|Reference|Crestor 40 mg of AstraZeneca Pharmaceuticals LP, USA
89191988|NCT02544724|Experimental|NM-IL-12|NM-IL-12 will be administered subcutaneously
89410268|NCT00102648|Experimental|Treatment (temozolomide and lonafarnib)|Patients receive temozolomide PO QD on days 1-7 and 15-21 and lonafarnib PO BID on days 8-14 and 22-28. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
89531067|NCT03341195|Active Comparator|4.Two way interactive automated calls|Parents/caregiver will receive two way (interactive) educational/reminder/proactive automated phone call related to routine immunization once a week till 20 weeks of age-parents will have the option to reply and receive more information related to immunization through phone call.
89191989|NCT03256266||healthy controls|healthy controls
89191990|NCT03256266||patients with allergy|patients with Food intolerances or Food allergy
89191991|NCT03256266||gastrointestinal disorders|patients with inflammatory bowel disease, irritable bowel disease, gluten sensitivity, short bowel syndrome
89191992|NCT00867880|Experimental|1|
89410269|NCT04216446|Experimental|Mobile Health Coaching Program during pregnancy|Eligible pregnant women would be randomized to intervention or the non-intervention arm after consenting to participate. Participants in the intervention arm will receive free subscription of m-Health program for six months of coaching. The program will provide individualized coaching on diet, supplement use and physical activity. Participants would undergo dietary screening at five points i.e. at baseline and at 6, 12, 18 and 24 weeks follow-up to monitor the improvement (if any) in diet, supplement use and physical activity. Women will receive advice in the form of recommendations after completing the questionnaire. Also, push messages containing tips and recommendations for diet, supplement use and physical activity would be delivered a maximum of three times a week. Furthermore, a subset of participants would undergo objective dietary assessment through biochemical testing of serum folate, serum ferritin, and serum calcium and serum vitamin D at baseline and at end line.
89410270|NCT04216446|No Intervention|Standard Counseling|"For the non-intervention arm, dietary counseling will be provided face to face by the trained research assistant at the baseline and scheduled follow-ups using the AKUH educational leaflet Diet during Pregnancy and American College of obstetricians and gynaecologists guidelines for physical activity. Alike intervention group, the non-intervention group will complete an interviewer based paperless screening questionnaire at five points i.e. at baseline and at 6, 12, 18 and 24 weeks follow up. Furthermore, a subset of participants would undergo objective dietary assessment through biochemical testing of serum folate, serum ferritin, and serum calcium and serum vitamin D at baseline and at end line."
89535670|NCT03224845|No Intervention|No intervention|Participants in the control group will receive their usual clinical care and will not be discouraged from seeking any intervention.
89535671|NCT02486393||type of surgery|patients undergoing parotid surgery
89535672|NCT05003973|Experimental|home-based anti-resistance exercise|
89410274|NCT01894282|Active Comparator|Manual Therapy|Spinal Manipulative therapy (SMT) for the purpose of this study we will allow the use of other types of MT, including non-thrust spinal mobilization and flexion-distraction technique.
89410275|NCT01894282|Experimental|Mind Body Intervention (MBI)|"Mind Body Intervention will consist of a combination of the previously described manual therapy and Cognitive Behavioral Therapy for pain (CBT-p). Cognitive Behavioral Therapy for pain management has three basic components. The treatment rationale, coping skills training and application and maintenance of learned coping skills."
89410276|NCT03545958|Experimental|High-intensity Interval Training (HIT)|Participants in this groups will receive 15 minutes in the mind-motor training (i.e., Square-Stepping Exercise) followed by a 45-minute HIT intervention.
89410277|NCT03545958|Active Comparator|Moderate-intensity Continuous Training (MCT)|Participants in this groups will receive 15 minutes in the mind-motor training (i.e., Square-Stepping Exercise) followed by a 45-min MCT intervention.
89410278|NCT03290287||New users of aclidinium bromide|This nested cohort will be composed of patients aged 40 years or older who have previously been diagnosed with COPD and who are new users of aclidinium bromide (monotherapy; concomitant with formoterol not in fixed-dose combination; and aclidinium/formoterol)
89410279|NCT03290287||New users of other COPD medication|This nested cohort will include patients aged 40 years or older who have previously been diagnosed with COPD and who are new users of other COPD medication: tiotropium, other LAMAs, LABA, LABA/ICS and LAMA/LABA.
89410280|NCT02295176|Experimental|Armolipid Plus|Armolipid Plus: 1 tablet daily in the evening after dinner for 24 weeks.
89410281|NCT02295176|Placebo Comparator|Placebo|1 tablet matching Armolipid Plus daily in the evening after dinner for 24 weeks
89410282|NCT04211142|Active Comparator|Laparoscopic repair|Laparoscopic Transabdominal Preperitoneal Inguinal Hernia Repair (TAPP repair)
89410283|NCT04211142|Active Comparator|Open repair|Open Inguinal Hernia Repair (Lichtenstein repair)
89410284|NCT03104218|Experimental|tDCS group|tDCS will be delivered using a direct current stimulator (constant current of 1.5 mA) via two 35cm2 (5 x 7 cm) saline-soaked surface sponge electrodes (parameters shown effective to enhance training). The center of the active electrode will be positioned over C3/C4 (international 10-20 EEG system; corresponding to the cortical representation of upper limb muscles), contralateral to the side of pain and the reference electrode over the contralateral supraorbital region. Current intensity will be ramped up (0-1.5 mA) and down (1.5-0 mA) over 15 seconds at the beginning and end of the 30 minutes stimulation period.
89531068|NCT03341195|No Intervention|5. Control Arm|One time counseling at the baseline survey.
89005096|NCT00204425|Experimental|1|exercise/soy isoflavone
89535673|NCT05003973|Experimental|usually care|
89535674|NCT03204799||normal group|normal group (without diabetes diagnosis/treatment and in normoglycemia
89535675|NCT03204799||prediabetes|high risk, impaired fasting glucose, impaired glucose tolerance
89535676|NCT03204799||drug naive type 2 diabetes|type 2 diabetes, anti-hypoglycemic drug naive
89535677|NCT03204799||type 2 diabetes with metformin monotherapy|type 2 diabetes with metformin monotherapy
89535678|NCT03204799||type 2 diabetes with SGLT2 inhibitor monotherapy|type 2 diabetes with SGLT2 inhibitor monotherapy
89535679|NCT03204799||dyslipidemia with ezetimibe therapy|dyslipidemia with ezetimibe therapy
89005097|NCT00204425|Experimental|2|exercise/isoflavone placebo
89535680|NCT03317327|Experimental|Nivolumab|Nivolumab, intravenous every 2nd week (1 cycle = 2 weeks), dose escalation schedule (1.0, 3.0 mg/kg), for a maximum of 12 months or until disease progression.
89535681|NCT03220243|Experimental|MSC-AFP Single Treatment Group|Eligible patients will be treated, single treatment group, no placebo arm.
89535682|NCT03204331|Experimental|Relugolix plus E2/NETA (Group A)|Relugolix co-administered with E2/NETA for 24 weeks.
89005098|NCT00204425|Experimental|3|exercise placebo/soy isoflavone
89191993|NCT00867880|Active Comparator|2|
88886341|NCT01415076|Placebo Comparator|Insertion without CO2 insufflation|Patients were randomly allocated to receive whole procedure or extubation-only CO2 insufflation, using a randomized computer-generated list.
88886342|NCT01415076|Experimental|Insertion with CO2|Patients were randomly allocated to receive whole procedure or extubation-only CO2 insufflation, using a randomized computer-generated list.
88886343|NCT01415102|Experimental|Cohort 1|Subjects will be assigned to receive either PF-05212372 or placebo in each period
88886344|NCT01415102|Experimental|Cohort 2|Subjects will be assigned to receive either PF-05212372 or placebo in each period
88886345|NCT01415115||Type 1 Diabetes|Must have been diagnosed with type 1 diabetes. Subject group will be measured on SCOUT and compared to Type 2 diabetes cohort.
88886346|NCT01415115||Type 2 Diabetes|Must have been diagnosed with Type 2 diabetes. This group will be compared to the Type 1 cohort.
88886347|NCT01415128|Active Comparator|Omeprazole|Omeprazole with single dose of avanafil (200 mg)
88886348|NCT01415128|Active Comparator|Rosiglitazone|Rosiglitazone with single dose of avanafil (200 mg)
88886349|NCT01415128|Active Comparator|Desipramine|Desipramine with single dose of avanafil (200 mg)
88886350|NCT01415141|Active Comparator|PR|"Treatment with Peginterferon and Ribavirin for up to 48 weeks~Those who achieve eRVR will receive 24 weeks of treatment"
88886351|NCT01415141|Active Comparator|TPR|"Treatment with Telaprevir, Peginterferon and Ribavirin. Patients will receive all 3 drugs for 12 weeks then switch to Peginterferon and Ribavirin for 36 weeks~Those who achieve eRVR will receive 12 weeks of treatment with all 3 drugs and then 12 weeks of treatment with the 2 drugs."
88886352|NCT01415154|Experimental|Scheduled Treatment Arm|3 Week TMS taper, clinical assessments and one NeuroStar TMS session every 4th week of block and TMS reintroduction as needed for clinical deterioration.
88886353|NCT01415154|Experimental|Monthly Observational Follow up Arm|3 Week TMS Taper, clinical assessments and office follow up every 4th week of block and NeuroStar TMS reintroduction as needed for clinical deterioration.
88886354|NCT01415193|Experimental|Selective Tibial Nerve Block|
88886355|NCT01415193|Active Comparator|Control: Sciatic Nerve Block|
88886356|NCT01415206|Experimental|Extended Staging Health Risk Intervention (S-HRI)|The S-HRI provides feedback on participants' stages of change for each risk and the single most important step they can take to begin progressing. A counselor will review the report with participants and provide motivational interviewing (MI) coaching and referrals to relevant behavior change services. Repeated computer and individual counseling contacts at baseline, 3, 6 and 12 months follow-up are designed to support participants through the process of changing multiple risk behaviors.
88886357|NCT01415206|Other|Usual Care|Participants in the usual care condition will complete the core assessments and the Staging Health Risk Assessment (S-HRA) online at baseline, 3, 6, 12, and 18 months follow-up but will not meet with the study MI coach and will NOT receive any feedback or printed report until the 18-month follow-up.
88886358|NCT01415219|Active Comparator|active rehabilitation|A program of 12 individual exercise sessions (3 per week during 4 weeks)
88886359|NCT01415219|No Intervention|conventional care|community based physiotherapy
88886360|NCT01415245|Experimental|Treatment|Device applied to saphenous vein graft
88886361|NCT01415245|No Intervention|Control|Saphenous vein graft without device support
88886362|NCT01415271|Experimental|Internet Intervention|
88886363|NCT01415284|Experimental|Hydroxyethylstarch 130/0.4|
88886364|NCT01415297|Experimental|NKP-1339|"NKP-1339 will be administered in single patient cohorts until ≥ Grade 2 toxicity encountered, at which time cohorts converted to a standard 3 + 3 dose escalation scheme.~When MTD is reached, an expanded cohort of up to 25 patients will be enrolled at the MTD."
88886365|NCT01415336|Active Comparator|AC|doxorubicin 60 mg/m², iv, day 1 Cyclophosphamide 600 mg/m², iv, day 1 every 3 weeks for 4 cycles
88886366|NCT01415336|Experimental|AX|doxorubicin 60 mg/m², iv, day 1 capecitabine 950 mg/m2, twice a day, via oral intake, day 1 to day 14 every 3 weeks for 4 cycles
88886367|NCT01415362|Active Comparator|Active tDCS|The subject will receive sessions of active tDCS remotely triggered by the EEG monitoring system each time seizure activity is detected during the 24-hour period.
88886368|NCT01415362|Sham Comparator|Sham tDCS|The subject will receive sessions of sham tDCS remotely triggered by the EEG monitoring system each time seizure activity is detected during the 24-hour period.
88886369|NCT01415375|Experimental|Prostate Cancer Screening Education|Men in the experimental intervention group received an educational pamphlet on prostate cancer testing as well as tailored telephone education in which the interventionist provided information, answered questions, and conducted a values clarification exercise with the participant.
88886370|NCT01415375|Other|Fruit and Vegetable Intake Education|Men in the attention control group received an educational pamphlet on daily recommended servings of fruits and vegetables as well as tailored telephone education in which the interventionist provided information, answered participant's questions, and discussed any barriers to eating fruits and vegetables.
88886371|NCT01415414||Group 1|
88886372|NCT01415466|Experimental|R|multiple dose of Rosuvastatin 20mg
88886373|NCT01415466|Experimental|O|multiple dose of CS-866 40mg
88886374|NCT01415466|Experimental|R+O|multiple dose of the combination of Rosuvastatin 20mg and CS-866 40mg
88886375|NCT01415479|Experimental|Quantitative|"Subjects view:~Computer-based presentation regarding colorectal cancer (CRC) and screening for CRC with colonoscopy, sigmoidoscopy, or stool testing. Includes a video from the American Cancer Society.~Computer-based presentation providing quantitative information regarding (a) the lifetime average probability of getting CRC or dying from it, (b) the reduction in mortality provided by undergoing regular screening with colonoscopy, and (c) the reduction in mortality provided by undergoing regular screening with fecal immunochemical testing (FIT)"
88886376|NCT01415479|Experimental|Default|"Subjects view:~Computer-based presentation regarding colorectal cancer (CRC) and screening for CRC with colonoscopy, sigmoidoscopy, or stool testing. Includes a video from the American Cancer Society.~Computer-based presentation that encourages subjects who are unwilling to undergo colonoscopy or are unsure about whether to undergo screening to get tested with Fecal Immunochemical Testing (FIT)."
89005099|NCT00204425|Placebo Comparator|4|exercise placebo/isoflavone placebo
89005100|NCT00230880|Experimental|Treatment|follow-up phone counseling
89005101|NCT00230880|No Intervention|Control|Usual care
89410285|NCT03104218|Sham Comparator|Placebo group|"The sham tDCS involves electrodes placed in an identical position to that used for active stimulation; however the stimulation will be turned on for 15 seconds and then off to provide participants with the initial itching sensation but without current for the remainder of the period. This procedure has been shown to effectively blind participants to the stimulation condition. The parameters on the tDCS will be set-up by a research assistant before each session. The treating physiotherapist will not have access to the control board of the tDCS."
89410286|NCT02253888|Experimental|TPV/r - Room condition|
89410287|NCT02253888|Experimental|TPV/r - Refrigerated conditions|
89410288|NCT03520244|Experimental|Exercise + Holistic Education|A 12-week exercise program with 6 bi-weekly education sessions.
89410289|NCT03520244|No Intervention|Wait list control|Participants in the control group will be offered the exercise + education sessions after the study is complete.
89410290|NCT05690737|Experimental|Tai Chi training|The participants in this arm will receive 24-week Tai Chi training (1 hour per day, 5 days per week) with 24-week follow-up. A modified 33-short form Yang-style Tai Chi Chuan will be adopted.
89410291|NCT05690737|Active Comparator|Standard prophylactic medication|Participants in this arm will receive 48-week standard migraine prophylactic medication following neurologist's recommendation.
89410292|NCT05430802|Experimental|Furmonertinib plus cisplatin/pemetrexed|furmonertinib 80mg/d for 9 weeks and cisplatin 75mg/m2 d1 iv + pemetrexed 500mg/m2 d1 iv at 21 day cycles for 3 cycles
89410293|NCT03132896||Patients with moderate or severe ARDS|
89410294|NCT05524038|Active Comparator|(QL) group|In (QL) group, (lateral Approach) :patient receive this block with 20 mg bupivacaine hydrochloride plus 4mg dexamethasone
89410295|NCT05524038|Active Comparator|(ESB) group|In (ESB) group, Erector Spinae Plane Block: patient receive this block with 20 mg bupivacaine hydrochloride plus 4mg dexamethasone
89410296|NCT04046731|Experimental|Study Group|Study team is developing a new diagnostic skin testing procedure for patients who receive NMBAs during surgery in order to determine Negative Predictive Values and Non-Irritant Concentrations.
89410297|NCT02295254||Research group|The study contain only one group: travelers who intended to travel to tropical destinations. The participants will give a feces sample before and after the travel.
89410298|NCT04953312|Experimental|COVID-19 patients (group 1)|Patients with a recent diagnosis (<7 days since first symptoms) of moderate or severe COVID-19
88922026|NCT05965414|Active Comparator|CS6253 Solution for Injection|"SAD: Single ascending doses: CS6253 Solution for Injection dosing, 50 mg/mL, will be weight based and provided from single use 2 mL vials containing approximately 100 mg CS6253 in phosphate buffered saline (PBS) solution~MAD: Multiple ascending doses (4x every 72 hours): CS6253 Solution for Injection dosing, 50 mg/mL, will be weight based and provided from single use 2 mL vials containing approximately 100 mg CS6253 in phosphate buffered saline (PBS) solution"
89410299|NCT04953312|Experimental|Chronic myeloid malignancies (group 2)|Adults with chronic myeloid malignancies including myelodysplastic syndromes with low risk MDS ; high risk MDS according to IPSS-R or with dysplastic or proliferative chronic myelomonocytic leukemia according to WHO2016
89410300|NCT04953312|Other|Control group (group 3)|Age-matched healthy donors
89410301|NCT02299154|Experimental|Patient with memory disorders|psychological questionnaires
89410302|NCT02299154|Experimental|Accompanier|psychological questionnaires
88922027|NCT05965414|Placebo Comparator|Placebo|SAD and MAD: Placebo control will be provided from vials containing physiological saline for injection in an equal amount as necessary for the active arm.
89005102|NCT04721847|Experimental|Pain Neuroscience Education|Pain Neuroscience Education (PNE) sessions. Additionally, treated with Transcutaneous Electrical Nerve Stimulation (TENS), Stretching and Strengthening exercises similar as in control group
89410303|NCT05686525|Experimental|TUMT|In this arm, patients will undergo Transurethral Microwave Thermotherapy (TUMT) where microwave energy is used to destroy the prostate tissue. TUMT is performed under local anaesthesia. Usually, the patient can be discharged from the hospital on the same day. If the patient cannot be discharged on the same day, he will be admitted to the urological ward. After the treatment, a transurethral catheter is inserted. This will be removed at the physician's discretion when spontaneous voiding is achieved with an acceptable residual volume (in general <100-150 ml), typically within four weeks.
89410304|NCT05686525|Experimental|PAE|In this arm, patients will undergo prostate artery embolisation (PAE) where blocking the blood flow to the prostate causes it to shrink. PAE is performed under local anaesthesia. Usually, the patient can be discharged from the hospital on the same day. If the patient cannot be discharged on the same day, he will be admitted to the urological ward. Patients with a permanent catheter prior to PAE will keep the catheter up to four weeks after the procedure.
89410305|NCT03520166|Placebo Comparator|Group-A|No treatment
89410306|NCT03520166|Experimental|Group-B|Medium frequency electrotherapy (interferential currents)
89410307|NCT03240835||CCRT±NACT|Patients treated with neoadjuvant chemotherapy(NC) (cisplatin and docetaxel) and CCRT (cisplatin) , or treated with CCRT only
89410308|NCT03545880|Experimental|Kinesiotaping|A Kinesiotaping will be provided over the upper trapezius muscle after the application of dry needling
89410309|NCT03545880|Placebo Comparator|Placebo|Individuals will not perform any action after the application of trigger point dry needling
89410310|NCT03517358|Active Comparator|Pharmacy|service of care: pharmacy
89410311|NCT03517358|Active Comparator|Case management|service of care: case management
89410312|NCT04067310|Experimental|Group Experimental|Participants who will use the spray skin protector
89410313|NCT04067310|Active Comparator|Group control|Participants who will use moisturizer Dnativ Revita Derm.
89410314|NCT03514238|Experimental|Adults (BMI: ≥30 kg/m2)|"Obese individuals will participate to three conditions:~Control Sitting Condition (C), Sitting for 35 minutes Acute Bout of Continuous Moderate Aerobic Exercise (MOD) 50-55% of heart rate reserve Acute Bout of High Intensity Interval Aerobic Exercise (HIIT) 85-90% heart rate reserve"
89410315|NCT03514238|Experimental|Adults (BMI: 18.5-24.9 kg/m2)|"Normal weight individuals will participate to three conditions:~Control Sitting Condition (C), Sitting for 35 minutes Acute Bout of Continuous Moderate Aerobic Exercise (MOD) 50-55% of heart rate reserve Acute Bout of High Intensity Interval Aerobic Exercise (HIIT) 85-90% heart rate reserve"
89410316|NCT03133052|Active Comparator|training group|Intervention: Internet-based adaptive cognitive control training program. 5 x 30 minutes per week, for 12 weeks.
88886377|NCT01415479|Experimental|Quantitative + Default|"Subjects view:~Computer-based presentation regarding colorectal cancer (CRC) and screening for CRC with colonoscopy, sigmoidoscopy, or stool testing. Includes a video from the American Cancer Society.~Computer-based presentation providing quantitative information regarding (a) the lifetime average probability of getting CRC or dying from it, (b) the reduction in mortality provided by undergoing regular screening with colonoscopy, and (c) the reduction in mortality provided by undergoing regular screening with fecal immunochemical testing (FIT)~Computer-based presentation that encourages subjects who are unwilling to undergo colonoscopy or are unsure about whether to undergo screening to get tested with Fecal Immunochemical Testing (FIT)."
88886378|NCT01415479|Active Comparator|Control|Subjects view a computer-based presentation regarding colorectal cancer (CRC) and available screening tests for CRC, primarily a video produced by the American Cancer Society.
89410317|NCT03133052|Placebo Comparator|control group|Intervention: placebo program: a fixed, primary difficulty level task. 5 x 30 minutes per week, for 12 weeks.
89410318|NCT05671783||Post-induction hypotension|Post-induction hypotension (pIOH) is a decrease during the first 20 min after anesthesia induction
88886379|NCT01415492|No Intervention|Usual Care|At recruitment this group only received five pamphlets from the study. Four of these pamphlets were from the American Cancer Society, and one from Quitworks (a smoking cessation program).
88886380|NCT01415492|Active Comparator|HD2|The intervention study information was delivered via print materials or access to a HD2 Web Site. Patients chose modality. ADDITIONAL NOTE: A sub-set of these participants was randomly selected to receive the Electronic Reminders through the intervention.
89005103|NCT04721847|Active Comparator|Conventional Physical therapy|Control group will be treated by TENS, stretching and strengthening exercises.
89410319|NCT05671783||Maintenance intraoperative hypotension|maintenance intraoperative hypotension (mIOH) when there is a decrease of blood pressure 20th min after induction, with or without pIOH
89410320|NCT05671783||Normotensive patients|Patients with normotension during surgery.
89410321|NCT03133130|Experimental|BMT101|cp-lasiRNA
89410322|NCT03133130|Placebo Comparator|Placebo|Normal Saline
89410323|NCT04172454|Experimental|AK104|AK104 in subjects with advanced melanoma and other selected advanced solid tumor including PD-1/PD-L1 relapsed/refractory tumors)
89410324|NCT03514160|Active Comparator|Group exercise|Group exercise training at a community site. Exercises included supervised upper and lower-body strength and balance exercises twice per week. Hand-made, weighted bars were used for resistance props and balance. The exercises included: chair squats; standing single leg hip abduction; hip extension; balance heal-to-toe walking; seated hip adduction and knee extension; wall push-ups; bent-over rows; shoulder press; elbow flexion and extension).
89410325|NCT03514160|No Intervention|Attention-Control group|Attendance to community site usual activities offered to older adults. Participants in this group were offered the exercise routine after completing the 12-week study.
89410326|NCT03545802|Experimental|Training|6 weeks of home-based high intensity interval training
89410327|NCT03132974|Experimental|SGHH|Admission to Sogyeonghwalhyeol-tang granule
89005104|NCT00204542|Active Comparator|A|Solaraze(R) 2x/day for 3 months
89410328|NCT03132974|Experimental|SGHH with manipulation therapy|Admission to Sogyeonghwalhyeol-tang granule and manipulation therapy
89410329|NCT03132974|Placebo Comparator|Placebo with manipulation therapy|
89410330|NCT03517280||Children with Neuroblastoma|Children undergoing treatment for Neuroblastoma at ITACI in Sao Paolo in Brazil who are under the age of 18 years.
89005105|NCT00204542|Active Comparator|B|Solaraze(R) 2x/day for 6 months
89410331|NCT02295332|Experimental|Cohort A|
89410332|NCT02295332|Experimental|Cohort B|
89410333|NCT04118868|Experimental|All participants|Pembrolizumab administered intralymphatically using the Sofusa® DoseConnect™device
89410334|NCT03514082||Adolescent Idiopathic Scoliosis|Subjects with AIS who are beginning to the conservative treatment.
89410335|NCT03990558||Primary ICH|Subject with acute brain injury will have data collected, including EEG, behavioral, clinical, and outcome measures.
89005106|NCT02962856|Experimental|BAY987517|All subjects are patched with the same product.
89410336|NCT03514004|Experimental|Intervention|"The ICT-based intervention is known as Project Clan. Each participant randomized to the intervention group will have access to the web platform and mobile applications of Project Clan - a virtual community that seeks to promote adolescent mental health and wellbeing as students interact, express themselves, and resolve concerns, with the support of peers and mental health professionals. During the three-month intervention, participants will have complete anonymity, unless trained psychologists supervising the platform as community counselors identify behaviors associated with suicide risk and proceed to follow an established emergency protocol. The counselors will be available to answer community questions and provide support on an individual basis."
89410337|NCT03514004|No Intervention|Control|Participants in the control group will also be assigned a username and password to access the website, but they will be met with a user interface that only displays a space to answer the corresponding assessments. In addition to the introductory presentation, they will be given a brochure with information regarding adolescent suicide and wellbeing and tips with regard to seeking help and assisting others. This will include the contact information for a telephone hotline, to ensure they can receive professional help if needed.
89005107|NCT02962518|Active Comparator|A Standard Treatment|"Patients undergo surgery using the fillet technique and intra-lesional injections of triamcinolone 10mg /ml every 4 to 6 weeks for 6 months."
89410338|NCT03545178||Diabetic patients using CGM/FGM|Evaluation of glucose control and application of hypoglycemia prediction models in diabetic patients wearing CGM and/or FGM devices for at least 50% of the time during the last 4 weeks prior to the medical consultation.
88886381|NCT01415492|Active Comparator|HD2+|The intervention study information was delivered via print materials or access to a HD2 Web Site. Patients chose modality. In addition participants received two coaching calls from Health Coaches. ADDITIONAL NOTE: A sub-set of these participants was randomly selected to receive the Electronic Reminders through the intervention.
88886382|NCT01415505|Other|1|Nebivolol and Valsartan free tablet combination
88886383|NCT01415544||Type 2 Diabetes|Those previously diagnosed with type 2 diabetes
88886384|NCT01415544||Type 1 Diabetes|Those previously diagnosed with type 1 diabetes
89410339|NCT03520088|Experimental|Inferior mesenteric Vein dissection|To improve and preserve the rectal nerve in the total mesorectal excision, its starts the dissection from the inferior mesenteric vein to the inferior mesenteric artery and through the pelvis
89410340|NCT03520088|Active Comparator|Inferior mesenteric Artery dissection|As standard, the dissection starts straight in the inferior mesenteric artery and through the pelvis
89410341|NCT03546504|Experimental|dental procedures modification and OT|Modifying dental environment and procedures to reduce sensory stimulation. Occupational therapy provides desensitization techniques around the dental visit and home oral hygiene and habit training for oral hygiene activities.
89410342|NCT03513926||Non-OSA group|Patients with out sleep apnea.
89410343|NCT03513926||OSA group|Patients with OSA, without cardiovascular comorbidities who could be treated with Continuous Positive Airway Pressure
89410344|NCT03513926||OSA with hypertension group|Patients with OSA, with hypertension who could be treated with Continuous Positive Airway Pressure
89410345|NCT03513926||OSA with CVE group|Patients with OSA, with a previous ictus or stroke who could be treated with Continuous Positive Airway Pressure
89410346|NCT04900350|Experimental|AK117+ azacitidine|"Phase 1: Subjects will receive escalating doses of A117 in combination with azacitidine 75 mg/m2 subcutaneous daily for 7 days of a 28 day cycle;~Phase 2: Subjects will receive AK117 at the recommended Phase 2 dose in combination with azacitidine 75 mg/m2 subcutaneous daily for 7 days of a 28-day cycle."
89410347|NCT03982550|No Intervention|Control Period|Participants will serve as their own controls. All 12-week control periods will take place before the RT intervention to ensure that results are not confounded by detraining effects or long-term cognitive benefits of RT. In addition, a control period equal in duration to the intervention allows direct within-subjects statistical comparisons, accounting for each participants' baseline and rate of aging - i.e. age-associated cognitive decline and arterial stiffening. Participants will not be monitored, but may be contacted for scheduling.
89410348|NCT03982550|Experimental|Intervention Period|Participants will perform a periodized and progressive total-body RT program emphasizing development of lower and upper body strength. All 36 training sessions (3 days per week for 12 weeks) will be performed at the CERC, supervised by an exercise specialist. Participants will be encouraged to continue normal activities of daily living and eating routines outside the RT program of the present study. Because this is a proof-of concept study on normal aging, participants may be contacted for scheduling, but will not be monitored outside of training.
89410349|NCT02292290|Active Comparator|Monotherapy 2|addition of Sulfonylurea or Pioglitazone to Metformin
89410350|NCT02292290|Experimental|Dual Therapy 1|Swap Liraglutide for sulfonylurea or pioglitazone taken as second line therapy (Metformin) first line)
89410351|NCT02292290|Active Comparator|Dual therapy 2|Maintain sulfonylurea or pioglitazone as second line therapy (Metformin first line)
89410352|NCT02292290|Experimental|Monotherapy|Addition of Liraglutide to Metformin
89410353|NCT02114034||Non-severe asthma|"Children Controlled without treatment or with low doses of inhaled corticosteroids (<500 mg / day beclometasone equivalent) asthma~and Children with normal EFR~and Children who did not have more severe exacerbation (assessed taking oral corticosteroids) in the previous year~and Children not admitted in the previous year for asthma"
89410354|NCT02114034||Severe asthma|"Asthmatic child who, despite treatment with a combination of inhaled corticosteroids (at least 800 mcg / day equivalent Beclomethasone) bronchodilators and long-acting or properly taken daily leukotriene (inhaler technique and compliance verified) presents one of the 3 criteria following:~Persistence of symptoms or chronic use of bronchodilators short duration of action at least three times a week for at least 3 months~exacerbations in the previous year:~at least one care unit admission or continued resuscitation~at least two hospitalizations for acute severe asthma requiring IV therapy~at least 2 courses of oral corticosteroids for exacerbations~post BD FEV <80% or UARS post BD> 150% predicted"
89410355|NCT02295410||Engaged in Home-Based CPT|Home-Based Telemental Health-Patients undergoing Home-Based CPT for PTSD
89410356|NCT02295410||Comparison|Treatment as Usual (TAU) Patients NOT receiving regular CPT or other evidence-based therapy for PTSD.
89531069|NCT03342677|Other|Single Arm|In this project, there is only one study group which comprises of patients with Hepatocellular Carcinoma (HCC) who will undergo Liver MRI with Primovist before hepatic transplantation.
88886385|NCT01415544||Gestational Diabetes|Those that are currently diagnosed with gestational diabetes
88886386|NCT01415544||Healthy Human Volunteers|Those that have not been diagnosed with any type of diabetes
88886387|NCT01415557|Placebo Comparator|Non-Fortified Control Product|Non-fortified control beverage
88886388|NCT01415557|Active Comparator|Micronutrient Fortified Test Product|Micronutrient fortified test beverage
88886389|NCT01415570||Chronic Hemodialysis Patients|Adult hemodialysis patients
88886390|NCT01415570||Chronic hemodialysis patients|Adult hemodialysis patients
88886391|NCT01415596|Placebo Comparator|Placebo|
89410357|NCT03943849|Experimental|Particulate bone graft plus autogenous dental pulp tissue|Dental pulp will be isolated from teeth extracted for non-periodontal reasons chairside. The isolated dental pulp will be mixed with hydrated particulate bone graft, and the mixture will be placed in the debrided extraction socket. The socket will be covered by a resorbable collagen membrane and sutured.
88813732|NCT02464410|Active Comparator|Enhanced Usual Care|In addition to covering the VHA's long-term OA informed consent process, the enhanced usual care (EUC) condition provides educational content related to the biology of pain response and an overview of pain conditions. The overall style is didactic. This EUC condition will include some information related to risks of opioid use as part of the informed consent and will consequently have sufficient face validity as an intervention on opioid safety to effectively blind participant to randomization. However, the EUC therapist will not use the motivational enhancement approach of discussing strategies for avoiding these risks. It is designed to be equal in length to the motivational intervention.
89410358|NCT03943849|Active Comparator|Particulate bone graft|Hydrated particulate bone graft will be placed in the debrided extraction socket. The socket will be covered by a resorbable collagen membrane and sutured.
89410359|NCT03545724|Experimental|Neofitoroid®|Treatment is made by the application of Neofitoroid® 2 times a day for 10 days.
89410360|NCT02299232|Active Comparator|dexmedetomidine 3mcg/kg|dexmedetomidine 3 mcg/kg intranasal 50 minutes before MRI
89410361|NCT02299232|Active Comparator|dexmedetomidine 4mcg/kg|dexmedetomidine 4 mcg/kg intranasal 50 minutes before MRI
88813733|NCT03006419|Active Comparator|Group A (Basiliximab group)|Basiliximab (Simulect) induction therapy: 20 mg IV at day of transplant (to be administered 2 hours prior to transplant and up to 4 hours after transplant) and second dosage (20 mg) at fourth day after kidney transplantation.
88813734|NCT03006419|Experimental|B (Low-dose Thymoglobulin group)|Thymoglobulin induction therapy (1 mg/kg rounded by 25 mg increments) at day of transplant followed by same dosage (1 mg/kg rounded by 25 mg increments) during day 1 and day 2 after transplant in order to complete 3 mg/kg accumulated dose.
88813735|NCT03000881|Experimental|Cohort 6|This is a sub-study testing the effect of real output applied under two adhesive strips after 8 hours.
88813736|NCT01047332|Active Comparator|Uncovered Wallstent|Endoscopically-placed biliary self-expanding metal stent (SEMS) (uncovered type).
88813737|NCT01047332|Experimental|Partially Covered Wallstent|Endoscopically-placed biliary self-expanding metal stent (SEMS) (partially covered type).
88813738|NCT03006497|No Intervention|Control|The control group will not participate in any exercise program. However, at the end, home based exercises and special advice will be given to the participants.
88813739|NCT03006497|Experimental|Intervention|The intervention group will participate in an exercise program based on motor learning principles for 4 weeks/3 sessions per week, for a total of 12 sessions of 30-45 minutes each.
88813740|NCT03405272|Experimental|recombinant anti-EGFR monoclonal antibody（SCT200）|Initially, 6.0mg/kg of SCT200 will be administered once a week for a maximum of 6 cycles. After 6 cycles, 8.0mg/kg of SCT200 will be administered every two weeks until disease progression.
88813741|NCT03006263|Experimental|Totally Laparoscopic Total Gastrectomy|Totally Laparoscopic Total Gastrectomy will be performed for the treatment of patients assigned to this group.
88813742|NCT03006263|Experimental|Laparoscopy Assisted Total Gastrectomy|Laparoscopy Assisted Total Gastrectomy will be performed for the treatment of patients assigned to this group.
88813743|NCT03000647|Active Comparator|Guided Pelvic floor exercises|Pelvic floor exercises guided by a physiotherapist
88813744|NCT03000647|Active Comparator|Non-guided pelvic floor exercises|Pelvic floor exercises not guided
88813745|NCT03405194|Experimental|Elvitegravir-Cobicistat-TAF-FTC|Elvitegravir 150mg po QD Cobicistat 150 mg po QD TAF 10 mg po QD FTC 200 mg QD
88813746|NCT03405194|Active Comparator|EFV-TDF-3TC|EFV 600 mg po QD TDF 300 mg po QD 3TC 300 mg po QD
88813747|NCT03006107|Experimental|intraligamentary injection of piroxicam|"intraligamentary injection Piroxicam is another NSAID that which has the ability for the treatment of pain, fever and inflammation in the body , has a half-life of 50h in the plasma , oral piroxicam reaches a peak concentration in the plasma within 2 to 4 hours .~The needle will be placed in the gingival sulcus at a 30- degree angle to the long axis of the tooth then apical pressure is applied until the needle wedged into the periodontal ligament between the tooth and the alveolar crest of the bone"
88813748|NCT03006107|Active Comparator|Intraligamentary mepevacaine|mepevacaine is an anesthetic (numbing medicine) that blocks the nerve impulses that send pain signals to brain . It is also used as an anesthetic for dental procedures.
88813749|NCT01046396|Active Comparator|Differin® Cream 0.1%|Adapalene Cream 0.1% - apply once daily on one side of the face for 3 weeks
88813750|NCT01046396|Active Comparator|Differin® Lotion 0.1%|Adapalene Lotion 0.1% - apply once daily on the opposite side of the face for 3 weeks
88813751|NCT01586039|Active Comparator|Compact Fluorescent Light 90 lux|90 lux exposure of a commercially available Compact Fluorescent Light (CFL).
88813752|NCT01586039|Experimental|Blue-depleted LED light 90 lux|90 lux exposure of a novel LED white light source that is depleted in the short-wavelength visible range (Biological Illumination LCC, FL).
88813753|NCT01586039|Active Comparator|Compact Fluorescent Light 50 lux|50 lux exposure of a commercially available Compact Fluorescent Light (CFL).
88813754|NCT01586039|Experimental|Blue-depleted LED light 50 lux|50 lux exposure of a novel LED white light source that is depleted in the short-wavelength visible range (Biological Illumination LCC, FL).
88813755|NCT01046084|Experimental|Investigational Test Product|Lansoprazole 30 mg Delayed-Release Capsule
88813756|NCT01046084|Active Comparator|Reference Listed Drug|Prevacid® 30 mg Delayed-Release Capsule
88813757|NCT01586741|Active Comparator|Polypropylene mesh|Reconstruction of the abdominal wall diastasis with insertion of a polypropylene mesh on 30 patients.
88813758|NCT01586741|Active Comparator|quill suture|Reconstruction of the abdominal wall diastasis with double row absorbable suture ( Quill Self-retaining system) on 30 patients.
88813759|NCT01586741|No Intervention|conservative treatment|Regular abdominal exercises workout for three months for 30 patients.
88813760|NCT01045694|Experimental|Botulinum Toxin Type A|Arm investigates the efficacy of Botulinum Toxin A injection for the treatment of basal thumb joint arthritis
88813761|NCT01045694|Active Comparator|Steroid - Triamcinolone Acetonide|Arm uses the standard of care - Steroid injection - as an active comparator to the experimental injection of Botulinum Toxin A for the treatment of basal thumb joint arthritis
88813762|NCT01045694|Placebo Comparator|Lidocaine|Arm uses plain lidocaine injection to serve as a baseline for evaluating the efficacy of Botulinum toxin as compared to steroid injection for the treatment of basal thumb joint arthritis.
88813763|NCT01586897|Experimental|Use of Medication Metronome|Providers allocated to intervention will automatically see an additional feature when logging on to their electronic health record medication prescription interface that enables them to schedule future laboratory testing for the pre-defined subset of study-specific medications. New prescription or dose adjustment by the PCP of one of these pre-specified medications used to treat type 2 diabetes, hypertension, or hyperlipidemia will initiate the follow-up result monitoring, patient outreach, and PCP reminders that constitute the Medication Metronome system.
88813764|NCT01586897|Active Comparator|Usual Care|PCPs allocated to the control arm will continue with usual care practices for laboratory monitoring.
88813765|NCT04378712|Experimental|Intervention Group|H2-O2 (66% hydrogen; 33% oxygen) inhalation. Patients in treatment group inhaled H2-O2 (66% hydrogen; 33% oxygen) at 3 L/min via nasal cannula by using the Hydrogen/Oxygen Generator (model AMS-H-03, Shanghai Asclepius Meditech Co., Ltd., China) until discharge.
88813766|NCT04378712|Other|Control Group|Usual care referred to the standard-of-care (including oxygen therapy) recommended by Chinese National Health Commission.
88813767|NCT04378556|Other|Nutrition|All participants received diet coaching, nutrition education and a per-meal protein prescription.
88813768|NCT01586975|Active Comparator|Clopidogrel 75 mg|Clopidogrel 75 mg daily
88813769|NCT01586975|Active Comparator|Aspirin 81 mg|open-label Aspirin 81 mg daily
88813770|NCT01586975|Active Comparator|Aspirin > 300mg|open-label Aspirin over 300 mg daily
88813771|NCT01724840|Experimental|GraftJacket|GraftJAcket is used as interpositional material
88813772|NCT01724840|Active Comparator|Tendon Interposition|Flexor carpi radialis tendon is used as interpositional material
88813773|NCT03000413|Experimental|Ketamine|Intravenous ketamine infusion: bolus 2mg per kg and continuous infusion (2mg/kg/h)
88813774|NCT03000413|Active Comparator|Fentanyl|Fentanyl: bolus infusion 1μg per kg and continuous infusion (1μg/kg/h)
88813775|NCT01724918|Other|100 mg IV|100 mg IV lacosamide infused over 30 minutes
88813776|NCT01724918|Other|200 mg IV|200 mg IV lacosamide infused over 30 minutes
88813777|NCT01724918|Other|400 mg IV|400 mg IV lacosamide infused over 30 minutes
88813778|NCT03000725|Active Comparator|UPLIFT|Project UPLIFT (Using Practice and Learning to Increase Favorable Thoughts) is a home-based intervention that teaches cognitive and mindfulness skills to people with epilepsy by phone to reduce their depression and improve quality of life (QOL).
88813779|NCT03000725|Active Comparator|USUAL CARE|Participants randomized to the UC group will receive printed educational materials on management of epilepsy in English or Spanish as preferred.
88813780|NCT01588457|Active Comparator|Lithium|This open methods advancement study will randomize BD patients with clinically significant symptoms to treatment with one of two mood stabilizers, lithium [Li] at baseline. Lithium is one of these two mood stabilizers. The person may or may not stay solely on lithium throughout the study.
88813781|NCT01588457|Active Comparator|Divalproex|This open methods advancement study will randomize BD patients with clinically significant symptoms to treatment with one of two mood stabilizers, divalproex (DV)at baseline. Divalproex is one of these two mood stabilizers. The person may or may not stay solely on divalproex throughout the study.
88813782|NCT01588457|Active Comparator|Lithium plus Quetiapine|Those who develop protocol defined depression will then be randomized to a mood stabilizer (lithium) + quetiapine [QT].
88813783|NCT01588457|Active Comparator|Lithium plus Lamotrigine|Those who develop protocol defined depression will then be randomized to a mood stabilizer (lithium) + lamotrigine (LM).
88813784|NCT01588457|Active Comparator|Divalproex plus Quetiapine|Those who develop protocol defined depression will then be randomized to a mood stabilizer (divalproex) + quetiapine [QT].
88813785|NCT01588457|Active Comparator|Divalproex plus Lamotrigine|Those who develop protocol defined depression will then be randomized to a mood stabilizer (divalproex) + lamotrigine (LM).
88813786|NCT01589315|Experimental|FEAST|Active right unilateral focal ECT
88813787|NCT04377776||Transplanted patients|Transplanted Kidney, Pancreas or Pancreatic Islet patients at MedicineTransplant Unit - San Raffaele Scientific Istitute
88813788|NCT03006029|Experimental|TAB08( Theralizumab)|TAB08 will be administered i.v. over 1 hour weekly for 3 weeks followed by 3 weeks of no treatment; with 6 weeks interval between start of each treatment cycle.
88813789|NCT04377854||MCS recipients|All recipients of durable MCS will be followed up on a yearly basis with collection of blood sample and clinical data for 25 years.
88813790|NCT04377854||Recipient of cardiac transplant|All recipients of cardiac transplantation(s) will be followed up on a yearly basis with collection of clinical data for 25 years.
88813791|NCT04377854||Watchful waiting at Rigshospitalet|Patients referred for evaluation for treatment with advanced treatment (LVAD/HTX) but -for whatever reason- these pts will be on watchful waiting at the Rigshospitalet.
88813792|NCT03000335||Relapse|B-ALL patients who have succumbed to relapse
88813793|NCT03000335||Remission|B-ALL patients who are in remission
89410362|NCT03517124|Experimental|Zirconia restorations|Dental restorations in surface modified zirconia bonded to tooth substance by dual cure resin cement
89410363|NCT03517124|Active Comparator|e.max|Restorations in e.max bonded to tooth substance by dual cure resin cement
89410364|NCT02060760||UTROPIA study cohort|At least two cTnI data points available (including baseline) with blood samples available for hs-cTnI testing. No intervention.
89410365|NCT03517046|Experimental|CartiLife (low-dose group)|Total defect volume in low-dose group is less than 2 ㎤. Low- and high-dose group are sequentially processed.
89410366|NCT03517046|Experimental|CartiLife (high-dose group)|Total defect volume in High-dose group is 2 ~ 4 ㎤.
89410367|NCT02963493|Experimental|melphalan flufenamide (melflufen) + dexamethasone|Melphalan flufenamide (melflufen) 40 mg Day 1 and dexamethasone 40 mg (20 mg for patients 75 years or older) on Days 1, 8, 15 and 22 of each 28-day cycle.
89410368|NCT02299310|Experimental|Valsartan|Valsartan 80mg/tablet, 1 tablet once daily (crossover)
88813794|NCT04377698|Active Comparator|Platelet Rich Fibrin group(PRF)|Following apicoectomy PRF gel was prepared and placed in the osseous defect followed by placement of PRF membrane
88813795|NCT04377698|Active Comparator|Freezed Dried Bone Allograft group(FDBA)|Following apicoectomy FDBA graft were prepared and placed in the osseous defect followed by placement of PRF membrane
89410369|NCT02299310|Active Comparator|Perindopril|Perindopril 4mg/tablet, 1 tablet once daily (crossover)
89410370|NCT05657899|Active Comparator|Cerclage|Intervention by cerclage fixation.
89410371|NCT05657899|Active Comparator|Tension Band Wiring|Intervention by tension band wiring
89410372|NCT03644199|Other|OGTT test|Comparison of responses to a OGTT between CF subjects and health control subjects
89410373|NCT03644199|Other|Mixed meal|Comparison of responses to a mixed meal through the day between CF subjects and health control subjects
89410374|NCT02292524|No Intervention|Arm I: Control|Men in this group consumed a tomato free diet for the duration of the study (less than or equal to 5 mg lycopene/day) and, thus, did not consume a tomato intervention product.
89410375|NCT02292524|Experimental|Arm II: Juice|Commercially-available tomato food product: men in this group consumed V8® juice (11-16.5 fl. oz./day).
89410376|NCT02292524|Experimental|Arm III: Soup|Commercially-available tomato food product: men in this group consumed Campbell's® Tomato Soup (2-2 ¾ cups/day).
89410377|NCT02292524|Experimental|Arm IV: Sauce|Commercially-available tomato food product: men in this group consumed Prego® spaghetti sauce (5-7 oz./day).
89410378|NCT04051489||Mobile App|Individuals with symptomatic knee osteoarthritis
89410379|NCT03513692|Active Comparator|Fill-Up composite resin|"In this arm of the study, participants will have the dental restoration completed with FillUp from Coltene, a composite resin a CE marked and licensed restorative material."
89410380|NCT03513692|Active Comparator|Conventional; composite|In this arm of the study, participants will have the dental restoration completed with a conventional composite resin using a CE marked and licensed restorative material.
89410381|NCT03513536|Experimental|Intervention 1|The women in this arm will receive the Citrus-Based Aromatherapy product to apply regularly for 6 days.
89410382|NCT03513536|Experimental|Intervention 2|The women in this arm will receive the Mint-Based Aromatherapy product to apply regularly for 6 days.
89410383|NCT03513536|Experimental|Intervention 3|The women in this arm will receive the Spice-Scented Aromatherapy product to apply regularly for 6 days.
89410384|NCT03513536|Placebo Comparator|Control|The women in this arm will receive a vegetable oil roll-on product to apply regularly for 6 days.
89410385|NCT03641391|Experimental|Direct electrical stimulation|Intraoperative direct cortical electrical stimulation or intraoperative direct subcortical electrical stimulation on language or language-associate areas, and the participants' after-discharge activity would be monitored. The participants would be undergone awake anesthesia and asked to perform language tasks during the stimulation.
89410386|NCT03641235||exacerbating COPD patients needing ICU admission|sputum collection
88813796|NCT03005873|Experimental|TLC599 LD group|12 mg DSP with 100 µmol PL (1.0 mL)
88813797|NCT03005873|Experimental|TLC599 HD group|18 mg DSP with 150 µmol PL (1.5 mL)
88813798|NCT03005873|Placebo Comparator|Placebo group|1.5 mL normal saline
88813799|NCT03005639|Experimental|Vemurafenib/Cobimetinib|Vemurafenib and cobimetinib as a combination has been approved by the United States Food and Drug Administration (FDA) for patients with more advanced melanoma. In this trial, vemurafenib and cobimetinib combination is considered to be experimental since safety of this combination prior to lymph node surgery has not been studied.
88813800|NCT03005795|Experimental|Music and colposcopy|Women will hear Mozarts symphony Nr. 40 during the colposcopic examination
88813801|NCT03005795|Active Comparator|Colposcopy without music|During the colposcopic examination women will not hear music
88813802|NCT01044290|Experimental|Outlook Intervention|"Subjects in the first group (Life Completion) completed a psychosocial intervention which consisted of meeting with the facilitator three times for 45-60 minutes each. In the first session, subjects were asked to discuss issues related to life review. In session two, participants spoke about issues of regret and forgiveness. In the final session, subjects focused on heritage and legacy."
88813803|NCT01044290|Active Comparator|Attention Control|"The subjects in the second group (attention control) met with a facilitator three times for 45 minutes and listened to a non-guided relaxation CD."
88813804|NCT01044290|No Intervention|Treatment as Usual|"Subjects in the third group (treatment as usual) were exposed to no intervention or attention control during the intervention window."
88813805|NCT01590875|Experimental|Adenosine arm|25 patients will be randomized to received 2 doses of adenosine 12 mg IV, 5 minutes apart after pulmonary vein isolation. During this time, will monitor for pulmonary vein reconnection, second dose of adenosine will be given only if no reconnection after initial dose.
88813806|NCT01590875|No Intervention|Observation arm|25 patients will be randomized to 10 minute period of observation for pulmonary vein reconnection after documentation of pulmonary vein isolation. This will serve as the control arm.
88813807|NCT03404414|Experimental|18F-FDG PET/MRI and 18F-FDG PET/CT|The patients were injected with 370 MBq of 18F-FDG in one dose intravenously and underwent PET/MRI or PET/CT scan 1 hour later
88813808|NCT01591655|Experimental|Mapracorat|Mapracorat ophthalmic suspension, 3%,
89410387|NCT02988661|Active Comparator|Chronic Disease Self-management Program (CDSMP)|A random sample of African American women with SLE selected from the Georgians Organized Against Lupus (GOAL) parent cohort will be used to recruit participants into the CDSMP. This group will be identified as the WELL Cohort.
89410388|NCT02988661|No Intervention|Usual Care|African American women consented into the parent Georgians Organized Against Lupus (GOAL) cohort who have not been selected to be enrolled in the intervention will comprise the usual care group. This group will continue their longitudinal assessments as part or the GOAL cohort data collection efforts.
89410389|NCT02292602|Experimental|Family-Based Weight Control Intervention|Families will receive the FBWC
88886392|NCT01415596|Active Comparator|Salbutamol|
89410390|NCT02292602|No Intervention|Control|Families will continue with standard of care at WIC
89410391|NCT05262933||coffee (n= 70)|Patients are planned to drink brewed coffee 2 hours before surgery.
88886393|NCT01415622|Experimental|PlasmaDerm|Treatment of small to medium-sized Ulcera crurum with the PlasmaDerm VU-2010 device in addition to standard care.
89410392|NCT05262933||control (n=70)|Patients are planned to drink water 2 hours before surgery.
89410393|NCT03641157||Group I Easy Intubation|Pediatric patients ages 0-3 years Easy Intubation (Cormach-Lehane score I-II)
89410394|NCT03641157||Group II Difficult intubation|Pediatric patients ages 0-3 years Difficult intubation (Cormach-Lehane score III-IV)
89410395|NCT02295488|Experimental|Desensitization|Blood intake for biological sampling during validated desensitization protocol (Alyostall®)
89410396|NCT02295566|Active Comparator|Nitric Oxide Group|Inhaled Nitric Oxide delivered via nasal canulae at 10ppm for 8 hours a night for 7 nights.
89410397|NCT02295566|Placebo Comparator|Control Group|Air/oxygen mix (according to clinical need) delivered via nasal canulae for 8 hours a night for 7 nights.
88886394|NCT01415622|Other|standard care|standard care of Ulcera crurum
88886395|NCT01415635|Experimental|Nutritional intervention|"The study will compare standard nutritional care (control group) with tailored nutritional care (the possibility to order small energy and protein-enriched dishes called Delights of Herlev Hospital)(intervention group)."
88886396|NCT01415661|Experimental|obese patient|
88886397|NCT01415661|Experimental|non obese patient|
88886398|NCT01415687|Active Comparator|PEG Arm|Patients randomized to this arm of the trial will be following preparation instructions using Polyethylene Glycol-Based Lavage in a split dose format
88886399|NCT01415687|Active Comparator|Pico-Salax + Bisacodyl Arm|Patients randomized to this arm will follow preparation instructions using Pico-Salax preparation plus Biscacodyl in a split dose format
88886400|NCT01415700|Experimental|Stimulator|
88886401|NCT01415700|Active Comparator|Orthosis|
88886402|NCT01415713|Experimental|Statin dose titration|"SLOG regimen:~S-1 20-40 mg/m2/b.i.d., day 1-7;Leucovorin 20 mg/m2/b.i.d., day 1-7;Oxaliplatin 85 mg/m2 in 250 mL of D5W,given as 2-hour intra-venous infusion, day 1;Gemcitabine 800 mg/m2 in 250 mL of normal saline, given as fixed dose-rate infusion,day 1;After the administration of gemcitabine, the infusion line should be flushed with 20 ml of normal saline and then 50 ml of 5% glucose solution before the administration of oxaliplatin; Every 14 days, as one cycle.Prophylactic G-CSF or GM-CSF will not be allowed in this study. In case of grade 4 or complication neutropenia, patients may receive G-CSF according to the regulation of National Insurance Bureru treated with appropriate antibiotics. Therapeutic G-CSF may be used at the discretion of attending physicians."
89410398|NCT05283681|Experimental|Risankizumab Dose A|Participants will receive 1 Subcutaneous (SC) injection of risankizumab Dose A administered via Prefilled Syringe (PFS) at Day 1 and followed for 140 days
89410399|NCT05283681|Experimental|Risankizumab Dose B|Participants will receive SC injections of risankizumab Dose B administered via PFS at Day 1 and followed for 140 days
89410400|NCT05283681|Experimental|Risankizumab Dose C|Participants will receive 1 SC injection of risankizumab Dose C administered via Auto-Injector (AI) at Day 1 and followed for 140 days.
89410401|NCT03513458|Experimental|Anakinra then Placebo|Subjects randomized to this arm will receive the experimental treatment of Anakinra on their first exposure to Dermatophagoides Farinae (dust mite) allergen challenge, followed by the Anakinra matching placebo on their second exposure.
89410402|NCT03513458|Experimental|Placebo then Anakinra|Subjects randomized to this arm will receive the inactive placebo on their first exposure to the Dust Mite Allergen challenge, followed by the experimental treatment of Anakinra on their second exposure.
89410403|NCT03641079|Experimental|brinjal peel extract containing cream|intervention-brinjal peel extract containing cream, dose-twice daily for 12 weeks
89410404|NCT03760471|Experimental|Collaborative palliative and oncology care|
89410405|NCT03643419|Sham Comparator|Laminectomy|
89410406|NCT03643419|Experimental|Laminectomy & Irradiation|
89410407|NCT03747835|Active Comparator|Exposure and Response Prevention|Inpatients will be provided three 90-minute sessions of Exposure and Response Prevention therapy each week.
89410408|NCT03747835|Active Comparator|Motivational Interviewing|Inpatients will be provided two 60-minute sessions of Motivational Interviewing each week.
89410409|NCT03516734|Experimental|Iron fortified lentils|Lentils will be fortified with iron in the lab setting at the Crop Development Center (CDC) of The University of Saskatchewan, Canada. The study will fortify lentil by spraying iron fortificant NaFeEDTA solution. A small sprayer will be placed at the beginning of the lentil polishing machine at a commercial lentil mill located near Saskatoon, Canada. The iron solution will be applied as a fine mist which will be absorbed into the lentil as it travels through the polishing drum. As the fortified lentil leaves the drum it will be bagged in 20 kg food grade bags. The expected concentration of Fe in the final product will be approximately 21 mg/100 g of lentil (fortified with NaFeEDTA solution with 1600 ppm of Fe).
89410410|NCT03516734|Active Comparator|Non iron-fortified lentils|It will be the same Saskatchewan (province of Canada) grown small cotyledon color lentil (Iron content 75-90ppm) without the iron fortification.
89410411|NCT03516734|Placebo Comparator|Usual Intake (no intervention)|It will be the usual intake of lentil- no additional lentil will be provided. However, participants will be free to consume lentils from anywhere (homemade or restaurants) if they want to, except our fortified lentils.
89410412|NCT05260905||Intervention|All participants will perform 2 experimental sessions, each involving a REHIT exercise session.
89410413|NCT03519698|Placebo Comparator|Warm water|12 l footbath with warm water (40 °C)
89410414|NCT03519698|Experimental|Warm water & Mustard|12 l footbath with warm water (40 °C) and 80 g mustard flour
89410415|NCT03519698|Experimental|Warm water & Ginger|12 l footbath with warm water (40 °C) and 80 g ginger flour
88813809|NCT01591655|Placebo Comparator|Vehicle|The vehicle of the mapracorat ophthalmic suspension
89410416|NCT02292680||NICU Tooth Study Cohort|All study subjects will have been cared for in the Mount Sinai NICU and have had the same hospital environment exposure.
89410417|NCT03513380|Experimental|Exergaming|free access to the exergame PedalTanks
88813810|NCT00916136|Active Comparator|Cutaneous Traction|Applied by using a strap on boot that attaches to the leg. A rope is attached to the boot. Weight is attached to the rope to use gravity to pull traction. The traction is left in place until patient is taken to surgery for reduction of the femur fracture.
88813811|NCT00916136|Active Comparator|Skeletal Traction|A small incision is made on the inside of the knee and a pin is surgically inserted through the bone. Weights are then attached that will pull traction on the broken femur. This traction pin will stay in until patient is taken to surgery for reduction of the femur fracture.
88813812|NCT01725074|Experimental|"Case Management CM CHD"|The intervention consists of a biweekly telephone or personal contact by trained case managers over the first 6-months and monthly contact over the second 6-months to assess well-being, everyday life (positive, neutral and negative daily events), and to inquire after health and personal problems on which basis the case manager offers practical or emotional support or a referral to the general practitioner if deemed necessary. During the contacts also medical control measures like blood pressure or weight are taken, and other study outcome measures like need for medical treatment.
88813813|NCT01725074|Experimental|Social Interaction|Identical as the CM CHD group, but with exclusion of medical control measures.
88813814|NCT01725074|No Intervention|Control Group|Patients assigned to the control group received usual care (no additional contact/support) and therefore stays under the standard supervision of the general practitioner i.e. as participant in the normal disease management program for CHD (quarterly check-ups).
88813815|NCT01725230|Experimental|Rosuvastatin|Single, oral dose of rosuvastatin 20mg in first period and in second period (after wash out) fostamatinib 100 mg twice daily, then single oral dose of rosuvastatin 20 mg plus continued oral dosing of fostamatinib 100 mg twice daily, then continue fostamatinib 100 mg twice daily
88813816|NCT01725230|Experimental|Simvastatin|Single, oral dose of simvastatin 40 mg in first period and in second period (after wash out) fostamatinib 100 mg twice daily, then single oral dose of simvastatin 40 mg plus continued oral dosing of fostamatinib 100 mg twice daily, then continue fostamatinib 100 mg twice daily
88813817|NCT01591733|Experimental|Treatment Arm|All participants will receive the FOLFIRINOX regimen, followed by capecitabine and short course radiation therapy.
88813818|NCT03005561|Experimental|Intervention|100 participants that will be participating in the Play Back meetings.
88813819|NCT03005561|No Intervention|Control|100 participants that will not be participating in the Play Back meetings.
88813820|NCT03005405|Active Comparator|restoration - control|Restoration
88813821|NCT03005405|Experimental|sealant - test|Sealant
88813822|NCT03005717|Experimental|Active High|Drug: LIPO 202 (Salmeterol Xinafoate for Injection), 0.2 mcg SX/mL Total Weekly Dose: up to 3.0 mcg SX
88813823|NCT03005717|Experimental|Active Low|Drug: LIPO 202 (Salmeterol Xinafoate for Injection), 0.02 mcg SX/mL Total Weekly Dose: up to 0.3 mcg SX
88813824|NCT03005717|Placebo Comparator|Placebo|Placebo for LIPO 202 (Salmeterol Xinafoate for Injection)
88813825|NCT02999243|Experimental|HIV self-testing|HIV self-testing kits plus harm reduction education materials will be offered to the intervention group.
88813826|NCT02999243|Placebo Comparator|Education|Harm reduction educational materials will be offered to the control group.
88813827|NCT03005483|Experimental|Gabapentin|Gabapentin 10 mg/kg in children submitted unilateral limb surgery
88813828|NCT03005483|Placebo Comparator|Placebo|Placebo in children submitted unilateral limb surgery
88813829|NCT01592435||Pred. & Invest.-All Study Participants|"Cedera AccuStitch Software is standard of care software currently used at sites.~Carestream DR LLI software is investigational software used for reconstruction."
88813830|NCT01593215|Active Comparator|Placebo first then yohimbine|placebo first, then yohimbine
88813831|NCT01593215|Active Comparator|Yohimbine first then placebo|Yohimbine first then placebo
88813832|NCT05511155||O-15|15 lt/min oxygen
88813833|NCT05511155||O-8|8 lt/min oxygen
88813834|NCT05511155||A-15|15 lt/min room air
88813835|NCT05511155||A-8|8 lt/min room air
88813836|NCT05423483|Experimental|Text Message Intervention|Parents in the intervention arm will receive text message reminders to restrict lethal means for 6 months.
88813837|NCT05423483|No Intervention|Treatment as Usual|Parents in the treatment as usual group will not receive the text message intervention.
88813838|NCT05504135||RMG Patients|
88813839|NCT01594385|Other|Seprafilm|The treatment group will receive Seprafilm while the control group will not receive Seprafilm. Allocation of patients will be in 1:1 ratio.
88813840|NCT01594385|No Intervention|No Seprafilm|This group will be treated according to the current standard of care. No seprafilm will be applied in this subset of patients.
88813841|NCT03005249|Experimental|neural stem cells therapy group|The patients will be assigned to neural stem cells therapy group for cerebral palsy.
88813842|NCT03005249|Experimental|the control group|The patients will be assigned to the control group for cerebral palsy.
88813843|NCT02247323||premenopausal women|premenopausal women with complex ovarian mass moderate for malignancy by risk of malignancy index score and low CA125.
88813844|NCT03005015|Experimental|Lenvatinib|Lenvatinib 24 mg orally every day. Treatment is continued until unacceptable toxicity, progressive disease or patient withdrawal
88813845|NCT03005015|Active Comparator|Doxorubicin|Doxorubicin 60 mg/m² iv bolus every 3 weeks. Treatment is continued for a maximum of 6 cycles or until unacceptable toxicity, progressive disease or patient withdrawal.
88813846|NCT03005171|Active Comparator|Epidural|"Epidural catheters will be placed in the 9th or 10th thoracic intervertebral space prior to induction of anesthesia.Through the thoracic epidural catheter 0.125% bupivacaine at a rate of 5 mL/h will be infused.~The infusion continues for 24h"
88886403|NCT01415726|Experimental|Cord blood stem cell|Human cord blood-derived multipotent stem cells (CB-SC) display unique phenotypes, such as the expression of embryonic stem (ES) cell markers, multipotential of differentiations, very low immunogenecity, and immune modulations. Stem Cell Educator will be used for isolation and purification of cord blood stem cells for the treatment.
88886404|NCT01415726|Experimental|Stem Cell Educator|used for the isolation and purification of cord blood stem cells.
88886405|NCT01415739||Novel Molecular NSCLC Classification (H & E staining, IHC)|Previously collected tissue samples are analyzed via H&E staining and IHC.
88886406|NCT01415778|Experimental|Active 1|12 subjects will receive ICI176,334-1 and Casodex 80 mg tablet
88886407|NCT01415778|Experimental|Active 2|12 subjects will receive ICI176,334-1 and Casodex 80 mg tablet
88886408|NCT01415778|Experimental|Active 3|12 subjects will receive ICI176,334-1 and Casodex 80 mg tablet
88886409|NCT01415778|Experimental|Active 4|12 subjects will receive ICI176,334-1 and Casodex 80 mg tablet
88886410|NCT01415791|Experimental|Active 1|8 subjects will receive ICI176,334-1
88886411|NCT01415804|Active Comparator|stentgraft|Stentgraft
88886412|NCT01415804|No Intervention|Medical management|Antihypertensive medication
88886413|NCT01415830|Experimental|Anti-scorpion venom serum Birmex|Patients 0 to 15 years with scorpion sting, will receive serum antiscorpion elaborated by Birmex
88886414|NCT01415830|Active Comparator|Anti-scorpion venom serum Alacramyn|Patients 0 to 15 years with scorpion sting, will receive other commercial serum antiscorpion (Alacramyn)
88886415|NCT01415856|Placebo Comparator|Sham Device (Torino II)|Device is designed to appear to be giving treatment when it is not actually giving treatment. Patients will wear this for a duration of two weeks.
88886416|NCT01415856|Active Comparator|Active Device (Torino II)|Device is giving treatment for 15 minutes every 2 hours for a total of two weeks.
88886417|NCT01415869||Cross Sectional|Patients with implanted non-pulsatile ventricular assist devices of any type and at any time after implantation
88886418|NCT01415869||Prospective|Patients with usual VAD indications will be invited to participate, when, in the opinion of their treating physician a VAD will be highly likely within one month.
88886419|NCT01415895|Experimental|ATNC05 - a study drug capsule|Naltrexone and Clonidine Combination (ATNC05)
88886420|NCT01415895|Placebo Comparator|placebo|
88886421|NCT01415973|Experimental|3 ounces of cooked, 85% lean ground beef|Subjects would consume 3 ounces of cooked, 85% lean ground beef at one setting on one day.
88886422|NCT01415973|Experimental|20 grams of Beef protein isolate|Subjects would consume 20 grams of beef protein isolate dissolved into 200mL water at one setting on one day.
89191994|NCT04040374|Experimental|AI-based diagnosis|• AI-based diagnosis will be performed based on analysis of endoscopic images (Olympus Optical, Tokyo, Japan). The investigators will use the Single Shot MultiBox Detector (SSD), a deep neural network architecture (https://arxiv.org/abs/1512.02325), and an optimal diagnostic cutoff from a prior report2. The AI system reviewed endoscopy images and reported those in which gastric cancer was detected, together with the coordinates (X, Y) of the lesions.
88886423|NCT01415999||patient|adult survivors of childhood malignancies
88886424|NCT01415999||control|healthy age-matched individuals
88886425|NCT01416038|Experimental|Vaccine|Cohort A: 0.5 mL of DPX-Survivac (injection)
89191995|NCT04040374|Active Comparator|Expert endoscopist diagnosis|The expert endoscopists are two physicians with experience of more than 20,000 endoscopies. The expert endoscopists will review the endoscopy images of each patient for 5 min. They will then report endoscopy images in which gastric cancer was detected and manually annotate the lesions in those images.
89191996|NCT00862420|Experimental|Clopidogrel|75 mg clopidogrel once daily from Day 1 to Week 12
89535683|NCT03204331|Experimental|Relugolix plus Delayed E2/NETA (Group B)|Relugolix co-administered with E2/NETA placebo for 12 weeks, followed by relugolix co-administered with E2/NETA for 12 weeks.
89535684|NCT03204331|Placebo Comparator|Placebo (Group C)|Relugolix placebo co-administered with E2/NETA placebo for 24 weeks.
89535685|NCT03317249||Pregnant Healthy|Pregnant females aged between 18-45 years who do not have IST syndrome
88886426|NCT01416038|Experimental|Vaccine + low dose cyclophosphamide|Cohort B: 0.1 mL DPX-Survivac (injection) with low dose cyclophosphamide (oral)
88886427|NCT01416038|Experimental|Vaccine + low dose cyclophosphamide.|Cohort C: 0.5 mL DPX-Survivac (injection) with low dose cyclophosphamide (oral)
88886428|NCT01416051|Active Comparator|Test|Subjects consumed a vegetable oil emulsion in yogurt at a food intake test and were asked to consume the product twice daily for 12 weeks.
88886429|NCT01416051|Placebo Comparator|Control Group|Subjects were given a placebo of milk fat in yogurt at food intake tests and asked to consume the placebo twice daily for 12 weeks.
88886430|NCT01416103|Experimental|Intervention group|Intervention group
88886431|NCT01416103|Placebo Comparator|Intervention control|Control group
88886432|NCT01416116|Experimental|Tramadol|Tramadol prior to QUTENZA
88886433|NCT01416116|Experimental|Lidocaine|Lidocaine prior to QUTENZA
88886434|NCT01416168|No Intervention|Control Arm|Usual post-surgical care
88886435|NCT01416168|Experimental|Intervention arm|In addition to usual post-surgical care, the patients will receive a 4 week geriatric nurse practitioner-centered intervention, based on the McCorkle model.
88886436|NCT01416207|Experimental|Avonex|4 weekly injections of Avonex (IM)
88886437|NCT01416220|Experimental|Lithium|Following the enrollment period, subjects will enter a six-week randomized treatment period with either lithium or paroxetine. Lithium carbonate will be commenced at 600mgs hs, with increase to 900mgs at day 7. Dose will be flexibly titrated to give a serum level between 0.5 and 1.1mmol/l. At visit 4, the dose of lithium may be adjusted (within the range of 0.6 and 1.1 mmol/l).
88886438|NCT01416220|Active Comparator|Paroxetine|Following the enrollment period, subjects will enter a six-week randomized treatment period with either lithium or Paroxetine.Paroxetine will be commenced at 10mgs and increased to 20mgs on day 7.At visit 4, the dose of paroxetine may be increased to 40mgs, if there is no response (less than 20% reduction in MADRS score) as per current Canadian guidelines.
88886439|NCT01416233|Experimental|autologous fat grafting|There is one arm of this study. People with anophthalmic sockets and orbital atrophy are given a single session of autologous fat grafting by a closed cannula technique and are observed to measure, by MRI, the amount of fat retained at one year
89005108|NCT02962518|Experimental|B Pressure Device|"Patients undergo surgery using the fillet technique and intra-lesional injections of triamcinolone 10mg /ml every 4 to 6 weeks for 6 months and are additionally treated with a non-customized pressure device."
89005109|NCT00409916|Placebo Comparator|Standard Care Arm|In the Standard Care Arm, the treating clinician will adjust therapy according only to the clinical assessment of signs and symptoms of heart failure since the ICG information is blinded to the treating clinician.
89005110|NCT00409916|Active Comparator|ICG Arm|In the ICG Arm, the treating clinician will adjust therapy according to the clinical assessment of signs and symptoms of heart failure, in addition to the ICG hemodynamic information obtained from the printed report.
89005111|NCT00413556|Active Comparator|1|
89191997|NCT00862420|Active Comparator|Ticlopidine|200 mg ticlopidine once daily from Day 1 to Week 12
89191998|NCT00321698|Experimental|Phase I Dose 1-4|"Group 1=radiation only; Group 2=Docetaxel IV over 30mins, 10mg/m2; weekly x 5 weeks starting on day one of radiation; Group 3=Docetaxel IV over 30mins, 20mg/m2; weekly x 5 weeks starting on day one of radiation; Group 4=Docetaxel IV over 30mins, 30mg/m2; weekly x 5 weeks starting on day one of radiation~Radiation: All men receive same radiation treatment protocol. External Beam, 45 Gy (1.8 Gy fractions), 5 per week (daily) x 5 weeks (25 fractions)"
89191999|NCT00321698|Experimental|Phase II MTD Dose|"Phase II with no phase I dose-limiting toxicities=Docetaxel IV over 30mins, 30mg/m2; weekly x 5 weeks starting on day one of radiation~Radiation: All men receive same radiation treatment protocol. External Beam, 45 Gy (1.8 Gy fractions), 5 per week (daily) x 5 weeks (25 fractions)"
89192000|NCT02569944|Active Comparator|perineal bag|Perineal bag was placed in infants to collect an urine sample.
89192001|NCT02569944|Experimental|Bladder stimulation|Bladder stimulation technique was used in infants of this arm to obtain an urine sample
89192002|NCT00725894||1|The Pediatric Locking Nail was designed to provide stable sub-rigid fixation of femoral fractures in children
89192003|NCT02544568|Experimental|High-Carb Meal|The 3 Groups (Control, T1DM, T2DM) will receive 4 meals with different compositions at 4 occasions (High-Carb, High-Fat, High-Protein, High-Fibr) .
89192004|NCT02544568|Experimental|High-Protein Meal|The 3 Groups (Control, T1DM, T2DM) will receive 4 meals with different compositions at 4 occasions (High-Carb, High-Fat, High-Protein, High-Fibr) .
89192005|NCT02544568|Experimental|High-Fat Meal|The 3 Groups (Control, T1DM, T2DM) will receive 4 meals with different compositions at 4 occasions (High-Carb, High-Fat, High-Protein, High-Fibr) .
89192006|NCT02544568|Experimental|High-Fibre Meal|The 3 Groups (Control, T1DM, T2DM) will receive 4 meals with different compositions at 4 occasions (High-Carb, High-Fat, High-Protein, High-Fibr).
89192007|NCT02569970|Active Comparator|FLUOXETINE|4 weeks of treatment before video-EEG monitoring
89192008|NCT02569970|Placebo Comparator|PLACEBO|1 month of treatment before EEG video.
89192009|NCT04066998|Experimental|Conjunctivitis|Patients treated with Dupilumab with conjunctivitis
89192010|NCT04066998|Other|No conjunctivitis|Patients treated with Dupilumab and showing no signs of ocular involvement
89192011|NCT00868036||Patch testing|Patch testing on patients with chronic idiopathic dermatitis.
89192012|NCT00725972|Experimental|Augmented Oxygen Delivery Group|"Hemodynamic management to a goal of O2 delivery of 600 ml/m2/min utilizing cardiac stroke volume variation with positive pressure ventilation to optimize fluid management.~Intervention: Augment O2 Delivery by hemodynamic protocol. (7/30/17: deleted original text which apparently was pasted from an entirely unrelated study having to do with age of transfused blood, presumably by the creator of this record, Cynthia Hatfield, in 2010. SLW)"
89192013|NCT00725972|Sham Comparator|Control|Patients having the same types of surgery but receiving usual anesthetic care. Intervention: High Risk Surgery. (7/30/17: deleted original text which apparently was pasted from an entirely unrelated study having to do with age of transfused blood, presumably by the creator of this record, Cynthia Hatfield, in 2010. SLW)
89192014|NCT00725790|Experimental|A|Vardenafil treatment group
89192015|NCT00725790|Placebo Comparator|B|Placebo treatment group
89192016|NCT00862498|Experimental|Group 1 Treatment in Clinic|Participants will complete the written disclosure treatment in a clinic setting.
89192017|NCT00862498|Experimental|Group 2 Treatment via telephone|Participants will complete the written disclosure treatment in their homes via telephone.
89192018|NCT00862498|No Intervention|Group 3 Waitlist|Individuals will be placed on a waitlist for a period of 4 months, during which they will receive a phone call every other week to assess their suicidal ideation and post-traumatic stress disorder symptom severity.
89192019|NCT00731276|Other|Four Regimens|"The study has four type of regimens, and dosing of irinotecan depends on genotype of patient.~Four Regimens are:~Weekly Irinotecan (Irinotecan given at day 1, 8 and 15) every four weekly~Weekly Xeliri ( Irinotecan given at day 1, 8 and 15)+ (Xeloda tabs 2000mg/m2 consumed over 14 days) every three weekly~Three-weekly Xeliri (Irinotecan given at day 1 only) + (Xeloda tabs 2000mg/m2 consumed over 14 days) every three weekly~Two-weekly FOLFIRI (Irinotecan given at day 1 only) + (CI Fluorouracil 600mg/m2 over 22hrs, IV Folinic Acid 200mg/m2 over 2hrs and IVP Fluorouracil 400mg/m2) every two weekly"
89192020|NCT00725868|Other|1|Data private hospitals, angioplasty, sampling of blood
89192021|NCT00868114|Experimental|1|3 weekly injections of intratumoral TNFerade plus radiation and 3 weekly intratumoral injections of dendritic cell vaccine
89192022|NCT00868114|Experimental|2|Radiation Only with 3 weekly intratumoral injections of dendritic cell vaccine
89192023|NCT00731354|Active Comparator|SAL|Each patient will have Suction Assisted Lipoplasty procedure on one side of the body (this will be considered the control side)
89192024|NCT00731354|Active Comparator|VAL|Each patient will have VASER- assisted lipoplasty on the opposite side of the body. This will be the comparison side.
89192025|NCT00725946|Experimental|Iodine-124 PET-CT scan|
89192026|NCT02569346|Active Comparator|Triumeq whole|Single-dose Triumeq as a whole tablet in a fasted state
89192027|NCT02569346|Experimental|Triumeq crushed + breakfast|Single-dose crushed and suspended Triumeq in a fasted state
89192028|NCT02569346|Experimental|Triumeq crushed + drip feed|250 ml drip feed (Nutrison) followed by a single-dose crushed and suspended Triumeq
89192029|NCT04066842||1 - Controls|Control Healthy controls
89192030|NCT04066842||2 - SSc|SSc Systemic Sclerosis
89192031|NCT04066842||3 - Cardiovascular|Cardiovascular Cardiovascular disease
89192032|NCT04066842||4 - SSc+Periodontitis|SSc+ Periodontitis Systemic Sclerosis with Periodontitis
89192033|NCT00731432|Experimental|A|Transmucosal Herbal Periodontal Patch (THPP)
89192034|NCT00731432|Placebo Comparator|B|Placebo Patch
89192035|NCT00726102|Active Comparator|Meat|Provide locally available meat daily to infants from 6 to 18 mos of age
89192036|NCT00726102|Active Comparator|Control|Daily provision of cereal to infants from 6-18 mos
89192037|NCT00726102|Active Comparator|Fortified rice cereal|Provide equi-caloric serving of fortified rice cereal on daily basis from 6-18 months of age
89192038|NCT00731510|Experimental|1|Carbohydrate supplements (drinks and gels)
89192039|NCT00731510|Placebo Comparator|2|Primarily Aspartame plus natural flavourings. Powder dissolved in water to provide non-distinguishable placebo drink.
89192040|NCT00726804|Other|2|
89192041|NCT00726960|Experimental|1|Aprepitant
89192042|NCT00726960|Placebo Comparator|2|Placebo
89192043|NCT00726128||VueLock™ Anterior Cervical Plate Group|VueLock™ Anterior Cervical Plate, Implanted in subjects having an ACDF (Anterior cervical discectomy and fusion)
89192044|NCT02570958|Experimental|Indocyanine green|
89192045|NCT00726206|Other|1|Recording of the movements Recording of the electroencephalogram
89192046|NCT02202590|Experimental|Imaging|Subject will swallow the SECM capsule and Imaging will be performed using the SECM Imaging system.
89192047|NCT00727038|Experimental|1|Lucentis (ranibizumab) with conventional treatment
89192048|NCT00727038|No Intervention|2|Conventional treatment
89192049|NCT00727116|Experimental|State-wide|All parents of newborns in Pennsylvania hospitals will receive the parent education materials
89192050|NCT00727116|Experimental|Central PA|All of Central PA new parents will receive the state-wide hospital-based intervention. In half of the 31 central PA counties, all primary care providers having offices in those counties provide an office-based booster intervention to new parents. The other half of central PA counties will receive the state-wide, hospital-based intervention, but not the office-based booster intervention.
89192051|NCT04018586|Experimental|Heat and Vacuum|AVACEN 100 device applies heat and vacuum to hand
89192052|NCT04018586|Active Comparator|Heat Only|AVACEN 100 device with heat only
89192053|NCT04018586|Sham Comparator|Sham|AVACEN 100 device with neither heat nor vacuum
89192054|NCT00726258|Placebo Comparator|1|Drip of physiological serum
89192055|NCT00726258|Active Comparator|2|Drip of ketamine
89192056|NCT00727142|Active Comparator|open shunt|functioning shunt
89192057|NCT00727142|Active Comparator|closed shunt|NON FUNCTIONING SHUNT
89192058|NCT04793802||Patients benefiting from HIGH-FLOW OXYGENATION + NONINVASIVE VENTILATION|Patients benefiting from high-flow oxygenation will have their physiotherapy session with non-invasive ventilation.
89192059|NCT04793802||Patients benefiting from HIGH-FLOW OXYGENATION|Patients benefiting from high-flow oxygenation will have their physiotherapy session without non-invasive ventilation.
89192060|NCT02569814|Other|Group 1|Subjects of Group 1 take Fimasartan/Amlodipine Combination Tablet and Rosuvastatin Individual Tablets at 1st day as period I. And then, after wash out for 2 weeks, as period II, subjects of Group 1 take a Fimasartan/Amlodipine/Rosuvastatin Combination Tablet at 15th day.
89192061|NCT02569814|Other|Group 2|Subjects of Group 2 take a Fimasartan/Amlodipine/Rosuvastatin Combination Tablet at 1st day as period I. And then, after wash out for 2 weeks, as period II, subjects of Group 2 take Fimasartan/Amlodipine Combination Tablet and Rosuvastatin Individual Tablets at 15th day.
89192062|NCT00726492|Experimental|CSWD + Hydro|Continuous short wave diathermy and hydrotherapy
89192063|NCT00726492|Experimental|Hydro alone|Hydrotherapy alone
89192064|NCT00726492|Experimental|CSWD alone|Continuous short wave diathermy alone
89192065|NCT00726492|No Intervention|Control|No treatment
89192066|NCT00726570|Experimental|SCD + LMWH|This group will receive sequential compression device therapy to the lower limbs from their ICU admission until the morning after surgery.
89192067|NCT00726570|Active Comparator|LMWH only|Patients in this group will receive only standard LMWH therapy during their ICU stay.
89192068|NCT00726726|Other|A|
89192069|NCT00726726|Experimental|B|
89192070|NCT00726726|Experimental|C|+ Other
89192071|NCT00731978|No Intervention|Standard|Standard intraoperative fluid management
89192072|NCT00731978|Experimental|Restricted|Restricted intraoperative fluid management
89192073|NCT00727350|Experimental|1|For centrally located T1 and T2 lesions 4 x 15 Gy over 2 weeks will be delivered. Lesions located peripherally will be treated with 3 x 20 Gy, also delivered within 2 weeks. For both schedules, there should be a minimum of 40 hours and a maximum of 8 days between 2 separate fractions. There should be a maximum of 2 fractions per week.
89192074|NCT00726362||1|patients with hyperlipidemia newly initiating a statin; or switched from current therapy to a statin, or require dosage adjustment for statin
89192075|NCT00732056|Experimental|1|3+3 cohort dose escalation
89192076|NCT00654381|Active Comparator|voglibose 0.2 mg three times a day (TID)|patient to receive a tablet containing 0.2 mg voglibose TID plus 2 placebo tablets matching BI 1356
89192077|NCT00654381|Experimental|BI 1356 low dose|patient to receive a tablet containing BI 1356 and matching placebo plus 3 placebo tablets matching voglibose
89192078|NCT00654381|Experimental|BI 1356 high dose|patient to receive 2 tablets containing BI 1356 plus 3 placebo tablets matching voglibose
89192079|NCT00654381|Placebo Comparator|placebo|patient to receive 2 placebo tablets matching BI 1356 plus 3 placebo tablets matching voglibose
89192080|NCT00727428|Experimental|Group A|
89192081|NCT02089880|Experimental|C-brace then stance control orthosis|
89535686|NCT03317249||Pregnant IST|Pregnant females aged between 18-45 years who have IST syndrome
89535687|NCT03072849||Stem Cell Transplant Recipients|Pediatric patients ages 6-18 years who have received allogenic hematopoietic stem cell transplant for any reason.
89005112|NCT00413556|Placebo Comparator|2|
89192082|NCT02089880|Experimental|Stance control orthosis then C-brace|
89192083|NCT00727584|Active Comparator|Arm I (multi-fraction radiotherapy)|Patients undergo 5 fractions of 20 Gy external-beam radiotherapy.
89192084|NCT00727584|Experimental|Arm II (single-fraction radiotherapy)|Patients undergo 1 fraction of 8 Gy external beam radiotherapy.
88886440|NCT01416246|Experimental|Fractionated Stem Cell Infusions|A single arm, open-label, single institution pilot trial is planned. Patients with chemosensitive MM and at least 7 x 10^6 CD34+ stem cells/kg (+/- 0.5 x 10^6 CD34+ stem cells/kg)available for use will be enrolled following initial induction or salvage therapy.
88886441|NCT01416259||APF530 Exposure, Granisetron and Moxifloxacin, Placebo|Arm 1:APF530 Exposure Arm 2:Granisetron IV Arm 3:Moxifloxacin Arm 4:Placebo
88886442|NCT01416311||Subjects prescribed REVOLADE|Subjects with chronic idiopathic thrombocytopenic purpura prescribed REVOLADE during study period
88886443|NCT01416324|Experimental|GSK2330672|experimental study drug
88886444|NCT01416324|Placebo Comparator|Placebo|placebo
88886445|NCT01416337|Experimental|Treatments A & B|Single 2 mg GSK1120212 oral tablet, fasted Single IV dose of 5 ug (no more than 7.4 kBq or 200 nCi) [14C]GSK1120212 Both doses are given together.
88886446|NCT01416350|Active Comparator|Part A - randomized, open-label parallel group|Part A is a randomized, open-label parallel group study evaluating PK/PD of a single azithromycin dose of 250 or 1000 mg. Data from Part A will be used to assess the dose resulting in induction/inhibition of various ex vivo biomarkers relative to a 250 mg dose of azithromycin (the clinical dose used in treatment of neutrophil-induced inflammatory conditions). This information will guide the range of doses to be studied in a FTIH study of a new chemical entity.
88886447|NCT01416350|Active Comparator|Part B - repeat dose group|Part B is a repeat dose study treating subjects with Azithromycin (250 mg every other day for 3 weeks), the dose approximates that used in the treatment of chronic neutrophil-related inflammatory conditions. This information will provide insight into whether the biomarker effects change over time on repeat dosing and any potential differences observed between single and repeat doses.
88886448|NCT01416363|Experimental|Treatment Arm ACB: Part 1|Subjects will receive treatment sequence ACB; A : Firategrast immediate release tablet 1200 milligram (mg) once only orally, C : Firategrast simulated gastro-retentive solution 1200 mg once only by naso-gastric route, B : Firategrast 3 hour release tablet 1200 mg once only orally. There will be a washout period of 5 days between doses.
88886449|NCT01416363|Experimental|Treatment Arm BAC: Part 1|Subjects will receive treatment sequence BAC; B : Firategrast 3 hour release tablet 1200 mg once only orally, A : Firategrast immediate release tablet 1200 mg once only orally, C : Firategrast simulated gastro-retentive solution 1200 mg once only by naso-gastric route. There will be a washout period of 5 days between doses.
88886450|NCT01416363|Experimental|Treatment Arm CBA: Part 1|Subjects will receive treatment sequence CBA; C : Firategrast simulated gastro-retentive solution 1200 mg once only by naso-gastric route, B : Firategrast 3 hour release tablet 1200 mg once only orally, A : Firategrast immediate release tablet 1200 mg once only orally. There will be a washout period of 5 days between doses.
88886451|NCT01416363|Experimental|Treatment Arm BCA: Part 1|Subjects will receive treatment sequence BCA; B : Firategrast 3 hour release tablet 1200 mg once only orally, C : Firategrast simulated gastro-retentive solution 1200 mg once only by naso-gastric route, A : Firategrast immediate release tablet 1200 mg once only orally. There will be a washout period of 5 days between doses.
88886452|NCT01416363|Experimental|Treatment Arm CAB: Part 1|Subjects will receive treatment sequence CAB; C : Firategrast simulated gastro-retentive solution 1200 mg once only by naso-gastric route, A : Firategrast immediate release tablet 1200 mg once only orally, B : Firategrast 3 hour release tablet 1200 mg once only orally. There will be a washout period of 5 days between doses.
88886453|NCT01416363|Experimental|Treatment Arm ABC: Part 1|Subjects will receive treatment sequence ABC; A : Firategrast immediate release tablet 1200 mg once only orally, B : Firategrast 3 hour release tablet 1200 mg once only orally, C : Firategrast simulated gastro-retentive solution 1200 mg once only by naso-gastric route. There will be a washout period of 5 days between doses.
88886454|NCT01416363|Experimental|Treatment Arm D: Part 2|Subject will receive D: Firategrast immediate release tablet 600 mg twice daily for 7 days
88886455|NCT01416363|Experimental|Treatment Arm E: Part 2|Subject will receive E: Firategrast 3 hour release tablet 1200 mg twice daily for 7 days
88886456|NCT01416363|Experimental|Treatment Arm F: Part 2|Subject will receive F: Firategrast simulated gastro-retentive solution 1200 mg twice daily for 7 days
88886457|NCT01416376|Active Comparator|50mg SRT2379|Single oral administration of 50mg SRT2379
88886458|NCT01416376|Active Comparator|250mg SRT2379|Single oral administration of 250mg SRT2379
88886459|NCT01416376|Active Comparator|1000mg SRT2379|Single oral administration of 1000mg SRT2379
88886460|NCT01416376|Placebo Comparator|Placebo|Single oral administration of placebo
88886461|NCT01416415|Experimental|Educational intervention|The educational intervention arm will contain subjects who will watch a video on proper eye drop instillation technique.
88886462|NCT01416415|Placebo Comparator|Attention placebo|The attention control placebo group will receive an educational intervention that mimics the amount of time and attention received by the treatment group. The video chosen is regarding healthy eating tips.
88886463|NCT01416454||Elective Cesarean delivery, age <35 yrs|Women undergoing elective cesarean delivery with a spinal anesthetic who are less than 35 y of age (at the time of delivery).
88886464|NCT01416454||Elective Cesarean delivery, age =>35 yrs|Women undergoing elective Cesarean delivery with a spinal anesthetic who are => 35 yrs of age (at the time of delivery).
88886465|NCT01416480|Experimental|Theobromine|Theobromine capsule 300mg
88886466|NCT01416480|Active Comparator|levodropropizine|levodropropizine syrup
88886467|NCT01416493|Experimental|bIAP treatment|
88886468|NCT01416506||Group 1|
88886469|NCT01416519|Experimental|Group 1|After extubation, starting non-invasive ventilation with face mask (1 hour) followed by assisted cough maneuver. Total of 18 calls in 72 hours distributed as long the patient was extubated.
88886470|NCT01416519|Experimental|Group 2|After extubation, starting early supplemental oxygen with Venturi (FiO2 50%) with gradual weaning, applying assisted deep inspiration technique with Voldyne(R) with four sets of 10 repetitions and assisted cough maneuver. Total of 18 calls in 72 hours distributed as long the patient was extubated.
88886471|NCT01416545|Active Comparator|Lifestyle counseling|Children received the same educational material for their parents and, additionaly, were exposed to a weekly educational program directed for cardiovascular prevention.
89005113|NCT00204698|Active Comparator|1|All subjects will be given active drug.
89410418|NCT03513380|No Intervention|Control|recommended to continue with their normal daily routine
89410419|NCT02299544|Experimental|OAB|"Patients with overactive bladder (OAB) with or without urge incontinence.~Two patient populations will be enrolled in the study:~Patients with no previous treatment with percutaneous tibial nerve stimulation (PTNS) [de novo patient group] and Patients with a documented success on PTNS therapy [prior-PTNS group]. Documented success on PTNS is defined by a ≥50% reduction in urinary frequency, and/or ≥50% fewer incontinence episodes, or a return to normal voiding frequency [<8 voids/day], based on retrospective diary review.~All patients will be treated with BlueWind Medical System."
89410420|NCT02295800||Mothers|HIV Infected mothers
89410421|NCT02295800||Infants|HIV exposed infants
89410422|NCT02295800||Healthcare workers|Facility based healthcare workers
89410423|NCT02292836||rosacea patients|Questionnaire testing on routine dermatologist patient population
89410424|NCT02292836||non-rosacea patients|Questionnaire testing on routine dermatologist patient population
89410425|NCT02960217|Experimental|Double-Blind UX007 Followed by Placebo|"Participants will first receive UX007 (dosed according to an age- and weight-based strategy, up to a maximum daily administration of 130 g) for 10 weeks. After a washout period of 2 weeks, they will then receive placebo for 10 weeks.~Participants will have the option of rolling into the open label Extension Period, to continue UX007 treatment for up to 3 years."
89410426|NCT02960217|Experimental|Double Blind Placebo Followed by UX007|"Participants will first receive Placebo for 10 weeks. After a washout period of 2 weeks, they will then receive UX007 (dosed according to an age- and weight-based strategy, up to a maximum daily administration of 130 g) for 10 weeks.~Participants will have the option of rolling into the open label Extension Period, to continue UX007 treatment for up to 3 years."
89410427|NCT02292914|Experimental|Robot-Assisted Surgery|patients undergoing robot assisted surgery for the treatment of cancer
89410428|NCT02292914|Active Comparator|Conventional Surgery|patients undergoing conventional surgery for the treatment of cancer
89410429|NCT02292992|Experimental|Nasal pillow CPAP|Nasal pillow CPAP
89410430|NCT02295878|Active Comparator|Treatment|400mg capsule containing seaweed extract (treatment)
89410431|NCT02295878|Placebo Comparator|Placebo|400mg capsule containing maltodextrin (placebo)
89410432|NCT02293070|Experimental|Repeat Cardiac MRI Post Cryoablation|All subjects in this study receive a follow up delayed enhanced cardiac MRI 2-6 weeks after they undergo a cryoablation procedure.
89410433|NCT03643497||Children with the usage of anti-infective drugs|Children received meropenem or linezolid monotherapy in the treatment of seven infectious diseases
89410434|NCT03519620|Experimental|SWWSV|Spirometric Values: Forced Vital Capacity; Forced Expiratory Volume in 1 second; Peak Expiratory Flow
89410435|NCT03643341|Experimental|Family Healthy Living Intervention|Children aged 8-12 and at least one caregiver will meet for 10 weekly face-to-face and online intervention sessions (1.5 hours per session). Four biweekly maintenance sessions will follow the main program.
89410436|NCT03643341|No Intervention|Wait-list control group|Children aged 8-12 will be randomly assigned to the wait-list control group until after the study.
89410437|NCT02299700||Autism Spectrum Disorder (ASD) Participants (6-9 years)|Participants with ASD aged 6 to 9 years will be observed for the usability of the Janssen Autism Knowledge Engine (JAKE) personal healthcare record (pHR) and biosensors in stage 1 and stage 2 (at laboratory sites).
89410438|NCT02299700||ASD Participants (13-17 years)|Participants with ASD aged 13 to 17 years will be observed for the usability of the JAKE pHR and biosensors in stage 1 and stage 2 (at laboratory sites).
89410439|NCT02299700||ASD Participants (3 or greater than 3 years)|Participants with ASD aged 3 or greater than 3 years will be observed for the usability of the JAKE pHR and biosensors in stage 2 (at clinical sites).
89410440|NCT02299778|Experimental|1mg of 13C6-p-aminobenzoic acid|
89410441|NCT05252169|Experimental|Proprioceptive Training|"Proprioceptive training will include : Stair climbing up and down,Standing with feet side by side and up and down,one leg standing,Walking heel to toes,Rising from a standard chair.~Swiss ball activity will be performed passively by the physical therapist in which child will sit on the ball and ball will be rolled from side to side,Extension rotation and flexion rotation will be performed to facilitate trunk rotation that will be performed with stabilized pelvis and hip.~Routine physical therapy will include passive stretching ,strength training and weight bearing exercises. total session will be of 60 minutes."
88813847|NCT03005171|Active Comparator|Lidocaine|"Intravenous lidocaine infusion will typically start in the operating room prior to induction of anesthesia at a rate of 2 to 3 mg/min. Postoperatively, the rate will be decreased to 0.5 to 1 mg/min.~The infusion continues for 24h"
89005114|NCT00228189|Active Comparator|A|Dendritic cells pulsed with CEA-peptide
89410442|NCT05252169|Placebo Comparator|Routine Physical Therapy|"Group A will be given routine physical therapy which will be of 60 minutes each session. The routine physical therapy will include~Passive stretching exercises~Weight bearing exercises~Functional strength training Duration of the treatment will be 3 days a week for 12 weeks i.e., 36 sessions. Each session will be of 60 minutes."
89410443|NCT03519542||Metastatic clear cell renal carcinoma (mRCC) patients|Metastatic clear cell renal carcinoma (mRCC) patients cadidates to receive Sunitinib 50 mg/day 4/2 schedule or Pazopanib 800mg/day until unaccetable toxicity or progression or death under standar clinical practice.
89531070|NCT03342599|Experimental|GNC Alpha Lipoic Acid Supplement|600mg/daily ingestion of GNC alpha lipoic acid with no change in lifestyle for 8 weeks
89531071|NCT03342599|Placebo Comparator|Cellulose Fiber Placebo|600mg/daily ingestion of Vital Nutrients placebo (cellulose starch) with no change in lifestyle for 8 weeks
88813848|NCT03005093||CAREGIVERS|Caregivers of pediatric patients with swallowing disorders will be recruited.
88813849|NCT03005093||CHILDREN OF CAREGIVERS|Pediatric patients with swallowing disorders will be recruited.
88819604|NCT02209532|Active Comparator|PINPOINT - Blue|The cervix will be injected 4 times with 1 ml of a 1.25 mg/ml solution of ICG followed by injection 4 times of a 1 ml solution of 1% Isosulfan blue. LN mapping with PINPOINT will be performed until the investigator identifies all 'ICG' nodes or determines that 'ICG' nodes cannot be identified. Once complete, the Investigator will begin mapping with Blue dye until all 'blue' nodes are identified or the investigator determines that 'blue' nodes cannot be identified. Once mapping with both Blue dye and PINPOINT have been completed and documented, LNs identified with Blue dye or PINPOINT will be excised.
88886472|NCT01416545|Placebo Comparator|Control group|The control group received written educational material directed for their parents and related to healthy lifestyle (nutrition, exercise and smoke quitting).
88886473|NCT01416597||Cross-Protection Studies|
88886474|NCT01416623|Experimental|Henatinib|Henatinib either at 12.5,25,37.5,50,62.5,75,87.5 or 100 mg, p.o. once daily
88886475|NCT01416662|Other|gemcitabine|gemcitabine
88886476|NCT01416701|Active Comparator|Vitamin D (D3, cholecalciferol)|
89531072|NCT03341117|Active Comparator|Acetylsalicylic acid|The patients were randomly assigned to received Acetylsalicylic acid 300 mg once daily for 90 days
88886477|NCT01416701|Placebo Comparator|Placebo (cellulose)|
89192085|NCT00727376||Observation|Esophageal cancer patients
89192086|NCT04018482|Experimental|Open label test arm|Subjects will have their right eye treated with 5% Povidone Iodine per standard institutional protocol prior to receiving their intravitreal injection (2 drops of PI followed by application of 3.5% non-preserved lidocaine gel for 10 minutes, followed by 1 drop of PI for 30 seconds prior to injection). Subjects will have their left eye treated with Avenova per the same application protocol as PI prior to receiving their intravitreal injection. Prior to and following disinfecting both eyes but before the injection, a physician will gently swab the inferior conjunctival fornix (white part of each eye below the lower eye lid) with an ocular brush. Swabs will be cultured to compare bacterial counts. Subjects will be asked to complete a questionnaire regarding comfort of the disinfectant and injection procedure in general immediately following the injection and 1-2 hours post-injection.
89192087|NCT00808041||Treatment|Breast cancer patients undergoing hormonal therapy before surgery.
89192088|NCT00727454|Placebo Comparator|1 Control|No treatment
89192089|NCT00727454|Experimental|2 CPAP|Continuous Positive Airway Pressure (CPAP) - REMStar Pro with C-Flex; Respironics, Inc., Murrysville, PA
89192090|NCT00727662|Experimental|1|Yoga
89192091|NCT00727662|Active Comparator|2|A Wellness Seminar series
89192092|NCT00805311|Experimental|CEA Group|Patients will undergo carotid endarterectomy (CEA) and receive medical treatment including medical therapy with statins (at least 10 mg atorvastatin irrespective of the baseline cholesterol level), aspirin (100 mg daily) and antihypertensive therapy (at least 50 mg losartan and 5 mg amlodipine 75 mg daily irrespective of the baseline arterial pressure level). Further conservative medical treatment includes modification of cardiovascular risk factors according to current recommendations.
89192093|NCT00805311|Active Comparator|OMT Group|Patients will receive conservative therapy - optimal medical treatment (OMT) including statins (at least 10 mg atorvastatin irrespective of the baseline cholesterol level), aspirin (100 mg daily) and antihypertensive therapy (at least 50 mg losartan and 5 mg amlodipine 75 mg daily irrespective of the baseline arterial pressure level). Further conservative medical treatment includes modification of cardiovascular risk factors according to current recommendations.
89192094|NCT00726440|Active Comparator|Group1-patient|The patient will be encouraged to use the Navigator® all the time and to modify his treatment according to the continous blood glucose measurements. The patients will follow an educational process in order to adapt insulin doses according to each sensor data.
89192095|NCT00726440|Active Comparator|Group2-diabetologist|"The patient will follow the same educational process as group 1 concerning insulin dose adaptation. They will use the continous glucose monitoring device according to the diabetologist's prescription and they will receive precise instructions to make considering results. The duration of the use of the Navigator® will be increased if one of the following criteria is observed at the consultation each 3 months:~HbA1c>=7.5%~1 severe hypoglycaemia or more~More than 4 benign hypoglycaemia per week~According to these criteria, every 3 months, the duration of the use of the monitoring system will be increased as following:~step 1: 3 sensors per month~step 2: 4 sensors per month~step 3: 5 sensors per month~step 4: continuous use"
89192096|NCT00726440|Placebo Comparator|Group3-Control|Usual follow up with self-monitoring blood glucose.
89192097|NCT04474314|Experimental|Higher dose IMR-687|Oral administration of once daily IMR-687
89192098|NCT04474314|Experimental|Lower Dose IMR-687|Oral administration of once daily IMR-687
89192099|NCT04474314|Placebo Comparator|Placebo|Oral administration of once daily Placebo
89192100|NCT00732290|Active Comparator|1|Clopidogrel then fluoxetine+clopidogrel
89192101|NCT00732290|Active Comparator|2|Fluoxetine+clopidogrel then clopidogrel
89192102|NCT02569788|Experimental|CIRT Arm|Patients included in this arm were treated with carbon ion radiotherapy (CIRT).
89192103|NCT00730002|Active Comparator|1- Healthy Subjects|Healthy Subjects- receive MRA
89192104|NCT00730002|Active Comparator|2 - patients with SLE, no neuropsych|Systemic Lupus Erythematosus(SLE) patients without neuropsychiatric symptoms - receive MRA
89192105|NCT00730002|Active Comparator|3 - patients with SLE with neuropsych|20 symptomatic neuropsychiatric systemic lupus erythematosus(NPSLE) patients.
89192106|NCT00730002|Active Comparator|4- healthy patients from other cohort|10 Healthy Controls (HC) from an existing cohort as part of another sponsored study.
89192107|NCT04460664||Subjects admitted to floor|COVID-19 patients admitted to the floor as initial place of hospitalization
89192108|NCT04460664||Subjects admitted or transferred to ICU|COVID-19 patients admitted to the ICU as initial place of hospitalization or transferred to ICU from floor
89531073|NCT03341117|Placebo Comparator|calcined magnesia|"The patients were randomly assigned to received placebo (calcinaned magnesia),~1 capsule 300 mg before each meal for a period of 90 days."
89531074|NCT05035719||Group 1|Cardiac patients
89535688|NCT05463497|Other|Group 1(N=10)|"Treatment A for Period 1 Treatment C for Period 2 Treatment B for Period 3~*Washout period : No washout period between period 1 and 2, more than 7 days between period 2 and 3"
89410444|NCT02295956|Experimental|Home Based Exercise and Nutrition Program|Series of physical and quality of life assessments administered to participants, taking about 20 minutes to complete. Participants instructed to perform resistance/strengthening exercises for 30 minutes two times each week. Exercise instructional booklet given to all participants describing all exercises. Participants to walk 20-30 minutes at least 3 times a week. Nutrition program discussed with participants. Participants receive phone calls from study staff every 2 weeks for 6 weeks to check for adherence, and if they are having any side effects from the exercise.
89410445|NCT03642561|Experimental|RFA group|Patients in RFA group will accept RFA treatment
89410446|NCT03642561|Active Comparator|TACE group|Patients in TACE group will accept TACE treatment
89410447|NCT03516500|Experimental|Iron Sucrose injection group|The investigators inject Iron Sucrose (100 mg dissolved in 50 mL saline) through a butterfly needle into the bronchus of the targeting segment.
89410448|NCT03642405||Methylphenidate-Group|The group is examined before and after intake of Methylphenidate
89410449|NCT03642405||Methylphenidate and know QT-prolonging SSRI|The group is examined before and after intake of Methylphenidate
89410450|NCT03642405||Methylphenidate and non-QT-prolonging SSRI|The group is examined before and after intake of Methylphenidate
89410451|NCT02299856||Myocarditis|Patients with strong clinical evidence for acute myocarditis (recent infection, elevated troponin and white blood cell count).
89410452|NCT02299856||Healthy Controls|Healthy volunteers without any signs of cardiac disease.
89410453|NCT03513224|Experimental|eDosette|
89410454|NCT03644043||Early stage of MCI symptoms|Subjects with cognitive decline representing MCI symptomology and with previous PET amyloid-beta (Aβ) imaging results.
89410455|NCT05283525|Placebo Comparator|Placebo Group #1 (6.75 gms Once-A-Day)|Placebo Group #1 (1 Dose; 6.75 gms per day): A total of 25 subjects will be given 1 placebo sachet; To be taken one in the morning in an empty stomach over a period of 90 consecutive days
89410456|NCT05283525|Placebo Comparator|Placebo Group #2 (6.75 gms Twice-A-Day)|Placebo Group #2 (2 Doses; 13.5 gms in two divided doses per day): A total of 25 subjects will be given 2 placebo sachets; To be taken one in the morning in an empty stomach and the other in the afternoon in an empty stomach over a period of 90 consecutive days
89410457|NCT05283525|Active Comparator|TRCAP21 Group #1 (6.75 gms Once-A-Day)|TRCAP21 Group #1 (1 Dose; 6.75 gms per day): A total of 25 subjects will be given 1 TRCAP21 sachet; To be taken one in the morning in an empty stomach over a period of 90 consecutive days
89410458|NCT05283525|Active Comparator|TRCAP21 Group #2 (6.75 gms Twice-A-Day)|TRCAP21 Group #2 (2 Doses; 13.5 gms in two divided doses per day): A total of 25 subjects will be given 2 TRCAP21 sachets; To be taken one in the morning in empty stomach and the other in the afternoon in an empty stomach over a period of 90 consecutive days
89410459|NCT03516422|Placebo Comparator|STANDARD CARE GROUP|The subject positioned so absorbent pads are in position to catch irrigation solution. The saline bottle will be held 10-15 cm from wound bed, and squeezed to spray all surfaces of wound in a sweeping motion, from clean to dirty area of wound. Irrigation will be repeated as necessary to remove exudate, slough, and debris from the wound until the solution draining from the wound is clear. Peri-wound skin will be cleansed using gauze and sterile normal saline and dry. Packing material will be applied (Acticoat®) into the wound cavity, undermining, or tunnel to fill the dead space without causing the wound to stretch or bulge or be packed tightly. Packing should be in contact with entire wound base and edges. Dressings changed once every 3 days by the patient's care provider.
88886478|NCT01416727|Experimental|OSkER|"Observed SKills in the Emergency Room - workplace-based supervision."
89410460|NCT03516422|Experimental|ULTRASOUND DEBRIDEMENT GROUP:|Low-frequency ultrasound SonicOne O.R. (Misonix, New York, US) generates ultrasound waves with 22.5 kHz frequency. Each probe is attached to a set of irrigation solution (saline 0.9%), they transform electric energy into mechanical vibrations to induce tiny particles of water from irrigation fluid. Absorbent pads are positioned to catch excess saline. With SonicOne set at continuous mode with minimum pump flow, the debridement will begin at most distal aspect of ulcer with the hand piece in constant motion until entire ulcer surface has been debrided until as much necrotic tissue has been removed. Peri-wound skin will be cleansed using gauze and sterile normal saline and dry. Packing material will be applied (Acticoat®) into wound cavity.
89410461|NCT02293148|Experimental|GSK1278863 (Part A)|All subjects will receive a single, oral 500 mg dose of GSK1278863 on Day 1 administered as 5 x 100 mg tablets of GSK1278863. Additional doses/cohorts may be added depending upon the emerging safety, tolerability, pharmacokinetic and/or pharmacodynamics findings at the 500 mg dose level in Part A
89410462|NCT02293148|Experimental|GSK1278863 (75 mg/500 mg)/Moxifloxacin 400 mg/Placebo (Part B)|Subjects will be assigned to one of four treatment sequences (A-1 x Moxifloxacin placebo tablet, 3 x 25 mg tablets of GSK1278863, 2 x GSK1278863 matched placebo; B-1 x Moxifloxacin placebo tablet, 5 x 100 mg tablets of GSK1278863; C-1 x Moxifloxacin placebo tablet, 5 x GSK1278863 matched placebo tablets; D-1 x 400 mg Moxifloxacin tablet, 5 x GSK1278863 matched placebo tablets) (ABDC, BCAD, CDBA, DACB) in accordance with the randomization schedule
89410463|NCT05283447|Experimental|Intervention|Specific manual therapy for GERD and hiatal hernia
89410464|NCT05283447|Placebo Comparator|Control|Manual therapy unrelated to GERD and hiatal hernia
89410465|NCT02300090||Intervention group|This group of patients (n=250) will receive the digital service (smart phone application and bluetooth inhaler device) in addition to current best care from their healthcare professional.
89410466|NCT02300090||Control group|This group of patients (n=250) will receive current best care alone. Control patients will not have access to the digital service.
89410467|NCT03643887|Experimental|FMT Capsule DE|FMT Capsule DE
89410468|NCT03643887|Placebo Comparator|Placebo Oral Capsule|Placebo Capsule
89410469|NCT03640923|Experimental|experimental group|Child with a proven infection of the mother or both biological parents known to HIV antenatal a swab of mucous membrane will be withdrawed
88886479|NCT01416727|Experimental|EPIC|"Emergency Psychiatry Immersion Course - simulation-based training."
89005115|NCT00228189|Experimental|B|Dendritic cells electroporated with CEA-mRNA
89005116|NCT00228189|Experimental|C|Dendritic cells pulsed with CEA-peptide, in combination with oxaliplatin/capecitabine
89005117|NCT00204737|Active Comparator|Prednisone|Prednisone 20mg daily x 2 weeks
89005118|NCT00204737|Placebo Comparator|placebo|placebo
88819605|NCT02755935|Experimental|Implanted|Subjects who meet the specified inclusion criteria and are implanted with the CI532 cochlear implant
88886480|NCT01416740|Experimental|Indirect MRA|After patient has signed consent and had blood tests to ensure normal kidney function (BUN and Creatinine) as well as serum and urine pregnancy tests for females to ensure there is no pregnancy, the patient will have an Indirect MRA. The participant will be weighed and the correct dose of 0.1 mmol/kg calculated. An IV will be inserted into participant's arm. The gadopentetate dimeglumine will be injected into the IV and the patient will be asked to gently exercise the shoulder (small windmills and flexion/extension) for 5 minutes. The patients then undergo MRI imaging 15-30 minutes after the injection. Contraindications include known allergy to gadopentetate dimeglumine, and renal failure with creatinine clearance of less than 30ml/min.
88886481|NCT01416753|Active Comparator|UCR|regulation of ultrafiltration and conductivity
88886482|NCT01416753|Active Comparator|UTR|regulation of ultrafiltration and temperature
89192109|NCT02570334|Experimental|HIV-infected children diagnosed before 7 months of life|HIV-infected children diagnosed before 7 months of life
88886483|NCT01416753|No Intervention|conventional dialysis|dry weight reduction without BVM
88886484|NCT01416766|No Intervention|Control|Control participants will receive usual care during their year of enrollment. At enrollment, prior to randomization, they will be informed that, if randomized to control status, they will be offered a free BP monitor and the opportunity to receive the study intervention after completing the exit interview in 1 year.
88886485|NCT01416766|Experimental|Intervention|Self-monitoring-nurse-primary care provider feedback loop After randomization, intervention participants will receive the intervention (free home BP monitor, assistance setting up to upload BP readings from home/work or clinic computer; feedback loop with nurse-driven protocols to manage uncontrolled hypertension and maintain control once attained).
89192110|NCT02570334|Experimental|HIV-exposed uninfected children|HIV-uninfected children born to HIV-infected mothers
89192111|NCT02570334|Experimental|HIV-unexposed uninfected children|Children born to HIV-uninfected mothers
89192112|NCT00732446|Active Comparator|2|antibiotic /steroid combination compared with individual administration of steroid and antibiotic
89192113|NCT00732446|Experimental|1|combination antibiotic steroid compared with individual administration of steroid and antibiotic - new therapeutic indication
89192114|NCT04065672|Experimental|Low-dose IL-2|One million units of rhIL-2 was administered subcutaneously five days every week for 4 weeks and then twice a week for 8 weeks. All patients were followed up for 3 months after treatment.
89192115|NCT00732524|Active Comparator|Glipizide arm|Glipizide XL is an insulin secretagogue and is an extended release tablet designed to provide a controlled rate of delivery. Glipizide XL was chosen because it is the most frequently used discharge oral medication in our ED. It has a quick onset of action within a few hours after oral ingestion, lasts for 24 hours and has a powerful glucose lowering effect. In addition, there are very few contraindications to Glipizide XL and there is published literature regarding their use in subjects with severe hyperglycemia
89192116|NCT00732524|Active Comparator|Glipizide + Glargine|Insulin Glargine is a recombinant human basal insulin analog. It was chosen since it is a non-peaking insulin with cover for 24 hours. It can be injected subcutaneously only once a day and has a low incidence of hypoglycemia
89192117|NCT00657267|Experimental|Single-Arm Study|
89192118|NCT00733850|Experimental|1|Kanglaite Injection plus Gemcitabine
89192119|NCT00733850|Active Comparator|2|Gemcitabine
89192120|NCT04016961|Experimental|Animal Assisted Therapy - Dog Session|Therapy dog added to PT and OT session
89192121|NCT04016961|Active Comparator|Treatment as usual - No Dog session|No dog added to PT and OT session - PT and OT session as usual standard of care
89192122|NCT00732602|Active Comparator|B|GLP-2 infusion
89192123|NCT00732602|Placebo Comparator|C|Sodium-chloride infusion
89192124|NCT00732602|Active Comparator|A|GIP-infusion
89192125|NCT00808197|Experimental|1|Observatory, longitudinal, 3-years follow up study
89192126|NCT00727896|Experimental|1 is experimental with SMS|Arm 1 is experimental with SMS intervention
89192127|NCT00727896|Active Comparator|2 is (active comparator) standard care|Arm 2 is the usual care arm (standard care)
89535689|NCT05463497|Other|Group 2(N=10)|"Treatment B for Period 1 Treatment A for Period 2 Treatment C for Period 3~*Washout period : more than 7 days between period 1 and 2, no washout period between period 2 and 3"
89535690|NCT05463497|Other|Group 3(N=10)|"Treatment A for Period I Treatment E Treatment D~*Washout period : No washout period between period 1 and 2, more than 7 days between period 2 and 3"
89192128|NCT00727766|Experimental|Cohort 1|Clofarabine 1 mg for 14 days followed by 14 days of rest. Each cycle is 28 days long.
89192129|NCT00727766|Experimental|Cohort 2|Clofarabine 2 mg for 21 days followed by 7 days of rest. Each cycle is 28 days long.
89192130|NCT00727766|Experimental|Cohort 3|Clofarabine 3 mg for 21 days followed by 7 days of rest. Each cycle is 28 days long.
88819606|NCT01440764|Experimental|F(40), then Saline, then IV.F|"On Test Day 1, participants received Aerosol Furosemide 40mg in 4ml saline by inhalation for 5-10 minutes.~On Test Day 2 (at least 24 hours after Test Day 1), participants received Aerosol Saline 4ml by inhalation for 5-10 minutes.~On Test Day 3 (at least 24 hours after Test Day 2), participants received Furosemide 15 mg diluted in 10 ml of saline by intravenous delivery for 5 minutes."
88819607|NCT01440764|Experimental|IV.F, then F(40), then Saline|"On Test Day 1, participants received Furosemide 15 mg diluted in 10 ml of saline by intravenous delivery for 5 minutes.~On Test Day 2 (at least 24 hours after Test Day 1), participants received Aerosol Furosemide 40mg in 4ml saline by inhalation for 5-10 minutes.~On Test Day 3 (at least 24 hours after Test Day 2), participants received Aerosol Saline 4ml by inhalation for 5-10 minutes."
89192131|NCT00727766|Experimental|Cohort 4|Clofarabine 4 mg for 21 days followed by 7 days of rest. Each cycle is 28 days long.
89192132|NCT00727766|Experimental|Cohort 5|Clofarabine 5 mg for 21 days followed by 7 days of rest. Each cycle is 28 days long.
89192133|NCT00727766|Experimental|Cohort 6|Clofarabine 6 mg for 21 days followed by 7 days of rest. Each cycle is 28 days long.
89192134|NCT00799071|Experimental|posaconazole|posaconazole as antifungal prophylaxis
89192135|NCT00730080||Sapropterin (Kuvan)|Individuals with phenylketonuria (PKU) who are beginning treatment with sapropterin.
88886486|NCT01416779|Experimental|Writing Group|This group will receive the writing intervention.
88886487|NCT01416779|No Intervention|No Intervention|Non Writing Group
88886488|NCT01416792|Experimental|Multiple-pass hemofiltration|
88886489|NCT01416818|Experimental|group 1|
88886490|NCT01416818|Active Comparator|group 2|
88886491|NCT01416818|Placebo Comparator|group 3|
88886492|NCT01416857|No Intervention|MOD|Group evaluated using the currently available ED measure of disability (MOD)
88886493|NCT01416857|Experimental|RDDT|Group will be evaluated using ED Rasch Disability Diagnostic Tool (RDDT)
88886494|NCT01416870|Experimental|Active 1|34 subjects will receive ICI176,334-1without water
88886495|NCT01416870|Experimental|Active 2|34 subjects will receive ICI176,334-1 with water
88886496|NCT01416870|Experimental|Active 3|34 subjects will receive Casodex 80 mg tablet
88886497|NCT01416883|Experimental|Active 1|8 subjects will receive ICI176,334-1
88886498|NCT01416896|Experimental|"New venous needle, the BME needle"|"Hemodialysis using the new venous needle, the BME needle."
88886499|NCT01416896|Active Comparator|"Standard venous needle, the standard needle"|"One hemodialysis using the standard venous needle, the standard needle (device)."
88886500|NCT01416909|Active Comparator|Dose Intervention - Opioid|Laxative Treatment: Participants Receiving Opioids for the Treatment of Pain. Participants will be taken off any laxative preparation they may already be on and will be put on laxative treatment based on the Constipation Treatment Protocol. The dose of laxative will be based on the dose of the opioid pain medication they are receiving.
88886501|NCT01416909|Active Comparator|Assessment Intervention - Opioid|Laxative Treatment: Participants Receiving Opioids for the Treatment of Pain. Participants will be taken off any laxative preparation they may already be on and will be put on laxative treatment based on the Constipation Treatment Protocol. The dose of laxative will be determined based on their severity of constipation.
88886502|NCT01416909|Other|Control Group - Opioid|Standard of Care: Participants Receiving Opioids for the Treatment of Pain will receive their usual care at Moffitt while participating in weekly assessments. After participation in the study is complete, participants will be offered the same protocol that is given to patients in the treatment groups.
88886503|NCT01416909|Active Comparator|Assessment Intervention - Vinca Alkaloid|Laxative Treatment: Participants Receiving a Specific Type of Chemotherapy (vinca alkaloids). Vinca alkaloids include medication such as Vincristine, Vinblastine, or Vinorelbine. Participants will be taken off any laxative preparation they may already be on and will be put on laxative treatment based on the Constipation Treatment Protocol. The dose of laxative will be based on their level of constipation.
88886504|NCT01416909|Other|Control Group - Vinca Alkaloid|Standard of Care: Participants Receiving a Specific Type of Chemotherapy (vinca alkaloids). Vinca alkaloids include medication such as Vincristine, Vinblastine, or Vinorelbine. Patients will receive standard of care while participating in weekly assessments. After participation in the study is complete, participants will be offered the same protocol that is given to patients in the treatment groups.
88886505|NCT01416922||LSIL|Women 21 years of age or older with an LSIL diagnosis
88886506|NCT01416948|Placebo Comparator|Sugar Pill|
88886507|NCT01416948|Active Comparator|Galantamine|
88886508|NCT01416948|Experimental|Methylphenidate|
88886509|NCT01416974|Experimental|consolidative therapy with autologous T cells genetically|A phase I trial of consolidation therapy with autologous T cells genetically targeted to the B cell specific antigen CD19 for patients with chronic lymphocytic leukemia following upfront chemotherapy with pentostatin, cyclophosphamide and rituximab.
88886510|NCT01417013|Active Comparator|Systane Ultra|Systane Ultra Lubricant Eye Drops
88886511|NCT01417013|Active Comparator|Optive|Optive Lubricant eye drops
88886512|NCT01417052|Experimental|50 mg LX3305 QD|
88886513|NCT01417052|Experimental|100 mg LX3305 QD|
88886514|NCT01417052|Experimental|150 mg LX3305 QD|
88886515|NCT01417052|Experimental|200 mg LX3305 QD|
88886516|NCT01417052|Experimental|250 mg LX3305 QD|
88886517|NCT01417052|Experimental|300 mg LX3305 QD|
88886518|NCT01417052|Experimental|400 mg LX3305 QD|
89437525|NCT03720366|Experimental|Arm 2: Administration of enasidenib and Arm 2 probes|Part 1: Subjects will receive prescribed doses of Arm 2 probes on Day -1, followed by the first enasidenib dose on Day 1. Subjects will continue to take enasidenib once daily for 27 more days. On Day 28, subjects will receive the Arm 2 probes again together with the Day 28 dose of enasidenib. Part 2: the subjects continue to receive daily doses of enasidenib for the next 28 days (equivalent to a cycle). The subject will continue in subsequent cycles until the end of the study (28 months) or termination
88886519|NCT01417052|Experimental|250 mg LX3305 BID|
88886520|NCT01417052|Experimental|500 mg LX3305 QD|
88886521|NCT01417052|Placebo Comparator|Placebo|
88886522|NCT01417065|Experimental|Temsirolimus|Starting dose 0.02 mg intravenous administered once.
88886523|NCT01417117||Spontaneous Intracerebral Hemorrhage|Patients with primary intracerebral hemorrhage within 24 hours of admission diagnosed by non-contrast head computed tomography (CT)
88886524|NCT01417130||Naproxen sodium (220 mg b.i.d)|Original assignment in the ADAPT trial
88886525|NCT01417130||Celecoxib (200 mg b.i.d.)|Original assignment in the ADAPT trial
88886526|NCT01417130||Placebo|Original assignment in the ADAPT trial
88886527|NCT01417143|Experimental|TKI258 (Dovitinib)|TKI258 (Dovitinib): 500 mg daily po medication with 5 days on/2 days off schedule. TKI258 (Dovitinib) will be provided by Norvatis for the study purpose. One cycle consists of 4 weeks
88886528|NCT01417169|Experimental|Micafungin|
88886529|NCT01417182|Experimental|Melanoma|
88886530|NCT01417221|Experimental|renal sympathetic modification|Renal artery ablation to modify sympathetic activity in patients with essential hypertension.
88886531|NCT01417221|No Intervention|Absolute medicine therapy|Maintenance of anti-hypertensive medications only
88886532|NCT01417247|Experimental|renal sympathetic modification|Renal artery ablation to modify sympathetic activity in patients with metabolic syndrome.
88886533|NCT01417247|No Intervention|Absolute medicine therapy|Maintenance of anti-metabolic syndrome medications only
88886534|NCT01417260||Nocebo|Told breastfeeding may worsen pain
88886535|NCT01417260||No treatment|Told nothing
89410470|NCT03519152|Experimental|study group one side|All patients were scheduled for open flap debridement surgery on at least two quadrants ≥1 weeks apart.One group will receive Low Dose Diclofenac tablets (25mg Diclofeanc and 325 mg paracetamol), BID for 3 days. The patients who are diagnosed with generalized moderate/severe chronic periodontitis will be included in study. For each quadrant, a flap was raised under local anesthesia (2% lignocaine with 1:80,000 epinephrine). In both the quadrants same technique of anesthesia will be employed. The location and the extent of surgery, volume of the local anesthesia given, and time required to perform the surgical procedure will be recorded in the patient file. Patients will be instructed to complete a pain diary chart for 3 days.
89410471|NCT03519152|Placebo Comparator|study group second side|Other group will receive Diclofeanc (50mg Diclofenac and 325mg paracetamol), BID for 3 days. The patients who are diagnosed with generalized moderate/severe chronic periodontitis were included in study. For each quadrant, aperiodontal flap was raised under local anesthesia (2% lignocaine with 1:80,000 epinephrine). In both the quadrants same technique of anesthesia will be employed. The location and the extent of surgery, volume of the local anesthesia given, and time required to perform the surgical procedure was recorded in the patient file. Patients were instructed to complete a pain diary chart for 3 days.
88886536|NCT01417260||Placebo|Told will improve pain
88886537|NCT01417273|Active Comparator|vitamin A, multiple sclerosis,|Patients with Multiple Sclerosis confirmed Relapsing Remitting Type who receive 25000 IU/day vitamin A for 6 months and 10000 IU/day for next 6 months
88886538|NCT01417273|Placebo Comparator|placebo/Multiple Sclerosis|Patients with Multiple Sclerosis confirmed Relapsing Remitting Type who receive 1 cap of placebo/day
88886539|NCT01417299|Active Comparator|RPh201 group|Patients will receive 400 microliter s.c., of RPh201 twice a week for 3 months
88886540|NCT01417299|Placebo Comparator|placebo group|Patients will receive 400 microliter s.c., of saline twice a week for 3 months
88886541|NCT01417312|Active Comparator|Green tea extract|
89410472|NCT03516344|No Intervention|Control|Subjects will remain at rest in supine position for one minute.
88886542|NCT01417312|Placebo Comparator|Placebo|
88886543|NCT01417338||Pulmonary hypertension group|Patients who were firstly diagnosed as pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension
88886544|NCT01417351|Placebo Comparator|400 IU Vitamin D3|Women in this study arm receive 400 IU of vitamin D3 per day, or what is in a standard prenatal multivitamin. They also receive a placebo study supplement.
88886545|NCT01417351|Experimental|2,000 IU Vitamin D3|Women in this arm receive 2,000 IU vitamin D per day: 400 IU from a standard prenatal multivitamin plus an additional 1,600 IU vitamin D3 in the study supplement.
88886546|NCT01417364|Active Comparator|Testosterone weekly injections continuously|Testosterone enanthate 100 mg Intramuscular (IM) weekly injections throughout the study
88886547|NCT01417364|Experimental|Cyclic testosterone administration|Testosterone injections 100 mg. IM weekly for one month alternating with placebo injections weekly for one month throughout the study
88886548|NCT01417364|Placebo Comparator|Placebo injections|Placebo injections weekly throughout the study.
88886549|NCT01417390|Experimental|Concurrent chemoradiotherapy|Patients receive radical radiotherapy with IMRT and cisplatin (40mg/m2) every week for six cycles during radiotherapy
88886550|NCT01417390|Experimental|Inductive and concurrent|Patients receive Gemcitabine (1000mg/m2 on day 1,8) and cisplatin (20mg/m2 on day 1-4) every three weeks for two cycles before the radiotherapy, then receive radical radiotherapy with IMRT and cisplatin (40mg/m2) every week for six cycles during radiotherapy.
88886551|NCT01417403|Experimental|Treatment (radiosensitization therapy)|Beginning 3 days before the initiation of radiotherapy, patients receive hydroxychloroquine PO QD or BID. Treatment continues until completion of radiotherapy.
88886552|NCT01417416||with combat training stress|
88886553|NCT01417416||without combat training stress|
88886554|NCT01417429|Active Comparator|Galantamine|galantamine will be given with intravenous nicotine
88886555|NCT01417429|Experimental|Nicotine|Subject will be given IV Nicotine
88886556|NCT01417442|Experimental|BRAF V600E POSITIVITY|This mutation will be analysed using the tumor tissues of the patients operated for thyroid diseases and diagnosed with papillary thyroid carcinoma. And mutation positive patients will be investigated for the aggressive characteristics of the tumor.
89410473|NCT03516344|Experimental|Iliac psoas muscle|In supine position with a high-density foam cushion under the subject's feet, they will be asked to make a push in the caudal direction, against the cushion, alternating between both feet with their knees stretched out, for one minute
88886557|NCT01417468|Experimental|CLSI - Known|Participants will be assigned to a specific learning group via the Canfield Learning Style Inventory (CLSI).
89410474|NCT03516344|Experimental|Diaphragmatic Breathing|Subjects perform five cycles of diaphragmatic breathing in the supine position.
88886558|NCT01417468|Active Comparator|CLSI - Unknown|Participants will be assigned to a traditional learning group (Control).
89410475|NCT03516344|Experimental|Liver pumping|A technique of hepatic supine pumping is performed by simultaneous compression in the right hypochondrium and epigastrium, in the opposite direction, during the inspiratory phase, stopping during the expiratory phase and repeating the maneuver for five respiratory cycles.
89410476|NCT03516344|Experimental|Spinal manipulation|A semi-direct vertebral manipulation, type Dog Technique in extension, will be performed on level D8
89410477|NCT02959983|Active Comparator|Eluxadoline|Eluxadoline 100 mg oral tablets twice daily (BID) with food for 12 weeks.
89410478|NCT02959983|Placebo Comparator|Placebo|Placebo matching eluxadoline oral tablets BID with food for 12 weeks.
89410479|NCT02293226|Experimental|Child ETI with chest compressions|endotracheal intubation (ETI) during child mannikin resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
88886559|NCT01417494|Experimental|Chemotherapy associated with bevacizumab|Chemotherapy (FOLFIRI, FOLFOX, LV5FU2) associated with bevacizumab
88886560|NCT01417494|Active Comparator|Chemotherapy|Chemotherapy (FOLFIRI, FOLFOX, LV5FU2)
88886561|NCT01417507||Supportive care (neurocognitive assessment and MRI)|"Patients undergo neurocognitive assessment using the CogState Test battery (the DET, the IDN, the OCLT, and the GMLT) at baseline* and at 12, 24, 36, 42, 48, 54, and 60 months. Patients also complete the EORTC QOL-30, the BCM20, and the EQ-5D questionnaires at baseline*, at 12, 24, 36, 48, and 60 months afterwards, and before undergoing any further treatment. Patients are instructed to complete a seizure and medication diary during study.~Patients undergo MRI scans at baseline*, at 12, 24, 36, 48, and 60 months, and at the time of radiological, clinical, or neurological failure."
88886562|NCT01417520||ECD|ECD patients of any gender and ethnicity age 2-80 years are eligible to enroll in this protocol
88886563|NCT01417546|Experimental|1|NHS-IL12 escalating doses on a 4 week schedule (Completed).
88886564|NCT01417546|Experimental|2|NHS-IL12 escalating doses on a 2 week schedule
88886565|NCT01417546|Experimental|3|NHS-IL12 expansion group on a 4 week schedule (Completed).
88886566|NCT01417572|Experimental|lidocaine|
88886567|NCT01417598|Experimental|Gait and balance group training|The balance-training program is based on scientifically well-established principles of exercise training and postural control as well as current research on training in elderly and PD. For the PD group it has been modified based on the current knowledge of the neurophysiology and the inevitable constraints on mobility and postural control resulting from basal ganglia degeneration. The training will be conducted as a progressive individually adjusted group program, led by experienced physiotherapists and researchers in order to challenge the specific balance disorder of every participant and endorse progression. It is progressive and specific balance program including dual- and multitasks. The program is performed 3 times/week for 10-12 weeks.
88886568|NCT01417598|Experimental|Gait and balance trainig + nordic walking|(only for Osteoporosis group)
88886569|NCT01417598|No Intervention|Control group|
88886570|NCT01417611|Experimental|i-scan-CE/SE|Study Group using i-scan SE and CE mode: i-scan-CE/SE group was explored whole colon from the cecum to the rectum with i-scan-CE 2+ and SE 2+ mode. They had a chance to switch from i-scan to WL to perform polyp removal using cold biopsy or polypectomy
88886571|NCT01417611|Experimental|i-scan-CE/SE/TE-c|Study Group using i-scan SE & CE mode as well as TE-c mode: i-scan-CE/SE/TE-c group was explored whole colon from the cecum to the rectum with i-scan CE2+, SE2+, TE-c mode. They had a chance to switch from i-scan to WL to perform polyp removal using cold biopsy or polypectomy
88886572|NCT01417624|Placebo Comparator|Control Group - Standard|"This will be a randomised controlled unblinded prospective study recruiting patients in sinus rhythm with LBBB (QRS width ≥ 120ms) and a LV ejection fraction of below 35% who meet the current guidelines for CRT implantation. Patients will be randomised to one of two groups (1:1 randomisation)~Conventional LV lead placement - the LV lead will be placed according to standard techniques without knowledge of the patient's CMR findings"
88922028|NCT05956002|Experimental|Sequence 1|Single oral dose of etrasimod 2 mg clinical IR tablet under fasted conditions (Reference) followed by single oral dose of etrasimod 2 mg mini tablets mixed with applesauce under fasted conditions (Test 1) followed by single oral dose of etrasimod 2 mg mini tablets mixed with chocolate pudding under fasted conditions (Test 2) followed by single oral dose of etrasimod 2 mg mini tablets mixed with water under fasted conditions (Test 3) followed by single oral dose of etrasimod 2 mg mini tablets mixed with yogurt under fasted conditions (Test 4)
89005119|NCT00198380|Experimental|1|
89005120|NCT00198419|Experimental|Vitrase|a single intradermal dose of 3 USP Units of Vitrase (ovine hyaluronidase) at one site and the same volume of saline at a distant site for comparative control
89005121|NCT00228306|Experimental|1|
89005122|NCT00228306|No Intervention|2|Control Group
89410480|NCT02293226|Experimental|Infant ETI with chest compressions|endotracheal intubation (ETI) during infant mannikin resuscitation with uninterrupted chest compressions
89410481|NCT03513146|Experimental|OPAMM group|"During the pre-feeding period, infants will receive mother's colostrum (to the maximum of 0.2 ml) by dropper to the oro-pharyngeal pouch, tongue and cheeks every 2 to 4 hours.~When an infant fits the criteria to start enteral feeding, 0.2 ml of own mother's milk will be given by dropper to the oro-pharyngeal pouch, tongue and cheeks and the remaining amount will be given by the regular gavage feeding on intervals and amount regulated by the feeding protocol.~This practice will be continued till the infants reach full oral feeding."
89410482|NCT03513146|No Intervention|Control Group|"During the pre-feeding period, preterm infants will remain NPO. When an infant fits the criteria to start enteral feeding, own mother's colostrum or milk will be given by the regular gavage feeding on intervals regulated by the feeding protocol.~This practice will be continued till the infants reach full oral feeding."
88886573|NCT01417624|Active Comparator|Active CMR guided Arm|"This will be a randomised controlled unblinded prospective study recruiting patients in sinus rhythm with LBBB (QRS width ≥ 120ms) and a LV ejection fraction of below 35% who meet the current guidelines for CRT implantation.Patients will be randomised to one of two groups (1:1 randomisation):~CMR guided LV lead placement - an expert panel will decide pre-operatively the optimal branch of the coronary sinus for LV lead placement based on the presence of myocardial scar tissue and coronary sinus anatomy. The operator will informed as to the optimal vein to target for delivery of the LV lead. Should this be technically unfeasible (e.g. due to pacing considerations or stability of LV lead position), then the most suitable vein will be used at the time of implantation."
88886574|NCT01417637|Active Comparator|low level laser|"In this group, the 890 nm diode laser (Ga As) Mustang 2000+, Russia) with frequency of 1500 Hz, and dose of 2 J/cm2 per point in the painful muscles.~Laser therapy for both the treatment and placebo groups will be applied on all painful muscles three times a week for four weeks."
88886575|NCT01417637|Placebo Comparator|Placebo|In Group 2 (placebo) the low power laser will be applied with a minimal dose that is very lower than the threshold necessary for therapeutic effects.
88886576|NCT01417650|Active Comparator|laser|In this group, the 890 nm diode laser (Mustang 2000+,Russia) will be used with frequency of 1500 Hz, and dose of 2 J/cm2 per point in the joint area and painful muscles if any.
88886577|NCT01417650|Placebo Comparator|placebo|In this group the low power laser will be applied with minimal dose that is very lower than the threshold necessary for therapeutic effects.
88886578|NCT01417663|Placebo Comparator|Alagebrium|"In this study there will be four different groups:~One Alagebrium 100 mg twice daily and exercise training 3x/week Two Placebo twice daily and exercise training 3x/week Three Alagebrium 100 mg twice daily and no exercise training Four Placebo twice daily and no exercise training"
88886579|NCT01417663|Other|Exercise training|"In this study there will be four different groups:~One Alagebrium 100 mg twice daily and exercise training 3x/week Two Placebo twice daily and exercise training 3x/week Three Alagebrium 100 mg twice daily and no exercise training Four Placebo twice daily and no exercise training"
88886580|NCT01417676|Experimental|Radiation|
88886581|NCT01417689|Active Comparator|Open-eyes|Patients in this arm are encourage to attempt eye drop instillation using the most commonly used technique that involves looking up, pulling inferior lid down and putting the drop in the inferior cul de sac.
88886582|NCT01417689|Experimental|Closed-eyes|Patients in this group are encouraged to attempt eye drop instillation with both eyes closed near the medial canthal region. After feeling contact with the drop on the skin the drop is expected to enter the eye when opening the eye and resuming blinking.
88886583|NCT01417702||Crohn´s disease - active|Patients in the active phase of the disease
88886584|NCT01417702||Crohn´s disease - quiescent|Patients in the quiescent phase of the disease
88886585|NCT01417702||Ulcerative colitis - active|Patients in the active phase of the disease
88886586|NCT01417702||Ucerative colitis - quiescent|Patients in the quiescent phase of the disease
88886587|NCT01417715||Crohn´s disease - active|Patients with Crohn´s disease in the active phase.
88886588|NCT01417715||Crohn´s disease - quiescent|Patients with Crohn´s disease in the quiescent phase.
88886589|NCT01417715||Ulcerative colitis - active|Patients with ulcerative colitis in the active stage.
88886590|NCT01417715||Ucerative colitis - quiescent|Patients with ulcerative colitis in the quiescent stage.
88886591|NCT01417754|Other|Toremifene|
88886592|NCT01417767|Experimental|CHG regimen|one course of CHG regimen (low-dose cytarabine, homoharringtonine and G-CSF priming)
88886593|NCT01417767|Active Comparator|Decitabine|one course of Decitabine (5-aza-deoxycytidine,Dacogen)
88886594|NCT01417819|Other|SMS reminder|SMS reminders four days and one day before their appointments
88886595|NCT01417832|Experimental|Treatment with Infiltrant/Adhesive|In this split-mouth design study, one of the three randomly selected approximal lesions will be treated with an infiltrant resin, one will be treated with an adhesive resin.
88886596|NCT01417832|Placebo Comparator|Placebo, placebo treatment|In this split-mouth design study, one of the three randomly selected approximal lesions will be treated with a placebo treatment: At baseline one caries lesion was cleaned with a microbrush for 30 seconds and the procedure was repeated after two minutes.
88886597|NCT01417845|Experimental|High Intensity Exercise|High intensity resistance and aerobic training
88886598|NCT01417845|Active Comparator|Moderate Intensity Exercise|Moderate intensity resistance and aerobic training
88886599|NCT01417858|Active Comparator|brimonidine 0.2%|
88886600|NCT01417858|Active Comparator|brimonidine 0.1%|
88886601|NCT01417871||case goup|Lifestyle counseling, ABC program
88886602|NCT01417871||control group|usual care
88886603|NCT01417884||ischemic heart disease|stable coronary artery disease, acute coronary syndromes
89410483|NCT03518996|Experimental|TMS/tACS|Subjects will receive 5 days of 3x daily rTMS (intermittent theta burst stimulation) or tACS (transcranial alternating current stimulation) targeted over the cerebellum.
88886604|NCT01417884||non-ischemic heart disease|inflammatory heart disease, heart failure (non-ischemic), valvular heart disease
89192136|NCT00730080||Control|Healthy individuals without phenylketonuria (PKU).
89005123|NCT00198458|Experimental|Vitrase|A single intradermal dose of 4.5 USP units of Vitrase at one site and the same volume of saline at a distant site for comparative control.
89005124|NCT00198497|Experimental|Vitrase|Single Hyaluronidase ophthalmic intravitreal injection
89005125|NCT00198497|Placebo Comparator|Placebo|Single Saline solution intravitreal injection
89005126|NCT00198536|Experimental|Ecabet 2.83%|Ecabet ophthalmic solution One drop in study eye 4 times daily for 90 days.
89005127|NCT00198536|Experimental|Ecabet 3.70%|Ecabet ophthalmic solution One drop in study eye 4 times daily for 90 days.
89005128|NCT00198536|Placebo Comparator|Vehicle|One drop of vehicle in study eye 4 times daily for 90 days.
89005129|NCT00409994|Experimental|Rapamycine|rapamycine 6 mg dd
89005130|NCT00231582|Experimental|1|1
89005131|NCT04721574|Active Comparator|Bright light therapy|Daily exposure to a high brightness LED light box for 30 minutes as soon as possible after awakening, preferably between 7 and 8 AM in the patient's hospital room The device emits 10,000 lux of cool-white fluorescent light at 50-75 cm from the screen to the cornea with an ultraviolet filter
89005132|NCT04721574|Sham Comparator|Sham Therapy|Light-therapy with filters that reduced lamp output to less than 50 lux. for 30 minutes as soon as possible after awakening.
89005133|NCT02963324|Experimental|Ivermectin|Single dose of ivermectin 12 mg (as 4 tablets of Stromectol (R) 3 mg) orally
89005134|NCT00474526|Experimental|US1A (MenACWY-CRM + Infant Vaccines)|"Received vaccines:~MenACWY: 2, 4, 6, and 12 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~Pneumococcal, HAV, and MMR-V: 12 months"
89005135|NCT00474526|Experimental|US1B (MenACWY-CRM + Infant Vaccines)|"Received vaccines:~MenACWY: 2, 4, 6, and 13 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~Pneumococcal, HAV, and MMR-V: 12 months"
89005136|NCT00474526|Experimental|US2 (Infant Vaccines Only)|"Received vaccines:~MenACWY: 12 and 15 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~Pneumococcal, HAV, and MMR-V: 12 months"
89005137|NCT00474526|Experimental|US3 (MenACWY-CRM + Infant Vaccines)|"Received vaccines:~MenACWY: 2, 4, 6, and 12 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~Pneumococcal, HAV, and MMR-V: 12 months"
89005138|NCT00474526|Experimental|US4A (Infant Vaccines Only)|"Received vaccines:~MenACWY: 12 and 15 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~Pneumococcal, HAV, and MMR-V: 12 months"
89005139|NCT00474526|Experimental|US4B (Infant Vaccines Only)|"Received vaccines:~MenACWY: 13 and 15 months DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~Pneumococcal, HAV, and MMR-V: 12 months"
89005140|NCT00474526|Experimental|US4C (Infant Vaccines Only)|"Received vaccines:~MenACWY: 18 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~Pneumococcal, HAV, and MMR-V: 12 months"
89005141|NCT00474526|Experimental|LA1A (MenACWY-CRM + Infant Vaccines)|"Received vaccines:~MenACWY: 2, 6, and 12 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months Pneumococcal, HAV, and MMR-V: 12 months"
89005142|NCT00474526|Experimental|LA1B (MenACWY-CRM + Infant Vaccines)|"Received vaccines:~MenACWY: 2, 6, and 13 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~Pneumococcal, HAV, and MMR-V: 12 months"
89005143|NCT00474526|Experimental|LA2 (Infant Vaccines Only)|"Received vaccines:~MenACWY: 12 and 15 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~Pneumococcal, HAV, and MMR-V: 12 months"
89005144|NCT00474526|Experimental|LA3A (MenACWY-CRM + Infant Vaccines)|"Received vaccines:~MenACWY: 2, 4, 6, and 16 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~DTaP, Hib: 16 months~Pneumococcal, HAV, and MMR-V: 12 months"
89005145|NCT00474526|Experimental|LA3B (MenACWY-CRM + Infant Vaccines)|"Received vaccines:~MenACWY: 2, 4, 6, and 17 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~DTaP, Hib: 16 months~Pneumococcal, HAV, and MMR-V: 12 months"
89005146|NCT00474526|Experimental|LA4 (Infant Vaccines Only)|"Received vaccines:~MenACWY: 12 and 15 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~DTaP, Hib: 15 months~Pneumococcal, HAV, and MMR-V: 12 months"
89005147|NCT00474526|Experimental|LA5 (MenACWY-CRM + Infant Vaccines)|"Received vaccines:~MenACWY: 2, 4, 6, and 12 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~Pneumococcal, HAV, and MMR-V: 12 months"
89005148|NCT00474526|Experimental|LA6A (Infant Vaccines Only)|"Received vaccines:~MenACWY: 12, and 15 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~Pneumococcal, HAV, and MMR-V: 12 months"
89005149|NCT00474526|Experimental|LA6B (Infant Vaccines Only)|"Received vaccines:~MenACWY: 13 and 15 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~Pneumococcal, HAV, and MMR-V: 12 months"
89005150|NCT00474526|Experimental|LA6C (Infant Vaccines Only)|"Received vaccines:~MenACWY: 18 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~Pneumococcal, HAV, and MMR-V: 12 months"
89005151|NCT00198770|Experimental|Crossover design - 1 arm|Meat week followed by mushroom week, counterbalanced order
89005152|NCT04722081|Experimental|Control Group|children received selected physical therapy exercises
89005153|NCT04722081|Experimental|Study Group|children received selected physical therapy exercises plus virtual reality training
89005154|NCT00478738|Other|GSK961081|GSK961081
89005155|NCT00228696|No Intervention|screening|this is a screening study and no intervention.
89410484|NCT03518996|Sham Comparator|Sham TMS/tACS|Subjects will receive 5 days of 3x daily sham stimulation of the cerebellum.
89410485|NCT01344447|Experimental|Arm 1|
89410486|NCT03516188|Experimental|Alginate-antacid group|Participants will take normal meals with late night supper (i.e.two chicken burgers and one cup or 250 ml of teh-tarik) plus alginate-antacid.
88886605|NCT01417897|Experimental|Insulin Glulisine: bolus injections before each main meal|Patients are already on an Insulin Glargine therapy when they start and will them after randomization receive additionally Insulin Glulisine bolus injections before each of the main meals.
88886606|NCT01417897|Active Comparator|Insulin Aspart: bolus injections before each main meal|Patients are already on an Insulin Glargine ± metformin therapy when they start the start and will them after randomization receive additionally Insulin Aspart bolus injections before each of the main meals.
88886607|NCT01417897|Active Comparator|Regular human insulin:bolus injections before each main meal|Patients are already on an Insulin Glargine ± metformin therapy when they start the start and will them after randomization receive additionally regular human insulin bolus injections before each of the main meals.
88886608|NCT01417910||Peripheral vascular disease|Subjects who have peripheral vascular disease
88886609|NCT01417923|Experimental|vitamin D|We enrolled 80 patients of the age 18-80 years suffering from chronic musculo-skeletal pain (low back pain, fibromyalgia, chronic widespread pain) at least 6 months. The 40 patients will receive daily doses of 4000 units of vitamin D for 6 weeks
88886610|NCT01417949|Active Comparator|Immediate arm|Immediate arm: ART should be initiated as soon as possible but no later than 3 days after initiation of OI treatment.
88886611|NCT01417949|Active Comparator|Deferred arm|Deferred arm: ART should be initiated after the completion of OI treatment which is achieved at the earliest at day 21 for PCP and at day 28 for TE. ART should be initiated no later than 6 weeks after initiation of OI treatment.
88886612|NCT01417962||Fetuses|Still birth and Termination of pregnancies
88886613|NCT01417962||Children|Includes Newborns, Infants and Children
88886614|NCT01417975|Experimental|Moderate Exercise Group|The moderate exercise condition will involve participants waking briskly (equivalent to moderate intensity) on a treadmill for 10 minutes. Moderate intensity exercise is defined as 40-68% of heart rate reserve (HRR). Heart rate (HR) will be monitored using a Polar RS100 Heart Rate monitor to serve as a guide for participants to attain the appropriate intensity.
88886615|NCT01417975|Active Comparator|Passive Sitting Group|The passive sitting condition will involve participants sitting passively in a chair for 10 minutes. Heart rate (HR) will be monitored in participants of the passive sitting group to help maintain group equivalency (with the moderate exercise condition) with regards to distraction effects and researcher contact.
88886616|NCT01417988|Experimental|Empiric TB treatment|Empiric initiation of 4 drug TB treatment (8 weeks of 4 drug, 16 weeks of 2 drug therapy) followed by ART (efavirenz-based) within 2 weeks
88886617|NCT01417988|Active Comparator|ART only arm|ART (efavirenz-based) only (+ pyridoxine 50mg) given within 2 weeks after enrolment
88886618|NCT01418027|Experimental|Intensive exercise|The subjects receive an intensive exercise for 6 months and a subsequent conventional exercise for another 6 months.
88886619|NCT01418027|No Intervention|Lifestyle counseling|Subjects receive a general lifestyle counseling for 12 months
88886620|NCT01418027|Experimental|Regular exercise|Subjects receive conventional exercise for 12 months
88886621|NCT01418040||High risk prostate cancer|Histologically confirmed patients with high risk prostate cancer seen at Calvary Mater Newcastle.
88886622|NCT01418053|Experimental|Hot Cataplasm with Caraway Oil|
89410487|NCT03516188|Experimental|Non antacid alginate group|Participants will take normal meals with late night supper (i.e.two chicken burgers and one cup or 250 ml of teh-tarik) plus antacid alone.
88886623|NCT01418053|Active Comparator|Hot Cataplasm with Olive oil|
88886624|NCT01418053|Active Comparator|Cold cataplasm with Olive oil|
88886625|NCT01418066|Placebo Comparator|Placebo|Tea decoction made of Graminis Flores abd Maidis stigmata.
88886626|NCT01418066|Experimental|Ayurvedic herbs|Tea decoction made of Murraya koenigii leaves, Punica granatum and Curcuma
88886627|NCT01418079|Experimental|PMS-3000|Human volunteers undergo oxygen desaturation in order to determine the accuracy of the device over a clinical range of oxygen saturations 70 - 100%.
88886628|NCT01418105|Active Comparator|Videofluroscopic swallow study (VFSS)|To investigate the swallowing ability of patients with neurologic problems
89410488|NCT03513068|No Intervention|Standard Of Care (SOC)|Standard of care long-term oxygen therapy
88886629|NCT01418105|Active Comparator|cervical spine isometric excercises|isometric exercises in patients with cervical spine scoliosis
88886630|NCT01418105|Active Comparator|Fiberoptic endoscopic esophageal study (FEES)|To investigate the anatomic structures during swallowing of patients with neurologic problems
88886631|NCT01418118|Experimental|Pressors|Epinephrine, Norepinephrine, Dobutamine, Dopexamine
88886632|NCT01418131|Active Comparator|Rectal tacrolimus|Active medications - Rectal tacrolimus made as an ointment at a concentration of 0.5mg/ml 3mls will be applied rectally twice a day
88886633|NCT01418131|Placebo Comparator|Rectal Placebo|Placebo 3ml applied rectally twice a day. Identical to Interventional agent expect for the lack of tacrolimus
88886634|NCT01418144|Experimental|Transversus abdominis plane (TAP) block|Transversus abdominis plane (TAP) block with ropivacaine
89410489|NCT03513068|Experimental|SOC + POC (Portable Oxygen Concentrator)|Standard of care long-term oxygen therapy + POC
89410490|NCT03516110||Prostate cancer subjects 60-<70 years|
89410491|NCT03516110||Prostate cancer subjects 70-<75 years|
88886635|NCT01418144|Placebo Comparator|Block with saline|Bilateral placement of 20 ml of saline 0,9% in the transversus abdominis plane
88886636|NCT01418157|Active Comparator|Acetazolamide|
88886637|NCT01418157|Placebo Comparator|Placebo|
89192137|NCT02569268||exposure population|No special intervention(s) .
89410492|NCT03516110||Prostate cancer subjects ≥ 75 years|
89410493|NCT02293304|Experimental|Self-etch approach|Application of universal adhesive as self-etch mode
89410494|NCT02293304|Experimental|Etch-and-rinse approach|Application of universal adhesive as etch-and-rinse mode
89005156|NCT00478426|Experimental|Treatment (sunitinib malate)|Patients receive sunitinib malate PO QD on days 1-28. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
89005157|NCT00228891|Active Comparator|2|Patients with diagnosed diabetic neuropathy will receive objective baseline testing and follow up testing every six months after the start of Pulsatile intravenous insulin therapy to monitor and assess diabetic neuropathy.
89192138|NCT04066920|Experimental|IBER treatment arm|This is the only arm in a single-arm phase II study.
88813890|NCT01045460|Experimental|ASCT + MILs + vaccine|Cyclophosphamide and filgrastim will be given to mobilize peripheral blood stem cells. Leukapheresis will be performed to collect peripheral blood from which activated marrow infiltrating lymphocytes will be produced. A melphalan conditioning regimen will be used prior to autologous stem cell transplant, and the MILs product will be administered on Days 3 and 4. The allogeneic myeloma vaccine will be administered on Days 21, 60, 180, and 300.
88813891|NCT03004313|Experimental|Migraine|"20 subjects experiencing 1-14 migraines per month will undergo the following:~Blood and urine samples will be collected~Complete a series of questionnaires; some of which will be completed daily~Quantitative Sensory Test (QST)will be performed~Magnetic Resonance Imaging (MRI)~PET imaging (during and outside of a migraine attack)"
88813892|NCT03004313|Active Comparator|Healthy|"20 healthy subjects will undergo the following:~Blood and urine samples will be collected~Complete a series of questionnaires; some of which will be completed daily~Quantitative Sensory Test (QST)will be performed~Magnetic Resonance Imaging (MRI)~PET imaging"
88813893|NCT03403790||Patients with depression in bipolar disorder|Patients with depression in bipolar disorder who are treated with quetiapine extended-release tablets for the first time
88813894|NCT05014919|Experimental|Vortioxetine -open label treatment period|"Vortioxetine - 5, 10, 15, and 20 mg/day, film-coated tablets, orally once daily.~Patients will receive a targeted dose of 10 mg/day vortioxetine, however the investigator has the possibility to adjust the dose in case of unsatisfactory response or in case of dose-limiting adverse events."
88813895|NCT05014919|Experimental|Vortioxetine -double-blind relapse prevention period|"Vortioxetine - 5, 10, 15, and 20 mg/day, encapsulated film-coated tables, orally once daily.~In the double-blind period, the patients will continue on the same fixed dose as during the end of the open label period"
88813896|NCT05014919|Placebo Comparator|Placebo -double-blind relapse prevention period|Placebo - encapsulated tablets, orally once daily.
88813897|NCT03403556|Experimental|Rosuvamibe ® Tab.|Rosuvastatin 10mg/Ezetimibe10mg
88813898|NCT03403556|Active Comparator|Monorova ® Tab.|Rosuvastatin 20mg
88813899|NCT05672537|Experimental|Durvalumab Combined with GemCis Neoadjuvant Therapy Group|
88813900|NCT05672537|Experimental|Surgical treatment group|
88813901|NCT03834428|Active Comparator|No Text Message Control|Participants randomized to this arm will receive education about the ICOUGH protocol which includes the importance of ambulation.
88813902|NCT03834428|Experimental|Text Message Intervention|Participants randomized to this arm will receive daily text message reminders to ambulate in the hospital in addition to education about the ICOUGH protocol which includes the importance of ambulation.
88813903|NCT03003845||Interstitial Cystitis|Patients with Interstitial Cystitis will be followed with Questionnaires and blood collection at 3, 6,and 12 months
88813904|NCT03400670|Active Comparator|Ventilator NCPAP|neonatal ventilator (SLE; Specialised Laboratory Equipment, UK) PEEP: 5 cmH2O
88813905|NCT03400670|Active Comparator|Infant Flow-driver NCPAP|infant flow-driver device (Infant Flow System, Viasys Corp., USA) PEEP:5-8 cmH2O, This group receive variable flow
88813906|NCT03400592|Experimental|irinotecan and nimotuzumab|Administration of irinotecan 180 mg/m2 IV once every 2 weeks and nimotuzumab 400 mg IV once weekly
88813907|NCT02218463|Active Comparator|Cetaphil|Apply a pea-sized amount to the labial adhesion with lateral traction twice daily
88813908|NCT02218463|Active Comparator|Estradiol Cream 0.01%|Apply a pea-sized amount to the labial adhesion with lateral traction twice daily
88813909|NCT03403478|No Intervention|Control group|The volunteers will be instructed to remain in an orthostatic position immersed in water up to the imaginary line of the xiphoid process for 45 minutes without performing jerky body movements.
88813910|NCT03403478|Experimental|LICE|The light-intensity continuou exercise (LICE) session comprises a 45-minute of guide walking into the pool at 55-60% of maximum heart rate (HRmax). The HR will be checked every 2 minutes during the whole session.
89410495|NCT03621267|Experimental|Interactive Stepping Exercise|"Interactive Stepping Exercise (1 hour, 3 times/week, 12 weeks)~The 1-hour training program will start with10 minutes warm-up session, after that 40 minutes of ISE, and ended with 10 minutes of cool down session.~Interactive Stepping Exercise (ISE) will perform on a thin mat that was partitioned into 24 squares. The ISE program included forward, backward, lateral and oblique steps, and step patterns were progressively made more complicated."
88886638|NCT01418170|Experimental|Two rcSMT group|A rcSMT will be performed to the C5-C6 segment. A thrust maneuver will then be given to the C5-C6 segment. A rotational inferior drop thrust maneuver will be performed. Immediately after the first rcSMT the subject will turn over on the chiropractic table to lie in the prone position for a post-rcSMT PPT measurement with the same algometer performed by the research assistant. These will be taken at 5-minute intervals. A second rcSMT will be performed at 30 minutes after the first rcSMT. The invention protocol will be repeated. The subject will turn over to the prone position for repeat PPT measurements at 5-minute intervals post-rcSMT for 30 mins. Once the subject has left the treatment area the clinician will mark on the treatment card whether the rcSMT was performed with or without cavitation for quality control purposes.
88886639|NCT01418170|Sham Comparator|One scSMT + One rcSMT Group|A scSMT will be performed with the contact hand of the clinician resting lightly on the paraspinal area of the neck of the subject. The subject's head will be rotated to 45 degrees and supported by the clinician's forearm, lying on headpiece. A inferior drop thrust will be applied to the drop piece. After the first scSMT maneuver the subject will turn over on the chiropractic table to lie in the prone position for a post-scSMT PPT measurement. PPT measurements will be taken at 5-minute intervals for 30 minutes. A rcSMT will be performed 30 minutes after the first scSMT. The subject will turn over to the prone position for repeat PPT measurements in 5-minute intervals for 30 minutes post-rcSMT. Once the subject has left the treatment area the clinician will mark on the treatment card weather the scSMT was performed adequately without cavitation and whether a cavitation occurred with the rcSMT.
88886640|NCT01418183|Experimental|5ml 5% levobupivacaine|5ml 5% levobupivacaine to both maxillary and mandibular branches of trigeminal nerve on experimental side. (total 10ml)
88886641|NCT01418183|Placebo Comparator|5ml normal saline|5ml for maxillary and mandibular branches of trigeminal nerve (total 10ml on controlled side)
88886642|NCT01418183|Experimental|2.5ml 5% levobupivacaine|2.5ml 5% levobupivacaine to both maxillary and mandibular branches of trigeminal nerve on experimental side. (total 10ml)
88886643|NCT01418235|Experimental|Group 1: MVA-C + gp140/MF59|
88886644|NCT01418235|Experimental|Group 2: MVA-C + gp140/MF59|
88886645|NCT01418235|Experimental|Group 3: DNA-C2 + MVA-C|
88886646|NCT01418235|Experimental|Group 4: DNA-C2 + MVA-C + gp140/MF59|
88886647|NCT01418274|Experimental|Single arm|
88886648|NCT01418287||Hospitalized|Subjects who are hospitalized due to influenza-like illness
88886649|NCT01418287||Non-hospitalized|Subjects who are not hospitalized
88886650|NCT01418300|Active Comparator|sequential therapy|first five day amoxicillin+PPI later five day PPI+clarithromycin+metronidazole
88886651|NCT01418300|Active Comparator|conventional triple thearpy|PPI+amoxicillin+clarithromycin
88886652|NCT01418313||DCE-MRI|Magnetic resonance imaging (MRI) with and without FDA approved contrast agents: MRI is a non invasive imaging technique used to visualize the internal structure of the body in detail. The MRI machine is an oversized magnet that is always on. It will be used in this study to provide anatomical and functional (MRI with contrast) information about atherosclerotic plaques.
88886653|NCT01418313||PET/CT and PET/MR|Positron emission tomography (PET)/ computer tomography (CT): PET is a nuclear medicine imaging technique, which produces images of functional processes in the body. The system detects pairs of gamma rays emitted indirectly by a positron-emitting radionuclide (tracer), which is introduced into the body on a biologically active molecule. Nowadays PET imaging is most useful in combination with anatomical imaging, such as CT scanners, thereby PET scanners are now available with integrated high-end multi-detector row CT scanners. Because the two scans can be performed in immediate sequence during the same session and with the patient not changing position between the two scans, areas of abnormality on PET images can be directly correlated with anatomy on the CT images.
88886654|NCT01418313||PET/MR|Positron emission tomography (PET)/MRI: PET is a nuclear medicine imaging technique, which produces images of functional processes in the body. The system detects pairs of gamma rays emitted indirectly by a positron-emitting radionuclide (tracer), which is introduced into the body on a biologically active molecule. To avoid the additional radiation deriving from the CT scan during PET/CT imaging, nowadays PET imaging can be paired with MR anatomical images.
88886655|NCT01418326||Sevoflurane|Sevoflurane exposure for radical cancer surgery
88886656|NCT01418326||Propofol|Propofol exposure for cancer surgery
88886657|NCT01418391|Experimental|morphine consumption|
88886658|NCT01418404|Experimental|Noxious TS in study A|Noxious TS in study A
88886659|NCT01418404|Active Comparator|Innocuous TS|Innocuous TS in study A
88886660|NCT01418404|Experimental|High Frequency of Noxious TS|High Frequency of Noxious TS in study B
88886661|NCT01418404|Active Comparator|Low Frequency of Noxious TS|Low Frequency of Noxious TS in study B
88886662|NCT01418404|Experimental|High Intensity of Noxious TS|High Intensity of Noxious TS in study C
89410496|NCT03621267|Active Comparator|Home exercise program|60 minutes, 3 times/week, 12 weeks of home exercise
89410497|NCT03512990|Experimental|Bupivacaine - Superior Trunk Block|"Patients scheduled for rotator cuff surgery received 6 mL of 0,5% bupivacaine in the superior Trunk.~6 mL of methylene blue will be injected into cadavers with the same technique."
88886663|NCT01418404|Active Comparator|Low Intensity of Noxious TS|Low Intensity of Noxious TS in study C
88886664|NCT01418430|Experimental|CHOP-daclizumab|
88886665|NCT01418456|Experimental|Active Antibiotic Group|Patients in the antibiotic group will remain on antibiotics until their foot ulcer heals or up to 20 weeks
88886666|NCT01418456|No Intervention|Non antibiotic group|
88886667|NCT01418469|Experimental|Caseinate protein intake|18 mg protein/kg body weight caseinate and 46 mg maltodextrin / kg body weight per 20 min sip feeding
88886668|NCT01418469|Experimental|Whey protein isolate intake|18 mg protein/kg body weight whey protein isolate and 46 mg maltodextrin / kg body weight per 20 min sip feeding
88886669|NCT01418469|Experimental|Soy protein intake|18 mg protein/kg body weight soy and 46 mg maltodextrin / kg body weight per 20 min sip feeding
89410498|NCT05212935||Children below 12 months of age receiving vaccines according to the National Vaccination Plan|"All children who received vaccination in their first 12 months of life between January 2018 and June 2022 in the Regional Vaccination Centers involved in the study.~Children will be classified in sub-groups, according to different vaccination schedules (single or co-administration) and order of vaccine uptake."
89410499|NCT03642093|Experimental|Frail|Subjects assessed and determined to be Frail and meet trial eligibility criteria will be enrolled on Frail Arm and begin a 4 Week program consisting of Nutritional Interventions and Physical Activity Interventions
89410500|NCT03642093|Active Comparator|Not Frail|Subjects assessed and determined to be Not Frail and meet trial eligibility criteria will be enrolled on Not Frail Arm and begin a 4 Week program consisting of Nutritional Interventions and Physical Activity Interventions
89410501|NCT02296268||Pre-Clinic Stroke Group|In- or out-patients with diagnosis of ischemic or hemorrhagic stroke who have been referred to the NSRC prior to the establishment of the Clinic and are willing/able to provide written informed consent and have no contraindications to exercise testing. Utilization of aerobic exercise will be monitored during their physiotherapy sessions (Aim 3).
89410502|NCT02296268||Post-Clinic Stroke Group|In- or out-patients with diagnosis of ischemic or hemorrhagic stroke who have been referred to the NSRC after the establishment of the Clinic and are willing/able to provide written informed consent and have no contraindications to exercise testing. Each patient will undergo an assessment in the Aerobics Clinic and will receive a prescription for aerobic training based on the assessment findings. Utilization of aerobic exercise will be monitored during their physiotherapy sessions (Aim 3).
89410503|NCT02296268||Stroke Rehabilitation Physiotherapists|Physiotherapists whose current practice involves working full-time or part-time on in- or out-patient stroke service at the NSRC. Their self-efficacy regarding the clinical utilization of aerobic exercise post-stroke will be conducted prior to, and after, implementation of the Aerobics Clinic.
89410504|NCT03512834|Experimental|Paclitaxel+Avelumab|Paclitaxel combination with Avelumab for inoperable angiosarcoma
89410505|NCT03642015|Experimental|listening music|The participants in the music group selected the music they preferred from different genres. During the 15-min intervention period before the gastroscopy procedure, the experimental group rested by listening to music and sitting on a comfortable chair
89410506|NCT03642015|No Intervention|Control|control group rested only by sitting on a comfortable chair
89410507|NCT03516032|Experimental|walking exercises|walking in the hospital corridor
89410508|NCT03516032|Experimental|balance exercises|heel rise exercises
88886670|NCT01418469|Experimental|soy+BCAA protein intake|18 mg protein/kg body weight soy+BCAA and 46 mg maltodextrin / kg body weight per 20 min sip feeding
88886671|NCT01418495||Ancillary-Correlative (pharmacokinetics of ch14.18)|Patients undergo blood sample collection at baseline and during and after course 1, 3, or 5 of treatment for pharmacokinetic analysis. Some patients undergo blood sample collection at baseline and during and after two treatment courses (1 and 3, 1 and 5, or 3 and 5).
89410509|NCT03641781|Active Comparator|Isometric strength training group|Knee pain athletes were assessed by The International Knee Documentation Committee (IKDC) 2000 Subjective Knee evaluation form and were assigned into ISOM group. ISOM group participants were involved in isometric strengthTraining at angle of 30°,45°,60° of knee flexion for 5 maximum contraction for both hamstring and quadriceps. 10 sessions were given on alternate day basis by using Biodex Isokinetic system.
89410510|NCT03641781|Active Comparator|Isokinetic strength training group|Knee pain athletes were assessed by The International Knee Documentation Committee (IKDC) 2000 Subjective Knee evaluation form and were assigned into ISOK group isokinetic training group randomly. ISOk group participants were involved in Training at speed of 30 deg/sec, 90deg/sec, 150/deg/sec 210deg/sec, 270deg/sec 5 repetition for both hamstring and quadriceps. 10 sessions were given on alternate day basis by using Biodex Isokinetic system.
89410511|NCT03641781|No Intervention|Healthy control group|Data for outcome parameters including Peak torque average peak torque average power agonist antagonist ratio by using biodex isokinetic system for both by isometric contraction method and isokinetic method. For performance test were recorded for healthy control of same age group to compare the training effect with healthy control values.
89410512|NCT03518762|Experimental|Sustained lung inflation|"Participants in this arm (n=80) received:~Sustained lung inflation (SLI) manoeuvre(s) was applied once or twice, based on the protocol algorithm.~Within the first 60 seconds of life, assessment for the need of advanced resuscitation (defined as the need for more than oxygen and tactile stimulation during resuscitation) was done;~Infants who needed advanced resuscitation were considered to receive SLI as a rescue approach.~Infants who needed only oxygen and tactile stimulation were considered to receive SLI as a prophylactic approach.~Then Continuous positive airway pressure (CPAP). Intermittent positive pressure ventilation (IPPV) was given through an ETT, if intubation was needed."
89410513|NCT03518762|Other|Control|"Participants in this arm (n=80) received:~Resuscitation according to the American academy of pediatrics guidelines.~Then Continuous positive airway pressure (CPAP). Intermittent positive pressure ventilation (IPPV) was given through an ETT, if intubation was needed."
88886672|NCT01418508|No Intervention|low protein diet|Behavioral: low protein diet 0.6g of proteins per kilo of body weight per day
89410514|NCT03641625|Experimental|Intervention|In addition to usual care during surgery, the intraoperative management will be additionally managed based on the guidance of muscular tissue oxygen saturation and non-invasive hemodynamic monitoring.
88886673|NCT01418508|Experimental|low protein diet plusα-keto acid|0.6g of proteins per kilo of body weight per day
88886674|NCT01418508|Experimental|very low protein diet plus α-keto acid|0.3g of proteins per kilo of body weight per day
88886675|NCT01418521|Active Comparator|Ringer-albumin|Patients receiving the standard care of ringer-albumin as volume replacement after cardiac surgery
88886676|NCT01418521|Experimental|Tetraspan|patients receiving a 3rd generation HES solution (tetraspan) for volume replacement after cardiac surgery
88886677|NCT01418560|Experimental|renal sympathetic modification|Renal artery ablation to modify sympathetic activity in patients with chronic renal failure.
88886678|NCT01418560|No Intervention|Absolute medicine therapy|Maintenance of anti-renal failure medications only
88886679|NCT01418573|Experimental|Palaeolithic-type meal 1|
88886680|NCT01418573|Experimental|Palaeolithic-type meal 2|
88886681|NCT01418573|Placebo Comparator|The reference meal|
88886682|NCT01418638||30 Patients with MDD.|30 Patients aged 18-65, who were diagnosed with MDD according to the DSM-IV criteria.
88886683|NCT01418651|Experimental|Milnacipran|Drug
88886684|NCT01418664|Active Comparator|Study group|Each woman in above group will recieve in addition to routine ferrous sulphate and calcium lactate, 4000IU of vitamin D
88886685|NCT01418664|No Intervention|control group|Women in this group will recieve ferrous sulphate and calcium lactate
88886686|NCT01418677|Active Comparator|Cohort 1|
88886687|NCT01418677|Active Comparator|Cohort 2|
88886688|NCT01418677|Active Comparator|Cohort 3|
88886689|NCT01418690||Non-invasive near infra-red device (NIRS)|
88886690|NCT01418716|Experimental|Facilitation|Facilitation is a change management process. In the TRANSIT study, the change consist in implementing the TRANSIT program in primary care clinics. In the facilitation group, external facilitators accompany, support, and empower clinical teams so they quickly develop a sense of ownership regarding new clinical practices and sustainably implement them with lower costs. External facilitators offer counseling, coaching, and various tools to an internal facilitation team composed of clinicians of the clinical team to support their efforts in implementing change in their practices. Facilitation activities are structured in a cycle of 4 steps, the Plan-Do-Study-Act cycle (PDSA cycle).
88886691|NCT01418716|Active Comparator|Passive diffusion|Clinical teams in primary care clinics implement the TRANSIT program without the help of facilitators.
88886692|NCT01418729|Active Comparator|Sorafenib plus Pravastatin|The treatment received will be sorafenib 400 mg/12 h + pravastatin 40 mg/24 h.
88886693|NCT01418729|Placebo Comparator|Sorafenib plus Placebo|The treatment received will be sorafenib 400 mg/12 h + placebo/24 h.
88886694|NCT01418742|Active Comparator|Doxycycline 100 mg BID oral use|
88886695|NCT01418742|Placebo Comparator|Placebo 100 mg BID oral use|
89410515|NCT03641625|No Intervention|Control|Patients will receive the usual care. Muscular tissue oxygen saturation and non-invasive hemodynamic monitoring will be used but blinded to care givers.
89410516|NCT03518684|No Intervention|Group 1|Group 1 in which they will receive the standard care during labor and delivery without the use of the obstetrical gel
89410517|NCT03518684|Experimental|Group 2|Group 2 in which they will have the standard care during labor and delivery with the vaginal application of the obstetrical gel according to the study protocol. Those 2 groups will be further divided into 4 subgroups where the parity will be accounted for (nulliparous [never delivered beyond 20 weeks of gestation in a previous pregnancy] or primiparous or more)
89410518|NCT05201690|Experimental|VV116 200 mg Group|VV116 200 mg Group
89410519|NCT05201690|Experimental|VV116 400 mg Group|VV116 400 mg Group
89410520|NCT05201690|Experimental|VV116 600 mg Group|VV116 600 mg Group
89410521|NCT05201690|Placebo Comparator|Placebo|VV116 Matching placebo tablets; Multiple doses
89410522|NCT01067859|Experimental|Arm 1|
89410523|NCT01067859|Experimental|Arm 2|
89410524|NCT01067859|Placebo Comparator|Arm 3|
89410525|NCT02296658|Experimental|S-1 based chemoradiotherapy|S-1,80mg/m2/d,peroral BID,in treatment days concurrently with intensity-modulated radiotherapy in a standard manner.
89410526|NCT03640689|Experimental|Intervention Group|Endovenous ablation + iliac US +/- iliac stenting
89410527|NCT03640689|Active Comparator|Control Group|Endovenous ablation of Great Saphenous Vein
89410528|NCT02300246|Experimental|Test Group|Alveolar socket post-extraction covered with PRF
89410529|NCT02300246|No Intervention|Control Group|Only clot (spontaneous healing)
89410530|NCT03619239|Experimental|Cohort 1|Patients will receive treatment with GX-I7 at a pre-determined dose (Level I) on Day1 of each cycle.
89410531|NCT03619239|Experimental|Cohort 2|Patients will receive treatment with GX-I7 at a pre-determined dose (Level II) on Day1 of each cycle.
89410532|NCT03619239|Experimental|Cohort 3|Patients will receive treatment with GX-I7 at a pre-determined dose (Level III) on Day1 of each cycle.
88886696|NCT01418755|Experimental|platelet rich plasma injection|Fifty consecutive and strictly selected patients, affected by Grade II or III chondromalacia, underwent one year treatment (9 injections) with autologous PRP in a liquid form with 2,0 to 2,5-fold platelets concentration. Outcome measures included the Lysholm, Tegner, IKDC, and Cincinnati scores. Magnetic resonance imaging was used to evaluate cartilage thickness and degree of degeneration.
88886697|NCT01417793|Experimental|Smoking Cessation Program|
88886698|NCT01418768|Experimental|Rehabilitation|
88886699|NCT01418781||Gout|Patients with ICD-9 for gout
88886700|NCT01418781||No Gout|Patients withOUT ICD-9 for gout
88886701|NCT01418781||Tophaceous gout|Patients with ICD-9 for tophaceous gout
88886702|NCT01418781||non-tophaceous gout|those with ICD-9 for gout other than the codes specific for tophaceous gout
88886703|NCT01418794|Active Comparator|Low dose rapamycin group|Concentration of rapamycin was 1.5%
88886704|NCT01418794|Experimental|High dose rapamycin group|Concentration of rapamycin is 2.5%
89410533|NCT03619239|Experimental|Cohort 4|Patients will receive treatment with GX-I7 at a pre-determined dose (Level IV) on Day1 of each cycle.
88886705|NCT01418807|Experimental|TRANSVAGINAL EXTRACTION|
88886706|NCT01418807|Active Comparator|TRANSUMBILICAL EXTRACTION|
88886707|NCT01418820|Experimental|Verum stimulation|repetitive transorbital alternating current stimulation (rtACS)
88886708|NCT01418820|Sham Comparator|Placebo stimulation|compared to verum stimulation the same electrode montage set-up is used during placebo stimulation, except that placebo patients receive a minimal stimulation
88886709|NCT01418846||adult hematology patients|
88886710|NCT01418846||pediatric patients age 5-18years|
88886711|NCT01418846||adult pneumology patients|
88886712|NCT01418859||radiation therapy only|Including criteria: cervical cancer patients after surgery with big tumor, deep invasion or tumor thrombi in the vascular system, but without lymph invasion, positive surgery margin or parametrium invasion. Patients in this group receive radiation therapy only. radiation therapy regimen: 3D-CRT pelvic radiation, 95%CTV DT 45Gy/25f. Radiation field include tumor bed and regional lymph nodes area. Upper border: branching of abdominal aorta. The radiation fields go down along the iliac vessels (including regions of 7mm out of the iliac vessels) and include the tumor bed region. Lower border: the inferior margin of obturator foramen.
88886713|NCT01418859||concurrent chemoradiotherapy|Including criteria: cervical cancer patients after surgery with big tumor, deep invasion or tumor thrombi in the vascular system, but without lymph invasion, positive surgery margin or parametrium invasion. Patients in this group receive concurrent chemotherapy and radiation therapy. radiation therapy regimen is the same with radiation therapy only group. Chemotherapy regimen: Topotecan (1.5mg /m2 d1,2, 1mg d3) and Cisplatin (25mg /m2 d1-3). Chemotherapy will be carry out in the 2nd and 6th week of radiation therapy.
88886714|NCT01418859||concurrent and additional chemotherapy|Including criteria: cervical cancer patients after surgery with big tumor, deep invasion or tumor thrombi in the vascular system, but without lymph invasion, positive surgery margin or parametrium invasion. Patients in this group receive concurrent chemotherapy and radiation therapy, and additional chemotherapy after concurrent treatment. radiation therapy regimen is the same with radiation therapy group. Chemotherapy regimen: Topotecan (1.5mg /m2 d1,2, 1mg d3) and Cisplatin (25mg /m2 d1-3). Chemotherapy will be carry out in the 2nd and 6th week of radiation therapy. Additional chemotherapy regimen is the same with concurrent chemotherapy, and will be carry out in the 4th and 8th week after radiation therapy.
88886715|NCT01418872|Active Comparator|Healthy Breakfast|"The activity will be performed at the school dining hall, scheduling 1 hour for breakfast,within the school hours, with maximum 50 children per turn It involves placing a table mat, a cup, a plate and two slices of bread per child, plus 1-liter bottle of milk for each four children and 1-liter bottle of oil for each twelve. The dining hall will be all set up before the students come in.~Participatory lesson : Ideal number of daily meals, Importance of daily breakfast for the activity, Time for breakfast, Basic components for a healthy breakfast, The role of cereals at breakfast, The role of dairy products at breakfast,The role of fruits at breakfast, Importance of exercise for cardiovascular health, The role of unhealthy habits: sedentary lifestyle.~The students will be invited to take the table mat and the cup, in which is inscribed: I am a heart-saver, so that they take them home and serve as a reminder of the activity.~A pamphlet of the NAOS strategy will also be delivered."
88886716|NCT01418872|Experimental|Didactic concerts|"The activity we are going to test consists in a communication and spreading strategy.~The activity will take place in the auditorium of the school, scheduling 1 hour for concert, within the school hours, and having maximum 50 children per turn.~Preparation of the auditorium for the activity 5 classic musical pieces and a story as a conducting thread. Children will be asked to clap and raise hands to participate in the mission of becoming a heart-savers: Ideal number of daily meals, Importance of daily breakfast for the activity, Time for breakfast, Basic components for a healthy breakfast, The role of cereals at breakfast, dairy products in breakfast, fruits at breakfast, Importance of exercise for cardiovascular health, The role of sedentary lifestyle.~Students will be invited to take the playbill as a bookmark format and a cup is inscribed: I am a heart-saver, so that they take them home and serve as a reminder of the activity. A NAOS strategy pamphlet will also be delivered."
88886717|NCT01418885||SIVD,VaD|vascular disease in patients with SIVD
88886718|NCT01418885||SIVD,VCIND|vascular cognitive impairment no dementia in patients with SIVD
88886719|NCT01418885||normal controls|normal elderly controls
88886720|NCT01418898|Experimental|Nutrient Fortified Beverage|
88886721|NCT01418898|Placebo Comparator|Control|
88886722|NCT01418911||diabetes type 2|type 2 diabetes patients 40-70 years of age hebrew speaking members of maccabi healthcare services
88886723|NCT01418950|Active Comparator|Control group|The control group will receive standard verbal counseling regarding outcome of premature infants
88886724|NCT01418950|Experimental|Study Group|Study Group will receive gestational age specific written information prior to receiving standard verbal counseling about outcome of premature infants.
88886725|NCT01418963|Experimental|Active|
88886726|NCT01418963|Placebo Comparator|Placebo|
88886727|NCT01418976|Experimental|Intensive Mobility Training (IMT)|Intensive Mobility Training will be used as an intensive physical therapy intervention. Participants will receive 3 hours per day for a 10 day session, be post-tested, and receive another 10 day session followed by two more testing sessions.
89410534|NCT03619239|Experimental|Cohort 5(Dose-expansion)|Optimal fixed dose of GX-I7 from Dose-escalation stage on Day1 of each cycle (Maximum tolerable dose or Maximum efficacious dose or Maximum administered dose level or consecutive lower or upper dose level which does not exceed Maximum tolerable dose based on Safety Monitoring Committee(SMC) decision)
89410535|NCT02296736||Pancreatic malignancy|All patients who have undergone surgery for presumed pancreatic malignancy in Derriford Hospital between Jan 2006 and Jan 14 and had a Computerised tomography (CT) scan.
89410536|NCT02293616|Experimental|Nitrate Rich|A nitrate rich beetroot juice supplement (Beet It Shot®, James White Drinks, UK) high in nitrates will be provided to the subjects. Subject's diet will be supplemented once daily while hospitalized up to 14 days with one 70 ml bottle containing 300 mg of dietary nitrate.
89410537|NCT02293616|Placebo Comparator|Nitrate Depleted|This group will consume a beetroot juice supplement (Beet It Shot®, James White Drinks, UK) that has had the nitrate removed from the beverage by the manufacturer. Patient's diet will be supplemented once daily with one 70 ml bottle while hospitalized up to 14 days.
89410538|NCT03640221|Experimental|Experimental|will receive two bottles of Ertugliflozin 15mg tablets (active drug) and a placebo for hydrochlorothiazide.
89410539|NCT03640221|Active Comparator|Active Comparator|will receive two bottles of Placebo for ertugliflozin and hydrochlorthiazide 12.5mg capsules (active drug)
89410540|NCT03640143||experimental group|children with clinical expression of lead poisoning data about venous blood lead will be reported
89410541|NCT02300324|Experimental|Standard v Beneforte v Beneforte Extra|This is a randomized, double-blinded, three-phase crossover trial investigating the bioavailability of SF following consumption of three types of broccoli + stilton soup containing different concentrations of glucoraphanin. The three types of soup are standard broccoli and stilton soup, beneforte broccoli and stilton soup, and beneforte extra broccoli and stilton soup.
88886728|NCT01418989|Experimental|1|
88886729|NCT01418989|Experimental|2|
88886730|NCT01419002|Experimental|Neoadjuvant RTx|
88886731|NCT01419002|Active Comparator|Surgery|
88886732|NCT01419041|Other|Arm A|CLCR: Creatinine clearance
88886733|NCT01419041|Other|Arm B|CLCR: Creatinine clearance
89410542|NCT03640767|Experimental|message-based lifestyle intervention|The intervention group will receive 4 mobile phone messages per week for 24 weeks.
89410543|NCT03640767|No Intervention|Control|no intervention
88886734|NCT01419093|No Intervention|5A Communication|Behavioral: 5 A intervention for physical activity
88886735|NCT01419106|No Intervention|Control|This arm of the study will NOT receive point of care ultrasound. They will receive all other standard care implemented during their visit to the ED (currently, ultrasound is NOT standard of care). The same blood tests will be done in both groups, as this will offer a means of comparing physiological changes between the two arms.
88886736|NCT01419106|Experimental|Ultrasound|This group WILL receive point of care ultrasound. The protocol they will receive is the ACES protocol (described above).
88886737|NCT01419119|Experimental|Group 1|Vitamin D3, 10 000 IU daily. Treatment to patients with Serum-vitamin D levels below 25 nmol/L
88886738|NCT01419119|Experimental|Group 2a|Vitamin D3 2000 IU daily, one of two arms that patients with Serum-vitamin D levels between 25 nmol/L and 49 nmol/l will be randomised to
88886739|NCT01419119|Experimental|Group 2b|Vitamin D3 2000 IU weekly, one of two arms that patients with Serum-vitamin D levels between 25 nmol/L and 49 mol/l will be randomised to
88886740|NCT01419119|Experimental|Group 3|Vitamin D3, 2000 IU daily i.e. 3 drops orally once daily for 12 weeks, treatment to patients with Serum-vitamin D levels between 50 and 74 nmol/L
88886741|NCT01419132|Placebo Comparator|High doses furosemide|administration of furosemide alone
88886742|NCT01419132|Experimental|HSS plus furosemide|administration of hypertonic saline solution plus high doses of furosemide bid
88886743|NCT01419145|Experimental|Multimodal intervention|
88886744|NCT01419145|Active Comparator|Standard Care|
88886745|NCT01419210|Experimental|Complementary and Alternative Medicine (CAM) therapies|This pilot program attends to the need for appropriate patient-centered interventions that integrate CAM with traditional care to maximize both quantity and QOL for women with ovarian cancer.
88886746|NCT01419223||Consent to participate (Group 1)|Active military and veterans who consent to participate in an INTRuST PTSD or TBI research trial.
88886747|NCT01419223||Decline to participate (Group 2)|Active military and veterans who decline to participate in an INTRuST PTSD or TBI research trial.
89410544|NCT02300480|Experimental|CTB group|Participants in this group will receive a single injection for calot's triangle block combined with PCIA post-operatively. CTB will be conducted by bile duct needle and 1.0% 10 ml ropivacaine will be injection in calot's triangle when before surgical dissection.Participants in this group will also receive PCIA after surgery,the regimens of PCIA are included tramadol 800 mg, flurbiprofenaxetil 100 mg with normal saline added up to a volume of 80 ml in total.
89535691|NCT05463497|Other|Group 4(N=10)|"Treatment D for Period 1 Treatment A for Period 2 Treatment E for Period 3~*Washout period : more than 7 days between period 1 and 2, no washout period between period 2 and 3"
88886748|NCT01419262|Experimental|2000 IU per day vitamin D|
88886749|NCT01419262|Active Comparator|400 IU per day vitamin D|
88886750|NCT01419288|Active Comparator|No Body weight support|
88886751|NCT01419288|Experimental|Body weight support|
88886752|NCT01419327||Group 1|Drug (incl. Placebo)
88886753|NCT01419353|Experimental|Follicular Estrogen, Antagonist, IVF|Follicular Estrogen in Antagonist IVF protocol
88886754|NCT01419353|Active Comparator|long IVF protocol|long IVF protocol
88886755|NCT01419379||1|
88886756|NCT01419392|Experimental|Sildenafil citrate|
88886757|NCT01419392|Placebo Comparator|placebo|
88886758|NCT01419405|Experimental|Pregabalin/placebo|
88886759|NCT01419405|Active Comparator|placebo/remifentanil|
88886760|NCT01419405|Placebo Comparator|placebo/placebo|
88886761|NCT01419405|Experimental|Pregabalin/Remifentanil|
88886762|NCT01419418||Peripheral Arterial Disease (PAD)|This is a longitudinal observational study. There were no interventions administered.
88886763|NCT01419431||Colon cancer patients|Laparoscopic resection
88886764|NCT01419444|Active Comparator|Traditional, Onsite Treatment|Onsite treatment using airflow exercises. Patients will receive face-to-face treatment with the research speech pathologist two times per week.
88886765|NCT01419444|Experimental|Telemedicine Treatment|Participants will receive treatment via telemedicine at select AHEC sites around the state of Arkansas. Treatments will occur twice per week with the research speech pathologist.
89410545|NCT02300480|Active Comparator|PCIA group|Participants in this group will receive PCIA post-operatively (tramadol 800 mg and flurbiprofen axetil 100mg with normal saline added up to a volume of 80ml in total ) .The PCIA pump was set up with a 5 ml loading dose, a 2 ml bolus dose, a 15 min lockout interval and background infusion at a rate of 1 ml/h.
89410546|NCT03518528||transdermal|transdermal estradiol (Vivelledot, Novartis) 100 µg on day 3, then 200 µg day 7 and every 4 days, until first pregnancy test. If pregnancy test is positive, treatment is to continue until 8 weeks.
89410547|NCT03518528||vaginal|Vaginal estradiol (Provames, Sanofi) 4mg per day from day 3 to first pregnancy test. If pregnancy test is positive, treatment is to continue until 8 weeks
89410548|NCT03518450|Active Comparator|Femoral Nerve Block|Ultrasound guided femoral nerve block, 30 ml of 0.25% bupivacaine and 4 mg of dexamethasone to be administered.
89410549|NCT03518450|Active Comparator|Adductor Canal Block|Ultrasound guided adductor canal block, at the proximal third of the canal, 30 ml of 0.25% bupivacaine and 4 mg of dexamethasone to be administered.
89410550|NCT03518450|Experimental|Apex Femoral Triangle Block|Ultrasound guided femoral triangle block, at the distal third of the triangle, 30 ml of 0.25% bupivacaine and 4 mg of dexamethasone to be administered.
89410551|NCT01348425|Experimental|Longer Stents|
89410552|NCT01348425|Experimental|Shorter Stents|
89410553|NCT02296814|Active Comparator|Sinusitis Hevert SL Tablet|two weeks treatment
89410554|NCT02296814|Placebo Comparator|Placebo for Sinusitis Hevert SL Tablet|two weeks treatment
89410555|NCT03515876||Control|Patients will receive intravenous propofol infusion.
89410556|NCT03515876||Dexmedetomidine 0.5 microgram/kg group|Patients will receive dexmedetomidine 0.5 microgram/kg and then intravenous propofol infusion.
89410557|NCT03515876||Dexmedetomidine 1 microgram/kg group|Patients will receive dexmedetomidine 1 microgram/kg and then intravenous propofol infusion.
88886766|NCT01419457|Experimental|Group 1|Normal hepatic function
88886767|NCT01419457|Experimental|Group 2|Mild hepatic impairment
89410558|NCT03515798|Experimental|Pembrolizumab|EC Paclitaxel + Pembrolizumab Injection
89410559|NCT03515798|Active Comparator|Standard neoadjuvant chemotherapy|EC Paclitaxel alone
89410560|NCT03512600|Experimental|Study group|"All patients will follow four different dietary interventions (with or without cacao) for 1 day prior to the taking of a urine sample.~After the sample is taken the patient will follow a washout period of 6 days before following a different diet and this process will be repeated for each patient until they have followed the four diets.~."
89410561|NCT03041701|Experimental|Phase 1 Dose Level 1: Ganitumab and Dasatinib|Phase I Dose Level 1: Combination of ganitumab and dasatinib with limited dose escalation of dasatinib
89410562|NCT03041701|Experimental|Phase 1 Dose Level 2: Ganitumab and Dasatinib|Phase I Dose Level 2: Combination of ganitumab and dasatinib with limited dose escalation of dasatinib
89410563|NCT03041701|Experimental|Phase 2 Dose Level 1: Ganitumab and Dasatinib|Phase 2 Dose Level 1: Combination of ganitumab and dasatinib at the maximum tolerated dose (MTD) (or highest safe dose)
88886768|NCT01419457|Experimental|Group 3|Moderate hepatic impairment
88886769|NCT01419457|Experimental|Group 4|Severe hepatic impairment
89410564|NCT03512522|Experimental|Online Group|An 8-week remotely-delivered pain self-management program tailored to older adults that have been experiencing pain for at least three months. Participants randomized to the Online Group will receive access to the course on the computer (online). A researcher will act as a guide who provides general support and encouragement, as opposed to a clinician who would offer comprehensive therapy. The guide will aim to contact participants weekly via telephone for approximately 5 to 10 minutes.
89410565|NCT03512522|Experimental|Workbook Group|An 8-week remotely-delivered pain self-management program tailored to older adults that have been experiencing pain for at least three months. Participants randomized to the Workbook Group will receive access to the course in a printed (workbook) format. A researcher will act as a guide who provides general support and encouragement, as opposed to a clinician who would offer comprehensive therapy. The guide will aim to contact participants weekly via telephone for approximately 5 to 10 minutes.
88886770|NCT01419470|Experimental|YHD1044 I|
88886771|NCT01419470|Experimental|YHD1044 III|
88886772|NCT01419470|Experimental|YHD1044 V|
88886773|NCT01419483|Experimental|Ketogenic diet|Diet designed to maintain elevated ketone levels during therapy
88886774|NCT01419587|Experimental|Ketogenic diet|Diet formulated to maintain elevated ketones during therapy
88886775|NCT01419600|Experimental|Group 1 - 4, single ascending dose AZD 8683|Subjects will participate in 1 of 4 groups. In each group, 6 subjects will receive AZD8683 and 2 subjects will receive placebo.
89410566|NCT03512522|No Intervention|Wait List Control Group|Participants who are randomly allocated to the wait list control group will be provided access to the course after the twelve-week period has passed.
89410567|NCT04464902|Other|knee extension constraint rehabilitation group|
89410568|NCT04464902|Other|placebo group|
89410569|NCT04464902|Other|control group|
89410570|NCT04464824||patient over 75 years of age with an emergency room visit|Patients over 75 years of age, with a visit to the emergency department between April 1, 2019 and September 30, 2019, with a non-hospitalization at the end of their visit to the emergency department.
89410571|NCT02293694|Active Comparator|self-injection|Women randomized to this arm will be trained to self-inject Sayana Press at home every three months
89410572|NCT02293694|Active Comparator|provider injection|Women randomized to this arm will received Sayana press from a family planning provider every three months.
89410573|NCT02297048|Experimental|RU 486 (mifepristone)|Subjects will receive 400 mg once a day of RU486
89410574|NCT02297048|Placebo Comparator|Placebo|Subjects will receive placebo once a day
89535692|NCT03073083|Active Comparator|Hamstring tendon autograft|ACL reconstruction surgery with hamstring tendon autograft
88886776|NCT01419600|Placebo Comparator|Group 1-4 single ascending dose Placebo|Subjects will participate in 1 of 4 groups. In each group, 6 subjects will receive AZD8683 and 2 subjects will receive placebo.
88886777|NCT01419613|Experimental|Motivational Interviewing|
88886778|NCT01419613|Active Comparator|Physical Activity Counseling|
88886779|NCT01419652|Active Comparator|continue hypglycemic meds|
88886780|NCT01419652|No Intervention|control - hold drug|
89410575|NCT02297126|No Intervention|Control Arm|4,000 patients receiving a new prescription for targeted medication(s) randomized into the control arm receive standard care (no intervention affecting drug selection, dosage, dosage form, frequency and duration of therapy). Healthcare costs and adverse events data collected and analyzed for 12 months from time of entry into study. List of targeted medications: codeine, amitriptyline, aripiprazole, atazanavir, atomoxetine, azathioprine, citalopram, clopidogrel, cyclophosphamide, doxepin, efavirenz, escitalopram, esomeprazole, fluconazole, simvastatin, fluorouracil, phenytoin, quetiapine, glyburide, lansoprazole, mercaptopurine, methadone, methotrexate, nortriptyline, omeprazole, pantoprazole, rasburicase, tacrolimus, thioguanine, tramadol, venlafaxine, voriconazole and warfarin
89410576|NCT02297126|Experimental|Pharmacogenetic Intervention Arm|2,000 patients receiving new prescription for targeted medication(s) identified in the control arm will be randomized to the intervention arm, consented and a tests will be performed from a blood sample. The treating physicians will be provided with the pharmacogenetic information and will determine if intervention is appropriate. Physician may elect to stay the course of therapy or alter drug selection, dosage, dosage form, frequency or duration of therapy based on the pharmacogenetic test results and input from clinical pharmacology consultations (if requested). Patients in the intervention arm will have their overall healthcare costs and clinical outcomes (specifically adverse events) followed and analyzed for a 1 year period from the time that they are entered into the study
88886781|NCT01419678|Experimental|'collection of blood samples for PK testing'|collection of PK samples around a dosing of Posaconazole
89410577|NCT02300636|Experimental|Training: open kinetic|"Co-contraction training in open kinetic chain position~8 weeks, 3 days in a week"
89410578|NCT02300636|Experimental|Training: closed kinetic|"Co-contraction training in closed kinetic chain position~8 weeks, 3 days in a week"
89410579|NCT02300636|Active Comparator|Training: Standard ACL rehabilitation|"Standard ACL rehabilitation~8 weeks, 3 days in a week"
88886782|NCT01419691|Experimental|Phase 2 Dose|Auranofin 6 mg orally in the morning / 6 mg orally in the evening
88886783|NCT01419730|Active Comparator|Vitamin D3 50,000 IU|Vitamin D3 50,000 IU: Patients will be assigned to receive a daily multivitamin, calcium supplement and 50,000 IU/week of vitamin D for a period of 24 weeks.
89410580|NCT02293772|Active Comparator|Hypoxic ambulatory|Ambulatory in normobaric hypoxia
89410581|NCT02293772|Experimental|Hypoxic Bedrest|Bedrest in normobaric hypoxia
89410582|NCT02293772|Active Comparator|Normoxic bedrest|Bedrest in normobaric normoxia
89410583|NCT03512444|Experimental|Negative pressure|"Negative pressure system is applied with negative pressure (Active)~at a participant's unilateral arm"
89410584|NCT03512444|No Intervention|No negative pressure|"Negative pressure system is applied without negative pressure (Inactive)~at a participant's contralateral arm"
88886784|NCT01419730|Active Comparator|Vitamin D3 50,000 IU and Physical Activity|Vitamin D3 50,000 IU and Physical Activity: Patients will be assigned to receive a daily multivitamin, calcium supplement, 50,000 IU/week of vitamin D, and a progressive walking and resistance band exercise prescription for a period of 24 weeks.
88886785|NCT01419730|No Intervention|Control|Patients will be assigned to receive a daily multivitamin, calcium supplement, vitamin D placebo, and standard care monitoring.
88886786|NCT01419743||patients with Vit D level of < 20ng/mL: Group 1|randomized to receive 400 IU of vitamin D per day
88886787|NCT01419743||patients with Vit D levels <20ng/mL: Group 2|Randomized to receive 2000IU of Vitamin D per day
89410585|NCT02956629|Experimental|HCV GT1|Male and female participants with HCV GT1a or GT1b infection take uprifosbuvir 450 mg + RZR 180 mg for 12 weeks.
89410586|NCT02956629|Experimental|HCV GT2|Male and female participants with HCV GT2 infection take uprifosbuvir 450 mg + RZR 180 mg for 12 weeks.
89410587|NCT02956629|Experimental|HCV GT3|Male and female participants with HCV GT3 infection take uprifosbuvir 450 mg + RZR 180 mg for 12 weeks.
89410588|NCT02956629|Experimental|HCV GT4|Male and female participants with HCV GT4 infection take uprifosbuvir 450 mg + RZR 180 mg for 12 weeks.
89410589|NCT02956629|Experimental|HCV GT5|Male and female participants with HCV GT5 infection take uprifosbuvir 450 mg + RZR 180 mg for 12 weeks.
89410590|NCT02956629|Experimental|HCV GT6|Male and female participants with HCV GT6 infection take uprifosbuvir 450 mg + RZR 180 mg for 12 weeks.
88886788|NCT01419743||patients with vit D levels between 20-30 ng/mL: Group 3|Randomized to receiving placebo
89410591|NCT02297204|Experimental|aflibercept|"2mg, as needed, intravitreal administration. All subjects will be treated with intravitreal (IVT) aflibercept injections as needed in the presence of clinically relevant diabetic macular edema (CR-DME). If CR-DME is not present the subject will not receive an IVT aflibercept injection and will be observed.~If a subject has recurrent CR-DME they will receive an IVT aflibercept 2.0 mg injection and interval between visits will be reduced to 4 weeks.~At week 12 through end of study, all subjects will be evaluated for focal laser treatment."
88886789|NCT01419743||patients with vit D levels between 20-30 ng/mL: Group 4|Randomized to receive 400IU of vitamin D per day
89410592|NCT02300714|Active Comparator|AP group|oblique view approach during transforaminal epidural block
89410593|NCT02300714|Active Comparator|OB group|oblique view approach during transforaminal epidural block
88886790|NCT01419743||patients with vit D levels between 20-30 ng/mL: Group 5|Randomized to receive 2000IU of vitamin D per day
88886791|NCT01419743||patients with vit D levels > 30ng/mL: Group 6|No treatment
88886792|NCT01419756||Single Arm|Imaging comparison study. No intervention.
88886793|NCT01419782|Experimental|Whole-body vibration|whole body vibration will be applied the right lower limb.
89410594|NCT03515642|Experimental|HIIT group|The HIIT modality consisted of 30-40 minutes (min) of steady-state, high-intensity training 3 d/wk on a stationary bicycle at the target heart rate (HR) range equivalent to 85% to 95% of the individual's maximum oxygen consumption rate (VO2max). Exercise will be performed at three sessions per week. All sessions will be supervised by an exercise physiologist during 6-weeks.
89535693|NCT03073083|Active Comparator|Patella tendon autograft|ACL reconstruction surgery with pattella tendon autograft
89410595|NCT03515642|Active Comparator|SIT group|The SIT modality consisted of 6 to 10 repetitions of a 30 s segment of all-out exercise interspersed with 2 min of recovery, 3 d/wk on a stationary bicycle at the target heart rate (HR) range equivalent to 90% to 95% of the individual's maximum oxygen consumption rate (VO2max).
89410596|NCT02293850|Experimental|single intra-tumoral injection|OBP-301 ; Cohort 1: 1x10 10 viral particle (VP)/ tumor Cohort 2: 1x10 11 viral particle (VP)/ tumor Cohort 3: 1x10 12 viral particle (VP)/ tumor
89410597|NCT02300792|Active Comparator|honey|Each patient in the honey group (group 1) took oral honey in a dose of 5 ml/kg/day (with a maximum dose of 150 ml/day) for four weeks.
88886794|NCT01419808|Active Comparator|Vascularized Bone Graft|Patients randomized to a vascularized bone graft will undergo a 1, 2-ICRSA vascularized bone graft based upon the 1,2 supra-retinacular vessels as described by Zaidemberg . (9. Zaidemberg C, Siebert JW, Angrigiani C. A new vascularized bone graft for scaphoid nonunion. J Hand Surg. 1991; 16A: 474-478.)
88886795|NCT01419808|Active Comparator|Non-Vascularized Bone Graft|Patients randomized to the non-vascularized group will undergo trapezoidal bone grafting from the iliac crest as described by Fernandez . (10. Fernandez DL. A technique for anterior wedge-shaped grafts for scaphoid nonunions with carpal instability. J Hand Surg [Am]. 1984 Sep;9(5):733-7.)
88886796|NCT01419821|Active Comparator|Vit D supplementation|Group 2-Infants with 25(OH)D below 15ng/ml receiving continued vitamin D supplementation of 800IU (4gtt/d) for one year.
88886797|NCT01419821|Placebo Comparator|Placebo group|Group 3- Infants with 25(OH)D below 15ng/ml those receiving the placebo.
88886798|NCT01419821|No Intervention|Normal group|Group 1- infants with 25(OH)D above 15ng/ml (normal levels) will receive no intervention.
88886799|NCT01419847|Active Comparator|topical Penlac nail lacquer|3-1 randomization of active to placebo
88886800|NCT01419847|Placebo Comparator|Placebo|
88886801|NCT01419886||Dysphagia|
88886802|NCT01419899|Experimental|Brief Intervention|This arm of the study will receive an assessments survey followed by a brief intervention concerning the relationship between the participants use of drugs and/or sexual risk and rik for HIV and hepatitis C infections. Following the intervention the participants will be offered free rapid testing for HIV and hepatitis C.
88886803|NCT01419899|No Intervention|Standard Care|This arm of the study will receive an assessments survey. Following the assessment the participants will be offered free rapid testing for HIV and hepatitis C.
88886804|NCT01419912|Experimental|soy milk|
88886805|NCT01419912|Experimental|cow's milk|
88886806|NCT01419925|Experimental|Group A|Two Multimeric-001 administrations followed by TIV
88886807|NCT01419925|Experimental|Group B|One administration of Multimeric-001 followed by TIV
88886808|NCT01419925|Experimental|Group C|One administration of adjuvanted M-001 followed by TIV
88886809|NCT01419925|Active Comparator|Group D|One administration of placebo followed by TIV
88886810|NCT01419938|Active Comparator|Light therapy for two weeks|
88886811|NCT01419938|Active Comparator|Light therapy and CBT|Two weeks of light therapy and after that 4 weeks of Cognitive behaviour therapy (CBT)
88886812|NCT01419951|Active Comparator|Clinic Only Behavioral Intervention|A 6 month intervention consisting of two phases: Phase I Intensive intervention is 6 sessions delivered in a group-based format in clinic (concurrent parent and child groups) every other week. Phase II Maintenance is 3 monthly clinic visits. Treatment targets 3 components: Dietary education, physical activity and parenting training.
88886813|NCT01419951|Active Comparator|Pediatrician Counseling|A one-time 45 minute visit with a board certified pediatrician that focuses on the AAP guidelines for eating and physical activity for preschool aged children.
88886814|NCT01419951|Experimental|Clinic + Home Behavioral Intervention|A 6 month intervention consisting of two phases: Phase I Intensive intervention is 12 weekly sessions that alternate between a group-based clinic session (concurrent parent and child groups) and individual home visits. Phase II Maintenance is 12 weeks of every other week visits alternating between clinic and home. Treatment targets 3 components: Dietary education, physical activity and parenting training.
88886815|NCT01419964|Experimental|Group 01|ACH24
88886816|NCT01419964|Placebo Comparator|Group 02|Placebo
89410598|NCT02300792|Placebo Comparator|molasses|Each patient in the molasses (placebo) group (group 1) took molasses in a dose of 5 ml/kg/day (with a maximum dose of 150 ml/day) for four weeks.
89410599|NCT02297282|Experimental|Behavioural Activation|Originally a component of Cognitive Therapy, behavioural activation is the use of strategies such as activity scheduling, master/pleasure ratings, and graded task assignments to change one's perception of specific situations. Behavioural Activation involves the use of activities to improve life situations or depressed mood.
89410600|NCT02297282|No Intervention|Wait List (Control Group)|The Control group (waitlist) will receive treatment as usual while they are waiting to start the BA intervention at the end of the Intervention Group Therapy time (28 sessions over an 18 week period). In addition to usual care, the control group will be assessed by clinical staff that offers treatment as usual for mood symptoms and quality of life measures during the waiting time.
88886817|NCT01419990|Experimental|GLPG0634 capsules|
88886818|NCT01419990|Placebo Comparator|Placebo capsules|
88886819|NCT01420003|Experimental|Allergen Challenge|
88886820|NCT01420042|Placebo Comparator|Placebo (lemon flavoured cordial)|NNZ-2566 reconstituted in Lemon flavoured cordial and Water for Injection. 6/8 subjects in each cohort (3 cohorts in total) to receive NNZ-2566 experimental treatment.
88886821|NCT01420042|Experimental|NNZ-2566|
88886822|NCT01420055|Experimental|fingolimod|
88886823|NCT01420094|Experimental|Arm 1|
88886824|NCT01420094|Active Comparator|Arm 2|
88886825|NCT01420094|Placebo Comparator|Arm 3|
88886826|NCT01420133|Experimental|Normal regimen|without special regimen for corticosteroid therapy
88886827|NCT01420133|Active Comparator|Standard arm|with diet low in salt and sugar
88886828|NCT01420159|Experimental|Methoxyflurane|
88886829|NCT01420159|Placebo Comparator|Normal Saline|
88886830|NCT01420172||Post hematopoietic stem cell transplantation|Patients who were seen post hematopoietic stem cell transplantation between 01Jan2000 and 30Jun2011
89005158|NCT00228891|Placebo Comparator|1|Control patients with diabetic neuropathy will receive objective testing at baseline and every six months to compare and measure results with patients who are receiving pulsatile intravenous insulin therapy.
88886831|NCT01420198|Experimental|Lifestyle intervention|Lifestyle intervention: 500 participants from Iraq with obesity and/or prediabetes (impaired fasting glucose) and we expect to recruit 308 participants. Half of them will be randomized to lifestyle intervention i.e. group counseling and physical activity during a period of 1 year. An equal amount of controls will have treatment as usual. Every third month blood tests and a physical exam will be conducted in the intervention group.
88886832|NCT01420198|No Intervention|Controls|Controls have treatment as usual. Every third month blood tests and a physical exam will be conducted in the control group.
89410601|NCT02297360|Active Comparator|Viviscal Extra-Strength Supplement|Viviscal Extra-strength tablets. One tablet taken by mouth in the morning and one tablet in the evening with food for 90 days.
89410602|NCT02297360|Placebo Comparator|Placebo Tablet|Placebo tablets. One tablet taken by mouth in the morning and one tablet in the evening with food for 90 days.
89410603|NCT02293928||Elective hybrid coronary revascularization|All patients are treated with non-enteric coated aspirin 75 mg once daily prior to study participation. Aspirin treatment is discontinued 8-10 days prior to surgery and resumed 6-9 hours after surgery. Left internal mammary grafting of the left descendent coronary artery is performed off-pump through an inferior J-hemisternotomy (JOPCAB). All patients receive an oral loading dose of aspirin 300 mg 6-9 hours after surgery followed by daily maintenance doses of 75 mg aspirin. An oral loading dose of clopidogrel 300 mg 12 hours prior to PCI is followed by daily maintenance doses of 75 mg for 12 months. Patients are followed for 1 year.
89410604|NCT02294006|Experimental|everolimus+octreotide LAR+metformin|everolimus+octreotide LAR+metformin
89410605|NCT01348347|Experimental|Volasertib|Patient to receive low, middle and high doses of Volasertib IV
89410606|NCT02294084|Experimental|Sitagliptin|Subjects will receive Sitagliptin in a dosage of 100 mg/day p.o. for 12 weeks. The dosage corresponds to 1 gift/day.
88886833|NCT01420211|Experimental|Primovist|
88886834|NCT01420224||Healthy volunteers|
88886835|NCT01420224||Chuvash polycythaemia|
88886836|NCT01420263|Active Comparator|Re-feeding gastric residuals|In the presence of significant gastric residuals (more than 1/3 of previous feed or > 2ml), residual volumes will be re-fed if the physician decision is to continue feeds as scheduled in the absence of other clinical signs and symptoms of feeding intolerance. This practice will be continued until full enteral feeding is achieved and maintained for a minimum of 48 hours.
88886837|NCT01420263|Active Comparator|Fresh feeding breastmilk/formula only|In the presence of significant gastric residuals (more than 1/3 of previous feed or > 2ml), residual volumes will be discarded and fresh breast milk or formula will be fed if the physician decision is to continue feeds as scheduled in the absence of other clinical signs and symptoms of feeding intolerance. This practice will be continued until full enteral feeding is achieved and maintained for a minimum of 48 hours.
88886838|NCT01420302|Experimental|LOGIC-Insulin|Blood glucose control (80-110 mg/dL) guided by the LOGIC-Insulin algorithm
88886839|NCT01420302|Active Comparator|Nurse-directed|Nurse-directed blood glucose control (80-110 mg/dL)
88886840|NCT01420328|Placebo Comparator|Placebo Arm|Obese subjects with near normal cholesterol
88886841|NCT01420328|Active Comparator|Vytorin Arm|Obese subjects with near normal cholesterol
88886842|NCT01420341|Active Comparator|Co-trimoxazole 12|Receive treatment with co-trimoxazole for 12 weeks.
88886843|NCT01420341|Experimental|Co-trimoxazole 20|Receive treatment with co-trimoxazole for 20 weeks.
88886844|NCT01420367|Experimental|Single dose of antibiotics|This group will receive one dose of IV metronidazole (12.5mg/kg up to 500mg) and cefazolin (25mg/kg up to 1g) in the pre-operative period and two post-operative IV 'doses' of normal saline 8 and 16 hours after the pre-operative dose, which will act as a placebo and facilitate blinding.
88886845|NCT01420367|Active Comparator|Three doses of antibiotics|This group will receive one pre-operative dose of IV metronidazole (12.5mg/kg up to 500mg) and cefazolin (25mg/kg up to 1g) and two post-operative doses of IV metronidazole (12.5mg/kg up to 500mg) and cefazolin (25mg/kg up to 1g) 8 and 16 hours after the pre-operative dose.
88886846|NCT01420393|Active Comparator|Rhythm Control|Patients randomized to catheter ablation-based AF rhythm control group will receive optimal Heart Failure therapy and one or more aggressive catheter ablation, which include PV antral ablation and LA substrate ablation with or without adjunctive antiarrhythmic drug.
88886847|NCT01420393|Active Comparator|Rate Control|Patients in the rate control group will receive optimal Heart Failure therapy and rate control measures to achieve a resting HR < 80 bpm and 6-minute walk HR < 110 bpm.
88886848|NCT01420406|Placebo Comparator|0 mg retinol|0 mg retinol activity equivalents (RAE) as white-fleshed sweet potatoes and a corn oil capsule
88886849|NCT01420406|Experimental|12 mg BC|12 mg of BC as orange-fleshed sweet potatoes and a corn oil capsule.
89410607|NCT02294084|Placebo Comparator|Placebo|Subjects will receive placebo for 12 weeks. Placebo will be given in 1 gift/day
89410608|NCT03640533|Experimental|Nanit-Insights intervention group|Nanit-Insights is an app-based intervention that provides parents with personalized sleep recommendations, based on their infant's developmental stage and weekly sleep data.
89410609|NCT03640533|No Intervention|Nanit-monitor control group|Participants in the control group will be given the same monitoring device, that will serve in this group as a baby-monitor only, without providing sleep recommendations to parents.
89410610|NCT04464746|No Intervention|Control|usual medical follow-up
89410611|NCT04464746|Active Comparator|Intervention|Implementation of a specific program to improve therapeutic adherence
89410612|NCT03640065|Experimental|freeze-dried probiotic sachets|
89410613|NCT03640065|Active Comparator|fermented dairy product (yogurt)|
89410614|NCT03515486|Experimental|Post-stroke mood disorders evaluation|Each patient will be assessed by a clinical evaluation, will have a standardized psychological evaluation, will perform a brain MRI and will be given a smartphone and an actimeter for a one-week period for the purpose of ecological evaluations.
89410615|NCT03512366|Experimental|Desarsda's technique|"These patients wil be operated by the Desarda's technique without using any prosthetic mesh. A strip of external oblique aponeurosis will be used to strengthen the defect.~Both field block and local infiltration with tumescent anaesthesia techniques will be used for anaesthesia~Intervention:~A strip will be separated from the upper leaf of the external oblique aponeurosis keeping its insertion and continuity with the muscle intact. This strip will be sutured with the inguinal ligament below and the muscle arch or conjoint tendon above behind the spermatic cord to form the new inguinal floor. Continuous non absorbable prolene 2-0 suture will be used to secure it to the inguinal ligament inferiorly , and will be secured superiorly to the internal oblique muscle using interrupted absorbable vicryl sutures."
89410616|NCT03512366|Active Comparator|Lichtenstein's technique|"These patients will be operated using prosthetic mesh described as Lichtenstein's tension free mesh hernioplasty.~Both field block and local infiltration with tumescent anaesthesia techniques will be used for anaesthesia.~Intervention :~A 6 × 11 cm polypropylene mesh will be fashioned to fit the posterior wall of the inguinal canal and sutured to the fibro-periosteum of the pubic bone and continued laterally, suturing the inferior edge of the mesh to the shelving edge of the inguinal ligament to a point 2 cm lateral to the internal ring. Laterally, 2 cm silt will be made through the mesh to accommodate the cord. while the two tails will be sutured to create a new deep ring made of mesh."
89410617|NCT02959671|Experimental|Lower Anterior EXD-952 Self-ligating Brackets|
89410618|NCT03515408|Experimental|Real rTMS (motor area)|Real rTMS targeting motor area for 30 min
88886850|NCT01420406|Experimental|6 mg of CX|6 mg of CX as tangerines and a corn oil capsule
88886851|NCT01420406|Experimental|1.0 mg RAE|1.0 mg RAE vitamin A as retinyl palmitate in corn oil, and white-fleshed sweet potatoes
88886852|NCT01420419|Experimental|Lanolin|Pea sized amount of lanolin to be applied to nipple and areola after every breast feed (approximately every 2-3 hours), until pain is completely resolved for a maximum of 7 days
88886853|NCT01420419|Other|Standard postpartum nursing care|Women in standard care control group may receive any other nursing intervention to manage their nipple pain, including (but not limited to): recommending application of expressed breast milk, analgesics (such as acetaminophen or ibuprofen), breast shells, air drying, changing position / latch, cold or warm compresses
88886854|NCT01420432|Experimental|Human umbilical cord-derived MSCs and DMARDs|Human umbilical cord-derived MSCs at a dose of 1.0E+6 MSC/kg, repeated after three months and DMARDs such as sulfasalazine,methotrexate,thalidomide po for 12 months
89192139|NCT00732836|Experimental|HAI Abraxane MTD|Dose escalation beginning Day 1, Cycle 2 dose level 180 mg/m^2 for maximum tolerated dose (MTD) of Hepatic Arterial Infusion of Abraxane (HAI Abraxane) following same dose intravenous Abraxane in Cycle 1 of 21 day cycle.
89410619|NCT03515408|Experimental|Real rTMS (parietal gyrus)|Real rTMS targeting parietal gyrus for 30 min
89410620|NCT03515408|Experimental|Real rTMS (both brain area)|Real rTMS targeting motor area and parietal gyrus for 15 min, separately
89410621|NCT03515408|Sham Comparator|Sham rTMS|Sham rTMS targeting motor area and parietal gyrus for 15 min, separately
89410622|NCT01597258||Crizotinib (Xalkori)|
89535694|NCT03073083|Active Comparator|Quadriceps tendon autograft|ACL reconstruction surgery with quadriceps tendon autograft
88886855|NCT01420432|No Intervention|DMARDs|DMARDs such as sulfasalazine,methotrexate,thalidomide po for 12 months
88886856|NCT01420445|Experimental|YHD001 dose level 1|YHD001 dose level 1
88886857|NCT01420445|Experimental|YHD001 dose level 2|YHD001 dose level 2
88886858|NCT01420445|Active Comparator|Pelargonium sidoides extract|Pelargonium sidoides extract (Syrup)
88886859|NCT01420445|Placebo Comparator|Placebo|Placebo for YHD001 & active comparator(syrup)
88886860|NCT01420471|Active Comparator|Saline-impregnated spacer|Saline-impregnated spacers are actively being used as the standard of care. It does not contain any active ingredients.
88886861|NCT01420471|Experimental|Triamcinolone-impregnated spacer|This study arm receives the experimental treatment, a Triamcinolone-impregnated spacer.
88886862|NCT01420484||different blood pressure intervals|
89192140|NCT00732836|Experimental|HAI Abraxane Expansion|HAI Abraxane dose expansion at MTD or dose level 3 (260 mg/m^2) if MTD not defined.
89192141|NCT00799149|Active Comparator|Gabapentin|Gabapentin (1200 mg) administered 30-90 min before the patient entered the operating room; Subsequent doses of Gabapentin (1200 mg)were administered on the mornings (08H00) of the first, second, and third postoperative days.
89410623|NCT02958267|Experimental|BMAC injection and PRP injection|Injection of bone marrow aspirate concentrate (BMAC) withdrawn from a bone near the hip into the knee joint (intra-articular) immediately followed by an injection of platelet-rich plasma (PRP) into the knee joint.
89410624|NCT02958267|Active Comparator|Gel-One® hyaluronate injection|Gel-One® is an hyaluronate gel used in the treatment of knee osteoarthritis by injection into the knee joint (intra-articular).
89410625|NCT02302352|Active Comparator|Probiotic|Oral probiotic 1g, once/day, containing: Lactobacillus paracasei, 10x9 CFU; Lactobacillus rhamnosus,10x9 CFU; Lactobacillus acidophillus, 10x9 CFU; Bifidobacterium lactis 10x9 CFU per sachet
88886863|NCT01420497|Active Comparator|methylprednisolone,infiltration|
88886864|NCT01420497|Active Comparator|epidural injection|
88886865|NCT01420510|Experimental|Adelmidrol|Efficacy of Adelmidrol vaginal gel in preventing vaginitis in oncologic patients
88886866|NCT01420510|Placebo Comparator|Placebo|Efficacy of Placebo in preventing vaginitis in oncologic patients
89410626|NCT02302352|Placebo Comparator|Placebo|Maltodextrin 1g per sachet, once/day
89410627|NCT02302430|Experimental|Treatment|Treatment group will receive either 20IU or 40IU intranasal oxytocin
89410628|NCT02302430|Placebo Comparator|Placebo|Placebo group will receive a saline nasal spray
89410629|NCT04485208|Experimental|Active|Patients will undergo ten to thirty minutes of transcranial ultrasound treatment. The sonification device will be aimed at the thalamus. Targeting will include reference to scalp fiducials based on the obtained MRI; confirmation of target accuracy will either be obtained by Doppler waveform confirmation or optical tracking technology which co-registers patient neuroimaging with real space.
89410630|NCT03640299|Experimental|ERAS procedure|"In this arm, ERAS perioperative cares patients planned to undergoing laparoscopic surgery, following the ERAS protocols.~Extensive preoperative counselling and education by surgeon and anesthetists.~No Bowel preparation.~6 h fast for solid food and carbohydrate loading with clear fuilds 2h before surgery.~Oral nonselective NSAIDs premedication.~Total Intravenous Anesthesia via TCI, wound infiltration and the transversus abdominis plane (TAP).~Minimally invasive surgery.~Maintenance of normothermia.~Avoidance of surgical drains and nasogastric tubes.~Nonselective NSAIDs postoperative medication.~Postoperative nausea and vomiting active control.~Early oral feeding and ambulation.~VTE prophylaxis postoperative."
89410631|NCT03640299|No Intervention|Traditional treatment procedure|"In this arm, control patients planned to undergoing laparoscopic surgery, following the traditional treatment protocols.~Conventional preoperative visits and education.~Mechanical bowel preparation.~Fasting overnight, and no fluids before surgery.~No oral nonselective NSAIDs premedication.~Continuous epidural anesthesia is administered before surgery. Sevoflurane and sufentanil maintain the depth of anesthesia.~Minimally invasive surgery.~No maintenance of normothermia.~Drainage tube insertion if needed.~Postoperative patient-controlled intravenous analgesia.~Postoperative Nausea Control if needed.~Conventional oral feeding and mobilization.~No bowel routine.~VTE prophylaxis postoperative."
89410632|NCT02300948|Experimental|PregVit-Folic 5®-5 mg folic acid|Prenatal multivitamin-mineral supplement called PregVit-folic 5® contains 5 mg of folic acid. All other vitamin and mineral doses are identical between the 2 supplements, except for folic acid. Both supplements are taken as 2 tablets daily, one tablet in the morning (am) and one tablet in the evening (pm). Both multivitamins are appropriate for periconceptional, prenatal, and post-partum supplementation.
89410633|NCT02300948|Active Comparator|PregVit®-1.1 mg folic acid|Prenatal multivitamin-mineral supplement called PregVit® contains 1.1 mg of folic acid. All other vitamin and mineral doses are identical between the 2 supplements, except for folic acid. Both supplements are taken as 2 tablets daily, one tablet in the morning (am) and one tablet in the evening (pm). Both multivitamins are appropriate for periconceptional, prenatal, and post-partum supplementation.
89410634|NCT03103828|Active Comparator|Computer-tailored intervention|
89410635|NCT03103828|Active Comparator|Motivational Interviewing|
88886867|NCT01420523|Experimental|Raltegravir-Maraviroc|Raltegravir 400 mg twice a day + Maraviroc 300 mg twice a day
88886868|NCT01420562||Posaconazole oral suspension|"One group of patients will receive posaconazole oral suspension as prophylactic agent.~Blood sampling: At day of transplantation, day 7 and 14, 9 blood samples will be collected to calculate AUC. Moreover, citrulline will be determined to objectively evaluate the severity of mucositis."
88886869|NCT01420562||Posaconazole oral tablet|"Once the oral tablet is available for adminstration to patients, a second group of patients will receive these tablets as prophylactic agent.~Blood sampling: At day of transplantation, day 7 and 14, 9 blood samples will be collected to calculate AUC. Moreover, citrulline will be determined to objectively evaluate the severity of mucositis."
88886870|NCT01420575|Experimental|Visual Decision Making Aid|Shared decision-making, in contrast to traditional medical decision-making, involves a collaborative process where patients discuss personal values and preferences and clinicians provide information to arrive at an agreed upon treatment decision. The focus of the intervention is to empower overweight patients with schizophrenia/schizoaffective disorder and help them efficiently arrive at a treatment decision that can be successfully implemented.
88886871|NCT01420575|Active Comparator|Usual Care|Usual care reflects the standard of care in psychiatry. Psychiatrists will recommend treatment for overweight patients with schizophrenia on olanzapine who have failed to lose weight despite life style and dietary modifications. They may recommend switching to a comparable antipsychotic with a lower incidence of weight gain.
88886872|NCT01420588||gastric cancer|
88886873|NCT01420588||gastritis|
88886874|NCT01420588||gastric ulcer|
88886875|NCT01420588||normal|
88886876|NCT01420614|Experimental|Radial|group of patients undergoing primary angioplasty by transradial approach
88886877|NCT01420614|Active Comparator|Femoral|group of patients undergoing primary angioplasty by transfemoral approach
89410636|NCT03103828|Active Comparator|Motivational Enhancement Therapy|
89410637|NCT03103828|No Intervention|Control Group|
89535695|NCT03317171|Experimental|Treated group|oral administration of flavonoids, DHA and EPA, once a day for 24 weeks.
88886878|NCT01420640|Active Comparator|Tai Chi|
88886879|NCT01420640|Active Comparator|Aerobic Exercise Training|
89410638|NCT02302508|Experimental|T2D patients with A1C ≤7.0|Clopidogrel, Prasugrel, Ticagrelor A single oral dose of clopidogrel 300 mg or prasugrel 60 mg or ticagrelor 180 mg in a randomized fashion on 3 different occasions (washout period of 12 days or more)
89410639|NCT02302508|Experimental|T2D patients with A1C>7.5|Clopidogrel, Prasugrel, Ticagrelor A single oral dose of clopidogrel 300 mg or prasugrel 60 mg or ticagrelor 180 mg in a randomized fashion on 3 different occasions (washout period of 12 days or more)
89410640|NCT02302508|Experimental|Insulino-treated|Clopidogrel, Prasugrel, Ticagrelor A single oral dose of clopidogrel 300 mg or prasugrel 60 mg or ticagrelor 180 mg in a randomized fashion on 3 different occasions (washout period of 12 days or more)
89410641|NCT02302508|Active Comparator|Non-diabetic healthy subjects|Clopidogrel, Prasugrel, Ticagrelor A single oral dose of clopidogrel 300 mg or prasugrel 60 mg or ticagrelor 180 mg in a randomized fashion on 3 different occasions (washout period of 12 days or more)
89410642|NCT03103984|Experimental|Control|The volunteers (overweight and obese) will receive nutritional counseling and a weight loss diet.
89410643|NCT03103984|Experimental|Immunosuppressed patients|The volunteers (liver transplantation) will receive nutritional counseling and a weight loss diet.
89410644|NCT02297594|Experimental|AK0529|Generic name: AK0529 Dosage Form: capsule
89410645|NCT02297594|Placebo Comparator|Placebo|Sugar placebo
89410646|NCT04484584||Complex Decongestive Therapy Group (CDT)|"Complex Decongestive Therapy Group: The treatment was applied by a specialist therapist who received CDT training. The study group rehabilitation and CDT application is 1 hour. CDT Treatment Protocol:~Deep abdominal technique application Neck region CDT application (supraclavicular fossa circular motion-Eflöraj) Circular movements on ipsilateral Axillar lymph nodes Circular movements on bottle neck cubital fossa Front arm bucket pumping pump push MLD application of dorsal and palmar face of the hand to ulnar and radial bundles~Bandage Treatment (Fingers and hand and forearm bandage): Patients can stay for 6-8 hours or until the next day.~Patients can do exercises in bandages. The patient is given home education.~The treatment was made for approximately 30-45 minutes. Patients were given exercise training at home. Orthopedic rehabilitation is the same as the control group."
89437526|NCT03720366|Experimental|Arm 3: Administration of Enasidenib and Arm 3 probes|Part 1: Subjects will receive prescribed doses of Arm 3 probes on Day -1, followed by the first enasidenib dose on Day 1. Subjects will continue to take enasidenib once daily for 27 more days. On Day 28, subjects will receive the Arm 3 probes again together with the Day 28 dose of enasidenib. Part 2: the subjects continue to receive daily doses of enasidenib for the next 28 days (equivalent to a cycle). The subject will continue in subsequent cycles until the end of the study (28 months) or termination.
89437527|NCT03718637|Active Comparator|Control|Surgical treatment alone, consisting of tendon debridement and repair. Ultrasounds preoperatively and 6 months postoperatively.
88813911|NCT03403478|Experimental|MICE|The moderate-intensity continuous exercise (MICE) will bem performed divided into 3 phases: warm-up (10 minutes), main part (30 minutes) and cool down (5 minutes). The warm-up and cool down will be performed at 55-60% HRmax. The main part will last 30 minutes and will be performed by 3 sets of 5 exercises lasting 2 minutes each one at 70-75% HRmax. For all phases, HR will be measured every 2 minutes during the whole session.
88819608|NCT01440764|Experimental|Saline, then F(40), then IV.F|"On Test Day 1, participants received Aerosol Saline 4ml by inhalation for 5-10 minutes.~On Test Day 2 (at least 24 hours after Test Day 3), participants received Aerosol Furosemide 40mg in 4ml saline by inhalation for 5-10 minutes.~On Test Day 3 (at least 24 hours after Test Day 2), participants received Furosemide 15 mg diluted in 10 ml of saline by intravenous delivery for 5 minutes."
88886880|NCT01420666|Active Comparator|Maxigesic 325|Maxigesic 325 (acetaminophen 325 mg + ibuprofen 97.5mg), three tablets four times a day, orally, with food
88819609|NCT01440764|Experimental|F(80), then Saline, then Saline|"On Test Day 1, participants received Aerosol Furosemide 80mg in 8ml saline by inhalation for 5-10 minutes.~On Test Day 2 (at least 24 hours after Test Day 1), participants received Aerosol Saline 8ml by inhalation for 5-10 minutes.~On Test Day 3 (at least 24 hours after Test Day 2), participants received Aerosol Saline 8ml by inhalation for 5-10 minutes."
88819610|NCT01440764|Experimental|Saline, then F(80), then Saline|"On Test Day 1, participants received Aerosol Saline 8ml by inhalation for 5-10 minutes.~On Test Day 2 (at least 24 hours after Test Day 1), participants received Aerosol Furosemide 80mg in 8ml saline by inhalation for 5-10 minutes.~On Test Day 3 (at least 24 hours after Test Day 2), participants received Aerosol Saline 8ml by inhalation for 5-10 minutes."
88819611|NCT01440764|Experimental|Saline, then Saline, then F(80)|"On Test Day 1, participants received Aerosol Saline 8ml by inhalation for 5-10 minutes.~On Test Day 2 (at least 24 hours after Test Day 1), participants received Aerosol Saline 8ml by inhalation for 5-10 minutes.~On Test Day 3 (at least 24 hours after Test Day 2), participants received Aerosol Furosemide 80mg in 8ml saline by inhalation for 5-10 minutes."
88819612|NCT03418389||Pediatric-onset Hypophosphatasia|
88819613|NCT01557452|Experimental|Givinostat|Patient received the dose of 0.75 mg/kg BID from December 28th, 2011 to January 27th, 2014
88819614|NCT03386799||Patient in wheelchair|Patient in wheelchair with E-motion device
88819615|NCT05298657||Poor IVF Treatment Responders|
88819616|NCT05298657||Hyper IVF Treatment Responders|
88819617|NCT05298657||Normal responders/ Control group|
88819618|NCT05283837|Experimental|Pertuzumab (ZRC-3277, Cadila Healthcare Ltd.,)|Pertuzumab (ZRC-3277) will be administered at a loading dose of 840 mg via IV infusion over 60 minutes (± 10 minutes) in Cycle 1 followed by 420 mg via IV infusion over 30 to 60 minutes in subsequent cycles then be given every 3 weeks, starting 3 weeks later till cycle 6.
88819619|NCT05283837|Active Comparator|Pertuzumab (Perjeta®, a product of Genentech, Inc.,)|Perjeta® will be administered at a loading dose of 840 mg via IV infusion over 60 minutes (± 10 minutes) in Cycle 1 followed by 420 mg via IV infusion over 30 to 60 minutes in subsequent cycles then be given every 3 weeks, starting 3 weeks later till cycle 6.
88819620|NCT01440920|Experimental|Cohort 1|0.3 mg
88819621|NCT01440920|Experimental|Cohort 2|1 mg
88819622|NCT01440920|Experimental|Cohort 3|3 mg
89410647|NCT04484584||Orthopedic Rehabilitation Group (OR)|"Orthopedic Rehabilitation Group: The treatment was made for approximately 30-45 minutes. Patients were given exercise training at home.~Orthopedic Rehabilitation Treatment Protocol:~Exercises to be done at 4 to 6 weeks: Wrist NEH (at the pain limit),active exercise,Grasp exercise~Exercises to be done at 6 to 8 weeks: Wrist NEH (at the pain limit),Active assistive / active exercise, Grasp exercise,Supination-pronation exercise. (Opposite baths and classical massage are recommended from orthopedics)~Exercises to be done at 8 to 10 weeks: Stretching exercises,Finger strengthening spring with Digiflex spring, Power web combo hand finger arm amplifier, Msd theraflex hand exercise dough, Theraband flevbar exercise bar.~Exercises to be done at 10 to 12 weeks Wrist strengthening exercises, Resistant exercises to all muscles."
89410648|NCT01742026||High Risk Oncohematological Patients|Detection Aspergillus PCR technique and Aspergillus AGA technique
89410649|NCT02297750|Active Comparator|single wire technique|single wire technique in patients undergoing ERCP with biliary cannulation
89410650|NCT02297750|Active Comparator|Double wire technique|double-wire technique in patients undergoing ERCP with biliary cannulation
89410651|NCT01682278||Amalgam cohort|Patients with medically unexplained physical symptoms attributed to dental amalgam restorations which the patient wish to have removed.
89410652|NCT01682278||MUPS-cohort|Patients with medically unexplained physical symptoms without attribution to amalgam and no explicit wish to remove amalgam.
89410653|NCT01682278||Dental cohort|Healthy comparison group: Subjectively healthy without diagnosed chronic disease or prescribed medication.
89410654|NCT01952574|Placebo Comparator|Placebo|"Participants received placebo on day 1 and at weeks 4 and 8 by subcutaneous injection during the double-blind treatment phase.~In the open-label treatment phase participants received 70 mg erenumab QM from week 12 to week 264 (last dose). After Protocol Amendment 3, participants still on study had their dose increased to 140 mg QM."
89410655|NCT01952574|Experimental|Erenumab 7 mg QM|"Participants received erenumab 7 mg on day 1 and at weeks 4 and 8 by subcutaneous injection during the double-blind treatment phase.~In the open-label treatment phase participants received 70 mg erenumab QM from week 12 to week 264 (last dose). After Protocol Amendment 3, participants still on study had their dose increased to 140 mg QM."
89410656|NCT01952574|Experimental|Erenumab 21 mg QM|"Participants received erenumab 21 mg on day 1 and at weeks 4 and 8 by subcutaneous injection during the double-blind treatment phase.~In the open-label treatment phase participants received 70 mg erenumab QM from week 12 to week 264 (last dose). After Protocol Amendment 3, participants still on study had their dose increased to 140 mg QM."
89410657|NCT01952574|Experimental|Erenumab 70 mg QM|"Participants received erenumab 70 mg on day 1 and at weeks 4 and 8 by subcutaneous injection during the double-blind treatment phase.~In the open-label treatment phase participants received 70 mg erenumab QM from week 12 to week 264 (last dose). After Protocol Amendment 3, participants still on study had their dose increased to 140 mg QM."
89410658|NCT01952574|Experimental|CHU Substudy: Erenumab 140 mg PFS|Participants in the open-label treatment phase in the United States randomized to self-administer 140 mg erenumab via two 70 mg injections using a prefilled syringe (PFS) on CHU substudy day 1 (under study site supervision), and at home on day 29 (week 4) and day 57 (week 8).
89410659|NCT01952574|Experimental|CHU Substudy: Erenumab 140 mg AI/Pen|Participants in the open-label treatment phase in the United States randomized to self-administer 140 mg erenumab via two 70 mg injections using an autoinjector/pen (AI)/pen) on CHU substudy day 1 (under study site supervision), and at home on day 29 (week 4) and day 57 (week 8).
89410660|NCT02302586|Active Comparator|Patient Controlled Analgesia (IV PCA)|Postoperative intravenous (IV) morphine PCA is being used for acute pain control: Basal infusion: 0.3 mg/kg/h Bolus: 1 mg, Lock-out time: 20 min, 4-h limit: 10-12,5 mg
89410661|NCT02302586|Active Comparator|Thoracic Paravertebral Block (TPVB)|Preoperative thoracic paravertebral block (TPVB) at 4 levels from T4 to T8 is being performed and total of 20 mL Bupivacaine 0.5% is deposited (5 mL per level by using landmark technique)
89410662|NCT03512054|Experimental|Experimental procedure|
89410663|NCT05430646|Experimental|CMUS group|Balloon dilatation and CMUS insertion were performed in this group.
89410664|NCT05430646|Active Comparator|Tandem DJ stent group|Balloon dilatation and Tandem DJ stent insertion were performed in this group.
89437528|NCT03718637|Experimental|Experimental|Identical surgical treatment plus Smith & Nephew bio-inductive patch implant. Ultrasounds preoperatively and 6 months postoperatively.
88886881|NCT01420666|Active Comparator|Acetaminophen|Acetaminophen 325 mg, three tablets four times a day, orally, with food
88886882|NCT01420666|Active Comparator|Ibuprofen|ibuprofen 97.5mg, three tablets four times a day, orally, with food
88886883|NCT01420666|Placebo Comparator|Placebo|Placebo tablets
88886884|NCT01420692|Active Comparator|Gliclazide MR|
88886885|NCT01420692|Active Comparator|Insulin Detemir|Early initiation of insulin detemir in contrast to Gliclazide MR treatment
88886886|NCT01420705||Low birth-weight cohort|Children previously enrolled in randomised trial NCT00146302 who are currently living within the Bandim Health Project study area
88886887|NCT01420718|Active Comparator|Mineral Trioxide Aggregate|partial pulpotomy using White ProRoot MTA. Partial pulpotomy includes removal of 1mm of coronal pulp and covering the remaining tissue with a suitable material.
88886888|NCT01420718|Experimental|iRoot BP|Partial pulpotomy using iRoot BP. Partial pulpotomy includes removal of 1mm of coronal pulp and covering the remaining tissue with a suitable material. Bioaggregate is the first nano particle, water based root end filling material. This product includes calcium silicate, calcium hydroxide, hydroxy apatite and Tantalum oxide. Compared to MTA,this material lacks Bismuth oxide and calcium aluminate. iRoot BP is the injectable for of Bioaggregate (Injectable Root Bioaggregate Paste).
88886889|NCT01420744|Experimental|BT086 infusion|
88886890|NCT01420744|Placebo Comparator|1% Human Albumin infusion|
88886891|NCT01420757|Active Comparator|open|open incisional hernia repair
88886892|NCT01420757|Active Comparator|laparoscopic|laparoscopic incisional hernia repair
88886893|NCT01420796|Experimental|Swallowing and breathing exercises|This group will perform both swallowing and breathing exercises for five weeks.
89192142|NCT00799149|Active Comparator|Etoricoxib|Etoricoxib (120 mg)administered 30-90 min before the patient entered the operating room; Subsequent doses of etoricoxib (120 mg)were administered on the mornings (08H00) of the first, second, and third postoperative days.
89410665|NCT02302664|Active Comparator|PRP Injection|Intervention - PRP Injection: The injection is the intervention. A blood sample is withdrawn from patient. Away from patient part of sample is spun down in centrifuge to produce 'Platelet Rich Plasma' (PRP). Patient returns to treatment area and their own PRP is then injected into tendon rupture gap. This is carried out by a surgeon or extended scope physiotherapist, generally in the outpatient clinic, after a local anaesthetic has been applied. Patient is lying face down during procedure, unaware of treatment given to tendon at back of leg. Remaining blood sample sent for analysis.
89410666|NCT02302664|Sham Comparator|Imitation Injection|Sham - Imitation Injection: The injection is the intervention. A blood sample is withdrawn from patient. Treatment is prepared. Patient returns to treatment area and a needle (no syringe) is inserted and held into tendon rupture gap to mimic injection (after local anaesthetic has been applied). No active ingredient given. Carried out by surgeon or extended scope physiotherapist, generally in the outpatient clinic. Patient is lying face down during procedure, unaware of treatment given to tendon at back of leg. Blood sample sent for analysis.
89410667|NCT01551472||3DKnee™ with e-plus Insert|Subjects who meet the indications for use criteria for the 3DKnee™ System with vitamin E UHMWPE tibial inserts (VE) and who are candidates for a primary knee arthroplasty.
89410668|NCT03104062|Other|Ticagrelor|Patients will be randomized to have Ticagrelor 90mg BID
89410669|NCT03104062|Other|Clopidogrel|Patientes will be randomized to have Clopidogrel 75mg once a day
89410670|NCT03515330|No Intervention|Standard of Care|Participants in the control arm will be instructed to take their immunosuppressant medications as prescribed and attend required follow-up as is standard of care, and will not receive the mHealth application.
89410671|NCT03515330|Experimental|mHealth Intervention|Participants in the intervention arm will receive the mHealth app either while they are an inpatient post-transplant, or at their first post-transplant clinic visit. Study personnel will assist participants assigned to the mHealth intervention arm with downloading the application and explain its functioning. Participants will then use the application to aid in immunosuppressant medication adherence post-transplant.
89410672|NCT02143206||Exercise Method|Patients attend exercise 80 minute exercise sessions of which 30 minutes includes aerobic exercise on a NuStep and Biodex elliptical machine. Patients pain levels are scored when using the NuStep then when using the Biodex and these scores are compared to determine which machine give the best outcome for pain management
89410673|NCT03103672||Groupe I|Patients who will receive inhalation anesthesia
89410674|NCT03103672||Groupe 2|Patients who will receive total intravenous anesthesia
89410675|NCT03511898|Experimental|THR-149 dose level 1|
89410676|NCT03511898|Experimental|THR-149 dose level 2|
89410677|NCT03511898|Experimental|THR-149 dose level 3|
89410678|NCT02254044|Experimental|bivatuzumab mertansine|dose escalation
89410679|NCT03103594|Active Comparator|DMSO alone|Half of the patients will undergo DMSO instillation
89410680|NCT03103594|Experimental|DMSO with Botox|The other half will be randomized to DMSO mixed with 200U of botulinum toxin instillation
89410681|NCT03515252|Experimental|Late stage lung cancer and liver cancer|Immune Killer Cells (IKC)
89410682|NCT02143284|Experimental|Endoscopy exploratory single arm|Exploratory single arm, the system will be used in otherwise standard procedures, and will be reviewed in terms of performance, usability, ease of use and safety.
89410683|NCT05430568||bypass graft, sternotomy|patients who have received coronary artery bypass graft surgery with conventional sternotomy procedure
89410684|NCT05430568||bypass graft, robot|patients who have received coronary artery bypass graft surgery with robot-assisted procedure
89410685|NCT05430568||valvular heart disease, sternotomy|patients who have received valvular replacement surgery with conventional sternotomy procedure
89192143|NCT00799149|Placebo Comparator|Sugar pill|Sugar pill administered 30-90 min before the patient entered the operating room. Subsequent doses of Sugar pill were administered on the mornings (08H00) of the first, second, and third postoperative days.
89410686|NCT05430568||valvular heart disease, robot|patients who have received valvular replacement surgery with robot-assisted procedure
89437529|NCT03707951|Experimental|N-acetylcysteine|N-acetylcysteine 1200 mg twice daily for 8 weeks; administered orally
89410687|NCT02302820|Active Comparator|Make Your Wishes Known|"A Decision Aid that uses interactions, videos, vignettes.~A formatted Advance Directive; saved data that may be revisited to produce a revised Advance Directive"
89410688|NCT02302820|Active Comparator|Mayo Clinic-Advance Health Care Planning|"Not an online decision aid~Written instructions, worksheets, and Advance Directive to complete"
89410689|NCT02302820|Active Comparator|Mydirectives.com|"Online decision aid that uses interactions, videos, and vignettes.~An electronically stored Advance Directive that may be printed."
89410690|NCT02302820|Active Comparator|Prepare|"An online decision aid that uses interactions, videos and vignettes.~A printed summary useful for transposing values and treatment wishes into an Advance Directive; a list of action steps."
89410691|NCT02301104|Experimental|Mild Hepatic Impairment|35 mg/m2/dose of TAS-102 orally, twice daily on days 1-5 and days 8-12 of each 28-day cycle. Number of cycles: approximately 4 or until discontinuation criteria is met.
89410692|NCT02301104|Experimental|Moderate Hepatic Impairment|35 mg/m2/dose of TAS-102 orally, twice daily on days 1-5 and days 8-12 of each 28-day cycle. Number of cycles: approximately 4 or until discontinuation criteria is met.
89410693|NCT02301104|Experimental|Severe Hepatic Impairment|"35 mg/m2/dose of TAS-102 orally, twice daily on days 1-5 and days 8-12 of each 28-day cycle. Number of cycles: approximately 4 or until discontinuation criteria is met.~The dose level of severe cohort, if enrolled, will be determined based on the Interim Assessment of mild and moderate cohorts."
89410694|NCT02301104|Experimental|Normal Hepatic Function|35 mg/m2/dose of TAS-102 orally, twice daily on days 1-5 and days 8-12 of each 28-day cycle. Number of cycles: approximately 4 or until discontinuation criteria is met.
89410695|NCT03102268||cholangiocarcinoma patients|cholangiocarcinoma patients without any anti-cancer therapy
89410696|NCT03102268||benign biliary stricture patients|benign biliary stricture patients without any therapy targeting the stricture
89410697|NCT02302898||Wt maintenance|Eating Behavior Evaluation Measurement of Functional gastric volume Measurement of gastric pouch and GJ sizes
89410698|NCT02302898||Wt Regain|Eating Behavior Evaluation Measurement of Functional gastric volume Measurement of gastric pouch and GJ sizes
89410699|NCT02959437|Experimental|Treatment Group A: Azacitidine + Pembrolizumab + Epacadostat|Part 1 is an open-label 3 + 3 + 3 dose-escalation design based on observing each dose level for a period of 21 days. Part 2 will evaluate the recommended dose determined in Part 1.
89410700|NCT02959437|Experimental|Treatment Group B: INCB057643 + Pembrolizumab + Epacadostat|Part 1 is an open-label 3 + 3 + 3 dose-escalation design based on observing each dose level for a period of 42 days. Part 1 will also contain dose-expansion cohorts in previously treated NSCLC and MSS CRC. Part 2 will evaluate the recommended dose determined in Part 1.
89410701|NCT02959437|Experimental|Treatment Group C: INCB059872 + Pembrolizumab + Epacadostat|Part 1 is an open-label 3 + 3 + 3 dose-escalation design based on observing each dose level for a period of 42 days. Part 1 will also contain dose-expansion cohorts in previously treated NSCLC and MSS CRC. Part 2 will evaluate the recommended dose determined in Part 1.
89410702|NCT05179304|Experimental|Oncoplastic technique with a droplet-shaped glandular flap|
89410703|NCT03102424|Experimental|Transcutaneous Electrical Nerve Stimulator (DW1330)|The 20 weeks of treatment of the DW1330 device, all the patients enrolled should perform 1 treatment within 1 hour after dinner 5 days a week.
89410704|NCT03102424|Placebo Comparator|Sham DW1330 device|The 20 weeks of treatment of the Sham DW1330 device, all the patients enrolled should perform 1 treatment within 1 hour after dinner 5 days a week.
89410705|NCT02297906|Experimental|Intranasal ketorolac|Ketorolac 0.5 mg/kg, maximum single dose = 30 mg. Administered once by intranasal route using a mucosal atomization device.
89410706|NCT02297906|Active Comparator|Intravenous ketorolac|Ketorolac 0.5 mg/kg, maximum single dose = 30 mg. Administered once by intravenous route.
89410707|NCT03619161|No Intervention|No cleaning (control)|Patients will have a bacterial culture taken from their bathtub and then continue regular care. We will offer to clean their bathrooms after the 4 week intervention period ends.
89410708|NCT03619161|Experimental|Bubbles|Patients will have a bacterial culture taken from their bathtub and have their bathrooms cleaned by the investigators
89410709|NCT03619161|Active Comparator|Bleach and Bubbles|Patients will have a bacterial culture taken from their bathtub, have their bathrooms cleaned by the investigators, and be given instructions to perform bleach baths twice weekly.
89410710|NCT02957331|Experimental|Propranolol arm|One half of qualifying and consenting subjects will be randomized to receive propranolol. This group will receive study drug 3 times daily (every 8 hours) starting at 20 mg. The dosage may be increased by up to 60 mg/day divided over three daily doses (or an additional 20 mg/dose) as necessary until the heart rate is less than 100. Study drug will be held for hypotension (systolic <100) or bradycardia (heart rate <60 beats per minute). The maximum daily dose for the treatment of hypertension of 640 mg will not be exceeded in this study.
89410711|NCT02957331|No Intervention|Non propranolol arm|Non beta blockade arm will receive standard of care treatment and will not receive beta blockade. If a subject randomized to no Inderal develops hypertension and increased heart rate, he/she will be treated according to standard of care by the trauma team caring for the patient.
89410712|NCT03510806|Placebo Comparator|Placebo|taste, color, and calorie-matched to supplement
89535696|NCT03317171|Placebo Comparator|Placebo group|oral administration of placebo compound, once a day for 24 weeks.
89410713|NCT03510806|Experimental|Supplement|Proprietary protein and fruit extract blend
89410714|NCT05430256||Premature children with neurological developmental disorder(such as ADHD)|Premature children with neurological developmental disorder (such as ADHD): n = 200
89410715|NCT05430256||Premature children with neurological developmental disorder(such as ASD)|Premature children with neurological developmental disorder (such as ASD): n = 50
89410716|NCT05430256||Premature infants with no neurodevelopmental disorders|Premature infants with no neurodevelopmental disorders: n = 200
89410717|NCT05430256||Age and gender match in non-preterm children|Age and gender match in non-preterm children: n = 200
89410718|NCT02297984||Acute ischemic stroke|Patients who suffered from acute ischemic stroke within 12 hours for the first time before entry into the study.
89410719|NCT00918112||Parkinson's Disease|Meets criteria for definite Parkinson's Disease
89410720|NCT00918112||Healthy Controls|- Must be in good health
89535697|NCT03220321|Active Comparator|IPS e.max hybrid abutment crown|
89410721|NCT02298062|Experimental|Infliximab|For one group of patients with resistance to intravenous immunoglobulin in Kawasaki disease , we will give them infliximab (5mg/kg) once.
89410722|NCT02298062|Active Comparator|IVIG|For the other group of patients with resistance to intravenous immunoglobulin in Kawasaki disease , we will give them IVIG (2g/kg) once.
89410723|NCT03510728|No Intervention|No single-session intervention-EMA|Participants will be assessed both using a computer and using their phone. However, they will not receive an intervention at the start of the study and will only be using their phone for ecological assessment only data collection.
89410724|NCT03510728|Active Comparator|Standard single-session intervention-EMA|Participants will take a computerized BMI with known efficacy, the college drinker's check up, and will be followed up. Participants in this condition will interact with their phone only for assessment purposes.
89410725|NCT03510728|Experimental|Augment single-session intervention-EMA|Participants will take a computerized BMI with known efficacy, the college drinker's check up, and will also take a computerized intervention developed to increase the use of protective behavioral strategies during drinking (Protective Behavioral Strategies Intervention). Participants in this condition will interact with their phone only for assessment purposes.
89410726|NCT03510728|Experimental|No single-session intervention-EMI|Participants in this group will not take a single-session intervention at baseline, but will be interacting with their phones during drinking occasions to promote protective behavioral strategy use (Ecological Momentary Intervention).
89410727|NCT03510728|Experimental|Standard single-session intervention-EMI|Participants will take a computerized BMI with known efficacy, the college drinker's check up, and will be followed up. Participants in this condition will be interacting with their phones during drinking occasions to promote protective behavioral strategy use (Ecological Momentary Intervention).
89410728|NCT03510728|Experimental|Augment single-session intervention-EMI|Participants will take a computerized BMI with known efficacy, the college drinker's check up, and will also take a computerized intervention developed to increase the use of protective behavioral strategies during drinking (Protective Behavioral Strategies Intervention). Participants in this condition will be interacting with their phones during drinking occasions to promote protective behavioral strategy use (Ecological Momentary Intervention).
89410729|NCT03101956|Experimental|L/S Manipulation Study Group|
89410730|NCT03101956|Active Comparator|Control Group|
89410731|NCT03511508|Active Comparator|ChroPreg|The participants in the intervention Group receive the midwife-coordinated, individualized and specialized intervention plus standard care
89410732|NCT03511508|No Intervention|Standard care alone|"Participants in the control group receive the standard care for pregnant women with chronic disease.~The standard care is given to the participants in the control group. The standard care for pregnant women with chronic disease include five routine visits at a non-specialized midwife and an individually scheduled number of visits with an obstetrician, depending on the type and severity of the chronic Medical disease and possible pregnancy complications.~The women in the control Group have the same amount of ultrasound examinations as do the women in the intervention Group.~Women in the control Group can attend auditorium antenatal classes at the hospital."
89410733|NCT02303054|Experimental|Bipolar Radiofrequency Focal Ablation|Men identified as having suspicious regions on an Prostatic multi-parametric MRI (mpMRI) of the prostate will be considered for enrollment. If followed by a positive MRI-US targeted biopsy of the prostate, men who be offered enrollment into the study. All men enrolled in the study will undergo bipolar radiofrequency ablation. Efficacy will be assessed through MRI-US biopsy after focal bipolar RFA.
89410734|NCT02303132|Other|Active MC|Patients with active MC will be included
89410735|NCT02303132|Other|MC in remission|Patients with MC in remission will be included
89410736|NCT02303132|Other|Controls|Patients without MC will be included
89192144|NCT00727974||1|"Diagnostic Criteria for CVS:~3 or more different episodes of vomiting, normal health between episodes, no abnormal test results to account for vomiting [such as endoscopic biopsies (looking at a body part with a lighted tube), hydronephrosis (water block kidney drainage), cholelithiasis (gallstones), pancreatitis (swelling of the pancreas), and hypoglycemia (too little sugar in the blood)];"
89410737|NCT03515018|Experimental|Hydroxyurea|Drug: hydroxyurea, pulse therapy
89410738|NCT03515018|Active Comparator|imatinib|Drug: imatinib, 400mg PO per day
89410739|NCT05891418|Experimental|Control Group with a standard eligibility notice|Control group was assigned to receive no email outreach in June and July beyond an eligibility redetermination notice.
89410740|NCT05891418|Experimental|Treatment group with a standard eligibility notice and assigned two email nudges|Assigned to receive an eligibility redetermination notice along with two informational emails about the benefits of Cost-Sharing Reduction Silver plans.
89410741|NCT05891366|Experimental|WAL0921|Single intravenous infusion of investigational drug WAL0921
89410742|NCT05891366|Placebo Comparator|Placebo|Single intravenous infusion of normal saline
89410743|NCT02297828|Experimental|Boussignac CPAP|"Boussignac CPAP with a 50% FiO2 (adjusted in a piece adapted to the system) and a pressure of 5cmH2O (measured with a manometer) is applied immediately after extubation and mantained for two hours after extubation in the post anesthesia care unit (PACU).~Arterial blood samples to measure PaO2 and PaO2/FiO2 ratio are collected before surgery and at 1, 2 and 24 hours after extubation. Spirometry is performed at the same intervals measuring FEV1 and FVC."
89005159|NCT00477412|Experimental|Treatment (combination chemotherapy)|"Participants receive Drug Combination I during courses 1, 3, 5, and 7 (if needed) and Drug Combination II during courses 2, 4, 6, and 8 (if needed) in the absence of disease progression or unacceptable toxicity.~Drug Combination I: Participants receive rituximab IV over 6 hours on day 1, cyclophosphamide IV over 3 hours BID on days 2-4, doxorubicin IV over 15-30 minutes on day 5, vincristine IV over 15-30 minutes on days 5 and 12, dexamethasone PO or IV on days 2-5 and 12-15, and bortezomib IV over a few seconds after the first dose of cyclophosphamide and immediately after vincristine and doxorubicin have been given on day 5.~Drug Combination II: Participants receive rituximab IV over 6 hours on day 1, methotrexate IV over 24 hours on day 2, and cytarabine IV over 2 hours every 12 hours on days 3-4."
89005160|NCT00410852|Experimental|A|
89410744|NCT02297828|Active Comparator|Ventury face mask|"Venturi mask with a 50% FiO2 is used immediately after extubation and mantained for two hours in the post anesthesia care unit (PACU).~Arterial blood samples to measure PaO2 and PaO2/FiO2 ratio are collected before surgery and at 1, 2 and 24 hours after extubation. Spirometry is performed at the same intervals measuring FEV1 and FVC."
89410745|NCT05891288|Experimental|bioactive group|Bioactive Pits & fissures sealant BioCoat® by Premier®.
89410746|NCT05891288|Active Comparator|Comparator group|Fluoride releasing resin based Pits & fissures sealant 3M™ Clinpro™ Sealant
89410747|NCT05891145|Experimental|Remimazolam group|General anesthesia was induced with 0.1 mg/kg of remimazolam and maintained with 0.1 mg•kg-1•h-1 remimazolam.
89410748|NCT05891145|Active Comparator|Control group|General anesthesia was induced with 0.1 mg/kg midazolam.
89410749|NCT05891080|Experimental|Safety run-in arm|In this arm, 6 patients with resectable or potentially resectable stage III non-small cell lung cancer will receive 4 circles of neoadjuvant toripalimab and JS004 combined with platinum-based doublet chemotherapy and those resectable after neoadjuvant therapy will be treated with surgery.
89410750|NCT05891080|Experimental|JS004 arm|Patients with resectable or potentially resectable stage III non-small cell lung cancer will be randomized into this arm (59 patients) and receive 4 circles of neoadjuvant toripalimab and JS004 combined with platinum-based doublet chemotherapy and those resectable after neoadjuvant therapy will be treated with surgery.
89410751|NCT05891080|Active Comparator|Control arm|Patients with resectable or potentially resectable stage III non-small cell lung cancer will be randomized into this arm (59 patients) and receive 4 circles of neoadjuvant toripalimab combined with platinum-based doublet chemotherapy and those resectable after neoadjuvant therapy will be treated with surgery.
89410752|NCT05891067|Experimental|SterkWerk|SterkWerk is a classroom-based approach (throughout the school year) for primary school groups 5-8 (children aged 8-12 years old) in which children are given specific roles to actively work on responsibility, ownership and prosocial behavior. SterkWerk consists of three main components: meaningful roles, classroom meeting and compliments.
89410753|NCT05891067|Active Comparator|Treatment-as-usual|Schools in the control group do not receive the intervention (do not receive material or training), and function as normal (treatment-as-usual). Control schools are requested to not start any social-emotional program during the school year 2023/2024.
89410754|NCT05891054|Experimental|Active breaks|"Active breaks consist of short breaks during academic classes other than physical education that include moderate to vigorous physical activity, usually unrelated to curricular content.~In this type of intervention, 2 active breaks are taken daily in a predetermined time slot. The development of each break is done through access to a specific digital platform where students follow the instructions of an avatar, which is in charge of guiding the realization of the active break. Each active rest involves a total of 4 minutes of activity, in which two sets of 20 seconds of work and 10 seconds of rest of four different exercises are performed, ending with a brief return to calm consisting of two deep breaths. The activities selected for each of the active breaks include aerobic and strengthening activities of moderate and vigorous intensity."
89437530|NCT03707951|Placebo Comparator|Placebo|Placebo (matched in appearance to N-acetylcysteine to preserve double-blind) twice daily for 8 weeks; administered orally
89437531|NCT03706690|Experimental|Durvalumab Therapy|Durvalumab (PD-L1 monoclonal antibody)1500 mg every 4 weeks [q4w] intravenously [iv] until clinical progression/deterioration or confirmed radiological progression)
89005161|NCT00410852|Experimental|B|
89437532|NCT03706690|Placebo Comparator|Placebo Therapy|Placebo (matching placebo for infusion every 4 weeks iv until clinical progression/deterioration or confirmed radiological progression)
89535698|NCT03220321|Experimental|VITA Enamic hybrid abutment crown|
89410755|NCT05891054|Experimental|Physically active learning|"Physically active learning consists of the incorporation of physical activity (usually of moderate-vigorous intensity) into the educational content taught in academic lessons that do not refer to physical education.~This type of intervention is carried out once a week for 1 hour outside the classroom, where physical activity (through movement, jumping, strengthening exercises, throwing, etc.) is incorporated into academic mathematics classes.~The mathematics teachers (with the support of the research team) are in charge of teaching the physically active classes. Prior to the development of each class, the research team, together with the mathematics teachers involved, meet and design the class according to the contents to be addressed."
89410756|NCT05891054|No Intervention|Control Group|The control group will receive the usual academic classes without any methodological modification during the intervention period.
89410757|NCT05891002||Biopsy Patient|Patient with a confirmed intracranial neoplasm scheduled for a biopsy with Cirq® Robotic Alignment Module Cranial and registration via Auto-Registration Software Universal Automatic Image Registration Cranial and Loop-X® Mobile Imaging Robot.
89410758|NCT05890989||INCREASED EPICARDIAL ADIPOSIS TISSUE|
88886894|NCT01420796|Experimental|Swallowing exercises|This exercises aim to increase strength and range of motion of mouth, larynx and pharynx structures. All patients will perform sustained vowel phonation of /a/, pushing plosive phonemes /pa/, /ta/, /ka/ in a forceful manner, suction of wet gauze, swallowing with tongue hold and modified supraglottic maneuver, in ten repetitions, ascending and descending gliding phonation of vowel /a/ and /u/, five repetitions of each vowel, and tongue rotation in oral vestibule, 3 series of 5 repetitions to each side.
88886895|NCT01420796|Experimental|Breathing exercises|Expiratory Muscle Training will be performed with Threshold® (Respironics HealthScan, Inc, Cedar Grove, Nova Iorque, EUA).
88886896|NCT01420822||Subjects prescribed ALLERMIST|Subjects with allergic rhinitis prescribed ALLERMIST during study period
88886897|NCT01420835|Active Comparator|Without Protocol Group|"The chinese auriculotherapy is a intervention used by Chinese Traditional Medicine in order to balance the body energy and to treat several kind of diseases using semi-permanent needles in specific points of the auricular pavilion.~Five points will be chosen to treat stress according to the symptoms and Chinese diagnosis."
88886898|NCT01420835|Active Comparator|Auriculotherapy with protocol|Auriculotherapy with stress protocol points. Five points are indicated for stress (Liver yang1, Liver yang2, Shenmen, Brainstem and Kidney).
88886899|NCT01420835|No Intervention|Control Group|Control Group won't receive any treatment and will be evaluated at the same time and the same way of interventions group
88886900|NCT01420861|Experimental|1000 mg GTx-758 BID|subjects will receive daily doses of 1000 mg GTx-758
88886901|NCT01420887|Experimental|Continuous Passive Motion|Subjects randomized to CPM therapy.
88886902|NCT01420887|Active Comparator|Physical Therapy|Subjects randomized to physical therapy.
88886903|NCT01420900|Active Comparator|ABG II / Trident|
89410759|NCT05890937|Experimental|Mental stress group|they were expected to take their exams just after the assessment and before measuring for the second time
89410760|NCT05890937|No Intervention|Control group|they were expected to take nothing for 30 min just after the assessment and before measuring for the second time
88886904|NCT01420900|Active Comparator|CLS / Trilogy|
88886905|NCT01420913|Active Comparator|Lyrica capsule(Pregabalin 150mg)|
88886906|NCT01420913|Experimental|YHD1119 A(Pregabalin SR 300mg)|
88886907|NCT01420913|Experimental|YHD1119 B(Pregabalin SR 300mg)|
88886908|NCT01420913|Experimental|YHD1119 C(Pregabalin SR 300mg)|
88886909|NCT01420978|Experimental|High volume CSF diversion|The EVD will be set to an initial level of 5 mmHg. The drain will remain in place at a level of ≤ 5 mmHg until at least day 10 after SAH before a weaning trial is attempted.
88886910|NCT01420978|Active Comparator|Conventional CSF diversion|The EVD will be set to a level of 15 mmHg for as long as needed for the treatment of hydrocephalus, and subsequently weaned at the discretion of the treating physician. Lowering the level of the EVD can be considered by the treating physician if sustained intracranial hypertension occurs
88886911|NCT01421004|Experimental|500 mg FMI capsule + 250 mg FMI tablet|BE phase sequence 1= 3 weeks on FMI capsule then 1 week on FMI tablet
88886912|NCT01421004|Experimental|500 mg TKI258 FMI capsule +250 mg FMI tablet|BE phase sequence 2= 3 weeks on FMI tablet then 1 week on FMI capsule
88886913|NCT01421030|Other|quality of life, clinical outcomes and costs|Quality of life, clinical outcomes and costs after two different treatment options in patients and closest relatives
88886914|NCT01421043|Experimental|triazolam liquid oral drops|
88886915|NCT01421043|Active Comparator|triazolam tablets|
88886916|NCT01421082|Experimental|LVRC Treatment|
88886917|NCT01421108|Experimental|Loss-framed messages|
88886918|NCT01421108|Experimental|gain-framed messages|"Adolescents will randomly assign to three groups: gain-framed message , loss-framed message and a control group. Each group of adolescents will read the respective pamphlets with the exception of the control group. The gain-framed pamphlet contains six positive messages with three related full-color images (6.1 X 4.5). The gain-framed pamphlet, entitled The Benefits of good oral hygiene, emphasizes the benefits of brushing, and flossing."
88886919|NCT01421121|Experimental|100U EV71 vaccine with adjuvant|120 infants received 2 doses of 100U EV71 vaccine with aluminium hydroxide adjuvant 28 days apart
88886920|NCT01421121|Experimental|200 U EV71 vaccine with adjuvant|120 infants received 2 doses of 200U EV71 vaccine with aluminium hydroxide adjuvant 28 days apart
89410761|NCT05890911||Study group|Participants with the diagnosis of sleep-disordered breathing
89410762|NCT05890911||Control group|Healthy participants without diagnosis of sleep-disordered breathing
89410763|NCT05890885|Experimental|Real - Sham|Real left prefrontal tDCS followed by sham tDCS after a 4-week washout period
89410764|NCT05890885|Experimental|Sham - Real|Sham tDCS followed by real left prefrontal tDCS after a 4-week washout period
89410765|NCT05890859|Other|DXA scans and physical tests|All patients are allocated to this arm and will undergod DXA scans and physical testing in addition to usual care/treatment
88886921|NCT01421121|Experimental|400U EV71 vaccine with adjuvant|120 infants received 2 doses of 400U EV71 vaccine with aluminium hydroxide adjuvant 28 days apart
88886922|NCT01421121|Experimental|200U EV71 vaccine without adjuvant|60 infants received 2 doses of 200U EV71 vaccine without adjuvant 28 days apart
88886923|NCT01421121|Placebo Comparator|Placebo|120 infants received 2 doses of placebo 28 days apart.
88886924|NCT01421173|Experimental|Vorinostat + GemBuMel|Vorinostat 200 mg by mouth on Days -8 to -2. Gemcitabine loading dose of 75 mg/m2 followed by continuous infusion. Remaining dose is 10 mg/m2/min on Day -8 and -3. Busulfan pharmacokinetics (PK) will be performed with the first dose of 105 mg/m2 by vein on Day -8. The doses of days -6 and -5 will be subsequently adjusted to target an area under curve (AUC) of 4,000 microMol.min-1. In the event that PK adjusting were not possible, a dose of busulfan of 105 mg/m2 will be administered on days -6 and -5. Melphalan 60 mg/m2 by vein on Days -2 and -3. Stem cells by vein over about 30-60 minutes on Day 0. Rituximab 375 mg/m2 on days +1 and +8 for cluster of differentiation antigen 20 (CD20+) tumors. G-CSF 5 mcg/kg/day subcutaneously beginning on Day +5 and continuing until neutrophil recovery is documented. Palifermin 60 mcg/kg by vein daily for 6 doses starting on Day 0. Dexamethasone 8 mg by vein twice a day from day -8 AM to day -2 PM.
88886925|NCT01421199|Other|Myringotomy|On arm
88886926|NCT01421238|Experimental|Resuscitation Default Arm|"After receiving a description of an impending delivery of a 23 week gestational infant, participants in this arm were presented with the following information:~The doctor goes on to say that at this hospital infants born at 23 weeks will receive resuscitation, unless their parents object. If you decline resuscitation please check the box below:~Please check if you decline resuscitation []"
88886927|NCT01421238|Experimental|Comfort Care Default Arm|"After receiving a description of an impending delivery of a 23 week gestational infant, participants in this arm were presented with the following information:~The doctor goes on to say that at this hospital infants born at 23 weeks will receive comfort care, unless their parents object. If you decline comfort care please check the box below:~Please check if you decline comfort care []"
88886928|NCT01421251||Matched cohorts - population based|Two cohorts: vaccinated individuals are matched to unvaccinated individuals on the basis of age, sex, and postal code of residence.
88886929|NCT01421368|Experimental|DMPA and tenofovir 1% gel|
88886930|NCT01421368|Experimental|Oral contraceptive and tenofovir 1% gel|
88886931|NCT01421394||single group study|
88886932|NCT01421407|Active Comparator|High Intensity Focused Ultrasound|
88886933|NCT01421407|No Intervention|Control group|
88886934|NCT01421420||Alzheimer's Disease|
88886935|NCT01421420||Mild Cognitive Impairment|
88886936|NCT01421420||Other forms of Dementia, not AD|
88886937|NCT01421420||Normal Elderly Individuals|
88886938|NCT01421433|Active Comparator|Tandrilax|Reference product Intervention: Drug: Tandrilax (caffeine+carisoprodol+sodium diclofenac+paracetamol)
88886939|NCT01421433|Experimental|Dolamin Flex|Test product Intervention: Drug: Dolamin Flex (Lysine clonixinate and cyclobenzaprine)
88886940|NCT01421485|Experimental|Integrated treatment Program|
88886941|NCT01421485|Active Comparator|Treatment as Usual|
88886942|NCT01421550|Active Comparator|Conservative treatment|Patients that randomize for conservative management of their umbilical hernia will be followed routinely at the polyclinical ward.
88886943|NCT01421550|Active Comparator|Surgical repair|Patients that randomize for surgical repair of their umbilical hernia will be operated in an elective setting after a careful preoperative work-up.
88886944|NCT01421563|Active Comparator|Anplag|
88886945|NCT01421563|Experimental|DP-R202|
88886946|NCT01421576|Active Comparator|High fat meal|
88886947|NCT01421576|Experimental|DP-R202|under fed condition
88886948|NCT01421615|Placebo Comparator|lotion|lotion:the patients in control group receive washing medicine and are followed up to the 4rd～7th days of postpartum.
88886949|NCT01421615|Experimental|lactobacilli capsule|
88886950|NCT01421615|Experimental|lactobacilli capsules|
88886951|NCT01421628|Experimental|exercise|
88886952|NCT01421680|Active Comparator|Ensure powder|Oral Nutritional Supplements with carbohydrate, lipid, protein, vitamin and minerals
88886953|NCT01421680|No Intervention|Standard care|Standard care without oral nutritional supplements
88886954|NCT01421693|Active Comparator|Gatifloxacin|Gatifloxacin 10mg/kg/day for 7 days
88886955|NCT01421693|Active Comparator|Ceftriaxone|"≥2-<14 years - 60mg/kg/ once daily for 7 days~14 years and older - 2g once daily for 7 days"
88886956|NCT01421706|Active Comparator|sibutramine-clopidogrel|sibutramine-clopidogrel
88886957|NCT01421706|Active Comparator|sibutramine-clarithromycin|sibutramine-clarithromycin
88886958|NCT01421732||Suspected dengue fever|Children aged 1-15 presenting at participating hospitals with symptoms of dengue fever
88886959|NCT01421745|Experimental|Cultural Competence Module|The module will include lecture, case studies, and discussion of cultural competence.
88886960|NCT01421758|Experimental|online social network|
88886961|NCT01421758|Active Comparator|web education control|
88886962|NCT01421784|Other|Cine-MRI|Rapid Cine-MRI
88886963|NCT01421823|Experimental|alpha agonist ointment|
88886964|NCT01421823|Placebo Comparator|Placebo|
88886965|NCT01421836|Active Comparator|ERCP guided stent insertion|
88886966|NCT01421836|Active Comparator|EUS guided stent insertion|
88886967|NCT01421901|Experimental|Ertapenem|
88886968|NCT01421901|Active Comparator|appendectomy|Appendectomy is compared to Ertapenem
88886969|NCT01421914|Other|Bupivacaine 0,5%|Single arm study
88886970|NCT01421927|Experimental|lenalidomide|
88886971|NCT01421940|Placebo Comparator|Control|Individuals who take placebo after total mesorectal excision
88886972|NCT01421940|Experimental|Udenafil|Individuals who take udenafil after total mesorectal excision
88886973|NCT01421953|Experimental|Patients|
88886974|NCT01421966|Experimental|CureXcell®|
88886975|NCT01421966|Sham Comparator|Sham injection|
88886976|NCT01421979|Experimental|exposure under sleep deprivation|Examination of the effects of EDs in combination with alcohol consumption and sleep deprivation.
89410766|NCT05890781|Other|Immune organoids from pediatric patient tissues using iPSC|To engineer immune organoids from pediatric patient tissues using induced-pluripotent stem cells (iPSC)
89410767|NCT05890768|Experimental|Lumateperone|Lumateperone 42 mg capsule 1 PO QD for 6 weeks
89410768|NCT05890768|Active Comparator|Risperidone|Risperidone starts 1 mg capsule PO QD for 1 week; then titrated blindly per clinical response and tolerability up to: 2 mg capsule QD starting in week 2; up to 3 mg capsule QD starting in week 3; and up to 4 mg capsule QD starting in week 4. Total risperidone exposure of 6 weeks.
89410769|NCT05890755||Healthy participants between 18 and 40 years of age|
89410770|NCT05890755||Healthy participants between 60 and 80 years of age|
88886977|NCT01421979|Experimental|Exercise after consumption|Examination of the effects of EDs in combination with alcohol consumption and exercise.
88886978|NCT01421992|Placebo Comparator|Arm 1: Methylphenidate versus baseline|
88886979|NCT01421992|Placebo Comparator|Arm 2: Placebo versus baseline|One table placebo per day during 3 week
88886980|NCT01422005|Experimental|Experimental group|Simultaneous Bimanual training: Patients who have had either an acute/subacute and a Chronic stroke will get training on the devices.
88886981|NCT01422005|Active Comparator|Control Group|Conventional Occupational Therapy: Patients who have had either an acute/subacute and Chronic Stroke with hemiperisis will get conventional therapy.
88886982|NCT01422018|Experimental|one arm for Anastin injection|intravitreal Avastin injection
88886983|NCT01422031||Regular Family Doctor (RFD)|People had a regular primary care doctor who is a family doctor
88886984|NCT01422031||Regular not Family doctor (RnFD)|People had a regular primary care doctor who is not a family doctor
88886985|NCT01422031||Not regular doctor (NRD)|People had no regular primary care doctor
88886986|NCT01422096|Experimental|leuprolide|leuprolide 11.25 mg IM with adrenal suppression/stimulation testing with dexamethasone/Cortrosyn and ovarian stimulation testing with r-hCG before and 3 weeks after injection
88886987|NCT01422109|Experimental|Group A|
88886988|NCT01422109|Active Comparator|Group B|
88886989|NCT01422122|Experimental|Vitamin D|Oral vitamin D3 in syrup form
88886990|NCT01422122|Placebo Comparator|placebo|Placebo syrup identical in colour and taste to that of intervention
88886991|NCT01422174||ICD implantation|Patients that receive an ICD implantation (non randomized, by clinical decision) will enter this group
88886992|NCT01422174||Non ICD implantation|Patients that do not receive ICD implantation (non randomized, by clinical decision); they can receive any other treatment (e.g. antiarrhythmic drugs)
88886993|NCT01422252|Experimental|Persons equipped|Precocious fall detection device
88886994|NCT01422252|No Intervention|Persons non-equipped|No fall detection device
88886995|NCT01422265||Cohort|
88886996|NCT01422291|Active Comparator|morphine|
88886997|NCT01422291|Experimental|Paracetamole, dexketoprofen|Paracetamole, dexketoprofen
89005162|NCT00410852|Active Comparator|C|
89410771|NCT05890703|Experimental|IMP2 (lidocaine-23%-tetracaine-7% gel)|
89410772|NCT05890703|Active Comparator|IMP1 (EMLA 5% cream)|
89410773|NCT05890612||Participants receiving PAXLOVID|Participants receiving PAXLOVID according to locally approved label.
89410774|NCT05890547||Study group|comprises 30 patients with Covid-19 infection representing the study group COVID-19 diagnosis will be based on a positive SARS-CoV-2 nasopharyngeal swab on real-time reverse transcription-polymerase chain reaction (RT-PCR) in the presence of clinical and/or radiological signs.
89410775|NCT05890547||Control group|comprises 30 patients without a history of Covid-19 infection as a control group.
89410776|NCT05890521|Experimental|Population Ⅰ|
89437533|NCT03704051||Breastfeeding First, then Bottle-feeding|Mother-infant dyads were observed while breastfeeding during their first visit to our laboratory and were observed while bottle-feeding expressed breast milk during their second visit to our laboratory.
89535699|NCT03075657|Active Comparator|Risperidone group|Schizophrenia patients with predominant negative symptoms on Risperidone monotherapy
88886998|NCT01422317|Experimental|n-3 fatty acids|Two gelatine capsules of Omacor-R (Pronova AS, Oslo) twice a day, each capsule containing eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) as ethylesters, in the average ratio of EPA to DHA of 1:2. Alpha-Tocopherol (4 mg) was added to each capsule.
88886999|NCT01422317|Active Comparator|Corn Oil|Two gelatine capsules twice a day, each containing 1 gram of corn oil. Alpha-Tocopherol (4 mg) was added to each capsule.
88887000|NCT01422330|Experimental|Etravirine|
88887001|NCT01422343||1|
88887002|NCT01422395|Experimental|freezing|
88887003|NCT01422395|No Intervention|No freezing|
88887004|NCT01422447|Experimental|community intervention|Feedback on assessment results: distribute relevant brochures and hold regular lectures on depression, anxiety and alcohol-abuse.
88887005|NCT01422447|Active Comparator|regular intervention control|the subjects in the control group live in the used model
88887006|NCT01422460|Experimental|Platelet Rich Plasma|intra articular injection 2ml of platelet-derived preparation rich in growth factors
88887007|NCT01422473|Experimental|EnSeal Device|EnSeal Trio Tissue Sealing Device
88887008|NCT01422486|Experimental|ezatiostat hydrochloride (Telintra®)|Patients received ezatiostat at a starting dose of 2000 mg total daily dose in divided doses (1000 mg PO b.i.d.) for three weeks (21 days) on therapy followed by a one-week (7 days) off therapy rest period in four-week (28 days) treatment cycles.
88887009|NCT01422512|Experimental|cell culture derived TIV|single dose of cell culture derived seasonal trivalent influenza vaccine (TIV)
88887010|NCT01422525||Trabeculectomy RNFL thickness OCT|
89410777|NCT05890508|Experimental|Electro-acupuncture group|The electro-acupuncture intervention will be conducted for 2 session per week during 16-week treatment duration, and will be followed up for 8 weeks. In this study, 7 acupoints are chosen:GV20(Baihui), EX-HN1(Sishencong), EX-HN3(Yintang), SP6(Sanyinjiao), ST36(Zusanli), ST40(Fenglong), and LR3(Taichong). The puncture is made in accordance with the standards of traditional Chinese medicine, to a depth of 1 to 3 cm depending on the thickness of the local tissues. The acupoints are subjected to 2-5 Hz electroacupuncture from an electroacupuncture device at an intensity (5 to 10 mA) that can produce a muscle twitch acceptable to the participant.
89410778|NCT05890508|Sham Comparator|Sham-acupuncture group|"For subjects assigned to the sham control group, Streitberger's non-invasive acupuncture needles (Gauge 8 x 1.2/ 0.30 x 30mm) will be applied to serve as a sham control at the corresponding non-acupoints, leave 0.5 cun from the corresponding acupoints, with the same stimulation modality. Addtionally, the stimulation will be a pseudo stimulation, which will be given by connecting the needle to the incorrect output socket of the electrical acupuncture stimulation instrument. The credibility and validity of this system have been well demonstrated.~."
89410779|NCT05890495|Experimental|Aqueous lidocaine|Subject issued 5 ml jar of aqueous 4% lidocaine and will dip tampon distal end into jar for 30 seconds prior to placement.
89410780|NCT05890495|Placebo Comparator|Saline|Subject issued 5 ml jar of sterile saline and will dip tampon distal end into jar for 30 seconds prior to placement.
89410781|NCT05890482|Experimental|Islamic Trauma Healing (ITH)|A lay-led, six-session group intervention that combines empirically supported exposure-based and cognitive restructuring techniques with Islamic principles.
89410782|NCT05890482|Other|Wait List/Delayed (ITH)|Six week waitlist condition and then crossed-over to six weeks of the ITH intervention
89410783|NCT05890456|Experimental|Treatment Arm|The SWIFT Program is a 9-12 month intervention that includes four components: (a) behavioral progress monitoring, (b) clinical supervision of the intervention elements and coordination with the school, (c) parent support to promote parent engagement/collaboration with the school and study routines in the home, and (d) behavioral skills coaching for students. SWIFT students will continue to receive any school-based services that were receiving prior to entering the study.
89410784|NCT05890456|Active Comparator|Services As Usual Control|The SAU students and families will continue to receive any services that they were receiving prior to their entry into the study. These may include school-based interventions and supports and related services as required in the student's Individualized Education Program.
89410785|NCT05890443|Experimental|Group exercised via mobile application|Individuals aged 40 and over with COPD were included in the study, while individuals with communication, mental, neurological and cognitive problems and unable to exercise were excluded from the study. Among those who met the inclusion criteria, those who had a smart-phone were assigned to the experimental group.
88887011|NCT01422551|Experimental|Cognitive Behavioral Stress Management|10 weekly 2-hour sessions of group-based cognitive behavioral stress management
88887012|NCT01422551|Active Comparator|Psycho-educational Control|a single day group-based psycho-educational seminar
88887013|NCT01422564|Active Comparator|Metal on Metal|Metal on Metal articulation system
88887014|NCT01422564|Active Comparator|HCLPC|THA using Highly Cross Linked Polyethylene cup System
88887015|NCT01422577|Active Comparator|Bright Narrow Band Imaging|Bright Narrow Band Imaging
88887016|NCT01422577|Active Comparator|White Light Endoscopy|White Light Endoscopy
89410786|NCT05890443|No Intervention|The group not included in the exercises via the mobile application.|Individuals aged 40 and over with COPD were included in the study. The individuals with communication, mental, neurological and cognitive problems and unable to exercise were excluded from the study. Those who did not have a smart-phone were assigned to the control group.
89410787|NCT05890391|Experimental|Time-Restricted Eating|Individuals in the TRE group applied a diet limited to 8 hours for 8 weeks.
89410788|NCT05890391|Experimental|Energy-Restricted Diet|Individuals in the ERD group followed a diet specially prepared for them for 8 weeks.
89410789|NCT05890339|Experimental|Laparoscopic Proximal Gastrectomy With Double-flap Technique|
89410790|NCT05890339|Active Comparator|Laparoscopic Total Gastrectomy With Roux-en-Y Reconstruction|
89410791|NCT05890326|No Intervention|Control group|No intervention was applied to fibromyalgia patients in this group. This was because it was a control group that would evaluate the effects on outcomes by comparing them with other intervention (behavioral) groups.
89410792|NCT05890326|Experimental|Motor imagery-based exercise protocol (MIEP)|Motor imagery-based exercise protocol (MIEP) applied in this group.
89410793|NCT05890326|Experimental|Pain neuroscience education (PNE)|Pain neuroscience education (PNE) applied in this group.
89410794|NCT05890326|Active Comparator|Combination Group|Both Pain neuroscience education (PNE) and Motor imagery-based exercise protocol (MIEP) applied in this group.
89535700|NCT03075657|Experimental|Risperidone with Ramelteon group|Schizophrenia patients with predominant negative symptoms on Risperidone with add-on Ramelteon therapy
88887017|NCT01422590|Active Comparator|Sitagliptin|
88887018|NCT01422590|Active Comparator|Mitiglinide|
88887019|NCT01422590|Experimental|Sitagliptin + Mitiglinide|
88887020|NCT01422603|Experimental|Clofarabine and Full intensity SCT|Cohort One: Patients suitable for full intensity conditioning will receive Clofarabine pre-conditioning followed by a Cyclophosphamide and Total Body Irradiation conditioned allogeneic stem cell transplant (SCT).
88887021|NCT01422603|Experimental|Clofarabine and Reduced intensity SCT|Cohort 2: Patients not suitable for a full intensity TBI-based transplant due to age or co-morbidity will receive Clofarabine pre-conditioning followed by a reduced intensity allogeneic stem cell transplant using Fludarabine, intravenous Busulphan and Campath 1H.
88887022|NCT01422616|Experimental|Low-dose rtPA (Recruitment completed in August 2015)|low-dose 0.6 mg/kg (maximum of 60 mg) i.v. rtPA
88887023|NCT01422616|Active Comparator|Standard-dose rtPA (Recruitment completed in August 2015)|standard-dose 0.9 mg/kg (maximum of 90 mg) i.v. rtPA
89005163|NCT00231933|Active Comparator|1|Participants will receive standard care incorporating illness management recovery
89005164|NCT00231933|Experimental|2|Participants will receive illness management recovery plus person-centered planning
89005165|NCT00231933|Experimental|3|Participants will receive illness management recovery plus person-centered planning and community integration
88887024|NCT01422616|Experimental|Early intensive BP lowering|"The trial is an assessment of BP lowering management strategies, using routinely available drugs.~Intensive blood pressure (BP) lowering to a target systolic BP range 130-140 mmHg within one hour and to maintain this level for at least 72 hours (or until hospital discharge or death if this should occur earlier). A standardised i.v. BP lowering regimen using locally available and approved i.v. BP lowering agents (e.g. Labetalol Hydrochloride, Metoprolol tartrate, Hydralazine Hydrochloride, Glycerol Trinitrate, Phentolamine mesylate, Nicardipine, Urapidil, Esmolol, Clonidine, Enalaprilat, Nitroprusside) will be used, commenced in the emergency department and later in a high dependency area (e.g. acute stroke or neurointensive care unit) as is usual for patients receiving rtPA."
88887025|NCT01422616|Active Comparator|Control / guideline-based BP management|"The trial is an assessment of BP lowering management strategies, using routinely available drugs.~Patients allocated to the control group will receive management of BP that is based on a standard guideline, as published by the American Heart Association (AHA). For this group, the attending clinician may consider commencing BP treatment if the systolic level is greater than 180 mmHg, however and the first line treatment will be oral (including nasogastric if required) and/or transdermal routes. Should control of systolic BP not be achieved via these routes, i.v. treatment may be started until the target systolic BP of 180 mmHg is achieved."
88887026|NCT01422629|Experimental|High Intensity Focused Ultrasound (HIFU)|
88887027|NCT01422642|Experimental|legacy posterior stabilized high-flexion|NexGen LPS-Flex total knee system
89535701|NCT03075657|Active Comparator|Haloperidol group|Schizophrenia patients with predominant positive symptoms on Haloperidol monotherapy
88887028|NCT01422642|Experimental|legacy posterior stabilized standard|standard NexGen LPS prosthesis
88887029|NCT01422668|Active Comparator|GI of Khalas dates|The Glycemic indices of the Khalas dates were measured for healthy and diabetic subjects.
88887030|NCT01422668|Experimental|GI of the Khalas dates with Coffee|measuring the effect of 100 ml of coffee consumption on the GI of the Khalas dates among healthy and diabetic subjects.
88887031|NCT01422681|Experimental|DECOPD|patients with severe COPD exacerbation on NIV treated with the minimally invasive extracorporeal carbon dioxide removal device (Decap Smart)
88887032|NCT01422707|Experimental|hydrocortisone|4 weeks hydrocortisone with pre- and post-intervention Dexamethasone and Cosyntropin to perform standardized adrenal stimulation testing
88887033|NCT01422733|Experimental|hydrocortisone, dexamethasone, Cosyntropin (ACTH), rhCG|12 weeks hydrocortisone, dexamethasone, and Cosyntropin (ACTH) to perform standardized adrenal stimulation testing; dexamethasone, and rhCG to perform standardized ovarian stimulation testing
88887034|NCT01422772|Experimental|Cohort I|0.5mg/1mL of VM202RY was intramuscularly injected into 4 sites
88887035|NCT01422772|Experimental|Cohort II|1mg/2mL of VM202RY was intramuscularly injected into 8 sites
88887036|NCT01422772|Experimental|Cohort III|2mg/4mL of VM202RY was intramuscularly injected into 8 sites
88887037|NCT01422785|Active Comparator|clindamycin phosphate 1.2%/tretinoin 0.025% gel alone|
88887038|NCT01422785|Active Comparator|clindamycin / tretinoin gel plus benzoyl peroxide|
88887039|NCT01422811|Experimental|Intervention|
88887040|NCT01422811|Other|Control|No Intervention
88887041|NCT01422863|Experimental|Lifestyle Intervention|
88887042|NCT01422902|Experimental|Plasticity-based Cognitive Training|Computerized plasticity-based adaptive cognitive training, up to 130 hours
88887043|NCT01422902|Active Comparator|Non-plasticity-based Training|Commercially available computerized training, up to 130 hours
88887044|NCT01422928|No Intervention|Standard treatment|"Patients receiving standard radiation therapy for gastrointestinal or urogenital cancers.~All subjects will be asked to give 20 mL of blood and complete the Edmonton Symptom Assessment Form (ESAS) on 3 occasions:~before radiation~at 1st follow up 4-10 weeks after radiation completion~at second follow up 6 months after 1st follow up"
88887045|NCT01422928|Experimental|Acupuncture|"Patients receiving standard radiation therapy for gastrointestinal or urogenital cancers with concurrent acupuncture once a week for 4 weeks.~All subjects will be asked to give 20 mL of blood and complete the Edmonton Symptom Assessment Form (ESAS) on 3 occasions:~before radiation~at 1st follow up 4-10 weeks after radiation completion~at second follow up 6 months after 1st follow up"
88887046|NCT01422941|Experimental|CAVU Attune Device|
88887047|NCT01422954|Active Comparator|Chloroquine immunisation|This group will receive chloroquine prophylaxis, and three times infected mosquito-bites.
88887048|NCT01422954|Experimental|Mefloquine immunisation|This group will receive mefloquine prophylaxis and infected mosquito-bites.
88887049|NCT01422954|Placebo Comparator|Mefloquine control|This group will receive mefloquine prophylaxis, and uninfected mosquito-bites.
88887050|NCT01422967|Active Comparator|Osteoarthritis group|
88887051|NCT01422967|Active Comparator|without osteoarthritis|
88887052|NCT01422980|Active Comparator|1 = Test product|Arm 1 - intervention 1 (test product)
88887053|NCT01422980|Placebo Comparator|2 = Control product|Arm 2 - intervention 2 (control product)
88887054|NCT01422993|Experimental|Excercise and Questionnaire|12 week exercise program followed by questionnaire.
88887055|NCT01423006|Experimental|Focal Prostate Radio-Frequency Ablation|Treatment is performed under a spinal or general anesthetic and will include the one to three regions of the prostate containing cancer based on the mapping biopsy.
88887056|NCT01423019|Active Comparator|Advantra Z|Proprietary ingredient for: stimulating thermogenesis, reducing weight, increasing lean muscle mass to total body mass, improving athletic performance, and suppressing appetite
88887057|NCT01423019|Active Comparator|Advantra Z + Naringin + Hesperiden|
89535702|NCT03075657|Experimental|Haloperidol with Ramelteon group|Schizophrenia patients with predominant positive symptoms on Haloperidol with add-on Ramelteon therapy
88887058|NCT01423019|Placebo Comparator|Sugar pill|Capsule contains inert ingredient.
88887059|NCT01423032|Experimental|Bendamustine|
88887060|NCT01423032|Active Comparator|Fludarabine|
88887061|NCT01423071||COPD with PH|COPD patients with confirmed diagnosis of PH.
88887062|NCT01423071||COPD without PH|COPD patients without confirmed diagnosis of PH
88887063|NCT01423071||PAH without COPD|PAH patients who do not suffer from COPD
89005166|NCT01086982|Experimental|Octreotide acetate LAR 30 MG|Test
89410795|NCT05890287|Experimental|Cohort A in advanced stages of first-line ± endocrine therapy without CDK4/6 inhibitors|Chidamide tablets, specification 5mg/ tablet. Administration method: Oral, 30mg/ time, twice a week; Endocrine drugs: (TAM, AI, fluvestran, etc.) According to patients' previous endocrine treatment, different endocrine drugs were selected according to researchers' judgment, and the dosage was used according to the instructions; OFS drugs (for premenopausal patients only).
89410796|NCT05890287|Experimental|Late-stage first-line ± endocrine therapy with CDK4/6 inhibitors in cohort B|Chidamide tablets, specification 5mg/ tablet. Administration method: Oral, 30mg/ time, twice a week; Endocrine drugs: (TAM, AI, fluvestran, etc.) According to patients' previous endocrine treatment, different endocrine drugs were selected according to researchers' judgment, and the dosage was used according to the instructions; OFS drugs (for premenopausal patients only).
89410797|NCT05890274|Experimental|AF and EKG Interpretation Project ECHO|All recruited participants participate in the AF and EKG Interpretation Project ECHO educational intervention.
89410798|NCT05890261|Experimental|Young healthy subjects|Young healthy subjects
89410799|NCT05890235|Experimental|Ningmitai Capsule group|Patients take Ningmitai capsule, 0.38 g/capsule, tid, 4 capsules each time, after meals, for 8 weeks.
89410800|NCT05890235|Active Comparator|Tamsulosin Hydrochloride Sustained-release Capsules group|Patients take Tamsulosin Hydrochloride Sustained-release Capsules ,0.2 mg/capsule, once daily, 1 capsule each time, for 8 weeks.
89410801|NCT05890235|Active Comparator|Combined group|Patients take Ningmitai capsule, 0.38 g/capsule, tid, 4 capsules each time, after meals, for 8 weeks and Tamsulosin Hydrochloride Sustained-release Capsules ,0.2 mg/capsule, once daily, 1 capsule each time, for 8 weeks.
89410802|NCT05890209|No Intervention|Personalized Weight Management group (PWM)|The group will receive a personalized diet and physical activity plan and five one-to-one online support meetings with a trained dietitian over the first 12 weeks of the program (in weeks 1, 2, 4, 8, and 12). The participants also will be given an evidence-based weight loss maintenance information booklet and advice (e.g.: dietary advice, physical activity recommendation, the importance of self-monitoring weight, diet, and physical activity). Participants will be asked to self-manage during weeks 12 - 24 and asked to maintain the diet, PA recommendations, and monitoring based on the advice and training provided in the first 12 weeks of the program.
89410803|NCT05890209|Experimental|PWM + Continuous Glucose Monitoring (CGM)|This group will receive the same support as the PWM group. The participants also will be given an evidence-based weight loss maintenance information booklet and advice (e.g.: dietary advice, physical activity recommendation, the importance of self-monitoring weight, diet, physical activity, and glucose level). In addition, participants will be provided with a CGM device and guidance on how to use this to support weight loss maintenance. They will be provided with CGM devices for the whole study duration.
89410804|NCT05890183|Experimental|Randomization to Combined Cognitive Training and Exercise (CT&E)|"The primary interventions for this arm of the protocol are Cognitive Training and Exercise sessions. The Cognitive Training will be conducted in a group format using Zoom videoconferencing, with participants logging into their individual Posit Science cognitive training accounts.~The Aerobic Exercise Program will consist of a physical exercise intervention of 150 minutes/week of moderate aerobic activity, over 4 days, including two group sessions (45 min duration) and two individual sessions (30 min duration in the heart rate zone), for 6 months. After the first 6 months, the group sessions will be once a week with the continuing goal of 150 minutes/week of moderate exercise."
89410805|NCT05890183|Active Comparator|Cognitive Training and Healthy Living Group (CT&HLG)|"The primary interventions for this arm of the protocol are Cognitive Training and the Healthy Living Group. The Cognitive Training will be conducted in a group format using Zoom videoconferencing, with participants logging into their individual Posit Science cognitive training accounts.~The participants in this arm will also participate in a Healthy Living Group, which is a didactic, educational and interactive group that is designed to offer very useful information and discussion of topics that are relevant to a healthy lifestyle. It includes manualized modules devoted to wellness, nutrition, insight, recovery, independent living, social skills, and hobbies. It meets 2 times/week for 6 months and then once a week for the next 6 months."
88887064|NCT01423123|Experimental|Neratinib|Paclitaxel (80 mg/m2 IV on days 1, 8, and 15 every 28 days) and trastuzumab (4 mg/kg/ loading dose, then 2 mg/kg) IV weekly beginning on day 1 of paclitaxel, neratinib orally daily beginning on day 1 of paclitaxel until disease progression.
88887065|NCT01423136||Routine postop care + Holter Monitoring|With sham remote ECG ST Monitoring
88887066|NCT01423136||Routine postop care + Holter + remote ECG monitoring|
88887067|NCT01423175|Experimental|ClAraC|
88887068|NCT01423175|Active Comparator|FLAMSA|
88887069|NCT01423188|Experimental|RVX000222, 200 mg daily|
88887070|NCT01423188|Placebo Comparator|Placebo|
88887071|NCT01423214|Experimental|Robotic LAR|Individuals who underwent robot-assisted surgery for primary rectal cancer
88887072|NCT01423214|Active Comparator|Lap LAR|Individuals who underwent laparoscopic surgery for primary rectal cancer
88887073|NCT01423227|Experimental|Home-based pulmonary rehabilitation|Home visit plus 8 weeks of once-weekly telephone calls
88887074|NCT01423227|Active Comparator|Hospital-based pulmonary rehabilitation|Standard twice-weekly 8-week outpatient pulmonary rehabilitation program
88887075|NCT01423240|Experimental|Lurasidone 20 mg|
88887076|NCT01423240|Experimental|Lurasidone 60 mg|
88887077|NCT01423240|Placebo Comparator|Placebo|
88887078|NCT01423266|Experimental|High Protein Group|12-week supervised weight loss program consisting of a HP diet defined as 30% of energy from protein, 40% from carbohydrates and 30% from fat
88887079|NCT01423266|Active Comparator|Standard Protein Group|12-week supervised weight loss program consisting of a SP diet defined as 15% of energy from protein, 55% from carbohydrates and 30% from fat
88887080|NCT01423292|Active Comparator|an odd numbered patients|TAP block with local anesthetics
88887081|NCT01423292|Placebo Comparator|an even numbered patients|TAP block without local anesthetics
88887082|NCT01423305|Experimental|Treatment A|Budesonide/formoterol capsule (Orion Pharma) for oral administration.
88887083|NCT01423305|Experimental|Treatment B|Budesonide/formoterol capsule (Orion Pharma) for oral administration.
88887084|NCT01423318|Experimental|A|
88887085|NCT01423318|Placebo Comparator|B|
89410806|NCT05890170||Short-term|"Patients treated at the Department of Oral Surgery and Stomatology at the University of Bern will be potentially be recruited. Patients treated with a dental implant with contour augmentation procedure and required post-operative follow-ups as standard of care (short-term group) will be invited to participate in this study. Patients who expressed an interest to participate in this study at the clinical/phone screening examination, would be informed of the purpose and timeline of the study. All potential subjects will be required to read, understand, and sign the consent form, which included a thorough explanation of the study design, as well as expected benefits and possible risks of participating in the study without limit of time.~Patients would received questionnaires. Data from questionnaires would be extracted by an independent investigator. Different variables would be included: 1) age, sex, systemic factors, date of the procedure; location and extension of the procedure..."
89410807|NCT05890170||Mid-term|"Patients treated at the Department of Oral Surgery and Stomatology at the University of Bern will be potentially be recruited. Patients treated with a dental implant with contour augmentation procedure done 1 to 5 years ago (mid-term group) will be invited to participate in this study. Patients who expressed an interest to participate in this study at the clinical/phone screening examination, would be informed of the purpose and timeline of the study. All potential subjects will be required to read, understand, and sign the consent form, which included a thorough explanation of the study design, as well as expected benefits and possible risks of participating in the study without limit of time.~Patients would received questionnaires. Data from questionnaires would be extracted by an independent investigator. Different variables would be included: 1) age, sex, systemic factors, date of the procedure; location and extension of the procedure..."
89410808|NCT05890170||Long-term|"Patients treated at the Department of Oral Surgery and Stomatology at the University of Bern will be potentially be recruited. Patients treated with a dental implant with contour augmentation procedure done >5 years ago (mid-term group) will be invited to participate in this study. Patients who expressed an interest to participate in this study at the clinical/phone screening examination, would be informed of the purpose and timeline of the study. All potential subjects will be required to read, understand, and sign the consent form, which included a thorough explanation of the study design, as well as expected benefits and possible risks of participating in the study without limit of time.~Patients would received questionnaires. Data from questionnaires would be extracted by an independent investigator. Different variables would be included: 1) age, sex, systemic factors, date of the procedure; location and extension of the procedure..."
89410809|NCT05890157|Experimental|Test ScRp+PRF|This site will treated by ScRp+PRF
89410810|NCT05890157|No Intervention|Control ScRp|This site will treated by ScRp only
89410811|NCT05890144|Experimental|"Intensive Intervention (Big Canoe)"|"20 participants will be randomly assigned to Arm 1. Participants in Arm 1 (the Big Canoe) will complete an intensive, multi-modular Indigenous cultural safety education training program that is offered online and led by trained facilitators. The curriculum in Arm 1 was developed by the San'yas Indigenous Cultural Safety Training Program in British Columbia with the support of the Ontario Indigenous Cultural Safety Training Program."
89410812|NCT05890144|Active Comparator|"Brief Intervention (Little Canoe)"|"20 participants will be randomly assigned to Arm 2. Participants in Arm 2 (the Little Canoe) will complete a brief, 2-hour, interactive, computer-based Indigenous race-bias education session that is offered in a computer lab with a researcher present and followed up with 2 reinforcement/reminder emails that ask questions about strategy usage at 6 and 8 weeks after the session. The intervention in Arm 2 is an Indigenous adaption of the Devine et al. (2012) anti-bias habit-breaking intervention."
89410813|NCT05890144|Other|Control|20 participants will be randomly assigned to Arm 3. Participants in Arm 3 (control) will complete a primary care-related training program that is time-attention matched to Arm 1 but does not contain any content on anti-bias, anti-oppression, Indigenous peoples, or any content related to the unannounced Indigenous standardized patient encounter.
89410814|NCT05890053|Experimental|HSK16149 40mg BID|HSK16149 40mg , orally twice a day, treatment period; 52-weeks fixed dose.
89410815|NCT05890040||patients watching surgery video|Situational and trait anxiety test will be applied to patients.
89410816|NCT05890040||patients who did not watch the surgery video|Situational and trait anxiety test will be applied to patients.
89410817|NCT05887687|Experimental|[68Ga]P3|Subjects with suspected or confirmed malignancy will receive an intravenous injection of 68Ga-P3 followed by PET imaging. The subjects will also receive a whole-body 18F-FDG PET/CT scan within a one-week period.
89410818|NCT05887505|Experimental|Vitamin D group|Oral supplementation of 1,728,000 IU vitamin D3 in 3 days
89410819|NCT05887505|Placebo Comparator|Placebo Group|Oral supplementation of placebo in 3 days
89410820|NCT05886686||Hospitalised inpatients|Ten patients admitted into the Acute Care of the Elderly (ACE) ward will be approached for inclusion in the study. Patients will be given written information about the trial. Nursing staff looking after these patients will be asked to utilise the device after vital sign measurements obtained from standard hospital equipment when conducting routine vital sign measurements. Nurses will do this for the duration of the admission of 7days, thus generating 28 paired data points for comparison.
89437534|NCT03704051||Bottle-feeding First, then Breastfeeding|Mother-infant dyads were observed while bottle-feeding expressed breast milk during their first visit to our laboratory and were observed while breastfeeding during their second visit to our laboratory.
88887086|NCT01423357|Experimental|Condom distribution and peer education|Youth peer educators distribute condoms and conduct condom demonstration in venues where people meet new sexual partners, i.e. bars, night clubs, sherbeens, guest houses
88887087|NCT01423357|No Intervention|Business as usual|
88819623|NCT05261685|Experimental|Hyperopic patients planned to undergo single-step transepithelial PRK|Patients with moderate hyperopia or hyperopic astigmatism were planned to undergo transepithelial PRK using the new single-step StreamLight PRK Technology.
88819624|NCT02209610|Other|Patients With Heart Failure: Neuromuscular Abnormalities|Patients with Heart Failure
88819625|NCT02209610|Other|Health Control Subjects and Neuromuscular Function|Health Control Subjects
88819626|NCT00371709|Experimental|Arm 1|
88819627|NCT00371709|Other|Arm 2|Historical Comparator: control data derived from the TAXUS IV and TAXUS V studies
88819628|NCT01441076|Experimental|Anakinra|Treatment with Anakinra 100mg subcutaneous daily with option to escalate dose up to 300mg subcutaneous daily
89410821|NCT05886686||Inpatients at home|"Fifteen patients admitted into the home-based ward would be approached for inclusion in the study. Participants will undergo a 20 minute education session then be supplied with the device, companion app (user interface) on a mobile tablet, and written information about the trial.~Participants will be asked to measure their vital signs four times a day, with one of those measurements occurring immediately after the clinical nurse' home review using standard hospital equipment for vital sign measurements (this matched pair of vital signs measurements will be taken as reference). Participants will do this for at least 7 days, thus generating 7 matched data points for comparison against reference, and 21 data points where participants independently conducted vital signs measurements with the Norbert sensor."
89410822|NCT05886387||High PEEP + Recruitment Maneuvers|Patients who received intraoperatively high PEEP (10-12 cmH2O) after a recruitment maneuvers as per the original study protocol
89410823|NCT05886387||Standard PEEP|Patients who received intraoperatively standard PEEP (0-5 cmH2O) without recruitment maneuvers
89410824|NCT05886114|Experimental|Structured Multi-domain Intervention|Multi-domain structured intervention will be tailored by Chinese traditional and social norms and then conducted among the intervention group. That includes: Nutritional and dietary instruction, Cognitive training, Physical exercises, and Vascular risks monitoring and control.
89410825|NCT05886114|Experimental|Self-Guided Intervention|Every 6-12 months, control group will receive a regular health education campaign to encourage a healthy lifestyle and a regular health monitoring and examination of blood pressure, weight, fasting blood glucose and liposome group
88887088|NCT01423370|Experimental|Group A|
89437535|NCT03694522|Experimental|Bemarituzumab + mFOLFOX6|Participants received 15 mg/kg bemarituzumab administered every 2 weeks (Q2W) with a single additional bemarituzumab 7.5 mg/kg dose on cycle 1 day 8. Participants also received mFOLFOX6 chemotherapy administered Q2W. Treatment continued until unacceptable toxicity, disease progression, or death.
88819629|NCT05244993|Experimental|AK105+Anlotinib Hydrochloride+Albumin Paclitaxel|AK105 200mg IV Day 1 Anlotinib Hydrochloride 12mg PO once daily on Days 1-14 Albumin paclitaxel 125mg/m2 IV Days 1, 8 Cycled every 21 days until disease progression, death or toxicity is intolerable (for subjects who can continue to tolerate the treatment, albumin paclitaxel lasts for at least 6 cycles)
88819630|NCT03008018|Other|KA2507 (HDAC6 inhibitor)|This is a single arm dose escalating study. Patients will be treated with open label KA2507 (HDAC6 inhibitor) capsules.
88819631|NCT02756949|Experimental|Smartphone-enabled app for linkage to care|Participants in this arm are randomised to receive the smartphone application which provides direct access to HIV-related laboratory test results.
88819632|NCT02756949|No Intervention|Standard of care|Participants in this arm are randomised to receive standard of care services.
88819633|NCT01504958|Active Comparator|Active rTMS with real cognitive training|High frequency rTMS stimulation to the left and right parietal cortex (somatosensory association cortex), left and right DLPFC (dorsolateral prefrontal cortex), and left superior temporal gyrus (Broca's area) paired with concurrent active cognitive training.
88819634|NCT01504958|Sham Comparator|Sham rTMS with real cognitive training|High frequency sham rTMS to the left and right parietal cortex (somatosensory association cortex), left and right DLPFC (dorsolateral prefrontal cortex), and left superior temporal gyrus (Broca's area) paired with concurrent active cognitive training.
88819635|NCT01504958|Sham Comparator|Sham rTMS with sham cognitive training|High frequency sham rTMS to the left and right parietal cortex (somatosensory association cortex), left and right DLPFC (dorsolateral prefrontal cortex), and left superior temporal gyrus (Broca's area) paired with concurrent sham cognitive training.
88819636|NCT02973945|Experimental|High Flow Nasal Cannula|During a 8 week Pulmonary Rehabilitation Program patients will receive oxygen through High Flow Nasal Cannula (HFNC) while they are training aerobic capacity on the treadmill.
88819637|NCT02973945|Active Comparator|The Venturi Mask|During a 8 week Pulmonary Rehabilitation Program patients will receive oxygen through The Venturi Mask (VM) while they are training aerobic capacity on the treadmill.
88819638|NCT01441466||Group without isolation|Patients in this arm are nursed together (in the same room) independent of viral agent.
88819639|NCT01441466||group with isolation|Patients in this arm are nursed separately until the test result of the PCR (polymerase chain reaction) for viral agents is known (within 24-48 hrs). RS-positive patients are nursed separately (separate room) from RS-negative patients
88819640|NCT05107167|Experimental|Electromagnetic stimulation|Electromagnetic stimulation of the phrenic nerve.
88819641|NCT01558700|Experimental|Duloxetine|Duloxetine capsule 30mg once a day for one week, then 60mg once a day for 15 weeks, then 30mg once a day for one week.
88819642|NCT01558700|Placebo Comparator|Sugar pill|Matching capsule given once a day for a total of 17 weeks.
88819643|NCT01506362|Experimental|A synthetic oligonucleotide for treatment of IBD.|BL-7040 is an orally available new chemical entity for the treatment of IBD. BL-7040 is a synthetic oligonucleotide with dual activity on both the nervous and immune systems.
88819644|NCT02757105|Experimental|Group A|BEKINDA 12 mg (Ondansetron Bimodal Release Tablets), once daily for 8 weeks
88819645|NCT02757105|Placebo Comparator|Group B|Placebo, once daily for 8 weeks
88819646|NCT01559948|Experimental|Lumbopelvic stabilization exercises plus sacroiliac joint belt|The participants will be instructed in the lumbopelvic stabilization program. Additionally, during the initial session, these participants receive a sacroiliac compression belt and be instructed to wear the belt during all waking hours for the first four weeks of the study.
88819647|NCT01559948|Active Comparator|Lumbopelvic stabilization exercise|The participants will be instructed in the lumbopelvic stabilization program.
88819648|NCT02758119|Experimental|Serious Game|"Participants in the serious game group will be pre-trained before the hands-on sessions with the serious game Staying Alive, available at http://www.stayingalive.fr/index_us.html This game aims at teaching the management of an out-of-hospital cardiac arrest to the general public and health professionals. In this game, the player faces a man who has experienced sudden cardiac arrest and learns the appropriate behavior, movements and techniques that can contribute to saving his life. The first level of the game lasts 4-5 minutes, depending on the skills of the player. It is a point and click game, displayed on a PC computer."
88887089|NCT01423370|Experimental|Group B|
88887090|NCT01423370|Experimental|Group C|
88887091|NCT01423370|Active Comparator|Group D|
88887092|NCT01423370|Placebo Comparator|Group E|
88887093|NCT01423383||Random Populations|The aim of this study is to determine the prevalence and incidence of keloid in large populations.
88887094|NCT01423409|Active Comparator|pictorial VAS|VAS with colours and 6 expressive faces
88887095|NCT01423409|Sham Comparator|usual VAS|VAS
88887096|NCT01423422||Frequency exposed patients|Patients exposed to the magnetic field with the specific frequency
88887097|NCT01423435|Experimental|Japanese|
88887098|NCT01423435|Experimental|Chinese|
88887099|NCT01423435|Experimental|South Korean|
88887100|NCT01423448|Experimental|Bulletin board|Participants will be given access to the online bulletin board (intervention) for a 6 month period
88887101|NCT01423448|No Intervention|Control|After 6 months participants allocated to the control group will receive access to the intervention
88887102|NCT01423487|Experimental|efficacy and safety|To investigate the efficacy and safety of Metformin in preventing patients with Risperidone from weight gain and amenorrhea.
88887103|NCT01423487|Placebo Comparator|placebo comparator|To investigate whether plcebo also could preventing patients with Risperidone from weight gain and amenorrhea.
88887104|NCT01423500|Other|MSD - Matched Sibling Donor|patients with a MSD receive a conditioning of TBI (12 Gy, 6 fractions) and VP16 60mg/kg for one day (-3)
88887105|NCT01423500|Other|MD - Matched Donor|patients with a HLA matched unrelated Donor (9/10 oder 10/10) receive TBI (12Gy in 6 fractions), VP16 60mg/kg/d on day -3 and ATG fresenius 20mg/kg/d on day -3,-2,-1
88887106|NCT01423500|Other|MMD - Mismatched Donor|Patients with a MMD receive stem cells either from cord blood, a haploidentical donor (parent) or from a non-related donor with a match less or equal 8/10
88887107|NCT01423513|Experimental|Fibular Taping|With the ankle in a neutral position, two strips of nonrigid hypoallergenic tape will be applied beginning at the distal aspect of the fibula, wrapping around the posterior aspect of the leg, and finishing superior and medial to the starting point. Next,a strip of rigid zinc oxide tape will be applied to the distal aspect of the fibula with tension.
88887108|NCT01423513|Sham Comparator|Sham Taping|Sham taping will be applied in the same manner as the fibular taping, but tension will not applied to the zinc oxide tape
88887109|NCT01423526|Placebo Comparator|Placebo|"Drug: Placebo tablets, oral administration, single administrations~Arms: Placebo"
88887110|NCT01423526|Experimental|DWP10292|"Drug: DWP10292 tablets, oral administration, single administrations~Arms: DWP10292"
88887111|NCT01423539|Active Comparator|A|
88887112|NCT01423539|Experimental|B|
88887113|NCT01423552||Post-heart transplant|All patients undergoing heart transplantation at the Queen Elizabeth Hosptial Birmingham in the last 12 months or in the next year.
88887114|NCT01423565|Experimental|Deep Brain Stimulation|
88887115|NCT01423578|Active Comparator|Hatha Yoga (HY)|Exercise and Smoking Cessation Counseling
88887116|NCT01423578|Experimental|Cardiovascular Exercise (CE)|Exercise and Smoking Cessation Counseling
88887117|NCT01423578|Other|Smoking Cessation Counseling Only|Control Group - Smoking Cessation Counseling
88887118|NCT01423591|Experimental|infliximab|
88887119|NCT01423591|Placebo Comparator|inactive powder|
88887120|NCT01423643||Main cohort|Adults infected with both HIV and Hepatitis C
88887121|NCT01423643||Control Group|Adults at risk for liver disease, but not infected with both HIV and Hepatitis C
88887122|NCT01423656|Experimental|LEO 29102|
88887123|NCT01423656|Placebo Comparator|LEO 29102 vehicle|
88887124|NCT01423669||Community dwelling adult population|
88887125|NCT01423695|Experimental|paclitaxel/trastuzumab|Single experimental arm in a phase II trial
88887126|NCT01423708|No Intervention|Control|Standard immunosuppression protocol with Tacrolimus, maintaining trough levels between 6 and 12 ng/ml in the first month, in association with steroids (20 mg/day with subsequent weaning within 3 months after transplantation).
88887127|NCT01423708|Experimental|Everolimus|Administration of Everolimus in association with Tacrolimus and steroids.
88887128|NCT01423721|Experimental|Bromihexine hydrochloride granules|16 mg granules
88887129|NCT01423721|Experimental|Bromihexine hydrochloride syrup|16 mg syrup
88887130|NCT01423747|Other|MSD - matched sibling donor|patients with a MSD receive a conditioning of total body irradiation (TBI) (12 Gy, 6 fractions) and VP16 60mg/kg for one day (-3)
88887131|NCT01423747|Other|MD - matched donor|patients with a HLA (Human Leukocyte Antigen) matched unrelated Donor (9/10 oder 10/10) receive total body irradiation (TBI) (12Gy in 6 fractions), VP16 60mg/kg/d on day -3 and ATG fresenius 20mg/kg/d on day -3,-2,-1
88887132|NCT01423747|Other|MMD - mismatched Donor|Patients with a mismatched donor receive stem cells either from cord blood, a haploidentical donor (parent) or from a non-related donor with a match less or equal 8/10
88887133|NCT01423786|Other|Please help|"Dr. Kumar left Nationwide Children's Hospital in 2014 and efforts to get ahold of her to complete her ct.gov entries have been unsuccessful as we are not able to get ahold of her.~In July 2014, she wrote in her Continuing Review application to the NCH IRB: 34 patients have been recruited and data has mostly been collected. Follow up calls have been made and no adverse events occurred during the study period.~No other information is available."
88887134|NCT01423799|Experimental|Nutritional product|Nutritional intervention containing immuno-nutrients
88887135|NCT01423799|Active Comparator|Control Group|Isocaloric and isonitrogenous control without immuno nutrients.
88887136|NCT01423825|Experimental|Sub C gp140/MF59C.1 Vaccine|Participants will receive Sub C gp140 vaccine (100 mcg) admixed with MF59C.1 adjuvant administered as one 0.5 mL injection intramuscularly (IM) in either deltoid at baseline and Month 3.
88887137|NCT01423825|Placebo Comparator|Sodium chloride for injection|Participants will receive placebo injection administered as 0.5 mL IM in either deltoid at baseline and Month 3.
88887138|NCT01423838|Active Comparator|Solifenacin|Anticholinergic molecule used in the treatment of overactive bladder.
88887139|NCT01423838|Active Comparator|Oxybutynin|Anticholinergic molecule used in the treatment of overactive bladder.
89005167|NCT01086982|Active Comparator|Sandostatin LAR ® (octreotide acetate LAR) 30 MG|
88887140|NCT01423864|Sham Comparator|conventional ECMO with intravenous steroid|refractory acute respiratory distress syndrome and multi-organ dysfunction syndrome unresponsive to conventional extracorporeal membrane oxygenation
89410826|NCT05882162|Active Comparator|Control Group|A scalpel number 15 was used to raise a triangular or envelope-shaped full-thickness mucoperiosteal flap. The bone in the buccal cavity of the third molar was removed with steel rounds and fissure burs to reach the cementum-enamel boundary. 3/4 of the tooth was cut bucco-lingually from 1-2 mm apical to the enamel cement border with the help of a high-speed surgical handpiece with a fissure steel bur. The root surface was positioned 2-3 mm apically from the surrounding alveolar bone level with the help of a steel round bur. The remaining enamel tissue and pulpal tissue in the coronal part were completely removed. Calcium silicate material was not used for pulp capping of the root pulp. During the procedure, the mandibular second molar's surface was curetted, and the surgical area was rinsed with saline solution to remove any potential surgical debris. The required number of simple sutures were used to close the surgical field without tension.
89410827|NCT05882162|Experimental|Test Group|A scalpel number 15 was used to raise a triangular or envelope-shaped full-thickness mucoperiosteal flap. The bone in the buccal cavity of the third molar was removed with steel rounds and fissure burs to reach the cementum-enamel boundary. 3/4 of the tooth was cut bucco-lingually from 1-2 mm apical to the enamel cement border with the help of a high-speed surgical handpiece with a fissure steel bur. The root surface was positioned 2-3 mm apically from the surrounding alveolar bone level with the help of a steel round bur. The remaining enamel tissue and pulpal tissue in the coronal part were completely removed. Calcium silicate material was used for pulp capping of the root pulp. During the procedure, the mandibular second molar's surface was curetted, and the surgical area was rinsed with saline solution to remove any potential surgical debris. The required number of simple sutures were used to close the surgical field without tension.
89410828|NCT05881486|Experimental|Fosaprepitant|Participants undergoing thoracoscopic pneumonectomy will receive 150 mg of fosaprepitant and 100 ml of normal saline, administer intravenously after the induction of general anesthesia.
89410829|NCT05881486|Active Comparator|Ondansetron|Participants undergoing thoracoscopic pneumonectomy received 8 mg of ondansetron and 100 ml of normal saline, administer intravenously after the induction of general anesthesia.
89410830|NCT05879575|Experimental|intervention group|receive weight training during 16-36 gestational weeks and observe pain condition
89410831|NCT05879575|No Intervention|control group|observe pain condition
89410832|NCT05869630|Experimental|Exercise Group|A total of 30 knee OA patients and 30 age/sex-matched healthy volunteers were included in the exercise and control groups. Exercises were performed twice a week under supervision and once a week as home program for eight weeks. Before and after exercise treatment, peripheral venous blood samples were taken from both groups. miRNA-146a, miRNA-155, miRNA-221-3p and miRNA-145 gene expressions were studied with the Real-time PCR method. miRNA-146a, miRNA-155, and miRNA-221-3p, miRNA-145 gene expressions were studied with the Real-time PCR method. The pain was evaluated with the Numeric Rating Scale (NRS), functional status with Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), depression level with the Beck Depression Inventory (BDI), and quality of life with Short Form-36 (SF-36).
89410833|NCT05869240|Experimental|BPB-101|
89410834|NCT05869123|Experimental|Online Adaptive Radiotherapy|Patients receive online adaptive radiotherapy with 5mm PTV margin. The CTV-N covered pelvic lymph nodes (common, internal and external iliac, obturator, and presacral) and CTV-V covered proximal vagina and any paravaginal or retracted parametrial tissue. A dose of 45 or 50.4Gy is delivered to CTV with online adaptive radiotherapy.
89410835|NCT05866328|Experimental|Intervention|Experimental Group (e-Motional Training and Individual Placement and Support)
89410836|NCT05866328|No Intervention|Control|Control Group (Individual Placement and Support)
88887141|NCT01423864|Experimental|Drug: intrapleural steroid instillation|refractory acute respiratory distress syndrome and multi-organ dysfunction syndrome unresponsive to conventional extracorporeal membrane oxygenation
88887142|NCT01423890|Other|Early Stage Breast Cancer|Women and men with node negative, ER positive breast cancer who are receiving (or will receive) endocrine therapy, and who are candidates for chemotherapy.
88887143|NCT01423903|Experimental|OPDC-51602|Subjects with advanced solid tumors will be treated with OPDC-51602 once daily by mouth
88887144|NCT01423929|Experimental|10 L O2/min|Oxygen breathing via Oxymask TM
88887145|NCT01423929|Sham Comparator|Room air|Room air breathing via Oxymask TM
88887146|NCT01423955|Placebo Comparator|Placebo|Placebo arm will receive NaCl 9mg/ml with a dose of 0.2 ml/kg. The placebo dose will be prepared prior to the surgery by a independent nurse. The calculated volume will match the volume of the active durg.
88887147|NCT01423955|Experimental|Erythropoietin|• Active substance: Erythropoietin zeta with the ATC-code: B03XA01. The drug is a Clear colorless solution for injection. The active substance will be diluted with NaCl 9mg/ml to a to a concentration of 2000 U/ml. A dose of 400U/kg will be prepared and marked before the operation. The drug will be administrated after the anesthesia induction and before the start of surgery.
89410837|NCT05858853|Experimental|Group 1|The experimental drug (recombinant human serum albumin injection) was administered 10 g/ day for 14 days
88887148|NCT01423968|Experimental|Lipopolysaccharide infusion|Lipopolysaccharide infusion; dosage 4ng/kg body weight
89410838|NCT05858853|Experimental|Group 2|The experimental drug (recombinant human serum albumin injection) was administered 20 g/ day for 7 days
89410839|NCT05858853|Active Comparator|Group 3|Control drug (human blood albumin injection) 10 g/ day for 14 days
89410840|NCT05858853|Active Comparator|Group 4|Control drug (human blood albumin injection) 20 g/ day for 7 days
88887149|NCT01423968|Placebo Comparator|saline|0.9% saline infusion
88887150|NCT01423981||Patients with keloid disorder.|All participants have a clinical diagnosis of keloid.
88887151|NCT01423994|Active Comparator|implantable loop recorder|
88887152|NCT01423994|Active Comparator|pacemaker|
88887153|NCT01424007|Experimental|Lower fat diet|Participants in this group will be individually counseled and receive print materials on a higher-carbohydrate, lower-fat diet.
88887154|NCT01424007|Experimental|Lower carbohydrate diet|Participants in this group will be individually counseled and receive print materials on a lower-carbohydrate, higher-monounsaturated fat diet.
89410841|NCT05852470|Experimental|Clareon Vivity/Vivity Toric Extended Vision|Previous implantation, defined as 90-180 days post second eye implantation, with Clareon Vivity/Vivity Toric Extended Vision IOL (intraocular lens)
89410842|NCT05852470|Active Comparator|Clareon/Clareon Toric Aspheric|Previous implantation, defined as 90-180 days post second eye implantation, with Clareon/Clareon Toric Aspheric IOL (intraocular lens)
89410843|NCT05851612|Active Comparator|group C(constant group)|Constant PEEP of 5 centimeter of water (cm H2O) will be applied
89410844|NCT05851612|Active Comparator|group D (driving group)|PEEP titration will be according to driving pressure
89410845|NCT05851612|Active Comparator|group O (oxygenation group)|PEEP titration will be according to oxygenation method
88887155|NCT01424007|Experimental|Walnut-rich diet|Participants in this group will be individually counseled and receive print materials on a lower-carbohydrate, walnut-rich higher-fat diet.
88887156|NCT01424020|Experimental|questionnaire|Patients suspected of peripheral artery disease and, as such, referred for a vascular investigations and submitted the WELCH questionnaire
88887157|NCT01424046|Experimental|basal insulin approach|Participants will be treated primarily with a daily basal insulin injection ( glargine) with later introduction of prandial coverage with a shortacting insulin.
88887158|NCT01424046|Active Comparator|standard therapy|Participants will continue current mixed insulin management and education
88887159|NCT01424059||fear of labor|Parous women with fear of labor
88887160|NCT01424085||Those receiving antibiotics|Patients who received one prophylactic dose of antibiotics.
88887161|NCT01424085||Placebo|Patients who did not receive one prophylactic dose of antibiotics (received placebo).
88887162|NCT01424111||Treatment|Those receiving an open-label, 10-20 mg/day, flexible-dose of escitalopram. The treatment period is 8 weeks long.
88887163|NCT01424111||Healthy Control|Those not receiving treatment.
88887164|NCT01424124|Experimental|YHD001 dose level 1|
88887165|NCT01424124|Experimental|YHD001 dose level 2|
88887166|NCT01424124|Active Comparator|Singulair|
88887167|NCT01424124|Placebo Comparator|Placebo|
88887168|NCT01424137|Other|Easyhaler type A|
88887169|NCT01424137|Other|Easyhaler type B|
88887170|NCT01424137|Other|Diskus inhaler|
88887171|NCT01424150|Experimental|Liberal|At the commencement of surgery a bolus of Hartmann's balanced salt crystalloid 10 ml/kg followed by 8 ml/kg/h will be administered until the end of surgery. A maintenance infusion will then continue at 1.5 ml/kg/h, for at least 24 hours, but this can be reduced postoperatively if there is evidence of fluid overload and no hypotension, and increased if there is evidence of hypovolaemia or hypotension. Alternative fluid types (crystalloid, dextrose, colloid) and electrolyte supplements will be allowed postoperatively in order to account for local preferences and patient biochemistry, for which we will collect data.
88887172|NCT01424150|Experimental|Restrictive|Will provide less than 2.0 L water and 120 mmol sodium per day. Induction of anaesthesia will limit IV bolus fluid to ≤5 ml/kg; no other IV fluids will be used at the commencement of surgery (unless indicated by goal-directed device [see below]). Hartmann's balanced salt crystalloid 5 ml/kg/h will be administered until the end of surgery, and bolus colloid/blood used intraoperatively to replace blood loss (ml for ml); then an infusion at 1 ml/kg/h until expedited cessation of IV fluid therapy within 24 hours. The rate of postoperative fluid replacement can be reduced if there is evidence of fluid overload and no hypotension, and can be increased if there is hypotension AND evidence of hypovolaemia.
88887173|NCT01424163|Experimental|Treatment 1 (Part A)|Dexpramipexole single dose (reduced dose)
88887174|NCT01424163|Experimental|Treatment 2 (Part A)|Dexpramipexole single dose (Standard dose)
88887175|NCT01424163|Experimental|Treatment 3 (Part A)|Dexpramipexole multiple dosing
89410846|NCT05837143|Experimental|Active Comparator: JV001|Subjects will receive a single intracoronary infusion of JV001 at a dose of 2×10^11vg/kg，6×10^11vg/kg，2×10^12vg/kg respectfully.
89410847|NCT05825716||Ifaa Basic|comparison group
89410848|NCT05825716||Ifaa Enhanced|intervention group 1
88887176|NCT01424163|Experimental|Treatment for Part B|Dexpramipexole multiple dosing
88887177|NCT01424176|Experimental|Dexpramipexole (dose 1)|Subjects with mild or moderate renal impairment.
88887178|NCT01424176|Experimental|Dexpramipexole (dose 2)|Subjects with severe renal impairment and end stage renal disease (ESRD).
88887179|NCT01424202|Experimental|Group B|Patients received (post-extubation) standard medical treatment (SMT), including NIV in case of specific indications plus daily sessions of mechanical in-exsufflation (MI-E).
88887180|NCT01424202|No Intervention|Group A|Patients received (post-extubation) standard medical treatment (SMT), including NIV in case of specific indications.
89410849|NCT05825716||Ifaa Enhanced + Livelihoods|intervention group 2
89410850|NCT05793307|Experimental|Cohort 1|Single intravenous administration of GC301 at a dose of 8.0 x 10^13 vector genomes per kilogram body weight
89410851|NCT05793307|Experimental|Cohort 2|Single intravenous administration of GC301 at a dose of 1.2 x 10^14 vector genomes per kilogram body weight
89410852|NCT05793307|Experimental|Cohort 3|Single intravenous administration of GC301 at a dose of 1.8 x 10^14 vector genomes per kilogram body weight
89410853|NCT05779137|Experimental|Mindfulness based cognitive therapy (MBCT)|62 patients will receive a mindfulness based intervention.
89410854|NCT05779137|No Intervention|Treatment as usual (TAU)|62 patients will receive treatment as usual, this will form a (passive) control group to the MBCT group.
89410855|NCT05772988|Experimental|Beta-alanine|Beta-alanine to be given for three weeks
89410856|NCT05772988|Placebo Comparator|Maltodextrin|Placebo to be given for three weeks
89410857|NCT05772260||Patients with autonomic dysfunction|Achalasia patients who have autonomic dysfunction in the heart rate variability test (HRV test) performed preoperatively.
89410858|NCT05772260||Patients with normal autonomic function|Achalasia patients without autonomic dysfunction in the heart rate variability test (HRV test) performed preoperatively.
89437536|NCT03694522|Placebo Comparator|Placebo + mFOLFOX6|Participants received placebo for bemarituzumab administered every 2 weeks with a single additional placebo dose on cycle 1 day 8. Participants also received mFOLFOX6 chemotherapy administered Q2W. Treatment continued until unacceptable toxicity, disease progression, or death.
89410859|NCT05771623|Experimental|Botulinum Toxin Type a Iontophoresis for Postburn Hypertrophic Scar|"The study group includes 38 postburn hypertrophic scar patients l receiving Botox iontophoresis once monthly for 3 months; in addition to their physical therapy program (Stretching exercises, Pressure Therapy and Massage) 2 sessions per week for 3 months.~Botulinum toxin type A (Botox Allergan ®, Irvine, CA, USA) is used. 100 U vacuum-dried powder in a single-use vial for reconstitution diluted in 2 mL of sterile, preservative-free 0.9% saline to constitute a solution at a concentration of 4 U/0.1 mL) is being administered once a month for a total period of three months.~The dose will be adjusted to 2.5 U/cm2 of the scar. The dose shouldn't exceed 100 units per session."
89410860|NCT05771623|Active Comparator|Traditional physical therapy for postburn hypertrophic scar|This group includes 38 patients with postburn hypertrophic scar who will receive the traditional PT (deep friction massage, stretching and pressure therapy).
89410861|NCT05770297|Active Comparator|Propolis|the subjects were asked to consume propolis 1 drop/10 kgbw/time given 2 times a day for 12 weeks. the dose will be calculated based on body weight by the certified nutritionist during the interview after the subject signs the informed consent form
89410862|NCT05770297|Placebo Comparator|Placebo|the subjects were asked to consume placebo (glucose-only contained) 1 drop/10 kgbw/time given 2 times a day for 12 weeks. the dose will be calculated based on body weight by the certified nutritionist during the interview after the subject signs the informed consent form
89410863|NCT05744635||Liver transplant patients, receiving tacrolimus containing immunosuppression|"Patients ≥ 18 years of age~Patients after liver- or simultaneous liver and kidney transplantation~Having received a tacrolimus containing immunosuppressant therapeutic regimen at least for four weeks (induction therapy), and TL is within 5-20 ng/ml before inclusion. Possible medications are the following (dosages and administration according to local (European) SmPC~Envarsus prolonged release tablet~Adport hard capsule~Advagraf prolonged-release hard capsule~Modigraf granule for oral suspension~Prograf hard capsule~Tacforius hard capsule"
89410864|NCT05736003|Experimental|Prolonged laparoscpic cholecystectomy|Patients received laparoscopic cholecystectomy for acute cholecystitis after 27 hours of symptoms
89410865|NCT05736003|Active Comparator|Delayed laparoscpic cholecystectomy|Patients received laparoscopic cholecystectomy for acute cholecystitis after 6 weeks of symptoms
89410866|NCT05733689|Experimental|Neoadjuvant chemotherapy with ctDNA testing|"The patients will be treated with one of the standard neoadjuvant protocols (FLOT or FOLFOX.) If no decline in ctDNA detected after 4 cycles, treatment will be switched to a different chemotherapy backbone (e.g. irinotecan based regimen, or taxane based if not used upfront).~ctDNA will be re-evaluated after 3 cycles (if a 21 day regimen) or 4 cycles (if a 14 day regimen) of the 2nd line regimen. If ctDNA is lower than the previous measurement, then the same regimen continues for 3-4 more cycles (depending on 14 day or 21 day cycle), followed by gastrectomy. Adjuvant treatment is given based on the investigator's discretion."
89410867|NCT05733533|Experimental|HRS-2261 oral tablet|
89410868|NCT05733533|Placebo Comparator|Matching placebo to HRS-2261|
89410869|NCT05723874|Experimental|Period 1 (Reference treatment (R)): BI 425809|
89410870|NCT05723874|Experimental|Period 2 (Test treatment (T)): bosentan + BI 425809|
89410871|NCT05718817|Experimental|XEN1101 25 mg/day|XEN1101 25 mg/day
88887181|NCT01424241|Experimental|Sandostatin LAR|This is a 9 month, open label dose escalation study of Sandostatin LAR therapy.
88887182|NCT01424254|Experimental|Video-Capsule Endoscopy|VCE will be performed in the early morning following 200 mg of simethicone and 250 - 500 mg of erythromycin (as per physician's prescription), ingestion also in the absence of contra-indications
88887183|NCT01424254|Experimental|Push Enterosopy|
88887184|NCT01424267||1|
88887185|NCT01424280|Experimental|Active drug|
88887186|NCT01424280|Placebo Comparator|Placebo|
88887187|NCT01424319|Experimental|ABT-627, Low dose|
88887188|NCT01424319|Experimental|ABT-627, High dose|
88887189|NCT01424319|Placebo Comparator|ABT-627, Placebo|
88887190|NCT01424332|Experimental|Treatment arm 1|darexaban, wash-out, ASA, wash-out, darexaban plus ASA
88887191|NCT01424332|Experimental|Treatment arm 2|darexaban, wash-out, darexaban plus ASA, wash-out, ASA
88887192|NCT01424332|Experimental|Treatment arm 3|ASA, wash-out, darexaban, wash-out, darexaban plus ASA
88887193|NCT01424332|Experimental|Treatment arm 4|ASA, wash-out, darexaban plus ASA, wash-out, darexaban
88887194|NCT01424332|Experimental|Treatment arm 5|darexaban plus ASA, wash-out, darexaban, wash-out, ASA
89410872|NCT05699200|Other|Spontaneous coronary artery dissection (SCAD) group|Subject with a history of SCAD will undergo a series of diagnostic studies to assess neurovascular function.
89410873|NCT05699200|Other|Healthy Control Group|Healthy subjects will undergo a series of diagnostic studies to assess neurovascular function.
89410874|NCT05684315|Experimental|soft tissue flossing therapy right lower limb|The study will be conducted in two rounds, 4 weeks apart. In round one, subjects will have their right leg flossed while performing the fatigue protocol.
88887195|NCT01424332|Experimental|Treatment arm 6|darexaban plus ASA, wash-out, ASA, wash-out, darexaban
88887196|NCT01424345|Active Comparator|control group|Dosages of immunosuppressants will be given according to the results of conventional post-transplant lab
88887197|NCT01424345|Experimental|ImmuKnow Study group|The dosages of immunosuppressants will be adjusted according to the results of ImmuKnow and conventional post-transplant lab
88887198|NCT01424358|Experimental|Web-based Educational|
88887199|NCT01424371||Adjuvanted Vaccine Group|
88887200|NCT01424371||Unadjuvanted Vaccine Group|
88887201|NCT01424371||Unvaccinated Elderly|
88887202|NCT01424384|Active Comparator|Citalopram|Marketed comparitor
88887203|NCT01424384|Experimental|Investigational Medicinal Product|GSK424887
88887204|NCT01424384|Placebo Comparator|Placebo To Match Treatment|Placebo control
88887205|NCT01424423|Experimental|Subjects receiving GSK1223249 in cohort 1|Eligible subjects will receive intravenous infusion of GSK1223249 with a starting dose of 0.02 milligrams per kilograms, followed by 0.2, 2, 10 and 30 milligrams per kilograms, administered by a programmable syringe pump.
88887206|NCT01424423|Placebo Comparator|Subjects receiving placebo in cohort 1|Eligible subjects will receive intravenous infusion of placebo, administered by a programmable syringe pump.
89410875|NCT05684315|Experimental|soft tissue flossing therapy left lower limb|The study will be conducted in two rounds, 4 weeks apart. In round one, subjects will have their left leg flossed while performing the fatigue protocol.
89410876|NCT05681455|Experimental|Experimental group|"A two-phase microcurrent with a frequency between 1.14 Hertz and 14.29 Hertz and currents between 0.1 and 0.9 mA will be applied.~A total of 15 sessions in 7.5 weeks. Twice a week. The session time with microcurrents will last 60 minutes."
89410877|NCT05681455|Placebo Comparator|Placebo group|"Microcurrent machines shall be operated in such a way that they have a light signal but do not emit current. Neither the physical therapists who place them nor the subjects will be able to distinguish current-emitting machines from placebo machines.~A total of 15 sessions in 7.5 weeks. Twice a week. The session time with placebo will last 60 minutes."
89410878|NCT05654181|Experimental|Cohort 1|Participants will receive up to 4 dose levels of PF-07328948 single dose and up to 2 single doses of matching placebo. Doses will be administered as oral suspensions and each dose level is to be determined.
89410879|NCT05654181|Experimental|Cohort 2|Participants will receive up to 4 dose levels of PF-07328948 single dose and up to 2 single doses of matching placebo. Doses will be administered as oral suspensions and each dose level is to be determined.
89410880|NCT05654181|Experimental|Cohort 3|Participants will receive up to 4 dose levels of PF-07328948 single dose and up to 2 single doses of matching placebo. Doses will be administered as oral suspensions and each dose level is to be determined.
89410881|NCT05640557|Experimental|Experimental group|The participants of the study will take part in exercises (proprietary exercise program), 2 times per week, 45 minutes, for 6 weeks. They will be measured before and after the 6-week exercise program.
89410882|NCT05640557|No Intervention|Control group|The study participants will not be subjected to any intervention, they will be measured twice, 6 weeks apart. They will be asked to lead their habitual lifestyle.
89410883|NCT05638360|Experimental|Ru-Yi-Jin-Huang-Saan|Participants received Ru-Yi-Jin-Huang-Saan patch topically twice daily for 6 days.
89410884|NCT05638360|Placebo Comparator|Placebo|Participants received a starch patch topically twice daily for 6 days.
89410885|NCT05608837|Experimental|High Dose UME - 6 drops OCS-01|"From baseline until week 4 all participants will receive 01 drop of OCS-01, six times a day.~At week 4, participants randomized to the high dose group will continue to receive 01 drop of OCS-01 six times a day until the primary end point at week 12.~Starting week 12 the treatment will be administered based on the retreatment criteria until the end of study at week 24."
89410886|NCT05608837|Experimental|Low Dose UME 3 drops OCS-01 and 3 drops Placebo|"From baseline until week 4 all participants will receive 01 drop of OCS-01, six times a day.~At week 4, the participants randomized to low dose group will receive 01 drop of OCS-01 three times a day and 01 drop of placebo three times a day,( total 6 drops each day) until the primary end point at week 12.~Starting week 12 the treatment will be administered based on the retreatment criteria until the end of study at week 24."
89410887|NCT05608837|Experimental|High dose PSME - 6 drops of OCS-01|"From baseline until week 4 all participants will receive 01 drop of OCS-01, six times a day.~At week 4, participants randomized to the high dose group will continue to receive 01 drop of OCS-01 six times a day until the primary end point at week 12.~Starting week 12 the treatment will be administered based on the retreatment criteria until the end of study at week 24."
89410888|NCT05608837|Experimental|Low dose PSME - 3 drops of OCS-01 and 3 drops of Placebo|"From baseline until week 4 all participants will receive 01 drop of OCS-01, six times a day.~At week 4, the participants randomized to low dose group will receive 01 drop of OCS-01 three times a day and 01 drop of placebo three times a day, (total 6 drops each day) until the primary end point at week 12.~Starting week 12 the treatment will be administered based on the retreatment criteria until the end of study at week 24."
89410889|NCT05607680|Placebo Comparator|Placebo|Placebo,SC,once a week*48week
89410890|NCT05607680|Experimental|IBI362 4.0mg|2mg,SC,once a week*4 week 4mg,SC,once a week*44 week
89410891|NCT05607680|Experimental|IBI362 6.0mg|2mg,SC,once a week*4 week 4mg,SC,once a week*4 week 6mg,SC,once a week*40 week
89410892|NCT05593887|Active Comparator|Hip Reconstruction surgery.|This group will undergo Hip reconstruction surgery Anterior approach overlying the iliac crest: open reduction and pelvic osteotomy. Lateral approach: derotation-varization osteotomy and shortening of femur and internal fixation.
89410893|NCT05593887|Active Comparator|Proximal femoral resection|This group will undergo PFR as described by resection of the proximal part of the femur below the level of the lesser trochanter by 2 to 3 cm and constructed a capsular flap across the acetabulum. The quadriceps muscle will be sutured around the resected end of the femur.
89192145|NCT00727974||2|"Diagnostic Criteria for Migraine:~5 or more different headaches, complete return to health in between headaches, headaches last 2-48 hours and get in the way everyday activity, headache affects one side of head, with pounding moderate-to-severe pain, one of the following: nausea, vomiting, photophobia (fear of light), phonophobia (fear of sound)."
89192146|NCT00733928|Other|1 - All Polyethylene Tibia|Total knee replacement with an all polyethylene tibial tray
89410894|NCT05593887|Active Comparator|Proximal femur valgus osteotomy|This group will undergo McHale Procedure.The patient is positioned in the lateral decubitus Position A straight incision is cantered over the greater trochanter and extends proximally. Head and neck are resected. A closing wedge, shortening, valgus-producing osteotomy of 40 to 50 degrees is marked just below the lesser trochanter and fixed by a plate.
89410895|NCT05580913|Experimental|Subjective auto-regulation training|Participants complete their resistance-training sets to termination based on rating of perceived exertion
89410896|NCT05580913|Experimental|Objective auto-regulation training|Participants complete their resistance-training sets to termination based on reaching a critical slow velocity
89410897|NCT05580913|Active Comparator|Traditional standardized training|Participants complete their resistance-training sets by lifting a prescribed percentage of their estimated one-repetition maximum (as determined from baseline four-repetition maximum strength testing)
89410898|NCT05570435|Experimental|YIYANG TangLv milk powder|30g of milk powder (Nestle YIYANG TangLv milk powder) containing 789 mg Reducose® extract, standardized to contain 1% 1-deoxynojirimycin (1-DNJ), 10% of an oil mix and 8% of soluble fiber reconstituted with 180 ml of warm water.
89005168|NCT00231972|Experimental|Project Enhance|Participants will receive the risk reduction program, Project Enhance
89410899|NCT05570435|Active Comparator|skimmed milk|25g of commercially available skimmed milk powder reconstituted with 180 ml of warm water.
89410900|NCT05560685|Other|Patient participants|Patients with risk factors for adjuvant endocrine therapy non-adherence or early discontinuation will complete patient-reported outcome (PRO) surveys via smart phone app at baseline and 2, 4, 8 and 12 weeks after adjuvant endocrine therapy initiation.
89410901|NCT05560685|Other|Team Member Participants|Feedback about the intervention will be obtained from patients and from members of the study teams and clinical teams caring for the patients who participate.
89410902|NCT05542498|Active Comparator|Mindfulness Training|5-lesson audio-guided mindfulness training program delivered over 5 consecutive days, with two additional writing activities on day 1 and day 5
89410903|NCT05542498|Active Comparator|Relaxation Training|5-lesson audio-guided relaxation training program delivered over 5 consecutive days, with two additional writing activities on day 1 and day 5
89410904|NCT05505305|Experimental|Time-restricted eating and high-intensity interval training|Seven weeks of time-restricted eating and high-intensity interval training with digital follow-up.
89005169|NCT00231972|Active Comparator|Active Comparison Condition|Participants will receive standard prevention case management
89410905|NCT05505305|No Intervention|Control|No intervention nor digital follow-up for seven weeks.
89437537|NCT03694158|Experimental|Treatment group|Dupilumab (Dupixent®) administered subcutaneously every two weeks. An initial dose of 600 mg (two 300 mg injections) followed by 300 mg given every other week.
89410906|NCT05504889||OPTIMOM residual samples|"Residual plasma samples collected in one of our prior studies monthly across pregnancy (OPTIMOM, NICHD 1U54HD085601-01, Clinical Trials.gov ID NCT02519790; K. Wisner, PI) will be evaluated for cholesterol and 4β-hydroxycholesterol.~These samples were obtained from women who gave their consent for use of their blood samples for future studies. All OPTI-MOM participants have been genotyped for variants in CYP3A5 using commercial allelic discrimination assays (ThermoFisher Scientific, Waltham, MA, with Taqman probes.)"
89410907|NCT05504889||Newly recruited subjects|Plasma samples will be collected from newly recruited subjects.
89410908|NCT05498454|Active Comparator|Breathworks Mindfulness for Health|an 8-week, online, protocol based mindfulness course designed to manage chronic pain and chronic health conditions
89410909|NCT05498454|Active Comparator|Breathworks Mindfulness for Stress|an 8-week, online, protocol based mindfulness course designed to manage stress
89410910|NCT05498454|No Intervention|Waiting list|The Waiting list will be for the whole sample of participants (acting as a waiting list control). From this, participants will be randomly allocated to one of the Arms above
89410911|NCT05497687|Experimental|12-week strength-building intervention|Participants in the intervention group will participate in a 12-week strength-building intervention comprising of face-to-face/remote sessions with telephone follow-ups.
89410912|NCT05497687|No Intervention|Routine care that they currently receiving provided by their primary healthcare providers|The control group will receive routine care that they currently receiving provided by their primary healthcare providers, which include unstructured patient education on lifestyle modification. The usual care does not include structured exercise training.
89410913|NCT05490862|Experimental|Obese Weight Loss group|Low-calorie diet and regular physical trainings will be administered to obese participants (BMI >30kg/m^2).
89410914|NCT05490862|Active Comparator|Obese Control group|Traditional weight loss recommendations will be provided to obese participants (BMI >30kg/m^2)
89410915|NCT05490862|No Intervention|Lean Control group|The data of these subjects will be used as a control
89410916|NCT05489887|Experimental|Subjects with ALK Wildtype or Unknown|"5 cycles of standard of care induction + naxitimab~Naxitimab on Days 1, 3, and 5 of each cycle"
89410917|NCT05489887|Experimental|Subjects with ALK aberration|"5 cycles of standard of care induction + naxitimab + ceritinib~Naxitimab on Days 1, 3, and 5 of each cycle Ceritinib once daily on every day of study"
89410918|NCT05487027|No Intervention|Control|This arm will have no intervention or instructions from researchers. Participants in this arm will perform their work planning as normal.
89410919|NCT05487027|Experimental|Intervention|Introduce a deliberate variation between workers in how much they care for physically strenuous users. Some workers may receive more strenuous work compared to before, some less.
89410920|NCT05480904||On campus|SJLIFE Study Campus Visit
89410921|NCT05480904||Remote|SJLIFE cohort: ALL, CNS tumors, and non-CNS solid tumors
89410922|NCT05466136|Experimental|Mental fatigue condition|Performing a completed incongruent version of Stroop task for 30min.
89410923|NCT05466136|Experimental|Control condition|Performing a completed congruent version of Stroop task for 30min.
89410924|NCT05453019|Experimental|tinnitus group|Patients who have tinnitus got cochlear implant
89410925|NCT05453019|Active Comparator|without tinnitus group|Patients who have no tinnitus got cochlear implant
89410926|NCT05446727|Experimental|QLB|Experimental: Quadratus Lumborum block group Quadratus Lumborum block group (QL) patients will receive a bilateral Quadratus Lumborum block using Ropivacaine 0.375%
89410927|NCT05446727|Experimental|ESP|Ultrasound-guided continuous ESP block with opioid PCA A high-frequency linear ultrasound transducer will be placed in a longitudinal parasagittal orientation 3 cm lateral to the T7/T8 spinous process. A Contiplex Echo ultra 360 18G needle with 20G × 55 cm Contiplex Echo catheter will be inserted using an in-plane superior-to-inferior approach to place the tip into the fascial plane on the deep (anterior) aspect of erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting erector spinae muscle off the bony shadow of the transverse process. A total of 30 mL of 0.375% ropivacaine
89410928|NCT05444114|Experimental|Mental Exercise A|Participants follow instructions on a 10-min audio clip
89192147|NCT00733928|Active Comparator|2 - Poly & Metal Tibia|Total knee replacement with a metal-backed tibial component
89410929|NCT05444114|Active Comparator|Mental Exercise B|Participants follow instructions on a 10-min audio clip
89410930|NCT05425511|Experimental|intervention group|The intervention group will have a longitudinal follow-up of seven months in total (a control period of 1 month, then 6 to 8 sophrology sessions during two months, then a 4-month follow-up).
89410931|NCT05425511|Active Comparator|control group|The control group will have a differed intervention (longitudinal follow-up of seven months in total beginning by a control period without intervention of 3 months, then 6 to 8 sophrology sessions during two months, then a 2-month follow-up).
89410932|NCT05418764|Experimental|Intervention group|Participants will receive standardized training by performing five hysterectomies on the Miya Model with a trainer who is a sub-PI at each Institution, with each of these training sessions filmed and then scored by blinded experts - Residents in the simulation arm will train until they reach a score of 27 on the modified Vagina Surgical Skills Index (VSSI)
89410933|NCT05418764|No Intervention|Control group|The training will be whatever is standard at their Institution
89410934|NCT05404139|Other|Arm 1 - Standard of Care|Participants in this group will receive standard of care radiation treatment and ADT. Participants will start ADT first. Androgen deprivation therapy will be delivered via injection every 4 months as per standard of care (for 8 months total). At the same time, or within 3 months of starting ADT, participants will begin radiation treatment. The radiation treatment course will consist of 2-5 sessions of radiation daily or every other day (the number of sessions will be determined by the physician depending on the location of cancer, number of cancer spots, etc.).
89437538|NCT03694158|Placebo Comparator|Placebo group|Placebo (preparation, administration, packaging, and labeling all equivalent to the treatment) administered subcutaneously every two weeks.
89437539|NCT03688126|Experimental|Self-Guided Lifestyle Intervention|Lifestyle modification program that is developed by the participant to meet his/her specific needs.
89437540|NCT03688126|Experimental|Structured Lifestyle Intervention|Lifestyle modification program that involves participants completing structured activities that target diet, physical exercise, and intellectual and social stimulation.
89410935|NCT05404139|Experimental|Arm 2 - Study Treatment|Participants in this group will receive standard of care radiation treatment and ADT, plus enzalutamide. Participants will start ADT first. Androgen deprivation therapy will be delivered via injection every 4 months as per standard of care (for 8 months total). At the same time, or within 3 months of starting ADT, participants will begin radiation treatment. The radiation treatment course will consist of 2-5 sessions of radiation daily or every other day (the number of sessions will be determined by the physician depending on the location of cancer, number of cancer spots, etc.). In addition, participants will take enzalutamide orally (by mouth) daily for 8 months. Participants will start the first pill within a month of enrollment. This pill can be taken around the same time of day with or without food.
89410936|NCT05398315|Experimental|Empathic Statements, MI, Male, No Backstory|Presence of empathic statements and MI techniques. Male narrator. No narrator backstory.
89410937|NCT05398315|Experimental|No Empathic Statements, No MI, Female, No Backstory|No empathic statements, MI techniques or narrator backstory. Female narrator
88887207|NCT01424423|Experimental|Subjects receiving GSK1223249 in cohort 2|Eligible subjects will receive intravenous infusion of GSK1223249 with a dose of 0.2 milligrams per kilograms administered by a programmable syringe pump.
88887208|NCT01424423|Placebo Comparator|Subjects receiving placebo in cohort 2|Eligible subjects will receive intravenous infusion of placebo, administered by a programmable syringe pump.
88887209|NCT01424423|Experimental|Subjects receiving GSK1223249 in cohort 3|Eligible subjects will receive intravenous infusion of GSK1223249 with a dose of 2 milligrams per kilograms administered by a programmable syringe pump.
88887210|NCT01424423|Placebo Comparator|Subjects receiving placebo in cohort 3|Eligible subjects will receive intravenous infusion of placebo, administered by a programmable syringe pump.
88887211|NCT01424423|Experimental|Subjects receiving GSK1223249 in cohort 4|Eligible subjects will receive intravenous infusion of GSK1223249 with a dose of 10 milligrams per kilograms administered by a programmable syringe pump.
89005170|NCT00229047||Vein Stripping|Patients undergoing elective varicose vein stripping in our vascular OR. Observe circulation in the exposed soleus/gastrocnemius muscle.
89410938|NCT05398315|Experimental|No Empathic Statements, No MI, Female, Backstory|No empathic statements or MI techniques. Presence of narrator backstory. Female narrator
89410939|NCT05398315|Experimental|Empathic Statements, MI, Female, Backstory|Presence of empathic statements, MI techniques and narrator backstory. Female narrator
89410940|NCT05398315|Experimental|No Empathic Statements, No MI, Male, No Backstory|No empathic statements, MI techniques or narrator backstory. Male narrator
89410941|NCT05398315|Experimental|Empathic Statements, MI, Male, Backstory|Presence of empathic statements, MI techniques and narrator backstory. Male narrator.
89410942|NCT05398315|Experimental|No Empathic Statements, MI, Female, Backstory|Presence of MI techniques and narrator backstory. No empathic statements. Female narrator.
89410943|NCT05398315|Experimental|Empathic Statements, No MI, Male, No Backstory|Presence of empathic statements. No MI techniques or narrator backstory. Male narrator.
89410944|NCT05398315|Experimental|No Empathic Statements, MI, Male, Backstory|Presence of MI techniques and narrator backstory. No empathic statements. Male narrator.
89410945|NCT05398315|Experimental|Empathic Statements, No MI, Female, No Backstory|Presence of empathic statements. No MI techniques or narrator backstory. Female narrator.
89410946|NCT05398315|Experimental|Empathic Statements, MI, Female, No Backstory|Presence of empathic statements and MI techniques. Female narrator. No narrator backstory.
89410947|NCT05398315|Experimental|No Empathic Statements, No MI, Male, Backstory|Presence of narrator backstory. No empathic statements or MI techniques. Male narrator.
89410948|NCT05398315|Experimental|Empathic Statements, No MI, Female, Backstory|Presence of empathic statements and narrator backstory. No MI techniques. Female narrator.
89410949|NCT05398315|Experimental|Empathic Statements, No MI, Male, Backstory|Presence of empathic statements and narrator backstory. No MI techniques. Male narrator.
89410950|NCT05398315|Experimental|No Empathic Statements, MI, Female, No Backstory|Presence of MI techniques. No empathic statements or narrator backstory. Female narrator.
89410951|NCT05398315|Experimental|No Empathic Statements, MI, Male, No Backstory|Presence of MI techniques. No empathic statements or narrator backstory. Male narrator.
89410952|NCT05386992|Experimental|Anthropometric study of children's feet and healthy standard last design:|"An anthropometric study of the feet of the subjects included in the sample will be carried out. The variables of interest used in this work are collected by digitizing the foot and ankle of each person, as well as through an anonymous questionnaire, which the study volunteers and their parents or legal guardians fill out and deliver.~From the data collected, 5 models of healthy standard last will be produced that are adapted to the anthropometric characteristics of our study population: sports last, boot last, sandal last, ballerina last and moccasin last."
89410953|NCT05376059|No Intervention|Control Condition|Participants in this group will not receive any oureach at all
89410954|NCT05376059|Experimental|How incentive receive|This will be a group that will receive a mailer emphasizing only how to seek treatment for mental health issues, including an incentive if they seek out mental health treatment (if they visit a therapist within 30 days, they will receive a gift card).
89410955|NCT05376059|Experimental|How incentive holdout|This will be a group that will receive a mailer emphasizing only how to seek treatment for mental health issues. This group is eligible for an incentive but not randomly assigned to it.
89410956|NCT05376059|Experimental|How incentive ineligible|This will be a group that will receive a mailer emphasizing only how to seek treatment for mental health issues. This group is not eligible for an incentive.
89410957|NCT05376059|Experimental|How and why incentive receive|This will be a group that will receive a mailer emphasizing both how to get help and why they should get help for mental health issues (i.e., listing out how mental health treatment can improve their lives), including an incentive if they seek out mental health treatment (if they visit a therapist within 30 days, they will receive a gift card).
89410958|NCT05376059|Experimental|How and why incentive holdout|This will be a group that will receive a mailer emphasizing both how to get help and why they should get help for mental health issues (i.e., listing out how mental health treatment can improve their lives). This group is eligible for an incentive but not randomly assigned to it.
89410959|NCT05376059|Experimental|How and why incentive ineligible|This will be a group that will receive a mailer emphasizing both how to get help and why they should get help for mental health issues (i.e., listing out how mental health treatment can improve their lives). This group is not eligible for an incentive.
89410960|NCT05349890|Experimental|CDX-1140 + TCR-T + Pembro|Patients will receive CDX-1440, TCR-T, and pembrolizumab.
89410961|NCT05335239|Experimental|Intervention group|Every third month, a dental nurse will visit at home and deliver professional dental cleaning and delivery of one new toothbrush and fluoride toothpaste (>4000ppm) (n:3) for the next three months. The visit is expected to take at the most 30 minutes.
89410962|NCT05335239|No Intervention|Controll group|Continuous with oral care as usual, either by themselves or nursing assisted (help with oral hygiene procedure) during the whole study period. Home care aides working with the control study participants deliver a toothbrush and fluoride toothpaste (> 4000 ppm) (n:3) every third month during the study period.
89410963|NCT05313269|Experimental|ISAFE technique|Adductor canal block catheter tip located in the fascial plane between sartorious muscle and femoral artery.
89410964|NCT05313269|Active Comparator|Conventional technique|Adductor canal block catheter tip located in lateral to the femoral artery.
89410965|NCT05310396|Experimental|Powdered cow's milk-based infant formula containing uniquely processed whey protein|Starter and follow up formula containing combination of an HMO blend, myelin nutrient blend, and MOS
89410966|NCT05310396|Active Comparator|Powdered infant fortified cow's milk|Standard Starter and follow up formula without added HMOs or MOS containing lower levels of myelin nutrients
89410967|NCT05307055|Experimental|Group A|double-blinded randomization into theta burst stimulation followed by baseline stimulation
89410968|NCT05307055|Experimental|Group B|double blinded randomization into baseline stimulation followed by theta burst stimulation
89437541|NCT03686566||13C-glucose infusion|Tumor samples of patients who receive the optional 13C-glucose infusion will be studied using flux analysis and metabolomic profiling.
89192148|NCT00805623|No Intervention|AW|no pacifier , no sucrose
89192149|NCT00805623|Active Comparator|AS|sucrose without pacifier
88887212|NCT01424423|Placebo Comparator|Subjects receiving placebo in cohort 4|Eligible subjects will receive intravenous infusion of placebo, administered by a programmable syringe pump.
88887213|NCT01424423|Experimental|Subjects receiving GSK1223249 in cohort 5|Eligible subjects will receive intravenous infusion of GSK1223249 with a dose of 30 milligrams per kilograms administered by a programmable syringe pump.
88887214|NCT01424423|Placebo Comparator|Subjects receiving placebo in cohort 5|Eligible subjects will receive intravenous infusion of placebo, administered by a programmable syringe pump.
88887215|NCT01424436|Experimental|GSK933776 1mg/kg|single dose
88887216|NCT01424436|Experimental|GSK933776 0.1 or 3mg/kg|single dose
88887217|NCT01424436|Experimental|GSK933776 3 or 6mg/kg|single dose
88887218|NCT01424449|Experimental|no treatment|Aripiprazole is a D2/D3 antagonist registered in the UK for use in the treatment of schizophrenia. It allows the highest clinically acceptable blockade of central D2/D3 receptors and will allow us to examine the amount of displaceable binding in the brain - a proposed reference tissue for [11C]PHNO.
88887219|NCT01424462|Experimental|Firategrast XRA|Low extended release tablet
88887220|NCT01424462|Experimental|Firategrast XRB|Medium extended releast tablet
88887221|NCT01424462|Experimental|Firategrast XRC|High extended release tablet
89192150|NCT00805623|No Intervention|PW|
89192151|NCT00805623|Experimental|PS|Pacifier and sucrose interventional
89192152|NCT04280172|Experimental|Cultural Competence Education|Participants in the intervention group will attend cultural competence education
88887222|NCT01424462|Experimental|Firategrast IR|Immediate Release reference tablet
88887223|NCT01424475|Other|PKD Patients|PKD Patients with LRRK2 mutation
88887224|NCT01424475|Other|Healthy Controls|Healthy Controls with no LRRK2 mutation
88887225|NCT01424488|Experimental|sugammadex group|4 mg/kg of sugammadex for reversal of pipecuronium-induced neuromuscular blockade
88887226|NCT01424488|Placebo Comparator|placebo group|3 ml of saline (placebo) for reversal of pipecuronium-induced neuromuscular blockade
88887227|NCT01424527||Chronic Obstructive Pulmonary Disease|Males and females 40 years of age or older with a diagnosis of COPD
89192153|NCT04280172|Active Comparator|Standard Mentoring Education|Participants in the control group will complete standard mentoring education that does not include a cultural competence component
88887228|NCT01424540|Experimental|Treatment A|GSK2336805 150mg
88887229|NCT01424540|Placebo Comparator|Treatment B|GSK2336805 Placebo
88887230|NCT01424553|Other|Cohort|All patients
88887231|NCT01424579|Experimental|Actual Diacutaneous Fibrolysis|The group received tree weeks of a daily protocolized treatment and additionally six sessions (two a week) of actual Diacutaneous Fibrolysis.
88887232|NCT01424579|Placebo Comparator|Placebo Diacutaneous Fybrolisis|This group received tree weeks of a daily protocolized treatment and additionally six sessions (two a week) of placebo Diacutaneous Fibrolysis.
88887233|NCT01424579|Other|No Diacutaneous Fibrolysis|This group received only tree weeks of a daily protocolized treatment.
88887234|NCT01424592||Study Group|Hospitalized inpatients referred by a general medicine service for evaluation of obstructive sleep apnea.
88887235|NCT01424605|Experimental|DLT intubation|
88887236|NCT01424618|Active Comparator|GnRh agonist|This arm will use a GnRH agonist to suppress pituitary-ovarian function
89192154|NCT00732914|Active Comparator|1|Sunitinib (first-line) followed by Sorafenib (second-line)
89192155|NCT00732914|Experimental|2|Sorafenib (first-line) followed by Sunitinib (second-line)
89192156|NCT00728052|Experimental|Subjects receiving treatment sequence ABCD|Subjects will receive treatment sequence ABCD; A= placebo, B= GSK598809 dose 1 (75 milligrams), C = GSK598809 dose 2, and D = GSK598809 dose 3.
89192157|NCT00728052|Experimental|Subjects receiving treatment sequence BACD|Subjects will receive treatment sequence BACD; B= GSK598809 dose 1 (75 milligrams), A= placebo, C = GSK598809 dose 2 and D = GSK598809 dose 3
89192158|NCT00728052|Experimental|Subjects receiving treatment sequence BCAD|Subjects will receive treatment sequence BCAD; B= GSK598809 dose 1 (75 milligrams), C = GSK598809 dose 2, A= placebo and D = GSK598809 dose 3.
89192159|NCT00728052|Experimental|Subjects receiving treatment sequence BCDA|Subjects will receive treatment sequence BCDA; B= GSK598809 dose 1 (75 milligrams), C = GSK598809 dose 2, D = GSK598809 dose 3 and A= placebo.
89192160|NCT00808275|Experimental|Dairy calcium|Diet with dairy calcium sources
89410969|NCT05301517|Experimental|Roxadustat|Participants will receive roxadustat, administered orally 3 times per week (TIW) for 12 weeks to achieve Hb levels of 100-120 g/L. The starting dose will be based on the participant's weight group. The maximum dose for individual participants may not exceed 3.5 milligrams (mg)/kilogram (kg) or 400 mg TIW whichever is lower.
89410970|NCT05301517|Active Comparator|SEPO®|Participants will receive SEPO®, injected subcutaneously TIW for 12 weeks to achieve Hb levels of 100-120 g/L. The starting dose will be 150 international units (IU)/kg subcutaneously TIW.
89410971|NCT05296304|Experimental|Bexarotene Combined With Radiotherapy|Patients will be initiated on bexarotene 150 mg daily on Day 1, with dose increase to 300 mg daily on Day 15. Patients will receive Cycle 1 of TSEB on Day 22 (with 2 Gy given on two consecutive days -Day 22 and 23), with safety assessment on Day 52. Efficacy will first be assessed on Day 52 and then again on Day 82 by global response assessment, including mSWAT. Patients who have less than 70% reduction from baseline mSWAT score will be eligible for subsequent cycles of TSEB (administered as 4 Gy over 2 consecutive days), until mSWAT score reduction of ≥ 70%, and up to a total of 6 cycles. Treatment may continue until disease progression, unacceptable toxicity, recommended termination by treating physician, or termination of the study.
89410972|NCT05280301|Experimental|Sous vide device|The intervention will be the use of a sous vide device to heat the water bath to 38 degrees celsius, rather than the traditional methods of manual water exchanges or placing the frostbitten tissue under running water.
89410973|NCT05274763|Experimental|Supportive Care (CCSH)|Patients undergo 4 to 8 sessions (2-4 per week) of CCSH over 30 minutes with a chaplain while impatient.
89410974|NCT05272280|Active Comparator|External oblique intercostal (EOI) block|
88887237|NCT01424618|Experimental|GnRH antagonist|A GnRH antagonist will be used to suppress pituitary-ovarian function
88887238|NCT01424631|Active Comparator|single incision laparoscopic appendectomy|
88887239|NCT01424631|Placebo Comparator|conventional laparoscopic appendectomy|
88887240|NCT01424657|Experimental|ERCP|ERCP is an endoscopic examination that allows opacification of the biliary tree by direct injection into the common bile duct through its distal opening in the duodenum at the ampulla of Vater
88887241|NCT01424657|Experimental|MRCP|The magnetic resonance cholangiopancreatography (MRCP)allows direct visualization of the biliary tree and pancreatic duct, similar to contrast cholangiography, but without the need for administration of contrast medium
88887242|NCT01424683||Endoscopic Vein Harvest (EVH)|A short saphenous vein segment is commonly used as a conduit for coronary artery bypass grafting (CABG), and clinicians must decide whether to obtain it by performing a traditional open vein harvest (OVH) or by performing an endoscopic vein harvest (EVH).
88887243|NCT01424683||Open Vein Harvest (OVH)|A short saphenous vein segment is commonly used as a conduit for coronary artery bypass grafting (CABG), and clinicians must decide whether to obtain it by performing a traditional open vein harvest (OVH) or by performing an endoscopic vein harvest (EVH).
88887244|NCT01424696||Cystic Fibrosis in 1st 3 months of life|Early Diagnosis: Children diagnosed with CF in first 3 months of life
88887245|NCT01424709|Experimental|Arm 1|Based on expression levels of RRM1 and BRCA1 mRNA，one of the four regimens will be given to each patient: Gemcitabine/cisplatin, Docetaxel/gemcitabine, CPT-11/Cisplatin, docetaxel monotherapy. The chemotherapy will be repeated every 3 week. Dose reduction or interruption for toxicity could take place at any time.
88887246|NCT01424709|Active Comparator|Arm 2|gemcitabine/cisplatin up to 6 cycles or disease progression or intolerable toxicity.
88887247|NCT01424735|Experimental|Mw.|Administration of immunomodulator Mw.
88887248|NCT01424748|Placebo Comparator|Placebo|Placebo juice
88887249|NCT01424748|Experimental|30 mL Tahitian Noni Juice|30 mL Tahitian Noni Juice per day dose
88887250|NCT01424748|Experimental|300 mL Tahitian Noni Juice|300 mL Tahitian Noni Juice per day
88887251|NCT01424748|Experimental|750 mL Tahitian Noni Juice|750 mL Tahitian Noni Juice per day
88887252|NCT01424761|Experimental|Placebo|Placebo:starch
88887253|NCT01424761|Experimental|Coenzyme Q10|
88887254|NCT01424787||OsvaRen treatment|Dialysis patients on OsvaRen treatment
88887255|NCT01424800|Experimental|change in blood pressure and blood flow|34 patients will form the experimental group, in which changes of blood pressure and blood flow will be induced and monitored.
88887256|NCT01424839|Other|Germinoma metastatic|"• Metastatic or incompletely staged germinomas (± teratoma) Do not receive chemotherapy in this protocol~Radiotherapy~Metastatic or incompletely staged pure germinoma 24 Gy (15 fractions) to craniospinal axis with a 16 Gy (10 fraction) boost to tumour bed and any intracranial metastases and spinal deposits (total tumour dose 40 Gy)~Metastatic germinoma plus teratoma (incompletely resected) 24 Gy (15 fractions) to craniospinal axis ; 30.4 Gy (19 fraction) boost to tumour bed and 16 Gy (10 frac-tion) boost to metastases (total tumour dose 54.4 Gy)"
89410975|NCT05272280|Active Comparator|Erector spinae plane block (ESPB)|
89410976|NCT05271448|Experimental|Continue ACEI or ARBs|Randomized to continue on prescribed ACE1 or ARBs
89410977|NCT05271448|Active Comparator|Hold ACEI or ARBs|Angiotensin converting enzyme inhibitor or angiotensin receptor blocker held >= 24 hours pre-cardiac catheterization and restarted post-catheterization after creatinine measurement (48-72 hours post)
89410978|NCT05268367|Experimental|3-Week Baseline|Participants in this arm are randomized to a 3-week baseline period with repeated weekly assessment after the initial intake. Following the 3-week baseline, participants receive 5 weekly sessions of Written Exposure Therapy (WET) followed by a 4-week follow-up phase with repeated weekly assessments, including a post-study evaluation one week after ending WET.
89410979|NCT05268367|Experimental|5-Week Baseline|Participants in this arm are randomized to a 5-week baseline period with repeated weekly assessment after the initial intake. Following the 5-week baseline, participants receive 5 weekly sessions of Written Exposure Therapy (WET) followed by a 4-week follow-up phase with repeated weekly assessments, including a post-study evaluation one week after ending WET.
89410980|NCT05254405|Experimental|Open-Label Infusion of Brexanolone|This is a single arm pilot study of open label brexanolone delivered intravenously over a continuous 60-hour period. Infusions will be administered in a certified healthcare setting in accordance with the Zulresso™ dosing, administration and safety guidelines.
89410981|NCT05252338|Experimental|Younger Adults group aged 18-55 years|Subjects will be enrolled in a staggered manner in up to 5 dose levels (provisional dose levels of 3, 6, 12, 20 and 28µg). All subjects will receive a single dose of CVSQIV on Day 1.
89410982|NCT05252338|Experimental|Adults group aged ≥65 years|Subjects will be enrolled in a staggered manner in up to 5 dose levels (provisional dose levels of 3, 6, 12, 20 and 28µg). All subjects will receive a single dose of CVSQIV on Day 1.
89410983|NCT05252208|Experimental|Stretching|Stretching
89410984|NCT05252208|Experimental|Walking|Walking
88887257|NCT01424839|Other|germinoma non-metastatic|"Chemotherapy:~• Non-metastatic fully staged germinoma (± teratoma) Two courses (1 and 3) of Etoposide and Carboplatin, alternating with two courses (2 and 4) of Etoposide and Ifosfamide Note: Bifocal germinoma (pineal+suprasellar) are treated as non-metastatic germinoma, if staging shows no additional dissemination~Radiotherapy~Non-metastatic pure germinoma in PR/SD After Chemotherapy: 24 Gy (15 fractions) to whole ventricles with a 16 Gy (10 fraction) boost to tumour bed (total tumour dose 40 Gy)~Non-metastatic germinoma in CR After Chemotherapy: 24 Gy (15 fractions) to whole ventricles~Non-metastatic germinoma plus teratoma (incompletely resected) After Chemotherapy: 24 Gy (15 fractions) to whole ventricles; 30.4 Gy (19 fraction) boost to tumour bed (total tumour dose 54.4 Gy)"
88887258|NCT01424839|Other|Non-germinoma non-metastatic standard risk|"Chemotherapy:~• Standard risk non-germinomatous malignant GCT Four courses of Etoposide, Cisplatin and Ifosfamide (standard treatment ) After Chemotherapy: 54 Gy focal radiotherapy in 30 fractions"
88887259|NCT01424839|Other|Non-Germinoma metastatic standard risk|Chemotherapy Four courses of Etoposide, Cisplatin and Ifosfamide (standard treatment ) Radiotherapy After Chemotherapy: 30 Gy (20 fractions) to craniospinal axis with 24 Gy (15 fraction) boosts to tumour site and any intracranial metastases (total tumour dose 54 Gy) and 20.8 Gy (13 fraction) boosts to spinal deposits (total dose 50.8 Gy)
88887260|NCT01424839|Other|Non-germinoma non-metastatic high risk|Chemotherapy Two courses of standard Etoposide, Cisplatin and Ifosfamide, followed by two dose intensified courses of Etoposide, Cisplatin and Ifosfamide with stem cell support Radiotherapy After Chemotherapy: 54 Gy focal radiotherapy in 30 fractions
88887261|NCT01424839|Other|Non-Germinoma metastatic high risk|Chemotherapy Two courses of standard Etoposide, Cisplatin and Ifosfamide, followed by two dose intensified courses of Etoposide, Cisplatin and Ifosfamide with stem cell support Radiotherapy After Chemotherapy: 30 Gy (20 fractions) to craniospinal axis with 24 Gy (15 fraction) boosts to tumour site and any intracranial metastases (total tumour dose 54 Gy) and 20.8 Gy (13 fraction) boosts to spinal deposits (total dose 50.8 Gy)
88887262|NCT01424839|No Intervention|Teratoma|collection of information on surgery, applied treatment and outcome
88887263|NCT01424852|Active Comparator|Probiotics in milk formula|B. lactis BB-12 and L. rhamnosus GG delivered in milk formula during the first year of infancy
88887264|NCT01424852|Placebo Comparator|Control milk formula|The children received milk formula with no probiotics
88887265|NCT01424891|Placebo Comparator|Placebo|Treatment with placebo over 8 weeks
88887266|NCT01424891|Active Comparator|Simvastatin 80 mg|treatment with 80 mg of simvastatin over 8 weeks
88887267|NCT01424891|Active Comparator|Sim10/Eze10|treatment with 10 mg of simvastatin in combination with 10 mg ezetimibe over 8 weeks
88887268|NCT01424904|Experimental|DGB-01|All subjects will receive DGB-01 during the study. Approximately one-half of the subjects during the first period and the other half during the second period.
88887269|NCT01424917||Heart Transplant|Heart Transplant subjects
88887270|NCT01424956||Asymptomatic Women who have Dense Breast Tissue|Women who have no signs or symptoms of breast cancer who have > 50% parenchymal density on mammography.
88887271|NCT01424969||PRFM Group|Patients were selected prospectively for the study based on a 3-part algorithm used to identify rotator cuff tears at risk for retear. A total algorithm score of 3 or greater was required for enrollment in the study.
88887272|NCT01424969||Control Group|The control group were recruited retrospectively. Patients who have undergone arthroscopic repair of rotator cuff tears with similar size characteristics without PRFM augmentation will be encouraged to participate by letter initially, and then by telephone invitation. The same inclusion and exclusion criteria applied. MRI, pain, and functional scores will be collected in the same manner as the PRFM group at one time point at least one year post operatively.
88887273|NCT01425008|Experimental|MLN2480|
88887274|NCT01425021||Total hip/knee joint revisions|All University of Utah orthopedic patients who have had total or partial joint arthroplasties at the time of revision surgery.
88887275|NCT01425034|Active Comparator|Cast group|The 'Cast' group will be placed in a thumb spica short arm cast with the thumb IP joint free. They will be allowed digit, thumb IP and elbow range of motion.
89410985|NCT05215106|Experimental|Durvalumab|All patients enrolled in the study will receive 2 administrations of durvalumab 10mg/kg monotherapy before any standard treatment.
88887276|NCT01425034|Active Comparator|Motion group|The 'Motion' group will be placed in a forearm based thumb spica splint with the thumb IP free. They will be allowed digit, thumb IP and elbow range of motion.
88887277|NCT01425047||Females ingesting mangosteen juice|
88887278|NCT01425047||Males ingesting mangosteen juice|
88887279|NCT01425060|Experimental|Contraceptive management program|
88887280|NCT01425060|Active Comparator|Usual care|The usual care condition will be given general information about contraceptive options and contact information for clinics and providers that provide contraceptive services.
88887281|NCT01425073|Experimental|Stop TMP/SMZ|Arm 1 will have patients discontinue trimethoprim-sulfamethoxazole (TMP/SMZ) prophylaxis; patients will follow up every 3 months with study staff.
88887282|NCT01425073|No Intervention|Standard of care TMP/SMZ prophylaxis|Arm 2 will continue standard of care treatment with trimethoprim-sulfamethoxazole (TMP/SMZ) prophylaxis.
89005171|NCT00204893|Experimental|Open label|Each participant will be treated with three 3900 mg doses of calcium formate on each study day (i.e., days 1-14).
89410986|NCT05206253|Experimental|Whole egg powder|Dietary supplementation with whole egg powder after resistance training sessions
89410987|NCT05206253|Active Comparator|Whey protein powder|Dietary supplementation with whey protein powder after resistance training sessions
89410988|NCT05206253|Placebo Comparator|Maltodextrin placebo|Dietary supplementation with maltodextrin placebo after resistance training sessions
89410989|NCT05198713|Experimental|Experimental|All participants will be fit with the study hearing aid and under go the same testing conditions.
89410990|NCT05185843|Experimental|Olezarsen|Olezarsen will be administered once every 4 weeks by subcutaneous (SC) injection for up to 153 weeks.
89410991|NCT05177731|Experimental|Investigational ( venetoclax, decitabine)|"Randomized participants will receive induction as decitabine on days 1-5 and venetoclax daily on days 1-28.~Second Induction (if not reach complete remission, but the percentage of blaste cells in bone marrow decreased by more than 50%):Re-induction with pre-induction therapy.~Consolidation: If patients with favorable risk and MRD (Minimal Residual Disease) negative or refuse to allo-HSCT (Hematopoietic stem-cell transplantation), intermediate-dose (2g/m2 q12h days 1-3) for 4 cycles. If patients with intermediate or poor risk or favorable risk but MRD positive, intermediate-dose cytarabine for 1-2 cycles and follow up with allo-HSCT.~For patients with FLT3 mutation, gilteritinib can be combined with the follow-up treatment after the end of initial induction."
89410992|NCT05177731|Experimental|"Standard of Care (Conventional Induction 7+3)"|"Randomized participants will receive cytarabine and idarubicin per standard of care as follows:~Induction: cytarabine on days 1-7 and idarubicin (12mg/m2) on days 1-3 .~Second Induction (if not reach complete remission, but the percentage of blaste cells in bone marrow decreased by more than 50%): Re-induction with pre-induction therapy.~Consolidation: If patients with favorable risk and MRD negative or refuse to allo-HSCT, intermediate-dose cytarabine (2g/m2 q12h days 1-3) for 4 cycles. If patients with intermediate or poor risk or favorable risk but MRD positive, intermediate-dose cytarabine for 1-2 cycles and follow up with allo-HSCT.~For patients with FLT3 mutation, gilteritinib can be combined with the follow-up treatment after the end of initial induction."
89410993|NCT05153811|Experimental|Non-Contingent Condition|Participants will wear a wrist biosensor with daily CM based on smartphone breathalyzer readings for 30 days; then for a second 30 days, encouragement to reduce drinking but payment not based on drinking.
89410994|NCT05153811|Experimental|mHealth and CM|Participants will wear a wrist biosensor with daily CM based on smartphone breathalyzer readings for 30 days; then for a second 30 days, weekly CM based on wrist biosensor readings. Participants will also interact with a mobile health application to facilitate drinking reduction.
89410995|NCT05153811|Experimental|CM|Participants will wear a wrist biosensor with daily CM based on smartphone breathalyzer readings for 30 days; then for a second 30 days, weekly CM based on wrist biosensor readings
89410996|NCT05139290|Experimental|Prototype Intervention|The prototype intervention will be likely family-based and focused on issues of communication, problem-solving, health system literacy, and family systems, all considered in the context of the African-American (AA) adult daughter role and cultural identity.
89410997|NCT05127265||adult ICU patients|adult patients aged 18 or older admitted to University of Florida Health Shands Gainesville ICU wards
89410998|NCT05120804|Active Comparator|Standard behavioral treatment|Nutrition and physical activity education along with behavior modification techniques
89410999|NCT05120804|Experimental|Standard behavioral treatment plus relationship skills training|Nutrition and physical activity education along with behavior modification techniques plus brief and structured counseling on family functioning
89411000|NCT05112315|Experimental|Predigraft|Subjects will have a clinical follow-up based on site standard of care and benefit from follow-up using Predigraft in addition of the standard of care: the investigator will receive an alert every time there is a subject's instability, instability based on the following criteria: allograft survival assessed by iBox decreased by at least 5% in the last 12 months.
89411001|NCT05112315|No Intervention|Standard of Care|Subjects will have a clinical follow-up based on site standard of care.
89411002|NCT05111288|Experimental|Pulsed electromagnetic field (PEMF) therapy|A portable PEMF device will be utilized. For the PEMF group, the device includes adjustable magnetic field strength range (X-axis: 0.22±0.05 mT, Y-axis: 0.20±0.05 mT and Z-axis: 0.06±0.02 mT) and working frequency (30±3Hz). This magnetic strength range and frequency will be maintained during 180 days of the study period. The subjects will be instructed to use their device three times per day: providing micromagnetic emitting on both hands (palms) during morning, afternoon and evening/night sessions. Each session takes 16 min (both hands, 8 min per hand) and thus subjects are exposed to therapy for 48 min per day. Subjects will use the device as outlined continuously up through the final days of testing.
88887283|NCT01425086||Incubator temperature support|Infant will be cared for in the current ongoing policy-driven temperature support provided by the incubator and handling as per bedside nursing interventions. Infant will be followed clinically until discharge from Lucile Packard Hospital (average 4 weeks).
88887284|NCT01425086||Embrace blanket warming|Infant will be placed and wrapped in the embrace blanket and cared for and monitored for temperature support and monitored by bedside nursing interventions, as needed. Infant will be followed clinically until discharge from Lucile Packard Hospital (average 4 week
88887285|NCT01425099|Experimental|Part 1|In Part 1, approximately 12 healthy subjects will receive DTG 50mg q24h for 5 days in Period 1. Subjects will then be administered DTG 50mg q24h in combination with prednisone 60mg for 5 days followed by a 5 day taper (60 mg Days 1-5, 50 mg Day 6, 40 mg Day 7, 30 mg Day 8, 20 mg Day 9 and 10 mg Day 10 - total duration of 10 days) in Period 2. There will be a screening visit 30 days before the first dose and a follow-up visit 7-14 days after the last dose of drug.
88887286|NCT01425099|Experimental|Part 2|If DTG Cτ is reduced by more than 50% in Part 1, Part 2 will be carried out where a second cohort of subjects will receive DTG 50mg q24h DTG for 5 days in Period 1 followed by DTG 50mg q24h in combination with prednisone 20mg for 5 days followed by a 5 day taper (20 mg Days 1-5, 10 mg Days 6 and 7, 5 mg Days 8-10 - total duration of 10 days) in Period 2. There will be a screening visit 30 days before the first dose and a follow-up visit 7-14 days after the last dose of drug.
89437542|NCT03686566||No 13C-glucose infusion|Tumor samples of patients who do not choose to receive the optional 13C-glucose infusion will be studied using metabolomic profiling alone.
89411003|NCT05111288|Sham Comparator|Sham PEMF therapy|The sham PEMF devices are modified to deliver no micromagnetic field when turned on. The subjects will be instructed to use their device three times per day: providing micromagnetic emitting on both hands (palms) during morning, afternoon and evening/night sessions. Each session takes 16 min (both hands, 8 min per hand) and thus subjects are exposed to therapy for 48 min per day. Subjects will use the device as outlined continuously up through the final days of testing.
89411004|NCT05110482|Active Comparator|syntocinon group|"in this group :5 mL syringe containing a bolus of 1 IU of oxytocin and infusion syringe which will be prepared with a 50 mL syringe containing 0.4 IU/mL of oxytocin and infusion rate of 7.5 IU/h will be administrated to the patient after delivery of the fetus shoulder, Additional bolus syringes will be prepared for use as rescue boluses if needed  which will be 5 ml syringe containing 3 IU of oxytocin"
88887287|NCT01425125|Experimental|Tolvaptan in euvolemic hyponatremia|This arm will test the effectiveness of tolvaptan in treating the hyponatremia of patients with euvolemic hyponatremia.
88887288|NCT01425138||Psoriasis|Published data on moderate-to-severe plaque psoriasis.
88887289|NCT01425151|Active Comparator|i-Gel|
88887290|NCT01425151|Experimental|ProSeal|
88887291|NCT01425164|Active Comparator|Carvedilol|
88887292|NCT01425164|Experimental|Ivabradine|
88887293|NCT01425177|Experimental|Normal saline irrigation|
88887294|NCT01425216|Experimental|Sorafenib arm|All patients will be treated with sorafenib.
88887295|NCT01425242|Experimental|Aliskiren|Half of all subjects with mild to moderate hypertension and a small abdominal aortic aneurysm are treated with aliskiren, combined with hydrochlorothiazide if hypertension cannot be treated sufficiently with aliskiren monotherapy
88887296|NCT01425242|Active Comparator|Amlodipine|Half of all subjects with mild to moderate hypertension and a small abdominal aortic aneurysm are treated with amlodipine, combined with hydrochlorothiazide if hypertension cannot be treated sufficiently with amlodipine monotherapy
88887297|NCT01425255||Parents of children with Type 1 diabetes|before and several weeks after initiating using RT-CGM of their children.
88887298|NCT01425320|Experimental|Fixed Combination dapsone/adapalene Formulation A Gel|Study medication will be applied once daily for 14 days to the face, upper chest, upper back, and shoulders.
88887299|NCT01425320|Experimental|Fixed Combination dapsone/adapalene Formulation B Gel|Study medication will be applied once daily for 14 days to the face, upper chest, upper back, and shoulders.
88887300|NCT01425320|Active Comparator|dapsone 5% gel (ACZONE®)|Study medication will be applied twice daily for 14 days to the face, upper chest, upper back, and shoulders.
88887301|NCT01425320|Active Comparator|adapalene 0.3% gel (Differin®)|Study medication will be applied once daily for 14 days to the face, upper chest, upper back, and shoulders.
88887302|NCT01425333|Active Comparator|Cystectomy|Patients undergoing cystectomy for ovarian endometrioma
88887303|NCT01425333|Active Comparator|Ablation|Patients undergoing ablation for ovarian endometrioma
88887304|NCT01425346||Normal Healthy|Normal, healthy males and females between the ages of 21 and 70 with healthy eyes as determined by a standard ophthalmic examination.
88887305|NCT01425385||Autoregulation monitoring|Patients will be grouped into Meld Score
89411005|NCT05110482|Active Comparator|carbetocin group|"in this group :5 mL syringe containing a bolus of 100 mcg of carbetocin and infusion syringe  which will be prepared with a 50 mL syringe containing normal saline will be administrated for the patient after delivery of the fetus shoulder. Additional bolus syringes will be prepared for use as rescue boluses if needed which will be 5 ml syringe containing 100 mcg of carbetocin"
89411006|NCT05108623|Experimental|Part 1: Monotherapy with agenT-797|3+3 Dose escalation of agenT-797 will be administered as a single intravenous (IV) infusion.
88887306|NCT01425398|Experimental|Rosuvastatin|Rosuvastatin 40 mg PO qd x 5 days before surgery and then from post-op day 0 to 5.
88887307|NCT01425398|Placebo Comparator|Placebo|Placebo 1 tab qd x 5d before operation and then from post-op day 0 to 5
88887308|NCT01425411|Experimental|Valsartan treatment|
88887309|NCT01425424|Experimental|Fasting glucose (blood sugar)|This group is associated with a diagnosis of prediabetes
88887310|NCT01425424|Experimental|Resting Blood pressure|This group is associated with a diagnosis of prehypertension.
88887311|NCT01425424|Experimental|Fasting Glucose & Resting Blood Pressure|coexisting prediabetes and prehypertension
88887312|NCT01425437||Patients with keloid|All patients will have a clinical diagnosis of keloid and will consent to participate in this study.
88887313|NCT01425450|Experimental|HF1020|
88887314|NCT01425450|Placebo Comparator|Placebo|
88887315|NCT01425476|Placebo Comparator|Placebo & cholecalciferol 400 IU|In this arm, the placebo is in place of celecoxib and the current RDA for cholecalciferol is used the control of the cholecalciferol higher dose.
88887316|NCT01425476|Active Comparator|Placebo & cholecalciferol 2,000 IU|
88887317|NCT01425476|Experimental|celecoxib 400 mg & cholecalciferol 2,000 IU|
88887318|NCT01425489||Observation|Patients with Krabbe Disease
88887319|NCT01425502|Other|All practices|The design is a stepped-wedge cluster randomised trial. All participating practices therefore receive the intervention at a start time which is randomised.
88887320|NCT01425554|No Intervention|Diagnostic study|
88887321|NCT01425580|Experimental|liraglutide|The present trial is a two centre, open, assessor-blinded and active-controlled, parallel-group trial, in combination with metformin. The trial will compare the treatment with liraglutide 1.8 mg (s.c) QD + metformin up to 1 g BID, with that of glimepiride 4 mg QD (comparator) + metformin up to 1 g BID, on LV function in subjects with type 2 diabetes.
88887322|NCT01425580|Active Comparator|glimepiride|4 mg p.o. (QD)
88887323|NCT01425606||blood test|to measure levels of sodium, albumin and acid - base status in venous blood
88887324|NCT01425619|Placebo Comparator|Placebo cream, Skin test, Anxiety, Pain|After placing a placebo cream on both arms, pain and anxiety resulting from performing allergy skin test on one of the arms will be evaluated
88887325|NCT01425619|Active Comparator|Anesthetic cream, pain and anxiety, skin test|After placing a placebo cream on one arm and anesthetic cream on the second arm, pain and anxiety resulting from performing allergy skin test on the second arm will be evaluated
89005172|NCT00232011|Experimental|1|
89005173|NCT00204971|Experimental|1|Nutritional supplement
88887326|NCT01425619|Active Comparator|Medical clown, placebo cream, skin test|After placing a placebo cream on both arms and after receiving care and treatment from a medical clown, pain and anxiety resulting from performing allergy skin test on one of the arms will be evaluated
88887327|NCT01425619|Active Comparator|Medical clown, Anesthetic cream, Skin test|After placing a placebo cream on one arm and anesthetic cream on the second arm and after receiving care and treatment from a medical clown, pain and anxiety resulting from performing allergy skin test on the second arm will be evaluated
88887328|NCT01425645|Active Comparator|Lifestyle and behavioural change support|Interventional arm will be offered a 12 month lifestyle program translating DM prevention issues to the family milieu
88887329|NCT01425645|No Intervention|control|Control arm will receive standard diabetes prevention care as outlined in the current Canadian diabetes association Clinical Practice Guidelines.
88887330|NCT01425658|Active Comparator|clonidine|The clonidine group (groupC) received bupivacaine 10mg combined with 75 microgram clonidine preservative free intrathecally
88887331|NCT01425658|Active Comparator|Fentanyl|The fentanyl group (groupF) received bupivacaine 10mg combined with 25 microgram clonidine preservative free intrathecally
88887332|NCT01425658|Placebo Comparator|distilled water|The placebo group (group P) received bupivacaine 10mg combined with 0.5ml distilled water intrathecally .
88887333|NCT01425684||schizophrenia|smokers and nonsmokers
88887334|NCT01425684||control|smokers and nonsmokers
88887335|NCT01425697|Active Comparator|2% Chlorhexidine Gluconate cloths|2% Chlorhexidine Gluconate wipes will be used 12 hours prior to cardiac surgery and then again 3 hours prior to cardiac surgery
88887336|NCT01425697|Other|Standard of Care Preoperative Preparation|Subject will receive standard of care preoperative preparation for the clinical site.
88887337|NCT01425710||Pheochromocytoma Group|Intraoperative esophageal doppler sonography during laparoscopic adrenalectomy performed for pheochromocytoma
88887338|NCT01425710||Control group|Intraoperative esophageal doppler sonography during laparoscopic adrenalectomy for non-pheochromocytoma adrenal tumor
88887339|NCT01425736|Placebo Comparator|Chemotherapy|"Chemotherapy~:Docetaxel(75mg/m²,1 time/21d, 6times);Cisplatin(75mg/m²,1 time/21d, 6 times);Fluorouracil(750mg/m²/d,5times/21d, 30times)"
88887340|NCT01425736|Experimental|Nimotuzumab and Chemotherapy|"Nimotuzumab treatment:(200mg/w,18weeks );~Chemotherapy treatment: Docetaxel(75mg/m²,1 time/21d, 6times，);Cisplatin(75mg/m²,1 time/21d, 6 times);Fluorouracil(750mg/m²/d,5times/21d, 30times),Nimotuzumab treatment:(200mg/w,18weeks )."
88887341|NCT01425762|Experimental|Choice Group|
88887342|NCT01425762|Active Comparator|No Choice Group|
88887343|NCT01425775|Active Comparator|Vitamin D|
88887344|NCT01425775|Placebo Comparator|Placebo|
88887345|NCT01425788|Active Comparator|Osiris Phleum pratense - Group A|"Group A up-dosing schedule from 1IR (index of Reactivity) /day to 240 IR/day in 11 days and thereafter 300 IR/day in 19 days.~Day 1-6: 1,2,4,6,8,10 IR/day Day 7-11: 30, 60, 120, 180, 240 IR/day Day 12-30: 300 IR/day"
88887346|NCT01425788|Active Comparator|Osiris Phleum pratense - Group B|"Group B Up-dosing schedule:~Day 1-5: 50 IR/day Day 6-10: 150 IR/day Day 11-30: 300 IR/day"
88887347|NCT01425788|Active Comparator|Osiris Phleum pratense - Group C|"Group C up-dosing schedule:~Day 1-10: 50 IR/day Day 11-20: 150 IR/day Day 21-30: 300 IR/day"
88887348|NCT05386940||PKN1 Tertile 1|
88887349|NCT05386940||PKN1 Tertile 2|
88887350|NCT05386940||PKN1 Tertile 3|
88887351|NCT05386862|No Intervention|Naturalistic Group|This group will followed as they follow their naturalistic cannabis use.
88887352|NCT05386862|Experimental|THC Reduction Group|This group will be asked to reduce the THC content and increase CBD content of their cannabis products to study the effect of PTSD symptom severity.
88887353|NCT05386823|Experimental|HF1K16|"Up 32 subjects, comprised of up to 4 cohorts of 8 subjects each, will receive a single IV dose of study drug. Six of the 8 subjects in each cohort will receive HF1K16 and 2 subjects will receive placebo in a blinded manner Cohort 1: up to 3 mg/m2 of HF1K16 or placebo~Cohort 2: up to 6 mg/m2 of HF1K16 or placebo~Cohort 3: up to 10 mg/m2 of HF1K16 or placebo~Cohort 4: up to 13 mg/m2 of HF1K16 or placebo"
88887354|NCT05386823|Placebo Comparator|Placebo|"Up 32 subjects, comprised of up to 4 cohorts of 8 subjects each, will receive a single IV dose of study drug. Six of the 8 subjects in each cohort will receive HF1K16 and 2 subjects will receive placebo in a blinded manner Cohort 1: up to 3 mg/m2 of HF1K16 or placebo~Cohort 2: up to 6 mg/m2 of HF1K16 or placebo~Cohort 3: up to 10 mg/m2 of HF1K16 or placebo~Cohort 4: up to 13 mg/m2 of HF1K16 or placebo"
88887355|NCT05386667||Control|Patients were not given anything after FGG.
88887356|NCT05386667||Flurbiprofen|Oral spray containing 0.075 g flurbiprofen administered after FGG
88887357|NCT05386667||Hypochlorous acid|Oral spray containing hypochlorous acid applied after FGG
88887358|NCT05386667||Hyaluronic acid|An oral spray containing the main component of the product is hyaluronic acid (sodium salt) with a high molecular weight of 30 mg / 100 g was given to patients after FGG
88887359|NCT05386498|Experimental|Precure composite insert technique|After curing of bonding agent a 2mm increment of composite will be placed on the gingival floor of the cavity and cured. a measured volume of composite(3mm height and 2mm width) will be cured outside the oral cavity on a flat plastic instrument for 40 seconds. a second increment of composite will be placed on the cavity and the precured composite will be pressed in the uncured increment and pressed outward against the matrix band and light cured for 20 seconds the rest of the cavity will be filled using the oblique layering technique.
88887360|NCT05386498|Experimental|Contact Making Instrument|"a 1-2mm increment of the composite will be placed in the gingival floor of the proxial box.~a contact forming instrument will be placed in this uncured increment and an outward force will be applied using the instrument from the inside of the matrix band. The composite will then be cured for 20 seconds to achieve a tight contact."
88887361|NCT05386498|Active Comparator|Incremental composite layering technique|Increments will be placed in 1-2mm increments in oblique layering manner by a flat plastic instrument and condenser .Each increment will be cured for 20 seconds till the cavity is slightly overfilled.
88887362|NCT05386446||Drug: Interferon Gamma|Ingaron (INN: recombinant human interferon gamma, lyophilisate for solution for intranasal administration 100,000 IU) in the regime of 3 drops in each nasal passage intranasally every other day for 10 days with a break of 7 days (2 10-day cycles)
89005174|NCT00204971|Placebo Comparator|2|placebo
89005175|NCT00205166|Active Comparator|1|Caffeine 400 mg PO 1 hour before adenosine infusion
89005176|NCT00205166|Active Comparator|2|Caffeine 200 mg po one hour before adenosine infusion
89005177|NCT00229242|Active Comparator|1|Diuretic-Based Hypertension Therapy
88819649|NCT02758119|Active Comparator|Online course|Participants in the lecture group will watch individually a 4-min video of a PowerPoint presentation with voiceover narration, given in the medical school of Paris Descartes University. The video is edited to contain the same informations on out-of-hospital cardiac management than the serious game, with the same duration.
88819650|NCT01443494|Experimental|NE group|Adjust NE dose to titrate MAP to usual level regardless of fluid responsiveness when after EGDT.
88819651|NCT05085171|Experimental|intervention(Enhanced package of care) Arm|The patients with advanced HIV disease that receive HIV care at the intervention clinics will receive the enhanced intervention package which will include: point of care CD4 testing with visitect, screening for TB and cryptococcal meningitis using Fujifilm LAM and semiquantitative crAg LFA respectively and pre-emptive treatment with isoniazid and rifapentine for one month. Those with a high crAg titers will receive treatment for CNS cryptococcal disease.
88819652|NCT05085171|No Intervention|Standard of care Arm|The patients with advanced HIV disease that receive HIV care at the standard of care clinics will receive the usual routine HIV care as per the Uganda national guidelines. That is CD4 testing with flowcytometry or other CD4 testing modalities available, screening for TB and cryptococcal meningitis using Alere LAM and crAg LFA respectively and pre-emptive treatment with isoniazid and rifapentine for 3-6 month. Treatment of all asymptomatic crAG positives with fluconazole as per guidelines.
88819653|NCT05083845|Active Comparator|Erector Spinae Plane Block with 20 ml %0.25 Bupivacaine|Following the visualization of the anatomical structures, the nerve block needle was advanced via the in-plane technique beneath the erector spinae muscles until the interfascial space was reached. After hydrodissection with 2 ml normal saline, 20 ml 0.25% bupivacaine was injected into the area.
88819654|NCT05083845|Active Comparator|Erector Spinae Plane Block with 30 ml %0.25 Bupivacaine|Following the visualization of the anatomical structures, the nerve block needle was advanced via the in-plane technique beneath the erector spinae muscles until the interfascial space was reached. After hydrodissection with 2 ml normal saline, 30 ml 0.25% bupivacaine was injected into the area.
88819655|NCT02758899||Diabetic Patients|Patients with diagnosis of type I or type II diabetes, in addition to clinical diagnosis of cervical myelopathy or cervical spondylosis requiring anterior cervical discectomy and fusion.
88819656|NCT02758899||Control Patients|Patients with no diagnosis of diabetes, with a clinical diagnosis of cervical myelopathy or cervical spondylosis requiring anterior cervical discectomy and fusion.
88819657|NCT04337385|Experimental|3 hours of Prolonged Sitting|Participants will sit continuously for three hours before receiving a mixed meal challenge.
88819658|NCT04337385|Experimental|3 hours of interrupted sitting with hourly HIIE|Participants will have their three hour sitting period interrupted with high intensity interval cycling exercise (HIIE) at 30, 90 and 150 minutes into the intervention. In each exercise bout, they will cycle at 90% peak power for 3 x 60 second periods with 75 seconds of recovery in-between.
88819659|NCT01560260|Experimental|Treatment (linsitinib)|Patients receive linsitinib 150mg orally (PO) twice daily (BID) on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88819660|NCT04337541|No Intervention|Normal recommendations, no mask|Normal behavior according to the authority's recommendations or
88819661|NCT04337541|Experimental|Normal recommendations AND mask|Normal behavior according to the authority's recommendations AND use of facial masks
88819662|NCT02979782||Endo-CABG, surgical group|the minimal invasive cardiac surgery group
88819663|NCT02979782||PCI, comparative surgical group|a comparative minimal invasive procedure
88819664|NCT02979782||Healthy volunteer, control group|to exclude any learning effect or natural variation in neurological testing
88819665|NCT04337229|Experimental|artificial intelligence techniques|Facial and body movements of newborns will be recorded by camera, and images will be processed in computer environment by using artificial intelligence techniques. As a result, it is planned to create a technology that determines the comfort level of the newborn quickly and simply and can be used by the mobile device.
88819666|NCT01507220|Active Comparator|Morphine sulfate|morphine sulfate (or Sponsor-approved equivalent)
88819667|NCT01507220|Experimental|EXPAREL|EXPAREL (bupivacaine liposome extended-release injectable suspension)
88819668|NCT02795481||Stroke patients|Adult stroke patients with suspected stroke will be recruited on admission to hospital. Recruitment will continue until 100 patients have received an MRI at 24h-72h post admission, up to a maximum recruitment threshold of 300 patients.
88819669|NCT02795481||Control patients|50 adult control patients will be recruited from the non-vascular, non-oncological surgical lists at each participating site
88819670|NCT02795481||Feeding control participants|15 healthy adult members of NHS staff will be recruited to participate in the feeding control sub-study at University Hospitals Coventry and Warwickshire NHS Trust only.
88819671|NCT02795481||Spasticity sub-group controls|10 healthy adult members of NHS staff at University Hospitals of North Midlands, will be recruited to take part as spasticity sub-study controls
88819672|NCT02795481||Traumatic brain injury patients|10 adult patients with an isolated traumatic brain injury at University Hospitals Coventry and Warwickshire NHS Trust and Imperial College Healthcare NHS Trust.
88819673|NCT01507688|Experimental|Arm 1 SSM Intervention|Stroke self-management program- Participants randomized to this program will receive 6 bi-weekly telephone sessions during the first 3 months followed by 3 monthly reinforcement telephone sessions coupled with 3 monthly group sessions during months 4-6.
88819674|NCT01507688|No Intervention|Arm 2 Usual Care|Usual care
88819675|NCT02366403|Experimental|SKY|a standardized meditation program
89411007|NCT05108623|Experimental|Part 2: agenT-797 in Combination with approved ICIs|Single prespecified dose of agenT-797 administered by IV infusion in combination with approved ICIs administered in accordance with manufacturer instructions and institutional guidelines as per standard of care
89411008|NCT05087810|Experimental|Subjects|All subjects will undergo accelerated oral hydration to induce diuresis and then acute psychological stress tasks to induce acute stress. Outcomes will measure changes to perceived bladder sensation in response to acute stress provocation.
89411009|NCT05044663||NASH related cACLD|NASH related cACLD (Liver Stiffness ≥10 kPa).
89411010|NCT05044663||Viral hepatitis (HBV / HCV) related cACLD|Viral hepatitis (HBV / HCV) related cACLD
89411011|NCT05040841|Experimental|Condition 1|"Includes 1 intervention:~S2/Peer: Enhanced peer group support."
89411012|NCT05040841|Experimental|Condition 2|"Includes 1 intervention:~S1/Text: Weekly check-in text messages."
89411013|NCT05040841|Experimental|Condition 3|"Includes 1 intervention:~M3/EAM: Electronic adherence monitoring (EAM) + outreach to the patient."
89411014|NCT05040841|Experimental|Condition 4|"Includes 3 interventions:~M3/EAM: Electronic adherence monitoring (EAM) + outreach to the patient; S1/Text: Weekly check-in text messages; S2/Peer: Enhanced peer group support."
89411015|NCT05040841|Experimental|Condition 5|"Includes 1 intervention:~M2/PRM: Pharmacy refill monitoring (PRM) + outreach to the patient."
89411016|NCT05040841|Experimental|Condition 6|"Includes 3 interventions:~M2/PRM: Pharmacy refill monitoring (PRM) + outreach to the patient S1/Text: Weekly check-in text messages; S2/Peer: Enhanced peer group support."
89411017|NCT05040841|Experimental|Condition 7|"Includes 3 interventions:~M2/PRM: Pharmacy refill monitoring (PRM) + outreach to the patient M3/EAM: Electronic adherence monitoring (EAM) + outreach to the patient; S2/Peer: Enhanced peer group support."
89411018|NCT05040841|Experimental|Condition 8|"Includes 3 interventions:~M2/PRM: Pharmacy refill monitoring (PRM) + outreach to the patient; M3/EAM: Electronic adherence monitoring (EAM) + outreach to the patient; S1/Text: Weekly check-in text messages."
89411019|NCT05040841|Experimental|Condition 9|"Includes 1 intervention:~M1/OTR: Outreach (OTR) to patient due to unsuppressed VL test result."
89411020|NCT05040841|Experimental|Condition 10|"Includes 3 interventions:~M1/OTR: Outreach to patient due to unsuppressed VL test result; S1/Text: Weekly check-in text messages; S2/Peer: Enhanced peer group support."
89411021|NCT05040841|Experimental|Condition 11|"Includes 3 interventions:~M1/OTR: Outreach to patient due to unsuppressed VL test result; M3/EAM: Electronic adherence monitoring (EAM) + outreach to the patient; S2/Peer: Enhanced peer group support."
89411022|NCT05040841|Experimental|Condition 12|"Includes 3 interventions:~M1/OTR: Outreach to patient due to unsuppressed VL test result; M3/EAM: Electronic adherence monitoring (EAM) + outreach to the patient; S1/Text: Weekly check-in text messages."
88887363|NCT05386446||Control: No intervention|Любой профилактический метод, включающий различные фармакологические методы лечения COVID-19, наряду с применением противовирусных и иммуномодулирующих средств, за исключением препаратов, назначаемых не по назначению или в исследовательских целях, а также IFN-G.
88887364|NCT01425112|Experimental|Topical/Subconjunctival|Depending upon the mode of administration
88887365|NCT05386433|Placebo Comparator|standard-of-care|Standard-of-care of COVID-19 includes oxygen inhalation, antibiotics, traditional medicine, etc.
89411023|NCT05040841|Experimental|Condition 13|"Includes 3 interventions:~M1/OTR: Outreach to patient due to unsuppressed VL test result; M2/PRM: Pharmacy refill monitoring (PRM) + outreach to the patient; S2/Peer: Enhanced peer group support."
88887366|NCT05386433|Experimental|standard-of-care plus Paxlovid|standard-of-care of COVID-19 plus Paxlovid
88887367|NCT05386381||Decompression alone|Patients undergone decompression surgery alone
88887368|NCT05386381||Decompression with fusion|Patient undergone decompression and lumbar fusion surgery
88887369|NCT05386316|Experimental|Intervention counties|Birthing persons who live in Kent County or Genesee County, Michigan, USA at the time of delivery.
88887370|NCT05386316|Active Comparator|Control counties|Birthing persons who live in the other Michigan, USA counties at the time of delivery.
88887371|NCT05386290||UC patients|Patients who were diagnosed moderate-to-severe ulcerative colitis (UC) and intend to be treated by biological agents (infliximab or vedolizumab) or traditional drugs (glucocoticoid, immunosupressive drugs and/or mesalazine) will be enrolled.
88887372|NCT05386290||CD patients|Patients who were diagnosed moderate-to-severe Crohn's Disease (CD) and intend to be treated by biological agents (infliximab or ustekinumab) or traditional drugs (glucocoticoid, immunosupressive drugs and/or mesalazine) will be enrolled.
89005178|NCT00229242|Active Comparator|2|Non-Diuretic-Based Hypertension Therapy
89005179|NCT00205361||1|well-nourished
89005180|NCT00205361||2|malnourished
89411024|NCT05040841|Experimental|Condition 14|"Includes 3 interventions:~M1/OTR: Outreach to patient due to unsuppressed VL test result; M2/PRM: Pharmacy refill monitoring (PRM) + outreach to the patient; S1/Text: Weekly check-in text messages."
89411025|NCT05040841|Experimental|Condition 15|"Includes 3 interventions:~M1/OTR: Outreach to patient due to unsuppressed VL test result; M2/PRM: Pharmacy refill monitoring (PRM) + outreach to the patient; M3/EAM: Electronic adherence monitoring (EAM) + outreach to the patient."
89411026|NCT05040841|Experimental|Condition 16|"Includes 5 interventions:~M1/OTR: Outreach to patient due to unsuppressed VL test result; M2/PRM: Pharmacy refill monitoring (PRM) + outreach to the patient; M3/EAM: Electronic adherence monitoring (EAM) + outreach to the patient; S1/Text: Weekly check-in text messages; S2/Peer: Enhanced peer group support."
89411027|NCT05029960|Experimental|Experimental|Brivaracetam at a dose of 50 mg twice daily for 6 months
89411028|NCT05027217||Standard ICU Arm (Main study)|We will retrospectively collect data from adults (≥18 years) admitted to a participating ICU prior to the COVID-19 surge in the country, who are invasively mechanically ventilated for more than 12 hours. We will include medical, surgical, trauma and neurological/neurosurgical patients who are COVID-19 negative.
89411029|NCT05027217||COVID19 ICU arm (COVID-19 sub-study)|We will retrospectively collect data from adults (≥18 years) admitted to a participating ICU who are invasively mechanically ventilated for more than 12 hours. We will include data from patients admitted with a confirmed diagnosis of acute respiratory failure due to COVID-19 infection.
89411030|NCT05027217||Non-COVID19 ICU arm (COVID-19 sub-study)|We will retrospectively collect data from adults (≥18 years) admitted to a participating ICU who are invasively mechanically ventilated for more than 12 hours. We will include data from medical, surgical, trauma and neurological/neurosurgical patients who are not admitted for COVID-19.
89411031|NCT05005000|Experimental|MFAT|
89411032|NCT05005000|Active Comparator|Steroid (Control)|
89411033|NCT04995055|Experimental|Period 1|Eligible subjects will be randomly assigned to contact lens wear sequence TEST/CONTROL in a bilateral fashion.
89411034|NCT04995055|Experimental|Period 2|Eligible subjects will be randomly assigned to contact lens wear sequence CONTROL/ TEST in a bilateral fashion.
89411035|NCT04987996|Experimental|GR-MD-02 + pembrolizumab|4 mg/kg GR-MD-02 in combination with standard pembrolizumab treatment.
89411036|NCT04987996|Placebo Comparator|Pembrolizumab Monotherapy|4 mg/kg placebo in combination with standard pembrolizumab treatment.
89411037|NCT04986670|Experimental|NutriCare|The oncology care team will provide participants with nutrition toolkit involving printed educational materials, a nutrition prescription, referral to registered dietitians (RDs) for remotely-delivered medical nutrition therapy counseling, and home-delivery of medically tailored meals.
89411038|NCT04986670|Active Comparator|NutriTool|The oncology care team will provide participants with a nutrition toolkit involving printed educational materials.
89411039|NCT04924205|No Intervention|Outpatient Physical Therapy|
89411040|NCT04924205|Experimental|Smart Orthotic Device (FM2 Knee Brace)|
89411041|NCT04924088|Experimental|Medical-legal partnership|Treatment group will receive the MLP intervention through the Connecticut Veterans Legal Center in partnership with the VA Connecticut Healthcare System. The MLP intervention can be categorized into seven activity components: initial in-person and subsequent in-person interviews; discussions with clients by phone; research and review of relevant documents; consultations with clinicians or other attorneys; interactions with opposing parties; time appearing at formal hearings; and travel time.
89411042|NCT04924088|Active Comparator|Referral to pro-bono lawyer|Control group will receive outside legal aid, i.e., control participants will be referred to pro-bono lawyers in the state.
89411043|NCT04916509||Palbociclib plus an aromatase inhibitor|"Adult metastatic breast cancer patients who initiated Palbociclib + an aromatase inhibitor.~Data will be retrospectively abstracted over an observational look-back period from 01st January 2015 to 30th September 2019.~Aligned with Locally Approved Indication"
89411044|NCT04916509||palbociclib plus fulvestrant|"Adult metastatic breast cancer patients who initiated Palbociclib + fulvestrant. Data will be retrospectively abstracted over an observational look-back period from 01st January 2015 to 30th September 2019.~Aligned with Locally Approved Indication"
89411045|NCT04897581|Experimental|Brief Behavioral Therapy for Insomnia, BBTI|Participants in this group will receive 3 sessions of BBTI over telehealth.
89192161|NCT00808275|Experimental|Non-dairy calcium|Diet with non-dairy calcium sources
89411046|NCT04897581|Experimental|Physical Self-Regulation, PSR|Participants in this group will receive 3 sessions of PSR over telehealth.
89411047|NCT04891380|Other|Cardiac arrest patients|Cardiac arrest patients receiving cardiopulmonary resuscitation with LUCAS 2 Active Decompression 2.
89005181|NCT00232245|Experimental|Fish oil|Patients prescribed 6g/day of fish oil containing total 1.8 g of EPA+DHA in a 1.5:1 ratio
89411048|NCT04891380|Other|Hypotension|Patients developed or may develope hypotension of non traumatic origin.
89411049|NCT04891380|Other|Intensive care patient transport|Patients who are transported from one intensive department to another.
89411050|NCT04891380|Other|LUCAS 2 Active Decompression|The hemodynamic measurements of the cardiac arrest patients in the present study will be compared with the hemodynamic measurements achieved in the previous study NCT02479152.
89411051|NCT04884048||Benign bone tumors|Patients with benign lesions confirmed either by histology or imaging follow-up showing lesion stability.
89411052|NCT04884048||Malignant bone tumors|Patients with malignant lesions confirmed by histology.
89411053|NCT04882774|No Intervention|Fluid Management|Fluid management protocol only
89005182|NCT00232245|No Intervention|Control|No fish oil exposure
89192162|NCT00727922|Experimental|1|
89192163|NCT00809289|Experimental|One|
89192164|NCT00809289|Placebo Comparator|Two|
89411054|NCT04882774|Experimental|Oral Treprostinil|Drug - oral treprostinil
89411055|NCT04878887|Other|IP-DRA|In plane distal radial artery catherterization
89411056|NCT04878887|Other|IP-PRA|In plane proximal radial artery catherterization
89411057|NCT04874558||Low-dose contrast-enhanced chest CT exam|Subjects will undergo a low-dose contrast-enhanced chest CT exam with coverage from the neck base through the lungs to the upper abdomen on a third-generation dual-source CT scanner as part of their routine clinical visit based on current guidelines.
89411058|NCT04866134|Experimental|Dose Escalation (Part A): ERAS-007 Monotherapy, BID-QW dosing|ERAS-007 monotherapy will be administered BID-QW in sequential ascending doses to participants with advanced or metastatic solid tumors until unacceptable toxicity, disease progression, or withdrawal of consent.
89411059|NCT04866134|Experimental|Dose Expansion (Part B): ERAS-007 Monotherapy, QW dosing|ERAS-007 monotherapy will be administered at 250 mg QW to participants with advanced or metastatic solid tumors that harbor specific molecular alterations.
89411060|NCT04866134|Experimental|Dose Expansion (Part C): ERAS-007 Monotherapy, BID-QW dosing (if necessary)|Depending on data generated from Part A, ERAS-007 monotherapy may be administered at the BID-QW RD to participants with advanced or metastatic solid tumors that harbor specific molecular alterations.
89411061|NCT04866134|Experimental|Dose Escalation (Part D): ERAS-007 BID-QW dosing in combination with ERAS-601|Experimental: Dose Escalation (Part D): ERAS-007 BID-QW dosing in combination with ERAS-601 ERAS-007 will be administered BID-QW in combination with ERAS-601 administered BID 3/1 to study participants with advanced or metastatic solid tumors that harbor specific molecular targets in sequential ascending doses until unacceptable toxicity, disease progression, or withdrawal of consent.
89411062|NCT04860700|Experimental|anlotinib hydrochloride|Patients receive anlotinib hydrochloride 12mg orally once daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89411063|NCT04846920|Experimental|Belzutifan 160 mg BID|Participants will receive belzutifan 160 mg orally twice daily (BID). Treatment will continue until progressive disease or discontinuation.
89411064|NCT04846920|Experimental|Belzutifan 160 mg TID|Participants will receive belzutifan 160 mg orally three times daily (TID). Treatment will continue until progressive disease or discontinuation.
89411065|NCT04846920|Experimental|Belzutifan 200 mg TID|Participants will receive belzutifan 200 mg orally TID. Treatment will continue until progressive disease or discontinuation.
89411066|NCT04846920|Experimental|Belzutifan 120 mg QD|Participants will receive belzutifan 120 mg orally once daily (QD). Treatment will continue until progressive disease or discontinuation.
89411067|NCT04780542|Experimental|Clinician-Guided iCBT|Both help-seeking students recruited from university clinics and non-help-seeking students recruited from needs assessment survey and outreach will receive internet delivered cognitive behavioral therapy guided by clinicians
89411068|NCT04780542|Active Comparator|Self-guided iCBT|Help-seeking students recruited from university clinics will receive self-guided internet delivered cognitive behavioral therapy while on waitlist. Non-help seeking students recruited from needs assessment survey and outreach will receive the self-guided version of internet delivered cognitive behavioral therapy.
89411069|NCT04774406||parp inhibitors|All patients treated at least with 1 PARPi
89411070|NCT04773730|Active Comparator|Posterior transversus abdominus block|"After the surgery end and while the patient in the supine position, with the side to be blocked is elevated~A 12-14 MHz linear array transducer will be placed transversely between the iliac crest and costal margin then slided from medial-lateral to visualize the posterior most part of the external oblique, internal oblique, and transversus abdominus muscles~Then 20 mL of bupivacaine0.25% will be injected between the transverses abdominus muscle and the fascia deep to the internal oblique muscle~The same steps will be repeated on the other side"
89411071|NCT04773730|Active Comparator|Quadratus lumborum block type 2|"After the surgery end and while the patient in the supine position, with the side to be blocked is elevated~A2-5 MHz curved array transducer will be placed at the level of the antero-superior iliac spine then the external oblique muscle will be followed posterolaterally until its posterior border will be visualized The probe will be tilted down to identify a bright hyperechoic line After that 20 mL of bupivacaine 0.25% will be injected under direct visualization on the posterior surface of quadrates lumborum muscle~The same steps will be repeated on the other side"
89411072|NCT04768400|Experimental|rocuronium|Neuromuscular blockade will be performed using rocuronium.
88887373|NCT05386251|Experimental|Behavioral Parent Training/Organization Skills Training|Parents will receive 8 weeks of a 90 minute behavioral parent training protocol that focuses on supporting academic and behavioral success in adolescents with ADHD. Teens will receive a simultaneous 8 weeks of a 90 minute organization skills training group. Both groups will be delivered via telehealth.
89411073|NCT04754100|Experimental|Allogeneic iNKT Cells|3+3 Dose escalation of agenT-797 will be administered by intravenous infusion every 2 weeks (each cycle is 14 days [2 weeks]).
89411074|NCT04743635|Experimental|Targeted Verifiable Subcision (TVS) with the Avéli device, mITT|"Modified intent to treat population (n=68). The modified intent to treat population was used to evaluate effectiveness.~The single procedure was conducted using the Avéli device for TVS. Cellulite can be treated on the thighs and buttocks"
89411075|NCT04743635|Experimental|Targeted Verifiable Subcision (TVS) with the Avéli device, Roll-in|The roll-in population (n=6) was excluded from the effectiveness analyses. For Investigators that have not previously performed an Avéli procedure, two (2) participants were classified as roll-in participants. The single procedure was conducted using the Avéli device for TVS. Cellulite can be treated on the thighs and buttocks
89411076|NCT04715113|Experimental|Normobaric hypoxia (FiO2 15%)|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
89411077|NCT04715113|Sham Comparator|Placebo-ambient air (FiO2 21%)|"Inhalation of room air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
88887374|NCT05386251|Sham Comparator|Peer support|Parents and teens will each participate in 8 weeks of a 90 minute peer support group focused on exchange of shared experience and group problem-solving difficulties. Both groups will be delivered via telehealth.
89411078|NCT04715113|Experimental|Normobaric hypoxia (FiO2 15%) under Sildenafil|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
89411079|NCT04715113|Active Comparator|Placebo-ambient air (FiO2 21%) under Sildenafil|"Inhalation of room air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
89411080|NCT04713657|Active Comparator|Propranolol|The target dose of Propranolol hydrochloride for this study target dose for this study will be 4 mg/kg/day divided in 4 doses. The concentration of propranolol solution is 20 mg/5 mL. Additionally, labeled syringes will be provided to families for accurate weight-based dosing. Treatment with propranolol will begin at 1 month of age and continue until surgical repair, which happens usually at 3 - 9 months of age.
89411081|NCT04713657|Placebo Comparator|Placebo|Placebo will be given in a volume that corresponds to the patient's weight. Additionally, labeled syringes will be provided to families for accurate weight-based dosing. Treatment with placebo will begin at 1 month of age and continue until surgical repair, which happens usually at 3 - 9 months of age. There is no current standard of care for pharmacologic therapy for infants with ToF. As such, there are no alternative treatments, and the placebo group is standard of care.
89411082|NCT04712110|Experimental|TAK-019|TAK-019 0.5 mL, intramuscular injection in the upper arm
89411083|NCT04712110|Placebo Comparator|Placebo|TAK-019 Matching Placebo, intramuscular injection in the upper arm
89411084|NCT04706546|Experimental|Hemodynamic effect of exercise under Sildenafil|"Inhalation of room air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise under SIldenafil."
89411085|NCT04706546|Other|Hemodynamic effect of exercise|"Inhalation of room air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
88887375|NCT05386212||control|regular nursing care instructions
88887376|NCT05386212||Expirement|web app healthcare instructions for relieving back pain
88887377|NCT05386186|Experimental|Glimepiride|All participants have background therapy of metformin 1500mg-2000mg, glimepiride1-4mg were added in the patients randomised to this arm considering the baseline HbA1c of the participants.
88887378|NCT05386186|Active Comparator|Sitagliptin|All participants have background therapy of metformin 1500mg-2000mg, Sitagliptin 100mg were added in the patients randomised to this arm regardless of the baseline HbA1c level in this arm.
88887379|NCT05386160|Active Comparator|Cataract phacoemulsification combines Ranibizumab|0.05 ml of ranibizumab was injected into the vitreous immediately after the operation
88887380|NCT05386160|Active Comparator|Cataract phacoemulsification|0.05 ml of ranibizumab was injected into the vitreous immediately after the operation
88887381|NCT05386121|Active Comparator|Erector spinae plane block (ESPB) group|30 child will receive a preoperative unilateral single shot US-guided erector spinae plane block at the level of T9 vertebra in the lateral position after induction of general anesthesia, using 0.5 mL/kg of bupivacaine 0.125%
88887382|NCT05386121|Active Comparator|Quadratus lumborum block (QLB) group|30 child will receive a preoperative unilateral single shot US-guided quadratus lumborum block at the level of L2 spinous process in the lateral position after induction of general anesthesia, using 0.5 mL/kg of bupivacaine 0.125%
88887383|NCT05386056|Experimental|Experimental: Pembrolizumab plus photodynamic therapy (PDT)|"Interventions:~Drug: Pembrolizumab~Drug: sinoporphyrin sodium (DVDMS)~Photodynamic therapy (PDT)"
88887384|NCT05386004|Experimental|BSSC group|Participants in the experimental group were allowed to focus with BSSC during uterine contractions in the first stage of labor.
88887385|NCT05386004|No Intervention|control group|The participants in the control group were provided with routine care in the first stage of labor. No intervention was made.
88887386|NCT05385939||Time period 1|Time period one included infants admitted to the current traditional, open bay NICU.
88887387|NCT05385939||Time period 2|Time period 2 included infants admitted to the private, single family room NICU.
89005183|NCT00232284|Active Comparator|Sertaline|8 week course of sertraline 50-100mg for those who fail to respond to CBT within first 4 weeks of study entry
89411086|NCT04704440|Experimental|Normobaric hypoxia (FiO2 15%)|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
89411087|NCT04704440|Sham Comparator|Placebo-ambient air (FiO2 21%)|"Inhalation of room air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
89411088|NCT04704440|Experimental|Normobaric hypoxia (FiO2 15%) under Sildenafil|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
89411089|NCT04704440|Active Comparator|Placebo-ambient air (FiO2 21%) under Sildenafil|"Inhalation of room air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
89411090|NCT04697875|Experimental|Normobaric hypoxia (FiO2 15%)|
89411091|NCT04697875|Sham Comparator|Placebo-ambient air (FiO2 21%)|
89411092|NCT04697862|Experimental|Normobaric hypoxia (FiO2 15%) under Sildenafil|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer), for approx. 1/2 hour. given by a facemask, first at rest and then during exercise under Sildenafil."
89411093|NCT04697862|Experimental|Normobaric hypoxia (FiO2 15%)|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
89411094|NCT04696029|Experimental|Difluoromethylornithine (DFMO)|study subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose of 2500 mg/m2 BID on each day of study.
89437543|NCT03681054|Experimental|Carbohydrate restricted diet|Dietary intervention: moderately carbohydrate restricted diet. Parallel phase starts after study period I and the diet is followed until labor.
89411095|NCT04653597|Experimental|Conservative airway management|decision to intubate will be withheld as long as the patient's state allows it. The patient will be closely monitored and decision of intubation will be made upon presence of regurgitation, seizure, shock, or sign of respiratory distress.
89411096|NCT04653597|Other|Routine practice|decision of intubation left at the discretion of the emergency physician
89411097|NCT04642508|Other|Prepectoral Reconstruction|Women with breast cancer or with high risk for breast cancer in whom a sparing mastectomy and prepectoral reconstruction was performed
89411098|NCT04635085|Experimental|Empowerment-based Cognitive behavioral therapy for insomnia for MCI (intervention)|Participants in the intervention group will participate in a 12-week empowerment-based CBT-I comprising face-to-face sessions supplemented with telephone follow-ups.
89411099|NCT04635085|No Intervention|Social Activities provided by the community centers (active control)|The control group will not receive any structured cognitive training or sleep promoting interventions during the study period. The participants in the control group will continue to participate in the social activities offered by the elderly community centers. They have access to the newspapers, board games and computer facility in the centers. Upon completion of collecting all evaluation data for both groups at the three different time points, the empowerment-based CBT-I will be offered to participants in the control group.
89411100|NCT04625699|Experimental|durvalumab+ tremelimumab|durvalumab will be administered Q4weeks and tremelimumab will be administered Q8 weeks
89411101|NCT04606927|Active Comparator|Natriuresis guided treatment|
89411102|NCT04606927|No Intervention|Standard of care|
89411105|NCT04533698||Resternotomy|
89411106|NCT04533698||No resternotomy|
89411107|NCT04513210||Changes in the lungs on admission|Patients with Covid-19 infection admitted to the University Hospital with changes in the ultrasound on admission, suggesting pneumonia.
88887388|NCT05385900|Experimental|Penpulimab in combination with anlotinib and chemotherapy|After receiving the corresponding neoadjuvant therapy for 3 cycles according to the established treatment plan, surgery should be performed within 3-6 weeks after drug withdrawal.
88887389|NCT05385874||Training cohort|The training cohort will be used for model development.
88887390|NCT05385874||Testing cohort|The testing cohort, a new cohort compared with the training cohort, will be used for model external validation.
88887391|NCT05385861|Experimental|nal-IRI (ONIVYDE®) and Carboplatin|nal-IRI (ONIVYDE®) and Carboplatin
88887392|NCT05385848|Experimental|PRP Injection Arm|"All patients recruited will come down to KKIVF Centre on Day 2-3 of the menstrual cycle to do blood tests (Anti-Mullerian Hormone (AMH)) and an ultrasound scan (Antral Follicular Count (AFC)). In the same menstrual cycle/month, autologous PRP injection will be done on Day 5-15 of the cycle.~Patients will return to KKIVF Centre 1-3 months after the PRP injection on Day 2-3 of the menstrual cycle to repeat blood tests (AMH) and Ultrasound scan (AFC).~IVF stimulation cycle as per KKIVF protocol will be started within 6 months from PRP injection. Patients will be followed up as per routine, with no more additional visits pertaining specifically to the study."
88887393|NCT05385835||1Nurses|"The research is a pre-post-test observation study without a control group, aiming to determine the effect of the training given to nurses on the knowledge and practices of brachial artery blood pressure measurement.~The research is carried out with a group of 60 nurses."
89411108|NCT04513210||No changes in the lungs on admission|Patients with Covid-19 infection admitted to the University Hospital without changes in the ultrasound on admission, suggesting pneumonia.
89411109|NCT04510584|Experimental|Atezolizumab and Bevacizumab|"A cycle will be every 3 weeks.~Atezolizumab will be given intravenously (by vein) at a dose of 1200 mg once every cycle. Bevacizumab will be given intravenously at a dose of 15 mg/kg once every cycle. Up to 17 cycles of study treatment may be given.~Participants may be able to receive the study treatment for more than 17 cycles if the participants and the study doctor thinks that they are benefiting."
89411110|NCT04500847|Active Comparator|Group 1|25 MCI and mild to moderate AD subjects
89411111|NCT04500847|Placebo Comparator|Group 2|10 MCI and mild to moderate AD subjects
89411112|NCT04484532|Experimental|Supportive Care (trivalent influenza vaccine)|Within 14 days of baseline influenza titer, patients receive trivalent influenza vaccine IM on day 0 (patients in cohorts 1 and 5 receive the vaccine at any time, patients in cohorts 2 and 3 receive the vaccine between days 14-25 of hypomethylating agent therapy course, and patients in cohort 4 receive the vaccine between days 21-365 from onset of cytotoxic chemotherapy). Patients then undergo titer assessment at days 25-90 and days 115-185.
89411113|NCT04483583|Active Comparator|ABCD-GENE >10 - Clopidogrel|Patients with an ABCD-GENE>10 score will be randomized in a 1:1 fashion to ticagrelor (60 mg/bid) or clopidogrel (75 mg/qd). Treatment will be maintained for 30 days.
89411114|NCT04483583|Experimental|ABCD-GENE >10 - Ticagrelor|Patients with an ABCD-GENE>10 score will be randomized in a 1:1 fashion to ticagrelor (60 mg/bid) or clopidogrel (75 mg/qd). Treatment will be maintained for 30 days.
89411115|NCT04483583|Active Comparator|ABCD-GENE <10 - Clopidogrel|Patients with an ABCD-GENE<10 will be treated with clopidogrel (75 mg/qd) for 30 days.
89411116|NCT04477681||Patients in therapeutic failure or relapse|Any child, adolescent or young adult, treated for a pediatric tumor or leukemia, in therapeutic failure or relapse without standard treatment option, not eligible / refusal of inclusion in a clinical study open on the territory and treated with an innovative drug within the framework of an ATU or outside AMM, in one of the centers of the SFCE (Société Française Cancer Enfant)
89411117|NCT04447989|Active Comparator|Cohort 1, sildenafil|Sildenafil (0.5 mg/kg IV or 1 mg/kg enteral) every 8 hours for 28 days
88887394|NCT05385822|No Intervention|Control|The control group will not recieve any training in the trial period but will have to answer the same questionnaires on erectile function (IIEF-EF) and international prostate symptom score (IPSS).
88887395|NCT05385822|Experimental|Pelvic Floor Muscle Training|Participants who are randomized to pelvic floor training will then undergo instruction in the anatomy, function and training of the pelvic floor muscles.
88887396|NCT05385744|Experimental|BCD-132|IV infusion every 24 weeks in combination with daily placebo tablets. The total duration of the blinded therapy is 100 weeks (a total of 5 treatment cycles with BCD-132 in combination with the daily placebo tablets)
88887397|NCT05385744|Active Comparator|Teriflunomide, 14 mg orally|Teriflunomide, 14 mg orally daily, in combination with intravenous placebo infusions. The total duration of the blinded therapy is 100 weeks (a total of 5 treatment cycles with intravenous placebo infusions in combination with daily teriflunomide tablets).
88887398|NCT05385731|Experimental|Nordic Walking (NWG)|"The Nordic Walk program consists of 3 moments:~warm-up, walk, and stretch. They will do a brief free walking warm-up for 3 minutes in the Self-selected walking speed - SSWS (3 'SSWS), then walk according to the training cycle, the intensity will be between 60 to 80% of the Heart of Ratio reserve. In addition, the intensity of the classes will be measured in each phase by the Borg Scale of Perceived Exertion."
88887399|NCT05385731|Active Comparator|Free walking (FWG)|"The free walking program consists of 3 moments:~warm-up, walk, and stretch. They will do a brief free walking warm-up for 3 minutes in the Self-selected walking speed - SSWS (3 'SSWS), then walk according to the training cycle, the intensity will be between 60 to 80% of the Heart of Ratio reserve. In addition, the intensity of the classes will be measured in each phase by the Borg Scale of Perceived Exertion.~Intervention administered:~24 sessions will be held twice a week, with each session taking an average of 60 minutes."
88887400|NCT05385731|No Intervention|Health Education (HEG)|"The control group will receive orientation and carry out the Health Education program and will have a duration of 3 months."
88887401|NCT05385627||Ankle block|Any participant receiving an ankle block (local infiltration analgesia).
88887402|NCT05385614|No Intervention|Control|Control group that will receive the app after primary endpoint was assessed.
88887403|NCT05385614|Experimental|Intervention|Experimental group that will receive the app at the start of their participation
88887404|NCT05385445|Experimental|Audit and Feedback Group 1|"The intervention Group 1 received the standard feedback report with a one-page summary of the CWC recommendations of interest. Group 1 did not receive any data specific to their prescribing."
88887405|NCT05385445|Experimental|Audit and Feedback Group 2|"Intervention Group 2 received the standard feedback report, CWC recommendation summary and practice-specific data related to their prescribing rates for the CWC recommendations of interest, compared to rates for other providers at their clinic, in their health region and in the province."
88887406|NCT05385445|No Intervention|Control|The control group received the standard feedback report with no information related to CWC.
88887407|NCT05385419|Other|Patients subjected for bronchoscopy or medical thoracoscopy|Bronchoscopic and thoracoscopic biopsies will be sent for both frozen section and permenant paraffin section
89411118|NCT04447989|Placebo Comparator|Cohort 1, placebo|Placebo (IV or enteral) every 8 hours for 28 days
88887408|NCT05385276|Experimental|Transverse supraumbilical incision|The skin incision will be performed as a straight transverse skin incision 3-5cm above the umbilicus after maximum retraction of the panniculus caudally using two towel clips, to facilitate the approach to the lower uterine segment.
88887409|NCT05385276|Experimental|Pfannenstiel Incision|The skin incision is a transverse upward concavity, typically initiated two finger breadths above the symphysis pubis and extended in the direction of the anterior superior iliac spine below and medial to it about (2 - 3 cm).
88887410|NCT05385250|Other|Bone sparring radiotherapy|Observational arm of bone-sparing radiotherapy
88887411|NCT05385198|Experimental|VOICE care|"The VOICE conversations contain minimal 5 consecutive conversations with parents. The conversations are not rigid or strictly protocolized but rather focus on issues related to the situation of the admission period of the infant and the conversations should be individualized based on the parent needs. Thus, depending on the situation of the infant and the home situation of the parents.~The content of the VOICE conversations is built up based on the admission pathway of the infant. Every VOICE conversation has its own focus, and these are presented in the 5 VOICE conversation guides. Basically, every VOICE conversation is about the support of parents and infant.~The principles of the VOICE conversations are Values, Opportunities, Integration, Control and Evaluation. The VOICE program focuses on a systematic and planned communications with parents during the NICU admission and follow-up 2-4 weeks after NICU discharge."
88887412|NCT05385198|No Intervention|Standard care|Standard care is defined as the standard family centered care (FCC) practices currently implemented in the NICU. Parents are allowed to visit the NICU for 3 hours every day and provide basic care to their infant. Standard care involves meetings with the doctors three times a week and the content is mainly directed to the medical condition and treatments of the infant. No other meetings between parents and doctors/nurses exists. The FCC principles implicate that parents and NICU staff work closely together on the NICU. This also involves unscheduled information and communication contact moments where short questions of parents will be addressed.
88887413|NCT05385185|Experimental|Leptomeningeal metastases received PD-1 inhibitor and recombinant human endostatin|Camrelizumab 200mg intravenously, once every 21 days or envafolimab 150mg subcutaneous injection,once a week Endostatin 30mg/d was administered intravenously for 7 days (d1-d7). The interval between Endostatin and next was 2 weeks.
88887414|NCT05385172||18-65 years old women|
89005184|NCT00232284|Placebo Comparator|Placebo|8 week course of placebo
89411119|NCT04447989|Active Comparator|Cohort 2, sildenafil|Sildenafil (1 mg/kg IV or 2 mg/kg enteral) every 8 hours for 28 days
89411120|NCT04447989|Placebo Comparator|Cohort 2, placebo|Placebo (IV or enteral) every 8 hours for 28 days
89411121|NCT04447989|Active Comparator|Cohort 3, sildenafil|Sildenafil (2 mg/kg IV or 4 mg/kg enteral) every 8 hours for 28 days
89411122|NCT04447989|Placebo Comparator|Cohort 3, placebo|Placebo (IV or enteral) every 8 hours for 28 days
89411123|NCT04392960|Experimental|18F-florbetaben PET-CT scans|
89411124|NCT04389957||Providers|The quantitative surveys will be delivered to the identified local quality stewards (N=73) and providers (N=657) for each enrolled site via the Research Electronic Data Capture (REDCap) platform at baseline (prior to VA-EQuIP) and 12 months following completion of the VA-EQuIP intervention. We will incorporate established methods of maximizing web survey responses, including multiple, carefully-timed, integrated email contacts.
89411125|NCT04389957||Patients|We expect 69 sites with 571 providers seeing 135,517 patients/year, corresponding to 95 providers/wave and 59 patients/provider/quarter. Patient data is retrospective and informs the primary outcome of provider adenoma detection rate. There is not a direct intervention for patients.
88887415|NCT05385146|Experimental|qigong group|The qigong group received Chan-Chuang qigong therapy with breathing meditation for 15 weeks.Qigong training program consisted of a warm-up, Chan-Chuang qigong, and breathing meditation. The whole process takes about 20 minutes.The qigong was monitored in terms of muscle elasticity and heart rate variability. After practicing the Chan-Chuang qigong, meditation with breathing was conducted for 10 minutes. In the meanwhile, sit down while relaxing with slow breathing and focus on the present feelings, with brain wave (NeuroSky's, Australia) to monitor and confirm that the eSense (attention and relaxation).
88887416|NCT05385146|No Intervention|control group|those in the control group received usual care during the same study period.
88887417|NCT05385133|Experimental|Computer guided condylar position|post-osteotomy condylar position was performed using patient specific surgical guides and pre-bent plates
88887418|NCT05385133|Experimental|Manual condylar position|post-osteotomy condylar position was performed using the conventional free hand approach
88887419|NCT05385120|Experimental|Group A-Shunt group|Patients who undergo temporary porto caval shunt (TPCS) during recipient hepatectomy in adult elective live donor liver transplantation
88887420|NCT05385120|No Intervention|Group B-No Shunt group|Patients who donot undergo temporary porto caval shunt (TPCS) during recipient hepatectomy in adult elective live donor liver transplantation
88887421|NCT05385081|Other|genomic profiling|"After informed consent a PET/CT scan is performed to determine disease spread and the best location for core needle biopsi. Genomic profiling is performed using Next Generation Sequencing, NGS, genpanel analysis by Oncomine Comprehensive vs 3 The result of NGS is discussed at weekly local and national tumor board meeting to decide a possible targeted treatment offer based on genomic profiling or a possibly treatment offer in a clinical trial.~Timelines in the course of investigation will be calculated using date of informed consent, PET/CT scan, biopsy, tumor board and date of start of next treatment, progression and death.~If the genomic profiling results in a targeted treatment offer the Growth Modulation Index is calculated from progressions-free survival on recent and current treatment. Treatment given without an actionable target is likewise evaluated for efficacy."
88887422|NCT05385068|Experimental|Niraparib combined with Anlotinib|Participants received Niraparib 200mg or 300mg QD PO continually and Anlotinib 10mg QD PO on Days 1-14 (21 days/cycle) .
88887423|NCT05385029||Thyroid functions in neonates born to COVID 19 positive mothers|thyroid hormone or antithyroid drugs
89411126|NCT04385888|Experimental|Low-calorie sweetener restriction|Participants will be instructed to avoid low-calorie sweetened beverages and other sources of low-calorie sweeteners, and to instead consume unsweetened alternatives, such as plain or sparkling water for 12 weeks.
89411127|NCT04385888|No Intervention|Usual consumption/control|Participants will continue low-calorie sweetener consumption, as usual.
89411128|NCT04380155|Experimental|Participants|All participants will perform three moderate intensity cycling trials of different duration (30, 60 and 120 min) in an energy replete state.
89411129|NCT04378101||Anorexia Nervosa Case|Participants in this group have a life-time history of anorexia nervosa as determined by an algorithm applied to their responses to an eating disorders screening questionnaire (ED100K) that is based on the Structured Clinical Interview for Axis 1 Disorders.
89411130|NCT04378101||Bulimia Nervosa Case|Participants in this group have a life-time history of bulimia nervosa as determined by an algorithm applied to their responses to an eating disorders screening questionnaire (ED100K) that is based on the Structured Clinical Interview for Axis 1 Disorders. These participants do not have a history of anorexia nervosa.
88887424|NCT05385029||Neonates born to mothers without COVID 19 infection|Thyroid drugs if indicated
88887425|NCT05385003|Experimental|Dietary Supplement: anserine|Subjects are instructed to take one capsule of anserine daily for a total of 3 months
88887426|NCT05385003|Experimental|Dietary Supplement: Sunflower peptide|Subjects are instructed to take one capsule of Sunflower peptide daily for a total of 3 months
89411131|NCT04378101||Binge-Eating Disorder Case|Participants in this group have a life-time history of binge-eating disorder as determined by an algorithm applied to their responses to an eating disorders screening questionnaire (ED100K) that is based on the Structured Clinical Interview for Axis 1 Disorders. These participants do not have a history of anorexia nervosa or bulimia nervosa.
89411132|NCT04378101||Control|Participants in this group have no history of disordered eating behaviors as determined by an algorithm applied to their responses to an eating disorders screening questionnaire (ED100K) that is based on the Structured Clinical Interview for Axis 1 Disorders.
89411133|NCT04375527|Experimental|Treatment (binimetinib, nivolumab)|Patients receive binimetinib PO BID on days 1-28 and nivolumab IV over 30 minutes on day 1. Treatment repeats every 4 weeks for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
89411134|NCT04356027||Standard of Care: Angiography, OCT, FFR, and VFR|Patients will have Pre-OCT Angiography, OCT pullbacks, a FFR measurement and a VFR analysis
89411135|NCT04351711||Patients SARS-CoV-2 with respiratory failure|Patients in intensive care
89411136|NCT04351711||Patients SARS-CoV-2 without respiratory failure|Patients hospitalized in normal hospital wards
88887427|NCT05385003|Placebo Comparator|Dietary Supplement: Placebo control|Subjects are instructed to take one capsule of placebo daily for a total of 3 months
89005185|NCT00205439||Fluorescence bronchosopy with sputum cytology|Patients undergo surgery with Fluorescence bronchosopy and sputum cytology.
89411137|NCT04351711||HEALTHY VOLUNTEERS|HEALTHY VOLUNTEERS
89411138|NCT04351711||NON-COVID-19 PATIENTS|Patient hospitalized at the CHU of Nîmes for an infection by a virus other than SARS-CoV-2
89411139|NCT04351711||PAUCISYMPTOMATIC SARS-COV-2+ PATIENTS|Patient positive for SARS-CoV-2 by RT-PCR at the CHU of Nîmes and presenting at most moderate clinical signs without respiratory insufficiency (O2 saturation greater than or equal to 96%) during the confinement period
89411140|NCT04351711||convalescent patients|Additional 1-year follow-up visit
89411141|NCT04334343|Active Comparator|Athletic group|
89411142|NCT04334343|Active Comparator|Sedentary exercise group|
89411143|NCT04334343|Active Comparator|Sedentary no-exercise group|
89411144|NCT04322370|Active Comparator|Group A|VersaWrap Treatment Arm- Zone 2 flexor tendon repair with the use of VersaWrap
89411145|NCT04322370|Active Comparator|Group B|Standard of Care Treatment Arm- Zone 2 flexor tendon repair
88819676|NCT02366403|Active Comparator|CPT-C|CPT-C (Cognitive Processing Therapy-cognitive only) is a standardized, manual-based treatment consisting of 12, 60-minute sessions which will be given twice per week. Sessions will focusing on specific issues, learning new therapeutic techniques and setting up homework for the following session including real-life application of learned CPT techniques.
88819677|NCT01509404|Active Comparator|Valcyte|valganciclovir per package insert guidelines for prophylaxis against CMV infection for 200 days post-transplant
88819678|NCT01509404|Active Comparator|Valcyte then Cytogam|valganciclovir per package insert guidelines for 100 days post-transplant with Cytogam 100 mg/kg administered at 90 days, 120 days, and 180 days post-transplant for prophylaxis against CMV infection
88819679|NCT04987593|Experimental|Intervention|Four probiotic strains to be consumed once daily
88819680|NCT01562132|Experimental|5FC plus fluconazole|Combination therapy with oral fluconazole and flucytosine
88819681|NCT01562132|Active Comparator|fluconazole alone|Fluconazole monotherapy
88819682|NCT04336761||Child suspected of infection with COVID-19.|Child included with positive included
88819683|NCT04849923|No Intervention|controll group|This group has no additional strength training
88819684|NCT04849923|Experimental|1 training per week|This group performs one strength training session per week
88819685|NCT04849923|Experimental|3 trainings per week|This group performs two strength training sessions per week
88819686|NCT02762331|Experimental|Vitamin C|Intravenous ascorbic acid 50 mg/kg in 50 mL normal saline every six hours for 48 hours.
88819687|NCT02762331|Placebo Comparator|Normal saline|Intravenous normal saline 50 mL every six hours for 48 hours
88819688|NCT02973867||Cohort called Elodie|Obese patients
88819689|NCT04338087||Fertility treatments|Men participating in fertility treatments.
88819690|NCT04338087||Spontaneous pregnancy|Men whose wives conceived spontaneously.
88819691|NCT02762799|Experimental|Leucostim® --> Neupogen®, subcutaneous injections|Healthy volunteers in this group will receive single subcutaneous injection Leucostim® on Day 1 followed by single subcutaneous injection Leucostim® on Day 29.
88819692|NCT02762799|Experimental|Neupogen® --> Leucostim®, subcutaneous injections|Healthy volunteers in this group will receive single subcutaneous injection Neupogen®, on Day 1 followed by single subcutaneous injection Leucostim® on Day 29.
88819693|NCT02762799|Experimental|Leucostim® --> Neupogen®, intravenous injections|Healthy volunteers in this group will receive single intravenous injection Leucostim® on Day 1 followed by single intravenous injection Leucostim® on Day 29.
88819694|NCT02762799|Experimental|Neupogen® --> Leucostim®, intravenous injections|Healthy volunteers in this group will receive single intravenous injection Neupogen® on Day 1 followed by single subcutaneous intravenous Leucostim® on Day 29.
88819695|NCT02762877||A|Patients with non-squamous NSCLC either newly diagnosed or progressing on any therapy (except erlotinib, gefitinib, or afatinib)
88819696|NCT02762877||B|Patients with non-squamous NSCLC who are progressing on erlotinib, gefitinib, or afatinib
88819697|NCT02737917|Experimental|Diffuse apneic oxygenation|This group of patients will receive the standard of care treatment of rapid sequence intubation (pre-oxygenation, induction and intubation) plus the application of oxygen.
88819698|NCT02737917|Other|Usual care|This group of patients will receive the standard of care treatment of rapid sequence intubation (pre-oxygenation, induction and intubation)
88819699|NCT02958813|Experimental|IMARA|IMARA blends three programs with the most relevance for AA women (SISTA) and girls (SiHLE) and families in psychiatric care (Project STYLE). Separate mother and daughter groups cover parallel content and run simultaneously, and joint activities enhance mothers' credibility as a resource for HIV/STI prevention, practice new communication skills, negotiate conflict, and strengthen the mother-daughter relationship. Activities reinforce the reciprocal impact of mothers and daughters, and enhance safe sex knowledge, attitudes, and skills. Woven throughout IMARA is the impact of alcohol and drug use on risk behavior, including condom use while high.
88887428|NCT05384990|Experimental|Stochastic Resonance stimulation|During this condition, participants will perform postural transitions like sit to stand, gait initiation, sit to walk and Timed Up and Go test while receiving stochastic resonance stimulation on legs and hip.
88887429|NCT05384990|No Intervention|No Stochastic Resonance stimulation|During this condition, participants will perform postural transitions like sit to stand, gait initiation, sit to walk and Timed Up and Go test without receiving any electrical stimulation.
88887430|NCT05384977|Experimental|[14C]-NV-5138|[14C]-NV-5138 oral solution
88887431|NCT05384639|Experimental|Dual-task Group|
88887432|NCT05384639|Active Comparator|Cycling Group|
88887433|NCT05384639|Active Comparator|Cognitive Group|
88887434|NCT05383755|Experimental|Digital intervention|Digital intervention for pregnant adolescents living with HIV.
88887435|NCT05379413||Early BoNT treatment|Patients with PSS treated with BoNT within the first Quartile of injection timing distribution
88887436|NCT05379413||Late BoNT treatment|Patients with PSS treated with BoNT within the third Quartile of injection timing distribution
88887437|NCT05379413||Not treated with BoNT|Natural controls with PSS not treated with BoNT
88887438|NCT05379374|Active Comparator|Bupivacaine group|0.25% bupivacaine 20 ml in TAP block
88887439|NCT05379374|Experimental|Bupivacaine morphine group|0.25% bupivacaine 20 ml with 3 mg morphine in TAP block
88887440|NCT05375708|Active Comparator|Systemic maintenance therapy|
88887441|NCT05375708|Experimental|Systemic maintenance therapy in combination with stereotactic body radiation therapy (SBRT)|
88887442|NCT05375279||LSGB vs EMB|Patients who already underwent EMB within the last six months with confirmed Amyloid Transthyretin -wild type (ATTRwT) will undergo LSGB.
89005186|NCT00205556|Other|1: low flux hemodialysis|standard treatment
88887443|NCT05372965|Experimental|Experimental: periodontitis|Our study will include 42 people with periodontitis patients and these two groups will be divided into two as smokers (21) and non-smokers (21).
88887444|NCT05372965|Active Comparator|Control: clinical healthy|Our study will include 42 people with clinical healthy patients and these two groups will be divided into two as smokers (21) and non-smokers (21).
88887445|NCT05339633|Other|Single Dose|All study subjects will receive a a single oral dose of radiolabeled microtracer of D-0502 following an overnight fast
88887446|NCT05335174||HPI monitor|
88887447|NCT05312060|Experimental|Pneumatic Compression (PC)|The PC will undergo two daily 30-minute sessions of sequential pneumatic compression.
89005187|NCT00205556|Active Comparator|2 on-line hemodiafiltration|
89411146|NCT04296903|Experimental|MID-C treatment|
89411147|NCT04271423|Active Comparator|Control|The flap procedure will consist of a full-thickness papilla preservation flap performed on the buccal and a full thickness flap on the palatal.
89411148|NCT04271423|Experimental|Test|The test will be a flapless technique, no flap will be reflected.
89411149|NCT04223999|Experimental|Intervention|In this arm, trial participants receive the intervention that is being tested, skullremodeling surgery. This is in combination with tumor treating fields and best practice medical treatment.
89411150|NCT04223999|Active Comparator|Control|"In this arm, the trial participant receives tumor treating fields and best practice medical treatment.~This serves as an active comparative control arm to the intervention."
89411151|NCT04218799|Experimental|Intranasal Mupirocin and Topical Chlorhexidine|
89411152|NCT04189445|Experimental|Futibatinib (Cohort A)|Advanced or metastatic solid tumors harboring FGFR1-4 rearrangements
89411153|NCT04189445|Experimental|Futibatinib (Cohort B)|Advanced or metastatic solid gastric or GEJ cancer harboring FGFR2 amplification
89411154|NCT04189445|Experimental|Futibatinib (Cohort C)|Myeloid or lymphoid neoplasm harboring FGFR1 rearrangement
89411155|NCT04183920|Active Comparator|Group A|Participants in this arm will be provided cranberry juice to consume for 42 days in total. After a 10-21-day washout period participants will receive placebo juice for 42 days.
89411156|NCT04183920|Active Comparator|Group B|Participants in this arm will be provided placebo juice to consume for 42 days in total. After a 10-21-day washout period participants will receive cranberry juice to consume for 42 days
89411157|NCT04148703|Experimental|Active group|in-office follow-up at 30 days post-implantation and after by remote monitoring (daily) without scheduled in-office follow-up during the study period (48 months). A remote FU will be planned every 9 months.
89411158|NCT04148703|Active Comparator|Control group|The patients randomized in the control group will be followed accordingto the guidelines; i.e. with an in-office follow-up at 30 days post-implantation and after followed with in-office follow-ups according to clinical practice.
89411159|NCT04125992|Experimental|Distal Radial|Patients who undergo coronary catheterization by accessing the distal radial artery in the snuff-box of the hand.
89411160|NCT04125992|Active Comparator|Forearm Radial|Patients who undergo conventional coronary catheterization by accessing the forearm radial artery.
89411161|NCT04100954|Experimental|Reinforced prosthesis|Implementation of a reinforced prosthesis with silver coating and double valve, whatever which type of prosthesis the patient previously had.
89411162|NCT04100954|Active Comparator|Standard prosthesis|Implementation of a standard prosthesis (simple valve, not reinforced), similar to the prosthesis the patient previously had.
89411163|NCT04093310|Experimental|Word catheter|The abscess is incised and the Word catheter is inserted into the residual cavity to create a neo-channel to prevent recurrence. The catheter is removed after 4 weeks during a consultation
89437544|NCT03681054|Experimental|Plant-protein based diet|Dietary intervention: plant-protein based diet, en emphasis on healthy Nordic foods. Parallel phase starts after study period I and the diet is followed until labor.
88887448|NCT05312060|Active Comparator|Antithromboembolic exercises (AE)|AE will perform two supervised antithromboembolic exercises sessions daily lasting 30 minutes.
88887449|NCT05299697|Experimental|TG103 15 mg|Administered subcutaneously (s.c., under the skin) once every week for 24 weeks. Doses gradually increased to 15 mg.
88887450|NCT05299697|Experimental|TG103 22.5 mg|Administered subcutaneously (s.c., under the skin) once every week for 24 weeks. Doses gradually increased to 22.5 mg.
88887451|NCT05299697|Placebo Comparator|Placebo|Administered subcutaneously (s.c., under the skin) once every week for 24 weeks.
88887452|NCT05296655||Laryngopharegeal reflux symptoms patients|patients with symptoms of laryngopharyngeal reflux detected at an outpatient appointment with an ENT doctor
88887453|NCT05296655||Asymptomatic laryngopharegeal reflux patients|patients without symptoms of laryngopharyngeal reflux who applied for an appointment with an otorhinolaryngologist
88887454|NCT05294653||Type 1 Diabetes|Classified according to American Diabetes Association [ADA] 2021 guidelines
88887455|NCT05294653||Type 2 Diabetes|Classified according to American Diabetes Association [ADA] 2021 guidelines
88887456|NCT05286918|Experimental|The intervention (CRP-guided) group|"Standard usual care (following GOLD initiative, including bronchodilator, and systemic steroid).~The attending doctor will use the CRP level to inform their decision to continue antibiotics around 3 hours from blood taking. These doctors will be provided pre-study training on CRP interpretation.~Every day from randomization, serum CRP testing will be encouraged to take. Once CRP has declined to <5mg/dL and the patient has remained afebrile for past 48 hours, antibiotic treatment will be reviewed for discontinuation. Otherwise, antibiotic treatment will be continued. A switch on the administration route, or a change of antibiotics due to adverse effect, allergy, or suggestion from culture result, is permitted according to in-patient physician's decisions. CRP will continue to be monitored daily upon discharge from that hospital (up to 28 days)."
88887457|NCT05286918|No Intervention|The usual care (control) group|Patients in the control arm will be treated with usual care (GOLD initiative). No CRP would be measured.No CRP would be measured.
89411164|NCT04093310|Active Comparator|Incision-drainage|This procedure performed under general or loco-regional anaesthesia consists in incising the abscess, draining the pus build-up and placing a wick in the residual cavity to promote progressive healing from the inside out.
89192165|NCT00809289|Active Comparator|Three|Administration of a single oral dse of 400mg moxifloxacin
89411165|NCT04090476|Experimental|BIG for Life Exercise Group|This arm includes the entire cohort enrolled who will participate in the three times a week one hour community exercise group for a total of 8 weeks
89411166|NCT04050293|Experimental|SPN-538|Patients will be treated with SPN-538 as a single dose once a day
89411167|NCT04050293|Placebo Comparator|Placebo|Patients will be treated with Placebo once a day
89411168|NCT04026776|Experimental|Preterm Group|Subjects with very low birth weight (<37 completed weeks' gestation and birth weight <1500 g) will receive a dietary intervention (high/low salt diet) and FDA approved drug, Allopurinol
89411169|NCT04026776|Active Comparator|Term-born control group|Subjects with birth weight ≥2500 g will receive a dietary intervention (high/low salt diet)
89411170|NCT03978871|Experimental|Growth Mindset|Persuasive education about emotions, brain development, and teenagers' ability to learn how to manage emotions
89411171|NCT03978871|Active Comparator|Brain Education|Neutral education about functions of different parts of the brain
89411172|NCT03975855||Suspicious axillary lymph nodes|All patients with histologically confirmed breast cancer or highly suspicious breast lesions presenting with suspicious axillary lymph nodes
89411173|NCT03969498||1- Obstetric APS women (oAPS)|No intervention, pure observational study.
89411174|NCT03969498||2-Women positive for F5rs6025 or F2rs1799963 polymorphis|No intervention, pure observational study.
89411175|NCT03969498||3-Women with negative thrombophilia screening (Control group|No intervention, pure observational study.
89411176|NCT03946449|Experimental|Fazirsiran (TAK-999, ARO-AAT) Cohort 1|"Administered on Day 1, Weeks 4 and 16 for a minimum of 3 doses.~Treatment Extension (optional enrollment): Administered every 12 weeks for 12 additional doses."
89411177|NCT03946449|Experimental|Fazirsiran (TAK-999, ARO-AAT) Cohort 1b|"Administered on Day 1, Weeks 4 and 16, for a minimum of 3 doses.~Treatment Extension (optional enrollment): Administered every 12 weeks for 12 additional doses."
89411178|NCT03946449|Experimental|Fazirsiran (TAK-999, ARO-AAT) Cohort 2|"Administered on Day 1, Weeks 4, 16, 28 and 40 for a minimum of 5 doses.~Treatment Extension (optional enrollment): Administered every 12 weeks for 12 additional doses."
89411179|NCT03916939|Experimental|Osteopathy|osteopathic treatment
89411180|NCT03916939|Placebo Comparator|simulated osteopathy|simulated osteopathic treatment
89411181|NCT03913637|Experimental|Strategy Training|In addition to receiving everything in Enhanced Usual Care, participants will engage in 10 sessions over 5 weeks with a trained research interventionist. Participants will describe activities they do, no longer do, or have never done using the cards from the Activity Card Sort as a guide. The therapist will ask the participants to use this information to identify and prioritize activity-based goals to address in the remaining sessions. These sessions will take place in a location of the participant's choice and will last approximately 1 hour.
89411182|NCT03913637|Active Comparator|Enhanced Usual Care|Enhanced usual care will allow older adults to interact with services and support. All mental health treatment (e.g., medications that you may be taking) and psychotherapy (e.g. counseling or social services) will be documented and monitored. Furthermore, all participants assigned to Enhanced Usual Care will receive the same assessments as other participants. The close monitoring will track potential changes in symptoms (e.g., depressive symptoms), and participants will be referred to services as appropriate.
89411183|NCT03909854|Active Comparator|Adaptive Pressure Control|The Adaptive Pressure Control arm is the baseline mode/protocol for medical intensive care unit mechanical ventilation
89411184|NCT03909854|Active Comparator|Assist Volume Control|The assist volume control arm is the new protocol that will be implemented and tested for feasibility
89411185|NCT03905668||ICU Patients|Adults in admitted to an ICU at University of Florida Health Gainesville with an expected length of stay greater than 24 hours which are not on any form of contact precaution or isolation. Patients will have continuous video, accelerometer, and electromyographic monitoring for up to seven days while in the ICU.
89411186|NCT03905668||ICU Patient Friends/Family Members|Adult visitors of participating ICU patients that are willing to provide feedback to the learning algorithms.
89411187|NCT03877510|Experimental|Open Label IPX203|All participants received oral administration of extended-release capsules IPX203 dosing regimen that was determined at the end of the IPX203 dose conversion period of Study IPX203-B16-02 (NCT03670953) for nine months of open-label therapy. The dose and dosing frequency was determined by the investigator to achieve the optimal balance of efficacy and safety.
89411188|NCT03872778|Experimental|Phase I Cohort I|"[68 Ga]-NeoB: 50 micrograms/dose at screening~[177Lu]-NeoB: 50 mCi (1.85 GBq) cycle 1, 60% Estimated Cumulative Dose (ECD) for cycles 2-4, q6w"
89411189|NCT03872778|Experimental|Phase I Cohort II|"[68 Ga]-NeoB: 50 micrograms/dose at screening~[177Lu]-NeoB: 60% ECD for 3 cycles (q6w)"
89411190|NCT03872778|Experimental|Phase I Cohort III|"[68 Ga]-NeoB: 50 micrograms/dose at screening~[177Lu]-NeoB: 80% ECD for 3 cycles (q6w)"
89411191|NCT03872778|Experimental|Phase I Cohort IV|"[68 Ga]-NeoB: 50 micrograms/dose at screening~[177Lu]-NeoB: 100% ECD for 3 cycles (q6w)"
89411192|NCT03872778|Experimental|Phase I Cohort V|"[68 Ga]-NeoB: 50 micrograms/dose at screening~[177Lu]-NeoB: 120% ECD for 3 cycles (q6w)"
89411193|NCT03872778|Experimental|Phase I Cohort VI|"[68 Ga]-NeoB: 50 micrograms/dose at screening~[177Lu]-NeoB: 100% ECD for 2 cycles (q6w)"
89411194|NCT03872778|Experimental|Phase I Cohort VII|"[68 Ga]-NeoB: 50 micrograms/dose at screening~[177Lu]-NeoB: 120% ECD for 2 cycles (q6w)"
89411195|NCT03872778|Experimental|Phase IIa|"[68 Ga]-NeoB: 50 micrograms/dose at screening~[177Lu]-NeoB: dose TBD based on Cohorts I-VI, 3 cycles q6w"
89411196|NCT03846427|Experimental|Zanubrutinib|Zanubrutinib 160 mg (two 80-mg capsules) orally twice daily with or without food until progressive disease, intolerable toxicity, or withdrawal of consent
89411197|NCT03831113|Experimental|Buprenorphine Magnitude Group|Subjects will receive alternating reductions of 1 mg and then 2 mg weekly. Subjects on thrice daily (TID) or four times daily (QID) dosing, as prescribed by their MAT provider, will be assigned to either the Magnitude or Frequency group (n=10).
89411198|NCT03831113|Experimental|Buprenorphine Frequency Group|Subjects will receive dose reductions of 2 mg on alternating intervals of 1 and 2 weeks. Subjects on TID or QID dosing, as prescribed by their MAT provider, will be assigned to either the Magnitude or Frequency group (n=10).
89411199|NCT03831113|Experimental|Buprenorphine Dosing Group|Subjects will receive dose reductions identical to either the Magnitude (alternating 1 and 2 mg reductions) or Frequency (2 mg reductions on alternating 1 and 2 week intervals) groups. Subjects on BID dosing, as prescribed by their MAT provider, will be assigned to the Dosing group (n=10).
89411200|NCT03824561||Vedolizumab 300 mg|Vedolizumab IV infusion 300 mg, at Weeks 0, 2 and 6, and every 8 weeks thereafter, for up to 54 weeks. Participants will receive IV infusion as part of routine medical care.
89411201|NCT03821857|Experimental|Women|18F-Flortaucipir and 11C-Pittsburgh compound-B radioligands will be used for experimental PET imaging of beta-amyloid and neurofibrillary tau pathology
89411202|NCT03818087||Elevate|Participants over the age of 70 years old with early-stage breast cancer will be recruited.
89411203|NCT04305236|Experimental|Abemaciclib and Fulvestrant|Abemaciclib will be administered orally at the dose of 150 mg twice daily. Fulvestrant will be administered intramuscularly at an initial loading dose of 500mg on days 1 and 15 of the first cycle and then 500 mg intramuscularly every first day of each subsequent cycle. One cycle is 28 days.
89536698|NCT02470871|Experimental|Low-dose CSL689|Single dose of subject's routine FVII replacement therapy (either eptacog alfa [activated] [ie, comparator drug 1] or pdFVII [ie, comparator drug 2]), followed by a single dose of CSL689 at the low dose
88819700|NCT02958813|Placebo Comparator|FUEL|FUEL Health Promotion Control combines two programs, FUEL and Project Balance Health Promotion. FUEL™ promotes healthy activities by encouraging good nutrition, exercise, and informed consumer behavior. FUEL™ does not explicitly address HIV/STI prevention. Investigators will present information from Balance's session about HIV/AIDS, condoms, and other STIs. Investigators will also insert the following sessions from Balance into FUEL: alcohol use, drug/marijuana use, nutrition, exercise, and violence to increase program length.
88819701|NCT02767011|Experimental|THEM|Patients receive telehealth electronic health care monitoring.
88819702|NCT02767011|No Intervention|Standard of Care (SOC)|Patients receive normal standard of follow-up care
88819703|NCT01447706|Active Comparator|Paclitaxel|Standard dosing paclitaxel: 80 mg/m2 QW intravenously)
88819704|NCT01447706|Experimental|MM-121 (SAR256212) + Paclitaxel|administered intravenously at 40 mg/kg loading dose on Cycle 1, Week 1 followed by 20 mg/kg QW for all subsequent doses
88819705|NCT02739789|Sham Comparator|Sham tDCS|"tDCS stimulation will be administered over the brain area of interest, but will be shorter in duration than the active treatment"
88819706|NCT02739789|Active Comparator|Active tDCS|tDCS stimulation will be administered over the brain area of interest
88819707|NCT02740413||Patients with Haemophilia A|Patients in The MHR diagnosed with Haemophilia A
88819708|NCT02740413||Patients with Haemophilia B|Patients in The MHR diagnosed with Haemophilia B
88819709|NCT01509638|Active Comparator|Group 1 Standard of Care|IV Morphine sulfate or Sponsor-approved equivalent via a patient-controlled analgesia (PCA) pump
88819710|NCT01509638|Active Comparator|Group 2 EXPAREL|bupivacaine liposome injectable suspension.
88819711|NCT04336917|Active Comparator|Group Rhomboid Intercostal and Subserratus Plane Block|In addition to routine standard perioperative and postoperative analgesic protocol participants will recieve Rhomboid Intercostal and Subserratus Plane Block under ultrasound guidence at the end of the surgery.
88819712|NCT04336917|No Intervention|Control Group|Routine standard perioperative and postoperative analgesic protocol will be given.
88819713|NCT01448486|No Intervention|Standard of Care HAART|Participants randomised to this arm will remain on their standard of care Highly Active Antiretroviral Therapy (HAART).
88819714|NCT01448486|Experimental|Raltegravir|Participants randomised to this arm will remain on their standard of care Highly Active Antiretroviral Therapy (HAART) with the addition of Raltegravir 400 mg twice daily (BID).
88819715|NCT00371475|Experimental|Arm 1|
88819716|NCT00371475|Other|Arm 2|Historical Comparator: control data derived from the TAXUS IV and TAXUS V clinical trials
88819717|NCT01562678|Experimental|Liraglutide|
88819718|NCT01562678|Placebo Comparator|Placebo|
88819719|NCT01562756|Experimental|HVLA-SM|High velocity, low amplitude lumbo-pelvic manipulation
88819720|NCT02767869|Experimental|Banaba|Banaba capsules, 500mg, two times per day before meals during 90 days
88819721|NCT02767869|Placebo Comparator|Placebo|Calcined magnesia capsules, 500mg, two times per day before meals during 90 days
89411204|NCT03761537|Experimental|Tralokinumab + TCS|4 subcutaneous (SC) injections of tralokinumab 150 mg as a loading dose on Day 0, followed by 2 SC injections of tralokinumab 150 mg every 2 weeks (Q2W) regimen for 26 weeks. The last administration of the Investigational Medicinal Product (IMP) occurred at Week 24. From Day 0 to Week 24, a Topical corticosteroid (TCS) cream was dispensed to the participants at each IMP dosing visit (e.g., Q2W). Participants were instructed to treat active lesions as needed and to discontinue the TCS treatment when control was achieved.
88887458|NCT05259254|Placebo Comparator|Standard Direct Observed Therapy (DOT)|After a patient was diagnosed with TB, they will be provided TB therapy which is consist of health education and anti-TB medication. Patient that is not in life-threatening condition typically will be treated as outpatient. Patient will receive medication that will be monitored closely through DOT, which is either by health facilities (by healthcare staff), or community (by family members or community members). Observation of medication will be conducted daily, and the health care staff will sign the DOT diary provided to the patient to verify the medication consumption.
88887459|NCT05259254|Active Comparator|Mobile application DOT|The mobile application will be consisting of four basic modules which are: 1) reminder system, 2) visual observed therapy, 3) feedback, and 4) health education. Researcher will teach patient on how to record, and send video of every dose of medication ingested every day. Participants also required to show their mouth is empty by opening their mouth and sticking out their tongue. The participants also are required to record and send the self-recorded video of ingesting the medication daily. Researcher will subsequently view the video through a password protected website. The observation of taking medication will be completed until the end of study period.
88887460|NCT05252624|Active Comparator|Active Comparator: Henagliflozin|Single 5 mg tablet, administered orally once daily for 6 months
88887461|NCT05252624|Placebo Comparator|Placebo Comparator: Placebo|Single 5 mg tablet, administered orally once daily for 6 months
88887462|NCT05237622|Other|High Flow|Standard HighFlow therapy after weaning from continuous positive airway pressure therapy will be applied on different flow levels. Starting with a flow level of 8l/min, the flow-rates will be changed every 30 minutes subsequently from 8-6-4-2-4-6-8 l/min. Meanwhile, data lung volume changes will be measured using electrical impedance tomography.
88887463|NCT05234411||Observational group|Eligible participants will be female patients aged 13 years or older, with regular menstrual cycle, who have been undergoing a KDT for at least 3 months and thus previously diagnosed with Drug resistant epilepsy or GLUT1DS.
88887464|NCT05216484|Experimental|two doses CoronaVac group|the third does was given 6 months after two doses CoronaVac group
88887465|NCT05216484|Experimental|two doses BBIBP-CorV|the third does was given 6 months after two doses BBIBP-CorV
88887466|NCT05216484|Experimental|first does CoronaVac and second does BBIBP-CorV|the third does was given 6 months after first does CoronaVac and second does BBIBP-CorV
88887467|NCT05216484|Experimental|first does BBIBP-CorV and second does CoronaVac|the third does was given 6 months after first does BBIBP-CorV and second does CoronaVac
88887468|NCT05214469||Case Group|Individuals diagnosed with knee-osteoarthritis
88887469|NCT05214469||Control Group|Individuals who do not have a chronic disease and are not diagnosed with osteoarthritis
88887470|NCT05167656|Experimental|Intraoral Manual Therapy plus exercise and education.|Six sessions of intraoral manual therapy plus exercise and counselling.
88887471|NCT05167656|Experimental|Extraoral Manual Therapy plus exercise and education.|Six sessions of extraoral manual therapy plus exercise and counselling.
89411205|NCT03761537|Placebo Comparator|Placebo + TCS|4 subcutaneous (SC) injections of placebo as a loading dose on Day 0, followed by 2 SC injections of placebo every 2 weeks (Q2W) regimen for 26 weeks. The last administration of the Investigational Medicinal Product (IMP) occurred at Week 24. From Day 0 to Week 24, a Topical corticosteroid (TCS) cream was dispensed to the participants at each IMP dosing visit (e.g., Q2W). Participants were instructed to treat active lesions as needed and to discontinue the TCS treatment when control was achieved.
89411206|NCT03733678|Experimental|Free SARC, Free LARC, Recommendation|Free SARC, Free LARC, Sequential recommendation
89411207|NCT03733678|Experimental|Free SARC, LARC=500, Recommendation|Free SARC, LARC=500 CFA, Sequential recommendation
88887472|NCT05167656|Active Comparator|Exercise and education.|Exercise and counselling alone without any manual therapy treatment.
88887473|NCT05122715|Other|OMNI PET/CT scan first|
88887474|NCT05122715|Other|DMI PET/CT scan first|
88887475|NCT05115422|Experimental|"Coping with Brain Fog intervention"|
88887476|NCT05113615|Active Comparator|tiotropium bromide|tiotropium bromide inhaler (Spiriva Respimat) will be used once daily (2 puffs) for a total of 8 days
88887477|NCT05113615|Placebo Comparator|Matching placebo|matching placebo inhaler will be used once daily (2 puffs) for a total of 8 days
88887478|NCT05037630|Experimental|Self-guided Digital Tool for Problematic Alcohol Use|Self-guided Digital Tool for Problematic Alcohol Use during 8 weeks with clinical telephone interviews pre ant post intervention.
88887479|NCT05030233|Experimental|Nurse-Administered Touch Intervention|Preterm infants will receive the nurse-administered touch intervention during one episode of essential nursing care.
88887480|NCT05030233|No Intervention|Standard Care|Preterm infants will receive one episode of essential nursing care delivered as standard care.
88887481|NCT05013957||Retrospective analysis|Methylome of existing neuroendocrine tumor samples from the biobank of Basel University Hospital will be evaluated
88887482|NCT05013957||Prospective analysis|Methylome analysis of tumor samples of neuroendocrine tumor patients undergoing an operation or biopsy will be prospectively evaluated
88887483|NCT04981977|Experimental|Care Transitions Intervention|Patient participants in this arm will receive the Care Transition Intervention.
89192166|NCT02570256|Experimental|Deficit-fields to reduce error|We hypothesize that a deficit-field design, using the statistics of a patient's errors to customize training, will provide optimal augmentation that varies during motion as needed. We will compare the training effects of error deficit-fields with previous methods of error augmentation to improve reaching ability.
89192167|NCT02570256|Experimental|Deficit-fields to expand range of motion|Amplifying augmentation can expand motor exploration and improve skill retention in patients. Using motor exploration patterns from each patient, we will form customized deficit-fields to recover normal joint workspace. We will compare augmentation training that either amplifies or diminishes the observed deficits (Expt-1). We also compare deficit-fields with our prior augmentation methods to determine the added value of increased customization (Expt-2).
89192168|NCT02570256|Experimental|Deficit-fields to improve function|Here we present visual distortion of whole body movement during manual tasks during standing, including reaching, grasping, and object manipulation. We compare the training effects of feedback based on deficit-fields versus practice with normal vision.
89192169|NCT02569034|Active Comparator|Young Adults|These participants will perform the Effort-Expenditure for Rewards Task (EEfRT) while an functional magnetic resonance imaging (fMRI) is performed. They will also complete a battery of both cognitive and anhedonia questionnaires.
89192170|NCT02569034|Experimental|Older Adults|These participants will perform the Effort-Expenditure for Rewards Task (EEfRT) while an functional magnetic resonance imaging (fMRI) is performed. They will also complete a battery of both cognitive and anhedonia questionnaires.
89192171|NCT05623722|No Intervention|Control Group|Patients receive the same administration of acute gastrointestinal injury and enteral nutrition strategy according to the guidelines, and the routine practice of the ICU. The interventions end on day 7 or cease when the patients are discharged from the ICU, dead, or withdraw their consent.
89192172|NCT05623722|Experimental|Erector Spinae Plane Block Group|"Patients receive the same administration of acute gastrointestinal injury and enteral nutrition strategy according to the guidelines, and the routine practice of the ICU.~Ultrasound-guided erector spinae plane block is performed at thoracic (T) level 8. An 18F catheter is placed on both sides of the thoracic vertebra deep into the erector spinae, and a bolus of 20 ml of 0.375% ropivacaine is administered bilaterally. Then, a continuous infusion of 20 ml of 0.375% ropivacaine on each side is followed at a rate of 2 ml/h every 12 hours. The interventions end on day 7 or cease when the patients are discharged from the ICU, dead, or withdraw their consent."
89192173|NCT02552667|Experimental|HCP1102+HGP0711Placebo|HCP1102Placebo+HGP0711Placebo(1week) -> HCP1102+HGP0711Placebo(4weeks) Each 1 capsule, once daily
89192174|NCT02552667|Active Comparator|HCP1102Placebo+HGP0711|HCP1102Placebo+HGP0711Placebo(1week) -> HCP1102Placebo+HGP0711(4weeks) Each 1 capsule, once daily
89192175|NCT00728000|Experimental|chemotherapy regimen|Gemcitabine and oxaliplatin are given intravenously (into the vein) every 2 weeks. Erlotinib is a pill that is taken by mouth daily.
89192176|NCT04066530|Experimental|AD-203|
89192177|NCT04066530|Active Comparator|Mucosta tab.|
89192178|NCT00808431|Experimental|Lifestyle counseling|Lifestyle counseling
89192179|NCT02569190|Experimental|Walkbot|Receive conventional physical therapy (session I for 30 min/day) with Walkbot training 3 days a week for 8 weeks, 20 session in all.
88887484|NCT04981977|Experimental|Care Transition Intervention and Peer Support|Patient participants in this arm will receive the Care Transition Intervention.
88887485|NCT04981977|Other|Usual Care|Patient participants in this arm will receive the usual discharge/transition care provided by the hospital.
88887486|NCT04883944|Experimental|Intervention group|All the enrolled infants will receive the heel stick procedure with the maternal involvement after mother will be trained on the application of the non-pharmacological techniques during the performance of the procedure.
89192180|NCT04235556||Historic cohort|Retrospective cohort of patients that were treated in the Hôpital Européen Georges Pompidou before the creation of the care pathway unit.
89192181|NCT04235556||Prospective cohort|All consecutive patients that meet the inclusion criterion and will begin a cancer care after the study start.
89192182|NCT00809367|Other|Collection of Leukemia Cells|Other: Collection of Leukemia Cells Collection of leukemia cells either by 1) routine blood draw 2) bone marrow aspirate or 3) leukopheresis
89192183|NCT00728208|Experimental|GSK372475|Drug
89192184|NCT02552433||Body Contouring Surgery|All patients who undergo BCS after bariatric surgery.
89192185|NCT00799305||COPD patients|
89192186|NCT00730314|Experimental|1|Unrelated donor
89192187|NCT00730314|Experimental|2|Cord Blood
89192188|NCT02553993|Experimental|Wii Fit|The Wii Fit training was conducted using the Wii Fit bundle from Nintendo, which consists of the Wii console, a Wii Balance Board, and the Wii Fit Plus balance game disc. The Wii balance board has 4 transducers, which could assess the player's force distribution and resultant movements in the center of pressure (COP). The participants stood on the board and used the change of COP to play the games. Five games (Tilt, Soccer Heading, Balance Bubble, Penguin Slide, and Perfect 10) were selected from the Wii Fit Plus package based on the motor demand of these games. The major movement patterns to play the games included right-left weight shifting and front-back weight shifting.
89411208|NCT03733678|Experimental|Free SARC, LARC=1000, Recommendation|Free SARC, LARC=1000 CFA, Sequential recommendation
89411209|NCT03733678|Experimental|Free SARC, LARC=2140, Recommendation|Free SARC, LARC=2140 CFA, Sequential recommendation
89411210|NCT03733678|Experimental|Free SARC, LARC=5000, Recommendation|Free SARC, LARC=5000 CFA, Sequential recommendation
89411211|NCT03733678|Experimental|Regular SARC, Free LARC, Recommendation|Regular price SARC, Free LARC, Sequential recommendation
89411212|NCT03733678|Experimental|Regular SARC, LARC=500, Recommendation|Regular price SARC, LARC=500 CFA, Sequential recommendation
89411213|NCT03733678|Experimental|Regular SARC, LARC=1000, Recommendation|Regular price SARC, LARC=1000 CFA, Sequential recommendation
89411214|NCT03733678|Experimental|Regular SARC, LARC=2140, Recommendation|Regular price SARC, LARC=2140 CFA, Sequential recommendation
89411215|NCT03733678|No Intervention|Regular SARC, LARC=5000, Recommendation|Regular price SARC, LARC=5000 CFA, Sequential recommendation
89411216|NCT03733678|Experimental|Free SARC, Free LARC, No Recommendation|Free SARC, Free LARC, Simultaneous recommendation
89411217|NCT03733678|Experimental|Free SARC, LARC=500, No Recommendation|Free SARC, LARC=500 CFA, Simultaneous recommendation
89411218|NCT03733678|Experimental|Free SARC, LARC=1000, No Recommendation|Free SARC, LARC=1000 CFA, Simultaneous recommendation
89411219|NCT03733678|Experimental|Free SARC, LARC=2140, No Recommendation|Free SARC, LARC=2140 CFA, Simultaneous recommendation
89411220|NCT03733678|Experimental|Free SARC, LARC=5000, No Recommendation|Free SARC, LARC=5000 CFA, Simultaneous recommendation
89411221|NCT03733678|Experimental|Regular SARC, Free LARC, No Recommendation|Regular Price SARC, Free LARC, Simultaneous recommendation
88887487|NCT04883944|Active Comparator|Standard care|All the enrolled infants will receive the heel stick procedure according to local protocol without the maternal involvement. The non-pharmacological techniques will be performed by a second nurse not involved in the heel stick procedure itself.
88887488|NCT04850378|No Intervention|Coagulation profile in Nephrotic syndrome|Investigation of the biochemical coagulation profile in patients with nephrotic syndrome.
88887489|NCT04850378|Experimental|Nephrotic syndrome|Nephrotic patients without diabetes.
88887490|NCT04850378|Experimental|Membranous nephropathy and nephrotic syndrome|Membranous nephropathy and nephrotic syndrome.
89411222|NCT03733678|Experimental|Regular SARC, LARC=500, No Recommendation|Regular Price SARC, LARC=500 CFA, Simultaneous recommendation
89411223|NCT03733678|Experimental|Regular SARC, LARC=1000, No Recommendation|Regular Price SARC, LARC=1000 CFA, Simultaneous recommendation
88887491|NCT04850378|Active Comparator|Atrial fibrillation|Atrial fibrillation with no kidney disease.
88887492|NCT04834882||Healthcare workers|Medical and paramedical staff in Reims University Hospital and EPSM Marne working in COVID-19 units and non COVID-19 units
88887493|NCT04809103|Experimental|Intratumoral Cisplatin Arm|Single arm approach. There is no comparator or placebo group. Cisplatin will be administered directly into a non-small cell lung cancer, following imaging verification and pathologic diagnosis, during a single bronchoscopic procedure.
88887494|NCT04804371|Other|18F-FDG PETCT scan|18F-FDG tracer (5 MBq/kg body weight of FDG; up to 550 MBq) will be injected into the intravenous
88887495|NCT04797234|Experimental|Control|There will be no intervention to the control group.
88887496|NCT04797234|Experimental|Experiment|The experimental group will be trained for 6 weeks.
88887497|NCT04830527|Experimental|Intervention group|Patients in experimental group will receive EMA prompts. Therapists in this group will receive a summarized PDF report before the beginning of the first psychotherapy session. The report will include graphic summarized data from the EMA prompts.
88887498|NCT04830527|Active Comparator|Control group|"Patients in control group will receive the EMA prompts in the same manner as patients in the experimental group.~Therapists in this group will not receive the PDF reports, and instead will get raw scores from a screening evaluation conducted with patients in the recruitment phase of the study."
88887499|NCT04776031|Experimental|Laser Treatment|Laser treatment using the R:GEN Laser System on Day 1 and at Week 24
88887500|NCT04771052||CORE program|Patients admitted to a dedicated COVID-19 units (CHUS Hôtel-Dieu de Sherbrooke - CIUSSS de L'Estrie - CHUS) with medical clearance (physical deconditioning; hemodynamically stable; oxygen therapy by nasal cannula < 4 L/min for saturation > 92%; resting respiratory rate < 24; and heart rate between 50 and 120 beats per minute).
88887501|NCT04771052||Control|Patients admitted to a dedicated COVID-19 units (CHAUR de Trois-Rivières, CIUSSS de la Mauricie-et-du-Centre-du-Québec) receiving usual care, matched to CORE a patient with similar characteristics (sex, age, preadmission provenance).
88887502|NCT04765371|Active Comparator|DEXAMETHASONE Arm|Patients will take 6 mg per day of Dexamethasone during 10 days
89411224|NCT03733678|Experimental|Regular SARC, LARC=2140, No Recommendation|Regular Price SARC, LARC=2140 CFA, Simultaneous recommendation
88887503|NCT04765371|Active Comparator|PREDNISOLONE Arm|Patients will take 60 mg per day of Prednisolone during 10 days
88887504|NCT04750356||Cohort A1|Healthcare workers and patients that have previously undertaken a swab or serology test to detect for the presence of SARS-CoV-2. Without the need to seek retrospective consent for the SARS CoV 2 Longitudinal Study, residual samples and derivatives from the Crick COVID -9 Consortium Testing centre and data will be used for the study
88887505|NCT04750356||Cohort A2|3,000 SARS-CoV-2 positive and 3,000 SARS-CoV-2 negative participants (randomly selected) from cohort A1 will be prospectively consented to the study. In addition, vaccine status will also be used to stratify the participants and recruit to the study.
88887506|NCT04750356||Cohort B|Employees at participating centres including but not limited to UCLH and The Francis Crick Institute who have their serology tested and/or are swabbed for viral (SARS-CoV-2 and seasonal viruses) detection as well as participants who are vaccinated will be prospectively consented to the study.
88887507|NCT04750356||Cohort C|Individuals recruited to other REC approved research studies where their samples are processed by the Crick COVID 19 Consortium Testing centre will also be consented in their existing study to allow the use of leftover study samples already collected and to be collected, for use in this longitudinal study.
88887508|NCT04744363|Experimental|AVT04 45 mg SC|Single dose Pre-filled syringe to be injected subcutaneously into thigh or abdomen
88887509|NCT04744363|Active Comparator|US Stelara 45 mg SC|Single dose Pre-filled syringe to be injected subcutaneously into thigh or abdomen
88887510|NCT04744363|Active Comparator|EU Stelara 45 mg SC|Single dose Pre-filled syringe to be injected subcutaneously into thigh or abdomen
88887511|NCT04727541|Experimental|Neoadjuvant therapy with Bintrafusp alfa|1200 mg of Bintrafusp alfa will be administered by intravenous infusion every 2 weeks for a total of 2 dosages (Q2W). Subsequently, the surgery will be performed.
88887512|NCT04673162|Experimental|A SOC plus MP|Standard treatment (currently desamethasone 6mg/daily for 10 days) plus Methylprednisolone 1gr daily iv on days 1,2,3
88887513|NCT04673162|Active Comparator|B SOC plus Pb|Standard treatment (currently desamethasone 6mg/daily for 10 days) plus Placebo
88887514|NCT04665375|Experimental|DOR/3TC/TDF|100mg of doravirine (DOR), 300mg of lamivudine (3TC), and 300mg of tenofovir disoproxil fumarate (TDF)
88887515|NCT04658082|Other|Non invasive glucose monitor|Single arm. All subjects will have glucose levels measured both by non invasive glucometer and by core lab
88887516|NCT04647071|Placebo Comparator|Control|Microcrystalline cellulose (9892- Capsules®) up to 400 mg.
88887517|NCT04647071|Experimental|Intervention|Garlic concentrated extract plus onion concentrated extract plus microcrystalline cellulose (9892- Capsules®) up to 400 mg.
88887518|NCT04638244|Experimental|BOMI Group (Intervention Group)|Listening to an expert-selected, theory-guided and self-chosen song each day actively in a personalized and focused way (Brief Online Music Intervention: BOMI) for 3 months
88887519|NCT04638244|Active Comparator|POM Group (Control Group)|Receiving psychoeducational online message (POM) (for focused reading for 5 minutes) daily for 3 months
88887520|NCT04572568||experimental group|"Ruptured AVMs:~AVMs not involved vital eloquent areas, or more than 5 mm away from functional fiber bundles, microsurgery or hybrid surgery can be performed;~Targeted embolization for hemorrhagic predictors could be considered as a monotherapy; embolization can be used as an adjunctive strategy to reduce flow or volume before microsurgery or stereotactic radiosurgery (SRS).~SRS for patients with a volume less than 10ml and not in the acute phase(< 3months) of hemorrhage. Volume-stage or dose-stage can be used for giant AVMs involving important eloquent areas.~Conservation can be used for AVMs that are prone to severe disability due to intervention.~Unruptured AVMs:~Interventions are recommended if unruptured AVMs are assessed as being at high rupture risk, or have refractory epilepsy or acceptable postoperative neurological deficits, otherwise conservative treatment is recommended. The choice of intervention strategy was the same as for ruptured AVM."
88887521|NCT04572568||control group|Patients who had not received a multidisciplinary assessment to develop a treatment plan were included in the control group. It should be noted that the multidisciplinary team for AVM was formed in June 2018, so the prospective AVM cohort from August 2011 to June 2018 and the AVM cohort after June 2018 without comprehensive evaluation of treatment regimens by the multidisciplinary team served as the control group.
88887522|NCT04566081|Active Comparator|iTALKbetter: deterministic|"Participants will receive the deterministic version of the iTALKbetter therapy for 6 weeks. Participants are required to use the therapy for 1.5 hours everyday to reach the required dose of 60 hours over the 6 week period.~iTALKbetter:deterministic version will randomise the order all of the words that are to be trained and participants will cycle through all of these words regardless of their performance until complete at which point the order is re-randomised and participants begin the cycle again."
88922029|NCT05956002|Experimental|Sequence 2|Single oral dose of etrasimod 2 mg mini tablets mixed with applesauce under fasted conditions (Test 1) followed by single oral dose of etrasimod 2 mg mini tablets mixed with water under fasted conditions (Test 3) followed by single oral dose of etrasimod 2 mg clinical IR tablet under fasted conditions (Reference) followed by single oral dose of etrasimod 2 mg mini tablets mixed with chocolate pudding under fasted conditions (Test 2) followed by single oral dose of etrasimod 2 mg mini tablets mixed with yogurt under fasted conditions (Test 4)
89411225|NCT03733678|Experimental|Regular SARC, LARC=5000, No Recommendation|Regular Price SARC, LARC=5000 CFA, Simultaneous recommendation
89411226|NCT03706079|Experimental|Tezepelumab|Tezepelumab subcutaneous injection
89411227|NCT03706079|Placebo Comparator|Placebo|Placebo: Placebo subcutaneous injection
89411228|NCT03683030|Experimental|Treatment Group|Ablation using Multi-electrode Radiofrequency (RF) Balloon Catheter (HELIOSTAR).
89411229|NCT03657160|Placebo Comparator|Placebo|Vedolizumab placebo-matching, intravenous (IV) infusion, once on Day -1 along with background graft-versus-host disease (GvHD) prophylaxis regimen prior to Allo-HSCT and once on Days +13, +41, +69, +97, +125, and +153 post Allo-HSCT up to the end of study treatment (up to 182 days).
89411230|NCT03657160|Experimental|Vedolizumab 300 mg|Vedolizumab 300 mg, IV infusion, once on Day -1 along with background GvHD prophylaxis regimen prior to Allo-HSCT and once on Days +13, +41, +69, +97, +125, and +153 post Allo-HSCT up to the end of study treatment (up to 182 days).
89411231|NCT03635320|Experimental|investigational group|using Trochanteric Fixation Nail Advanced to treat the fracture
89411232|NCT03635320|Active Comparator|the control group|Using Proximal Femoral Nail Antirotation to treat the fracture
88819722|NCT01449266|Other|Dotarem®-injected patients|Male or female subjects, aged ≥18 years,suffering from end-stage renal failure and requiring hemodialysis treatment 3 times per week, were submitted to a single Dotarem® IV injection at 0.1 mmol/kg before being submitted to 3 hemodialysis sessions to assess the decrease of Dotarem® concentration in the blood.
88819723|NCT01509872|Experimental|Trauma-Focused Cognitive Behavioral Therapy|Trauma-Focused Cognitive Behaviour Therapy (Cohen, Mannarino, Deblinger, 2006; Smith and Saunders, 2005) is a child-friendly, manualised psychological intervention for children who experience nightmares, flashbacks, anxiety, anger, social isolation, poor concentration or self-blame after experiencing or witnessing a violent and terrifying life event (e.g. rape, murder, abduction etc). This intervention was culturally modified for use with war-affected children.
89411233|NCT03623620|Experimental|Digital delivery of MBCT (Mindful Mood Balance for Moms)|Subjects will receive digital delivery of mindfulness-based cognitive therapy (Mindful Mood Balance for Moms) for 12 weeks, along with the usual care they would receive from their provider.
89411234|NCT03623620|No Intervention|Usual Care|Subjects will receive only usual care, the care they would normally receive from their community provider, for 12 weeks.
89411235|NCT03587870|Experimental|Bolus enteral nutrition with Fresubin Intensive|Bolus nutrition over 30-40 minutes every 4 hours with Fresubin Intensive
89411236|NCT03587870|Active Comparator|Continuous enteral nutrition with Fresubin Intensive|Continuous nutrition over 20 hours per day with Fresubin Intensive (standard)
89411237|NCT03576274|Experimental|Technology Enhanced Home Exercise only|Participants in TEHE group will receive a combined technology and home exercise program. Participants will schedule an online meeting with the research team for exercise goal setting and preference. Participants will receive a daily symptoms survey. They will receive, reminder, motivation message and physical performance feedback though the mobile phone application.
89536699|NCT02470871|Experimental|High-dose CSL689|Single dose of subject's routine FVII replacement therapy (either eptacog alfa [activated] [ie, comparator drug 1] or pdFVII [ie, comparator drug 2]), followed by a single dose of CSL689 at the high dose.
88819724|NCT01509872|Active Comparator|A Child Friendly Space|A Child Friendly Space is a psychosocial intervention combining creative (e.g. art), imaginative (e.g. drama), physical (e.g. football), communicative (e.g. group discussions) and manipulative activities (e.g. story telling). It aids children's natural development by providing a safe place for children to learn, express themselves, grow and develop, supported by trained animators and peer educators.
88819725|NCT02767947|Experimental|Luliconazole Cream 1%|Luliconazole cream 1% will be applied once daily in the morning for 7 days to the area affected with tinea corporis and approximately 1 inch of the immediate surrounding area.
88819726|NCT02767947|Placebo Comparator|Vehicle Cream|Vehicle cream (containing no active ingredient) will be applied once daily in the morning for 7 days to the area affected with tinea corporis and approximately 1 inch of the immediate surrounding area.
88819727|NCT01509950|Active Comparator|Staples|Use of staples for skin closure at cesarean section
88819728|NCT01509950|Active Comparator|Prolene non-absorbable sutures|Use of Prolene non-absorbable sutures for skin closure at cesarean section
88819729|NCT01509950|Active Comparator|Absorbable sutures|Use of absorbable sutures for skin closure at cesarean section; monocryl or vicryl.
88819730|NCT02769351||periph. minimal invasive ultrafiltration|Patients with volume overload receiving ultrafiltration
88819731|NCT02770287|Experimental|Venus Freeze Diamond Polar treatment|Subjects will receive three treatments with the study device, at four week intervals, followed by a one month follow-up visit after the last treatment.
88819732|NCT02770365|Experimental|Test Product|estradiol cream
88819733|NCT02770365|Active Comparator|Reference Product|estradiol cream
88819734|NCT02770365|Placebo Comparator|Placebo product|Placebo cream
88819735|NCT04336449|Experimental|Cohort 1 100 mg eptinezumab|
88819736|NCT04336449|Experimental|Cohort 2 300 mg eptinezumab|
89411238|NCT03576274|Experimental|Technology Enhanced Home Exercise plus|"In additional to the TEHE program, participants will receive auricular point acupressure (APA) training on how to locate the ear points, place the seeds and apply the pressure on the seed.~Participants will be instructed to press the tape and seeds covering each ear point for 3 minutes per time with a 2-second pause in between pressing, three times daily (morning, afternoon and evening: 9 minutes total).~The tape and seeds will remain on ear points for 5 days. Participants will be instructed to remove both at the end of the 5th day."
89411239|NCT03576274|Experimental|Technology Enhanced Home Exercise-Mindfulness intervention|"In addition to the TEHE program, the TEHE+MBI group will receive a audio-recording of a mindfulness-based body scan.~During the weekly study visit: Participants will be instructed to listen to the recorded mindfulness-based body scan in the morning and before bedtime.~At home: Participants will be asked to listen to this audiotape daily in the morning and before bedtime."
89411240|NCT03576274|No Intervention|Control (usual care)|The control group will receive instructions on how to use the physical activity tracker and mEMA application. Participants will be asked to meet with a research team member weekly to discuss their fatigue experience and receive general information about fatigue management.
89411241|NCT03576274|Active Comparator|Auricular Point Acupressure only|"Participants will receive auricular point acupressure (APA) training on how to locate the ear points, place the seeds and apply the pressure on the seed.~Participants will be instructed to press the tape and seeds covering each ear point for 3 minutes per time with a 2-second pause in between pressing, three times daily (morning, afternoon and evening: 9 minutes total).~The tape and seeds will remain on ear points for 5 days. Participants will be instructed to remove both at the end of the 5th day."
89411242|NCT03539068|No Intervention|WEB-ED Only Control Arm|Veterans who screen positive on one or more mental health screens in WEB-ED will be eligible for RCT and those who consent and are randomly assigned to the no intervention control group will receive no further intervention but asked to participate in a subsequent study phase that addresses VA and post-deployment care access
89411243|NCT03539068|Experimental|WEB-ED+ Treatment Arm|"Veterans who screen positive on one or more mental health screens in WEB-ED will be eligible for RCT and those who consent and are randomly assigned to the WEB-ED+ Group. WEB-ED+ augments Current WEB-ED in a next step online interface via Pharos. If successful, this enhancement could be integrated into the next iteration of WEB-ED. Enhancements include:~An eHealth interface tailored to Veterans' VA and MHV enrollment needs, links for an electronic interface with VA enrollment, MHV and MHV premium status enrollment, and secure messaging guidance.~Shared decision making (SDM) interface: Veteran SDM-related educational (e.g., existing YouTube videos) and structured questions about treatment concerns, preferences, and questions and can be accessed through postal and email distribution or Pharos portal.~Access to a health coach (the research coordinators) will be available through a toll-free number to assist both Veterans and providers/Transition Patient Advocates."
89536700|NCT02471027||Experimental group|2009 FIGO staging ⅠB2 or ⅡA2，the treatment is neoadjuvant chemotherapy combined with cervical cancer radical surgery .
88819737|NCT04336449|Placebo Comparator|Placebo|
88887523|NCT04566081|Active Comparator|iTALKbetter: reactive|"Participants will receive the reactive version of the iTALKbetter therapy for 6 weeks. Participants are required to use the therapy for 1.5 hours everyday to reach the required dose of 60 hours over the 6 week period.~iTALKbetter reactive version is identical to the deterministic version for the first cycle only. From then on the words participants are trained on can change depending on their performance on that word over a number of cycles. Words that participants are failing to retrieve over a number of cycles will be retired from the therapy as they are deemed too difficult for a given participant. Similarly words that are correctly retrieved over a number of consecutive cycles are also retired from the therapy as they are deemed to have been learned. In this way iTALKbetter reactive version will gradually give each participant a personalised corpus of words that they can train on, focusing on the words where they stand to make the most improvements."
88887524|NCT04560556||POC Testing Alone|POC HIV testing (the current standard of care) will be conducted for persons entering jail during the first two-month period.
88887525|NCT04560556||POC and 4th Generation Testing|POC plus 4th Generation HIV Testing will be conducted for persons entering jail during the second two-month period.
88887526|NCT04560556||4th Generation Testing Alone|4th Generation HIV Testing will be conducted for persons entering jail during the third two-month period.
88887527|NCT04531566|Experimental|Oral Feed Intervention Group|
88887528|NCT04531566|Active Comparator|Usual care|
88887529|NCT04524221|Experimental|PTG-100|Patients will receive either placebo (fake drug) or PTG-100 (real drug) in capsule form twice daily for 42 days.
88887530|NCT04524221|Placebo Comparator|Placebo|Patients will receive either placebo (fake drug) or PTG-100 (real drug) in capsule form twice daily for 42 days.
88819738|NCT01510652|Active Comparator|Quad Group|Patients in the Quad group will be implanted with St. Jude Medical (SJM) quadripolar Left Ventricular (LV) lead Quartet
88819739|NCT01510652|Active Comparator|BiP Group|Patients in the BiP Group will be implanted with a standard (regulatory approved and commercially available) bipolar left ventricular lead from other companies (non St. Jude Medical leads)
88819740|NCT02770521|Experimental|Treprostinil (Part A)|Treprostinil administered as a single subcutaneous (SC) bolus injection.
88819741|NCT02770521|Placebo Comparator|Placebo (Part A)|Placebo administered as a single SC bolus injection.
88819742|NCT02770521|Experimental|LY900014 (Part B)|LY900014 (test) administered as a single SC bolus injection.
88819743|NCT02770521|Active Comparator|Insulin Lispro (Part B)|Insulin lispro (reference) administered as a single SC bolus injection.
88819744|NCT02346240|Experimental|CZP 200 mg|"Certolizumab Pegol (CZP) subcutaneous (sc) injection 400 mg at Weeks 0, 2, 4, followed by CZP 200 mg every two weeks (Q2W) from Week 6 to Week 14.~The treatment received from Week 16 to Week 48 is based on initial treatment and response to treatment at Week 16:~Subjects with a PASI75 response at Week 16 will be re-randomized to receive either CZP 200 mg Q2W or CZP 400 mg every 4 weeks (Q4W; with Placebo administered on alternate dosing weeks to maintain the blind) or Placebo Q2W.~Subjects who do not achieve a PASI75 response at Week 16 will be removed from blinded study medication and escape to CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study.~Subjects can enter a 96-week open-label extension period after completing the Maintenance Period and receive CZP under certain conditions."
89411244|NCT03508726|Experimental|Phase I dose escalation cohort|Participants will receive radiation therapy over 5 weeks, during which time they will be receiving ascorbate infusions three times a week. Ascorbate infusions will be continued until the end of radiation therapy. Surgery will be performed 4-6 weeks from the end of radiation.
89411245|NCT03508726|Experimental|Phase II Cohort|Participants will receive radiation therapy over 5 weeks, during which time they will be receiving intravenous (IV) ascorbate infusions three times a week. Ascorbate infusions will be continued until the end of radiation therapy. Surgery will be performed 4-6 weeks from the end of radiation.
89411246|NCT03499964|Experimental|Optilume Treatment|The treatment arm will be the Urotronic Optilume Drug Coated Balloon (DCB).
89411247|NCT03499964|Active Comparator|Control Treatment|The control arm will be treated by a urethral dilation method considered to be best standard of care for the study site and subject. A control treatment may be either a rod, uncoated balloon or DVIU.
89411248|NCT03437694|Experimental|Medication Optimization Intervention|This group will represent those participants whose medical records have been provided to the pharmacist.
89411249|NCT03437694|Active Comparator|Medication Optimization Control|This group will represent those participants whose medical records have not been provided to the pharmacist.
89411250|NCT03404661||Pancreas Cancer Subjects|Patients with pancreas cancer will receive Synthetic Human Secretin during an endoscopy procedure.
89411251|NCT03404661||Control Subjects|Controls will receive Synthetic Human Secretin during an endoscopy procedure. Controls are at an elevated risk of pancreas cancer, including pancreatic cystic neoplasms.
89411252|NCT03404661||Familial Pancreatic Cancer Subjects|Subjects who have a family history of pancreas cancer will receive Synthetic Human Secretin during an endoscopy procedure.
89411253|NCT03370172|Experimental|Cohort 1|Cohort 1 participants will receive a single peripheral intravenous (IV) infusion of BAX 888 at a dose of 2.0*10^12 capsid particles per kilogram (cp/kg) on the day of dosing (Day 0).
88887531|NCT04500951|Experimental|Optimized resting environment|"The optimized resting environment will consist of the following complex intervention.~Technically assisted noise control in regards of alarms in the patient room~Visual signing reminding staff that the patient is not to be disturbed during rest~Individual optimization of room environment according to information received from relatives~Individual optimization of room environment and positioning according to systematized knowledge on best practice in the intervention ward including auditory and visual stimuli"
88887532|NCT04500951|Other|Standard resting environment|Standard resting environment, will consist of a basic positioning either reclined in bed or reclined in wheelchair according to regular procedures of the ward.
88887533|NCT04452175|Experimental|HIGH 5%|
88887534|NCT04452175|Active Comparator|LOW 1.7%|
88887535|NCT04444687||SARS-CoV-2-positive 01|SARS-CoV-2-positive patient, no symptoms, low viral load in tracheal aspirate, RNAemia not detectable
88887536|NCT04444687||SARS-CoV-2-positive 02|SARS-CoV-2-positive patient, symptoms, high viral load in tracheal aspirate, RNAemia not detectable
88887537|NCT04444687||SARS-CoV-2-positive 03|SARS-CoV-2-positive patient, symptoms, high viral load in tracheal aspirate, RNAemia detectable
88887538|NCT04444687||Control|Control patients, SARS-CoV-2-negative
88887539|NCT04431622|Experimental|Effects of hearing aid algorithms|Neural processing and cognitive effort will be assessed in individuals who listen to stimuli generated with linear and fast-acting compression hearing aid algorithms and with actual hearing aids.
88887540|NCT04421677|Experimental|Phenylbutyrate|Open-label phenylbutyrate
89411254|NCT03370172|Experimental|Cohort 2|Cohort 2 participants will receive a single peripheral IV infusion of BAX 888 at a dose of 6.0*10^12 cp/kg on the day of dosing (Day 0).
89411255|NCT03370172|Experimental|Cohort 3|Cohort 3 participants will receive a single peripheral IV infusion of BAX 888 at a dose of 1.2*10^13 cp/kg on the day of dosing (Day 0).
89411256|NCT03351803||Participants with Ashkenazi ancestry|
89411257|NCT03279692|Experimental|Pembrolizumab|"Pembrolizumab will be administered every 3 weeks~Pembrolizumab will be administered through IV infusion"
89411258|NCT03276702||Participants|St. Jude Children's Research Hospital patients with relapsed or progressive solid tumor will be asked to complete a questionnaire on two occasions and optional re-biopsy of tumor tissue.
89411259|NCT03152929|Active Comparator|Paravertebral Block|The Paravertebral Block is performed along the spine utilizing ultrasound guided technique (20-30 mL 0.5% Ropivacaine)
89411260|NCT03152929|Active Comparator|Pectoral Nerve Block|The Pectoral Nerve Block is performed anteriorly, at the level of the axillary line, also utilizing ultrasound guided technique (20-30 mL 0.5% Ropivacaine)
89411261|NCT03139266|Experimental|UPLIFT|The Project UPLIFT intervention was designed for delivery to groups of six to eight people by telephone or Internet, though for this study the intervention will be web based only. The telephone intervention comprised eight hour-long sessions, each including check-in, instruction, skill building, and discussion, with homework between sessions. The Web intervention contains the same elements: check-in, video instruction, skill building, a discussion board, and homework between sessions. Instruction focuses on increasing knowledge about depression, cystic fibrosis (CF), cognitive behavioral therapy (CBT), and mindfulness and skills related to CBT and mindfulness.
89411262|NCT03139266|Other|Control Group|Treatment-as-usual
89411263|NCT03100786|Active Comparator|Dexamethasone|standard anti-tuberculosis drugs plus dexamethasone for 6-8 weeks
89411264|NCT03100786|Placebo Comparator|Identical placebo|standard anti-tuberculosis drugs plus placebo for 6-8 weeks
89411265|NCT03047239|Experimental|Open angle glaucoma|SENSIMED Triggerfish
89411266|NCT03011541|Other|Arm 1|BMSC provided retrobulbar, subtenon and intravenous for one or both eyes
89411267|NCT03001882|Experimental|Combination therapy|Nivolumab + Ipilimumab
89411268|NCT02985151|Active Comparator|High Energy Treatment Group|Subjects in this group will receive at least two Syneron-Candela CO2RE laser treatments set at either the Mid mode or the Deep mode of the laser at visits three months apart. Thereafter, individuals in this group will be offered a third optional treatment at one of these settings.
89411269|NCT02985151|Placebo Comparator|Low Energy Placebo Group|Subjects in this group will receive at least two Syneron-Candela CO2RE laser treatments set at the Light mode of the laser at visits three months apart. The Light mode is a low energy setting that superficially cleanses the skin, and would not affect the scar, which is deeper in the skin. Individuals in this group will be offered two optional high energy treatments subsequent to receiving the two light energy treatments.
89411270|NCT02932956|Experimental|GAP T cells + Fludarabine and Cytoxan|GPC3-Car (GAP T cells) along with lymphodepleting chemotherapy (Cytoxan and Fludarabine) will be administered to patients with GPC3-positive solid tumors.
89411271|NCT02891148|Experimental|BI 690517|
89411272|NCT02843165|Experimental|Checkpoint blockade immunotherapy plus SBRT|Checkpoint blockade immunotherapy (CBI) plus stereotactic body radiation therapy (SBRT)
89411273|NCT02843165|Active Comparator|Checkpoint blockade immunotherapy|Checkpoint blockade immunotherapy (CBI) alone
89411274|NCT02833194||Leiden Group|Women with an isolated F5 rs6025 polymorphism or an isolated F2 rs1799963 polymorphism.
89411275|NCT02833194||aP1Ab-positive|"Inclusion in the aP1Ab Group:~Initially positive for aP1Ab~Second positive aP1Ab test six months later"
89411276|NCT02833194||Thrombophilia-negative|Women with completely negative thombophilia screening results.
89411277|NCT02807467|Experimental|Dexmedetomidine|Dexmedetomidine is a potent selective α-2-adrenergic receptor agonist frequently used for sedation in the ICU, also among critically ill patients. It promotes sedation, anxiolysis, and moderate analgesia with minimal respiratory depression and has been shown to reduce severity and duration of ICU delirium.
89411278|NCT02807467|Active Comparator|Propofol|Standard therapy for ICU delirium.
89411279|NCT02795052|Other|Arm 1- Intravenous and Intranasal BMSC|Intervention- Autologous bone marrow aspiration and separation of Bone Marrow Derived Stem Cell (BMSC) fraction then provided intravenously and intranasally (lower 1/3 of nasal passages).
89411280|NCT02794428|Active Comparator|Eflornithine|
89411281|NCT02794428|Placebo Comparator|Eflornithine Placebo|
89411282|NCT02741986||Physicians|"All surgeons and anesthesiologists at large single-center tertiary academic center will be recruited to participate in this study.~Intervention: Risk estimation prior to surgery and immediately after the surgery.~Physicians will be asked to provide their risk scores (ranging from 0 to 100) for postoperative complications prior to surgery and immediately after the surgery for the same patients that IPS is producing the scores. Physicians will provide scores both before and after reviewing the risk scores produced by the IPS."
89411283|NCT02741986||Intelligent Perioperative System (IPS)|"Intelligent perioperative system (IPS) is designed as the set of computer softwares and algorithms that in real-time predict risk for postoperative complications using routine clinical data in electronic health records. The system is designed as the self-learning system with the ability to interact with physicians and solicit their feedback.~Intervention: Risk estimation prior to surgery and immediately after the surgery.~The IPS system will generate risk scores (ranging from 0 to 100) for postoperative complications prior to surgery and immediately after the surgery for patients taken care by the physicians enrolled in the study."
89411284|NCT02740179|Experimental|Eplerenone|Eplerenone 50 mg twice daily along with lifestyle modification (counseling regarding diet and healthy activity) for 12 months
89411285|NCT02740179|Placebo Comparator|Placebo|Placebo twice daily along with lifestyle modification (counseling regarding diet and healthy activity) for 12 months
89411286|NCT02679144|Experimental|Difluoromethylornithine (DFMO)|Subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose of 750 mg/m2 ± 250 mg/m2 BID (strata 1, 2, 3, and 4) OR 2500 mg/m2 BID (stratum 1B) on each day of study.
89411287|NCT02650986|Experimental|Cohort I (cyclophosphamide, TCR/dnTGFbetaRII)|Patients undergo leukapheresis on day -6 and receive cyclophosphamide IV over 2 hours on days -5 and -4. Patients then receive TGFbDNRII-transduced autologous tumor infiltrating lymphocytes IV over 15 minutes on day 0. Eligible patients who showed initial response/disease control, may receive a second TGFbDNRII-transduced autologous tumor infiltrating lymphocytes infusion at any time after progression is confirmed.
89411288|NCT02650986|Experimental|Cohort II (decitabine, cyclophosphamide, TCR/dnTGFbetaRII)|Patients undergo leukapheresis on day -6 and receive decitabine IV over 1 hour on days -6 to -4 and cyclophosphamide IV over 2 hours on days -3 and -2. Patients then receive TGFbDNRII-transduced autologous tumor infiltrating lymphocytes IV over 15 minutes on day 0. Eligible patients who showed initial response/disease control, may receive a second TGFbDNRII-transduced autologous tumor infiltrating lymphocytes infusion at any time after progression is confirmed.
89411289|NCT02619409|Placebo Comparator|Bupivacaine Only|The bupivacaine only group will receive bupivacaine 0.5% 3cc plus sterile saline 0.1cc.
89411290|NCT02619409|Active Comparator|EPI25 group|The EPI25 group will receive bupivacaine 0.5% 3cc, epinephrine 1:1000 0.025cc, and sterile saline 0.075cc.
89411291|NCT02619409|Active Comparator|EPI50 group|The EPI50 group will receive bupivacaine 0.5% 3cc, epinephrine 1:1000 0.05cc, and sterile saline 0.05cc.
89411292|NCT02619409|Active Comparator|EPI75 group|The EPI75 group will receive bupivacaine 0.5% 3cc, epinephrine 1:1000 0.075 cc, and sterile saline 0.025%.
89411293|NCT02619409|Active Comparator|EPI100 group|The EPI100 group will receive bupivacaine 0.5% 3cc, and epinephrine 1:1000 0.1cc
89536701|NCT02471027||control group|2009 FIGO staging ⅠB2 or ⅡA2，the treatment is cervical cancer radical surgery.
89536702|NCT02470793|Active Comparator|DSAEK group|Subjects operated of Descemet Stripping Automated Endothelial Keratoplasty.
89411294|NCT02582866|Experimental|Lacosamide|"Lacosamide (LCM) will be administered orally twice daily from 200 mg/day to 600 mg/day (at approximately 12 hour intervals in the morning and in the evening) in 2 divided doses. Medication must not be chewed and must be swallowed with a sufficient amount of fluid. The investigator may maintain the subject's LCM dose, decrease the dose in decrements of 100 mg/day per week to a minimum dose of LCM 200 mg/day, or increase the dose in increments of 100 mg/day per week up to a maximum dose of LCM 600 mg/day.~Subjects stopping LCM should be tapered off LCM at recommended decreasing steps of 200 mg/day/week. A slower taper (eg, 100 mg/day/week) or faster taper is permitted, if medically necessary; however, the maximum duration of tapering should not exceed 6 weeks."
89411295|NCT02559778|Active Comparator|Standard Immunotherapy without DFMO|One of the following drugs will be chosen for each subject based on molecular guided results: ceritinib, dasatinib, sorafenib or vorinostat. This will be followed standard immunotherapy with Dinutuximab/GM-CSF/IL-2 and isotretinoin. At the end of immunotherapy, DFMO will be given to all subjects BID for 730 days.
89411296|NCT02559778|Active Comparator|Standard Immunotherapy with DFMO|One of the following drugs will be chosen for each subject based on molecular guided results: ceritinib, dasatinib, sorafenib or vorinostat. This will be followed standard immunotherapy with Dinutuximab/GM-CSF/IL-2 and isotretinoin PLUS 1000mg/m2 BID of DFMO. At the end of immunotherapy, all subjects will go on to receive DFMO BID for 730 days.
89411297|NCT02512432|Other|Keratoconus|
89411298|NCT02491476|Experimental|micro-macroelectrodes|All patients will be implanted with usually 4 intracerebral micro-macroelectrodes(replacing the regular clinical macroelectrodes). The primary and secondary outcomes will then be assessed.
89411299|NCT02465307||Delirium group|ICU patients with a positive Confusion Assessment Method (CAM) score; observational using accelerometers, commercially available camera, and Internet Pod (iPod).
89411300|NCT02465307||Control group|ICU patients with a negative Confusion Assessment Method (CAM) score; observational using accelerometers, commercially available camera, and Internet Pod (iPod).
89411301|NCT02465307||Healthy control group|Healthy subjects that sleep in their home environment; observational using accelerometers, cortisol swabs, and Internet Pod (iPod)
88887541|NCT04413240|Experimental|Telerehabilitation group|"Patients in this group will undergo 20 sessions (1 hour a day, 5 days a week for 4 consecutive weeks) of multidomain telerehabilitation (motor, speech and/or cognitive) with VRRS, K-Wand and Khymu connected to a workstation (Telecockpit)."
88887542|NCT04413240|Active Comparator|Conventional rehabilitation group|"The patients assigned to this group will undergo 20 sessions (1 hour a day, 5 days a week for 4 consecutive weeks) of multidomain rehabilitation (motor, speech and/or cognitive). It is not possible a priori to precisely define the instruments that will be used during rehabilitation management. The telerehabilitation or conventional treatment methods (type of therapeutic exercise, modality of cognitive stimulation and/or taking care of speech therapy) will be determined for each patient on the basis of the needs emerging from the physiatric examination performed at T0, defined according to the Individual Rehabilitation Project and applied according to each Rehabilitation Program (motor, cognitive and/or speech therapy) periodically updated."
88887543|NCT04399200||Sleep-disordered breathing group|Sleep-disordered breathing (SDB) patients (AHI>15/h, measured by polysomnography performed 3 months after stroke)
88887544|NCT04399200||Control group|Control patients with no SDB (AHI<15/h, measured by polysomnography performed 3 months after stroke)
88887545|NCT04347538|No Intervention|Control Group, No intervention|control group, no nasal irrigation
88887546|NCT04347538|Experimental|Saline Nasal Irrigation|Nasal irrigation BID with normal saline
88887547|NCT04347538|Experimental|Saline with Baby Shampoo Nasal Irrigation|Nasal irrigation BID with normal saline and 1/2 teaspoon baby shampoo
88887548|NCT04340206|Experimental|face-to-face support and Chatbot online support group|Experimental, Intervention Group A: face-to-face support and Chatbot online support group: 5-week intervention according to ACT principles with the web- and mobile-based Youth Compass plus program, face-to-face support (2 meetings) and weekly online support and feedback from the Chabot eCoach built within the program (one third of the participants is randomly assigned to this group)
88887549|NCT04340206|Experimental|only chat-robot online support group|Experimental, Intervention Group B: only chat-robot online support group: 5-week intervention according to ACT principles with the web-and mobile-based Youth Compass plus program, no face-to-face support, and weekly online support and feedback from the chatbot eCoach built within the program (one third of the participants is randomly assigned to this group)
88887550|NCT04340206|Experimental|Experimental Control|"Experimental Control:~Control group, no intervention (one third of the participants is randomly assigned to this group)"
88887551|NCT04334031|Experimental|IMMINeNT cohort|
88887552|NCT04323501|Experimental|Experimental treatment group|"This group will undergo an intensive-rehabilitation treatment of post-stroke sensorimotor disability based on a guided self-rehabilitation contract. This approach is based on the fact that the patient must complete a diary of his self-rehabilitation activity in order to verify its correct and full execution. The treatment protocol will be defined on the basis of the clinical picture (patterns) manifested by the patient (the intensity and frequency of the exercises will be adapted according to the characteristics of each patient). The duration of treatment will be the same for all patients. The exercises will be performed every day throughout the study period (12 months).~Before undertaking the intensive self-management treatment, each patient will undergo 10 sessions of neurorehabilitation treatment at the UOC Neurorehabilitation of the Integrated University Hospital according to normal clinical practice, during which the patient will be provided with infographic support material."
89411302|NCT02453373|Experimental|ThermoSuit Cooling Induction|Induction of therapeutic hypothermia (32-34 degrees C) using the LRS ThermoSuit System. Prior to initiating hypothermia, Magnesium Sulfate will be administered intravenously to control shivering and tPA administered intravenously (if indicated). Induction doses of propofol or etomidate will be used to aid in the suppression of patient discomfort. Neurothrombectomy will be performed if indicated.
89411303|NCT02453373|No Intervention|Historical Control|Historical patients treated for ischemic stroke using conventional medical treatments, but without induced hypothermia.
89411304|NCT02452008|Experimental|Arm 1: Enzalutamide with LY2157299|
89411305|NCT02452008|Experimental|Arm 2: Enzalutamide alone|
89411306|NCT02450318|Experimental|Slow-paced walking|Subjects will complete 47 minutes of walking at slow pace.
89005188|NCT02962206|Active Comparator|Standard of care|Patients will undergo standard closed fracture reduction. The sedation type, reduction method, and immobilization method will be at the discretion of the treating physician. Point-of-care ultrasound will not be used.
89005189|NCT02962206|Experimental|Experimental Group|Patients will undergo standard closed fracture reduction with the addition of point-of-care ultrasound use to assess post-reduction dorsal angulation. The sedation type, reduction method, and immobilization method will be at the discretion of the treating physician.
89005190|NCT00229437|Experimental|TAK-128 5 mg QD|
89005191|NCT00229437|Experimental|TAK-128 50 mg QD|
89005192|NCT00229437|Experimental|TAK-128 100 mg QD|
89005193|NCT00229437|Placebo Comparator|Placebo QD|
89005194|NCT00205829|Experimental|Active Therapy|Occipital nerve stimulation (ONS) therapy delivered to a subject implanted with a bion ONS device
89005195|NCT00205907|Experimental|single|BLVR treatment
89411307|NCT02447874|Experimental|Standard dose|Subjects with sickle cell disease (SCD) and vaso-occlusive painful events (VOE) will be randomized to receive an intravenous (IV) infusion of a standard dose of arginine (100 mg/kg) three times a day for seven days or until discharged from the hospital, whichever occurs first
89411308|NCT02447874|Experimental|Loading dose + standard dose|Subjects with sickle cell disease and vaso-occlusive painful events (VOE) will be randomized to receive an intravenous (IV) infusion of an initial loading dose of arginine (200 mg/kg) given over 30 minutes and then receive an intravenous (IV) infusion of a standard dose of arginine (100 mg/kg) three times a day for seven days or until discharged from the hospital, whichever occurs first
89411309|NCT02447874|Experimental|Loading dose + continuous infusion|Subjects with sickle cell disease and vaso-occlusive painful events (VOE) will be randomized to receive an intravenous (IV) infusion of an initial loading dose of arginine (200 mg/kg) given over 30 minutes and then receive a continuous intravenous (IV) infusion of 300 mg/kg/24hr for 7 days or until discharged from the hospital, whichever occurs first
89411310|NCT02402582|Experimental|Family-Centered Empowerment Model|Have the same in-patient, pre-intervention, and post-intervention follow-up care as Control Group. However, rather than routine care and follow-up during the intervention period, they recieved than 4 stage intervention using the Family Centered Empowerment Model.
89411311|NCT02402582|Active Comparator|Control|Same in-patient, pre-intervention, and post-intervention follow-up care as Experimental Group. However, rather than 4 stage intervention they receive routine care and follow-up.
89411312|NCT02365051|No Intervention|usual care|Older adults with dementia and their family caregivers receive all services for which they are eligible in the Connecticut Home Care Program for Elders.
89005196|NCT00205946|Placebo Comparator|Placebo|
89411313|NCT02365051|Experimental|COPE plus usual care|Older adults with dementia and their family caregivers receive Usual care plus the intervention: Care of Persons with Dementia in their Environments.
89411314|NCT02098161|Experimental|Treatment (SMAC mimetic LCL161)|Patients receive SMAC mimetic LCL161 PO on days 1, 8, 15, and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89411315|NCT01734928|Experimental|Pomalidomide, Bortezomib and Low Dose Dexamethasone|4 mg of Pomalidomide will be taken orally on Days 1-14 of a 21-day cycle along with 1.3 mg/m2 of Bortezomib administered subcutaneously on Days 1, 4, 8 and 11 of 21 days for cycles 1 -8 and on days 1, 8 of 21 days for cycle 9 and onward until disease progression, and Dexamethasone 20 mg/day [≤ 75 years old] or 10 mg/day [> 75 years old] orally on days 1, 2, 4, 5, 8, 9, 11, 12 of 21 days for cycles 1-8 and on days 1, 2,8, 9 of 21 days for cycles 9 and onward until disease progression.
89536703|NCT02470793|Experimental|DMEK group|Subjects operated of Descemet Membrane Endothelial Keratoplasty.
89005197|NCT00205946|Active Comparator|Bupropion|
89005198|NCT00229515|Active Comparator|1|Patients will receive abciximab infusion at standard regimen prior undergoing percutaneous coronary intervention for STEMI followed by BMS implantation in the culprit lesion
89005199|NCT00229515|Experimental|2|Abciximab followed by implantation of sirolimus-eluting stent in the culprit lesion
89005200|NCT00229515|Experimental|3|tirofiban infusion followed by bare metal stent implantation
89005201|NCT00229515|Experimental|4|tirofiban and sirolimus-eluting stent
89005202|NCT00229554||Group 1|Male and female veterans age 50-75 who have had one or more primary care visits at a VA Medical facility in the past two years.
89005203|NCT00229593|Active Comparator|1|100 mg Testosterone gel daily for 3 weeks
89005204|NCT00229593|Active Comparator|2|2 mg Nestorone gel daily for 3 weeks
89005205|NCT00229593|Active Comparator|3|4 mg Nestorone gel daily for 3 weeks
89005206|NCT00229593|Active Comparator|4|100 mg Testosterone gel + 2 mg Nestorone gel
89005207|NCT00229593|Active Comparator|5|100 mg Testosterone gel + 4 mg Nestorone gel
89005208|NCT00229593|Active Comparator|6|100 mg Testosterone Gel + 6 mg Nestorone Gel daily for 3 weeks
89005209|NCT00229593|Active Comparator|7|100 mg Testosterone Gel + 8 mg Nestorone gel daily for 3 weeks
89005210|NCT00229671|Experimental|Patients with prescriptions under 21|Pediatric visits with prescriptions. These patients parents will be given survey 1.
89005211|NCT00229671|Experimental|Patients who completed Survey 1|Patients with prescriptions under 21 whose parents complete survey 1 will be given survey 2
89005212|NCT00411203|Active Comparator|Tamoxifen Citrate|
89005213|NCT00411203|Placebo Comparator|Placebo|
89411316|NCT01734928|Active Comparator|Bortezomib and Low Dose Dexamethasone|1.3 mg/m2 of Bortezomib will be administered subcutaneously on Days 1, 4, 8 and 11 of 21 days for cycles 1 -8 and on Days 1, 8 of 21 days for cycle 9 and onward until disease progression along with Dexamethasone 20 mg/day [≤ 75 years old]or 10 mg/day [> 75 years old] orally on days 1, 2, 4, 5, 8, 9, 11, 12 of 21 days for cycles 1-8 and on Days 1, 2, 8, 9 of 21 days for cycles 9 and onward until disease progression.
89005214|NCT00411281|Experimental|Group I|Patients receive very low-dose cytarabine subcutaneously twice daily on days 1-7. Treatment repeats every 14 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients achieving stable disease or complete or hepatic clinical remission undergo observation.
89005215|NCT00411281|Other|Group II|Patients are observed. If symptoms of intermediate- or high-risk disease develop, patients may crossover to group I.
89005216|NCT00206414|Experimental|Iressa Day 1 with Arimidex and Faslodex|Subjects randomized to Iressa on Day 1 in combination with Arimidex and Faslodex.
89005217|NCT00206414|Active Comparator|Iressa Day 21 with Arimidex and Faslodex|Subjects randomized to Iressa Day 21 in combination with Arimidex and Faslodex
89411317|NCT01682616|Experimental|Arm 1|Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
89005218|NCT00206492|Experimental|Iressa and Tamoxifen|Iressa and Tamoxifen
89005219|NCT00413595||Observation|Adult patients (18 - 55 years of age) with an acute cerebrovascular event of any etiology and the genetic diagnosis (a-galactosidase defect) of Fabry disease
89005220|NCT00206648|Experimental|Arm 1|
89005221|NCT00206648|Active Comparator|Arm 2|
89005222|NCT01056159|Experimental|Albuterol dry powder inhaler|The participants will receive albuterol delivered with the a DPI (dry powder inhaler) and placebo with an HFA MDI inhaler (hydrofluoroalkane metered dose inhaler).
89005223|NCT01056159|Active Comparator|Albuterol HFA MDI|The participants will receive albuterol delivered with an HFA MDI inhaler (hydrofluoroalkane metered dose inhaler) and placebo with albuterol in a DPI (dry powder inhaler).
89005224|NCT00232791|Experimental|1|CYPHER SELECT™ Sirolimus-eluting Coronary Stent
89005225|NCT00232791|Active Comparator|2|CYPHER™ Sirolimus-eluting Coronary Stent
89411318|NCT01644747|Active Comparator|active tDCS|a group named G1 and treated by medication with SSRIs (Selective Serotonin Reuptake Inhibitors) or SNRIs (Serotonine-Norepinephrine Reuptake Inhibitors) for 48 unipolar patients or with Lithium for 12 bipolar patients stabilized for at least 4 months and 10 sessions of active anodal tDCS at 2 sessions per day (1 morning and 1 afternoon with a gap of 3h) for 5 days with an electric current 2 mA.
89411319|NCT01644747|Sham Comparator|sham tDCS|a group named G2 and treated by medication with SSRIs or SNRIs for 48 unipolar patients or with Lithium for 12 bipolar patients stabilized for at least 4 months and sham tDCS.
89411320|NCT01430572|Experimental|Pazopanib + Everolimus|Pazopanib 200 mg and Everolimus 5.0 mg oral dosing every other day (except for lead in 5 days of Cycle 1 where both drugs administered daily).
89411321|NCT01224288|Experimental|DCE-CT Scans|DCE-CT = Dynamic contrast enhanced CT - DCE-CT scans 4 weeks prior to and 8 weeks after starting treatment on study 2010-0085.
89005226|NCT00424710|Other|Single Arm study|"Single arm study:~Drug: ranibizumab intravitreal injection liquid, 0.5 mg ranibizumab intravitreally, once a month for 1 year"
89192189|NCT02553993|Experimental|Tetrax biofeedback|"The Tetrax biofeedback games aimed at postural rehabilitation to help patients or athletes improve their balance abilities. There were 11 games in Tetrax system; 8 games (Speedtrack, Catch, Skyball, Gotcha, Speedball, Tag, Freeze, Immobilizer) were chosen based on the same principle as those used for choosing Wii Fit games. The parameters of games' difficulties included target size and/or speed of target movement, which could be adjusted according to the patients' ability.~For the Wii Fit or Tetrax group, at each session, the supervising therapist chose 3 to 5 games for participants according to their ability, needs, and favorites."
89411322|NCT00950430|Experimental|PiB PET, FDG PET, Tau PET|
89005227|NCT00206843|Experimental|Results available|
89005228|NCT00206843|No Intervention|Results blinded|
89005229|NCT00232830|Experimental|1|Cypher Sirolimus-eluting Coronary Stent
89005230|NCT00232830|Active Comparator|2|Bare-metal stent
89005231|NCT00206960|Active Comparator|1|
89005232|NCT00206960|Active Comparator|2|
89005233|NCT00232869|Experimental|1|Sirolimus Coated Cordis SMART™ nitinol selfexpandable stent
89005234|NCT00232869|Active Comparator|2|SMART™ bare-metal stent
89411323|NCT00909051||Group 1|
89005235|NCT00206999|Experimental|1|
89005236|NCT00207077|Experimental|A|
89005237|NCT00229983|Experimental|Motivational Enhancement Therapy|Adolescents who are randomized to the experimental intervention will attend three 60-minute counseling sessions, delivered 2-4 weeks apart. The intervention will include a structured, developmentally appropriate, approach to identification of drug- and alcohol-related risks and problems, and establishment of goals for behavioral change.
89005238|NCT00229983|No Intervention|Enhanced Standard Care|Adolescents who are randomized to Enhanced Standard Care will receive the usual care at the outpatient adolescent substance abuse program. This will include an evaluation by pediatric and mental health staff and could include treatment in a group therapy program, urine drug testing, buprenorphine replacement therapy (for those dependent on opioids), and psychopharmacology evaluation and management.
89005239|NCT00207116|Experimental|A|
89005240|NCT00232908|Experimental|1|
89005241|NCT00207155|Experimental|A|
89005242|NCT00413673|Experimental|1|PRK
89411324|NCT00787865||Krabbe Disease|Children with infantile Krabbe disease
89411325|NCT00787865||Low Enzyme/No Krabbe Disease|Children without disease who have low enzyme levels
89411326|NCT00787865||Control|Children with no disease and normal enzyme levels
89411327|NCT00787865||Motor Disability|Children at risk of developing motor disability
89411328|NCT00724607||TBI (Case) Group|Members of the TBI group have sustained a TBI in accordance with inclusion/exclusion criteria. However, the investigative staff administering, scoring, analyzing and interpreting the data will be blinded to the group status of the participant.
89411329|NCT00724607||Non-TBI (Control) Group|Members of the Non-TBI group have not sustained a TBI and are in accordance with other provisions of the inclusion/exclusion criteria. However, the investigative staff administering, scoring, analyzing and interpreting the data will be blinded to the group status of the participant. This longitudinal study will utilize a control group to account for normal aging and other control factors.
89411330|NCT00724607||Non-TBI Non-deployed (Control) Group|Members of the Non-TBI Non-Deployed group have neither sustained a TBI nor have been deployed but are in accordance with other provisions of the inclusion/exclusion criteria. However, the investigative staff administering, scoring, analyzing and interpreting the data will be blinded to the group status of the participant. This longitudinal study will utilize this Non-deployed control group to account for deployment-specific factors.
89411331|NCT00667459|Experimental|Investigational|PRESTIGE® LP Cervical Disc
89411332|NCT00667459|Active Comparator|Control|Control patients who received a ACDF fusion treatment from a previous IDE trial (NCT00642876)
89411333|NCT00546429||A|Monitoring of trochanteric fractures after treatment with the ATN system.
89411334|NCT00453544|Experimental|Enhanced consent - A|The intervention was an enhanced consent process, including a multimedia aid for a moderate risk hypothetical protocol
89411335|NCT00453544|Experimental|Enhanced consent - B|The intervention was an enhanced consent process, including multimedia aide for a higher risk hypothetical protocol
89411336|NCT00453544|Active Comparator|Routine consent - A|This was a comparison condition - a routine consent process, including a printed consent document, for a moderate risk hypothetical protocol
88887553|NCT04323501|Active Comparator|Control group|The patients allocated to the control group, during the study period they will undergo conventional outpatient rehabilitation treatment (usual care) at the Neurorehabilitation Unit of the AOUI according to the clinical practice through the procedures provided for by the Health System National.
88887554|NCT04318951|Experimental|Intensive communicative-pragmatic social interaction.|Intensive Language-Action Therapy (ILAT).
88887555|NCT04318951|Other|Standard care.|All participants will receive standard care.
88887556|NCT04308928||Children with suspected meningitis|Patients must have a clinical diagnosis of meningitis including one or more of the following symptoms: headache, irritability, vomiting, fever and neck stiffness (Table 1). The diagnosis of probable or possible TBM is based on 1) clinical findings 2) CSF results 3) neuroimaging findings 4) evidence for TB outside the central nervous system and 5) additional laboratory criteria. A scoring system then determines whether a patient falls in the probable or possible TBM category. Points are allocated for a positive finding in each of the categories, with a maximum score for each category. A total score of at least 10 is compatible with probable TBM, while a total score of at least 6 equates with a possible TBM diagnosis.
88887557|NCT04308928||Children with definite tuberculous meningitis|Definite TBM requires demonstration of acid- fast bacilli in the CSF, Mycobacterium tuberculosis culture from CSF, a positive nucleic acid amplification test (PCR) of CSF or histopathological evidence of Mycobacterium tuberculosis from a central nervous system site.
88887558|NCT04293601|Experimental|Experimental group|"All enrolled neonates will receive interventions that will be performed with different frequency and method according to newborns' risk factors, as well as the following standard interventions received by control group's newborns:~appropriate use of hydrocolloid, headbands, masks and prongs~frequently assess skin integrity~humidity and heat gases"
88887559|NCT04293601|Other|Standard care|"Newborns have received the interventions according to local protocol (standard nursing care) in 2018, as detailed in the assigned intervention"
88887560|NCT04257565|Active Comparator|Control group|The Control Group will receive usual and customary care from their vascular specialist.
89192190|NCT02553993|Placebo Comparator|Conventional weight-shifting|The conventional weight-shifting exercise group performed balance exercises with the similar movements and time required by the 2 exergame systems but without video games. By using occupational activities, participants did weight shifting in the sagittal and frontal planes. The investigators also used a balance board (Reebok Core board) for multi-directional weight shifting training
89192191|NCT04065230||TAF antiviral therapy group|
89192192|NCT00728078|Experimental|1|low-dose thalidomide adjuvant therapy after RFA for HCC
89192193|NCT00728078|No Intervention|2|control group
89411337|NCT00453544|Active Comparator|Routine consent - B|This was a comparison condition - a routine consent process, including a printed consent document, for a higher risk hypothetical protocol
89411338|NCT00280657|Experimental|Arm 1|
89411339|NCT00280657|Active Comparator|Arm 2|
89411340|NCT00280657|Placebo Comparator|Arm 3|
89411341|NCT05421520|Experimental|A novice with ai-assisted assistance|When patients are randomly assigned to the experimental group, the visiting physician will perform endoscopic ultrasound with the assistance of the ai-assisted system
89411342|NCT05421520|No Intervention|A novice without ai-assisted assistance|When the patients were randomly assigned to the control group, the visiting physician would not perform endoscopic ultrasonography with the assistance of the AI-assisted system
89411343|NCT03514862|Experimental|Intervention|Participants will participate in 4 weeks of the Mindfulness-Based Intervention (MBI) and then will be invited to continue to participate in 4 additional Mindfulness Booster Training.
89411344|NCT03514862|Active Comparator|Control|Participants will participate in 4 weeks of the Mindfulness-Based Intervention (MBI) and then continue to Self-Practice for 4 weeks.
89411345|NCT03103516|Experimental|early epidural decompression group|The patients will be assigned to early (within 24 hours after spinal cord injury) epidural decompression group (n=100) according to the patient's condition and operation time.
89411346|NCT03103516|Experimental|delayed epidural decompression group|The patients will be assigned to delayed (exceed 24 hours after spinal cord injury) epidural decompression group (n=100) according to the patient's condition and operation time.
88887561|NCT04257565|Experimental|Intervention Group|The Intervention Group will receive usual and customary care from their vascular specialist and they will be provided and trained to use the wheeled knee walker.
88887562|NCT04223362|Experimental|Pulmonary rehabilitation + Community-based physical activity programme|After pulmonary rehabilitation, the experimental group will integrate a community-based physical activity programme.
88887563|NCT04223362|Active Comparator|Pulmonary Rehabilitation|The control group will only receive pulmonary rehabilitation, which integrates physical activity recommendations.
88887564|NCT04203472|Experimental|Budesonide or budeosonide/formoterol administered by DPI|In every patient cough severity and tolerance of therapy will be analyzed during therapy with budesonide and/ or formoterol administered by DPI for 14 days
88887565|NCT04203472|Active Comparator|Budesonide or budeosonide/formoterol administered by MDI|In every patient inhaler will be changed and cough severity and tolerance of therapy will be analyzed during therapy with the same drugs administered by MDI . Order of using different types of inhalers will be accidental
88887566|NCT04168814||Oncology patients (Immunotherapy alone or in combination))|"Outpatients, over 18 years old, with locally advanced or metastatic solid tumors (with the idea of homogenizing the sample as far as possible and in line with what has been published up to now, also stratified in line with Globocan).~Patients under targeted active treatment either exclusively or in combination with chemotherapy or radiotherapy. Targeted therapy (immunotherapy) defined with: PD1, PDL1 inhibitors. At least 12 weeks of treatment."
88887567|NCT04168814||Oncology Patients (Chemo-Radiotherapy group).|"Outpatients, over 18 years old, with locally advanced or metastatic solid tumors (with the idea of homogenizing the sample as far as possible and in line with what has been published up to now, also stratified in line with Globocan).~Patients under active treatment either in combination with chemotherapy or radiotherapy. At least 12 weeks of treatment."
88887568|NCT04134871|Experimental|Intervention group|Participants randomised to the intervention group will be invited to attend a group education session where they will be given a step counter and activity diary, they will be invited to weekly group walks and fortnightly coaching 1-1 sessions aimed at setting and reviewing goals to increase physical activity and reduce sedentary behaviour
88887569|NCT04134871|No Intervention|Control group|Participants randomised to the control group will be given an information leaflet about being more active during a one-off 1-1 consultation.
88887570|NCT04072146|Experimental|Varenicline oral tablet 1mg, then OC-01 (varenicline solution) nasal spray 0.12 mg|OC-01 0.12 mg was administered intranasally 50 ul into each nostril in a fasted state
88887571|NCT04072146|Active Comparator|OC-01 (varenicline solution) nasal spray 0.12 mg, then Varenicline oral tablet 1 mg|Varenicline oral tablet 1mg was administered orally in a fasted stated with 200 ml water
88887572|NCT04058847|Experimental|Intervention|Use of Your Heart Forecast and an e-mail follow up-program.
88887573|NCT04058847|No Intervention|Control|The control group uses standard regime (business as usual).
88887574|NCT04040153|Experimental|Guiding Good Choices|Enrollment in the intervention, Guiding Good Choices, a substance use initiation prevention program, will be recommended by the pediatrician to parents of those adolescents empaneled with an intervention arm pediatrician
88887575|NCT04040153|No Intervention|Control|Parents of adolescents empaneled with a control arm pediatrician will not be offered Guiding Good Choices
88887576|NCT04001972|Experimental|Intervention group|Brief advice (AWARD model) + NRT-S + IM Apps and Chatbot
88887577|NCT04001972|Active Comparator|Control group|Brief advice (AWARD model) + regular SMS
88887578|NCT03987906|Experimental|Symptom screening with Targeted Early Palliative Care (STEP)|The experimental arm receives routine symptom screening at every outpatient visit; if symptoms are above a certain threshold, then a triggered email is sent to a triage nurse, who calls the patient to offer early referral to and follow-up by a symptom control and palliative care team.
88887579|NCT03987906|No Intervention|Standard Oncology Care|The control arm receives standard oncology care, which includes routine symptom screening at every outpatient visit.
88887580|NCT03963570|Experimental|Safe Step - digital exercise program|Participants randomized to the experimental group will receive full access to the Safe Step application and create their own individual program of strength and balance exercises. During 1 year the participants are recommended to exercise at least 30 minutes, 3 times a week and continuously progress their program. In addition they will every month receive an email with general falls prevention information in a short video.
88887581|NCT03963570|Other|Control group|During 1 year, the participants randomized to the control group will receive an email every month with general falls prevention information in a short video.
88887582|NCT03945084|Experimental|Experimental Arm|Patients assigned to experimental arm will receive Niraparib 300 mg or 200 mg daily (based on weight and platelet count) plus best supportive care (BSC), in 28-day cycles, until disease progression or unacceptable toxicity or death.
88887583|NCT03945084|Other|Control Arm|Patients assigned to control arm will receive best supportive care alone, until disease progression or death.
88887584|NCT03920241||MBSR group|Attendants to Mindfulness-Based Stres Reduction programs offered to the community by Complutense University
88887585|NCT03920241||CCT group|Attendants to Compassion Cultivation Training programs offered to the community by Complutense University
89192194|NCT00653991|Experimental|SOLVE-IT|Participants will receive the intervention SOLVE-IT. The SOLVE-IT intervention is a videogame designed to optimize self-regulation, reduce shame, and reduce risky choices for young men who have sex with men (YMSM).
88887586|NCT03920241||Control group|Control group matched by age, gender, and meditation experience.
88887587|NCT03896191||Stable, satisfied primary TKR|Participants who have a stable TKR (as assessed by the surgical team) and are satisfied with their knee replacement (as assessed by a questionnaire).
88887588|NCT03896191||Unstable, dissatisfied primary TKR|Participants who are dissatisfied with their TKR, with instability (including instability due to aseptic loosening) and consequently awaiting revision TKR.
89192195|NCT00653991|Active Comparator|Waitlist Control|Participants will receive the intervention, SOLVE-IT, a video game designed to optimize self-regulation reduce shame, and reduce risky sexual choices for YMSM, after a 6-month waitlist period.
89411347|NCT02298140|Experimental|SMS reminders|This arm will receive automated mobile phone text message reminders for health workers in outpatient departments of public and private health facilities on issues related to care of malaria patients and suspected patients.
89411348|NCT05089396|Active Comparator|conventional dentally anchored maxillary protraction|A petit facemask will be used for maxillary protraction along with a facemask splint (two acrylic bite blocks connected through a transpalatal arch). a force of 380 gm to 400 gm will be applied through the extra-oral elastics the will be attached to the facemask on one side and to the facemask splint on the other side.
89411349|NCT05089396|Experimental|skeletally anchored maxillary protraction|A petit facemask will be used for maxillary protraction along with a facemask splint (two acrylic bite blocks connected through a transpalatal arch) in addition, two miniscrews will be inserted in the anterior region of the palate one on each side of the midline to provide skeletal anchorage for the facemask splint. a force of 380 gm to 400 gm will be applied through the extra-oral elastics the will be attached to the facemask on one side and to the facemask splint on the other side.
89411350|NCT02303210|Other|hearing aid NaidaUP|Within subject design: compare frequency lowering one with frequency lowering two.
89411351|NCT02303210|Other|hearing aid NaidaSP|Within subject design: compare frequency lowering one with frequency lowering two.
89411352|NCT05076994|Experimental|Patient Education Tool|
89411353|NCT05076994|Active Comparator|Standard Care|
89411354|NCT03510572|Experimental|Healthy volunteer|Cognitively healthy subjects will receive a single IV injection of [18F]PI-2620.
89411355|NCT03510572|Experimental|Alzheimer's Disease|Alzheimer's Disease Subjects will receive a single IV injection of [18F]PI-2620.
89411356|NCT03510572|Experimental|Frontotemporal dementia|frontotemporal dementia Subjects will receive a single IV injection of [18F]PI-2620.
89411357|NCT03510572|Experimental|Parkinson's disease|Parkinson's disease Subjects will receive a single IV injection of [18F]PI-2620.
89411358|NCT03511274|Experimental|Hygiene based educational film|Women randomised to receive the CMV educational intervention will fill in a questionnaire and view the film. The website will also contain interactive information about CMV and how to prevent it. After watching the film and reading the information, women will be asked to fill in a post-intervention questionnaire. The website will be accessible via the participants' own mobile device or computer or dedicated study tablets or computers on-site. Using a web-based intervention, we will be able to monitor use of the educational intervention and also collect data in real time.
89411359|NCT03511274|No Intervention|Treatment as usual (TAU)|Women who are randomised to the TAU group will also be asked to log-on the website. Instead of receiving specific information about prevention of CMV in pregnancy, they will receive information about routine antenatal immunisation. In the UK, the Department of Health recommends that all pregnant women should be offer immunisation against pertussis (whooping cough) and influenza (if pregnant during the influenza session). This will ensure that participants in the TAU arm of the study also derive benefit from the study.
89411360|NCT05030896|Experimental|Experimental group|Participants will receive EPM and they will perform exercise program during 1 month.
89411361|NCT05030896|Experimental|Control group|Participants will receive needling puncture and they will perform exercise program during 1 month.
89411362|NCT03510494|Experimental|Intervention|Trebling of weekly curricular physical education (270 minutes per week)
89411363|NCT03510494|No Intervention|Control|Standard curriculum physical education (90 minutes per week)
89005243|NCT00207194|Active Comparator|Automated Telephone Program|The intervention was a totally automated, computer-based, interactive telephone counseling system called Telephone- Linked-Care, designed to monitor, educate, and counsel African-American adults with hypertension and to provide summary data regularly to the patient's primary care provider.
89005244|NCT00207194|Placebo Comparator|Health Behavior Education|The comparator group received health education relating to the management of hypertension. Members of this group also received standard primary medical care.
89005245|NCT00207233|Active Comparator|1|Will receive MCT study oil to supplement into liquid meal replacements.
89005246|NCT00207233|Placebo Comparator|2|Will receive LCT oil to supplement into their liquid meal replacements.
89411364|NCT05015608|Experimental|Savolitinib + Osimertinib|Savolitinib orally once per day (QD) + Osimertinib orally QD,21day cycles (every 3 weeks)
89411365|NCT05015608|Active Comparator|Pemetrexed combined with platinum|Pemetrexed combined with platinumon on Day 1 of 21day cycles (every 3 weeks)
89411366|NCT02301260|Experimental|Speed of Processing Training (SPT)|SPT will be administered on a laptop computer twice a week for 5 weeks (10 training sessions).
89411367|NCT02301260|Placebo Comparator|Placebo control group|Placebo control exercises will be administered on a laptop computer twice a week for 5 weeks (10 sessions)
89411368|NCT05009836|Experimental|Savolitinib|Savolitinib 600 mg or 400 mg QD orally +Osimertinib 80 mg QD orally ( every 3 weeks)
89411369|NCT05009836|Placebo Comparator|placebo|placebo 600 mg or 400 mg QD orally+ Osimertinib 80 mg QD orally ( every 3 weeks)
89411370|NCT03510416|Experimental|apatinib combined with TACE|Apatinib is administered after TACE 4-7 days, and TACE treatment is performed after discontinuation of apatinib for 4 days.Every 28 days is a cycle.
89411371|NCT03507920|Experimental|Neck passive mobilizations|
89411372|NCT03507920|Placebo Comparator|Manual contact|
89411373|NCT02301338||Usual Care|"The patient will get instructions on: - Follow-up appointment date/time with your surgeon - Proper diet - Medications - Communicating concerning symptoms with the surgeon~The patient will answer questions on:~Social support~Quality of life"
89411374|NCT02301338||Phone Calls|"In addition to what the usual care group gets, the patient will also receive weekly phone calls by a geriatrics RN following hospital discharge.~The patient will answer questions on:~Social support~Quality of life"
89411375|NCT02306486|Placebo Comparator|z250 resin composite|(n=31) Treated with distilled water (placebo) and restored with a methacrylate resin-based-composite (Z250, 3M ESPE, shade: A3)
89411376|NCT02306486|Active Comparator|z250 resin composite + oxalic acid|(n=31) treated with 0.5% oxalic acid (Desenssiv, SSWhite)(intervention)// and restored with a methacrylate resin-based-composite (Z250, 3M ESPE, shade: A3)
89411377|NCT02306486|Placebo Comparator|p 90 resin composite|(n=31) Treated with distilled water (placebo) and restored with a silorane resin-based-composite.
89411378|NCT02306486|Active Comparator|p 90 resin composite + oxalic acid|(n=31) treated with 0,5% oxalic acid (Desenssiv SSWhite)(Intervention)/ and restored with a silorane resin-based-composite (Filtek Silorane p90, £M ESPE, shade:)
89411379|NCT03511040|Experimental|Lumenate Intraluminal Device|Dilation of vasospastic intracranial vessels
89411380|NCT03671122||PREFERS main study|500 patients with new onset heart failure will be characterized into those with HFpEFand HFrEF at baseline and undergo Cardiac imaging by Doppler echocardiography and cMRI, blood tests for biomarker analysis
89411381|NCT03671122||CABG PREFERS|500 Patients undergoing elective by pass surgery with or without diastolic or systolic dysfunction as Proxy for HFpEF and HFrEF will undergo Cardiac imaging by Doppler echocardiography and cMRI, blood tests for biomarker analysis and cardiac biopsies
89411382|NCT03510962|Active Comparator|Group 1: no intervention|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva.The subject is then given 100 ml of test mixed fruit juice,Tropicana® Mixed Fruit Juice, (PepsiCo, Inc) to drink. The subject will sip, swish and swallow the drink within 2 minutes.~Unstimulated saliva samples are collected from the subject to measure the pH of saliva after 5, 15, 30, 45 and 60 minutes of consumption of the test mixed fruit juice."
89411383|NCT03510962|Experimental|Group 2: tap water gargle|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva.The subject is then given 100 ml of test mixed fruit juice,Tropicana® Mixed Fruit Juice, (PepsiCo, Inc) to drink. The subject will sip, swish and swallow the drink within 2 minutes.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test mixed fruit juice.~The subject will use 10 ml of tap water as mouth rinse to swish for 60 seconds and spit. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention."
89411384|NCT03510962|Experimental|Group 3: 0.2% chlorhexidine|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva. The subject is then given 100 ml of test mixed fruit juice, Tropicana® Mixed Fruit Juice, (PepsiCo, Inc) to drink. The subject will sip, swish and swallow the drink within 2 minutes.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test mixed fruit juice.~The subject will use 10 ml of 0.2% Chlorhexidine mouth rinse (Rexidine®, Indoco Remidies Ltd, Mumbai, India) to swish for 60 seconds and spit. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention."
89411385|NCT03510962|Experimental|Group 4: fluoridated tooth paste|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva. The subject is then given 100 ml of test mixed fruit juice, Tropicana® Mixed Fruit Juice, (PepsiCo, Inc) to drink. The subject will sip, swish and swallow the drink within 2 minutes.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test mixed fruit juice.~The subject will Brush with fluoridated toothpaste (Colgate Total®, Colgate-Palmolive Company, Mumbai, India) for 2 minutes using soft brush.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the brushing as an intervention."
89536704|NCT02473601|Experimental|Mivacurium Chloride by liver dysfunction|Mivacurium Chloride 0.2mg/kg,during anesthesia induction. Mivacurium Chloride 6mg/kg/h,during anesthesia maintenance
89536705|NCT02473601|Other|Mivacurium Chloride by normal liver function|Mivacurium Chloride 0.2mg/kg,during anesthesia induction. Mivacurium Chloride 6mg/kg/h,during anesthesia maintenance
88819772|NCT01564628||All study participants|Population from 2 sites, sequential design with all patients undergoing CADScor1 intervention followed by the diagnostic testing the patients were referred to (procedure done according to standard of care and not part of study; computerized tomographic angiography (CTA) and, if relevant, coronary angiography (CAG) at Site 1 and CAG at site 2).
88819773|NCT05348655||Pre Covid-19 cohort|"Children hospitalized in the Pediatric Department of the  Hôpital Femme Mère Enfant , Lyon, France with a RT-PCR positive for RSV during the 2019-2020 winter epidemic"
88819774|NCT05348655||Per Covid-19 cohort|"Children hospitalized in the Pediatric Department of the  Hôpital Femme Mère Enfant , Lyon, France with a RT-PCR positive for RSV during the 2020-2021, 2021-2022, 2022-2023, and 2023-2024 epidemic. The need for continuation of the study will be reassessed after each season"
88819775|NCT01564706|Experimental|Healthy Volunteers|Healthy male or female subjects, between 18 and 85 years of age.
88819776|NCT05349825||Patients with Hypertensive episode|50 individuals presenting with a hypertensive episode (patients under 60, >140/90 mmHg, patients over 60, >150/90 mmHg, according to the JNC8 guidelines) while under losartan treatment
88887589|NCT03886467|Active Comparator|Nutrition Education|Households will participate in community-based nutrition education program specifically targeting child nutrition and milk consumption, in addition to general community development activities
88887590|NCT03886467|No Intervention|Control|community development activities only.
88887591|NCT03882463|Experimental|insulin pump function|continuous glucose monitoring and then continuous glucose monitoring with the stop insulin pump function
88887592|NCT03881228|Experimental|Intervention|"at enrollment, caretakers will receive an educational booklet for caretakers explaining why IPT needs to be given~at enrollment and weekly for 24 weeks, caretakers will receive a children's storybook, with weekly installments, over the 6-month course of IPT as a non-monetary incentive~weekly, caretakers will receive short messages services (SMS) reminders delivered to the caretaker for the weekly pick-up."
88887593|NCT03881228|No Intervention|Standard of care|Routine care at the health facility
88887594|NCT03861481|Experimental|Rozanolixizumab|Subjects will be randomized to receive predefined subcutaneous doses of rozanolixizumab at a specified frequency
88887595|NCT03861481|Placebo Comparator|Placebo|Subjects will be randomized to receive predefined subcutaneous doses of placebo at a specified frequency
88887596|NCT03853941|No Intervention|Control|Patients in the control group will receive treatment as usual.
88887597|NCT03853941|Experimental|Experimental|The experimental group will receive clinical treatment as usual, however, the healthcare professionals treating them will have received training on how to enhance patient adherence via the use of a motivationally supportive communication style. Thus, the style/language healthcare professionals use to convey usual treatment recommendations may differ.
88887598|NCT03821649|Experimental|SOONER Training and Naloxone Kit|Participants in this arm will be shown the SOONER overdose response training video at the time of recruitment and given the SOONER Naloxone kit to take home.
88887599|NCT03821649|Active Comparator|Community or Hospital-Based Training|Control arm - participants in this arm will be referred to the standard of care for Naloxone training. This standard of care includes community-based OEND programs and/or an existing hospital-based OEND program..
88887600|NCT03811262|Active Comparator|ESP BLOCK|Intervention:30 ml of 0.25% Levobupivacaine where: ESP block as described by Forero at T5 level (single injection between transversour process and erector spinae muscles)
88887601|NCT03811262|Active Comparator|PECS block|Intervention:30 ml of 0.25% Levobupivacaine where:PECS II block as described by Blanco.
88887602|NCT03758833|Active Comparator|SET|patients receiving the elective single embryo transfer
88887603|NCT03758833|Experimental|SET+NGS|patients receiving the elective single embryo transfer evaluated genetically by NGS
88887604|NCT03758833|Active Comparator|DET|patients receiving the elective double embryo transfer
88887605|NCT03758833|Experimental|DET+NGS|patients receiving the elective double embryo transfer evaluated genetically by NGS
88887606|NCT03730974|Experimental|Experimental arm AB (Ball blanket + TAU)|"Participants will be randomized into either sequence AB or BA each lasting four weeks.~Patients that are randomized to the AB sequence receive intervention A (Protac Ball BlanketTM 7 kg Flexible) in the first two weeks and treatment B treatment as usual (TAU) in the second period."
88887607|NCT03730974|Experimental|Experimental arm BA (TAU + Ball blanket)|Patients that are randomized to the BA sequence receive treatment B (TAU) in the first period and intervention A in the second period (Protac Ball BlanketTM 7kg Flexible).
88887608|NCT03716466||Endotracheal intubation|Cases with prophylactic endotracheal intubation during urgent endoscopy procedure for upper gastrointestinal bleeding .
88887609|NCT03716466||No airway intervention|Cases without airway intervention during urgent endoscopy procedure for upper gastrointestinal bleeding
88887610|NCT03708198|Other|Intercostal Nerve Block|The study participants will be given a standard 266 mg single dose injection of liposomal bupivacaine by the surgeon at the start of the surgery.
88887611|NCT03706729|Experimental|Spraino intervention group|Participants will use Spraino® as a measure to prevent future lateral ankle sprains during all training sessions and games.
88887612|NCT03695068|Experimental|RISE Intervention|Reading Instruction for Students who are English Learners (El) with Reading Difficulties (RISE): The RISE intervention is a multi-phase treatment that first accelerates basic skills through an emphasis on word reading (e.g., multi-syllable words, morphology, high-frequency words commonly misread; Phase 1), and then provides a longer-term emphasis on fluency and comprehension through systematically varying text difficulty and genre (Phase 2). To assure that students have minimal loss during the summer, RISE adds a summer Book Club that includes provision of books with comprehension activities for students in the RISE intervention arm (Phase 3). This entire approach takes two full academic years and two summers to be replicated across two cohorts.
88887613|NCT03695068|No Intervention|Business as Usual Comparison Condition|Participants assigned to the Business as Usual (BAU)or comparison condition will participate in an elective class that includes such options as music, cooking, film, study time, or high stakes test preparation.
88887614|NCT03683498|Experimental|Regulatory T-cell enriched infusion|"Dose escalation sequential cohorts Regulatory T-cell enriched infusion (Cells/kg) will be administered. The cohorts will be dose escalated per the schema below:~Dose-level A: 0.5 x 10ˆ6 Cells/kg Dose-level B: 1 x 10ˆ6 cell/kg Dose-level C: 2 x 10ˆ6 cell/kg"
88887615|NCT03654599|Experimental|Baseline and Digital Stories (DS)|In-person baseline surveys using the web-based data collection platform, Research Electronic Data Capture before the random assignment to DS arm. Eight Digital Stories Intervention (4 patient and 4 caregiver stories about hematopoietic stem cell transplantation (HCT) over the course of 4 weeks (2 videos per week) with a weekly email notification and reminder phone call. Each story was made with voice, images, and sound (3-5 minutes each).
89192196|NCT02561988|Experimental|Avapritinib (also known as BLU-285)|Avapritinib tablets for oral administration. Avapritinib will be dosed daily for 28 day cycles.
89192197|NCT04066088|Sham Comparator|Placebo|
88819777|NCT05349825||Patients with controlled hypertension|50 patients whose blood pressure was regulated while receiving losartan treatment and who were admitted to the ED for reasons other than hypertensive episode. The eligible patients matching the inclusion and exclusion criteria were recruited for the study.
89192198|NCT04066088|Experimental|GXR|Immediately following the 8-week blinded randomized trial, an 8-week open-label continuation phase will be pursued to further define efficacy and tolerability of GXR, and to establish its safety with specific focus on metabolic profile.
89192199|NCT00799461|Experimental|Arm I (full website access w/ PST; first study only)|Patients receive full access to INSPIRE website for 6 months, which offers an individually tailored greeting home page with links to information on each of the target areas identified as being elevated on baseline assessment and how to manage the complications; a bulletin board with input from other survivors that is solicited, edited, and posted weekly; resource pages; and an opportunity to send secure messages with questions or comments. Patients also undergo 4-8 phone-based PST sessions with a behavioral health specialist.
89192200|NCT00799461|Experimental|Arm II (full website access without PST)|Patients receive full access to INSPIRE website for 6 months as in arm I.
89192201|NCT00799461|Sham Comparator|Arm III (delayed website access)|Patients do not have access to INSPIRE website for 6 months. After 6 months, patients receive full access to INSPIRE website for 3 months.
89192202|NCT02570178|No Intervention|standard practice advice|standard practice advice
89192203|NCT02570178|Other|balance training|balance training using the Nintendo™ Wii console and its balance board.
89192204|NCT00733148||1|Routine Care
89192205|NCT00733148||2|Insulin infusion based on model predictive algorithm (MPC)
89192206|NCT00730392|Experimental|1 drug, 2 placebo|"Etanercept~Placebo"
89192207|NCT00809601|Experimental|1|
89192208|NCT01875458||CASES|Adults with current or past history of bisphosphonate treatment (exposed) with Bisphosphonate related Osteonecrosis of the Jaws (BRONJ), or, Adults with current or past history of bisphosphonate treatment (exposed) with atypical fracture
89192209|NCT01875458||COUNTER MATCHED CONTROLS|Adults with current or past history of bisphosphonate treatment (exposed) without bisphosphonate related osteonecrosis of the jaws (BRONJ, or, Adults with current or past history of bisphosphonate treatment (exposed) with typical fracture or joint replacement or osteoporosis
89192210|NCT01875458||MATCHED CONTROLS|Adults without current bisphosphonate treatment (unexposed) with Typical fracture (healthy fracture patients) Adults without current bisphosphonate treatment (unexposed) without BRONJ (healthy oral surgery subjects or adults with radionecrosis of the jaws)
89192211|NCT01875458||Healthy Adult Volunteers|Healthy volunteers with or without current bisphosphonate treatment without jaw or extremity pathologies or injuries to contribute blood and saliva samples only.
89192212|NCT00730470|Experimental|1|
89192213|NCT00734084|Other|Preservation Unicompartmental Knee|Minimally invasive orthopaedic implant for single compartment knee arthritis
89192214|NCT00728286||Type 2 diabetes mellitus|We aim to determine the effects of dual antiplatelet therapy with aspirin 75mg once a day and clopidogrel 75mg once a day on platelet dependent thrombogenicity in patients with type 2 diabetes mellitus and acute coronary syndrome. Eighty patients (40 with type 2 diabetes and 40 without) have been studied one week after Non ST-elevation acute coronary syndrome. All patients were on secondary prevention therapy as recommended by international guidelines.
89192215|NCT01528046|Experimental|Metformin in Combination with VIT|Participants will receive metformin in combination with vincristine, irinotecan and temozolomide (VIT).
89192216|NCT00652899|Experimental|Total Body Irradiation|"This group includes patients that received all chemotherapy, infusion of natural killer (NK) cells and total body irradiation per protocol.~1. Allopurinol 300 mg by mouth daily (unless known allergy) before beginning chemotherapy and continuing through day 14 post NK cell infusion. 2. Cyclophosphamide 60 mg/m^2 on Days 4 and 5 preceding NK cell infusion. 3. Fludarabine phosphate 25 mg/m^2 on Days 6 through 2 preceding NK cell infusion. 4. Radiation: total-body irradiation 200 cGy Day 1 preceding NK cell infusion. 5. Allogeneic natural killer cells- Given day 0 - dose of 1.5-8.0 * 10^7/kg. 6. Aldesleukin 10 million units 3 times/week for a total of 6 doses beginning Day 0."
89192217|NCT00652899|Experimental|No Total Body Irradiation|"This group includes patients that received chemotherapy and infusion of natural killer cells, but did not receive total body irradiation.~1. Allopurinol 300 mg by mouth daily (unless known allergy) before beginning chemotherapy and continuing through day 14 post NK cell infusion. 2. Cyclophosphamide 60 mg/m^2 on Days 4 and 5 preceding NK cell infusion. 3. Fludarabine phosphate 25 mg/m^2 on Days 6 through 2 preceding NK cell infusion. 4. Allogeneic natural killer cells- Given day 0 - dose of 1.5-8.0 * 10^7/kg. 5. Aldesleukin 10 million units 3 times/week for a total of 6 doses beginning Day 0."
89192218|NCT04147962||Patients with dry eye disease with meibomian gland dysfunction|"Collected data from patient records for consultations Day 0, Day 15 and Day 45 (3 treatment sessions) and Months 3, Months 6 (follow-up consultations).~- parameters used for each treatment session: duration of treatment session and intensity of intense pulsed light"
89192219|NCT00734240|Experimental|A|single-dose cohort (n=4, randomized 3 active : 1 placebo) receiving ISIS 355312 or placebo
89192220|NCT00734240|Experimental|B|single-dose cohort (n=4, randomized 3 active : 1 placebo) receiving ISIS 353512 or placebo
89192221|NCT00734240|Experimental|C|single-dose cohort (n=4, randomized 3 active : 1 placebo) receiving ISIS 353512 or placebo
88819778|NCT01451996|Other|Claritin ads|Subject will be given 10mg Claritin tablet and then watch a movie that includes commercials for Claritin.
89192222|NCT00734240|Experimental|AA|multiple-dose cohort (n=4, randomized 3 active : 1 placebo) receiving 353512 or placebo
89192223|NCT00734240|Experimental|BB|multiple-dose cohort (n=4, randomized 3 active : 1 placebo) receiving ISIS 353512 or placebo
89192224|NCT00734240|Experimental|CC|multiple-dose cohort (n=4, randomized 3 active : 1 placebo) receiving ISIS 353512 or placebo
89192225|NCT00734240|Experimental|G|single-dose cohort (n=4, randomized 3 active : 1 placebo) receiving ISIS 353512 or placebo
89192226|NCT00734240|Experimental|H|single-dose cohort (n=4, randomized 3 active : 1 placebo) receiving ISIS 353512 or placebo
89192227|NCT00734240|Experimental|I|single-dose cohort (n=4, randomized 3 active : 1 placebo) receiving ISIS 353512 or placebo
89192228|NCT00734240|Experimental|GG|multiple-dose cohort (n=4, randomized 3 active : 1 placebo) receiving ISIS 353512 or placebo
88887616|NCT03654599|Active Comparator|Baseline and Information Control (IC)|In-person baseline surveys using the web-based data collection platform, Research Electronic Data Capture (REDCap) before the random assignment to IC arm. Eight Information Control Intervention videos containing only information about post-HCT care (as opposed to story/narrative) over the course of 4 weeks (2 videos per week) with a weekly email notification and reminder phone call.
88887617|NCT03648476|Experimental|ICAN|6-week group therapy intervention with clinical RA comprised of 6 90-120 minute sessions beginning after Time 1 testing
89192229|NCT00734240|Experimental|HH|multiple-dose cohort (n=4, randomized 3 active : 1 placebo) receiving ISIS 353512 or placebo
89192230|NCT00734240|Experimental|II|multiple-dose cohort (n=4, randomized 3 active : 1 placebo) receiving ISIS 353512 or placebo
89192231|NCT00734240|Experimental|F (100 mg)|single-dose cohort (n=4, randomized 3 active: 1 placebo) receiving ISIS 353512 or placebo
89192232|NCT00734240|Experimental|Dose-Titration 1|multiple-dose cohort (n=4, randomized 3 active: 1 placebo) receiving ISIS 353512 or placebo
89192233|NCT00734240|Experimental|F (200 mg)|single-dose cohort (n=4, randomized 3 active: 1 placebo) receiving ISIS 353512 or placebo
89192234|NCT00734240|Experimental|Dose-Titration 7|multiple-dose cohort (n=4, randomized 3 active: 1 placebo) receiving ISIS 353512 or placebo
89192235|NCT00808587||No Treatment|
89192236|NCT04066452||Single-group studies|"Patients will be informed about the study and their written informed consent will be requested.~Once included in the study:~A series of clinical, analytical and echocardiographic parameters will be collected and measured~Will be performed:~Bone-cardiac scintigraphy with Tc-DPD (or similar: Tc-PYP or Tc-HMDP)~Analytical to rule out monoclonal protein:~Proteinogram and serum immunoglobulins.~Light chains free in serum -Freelite-~Immunofixation in serum and urine.~The number of readmissions, emergency visits and mortality in the following 12 months will be recorded to compare the readmission and mortality rates in one year of patients with and without CA.~The prescribed pre- and post-diagnostic treatments will be described, according to clinical practice (without intervention).~No intervention, whether diagnostic or follow-up, that is not the usual clinical practice will be applied to patients."
89192237|NCT00733382|Experimental|1|
89192238|NCT00733382|Active Comparator|2|
89192239|NCT00728442|Experimental|1|medical decision based on computerized guideline-based decision support system
89192240|NCT00728442|No Intervention|2|
89192241|NCT00733460|Experimental|BF-PET|
89192242|NCT04065308|Experimental|Experimental arm|"Daratumumab plus DCEP,combination therapy is administered total of three cycles,every 4weeks(28 days).~Daratumuamb 16mg/kg body weight in 500mL (the first dose,16mg/kg body weight in 1000mL) Weeks 1 to 8: weekly Weeks 9-24 : every 2 weeks if ASCT ineligible or PR but Plasmacytoma response <CR: every 2 weeks for 12weeks and then every 4 weeks for 8weeks (Total of 8 times, additional administration of daratumumab) if ASCT eligible: From 6 to 12 weeks after ASCT, administration of daratumumab is initiated within 12 weeks of ASCT and twice a month for 12 weeks and then every a months for 8 weeks. (Total of 8 additional administration of daratumumab after ASCT)~dexamethasone :40mg/day D1-4, intravenous~cyclophosphamide: 400mg/m2 D1-4, intravenous~etoposide: 40mg/m2 D1-4, intravenous~cisplatin : 7mg/m2 D1-4, intravenous Pegteograstim: 6mg once, SC on day 5 or 6 of each 28-day cycle"
89192243|NCT00728598||1|Proliferative diabetic retinopathy, active.
89192244|NCT00728598||2|Proliferative diabetic retinopathy, quiescent.
89192245|NCT00728598||3|Control group. Patients with macular hole or idiopathic epiretinal membrane receiving vitrectomy for their disease.
89192246|NCT00733538|Active Comparator|1|patients receiving zometa treatment
89192247|NCT00733538|No Intervention|2|No treatment, just follow-up
89192248|NCT00730548|Experimental|1|Remote Arm (OptiVol plus Connexus Telemetry plus CareLink plus Intervention Algorithm), Clinical Management Alerts ON
89192249|NCT00730548|No Intervention|2|No Care Alerts available, standard treatment of the patient
89192250|NCT00728156|Active Comparator|C|Patients assigned to clopidogrel in addition to their standard care.(all patients will be on aspirin)We aim to study the effect of clopidogrel as dual antiplatelet therapy in patients with established coronary artery disease and type 2 diabetes. Ninety patients with type 2 diabetes and stable coronary artery disease has been randomly treated with clopidogrel or placebo (45 each) for one week in addition to their standard care (including aspirin,75 mg once daily).
89192251|NCT00728156|Placebo Comparator|P|Patients assigned to placebo in addition to their standard care.(all patients will be on aspirin).This is a single-centre randomised double-blind placebo-controlled parallel design study, comparing efficacy of clopidogrel versus placebo in patients with T2DM and coronary artery disease. Ninety patients have completed the study. All patients were on their routine medications as per standard practice. After informed consent, participants were randomised to receive either clopidogrel 75mg daily or placebo for 7 days.
89192252|NCT02569554|Experimental|PF-06463922|each subject will receive four single doses of PF-06463922 without food, with food, with rabeprazole (without food), and one of the two new formulations without food.
89437545|NCT03671330|Experimental|Ribociclib|"Patients in pre- and postmenopausal cohorts will be randomized in the 1:1 ratio to the experimental arm or the control arm.~Premenopausal experimental arm: NSAI + Goserelin + Ribociclib; For pre-menopausal only, patient is an adult, female ≥ 18 years old and < 60 years old at the time of informed consent.~It is the investigators choice for NSAI based on patient's past medical history.~Postmenopausal experimental arm:~Letrozole + Ribociclib~PK Cohort: Open-label ribociclib + Letrozole treatment combination.~For postmenopausal only, patient is an adult, female ≥ 18 years old at the time of informed consent"
88887618|NCT03648476|Other|WLC: Waitlist Control|WLC participants will delay treatment until after time two testing 8-weeks from time one testing. Participants will then begin 6 90-120 minute therapy sessions.
88887619|NCT03641196|No Intervention|No treatment of deep bite|No treatment of deep bite. These participants will be evaluated during a 6-month follow-up period. In cases were significant problems arise during the follow-up period, the participant will be removed from the study and the appropriate treatment conducted.
88887620|NCT03641196|Active Comparator|Fixed appliance|Fixed appliance: Treatment with a cemented modified palatal Nance appliance presenting a bite-plane.
88887621|NCT03641196|Active Comparator|Composite bite plane|Composite bite plane: Treatment with a composite build up in the palatal aspect of the upper central incisors.
88887622|NCT03608982|Experimental|Simulated patient|The materials in this course are standardized, and consist of lectures with a slide show, questions & answers conversations, and practical exercises on fellow-students. The courses are being taught by professional first aid tutors from the Belgian Red Cross. During the practical exercises, a simulated patient will unexpectedly enter the room requiring treatment.
88887623|NCT03608982|Active Comparator|No simulated patient|The course materials in the control courses are also standardized. Instead of using simulated patients, however, video clips will be shown to demonstrate the first aid techniques.
88887624|NCT03578393|Experimental|Intervention|Will visualize an Educational Virtual Reality video in preoperative period to reduce perioperative anxiety.
88887625|NCT03578393|No Intervention|Usual treatment|Will be applied the usual treatment (provide information on the anaesthetic-surgical process).
88887626|NCT03562806|Experimental|PET/MR (single arm)|PET and MR sequence acquisition on SIGNA PET/MR device
88887627|NCT03559426|Active Comparator|Antipsychotic Maintenance|Participants continue to receive antipsychotic treatment at the original dose for the 24 month duration of the trial. Increases or minor adjustments to antipsychotic medication are permitted.
88887628|NCT03559426|Experimental|Antipsychotic Reduction|Antipsychotic medication is gradually reduced and discontinued if possible. A flexible individualised antipsychotic reduction schedule is devised for each patient by the research team, based on the participant's initial antipsychotic regime. Antipsychotic dose is reduced incrementally every two months, with flexibility to speed up or slow down the schedule in discussion with the patient. The antipsychotic reduction extends over a period of between six to 12 months, although this may be extended according to individual circumstances.
88887629|NCT03557762|Experimental|Immediate Mindfulness|A 4 week smartphone app-based mindfulness intervention program with in-app activities for 20-30 minutes every day, with a minimum of 4 days of activity in a week.
88887630|NCT03557762|Other|Waitlist Control Mindfulness|No intervention for 4 weeks, after which there will be assessments immediately post-waiting and at 3 months post-baseline. After this, participants will get the same 4 week smartphone app-based mindfulness intervention program.
88887631|NCT03537937|Active Comparator|Lower SpO2 Target|During invasive mechanical ventilation in a study location, the fraction of inspired oxygen will be titrated to target an arterial oxygen saturation of 90% (range 88-92%).
88887632|NCT03537937|Active Comparator|Intermediate SpO2 Target|During invasive mechanical ventilation in a study location, the fraction of inspired oxygen will be titrated to target an arterial oxygen saturation of 94% (range 92-96%).
88887633|NCT03537937|Active Comparator|Higher SpO2 Target|During invasive mechanical ventilation in a study location, the fraction of inspired oxygen will be titrated to target an arterial oxygen saturation of 98% (range 96-100%).
88887634|NCT03491280||Group 1|Subjects with unclear rare diseases, clinically characterized in the context of outpatient/ inpatient standard care at the University Hospital Tübingen (UKT) or cooperating location, genetic diagnostic (NGS diagnostic) must be performed.
88887635|NCT03491280||Group 2|Subjects with unclear rare diseases, genetic diagnostic (NGS diagnostic) is already performed.
88887636|NCT03484000|Experimental|Immediate MBCR group|The Online Mindfulness Based Cancer Recovery (MBCR) program intervention is delivered in 12 weekly real-time interactive 55-minute sessions offered over consecutive weeks.
88887637|NCT03484000|Other|Waitlist control group|Treatment as usual, followed by a delayed (wait-list) intervention of the same Online Mindfulness Based Cancer Recovery (MBCR) program after the post-CT assessment.
88887638|NCT03444753|Experimental|Arm A|BMS-986299
88887639|NCT03444753|Experimental|Arm B|BMS-986299 in combination with nivolumab and ipilimumab
88887640|NCT03413982||BC Patients|Patients with bladder cancer. This registry involves no intervention. Blood, urine, and tissue samples will be collected to be used for research.
88887641|NCT03337945|Experimental|"Basel phenotyping cocktail capsule"|"Oral intake of Basel phenotyping cocktail capsule and pharmacokinetics (PK) sampling"
88887642|NCT03314480||Midfacial fracture suspected patients|Patients who are suspected of maxillofacial fracture
88887643|NCT03314480||Mandibular fracture suspected patients|Patients who are suspected of a mandibular fracture
88887644|NCT03286309|Experimental|EMG-driven soft robot hand|subjects will receive EMG-driven soft robot hand system.
88887645|NCT03286309|Placebo Comparator|sham group|subjects will receive passive pre-programmed soft robot hand system.
89192253|NCT00728234||1|all infants born below 30 weeks gestational age at the medical university vienna within the study period (01/2000 - 12/2002)
89411386|NCT03510962|Experimental|Group 5: Polyol containing gum|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva. The subject is then given 100 ml of test mixed fruit juice, Tropicana® Mixed Fruit Juice, (PepsiCo, Inc) to drink. The subject will sip, swish and swallow the drink within 2 minutes.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test mixed fruit juice.~The subject will chew polyol containing gum (Orbit®, Wrigley Company) for 5 minutes and spit.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the chewing gum as an intervention."
89411387|NCT03510962|Experimental|Group 6: 1% sodium bicarbonate solution|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva. The subject is then given 100 ml of test mixed fruit juice, Tropicana® Mixed Fruit Juice, (PepsiCo, Inc) to drink. The subject will sip, swish and swallow the drink within 2 minutes.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test mixed fruit juice.~The subject will use 10 ml freshly prepared 1% sodium bicarbonate w/v solution to swish for 60 seconds and spit.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention."
89411388|NCT02646124|Experimental|Diazepam|Naproxen +Diazepam
89005247|NCT00207311|Placebo Comparator|Xenical placebo|Xenical placebo PO three times daily with meals plus enrollment into the Xenicare program for 36 weeks followed by 48 weeks of therapy with Pegasys (180mcg/ml) plus weight based ribavirin for HCV genotype 1 or 4 and 24 weeks of therapy with Pegasys (180mcg/ml) plus 800mg ribavirin for HCV genotypes 2 and 3.
89411389|NCT02646124|Active Comparator|Placebo|Naproxen + Placebo
89411390|NCT02306564|Experimental|Group A|Group A will include patients at risk of OHSS receiving Cabergoline 0.5mg daily for 8 days (Dostinex®, Pfizer Australia Pty Ltd ) from the day of oocyte pick up for prevention of hyperstimulation
89411391|NCT02306564|No Intervention|Group B|Group B will include patients AT RISK of ovarian hyperstimulation syndrome (OHSS) not receiving Cabergoline.
89411392|NCT02306564|No Intervention|Group C|Group C will serve as a control group and will include age & BMI matched patients NOT AT RISK of OHSS, and not receiving cabergoline.
89411393|NCT02301494|Experimental|Fluocinonide (Vanos) cream 0.1%|Fluocinonide (Vanos) cream 0.1% will be applied as currently approved by the FDA for treatment of corticosteroid responsive disorders of the skin. Treatment will continue for 4 months with a follow up at 6 and 12 months.
89411394|NCT02301494|Experimental|3.75% Imiquimod (Zyclara) Cream|3.75% Imiquimod (Zyclara) Cream will be used as currently labeled by the FDA for treatment of actinic keratoses. Treatment will continue for 4 months with follow up at 6 and 12 months.
89411395|NCT03101800|Experimental|Azathioprine and Allopurinol|
89411396|NCT03101800|Active Comparator|Azathioprine|
89411397|NCT03507842|Experimental|High-dose cytarabine|High-dose cytarabine 3.0 g/m2 q12hr 3-hour iv infusion on days 1, 3, 5 plus daunorubicin 45 mg/m2/day continuous iv infusion for 3 days (D1-3).
89411398|NCT03507842|Experimental|high-dose daunorubicin|cytarabine 200 mg/m2/day continuous iv infusion for 7 days (D1-7) plus high-dose daunorubicin 90 mg/m2/day continuous iv infusion for 3 days (D1-3).
89411399|NCT04464044|Experimental|DDT2 Toric|Verofilcon A toric contact lenses worn in both eyes
89411400|NCT04435132|Experimental|PCNL with the aid of the robotic device|Patients will undergo prone PCNL under fluoroscopic guidance and with the aid of the robotic device.
89411401|NCT03132584|Experimental|Cyclophosphamide and Alemtuzumab|"After the screening procedures confirm participation in the research study:~The investigators are looking for the highest dose of the combination of study drugs that can be administered safely without severe or unmanageable side effects in participants that have CD52 positive aggressive lymphoma. Not everyone who participates in this research study will receive the same dose of the study drug. The dose given will depend on the number of participants who have been enrolled in the study prior and how well the dose was tolerated.~Cyclophosphamide~Alemtuzumab"
89411402|NCT03507764|No Intervention|Control Group|"During the randomized study phase (6 months),subjects will perform their usual activity without access to the treadmill workstation in the dispatch center.~After six months, all subjects will continue to be assessed with free access to the treadmill workstation at the workplace."
89411403|NCT03507764|Experimental|Experimental Group|"During the randomized study phase, subjects will have an open access to the treadmill workstation with the indication to use it for at least one hour (continuous or split) on working days.~After six months, all subjects will continue to be assessed with free access to the treadmill workstation."
89411404|NCT02301650||group A|The one year old children born in Beijing Ditan hospital and whose mothers had taken Lamivudine in late pregnancy
89411405|NCT02301650||group B|The one year old children born in Beijing Ditan hospital and whose mothers had taken Telbivudine in late pregnancy
89411406|NCT02301650||group C|The one year old children born in Beijing Ditan hospital and whose mothers had taken Tenofovir in late pregnancy
89411407|NCT02301650||group D|The one year old children born in Beijing Ditan hospital and whose mothers untreated in late pregnancy
89411408|NCT03600844|Experimental|Phase 1 Intervention|Phase 1 intervention communities will be offered Community distribution of SP for IPTp in addition to routine ANC IPTp distribution throughout the project.
89192254|NCT00734318|Experimental|Flutiform 250/10 micrograms|Flutiform 250/10 micrograms (2 puffs bd)
89192255|NCT00734318|Experimental|Flutiform 50/5 micrograms|Flutiform 50/5 micrograms (2 puffs bd)
89411409|NCT03600844|Active Comparator|Phase 1 Comparison/Phase 2 Intervention|During Phase 1 (intervention months 1 through 12), these communities will be offered only usual treatment--SP for IPTp at in facilities during routine ANC. During Phase 2 (intervention month 13 through the end of the project), these communities will be offered Community distribution of SP for IPTp, in addition to routine ANC IPTp distribution.
89411410|NCT03510338|Experimental|Sublingual sildenafil (fasted)|Subjects receive a single dose of 100 mg sildenafil
89411411|NCT03510338|Active Comparator|Oral sildenafil (fed)|Subjects receive a single dose of 50 mg sildenafil (Viagra)
89411412|NCT03510338|Experimental|Sublingual sildenafil (fed)|Subjects receive a single dose of 100 mg sildenafil
89411413|NCT03510338|Active Comparator|Oral comparator (fasted)|Subjects receive a single dose of 50 mg sildenafil (Viagra)
89411414|NCT03510260|Placebo Comparator|Control Group|Subject will undergo regular consenting only. At our unit consent for an elective cesarean delivery occurs in the same day of surgery, few hours before the procedure in a private room in labor and delivery while awaiting surgery. The COMRADE questionnaire (our primary outcome) will be obtained after the completion of the paper consent form.
89411415|NCT03510260|Experimental|Study Group I|Subject will receive an electronic invitation to complete the consent process electronically and will proceed through the Confirmed Consent system prior to arrival to labor and delivery on day of surgery, which is the routine patient flow at this time. The COMRADE questionnaire (our primary outcome) will be obtained prior to the initiation of the traditional consent (as in control group) before the completion of the paper consent form, in order to assess satisfaction and understanding of the e-confirmed consenting process completed before the procedure. After completion of the survey, the subject will sign the regular paper consent for the procedure as standard in our institution.
89411416|NCT03510260|Experimental|Study Group II|Subject will undergo the same intervention as group II but the COMRADE survey questionnaire will be obtained after the paper consent is obtained in order to assess whether both methods combined together improve the subjects' satisfaction of the consenting methods and better understanding of the surgical procedure.
89411417|NCT02303366|Experimental|SABR + MK-3475|SABR treatment (20Gy in 1 fraction) to at least one metastases (to a maximum of 5 metastases) followed by 8 cycles of 3 weekly treatment with MK-3475 (200mg IV per dose).
89411418|NCT02306642||Premature Acute Kidney Injury in NICU|This group of babies born less than 1500 grams will have experienced acute kidney injury based on the modified KDIGO guidelines for acute kidney injury.
89411419|NCT02306642||Premature No Acute Kidney Injury in NICU|This group of babies born less than 1500 grams will have not experienced acute kidney injury in the NICU.
89411420|NCT02306642||Term No Acute Kidney Injury|This group of babies born at term will have not experienced any acute kidney injury.
88887646|NCT03242070|Experimental|Theory-based PP eLearning Program(T-PeP)|"Theory-based PP eLearning Program (T-PeP) was developed based on self-efficacy theory42-44 to improve older adults' use of PPs for managing their care and includes learning modules, discussion boards, and other resources. Considering variations in the types and usability of PPs used by patients nationwide, T-PeP was developed as a vendor-agnostic (not tied to a specific vendor) program."
88887647|NCT03242070|No Intervention|Control Group|No specific intervention will be provided to the control group participants
88887648|NCT03203694|Experimental|Walking intervention|The walking program will consist of 45 minutes of walking (at a moderate pace) 5 days per week for 8 weeks.
88887649|NCT03203694|No Intervention|Control|Subjects will be instructed to continue their usual lifestyle for 8 weeks.
88887650|NCT03203694|Experimental|Lower body heating|This intervention consists of 60 minutes of lower body heating (40-42 degree C) 7 days per week for 7 days.
88887651|NCT03170700|No Intervention|Control|Participants will receive a nutrition program without parental feeding content. They will attend the nutrition program (Eating Smart • Being Active).
88887652|NCT03170700|Experimental|In-person|Nutrition program with in-person parental feeding content.
88887653|NCT03170700|Experimental|Online|Nutrition program with online parental feeding content.
88887654|NCT03142035|Experimental|Dienogest|patients will receive daily dienogest (2mg) for a total of 3 months (84 days)
88887655|NCT03142035|Active Comparator|GnRH agonist|patients will receive a single GnRH-a injection (3.25mg) every 28 days for three months.
88887656|NCT03142035|Other|Control Group|patients will not receive any medical intervention and will proceed with their IFV/ICSI cycles.
88887657|NCT03076723|Sham Comparator|Fixed opening pressure|The shunt opening pressure is changed to the same setting as at surgery.
88887658|NCT03076723|Experimental|Individual shunt opening pressure|The shunt opening pressure is adjusted (up one step, down one step or unchanged) according to an individual analysis of the pulsatility curve (as assessed after shunt surgery).
88887659|NCT03057652|Experimental|ReWalk, then EKSO, then REX|Subjects will be asked to complete a screening visit, baseline and post assessment for each intervention training (ReWalk, EKSO, REX) and up to 15 training sessions per device.
88887660|NCT03057652|Experimental|ReWalk, then REX, then EKSO|Subjects will be asked to complete a screening visit, baseline and post assessment for each intervention training (ReWalk, EKSO, REX) and up to 15 training sessions per device.
89411421|NCT02301806|Experimental|Sitagliptin|sitagliptin 50 mg tablet by mouth 12 weeks
89411422|NCT02301806|Active Comparator|Glimepiride|glimepiride 1 mg tablet by mouth 12 weeks
89411423|NCT03103204|Experimental|Normal weight full-mouth disinfection|"Normal weight (body mass index 18.5 - 24.9 kg/m2) individuals with chronic periodontitis~Full-mouth manual scaling and root planing within 24 hours~tongue cleaning with chlorhexidine gel 1% for 1 minute~tonsils disinfection with chlorhexidine spray 0.2%~rinsing with 15mL of 0.2% chlorhexidine solution for 30 seconds before and after dental scaling~subgingival irrigation of all periodontal pockets with 1% chlorhexidine solution~daily rinsing with 0.2% chlorhexidine solution (15mL/30 seconds/2 times a day"
89411424|NCT03103204|Experimental|Overweight full-mouth disinfection|"Overweight (body mass index 25.0 - 29.9 kg/m2) individuals with chronic periodontitis~Full-mouth manual scaling and root planing within 24 hours~tongue cleaning with chlorhexidine gel 1% for 1 minute~tonsils disinfection with chlorhexidine spray 0.2%~rinsing with 15mL of 0.2% chlorhexidine solution for 30 seconds before and after dental scaling~subgingival irrigation of all periodontal pockets with with 1% chlorhexidine solution~daily rinsing with 0.2% chlorhexidine solution (15mL/30 seconds/2 times a day"
89535703|NCT02451865|Experimental|Treatment (binimetinib and docetaxel)|Patients receive binimetinib PO BID on days 1-21 and docetaxel IV on day 21. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who have stable disease or better after completing 6 courses of binimetinib and docetaxel may continue receiving binimetinib PO BID in the absence of disease progression or unacceptable toxicity.
89411425|NCT03103204|Experimental|Obesity I full-mouth disinfection|"Obesity I (body mass index 30.0 - 34.9 kg/m2) individuals with chronic periodontitis~Full-mouth manual scaling and root planing within 24 hours~tongue cleaning with chlorhexidine gel 1% for 1 minute~tonsils disinfection with chlorhexidine spray 0.2%~rinsing with 15mL of 0.2% chlorhexidine solution for 30 seconds before and after dental scaling~subgingival irrigation of all periodontal pockets with with 1% chlorhexidine solution~daily rinsing with 0.2% chlorhexidine solution (15mL/30 seconds/2 times a day"
89411426|NCT03103204|Experimental|Obesity II full-mouth disinfection|"Obesity II (body mass index 35.0 - 39.9 kg/m2) individuals with chronic periodontitis~Full-mouth manual scaling and root planing within 24 hours~tongue cleaning with chlorhexidine gel 1% for 1 minute~tonsils disinfection with chlorhexidine spray 0.2%~rinsing with 15mL of 0.2% chlorhexidine solution for 30 seconds before and after dental scaling~subgingival irrigation of all periodontal pockets with with 1% chlorhexidine solution~daily rinsing with 0.2% chlorhexidine solution (15mL/30 seconds/2 times a day"
89411427|NCT03103204|Experimental|Obesity III full-mouth disinfection|"Obesity III (body mass index ≥ 40.0 kg/m2) individuals with chronic periodontitis~Full-mouth manual scaling and root planing within 24 hours~tongue cleaning with chlorhexidine gel 1% for 1 minute~tonsils disinfection with chlorhexidine spray 0.2%~rinsing with 15mL of 0.2% chlorhexidine solution for 30 seconds before and after dental scaling~subgingival irrigation of all periodontal pockets with with 1% chlorhexidine solution~daily rinsing with 0.2% chlorhexidine solution (15mL/30 seconds/2 times a day"
89411428|NCT02301884|Experimental|Allergen extract|"Causal allergen such as D. farinae (30 AU/ml), D. pteronyssinus (30 AU/ml), cat hair (10 AU/ml), dog hair/dander (1:1/10 w/v), or combination of those.~Allergen extract, HollisterStier, New Orleans, USA. Intralymphatic injection in volume of 0.1 ml, three times with 4-week interval. Concentration was increased, decreased, or unchanged at 2nd or 3rd injection according to local or systemic reaction after previous injection"
89411429|NCT04724512|Active Comparator|polypropylene|patients randomised to receive polypropylene sutures.
89411430|NCT04724512|Active Comparator|polyglactin|patients randomised to receive polyglactin sutures.
89411431|NCT02301962|Experimental|Panitumumab arm|Subjects will receive panitumumab 6 mg/kg intravenously as monotherapy every 14 days until disease progression, intolerability, withdrawal of consent, or death.
89411432|NCT03507374|Placebo Comparator|Placebo Comparator|After review of eligibility criteria, 20 patients will be randomized to the placebo arm of the study where patient will administer one subcutaneous injection of placebo every two weeks for a total of 52 weeks. Additionally, per standard-of-care, patient will also be treated with atorvastatin 40-80 mg.
89411433|NCT03507374|Active Comparator|Active Comparator|After review of eligibility criteria, 20 patients will be randomized to receive the investigational treatment of alirocumab 150mg which will be administered subcutaneously with a single-dose pre-filled pen syringe every 2 weeks for a total of 52 weeks. Additionally, per standard-of-care, patient will also be treated with atorvastatin 40-80 mg
89411434|NCT05141890|Experimental|Probiotic|Participants will be given the probiotic supplement Lp299v. The supplement is taken by mouth in the form of capsules. Participants will undergo a screening visit. After 7-11 weeks of taking Lp299v, they will return for their final visit. Blood will be drawn before and after the 7- 11 week intervention.
89411435|NCT03510026|Other|Low thermal device preparation|One participant acts simultaneously as a control and active comparator. One internal thoracic artery is prepared with the normal electrocautery device. The other internal thoracic artery is prepared with the new low thermal device. The participant does not know, which internal thoracic artery is defined to be prepared with the low thermal device.
89411436|NCT02302040|Experimental|AIM2ACT|AIM2ACT uses existing mHealth technology developed by the study team to elucidate tailored intervention targets for each family. AIM2ACT then facilitates collaborative caregiver/adolescent asthma management by automatically guiding dyads through a structured process that includes the supportive behavioral management strategies of goal setting, contingency management, and problem solving communication. Skills-training videos for adolescents and caregivers provide guidance on how to complete each collaborative asthma management component.
88819779|NCT01451996|Other|Zyrtec ads|Subject will be given 10mg Claritin tablet and then watch a movie that includes commercials for Zyrtec.
88819780|NCT04335825|Active Comparator|phacotrabeculectomy|patients undergoing phacotrabeculectomy
88819781|NCT04335825|Active Comparator|ExPress device implantation|patients undergoing ExPress antiglaucoma surgery combined with phacoemulsification
88819782|NCT04903860|Active Comparator|Single use reamers|Total hip replacement with the use of disposable reamers
88819783|NCT04903860|Active Comparator|conventional ancillary|Total hip replacement with the use of conventional reamers
88819784|NCT02742129|Experimental|AIR001 Crossover to Placebo|Phase 1: Participants will wear an accelerometer device daily but take no study drug for 14 days (washout period). On day 15, participants begin phase I study drug Nebulized Sodium Nitrite (AIR001) at 46 mg, at minimum of 4 hours apart, for 3 doses per day during the active portion of the participant's day. On day 22 participants increase study drug dose to 80 mg at the same frequency. Regardless of participant's ability to tolerate study drug or if the participant requires down-titration, participants will begin Phase 2. Phase 2: Is identical to Phase 1 except subject will be taking Placebo instead of AIR001.
88819785|NCT02742129|Placebo Comparator|Placebo crossover to AIR001|Phase 1: Participants will wear an accelerometer device daily but take no study drug for 14 days (washout period). On day 15, participants begin phase I study drug (Placebo) at 46 mg, at minimum of 4 hours apart, for 3 doses per day during the active portion of the participant's day. On day 22 participants increase study drug dose to 80 mg at the same frequency. Regardless of participant's ability to tolerate study drug or if the participant requires down-titration, participants will begin Phase 2. Phase 2: Is identical to Phase 1 except subject will be taking Nebulized Sodium Nitrite (AIR001) instead of Placebo.
89005248|NCT00207311|Active Comparator|Xenical (orlistat)|Xenical (orlistat) 120mg PO three times daily with meals plus enrollment into the Xenicare program for 36 weeks followed by 48 weeks of therapy with Pegasys (180mcg/ml) plus weight based ribavirin for HCV genotype 1 or 4 and 24 weeks of therapy with Pegasys (180mcg/ml) plus 800mg ribavirin for HCV genotypes 2 and 3.
89192256|NCT00734318|Active Comparator|Flixotide pMDI 250 mcg + foradil pMDI 24 micrograms|Flixotide pMDI 250 mcg (2 puffs bd) + foradil pMDI 24 50/5 mcg (bd)
89192257|NCT00734318|Active Comparator|Flixotide pMDI 250 micrograms|Flixatide pMDI 250 micrograms (2 puffs bd)
89192258|NCT04052412|Experimental|NSCLC with Immunotherapy without radiation|The biodistribution and kinetics of the 18F-AraG compound will be assessed in non-small cell lung cancer patients undergoing immunotherapy without adjuvant radiation therapy
89192259|NCT04052412|Experimental|NSCLC with Immunotherapy with radiation|The biodistribution and kinetics of the 18F-AraG compound will be assessed in non-small cell lung cancer patients undergoing immunotherapy with adjuvant radiation therapy
89192260|NCT00733616|Experimental|1|
89192261|NCT00728832|Active Comparator|1|No test dose + DepoDur + flush with 1 mL normal saline
89192262|NCT00728832|Experimental|2|Test dose + flush with 1 mL normal saline + 3-minute wait + DepoDur + flush with 1 mL normal saline
89192263|NCT00728832|Experimental|3|Test dose + flush with 1 mL normal saline + 10-minute wait + DepoDur + flush with 1 mL normal saline
89192264|NCT00728832|Experimental|4|Test dose + flush with 1 mL normal saline + 15-minute wait + DepoDur + flush with 1 mL normal saline
89192265|NCT00728832|Experimental|5|Test dose + No flush + 3-minute wait + DepoDur + flush with 1 mL normal saline
89192266|NCT03924804|Experimental|Group A: 2 ml/kg group|
89192267|NCT03924804|Experimental|Group B: 8 ml/kg group|
89192268|NCT03924804|Experimental|Group C: 16 ml/kg group|
89192269|NCT00733694|Other|LCS® Complete™ Mobile Bearing Knee Systems|An orthopaedic implant for primary total knee replacement with a mobile bearing knee
89192270|NCT00733772|Experimental|A|healthy lifestyle counseling + 30 grams/day supplement of Flaxseed
89192271|NCT00733772|Sham Comparator|B|TLC diet
89192272|NCT00728312|Active Comparator|1|Aripiprazole (Abilify), flexible dosing 5-15 mg per day
89192273|NCT00728312|Placebo Comparator|2|Placebo look-alike, flexible dosing 5-15 mg per day
89192274|NCT00728390|Experimental|1|
89192275|NCT00734552|Active Comparator|1|α-Keto Acid plus low protein diet
89192276|NCT00734552|Other|2|Normal protein diet
89192277|NCT00728546|Experimental|INA dose adjustment, NAT2|The dose of the re-challenged INH is followed by the results of the genotyping of NAT2 in each patient.
89192278|NCT02568722|Active Comparator|Standard RRT initiation|RRT initiation will be guided by the presence of one or more clinical indications. Even in the absence of one of these indications, RRT may be commenced at the discretion of the treating physician.
89192279|NCT02568722|Experimental|Accelerated RRT initiation|A dialysis catheter will be placed and RRT initiated as soon as possible and within 12 hours of the patient meeting the eligibility criteria.
89192280|NCT00738608||1|33 pat. with verum
89192281|NCT00738608||2|33 Pat. with placebo
89192282|NCT00738686|Experimental|1|Single-arm study, no placebo or control group
89192283|NCT04064216||Robot assisted laparoscopic surgery|This group will be consisted of patients that will undergo robot assisted laparoscopic surgery for benign gynecologic disorders
89192284|NCT04064216||Conventional laparoscopic surgery|This group will be consisted of patients that will undergo conventional laparoscopic surgery for benign gynecologic disorders
89192285|NCT00617890|Experimental|Group 1: 0.3 mg/kg|Participants received robatumumab 0.3 mg/kg intravenously (IV) as a single dose on Day 1, followed by surgery on Day 10 to 14, and four weeks later, resumption of robatumumab 0.3 mg/kg on the same calendar day (± 3 days) once every 2 weeks until disease recurrence or up to 1 year of dosing. This group comprised participants with resectable osteosarcoma that relapsed within 6 months of prior definitive treatment (eg surgical metastasectomy) and having at least one prior chemotherapy regimen containing a platinum agent and doxorubicin.
89192286|NCT00617890|Experimental|Group 1: 10 mg/kg|Participants who received robatumumab 10 mg/kg IV as a single dose on Day 1, followed by surgery on Day 10 to 14, and four weeks later, resumption of robatumumab 10 mg/kg on the same calendar day (± 3 days) once every 2 weeks until disease recurrence or up to 1 year of dosing. This group comprised participants with resectable osteosarcoma that relapsed within 6 months of prior definitive treatment (eg surgical metastasectomy) and having at least one prior chemotherapy regimen containing a platinum agent and doxorubicin.
89192287|NCT00617890|Experimental|Group 2: 10 mg/kg|Participants received robatumumab 10 mg/kg IV biweekly until disease recurrence or up to 1 year of dosing. This group comprised participants with relapsed and unresectable osteosarcoma refractory to prior chemotherapy with a platinum- and doxorubicin-containing regimen.
89411437|NCT02302040|Active Comparator|Self-Guided|Participants in the self-guided control condition will be given general information on supportive behavioral management techniques they can use to target improvement in asthma self-management behaviors. The control condition will serve as an attention control and is designed to optimize recruitment and sustain interest while concurrently having a minimal impact on asthma management.
89411438|NCT02639650|Active Comparator|control group|etoposide, methotrexate ,actinomycin D,vincristine, cyclophosphamide(EMA-CO), two weeks a cycle
89005249|NCT04721496|Experimental|Trained|Athletes who had at least 2 years of continuous strength training experience, and at least 6 months of training with unstable situations and device
89411439|NCT02639650|Experimental|study group|paclitaxel + cisplatin or carboplatin，two weeks a cycle
89411440|NCT03509870|Other|mesenchymal stromal cells|mesenchymal stromal cells in collagen scaffold
89411441|NCT03581734|Active Comparator|OPV only|The vaccine will be available in prefilled vials containing 10 doses. Each vial will be labelled with the study ID of the participant. Therefore, for participants randomized to arm A and arm C, there will be 3 vials per participant for the 3 doses of the bOPV vaccine to be given 28 weeks apart. Any remaining, non-used doses of vaccine in the vial will be discarded.
89411442|NCT03581734|Active Comparator|Shanchol only|Each dose of vaccine is 1.5ml in volume. Each vial will be labelled with the study ID of the participant. One vial will be used per participant per study visit. OCV was studied in a double-blind, randomized, placebo-controlled trial in Kolkata, India. Participants were 1 year and above in age. In these studies, 100 children aged 1-17 were administered 2-doses of OCV or placebo separated by an interval of two weeks, with 80% of vaccinated showing over 4 fold rise in serum V. cholerae O1 antibody titers, showing that the 2-dose regimen was well-tolerated, safe and immunogenic
89411443|NCT03581734|Experimental|OPV-OCV co-administered|"Our primary analysis will be to compare seroconversion (defined as a change of status from seronegative to seropositive titers, or a ≥4-fold rise in antibody titer) for OPV1 and OPV 3 antibodies between Arm A and Arm C, to determine whether seroconversion to bOPV when administered with Shanchol is non-inferior to seroconversion to bOPV when bOPV is administered alone.~Our second objective will be to compare vibriocidal antibody seroconversion (also, ≥4-fold rise in antibody titers) to Shanchol when co-administered with OPV or when Shanchol is administered alone, Arm B compared to Arm C"
89411444|NCT02306798|Experimental|Formulation D|TP05
88887661|NCT03057652|Experimental|EKSO, then ReWalk, then REX|Subjects will be asked to complete a screening visit, baseline and post assessment for each intervention training (ReWalk, EKSO, REX) and up to 15 training sessions per device.
88887662|NCT03057652|Experimental|EKSO, then REX, then ReWalk|Subjects will be asked to complete a screening visit, baseline and post assessment for each intervention training (ReWalk, EKSO, REX) and up to 15 training sessions per device.
88887663|NCT03057652|Experimental|REX, then EKSO, then ReWalk|Subjects will be asked to complete a screening visit, baseline and post assessment for each intervention training (ReWalk, EKSO, REX) and up to 15 training sessions per device.
88887664|NCT03057652|Experimental|REX, then ReWalk, then EKSO|Subjects will be asked to complete a screening visit, baseline and post assessment for each intervention training (ReWalk, EKSO, REX) and up to 15 training sessions per device.
88887665|NCT03053713|Active Comparator|Mediterranean Diet Pattern|Mediterranean diet pattern x 12 weeks.
88887666|NCT03053713|Placebo Comparator|Habitual Diet|Habitual diet (control) x 12 weeks.
88887667|NCT03008746|Experimental|not Pseudomonas aeruginosa colonized|
88887668|NCT03008746|Experimental|Pseudomonas aeruginosa colonized|
88887669|NCT03008746|Experimental|Pseudomonas aeruginosa OprD mutant colonized|
88887670|NCT02980003|Active Comparator|isotonic saline|patients will start hydration with isotonic saline 6 hours before angiography and continue for 12 hours after the procedure. The infusion rate will be 1 mL/kg/h in the first 5 hours they will receive isotonic saline at 1 mL/kg/h (reduced to 0.5 mL/kg/h if with ejection fraction <35% or New York Heart Association (NYHA) functional class III or IV). Then, will be infused at 3 mL/kg/h for 1 hour immediately before contrast medium injection; following this, patients will receive the same fluid at a rate of 1 mL/kg/h
89005250|NCT04721496|Experimental|Untrained|Athletes who had at least 2 years of continuous strength training experience, but no training experience with unstable situations and devices
89005251|NCT00207350|Other|Brain tumor|Neurosurgical use of Interstitial Laser therapy
89005252|NCT00207389||Laparoscopic gastric bypass|Patients undergoing Laparoscopic gastric bypass
89005253|NCT00207389||Open gastric bypass|Patients undergoing Open gastric bypass
89192288|NCT00617890|Experimental|Group 3: 10 mg/kg|Participants received robatumumab 10 mg/kg IV biweekly until disease recurrence or up to 1 year of dosing. This group comprised participants with Ewing sarcoma refractory to prior treatment with at least 3 of the following agents: ifosfamide, etoposide, cyclophosphamide, doxorubicin, or vincristine.
89192289|NCT02569736||Tocilizumab|Patients with active moderate to severe RA fulfilling ACR criteria and requiring TCZ treatment, according to the EU label and French authority recommendations, who accept to enter the study and to sign the informed consent.
89192290|NCT02569736||Methotrexate|Patients with active moderate to severe RA fulfilling ACR criteria and requiring MTX treatment, according to the EU label and French authority recommendations, who accept to enter the study and to sign the informed consent.
89192291|NCT02569736||Healthy Controls|Healthy controls will be defined as people non-affected by an inflammatory disease (such as RA, ankylosing spondylitis, lupus…). This group will be constituted with patients affected by sciatica, osteoarthritis, osteoporosis…
89192292|NCT04066010|No Intervention|Control|
89192293|NCT04066010|Other|Intervention|Mobile application intervention
89192294|NCT00730626|Experimental|1|L.acidophilus and B.lactis (1x10E9 of each probiotics) with 40 mg of green the extract
89192295|NCT00730626|Experimental|2|L.acidophilus and B.lactis (1x 10E10 of each probiotics) with 40 mg of green tea extract
89192296|NCT00730626|Placebo Comparator|3|Placebo
89192297|NCT00870766|Active Comparator|CT|All patients in the CT arm undergo abdominal CT scanning within 24 hours of admission to the ER.
89192298|NCT00870766|No Intervention|Current practice|The patients in the current practice arm are referred to radiological examinations, such as US, plain radiography or CT, based on the clinical need only.
89192299|NCT00728780|Experimental|A|ABT-143 15/135mg
89192300|NCT00728780|Active Comparator|B|ABT-335 135mg and rosuvastatin 15mg
89192301|NCT00870844|Experimental|Lu AA24493 (CEPO): 0.5 mcg/kg|
89192302|NCT00870844|Experimental|Lu AA24493 (CEPO): 5.0 mcg/kg|
89192303|NCT00870844|Experimental|Lu AA24493 (CEPO): 50.0 mcg/kg|
89192304|NCT00870844|Placebo Comparator|Placebo|
89192305|NCT00734708|Experimental|A|positive drug (0.3% Trafermin contained)
89192306|NCT00734708|Placebo Comparator|P|control
89192307|NCT04066296|Active Comparator|Liposomal Bupivicaine|Treatment with liposomal bupivicaine
89192308|NCT04066296|Active Comparator|Standard Local Anesthestic|Treatment with Standard Local Anesthestic
89192309|NCT00862576||1|Burning Mouth Syndrome Group
89005254|NCT00233142|Experimental|Expressive writing|Expressive writing
89192310|NCT00862576||2|Control Group
89192311|NCT02341014|Experimental|Carfilzomib, Romidepsin, Lenalidomide|All patients will be treated with romidepsin administered intravenously on days 1 and 8 of a 21-day cycle. Lenalidomide will be taken orally daily for days 1-14 of a 21-day cycle. The carfilzomib will be given weekly on days 1, and 8 of a 21-day cycle. Once a MTD is determined this dosing level will be used for the phase IIa portion. Cycles will be continued as above until the patient's wishes to be removed from the study, unacceptable toxicity develops, disease progression, treating physician recommends removal, or termination of study occurs.
89192312|NCT00738764|Experimental|Cohort 1|PDL192 Dose Level 1
89192313|NCT00738764|Experimental|Cohort 2|PDL192 Dose Level 2
89192314|NCT00738764|Experimental|Cohort 3|PDL192 Dose Level 3
89192315|NCT00738764|Experimental|Cohort 4|PDL192 Dose Level 4
89192316|NCT00738764|Experimental|Cohort 5|PDL192 Dose Level 5
89192317|NCT00738764|Experimental|Cohort 6|PDL192 Dose Level 6
89192318|NCT00868270||Children with UTIs|
89192319|NCT00730782|Active Comparator|1|The experimental vaccine PfAMA1 formulated in Alhydrogel
89192320|NCT00730782|Active Comparator|2|The experimental vaccine PfAMA1 formulated in Montanide ISA720
89192321|NCT00730782|Active Comparator|3|The experimental vaccine PfAMA1 formulated in ASO2A
89192322|NCT00868426|Experimental|1|Budesonide/Formoterol Batch 1
89192323|NCT00868426|Experimental|2|Budesonide/Formoterol Batch 2
89192324|NCT00868426|Experimental|3|Budesonide/Formoterol Batch 1 and charcoal
89192325|NCT03872856|Active Comparator|BP-ICAN|Participants in the BP-ICAN arm will receive a home blood pressure monitor to be used twice daily for 12 months. Participants' home blood pressure measurements will be shared with their provider and participants will receive a series of text messages including topics on the importance of managing hypertension, reminders to measure blood pressure with their device, and motivational messages on diet and exercise.
89411445|NCT04980430||Primary Care and Ophthalmology clinic patients|Participants will be recruited from primary care and ophthalmology clinics in New York City
89411446|NCT02306876|Experimental|PF-06412562 3mg|PF-06412562 3mg BID
89411447|NCT02306876|Placebo Comparator|Placebo|Placebo BID
89411448|NCT02306876|Experimental|PF-06412562 15mg|PF-06412562 15mg BID
89411449|NCT04347226|Experimental|BMS-986253|BMS-986253 2400mg IV
89411450|NCT04347226|No Intervention|Standard of Care treatment|Usual treatment of COVID-19 per study physician discretion
89411451|NCT02302118||Surgical approach|Group A: Esophagogastrectomy Group B: Extended gastrectomy
88819786|NCT04335747||Group 1|Patients with inflammatory rheumatic diseases who are hospitalised due to a COVID-19 infection
89411452|NCT04962178|Experimental|Early Invasive Strategy|Procedure: Primary PCI
89411453|NCT04962178|Active Comparator|Conservative Strategy|Procedure: Optimal medical therapy with primary PCI not performed.
89411454|NCT02302196||Autologous Fat Grafting of the breast|Approximately 100 women who have had a lumpectomy and qualify, will be offered Autologous Fat Grafting (AFG) procedure. Patients will be assessed 3 months post grafting for safety and efficacy by Breast-Q survey, mammography BIRADS scoring and physical assessment. The AFG may be repeated x 2 at a 3-6 month interval if deemed necessary by the treating surgeon, then reassessed again 3 months later in the same way. Repeat mammogram will be done 1 year post AFG.
89411455|NCT02302196||Control arm standard treatment|Retrospective chart review will be done in 100 women who have undergone standard treatment for breast contour defect after lumpectomy.The control group will be measured by compiling BIRADS scores as well as frequency of subsequent surgical intervention (as necessitated by increased BIRADS scores or by new physical findings on exam) over a 5 year period post lumpectomy.
89411456|NCT03509714|Active Comparator|Experimental: Part 1 Oxaloacetate Random|Participants take 2 capsules Jubilance 100 mg Oxaloacetate/150 mg Ascorbic Acid blend per day during their entire menstrual cycle (approximately 28 days) or 2 capsules of 250 mg rice flour (Placebo). After one menstrual cycle, they cross-over to the other option.
89411457|NCT03509714|Active Comparator|Experimental: Part 2 Oxaloacetate Second|Participants take 2 capsules of 250 mg rice flour (Placebo) per day during their entire menstrual cycle (approximately 28 days). After one menstrual cycle, they cross-over to 2 capsules of Jubilance 100 mg Oxaloacetate/150 mg Ascorbic Acid blend.
89411458|NCT02303522||All subjects|All subjects will be included in a unique cohort
89411459|NCT03101878|Experimental|Ionis AGT-LRx|Ascending single and multiple doses of Ionis AGT-LRx administered subcutaneously.
89411460|NCT03101878|Placebo Comparator|Placebo|Saline .9%
89411461|NCT02302274||flecainide infusion test|Patients with suspect Brugada Syndrome will be asked to undergo flecainide infusion (2 mg/Kg up to 150 mg maximum dose) over 10 minutes and their ECG will be continuously monitored. The objective of the study is to investigate if they show conversion from type 2 or type 3 ECG to a diagnostic type 1 ECG.
88819787|NCT04335747||Group 2|Patients without inflammatory diseases who are hospitalised due to a COVID-19 infection
88819788|NCT04335747||Group 3|Patients with inflammatory rheumatic diseases who are having routine blood samples taken under the COVID-19 epidemic after inclusion and who have NOT been hospitalised due to a COVID-19 infection
88819789|NCT04335747||Group 4|Healthy subjects from the Danish Blood Donors have NOT been hospitalised due to a COVID-19 infection
88819790|NCT04336059|Other|group 1|will receive sham PENG block with normal saline in total volume of 20 ml.
88819791|NCT04336059|Experimental|group 2|will receive real PENG block with bupivacaine (0.25%) in total volume of 20 ml.
88819792|NCT05348187|Other|Clinical Performance Study Protocol for therascreen® KRAS RGQ PCR Kit|The therascreen KRAS RGQ PCR Kit is a real-time qualitative PCR assay used on the Rotor-Gene Q MDx instrument for the detection of somatic G12C mutations in the human KRAS oncogene using DNA extracted from formalin fixed paraffin-embedded (FFPE) Colorectal Cancer (CRC) and Non-small Cell Lung Cancer (NSCLC) tissue. The therascreen KRAS RGQ PCR Kit is intended to aid in the identification of cancer patients who may be eligible for treatment with AMG 510.
88819793|NCT01512446|Active Comparator|Alendronate|
88819794|NCT01512446|Placebo Comparator|Placebo|
88819795|NCT04334967|Experimental|Treatment Arm|Patients in the treatment arm will receive 200 mg oral hydroxychloroquine. Day 1: 400 mg doses twice (800 mg total). Days 2-5: 200 mg dose twice (400 mg total daily).
88819796|NCT04334967|Active Comparator|Control Arm|Patients in the control arm will receive 500 mg oral Vitamin C. Day 1: 1000 mg dose twice (2000 mg total) Days 2-5: 500 mg dose twice (1000 mg total daily).
88819797|NCT01565330|Experimental|111 MBq (3 mCi) AD Group|Subjects with AD who received 111MBq (3 mCi) of florbetapir F 18; MBq=megabecquerel
88819798|NCT01565330|Experimental|111 MBq (3 mCi) Control Group|Healthy controls who received 111MBq (3 mCi) of florbetapir F 18
88819799|NCT01565330|Experimental|370 MBq (10 mCi) AD Group|Subjects with AD who received 370MBq (10 mCi) of florbetapir F 18
88819800|NCT01565330|Experimental|370 MBq (10 mCi) Control Group|Healthy controls who received 370MBq (10 mCi) of florbetapir F 18.
88819801|NCT04335123|Experimental|Open Label Losartan|50 patients with COVID-19 and respiratory failure who meet criteria and agree to participation in the study will be placed on losartan 25 mg once daily on study day 0. If parameters are met the dose of losartan will be increased to 50 mg once daily on study day 3. Participants will continue losartan until they experience resolution of respiratory failure (normal oxygen levels on room air), are discharged from the hospital, meet stoppage criteria or complete 14 days of therapy.
88819802|NCT05347953||Single arm|Patients with self-reported symptoms of positional dependent palpitations
89411462|NCT02303600|Experimental|biomarker treatment arm|Patients in biomarker guided positive treatment arm were given Montelukast Sodium Tablets (p.o., 10mg, q.d.) . Patients in biomarker guided negative treatment arm were given placebo tablets (main excipient lactose monohydrate).
89411463|NCT02303600|Active Comparator|standard treatment arm|Patients in standard treatment arm were given Montelukast Sodium Tablets (p.o., 10mg, q.d.) .
89411464|NCT05245240|Experimental|Severe OSA group|Dietary and physical activity intervention
89005255|NCT00233142|Sham Comparator|Neutral writing|Non-expressive writing
89005256|NCT02962700|Experimental|CVVHF|CVVHF for 48 h interstitial tissue concentrations of lactate, pyruvate, glucose and glycerol were obtained at baseline, 6, 12,18 and 24 hours after initiation of renal replacement by using muscle microdialysis.
89411465|NCT05245240|Experimental|Mild OSA group|Dietary and physical activity intervention
89411466|NCT02307110|Other|1 arm study|cross-sectional observation
89411467|NCT03505034|Experimental|Umbilical Cord Mesenchymal Stem Cells|Intrathecal Transplantation of Umbilical Cord Mesenchymal Stem Cells
89411468|NCT05244850||One group|Stroke patients
89411469|NCT03507296||Chronic low back pain patients|
89411470|NCT03507296||Asymptomatic subjects|
89411471|NCT02817178|Other|Additional biological samples|"Additional blood samples will be realized specifically to the study at baseline, at 1 month, at 3 months, and 1 month after surgery (if applicable).~Peripheral Blood Mononuclear Cell (PBMC) and plasma will be collected. Tissue tumor is collected during surgery if applicable."
89411472|NCT02303756|Experimental|Pillcam® COLON Capsule|Detection of neoplastic lesions in colon and rectum compared to colonoscopy
89411473|NCT04730986|Experimental|Intervention Arm|This is a single-arm study with all enrolled patients receiving the same ED GOAL Nursing intervention
89411474|NCT04463342|Experimental|Non Coated Glass Ionomer|A faster, easier procedure is great, but you want assurance that reducing chair time doesn't mean compromising on performance. KetacTM Universal AplicapTM Glass Ionomer Restorative saves time by eliminating the need for a coating-yet still delivers the compressive strength and surface hardness that are higher than several competitive glass ionomers which require one.This advancement is the latest in 3M's 30-year history of developing proven and trusted glass ionomers.
89411475|NCT04463342|Active Comparator|Conventional Glass Ionomer with Coat|"A bulk-fill, packable and fast-setting conventional glass ionomer. Because it's less technique sensitive than a composite it's ideal for difficult-to-isolate posterior restoration. High compressive strength and marginal integrity make it a glass ionomer of choice for posterior restorations.Ketac Conditioner Dentin Pretreatment is required; Ketac Glaze Light-Cured Varnish applied on the top of the restoration to avoid moisture contamination."
89411476|NCT05244772|Experimental|Remote monitoring|At discharge, patients in the remote monitoring group receive verbal and paper care- and recovery instructions from a day care ward nurse and in adittion they will have a monitoring application installed on theirpersonal smartphone. Once they are back home, they can start recording pain and nausea and ask questions about their recovery with the application and report back the anaesthesia backoffice.
89411477|NCT05244772|No Intervention|Standard care|At discharge, patients in the standard care group receive verbal and paper care- and recovery instructions from a day care ward nurse.
89411478|NCT02303834|No Intervention|Control|The control group will not be fitted with CPAP.
89411479|NCT02303834|Experimental|CPAP group|The group will wear a CPAP device throughout the night. The mask fits comfortably over the nose and delivers a steady stream of air under slight pressure (auto-set).
89411480|NCT02303912|Other|Open label dose escalation|"Nuc-1031 IV injection on day 1 and day 8 repeated every 21 days Carboplatin IV infusion on day 1 repeated every 21 days.~Dose escalation will be done using 3+3 dose escalation design"
89411481|NCT03507218||1|Children with Pediatric Acute-onset Neuropsychiatric Syndrome (PANS)
89411482|NCT01597492|Experimental|Belimumab plus Early Vaccination|Belimumab plus Early Vaccination
89411483|NCT01597492|Experimental|Belimumab plus Late Vaccination|Belimumab plus Late Vaccination
89411484|NCT04483726|Experimental|MIDP|minimally invasive distal pancreatectomy
89411485|NCT04483726|Sham Comparator|ODP|open distal pancreatectomy
89192326|NCT03872856|No Intervention|Control|Participants in the control arm will receive care as usual for the treatment of hypertension
89411486|NCT03423602|Experimental|Investigational device|To confirm safety and performance of the PerQseal® Closure Device (DP2-FA1-4) and PerQseal® Introducers (DP2-FA1-5 and DP2-FA1-6) to percutaneously close femoral artery punctures and to induce arterial haemostasis in patients undergoing endovascular procedures requiring an arteriotomy created by 12 to 20 F sheaths.
89411487|NCT04051645|Experimental|Breathing through a system with adjustable flow resistance|During the experiment, the volunteers will breathe through ten adjustable flow resistances and their work of breathing will be measured.
89411488|NCT04569994|Experimental|Part 1|Healthy volunteers will receive either NNC0363-0845 or placebo
89411489|NCT04569994|Experimental|Part 2|Participants with T1D will receive either NNC0363-0845 or insulin degludec
89411490|NCT04569994|Experimental|Part 3|Participants with T1D will receive NNC0363-0845
89411491|NCT02307344|Active Comparator|Nigella Sativa Supplement|Fifty patients suffering from Nonalcoholic Steatohepatitis or Liver Steatosis will ingest capsules containing 2 grams of Nigella Sativa divided into 1 grams twice a day.
89411492|NCT02307344|Active Comparator|Patients receiving a placebo tablet|Twenty patients suffering from Nonalcoholic Steatohepatitis or Liver Steatosis will ingest placebo capsules twice a day, that look like the capsules of those receiving the Nigella Sativa.
89411493|NCT05374096|Experimental|Music Via Headphones|Headphones will be placed with patient-selected music playing for the duration of the surgical procedure.
89411494|NCT05374096|Placebo Comparator|Silence Via Headphones (Control)|Headphones will be placed with silence for the duration of the surgical procedure.
88887671|NCT02980003|Active Comparator|i.v. sodium bicarbonate|in the first 5 hours patients will receive isotonic saline at 1 mL/kg/h (reduced to 0.5 mL/kg/h if with ejection fraction <35% or NYHA functional class III or IV). Then, a solution of 1.4% sodium bicarbonate (167 mEq/L; 334 milliosmol (mOsm/L)) will be infused: the initial intravenous bolus will be 3 mL/kg/h for 1 hour immediately before contrast medium injection; following this, patients will receive the same fluid at a rate of 1 mL/kg/h (reduced to 0.5 mL/kg/h if with ejection fraction <35% or NYHA functional class III or IV) during the exposure to contrast and for 6 hours after the procedure. Later, patients will resume hydration with isotonic saline for further 6 hours.
88887672|NCT02980003|Experimental|oral sodium bicarbonate:|"patients will start hydration with isotonic saline as well as Arm Hydration Alone. One hour before the angiography and 3 hours after patients will receive oral sodium bicarbonate at the dose of 4 g (47.6 mEq) dissolved in 60 mL of water. The drug will be weighed with a precision balance with a sensitivity of ± 0.1 mg and placed in a labeled sterile plastic container. The label will report the lot number, expiry date of the sodium bicarbonate lot, the signature of the pharmacist carrying out the weighing process, a serial number to identify the sample and the patient identification number.~Documentation will be stored in the Laboratory of Galenic Preparations, Pharmacy Division, of the hospital."
88887673|NCT02884323|Experimental|geko device arm|
88887674|NCT02786875|Experimental|Group A (high intensity program):|"Diet: low glycemic index (GI) Mediterranean diet. All carbohydrate foods will be low GI choices (GI<70 on bread scale, e.g. legumes, pasta al dente, barley, oat, apples, oranges, berries, nuts) within a healthy Mediterranean diet (≥5 servings veg/fruit per day, ≤1 serving red meat+cold cuts/week, <7% SFA).~Moderate physical activity: brisk walk of at least 30min per day (or approximately 5000 steps) more than the habitual physical activity.~Vitamin D supplement (cholecalciferol) up to 4000 IU/day to reach blood levels of 60-80 ng/ml of 25(OH)D."
88887675|NCT02786875|Active Comparator|Group B (lower intensity program)|"Diet: general recommendations for a healthy Mediterranean diet (≥5 servings veg/fruit per day, ≤1 serving red meat+cold cuts/week, <7% SFA).~Basic physical activity: general recommendations to avoid sedentary behaviour. Vitamin D supplement (cholecalciferol) will be given only if vitamin D insufficiency is detected to reach blood levels of 30 ng/ml of 25(OH)D."
88887676|NCT02780089||Prospective Patients|There will be 1,600 prospective patients recruited over a period of two years and followed-up for a planned minimum of three years. For the prospective cohort, patients will be recruited after the course of treatment has been decided by the physician and prior to the start of treatment.Prior advanced melanoma treatment information will be collected from patient charts for pre-treated patients. Patients will be followed for a minimum of 3 years from their study index date until death, withdrawal of consent, lost to follow-up/record, or end of study, whichever comes first. Study index date will be the date when first study therapy is initiated.
88887677|NCT02780089||Treatment Group No. 1|Immune checkpoint inhibitor patients who remain on an immune checkpoint inhibitor therapy. Defined as immune checkpoint inhibitor therapy patients who either remained on their initial (index) immune checkpoint inhibitor therapy or switched to another immune checkpoint inhibitor therapy during the study period. Patients in this group remained on an immune checkpoint inhibitor therapy and did not switch to a non-immune checkpoint inhibitor therapy anytime during the study period.
88887678|NCT02780089||Treatment Group No. 2|Immune checkpoint inhibitor patients who switched to a non-immune checkpoint inhibitor therapy. Defined as patients who switched from their index immune checkpoint inhibitor therapy to a non-immune checkpoint inhibitor therapy anytime during the study period.
88887679|NCT02780089||Treatment Group No. 3|Targeted therapy patients who remain on a targeted therapy. Defined as targeted therapy patients who either remained on their initial (index) targeted therapy or switched to another targeted therapy during the study period. Patients in this group remained on a targeted therapy and did not switch to a non-targeted therapy anytime during the study period.
88887680|NCT02780089||Treatment Group No. 4|Targeted therapy patients who switched to a non-targeted therapy. Defined as patients who switched from their index targeted therapy to a non-targeted therapy anytime during the study period.
88887681|NCT02780089||Treatment Group No. 5|Chemotherapy/other therapy patients who remain on a chemotherapy/other therapy. Defined as chemotherapy/other therapy patients who either remained on their initial (index) chemotherapy/other therapy or switched to another chemotherapy/other therapy during the study period. Patients in this group remained on a chemotherapy/other therapy and did not switch to an immune checkpoint inhibitor therapy or targeted therapy anytime during the study period.
88887682|NCT02780089||Treatment Group No. 6|Chemotherapy/other patients who switched to an immune checkpoint inhibitor therapy or targeted therapy. Defined as patients who switched from their index chemotherapy/other therapy to an immune checkpoint inhibitor therapy or targeted therapy anytime during the study period.
88887683|NCT02780089||Retrospective Patients|Retrospective cohort of 600 patients with unresectable or metastatic melanoma, receiving therapies other than immune checkpoint inhibitor or targeted therapies during the four year period prior to the release of ipilimumab (March 25, 2007 -March 24, 2011), will be identified. The data for these 600 retrospective patients will be used as a benchmark for treatment patterns and outcomes prior to the marketed availability of immune checkpoint inhibitors or targeted therapies.
88887684|NCT02778256|Experimental|Vestibular stimulation|Patients of this group will receive a specific vestibular stimulation technique.
88887685|NCT02778256|Sham Comparator|Sham vestibular stimulation|This group of patients will receive sham vestibular stimulation, similar to experimental group vestibular stimulation in the range of under threshold frequencies undistinguished from real vestibular stimulation. The absence of vestibular nystagmic response confirms that the stimulus is sham.
88887686|NCT02767882|Active Comparator|Group D1|Patients from group D will be given a bolus injection of 2 ml saline with 2 ml dexamethasone (4mg/ml) before skin incision.
88887687|NCT02767882|Experimental|Group D2|4ml bolus injection of dexamethasone (4mg/ml) will be given intravenously prior to incision.
89192327|NCT00870922|Experimental|TMD group|Participants will receive ART and have Therabite (mouth opening) and pain (VAS) measured before and after ART
89192328|NCT00868504||examined by endoscopy|Patients, examined by endoscopy, being screened for GI tract tumors
89192329|NCT03853746|Experimental|Ocrelizumab|All participants will receive Ocrelizumab
89192330|NCT00868582||FDG-PET|F-18 fluorodeoxyglucose (FDG-PET)
89192331|NCT00868582||NaF-18 PET|F-18 sodum-fluoride (NaF-18 PET)
89192332|NCT03037242|Other|Transtibial pullout technique|Evaluation of the clinical and radiographic outcomes for patients undergoing a meniscus root repair (MRR) using a transtibial pullout technique.
89192333|NCT00868660|Experimental|ZP1848|Healthy Subjects or Crohn's Disease patients
89192334|NCT00868660|Placebo Comparator|Placebo|Healthy subjects or Crohn's Disease patients
89192335|NCT00712166|Placebo Comparator|Placebo three times daily (TID)|
89192336|NCT00712166|Experimental|AZLI 75 mg three times daily (TID)|
89192337|NCT00868738|Active Comparator|Vitamin D|Subjects will be provided supplemental vitamin D3 (1000 IU), given once daily as a softgel or liquid. Subjects will be instructed to take the supplement daily for 8 weeks.
89192338|NCT00868738|Placebo Comparator|Placebo|Subjects will be provided a placebo, given once daily as a softgel or liquid. Subjects will be instructed to take the supplement daily for 8 weeks.
89192339|NCT00652743|Experimental|GSK1562902A M6 Group|Healthy male or female adults, primed with 2 doses of adjuvanted investigational H5N1 vaccine (A/Vietnam/1194/04 strain) and boosted 6 months (M6) after primary vaccination with one dose of Pandemic influenza candidate vaccine (GSK1562902A) in study 109630 (NCT00449670), administrated intramuscularly (IM) in the deltoid region of the non-dominant arm.
89192340|NCT00652743|Experimental|GSK1562902A M12 Group|Healthy male or female adults, primed with 2 doses of adjuvanted investigational H5N1 vaccine (A/Vietnam/1194/04 strain) in study 109630 (NCT00449670) receiving one dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, at 12 Months (M12) after the primary vaccination, administrated intramuscularly (IM) in the deltoid region of the non-dominant arm.
89192341|NCT00652743|Experimental|GSK1562902A M36 Group|Healthy male or female adults, primed with 2 doses of adjuvanted investigational H5N1 vaccine (A/Vietnam/1194/04 strain) in study 109630 (NCT00449670) receiving one dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, at 36 Months (M36) after the primary vaccination, administrated intramuscularly (IM) in the deltoid region of the non-dominant arm.
89192342|NCT00730860|Experimental|RFA+TACE|treatment of hepatocellular carcinoma by radiofrequency ablation associated with postoperative transhepatic arterial chemoembolization
89192343|NCT00730860|Active Comparator|RFA only|treatment of hepatocellular carcinoma by radiofrequency ablation only
89192344|NCT00868816|Experimental|1|12 cycles of oxaliplatine based adjuvant chemotherapy
89192345|NCT00868816|Active Comparator|2|8 cycles of oxaliplatine based adjuvant chemotherapy
89192346|NCT02569866|Active Comparator|Antibiotics Group|Capsules containing cephalexin/500mg will be administrated to the subjects, 4 times daily, for seven days during the postoperative period of reduction mammaplasty.
88887688|NCT02767882|Placebo Comparator|Group C|4ml bolus injection of 0.9% saline will be given intravenously prior to incision
89192347|NCT02569866|Placebo Comparator|Placebo Group|Capsules containing placebo/500mg will be administrated to the subjects, 4 times daily, for seven days during the postoperative period of reduction mammaplasty.
89192348|NCT00868894|Experimental|1|
89192349|NCT00868894|Experimental|2|
89192350|NCT00868894|Placebo Comparator|3|
89192351|NCT00868894|Active Comparator|4|
89192352|NCT00730938|Active Comparator|1|
89192353|NCT00730938|Placebo Comparator|2|Saline placebo
89192354|NCT00712010|Experimental|Whey protein native|Whey protein native versus the 6 other arms
89192355|NCT00712010|Experimental|Whey protein microgels|Whey protein microgels versus the 6 other arms
89192356|NCT00712010|Experimental|Hydrolyzed whey protein|Hydrolyzed whey protein versus the 6 other arms
89192357|NCT00712010|Experimental|Casein native|Casein native versus the 6 other arms
89192358|NCT00712010|Experimental|Hydrolyzed casein|Hydrolyzed casein versus the 6 other arms
89192359|NCT00712010|Experimental|Total milk protein native|Total milk protein native versus the 6 other arms
89192360|NCT00712010|Experimental|Hydrolyzed milk protein|Hydrolyzed milk protein versus the 6 other arms
89192361|NCT00731016|Other|1|Zoledronic acid, pravastatin
89192362|NCT00868972|Active Comparator|Embolic protection|Percutaneous renal stenting using a distal embolic protection device (filter wire ex; Cordis Endovascular, USA).
89192363|NCT00868972|Sham Comparator|No embolic protection|Percutaneous renal stenting intervention without embolic protection
89192364|NCT00731172|Experimental|1|20 mg copaxone(glatiramer acetate)subcutaneous injection(daily through week 12)
89192365|NCT00731172|Placebo Comparator|2|placebo subcutaneous injection(daily through week 12)
89192366|NCT00738842|Experimental|1|
89192367|NCT00738842|Placebo Comparator|2|
89192368|NCT00809913|Experimental|Short treatment|7 days of standard antibiotic treatment (preferably ciprofloxacin) followed by 7 days of placebo
89192369|NCT00809913|Active Comparator|Standard treatment|14 days of standard antibiotic treatment (initial b-lactam or fluoroquinolone followed by ciprofloxacin through the 8th till 14th day)
89192370|NCT00729222|Placebo Comparator|1|Placebo
89192371|NCT00729222|Experimental|2|rolofylline
89192372|NCT03896386|Other|Use of seizure diary|People diagnosed with epilepsy that lives with a dog that is able to anticipate the onset of a seizure. They will be ask to use a diary (bespoke smartphone app) to register the occurrence of seizures and the alerting behaviour of the dogs.
89192373|NCT00734786|Placebo Comparator|2|Volunteers will be their own control by randomly receiving the active on one face side and the placebo on the opposite one.
89192374|NCT00808743|Active Comparator|Group 1|Patients receive oral celecoxib twice daily and oral placebo twice daily
89192375|NCT00808743|Experimental|Group 2|Patients receive oral celecoxib twice daily and oral ursodeoxycholic acid twice daily
89192376|NCT00869596|Placebo Comparator|1|Placebo
89411495|NCT02307422||Case|Diabetic patients undergoing coronary angiography (both sexes), who are age 18-90, and admitted in the Department of Cardiology in the University General Hospital of Ioannina and Catheterization Laboratory of 1st IKA Hospital in Athens and undergo coronary angiography for clinical purposes will be studied. Presence epicardial vessel stenosis (>50%), and multi-vessel disease will be recorded. Excluded: previous history of revascularization procedure or moderate to severe stenosis. Patient samples will be evaluated for quantitative levels of the biomarkers Lp(a) and OXPL/apoB. IL-1 Genotypes, and other SNPs associated with CAD will be assessed in this group and related to levels of Lp(a) and oxidized phospolipids. No interventions other than the post-hoc DNA testing will be performed.
89411496|NCT02307422||Control|Non-diabeticpatients undergoing coronary angiography (both sexes), who are age 18-90, and admitted in the Department of Cardiology in the University General Hospital of Ioannina and Catheterization Laboratory of 1st IKA Hospital in Athens and undergo coronary angiography for clinical purposes will be studied. Presence epicardial vessel stenosis (>50%), and multi-vessel disease will be recorded. Excluded: previous history of revascularization procedure or moderate to severe stenosis. Patient samples will be evaluated for quantitative levels of the biomarkers Lp(a) and OXPL/apoB. IL-1 Genotypes, and other SNPs associated with CAD will be assessed in this group and related to levels of Lp(a) and oxidized phospolipids. No interventions other than the post-hoc DNA testing will be performed.
89411497|NCT03509480|Active Comparator|Curettage with Vitoss|ultraporous beta-tricalcium phosphate mixed with autologous bone marrow aspirate for patients undergoing surgical curettage for benign bone lesions
89411498|NCT03509480|Active Comparator|Curettage with Prodense|ultraporous beta-tricalcium phosphate mixed with calcium sulfate for patients undergoing surgical curettage for benign bone lesions
89411499|NCT03509402|Experimental|Short implants|A full-arch screw-retained mandibular prosthesis with distal cantilevers supported by five interforaminal short implants (ASTRA TECH Implant System, OsseoSpeed™ 4.0 S, length: 6mm)
89411500|NCT03509402|Active Comparator|Long implants|A full-arch srew-retained mandibular prosthesis with distal cantilevers supported by five interforaminal short implants (ASTRA TECH Implant System, OsseoSpeed™ 4.0 S, length: ≥11mm)
89411501|NCT05243758|Active Comparator|Group video fiberscope of experienced practitioner|More experienced physician: endotracheal intubation with video fiberscope Assoc. Dr. The group in which Ersin Köksal performed endotracheal intubation using a video fiberscope( Karl Storz GmbH &Co. KG, Tuttlingen, Germany) consisted of 15 patients.Endotracheal intubation was performed by two practitioners using two different devices. Intubation times, number of attempts, failed attempts, postoperative complications and hemodynamic responses were recorded.
89411502|NCT05243758|Active Comparator|Group video laryngoscope of experienced practitioner|More experienced physician: Endotracheal intubation with DCI video laryngoscopeThe group in which Assoc. Dr. Ersin Köksal performed endotracheal intubation using a DCI video laryngoscope(Storz DCI Video Laryngoscope (Karl Storz GmbH &Co. KG, Tuttlingen, Germany) consisted of 15 patients.Endotracheal intubation was performed by two practitioners using two different devices. Intubation times, number of attempts, failed attempts, postoperative complications and hemodynamic responses were recorded.
89411503|NCT05243758|Active Comparator|Group video fiberscope of less experienced practitioner|Endotracheal intubation with video fiberscope: The group in which DrHalil Cebeci applied endotracheal intubation using a video fiberscope( Karl Storz GmbH &Co. KG, Tuttlingen, Germany) consisted of 15 patients. Endotracheal intubation was performed by two practitioners using two different devices. Intubation times, number of attempts, failed attempts, postoperative complications and hemodynamic responses were recorded.
88819803|NCT02742987|Experimental|Ticagrelor group|Ticagrelor 90 mg twice daily + standard medical therapy
88819804|NCT02742987|Experimental|Clopidogrel group|Clopidogrel 150 mg once daily + standard medical therapy
88819805|NCT05452473|Experimental|CDSS-assisted screening endoscopy|Participants will be tested for CDSS-assisted screening upper gastrointestinal endoscopy
89005257|NCT02962700|Active Comparator|IHD for 4 hours|"Intermittent haemodialysis was carried out during the first 4 h at day 1 and day 2 of the study period.~Interstitial tissue concentrations of lactate, pyruvate, glucose and glycerol were obtained at baseline, 6, 12,18 and 24 hours after initiation of renal replacement by using muscle microdialysis."
89005258|NCT00233220|Experimental|1|Patients and doctors will take part in a multicomponent, multi-level intervention.
89192377|NCT00869596|Active Comparator|2|Fluticasone 440 mcg
89192378|NCT00869596|Active Comparator|3|Fluticasone 1980 mcg
89192379|NCT03743376|No Intervention|Standard ART|Subjects will receive standard ART for 48 weeks
89192380|NCT03743376|Experimental|UB-421(25mg/kg) Q2W add-on treatment|UB-421(25 mg/kg) Q2W plus standard ART for 48 weeks
89192381|NCT03743376|Experimental|UB-421(25mg/kg) Q4W add-on treatment|UB-421(25 mg/kg) Q4W plus standard ART for 48 weeks
89192382|NCT00734864|Other|1|Subjects taking EIAEDs (CYP3A enzyme-inducing anti-epileptic drugs).
89192383|NCT00734864|Other|2|Subjects NOT taking EIAEDs (CYP3A enzyme-inducing anti-epileptic drugs).
89192384|NCT00869674|No Intervention|Routine pathologic method|Half of each sentinal lymph node will have rountine pathologic examination as normal practice.
89192385|NCT00869674|Experimental|GeneSearch BLN Assay|Half of each sentinal lymph node will have GeneSearch BLN testing.
89192386|NCT03728478|No Intervention|Treatment arm 1: Step-up|JIA patients managed with a Treat-To-Target strategy (T2T)
89192387|NCT03728478|Experimental|Treatment arm 2: Step-down|JIA patients treated with an early combined therapy
89192388|NCT00738998|Experimental|Questionnaire and Telephone Assessments|Breast cancer patients assigned to one or two groups: Group 1) enrolled at beginning of anastrozole treatment; or Group 2) if beginning third year of anastrozole treatment.
89192389|NCT00653523|Experimental|Ezetimibe + Simvastatin|Ezetimibe 10 mg + Simvastatin 20 mg
89192390|NCT00739076|Experimental|1|Virtual Reality Hypnosis
89192391|NCT00739076|Experimental|2|Virtual Reality Distraction
89192392|NCT00739076|Experimental|3|Standard treatment.
89192393|NCT00869830|Experimental|biofeedback|
89192394|NCT00739154||1|glaucoma patients who also suffer from epileptic disorder and receiving chronic oral Phenytoin treatment
89192395|NCT00739154||2|glaucoma patients who also suffer from epileptic disorder receiving anti-convulsant treatment other then Phenytoin
89192396|NCT00739154||3|glaucoma patients with no epileptic disorder and not receiving anti-convulsant treatment
89192397|NCT00799851|Active Comparator|Variceal band ligation|VBL was performed with a multiband ligation device (Euroligator System®). The first band was placed at or close to the gastroesophageal junction, with subsequent bands being placed proximally in a slightly spiral pattern. All visible varices within the distal esophagus were treated, with a maximum of 10 bands being placed in each session. There was a 3-week interval between each treatment session. When VBL was technically impossible due to scarring, sclerotherapy with ethanolamine oleate was performed on thin vessels.
89192398|NCT00799851|Active Comparator|cyanoacrylate injection|"CI group received intravariceal injections of 0.5 ml of N-butyl-2-cyanoacrylate (Histoacryl®) diluted in 0.5 ml of Lipiodol (Lipiodol®). Before injection of the Histoacryl-Lipiodol mixture, the catheter was filled up with 1 ml of Lipiodol. After puncturing the EV, the mixture was injected inside it and followed by injection of 1 ml of distilled water. Finally the catheter was retracted. To minimize the risk of embolism, a maximum of two medium or large vessels, in opposite walls, were treated in each session and not more than 0.5 ml of Histoacryl® was injected into each vessel.~A second injection was performed in any EV that maintained blood flow (medium or large size, blue, depressive at palpation with the catheter), in a bi-weekly interval basis. A chest x-ray was performed to evaluate the location of the Histoacryl-Lipiodol solution. Small vessels were treated with ethanolamine oleate sclerotherapy."
89192399|NCT02544412|Experimental|Intervention Group|"A novel mindfulness-based well-being training for preservice teachers will be employed. The intervention will be held once a week for 8-10 weeks. Two 4-hour days of mindfulness will also be implemented during the intervention period. The intervention will involve training in a range of attentional and constructive (Dahl, Lutz, & Davidson) contemplative practices. During the follow-up period participants will receive weekly 15 minute booster trainings."
89192400|NCT02544412|No Intervention|Control Group|Teacher education as usual. These participants will continue with the prescribed teacher training regime established by the Early Education Certification Program at the university.
89192401|NCT02717442|Experimental|OTO-104|12 mg dexamethasone
89192402|NCT02717442|Placebo Comparator|Placebo|
89192403|NCT00799929|Active Comparator|ARM A - Mini IVF|The Mini IVF method entails pre-treatment with oral contraceptive pills. Ovarian stimulation is achieved using an oral anti-estrogen in conjunction with injections of gonadotropin (225IU-600IU per cycle), with initial dose of 75IU-150IU per injection. Ovulation is induced by a GnRH (gonadotropin-releasing hormone) agonist nasal spray/hCG (human chorionic gonadotropin) injection. Retrieved oocytes following in vitro fertilization (IVF/ICSI) are cultured to the blastocyst stage. Blastocyst stage embryos are vitrified using the CryoTop method. No fresh embryo transfer is conducted. Subsequently, SET of a thawed blastocyst is performed in a natural cycle/HRT that does not involve ovarian stimulation. SETs are conducted until pregnancy is achieved or all vitrified blastocysts have been used.
89411504|NCT05243758|Active Comparator|Group video laryngoscope of less experienced practitioner|Endotracheal intubation with DCI video laryngoscope:The group in which Dr.Halil Cebeci applied endotracheal intubation using a DCI video laryngoscope(Karl Storz GmbH &Co. KG, Tuttlingen, Germany) consisted of 15 patients.Endotracheal intubation was performed by two practitioners using two different devices. Intubation times, number of attempts, failed attempts, postoperative complications and hemodynamic responses were recorded.
88887689|NCT02420184|Experimental|CPAP Therapy|Participants will receive standard medical care for CKD as well as CPAP therapy for the duration of the study (1 year).
88887690|NCT02420184|Placebo Comparator|No CPAP|Participants will receive standard medical care for CKD.
88887691|NCT02319408|No Intervention|No radiation|Lobectomy for lung cancer without preoperative radiation
88887692|NCT02319408|Experimental|Preoperative radiation|Lobectomy for lung cancer with preoperative radiation
88887693|NCT02264223|Active Comparator|Capsule (aglycone)|"single bolus 40mg isoflavone formulation of fermented extract in freeze-dried capsule.~Fermented red clover isoflavones in aglycone form"
88887694|NCT02264223|Active Comparator|Tablet (aglycone)|"single bolus 40mg isoflavone aglycone formulation of fermented extract in freeze-dried tablet.~Fermented red clover isoflavones in aglycone form"
88887695|NCT02264223|Active Comparator|Yoghurt (aglycone)|"single bolus 40mg isoflavone aglycone formulation of fermented extract mixed with yoghurt~Fermented red clover isoflavones in aglycone form"
88887696|NCT02264223|Active Comparator|Liquid extract (aglycone)|"single bolus 40mg isoflavone aglycone formulation of fermented extract in liquid~Fermented red clover isoflavones in aglycone form"
88887697|NCT02264223|Active Comparator|Tablet unfermented (glycoside)|"single bolus 40mg isoflavone aglycone equivalent tablet formulation of unfermented red clover isoflavones~Unfermented glycosides (as aglycone equivalents)"
88887698|NCT02246257|Other|Intervention|"In the intervention group all patients will receive statins according to national guidelines. Stepwise introduction of pharmacological therapy targeting 1) hyperlipidaemia, 2) hypertension, 3) hyperglycaemia and 4) microalbuminuria and behaviour modification will be controlled by the project team in an outpatient rheumatology department.~Hyperlipidaemia: LDL > 2.5 is treated with 40 mg Simvastatin; Hypertension: BT > 140/90 mmHg treated with 100 mg OD Losartan; Diabetes: DM BT > 130/80 mmHg treated with 100 mg OD Losartan; Microalbuminuria: Urinary albumin creatinin ratio > 30 mg treated with 100 mg OD Losartan; Hyperglycaemia: HBA1C > 48 mmol/mol treated with 500 mg increased dose to 2,000 mg in 4 weeks Metformin"
88887699|NCT02246257|Other|Control|"In the control group patients will be refered to general practice for pharmacological therapy according to national guidelines targeting 1) hyperlipidaemia, 2) hypertension, 3) hyperglycaemia and 4) microalbuminuria.~Hyperlipidaemia: LDL > 2.5 is treated with 40 mg Simvastatin; Hypertension: BT > 140/90 mmHg treated with 100 mg OD Losartan; Diabetes: DM BT > 130/80 mmHg treated with 100 mg OD Losartan; Microalbuminuria: Urinary albumin creatinin ratio > 30 mg treated with 100 mg OD Losartan; Hyperglycaemia: HBA1C > 48 mmol/mol treated with 500 mg increased dose to 2,000 mg in 4 weeks Metformin"
88887700|NCT02197221|Experimental|Bortezomib-Melphalan|Bortezomib will be administered on days: -6, -3 +1, +4. Melphalan will be administered on day -2. The PBSC will be injected on day 0.
88887701|NCT02197221|Active Comparator|Melphalan|Melphalan will be administered on day -2. The PBSC will be injected on day 0.
89005259|NCT00233220|Active Comparator|2|Patients will receive usual care.
89411505|NCT02311556|Experimental|DSC-PMR|DSC-PMR (dynamic susceptibility-weighted contrast- enhanced perfusion magnetic resonance imaging) at baseline (screening or time of radiosurgery) and after radiosurgery
89411506|NCT04372030|Other|General population|There is only one arm wishing to participate
89411507|NCT02311634|Experimental|Electrical pudendal nerve stimulation|At a frequency of 2.0 Hz and a moderate intensity (25~35 mA); 60 minutes three times a week for a total of three weeks
88887702|NCT02131779|Experimental|Co-Educational Workshops|Community health advisors will be trained using traditional/classroom methods and provided with technical assistance/support to implement the 4 part health series with men and women dyads. Technical assistance and support will be given as needed to community health advisors. Workshop sessions will include didactic lecture, group discussions, video and group exercises.
89411508|NCT02311634|Active Comparator|Transvaginal ES|At a current intensity of < 60 mA (in 5% increments from 0 mA to the intensity that is sensed without obvious discomfort) and frequencies of 12.5 to 30 Hz, 45 min three times a week for a total of four weeks.
89411509|NCT00109590|Experimental|Arm A: LPV/r x 7d|NVP 200 mg orally, single dose at onset of labor, ZDV 300 mg orally at onset of labor, every 3 hours during labor and BID for 7 days postpartum, ddI 250 mg orally daily (if body weight <60 kg) or 400 mg orally twice daily (if body weight >= 60 kg) at the onset of labor, during labor, and for 7 days postpartum, LPV/r 400/100mg orally twice daily at the onset of labor, during labor and for 7 days postpartum.
89411510|NCT00109590|Experimental|Arm B: no LPV/r|NVP 200 mg orally, single dose at onset of labor, ZDV 300 mg orally at onset of labor, every 3 hours during labor and twice daily for 7 days postpartum , ddI 250 mg orally daily (if body weight <60 kg) or 400 mg orally daily (if body weight >= 60 kg) at the onset of labor, during labor, and for 30 days postpartum.
89411511|NCT00109590|Experimental|Arm C: LPV/r x 30d|NVP 200 mg orally, single dose at onset of labor, ZDV 300 mg orally at onset of labor, every 3 hours during labor and twice daily for 7 days postpartum , ddI 250 mg orally daily (if body weight <60 kg) or 400 mg orally daily (if body weight >= 60 kg) at the onset of labor, during labor, and for 30 days postpartum,LPV/r 400/100mg orally twice daily at the onset of labor, during labor and for 30 days postpartum.
89411512|NCT05243446||Study group|Hypotensive treatment including Losartan
89411513|NCT05243446||Control group|Hypotensive treatment without renin-angiotensin-aldosteron system blockers.
89411514|NCT02311712|Active Comparator|Capsule sponge|Capsule sponge cytology examination coupled with H&E staining analysed for the presence of atypia and p53 immunohistochemistry
89411515|NCT02311712|No Intervention|Control|No intervention
89411516|NCT05234008|Experimental|home therapy group|one group of 15 participants (i.e. persons with CLBP) performing a six-week HIT exercise intervention with a total of 12 rehabilitation sessions (two sessions per week).
89411517|NCT03506984|Experimental|Group A|the participant will do a program of inspiratory muscle training for 10-15 minutes once daily using Threshold Inspiration Muscle Training Device
89411518|NCT03506984|Experimental|Group B|the participant will start cycling slowly for five minutes without resistance at the beginning of the exercise as warming up, then the active phase will last 20-30 minutes, then decrease the speed with no resistance at the end of the exercise as cooling down using Electronic Bicycle Ergometer
89411519|NCT02143362|Experimental|Dexmedetomidine group|"Infusion of dexmedetomidine(0.8μg/kg) at10 minutes before anesthesia induction.~Infusion of dexmedetomidine at 0.4 μg•kg-1•h-1during anesthesia maintenance.~The infusion rate of dexmedetomidine was reduced to 0.1 μg•kg-1•h-1 for awaken test."
88887703|NCT02131779|Active Comparator|Men's Workshops|Community health advisors will be trained using traditional/classroom methods and provided with technical assistance/support as needed to deliver 4 part educational sessions to men only groups to relay information about making an informed decision about prostate cancer screening. Workshop sessions will include didactic lecture, group discussions, video and group exercises.
89411520|NCT02143362|Placebo Comparator|Control group|"Infusion normal saline(0.8μg/kg) at 10 minutes before anesthesia induction.~Infusion normal saline at 0.4 μg•kg-1•h-1 during anesthesia maintenance.~The infusion rate of normal saline was reduced to 0.1 μg•kg-1•h-1 for awaken test."
89411521|NCT03509324|Other|duration of disease|different duration of disease receive insulin LISPRO
89411522|NCT02304068|Other|Intra-vitreal injection|
89411523|NCT02143440|Other|Newly diagnosed type 2 patients|The initial assessment of daily insulin dose.
89411524|NCT04906564||Moyamoya disease patients|"Moyamoya disease patients' inclusion Criteria:~1. Written informed consent is obtained; 2. Patients with age between 4-60 years; 3. Cerebral digital subtraction contrast angiography (DSA) reveal severe stenosis or occlusion of the distal internal carotid or proximal middle and anterior cerebral arteries with prominent lenticulostriate 'moyamoya collaterals'.~Exclusion Criteria:~1. There are other vascular diseases, including systemic vasculitis, neurofibroma, meningitis, sickle cell disease, down's syndrome, and previous basilar radiotherapy; 2. Patients with cardiogenic embolism, including a history of atrial fibrillation, valvular disease or cardiac valve replacement; 3. Physical or subjective failure to cooperate with the examination or serious comorbid diseases."
89411525|NCT02311790|Experimental|Trans-C16:1 supplement|Volunteers will take trans-C16:1 supplement for 3 weeks
89411526|NCT02311790|Experimental|Cis-C16:1 supplement|Volunteers will take cis-C16:1 supplement for 3 weeks
89411527|NCT02143518|Experimental|100 µg Na-GST-1/Alhydrogel|High Dose Na-GST-1/Alhydrogel® Only
89411528|NCT02143518|Experimental|30 µg Na-GST-1/Alhydrogel + CpG 10104|Low Dose Na-GST-1/Alhydrogel® Plus 500 µg CpG 10104
89411529|NCT02143518|Experimental|100 µg Na-GST-1/Alhydrogel + CpG 10104|High Dose Na-GST-1/Alhydrogel® Plus 500 µg CpG 10104
89411530|NCT03504878||Patients undergoing laparoscopic appendectomy|Appendix removal via scope.
89411531|NCT03504878||Patients undergoing open appendectomy|Open operation for removal of appendix
89411532|NCT02254590|Experimental|IEDL|Endoscopic decompression of spinal stenosis
89411533|NCT04805632||Dialysis|Patients on hemodialysis or peritoneal dialysis who received 2 administrations of Gam-COVID-Vac (Sputnik V) vaccine against SARS-CoV-2 infection
89192404|NCT00799929|Active Comparator|Arm B - Conventional IVF|The standard IVF method entails pre-treatment with a GnRH analog injections in the midluteal phase. Controlled ovarian hyperstimulation is achieved with injections of gonadotropin (150IU-300IU/day). Ovulation is induced by hCG injection and retrieved oocytes following in vitro fertilization (IVF/ICSI) are cultured to the blastocyst stage. If this occurs on day 5, then fresh SET/DET (single embryo transfer/double embryo transfer) is performed. Remaining blastocysts are cryopreserved and transferred in subsequent natural cycles/HRT (hormone replacement therapy) that does not involve ovarian stimulation.
89411534|NCT04805632||Healthy|Medical staff who received 2 administrations of Gam-COVID-Vac (Sputnik V) vaccine against SARS-CoV-2 infection
89411535|NCT03506906|Active Comparator|Conventional-approach|The non-invasive ventilation therapy will be optimized according to routine tests (blood gas analysis, lung function, ventilator's built-in software analysis)
89411536|NCT03506906|Experimental|Sleep studies-based approach|Additionally to the routine tests, the results of a nocturnal polysomnography and transcutaneous capnometry under the non-invasive ventilation therapy will be considered for the therapy optimization.
89411537|NCT03506828|Active Comparator|Surgical sympathectomy|All patients in this group will have standard surgical procedure
89411538|NCT03506828|Active Comparator|Radiofrequency ablation with phenol injection|patient will receive radiofrequency ablation of T2 and T3 sympathetic ganglia + phenol 6% (0.5ml) injection
89411539|NCT00546598|Other|Duraloc Option COC Hip|
89411540|NCT02307734|Experimental|Quit Smoking for a Healthy Family|The experimental/intervention study arm focuses on providing smoking cessation education and support through 2 LHW outreach small group educational sessions (4-5 weeks apart) and 2 individual follow-up telephone calls to smoker and family participants separately.
89411541|NCT02307734|Active Comparator|Healthy Living|"In this comparison arm, participants will receive the same number of contacts on the same schedule and in the same format (2 small group sessions and 2 telephone calls). The comparison LHWs will receive training about Healthy Living focusing on nutrition and physical activity education. Participants will also receive the Smoking Cessation Resource Handout."
89411542|NCT03506750|Experimental|IVC-1day|patients with proliferative diabetic retinopathy receiving IVC 1 days before surgery
89411543|NCT03506750|Experimental|IVC-2day|patients with proliferative diabetic retinopathy receiving IVC 2 days before surgery
89411544|NCT03506750|Experimental|IVC-3day|patients with proliferative diabetic retinopathy receiving IVC 3 days before surgery
89411545|NCT03506750|Experimental|IVC-4day|patients with proliferative diabetic retinopathy receiving IVC 4 days before surgery
89411546|NCT03506750|Experimental|IVC-5day|patients with proliferative diabetic retinopathy receiving IVC 5 days before surgery
89411547|NCT03506750|Experimental|IVC-6day|patients with proliferative diabetic retinopathy receiving IVC 6 days before surgery
89411548|NCT03506750|Experimental|IVC-7day|patients with proliferative diabetic retinopathy receiving IVC 7 days before surgery
89411549|NCT03506750|Sham Comparator|IVC-sham|patients with proliferative diabetic retinopathy receiving sham IVC
89411550|NCT03506750|Placebo Comparator|non-DR|patients with other retinopathy (idiopathic macular hole or epiretinal membrane)
89411551|NCT00054964|Experimental|Albuterol HFA-BOI|
89411552|NCT00054964|Active Comparator|Albuterol HFA-MDI|
89411553|NCT02781558|Experimental|SOF/VEL|SOF/VEL FDC for 12 weeks
89411554|NCT02781558|Experimental|SOF/VEL + RBV|SOF/VEL FDC + RBV for 12 weeks
89411555|NCT05073796|Experimental|Interventional arm|Participants will receive the intervention as descibed in the respective section.
89411556|NCT02307890||Liver transplantation group|Participants will include all deceased adult liver transplant donors (>16 years of age) whose livers are being utilised for transplantation in the Scottish Liver Transplant Unit in the Royal Infirmary of Edinburgh. Exclusion criteria will include paediatric liver transplant donors (<16 years of age).
89411557|NCT02304146||High ligation and stripping (surgery)|6-10 years post classical stripping of the great saphenous vein.
89192405|NCT00734942|Experimental|1|intervention group
89411558|NCT02304146||Foam sclerotherapy|6-10 years post post ultrasound guided foam sclerotherapy of the great saphenous vein.
89411559|NCT05073640|Active Comparator|Pentoxifylline|Pentoxifylline (Oxopurin 400 mg)
89411560|NCT05073640|Placebo Comparator|Placebo|Placebo (105 mg Lactose and 510 mg Dextrose)
88887704|NCT02076958|Active Comparator|Traditional/classroom|Community health advisors trained using traditional/classroom methods and provided with technical assistance/support as needed
89192406|NCT00734942|No Intervention|2|waiting group
89411561|NCT02304224|No Intervention|Control|the patients with sepsis admitted in the intensive care unit aren't applied with eye masks at night
89411562|NCT02304224|Experimental|Eye masks|the patients with sepsis in the intensive care unit are applied with eye masks at night in the duration of admission
89411563|NCT02143596|Active Comparator|Bun/Cr based hydration|receive intravenous normal saline infusion and adjust infusion rate by Bun/Cr followed in the first 72 hours
89411564|NCT02143596|No Intervention|control|receive intravenous normal saline infusion as clinician's adjustment
89411565|NCT05073094|Experimental|Esmolol|1 mg/kg (max. 100 mg) as a bolus before aortic cross-clamping and 2 mg/kg (max. 200 mg) in the cardioplegia solution
89411566|NCT05073094|Placebo Comparator|Placebo|Equivalent volume of saline as a bolus before aortic cross-clamping and in the cardioplegic solution
89411567|NCT03509246|Experimental|Pegylated liposomal doxorubicin plus Bortezomib combination|At BRCA wild-type platinum-resistant recurrent ovarian cancer patients, Pegylated liposomal doxorubicin and Bortezomib combination therapy for six cycles.
89411568|NCT03509168|Active Comparator|Misoprostol Pfizer Brand arm|participants receive a single dose of 400mcg vaginal misoprostol preoperatively (60minutes before) during open myomectomy
89411569|NCT03509168|Other|No misoprostol arm|standard of care
89411570|NCT04330534|Experimental|BCX9930|Parts 1, 2 and 3
89411571|NCT04330534|Placebo Comparator|Placebo|Parts 1 and 2 only
89411572|NCT03509090|Active Comparator|ESP block group|Unilateral ESP block will be applied as postoperative regional analgesia technique in addition to the multimodal therapy. Then she is positioned in a right lateral position to perform ESP blocks. The skin will be disinfected and ESP block at one side will be performed in the lateral decubitus position and at T4 transverse process level by using 10-MHz linear ultrasound probe (Logic Ebook XP General Electrics, USA). The probe will be located 3 cm lateral to T4 spinous process in longitudinal parasagittal orientation. An 8 cm 21 gauge needle (BRAUN Stimuplex A®, Germany) will be inserted by using out of the plane technique. The ESP blocks proceed with 15 ml of 0,25% bupivacaine, 7,5 ml 1 % lidocaine, ,7,5 ml 0,9 % NaCl as total 30 ml . The injections will be applied after the confirmation of location by hidrodisection developed anterior to erector spinae muscle with 1-2 ml of local anesthetic solution.
89411573|NCT03509090|Active Comparator|Control group|In this group, patients will receive only multimodal analgesic treatment including patient-controlled analgesia prepared with tramadol. Patient-controlled analgesia (PCA) with tramadol at 3mg/cc concentration is programmed with no basal infusion, demand dose 10 mg and 20-minute lock-out interval. Also, patients received 1 gr paracetamol in every 6 hours.
89411574|NCT05072938|Active Comparator|Nizatidine Monotherapy|Nizatidine Monotherapy
88887705|NCT02076958|Experimental|Technology|Community health advisors trained using technology/online methods and provided minimal technical assistance/support
88887706|NCT02010385|Active Comparator|Octreotide|One subcutaneous injection - 1 mL
88887707|NCT02010385|Placebo Comparator|Saline|One subcutaneous injection - 1 mL
88887708|NCT01949714||Pheochromocytoma patients|Pheochromocytoma patients
89411575|NCT05072938|Experimental|Rebamipide/Nizatidine Combination Therapy|Rebamipide/Nizatidine Combination Therapy
89411576|NCT03041311|Experimental|trilaciclib+etoposide/carboplatin/atezolizumab|"Induction: Patients received trilaciclib 240 mg/m² administered intravenously (IV) once daily prior to E/P/A on Days 1, 2 and 3 of each 21-day E/P/A therapy cycle (up to 4 cycles in total). Etoposide 100 mg/m² was administered IV daily on Days 1, 2, and 3 of each 21-day cycle. Carboplatin was administered on Day 1 of each 21-day cycle using the Calvert formula with a target area under the concentration-time curve (AUC) = 5 milligrams per milliliter per minute (mg/mL/min) to calculate the dose. Atezolizumab 1200 mg was administered as an IV infusion on Day 1 of each 21-day cycle.~Maintenance: Following the induction phase, patients received maintenance atezolizumab at a dose of 1200 mg on Day 1 of every 21-day cycle until disease progression, unacceptable toxicity or discontinuation by the patient or investigator."
89536706|NCT04315961|Experimental|Within-Subjects Dose Conditions|All participants will receive the same drug conditions, but the order in which the participants receive the drug conditions will be different across participants. Thus, comparisons of the drug conditions on mood and choice will be compared within-subjects (e.g., between drug and placebo) and not between arms.
88887709|NCT01459302||Familial and Sporadic ALS|Individuals with ALS and families with a history of two or more people in the family who have had ALS or other forms of motor neuron disease.
88887710|NCT01079325|Experimental|SB-509|
89411577|NCT03041311|Experimental|placebo+etoposide/carboplatin/atezolizumab|"Induction: Patients received placebo administered IV once daily prior to E/P/A on Days 1, 2 and 3 of each 21-day E/P/A therapy cycle (up to 4 cycles in total). Etoposide 100 mg/m² was administered IV daily on Days 1, 2, and 3 of each 21-day cycle. Carboplatin was be administered on Day 1 of each 21-day cycle using the Calvert formula with a target AUC = 5 mg/mL/min to calculate the dose. Atezolizumab 1200 mg was administered as an IV infusion on Day 1 of each 21-day cycle.~Maintenance: Following the induction phase, patients received maintenance atezolizumab at a dose of 1200 mg on Day 1 of every 21-day cycle until disease progression, unacceptable toxicity or discontinuation by the patient or investigator."
89411578|NCT02311868|Experimental|SYNBIOTIC|Patients of this group assumed Probinul-Neutro® po 5g three times a day for 30 day
89411579|NCT02311868|Placebo Comparator|Placebo|patients of this group received 5g of placebo 3 times a day for 30 days
89411580|NCT05072860|Experimental|Topical tranexamic acid|temporary uterine packing with gauze of the dimensions soaked with 2 gm tranexamic diluted in 60ml saline acid or placebo
88887711|NCT01079325|Placebo Comparator|Placebo|Saline
88887712|NCT00704561|Active Comparator|DES - Zotarolimus Drug eluting stents|Zotarolimus Drug eluting stents in overlap
88887713|NCT00704561|Active Comparator|BMS -Bare metal stent|Bare metal stent
88887714|NCT00223145|Experimental|Arm 1|Androgen blockade for 6 months + Radiotherapy 70 Gy
88887715|NCT00223145|Experimental|Arm 2|Androgen blockade for 6 months + Radiotherapy 76 Gy
88887716|NCT00223145|Active Comparator|Arm 3|Radiotherapy alone with 76 Gy
88887717|NCT01425840|Experimental|Liposomal lidocaine, topical anesthesia|Efficacy of Liposomal lidocaine in topical anesthesia.
88887718|NCT01425905|Experimental|Depression Prevention|
88887719|NCT01425905|Active Comparator|Health Education|
88887720|NCT01425918|Experimental|Social Enhancement Intervention|"For 5 months children will come in 4 days a week for 2-2.5 hours a session to participate in a classroom in an attempt to increase social communication and understanding.~Parent education sessions once a week for 2 hours each session over the 5-month period."
88887721|NCT01425918|Active Comparator|Parent Education|o Parent education sessions once a week for 2 hours each session over the 5-month period.
88887722|NCT01425931||Extracorporeal circulation|all patients were measured by microcirculation device O2C
88887723|NCT01425957|Other|MCI Patient with Lumbar puncture|PartB: Patients affected by amnestic Mild Cognitive Impairment (aMCI).
88887724|NCT01425983|Active Comparator|amino acid composition (asn01)|Dietary supplement: specific amino acid composition with micronutrients
88887725|NCT01425983|Placebo Comparator|Sugar powder|Placebo contains no amino acids and no micronutrients and is identical in appearance and solution properties.
88887726|NCT01425996|Experimental|Lipotecan® (TLC388)|"Dosage form: 40mg TLC388 base/vial lyophilized cake Dose: Chemotherapy, i.v. q.w. x 6 doses (dose-escalation)~* The dosage regimen would be escalated gradually until MTD had been found out."
88887727|NCT01426022|Placebo Comparator|Alcohol|"3 glasses of sparkling white wine (30g alcohol) with dinner~3 glasses of alcohol free sparkling white wine (<2g alcohol) with dinner"
88887728|NCT01426022|Experimental|Ambiance|"Pleasant ambiance~Unpleasant ambiance"
88887729|NCT01426048||Patients operated on with the TVT|
88887730|NCT01426061|Experimental|Reflexology plus conventional treatment|
88887731|NCT01426061|Experimental|Homeopathy plus conventional treatment|
88887732|NCT01426061|No Intervention|Conventional treatment|
88887733|NCT01426087|Experimental|endoscopic and somatostatin treatment|
88887734|NCT01426087|Other|endoscopic therapy|
88887735|NCT01426100|Experimental|CKD-828 40/2.5mg|
88887736|NCT01426100|Experimental|CKD-828 40/5mg|
88887737|NCT01426100|Active Comparator|Telmisartan 80mg|
88887738|NCT01426126|Experimental|Genexol PM|Genexol PM intravenous infusion every 3 weeks
88887739|NCT01426139|Experimental|Biotronik Orsiro DES|
88887740|NCT01426152||Low level progesterone group (1)|Progesterone < 1.50 ng/mL on day of ovulation induction
88887741|NCT01426152||Medium level progesterone group (2)|Progesterone 1.51-1.99 ng/mL on the day of ovulation induction
88887742|NCT01426152||High level progesterone group (3)|Progesterone > 1.99 ng/mL on the day of ovulation induction
88887743|NCT01426165|Experimental|Magnesium 8 grams over 4 hours|
88887744|NCT01426165|Experimental|Magnesium 8 grams over 8 hours|
89411581|NCT05072860|Placebo Comparator|normal saline|temporary uterine packing with gauze of the dimensions soaked with 2 gm placebo to tranexamic diluted in 60ml saline acid
88887745|NCT01426243|Active Comparator|Voluntary HIV positive subjects|40 HIV positive adults under HAART for at least one year (and stable on treatment for at least 3 months prior to enrolment), > 350 CD4/mm3 (with half of them a nadir < 200 CD4/mm3) and a viral load < 50 copies/mL for at least 6 months. Patients were HCV negative or non-replicative and treated for at least 2 years with normal ALT and negative HBs antigen.
88887746|NCT01426243|Other|HIV negative subjects|Voluntary HIV negative subjects matched according to age (18-40 years and 40-55 years) and with HIV positive subjects, vaccinated at J0 and followed over one year
89411582|NCT02311946|Experimental|Cohort 1|Cohort 1 will receive a 125 mg round yellow palbociclib tablet containing succinic acid
88887747|NCT01426256|Experimental|Cholecalciferol (Vitamin D3)|Patients will be given 250,000 IU cholecalciferol in one bolus oral dose while they are in the hospital. Three months after the initial bolus dose, patients will take 50,000 IU oral cholecalciferol every other week for 9 months.
88887748|NCT01426256|No Intervention|Placebo|Patients will be given placebo pills in one bolus oral dose while they are in the hospital. Three months after the initial bolus dose, patients will take a placebo pill every other week for 9 months.
88887749|NCT01426282|No Intervention|control|
88887750|NCT01426282|Experimental|nurse education|
88887751|NCT01426295|Experimental|Caphosol|
89192407|NCT00862732|Active Comparator|1 Cognitive Behavioural Therapy|Intervention group will receive a series of sessions of cognitive behaviour therapy. Delivery of CBT will be by three therapists; PI and two other Medical Officers. Each session will last for 30- 45 minutes and they will be delivered at the participant's residence (or at an alternative place of participant's choice) at two weeks intervals. They will be followed-up for three months from the cessation of CBT sessions.
88887752|NCT01426295|Active Comparator|Référence|•Bicarbonate de sodium à 1.4% Biosedra Versylène® or PAROEX® :
88887753|NCT01426308||Method Comparison Group|The method comparison group will consist of de-identified, leftover DNA samples from patients referred for post-natal cytogenetic testing.
88887754|NCT01426308||Clinical Specificity Group|The clinical specificity group will consist of de-identified, leftover DNA samples from non-phenotypic patients, or patients not referred for post-natal cytogenetic testing.
88887755|NCT01426321|Active Comparator|Imaging guided LV lead positioning|
88887756|NCT01426321|No Intervention|Standard LV lead positioning|The LV lead position is decided at the discretion of the treating physician. Cardiac CT images are available for viewing, but no echocardiography data regarding segmental myocardial strain are available.
88887757|NCT01426334|Experimental|Treatment (dasatinib and cyclosporine)|Patients receive dasatinib PO QD on days 1-28 and cyclosporine PO BID on days 8-28. Treatment repeats every 28 days for 4 months in the absence of disease progression or unacceptable toxicity.
88887758|NCT01426399|Experimental|LC15-0444|LC15-0444 50mg qd
88887759|NCT01426399|Experimental|Metformin|Metformin 1000mg bid
88887760|NCT01426399|Experimental|LC15-0444+Metformin|LC15-0444 50mg qd +Metformin 1000mg bid
88887761|NCT01426451|Experimental|Theatre intervention|The theatre expression workshops will run for 12 weeks, with one 75-minute workshop per week. They will be incorporated into the regular class timetable and will be run by the two members of the intervention team who have training in theatre and psychology, and the homeroom teacher, whose level of direct involvement will increase gradually as he or she becomes familiar with the workshops.
88887762|NCT01426451|Experimental|Group tutoring intervention|In each classroom assigned to the tutorship intervention, two academic resource assistants will provide weekly in-class support to students for the same length of time than the drama workshop (75 minutes weekly). Individualized student objectives on reading fluency and math will be implemented (one in math and one in reading per student).
88887763|NCT01426451|No Intervention|No intervention|Classes not participating neither in drama workshops nor in group tutoring activities will fill out a questionnaire as a basis for comparison.
88887764|NCT01426477||Veritas Collagen Matrix|Observational study of subjects who undergo open ventral hernia repair using Veritas Collagen Matrix in an underlay technique.
89192408|NCT00862732|Active Comparator|2 Treatment as usual|Will be referred to the MO(MH). They also will be followed-up for an equal length of time period as of the participants in the intervention group.
89192409|NCT00808977|Experimental|Dersalazine|
89192410|NCT00808977|Active Comparator|Mesalazine|
89192411|NCT00808977|Placebo Comparator|Placebo|
89192412|NCT04065854|No Intervention|Control|The control group will receive standard brief falls assessment and advice.
89192413|NCT04065854|Active Comparator|Intervention|Therapy intervention.
89192414|NCT02544334||RA - naïve to biologics|This group will consist of 25 Rheumatoid Arthritis (RA) adult subjects who have not been treated with biologics (naïve to biologics). During the exam the following will take place: the multidimensional health assessment questionnaire (MDHAQ), dental exam, saliva collection, and dental plaque will be removed from different tooth surfaces for supragingival.
88887765|NCT01426490|Other|Vitamin C|Vitamin C as control group.
88887766|NCT01426490|Experimental|Vitamin B6|
88887767|NCT01426490|Experimental|Folic acid|
88887768|NCT01426490|Experimental|Vitamin B6 plus folic acid|
88887769|NCT01426542|Experimental|Topiramate|
88887770|NCT01426542|Active Comparator|Control|These infants will undergo surgery, but will not receive topiramate
88887771|NCT01426568|Active Comparator|Course of Multi-Convergent Thearpy|
88887772|NCT01426568|No Intervention|Waiting List for Multi-Convergent Therapy|
88887773|NCT01426607|Experimental|AMO|Adjustable mandibular repositioning appliance
88887774|NCT01426607|Placebo Comparator|placebo|placebo device in upper jaw
89192415|NCT02544334||Healthy Controls|This group will consist of 25 adult subjects which will be healthy controls from members of the same household as the 25 naive to biologics, and be of the same age. During the exam the following will take place: dental exam, saliva collection, and dental plaque will be removed from different tooth surfaces for supragingival.
89411583|NCT02311946|Experimental|Cohort 2|Cohort 2 will receive a 125 mg oval yellow palbociclib spray-dried dispersion tablet containing HMPC E3
89411584|NCT02311946|Experimental|Cohort 3|Cohort 3 will receive a 125 mg oval yellow palbociclib spray-dried dispersion tablet with HMPC E3 and succinic acid.
89411585|NCT02311946|Experimental|Cohort 4|Cohort 4 will receive a 125 mg oval white/yellow palbociclib bilayer tablet with tartaric and succinic acid.
89411586|NCT02311946|Experimental|Cohort 5|Cohort 5 will receive a 125 mg oval yellow palbociclib fluid bed granulation tablet with succinic acid.
89411587|NCT02311946|Experimental|Cohort 6|Cohort 6 will receive a 125 mg palbociclib oral solution
89411588|NCT05072392|Experimental|Foley-assisted|"The tip of the nasal endotracheal tube will be telescoped onto a 16g Foley catheter. If a ballooned catheter is used then the inflation port may be cut off prior to use. The catheter tip is then fed through the pre-selected primary nare, until the tip of the endotracheal tube is in the oropharynx. The catheter is then removed from the tip of the nasal endotracheal tube through the mouth and disposed of. If the nasal endotracheal tube is inappropriately sized, a half size above or below may be used. If difficult to pass, the anesthetist may opt to use the other side nare.~Following this, the anesthetist will complete the rest of the intubation as usual."
89411589|NCT05072392|No Intervention|Control|"The endotracheal tube is passed through the pre-selected primary nare, until the tip of the endotracheal tube is in the oropharynx. If the nasal endotracheal tube is inappropriately sized, a half size above or below may be used. If difficult to pass, the anesthetist may choose to use the other side nare.~Following this, the anesthetist will complete the rest of the intubation as usual."
89411590|NCT02312024||Patients with severe sepsis/septic shock|Use of CytoSorb adsorber in patients with severe sepsis/septic shock
89411591|NCT02312024||Cardiac surgery with CPB: preemptive use|Use of CytoSorb adsorber in patients with cardiac surgery with CPB: preemptive use
89411592|NCT02312024||Cardiac surgery with CPB: postop. use|Use of CytoSorb adsorber in patients with cardiac surgery with CPB: postoperative use
89411593|NCT02312024||Patients with other indications|Use of CytoSorb adsorber in patients with other indications
89411594|NCT02304536|Active Comparator|FSH|will receive urinary purified FSH (Fostimon® IBSA, Switzerland) 75IU daily for 7 days starting from the 3rd day of menstruation or progesterone withdrawal bleeding. If the follicle does not exceed 9mm the dose will be increased by 37.5IU every 7 days. The cycle will be cancelled if no follicles exceed 9mm 4 weeks after starting FSH. This was combined with oral metformin (Cidophage® CID, Egypt) 500 mg three times per day.
89411595|NCT02304536|Active Comparator|Ovarian drilling|70 women will have laparoscopic ovarian drilling in which the ovaries will be stabilised by grasping the ovarian ligament and monopolar diathermy will be used to do 4-10 punctures in each ovary. The number of punctures will be individualised according to the size of the ovary. Serial vaginal ultrasound scans were done starting from the 10th day of menstruation, the frequency of monitoring will be individualized according to the women's response.
89411596|NCT05408221|Experimental|Rulonilimab|with PD-1 Inhibitors
89005260|NCT00233259|Active Comparator|1|Multiple risk factor intervention, that will include diet, physical activity, stress management, social support, and smoking cessation components
89411597|NCT05408221|Placebo Comparator|Rulonilimab placebo|without PD-1 Inhibitors
89411598|NCT02644096|No Intervention|conventional treatment|After surgery, patients with total hip replacement are only seen once 3 months after surgery, and they have no further contact with the hospital.
89411599|NCT02644096|Other|Intervention|counselling and support after discharge from hospital
88819806|NCT05452473|Placebo Comparator|Conventional routine screening endoscopy|Participants will be tested for Conventional routine screening upper gastrointestinal endoscopy
88819807|NCT04737993|Active Comparator|prf shoulder joint|pulsed rf stimulation of joint capsel and prf stimlation of subscapular nerve
88819808|NCT04737993|Active Comparator|prf subscapular nerve|pulsed RF stimulation of subscapular nerve
88819809|NCT04737993|Active Comparator|subscapular nerve block|lidocain injection of subscapular nerve
89005261|NCT00233259|Placebo Comparator|2|Control group
89005262|NCT00207857||With and Without PFTs|
89411600|NCT03504722|Experimental|RESCUE+PE|RESCUE is designed to adapt to individualized needs based on each veteran's performance. The volunteer training consists of weekly sessions lasting 90 minutes each and occurring at area Society for the Prevention of Cruelty to Animals (SPCA) facilities.All veterans will receive individualized, evidence-based prolonged exposure therapy. Foa's PE protocol will be used given consensus statements indicating that exposure therapy is currently the most appropriate psychotherapy for PTSD.
89411601|NCT03504722|Active Comparator|PE+delayed RESCUE|All veterans will receive individualized, evidence-based prolonged exposure therapy. Foa's PE protocol will be used given consensus statements indicating that exposure therapy is currently the most appropriate psychotherapy for PTSD.
89411602|NCT05072002||pregnant women with low back pain|
89411603|NCT02304614||Group 1|Patients who have undergone Breast conserving Therapy
89411604|NCT03625999|Experimental|Training Group|Parents and children selected for the Training group will be lent a laptop for the duration of the at-home training, and assisted in opening the video game training exercise. Parents and children will be shown the game's operation and controls, including a home visit to the family's house to help them establish the game as part of routine. Parents will be asked to engage their children in the video game training exercise (on the laptop) for a minimum of 20 minutes, 3 times a week, for 4 weeks. The app will log all responses as well as time spent playing.
89411605|NCT03625999|No Intervention|Wait-List Control|The families assigned to the wait-list control group will not receive access to the game until after 4 weeks and completion of the secondary round of testing at the lab. After the second lab visit and completion of the testing, families will be given access to the video game training exercise (on a loaned laptop), walked through the game's operation and controls, and encouraged to use it as often as they or their child like. If the child plays the game for a minimum of 20 minutes, 3 times per week, for 4 weeks, the family will be invited back to CARE for post-testing.
89411606|NCT04211194||Patients with upper gastrointestinal bleeding|Patients with upper gastrointestinal bleeding undergoing endoscopic procedures at AdventHealth Hospitals in Central Florida
89411607|NCT04196842|Experimental|Telemonitoring|Blood pressure and heart rate monitoring, scale, activity tracker.
89411608|NCT04196842|No Intervention|No intervention|No intervention.
89411609|NCT03508856|Experimental|Picato 0.015% gel|Picato 0.015% gel, is a topical treatment for actinic ketatoses.
89411610|NCT03132428||P Neonates|Premature (P) neonates [at least 27 weeks but less than 34 weeks of gestational age]
89411611|NCT03132428||TNT Neonates|Term-Near-Term (TNT) neonates at least 34 weeks of gestational age
89411612|NCT02643628|Experimental|Microneedling Only|All eligible scars within the treatment areas on each side of the face will receive microneedling treatment. The device will be rolled in a horizontal direction with medium pressure. After every roll, the device will be lifted and positioned a few millimeters inferior to the previous starting point. Rolling will be repeated until the entire skin area has been treated. The device will then be reoriented vertically and rolling will be repeated in a vertical direction.
89411613|NCT02643628|Experimental|Microneedling followed by Bellafill treatment|Subjects undergo microneedling as described for the Microneedling Only group. Then at Week 12, all eligible scars within the treatment areas on each side of the face will be treated with Bellafill (injected using a standard tunneling technique). A touch-up treatment is allowed at Month 1 after initial treatment, if additional treatment is required to achieve optimal correction.
89411614|NCT03508778|Experimental|FluidVision|FluidVision AIOL implanted in the capsular bag of the eye during cataract surgery. Both eyes were implanted, with the second eye surgery occurring after the Week 1 follow up for the first eye surgery.
89411615|NCT03508778|Active Comparator|PanOptix|Commercially available trifocal IOL implanted in the capsular bag of the eye during cataract surgery. Both eyes were implanted, with the second eye surgery occurring after the Week 1 follow up for the first eye surgery.
89411616|NCT02643472|Other|Care Notebook|Parents of infants who were discharged from the Children's National NICU will be randomized to receive enhanced usual care by provision of a NICU care resource notebook. Parents will be notified about group assignment prior to discharge. Stratification will occur according to birth weight.
89411617|NCT02643472|Experimental|Care Notebook + Parent Navigator|Parents of infants who were discharged from the Children's National NICU will be randomized to receive a care notebook + Parent Navigation. Parents will be notified about group assignment prior to discharge. Stratification will occur according to the birth weight.
89411618|NCT02738840|Experimental|Prodigy MRI or Proclaim Elite MR|"The Prodigy MRI system is only MR conditional for scans of the head and extremities (upper except shoulder, lower except hip).~The Proclaim Elite system is MR conditional for scans of the head, extremities or any other body part."
89411619|NCT03508700|Experimental|TNX-102 SL 5.6 mg|2 tablets of TNX-102 SL 2.8 mg taken simultaneously and sublingually (under the tongue) each day at bedtime starting on Day 0 for 40 weeks
89005263|NCT00411320|Active Comparator|Group 1|Smokers with asthma
89005264|NCT00411320|Active Comparator|Group 2|Ex-smokers with asthma
89411620|NCT04038736|Experimental|Healthy subjects at averge risk for CRC|All subjects are healthy who didn't have any known polyps in past colonoscopy and who arw candidates for CRC screening
89411621|NCT04038736|Experimental|Healthy subjects at high risk for CRC|Subjects who had polyps in former colonoscopy, subjects who have family history of CRC or subjects who have positive stool blood test.
89411622|NCT02304692|Sham Comparator|Oticon Medical Machined Abutment|A non surface modified abutment is used
88813912|NCT03403478|Experimental|HIIE|The high-intensity intervaled exercise (HIIE) will bem performed divided into 3 phases: warm-up (10 minutes), main part (15 minutes) and cool down (5 minutes). The warm-up and cool down will be performed at 55-60% HRmax. The main part will last 15 minutes and will be performed by 2 sets of 5 exercises lasting 30 seconds to each exercise combined with 1 minute of active recovery. The exercise moment will be performed at 80-85% HRmax and the 1-minute active recovery at 55-60% HRmax. For both warm-up and cool down, HR will be measured every 2 minutes. For main part, HR will be measured at the end of each 30-seconds from exercise.
88887775|NCT01426620|Experimental|Blueberry powder|This is a two-part open-label clinical trial of blueberry powder administered to patients with stage IV NSCLC in combination with docetaxel as a second line treatment. Patients will initially be enrolled in part 1 of the study, which is the feasibility/toxicity evaluation section of the study. Once the part I enrollment is completed, the patients will be enrolled in part 2 of the study.
88887776|NCT01426633|Experimental|Gemcitabine + Trabectedin|
88887777|NCT01426646|Experimental|S-1 treatment|S-1 was administered at 40mg/m2 orally twice daily (days 1-28) every 42 days. Patients received a maximum of eight cycles.
88887778|NCT01426646|Experimental|S-1 plus cisplatin treatment|"S-1 plus cisplatin every 3 weeks, A total of eight cycles~S-1: 40mg/m2 orally twice daily (days 1-14)~Cisplatin: 60mg/m2 IV on day 1"
88887779|NCT01426659|Active Comparator|"Protocol say and do"|reeducation implicit 5 minutes every day at home and 30 minutes of speech therapy every week
88887780|NCT01426659|Active Comparator|"no stimulation say and do"|
88887781|NCT01426672|Experimental|Monovision Correctoin|Monovision correction
88887782|NCT01426698|Active Comparator|Immediate cord clamping|Infants in this arm will have had immediate cord clamping at birth which is routine care at the hospital
88887783|NCT01426698|Experimental|Delayed Cord Clamping|Intervention: Following the delivery of the infant, the obstetrician holds the infant approximately 10-15 inches below the mother's introitus at vaginal delivery or 10 to 15 inches below the level of the placenta at Cesarean section. The research nurse records the time when the infant's buttocks are delivered from the vagina or the uterus and counts out the time elapsed in ten second intervals to the obstetrician while he/she is doing the suctioning and drying maneuvers. At 30 to 45 seconds, the obstetrician milks the umbilical cord once, clamps, and cuts it. If the baby appears jeopardized in any way, the obstetrician can alter the protocol for the safety of the infant.
89005265|NCT00411320|Active Comparator|Group 3|Non-smokers with asthma
89005266|NCT00411320|No Intervention|Group 4|Non smokers without asthma
89005267|NCT00411320|No Intervention|Group 5|Smokers without asthma or COPD
89005268|NCT01089556|Experimental|Duloxetine|"Initial Treatment:~Duloxetine 30 milligram (mg) daily for 1 week~Duloxetine 60 mg daily for 7 weeks~Intensive Treatment:~Duloxetine 90 mg (60 mg in the morning, 30 mg in the evening) daily for 1 week~Duloxetine 120 mg (60 mg twice daily) daily for 7 weeks"
89411623|NCT02304692|Experimental|Oticon Medical Modified Abutment|A surface modified abutment is used
88813913|NCT03403478|Experimental|Aquatic exercise training|The participants will be submitted to a 12-weeks of aquatic exercise program, twice a week, for 1 hour each day.
89411624|NCT05071378|Experimental|Intervention Group|This arm will be enrolled in the intervention prior to any data collection
89411625|NCT05071378|No Intervention|Wait listed control|This arm will receive the intervention after all study data is collected
89411626|NCT02307968||inner thigh insulin injection|inject insulin at inner thigh site is the intervention arm. So we inject insulin at this site to see if this site is suitable for insulin injection.
89411627|NCT02307968||outer thigh insulin injection|outer thigh site for insulin therapy is the usual site
89411628|NCT02312180|Experimental|Cohort 1|low dose group of 2 mg/kg Plasminogen (Human) Intravenous
89411629|NCT02312180|Experimental|Cohort 2|mid-dose group of 6 mg/kg Plasminogen (Human) Intravenous
89411630|NCT05070832|Experimental|Hyperthermia Group|The neoadjuvant therapy is hyperthermia combined with concurrent radiochemotherapy for this group.
89411631|NCT05070832|No Intervention|Non-hyperthermia group|The neoadjuvant treatment is concurrent radiochemotherapy, which is standard treatment for LARC according to the guidelines.
89411632|NCT03504566|Other|Intervention|All patients recieve, in randomomized order a four way treatment schedule. Due to the nature of the study, the individual patient will serve as his/hers own comparator.
89411633|NCT03508544|Active Comparator|Lumbar ESP block|Ultrasound-guided lumbar Erector spinae plane (ESP) block performed at the begining of the surgery with 40 ml of a bupivacaine/lidocaine mixture. Perioperative and postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed
89411634|NCT03508544|Active Comparator|QLB Block|Ultrasound-guided transmuscular quadratus lumborum block (QLB) performed at the begining of the surgery with 40 ml of a bupivacaine/lidocaine mixture. Perioperative and postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed
88813914|NCT03834584|Experimental|AG-636|AG-636 dosed orally.
88813915|NCT03003689|Active Comparator|Scaling and Root Planing|"Hand instruments + ultrasonic scaler~PD, CAL, plaque index and gingival bleeding index will be measured at baseline, 6 weeks and 3 months. Microbial load will be measured at baseline and 3 months."
88813916|NCT03003689|Experimental|Scaling and Root Planing + Er:YAG Laser|"Er:YAG Laser, hand instruments + ultrasonic scaler~PD, CAL, plaque index and gingival bleeding index will be measured at baseline, 6 weeks and 3 months. Microbial load will be measured at baseline and 3 months."
88813917|NCT03830372|Experimental|VR Tier One|"Patients will receive:~10 sessions of 20 minutes of VR Tire One therapeutic game,~60 minutes of individual physiotherapy based on the Bobath and PNF concept with elements of manual therapy,~30 minutes individual aerobic training,~30 minutes balance exercises."
88813918|NCT03830372|Active Comparator|Control|"Patients will receive:~10 sessions of 20 minutes of Schultz Autogenic Training,~60 minutes of individual physiotherapy based on the Bobath and PNF concept with elements of manual therapy,~30 minutes individual aerobic training,~30 minutes balance exercises."
88813919|NCT03003923|Experimental|Taste Exposure|Children will be repeatedly offered the single vegetable which is unfamiliar to them over the 12 week period. Children will be in their natural setting at nursery and will be offered 40g of the vegetable by their usual nursery staff. The vegetable will be weighed before and after using a digital scale by the researcher.
88813920|NCT03003923|Experimental|Nutritional Education|Nursery staff will be trained by the PhunkyFoods team to deliver the nutritional education programme. Children will be taught Eat Well (learning about different food groups) and Strive for Five (learning about eating fruits and vegetables) components of the PhunkyFoods education programme by their usual nursery staff. Nurseries will be advised to deliver as much as possible of the two components over the 12 week period.
88813921|NCT03003923|Experimental|Taste Exposure and Nutritional Education|Children will be repeatedly offered a single unfamiliar vegetable over the 12 week period as well as receive the PhunkyFoods educational programme (Eat Well and Strive for Five components). Children will be in their natural setting at nursery and will be offered the vegetable and nutritional education by their usual nursery staff.
88813922|NCT03003923|No Intervention|Control|Children will be offered single unfamiliar vegetable at the beginning, end and at the follow-up. There will be no repeated taste exposure or education during the study phase or follow-up; they will be offered the nutritional education after the study has completed.
88813923|NCT02247947||dead|Patients dead until day 20 (primary outcome measure)
88813924|NCT02247947||survivors|patients alive after day 20 (primary outcome measure)
88813925|NCT00919724||HIV-Infected|HIV-infected participants who are not currently receiving antiretroviral medications
88813926|NCT00919724||HIV-Uninfected|HIV-uninfected participants matched in age, sex, smoking status, and height to the HIV-infected participants
88813927|NCT00919802|Active Comparator|Oxytocin|Oxytocin, 40 IU intranasally, once
88813928|NCT00919802|Placebo Comparator|Saline as a nasal spray|Saline, 4ml intranasally, once
88813929|NCT02222129|Active Comparator|Bupivacaine|Surgical site infiltration of 0.25% bupivacaine.
88813930|NCT02222129|Experimental|Liposomal bupivacaine|Surgical site infiltration of liposomal bupivacaine.
88813931|NCT03403322|Other|First test|All measures were evaluated
88813932|NCT03403322|Other|Second test|All measures were evaluated
88813933|NCT03003611||Hypnose|the group of patient who's operated under hypnose sedation
88813934|NCT03003611||traditional anesthesia|The match is realized with a patient operated in the same period as the patient in the hypnose group and it's need a comparative type of surgery.
88813935|NCT03400358||Medical abortion|150 singleton multiparous patients are planning to complete the study period. Study group constitute of second trimester pregnancies between 14-24 weeks of gestation. All participants were multiparous and had no systemic illnesses. The uterocervical angle will be measured in all participants before the induction of labor.
88813936|NCT03003455|Active Comparator|Conventional Nasotracheal Intubation (CVT)|Blind passage of an endotracheal tube via the nare followed by videolaryngoscopy-assisted passage through the glottis, with or without the aid of Magill forceps
88887784|NCT01426750|Experimental|IOS, TFR|industrialized oral supplementation (IOS) and tube feeding regimen (TFR) with Nutren 1.0 or Jr (Nestlé-Clinical Nutrition).
88887785|NCT01426776|Other|heart valve replacement|a normal surgery that rheumatic valvular heart disease patients received.
88887786|NCT01426802|Experimental|Vildagliptin 50 bid|
88887787|NCT01426815|Placebo Comparator|Placebo|
88887788|NCT01426815|Experimental|Golimumab 50mg (Simponi ®)|
88887789|NCT01426880|Experimental|Carboplatin + background treatment|Carboplatin AUC 2 min/mL weekly, infusion will be used as Add-on to the background therapy (same as comparator arm)
88887790|NCT01426880|Active Comparator|background treatment only|background treatment with NLPD (Myocet), Paclitaxel, Herceptin (Trastuzumab fpr Her2 pos), Tyverb (Lapatinib for Her2 pos), Avastin (Bevacizumab for triple negative) agents are used according to marketed formulation via normal procedures at each site and applied according to recommendations of the manufacturers.
88887791|NCT01426893||1|The inhaler device usage in patients with asthma or COPD
88887792|NCT01426906|Experimental|Study A|
88887793|NCT01426906|Experimental|Study B|
88887794|NCT01426919||Suspected traumatic brain injury with head CT|
88887795|NCT01426971|Experimental|Ibuprofen+caffeine|2 capsules
88887796|NCT01426971|Active Comparator|Ibuprofen|2 capsules
88887797|NCT01426035|Experimental|GROUP 1|
88887798|NCT01426035|Active Comparator|GROUP 2|
88887799|NCT01426984|Experimental|BPD adults|adults with Borderline Personality Disorder (BPD)
88887800|NCT01426997||High inflammation group (CRP>3 mg/L)|Forty-five participants each with a diagnosis of major depressive disorder and a CRP level >3 mg/L
88887801|NCT01426997||Medium inflammation group (CRP=1-3 mg/L)|Forty-five participants each with a diagnosis of major depressive disorder and a CRP level = 1-3 mg/L
88887802|NCT01426997||Low inflammation group (CRP<1 mg/L).|Forty-five participants each with a diagnosis of major depressive disorder and a CRP level <1 mg/L
88887803|NCT01427010|Experimental|Reirradiation of recurrent and 2nd primary head/neck cancer.|
88887804|NCT01427036|Experimental|MISS surgery group|hip screw MISS® (Minimally Invasive Screw System) : minimally invasive approach
88887805|NCT01427036|Active Comparator|PHS surgery group|PHS® hip screw design for standard approach
88887806|NCT01427049||renal denervation|Adults with a systolic BP ≥160 mmHg (≥150 mmHg for type 2 diabetics) with a stable drug regimen including 3 or more antihypertensive medications, including a diuretic, or inability to follow a stable drug regimen due to unacceptable side-effects of antihypertensive medication.
88887807|NCT01427062|Experimental|anticipatory and compensatory postural control training|Subjects in the experimental group were trained the speed and amplitude of anticipatory postural adjustment during fall-prone activities and postural response to perturbation during walking. Training was provided with preparatory cues, computerized machines and treadmill.
88887808|NCT01427062|Active Comparator|strength-focused training|Subjects in control group were provided with strength training of leg muscles using machines and during functional activities.
88887809|NCT01427075|Experimental|lateral pharyngoplasty|lateral pharyngoplasty
88887810|NCT01427088|Experimental|repetitive TMS|repetitive TMS is a quantified stimulation method of specifie area of brain, for which CR Technology, TAMAS for repetitive TMS was used.
88887811|NCT01427114|Experimental|R-CVP|6 cycles of R-CVP followed by 2 cycles of rituximab
88887812|NCT01427140|Active Comparator|Saturated fatty acid group|Addition of saturated fatty acids to the diet inte the form of pastries
88887813|NCT01427140|Active Comparator|Polyunsaturated fatty acid group|Addition of polyunsaturated fatty acids to the diet in the form of pastries
88887814|NCT01427153|Active Comparator|Corticosteroid|Corticosteroid injection
88887815|NCT01427153|Active Comparator|Orthopaedic Manual Physical Therapy|OMPT consists of joint and soft-tissue mobilizations and the exercises that reinforce the manual techniques.
88887816|NCT01427166|Experimental|Ultrasound imaging|Cords that are present in the participant's axilla and/or arm will be imaged with an ultrasound
88887817|NCT01427192|Experimental|acetazolamide|1 week therapy, cross-over design
88887818|NCT01427192|Placebo Comparator|Placebo tablet|One week, cross-over design
88887819|NCT01427192|Experimental|supplemental oxygen during nights|One week, cross-over design
88887820|NCT01427192|Experimental|Non-invasive ventilation|One week, cross-over design
88887821|NCT01427192|Sham Comparator|room air|room air applied via sham-oxygen-concentrator
88887822|NCT01427205|Experimental|Group A: Cetuximab + OSI-906|Cetuximab loading dose of 400 mg/m2 by vein (IV) then 250 mg/m2 weekly + OSI-906 150 mg orally twice a day. 21-Day Cycle.
88887823|NCT01427205|Experimental|Group B: Cetuximab + Placebo|Cetuximab loading dose of 400 mg/m2 by vein (IV) then 250 mg/m2 weekly + Placebo orally twice a day. 21-Day Cycle.
88887824|NCT01427218|Experimental|Medication Therapy Management (MTM)|Medication Therapy Management visits with a pharmacotherapist will occur at a minimum of 6-9 weeks, 20-24 weeks, and 28-32 weeks. Additional interim face to face and telephonic visits may be scheduled based on patient's progress with meeting treatment goals and need for follow-up physical assessment and laboratory analysis.
88887825|NCT01427218|Placebo Comparator|Usual Care|Visits with a pharmacotherapist to create an accurate list of medications for those patients randomized to placebo (who receive usual care by their cardiologist and primary care provider).
88887826|NCT01427231|Active Comparator|Drink with 50 g glucose|The glucose drink contains 50 g of glucose soluted in 250 ml of water and lemon juice.
88887827|NCT01427231|Active Comparator|Drink with 100 gram of sacharose|The sacharose drink contains 100 g of sacharose soluted in 250 ml of water and lemon juice.
88887828|NCT01427231|Placebo Comparator|Placebo with sweeteners|The placebo contains a mixture of artificial sweeteners in order to have the same sweetness and appearance of the test drinks (the glucose drink and the sacharose drink).
88887829|NCT01427244|Experimental|Trastuzumab|Open Label
88887830|NCT01427257|Active Comparator|PB1023 Formulation A|
88887831|NCT01427257|Active Comparator|PB1023 Formulation B|
88887832|NCT01427257|Active Comparator|PB1023 Formulation B (2-8C)|
88887833|NCT01427270|Experimental|OXN|Oxycodone/Naloxone controlled-release tablets (OXN)
88887834|NCT01427270|Active Comparator|OXY|Oxycodone HCl controlled-release tablets (OXY)
89411635|NCT03508544|Sham Comparator|Control|Perioperative and postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed.
89411636|NCT04435054|Other|Non invasive tests|
89411637|NCT02304770|Experimental|cervical persistent high risk HPV infection|Aminolaevulinic acid photodynamic therapy for the treatment of patients with cervical persistent high risk HPV infection
89411638|NCT02304770|Experimental|CIN 1 with high risk HPV infection|Aminolaevulinic acid photodynamic therapy for the treatment of patients with CIN 1 and high risk HPV infection
89411639|NCT02304770|Experimental|CIN 2/3|Aminolaevulinic acid photodynamic therapy for the treatment of patients with CIN 2/3
89411640|NCT03101410|Experimental|gluten|Selected participants will be randomly allocated to treatment group (gluten or gluten free)
88887835|NCT01427270|Placebo Comparator|Placebo|Placebo tablets to match OXN or OXY
88887836|NCT01427283|Experimental|OXN|Oxycodone/Naloxone controlled-release tablets (OXN)
88887837|NCT01427283|Active Comparator|OXY|Oxycodone HCl controlled-release tablets (OXY)
88887838|NCT01427283|Placebo Comparator|Placebo|Placebo tablets to match OXN or OXY
88887839|NCT01427322|Experimental|lapatinib + radiation therapy|lapatinib given orally 2-4 hours prior to first fraction of radiation
88887840|NCT01427322|Active Comparator|No therapy prior to radiation|Radiation therapy alone
88887841|NCT01427335|Placebo Comparator|saline|0.9% saline intravenous infusion
88887842|NCT01427335|Experimental|calcium|Calcium intravenous infusion
88887843|NCT01427348|Experimental|with assistant|head extension by an assistant during direct laryngoscopy
88887844|NCT01427348|Active Comparator|without assistant|without the help of an assistant during direct laryngoscopy
88887845|NCT01427387|Experimental|Part-1 ASP group|ASP0456 receiving group
88887846|NCT01427387|Placebo Comparator|Part-1 Placebo group|Placebo treatment
88887847|NCT01427387|Experimental|Part-2 group|cross-over study group to evaluate food effect on ASP0456 plasma concentration
88887848|NCT01427400|Experimental|Expander Placement, Botulinum Toxin-A|During surgery, administered only once, 5 cc in 5 different locations on chest muscle.
88887849|NCT01427400|Placebo Comparator|Tissue expander Placement WITH Saline|During surgery, administered only once, 5 cc in 5 different locations on chest muscle.
88887850|NCT01427413||Hyper1|Only patients who achieved hyperstimulation pathology after external administration of gonadotrophin during IVF treatment
88887851|NCT01427426|Experimental|All Greens|Subjects will consume the All Greens product daily. Product is prepared by mixing with either water, juice or in a smoothie.
89411641|NCT03101410|Experimental|gluten fee|Selected participants will be randomly allocated to treatment group (gluten or gluten free)
89411642|NCT03504332|Experimental|Calcium Hydroxide in revascularization|Revascularization of necrotic anterior teeth: canals disinfection step. Pure Calcium Hydroxide powder mixed with saline will be placed as intra-canal medication in the 1st visit of dental pulp revascularization.
89411643|NCT03504332|Active Comparator|Di-antibiotic paste in revascularization|Revascularization of necrotic anterior teeth: canals disinfection step. Mix 1:1 ciprofloxacin: metronidazole to a final concentration of 0.1 mg/ml, placed as intra-canal medication in the 1st visit of dental pulp revascularization.
89411644|NCT05070676|Experimental|Lateral cephalometric radiographs of pre-adolescent patients (8-13) years old.|
89411645|NCT02304848|Experimental|DBS (Deep Brain Stimulation)|DBS ( Deep Brain Stimulation) ( both high and low frequency deep brain stimulation will be applied to the subthalamic nucleus)
89411646|NCT03919864|Other|CONNECT Intervention Group|CONNECT includes a multi-component e-tool with the following: (1) a brief educational video that seeks to empower and educate caregivers about the importance of self-care and benefits of supportive care resource use; (2) an assessment of multidimensional supportive care needs (e.g., psychological, behavioral, social, financial, educational, spiritual); (3) a tailored resource list that includes local and national resources corresponding to caregivers needs (Table1); and (4) an optional automated referral to a caregiver navigator to facilitate connection to resources.
88887852|NCT01427426|Sham Comparator|Control formulation|Subjects will consume a product of similar consistency and comparable taste that does not have the same healthy ingredients as the All Greens.
88887853|NCT01427439||Major Depressive Disorder|
88887854|NCT01427452||Living Kidney Donor, Transplant Recipient, Healthy Control|Living kidney donors and their transplant recipient will be enrolled. Also, a smaller cohort of healthy controls (potential donors who were medically suitable but not used) will be enrolled.
88887855|NCT01427465|Experimental|Consult|Consult
88887856|NCT01427465|Experimental|Newsletter|Newsletter
89411647|NCT03919864|Other|CONTROL Group|Control arm participants will receive a generic (i.e., not tailored) printed list of hospital, community, and national supportive care resources. Control participants will not receive the educational video, complete the E-tool Preference survey, or have an option for an automated referral to a caregiver navigator
88887857|NCT01427465|Experimental|Parent Letter|Parent Letter
88887858|NCT01427465|Active Comparator|Control|Control
88887859|NCT01427478|Experimental|AFATINIB|Radiotherapy combined with a chemotherapy by Cisplatin IV at the dose of 100mg/m2 every 3 weeks, followed by a maintenance therapy with BIBW 2992 for 1 year at the dose of 40 mg/during the 1st month and then 50 mg/d during the 11 following months
88887860|NCT01427478|Placebo Comparator|PLACEBO|Radiotherapy associated with a chemotherapy by Cisplatin IV at the dose of 100mg/m2 every 3 weeks, followed by a maintenance therapy with placebo of BIBW 2992 for 1 year at the dose of 40 mg/during the 1st month and then 50 mg/d during the 11 following months
88887861|NCT01427491|Active Comparator|Aquacel® Ag|
88887862|NCT01427491|Active Comparator|Mepilex® Border Ag|
88887863|NCT01427543|Experimental|MILE group sessions|Participants will attend 6 - 2 hour long, interactive, culturally congruent, group sessions that address knowledge, beliefs, attitudes, and skills related to reducing HIV risk behaviors.
89411648|NCT05070598|Experimental|Camrelizumab +Pyrotinib + Nab-paclitaxel + Tegafur|Camrelizumab Q3W d1 Pyrotinib d1-21 Nab-paclitaxel Q3W d1 Tegafur d1-14
89411649|NCT02308436|Experimental|Candida Mouthwash with Curolox™ Peptide|Repeated applications 2.5 ml or 5 ml twice daily
88887864|NCT01427543|No Intervention|Control|These subjects will be provided with access to post-incarcerations services that will be provided by the Center for Health Justice.
88887865|NCT01427556||Breakfast Eaters|Women who self-report eating breakfast regularly.
88887866|NCT01427556||Non-Breakfast Eaters|Women who self-report skipping breakfast regularly.
88887867|NCT01427569|Experimental|IZN-6D4 Gel|patients in this arm will be treated by twice a week bandaging the wound with active IZN-6D4 Gel
88887868|NCT01427569|Placebo Comparator|Placebo Hydrogel|patients in this arm will be treated by twice a week bandaging the wound with a hydrogel used for wound care, but without the active IZN-6D4
88887869|NCT01427621|Experimental|RIPCcom group|
88887870|NCT01427621|No Intervention|Control group|
88887871|NCT01427634|Active Comparator|Palliative Care|Receive ongoing counseling and symptom assessment as well as clarification and documentation of goals of care, starting before implantation and continuing throughout the course of the study. Intervention patients will also be followed by the inpatient palliative care consultation service when hospitalized for their initial VAD implantation and during any subsequent hospitalizations as needed
88887872|NCT01427634|Other|Control|Usual Care
88887873|NCT01427647|Active Comparator|Control group|Control group: open surgery under general anesthesia
88887874|NCT01427647|Active Comparator|Epidural group|Epidural group: Open surgery under thoracic epidural anesthesia
88887875|NCT01427647|Active Comparator|Laparoscopic group|Laparoscopic group: Laparoscopic surgery under general anesthesia
88887876|NCT01427660|Active Comparator|Traditional CERSG Arm|CHWs will provide and review with patients language-appropriate versions of the AHRQ consumer guides. CHWs will highlight key points on each page, review information on each medication and elicit and address questions. They will use the autonomy enhancing, motivational-interviewing based skills. As with the first arm, CHWs will schedule follow-up clinic appointments for participants who note a specific treatment change they would consider and will call participants two times after the session at three and six weeks to address additional questions and to follow up on any goals the participant set.
88887877|NCT01427660|Experimental|Web-Based Materials Arm|Participants randomized to this arm will be scheduled within 3 weeks of enrollment to have a one-hour face-to-face session with a CHW who will deliver the ipad platform personally tailored diabetes medication decision aid. Participants will receive a printed tailored preference summary at the completion of this visit. If participants note a specific treatment change they would like to discuss with their providers, the CHW will facilitate scheduling a clinic visit within the next month. Finally, CHWs will call participants two times after the session at 3 and 6 weeks to assess if the participant has additional questions and to follow up on any treatment or other goals the participant set during their session.
88887878|NCT01427673|Active Comparator|CPAP Procedure control group|Overlap patients randomly assigned to the CPAP titrated per AASM guidelines.
88887879|NCT01427673|Experimental|Bipap procedure group|Overlap patients randomized to Bipap titrated per AASM guidleines with an IPAP to EPAP diffrence of at least 8 cm H2O.
88887880|NCT01427686|Active Comparator|Dobutamine|Start Dobutamine. If no success switch to Dopamine.
88887881|NCT01427686|Active Comparator|Dopamine|Start Dopamine. If no success switch to Dobutamine.
88887882|NCT01427699|Experimental|T2-18C3 therapeutic antibody|9 subjects will receive the T2-18C3 therapeutic antibody.
88887883|NCT01427777||HPV Vaccine|People that receive HPV vaccine in V501-030
88887884|NCT01427816|Experimental|KCT-0809 ophthalmic solution, low dose|
88887885|NCT01427816|Experimental|KCT-0809 ophthalmic solution, high dose|
89192416|NCT02544334||RA responsive to anti-TNF|This group will consist of 25 adult subjects with Rheumatoid Arthritis (RA) who have been responsive to first line anti-TNF-alpha therapy. During the exam the following will take place: the multidimensional health assessment questionnaire (MDHAQ), dental exam, saliva collection, and dental plaque will be removed from different tooth surfaces for supragingival.
89192417|NCT02544334||RA non responsive to anti-TNF|This group will consist of 25 adult subjects with Rheumatoid Arthritis (RA) who are resistant to two or more anti-TNF-alpha therapies, and be of the same age as the RA responsive to anti-TNF group. During the exam the following will take place: the multidimensional health assessment questionnaire (MDHAQ), dental exam, saliva collection, and dental plaque will be removed from different tooth surfaces for supragingival.
89192418|NCT00800007|Active Comparator|ANZ-521|
89192419|NCT00800007|Placebo Comparator|Placebo|
89192420|NCT00739232|Active Comparator|Active|Active
89192421|NCT00739232|Placebo Comparator|Placebo|Placebo
89192422|NCT02569008|Experimental|1 ml / Kg|Patients receive a Fluid challenge with Compound Sodium Lactate 1 ml/Kg IV over 5 minutes
89411650|NCT02308514|Active Comparator|conservative care|this group of patients will receive the conservative care: myofascial point release and radial head mobilisation
89411651|NCT02308514|Experimental|cryostimulation|this group of patients will receive the conservative care :myofascial point release and radial haed mobilisation and the cryostimulation (30-40 second of cold air application (-70 celsius degree) in order to lower skin temperature around the lateral epicondyle at 4 celsius degree.
89411652|NCT03884452|Experimental|Atorvastatin 80 mg|80 mg atorvastatin taken orally, once daily for 12 weeks
89411653|NCT03884452|Experimental|Ezetimibe + Atorvastatin 40 mg|10 mg ezetimibe and 40 mg atorvastatin taken orally, once daily for 12 weeks
89411654|NCT03884452|Experimental|Ezetimibe + Atorvastatin 80 mg|10 mg ezetimibe and 80 mg atorvastatin taken orally, once daily for 12 weeks
89411655|NCT03884452|Experimental|Simvastatin 80 mg|80 mg simvastatin taken orally, once daily for 12 weeks
89411656|NCT03884452|Experimental|Ezetimibe + Simvastatin 40 mg|10 mg ezetimibe and 40 mg simvastatin taken orally, once daily for 12 weeks
89411657|NCT03884452|Experimental|Ezetimibe + Simvastatin 80 mg|10 mg ezetimibe and 80 mg simvastatin taken orally, once daily for 12 weeks
89411658|NCT02308592|Placebo Comparator|Standard Resource Sheet|Women allocated to the control intervention will login to the study website and receive a printable PDF containing references to standard published information on antidepressant use in pregnancy. This ensures women have access to accurate information on the benefits and risks of antidepressant medication in pregnancy (even though they will not receive the PDA).
89411659|NCT02308592|Active Comparator|Electronic Patient Decision Aid|"The electronic Patient Decision Aid (PDA) is an interactive website with 3 main sections:~Evidence-based information on (a) depression in pregnancy, (b) each treatment option and procedure;~(a) Evidence-based information on the risks and benefits of both untreated depression and antidepressant treatment, (b) exercises to help women determine which risks and benefits are most important to them; and~A summary section that outlines the information reviewed and which benefits and risks they deemed most important.~At the end of the PDA, women allocated to this intervention will ALSO receive the standard resource sheet which is being used as the placebo comparator."
89411660|NCT02305082||Fast-track group|Patients treated according to the enhanced recovery pathway. This group is examined prospectively.
89411661|NCT02305082||Control group|Patients treated according to the historic recovery pathway. This group is examined retrospectively.
89411662|NCT03882892|Placebo Comparator|Placebo + Atorvastatin|Participants who received placebo in the parent study (P00692) receive placebo (blinded) + atorvastatin (10 mg/day; open-label) in this study.
89411663|NCT03882892|Experimental|Ezetimibe + Atorvastatin|Participants who received ezetimibe + atorvastatin, or atorvastatin alone, in the parent study (P00692) receive ezetimibe (blinded) + atorvastatin (10 mg/day; open-label) in this study.
89411664|NCT02305160|Experimental|Butantan|The new pulmonary surfactant produced by Butantan Institute. Butantan Surfactant: 100 mg/kg, IT, maximum of 3 doses.
89411665|NCT02305160|Active Comparator|Control|The pulmonary surfactants commercially available in Brazil Survanta or Curosurf: 100 mg/kg, IT, maximum of 3 doses.
89411666|NCT03101332|Experimental|VR-CBT|Virtual Reality cognitive behavior therapy. 10-12 sessions of individual Cognitive Behavior Therapy with exposure tasks carried out through Virtual Reality.
89411667|NCT03504176||Intervention|Patients will be ventilated according to the bundle; including ventilation targets, tidal volume, end expiratory pressure-fraction of inspired oxygen titration.
88887886|NCT01427816|Placebo Comparator|Placebo|
88887887|NCT01427829|Experimental|Intervention (CaPRA)|
88887888|NCT01427829|No Intervention|Control (usual care)|
88887889|NCT01427842|Experimental|DEVINE vancomycin regimen|This is the intervention arm and will be the pharmacokinetically derived vancomycin dosing regimen.
89411668|NCT03504176||Control|Standard of care prior to implementation of the ventilation bundle
89411669|NCT05069506|Experimental|Glucose as reference food|Twelve healthy, normal-weight subjects (male: 4, female: 8) after 10-14 hr fast, consumed 25g available carbohydrate from glucose, three times, in different weeks as reference foods along with 250ml water; and 25g available carbohydrates from a) goat milk yogurt, b) goat milk yogurt and currants, c) currants, d) sultanina raisins, one time each, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
89411670|NCT05069506|Experimental|Goat milk as test food|Twelve healthy, normal-weight subjects (male: 4, female: 8) after 10-14 hr fast, consumed 25g available carbohydrate from glucose, three times, in different weeks as reference foods along with 250ml water; and 25g available carbohydrates from a) goat milk yogurt, b) goat milk yogurt and currants, c) currants, d) sultanina raisins, one time each, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
88887890|NCT01427855|Experimental|High Saturated Fat Red Meat Diet|
88887891|NCT01427855|Experimental|High Saturated Fat White Meat Diet|
88887892|NCT01427855|Experimental|High Saturated Fat Non-Meat Diet|
88887893|NCT01427855|Experimental|Low Saturated Fat Red Meat Diet|
88887894|NCT01427855|Experimental|Low Saturated Fat White Meat Diet|
88887895|NCT01427855|Experimental|Low Saturated Fat Non-Meat Diet|
88887896|NCT01427868|Experimental|LB80380 maleat salt|
88887897|NCT01427868|Active Comparator|LB80380 free base|
88887898|NCT01427894|Experimental|Maternal Singing|Maternal singing during Kangaroo Care of stable preterm infants
88887899|NCT01427894|No Intervention|Kangaroo Care|Kangaroo Care without singing
88887900|NCT01427946|Experimental|Retaspimycin HCl (IPI-504) and Everolimus|Retaspimycin HCl (IPI-504) and everolimus will be administered on a 21-day cycle. All patients will remain on study until progression of disease or intolerability to study treatments occurs.
89192423|NCT02569008|Experimental|2 ml/Kg|Patients receive a Fluid challenge with Compound Sodium Lactate 2 ml/Kg IV over 5 minutes
89192424|NCT02569008|Experimental|3 ml/Kg|Patients receive a Fluid challenge with Compound Sodium Lactate 3 ml/Kg IV over 5 minutes
89192425|NCT02569008|Experimental|4 ml/Kg|Patients receive a Fluid challenge with Compound Sodium Lactate 4 ml/Kg IV over 5 minutes
89192426|NCT00735020|Experimental|1|
89192427|NCT00735020|Active Comparator|2|
89192428|NCT04065906|Experimental|NIRS group|Children with ADHD, 12 sessions of NIRS feedback, for two sessions per week.
89192429|NCT04065906|Other|Drug group|Children with ADHD, 6 weeks' treatment of either methylphenidate or tomoxetine
89192430|NCT04065906|Other|Control group|Healthy children, 12 sessions of NIRS feedback, for two sessions per week.
89192431|NCT02544256|Experimental|Mild hypothermia|After induction to general anaesthesia the patients will be cooled to 33° C. Targeted body temperature 33,8° C - 34,8° will be maintained up to the end of microcirculation measurement after aneurysm clipping.
89192432|NCT02544256|No Intervention|Normothermia|The body temperature will be maintained in the range 35,8° C - 36,8° C.
89192433|NCT00739388|Experimental|Arm: 5-azacytidine|5-azacytidine 100 mg/m2/day s.c. on days 1-5 of a 28-day cycle.
89192434|NCT00809211|Experimental|Nilotinib|
89192435|NCT00862888|Placebo Comparator|Cohort 1; Study Period 1, 2, 3 or 4|Cohort 1: Exploring two single doses of PF-00446687 200 mg as well as sildenafil 100mg and placebo (double dummy design)
89192436|NCT00862888|Placebo Comparator|Cohort 2; study periods 1, 2, 3 or 4|Cohort 2: Exploring single doses of PF-00446687 20 mg - 175 mg. Subjects to receive two of 3 possible doses of PF-00446687 as well as a single dose of sildenafil 100mg and placebo (double dummy design).
89192437|NCT00729456|No Intervention|1|
89192438|NCT00729456|Other|2|Patients receive a single session, one-to-one workshop (carers may be included if appropriate) in their own home, lasting 60 - 120 minutes.
89192439|NCT00800085|No Intervention|FDR of type 1 diabetes patients receiving glucose 20%|First Degree Relatives of diabetes type 1 patient with a high, intermedian or low risk (accoring to the criteria of the protocol), for developing diabetes type 1.
89192440|NCT00731250|Placebo Comparator|PART 1-Visit 1-Placebo|Eligible subjects will receive matching placebo tablets
89192441|NCT00731250|Experimental|PART 1-Visit 1-Capsaicin|Eligible subjects will receive incremental capsaicin doses
89192442|NCT00731250|Placebo Comparator|PART 1-Visit 2-Placebo|Eligible subjects will receive matching placebo tablets
89192443|NCT00731250|Experimental|PART 1-Visit 2-Capsaicin|Eligible subjects will receive maximum capsaicin dose
89192444|NCT00731250|Placebo Comparator|PART 1-Visit 3-Placebo|Eligible subjects will receive matching placebo tablets
89192445|NCT00731250|Experimental|PART 1-Visit 3-Capsaicin|Eligible subjects will receive matching placebo tablets incremental capsaicin doses
89192446|NCT00731250|Placebo Comparator|PART 2-Visit 1-Placebo|Eligible subjects will receive matching placebo tablets
89192447|NCT00731250|Experimental|PART 2-Visit 1-SB-705498|Eligible subjects will receive SB-705498 tablets
89192448|NCT00731250|Experimental|PART 2-Visit 2-Capsaicin|Eligible subjects will receive matching placebo tablets incremental capsaicin doses
89192449|NCT04041076||Elective Surgical Patients in Tuen Mun Hospital|Patients who received elective surgical operation in Tuen Mun Hospital from 1July 2012 to 30June 2018
89192450|NCT00735098|Experimental|1|KBA exercise protocol
89192451|NCT00735098|Experimental|2|strength training exercise protocol
89192452|NCT00735098|Experimental|3|KBA and strength training protocol
89192453|NCT00735098|Sham Comparator|4|
89192454|NCT00800163|Experimental|ED Physician Activation/Immediate Transfer|
89192455|NCT00871078||A|HIV-positive patients with CD4 cell counts below 100 cells/mm³ at some point of time in their medical history lasting for at least 6 months
88887901|NCT01427985|Experimental|Relaxation followed by analgosedation|Give Atropin, then Mivacurium, immediately followed by Fentanyl
88887902|NCT01427985|Active Comparator|Analgosedation followed by Relaxation|Give atropin, then Fentanyl, then Mivacurium
89192456|NCT00871078||B|HIV-positive patients with CD4 cell counts never below 100 cells/mm³ in their medical records
89192457|NCT00871078||C|HIV-negative patients (control group)
89192458|NCT04065594|Experimental|PRP dressing|
89192459|NCT04065594|Experimental|conventional ordinary dressing|
89192460|NCT00735176|Experimental|Artificial Cervical Disc|Anterior cervical discectomy, followed by insertion of the Discover™ Artificial Cervical Disc
89192461|NCT00735176|Active Comparator|ACDF|Anterior cervical discectomy and fusion (ACDF)
89192462|NCT00862966|Experimental|citrate|
89192463|NCT00862966|Active Comparator|heparin|
89192464|NCT02569320|Experimental|Treatment (pomalidomide, dexamethasone, HDAC inhibitor AR-42)|Patients receive pomalidomide PO daily on days 1-21, dexamethasone PO BIW or TIW weeks 1-3, and HDAC inhibitor AR-42 PO BIW or TIW for weeks 1-3. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
89192465|NCT00739466|Experimental|low dose|Liposomal Alendronate dose of 0.001 mg
89192466|NCT00739466|Experimental|high dose|Liposomal Alendronate dose of 0.01 mg
89192467|NCT00739466|Placebo Comparator|placebo|IV saline infusion
89192468|NCT02544178||diagnostic procedure|neurocognitive tests before and after radiotherapy
89192469|NCT00863044|Active Comparator|High frequency ventilation|high frequency ventilation
89192470|NCT00863044|Placebo Comparator|Apnea|lung ventilation will be stopped during distal anastomosis as is commonly done
89192471|NCT00739544|Other|1|Quantitative sensory testing (QST) of healthy women to create reference values for QST evaluation of women treated for breast cancer
89192472|NCT00735332|Experimental|Single-Arm|
89192473|NCT00869908||A|
89192474|NCT00734058|Experimental|Persistent AF|Treatment arm to be compared with historical control.
89192475|NCT00731562|Experimental|Varenicline Controlled Release, Fasted|
89005269|NCT01089556|Experimental|Pregabalin+Duloxetine|"Initial Treatment:~Pregabalin 150 mg daily for 1 week~Pregabalin 300 mg (150 mg twice daily) daily for 7 weeks~Intensive Treatment:~Pregabalin 300 mg (150 mg twice daily) daily for 8 weeks~Duloxetine 30 mg daily for 1 week~Duloxetine 60 mg daily for 7 weeks"
89192476|NCT00731562|Experimental|Varenicline Controlled Release, Fed|
89192477|NCT00739700||A|There is only one cohort of subjects, the critically ill. The NIBP will be correlated with the IABP in each subject.
89192478|NCT00870064|Other|Formal Operative Treatment|Children randomized to the formal operative management arm will be taken to the Operating Room within 24 hours for irrigation and debridement and appropriate bone management.
89192479|NCT00870064|Other|Emergency Department Treatment|Children in the Emergency Department Treatment arm will have a washout in the emergency room under conscious sedation, a closed reduction and home antibiotics.
89192480|NCT00734136|Other|1|50 surgical subjects undergoing either liver transplantation or hepatic resection
89192481|NCT00734136|Other|2|50 Subjects with Liver disease who are are not surgical candidates
89192482|NCT04695392|Experimental|Intervention|R2 Bundle
89192483|NCT00870142|Experimental|A|AMLODIPINE (as BESILATE) TABLETS 10 mg, single dose
89192484|NCT00870142|Active Comparator|B|Norvasc® 10 mg Tablets, single dose
89192485|NCT00731796||1|Stroke victims with a visual field deficit that undergo vision restoration therapy
89192486|NCT00731796||2|Stroke victims with a visual field deficit who do not undergo any rehabilitation intervention
89192487|NCT00731796||3|Stroke victims that do not have a visual field deficit
89192488|NCT00731796||4|Normal individuals who have not had a stroke and do not have a visual field deficit
89192489|NCT00870220|Experimental|GH alone, Low dose E2 patch, Very Low-dose E2 patch|"Group 1: Growth hormone alone, no E2. Group 2: Growth Hormone plus Estradiol patch dose A(14 mcg/d x 10 d) x 6 months then Estradiol patch dose B(25 mcg/d x 10 d) x 6 months.~Group 3: Growth Hormone plus Estradiol patch dose B(25 mcg/d x 10 d) x 6 months then Estradiol patch dose C(25 mcg/d x 3 w) x 6 months."
89192490|NCT00735410|Experimental|1|
89192491|NCT00729768|Experimental|1|
89192492|NCT00729768|Active Comparator|2|
89192493|NCT00734370|Experimental|VRET|Virtual Reality Exposure Therapy for agoraphobic participants
89192494|NCT00734370|Active Comparator|Exposure in vivo|Standard exposure in vivo for panic disorder
89192495|NCT00734370|No Intervention|Wait-list control|Wait-list control group. Participants from this arm are randomized to the two active conditions after 10 weeks of waiting.
89192496|NCT00871156|Active Comparator|Part 1|Tafenoquine + Chloroquine vs. Chloroquine alone
89192497|NCT00871156|Placebo Comparator|Part 2|Chloroquine alone, Tafenoquine alone or Chloroquine+Tafenoquine
89192498|NCT00734448|Experimental|A,1|Gestational diabetes patients who take myo-inositol
89192499|NCT00735488||A|Thalassemia Minor carriers
89192500|NCT00735488||B|Sickle cell carriers
89192501|NCT00738504||1|
89192502|NCT00738504||2|
89192503|NCT00738504||Group 1|Group 1 (Carbohydrate Restrictive Strategy). Patients received intravenous hydration with a glucose free solution (Ringer III) and enteral nutritional formula containing 33.3% carbohydrates, 16,7% proteins and 50% lipids (Glucerna, Abbott Laboratories). These patients received regular insulin subcutaneously four times daily, aiming to maintain blood glucose levels at least below 180 mg/dl, and, in stable patients, ideally below 150 mg/dl.
89192504|NCT00738504||Group 2|Group 2 (Intensive Insulin Therapy). Continuous intravenous insulin infusion was adjusted to maintain glycemic levels at least below 150 mg/dl, and, in stable patients and ideally, between 80 to 120 mg/dl. Patients were submitted to capillary glycemic measurements every 2 hours. The insulin dose was adjusted according to an algorithm run by nurses and overseen by physicians. These patients received glucosaline (5% glucose + 0.9 NaCl) hydration and enteral nutrition with a formula containing 45% carbohydrates, 17% proteins and 38% lipids (Diason, Nutricia Clinical Care Ltd).
89192505|NCT04039906|No Intervention|Removal of needle with existing method|Participants will remove needles from syringes with the existing method like they are already doing. (Record the time required for the needle removal procedure by photographing during 24 hours/7 days.)
89192506|NCT04039906|Experimental|Removal of needle with using ANDYs|Participants will remove needles from syringes with Andy. (Record the time required for the needle removal procedure by photographing during 24 hours/7 days.)
89192507|NCT04064372|Experimental|Mindful Response to Adversity|"The treatment condition will be trained in techniques designed to teach a mindful approach to adversity. These techniques will include: normalizing, attention, equanimity, non-judgment, de-centering, accepting of experiences, and impermanence. Participants will be instructed on the mindset, asked to write about an instance of non-judgment and share with a partner, and then guided through a short training designed to practice each skill."
89192508|NCT04064372|Active Comparator|Strength-based approach to adversity|The control condition will be trained in techniques designed to teach a typical narrative self-analysis / strengths-based approach to adversity. These techniques will include: choosing the best approach, minimizing stress, and identifying and enhancing personal strengths. Participants will be instructed on the mindset, asked to write about an instance of personal strength and share with a partner, and then guided through a short training designed to practice each skill.
89192509|NCT00734526|Experimental|Dose Level 1|"Temozolomide + Radiation, Followed by Higher Dose Temozolomide in a Shorter Cycle~Temozolomide 75mg/m^2 daily during radiation therapy, and 150mg/m^2 in the first cycle of adjuvant therapy. Dose Level 1 will receive sorafenib in the adjuvant phase (following radiation therapy) at the dose of 400mg BID in combination with standard dose temozolomide 150-200 mg/m^2 two days out of 28 day cycle. Radiotherapy 2.0 Grey (Gy)/day given daily 5 days per week for total of 60.0 Gy over 6 weeks."
89192510|NCT00734526|Experimental|2|Temozolomide + Lower Dose Sorafenib + Radiation, Followed by Higher Dose Temozolomide in a Shorter Cycle + Higher Dose Sorafenib
89192511|NCT00734526|Experimental|3|Temozolomide + Lower Dose Sorafenib + Radiation, Followed by Lower Dose Temozolomide in a Longer Cycle + Lower Dose Sorafenib
89411671|NCT05069506|Experimental|Goat milk and currants as test food|Twelve healthy, normal-weight subjects (male: 4, female: 8) after 10-14 hr fast, consumed 25g available carbohydrate from glucose, three times, in different weeks as reference foods along with 250ml water; and 25g available carbohydrates from a) goat milk yogurt, b) goat milk yogurt and currants, c) currants, d) sultanina raisins, one time each, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
89411672|NCT05069506|Experimental|Currants as test food|Twelve healthy, normal-weight subjects (male: 4, female: 8) after 10-14 hr fast, consumed 25g available carbohydrate from glucose, three times, in different weeks as reference foods along with 250ml water; and 25g available carbohydrates from a) goat milk yogurt, b) goat milk yogurt and currants, c) currants, d) sultanina raisins, one time each, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
89411673|NCT05069506|Experimental|Sultanina raisins as test food|Twelve healthy, normal-weight subjects (male: 4, female: 8) after 10-14 hr fast, consumed 25g available carbohydrate from glucose, three times, in different weeks as reference foods along with 250ml water; and 25g available carbohydrates from a) goat milk yogurt, b) goat milk yogurt and currants, c) currants, d) sultanina raisins, one time each, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
89411674|NCT05069506|Experimental|Goat milk as preload|Forty-five healthy subjects (male: 12, female: 33) were offered a standardized breakfast and 2h after consumed one of the two preloads (goat milk yogurt and milk with lactic acid) served as snack in random order. Three hours after, subjects were given ad libitum access to a meal (lunch and dessert). Foods were weighed at the time of serving and any leftovers were weighed again after meal to determine the amount of food consumed. Fingertip capillary blood glucose samples were collected before and after foods. Subjective appetite ratings were collected using 100mm visual analogue scales (VAS).
89411675|NCT05069506|Experimental|Milk with lactic acid as preload|Forty-five healthy subjects (male: 12, female: 33) were offered a standardized breakfast and 2h after consumed one of the two preloads (goat milk yogurt and milk with lactic acid) served as snack in random order. Three hours after, subjects were given ad libitum access to a meal (lunch and dessert). Foods were weighed at the time of serving and any leftovers were weighed again after meal to determine the amount of food consumed. Fingertip capillary blood glucose samples were collected before and after foods. Subjective appetite ratings were collected using 100mm visual analogue scales (VAS).
89411676|NCT02312336|Placebo Comparator|Cohort A|Cohort A - Room temperature coronary perfusate
89411677|NCT02312336|Active Comparator|Cohort B|Cohort B - Cooled coronary perfusate
89411678|NCT03504098||Lung cancer patients tumor|Using to analysis metabolomic markers, one carbon folate nutrition levels in lung cancer patients.
89411679|NCT03504098||Lung cancer patients blood|Using to analysis folate, B12, homocysteine levels in plasma and RBC. Using to analysis cDNA gene test in buffy coat.
89411680|NCT03504098||Lung cancer patients|Supply nutrition counseling
89411681|NCT04434742|Experimental|Intervention group|The subjects in this group receive complex interventions, including structured assessment, health education, goal empowerment, and care coordination supported by a health-social team.
89411682|NCT04434742|Other|Control group|The control group received usual discharge care and community resources that were made available to them as appropriate. A monthly social call was made to each client in the control group in order to exclude social effects. The contents of the social call, such as asking about entertainment and clients' hobbies, were set in the protocol.
89411683|NCT02312414|No Intervention|IVIR|Patients given IV iron (Sodium ferric gluconate, [125 mg/100 ml] from week 1 to week 4
89411684|NCT02312414|Experimental|IVIR Carnitine|Patients given Carnitine (20mg/kg, IV) perior to IV iron (Sodium ferric gluconate, [125 mg/100 ml] from week 4 to week 8.
89411685|NCT05069272|Active Comparator|Intervention|Synergistic combination of Bakuchiol and Ethyl Linoleate
89411686|NCT05069272|Placebo Comparator|Vehicle|No active ingredients
89536707|NCT02470559|Experimental|Treatment (aldesleukin, sargramostim, HER2Bi-aACT)|Patients receive HER2Bi-aATC IV over 5-15 minutes and IP within 3-4 days of IV dose weekly for 4 weeks. Patients also receive low-dose aldesleukin SC daily and sargramostim SC twice weekly beginning 3 days before the first HER2Bi-aATC infusions infusion and ending 7 days after the last HER2Bi-aATC infusion. Treatment continues in the absence of disease progression or unacceptable toxicity.
88887903|NCT01427998|Active Comparator|olive leaf extract|Olive leaf polyphenol concentrate (OLPC) extraction OLPC was prepared from olive leaves as follows (Zaslave et al, 2005) : The leaves were randomly picked from the Barnea cultivar in the Jezreel Valley region of Israel and immediately freeze-dried on dry ice. After the leaves were thoroughly rinsed with sterile distilled water to remove dust, insecticides, and contaminating material, the leaves were ground and successively Soxhlet extracted with hexane for 3 h and 80% aqueous ethanol for 6 h. The alcoholic extract was concentrated under reduced pressure at 25 °C, and reconstituted with 30% ethanol in water.
88887904|NCT01427998|Placebo Comparator|placebo|matched placebo
88887905|NCT01428011||No treatment|African American/Black and Caucasian/White patients with hypertension
88887906|NCT01428037|Experimental|Misoprostol Vagianl Tablet|Misoprostol Vaginal Tablet 25 mcg.
88887907|NCT01428037|Placebo Comparator|Placebo|Tablet without active ingredient
88887908|NCT01427127|Experimental|ramosetron|Patients received intravenous ramosetron 0.3 mg at the end of surgery and 24hr after surgery.
88887909|NCT01427127|Placebo Comparator|Normal saline|Patients received intravenous normal saline at end of surgery and 24hr after surgery.
88887910|NCT01428050|Experimental|3% saline|Patients will received 3% saline in conjunction with lactated ringers solution intra and post operatively for a net reduction in total fluid administration
88887911|NCT01428050|Active Comparator|Lactated Ringers|15cc/kg/hr of lactated ringers solution intraoperatively
88887912|NCT01428102||RapidTEG|Samples tested with TEG which are both citrated and non-citrated and are activated using the reagent RapidTEG.
88887913|NCT01428102||Kaolin|Samples tested with TEG which are both citrated and non-citrated and are activated using the reagent Kaolin.
88887914|NCT01428154|Experimental|Darbepoetin alfa|
88887915|NCT01428167||Thyroidectomy|All patients undergoing thyroidectomy for a variety of indications.
88887916|NCT01428180||Indomethacin|Infants treated with Indomethacin
88887917|NCT01428180||Ibuprofen|Infants treated with Ibuprofen
88887918|NCT01428180||Ligation|Infants undergoing surgical ligation
88887919|NCT01428206|Other|Liverpool care pathway|Liverpool care pathway for dying at nursing homes
88887920|NCT01428206|No Intervention|control|Usual care is performed for the control group
88887921|NCT01428232|Experimental|BFHI steps 1-9|Hospital retrained in BFHI steps 1-9 Mothers can call hospital to obtain BF support/Mothers given phone # of maternity nurse whom she can call or go see if she has BF problems
88887922|NCT01428232|Experimental|BFHI steps 1-9 +well-child clinic|Hospital retrained in BFHI steps 1-9 Mothers can call hospital to obtain BF support/Mothers given phone # of maternity nurse whom she can call or go see if she has BF problems Provision of BF support during 1) clinic visit to obtain birth certificate or home visit if mother does not come into clinic and 2) well-child clinics Flyers to mother with culturally appropriate messages designed to address some of the most important local barrier to EBF
88887923|NCT01428232|No Intervention|usual care|
88887924|NCT01428271||Herniorrhapy with caudal block|Children aged 0-72 months who are scheduled to undergo elective inguinal herniorrhapy under general anesthesia with caudal block
88887925|NCT01428284|Experimental|001|Canagliflozin/Probenecid
88887926|NCT01428297|Experimental|Cohort A and B, BPR277 and Placebo (vehicle)|
88887927|NCT01428297|Experimental|Part 2 BPR277|
88887928|NCT01428297|Placebo Comparator|Part 2 Placebo (vehicle)|
88887929|NCT01428297|Experimental|Part 3 BPR277 and Placebo (vehicle)|
88887930|NCT01428310|Active Comparator|Anatabloc(TM)|dissolvable bit containing dietary ingredients, binders, fillers, and flavors
88887931|NCT01428310|Active Comparator|CigRx(R)|dissolvable bit containing dietary ingredients, binders, fillers, and flavors
88887932|NCT01428349|Experimental|Attention to Context|
88887933|NCT01428349|Experimental|Affective Cognitive Control|
88887934|NCT01428375|Active Comparator|(1) Active (Paracetamol) arm: n=60|(Paracetamol)
88887935|NCT01428375|Placebo Comparator|(2) Placbo (Sterile water) arm: n=60|Sterile water
88887936|NCT01428388|Active Comparator|Bevacizumab|
88887937|NCT01428388|Active Comparator|Ranibizumab|
88887938|NCT01428401|Experimental|Arm A|
88887939|NCT01428401|Placebo Comparator|Arm B|
88813937|NCT03003455|Experimental|Nasotracheal Intubation Over a Bougie (NIB)|Nasotracheal intubation over a bougie, placed with videolaryngoscopy assistance, via a nasopharyngeal airway with or without the aid of Magill forceps
88813938|NCT03400280|Experimental|Best practice|Postoperative care according to a best practice algorithm for postoperative care focussing on early detection and minimally invasive management of postoperative pancreatic fistula.
88813939|NCT03400280|No Intervention|Current practice|Postoperative care according to current usual practice.
88813940|NCT03404726|Experimental|Dose Escalation|Dose escalation with sequential cohorts enrolling patients with AML, MDS, or CMML. Patients will be treated in 28-day cycles with once daily oral administration of BAY2402234
88813941|NCT03404726|Experimental|Dose Expansion: AML|After completion of dose escalation, an expansion cohort comprised of patients with AML will start. These patients will be treated in 28 day cycles with once daily oral administration of BAY2402234 at the maximum tolerated dose or pharmacologically active dose.
88887940|NCT01428414|Active Comparator|Trastuzumab+ Carboplatin+Paclitaxel|Neoadjuvant treatment regimen:Trastuzumab,Carboplatin,Paclitaxel
88887941|NCT01428414|Active Comparator|Trastuzumab+Epirubicin+Paclitaxel|Neoadjuvant treatment regimen:Trastuzumab,Epirubicin,Paclitaxel
88887942|NCT01428427|Experimental|Cohort|Dose escalation to maximum tolerated dose of GSK1120212 and Gemcitabine.
88887943|NCT01428440|Other|no treatment|
88887944|NCT01428466|Experimental|GSK2585823|external preparation
88887945|NCT01428466|Active Comparator|Benzoic peroxide 3%|external preparation
88887946|NCT01428466|Active Comparator|Benzoic peroxide 5%|external preparation
88887947|NCT01428466|Placebo Comparator|Vehicle|external preparation
88887948|NCT01428479|Experimental|Treatment Arm A|In Arm A subjects will receive 100 mg of GR121167 in Period 1 and 300 mg of GR121167 in Period 2. In Period 3 subject will receive single doses of placebo on Day 1 and multiple doses of placebo from Day 3 to Day 8
88887949|NCT01428479|Experimental|Treatment Arm B|In Arm B subjects will receive 100 mg of GR121167 in Period 1 and placebo in Period 2. In Period 3 subject will receive 600 mg of GR121167 as single dose on Day 1 and multiple doses of GR121167 from Day 3 to Day8
88887950|NCT01428479|Experimental|Treatment Arm C|In Arm C subjects will receive placebo in Period 1, 300 mg of GR121167 in Period 2. In period 3 subject will receive 600 mg of GR121167 single dose on Day 1 and multiple doses from Day 3 to Day 8
88887951|NCT01428492|Experimental|Part 1-Dose Escalation|GSK2110183 is administered in combination with bortezomib and dexamethasone until MTD is met.
88887952|NCT01428492|Experimental|Part 2- Pharmacokinetic/Pharmacodynamics Cohort|Once the MTD(s) has been determined, up to 9 subjects of the total enrolled in Part 2 will be entered in the Pharmacokinetic/Pharmacodynamic Cohort. Subjects will be enrolled in this cohort to explore whether exposure to GSK2110183 at dose identified in Part 1 is similar when GSK2110183 is administered alone or in combination with bortezomib and dexamethasone. The same relationship will be explored for bortezomib and dexamethasone when the two drugs are give alone or in combination with GSK2110183.
88887953|NCT01428492|Experimental|Part 2- Safety/Clinical Activity Cohort|"Enrolment into the safety/clinical activity cohort in Part 2 will begin prior to enrollment in the PK/PD cohort. Subjects with relapsed multiple myeloma who are either bortezomib sensitive or naive after failing one line of prior systemic therapy will be enrolled in the Safety/Clinical Activity cohort. Bortezomib sensitive is defined as having a response (PR or better) to the last bortezomib-containing therapy lasting at least 60 days beyond the end of therapy. A minimum of 15 subjects and a total of 40 subjects will be enrolled. This expansion cohort will further characterize the safety and clinical activity profile of GSK2110183 to inform the future development of this combination regimen."
88887954|NCT01428505|Other|no treatment|
88887955|NCT01428518||Patients with bipolar disorder|Patients with bipolar disorder prescribed lamotrigine tablets for the first time
89192512|NCT00734526|Experimental|4|Temozolomide + Higher Dose Sorafenib + Radiation, Followed by Lower Dose Temozolomide in a Longer Cycle + Higher Dose Sorafenib
89192513|NCT00729404|Experimental|Arm 1|
89192514|NCT00729404|Experimental|Arm 2|
89192515|NCT00876304|Experimental|PF-04802540|
89411687|NCT02305394|Experimental|PK group (ketamine and propofol)|propofol 1.5 mg/kg and ketamine 0.3 mg/kg will be administered to participants separately by intravenous infusion.When patients become unconscious, succinylcholine 1 mg/kg (a muscle relaxant) will be administered intravenously. After 1 minute of succinylcholine infused, ECT will be performed with bitemporal electrode placement using a stimulus dose of 1.0-millisecond pulse width, 60-Hz frequency, 6.0-second stimulus duration, and 0.8-A maximal stimulus intensity.
89411688|NCT02305394|Active Comparator|P group (propofol group)|propofol 1.5 mg/kg and normal saline [weight(kg)×0.3÷10]ml will be administered to participants separately by intravenous infusion.When patients become unconscious, succinylcholine 1 mg/kg (a muscle relaxant) will be administered intravenously. After 1 minute of succinylcholine infused, ECT will be performed with bitemporal electrode placement using a stimulus dose of 1.0-millisecond pulse width, 60-Hz frequency, 6.0-second stimulus duration, and 0.8-A maximal stimulus intensity.
89411689|NCT02305472|Experimental|NeoVas BCS|The NeoVas sirolimus-eluting bioresorbable coronary scaffold system is a PLLA-based polymer scaffold and contains the antiproliferative drug sirolimus.
89411690|NCT05069194||COPD|Patients with chronic obstructive pulmonary disease
89411691|NCT05069194||High Risk|People who do not suffer from COPD, but have high risk factor for COPD.
89411692|NCT05069194||Health|People who do not suffer from COPD and do not have a high risk factor for COPD either.
89411693|NCT02305550|Experimental|electrical synthesis nitric oxide|Participants will breath 20 minutes of electrical pulsed plasma discharge synthesis of nitric oxide at 25 parts per million
89411694|NCT03673852|Other|Peer Wellness Enhancement (WE Harambee)|This project employs a pragmatic, stepped wedge experimental design in which 60 BHH participants are randomly assigned to one of 3 waves of WE Harambee implementation (20 in each wave) during the 2 year study. Participants in this arm receive the WE Harambee Wellness Enhancement and are enrolled in a Behavioral Health Home. WE Harambee is a 6-month peer-delivered whole health intervention intended to address the 8 dimensions of wellness and the social determinants of health.
89411695|NCT03673852|Other|Behavioral Health Home enrollment|"In the stepped wedge experimental design, 40 participants at any time during the 2 year study are receiving only the Behavioral Health Home (BHH) intervention. The 2010 Patient Protection and Affordable Care Act (ACA) established a health home option under Medicaid that serves enrollees with chronic conditions including serious mental illness and chronic physical illness."
89411696|NCT02308670||RRMS changing from 20mg to 40mg GA|Relapsing-remitting Multiple Sclerosis patients who are switching from 20mg of glatiramer acetate (GA) to 40mg. The investigator is not influencing this clinical decision, just measuring its impact using MRI metrics.
89411697|NCT03506516|Experimental|single type|Restricted to drinking only one type of alcohol
89411698|NCT03506516|Active Comparator|mixed type|Drinking and mixing different types of alcohols freely
89411699|NCT03099928||Qualitative Interviews|
89411700|NCT02312492|Experimental|18:1 diet|Oleic Diet - volunteers will consume oleic enriched food for a period of 5 weeks.
89411701|NCT02312492|Experimental|16:0 diet|Palmitic diet - Volunteers will consume palmitic enriched food for a period of 5 weeks.
89411702|NCT02312492|Experimental|18:0|Stearic Diet - Volunteers will receive Stearic enriched food for a period of 5 weeks.
89411703|NCT02312570|Experimental|PRP Concepts Fibrin Bio-Matrix|PRP Concepts Fibrin Bio-Matrix in addition to usual and customary practice
89192516|NCT00876304|Placebo Comparator|Placebo|
89192517|NCT00735722|Active Comparator|Concomitant HIFU ablation|HIFU AF Ablation
89192518|NCT00735722|No Intervention|Best medical treatment|Best medical treatment
89411704|NCT02312570|Other|Usual and Customary Practice|Usual and customary practice for non-healing pressure wounds
89411705|NCT03670446|Experimental|Pharmacists' intervention|A group of participants assigned to a pharmaceutical intervention
89411706|NCT03670446|No Intervention|Routine therapy|A group of participants assigned to a control (routine therapy)
89411707|NCT02643394|Active Comparator|Oral Acetaminophen|Oral Acetaminophen 1-hour before surgery
89411708|NCT02643394|Active Comparator|Intravenous Acetaminophen|Intravenous Acetaminophen within 1-hour prior to anesthetic emergence
88887956|NCT01428531||Patients prescribed fondaparinux|
88887957|NCT01428544||Patients with VTE treated with fondaparinux|Patients with VTE treated with fondaparinux
88887958|NCT01428570|Experimental|Pentax-AWS|Patients in this group will be intubated using Pentax-AWS
88887959|NCT01428570|Active Comparator|laryngoscopy|Patients in this group will be intubated using Macintosh laryngoscope.
88887960|NCT01428596|Experimental|Arm I|Lower dose HIVAX vaccine
88887961|NCT01428596|Placebo Comparator|Arm II|lower dose, placebo control
88887962|NCT01428596|Experimental|Arm III|Higher dose HIVAX vaccine
88887963|NCT01428622|Placebo Comparator|Placebo + BI 54903|"patient to receive 2 puffs of respimat A and 2 puffs of respimat B"
88887964|NCT01428622|Experimental|Olodaterol low dose + BI54903|"patient to receive 2 puffs of respimat A and 2 puffs of respimat B"
88887965|NCT01428622|Active Comparator|Olodaterol medium dose + BI54903|patient to receive 2 puffs of each device
88887966|NCT01428622|Experimental|Olodaterol high dose + BI54903|patient to receive 2 puffs of each device
88887967|NCT01428622|Experimental|Olodaterol l dose + BI54903|patient to receive 2 puffs of each device
88887968|NCT01428622|Experimental|Olodaterol m dose + BI54903|patient to receive 2 puffs of each device
88887969|NCT01428622|Experimental|Olodaterol h dose + BI54903|patient to receive 2 puffs of each device
88887970|NCT01428648|Active Comparator|intervention|group of patients receiving ballroom dancing classes
88887971|NCT01428648|No Intervention|control|group of patients who will not receive dancing classes.
88887972|NCT01428141|Experimental|E7050|
88887973|NCT01428687|Active Comparator|Increase Sleep Gradually|Subjects in this condition are taught to increase their sleep by 30 minutes per night during week 1 of the intervention; 60 minutes during week 2; and 90 minutes during week 3. Following the sleep intervention, these participants receive a standard behavioral with loss intervention.
88887974|NCT01428687|Active Comparator|Increase Sleep Immediately|Subjects in this condition are taught to increase their sleep by 90 minutes per night starting in week 1. Following the sleep intervention, these participants receive a standard behavioral with loss intervention.
88887975|NCT01428687|Active Comparator|No Intervention: Control Group|This group is told to make no changes in their sleep habits. Following the sleep intervention, these participants receive a standard behavioral with loss intervention.
88887976|NCT01428726|Placebo Comparator|Placebo|
88887977|NCT01428726|Experimental|NT-KO-003 low dose|
88887978|NCT01428726|Experimental|NT-KO-003 high dose|
88887979|NCT01428752||Family history|30- to 49-year-old asymptomatic subjects with a first relative history of colorectal cancer
88887980|NCT01428804|Active Comparator|active tDCS|a group named G1 and treated by medication with escitalopram (Seroplex®) stabilized for at least 1 month and 10 sessions of tDCS anode active at 2 sessions per day (1 morning and 1 afternoon) for 5 days with an electric current 2 mA
88887981|NCT01428804|Sham Comparator|sham tDCS|a group named G2 and treated by medication with escitalopram (Seroplex®) stabilized for at least 1 month and sham tDCS.
88887982|NCT01428817|Active Comparator|Carbetocin 20mcg|
88887983|NCT01428817|Active Comparator|Carbetocin 40mcg|
88887984|NCT01428817|Active Comparator|Carbetocin 60mcg|
88887985|NCT01428817|Active Comparator|Carbetocin 80mcg|
88887986|NCT01428817|Active Comparator|Carbetocin 100mcg|
88887987|NCT01428830|Experimental|7-day catheterization|
88887988|NCT01428830|Active Comparator|14-day catheterization|
88887989|NCT01428843|Active Comparator|Ferrisat|Infusion of Ferrisat (50mg/ml) at inclusion under usual practices
88887990|NCT01428843|Placebo Comparator|Placebo|Infusion of placebo at inclusion visit
88887991|NCT01428869||statin+ASA+dutasteride|
88887992|NCT01428869||statin+ASA|
88887993|NCT01428869||dutasteride+statin|
88887994|NCT01428869||dutasteride+ASA|
88887995|NCT01428908|Experimental|children group A|600 children aged 2-5 years old, will be vaccinated on day0
88887996|NCT01428908|Experimental|infants group A|600 infants aged 6-23 months old, will be vaccinated on day0, 28
88887997|NCT01428908|Active Comparator|children group B|600 children aged 2-5 years old, will be vaccinated on day0
88887998|NCT01428908|Active Comparator|infants group B|600 infants aged 6-23 months old, will be vaccinated on day0, 28
88887999|NCT01428921|Experimental|Extended Education|"Standard education programme as described above,~Plus~Face-to-face session (Part 1: Knowledge Enhancement Session, Part 2: Brief Motivation Interview Session) after the morning of CPAP titration~Follow-up phone call would be arranged within 1 week after using CPAP.~Video, slides and booklets would be used as education media."
88888000|NCT01428921|No Intervention|Standard education|- Each subject will receive advice from Sleep Lab staff on the need for CPAP treatment, and the care of CPAP device and mask.
89411709|NCT02143674|Experimental|INTERVENTION|Muscle stretching and Strength Training
89411710|NCT02143674|Experimental|Educated about physical exercises|
88888001|NCT01428934||Intermediate risk population|Population aged between 35 to 74 years who have an intermediate cardiovascular risk, defined as coronary risk between 5% -15% at 10 years according to the Framingham adapted risk equation or vascular mortality risk between 3-5% at 10 years according to the SCORE equation [27].
88888002|NCT01428947||Coronary angiography|Patents scheduled for elective coronary angiography
88888003|NCT01428960|Experimental|Palm Mid Fraction|
88888004|NCT01428960|Experimental|Shea Butter|
88888005|NCT01428960|Experimental|High Oleic Sunflower Oil|
88888006|NCT01428986||Maraviroc|Those whose take maraviroc as a part of their HIV treatment
88888007|NCT01428986||No maraviroc|Those who do not take maraviroc
88888008|NCT01428999|Experimental|probiotics|1 pack bid use for 3 weeks
88888009|NCT01428999|Placebo Comparator|Placebo|placebo 1pack bid for 3 weeks
88888010|NCT01429012|Experimental|Mesenchymal Stem Cells|"2 ml with 40 X 10E6 Mesenchymal Stem Cells (MSC) will be injected in the nonunion space of the bone fracture.~MSC will be injected even if the number of available cells is lower than 40 X 10E6.~The injection of MSC in the nonunion space will be performed percutaneously using a 3-mm trephine needle under fluoroscopic control and loco-regional or general anesthesia, as deemed appropriate by the anesthetist."
88888011|NCT01429012|Placebo Comparator|Culture medium without MSC.|Culture medium used to resuspend the Mesenchymal Stem Cells.
88888012|NCT01429025|Experimental|rituximab, bendamustine and lenalidomide|Patients receive rituximab IV on day 1, bendamustine IV on days 1-2, and lenalidomide PO on days 1-10. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
88888013|NCT01429090|Experimental|Test|Pharmacokinetics and -dynamics after single dose administration of 2 coated tablets Vagantin® (coated tablets of 50 mg methantheline bromide)
88888014|NCT01429090|Active Comparator|Reference|Pharmacokinetics and -dynamics after single dose administration 100 ml methantheline solution (100 mg methantheline bromide)
88888015|NCT01429103||Early Perimenopause|Early perimenopause is defined as the presence of irregular periods (cycle length differs by 7 days from usual).
88888016|NCT01429103||Late Perimenopause|Late perimenopause is defined as at least 2 skipped periods over the past 12 months (cycle double usual length) and one period of amenorrhea (over 60 days without a period), with at least one menstrual cycle over the past 12 months.
88888017|NCT01429116|Experimental|tasimelteon|20 mg tasimelteon capsules, PO daily for 24 months + 12 month optional extension
88888018|NCT01429129|Experimental|Nicotine Replacement Therapy|
88888019|NCT01429129|No Intervention|Control|
88888020|NCT01429142|Experimental|AIMS intervention|see http://bmchealthservres.biomedcentral.com/articles/10.1186/1472-6963-13-274
88888021|NCT01429142|Active Comparator|Treatment as usual|see http://www.tandfonline.com/doi/abs/10.1080/08870446.2014.1001392
88888022|NCT01429155||Liver transplant recipeints|Patients suffering from chronic hepatitis C that required a living donor liver transplant.
88888023|NCT01429155||Liver Donors|Patients who donated part of their liver to a patient suffering from chronic hepatitis C
88888024|NCT01429181|Experimental|Non Racemic Methadone|Non-Racemic Methadone Hydrochloride 5 mg Capsules containing a non-racemic mixture of methadone isomers.
88888025|NCT01429181|Placebo Comparator|Placebo|Matching placebo capsules
88888026|NCT01429194|Experimental|ACE procedure|ACE procedure for the treatment of obesity
88888027|NCT01429246|Active Comparator|Normal Salt|100% Sodium Chloride
88888028|NCT01429246|Experimental|Salt Substitute|65% Sodium Chloride, 25% Potassium Chloride, 10% Magnesium Sulphate)
88888029|NCT01429311||ADEH+|Subjects classified as Atopic Dermatitis (AD) and history of previous Eczema Herpeticum (EH) as defined by the ADRN Standard Diagnostic Criteria
88888030|NCT01429311||ADEH-|Subjects classified as AD without a history of EH as defined by the ADRN Standard Diagnostic Criteria
89411711|NCT02308904|Other|Laboratory Studies for Pituitary-Gonadal Function|"Females: We expect to enroll approximately 15 females ages 12 years and older.~Males: We expect to enroll approximately 15 males ages 12 years and older."
89411712|NCT02308904|Other|Data on iron burden and chelation history|"Retrospective data, as listed in this section, will be obtained from chart review and results of relevant clinical data.~Iron burden data~Assay for non-transferrin bound iron (NTBI)~Chelation data~Oxidant stress~History or presence of hypogonadism"
89411713|NCT02308904|Other|Pituitary MRI|MRI has been shown to demonstrate well the changes related to iron toxicity in the pituitary gland.
88888031|NCT01429311||Non-atopic Controls|"Subjects classified as Non-Atopic controls as defined by the ADRN Standard Diagnostic Criteria"
88888032|NCT01429324||Cardiac disease|Aortic arch surgery
88888033|NCT01429337|Experimental|Normal hepatic function - group 1|Matched control for group 2 and 3 - healthy volunteers matched with respect to age, body weight, BMI and gender to subjects in mild and moderate hepatic function groups. Subjects will be treated with midostaurin 50mg b.i.d from days 1-6 and 50mg o.d on day 7.
88888034|NCT01429337|Experimental|Mild hepatic impairment - group 2|Subjects with mild impaired hepatic function - Child Pugh A classification score 5-6. Subjects will be treated with midostaurin 50mg b.i.d from days 1-6 and 50mg o.d on day 7.
88888035|NCT01429337|Experimental|Moderate hepatic impairment - group 3|Subjects with moderate hepatic function - Child Pugh B classification score 7-9. Subjects will be treated with midostaurin 50mg b.i.d from days 1-6 and 50mg o.d on day 7.
88888036|NCT01429337|Experimental|Severe hepatic impairment - group 4|Subjects with severe hepatic impairment function - Child Pugh C classification score 10-15. Subjects will be treated with a single dose of midostaurin of 50mg on day 1.
88888037|NCT01429337|Experimental|Normal hepatic function - group 5|Matched control for group 4 - healthy volunteers matched with respect to age, body weight, BMI and gender to subjects in severe hepatic function group. Subjects will be treated with a single dose of midostaurin of 50mg on day 1.
88888038|NCT01429363|Experimental|Targeted disc decompression|
88888039|NCT01429402|Experimental|study group I|For primary lip surgery, immediately after primary lip repair will received botulinum toxin injection (1-2U/kg, at 25U/mL) into the bilateral aberrant oriented orbicularis ocuris muscle via 4 superficial injection site
88888040|NCT01429402|Experimental|Study Group II|For revision lip surgery, immediately after revision lip surgery 3 injection of 2.5U of botulinum toxin with a distance of 0.5 cm from each injection and operative wound are injected over both sides of upper lip in a adult on the operation room.
88888041|NCT01429402|Placebo Comparator|Control Group I|Similar amount as group I (in C.C.) of normal saline will be injected after primary lip surgery at 3 months of age.
88888042|NCT01429402|Placebo Comparator|Control II|Similar amount (in C.C.) as Study Group II of normal saline will be injected after revision lip surgery (secondary cleft lip repair).
88888043|NCT01429415|Experimental|Experimental Group|Magnesium Sulfate Sandoz/PPC 600mg and Salbutamol (GlaxoSmithKline/Pharmascience) 5mg by inhalation via Aeroneb Go nebulizer (Philips) with Idehaler Pocket chamber DTF q 20 minutes, 3 treatments.
88888044|NCT01429415|Placebo Comparator|Control Group|Sodium Chloride USP PPC/Omega (5.5%) placebo and salbutamol GlaxoSmithKline/Pharmascience 5 mg by inhalation via Aeroneb Go nebulizer Philips with Idehaler Pocket chamber DTF q 20 minutes, 3 treatments.
88888045|NCT01429428|Placebo Comparator|Stockings side one|This side of the compression stockings is just the fabric (placebo).
88888046|NCT01429428|Active Comparator|Stocking side two|This side of compression stocking emits far-IR radiation.
88888047|NCT01429467|Other|Continuous Glucose Monitoring (CGM)|10 participants from phase 1 will undergo 6 weeks of CGM with telemedicine support at weeks 1,3 + 5. After this period HIF, Erythropoietin, VEGf and cortisol will again be measured and compared with the subjects glucose variability.
89411714|NCT03545646|Experimental|Treatment Group|Treatment with the investigational device - High Intensity Focused ElectroMagnetic System
89411715|NCT02305628||Cohort|Method of continuous surveillance per standard of care
89411716|NCT03101644|Other|Darunavir|All patients treated with darunavir
89411717|NCT03115918|Active Comparator|Pancreatic Duct Stent Placement|Subject will have placement of either the Advanix or Cook Pancreatic Stent placed.
89411718|NCT03115918|Active Comparator|No Pancreatic Duct Stent Placement|Subject will not have a pancreatic Duct stent placed.
89411719|NCT03508466||Group 1|adult participants from 18-65 years of age previous hypersensitivity reaction grades I-IV to intravenous ferric carboxymaltose (Ferinject)
89411720|NCT03508466||Group 2|adult participants from 18-65 years of age previous intravenous ferric carboxymaltose (Ferinject) and no hypersensitivity reaction
89411721|NCT03508466||Group 3|adult participants from 18-65 years of age previous hypersensitivity reaction grades I-IV to iron sucrose (Venofer)
89411722|NCT03508466||Group 4|adult participants from 18-65 years of age previous intravenous iron sucrose (Venofer) and no hypersensitivity reaction
89411723|NCT03545100|Experimental|experimental group|motor control therapy
89411724|NCT03545100|Active Comparator|control group|regular physical therapy
89411725|NCT03132272|Experimental|Immunoadsorption with Globaffin for Alzheimer Dementia|Immunoadsorption with Globaffin
89411726|NCT03627234|Experimental|Same Day Discharge|Same day discharge after hysterectomy is the standard of care at George Washington University Hospital.
89411727|NCT03627234|Experimental|Overnight stay|Overnight stay is not the standard of care at George Washington University Hospital. It is being used as an experimental condition.
89411728|NCT02305706|Experimental|Right|patients will be positioned on the right-lateral position at the start of colonoscopy
89411729|NCT02305706|Active Comparator|Left|patients will be positioned on the left-lateral position at the start of colonoscopy
88888048|NCT01429480|Active Comparator|TAP Block|
88888049|NCT01429480|Active Comparator|II/IH Block|
89411730|NCT02623309|Experimental|HAPLO graft|"Conditioning regimen~Fludarabin : 30 mg/m2/day for 4 days: from D-5 à J-2.~Busulfan IV : 130 mg/m2/day for 2 days : drom D-4 to D-3. + 1 day of Thiotepa : 5mg/kg at D-6.~Prophylaxis regimen for GVHD~F CSA and MMF (starting day +5)~Additional immunosuppression: PT-HDCy (50 mg/kg/day) on days +3 and +4~Hematopoietic Stem Cell Graft PBSC graft will be preferred for a minimal targeted cell dose of 4 x 106 CD34+cells/kg GCSF (Neupogen ®) during 4 to 5 days (D-4 to D-1): SC 10 µg/kg/d."
89411731|NCT02623309|Active Comparator|MUD graft|"Conditioning regimen~Fludarabin : 30 mg/m2/day for 5 days: from D-6 to D-2.~Busulfan IV : 130 mg/m2/day for 2 days: from D-4 to D-3.~Prophylaxis regimen for GVHD~CSA and MMF will be used from day -1 after UD~Additional immunosuppression: Rabbit ATG (2.5 mg/kg/day) on days -3 and -2~Hematopoietic Stem Cell Graft PBSC graft will be preferred for a minimal targeted cell dose of 4 x 106 CD34+cells/kg"
89411732|NCT05068804|Experimental|cooling|The participants in the cooling trial put cold towels on their forehead and neck for 3 min in the shaded dugout during their offensive half innings when they were not scheduled to hit or on base. Each participant received the cooling intervention 3 to 4 times in each game. After each use, the towels were kept in a cooler that contained water mixed with ice and salt to keep the temperature at approximately 0℃.
89411733|NCT05068804|Placebo Comparator|Control|The participants in the control trial sat in the shaded dugout without any cooling intervention.
88888050|NCT01429480|Active Comparator|Control Group|
88888051|NCT01429506|Active Comparator|Sleeve gastrectomy|Will undergo laparoscopic sleeve gastrectomy
88888052|NCT01429506|Active Comparator|Intensive medical management|Will receive VLCD, exenatide, metformin, insulin detemir
88888053|NCT01429519|Experimental|Treatment|
88888054|NCT01429545|Active Comparator|Group 1 - Atosiban|Patients on single agent atosiban alone
89411734|NCT03545022|Active Comparator|Active acupuncture|For both types of treatment, 0.25x30mm stainless steel needles were used (Dux, Brazil).The protocols were differentiated by needle size, in which the placebo needle is not inserted into the patient's skin and has an identical appearance to the active needle.The needle measuring 0.25x30mm was used as an active needle. The needles were inserted partially into an opaque guide tube filled with condensation silicone. This process was used to simulate the needle insertion for the patient and the acupuncturist and for the needle support. The active needle as well as the placebo needle were attached to the skin with an adhesive pedestal to hold the needle in place, even without inserting it into the skin.
89411735|NCT03545022|Placebo Comparator|Placebo acupuncture|For both types of treatment, 0.25x30mm stainless steel needles were used (Dux, Brazil).The protocols were differentiated by needle size, in which the placebo needle is not inserted into the patient's skin and has an identical appearance to the active needle. In the placebo needle, the needles were cut in 5mm, to measure 0.25x25mm. The needles were inserted partially into an opaque guide tube filled with condensation silicone. This process was used to simulate the needle insertion for the patient and the acupuncturist and for the needle support. The active needle, as well as the placebo needle, were attached to the skin with an adhesive pedestal to hold the needle in place, even without inserting it into the skin.
89411736|NCT05068180|Experimental|Neuroleptanalgesia group|Droperidol 1.25 mg and fentanyl 0.025 mg (diluted with normal saline up to 5ml) is to be administrated intravenously 30 minutes before the end of the procedure.
89411737|NCT05068180|Placebo Comparator|Control group|The same volume of normal saline is to be administrated intravenously 30 minutes before the end of the procedure.
89411738|NCT02143908|Placebo Comparator|placebo supplementation|2000 mg placebo tablets/day
89411739|NCT02143908|Active Comparator|Supplementation|lysine 2000 mg tablets/day supplementation
89411740|NCT02847364|Experimental|Chewing gum group|The patients will be asked to chew on a regular chewing gum starting morning of post-operative day 1 until the first bowel movement.
89411741|NCT02847364|No Intervention|Control group|These patients will not be offered any food/beverage orally. Patients will be asked not to eat or chew anything till the first bowel movement.
89005270|NCT01089556|Experimental|Pregabalin|"Initial Treatment:~Pregabalin 150 mg daily for 1 week~Pregabalin 300 mg (150 mg twice daily) daily for 7 weeks~Intensive Treatment:~Pregabalin 450 mg (300 mg in the morning, 150 mg in the evening) daily for 1 week~Pregabalin 600 mg (300 mg twice daily) daily for 7 weeks"
89411742|NCT02143986||Macrophagic activation syndrome|
88888055|NCT01429545|Experimental|Group 2|Patients on combination of atosiban and nifedipine
88888056|NCT01429571||Systemic and local antibiotics|
88888057|NCT01429571||Local antibiotics|
88888058|NCT01429571||No antibiotics|
88888059|NCT01429597||Observation|All Patients with a diagnosis of Fabry disease with N215S
88888060|NCT01429610|Experimental|Rituximab+mVPDL|Patients who were CD20(+), newly-diagnosed adult ALL and treated with rituximab + mVPDL treatment plan
88888061|NCT01429636|Experimental|Applied Relaxation (AR)|
88888062|NCT01429636|Experimental|Modified Relaxation (MR)|
88888063|NCT01429649|Experimental|ablation|Cryoablation or Radiofrequency ablation for the pGGO
88888064|NCT01429649|No Intervention|Follow up CT scann|The patients will receive follow up with CT scan every 6-9 months.
88888065|NCT01429662|Sham Comparator|Lifestyle Education (LE)|Lifestyle Education (LE) Participants in this group will receive conventional care and lifestyle education on dietary choice and exercise.
88888066|NCT01429662|Experimental|Modified Relaxation (MR)|Modified Relaxation (MR) This technique intend to train participants in a group of 8-10 in only 1 session that lasts 60 minutes. After completing the training, participants will be given a hand-out on MR. They will be asked to practice MR at home once a day for 15-20 minutes during their leisure times, for at least 5 days a week during the whole 16 weeks of the study period.
88888067|NCT01429675|Active Comparator|Bonviva|
88888068|NCT01429675|Experimental|DP-R206|
88888069|NCT01429688|Experimental|DP-R202|Multiple oral administration for 3 days
88888070|NCT01429688|Active Comparator|Anplag|Multiple oral administration for 3days
88888071|NCT01429701|Experimental|Test association cream|polymyxin B sulphate + prednisolone + benzocaine + clioquinol
88888072|NCT01429701|Active Comparator|Comparative association cream|betamethasone + gentamicin + tolnaftato + clioquinol
88888073|NCT01429714|Experimental|Intervention: individually tailored ECS|Individually tailored duration of elastic compression therapy, based on signs and symptoms according to the Villalta scale, following an initial therapeutic period of 6 months.
88888074|NCT01429714|Active Comparator|Control: ECS 24 months|Elastic compression therapy with a standard duration of 24 months
88888075|NCT01429740|Experimental|PF-05180999|
88888076|NCT01429740|Placebo Comparator|Placebo|
88888077|NCT01429753|Active Comparator|Standard LV lead placement|
88888078|NCT01429753|Experimental|Advanced Imaging Guided LV Lead Placement|
88888079|NCT01429779|Experimental|Movicol|Administration of 1 sachet of Movicol® daily during one week preoperatively (experimental care) and 2 sachets of Movicol® daily postoperatively (standard care).
88888080|NCT01429779|No Intervention|Control|Control group; standard postoperative care (administration of 2 sachets of Movicol® postoperatively daily)
88888081|NCT01429818|Experimental|Glimepiride/metformin|
88888082|NCT01429818|Active Comparator|Metformin|
88888083|NCT01429831|Experimental|Aripiprazole|
88888084|NCT01429844|Active Comparator|Tacrolimus|Tacrolimus in combination with mycophenolate mofetil and steroids for denovo immunosuppression after lung transplantation
89411743|NCT02143986||Still's disease|
89411744|NCT02143986||Hyperferritinemia|
89411745|NCT02143986||Sepsis|
89411746|NCT05515627|Experimental|Atezolizumab|Atezolizumab 1200 mg IV every 3 weeks for 24 weeks
89411747|NCT03503708|Experimental|Intervention Group|All the eligible participants will receive Livitol-17 capsules. It consist of 390 mg of whole herbs and extract of Phyllanthus niruri (Bhumyamalaki), Boerhaavia diffusa (Punarnava) and Picroorrhiza kurroa (Katuki).
89192519|NCT00731952|Experimental|Velcade and Vorinostat|Subjects will receive one of 3 doses of Velcade (at a dose of 1.0 - 1.6 mg/m2 once weekly for 3 weeks) and one of 4 doses of Vorinostat (at a dose of 100mg every day 3 times a week for 3 weeks to 300mg twice per day, 3 times per week for 3 weeks). Doses determined by a predetermined escalation schedule.
89005271|NCT01089556|Experimental|Duloxetine + Pregabalin|"Initial Treatment:~Duloxetine 30 mg daily for 1 week~Duloxetine 60 mg daily for 7 weeks~Intensive Treatment:~Duloxetine 60 mg daily for 8 weeks~Pregabalin 150 mg daily for 1 week~Pregabalin 300 mg (150 mg twice daily) daily for 7 weeks"
89005272|NCT00411359|Experimental|Cardiac rehabilitation|8-week cardiac rehabilitation programme
89005273|NCT00411359|No Intervention|Monitoring|Carry on life as normal
89005274|NCT00237159|Experimental|ZOL446|
89411748|NCT02144064|Active Comparator|Group A(heparin group)|Group A (n = 100) are put on Inj. UFH (Cal-heparin) 5000 U subcutaneous twice daily plusAspirin 81 mg/day (Juspirin) with the ﬁrst positive pregnancy test, Inj. UFH is given either into anterior abdominal wall or anterior aspect of thigh subcutaneously
89411749|NCT02144064|No Intervention|Group B|group B (n = 100) receive no thing
89411750|NCT02312648|Active Comparator|Early mobilization Group|Patients will perform deep breaths (3 sets of 10 repetitions), once a day, for 30 minutes until 7th postoperative day. Non invasive ventilation will be installed after orotracheal extubation for 30 to 60 minutes.Early mobilization protocol consist of upper and lower (cycle ergometer) limb exercises, chair transfer, deambulation for 10 to 20 minutes, step exercise (six times).
89411751|NCT02312648|Other|Control Group - Respiratory exercise|Respiratory exercises with patient sitting in bed with a high headboard 45, the same breathing exercises will be held
88888085|NCT01429844|Active Comparator|Cyclosporine|Cyclopsorine in combination with mycophenolate mofetil and steroids for denovo immunosuppression after lung transplantation
88888086|NCT01429870|Active Comparator|Steroid active treatment|Triamcinolone acetonide 0.1% in unguentum leniens topically
89192520|NCT04065932|Experimental|BMS-985165-01 prototype formulation 1|
88888087|NCT01429870|Placebo Comparator|Vehicle|unguentum leniens topically
89192521|NCT04065932|Experimental|BMS-986165 Tablet|
89192522|NCT04065932|Experimental|BMS-985165-01 prototype formulation 2|
89192523|NCT04065932|Experimental|BMS-985165-01 prototype formulation 3|
89192524|NCT04065932|Experimental|BMS-985165-01 prototype formulation 3 or 4|
89192525|NCT04065932|Experimental|BMS-985165-01 prototype formulation 3, 4 or 5|
89192526|NCT06147674||VQm PHM™|Non-invasive measurements obtained with the VQm PHM™ compared to current standard of care.
88888088|NCT01429896|Experimental|Arm 1|Exercise followed by sleep restriction followed by control challenge
89411752|NCT02090530||Advanced Cancer Patients|Individuals with advanced or refractory cancer must be identified by study personnel or their treating physician, deemed eligible for this study, and voluntarily agree to be enrolled in this protocol through an informed consent. Biospecimen collection includes a fresh tumor biopsy, previously obtained tumor specimens or blocks (if available), whole blood, serum, plasma and buccal smear.
89411753|NCT02144142|Experimental|Moisturizer with each subject's own antimicrobial bacteria|Each subject will have a moisturizer containing their own antimicrobial bacteria species spread over their arms in the clinic
88888089|NCT01429896|Experimental|Arm 2|Sleep restriction followed by exercise followed by control challenge
88888090|NCT01429896|Experimental|Arm 3|control followed by sleep restriction followed by exercise
88888091|NCT01429896|Experimental|Arm 4|control followed by exercise followed by sleep restriction
88888092|NCT01429896|Experimental|Arm 5|Sleep Restriction followed by control followed by exercise
88888093|NCT01429896|Experimental|Arm 6|Exercise followed by control followed by sleep restriction
88888094|NCT01429935|Active Comparator|Ginger powder|
88888095|NCT01429935|Active Comparator|Ibuprofen|capsules of Ibuprofen 400 mg
89411754|NCT02309060|Experimental|Storytelling Video Intervention (sTVi)|"We will develop a series of 4 videos, each episode approximately 30 minutes long, which will illustrate the key principles of Acceptance and Commitment Therapy.~We will add a short, non-narrative, epilogue at the end of each of the 4 episodes that summarizes key messages and provides information on identifying signs of depression and suggestions for efficacious treatments.~In addition, we will develop an accompanying personal journal for participants that includes a brief self-help guide which encourages participants to write about what they learned in the videos and how they will take similar steps in their own lives to cope with depression."
89411755|NCT03101098|Experimental|Retroperitoneal hysterectomy|In subjects allocated to the experimental group, which the uterine vessels were ligated where it originates from the internal iliac artery,
88888096|NCT01429935|Placebo Comparator|placebo|capsules contain starch
88888097|NCT01429948||Case group|Healthy subjects with silent cerebral infarction
88888098|NCT01429948||Control group 1|Patients with acute cryptogenic embolic stroke
88888099|NCT01429948||Control group 2|Patients with acute stroke with conventional stroke mechanisms
89192527|NCT06147648|Experimental|Experimental: Single arm observational registry study Drug: Tacrolimus Sustained-release Capsules|"Drug: Tacrolimus Sustained-release Capsules~After liver transplantation, immediate-release tacrolimus was administered for acute rejection prevention, and after 3 months, it was converted into tacrolimus sustained-release capsules in a ratio of 1:1 to 1:1.2; (The specific medication plan is decided by the clinician according to the actual situation)"
89192528|NCT06147635|Experimental|Intervention group|Micro-encapsulated tributyrin granules, 4 grams three times daily, for a maximum of 14 days
89192529|NCT06147635|Placebo Comparator|Control group|Micro-encapsulated sunflower oil granules, 4 grams three times daily, for a maximum of 14 days
89192530|NCT06147570|Experimental|HS-10365|160 mg BID of HS-10365
89192531|NCT06147557|Experimental|Heat therapy|14 heat sessions of whole-body immersed in a 45°C water bath for 5 minutes.
88888100|NCT01429961|Experimental|SOX|TS-1, Oxaliplatin regimen (3week) Oxaliplatin 130 mg/m2 IV Day 1 S-1 40 mg/m2 b.i.d. Day1-14
88888101|NCT01429974||volunteers|
88888102|NCT01430013|Experimental|Endostar|CHOPT chemotherapy plus Endostar
88888103|NCT01430039||Crohn's, ulcerative colitis|Patients with diagnosed with Crohn's disease or ulcerative colitis who agreed to participate in the study and singed informed consent and answered a Crohn's disease activity index questioner for Crohn's disease or the ulcerative colitis activity index questioner for ulcerative colitis.
88888104|NCT01430039||No disease|Healthy subjects with no known inflammatory disease. For basal serum levels of syndecan 1
88888105|NCT01430052|Other|Gemcitabine , S-1|Gemcitabine 1000mg/m2 on Day 1 and 8, every 3 weeks. S-1 60-100mg/day on Day 1 to 14, every 3 weeks
88888106|NCT01430052|Experimental|Gemcitabine, S-1, radiotherapy|Gemcitabine 600mg/m2 on Day 1 and 8, every 3 weeks. S-1 60-100mg/day on Day 1 to 14, every 3 weeks with radiotherapy 50.4Gy in 28 fractions
88888107|NCT01430065|Experimental|Tacrolimus and ASP015K|
88888108|NCT01430078|Experimental|Regimen A|ASP015K oral tablet
88888109|NCT01430078|Experimental|Regimen B|ASP015K solution delivered to distal small bowel via oral capsule
88888110|NCT01430078|Experimental|Regimen C|ASP015K solution delivered to ascending colon via oral capsule
88888111|NCT01430078|Experimental|Regimen D|ASP015K solution delivered to distal transverse colon via oral capsule
88888112|NCT01430117|Experimental|1|"Poa pratensis allergen extract at 4 different concentrations.~Positive control.~Negative control."
88888113|NCT01430143|Experimental|600 kcal/day|Exercise combusting 600 kcal/day, 7 days/week for 12 weeks.
88888114|NCT01430143|Experimental|300 kcal/day|Exercise combusting 300 kcal/day, 7 days/week for 12 weeks.
88888115|NCT01430143|No Intervention|Sedentary|Continued sedentary living.
88888116|NCT01430156|Active Comparator|Heme arginate (Normosang)|This arm will receive 2 doses of Heme Arginate (trade name Normosang); 1 dose prior to transplant and another on day 2. This is a product derived from human hemin and has been used for over 20 years in clinical practice with few side-effects.
88888117|NCT01430156|Placebo Comparator|0.9% saline|The saline will be given as an IV infusion in the same manner as the Heme Arginate (active comparator) infusion.
88888118|NCT01430195|Experimental|Afamelanotide + NB-UVB: Experimental|Subject in this arm will receive both afamelanotide implants (one implant administered every 28 days, 4 implants in total) and NB-UVB light (administered thrice weekly, 72 treatments in total).
88888119|NCT01430195|Active Comparator|NB-UVB alone: Active Comparator|Subjects in this arm will receive NB-UVB light only (administered thrice weekly, 72 treatments in total).
88888120|NCT01430208|Active Comparator|mini-resectoscope|
88888121|NCT01430208|Active Comparator|tradiorional resectoscope|
88888122|NCT01430208|Active Comparator|bettocchi resectoscope|
88888123|NCT01430221|Experimental|MB-PHP Group|Mindfulness-based Personalized Health Planning (MB-PHP)with health coaching. MB-PHP includes weekly small group meetings for 22-weeks and 10 bi-weekly telephonic health coaching.
88888124|NCT01430221|Active Comparator|SAGE Group|Structure & Guided Education (SAGE) includes small group-education sessions once per week for 22 weeks. Subjects also participate in 10 bi-weekly telephone calls with education partners who use supportive listening techniques..
88888125|NCT01430234|Other|Panzytrat fixed dose vs. self-dosing|In Phase I (week 1-4) patients will use the fixed amount of lipase as was prescribed by their treating physician. Phase II (week 5-9) patients will start the self-dosage regimen with pancreatic enzymes (without exceeding the maximum amount of 16 capsules per day). They are properly educated by the researcher and dietician how to adjust the amount of pancreatic enzymes to the fat intake in their diet.
88888126|NCT01430247|Other|Amblyopia screening|
88888127|NCT01430260|Experimental|ciclesonide nasal spray|ciclesonide nasal spray, alone
88888128|NCT01430260|Active Comparator|Levocetirizine|Levocetirizine, alone
88888129|NCT01430260|Active Comparator|Ciclesonide nasal spray & Levocetirizine|Ciclesonide nasal spray & Levocetirizine in combination
88888130|NCT01430273||Planned hip or knee arthroplasty|Patients with planned hip or knee arthroplasty
88888131|NCT01430273||urgent hip or knee arthroplasty|Patients with hip or knee arthroplasty in emergency.
88888132|NCT01430286|Experimental|Psycho-educational program|This group is trained for a 3 month period by a web-based psycho-educational program, Lifestyle Counseling, etc.
88888133|NCT01430286|Active Comparator|Standard treatment|This group will receive treatment as usual : consultation in memory clinic every 6 months during the AD patient's consultation.
88888134|NCT01430312|Experimental|Verum|Topical application of verum (azelaic acid pre-foam formulation) on the skin
88888135|NCT01430312|Placebo Comparator|Vehicle|Topical application of vehicle formulation (same as verum but without active drug substance) on the skin
88888136|NCT01430312|Placebo Comparator|Negative control|Topical application of distilled water (negative control) on the skin
88888137|NCT01430312|Active Comparator|Positive control|Topical application of 0.5% Sodium Lauryl sulfate (positive control) on the skin
88888138|NCT01430338||BAT|brown adipose tissue detected, undetected
88888139|NCT01430364|Active Comparator|BIOSS implantation|
88888140|NCT01430377|Experimental|SB predilatation|
88888141|NCT01430416|Experimental|AEB071|
88888142|NCT01430429|Experimental|NI-0801|
88888143|NCT01430481|Active Comparator|Standard Rosehip Powder (A)|6 capsules of standardized hip powder of Rosa canina made from the seeds and husks of the fruits from a subtype of R. canina hip powder (i.e., rosehip)
88888144|NCT01430481|Experimental|New rosehip formulation (B)|6 capsules of modified hip powder of Rosa canina made from the seeds and husks of the fruits from a subtype of R. canina hip powder (i.e., rosehip)
88888145|NCT01430481|Experimental|New rosehip formulation in half dose (C)|3 capsules of modified hip powder of Rosa canina made from the seeds and husks of the fruits from a subtype of R. canina hip powder (i.e., rosehip)
88888146|NCT01428674|Experimental|10 minutes reading|
88888147|NCT01428674|Experimental|20 minutes touch|
88888148|NCT01428674|Experimental|20 minutes reading|
88888149|NCT01428674|Experimental|10 minutes touch|
88888150|NCT01430494||No treatment|
88888151|NCT01430507|Experimental|Medium Dose|Medium Dose Revamilast
88888152|NCT01430507|Experimental|High Dose|High Dose Revamilast
88888153|NCT01430507|Placebo Comparator|Placebo|Matching Placebo in Triple Dummy Format
88888154|NCT01430507|Experimental|Low dose|Low dose Revamilast
88888155|NCT01430520|Active Comparator|Escitalopram|
88888156|NCT01430520|Placebo Comparator|Placebo|
88888157|NCT01430533|Experimental|Verum|Topical application of verum (azelaic acid pre foam formulation) on the skin
88888158|NCT01430533|Placebo Comparator|Vehicle|Topical application of vehicle formulation (same as verum but without active drug substance) on the skin
88888159|NCT01430533|Placebo Comparator|Negative control|Topical application of distilled water (negative control) on the skin
88888160|NCT01430598|Active Comparator|A|Subacromial decompression before repair of a complete rotator cuff tear.
88888161|NCT01430598|Active Comparator|B|Subacromial decompression after repair of a complete rotator cuff repair.
88888162|NCT01430650|Experimental|Oral strogen|
88888163|NCT01430650|Experimental|Transdermal strogen|
88888164|NCT01430663||Hematological patients with proven or probable aspergillosis|
88888165|NCT01430663||Hematological patients with possible aspergillosis|
88888166|NCT01430676||Danish Ventral Hernia Database|Patients registered in the Danish Ventral Hernia Database during January 1st 2007 to december 31st 2010
88888167|NCT01430689|Experimental|Inactivated Influenza Vaccine Trivalent Types A and B|Women will be vaccinated with Influenza vaccine: Inactivated Influenza Vaccine Trivalent Types A and B
88888168|NCT01430689|Active Comparator|Meningococcal Polysaccharide-Diphtheria Toxoid Conjugate|Women will be vaccinated with IM injection of Meningococcal Polysaccharide-Diphtheria Toxoid Conjugate Vaccine
88888169|NCT01430702|Experimental|Computerized medication delivery unit|Those hospitalized patients that meet all inclusion and exclusion criteria will be provided with a computerized medication delivery unit for use in their homes for the 30-day period following discharge.
88888170|NCT01430715|Experimental|Outside play|
88888171|NCT01430715|Experimental|Active video game|
88888172|NCT01430728||Very low birthweight infants|
88888173|NCT01430767||Depression|Ten subjects with diagnosis of major depressive disorder from the Wake Forest University Student Health Clinic, being treated with FDA-approved standard-of-care medication for depression.
88888174|NCT01430767||ADHD|Ten subjects with a diagnosis of attention-deficit hyperactivity disorder (ADHD) from the Wake Forest University Student Health Clinic, being treated with FDA-approved standard-of-care medication for their ADHD.
88888175|NCT01430780||control group|placebo
88888176|NCT01430780||nitrate group|Isosorbide Mononitrate orally 20mg twice per day.
88888177|NCT01430793|Active Comparator|Vitamin D 600,000 IM|Vitamin D3 600,000 units will be given by intramuscular injection
88888178|NCT01430793|Active Comparator|Vitamin D 600,000 orally|Vitamin D3 600,000 units will be given orally
88888179|NCT01430793|Active Comparator|Vitamin D 200,000 IM|Vitamin D3 600,000 units will be given by intramuscular injection
88888180|NCT01430793|Active Comparator|Vitamin D 200,000 orally|Vitamin D 200,000 units will be given orally
88888181|NCT01430806|Other|Dronedrone Arm|
88888182|NCT01430832||Normal Development|The infant's development level will be assessed using a phone interview with parents
88888183|NCT01430832||Abnormal Development|The infant's level of development will be assessed using a phone interview with parents
88888184|NCT01430858|Other|Strain Gauge|We wish to determine the relationship between tibial bone strain (recorded from implanted tibial strain gauges) and measured displacements of the limb and pelvis (using video motion analysis) during vibration exercise and a range of habitual locomotor activities. Only healthy volunteers will be recruited to this one arm.
88888185|NCT01430871||Carcinoid syndrome|Patients: Men and women age 18 years or older with carcinoid syndrome attending the Sheffield neuro-endocrine tumour clinic
88888186|NCT01430871||Healthy Volunteers|Control group: Healthy men and women individually matched to the patients by gender, age, height and BMI
88888187|NCT01430884||Aspirate Blood|
88888188|NCT01430910|Experimental|1|CAZ104 (2000mg Ceftazidime/500mg Avibactam)
88888189|NCT01430910|Active Comparator|2|500mg Avibactam
88888190|NCT01430910|Active Comparator|3|2000mg Ceftazidime
88888191|NCT01430923|Experimental|Refrigeration free Latanoprost|Latanoprost refrigeration free formulation as per randomization schedule.
88888192|NCT01430923|Active Comparator|latanoprost 2-8˚ C|latanoprost stored at 2-8˚ C
88888193|NCT01430949|Experimental|Over-the-Wire Mesh Ablation System|
88888194|NCT01430962||General Anesthesia|Patients will receive Total Intravenous Anesthesia (TIVA) with a combination of Propofol, Ketamine and neuromuscular blockade by anesthesia. Either an LMA or an ETT will be used to secure airway.
88888195|NCT01430962||Moderate Sedation|Patients will receive moderate sedation given by the physician performing EBUS with a combination of Versed and Fentanyl per hospital protocol.
88888196|NCT01430988||Head Injured Group|Subjects who are suspected of a traumatically induced structural brain injury and/or clinical manifestations of functional brain injury, as a result of insult to the head from an external force, e.g., the head being struck by an object, the head striking an object, the head being exposed to forces generated from a blast or explosion, and/or the brain undergoing an acceleration/deceleration movement without direct external trauma to the head will be recruited from patients who enter the Emergency Department at hospitals that are participating as clinical sites for this study
88888197|NCT01430988||Normal Control Group|A normal control group will be recruited for comparison and will consist of Emergency Department patients who have sustained an injury but do not exhibit any trauma above the clavicle and no history of Road Traffic Accident requiring an ED visit or TBI within the past one (1) year, and no primary complaint of syncope.
88888198|NCT01430988||Head Injured Control Group|A 'head injured' control group will be recruited and will consist of Emergency Department patients who are suspected or who have sustained a head injury but do not report or manifest symptoms, e.g. facial lacerations and/or whiplash.
88888199|NCT01431001|Experimental|Coil Configuration A|Cervel Neurotech Deep Shaped-Field repetitive transcranial magnetic stimulator (DSF-rTMS)
88888200|NCT01431001|Experimental|Coil Configuration B|Cervel Neurotech Deep Shaped-Field repetitive transcranial magnetic stimulator (DSF-rTMS)
88888201|NCT01431027||Diastolic Function|Patients scheduled for cardiac catheterization.
88888202|NCT01431040|Active Comparator|Group A|Group A will have no bowel preparation and be permitted a regular diet the day prior to surgery until midnight.
88888203|NCT01431040|Active Comparator|Group B|Participants in this group will consume a clear liquid diet and perform 2 Fleets enemas in the late afternoon the day before surgery and nothing after midnight.
88888204|NCT01431053|Experimental|Exemestane + Aspirin|
88888205|NCT01431053|Active Comparator|Exemestane|
88888206|NCT01431066|Placebo Comparator|Control|Sham device that resembles the Actipatch PRFE device, including the light that illuminates when active, but the transmitting function has been disabled.
88888207|NCT01431066|Experimental|Actipatch|Use of the Actipatch PRFE device that is integrated into a viscoelastic heel pad for the treatment of plantar fasciopathy
88888208|NCT01431092|Experimental|Melatonin|
88888209|NCT01431092|Placebo Comparator|Placebo|
88888210|NCT01431118|Active Comparator|sports intervention male|male athletes of the german national dragon boat team
88888211|NCT01431118|Active Comparator|sports intervention women|women athletes of the german national dragon boat team
88888212|NCT01431183|Active Comparator|mailed reminder notice|Seasonal influenza vaccination reminder sent by postal mail
88888213|NCT01431183|No Intervention|No reminder notice|No seasonal influenza vaccination reminder sent by postal mail
88888214|NCT01431196|Experimental|DENDRITIC CELL VACCINATION|Px will receive standard neoadjuvant chemotherapy plus active vaccination. we will compare results with an historic cohort of patients treated with the same chemotherapy without the vaccines
88888215|NCT01431222|Active Comparator|percutaneous treatment|
88888216|NCT01431222|No Intervention|optimal medical treatment|
88888217|NCT01431235|No Intervention|standard addiction treatment|10 sessions of standard addiction treatment. No ADHD treatment.
88888218|NCT01431235|Experimental|addiction treatment and ADHD treatment|10 sessions cognitive behavioral therapy on addiction treatment combined with 5 sessions on ADHD treatment.
88888219|NCT01431248||Azithromycin|Azithromycin 1gm PO once
88888220|NCT01431248||Erythromycin 250mg|Erythromycin 250mg IV Q 6hrs x 48 hours followed by 500 mg PO Q 8 hours x 5 days.
88888221|NCT01431261|Active Comparator|Pain Management + Training|Education in pain management strategies and treatment sessions including instructions in neck exercises and aerobic training
88888222|NCT01431261|Active Comparator|Pain Management|Education in pain management strategies
88888223|NCT01431352|Experimental|Letrozole+ Chinese herbal medicine granules|
88888224|NCT01431352|Placebo Comparator|Letrozole+ Chinese herbal medicine granules placebo|
88888225|NCT01431365|Experimental|Moderate Exercise Group|The moderate exercise condition will involve participants walking briskly (equivalent to moderate intensity) on a treadmill for 10 minutes. Moderate intensity exercise will be defined as 40-68% of the resting heart rate reserve. Heart rate (HR) will be monitored in participants using a Polar RS100 Heart Rate monitor to serve as a guide for participants to attain the appropriate intensity.
88888226|NCT01431365|Active Comparator|Passive Sitting Group|The passive sitting condition will involve participants sitting passively for 10 minutes on a chair. Heart rate (HR) will be monitored in participants of the passive sitting group to help maintain group equivalency (with the moderate exercise condition) in regards to distraction effects and researcher contact.
88888227|NCT01431378||CNS|CNS: Known or suspected pathology in the posterior fossa
88888228|NCT01431378||Thorax|Thorax: Patients referred for staging of a known or suspected lung cancer
88888229|NCT01431378||Abdomen 1|Abdomen: Patients with acute flank pain and suspected urolithiasis
88888230|NCT01431378||Abdomen 2|Abdomen: Patients with a known or suspected focal liver lesion
88888231|NCT01431404|Active Comparator|Enbrel, prefilled syringe|
88888232|NCT01431404|Experimental|HD203, prefilled syringe|
88888233|NCT01431417||Healthy volunteers|Healthy volunteers, less than 35 years old and presenting with no shoulder condition
88888234|NCT01431417||Patients with rotator cuff condition|Patients with rotator cuff condition, conservative treatment indicated
88888235|NCT01431417||Patients with shoulder instability|Patients with shoulder instability, conservative treatment indicated
88888236|NCT01431417||Patients with proximal humerus fracture|Patients with diaphyseal humerus fracture or subcapital humerus fracture treated surgically or conservatively, at 6 weeks post stabilization. (Surgical and conservative treatment will be considered as the same population from the functional point of view as functional outcome is similar) (Handoll et al. 2003).
88888237|NCT01431417||Patients with frozen shoulder|Patients with frozen shoulder, conservative treatment indicated
88888238|NCT01431430|Experimental|Cholecalciferol 100 000 UI|Cholecalciferol 100 000 UI FORTHIGHTLY for 2 months then monthly for 22 months
88888239|NCT01431430|Active Comparator|Cholecalciferol 12 000 UI (Control)|Cholecalciferol 12 000 UI FORTHIGHTLY for 2 months then monthly for 22 months.
88888240|NCT01431443|Experimental|Dark chocolate|
88888241|NCT01431443|Placebo Comparator|Placebo chocolate|Placebo intervention
88888242|NCT01431456|Active Comparator|Dabigatran|Dabigatran
88888243|NCT01431456|Active Comparator|Rivaroxaban|Rivaroxaban
88888244|NCT01431456|Active Comparator|Nadroparin|Nadroparin
88888245|NCT01431469|Placebo Comparator|Cow's Milk|Powdered Whole Cow's Milk
88888246|NCT01431469|Experimental|Follow-On Formula|Powdered Follow-On Formula with added long-chain Polyunsaturated fatty acid, prebiotics, and polysaccharide
88888247|NCT01431495|Active Comparator|plavix|patient treated by the princeps
88888248|NCT01431495|Active Comparator|Pidogrel|patient treated by Pidogrel
88888249|NCT01431547|Experimental|Part 1: Dalotuzumab|
88888250|NCT01431547|Experimental|Parts 2 and 3: Dalotuzumab + ridaforolimus|
88888251|NCT01431560|Active Comparator|metallic implant|fixation of the ankle fracture with metallic implants
89192532|NCT06147544|Experimental|PB-718|"Low dose level of PB-718 administered on the first day of week 1-12 according to the dose-escalation design~Medium dose level of PB-718 administered on the first day of week 1-12 according to the dose-escalation design~High dose level of PB-718 administered on the first day of week 1-12 according to the dose-escalation design"
89411756|NCT03101098|Active Comparator|Classical hysterectomy|The operative technique of classical total laparoscopic hysterectomy (TLH) performed in the control group was comparable to that of retroperitoneal TLH, except for one that coagulation and transection of uterine artery was achieved using an energy device alongside the cervix
88888252|NCT01431560|Active Comparator|biodegradable implant|fixation of the ankle fracture with Freedom plate and screws
88888253|NCT01431586|Experimental|Single dose JDTic 1 mg, 3 mg, or 10 mg|
88888254|NCT01431599|Experimental|short-course|
88888255|NCT01431612|Active Comparator|Esmolol|50 µg/kg/min of the ß-1-receptor-blocker esmolol (Qilu Pharmaceutical Co, Shandong, China) wss infused intravenously over 3 hours
88888256|NCT01431612|Active Comparator|Phenylephrine|Intravenous infusion of 0.01 µg/kg/min of phenylephrine (alpha1-adrenergic agonist) over 3 hours.
88888257|NCT01431612|Placebo Comparator|Lactated Ringer´s solution|10 ml/h lactated Ringer's solution without active drug was infused intravenously over 3 hours.
88888258|NCT01431625|Active Comparator|COPD with emphysema-predominant|The degree of involvement of the lung parenchyma and the airway are assessed by computed tomography. The HRCT is performed using 2-mm collimation, scan time 1.0 s, 120 kVp, and 200 mA. Images at three different levels (a cranial section is obtained 1 cm above the superior margin of the aortic arch, a middle section is taken at 1 cm below the carina, and a caudal section is taken approximately 3 cm above the top of the diaphragm) are selected and LAA% is then automatically calculated. The identification threshold of normal lung density and LAA is set at -960 HU. The cut-off level between high or low LAA% is the mean + 2SD of LAA% of the asymptomatic non-COPD smokers.
88888259|NCT01431625|Active Comparator|COPD with airway-predominant|The degree of involvement of the lung parenchyma and the airway are assessed by computed tomography. The HRCT is performed using 2-mm collimation, scan time 1.0 s, 120 kVp, and 200 mA. Images at three different levels (a cranial section is obtained 1 cm above the superior margin of the aortic arch, a middle section is taken at 1 cm below the carina, and a caudal section is taken approximately 3 cm above the top of the diaphragm) are selected and LAA% is then automatically calculated. The helical scan is performed using 120 kVp, 50 mA, 3-mm collimation, and pith 1.0. The dimensions of the right apical segmental bronchus are measured and WA% is calculated. The cut-off level between high or low WA% is the mean + 2SD of WA% of the asymptomatic non-COPD smokers.
88888260|NCT01431651|Experimental|probiotic, lifestyle counseling|
88888261|NCT01431690|Experimental|Warfarin and Epanova|
88888262|NCT01431690|Active Comparator|Lovaza|
88888263|NCT01431729||mucositis|
88888264|NCT01431742|Experimental|BEMA Buprenorphine|buprenorphine buccal soluble film
88888265|NCT01431781|Experimental|stilamin+common daily treatment|
88888266|NCT01431781|Active Comparator|common daily treatment|
88888267|NCT01431833|Experimental|Moderate hepatic|
88888268|NCT01431833|Experimental|Severe Hepatic|
88888269|NCT01431833|Experimental|Matched control|
88888270|NCT01431859|Placebo Comparator|Subcutaneous injection of placebo|
88888271|NCT01431859|Active Comparator|Birch pollen immunotherapy|
88888272|NCT01431872||Post menopausal breast cancer patients|
88888273|NCT01431885|Active Comparator|PLAT|Diagnosis of preterm labor will be made by the March of Dimes Preterm Labor Assessment Toolkit Algorithm B, incorporating transvaginal ultrasound measurement of cervical length, and vaginal fetal fibronectin
88888274|NCT01431885|Placebo Comparator|Cervical Change|Diagnosis of preterm labor will be made by cervical change by digital examination
88888275|NCT01431898|Experimental|Multiple-dose, dose-escalation study of GS-9669|Multiple-dose, dose-escalation study of GS-9669, a nonnucleotide NS5B inhibitor of hepatitis C virus (HCV), in subjects with chronic HCV infection. Dosing is planned in up to 7 unique dosing cohorts. Each cohort will be comprised of 10 genotype 1a (Cohorts 1, 2, 3, 4, and 5) or genotype 1b (Cohort 6 and 7), with eight subjects randomized to receive active drug and two subjects randomized to receive placebo per cohort.
88888276|NCT01431911||Patients diagnosed with COPD|Patients diagnosed with COPD using ICD codes with a COPD-related exacerbation and receiving maintenance therapy
88888277|NCT01431924||Adolescent and adult patients with asthma|Adolescents and Adults age 12-65 with an ICD-9 code for asthma and a prescription for an inhaled corticosteriod or a corticosteriod/salmeterol combination
88888278|NCT01431937|Active Comparator|GSK2018682|Active Drug
88888279|NCT01431937|Placebo Comparator|Placebo Control|Placebo
88888280|NCT01432028|Active Comparator|Non-oral hormone therapy|3 mg/day intranasal estradiol daily or 1,5 mg/day transdermal estradiol and 200 mg/day vaginal micronized progesterone for 14 days/month
88888281|NCT01432028|Active Comparator|oral homone therapy|estradiol 1mg and drospirenone 2 mg/day
88888282|NCT01432067|Other|Adaptated physical activity|Physical activity advices adaptated to physical status of patients
89192533|NCT06147544|Placebo Comparator|Placebo|Matched placebo administered on the first day of week 1-12 according to the dose-escalation design
89192534|NCT06147492|Other|laTME|Laparoscopic Total Mesorectal Excision
89192535|NCT06147492|Other|taTME|a transanal bottom-up approach was employed for the Total Mesorectal Excision procedure
89411757|NCT02447120||Normal Eyes|Subjects with no known ocular diseases will be scanned with the Maestro device
89411758|NCT05067322|Experimental|Minecraft|This group played the video game under development in Minecraft
89411759|NCT05067322|Placebo Comparator|Control|This group played another game.
89411760|NCT02254356|Experimental|Zilver|
89411761|NCT01405066|Experimental|Dose Reports and Educational Seminar|
89411762|NCT04475770|Experimental|Real SNAGs|Real SNAGs group consists of 16 participants, where the Mulligan concept lumbal SNAGs is applied and evaluations are made before and after.
89192536|NCT06147453|Active Comparator|Aerobika OPEP device|"The OPEP system (Aerobika®) combines positive expiratory pressure therapy and airway vibrations to help mobilize pulmonary secretions. OPEP therapy (Aerobika ®) enforces resistance to exhalation at the mouth, while the airway vibration technology transmits movements upstream during exhalation so that airway walls may become free from mucus.~Participants will take home the device and use it twice daily for 16 weeks."
88888283|NCT01432067|Other|Standard physical activity|Daily physical activities based on a standard guide
88888284|NCT01432080|No Intervention|Standard of Care|Standard of Care includes fluids, antipyretics, ribavirin for RSV infection, and oseltamivir for influenza infection, and intravenous immune globulin for patients with low IgG levels.
88888285|NCT01432080|Experimental|SAMS|Subjects randomized to the SAMS arm will receive a four-drug combination (Steroids, Azithromycin, Montelukast, and Symbicort).
88888286|NCT01432093|Active Comparator|Intensive glycemic management|Multifaceted approach to achieve strict glucose goals of 90 to 120 mg/dL in the ICU and hospital wards.
88888287|NCT01432093|Active Comparator|Conventional management|Conventional treatment to control hyperglycemia with a target glucose goal of 120 to 150 mg/dL in the ICU and 140 to 180 mg/dL on the hospital floors.
88888288|NCT01432106|Active Comparator|Aliskiren/Valsartan (Valturna)|Valturna contains two prescription medicines in one tablet that work together to lower blood pressure. It contains aliskerin (Tekturna), a direct rennin inhibitor (DRI), and valsartan (Diovan), an angiotensin II receptor blocker (ARB). Aliskerin reduces the effect of rennin, and the harmful process that narrows blood vessels. It also helps blood vessels relax and widen so blood pressure is lower. Valsartan can help lower blood pressure by blocking a potent chemical, angiotensin II, which leads to blood vessel constriction and narrowing.
88888289|NCT01432106|Active Comparator|Ramipril|Ramipril (Altace) is an angiotensin-converting enzyme inhibitor (ACEI). It is a chemical compound that helps create a protein named angiotensin II. Angiotensin II can raise blood pressure by causing your blood vessels to narrow. Altace helps lower blood pressure by decreasing the amount of ACE the body makes. Ramipril has been proven by the investigators to stabilize decline in kidney function in African American patients with evidence of damage.
89192537|NCT06147453|No Intervention|Standard of care|Standard of care management for 16 weeks.
89192538|NCT06147440|Experimental|Dietary pattern 1|Participants receive a standardized diet following the recommendation of DACH nutrition societies.
89192539|NCT06147440|Experimental|Dietary pattern 2|Participants receive a standardized diet following the recommendation of DACH nutrition societies.
89192540|NCT06147401|Experimental|PENG - LFCN Block|group in which PENG and LFCN Block was performed. After performing neuraxial anesthesia, the PENG associated with LFCN block will be performed. Under ultrasound guidance, 20ml and 5ml of Ropivacaine 0.5% will be administered respectively.
89411763|NCT04475770|Sham Comparator|Sham SNAGs|The Sham SNAGs group consists of 16 participants who performed the same positioning as the Real SNAGs group and evaluated twice with a similar interval without any intervention to the spine.
89411764|NCT03538158|Experimental|Intervention condition - Fittle Senior|Participants will have access to the Fittle Senior System which will provide guided exercises and social support.
89411765|NCT03538158|Placebo Comparator|Control condition - paper and pencil|Participants will have a written booklet with exercises that they may do it on their own.
89411766|NCT02305862|Experimental|low dose group (5mg)|low dose Rosuvastatin
89411767|NCT02305862|Experimental|high dose group (20mg)|high dose Rosuvastatin
89411768|NCT03101176|Experimental|Experimental: Single Arm|All consenting patients will undergo mpUS imaging prior to surgery with the ultrasound contrast agent Sonovue for the CEUS specific mode.
89411769|NCT03753828||patients de novo colonized by fungi|Patients in Cystic Fibrosis de novo colonized by fungi during their follow-up
89411770|NCT02305940|Active Comparator|Doxycycline|Doxycycline: oral dose of 100 mg once daily, for a total duration of 52 weeks.
89411771|NCT02305940|Placebo Comparator|Placebo|Placebo: an oral dose of one capsule once daily, for a total duration of 52 weeks.
89411772|NCT03099460|Experimental|ocular electroacupuncture|Patients will receive electroacupuncture for 40 mins with certain parameter at ocular area, once daily, 5 times a week and 6 weeks in all. The acupoints are selected based on the anatomy of extraocular muscles innervated by abducens nerve.
89411773|NCT03099460|Experimental|ocular acupuncture|Patients will receive acupuncture for 40 mins at ocular area, once daily, 5 times a week and 6 weeks in all. The acupoints are selected based on the anatomy of extraocular muscles innervated by abducens nerve.
89411774|NCT03099460|Sham Comparator|sham acupuncture|Patients will receive sham acupuncture for 40 mins at ocular area, once daily, 5 times a week and 6 weeks in all. The acupoints are selected based on the anatomy of extraocular muscles innervated by abducens nerve. When the care provider performed operating acupuncture, the needles of sham acupuncture set will not be inserted into the skin of patient.
89411775|NCT03544554|Experimental|Intervention group and control group|This research is planned with semi experimental design
89192541|NCT06147401|Active Comparator|FIC Block|group in which FIC Block was performed After performing neuraxial anesthesia, FIC block will be performed. Under ultrasound guidance, 20 ml of Ropivacaine 0.5% will be administered.
89192542|NCT06147388||CIN 2, CIN 3|Bioptically verified CIN 2 or CIN 3 lesion
89411776|NCT03099772|Experimental|CBT-IU|Cognitive-behavioral therapy for intolerance of uncertainty
89411777|NCT02312804|Experimental|Dose Escalation|To determine the MTD/RP2D of BGJ398 when combined with carboplatin and paclitaxel in subjects with locally advanced for metastatic solid tumors.
89411778|NCT02312804|Experimental|Expansion Cervical Cancer|To assess the anti-tumor effect of BGJ398 when combined with carboplatin and paclitaxel in cervix cancer.
89411779|NCT03100630|Active Comparator|Treatment A: RO7239361|RO7239361 subcutaneous injections on specified days; abdomen
89411780|NCT03100630|Active Comparator|Treatment B: RO7239361|RO7239361 subcutaneous injections on specified days; arm
89411781|NCT03100630|Active Comparator|Treatment C: RO7239361|RO7239361 subcutaneous injections on specified days; thigh
89411782|NCT02306018||EV1000™/volumeView™|
89411783|NCT03099616|Active Comparator|CLADS group|Anesthesia will be induced with Propofol administered by CLADSwhich will be set to deliver Propofol according to lean body weight (LBW). A BIS-value of 50 will be used as the target for induction of anesthesia. Thereafter anaesthesia maintenance will be done with Propofol, with the dosing based on adjusted body weight (ABW), and administration controlled with CLADS tuned to consistent anaesthetic depth (BIS-50) feedback from the patients.
89411784|NCT03099616|Active Comparator|Desflurane group|Anesthesia will be induced with Propofol administered by CLADSwhich will be set to deliver Propofol according to lean body weight (LBW). A BIS-value of 50 will be used as the target for induction of anesthesia.Thereafter anaesthesia maintenance will be done with desflurane using an agent specific vaporiser, whose dial concentration will be adjusted to maintain a BIS of 50-55 in all the patients
89411785|NCT04463966|Active Comparator|Study|Tranexamic acid 1 gm (100 mg/ml) slowly intravenous infusion during delivery ( administered over 10 minutes at 1 ml/minute) .
89411786|NCT04463966|No Intervention|Control|control group will not be given tranexamic acid
89411787|NCT00794248|Experimental|Clarinex followed by Allegra|Clarinex 5 mg by mouth daily for 7 days followed by Allegra 180 mg by mouth daily for 7 days, with 5-28 days washout between treatments.
89411788|NCT00794248|Experimental|Allegra followed by Clarinex|Allegra 180 mg by mouth daily for 7 days followed by Clarinex 5 mg by mouth daily for 7 days, with 5-28 days washout between treatments.
88888290|NCT01432119|Experimental|Arm 1 SIR-Spheres + Cetuximab|"Arm 1: SIR-Spheres with yttrium-90 attached and cetuximab. SIR-Spheres Day 1 of Cycle 1; Cetuximab start 200 mg/m2 by vein (IV) Weeks 2-4 of Cycle 1, then weekly Cycles 2+. 28-day Cycles. Nuclear medicine break-through scan performed within 29 days before receiving SIR-Spheres. The results of this test will be used to determine if a full or partial dose of SIR-Spheres with yttrium-90 microspheres will be delivered."
88888291|NCT01432119|Experimental|Arm 2 SIR-Spheres + Cetuximab + Erlotinib.|"Arm 2: SIR-Spheres with yttrium-90 attached, cetuximab, and erlotinib. Physicians will assign patients to Arm 1 or Arm 2 based on their discretion. SIR-Spheres on Day 1 of Cycle 1; Cetuximab start 200 mg/m2 by vein (IV) Weeks 2-4 of Cycle 1, then weekly Cycles 2+. 28-day Cycles. Erlotinib start 100 mg by mouth daily starting with Cycle 2. 28-day Cycles. Nuclear medicine break-through scan performed within 29 days before receiving SIR-Spheres. The results of this test will be used to determine if a full or partial dose of SIR-Spheres with yttrium-90 microspheres will be delivered."
89192543|NCT06147375|Experimental|immunosuppressive withdrawal|After enrollment,the recipients will take IS withdrawal follow the protocol of this study.Following enrollment, recipients will be examined at several time periods such as peripheral blood test,liver function , liver biopsy, and other relevant indicators to determine immunosuppressant withdrawal condition and adverse effects.
88888292|NCT01432132||Head & Neck Patients|Patients undergoing surgical treatment for head and neck cancer.
88888293|NCT01432132||Clinicians|Clinical staff who care for head and neck surgical participants during active treatment.
88888294|NCT01432158|Experimental|PCV-13 group|1 dose of Prevenar-13
89411789|NCT04463732||Healthy group|Subjects are above 20 years old. Their condition is healthy with no history of inspiratory disease. They can cooperate with the measurements of this study.
89411790|NCT05066542|Active Comparator|NDPP Standard of Care SOC|Participants in this arm will participate in the traditional NDPP program delivered virtually by certified NDPP coaches. During Months 1-4 participants will attend a 60-minute virtually facilitated session of the NDPP curriculum. During Months 5-8, virtual NDPP curriculum sessions will be held every two weeks. During Months 9-12, participants will attend a monthly 60-minute NDPP curriculum session. Participants will submit a weekly weight report during the 12 month participation and will complete the ASA 24 hour food recall every 90 days.
89437546|NCT03671330|Placebo Comparator|Ribociclib Placebo|"Patients in pre- and postmenopausal cohorts will be randomized in the 1:1 ratio to the experimental arm or the control arm.~Premenopausal control arm: NSAI + Goserelin + Placebo; For pre-menopausal only, patient is an adult, female ≥ 18 years old and < 60 years old at the time of informed consent.~It is the investigators choice for NSAI based on patient's past medical history.~Postmenopausal control arm:~Letrozole + Placebo For postmenopausal only, patient is an adult, female ≥ 18 years old at the time of informed consent"
89437547|NCT03667599|Experimental|Home care|This is the arm for patients who receive their transplant care in their homes.
89437548|NCT03667599|No Intervention|Hospital Care|Standard of care for stem cell transplant recipients where the aftercare is done in hospital.
88888295|NCT01432158|Experimental|PPV-23 group|1 dose of Pneumovax-II
89437549|NCT03667599|No Intervention|Clinic Care|Standard of care for stem cell transplant recipients who live at home but receive aftercare in the daily outpatient clinic.
88888296|NCT01432184|Active Comparator|Intervention|an alarm threshold at a value of 90% of the resting baseline cerebral saturation value (baseline - 10%) will be established. To minimize the probability of patients reaching significant decreases rSO2 values, interventions to improve cerebral oxygenation will be initiated according to the strategies described in the algorithm. The success and failure of these interventions will be noted. As in the Control group, the screen will remain blinded in the ICU and the intensivist will not see the values.
88888297|NCT01432184|No Intervention|Control|the cerebral oxymetry screen will be blinded and changes in NIRS values will be unknown to the anesthesiologist. The management of the case will proceed as per normal local practice. The screen will remain blinded in the ICU and the intensivist will not see the values.
88888298|NCT01432197|Experimental|Occupational therapy intervention|"Intervention group: Standard treatment and care added with an ADL intervention program: 1) ADL training, 2) home modifications, 3) delivery and supervision in adaptive equipments, and 4) instruction in self-training programs.~Control group: Standard treatment and care. No occupational therapy intervention."
88888299|NCT01432197|No Intervention|Standard treatment and care|Control group: Standard treatment and care. No occupational therapy intervention.
88888300|NCT01432210|Other|Tomato Meal|A tomato meal will be fed with and without avocado.
88888301|NCT01432210|Other|Carrot Meal|A carrot meal will be fed with and without avocado.
88888302|NCT01432223|Experimental|Nab-paclitaxel|Nab-paclitaxel q3w 260mg/m2
88888303|NCT01432249||Enbrel|The patients who are prescribed Enbrel for pediatric psoriasis
88888304|NCT01432314|Experimental|Treatment group|Child A Hepatocellular carcinoma patients with unilobar portal vein invasion.
88888305|NCT01432340||Vaccinated group|Children between 6months- 10years of age who have received the influenza vaccine
88888306|NCT01432340||Unvaccinated group|Eligible children between 6months and 10years who didn't receive the influenza vaccine
88888307|NCT01432353|Experimental|Single Arm|
88888308|NCT01432392||1|
88888309|NCT01432418|Experimental|wheelchair training|
88888310|NCT01432418|No Intervention|Control|Standard of care only
88888311|NCT01432431|Experimental|Supportive care (spiritual care)|See Detailed Description.
88888312|NCT01432470|Experimental|Oxytocin, Intravaginal administration|
88888313|NCT01432470|Placebo Comparator|Placebo, Intravaginal administration|
88888314|NCT01432496|Experimental|Ropivacaine 150 mg|Nebulization of Ropivacaine 150 mg in the peritoneal cavity with the Aeroneb Pro system
88888315|NCT01432496|Placebo Comparator|Saline 15 ml|Nebulization of Saline 15 ml in the peritoneal cavity with the Aeroneb Pro system
88888316|NCT01432522|Experimental|epinephrine IN, epinephrine IM, saline IN|"Intranasal saline~Intramuscular epinephrine~Intranasal epinephrine"
88888317|NCT01432613|Other|MRI-oriented muscle biopsy|Muscle sample will be done following the usual care.
88888318|NCT01432639|Experimental|Experimental group|Patients undergoing the exercise-based cardiac rehabilitation program (intervention)
89535704|NCT03224143|Experimental|Doll Therapy Intervention (DTI)|"The DTI involves the presentation of a doll produced by a Swedish brand and conceived for Doll Therapy use. It is designed to recreate the sensation of touching, looking and holding a child in the arms. The doll presentation involves five standard steps:~A nurse (whom the patient knows) accompanies the patient in the room and invites her to sit on the chair.~The nurse presents the object (doll or cube) to the patient.~The nurse leaves the patient alone with the object.~Interaction with the object: it lasts 3 minutes starting from the moment when the nurse leaves the room. This phase is interrupted if the patient drops the object before the time limit.~The nurse returns into the room and takes back the object."
89437550|NCT03666897|Other|DTI Outcomes and Biomarkers|Imaging and Lab Collection
89437551|NCT03664960|Experimental|1 to 3.0 mg/kg of AK002|Subjects in this arm will receive 26 monthly doses of AK002: a first dose of 1 mg/kg, followed by monthly doses of 3 mg/kg
88888319|NCT01432639|No Intervention|Control group|Usual medical care
88888320|NCT01432652||vascular surgery|Patients undergoing vascular surgery
88888321|NCT01432665|Experimental|Placebo|30 subjects administered a placebo
88888322|NCT01432665|Experimental|sildenafil + testosterone combination drug 1|30 subjects are given combination drug 1 (sildenafil 25mg and testosterone 0.25mg)
88888323|NCT01432665|Experimental|Sildenafil and testosterone combination drug 2|Sildenafil 50mg and testosterone 0.25mg
88888324|NCT01432665|Experimental|Sildenafil and testosterone combination drug 3|30 subjects are given sildenafil 25mg and testosterone 0.50mg
88888325|NCT01432665|Experimental|Sildenafil and Testosterone Combination drug 4|30 subjects are given sildenafil 50mg and testosterone 0.50mg
88888326|NCT01432665|Experimental|Sildenafil 50mg|30 subjects are given sildenafil 50mg
88888327|NCT01432665|Experimental|Testosterone 0.50mg|30 subjects are given testosterone 0.5mg
88888328|NCT01432678||asthma patients|controlled asthma partly controlled asthma uncontrolled asthma
88888329|NCT01432691|Other|Surgery|RSA study on hemi
88888330|NCT01432704|Placebo Comparator|placebo capsules|Identically appearing placebo capsules not containing colecalciferol
89437552|NCT03661840|Experimental|Acceptance and Commitment Therapy|Participants will receive both the ACT intervention and medication management that is given as usual treatment.
89005275|NCT01089127|Experimental|Indacaterol 18.75 μg|Patients inhaled indacaterol 18.75 μg once daily in the morning via the Concept1 single-dose dry-powder inhaler (SDDPI). In addition, patients inhaled placebo to salmeterol twice daily, once in the morning and once in the evening, via the manufacturer's proprietary Diskus inhaler. Treatment continued for 2 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. Albuterol via a multi-dose dry-powder inhaler (MDI) was available for rescue use throughout the study.
89005276|NCT01089127|Experimental|Indacaterol 37.5 μg|Patients inhaled indacaterol 37.5 μg once daily in the morning via the Concept1 single-dose dry-powder inhaler (SDDPI). In addition, patients inhaled placebo to salmeterol twice daily, once in the morning and once in the evening, via the manufacturer's proprietary Diskus inhaler. Treatment continued for 2 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. Albuterol via a multi-dose dry-powder inhaler (MDI) was available for rescue use throughout the study.
89005277|NCT01089127|Experimental|Indacaterol 75 μg|Patients inhaled indacaterol 75 μg once daily in the morning via the Concept1 single-dose dry-powder inhaler (SDDPI). In addition, patients inhaled placebo to salmeterol twice daily, once in the morning and once in the evening, via the manufacturer's proprietary Diskus inhaler. Treatment continued for 2 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. Albuterol via a multi-dose dry-powder inhaler (MDI) was available for rescue use throughout the study.
89005278|NCT01089127|Experimental|Indacaterol 150 μg|Patients inhaled indacaterol 150 μg once daily in the morning via the Concept1 single-dose dry-powder inhaler (SDDPI). In addition, patients inhaled placebo to salmeterol twice daily, once in the morning and once in the evening, via the manufacturer's proprietary Diskus inhaler. Treatment continued for 2 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. Albuterol via a multi-dose dry-powder inhaler (MDI) was available for rescue use throughout the study.
89005279|NCT01089127|Active Comparator|Salmeterol 50 μg|Patients inhaled salmeterol 50 μg twice daily, once in the morning and once in the evening, via the manufacturer's proprietary Diskus inhaler. In addition, patients inhaled placebo to indacaterol once daily in the morning via the Concept1 single-dose dry-powder inhaler (SDDPI). Treatment continued for 2 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. Albuterol via a multi-dose dry-powder inhaler (MDI) was available for rescue use throughout the study.
89005280|NCT01089127|Placebo Comparator|Placebo|Patients inhaled placebo to indacaterol once daily in the morning via the Concept1 single-dose dry-powder inhaler (SDDPI). In addition, patients inhaled placebo to salmeterol twice daily, once in the morning and once in the evening, via the manufacturer's proprietary Diskus inhaler. Treatment continued for 2 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. Albuterol via a multi-dose dry-powder inhaler (MDI) was available for rescue use throughout the study.
89005281|NCT01087957|Active Comparator|Ankle-Foot Orthosis (AFO)|Comparison of WalkAide device against Ankle-Foot Orthosis (AFO)
89005282|NCT01087957|Active Comparator|WalkAide|Comparison of WalkAide device against Ankle-Foot Orthosis (AFO)
89005283|NCT00233532|Other|1|
89005284|NCT00233532|Other|2|
89005285|NCT00233532|Other|3|
89005286|NCT00233571|Experimental|Adalimumab 40mg subcutaneous (SC) every other week (EOW)|Adalimumab 40mg subcutaneous (SC) every other week (EOW)
89005287|NCT00237198|Experimental|Letrozole|
89411791|NCT05066542|Experimental|NDPP + Basketball (BB)|Participants in this arm will participate in the traditional NDPP program delivered virtually by certified NDPP coaches along with virtual fitness sessions and in-person basketball sessions. During Months 1-4, participants will attend a 60-minute virtually facilitated session of the NDPP curriculum, followed by a 30-minute virtual fitness session. During that same week, participants will meet in person, for a 90-minute BB session. During Months 5-8, virtual NDPP curriculum sessions will be held every two weeks and there will no longer be a 30-minute online fitness session succeeding the session. During this same four-month period, 60-minute, in-person BB sessions will be held weekly. During Months 9-12, participants will attend a monthly 60-minute NDPP curriculum session and bi-weekly 60-minute in-person BB sessions. Participants will submit a weekly weight report during the 12 month participation and will complete the ASA 24 hour food recall every 90 days.
89005288|NCT00208169|Experimental|1|Aripiprazole start dose at 5 mg/day by day 4-6 increase to 10 mg/da and day 7 and subsequent visits flexible dosing from 10 up to 30 mg/day.
89192544|NCT06147362|Experimental|68Ga-NOTA-PEG2-RM26|Participants will be injected with 2 MBq/kg of 68Ga-NOTA-PEG2-RM26 limited to 100-200 MBq and then undergo PET/CT examination.
89411792|NCT02309450|Experimental|Asunaprevir, Daclatasvir and BMS - 791325|
89411793|NCT04475224|Other|Open-label|
89411794|NCT05401201|Experimental|Study group|Subjects in the study group will use the Lumoral device five to seven times a week according to the verbal and written instructions provided to them. In addition, they will brush their teeth twice daily in their customary manner while using the provided sonic toothbrush and regular toothpaste.
88813942|NCT03404726|Experimental|Dose Expansion: MDS|After completion of dose escalation, an expansion cohort comprised of patients with MDS will start. These patients will be treated in 28 day cycles with once daily oral administration of BAY2402234 at the maximum tolerated dose or pharmacologically active dose.
89005289|NCT01087723|Experimental|Bivalirudin|Given immediately upon enrollment as an intravenous (IV) bolus of 0.75 mg/kilogram (mg/kg), followed immediately by an infusion of 1.75 mg/kg/hour (mg/kg/h). This infusion was to be run continuously until completion of PCI, at which time the infusion was reduced to 0.25 mg/kg/h for at least 4 hours. An optional PCI-dose infusion of 1.75 mg/kg/h was also permitted for up to 4 hours at the discretion of the operator.
89192545|NCT06147349||Experimental|Patients with kidney cancer who underwent radical or partial kidney removal surgery
89192546|NCT06147297|Experimental|Intervention group|Receive the music-based program once a week for 4 weeks, each session is 60 to 90 minutes, and participants will complete the survey before- and after- the program.
89192547|NCT06147297|No Intervention|Wait-list group|Complete the survey before- and after the 4-week waiting period. Then the waitlist group will also be offered the program, and invited to complete an optional post-program survey
89411795|NCT05401201|Active Comparator|Control group|Subjects in the control group will brush their teeth in their customary manner twice daily while using the provided sonic toothbrush and regular toothpaste. They will not receive any additional intervention.
89411796|NCT03506126|Experimental|Leucine Adults > 60|In this arm, all subjects will receive all 8 of the leucine test levels, assigned in random order.
89411797|NCT05066620|Experimental|Intervention group|Chinese herbal medicine FYTF-919: Oral liquid 33ml TID (for patients who are unconscious or dysphagia, a dose of 25ml * Q6H will be given through nasal feeding)
89411798|NCT05066620|Placebo Comparator|Control group|Placebo treatment: Oral liquid 33ml TID (or patients who are unconscious or dysphagia, a dose of 25ml * Q6H will be given through nasal feeding)
88888331|NCT01432704|Active Comparator|colecalciferol capsules|Once weekly peroral colecalciferol capsules (Dekristol®, Swiss-Caps, Switzerland) containing 20 mg of colecalciferol corresponding to 20000 IU or 0.5 mg of vitamin D3 for a duration of 12 months
88888332|NCT01432717|Experimental|ACE-536|Subjects assigned to 1 of 5 possible dosing groups.
88888333|NCT01432717|Placebo Comparator|Placebo|
88888334|NCT01432743|Experimental|Cartomerge|Use of Cartomerge to guide ablation
88888335|NCT01432743|Active Comparator|NavX Fusion|Use of NavX fusion to guide ablation
88888336|NCT01432769|Active Comparator|individualized diet|patients will receive a diet individualized to their calorie and protein requirements besides to dietary supplementation with a polymeric formula
88888337|NCT01432769|No Intervention|standardized diet|"patients in the standardized diet will receive the dietary management established by the hospital"
88888338|NCT01432782|Placebo Comparator|Placebo|Placebo arm: per-endoscopic injection of saline
89192548|NCT06147271|Active Comparator|intervention|All adult patients undergoing a heart transplant between January 2017 and December 2023 at Hospital de Messejana randomized to SGLT2i intervention
89192549|NCT06147271|No Intervention|no intervention|All adult patients undergoing a heart transplant between January 2017 and December 2023 at Hospital de Messejana randomized to routine surveillance
89192550|NCT06147232|Active Comparator|Sotagliflozin|In the active arm, participants will be treated with Sotagliflozin 200mg as an oral tablet once daily for 12 weeks.
89411799|NCT03498781|Experimental|Exercise-only intervention|Participants will receive information regarding the health benefits of regular aerobic and resistance training exercise and current physical activity guidelines for adults.
88888339|NCT01432782|Active Comparator|Botulinum toxin|Botulinum toxin (Botox) 100 u in 4 ml, injected per-endoscopically
88888340|NCT01432795|Experimental|Test series of 6 types of gliding aids|"Each study subjects tests a series of gliding aids or stocking butlers:~4 gliding aids~2 stocking butlers, one with and without handle~3 medical compression stockings with open tip, compression class 3 (36-46mmHg)~3 medical compression stockings w. closed tip, compression class 3 (36-46mmHg)~2 superimposed stockings with closed tip, compression class 1 (18-21 mmHg)"
88888341|NCT01432821|Experimental|Apomorphine|"After randomization healthy volunteers or patients with idiopathic generalized epilepsy receive:~-sequence A: 1 mg/kg and then 5 mg/kg of apomorphine"
88888342|NCT01432821|Placebo Comparator|Saline|"After randomization healthy volunteers or patients with idiopathic generalized epilepsy receive:~sequence B: 2 injections of saline"
88888343|NCT01432834|Other|LASIK group (LG group)|Volunteers of this group received LASIK treatment.
88888344|NCT01432834|Other|PRK group (PG group)|Volunteers of this group received PRK treatment
88888345|NCT01432860|Active Comparator|In-person Counseling and Education|In the in-person training the Research Assistant demonstrates the use of a mm ruler, a lighted magnifying lens, a set of body maps and a scorecard, 4 pens, ABCDE rule on the skin exam card and discusses the ABCDE rule by pointing to the color examples on the skin exam card. 165 pairs (330 subjects) are randomized to this arm.
88888346|NCT01432860|Active Comparator|Workbook|The workbook, which includes all of the information delivered in the in-person intervention, is 39 pages in length, and has 76 color figures. Each element of the in-person training represents a chapter in the workbook. The introduction explores the partners' understanding of melanoma and their personal risk of developing another melanoma, and attitudes about the benefit of early detection assisted by a partner. The early detection segment uses a skin diagram to illustrate the difference between thin and thick melanoma and presents the treatment based on the depth of the melanoma. 165 pairs (330 subjects) are randomized to this arm.
89192551|NCT06147232|Placebo Comparator|Placebo|In the placebo arm, participants will be treated with a matched placebo as an oral tablet once daily for 12 weeks.
89411800|NCT03498781|Sham Comparator|Control intervention|Participants will receive information regarding the health risks of chronic stress as well as suggested methods to reduce stress.
89411801|NCT05066152|Experimental|Probiotic|For 8 weeks of interventional period, the patient received 10 probiotic drops (1x1010 Cfu LGG) once daily at breakfast.
89411802|NCT05066152|Placebo Comparator|Placebo|For 8 weeks of interventional period, the patient received 10 probiotic drops (placebo) once daily at breakfast.
89192552|NCT06147219|Active Comparator|primary dynamization interlocking intramedullary tibial nail|
89192553|NCT06147219|Active Comparator|standard interlocking intramedullary tibial nail|
89192554|NCT06147180||Minimally invasive esophageal cancer resection group|Surgical Procedures: minimally invasive esophagectomy
89192555|NCT06147180||Open esophageal cancer resection group|Surgical Procedures: open esophagectomy
89192556|NCT06147141|Experimental|Online Peer Companion Intervention group (OPCI)|experimental group
88888347|NCT01432860|No Intervention|Control|Education and counseling as usually delivered in clinical practice. 100 pairs (200 subjects) are randomized to this arm.
88888348|NCT01432860|Active Comparator|Tablet Computer-Based Education|Education will be given by an interactive tablet app. Each pair will view video recordings of certain parts of the in-person presentation as well as select slides from the in-person PowerPoint presentation. Parts of the workbook will be incorporated as well. 70 pairs (140 subjects) are randomized into this arm.
88888349|NCT01432873|Experimental|Experimental|Oral selenium therapy arm
88888350|NCT01432873|Placebo Comparator|Placebo|Oral placebo
89192557|NCT06147141|Placebo Comparator|Wait-List Group (WLG)|control group
88888351|NCT01432912|No Intervention|Patients|
88888352|NCT01432925|Other|evaluation surgical intervention at week 8|
88888353|NCT01432925|Other|evaluation surgical intervention at week 14|
88888354|NCT01432964||1|Adult patients (>18 years) presenting a unilateral orbital blow-out or blow-in fracture of ≥ 2.0cm2, causing an actual or expected functional or aesthetical deficit.
88888355|NCT01432977|Active Comparator|comparateur|paracetamol / droperidol
88888356|NCT01432977|Experimental|Eperimental|paracetamol / ondansetron
88888357|NCT01432990|Experimental|robotic gait training|conventional physical therapy plus robot gait training program for SCI patients.
88888358|NCT01432990|No Intervention|control|Conventional physical therapy program for 60 minute per day for 5 working day per week.
88888359|NCT01433003|Active Comparator|Standard-dose plasma exchange|50-75 ml/kg/day
88888360|NCT01433003|Experimental|High-dose Plasma Exchange|125 ml/kg/day up to 10 L/day
88888361|NCT01433029||Conventional Rater (CR)|CR Group receives conventional training from PI about how to rate coronary artery bypass (CAB) videos.
88888362|NCT01433029||Video Rater (VR)|VR Group receives conventional training from PI about how to rate CAB videos, along with a video rater training manual.
88888363|NCT01433029||CAB Recording|CAB recording of performance cardiothoracic surgeon or surgical trainee in 1st, 2nd, or 3rd year of training.
88888364|NCT01433068|Experimental|NBTXR3|
89411803|NCT02309606||Migraine without aura|Migraine patients suffering from migraine 0-4 days per month.
89411804|NCT02309606||Healthy controls|Healthy controls with no history of migraine or other primary headaches.
89411805|NCT02309606||Chronic migraine|Migraine patients with chronic migraine
89411806|NCT03100708||Patient with peritoneal carcinomatosis|Patient with peritoneal carcinomatosis and the Indication for local therapy. The Clinics tumor-board advice is needed.
89411807|NCT05493085|Active Comparator|Quadratus Lumborum|Patients will receive Ultrasound-guided quadratus lumborum block
89411808|NCT05493085|Active Comparator|Caudal epidural|Patients will receive single Caudal epidural injection
89437553|NCT03661840|Active Comparator|Treatment as Usual|Treatment as usual will include ongoing provision of usual treatment options for pain management.
89437554|NCT03660631|Experimental|CVRS Early Intervention|Patients participating in intervention offices will receive the pharmacist-led CVRS intervention for 12 months.
89437555|NCT03660631|Other|CVRS Delayed Intervention|Patients participating in control site offices will not have any contact with the CVRS pharmacist for the first 12 months of their participation in the study. They will receive the study intervention during months 13-24.
89437556|NCT03653637|Experimental|Project Life Force|"A novel, 10-session intervention to enhance currently mandated VA suicide safety planning in a group setting to support its implementation. PLF is a manualized, weekly 90-minute group treatment lasting 10 weeks coinciding with the time frame for enhanced monitoring of Veterans identified as high-risk. Session content is described in Table 1 (see appendix A). Six of the PLF sessions correspond to a step of the safety plan and teach skills to maximize the use of that particular step of the plan. The use of emotion regulation skills in PLF differs from other DBT interventions in that it focuses primarily on emotion regulation, distraction and developing social support in the specific context of implementing a safety plan. Mindfulness is not covered. PLF is augmented with additional skill modules on physical health management, education pertaining to suicide risk, promoting positive emotion and suicide prevention mobile apps. PLF patients also receive usual care."
88888365|NCT01433094|Experimental|Falloon et al. Psychoeducation Program|The intervention aims to improve communication and problem-solving abilities in patients and their families by sessions focused on: assessment of the individual's and the family's strengths, weaknesses, and goals; education about schizophrenia and treatment; communication skills training; problem-solving
88888366|NCT01433094|Active Comparator|Generic Treatment|The comparator is a treatment with generic informative prospect on the disorders and with the same frequencies as the Intervention. Treatment sessions are provided on a weekly basis for 6 months (1 hour for each session) (groups of about 8-9 persons - patients and caregivers).
88888367|NCT01433120|Experimental|Probiotic L. casei F19|
89437557|NCT03653637|Active Comparator|Treatment-As-Usual|The comparison condition will be an assessment-only treatment-as-usual (TAU). Research team will track number of individual mental health appointments, SPC outreach contacts, and usage patterns of safety plans. Veterans in both randomized conditions will be receiving the mandated monitoring, outreach, and involvement of SPC staff and clinical team management that constitutes standard VA care for suicidal individuals.
89437558|NCT03652051|Experimental|AZR-MD-001 Low Dose|AZR-MD-001 Low Dose will be dosed up to once daily.
89437559|NCT03652051|Experimental|AZR-MD-001 Mid Dose|AZR-MD-001 Mid Dose will be dosed up to once daily.
89437560|NCT03652051|Experimental|AZR-MD-001 High Dose|AZR-MD-001 High Dose will be dosed up to once daily.
88888368|NCT01433120|Experimental|Flax seed fibres|
88888369|NCT01433120|Placebo Comparator|Placebo|
88888370|NCT01433133|Experimental|1|• Genotype 3 chronic HCV with detectable serum HCV RNA
88888371|NCT01433185|Experimental|Text message (SMS)|Text messages sent to women before and after delivery
88888372|NCT01433185|No Intervention|Usual care (current standard of care)|Current standard of care for women enrolled in PMTCT programs
88888373|NCT01433211||No treatment|
88888374|NCT01433276|Experimental|Totilac|
88888375|NCT01433276|Active Comparator|Ringer's lactate|
88888376|NCT01433302||Punch Biopsy|
88888377|NCT01433341||Young athletes|
88888378|NCT01433367||CerPass® Total Disc Replacement|
88888379|NCT01433380|Experimental|600 mg PF-05175157|Subjects will receive one dose of PF-05175157. The sequence of receiving 600 mg PF-05175157 or placebo will be randomized.
88888380|NCT01433380|Placebo Comparator|Placebo|Subjects will receive one dose of placebo. The sequence of receiving placebo or 600 mg PF-05175157 will be randomized.
88888381|NCT01433393|Experimental|TAK-875 25 mg|
88888382|NCT01433393|Experimental|TAK-875 50 mg|
88888383|NCT01433393|Placebo Comparator|Placebo|
88888384|NCT01433406|Experimental|TAK-875 25 mg|(long-term monotherapy or long-term combination therapy with anti-diabetic drugs)
88888385|NCT01433406|Experimental|TAK-875 50 mg|(long-term monotherapy or long-term combination therapy with anti-diabetic drugs)
88888386|NCT01433419|Experimental|TAK-875 25 mg|
88888387|NCT01433419|Experimental|TAK-875 50 mg|
88888388|NCT01433432|Active Comparator|Purinethol|Subjects who previously received 12 weeks of Purinethol (at 1-1.5 mg/kg)in the original study will now receive 80 mg DR-6MP (2 x 40 mg tablets) once dailyh, in the evening, for an additional 12 weeks
88888389|NCT01433432|Experimental|Test Drug|Subjects who previously received test drug (80 mg DR-6MP) for 12 weeks in the original study, will continue to receive 80 mg DR-6MP (2 x 40 mg tablets) once daily, in the evening, for an additional 12 weeks
88888390|NCT01433445|Experimental|Cohort 1|Subjects will be treated with ruxolitinib 5 mg twice daily (BID) and panobinostat 10 mg three times per week (TIW) every other week (QOW) on a 28 day cycle
89411809|NCT02306252|Experimental|CARE Intervention|This group will be contacted to make an appointment for outpatient Occupational and Physical therapy. The therapist will determine the type, frequency and length of treatment. Follow up phone calls will be made to ensure appointments are made, kept and rescheduled as needed.
89411810|NCT02306252|No Intervention|CARE Control|Patients randomized to this arm will receive contact information and a brochure outlining the services available within the supportive care program. The study coordinator will provide the information based on their results and assist the patient with contacting the program if desired.
89411811|NCT05395585|No Intervention|Spontaneous separation|
89411812|NCT05395585|Experimental|Manual separation|
89411813|NCT03508310|Experimental|Intervention|29-minute clinic waiting room video intervention that includes three vignettes and a 2-part animation sequence about main characters who model overcoming challenges to optimal HIV care. The video was played on continuous loop in recognition of typically short patient wait times. Waiting room posters used images from the video to direct patients' attention to the video and reinforce prevention messages.
89411814|NCT03508310|No Intervention|Comparison|Historical comparison condition. Patients were exposed to standard waiting room environment (absent of intervention video and posters).
89411815|NCT02306330|Experimental|Malditof|Specimens of patients (diagnostic aspirates from normally sterile sites: cerebrospinal fluid (CSF), deep abscesses, joint fluid, peritoneal fluid, and pleural fluid, deep tissue biopsies) in Malditof arm will be performed by Malditof instrument to identify the pathogens. It takes 20 minutes for Malditof to identify the pathogens. Then patients will be treated based on these results.
89411816|NCT02306330|Active Comparator|Routine clinical microbiology|Specimens of patients (diagnostic aspirates from normally sterile sites: cerebrospinal fluid (CSF), deep abscesses, joint fluid, peritoneal fluid, and pleural fluid, deep tissue biopsies) in routine clinical microbiology arm will be conducted by the routine clinical microbiologies and followed the treatment process of the hospital.
89411817|NCT02643082|Experimental|GFF MDI, 14.4/9.6μg|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI)
88888391|NCT01433445|Experimental|Cohort 2|Subjects will be treated with ruxolitinib 10 mg twice daily (BID) and panobinostat 10 mg three times per week (TIW) every other week (QOW) on a 28 day cycle
88888392|NCT01433445|Experimental|Cohort 3|Subjects will be treated with ruxolitinib 15 mg twice daily (BID) and panobinostat 10 mg three times per week (TIW) every other week (QOW) on a 28 day cycle
88888393|NCT01433445|Experimental|Cohort 4|Subjects will be treated with ruxolitinib 15 mg twice daily (BID) and panobinostat 15 mg three times per week (TIW) every other week (QOW) on a 28 day cycle
88888394|NCT01433445|Experimental|Cohort 5|Subjects will be treated with ruxolitinib 15 mg twice daily (BID) and panobinostat 20 mg three times per week (TIW) every other week (QOW) on a 28 day cycle
88888395|NCT01433445|Experimental|Cohort 6/6+|Subjects will be treated with ruxolitinib 15 mg twice daily (BID) and panobinostat 25 mg three times per week (TIW) every other week (QOW) on a 28 day cycle
88888396|NCT01433458|Experimental|RLX030: Group 1 mild hepatic impairment|Patients with mild hepatic impairment will receive a single IV 24 hour infusion of RLX030
88888397|NCT01433458|Experimental|RLX030: Group 2 moderate hepatic impairment|Patients with moderate hepatic impairment will receive a single IV 24 hour infusion of RLX030
88888398|NCT01433458|Experimental|RLX030: Group 3 severe hepatic impairment|Patients with severe hepatic impairment will receive a single IV 24 hour infusion of RLX030
88888399|NCT01433458|Active Comparator|RLX030: Group 4 - healthy volunteers|Participants will receive a single IV 24 hour infusion of RLX030. This group will consist of 3 sub-groups to match patients of groups 1, 2and 3.
89192558|NCT06147089|No Intervention|Control Group|The control group will receive no behavioral intervention and is instructed to continue with their normal sleep and nutritional habits.
89411818|NCT02643082|Placebo Comparator|Placebo MDI|Placebo Metered Dose Inhaler (MDI)
89411819|NCT00353496|Experimental|lanreotide (Autogel formulation)|
89411820|NCT00353496|Placebo Comparator|Placebo|
89411821|NCT03508154|Active Comparator|Control Meal 1|Control carbohydrate solution
89192559|NCT06147089|Experimental|Sleep intervention|The sleep intervention group will receive personalised sleep advice to promote better sleep during night shift periods. This intervention will last 3 months.
89411822|NCT03508154|Active Comparator|Control Meal 2|Control carbohydrate solution
89411823|NCT03508154|Experimental|Experimental Nutritional Product|Study nutritional formulation
89411824|NCT05313373|Experimental|Virtual Reality Group|
89411825|NCT05313373|No Intervention|Control Group|
89411826|NCT02309684||Study Population|Study population are subjects at least 18 years old and of any ethnic background with a full thickness diabetic foot ulcer or venous leg ulcer, where the ulcer has been diagnosed/present for greater than 4 weeks duration.
88888400|NCT01433484|Active Comparator|Maintenance of Weight Loss--Control|The control arm will receive bi-monthly telephone contacts during the one-year maintenance phase.
88888401|NCT01433484|Experimental|Maintenance of Weight Loss--Experimental|The experimental arm will receive monthly telephone contacts for one year during the maintenance phase.
88888402|NCT01433510|Experimental|Grazax Tablets 75000 SQT|Timothy Extract
88888403|NCT01433523|Placebo Comparator|Placebo|
88888404|NCT01433523|Experimental|ALK HDM AIT 6 DU|
89192560|NCT06147089|Experimental|Nutritional Intervention|The nutritional intervention group will receive personalised nutrition advice to promote better metabolic health during night shift periods. This intervention will last 3 months.
88888405|NCT01433523|Experimental|ALK HDM AIT 12 DU|
88888406|NCT01433536||cranial trauma and fracture|Individuals presenting a cranial trauma that are classified at equal to or less than 8 on the Glasgow scale, combined with a fracture to the femur, tibia, or pelvis resulting from a high-velocity impact
88888407|NCT01433536||cranial trauma|Individuals presenting a cranial trauma that are classified at equal to or less than 8 on the Glasgow scale
88888408|NCT01433536||spinal trauma with fracture|Individuals presenting a spinal fracture that are classified with an ASIA score of A, B, or C, combined with a fracture to the femur, tibia, or pelvis resulting from a high-velocity impact
88888409|NCT01433536||spinal trauma|Individuals presenting a spinal fracture that are classified with an ASIA score of A, B, or C
88888410|NCT01433536||high velocity fracture, inferior limb|Individuals that present a fracture to the femur, tibia, or pelvis resulting from a high-velocity impact
88888411|NCT01433536||Control|Healthy individuals
88888412|NCT01433562|Experimental|DLBS1425|
88888413|NCT01433562|Placebo Comparator|Placebo|
88888414|NCT01433575|Experimental|A|
88888415|NCT01433575|Experimental|B|
89192561|NCT06147050|Experimental|Metformin|"Drug: Metformin~Patients assigned to the metformin arm will receive a 500-mg dose of metformin extended-release formulation twice daily for a period of 30 days~500 mg extended-release tablet (Twice Daily)~Participants will be randomised in a 1:1 ratio to receive 1 dose of Metformin or Placebo on same day as randomisation"
88888416|NCT01433588|Active Comparator|Calmer|This therapeutic platform, called the Calmer interacts with the infant to help reduce stress to help promote better outcomes. It is being tested to see if it mimics Kangaroo care, maternal skin to skin, to help promote better health outcomes. Infants would be placed on it prior, during and after bloodwork to see if it elicits a favorable response.
88888417|NCT01433588|Placebo Comparator|Standard Care|Standard of care during bloodwork is receiving a soother and facilitated tucking.
88888418|NCT01433601|No Intervention|Self Supervised Treatment (SST)|Treatment according to the National Treatment Guidelines in Vietnam including treatment counseling before initiation of ART and clinical follow up every 3 months. The patient is self responsible to take the drugs and no additional adherence support is provided.
89437561|NCT03652051|Sham Comparator|AZR-MD-001 Vehicle|AZR-MD-001 Vehicle will be dosed up to once daily.
88888419|NCT01433601|Experimental|Enhanced Treatment Support (ETS)|Treatment according to the National Treatment Guidelines in Vietnam including treatment counseling before initiation of ART and clinical follow up every 3 months. In addition adherence support is provided according to the description under intervention.
88888420|NCT01433614|Active Comparator|Epirubicin + paclitaxel (Taxol)|Epirubicin 75mg/m2 i.v., paclitaxel 175 mg/m2 i.v. on day 1 every 21 days.
88888421|NCT01433614|Active Comparator|Paclitaxel + epirubicin + capecitabine|Paclitaxel 155 mg/m2 i.v., epirubicin 75 mg/m2 i.v day 1, capecitabine 1650 mg/m2 p.o. on days 1-14 every 21 days.
88888422|NCT01433627|Experimental|trans-radial and short-term Bivalirudin|Patients will be randomized to receive a trans-radial intervention and concomitant bivalirudin infusion. bivalirudin will be stopped at the end of PCI.
89411827|NCT03478579||Emergency physicians|The observational group will be composed of emergency physicians working in the French Midi-Pyrenees region. Physicians must work since 2 years in emergency service
89411828|NCT03490500||S100B protein dosage|Biological
89411829|NCT05065138|Experimental|After receiving standardized training on Helicobacter pylori eradication|After the gastroenterologists receive standardized training to eradicate Helicobacter pylori, they recruit Helicobacter pylori-positive patients for treatment.
88888423|NCT01433627|Experimental|trans-radial and long-term bivalirudin|"Trans-radial intervention: will be performed according to institutional guidelines and established local practice.~Bivalirudin: given immediately upon enrolment as bolus of 0.75 mg/kg followed immediately by an infusion of 1.75 mg/kg/h. This infusion should be run continuously until completion of PCI at which time the infusion should be reduced to a dose of 0.25 mg/kg/h for at least 6 hours. An optional higher-dose infusion of 1.75 mg/kg/h is also permitted for up to 4 hours in the prolonged infusion arm but prohibited in the short bivalirudin group."
88888424|NCT01433627|Experimental|trans-radial and standard of care pharmacology|"Trans-radial intervention: will be performed according to institutional guidelines and established local practice.~unfractionated heparin (UFH) which may be followed by the addition of a glycoprotein IIb/IIIa inhibitor"
88888425|NCT01433627|Experimental|trans-femoral and short-term bivalirudin|"Trans-femoral intervention: will be performed according to institutional guidelines and established local practice. Access closure devices are allowed as per local practice.~Bivalirudin will be given immediately upon enrolment as bolus of 0.75 mg/kg followed immediately by an infusion of 1.75 mg/kg/h. This infusion should be run continuously until completion of PCI."
88888426|NCT01433627|Experimental|Trans-femoral and long-term bivalirudin|"Trans-femoral intervention: will be performed according to institutional guidelines and established local practice. Access closure devices are allowed as per local practice.~Bivalirudin will be given immediately upon enrolment as bolus of 0.75 mg/kg followed immediately by an infusion of 1.75 mg/kg/h. This infusion should be run continuously until completion of PCI at which time the infusion should be reduced to a dose of 0.25 mg/kg/h for at least 6 hours. An optional higher-dose infusion of 1.75 mg/kg/h is also permitted for up to 4 hours in the prolonged infusion arm but prohibited in the short bivalirudin group."
88888427|NCT01433627|Active Comparator|trans-femoral and standard of care pharmacology|Trans-femoral intervention: will be performed according to institutional guidelines and established local practice. Access closure devices are allowed as per local practice. Unfractionated heparin (UFH) (100 IU/kg with no glycoprotein IIb/IIIa inhibitor (GPI) and 60 IU/kg with a GPI); +/- routine or bail out eptifibatide (two 180 μg /kg boluses with a 10 minute interval followed by an infusion of 2.0 μg /kg/min for 72-96 hours) or tirofiban (25 μg/kg followed by an infusion of 0.15 μg/kg/min for 18 to 24 hours) or abciximab (bolus of 0.25 mg/kg followed by an infusion of 0.125 μg/kg/min for 12-24 hours (maximum dose, 10 μg/min).
88888428|NCT01433640||Contrast-enhanced Mammography|Subjects will undergo 2D imaging with iodine contrast.
88888429|NCT01433640||Contrast-enhanced Breast Tomosynthesis|Subjects will undergo 3D imaging with iodine contrast.
88888430|NCT01433640||Contrast-enhanced MRI|Each subject imaged with iodine contrast will also be imaged with contrast-enhanced MRI using gadolinium.
88888431|NCT01433653|Experimental|CG-CBT|
88888432|NCT01433653|No Intervention|wait list control|
89192562|NCT06147050|Placebo Comparator|Placebo Control|"Other: Placebo control~• Participants will be randomised in a 1:1 ratio to receive 1 dose of Metformin or Placebo on same day as randomisation"
89411830|NCT05065138|No Intervention|Before receiving standardized training on Helicobacter pylori eradication|Gastroenterologists recruited patients with Helicobacter pylori positive for treatment before receiving standardized training on Helicobacter pylori eradication.
89005290|NCT01087723|Active Comparator|Standard of Care: Heparins with Optional GPI|"Standard-of-care anti-thrombotic therapy as outlined in the European Society of Cardiology Dosing Guidelines for Management of STE-ACS, not including bivalirudin: UFH (100 international units/kg [IU/kg] without GPI and 60 IU/kg with GPI). Any of the following approved GPIs were used either as a routine strategy or as a bail out: eptifibatide (two 180-micrograms/kilogram [μg/kg] IV boluses with a 10-minute [min] interval followed by an infusion of 2.0 μg/kg/min for 72-96 hours); tirofiban (25 μg/kg followed by an infusion of 0.15 μg/kg/min for 18-24 hours); or abciximab (bolus of 0.25 mg/kg followed by an infusion of 0.125 μg/kg/min for 12-24 hours [maximum dose of 10 μg/min]).~For this study, the control consisted of treatment with UFH or low molecular weight heparin (LMWH) with or without GPI and is referred to as heparins with optional GPI."
89005291|NCT01087528|Experimental|1|Subjects that are indicated for colonoscopy, who are suspected or known to suffer from large bowel diseases.
89192563|NCT06147024|Active Comparator|historical control group|conventional preoperative assessment
89411831|NCT02309762|Experimental|FB825|6 cohorts of subjects are planned to be dosed by IV injection, with single- ascending doses ranging from 0.003 - 10 mg/kg
89411832|NCT02309762|Placebo Comparator|Placebo|Placebo
89411833|NCT04463888|Experimental|Robot training with Smart Home-based Exoskeleton Robot System|In addition to receiving hospital occupational therapy training twice a week, the participants will receive 60 minutes of home-based robot assisted tenodesis-grip training per day, 5 days a week, for 4 weeks .
89411834|NCT04463888|Active Comparator|control group|In addition to receiving hospital occupational therapy training twice a week, the participants will receive 60 minutes of home-based specific motor task training per day, 5 days a week, for 4 weeks .
88888433|NCT01433666|Experimental|roflumilast 100ug|
88888434|NCT01433666|Experimental|roflumilast 300ug|
89005292|NCT00208247|Experimental|CBT|The cognitive behavioural treatment developed by Salkovskis, Warwick and co-workers was used, with adaptations for the specific setting.
88888435|NCT01433666|Experimental|roflumilast1000ug|
88888436|NCT01433666|Placebo Comparator|placebo|
89192564|NCT06147024|Experimental|3D printed lesion model group|using 3D printed lesion models for preoperative planning
89411835|NCT03508076|Sham Comparator|Sham Capsule|Patients swallowed 1 sham Vibrating capsule with water every three days，recorded his defecation time, defecation frequency and bristol score.The total capsule need to take 12.
89005293|NCT00208247|Experimental|STPP|The short-term psychodynamic psychotherapy (STPP).
89005294|NCT00208247|Experimental|Waiting List|Patients in the waiting-list group were asked to keep in touch with their GP, who had been informed of the trial in writing. The patients and their GPs were instructed not to begin any other treatment during the study period. After 6 months, the patients on the waiting list were re-evaluated for inclusion and exclusion criteria and, if they still met the criteria, re-randomized to CBT or STPP.
89192565|NCT06146998|Experimental|3D model group|Received a explanation combined with 3D medical education model
89192566|NCT06146998|Active Comparator|traditional explanation group|Received a regular explanation
89192567|NCT06146933|Experimental|Subject glucometer measurement|
89411836|NCT03508076|Experimental|Vibration Capsule of low level|Patients swallowed 1 low level vibration Capsule Vibrating capsule with water every three days，recorded his defecation time, defecation frequency and bristol score.The total capsule need to take 12.
89411837|NCT03508076|Experimental|Vibration Capsule of high level|Patients swallowed 1 high level vibration Capsule Vibrating capsule with water every three days，recorded his defecation time, defecation frequency and bristol score.The total capsule need to take 12.
88888437|NCT01433679|Experimental|Website intervention|Participants randomly assigned to the Website Intervention arm receive access to the motivational rewards website. The website displays the individual's physical activity data and allocates reward points based on the amount and intensity of physical activity. The website also allows reward points to be redeemed for various rewards such as gift cards to retail outlets, donations to charities, small tangible goods, and customization of participants' cartoon-like avatars on the website.
89411838|NCT03473977|Experimental|Benralizumab|Subcutaneous dose of 30 mg of Benralizumab every 4 weeks
89411839|NCT03473977|Placebo Comparator|Placebo|Subcutaneous dose of Placebo every 4 weeks
89411840|NCT03503084|Experimental|TCC group|Classical Yang's TCC exercise
89411841|NCT03507998|Experimental|CGX1321 Dosing|"Dose Escalation Phase: Ascending doses of CGX1321 will be administered by cohort to determine the maximum tolerated dose. Patients will receive CGX1321, once daily, orally, for 3 weeks (21 days) followed by a one week (7 day) washout period in each 28 day cycle, according to the cohort they are assigned.~Dose Expansion Phase: Patients will receive the recommended dose (identified in the Dose Expansion Phase) of CGX1321"
88888438|NCT01433679|No Intervention|Control|Participants in the control group will not have access to the motivational website. No other product or intervention will be introduced to the control group.
88888439|NCT01433692|Experimental|intervention group|
88888440|NCT01433692|Other|control group|
88888441|NCT01433705|Other|Rb-82 and N-13 ammonia Pet scans|Rest and vasodilator stress Rb-82 images and N-13 ammonia images will be taken according to standard clinical imaging protocol. Each of these two imaging studies require the injection of Rb-82 and N-13 ammonia by intravenous administration (IV) in the patient's arm.
88888442|NCT01433705|Other|F-18 FDG Imaging and Rb-82|Volunteers not excluded by abnormal rest/stress imaging with Rb-82, will begin F-18 FDG protocol.
88888443|NCT01433705|Other|F-18 FDG Imaging and N-13 ammonia|Volunteers not excluded by abnormal rest/stress imaging with N-13 ammonia, will begin F-18 FDG protocol.
88888444|NCT01433718|Experimental|ACL prevention training|
88888445|NCT01433744|Experimental|Chronic periodontal disease|C-reactive protein levels assesments and periodontal treatment
88888446|NCT01433744|No Intervention|Periodontally healthy|
88888447|NCT01433757|Active Comparator|Ampicillin|Patients who are randomly selected to receive the active drug will receive Ampicillin (2mg daily for adults and 1 mg daily for children).
89411842|NCT01361464|Experimental|Treatment (tipifarnib)|Patients receive tipifarnib orally twice daily on days 1-21. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
89411843|NCT03424213||white low aggressive|low aggressive = Gleason score < 7 and stage cT1-cT2 and PSA < 10 ng/ml
89411844|NCT03424213||white high aggressive|high aggressive = Gleason score ≥ 8 or PSA > 20 ng/ml or Gleason score = 7 and stage cT3-cT4
88888448|NCT01433757|Placebo Comparator|Placebo|Patients who are randomly selected to receive the placebo will be given a sugar pill that resembles the active drug.
88888449|NCT01433770|Experimental|Alefacept action on memory T cells|
88888450|NCT01433796||Antiretroviral therapy, tuberculosis|Patients eligible for starting ART in health centres in Ethiopia
88888451|NCT01433835|Placebo Comparator|Placebo|
89411845|NCT03424213||white intermediate aggressive|intermediate aggressive = all other cases
88888452|NCT01433835|Experimental|MBX-400|
88888453|NCT01433848||Child A liver cirrhosis|
88888454|NCT01433848||Child B liver cirrhosis|
88888455|NCT01433848||Child C liver cirrhosis|
88888456|NCT01433861|Active Comparator|LAPG|LAPG : laparoscopy-assisted proximal gastrectomy with double tract reconstruction group
88888457|NCT01433861|Active Comparator|LATG|LATG : laparoscopy-assisted total gastrectomy group
88888458|NCT01433874|Experimental|Pulmonary recruitment maneuver|A pulmonary recruitment maneuver consisting five manual pulmonary inflations was performed with a maximum pressure of 60 cmH2O. The anesthesiologist held the fifth positive pressure inflation for approximately 5 seconds.
88888459|NCT01433874|Experimental|Intraperitoneal normal saline infusion|The upper part of the abdominal cavity was evenly and bilaterally filled with the 0.9% normal saline in the amount of 500cc we will leave the fluid in the abdominal cavity.
88888460|NCT01433874|Experimental|combined group|The upper part of the abdominal cavity was evenly and bilaterally filled with the 0.9% normal saline in the amount of 500cc. Later, a pulmonary recruitment maneuver consisting of five manual pulmonary inflations was performed with a maximum pressure of 60 cmH20. The anesthesiologist held the fifth positive pressure inflation for approximately 5 seconds.
89005295|NCT00233688|Experimental|1|QUANTUM LP™ STENT GRAFT SYSTEM
89411846|NCT03424213||AA low aggressive|low aggressive = Gleason score < 7 and stage cT1-cT2 and PSA < 10 ng/ml
89411847|NCT03424213||AA high aggressive|high aggressive = Gleason score ≥ 8 or PSA > 20 ng/ml or Gleason score = 7 and stage cT3-cT4
89411848|NCT03424213||AA intermediate aggressive|intermediate aggressive = all other cases
89437562|NCT03648359|Other|Enrolled AS patients|Patients with prostate cancer enrolled i active surveillance protocol using PSA, digital rectal examination and conventional TRUS-biopsies
89437563|NCT03631628|Experimental|MT+ Bilateral TENS|All subjects will undergo 16 sessions of treatment (2 times per week, for 8 weeks). Subjects will receive 1.5 hours rehabilitation program: 30 minutes of MT+bilateral TENS and 1 hour conventional training of standardized upper limb training.
89437564|NCT03631628|Placebo Comparator|sham-MT+ Bilateral TENS|All subjects will undergo 16 sessions of treatment (2 times per week, for 8 weeks). Subjects will receive 1.5 hours rehabilitation program: 30 minutes of sham-MT+bilateral TENS and 1 hour conventional training of standardized upper limb training.
89411849|NCT03099226|Experimental|Group 1 - BIA 5-453 50 mg or placebo|"This study investigated the doses of 50, 100 and 200 mg of Etamicastat (BIA 5-453) during 10 days administered q.d. in the morning under fasting conditions.~On Day 1 and Day 10, patients remained fasted from a minimum of 8 hours before drug administration until after the collection of the 4 hour PK timepoint. Individuals were served a meal following the 4 hour timepoint and had free access to a maximum of 2.5 litres of water per day. However they were not allowed to drink 1 hour before and 1 hour after the dosing except for the 250 mL taken with the IMP at administration.~On other administrations days, patients remained fasted for a minimum of 8 hours before drug administration and the treatments were administered one hour before a standardized breakfast.~The patients were administered between 7:00 and 9:00 o'clock a.m"
89411850|NCT03099226|Experimental|Group 2 - BIA 5-453 100 mg or placebo|"This study investigated the doses of 50, 100 and 200 mg of Etamicastat (BIA 5-453) during 10 days administered q.d. in the morning under fasting conditions.~On Day 1 and Day 10, patients remained fasted from a minimum of 8 hours before drug administration until after the collection of the 4 hour PK timepoint. Individuals were served a meal following the 4 hour timepoint and had free access to a maximum of 2.5 litres of water per day. However they were not allowed to drink 1 hour before and 1 hour after the dosing except for the 250 mL taken with the IMP at administration.~On other administrations days, patients remained fasted for a minimum of 8 hours before drug administration and the treatments were administered one hour before a standardized breakfast.~The patients were administered between 7:00 and 9:00 o'clock a.m"
89411851|NCT03099226|Experimental|Group 3 - BIA 5-453 200 mg or placebo|"This study investigated the doses of 50, 100 and 200 mg of Etamicastat (BIA 5-453) during 10 days administered q.d. in the morning under fasting conditions.~On Day 1 and Day 10, patients remained fasted from a minimum of 8 hours before drug administration until after the collection of the 4 hour PK timepoint. Individuals were served a meal following the 4 hour timepoint and had free access to a maximum of 2.5 litres of water per day. However they were not allowed to drink 1 hour before and 1 hour after the dosing except for the 250 mL taken with the IMP at administration.~On other administrations days, patients remained fasted for a minimum of 8 hours before drug administration and the treatments were administered one hour before a standardized breakfast.~The patients were administered between 7:00 and 9:00 o'clock a.m"
88888461|NCT01433874|Placebo Comparator|Control group|Co2 was removed by passive exsufflation through the port site
88888462|NCT01433887|Experimental|Genotype 6|Genotype 6 chronic hepatitis C patients will be treated with Peginterferon alfa-2a plus ribavirin for 48 weeks
88888463|NCT01433887|Experimental|Genotype 1|Genotype 1 chronic hepatitis C patients will be treated with Peginterferon alfa-2a plus ribavirin for 48 weeks
88888464|NCT01433887|Experimental|Genotype 2/3|Genotype 2/3 chronic hepatitis C patients will be treated with Peginterferon alfa-2a/2b plus ribavirin for 24 weeks
88888465|NCT01433900|Active Comparator|Tafluprost|1 drop of tafluprost to eligible eye(s) once daily (at 9 pm)
88888466|NCT01433900|Active Comparator|Latanoprost|1 drop of latanoprost to eligible eye(s) once daily (at 9 pm)
88888467|NCT01433952|Placebo Comparator|0 mg Thiamine|
88888468|NCT01433952|Experimental|100 mg Thiamine|
88888469|NCT01433952|Experimental|500 mg Thiamine|
88888470|NCT01433952|Experimental|1500 mg Thiamine|
88888471|NCT01434004|Experimental|Lifestyle counseling|"Diet component: focus on increasing intake of whole grains, soybeans, soybean products, other beans, and vegetables.~Physical Activity: encourage completion of morning exercise sessions. Mindfulness Stress Reduction: training in mindfulness meditation, including dealing with intensive physical symptoms and difficult emotional situations."
88888472|NCT01434004|No Intervention|Control group|Usual care (watchful waiting).
88888473|NCT01434017|Active Comparator|Dexamethasone|Patients will receive dexamethasone 250 mcg/kg just after induction of anesthesia.
88888474|NCT01434017|Active Comparator|Dexamethasone and Droperidol|Patients will receive dexamethasone 250 mcg/kg + droperidol 10 mcg/kg just after induction of anesthesia.
88888475|NCT01434017|Active Comparator|Dexamethasone and Ondansetron|Patients will receive dexamethasone 250 mcg/kg + ondansetron 150 mcg/kg just after induction of anesthesia.
88888476|NCT01434056||Liver transplantation waiting list|Patients waiting for liver transplantation with chronic end staged liver disease
89411852|NCT03505970|Experimental|Sodium bicarbonate|0.3 g∙kg-1body mass of sodium bicarbonate
89411853|NCT03505970|Placebo Comparator|Placebo|Individuals will ingest 0.3 g/kg maltodextrin before undergoing exercise
89411854|NCT03317743|Experimental|NOV140101 (IDX-1197)|
89411855|NCT04078828|Active Comparator|PR|
89411856|NCT04078828|Active Comparator|Non-PR|
89411857|NCT03505814|Experimental|Optiflow Group|high flow (6l/min), humidified oxygen administred into nasal cannula for post-extubation new born ventilated patients.
89411858|NCT03505814|Active Comparator|Control Group|Conventional oxygen therapy for post extubation care
89411859|NCT02012179|Experimental|Low sodium diet|Low sodium diet (65 mmol or 1500 mg/day)
89411860|NCT02012179|No Intervention|Usual Care|General advice to limit dietary sodium as it is provided during routine clinic practice
88888477|NCT01434069|Experimental|Combination Therapy: FOLFIRI and SOM 230|"Treatment will be administered on an outpatient basis. FOLFIRI is administered by IV infusion every 2 weeks. The dose should be based on the patient's actual baseline body weight; the dose will be recalculated if there is a weight change of > 10% from baseline.~SOM 230 will be administered as an intramuscular dose determined by the dosing schema, every 28 days."
88888478|NCT01434095|Active Comparator|half-dose PDT(photodynamic therapy)|The study include single arm; treated group, and no control group was included.
88888479|NCT01434108|Experimental|Ornithine-phenylacetate|Administration of OP (OCR-002) during 5 days in addition to standard treatment of gastrointestinal bleeding.
88888480|NCT01434108|Placebo Comparator|Saline iv|Administration of control infusion (saline infusion) during 5 days in addition to standard treatment of gastrointestinal bleeding.
88888481|NCT01434134|Experimental|Metoprolol|Tablet, target dose 100 mg once daily
88888482|NCT01434134|Placebo Comparator|Placebo for Metoprolol|Tablet, target dose 100 mg once daily
88888483|NCT01434134|Experimental|Candesartan|Tablet, target dose 32 mg once daily
88888484|NCT01434134|Placebo Comparator|Placebo for Candesartan|Tablet, target dose 32 mg once daily
88888485|NCT01434147|Experimental|induction chemotherapy + radiochemotherapy|preoperative induction chemotherapy in combination with bevacizumab followed by combined radiochemotherapy with capecitabine induction chemotherapy: starts within 28 days after bioptical diagnosis. All patients are administered with capecitabine (Xeloda®) 1000 mg/m2 bid during 14 days (d1-d14), oxaliplatin 130 mg/m2 and bevacizumab (Avastin®) 7.5 mg/kg body weight on day 1; repetition days 22 and 43 (3 cycles) Combined radiochemotherapy: starts at the earliest one week after concluded third cycle of induction chemotherapy. Radiotherapy takes place on 5 x 5 days (dose: 1.8 Gy; cumulative dose: 45 Gy). For chemotherapy patients are administered with capecitabine (Xeloda®) 825mg/m² bid, on each radiation day during the first 4 weeks of radiochemotherapy.
88888486|NCT01434160|Experimental|Arm 1|
88888487|NCT01434173||Group 1|
88888488|NCT01434173||Group 2|
89411861|NCT02309918|Other|LDV/SOF FDC|Ledipasvir/Sofosbuvir fixed dose combination (FDC) tablet (LDV 90 mg/SOF 400 mg) once daily
89411862|NCT03098914||Beijing Haidian Hospital|
89411863|NCT03098914||Chinese PLA General Hospital|
89411864|NCT03098914||Beijing Tsinghua Chang gung Hospital|
89411865|NCT04051255|Experimental|Smokers aggressive periodontits|The patients were treated by a single-session of periodontal debridement under local anaesthesia during 45 minutes, using an ultrasonic instrument#, using subgingival tips* and irrigation with sterile saline solution, by the same operator (MGC, Paulista University, São Paulo, Brazil). After the debridement, all patients has prescribed with Amoxicillin 500 mg and Metronidazole 400 mg, every 8 hours, for 10 days (Casarin et al., 2012). Subjects were extensively informed about the intake of the prescribed medication. Subjects were clinically and microbiologically monitored at baseline (before therapy) and at 3 and 6 months post-therapy. During the monitored sessions, oral hygiene was evaluated and home care instructions were re-emphasized. Additionally, all subjects were recalled monthly for oral hygiene instructions.
89411866|NCT04051255|Experimental|Non-smokers aggressive periodontits|The patients were treated by a single-session of periodontal debridement under local anaesthesia during 45 minutes, using an ultrasonic instrument#, using subgengival tips* and irrigation with sterile saline solution, by the same operator (MGC, Paulista University, São Paulo, Brazil). After the debridement, all patients was prescribed with Amoxicillin 500 mg and Metronidazole 400 mg, every 8 hours, for 10 days (Casarin et al., 2012). Subjects were extensively informed about the intake of the prescribed medication. Subjects were clinically and microbiologically monitored at baseline (before therapy) and at 3 and 6 months post-therapy. During the monitored sessions, oral hygiene was evaluated and home care instructions were re-emphasized. Additionally, all subjects were recalled monthly for oral hygiene instructions.
89411867|NCT03538834|Experimental|Cod meal from residual material|Dietary supplement: cod meal from residual material, 8 g protein daily for 8 weeks
89411868|NCT03538834|Placebo Comparator|Control|Control group receive tablet containing fillers and no protein
89411869|NCT03920072|Other|Open label|All subjects will be administered subcutaneously burosumab every 4 weeks at the dosage defined in study UX023-CL303 or UX023-CL304 until December 2021 or when the drug becomes commercially available.
89411870|NCT03534154||TBI - MRI / bloods / cognitive / clinical outcomes|Work package 1. In a large multi-centre cohort of adult moderate/severe TBI patients we aim to identify the most informative plasma biomarker(s) of the severity of axonal injury. We will characterise their time course, focusing on neurofilament light (NFL) and tau, and relate these to magnetic resonance imaging (MRI) measures of axonal injury. Using logistic regression we will then test whether these measures contribute to the prediction of clinical outcome at twelve months
88813943|NCT03403166||DASH diet|The DASH diet consisted of a high intake of fruits, vegetables, and low-fat dairy products. It included a wide range of sources of protein, such as meat, fish, poultry, nuts, and beans. Sugar-sweetened beverages, desserts, and red meat were restricted. In terms of nutrients, the DASH diet had a high amount of fiber and protein; low amounts of saturated fat, total fat, and cholesterol; and intake of potassium, magnesium, and calcium at levels close to the 75th percentile of U.S. consumption.
89411871|NCT03534154||TBI - Advanced MRI / bloods / cognitive / clinical outcomes|Work package 2. In a subgroup of the patients recruited to WP1 we will use advanced MRI and longitudinal assessments to provide a more detailed description of the relationship between the plasma biomarkers and outcome after TBI. We will test whether advanced diffusion and myelin integrity measures correlate with plasma biomarkers and whether early plasma biomarker levels predict neurodegeneration measured by progressive atrophy after TBI.
89411872|NCT03534154||TBI - microdialysis / adv. MRI / cognitive / clinical|Work package 3. In a second subgroup of patients recruited to WP1 we will combine microdialysis, neuroimaging and plasma sampling of axonal proteins to provide a deeper understanding of the mechanisms of axonal injury progression and use this approach to investigate the axonal origin of the plasma biomarkers.
89411873|NCT03534154||Healthy volunteer|Single assessment using MRI, bloods and cognitive testing.
89411874|NCT03502928|Active Comparator|Conventional Treatment|Motor Control + Manual Therapy
89411875|NCT03502928|Experimental|Experimental Treatment|Motor Control + Manual Therapy + Dry Needling
89411876|NCT03505736||Diagnostic (stress test)|Within 2 years of initiating anti-estrogen therapy or 2 years after completing chemotherapy, participants undergo a stress test which consists of receiving adenosine IV over 1-5 minutes or regadenoson IV over 2 minutes and then undergoing CMR imaging over 45-60 minutes at baseline, and again 3-6 months later.
89411877|NCT03532750|No Intervention|Control|This arm will undergo no study procedures and continue with best medical management. This entails managing pain and draining excess fluid.
89411878|NCT03532750|Experimental|Particle|Randomized to receive either the Embozene or Embosphere particles
89411879|NCT03532750|Experimental|Coil|Randomized to receive either Ruby or Interlock detachable coils
89411880|NCT04027114|Experimental|Behavioural Physical Activity (PA) intervention|
89411881|NCT04027114|No Intervention|Wait list control|
88813944|NCT03403166||Fruits and vegetables diet|Potassium and magnesium intake was similar to the 75th percentile of U.S. consumption. Fiber intake was high. The fruits and vegetables diet consisted of more fruits and vegetables and fewer snacks and desserts than the control diet, but otherwise was similar to the control diet.
89411882|NCT02309996|Experimental|Supervisor Training Program|All supervisors from work units randomized to the intervention will receive a supervisor training program, the Supervisor/Manager Accommodation Recognition & Training (SMART) Program. This training program is modeled on a program developed by Shaw and colleagues of the Liberty Mutual Research Institute for Safety (LMRIS). The aim of the training program is to prevent/reduce work disability by improving supervisor communication, response to workplace injury, and problem solving mechanisms. The training program is designed to be administered by two facilitators to groups of 10 to 12 supervisors, during one 4-hour session or two 2-hour sessions. The training program delivery mode includes PowerPoint presentation with supplementary audio or video segments, case studies, and group discussion.
89411883|NCT02309996|No Intervention|No Supervisor Training Program|All supervisors from work units randomized to the control group will not receive the supervisor training program.
89411884|NCT03103126|No Intervention|Control|Standard care.
89411885|NCT03103126|Experimental|Combined resistance exercise and walking|Combined resistance exercise and walking.
88813945|NCT03403166||Control diet|For the control diet, macronutrient intake was similar to average U.S. consumption and intake of potassium, magnesium, and calcium were similar to the 25th percentile of U.S. consumption. Sodium intake was approximately 3 g/day in each diet.
88813946|NCT03400202||Group A: Dark Circles None|Group A includes participants with Dark Circle Severity Scale score 0 (None). Assessments of the participant's eye dark circles will be made after facial cleansing, utilizing in vivo skin imaging and quality of life questionnaires.
88813947|NCT03400202||Group B: Dark Circles Mild|Group B includes participants with Dark Circle Severity Scale score 1 to 3 (Mild). Assessments of the participant's eye dark circles will be made after facial cleansing, utilizing in vivo skin imaging and quality of life questionnaires.
88813948|NCT03400202||Group C: Dark Circles Moderate|Group C includes participants with Dark Circle Severity Scale score 4 to 6 (Moderate). Assessments of the participant's eye dark circles will be made after facial cleansing, utilizing in vivo skin imaging and quality of life questionnaires.
88813949|NCT03400202||Group D: Dark Circles Severe|Group D includes participants with Dark Circle Severity Scale score 7 to 9 (Severe). Assessments of the participant's eye dark circles will be made after facial cleansing, utilizing in vivo skin imaging and quality of life questionnaires.
88813950|NCT02981147|Experimental|Intervention|Phytus (Cisti, thyme and Ivy leaves) given to patients on day 1 and day 4. On 4th day, night and day cough score along with adverse event will be assessed. Sponsor will bear the treatment cost during the study time period.
88813951|NCT03400124|Active Comparator|ISBCS|The intervention group will undergo cataract surgery of both eyes on the same day (ISBCS)
88813952|NCT03400124|Active Comparator|DSBCS|The usual care / control group will undergo cataract surgery of both eyes on separate days, with a time period of at least two weeks between surgeries (DSBCS).
88813953|NCT03403088|Experimental|Group LA|INTERVENTION: to apply Laser (780 nm and 70mW) at the cementum-enamel junction fat the teeth affected by sensitivity
88813954|NCT03403088|Placebo Comparator|Group LA-P|INTERVENTION: to apply Laser (780 nm and 70mW) at the cementum-enamel junction at the teeth affected by sensitivity with the laser device having no effective laser emission, only guided by light
89411886|NCT02313350|Experimental|Chemonucleolysis with Discogel|Discogel® is a class III medical device (CE0459 mark on 28/09/2007) constituted by a radiopaque jellified ethanol. Discogel® is provided in a kit containing a 2 ml solution for injection with two disposable 1ml syringes. Discogel® chemonucleolysis for herniated disc-related sciatica is performed under local anesthesia. A volume of 0.9 ml of Discogel® is finally slowly injected during 10 to 15 minutes
89411887|NCT02313350|Active Comparator|Open discectomy|surgery : The comparator is open surgical discectomy. The procedure will be performed under general anesthesia. It will consist in removing the disc herniation after exposition and examination of the nerve root
89411888|NCT05064748|Experimental|Treatment Cohort|
89411889|NCT02316626|Experimental|Subcutaneous progesterone|Luteal phase support cycles will involve once-daily administration of 25 mg of SC P from the day after insemination for 14 days.
89411890|NCT02316626|Active Comparator|Vaginal Progesterone|Luteal phase support cycles will involve once-daily administration of 90 mg vaginal gel from the day after insemination for 14 days.
88888489|NCT01434199|Experimental|UPD guided group|Both the colonoscopist and assistant will be viewing the imager screen during the whole procedure.
88888490|NCT01434199|No Intervention|non-UPD guided group|Conventional colonoscopy would be done without image guidance.
88888491|NCT01434212||Interferon and ribavirin|All the patients followed the standard treatment protocol.
88888492|NCT01434225|Experimental|Bumetanide|Bumetanide - Standard Phenobarbital plus either 0.05 mg/kg,0.1 mg/kg, 0.2 mg/kg, or 0.3 mg/kg of bumetanide as determined by the the dose escalation design Maximum dose allowed is 0.3mg/kg given up to 4 times at 12 hourly intervals (total of 1.2mg/kg).
88888493|NCT01434238|Experimental|Intervention participant|
88888494|NCT01434251|Active Comparator|Standard care|Infants will be treated according to the treatment policy operative in the Neonatal Intensive Care Unit (NICU) of the Wilhelmina Children's Hospital/University Medical Centre Utrecht (UMCU): anti-hypotensive therapy will be started when the mean blood pressure (in mmHg) is below the gestational age in weeks.
88888495|NCT01434251|Other|Delayed intervention|Anti hypotensive therapy will be started when the mean blood pressure (in mmHg) is < (gestational age in weeks - 5 mmHg) or when there is clinical or biochemical evidence of impaired tissue perfusion.
88888496|NCT01434264|Experimental|Self-selected energy healing|Self-selected healing in the self-selection arm
88888497|NCT01434264|No Intervention|self-selected control|Self-selected control in the self-selection arm
88888498|NCT01434264|Experimental|randomized to energy healing|Randomized to healing in the randomization arm
89411891|NCT03502850|Experimental|ASK120067|patients take ASK120067 orally once per day at different dose
89411892|NCT03100162|Placebo Comparator|Placebo|Individuals receive a placebo daily, for 3 months.
89411893|NCT03100162|Active Comparator|Probiotic 2g|Individuals receive 2 g of probiotic daily, for 3 months.
89411894|NCT03100162|Active Comparator|Probiotic 4g|Individuals receive 4 g of probiotic daily, for 3 months.
89411895|NCT03505658|Experimental|Intervention|The Intervention is educational with 6 workshops for 2 hrs a week. Data/ assessments are collected, pre and post the 6 weeks intervention and 6 months post follow-up.
89411896|NCT03505658|No Intervention|Control|One or two non-intervention related workshop talks are given; 1 hr each during the same 6 weeks as the intervention arm. Pre and post assessment/ data collection and 6 months follow-up are completed.
88888499|NCT01434264|No Intervention|Randomized control|Randomized to control in the randomization arm
88888500|NCT01434277|Experimental|Healthy Subjects|Healthy Subjects instill 1-2 drops of the experimental eye drops into each eye four times per day for two weeks.
88888501|NCT01434277|Experimental|Dry-Eye Subjects|Dry-Eye Subjects instill 1-2 drops of the experimental eye drops into each eye four times per day for two weeks.
89005296|NCT00233688|Active Comparator|2|Surgical intervention
89411897|NCT05063890|Experimental|Muscle Specific MET|
89411898|NCT05063890|Experimental|Movement specific MET|
89411899|NCT03502772|Experimental|Pilates exercises group|
89411900|NCT03502772|Active Comparator|Home exercise program group|
89411901|NCT03505502|Placebo Comparator|placebo arm|group receive i/v saline plus irrigation of the myoma bed with normal saline
89411902|NCT03505502|Experimental|IV tranexamic acid group|group received IV tranexamic 1gm in normal saline
89411903|NCT03505502|Active Comparator|topical tranexamic acid group|group received topical tranexamic 2gm in normal saline
89411904|NCT03977896|Experimental|11C-MET PET/MRI|
89411905|NCT03501758||Remission with treatment|Patients randomized to continue medical treatment with biologics
89411906|NCT03501758||Remission without treatment|Patients randomized to stop medical treatment with biologics
89411907|NCT02316704|Active Comparator|OsseoTi™ G7 large|OsseoTi™ G7 acetabular cup and an E1™ liner holding largest possible femoral head (36mm-44mm)
89411908|NCT02316704|Active Comparator|OsseoTi™ G7 32|OsseoTi™ G7 acetabular cup and an E1™ insert holding a 32mm femoral head
89411909|NCT02316704|Active Comparator|conventional PPS coated G7 large|conventional PPS coated G7 acetabular cup and an E1™ insert holding largest possible femoral head (36mm-44mm)
89411910|NCT02316704|Active Comparator|conventional PPS coated G7 32|conventional PPS coated G7 acetabular cup and an E1™ insert holding a 32mm femoral head
89411911|NCT03501680|Experimental|Group A: intensive insulin|Group A: intensive insulin (glycemic control 4.4-6.1mmol/L)
89411912|NCT03501680|Active Comparator|Group B: standard insulin|Group B: standard insulin (glycemic control 7.8-10.0 mmol/L),
88888502|NCT01434303|Experimental|Treatment (entinostat, lapatinib ditosylate and trastuzumab)|Patients receive entinostat PO on days 1 and 15 and lapatinib tosylate PO on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients in the Phase I Trastuzumab Cohort also receive maintenance dose of trastuzumab IV over 30-90 minutes every 3 weeks.
88888503|NCT01434355||Correlative studies|Patients and parents or siblings undergo saliva sample collection. DNA extracted from saliva samples and from patients' archived tumor tissue samples is genotyped and analyzed by methylation arrays, including methylation-specific PCR (pyrosequencing) assays. Genetic variation between pediatric germ cell tumors and parent or sibling is also analyzed. Patients' and family members' health history, demographics, and environmental exposures are collected by questionnaires or telephone interviews. Medical history, such as chronic conditions, prescribed medications and congenital abnormalities, including cryptorchidism, is also collected. Birth characteristics of the child, including birth weight and gestational age, are also captured.
88888504|NCT01434381|Experimental|Pfs25-EPA/Alhydrogel|Dose-escalation of Pfs25-EPA/Alhydrogel. Participants will receive 1 of 3 doses of Pfs25-EPA/Alhydrogel- 8 micro g, 16 micro g, or 47 micro g.
88888505|NCT01434394|Experimental|Neo-adjuvant Erbitux-based chemotherapy|Neo-adjuvant Erbitus-based chemotherapy before surgery: Erbitus, Docetaxel, Cisplatin.
88888506|NCT01434394|No Intervention|Surgery and radiotherapy|Surgery and post-operative radiotherapy.
88888507|NCT01434407|Experimental|Low AGE meal|Test meal prepared by boiling/steaming the food
88888508|NCT01434407|Experimental|High AGE meal|Test meal prepared by frying/grilling the food
88888509|NCT01434420|Experimental|Triple negative breast cancer|Triple negative breast cancer
88888510|NCT01434459|Experimental|Gemcitabine with TheraSphere|
89411913|NCT03501680|Active Comparator|Group C: plasmapheresis|Group C: plasmapheresis
89411914|NCT03502694|Experimental|Regimen A (Low-Dose Lumicitabine)|Participants will receive a single 750 milligram (mg) loading dose (LD) (Dose 1) of lumicitabine and matching placebo followed by nine 250 mg tablets as maintenance doses (MDs) (Doses 2 to 10) of lumicitabine and matching placebo administered twice daily during Day 1 to Day 5/6 (depending on the timing of the LD).
88888511|NCT01434485||Nexium|
88888512|NCT01434524|No Intervention|Control|normal dietary
89005297|NCT01085812|Experimental|2|40, 80 or 120 mg/day Levomilnacipran ER capsules, oral administration, once daily dosing.
89411915|NCT03502694|Experimental|Regimen B (High-Dose Lumicitabine)|Participants will receive a single 1000 mg LD (Dose 1) of lumicitabine followed by nine 500 mg tablets as MDs (Doses 2 to 10) of lumicitabine and matching placebo tablet, administered twice daily during Day 1 to Day 5/6 (depending on the timing of the LD).
89411916|NCT03502694|Placebo Comparator|Regimen C (Placebo)|Participants will receive a placebo LD (Dose 1) followed by nine MDs (Doses 2 to 10) of matching placebo, administered twice daily during Day 1 to Day 5/6 (depending on the timing of the LD).
89411917|NCT05059756|Experimental|Treatment group|PTNS and PFR (twice daily)
89411918|NCT05059756|Experimental|Control group|Sham PTNS and PFR (twice daily)
89411919|NCT03486912|Experimental|BMS-986036 Dose Level 1|
89411920|NCT03486912|Experimental|BMS-986036 Dose Level 2|
89411921|NCT03486912|Experimental|BMS-986036 Dose Level 3|
89411922|NCT03486912|Placebo Comparator|Placebo|
89411923|NCT02310074|Experimental|Pulsatile Gonadotropin Releasing Hormone|Pulsatile Gonadotropin Releasing Hormone: subjects in the GnRH group initiated a regimen of pulsatile GnRH administered subcutaneously via a portable infusion pump for 18 months.
89411924|NCT02310074|Active Comparator|combination gonadotropin therapy|combined human chorionic gonadotropin (hCG)/urinary Follicle-Stimulating Hormone (uFSH) therapy:HCG treatment was maintained alone for 6 months and then uFSH was added for the next 12 months
89411925|NCT05059912|Experimental|CD7 positive relapsed or refractory T cell lymphoma|Humanized CD7 CAR-T cells intravenously infused to patient with R/R T-NHL[ at a dose of (0.5- 5)x10^6 CD7 CAR-T cells/kg
89005298|NCT01085812|Placebo Comparator|1|Matching placebo capsules, oral administration, once daily dosing.
89192568|NCT06146920|Other|Active Surveillance|Patients with 12 month history of immune checkpoint inhibitors (ICI) with stable or partial or complete responses and negative ctDNA at pre-screening, will stop ICI therapy and begin active surveillance with blood draws and standard of care imaging for 12 months.
89192569|NCT06146907|Active Comparator|cognitive motor dual task|24 participants
88888513|NCT01434524|No Intervention|LIVACT|The present study used LIVACT for preoperative supplementation, commencing two weeks prior to surgery, and continuing for at least 6 months postoperatively with careful monitoring of compliance.
89005299|NCT00208286|Other|PFC Sigma Fixed Bearing|PFC Sigma Fixed Bearing system for use in total knee arthroplasty
89411926|NCT05063968|Experimental|Part A - Single Ascending Dose (SAD) phase: Experimental|
88888514|NCT01434537||SCAN|Venepuncture performed with support of the AccuVein 300 vein scanner.
89005300|NCT00208286|Active Comparator|PFC Sigma Mobile Bearing|PFC Sigma Mobile Bearing system for use in total knee arthroplasty
89192570|NCT06146907|Active Comparator|exergaming|24 participants
89192571|NCT06146881|Experimental|Diquafosol sodium 3% group|Diquafosol sodium 3% 4 times a day for 4 weeks before cataract surgery and 21 days after surgery
89411927|NCT05063968|Placebo Comparator|Part A - Single Ascending Dose (SAD) phase:Placebo|
89411928|NCT05063968|Experimental|Part B - Food Effect (FE) phase: Experimental 1|
89411929|NCT05063968|Experimental|Part B - Food Effect (FE) phase: Experimental 2|
89411930|NCT05063968|Experimental|Part C - multiple ascending dose (MAD) phase: Experimental|
89411931|NCT05063968|Placebo Comparator|Part C - multiple ascending dose (MAD) phase:Placebo|
89411932|NCT02313584|Active Comparator|Short Group|The patients taking dabigatran for 1 month after the radiofrequent catheter ablation for paroxysmal atrial fibrillation.
89411933|NCT02313584|Placebo Comparator|Conventional Group|The patients taking dabigatran for 2 months after the radiofrequent catheter ablation for paroxysmal atrial fibrillation.
89411934|NCT02310152|Active Comparator|Active Treatment: CBT|Cognitive Behavioral Therapy
89411935|NCT02310152|Experimental|Experimental Treatment: SPACE|Parent-Based Treatment of Childhood and Adolescent Anxiety Disorders
89411936|NCT05063578|Experimental|Participant|
89411937|NCT02310230|Other|Blinded Group|Data from the ExSpiron Respiratory Variation Monitor (minute ventilation, tidal volume, and respiratory rate) will not be displayed. The anesthesia provider will care for the patient in the usual manner.
89411938|NCT02310230|Experimental|Monitor Group|The ExSpiron Respiratory Variation Monitor will display continuous real-time measurements of minute ventilation, tidal volume, and respiratory rate, and the anesthesia provider will be instructed to utilize this information in the care of the patient as they deem appropriate.
88888515|NCT01434537||NO_SCAN|Venepuncture without support of the vein scanner.
89005301|NCT00208364|Other|Pinnacle Acetabular Cup System|A cementless acetabular cup with metal liner for use in total hip replacement
89005302|NCT01085734|Active Comparator|Group 1|Group 1 receives Avastin at baseline followed by sham Osurdex at week 1. Additional Avastin based on macular edema
89005303|NCT01085734|Active Comparator|Group 2|Group 2 receives Avastin at baseline followed by Osurdex at week 1. Retreatment with Avastin based on macular edema
89192572|NCT06146881|Active Comparator|Sodium hyaluronate 0.1% group|Sodium hyaluronate 0.1% 4 times a day for 4 weeks before cataract surgery and 21 days after surgery
89192573|NCT06146842|Active Comparator|DPE Group|Subjects will receive an epidural catheter via a dural puncture epidural technique.
89192574|NCT06146842|Active Comparator|EPL Group|Subjects will receive an epidural catheter via a traditional epidural technique.
89192575|NCT06146751||patients with ventricular aneurysm and after percutaneous ventricular reconstruction|Patients with ventricular aneurysm and after percutaneous ventricular reconstruction undergo a novel ferumoxytol-enhanced cardiac magnetic resonance imaging and transthoracic echocardiography.
89192576|NCT06146738||Palliative Care|Best supportive care without surgical intervention
89192577|NCT06146738||Tumor biopsy|Tumor biopsy
89192578|NCT06146738||Tumor resection|Maximal safe resection of the tumor
89192579|NCT06146725||Tumor resection|Tumor resection
89192580|NCT06146725||Tumor biopsy|Tumor biopsy
89411939|NCT02667652|Active Comparator|short biliarypancreatic limb|short biliarypancreatic limb
89411940|NCT02667652|Active Comparator|long biliarypancreatic limb|long biliarypancreatic limb
88888516|NCT01434550|Active Comparator|TBRI Subgroup: TBRI and SBRT|"Six patients will be asked to be part of a subgroup called TBRI (Tissue, Blood, Research Imaging). In this subgroup, we want to study if there is early death of tumor cells from the treatment by looking at the tumor using PET/CT scans and biopsies, and by testing the participant's body's white blood cells taken by a procedure called leukapheresis.~Participants do not have to take part in the TBRI subgroup to get treatment on this study with SBRT.~SBRT:~30 Gy in 5 fractions to pancreatic tumor~50 Gy in 5 daily consecutive fractions unresectable portion and avoiding bowel, stomach, and duodenum"
89411941|NCT02310308|Active Comparator|xylitol chewing gum|Intervention chewing gum administration Each subject will be instructed to chew 1 or 2 pellets for 5 min 3 times a day (2 in the morning, 2 after the midday meal and 1 in the afternoon). Thus, the total daily intake of magnolol and honokiol in MX group will be 11.9 mg/day. The daily use of the two different chewing gums will be carried out for 12 months.
88888517|NCT01434550|Active Comparator|SBRT Alone|"30 Gy in 5 fractions to pancreatic tumor~50 Gy in 5 daily consecutive fractions unresectable portion and avoiding bowel, stomach, and duodenum"
89411942|NCT02310308|Experimental|Xylitol-magnolia chewing gum|Intervention chewing gum administration Each subject will be instructed to chew 1 or 2 pellets for 5 min 3 times a day (2 in the morning, 2 after the midday meal and 1 in the afternoon). Thus, the total daily intake of magnolol and honokiol in MX group will be 11.9 mg/day. The daily use of the two different chewing gums will be carried out for 12 months.
88888518|NCT01434563||HIV positive|Subjects must have documented HIV, be english speaking, with life expectancy greater than 6 months, and must have adequate information available in their medical record to apply HAND predictive algorithm (HIV-associated neurological disease)
89411943|NCT02310308|Placebo Comparator|Control chewing gum|Intervention chewing gum Each subject will be instructed to chew 1 or 2 pellets for 5 min 3 times a day (2 in the morning, 2 after the midday meal and 1 in the afternoon). Thus, the total daily intake of magnolol and honokiol in MX group will be 11.9 mg/day. The daily use of the two different chewing gums will be carried out for 12 months.
89411944|NCT02144298||cold blood cardioplegia|observe the perioperative course of sublingual microcirculatory alterations in patients undergoing coronary artery bypass grafting (CABG) using cold blood cardioplegia.
89005304|NCT00208403|Active Comparator|1|Acryloc™ GHV
88888519|NCT01434563||HIV negative|Must have documented negative HIV test within 12 months of study entry, have no traumatic brain injury or history of chronic neurological illness/psychiatric conditions (such as bipolar or depression),be english speaking and have no history of drug or alcohol abuse.
88888520|NCT01434576|Experimental|HGS1025 2 mg/kg|
88888521|NCT01434576|Experimental|HGS1025 10 mg/kg|
88888522|NCT01434576|Placebo Comparator|Placebo|
88888523|NCT01434589|No Intervention|Wait list control|
88888524|NCT01434589|Experimental|STICA Intervention|
88888525|NCT01434615|Experimental|No-CRT|Patients who meet CRT device implantation guidelines (i.e., meet CRT indication and on optimal medical therapy) but who do not get a CRT-P or CRT-D device implanted
88888526|NCT01434615|Experimental|CRT|Patients who meet CRT device implantation guidelines (i.e., meet CRT indication and on optimal medical therapy) and receive CRT-P or CRT-D device
88888527|NCT01434628|Experimental|PrePex™ device|Adult male circumcision by the PrePex™ device
88888528|NCT01434706|Other|Nucleic Acid Amplification Testing|Nucleic Acid Amplification Testing
88888529|NCT01434719||S.suis cases|This group consists of human cases with S.suis infection (confirmed or probable) admitted to National Hospital for Tropical Diseases in 2010.
88888530|NCT01434719||Sepsis controls|This group consists of hospital controls diagnosed with sepsis (not caused by S.suis) admitted to National Hospital for Tropical Diseases in 2010.
88888531|NCT01434732|Experimental|Umbilical Cord Milking|Umbilical Cord Milking involved milking the umbilical cord at birth.
88888532|NCT01434732|Active Comparator|Immediate Cord Clamping|Umbilical cord is clamped soon after birth without any milking of the cord.
88888533|NCT01434758||Children|Children age 0-15 years presenting to NHP thought to have TB infection
88888534|NCT01434784||Surgery alone|Patients undergoing any kind surgery for lung cancer, no additional surgery, quality of life assessment with the provisional updated lung cancer module within 3 months after surgery
88888535|NCT01434784||Surgery in combination with any other tx|Patients undergoing any kind surgery for lung cancer, additional therapy is permitted, quality of life assessment with the provisional updated lung cancer module within 3 months after surgery
88888536|NCT01434784||Surgery (late effects)|Patients undergoing any kind surgery for lung cancer, additional therapy is permitted, quality of life assessment with the provisional updated lung cancer moduleat least 3 months after surgery and 3 months after any other active treatment
88888537|NCT01434784||Chemotherapy alone|Patient undergoing any kind of chemotherapy for lung cancer, no additional therapy, quality of life assessment with the provisional updated lung cancer module during or up to 4 weeks after completion of therapy
88888538|NCT01434784||Radiotherapy alone|Patient undergoing radiotherapy for lung cancer, no additional therapy, quality of life assessment with the provisional updated lung cancer module during or up to 3 months after completion of therapy
88888539|NCT01434784||Sequential radiochemotherapy|Patient undergoing sequential radiochemotherapy for lung cancer, no surgery, no targeted therapy, quality of life assessment with the provisional updated lung cancer module during or up to 3 months after completion of therapy
88888540|NCT01434784||Concurrent radiochemotherapy|Patient undergoing concurrent radiochemotherapy for lung cancer, no surgery, no targeted therapy, quality of life assessment with the provisional updated lung cancer module during or up to 3 months after completion of therapy
88888541|NCT01434784||Targeted therapy alone|Patient undergoing targeted therapy for lung cancer, no surgery, no radiochemotherapy , quality of life assessment with the provisional updated lung cancer module during or up to 4 weeks after completion of therapy
88888542|NCT01434784||Targeted therapy in combination|Patient undergoing targeted therapy for lung cancer, additional therapies permitted, quality of life assessment with the provisional updated lung cancer module during or up to 3 months after completion of therapy
89005305|NCT00208403|Active Comparator|2|Palacos R
89411945|NCT02144298||cristalloid cardioplegia|observe the perioperative course of sublingual microcirculatory alterations in patients undergoing coronary artery bypass grafting (CABG) using cristalloid cardioplegia.
89411946|NCT04412434|Other|patients with acute ischemic stroke|This open-label prospective study will be conducted in the single medical center (RAMBAM Medical Center) and will include at least 200 patients with acute ischemic stroke resulted from MCA or ICA occlusion.
89411947|NCT02316782||Non-blinded IVUS assessment|The non-blinded arm will use the angiogram and IVUS grayscale and VH-IVUS to guide the procedure.
89411948|NCT02316782||Blinded IVUS assessment|After routine coronary angiogram, the physicians in the blinded arm of the study will only use the angiogram to guide the DES stenting procedure;
89411949|NCT03545568|Other|Experimental: sialic acid|
89411950|NCT03845374|Experimental|Conventional Antibiotics+ Hyper-CL™ lens|Conventional treatment with topical Antibiotics+ Hyper-CL™ lens
89192581|NCT06146712|Experimental|Intervention Arm: 'Dream the night away' nighttime lotion|"The product should be applied once daily at night (30 minutes before bedtime). Participants should apply two teaspoons (one teaspoon of lotion covers approximately the size of the fingertip from tip to first knuckle) of lotion (3 mg of melatonin) and use it wherever they would usually use body lotion (paying particular attention to areas of tension in shoulders, neck, and temples, or on their legs and feet if they experience restless legs or muscle tightness).~Participants should do this for 20 nights."
89005306|NCT00233727|Active Comparator|HPV DNA Testing + Cryosurgery|"Patients will undergo a Screen and Treat program utilizing HPV DNA testing of clinician-collected cervical samples, followed by cryosurgery of screen positive women."
89192582|NCT06146660||Participants receiving mavacamten for oHCM|
89411951|NCT03845374|No Intervention|Conventional Antibiotics|Conventional treatment with topical Antibiotics
89411952|NCT02140710|Active Comparator|Osteopathic treatment group|visceral osteopathic treatment algorithm
89411953|NCT02140710|No Intervention|Control group|no intervention
89411954|NCT05063422|Experimental|Mild Resorption of mandibular ridge|Loss of upto 1/3 of original vertical height
89411955|NCT05063422|Experimental|Moderate Resorption of mandibular ridge|2. Moderate Resorption: Loss of upto 1/3 to 2/3 of original vertical height
89411956|NCT05063422|Experimental|Severe Resorption of mandibular ridge|3. Severe Resorption: Loss of 2/3 or more of original vertical height
88813955|NCT03403088|Experimental|Group DE|INTERVENTION: to brush teeth with a blinded dentifrice with 0,45% of stannous fluoride and a soft-bristled manual toothbrush (Johnson & Johnson®).
88813956|NCT03403088|Placebo Comparator|Group DE-P|INTERVENTION: to brush teeth with a blinded dentifrice with 1500 ppm of available fluoride and a soft-bristled manual toothbrush (Johnson & Johnson®).
88813957|NCT03403088|Experimental|Group RGI|INTERVENTION: to apply a thin layer of resin based glass-ionomer product on the cervical surface of the affected teeth affected by sensitivity following the manufacturer instructions.
88813958|NCT03403088|Experimental|Group RX|INTERVENTION: to apply Adper Single Bond Plus Adhesive in accordance with the manufacturer instructions, at the teeth affected by sensitivity
88813959|NCT03403010|No Intervention|Control period|In this group conventional physiotherapy of the child will be continued and the therapist will be asked not to use any gaming activities. Also during the control period, the frequency and duration of the therapy sessions will not be influenced by the researchers.
88813960|NCT03403010|Active Comparator|Intervention period|In this group the usual individual physiotherapy program of the child will be continued as performed before the study and will be executed by the child's usual, familiar physiotherapist. The therapist will be asked to use the rehabilitation-specific gaming software every therapy session, for at least 15 to 20 minutes. The therapist will receive an extensive introduction and demonstration of the software and the researchers will participate in at least one therapy session.
88813961|NCT03403010|No Intervention|Wash-out period|The wash-out period is considered after each intervention period. As during the control period, therapy will be continued as usual during the washout-period but no gaming is allowed during therapy.
88813962|NCT03003377|Experimental|Device: laryngeal mask supreme|Determine the Sevoflurane concentration associate with remifentanil for the insertion of the laryngeal mask supreme
88813963|NCT03003377|Active Comparator|Device: laryngeal mask proseal|Determine the Sevoflurane concentration associate with remifentanil for insertion of the laryngeal mask ProSeal
88813964|NCT03003221|Active Comparator|AIR-P Dental Toolkit|Families will be provided with the Autism Intervention Research Network on Physical Health (AIR-P) Dental Toolkit.
89005307|NCT00233727|Active Comparator|VIA + Cryosurgery|"Patients will undergo a Screen and Treat program utilizing visual inspection of the cervix with acetic acid (VIA), followed by cryosurgery of screen positive women."
89411957|NCT03501602|Active Comparator|LMA protector group|The LMA Protector is a single use supraglottic airway device. This airway device provides access and functional separation of the respiratory and digestive tracts
89005308|NCT00233727|No Intervention|Delayed Evaluation and Treatment|Patients will undergo a similar screening process at entry, but will be randomized to have evaluation and treatment delayed until 6 months after screening.
89005309|NCT01084603|Experimental|Oral Nicotine 1|One oral administration of 1 mg nicotine
89005310|NCT01084603|Experimental|Oral Nicotine 2|Two oral administrations of 1 mg nicotine
89005311|NCT01084603|Experimental|Oral Nicotine 4|Four oral administrations of 1 mg nicotine
89005312|NCT01084603|Active Comparator|NiQuitinTM Nicotine Lozenge 4 mg|One 4 mg marketed nicotine lozenge
89411958|NCT03501602|Active Comparator|I-gel LMA group|The I-gel is an alternative supraglottic device which provides the seal over the airway versus an inflatable cuff.
89411959|NCT05063188|Active Comparator|Control group|
89005313|NCT01084603|Active Comparator|Nicorette® Gum 4 mg|One marketed Nicorette® nicotine gum 4 mg chewed for 30 minutes
89411960|NCT05063188|Experimental|Intervention group|
89411961|NCT02316860|Other|History of reflex syncope|Passive tilt test in athletes with a history of reflex syncope
89411962|NCT02316860|Other|No history of reflex syncope|Passive tilt test in athletes without history of reflex syncope
89411963|NCT05063266|Active Comparator|Group A|Deep Breathing exercise
89411964|NCT05063266|Experimental|Group B|Inspiratory Muscle Training
89411965|NCT03501524|Experimental|VATS evacuation|patients selected for VATS after failure of first thoracostomy tube drainage
89411966|NCT03501524|Experimental|thoracostomy tube|patients selected for thoracostomy tube reinsertion after failure of drainage with first thoracostomy tube
89411967|NCT03782350|Experimental|Tranexamic Acid Dosage 1|A bolus of 30 mg/kg Tranexamic Acid for 20 min followed by a maintenance dose of 16 mg/kg/h Tranexamic Acid until the end of surgery, and a pump prime dose 2 mg/kg.
89411968|NCT03782350|Active Comparator|Tranexamic Acid Dosage 2|A bolus of 10 mg/kg Tranexamic Acid for 20 min followed by a maintenance dose of 2 mg/kg/h Tranexamic Acid until the end of surgery, and a pump prime dose 1 mg/kg.
89411969|NCT02310386|Active Comparator|activated BEMER-device|Activated BEMER electromagnetic field therapy (BEMER, Innomed International, AG, Lichtenstein).
89411970|NCT02310386|Sham Comparator|inactivated BEMER-device|Inactivated BEMER electromagnetic field therapy (BEMER, Innomed International, AG, Lichtenstein).
89411971|NCT02313740||Healthy adults group|Healthy adults aged 18 to 59 years Butantan Fragmented Inactivated Trivalent Influenza Vaccine
89411972|NCT02313740||Elderly group|Elderly aged over than 60 years completed Butantan Fragmented Inactivated Trivalent Influenza Vaccine
89005314|NCT00208442|Active Comparator|Marathon™|Moderately cross-linked polyethylene liner in a modular acetabular component
89005315|NCT00208442|Active Comparator|Enduron™|Standard UHMWPE polyethylene liner in a modular acetabular component
89005316|NCT01084174|Experimental|Active SLIT/Placebo OIT|These subjects will receive peanut powder given orally and placebo extract given sublingually.
89192583|NCT06146569|Experimental|Transcutaneous Auricular Vagus Nerve Stimulation|Each patient in the Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) group will receive a treatment protocol consisting of taVNS. The treatment will be administered for five days beginning on the first day of pain experienced between the 1st and 2nd menstrual cycles.
88813965|NCT03003221|Experimental|Parent Training|Families randomized to the Parent Training condition will be provided with the AIR-P Dental Toolkit and a 10-week behavioral parent-training intervention with additional booster sessions.
89005317|NCT01084174|Experimental|Active OIT/Placebo SLIT|These subjects will receive peanut extract given sublingually and placebo powder given orally.
89005318|NCT00237393|Experimental|1|Quetiapine
89005319|NCT00237393|Placebo Comparator|2|
89005320|NCT00208559|Other|1 Open Label|Open Label
89005321|NCT00233805|Active Comparator|1|Bare metal Bx Velocity™ Balloon-Expandable Stent mounted on the Raptor® rapid exchange delivery system
89005322|NCT00233805|Experimental|2|Sirolimus coated modified Bx Velocity™ Balloon-Expandable Stent mounted on the Raptor® rapid exchange delivery system
89005323|NCT01084135|Experimental|Rivastigmine- Liquid form|At the baseline visit (week 0), the subject will begin rivastigmine treatment at a dose of 0.75 mg bid. This dose will be continued for two weeks and then increased to 1.5 mg bid for an additional eight weeks. At the week 10 safety visit, the dose will be increased to 4.5 mg/day (3.0 mg and 1.5 mg) for an additional 10 weeks. If a subject is unable to tolerate a particular dose, the dose will be lowered to the previously tolerated dose, down to a minimum of 0.75 mg bid. If the subject is unable to tolerate the 0.75 mg bid dose he/she will be dismissed from the study.
89005324|NCT01084135|Placebo Comparator|Liquid placebo|Subjects receiving placebo will maintain matched titration volume increase as treatment arm. The placebo will be matched to liquid rivastigmine in consistency and taste.
89411973|NCT02310542|Experimental|MARS-SPAD|Patients will receive first the MARS albumin dialysis system and then, in a second time, the SPAD albumin dialysis system.
89411974|NCT02310542|Experimental|SPAD-MARS|Patients will receive first the SPAD albumin dialysis system and then, in a second time, the MARS albumin dialysis system.
89411975|NCT03098680|Experimental|Group A (Placebo, Salbutamol, Nicardipine, Dobutamine)|"Participants will receive each drug, to be given on separate study days. The drugs will be given as a 3 stage infusion with dose increasing at each stage. Each stage will be 30 minutes in duration.~Placebo; Salbutamol(Albuterol) Sulfate (Dose: 2mcg/min, 5mcg/min, 10mcg/min); Nicardipine Hydrochloride (Dose: 1mg/hr, 2.5mg/hr, 5mg/hr); Dobutamine Hydrochloride (Dose: 1mcg/kg/min, 2.5mcg/kg/min, 5mcg/kg/min)"
89411976|NCT03098680|Experimental|Group B (Placebo, Phenylephrine, Verapamil, Phentolamine)|"Participants will receive each drug, to be given on separate study days. The drugs will be given as a 3 stage bolus with dose increasing at each stage. Each stage will be 30 minutes apart.~Placebo; Phenylephrine Hydrochloride (Dose: 100mcg, 200mcg, 300mcg); Verapamil Hydrochloride (Dose: 1mg, 2.5mg, 5mg); Phentolamine Mesylate (Dose: 1mg, 2mg, 3mg)"
89411977|NCT02317094|Other|Control|Participants receive care as usual (various DMARDs, different from patient to patient).
89411978|NCT02317094|Experimental|Blood-flow restricted tranining|Participants will receive care as usual (various DMARDs, different from patient to patient) + 12 wks of low-intensity blood-flow restricted training twice per week.
89411979|NCT03098446|Experimental|Prolonged sitting with exercise|Subjects will be asked to undergo prolonged sitting (~14-hours/day) for 4 days. On the evening of day 4, they will be asked to run at 65% of VO2max for 1-hour.
89411980|NCT03098446|Experimental|Prolonged sitting without exercise|Subjects will be asked to undergo prolonged sitting (~14-hours/day) for 4 days. Subjects will not be asked to complete the acute bout of exercise to serve as a control.
89411981|NCT02313818|Experimental|CPT-C|Cognitive Processing Therapy-Cognitive Only (CPT-C) conducted twice weekly for 4-24 sessions based on good end state functioning.
89411982|NCT03098524|Experimental|Low tidal volume ventilation (LTV arm)|During cardiopulmonary bypass, mechanical ventilation is maintained with 5 acts/minute, tidal volume = 3 ml/kg (ideal body weight) with positive end-expiratory pressure = 5 cmH2O
89411983|NCT03098524|Placebo Comparator|No ventilation (noV arm)|No mechanical ventilation during cardiopulmonary bypass.
89411984|NCT02313896|No Intervention|Standard of Care|Patients recieve standard care. On discharge they receive an information packet about cirrhosis and hepatic encephalopathy. They will continue to follow with their doctor as usual.
89411985|NCT02313896|Experimental|Phone calls|On discharge, patients will receive an information package about cirrhosis and hepatic encephalopathy. In addition to regular visits with the doctor, they will receive phone calls from one of our research providers who will be a nurse practitioner, doctor, or physician assistant. In the first 2 weeks after discharge, they will receive phone calls every other day. For the following 10 weeks, they will receive phone calls once a week.
89411986|NCT03098368|Active Comparator|Patient (active) group|"Rotigotine titration up to 16 mg/24 hr~Starting dose 2 mg/24 hr up titrate 2 mg weekly to optimal/maximum dose~Duration up to 12 weeks~The treatment was titrated until optimal dosage~(that which patient/ caregiver felt that nocturnal hypokinesia and/or early morning akinesia was adequately controlled)~(or patient can not tolerated the side effects such as dyskinesia)~All previous dopaminergic medications were not allowed to adjusted during the study period."
89411987|NCT03098368|Placebo Comparator|Control (placebo) group|"Placebo transdermal patch were titration with the same protocol as active group.~Duration up to 12 weeks~The treatment (placebo patch) was titrated until optimal dosage~(that which patient/ caregiver felt that nocturnal hypokinesia and/or early morning akinesia was adequately controlled)~(or patient can not tolerated the side effects such as dyskinesia)~All previous dopaminergic medications were not allowed to adjusted during the study period."
89411988|NCT02310854|Active Comparator|ACL Reconstruction|Primary reconstructive surgery of ACL with hamstring autograft (All-inside, Arthrex, Napels, Florida, USA)
89411989|NCT02310854|Experimental|ACL Repair|Primary augmented suture of ACL using Dynamic Intraligament Stabilization (DIS; Mathys Medical Bettlach, Switzerland)
89411990|NCT04434820|No Intervention|standard dressing group|patients will receive sterile wound dressing of gauze and tape for 4 days.
88813966|NCT03402776|No Intervention|good resp. after 3 vacc. inject.|no randomization for a 4th dose.
88813967|NCT03402776|Experimental|bad resp. after 3 vacc. inj., 4th inj|After randomization, these patients will receive a 4th dose one month after the 3rd dose.
88813968|NCT03402776|No Intervention|bad resp. after 3 vacc. inj., no 4th inj|After randomization, these patients will not receive a 4th dose one month after the 3rd dose.
88813969|NCT03404570|Experimental|High Dose (4 mg)|Oral tablet containing 2 mg of active drug, dexmecamylamine HCl. Subjects will be instructed to take two tablets by mouth once daily (in the morning).
88813970|NCT03404570|Experimental|Low Dose (2 mg)|Oral tablet containing 1 mg of active drug, dexmecamylamine HCl. Subjects will be instructed to take two tablets by mouth once daily (in the morning).
88813971|NCT03404570|Placebo Comparator|Placebo|Oral tablet containing no active drug. Subjects will be instructed to take two tablets by mouth once daily (in the morning).
88813972|NCT03409796|Other|Group A: Gluten 3 gm|Gluten 3 gram (gm), powder, orally, once daily up to 14 days.
88813973|NCT03409796|Other|Group B: Gluten 10 gm|Gluten 10 gm, powder, orally, once daily up to 14 days.
88813974|NCT03408080|Experimental|Open Arm|All subjects will receive the same dosage throughout the study.
88813975|NCT03402698|Experimental|cholecalciferol|cholecalciferol at a dose 1000 IU /day for 3 months
88813976|NCT03406520|Experimental|Chlorhexidine-impregnated disk|The chlorhexidine-impregnated disk, will be applied to the peritoneal dialysis catheter exit-site and the disk will be changed once a week
88813977|NCT02248181||Idiopathic PD patients|
88813978|NCT03002909|Active Comparator|epidural group|an epidural catheter will be inserted under sterile conditions through the T9- 12 interspace using the 'loss-of-resistance' technique. The catheter will be advanced 4 cm cephalad. .
88813979|NCT03002909|Active Comparator|preperitoneal group|preperitoneal catheters will be placed in the subfascial (ie, pre-peritoneal) space under direct vision.
89192584|NCT06146569|Sham Comparator|Sham Transcutaneous Auricular Vagus Nerve Stimulation|Each patient in the sham Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) group will receive a treatment protocol consisting of sham taVNS. The treatment will be administered for five days beginning on the first day of pain experienced between the 1st and 2nd menstrual cycles.
88888543|NCT01434797||Confirmed CVCP infection before removal|Patients with permanent central venous catheter infection confirmed by conventional method
88888544|NCT01434797||Presumed CPVP infection before removal|Patients with probable permanent central venous catheter infection (standard methods for infection detection not conclusive)
88888545|NCT01434797||Uninfected CVCP before removal|Patients with planned permanent central venous catheter removal (no infection)
88888546|NCT01434836|Active Comparator|active tDCS and working memory training|
88888547|NCT01434836|Placebo Comparator|sham tDCS and working memory training|
88888548|NCT01434849|Experimental|Timolol|Application of 1-2 drops of Timolol maleate 0.5% ophthalmic aqueous solution to hemangioma twice daily.
88888549|NCT01434849|Placebo Comparator|Placebo|Application of 1-2 drops of placebo gel twice daily to hemangioma.
88888550|NCT01434862|Experimental|Closed loop with pramlintide|Pramlintide will be provided to study subjects who will subsequently be admitted for inpatient testing with the closed loop system. The term closed loop refers to insulin adjustment automatically regulated by computer input to the insulin pump based on monitoring (often a combination of patient blood glucose (BG) testing and/or continuous glucose monitoring (CGM)).
88888551|NCT01434862|Experimental|Closed loop without pramlintide|This visit is necessary to assess how well the closed loop system works without the pramlintide (how well it protects from hypoglycemia and hyperglycemia). It will be the exact protocol as for the closed loop with pramlintide but without the medication.
89192585|NCT06146517|Experimental|Clevr Blends Arm|"Weeks 1-4: Participants will take one 6 oz serving daily of Clevr Blends Sleeptime 20 - 60 minutes before bed. The product comes with a scoop that measures 3 tsp. Participants should mix a full scoop with 6oz of water and froth using the frother that will be provided.~Weeks 5-8: Participants will take one serving daily of Clevr Blends Matcha, before 1pm. The product comes with a scoop that measures 3 tsp. Participants should mix a full scoop with 6oz of water and froth using the frother that will be provided.~Weeks 9-12: Participants will take one serving daily of Clevr Blends Chai, before 1pm. The product comes with a scoop that measures 3 tsp. Participants should mix a full scoop with 6oz of water and froth using the frother that will be provided."
89192586|NCT06146491|Active Comparator|Drugs|oral combination of paracetamol (500mg) - ibuprofen (400mg) will be given to group A. they are provided in tablet and prescribed at 8 hourly for three days
89192587|NCT06146491|Active Comparator|Drug|Transdermal diclofenac patch - 200mg for group B. Patch is applied on right hand in deltoid region , and ask the patient to change patch every 24 hourly.
89192588|NCT06146478|Experimental|Thalidomide Group|In addition to routine β-thalassemia treatment patients in this group also received thalidomide at an average dose of 1.5mg/kg/day
89192589|NCT06146478|No Intervention|Non-Thalidomide Group|Participants received routine treatment for β-thalassemia such as regular blood transfusion and hydroxyurea at an average dose of 20mg/kg/day
89192590|NCT06146426|Experimental|Early diet|The patients of early group will be performed water swallowing test at bedside after 2 hours of extubation. Before performing the Water Swallow Test, the patient must be evaluated for readiness.This interventional group of patients will be initiated with sips of water (warm or cold as patient prefers) at 2 hours of extubation (post-operative day 0) followed by clear liquid diet (tea, clear juice/ soup, gelatin) at 4 hours. If well tolerated, then slowly progress to a full liquid and solid diet as the patient preferred pace.
88888552|NCT01434862|Experimental|Open loop with pramlintide|The term open loop refers to insulin infusions regulated in their delivery based on patient self-monitoring and adjustment. The study subject will be in charge of their insulin treatment while also receiving pramlintide.
88888553|NCT01434888|Active Comparator|Tafluprost 0.0015%|
88888554|NCT01434888|Active Comparator|Timolol 0.5%|
88888555|NCT01434888|Experimental|Fixed-dose combination of tafluprost 0.0015% and timolol 0.5%|
88888556|NCT01434901|Experimental|Normal Glucose Tolerance|Healthy individuals exhibiting plasma glucose levels less than 140mg/dl two hours after ingestion of 75-g of glucose.
89411991|NCT04434820|Active Comparator|External negative pressure dressing system group|patients will receive placement of a sterile dressing of gauze and occlusive adhesive over the closed incision. The dressing's tubing will then be attached to a compact, portable negative-pressure therapy unit (Yuwell 7E-A portable suction unit) that will deliver -80 mm Hg of continuous pressure to the dressing and will remove exudates into a disposable canister for 4 days.
88888557|NCT01434901|Experimental|Impaired Glucose Tolerance|Healthy individuals exhibiting plasma glucose levels between 140 and 199 mg/dl two hours after ingestion of 75-g of glucose.
89411992|NCT02310932|Experimental|Healthy Living Intervention|The Healthy Living Intervention group will participate in an intervention designed to improve depression, anxiety, diabetes and CVD outcomes. This will be achieved through a 12 month intervention which consists of participation in healthy living groups and integrated collaborative clinic care at their Primary Health Clinic (PHC).
89411993|NCT02310932|Placebo Comparator|Enhanced Standard Care Model|"Patients in control groups will receive an enhanced standard care model, which includes providing referrals for mental health needs."
89411994|NCT05062486|Experimental|Resveratrol, Quercetin, Curcumin (RQC)|Resveratrol (100mg BID), Quercetin (120mg BID), Curcumin (1000mg BID); 24 months
89411995|NCT05062486|Active Comparator|Curcumin|Curcumin (1000mg BID); 24 months
89411996|NCT02317172|Experimental|Gel-based artificial saliva|Continuous oral intake of edible gel-based artificial saliva (30-50 ml/day) for four weeks
89411997|NCT02314130|Experimental|Dietary therapy Standardized diet|The study was constituted by sixty-six patients, thirty-three in each group. Patients on not industrialized enteral diet (standardized diet group) entered at random in the study and were matched by gender, age, socioeconomic status and medical diagnosis to patients using commercial diet (commercial group). The evaluation consisted of anthropometric measures of weight, height, arm circumference, triceps skin fold and biochemical índices at baseline and at the end of the intervention.
89411998|NCT02314130|No Intervention|Dietary therapy Commercial diet group|The study was constituted by sixty-six patients, thirty-three in each group. Patients on not industrialized enteral diet (standardized diet group) entered at random in the study and were matched by gender, age, socioeconomic status and medical diagnosis to patients using commercial diet (commercial group). The evaluation consisted of anthropometric measures of weight, height, arm circumference, triceps skin fold and biochemical índices at baseline and at the end of the intervention.
89411999|NCT02314208|Active Comparator|Xenbilox|Xenbilox (chenodeoxycholic acid) 1000mg capsule by mouth every day for 2 months
89412000|NCT02314208|Active Comparator|Resveratrol|Resveratrol 80mg capsule by mouth every day for 2 months
89412001|NCT02314208|Active Comparator|Tahor|Tahor (atorvastatin) 40mg tablet by mouth every day for 2 months
89412002|NCT03098212|Experimental|Aromatherapy|Receive essential oil diffuse by Aroma diffuser during labor. Pain score and dose of analgesics drug are recorded
89412003|NCT03098212|No Intervention|Non-aromatherapy|This group receive pain control by standard of care without essential oil (aromatherapy)
89412004|NCT02317250|Experimental|prompt amyloid imaging, delayed FDG-PET|Subject's managing physicians will be given the results of amyloid imaging scans immediately. FDG-PET results will be released two years after scanning.
89412005|NCT02317250|Experimental|prompt FDG-PET, delayed amyloid imaging|Subject's managing physicians will be given the results of FDG-PET scans immediately. Amyloid imaging results will be released two years after scanning.
89412006|NCT02317250|Experimental|prompt FDG-PET, prompt amyloid imaging|Both FDG-PET and amyloid imaging scan results will be made immediately available to the managing physician.
89412007|NCT02317250|Active Comparator|delayed FDG-PET, delayed amyloid imaging|Neither FDG-PET nor amyloid imaging scan results will be released to the managing physician for 2 years.
89412008|NCT05059288|Experimental|Investigation Mask|Non invasive ventilation mask
88888558|NCT01434901|Experimental|Type 2 Diabetes Mellitus|Healthy individuals exhibiting plasma glucose levels greater than 150 mg/dL under fasting conditions OR greater than 199 mg/dl two hours after ingestion of 75-g of glucose.
88888559|NCT01434914|Active Comparator|verum|
88888560|NCT01434914|Placebo Comparator|Placebo|
88888561|NCT01434927||Colonoscopy outpatients|All patients referred to our Unit to undergo colonoscopy for any indication
89412009|NCT03502538|Experimental|Curaprox 5460 Ultra Soft|Brushing with a Curaprox Ultra Soft 5460 toothbrush for one minute timed without orientations about brushing techniques and without supervision
89412010|NCT03502538|Active Comparator|Oral-B Indicator Plus|Brushing with a Oral-B Indicator Plus toothbrush for one minute timed without orientations about brushing techniques and without supervision
89412011|NCT03100318|Experimental|FYU-981|
89412012|NCT03100318|Active Comparator|Benzbromarone|
89412013|NCT04463420|Experimental|Test Group|Intervention group: : Hydroxychloroquine 400 mg only on the first day / one naproxen 250 mg every 12 hours for 5 days / 500 mg azithromycin on the first day and 250 mg on the second to fifth days / 40 mg famotidine every 12 hours for 5 days / 25 mg prednisolone daily for 5 days / PHR160 spray one hour oral puff with Demyar ten times a day for ten days in a row, for ten days.
89412014|NCT04463420|Placebo Comparator|Control Group|Control group: Hydroxychloroquine 400 mg only on the first day / one naproxen 250 mg every 12 hours for 5 days / 500 mg azithromycin on the first day and 250 mg on the second to fifth days / 40 mg famotidine every 12 hours for 5 days Daily / 25 mg prednisolone daily for 5 days / placebo spray one hourly oral puff ten times a day for ten days in a row, for ten days
88888562|NCT01434940|Experimental|Alzheimer|Patients suffering of Alzheimer disease
88888563|NCT01434940|Experimental|Depression|Patients suffering from depression
88888564|NCT01434940|Experimental|Healthy|Healthy volunteers
89412015|NCT02311010|No Intervention|CYP 3 A 5 *3/*3 control group|CYP 3 A 5 *3/*3 control group will receive 0,20 mg/kg of Advagraf®
89412016|NCT02311010|Active Comparator|CYP 3 A 5 *3/*3|CYP 3 A 5 *3/*3 will receive 0,25 mg/kg of Advagraf®
88888565|NCT01434953|Experimental|Labeled|
88888566|NCT01434953|Active Comparator|Unlabeled|
88888567|NCT01434966|Experimental|Lumbopelvic Manipulation|The lumbopelvic joint manipulation (Grade V mobilization) will be performed on the ipsilateral side of the test limb. The participant will be passively side-bent towards and rotated away from the selected lumbopelvic region which is followed by the delivery of a posterior/inferior force through the opposite anterior superior iliac spine. If a cavitation is not heard or felt by the patient or clinician, the technique will be repeated. If the second attempt does not produce cavitation the procedure will be repeated on the contralateral side using similar methods. If cavitation is not heard or felt by the participant or clinician following the second attempt on the contralateral side, the participant will proceed with the assessment of quadriceps strength and activation as usual.
88888568|NCT01434966|Experimental|TENS- Spine|The TENS electrodes will be applied lateral to L1 and L2 and lateral to S5 and S1. The TENS unit will be set to deliver a continuous TENS biphasic pulsatile current at 150 Hz, with a phase duration of 150 microseconds. The TENS unit will be worn during all exercise testing and for the first 30 minutes of quadriceps force output and activation testing. After the 30 minute post-intervention measures (Post30) are obtained, the TENS unit will be turned off.
88888569|NCT01434966|Experimental|TENS- Knee|The TENS electrodes will be applied on the medial and lateral superior, as well as the medial and lateral inferior, borders of the patella. Care will be taken not to place TENS electrodes on the quadriceps muscles or muscles of the anterior leg. The TENS unit will be set to deliver a continuous TENS biphasic pulsatile current at 150 Hz, with a phase duration of 150 microseconds. The TENS unit will be worn during all exercise testing and for the first 30 minutes of quadriceps force output and activation testing. After the 30 minute post-intervention measures (Post30) are obtained, the TENS unit will be turned off.
88888570|NCT01434979||Controls|Active Duty,DoD Beneficiary, or civilian men and women between the ages of 18 and 45 years, with a waist circumference ≤ 39.4 inches (100 cm) will be asked to participate.
88888571|NCT01434979||Exertional Heat Illness / Stroke|Active duty men and women between the ages of 18 and 45 years will be asked to participate. They must have a clinically documented heat stroke within the last year; they will not be tested any sooner than six weeks following the heat stroke. Heat stroke for the purpose of this study is defined as: a syndrome of hyperthermia, physical collapse or debilitation, and encephalopathy as evidenced by delirium, stupor, or coma, occurring during or immediately following exertion or significant heat exposure.
88888572|NCT01434992||H. pylori gastritis|
88888573|NCT01435005|Active Comparator|High Volume|Participate in one year of high volume (300 minutes per week) aerobic exercise with free provision of a personal trainer, membership to an exercise facility, body composition assessment.
88888574|NCT01435005|Active Comparator|Moderate Volume|Participate in one year of moderate volume (150 minutes per week) aerobic exercise with free provision of a personal trainer, membership to an exercise facility, body composition assessment.
89412017|NCT02311010|Active Comparator|CYP 3 A 5 *1/*3|CYP 3 A 5 *1/*3 will receive 0,30 mg/kg of Advagraf®
89412018|NCT02311010|Active Comparator|CYP 3 A 5 *1/*1|CYP 3 A 5 *1/*1 will receive 0,35 mg/kg of Advagraf®
89412019|NCT02314286|Placebo Comparator|control|"After signing an informed consent form and filling a demographic and medical questionnaire, a randomization 1:1 will be carried. 50 women will be in the control arm. the group will be treated according to ACOG guidelines (Appendix). After the delivery, a small placenta sample will be collected.~Control group will be treated with placebo."
89412020|NCT02314286|Experimental|treatment|50 women will be in the treatment arm. the group will be treated according to ACOG guidelines (Appendix). After the delivery, a small placenta sample will be collected. In addition, following randomization experimental group will be treated with Rosuvastatin 40mg that will be administrated orally with or without food. Treatment will be carried within the first hour following delivery. Another dose will be given 24 hours after first administration. Control group will be treated with placebo.
89412021|NCT02317406|Active Comparator|Probiotics|Biostime probiotics sachet children's formula, 1.5g/d/sachet, administrated during the consumption of the first feeding-bottle of the day. Duration: 4 weeks
89412022|NCT02317406|Placebo Comparator|Probiotics simulation|Biostime probiotics sachet children's formula（placebo）, 1.5g/d/sachet, administrated during the consumption of the first feeding-bottle of the day. Duration: 4 weeks
89412023|NCT05061784||MEN-1 patients who underwent routine thymectomy during parathyroidecotmy|A case series was built after review of available literature by searching four databases (PubMed, Embase, Medline and Cochrane Library) for observational studies or case reports on routine prophylactic TCT for MEN-1 and the development of thymic carcinoids.
89412024|NCT03132194|Experimental|DPSG 7.5%|"DPSG 7.5% (Taro Pharmaceuticals USA)~Topical, twice daily on the face for 84 days."
89412025|NCT03132194|Placebo Comparator|Vehicle Gel|"Placebo product (Taro Pharmaceuticals Inc.)~Topical, twice daily on the face for 84 days."
89412026|NCT03132194|Active Comparator|Aczone|"dapsone 7.5~Topical, twice daily on the face for 84 days."
89412027|NCT05061628|Experimental|JS006 as Monotherapy|"JS006 as Monotherapy dose-escalation：5 proposed dose levels（18mg, 60mg, 180mg, 600mg, 1800mg).~JS006 as Monotherapy dose-extension：1 or 2 proposed dose levels, to be determined."
89412028|NCT05061628|Experimental|JS006 in combination with Toripalimab|"JS006 in combination with Toripalimab dose-escalation：2 or 3 proposed dose levels, to be determined.~JS006 in combination with Toripalimab dose-extension：1 or 2 proposed dose levels, to be determined.~JS006 in combination with Toripalimab indications expansion: 2 to 4 specific tumor types are selected for indication expansion after the combination dose-expansion is completed."
89005325|NCT01083316|Experimental|Single Arm - Investigational|"Induction:~Bortezomib (Velcade) 1.3 mg/m2/dose IV Days 1, 4, 8, 11 repeated every 21 days~Dexamethasone 20 mg PO/IV Days 1, 4, 8, 11 repeated every 21 days~Conditioning:~Bortezomib 1.0 mg/m2/dose will be administered on Days +6, -3, +1, + 4~Melphalan 70-100 mg/m2/day IV on days -2 and -1"
89412029|NCT05010616|Experimental|Three-dimensional digital simulation with fixed appliance|The records will be obtained at the first visit, which will be one week before placing brackets. At the second visit, the orthodontic appliances will be applied; then assessments will be taken after 15 minutes of showing the patient the digital simulation of their teeth alignment at the end of orthodontic treatment.
89412030|NCT02314442|Active Comparator|ALN-PCSSC|
89412031|NCT02314442|Placebo Comparator|Sterile Normal Saline (0.9% NaCl)|
89412032|NCT03614572|Experimental|Group MI|The structure and content of the active intervention programme will be developed and adopted on the basis of previous research on sleep educational programme and motivational interviewing techniques. The whole treatment package consists of 4 sessions of group therapy (n=6-8) followed by 3 week daily text reminders.
89412033|NCT03614572|No Intervention|Control group|Control group will no receive any intervention
89412034|NCT03501290|Other|Oral Nutritional Supplement Group|All patients will be in one group, receiving the active product, Oral Nutritional Supplement with 'Fortimel® Protein supplementation'
89412035|NCT05058586|Active Comparator|Conventional theraphy group|13 patients received twenty sessions of conventional therapy for four weeks
89412036|NCT05058586|Active Comparator|Anti gravity treadmill training|13 patients received twenty sessions of conventional therapy for four weeks and Alter-G training was performed 3 days/week for 4 weeks, with up to 30 min. of training per session.
89412037|NCT05058586|Active Comparator|Underwater walking therapy group|13 patients received twenty sessions of conventional therapy for four weeks and three sessions of aerobic exercise treatment of 45 minutes per week underwater
89412038|NCT03505268|Experimental|telemedicine intervention|The intervention group, in addition to usual care, will get 10 telemedicine interventions by a certified nurse and dietitian who both specialize in treatment of type 1 diabetes.
89412039|NCT03505268|No Intervention|usual care|Usual care consisted of visits to the diabetes center every three months and communication with their doctor by phone when needed.
89412040|NCT02311088|Experimental|Caffeine|Caffeine capsules. 200 mg twice daily orally for 7-10 days.
89412041|NCT02311088|Placebo Comparator|Placebo|Matching placebo capsules twice daily orally for 7-10 days.
89412042|NCT05058352|Experimental|HS269|Multiple doses of HS269 tablets
89412043|NCT02314676|Experimental|PEG-somatropin|
89412044|NCT03501212|Active Comparator|Interventional|EMLA group layer of 2.5 gr EMLA cream (standard adult dose) was applied to both wrists
89412045|NCT03501212|Placebo Comparator|Placebo|Placebo cream was applied to both wrists
89412046|NCT02317484||Ipragliflozin (SGLT2 inhibitor)|
88813980|NCT04347590|Experimental|Unblinded CGM|"CGM data will be unblinded, with Hypo/hyperglycemia alarms on. Data will be recorded from CGM every three hours and intervention to adequate glucose intake will be performed to keep glycemia in normal range (72-144mg/dl) if necessary."
88813981|NCT04347590|Other|Blinded CGM|Hypo/hyper alarms are off. CGM data will be blinded. Glucose intake will be adequate according to at least 2 capillary glycemic tests per day.
89412047|NCT02140866|Experimental|Hand Exercise|The intervention group will receive an exercise program for the hand/arm in combination with a compensatory intervention program (CIP).
88813982|NCT03402620|Active Comparator|four ampoules group|gonadotropin starting dose is 4 ampoules daily
88813983|NCT03402620|Active Comparator|six ampoules group|gonadotropin starting dose is 6 ampoules daily
88813984|NCT03003143|Experimental|Vigabatrin treatment group|
88813985|NCT03002987|Active Comparator|Intervention, education|Education of leaders (3 hours) in how to implement Active Pregnancy policy at their departements/workplaces
88813986|NCT03002987|No Intervention|control|as usual
89412048|NCT02140866|Active Comparator|Compensatory Intervention Program (CIP)|The control group will receive the Compensatory Intervention Program (CIP) only.
89412049|NCT03502460|Other|ORFALU|"Lung ultrasound consists of the application of a high-frequency ultrasound probe type Trans Thoracic Echography (ETT) on the anterior and lateral chest of the patient. Since air and bone do not pass through the US, it is the artefacts due to these structures that constitute ultrasound lung semiology.~Esophageal Doppler is a means of monitoring cardiac output measuring stroke volume (SV)."
89412050|NCT02141022|Experimental|PACR Program: Plasticity based, Adaptive Cognitve Remediation|PACR Program Use: To use PACR, the participant navigates to the PACR study web site. The participant then logs into the PACR (using a study provided screen name and study identification number). A game-like experience begins, where the participant is presented with games in a set order. Each game consists of targeted exercises that contain the core science stimuli and tasks. The scheduling mechanism ensures that a participant progresses through the exercises in a defined order, generally moving from more simple (early sensory processing) exercises to more complex (multimodal, cognitive control) exercises over the course of the three-month experience.
89412051|NCT02141022|Active Comparator|Ordinary Computer Games|Active Control Program Use (Ordinary Computer Games): The active control program is composed of 13 ordinary computer games matched to the PACR condition overall. This condition is designed to be a face-valid approach to cognitive remediation. The control condition is also designed to account for nonspecific treatment effects, including placebo response, interactions with research personnel, and experience with computers and computer-related activities, and any halo or expectation effect on study assessments.
88888575|NCT01435057|Active Comparator|endurance training|"Endurance training:~Supervised, twice a week, each training session consists of a 20 min warm up and cool down period and a minimum of 40min tread mill, rawing device or bicycle training.~During the study period of 24 months, we will perform an open randomized, prospective training intervention study comparing the effects of three times a week either strength or endurance training on reduction of visceral fat area as determined by MRI scans at the level of L4-L5."
89005326|NCT01083160||Non responders to other anti-TNF|Patients with lack of efficacy to infliximab or etanercept treated with adalimumab according to the routine clinical practice of the participating centers. A 40 mg dose was administered every other week for 24 weeks.
89005327|NCT01083121||Adalimumab|Participants who were prescribed with adalimumab per approved prescribing information of adalimumab in Korea.
89005328|NCT01082614|No Intervention|Standard fluid management|standard intraoperative fluid management as determined by usual monitoring and decision making applied by anesthesiology team
89005329|NCT01082614|Experimental|Goal directed therapy|Intraoperative fluid management guided by stroke volume variation determined by arterial pressure pulse wave contour analysis
89412052|NCT02642614|Experimental|BI 1026706 low dose|
89412053|NCT02642614|Experimental|BI 1026706 medium|
89412054|NCT02642614|Experimental|BI 1026706 high dose|
89412055|NCT02642614|Placebo Comparator|Placebo|
89412056|NCT03501134||Tumor treating fields|Patients diagnosed with WHO Grade IV malignant glioma who are approved and planned to use the NovoTTF device
89412057|NCT02781324|Experimental|Ultrasonic Bone Scalpel Group|Surgeons will use the ultrasonic bone scalpel, to their discretion, along with standard of care manual devices when performing the posterior spinal fusion.
89005330|NCT00208793|Experimental|Calcium|Calcium 2,000 mg/day as calcium carbonate in two divided doses with food
89005331|NCT00208793|Experimental|Vitamin D3|Vitamin D3 800 IU given as 400 IU twice daily with food over 6 months
89005332|NCT00208793|Experimental|Calcium and vitamin D3 combined|Calcium 2,000 mg (as calcium carbonate) + vitamin D3 800 IU given in equal divided doses twice daily with meals over 6 months
89412058|NCT02781324|Active Comparator|Standard of Care Group|Surgeons will use, to their discretion, only standard of care manual devices when performing the posterior spinal fusion.
89412059|NCT04435210|Experimental|Nifedipine arm|Participants in this arm will be pregnant women with severe hypertension who will receive nifedipine
89412060|NCT04435210|Experimental|Hydralazine|Participants in this arm will be pregnant women with severe hypertension who will receive hydralazine
89412061|NCT03501056|Experimental|cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
89412062|NCT03501056|Active Comparator|Cryotherapy & Activated CIK and bispecific antibody|the maximum tumor length≥2cm, use cryotherapy. the maximum tumor length<2 cm,Biological/Vaccine:Activated CIK and bispecific antibody CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
89412063|NCT03501056|No Intervention|conventional therapy|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
89412064|NCT03100084||I. Post Dates|"Pregnant women referred for clinical post term evaluation and/or labour induction.~Blood sampling."
88888576|NCT01435057|Active Comparator|strength training|"Strength training:~Supervised, twice a week, each training session consists of a 20 min warm up and cool down period and a minimum of 40min circle training~During the study period of 24 months, we will perform an open randomized, prospective training intervention study comparing the effects of two to three times a week either strength or endurance training on reduction of visceral fat area as determined by MRI scans at the level of L4-L5."
89005333|NCT00208793|Placebo Comparator|Placebo|
89005334|NCT00233883|Experimental|1|
89005335|NCT00233883|Active Comparator|2|
89412065|NCT03100084||II. Induction of Labour|"Pregnant women ≥37+0 GW (gestational week) referred for labour induction (any cause).~Blood sampling."
89412066|NCT03100084||III. All Outpatients|"Pregnant women ≥37+0 GW presenting for any medical reason at OUH outpatient clinic.~Blood sampling"
89412067|NCT03100084||IV. Diabetes in Pregnancy|Pregnant women ≥36+0 GW with pregestational or gestational diabetes. Blood sampling.
89412068|NCT03100084||V. Reduced Fetal Movements|"Pregnant women ≥37+0 GW with reduced fetal movements and/or referred due to reduced symphysis-fundal height.~Blood sampling."
89412069|NCT03100084||VI. Hypertensive Disorders in Pregnancy|"Pregnant women referred for preeclampsia (or other pregnancy induced hypertensive disorders) and/or suspected fetal growth restriction; longitudinal cohorts.~Blood sampling."
89412070|NCT03100084||VII. All Labour Admissions|All pregnant women ≥37+0 GW admitted for labour. Blood sampling.
89412071|NCT03502382|Other|radilogical|Radiological: standing antero-posterior full-length digital images of the lower extremities
89412072|NCT03292146|Experimental|Active Denosumab 60mg Injection|Denosumab 60mg injection at baseline study visit and 6 month study visit. Alendronate 70mg PO weekly starting at Month 12 through 24 months.
88888577|NCT01435070||Distal radius fracture|Patients aged 18 years and older with a fracture of the distal radius, within 3 cm of the radiocarpal joint
88888578|NCT01435083|Experimental|nocturnal polyuria patient with desmopressin MELT|
88888579|NCT01435096|Experimental|BN80927|
88888580|NCT01435109|No Intervention|Usual Care|
88888581|NCT01435109|Experimental|Patient Behavioral Intervention|Patients receive a 12-month intervention consisting of monthly phone calls focusing on exercise, weight management, and cognitive behavioral pain management.
88888582|NCT01435109|Experimental|Provider Intervention|Primary care providers receive patient-specific osteoarthritis information and treatment recommendations at the point of clinical care.
89412073|NCT03292146|Placebo Comparator|Placebo|Placebo injection at baseline study visit and 6 month study visit. Alendronate 70mg PO weekly starting at Month 12 through 24 months.
89412074|NCT03132506||paper-based patient-reported-outcomes|
89005336|NCT01081873||Advanced prostate cancer participants|Participants with advanced prostate cancer treated with Lucrin /Lucrin- Tri-depot (leuprolide) or any other treatment within local reimbursement guidelines.
89005337|NCT01081795|Experimental|Topiramate (JNS019) 50 mg|In titration period, topiramate 25 milligram (mg) tablet will be given once daily in evening orally for 7 days; then topiramate 25 mg tablet twice daily orally from Day 8 to Day 14; then topiramate 25 mg tablet twice daily along with matching placebo tablet once daily in the evening orally from Day 15 to Day 21; then topiramate 25 mg tablet along with matching placebo tablet twice daily orally from Day 22 to Day 28 and will be continued further for 18 weeks in the fixed dose period.
89005338|NCT01081795|Experimental|Topiramate 100 mg|In titration period, topiramate 25 mg tablet will be given once daily in the evening orally for 7 days; then topiramate 25 mg tablet twice daily orally from Day 8 to Day 14; then topiramate 25 mg tablet twice daily (1 tablet in the morning and 2 tablets in the evening) orally from Day 15 to Day 21; then 2 topiramate 25 mg tablets twice daily orally from Day 22 to Day 28 and will be continued further for 18 weeks in the fixed dose period.
89005339|NCT01081795|Placebo Comparator|Placebo|In titration period, matching placebo tablet will be given once daily in evening orally for 7 days; followed by matching placebo tablet twice daily orally from Day 8 to Day 14; followed by matching placebo tablet twice daily (1 tablet in the morning and 2 tablets in the evening) orally from Day 15 to Day 21; followed by 2 matching placebo tablets twice orally from Day 22 to Day 28 and will becontinued further for 18 weeks in the fixed dose period.
89005340|NCT04710186||Male patients with PAD|The cohort was built to collect information about the role of androgen receptor, insulin receptor and Insulin-like Growth Factor 1 Receptor (IGF-IR) expression in patients with peripheral artery disease referred to Vascular Surgeon Specialist.
89005341|NCT00234000|Experimental|Arm 1|see description in intervention
89005342|NCT00209105||1|Participants who have experienced early-life trauma will undergo a series of diagnostic tests.
89005343|NCT00209144|Experimental|Angioplasty with Insulin|Coming in with acute infarct and received angioplasty with intensive insulin therapy
89005344|NCT00209144|No Intervention|Angioplasty w/o Insulin|Coming in with acute infarct and received angioplasty
89005345|NCT00234156|Active Comparator|renal disease|"High fat diet: The composition will be: 35% of energy as fat, 50% carbohydrate, 15% protein (~1.3 g/kg), sat:mono:poly 1:3:1, cholesterol 200 mg/d, 30% starch,15% sugar, 3% fructose, and 25 gm fiber/d. This relatively high fat diet, which falls within the recommendations by the National Kidney Foundation for hemodialysis patients, will suppress fatty acid synthesis in normal volunteers.~Fructose in 360 ml water will be orally administered as 1.4 g/kg (~100 g or 400 kcal for a 70 kg person), divided into 30 mL (1 ounce) doses given every 1/2h for 6 hours."
89005346|NCT00234156|Active Comparator|normal|"High fat diet: The composition will be: 35% of energy as fat, 50% carbohydrate, 15% protein (~1.3 g/kg), sat:mono:poly 1:3:1, cholesterol 200 mg/d, 30% starch,15% sugar, 3% fructose, and 25 gm fiber/d. This relatively high fat diet, which falls within the recommendations by the National Kidney Foundation for hemodialysis patients, will suppress fatty acid synthesis in normal volunteers.~Fructose in 360 ml water will be orally administered as 1.4 g/kg (~100 g or 400 kcal for a 70 kg person), divided into 30 mL (1 ounce) doses given every 1/2h for 6 hours."
89005347|NCT00209222|Active Comparator|1|induction: R-CHOP consoldiation : TBI/Cyclo
89005348|NCT00209222|Experimental|2|induction: R-CHOP/DHAP consolditaion: TBI/TAM
89005349|NCT00209261|Active Comparator|1|
89005350|NCT00209261|Active Comparator|2|
89005351|NCT00237549|Experimental|Intervention|The 334 general practices in Denmark, United Kingdom and the Netherlands have been randomised to screening for diabetes followed by routine care (RC group) according to national guidelines, or screening followed by multifactorial treatment (IT group).
89192591|NCT06146426|No Intervention|Conventional diet|Patients in this group will receive the existing standard (conventional) post-operative diet regimen that is sips of water on the day of surgery and initiation of solid oral diet on next day (post-operative day 1)
89192592|NCT06146387|Experimental|Investigational Formula|"Feihe Investigational Formula~Contains 2 kinds of HMOs~5 kinds of phospholipid content reached the level of breast milk~DHA&ARA reaches the content and proportion of breast milk in China~Comprehensive nutrition: OPO, probiotics, lactoferrin, CPP, nucleotide, choline, inositol, taurine, L-carnitine, GOS, lutein"
89192593|NCT06146387|Active Comparator|Control Formula|Control formula contains comparable macronutrients and micronutrients, but does not contain HMO, DHA and ARA.
89192594|NCT06146387|Other|Breastfeeding|breastmilk-feeding
89192595|NCT06146361|Experimental|COVID-19 Group Problem Solving|
89192596|NCT06146361|Active Comparator|Standard of Care|
89192597|NCT06146361|Experimental|Group Problem Solving Plus Booster Session|
89192598|NCT06146309|Experimental|Patients with unilateral BRVO|
89192599|NCT06146309|No Intervention|Healthy individuals|
89192600|NCT06146296|Experimental|Intra-epidermal Vitamin C injection|
89192601|NCT06146296|Active Comparator|Oral Vit-C supplement|
89412075|NCT03132506||on web-based patient-reported-outcomes|
89412076|NCT02144376|Placebo Comparator|Maltodextrin|7 days without use of laxatives other than standardised rescue therapy 7 grams maltodextrin taken 3 times daily, at least 4 hours apart, for up to 7 days
89192602|NCT06146296|No Intervention|Control group|
89412077|NCT02144376|Active Comparator|Ispaghula|7 days without use of laxatives other than standardised rescue therapy 7 grams ispaghula/ psyllium taken 3 times daily, at least 4 hours apart, for up to 7 days
89412078|NCT03249532|Active Comparator|standard hemodialysis|prescription of dialysate temperature: 36.5 degrees celsius prescription of convection volume: 0 Liters (L)
89412079|NCT03249532|Active Comparator|cool hemodialysis|prescription of dialysate temperature: 35.5 degrees celsius prescription of convection volume: 0 L
89412080|NCT03249532|Active Comparator|low volume hemodiafiltration|prescription of dialysate temperature: 36.5 degrees celsius prescription of convection volume: 15 L
88888583|NCT01435109|Experimental|Patient and Provider Interventions|Patients receive a 12-month intervention consisting of monthly phone calls focusing on exercise, weight management, and cognitive behavioral pain management; primary care providers receive patient-specific osteoarthritis information and treatment recommendations at the point of clinical care.
88888584|NCT01435135|Experimental|Group I|ALVAC-HIV + AIDSVAX B/E or ALVAC-HIV placebo + AIDSVAX B/E placebo at Weeks 0 and 24
88888585|NCT01435135|Experimental|Group II|AIDSVAX B/E or AIDSVAX B/E placebo at Weeks 0 and 24
88888586|NCT01435135|Experimental|Group III|ALVAC-HIV or ALVAC-HIV placebo at Weeks 0 and 24
88888587|NCT01435148|Experimental|Stimulation of SGC then VACNAC targets|Stimulation of the subgenual cingulate cortex (SGC) target will take place first, followed by stimulation of the ventral anterior capsule nucleus accumbens target (VACNAC) if no clinical response after a minimum of 4 months.
88888588|NCT01435148|Experimental|Stimulation of VACNAC then SGC targets.|Stimulation of the ventral anterior capsule nucleus accumbens target (VACNAC) will take place first, followed by stimulation of the subgenual cingulate cortex target (SGC) if no clinical response after a minimum of 4 months.
89005352|NCT00209378|Active Comparator|heparin|Citrate regional anticoagulation is compared with standard systemic heparinization.
89192603|NCT06146244||Native bone|the evolution of the SSI and its change after 3 months of placing the implant in native bone in the antral area
89192604|NCT06146244||Regenerated Bone|the evolution of the SSI and its change after 3 months of placing the implant in regenerated bone in the antral area
89192605|NCT06146205|Active Comparator|Direct lateral approach|
89192606|NCT06146205|Experimental|Spaire approach|
89192607|NCT06146192||Colchicine|
89192608|NCT06146192||No colchicine|
89412081|NCT03249532|Active Comparator|high volume hemodiafiltration|prescription of dialysate temperature: 36.5 degrees celsius prescription of convection volume: 25 L
89412082|NCT02254122|Experimental|BEA 2180 BR|
89005353|NCT00209378|Active Comparator|Citrate|regional anticoagulation with citrate containing replacement solution
89192609|NCT06146166|Experimental|Oral herbal supplement|Oral supplement containing an herbal blend
89192610|NCT06146166|Placebo Comparator|Oral Placebo Supplement|Oral placebo supplement
89192611|NCT06146140|Experimental|Oral Herbal Supplement|Oral supplement containing an herbal blend
89192612|NCT06146140|Placebo Comparator|Oral Placebo Supplement|Oral placebo supplement
89192613|NCT06146127||Combined hepatocellular cholangiocarcinoma|
89412083|NCT02254122|Placebo Comparator|Placebo|
89192614|NCT06146127||hepatocellular carcinoma|
89192615|NCT06146127||cholangiocarcinoma|
89192616|NCT06146114||experimental group|"Prostate cancer patients confirmed by histopathology in our hospital from January 2018 to July 2023;~Men aged ≥ 18 years old;~The expected survival time is greater than 12 weeks;~The KPS functional status score is greater than 60, and the ECOG status score is 0-2 points;~The subjects voluntarily joined this study, signed an informed consent form, had good compliance, and cooperated with follow-up."
89192617|NCT06146062|Experimental|Intervention|"Final product is a MSC solution at the concentration of 2.106/kg in 150 mL of NaCl 0.9% and human albumin 0.5%, conditioned aseptically and identified for IV administration.~3 injections one week apart."
88888589|NCT01435161|Active Comparator|Nifedipine|Patients in arm 1 receive Nifedipine;
88888590|NCT01435161|Active Comparator|Telmisartan|Arm 2 receive telmisartan
88922030|NCT05956002|Experimental|Sequence 3|Single oral dose of etrasimod 2 mg mini tablets mixed with chocolate pudding under fasted conditions (Test 2). Followed by single oral dose of etrasimod 2 mg clinical IR tablet under fasted conditions (Reference).followed by single oral dose of etrasimod 2 mg mini tablets mixed with water under fasted conditions (Test 3). Followed by single oral dose of etrasimod 2 mg mini tablets mixed with applesauce under fasted conditions (Test 1) Followed by single oral dose of etrasimod 2 mg mini tablets mixed with yogurt under fasted conditions (Test 4)
89192618|NCT06146062|Placebo Comparator|control|The placebo will be a solution of NaCl 0.9% 3 injections one week apart.
89192619|NCT06146036|Experimental|HIIT snacks|3 x 6×1 minute cycling intervals at 90% at HRmax
89192620|NCT06146036|Experimental|Sprint snaks|3×20-second 'all-out' cycling with 1-4 hours recovery between sprints
89192621|NCT06146036|Experimental|Control|No exercise. Rest.
89192622|NCT06146023|Active Comparator|Conventional|Conventional microsurgery with conventional microsurgical instruments and conventional surgical microscope
89192623|NCT06146023|Experimental|Robotic|Robot-assisted microsurgery with microsurgery robot and robotic microscope
89192624|NCT06146010||german leptomeningeal disease register|The aim of the leptomeningeal disease register is to establish an internet-based cancer register in which patients with leptomeningeal disease are recorded at the time of diagnosis and after appropriate information and consent to data collection. Due to the rapid progression of the disease and potential rapid deterioration, inclusion must take place at the time of diagnosis. The course of the disease in individual patients is then documented retrospectively on the basis of routine clinical care data for the entire duration of the study or until the death of the participating patients.
89412084|NCT02314754|Experimental|71-77 days gestational age|Women whose pregnancies are estimated to have a gestational age of 71-77 days.
89412085|NCT02314754|No Intervention|64-70 days gestational age|Women whose pregnancies are estimated to have a gestational age of 64-70 days.( Women in this arm receive the standard of care for medical termination of pregnancy in the stated gestational age range).
89412086|NCT02144454|Active Comparator|Meal rich in saturated fats|Subjects are asked to consume a breakfast (0 min) and lunch (330 min) rich in saturated fats
89412087|NCT02144454|Experimental|Meal rich in monounsaturated fats|Subjects are asked to consume a breakfast (0 min) and lunch (330 min) rich in monounsaturated fats
89412088|NCT02144454|Experimental|Meal rich in n-6 polyunsaturated fats|Subjects are asked to consume a breakfast (0 min) and lunch (330 min) rich in n-6 polyunsaturated fats
89412089|NCT02317640|Active Comparator|Stand Training Alone|Standing training will be prescribed 3 days/week (1.5 hours/sessions) for 60 sessions. All individuals randomized to stand training will train with BWST with manual assistance and will undergo a stand evaluation. During the evaluation the participants will be placed on the treadmill in an upright position and suspended in a harness by an overhead cable (i.e. BWST). A trainer will be positioned to assist the participant while standing and to provide manual assistance if needed. The amount of BWS and level of assistance given for each body segment will be recorded. The BWS level at which the participant can independently support good standing posture will also be recorded. Standing time while on treadmill and overground will be recorded daily as part of the training sessions.
89412090|NCT02317640|Experimental|ST with placebo or testosterone|Stand Training as described above with Placebo or testosterone Gel applied by a pump. After a baseline testing period, TRT will begin in the treatment groups by application of a daily dose of 40.5 mg of testosterone or placebo gel. The gel is to be applied to the upper arms and shoulders and is absorbed and eliminated over the course of a day. To ensure proper dosing serum T concentration will be assessed at screening, baseline, 2 weeks, 1 month and 3 month time points. As such, follow-up with the participant will be necessary to determine the correct replacement dose of TRT, and adjustment of dose if needed, (i.e. 40.5 mg up to 81 mg of gel). If serum T levels are not within normal range at the 2 week time point, the dose will be increased in increments of 20.25 mg up to 81 mg.
89412091|NCT02317640|Experimental|ST with Placebo or Testosterone and ES|"Stand Training described above with Placebo or testosterone gel applied by a pump. Electrical stimulation will be applied via bifurcated leads and self-adhesive reusable surface electrodes. The electrodes will be applied over the motor points (both legs) on the following muscles: gluteus maximus (GL), rectus femoris (RF), biceps femoris (BF), gastrocnemei (GC), and anterior tibialis (TA) of both legs. Two electrodes will be used for each muscle. One RT300 portable stimulator (Restorative Therapies, Inc., Baltimore, MD) will be used to induce the electrical stimulation with 10 sets of electrodes for stimulation."
89412092|NCT02317640|Experimental|ST with ES|Stand Training as described above in Stand Training alone and Electrical Stimulation as described above in ST with Placebo or Testosterone and ES.
89412093|NCT05058118|Experimental|FL058|a single ascending dose (SAD) of intravenous (IV) FL058(50mg~2000mg)
89412094|NCT05058118|Placebo Comparator|Placebo|FL058 Placebo
89412095|NCT02144532|Experimental|Patients with EDS hypermobility type|Patients with EDS hypermobility type wearing compression garment then compression garment removal
89412096|NCT03500978|Experimental|Peer CBT Intervention|Women allocated to the peer-specialist delivered CBT intervention group will be mailed an intervention workbook (CBT exercises) and have their first telephone-based intervention session scheduled. The CBT intervention group will receive 8 telephone-based CBT intervention sessions (over 9 weeks) delivered by peer specialists. Each session will last up to 30 minutes.
89412097|NCT03500978|No Intervention|Control|Women allocated to the observation-only control group will not receive any intervention.
89412098|NCT02716948|Experimental|Treatment (nivolumab, stereotactic radiosurgery)|Patients receive nivolumab IV over 60 minutes on day 1. Patients then undergo stereotactic radiosurgery on day 8 per standard of care. Courses with nivolumab repeats every 14 days in the absence of disease progression or unacceptable toxicity.
89412099|NCT03500900|Experimental|Vildagliptin|DPP-4 inhibitor, acute administration (50 mg.)
89412100|NCT03500900|Placebo Comparator|Placebo|Placebo treatment, acute administration
89412101|NCT02144688|Experimental|Change in ARVs to improve cognition|Change in ARVs to improve cognition: Personalized change in antiretrovirals will be based on CSF analysis
89412102|NCT02320760|Experimental|Physical activity on prescription|
89412103|NCT02320760|No Intervention|Ordinary care|
89412104|NCT05046652||One bag of convalescent plasma therapy|Four patients had been administered one dose of 200 mL CP with an antibody titer of 1:320.
89412105|NCT05046652||Two bags of convalescent plasma therapy|Four patients had been administered two doses of 200 mL CP with an antibody titer of 1:320.
89412106|NCT04463186|Experimental|Experimental|subjects participated in three experimental trials: Static stretching for 2 minutes (SS2), static stretching for 4 minutes (SS4), and static stretching for 8 minutes (SS8). Strength was measured before (pre), immediately after (post), and at 10- and 20- minutes post stretching.
88888591|NCT01435187||Infant Pulmonary Function Testing (iPFT)|A standardized method of performing infant PFTs using the raised volume rapid thoracoabdominal compression (RVRTC) technique will be used. This test will be performed on infants at one year (corrected age). The target sample size of 180 studies will represent the largest number of RVRTC PFTs in the preterm population and will enhance study of the relationship between lung function at 1 year of age and clinical and biologic factors associated with respiratory disease. Although the primary PFT measures will be derived from RVRTC, V'maxFRC, respiratory system compliance (Crs) and resistance (Rrs) will also be measured because these can be easily obtained. Crs and Rrs will be obtained using the single breath occlusion method.
88888592|NCT01435200|Experimental|Intravenous iron|Iron sucrose 200 mg intravenous infusion in 15 minutes
89437565|NCT03621670|Experimental|MenB+PCV Group|Approximately 800 subjects enrolled in this group will receive rMenB+OMV NZ (Bexsero) concomitantly with PCV13 (Prev-nar13) and other RIV (Pediarix, Hiberix, Rotarix, M-M-R II, Varivax) at 2, 4, 6 and 12 months of age. Subjects who have received 3 PCV13 doses before 12 months of age but have not received their fourth booster dose will either receive PCV13 or PCV20 at 12 months of age (Visit 5).
88888593|NCT01435200|Placebo Comparator|Oral iron|Ferrous fumarate 200 mg oral three times a day
88888594|NCT01435213|Experimental|Atipamezole|
88888595|NCT01435213|Experimental|Atomoxetine|
88888596|NCT01435213|Experimental|Ketamine|
88888597|NCT01435213|Experimental|Insulin-induced hypoglycemia|
88888598|NCT01435213|Experimental|Cold pressor test|
88888599|NCT01435213|Experimental|Placebo|
88888600|NCT01435239|Experimental|resting volume group|
88888601|NCT01435239|Active Comparator|maximum volume group|
88888602|NCT01435252|Experimental|Arm A|Patients will be treated with chemoradiation in combination with concurrent cetuximab. Two weeks after end of chemoradiation the consolidation phase will start and patients will receive biweekly consolidation cetuximab, maximally 6 infusions over 12 weeks.
88888603|NCT01435252|Experimental|Arm B|Patients will be treated with chemoradiation in combination with concurrent cetuximab.
89412107|NCT02141100|Experimental|6-thioguanine, 6-mercaptopurine and methotrexate|"This is the only treatment arm; all eligible patients will receive standard methotrexate/6-mercaptopurine (6MP/MTX) maintenance therapy supplemented with 6-thioguanine (6TG).~Patients are enrolled when they have 12 to 3.5 months remaining of their maintenance therapy. After dose reduction in 6MP to 2/3 of the current dose 6TG therapy is initiated with a starting dose of 2.5 mg/m2/day. The 6TG dose will hereafter be increased at 2.5 mg/m2/day every 14 days until a max. of 12.5 mg/m2/day is reached or until the thiopurine metabolite profile (Ery-TGN/Ery-MeMP) has been increased by at least a factor 5."
89412108|NCT05057650|Experimental|Intervention|Vegan food for 5 weeks: approximately 50 participants volunteered for the intervention.
89412109|NCT04462718|Active Comparator|CONTROL GROUP:|You will be provided exclusively therapeutic exercises protocol to develop in the home setting that you must perform following a daily activity for three weeks.
89412110|NCT04462718|Experimental|EXPERIMENTAL GROUP|"After the initial evaluation, the first 10 treatment sessions will be developed at the rate of five daily sessions in the first week, three sessions on alternate days in the second week and two sessions on alternate days in the third week (3 weeks in total), applying the monopolar capacitive diathermy with radiofrequency in the anterior aspect of the knee, in dynamic application in one of the members: affect or randomized (uni or bilateral pathology, respectively). This diathermy will be combined with a therapeutic exercise program supervised by a Physiotherapist.~The treatment is administered with a pulsatile short-wave equipment and inductive electrodes of 100 W peak power, with a frequency of application of twice daily with a dose submitis (grade I), for 10 min, with a frequency of repetition of the impulses of 46 Hz and a pulse duration of 0.2 ms."
89412111|NCT02141178|Active Comparator|Bupivacaine|Patients will received 0.5% Bupivacaine subcutaneously for local anesthesia during surgery
89412112|NCT02141178|Experimental|Exparel|Patients will received Exparel subcutaneously for local anesthesia during surgery
89005354|NCT00234273|Experimental|Therapeutic education combining dietary and rehabilitation|Therapeutic education combining dietary and rehabilitation (APA)
89412113|NCT05057338|Experimental|CoreDISTparticipation|"a) at the MS-OP clinic, in addition to the regular consultations, the patient will have a structured digital conversation with the MS-nurse addressing work related issues and a session with a physiotherapist exploring possibilities for change in balance and walking; b) in the municipality, a physiotherapist will continue exploration of improvements, followed by four weeks of GroupCoreDIST focusing on balance, walking and physical activity and conducted in groups of 3-5 individuals with MS and led by a physiotherapist.~To promote participation in employment, a structured digital meeting between each patient, the MS-nurse, the patient's employer, and the physiotherapist will take place; followed by c) four weeks of outdoor group based exercises and physical activity led by a physiotherapist, complemented with an evaluation form regarding employment and physical activity."
89412114|NCT05057338|Active Comparator|Standard care|The control group will receive the usual consultations at the MS-OP clinic including exploration of possibilities for change in balance and walking together with physiotherapist at the MS-OP clinic. The control group will furthermore follow standard care (their usual follow-up) in the municipality.
89412115|NCT02314832|Active Comparator|Continuous femoral nerve block|patients receiving continuous femoral nerve block for analgesia after total knee arthroplasty
89412116|NCT02314832|Active Comparator|adductor canal block|adductor canal block group will receive adductor canal block for analgesia after TKA
89412117|NCT02141256|Experimental|Protein enriched products|Protein enriched products will be given to elderly residents of a care home for 10 days. Does this lead to an increased protein intake or do elderly compensate for the extra amount of protein?
89412118|NCT05057104||CK-SBRT with TACE group|
89412119|NCT05057104||Conversion hepatectomy after CK-SBRT plus TACE|
89412120|NCT03500822|Experimental|Metronome-paced tachypnea|Dynamic hyperinflation by the method of metronome-paced tachypnea.
89412121|NCT03500822|Experimental|Exspiratory-stenosis breathing|Dynamic hyperinflation by the method of expiratory-stenosis breathing.
89412122|NCT02141412|Active Comparator|Group I|Patients in Group I will receive dexmedetomidine 0.25 µg/kg IV (over 10 min) at closure of sevoflurane
89412123|NCT02141412|Active Comparator|Group II|Patients in Group II will receive dexmedetomidine 0.5 µg/kg IV (over 10 min) at closure of sevoflurane
89412124|NCT02141412|Active Comparator|Group III|Patients in Group III will receive dexmedetomidine 1 µg/kg IV (over 10 min) at closure of sevoflurane
89412125|NCT02141412|Placebo Comparator|Group IV|Patients in Group IV will receive same volume of normal saline at closure of sevoflurane
89412126|NCT03098992|Active Comparator|Fotona Dynamis Er:YAG Laser System|Active treatment with Fotona Dynamis Er:YAG Laser System
89412127|NCT03098992|Sham Comparator|Fotona Dynamis Er:YAG Laser System with Sham handpience|Sham treatment with a sham handpiece and parameter presentations masked
89412128|NCT04463264|Experimental|NTX active treatment|Intervention: NTX (500 mg every 6 hours for 14 days) orally with food (P.O.).
89412129|NCT04463264|Placebo Comparator|Intervention: placebo|Placebo (1 tablet every 6 hours for 14 days) orally with food (P.O.).
89412130|NCT03210558|Active Comparator|Group A|Testosterone cream 1% (Andro-Feme® )
89412131|NCT03210558|Placebo Comparator|Group B|Placebo cream
89412132|NCT05060224|Experimental|Low Level Laser|EasyLaser: Low Level Laser 808 nm and 500 mW. The first four treatments where planned as two treatments per week. The remaining six treatments where planned as once a week.
89412133|NCT02317718||Normal vitamin D levels group|MORE THAN 20 NG/ML VITAMIN D LEVELS
89412134|NCT02317718||Deficient Vitamin D GROUP|LESS THAN 20 NG/ML LEVELS
89412135|NCT03502226|Experimental|Intervention group|Received tailored feedback regarding sexual health risks
89412136|NCT03502226|No Intervention|Control group|Did not receive tailored feedback.
89412137|NCT05036824||COVID-19 patients|"Patients admitted to hospital with COVID-19, PCR+ SARS-CoV-2 infection administered thromboprophylaxis with tinzaparin.~Dosage: intermediate or therapeutic dose Frequency of tinzaparin administration: once daily Duration: Unknown"
89412138|NCT03544476|Experimental|Mobile phone TB treatment support app|Daily use of the mobile phone TB treatment support app plus usual care. Participants will be asked to self-report daily TB medication administration, side-effects when applicable, and complete the direct adherence paper-based test randomly on 3-4 days of the week during the intensive treatment phase (first two months) and then 1-2 times per week during the maintenance phase (about month 3-6).
89412139|NCT03544476|Active Comparator|Usual care|Usual care consists of outpatient treatment management from the time of diagnosis (unless symptoms are severe and hospitalization is recommended), routine clinical and laboratory tests, and follow-up appointments determined by the clinician. In general, patients receive 1-2 month's supply of medication and are asked to return monthly for follow-up.
89412140|NCT03500666|Experimental|Robot lateral neck lymph node dissection|Robot neck lateral lymph node dissection was performed in patients with thyroid cancer and lateral cervical lymph node metastasis.
89412141|NCT03500666|Experimental|Total endoscopic lateral cervical lymph node dissection|Patients with thyroid cancer and lateral cervical lymph node metastases underwent total endoscopic neck dissection.
89412142|NCT05045560||antenatal diagnosis of anorectal malformation|Groupe 1 : antenatal diagnosis of anorectal malformation
89412143|NCT05045560||postnatal diagnosis of anorectal malfiormation with associated anomalies on antenatal ultrasound|Groupe 2 : postnatal diagnosis of anorectal malfiormation with associated anomalies on antenatal ultrasound
89412144|NCT05045560||postnatal diagnosis of anorectal malformation with anormal antenatal ultrasound|Groupe 3 : postnatal diagnosis of anorectal malformation with anormal antenatal ultrasound
89412145|NCT04462250|Active Comparator|Control|Subjects will use the smartphone app to manage use of prescribed opioid medications to earn points but there will be no reward provided.
89412146|NCT04462250|Active Comparator|Contingency Management - Virtual Pet|Subjects will use the smartphone app to manage use of prescribed opioid medications to earn points, which can be used in the care of a virtual pet.
89412147|NCT04462250|Active Comparator|Contingency Management - Monetary|Subjects will use the smartphone app to manage use of prescribed opioid medications to earn points, which will be paid out at the end of the one-week trial in the form of a monetary reward.
89412148|NCT03095560|Experimental|Semi-immersive virtual training with shadow (S-IVTS)|All the participants underwent a neurocognitive-rehabilitative training consisting of 24 sessions of BTsN. Each treatment session lasted 45 minutes, and was repeated three times a week for 8 weeks. in the BTsN device used in the S-IVTS group the projector is located behind the patient, thus the shadow of the patient is projected on the screen.
89412149|NCT03095560|Experimental|Semi-immersive virtual training without shadow (S-IVT)|All the participants underwent a neurocognitive-rehabilitative training consisting of 24 sessions of BTsN. Each treatment session lasted 45 minutes, and was repeated three times a week for 8 weeks. in the BTsN device used in the S-IVT group the projector is located in front of the patient and the shadow is not visible.
89412150|NCT02315222|Active Comparator|Test|Dietary Supplementation
89412151|NCT02315222|Placebo Comparator|Control|Placebo Supplementation
89412152|NCT02144766|Experimental|Ropivacaine|caudal block with 1 ml/kg of ropivacaine 0.2%
89412153|NCT02144766|Placebo Comparator|saline|caudal block with 1 ml/kg of saline
89412154|NCT05035966||Prediabetes|In the case-control study, prediabetes was diagnosed according to the diagnostic criteria recommended by the WHO in 1999. Prediabetes was defined as impaired fasting glucose (FPG ≥6.1 mmol/L and <7.0 mmol/L, and 2-h post-glucose load <7.8 mmol/L) and/or impaired glucose tolerance (FPG <6.1 mmol/L, and 2-h post-glucose load ≥7.8 mmol/L and <11.1 mmol/L). In the nested case-control study, new-onset prediabetes was defined as FPG ≥6.1 mmol/L and <7.0 mmol/L.
89412155|NCT05035966||Healthy control|In the case-control study, healthy control was defined as FPG <6.1 mmol/L and 2-h post-glucose load <7.8 mmol/L. In the nested case-control study, healthy control was defined as FPG <6.1 mmol/L.
88813987|NCT03402542||Cholecystectomy|Patients with a symptomatic vesicular lithiasis, having undergone cholecystectomy during a scheduled hospitalization in the CHU Brugmann Hospital between May 2016 and November 2017.
89412156|NCT03502304|Active Comparator|Control group|No-exercise
89412157|NCT03502304|Experimental|Endurance training plus resistant training|To concurrent training (endurance training plus resistant training, RT) program will be use cycle ergometers adapted for obese adults (OXFORDTM, model BE2601, OXOFORD Inc, Santiago, Chile) were used. Prior to the CT intervention, all subjects were familiarized (during 3 sessions) with the training protocols. The CT intervention included 3 weekly sessions of both ET and RT. The core part of each session included RT followed by ET exercises (for 50 and 30 minutes, respectively) and was preceded and followed by a 5-minute warm-up and cool-down with callisthenic movements.
89412158|NCT03498482|Experimental|FORNET|During FORNET, the client, with the assistance of the therapist, constructs a chronological narrative of his or her entire life with a focus on exposure to traumatic stress and committed violence. Empathic understanding, active listening, congruency and unconditional positive regard are key components of the therapist's behavior. The therapist asks in detail for the client's emotions, cognitions, physiological reactions, and sensory informations during traumatic and aggressive events to link them to an autobiographical context, namely time and place. In total the individuals receive 8 sessions of FORNET, every session lasting between 1.5 and 2 hours depending on the needs of the participant.
89412159|NCT02144844|Experimental|Insight-Plus Cognitive Behavioral Intervention|Insight-Plus is a 6-session, manualized, cognitive behavioral intervention (CBI) culturally tailored for a diverse group of rural low-income women at low and high risk for antepartum depression.
89412160|NCT02144844|No Intervention|Treatment as Usual (TAU)|Treatment as Usual (TAU) Control
89412161|NCT03498404|Experimental|Photodynamic Therapy and SRP|"Procedure/Surgery: Photodynamic Therapy After a surgical access, the periodontal pockets of teeth selected to receive antimicrobial photodynamic therapy (aPDT) will be irrigated with distilled water. Shortly thereafter, the dye will be applied (phenothiazine hydrochloride- 10mg/mL) from the bottom of the pocket. After 1 minute, irrigation will be performed with distilled water to remove the excess of dye. The stained area will be irradiated with a diode laser (660 nm and a 60 mW/cm²). Six sites per tooth under treatment will be irradiated (10 seconds/ site). Teeth with furcation lesion will increase over 60 seconds into the lesion. Before the application, the supragingival plaque will be removed.~Treatment with TFDa in the Test Group maintained the protocol of applications in the periods of 2, 7 and 14 days post-surgical intervention."
89412162|NCT03498404|Sham Comparator|SRP and Sham Photodynamic Therapy|Procedure/Surgery: Sham Photodynamic Therapy After a surgical access, the periodontal pockets of teeth selected will receive a simulation of antimicrobial photodynamic therapy (aPDT): irrigation with distilled water and simulated laser application. Before the application, the supragingival plaque will be removed.
89412163|NCT05056558|Experimental|Baricitinib|Continued SOC together with oral 4 mg Baricitinib from day 1 to day 14
89412164|NCT05056558|Placebo Comparator|Placebo|Continued SOC according as mentioned in operational definition in the protocol
89412165|NCT02317796|Placebo Comparator|Placebo|
89412166|NCT02317796|Active Comparator|100 mg q.d.|
89412167|NCT02317796|Active Comparator|100 mg b.i.d.|
88888604|NCT01435278|Active Comparator|Glucosanol|2 tablets 3 times a day
88888605|NCT01435291|Experimental|Advagraf|
88888606|NCT01435291|Active Comparator|Prograf|
88888607|NCT01435317|Experimental|standard|Standard treatment with the ANM T30 CR®-System
89412168|NCT02317796|Active Comparator|200 mg q.d.|
89412169|NCT02317796|Active Comparator|200 mg b.i.d.|
88888608|NCT01435330|Experimental|BVS857|
88888609|NCT01435330|Placebo Comparator|Placebo|
88888610|NCT01435395|Experimental|Therapy|Therapy with temozolomide, bevacizumab and bortezomib
88888611|NCT01435434|Experimental|sepax, ignite, fracture healing|the mesenchymal cells will be separated by sepax separation system and demineralized bone matrix will be done using IGNITE INJECTABLE REPAIR GRAFT
88888612|NCT01435447|Experimental|FLu-Bu-Cy|Patients received Fludarabine and iv Busulfan and post-infusion Cyclophosphamide as conditioning
88888613|NCT01435473||Children undergoing heart surgery|The study will follow children undergoing cardiac surgery at The Hospital for Sick Children from pre-consultation, throughout surgery, recovery and post-operative follow-up
88888614|NCT01435486|Active Comparator|caffeine Citrate|
88888615|NCT01435486|Placebo Comparator|Normal saline|
88888616|NCT01435499|Experimental|Cohort A|Cohort A will receive four doses of vaccine, each containing 5E7 melanoma GVAX cells.
88888617|NCT01435499|Experimental|Cohort B|Cohort B will receive four doses of vaccine, each containing 2E8 melanoma GVAX cells.
88888618|NCT01435499|Experimental|Cohort C|Cohort C will receive four doses of vaccine, each containing 2E8 melanoma GVAX cells. One day prior to each vaccination, patients in cohort C will receive a single, low dose of intravenous cyclophosphamide.
88888619|NCT01435525||Nexium|
88888620|NCT01435538|Experimental|Care pathway teams.|In this experimental arm, the interprofessional teams will develop and implement a care pathways.
88888621|NCT01435538|No Intervention|Usual care teams.|In the no intervention arm, the interprofessional teams will deliver usual care without implementing the intervention.
88888622|NCT01435564|Active Comparator|pedometer|
88888623|NCT01435564|Experimental|Mobile phone physical activity intervention|
88888624|NCT01435629||Norditropin®|
88888625|NCT01435642||A|
88888626|NCT01435681||DYT-1 Postive|This group includes those participants who enroll having a genetically confirmed primary generalized dystonia diagnosis.
88888627|NCT01435681||Control|This group includes healthy subjects between the ages of 18 and 80.
89412170|NCT05055700|Experimental|Intervention group|This arm will review a mobile app to learn information about prenatal genetic testing before their appointment with maternal-fetal medicine specialists.
89412171|NCT05055700|No Intervention|Control group|This arm will only receive usual care - visit maternal-fetal medicine specialists.
89412172|NCT02317952|Experimental|New Extensively Hydrolyzed Formula|Administered in context of oral food challenge and then for 16 weeks.
88888628|NCT01435694|Experimental|Robot-assisted gait training|Subjects will wear a harness attached to a system to provide body weight support and they will walk on a treadmill with the help of a robotic-driven gait orthosis. The legs are guided according to a physiological gait pattern. The torque of the knee and hip drives can be adjusted from 100% to 0% for one or both legs. The speed of the treadmill can be adjusted from 0 km/h to approximately 3 km/h and body weight support from 0% to 100%. Training sessions will last for an hour with 30 minutes of real walking time, because subject set-up in the device take approximately 30 minutes.
88888629|NCT01435694|Active Comparator|Conventional Therapy|Training sessions will focus on locomotor function improvements. Subjects will receive 45 minutes of individual conventional physiotherapy for session. During the first 5-10 minutes the subjects will perform lower-limb and core stretching exercises to increase muscles flexibility; then they'll deal with lower-limb muscles strengthening exercises tailored on their baseline characteristics (10 minutes). After that they will be trained on walking abilities (like walking at different speeds, rapid changes directions) for 30 minutes with or without assistive aids.
88888630|NCT01435707|Experimental|Caudal 40 group|subjects who undergo caudal epidural block with triamcinolone 40 mg
88888631|NCT01435707|Experimental|STE 20 group|subjects who undergo selective transforaminal block with triamcinolone 20 mg
88888632|NCT01435707|Experimental|Caudal 20 mg|subjects who undergo caudal epidural block with triamcinolone 20 mg
88888633|NCT01435707|Experimental|STE 40 group|subjects who undergo selective transforaminal block with triamcinolone 40 mg
88888634|NCT01435720|Experimental|Cohort 1|0.0125 mg/kg
88888635|NCT01435720|Experimental|Cohort 2|0.05 mg/kg
88888636|NCT01435720|Experimental|Cohort 3|0.2 mg/kg
88888637|NCT01435720|Experimental|Cohort 4|0.375 mg/kg
89192625|NCT06145984|Other|Mindfulness first intervention, Fantasizing second intervention|Diary measures of thought patterns (experience sampling method [ESM]), behavioural measures (using the Sustained Attention to Response Task [SART]), actigraphy, (neuro)physiological measures (impedance cardiography [ICG], electrocardiography [ECG] and electroencephalogram [EEG]) and measures of depressive mood (self-report questionnaires) will be performed during the week before (pre-) the interventions and the week during (peri-) performance of the interventions. In-between pre-and peri-intervention measures, there is a one month wash-out period. In this arm mindfulness will be the first performed intervention, fantasizing the second performed intervention. The order of the interventions will be counterbalanced across participants.
89192626|NCT06145984|Other|Fantasizing first intervention, Mindfulness second intervention|Diary measures of thought patterns (experience sampling method [ESM]), behavioural measures (using the Sustained Attention to Response Task [SART]), actigraphy, (neuro)physiological measures (impedance cardiography [ICG], electrocardiography [ECG] and electroencephalogram [EEG]) and measures of depressive mood (self-report questionnaires) will be performed during the week before (pre-) the interventions and the week during (peri-) performance of the interventions. In-between pre-and peri-intervention measures, there is a one month wash-out period. In this arm fantasizing will be the first performed intervention, mindfulness the second performed intervention. The order of the interventions will be counterbalanced across participants.
89192627|NCT06145971|No Intervention|Baseline phase|Randomly allocated baseline phase (no intervention) of 5, 7, or 9 days.
89192628|NCT06145971|Experimental|Intervention - bCBTi|Two sessions of brief Cognitive Behavioural Therapy for insomnia (bCBTi). This will involve a clinical psychologist meeting with the participant for two sessions, three days apart, to provide bCBTi, which will involve a cognitive and a behavioural therapy technique.
89192629|NCT06145958||No androgen deprivation|Those patients not given androgen deprivation therapy
89192630|NCT06145958||Short course androgen deprivation|Those patients given 6 months of androgen deprivation therapy
89192631|NCT06145958||Long course androgen deprivation|Those patients given 24 months of androgen deprivation therapy
89192632|NCT06145932|Experimental|rTMS treatment group|treated with real rTMS 1800 pulses / day,for 10 days
89192633|NCT06145932|Sham Comparator|Sham rTMS treatment group|treated with sham rTMS 1800 pulses / day,for 10 days
89192634|NCT06145880||Mild pre-capillary PH|Right heart catheterisation (performed as part of usual care) diagnoses pulmonary hypertension and categorises it as mild and pre-capillary.
89192635|NCT06145880||Moderate pre-capillary PH|Right heart catheterisation (performed as part of usual care) diagnoses pulmonary hypertension and categorises it as moderate and pre-capillary.
89192636|NCT06145880||Severe pre-capillary PH|Right heart catheterisation (performed as part of usual care) diagnoses pulmonary hypertension and categorises it as severe and pre-capillary.
89192637|NCT06145880||Post capillary PH|Right heart catheterisation (performed as part of usual care) diagnoses pulmonary hypertension and categorises it as post-capillary.
89192638|NCT06145880||No PH|Right heart catheterisation (performed as part of usual care) demonstrates normal pulmonary pressures (i.e. no evidence of pulmonary hypertension).
88888638|NCT01435733||Parents of children with ASD|Parents with one or more children diagnosed with Autism Spectrum Disorder
88888639|NCT01435811|Experimental|Norovirus challenge pool (GII.4, CIN-1)|
89192639|NCT06145841||Pathogen metagenomic next-generation sequencing group|This group uses metagenomic next-generation sequencing along with traditional pathogen detection techniques to test for infectious pathogens. The follow-up times are the 1st, 2nd, 3rd, and 4th weeks after being diagnosed with severe pneumonia or sepsis.
89005355|NCT00234273|Active Comparator|Therapeutic education primarily focused on dietary|Therapeutic education primarily focused on dietary
89005356|NCT00237627|Experimental|Part 1|Doxil + PS-341
89005357|NCT00237627|Experimental|Part 2|Doxil + Velcade
89005358|NCT00209495|Placebo Comparator|A|
89005359|NCT00209495|Experimental|B|Pregabalin
89005360|NCT00209495|Experimental|C|Pregabalin + dexamethasone
89005361|NCT00414141|Experimental|1|Grass MATA MPL
89005362|NCT00414141|Placebo Comparator|2|
89005363|NCT01081678|Placebo Comparator|Placebo|Participants received placebo to romosozumab administered by subcutaneous injection on day 1 and at weeks 2, 6, and 12.
89005364|NCT01081678|Experimental|Romosozumab 70 mg|Participants received 70 mg romosozumab administered by subcutaneous injection on day 1 and at weeks 2, 6, and 12.
89005365|NCT01081678|Experimental|Romosozumab 140 mg|Participants received 140 mg romosozumab administered by subcutaneous injection on day 1 and at weeks 2, 6, and 12.
89005366|NCT01081678|Experimental|Romosozumab 210 mg|Participants received 210 mg romosozumab administered by subcutaneous injection on day 1 and at weeks 2, 6, and 12.
89005367|NCT00209612|Experimental|1|Paclitaxel+Irinotecan
89005368|NCT01081249|Experimental|Placebo then Oxytocin|Participant was randomized to receive placebo before the first psychotherapy session, and then received the active drug at the second visit.
89005369|NCT01081249|Experimental|Oxytocin then placebo|Participant was randomized to receive placebo before the first psychotherapy session, and then received the active drug at the second visit.
89005370|NCT00209651|Experimental|1|Irinotecan and S-1
89005371|NCT02961855|Experimental|Clife1 gel (lidocaine plus diclofenac)|Clife1 gel (lidocaine plus diclofenac) Topical gel containing lidocaine (2%) plus diclofenac (0.5%) (15 g in total) Application of the gel bid from first day post-surgery to day 3 and once daily from day 4 to day 6
89005372|NCT02961855|Active Comparator|Clife2 gel (lidocaine)|Clife2 gel (lidocaine) Topical gel containing lidocaine (2%) (15 g in total) Application of the gel bid from first day post-surgery to day 3 and once daily from day 4 to day 6
89005373|NCT00209690|Experimental|1|
89005374|NCT01081132|Experimental|Extended-release Guanfacine HCl|
89005375|NCT01081132|Placebo Comparator|Placebo|
89005376|NCT01080625|Experimental|phenylephrine|100 mcg of phenylephrine is administered at the time of reperfusion
89005377|NCT01080625|Experimental|epinephrine|10 mcg of epinephrine is administered iv at the time of reperfusion
89005378|NCT01080625|Placebo Comparator|control|10 ml of normal saline is administered at the time of reperfusion
89005379|NCT00209729|Experimental|1|Docetaxel plus S-1
89005380|NCT01089790|Experimental|1|
89005381|NCT01089790|Active Comparator|2|
89005382|NCT01089010|Experimental|Treatment Sequence 1|Treatment sequence 1 consisted of three dosing periods in which patients received single oral doses of placebo, 250 mg, and 500 mg of CK-2017357, in that order, with approximately one week between each dose. Each patient acted as their own control, as all doses were represented in each treatment sequence.
89005383|NCT01089010|Experimental|Treatment Sequence 2|Treatment sequence 2 consisted of three dosing periods in which patients received single oral doses of placebo, 500 mg, and 250 mg of CK-2017357, in that order, with approximately one week between each dose. Each patient acted as their own control, as all doses were represented in each treatment sequence.
89005384|NCT01089010|Experimental|Treatment Sequence 3|Treatment sequence 3 consisted of three dosing periods in which patients received single oral doses of 250 mg, placebo and 500 mg of CK-2017357, in that order, with approximately one week between each dose. Each patient acted as their own control, as all doses were represented in each treatment sequence.
89005385|NCT01089010|Experimental|Treatment Sequence 4|Treatment sequence 4 consisted of three dosing periods in which patients received single oral doses of 250 mg, 500 mg and placebo of CK-2017357, in that order, with approximately one week between each dose. Each patient acted as their own control, as all doses were represented in each treatment sequence.
89005386|NCT01089010|Experimental|Treatment Sequence 5|Treatment sequence 5 consisted of three dosing periods in which patients received single oral doses of 500 mg, placebo, and 250 mg of CK-2017357, in that order, with approximately one week between each dose. Each patient acted as their own control, as all doses were represented in each treatment sequence.
89005387|NCT01089010|Experimental|Treatment Sequence 6|Treatment sequence6 consisted of three dosing periods in which patients received single oral doses of 500 mg, 250 mg, and placebo of CK-2017357, in that order, with approximately one week between each dose. Each patient acted as their own control, as all doses were represented in each treatment sequence.
89005388|NCT01085266|Experimental|Dimebon (latrepirdine)|Patients receive dimebon 10mg orally 3 times per day for 1 week and 20 mg orally 3 times per day thereafter.
89005389|NCT01084330|Experimental|AUY922|
89005390|NCT01084330|Active Comparator|Docetaxel or Irinotecan|
89412173|NCT02317952|Active Comparator|Comparator Formula|Administered in context of oral food challenge and then for 16 weeks.
89412174|NCT05045248|Experimental|Patients|Each patient is administered 2 drops of Apraclonidine 0.5% solution to the most affected eye. Objective measurements of ptosis will be taken before drug administration and at 1, 5, 30, 60 minutes after drug administration in order to analyze any change in ptosis.
89412175|NCT02144922|Placebo Comparator|Control|Patients continue taking their antihypertensive medication alone.
88888640|NCT01435811|Placebo Comparator|Sterile water|
88888641|NCT01435837|Experimental|Caffeine and hydration.|"200 mg of caffeine (over the counter caffeine tablet)~1 liter of water"
88888642|NCT01435837|Placebo Comparator|No caffeine, no hydration.|
88888643|NCT01435850|Sham Comparator|HIP STEM SL PLUS|study group
88888644|NCT01435850|Active Comparator|HIP STEM SL PLUS MIA|control group
88888645|NCT01435863|Experimental|SP-02L|
88888646|NCT01435876|Active Comparator|Surgical arm|UNIOCULAR/BINOCULAR RECESSION/RESECTION PROCEDURES
88888647|NCT01435876|Active Comparator|Exercises|ORTHOPTICS/MINUS LENS THERAPY
88888648|NCT01435876|Active Comparator|Postoperative Exercises|POST SURGICAL ORTHOPTICS/MINUS LENS
88888649|NCT01435876|Active Comparator|Surgical|
88888650|NCT01435915|Experimental|Subjects receiving ropinirole|Eligible subjects will receive single and multiple oral dose of ropinirole prolonged release tablet in sequence over 14 days without dosing on washout period from Day 2 to Day 7.
88888651|NCT01435941||Respondents who report episodic migraines (EM)|Survey respondents whose headaches meet the diagnostic criteria for migraine and report that they experienced between 1 and 14 headache days in the month prior to the survey administration
88888652|NCT01435954||Patients with Benign Prostatic Hyperplasia (BPH)|Insured male patients age 50 or older with BPH but no evidence of acute urinary retention (AUR) or prostate surgery at the index date
89412176|NCT02144922|Active Comparator|Pitavastatin|Pitavastatin 4 mg is given to study patients after a baseline assessment and continued for 1 year without further dose titration. Patients continue taking their antihypertensive medication during the entire follow-up period.
89412177|NCT05055310||Normal elderly|normal cognitive group
88888653|NCT01435967||Cohort A|Children aged <=5 years in Belgium, with opportunity to receive Rotarix, requiring hospitalisation during which rotavirus detection test was performed and with available results.
88888654|NCT01435980|No Intervention|basal treatment|basal treatment
88888655|NCT01435980|Experimental|Gastric Bypass|basal treatment and Gastric Bypass
88888656|NCT01435980|Experimental|Exenatide|basal treatment and Exenatide
89005391|NCT00209807|Experimental|1|subjects with MDD randomized to Escitalopram
89005392|NCT00209807|Active Comparator|2|MDD patients receiving reboxetine
89005393|NCT00209807|Other|3|Healthy volonteers
89412178|NCT05055310||aMCI|amnestic mild cognitive impairment
89412179|NCT05055310||AD|Alzhiemer's disease
89412180|NCT02315300|Experimental|Study Tretament|Long term ECG measurement is performed with the 12-lead ECG system medilog® DARWIN FD12 from Schillermed to detect different ECG parameter. The continuous glucose monitoring (CGM) system G4 from Dexcom use a tiny sensor inserted under the skin to check glucose levels in tissue fluid. The sensor stays in place for 7 days in parallel to the ECG measurement. A transmitter sends information about glucose levels via radio waves from the sensor to a pagerlike wireless monitor.
88888657|NCT01435993|Experimental|Active|GSK1223249 slow (60 minutes) intravenous infusion
88888658|NCT01435993|Placebo Comparator|Placebo|Saline slow (60 minutes) intravenous infusion
88888659|NCT01436019||anti-TNF treatment|Children or young adolescents with juvenile idiopathic arthritis receiving either infliximab, adalimumab or etanercept.
88888660|NCT01436058|Experimental|stem cell recipient|patients with ankle joint osteoarthritis
88888661|NCT01436097|Active Comparator|Usual Care arm|Participants will have access through the Way to Health portal to web-based educational materials and recipes related to healthy eating. They will be informed they will receive up to $50 in reimbursements for completing the surveys that are part of the Way To Eat program as follows: $20 for completing the intake questionnaire and weigh-in and $30 reimbursements for completing the exit questionnaire and weigh-in.
88888662|NCT01436097|Experimental|Information provision intervention|Participants in the Information provision group will receive the same care as those in the Usual Care arm. In addition, the Information provision group participants will receive weekly reminders about the benefits of eating five servings of fruits and vegetables a day and their Way to Health portal will provide graphical depictions of their produce purchase proportions through information from their Price Plus card. This data will be available to them throughout the entire intervention.
88888663|NCT01436097|Experimental|Information provision + flat incentive|Participants assigned to the Information provision + flat group will earn back 15% of what they spent on groceries for the week if they spend at least 15% of their total grocery budget on fresh produce in addition to receiving the same treatment as the Information provision arm.
88888664|NCT01436097|Experimental|Information provision + tiered incentive|In addition to receiving all features of the Information provision treatment the participants assigned to the Information provision + tiered incentive group would earn back increasing percentages of their grocery spending for meeting increasing targets of produce consumption. In this arm, the more participants spend on produce the more money they can earn back.
88888665|NCT01436123|Experimental|Stenting + Micro-infusion|Step 1 - implantation of everolimus-eluting stent with imaging by MSCT, IVUS and OCT; Step 2 - injection of stem cells containing gold nanoparticles with silica-iron oxide shells.
88888666|NCT01436123|Active Comparator|Stenting|Put in everolimus-eluting stent
88888667|NCT01436136|Active Comparator|Intervention group|Patients randomised to the intervention group will follow an intensive 52 week period using a clinical protocol aimed to manage CVD risk in HIV individuals with the use of regular visits to a nurse led CVD risk management clinic, within a multi disciplinary approach to care with the involvement of treating physicians, nurses, dieticians, smoking cessation advisors and an exercise physiologist or personal trainer with the aim to reach their individualised CVD risk target.
88888668|NCT01436136|Active Comparator|Usual care (control) group|Within the context of an open, cohort study, GPs managing matched control patients allocated usual care will be unaware of the details of the intervention arm and asked to apply their usual pattern of patient visits and treatment strategies to achieve optimal reduction of CVD risk.
88888669|NCT01436188|Other|001 (Healthy Elderly Cohort 1)|standard frequent CSF sampling procedure for 36 hours
88888670|NCT01436188|Other|002 (Healthy Elderly Cohort 2)|an alternative frequency of CSF sampling procedure for 36 hours
88888671|NCT01436188|Other|003 (Healthy Elderly Cohort 3)|standard frequent CSF sampling procedure on Day 1 for 36 hours with 800 mg Ibuprofen administered on Day 1
88888672|NCT01436188|Other|004 (Elderly Volunteers with MCI or AD)|standard CSF sampling procedure for 36 hours
88888673|NCT01436188|Other|005 (Healthy Eldely Cohort 5)|an alternative lower frequency of CSF sampling in comparison to Cohort 1
88888674|NCT01436214|Experimental|APC-100|
88888675|NCT01436240||Spanish-speaking Latino participants|The investigators will conduct up to two rounds of PRO-CTCAE (patient-reported outcome- Common Terminology Criteria for Adverse Events) version questionnaire administration followed by cognitive interviews in Spanish-speaking Latino patients who are receiving cancer treatment or who have completed treatment for cancer within the past six months at one of the participating sites.
88888676|NCT01436318||Respiratory Function|Children will undergo one session of pulmonary function and strength testing
88888677|NCT01436331|Active Comparator|Treatment As Usual (TAU)|
88888678|NCT01436331|Experimental|TAU+CBT for pts+Family Intervention+CM|
88888679|NCT01436344||1|"Cases: 30 patients with known paroxysmal atrial fibrillation (pAF) will consecutively be recruited from the cardiology ward and the cardiological ambulatory. They will form the cases group."
88888680|NCT01436344||2|Controls: For every case patient, an age (+/- one year) and gender matched control person (n=30) without known paroxysmal atrial fibrillation will be included and matched to every case patient.
88888681|NCT01436409|Other|only vaginal touch|
88888682|NCT01436409|Experimental|vaginal touch +echography|
88888683|NCT01436422|Experimental|TetraVax-DV Vaccine - Admixture TV003|Participants will receive the TetraVax-DV Vaccine - Admixture TV003 at Day 0 and Day 180.
89412181|NCT02141568|Experimental|Intervention Group for Prospective Study|"Intervention: Medical and psychological treatment at the Soroka UMC functional neurology outpatient clinic. Treatment will be conducted by a multidisciplinary staff. Patients will undergo an initial meeting with a neurologist and afterwards will be directed to other members of the team (psychologist, physical therapist) on a case by case basis."
88888684|NCT01436422|Experimental|TetraVax-DV Vaccine - Admixture TV005|Participants will receive the TetraVax-DV Vaccine - Admixture TV005 at Day 0 and Day 180.
88888685|NCT01436422|Placebo Comparator|Placebo|Participants will receive the placebo at Day 0 and Day 180.
88888686|NCT01436448|Experimental|Probiotics Lactobacillus Rhamnosus|dose of 1010 Colony forming Units (CFU) once daily till delivery will be given orally
88888687|NCT01436448|No Intervention|Placebo|Microcrystalline cellulose/d each, up till deliver
88888688|NCT01435902|Active Comparator|Fluticasone Furoate/Vilanterol|Fluticasone furoate/vilanterol inhalation powder once daily + Placebo inhalation powder twice daily for 4 weeks
88888689|NCT01435902|Active Comparator|Fluticasone Propionate|Fluticasone propionate inhalation powder twice daily + Placebo inhalation powder once daily for 4 weeks
88888690|NCT01436474|Experimental|Varenicline|We will be comparing Varenicline to placebo in a single-blinded placebo controlled, randomized study
88888691|NCT01436474|Placebo Comparator|Placebo|We will be using a placebo in a randomized, controlled, single-blinded trial to look at varenicline for the indication of facilitating opioid tapering in opioid-dependent patients with chronic pain.
88888692|NCT01436513|Experimental|A|Premarin reference tablet as a single oral dose under fasted conditions
88888693|NCT01436513|Experimental|B|Premarin new tablet as a single oral dose under fasted conditions
88888694|NCT01436513|Experimental|C|Premarin reference tablet as a single oral dose under fed conditions
88888695|NCT01436513|Experimental|D|Premarin new tablet as a single oral dose under fed conditions
88888696|NCT01436539|Experimental|Adefovir Dipivoxil and polyene phosphatidylcholine|Adefovir Dipivoxil 10 mg once daily for 48 weeks plus Polyene phosphatidylcholine (PPC) 456 mg three times per day for 48 weeks
88888697|NCT01436539|Active Comparator|Adefovire Dipivoxil|Adefovir Dipivoxil 10 mg once daily for 48 weeks
88888698|NCT01436565|Experimental|dose escalation and expansion|SAR245408 taken every day in the morning: no eating 2 hours prior and 1 hour after dose; SAR256212 will be given weekly by IV infusion over 1 hour, right after the SAR245408 oral dose
88888699|NCT01436578||All Participants|All participants treated with posaconazole oral suspension during the pre-specified surveillance period.
88888700|NCT01436604|Other|LV dysfunction group|Cardiac MRI
88888701|NCT01436604|Other|Control group|Cardiac MRI
88888702|NCT01436630||Stroke|"To accomplish the study it was assessed a group of 12 post-stroke patients who were admitted in the Rehabilitation Clinic inside the University. As inclusion criteria it was established to be able to walk alone without supervision and with no aids.~All the patients signed an informed consent before performing the tests. To characterize the sample it were used the Fugl-Meyer scale, Orpington test, Mini Exam of the Mental State and some other data regarding the age, gender, type of the lesion and side of the lesion."
88888703|NCT01436669|Experimental|Home Monitoring|All participants will receive a home telemonitoring system which will allow cancer patients receiving chemotherapy to test their blood count at home.
88888704|NCT01436695||Epicall group|patients will be connected to Epicall sensor
88888705|NCT01436721|No Intervention|Surgicel® absorbable Haemostat|
88888706|NCT01436734|Experimental|GIP|
88888707|NCT01436747|Active Comparator|Paricalcitol|
88888708|NCT01436747|Placebo Comparator|Matching placebo|
88888709|NCT01436773||Recent Acute Coronary Event|Patients admitted to the hospital for recent STEMI or NSTEMI.
88888710|NCT01436773||Stable Coronary Artery Disease|Patients with known Coronary Artery Disease without recent acute coronary event.
88888711|NCT01436773||No Coronary Artery Disease|Patients with no evidence of coronary artery disease, assessed by coronary angiography.
88888712|NCT01436786|Experimental|Guided Imagery Intervention|The 12 week intervention consists of a set of 4 GI compact discs (CDs), each 20 minutes in length. Participants will be instructed to listen to the CD once a day in a recommended order for weeks 1-4 and used in any order for weeks 5-12.
88888713|NCT01436786|No Intervention|Control group|continues usual plan of care
88888714|NCT01436812|Placebo Comparator|zero end-expiratory pressure|not applying PEEP during operation just applying TV=IBW*6-8ml IBW = (male; 50+0.91[(Ht-cm)-152.4], female; 45.5 +0.91[(Ht-cm)-152.4], RR 8-12/min,
88888715|NCT01436812|Active Comparator|positive end expiratory pressure|applying PEEP 10cmH2O during operation just applying TV=IBW*6-8ml IBW = (male; 50+0.91[(Ht-cm)-152.4], female; 45.5 +0.91[(Ht-cm)-152.4], RR 8-12/min,
88888716|NCT01436825||Group 1|
88888717|NCT01436838||Group 1|
88888718|NCT01436851|Experimental|Storage mite and placebo nasal challenge|Provocation in the nose with an allergen extract of a storage mite (A. Siro or L. Destructor) and with placebo allergen extract (physiologic salt water)
88888719|NCT01436877|Experimental|device|Insertion of Temporary Implantable Nitinol Device (TIND)
88888720|NCT01436890|Experimental|Low dose|Low dose revamilast
88888721|NCT01436890|Experimental|Medium dose|Medium dose Revamilast
88888722|NCT01436890|Experimental|High dose|High dose Revamilast
88888723|NCT01436890|Placebo Comparator|Placebo|Matching placebo in triple dummy format
88888724|NCT01436916|Active Comparator|oral cholecalciferol + lifestyle counselling|will receive Oral cholecalciferol
88888725|NCT01436916|Placebo Comparator|Placebo + lifestyle counselling|will receive placebo
88888726|NCT01436929|Experimental|Silymarin|Silymarin: prophylactic administration of silymarin with anti-TB drugs Placebo: prophylactic administration of placebo with anti-TB drugs
88888727|NCT01436929|Placebo Comparator|Placebo|administration of placebo with anti-TB drugs
88888728|NCT01436942|Experimental|Exercise group|
88888729|NCT01436942|No Intervention|Control group|
88888730|NCT01436955|Experimental|A|
88888731|NCT01436955|Placebo Comparator|B|
88888732|NCT01436981||CABG with papaverine|Patients with CABG procedure
88888733|NCT01436994|Active Comparator|Block and Replace|Carbimazole is commenced in a dose of 0.75 mg/kg/day. The intention is to completely prevent endogenous thyroxine production. Thyroxine is then added in a replacement dose as the thyroid hormone levels fall into the lower half of the laboratory normal range. The principal measure of control during the first 6 months will be thyroid hormone levels rather than TSH.
88888734|NCT01436994|Active Comparator|Dose Titration|"Carbimazole is commenced in a dose of 0.75 mg/kg/day until thyroid hormone levels fall into the local laboratory normal range. The dose is then reduced to 0.25 mg/kg/day with the intention of maintaining the euthyroid state. The principal measure of control during the first 6 months will be thyroid hormone levels rather than TSH.~Carbimazole is the preferred treatment because of the increased risk of hepatotoxicity with propylthiouracil but patients who are treated with propylthiouracil can also be recruited and randomised. 1mg of carbimazole is approximately equivalent to 10 mg of propylthiouracil.~Drug: Carbimazole 5mg and 20 mg tablets. Administered as a once or twice daily regimen with total daily dose adjusted according to prevailing biochemistry Drug: propylthiouracil 50 mg tablets administered once daily with the dose adjusted according to the prevailing biochemistry."
88888735|NCT01437020|Experimental|Dose escalating-IV infusion of SCH708980 and Ambisome|
88888736|NCT01437046|Experimental|Doxazosin|Doxazosin 16mg/day
88888737|NCT01437046|Placebo Comparator|Placebo|Placeno
88888738|NCT01437059|Active Comparator|ALN-PCS02|
88888739|NCT01437059|Placebo Comparator|Sterile Normal Saline (0.9% NaCl)|
88888740|NCT01437072||Total study population|
88888741|NCT01437137|Active Comparator|LMA group|
88888742|NCT01437137|Experimental|I-gel group|
88888743|NCT01437150|Experimental|Simple posterior wall fracture|Simple posterior wall fracture means the fracture was only occurred in the posterior wall of acetabular.
88888744|NCT01437150|Experimental|Complex posterior wall fracture|Complex posterior wall fracture means the fracture was not only occurred in the posterior wall of acetabular, but also occurred in other part of acetabular.
88888745|NCT01437163|Sham Comparator|Red Incandescent light source|
88888746|NCT01437163|Active Comparator|TopHat 655|
88888747|NCT01437202||high risk group|Identified by the predictive model using 2 genotypes and disease stage
88888748|NCT01437202||intermediate risk group|Identified by the predictive model using 2 genotypes and disease stage
88888749|NCT01437202||Low risk group|Identified by the predictive model using 2 genotypes and disease stage
88888750|NCT01437228|Other|povidone iodine|30-second vaginal scrub with povidone- iodine solution.
88888751|NCT01437228|Placebo Comparator|CONTROL|
88888752|NCT01437241||etravirine|Antiretroviral regimens based on etravirine plus 2 active nucleos(t)ide reverse-transcriptase inhibitors (NRTIs)
88888753|NCT01437254|Experimental|Arm Number 1 CPERT|1 CPERT scan, blood and vital sign collection
89412182|NCT02141568|No Intervention|No Intervention|Patient records will be analyzed via Clalit Health Service electronic records. No additional intervention will occur
89412183|NCT05036200|Experimental|four pulsed dye laser sessions were administered every eight weeks in the 21 patients|
89412184|NCT02318030||Solid organ transplant|
89412185|NCT02318030||Hematopoietic Stem Cell Transplant|
89412186|NCT02318108|Experimental|Intervention|Mentored organizational change and feedback.
89412187|NCT02318108|Other|Education only|Education and feedback.
89412188|NCT03095482|Active Comparator|Active tDCS + In Vivo Exposure|Participants assigned to this condition will receive excitatory transcranial direct current stimulation (tDCS) of the left medial prefrontal cortex (lmPFC) and inhibitory tDCS of right dorsolateral prefrontal cortex (rdlPFC). tDCS will be administered for 20 minutes at 1.7 mA, followed by 30 minutes of in vivo exposure therapy.
89412189|NCT03095482|Sham Comparator|sham tDCS + In Vivo Exposure|Participants assigned to this condition will receive sham transcranial direct current stimulation (tDCS), which will consist of 30 seconds of stimulation at the beginning and end of tDCS administration. Electrode positioning will be counterbalanced across participants (i.e., either mPFC+ or mPFC-, with same electrode positioning as the active comparators). Sham tDCS will be administered for 20 minutes, followed by 30 minutes of in vivo exposure therapy.
88888754|NCT01437254|Active Comparator|Arm Number 2 GPERT|1 GPERT Scan
88888755|NCT01437280|Experimental|CGTG-102|CGTG-102 is an oncolytic adenovirus
89412190|NCT02261064|Experimental|Telmisartan/Amlodipine low dose, fed|Telmisartan low dose/Amlodipine fixed-dose combination
89412191|NCT02261064|Active Comparator|Telmisartan/Amlodipine low dose, fasted|Telmisartan low dose/Amlodipine fixed-dose combination
88888756|NCT01437293|Experimental|Experimental|L-dopa / carbidopa / entacapone (LCE)
88888757|NCT01437306|Experimental|Lofexidine following overnight fast|A single dose of lofexidine (400 mcg or 2 x 200 mcg tablets) will be given to subjects following a minimum 10 hour overnight fast.
88888758|NCT01437306|Experimental|Lofexidine Following a High Fat Meal|A single dose of lofexidine 400 mcg (or 2 x 200 mcg tablets) will be administered to subjects following a standard high-fat meal.
88888759|NCT01437332||Diabetes|
88888760|NCT01437332||Nerve injury|
88888761|NCT01437332||Other|
88888762|NCT01437358||intensive care unit|
89412192|NCT02261064|Experimental|Telmisartan/Amlodipine high dose, fed|Telmisartan high dose/Amlodipine fixed-dose combination
89412193|NCT02261064|Active Comparator|Telmisartan/Amlodipine high dose, fasted|Telmisartan high dose/Amlodipine fixed-dose combination
89412194|NCT02318186||0 months - 1 year|
89412195|NCT02318186||11-16 years|
89412196|NCT02318186||7-11 years|
89412197|NCT02318186||4-6 years|
89412198|NCT02318186||1-3 years|
89412199|NCT05044858|Experimental|Midpoint transverse process block group|Patients will receive midpoint transverse process block after induction of general anesthesia and before surgical incision
89412200|NCT05044858|Sham Comparator|Sham group|Patients will receive general anesthesia and the same intervention steps will be performed i.e., the block under investigation but instead of local anesthetic a placebo (2ml normal saline) will be injected (sham block)
89412201|NCT02320916|Active Comparator|23Gauge|Arterial blood puncture will be performed using a 23Gauge needle
89412202|NCT02320916|Active Comparator|25Gauge|Arterial blood puncture will be performed using a 25Gauge needle
89412203|NCT02955966|Experimental|Patient with invasive pulmonary aspergillosis|Blood collection and imaging 18F-FDG-PET/CT
89412204|NCT03498326|Experimental|gemcitabine|one group patients receive the standard gemcitabine treatment at 1,8,15 of the chemotherapy cycle after R0 resection.
89412205|NCT03498326|Experimental|gemcitabine plus celecoxib|the other group patients receive the standard gemcitabine treatment at 1,8,15 of the chemotherapy cycle after R0 resection, and receive additional celecoxib every days during chemotherapy period.
89412206|NCT02141724||neuromuscular patients|neuromuscular patients using wheelchair
89412207|NCT03498248|Experimental|Neutropenia in chemotherapy|Neutropenia after cytotoxic chemotherapy
89412208|NCT02141802|Active Comparator|Control|Normal standing time
89412209|NCT02141802|Experimental|Doubling standing time|Doubled standing time calculated by doubling baseline standing time
89412210|NCT01360996|Experimental|3 mg DRSP/20 μg EE--normal weight|"Folate-boosted 3 mg DRSP/20 μg EE-24/4 oral contraceptive~Normal weight -BMI 18-24.9 kg/ m2"
89412211|NCT01360996|Experimental|3 mg DRSP/20 μg EE- Overweight|"Folate-boosted 3 mg DRSP/20 μg EE-24/4 oral contraceptive~BMI 25-29.9 kg/ m2"
89412212|NCT01360996|Experimental|3 mg DRSP/20 μg EE- Grade 1 obese|"Folate-boosted 3 mg DRSP/20 μg EE-24/4 oral contraceptive~BMI 30-34.9 kg/ m2"
89412213|NCT02254434|Experimental|Eltrombopag 50 mg|Each volunteer will receive orally, single dose of tablet eltrombopag 50 mg under fasting conditions
89412214|NCT03498170|Other|Period 1 and Period 2|"Period 1 - BCT197 14mg on Day 1~Period 2 - itraconazole 200mg on Day 1 to 14 and BCT197 14mg on Day 7"
89412215|NCT03544944|Experimental|TJP-008-1|
89412216|NCT03544944|Experimental|TJP-008-2|
89412217|NCT03544944|Active Comparator|Coolprep powder|
89412218|NCT05055544|Active Comparator|Fosfomycin|a single dose of fosfomycin (3 g) powder dissolved in 75 ml water and 2 placebo tablets t.i.d. for 7 days (group A)
89192640|NCT06145841||Conventional pathogen detection group|This group only used conventional pathogen detection methods for the identification of infectious pathogens. Follow-up was conducted at the 1st, 2nd, 3rd, and 4th weeks after the diagnosis of severe pneumonia or sepsis. The conventional means of pathogen detection include, but are not limited to, fungal serology tests, cryptococcal capsular antigen detection, CMV-DNA tests, sputum smear microscopy, gamma interferon release assays, Xpert MTB/RIF, BLAF culture, blood and bone marrow cultures, radiological examinations, and histopathological examinations.
89412219|NCT05055544|Active Comparator|Bearberry|a single dose of placebo powder dissolved in 75 ml water and 2 bearberry tablets t.i.d. for 7 days (group B).
89412220|NCT02315456|Other|Capsule centration|Capsulorhexis made with capsule centration
89412221|NCT02315456|Other|Pupil centration|Capsulorhexis made with pupil centration
89412222|NCT03498092|Experimental|Bupivacaine-Dexmedetomidine group|After general anesthesia, patients will receive a cocktail of isobaric bupivacaine 2.5 mg/ml plus 5 micrograms (mcg)/ml adrenaline and 1mcg/kg dexmedetomidine in a volume of 0.5 ml/kg injected superficial to serratus muscle between and below latissimus dorsi muscle.
89412223|NCT03498092|Active Comparator|Bupivacaine group|After general anesthesia, patients will receive a cocktail of isobaric bupivacaine 2.5 mg/ml plus 5 micrograms (mcg)/ml adrenaline in a volume of 0.5 ml/kg injected superficial to serratus muscle between and below latissimus dorsi muscle.
89412224|NCT03498092|Placebo Comparator|Saline group|This group will serve as a control and blinding group and will receive saline infiltration in the same manner.
89412225|NCT05055388||Group with sepsis complicated with multidrug-resistant bacteria|Obstetrics diagnosed with sepsis were divided to group with sepsis complicated with multidrug-resistant bacteria if microbial culture results showed multidrug-resistance.
89412226|NCT05055388||Group with sepsis complicated with none multidrug-resistant bacteria|Obstetrics diagnosed with sepsis were divided to group with sepsis complicated with none multidrug-resistant bacteria if microbial culture results showed none-multidrug-resistance or no positive result of microbial culture.
89412227|NCT02145234|Experimental|SAD Panel 1:BMS-986089/Placebo|"BMS-986089 in a single subcutaneous administration~OR~Placebo matching with BMS-986089 in a single subcutaneous administration"
89412228|NCT02145234|Experimental|SAD Panel 2:BMS-986089/Placebo|"BMS-986089 in a single subcutaneous administration~OR~Placebo matching with BMS-986089 in a single subcutaneous administration"
89412229|NCT02145234|Experimental|SAD Panel 3:BMS-986089/Placebo|"BMS-986089 in a single subcutaneous administration~OR~Placebo matching with BMS-986089 in a single subcutaneous administration"
89412230|NCT02145234|Experimental|SAD Panel 4:BMS-986089/Placebo|"BMS-986089 in a single subcutaneous administration~OR~Placebo matching with BMS-986089 in a single subcutaneous administration"
89412231|NCT02145234|Experimental|SAD Panel 5:BMS-986089/Placebo|"BMS-986089 in a single subcutaneous administration~OR~Placebo matching with BMS-986089 in a single subcutaneous administration"
89412232|NCT02145234|Experimental|MAD Panel 1:BMS-986089/Placebo|"BMS-986089 in multiple subcutaneous administrations weekly~OR~Placebo matching with BMS-986089 multiple subcutaneous administrations weekly"
89412233|NCT02145234|Experimental|MAD Panel 2:BMS-986089/Placebo|"BMS-986089 in multiple subcutaneous administrations weekly~OR~Placebo matching with BMS-986089 in multiple subcutaneous administrations weekly"
89412234|NCT02145234|Experimental|MAD Panel 3:BMS-986089/Placebo|"BMS-986089 in multiple subcutaneous administrations weekly~OR~Placebo matching with BMS-986089 in multiple subcutaneous administrations weekly"
89412235|NCT02145234|Experimental|MAD Panel 4:BMS-986089/Placebo|"BMS-986089 in multiple subcutaneous administrations weekly~OR~Placebo matching with BMS-986089 in multiple subcutaneous administrations weekly"
89412236|NCT02145234|Experimental|MAD Panel 5:BMS-986089/Placebo|"BMS-986089 in multiple subcutaneous administration every 2 weeks~OR~Placebo matching with BMS-986089 in multiple subcutaneous administrations weekly"
89412237|NCT02145234|Experimental|MAD Panel 6:BMS-986089/Placebo|"BMS-986089 in multiple subcutaneous administrations weekly~OR~Placebo matching with BMS-986089 in multiple subcutaneous administrations weekly"
89412238|NCT02145234|Experimental|MAD Panel 7:BMS-986089/Placebo|"BMS-986089 a single subcutaneous administrations weekly~OR~Placebo matching with BMS-986089 a single subcutaneous administration every 2 weeks"
89412239|NCT03501914|Experimental|Mindfulness Based Intervention|Mindfulness principles based manualized intervention will be provided to the participants which is developed by colleagues in Manchester. This intervention will be adapted to be accessible for people having intellectual disability (ID) in Pakistan.Sessions will take place once-weekly for 12 weeks including an initial orientation session. It will include breathing, soles of the feet, body scan, guided meditation, mindful stretching and walking
88888763|NCT01437371|Other|optimized|The purpose of this study is to determine if there is an interest to optimize HF management in patients over 80 years old. The primary objective is to assess the effect of HF optimized management (guidelines of the European society of Cardiology (ESC) on QOL in aged over 80 year's old at 6 months
88888764|NCT01437371|Other|usual care|
88888765|NCT01437384|Experimental|E5501 plus minus verapamil; plus minus cyclosporine|
88888766|NCT01437410||EUS-FNA|
88888767|NCT01437436||obesity|otitis media patient with obesity
89412240|NCT05055154|Experimental|Very low calorie diet|Use of very low calorie diet prepared in the hospital
89412241|NCT03500588||normotensive pregnant women more than 20 weeks gestation.|One hundred and forty-five pregnant women after 20 weeks with normal blood pressure were evaluated for VEGF gene mutation.
89412242|NCT03500588||Pregnant women after 20 weeks with preeclampsia.|One hundred and forty-five pregnant women after 20 weeks with preeclampsia were evaluated for VEGF gene mutation by using PCR and Pulsitality index of umbilical artery by doppler velocimetry.
89412243|NCT05044624|Other|Margin, Tumor-Free|
89412244|NCT03501836|Experimental|Rapid Rhythm Handheld 8-lead ECG Device|Participants will have measurements taken with the 8 lead ECG system, which will be compared to the conventional standard care 12 lead ECG.
89192641|NCT06145828||Cytokine Adsorption Combined with Standard Treatment Group|This group receives cytokine adsorption combined with standard treatment, specifically via hemoperfusion using the standard 211 protocol: two hemoperfusions within the first 24 hours, followed by one hemoperfusion daily. Each hemoperfusions session does not exceed 6 hours, lasting a total of 3 days. All patients also undergo blood perfusion treatment with the addition of a plasma separator.
89412245|NCT05055232|Experimental|XZP-3621|The first part is a dose-escalation design in patients with ALK/ROS1-positive solid tumor. The second part is an expansion in non-small cell lung Cancer (NSCLC) characterized by abnormalities in ALK expression.
89412246|NCT02145312|Experimental|BYL719|BYL719 is an oral class I α-specific PI3K inhibitor belonging to the 2-aminothiazole class of compounds.
89412247|NCT03500432|Active Comparator|periprostatic group|local anesthesia of trnasperineal prostate biopsy with subcutaneous local anesthesia+periprostatic block
89412248|NCT03500432|Active Comparator|PAT group|local anesthesia of trnasperineal prostate biopsy with subcutaneous local anesthesia+periapical triangle (PAT) block
88888768|NCT01437436||non obesity|otitis media patient with non obesity
88888769|NCT01437475|Experimental|Sci-B-Vac|The study involves only one, open label arm. Rate of immunization will be compared to results obtained using the ENGERIX B vaccine among HIV positive persons in formerly published, historical cohorts.
88888770|NCT01437514|Experimental|lower risk group with pSRT|the patients that was divided into the lower risk group that the mesorectum involvement less than 5mm, and no lymph node larger than 8mm according to the preoperative CT, MRI and Endosonography,and these patients accept the preoperative short-course radiotherapy before the surgery
88888771|NCT01437514|No Intervention|lower risk group with operation only|the patients that was divided into the lower risk group that the mesorectum involvement less than 5mm, and no lymph node larger than 8mm,according to the preoperative CT, MRI and Endosonography,and these patients have a operation directly without preoperative radiotherapy.
88888772|NCT01437514|Experimental|higher risk group with pSRT|the patients that was divided into the higher risk group that the mesorectum involvement more than 5mm, or with lymph node larger than 8mm according to the preoperative CT, MRI and Endosonography,and these patients have a operation directly without preoperative radiotherapy.these patients have the preoperative short-course radiotherapy before the surgery.
88888773|NCT01437514|No Intervention|higher risk group with operation directly|the patients that was divided into the higher risk group that the mesorectum involvement more than 5mm, or with lymph node larger than 8mm according to the preoperative CT, MRI and Endosonography,and these patients have a operation directly without preoperative radiotherapy.
88888774|NCT01437553|Other|IVUS|Patients undergoing catheterization due to acute coronary syndrome will have IVUS done with grayscale and iMAP analysis performed.
89005394|NCT04571671||Study group|Women with Müllerian anomalies who have received an oocyte donation. The diagnosis of Müllerian anomalies is established when a cavity is demonstrated uterine abnormality with any of the defects described in the American classifications or European in transvaginal ultrasound, hysteroscopy or hysterosalpingography (HSG). The differential diagnosis in case of doubts is established with 3D ultrasound, MRI or hystero / laparoscopy. All the septa have been resected prior to performing the OVODON cycle.
89412249|NCT03500432|Experimental|TPA switch group|local anesthesia of trnasperineal prostate biopsy with subcutaneous local anesthesia+TPA switch (transperineal prostate biopsy local anesthesia switch) block
89412250|NCT05035108|Experimental|extensive hepatectomy patient|hiHep bioartificial liver therapy
89412251|NCT02318420|Experimental|Women in labour|"All women in labour during the study period (4 months baseline and the 9th-12th month of the intervention) will be included for this pre- vs. post-study of the PartoMa intervention.~The following subgroups will be studied in-depth:~All stillbirths~All maternal deaths~All women with severe hypertensive disorders~A randomized selected group of women delivering a the study site, approximately 300-600 each year."
89412252|NCT02318420|Experimental|Health care providers|All health care providers (physicians and nurse-midwives) working at the Department of Obstetrics during the study period will be invited to participate in knowledge tests of obstetric care and qualitative participant observations as well as in-depth interviews regarding quality of care. This is a part of evaluating the use and effectiveness of the PartoMa intervention.
89412253|NCT05044702|Experimental|Retro walking|Retro walking
89412254|NCT05044702|Active Comparator|conventional physical therapy|Conventional Physical therapy
88888775|NCT01437566|Placebo Comparator|GDC-0941 Matching Placebo + Fulvestrant (Arm E)|Participants with PIK3CA mutation will receive fulvestrant 500 mg as 2 IM injections of 250 mg on Days 1 and 15 of Cycle 1 and on Day 1 of each subsequent cycle and GDC-0941 matching placebo QD orally starting on Day 1 of Cycle 1, each cycle of 28 days. Study treatment will continue until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
89412255|NCT03497858|Experimental|coconut water|participants will complete the simulated basketball game with coconut water supplementation
89412256|NCT03497858|Placebo Comparator|Placebo - water|participants will complete the simulated basketball game with water supplementation
89412257|NCT03497858|Experimental|Sports drink|participants will complete the simulated basketball game with sports drink supplementation
89412258|NCT02321072|Active Comparator|High-normal PaO2|In patients requiring respiratory monitoring, supplemental oxygen is titrated to achieve a PaO2 of 120 mmHg (16 kPa), range 105-135 mmHg (14-18 kPa).
89412259|NCT02321072|Active Comparator|Low-normal PaO2|In patients requiring respiratory monitoring, supplemental oxygen is titrated to achieve a target PaO2 of 75 mmHg (10 kPa), range 60-90 mmHg (8-18 kPa).
89412260|NCT02315690|Active Comparator|Reactive case detection (RACD)|Individuals in RACD Target Areas will be tested by RDT (rapid diagnostic test) and if positive, taken to the nearest health facility for treatment with artemether-lumefantrine per national policy.
88888776|NCT01437566|Experimental|GDC-0941-260 mg + Fulvestrant (Arm D)|Participants with PIK3CA mutation will receive fulvestrant 500 mg as 2 IM injections of 250 mg on Days 1 and 15 of Cycle 1 and on Day 1 of each subsequent cycle and GDC-0941 260 mg QD orally starting on Day 1 of Cycle 1, each cycle of 28 days. Study treatment will continue until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
88888777|NCT01437566|Experimental|GDC-0941-340 mg + Fulvestrant (Arm A)|Participants will receive fulvestrant 500 milligrams (mg) as 2 intramuscular (IM) injections of 250 mg on Days 1 and 15 of Cycle 1 and on Day 1 of each subsequent cycle and GDC-0941 340 mg once daily (QD) orally starting on Day 15 of Cycle 1, each cycle of 28 days. Study treatment will continue until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
88888778|NCT01437566|Placebo Comparator|GDC-0948 or GDC-0980 Matching Placebo + Fulvestrant (Arm C)|Participants will be randomized in 1:1 ratio to receive GDC-0948 matching placebo or GDC-0980 matching placebo with fulvestrant. Participants will receive fulvestrant 500 mg as 2 IM injections of 250 mg on Days 1 and 15 of Cycle 1 and on Day 1 of each subsequent cycle and GDC-0948 or GDC-0980 matching placebo QD orally starting on Day 15 of Cycle 1, each cycle of 28 days. Study treatment will continue until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
89412261|NCT02315690|Experimental|Reactive focal mass drug administration (fMDA)|In the fMDA arm, all individuals in the Target Area will receive dihydroartemisinin-piperaquine (DHAp) once daily for 3 days with the first dose taken no later than 5 weeks from the index case presentation (goal within one week).
89412262|NCT02639338|Experimental|SOF/VEL/VOX|SOF/VEL/VOX tablet for 8 weeks
89412263|NCT02639338|Experimental|SOF/VEL|SOF/VEL tablet for 12 weeks
89412264|NCT01754857|Experimental|Bendamustine, rituximab, lenalidomide|"INDUCTION: Bendamustine 90mg/m2 IV D1&2 and rituximab IV D1 (up to day 5 of course 1) every 28 days for 6 cycles. Patients with objective response move to maintenance therapy. Patients with objective response after 4 courses are eligible to for maintenance therapy if ongoing induction therapy is associated w/unacceptable toxicity.~MAINTENANCE: At 6-12 wks post induction therapy, patients receive rituximab IV on day 1 of odd-numbered cycles for 24 cycles; lenalidomide 5mg PO daily on days 1-21 of each cycle (28 day cycles). Dose escalation to 10mg daily on days 1-21 allowed at start of cycle 2 or at start of subsequent cycles in subjects w/acceptable toxicities. Lenalidomide dose escalation only allowed at start of a new cycle up to a max dose of 10 mg/day on days 1- 21. Subjects entering maintenance with CrCl ≥40 & <60mL/min will begin dosing at 5mg every other day on days 1-21. Patients with excessive toxicity from lenalidomide may continue maintenance therapy with rituximab alone."
89412265|NCT03497702|Experimental|Experimental|Patients receive neoadjuvant chemotherapy (doxorubicin 60mg/m2 IV and cyclophosphamide 600mg/m2 IV on day 1 every 3 weeks for 4 cycles followed by docetaxel 75mg/m2 IV on day 1 every 3 weeks for 4 cycles) plus letrozole with or without leuproelin depending on menopausal status
89412266|NCT02321150|Active Comparator|Sutures|After pterygium removal the conjunctival graft to cover bare sclera will be secured with interrupted 8.0 polyglactin sutures.
89412267|NCT02321150|Experimental|Cautery|After pterygium removal the conjunctival graft to cover bare sclera will be secured with bipolar electrocautery, power set at 25 until whitening of tissue observed.
89412268|NCT02900352|Experimental|Zonisamide|Subjects will receive zonisamide titrated to a target dose of 500mg orally, daily, double-blind (Titration of dose to 500mg oral, daily, over 7 weeks, then 9 weeks of treatment at that dose). Subjects may increase their dose to 600mg daily during the target treatment period if it is thought to be beneficial.
89412269|NCT02900352|Placebo Comparator|Placebo|Patients will receive placebo pills that are made to match the zonisamide medication (via over-encapsulation, double-blind, subjects will receive same number of capsules as the active medication group)
89412270|NCT02318498|Active Comparator|Prospective MINCA patients|Patients with MINCA prospectively investigated with an early CMR with latest technique
89412271|NCT02318498|Placebo Comparator|Historical MINCA patients|Patients with MINCA investigated earlier with a late CMR (median 12 days)
89412272|NCT05034406|Experimental|Lidocaine group|A total amount of 6 mL of 2% lidocaine was injected at the three trocar insertion sites (2 mL at each insertion site) prior to incision and 10 mL of 2% lidocaine was injected at the end of procedure, under the direct visualization of laparoscope, below and around the defect of the peritoneum at the site of varicocele.
89412273|NCT05034406|Experimental|Levobupivacaine|Total amount of 6 mL of 0.5% levobupivacaine was injected at the three trocar insertion sites (2 mL at each) prior to incision and 10 mL of 2% lidocaine was injected at the end of procedure, under the direct visualization of laparoscope, below and around the defect of the peritoneum at the site of varicocele.
89412274|NCT05034406|No Intervention|Control group|No local or peritoneal administration of any local anesthetic prior, during and after the surgical procedure
88888779|NCT01437566|Experimental|GDC-0980-30 mg + Fulvestrant (Arm B)|Participants will receive fulvestrant 500 mg as 2 IM injections of 250 mg on Days 1 and 15 of Cycle 1 and on Day 1 of each subsequent cycle and GDC-0980 30 mg QD orally starting on Day 15 of Cycle 1, each cycle of 28 days. Study treatment will continue until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
88888780|NCT01437579|Active Comparator|Botulinum toxin|Bladder intratrigonal injection of botulinum toxin (100 units) in 10 injection sites during cystoscopy under general anesthesia
88888781|NCT01437579|Sham Comparator|cystoscopy with hydrodistension|cystoscopy with hydrodistension under general anesthesia
88888782|NCT01437592|Experimental|IDeg|
88888783|NCT01437618||BRAF mutant mCRC|
89412275|NCT02318576|No Intervention|Control|This group will do nothing for the 12 week program.
89412276|NCT02318576|Experimental|Cognitive Trained Group|This group will train three time a week for one hour on the given computerized cognitive training website for the 12 week program.
89412277|NCT02254668|Experimental|Everolimus (Certican®)|Electronic (computer-assisted) randomization of an immunosuppressive protocol WITH Everolimus (Certican®). No protocol with Mycophenolate mofetil (CellCept®). Daily dosage administered depending on blood concentration (control interval 6-12 months)
89412278|NCT02254668|Active Comparator|Mycophenolate mofetil (CellCept®)|Electronic (computer-assisted) randomization of an immunosuppressive protocol WITHOUT Everolimus (Certican®), instead administration of Mycophenolate mofetil (CellCept®). No protocol with Everolimus (Certican®). Daily dosage administered depending on blood concentration (control interval 6-12 months)
89192642|NCT06145828||Standard Treatment Group|This group receives only standard treatment . Standard treatment includes symptomatic supportive therapy, etiological therapy, fluid resuscitation, application of vasopressors, and non-invasive or invasive ventilation therapy.
89412279|NCT03097978|Experimental|RIC arm system with pattern recognition|Subject will be fit with a custom socket and receive training on pattern recognition with the RIC arm prosthesis. Once appropriate training has occurred, outcome measures will be completed followed by a home trial for at least 6 weeks with the device. Outcome measures will be collected at the conclusion of the 6 week home trial.
88888784|NCT01437631|Experimental|endoclip|The group of patients who undergo prophylactic clip application after colonoscopic polypectomy of a large pedunculated polyp(>1cm).
88888785|NCT01437631|No Intervention|no endoclip|The group of patients who do not undergo prophylactic clip application after colonoscopic polypectomy of a large pedunculated polyp(>1cm).
88888786|NCT01437644|Active Comparator|Botulinum Toxin TypeA|"A single dose of active drug or placebo will be administered immediately prior to surgery.~The injections will be given to the anaesthetised child before the surgical procedure begins. The surgeon will perform the injections at three muscle groups around each hip: the adductors, hamstrings and iliopsoas muscles. Two units per kilogram will be given at each site. The maximum dose will be 12 units per kilogram or 500 units in total (whichever is the lesser), divided equally between six or three sites. A total of 2 ml of isotonic saline will be used to dissolve the contents of the trial vial of Botox. Each active drug vial will contain 100 iu of the Botox preparation. The volume injected will be dependent on the weight of the child. Injections of normal saline will be administered in those children randomised to the placebo arm of the study."
88888787|NCT01437644|Placebo Comparator|Saline|The injections will be given to the anaesthetised child before the surgical procedure begins. The surgeon will perform the injections at three muscle groups around each hip: the adductors, hamstrings and iliopsoas muscles. Injections of normal saline will be administered in those children randomised to the placebo arm of the study. The volume of normal saline injected will be equal to the volume of normal saline that would have been used if the child had been randomised to botulinum toxin. The injector will be blinded, as the solution is drawn up by unblinded nurses.
88888788|NCT01437670||dry mouth patients with solifenacin|dry mouth patients with solifenacin 5mg, 10mg
88888789|NCT01437683||traumatic brain injury patients|a large group of traumatic brain injury patients
89192643|NCT06145802|Experimental|GT316 treatment group|
89192644|NCT06145685|Active Comparator|Previous smokers - Minimally invasive|Minimally invasive non-surgical periodontal treatment
89192645|NCT06145685|Active Comparator|Previous smokers - Conventional|Conventional non-surgical periodontal treatment
88888790|NCT01437696|Experimental|Vitamin D fortified food 500 IU|One portion of a specific food item will be provided each day. 500 IU Vitamin D added.
88888791|NCT01437696|Experimental|Vitamin D fortified food 1000 IU|One portion of a specific food item will be provided each day. 1000 IU Vitamin D added.
88888792|NCT01437696|Placebo Comparator|Placebo|One portion of a specific food item will be provided each day. No vitamin D added.
88888793|NCT01437748|Experimental|Indacaterol maleate|Indacaterol 300 mcg via Breezehaler Inhaler will be administered by a third independent investigator not involved in the performing of any of the tests decribed, following a randomization list
88888794|NCT01437748|Active Comparator|Tiotropium bromide|Tiotropium 18 mcg, via HandiHaler inhaler will be administered by a third independent investigator not involved in the performing of any of the tests decribed, following a randomization list
89535705|NCT03224143|Active Comparator|Active control group (SI)|"The SI involves the presentation of a non-anthropomorphic object, a soft foam rubber cube covered with a coloured and velvety textile. The procedure is the following:~A nurse (whom the patient knows) accompanies the patient in the room and invites her to sit on the chair.~The nurse presents the cube to the patient.~The nurse leaves the patient alone with the cube.~Interaction with the cube: it lasts 3 minutes starting from the moment when the nurse leaves the room. This phase is interrupted if the patient drops the object before the time limit.~The nurse returns into the room and takes back the cube."
89192646|NCT06145685|Active Comparator|Smoker|Conventional non-surgical periodontal treatment
89535706|NCT03224065|No Intervention|Recommended therapy group|Guideline recommended regimen for treatment, regardless of antibiotic resistant genotype test results
89535707|NCT03224065|Experimental|Optimized therapy group|Optimized therapy based on antibiotic resistant genotype test results
88888795|NCT01437761||2008 Sorbent system|Hemodialysis with the 2008 Sorbent system
88888796|NCT01437774|Active Comparator|Concentric Thrombectomy Catheter|Control Arm
88888797|NCT01437774|Experimental|Reverse ReStore mechanical thrombectomy|Reverse ReStore Device mechanical thrombectomy Each arm will use either ReStore or Merci as the primary thrombectomy device
88888798|NCT01437800|Experimental|Glimepiride / Extended release Metformin|Pharmaceutical Form: Tablets Dosage: (4/850 mg). Administration way: Oral On fasting conditions
88888799|NCT01437813|Experimental|Group A: Glimepiride / Extended Release Metformin|Pharmaceutical Form: Tablets Dosage: 4 mg / 850 mg Administration way: Oral
88888800|NCT01437826|Experimental|antioxidants|tablets composed of 200 mcg selenium [as l-selenomethionine], 30 mg zinc, 2 mg vitamin A [retinol], 180 mg vitamin C [ascorbic acid] and 30 mg vitamin E [D-α-tocopherol acetate]
88888801|NCT01437826|Placebo Comparator|Sugar pill|placebo had an identical appearance as intervention
88888802|NCT01437839|Experimental|1|Period I: fasting state, Period II: fed state
89192647|NCT06145685|Active Comparator|Non-smoker|Conventional non-surgical periodontal treatment
89535708|NCT02489513|Other|Single group assignment|[14C]-AG-120
89535709|NCT02451397||Dr.Tang's research group|Chinese lifestyle associated with osteoporosis
88888803|NCT01437839|Experimental|2|Period I: fed state, Period II: fasting state
88888804|NCT01437865|Experimental|Gadofosveset enhanced MRI Axilla|
88888805|NCT01437904|Experimental|Outpatient|Outpatient recovery following Percutaneous nephrolithotomy
88888806|NCT01437904|Sham Comparator|In hospital|Inpatient recovery following Percutaneous nephrolithotomy
88888807|NCT01437917|Experimental|Bread with 20% amylose content|Bread with 20% amylose content
88888808|NCT01437917|Experimental|Bread with 10% amylose content|Bread with 10% amylose content
88888809|NCT01437917|Experimental|carbohydrates|50g of carbohydrates ingested with 400 ml of water
88888810|NCT01437930|Placebo Comparator|placebo|products (sausage, bread rolls, milk beverage, wafers) enriched with 20g sunflower oil/d
88888811|NCT01437527|Experimental|Interventional arm|Body image therapy with Anamorphic Micro software
88888812|NCT01437527|Active Comparator|control arm|Body image therapy as usual
88888813|NCT01437982|Experimental|Loteprednol Etabonate|Ophthalmic Gel 0.5%
88888814|NCT01437982|Experimental|Prednisolone Acetate 1% Oph Susp|Ophthalmic suspension 0.5%
88888815|NCT01438021|Experimental|Treatment (intraventricular chemotherapy)|Patients receive intraventricular methotrexate continuously on days 1-14. Treatment continues in the absence of disease progression or unacceptable toxicity.
88888816|NCT01438086|Active Comparator|mecasermin low dose|
89535710|NCT03317015|Experimental|Group A - Nasacort®|Nasacort® will be sprayed twice in each nostril once every morning
88888817|NCT01438086|Active Comparator|mecasermin high dose|
88888818|NCT01438086|Placebo Comparator|saline placebo|
88888819|NCT01438099||normal subjects|parturients admitted to the labor ward who request epidural analgesia with BMI < 30
88888820|NCT01438099||obese subjects|parturients admitted to the labor ward who request epidural analgesia with BMI > 30
88888821|NCT01438112|Experimental|CG0070 oncolytic virus|Interventions: CG0070 oncolytic virus intravesical instillations weekly X6 with each instillation lasting 45 minutes after prior transduction agent of DDM intravesically for 15 minutes
88888822|NCT01438112|Active Comparator|Chemotherapy or Interferon|"Quadruple Choice as interventions~Mitomycin C~Interferon~Valrubicin~Gemcitabine"
88888823|NCT01438125|Active Comparator|MF-4181|Scar halves randomized to treatment with device, opposite side treated per standard of care
88888824|NCT01438125|Active Comparator|Standard surgical wound closure|
88888825|NCT01438138||Correlative studies|Archived bone marrow mononuclear cells are analyzed by single cell network proteomic profiling assay, the My Profile™ AML Risk of Relapse Assay. Molecular markers analyzed include Flt3-ITD, NPM1, and MRA. Results are then correlated with each patient's clinical data including patient's age, race/ethnic background, gender, treatment received, and outcomes.
88888826|NCT01438164||oncologic patients|initial staging
88888827|NCT01438190|Experimental|Experimental|Metformin plus step-down protocol
88888828|NCT01438190|Active Comparator|Control|Placebo and step-up protocol
88888829|NCT01438203|Experimental|Thrust manipulation|Clinicians will use thrust manipulation at a targeted level to provide the treatment on selected individuals
88888830|NCT01438203|Active Comparator|Non-thrust manipulation|Clinicians will apply non-thrust manipulation (targeted) as performed in a clinical manner for treatment for included individuals
88888831|NCT01438216||VUmc IC|Due to multicentre, 2 groups of patient in 1 cohort
88888832|NCT01438216||UMCN IC|Due to multicentre, 2 groups of patient in 1 cohort
88888833|NCT01438242|Experimental|Assay Guided Treatment - Genecept Asay|Subjects donate DNA sample for genetic testing and treatment decisions take genetic results into account. Genetic analysis is performed using the Genecept Assay, a genetic test which analyzes seven pharmacodynamic and three pharmacokinetic genes important in psychiatric disorders
88888834|NCT01438242|Experimental|Clinician's utilizing Assay Guided Treatment in Psychiatry|Prescribing clinicians responsible for the treatment of patients age 18 and older with a primary diagnosis of Major Depressive Disorder or Generalized Anxiety disorder, and for whom the Genecept Assay has been utilized to perform genetic testing.
88888835|NCT01438255||Alvesco|
88888836|NCT01438268||Reconstructive breast cancer patients|Patients having unilateral, bilateral immediate or delayed TRAM flaps who are discharged 18 hours postoperatively
88888837|NCT01438281|Experimental|SYL1001|
88888838|NCT01438320|Experimental|Quercetin|Quercetin is a bioflavonoid.
88888839|NCT01438333|Experimental|Lactobacillus brevis|
88888840|NCT01438333|Placebo Comparator|Placebo|5 tablets a day for 6 weeks
88888841|NCT01438346|Active Comparator|Substance Abuse Education (SED)|The Substance Abuse Education (SED) group will serve as the control intervention in which participants will receive instruction on a variety of topics included in the substance abuse treatment program curriculum. These will include, but are not limited to, information about anger management, smoking cessation, women's issues, and stress management, and approaches to help reduce cravings. Each week the TAU group will meet and a House of Hope (HOH) clinical staff member will discuss the above and related issues and how these may help individuals deal with their substance abuse and related psychological issues.
88888842|NCT01438346|Experimental|Mind-body Bridging (MBB)|Participants in the experimental Mind-Body Bridging (MBB) group, in addition to their usual treatment for substance abuse, will additionally receive instruction on the basics of MBB, and will learn MBB techniques to help deal with their cravings and comorbid psychological conditions. A workbook will be incorporated into the curriculum to provide MBB participants with daily exercises and activities to help facilitate adherence to the MBB program.
88888843|NCT05607927|Other|Parks surgery group|The CRII patients received Parks surgery
88888844|NCT05607927|Experimental|PE-Bacon surgery group|The CRII patients received PE-Bacon surgery
88888845|NCT05607433|Experimental|Air Q ILA group|Air Q supraglottic device will be placed in the participants in this group .
88888846|NCT05607433|Experimental|Ambu AuraGain group|Ambu AuraGain supraglottic device will be placed in the participants in this group .
89535711|NCT03317015|Active Comparator|Group B - Flixonase®|Flixonase® will be sprayed twice in each nostril once every morning
89535712|NCT03204487|Experimental|Patients with glaucoma or ocular hypertension|
89192648|NCT06145672|Active Comparator|Mature Alopecic Scars|Follicular Unit Extraction and implantation for Alopecic Scars in beard Follicular Unit Extraction and implantation for Alopecic Scars in scalp Follicular Unit Extraction and implantation for Alopecic Scars in eyebrow Follicular Unit Extraction and implantation for Alopecic Scars in Moustache
89412280|NCT03097978|Experimental|RIC arm system with direct control|Subject will be fit with a custom socket and receive training on direct control with the RIC arm prosthesis. Once appropriate training has occurred, outcome measures will be completed followed by a home trial for at least 6 weeks with the device. Outcome measures will be collected at the conclusion of the 6 week home trial.
89412281|NCT03097978|Experimental|Commercial system with PR control|Subject will be fit with a custom socket and receive training on pattern recognition with a conventional, commercial prosthesis system. Once appropriate training has occurred, outcome measures will be completed followed by a home trial for at least 6 weeks with the device. Outcome measures will be collected at the conclusion of the 6 week home trial.
89412282|NCT03097978|Experimental|Commercial system with Direct Control|Subject will be fit with a custom socket and receive training on direct control with a conventional, commercial prosthesis system. Once appropriate training has occurred, outcome measures will be completed followed by a home trial for at least 6 weeks with the device. Outcome measures will be collected at the conclusion of the 6 week home trial.
89412283|NCT02315924|Experimental|coronary and cerebral stenosis|
89412284|NCT02315924|Active Comparator|coronary or cerebral stenosis|
89412285|NCT03040687|Experimental|Anti-CS6 group|Anti-CS6 BSIgG and challenge strain CS6-expressing ETEC (B7A)
89412286|NCT03040687|Experimental|Anti-whole cell B7A|Anti- whole cell B7A (killed) BSIgG and challenge strain CS6-expressing ETEC (B7A)
89412287|NCT03040687|Experimental|control Immunoglobulin group|Negative Control (Nonhyperimmune BSIgG placebo) and challenge strain CS6-expressing ETEC (B7A)
89412288|NCT03544398|Active Comparator|exoskeleton|We will use exoskeleton type robot assisted gait training for spinal cord injury rehabilitation
89412289|NCT03544398|Active Comparator|end-effector|We will use end-effector type robot assisted gait training for spinal cord injury rehabilitation
89412290|NCT03544398|Placebo Comparator|conventional physiotherapy|
89412291|NCT03500276|Experimental|Yoga program|"12 weeks of Yoga in daily life practice, 2x weekly for 90 minutes including physical exercises (asanas), breathing exercises (pranayama), relaxation and meditation exercises."
89412292|NCT03500276|Active Comparator|Arthritis-education control|12 weeks of arthritis - education classes, consisting of 1x weekly sessions for 120 minutes including lectures on arthritis and related issues followed by group discussion.
89412293|NCT03098134|Experimental|VR-Video-Exposure|
88888847|NCT05607212|Experimental|Kettlebell Swing Group|Participants will perform two-handed kettlebell swings
89192649|NCT06145672|Experimental|Immature Alopecic Scars|Follicular Unit Extraction and implantation for Alopecic Scars in beard Follicular Unit Extraction and implantation for Alopecic Scars in scalp Follicular Unit Extraction and implantation for Alopecic Scars in eyebrow Follicular Unit Extraction and implantation for Alopecic Scars in Moustache
88888848|NCT05607212|Active Comparator|Active Comparator Group|Participants will perform an isometric hold of a kettlebell for 30 seconds followed by 30 seconds of rest for a total of 10 intervals.
88888849|NCT05607212|Other|Control group|participants will be educated on the benefit of a kettlebell swing.
89192650|NCT06145659|Experimental|Linkage Model|Preschool and Me intervention
89192651|NCT06145659|No Intervention|Treatment as Usual|Preschool and Me intervention is not used
89412294|NCT03098134|Active Comparator|Education-Video-|
89412295|NCT05270785|Experimental|Suicidal Teens Accessing Treatment - Primary Care (STAT-PC)|This group will undergo a brief, suicide prevention intervention based on motivational interviewing that focuses on mental health care seeking behavior, problem-solving, and referrals plus brief case management
89412296|NCT05270785|Experimental|Youth-Nominated Support Team (YST-III)|This group will undergo a brief, suicide prevention intervention originally developed for youth who have been psychiatrically hospitalized due to a suicide attempt or suicidal ideation that has been adapted
89412297|NCT03097354||Non-students|Ad-hoc sample of German adults, not currently enrolled at a university, lifetime alcohol users, no intervention/observational survey study design
89412298|NCT03097354||University students|Ad-hoc sample of German adults, currently enrolled at a university (most likely in Dresden, Germany), lifetime alcohol users, no intervention/observational survey study design
89412299|NCT02321306|Experimental|LUM001|LUM001 administered orally once each day.
89412300|NCT02316080|Experimental|Desensitizing therapy|14 groups (7 treated with in-office dental bleaching and 7 treated with home-use dental bleaching) . There will be 7 different types of dessensitizing agents that will be used together with the dental bleaching treatment
88888850|NCT05605028|Experimental|Mental Health lifestyle intervention|The intervention will focus on identifying risk factors for depression and anxiety and will quantitate the educational component of the POWER Obesity group intervention delivered by mental health professionals that are currently presenting for 30 min during the Monday session to address the root causes of obesity as well as to encourage positive lifestyle changes (e.g. sleep, diet, sun exposure, circadian rhythms, and addictions). The previously published hypothesis identifies triggers, that combined, could cause mental health problems. The 10 groups of triggers are: (1) Genetic, (2) Developmental, (3) Lifestyle, (4) Circadian Rhythm, (5) Addiction, (6) Nutrition, (7) Toxic, (8) Social/Complicated Grief, (9) Medical Condition, and (10) Frontal Lobe. Each of these factors will be dealt with in the lifestyle intervention.
88888851|NCT05605028|Active Comparator|Dietitian-led|A group of participants that visit a dietitian will be the control.
88888852|NCT05596370||biliary cancer|cholangiocarcinoma gallbladder cancer
88888853|NCT05596370||pancreatic tumor|pancreatic cancer pancreatic ductal adenocarcinoma pancreatic neuroendocrine tumor
88888854|NCT05596110|Experimental|TENS and KT|TENS will be applied on the medial and lateral joint lines of the knee and ankle joints and the anterior and posterior joint lines of the hip joint of both legs. In addition, KT will be applied to major postural muscles including the bilateral gluteus medius, quadriceps, and gastrocnemius of the participants.
88888855|NCT05596110|Sham Comparator|TENS and sham taping|TENS will be applied on the medial and lateral joint lines of the knee and ankle joints and the anterior and posterior joint lines of the hip joint of both legs. In addition, sham tapes will be applied to major postural muscles including the bilateral gluteus medius, quadriceps, and gastrocnemius of the participants.
88888856|NCT05596110|Sham Comparator|KT and sham TENS|KT will be applied to major postural muscles including the bilateral gluteus medius, quadriceps, and gastrocnemius of the participants. In addition, sham TENS will be applied on the medial and lateral joint lines of the knee and ankle joints and the anterior and posterior joint lines of the hip joint of both legs.
88888857|NCT05596110|Sham Comparator|Sham TENS and sham taping|Sham TENS will be applied on the medial and lateral joint lines of the knee and ankle joints and the anterior and posterior joint lines of the hip joint of both legs. In addition, sham tapes will be applied to major postural muscles including the bilateral gluteus medius, quadriceps, and gastrocnemius of the participants.
88888858|NCT05578859|Experimental|AMG510|Each participant will receive a single oral dose of AMG510 on Day 1 after an overnight fast.
88888859|NCT05548946|Other|General population|In this group, younger adults (18-64) and older (from 65 and older) from the general population are included. The participants fill in questionnaires.
88888860|NCT05548946|Other|Clinical Population|In this group, in- and outpatients from the clinical population are included. This are older adults, from the age of 65 with varying psychological pathologies (such as anxiety disorders, mood disorders, substance use disorders, developmental disorders, personality pathology, grief, trauma-related disorders, psychosocial problems, psychosis and schizophrenia-related disorders and somatic disorders). The patients fill in questionnaires and a randomly selected smaller group of patients will conduct a clinical interview.
88888861|NCT05515328|Experimental|Part A: Arm 1|
88888862|NCT05515328|Experimental|Part B: Arm 1 - Reference|
88888863|NCT05515328|Experimental|Part B: Arm 2 - Treatment|
88888864|NCT05502601|No Intervention|Control|The control group will be comprised by those who will not receive any specific oral care intervention. For ethical reasons, the control group will receive periodontal therapy at the Endo of the study (after 6 months). In those cases presenting periodontal disease progression in a single tooth, the patients will be treated and withdrawn from the study
88888865|NCT05502601|Active Comparator|Non-surgical periodontal treatment|"Periodontal treatment will be performed with scaling and root planning (SRP).SRP will be performed under local anesthesia during a single, 2-hour, full-mouth ultrasonic and hand instrument debridement using curettes.~Oral hygiene instructions (patient education and motivation to control plaque and calculus accumulation)"
88888866|NCT05496855|Active Comparator|Conventional follow-up|Conventional follow-up strategy with blood tests and face-to-face visits at the hospital every 6 months
88888867|NCT05496855|Experimental|Remote monitoring|Monthly remote monitoring of patient-reported outcomes and triage of patients using an algorithm will guide healthcare providers in scheduling patients for a video consultation or face-to-face hospital visits.
88888868|NCT05485688||Sleep apnea|60 moderate-to-severe OSA patients (AHI≧15/hour, 30 obese [BMI>=27] & 30 non-obese [BMI<27])
88888869|NCT05485688||Control|40 age-, gender-, BMI-matched controls without OSA.
88888870|NCT05484830|Active Comparator|Individualised HDR-approach|HMS Plus® Hemostasis Management System (Medtronic International, Tolochenaz, CH).
88888871|NCT05484830|Active Comparator|Conventional ACT-approach|ACT Hemostasis Management
88888872|NCT05473884||lesion preparation with POBA in femoropopliteal Artery occlusion|Patients with femoropopliteal artery occlusion were treated by plain old balloon angioplasty followed with DCB.
88888873|NCT05473884||lesion preparation with debulking devices in femoropopliteal Artery occlusion|Patients with femoropopliteal artery occlusion were treated by other lesion preparation devices, like Chocolate balloon, Shockwave balloon, TurboHawk, Jetstream and Rotarex and then followed by DCB.
88888874|NCT05463757||Oral hedgehog inhibitor|Oral hedgehog inhibitors vismodegib (Erivedge) or sonidegib (Odomzo)
88888875|NCT05451446|Experimental|proprietary water|Participants in this group will consume a proprietary water blend for 5-free living days and then throughout their heat stress environment day.
88888876|NCT05451446|Active Comparator|carbohydrate-electrolyte drink|Participants in this group will consume a commercial carbohydrate-electrolyte drink for 5-free living days and then throughout their heat stress environment day.
88888877|NCT05451446|Placebo Comparator|distilled water|Participants in this group will consume distilled water for 5-free living days and then throughout their heat stress environment day.
88888878|NCT05426447|Experimental|Reduced protein diet|"A 6-week eucaloric dietary intervention of reduced protein intake (~1g protein/kg body mass). The diet will, hence, contain ~7E% protein, ~63E% carbohydrate, and ~29E% fat.~Participants are free-living and receive all food pre-packed from the study kitchen. The energy provision will be set to match energy balance."
89412301|NCT02316080|Experimental|Dental Bleaching|2 groups of dental bleaching treatment - 16% carbamide peroxide and 35% peroxide
89412302|NCT03095404|Experimental|Low Dose Lidocaine|60 cc syringe with 2 vials of 1% lidocaine (40cc's) low dose solution using adjusted body weight formula
89412303|NCT03095404|Experimental|High Dose Lidocaine|60 cc syringe with 2 vials of 2% lidocaine (40 cc's) high dose solution using adjusted body weight formula
89412304|NCT02145546|Experimental|Amiodarone|Patient will take Amiodarone orally
89412305|NCT02145546|Experimental|Sotalol|Patients will take sotalol orally
89412306|NCT02145546|Experimental|Propafenone|Patients will take propafenone orally
89412307|NCT02145546|No Intervention|Control|Patients will take no antiarrhythmic drugs except β-blocker
89412308|NCT03039673|Experimental|low dose interleukin-2|"Patients randomized to this arm will receive subcutaneous injections of low-dose interleukin-2 in addition to oral Riluzole treatment.~Intervention: Riluzole Intervention: IL-2"
89412309|NCT03039673|Placebo Comparator|Placebo|"Patients randomized to this arm will receive subcutaneious placebo injections (5% glucose water solution) in addition to oral Riluzole treatment.~Intervention: Riluzole Intervention: 5% glucose water solution"
89412310|NCT02316158|Experimental|Webb-based support and education|It contains of two parts 1) evidence based information (about mental diseases, early signs, coping strategies, what you can do for your relative or close friend, what you can do for yourself, addresses to networks and web sites, relevant juridical issues, etc), 2) FAQ, where you directly can find answers to common questions.
89412311|NCT02316158|Active Comparator|Available support in society|Available support in society for young persons presented in a brochure
89412312|NCT03097432||ORALVAC COMPACT BÄUME|This non-interventional study was initiated to document the up-dosing period of children and adults with allergic rhinoconjunctivitis and/or allergic asthma treated with a SLIT containing purified, aqueous extracts of birch, alder, and hazel pollen. The following up-dosing schemes were freely selectable: scheme A consists of an up-dosing period of 12 days at the patient´s home using the standardized pollen extract in three different solution strengths to reach the maximum dose; scheme B performed only with the highest solution strength at the physician's office within 2 hours; and the new scheme C which is a regimen for initiation at the physician's office and continuation at the patient's home also exclusively using the highest solution strength and takes 4 days.
89412313|NCT04461782|Experimental|Lactobacillus plantarum|"Oral intake 1 cap daily~1E+09 cfu/cap of Lactobacillus plantarum"
89412314|NCT02145624|Active Comparator|Repevax|Repevax in pregnancy
89412315|NCT02145624|Active Comparator|Boostrix-IPV|Boostrix-IPV in pregnancy
89412316|NCT02145624|No Intervention|unvaccinated|unvaccinated mothers
89412317|NCT03042559|Active Comparator|Protonics knee brace|All subjects were fitted with a regular-sized Protonics knee brace with resistive settings to resist knee flexion.
89412318|NCT03042559|Experimental|Sport cords|Resistive sports cord to resist knee flexion.
89412319|NCT05033938|Active Comparator|Early Mobilization|Post-operatively subjects receive a removable wrist splint that can be taken off for early wrist mobilization
89412320|NCT05033938|Active Comparator|Late Mobilization|Post-operatively subjects receive a splint and are not instructed to not move their wrist till the 2 week follow up visit.
89412321|NCT02321384|Experimental|A: SAD Cohorts - RO6889678/Matching Placebo|Healthy participants will be enrolled into 1 of 6 planned SAD cohorts to receive single dose of RO6889678/matching placebo in fasted state as per anticipated dose escalation sequence (30 milligrams [mg], 100 mg, 300 mg, 600 mg, 1000 mg and 1500 mg). Cohort 1 will be split in 2 groups: 2 participants will be dosed 1 day (1 on RO6889678 and 1 on matching placebo) and 3 participants (2 on RO6889678 and 1 on matching placebo) will be dosed at least 24 hours afterward following satisfactory safety assessment for first 2 participants. Cohort 2 & beyond will include 8 healthy participants with 6 participants randomly assigned to RO6889678 & 2 randomly assigned to placebo. Participants who will tolerate fasted dose and agree to continue in food-effect SAD cohort, will receive single dose (dose level, either 300 mg or 600 mg, decided based on PK and safety data of first 2 SAD cohorts) of RO6889678/matching placebo with US FDA recommended high-fat and high-calorie breakfast on Day 16.
89412322|NCT02321384|Experimental|B: MAD Cohorts - RO6889678/Matching Placebo|Healthy participants will be enrolled into 1 of 4 planned MAD cohorts to receive RO6889678 or matching placebo (at a dose that will be decided as per the safety, tolerability and PK data from SAD 4 cohort) twice daily (BID) for 14 days except for Day 14, where only one dose in the morning will be given. Each of the MAD cohorts will include 8 healthy participants with 6 participants randomly assigned to RO6889678 and 2 participants randomly assigned to placebo. All participants enrolled to the MAD cohorts will receive an oral microdose of midazolam (100 micrograms [mcg]) before (Day -1) and after (Day 14) the repeat treatment with RO6889678 or matching placebo.
89437566|NCT03621670|Placebo Comparator|Placebo+PCV Group|Approximately 400 subjects enrolled in this group will receive PCV13 concomitantly with placebo and other RIV at 2, 4, 6 and 12 months of age. Subjects who have received 3 PCV13 doses before 12 months of age but have not received their fourth booster dose will either receive PCV13 or PCV20 at 12 months of age (Visit 5).
89437567|NCT03610906||Pediatrics with Tumors|Pediatrics who have a tumor specimen that is suspected to be craniopharyngioma, but is deemed superfluous to the clinical care of the patient (e.g. pathological diagnosis).
89437568|NCT03610737|Active Comparator|MILD with CMM|The MILD procedure is an image-guided minimally-invasive lumbar decompression with conventional medical managment
89412323|NCT02321384|Experimental|C:RTV-Boosted SAD & MAD Cohorts-RO6889678/Matching Placebo+RTV|Healthy participants will be enrolled in up to 3 SAD cohorts (2 compulsory and 1 optional) and up to 3 MAD cohorts (1 compulsory and 2 optional) to receive RO6889678 in combination with RTV in fed state. Participants of the first 2 RTV-boosted SAD cohorts will receive 100 mg RO6889678 + 100 mg RTV and 300 mg RO6889678 + 100 mg RTV respectively. Based on the PK and safety evaluation of the first 2 RTV-boosted SAD cohorts, another SAD cohort may be enrolled to receive a different dose of RO6889678 in combination with RTV. MAD RTV-boosted cohort will start based on the safety, tolerability and PK data of the RTV-boosted SAD cohorts. All participants enrolled to the RTV-boosted MAD cohorts will receive RO6889678 or placebo together with RTV on BID schedule for 14 days, and additionally an oral microdose of midazolam (100 mcg) before (Day -1) and after (Day 14) the treatment.
89412324|NCT03095326|Experimental|Zinc Syrup 1.5 mg/kgbw/day|Patient were given zinc formula in the form of syrup with dosage of 1.5 mg/kg body weight/day with a maximum dose of 50 mg/day. The amount of syrup given is estimated to be enough for 4 weeks.
89412325|NCT03095326|Placebo Comparator|Sucrose syrup|Patient were given sucrose syrup as placebo. The syrup was made in the same flavor and consistency as the zinc syrup.
89412326|NCT02780856|Other|Sound and unsound teeth|Sound (ICDAS 0) canines or incisors and unsound (ICDAS 2 or 3) molars or pre-molars - imaging with the Calcivis System
89412327|NCT03095092|Experimental|BIA 6-512 fed|BIA 6-512 400 mg following a standard meal
88888879|NCT05426447|Active Comparator|Normal protein diet|"A 6-week eucaloric dietary intervention of normal protein intake (~2g protein/kg body mass). The diet will, hence, contain ~16E% protein, ~53E% carbohydrate, and ~30E% fat.~Participants are free-living and receive all food pre-packed from the study kitchen. The energy provision will be set to match energy balance."
89535713|NCT03316937|Experimental|Teflon Scaler|The buccal and lingual surface of the 23 participants' crowns will be randomly assigned to receive scaling and root planing with either Teflon scalers, or non-Teflon scalers after implant crown delivery. Each patient will act as their own control.
89535714|NCT03316937|Experimental|Non Teflon Scaler|The buccal and lingual surface of the 23 participants' crowns will be randomly assigned to receive scaling and root planing with either Teflon scalers, or non-Teflon scalers after implant crown delivery. Each patient will act as their own control.
88888880|NCT05399966|Experimental|Monarda Didyma extract|Monarda Didyma extract
88888881|NCT05399966|Placebo Comparator|Placebo|Maltodextrin
88888882|NCT05390034|Experimental|ART|Developed by Berking and Whitley (Berking & Whitley, 2014), this transdiagnostic program aims to improve general emotion regulation skills, and more specifically by increasing participants' emotion regulation flexibility. ART targets several skills, such as acceptance, tolerance, non-judgmental awareness, self-support, analysis of the causes of emotions and emotional modification. This intervention consists of 9 sessions (2 hours each), each of which starts with the presentation of a vicious circle for psycho-education. This vicious circle is then transformed into a virtuous circle by introducing an emotion regulation skill. Participants are invited to reflect, discuss and practice this skill. Exercises are also recommended at home, with the help of audios and a written workbook made available. All the material was translated into French for the purpose of this research.
88888883|NCT05390034|Active Comparator|Relaxation|The relaxation group will be based mainly on the intervention developed by Dominique Servant (Relaxation and meditation, 2021), adapted for this research for the group format and divided into 9 modules (2 hours each). This intervention proposes an added psycho-education part similar to the dedicated session of the ART program, followed by the teaching of different relaxation techniques to the participants, who are invited to test them in session and then to practice them at home. This control group focuses on a specific component present in the ART group (relaxation), allowing us to assess the impact of the other components of the ART program and thus explore our flexibility hypothesis (requiring several emotion regulation skills). Note that the mindfulness meditation components were removed from the program for this study, as they were considered a second emotion regulation skill.
88888884|NCT05373316|Experimental|MR-guided hypofractionated focal boost radiotherapy|External beam MR-guided (MR-linac) radiotherapy to the prostate and seminal vesicles of 5x7Gy (once weekly) with an isotoxic integrated focal boost up to 50Gy to the intraprostatic tumor as visible on multiparametric MR
88888885|NCT05371275|Experimental|Palbociclib|125 mg of palbociclib once daily for 21 consecutive days
88888886|NCT05370794||standard IVM: urinary purified gonadotropins (uFSH and uhCG)|"uhCG = Pregnyl®, 5000IU/ vial, Organon-Merck: final concentration 100mIU/ml + uFSH = Menopur® 75mIU/ml, Ferring: final concentration 75mIU/ml.~Administered during 30h of in vitro maturation culture"
88888887|NCT05370794||Experimental IVM: recombinant gonadotropins (rFSH and rhCG)|"rhCG= Ovitrelle®, 250g/0.5ml = 26000IU/ml, Merck-Serono : final concentration 100mIU/ml + rFSH = Gonal F®, 300IU/0.5ml, Merck-Serono: final concentration 75mIU/ml.~Administered during 30h of in vitro maturation culture"
88888888|NCT05343507|Experimental|Ketalar arm|Patients will receive ketamine (sold in the form of Ketalar) intravenously, up to 0.75 µg/ml concentration, for a maximum of 90' minutes. Ketalar concentration will be increased slowly in a step-wise manner unless new signs of consciousness are evident.
88888889|NCT05343507|Placebo Comparator|Placebo arm|Patients will receive placebo (saline solution)
88888890|NCT05340712|Experimental|IT formula|The test product (IT formula) is an infant formula based on cow's milk proteins containing a high level of lactose, a prebiotic, a high concentration of magnesium and a mix of probiotics.
89412328|NCT03095092|Experimental|BIA 6-512 fasting|BIA 6-512 400 mg following at least 8 h of fasting
89412329|NCT02318810|Active Comparator|Rocuronium 0.3 mg/kg|Patients receive rocuronium 0.3 mg/kg
89412330|NCT02318810|Active Comparator|Rocuronium 0.6 mg/kg|Patients receive rocuronium 0.6 mg/kg
89412331|NCT02318810|Active Comparator|Rocuronium 0.9 mg/kg|Patients receive rocuronium 0.9 mg/kg
89412332|NCT02318810|Placebo Comparator|Placebo|Patients receive saline
89535715|NCT03204565|Experimental|CAF + HA (Test)|coronally advanced flap with hyaluronic acid
89535716|NCT03204565|Active Comparator|CAF (control)|coronally advanced flap alone
89535717|NCT03321227|Experimental|Snack skipping|No snack provided
89535718|NCT03321227|Experimental|Whole eggs|2 whole large eggs as a snack
89535719|NCT03321227|Experimental|Egg whites|2 egg whites as a snack
89535720|NCT03321227|Experimental|Egg yolks|2 egg yolks as a snack
89535721|NCT03321227|Active Comparator|Yogurt|Full fat yogurt as a snack
89412333|NCT02141880||Treatment|All subjects will be under the same protocol which is eating and drinking on one afternoon.
89412334|NCT03766477||Individuals with sleep bruxism|"Individuals with sleep bruxism evaluated in three different methods regarding their sleep quality:~Pittsburgh Sleep Quality Index (IQSP) and Johansson~Smartphone APP~Polysomnography"
89412335|NCT03098056|Experimental|PROG2|All subjects will be participating in a lifestyle change program - specifically a high protein, limited carbohydrate food plan (High Phyto-PRO food plan), physical activity and a cognitive behavioral program consisting of 11 group visit. Participants will be recieving nutritional Supplements.
88888891|NCT05340712|Placebo Comparator|Standard formula|The control product is a standard infant formula based on cow's milk proteins containing usual lactose and magnesium content, no prebiotic nor probiotic.
88888892|NCT05321914|No Intervention|Control|Habitual physical activity
88888893|NCT05321914|Experimental|Morning exercise|Exercise training in the morning (6:00-10:00am)
88888894|NCT05321914|Experimental|Evening exercise|Exercise training in the evening (4:00-8:00pm)
88888895|NCT05309941|Experimental|Internal Cues Messaging|Participants will view a five-minute video focusing on intuitive eating principles.
88888896|NCT05309941|Active Comparator|External Cues Messaging|Participants will view a five-minute video focusing on traditional nutrition education principles.
88888897|NCT05303298|Experimental|Anti-reflux Oesophageal Stent Group (AOSG)|All patients randomised to this arm will receive an anti-reflux fully covered self-expanding metal oesophageal stent
88888898|NCT05303298|Active Comparator|Conventional Oesophageal Stent Group (COSG)|All patients randomised to this arm will receive a conventional fully covered self-expanding metal oesophageal stent that does not contain an anti-reflux mechanism
88888899|NCT05290883|Experimental|Group A: Yoghurt drink (polar lipid) intervention|
88888900|NCT05273281|Experimental|TAQLA|Transabdominal plain block -group. Ropivacaine Hydrochloride Inj 5mg/ml 20 ml perineurally per side.
88888901|NCT05273281|Experimental|TAQLB|Quadratus lumborum block -group. Ropivacaine Hydrochloride Inj 5mg/ml 20 ml perineurally per side.
88888902|NCT05273281|No Intervention|TAQLC|Control group. Pain relief only with intravenous and peroral drugs.
88888903|NCT05243394|Experimental|Gamified virtual reality environtment + tDCS + treadmill gait training|The first group will follow an 18-session gait training protocol for 6 weeks. Duration of the sessions will progressively increase from 20 to 45 minutes from first session to last. They will be immersed in a gamified virtual reality environment in which they will interact with the in-game ambient by having their feet represented on the screen and move as their own on the treadmill. They will also receive tDCS for the first 20 minutes of each session.
89005395|NCT04571671||Control group|Patients who receive donated oocytes and who do not present Müllerian anomalies. An absence of AM, a transvaginal ultrasound, an HSG or a normal hysteroscopy with a uterine cavity with a normal shape and absence of intracavitary images is considered
89412336|NCT03544788|Experimental|Cirvo™ Therapy|
89412337|NCT03500120||Primary Aldosteronism|Aldosterone/renin concentration ratio(ARR)≥1.0 (ng/dl)/(mIU/l) and 2. PAC post-FST≥6 ng/dl
89412338|NCT03500120||non Primary Aldosteronism|1. ARR≥1.0 (ng/dl)/(mIU/l) and 2. PAC post-FST<6 ng/dl
89412339|NCT01684735||women with BRCA and chemotherapy|women recently diagnosed with breast cancer and start with neo-adjuvant chemotherapy (6 cycles) before surgery/therapy
89412340|NCT05054764||Participants with CLTI and BTK lesions planned for revascularization|The study population will be CLTI patients presenting with lower limb tissue loss (ulcer or gangrene) and BTK lesions who are candidates for revascularization for limb salvage.
89412341|NCT02141958|Experimental|Fenretinide|Fenretinide will be administrated orally once per day for 21 consecutive days, in up to three treatment cycles of ascending doses, with a minimum of 7-day drug-free period between cycles. Twelve (12) patients will be on Fenretinide.
89412342|NCT02141958|Placebo Comparator|Placebo|Four (4) patients will be on Placebo.
89412343|NCT02142036|Experimental|ATI based targeted therapy.|EMA-approved ATI based targeted therapy. Patients will receive therapy based on molecular aberrations identified in the metastatic lesion.
89412344|NCT05501743|Experimental|Study treatment group (T)|The treatment by intra-articular injection of autologous microfat and PRP will be performed during a half-day outpatient stay in the hand and limb repair surgery department at the Hôpital de la Timone. The total duration of the procedure is approximately 4 hours and includes 2 surgical times performed in the operating room and an intermediate waiting time for the patient in an outpatient room during the preparation of the experimental products.
89437569|NCT03610737|Active Comparator|CMM alone|Patient in the CMM alone group can have physical therapy, home exercise, pain medication, epidural steroid injections, nerve blocks, and other lumbar steroid injections.
89412345|NCT05501743|Active Comparator|Reference treatment group (R)|The surgical treatment by total denervation of the wrist will be performed during a one-day outpatient stay in the hand and limb surgery department at the Hôpital de la Timone. It will be performed under loco-regional anesthesia by axillary plexus block.
89412346|NCT05053984|Experimental|Neuromodulation|This study has only 1 arm and the control group is their baseline data
89412347|NCT03494582|Experimental|Sacral Hysteropexy|Abdominal approach for uterine suspension
89412348|NCT03494582|Experimental|sacrospinous Hysteropexy|Transvaginal approach for uterine suspension
89412349|NCT05053594|Experimental|Group N10|Reversal with neostigmine 10 mcg/kg and atropine 5 mcg/kg
89412350|NCT05053594|Experimental|Group N20|Reversal with neostigmine 20 mcg/kg and atropine 10 mcg/kg
89412351|NCT05053594|Experimental|Group N30|Reversal with neostigmine 30 mcg/kg and atropine 15 mcg/kg
89412352|NCT05053594|Placebo Comparator|Group P|Spontaneous reversal (placebo)
88888904|NCT05243394|Experimental|Gamified virtual reality environtment + treadmill gait training|The second group will follow an 18-session gait training protocol for 6 weeks. Duration of the sessions will progressively increase from 20 to 45 minutes from first session to last. They will be immersed in a gamified virtual reality environment in which they will interact with the in-game ambient by having their feet represented on the screen and move as their own on the treadmill.
88888905|NCT05243394|Active Comparator|Treadmill gait training|The third group will follow an 18-session gait training protocol for 6 weeks. Duration of the sessions will progressively increase from 20 to 45 minutes from first session to last.
88888906|NCT05228847|Active Comparator|Human milk-derived HMF|Fortification with human milk-derived product
88888907|NCT05228847|Other|Bovine milk-derived HMF|Current standard practice: Fortification with bovine milk-derived product
88888908|NCT05226962|Active Comparator|Ketone|An acute bout of exercise performed after the ingestion of a commercial ketone monoester supplement.
88888909|NCT05226962|Placebo Comparator|Control|An acute bout of exercise performed after the ingestion of a taste-matched placebo supplement.
88888910|NCT05215210|Experimental|Bitter-gourd|dried bitter-gourd supplements
88888911|NCT05215210|Active Comparator|Cucumber|dried cucumber supplements
88888912|NCT05186064|Experimental|whole genome sequencing after standard of care resection at first relapse|
88888913|NCT05175651|Experimental|Subjects identified by Optum Health|10,000 individuals identified by Optum Health as likely meeting inclusion criteria by claims analysis.
89412353|NCT04462016|Active Comparator|Reference drink|Healthy volunteers' blood glucose response to reference drink (glucose)
89412354|NCT04462016|Experimental|Test drink|Healthy volunteers' blood glucose response to test drink (calamansi)
89412355|NCT02324426|Experimental|Reduced Glutathione|The study medication is packaged in sterile 1 ml pre-filled syringes, each containing 200 mg/ ml of reduced glutathione (GSH), which will be delivered intranasally.
89437570|NCT03589339|Experimental|NBTXR3 activated by SABR followed by anti-PD-1 monotherapy|Intratumoral injection of NBTXR3 followed by SABR followed by monotherapy with nivolumab or pembrolizumab
89535722|NCT02451319|Active Comparator|first group|Patients undergoing Retrograde Intrarenal Surgery with 20w holmium laser device who have 1-2 cm diameter kidney stones
89535723|NCT02451319|Active Comparator|second group|Patients undergoing Retrograde Intrarenal Surgery with 30w holmium laser device (working over 20w power) who have 1-2 cm diameter kidney stones
89535724|NCT02451319|Active Comparator|third group|Patients undergoing Retrograde Intrarenal Surgery with 30w holmium laser(working under 20w power) device who have 1-2 cm diameter kidney stones
89535725|NCT02486159|Experimental|Herbal plaster and Acupuncture|"In the first year: Acupoint herbal plaster applications every one week over a 4-week period for a total of 4 applications.~In the second year: Acupoint herbal plaster used as the same method as first year, and combined with Acupuncture treatment in the same time."
89535726|NCT03224377||rheumatoid arthritis patients|Complete blood count Esr Crp Liver function test Kidney function test Hepatitis markers Rheumatoid factor Urine analysis Anti cyclic citrullinated peptide antibodies Anti mutated citrullinated vimentin antibodies
89535727|NCT03224377||healthy control|Complete blood count Esr Crp Liver function test Kidney function test Hepatitis markers Rheumatoid factor Urine analysis Anti cyclic citrullinated peptide antibodies Anti mutated citrullinated vimentin antibodies
89535728|NCT02489435|Experimental|10 mg VM-1500 or Placebo|VM-1500 for 9 volunteers, Placebo for 3 volunteers.
89535729|NCT02489435|Experimental|20 mg VM-1500 or Placebo|VM-1500 for 9 volunteers, Placebo for 3 volunteers.
89535730|NCT02489435|Experimental|30 mg VM-1500 or Placebo|VM-1500 for 9 volunteers, Placebo for 3 volunteers.
89535731|NCT02451787|Experimental|Active|vitamin D supplementation group (2500 IU day for 3 months)
89535732|NCT02451787|Placebo Comparator|Control|no vitamin D supplementation
89535733|NCT03321149|Experimental|RiseTx|Participants were given access to the RiseTx application and an activity monitor to participate in the five phase intervention.
89535734|NCT03224221|Experimental|Apatinib with Chemotherapy|Apatinib with Chemotherapy(Fluorouracil and platinum)，patients will receive Apatinib at 500mg/times,oral one times daily for 28 days.the dosage of the fluorouracil and platinum need to be determined by the doctors according to the actual condition of the patients
89535735|NCT03224221|Active Comparator|Chemotherapy|Chemotherapy (Fluorouracil and platinum)，the dosage of the fluorouracil and platinum need to be determined by the doctors according to the actual condition of the patients.
89535736|NCT03204253|Experimental|rFSH + r-LH in combination|treatment group
89437571|NCT03588585|Active Comparator|Tension|foley balloon will be placed on tension and taped to thigh at 10 cm. Misoprostil will be placed in posterior vaginal vault.
89535737|NCT03204253|Active Comparator|rFSH alone|control group
89535738|NCT02486003||mTBI athletes|College athletes who undergo an mTBI during the season
89535739|NCT02486003||Control athletes|College athletes who do not undergo an mTBI during the season
89535740|NCT02486003||Control non-athletes|Control non-athletes with long term follow-up of approximately 4-6 weeks and 3-5 months
89535741|NCT03204175|Experimental|Fit Plus|The experimental arm will receive the Fit For School expanded intervention, which addresses pupil handwashing, toothbrushing, and school sanitation maintenance. Interventions will begin in July 2017.
89412356|NCT03097510|Experimental|Transcendental Meditation|The TM technique is a simple, natural, effortless technique that allows the mind to experience finer levels of the thinking process until the mind transcends and experiences the source of thought, a state of deep, integrated relaxation. During the meditation session, the active mind settles down to a silent yet fully awake state of awareness. TM was taught to study participants by certified instructors, using standardized procedures for teaching.
89412357|NCT03097510|No Intervention|Wait list control|This wait list group served as the control group. After the study was completed, the wait-list controls were given the option to learn the TM technique as their reward for participating as controls during the 4 month study.
88888914|NCT05164159|Active Comparator|propofol group|During induction, the propofol group starts the effect site concentration at 4.0 ng/ml with TCI and adjusts it to around 3.0 ~ 4.0 ng/ml after intubation to maintain an appropriate EEG-based depth of anesthesia.
89412358|NCT02142114|Active Comparator|Eye injection by 30 gauge needle|Consented patients receiving monthly bi-lateral injections of the same dose of ranibizumab will have one eye injected with a 30 gauge needle and the other eye injected with a 32 gauge needle. Bi-lateral injections may be performed on the same day or with one week of each other, depending on the subject preference and their normal injection regimen. On the first visit following enrollment in the study, the eye to receive the injection from the 30 or 32 gauge needle will be determined randomly. The other eye will be injected with the other needle size (may be that day or within 1 week of the 1st injection). When the patient returns for their next set of bi-lateral injections, the eyes receiving the 30 and 32 gauge needle injection will switch.
89412359|NCT02142114|Active Comparator|Eye injection by 32 gauge needle|
89412360|NCT05053516|Other|the intervention group|The intervention group will participate in the training program of this study, while the control group will receive the existing routine training program.
89412361|NCT05053516|Other|the control group|The intervention group will participate in the training program of this study, while the control group will receive the existing routine training program.
89412362|NCT02318888|Experimental|Surgery and Icodextrin|Icodextrin 4% instilled every 30 minutes during surgery and 1000 ml instilled before closure of abdomen
89412363|NCT02318888|Active Comparator|Surgery|No instillations during surgery
89412364|NCT02142192|Experimental|natalizumab|natalizumab 300mg SC every 4 weeks for up to 12 treatment administrations (i.e. Day 1 through Week 44)
89412365|NCT02145702|Experimental|Exercise Group|Subjects randomized to this group will start 12 weeks of supervised aerobic exercise after baseline testing.
89412366|NCT02145702|Experimental|Control Group|Subjects randomized to this group will continue with 12 weeks of Standard Care. After 12 weeks, the subjects will cross over to the exercise arm and undergo baseline testing again and then start 12 weeks of exercise intervention.
89412367|NCT05033860|Experimental|Intervention group|Leaflets containing knowledge of COVID-19 and vaccination were distributed, and questionnaire surveys were conducted afterwards.
89412368|NCT05033860|No Intervention|Control group|Questionnaire surveys were conducted without leaflets distribution.
89412369|NCT02145780|Experimental|2g of grape polyphenol extract supplement|Men will have to consume daily 2g of grape polyphenol extract during the 31 days of overfeeding.
88888915|NCT05164159|Experimental|remimazolam group|Arm Description: In the remimazolam group, start remimazolam at 6 mg/kg/hr and adjust it to 1 mg/kg/hr after loss of consciousness to maintain an appropriate EEG-based depth of anesthesia.
88888916|NCT05164146|Active Comparator|propofol group|During the induction, propofol was controlled according to sedline (Psi target 40)
88888917|NCT05164146|Experimental|remimazolam group|During induction, remimazolam dose was controlled according to sedline (Psi target 40)
89412370|NCT02145780|Placebo Comparator|2g of placebo (lactose)|Men will have to consume daily 2g of placebo during the 31 days of overfeeding.
89412371|NCT02749045|Other|Image acquisition arm|Subjects who have undergone a clinically indicated fractional flow reserve measurement in the cardiac catheterization laboratory will receive standard dose Tc-99m sestamibi and undergo resting SPECT image acquisition within three hours from end of cardiac catheterization procedure.
89412372|NCT02321540|Experimental|Ibrutinib|"Participants in Part 1 receive dose level of Ibrutinib depending on study joined. First group of participants receive lowest dose level of Ibrutinib. Each new group receives a higher dose of Ibrutinib than the group before it, if no intolerable side effects were seen. This continues until highest tolerable dose of Ibrutinib is found.~Participants in Part 2 receive Ibrutinib at highest dose that was tolerated in Part 1 or 840 mg daily.~Starting level of Ibrutinib: 560 mg by mouth daily in a 28 day cycle."
89412373|NCT03544320|Active Comparator|Activity Monitoring-Wrist worn wearable|Participants in the activity monitoring-wrist worn wearable group will be randomly assigned to track their activity using a Fitbit Charge 2 for 6 months.
89412374|NCT03544320|Active Comparator|Activity Monitoring-Waist-worn wearable|Participants in the activity monitoring-waist worn wearable group will be randomly assigned to track their activity using a Fitbit Zip for 6 months.
89412375|NCT02321618|Experimental|BP measurement & pharmacy|BP measurements performed by barber, role model poster exposure in barbershop, and BP medication management visits with study pharmacist
89412376|NCT02321618|Other|BP educational materials|Exposure to hypertension educational materials in barbershop
89412377|NCT02324582|Experimental|Intravenous MK-3475/ Intravesical BCG|3 subjects will be treated at a dose of 100 mg MK-3475 at 100 mg every 3 weeks (Q3W) intravenously (IV) for 6 doses and 1 vial intravesicular BCG suspended in 50 ml preservative-free saline once per week of 6 weekly doses 12 subjects will be treated at a dose of 200 mg MK-3475 at 100 mg every 3 weeks (Q3W) intravenously (IV) for 6 doses and 1 vial intravesicular BCG suspended in 50 ml preservative-free saline once per week of 6 weekly doses
89412378|NCT01255891|Other|Adjuvant|Adjuvant suppression plus radiation therapy
89412379|NCT02321696|Experimental|Acupuncture and eccentric exercise|Treatment will be performed according to traditional Chinese methods (STRICTA: Standards for reporting interventions in controlled trials of acupunc-ture). Therapists will select points frequently recommended for the treatment of LE. As local point, LI11 and LI10 over the muscular origin of the lateral extensor group of the forearm will be used, and LU5 in the cubical region. LI4 and TE5 will be regional points for pain therapy in the upper limb, GB34 will be used as a distal point for treatment of tendinosis in general, and ST36 for treatment of pain. Needles will be inserted down to the musculature and obtaining De Qi sensation and will remain in situ for 20 min. All patients will receive four treatment sessions; this may be extended to eight depending on patient's pain report and the therapists' clinical evaluation. Maximum treatment period is 4 weeks. Patients will also be instructed in eccentric strength exercises for daily home training from enrolment and 12 weeks forward.
89412380|NCT02321696|Experimental|Physiotherapy and eccentric exercise|"Manual techniques as gliding mobilization of elbow, therapists are spezialised in manual therapy. At least four treatment sessions will be performed, but depending on the patient's perceived intensity of pain and the therapists' clinical evaluation, a maximum of eight treatment session can be given. All treatment session will be performed during a period of maximum 4 weeks.~In addition, patients will be instructed in eccentric strength exercises for daily home training from enrolment and 12 weeks forward."
88888918|NCT05156333|Placebo Comparator|Placebo|Daily oral administration of 1 capusle of placebo, composed of: hydroxypropylmethylcellulose; Anti-caking agent: Magnesium salts of fatty acids, Dioxide of silicon; Dye: E171.
89412381|NCT02321696|Active Comparator|Watchful waiting and eccentric exercise|Patients will be instructed in eccentric strength exercises for daily home training from enrolment and 12 weeks forward.
89412382|NCT02777190|Experimental|Oral misoprostol|oral misoprostol given 25 mcg every 2 hours
89412383|NCT02777190|Active Comparator|Vaginal misoprostol|vaginal misoprostol given 25 mcg every 4 hours
88888919|NCT05156333|Active Comparator|Probiotic|Daily oral administration of 1 capsule of mixture of probiotics and milk glycoproteins with prebiotic action); Cornstarch; Anti-caking agents: Vegetable magnesium stearate, Silicon dioxide; Capsule orally administered: Hydroxypropylmethylcellulose (coloring: E171).
88888920|NCT05132517||Stroke Patients|Ischemic-/hemorragic stroke patients, who admitted on the stroke unit.
89412384|NCT03494426|Experimental|interventional group|patients will receive Radiofrequency thoracic sympathectomy then will receive pregabalin ,tramadol,and tricyclic antidepressants
89412385|NCT03494426|Active Comparator|control group|patients will receive pregabalin ,tramadol,and tricyclic antidepressants
89412386|NCT03494270|Experimental|Rosuvamibe Tab|Rosuvastatin 10mg/Ezetimibe 10mg qd for 24 weeks
89412387|NCT03494270|Active Comparator|Monorova Tab|Rosuvastatin 20mg qd for 24 weeks
89412388|NCT03497468|Active Comparator|Control group|Patients in this group will receive combined exercise training included aerobic and strengthening exercises, 3 times a week for 6 weeks. All exercise sessions will be performed under the supervision of a physiotherapist.
89412389|NCT03497468|Experimental|Training group|Patients in this group will receive task-oriented training additional to combined exercise training 3 times a week for 6 weeks. Task-oriented training included more functional daily life mobility activities like reaching, obstacle walking, stairs climbing. All exercise sessions will be performed under the supervision of a physiotherapist.
89412390|NCT02319122|Other|Progressive Resistance Training|"The key for the PRT is the timely progression of load, based on the child's individual level of strength, which ensures progressive overload.~Every training session will consist of a warm up, progressive resistance exercises and a cool down period. During warm up and cool down periods.These exercises will be the same for both training groups.~The strength training exercises have been chosen to strengthen the main lower extremity muscle groups which are important for the gait: sit-to-stand, lateral step-ups, the half knee rise, heel-rises and bridging.~All these exercises are performed loaded according to the individual level. Three sets of 8 to 10 repetitions of each exercise will be practiced on 3 non-consecutive days with moderate velocity."
89412391|NCT02319122|Other|High Intensity Interval Training|The High Intensity Circuit Training is a sub form of High Intensity Interval Training. The key feature is the very little rest between the exercises which causes a consistent elevation of the participant's heart rate and a short duration of the whole exercise session. Every training session consists of a warm-up, a circuit of 5 exercises (the same as these in the PRT group) and a cool-down period. The children will be asked to train 3 times a week on non-consecutive days and to perform 3 sets. Exercise workload is controlled by determination of time intervals (30 seconds). The children will be instructed to perform as many repetitions as possible during the exercise interval and to keep the rest between the exercises short (it must not exceed 30 seconds).
89437572|NCT03588585|Active Comparator|No tension|The foley balloon will be loosely taped without tension to the patient's thigh. Misoprostil will be placed in the posterior vaginal vault.
89535742|NCT03204175|Active Comparator|Comparator|This group will receive the Fit Plus intervention after the trial is complete (January 2017)
88888921|NCT05114447||Clinical sample|a) clinical cases of severe/uncontrolled asthma attending hospital specialist centres already included in the online RItA Registry and b) new clinical cases of severe/uncontrolled asthma attending the clinical centres and not yet included in the online RItA Registry, with the following characteristics: adult subjects with a diagnosis of asthma since at least one year with a) uncontrolled asthma, despite regular treatment with GINA (Global Initiative for Asthma) step 4 level, in the last three months or b) controlled asthma with a step 5 level treatment according to GINA (Global Initiative for Asthma).
89005396|NCT04571476|Experimental|UTB-VBN-EBUS group|Ultrathin bronchoscope with a 3.0-mm outer diameter and a 1.7-mm working channel was used in this group. Specimens were obtained using 1.5-mm biopsy forceps and 1.4-mm cytology brush with the guidance of VBN and EBUS.
89412392|NCT02432209|Active Comparator|Intensive Lifestyle Mod. Intervention|The intensive lifestyle modification intervention will consist of caloric restriction (consumption of approximately 1200-1500 kcal/d), use of an over-the-counter weight loss medication (Alli, which is brand name Orlistat, a gastric lipase inhibitor that limits gut fat absorption), and moderate physical activity (goal of reaching 10,000 steps a day). The pretreatment intervention will last 16 weeks and is designed to promote a weight loss of approximately 7% of total body weight.
88888922|NCT05114447||Epidemiological sample|a) epidemiological cases of severe/uncontrolled asthma from a general population Pisa cohort already inserted in the online RItA Registry and b) new epidemiological cases of severe/uncontrolled asthma from pre-existing Pisa cohort not yet included in the online RItA Registry, with the following characteristics: adult subjects with at least one asthma attack in the last 12 months or wheezing and/or asthma therapy in the last 12months.
88888923|NCT05111431|Experimental|Dexmedetomidine Hydrochloride Nasal Spray|
88888924|NCT05111431|Placebo Comparator|Dexmedetomidine hydrochloride nasal spray blank preparation|
88888925|NCT05093426||Insomnia in Breast cancer cohort|A single cohort will be observed in Stage 1 to assess the prevalence of insomnia suffered by participants who suffer from breast cancer. A subset of participants will continue to Stage 2 to use a digital sleep diary app for an observational period of 3 weeks.
88888926|NCT05072275||Subjects receiving care from Scripps Health physicians in Cardiology and Primary Care|A confidential data request will be submitted to screen the Scripps Health EHR system for individuals meeting study inclusion criteria and having seen a participating study physician in the past two years.
88888927|NCT05056090|Experimental|Patients will receive MV in PP|Patients assigned to the intervention group will be turned in PP within the two hours after randomization for at least 16 consecutive hours. Then, patients will be turned in SP. Then, PP sessions are repeated as long as stopping criteria for PP are not met
89005397|NCT04571476|Active Comparator|TB-VBN-EBUS-GS group|Thin bronchoscope with a 4.0-mm outer diameter and a 2.0-mm working channel was used in this group. Specimens were obtained using 1.5-mm biopsy forceps and 1.4-mm cytology brush with the guidance of VBN-EBUS and a 1.95-mm outer diameter guide sheath.
88888928|NCT05056090|No Intervention|Patients will receive MV in SP|
88888929|NCT05044325|Experimental|Part 1 Cohort 1: GSK3884464 and placebo|Participants will be randomized in one of 3 treatment sequences in a 1:1:1 ratio. Within each period, allocation to GSK3884464 and placebo will be 2:1. In period 1, participants will receive GSK3884464 (Dose 1) + Placebo; in period 2: GSK3884464 (Dose 2) + Placebo and in period 3: GSK3884464 (Dose 3) + Placebo. There will be a minimum of 7 days washout period between dosing in each session.
88888930|NCT05044325|Experimental|Part 1 Cohort 2: GSK3884464 and placebo|Participants will be randomized in one of 3 treatment sequences in a 1:1:1 ratio. Within each period, allocation to GSK3884464 and placebo will be 2:1. In period 1, participants will receive GSK3884464 (Dose 4) + Placebo; in period 2: GSK3884464 (Dose 5) + Placebo and in period 3: GSK3884464 (Dose 6) + Placebo. There will be a minimum of 7 days washout period between dosing in each session.
88888931|NCT05044325|Experimental|Part 1 Cohort 3: GSK3884464 and placebo|Participants will be randomized in one of 3 treatment sequences in a 1:1:1 ratio. Within each period, allocation to GSK3884464 and placebo will be 2:1. In period 1, participants will receive GSK3884464 (Dose 7) + Placebo; in period 2: GSK3884464 (Dose 8) + Placebo and in period 3: GSK3884464 (Dose 9) + Placebo. There will be a minimum of 7 days washout period between dosing in each session.
89412393|NCT02432209|Placebo Comparator|Standard Lifestyle Intervention|Women in the standard lifestyle intervention (standard) will receive publicly available written materials that promote engagement in moderate physical activity with target of 10,000 steps a day. Detailed instruction of physical activity will not be provided.
89437573|NCT03582280|Experimental|Amorous Calcium Carbonate (ACC) - Amor|"The investigational product will include:~Amor powder, each eppendorf contains 200mg Calcium~Amor Inhaled Double Pack - 1% ACC in 8 ml suspension"
89437574|NCT03575650||Cardiac imaging modalities|Repeat echocardiography (cECHO), cardiac MRI (cMRI) scans and cardiac CT (cCT) scans will be performed to evaluate myocardial dysfunction and deformation; myocardium inclusing tissue abnormalities, cardiac morphology and function and; coronary artery lesions and coronary artery calcium score.
88888932|NCT05044325|Experimental|Part 2 Cohort 4: GSK3884464 or placebo|Participants will be randomized to receive either GSK3884464 (Dose X) or placebo in sequential design according to randomization schedule. Participants will receive repeat daily doses of the study intervention or placebo based on PK data obtained in Part 1.
89412394|NCT00108732|Experimental|Treatment (vaccine therapy)|"Patients receive vaccinia-PSA-TRICOM vaccine SC on day 1 and sargramostim (GM-CSF) SC on days 1-4 during weeks 1-4. Beginning in week 5, patients receive fowlpox-PSA-TRICOM vaccine SC on day 1 and GM-CSF SC on days 1-4. Treatment with fowlpox-PSA-TRICOM vaccine and GM-CSF repeats every 4 weeks for 3 courses (weeks 5-16). Beginning in week 17, patients receive fowlpox-PSA-TRICOM vaccine and GM-CSF as above every 12 weeks in the absence of clinical or biochemical disease progression or unacceptable toxicity.~Patients with biochemical or clinical disease progression receive androgen ablation therapy comprising oral bicalutamide once daily for 1 month and goserelin SC once every 4 weeks in addition to fowlpox-PSA-TRICOM vaccine and GM-CSF. Treatment continues in the absence of further clinical or biochemical disease progression."
89412395|NCT02319200|Experimental|Metformin|"1000 mg (2x500 mg) at morning and 1000 mg (2x500 mg) at afternoon (2000 mg per day)~Metformin daily during 36 months"
88888933|NCT05044325|Experimental|Part 2 Cohort 5: GSK3884464 or placebo|Participants will be randomized to receive either GSK3884464 (Dose Y) or placebo in sequential design according to randomization schedule. Participants will receive repeat daily doses of the study intervention or placebo based on PK data obtained in Part 1 and ongoing PK data in Part 2.
88888934|NCT05044325|Experimental|Part 2 Cohort 6: GSK3884464 or placebo|Participants will be randomized to receive either GSK3884464 (Dose Z) or placebo in sequential design according to randomization schedule. Participants will receive repeat daily doses of the study intervention or placebo based on PK data obtained in Part 1 and ongoing PK data in Part 2.
88888935|NCT05035199||Patients with psychiatric disorders|Patients with psychiatric disorders of the affective spectrum.
88888936|NCT05029713||liver transplanted patients without sarcopenic obesity (controls)|All liver transplanted patients followed as outpatients at out clinic, which lack at least one of the two conditions (muscle strenght and muscle mass) used to identify sarcopenic obesity.
88888937|NCT05029713||liver transplanted patients with sarcopenic obesity (cases)|All liver transplanted patients followed as outpatients at out clinic, with both muscle strenght and muscle mass.
88888938|NCT05016232|Experimental|Strength Based Case Management (SBCM)|Stage 1: Support, facilitate, and assist in linkage to PrEP clinic and to facilitate initiation of, and obtaining, PrEP medications.
88888939|NCT05016232|Experimental|PrEP adherence training and counseling|"Stage 2: Stepped Intervention:~Initially TGW in this arm will receive daily 2-way gender-affirming text message reminders, and~Then those continuing to have poor adherence will receive the 4 (once per week for 3 to 4 weeks) more intensive counseling session with a clinical interventionist."
88888940|NCT05016232|No Intervention|Standard of Care:Stage 1|Stage 1: Referral to local PrEP clinic
88888941|NCT05016232|No Intervention|Standard of Care: Stage 2|Stage 2: Standard clinical PrEP care: Doctor visit every three months to assess for side effects, do blood work, and receive a HIV test.
88888942|NCT05015543|Experimental|Patients paticipating in the Personal Training Program|The study patients complete two training sessions per week (60 minutes each) under supervision (16 weeks)
88888943|NCT04975568|Experimental|Therapeutic Exercise Controlled Through App With face-to-face|3 months treatment using app for HTEP and 6 people therapeutic exercise group every 15 days
88888944|NCT04975568|Active Comparator|Therapeutic Exercise Controlled Through App|3 months treatment using app for HTEP
88888945|NCT04956939||Group 1|PD patients receiving low frequency dose of levodopa.
88888946|NCT04956939||Group 2|PD patients receiving high frequency dose of levodopa.
88888947|NCT04956939||Control Group|Spouses of PD patients without PD diagnosis
88888948|NCT04955470|Experimental|Intravenous ketamine|Infusion of 0.5 mg/kg of ketamine, at maximum dose of 40 mg, over 40 minutes.
88888949|NCT04955470|Active Comparator|Intravenous midazolam|Infusion of 0.03 mg/kg of midazolam, at maximum dose of 2 mg, over 40 minutes.
88888950|NCT04955470|Placebo Comparator|Intravenous saline|Infusion of 0.9% saline over 40 minutes.
88888951|NCT04944121|Experimental|RSLV-132|RSLV-132 is an enzymatically active ribonuclease designed to digest the ribonucleic acid contained in autoantibodies and immune complexes and thereby render them biologically inert. A dose of 10 mg/kg will be administered by intravenous infusion on Days: 1, 8, 15, 29, 43, and 57
88888952|NCT04944121|Placebo Comparator|Placebo|Sodium chloride 0.9% will be administered by intravenous infusion on Days: 1, 8, 15, 29, 43, and 57
88888953|NCT04925401|Experimental|Information brochure Arm|The experimental group will receive an information brochure on fever in children and how to deal with a febrile episode and usual medical management.
88888954|NCT04925401|No Intervention|Habitual care|The control group will receive the usual medical management
88888955|NCT04922645|Experimental|Ferric citrate (commercially available, Auryxia)|Ferric citrate, (commercially available Auryxia), supplied as tablets for oral administration containing 1 gram ferric citrate (210 milligrams of ferric iron). Administered orally with meals or snacks.
89412396|NCT02319200|Placebo Comparator|placebo tablet|2 tablets at morning and 2 tablets at afternoon 4 tablets per day
89412397|NCT02145936|Experimental|oleic acid diet|Participants are provided with meals enriched in oleic acid (18:1)
89412398|NCT02145936|Experimental|palmitic acid diet|Participants are provided with meals enriched in palmitic acid (18:0)
89412399|NCT02145936|Experimental|stearic acid diet|Participants are provided with meals enriched in stearic acid (18:0)
89412400|NCT02142270||Victims of cardiac arrest, either SCD or aborted SCA|
89412401|NCT02142270||Premature death|"All residents of districts of interest will be surveyed during 3 years. premature deaths occurring in residents of districts of interest will be checked for past medical history, circumstances of death, and autopsy report (if possible). Investigators will also analyze the employment of resuscitation attempts during the timeframe of sudden cardiac arrest (SCA) in various patient populations throughout African countries.~The arm group of the study is every resident of the district of interest"
89412402|NCT02319278|Active Comparator|Myocarditis|
89412403|NCT02319278|Active Comparator|Cardiac sarcoid|
89412404|NCT02319278|Active Comparator|Cardiac Transplant|
89412405|NCT02319278|Placebo Comparator|Healthy Volunteers|
89412406|NCT02142348||osteoprosis research|
89412407|NCT02324738|Experimental|Healthy Volunteer|All subjects will receive Mefloquine and Dihydroartemisinin-piperaquine, wash out then will receive Mefloquine
89412408|NCT03497234|Experimental|All women eligible to participate|All women presenting who sign the consent and found eligible will have a VF and AF sample taken and analyzed on the Perilynx Analyzer to measure AF and VF fluid. This does not affect their regular standard of care and diagnosis
89412409|NCT02146014|Experimental|Transcranial Direct Current Stimulation|These subjects will receive real transcranial direct current stimulation.
89412410|NCT02146014|Placebo Comparator|Sham tDCS|These subjects will receive sham transcranial direct current stimulation (placebo)
89412411|NCT02321852|Experimental|Verum/Placebo|This group will start with triflusal and after washout will receive placebo
89412412|NCT02321852|Experimental|Placebo/Verum|This group will start with placebo and will receive triflusal after washout.
89535743|NCT02486081||children with intelligent disabilities|children with ID will be measured via a smart soccer ball. Performance will be measured as acceleration, total time for completion, total distance
89535744|NCT02486081||typical-developed children (TD)|TD children will be measured via a smart soccer ball. Performance will be measured as acceleration, total time for completion, total distance
89535745|NCT03204097|Placebo Comparator|group 1|Scaling and root planing (SRP) followed by placebo gel local drug delivery
89535746|NCT03204097|Active Comparator|group 2|SRP followed by 1% Alendronate (ALN) gel
89412413|NCT02146092|Active Comparator|Standard physiotherapy|Standard physiotherapy includes routine physiotherapy care as per current institutional standards. This consists of two daily visits by the physiotherapist. During the visits, the patient will be taught deep breathing and will be instructed to practice it 10 times every hour. They are also shown shoulder movements and lung expansion exercises. They will receive a sheet summarizing the exercises for future reference. The patient is discharged from physiotherapy when they are ambulatory, on room air, and able to clear their respiratory secretions independently, although they will be asked to continue the exercises on their own until 30 days from surgery.
89412414|NCT02146092|Experimental|Incentive Spirometry|"Patients in the Incentive Spirometry arm will receive standard physiotherapy care in addition to training and use of an incentive spirometer. The physiotherapy care includes routine care as per current institutional standards.~They will also receive an incentive spirometer on the first postoperative day and will be taught how to use it with an accompanying instructional sheet for later reference. Teaching will emphasize slow deep breathing, sustained vacuum pressure, and gradual increase in difficulty. Patients will be instructed to use the spirometer 10 times every hour until 30 days after surgery."
89412415|NCT03499886|Experimental|Ketamine Hydrochloride 50Mg/1mL|"In the intervention group, Ketamine Hydrochloride 50Mg/1mL was administered rapidly at a dose of 0.5 mg / kg (within 5 seconds). Patient assessment was performed before and two minutes after ketamine injection, and then every 5 minutes after the reduction of the fracture, by an anesthetist blind to the type of intervention."
89412416|NCT03499886|Experimental|Ketamine Hydrochloride 50Mg/mL|in the control group, ketamine 1.5 mg / kg was slowly injected for 30 to 60 seconds. Patient assessment was performed before and two minutes after ketamine injection, and then every 5 minutes after the reduction of the fracture, by an anesthetist blind to the type of intervention.
89412417|NCT02319356|Active Comparator|Beetroot juice (BRJ)|beetroot juice
89412418|NCT02319356|Placebo Comparator|Placebo (PL)|placebo juice
89412419|NCT02324894|Other|MRI screening|Diagnostic screening. The normal eligible screening population will first undergo a mammography, then an echography screening followed by a fast MRI screening.
89412420|NCT02142582|Active Comparator|WHO ORS|Participants will be instructed to dilute contents of the provided ORS to a 1 liter bottle and sip all day.
89412421|NCT02142582|Active Comparator|Commercial ORS|Participants will be instructed to dilute contents of the provided ORS to a 1 liter bottle and sip all day.
89412422|NCT02142660||Sprayshield|Applied to the operating zone during an ablation of gastric died ring at obese patients programmed for the second bariatric surgery to type of bypass gastric or of gastrectomie
89412423|NCT02325050|Experimental|Group 1|Participants will receive MVA-BN-Filo/ Ad26.ZEBOV (Day 1 /Day 15) or Placebo (Day 1/Day 15). Participants will receive Ad26.ZEBOV (5x10^10 vp) on Day 360.
88888956|NCT04922645|Active Comparator|Standard of care phosphate lowering therapy|Non-Auryxia phosphate-lowering therapy administered as standard of care.
88888957|NCT04922567|Experimental|lenalidomide + CHOP regimen|
88888958|NCT04922567|Active Comparator|CHOP regimen|
88888959|NCT04899882|No Intervention|Control group|
88888960|NCT04899882|Experimental|KinHémo group|
88888961|NCT04873232|Experimental|Engensis|Patients who have received Engensis in protocol VMDN-003-2
88888962|NCT04873232|Placebo Comparator|Placebo|Patients who have received Placebo in protocol VMDN-003-2
88888963|NCT04851704|Experimental|Intervention: Tuning in to Kids parenting program|Intervention groups receive the Tuning in to Kids parenting program
88888964|NCT04851704|No Intervention|Control: Business as usual|"Control groups have business as usual, and then get offered the intervention program after 6 months follow-up assessment."
89412424|NCT02325050|Experimental|Group 2|Participants will receive MVA-BN-Filo/Ad26.ZEBOV (Day 1 /Day 29) or placebo (Day 1/Day 29). Participants will receive Ad26.ZEBOV (5x10^10 vp) on Day 360.
89005398|NCT04571476|Active Comparator|TB-VBN-EBUS-non-GS group|Thin bronchoscope with a 4.0-mm outer diameter and a 2.0-mm working channel was used in this group. Specimens were obtained using conventional biopsy forceps and cytology brush with the guidance of VBN and EBUS, but without guide sheath.
89412425|NCT02325050|Experimental|Group 3|Participants will receive MVA-BN-Filo /Ad26.ZEBOV/ (Day 1/Day 57) or placebo (Day 1/Day 57). Participants will receive Ad26.ZEBOV (5x10^10 vp) on Day 360.
89412426|NCT02325050|Experimental|Group 4|Participants will receive Ad26.ZEBOV/ MVA-BN-Filo (Day 1/Day 29) or placebo (Day 1/Day 29). Participants will receive Ad26.ZEBOV (5x10^10 vp) on Day 360.
89412427|NCT02325050|Experimental|Group 5|Participants will receive MVA-BN-Filo (Day 1 and Day 15) or placebo (Day 1 and Day 15). Participants will receive Ad26.ZEBOV (5x10^10 vp) on Day 360.
89412428|NCT02325050|Experimental|Group 6|Participants will receive Ad26.ZEBOV (Day 1 and Day 15) or placebo (Day 1 and Day 15). Participants will receive MVA-BN-Filo (1*10^8 TCID50) on Day 360.
88888965|NCT04835077|Experimental|Structured Aerobic Exercises|"Following the training on aerobic exercise content and effectiveness;~First Week; participants 5 minutes warm-up, 20 minutes of aerobic exercise with 60-70% of maximum heart rate, and 5 minutes of cool down.~In the following weeks, the aerobic exercise duration of all participants will be increased by 5 minutes compared to the previous week.~The duration of the sessions in the 7th and 8th weeks will progressively progress to 40 minutes and the intensity to 75-80% of the maximum heart rate."
88888966|NCT04835077|Experimental|Postural Stabilization Exercises|"Exercises; It will consist of postural exercises to be done in prone, supine, side lying, crawling, sitting and standing positions. All exercises will be done in 2 sets per day, the number of repetitions will be determined individually and progressed.~Breathing exercises~Four-way stretching and strengthening of the neck muscles~Shoulder girdle stretching and strengthening exercises~Hip flexors, hamstring, itb, lumbar extensor stretching and strengthening~Lying down exercises in the crawling position~Shuttle movement~Plank movement~Toe taps~Bridging~Straight leg lift~Straight leg raises in side-lying~Prone knee flexion"
89412429|NCT02325050|Experimental|Group 7|Participants will receive Ad26.ZEBOV/ MVA-BN-Filo (Day 1/Day 15) or Placebo (Day 1/Day 15). Participants will receive Ad26.ZEBOV (5x10^10 vp) on Day 360.
89412430|NCT02325050|Experimental|Group 8|Participants will receive Ad26.ZEBOV/ MVA-BN-Filo (Day 1 /Day 29) or Placebo (Day 1/Day 29). Participants will receive Ad26.ZEBOV (1x10^11 vp) on Day 360.
89412431|NCT02325050|Experimental|Group 9|Participants will receive MVA-BN-Filo/ Ad26.ZEBOV (Day 1 /Day 8) or Placebo (Day 1/Day 8).
89412432|NCT02325050|Experimental|Group 10|Participants will receive MVA-BN-Filo/ Ad26.ZEBOV (Day 1 /Day 15) or Placebo (Day 1/Day 15).
88888967|NCT04835077|No Intervention|Control|The individuals without any treatment will continue their normal lives and will be included in the study as a control group. Exercise will be given after 8 weeks.
88888968|NCT04801745|Experimental|Healthy Vegan Diet|Education on healthy vegan diet
88888969|NCT04801745|Experimental|Healthy Vegan Diet with Amla fruits|Education on healthy vegan diet, 3g of powdered amla fruits per day
88888970|NCT04801745|Active Comparator|My Plate - Low Purine|"Education on My Plate diet with emphasis on choosing low purine protein options."
88888971|NCT04801745|Experimental|My Plate - Low Purine with Amla Fruits.|"Education on My Plate diet with emphasis on choosing low purine protein options and with an addition of 3g of amla powder per day."
88888972|NCT04788368||Patients treated with TEM - transanala microsurgery|Early rectal cancer treated with TEM - full thickness resection
88888973|NCT04788368||Patients treated with ESD|Early rectal cancer treated with the endoscopic treatment ESD - endoscopic submucosal resection
88888974|NCT04788368||Patients treated with EMR|Early rectal cancer treated with the endoscopic treatment EMR - endoscopic mucosal resection
88888975|NCT04765774|Experimental|The Effect of Expressive Touch Applied After Lumbar Disc Herniation Surgery|Expressive touch reduces pain and keeps vital signs and NIRS values within normal limits by touching the arms and hands of the patients through energy transfer.
89535747|NCT03204097|Active Comparator|group 3|SRP followed by Aloevera (AV) gel
89535748|NCT03321071|Experimental|Healthy Summer Learners|Similar to typical summer day camp procedures, students attending Healthy Summer Learners will be dropped-off and picked-up at camp. The physical activity component of the program was designed with the expertise and input from B&G Club youth program staff. The academic component was informed by school district personnel. The program was also designed to be analogous to typical summer day camp program in terms of operating weeks (10 weeks) length of program day (i.e., 8am-5pm), and program component time blocks (~45min-1hr time blocks).
89535749|NCT03321071|Active Comparator|21st Century Learning Center|Children in this condition will attend a 21st Century Summer Learning Program.
89535750|NCT03321071|No Intervention|Passive control|Children in this condition will not attend a summer program.
88888976|NCT04765774|Experimental|The Effect of Music Applied After Lumbar Disc Herniation Surgery|Patients listening to music are distracted and their pain is reduced, vital signs and NIRS values are kept within normal limits.
88888977|NCT04765774|No Intervention|Pain, vital signs and NIRS values of patients after lumbar disc hernia surgery|No intervention is applied to the patients in this group and the effectiveness of the interventions used on the patients in the other group is measured.
88888978|NCT04715061|Experimental|Cancer patients with MRI|9 cancer patients will be recruited and received the 3 experimental conditions : first the rest condition (with MRI), then randomly MICE condition and HIIT condition (with MRI).
88888979|NCT04715061|Experimental|Cancer patients without MRI|9 cancer patients will be recruited and received the 3 experimental conditions : first the rest condition, then randomly MICE condition and HIIT condition, all without MRI.
88888980|NCT04715061|Active Comparator|Healthy patients|9 healthy patients will be recruited and received 2 experimental conditions : first the rest condition (with a MRI), then HIIT condition (with MRI).
89535751|NCT02486237||Type 2 diabetes mellitus|Type 2 diabetes mellitus patients, no intervention is performed besides usual clinical practice
89535752|NCT03223831|Active Comparator|Partially covered duodenal stent (PCDS)|The PCDS used in the current study is a partially covered metallic pyloro-duodenal stent. It consists of two portions. The stent is 2cm in diameter and the proximal 2cm of the stent is uncovered and flared. The remaining of the stent is covered, where a polytetrafluoroethylene (PTFE) membrane is held between two nitinol mesh.
89535753|NCT03223831|Active Comparator|Uncovered duodenal stent (UDS)|The UCDS used in the current study is an uncovered stent made of nitinol wire, with a diameter of 20mm. This stent is an unfixed-cell braided stent with low axial force, high flexibility and good conformability.
89535754|NCT03320993|Active Comparator|Low Protein-Low Fat study|Subjects will receive a mixed meal with carbohydrates (70g) plus a low content of proteins and fats
89535755|NCT03320993|Experimental|High Protein-High Fat study|Subjects will receive a mixed meal with the same carbohydrates content of arm 1 (70g), but a greater amount of fats and proteins
89535756|NCT03320993|Experimental|High Protein-High Fat & alcohol study|Subjects will receive the same mixed meal of the High Protein-High Fat study plus 0,7g of alcohol per Kg of weight
89535757|NCT02485769|Experimental|PF-06650833|Active arm , PF-06650833 kinase.
89535758|NCT02485769|Placebo Comparator|Placebo|Placebo arm
89535759|NCT03223519|Experimental|Comboprofen|Triple combination of Ibuprofen, Magnesium and Vitamin C.
89535760|NCT03223519|Placebo Comparator|Placebo|
89535761|NCT03223519|Active Comparator|Ibuprofen|
89535762|NCT03223519|Active Comparator|Magnesium|
89535763|NCT03223519|Active Comparator|Vitamin C|
89535764|NCT03320915|Experimental|Cholecalciferol|Cholecalciferol 5mg (200,000 IU)
89535765|NCT03320915|No Intervention|Usual care|Usual care
89535766|NCT03220165|Experimental|Treatment|MGL-3196
89535767|NCT02488889|Active Comparator|Varenicline vs placebo|Participants will be titrated on varenicline as follows: days 1-3, .5 mg per day; days 4-7, .5 mg twice per day, and days 7-12, 1 mg twice per day. Placebo and varenicline pills will be matched in number of pills and packaging of active medications.
89535768|NCT02488889|Active Comparator|Alcohol beverage vs. placebo beverage|During each experimental session, participants will ingest a beverage containing placebo (0.0 g/kg; 1% volume of ethanol as taste mask) or alcohol (0.8 g/kg). The beverage will be administered in clear plastic-lidded cups in 2 equal portions that will be consumed during a 5-minute interval and separated by a 5-minute interim rest. The beverages will contain 190-proof ethanol prepared with water, flavored drink mix, and a sucralose-based sugar substitute. Doses for women will be 85% of those of men to adjust for sex differences in total body water.
89535769|NCT03220087||Group A - Uncontrolled CS|Patients who have had at least one episode of uncontrolled CS, according to medical criteria, since the start of their treatment for NET.
88888981|NCT04700774|Experimental|mBA|Motor enhanced behavioral activation. 10 sessions.
89192652|NCT06145633|Experimental|Treatment (vorinostat, 177Lu-PSMA-617)|Patients receive vorinostat PO QD for 28 days and then receive gallium Ga 68 gozetotide IV and undergo a PET scan on trial. Patients may go on to receive 177Lu-PSMA-617 IV per SOC on day 1 of each cycle. Treatment repeats every 6 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT and bone scan on trial and during follow-up, as well as a SPECT/CT and FDG PET/CT during screening and on trial. Patients undergo blood sample collection on trial and may also optionally undergo biopsy during screening and on trial.
89412433|NCT02687646|Experimental|Allogeneic Mesenchymal Cells|All patients will receive Adult Allogeneic Mesenchymal Cell from adipose tissue. It is not considered ethical the inclusion of a control group.
89412434|NCT02319512|Experimental|Chewing gum|Chewing gum was administered every fourth hour (08.00-12.00, 12.00-16.00 and 16.00-20.00). During each four-hour period, patients chewed two pieces of gum for 30 minutes each. Chewing gum was used during the whole hospital stay.
89412435|NCT02319512|Sham Comparator|Control|Controls received standard care and sips of glucose, in total 3.6g/day in a 12-ml mixture per day, the same amount of glucose per day as the treatment group received via the chewing gum
89412436|NCT02142816|Active Comparator|Doppler|Fluid directed by oesophageal doppler
89412437|NCT02142816|Active Comparator|PVI|Fluid therapy directed by Pleth Variability Index
88888982|NCT04700774|Experimental|BA|Standard behavioral activation. 10 sessions.
89412438|NCT02442050|Experimental|del Nido solution|Administering of cardioplegia using del Nido solution in eligible patients.
89412439|NCT02442050|Active Comparator|Blood-based cardioplegia|Administering of cardioplegia using current standard of care blood-based cardioplegia protocol.
88888983|NCT04700774|No Intervention|Waitlist|10 week waitlist.
89535770|NCT03220087||Group B - Controlled CS|Patients who have not had any episode of uncontrolled CS, according to medical criteria, in the last 12 months.
88888984|NCT04654104||Healthy never smokers|Clinical evaluation of immune check points expression. A prospective study
88888985|NCT04654104||Smokers with normal lung function|evaluation of immune check points expression
88888986|NCT04654104||Lung cancer|evaluation of immune check points expression
88888987|NCT04654104||COPD|evaluation of immune check points expression
88888988|NCT04651465|Experimental|Tuning in to Kids parenting program|Intervention groups receive the Tuning in to Kids parenting program
88888989|NCT04651465|No Intervention|Business as usual|"control groups have business as usual, and then get offered the intervention program after one year follow-up assessment."
88888990|NCT04636632|Experimental|Weekly Arm|fosaprepitant 150mg/m2 weekly in concurrent with radiotherapy during concurrent chemoradiotherapy
89192653|NCT06145568||Pregnant Women|Pregnant Women
88888991|NCT04636632|Active Comparator|Triweekly Arm|fosaprepitant 150mg/m2 triweekly in concurrent with chemotherapy during concurrent chemoradiotherapy
88888992|NCT04633603||All patients|There is no pre-specified group or subgroup of participant(s) assigned to receive the specific intervention(s) (or no intervention) according to the protocol. All patients get the same possibility to register their data and follow management advice.
88888993|NCT04632225|Active Comparator|Engensis|64 mg Engensis per Treatment Cycle, with each of 3 cycles composed of 2 days of 128 injections each to the right and left target muscles, spaced 2 weeks apart
88888994|NCT04632225|Placebo Comparator|Placebo|32 mL of Placebo per Treatment Cycle, with each of 3 cycles composed of 2 days of 128 injections each to the right and left target muscles, spaced 2 weeks apart
89412440|NCT03544710|Experimental|Bathing|Intervention was Preoperative bathing with antiseptic. Given warm water and a tablet soap containing chloroxylenol antiseptic. Asked to bathe under supervision for standardization. Given a clean theatre gown to put on. Taken through the routine pre-operative preparation procedures which involved; Putting an intravenous cannula; administering prophylactic antibiotics. Administering intravenous normal saline 1 liter. taking off a blood sample (3mls) for blood grouping and cross matching. Putting urethral catheter for drainage of urine, Getting an informed consent from the client for the procedure to be done. Informing the theatre team.
89412441|NCT03544710|No Intervention|No bathing|"No intervention done for participants in this arm. They go through the routine ward procedure as below.~Putting an intravenous cannula; administering prophylactic antibiotics. Administering intravenous normal saline 1 liter. taking off a blood sample (3mls) for blood grouping and cross matching. Putting urethral catheter for drainage of urine, Getting an informed consent from the client for the procedure to be done. Informing the theatre team."
89412442|NCT02647554|Experimental|Ulinastatin group|Ulinastain treatment group：400,000 IU ulinastatin will be reconstituted in 10 mL of 0.9% normal saline, and then dissolved in 100 mL of 0.9% normal saline every 8 hours for 10 days in a double-blind fashion.
89412443|NCT02647554|Placebo Comparator|Placebo group|Placebo control group：Matching with medication
89412444|NCT02325128|Experimental|Post-Exposure Nap|Sleep-enhancement of extinction memory: At the end of the third and fourth of 5 exposure therapy sessions, all participants deliver a speech designed to elicit significant social anxiety. Following this speech, this arm will be given a 2-hour sleep opportunity with polysomnographic (PSG) monitoring.
89412445|NCT02325128|Active Comparator|Post-Exposure Wake|At the end of the third and fourth of 5 exposure therapy sessions, all participants deliver a speech designed to elicit significant social anxiety. Following this speech, this arm will be instrumented for PSG but, instead of napping, will undergo 2 hours of quiet wakefulness. Therefore, this arm will not undergo sleep-enhancement of extinction memory.
89412446|NCT02322086|Experimental|PH-10|Active treatment
89412447|NCT03499652||derivation cohort|The data of derivation cohort are used to derive the neonatal bacterial meningitis risk score
88888995|NCT04629131|Experimental|Cohort 1 TNM002 10 μg/kg/Placebo|Sentinel dosing will be conducted for Cohort 1. Two participants will be dosed (1 with TNM002, 1 with placebo) at least 72 hours prior to subsequent dosing. The remaining participants will only be dosed if no significant safety signals are identified in the sentinel participants. In total, eight subjects will be randomly assigned to receive either TNM002 or placebo at a 3:1 ratio (i.e. 6 subjects receive TNM002 and 2 with placebo).
88888996|NCT04629131|Experimental|Cohort 2 TNM002 35 μg/kg/Placebo|Eight subjects will be randomly assigned to receive either TNM002 or placebo at a 3:1 ratio (i.e. 6 subjects receive TNM002 and 2 with placebo).
88888997|NCT04629131|Experimental|Cohort 3 TNM002 100 μg/kg/Placebo|Eight subjects will be randomly assigned to receive either TNM002 or placebo at a 3:1 ratio (i.e. 6 subjects receive TNM002 and 2 with placebo).
88888998|NCT04629131|Experimental|Cohort 4 TNM002 250 μg/kg/Placebo|Eight subjects will be randomly assigned to receive either TNM002 or placebo at a 3:1 ratio (i.e. 6 subjects receive TNM002 and 2 with placebo).
88888999|NCT04583358|Active Comparator|AMT-101|AMT-101 Tablet
88889000|NCT04583358|Placebo Comparator|Placebo|Placebo Tablet
88889001|NCT04576650|Experimental|Summit system|Implantation of Summit system, consisting of one or two Medtronic Activa(R) RC+S grids with wireless communication capabilities.
88889002|NCT04545060|Experimental|VIR-7831 (Sotrovimab)|Participants received 500 mg sotrovimab administered intravenously (IV)
88889003|NCT04545060|Placebo Comparator|Placebo|Participants received placebo administered intravenously (IV)
88889004|NCT04527913|Experimental|Control group|15 patients receiving oral hygiene instructions as determined by their group allocation (use of manual toothbrush alone)
88889005|NCT04527913|Experimental|Test group 1|15 patients receiving oral hygiene instructions as determined by their group allocation (manual toothbrush plus dental floss)
88889006|NCT04527913|Experimental|Test group 2|15 patients receiving oral hygiene instructions as determined by their group allocation (manual toothbrush plus interdental brushes)
88889007|NCT04527913|Experimental|Test group 3|15 patients receiving oral hygiene instructions as determined by their group allocation (manual toothbrush plus rubber interdental picks)
88889008|NCT04481321||Patient with benign gynaecologic disease|Patients consulting for endometriosis, pelvic pain, abnormal uterine bleeding and/or infertility, or for a pelvic mass,
88889009|NCT04469270|Experimental|Engensis|16 (ea) 0.25mg (0.5 mL) injections in each of the right and left gastrocnemius muscles on Days 0, 14, 90, and 104.
88889010|NCT04469270|Placebo Comparator|Placebo|16 0.5 mL injections in each of the right and left gastrocnemius muscles on Days 0, 14, 90, and 104.
88889011|NCT04455152|Experimental|Self-control|two-week period of practicing self-control (attempting to avoid eating sweet foods) and self-monitoring success in doing so
89192654|NCT06145542|Experimental|AR group: aerobic exercise before resistance exercise|
88889012|NCT04455152|No Intervention|wait list|waiting 2 weeks after baseline assessment before gaining access to web-based self-help
89192655|NCT06145542|Active Comparator|RA group: resistance training before aerobic training|
89192656|NCT06145529|Experimental|EG1: 15 min RT (FunctionalHIIT) circuit program|Volume: ≃10 min/day three times per week at moderate to high intensity (7-10 RPE). Intensity: During the study the children will instruct to follow the movements targeting firstly 6-7 and 9-10 at the end. Frequency: 3 times per week. Type of exercise: For the FunctionalHIIT program the participants will perform eight weight-bearing exercises in circuit format (i.e., push-ups, squats, planks, etc.). Training load variation: Initially, participants will start at an intensity level of 6-7 on the Borg's CR-10 scale, and this will increase by 1 point every two weeks until reaching 9-10 out of 10. The training duration during the main portion will increase by 5 seconds every two weeks, while the recovery interval between exercises will decrease. The exercises themselves will become progressively more challenging over the course of the training program and change every two weeks.
89192657|NCT06145529|Experimental|EG2: 15 min RT (FunctionalHIIT) circuit program with gamification|The EG2 training part will develop following the same protocol described in EG1.For the gamification experience, students will embark on a superhero-themed narrative journey where they must train diligently to earn points and badges, improving their avatars along the way. The ultimate goal is to defeat a super villain in the final battle after 8 weeks. The RETRAGAM study utilizes a self-created app (accessible at https://goo.su/GVgSPW) for the gamification story, point tracking, and personalization of children's avatars. As part of the flipped classroom approach, children can access the platform to preview upcoming exercises and educational content (i.e., benefits of RT, knowledge of the muscles, bones and joints involved in exercises, postural habits, etc.).
88889013|NCT04395053|Experimental|Treatment group TR|Intervention: Drug: SHR1459, new formulation; Intervention: Drug: SHR1459, old formulation.
88889014|NCT04395053|Experimental|Treatment group RT|Intervention: Drug: SHR1459, old formulation; Intervention: Drug: SHR1459, new formulation.
88889015|NCT04382391|Experimental|gammaCore Sapphire® (nVNS) plus standard of care|Subjects will be administered study treatment with the nVNS device 3 times per day (prophylaxis) and also as needed for acute respiratory symptoms.
88889016|NCT04382391|Active Comparator|standard of care alone|Will receive standard of care therapies to treat CoViD-19 infection and symptoms
88889017|NCT04375202|Experimental|Colchicine plus current care|Colchicine 0.5 mg three times a day if weight is less than 100 kg; 1 mg twice a day if weight is more than 100 kg for 30 days or up to discharge. Reduce based on gastrointestinal symptoms appearance at discretion of the Investigator.
88889018|NCT04375202|No Intervention|Current care alone|Current care
88889019|NCT04364373|Active Comparator|D2 lymph node dissection|"For tumours in splenic flexure and proximal and mid part of descending colon lymph nodes 232 and 231 will be removed.~For tumours in distal part of descending colon and proximal sigmoid lymph nodes 231, 232 and partially 241, 242 (considering variation of the feeding artery) will be removed.~For tumours in the mid part of sigmoid colon lymph nodes 241, 242 will be removed.~For tumours in the rectosigmoid junction 251, 252 groups of the lymph node will be removed."
89192658|NCT06145529|No Intervention|CG (Control group)|We will provide general advice to the CG participants though an information meeting that will indicated to maintain their lifestyle. At the end of the intervention, in order to comply with the ethical commitment, PE teachers will be instructed on the RT programme and the RETRAGAM app to allow them to carry out the intervention autonomously when they consider.
89192659|NCT06145516|Experimental|Cognitive behavioral therapy for insomnia (CBT-I)|The CBT-I treatment will be administered in self-guided digital format over 4 weeks with addition of telehealth video-consultations with a psychologist one time per week. The CBT-I will focus on sleep restriction therapy and stimulus control, which have shown the highest efficacy for sleep improvement among components typically incorporated. A booster session will be provided 1-2 weeks postoperative.
89192660|NCT06145516|Active Comparator|Sleep education therapy (SET)|The sleep education therapy will be administered in self-guided digital format over 4 weeks with addition of telehealth video-consultations with a research nurse one time per week. The SET will focus on sleep physiology, different sleep disturbances and sleep hygiene measures. A booster session will be provided 1-2 weeks postoperative.
89192661|NCT06145490|Other|Panic Disorder|Participants will be randomized to start with either the caffeine condition or the placebo condition. Participants will complete session 2 with the other condition (condition not allocated to in session 1).
89192662|NCT06145490|Other|Healthy controls|Participants will be randomized to start with either the caffeine condition or the placebo condition. Participants will complete session 2 with the other condition (condition not allocated to in session 1).
89192663|NCT06145451|Experimental|Treatment group|The Family Success Network is a multi-tier, multi-component community-based maltreatment prevention program that offers tailored preventive services for caregivers of children aged 0-18. Average lengths of service completion is approximately 3 months.
89192664|NCT06145451|No Intervention|Waitlist Control Group|Families in the Control Group will not receive any FSN services except concrete support of upto $500.
89192665|NCT06145438|Active Comparator|Leuprolide Acetate|Leuprolide Acetate, brand name Tapros 3.75 mg, injected intramuscularly every month for 3 months
89192666|NCT06145438|Experimental|Dienogest|Dienogest 2 mg, brand name Nelandoz 2mg, administered orally, every day for 3 months
89192667|NCT06145438|Experimental|Depot medroxyprogesterone acetate|Depot medroxyprogesterone acetate, brand name Depo Provera 150mg/ml, injected intramuscularly, every month for 3 months
89192668|NCT06145438|Experimental|Combined Oral Contraceptive|Levonogestrel 150 mcg + etinilestradiol 30 mcg, brand name Mycrogynon, administered orally, every day for 3 months
89412448|NCT03499652||validation cohort|The data of validation cohort are used to validate the neonatal bacterial meningitis risk score
89412449|NCT02325206|Experimental|dapafliflozin|one administration of 10mg dapagliflozin as tablet
89412450|NCT02325206|Placebo Comparator|placebo|one administration as tablet identical to the experimental drug
89412451|NCT03499574|Experimental|Biofeedback group|Dysphagia therapy using surface EMG as biofeedback - 10 x 45 minute sessions of swallow strength and skill training using surface electromyography as biofeedback tool. This group will also receive usual care provided by Speech and Language Therapists, which may involve assessment, review, therapy, patient/family education.
89412452|NCT03499574|Other|Control group|This group will receive usual care provided by Speech and Language Therapists, which may involve assessment, review, therapy, patient/family education
89412453|NCT02325284||Healthy adults|
89192669|NCT06145425|Experimental|Single arm|Participants will be asked to utilize the app.
89412454|NCT02322398||Group A|Patients who had been stimulated with a starting dose of 150-300 IU/d rFSH plus 75-150 IU/d rLH in 2:1 ratio.
89412455|NCT02322398||Group B|Patients who had been stimulated with a starting dose of 150-300 IU/d hMG.
89412456|NCT02319590||heart failure, no CAD, QRS < 150ms|no CAD, QRS < 150ms
89412457|NCT02319590||heart failure, CAD QRS < 150ms|CAD, QRS < 150ms
89412458|NCT02319590||heart failure, CAD > 150ms|CAD, QRS > 150ms
89412459|NCT02319590||heart failure, no CAD, > 150ms|no CAD, QRS > 150ms
89412460|NCT02325362|Experimental|Miglustat then placebo|10 patients will received Miglustat then the placebo
89412461|NCT02325362|Experimental|Placebo then Miglustat|10 patients will received Placebo then Miglustat
89412462|NCT03499340|Experimental|Text-only PWL, absolute risk|Exposure to FDA-mandated warning labels, without a graphic image, accompanied by risk information about smoker's risk of a smoking-related disease
89412463|NCT03499340|Experimental|Text-only PWL, relative risk|Exposure to FDA-mandated warning labels, without a graphic image, accompanied by risk information about smoker's risk and non-smoker's risk of a smoking-related disease
89412464|NCT03499340|Experimental|Low arousal graphic PWL, absolute risk|Exposure to FDA-mandated warning labels, paired with a low arousal graphic image, accompanied by risk information about smoker's risk of a smoking-related disease
89412465|NCT03499340|Experimental|Low arousal graphic PWL, relative risk|Exposure to FDA-mandated warning labels, paired with a low arousal graphic image, accompanied by risk information about smoker's risk and non-smoker's risk of a smoking-related disease
89412466|NCT03499340|Experimental|High arousal graphic PWL, absolute risk|Exposure to FDA-mandated warning labels, paired with a high arousal graphic image, accompanied by risk information about smoker's risk of a smoking-related disease
89412467|NCT03499340|Experimental|High arousal graphic PWL, relative risk|Exposure to FDA-mandated warning labels, paired with a high arousal graphic image, accompanied by risk information about smoker's risk and non-smoker's risk of a smoking-related disease
89412468|NCT03004664||Support Empowerment Model|"The Center for Diabetes Education at the University of New Mexico Hospital (CDE) uses the Diabetes Self-Management Support Empowerment Model (DSMS). The DSMS combines a series of clinically informed group didactic sessions that use a patient self-determination approach to empower patients to take control of their own diabetes health with follow-up supports to sustain self-management gains achieved during the sessions. Patients attend a six-week group instructional session with 9 hours of class plus an individual follow-up with a certified diabetes educator. The group sessions have discussion supported by didactic conversation maps where the facilitator guides but does not control the conversation based on session thematic goals."
89412469|NCT03004664||The Chronic Care Model|One Hope Centro de Vida Diabetes Program is based on the Chronic Care Model (CCM). The CCM involves 6 synergistic domains: 1.) Improved access to care, 2.) Patient self-management support, 3.) Patient decision support, 4.) Care coordination, 5.) Integrated health information systems, and 6.) Access to community resources. To create a holistic care regime, the CCM focuses on addressing social determinants of health by meeting the medical, cultural, and linguistic needs of patients through integration of cultural norms and social relationships from the patient population into program design.
89412470|NCT02322554||wounds treated with CTPs|All cellular and tissue based products currently reimbursed in the hospital based outpatient department, administered at intervals as determined in the course of clinical practice
89412471|NCT03499262|Experimental|Group Social ABcs|Participants receiving Group Social ABCs intervention
89412472|NCT04462094|Active Comparator|End-of-surgery|Low-dose ketamine (0.3 mg/kg) in 3 ml normal saline solution given at the end of surgery
88889020|NCT04364373|Experimental|D3 lymph node dissection|"For tumours in splenic flexure and proximal and mid part of descending colon lymph nodes 232, 231 and 253 will be removed.~For tumours in distal part of descending colon and proximal sigmoid lymph nodes 231, 232 and 253 and partially 241, 242 (considering variation of the feeding artery) will be removed.~For tumours in the mid part of sigmoid colon lymph nodes 241, 242 and 253 will be removed.~For tumours in the rectosigmoid junction 251, 252 and 253 groups of the lymph node will be removed."
89412473|NCT04462094|Placebo Comparator|Induction|Low-dose ketamine (0.3 mg/kg) in 3 ml normal saline solution given at induction
89412474|NCT02325440|Experimental|Natalizumab - Washout - Fingolimod|One experimental arm: Patients receive one final dose of natalizumab 300mg followed by an 8-week washout Phase and subsequent 32-week treatment Phase with fingolimod 0.5mg o.i.d.
89412475|NCT02319746|Experimental|Experimental group|The subjects of experimental group will receive a cognitive-behavioral treatment program specific for reduce cannabis use composed of 16 weekly sessions (one hour in duration), in addition to regular psychiatric review and pharmacological treatment. The group will consist of 6-8 subjects.
89412476|NCT02319746|Active Comparator|Control group|The control group will receive standard care for psychotic episodes which includes pharmacological treatment and psychoeducation, following the same format as the experimental group. 16 weekly sessions of psychoeducation (one hour in duration) will be conducted, in addition to regular psychiatric review and pharmacological treatment. Like the experimental group the group will consist of 6-8 subjects.
88889021|NCT04345744|Experimental|Test group 1|administration of a hyaluronic and 0.2% chlorhexidine mouth rinse
89412477|NCT03499184|Experimental|Local Probiotics|P Flor (Lactobacillus reuteri 1.2 billion CFU) will be delivered locally every 12 hours for 12 weeks
89412478|NCT03499184|Experimental|Systemic Probiotics|P Flor (Lactobacillus reuteri 1.2 billion CFU) will be administered every 12 hours for 12 weeks
88889022|NCT04345744|Experimental|Test group 2|administration of chlorhexidine 0.2% mouth rinse
88889023|NCT04345744|Active Comparator|Control Group|No administration of mouth rinses after surgery
88889024|NCT04329572|Experimental|HCQ + AZT|All patients included in the study will receive HCQ (400 mg BID on D1 and 400 mg/day on D2 to D5) and AZT (500 mg/ 5 days) on top of standard care.
88889025|NCT04323137|No Intervention|Control|This group receives no additional pro-vaccination intervention beyond the health system's normal efforts. Although some patients are currently targeted for flu vaccination encouragement due to a non-ML assessment that they are at high risk for complications, these patients are not told that they are at high risk or that they have been targeted.
88889026|NCT04323137|Experimental|High risk only|This group receives messages telling them they have been identified to be at high risk for flu complications without specifying how or why the health system believes this to be the case.
88889027|NCT04323137|Experimental|High risk based on medical records|This group receives messages telling them they have been identified to be at high risk for flu complications via analysis of their medical records.
88889028|NCT04323137|Experimental|High risk based on algorithm|This group receives messages telling them they have been identified to be at high risk for flu complications via analysis of their medical records by an AI/ML system.
88889029|NCT04323137|No Intervention|Sub-threshold patients|Patients in this group is in the top 11-20% of risk for flu and complications, slightly lower risk than those included in the intervention, who are in the top 10% of risk for flu and complications. This group of patients does not receive an intervention, but are monitored for flu shots as a comparison to target patients.
89412479|NCT03499184|Active Comparator|Systemic Antibiotics|Amoxil 500 mg capsule and Flagyl 400 mg tablet by mouth, will be given every 8 hours for 5 days
89412480|NCT03497078|Other|Refered patients for scintigraphy|
89412481|NCT03497000|Experimental|OCTA group|Patients in this group underwent OCTA-guided half-dose photodynamic therapy.
89412482|NCT03497000|Active Comparator|ICGA group|Patients in this group underwent normal ICGA-guided half dose photodynamic therapy.
89412483|NCT03494114|Experimental|COPD Patients|Folate imaging will be performed with 68Ga-EC2115 prior to scheduled bronchoscopy, which will be performed for clinical purposes to evaluate a suspicious lung nodule. The unused portion of the bronchoalveolar lavage (not necessary for clinical purposes), will be interrogated to compare PET imaging with parameters of inflammation in BAL, including the number/percentage of macrophages expressing FRβ. In addition, PET imaging data will be compared with disease severity, based on pulmonary function testing.
89412484|NCT03494114|Experimental|Individuals without COPD|Folate imaging will be performed with 68Ga-EC2115 prior to scheduled bronchoscopy, which will be performed for clinical purposes to evaluate a suspicious lung nodule. The unused portion of the bronchoalveolar lavage (not necessary for clinical purposes), will be interrogated to compare PET imaging with parameters of inflammation in BAL, including the number/percentage of macrophages expressing FRβ.
89412485|NCT02322632|Experimental|Paricalcitol Capsules, 4 mcg|Paricalcitol Capsules, 4 mcg of Dr. Reddy's Laboratories Limited
89412486|NCT02322632|Experimental|Zemplar Capsules, 4 mcg|Zemplar Capsules, 4 mcg of Abott Laboratories USA
89412487|NCT00107952|Experimental|Telavancin|
89412488|NCT00107952|Active Comparator|Vancomycin|
89412489|NCT03499106|Experimental|Healthy Volunteers|Period 1: Single dose of IW-1973. Period 2: ITZ is dosed once daily (QD) for 17 days; a single dose of IW-1973 is administered 1 hour after the fourth ITZ QD dose.
89412490|NCT02325596||control|Patients with only nasal septum deviation
89412491|NCT02325596||CRS sNP|Chronic Rhinosinusitis patients without nasal polyps
89412492|NCT02325596||atopic CRS wNP|Chronic Rhinosinusitis patients with allergic constitution and nasal polyps
89412493|NCT02325596||non-atopic CRS wNP|Chronic Rhinosinusitis patients with nasal polyps but not allergic constitution
89412494|NCT02146404|Active Comparator|Euglycemia|Plasma glucose levels will be clamped at a constant value of ~5.0 mmol/l
89412495|NCT02146404|Experimental|Hypoglycemia|Plasma glucose levels will be clamped at a stable value of ~3.0 mmol/l
89535771|NCT02485535|Experimental|Treatment (selinexor)|Beginning on day 60-100 after allo-SCT without evidence of GVHD above grade 1 and disease relapse with stable hematopoietic recovery, patients receive selinexor PO on day 1 of each week or on days 1 and 3 of weeks 1-3. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
88889030|NCT04323137|No Intervention|Household members|This group of patients share an address with target high-risk patients (in arms 1-4). This group does not receive an intervention but is monitored for spillover effects of the intervention.
88889031|NCT04322552|Experimental|Treament|In phase A, subjects receiving a single 0.25 mg of digoxin orally and wash-out for 5 days, then apatinib once daily will be conducted on D5 through D16 ； In addition, a single dose of 0.25 mg digoxin (in combination with apatinib) will be orally administered in fasting conditions on D12；
88889032|NCT04321148|Other|standard of care PCI|
88889033|NCT04321148|Experimental|Impella-protected PCI|
88889034|NCT04316104|Experimental|CuidaTXT|This intervention, CuidaTXT [Spanish for self-care and texting], will be available in English and Spanish, incorporate two-way messaging and will tailor text messages to the preferences of Latino caregivers. CuidaTXT will be multicomponent and based on the Stress Process Framework as supported by evidence. The intervention will incorporate social support and coping components including dementia education, problem-solving skills training, social network support, care management and referral to community resources.
88889035|NCT04285814||Normal CMA|150 women whose blood samples will be drawn for WFC testing who previously had a CMA performed with normal results.
88889036|NCT04285814||Abnormal CMA|150 women whose blood samples will be drawn for WFC testing who previously had a CMA performed with abnormal results.
88889037|NCT04240717|Experimental|Patient Decision Aid|Patients review an interactive, web-based Patient Decision Aid regarding their treatment options. Afterwards they receive medical consultation.
88889038|NCT04240717|No Intervention|Treatment As Usual|Patients receive medical consultation.
88889039|NCT04234061|Experimental|Single|ibrutinib and Tisagenlecleucel
88889040|NCT04189848|Experimental|Semaglutide followed by dulaglutide|The 2 treatments will be administered at least 30 minutes apart, one in each side of the stomach
88889041|NCT04189848|Experimental|Dulaglutide followed by semaglutide|The 2 treatments will be administered at least 30 minutes apart, one in each side of the stomach
88889042|NCT04179695|Experimental|consultation with Parkinsun|
88889043|NCT04179695|Active Comparator|consultation as usual without Parkinsun|
88889044|NCT04156334|Experimental|computer-controlled intraosseous anaesthesia|Patients will receive the local anaesthetic using computer-controlled intraosseous anaesthesia (Quicksleeper 5) before the tooth extraction in general anaesthesia.
88889045|NCT04156334|Experimental|infiltrative or conductive local anaesthesia|Patients will receive a local anaesthetic using carpule before the tooth extraction in general anaesthesia.
88889046|NCT04092764|Experimental|Participants Receiving Electroacupuncture|Participants will receive electroacupuncture for 30 minutes once per week for a total of 3 weeks.
88889047|NCT04078906|No Intervention|Control group|Conventional IVLE (Intralipid) from D0 at 1g/kg/day and increase by 1 g/kg daily till reaching 3 g/kg/day.
88889048|NCT04078906|Experimental|Experimental group|n3-LCPUFA enriched IVLE (SMOFlipid) from D0 at 1g/kg/day and increase by 1 g/kg daily till reaching 3 g/kg/day.
88889049|NCT04036968|Placebo Comparator|Placebo+Placebo|Within-subject double-blind, double-dummy administration of placebo + placebo. Order of dose randomized session days 2-5.
88889050|NCT04036968|Active Comparator|Hydromorphone+Placebo|Within-subject double-blind, double-dummy administration of hydromorphone (oral) 4mg + placebo. Always administered during session 1.
88889051|NCT04036968|Experimental|Hydromorphone (oral) 4mg + Cannabidiol 50mg|Within-subject double-blind, double-dummy administration of hydromorphone (oral) 4mg + cannabidiol (oral) 50mg. Order of dose randomized session days 2-5.
89412496|NCT02319902|Placebo Comparator|Standard cold carbon dioxide gas|Standard cold carbon dioxide gas
89412497|NCT02319902|Active Comparator|Heated humidified carbon dioxide gas|Heated humidified carbon dioxide gas
89412498|NCT03494036|Experimental|Synbiotic|Synbiotic capsule containing 3x1.000.000.000 Colony Forming Units probiotics (Lactobacillus helveticus R0052 60%, Bifidobacterium infantis R0033 20%, dan Bifidobacterium bifidum R0071 20%) and fructooligosaccharide 80 mg. The dosage is once daily and it is given for 60 days
89412499|NCT03494036|Placebo Comparator|Placebo|Placebo capsule containing saccharum lactis. The dosage is once daily and it is given for 60 days
89412500|NCT02146638|Active Comparator|Morphine|Patients received morphine 0.02 mg/Kg/h infused at 2 ml/h for 24 hours. The infusion contained morphine and saline.
89412501|NCT02146638|Experimental|Fentanyl|Patients received Fentanyl 0.3 mcg/Kg/h infused at 2 ml/h for 24 hours. The infusion contained morphine and saline.
89412502|NCT03498950|No Intervention|Placebo Group|submitted to the routine laser therapy protocol in addition to simulated laser irradiation on the taste papillae
89412503|NCT03498950|Experimental|Test Group|submitted to the same laser therapy protocol as that of the Placebo Group, however, laser irradiation on the taste papillae will be effective.
89412504|NCT02146716|No Intervention|Control|
89192670|NCT06145412|Experimental|Xevinapant in Combination with Post-Operative Cisplatin and Radiotherapy|The study will consist of three phases: 2) concurrent radiation, cisplatin, and xevinapant, and 3) adjuvant xevinapant. Concurrent Chemoradiation Subjects will undergo FDG PET/CT simulation and standard radiation treatment planning. FDG PET/CT (Simulation or diagnostic) will also be utilized to rule out distant metastases. Subjects who meet criteria for the treatment phase will undergo standard of care adjuvant radiation (60-70 Gy administered in 2 Gy fractions) with concurrent cisplatin (2-3 cycles, with 100mg/m2 per cycle q3 weeks), and xevinapant (oral dose of 200mg per day on days 1-14 every 21 days for 3 cycles) Adjuvant Phase After completion of concurrent chemoradiation, patients will undergo an additional 3 cycles of xevinapant (oral dose of 200mg per day on days 1-14 every 21 days for 3- cycles)
89192671|NCT06145399|Experimental|Participants with Breast Cancer|Participants with histologically confirmed AR+ breast cancer
89192672|NCT06145295|Experimental|experiment group (online support group)|The experimental group engaged with the mobile application use for four weeks, with specific tasks including completing the four mandatory courses within one month and submitting at least two health records and online posts every week.
89192673|NCT06145295|Other|control group|The control group participates in the offline group intervention that last for four weeks. Participants in the control group will participant in four weekly workshop that last between 1 hour to 1.5 hours.
89192674|NCT06145269|Active Comparator|New oral anticoagulant (rivaroxaban)|We will use (rivaroxaban) 15 mg oral tablets twice a day, After 21 days: Should transition to 20 mg orally once a day untill we complete 6 months from the starting the treatment.
89192675|NCT06145269|Active Comparator|Marevan (warfarin)|Initiate warfarin on day 1 or 2 of parenteral anticoagulation therapy (eg, LMWH or unfractionated heparin) Overlap warfarin and parenteral anticoagulant for at least 5 days until desired INR (>2.0) maintained for 24 hours, then discontinue parenteral therapy and continue only with (warfarin) tablets 5 mg/day for 6 months.
89192676|NCT06145230||Under 60 group|Colorectal cancer paitents aged under 60 years old ( do not include 60 years old)
89192677|NCT06145230||60-69 group|Colorectal cancer paitents aged 60-69 years old
89192678|NCT06145230||70-79 group|Colorectal cancer paitents aged 70-79 years old
89192679|NCT06145230||80 and over group|Colorectal cancer paitents aged 80 and over 80 years old
89192680|NCT06145217|Experimental|SPRYCEL® (dasatinib) 100 mg Film-Coated Tablets|To evaluate the drug-drug interaction between SPRYCEL® 100 mg (US sourced) and Omeprazole under fasted conditions in healthy, adult, human subjects.
89192681|NCT06145204||single-group|"Adult patients suffering from lymphoedema of one or both lower limbs, capable of expressing their wishes and cared for their pathology at the Godinne Lymphoedema Reference Center.~There is no intervention (observational study). Questionnaires will be given at the beginning (Day 0) and the end (Day 4) of the cure : Lymph-iCf-LL, OMSPQ, BPI-sf, DN4."
89192682|NCT06145178|Experimental|Group 1|Low dose SPYVLP01 alone
89192683|NCT06145178|Experimental|Group 2|High dose SPYVLP01 alone
89192684|NCT06145178|Experimental|Group 3|Low dose + Alhydrogel
89192685|NCT06145178|Experimental|Group 4|High dose + Alhydrogel
89192686|NCT06145178|Experimental|Group 5|Low dose + Matrix-M
89192687|NCT06145178|Experimental|Group 6|High dose + Matrix-M
89192688|NCT06145165|Placebo Comparator|RP group:Nerve block with ropivacaine and intravenous analgesia group|The ropivacaine group will use ultrasound high-frequency line array probe for ACB and convex array probe for iPACK block before induction of general anesthesia
89192689|NCT06145165|Experimental|LP group ：Nerve block with liposomal bupivacaine and intravenous analgesia group|The liposomal bupivacaine group will use ultrasound high-frequency line array probe for ACB and convex array probe for iPACK block before induction of general anesthesia
89192690|NCT06145165|Placebo Comparator|control group：Intravenous analgesia group|General anesthesia was induced directly
89192691|NCT06144216|Experimental|CLOE Outreach Intervention|Participants enrolled in CLOE intervention
89192692|NCT06144021|Experimental|Kefir Postbiotics Group|"30 healthy adult participants~Appearance and formulation: Yellow powder/capsule with unique flavor and no off-flavor~Period of use: 12 months~Storage method: Store at room temperature~Manufacturing method: The whey postbiotics derived from kefir lactic acid bacteria used in the test food are produced in the laboratory at Hanyang University, and additional ingredients are purchased from finished products. Laboratory collects the ingredients and delivers them to the manufacturer, Neo Natural, to manufacture them so that there are no differences in properties and formulations."
88889052|NCT04036968|Experimental|Hydromorphone (oral) 4mg + Cannabidiol 100mg|Within-subject double-blind, double-dummy administration of hydromorphone (oral) 4mg + cannabidiol (oral) 100mg. Order of dose randomized session days 2-5.
88889053|NCT04036968|Experimental|Hydromorphone (oral) 4mg + Cannabidiol 200mg|Within-subject double-blind, double-dummy administration of hydromorphone (oral) 4mg + cannabidiol (oral) 200mg. Order of dose randomized session days 2-5.
88889054|NCT03980171|Experimental|Obinutuzumab+venetoclax+lenalidomide|Patients in both dose escalation and dose expansion will receive 6 cycles of induction treatment consisting of obinutuzumab (flat dose of 1000mg) and protocol defined dose levels of venetoclax and lenalidomide.
88889055|NCT03926013|Experimental|Part 1: Dose Escalation|Participants with metastatic castration-resistant prostate cancer (mCRPC) will receive JNJ-63898081. Ascending dose levels will be sequentially tested.
89192693|NCT06144021|Placebo Comparator|Control Group|"30 healthy adult participants~Appearance and formulation: Yellow powder/capsule with unique flavor and no off-flavor~Period of use: 12 months~Storage method: Store at room temperature~Manufacturing method: The same product without whey postbiotics."
89192694|NCT06143358|Experimental|treatment group|Qingkepingchuan Granules+Conventional basic therapy
89192695|NCT06143358|Other|control subjects|Conventional basic therapy
89192696|NCT06142942|Experimental|2 days per week group|Participants in this group complete 2 training sessions each week (Monday and Thursday).
89192697|NCT06142942|Experimental|3 days per week group|Participants in this group complete 3 training sessions each week (Monday, Wednesday, and Friday).
89192698|NCT06142942|Experimental|4 days per week group|Participants in this group complete 4 training sessions each week (Monday, Tuesday, Thursday, and Friday).
89192699|NCT06142942|No Intervention|No-exercise Control group|This group does not complete any training intervention. They are asked to maintain their regular physical activity habits.
89192700|NCT06142110|Active Comparator|Assessment of professional football player|Respiratory muscle strength and functional movement quality of professional football players were evaluated. Functional movement screen and portable spirometer were used for evaluation.
89192701|NCT06142110|Active Comparator|Assessment of sedantery individuals|Respiratory muscle strength and functional movement quality of sedantery individuals were evaluated. Functional movement screen and portable spirometer were used for evaluation.
89192702|NCT06141681||Healthy volunteers|>18 years old healthy
89192703|NCT06141681||Patients in critical care unit|patient in ICU with requirement for hemodynamic monitoring
89192704|NCT06141681||Patients with ventilatory support in the operating room or critical care unit|patient in the ICU or operating room with a requirement for hemodynamic monitoring and ventilatory support
89192705|NCT06141512|Experimental|Reduced-exertion high-intensity interval training (REHIT)|"All participants complete 6 weeks (3 sessions/week) of an exercise intervention labelled 'REHIT'.~Exercise sessions involve 10 minutes of unloaded cycling interspersed with 2 x 20 sec 'all-out' sprints against a resistance of 7.5% of participant's body weight. Sprints begin at 1:40 min and 5:40 min."
89192706|NCT06140823||prospective general population cohort|Males and females age >= 40 years, without a personal history of HCC or current HCC and at least two clinical visits to their HCO, within the last year, before the study start date.
89192707|NCT06140823||Prospective cirrhosis population cohort|Males and females age >= 40 years, with liver cirrhosis and without a personal history of HCC or current HCC, that have at least two clinical visits to their HCO, within the last year, before the study start date.
89192708|NCT06140823||Prospective no_cirrhosis population cohort|Males and females age >= 40 years, without a personal history of HCC or current HCC and without a diagnosis of liver cirrhosis, that have at least two clinical visits to their HCO, within the last year, before the study start date.
89192709|NCT06140602|Experimental|Intervention shake|The pecan shake is comprised of 1% milk, chocolate powder (Nesquik), soy lecithin, whole blended pecans, and water.
89192710|NCT06140602|No Intervention|Control shake|the control cream shake is comprised of 1% milk, chocolate powder (Nesquik), soy lecithin, dextrin, heavy whipping cream, and water.
89192711|NCT06139432|Experimental|Active transcranial Direct Current Stimulation|Active transcranial Direct Current Stimulation (tDCS): Stimulation of 2mA for 20 minutes
89192712|NCT06139432|Sham Comparator|Sham transcranial Direct Current Stimulation|Sham transcranial Direct Current Stimulation (tDCS): Effective stimulation of 2.5 mA for 30 seconds, then the stimulation stops. The complete session lasts 20 minutes, with 19 minutes and 30 seconds without stimulation.
88889056|NCT03926013|Experimental|Part 2: Dose Expansion|Participants with mCRPC or renal cell carcinoma (RCC) will receive JNJ-63898081 at the recommended Phase 2 dose (RP2D) determined in Part 1.
89535772|NCT03219931|Active Comparator|Active group - Breastfeeding infants|In this Group will be enrolled only infants who are breastfed. This Group will take the active product containing 5 drops of active product (108 viable cells/strain) of Bifidobacterium breve BR03 and Bifidobacterium breve B632.
88889057|NCT03860077|Experimental|Very Low Nicotine Content Cigarettes|
88889058|NCT03860077|Active Comparator|Normal Nicotine Content Cigarettes|
88889059|NCT03848793|Other|HS-20004 or placebo treatment (Low dose)|HS-20004 or placebo SC once daily (Low dose)
88889060|NCT03848793|Other|HS-20004 or placebo treatment (median dose 1)|HS-20004 or placebo SC once daily (median dose 1)
88889061|NCT03848793|Other|HS-20004 or placebo treatment (median dose 2)|HS-20004 or placebo SC once daily (median dose 2)
88889062|NCT03848793|Other|HS-20004 or placebo treatment (high dose)|HS-20004 or placebo SC once daily (high dose)
88889063|NCT03848351|No Intervention|Control Group|70 patients not receiving oral hygiene instructions or devices and continuing with their routine oral hygiene habits
89535773|NCT03219931|Active Comparator|Active Group - Bottlefeeding infant|In this active Group will be enrolled only infant who are bottle-fed. This Group will take the active product containing 5 drops of active product (108 viable cells/strain) of Bifidobacterium breve BR03 and Bifidobacterium breve B632.
89535774|NCT03219931|Placebo Comparator|Placebo group - Breastfeeding infants|In this placebo Group will be enrolled only infants who are breastfed. This arm will receive a supplementation with a same product equal to the active product but without bifidobacterium inside.
89535775|NCT03219931|Placebo Comparator|Placebo group - Bottlefeeding infants|In this placebo Group will be enrolled only infants who are bottlefed. This arm will receive a supplementation with a same product equal to the active product but without bifidobacterium inside.
89535776|NCT03203863||Puente Alto, Chile, 2009-2011.|anthropometric measures of fatness
89535777|NCT03320681|Active Comparator|Active Stimulation|Acupuncture needles will be inserted into the auricular zones and electrical stimulation will be given for 20 minutes.
89535778|NCT03320681|Other|Dry Needling|Acupuncture needles will be inserted into the auricular zones for 20 minutes. However, no electrical stimulation will be given
89535779|NCT03203785|Experimental|Carbohydrate|30g of carbohydrate (maltodextrin) diluted in 300ml of water. Athletes will drink 100ml before and 100ml in the first and second interval between exercise.
89535780|NCT03203785|Placebo Comparator|Placebo|300 ml of a non-caloric drink. Athletes will drink 100ml before and 100ml in the first and second interval between exercise.
89535781|NCT02485457|Experimental|Low volume|"The protocol will follow the following steps :~basal measurements (heart rate, arterial pressure, stroke volume estimated by esophageal Doppler, stoke volume estimated by Nicom)~followed by passive leg rising and additional measurements (heart rate, arterial pressure, stoke volume estimated by esophageal Doppler, stoke volume estimated by Nicom)~second basal measurements (heart rate, arterial pressure, stoke volume estimated by esophageal Doppler, stoke volume estimated by Nicom)~followed by low volume loading (250 ml of Ringer solution) and additional measurements (heart rate, arterial pressure, stoke volume estimated by esophageal Doppler, stoke volume estimated by Nicom)"
89535782|NCT02485457|Experimental|High volume|"The protocol will follow the following steps :~basal measurements (heart rate, arterial pressure, stroke volume estimated by esophageal Doppler, stoke volume estimated by Nicom)~followed by passive leg rising and additional measurements (heart rate, arterial pressure, stoke volume estimated by esophageal Doppler, stoke volume estimated by Nicom)~second basal measurements (heart rate, arterial pressure, stoke volume estimated by esophageal Doppler, stoke volume estimated by Nicom)~followed by low volume loading (500 ml of Ringer solution) and additional measurements (heart rate, arterial pressure, stoke volume estimated by esophageal Doppler, stoke volume estimated by Nicom)"
89535783|NCT03220009|Active Comparator|Arm I (nivolumab, ipilimumab, surgery, active surveillance)|"PART I: Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 1. Within 3-6 weeks after receiving nivolumab and ipilimumab, patients undergo surgery per standard of care. Within 84 days of last surgical resection, patients may also undergo adjuvant RT, if clinically appropriate.~PART II: Patients undergo active surveillance for 1 year."
89535784|NCT03220009|Experimental|Arm II (nivolumab, ipilimumab, surgery, nivolumab)|"PART I: Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 1. Within 3-6 weeks after receiving nivolumab and ipilimumab, patients undergo surgery per standard of care. Within 84 days of last surgical resection, patients may also undergo adjuvant RT, if clinically appropriate.~PART II: Patients receive nivolumab IV over 30 minutes once every 2 weeks for 4 doses. Patients then continue to receive nivolumab IV over 30 minutes once every 4 weeks for up to 11 doses in the absence of disease progression or unacceptable toxicity."
89535785|NCT03316703|Active Comparator|Conventional open surgery|Fixation of a proximal vertebra, a vertebra distal to the fractured vertebra, and also of the fractured vertebra with a pedicle fixation system using the conventional open to implant placement without subsequent arthrodesis.
89535786|NCT03316703|Experimental|Minimally invasive percutaneous surgery|Fixation of a proximal vertebra, a vertebra distal to the fractured vertebra, and also of the fractured vertebra with a pedicle fixation system using the percutaneous minimally invasive approach to implant placement without subsequent arthrodesis.
89535787|NCT03316625|Experimental|Bone mineral density|Bone densitometry measurement : Measurement of bone mineral densitometry with bone densitometry
89535788|NCT03203707|Experimental|Interpersonal and Social Rhythm Therapy+DIR|IPSRT plus referral for community treatment for any psychiatric conditions identified through the psychiatric assessment at intake.
89535789|NCT03203707|No Intervention|Data-Informed Referral (DIR)|Referral for community treatment for any psychiatric conditions identified through the psychiatric assessment at intake.
89535790|NCT02485613||bortezominb and dexamethasone group|
89535791|NCT03223363|Experimental|Development Group|Development Group is used to establish the prediction model.2D and 3D ultrasonography are performed in this group. Through statistical analysis we obtain a new model.
89535792|NCT03223363|Other|Validation group|Validation Group is used to confirm the efficacy of the prediction model.2D and 3D ultrasonography are performed in this group.Absolute and percentage error are calculated and compared with a common formula to confirm the accuracy of this new model.
89412505|NCT02146716|Experimental|Energetic Resonance by Cutaneous Stimulation|Energetic Resonance by Cutaneous Stimulation session in addition to standard treatment for patients with withdrawal alcohol symptoms.
89412506|NCT02322944|Experimental|Intervention group|The intervention group will take the treatment quality improvement strategies and tools into implementation.
89412507|NCT02322944|No Intervention|Control group|The control group will maintain the routine practice pattern.
89412508|NCT02322944|Experimental|Process optimization group|The process optimization group's clinical pathways and team building will be re-organized for the purpose of quality improvement, and develop individualized treatment strategies and process.
89412509|NCT02550522|Experimental|BCI|Brain-computer interface (BCI) platform including two implanted remotely powered ElectroCorticoGraph (ECoG) recording devices and an exoskeleton
89412510|NCT02325752|No Intervention|Control|Patients in the control group received usual care by the hospital. There was no contact between the patients in the control group and the study team throughout the 3 months interval. A scheduled telephone call was made at the end of 3 months when they were invited to participate in a telephone survey.
89412511|NCT02325752|Active Comparator|Intervention|Intervention
89412512|NCT02254200|Experimental|Fatmax group|Group who performed a continuous training program at the intensity eliciting the maximal fat oxidation
89412513|NCT02254200|Experimental|HIIT group|Group who performed a continuous training program with high intensity interval
89412514|NCT03498872|Active Comparator|Able-bodied individuals|
89412515|NCT03498872|Experimental|Transtibial amputee|
88889064|NCT03848351|Active Comparator|Test Group|"70 patients receiving intense oral hygiene instructions assisted by specific software or devices as well as oral hygiene (OH) tools (electric toothbrush, interdental floss, toothpaste) Thus, interventions will consist of.~Oral Hygiene Instruction (OHI)~Professional supragingival scaling and polishing"
88889065|NCT03847493||Patients with suspected sepsis|Patients admitted in the ICU with the clinical suspicion of infection/sepsis.
88889066|NCT03847493||Non-sepsis Patients (control group)|Patients admitted in the ICU with other conditions apart from infection/sepsis.
88889067|NCT03763448|Experimental|Infrapatellar Fat Pad Preservation|The IPFP retention of more than 80% in actual operation shall be regarded as IPFP retention.
89412516|NCT03498872|Experimental|Transfemoral amputee|
89412517|NCT03493880||naCT|Advanced gastric cancer or esophagogastric cancer receiving neoadjuvant (preoperative) chemotherapy.
89412518|NCT03493880||naCRT|Advanced gastric cancer or esophagogastric cancer receiving neoadjuvant (preoperative) chemoradiotherapy.
89412519|NCT02354118|Active Comparator|Control Group|Heparinized saline catheter flush - The control group will have their port catheters flushed with 20mL saline + 5mL heparin 100 units/mL; q 3 months
89412520|NCT02354118|Experimental|Intervention Group|Saline-only catheter flush - The intervention group will have their port catheters flushed with saline only.
89412521|NCT03498794|Active Comparator|Ureteral stent|"Technique of ureteral stent insertion:~All patients will be in lithotomy position, and an endoscopy operating table with fluoroscopic imaging capability will be used. Before the procedures, all patients will have retrograde ureteropyelography. Then, a 0.035-inch hydrophilic guide wire will be placed into the renal pelvis under the guidance of flexible cystoscope.~The ureteral stent will be inserted retrograde by using flexible cystoscope, under mild sedation or local anesthesia by instilling 2% xylocain gel per urethra. Patients will be covered by specific antimicrobial therapy according to urine and/or blood culture. This treatment will be continued until there was no fever and any evidence of infection disappeared. A Foley's catheter will be left in the bladder for 2 hours in all patients. In each case the type of stent will be that of 5 or 6 F, with side-holes and remain in place until definitive treatment of stone."
89535793|NCT02485379|Other|Prostate biopsy|"Systematic biopsies (SB) and targeted biopsies (TB) are performed in the same patients by two independent operators. In patients without abnormalities on mp-MRI, no targeted biopsies will be carried out and the detection of clinically significant cancer will be considered as negative for the TB strategy."
89192713|NCT06137131|Experimental|straw phonation in air|Participants will be asked to phonate an /u/ vowel through a stirring straw in air with slightly pursed lips and a soft voice onset.
89192714|NCT06137131|Experimental|straw phonation in 2 cm water|Participants will be asked to phonate an /u/ vowel through a stirring straw, placed 2 cm below the water surface, with slightly pursed lips and a soft voice onset.
89192715|NCT06137131|Experimental|straw phonation in 5 cm water|Participants will be asked to phonate an /u/ vowel through a stirring straw, placed 5 cm below the water surface, with slightly pursed lips and a soft voice onset.
89535794|NCT03223285|Experimental|Real Treatment Group|Patients included in this group will receive 3 multifaced physiotherapy/osteopathic treatments + experimental manoeuvres, 1 treatment/week. Each session will last about 30 minutes.
89535795|NCT03223285|Sham Comparator|Sham Treatment Group|Patients included in this group will receive 3 multifaced physiotherapy/osteopathic treatments + sham manoeuvres, 1 treatment/week. Each session will last about 30 minutes.
89535796|NCT02484833|Active Comparator|FOLFIRI + Cetuximab until disease progression|FOLFIRI + Cetuximab until disease progression
89535797|NCT02484833|Experimental|FOLFIRI + Cetuximab followed by Cetuximab alone|FOLFIRI + Cetuximab for 8 cycles followed by Cetuximab alone until disease progression
89535798|NCT03204019|Experimental|Tegafur and Temozolomide|Drugs should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
89535799|NCT03204019|Active Comparator|Tegafur and Temozolomide combined with Thalidomide|Drugs should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
89535800|NCT02484521|Active Comparator|Schizophrenia patients|Patients diagnosed with Schizophrenia. Will be assigned to PPI monitoring device protocol, according to unified protocol and have questionnaires to assess their status.
89535801|NCT02484521|Other|Healthy subject|This group would be assigned to PPI monitoring device protocol, according to a unified protocol similar to group of patients but not to questionnaires.
89535802|NCT02484599|Experimental|CAT active attention bias modification|Active computerized attention training (CAT). Attention training via repeated trials of a modified anti-saccade task with concurrent assessment of eye-movements intended to direct attention towards food stimuli using pictorial food and non-food stimuli (see Werthmann, Field, Roefs, Nederkoorn, & Jansen, 2014).
89535803|NCT02484599|Placebo Comparator|CAT sham bias modification|Sham computerized attention training. Attention training via repeated trials of a modified anti-saccade task with concurrent assessment of eye-movements not intended to change attention processing of food stimuli using pictures of two different non-food stimuli categories (e.g. household and musical instruments).
89535804|NCT02450461||Asthma|20 patients with asthma
89535805|NCT02450461||Controls|20 control subjects with no apparent lung disease and normal lung function testing. Matched for gender, age and smoking history.
89535806|NCT03223129|Other|Patients with normal glucose tolerance|"Patients included in this arm will have a plasma glucose below 140 mg/dl after a 2 h oral glucose tolerance test with a glucose load of 75 g.~All patients in this arm will undergo oral glucose tolerance test with increasing glucose load and a graded intravenous glucose infusion were plasma glucose levels are held at the same level as during the oral glucose tolerance test."
89535807|NCT03223129|Other|Patients with impaired glucose tolerance|"Patients included in this arm will have a plasma glucose between 140 mg/dl to 199 mg/dl after a 2 h oral glucose tolerance test with a glucose load of 75 g.~All patients in this arm will undergo oral glucose tolerance test with increasing glucose load and a graded intravenous glucose infusion were plasma glucose levels are held at the same level as during the oral glucose tolerance test."
89535808|NCT03223129|Other|Patients with type 2 diabetes mellitus|"Patients included in this arm will have a plasma glucose above 200 mg/dl after a 2 h oral glucose tolerance test with a glucose load of 75 g.~All patients in this arm will undergo oral glucose tolerance test with increasing glucose load and a graded intravenous glucose infusion were plasma glucose levels are held at the same level as during the oral glucose tolerance test."
89535809|NCT03203551|Placebo Comparator|C; Control; Saline solution|"Disinfection protocol:~brushing the palate (3 times a day/ 2 minutes);~brushing the total prostheses with neutral liquid soap (3 times a day/ 3 minutes);~immersing the total prostheses in Saline solution (once a day/ 20 minutes) before the last brushing of the day;~the prostheses must be conditioned in a vessel with water during the whole night period.~Periods of analysis (Baseline, 7 and 37 days):~the prostheses will be evidenced and photographed.~the biofilm present on the inner surface of the prostheses will be collected;~photographe of the participants' palate;~collected the palate biofilm."
89535810|NCT03203551|Experimental|HS0.25%; 0.25% Sodium Hypochlorite|"Disinfection protocol:~brushing the palate (3 times a day/ 2 minutes);~brushing the total prostheses with neutral liquid soap (3 times a day/ 3 minutes);~immersing the total prostheses in 0.25% Sodium Hypochlorite (once a day/ 20 minutes) before the last brushing of the day;~the prostheses must be conditioned in a vessel with water during the whole night period.~Periods of analysis (Baseline, 7 and 37 days):~the prostheses will be evidenced and photographed.~the biofilm present on the inner surface of the prostheses will be collected;~photographe of the participants' palate;~collected the palate biofilm."
89535811|NCT03203551|Experimental|RC10%; 10% Ricinus communis|"Disinfection protocol:~brushing the palate (3 times a day/ 2 minutes);~brushing the total prostheses with neutral liquid soap (3 times a day/ 3 minutes);~immersing the total prostheses in 10% Ricinus communis (once a day/ 20 minutes) before the last brushing of the day;~the prostheses must be conditioned in a vessel with water during the whole night period.~Periods of analysis (Baseline, 7 and 37 days):~the prostheses will be evidenced and photographed.~the biofilm present on the inner surface of the prostheses will be collected;~photographe of the participants' palate;~collected the palate biofilm."
89535812|NCT03203551|Experimental|CT0.5%; 0.5% Chloramine T|"Disinfection protocol:~brushing the palate (3 times a day/ 2 minutes);~brushing the total prostheses with neutral liquid soap (3 times a day/ 3 minutes);~immersing the total prostheses in 0.5% Choramine T (once a day/ 20 minutes) before the last brushing of the day;~the prostheses must be conditioned in a vessel with water during the whole night period.~Periods of analysis (Baseline, 7 and 37 days):~the prostheses will be evidenced and photographed.~the biofilm present on the inner surface of the prostheses will be collected;~photographe of the participants' palate;~collected the palate biofilm."
89412522|NCT03498794|Active Comparator|Percutaneous nephrostomy tube|"Technique of PCN insertion:~Percutaneous nephrostomy will be performed in the angiography suite by a urologist with the patient under local anesthesia. All the patients will be given non-nephrotoxic antibiotics pre-operatively. The patients will be placed on the ultrasound table with fluoroscopic imaging capability in prone position and a pillow placed under the abdomen on the affected side to support the kidney. Then the initial puncture site will be chosen, cleaned and draped. Local anesthesia was injected and a stab incision was given at the puncture site. The 18-gauge Chiba needle will be inserted at the renal angle or at the posterior axillary line under ultrasound guidance into dilated pelvicalyceal system. Urine or pus drained out spontaneously or will be sucked with a disposable syringe and sample was sent to the laboratory for culture and sensitively."
89412523|NCT03496688|Active Comparator|bone substitute material MCBA|Sinus floor augmentation: a bony window was created along the lateral wall of the sinus, the sinus membrane was carefully elevated and the created space was augmented using mineralized sol-vent-dehydrated bone allograft material.
89412524|NCT03496688|Active Comparator|bone substitute material FDBA|Sinus floor augmentation: a bony window was created along the lateral wall of the sinus, the sinus membrane was carefully elevated and the created space was augmented using freeze-dried mineralized bone allograft material.
88889068|NCT03763448|Active Comparator|Infrapatellar Fat Pad Resection|In the clinical practice, more than 80% of IPFP volume is commonly resected by surgeons during total knee arthroplasty. The investigators hereby define resection of more than 80% IPFP volume as IPFP excision.
88889069|NCT03729206|Experimental|Sublingual microscopy|
88889070|NCT03687411|Experimental|ULTRA-SINE (phases 1-4)|"There will be four phases in this proposed uSINE system. In first phase attending anaesthetist will use the automated spinal landmark system for neuraxial needle insertion to place the neuraxial anaesthesia in non-obese patients.~For the second phase, obese patients will have ultrasound scan of their lumbar back and no needle insertion is involved.~In third phase, conventional ultrasonography is used prior to the needle insertion, and needle insertion is conducted manually as per routine practice. The images collected in the system will be used for annotation and evaluation which serves as training material for uSINE to optimize its algorithm to improve landmark identification for obese patients. The fourth phase will have uSINE system used prior to the needle insertion, with the neuraxial needle insertion conducted manually as per routine practice. The identification accuracy and first-attempt puncture success rate of uSINE will be determined."
88889071|NCT03674307|Experimental|No screening|No further screening for asymptomatic coronary artery disease after wait-list entry
88889072|NCT03674307|Active Comparator|Regular screening|Regular (yearly or 2nd yearly) screening for asymptomatic coronary artery disease after wait-list entry
88889073|NCT03670004||Unilateral Below Knee Amputation|Individuals who walk with a below knee prosthesis
88889074|NCT03670004||Non-Impaired|Able-bodied controls
88889075|NCT03658044|Experimental|Participation in the internet forum|Other: Patients will be encouraged to participate in an internet forum communicating with other patients at least once per week. Participation in the internet forum
88889076|NCT03658044|Active Comparator|No participation in the internet forum|"Placebo Patients will not be able to enter or read in the forum, but will be able to read general information on the webpage where the forum is placed."
88889077|NCT03643016|Experimental|Group with Virtual Epileptic Patient brain access data|
88889078|NCT03643016|No Intervention|Group without Virtual Epileptic Patient brain access data|
88889079|NCT03637413|Experimental|Hindmilk|Hindmilk, the milk at the end of a breast pumping session, has higher fat and energy content compared to the composite milk.
88889080|NCT03576495|Experimental|Early Intervention / Retention Group|"The investigators will assess the residents' knowledge, attitudes, and skills prior to and after the PACTS curriculum administration at half the sites (Early Intervention/Retention Group).~Follow-up testing will be conducted after one year to evaluate learner retention.~Further, the investigators will test post-exposure effect retention in the Early Intervention Group at the end of year 2."
88889081|NCT03576495|Active Comparator|Delayed Intervention Group|"The investigators will conduct baseline testing prior to the standard residency curriculum, and administer the PACTS curriculum the following year.~Both between- and within-group differences will be examined based on curriculum exposure in intervention year 1 as well as within-group differences for the Delayed Intervention Group at the end of year 2."
88889082|NCT03571347|Experimental|Self Help Plus|SH+ programme has been developed by WHO and collaborators working in the humanitarian field, with expertise in global mental health and psychosocial interventions. SH+ programme consists of a pre-recorded audio course, complemented with bibliotherapy, and thanks to this format not requiring much time from experts for implementation. SH+ consists of 5 sessions.
88889083|NCT03571347|Other|Enhanced Treatment As Usual|Control arm participants will receive routine social support and/or care according to ordinary practice and following local regulations. Additionally, they will receive baseline and follow-up assessments according to the study schedule, and information about freely available mental health services, social services and community networks providing support to asylum seekers and refugees, and NGOs' contact details.
89412525|NCT03496688|Active Comparator|bone substitute material ABB|Sinus floor augmentation: a bony window was created along the lateral wall of the sinus, the sinus membrane was carefully elevated and the created space was augmented using anorganic bovine bone material.
88889084|NCT03558724|Experimental|NIR endoscopy with 4.5 mg bevacizumab-800CW|"A non-randomized, non-blinded, prospective, feasibility study.~IV-administration of 4.5 mg of the fluorescent tracer bevacizumab-800CW to a total of 5 patients with locally advanced esophageal cancer. The optimal dose will be expanded to include 30 patients.~Molecular fluorescence endoscopy: 2-3 days after administration, molecular fluorescence endoscopy will be performed with additional measurements of fluorescence signals."
88889085|NCT03558724|Experimental|NIR endoscopy with 10 mg bevacizumab-800CW|"A non-randomized, non-blinded, prospective, feasibility study.~IV-administration of 10 mg of the fluorescent tracer bevacizumab-800CW to a total of 3 patients with locally advanced esophageal cancer. The optimal dose will be expanded to include 30 patients.~Molecular fluorescence endoscopy: 2-3 days after administration, molecular fluorescence endoscopy will be performed with additional measurements of fluorescence signals."
88889086|NCT03558724|Experimental|NIR endoscopy with 25 mg bevacizumab-800CW|"A non-randomized, non-blinded, prospective, feasibility study.~IV-administration of 25 mg of the fluorescent tracer bevacizumab-800CW to a total of 3 patients with locally advanced esophageal cancer. The optimal dose will be expanded to include 30 patients.~Molecular fluorescence endoscopy: 2-3 days after administration, molecular fluorescence endoscopy will be performed with additional measurements of fluorescence signals."
88889087|NCT03547037|Experimental|Phase 1a: JNJ-63723283 (Monotherapy)|Participants will receive monotherapy of JNJ-63723283 intravenously. The subsequent dose levels of JNJ-63723283 will be escalated using Bayesian logistic regression model (BLRM).
88889088|NCT03547037|Experimental|Phase 1b: Erdafitinib Combination|Participants will receive erdafitinib in combination with JNJ-63723283 which will be escalated using BLRM.
88889089|NCT03533660|Active Comparator|Feedback|Participant will receive a brief feedback on data downloaded from the ABM and information about treatment resources
88889090|NCT03533660|Active Comparator|Enhanced usual care|Participant will receive information about remaining abstinent and about treatment resources
88889091|NCT03512496|Placebo Comparator|Acute energy drink - Control|Coloured Water was given 40 min prior to the OGTT test.
88889092|NCT03512496|Active Comparator|Acute energy drink - Caffeine|Sugar Free energy drink at 5mg/kg caffeine was given 40 min prior to OGTT test.
88889093|NCT03512496|Sham Comparator|Acute energy drink- Decaf|Sugar free decaf energy drink (vitamins only) was given 40 min prior to OGTT test. Amount of drink was same as that of Caffeine
88889094|NCT03416127|Experimental|Propolis|Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.
88889095|NCT03416127|Experimental|Metformin|Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.
88889096|NCT03416127|Placebo Comparator|Placebo|Placebo capsules, two times per day before break-fast and dinner during 12 weeks.
88889097|NCT03399149||"Before phase"|Retrospective study of ICU admissions of hematology patients for respiratory and hemodynamic reasons Time period: January 2012 to March 2017
88889098|NCT03399149||"After Phase: Systematic evaluation by an intensivist"|"Corresponding to the period after the implementation of a systematic intensivist evaluation Daily screening of systolic blood pressure, oxygen saturation and oxygen requirements of all patients hospitalized in hematology wards. Systematic evaluation of any patient presenting the inclusion criteria by an intensivist and collegial care planning.~Time period: From March 2017 to end of study"
88889099|NCT03293069|Experimental|Deferiprone|Half of participants will receive twice-daily oral deferiprone taken over 12 months.
88889100|NCT03293069|Placebo Comparator|Placebo|Half of participants will receive the placebo Twice-daily oral placebo taken over 12 months
88889101|NCT03266315|Experimental|Probiotics|subjects will be randomly assigned to receive FloraBaby
88889102|NCT03266315|Placebo Comparator|Placebo|subjects will be randomly assigned to receive placebo
88889103|NCT03232346|Experimental|Regimen 1|Rapid Monday to Friday oral naltrexone-induction procedure
88889104|NCT03232346|Experimental|Regimen 2|5-week buprenorphine taper from maintenance dose of 8, 6, or 4mg
88889105|NCT03227731|Active Comparator|Arm A (Intervention - Truvada)|Standard HIV Prevention strategy plus a once daily dose of Truvada (FTC 200mg/TDF 300mg tablet) initiated in pregnancy and continuing until cessation of breastfeeding or 18 months postdelivery whichever is earliest and thereafter the option to continue PrEP post breastfeeding cessation.
88889106|NCT03227731|No Intervention|Arm B (Control - Standard of Care)|Standard HIV Prevention strategy throughout pregnancy until 18 months postdelivery plus the offer to initiate PrEP post breastfeeding cessation
88889107|NCT03209349|Experimental|Water Exchange Sigmoidoscopy|"As per standard practices, the patient will be walked to the procedure room and positioned in the left lateral position on the procedure bed, without pre-operative anesthesia. The procedures will be completed within the ambulatory endoscopy clinic at Kelowna General Hospital. The study will use the same colonoscopes that are already being used at KGH for colonoscopy. These are the Olympus 190 series colonoscopes. They can and will be fitted to support both water and air exchange.~For patients assigned the water exchange intervention arm, the insertion of the scope will be followed by infusion and suction of water to minimally distend the lumen. If the lumen does not open, the instrument will be retracted slightly and the infusion started again. As the scope is inserted and progressed through the intestinal lumen some of the infused water will be suctioned back constantly, exchanging clean for opaque water."
89412526|NCT03496688|Active Comparator|bone substitute material EB|Sinus floor augmentation: a bony window was created along the lateral wall of the sinus, the sinus membrane was carefully elevated and the created space was augmented using equine-derived bone material.
89412527|NCT03496688|Active Comparator|bone substitute material HA-β-TCP 30/70|Sinus floor augmentation: a bony window was created along the lateral wall of the sinus, the sinus membrane was carefully elevated and the created space was augmented using synthetic micromacroporous bi-phasic calcium-phosphate block consisting of 70% beta-tricalcium phosphate and 30% hy-droxyapatite material.
89412528|NCT03496688|Active Comparator|bone substitute material BC|Sinus floor augmentation: a bony window was created along the lateral wall of the sinus, the sinus membrane was carefully elevated and the created space was augmented using bioapatite-collagen material.
89412529|NCT02325830|Experimental|Treatment Group|Implantation of the CARILLON Mitral Contour System
89412530|NCT02325830|No Intervention|Control Group|Optimized stable medical therapy
88922031|NCT05956002|Experimental|Sequence 4|Single oral dose of etrasimod 2 mg mini tablets mixed with water under fasted conditions (Test 3). Followed by single oral dose of etrasimod 2 mg mini tablets mixed with chocolate pudding under fasted conditions (Test 2). Followed by single oral dose of etrasimod 2 mg mini tablets mixed with applesauce under fasted conditions (Test 1). Followed by single oral dose of etrasimod 2 mg clinical IR tablet under fasted conditions (Reference). Followed by single oral dose of etrasimod 2 mg mini tablets mixed with yogurt under fasted conditions (Test 4)
89412531|NCT02146794|Experimental|Renal denervation|renal denervation
89536708|NCT05081531|Other|Adaptive Radiotherapy in Head and Neck cancer patients|"Patients will be treated with a total dose of 66 Gy, 60 Gy and 54 Gy on PTV1, PTV2 and PTV3, respectively, delivered in 30 fractions, 5 fractions per week.~At week 3 from RT start, patients will repeat contrast simulation CT with, and MRI and FDG-PET scan for treatment replanning. Patient will start with the new plan in week 4."
88889108|NCT03209349|Active Comparator|Air Insufflation Sigmoidoscopy|"As per standard practices, the patient will be walked to the procedure room and positioned in the left lateral position on the procedure bed, without pre-operative anesthesia. The procedures will be completed within the ambulatory endoscopy clinic at Kelowna General Hospital. The study will use the same colonoscopes that are already being used at KGH for colonoscopy. These are the Olympus 190 series colonoscopes. They can and will be fitted to support both water and air exchange.~For patients assigned to the air insufflation intervention arm, extended sigmoidoscopy will be performed with the minimum insufflation required to reach the cecum."
88889109|NCT03203512|Active Comparator|Intervention|Fish oil capsules
88889110|NCT03203512|Placebo Comparator|Placebo|High-oleic safflower oil capsules
88889111|NCT03200015|Experimental|Metformin arm|Metformin 850 mg tablets. Initial dose 425 mg twice a day for 1 week, followed by 850 mg twice a day for 1 week, titrated to a maximum dose 850 mg every 8 hours until disease response evaluation study date (Computed tomography or positron emission tomography)
88889112|NCT03149640|Experimental|Inhaled amikacin|Inhaled amikacin at day 4, day 5 and day 6 of invasive mechanical ventilation: 20 mg/kg of ideal body weight, maximum 2 g per day.
88889113|NCT03149640|Placebo Comparator|Placebo|Once a day, inhaled placebo at day 4, day 5 and day 6 of invasive mechanical ventilation.
89192716|NCT06137131|Active Comparator|/u/ control condition|Participants will be asked to phonate an /u/ vowel with slightly pursed lips and a soft voice onset but without a straw.
89192717|NCT06134167|Experimental|Transdermal Compress Device|The Transdermal Compress device is a bone-anchored transdermal implant that addresses the shortcomings of a socket prosthesis and provides options to amputees who are not able to utilize a conventional socket prosthesis.
89192718|NCT06133673||Schools|Prevalence questionnaire data will be collected from 20 schools.
89192719|NCT06133673||Autistic children and young people (CYP)|10 semi-structured qualitative interviews will be conducted with autistics CYP.
89192720|NCT06132841|Experimental|Cohort 1|Participants will receive repeated doses of AZD6234 or placebo via SC injection
89192721|NCT06132841|Experimental|Cohort 2|Participants will receive repeated doses of AZD6234 or placebo via SC injection
89192722|NCT06132698|Experimental|Enrolled patients were treated with an immune checkpoint inhibitor combined with pemetrexed intrathe|
89192723|NCT06129643|Active Comparator|Conventional group A|
89192724|NCT06129643|Experimental|Dual laser group (Er,Cr:YSGG/Diode)|
89192725|NCT06129643|Experimental|Combined group (EDTA/Diode):|
89535813|NCT02485145|Experimental|A/B|In this crossover trial, the A/B group will receive the test product (A) and then the placebo (B). The topical product contains the following: Diclofenac 3%, Baclofen 2%, Orphenadrine Citrate 5% and Bupivacaine 2% in a VersaPro cream, while the placebo is the VersaPro cream alone. Participants will use the test product for 7 days, applying the topical product to the hands twice a day. There will be a 7 day washout period, and then participants will be given the placebo cream, which will be used for 7 days, applying the topical placebo to the hands twice a day.
89192726|NCT06128096||SGLT-2 inhibitor group|"Patients will be given a recommended dose of SGLT-2 inhibitor by cardiologist in a form of tablets based on clinical indication. The SGLT-2 inhibitor includes :~Tab Empagliflozin 10mg OD~Tab Dapagliflozin 10mg OD~After administration of SGLT-2 inhibitor, the cardiac function and epicardial adipose tissue thickness will be measured (baseline and 6 month) post intervention"
89192727|NCT06128096||Control group|Patient will not be given SGLT-2 inhibitor and continue SOC up to 6 months. The cardiac function and epicardial adipose tissue thickness will be measured (baseline and 6 month) post intervention
89192728|NCT06127017|Placebo Comparator|Titanium bar|6 implants in each participant will be immediately loaded and splinted with intraorally welded titanium bar.
88889114|NCT03141736|Active Comparator|KMC & WHO protocol (0-1 hour)|The combination of Kangaroo Mother Care (KMC) as continuously as possible together with routine World Health Organization (WHO) thermoregulation care (warm delivery rooms, immediate drying after birth, early and exclusive breastfeeding, postponement of bathing and weighing, and appropriate bundling.
88889115|NCT03141736|Active Comparator|KMC & WHO protocol (1-24 hours)|The combination of Kangaroo Mother Care (KMC) as continuously as possible together with routine World Health Organization (WHO) thermoregulation care (warm delivery rooms, immediate drying after birth, early and exclusive breastfeeding, postponement of bathing and weighing, and appropriate bundling.
88889116|NCT03141736|Experimental|KMC, WHO protocol & bag (0-1 hour)|The combination of Kangaroo Mother Care (KMC) as continuously as possible together with the use of a plastic bag in combination with routine World Health Organization (WHO) thermoregulation care (warm delivery rooms, immediate drying after birth, early and exclusive breastfeeding, postponement of bathing and weighing, and appropriate bundling.
88889117|NCT03141736|Experimental|KMC, WHO protocol & bag (1-24 hours|The combination of Kangaroo Mother Care (KMC) as continuously as possible together with the use of a plastic bag in combination with routine World Health Organization (WHO) thermoregulation care (warm delivery rooms, immediate drying after birth, early and exclusive breastfeeding, postponement of bathing and weighing, and appropriate bundling.
88889118|NCT03090841||CMV cases|bio-specimen collected for pregnant women with CMV infection
88889119|NCT03090841||Control cases|bio-specimen collected for pregnant women carrying a fetus with aneuploidy-dysgonosomy
88889120|NCT03036423|Active Comparator|Online video education|Participants will have computer access to a library of videos, including various lectures and demonstrations of interest, from which to select and view.
88889121|NCT03036423|Active Comparator|Computerized mental exercises|Participants will use a computer to do a variety of activities which are customizable to their own abilities and progress.
88889122|NCT02986334|No Intervention|No Treatment Intervention|Observational Subjects randomized to this arm will be asked to discontinue their current pain medications for the length of the study. This arm is not blinded, as both study staff and participants will be aware that they are not receiving a study treatment.
88889123|NCT02986334|Active Comparator|Active Treatment Intervention|Naproxen & Omeprazole Subjects randomized to this arm will be asked to discontinue their current pain medications and take one 500mg naproxen capsule and one 40mg omeprazole capsule twice a day for the length of the study. This arm is double-blind, as neither participants nor study staff will know what medication the participants is receiving (blind to active versus placebo treatment).
88889124|NCT02986334|Placebo Comparator|Placebo Treatment Intervention|Subjects randomized to this arm will be asked to discontinue their current pain medications and take two placebo capsules twice a day for the length of the study. This arm is double-blind, as neither participants nor study staff will know what medication the participants is receiving (blind to active versus placebo treatment)
88889125|NCT02966483|Experimental|Transanal Total Mesorectal Excision|The rectum is mobilized and resected transanally (from bottom to up) according to TME principles, via transanal platform (either rigid or flexible platform).An ideal TaTME is defined as the extraperitoneal portion of the rectum being mobilized from below.
88889126|NCT02966483|Active Comparator|Laparoscopic Total Mesorectal Excision|The traditional laparoscopic TME (LpTME) was performed via standard laparoscopic techniques, including multiple trocars and conventional laparoscopic instruments.
88889127|NCT02933073|Experimental|OncoImmunome/Vaccine Phase|Women with Stage III/IV Ovarian Cancer who have received the standard of care treatment (surgical debulking and chemotherapy) for their cancer and are now in clinical remission will be given the experimental drug (vaccine) called OncoImmunome, which has been produced specifically for each participant.
88889128|NCT02863718|No Intervention|Watch & wait|Watch & wait
88889129|NCT02863718|Placebo Comparator|Placebo 420 mg/d|Placebo 420mg/d
88889130|NCT02863718|Active Comparator|Ibrutinib 420mg/d|Ibrutinib 420mg/d
88889131|NCT02836106|Experimental|Healthy|Lean subjects (BMI<25) with a waist circumference of <94 cm for men and<80 cm for women. Subjects will be randomly assigned to eat butter, cheese, whipped cream and sour cream in a cross-over design.
88889132|NCT02836106|Experimental|Obese|Overweight and obese subjects (BMI≥25) with a waist circumference of ≥94 cm for men and ≥80 cm for women. Subjects will be randomly assigned to eat butter, cheese, whipped cream and sour cream in a cross-over design.
88889133|NCT02813850|No Intervention|control|standard medical care
88889134|NCT02813850|Experimental|oxygen therapy|
88889135|NCT02679495|Active Comparator|Lifestyle intervention|A better lifestyle that are supposed to prevent gastric cancer occurrence are advised to patients. Measures includes dietary change and cessation of smoking and alcohol abuse. Behavioural and cognitive strategies from investigators are performed to patients to ensure adherence to established intervention.
88889136|NCT02679495|No Intervention|No intervention|No meassures are taken to change life style of enrolled patients.
88889137|NCT02668289|Other|interventional|consent, screening, xrays, PVS impressions, photographs, CBCT, anesthesia, extraction, clinical measurements
88889138|NCT02655315|Active Comparator|DEFERIPRONE|Half of participants will receive the deferiprone (DFP) to 15 mg / kg twice daily morning and evening (30mg / kg per day).The treatment lasts nine months.
89192729|NCT06127017|Active Comparator|PEEK bar|6 implants in each participant will be immediately loaded and splinted with PEEK bar.
88889139|NCT02655315|Placebo Comparator|PLACEBO|Half of participants will receive the placebo twice daily morning and evening. The treatment lasts nine months.
89192730|NCT06125210|Experimental|intervention group|
89192731|NCT06125210|No Intervention|control group|
89536709|NCT02473211|Experimental|SOF+DCV|Participants will receive Sofosbuvir (SOF) 400 mg and Daclatasvir (DCV) 60 mg daily for 12 weeks.
89412532|NCT03496532|Experimental|Pulse generator change under sedation|"The efficacy of every set will be measured on induced changes in LFP recorded from the STN electrodes.LFP will be compared between before, during and right after each stimulation conditions. The stimulation order will be randomized. All other stimulation parameters will be the same (macrocontact with most beta-oscillations, 1 minute, 1.5mA) .~Hence 4 sets of 1 minutes of STN stimulation will be performed, for:~Symmetrical biphasic pulses versus standard pseudo monophasic pulses (study I; 2 sets).~Pseudorandom uniform distribution stimulation paradigms versus pseudorandom Poisson distribution stimulation paradigms (study II: 2 sets)."
89412533|NCT03496532|Experimental|First pulse generator implantation under general an|The depth of anesthesia will be documented, recording the BIS spectral analysis index. The difference in spectral amplitude density of LFP, in particular in beta band oscillations will be correlated with the depth of anesthesia as measured with the BIS index.
89412534|NCT03496454|Other|PfSPZ Challenge|this is a basic sciences protocol designed to study the effect of pre-exposure to Plasmodium falciparum (Pf) on malaria parasite kinetics, clinical symptoms and immunity after Controlled Human Malaria Infection by administration of an injection PfSPZ Challenge in Gambian adults. Based on a well-defined serological profile representing the extremes of current malaria exposure in The Gambia, two cohorts will be identified to study the impact of naturally acquired immunity on susceptibility for a Controlled Human Malaria Infection. The classification as a clinical trial results from the administration of the PfSPZ Challenge to the healthy volunteers
89412535|NCT02319980|Active Comparator|Surgical intervention|All participants in this group will be assigned to receive extracranial-intracranial arterial bypass surgery.
89412536|NCT02319980|No Intervention|Conservative management(medical management)|All participants in this group will be assigned to receive conservative management or medical management which involves drug therapy as considered appropriate for medical symptoms by the treating investigator.
89412537|NCT02325908||Hemodialysis patients|Dialysis patients will have their estimated dry weight measured with calf segmental bioimpedance. Based on these measurements, their dry weight will be adjusted and the amount of fluid removed during subsequent dialysis treatments will be increased by 200-300mL. The additional fluid removal will occur during 3 consecutive hemodialysis sessions. In addition, these subjects will also use VStim during these treatments. to prevent common intradialytic symptoms by promoting vascular refilling.
89005399|NCT04571593|Experimental|Digital Yoga Nidra|"Participants will voluntarily complete a ~30-minute remote Yoga Nidra practice, synchronously (through Zoom Wednesdays at 10 pm ET) or asynchronously (through YouTube, using the Zoom recording, any time they like).~They may voluntarily repeat this practice as often as they like. Recordings are updated weekly, to reflect the ongoing Zoom class. Yoga Nidra scripts from Satyananda Saraswati's Yoga Nidra book (1976) are used for this class."
89005400|NCT01082068|Experimental|Arm 1|XL147 (SAR245408) + letrozole
89005401|NCT01082068|Experimental|Arm 2|XL765 + letrozole
89005402|NCT01086748|Experimental|160 mg LY2140023|80 mg LY2140023 administered orally, twice daily (BID) for up to 7 weeks.
89005403|NCT01086748|Active Comparator|4 mg Risperidone|2 mg risperidone administered orally, BID for up to 7 weeks.
89005404|NCT01086748|Placebo Comparator|Placebo|Placebo administered orally, BID for up to 7 weeks.
89412538|NCT02325908||Healthy Controls|No Intervention was administered. Both groups had their hydration status measured with segmental bioimpedance The group of healthy subjects was studied in order to obtain a range of values for normal hydration status.
89412539|NCT05131412||mesenchymal stromal cell|Patients treated with mesenchymal stromal cell
89412540|NCT05131412||non-mesenchymal stromal cell|Patients treated without mesenchymal stromal cell
89412541|NCT02320370|Experimental|Treatment 1|NeuroConn DC Stimulator Plus tDCS treatment protocol no 1
89412542|NCT02320370|Experimental|Treatment 2|NeuroConn DC Stimulator Plus tDCS treatment protocol no 1
89412543|NCT02320448|Experimental|PIPAC|"PIPAC with cisplatin (7.5mg/m2 in 150 ml saline) and doxorubicin (1.5mg/m2 in 50 ml saline) in patients with peritoneal metastases (PM) from any origin besides colorectal/appendiceal cancers in whom oxaliplatin (92mg/m2 in 150 ml dextrose) will be used.~The aerosolised chemotherapy will be nebulized at a flow of 0.5ml/min at a maximum pressure of 200 PSI during a standard laparoscopy with an intraabdominal pressure of 12mmHg. The CO2 will be evacuated 30 minutes after administration of chemotherapy and the patient is closed similar to a standard laparoscopy."
89412544|NCT03496376|Experimental|Kinesio Taping Group|Kinesio Taping Group received three different deep breathing exercises (diaphragmatic, thoracic, and lateral basal), each consisting of three sets of 10 repetitions, with 30 seconds of rest between each set plus thoracic kinesio taping application.
89412545|NCT03496376|Active Comparator|Control Group|Control Group received three different deep breathing exercises (diaphragmatic, thoracic, and lateral basal), each consisting of three sets of 10 repetitions, with 30 seconds of rest between each set.
89412546|NCT02323022|Experimental|IAC regimen|Patients in this arm will receive an IAC induction therapy
88889140|NCT02436733|Experimental|Immediate pleurectomy/decortication|immediate P/D followed by three cycles of pemetrexed 500mg/m2 IV and cisplatin 75 mg/m2 IV, both drugs given on day 1, every three weeks for non-progressing patients
88889141|NCT02436733|Active Comparator|Delayed pleurectomy/decortication|three cycles of pemetrexed 500mg/m2 IV and cisplatin 75 mg/m2 IV, both drugs given on day 1, every three weeks followed by P/D, for non-progressing patients.
88889142|NCT02426502|Experimental|Conversion to once daily dosing|The conversion to a once daily dosing regimen will be accomplished in three phases (1-conversion to Advagraf; 2-conversion of non-immunosuppressant drugs and; 3-conversion of patients taking twice daily MPA to once daily MPA). No control group.
88889143|NCT02360891||patients|follow up of patients with amyotrophic lateral sclerosis from the first signs to the end of the disease
88889144|NCT02360891||neurological controls|patients with other neurological disease
89412547|NCT02323022|Active Comparator|High-dose IA regimen|Patients in this arm will receive an IA induction therapy, in which the idarubicin dose should be 10mg/msq/d
88889145|NCT02360891||healthy controls|age matched healthy controls
88889146|NCT02360683||patients with Parkinson's disease|Large population of Parkinson's patients who benefit from subthalamic stimulation
88889147|NCT02275156|Experimental|Evolocumab|Participants received a single 140 mg dose of evolocumab subcutaneously on Day 1.
88889148|NCT02185235|Experimental|Biofeedback & Electrical Stimulation|Twice a week, 20 minutes for each time. One course includes 18 times treatment.
88889149|NCT02185235|Active Comparator|Biofeedback & Pelvic Floor Training|Pelvic floor training every 20 minutes for each time, twice a week. and total for 18 times.
88889150|NCT02124902|Experimental|Washington University: Neoadjuvant docetaxel and carboplatin|Docetaxel will be administered intravenously at a dose of 75mg/m2 over 60 minutes on Day 1 of each 21-day cycle. Carboplatin AUC 6 will be administered intravenously over 30 minutes on Day 1 of each 21-day cycle immediately following docetaxel infusion. A total of 6 cycles will be given.
88889151|NCT02124902|Experimental|Baylor: Neoadjuvant docetaxel and carboplatin|Docetaxel will be administered intravenously at a dose of 75mg/m2 over 60 minutes on Day 1 of each 21-day cycle. Carboplatin AUC 6 will be administered intravenously over 30 minutes on Day 1 of each 21-day cycle immediately following docetaxel infusion.
89005405|NCT01086748|Experimental|80 mg LY2140023|40 mg LY2140023 administered orally, BID for up to 7 weeks.
89005406|NCT04999735||Patients with FSHD|CHDR Monitoring Remotely (MORE) Withings Steel HR Withings Body+ scale Withings Blood Pressure Monitor
89412548|NCT02323022|Active Comparator|Intermediate-dose IA regimen|Patients in this arm will receive an IA induction therapy, in which the idarubicin dose should be 12mg/msq/d
89412549|NCT03496142|Active Comparator|Transperineal prostate biopsy|Patient will have a transperineal prostate biopsy.
89412550|NCT03496142|Active Comparator|Transrectal prostate biopsy|Patient will have a transrectal prostate biopsy.
89412551|NCT03496064||Anterior circulation LVO patients with ASPECTS <6|
89412552|NCT03496064||Anterior circulation LVO patients with NIHSS<8|
89412553|NCT03496064||Posterior versus anterior circulation LVO patients|
89412554|NCT03496064||LVO patients with isolated PCA or ACA occlusions|
89005407|NCT04999735||Healthy controls|CHDR Monitoring Remotely (MORE) Withings Steel HR Withings Body+ scale Withings Blood Pressure Monitor
89005408|NCT00234546|Experimental|1|Dysport
89005409|NCT00234546|Placebo Comparator|2|Placebo
89005410|NCT04994002|Experimental|Cohort 1: CERC-006 (0.5 mg)|Approximately 5 participants will receive CERC-006 at a dose of 0.5 mg twice daily for 28 days.
89005411|NCT04994002|Experimental|Cohort 2: CERC-006 (1 mg)|Following a safety review, if there are no clinically important safety findings in Cohort 1, a second cohort of approximately 5 participants will be enrolled to receive CERC-006 at a dose of 1 mg twice daily for 28 days.
89412555|NCT03496064||Tandem lesions versus non-tandem lesion|
89005412|NCT04990336|Experimental|DDC(Dachaihu decoction compound) Group|Treated with Dachaihu decoction compound and regular therapies
89005413|NCT04990336|Active Comparator|RSM(rhubarb single medicine) Group|Treated with rhubarb single medicine and regular therapies
89005414|NCT04990336|Other|N Group|Treated with regular therapies and without traditional Chinese medicine
89412556|NCT03496064||Bridging vs Direct MT|
89005415|NCT04991272|Active Comparator|warming group|Warming group patients are applied prewarming with bair-hugger (43'C)(warm touch, COVIDIEN, full body blanket) for 10 minutes in the preanesthetic unit prior to induction of anesthesia. During operation, prewarmed intravenous fluid which was stored in the warming cabinet for more than 8 hours is connected and infused. Forced air blanket (warm touch, COVIDIEN, upper body blanket) with 38'C is applied for all patients during the operation.
89005416|NCT04991272|No Intervention|no warming group|No warming group patients are not applied prewarming devices. Intravenous fluid stored in room air is connected and infused during the operation. Forced air blanket (warm touch, COVIDIEN, upper body blanket) with 38'C is applied for all patients during the operation.
89005417|NCT02277886|Experimental|Alginos plus Nexium|sodium alginate 20ml (50mg/ml) once at bed time, and esomeprazole (40mg/tablet) 1 tablet once before breakfast, 4 weeks
89005418|NCT02277886|Active Comparator|Nexium alone|esomeprazole (40mg/tablet) 1 tablet once before breakfast, 4 weeks
89005419|NCT02277964||RRMS with treatment change|"All patients with treatment change from natalizumab 300mg iv monthly to fingolimod 0.5mg orally/daily.~16 patients were switched with an interval of 8 weeks until october 2013. After an interims analysis the interval has been changed to 4 weeks (after october 2013)."
89192732|NCT06122064|Active Comparator|Arm I (standard of care)|Patients attend a standard of care visit with their clinician on study.
89412557|NCT02320526|Experimental|Control|Control intervention: Subjects will continue their life unaltered during the 14 days intervention period
89412558|NCT02320526|Experimental|Continuous walking|Training intervention: Subjects will perform continuous walking for one hour per day at every weekday during the 14 days intervention period
89412559|NCT02320526|Experimental|Interval Walking|Training intervention: Subjects will perform interval walking for one hour per day at every weekday during the 14 days intervention period. Interval walking will be performed as repeated cycles of three minutes of slow and hree minutes of fast walking during the entire training session
88889152|NCT02067182|Experimental|Oral Anticoagulation with Dabigatran|"The recommended daily dose of Pradaxa is 300 mg taken as one 150 mg capsule twice daily.~For the following patients the recommended daily dose of Pradaxa is 220 mg taken as one 110 mg capsule twice daily:~Patients aged 75 years or above~Cr-Cl 30-50 ml/min~Patients who receive concomitant verapamil~For the following groups, the daily dose of Pradaxa of 300 mg or 220 mg should be selected based on an individual assessment of the thromboembolic risk and the risk of bleeding:~Patients with moderate renal impairment~Patients with gastritis, esophagitis or gastroesophageal reflux~Other patients at increased risk of bleeding"
88889153|NCT02067182|No Intervention|No Oral Anticoagulation|
88889154|NCT02003612||All subjects|All subjects
88889155|NCT01940341|Experimental|TAF 25 mg|TAF + TDF placebo for 96 weeks (per amendment 1 & 2) or 144 weeks (per amendment 3).
88889156|NCT01940341|Active Comparator|TDF 300 mg|TDF + TAF placebo for 96 weeks (per amendment 1 & 2) or 144 weeks (per amendment 3).
88889157|NCT01940341|Experimental|Open-label TAF|"All participants who complete the double-blind period (96 weeks or 144 weeks) will be eligible to receive open-label TAF until Week 384 of the study.~After the end of study treatment, participants can either switch to commercially available anti-HBV treatments in their country or will be followed every 4 weeks, for up to 24 weeks off treatment (treatment-free follow-up (TFFU)) for safety assessment."
88889158|NCT01877837|Experimental|Related donor|"Matched sibling donors (9-10/10 marrow/PBSC or 5-6/6 UCB (single) with a total TNC dose of greater than 5 x 107/kg recipient weight), age 2-30 years after conditioning regimen Alemtuzumab , Fludarabine, and Melphalan.~1) Patients will receive a conditioning regimen composed of Alemtuzumab, Fludarabine, and Melphalan as detailed in the table below.~Day Treatment~-22 Alemtuzumab 3mg IV (test dose)~-21 Alemtuzumab 10mg IV~-20 Alemtuzumab 15mg IV~-19 Alemtuzumab 20mg IV~-8 Fludarabine 30mg/m2 IV~-7 Fludarabine 30mg/m2 IV~-6 Fludarabine 30mg/m2 IV~-5 Fludarabine 30mg/m2 IV~-4 Fludarabine 30mg/m2 IV~-3 Melphalan 140mg/m2 IV~-2 Rest Day~-1 Rest Day~0 Stem Cell Infusion"
88889159|NCT01624142|Experimental|Evolocumab|Participants received 420 mg evolocumab every month (participants not on lipid apheresis) or every 2 weeks (participants on lipid apheresis) for up to 5 years. Participants could switch dosing regimens at week 12 or 24 based on LDL-C and serum unbound proprotein convertase subtilisin/kexin type 9 (PCSK9) levels.
88889160|NCT01539746|Experimental|TAVI without predilation|
88889161|NCT01539746|Active Comparator|Standard TAVI procedure|
88889162|NCT01535807|Active Comparator|CorMatrix Group|"The treatment Cormatrix group will receive the CorMatrix ECM during surgery for the closure of the pericardium according to the specific recommended surgical technique."
88889163|NCT01535807|No Intervention|Control|"The control No Intervention group will not receive the CorMatrix ECM during surgery, leaving the pericardium open according to current standard of care."
88889164|NCT01375764|Active Comparator|Ezetimibe|Participants received placebo subcutaneous injection once every 4 weeks and 10 mg ezetimibe orally once a day for 12 weeks.
88889165|NCT01375764|Experimental|Evolocumab + Ezetimibe|Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks and 10 mg ezetimibe orally once a day for 12 weeks.
88889166|NCT01375764|Experimental|Evolocumab 280 mg|Participants received 280 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
88889167|NCT01375764|Experimental|Evolocumab 350 mg|Participants received 350 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
88889168|NCT01375764|Experimental|Evolocumab 420 mg|Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
88889169|NCT01286038|Experimental|Eltrombopag Treatment|Phase I: Dose Escalation
88889170|NCT01253707|Experimental|Dose Escalation|
88889171|NCT00722046|Experimental|PF-04360365 0.1 mg/kg|
88889172|NCT00722046|Experimental|PF-04360365 0.5 mg/kg|
88889173|NCT00722046|Experimental|PF-04360365 1 mg/kg|
88889174|NCT00722046|Placebo Comparator|Placebo|
88889175|NCT00722046|Experimental|PF-04360365 3 mg/kg|
89412560|NCT02320604|Experimental|Obese Subjects 1mg/kg|8 obese subjects will receive 1mg/kg Ambisome i.v. infused over 45 minutes
89412561|NCT02320604|Experimental|Obese Subjects 2mg/kg|8 obese subjects will receive 2mg/kg Ambisome i.v. infused over 90 minutes
89412562|NCT01366638|Experimental|Treatment-Naive: TMC435 100 mg 12 Wks+PR 24/48|Participants will receive TMC435 100 mg once daily with PegIFNa-2b and ribavirin (PR) for 12 weeks (Wks), followed by PR until Week 24 or Week 48. Treatment will be stopped at Week 24 in participants who achieve plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels <1.2 log10 IU/mL detectable or undetectable at Week 4, and undetectable plasma HCV RNA levels at Week 12. All other participants will continue PR until Week 48.
89412563|NCT01366638|Experimental|Prior Relapser: TMC435 100 mg 12 Wks+PR 24/48|Participants will receive TMC435 100 mg once daily with PegIFNa-2b and ribavirin (PR) for 12 weeks (Wks) followed by PR until Week 24. Treatment will be stopped at Week 24 in participants who achieve plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels <1.2 log10 IU/mL detectable or undetectable at Week 4, and undetectable plasma HCV RNA levels at Week 12. All other participants will continue PR until Week 48.
89412564|NCT01366638|Experimental|Prior Non-Responder: TMC435 100 mg 12 Wks+PR 48|Participants will receive TMC435 100 mg once daily with PegIFNa-2b and ribavirin (PR) for 12 weeks (Wks) followed by PR until Week 48.
89412565|NCT03544086||test group|First group is the first 10 patients
89412566|NCT03544086||study group|following 150 patients
89412567|NCT02320682|Active Comparator|Exeter femur component and Delta TT acetabular component|
88889176|NCT00722046|Experimental|PF-04360365 8.5 mg/kg|
88889177|NCT00614523|Experimental|Romiplostim|Weekly subcutaneous dosing based on platelet count for 26 weeks during the Test Treatment Period and for 24 weeks during the Extended Treatment Period, separated by a 4-week interim washout period. Starting dose is at 750 μg, up to a maximum dose of 1000 μg, or reduced to a minimum of 250 μg.
88889178|NCT00614523|Placebo Comparator|Placebo|Weekly subcutaneous dosing with blinded matching placebo dose level for 26 weeks during the Test Treatment Period and for 24 weeks during the Extended Treatment Period, separated by a 4-week interim washout period.
88889179|NCT00523341|Experimental|Denosumab|Participants received a 60 mg subcutaneous injection of denosumab every 6 months for seven years.
88889180|NCT00364013|Experimental|FOLFOX + Panitumumab|Participants received panitumumab, 6 mg/kg on Day 1 and FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or unacceptable toxicity.
88889181|NCT00364013|Active Comparator|FOLFOX|Participants received FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or until unacceptable toxicity.
88889182|NCT00345839|Experimental|Cinacalcet|
88889183|NCT00345839|Placebo Comparator|Placebo|
88889184|NCT00330759|Active Comparator|zoledronic acid|denosumab placebo with active zoledronic acid
88889185|NCT00330759|Experimental|denosumab|active denosumab with zoledronic acid placebo
88889186|NCT00113763|Experimental|Panitumumab plus best supportive care|Panitumumab will be administered by intravenous infusion at a dose of 6 mg/kg once every 2 weeks until participants develop progressive disease or are unable to tolerate study drug. Participants will also receive best supportive care (BSC) as judged appropriate by the investigator and according to institutional guidelines.
88889187|NCT00113763|Other|Best Supportive Care|Best supportive care will be defined in this study as the best care available as judged appropriate by the investigator and according to institutional guidelines and will include antibiotics, analgesics, radiation therapy for pain control (limited to bone metastases), corticosteroids, transfusions, psychotherapy, growth factors, palliative surgery, or any symptomatic therapy as clinically indicated. For the purpose of this study, best supportive care will not include anti-neoplastic chemotherapy.
88889188|NCT00102323|Placebo Comparator|Placebo|
89412568|NCT02320682|Active Comparator|SP-CL femur component and Delta TT acetabular component|
89412569|NCT02320682|Active Comparator|SP-CL femoral component and Delta PF acetabular component|
89412570|NCT02320682|Active Comparator|Exeter femoral component and Delta PF acetabular component|
89412571|NCT02146872||Very Premature CAD|Patients who have received a coronary intervention procedure on the basis of atherosclerosis before the age of 40
89412572|NCT02146872||Healthy middle-aged 1st degree relatives|Healthy 1st degree relatives aged 30-65 years of patients with very premature CAD.
89412573|NCT02146872||PCAD families|Families severely affected by premature CAD
89412574|NCT02147028|Experimental|Hippocampal sparing whole brain RT|30 Gy in 10 fractions hippocampal sparing whole brain radiotherapy will be administered by Helical Tomotherapy, IMRT, or VMAT
89412575|NCT02147028|Active Comparator|Control: Conventional whole brain RT|30 Gy in 10 fractions conventional whole brain radiotherapy will be administered
88889189|NCT00102323|Experimental|AMG 531|Active Investigational Product
88889190|NCT01438359|Experimental|PA21 and Furosemide with food|
88889191|NCT01438359|Experimental|No PA21; Furosemide with food|
88889192|NCT01438359|Experimental|PA21 with food and Furosemide 2hrs later|
88889193|NCT01438372|Experimental|Intravenous iron sucrose arm|
88889194|NCT01438372|Active Comparator|Oral ferrous sulfate|
88889195|NCT01438385||Interventional Endoscopy|Any group that went Interventional Endoscopy procedures.
88889196|NCT01438398|Other|Submucosal Endoscopic Mucosal Flap Technique|Submucosal Endoscopic Mucosal Flap Technique
88889197|NCT01438437|Active Comparator|Percutaneous acetic acid|
89412576|NCT02323178|Experimental|eltrombopag|
89536710|NCT02473055|Experimental|Kangaroo care|kangaroo Care was skin-to-skin, chest-to-chest placement of preterm infant wearing only a diaper placed up against mother's chest and covered in one receiving blanket folded into fourth
88889198|NCT01438437|Active Comparator|Radiofrequency ablation|
88889199|NCT01438450|No Intervention|Supportive|Supportive therapy
88889200|NCT01438450|Active Comparator|Oral|Oral thalidomide and capecitabine
88889201|NCT01438463|Placebo Comparator|placebo|
88889202|NCT01438463|Experimental|PURETHAL Mites, 6,667 AU/ml|
88889203|NCT01438463|Experimental|PURETHAL Mites, 20,000 AU/ml|
88889204|NCT01438463|Experimental|PURETHAL Mites, 50,000 AU/ml|
88889205|NCT01438463|Experimental|PURETHAL Mites, 100,000 AU/ml|
88889206|NCT01438502||HyperHAES|
88889207|NCT01438515|Experimental|Systemic decolonization|7-day course of 4% chlorhexidine gluconate daily washes and 2% mupirocin ointment to the anterior nares twice daily in addition to oral rifampin (600mg daily), and doxycycline (100mg twice daily)
88889208|NCT01438515|Active Comparator|Standard decolonization|7-day course of 2% mupirocin ointment to the anterior nares twice daily and 4% chlorhexidine gluconate washes once per day.
89412577|NCT02147808|Experimental|All subjects|All subjects will receive a single oral midazolam dose on Day 1 while fasting. Days 2 to 4 will be Washout days. On Day 5, subjects will begin a 5-day regimen of telotristat etiprate. On Day 9, subjects will receive a morning dose of telotristat etiprate with a single dose of midazolam while fasting.
89412578|NCT02323256|Experimental|newly cochlear implanted adult patients|longitudinal group
88889209|NCT01438554|Experimental|Pazopanib and GSK1120212|Treatment will be administered on an outpatient basis. Both drugs are taken orally. Each cycle lasts 28 days. The doses of each drug will depend on when patient enters study.
88889210|NCT01438567|Experimental|OXN PR tablets|
88889211|NCT01438567|Active Comparator|OxyPR tablets|
88889212|NCT01438580|Experimental|standard intensity warfarin group|Eligible 80 patients(83.14±4.05,33.0%)with chronic NVAF were randomly assigned to this group and the target international normalised ratio(INR) was 2.1-3.0
88889213|NCT01438580|Experimental|low intensity warfarin group|Eligible 81 patients(84.0±4.71,33.5%)with chronic NVAF were randomly assigned to this group and the target international normalised ratio(INR) was 1.5-2.0
88889214|NCT01438580|Active Comparator|aspirin group|Eligible 81 patients(83.4±5.13,33.5%)with chronic NVAF were randomly assigned to this group and 100mg aspirin was administrated every day
88889215|NCT01438593|Experimental|HUCB, Medicine, Rehabilitation|Stroke patients are received intracerebral implantation of human cord blood stem cells (CD34+), Antiplatelet Medication, and Rehabilitation.
89005420|NCT02278042|Active Comparator|9% Fuctose|Milk Sweetened with fructose in an amount that the added fructose contributes 9% of the calories required for weight maintenance.
89412579|NCT02323256|Experimental|newly cochlear implanted children|longitudinal group
89412580|NCT02323256|Active Comparator|cochlear implanted adult patients (CI>1 year)|transversal group
89412581|NCT02323256|Active Comparator|normal hearing adult subjects|transversal group
89412582|NCT02147886|Experimental|Cabaletta 15gr|Cabaletta 15gr
89412583|NCT02147886|Experimental|Cabaletta 30gr|Cabaletta 30gr
89412584|NCT03543072||exposure group|exposed to some factors
89412585|NCT03543072||control group|not exposed to some factors
89412586|NCT02147964|Experimental|Acyline; T Gel; placebo dutasteride, placebo ketoconazole|"All men will receive Acyline 300 ug/kg subcutaneous (SQ) injections every 2-weeks + Testosterone 1% Gel 5g daily and then randomly assigned.~Group 1: placebo oral ketoconazole + placebo oral dutasteride for 4 months"
89412587|NCT02147964|Experimental|Acyline; T gel; Ketoconazole; placebo|"All men will receive Acyline 300 ug/kg SQ injections every 2-weeks + Testosterone 1% Gel 5g daily and then randomly assigned.~Group 2: oral ketoconazole 400 mg + placebo oral dutasteride for 4 months"
89412588|NCT02147964|Experimental|Acyline; Tgel; Ketoconazole; Dutasteride|"All men will receive Acyline 300 ug/kg SQ injections every 2-weeks + Testosterone 1% Gel 5g daily and then randomly assigned.~Group 3: Ketoconazole 400mg orally daily + Dutasteride 2.5 mg orally on day 1, followed by 0.5mg daily for 4 months"
89412589|NCT02147964|Experimental|Acyline; Tgel; HCG|"All men will receive Acyline 300 ug/kg SQ injections every 2-weeks + Testosterone 1% Gel 5g daily and then randomly assigned.~Group 4: Human Chorionic gonadotropin (HCG) 60 IU injection every other day for 4 months."
89412590|NCT03491852|Experimental|BOOST Intervention|"The BOOST intervention consists of 8 group-based, weekly one-hour sessions. While every BOOST session is different, in general they will focus on helping participants fight back against stigmatizing thoughts and develop a sense of self-worth and empowerment. BOOST sessions are group-based and facilitated by trained clinicians, with the aid of a peer support worker to provide unique insights on living with and overcoming self-stigma. Content of sessions involve group discussions, exercises conducted in session, and between-session missions (i.e., home practice activities)."
89412591|NCT03491852|Active Comparator|Waitlist Controls|Participants on the waitlist will still receive treatment as usual, which includes medical, psychosocial, and occupational interventions to help maximize patients' integration within the community and support recovery from a first episode of psychosis. Frequency of contact largely depends on the individual needs of patients. Waitlist controls will be offered the BOOST intervention 3 months post-enrollment.
89412592|NCT03493334|Experimental|Visual feedback|Participants in this group will receive visual feedback of their neck when performing 10 repetitions of each of neck movements (flexion, extension, side-flexion and rotation).
89412593|NCT03493334|Active Comparator|No visual feedback|Participants in this group will perform 10 repetitions of each of neck movements (flexion, extension, side-flexion and rotation) without feedback.
89412594|NCT02147106||Videoconsultation|Performing two videoconsulations with the treating medical oncologist
89412595|NCT03495830||Carotid endarterectomy|Patients that underwent intervention (CEA or CAS) are followed by clinical examination and carotid duplex on 12, 24 and 36 month If there is coexisting contralateral carotid stenosis with grade greater than 50% and not requiring interventional treatment (CEA or CAS), patient should cross in optimal medical therapy group.
88889216|NCT01438606|Experimental|1 x 10^4 PFU VSV-Indiana HIV gag vaccine (Group 1)|Participants will receive 1 x 10^4 PFU of the study vaccine by intramuscular (IM) injection in each deltoid at baseline and Week 8. (1 x 10^4 PFU is the nominal dose; the actual dose is 4.6 x 10^3 PFU given as 2.3 x 10^3 PFU in each deltoid)
89412596|NCT03495830||Optimal medical therapy group|Patients not subjected to intervention (or in whom one carotid has been treated with CAS or CEA and contralateral has stenosis is greater than 50%) will be followed with carotid duplex (at 12, 24 and 36 months) and MRI imaging of carotid tree from aortic arch up to the circle of Willis after 12 and 36 months.
89412597|NCT02780700|Experimental|Nintedanib|
89412598|NCT02780700|Experimental|Nintedanib plus capecitabine|
88889217|NCT01438606|Placebo Comparator|Placebo injection (normal saline) (Group 1)|Participants will receive placebo by IM injection in each deltoid at baseline and Week 8.
88889218|NCT01438606|Experimental|1 x 10^5 PFU VSV-Indiana HIV gag vaccine (Group 2)|Participants will receive 1 x 10^5 PFU of the study vaccine by IM injection in each deltoid at baseline and Week 8. (1 x 10^5 PFU is the nominal dose; the actual dose is 4.6 x 10^4 PFU given as 2.3 x 10^4 PFU in each deltoid)
89005421|NCT02278042|Active Comparator|18% Sucrose|Milk Sweetened with sucrose in an amount that the added sucrose contributes 18% of the calories required for weight maintenance.
89005422|NCT02278042|Active Comparator|18% High fructose corn syrup|Milk Sweetened with High fructose corn syrup (HFCS) in an amount that the added HFCS contributes 18% of the calories required for weight maintenance.
89005423|NCT02278042|Active Comparator|9% Glucose|Milk Sweetened with glucose in an amount that the added glucose contributes 9% of the calories required for weight maintenance.
89005424|NCT02278042|Active Comparator|Unsweetened Milk|Unsweetened milk consumed in amount the contributes 18% of the calories required for weight maintenance.
89005425|NCT00237783|Active Comparator|standard dialysate sodium (140 mmol/L)|dialysate sodium (140 mmol/L)
89005426|NCT00237783|Experimental|individualized dialysate sodium|individualized dialysate sodium (same concentration as the average pre-HD serum sodium during the baseline period)
89005427|NCT04991662|Experimental|metaraminol group|During the cesarean section, metaraminol 2ug/kg/min is preventively infused after anesthesia to prevent and treat hypotension.
89005428|NCT04991662|Experimental|phenylephrine group|During cesarean section, preventive infusion of phenylephrine 0.54ug/kg/min after anesthesia to prevent and treat hypotension.
89005429|NCT04991662|Experimental|norepinephrine group|During cesarean section, preventive infusion of norepinephrine 0.08ug/kg/min after anesthesia to prevent and treat hypotension.
89005430|NCT04997941|Experimental|Tamoxifen 40mg|Tamoxifen 20mg b.i.d - Participants will be treated for 14 days.
89005431|NCT04997941|Active Comparator|Tamoxifen 20mg|Tamoxifen 10mg b.i.d - Participants will be treated for 14 days.
89005432|NCT00413790|Experimental|1|Darifenacin
89005433|NCT00413790|Active Comparator|2|Tolterodine
89005434|NCT00413790|Placebo Comparator|3|Placebo
89005435|NCT04571710|Experimental|Treatment group|Intervention: Drug: SHR1258 400mg
89005436|NCT04993612||No pulmonary Hypertension|
89005437|NCT04993612||pulmonary Hypertension Group 1|
89005438|NCT04993612||pulmonary Hypertension Group 2|
89005439|NCT04993612||pulmonary Hypertension Group 3|
89005440|NCT04993612||pulmonary Hypertension Group 4|
89005441|NCT04993612||pulmonary Hypertension Group 5|
89005442|NCT04999774||School-age children|"Each SAC will be asked to supply fecal and blood samples for testing with:~Stool microscopy~Baermann method~Real-time PCR for S. stercoralis~Lateral flow rapid test~ELISA serology (NIE/SsIR and IgG Ratti)"
89005443|NCT02962245|Active Comparator|berberine group|regular treatment and receive oral berberine 300mg three times daily untill recurrence in one year
89005444|NCT02962245|Placebo Comparator|regular treatment group|regular treatment untill recurrence in one year
89005445|NCT04992754||Pregnant women over 18 years old coming to consult at the gynecology department|Pregnant women over 18 years old coming to consult at the gynecology department in the Montpellier's hospital
89005446|NCT04990180|Experimental|Shared Decision Making Intervention|The intervention is a shared decision making consultation supported by a patient decision aid and decision coaching for healthcare professionals.
89005447|NCT04571203|Experimental|Phase I Study of Combined DD Kidney and HCT Transplant|Single arm Phase 1 non randomized dose finding study for safety, feasibility and efficacy of deceased donor vertebral body (VB) marrow cell infusion
89005448|NCT00210275|No Intervention|Control|Usual practice; no additional information provided.
89005449|NCT00210275|Experimental|Printed Educational Message #1|Information about Angiotensin-converting enzyme inhibitors, hypertension treatment, and cholesterol lowering agents for diabetes
89005450|NCT00210275|Experimental|Printed Educational Message #2|Retinal screening for diabetes
89005451|NCT00210275|Experimental|Printed Educational Message #3|Diuretics for hypertension
89005452|NCT01059903|Experimental|Rotigotine PR2.2.1 first|Rotigotine transdermal patch 4.5 mg/10 cm^2, test drug product PR2.2.1 followed by Rotigotine transdermal patch 4.5 mg/10 cm^2, reference drug product PR2.1.1 separated by a washout phase of at least 5 days
89005453|NCT01059903|Experimental|Rotigotine PR2.1.1 first|Rotigotine transdermal patch 4.5 mg/10 cm^2, reference drug product PR2.1.1 followed by Rotigotine transdermal patch 4.5 mg/10 cm^2, test drug product PR2.2.1 separated by a washout phase of at least 5 days
89005454|NCT04996771|Experimental|Surufatinib Combined With Toripalimab and Chemotherapy|
89412599|NCT03493256||type 2 neurological complications present|The group of patients diagnosed with postoperative cognitive dysfunction (POCD) or postoperative delirium (POD), or both concurrently.
89412600|NCT03493256||type 2 neurological complications absent|The group of patients without neurological complications.
89412601|NCT02151396|Experimental|Cogmed Working Memory Training|Cogmed (TM) working memory training following standard, recommended administration procedures
89412602|NCT03495752|Experimental|Pre/Post Repeated Measures|Performance on the forward-step-down test (FSDT) before and at one, five, and ten minutes following the Bruce Fatigue Protocol
89005455|NCT04996771|Experimental|Surufatinib Combined With Chemotherapy|
89005456|NCT04996615||high risk population|women at high risk of breast cancer undergoing enhanced MRI
89005457|NCT00210314|Active Comparator|High-dose methotrexate alone|
89005458|NCT00210314|Experimental|High-dose methotrexate associated with high dose cytarabine|
89005459|NCT04990024|Experimental|Mediterranean Diet|50 participants will be randomized to this arm. The intervention consists of 5 individual (visits 1,3,5,7,9) and 8 group (visits 1,2,3,4,5,6,7,8) educational sessions on Mediterranean diet in patients on Liraglutide, over a period of 24 weeks. Dietary assessments and adherence questionnaires will be held on several visits to assess adherence.
89412603|NCT02147262|Active Comparator|ACA-doxy 14 days|patients with chronic atrophic acrodermatitis treated with doxycycline for 14 days
89412604|NCT02147262|Active Comparator|ACA-doxy 28 days|patients with chronic atrophic acrodermatitis treated with doxycycline for 28 days
89412605|NCT02447276|Experimental|Group A|Group A will receive REGN475 dosing regimen 1
89412606|NCT02447276|Experimental|Group B|Group B will receive REGN475 dosing regimen 2
89412607|NCT02447276|Experimental|Group C|Group C will receive REGN475 dosing regimen 3
89412608|NCT02447276|Experimental|Group D|Group D will receive REGN475 dosing regimen 4
89412609|NCT02447276|Experimental|Group E|Group E will receive matching placebo
89412610|NCT02151552|Experimental|Endotoxin and [18F](+/-)NOS|All volunteers in this study will receive endotoxin in a single segment of the lung to induce mild, self-limited inflammation. They will also be imaged before and after endotoxin instillation with the novel PET tracer [18F](+/-)NOS.
89412611|NCT03491774|Experimental|Montessori Intervention|Participants will receive Montessori intervention for three months,twice weekly sessions over the period of three months.
89412612|NCT05064644|Active Comparator|Plant stanol ester comparator|Product that contains plant stanol ester
89412613|NCT05064644|Placebo Comparator|Placebo comparator|Placebo product
89412614|NCT04926272|Experimental|18F-92, PET/CT|PET/CT perform after injecting 18F-92
89412615|NCT03495518|Active Comparator|Symptom feedback to Health Care Provider|"For those randomized to the intervention arm, symptom screening using SPARK will be completed once daily for 5 days on an iPad using the approach refined in aim 2. Daily SSPedi reports will be printed and provided in the patient chart. On days 1 and 3±1, a report describing symptoms that are a lot or extremely bothersome will be emailed to the physician providing direct medical care"
89412616|NCT03495518|Active Comparator|Standard of care|For those randomized to the control arm, a clinical research associate will visit the participant on days 1 and 5±1 and will obtain SSPedi scores on an iPad. Reports will not be printed or emailed to the physician.
89412617|NCT03495362|Experimental|Intervention group|"Ingredients: yeast beta-glucan, and capsule shell Capsule, per capsule with 500mg insoluble beta-glucan, twice a day, 1 capsule each time.~The intervention period is about 3 months."
89412618|NCT03495362|Placebo Comparator|Placebo group|Ingredients: starch, and capsule shell Capsule, per capsule with 500mg starch, twice a day, 1 capsule each time. The intervention period is about 3 months.
89412619|NCT03493100|Experimental|oral nutritional supplementation|This group receives optimized nutritional support, by ONS for a period of four weeks.
89412620|NCT03493100|Other|Control|The control group will receive treatment according to usual care.
89412621|NCT02323412|Experimental|Amoxicillin|Amoxicillin (Amoksicillintrihydrat) tablets 750 mg 1x3 for 100 days (oral intake). The tablets will be encapsulated in Capsugel DB-caps AAel Swedish orange.
89412622|NCT02323412|Placebo Comparator|Placebo|Placebo capsules for 100 days of daily (1x3), oral intake. The placebo tablets will also be encapsulated in Capsugel DB-caps AAel Swedish orange.
89412623|NCT03493022|Experimental|Test Granola|50.5 g Test Granola
89412624|NCT03493022|Placebo Comparator|Control Granola|54.3 Control Granola
89412625|NCT02323490|Experimental|with microfractures|Standardized meniscal repair with bone marrow stimulation techniques (microfractures)
89412626|NCT02323490|Placebo Comparator|without microfractures|Standardized meniscal repair without augmentation
89412627|NCT02323568|Other|Gynecological consulation|
89412628|NCT04537910|Experimental|LY3819253|Participants received single subcutaneous (SC) doses of 150 milligram (mg), 350 mg or 700 mg LY3819253.
89412629|NCT04537910|Placebo Comparator|Placebo|Participants received a single SC dose of Placebo.
89412630|NCT04821362|No Intervention|Standard technique group|In this group, peripheral intravenous catheter insertion will be performed routinely.
89412631|NCT04821362|Active Comparator|Ultrasound group|In this group, peripheral intravenous catheter insertion will be performed with ultrasound. A linear probe will be used for procedures.
89412632|NCT04821362|Active Comparator|Near Infrared Device Group|In this group, peripheral intravenous catheter insertion will be performed with AccuVein AV 400.
89412633|NCT04692584|Experimental|The Lullaby Group|In this group, their mothers sang a lullaby during the vaccination process. Each mother touched her baby's hands and body while singing a lullaby and hugged her baby after the procedure.
89412634|NCT04692584|No Intervention|Control Group|"In this group, their mothers did not sing a lullaby during the vaccination process.~Mothers touched their infant's hands and body and talk to their infants during and after vaccination. Mothers hugged their infant after the procedure."
89412635|NCT03109730|Experimental|Cohort B1|ABI-H0731 or Placebo in varying doses by mouth for 28 days
89412636|NCT03109730|Experimental|Cohort B2|ABI-H0731 or Placebo in varying doses by mouth for 28 days
89412637|NCT03109730|Experimental|Cohort B3|ABI-H0731 or Placebo in varying doses by mouth for 28 days
89412638|NCT03109730|Experimental|Cohort B4|ABI-H0731 or Placebo in varying doses by mouth for 28 days
89412639|NCT03109730|Experimental|Cohort B5|ABI-H0731 or Placebo in combination with entecavir or tenofovir for 28 days
89412640|NCT03109730|Experimental|Cohort B6|ABI-H0731 or Placebo, in combination with a commerically-approved nucleos(t)ide plus PegIFN in treatment-experienced patients, for 28 days
89412641|NCT02323724||Selected Papillary carcinoma|Cases with histological diagnosis of papillary carcinoma (CP) and previous cytological diagnosis in groups III, IV and V Bethesda, collected between October 1989 and July 2014 in Corporació Parc Taulí.
89412642|NCT02323802|Experimental|educational group intervention|"The group educational food intervention: it provides the delivery of information leaflet and inclusion in groups on a weekly basis for the first 3 meetings, and then, there are other 2 meetings on the third and sixth month by the AMI.~The meetings will cover education to self-nutrition, physical activity and learning techniques for stimulus control and management of high-risk situations."
89412643|NCT02323802|Active Comparator|prescriptive diet|An objectives food scheme elaborated for each patients will provide the reduction in caloric intake (equivalent to 500-600 calories in deficit if compared to the estimated daily requirement, based on the RDAs) and a reduced intake of lipids, which does not exceed 30% of total calories introduced, with a contribution of saturated fat no more than 7-9% .
89412644|NCT03495206|Experimental|Y-2(Edaravone And Borneol) sublingual tablet|
89412645|NCT04230122|Experimental|10 milligram (mg) LY3478006 - Intravenous (IV)|Participants received single dose of 10 mg LY3478006 administered IV. Due to early termination of the study Cohort 2 to 6 (30 mg, 100 mg, 300 mg, 600 mg, and 1000 mg LY3478006 IV) were not explored for safety reasons following dosing of the first 4 participants in Cohort 1.
89412646|NCT04230122|Placebo Comparator|Placebo - IV|Participants received single dose of placebo administered IV. Placebo IV Cohorts 2 through 6 were not explored as study was terminated for safety reasons following dosing of the first 4 participants in cohort 1.
89412647|NCT04230122|Experimental|100 mg LY3478006 - Subcutaneous (SC) (Cohort 7)|100 mg LY3478006 cohort 7 SC dose was not explored as study was terminated for safety reasons following dosing of the first 4 participants in cohort 1.
89412648|NCT04230122|Placebo Comparator|Placebo - SC (Cohort 7)|Placebo cohort 7 SC dose were not explored as study was terminated for safety reasons following dosing of the first 4 participants in cohort 1.
89412649|NCT04223024|Experimental|CCRT + Nimotuzumab|Patients whose plasma EBV DNA> 0 copy/mL or SD/PD according to RECIST after two cycle induction chemotherapy( TPF :Paclitaxel liposome135mg/m2 d1+DDP 25mg/m2 d1-d3+ 5-fu 750mg /m2/day civ120h, every 3 weeks for 2 courses) will have concurrent cisplatin (100mg/m2, every three weeks,D1,D22,D43 of intensity modulated radiotherapy) + nimotuzumab (200mg, once a week during radiotherapy, a total of 7 weeks)
88889219|NCT01438606|Placebo Comparator|Placebo injection (normal saline) (Group 2)|Participants will receive placebo by IM injection in each deltoid at baseline and Week 8.
89412650|NCT04223024|Active Comparator|CCRT alone|Patients whose plasma EBV DNA> 0 copy/mL or SD/PD according to RECIST after two cycle induction chemotherapy( TPF :Paclitaxel liposome135mg/m2 d1+DDP 25mg/m2 d1-d3+ 5-fu 5-fu 750mg /m2/day civ120h, every 3 weeks for 2 courses) will have concurrent cisplatin (100mg/m2, every three weeks,D1,D22,D43 of intensity modulated radiotherapy) )
89412651|NCT04202354|Experimental|ARO-HSD|
89412652|NCT04202354|Placebo Comparator|Placebo|
89412653|NCT03491696|Experimental|Patients|It is an open label study, designed with 14 patients, men and women, from 18 to 60 years old, hospitalized for a characterized depressive episode (as defined by International Classification of Diseases version 10 criteria). They have to be refractory to an antidepressant treatment prescribed in primary care medicine and have a Dexamethasone Suppression Test (DTS) non-suppression status. All patients included will take the association of SSRI/SNRI and METYRAPONE for 28 days.
89412654|NCT04077086|Experimental|Intervention|Children at Intervention schools will receive free spectacles of a design they select, based on the child's measured refractive power and dispensed at school by the study optometrist. Additionally, teachers (but not children) in eligible classes will be informed that if 80% spectacle compliance as measured across three separate unannounced inspections was achieved, they will be given an incentive of an conditional cash transfer. The cash transfer will be deposited into the teacher's bank accounts directly.
89412655|NCT04077086|No Intervention|Control|Children at Control schools will receive a glasses prescription and letter to the parents informing them of the refractive status of their child, with free glasses provided only at the end of the trial. No teacher incentive will be offered. Service offered to the Control group exceeds standard care, in that no school-based programs of vision screening and refraction currently exist in the study area, or in most of rural China.
88889220|NCT01438606|Experimental|1 x 10^6 PFU VSV-Indiana HIV gag vaccine (Group 3)|Participants will receive 1 x 10^6 PFU of the study vaccine by IM injection in each deltoid at baseline and Week 8. (1 x 10^6 PFU is the nominal dose; the actual dose is 4.8 x 10^5 PFU given as 2.4 x 10^5 PFU in each deltoid)
88889221|NCT01438606|Placebo Comparator|Placebo injection (normal saline) (Group 3)|Participants will receive placebo by IM injection in each deltoid at baseline and Week 8.
88889222|NCT01438606|Experimental|1 x 10^7 PFU VSV-Indiana HIV gag vaccine (Group 4)|Participants will receive 1 x 10^7 PFU of the study vaccine by IM injection in each deltoid at baseline and Week 8. (1 x 10^7 PFU is the nominal dose; the actual dose is 4.2 x 10^6 PFU given as 2.1 x 10^6 PFU in each deltoid)
89412656|NCT03492866|Active Comparator|Gentamicin Sulfate|All subjects will be treated with topical gentamycin applied twice daily (1 fingertip unit (FTU)) to the right half of the scalp. Total study period: 6 months.
88889223|NCT01438606|Placebo Comparator|Placebo injection (normal saline) (Group 4)|Participants will receive placebo by IM injection in each deltoid at baseline and Week 8.
89412657|NCT03492866|No Intervention|No treatment|The medication won't be applied to the left half of the scalp.
89192733|NCT06122064|Experimental|Arm II (standard of care, conversation aid)|Patients attend a standard of care visit with the use of the shared decision-making conversation tool by the clinician on study.
89412658|NCT03492788|Active Comparator|ECGI-optimized VV-offset|
89412659|NCT03492788|Placebo Comparator|Zero VV-offset|
89412660|NCT03491618|Active Comparator|PARALLEL|Thick canulae (18 gauge) placed parallel to Medial Branch under fluoroscopy.
89412661|NCT03491618|Active Comparator|PERPENDICULAR|Thin canulae (22 gauge) placed perpendicular to Medial Branch under fluoroscopy.
89412662|NCT02323958|Experimental|Acupoint stimulation|Electrical stimulation is given through electrodes attached to acupoints
89412663|NCT02323958|Placebo Comparator|Non-acupoint stimulation|Electrical stimulation is given through electrodes attached to non-acupoints
89412664|NCT02323958|Sham Comparator|Control stimulation|Electrode attached but no stimulation is given
89412665|NCT02324036|Experimental|Coached Care+EMPATHy;|EMPATHy Toolkit: Patient coaching with computer assisted preference assessment
88889224|NCT01438606|Experimental|1 x 10^8 PFU VSV-Indiana HIV gag vaccine (Group 5)|Participants will receive 1 x 10^8 PFU of the study vaccine by IM injection in each deltoid at baseline and Week 8. (1 x 10^8 PFU is the nominal dose; the actual dose is 3.4 x 10^7 PFU given as 1.7 x 10^7 PFU in each deltoid)
88889225|NCT01438606|Placebo Comparator|Placebo injection (normal saline) (Group 5)|Participants will receive placebo by IM injection in each deltoid at baseline and Week 8.
88889226|NCT01438619||representitives of Goyang city|"Representative population of Goyang city who were randomly selected by digit dialing (RDD) method~Volunteers who are reside in Goyang city"
89412666|NCT02324036|Active Comparator|Routine Coached Care|Patient coaching only
89412667|NCT03492710|Experimental|IGIV-SN|Immunoglobulin, Supplied in 5g (100mL) and/or 10g (200mL)
89412668|NCT02780388|Placebo Comparator|Placebo|Participants will receive a single intravascular (IV) dose of placebo matched to VIB4920 (formerly MEDI4920) once every 2 weeks (Q2W) from Day 1 up to 12 weeks.
89412669|NCT02780388|Experimental|VIB4920 75 mg|Participants will receive a single IV dose of VIB4920 75 mg Q2W from Day 1 up to 12 weeks.
89412670|NCT02780388|Experimental|VIB4920 500 mg|Participants will receive a single IV dose of VIB4920 500 mg Q2W from Day 1 up to 12 weeks.
89412671|NCT02780388|Experimental|VIB4920 1000 mg|Participants will receive a single IV dose of VIB4920 1000 mg Q2W from Day 1 up to 12 weeks.
89412672|NCT02780388|Experimental|VIB4920 1500 mg|Participants will receive a single IV dose of VIB4920 1500 mg Q2W from Day 1 up to 12 weeks.
89412673|NCT02324114|Experimental|Rectal cancer|Detect plasma Hsp90α concentration of patients,
89412674|NCT03954938|Sham Comparator|Neutral-Look|Subjects will be instructed to look at cocaine associated images and respond naturally.
89412675|NCT03954938|Experimental|Positive|Subjects will be instructed to look at cocaine associated images and anticipate the positive aspects of engaging with the items shown.
89412676|NCT03954938|Active Comparator|Negative|Subjects will be instructed to look at cocaine associated images and anticipate the negative aspects of engaging with the items shown.
89412677|NCT03789188||Healthy Volunteers|CC Registered Nurses
88889227|NCT01438632|Experimental|jet injector|Jet injectors deliver insulin at a high velocity (typically >100m/s) across the skin in the subcutaneous tissue, without the use of a needle
88889228|NCT01438632|Active Comparator|conventional insulin pen|
88889229|NCT01438645|Experimental|ScopeGuide-assisted colonoscopy|These patients will undergo colonoscopy with the assistance of the Olympus ScopeGuide system.
88889230|NCT01438645|No Intervention|Conventional colonoscopy|These patients will undergo colonoscopy identical to that in the intervention arm, except with endoscopes lacking the ScopeGuide system.
88889231|NCT01438658||All|A cohort of all the patients.
88889232|NCT01438671|Experimental|All participants|Nintendo Wii Fit Balance training followed by traditional balance training
88889233|NCT01438684|Active Comparator|RPh201 group|7 patients will receive the treatment
88889234|NCT01438684|Placebo Comparator|non RPh201 group|3 patients will receive placebo
88889235|NCT01438697|Experimental|Internet Intervention|Assigned to Sleep Healthy Using the Internet (SHUTi)
89412678|NCT02148042||Anorexics|
89412679|NCT02148042||Controls|
89412680|NCT02148120|Active Comparator|CHF1535 NEXThaler 100/6, 1 puff|Beclometasone Dipropionate 100 µg + Formoterol Fumarate 6 µg
89412681|NCT02148120|Active Comparator|CHF1535 NEXThaler 100/6 µg, 4 puffs|Beclometasone Dipropionate 400 µg + Formoterol Fumarate 24 µg
89412682|NCT02148120|Experimental|CHF1535 NEXThaler 200/6 µg, 1 puff|Beclometasone Dipropionate 200 µg + Formoterol Fumarate 6 µg
89412683|NCT02148120|Experimental|CHF1535 NEXThaler 200/6 µg, 4 puffs|Beclometasone Dipropionate 800 µg + Formoterol Fumarate 24 µg
89412684|NCT02148120|Placebo Comparator|Placebo NEXThaler|Placebo
89412685|NCT03543930||Major open vascular surgery|Surgical procedures on the abdominal aorta requiring median abdominal incision
89412686|NCT03543930||Endovascular aortic repair|Abdominal aortic repair with endovascular approach
89412687|NCT03901820|No Intervention|DrApp Without SIMDA|There are approximately 100 inpatients in whom the indications were registered through the use of DrApp, before the implementation of the drug interactions detection module.
89412688|NCT03901820|Experimental|DrApp With SIMDA|There are approximately 100 inpatients in whom the indications were registered through the use of DrApp, AFTER the implementation of the drug interactions detection module (SIMDA).
89412689|NCT02148198|Active Comparator|1g NWT-03, then placebo|7 days 1g NWT-03, followed by 7 days placebo, separated by a 5-day wash-out period
89412690|NCT02148198|Placebo Comparator|placebo, then 1g NWT-03|7 days placebo, followed by 7days 1g NWT-03, separated by a 5-day wash-out period
88889236|NCT01438697|Active Comparator|Patient Education Website|Assigned to Patient Insomnia Educational Website
88889237|NCT01438723|Experimental|metformin|
88889238|NCT01438723|Placebo Comparator|placebo|
88889239|NCT01438736|Experimental|Desogestrel, Etonogestrel|Arm 1: 75 microgr desogestrel POP (cerazette) daily for 3 months followed by etonogestrel implant (Nexplanon, 68 mg etonogestrel) for following 6 months
88889240|NCT01438736|Experimental|Etonogestrel|Arm 2: Women staring straight with Nexplanon implant for 6 months
88889241|NCT01438749|Active Comparator|A|
88889242|NCT01438749|Placebo Comparator|B|
88889243|NCT01438749|Experimental|C|
89192734|NCT06117839||1|"first group is patients will be treated with regular bone cement . Patients will be routinely monitored for clinical signs of infection, including cellulitis or draining sinuses. Radiographs were obtained at 2,6 and 12 months.~Laboratory tests as CRP and CBC will beused to assess the infection.~A negative CRP indicate clean field ."
89192735|NCT06117839||2|"the second one is patient will be treated with antibiotic loaded bone cement, commonly used antibiotic includeGentamycin powder.~Patients will beroutinely monitored for clinical signs of infection, including cellulitis or draining sinuses. Radiographs were obtained at 2,6 and 12 months.~Laboratory tests as CRP and CBC used to assess the infection.~A negative CRP indicate clean field."
89192736|NCT06116409||M-TAPA GROUP|Group 1 patients will receive a modified thoracoabdominal nerve block (M-TAPA) with a perichondrial approach using 40 ml of 0.25% bupivacaine guided by ultrasound (US).
89192737|NCT06116409||CONTROL GROUP|Patients in Group 2 (the control group) will receive routine multimodal analgesia, which includes tramadol at a dose of 1 mg/kg and paracetamol at a dose of 15 mg/kg.
89192738|NCT06113029||Healthy group|Participants not known to have neither chronic liver diseases nor Psychiatric disorders
89192739|NCT06113029||Diseased group|Participants known to have chronic liver diseases
89192740|NCT06105697|Experimental|Blood flow restriction (Experimental I)|Running with Blood Flow Restriction on the treadmill for 4 sets of 5 minutes,1' interset rest using a periodization methodology in soccer (Match Day 4 and Match Day 3).
89192741|NCT06105697|Experimental|Non-Blood flow restriction (Experimental II)|Running without Blood Flow Restriction on the treadmill for 4 sets of 5 minutes,1' interset rest using a periodization methodology in soccer (Match Day 4 and Match Day 3).
89192742|NCT06104904|Experimental|Managing Anxiety in Pediatric Primary Care (MAPP)|Participants receive approximately 4 sessions of a primary care provider-delivered intervention for reducing youth anxiety symptoms based on exposure therapy.
89192743|NCT06104904|Placebo Comparator|Enhanced Usual Care (EUC)|Participants receive a list of resources on how to reduce anxiety (e.g., videos, books, etc.).
89192744|NCT06104293|Other|Group 1|Concentration A - Concentration B - Concentration C - Concentration D
89192745|NCT06104293|Other|Group 2|Concentration B - Concentration C - Concentration D - Concentration A
89192746|NCT06104293|Other|Group 3|Concentration C - Concentration D - Concentration A - Concentration B
89192747|NCT06102057|Active Comparator|Conventional Arm|standard FDG-PET-based radiotherapy with concurrent standard of care chemotherapy
89192748|NCT06102057|Experimental|Experimental Arm|FDG-PET-based small volume accelerated radiotherapy with concurrent standard of care chemotherapy
89192749|NCT06101498|Experimental|Conventional fluid therapy|Patients who received conventional fluid therapy
89192750|NCT06101498|Experimental|Non invaziv goal directed therapy|Patients who received non invaziv goal directed therapy
89192751|NCT06101498|Experimental|Minimal invaziv goal directed therapy|Patients who received minimal invaziv goal directed therapy
89192752|NCT06100198|Experimental|Intervention group|A one-group pretest-posttest design was adopted. Participants participated in 3 nutrition and exercise courses, each lasting 2 hours (including 1 hour nutrition course and 1 hour exercise course) with an interval of 1 week between each course. All subjects underwent anthropometric measurements and completed questionnaires one week before the start of the course and one week after the end of the course. A repeat assessment was conducted 6 months after the course intervention.
89192753|NCT06091904|Experimental|sufentanil group|sufentanil is administered for analgesic during general anesthesia
89192754|NCT06091904|Active Comparator|remifentanil group|remifentanil is administered for analgesic during general anesthesia
89192755|NCT06090175|Experimental|projector colleyscope group|Approximately 10 minutes for the child. Inhaler medication will be given with a mask that lasts. Before starting the procedure, the child will be introduced to the projector colleidoscope. Before the procedure, this device, which looks like a toy, will be projected onto the wall to divert attention. The projection will continue throughout the inhaler medication administration process. Vital signs (pulse, blood pressure, SPo2, respiration) before and after the application, Child Fear Scale will be evaluated by the researcher and the parent and recorded in the intervention follow-up form by the researcher.
89412691|NCT02148198|Active Comparator|2g NWT-03, then placebo|7 days 2g NWT-03, followed by 7 days placebo, separated by a 5-day wash-out period
89412692|NCT02148198|Placebo Comparator|placebo, then 2g NWT-03|7 days placebo, followed by 7days 2g NWT-03, separated by a 5-day wash-out period
89005460|NCT04990024|Experimental|High protein/Low Carbohydrate Diet|50 participants will be randomized to this arm. The intervention consists of 5 individual (visits 1,3,5,7,9) and 8 group (visits 1,2,3,4,5,6,7,8) educational sessions on HP/LC diet in patients on Liraglutide, over a period of 24 weeks. Dietary assessments and adherence questionnaires will be held on several visits to assess adherence.
89412693|NCT02148198|Active Comparator|5g NWT-03, then placebo|7 days 5g NWT-03, followed by 7 days placebo, separated by a 5-day wash-out period
89412694|NCT02148198|Placebo Comparator|placebo, then 5g NWT-03|7 days 5g NWT-03, followed by 7 days placebo, separated by a 5-day wash-out period
89412695|NCT03492632||Women with Psoriasis|Reproductive age women newly diagnosed with psoriasis
89412696|NCT03492632||Women without Psoriasis|Reproductive age women without psoriasis to serve as control
89412697|NCT02147340||Heart failure patients with ICD|Heart failure patients with ICD and RPM system equipped with sensors for the measurement of weight and pressure
89412698|NCT02324192|Other|Normal ultrasonography|Patients with normal ultrasonography findings
89192756|NCT06090175|Experimental|Matching card group|Approximately 10 minutes for the child. Inhaler medication will be given with a mask that lasts. The child will be allowed to play with the matching cards 2-3 minutes before starting the drug treatment and will then be encouraged to play throughout the procedure. Vital signs (pulse, blood pressure, SPo2, respiration) before and after the application, Child Fear Scale will be evaluated by the researcher and the parent and recorded in the intervention follow-up form by the researcher.
89192757|NCT06090175|No Intervention|Control group|Approximately 10 minutes for the child. Inhaler medication will be given with a mask that lasts. Nothing will be shown to the child during the application. Vital signs (pulse, blood pressure, SPo2, respiration) before and after the application, the Child Fear Scale will be evaluated by the researcher and the parent and recorded by the researcher in the intervention follow-up form.
89192758|NCT06088992|Experimental|HG004|
89192759|NCT06087757|Experimental|Open Label|
89192760|NCT06087757|Experimental|Blinded randomize withdrawal|
89192761|NCT06086795|Active Comparator|Egg whites|3 large egg equivalent of liquid egg whites per day for 4 weeks
89192762|NCT06086795|Experimental|Egg yolks|3 large egg equivalent of liquid egg yolks per day for 4 weeks
89192763|NCT06086795|Experimental|Whole eggs|3 large whole eggs per day for 4 weeks
89412699|NCT02324192|Other|Inflammatory ultrasonography|Patients with inflammatory ultrasonography findings
89412700|NCT03491462|Experimental|Arimoclomol|248 mg arimoclomol base (equivalent to 400 mg arimoclomol citrate) 3 times daily
89412701|NCT03491462|Placebo Comparator|Placebo|248 mg matching placebo 3 times daily
89412702|NCT02147496|Experimental|2% M.F. Milk|Dietary treatment: 2% m.f. milk
89412703|NCT02147496|Experimental|1% M.F. Chocolate Milk|Dietary treatment: 1% m.f. chocolate milk
89412704|NCT02147496|Experimental|1.5% M.F. Drinkable Yogurt|Dietary treatment: 1.5% m.f. drinkable yogurt
89412705|NCT02147496|Experimental|Tropical Punch|Dietary treatment: fruit-flavoured beverage
89412706|NCT02147496|Experimental|Water|Dietary treatment: calorie-free control
89412707|NCT02147574|Experimental|antiperistaltic ileosigmoid anastomosis|To assess the operative results after laparoscope subtotal colectomy with antiperistaltic ileosigmoid anastomosis for the slow-transit constipation.
89412708|NCT02147652|Experimental|Personalized music|
89412709|NCT04584554|Experimental|Intervention|
89412710|NCT02147730||surgical patients|all surgical patients undergoing gastrectomy, knee-hip-shoulder arthroplasty, hallux valgus surgery, hernia repair, saphenectomy, cesarean section,colectomy, hysterectomy, nephrectomy mastectomy during study period
89412711|NCT03109808|Experimental|e-health strategy|Assigned intervention: e-health strategy
89412712|NCT03109808|Active Comparator|Traditional Oral Hygiene Education|Assigned intervention: traditional oral hygiene education
89412713|NCT02151630|Active Comparator|Pyruvic acid|Patients will receive pyruvic acid solution 70% prepared by solving of pyruvic acid in water/ethanol solution. Patients will be advised to apply the solution twice daily for a period of four weeks. Application of petrolatum to the surrounding normal skin protects against the corrosive effect of the concentrated acid.
89412714|NCT02151630|Active Comparator|Salicylic acid|Patients will receive a combination of salicylic acid 16.7%, lactic acid 16.7%, and collodion 100%. Patients will be advised to apply the solution twice daily for a period of four weeks. Application of petrolatum to the surrounding normal skin protects against the corrosive effect of the concentrated acid.
88889244|NCT01438762|Active Comparator|Information and patient education|All subjects will receive one-to-one patient education delivered by a physiotherapist. The information will be standardized and cover the topics of: why does it hurt: pain management; information of how to reduce physical activity if necessary; how to return slowly to sports; how to cope with knee pain and information of how to increase knee alignment during walking and stair walking. The patients will also receive this information in written form. This information is expected to take approximately 45minutes per patient.
88889245|NCT01438762|Active Comparator|Information, education and physiotherapy|"Patients will receive one-to-one patient education delivered by a physiotherapist. The information will be standardized and cover the topics of: why does it hurt: pain management; information of how to reduce physical activity if necessary; how to return slowly to sports; how to cope with knee pain and information of how to increase knee alignment during walking and stair walking.~In addition the patients will receive supervised multimodal physiotherapy carried out by a physiotherapist with previous experience in treating adolescents and PFPS and has more than two years of practical experience in these areas."
88889246|NCT01438762|No Intervention|Observational cohort|Those who do not wish to participate in the randomization procedure will be followed through an observational cohort. The observational cohort will be followed at the same time-points and they will be asked which treatment they have received.
88889247|NCT01438788|Experimental|All patients on a low protein diet|
88889248|NCT01438801|Experimental|NutropinAq|
88889249|NCT01438827|Active Comparator|Avanz Phleum pratense 15,000 SQ+|
88889250|NCT01438827|Active Comparator|Avanz Phleum pratense 4,000 SQ+|
88889251|NCT01438827|Placebo Comparator|Injection with no active grass component|
88889252|NCT01438853|Experimental|TNX-832|Anti-tissue factor antibody
88889253|NCT01438853|Placebo Comparator|Drug Placebo|Placebo control
88889254|NCT01438866|Experimental|Preventing occlusal caries|Comparing preventing effect of fissure sealants vs. fluoride varnish
88889255|NCT01438879||pleocytosis group|40 patients with clinical signs of CNS infection and having CSF pleocytosis.
88889256|NCT01438879||non-pleocytosis group|20 patients not having CNS infection clinically and not having CSF pleocytosis.
88889257|NCT01438892||tDMARDs Group|traditional DMARDs
88889258|NCT01438892||Biologics group|Biologics used in RA
88889259|NCT01438905|No Intervention|Control|Parameters will be identical to the lower intensity (Small amplitude oscillation mobilization; Grade IV) talocrural mobilization. No force, other than light hand contact will be applied by the therapist.
88889260|NCT01438905|Experimental|Lower intensity mobilization|The subject will be in a seated position and the therapist will stabilize the distal tibia with one hand and make contact the anterior talus with the opposite hand. Three 60-second anterior to posterior joint mobilizations of the talus (small amplitude at end range; Grade IV) will be applied by the therapist with one minute rest in between sets.
88889261|NCT01438905|Experimental|Higher intensity mobilization|The subject will be in a seated position and the therapist will grasp the dorsum of the foot with their fingers. The ankle will be dorsiflexed until the restrictive barrier is reached. A small amplitude, quick thrust at end of range (High velocity, low amplitude; Grade V mobilization/manipulation) will be applied. If joint cavitation is not felt or heard by the therapist or subject the technique will be repeated one additional time.
88889262|NCT01438918|Active Comparator|200 mg|High dose active comparator
88889263|NCT01438918|Active Comparator|50 mg|Low dose active comparator
88889264|NCT01438918|Placebo Comparator|Placebo|Placebo comparator to be used for control purposes
88889265|NCT01438931|Placebo Comparator|Placebo group|Loading infusion of Placebo over 10 minutes followed by maintenance infusion of Placebo
88889266|NCT01438931|Active Comparator|DA-9501 0.5 mcg/kg group|Loading infusion of Dexmedetomidine 3.0 mcg/kg/hr over 10 minutes followed by maintenance infusion of Dexmedetomidine 0.2-0.7 mcg/kg/hr
88889267|NCT01438931|Active Comparator|DA-9501 1.0 mcg/kg group|Loading infusion of Dexmedetomidine 6.0 mcg/kg/hr over 10 minutes followed by maintenance infusion of Dexmedetomidine 0.2-0.7 mcg/kg/hr
88889268|NCT01438944|Other|Nicabate 21mg transdermal NRT|21mg Transdermal NRT applied for 24hrs over a 14day period.
88889269|NCT01438970|Other|ALFApump system implantation|Implantation of ALFApump system
88889270|NCT01438983||breastfeeding infants|
89412715|NCT03494972|Active Comparator|drain|Tetracyclin drain
89412716|NCT03494972|Sham Comparator|No-drain|No drain
89412717|NCT02148354|Experimental|Group with support by the therapist.|Intervention group that do the Smiling is Fun program and receives support by the therapist (a brief weekly two-minute call without clinical content).
89412718|NCT02148354|Experimental|Group without support by the therapist|Intervention group that do the Smiling is Fun program and does not receive support by the therapist.
89412719|NCT02148354|Other|Waiting list control group|"Control group that could access the Smiling is Fun program after waiting for 12 weeks.~After that time, those participants still interested were randomly assigned to one of two intervention conditions (with or without support by the therapist)."
89412720|NCT03494894||patients with Cystic Fibrosis and Primary Ciliary Dyskinesia|
89412721|NCT02224573|Experimental|GWP42003-P|
88889271|NCT01438983||bottle feeding infants|
88889272|NCT01439022|Experimental|Exercise Programme|6 months 2 x a week aerobic and anaerobic exercise delivered in community facilities by an exercise professional and supported by a physiotherapist.
88889273|NCT01439022|Active Comparator|Hand writing programme|6 months 2 x a week hand writing practice. Performed in the home supported by a physiotherapist (5 support sessions)
88889274|NCT01439048||Term infants|Infants born at greater than 37 weeks gestation
88889275|NCT01439048||Preterm Infants|Infants born at less than 37 weeks gestation
88889276|NCT01439100|Active Comparator|OXN PR|Oxycodone/Naloxone Prolonged Release tablets
88889277|NCT01439100|Placebo Comparator|Dummy tablet|Placebo
88889278|NCT01439152|Experimental|BAY94-9343 (Dose-Escalation)|BAY94-9343 was administered intravenously in this study. The starting dose for this first-in-man study was 0.15 mg/kg administered as a 1 hour infusion every 21 days. (ENROLLMENT CLOSED).
88889279|NCT01439152|Experimental|BAY94-9343 (Expansion)|"After Maximum tolerated dose (MTD) had been defined, expansion cohorts were conducted at the MTD dose. Overall up to 32 subjects were planned to be enrolled in the expansion cohort:~Ovarian Carcinoma, 20 subjects~Mesothelioma, 6-12 subjects (ENROLLMENT CLOSED)."
88889280|NCT01439152|Experimental|BAY94-9343 (1.8 mg/kg)|This part of study was randomized and open-label. BAY94-9343 in two parallel dose cohorts of twenty (20) patients with recurrent platinum-resistant or platinum partially-sensitive ovarian cancer and up to four (4) patients with advanced malignant epithelioid peritoneal mesothelioma and eight (8) patients with advanced pleural mesothelioma.
88889281|NCT01439152|Experimental|BAY94-9343 (2.2 mg/kg)|This part of study was randomized and open-label. BAY94-9343 in two parallel dose cohorts of twenty (20) patients with recurrent platinum-resistant or platinum partially-sensitive ovarian cancer and up to four (4) patients with advanced malignant epithelioid peritoneal mesothelioma and eight (8) patients with advanced pleural mesothelioma.
88889282|NCT01439178|Experimental|Intravitreal Avastin Day 2|randomized to either treatment with preoperative IVB 2 days before PPV (Group A) or 7 days before PPV (Group B).
88889283|NCT01439178|Active Comparator|Intravitreal Avastin Day 7|randomized to either treatment with preoperative IVB 2 days before PPV (Group A) or 7 days before PPV (Group B).
88889284|NCT01439191|Experimental|combination agent group|
88889285|NCT01439191|Experimental|single agent group|In this arm, patients would be treated with Cipterbin® for 12 or 24 weeks
88889286|NCT01439230|Experimental|Investigational Test Product|Donepezil 10 mg Tablets
88889287|NCT01439230|Active Comparator|Reference Listed Drug|Aricept® 10 mg Tablets
88889288|NCT01439243|Experimental|Investigational Test Product|Donepezil 10 mg Tablets
88889289|NCT01439243|Active Comparator|Reference Listed Drug|Aricept® 10 mg Tablets
88889290|NCT01439256|Experimental|Computer Controlled Telephone Counseling|This arm intervenes with subjects and their treating physicians. The intervention is periodic medical adherence promotion counseling for subjects regarding their prescribed HTN medications through a computer-controlled telephone counseling program that has data on subject's recent BP values and their prescribed HTN medications. The subjects' treating physicians receive at regularly scheduled office visits information about subject's recent BP and medication adherence for each prescribed medication and also get physician information and management recommendations
88889291|NCT01439256|No Intervention|Usual Care|In this arm, patients with hypertension that is not adequately controlled receive usual care from their physicians. Usual care is defined as receiving regular care from the physician and no additional care or intervention from the study.
88889292|NCT01439295||Preterm less than 33 weeks|This cohort will be composed of premature infants born before 33 weeks of gestational age, admitted to the neonatal intensive care unit at Sainte-Justine hospital and receiving parenteral nutrition (PN) during their first week of life.
88889293|NCT01439308|Placebo Comparator|Arm 1|3 incremental capsaicin doses
88889294|NCT01439308|Active Comparator|Arm 2|3 incremental capsaicin doses
88889295|NCT01439321||Patient with Chronic Immune Thrombocytopenic Purpura|Patients with chronic ITP who switch from their previous treatment of corticosteroids, rituximab, or eltrombopag or romiplostim to eltrombopag or romiplostim and have been on the new treatment for at least four weeks
88889296|NCT01439334|Experimental|Online Program Brief|Online Program Brief
88889297|NCT01439334|Experimental|Online Program Extended Length|Online Program Extended Length
88889298|NCT01439334|Active Comparator|Control|Control
88889299|NCT01439386|Active Comparator|AF ablation with or without AFL ablation|Pulmonary vein antral isolation (PVAI)with or without cavo-tricuspid isthmus (CTI) ablation
88889300|NCT01439386|Active Comparator|AFL ablation only|Cavo-tricuspid isthmus ablation only
88889301|NCT01439399|Active Comparator|Lidocaine|Intravenous lidocaine administered preoperatively (anesthesia induction) and postoperatively during 48 hours
88889302|NCT01439399|Active Comparator|Ketamine|Intravenous ketamine administered preoperatively (anesthesia induction) and postoperatively during 48 hours
89412722|NCT04520750|Experimental|Open label treatment arm|PTX-022 QTORIN
89412723|NCT01360840|Placebo Comparator|Placebo + Standard of care (SoC)|
88889303|NCT01439399|Active Comparator|Ketamine-Lidocaine|Intravenous association of ketamine and lidocaine administered preoperatively (at anesthesia induction) and postoperatively during 48 hours.
88889304|NCT01439399|Placebo Comparator|Saline 0,9%|Control group
88889305|NCT01439425|Experimental|weight loss|balanced diet scheme, based on a caloric intake reduction related to BMI and sex (range: 1200-1500 kcal/d for women, 1300-1600 kcal/d for men).
88889306|NCT01439438|Active Comparator|Test formulation|Test product: Topiramate 100 mg coated tablets produced by Dr. Reddy's Laboratories Ltd. in Period 1, followed by 28 days washout period during which no medication was administered; followed by reference product: Topamax® 100 mg coated tablets in Period 2
88889307|NCT01439438|Active Comparator|Reference formulation|Topamax® 100 mg coated tablets marketed by Janssen-Cilag farmacêutica Ltda. in Period 1, followed by 28 days washout period during which no medication was administered; followed by test product: Topiramate 100 mg coated tablets produced by Dr. Reddy's Laboratories Ltd. in Period 2
88889308|NCT01439451|Experimental|experimental|perturbation training during walking
88889309|NCT01439451|Active Comparator|controls|treadmill walking
88889310|NCT01439464|Active Comparator|Control device|
88889311|NCT01439464|Experimental|Investigational device|
88889312|NCT01439490|Experimental|FES-PET|Patients undergo FES-PET prior to obtaining histology
88889313|NCT01439503|No Intervention|Control|Men receiving the control condition will be comprised of standard of care counseling from the clinic plus a variety of free condoms and water-based lubricants. They will also provide a specimen for STD testing, and receive text message questions for 12 weeks. The text messaging system will be used to collect self-reported dependent variables from men on a weekly basis. Texting will also serve as a constant method of contact between the PD and the enrolled men to remind them of follow-up assessments. In addition, the participants will complete the ACASI questionnaire to assess their sexual behavior, as well as demonstrate their condom application ability.
88889314|NCT01439503|Experimental|Treatment|Men receiving the treatment condition will receive text messages each week after their enrollment date and this will continue for 12 weeks to collect self-reported dependent variables. Text messaging will also be used to confirm and remind men about the day of each follow-up assessment. Each participant will also provide a specimen for STD testing, as well complete the ACASI questionnaire to assess sexual behavior and demonstrate their condom application ability. These participants will also be provided with a variety of free condoms and water-based lubricants. In addition, men in the treatment condition will also be enrolled in an education program.
88889315|NCT01439516|Experimental|Information|Participants randomized to this arm of the study will received the PREPARED educational book and video.
88889316|NCT01439516|Experimental|Information and Financial Assistance|Participants randomized to this arm of the study will receive the PREPARED educational book and video plus financial assistance for family members to cover costs associated with an evaluation for becoming a live kidney donor.
89412724|NCT01360840|Experimental|EMD 525797 750 mg + SoC|
89412725|NCT01360840|Experimental|EMD 525797 1500 mg + SoC|
88889317|NCT01439516|No Intervention|Usual Care|Participants randomized to this arm of the study will receive usual care from their physician.
88889318|NCT01439529|Active Comparator|Nominal|CRT device is programmed with the nominal values.
88889319|NCT01439529|Experimental|Narrow QRS|CRT device is programmed by QRS optimization
88889320|NCT01439542|Experimental|Radiotherapy|
88889321|NCT01439607|Experimental|Bone marrow and blood sampling|
89412726|NCT03529292|Experimental|Matrix and Cells obtained by the AmeaCell® device|
89412727|NCT02151708|Active Comparator|motilitone 90mg|Eligible subjects were randomly allocated in a 1:1:1 ratio to receive either 90mg motilitone or 180mg motilitone or placebo motilitone three times daily for 2weeks.
89412728|NCT02151708|Active Comparator|motilitone 180mg|Eligible subjects were randomly allocated in a 1:1:1 ratio to receive either 90mg motilitone or 180mg motilitone or placebo motilitone three times daily for 2weeks.
89412729|NCT02151708|Placebo Comparator|placebo|Eligible subjects were randomly allocated in a 1:1:1 ratio to receive either 90mg motilitone or 180mg motilitone or placebo motilitone three times daily for 2weeks.
89412730|NCT03490058||Young women|Sexually active HIV-uninfected women between 16-25 years of age will be given Truvada.
89412731|NCT02148432|Experimental|dexmedetomidine 0.5 mcg/kg/hr|
89412732|NCT02148432|Active Comparator|dexmedetomidine 1.0 mcg/kg/hr|
89412733|NCT01976455||20% calorie depletion|During each 11-day stays the volunteer will have 9 days of calorie depletion (20% one stay and 40% the other).
89412734|NCT01976455||40% calorie depletion|During each 11-day stays the volunteer will have 9 days of calorie depletion (20% one stay and 40% the other).
89412735|NCT03096964|Experimental|Nordic walking|Experimental: Nordic walking Training The total period of training was composed by 8-week of walking with poles, three sessions per week. The cycles were divided into eight microcycles composed by three training sessions. Each training session took 60 min. Nordic walking aerobics training were used during the training period. These exercises were performed alternating volume and intensity. Exercise intensities were controlled using the cardiac monitor, and the zone was since 70% to 105% of the heart rate at the second ventilatory threshold. And volume was controlled using the time of the session.
89536711|NCT02473055|No Intervention|control|control infants remained prone in an incubator wearing only diaper
89536712|NCT02470637|Experimental|SAR439065 + insulin lispro|1 of 6 sequences with single administration of 3 dose levels of SAR439065 (Afrezza Technosphere insulin) and 3 dose levels of insulin lispro with a washout duration between dosing days (7 to 28 days)
89412736|NCT03096964|Experimental|Free Walking|Experimental: Free walking Training The total period of training was composed by a 8-week cycles of walking without poles, with three sessions per week. The cycles were divided into eight microcycles composed by three training sessions. Each training session took 60 min. Free walking aerobics training were used during the training period. These exercises were performed alternating volume and intensity. Exercise intensities were controlled using the cardiac monitor, and the zone was since 70% to 105% of the heart rate at the second ventilatory threshold. And volume was controlled using the time of the session.
89412737|NCT02151864|Experimental|LDE225|LDE225 200mg-800mg oral daily
89412738|NCT03350984|Experimental|NPH insulin group|Patients receiving NPH twice daily, 2/3 in the morning and 1/3 in the night. A correctional dose of lispro insulin will be given for any blood glucose >180 mg/dL. If subjects were not eating, they shouldn't receive dose of NPH insulin. Intervention Drug: NPH insulin
88889322|NCT01439646||Non neutropenic, ICU, empiric ,antifungals|
89412739|NCT03350984|Active Comparator|Glargine and Lispro insulin group|"Half of the total of Glargine and Lispro insulin dose will be given as glargine once daily, either in the morning or in the evening, depending on when the patient was enrolled. The other half of the total daily insulin dose will be given as Lispro; doses were divided equally for breakfast, lunch, and dinner. An additional correctional dose of Lispro will be given for any blood glucose >180 mg/dL. If subjects were not eating, they received glargine once daily and they shouldn't receive doses of lispro.~Intervention drug: Glargine and Lispro"
89412740|NCT02148510|Experimental|Monobloc|Treatment with an appliance that holds the lower jaw in a fixed protruded position
89412741|NCT02148510|Active Comparator|Bibloc|Bibloc device where a maxillary splint is connected to a mandibular splint by a connector allowing a slight opening of the jaw without compromizing the protrusion (Narval)
88889323|NCT01439685||Biliary Stent plus Photodynamic therapy|Biliary Stent plus Photodynamic therapy
88889324|NCT01439685||Biliary Stent group|Biliary Stent group
89412742|NCT03504423|Experimental|CPI-613, mFolfirinox|"CPI-613, mFolfirinox~CPI-613 at 500 mg/m2 IV infusion at a rate of 4mL/min via a central venous port on day 1 and 3 of a 14-day cycle.~mFolfirinox (given immediately after CPI-613 administration): Oxaliplatin (Eloxatin) at 65 mg/m2 given as a 2 hr IV infusion, Folinic acid at 400 mg/m2 given as a 90 min (1.5hr) infusion immediately after Oxaliplatin, and concurrently with Irinotecan (irinotecan at 140mg/m2 given as a 90 min IV infusion) via a Y-connector, Flurouracil at 400 mg/m2 as bolus followed by a 46 hr infusion at 2400mg/m2 starting immediately after completion of folinic acid and Irinotecan."
89412743|NCT03504423|Active Comparator|Folfirinox|"Folfirinox~Folfirinox: Oxaliplatin (Eloxatin) at 85 mg/m2 given as a 2 hr IV infusion, Folinic acid at 400 mg/m2 given as a 90 min (1.5hr) infusion immediately after Oxaliplatin, and concurrently with Irinotecan (irinotecan at 180mg/m2 given as a 90 min IV infusion) via a Y-connector, Flurouracil at 400 mg/m2 as bolus followed by a 46 hr infusion at 2400mg/m2 starting immediately after completion of folinic acid and Irinotecan."
89412744|NCT05053048|Experimental|STD-SL-PLUS stem|Rectangular SL straight stems made of titanium alloy (Ti-6Al-7Nb). The control stem (STD-SL-PLUS stem) underwent alumina grit blasting to reach the adequate roughness of 4-6 micron.
88889325|NCT01439698||RFA for Pancreatico-biliary disorders|Subjects who will receive radiofrequency ablation for pancreatico-biliary disorders, including malignancies.
88889326|NCT01439737||asthma|
88889327|NCT01439750|Experimental|Phase I|The phase I portion of the study is a standard dose-escalation schemed designed to determine the maximum tolerated dose (MTD) of cladribine in the combination of bortezomib, cladribine, and rituximab therapy. The MTD is defined as the dose level in which ≤1 out of 6 patients have dose-limiting toxicity (DLT). Rituximab 375 mg/m2 on day 5,12, 19, 26 for 1st cycle, then day 5 of cladribine for next 5 cycles and then every 2 months maintenance dose. Cladribine 3-5 mg/m2 days 1-5 for 6 cycles. Bortezomib 1.6 mg/m2 sub Q days 12,19,26 for 3 cycle, then every 2 weeks maintenance dose until toxicity or progression.
88889328|NCT01439750|Experimental|Phase II|The phase II portion of the study is a two-arm, single-stage design with no interim analysis. One arm will accrue newly diagnosed patients, and one arm will accrue relapsed patients. In each arm, the progression-free survival rate at 2 years will be used as the primary endpoint for determining whether the treatment is sufficiently active in each arm. No comparisons will be made between the arms. Rituximab 375 mg/m2 on day 5,12,19,26 for 1st cycles, then day 5 montly for next 5 cycles, then every 2 months maintenance dose. Cladribine 3-5 mg/m2 days for 6 cycles (dose determined from phase I). Bortezomib 1.6 mg/m2 weekly on day 12,19,26 for 3 cycles then every 2 weeks as maintenance dose until toxicity or progression.
88889329|NCT01439789|Active Comparator|rhNRG-1|Recombinant human neuregulin-1 administration in addition to basic therapy of chronic heart failure
88889330|NCT01439789|Placebo Comparator|Plaebo|Excipient placebo in addition to basic therapy of chronic heart failure
88889331|NCT01439828|Experimental|Experimental : N-acetylcystein|N-acetylcystein and placebo doses will be increased if craving decreases <25% compared to the previous visit. The doses start at 200 mg x 4/24h to 800 mg x 4/24h
88889332|NCT01439828|Placebo Comparator|Placebo Comparator|N-acetylcystein and placebo doses will be increased if craving decreases <25% compared to the previous visit. The doses start at 200 mg x 4/24h to 800 mg x 4/24h
88889333|NCT01439841|Experimental|Probiotics|A multi-strain Probiotic consisting of Lactobacillus rhamnosus GG, Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. lactis Bb-12 added to fermented skimmed milk (Biola®, TINE SA, Oslo), 250 mL/day for 8 weeks.
88889334|NCT01439841|Placebo Comparator|Placebo|Fermented and subsequently heat-treated, sterile skimmed milk (TINE SA) as active placebo.
89412745|NCT05053048|Active Comparator|NT-SL-PLUS Stem|Rectangular SL straight stems made of titanium alloy (Ti-6Al-7Nb). The experimental stem (NT SL-PLUS) underwent alumina grit blasting to reach the adequate roughness of 4-6 micron. The surface of the NT SL-PLUS stem was thereafter additionally treated chemically by short-acid etching with HF and mechanically by dry ice blasting in order to loosen and remove the residual alumina particles up to 96% without changing the existing surface microtopography.
89412746|NCT04461548|Experimental|Experimental group 1: Best Possible Self|Participants are asked to think and write about their best possible future self and to imagine this positive future subsequently.
89412747|NCT04461548|Experimental|Experimental group 2: Best Possible Self + next steps|Participants are asked to think and write about their best possible future self and what the next steps could be to reach that best possible future. Subsequently, participants are asked to imagine this positive future.
89412748|NCT04461548|Experimental|Experimental group 3: Self-compassion|Participants are asked to think and write about a self-compassion exercise and to imagine this content subsequently.
89412749|NCT04461548|Active Comparator|Active control group|Participants are asked to think and write about a neutral task that is comparable to the experimental groups.
89412750|NCT05176717|Experimental|QR-421a 180/60 µg|180 µg loading dose administered on Day 1, 60 µg maintenance dose administered at Month 3 and every 6 months thereafter
89412751|NCT05176717|Experimental|QR-421a 60/60 µg|60 µg loading dose administered on Day 1, 60 µg maintenance dose administered at Month 3 and every 6 months thereafter
89412752|NCT05176717|Sham Comparator|Sham-procedure|Sham-procedure (no experimental drug administered) on Day 1, Month 3 and every 6 months thereafter
89412753|NCT03097198|Experimental|PbN-TED|Treated with plum-blossom needle first for 10 times during 20 days, followed with a one-month wash-out period and a 10-day period with Tropicamide Eye Drops.
89412754|NCT03097198|Experimental|TED-PbN|Treated with Tropicamide Eye Drops for 10 days first, followed with a one-month wash-out period and 10 times of plum-blossom needle treatment for 20 days.
89412755|NCT02324348|Placebo Comparator|Immediate coronary stenting|Within enrolled patients who agreed to participate in the study, signed informed consent and being satisfied with inclusion and exclusion criteria, stent implantation is done on the initial procedure in immediate coronary stenting group
89412756|NCT02324348|Active Comparator|Deferred coronary stenting|Within enrolled patients who agreed to participate in the study, signed informed consent and being satisfied with inclusion and exclusion criteria, only TIMI Ⅲ flow achievement is done on the initial procedure and stent implantation is deferred after 5-7 days admission in the deferred coronary stenting group.
89412757|NCT02770248|Experimental|SIMBRINZA|Brinzolamide 1% / Brimonidine 0.2% tartrate ophthalmic suspension, 1 drop 3 times per day in each eye at 8 AM, 3 PM, and 10 PM for 28 days
89412758|NCT02770248|Active Comparator|Vehicle|Vehicle, 1 drop 3 times per day in each eye at 8 AM, 3 PM, and 10 PM for 28 days
89412759|NCT05053282||master endurance athletes|men aged 65 to 75 with more than 150 minutes of running activity per week at least 15 years history of running
89412760|NCT05053282||elderly sedentary|men aged 65 to 75 with no history of regular physical activity training and no more practice than 150 minutes of moderate or 75 minutes of vigorous intensity per week according the ACSM recommendations
89412761|NCT05053282||young endurance athletes|men aged 20 to 30 with more than 150 minutes of running activity per week at least 3 years history of running
89412762|NCT05053282||young sedentary|men aged 20 to 30 with no history of regular physical activity training and no more practice than 150 minutes of moderate or 75 minutes of vigorous intensity per week according the ACSM recommendations
89412763|NCT04459130|Experimental|Child Obesity Program|"Firstly, overweight and obese students will be determined by measuring their height and weight. While selecting children for the experimental group, random numbers table will be used. As a result of statistical analysis, 33 students will be selected to the Experiment group. Child Obesity Program (COP) will be applied to students in the experimental group for 10 weeks. Before the program is implemented, children's height, weight, subcutaneous adipose tissue measurements will be made. The pedometer wristband will be distributed.~Pretest: BMI, weight average, subcutaneous adipose tissue measurement and application of scales~- Children's Dietary Self- Efficacy Scale-CDSS~- Food Behavior Scale~- Child Heart Health Development Attitude Scale (exercise, stress, nutrition subscales)~-Daily Food Consumption Form~-Drink Consumption Form~Health Perception Form~Follow-ups will be performed in the 6th and 9th months after the intervention"
89412764|NCT04459130|No Intervention|Control Grup|"Firstly, overweight and obese students will be determined by measuring their height and weight. When selecting children for the control group, random numbers table will be used. As a result of statistical analysis, 33 students will be selected to the Control group. First, children's height, weight, subcutaneous adipose tissue measurements will be made. The pedometer wristband will be distributed. The control group will be trained for a daily healthy diet and physical activity.~Pretest: BMI, weight average, subcutaneous adipose tissue measurement and application of scales~- Children's Dietary Self- Efficacy Scale-CDSS~- Food Behavior Scale~- Child Heart Health Development Attitude Scale (exercise, stress, nutrition subscales)~-Daily Food Consumption Form~-Drink Consumption Form~Health Perception Form~Follow-ups will be performed in the 6th and 9th months after the intervention"
89412765|NCT05044390||lung transplantation|Lung transplantation performed for end-stage interstitial lung disease secondary to pleuroparenchymal fibroelastosis.
88889335|NCT01439841|No Intervention|Control|No intervention
88889336|NCT01439893|Active Comparator|rhNRG-1|Recombinant human neuregulin-1 administration in addition to basic therapy of chronic heart failure
88889337|NCT01439893|Placebo Comparator|Placebo|Excipient placebo in addition to basic therapy of chronic heart failure
88889338|NCT01439906||Adult degenerative scoliosis|Patients aged 40-75 years affected by lumbar or thoraco-lumbar degenerative kyphoscoliosis presenting chronic low back pain from six months at least and/or neurological deficits who underwent a surgical correction of the deformity
88922032|NCT05946252|Experimental|Motor Imagery Group|"Risky pregnant women who have completed the 12th week of pregnancy, received inpatient treatment and have any of the following risk factors will be included in the study:~Pregnant women who are at risk for obstetric outcomes such as cervical insufficiency, multiple pregnancy and uncontrolled gestational diabetes, and physical activity restriction is recommended due to these conditions, and exercise is contraindicated,~Pregnant women with a maternal body mass index above 30, which causes them to be physically inactive"
89005461|NCT04990024|Active Comparator|Low Fat Diet|50 participants will be randomized to this arm. The intervention consists of 5 individual (visits 1,3,5,7,9) and 8 group (visits 1,2,3,4,5,6,7,8) educational sessions on low fat diet in patients on Liraglutide, over a period of 24 weeks. Dietary assessments and adherence questionnaires will be held on several visits to assess adherence.
89192764|NCT06080191|Experimental|Single arm|"A single IV infusion of CD19-CAR_Lenti_ALLO (allogeneic CD19-directed chimeric antigen receptor T-cells) on Day 0 after lymphodepletion. Patients will be divided in two cohorts based on donor HLA matching: cohort A (fully matched, familial or unrelated donor); cohort B (haploidentical donor).~Patients will receive the following lymphodepletion:~Fludarabine (Flu) 30 mg/m2 per day on days -5, -4 and -3~Cyclophosphamide (Cyclo) 1000 mg/m2 per day on days -5, -4 and -3.~CD19-CAR_Lenti_ALLO will be infused at the following dose levels:~Cohort A:~DL1: 3.0 x10^6 CAR+ cells/kg~DL2: 5.0x10^6 CAR+ cells/kg~Cohort B:~DL1: 1x10^6 CAR+ cells/kg~DL2: 3x10^6 CAR + cells/kg~If 2 DLT are observed in the dose level 1, an additional DL0 of 2.0x10^6 CAR+ cells/kg (cohort A) or 0.5x10^6 CAR+ cells/kg (cohort B) will be explored."
89192765|NCT06079060|Experimental|Synthetic Nitrile Condom (61mm)|61mm width synthetic Nitrile condoms
89192766|NCT06079060|Active Comparator|Control Latex Condom|61mm width Natural Rubber Latex condoms
89005462|NCT04999501|Experimental|65 - 75 years|All volunteers aged 65 - 75 will be subjected to 12 weeks of full body resistance exercise training (3 times per week).
89192767|NCT06078813|Experimental|Low baseline VCF risk|"All of:~No VCF~Predominantly sclerotic lesion (as determined by the Investigator based on MRI)~Normal spinal alignment~<50% vertebral body involvement"
89412766|NCT03619005|Placebo Comparator|Placebo|
89412767|NCT03619005|Active Comparator|Prasterone|
89412768|NCT02686346|Experimental|BV-ICE|"Phase I:~4 cycles of treatment, every 21 days: Brentuximab Vedotin (BV) + Etoposide- Carboplatine - Ifosfamide (ICE) = BV-ICE for cycles 1 to 3 and BV alone at cycle 4;~Phase II:~4 cycles of treatment, every 21 days: BV-ICE for cycles 1 to 3, BV alone at cycle 4"
89005463|NCT04999501|Experimental|85 years and over|All volunteers over the age of 85 will be subjected to 12 weeks of full body resistance exercise training (3 times per week).
89192768|NCT06078813|Experimental|High baseline VCF risk|"Any of:~Pre-existing VCF~Predominantly lytic lesion (as determined by the Investigator based on MRI)~Spinal deformity~≥50% vertebral body involvement"
88889339|NCT01439932|Experimental|ankle mobilization for pain release|"stretching exercise for the plantar fascia and triceps surae muscles three times a day throughout the study period.~During each visit the exercise performance will be checked by the therapist. In addition, participants from both groups will get ultra sound therapy in frequency of 1 MHz, power of 1.5 watts per centimeter-squared, pulses of 50% for 5 minutes.~The study group will receive the same treatment and a number of manual techniques that include antero-posterior (AP) mobilization for talocrural joint in two variations (weight baring and non-weight baring) to improve the range of dorsi flexion, subtalar joint mobilization to improve range of eversion and mid-tarsal mobilization to improve pronation / supination of the forefoot. Each technique will be carried out for 1 to 1.5 minutes for a total of 5 minutes of manual treatment.~All patients will receive information and guidance to practice at home."
88889340|NCT01439958|Experimental|L-CsA|Twice daily inhalation of L-CsA
88889341|NCT01439984|Experimental|PED-1|PED-1 (Clomipramine 15 mg)
88889342|NCT01439984|Placebo Comparator|placebo|
88889343|NCT01440023|Experimental|CBIT + Response Inhibition Training|CBIT is an 8 session treatment protocol held over 10 weeks. In CBIT, core components are implemented across the various therapy sessions. These core components include habit reversal training (HRT), functional assessment/function-based interventions, and a behavioral reward program for the child. Each core component is briefly described below. HRT/CBIT involves three components, awareness training, competing response training, and social support training (Woods, Twohig, Roloff, & Flessner, 2003). For this condition, CBIT will be combined with adjunctive computerized response inhibition training, which will be delivered over the first 4 weeks of the CBIT treatment.
88889344|NCT01440023|Placebo Comparator|Experimental: CBIT + Placebo Computer Training|In this condition, participants receive the same package of CBIT treatment, which consists of awareness training, competing response training, and social support training (Woods, Twohig, Roloff, & Flessner, 2003). Additionally, the standard CBIT treatment is combined with computer-based placebo cognitive training that is irrelevant to the target cognitive ability (i.e., response inhibition). During the first 4 weeks of the CBIT treatment, participants will receive 8 sessions of placebo cognitive training.
88889345|NCT01440036||Carotid endarterectomy|Patients that have the common indication for the treatment of carotid artery stenosis by surgery - CEA (carotid endarterectomy), symptomatic and asymptomatic patients.
88889346|NCT01440062|Experimental|Verum (high dose)|verum arm receiving high dose Vitamin D oil
88889347|NCT01440062|Experimental|Verum (low dose)|low dose arm receiving neutral oil and low dose of Vitamin D
88889348|NCT01440075|Other|Patients KD|Adults with a history of KD disease in childhood
88889349|NCT01440075|Other|Case Control|Control group, healthy volunteers matched for age and sex with the KD group
88889350|NCT01440088|Experimental|TH-302 in Combination with Doxorubicin|
88889351|NCT01440088|Active Comparator|Doxorubicin|
88889352|NCT01440114|Active Comparator|fentanyl group|First arm: intervention group. Patient in this group received fentanyl 1 mcg/kg (concentration 10mcg/ml) intravenous route 15 minutes before the end of surgery.
88889353|NCT01440114|Placebo Comparator|controlled group|patient in this group received NSS 0.1 ml/kg 15 minutes before the end of surgery
88889354|NCT01440127|Experimental|Metformin|Subjects in this arm are randomized to receive metformin during the period of time between planning the surgery or biopsy and the actual procedure. After approximately 1 week of taking metformin, we will re-check the blood glucose. We will draw blood for cancer stem cells (about 2 teaspoons) and ask about symptoms. Subjects will stop taking metformin 2 days before the procedure.
88889355|NCT01440127|No Intervention|Observation|No metformin will be given prior to the scheduled surgery or biopsy.
88889356|NCT01440140|Experimental|Closed loop (algorithm)|
88889357|NCT01440140|Placebo Comparator|Open loop|
88889358|NCT01440153|Experimental|Active Intervention|
88889359|NCT01440153|Active Comparator|passive intervention|
88889360|NCT01440166|Experimental|Cohort 1 / Dose level 1|Single dose orally: CAT-1004 Dose level 1 or placebo
88889361|NCT01440166|Experimental|Cohort 2 / Dose level 2|Single dose orally: CAT-1004 Dose level 2 or placebo
88889362|NCT01440166|Experimental|Cohort 3 /Dose level 3|Single dose orally: CAT-1004 Dose level 3 or placebo
88889363|NCT01440166|Experimental|Cohort 4/ Dose level 4|Single dose orally: CAT-1004 Dose level 4 or placebo
88889364|NCT01440166|Experimental|Cohort 5/ Dose level 5|Single dose orally: CAT-1004 Dose level 5 or placebo
88889365|NCT01440166|Experimental|Cohort 2/ Dose level 2 ( FE)|Single dose orally (Under fed conditions): CAT-1004 Dose level 2 or placebo
88889366|NCT01440166|Experimental|Cohort 3/ Dose level 3 (FE)|Single dose orally (Under fed conditions): CAT-1004 Dose level 3 or placebo
88889367|NCT01440166|Experimental|Cohort 6 / Dose level 6 (FE)|Single dose orally (Under fed conditions) CAT-1004 Dose level 4 or placebo Subjects may be reenrolled from Cohort 4.
88889368|NCT01440166|Experimental|Cohort 7 / Dose level 7 (FE)|Single dose orally (Under fed conditions)CAT-1004 Dose level 5 or placebo Subjects may be reenrolled from Cohort 5.
88889369|NCT01440192|Experimental|Cohort A: 1 Unit PDA001 (cenplacel-L)|
88889370|NCT01440192|Experimental|Cohort B: 1 Unit PDA001 (cenplacel-L)|1 unit PDA001(cenplacel-L)
88889371|NCT01440205|Experimental|Easy list of healthy habits|"In this condition, participants will be prompted to think about a list of healthy behaviors and check off (privately - they will never send this flyer back or show it to anyone) whether yes they conform to the healthy habit or no they do not. The list of healthy behaviors is a list that most people will find fairly easy, and thus most participants will answer yes to each habit. The final question will be a prompt to get a flu shot. The hope is that when people realize how healthy their habits are, it will seem natural to them to engage in yet another healthy habit and receive a flu shot."
88889372|NCT01440205|Experimental|Challenging list of healthy habits|"In this condition, participants will be prompted to think about a list of healthy behaviors and check off (privately - they will never send this flyer back or show it to anyone) whether yes they conform to the healthy habit or no they do not. The list of healthy behaviors is a list that most people will find fairly difficult, and thus most participants will answer no to each habit. The final question will be a prompt to get a flu shot. The hope is that when people realize how unhealthy their habits are, it will seem wise to engage in one healthy habit that is easy (to make up for other bad behaviors) and receive a flu shot."
88889373|NCT01440205|Experimental|Control|A control condition with no list of healthy behaviors.
88889374|NCT01440218||Patients with idiopathic diseases|Study population is limited to individuals with a rare severe illness, and/or their family members.
88889375|NCT01440231|Placebo Comparator|Arm 1|
88889376|NCT01440231|Experimental|Arm 2|
88889377|NCT01440231|Experimental|Arm 3|
88889378|NCT01440231|Experimental|Arm 4|
88889379|NCT01440231|Experimental|Arm 5|
88889380|NCT01440270|Experimental|Neo-adjuvant Erbitux-based chemotherapy|Neo-adjuvant Erbitux-based chemotherapy before surgery: Erbitux, Docetaxel, Cisplatin.
88889381|NCT01440309|Experimental|allogenic mesenchymal stem cells (MSCs)|Patients who have primary biliary cirrhosis.
89412769|NCT03618927|Experimental|Daily physical activity intervention|The intervention consisted of a DPA program designed by a national organization with expertise in school-based physical activity programming and delivered in school by teachers. The program was offered to students in grades 4 through 8 and consisted of 20 minutes of structured DPA in school for 20 consecutive weeks. The DPA activities included jumping jacks, squats, running and other body weight exercises.
89412770|NCT03618927|No Intervention|Control - treatment as usual|Participants in control classes completed regular school activities as per the Ontario curriculum.
89412771|NCT03489044|Experimental|Active treatment arm (Levetiracetam)|When in the active arm, after a baseline visit, participants will up-titrate Levetiracetam in 250mg steps at intervals of one week to Levetiracetam 500mg twice daily (two tablets twice daily). Participants will be maintained on Levetiracetam 500mg bd for four weeks and have a further full assessment at 8 weeks after being on Levetiracetam. Participants will then down-titrate Levetiracetam by 250mg every week until weaned to nil.
89412772|NCT03489044|Placebo Comparator|Control arm (placebo oral tablets)|When in the control arm, after a baseline visit, participants will up-titrate placebo (manufactured to look identical to Levetiracetam 250mg) in one tablet steps at intervals of one week to two tablets twice daily. Participants will be maintained on placebo for four weeks and have a further full assessment at 8 weeks after being on placebo. Participants will then down-titrate placebo by one tablet every week until weaned to nil.
89412773|NCT02630654||GEP NETs|Patients with a suspected diagnosis of metastatic GEP NETs
88889382|NCT01440309|Active Comparator|ursodeoxycholic acid (UDCA)|Patients who have primary biliary cirrhosis.
89412774|NCT02630654||Healthy controls|Healthy controls matched by age and gender.
89412775|NCT01344369|Experimental|Investigational Test Product|Norethindrone/Ethinyl Estradiol 0.4 mg/0.035 mg Chewable Tablets (Teva)
89412776|NCT01344369|Active Comparator|Reference Listed Drug|FEMCON® Fe 0.4 mg/0.035 mg Chewable tablets (Warner Chilcott)
89412777|NCT03491306|Active Comparator|Group 1|patients will receive partial denture constructed from breflex material
89412778|NCT03491306|Experimental|Group 2|patients will receive partial denture constructed from PEEK material
88889383|NCT01440348|Experimental|Achilles allograft|
89412779|NCT03491072|Experimental|Transcutaneous electrical nerve stimulation (TENS)|Patients will receive IV fentanyl 1µg /Kg with the application of conventional TENS in which constant mode will be chosen. Assessment of pain will be done using visual analogue scale (VAS), every 10 minutes. If VAS ≥ 3 this indicates giving IV increments of 20µg of fentanyl.
88889384|NCT01440361|Experimental|Belimumab|Reconstituted solution for intravenous infusion
88889385|NCT01440361|Placebo Comparator|Normal saline|Solution for intravenous infusion
88889386|NCT01440400|No Intervention|Conventional spinal anesthesia|
88889387|NCT01440400|Experimental|Ultrasound guided spinal anesthesia|
88889388|NCT01440426|Active Comparator|Autologous connective tissue graft|Soft tissue harvested from patient palate
88889389|NCT01440426|Experimental|Collagen Matrix Construct|Mucograft collagen matrix manufactured by Geistlich AG, Switzerland
88889390|NCT01440439|Active Comparator|Insulin detemir|Metabolism during and after submaximal exercise during treatment with insulin detemir
89412780|NCT03491072|Active Comparator|Fentanyl|Patients will receive IV fentanyl 1µg /Kg. Assessment of pain will be done using visual analogue scale (VAS), every 10 minutes. If VAS ≥ 3 this indicates giving IV increments of 20µg of fentanyl.
89412781|NCT03503409|Experimental|AG-120|Subjects enrolled will receive continuous 28-day cycles of AG-120 - 500 mg. AG-120 will be dispensed on Day 1 of each treatment cycle
89412782|NCT03490994|Experimental|Rivaroxaban|Rivaroxaban
89412783|NCT03490994|Active Comparator|Warfarin|warfarin + enoxaparin
88889391|NCT01440439|Active Comparator|Insulin glargine|Metabolism during and after submaximal exercise during treatment with insulin glargine
88889392|NCT01440478|Experimental|LY2140023 + ammonium chloride|1 g of ammonium chloride administered orally every 3 hours for 33 hours (totaling 12 doses) in combination with a single 80 mg dose of LY2140023 administered orally 17 hours after first dose of ammonium chloride (acidified urine). All participants will receive the three treatments in a randomized order. There will be a minimum of a 5 day wash out period between treatment periods.
88889393|NCT01440478|Experimental|LY2140023 + sodium bicarbonate|4 g of sodium bicarbonate administered orally every 4 hours for 32 hours (totaling 9 doses) in combination with a single 80 mg dose of LY2140023 administered orally 18 hours after first dose of sodium bicarbonate (alkalized urine). All participants will receive the three treatments in a randomized order. There will be a minimum of a 5 day wash out period between treatment periods.
89412784|NCT03179462|Experimental|Pork intake|Subjects will consume 2 ounces of cooked lean pork following diet normalization for 3 days.
89412785|NCT03179462|Experimental|Mixed nuts intake|Subjects will consume 1 ounce of mixed nuts following diet normalization for 3 days.
89412786|NCT03179462|Experimental|Tofu intake|Subjects will consume 2 ounces of tofu following diet normalization for 3 days.
89412787|NCT02031705|Active Comparator|cavotricuspid isthmus ablation|Isthmus ablation was performed in paroxysmal atrial fibrillation patients.
88889394|NCT01440478|Experimental|LY2140023|A single 80 mg dose of LY2140023 administered orally (normal urine). All participants will receive the three treatments in a randomized order. There will be a minimum of a 5 day wash out period between treatment periods.
88889395|NCT01440491|Other|physiotherapy orientated|"G1 patients were orientated by the physiotherapist during the performance of physiotherapy exercises, using the booklet~G2 received the booklet to self perform the physiotherapy exercises"
88889396|NCT01440530|Experimental|Educational Intervention|
88889397|NCT01440530|Active Comparator|Control Group (usual care)|
88889398|NCT01440582|Experimental|Panobinostat + Bortezomib + Lenalidomide + Dexamethasone|"Induction Starting Doses: Lenalidomide 25 mg orally daily on days 1-14; Bortezomib 1.3 mg/m^2 intravenous (IV) daily on days 1, 4, 8 and 11; Dexamethasone 20 mg orally daily on days 1, 2, 4, 5, 8, 9, 11, 12 and Panobinostat orally 10 mg on days 1, 3, 5, 8, 10 and 12. Induction therapy consists of 21 day cycle in Part A and 28 day cycle in Part B.~Symptom Questionnaire completed on day 1 of each cycle."
88889399|NCT01440608|Experimental|Zinc therapy|High-dose zinc, equivalent 20 mg elemental zinc, to be given once per day for 14 days
88889400|NCT01440608|Experimental|Albendazole|Albendazole to be given once on the day of enrollment. Placebo will then be given for 13 days following.
88889401|NCT01440608|Placebo Comparator|Placebo|Placebo will be given for 14 days
88889402|NCT01440621|Active Comparator|Arm M|Will be treated with Tab Modafinil (generic) 100mg Once a Day in the Morning starting from Day 1 of RT till the first follow-up.
88889403|NCT01440621|Placebo Comparator|Arm P|Will be given placebo (Tab Pyridoxine 10mg) which physically resembles Tab Modafinil 100mg.
88889404|NCT01440660||Leaking Phenotype|Retinal thickness (RT) increase (increase in RT above normal range as measured by OCT, considering the macular thickness normative data) in the central subfield, the inner ring and/or the outer ring.
88889405|NCT01440660||Ischemic Phenotype|Neovascular disease activity as shown by microaneurysms (MA) turnover (MA formation rate >= 2, i.e. number of new MA per year) computed from CFP using the RetmarkerDR software.
88889406|NCT01440673|Active Comparator|aprepitant 125mg|NK1 receptor antagonist
88889407|NCT01440673|Active Comparator|Aprepitant 80 mg|
88889408|NCT01440686|Experimental|HL-032 30mg|A single dose 30mg administered orally
88889409|NCT01440686|Experimental|HL-032 60mg|A single dose 60mg administered orally
88889410|NCT01440686|Experimental|HL-032 120mg|A single dose 120mg administered orally
88889411|NCT01440712|Experimental|Gastrografin|Patients located in this group will be treated with the administration of 100 ml of gastrografin by the nasogastric tube, only once, after the diagnosis of postoperative ileus.
88889412|NCT01440712|Placebo Comparator|physiological serum|Patients included in this group will be treated with 100 ml of physiological serum 0,9% by the nasogastric tube, only once, after the diagnosis of postoperative ileus.
88889413|NCT01440725|Experimental|PRP|Administration of 4-8cc of autologous Platelet-rich plasma (PRP)into the muscle wound after the evacuation of the haematoma.
88889414|NCT01440725|Active Comparator|Evacuation of haematoma|Evacuation of the hematoma, and simulation of the administration of PRP
88889415|NCT01440738|Experimental|health workshops|Health promotion group intervention
88889416|NCT01440738|No Intervention|comparison group|usual care
88889417|NCT01440751|Experimental|ologen Collagen Matrix|When performing glaucoma surgery, a trabeculectomy, use ologen Collagen Matrix instead of MMC before closing the conjunctiva
88889418|NCT01440751|Active Comparator|Mitomycin-C (MMC)|When performing glaucoma surgery, a trabeculectomy, use MMC as antifibrotic agent before closing the conjunctiva
88889419|NCT01440790|Placebo Comparator|Glucose bolus alone|50g glucose dissolved in water and consumed within 5 minutes.
88889420|NCT01440790|Experimental|Glucose sipping alone|50g glucose dissolved in water and consumed gradually over 3 hours.
88889421|NCT01440790|Active Comparator|Glucose bolus plus 1g vitamin C|50g glucose dissolved in water and consumed in 5 minutes with 1g vitamin C
88889422|NCT01440790|Experimental|Glucose sipping plus 1g vitamin C|50g glucose dissolved in water and consumed gradually of 3 hours. In addition 1g vitamin C will be taken with the first mouthful of glucose solution.
88889423|NCT01440829|Experimental|LOLA group|Intervention: LOLA (30g per day) for a week.
88889424|NCT01440829|No Intervention|Control group|Patients will not be treated with LOLA.
88889425|NCT01440842|Experimental|Closed-loop (Model Predictive Control Algorithm)|
88889426|NCT01440842|Active Comparator|Open loop (Standard treatment)|
88889427|NCT01440855|Active Comparator|CIS Fact Sheet (CIS: Cancer Information Service)|CIS Fact Sheet, available on the Cancer Information Service website. Used to control for attention. 5-page document provides information about the CIS:What is it, How can CIS information specialists help me, How can I use CIS's services. Also includes definitions of glossary terms and a table of email and website addresses.
88889428|NCT01440855|Experimental|Facing Forward booklet|NCI's Facing Forward 61-page booklet, which describes common feelings and reactions that cancer survivors experience during the re-entry phase and offers behavioral recommendations to help them through this period, i.e., ways of dealing with common problems and guidelines for managing physical, social, and emotional health. Booklet sections: Congratulations on Finishing Your Cancer Treatment, Getting Follow-up Medical Care, Ways to Manage Physical Changes, Body Changes and Intimacy, Your Feelings, Social and Work Relationships, Reflection, 6-page Appendix, which provides information on Financial and Legal Matters, and Resource Organizations.
88889429|NCT01440868|Experimental|SLI group|In this group the preterm infants will receive sustained lung inflation (SLI) with mask in the delivery room
88889430|NCT01440868|No Intervention|Control|Preterm infants will be assisted in the delivery room without sustained lung inflation.
88889431|NCT01440894||Body Analysis|
88889432|NCT01440907|Experimental|Intervention Group|Those age 65 or older who are discharged from Maimonides Medical Center to home during the study period and enrolled in the Care Coordination Program
88889433|NCT01440907|No Intervention|Control Group|Those age 65 or older who are discharged from Maimonides Medical Center to home
88889434|NCT01440933|Active Comparator|Magnesiumsulphate|
88889435|NCT01440933|Placebo Comparator|Physiologic saline|
88889436|NCT01440985|Experimental|Nicotine Gum|After being randomized to the gum or tablet, dosage will be based on baseline level of nicotine dependence. Highly dependent smokers will receive nicotine 4 mg gum, while low nicotine-dependent smokers will receive nicotine 2 mg gum to help them quit. Subjects will be advised to use the treatment frequently, according to the product labeling, in order to minimize or avoid symptoms of tobacco withdrawal. Study medication will be used for 12 weeks.
88889437|NCT01440985|Active Comparator|Nicotine Microtab|After being randomized to the gum or tablet, subjects will receive instructions according to their baseline level of nicotine dependence. Highly dependent smokers will be instructed to use a 4 mg dosage of the Microtab (2 x 2 mg tablets), while low nicotine-dependent smokers will be instructed to use a 2 mg dosage of the Microtab to help them quit. Subjects will be advised to use the treatment frequently, according to the product labeling, in order to minimize or avoid symptoms of tobacco withdrawal. Study medication will be used for 12 weeks.
88889438|NCT01440998|Experimental|Treatment (dasatinib, paclitaxel, carboplatin)|Patients receive induction therapy comprising dasatinib PO QD for 14 days. *Beginning 7 days later, patients receive paclitaxel IV over 3 hours and carboplatin IV on day 1, and dasatinib PO QD on days 1-21. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
89412788|NCT02031705|Placebo Comparator|control group|Control group was performed no additional cavotricuspid isthmus ablation.
88889439|NCT01441011|Experimental|Group (GRP) phone counseling|The group phone counseling includes 26 bi-weekly phone sessions from 6 to 18 months and focuses on group problem-solving. Women continue in the same group as in weight loss intervention phase.
88889440|NCT01441011|Active Comparator|Mail-based Comparison Condition|Participants in this group will receive a newsletter by mail every other week for 12 months starting after the initial 6 month weight loss period. The newsletters will provide problem-solving tips and will review nutrition and physical activity information.
88889441|NCT01441024|Experimental|1|DAS181
88889442|NCT01441024|Placebo Comparator|2|Placebo
88889443|NCT01441128|Experimental|Arm 1|The starting doses will be 200 mg by mouth, twice a day of PF 02341066 in tablet form and 30 mg by mouth once a day of PF 0029804 in tablet form. Thedose of each drug in the combination will be escalated or de-escalated until the maximum tolerated combined dose is reached. Patients will then be treated with the maximum tolerated combined dose.
88889444|NCT01441128|Experimental|Arm 2|45 mg by mouth once a day of PF-00299804 in tablet form until progressive disease and then the maximum tolerated combined dose of PF-02341066 (given by mouth twice a day in tablet form) and PF-00299804 (given by mouth once a day in tablet form).
88889445|NCT01441141||Arm 1|Subjects with SCD
88889446|NCT01441141||Arm 2|Subjects without SCD
88889447|NCT01441154||Group 1|Adults with clinical indication for withdrawal from thyroid hormone replacement therapy in preparation for nuclear medicine imaging or therapeutic procedures with radioactive iodine
88889448|NCT01441193|Experimental|HIV-1 Tat/delta-V2 Env combined vaccine|Tat 7.5 microg and delta-V2 Env 100 microg associated proteins administered i.d. (priming) at week 0, 4 and 8 or i.m. (boosting) at weeks 24 and 36
88889449|NCT01441193|Active Comparator|HIV-1 delta-V2 Env vaccine|delta-V2 Env 100 microg administered i.d. (priming) at week 0, 4 and 8 or i.m. (boosting) at week 24 and 36
88889450|NCT01441193|Active Comparator|HIV-1 Tat vaccine 7.5 microg|Tat 7.5 microg administered i.d. (priming) at week 0, 4 and 8 or i.m. (boosting) at week 24 and 36
88889451|NCT01441193|Active Comparator|HIV-1 Tat vaccine 30 microg|Tat 30 microg administered i.d. at week 0, 4 and 8
88889452|NCT01441206|Other|rifampin|Cohort 1 will include infants who will be receiving up to 4 doses rifampin per study protocol.
88889453|NCT01441206|No Intervention|rifampin per standard of care|Cohort 2: Receiving rifampin per standard of care
88889454|NCT01441219|Experimental|Colon 2|using Colon 2 capsule in detecting bleeding events in small bowel
88889455|NCT01441232|Experimental|Treatment A|
88889456|NCT01441232|Experimental|Treatment C|
88889457|NCT01441232|Active Comparator|Treatment B|
88889458|NCT01441258|Experimental|Dialectical Behavior Therapy Skills (DBT-S) Groups|Patients in the Dialectical Behavior Therapy Skills (DBT-S) group will receive the newly adapted 18-week group-skills training protocol, one-and-a-half hours in length, with weekly homework assignments to facilitate skill generalization.
88889459|NCT01441258|Placebo Comparator|Wait List-Treatment as Usual|Participants assigned to the wait-list condition will be given the opportunity to participate in a DBT skills group after their 18-week wait period has ended.
88889460|NCT01441271|Active Comparator|total abdominal colectomy|the standard of care for fulminant clostridium difficile colitis is a total abdominal colectomy
88889461|NCT01441271|Experimental|Ileal diversion and lavage|The tested intervention in this trial will be: intraoperative colonic lavage using a high volume polyethylene glycol/electrolyte solution, that will clear Clostridium difficile infection resulting in eradication of FCDC while preserving the colon.
88889462|NCT01441284|Active Comparator|Process 1|10 weeks of pramipexole treatment 2 weeks wash-out period (cross-over) 10 weeks placebo treatment
88889463|NCT01441284|Placebo Comparator|Process 2|10 weeks of placebo treatment 2 weeks wash-out period (cross-over) 10 weeks pramipexole treatment
88889464|NCT01441297|Experimental|study arm|BIBF 1120 study arm
88889465|NCT01441310|Experimental|Laparoscopic sentinel node navigation surgery|Laparoscopic sentinel node navigation surgery
88889466|NCT01441323|No Intervention|Control (C)|
88889467|NCT01441323|Experimental|Nutrition (N)|
88889468|NCT01441323|Experimental|Strength Training & Nutrition (ST)|
88889469|NCT01441336|Experimental|Laparoscopic gastrectomy|"Laparoscopic gastrectomy procedure:~D2 lymphadenectomy & total omentectomy in case of tumor with serosa exposure under laparoscopic exploration"
88889470|NCT01441362|Active Comparator|90 degrees rotation|Double-lumen tube intubation with 90 degrees rotation
88889471|NCT01441362|Experimental|180 degrees rotation|Double-lumen tube intubation with 180 degrees rotation
88889472|NCT01441375||Sickle cell patients non-transfused|
88889473|NCT01441375||Sickle cell patients transfused with no ICT|
88889474|NCT01441375||Sickle cell patients transfused with ICT|
89412789|NCT03618459||Breast-surgery patients|A consecutive cohort of adult patients undergoing breast surgery with a combined anesthesia technique, employing a thoracic single-shot paravertebral block performed before surgery. Operations performed were in all cases unilateral tumor resections, lumpectomies and mastectomies without axillary lymphadenectomy.
89412790|NCT02031783|Experimental|mixture of glucose and fructose|mixture of glucose and fructose
88889475|NCT01441388|Experimental|Dose Escalation|Histological or cytological diagnosis of advanced/metastatic solid tumor that is resistant to standard therapy or for which no standard therapy is available.
88889476|NCT01441388|Experimental|Expansion Population 1|Patients with histologically confirmed metastatic renal cell cancer with no prior systemic therapy directed at the malignant tumor.
88889477|NCT01441388|Experimental|Expansion Population 2|Patients with histologically confirmed metastatic renal cell cancer whose prior systemic therapy directed at the malignant tumor was single agent VEGF inhibitor and who now have acquired resistance to this treatment.
88889478|NCT01441388|Experimental|Expansion Population 3|Patients with histologically confirmed glioblastoma whose disease has failed on previous therapy, and which must have included treatment with external beam radiation and temozolomide chemotherapy, and who now have radiographically recurrent or progressive disease.
88889479|NCT01441388|Experimental|Expansion Population 4|Patients with histologically confirmed advanced-stage (unresectable or metastatic) hepatocellular carcinoma who have not received previous systemic therapy directed at the malignant tumor will be eligible to receive crizotinib plus sorafenib, should this combination be tested.
88889480|NCT01441427|Experimental|G-CSF|
88889481|NCT01441427|Experimental|EPO|
88889482|NCT01441427|Experimental|G-CSF and EPO|
88889483|NCT01441427|Placebo Comparator|Placebo|
88889484|NCT01441453|Other|Preoperative FibroScan|
88889485|NCT01441518|Experimental|Home care|
88889486|NCT01441518|Active Comparator|Hospital care|
88889487|NCT01441531|Experimental|Gabapentin|Gabapentin 600 mg po given 1 hour before surgery
88889488|NCT01441531|Placebo Comparator|Placebo sugar pill|
89412791|NCT02031783|Active Comparator|Glucose|Single glucose
89412792|NCT03618069|No Intervention|routine investigation|
89412793|NCT03618069|Active Comparator|study protocol CCI (CTA, cardiac CT) and MRI scans|
89412794|NCT01360762|Experimental|Pentamidine Secondary Prophylaxis (PSP)|"Patients with co-infection of human immunodeficiency virus (HIV)and visceral leishmaniosis (VL), having being treated for VL, are allocated to pentamidine secondary prophylaxis, to prevent VL relapses. The treatment period is of 12 months, plus an extended treatment period of 0 to 6 months depending on the immunosuppression status, plus 12 months follow-up after the extended treatment period."
88889489|NCT01441544|Experimental|VAREITY|
88889490|NCT01441544|Experimental|NON-VARIETY|
88889491|NCT01441609||the value of anti-HBs =0 mIU/ml|Recent serological testing result show HBsAg, HBeAg, anti-HBe, anti-HBc, HBV DNA and Pre-S1 should be negative. had vaccinated hepatitis B vaccine and the value of anti-HBs be zero.
88889492|NCT01441609||the value of anti-HBs≤5mIU/ml|Recent serological testing result show HBsAg, HBeAg, anti-HBe, anti-HBc, HBV DNA and Pre-S1 should be negative. had vaccinated hepatitis B vaccine and the value of anti-HBs≤5mIU/ml.
88889493|NCT01441609||5mIU≤anti-HBs≤10mIU/ml|Recent serological testing result show HBsAg, HBeAg, anti-HBe, anti-HBc, HBV DNA and Pre-S1 should be negative. had vaccinated hepatitis B vaccine and the value of 5mIU≤anti-HBs≤10mIU
89192769|NCT06075836||Readers/Participants|"Reader Selection: 30 readers will be selected from the following five clinical specialty groups:~emergency medicine (ED)~adult intensive care (ICU)~adult general medicine (AGM)~radiographers (Rad)~general radiologists~Each specialty group consists of 6 members of ranked seniority. For the physicians this consists of:~Two 'Juniors' (Foundation Year 1 - Specialty Training 2 years)~Two 'Middle Grades' (Registrar from Specialty Training 3 to 6 years)~Two Consultants~For the radiographers, this consists of:~Two 'Junior/Newly qualified radiographers' (up to 18 months experience post qualification)~Two 'Mid-experience radiographers' (approx. 3 years' experience)~Two 'Reporting radiographers' (5+ years' experience)"
89192770|NCT06075836||Ground truthers|Two consultant thoracic radiologists. A third senior thoracic radiologist's opinion (>20 years experience) will undertake arbitration.
89192771|NCT06075511||Renal Failure Sleeve Gastrectomy|Subjects that have renal failure and are undergoing a sleeve gastrectomy per standard clinical care will perform a 6-minute walk distance (6MWD) evaluation, activity monitoring, continuous glucose monitor (CGM), blood pressure monitoring, complete mixed meal test, and composition body scan to gather additional information for researchers.
89412795|NCT04382924|Experimental|Treatment Arm A|NP-120 (Ifenprodil) 20 mg TID + Standard of Care
89412796|NCT04382924|No Intervention|Control Arm|Standard of Care only
89412797|NCT04382924|Experimental|Treatment Arm B|NP-120 (Ifenprodil) 40 mg TID + Standard of Care
89412798|NCT05034016|Experimental|HM experimental group|Intraocular implant test product
89412799|NCT05034016|No Intervention|Natural observation control group|Natural observation of the disease changes, no surgical intervention
89412800|NCT05693233|Experimental|Healthy person|Healthy person
89412801|NCT02816996|Experimental|Hand-holding|Subjects will be randomized to be in the handholding, stress ball, or control study arms. The randomization will be 1:1:1.
89412802|NCT02816996|Experimental|Stress Ball|Subjects will be randomized to be in the handholding, stress ball, or control study arms. The randomization will be 1:1:1.
88889494|NCT01441609||anti-HBs≥1000mIU|Recent serological testing result show HBsAg, HBeAg, anti-HBe, anti-HBc, HBV DNA and Pre-S1 should be negative. had vaccinated hepatitis B vaccine and the value of anti-HBs≥1000mIU.
88889495|NCT01441622|Experimental|AL539|Device AL539
89412803|NCT02816996|No Intervention|Nothing|Subjects will be randomized to be in the handholding, stress ball, or control study arms. The randomization will be 1:1:1.
89412804|NCT05439343|Experimental|Adductor canal block|Allocation of which limb is to receive adductor canal block is determined by randomization, using a computer-generated random sequence and opaque sealed envelopes. After completion of the TKA surgery and surgical suturing, adductor canal block will be performed by an anesthesiologist. Under ultrasound guidance, the femoral artery and the saphenous nerve are identified in the middle one-third of the thigh, deep to the sartorious muscle in the adductor canal. The sartorious and adductor muscles form the roof and the floor of the canal, respectively. Following skin infiltration, 20 mL of 0.25% bupivacaine with 1:400000 epinephrine is injected through a 3-inch, 23-gauge, short bevel block needle.
89412805|NCT05439343|Experimental|Local infiltration|Allocation of the other limb to receive local infiltration is determined after randomization of the knee allocated for adductor canal block in the same patient. The chosen knee is infiltrated by the orthopedic surgeon intraoperatively with a 150-ml mixture of 150 mg bupivacaine, 10 mg morphine, 30 mg ketorolac, and 0.5 mg epinephrine. The posterior capsule is infiltrated before placement of the prosthesis, and the periarticular and superficial soft tissues are infiltrated after the prosthesis is in place and before wound closure.
89412806|NCT03097042|Active Comparator|Study group|The catheter will be pulled back slowly and without rotation
89412807|NCT03097042|Active Comparator|Control Group|The catheter will be pulled back by rotating 360 degrees round itself
89412808|NCT00002601|Experimental|Doxorubicin/Ifosfamide + Melphalan/CDDP + PSCT|"Cycle 1 Day -8 through Day -4 (96h) Doxorubicin 150 mg/m2 (CI) + Ifosfamide 14 g/m2 mixed with mesna (CI) Day -3 Mesna 3.5 g/m2 over 24 h Day -2 12.5% of stem cell reinfused.~Cycle2 Day -11 Melphalan 75 mg/m2 + Cisplatin 100 mg/m2 Day -10 thru Day -6 G-CSF 5ug/kg Day -4 Melphalan 75 mg/m2 + Cisplatin 100 mg/m2 Day -3 12.5% if stem cell reinfused Day 0 37.5% of stem cell reinfused"
88889496|NCT01441648||experimental group|(1) age 20-35 years old (2) myopia less than -6.00D and astigmatism less than -1.50D (3) previous soft contact lens wear discontinued for at least 2 weeks. Exclusion criteria includes: (1) subjects with previous Rigid Gas Permeable (RGP) wear (2) any ocular inflammation or infection, dry eye syndrome, glaucoma, ocular trauma or surgery, and topical medication instillation (3) diabetic mellitus (4) pregnancy (5) any corneal disorders or dystrophies.
88889497|NCT01441661||Sunitinib Renal Cell Carcinoma|Patients diagnosed with Renal Cell Carcinoma (RCC) and treated with Sunitinib from 2008 to present will be eligible. This will include current active patients as well as patients who have expired and have medical records available.
88889498|NCT01441674|Experimental|Animal Assisted Therapy Visit 1|Standard OT Therapy with Animal Assisted Therapy at Visit 1 and Not at Visit 2
88889499|NCT01441674|Experimental|Animal Assisted Therapy at Visit 2|Standard OT Therapy with Animal Assisted Therapy at Visit 2 and not Visit 1
88889500|NCT01441700|Active Comparator|Prone position|
88889501|NCT01441700|Active Comparator|Supine position|
88889502|NCT01441713||Pharmaceutical group|Patients in pharmaceutical castration treatment for advanced prostate cancer
88889503|NCT01441713||Surgical group|Patients having undergone surgical castration treatment for advanced prostate cancer
88889504|NCT01441726||Training of staff|
88889505|NCT01441726||No training of staff|
88889506|NCT01441739||NEC suspected - Final diagnosis NEC|
88889507|NCT01441739||NEC suspected - Final diagnosis no NEC|
88889508|NCT01441739||Controls|
88922033|NCT05946252|Active Comparator|Control Group|"Risky pregnant women who have completed the 12th week of pregnancy, received inpatient treatment and have any of the following risk factors will be included in the study:~Pregnant women who are at risk for obstetric outcomes such as cervical insufficiency, multiple pregnancy and uncontrolled gestational diabetes, and physical activity restriction is recommended due to these conditions, and exercise is contraindicated,~Pregnant women with a maternal body mass index above 30, which causes them to be physically inactive"
89192772|NCT06068842||Participants Undergoing Chart Review|Participants treated for non small cell lung cancer undergoing chart review and retrospective mesenchymal epithelial transition (MET) overexpression (OE) testing of tissue biopsies.
88922034|NCT05940415||Patients with low-risk of prostate cancer based on USTC diagnostic model and serum PSA levels.|Patients with PSA between 4 to 10 ng/ml and USTC model predicted probability of cancer less than 0.05 (https://ustcprostatecancerprediction.shinyapps.io/dynnomapp/).
89005464|NCT04990882||Low Experience Group|Nuclear medicine physicians or radiologists with a prior experience with 68Ga-FAPI PET/CT of less than 30 studies.
89192773|NCT06066736||Patients with Ventilator-associated pneumonia|Patients having presented an episode of ventilator-associated pneumonia, undergoing invasive mechanical ventilation ≥ 48h
89192774|NCT06066099|Experimental|Part A: Single Ascending Doses|"Participants will be randomized to receive a single oral dose of AP31969 or matching placebo in 1 of 5 groups.~Participants in an additional food effect assessment group will be randomized to receive 2 single oral doses of AP31969 or matching placebo; 1 dose in fasted and 1 dose in fed state in a 2-period, fixed-sequence design (first fasted, then fed with at least 1 week washout between periods)."
89192775|NCT06066099|Experimental|Part B: Multiple Ascending Doses|Participants will be randomized to receive multiple oral doses of AP31969 or matching placebo for 10 days in 1 of 4 groups.
89192776|NCT06065475|Experimental|Thyroid Cartilage Plane Block Group (T Group)|Ultrasound-guided bilateral Thyroid Cartilage Plane Block is performed using the thyroid cartilage plate as an anatomical landmark. 3ml of 2% lidocaine is injected on the surface of the thyroid cartilage plate. Subsequently, perform fiberoptic bronchoscope-guided oropharyngeal, subglottic, and tracheal surface anesthesia. After completing surface anesthesia, perform fiberoptic bronchoscope-guided tracheal intubation, securing it properly.
89192777|NCT06065475|No Intervention|the Control Group （C Group）|Patients in the C Group receive airway surface anesthesia using the fiberoptic bronchoscope-guided local anesthetic spray method throughout the procedure.
89192778|NCT06065189|Experimental|CS-101 injection|Autologous CD34+(cluster of differentiation 34) hematopoietic stem cell suspension modified by in vitro base editing technique
89192779|NCT06064903|Experimental|CD7-CART01|"A single IV infusion of CD7-CART01 (CD7-directed chimeric antigen receptor T-cells) on Day 0 after lymphodepleting regimen.~Patients will receive the following lymphodepleting regimen:~Fludarabine 30 mg/m2 per day over 1 hour on days -6, -5, -4 and -3~Cyclophosphamide 1000 mg/m2 per day on days -4 and -3.~CD7-CART01 will be infused at the following dose levels:~DL1: 0.5 x 10^6 CAR+ cells/kg~DL2: 1 x 10^6 CAR+ cells/kg~If 2 DLTs are observed an additional DL0 of 0.25 x 106 CAR+ cells /kg will be explored."
89005465|NCT04990882||Intermediate Experience Group|Nuclear medicine physicians or radiologists with a prior experience with 68Ga-FAPI PET/CT of more than 30 studies and less than 300 studies.
89192780|NCT06061510|Experimental|fish oil group|Fish oil supplement capsules contained omega-3 polyunsaturated fatty acids supplied by Royal DSM Group, the Netherlands. Each 100 grams of fish oil capsules contains mainly 36.86 grams of EPA, 17.47 grams of DHA and other types of fatty acids.
89192781|NCT06061510|Placebo Comparator|The placebo group|The placebo for fish oil contained corn oil (Each 100 grams of corn oil contained 45.64 grams of linoleic acid, 25.62 grams of oleic acid, 17.0 grams of palmitic acid, and other fatty acids).
89192782|NCT06060509|Experimental|Wheat corn germ blended oil group|Participants in the intervention group replaced the daily cooking oil with wheat and corn germ oil, and were given 25-30 g of cooking oil per day according to the recommended intake of the Chinese Nutrition Society. Lunch and dinner were cooked using a uniform recipe for both intervention and control groups, and breakfast was self-cooked under the uniform dietary guidelines.
89192783|NCT06060509|Other|Peanut oil group|Participants in the Peanut oil group replaced the daily cooking oil with Peanut oil, and were given 25-30 g of cooking oil per day according to the recommended intake of the Chinese Nutrition Society. Lunch and dinner were cooked using a uniform recipe for both intervention and control groups, and breakfast was self-cooked under the uniform dietary guidelines.
89192784|NCT06060210|Placebo Comparator|Group A|50-ml volume of normal saline
89192785|NCT06060210|Active Comparator|Group B|50-ml volumes, and the ketamine concentration is 1 mg/ml
89192786|NCT06059586|Experimental|Pelvic health Assessment and Intervention|
89192787|NCT06049043|Experimental|Intervention to Help Orient Men to Excel (IN-HOME)|Professional development training for CHWs on African American and Latino male caregiver needs
89192788|NCT06049043|Other|Control|"AARP's English Care at Home resource webpage"
89192789|NCT06047470|Active Comparator|Kangaroo Care Arm (KC)|Lactating parents will be asked to arrive at the NICU 2 hours after they have fully expressed their breasts at home and to provide their infants with kangaroo care for 1 hour. Following KC and while still at the infant's bedside, lactating parents will be asked to pump from both of their breasts using a hospital grade pump available in the NICU. Study personnel will weigh the collected milk to determine the total volume of milk expressed by mass. The milk collected from both breasts will be gently swirled six times or more until the fat layer is incorporated in the bottle and will be combined into one bottle. Study personnel will take one 6 mL aliquot from the collected milk for compositional analysis. The remainder of the milk will be saved in the NICU per routine so that it can be fed to the infant later.
89199100|NCT02543307|Experimental|Nurse-led Patient Pathways|Patients were cared for under the three NPP developed for the orthopedic populations: NPP-1) patients with total hip arthroplasty; NPP-2) exploration and decompression of the spinal cord; and NPP-3) rotator cuff reconstruction. NPP are characterized by four principles: evidence-based nursing, patient and family centred care, comprehensive discharge planning beyond hospital discharge and nurses' responsibility for patients' processes. The principles support and strengthen patient and family preferences as well as formalize nursing activities, and therefore contribute to process transparency in relation to other health care professionals. Aims: to improve patients' and health care professionals' as well as institutional outcomes.
89005466|NCT04990882||High Experience Group|Nuclear medicine physicians or radiologists with a prior experience with 68Ga-FAPI PET/CT of more than 300 studies.
89005467|NCT00413829|Other|1|
89005468|NCT04999267|Experimental|INVEST Intervention|
88889509|NCT01441752|Experimental|Chemotherapy + TCM group|"The chemotherapy for NSCLC patients is a combination of Vinorelbine, 25mg/m2, d1, 8 and DDP, 75mg/m2, d1 (NP) giving three-weekly for four cycles.~Prescriptions formulated into granules origin from Professor Liu Jiaxiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe . Each package contained 20g of water-soluble herbal granules that were manufactured at a Good Manufacture Practice standard facility (Tian Jiang Ltd, Jiangyin, China). Each package was labeled with a serial number. The prescription form comprised the stock list with both the name and serial number."
88889510|NCT01441752|Placebo Comparator|Chemotherapy + placebo group|The chemotherapy for NSCLC patients is a combination of Vinorelbine, 25mg/m2, d1, 8 and DDP, 75mg/m2, d1 (NP) giving three-weekly for four cycles.we compromise the raw materials for the placebo including 10% of Chinese medicine, food color and artificial flavors. The placebo and therapeutic packages were stored in different cabinets, and only the dispensing technician knew the contents of the packages.
88889511|NCT01441778|Active Comparator|NSS irrigation salt|
88889512|NCT01441778|Experimental|BHS nasal irrigaiton salt|
88889513|NCT01441791|Experimental|Lung protective strategy ventilation|Lung protective strategy ventilation: PEEP at 12 cmH2O, Recruitment maneuvers (after intubation, after any disconnection from the mechanical ventilator, directly before detubation)
88889514|NCT01441791|No Intervention|Conventional Strategy|"PEEP at maximum 2 cmH2O, if possible 0 cmH2O~No recruitment maneuvers Patients are randomized and intra-operatively ventilated with conventional strategy (PEEP at maximum 2 cmH2O without recruitment maneuvers)."
88889515|NCT01441804|Experimental|24-Week treatment group|Genotype 1 chronic hepatitis C patients with IL28B CC Polymorphism and rapid virological response(undetectable HCV RNA at weeks 4) in this group will be treated with Peginterferon alfa-2a plus ribavirin for an additional 20 weeks
88889516|NCT01441804|Active Comparator|48-Week treatment group|Genotype 1 chronic hepatitis C patients with IL28B CC Polymorphism and rapid virological response(undetectable HCV RNA at weeks 4) in this group will be treated with Peginterferon alfa-2a plus ribavirin for an additional 44 weeks
88889517|NCT01441817|Other|Surgery|
88889518|NCT01441830|Sham Comparator|sham rESWT|
88889519|NCT01441830|Active Comparator|rESWT|
88889520|NCT01441856|Active Comparator|Open or Laparocopic Left|Open or Laparoscopic left hemihepatectomy
88889521|NCT01441856|Active Comparator|Open or Laparoscopic Right|Open or Laparoscopic right hemihepatectomy
88889522|NCT01441856|Active Comparator|Prospective registry|Prospective registry of patients that cannot be randomized (both open and laparoscopic left + right hemihepatectomy)
88889523|NCT01441869|Experimental|A|5-mg Onglyza (saxagliptin) tablet +1000-mg Diabex extended release tablet
88889524|NCT01441869|Experimental|B|5-mg saxagliptin/1000 mg metformin extended release fixed dose combination tablet
88889525|NCT01441869|Experimental|C|5-mg Onglyza (saxagliptin) tablet + 500-mg Diabex extended release tablet
88889526|NCT01441869|Experimental|D|5-mg saxagliptin/500 mg metformin extended release fixed dose combination tablet
88889527|NCT01441908|No Intervention|Control Group|Control Group
88889528|NCT01441908|Active Comparator|Statin|Receiving Statin
88889529|NCT01441921|Active Comparator|Control diet|Low-fat normocaloric diet (30% fat, 55% carbohydrates, 15% proteins)
88889530|NCT01441921|Experimental|Pistachio diet|Diet supplemented with 2 ounces of pistachio (35% fat, 50% carbohydrates adn 15% protein)
88889531|NCT01441934|Active Comparator|Sildenafil citrate|20 mg t.i.d.
88889532|NCT01441934|Placebo Comparator|Sugar pill|
88889533|NCT01441999|Active Comparator|Less rigid rods|Titanium rods that have a soft, plastic end
88889534|NCT01441999|Active Comparator|Rigid Rods|Titanium rods
88889535|NCT01442012|Active Comparator|Group A|Patients receive cutaneous stimulation and self-stimulation of acupuncture points Pericardium 6, Heart 7 and Stomach 25
88889536|NCT01442012|Sham Comparator|Group B|Patients receive cutaneous stimulation and self-stimulation of acupuncture points Gall Bladder 34, Kidney 6 and Liver 3
88889537|NCT01442025|Placebo Comparator|Cohort 1 =Control Group|the dose of IFX will be increased by 5 mg/kg (maximally 1 time) based on symptom relapse (usual clinical practice) Dose will be kept stable ofr the rest of the trial Dose decreases will not be allowed.
88889538|NCT01442025|Active Comparator|Cohort 2|Dose of IFX will be increased by 2.5 mg/kg (maximally 2 times) if the following criteria are met A dose increase is maintained for the following infusions
88889539|NCT01442025|Active Comparator|Cohort 3|Dose of IFX will be increased by 5 mg/kg (maximally 1 time) if the following criteria are met A dose increase is maintained for the following infusions
88922035|NCT05928546|Placebo Comparator|Group(I):scaling and root planing only|10 sites will receive non-surgical periodontal therapy (scaling and root planing) .
88889540|NCT01442051|Experimental|Acute Normovolemic Hemodilution|A pilot study will be performed. Intraoperative data including vital signs, procedures performed, and transfusions of allogenic blood will be collected prospectively. Postoperative outcomes, including transfusions of allogenic blood, perioperative complications, and 30-day mortality will be collected prospectively. These outcomes will be compared to historical controls to assess for the safety and efficacy of ANH in ovarian cancer cytoreductive surgery.
89412809|NCT05033704|Experimental|(Group A)|"Twenty-four of the 48 patients will receive an intraoperative intravenous infusion of 5% human plasma protein fraction PPF, (A group). PPF 5% Octapharma 5 % is a colloid solution containing (47.6-52.5% proteins, of which 45.6-52.5 gm/L albumin and 142.5-157.5 mmol/L sodium).~Fluids will be given targeting euvolemic state which is defined as central venous pressure (CVP) 5-10 mmHg or Stroke volume variation (SVV) of ≤ 13%. Central venous pressure (CVP) CVP of -1 to 1 mmHg or Stroke volume variation (SVV) of 18-21% (12) will be targeted during transaction times. The transfusion trigger will be Hemoglobin of ≤8 gm/dl."
89412810|NCT05033704|No Intervention|(Group RS)|24 patients will receive an intraoperative intravenous infusion of crystalloids (0.9 % normal saline and/ or Lactated Ringer's solution) (RS group). Fluids will be given targeting euvolemic state which is defined as central venous pressure (CVP) 5-10 mmHg or Stroke volume variation (SVV) of ≤ 13%. Central venous pressure (CVP) CVP of -1 to 1 mmHg or Stroke volume variation (SVV) of 18-21% (12) will be targeted during transaction times. The transfusion trigger will be Hemoglobin of ≤8 gm/dl.
88889541|NCT01442077|Active Comparator|arm 1|Series of 12 treatments, in which the subject will be treated twice a week for 3 weeks (6 treatments), then would be discontinuation of the study for 3 weeks, and at the end of this period will be treated twice a week for 3 weeks (6 treatments.
88889542|NCT01442077|Active Comparator|arm 2|Series of 12 treatments, in which the subject will be treated twice a week for 6 consecutive weeks, without intermission.
89412811|NCT03044431||Cell therapy treated|All patients/participants enrolled will undergo cell therapy
89412812|NCT03618303|Experimental|Interventional|All patients will undergo the same intervention of having a PET-MRI scan and optical coherence tomography.
89412813|NCT04335032|Experimental|Eicosapentaenoic acid gastro-resistant capsules|"Eicosapentaenoic acid free fatty acid (EPA-FFA) 500mg gastro-resistant capsules 2g daily (two capsules twice daily).~One capsule of EPA-FFA gastro-resistant capsules contains 500mg EPA-FFA in a capsule containing gelatin, glycerol, sorbitol, titanium dioxide, FD&C blue No. 1, hypromellose phthalate, dibutyl sebacate."
89412814|NCT04335032|Placebo Comparator|Placebo|Placebo capsules that cannot be visually differentiated from the active treatment
89412815|NCT03094936|Other|Group A|This group own twenty patients who met all the inclusion criteria. These will be treated with APC.
89412816|NCT03094936|Active Comparator|Group B|This group own twenty patients who met all the inclusion criteria. These will be treated with APC plus Endoscopic Suture Technique (OverStitch TM).
88889543|NCT01442077|Active Comparator|arm 3|Series of 8 treatments, in which the subject will be treated twice a week for two weeks (4 treatments), then would be discontinuation of the study for 3 weeks, and at the end of this period will be treated twice a week for two weeks (4 treatments).
88889544|NCT01442077|Active Comparator|arm 4|Series of 6 treatments, in which the subject will be treated once a week for 3 weeks (3 treatments), then would be discontinuation of the study for 3 weeks, and at the end of this period will be treated once a week for 3 weeks (3 treatments).
88889545|NCT01442116|Experimental|Hypertensives|
88889546|NCT01442142|Experimental|Appetitie Awareness|"Parents and kids assigned to this group with learn about appetite awareness and to appropriately respond to their hunger meter."
88889547|NCT01442142|Experimental|Cue Reactivity and Sensitivity Training|Parents and kids in this group learn about how external cues can lead to overeating and how to better respond to these cues.
88889548|NCT01442142|Experimental|Combined CAAT/CRST|In this 14 week intervention combining Children's Appetite Awareness Training (CAAT) and Cue Reactivity and Sensitivity Training (CRST), parents and kids learn about both internal hunger cues and external cues that can cause one to overeat. Skills to learn the internal hunger cues and better responses to external cues are taught.
88889549|NCT01442142|No Intervention|Control|Between baseline and the post-intervention data collection point, no intervention is given. Participants are given a take home binder of intervention materials at that second data collection point; they have the option of reviewing the material prior to the final follow-up data collection point.
88889550|NCT01442168|Experimental|Sevuparin/DF02|Sevuparin/DF02 plus anti-malarial regimen (Malanil®)
89412817|NCT03490526|Experimental|Root canal disinfection with XP-endo Finisher|
89412818|NCT03490526|Active Comparator|Root canal disinfection with passive ultrasonic irrigation|
89412819|NCT03095014|Experimental|Cesarean Myomectomy|Myomectomy plus Cesarean section
89412820|NCT03095014|Active Comparator|Cesarean section|Cesarean section only
88889551|NCT01442168|Active Comparator|Control|Anti-malarial regimen (Malanil®) alone
88889552|NCT01442207|Active Comparator|Placement of Cervical Cerclage|Cervical Cerclage is to be placed in an inpatient hospital setting within 24 to 72 hours of being assigned to this treatment group
88889553|NCT01442207|Placebo Comparator|Expectant Management|"Participants assigned to the expectant management group will be followed by their doctor and managed per standard management which includes:~Standard management for placenta previa.~Hospital admission for vaginal bleeding/hemorrhage~Antenatal corticosteroids > 24w0d of gestation~Tocolytic therapy per physician's discretion~Magnesium sulfate for neuroprotection~Fetal Heart Rate Monitoring~Avoidance of digital examinations of the cervix~Elective delivery no earlier than 36w0d gestation unless indicated (uncontrolled hemorrhage, imminent delivery, Premature rupture of the membranes (PROM) > 34 wks, worsening maternal or fetal condition )~Fetal Fibronectin (fFN) test collected at the time of transvaginal Ultrasound."
88889554|NCT01442233|Experimental|plasma exchange|6 plasma exchanges during 2 weeks after randomization
88889555|NCT01442233|Sham Comparator|sham exchange|6 sham plasma exchanges during 2 weeks after randomization
88889556|NCT01442259|Experimental|All study subjects|
88889557|NCT01442272|No Intervention|Habitual medication withuot additional|
89412821|NCT04247438|Other|Biofilm formation|Biofilm formation after 12 and 36 h on PMMA (polymethyl methacrylate) dentures and the number of brushing cycles needed to remove it.
89412822|NCT02770170|Experimental|BI 655064 dose 1|
89412823|NCT02770170|Experimental|BI 655064 dose 2|
89412824|NCT02770170|Experimental|BI 655064 dose 3|
89412825|NCT02770170|Placebo Comparator|Placebo|
89412826|NCT03490448|Other|intervention group|aerobic exercise and appropriate caloric control
89412827|NCT02031861|Experimental|nifedipine CR tablets (Xin Ran)|Subjects will take a nifedipine controlled-release tablet (30 mg, Xin Ran) orally in every morning for a 12-week treatment period.
89412828|NCT02031861|Active Comparator|nifedipine CR tablets (Adalat)|Subjects will take a nifedipine controlled-release tablet (30 mg, Adalat) orally in every morning for a 12-week treatment period.
89412829|NCT03617991|Experimental|Exercise Group|Participants will be provided an 8-week home exercise program that they will complete. The participants will also be provided all of the equipment. An investigator will contact them weekly to ensure compliance and send You Tube videos with new Phases.
89412830|NCT03617991|No Intervention|Control Group|The control group will be contacted weekly to check on health status.
89412831|NCT03938402|Experimental|PEEP 5|
89412832|NCT03938402|Experimental|PEEP 10|
89412833|NCT03938402|Experimental|PEEP 15|
89412834|NCT05052424||Children with MIS-C|"Children (age <18 years) hospitalized in the Children´s University Hospital of Cologne diagnosed with MIS-C (WHO criteria)~Assessment of clinical data~Blood samples are taken before therapy and on days 1,2,5,7 und 9.~RNA and protein expression of cytokines and immune cell-related markers will be determined via multiplex ELISA, FACS, quantitative PCR, RNAseq, and Western blot."
88889558|NCT01442272|Active Comparator|Habitual medication plus Hidroferol®|
88889559|NCT01442272|Active Comparator|Habitual medication plus Zemplar®|
88889560|NCT01442285|Experimental|personalized, motivational messages|A Healthcare Provider Report will be reviewed by oncologist. If mental health functioning scores are elevated or high range,treatment plan is constructed. Subjects receive personalized Patient Feedback Report after each assessment which will include motivationally tailored messages and suggestions for action.
88889561|NCT01442285|No Intervention|Control Group|Control subjects will receive a resource packet upon initial diagnosis consisting of brochures and printed material describing local resources and support groups as part of their routine care. At 12 months, subjects will receive the full assessment with reports and referrals.
88889562|NCT01442298|Active Comparator|conventional treatment|the Standard method;tourniquet pressure based on systolic blood pressure, plus a safety margin.
89412835|NCT02645474|Active Comparator|Paravertebral block with ropivacaine|Patients are treated with an older technique (paravertebral block with ropivacaine), somehow established in treating pain after breast surgery. This technique has been shown to be effective but has an intrinsic risk of iatrogenic pneumothorax and is considered technically demanding.
88889563|NCT01442298|Experimental|limb occlusion pressure(LOP)|cuff pressure is based on limb occlusion pressure measurement
88889564|NCT01442311|Experimental|enhanced DOT (PEG/RBV-DOT)|Subjects randomized to the PEG/RBV-DOT arm receive weekly provider-administered pegylated interferon alfa-2a injections plus modified directly observed ribavirin therapy. We describe this as modified because ribavirin ingestion is observed at the methadone window three to six days per week based on the participants' methadone pick-up schedule, and only one of two daily doses is observed.
88889565|NCT01442311|Active Comparator|standard DOT (PEG-DOT)|Subjects randomized to the Peg-DOT arm receive standard on-site treatment (weekly provider-administered pegylated interferon alfa-2a injections) and self-administered twice-daily oral ribavirin. Subjects in the PEG-DOT arm are dispensed monthly medication bottles of ribavirin, and ingest the ribavirin at home.
88889566|NCT01442324|Experimental|IRE|Patients will be subjected to irreversible electroporation (IRE) as the sole treatment of nodules not considered treatable by resection or thermal ablation.
88889567|NCT01442402||2 APOL1 genotypes|African American transplant recipients with homozygous APOL1 gene variants
88889568|NCT01442402||0 or 1 APOL1 genotypes|African American transplant recipients without homozygous APOL1 gene variants
88889569|NCT01442415|Other|Lifestyle Modification|Weekly 2 hour study sessions for 10 weeks; each session includes one hour of physical activity and one hour of dietary counseling
88889570|NCT01442428|Experimental|Steroid+Statin|"Dexamethasone: 4 mg 3x daily for 2 weeks, then 2x daily for 1 week, then once daily for 1 week;~Atorvastatin: 80 mg once daily (equivalent to 30mg ± 10mg with rifamycin co-administration)"
89412836|NCT02645474|Experimental|PECS block with ropivacaine|Patients are treated with PECS block, which has been already adopted in common clinical practice as an alternative to paravertebral block for postoperative pain treatment after breast surgery. This technique is thought to be somehow simpler to perform and safer with regard to pneumothorax, however no studies have been done yet to statistically compare the two blocks with regard to safety and effectiveness.
89412837|NCT05052814|Experimental|Calcium hydroxide ( Ca(OH)2 )|Root canal medicament which was placed into root canals with a lentulo spiral.
89412838|NCT05052814|Experimental|Chlorhexidine gel (CHX gel)|Root canal medicament which was placed into root canals with a lentulo spiral.
89412839|NCT05052814|Experimental|Calcium hydroxide+ CHX gel|Root canal medicament which was placed into root canals with a lentulo spiral.
89412840|NCT03615417|Experimental|HFNC - High Flow Nasal Cannula|Participants are preoxygenated by High Flow Nasal Cannula (HFNC) OptiFlow.
89412841|NCT03615417|Active Comparator|FM - FaceMask|Participants are preoxygenated by standard anesthesia FaceMask.
89412842|NCT03490370|Experimental|Electronic Muscle Stimulation Activity|Electro-muscular stimulation using NeuroTrac MyoPlus 2/4. All participants taking part will be allocated to the Electronic Muscle Stimulation Activity (EMS) intervention from baseline for the duration of 12 weeks. There will be 6 EMS sessions of 35mins/per session each week.
89412843|NCT02155530|Experimental|High efficacy statin group (homogeneous)|homogenous neointimal pattern at baseline OCT and randomized to atorvastatin 40 mg group
89412844|NCT02155530|Active Comparator|Low efficacy statin group (homogeneous)|homogenous neointimal pattern at baseline OCT and randomized to pravastatin 20 mg group
89412845|NCT02151942||Control group|Procedure/Surgery : Endovascular Aneurysm Repair with no prior procedure rehearsal
89412846|NCT02151942||Rehearsal group|Procedure/Surgery : Endovascular Aneurysm Repair with prior procedure rehearsal
89412847|NCT05043844|No Intervention|Control|In the control group, an investigator performed only a pulmonary recruitment maneuver on the Trendelenburg position before the emergence of anesthesia.
89005469|NCT04993534|Experimental|Psychological First Aid + Stepped-care intervention (DWM/PM+)|"All participants will be offered individual Psychological First Aid (PFA), a WHO developed support strategy that involves humane, supportive and practical help for individuals suffering from serious humanitarian crises.~The treatment group will receive the stepped-care program consisting of DWM (step 1) and Problem Management Plus (PM+).~The DWM program has been developed by WHO and collaborators working in the humanitarian field. DWM was designed to be relevant for large segments of adversity-affected populations: it is intended to be transdiagnostic, and easily adaptable to different cultures and languages.~PM+ is a new, brief, psychological intervention program based on cognitive-behavioral therapy (CBT) techniques that are empirically supported."
89412848|NCT05043844|Experimental|Abdominal binder|In the abdominal binder group, a pulmonary recruitment maneuver was performed on the Trendelenburg position and the abdominal binder which had a standard height of 22 cm was placed on the abdomen of the patient before the emergence of anesthesia.
89412849|NCT05051956||CDK4/6 inhibitors|The patient who is started on one of the CDK 4/6 inhibitors (palbociclib 125 mg 3 weeks on 1 week off) or ribociclib 600 mg 3 weeks on 1 week off) will be followed up for adverse events.
89412850|NCT02769858|Experimental|Light Therapy|Participants will use commercially-available light therapy glasses (Re-Timer) daily for 60 minutes for five weeks.
89412851|NCT03490214|Experimental|Muscular Dystrophia|Multispectral Optoacoustic Tomography (MSOT) of muscles (left and right, total 8 sites) leg proximal: Musculus quadriceps, distal: Musculus triceps surae arm proximal: Musculus biceps, distal: Musculus brachioradialis
89412852|NCT03490214|Active Comparator|Healthy Volunteer|Multispectral Optoacoustic Tomography (MSOT) of muscles (left and right, total 8 sites) leg proximal: Musculus quadriceps, distal: Musculus triceps surae arm proximal: Musculus biceps, distal: Musculus brachioradialis
89412853|NCT02152020||Cancer survivors|
89412854|NCT05051800|Experimental|Early Intervention|Families will receive the online program to support coping and communication near the time of a child's cancer diagnosis
89412855|NCT05051800|Active Comparator|Delayed Intervention|Families will receive the online program to support coping and communication approximately 6 months after a child's cancer diagnosis
89412856|NCT05051410|No Intervention|control|single visit root canal treatment will be performed with no additional irrigation.
89412857|NCT05051410|Experimental|intracanal cryotherapy with needle irrigation|single visit root canal treatment will be performed with additional irrigation with cold saline using needle irrigation.
89412858|NCT05051410|Experimental|intracanal cryotherapy using Endovac system|single visit root canal treatment will be performed with additional irrigation with cold saline using EndoVac system.
88889571|NCT01442428|Active Comparator|NSAID+Statin|"Naproxen: 250 mg 3x daily for 2 weeks, then 2x daily for 1 week, then once daily for 1 week;~Atorvastatin: 80 mg once daily (equivalent to 30mg ± 10mg with rifamycin co-administration)"
88889572|NCT01442428|Active Comparator|Steroid+Placebo|"Dexamethasone: 4 mg 3x daily for 2 weeks, then 2x daily for 1 week, then once daily for 1 week;~Placebo"
88889573|NCT01442428|Active Comparator|NSAID+Placebo|"Naproxen: 250 mg 3x daily for 2 weeks, then 2x daily for 1 week, then once daily for 1 week;~Placebo"
88889574|NCT01442441||chronic pancreatitis|
88889575|NCT01442454||Chronic Pancreatitis|
88889576|NCT01442467||Mild to Severe MAC|
88889577|NCT01442467||No to mild MAC|
88889578|NCT01442480|Experimental|Fish oil|
88889579|NCT01442480|Experimental|Olive oil|
88889580|NCT01442506||Barrett|
88889581|NCT01442519|Active Comparator|Intravesical BCG alone|
88889582|NCT01442519|Experimental|Intravesical sequential BCG and EMDA MMC|
88889583|NCT01442532|Experimental|1|
88889584|NCT01442532|Experimental|2|
88889585|NCT01442532|Experimental|3|
88889586|NCT01442532|Placebo Comparator|4|
88889587|NCT01442532|Experimental|5|
88889588|NCT01442545|Experimental|001|
88889589|NCT01442558|Active Comparator|SCL|Supraclavicular ultrasound-guided brachial plexus block
88889590|NCT01442558|Active Comparator|ICL|Infraclavicular ultrasound-guided brachial plexus block
88889591|NCT01442558|Active Comparator|AX|Axillary ultrasound-guided brachial plexus block
88889592|NCT01442571|Experimental|Hyaluronic Acid Injection, pain, function|
88889593|NCT01442571|Placebo Comparator|Saline Injection|
88889594|NCT01442584|Experimental|fertility restoration by transplantation|fertility restoration by transplantation of ovarian cortex slivers that were cryopreserved prior to chemotherapy
89412859|NCT02769624|Experimental|Treprostinil|A dose of 18mcg (3 breaths) will be administered using the Tyvaso® (treprostinil) inhalation system. Tyvaso® (treprostinil) inhalation solution is supplied in 2.9 mL clear ampules packaged as four ampules in a foil pouch. Frequency and duration- 3 times over 1 study visit.
89412860|NCT02769624|Placebo Comparator|Placebo|A dose of 3 breaths of placebo will be administered using the Tyvaso® (treprostinil) inhalation system. Placebo will be supplies in matching ampules to treprostinil. Volume will match that of treprostinil. Frequency and duration- 3 times over 1 study visit.
89412861|NCT02228954||Renal Cell Cancer|
89412862|NCT05032924|Experimental|PPR group|Receive PRP injection only (PRP form Regen Kit BCT 1)
89412863|NCT05032924|Placebo Comparator|HA group|Receive HA injection only (HYAJOINT Synovial Fluid Supplement, active ingredient: Sodium Hyaluronate 25 mg, package: 2.5 mL per syringe)
89412864|NCT03446768|Active Comparator|Reactive Care (RC)|Participants in the RC arm of the study will be provided access to the COPD Information Line if they feel they would benefit from the support of a peer health coach. Peer health coaches working the information line are patients also living with COPD who can offer peer level support.
89412865|NCT03446768|Active Comparator|Proactive Care (PC)|Participants in the PC arm of the study will be provided access to the COPD Information Line if they feel they would benefit from the support of a peer health coach. Peer health coaches working the information line are patients also living with COPD who can offer peer level support. Additionally, the PC group will also receive access to an online study portal which houses an educational health curriculum covering topics related to COPD and OSA. The portal allows participants to send online messages to peer coaches and respiratory therapist coaches. PC group will also receive weekly updates.
89412866|NCT03543774|Active Comparator|simvastatin treatment|
89412867|NCT03543774|Sham Comparator|EZE/simvastatin 10/20 mg treatment|
89412868|NCT03543774|Sham Comparator|EZE/simvastatin 10/40 mg treatment|
89412869|NCT05032768||Severe radiation dermatitis|RTOG/EORTC grade 2 and above
89412870|NCT05032768||No or mild radiation dermatitis|RTOG/EORTC grade 0 or 1
89412871|NCT02152098|Experimental|Chronic Exercise|Chronic Exercise
89412872|NCT02152098|Experimental|Acute Early onset of rehabilitation|Acute Early onset of rehabilitation
89412873|NCT02152098|Experimental|Chronic control|Chronic control
89412874|NCT02152098|Experimental|Acute Delayed onset of rehabilitation|Acute Delayed onset of rehabilitation
88889595|NCT01442597|Active Comparator|Individual clinician-provided CBT|Individual treatment provided by a trained Cognitive Behavioral Therapy (CBT)clinician who will cover the same skills provided by the CBT4CBT computer program.
89412875|NCT03096574||Pregnant women|"Over the age of 16~Under the care of staff working in: University Hospital Southampton NHS Foundation Trust, St Georges Healthcare NHS Trust, Oxford University Hospitals NHS Foundation Trust or University Hospitals Bristol NHS Foundation Trust~Able to read and write in English and give fully informed consent"
89412876|NCT03096574||Maternity healthcare professionals|"Over the age of 18~Working in obstetrics or midwifery who regularly care for women in pregnancy at University Hospital Southampton NHS Foundation Trust, St Georges Healthcare NHS Trust, Oxford University Hospitals NHS Foundation Trust or University Hospitals Bristol NHS Foundation Trust~Able to read and write in English and give fully informed consent"
89412877|NCT03096574||UK General Practitioners|"Fully-qualified general practitioners practicing in the UK~Able to read and write in English and give fully informed consent"
88889596|NCT01442597|Experimental|CBT4CBT|A computerized program that teaches skills for stopping drug use and increasing coping skills such as how to understand patterns of drug use, coping with cravings, etc.
88889597|NCT01442597|Active Comparator|Standard Treatment as Usual (TAU)|Treatment that would normally be received at the clinic typically consisting of individual or group counseling sessions focusing on substance abuse.
89412878|NCT02676284|Experimental|Durolane SJ|single dose injection. One infiltration of the study product in the trapeziometacarpal (TMC) joint. The study treatment contains sodium hyaluronate 20 mg/mL, in a 1 mL prefilled syringe.
89412879|NCT02155686|Experimental|Biosensors|Participants in this arm are equipped both with home telecare/automation and with biometric sensors
89412880|NCT02155686|Active Comparator|Automation|Participants in this arm are equiepd with home automation only
89412881|NCT05032300|Active Comparator|focused shockwave therapy|Patients will receive 6 sessions of focused shockwave therapy.
89535814|NCT02485145|Experimental|B/A|In this crossover trial, the B/A group will receive the placebo (B) and then the test product (A). The product contains the following: Diclofenac 3%, Baclofen 2%, Orphenadrine Citrate 5% and Bupivacaine 2% in a VersaPro cream, while the placebo is the VersaPro cream alone. Participants will use the placebo product for 7 days, applying the placebo product to the hands twice a day. There will be a 7 day washout period, and then participants will be given the test cream, which will be used for 7 days, applying the topical product to the hands twice a day.
89535815|NCT03223207||Control Group|The control group will include CIED patients who have been evaluated in the ED at The Heart Hospital Baylor Plano and Baylor Regional Medical Center at Plano. A minimum of 50 devices not compatible with the CareLink Express® system will be prospectively interrogated in the traditional evaluation method using the device manufacturer representative.
88889598|NCT01442610|Experimental|Rasagiline|Effect of Rasagiline on sleep parameters in PD Patients
88889599|NCT01442610|Placebo Comparator|Placebo|Effect of placebo on sleep parameters in PD Patients
88889600|NCT01442623|Active Comparator|Conventional Vestibular Rehabilitation|Six week program of conventional vestibular rehabilitation.
88889601|NCT01442623|Experimental|Nintendo Wii Vestibular Rehabilitation|Six week program of vestibular rehabilitation using the Nintendo Wii Fit Plus.
89412882|NCT05032300|Active Comparator|control|Patients in the control group will be treated using the home therapy protocol only.
89412883|NCT02155764|Experimental|Octacalcium phosphate|Bone augmentation, after tooth extraction, with Octacalcium phosphate (synthetic bone graft material) in combination with resorbable collagen membrane Bio-Gide.
89412884|NCT02155764|Active Comparator|Bio-Oss|Bone augmentation, after tooth extraction, with Bio-Oss (bovine-derived xenograft)in combination with resorbable collagen membrane Bio-Gide
89412885|NCT02155764|Active Comparator|Tricalcium phosphate|Bone augmentation, after tooth extraction, with Tricalcium phosphate (synthetic bone graft material) in combination with resorbable collagen membrane Bio-Gide.
89412886|NCT01829750|Sham Comparator|Control|"(Stage 1) No active intervention after standard surgical treatment~(Stage 2) Rescuing transplantation by cardiac progenitor cell infusion is applicable in patients, along with their written consent, 4 months after palliations who were assigned as control group in stage 1."
89412887|NCT01829750|Active Comparator|Cardiac progenitor cell infusion|(Stage 1) single dose, intracoronary infusion of 0.3 million cells/kg cardiac progenitor cells
89412888|NCT05032456|Experimental|Virtual Reality Group|Investigators used Oculus Quest All-in-one Virtual Reality Gaming Headset (128 GB) VR system. Before the intervention, the investigators introduced the equipment and instructed study participants on how to wear and activate the headsets. The laboring women who enrolled in the virtual reality group first wore the headsets in early labor (Cervical dilation 3 cm) for 20 minutes. The patients were offered to choose among several virtual environments including orange sunset, green meadows, black beginning, red savannah, blue deep, blue moon, blue ocean, white winter, and red fall. Cards printed out from the images of the Nature Trek application representing these novel immersion options were provided to the patients to help them pick up their preferred environment in advance. The second implementation of virtual reality headsets was after the epidural analgesia in the active phase of labor for another 20 minutes (Cervical dilation 6-7cm).
89412889|NCT05032456|No Intervention|Control Group|For participants randomized to the control group, virtual reality headsets were not used and the clinic's standard of care in laboring women was followed. Participants in this group filled out a visual pain rating scale both in the latent and active phases of labor.
89412890|NCT02152176|Experimental|Patient Controlled Analgesy group|Titration of morphine by Patient Controlled Analgesy. The opioid titration will be performed by the patient using PCA (Vygon Freedom 5) according to the principle of self with a refractory period of 5 minutes.
89005470|NCT04993534|Other|Psychological First Aid + usual care|"All participants will be offered individual Psychological First Aid (PFA), a WHO developed support strategy that involves humane, supportive and practical help for individuals suffering from serious humanitarian crises.~In addition, both the groups will receive care-as-usual (CAU); they will be allowed to receive any usual care. CAU may include community care, social/legal support, and psychoeducation."
88889602|NCT01442636|Experimental|Xience Prime stent|Patients with critical limb ischemia due to below the knee arterial lesion between 30 and 100mm in length, treated with the XIENCE PRIME™ Everolimus Eluting Coronary Stent System.
88889603|NCT01442662|Experimental|pazopanib, gemcitabine|pazopanib tablets (200mg) per os, 800mg/day continuously gemcitabine IV, 2 injection per cycle
88889604|NCT01442701||No triclosan / Triclosan|Participants are randomized to receive household and personal cleaning products from one of 2 arms: products that either do not contain triclosan or that may contain triclosan. Participants select products from an arm-specific list of commercially available items.
88889605|NCT01442727|Placebo Comparator|Placebo|Patients who receive control (placebo)
88889606|NCT01442727|Active Comparator|Selenium|Patients who receive treatment (selenium)
88889607|NCT01442740|Experimental|15-degree Reverse Trendelenburg Position|Patients will be placed on the operating table in a position where the lower extremities are leveled lower than the head and neck. The angle of incline will be set at 15 degrees from the horizontal.
88889608|NCT01442740|No Intervention|0-degree Supine Position|Patients will be placed on the operating table in the standard, 0-degree supine position.
88889609|NCT01442753|Active Comparator|Intervention Group|Families will be randomized to either receive the intervention (family-skills training) immediately. The intervention will be delivered over eight weeks. Sessions will be divided between self-reflection, didactics, and skill-building exercises all aimed at developing strong parenting practices and facilitating relationship building between parents and youth.
88889610|NCT01442753|Active Comparator|Control Group|Control group will receive the intervention (family-skills training) in approximately ten months. The intervention will be delivered over eight weeks. Sessions will be divided between self-reflection, didactics, and skill-building exercises all aimed at developing strong parenting practices and facilitating relationship building between parents and youth.
88889611|NCT01442766|Experimental|Donepezil|
88889612|NCT01442766|Placebo Comparator|Placebo|
88889613|NCT01442805|Experimental|RV|Cognitive Behavioral Therapy with Virtual Reality Exposures
88889614|NCT01442805|Experimental|IMAGO|Cognitive Behavioral Therapy with Exposure Therapy through Imagination
88889615|NCT01442818|Experimental|Scheduled IV post op|Patient's will receive scheduled nurse administered IV pain medications post operatively.
88889616|NCT01442818|Experimental|PCA post op|Patients will receive PCA for pain control post operatively.
88889617|NCT01442831|Experimental|Human ADME|
89412891|NCT02152176|No Intervention|Control group|titration will be perform in the usual manner in accordance with the recommendations : a nurse will assess pain using a visual analog scale in the control group to assess the need for a new bolus of morphine
89412892|NCT02155842|Experimental|High intensity endurance exercise|Four weeks comprehensive cardiac rehabilitation with moderate volume high intensity endurance exercise, followed by 6 months non-supervised endurance exercise
89412893|NCT02155842|Active Comparator|Moderate continuous endurance exercise|Four weeks comprehensive cardiac rehabilitation with moderate volume moderate intensity endurance exercise, followed by 6 months non-supervised endurance exercise
89412894|NCT03094780|Other|Quality of Life Counseling|
88889618|NCT01442857|Experimental|Block technique|"Active Comparator: Arm 1: catheter injection 40 ml of LA through the catheter~Active Comparator: Arm 2: catheter and transarterial injection 20 + 10 ml transarterial block and 10 ml through the catheter"
88889619|NCT01442870|Experimental|Metformin|Metformin
88889620|NCT01442870|No Intervention|No metformin|No metformin during primary endpoint assessment period (at least 3 weeks). Patients will subsequently be initiated on metformin.
88889621|NCT01442883||treatment resistant hypertensives with CKD 3-5|
88889622|NCT01442909|Active Comparator|D followed by P|Docetaxel 60 mg/m2 intravenous infusion (IV) day 1 every 3 weeks for 4-6 cycles (stable disease up to 4 cycles, partial or complete response up to 6 cycles), followed by pemetrexed 500 mg/m2 IV day 1 every 3 weeks for 4-6 cycles (stable disease up to 4 cycles, partial or complete response up to 6 cycles).
88889623|NCT01442909|Active Comparator|P followed by D|"Pemetrexed treatment followed by docetael (in reverse sequence of Arm D followed by P"
88889624|NCT01442922||Human Meniscus Allograft (HMA)|Patients with degenerative disk disease at L3-L4, L4-L5, or L5-S1 scheduled to undergo surgery for (HMA) implantation to replace the nucleus pulposus.
88889625|NCT01442935|Active Comparator|Arm A1 : Folfiri + targeted therapy|"Every 2 weeks :~irinotecan 180 mg/m² D1~Folinic acid 400 mg/m² D1~5FU 400 mg/m² bolus~5FU 2400 mg/m² infusion over 46 h, D1~And targeted therapy in function of Kras:~For mutated Kras = bevacizumab: 5 mg/kg IV on D1 of each cycle of chemotherapy, every 14 days~For non-mutated Kras = cetuximab : 500 mg/m² IV, on D1 of each cycle of chemotherapy, every 14 days."
88889626|NCT01442935|Active Comparator|Arm A2 : Folfox 4 + targeted therapy|"Every 2 weeks :~oxaliplatin 85 mg/m² D1~Folinic acid 400 mg/m² D1~5FU 400 mg/m² bolus~5FU 2400 mg/m² infusion over 46 h, D1~And targeted therapy in function of Kras:~For mutated Kras = bevacizumab: 5 mg/kg IV on D1 of each cycle of chemotherapy, every 14 days~For non-mutated Kras = cetuximab : 500 mg/m² IV, on D1 of each cycle of chemotherapy, every 14 days."
88889627|NCT01442935|Experimental|Arm B : Folfirinox + targeted therapy|"Every 2 weeks :~oxaliplatin 85 mg/m² D1~irinotecan 150 mg/m² D1~Folinic acid 400 mg/m² D1~5FU 400 mg/m² bolus~5FU 2400 mg/m² infusion over 46 h, D1. From D7 to D12, prophylactic G-CSF such as Granocyte® will be administered.~And targeted therapy in function of Kras:~For mutated Kras = bevacizumab: 5 mg/kg IV on D1 of each cycle of chemotherapy, every 14 days~For non-mutated Kras = cetuximab : 500 mg/m² IV, on D1 of each cycle of chemotherapy, every 14 days."
89412895|NCT05027061||Cohort 1|Non-valvular atrial fibrillation (NVAF) participants receiving oral anticoagulant - Warfarin
89412896|NCT05027061||Cohort 2|NVAF participants receiving oral anticoagulant - Apixaban
89412897|NCT05027061||Cohort 3|NVAF participants receiving oral anticoagulant - Dabigatran
89412898|NCT05027061||Cohort 4|NVAF participants receiving oral anticoagulant - Edoxaban
88889628|NCT01442948||Acute coronary syndrome|
88889629|NCT01442948||Stable Angina|
88889630|NCT01442961|Active Comparator|laparoscopy|Intervention: Procedure: laparoscopy
89412899|NCT05027061||Cohort 5|NVAF participants receiving oral anticoagulant - Rivaroxaban
89412900|NCT05027061||Cohort 6|NVAF participants not receiving oral anticoagulants
89412901|NCT03488888|Sham Comparator|Normal Saline|"General Anesthesia + Bilateral Pectoral injection of Normal Saline 0,9%~Ultrasound-guided visualization of Pectoralis major and pectoralis minor muscles~Injection of 10 mL normal saline 0,9% between muscles lateral to the thoracoacromial artery.~Visualization of Pectoralis menor and Serratil Muscles~3- Injection of 20 mL of normal saline 0,9% between Pectoralis minor and serratil muscles 4-Visualize the hydrodissection performed by the solution"
89535816|NCT03223207||CareLink Express|The study group will include CIED patients who present to the ED and receive a device evaluation using the CareLink Express® system. A minimum of 50 devices will be prospectively evaluated using CareLink Express®.
89535817|NCT02637141|Experimental|AMG 714 150 mg|Participants received 150 mg AMG 714 via subcutaneous injection once every 2 weeks for a total of 6 doses over 10 weeks from day 0. Participants received gluten-free cookies twice a day for the first 2 weeks and gluten-containing cookies twice a day from weeks 2 to 12 (gluten-challenge).
89535818|NCT02637141|Experimental|AMG 714 300 mg|Participants received 300 mg AMG 714 via subcutaneous injection once every 2 weeks for a total of 6 doses over 10 weeks from day 0. Participants received gluten-free cookies twice a day for the first 2 weeks and gluten-containing cookies twice a day from weeks 2 to 12 (gluten-challenge).
89535819|NCT02637141|Placebo Comparator|Placebo|Participants received placebo subcutaneous injection once every 2 weeks for a total of 6 doses over 10 weeks from day 0. Participants received gluten-free cookies twice a day for the first 2 weeks and gluten-containing cookies twice a day from weeks 2 to 12 (gluten-challenge).
89536713|NCT02473133|Experimental|Personalized dose redistribution|Patients in the will receive an individualized radiotherapy prescription up to a total dose of 74 Gy given in 6.6 weeks if they have a positive FDG-PET at 42Gy (about two thirds of patients are expected as positive). An initial dose of 50 Gy will be delivered in 5 weeks (single daily fractions of 2 Gy), then an additional dose up to 24 Gy will be delivered over 1.6 week using a twice-a-day fractionated radiotherapy.
88889631|NCT01442961|Active Comparator|vaginal|Intervention: Procedure: vaginal
88889632|NCT01442974|Experimental|Gemcitabine plus nab-paclitaxel|This is a single arm study.
88889633|NCT01442987|Experimental|Irbesartan/Atorvastatin A|
88889634|NCT01442987|Active Comparator|Irbesartan|
89412902|NCT03488888|Experimental|Bupivacaine|"General Anesthesia + Bilateral Pectoral injection of 30 mL of 0.25% Bupivacaine~Ultrasound-guided visualization of Pectoralis major and pectoralis minor muscles~Injection of 10 mL of local anesthetic between muscles lateral to the thoracoacromial artery.~Visualization of Pectoralis minor and Serratil Muscles~3- Injection of 20 mL of local anesthestic between Pectoralis minor and Serratil muscles 4-Visualize the hydrodissection performed by the solution"
89412903|NCT05031676|Experimental|group 1|Intervention consists at induction : direct intravenous lidocaine 1.5 mg/kg; clonidine 2 μg/kg in 250 ml of isotonic saline, started as soon as the venous route is taken and over a period of approximately 15 minutes; magnesium sulfate 50 mg/kg in the same isotonic saline as clonidine.
89412904|NCT05031676|No Intervention|group 2|In classic induction: fentanyl at a dose of 2 µg/kg. Following induction in all patients consisted of the administration of propofol 2-3 mg/kg in titration, rocuronium 0.6 mg/kg, ketamine 0.5 mg/kg, methylprednisolone 120 mg.
89412905|NCT03615339|Experimental|Molkosan|"Consumption of Molkosan (fermented whey) 20ml to be diluted in 200ml water prior to use twice a day (morning & evening).~Total duration was 6 weeks."
89412906|NCT02769312|Sham Comparator|Sham Stimulation|A sham coil is being used to compare against active coil.
89412907|NCT02769312|Active Comparator|Active Stimulation|An active coil is being used to compare against sham coil.
89412908|NCT03616743|Experimental|Brief pain and smoking arm|The experimental arm incorporated a novel psychoeducational component that addressed associations between cigarette smoking and chronic pain
89412909|NCT03616743|Active Comparator|Brief smoking control arm|"The brief smoking control arm was comprised of the 5A's of smoking cessation."
89412910|NCT03489902|Experimental|Transobturator arm|Transobturator Paravaginal Repair
89412911|NCT03489902|Experimental|Transvaginal arm|traditional transvaginal Paravaginal Repair
89412912|NCT03617757|Experimental|All recruited patients|Blood taking procedure, oral glucose tolerance test and questionnaire will be included.
88889635|NCT01442987|Active Comparator|Atorvastatin A|
88889636|NCT01442987|Placebo Comparator|Placebo|
88889637|NCT01442987|Experimental|Irbesartan/Atorvastatin B|
88889638|NCT01442987|Active Comparator|Atorvastatin B|
88889639|NCT01443013||Cohort of Renal Transplant recipients|
88889640|NCT01443039|Experimental|phenotypical approach|phenotypical approach
88889641|NCT01443052||post-stroke patients|Stroke patients who had only one cerebrovascular accident, at least one year before inclusion and Able to walk without using assisting devices or ambulatory aids
88889642|NCT01443052||healthy subjects|Aged 65 to 80 years
88889643|NCT01443052||fallers|Reported 2 or more falls within 6 months prior to the beginning of the study and Able to walk without using assisting devices or ambulatory aids
88889644|NCT01443065|Active Comparator|Arm A : simplified Folfox 4|"Every 2 weeks :~Oxaliplatin : 85 mg/m2 over 120 mn (2h) IV on D1~Folinic acid : 400 mg/m² (racemic form) (or 200 mg/m² if L-folinic acid) over 2 h IV on D1 followed by :~5-fluoro-uracil : 400 mg/m² in IV bolus on D1 followed by :~5-fluoro-uracil : 2400 mg/m² in IV infusion over 46 h"
88889645|NCT01443065|Experimental|Arm B : simplified FOLFOX 4 + panitumumab|"Every 2 weeks :~Oxaliplatin : 85 mg/m2 over 120 mn IV on D1~Folinic acid : 400 mg/m² (racemic form) (or 200 mg/m² with L-folinic acid) over 2 h IV on D1 (in Y to oxaliplatin) followed by :~5-fluoro-uracil : 400 mg/m², IV bolus on D1, followed by :~5-fluoro-uracil : 2400 mg/m², IV infusion IV over 46 h~Panitumumab : 6 mg/kg de 60 à 90 mn ± 15 mn IV every 14 days, just before chemotherapy administration (oxaliplatin and folinic acid), on Day 1 of each cycle. If the 1st infusion of panitumumab is well tolerated, the next infusions can be administered over 30 ± 10 mn."
89005471|NCT02210104|Experimental|Ipilimumab + Cyclophosphamide + CD4+T Cells|Starting Dose of Ipilimumab 1.0 mg /kg by vein on Days 1, 22, 43, and 64. Cyclophosphamide 300 mg/m2 administered intravenously 2 days prior to T cell infusion as an outpatient procedure. Antigen-specific CD4+ T cells administered at a dose 10^10 cells/m^2.
89005472|NCT02210143||AERSA-I gingival recession|The AERSA classification was developed based on 15 mm2 which is the lowest cut-off point and the group of AERSA ≤ 15 mm2 named as AERSA-I (low risk group)
89005473|NCT02210143||AERSA-II gingival recession|AERSA > 15 mm2 named as AERSA-II (high risk group).
89005474|NCT02210143||Miller gingival recession|Gingival recessions classified according to Miller
89005475|NCT02210182|Experimental|Oral pentamidine|Oral pentamidine given at 300 mg, 600 mg, 900 mg or 1200 mg QD x 3 consecutive days
89005476|NCT02210182|Placebo Comparator|Placebo|Placebo given at 300 mg, 600 mg, 900 mg or 1200 mg QD x 3 consecutive days
89412913|NCT03489824|Experimental|modified-WIM colonoscopy in RLP|Modified-water immersion method colonoscopy is performed to patients with right-lateral starting position (RLP). Patients will lie in the right lateral position with both hips and knees flexed at the beginning and change the position into supine and at last left-lateral position when it is needed.
89412914|NCT03489824|Active Comparator|modified-WIM colonoscopy in LLP|Modified-water immersion method (WIM) colonoscopy is performed to patients with left-lateral starting position (LLP). Patients will lie in the left lateral position with right hip and knee flexed and left leg straight at the beginning and change the position into supine and at last right lateral position when it is needed.
89412915|NCT03543696|Experimental|Single Dose Radiotherapy (SDRT)|Single Dose Radiotherapy (SDRT) at a prescription dose of 24 Gy to all detectable metastatic lesions
89412916|NCT03615261|Experimental|Mothers and Babies (Enhanced)|"The course is a manualized stress-reduction intervention with an integrated tech suite designed for timely detection and response to stress. Based on Cognitive-Behavioral Therapy & attachment theory, MB is divided into 3 sections: Pleasant Activities; Thoughts; Contact with Others. Each module has been enhanced with mindfulness as a strategy to help center participants and facilitate practice of skills. Participants receive skills training in each of the three sections as tools to improve and manage their mood. The MB course emphasizes developing & strengthening the bond with the baby. The technology enhancement includes wearing a BioStamp sensor, and text message-based extra intervention content. Participants get worksheets linked to the 12 sessions."
89412917|NCT02148744|Experimental|XmAb7195 or Placebo|
89412918|NCT01632644||Physicians|Physicians performing skin biopsies
89412919|NCT01632644||Patients|Patients who have had skin biopsies
89412920|NCT05034510|Active Comparator|Low frequency 80 Hz then short pulse width 30 usec stimulation|Each participant will undergo to low frequency stimulation for 4 weeks, then will switch to short pulse width stimulation paradigm for 4 weeks according to the crossover design.
89412921|NCT05034510|Active Comparator|Short pulse width 30 usec then low frequency 80 Hz stimulation|Each participant will undergo to short pulse width stimulation paradigm for 4 weeks, then will switch to low frequency for 4 weeks according to the crossover design.
89412922|NCT03488810|Active Comparator|Arm A: ADT + radiation therapy|"Patient will receive 2 injections of a three-monthly LHRH agonist depot plus non-steroidal anti-androgen (rescue treatment) (e. g. flutamide, bicalutamide) PO daily for 4 weeks, started 2 weeks before the first LHRH agonist injection.~All patients will receive standard fractionation radiation therapy (RT) between 0 and 12 weeks after first injection of LHRH agonist."
88889646|NCT01443065|Experimental|Arm C : simplified FOLFOX 4 + AMG 102|"Every 2 weeks :~Oxaliplatin : 85 mg/m2 over 120 mn IV on D1~Folinic Acid : 400 mg/m² (racemic) (or 200 mg/m² with L-folinic acid) over 2 h IV on D1 (in Y/concomitant with oxaliplatin) followed by :~5-fluoro-uracil : 400 mg/m² IV bolus on D1 followed by :~5-fluoro-uracil : 2400 mg/m² in IV perfusion over 46 h~AMG 102 : 10 mg/kg over 60 ± 15 mn IV every 14 days, just before chemotherapy administration (oxaliplatin and folinic acid), on Day 1 of each cycle. If the first infusion is well tolerated (without severe infusion-related reactions), the following infusions can be administered over 30 ± 10 mn."
88889647|NCT01443091|Experimental|Colostrum|
89412923|NCT03488810|Experimental|Arm B: ADT + radiation therapy + Apalutamide|"Patients will receive 2 injections of a three-monthly LHRH agonist depot. Apalutamide treatment: 240 mg PO daily, started the same day as the first LHRHa injection, for 6 months.~All patients will receive standard fractionation radiation therapy (RT) between 0 and 12 weeks after first injection of LHRH agonist."
89412924|NCT03615027|Experimental|Intervention|see detailed description
88889648|NCT01443091|Placebo Comparator|Sterile water|
88889649|NCT01443104|Active Comparator|Orsiro Stent|Sirolimus-eluting Stent with a Biodegradable Polymer
88889650|NCT01443104|Active Comparator|Xience Prime Stent|Everolimus-eluting Stent with a Durable Polymer
89412925|NCT03492242||Adverse drug reaction induced by immune checkpoint inhibitors|Case reported in the World Health Organization (WHO) and the Base Nationale de PharmacoVigilance of patient treated by ICI, with a chronology compatible with the drug toxicity
89412926|NCT03572283|Experimental|Bethanechol|Patients with pancreatic adenocarcinoma will receive bethanechol prior to pancreatic surgery
89412927|NCT02254824|Active Comparator|Normal-dose statin|Lifestyle modification with Normal-dose statin
89412928|NCT02254824|Active Comparator|Lifestyle modification + Xuezhikang|Lifestyle changes with Xuezhikang
88889651|NCT01443117|Experimental|Step 1: PPV-23 Vaccine (Arm 1a)|Participants will receive one intramuscular (IM) injection of 0.5 mL of the PPV-23 vaccine at baseline.
88889652|NCT01443117|Experimental|Step 1: PCV-13 Vaccine (Arm 1b)|Participants will receive one IM injection of 0.5 mL of the PCV-13 vaccine at baseline.
88889653|NCT01443117|Placebo Comparator|Step 1: Placebo Vaccine (Arm 1c)|Participants will receive one IM injection of 0.5 mL of the placebo vaccine at baseline.
88889654|NCT01443117|Experimental|Step 2: PPV-23 Vaccine (Arm 2a)|Participants will receive one IM injection of 0.5 mL of the PPV-23 vaccine 6 months after delivery.
88889655|NCT01443117|Experimental|Step 2: PCV-13 Vaccine (Arm 2b)|Participants will receive one IM injection of 0.5 mL of the PCV-13 vaccine 6 months after delivery.
88889656|NCT01443143|Experimental|Commercial diet|Commercially available diet program (i.e., Nutrisystem D) that includes pre-packaged low-glycemic index portion-controlled entrees and snacks that are supplemented with grocery items in accordance with a structured meal plan.
88889657|NCT01443143|No Intervention|Usual Diet|Participants' usual consumption of food and beverages.
89412929|NCT02254824|Active Comparator|Lifestyle modification|Lifestyle modification
89412930|NCT03617601||> 4 MET|Patients with functional capacity over 4 MET
89412931|NCT03617601||< 4 MET|Patients with functional capacity under 4 MET
88889658|NCT01443169|Experimental|Sequence 1|
88889659|NCT01443169|Experimental|Sequence 2|
88889660|NCT01443169|Experimental|Sequence 3|
88889661|NCT01443169|Experimental|Sequence 4|
89412932|NCT01525316|Experimental|Bovine Lactoferrin|Lactoferrin is a freeze-dried protein purified directly from fresh bovine milk.
88889662|NCT01443182|Experimental|STAIR + MPE|A two-phased treatment with Skills Training in Affective and Interpersonal Regulation (STAIR) in Phase 1 en modified prolonged exposure (MPE) in Phase 2
88889663|NCT01443182|Active Comparator|STAIR + EMDR|a two-phase treatment Phase 1: Skills Training in Affective and Interpersonal Regulation (STAIR) Phase 2: Eye Movement Desensitization and Reprocessing (EMDR)
88889664|NCT01443195|Experimental|Iron suplementation|Iron supplementation with IPC in a dose of 4 mg/kg/day of elemental iron started not before 4 weeks of age and as soon as 120 ml/kg/day of enteral feedings is tolerated given together with the first morning meal
88889665|NCT01443208|Experimental|50 mg|
88889666|NCT01443208|Experimental|100 mg|
89412933|NCT01525316|Placebo Comparator|Maltodextrin|Maltodextrin is an inert sugar.
89412934|NCT03616665|Other|CBASPersonalized|Within the psychotherapy CBASPersonalized, the original specific six interpersonal CBASP strategies are augmented with intrapersonal evidence-based strategies. According to the frequently diagnosed comorbid disorders of PDD the following modules have been added: a) treatment of anxiety disorders and treatment of traumatic experiences, b) regulating intensive emotions, c) coping with resistant problems like pain, and d) relapse prevention. In addition, therapists adjust their strategies and therapeutic relationship according to the impairment in personality functioning and maladaptive personality traits of the patient.
89412935|NCT03488732||Patients undergonig transcatheter valvular interventions|
89412936|NCT01673386|Experimental|Tivozanib Hydrochloride|1.5 mg oral tivozanib hydrochloride daily on a 3 weeks on/1 week off schedule for 12 weeks, followed by 50 mg oral sunitinib daily on a 4 weeks on/2 weeks off schedule for 12 weeks.
89412937|NCT01673386|Active Comparator|Sunitinib|50 mg oral sunitinib daily on a 4 weeks on/2 weeks off schedule for 12 weeks, followed by 1.5 mg oral tivozanib hydrochloride daily on a 3 weeks on/1 week off schedule for 12 weeks.
88889667|NCT01443208|Experimental|200 mg|
89192790|NCT06047470|Placebo Comparator|Control Arm (CON)|Lactating parents will be asked to arrive at the NICU 3 hours after they have fully expressed their breasts at home. Lactating parents will be taken to a private room where they will be asked to pump from both of their breasts using a hospital grade pump available in the NICU. Study personnel will weigh the collected milk to determine the total volume of milk expressed by mass. The milk collected from both breasts will be gently swirled six times or more until the fat layer is incorporated in the bottle and will be combined into one bottle. Study personnel will take one 6 mL aliquot from the collected milk for compositional analysis. The remainder of the milk will be saved in the NICU per routine so that it can be fed to the infant later. Lactating parents will then provide their infants with kangaroo care for 1 hour.
89412938|NCT00103740|Experimental|Zoledronic acid and placebo to risedronate|Participants received zoledronic acid 5.0 mg i.v. infusion one dose, 60 days of oral placebo to risedronate, calcium 500mg bid and vitamin D 400 to 1000 IU daily during the core period, and received only calcium and vitamin D supplements during the extended observation period.
89192791|NCT06043700||All Participants|Participants with or without symptoms of AD will be enrolled and observed in this study.
89412939|NCT00103740|Active Comparator|Risedronate and placebo to zoledronic acid|Participants received 60 days of oral risedronate 30 mg, one i.v. infusion of placebo to zoledronic acid infusion, calcium 500mg bid and vitamin d 400 to 1000 IU daily during the core period, and received only calcium and vitamin D supplements during the extended observation period.
89412940|NCT03131804|Experimental|Interventional Participants|Patients will represent their own controls (pre and post intervention), in the HD unit of Al Qassimi Hospital, Sharjah, United Arab Emirates.
88889668|NCT01443221|Active Comparator|Free combination|Free combination of Mitiglinide 10mg and Metformin 500mg
88889669|NCT01443221|Experimental|Fixed-dose combination|Fixed-dose combination of Mitiglinide 10mg and Metformin 500mg
89412941|NCT03616509|Experimental|Placebo and Growth Hormone|2 months on placebo followed by 12 months on GH
89412942|NCT03616353|Experimental|Group 1: Corticosteroid Injection|Patients in this group will undergo an injection of corticosteroid into the carpal tunnel as per current treatment practices.
89412943|NCT03616353|Experimental|Group 2: Perineural Hydrodissection|Patients in this group will undergo a perineural hydrodissection plus an injection of corticosteroid into the carpal tunnel, as a novel technique.
89412944|NCT03488576|Active Comparator|Complete Peeling|Patient underwent scheduled vitrectomy for epiretinal membrane or macular hole with complete macular peeling of the internal limiting membrane.
89412945|NCT03488576|Experimental|Foveal Sparing|Patient underwent scheduled vitrectomy for epiretinal membrane or macular hole with partial peeling the internal limiting membrane (foveal sparing).
88889670|NCT01443234|Experimental|OxIGen program|Internet based intervention taking place over 4 weeks
88889671|NCT01443234|Placebo Comparator|OxIGen: control version|A control version of the internet-based OxIGen intervention
88889672|NCT01443247|Experimental|platelet support + anti-d|
89192792|NCT06041880|Experimental|4-weeks of passive calf stretching for 30 minutes 5 days a week|A modified plantar fasciitis ankle splint will be used to passively stretch the calf muscle.
88889673|NCT01443247|No Intervention|platelet support|
88889674|NCT01443273||Infants with thrombotic events|All infants (premature and term) diagnosed at the Neonatal Intensive Care Unit with thrombotic events
88889675|NCT01443312||Thalassemia Intermedia Patients|Patients with Beta Thalassemia Intermedia treated at the Pediatric Hematology Unit. The characterization of Thalassemia Intermedia was based on age at diagnosis (Older than 2 ys) and / or clinical characteristics that are milder than Thalassemia Major in patients homozygous for beta globin genes.
89192793|NCT06041880|No Intervention|4-weeks of no-stretching|No device will be used to stretch the calf muscle. Participants will go about their normal daily activity for 4-weeks.
89192794|NCT06039852|Experimental|Novel Postural Management Night-time Intervention Components|Intervention Arm
89192795|NCT06038331|Experimental|SclerFIX-IP|Treated, devitalised and sterile graft of umbilical cord amniotic membrane
89192796|NCT06034262|Experimental|SclerFIX-IP|Treated, devitalised and sterile graft of umbilical cord amniotic membrane
89192797|NCT06033027|No Intervention|Baseline phase|
89192798|NCT06033027|Experimental|Soft-robotic glove phase|
88889676|NCT01443325|Experimental|lidocaine patch|
88889677|NCT01443338|Active Comparator|Triptergium Wilfordii|a kind of traditional chinese medicine
89192799|NCT06033027|No Intervention|Retention phase|
89412946|NCT03094858|Active Comparator|Comparison group|Equipment only comparison group will use Smartphone and Wristband to monitor sedentary behavior
88889678|NCT01443338|Active Comparator|Acitretin|
88889679|NCT01443351||ITP patients|Patients with refractory ITP eligible for treatment with TPO-ra
88889680|NCT01443416|Experimental|13-valent pneumococcal conjugate vaccine|12 month booster dose of Prevenar
88889681|NCT01443416|Experimental|10-valent pneumococcal conjugate vaccine|12 month booster dose of Synflorix
88889682|NCT01443429|Experimental|subjects with normal renal function|
89412947|NCT03094858|Experimental|Intervention group|Intervention group will receive prompts from Smartphone to reduce sedentary behavior using information from Wristband
89412948|NCT01281644|No Intervention|No Laser Treatment|
89412949|NCT01281644|Active Comparator|45-60 J Diode Laser Therapy|Diode laser therapy will be initiated at 45-60 J for 30 ms to 100 ms.
89412950|NCT02148822||Malnourished|Children with either height for age z score or body mass index for age z score below 2 standard deviations according to the World Health Organization Growth Standards for children younger than 5 years and the 2007 WHO Growth Reference for children of 5 years or older.
89412951|NCT02148822||Not malnourished|Children with either height for age z score or body mass index for age z score equal or higher than 2 standard deviations according to the World Health Organization Growth Standards for children younger than 5 years and the 2007 WHO Growth Reference for children of 5 years or older.
89412952|NCT02869893|Other|Healthy Participants|MRCP with Secretin and MR elastography will be performed on all participants.
89412953|NCT03616275|Experimental|HRV biofeedback group|8 once-a-week, individual, 30-min sessions of HRV biofeedback and 1 session of healthy lifestyle education
89412954|NCT03616275|No Intervention|control group|1 session of healthy lifestyle education
89412955|NCT05119790|Experimental|Cohort A|
88889683|NCT01443429|Experimental|patients with mild renal impairment|
88889684|NCT01443429|Experimental|patients with moderate renal impairment|
88889685|NCT01443429|Experimental|patients with severe renal impairment|
88889686|NCT01443455|Experimental|VideoDance|
88889687|NCT01443455|Active Comparator|Brisk Walking|
88889688|NCT01443455|Other|Delayed entry control|Participants who are randomized to the delayed entry non-exercise control group receive the American Heart Association pamphlet, but no direct support for exercise implementation. After they have completed six months of follow up, they are invited to select any combination of dancing and walking that they prefer and then receive support and instruction according to the protocols described above.
88889689|NCT01443481|Experimental|TKI258 normal hepatic function|TKI258 Capsule, @ 500 mg p.o. o.d. 5 days on/2 days off
89412956|NCT05050786|Active Comparator|Standard wound dressing|
88889690|NCT01443481|Experimental|TKI258 mild hepatic impairment|TKI258 capsule @ 500 or 400 mg p.o. o.d. 5 days on/2 days off
88889691|NCT01443481|Experimental|TKI258 moderate hepatic impairment|TKI258 capsule @ starting dose at 400 mg p.o. o.d. 5 days on/2 days off
88889692|NCT01443481|Experimental|TKI258 severe hepatic impairment|TKI258 capsule Starting dose to be determined based on the study outcome of the mild and moderate hepatic impairment groups
88889693|NCT01443507|Experimental|high intensity long interval|A group training four by four minutes interval at 90-95% of maximal heart rate dispersed by three minutes active pauses at 70% of maximal heart rate.
88889694|NCT01443507|Experimental|long duration at moderate training|a continuous training group exercising at 70% of maximal heart rate for 90 minutes.
88889695|NCT01443520|Placebo Comparator|Placebo|
88889696|NCT01443520|Active Comparator|Duloxetine|
88889697|NCT01443520|Active Comparator|Venlafaxine|
88889698|NCT01443533|Experimental|LARC script|Received routine postpartum counseling and LARC script.
88889699|NCT01443533|No Intervention|No LARC script|Received only routine postpartum counseling
88889700|NCT01443559|Experimental|Xenogenic cornea|
88889701|NCT01443559|Active Comparator|human cornea|
88889702|NCT01443572|Experimental|desflurane group|
88889703|NCT01443572|Active Comparator|sevoflurane group|
88889704|NCT01443611||Infants with first episode of Febrile Convlusions|
88889705|NCT01443624|Experimental|critical care patients venofer|Critically ill patients are injected with Venofer (ferric hydroxide sucrose) 100mg IV in one hour (in critically ill patients the injection could be repeated on day 2 (200mg) and 4 (100mg) depending on treatment
88889706|NCT01443650|Experimental|alirocumab SAR236553 (REGN727) (Formulation A x 1)|A single subcutaneous injection of Formulation A
89412957|NCT05050786|Experimental|Negative Pressure Wound Therapy (NPWT)|
89412958|NCT03614871||No arms|There are no interventions
89412959|NCT02152332|Experimental|Treatment Sequence Group ADBC|Participant will receive Treatment A (JNJ-54861911, 50 milligram (mg) once daily for 7 days plus moxifloxacin-matched placebo on Day 7) followed by Treatment D (JNJ-54861911-matched placebo once daily for next 7 days plus moxifloxacin 400 mg on Day 7 of second treatment regimen, then Treatment B (JNJ-54861911, 150 mg once daily for next 7 days plus moxifloxacin-matched placebo on Day 7 of third treatment regimen followed by Treatment C (JNJ-54861911-matched placebo once daily for next 7 days plus moxifloxacin-matched placebo on Day 7 of fourth treatment regimen).
89412960|NCT02152332|Experimental|Treatment Sequence Group BACD|Participant will receive Treatment B (JNJ-54861911, 150 mg once daily for 7 days plus moxifloxacin-matched placebo on Day 7) followed by Treatment A (JNJ-54861911, 50 mg once daily for next 7 days plus moxifloxacin-matched placebo on Day 7 of second treatment regimen), then Treatment C (JNJ-54861911-matched placebo once daily for next 7 days plus moxifloxacin-matched placebo on Day 7 of third treatment regimen) followed by followed by Treatment D (JNJ-54861911-matched placebo once daily for next 7 days plus moxifloxacin 400 mg on Day 7 of fourth treatment regimen).
89412961|NCT02152332|Experimental|Treatment Sequence Group CBDA|Participant will receive Treatment C (JNJ-54861911-matched placebo once daily for next 7 days plus moxifloxacin-matched placebo on Day 7) followed by Treatment B (JNJ-54861911, 150 mg once daily for next 7 days plus moxifloxacin-matched placebo on Day 7 on second treatment regimen), then Treatment D (JNJ-54861911-matched placebo once daily for next 7 days plus moxifloxacin 400 mg on Day 7 of third treatment regimen) followed by Treatment A (JNJ-54861911, 50 mg once daily for next 7 days plus moxifloxacin-matched placebo on Day 7 of fourth treatment regimen).
89412962|NCT02152332|Experimental|Treatment Sequence Group DCAB|Participant will receive Treatment D (JNJ-54861911-matched placebo once daily for 7 days plus moxifloxacin 400 mg on Day 7) followed by Treatment C (JNJ-54861911-matched placebo once daily for next 7 days plus moxifloxacin-matched placebo on Day 7 of second treatment regimen), then Treatment A (JNJ-54861911, 50 mg once daily for next 7 days plus moxifloxacin-matched placebo on Day 7 of third treatment regimen) followed by Treatment B (JNJ-54861911, 150 mg once daily for next 7 days plus moxifloxacin-matched placebo on Day 7 on fourth treatment regimen).
89412963|NCT03488498||Receiving NSAID medication|Receiving NSAID medication
89412964|NCT03488498||Receiving NSAID medication and weight bath therapy,|
89412965|NCT03488498||Receiving weight bath therapy,|
89412966|NCT03492086|Experimental|Rosemary and alkylglycerol capsules|
89412967|NCT03492086|Placebo Comparator|Control capsules|
89412968|NCT03616197|Active Comparator|Group 1|"Thin Biotype group has described as Group 1. The biotypes of the terminal teeth adjacent to the free gingival graft region were determined by the Probe transparency method.~The mesial terminal tooth (MTT) was defined as the first tooth adjacent to the mesial side of the tooth / teeth to which the FGG will be applied. The distal terminal tooth (DTT) was defined as the first tooth adjacent to the distal side of the tooth / teeth to which the FGG will be applied. If MTT and DTT had thin biotype, the patient was assigned to the thin biotype group."
89412969|NCT03616197|Active Comparator|Group 2|"Thick biotype group has described as Group 2. The biotypes of the terminal teeth adjacent to the free gingival graft region were determined by the Probe transparency method.~The mesial terminal tooth (MTT) was defined as the first tooth adjacent to the mesial side of the tooth / teeth to which the FGG will be applied. The distal terminal tooth (DTT) was defined as the first tooth adjacent to the distal side of the tooth / teeth to which the FGG will be applied. If MTT and DTT had thick biotype, the patient was assigned to the thick biotype group."
89412970|NCT05050630|Experimental|TR2-ICE|All patients eligible for inclusion were treated with TR2-ICE, and the first efficacy evaluation was conducted after the second course of treatment. If the patient can achieve complete response (CR), partial response (PR), and disease stability (SD), the clinical benefit is considered, and the TR2-ICE treatment regimen is continued. The second efficacy assessment was performed after the 4th course of treatment. If patients achieved complete response (CR) or partial response (PR) compared to baseline, the clinical treatment was considered effective and the TR2-ICE treatment regimen was continued. After the completion of six courses of induction chemotherapy, an end-of-course assessment was performed. Patients with CR and PR can choose to undergo autologous hematopoietic stem cell transplantation consolidation therapy, or lenalidomide or Tirelarizin monotherapy or both combination maintenance therapy.
89412971|NCT02155998||PREVENT study patients|Patients with locally advanced prostate cancer with high and very high risk of recurrence, who underwent surgery or radiotherapy within 3 months prior to enrolment, 18 years and older, consented to participate in this non-interventional study, being treated for prostate cancer in the oncology institutions / departments in the Russian Federation.
89412972|NCT05118308|Experimental|Transjugular approach|Transjugular hepatic venous pressure gradient measurement with liver biopsy (HVPG-LB).
89412973|NCT05118308|Experimental|Endoscopic ultrasound approach|Endoscopic ultrasound portal pressure gradient measurement with liver biopsy (EUS-PPG-LB)
89005477|NCT02210260|Active Comparator|Continuous infusion of local anaesthetic|Continuous infusion of local anaesthetic into the surgical wound
89412974|NCT03617289|Experimental|Treatment|Receiving Magnesium Sulfate
89412975|NCT03617289|Placebo Comparator|Placebo|Receiving Dextrose 5% in Water (D5W)
89412976|NCT02152410|Experimental|acupuncture group|The patient receives acupuncture session lasts between 20 to 30 minutes. Acupuncture will be applied according to the standards for reporting interventions in clinical trials of acupuncture (STRICTA).
89005478|NCT02210260|Experimental|Spinal and infusion of local anaesthetic|A one off spinal anaesthetic plus a continuous infusion of local anaesthetic into the surgical wound
89005479|NCT02210299|Other|Exposure study|2-6 months-old children and 12-18 months-old children
89005480|NCT02210338|Experimental|Karl Storz C-MAC|Intubation of patient using the Karl Storz C-MAC video laryngoscope
89005481|NCT02210338|Experimental|Bonfils Intubation Fibrescope|Intubation of patient using Bonfils Intubation Fibrescope
89005482|NCT00234702|Experimental|1|
89005483|NCT00234702|Placebo Comparator|2|
89005484|NCT04570735||patients with type 2 diabetes and diabetic kidney disease|
89005485|NCT04570735||patients with type 2 diabetes and no diabetic kidney disease|
89412977|NCT02152410|Active Comparator|Morphine group|Each patient must receive a bolus of 5 mg of morphine (5 cc) and 2 mg (2cc) every 10 minutes if no improvement (VAS> 30).
89412978|NCT02236845|Experimental|Lacrima medical active device|
89412979|NCT02236845|Sham Comparator|Lacrima medical sham device|
89412980|NCT05050396|Experimental|Cooled radio frequency|In CRF, water circulates inside the probe to remove heat, modulating the thermal heat in the tissue to around 60°C, and alters the overall size, shape, and projections of lesions compared to conventional RFA. It is postulated that the greater sized CRF lesions may reduce the number of technical failures in the setting of a complex and variable neuronal innervation to the knee. The ability to target a greater amount of neuronal tissue is believed to produce long-term pain relief at least to the duration of relief produced by conventional RFA [27]
88889707|NCT01443650|Experimental|alirocumab SAR236553 (REGN727) (Formulation B x 1)|A single subcutaneous injection of Formulation B
88889708|NCT01443650|Experimental|alirocumab SAR236553 (REGN727) (Formulation A x 2)|2 single subcutaneous injections of Formulation A
88889709|NCT01443663|Experimental|Group 1 (Previously Received H5N1 VN 04 ca Vaccine)|Participants will have previously received two doses of 10^7.5 tissue culture infectious dose (TCID)50 of H5N1 A/VN/1203/04 x A/AA/6/60 ca LAIV (H5N1 VN 04 ca). In this study, they will receive one dose of the H5N1 vaccine at baseline.
88889710|NCT01443663|Experimental|Group 2 (Previously Received H5N1 HK 03 ca Vaccine)|Participants will have previously received two doses of 10^7.5 TCID50 of H5N1 A/HK/213/03 x A/AA/6/60 ca LAIV (H5N1 HK 03 ca). In this study, they will receive one dose of the H5N1 vaccine at baseline.
88889711|NCT01443663|Experimental|Group 3 (Previously Received H7N3 ca Vaccine)|Participants will have previously received two doses of 10^7.5 TCID50 of H7N3 A/ck/BC/CN-6/04 x A/AA/6/60 ca LAIV (H7N3 ca). In this study, they will receive one dose of the H5N1 vaccine at baseline.
88889712|NCT01443663|Experimental|Group 4 (Have Not Previously Received LAIV)|Participants will have not previously received an LAIV of any kind. In this study, they will receive one dose of the H5N1 vaccine at baseline.
88889713|NCT01443663|Experimental|Group 5 (Have Not Previously Received LAIV)|Participants will have not previously received an LAIV of any kind. In this study, they will receive two doses of the H5N1 vaccine at baseline and Day 28.
88889714|NCT01443676|Active Comparator|Radiotherapy|Radiotherapy
88889715|NCT01443676|Experimental|Radiotherapy plus Bevacizumab|Radiotherapy plus Bevacizumab
88889716|NCT01443689|Experimental|Group1 :Conventional plus hUCMSCs treatment|Participants will be given conventional therapy plus human cord mesenchymal stem cells transplantation with a 6 months follow-up.
88889717|NCT01443689|Experimental|Group 2: Conventional plus hCBMNCs and hUCMSCs therapy|Participants will be given conventional therapy plus combination of hCBMNCs together with hUCMSCs transplantation with a 6 months follow-up.
89005486|NCT04570735||patients with obesity, no diabetes and no kidney disease|
88889718|NCT01443689|Active Comparator|Group 3:Conventional therapy|Participants will be given conventional therapy only with a 6 months follow-up.
88889719|NCT01443702|Placebo Comparator|Placebo|
88889720|NCT01443702|Active Comparator|Lapis judaicus|
88889721|NCT01443715|Experimental|Stepped Care IPT-A - Interpersonal Psychotherapy|IPT-A focuses on communication and problem-solving skills.
88889722|NCT01443715|Active Comparator|Treatment as Usual|Treatment as Usual is the standard treatment received in the community
88889723|NCT01443741|Active Comparator|FIT Therapy|Patient with functional insulin therapy
88889724|NCT01443741|Active Comparator|Traditional way|Patient with traditional way
88889725|NCT01443754||Hybrid group|Patients with multi-vessel coronary artery disease (CAD) amenable to hybrid revascularization (LIMA-LAD surgical revascularization followed by PCI)
88889726|NCT01443767||Partial liver resection|Adult patients scheduled for elective partial liver resection
88889727|NCT01443780|Experimental|sellenium + Q10|Active dietary supplement that is compared against a placebo arm
88889728|NCT01443780|Placebo Comparator|Sugar pills|Placebo arm that is compared against active intervention with a dietary supplement with selenium + Q10
88889729|NCT01443806|Experimental|Oseltamivir, genetic testing|
88889730|NCT01443832||iron absorption|
88922036|NCT05928546|Active Comparator|Group(Ⅱ):scaling and root planing with application of quercetin nanoemulgel|10 sites will receive non-surgical periodontal therapy followed by the application of quercetin nanoemulgel local delivery 2 times one at the day of non-surgical periodontal therapy and after 2 weeks.
88922037|NCT05926830|Experimental|Sonovein Treatment|
89536714|NCT02473133|Sham Comparator|No dose redistribution|Patients will receive a single prescription of 66 Gy in 33 fractions in 6.6 weeks, with 2 Gy fractions given once daily, 5 days a week, without target volume reduction or adaptation (whatever the FDG-PET result).
89536715|NCT01375673|Experimental|Exercise|Exercise: Walking Strength Training Bicycling
89536716|NCT01375673|No Intervention|Usual Care|Usual Care
89536717|NCT02470715||Molecular profile|Molecular profiled group receiving treatment based on genetics
88889731|NCT01443871|Experimental|Aromatherapy|Experimental procedures were conducted in the morning. Subjects individually entered the closed room where the temperature was kept at 25-26 oC and humidity 50-60%. The subjects were blinded using mask and were seated comfortably with eyes closed during experimental period. The EEG was recorded using silver electrodes. EEG activity was monitored 4 areas (F7, F8, T3 and T4) and ground electrodes. The experiments were divided into 3 parts. The first part, no-odor were recorded EEG activity for 10 minutes as a baseline. The second part, subject was exposure to the odor for 10 minutes as during inhalation. The last part, the odor was dispersed and assessed EEG activity for 10 minutes as after inhalation.
88889732|NCT01443871|Placebo Comparator|Pure water|Experimental procedures were conducted in the morning. Subjects individually entered the closed room where the temperature was kept at 25-26 oC and humidity 50-60%. The subjects were blinded using mask and were seated comfortably with eyes closed during experimental period. The EEG was recorded using silver electrodes. EEG activity was monitored 4 areas (F7, F8, T3 and T4) and ground electrodes. The experiments were divided into 3 parts. The first part, no-odor were recorded EEG activity for 10 minutes as a baseline. The second part, subject was exposure to the water for 10 minutes as during inhalation. The last part, the water was dispersed and assessed EEG activity for 10 minutes as after inhalation.
88889733|NCT01443884|Experimental|Group 1|After a 1 week baseline, volunteers will consume two packets of grape powder stirred into water for three weeks. Each packet will contain the equivalent of approximately 2 servings of fresh grapes (46 grams of powder). Following a two week washout period, volunteers will cross-over to a placebo powder.
88889734|NCT01443884|Experimental|Group 2|After a 1 week baseline, volunteers will consume two packets of placebo powder stirred into water for three weeks. Following a two week washout period, volunteers will cross-over to grape powder for three weeks.
88889735|NCT01443897|Placebo Comparator|Group 1|Untreated mushrooms plus placebo capsule.
88889736|NCT01443897|Experimental|Group 2|UVB-treated mushrooms (400 IU vitamin D2 per serving) plus placebo capsule.
88889737|NCT01443897|Experimental|Group 3|UVB-treated mushrooms (1,000 IU vitamin D2 per serving) plus placebo capsule.
88889738|NCT01443897|Experimental|Group 4|Untreated mushrooms plus 1,000 IU Vitamin D2 in capsule
88889739|NCT01443962|Experimental|Zero positive end expiratory pressure|Number: 30, apply no PEEP during the pneumoperitoneum during the laparoscopic cholecystectomy PEEP was not applied whole investigation period
88889740|NCT01443962|Active Comparator|positive end expiratory pressure|applying PEEP 10 cmH2O during pneumoperitoneum continuously
88889741|NCT01443975||All patients|Measurement with x-pander in acetabulum prior to inserting the artificial hip socket.
88889742|NCT01443988|Active Comparator|iStent|Implantation of two iStent devices
88889743|NCT01443988|Active Comparator|Drug|Travoprost drops
88889744|NCT01444001|Experimental|Pneumococcal Vaccine Dose 1 (Low dose)|Participants will receive 2 injections of Dose 1 investigational Pneumococcal vaccine (Low dose) on Day 0 and Day 30, respectively.
88889745|NCT01444001|Experimental|Pneumococcal Vaccine Dose 2 (Middle dose)|Participants will receive 2 injections of the investigational Pneumococcal vaccine (Middle dose) on Day 0 and Day 30, respectively.
88889746|NCT01444001|Experimental|Pneumococcal Vaccine Dose 3 (High dose)|Participants will receive 2 injections of the investigational Pneumococcal vaccine (High dose) on Day 0 and Day 30, respectively.
88889747|NCT01444014|Experimental|YF476|
88889748|NCT01444053||Wearers of contact lenses without UV Protection|Subjects who have worn a soft contact lens without UV protection for the past five years or more.
89536718|NCT03108599|Experimental|Intervention|All participants in the intervention arm will receive two interventions: an enhanced cab intervention alone, and then the enhanced cab conditions combined with a behavioral sleep intervention.
88889749|NCT01444053||Wearers of contact lenses with UV Protection|Subjects who have worn a soft contact lens with UV protection for the last 5 years or more.
88889750|NCT01444066|Placebo Comparator|dilation to 27 French|
88889751|NCT01444066|Experimental|Dilation of the esophagus to 54 French|Esophagus will be dilated with a Savory dilator
88889752|NCT01444079||Liver transplant recipients|Recipients who will undergo liver transplantation during study period
89536719|NCT03108599|No Intervention|Control|Usual practices with regards to cab conditions and access to workplace programs for preventing sleep and fatigue problems.
89536720|NCT02470481||Cohort 1|Participants with psoriatic arthritis among psoriasis particiants attending dermatology clinics.
88889753|NCT01444118|Experimental|EGF Vaccine|Patients in this arm will receive a low dose of Cyclophosphamide and the recombinant human rEGF-P64K/Montanide ISA 51 vaccine in addition to Best Supportive Care.
88889754|NCT01444118|No Intervention|Best Supportive Care|Patients in this arm will receive best supportive care
88889755|NCT01444131|Placebo Comparator|Varenicline and Placebo Patch|Varenicline and Nicotine Patch (placebo)
88889756|NCT01444131|Active Comparator|Varenicline and Nicotine Patch|Varenicline and Nicotine Patch 15mg
88889757|NCT01444144||Ankle Fracture|Patients aged 55 years at time of surgery undergoing treatment for ankle fractures.
88889758|NCT01444157|Experimental|Palliative homecare nursing group|In addition to the standard homecare nursing the families will receive six home visits from a research nurse with at least 1 year specialised palliative care experience. During the first 2 hour visit a family assessment is obtained containing identification of family roles, resources and coping strategies. The first home visit takes place no later than one week after randomization. The visits continues every third week up to 16 weeks, each visit with a duration of 1,5 hours. At every visit the EORTC-QLQ-C30 patient administered questionnaire is used to identify the nature, frequency and intensity of the patients physical and psychosocial problems.
88889759|NCT01444157|No Intervention|Standard homecare nursing group|Patients continue to receive the standard homecare nursing. They can contact municipality services for visitation to homecare nursing if they feel that additional homecare is needed or if they do not yet receive this service and feel they need homecare nursing.
88889760|NCT01444170|Placebo Comparator|Sugar pill|"Placebo sugar pill was used as a sham control"
88889761|NCT01444170|Experimental|dicreatinol sulfate|
88889762|NCT01444183|Active Comparator|Progressive muscle relaxation|Subjects practice a progressive muscle relaxation exercise for 15 minutes every AM and 5 minutes every PM
88889763|NCT01444183|Sham Comparator|Sham exercise|Subjects practice a sham exercise consisting of focused attention activities
88889764|NCT01444196|Other|Desloratadine dose|"Study group: 5 mg Desloratadine during the whole study~Study group: 5 mg every day for 14 (+-2 days) start with Visit 2, 10 mg every day for 14 (+-2 days) start with Visit 3, 20 mg every day for 14 (+-2 days) start with Visit 4."
88889765|NCT01444196|Other|Dose of Desloratadine|"Study group: 5 mg Desloratadine during the whole study~Study group: 5 mg every day for 14 (+-2 days) start with Visit 2, 10 mg every day for 14 (+-2 days) start with Visit 3, 20 mg every day for 14 (+-2 days) start with Visit 4."
88889766|NCT01444235|Active Comparator|Custodiol|After cross clamping of the aorta on cardiopulmonary bypass, the Custodiol solution, at a temperature of 4 - 6°C, will be infused antegrade into the root of the aorta.
88889767|NCT01444235|Experimental|Custodiol-N|After cross clamping of the aorta on cardiopulmonary bypass, the Custodiol-N solution, at a temperature of 4 - 6°C, will be infused antegrade into the root of the aorta.
88889768|NCT01444248|Experimental|Amaryl MEX|
88889769|NCT01444248|Active Comparator|Amaryl M|
88889770|NCT01444261|Active Comparator|Intervention|Fer-in-Sol drops and iron-fortified cereal
88889771|NCT01444261|Other|Control|No intervention
88889772|NCT01444274||Obalon Gastric Balloon|One or two balloons administered to each patient
88889773|NCT01444313|Other|nelfilcon A OD / narafilcon A OS|Soft contact lens without UV protection worn on the right eye (OD) and soft contact lens with UV protection worn on the left eye (OS).
88889774|NCT01444313|Other|narafilcon A OD / nelfilcon A OS|Soft contact lens with UV protection worn on the right eye (OD) and soft contact lens without UV protection worn on the left eye (OS).
88889775|NCT01444326|Experimental|Dairy diet|
89192800|NCT06030999|Active Comparator|Study product A (Wonderlab wonder4shape)|"2g/bottle, containing the following probiotics total dosage 2.0*1010 CFU:~CECT7527, CECT7528, CECT7529~Maltodextrin~Lactobacillus acidophilus~Fructose oligosaccharides~Grapefruit, Lemon and Apple powder"
89192801|NCT06030999|Active Comparator|Study product B (Wonderlab wonder4shape)|"2g/bottle, containing the following probiotics total dosage 1.0*1010 CFU:~Maltodextrin~Lactobacillus acidophilus"
89192802|NCT06030999|Placebo Comparator|Study product C (placebo)|"2g/bottle, containing the following ingredients:~Maltodextrin~Grapefruit powder~Lemon powder"
88889776|NCT01444326|Placebo Comparator|Control diet|
88889777|NCT01444339|Experimental|Pneumococcal Vaccine Formulation 1|Participants will receive an injection of pneumococcal vaccine (Formulation 1, 1 middle dose) on Day 0 and Day 30, respectively.
89536721|NCT02472821|Active Comparator|Interactive Lesson|Subjects will receive a community-based face-to-face interactive youth educational program on hearing health
88889778|NCT01444339|Experimental|Pneumococcal Vaccine Formulation 2|Participants will receive an injection of Pneumococcal vaccine (Formulation 2, 2 low doses) on Day 0 and Day 30, respectively.
88889779|NCT01444339|Experimental|Pneumococcal Vaccine Formulation 3|Participants will receive an injection of pneumococcal vaccine (Formulation 3, 2 middle doses) on Day 0 and Day 30, respectively.
88889780|NCT01444339|Experimental|Pneumococcal Vaccine Formulation 4|Participants will receive an injection of pneumococcal vaccine (Formulation 4, 2 middle doses) on Day 0 and Day 30, respectively.
88889781|NCT01444339|Experimental|Pneumococcal Vaccine Formulation 5|Participants will receive an injection of pneumococcal vaccine (Formulation 5, 2 high doses) on Day 0 and Day 30, respectively.
88889782|NCT01444339|Placebo Comparator|Pooled placebo Group|Participants will receive an injection of a placebo on Day 0 and Day 30, respectively.
88889783|NCT01444352|Experimental|Vaccine Formulation 1 (Low dose)|Participants will receive 2 injections of Pneumococcal Vaccine Formulation 1 (Low dose).
88889784|NCT01444352|Experimental|Vaccine Formulation 2 (Middle dose)|Participants will receive 2 injections of Pneumococcal Vaccine Formulation 2, (Middle dose).
88889785|NCT01444352|Experimental|Vaccine Formulation 3 (High dose)|Participants will receive 2 injections of Pneumococcal Vaccine Formulation 3, (High dose).
88889786|NCT01444352|Placebo Comparator|Placebo Pooled|Participants who receive 2 injections of tris buffered saline
88889787|NCT01444404|Experimental|Dose Expansion|The dose expansion will consist of up to 20 subjects and the dose level of AMG 820 will be dependent upon emerging safety and PK data from the dose escalation part of the study.
88889788|NCT01444404|Experimental|Dose Escalation|The dose escalation part of the study is aimed at evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of AMG 820.
88889789|NCT01444443|Experimental|Closed-loop glucose control|Blood glucose controlled by control algorithm.
88889790|NCT01444443|Active Comparator|Open-loop glucose control|Blood glucose controlled by patient
88889791|NCT01444482|Experimental|Matrix M adjuvanted influenza vaccine|1 human dose of seasonal influenza vaccine formulated with 50 µg Matrix M
88889792|NCT01444482|Active Comparator|Seasonal influenza vaccine|1 human dose of seasonal influenza vaccine
88889793|NCT01444508|Active Comparator|crystalloid|
88889794|NCT01444508|Placebo Comparator|colloid|
88889795|NCT01444521|Experimental|single-arm Irinotecan-Cisplatin|
88889796|NCT01444534|Experimental|use of the diabetes application|
88889797|NCT01444534|Active Comparator|Control arm without app (usual care)|
88889798|NCT01444547|Experimental|single-arm Paclitaxel-Cisplatin|
88889799|NCT01444560||Cutaneous Melanoma|
88889800|NCT01444560||Cutaneous Melanoma Metastases|
88889801|NCT01444560||Benign Melanocytic Nevi|
89192805|NCT06025136|Experimental|Intervention Group|Patients who are visited in their rooms on the evening of the day before the surgery will be given a gel pillow with a cooling surface feature for night use. Patients will be asked to note the time they go to bed for a night's sleep and the time they wake up on the morning of the surgery. If patients stop using pillows at night, they will be asked to inform the investigator when they come to their room in the morning.Patients will be visited again on the morning of the surgery day.The Richard Campbell Sleep Scale was used to evaluate the nighttime sleep quality of the patients;General Comfort Scale to evaluate comfort.
88889802|NCT01444573|Active Comparator|Group 2 (Lenient control <120bpm)|
88889803|NCT01444573|Active Comparator|Group 1 (Strict control <80 bpm)|
88889804|NCT01444586||Group 1|
88889805|NCT01444599||low FFR group (<0.8)|the patient with FFR values less than 0.8
88889806|NCT01444599||high FFR group (>0.8)|the patient with FFR values greater than 0.8
88889807|NCT01444612||Cancer-related surgery patient records|Healthcare claims records from patients aged 18 years or older with at least one primary inpatient discharge diagnosis of cancer and a cancer-related surgery during the hospitalization
88889808|NCT01444625|Experimental|Dark chocolate|Flavanol-rich chocolate
88889809|NCT01444625|Placebo Comparator|Placebo chocolate|Flavanol-free chocolate
88889810|NCT01444638|Experimental|Ultrasound|Trainees will receive pre-procedure U/S guided examination of the parturient's back.
88889811|NCT01444638|No Intervention|Control|Control group. (Standard practice) Trainees will NOT receive pre-procedure U/S guided examination.
88889812|NCT01444664|Experimental|Aneurysm|
88889813|NCT01444677|Experimental|MB12066 300mg|single dose
88889814|NCT01444677|Active Comparator|MB12066 400mg|single dose
88889815|NCT01444677|Active Comparator|MB12066 100mg|multiple dose
88889816|NCT01444677|Active Comparator|MB12066 200mg|multiple dose
88889817|NCT01444677|Placebo Comparator|Placebo|Placebo 300mg(single dose), 400mg (single dose), 100mg (multiple dose), 200mg (multiple dose)
88889818|NCT01444690|Experimental|Active|Dimiracetam 400 mg capsules
88889819|NCT01444690|Placebo Comparator|Pseudo-placebo|Dimiracetam 25 mg capsules
88889820|NCT01444703|Placebo Comparator|sugar solution|Gargle 5 minutes before induction of general anesthesia with sugar solution.
88889821|NCT01444703|Active Comparator|licorice|Gargle 5 minutes before induction of general anesthesia with licorice solution.
88889822|NCT01444729||xiapex|Subject treated with Xiapex
88889823|NCT01444729||Surgery|Fasciotomy or fasciectomy
88889824|NCT01444755||1-Neoadjuvant Chemotherapy|This arm will take a neoadjuvant chemotherapy regimen previous gastrectomy operation.
88889825|NCT01444755||2 Surgery|Surgery will be performed in patients of this arm.
88889826|NCT01444807|Experimental|Sorafenib|Active Arm
88889827|NCT01444807|No Intervention|Best Supportive Care|Comparator
88889828|NCT01444820|Experimental|Hypofractionation|One phase technique (IMRT or 3D-CRT): radiotherapy to the prostate + pelvic lymphnodes
88889829|NCT01444820|Other|Conventional|two-phase technique (IMRT or 3D-CRT): 1) whole pelvis including the prostate and regional lymph nodes; 2) boost to the prostate
88889830|NCT01444846|Active Comparator|SPI-1005 Low dose|200mg SPI-1005, capsule, bid, po, x4d
88889831|NCT01444846|Active Comparator|SPI-1005 Middle Dose|400mg SPI-1005, capsule, bid, po, x4d
88889832|NCT01444846|Active Comparator|SPI-1005 High Dose|600mg SPI-1005, capsule, bid, po, x4d
88889833|NCT01444846|Placebo Comparator|Placebo|0mg SPI-1005, capsule, bid, po, x4d
88889834|NCT01444859|Placebo Comparator|Placebo capsule|40 subjects allocated to daily placebo capsule for 10 weeks
88889835|NCT01444859|Experimental|Trenev Trio®/Healthy Trinity®|80 subjects allocated to Trenev Trio®/Healthy Trinity® for 10 weeks
88889836|NCT01444872|Experimental|TRV120027|TRV120027 administered as an IV infusion
88889837|NCT01444872|Placebo Comparator|Normal Saline|Normal Saline administered as an IV infusion
88889838|NCT01444885|Experimental|Cilostazol|To investigate the efficacy and safety of Pletaal(Cilostazol) in comparison with placebo for 4 weeks in vasospastic angina patients who have an insufficient response to Amlodipine (Calcium channel blocker).
88889839|NCT01444976|Active Comparator|topical pharyngeal anesthesia|There were 26 patients who had the procedure under topical pharyngeal anesthesia.
88889840|NCT01444976|Active Comparator|midazolam|There were 25 patients who received midazolam.
89412981|NCT05050396|Experimental|Thermocoagulant radio frequency|Conventional radiofrequency Ablation RFA of the knee can be performed under fluoroscopic, or other imaging, guidance, with a cannula advanced into the joint towards the area connecting the shaft to the epicondyle. The area is stimulated to identify the nerve position and to ensure that no motor nerves are activated, as evidenced by absence of fasciculations. The RF electrode is then advanced through the cannula to the target area [18] The electrode tip heats up targeted local tissue within a few millimeters to a temperature typically greater than 47°C (ranging from 70°C to 90°C) for 120 130 seconds, generated through an electromagnetic field with a frequency of 250 kHz . [15,18] The ablative heat is provided via flow of electrical current, generating a well-delineated lesion [24]
89412982|NCT02148900||Marfan|Diagnosis of Marfan syndrome, according to Ghent criteria.
89412983|NCT02148900||Marfan Related Disorders|Diagnosis of Loeys-Dietz syndrome, vascular Ehlers-Danlos syndrome, or Familial Thoracic Aortic Aneurysm and Dissection.
88889841|NCT01444976|No Intervention|hypnosis|There were 27 patients receiving hypnosis.
89412984|NCT02148900||Control Subjects|Unaffected by Marfan or Marfan related disorders.
89412985|NCT03615963||normal|patient complains of anginal chest pain but coronary angiography is normal
89412986|NCT03615963||coronary artery disease|patient complains of chest pain with coronary angiography showing atherosclerotic plaques causing luminal obstruction
89412987|NCT02148666||experimental : intracoronary stem cells|intracoronary stem cells will be injected in infarct related artery.
89412988|NCT05043688|Experimental|Neoadjuvant Chemotherapy With SHR-1210|"Neoadjuvant Chemotherapy： Paclitaxel（Albumin Bound）100mg/m2, Day 1,8,15，Carboplatin AUC=5mg/ml/min，Day 1，SHR-1210 200mg，Day 1，every 3 weeks, 2 cycles.~Postoperative adjuvant treatment：SHR-1210 maintenance"
88889842|NCT01444989|Experimental|Patients without actinic keratosis|Patients with out the diagnosis of actinic keratosis will receive the experimental questionnaire.
88889843|NCT01444989|Experimental|Patients with Actinic Keratosis|Patients with the diagnosis of actinic keratosis will receive the experimental questionnaire.
88889844|NCT01445002|Experimental|BM32 low dose|3 subcutaneous injections of 10 micrograms in a time span of 8 weeks
88889845|NCT01445002|Experimental|BM32 medium dose|3 subcutaneous injections of 20 micrograms in a time span of 8 weeks
88889846|NCT01445002|Experimental|BM32 high dose|3 subcutaneous injections of BM32 over a time span of 8 weeks
88889847|NCT01445002|Placebo Comparator|Placebo|3 subcutaneous injections over a time span of 8 weeks
88889848|NCT01445015|Experimental|Stress management program|
88889849|NCT01445015|Active Comparator|peer viewed movies|
88889850|NCT01445041|Experimental|Single infusion of UCB|(autologous red blood cell and volume reduced cord blood cells)
88889851|NCT01445041|Experimental|Three infusions of UCB|(autologous red blood cell and volume reduced cord blood cells)
88889852|NCT01445054|Experimental|1-Arm 1|Subjects with primary or metastatic cancer other than melanoma, basal cell carcinoma, sarcoma, or lymphoma.
88889853|NCT01445158||1|bone marrow or stem cell donors ages 10 to 15
88889854|NCT01445158||2|bone marrow or stem cell donors ages 16 to 26
88889855|NCT01445197|Experimental|Biostate|
88889856|NCT01445210|Active Comparator|0,2% Ropivacaine|"Patients randomized to the experimental group receive a continuous infusion of 0,2 % Ropivacaine by elastomeric infusion pump at 5 ml/h in the saphenous catheter after major ankle surgery. Infusion for 48 postoperative hours.~All patients receive a preoperative single shot of Ropivacaine around saphenous and sciatic nerve and a postoperative continuous sciatic nerve block."
88889857|NCT01445210|Placebo Comparator|Control|"Patients randomized to the control group receive a continuous infusion of isoton saline by elastomeric infusion pump at 5 ml/h in their catheter after major ankle surgery. Infusion for 48 postoperative hours.~All patients receive a preoperative single shot of Ropivacaine around saphenous and sciatic nerve and a postoperative continuous sciatic nerve block."
88889858|NCT01445223|Active Comparator|lopinavir/ritonavir|400/100 mg BID + 2 NRTIs BID
88889859|NCT01445223|Active Comparator|atazanavir/ritonavir|300mg+100mg QD+ 2 NRTI QD
88889860|NCT01445223|Active Comparator|efavirenz|600mg QD + 2NRTI QD
88889861|NCT01445236|Experimental|Weaning patients|
88889862|NCT01445249|Active Comparator|Landmark guided ankle block|This group will receive a landmark guided ankle block.
88889863|NCT01445249|Active Comparator|This group will be given a PNS guided ankle block|Peripheral nerve stimulation will be used in this group to guide local anaesthetic infiltration. The technique is termed medial forefoot block.
89412989|NCT05043688|Experimental|Neoadjuvant Radiochemotherapy With SHR-1210|"Neoadjuvant Radiochemotherapy： Paclitaxel 50mg/m2, Day 1,8,15,22,29，Carboplatin AUC=2mg/ml/min，Day 1,8,15,22,29，SHR-1210 200mg，Day 1,22, 5 cycles.~Radio therapy d1-23. Postoperative adjuvant treatment：SHR-1210 maintenance"
89412990|NCT05043688|Other|Neoadjuvant Radiochemotherapy Without SHR-1210|"Neoadjuvant Radiochemotherapy： Paclitaxel 50mg/m2, Day 1,8,15,22,29，Carboplatin AUC=2mg/ml/min，Day 1,8,15,22,29， 5 cycles.~Radio therapy d1-23. Postoperative adjuvant treatment：according to the recommendations of the guidelines and the investigators"
89412991|NCT03615885|Placebo Comparator|Placebo Drink|Placebo drink attempted to match for total energy, appearance and taste of Montmorency tart cherry juice.
89412992|NCT03615885|Experimental|Montmorency Tart Cherry Capsules|10 capsules consumed to match total anthocyanin content to Montmorency tart cherry juice.
89412993|NCT03615885|Experimental|Montmorency Tart Cherry Juice|Single-bolus of Montmorency tart cherry juice (130 mL)
89412994|NCT03614715|Experimental|CinnaGen interferon beta-1a|CinnoVex® (IFNβ-1a, Prefilled syringe produced by CinnaGen Company) in prefilled syringe in healthy volunteers. (Stage 1: 30 µg or 60 µg)(Stage 2: 30 µg)
89412995|NCT03614715|Active Comparator|Biogen interferon beta-1a|Avonex® (IFNβ-1a, Prefilled syringe produced by Biogen Company) in prefilled syringe in healthy volunteers. (Stage 1: 30 µg or 60 µg)(Stage 2: 30 µg)
89412996|NCT05131802||Postcholecystectomy group|which included patients that had undergone cholecystectomy.
89412997|NCT05131802||Biliary intervention group|included patients who had undergone at least one of the following procedures for treatment of benign pathology: endoscopic sphincterotomy (ES) and endoscopic stenting.
89412998|NCT00363038|Experimental|Bruising|Bruises at three time points: immediate after bruise creating, and at 1 and 2 weeks.
89412999|NCT03614637||Cannabis User Group|Forty eight participants who are regular Cannabis users with a self-reported frequency of at least once weekly over the past 6 months of screening visit.
89413000|NCT03614637||Non-Cannabis User Group|Twenty four participants who self-report no Cannabis use in the past 6 months of screening visit and fewer than 10 times during their lifetime
88889864|NCT01445262||Subjects prescribed levocetirizine tablets|Subjects prescribed levocetirizine tablets for treatment of allergic rhinitis, urticaria, eczema, dermatitis, skin irritation, prurigo or pruritus cutaneous
88889865|NCT01445275||Ancillary-Correlative (Health Services Research)|Outcome data, such as incidence and stage at diagnosis of ovarian, fallopian tube, and peritoneal cancers; number and timing of screening and serum tests performed; number and timing of pelvic ultrasounds performed; surgical procedures performed; cancer-specific and overall survival (if available); and the incidence, type, and grade of significant adverse events, are collected from the Gynecologic Oncology Group (GOG)-0199 records and analyzed. Cost of each medical intervention is also estimated.
88889866|NCT01445379|Experimental|1|Ipilumumab (DSE) given on day 1 of 21 day cycle for 4 cycles, from cycle 5+ ipilumumab will be given ~every 12wks
88889867|NCT01445392|Experimental|1|Multi-cycle cohort
89413001|NCT04876352|Experimental|VR-training|Upper limb/handwriting exercises in an immersive virtual reality setting
89413002|NCT04876352|Active Comparator|RS-training|The same upper limb/handwriting exercises in a real setting
88889868|NCT01445392|Experimental|2|Single cycle cohort
89413003|NCT04876352|Other|Healthy subjects|Age- and sex-matched healthy subjects recruited to compare clinical and fMRI characteristics at baseline.
89413004|NCT03489668|Active Comparator|PCOS|Metformin administration 1500mg/day
89413005|NCT03489668|No Intervention|Control|
88889869|NCT01445418|Experimental|Arm 1|Standard dose escalation
88889870|NCT01445418|Experimental|Arm 2|Expanded cohort
88889871|NCT01445431|Experimental|Virgin Coconut Oil|
88889872|NCT01445431|Active Comparator|Mineral Oil|
88889873|NCT01445444|Experimental|HRT group|This group receives habit reversal training immediately.
88889874|NCT01445444|Active Comparator|TAU group|This group receives treatment as usual for 8 weeks.
88889875|NCT01445561|Experimental|1|100,000 international units/m2 SQ daily for 5 days
88889876|NCT01445561|Experimental|2|200,000 international units/m2 SQ daily for 5 days
89413006|NCT02872311|Active Comparator|High Dose Influenza Vaccine|This group will be administered High Dose (HD) influenza vaccination (0.5 mL intramuscular (IM) injection) in the first and second years of the study.
89413007|NCT02872311|Active Comparator|Adjuvanted Influenza Vaccine|This group will be administered adjuvanted influenza vaccination (0.5 mL intramuscular (IM) injection) in the first and second years of the study.
89536722|NCT02472821|Active Comparator|Interactive lesson + Web-based booster|Subjects will receive a community-based face-to-face interactive youth educational program on hearing health followed by an Internet-based educational booster
88889877|NCT01445587|Experimental|GSK2110183|The oral dose of GSK2110183 the subjects received will be dependent on when the subject is enrolled to the study. GSK2110183 will be provided in 25mg and 50mg capsules containing the hydrochloride salt form of the API, microcrystalline cellulose, magnesium stearate, and microcrystalline cellulose (optional). They are filled into hard gelatin capsules. The 25mg tablets are opaque, swedish orange, size 2 capsules with no external markings, filled with a white powder. The 50mg tablets are opaque, white, size 1 capsules with no external markings, filled with a white powder.
88889878|NCT01445587|Other|Bortezomib|Bortezomib salvage therapy will be administered as a 3 to 5 second intravenous (IV) push at 1.3 mg/m2 on Days 1, 8, and 15 in each 21-day cycle until one of the Treatment Discontinuation Criteria is met.
88889879|NCT01445600||ALTARGO(retapamulin)|The subjects with bacterial skin and skin structure infections (SSSI)
88889880|NCT01445639|Experimental|Dexmedetomidine group|
88889881|NCT01445639|Placebo Comparator|Placebo group|
88889882|NCT01445691|Experimental|5-ALA (Gliolan)|Fluorescent substance to help visualize and remove as much tumor as possible without harming healthy tissue.
88889883|NCT01445704|Experimental|Probiotics|Patients treated with a probiotic (in capsule form) once daily for 12 weeks
88889884|NCT01445704|Placebo Comparator|Placebo|Patients treated with a placebo (in capsule form) identical to that of the probiotic capsule once daily for 12 weeks
88889885|NCT01445743|Experimental|Biological/Vaccine: Tdap Vaccine|Biological: Tdap Intervention women will receive a blinded dose of Tdap vaccine (ADACEL)
88889886|NCT01445743|Placebo Comparator|Placebo Comparator: Physiologic Saline solution|Administration of Tdap vaccine or placebo as a single 0.5 mL of Saline (0.9% NaCl) solution
88889887|NCT01445756|Active Comparator|Topical Lidocaine|Topical Lidocaine
88889888|NCT01445756|Placebo Comparator|Placebo|Placebo
88889889|NCT01445782|Experimental|1|AZD2115
88889890|NCT01445782|Placebo Comparator|2|Placebo to AZD2115
88889891|NCT01445808|Experimental|Psychodynamic Motivation and Training Program (PMT)|
88889892|NCT01445808|Active Comparator|Advice in Exercise Training|One session of advice in exercise training based on the results of spiroergometry
88889893|NCT01445808|Other|Treatment as usual (TAU)|Usual care by family doctor and cardiologist
88889894|NCT01445834||Incontinent women|
88889895|NCT01445860|Experimental|Treatment|
88889896|NCT01445925|Active Comparator|Pulmonary vein isolation|Patients will undergo pulmonary venous isolation plus pharmacological substrate modification
88889897|NCT01445925|Experimental|Pulmonary vein isolation + Linear Lesions|Patients will undergo pulmonary venous isolation plus both pharmacological and interventional substrate modification
88889898|NCT01445938|Experimental|Step 1 (SAR97276A od)|1 group of paediatric patients will receive 0.5 mg/kg SAR97276A administration once daily (od) for 3 days
88889899|NCT01445938|Experimental|Step 1 (SAR97276A bid)|1 group of paediatric patients will receive 0.25 mg/kg SAR97276A administration twice daily (bid) for 3 days
88889900|NCT01445938|Active Comparator|Step 1 (ACTs)|1 group of paediatric patients will receive arthemeter + lumefantrine (ACTs) bid for 3 days
88889901|NCT01445938|Experimental|Step 2 (SAR97276A)|1 or 2 groups of paediatric patients will receive SAR97276A once daily (od) or twice a day (bid) administration for 3 days (the choice of the od or bid regimen will be based on the results obtained in step 1)
88889902|NCT01445938|Active Comparator|Step 2 (ACTs)|1 group of paediatric patients will receive arthemeter + lumefantrine (ACTs) bid for 3 days
88889903|NCT01445938|Experimental|Step 3 (SAR97276A)|1 group of paediatric patients (2 to 11 years old) will receive: SAR97276A od or bid administration for 3 days (depending on results of step 1)
88889904|NCT01445964|Experimental|1|SLCO2B1 wild type allele
88889905|NCT01445964|Experimental|2|SLCO2B1 variant allele
88889906|NCT01446029|No Intervention|Usual Care|
88889907|NCT01446029|Active Comparator|Intervention Device|
88889908|NCT01446055|Experimental|ResQ process group|Autologous BM-MNC is enriched with ResQ process(an automatic cell separator). Then the cell product is transplanted into the ischemia limbs of a patient.
88889909|NCT01446055|Active Comparator|Ficoll-based conventional method|A conventional method based on Ficoll cell separation is used to process bone marrow.
88889910|NCT01446068|Experimental|Lean Subjects|
88889911|NCT01446068|Experimental|Obese subjects|
88889912|NCT01446081|Experimental|Exercise|Patients will receive an individualized, supervised mixed-modality exercise program created by a CSEP-Certified Exercise Physiologist (CEP).
88889913|NCT01446081|No Intervention|Control|Participants assigned to this arm will receive usual care.
88889914|NCT01446094|Other|single-arm|Additional images collected during routine cardiac MRI (CMR) with diagnostic imaging agent, regadenoson.
88889915|NCT01446107|Experimental|fissure sealant|single placement of resin fissure sealant on tooth surface
88889916|NCT01446107|Experimental|fluoride varnish|application of a 5% sodium fluoride varnish every 6 months
88889917|NCT01446107|Experimental|SDF solution|application of a 38% silver diamine fluoride solution onto tooth surface every year
88889918|NCT01446107|Placebo Comparator|control|application of water onto tooth surface every year
88889919|NCT01446120|Experimental|Insulin loaded Orally Dissolved Films (insulin-ODF)|
88889920|NCT01446120|Active Comparator|Human Insulin Specific RIA Kit <5uCi|
88889921|NCT01446146|Experimental|IDM intervention|Will receive a 40 minute intervention session with a clinician, learning about PTSD treatment options and choosing a preferred treatment.
88889922|NCT01446146|Placebo Comparator|Treatment as usual plus placebo session|Will work with provider to select a treatment plan and will receive a 40 minute session without IDM intervention.
88889923|NCT01446172||cognitive, schema focused, guided mastery, exposure|
88889924|NCT01446185|Other|a HR+, N- or pN1(mi), Her2- breast cancer adjuvant population|
88889925|NCT01446198||AHPV positive and negative subjects|
89536723|NCT02472821|No Intervention|No-intervention control|No interventions; pre- and post- measures only.
89413008|NCT02872311|Active Comparator|Standard Dose Influenza Vaccine+HD|This group will be administered standard dose flu vaccination (0.5 mL intramuscular (IM) injection) in the first year of the study and high dose influenza vaccine (0.5 mL intramuscular (IM) injection) in the second year of the study.
89413009|NCT02872311|Active Comparator|Standard Dose Influenza Vaccine +Adj|This group will be administered standard dose flu vaccination (0.5 mL intramuscular (IM) injection) in the first year and adjuvanted influenza vaccination (0.5 mL intramuscular (IM) injection) in the second year of the study.
89413010|NCT02872311|Active Comparator|Standard Dose Influenza Vaccine+Recomb|This group will be administered a standard dose flu vaccination (0.5 mL intramuscular (IM) injection) in the first year and recombinant influenza vaccination (0.5 mL intramuscular (IM) injection) in the second year of the study.
89413011|NCT04461470||London|pulsed electro resonance hz 4, hz 3, hz 2, hz 3.5 and residual hz 5
89413012|NCT04461470||All United Kingdom|pulsed electro resonance hz 4, hz 3, hz 2, hz 3.5 and residual hz 5
89413013|NCT05120336|Experimental|Non-depressed control participants: sham first, active taVNS second|Non-depressed control participants receive sham stimulation in the first session (biphasic stimulation with a frequenyc of 25 Hz, 30s OFF/30s ON at the earlobe (sham) for 1.5 h). In a second identical session, they receive active stimulation with the same parameters (at the cymba conchae).
89413014|NCT05120336|Experimental|Patients with major depressive disorders: sham first, active taVNS second|participants with depression receive sham stimulation in the first session (biphasic stimulation with a frequenyc of 25 Hz, 30s OFF/30s ON at the earlobe (sham) for 1.5 h). In a second identical session, they receive active stimulation with the same parameters (at the cymba conchae).
88889926|NCT01446211|Experimental|Test group - gusperimus|Both severity subgroups (severe and non-severe) will be treated with gusperimus + glucocorticoids.
88889927|NCT01446211|Active Comparator|Control group|"The severe subgroup will receive a course (13 - 22 weeks) of cyclophosphamide followed by methotrexate + glucocorticoids. Patients intolerant to methotrexate and patients with impaired renal function will receive azathioprine + glucocorticoids.~The non-severe subgroup will receive methotrexate + glucocorticoids(or azathioprine + glucocorticoids for those previously intolerant to methotrexate or with impaired renal function)."
88889928|NCT01446224||Subjects who experience cardiac ischemia|Subjects who experience cardiac ischemia including myocardial infarction, unstable angina, transient ischemic attack, and cerebrovascular accident
88889929|NCT01446224||Subjects who do not experience cardiac ischemia|Subjects who do not experience cardiac ischemia
88889930|NCT01446224||Subjects who experience Torsades de Pointes|Subjects who experience Torsades de Pointes
88889931|NCT01446224||Subjects who do not experience Torsades de Pointes|Subjects who do not experience Torsades de Pointes
88889932|NCT01446263|Active Comparator|Radial access|
88889933|NCT01446263|Active Comparator|Femoral access|
88889934|NCT01446276|Experimental|Resveratrol|Resveratrol 500mg 3 times daily for six month
88889935|NCT01446276|Placebo Comparator|Placebo|Placebo 1 tablet 3 times daily for six month
88889936|NCT01446276|No Intervention|Control group|Men without non-alcoholic fatty liver disease
88889937|NCT01446302|Active Comparator|Double meal on a HD day|A standardized meal is served 1 h after start of HD and 1 h after end of HD
88889938|NCT01446302|No Intervention|Single meal on a HD day|A standardized meal is served 1 h after start of HD. After the meal participants fast for 9 h (6 h after end of HD).
88889939|NCT01446302|No Intervention|Single meal on a non-HD day|A standardized meal is served 1 h after study start. After the meal participants fast for 9 h.
89413015|NCT05120336|Experimental|Patients with major depressive disorders: active taVNS first, sham second|participants with depression receive active stimulation in the first session (biphasic stimulation with a frequenyc of 25 Hz, 30s OFF/30s ON at the cymba conchae (active) for 1.5 h). In a second identical session, they receive sham stimulation with the same parameters (at the earlobe).
89413016|NCT05120336|Experimental|Non-depressed control participants: active taVNS first, sham second|Non-depressed control participants receive active stimulation in the first session (biphasic stimulation with a frequenyc of 25 Hz, 30s OFF/30s ON at the cymba conchae (active) for 1.5 h). In a second identical session, they receive sham stimulation with the same parameters (at the earlobe).
89413017|NCT03614559||CTO PCI group and non CTO PCI group|CTO PCI group： Succession of CTO revascularization non CTO PCI group： Failure or not tried to revascularization
88889940|NCT01446302|No Intervention|Single meal (healthy controls)|A standardized meal is served 1 h after study start. After the meal participants fast for 9 h.
88889941|NCT01446315|Experimental|Asthma APGAR|Use of new asthma care tools. Primary care practices will be provided and educated about the Asthma APGAR tool system to guide asthma care. The practices will adopt this system for all people in their practices with asthma. Outcomes will be assessed only for those who meet enrollment criteria and sign informed consent.
88889942|NCT01446315|Placebo Comparator|Usual care|Usual asthma care as provided by the sites.
88889943|NCT01446328|Active Comparator|Amisulpride|
88889944|NCT01446328|Active Comparator|Aripiprazole|
88889945|NCT01446328|Active Comparator|Olanzapine|
88889946|NCT01446341|Active Comparator|Immobilization|50 patients will be randomly assigned to have their lateral ankle sprain immobilized in a below knee cast
88889947|NCT01446341|Active Comparator|Functional Rehabilitation|50 patients will be randomly assigned to a functional rehabilitation program for their lateral ankle sprain
88889948|NCT01446354||Cardiac surgery with HCA|Patients undergoing cardiac surgery with the help of hypothermic cardiac arrest for pathologies of the proximal aorta
88889949|NCT01446380||Pseudoxanthoma elasticum|
88889950|NCT01446406|Active Comparator|MONARCA|MONARCA self-monitoring application on a cell phone to monitor affective symptoms every day.
88889951|NCT01446406|Placebo Comparator|NON-MONARCA|This is the same mobile phone as the MONARCA mobile phone. Yet the MONARCA application has not been installed. The mobile phone can only be used as a normal mobile phone for communication purposes.
88889952|NCT01446445|Active Comparator|1.A (Prophylaxis-SPC)|Prophylaxis for CMV infection and Ganciclovir/ Valganciclovir doses according to summaries of product characteristics (SPC).
88889953|NCT01446445|Experimental|1.B (Prophylaxis- PK model)|Prophylaxis for CMV infection and Ganciclovir/Valganciclovir doses according to pharmacokinetic model.
88889954|NCT01446445|Active Comparator|2.A (Treatment-SPC)|Treatment for CMV infection/disease and Ganciclovir/ Valganciclovir doses according to summaries of product characteristics (SPC).
88889955|NCT01446445|Experimental|2.B (Treatment-PK model)|Treatment for CMV infection/disease and Ganciclovir/Valganciclovir doses according to pharmacokinetic model
88889956|NCT01446458|Experimental|5-Fluorouracil, Oxaliplatin, Irinotecan|5-Fluorouracil, Oxaliplatin, Irinotecan are administered as a modified FOLFIRINOX regimen every 15 days. Subjects receive bi-weekly cycles of therapy on the 1st week, the 3rd week, the 5th week and finally the 7th week for a total of 4 cycles. Assessments include history and physical, laboratory tests on a weekly basis throughout the treatment period prior to and including week 8 assessment for stereotactic body radiotherapy (SBRT).
88889957|NCT01446471||Cardiac Arrest|Patients in Cardiac Arrest will be enrolled
88889958|NCT01446484|Experimental|T reg therapy|Kidney transplantation, followed by immunotherapy given along with autologous CD4+CD25+CD127lowFoxP3+ T regulatory cells infusions
88889959|NCT01446484|Active Comparator|Immunosuppression|Patients will undergo immunosuppressive therapy followed by living related kidney transplantation
88889960|NCT01446497|Active Comparator|Timolol|non selective beta blocker, aqueous humor suppressant ophthalmic solution
88889961|NCT01446497|Active Comparator|Combigan (Timolol/Brimonidine) combination drug|Brimonidine: alpha-2 agonist
88889962|NCT01446510||Hospitalized Medical Patients|All hospitalized medical adult patients
88889963|NCT01446523|Placebo Comparator|Lactulose|Group L receives lactulose Group NL receives placebo
88889964|NCT01446523|Placebo Comparator|Placebo|Group NL receives placebo
88889965|NCT01446536|No Intervention|Control group|This arm which was control group, was randomly selected among patients with acute decompensated heart failure in whom the checklist was not used. This group was managed as per the standard guidelines.
88889966|NCT01446536|Active Comparator|Checklist (intervention) cohort|checklist was used in this group arbitrarily by their treating physician
88889967|NCT01446549|Experimental|Deep Brain Stimulation|
89413018|NCT03614559||Initially attempted and re-attempted|PCI initially attempted group： First time to try to revascularization PCI re-attempted group: Second or more time to try to revascularization
89413019|NCT03614559||PCI during China Club or not|PCI during Chronic Total Occlusion Club， China Club : CAG in 2016.11.04 Another group: CAG in other time
89413020|NCT03614559||Morning，Afternoon，Night|Morning group:（8:00-12:59） Afternoon group：（13:00-17:59） Night group：（after 18:00）
89413021|NCT03488342|Other|Rives technique|Rives technique for primary inguinal hernia
88889968|NCT01446549|Experimental|Locomotor Exercise|
88889969|NCT01446562|Experimental|Y90 Ibritumomab Tiuxetan|Addition of Y90 Ibritumomab Tiuxetan RIT to CHOP-R treatment for follicular lymphoma-patients also receive maintenance Rituximab every 3 months for 2 years after the Y90 Ibritumomab Tiuxetan
88889970|NCT01446588|Experimental|Yoga|Yoga group
88889971|NCT01446601|Experimental|Treatment|The Treatment Arm is implanted with the HGNS System and therapy is turned on at 1 month post-implant.
88889972|NCT01446601|Other|Control|The Control Arm is implanted with the HGNS System and therapy is turned on at 7 months post-implant.
88889973|NCT01446614|Experimental|MSC|Intravenous autologous bone marrow derived mesenchymal stem cells infusion to patients with Parkinson's disease.
88889974|NCT01446627||metal staples|
88889975|NCT01446627||Insorb vicryl staples|
88889976|NCT01446640|Experimental|MSC|Intravenous combined with intrathecal administration of autologous bone marrow derived mesenchymal stem cells to patients with spinal cord injury.
89005487|NCT04570813|Experimental|artistic activities|"participants will do a 3-month cycle of weekly artistic activities at the MAMAC Museum, which are structured 2-h-long art-based workshops"
89005488|NCT04570813|No Intervention|No artistic activities|The control group is composed of participants who do not take part in art-based activities,
89005489|NCT04570696||Adult haemophilia patients|Adult (≥ 18 years old) haemophilia patients, only men
89005490|NCT04570540||OSA|Obstructive Sleep Apnea as confirmed by full-night attended in-lab polysomnography showing an apnea-hypopnea index of >=15 per hour or, alternatively, an apnea-hypopnea index >=5 with excessive daytime sleepiness as defined by an Epworth Sleepiness Scale score >9.
89005491|NCT04570540||OSA+SH|Obstructive Sleep Apnea as confirmed by full-night attended in-lab polysomnography showing an apnea-hypopnea index of >=15 per hour or, alternatively, an apnea-hypopnea index >=5 with excessive daytime sleepiness as defined by an Epworth Sleepiness Scale score >9. Furthermore, co-existing hypoventilation during sleep, defined by the presence of intermittent hypercapnia as measured by transcutaneous capnometry and arterialized capillary blood gas analysis.
89005492|NCT04570540||OHS|Obstructive Sleep Apnea as confirmed by full-night attended in-lab polysomnography showing an apnea-hypopnea index of >=15 per hour or, alternatively, an apnea-hypopnea index >=5 with excessive daytime sleepiness as defined by an Epworth Sleepiness Scale score >9. Furthermore, co-existing hypoventilation during wakefulness, defined by a PCO2>45mmHg as measured by arterialized capillary blood gas analysis.
89005493|NCT04570462|Experimental|Experimental Arm- Induction of Mild Hypothermia Protocol|Determination of metabolic rate by the metabolic cart (noninvasive connection of the device to the ventilator for 20 minutes). Initiate hypothermia (established Northwell hypothermia status post cardiac arrest protocol) using the Arctic Sun. The Arctic Sun 5000® is set to a temperature of 34.5 C to lower the body temperature.
89005494|NCT04570189||Phase I|Twenty subjects, 10 unventilated and 10 ventilated patients, will undergo clinical auscultation of the heart and lungs with the Auscul-X, a conventional stethoscope and an electronic stethoscope (Littmann 3200).
89005495|NCT04570189||Phase II|Twenty subjects, 10 unventilated and 10 ventilated patients, will undergo clinical auscultation of the heart and lungs with an Auscul-X with wireless capability, a conventional stethoscope and an electronic stethoscope (Littmann 3200). Phase II shall begin upon appropriate Health Canada approvals for the Auscul-X with wireless capability.
89005496|NCT04570345|Experimental|Ticagrelor monotherapy|Ticagrelor monotherapy after 3-month DAPT(aspirin with ticagrelor)
89005497|NCT04570345|Active Comparator|Aspirin with P2Y12 receptor inhibitor|Aspirin with P2Y12 receptor inhibitor after 3-month DAPT(aspirin with ticagrelor)
89005498|NCT04570228|Active Comparator|Treatment group|Pulmonary artery denervation with the TIVUS™ System will be performed immediately after the right heart catheterization and pulmonary artery angiography.
89005499|NCT04570228|Sham Comparator|Sham control group|A sham treatment of pulmonary artery denervation with the TIVUS™ System will be performed immediately after the right heart catheterization pulmonary artery angiography. The sham procedure will be identical to the denervation procedure, with the only exception that the procedure will use a sham setting on the control console.
89005500|NCT04570072|Experimental|Probiotic|Formula probiotic contains freeze-dried Lactobacillus paracasei, Bifidobacterium animals, Bifidobacterium longum, Bifidobacterium bifidum, and Lactobacillus plantarum, each at a dosage of 3.0 × 10^10 colony forming unit per 2g sachet.
89005501|NCT04570072|Placebo Comparator|Placebo|Placebo made with only the excipients. The placebo sachet was matched to the study probiotic products for taste, color, and size.
89005502|NCT04570306||Belimumab-treated SLE patients|SLE patients with active disease who will be started on add-on treatment with belimumab on top of standard of care.
89005503|NCT04570033|Experimental|patients with hyperparathyroidism|We prospectively enrolled 65 consecutive patients with primary hyperparathyroidism (PHPT) who underwent neck ultrasound (US) and parathyroid scintigraphy (99mTc/99mTc-MIBI dual phase). Twenty-two patients had unsuccessful parathyroid surgery prior to the study
89005504|NCT04569721|Experimental|CT guided splanchnic cryoablation|Obese patients with type 2 diabetes receiving CT guided splanchnic cryoablation.
89005505|NCT00234858|Active Comparator|1|
89005506|NCT00234858|Active Comparator|2|
89005507|NCT04569838|Experimental|Bendamustine hydrochloride injection|Bendamustine hydrochloride injection 120 mg/m² or 100 mg/m² intravenously (IV) on Day 1 and Day 2 of 21-day cycle (6-8 cycles maximum) for non-hodgkin's lymphomas or chronic lymphocytic leukemia. After 6-8 cycles, the course of treatment could be added based on patient's benefit and investigator's determination.
89005508|NCT04569916|Experimental|treatment group|radiotherapy combined with irinotecan liposome and apatinib followed by PD-1 antibody and apatinib
89413022|NCT03488342|Other|Lichtenstein repair|Lichtenstein repair for primary inguinal hernia
89413023|NCT03614403|Experimental|Vitamin D|Intervention patients will be received a single dose of 300000 IU vitamin D via intramuscular injection
89413024|NCT03614403|No Intervention|control|Control patients will not be received any intervention
89413025|NCT04461314|Other|Peer-led counselling|"About 50 university students trained as peer telephone counsellors through a structured training programme.~About 200 Drug-abusing youth and young adults received telephone-based, Peer-led Brief Motivational Interviewing (BMI)"
88889977|NCT01446653|Experimental|EARLY|Motivational Interviewing plus feedback counseling with information via video and brochures
88889978|NCT01446653|Active Comparator|Video Information|Providing FASD information via documentary video clips
88889979|NCT01446653|Active Comparator|Informational Brochure|Participants will receive informational brochures on contraception, women and drinking, and cutting down your drinking.
88889980|NCT01446679||atrovastatin group|Who receive atrovastatin
88889981|NCT01446692||Patients with suboptimal response|
88889982|NCT01446692||Patients with symptomatic remission|
88889983|NCT01446718||Gardasil Vaccine|"This is an extension of follow up for participants who received 3 doses of Gardasil vaccine in the Immunogenicity and Safety of Quadrivalent Human Papillomavirus Vaccine in HIV-Infected Pre-Adolescent Girls and Boys in Kenya study."
88889984|NCT01446731|Experimental|Arm A|DC vaccine (mRNA transfected dendritic cell) + Docetaxel
88889985|NCT01446731|Active Comparator|Arm B|Docetaxel alone
88889986|NCT01446757|Experimental|The intervention group|The intervention group will receive Comprehensive Geriatric Assessment and follow up as a complement to the same standard health care services as the control group. The Comprehensive Geriatric Assessment and follow up will be provides through an outpatient facility that tailors care from a holistic perspective and, based on each patient's individual needs in line with the policy program that Sweden's pensioners' organizations have presented in 2010 together with the Swedish Association of Geriatric Medicine. The team includes, among other things. a. geriatricians, nurses, physiotherapists, assistance officer, dietician, pharmacist and co-operation with the dental hygienist.
88889987|NCT01446757|Placebo Comparator|Control group|The control group will receive care in the same way as usual meaning access to primary care, hospital in- and outpatient care and care received by the municipality. The only difference between the two groups are that the control group will not have access to the geriatric care team.
88889988|NCT01446783|Active Comparator|mecasermin + Ehlers-Danlos|
88889989|NCT01446783|Placebo Comparator|Saline + Ehlers-Danlos|
88889990|NCT01446783|Active Comparator|Mecasamin + healthy control|
89413026|NCT02871375|Other|DT1 MF, then Habitual|Delefilcon A multifocal contact lenses in Period 1, followed by subject's habitual multifocal contact lenses in Period 2. Each product worn bilaterally (in both eyes) for 14 ± 3 days.
89413027|NCT02871375|Other|Habitual, then DT1 MF|Subject's habitual multifocal contact lenses in Period 1, followed by delefilcon A multifocal contact lenses in Period 2. Each product worn bilaterally (in both eyes) for 14 ± 3 days.
89413028|NCT03488264||United States|50 participants will be recruited from the United States.
89413029|NCT03488264||Jamaica|50 participants will be recruited from Jamaica.
89413030|NCT02032017|Experimental|Percutaneous assisted approach|In this technique, a second small incision (1 cm) at the anterior border of the femur is made. A canulla is placed underneath the muscle and used to pass the reamers in the direction of the acetabulum. There's no need to enlarge the skin incision or to release more muscle insertion to achieve good working access to the acetabulum. Two advantages can be defined: sparing of the gluteus medius muscle and safe access to the acetabulum to obtain perfect positioning of the implants.
89413031|NCT02032017|Active Comparator|Anterolateral approach|A standard transgluteal approach is used. This means a large part of the gluteus medius muscle is released to obtain good access to the acetabulum.
88889991|NCT01446783|Placebo Comparator|Saline + healthy control|
88889992|NCT01446822|Experimental|Bipolar transurethral resection|
88889993|NCT01446822|Active Comparator|Monopolar transurethral resection|
88889994|NCT01446835|Experimental|nelfilcon A|Nelfilcon A printed contact lens randomly assigned to one eye, with etafilcon A printed contact lens assigned to the fellow eye for contralateral wear. Lenses will be worn for 20 minutes.
88889995|NCT01446835|Active Comparator|etafilcon A|Etafilcon A printed contact lens randomly assigned to one eye, with nelfilcon A printed contact lens assigned to the fellow eye for contralateral wear.
88889996|NCT01446848|Experimental|iron supplement|open-label iron supplement intervention group
88889997|NCT01446861||Cystic fibrosis patients|Consecutive cystic fibrosis patients attending regular Controls at the CF clinic in Bergen
88889998|NCT01446861||Healthy controls|Age and gender matchet healthy Controls recruited by Board notice and advertising.
88889999|NCT01446887|No Intervention|non-prophylactic anticoagulation|without prophylactic anticoagulation
88890000|NCT01446887|Experimental|prophylactic anticoagulation|prophylactic anticoagulation by rivaroxaban
88890001|NCT01446900|Experimental|Rituximab cladribine|
88890002|NCT01446926|Experimental|Group 1: Adults High Dose (Formulation 1)|Adults who will receive a single injection of high dose investigational Pneumococcal vaccine
88890003|NCT01446926|Placebo Comparator|Group 2: Adults Placebo|Adult participants who will receive an injection of placebo
88890004|NCT01446926|Experimental|Group 3: Toddlers High Dose (Formulation 1)|Toddlers who will receive a single injection of high dose Pneumococcal vaccine
88890005|NCT01446926|Placebo Comparator|Group 4: Toddlers Placebo|Toddlers who will receive a single injection of placebo
88890006|NCT01446926|Experimental|Group 5: Infants Low Dose (Formulation 2)|Infants who will receive 3 injections of low dose low dose Pneumococcal vaccine
88890007|NCT01446926|Placebo Comparator|Group 6: Infants Placebo|Infants who will receive 3 injections of placebo
89413032|NCT03492008|Active Comparator|Conventional technique|Nasogastric tube
89413033|NCT03492008|Experimental|Contralateral cricothyroid pressure|Nasogastric tube
89413034|NCT03492008|Experimental|Ipsilateral head turning|Nasogastric tube
89413035|NCT03615729||Rheumatoid arthritis patients|A total of 55 rheumatoid arthritis patients diagnosed according to 2010 ACR / EULAR Rheumatoid Arthritis Classification Criteria recruited from Clinical Rheumatology unit, Internal Medicine, Assiut University Hospitals
89413036|NCT03615729||controls|A total of 33 age and sex matched healthy controls randomly selected from healthy volunteers
89413037|NCT03488186|Experimental|Lansoprazole Capsules|Lansoprazole Capsules of Beijing Sihuan Pharm, 30 mg
89413038|NCT03488186|Active Comparator|Lansoprazole enteric-coated Capsules|Lansoprazole enteric-coated Capsules of Takeda Pharmaceutical Company Limited, 30 mg
89413039|NCT05103644|Experimental|study|breast cancer patient received Atorvastatin 80 mg
89413040|NCT05103644|Placebo Comparator|control group|breast cancer patient received placebo
89413041|NCT03614325|Experimental|Virtual Reality Immersive Relaxation|"Patients in the experimental group will wear a headset and be immersed in a virtual reality environment during their surgery. There are various short videos and environments such as sitting on a beach that are designed to promote relaxation and calmness.~Throughout their surgery patients will be monitored according to current anesthesia standards. The relaxation programming will run for the duration of the operative procedure. At the end of the procedure the headset will be removed and standard postoperative care will commence."
88890008|NCT01446926|Experimental|Group 7: Infants Middle Dose (Formulation 3)|Infants who will receive 3 injections of middle dose Pneumococcal vaccine
89413042|NCT03614325|No Intervention|Usual Anesthesia Care|Patients in the usual care arm will undergo the current standard of care for hand/wrist surgery and postoperative recovery. They will be asked to refrain from using a virtual reality headset during their surgery.
89413043|NCT03615651|Placebo Comparator|Placebo|All study participants will receive the study product and the placebo in a randomized, double-blind crossover fashion. Probiotic and placebo products have similar appearance and taste.
89413044|NCT03615651|Experimental|Probiotic|All study participants will receive the study product and the placebo in a randomized, double-blind crossover fashion. Probiotic and placebo products have similar appearance and taste.
89413045|NCT03491930|Experimental|Interventional Cohort|"VA MOVE! Coach app: Weight loss using the VA MOVE! Coach weight loss app which presents positive feedback, education in nutrition and portion sizes, coping mechanisms, charts and graphs. App will be used for three months.~Telephone Coaching: Weekly phone coaching will provide further support and assist with problem solving and goal setting for a three month period.~Standard of care for weight loss (the 2013 AHA/ACC/TOS guidelines). Followed for three months.~Pre and post weight loss metabolic measurements will be obtained."
89413046|NCT03491930|Active Comparator|Control Cohort|"Standard of care for weight loss (2013 AHA/ACC/TOS guidelines). Followed for three months.~Pre and post weight loss metabolic measurements will be obtained."
88890009|NCT01446926|Experimental|Group 8: Infants Middle Dose (Formulation 4)|Infants who will receive 3 injections of middle dose Pneumococcal vaccine
88890010|NCT01446926|Placebo Comparator|Group 9: Infants Placebo|Infants who will receive 3 injections of placebo
88890011|NCT01446926|Experimental|Group 10: Infants High Dose (Formulation 1)|Infants who will receive 3 injections of high dose Pneumococcal vaccine
88890012|NCT01446926|Placebo Comparator|Group 11: Infants Placebo|Infants who will receive 3 injections of placebo
88890013|NCT01446939||Parkinson's disease|Patients with primary Parkinson's disease
88890014|NCT01446939||Essential tremor|Patients with essential tremor
88890015|NCT01446939||Healthy volunteers|Healthy volunteers
88890016|NCT01446952|Experimental|Dose Escalation|Vitamin E δ-Tocotrienol will be administered orally as a single agent once. Vitamin E δ-Tocotrienol is supplied as 100-mg, 200-mg, and 400-mg capsules.
88890017|NCT01446978|Active Comparator|initial single dose of hep A vaccine|The participants will receive a single dose of hepatitis A vaccine at 0+1+6 months
88890018|NCT01446978|Active Comparator|initial double dose|Participants will receive one dose of hepatitis A vaccine in each M. deltoids and an additional dose at 6 months later
88890019|NCT01446991|Experimental|Favorable prostate cancer with pubic arch interference|Men in this arm have chosen brachytherapy for management of localized prostate cancer and do not require androgen ablation for oncologic reasons but have an enlarged prostate causing pubic arch interference and thus require prostate size reduction prior to brachytherapy. They will have 2-3 months of Degarelix with measurement of prostate volume at 8 and 12 weeks.
89413047|NCT03614091|Active Comparator|Paravertebral plane block group|The TPVB will be administered at the T4 level with the patient in the sitting position.The ultrasound probe will be placed 5 cm from the midline in the craniocaudal direction and moved medially to identify the transverse process and parietal pleura. The superior costotransverse ligament was identified as a collection of homogeneous linear echogenic bands alternating with echo-poor areas running from one transverse process to the next. Bubivacaine0.5%, 20 ml will be deposited in the space between the pleura and the costotransverse ligament.
89413048|NCT03614091|Active Comparator|Erector spinae plane block group|the transducer will be placed in a transverse orientation to identify the spinous process, lamina,and transverse process.The tip of the transverse process will be centered on the ultrasound screen, and the transducer will be rotated 90 degrees into a longitudinal orientation to obtain a parasagittal view. Depending on the level imaged, 2 or 3 hypoechoic muscle layers were identiﬁed overlying the tip of the transverse processes. From T1 to T5 the erector spinae, rhomboid major and trapezius muscles are visible posterior and superfacial to the transverse processes. An 8cm 22-gauge block needle will be Inserted in-plane to the ultrasound beam in a cephalad-to-caudad Direction to place the needle tip between the posterior fascia of Erector spinae and the tip of the targeted transverse process.following which a total of 20 mL of 0.5%bupivacaine will be injected.
89413049|NCT03887624|Experimental|Experimental group|Ethosuximide(2 weeks) + Escitalopram (4 weeks)
89413050|NCT03887624|Placebo Comparator|Control group|Placebo(2 weeks)+Escitalopram(4 weeks)
89413051|NCT03614247|Active Comparator|RIRS|Patients underwent retrograde intrarenal surgery for lower calyceal stone between 1cm and 2cm in size
89413052|NCT03614247|Active Comparator|Micro-PNL|Patients underwent micro percutaneous nephrolithotomy (tract size <10 F) for lower calyceal stone between 1cm and 2cm in size
89413053|NCT03614247|Active Comparator|Ultramini-PNL|Patients underwent ultra-mini percutaneous nephrolithotomy (tract size <15 F) for lower calyceal stone between 1cm and 2cm in size
88890020|NCT01446991|Experimental|Intermediate risk prostate cancer, 6 months Degarelix|Men in this arm have higher risk prostate cancer (upper tier intermediate risk by National Comprehensive Cancer Network [NCCN] guidelines) and require 6 months of androgen ablation in conjunction with brachytherapy. Prostate size must be > 40 cc at baseline so that prostate size reduction measurements are appropriate. Prostate measurements by transrectal ultrasound with be taken at 12 weeks and 20 weeks.
89413054|NCT03614247|Active Comparator|Mini-PNL|Patients underwent mini percutaneous nephrolithotomy (tract size <20 F) for lower calyceal stone between 1cm and 2cm in size
89413055|NCT03614247|Active Comparator|Standard PNL|Patients underwent standard percutaneous nephrolithotomy (tract size >25 F) for lower calyceal stone between 1cm and 2cm in size
89413056|NCT03486002|Other|Cleansweep closed suction system|
89413057|NCT03486002|Other|Halyard closed suction system|
89413058|NCT03489590|Experimental|19F MRI with PFP|PFP gas will be administered using a full-face mask during the MRI. Images are acquired during 12-second breath-hold after every 3rd breath. Before and after the MRI is complete, participants will perform spirometry maneuvers in a room outside of the magnet.
88890021|NCT01447043||Group 1|
88890022|NCT01447056|Experimental|LMP Specific T cells|LMP specific T cells will be given by intravenous injection over 1-10 minutes through either a peripheral or a central line and the IV flushed with saline. The volume of infusion will depend upon the concentration of the cells when frozen, the dose level, and the size of the patient.
88890023|NCT01447069|Active Comparator|Salbutamol|The patients in the study groups will receive the selective β2 agonist, Salbutamol, in addition to their ongoing optimal heart failure therapy.
88890024|NCT01447069|No Intervention|control|The patients in the control group will continue with their regular optimal medical therapy without any intervention.
88890025|NCT01447082||Quetiapine XR group|
88890026|NCT01447082||Non-quetiapine comparison group|
88890027|NCT01447095|Active Comparator|Low dose prostacyclin|
88890028|NCT01447095|Active Comparator|High dose prostacyclin|
88890029|NCT01447095|Placebo Comparator|Placebo|
88890030|NCT01447108|Experimental|TN patients|Patients suffering from Trigeminal neuralgia
88890031|NCT01447134||Surgical|Group (a) [Those to undergo surgical excision or biopsy] patients will receive RGD-K5 scan within two weeks of conventional image evaluations. The image result will be confirmed with histopathological results.
88890032|NCT01447134||Chemotherapy concurrent Radiation|Group (b) patients [Those with N2c-3M0 disease to receive chemotherapy followed by concurrent chemoradiotherapy] will receive RGD-K5 scan prior to beginning of the therapy, after induction chemotherapy, within two weeks after concurrent chemoradiotherapy and two months after completion of concurrent chemoradiotherpy; all within two weeks of conventional image evaluations.
89005509|NCT04569643||Main|Patients with cerebral small vessel disease and periodic limb movement index equal or more than 15 movements per hour of sleep.
89005510|NCT04569643||Control|Patients with cerebral small vessel disease and periodic limb movement index less than 15 movements per hour of sleep.
89413059|NCT02867709|Experimental|Ubrogepant 25 mg|1 ubrogepant 25 milligram (mg) tablet, orally for treatment of a qualifying migraine attack. Participants had the option to take a second dose, placebo-matching ubrogepant tablet or rescue medication, orally, 2 to 48 hours after initial dose.
89413060|NCT02867709|Experimental|Ubrogepant 50 mg|1 ubrogepant 50 mg tablet, orally for treatment of a qualifying migraine attack. Participants had the option to take a second dose, placebo-matching ubrogepant tablet or rescue medication, orally, 2 to 48 hours after initial dose.
89413061|NCT02867709|Placebo Comparator|Placebo|1 placebo-matching ubrogepant tablet, orally for treatment of a qualifying migraine attack. Participants had the option to take placebo-matching ubrogepant tablet or rescue medication, orally, 2 to 48 hours after initial dose.
89413062|NCT02446028|Experimental|BIOD-531|BIOD-531 injected twice daily
89413063|NCT02446028|Active Comparator|Humalog® Mix 75/25|Humalog® Mix 75/25 injected twice daily
89413064|NCT03485846|Experimental|Narlaprevir + Ritonavir + Daclatasvir|All of enrolled patients receive equal study therapy with Narlaprevir/Ritonavir/Daclatasvir daily for 12 weeks
89413065|NCT04461392|Experimental|Oncology patients|Patients diagnosed with cancer and treated with chemotherapy and/or radiotherapy
89413066|NCT04909671|Active Comparator|CAD arm|Patients allocated to CAD arm will receive during colonoscopy withdrawal high definition white light endoscopy aided with artificial intelligence device (Gi Genius, Medtronic)
89413067|NCT04909671|Placebo Comparator|WLE arm|Patients allocated to WLE arm will receive during colonoscopy withdrawal high definition white light endoscopy as standart of care.
89413068|NCT02032095|Experimental|GB-0998|
89413069|NCT03614169|Experimental|Direct HIS-pacing|In this arm a right ventricular (RV) lead or implantable cardioverter defibrillator (ICD) lead is placed first and then implantation of a HIS-pacing lead is attempted. If it is not possible to find and pace HIS or it is not possible to correct the LBBB, a left ventricular (LV) lead is implanted instead.
88890033|NCT01447134||RGD-K5 scan|Group (c) patients [Those with M1 disease to receive biotherapy or chemotherapy] will receive RGD-K5 scan prior to the beginning of the first line systemic therapy, two weeks after beginning of the first line systemic therapy, within two weeks of first response evaluation for the first line systemic therapy, and within two weeks after end of the first line systemic therapy; each RGD-K5 scan would be performed within two weeks of conventional image studies. The systemic therapy might be biotherapy or chemotherapy.
88890034|NCT01447160|Experimental|facet joint infiltration|The experimental group will be submitted to intra-articular infiltration of six facet joints (L3/L4;L4/L5;L5/S1 bilaterally) with triamcinolone hexacetonide
88890035|NCT01447160|Active Comparator|intramuscular injection|The control group which were submitted to triamcinolone acetonide intramuscular injection of six lumbar paravertebral points
88890036|NCT01447173|Experimental|2000 IU vitamin D Daily|
88890037|NCT01447173|Placebo Comparator|400 IU Vitamin D pill|
88890038|NCT01447186||Patient Decision Aid for Spanish Speaking Men|Spanish-Language Slide Set
88890039|NCT01447199||Gene Mutation|Group with increased risk for developing colorectal and/or other cancers as the result of an inherited gene mutation, family history of cancer, or an early age of cancer onset.
88890040|NCT01447199||No Cancer History|Group with little/no personal or family history of cancer.
88890041|NCT01447199||Spouses|Spouses of those who may have an increased risk for developing colorectal and/or other cancers as the result of an inherited gene mutation, family history of cancer, or an early age of cancer onset, or little/no personal or family history of cancer.
88890042|NCT01447212|Experimental|Hydromorphone|Phase I: Injectable Hydromorphone is received for 6 months of the study. Phase II: At 6 months, participants are randomized to either: 1) stay on injectable hydromorphone; or 2) switch to oral hydromorphone, for another six months.
89192806|NCT06025136|No Intervention|Control Group|The patients who were visited in their rooms on the evening of the day before the operation will be given pillows that have the same characteristics as the pillows that the patients in the study group will use, but do not have a gel surface, to use at night. Patients will be asked to note the time they go to bed for a night's sleep and the time they wake up on the morning of the surgery.Participants in the control group will receive no other interventions.Patients will be visited again on the morning of the surgery day.The Richard Campbell Sleep Scale was used to evaluate the nighttime sleep quality of the patients;General Comfort Scale to evaluate comfort levels.
89192807|NCT06019767|Experimental|Cognitive Processing Therapy (CPT)|Groups of 6-8 receive CPT to treat PTSD
88890043|NCT01447212|Active Comparator|Diacetylmorphine|Phase I: Injectable Diacetylmorphine is received for 6 months of the study. Phase II: At 6 months, participants are randomized to either: 1) stay on injectable Diacetylmorphine; or 2) switch to oral Diacetylmorphine, for another six months.
88890044|NCT01447251|Experimental|A: Newly Diagnosed/CPAP/NO DM/PreDx DRS|patients who have newly-diagnosed obstructive sleep apnea (OSA) requiring continuous positive airway pressure (CPAP) therapy without diabetes and are given the result of the diabetes risk score
89192808|NCT06017284|Experimental|Chemotherapy + Thalidomide|nab-paclitaxel (120 mg per square meter of body-surface area) followed by gemcitabine (1000 mg per square meter) on days 1, 8, and 15 every 4 weeks. Thalidomide 100 mg/day, once a day, orally intake at night.
89192809|NCT06017284|Active Comparator|Chemotherapy|"nab-paclitaxel (120 mg per square meter of body-surface area) followed by gemcitabine (1000 mg per square meter) on days 1, 8, and 15 every 4 weeks.~placebo 100 mg/day, once a day, orally intake at night."
89192810|NCT06016439|Experimental|Arthroscopic rotator cuff partial repair with superior capsule augmentation with LHBBT|"If a tear is intra-operatively determined irreparable, randomization takes place.~Irreparable tears that are randomly selected to receive arthroscopic rotator cuff partial repair including superior capsular augmentation with proximal part of the long head of the biceps tendon. The long head of the biceps tendon will be released from bicipital groove and proximal part of the tendon will be used to cover the rotator cuff gap and anchored to the greater tuberosity."
89192811|NCT06016439|Active Comparator|Arthroscopic partial rotator cuff repair|"If a tear is intra-operatively determined irreparable, randomization takes place.~Irreparable tears that are randomly selected to receive arthroscopic partial repair."
89192812|NCT06016439|Other|Arthroscopic rotator cuff repair|Arthroscopic complete repair.
89192813|NCT06016439|No Intervention|Rotator cuff tear conservative treatment|Conservative treatment following physiotherapy protocol.
89192814|NCT06014424|Experimental|CBD|Participants randomized to the CBD arm will be titrated up to a maximum dose of 800 mg/day
89192815|NCT06014424|Experimental|Placebo|Participants randomized to the placebo will be titrated up to a maximum dose of 800 mg/day
89192816|NCT06007209|Active Comparator|Ultrasound guided|Pressure on the subclavian artery against the 1st rib and on the common femoral artery against the pelvis for 3 minutes using an ultrasound probe visualizing the arteries, the underlying bones and the compression of the arteries.
89192817|NCT06007209|Active Comparator|Blind techniques|Pressure on the subclavian artery against the 1st rib and on the common femoral artery against the pelvis for 3 minutes using the medic's hand based on anatomical land marks and palpation of pulse.
88890045|NCT01447251|Experimental|B: Newly Diagnosed/CPAP/NO DM/NO PreDx DRS|patients who have newly-diagnosed OSA requiring CPAP therapy without diabetes and are not given the result of the diabetes risk score
88890046|NCT01447251|Active Comparator|C: Controls|age, sex, and BMI-matched controls without OSA or diabetes
88890047|NCT01447251|Active Comparator|D: Controls on CPAP|age, sex, BMI, and OSA severity matched patients on CPAP therapy for OSA
88890048|NCT01447264|Placebo Comparator|Land exercises|The patients of this group will perform the same exercises from water exercises
88890049|NCT01447264|Active Comparator|Water exercises|The patients of this group will perform the same exercises from land exercises
88890050|NCT01447264|No Intervention|Control group|No intervention will be recommended
88890051|NCT01447277|Experimental|Femoral and Sciatic Block|Administration of preoperative femoral and sciatic nerve blocks
88890052|NCT01447277|Other|Femoral Block Only|Administration of a femoral nerve block prior to surgery
88890053|NCT01447290||Women being evaluated for preeclampsia|
89413070|NCT03614169|Active Comparator|Biventricular pacing|In this arm an RV-lead or ICD-lead is placed first and then implantation of a LV-pacing lead is attempted. If this is not possible due to anatomical difficulties (no coronary sinus (CS) access, no available branches other than v cordis anterior or v cordis media) or electrical difficulties (no capture below 4 V at 1.0 msec or phrenic nerve stimulation < 2x pacing threshold)
89413071|NCT03613857||Clopidogrel group|Anterior myocardial infarction patients undergoing percutaneous coronary intervention take loading dose 600 mg oral clopidogrel (plavix) tablets before the procedure.
89413072|NCT03613857||Ticagrelor group|Anterior myocardial infarction patients undergoing percutaneous coronary intervention take loading dose180 mg oral ticagrelor (brilique) tablets before the procedure.
88890054|NCT01447303||Outcomes following viscosupplemantation|Patients with documented knee osteoarthritis receiving viscosupplementation of the knee.
88890055|NCT01447316||Bariatric surgery|Patients undergoing bariatric surgery for weight loss.
88890056|NCT01447355|Experimental|Prevention (cholecalciferol)|Participants receive cholecalciferol PO twice weekly for up to 8-9 weeks.
88890057|NCT01447368|Experimental|Cinacalcet treatment|Oral Cinacalcet treatment arm, 25mg daily to be administered and gradually step up as required to control iPTH between 2 - 9 times lab reference range, Maximum dose to be given is 100mg daily
88890058|NCT01447368|Active Comparator|Surgical total parathyroidectomy|Surgical total parathyroidectomy with forearm autografting will be performed for patients randomized to this arm.
88890059|NCT01447381||mycophenolate mofetil|Moderate to severe atopic dermatitis being treated with systemic mycophenolate mofetil
88890060|NCT01447381||cyclosporine|Moderate to severe atopic dermatitis being treated with systemic cyclosporine
88890061|NCT01447381||azathioprine|Moderate to severe atopic dermatitis being treated with systemic azathioprine
88890062|NCT01447381||methotrexate|Moderate to severe atopic dermatitis being treated with systemic methotrexate
88890063|NCT01447394|Experimental|Arm 1: Pegylated Interferon Lambda + Ribavirin|
88890064|NCT01447394|Active Comparator|Arm 2: Pegylated Interferon Alfa-2a + Ribavirin|
88890065|NCT01447459|Experimental|Reinforced Education|"The caregivers of the subjects enrolled in this group will be administered two survey instruments at enrollment (t0), and again via telephone at 2 weeks (t1), 1 months (t2), and 3 months (t3) after enrollment.~This group will also receive reinforced asthma education via telephone at 2 weeks, 1 month, and 3 months after enrollment."
89192818|NCT06000436|Experimental|Intervention/treatment|Health education, mobile applications, monitoring, Cardiovascular disease risk assessment
89413073|NCT03613389|Experimental|oral topical vitamin E|
89413074|NCT03613389|No Intervention|voriconazole and levofloxacin|
88890066|NCT01447459|No Intervention|No Reinforced Education|"The caregivers of the subjects enrolled in this group will be administered two survey instruments at enrollment (t0), and again via telephone at 2 weeks (t1), 1 month (t2), and 3 months (t3) after enrollment.~This group will not receive reinforcing of the asthma education at 2 weeks, 1 month, and 3 months after enrollment."
88890067|NCT01447472|Experimental|MDMA|One single dose of MDMA (1.5 mg/kg; range 75-100 mg)
89192819|NCT06000436|Active Comparator|Active group|Cardiovascular disease risk assessment
89192820|NCT05997680|Experimental|Yoga group|Participants with CHD undergoing neurodevelopmental assessments and benefiting from the 8-week yoga intervention in addition to standard of care.
89413075|NCT03613779|Experimental|LUS-guided therapy group|"LUS-guided therapy group. Patients randomly allocated to this arm will receive standard of care + LUS examination accessible to treating physician in every visit. Depending on the results of LUS examination, a low dose or high dose of diuretics will be administered.~A standardized algorithm will be provided to ensure compliance to guideline-recommended medical therapy for heart failure."
88890068|NCT01447485|Experimental|Valsartan 20 mg or 40 mg|
88890069|NCT01447498|No Intervention|Control group|
88890070|NCT01447498|Active Comparator|Screening and risk assessment|
88890071|NCT01447537|Active Comparator|Exercise, relaxation|Active comparator: Exercise + relaxation Patients will perform exercise + relaxation for 3 months
88890072|NCT01447537|Other|Relaxation|Relaxation without exercise Patients will receive only relaxation for 3 months
88890073|NCT01447550||Bosentan|Bosentan
88890074|NCT01447563|Experimental|Clopidogrel tablets 75mg|subjects received a single 75 mg tablet of the reference formulation, given with 250 mL water
88890075|NCT01447563|Experimental|Clopidogrel|subjects received a single 75 mg tablet of the test formulation, given with 250 mL water
88890076|NCT01447589|Experimental|Nelfinavir plus radical radiotherapy|Nelfinavir given in combination with radical RT
88890077|NCT01447602|Experimental|Interpersonal psychotherapy (IPT-A)|Interpersonal psychotherapy for depressed adolescents which focuses on identifying problematic relationships connected to onset or maintenance of depression and suicidal behavior. The treatment teaches skills such as communication and problem-solving to the adolescent and parents.
88890078|NCT01447615|Experimental|Bridges|
88890079|NCT01447615|Experimental|Bridges PLUS|
88890080|NCT01447615|Other|Usual Care|
89192821|NCT05997680|No Intervention|Waitlist control group|Participants with CHD undergoing neurodevelopmental assessments at the same time as the yoga group participants and benefiting from standard of care only during the 8 weeks of the intervention. The yoga intervention will be made available to all waitlist control group participants once their trial wave is completed.
88890081|NCT01447641||Cluster headache|Cluster headache sufferers (both chronic and episodic)
88890082|NCT01447654|Active Comparator|Losartan|
88890083|NCT01447654|Placebo Comparator|Placebo|
88890084|NCT01447680||Blood samples, low risk population|
88890085|NCT01447680||Blood samples, high risk population|
88890086|NCT01447680||Blood samples, known HIV positive|
88890087|NCT01447732|Experimental|Part 1|Dose escalation in subjects with advanced solid tumors with Part 1 which includes intervention of CEP-37250/KHK2804
88890088|NCT01447732|Experimental|Part 2|Subjects with colorectal or pancreatic cancer Part 2 which includes intervention of CEP-37250/KHK2804
88890089|NCT01447745||Observational, longitudinal study|Adult men and women representative of the population of asymptomatic adult men and women aged from 35-65 years living in the Québec City metropolitan area
88890090|NCT01447758|Experimental|LEO 29102 2,5 mg/g cream|
88890091|NCT01447758|Placebo Comparator|LEO 29102 Cream Vehicle|
88890092|NCT01447771|Experimental|Lifestyle counseling|Decision control preference intervention
88890093|NCT01447784|Placebo Comparator|Placebo|
88890094|NCT01447784|Experimental|ToleroMune HDM Dose 1|
88890095|NCT01447784|Experimental|ToleroMune HDM Dose 2|
88890096|NCT01447784|Experimental|ToleroMune HDM Dose 3|
88890097|NCT01447797|Experimental|HCP0912|Irbesartan/Atorvastatin combination tablet
88890098|NCT01447797|Active Comparator|Irbesartan and Atorvastatin|coadministration of irbesartan and atorvastatin
88890099|NCT01447810|Experimental|Treatment|
88890100|NCT01447836||Sepsis|Sepsis patients who are admitted to SICU of our clinical center.
88890101|NCT01447836||Control|Postoperative patients who underwent abdominal surgery and then was directly transferred to SICU of our clinical center.
88890102|NCT01447862|Active Comparator|Vernakalant|Initially, patients will be given 3mg/kg Vernakalant in 100ml normal saline over 10min. If atrial fibrillation continues after another 15 minutes of observation, patients will receive a second infusion of Vernakalant (2mg/kg), again over 10 minutes. If the initial rhythm has not converted to sinus rhythm after 2 hours, consented patients will be treated with electrical cardioversion using a standard routine protocol.
88890103|NCT01447862|Active Comparator|Ibutilide|Patients will be given 1mg of ibutilide in 100ml normal saline intravenously over 10min. If atrial fibrillation continues after another 10 minutes of observation, patients will receive a second infusion of 1mg ibutilide, again over 10min. If the initial rhythm has not converted to sinus rhythm after 2 hours, consented patients will be treated with electrical cardioversion using a standard routine protocol.
88890104|NCT01447901||previously treated LPLD Cohort|Subjects in Cohort 1 (previously treated LPLD Cohort) must have received AMT-011 during Studies CT-AMT-011-01 or -02
88890105|NCT01447901||untreated LPLD control Cohort|Subjects in Cohort 2 (untreated LPLD control Cohort)) may have completed study PREPARATION-02 or known patients with genetically confirmed LPLD
88890106|NCT01447901||normal healthy control Cohort|Volunteers in Cohort 3 (normal healthy control Cohort) must not have LPLD
88890107|NCT01447940|Placebo Comparator|Conventional Care|Patients will have conventional care with 2 standard visits (inclusion and 12 months) + HbA1c measure at 6 months. Patients won't use Meos ePortal
88890108|NCT01447940|Experimental|Meos ePortal use|Patients will use Meos ePortal + 2 standard visits (inclusion and 12 months) + additional visits if necessary + HbA1c measure at 6 months
88890109|NCT01447953|Experimental|Activity targeted pain rehabilitation|A new activity and life-role targeting pain rehabilitation program (ALAR) has been developed to reduce psychosocial barriers to rehabilitation progress, promote re-integration into life-role activities and facilitate return-to-work.
88890110|NCT01447953|Active Comparator|Treatment as usual|Usual treatment consisting of multimodal rehabilitation provided by multi-professional teams in primary health care in the County of Dalarna, Sweden.
88890111|NCT01447966|No Intervention|Treatment as Usual|Participants randomized to the TAU arm will be instructed to continue receiving their prior interventions as recommended by their providers (e.g., psychotherapy, social skills training, behavioral interventions, family participation in family therapy or a parenting class, or pharmacological interventions). Treatment changes (e.g., medication increase, starting psychotherapy in the community) are not prohibited and will be monitored. Thus, treatment will continue as it would in standard practice.
88890112|NCT01447966|Experimental|Immediate CBT|Therapists will work with families for 12 twice weekly sessions, each lasting up to 60 minutes implementing a developmentally appropriate modulated cognitive behavioral therapy approach. A manualized CBT protocol will be followed.
88890113|NCT01447979|Experimental|All patients|this is the only arm of the study, and concerns all patients.
88890114|NCT01448005||wearable defibrillator use|subjects will use a wearable defibrillator
88890115|NCT01448018|Active Comparator|ranibizumab|patients in this arm receive 3 monthly injection of ranibizumab
88890116|NCT01448018|Active Comparator|Hemodilution|hemodilution using erythrocytapheresis is performed as early as possible after inclusion, in order to lessen hematocrit level (target hematocrit of 35%)
88890117|NCT01448018|Active Comparator|ranibizumab and hemodilution|patients receive both treatments
88890118|NCT01448031|Experimental|1|Capsule ASA 81mg/esomeprazole 20mg
88890119|NCT01448031|Active Comparator|2|ASA (Acetylsalicylzuur Apotex cardio 80 mg) Tablet 80 mg
88890120|NCT01448070|Experimental|NN729 manufacturing process|
88890121|NCT01448070|Active Comparator|Current manufacturing process|
88890122|NCT01448083||Neuroendocrine tumor patients|
88890123|NCT01448096|Experimental|primary breast DLBCL|isolated breast involvement with or without nodal disease
88890124|NCT01448109|Active Comparator|Hydrocortisone|
88890125|NCT01448109|Placebo Comparator|Sterile air filled vial|
88890126|NCT01448122|Active Comparator|Avene Compact Honey SPF 50|Study product will be scraped from compact case and weighed. Product will be applied to half the area to be exposed with visible light at a concentration of 2 mg/mL.
88890127|NCT01448122|No Intervention|No intervention|Half of the area to be exposed to visible light will have no study product applied.
88890128|NCT01448135|Experimental|Vital AF|
88890129|NCT01448135|Active Comparator|Osmolite 1.2|
88890130|NCT01448148|Experimental|Cognitive intervention|Use of Memo protocol for 8 weeks
89192822|NCT05996809||Patients who underwent an index gynecologic surgery|The population will consist of patients who underwent an index gynecologic surgery (performed at least 2 years prior to the start of the study) during which COSEAL was used
89192823|NCT05992168|Experimental|Stent-Retriever arm|Device: Stent-Retriever
89192824|NCT05991453|Active Comparator|Propofol total intravenous anesthesia (TIVA)|No administration of inhaled agent.
89192825|NCT05991453|Active Comparator|inhaled volatile general anesthesia (INVA)|Must administer inhaled agent.
89192826|NCT05990166|Experimental|Active intervention|Mineral-enriched powder
89192827|NCT05990166|Placebo Comparator|Placebo|Placebo powder
88890131|NCT01448148|Experimental|Psychosocial intervention|"Use of Programme d'intervention psychosociale axé sur le bien-être psychologique for 8 weeks"
88890132|NCT01448148|No Intervention|no contact control group|waiting list
88890133|NCT01448174|Active Comparator|atorvastatin|"The prospective, randomized, double-blind, placebo-controlled study:~will be preceded by one month non-pharmacological treatment of hyperlipidemia (prerandomization phase)~130 hyperlipidemic hemodialysis (HD) patients will be randomly assigned to receive blinded study drug: 65 patients will be allocated to start with atorvastatin and 65 patients - with placebo.~Atorvastatin will be administered and monitored according to the K/DOQI guidelines (2003).~The prospective, observational study:~- 35 hyperlipidemic patients will be followed for 30 weeks on the prescribed non-pharmacological treatment of hyperlipidemia"
88890134|NCT01448174|No Intervention|Lifestyle counseling|"Protocol of the prospective study in obese persons:~after taking the anthropometric measurements and collecting a blood sample, the start of weight lowering therapy with a prescribed diet and planned physical activity~follow-up for 30 weeks (measurement of body weight every week)."
88890135|NCT01448174|No Intervention|The controls (healthy volunteers)|
88890136|NCT01448200|Experimental|Part I: single dose escalation in healthy volunteers|"There will be three sequential single dose cohorts:~Cohort A: PPI-668 dose D1 or placebo~Cohort B: PPI-668 dose D2 or placebo~Cohort C: PPI-668 dose D3 or placebo"
88890137|NCT01448200|Experimental|Part I: multiple dose administration to healthy volunteers|"Upon completion of the single dose escalation phase, an additional cohort will receive repeat doses:~Cohort D: highest well-tolerated dose from Cohorts A-C or placebo once daily for five days"
88890138|NCT01448200|Experimental|Part II: multiple dose escalation in HCV subjects|"Upon completion of Part I, there will be 3, and potentially 4, sequential cohorts of HCV patients:~Cohort E (genotype-1): PPI-668 dose E1 or placebo~Cohort F (genotype-1): PPI-668 dose E2 or placebo~Cohort G (genotype-1): PPI-668 dose E3 or placebo~Cohort H (genotype-1): if necessary for dose-response assessment; dose to be determined~Cohort I (genotype-2 or -3): PPI-668 dose E4 or placebo"
88890139|NCT01448226||proven or probable aspergillosis|
88890140|NCT01448226||possible aspergillosis|
88890141|NCT01448239|Experimental|alirocumab SAR236553 (REGN727) - Dose A|A single subcutaneous injection of Dose A
88890142|NCT01448239|Experimental|alirocumab SAR236553 (REGN727) - Dose B|A single subcutaneous injection of Dose B
88890143|NCT01448252|Active Comparator|TCV|multiple T cell vaccinations against nine myelin peptides at days 1, 30, 90, 180
88890144|NCT01448252|Sham Comparator|Placebo|saline injections subcutaneously at the same 4 time points with active treatment
88890145|NCT01448265|Experimental|Paroxysmal atrial fibrillation.|
88890146|NCT01448278|Experimental|All-inside technique|
88890147|NCT01448278|Active Comparator|Classical technique|
88890148|NCT01448291|Experimental|Nuvaring|This is a single-group study in which data points after use of the etonogestrel/ethinyl estradiol vaginal ring will be compared to baseline.
88890149|NCT01448304|Experimental|alirocumab SAR236553 (REGN727) - Dose A|A single subcutaneous injection of Dose A
88890150|NCT01448304|Experimental|alirocumab SAR236553 (REGN727) - Dose B|A single subcutaneous injection of Dose B
88890151|NCT01448317|Experimental|Cohort 1|Alirocumab dose 1 versus placebo
88890152|NCT01448317|Experimental|Cohort 2|Alirocumab dose 2 versus placebo
88890153|NCT01448317|Experimental|Cohort 3|Alirocumab dose 3 versus placebo
88890154|NCT01448317|Experimental|Cohort 4|Alirocumab dose 4 versus placebo
88890155|NCT01448330|Experimental|HCP0911|clopidogrel/aspirin combination tablet
88890156|NCT01448330|Active Comparator|clopidorel and aspirin|coadministration of clopidogrel and aspirin
88890157|NCT01448343|Experimental|FMS|Patients who received blood transfusion using FMS
88890158|NCT01448369|Active Comparator|EyeGiene|EyeGiene (Eyedetec Medical Inc., US) is a self-contained, convenient warm compress system for the eyes. The system is composed of a reusable eye mask and one time use warmers that are inserted into the eye mask. The warming units are activated by squeezing just prior use and deliver 40°C heat for up to 5 minutes within 30-60 seconds.
88890159|NCT01448369|Active Comparator|Blephasteam|Blephasteam (Spectrum Théa, France) is an eyelid warming device that can be conveniently used at home. The goggles provide standardised heat of about 38 degrees to liquefy lipids and also humidify the chambers with mineral water to ensure optimal moisture levels.
88890160|NCT01448369|Placebo Comparator|Control- Hot Compress|The participants in this group will be using warm compresses with a hot towel.
88890161|NCT01448382|Experimental|Healthy volunteers|healthy volunteers
88890162|NCT01448382|Experimental|GI bleeding subjcets|Symptomatic patients referred to undergo standard Gastroscopy (EGD) as part of their standard medical care
88890163|NCT01448395|Experimental|1|
88890164|NCT01448408||Forme Fruste Keratoconus group (FFKG)|FFK eyes had to present a) no apparent signs of KC in clinical examination b) stage 0 in the Amsler-Krumeich scale, and c) demonstrate a KISA index value between 60-100%
88890165|NCT01448408||Normal Group (CG)|Eligibility for participation in the CG was confirmed by consecutive topographies, while all CG participants had to present uneventful ophthalmologic history, no indications of corneal pathology in slit-lamp biomicroscopy and Placido disk-based videokeratography and KISA index value less than 60%, as well.
88890166|NCT01448434|Experimental|Ex- vivo cultured adult allogeneic MSCs|Single intraarticular dose of allogeneic MSCs
88890167|NCT01448434|Placebo Comparator|Plasmalyte-A|Single intraarticular dose of 2ml Plasmalyte
88890168|NCT01448460||Fertility Patients|IVF patients with extra eggs or other subjects who desire egg vitrification for fertility preservation
88890169|NCT01448473|Experimental|4 views radiograph serie|The 4-film series will include the following views: anterior-posterior; one lateral; Waters, and Townes views.
88890170|NCT01448473|Active Comparator|2-view radiography serie|The 2-film series will include the following views: anterior-posterior and one lateral.
88890171|NCT01448499|Experimental|Clozapine|Clozapine monotherapy
88890172|NCT01448499|Experimental|Amisulpride|Amisulpride monotherapy
88890173|NCT01448499|Experimental|Augmentation|Augmentation of clozapine with amisulpride
88890174|NCT01448512|Other|Usual Care|Participation in 4 time matched sessions on health education topics
88890175|NCT01448512|Experimental|PartnerPlus intervention|Four group counseling sessions focused on prevention of mother to child transmission (PMTCT) sexual risk reduction & adherence.
88890176|NCT01448538||Group 1|
88890177|NCT01448551|Experimental|Text Messaging|
88890178|NCT01448551|No Intervention|Control|Participation in the MPOWER program without receiving tailored text messages
88890179|NCT01448564|Active Comparator|Laser therapy|Recently has been using the LED, known by its acronym in English LED (Light Emitting Diode), devices that are light-emitting non-coherent and monochromatic, having a longer wavelength (± 10 - 30 nm) compared to lasers. The difference between the fundamental radiation emitted by a laser and an LED is the coherence of the beam.
88890180|NCT01448564|Placebo Comparator|Placebo Laser therapy|
88890181|NCT01448577||Dose 3 x 1011 gc/kg|Subjects received AMT-011 at dose 3 x 1011 gc/kg
88890182|NCT01448577||Dose 1 x 1012 gc/kg|Subjects received AMT-011 at dose 1 x 1012 gc/kg
88890183|NCT01448590||Epidural Resite|After ADP, those patients who receive an epidural resite.
88890184|NCT01448590||Spinal catheter|After ADP, those who receive the epidural catheter into the spinal space
88890185|NCT01448603||Placebo|Subjects previously randomised to placebo in TR002
88890186|NCT01448603||ToleroMune Ragweed Regimen 1|Subjects previously randomised to receive ToleroMune Ragweed regimen 1 in study TR002
88890187|NCT01448603||ToleroMune Ragweed Regimen 2|Subject previously randomised to receive ToleroMune Ragweed regimen 2 in study TR002
88890188|NCT01448603||ToleroMune Ragweed regimen 3|Subject previously randomised to receive ToleroMune Ragweed regimen 3 in study TR002
88890189|NCT01448603||ToleroMune Ragweed regimen 4|Subjects previously randomised to receive ToleroMune Ragweed regimen 4 in study TR002
88890190|NCT01448629|Experimental|River|
88890191|NCT01448629|Active Comparator|Standard Care|Standard Care can have several manufacture and brand names. Standard Care is defined af the participants currently used stoma care product.
88890192|NCT01448642|Active Comparator|Atorvastatin|
88890193|NCT01448642|Placebo Comparator|Placebo|
88890194|NCT01448655||Test group with Iscador® Qu|The test group will receive the mistletoe extract Iscador® Qu as supportive treatment in addition to post-operative conventional oncological therapy (radio-, chemo-, targeted therapy).
88890195|NCT01448655||Control group|The parallel control group will receive no mistletoe but only post-operative conventional oncological therapy (radio-, chemo-, targeted therapy).
88890196|NCT01448668||Test group with Iscador® Qu|The test group will receive the mistletoe extract Iscador® Qu as supportive treatment in addition to post-operative conventional oncological therapy (radio-, chemo-, targeted therapy).
88890197|NCT01448668||Control group|The parallel control group will receive no mistletoe but only post-operative conventional oncological therapy (radio-, chemo-, targeted therapy).
89192828|NCT05988996||African American and Black|One cohort includes families that identify as Black, African American, or African attending the racially concordant peer group sessions.
88890198|NCT01448681||SICU patients with ICP|Surgical intensive care unit patients with elevated intracranial pressure
88890199|NCT01448694||Blood donors|Healthy volunteers who are donating a pint of whole blood
88890200|NCT01448720|Experimental|Paliperidone palmitate|
88890201|NCT01448733|Experimental|Acanya Plus Atralin|A single, open-label arm treating acne with Cerave lotion plus Acanya gel in the morning in combination with Cerave lotion plus Atralin gel in the evening.
88890202|NCT01448746|Experimental|intermittent pneumatic compression|another arm include intermittent pneumatic compression plus low molecular weight heparin
88890203|NCT01448772|Active Comparator|Marinol|
88890204|NCT01448772|Experimental|oral solution|
88890205|NCT01448785|Active Comparator|abiliti Group|Subjects will receive implanted abiliti System. The device will be activated to deliver therapy at implant. Gastric stimulation performance testing, therapy adjustment and dietary/exercise counseling will be conducted at each visit.
88890206|NCT01448785|Active Comparator|Gastric Band Group|Subjects will receive an implanted laparoscopic adjustable gastric band. The subjects will have their band adjusted following the standard of care. Dietary/exercise counseling will be conducted at each visit.
88890207|NCT01448798|Experimental|gelatine-thrombin matrix|Nerves-paring during robotic-assisted laparoscopic prostatectomy is conducted without mono- or bipolar electrocautery and clipping by using a hemostatic gelatine-thrombin matrix.
88890208|NCT01448798|Sham Comparator|Control|Nerve-sparing during robotic-assisted radical prostatectomy is conducted with the use of mono- and bipolar electrocautery and surgical clipping.
88890209|NCT01448811|Experimental|AEP monitoring|
88890210|NCT01448811|Active Comparator|RSS monitoring|
88890211|NCT01448837|Active Comparator|Bimatoprost/Timolol drops|The patients will be treated with bimatoprost/timolol fixed combination therapy
88890212|NCT01448837|Active Comparator|Latanoprost drops|The patients will be crossed over to therapy with latanoprost
88890213|NCT01448863||CONTROL|Fertile women (egg-donors)
88890214|NCT01448863||WITH PCO|Obese women with Polycystic Ovarian Syndrome
88890215|NCT01448863||NO PCO|Obese women without Polycystic Ovarian Syndrome
88890216|NCT01448876||chlamydia care as usual|
88890217|NCT01448889|Active Comparator|100% oxigen|patients will recive 100% oxigen in a mask with reservoir from the begginind of the procedure to 4 hours after its termination
88890218|NCT01448889|Placebo Comparator|placebo|patients will recive 21% oxigen (room air) in a mask with reservoir from the begginind of the procedure to 4 hours after its termination
88890219|NCT01448902|Experimental|OC000459|
88890220|NCT01448902|Placebo Comparator|Placebo|
88890221|NCT01448928||Group 1|
88890222|NCT01448941|Active Comparator|Primary arthrodesis TMT 1|Arthrodesis TMT 1 when instability is present. Primary arthrodesis TMT 2 and 3 when instability present
89192829|NCT05988996||Latino English Preferred|One cohort includes families that identify as Latino, Hispanic, Chicano and language preference of English attending the ethnically concordant peer group sessions.
88890223|NCT01448941|Experimental|Temporary extraarticular plate fixation|Temporary extraarticular plate fixation of TMT 1 when instability is present. Primary arthrodesis TMT 2 and 3 when instability present
88890224|NCT01448980|Active Comparator|Physical therapy|The control group will receive physical therapy 2 time per week for 6 weeks
88890225|NCT01448980|Experimental|Thai Traditional Massage|The experimental group will receive Thai traditional massage program 2 times per week for 6 weeks.
88890226|NCT01448993|Placebo Comparator|Placebo|Taking placebo 3 times per week for four weeks
88890227|NCT01448993|Active Comparator|AZI|
88890228|NCT01449019|Active Comparator|intravenous infusion|
88890229|NCT01449019|Experimental|intraduodenal perfusion|
88890230|NCT01449032|Active Comparator|MSC|Adipose derived stem cells
88890231|NCT01449032|Placebo Comparator|Saline|
88890232|NCT01449045|Placebo Comparator|Community Case Management|Provision of access to prompt diagnosis and treatment for malaria by community volunteers in the village (PECADOM)
88890233|NCT01449045|Experimental|Community Case Management plus IPTc|Monthly Intermittent Preventive Treatment with sulfadoxine pyrimethamine plus amodiaquine, in addition to community case management
88890234|NCT01449058|Experimental|BYL719 + MEK162|BYL719 plus MEK162. Dose escalation with a starting dose for the first cohort of 200mg QD BYL719 and 30mg BID MEK162
88890235|NCT01449084|Active Comparator|early removal of pancreatic duct stent|immediate removal of the pancreatic duct stent at the end of the ERCP procedure
88890236|NCT01449084|No Intervention|leaving the stent in place|the pancreatic duct stent is left in place
89192830|NCT05988996||Latino Spanish preferred|One cohort includes families that identify as Latino, Hispanic, Chicano and language preference of Spanish attending the ethnically and linguistically concordant peer group sessions.
88890237|NCT01449097|Experimental|Adductor-Canal-Blockade|
88890238|NCT01449097|Active Comparator|The femoral nerve block|
88890239|NCT01449097|Placebo Comparator|Placebo|
88890240|NCT01449110|Placebo Comparator|Placebo in PP|Placebo arm in primary cardiovascular prevention (PP)
88890241|NCT01449110|Placebo Comparator|Placebo in SP|Placebo arm in secondary cardiovascular prevention (SP)
88890242|NCT01449110|Active Comparator|Grape extract in PP|Grape extract obtained without resveratrol in primary cardiovascular prevention
88890243|NCT01449110|Active Comparator|Grape extract in SP|Grape extract without resveratrol in secondary cardiovascular prevention
88890244|NCT01449110|Experimental|Resveratrol-enriched grape extract in PP|Resveratrol-enriched grape extract (Stilvid) in primary cardiovascular prevention
88890245|NCT01449110|Experimental|Resveratrol-enriched grape extract in SP|Resveratrol-enriched grape extract (Stilvid) in secondary cardiovascular prevention
88890246|NCT01449123|Experimental|Inhaler|Subjects prescribed fixed dose combinations perform Mannitol Challenge Test and Reversibility Test once
88890247|NCT01449136|Experimental|antibacterial cement|
88890248|NCT01449188|Active Comparator|ondansetron, 8 mg IV over 15 minutes|the lower ondansetron IV dose will be used in one of the four treatment periods
88890249|NCT01449188|Active Comparator|ondansetron, 32 mg IV over 15 minutes|the higher ondansetron IV dose will be used in one of the four treatment periods
88890250|NCT01449188|Placebo Comparator|placebo for ondansetron, IV over 15 minutes|placebo for ondansetron IV dose will be used in one of the four treatment periods
88890251|NCT01449188|Active Comparator|moxifloxacin, 400mg tablet (oral)|moxifloxacin is known to produce mild QT prolongation and will be used in one of the four treatment periods
88890252|NCT01449201|Experimental|PF-00299804|
88890253|NCT01449214|Experimental|Ultrasound|Use of ultrasound to identify interlaminar spaces for needle insertion. Intervention/Procedure: ultrasound-guided technique.
88890254|NCT01449214|Active Comparator|Landmarking|Use of manual palpation to identify anatomic landmarks for needle insertion. Procedure/Intervention: landmark-guided technique.
88890255|NCT01449253|Active Comparator|Monotherapy|Sildenafil will be started at 20mg OD and then increased to 20mg TDS if there is no fall in BP. Total duration is of 6 months
88890256|NCT01449253|Active Comparator|Sequential Therapy|Bosentan will be started at 62.5mg BD for 4 weeks and then increased to 125mg BD. Sildenafil will be started be added after 3 months. Sildenafil will be started at 20mg OD and then increased to 20mg TDS if there is no fall in BP. Total duration is of 6 months. Bosentan and sildenafil will be in combination in the last 3 months. No fixed dose combination will be used.
88890257|NCT01449253|Active Comparator|Combination therapy|Bosentan will be started at 62.5mg BD for 4 weeks and then increased to 125mg BD. Sildenafil will be started at 20mg OD and then increased to 20mg TDS if there is no fall in BP. Total duration is of 6 months. No fixed dose combination will be used.
88890258|NCT01449292|Experimental|Treatment plus Optimal Medical Therapy|Patients will be treated with the AeriSeal System and Optimal Medical Therapy
88890259|NCT01449292|Active Comparator|Optimal Medical Therapy|Patients will be treated according to Optimal Medical Therapy
88890260|NCT01449318|No Intervention|Patients undergoing hysterectomy|
88890261|NCT01449344|Experimental|R-HAD + Bortezomib|
88890262|NCT01449344|Active Comparator|R-HAD|
88890263|NCT01449357|Experimental|zalutumumab|
88890264|NCT01449383|Active Comparator|low meat high fibre (lmhf)|consumption of less than 30g red meat per day and at least 40g dietary fibre per day
88890265|NCT01449383|Active Comparator|high meat low fibre (hmlf)|consumption of 200g red meat and not more than 20g dietary fibre per day
88890266|NCT01449396|Sham Comparator|SHAM ACUPUNCTURE|Sham intervention: acupuncture needle without puncture nor stimulation
88890267|NCT01449396|Experimental|REAL ACUPUNCTURE|Experimental: acupuncture in selected points of the protocol designed
88890268|NCT01449396|Other|Control|Bed Rest
88890269|NCT01449422|Experimental|URGO 310 3082|
88890270|NCT01449422|Active Comparator|Aquacel|
88890271|NCT01449448|Experimental|NSAID|Test Group: This group was given subacromial injections of Ketorolac.
88890272|NCT01449448|Active Comparator|Steroid|This group was given a subacromial injection triamcinolone.
88890273|NCT01447992|Experimental|Portable artificial pancreas system with Control-To-Range|
88890274|NCT01449474|Experimental|Group 1|Patient matched instruments
88890275|NCT01449474|Experimental|Group 2|Jig based instruments
89192831|NCT05988541|Other|Atraumatic rotator cuff tendon repair|Ultrasonography imaging of the operated shoulder
89192832|NCT05988541|Other|Contralateral shoulder|Ultrasonography imaging of the contralateral shoulder
89413076|NCT03613779|Active Comparator|Control group.|"Control group. Patients randomly allocated to this arm will receive standard of care + LUS examination blinded to the treating physician in every visit. Diuretic titration will be based on standard practice (physical examination, symptoms and lab results).~A standardized algorithm will be provided to ensure compliance to guideline-recommended medical therapy for heart failure."
88890276|NCT01449487|Active Comparator|PPC-5650|
88890277|NCT01449487|Placebo Comparator|Placebo|
88890278|NCT01449500|Placebo Comparator|Placebo|Placebo
88890279|NCT01449500|Active Comparator|L. reuteri|"L. reuteri will be delivered at a dose of 1x108 CFU of each strain of L. reuteri giving a final dose of L. reuteri of 2x108 CFU. One dose is to be taken once per day giving a dose of L. reuteri of 2x108 CFU/day.~Intervention: Dietary Supplement: L. reuteri DSM 17938 and ATCC PTA 6475"
88890280|NCT01448954|Experimental|ADC3680B oral|
88890281|NCT01448954|Placebo Comparator|Placebo oral|
88890282|NCT01449552|Experimental|Group A|No clamp and placebo
89192833|NCT05987657|Other|Salivary and blood progesterone dosage|IVF patients with fresh embryo transfer having a dosage of progesterone, salivary and blood, on triggering day
88890283|NCT01449552|Experimental|Group B|Tranexamic acid
88890284|NCT01449552|Experimental|Group C|Drain clamping
88890285|NCT01449552|Experimental|Group D|Drain clamping and tranexamic acid
88890286|NCT01449565|Active Comparator|Naltrexone|
88890287|NCT01449565|Placebo Comparator|Placebo|
88890288|NCT01449578|Experimental|Part A, Treatment 1|Dexpramipexole single dose (SAD Dose 1)
88890289|NCT01449578|Placebo Comparator|Part A, Treatment 1 placebo|Dexpramipexole single dose placebo (SAD Dose 1)
88890290|NCT01449578|Experimental|Part A, Treatment 2|Dexpramipexole single dose (SAD Dose 2)
88890291|NCT01449578|Placebo Comparator|Part A, Treatment 2 placebo|Dexpramipexole single dose placebo (SAD Dose 2)
88890292|NCT01449578|Experimental|Part A, Treatment 3|Dexpramipexole single dose (SAD Dose 3)
88890293|NCT01449578|Placebo Comparator|Part A, Treatment 3 placebo|Dexpramipexole single dose placebo (SAD Dose 3)
88890294|NCT01449578|Experimental|Part B, Treatment 1|Dexpramipexole multiple dose (MAD Dose 1)
88890295|NCT01449578|Placebo Comparator|Part B, Treatment 1 placebo|Dexpramipexole multiple dose placebo (MAD Dose 1)
88890296|NCT01449578|Experimental|Part B, Treatment 2|Dexpramipexole multiple dose (MAD Dose 2)
88890297|NCT01449578|Placebo Comparator|Part B, Treatment 2 placebo|Dexpramipexole multiple dose placebo (MAD Dose 2)
88890298|NCT01449604|Active Comparator|stereotactic radiosurgery|Radio surgery single fraction 12 Gy
88890299|NCT01449604|Active Comparator|stereotactic radiotherapy|Stereotactic radiotherapy hypo fraction 18 Gy in 3 fraction
88890300|NCT01449617||Aspirin plus clopidogrel|Patients undergoing stenting for critical carotid stenosis, either symptomatic (previous events of cerebral ischemia) or asymptomatic, undergoing CAS.
88890301|NCT01449643|Active Comparator|IMT Group|Threshold IMT provides consistent and specific pressure for inspiratory muscle strength and endurance training, regardless of how quickly or slowly patients breathe. This device incorporates a flow-independent one-way valve to ensure consistent resistance and features an adjustable specific pressure setting (in cm H20). When patients inhale through Threshold IMT, a spring-loaded valve provides a resistance that exercises respiratory muscles through conditioning.
88890302|NCT01449643|Sham Comparator|Sham Group|Non-training protocol
88890303|NCT01449656||LMA proseal|
88890304|NCT01449656||LMA Supreme|
89192834|NCT05986487||Patients with nocturnal hypertension and/or non-dipper pattern and diagnosed with OSA|Patients with nocturnal hypertension and/or non-dipper pattern who undergo a sleep test, obtaining the diagnosis of obstructive sleep apnea, will be treated following the clinical practice standards.
89192835|NCT05986487||Patients with nocturnal hypertension and/or non-dipper pattern and without OSA|Patients with nocturnal hypertension and/or non-dipper pattern undergoing a sleep test, the result of which is negative for obstructive sleep apnea disease.
89413077|NCT02236923||Group A: Single procedure|Group A consists of patients recorded as having only had an ascending aortic dissection repair procedure.
89413078|NCT02236923||Group B: Multiple procedures|Group B consists of patients who had an ascending aortic dissection repair procedure together with any other surgical intervention.
89413079|NCT03044353|Experimental|Group 1: Cardiac TTR amyloidosis (ATTR-CM) participants|Cardiac transthyretin (TTR) amyloidosis (transthyretin amyloid cardiomyopathy [ATTR-CM]) participants with mutant genotypes primarily associated with familial amyloidotic cardiomyopathy (FAC) and wild-type TTR will be included. Participants will receive 6 anti-SAP treatments, consisting of carboxy pyrrolidine hexanoyl pyrrolidine carboxylate (CPHPC) followed by anti-SAP monoclonal antibody (mAb) at monthly intervals. During each anti-SAP treatment, participants will receive CPHPC intravenous (IV) infusion once daily for up to 72 hours. After 72 hours of CPHPC administration, participants will be administered intravenous infusion of anti-SAP mAb over 6-8 hours each on Days 1 and 3. The starting dose level of anti-SAP mAb will be 600 milligrams (mg) (divided into 2 infusions of 300 mg). In each treatment session, CPHPC will be administered as subcutaneous (SC) injection for 11 days from the day of first dose of anti-SAP mAb.
89413080|NCT03044353|Experimental|Group 2: Post-chemotherapy AL Amyloidosis participants|Immunoglobin light chain amyloidosis (AL) participants who attain either a very good partial response (VGPR), or complete response (CR), to systemic chemotherapy (including autologous stem cell transplantation) will be included. Participants will receive 6 anti-SAP treatments, consisting of CPHPC followed by anti-SAP mAb at monthly intervals. During each anti-SAP treatment, participants will receive CPHPC IV infusion once daily for up to 72 hours. After 72 hours of CPHPC administration, participants will be administered IV infusion of anti-SAP mAb over 6-8 hours each on Days 1 and 3. The starting dose level of anti-SAP mAb will be 600 mg (divided into 2 infusions of 300 mg). In each treatment session, CPHPC will be administered by as SC injection for 11 days from the day of first dose of anti-SAP mAb.
88890305|NCT01449695|Experimental|Lifestyle counseling|Group consultation and individual nurse consultation
88890306|NCT01449695|Experimental|e health|An individual web based entry
88890307|NCT01449695|No Intervention|usual care|Usual care
88890308|NCT01449760|No Intervention|No treatment|
88890309|NCT01449760|Active Comparator|Physical Therapy|
88890310|NCT01449760|Experimental|Wii Balance group|
88890311|NCT01449773|Experimental|n-3 PUFAs|
88890312|NCT01449773|Placebo Comparator|Corn and soybean oil pill|
88890313|NCT01449786|Experimental|treatment with rMal d 1|these apple and birch pollen allergic patients are treated with daily sublingual application of 25µg recombinant Major apple allergen, Mal d 1 during 4 months
88890314|NCT01449786|Active Comparator|treatment with rBet v 1|These apple and birch pollen allergic patients are treated with daily sublingual application of 25µg recombinant Major birch pollen allergen,Bet v 1 during 4 months
88890315|NCT01449786|Placebo Comparator|treatment with placebo drops|These apple and birch pollen allergic patients are treated daily with placebo applied sublingually during 4 months
88890316|NCT01449799|Experimental|Sequence 1|In period 1, subjects will be administered GSK961081/fluticasone propionate blend via Diskus inhaler followed by the administration of GSK961081 and fluticasone propionate concurrently via separate Diskus inhalers in period 2. In period 3 and period 4, the subjects will receive fluticasone propionate and GSK961081 respectively.
88890317|NCT01449799|Experimental|Sequence 2|In period 1, subjects will be administered GSK961081 and fluticasone propionate concurrently via separate Diskus inhalers followed by administration of GSK961081 in period 2. In period 3 and period 4, the subjects will receive GSK961081/fluticasone propionate blend via Diskus inhaler followed by the administration of fluticasone propionate respectively.
88890318|NCT01449799|Experimental|Sequence 3|In period 1, subjects will be administered GSK961081 followed by administration of fluticasone propionate in period 2. In period 3, subjects will be administered GSK961081 and fluticasone propionate concurrently via separate Diskus inhalers followed by GSK961081/fluticasone propionate blend via Diskus inhaler in period 4.
88890319|NCT01449799|Experimental|Sequence 4|In period 1, subjects will be administered fluticasone propionate followed by the administration of GSK961081/fluticasone propionate blend via Diskus inhaler in period 2. The subjects will receive GSK961081 in period 3 and concurrent administration of GSK961081 and fluticasone propionate in period 4.
88890320|NCT01449825||Prescriber compliance group|Adult (18+ years) new users of pazopanib with an indication of RCC evaluated for prescriber compliance
88890321|NCT01449825||Incidence of liver chemistry test (LCT) elevation group|Adult (18+ years) new users of pazopanib, sunitinib, bevacizumab, and sorafenib in monotherapy who have a baseline LCT evaluated for LCT elevations
88890322|NCT01449825||Incidence of drug induced liver injury (DILI) cases group|Adult (18+ years) new users of pazopanib, sunitinib, bevacizumab, and sorafenib with RCC (as defined by ICD-9 codes) longitudinally followed up in order to capture occurrences of LCT elevations consistent with Hy's Law to evaluate for drug-induced liver injury
88890323|NCT01449825||Incidence of cases of ALF group|Adult (18+ years) new users of pazopanib, sunitinib, bevacizumab, and sorafenib with RCC (as defined by ICD-9 codes) longitudinally followed up in order to capture occurrences of ICD-9 codes indicative of possible ALF to evaluate for drug-induced liver injury
88890324|NCT01449838|Placebo Comparator|Saline|Subjects were administered single dose or twice daily for 2.5 days repeat dose of placebo by the intravenous route.
88890325|NCT01449838|Experimental|Colistimethate sodium|2.5 milligrams (mg)/kilogram (kg) of CMS-NA (as colistin activity or 75,000 International Unit/kg) was administered as single dose or twice daily for 2.5 days repeat dose by the intravenous route.
88890326|NCT01449877|Active Comparator|Trimethoprim-Sulfamethoxazole|1 tablet every other day, morning.
88890327|NCT01449877|Placebo Comparator|Starch tablet|1 starch tablet every other day, morning.
88890328|NCT01449890|Experimental|E-mail follow up care|After having terminated inpatient CBT patients receive follow up care by email for 12 weeks (on average one contact per week). The follow up care aims at supporting the patients in continuing exercises they have learned during the initial treatment phase in order to cope with depression, e.g. integrating positive activities in their all day life or monitoring the interdependence of cognition, emotion and behaviour.
88890329|NCT01449890|No Intervention|Treatment as usual|After having terminated inpatient CBT patients receive treatment as usual within routine care.
88890330|NCT01449903||Rebilda DC|
88890331|NCT01449903||Clearfil Core DC / Plus|
88890332|NCT01449903||Multicore Flow|
89192836|NCT05983588|Experimental|Verum|RAVICTI 1.1 g/ml oral liquid (glycerol phenylbutyrate (GPB)) Duration of Treatment: 26 weeks, twice daily
89192837|NCT05983588|Placebo Comparator|Placebo|Matching Placebo, oral liquid Duration of Treatment: 26 weeks, twice daily
89192838|NCT05983380|Experimental|Experimental|Participants will receive hand mobility and grip strengthening exercises in addition to the usual care for breast cancer-related lymphedema of the upper limb.
89192839|NCT05983380|Active Comparator|Comparison|Participants will receive only the usual care for breast cancer-related lymphedema.
89437575|NCT03574623|Experimental|CCFES|Contralaterally Controlled Functional Electrical Stimulation (CCFES) uses an electrical stimulator and surface electrodes placed over the paretic finger and thumb extensors to deliver stimulation with an intensity that is proportional to the degree of opening of the contralateral unimpaired hand wearing an instrumented glove. Thus, volitional opening of the nonparetic hand produces stimulated opening of the paretic hand. During the lab visits, participants in the CCFES group will use CCFES to assist hand opening during occupational therapy task practice. During their home sessions, participants in the CCFES group will use CCFES to perform hand opening exercise.
88890333|NCT01449916|Experimental|Simplified Severe Sepsis Protocol|This protocol consists of an early aggressive fluid strategy, early blood cultures and antibiotics, and, when appropriate, blood transfusion and titratable dopamine. Monitoring is based on physical exam findings.
88890334|NCT01449916|Active Comparator|Usual care|Early blood cultures and antibiotics. Monitoring by study nurses as in experimental arm. Other interventions are according to admitting (non-study) doctors' orders.
88890335|NCT01449942|Experimental|DZ1|DZ1 group receives DZ1 intratumoral injection in combination with radiation therapy.
88890336|NCT01449942|Placebo Comparator|Saline|Placebo group receives saline injection in combination with radiation therapy.
88890337|NCT01449968||home visit of UMG|home visit with evaluation and management of the situation (control over in-home telephone)
88890338|NCT01449968||telephone management|geriatric mobile unit provides a telephone advice only to the general practitioner with guidance and recommendations (call control)
88890339|NCT01449981|Experimental|Integrated Twelve-Step Facilitation|
88890340|NCT01449981|Experimental|Cognitive Behavioral Therapy|
88890341|NCT01449994|Placebo Comparator|Placebo-Activator|Treatment with Placebo Activator IV
88890342|NCT01449994|Active Comparator|Activator|Treatment with Activator IV adjusting instrument
88890343|NCT01450072|Sham Comparator|Control arm|Venography and sham angioplasty
88890344|NCT01450072|Active Comparator|Active arm|therapeutic balloon angioplasty
88890345|NCT01450163|Active Comparator|Pregabalin|
88890346|NCT01450163|Placebo Comparator|Placebo|
88890347|NCT01450267|Placebo Comparator|Physiological solution|
88890348|NCT01450267|Experimental|Reduced Inhaled Glutathione|
88890349|NCT01450436||preterm infants (<35 weeks gestation)|
88890350|NCT01450449|Experimental|Arm 1 - Short Course Radiotherapy|Short Course
88890351|NCT01450449|Active Comparator|Arm 2 - Standard Course Radiotherapy|Standard Course
88890352|NCT01450891||total patient group|all new consecutive patients of the participating memory clinics who are suspected of having a primary neurodegenerative disease, meaning that all patients with subjective as well as objective memory complaints are included
88890353|NCT01450995|Active Comparator|Treximet|
88890354|NCT01450995|Active Comparator|Imitrex and Aleve|
88890355|NCT01451320|Active Comparator|rapid streptokinase|3-hour infusion of 1.5 million units of streptokinase (16 patients, 16 episodes), repeat once 24 hours later if needed (maximum total dose 3 million units).
89413081|NCT03044353|Experimental|Group 3: Newly diagnosed Mayo stage II/IIIa AL participants|Newly diagnosed Mayo stage II/IIIa AL participants who attain a free light chain CR during the first 3 cycles of first-line chemotherapy where the first cycle was cyclophosphamide, bortezomib, dexamethasone (CyBorD) will be included. Participants will receive 6 anti-SAP treatments, consisting of CPHPC followed by anti-SAP mAb at monthly intervals. During each anti-SAP treatment, participants will receive CPHPC IV infusion once daily for up to 72 hours. After 72 hours of CPHPC administration, participants will be administered IV infusion of anti-SAP mAb over 6-8 hours each on Days 1 and 3. The starting dose level of anti-SAP mAb will be 600 mg (divided into 2 infusions of 300 mg). In each treatment session, CPHPC will be administered as SC injection for 11 days from the day of first dose of anti-SAP mAb.
89413082|NCT03613701||Moyamoya disease patients|Moyamoya disease patients/Healthy volunteers
88890356|NCT01451320|Active Comparator|high dose tpa|5-hour infusion of 90 mg t-PA(Tissue plasminogen activator) after 10 mg bolus (10 patients, 12 episodes), repeat once 24 hours later if needed (maximum total dose 200 mg)
89413083|NCT03614013||Immunotherapy responders/non-responders|paraffin samples and relevant clinical data including RECIST 1.1 will be obtained from metastatic gastric cancer patients
89413084|NCT03613311||Evident urodynamic stress incontinence(USI)|Between November 2011 and January 2017, medical records of all women with ≥stage II cystocele who underwent urodynamic studies in a medical center were reviewed. USI is noted during filling cystometry and is defined as the involuntary leakage of urine during increased abdominal pressure, in the absence of a detrusor contraction.
88890357|NCT01451320|Active Comparator|slow streptokinase|24-hour infusion of 1.5 million units of streptokinase (41 patients, 41 episodes), repeat once 24 hours later if needed (maximum total dose 3 million units).
88890358|NCT01451320|Active Comparator|half-dose slow infusion tpa|6-hour infusion of 50 mg t-PA (Tissue plasminogen activator) without bolus (27 patients, 27 episodes), repeat once 24 hours later up to 3 times if needed (maximum total dose 150 mg).
88890359|NCT01451320|Active Comparator|low dose slow infusion tpa|6-hour infusion of 25 mg t-PA(Tissue plasminogen activator) without bolus (108 patients, 124 episodes), repeat once 24 hours later up to 6 times if needed (maximum total dose 150 mg).
88890360|NCT01451489|Active Comparator|Cyclophosphamide|CTX
88890361|NCT01451489|Experimental|FK506|0.05-0.1mg/kg/d;adjust the dose according the serum concentration(aim 5-10ng/ml),maximum dose 6mg/day;divided in twice, interval 12 hours.
88890362|NCT01451697|Experimental|Experimental: Cognitive Remediation|The remediation intervention will consist of a sequence of computerized cognitive exercises designed to improve a variety of aspects of attention, through repeated drill-and-practice (Bell, Bryson, Greig, Corcoran, & Wexler, 2001; Bracy, 1995; Kurtz et al., 2007). Exercises will be started and continued at the highest level of difficulty, in order to best establish improvement over time. Components of the planned intervention produce performance gains on practiced tasks (e.g., Wexler et al., 1997) and generalization of improvement to other tasks (Kurtz et al., 2007). All training on computer exercises will be conducted with coaching from staff trained in these procedures.
88890363|NCT01451697|Placebo Comparator|Control (Placebo)|The placebo control condition will consist of structured relaxation training, which will involve viewing and participating with meditation and stress-reduction DVDs, and listening to and following a CD of Progressive Muscle Relaxation. Participants will benefit from learning stress reduction techniques in this condition, but will not exercise any of the cognitive domains of interest targeted in the treatment group.
88890364|NCT01451853|Active Comparator|SPI-1005 Low Dose|200 mg SPI-1005, capsule, po, bid, x3d surrounding each cycle of chemotherapy
88890365|NCT01451853|Active Comparator|SPI-1005 Middle Dose|400 mg SPI-1005, capsule, po, bid, x3d surrounding each cycle of chemotherapy
88890366|NCT01451853|Active Comparator|SPI-1005 High Dose|600 mg SPI-1005, capsule, po, bid, x3d surrounding each cycle of chemotherapy
88890367|NCT01451853|Placebo Comparator|Placebo|0 mg SPI-1005, capsule, po, bid, x3d surrounding each cycle of chemotherapy
88890368|NCT01452243|Experimental|Calcium and vitamin D|The pharmacological intervention will be the daily administration of chewable tablets containing vitamin D and calcium.
88890369|NCT01452256|Experimental|Desflurane|Desflurane for pharmacological conditioning
88890370|NCT01452256|Experimental|Propofol|
88890371|NCT01452373|Placebo Comparator|Control (placebo)|
88890372|NCT01452373|Experimental|DHEA + Acolbifene|
88890373|NCT01452607|Experimental|SPI-1005 Capsule 200mg Ebselen x1|Lowest Dose Evaluated, 200mg Ebselen Total, Delivered as a Single Dose
88890374|NCT01452607|Experimental|SPI-1005 Capsule 200mg Ebselen x2|2x Lowest Dose Evaluated, 400mg Ebselen Total, Delivered as a Single Dose
88890375|NCT01452607|Experimental|SPI-1005 Capsule 200mg Ebselen x4|4x Lowest Dose Evaluated, 800mg Ebselen Total, Delivered as a Single Dose
88890376|NCT01452607|Experimental|SPI-1005 Capsule 200mg Ebselen x8|8x Lowest Dose Evaluated, 1600mg Ebselen Total, Delivered as a Single Dose
88890377|NCT01452607|Placebo Comparator|SPI-1000 Capsule 0 mg Ebselen Placebo|Matching Placebo Capsule, 0mg Ebselen Total, Delivered as a Single Dose
88890378|NCT01452672|Active Comparator|RT to chest wall and S/C|Irradiation of the chest-wall and supraclavicular fossa
88890379|NCT01452672|Experimental|RT to chest wall|Irradiation of the chest-wall alone
88890380|NCT01452958|Experimental|TNF-α|Beromun, Boehringer-Ingelheim, Germany
88890381|NCT01452958|Experimental|Endotoxin|
88890382|NCT01453062||Patients with a diagnosis of CLL|Patients with a diagnosis of CLL
88890383|NCT01453608|Experimental|Ferinject (ferric carboxymaltose)|
88890384|NCT01453608|Placebo Comparator|Placebo (saline)|
88890385|NCT01454128|Active Comparator|Non-EPB|with exercise
88890386|NCT01454128|Experimental|EPB with exercise|with exercise
88890387|NCT01454232|Other|gastric surgery|obese patients addressed for gastric surgery
88890388|NCT01454232|Active Comparator|lean healthy subjects evaluated once|lean healthy subjects evaluated once
88890389|NCT01454375|No Intervention|Control Arm|No change in current practice
88890390|NCT01454375|Experimental|Referral fo QuitNow Services|Behavioural - referral to QuitNow Services, smoking cessation counseling telephone line supported by the Ministry of Healthy Living and Sport
88890391|NCT01454492||Allergy rhinitis|Allergy rhinitis patients group
88890392|NCT01454492||Non- Allergy rhinitis|Non- Allergy rhinitis patients group
88890393|NCT01454648||Physician-staffed|Patients treated by physician-staffed emergency medical service (EMS) unit
88890394|NCT01454648||Paramedic-staffed|Patients treated by paramedic-staffed emergency medical service (EMS) unit
88890395|NCT01454700|Experimental|CSII plus CGM|Patients who has never been treated with insulin pump are randomized to 12 months with insulin pump therapy plus continuous glucose monitoring.
88890396|NCT01454700|Active Comparator|Multiple daily insulin injections|randomized to 12 months standard/usual insulin regimen (multiple daily injections). (stays on insulin pen).
88890397|NCT01454752|Active Comparator|Intermittent parasite clearance|Children sleeping under a long-lasting insecticidal net (LLIN) receive an additional intermittent preventive treatment for clearance of asymptomatic malaria infection given once a year at the end of the malaria transmission season
88890398|NCT01454752|Placebo Comparator|Control|Children sleeping under a long-lasting insecticidal net (LLIN) receive placebo
88890399|NCT01454869|Active Comparator|Standard care|nac + salotamul
89413085|NCT03613311||Occult USI|Between November 2011 and January 2017, medical records of all women with ≥stage II cystocele who underwent urodynamic studies in a medical center were reviewed. USI is noted during filling cystometry and is defined as the involuntary leakage of urine during increased abdominal pressure, in the absence of a detrusor contraction after prolapse reduction by vaginal gauze.
89413086|NCT03613311||ND USI|Between November 2011 and January 2017, medical records of all women with ≥stage II cystocele who underwent urodynamic studies in a medical center were reviewed. No USI was noted in this group.
89413087|NCT02032329|Experimental|FastFES|Single Group Study - see Intervention Description
89413088|NCT02259777|Experimental|Telmisartan/Amlodipine, fed|
89413089|NCT02259777|Active Comparator|Telmisartan/Amlodipine, fasted|
88890400|NCT01454869|Experimental|heparin group|heparin group
88890401|NCT01454973||Healthy obese individuals|
88890402|NCT01455116|Experimental|Mild induced hypothermia|Induced hypothermia to 32-34 degrees Celsius (90 - 93 degrees Fahrenheit)
88890403|NCT01455116|No Intervention|Fever Respect|Standard of care septic shock therapy according to Surviving Sepsis Campaign guidelines
88890404|NCT01455259|Experimental|AdCD40L|Treatments once a week with 2.5x10e11 VP AdCD40L, maximum 4 treatments (total dose 1x10e12 VP). If no effect in less than 2 out of 6 melanoma patients, the following 9 melanoma patients and 6 patients with other solid tumors will receive preconditioning therapy 1-2 days prior to first and last treatment with 300mg/m2 cyclophosphamid. The next 9 melanoma patients will receive one local radiotherapy.
88890405|NCT01455272|Experimental|high-risk leukemia|
88890406|NCT05964387|Experimental|SDF|38% SDF applied to hypomineralized permanent molar two weeks prior to restorative care of the tooth.
88890407|NCT05964387|Placebo Comparator|Placebo|Inert liquid (colored water) applied to hypomineralized permanent molar two weeks prior to restorative care of the tooth.
88890408|NCT05964374|No Intervention|Control|Routine post-operative clinical care.
88890409|NCT05964374|Experimental|Intervention|Goal-directed therapy algorithm in addition to routine post-operative clinical care.
88890410|NCT05964348||Patient with infrarenal abdominal aortic aneurysms|Patient with infrarenal abdominal aortic aneurysms treated with EVAR
88890411|NCT05964309|Experimental|Supine group(Control group)|Supine group (flat head position- n=28) during pre-oxygenation patients will be in supine position
88890412|NCT05964309|Experimental|sitting group|Sitting position (90 degree head up position- n=28) during pre-oxygenation patients will be in 90 degree head up position
88890413|NCT05964270|Active Comparator|Intervention group (IG)|participants of the intervention group (IG) will get a login for the e-coach MM, and access to eight modules: medication, outpatient visit preparation, periodic assessment, messaging service, alerts, information, ad hoc complaint, personal care plan. IG participants information is collected on a web platform that automatically invites enrolled patients. The e-coach MM is available 24/7.
88890414|NCT05964270|No Intervention|Control group (CG)|Participants in the CG (control group) will only get a login for a 'dummy version' without the modules, besides the periodic assessments (questionnaires), at the same time as the IG
88890415|NCT05964257|Experimental|HU-014|
88890416|NCT05964257|Placebo Comparator|Placebo|
89413090|NCT03613935|Placebo Comparator|Product 1|Normal glucose, isosweet, homogeneous: 43 g glucose beverage, with a 43 g glucose equivalent sweetness homogenously delivered
89413091|NCT03613935|Active Comparator|Product 2|Low glucose, isosweet, heterogeneous: 30 g glucose beverage with 43 g glucose equivalent sweetness heterogeneously delivered
89413092|NCT03613935|Active Comparator|Product 3|Low glucose, less sweet, homogeneous: 30 g glucose beverage with a 30 g glucose equivalent sweetness homogenously delivered
89413093|NCT03613935|Active Comparator|Product 4|Low glucose+sucralose, isosweet, homogeneous: 30 g glucose + 18 mg sucralose beverage with a 43 g glucose equivalent sweetness homogenously delivered
89413094|NCT03613623||Patients|Patients diagnosed with acromegaly and currently taking long-acting somatostatin analogues for treatment.
89413095|NCT03613623||Physicians|Physicians for those treating the patients enrolled in the study.
89413096|NCT03261375|Experimental|Renal denervation (RDN) Group|Receive standardized 2 drugs (Nifedipine and hydrochlorothiazide) treatment and renal denervation treatments (RDN)
89413097|NCT03261375|Sham Comparator|Control Group|Receive standardized 2 drugs (Nifedipine and hydrochlorothiazide) treatment and renal artery angiography only
89413098|NCT03613233|Active Comparator|traditional glaucoma surgery|glaucoma procedures such as trabeculectomy, iridencleisis, non - penetrating deep sclerectomy
89413099|NCT03613233|Active Comparator|microinvasive glaucoma surgery (MIGS)|glaucoma procedures such as : canaloplasty (traditional, ABiC, modified), iStent, XEN, Cypass,Hydrus- and with any other microinvasive IOP reducing device
89413100|NCT03613545|Experimental|fecal microbiota transplantation|fecal microbiota transplantation
89413101|NCT03613545|Sham Comparator|placebo fecal microbiota transplantation|Infusion of sham
89413102|NCT03613545|Sham Comparator|Traditional treatments|Traditional treatments according to associated guidelines such as probiotics, antibiotics or antidepressants
89413103|NCT01361308|Experimental|Brisdelle (paroxetine mesylate)|Brisdelle (paroxetine mesylate)
89413104|NCT01361308|Placebo Comparator|Placebo Capsules|Placebo Capsules
89413105|NCT03613467||VATS lobectomy|Pathologic N2 NSCLC patients who received lobectomy by video-assisted thoracoscopic surgery
89413106|NCT03613467||Thoracotomy lobectomy|Pathologic N2 NSCLC patients who received lobectomy by thoracotomy
89413107|NCT02032251|Experimental|ginger|The patients with infertility that underwent oral administration of ginger.
89413108|NCT02032251|Placebo Comparator|Placebo|The patients with infertility that receive placebo.
89413109|NCT03612765|Experimental|Intervention group|Participants in the intervention group will receive face-to-face intervention sessions that include interviews, discussions and didactic teaching.
89413110|NCT03612765|No Intervention|Control group|Participants in the control group will receive usual care that normally includes three monthly outpatient doctor consultations and when necessary, heart failure nurse referral.
89413111|NCT03612999|Experimental|CGM and Activity Tracker|Subjects receive a continuous glucose monitor (CGM) and activity tracker and are instructed to record daily activities and psychological data.
89413112|NCT03612297||ATOUTBIO|Selective reporting of antibiotic susceptibility tests for all E. coli identified in urine cultures of adults.
89413113|NCT03612297||EVOLAB|Complete reporting of antibiotic susceptibility tests for all E. coli identified in urine cultures of adults.
89413114|NCT02872935|Placebo Comparator|Placebo: Normal Saline|1ml of Normal Saline will be given intravenously with the administering of the spinal dose
89413115|NCT02872935|Experimental|Glycopyrrolate group|1ml of Glycopyrrolate ( .2mg /ml) will be given intravenously with the administering of the spinal dose
89413116|NCT00103662|Experimental|G-CSF plus plerixafor|
89413117|NCT00103662|Placebo Comparator|G-CSF plus placebo|
89413118|NCT03612219|Experimental|IMRT with CC+Adjuvant Apatinib|Treat with Apatinib mesylate tablet for adjuvant treatment(the dose was 250 mg,orally,qd,28 days for an observation period,Six cycles)of local advanced nasopharyngeal carcinoma after Intensity-modulated radiation therapy (IMRT) with concurrent chemotherapy(cisplatin).
89413119|NCT03612219|Active Comparator|IMRT with CC|Only obeservation after Intensity-modulated radiation therapy (IMRT) with concurrent chemotherapy(cisplatin).
89413120|NCT03612843||Dry needle|Dry needling is provided as a part of a comprehensive treatment program by a physical therapist. The patient and the therapist will record any adverse events that occur.
89413121|NCT03746262||Patients - Stage I treated with surgery|ctDNA measures will be taken and descriptive statistics will be estimated. These include means, standard deviations, and 95% confidence intervals. Next, within group changes in ctDNA levels will be measured for each of the four groups. These change values will be estimated with 95% confidence intervals. In addition, paired t-tests will be performed to determine whether there were statistically significant changes in ctDNA levels at time points post-treatment or follow-up. After these paired analyses are performed, an exploratory longitudinal mixed model will be fit to examine the change in ctDNA levels.
89413122|NCT03746262||Patients - Stage I treated with radiotherapy|ctDNA measures will be taken and descriptive statistics will be estimated. These include means, standard deviations and 95% confidence intervals. Next, within group changes in ctDNA levels will be measured for each of the four groups. These change values will be estimated with 95% confidence intervals. In addition, paired t-tests will be performed to determine whether there were statistically significant changes in ctDNA levels at time points post-treatment or follow-up. After these paired analyses are performed, an exploratory longitudinal mixed model will be fit to examine the change in ctDNA levels.
89413123|NCT03746262||Patients - Stage II treated with surgery & chemotherapy|ctDNA measures will be taken and descriptive statistics will be estimated. These include means, standard deviations and 95% confidence intervals. Next, within group changes in ctDNA levels will be measured for each of the four groups. These change values will be estimated with 95% confidence intervals. In addition, paired t-tests will be performed to determine whether there were statistically significant changes in ctDNA levels at time points post-treatment or follow-up. After these paired analyses are performed, an exploratory longitudinal mixed model will be fit to examine the change in ctDNA levels.
88890417|NCT05964244|Experimental|Noninvasive ventilation (CPAP or bilevel) with the Vela investigational mask for 1 hour|Pressure settings for noninvasive ventilation to be set as required to provide optimal respiratory support for each patient. Not to be changed during the 2 hours of the study.
89413124|NCT03746262||Patients - Stage III treated with chemoradiotherapy|ctDNA measures will be taken and descriptive statistics will be estimated. These include means, standard deviations and 95% confidence intervals. Next, within group changes in ctDNA levels will be measured for each of the four groups. These change values will be estimated with 95% confidence intervals. In addition, paired t-tests will be performed to determine whether there were statistically significant changes in ctDNA levels at time points post-treatment or follow-up. After these paired analyses are performed, an exploratory longitudinal mixed model will be fit to examine the change in ctDNA levels.
89413125|NCT05030116|Experimental|Experimental group|
89413126|NCT05030116|Active Comparator|Control Group|
89192840|NCT05981664|Experimental|with adapter|All participants are in the experimental group baseline speed and accuracy using minecraft videogame will serve as baseline data and each subject will be their own control. participants will be given an adapter to support onehanded game play and an xbox system to use at home for a week. Follow-up data (speed and accuracy of minecraft) will be reevaluated one week later. Qualitative interview data will assist in understanding facilitators and barriers for use. On baseline and reassessment, the QUEST 2.0 and VAS will be administered as the primary outcome measures in addition to secondary outcome measures (speed and accuracy of minecraft).
88890418|NCT05964244|Active Comparator|Noninvasive ventilation (CPAP or bilevel) with the standard mask (Nivairo) for 1 hour|Pressure settings for noninvasive ventilation to be set as required to provide optimal respiratory support for each patient. Not to be changed during the 2 hours of the study.
89192841|NCT05979506|Experimental|Wraps (body and feet) as well as scalp care|The skin care consisting of wraps (body and feet) and scalp care, will be carried out consecutively over 3 days, in the hospital (outpatient or in day/traditional hospitalization).
89192842|NCT05977673|Experimental|Tislelizumab|Tislelizumab single dose every 3 weeks up to 35 total administration
89192843|NCT05977465|No Intervention|Control group|include twenty-five patients who will receive placebo tablets once daily for three months, plus their antidiabetic drugs ( Dpp4 inhibitor and metformin)
89413127|NCT05049304|Experimental|OA-enriched functional olive oil|
89413128|NCT05049304|Active Comparator|Olive oil not enriched in OA|
89413129|NCT02148978|Experimental|Saxagliptin administration|Saxagliptin Administration- The participants in this study will undergo an OGTT (Oral Glucose Tolerance Test) at recruitment and then will start treatment with the DPP IV inhibitor- Saxagliptin. After 6 weeks of treatment the participants will return to perform a second OGTT.
89413130|NCT04470154|Experimental|Stage I: 0.05 μg/kg|IV HSK21542 0.05 μg/kg solution（active or placebo） administered after each dialysis session within 2h±30 min (3 times/week).
89413131|NCT04470154|Experimental|Stage I: 0.15 μg/kg|IV HSK21542 0.15 μg/kg solution（active or placebo） administered after each dialysis session within 2h±30 min (3 times/week).
89413132|NCT04470154|Experimental|Stage I: 0.30 μg/kg|IV HSK21542 0.30 μg/kg solution（active or placebo） administered after each dialysis session within 2h±30 min (3 times/week).
89413133|NCT04470154|Experimental|Stage I: 0.80 μg/kg|IV HSK21542 0.80 μg/kg solution（active or placebo） administered after each dialysis session within 2h±30 min (3 times/week).
89413134|NCT04470154|Experimental|Stage II: 0.3 μg/kg|IV HSK21542 0.3 μg/kg solution（active or placebo） administered after each dialysis session within 10 min (3 times/week).
89413135|NCT04470154|Experimental|Stage II: 0.6 μg/kg|IV HSK21542 0.3 μg/kg solution（active or placebo） administered after each dialysis session within 10 min (3 times/week).
89413136|NCT03612609|Other|blood, urine and semen sample|15 patients, with acute dengue virus infection and a positive RNA detection in blood or/and urines
89413137|NCT02255136|Experimental|Individualized homeopathic medicines|Psorinum, Tuberculinum, Medorrhinum, Calcarea carbonica, Natrum sulphuricum etc. as indicated; Rescue medicines, e.g. Aralea racemosa, Arsenicum album, Histamine hydrochloride, House dust, Ipecacuanha, Antimonium tartaricum, Grindelia robusta etc. as indicated; 5 ml dose of indicated homeopathic medicine in centesimal or 50 millesimal potencies as appropriate; administered twice daily for 1 year
89413138|NCT02255136|Placebo Comparator|Intervention placebo|5 ml dose made up of single drop of rectified spirit in 5 ml distilled water, identical in appearance of homeopathic medicine, to be administered twice daily for 1 year
88890419|NCT05964166|Experimental|Tetragraph|
88890420|NCT05964127|Active Comparator|Group A - Non-surgical hand instruments|After appropriate local anaesthesia of the treatment site supragingival, subgingival and implant surface debridement will be undertaken with Hu-Friedy titanium implant hand instruments only. Any remaining supragingival deposits will be polished using a contra-angle handpiece, rubber cup and Cleanic polishing paste.
88890421|NCT05964127|Active Comparator|Group B - Non-surgical Air-flow|After appropriate local anaesthesia of the treatment site supragingival, subgingival and implant surface debridement will be undertaken using EMS PerioFlow with Plus powder (Erythritol) and supplemented with EMS Piezon and EMS AirFlow and Plus powder as required.
88890422|NCT05964127|Active Comparator|Group C - Surgical Air-flow|After appropriate local anaesthesia of the treatment site a full thickness mucoperiosteal flap will be raised to adequately expose the tissue defect. Supragingival, subgingival and implant surface debridement will be undertaken using EMS PerioFlow with Plus powder (Erythritol) and supplemented with EMS Piezon and EMS AirFlow and Plus powder as required.
88890423|NCT05964114|Experimental|Starting dose of vancomycin standard vs MIPD|Comparison of vancomycin initial dosing via standard of care (flat dose adjusted for renal function) versus model informed precision dosing (starting dose adjusted using pharmacokinetic models).
88890424|NCT05964101|Experimental|Nivolumab|Neoadjuvant treatment stage: Nivolumab 360mg, Carboplatin AUC5+ paclitaxel 100 mg/m ², iv, 3 weeks per cycle, 2-4 cycles in total; Surgical treatment stage: Patients with primary tracheal squamous cell carcinoma received radical surgery after neoadjuvant therapy, and patients who could not or refused surgical treatment due to various reasons were treated with multidisciplinary discussion.
88890425|NCT05964088||Group1|These critically ill patients were directly admitted to the intensive care unit from the emergency department
88890426|NCT05964088||Group 2|These critically ill patients were were initially managed on the medical floor and later transferred to the intensive care unit for worsening respiratory status
88890427|NCT05964062|Experimental|active rTMS treatment|10 sessions of active rTMS would be delivered to the right preSMA daily, with a session of 1800 pulse.
88890428|NCT05964062|Sham Comparator|sham rTMS treatment|5 sessions of sham rTMS would be delivered to the right preSMA daily, with a session of 1800 pulse.
88890429|NCT05964049|Experimental|active rTMS treatment|5 sessions of active rTMS would be delivered to the left DMPFC daily, with a session of 1800 pulse and inter-session interval of 20 min.
88890430|NCT05964049|Sham Comparator|sham control|5 sessions of sham rTMS would be delivered to the left DMPFC daily, with a session of 1800 pulse and inter-session interval of 20 min.
88890431|NCT05963971|Experimental|PEDALL|The intervention group (PEDALL) will receive twenty-six contact hours of virtually-delivered nutrition education. Participants and/or caregivers will meet with their nutrition educator once weekly for one hour for six months.
88890432|NCT05963971|Active Comparator|Standard of Care (SOC)|Subjects randomized to SOC will receive printed educational materials at study entry and will continue to receive nutritional education/care per their institution's standards of care.
88890433|NCT05963958|Experimental|Active HD-tDCS|HD-tDCS is delivered on 10 consecutive weekdays, with two sessions per day (in the morning and in the afternoon). For each participant, a 3-mA current is applied via a center anode. The electric current was supplied to the active group and presented an acceleration time of 30 s, maintained at 3 mA for 30 min and then reduced for 30 s. And a maintenance dosage of dexmedetomidine (0.2 - 0.7 mcg/kg per hour).
88890434|NCT05963958|Placebo Comparator|Sham HD-tDCS|HD-tDCS is delivered on 10 consecutive weekdays, with two sessions per day (in the morning and in the afternoon). For the simulated condition, the investigators maintained the same 30-second acceleration up to a total of 3 mA, followed immediately by a 30-second deceleration. And a maintenance dosage of dexmedetomidine (0.2 - 0.7 mcg/kg per hour).
89413139|NCT04715529|Experimental|FZJ-003|
89413140|NCT04715529|Placebo Comparator|Placebo|
89413141|NCT03094624|Experimental|Amusia|Since 2006, recruitment of amusia participants has been organized in the Lyon region, and some 20 participants (and their matched controls in terms of age, sex, laterality, musical practice, number of years of study) have already taken part various studies conducted at the CRNL. The recruitment of amusia participants and controls is continued in order to maintain a sufficient number of participants and compensate for the withdrawals within the cohort already constituted (lack of availability, geographical distance, etc.).
88890435|NCT05963945||Retrospective collection for the period October 18th, 2022, and November 17th, 2022|A total of 1,073 chest X-rays were acquired within the specified period at the department. The data collection remained intact and unaffected throughout the testing phase, ensuring the integrity of the dataset. The collected sample accurately represents the prevalence of findings within the observed population. After excluding ineligible studies such as X-rays from patients under 18 years of age, lateral projection X-rays, and scans of insufficient quality, a total of 956 relevant CXRs were identified for further assessment.
88890436|NCT05963919||Asthma Group|6 minute walk test, Pulmonary function test, Respiratory muscle strength test, Lower extremity muscle strength test
88890437|NCT05963919||Control Group|6 minute walk test, Pulmonary function test, Respiratory muscle strength test, Lower extremity muscle strength test
88890438|NCT05963880|Experimental|Advanced CKD group|Patients with eGFR < 30 ml/min/1.73m2 not on dialysis
88890439|NCT05963880|Experimental|Dialysis groups|Patients on hemodialysis or peritoneal dialysis
88890440|NCT05963880|Experimental|Hypertension group|Patients with BP > 135/85 mmHg or taking any antihypertensive medication with normal kidney function (eGFR > 60 ml/min/1.73m2)
88890441|NCT05963880|Active Comparator|Control group|Normotensive patients without any antihypertensive drugs or chronic kidney disease
89192844|NCT05977465|Experimental|Empagliflozin group|include twenty five patients who will receive Empagloflozin 25 mg once daily for three months, plus their antidiabetic drugs ( Dpp4 inhibitor and metformin)
89192845|NCT05975554|Experimental|Low dose interleukin-2|Commercially available aldesleukin with a UK marketing authorisation will be used and will be initially prepared as per SmPC.
89192846|NCT05975554|Active Comparator|Control|Standard of care treatment
89192850|NCT05969574||AMH <1.3, at least 1 pregnancy or at least 1 miscarriage|Participants will not undergo any additional intervention compared to normal clinical assessment and routine testing of the ovarian reserve, which includes AMH and AFC. Investigators will follow standard stimulation protocols and medications.
89192851|NCT05969574||AMH <1.3, at least 1 pregnancy and no miscarriage|Participants will not undergo any additional intervention compared to normal clinical assessment and routine testing of the ovarian reserve, which includes AMH and AFC. Investigators will follow standard stimulation protocols and medications.
89192852|NCT05969574||AMH ≥ 1.3, at least 1 pregnancy or at least 1 miscarriage|Participants will not undergo any additional intervention compared to normal clinical assessment and routine testing of the ovarian reserve, which includes AMH and AFC. Investigators will follow standard stimulation protocols and medications.ons.
89192853|NCT05969574||AMH ≥1.3, at least 1 pregnancy and no miscarriage|Participants will not undergo any additional intervention compared to normal clinical assessment and routine testing of the ovarian reserve, which includes AMH and AFC. Investigators will follow standard stimulation protocols and medications.
89192854|NCT05968274|Other|"Arm A"|"First stimulation period: real stimulation, total 8 sessions, session frequency: weekdays every other day (i.e. duration 2.5 weeks)~Washout period: no stimulation, duration: 1 week~Second stimulation period: sham stimulation, total 8 sessions, session frequency: weekdays every other day (i.e. duration 2.5 weeks)"
89192855|NCT05968274|Other|"Arm B"|"First stimulation period: sham stimulation, total 8 sessions, weekdays every other day (i.e. 2.5 weeks)~Washout period: no stimulation, 1 week~Second stimulation period: real stimulation, total 8 sessions, weekdays every other day (i.e. 2.5 weeks)"
89192856|NCT05965167|Experimental|Treatment A EBP05 2.5 mg|Single dose of oral EBP05 2.5 mg
89192857|NCT05965167|Experimental|Treatment B EBP05 1.5 mg|Single dose of oral EBP05 1.5 mg
89192858|NCT05965167|Experimental|Treatment C Forteo 20 mg|Single SC injection of Forteo 0.02 mg
89192859|NCT05965167|Experimental|Treatment D EBP11 1.5 mg|Single dose of oral EBP11 1.5 mg
89192860|NCT05965167|Experimental|Treatment E EBP11 BID (dose determined after IA)|Based on PK data from 1st Interim Analysis BID administration of oral EBP11. The selected BID dose to be administered will be either 1.5, 2.0 or 2.5 mg.
89413142|NCT03094624|Sham Comparator|Matched controls|Matched controls of age, sex, laterality, musical practice, number of years of studies.
89192861|NCT05965167|Experimental|Treatment F EBP11 BID (dose determined after IA)|BID administration of oral EBP11 tablets 1.5 mg tablets (3 x 0.5 mg tablets) as first dose and 2.5 mg (5 x 0.5 mg tablets) as second dose.
89192862|NCT05965167|Experimental|Treatment G EBP11 1.5 mg|Single dose of oral EBP11 1.5 mg
89192863|NCT05965167|Experimental|Treatment I EBP22 1.5 mg|Single dose of oral EBP22 1.5 mg
89192864|NCT05965167|Experimental|Treatment J EBP22 1.5 mg|Single dose of oral EBP22 1.5 mg
88890442|NCT05963789|Experimental|Group A or cervical proprioception group CPG|Patients will receive traditional exercises for shoulder impingement plus cervical proprioception exercises using laser pointer
88890443|NCT05963789|Active Comparator|Group B or control group CG|Patients will receive traditional exercises for shoulder impingement (stretching, strengthening, stabilization)
88890444|NCT05963776||case|cases are cirrhotic with hepatocellular carcinoma
88890445|NCT05963776||control|patients with cirrhosis
88890446|NCT05963750|Experimental|virtual reality during the surgery|Group with the use of virtual reality during the surgery
88890447|NCT05963750|No Intervention|control|Group without the use of virtual reality during the surgery
88890448|NCT05963724|Experimental|Real-Time Computer Aided Detection|
88890449|NCT05963724|Active Comparator|Standard Colonoscopy|
88890450|NCT05963685||pre implementation period|stroke patients transferred within the 6 months before introduction of the alarming system
89192865|NCT05965167|Experimental|Treatment K oral EBP formulation determined based on IA results|Single dose of oral 1.5 mg of the selected oral formulation (EBP11 or EBP22) based on the results of all Cohort 1 and 2 Interim Analyses
89413143|NCT02152644||amyloid|unique cohort of Adult patients older than 21 years with carpal tunnel syndrome with surgical indication (moderate to severe symptoms that do not respond to conservative treatment physiotherapy, splinting, activity modification) for more than 6 months.
88890451|NCT05963685||implementation period|stroke patients transferred within the 6 months after introduction of the alarming system
88890452|NCT05963685||post implementation period|stroke patients transferred within the 6-12 months after introduction of the alarming system
89413144|NCT03046017|Active Comparator|real tDCS|In this group, the tDCS stimulates areas of the brain being examined in this study to increase their activity.
89413145|NCT03046017|Sham Comparator|sham tDCS|In this group, sham tDCS does not provide real stimulation though participants will not know this until the debriefing at the end of the study. Sham will be used to determine if the results of this study are due to the tDCS or other reasons.
89413146|NCT03046017|Other|control group|In this group, participants will receive tDCS but will only receive a cream on their lower back.
89413147|NCT02255214||Surgical Patient|These are the results from the blood samples taken from the study participants.
89413148|NCT05383989|Experimental|UniVenture- face-to-face (in-person format)|Personality-matched wellness program condition in face-to-face format (i.e., high AS student receives face-to-face AS program; high HOP student receives face-to-face HOP workshop: high SS student receives face-to-face SS workshop; high IMP student receives face-to-face IMP workshop)
89413149|NCT05383989|Active Comparator|UniVenture- online (distance-delivery format)|Personality-matched wellness program condition in distance-delivery format (i.e., high AS student receives online (distance-delivered) AS workshop; high HOP student receives online (distance-delivered) HOP workshop: high SS student receives online (distance-delivered) SS workshop; high IMP student receives online (distance-delivered) IMP workshop
89413150|NCT05383989|Placebo Comparator|UniVenture- service as usual (control)|Services-as-usual offered by the respective university
88890453|NCT05963620||percutaneous coronary intervention (PCI)|percutaneous coronary intervention (PCI) with sirolimus-eluting stents
88890454|NCT05963620||coronary artery bypass grafting (CABG)|coronary artery bypass graft surgery
88890455|NCT05963607|Experimental|Heavy blanket|Wear heavy blanket overnight for 6 weeks
88890456|NCT05963607|Active Comparator|Light blanket|Wear light blanket overnight for 6 weeks
88890457|NCT05963594|Active Comparator|T2D Sequence AB|Where A = 50 g Oligomalt and B = 50 g Glucidex 40.
89192866|NCT05965167|Experimental|Treatment L BID of oral EBP formulation determined based on IA results|BID dose of oral 1.5 mg of the selected oral formulation (EBP11 or EBP22) based on the results of all Cohort 1 and 2 Interim Analyses
89192867|NCT05965167|Experimental|Treatment M BID of EBP05 2.5 mg|BID dose of oral EBP05 2.5 mg
89192868|NCT05965167|Experimental|Treatment N single dose of Treatment K|Single dose of Treatment K
88890458|NCT05963594|Active Comparator|T2D Sequence BA|Where A = 50 g Oligomalt and B = 50 g Glucidex 40.
89192869|NCT05965167|Experimental|Treatment H EBP22 2.5 mg (5 x 0.5 mg).|Singe dose of oral EBP22 2.5 mg (5 x 0.5 mg).
88890459|NCT05963594|Active Comparator|HAO Sequence ABCD|Where A = 50 g Oligomalt, B = 50 g Glucidex 40, C = 33 g Oligomalt, and D = 33 g maltodextrin Glucidex 40.
88890460|NCT05963594|Active Comparator|HAO Sequence BDAC|Where A = 50 g Oligomalt, B = 50 g Glucidex 40, C = 33 g Oligomalt, and D = 33 g maltodextrin Glucidex 40.
88890461|NCT05963594|Active Comparator|HAO Sequence DCBA|Where A = 50 g Oligomalt, B = 50 g Glucidex 40, C = 33 g Oligomalt, and D = 33 g maltodextrin Glucidex 40.
88890462|NCT05963594|Active Comparator|HAO Sequence CADB|Where A = 50 g Oligomalt, B = 50 g Glucidex 40, C = 33 g Oligomalt, and D = 33 g maltodextrin Glucidex 40.
88890463|NCT05963490|Active Comparator|monotherapy|a total of 45 patients will receive regorafenib monotherapy.
88890464|NCT05963490|Experimental|combination therapies|a total of 45 patients will first receive 1 cycle of regorafenib and toripalimab followed by SABR/LDRT radiotherapy. Regorafenib and toripalimab will be continued after the completion of radiotherapy.
88890465|NCT05963477||Age Group|Neonates Infants Children
88890466|NCT05963477||Gender|Male Female
88890467|NCT05963477||Selective/Emergency|Selective Emergency
88890468|NCT05963477||Wound Class|Clean Clean-contaminated Contaminated Infected
88890469|NCT05963477||Risk Factors|Yes No
88890470|NCT05963477||Type of Incisions|Midline Trransverse Oblique
88890471|NCT05963412|Experimental|Online Individual Intervention Program|The online intervention program (namely, Meaning-Centered Coping Program) consists of eight individual sessions, each lasting approximately 60 min. Sessions were conducted per week.
89192870|NCT05964725|Experimental|Receive traditional medical therapy and transcranial direct current stimulation|intravenous methylprednisolone infusion (dose of 1 mg/kg/day, maximum 60 mg/day) for 5 to 10 days. Patients included in this study were routinely examined and tested for audiometry, including otoscopy, pure tone audiometry, acoustic impedance, brainstem evoked potential, and tinnitus detection. After completion, the 32-guide EEG collector from Bricon was used to collect changes in neural activity in all subjects.
89413151|NCT03542292|Experimental|placental drainage group|In study group; umbilical cord was clamped from fetal side but unclamped from maternal side. After that unclamped side of umblical cord was left open to drain the blood until the flow ceased. The blood was collected in the metal bowl and measured using a measuring jar. Care was taken not to mix the drained blood from the cord with the blood lost during the third stage.
89413152|NCT03542292|Active Comparator|no placental drainage group|In control group the umblical cord was clamped both sides.
89413153|NCT05043610|Experimental|Cohort 1|In the experimental group, 3-7 days after an acute anterior myocardial infarction treated successfully with primary percutaneous coronary intervention, 120 patients will receive a single intracoronary infusion of 10^7 umbilical cord-derived Wharton's Jelly Mesenchymal Stem Cells (WJ-MSCs) alongside conventional treatment.
88890472|NCT05963412|No Intervention|No Intervention: Waitlist Control Group|A wait-list control group was used. Participants assigned to the wait-list control group did not receive the intervention immediately. After the final assessment was administered (eight weeks later since the initial assessment), they were able to participate in the same intervention program if they wanted.
88890473|NCT05963386|Experimental|177Lu-DOTA-EB-FAPI|177Lu-DOTA-EB-FAPI A maximum of 2 cycles of 100 mCi (3.7 GBq) 177Lu-DOTA-EB-FAPI, each. Route of administration: Slow intravenous infusion/injection (i.v.) Duration of treatment: 2 cycles, every 6 weeks
88890474|NCT05963373||Chronic diseased attendants above 18years old|
88890475|NCT05963373||Healthy attendants|
88890476|NCT05963334|Experimental|Weekly dose of carboplatin / paclitaxel (n=21)|Patients in this group received the weekly dose regimen, where the dose of carboplatin administered intravenously once/week was calculated using the Calvert equation to yield an area under the curve (AUC) = 2
88890477|NCT05963334|Active Comparator|3-Week collective dense dose of carboplatin / paclitaxel (n=28)|Patients in this group received the three-week collective dose regimen, where the dose of carboplatin was administered intravenously once on day 1/ every three weeks (21 days) and was calculated using the Calvert equation to yield an AUC = 6
89413154|NCT05043610|Active Comparator|Cohort 2 (Control Group)|In the control group, after an acute anterior myocardial infarction treated successfully with primary percutaneous coronary intervention, 120 patients will receive only conventional treatment.
88890478|NCT05963321|Active Comparator|Active cerebellum electrode and active M1 electrode|"The patient will receive active cerebellar stimulation with the anode electrode positioned in the cerebellum and active cortical stimulation with the anode electrode placed in the primary motor cortex.~In both cerebellar and cortical stimulations, the cathode will be positioned in the contralateral supraorbital region.~The equipment will apply a current of 2 mA for 20 minutes."
89413155|NCT02149056||Impaired Glucose Tolerance|
89413156|NCT02149134|Experimental|New extensively hydrolyzed casein formula|Subjects with cow's milk allergy treated with a new formula
88890479|NCT05963321|Active Comparator|Sham cerebellar electrode and active M1 electrode|"The patient will receive sham cerebellar stimulation with the anode electrode positioned in the cerebellum and active cortical stimulation with the anode electrode placed in the primary motor cortex.~In both cerebellar and cortical stimulations, the cathode will be positioned in the contralateral supraorbital region.~The equipment will apply a current of 2 mA for 20 minutes."
88890480|NCT05963321|Active Comparator|Active cerebellum electrode and sham M1 electrode|"The patient will receive active cerebellar stimulation with the anode electrode positioned in the cerebellum and sham cortical stimulation with the anode electrode placed in the primary motor cortex.~In both cerebellar and cortical stimulations, the cathode will be positioned in the contralateral supraorbital region.~The equipment will apply a current of 2 mA for 20 minutes."
89192871|NCT05964725|Sham Comparator|Receive traditional medical therapy and sham stimulation|Similarly, intravenous methylprednisolone infusion (dose of 1 mg/kg/day, maximum 60 mg/day) for 5 to 10 days. By controlling the tDCS stimulator to mimic only the first 30 seconds of tDCS stimulation, after 30 seconds of pathway resistance control, so that the stimulation intensity is below the threshold, without giving real stimulation, in this process, the position of the stimulation target is not changed, and the rest of the operation is the same.
89192872|NCT05960032|Experimental|Zavegepant|Participants receiving Zavegepant for the treatment phase of the study
89192873|NCT05957952|Sham Comparator|Exercise group|Motor control exercise
89192874|NCT05957952|Experimental|Dynamic taping with exercise group|Motor control exercise combined with dynamic taping
89192875|NCT05952739||Disease group|No interventions
89192876|NCT05952739||Control group|No interventions
89413157|NCT05042752|No Intervention|No intervention arm|Standard care of AHF on a patient admitted on a HAH unit consists in physical examination and basic complementary tests
89413158|NCT05042752|Experimental|Experimental arm|Clinical ultrasound on HAH admitted patient. Clinical handheld Ultrasound consists of inferior vena cava diameter measurement and lung ultrasound protocol in order to guided Diuretic Therapy
89413159|NCT02149212|Active Comparator|Clinical Treatment|Phlebotonics: Aminaftone 75 mg BID Limb elastic compression support (Elastic stockings: Venosan / Elastic Bandages: Atamed) Unna boot dressing
89413160|NCT02149212|Active Comparator|Iliac vein stenting|Wallstent
89413161|NCT03612063|Experimental|Fitbit Iconic HR and Garmin Vivosmart HR|
89413162|NCT03612063|Experimental|Fitbit Iconic HR and TomTom Spark 3|
89413163|NCT03612063|Experimental|Garmin Vivosmart HR and TomTom Spark 3|
89413164|NCT03612063|Experimental|Fitbit Iconic HR and Apple Watch III|
89413165|NCT03612063|Experimental|Apple Watch III and Garmin Vivosmart HR|
89413166|NCT03612063|Experimental|Apple Watch III and TomTom Spark 3|
88890481|NCT05963321|Sham Comparator|Sham cerebellar electrode and sham M1 electrode|"The patient will receive sham cerebellar stimulation with the anode electrode positioned in the cerebellum and sham cortical stimulation with the anode electrode placed in the primary motor cortex.~In both cerebellar and cortical stimulations, the cathode will be positioned in the contralateral supraorbital region.~The equipment will apply a current of 2 mA for 20 minutes."
88890482|NCT05963308|Experimental|"Online group intervention Healthy Minds"|
88890483|NCT05963308|No Intervention|Control group|"Like the intervention group, the control group will complete an online set of questionnaires at the following time points:~Baseline~First follow-up (2 months after baseline)~Second follow-up (6 months after baseline)~Third follow-up (12 months after baseline)~The questionnaires will cover the following domains:~Sociodemographic and biopsychosocial factors~Symptoms associated with the primary mood disorder~Cognitive difficulties and distortions~Self-efficacy in relation to returning to work~Work accommodations and natural supports~Relationship with immediate supervisor~Work functioning~Return-to-work time (number of days away from work)"
88890484|NCT05963295|Active Comparator|patient with hematlolgical malignancies|
88890485|NCT05963295|Active Comparator|control group|
88890486|NCT05963282||Sacubitril/valsartan|Prescribed sacubitril/valsartan
88890487|NCT05963282||ACEi/ARB|Prescribed ACEi or ARB
88890488|NCT05963191|Experimental|CAD-EYE group: Colorectal cancer screening with CAD EYE colonoscopy|The colonoscopy procedure for each patient will be no different from a conventional colonoscopy examination. In the CAD EYE group, descent is performed under white light, with the CAD EYE system switched on (device with CE mark). When polyps are detected, they are rigorously described and histological predictions of endoscopist and CAD EYE will be reported separately.
88890489|NCT05963191|No Intervention|CE group : Colorectal cancer screening with indigo carmine chromo colonoscopy|The colonoscopy procedure for each patient will be no different from a conventional colonoscopy examination. In the CE group, descent is performed under white light with indigo carmin chromoendoscopy (0.4%) applied through a catheter spray. When polyps are detected, they are rigorously described and histological prediction of the endoscopist reported.
88890490|NCT05963178|Experimental|Cohort|
88890491|NCT05963165|Experimental|Experimental group|Patients who will perform non-phonatory exercises in parallel with medical therapy for the first week
88890492|NCT05963165|No Intervention|Control group|patients who will perform standard medical therapy only during the first week.
88890493|NCT05963126||Patients with hypertension, resistant hypertension, and secondary hypertension|Patients with arterial hypertension, resistant arterial hypertension, and secondary hypertension.
88890494|NCT05963100|Experimental|Experimental 1*10^6/kg|
88890495|NCT05963100|Experimental|Experimental 1*10^7/kg|
88890496|NCT05963100|Experimental|Experimental 3*10^6/kg|
88890497|NCT05963100|Experimental|Experimental 2*10^7/kg|
88890498|NCT05963087|Experimental|Advanced CRC|Patients with BRAF Mutated Advanced CRC were given Cetuximab in Combination With Dabrafenib and Tislelizumab
88890499|NCT05963035|Experimental|18F-PFPN PET|A positron probe for the targeted melanin
88890500|NCT05962983|Experimental|SSBC participants|Participants will attend a 6-week diet and exercise changes program (SSBC).
88890501|NCT05962944||Laboratory testing|Slides reviewed in the laboratory to test the platform for suitability prior to involving patients
88890502|NCT05962944||Remote ROSE on the same site as the laboratory|The next phase will involve remote ROSE being performed on the same site as the laboratory in an ultrasound room located on the Royal Cornwall Hospitals Truro site.
88890503|NCT05962944||Remote ROSE at a site external to the laboratory|Phase 3 will involved remote ROSE being performed on a different site to the laboratory. The ultrasound room at The Royal Cornwall Hospital's Camborne and Redruth site.
88890504|NCT05962931|Experimental|Bioengineered Artificial Mesenchimal Sheet (BAMS)|Allogenic adipose-derived adult mesenchymal stem cells expanded on fibrinhyaluronic biological matrix
88890505|NCT05962931|Active Comparator|Standard treatment (Control)|Standard treatment
88890506|NCT05962918|Experimental|perineal massage|intervention group with perineal massage
88890507|NCT05962918|No Intervention|control group|The group that received routine hospital protocol and was not massaged.
88890508|NCT05962879|Experimental|Resilience Training for Teens|A brief 6-session group-based behavioral intervention for teens at risk of a mental illness.
88890509|NCT05962879|No Intervention|Waitlist|A one year waitlist period where participants will not participate in Resilience Training for Teens. Following that one year waitlist period, they can participate in Resilience Training for Teens.
88890510|NCT05962853|Experimental|Experimental group ( TENS will be applied )|After 30 minutes of TENS application 2 hours after the surgery, TENS will be applied 3 times at 8 hour intervals. Postoperatively at the 2nd hour (just before TENS), at the 3rd hour (1 hour after the onset of TENS), at the 10th hour (just before the TENS), at the 11th hour (1 hour after the start of TENS), at the 18th hour ( Just before TENS) at the 19th Hour (1 hour after the start of TENS). TENS application hours will be arranged according to the patient in order to protect sleep integrity.
88890511|NCT05962853|No Intervention|Control Group ( TENS will not be applied )|Application of the control group: TENS will not be applied to this group.
88890512|NCT05962840|Placebo Comparator|Placebo arm|Patients with active AAV will be treated with Rituximab and glucocorticoid to induce remission. And the placebo of Telitacicept would be given 80 mg every week subcutaneously for 12 months. Glucocorticoid would be tapered as recommended by 2022 EULAR AAV recommendation (as protocol of PEXIVAS study)
88890513|NCT05962840|Experimental|Telitacicept treatment arm|Patients with active AAV will be treated with Rituximab and glucocorticoid to induce remission. And the Telitacicept would be given 80 mg every week subcutaneously for 12 months. Glucocorticoid would be tapered as recommended by 2022 EULAR AAV recommendation (as protocol of PEXIVAS study)
88890514|NCT05962814|Experimental|fNIRS|Infants who have a test completed with EarGenie MVP in a single test session
88890515|NCT05962775|No Intervention|Control|In eligible patients allocated to control group, no interventions will be done before ART cycle.
89413167|NCT05048290|Experimental|Group I (communication workshops, video, surveys)|Participants complete 2 communication workshops about conversational skills and development of a video about the summer student's research experience over 3 hours each during the second week of the summer research experience and 2-3 weeks before the conclusion of summer experience. Participants also complete surveys over 15 minutes each about their communication, their engagement with research, mentoring experience, and current career intentions, before participating in the workshop, after the second workshop and at 6 months after the conclusion of the summer experience.
89413168|NCT05048290|Active Comparator|Group II (generic communication workshops, surveys)|Participants complete 2 generic communication workshops about networking and presentation skills over 3 hours each during the second week of the summer experience and 2-3 weeks before the conclusion of summer experience. Participants also complete surveys over 15 minutes each about their communication, their engagement with research, mentoring experience, and current career intentions, before participating in the workshop, after the second workshop and at 6 months after the conclusion of the summer experience.
89413169|NCT03611985|Experimental|Epidiferphane + taxane chemotherapy|
89413170|NCT05029804|Experimental|Intervention Group|"After the initial assessment, patients in this group will be educated by the researcher on walking exercise by using the transtheoritical model. The data will be collected from the patients in the experimental group at baseline, 1st, 3rd, and 6th months of the programme.~The data will be collected by using Exercise Stages of Change Questionnaire, Exercise Processes of Change Scale, Pedometer, Patient Compliance in Type 2 Diabetes Mellitus Treatment Scale, and patient identification that includes five domain. These domains include questions about the patients' sociodemographic characteristics, habits, knowledge of diabetes and its treatment, exercise status, and the evaluation of the metabolic control variables."
89413171|NCT05029804|No Intervention|Control|"No intervention will be applied to this group. The data will be collected from the patients in the control group at baseline, 1st, 3rd, and 6th months.~The data will be collected by using Exercise Stages of Change Questionnaire, Exercise Processes of Change Scale, Pedometer, Patient Compliance in Type 2 Diabetes Mellitus Treatment Scale, and patient identification that includes five domain. These domains included questions about the patients' sociodemographic characteristics, habits, knowledge of diabetes and its treatment, exercise status, and the evaluation of the metabolic control variables."
89413172|NCT03611517|Experimental|Sexual rehabilitation programme|The intervention exists of a nurse-led sexual rehabilitation programme, which is provided in addition to the care as usual. The intervention consists of four one-hour sessions at 1 month, 3, 6, and 12 months after RT. Women treated with RTBT will receive an additional appointment with the nurse (2 months after RTBT). Furthermore, the latter group receives a vaginal dilator set.
89413173|NCT03611517|No Intervention|Care as usual|The control group receives the optimal care as usual, according to each participating hospital's guidelines. Additionally, all patients receive an information booklet including information concerning sexuality after RT for GC. Patients who underwent RTBT also receive a vaginal dilator set.
89413174|NCT05029492|Active Comparator|Diet group|Giving a low caloric diet
89413175|NCT05029492|Experimental|Visceral manipulation with diet group|Giving visceral manipulation added to a low-calorie diet
89413176|NCT02865915|Placebo Comparator|Placebo|Plain, round, biconvex, white film-coated tablets that appear identical to MLE4901 tablets
89413177|NCT02865915|Experimental|MLE4901|Plain, round, biconvex, white film-coated tablets administered twice per day
89413178|NCT05029648||Cohort|Simple cohort
89413179|NCT05029258||Locally advanced cervical cancer patients treated with standard of care chemoradiation|
88890516|NCT05962775|Experimental|Ethanol sclerotherapy|In eligible patients allocated to study group, endometrioma/s will be aspirated and treated with ethanol for 10 minutes 1-2 cycles before ART.
88890517|NCT05962749||Children With Cerebral Palsy|
88890518|NCT05962697|Experimental|SA controller|Synergy assistance controller
88890519|NCT05962697|Other|early testing|up to 5 participants testing the SA controller in one visit
88890520|NCT05962684||ERAS|
88890521|NCT05962671|Active Comparator|Opioid-sparing based anesthesia|Intraoperative opioid-sparing maintenance comprised dexmedetomidine bolus dose of 1 mcg/kg followed by 0.3 mcg/kg/h, propofol 4-8 mg/kg/h and ketamine 25 mg/h for a max of 50 mg during the procedure, targeting bispectral index (BIS) between 45%-60%. The lean body weight will be used for calculation of the drugs.
88890522|NCT05962671|Active Comparator|Sevoflurane-based anesthesia|Intraoperative sevoflurane-based anesthesia, 0.8 to 1.0 Minimum alveolar concentration will be used combined with fentanyl 1 mcg/kg followed by 1 -2 mcg/kg/h and cis-atracurium, to keep bispectral index between 45% to 60%.
88890523|NCT05962658||Fibromyalgia|Our sample consisted of 11 women with fibromyalgia enrolled according to the criteria of the American College of Rheumatology (ACR). Participants were underwent to clinical and electrophysiological assessments using the McGill Pain Questionnaire, the Hospital Anxiety and Depression Scale, and qEEG in frontal (F3, F4, Fz, F7, F8) and central (C3, C4,Cz) areas. qEEG data was collected with patients in resting eyes-closed: the relative spectral power of the frequency bands delta, theta, alpha and beta was evaluated.
88890524|NCT05962658||Healthy individuals|A control group was enrolled and data was collected from healthy subjects to confirm different patterns of cortical electrical activity in people with fibromyalgia. For that, self-declared healthy and pain-free individuals, matched by gender and age with the women with fibromyalgia included in the sample were recruited through advertising in digital media.
88890525|NCT05962645|Experimental|Group A|Healthy Participants (HP)
88890526|NCT05962645|Experimental|Group B|Participants with COPD
88890527|NCT05962632|Experimental|Clinical-based preventive platform|applying of Fluoride varnish every 3 months
88890528|NCT05962632|Experimental|Home-based preventive platform|topical remineralizing agent
88890529|NCT05962632|Experimental|E health platform|Mobile application
88890530|NCT05962632|Active Comparator|Basic preventive measures|tooth brushing/fluoridated toothpaste over the counter 1450 ppm, interdental cleaning, fluoride rinse OTC
88890531|NCT05962619|Experimental|Arthrocentesis alone|Arthrocentesis alone in management of temporomandibular joint dysfunction in the form of anterior disc displacement with reduction.by lavage by normal saline and during the lavage the mandible is moved through opening, excursive, and protrusive movements to facilitate lysis of adhesions.
88890532|NCT05962619|Experimental|arthrocentesis with hyaluronic acid injection|arthrocentesis with hyaluronic acid injection in management of temporomandibular joint dysfunction in the form of anterior disc displacement with reduction. after arthrocentesis is completed, lavage is done by hyaluronic acid injection
88890533|NCT05962593|Placebo Comparator|Telephone call|A postoperative telephone call
88890534|NCT05962593|No Intervention|No telephone call|No telephone call
88890535|NCT05962580|Experimental|Isolated anterior cruciate ligament recnostruction with lateral extra articular tenodesis|Arthroscopic anatomical single bundle anterior cruciate ligament reconstruction with modified Lemiere technique for extra-articular tenodesis
88890536|NCT05962580|Active Comparator|Isolated anterior cruciate ligament recnostruction without lateral extra articular tenodesis|Arthroscopic anatomical single bundle anterior cruciate ligament reconstruction only
88890537|NCT05962567|No Intervention|Healthy individuals|No intervention
88890538|NCT05962567|Active Comparator|Stage II periodontitis patients|Non-surgical periodontal therapy by ultrasonic and universal curettes
88890539|NCT05962554|Experimental|Intervention group|The group that will be first randomly allocated to iJobs.
88890540|NCT05962554|Experimental|Waiting list control group|This group will receive the intervention 2-weeks after the intervention group finishes it.
89413180|NCT03097900|Active Comparator|Treatment (Caffeine Citrate) group|25 patients after elective colorectal surgery will be given 100 mg caffeine citrate orally diluted in 50 ml apple flavored water three times per day starting on the morning of postoperative day 1 after surgery until flatus will occur for the first time or to a maximal period time of 7 days, whichever comes earlier.
89413181|NCT03097900|Placebo Comparator|Placebo (Water) group|25 patients after elective colorectal surgery will be given 50 ml apple flavored water three times per day starting on the morning of postoperative day 1 after surgery until flatus will occur for the first time or to a maximal period time of 7 days, whichever comes earlier.
88890541|NCT05962528|Experimental|Type 1 group|Toric soft lens with high sagittal height
88890542|NCT05962528|Experimental|Type 2 group|Toric soft lens with low sagittal height
88890543|NCT05962528|Experimental|Type 3 group|Spherical soft lens with high sagittal height
88890544|NCT05962528|Experimental|Type 4 group|Spherical soft lens with low sagittal height
88890545|NCT05962528|Placebo Comparator|Control group|Traditional spherical soft lens
88890546|NCT05962515||1|All patients in group 1 (n:22) had DN treatment applied to the piriformis muscle once a week for a total of 3 times under US guidance.
88890547|NCT05962515||2|All patients in group 2(n:22) had exercise programme for 3 weeks.
88890548|NCT05962437|Experimental|STANZA-Spain|Digital Acceptance and Commitment Terapy (ACT). It consists of 41 structured ACT lessons, incorporating mindfulness practices and daily activities to facilitate behavior change and promote gradual pacing of daily activities and exercise. The core content was designed to be completed within 8 weeks, with a 4-week maintenance period thereafter to strengthen skills.
88890549|NCT05962437|Active Comparator|FibroST-Spain|A digital active control intervention is implemented to control for study engagement, expectations, and healthcare provider interaction biases. Components of this active comparator include daily symptom and function tracking (Daily Symptom Tracker), symptom and function monitoring, and access to health education articles about fibromyalgia.
88890550|NCT05962437|Active Comparator|Treatment as Usual (TAU)|Usual care is mainly carried out by general practitioners and rheumatologists through regular consultations. Clinicians prescribe medications and provide some counselling.
88890551|NCT05962411|No Intervention|Dress in School Uniforms|Simulated clients dress in school uniforms, enter e-cigarette stores, and act as minor buyers.
88890552|NCT05962411|Experimental|Dress in Professional Attire|"Simulated clients dress in business casuals, enter e-cigarette stores, and act as potential adult e-cigarette buyers."
88890553|NCT05962359|No Intervention|Non-treatment Model Building|
88890554|NCT05962359|Experimental|Communication Treatment|
88890555|NCT05962333|Experimental|Intra-arterial delivery of autologous MABs|Autologous MABs will be injected three times in left arm to treat biceps brachii muscle
88890556|NCT05962307||Hepatis Delta|Bulevirtide (BLV) at a dose of 2 mg/day subcutaneously
88890557|NCT05962281|Active Comparator|Individualized tDCS|Each participant will be screened according to their brain scan, they will receive individualized dose of tDCS currents.
88890558|NCT05962281|Active Comparator|Fixed currents tDCS|All of the participant will receive standardized dose of tDCS currents intensity of 2 mA.
88890559|NCT05962281|Sham Comparator|Sham tDCS|The electrodes will applied to the cortical areas, however none of all of the participant will receive the current dose of tDCS.
89413182|NCT03096652|Active Comparator|Midline approach|Standard midline incision, then optimal debulking (hysterectomy + lymphadenectomy +/- omentectomy).
89413183|NCT03096652|Active Comparator|Modified approach|Panniculectomy with vertical incision of the rectus sheath then optimal debulking (hysterectomy + lymphadenectomy +/- omentectomy).
89413184|NCT03096496||GIMEMA APL0406 patients|APL survivors previously enrolled in GIMEMA APL0406 clinical trial and in 1st molecular CR after third consolidation treatment.
89413185|NCT05047666||Cases Group|Also called in our study 'Case-Positives'. These are those with respiratory symptoms suspected of COVID-19 that actually test positive (PCR).
89413186|NCT05047666||Symptomatic Control Group|Also called in our study 'Case-Negatives'. These are those with respiratory symptoms suspected of COVID-19 that actually test negative for SARS-CoV-2 but positive for any other pathogen included in our respiratory PCR-based panel.
89413187|NCT05047666||Healthy Control Group|At the community.
88890560|NCT05962268|Experimental|Video based education|"The video was prepared by the researchers in line with the literature. Expert opinion was obtained from 10 individuals with at least a doctorate and studies on the subject of video content. In line with expert opinions, the video content was updated and finalized. Patient education with the prepared video was provided by one of the researchers involved in the study. The video education took 20 minutes in total.~Topics: Video recordings on of fistula care was done by the researchers in the vocational skills laboratory. The video flow plan included the introduction of the materials to be used in fistula care as well as the researcher's presentation of how to manage the fistula. Fistula care steps were performed on the simulation model. In addition, the precautions to be taken during the application and what to do in case of possible complications were also shown."
88890561|NCT05962268|Experimental|Face to face education|The patients were trained on fistula care by the researcher. Fistula care training was given to the patients in the control group using face-to-face education technique. In this training, researcher verbally explained fistula care to patients. The training was conducted one-on-one with the patient in the patient's room and lasted 10 minutes. The training was presented to the patient through the lecture method. The training was also supported by the question-and-answer method. The training was given twice, one week apart, when patients came for hemodialysis treatment after the condition of the patients on dialysis stabilized.
88890562|NCT05962255|Experimental|0.9 % Sodium Chloride solution|Patients receiving an intravenous infusion of 0.9% NaCl
88890563|NCT05962255|Active Comparator|5% Glucose solution|Patients receiving an intravenous infusion of 5% glucose
88890564|NCT05962203|Experimental|Multi-factorial geriatric assessment, monitoring & management systems|All participants in the observational/interventional study (MV-FIT) will receive guideline-based, multi-factorial geriatric assessment, monitoring & managements (multi-component healthcare). Other: GFR Measuremments, Blood sampling, Urine sampling
88890565|NCT05962190|Experimental|High fat, high SFA|~60% of total energy is from fat, of which ~45% is from SFA, ~55% is from PUFA
88890566|NCT05962190|Experimental|High fat, high UFA|~60% of total energy is from fat, of which ~25% is from SFA, ~75% from UFA
88890567|NCT05962138|Experimental|Sleepio (dCBT-I)|"6-10 weeks of digital cognitive behavioural therapy for insomnia (Sleepio) delivered online.~Participants will also receive a booklet with general advice for patients with fibromyalgia, including sleep hygiene."
89005511|NCT04569760|Experimental|Cannabinoid Oil - Oral Preparation|"50mg CBD: 2mg of THC in each 1ml drop in MCT Oil, flexibly dosed at 200-800 mg per day.~Dosing will start at 2 mls twice a day for one week and be titrated to 4 mls twice/daily for one week. At the end of Week 2, dose may be titrated to 6 mls twice a day ; then at the end of Week 4, dose may be titrated to 8 mls twice daily (the maximum of 800 mg/day total dose of High CBD).~The dose will be titrated in increments of 200 mg (4 mls)/day/week if participants are tolerating their current dose, are experiencing no adverse events and have not fully responded so that they may potentially reach 800 mg/day/week by Week 4."
89413188|NCT02149446|Experimental|Surgisis reinforcement of staple line|The stapler used to divide the pancreas is reinforced with Surgisis (COOK Medical).
89413189|NCT02149446|No Intervention|No reinforcement of staple line|The stapler used to divide the pancreas is not reinforced with any material
89413190|NCT03543618|Sham Comparator|Control|Installation of conventional design dental implant
89413191|NCT03543618|Active Comparator|Sloped|Installation of sloped design dental implant
89413192|NCT02149602||oropharyngeal and hypopharyngeal HNSCC|Intensity Modulated Radiotherapy HPV positive and HPV negative
88890568|NCT05962138|No Intervention|Treatment as usual|Participants will receive a booklet published by Versus Arthritis designed for patients with fibromyalgia with general advice, including sleep hygiene.
88890569|NCT05962099||NAFLD|
88890570|NCT05962099||Controls (non-NAFLD)|
88890571|NCT05962073|No Intervention|NIV|Non-invasive ventilation application for preoxygenation
88890572|NCT05962073|Active Comparator|HFNC|High flow oxygen therapy application for preoxygenation
88890573|NCT05962060|Experimental|Electrical Muscle Stimulation|"This group will receive PNF techniques (rhythmic initiation to stabilizing reversals and then then followed by dynamic reversals) with EMS to improve their spasticity, gait and lower limb functions. PNF exercises involved PNF pelvic patterns, PNF lower extremity D1 Flexion and PNF lower extremity D1 extension, repeated 10 to 20 times or up to patient's tolerance, up to 4 weeks.~When patients will perform PNF pattern electrodes of EMS will be placed at desired points of upper- extremity such that there will movement by patient effort and EMS will produce contraction of muscles simultaneously thus enhancing the function of extremity. Daily this combination will be used for patients to find the desired results. the time for period of 6 weeks for 5 days a week on regular basis. EMS Parameters to be implemented; Stimulus pulse: Symmetric Biphasic. Amplitude: 0-60mA. Pulse width: 300µsec Frequency: 25 to 50 H. Duty cycle: 10sec off 10 sec on."
89413193|NCT05047276|Experimental|AloCelyvir|Delivery of Icovir-5 by mesenchymal carrier cells in uveal melanoma patients with hepatic metastases.
89413194|NCT00354835|Active Comparator|Arm I (chemotherapy, radiotherapy)|Patients receive VAC chemotherapy comprising vincristine IV over 1 minute on day 1 of weeks 1-13, 16, 19-25, 28, 31-37, and 40; dactinomycin IV over 1-5 minutes on day 1 of weeks 1, 4, 13, 16, 19, 22, 25, 28, 31, 34, 37,and 40; and cyclophosphamide IV over 1 hour on day 1 of weeks 1, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34, 37, and 40. Patients may also undergo radiotherapy 5 days a week for 4-6 weeks beginning in week 4.
88890574|NCT05962060|Active Comparator|Proprioceptive Neuromuscular Facilitation|"This group will receive PNF techniques (rhythmic initiation to stabilizing reversals and then followed by dynamic reversals) to improve their spasticity, gait and lower limb functions.~PNF exercises involved PNF pelvic patterns, PNF lower extremity D1 Flexion and PNF lower extremity D1 extension, each exercise was repeated 10 to 20 timesor up to patient's tolerance, progressed from rhythmic initiation to stabilizing reversals and then the followed by dynamic reversals up to 4 weeks of 10 therapy session. The treatment was provided 3 days per week on alternate basis, for 6 weeks (18 sessions). Participants were re-assessed on the outcome scale at end of 6 weeks."
89413195|NCT00354835|Experimental|Arm II (chemotherapy, radiotherapy)|Patients receive VAC chemotherapy alternating with VI chemotherapy comprising vincristine IV over 1 minute on day 1 of weeks 1-13, 16, 17, 19, 20, 22-26, 28, 31-34, 37, 38, and 40; dactinomycin IV over 1-5 minutes on day 1 of weeks 1, 13, 22, 28, 34, and 40; cyclophosphamide IV over 1 hour on day 1 of weeks 1,10, 13, 22, 28, 34, and 40; and irinotecan hydrochloride IV over 1 hour on days 1-5 of weeks 4, 7, 16, 19, 25, 31, and 37. Patients may also undergo radiotherapy 5 days a week for 4-6 weeks beginning in week 4.
89413196|NCT02768298|Experimental|LCZ696|LCZ696 100 mg oral twice daily (bid) for 2 weeks followed by LCZ696 200 mg oral bid for 10 weeks.
89413197|NCT02768298|Active Comparator|Enalapril|"Enalapril 5 mg oral twice daily (bid) for 2 weeks followed by enalapril 10 mg oral bid for 10 weeks.~Patients who prior Screening were at a stable daily dose of enalapril above 10 mg per day (or corresponding doses of other ACEI/ARB) started the study at a dose of enalapril 10 mg bid."
89413198|NCT05028478|Experimental|Single Arm|"Four planned CN202 dose level of 1 mg/kg, 3 mg/kg, 10 mg/kg, 20 mg/kg~Subjects will receive CN202 by intravenous infusion (IV) on Day 1 of each cycle (once every 2 weeks) for up to 24 months"
89413199|NCT05028322|Active Comparator|Intra-muscular vaccination (Group 1)|This group corresponds to the use of the vaccine as used in the current recommendations.
89413200|NCT05028322|Active Comparator|Intra-dermal vaccination group without application of IMIQUIMOD cream (Group 2)|Administration mode change for Intra-dermal vaccination. ( Instead of Intra-musculaire ) , to have a comparative with the experimental group.
89413201|NCT05028322|Experimental|Intra-dermal vaccination group with application of IMIQUIMOD cream (Group 3)|"Intra-dermal vaccin administration, with an immunity booster few minutes before by IMIQUIMOD application cream.~Experimental group."
89413202|NCT03096340|Experimental|IT-141|
88890575|NCT05962047|Experimental|Group 1|Augmented Reality games
88890576|NCT05962047|Active Comparator|Group 2|Traditional therapy
88890577|NCT05962021|Experimental|19DEL cohort|Patients who participated in the trial with EGFR 19DEL mutation will be included in this arm.
88890578|NCT05962021|Experimental|L858R cohort|Patients who participated in the trial with EGFR L858R mutation will be included in this arm
88890579|NCT05961995|Experimental|HFN Meditation|Subjects will complete guided meditation sessions 3 x a week for six weeks delivered in the app via video, as well as pre- and post-meditation psychological state assessments.
88890580|NCT05961982|Experimental|Treatment (EUS-RFA)|Patients undergo standard of care EUS-FNA followed by EUS-RFA on study and may undergo repeat EUS-RFA or EUS-guided chemoablation during surveillance. Patients undergo MRI/MRCP, CT, or EUS-FNA at baseline and at follow-up timepoints.
88890581|NCT05961969||Patients undergoing robotic Transabdominal Top-down Intersphincteric Resection|Patients undergoing robotic Transabdominal Top-down Intersphincteric Resection with Double-stapling Coloanal Anastomosis
88890582|NCT05961943|Experimental|RESPONSE-2-PAD|All participants will use the activPAL accelerometer to quantify sedentary time/physical activity. The 6-minute-walk test will be assessed. Participants will receive the 12 week tailored intervention (RESPONSE-2-PAD link, coaching calls and activity tracker). Participants will be followed up at 12-weeks and again at six months.
88890583|NCT05961930||Surgeons estimate of postoperative infection|All surgeons will be asked to fill in a questionnaire, containing 5 questions, pertaining to the estimated risk of postoperative infection (within 30days). Thus there is a single arm and no comparison.
88890584|NCT05961917|Active Comparator|Group low PEEP|Positive end-expiratory pressure will be set at 5 cmH2O during controlled mechanical ventilation.
88890585|NCT05961917|Active Comparator|Group high PEEP|Positive end-expiratory pressure will be set at 10 cmH2O during controlled mechanical ventilation.
88890586|NCT05961904|Experimental|Study group|Study group with receive orally breast milk
88890587|NCT05961904|No Intervention|Control group|no intervention
88890588|NCT05961891|Experimental|Patients with Finger Tip Amputations|Patients with Finger Tip Amputations
89413203|NCT02152722||Total Body Irradiation Subjects|Subjects undergoing total body irradiation prior to chemotherapy. It is expected that all of these subjects will be receiving ablative radiation prior to bone marrow transplant. Breath will be collected before and after the first radiation exposure on each day of total body irradiation.
89413204|NCT02149680||Experimental group|Patient who has had an epidural blood patch following accidental dura puncture during pregnancy
88890589|NCT05961878|Experimental|Sarcopenic|subjects with sarcopenia diagnosis
88890590|NCT05961878|Placebo Comparator|Non sarcopenic|subjects without sarcopenia diagnosis
88890591|NCT05961852|Experimental|Treatment arm|Cutting and drug-coated balloon angioplasty
89413205|NCT02149680||Control Group|Women in the same group, equal numbers of those with or without epidurals, without accidental dural puncture, similar parity would constitute the control group. They would be chose at random, 10 times the number in the experimental group (n = 600).
89413206|NCT05028244|Experimental|Intervention group|Selected patients undego lower extremity ultrasound for diagnosis of deep vein thrombosis 2 times per week (mondays and thursdays) in a period of 3 weeks (21 days) of follow up
89413207|NCT05028244|No Intervention|control group|This group only undergo the first ultrasound assesment to discard previos thrombosis not detected during hospitalization or ambulatory
88890592|NCT05961813|Experimental|Intervention group in protesic implant orthopedic surgery|58 patients programmed for knee or hip replacement surgeries, or spinal arthrodesis surgery who will be sent to a specialized preventive medicine consult to quit smoking.
88890593|NCT05961813|Experimental|Intervention group in general and urological surgery|58 patients programmed for colorrectal surgery due to colorrectal cancer, cistectomy, radical prostatectomy and partial or total nefrectomy, who will be sent to a specialized preventive medicine consult to quit smoking.
88890594|NCT05961813|Active Comparator|Control group in protesic implant orthopedic surgery|58 patients programmed for knee or hip replacement surgeries, or spinal arthrodesis surgery who will receive a brief intervention for smoking cessation.
88890595|NCT05961813|Active Comparator|Control group in general and urological surgery|58 programmed for colorrectal surgery due to colorrectal cancer, cistectomy, radical prostatectomy and partial or total nefrectomy, who will receive a brief intervention for smoking cessation.
88890596|NCT05961800|Experimental|Quantitative Sensory Testing|Participants with chronic low back pain and a scheduled lumbar medial branch block undergo quantitative sensory testing.
88890597|NCT05961787|Experimental|DCB ARM|patients with large primary coronary artery lesions (3.0mm≤ vessel diameter ≤4.0mm, lesion length ≤35mm).
88890598|NCT05961787|Active Comparator|DES ARM|patients with large primary coronary artery lesions (3.0mm≤ vessel diameter ≤4.0mm, lesion length ≤35mm).
88890599|NCT05961774|Experimental|High frequency repetitive transcranial magnetic stimulation|This group will receive high frequency repetitive transcranial magnetic stimulation.
88890600|NCT05961774|Active Comparator|Neuromuscular electrical stimulation|This group will receive neuromuscular electrical stimulation.
88890601|NCT05961761|Experimental|Propranolol + pembrolizumab|pembrolizumab 2 mg/kg every 3 weeks and propranolol 40 mg x2 daily until progression, unacceptable toxicity or patient withdrawal for a maximum of two years.
88890602|NCT05961735||Patients with PECS II Block|
88890603|NCT05961735||Patients with Combined Serratus Anterior Plane Block|
88890604|NCT05961722||Group 1|
88890605|NCT05961722||Group 2|
88890606|NCT05961722||Group 3|
88890608|NCT05961683|No Intervention|Infants receiving non invasive ventilation without NIV plus|
89192877|NCT05950646|Experimental|Dexmedetomidine-esketamine combination|Dexmedetomidine-esketamine combination will be infused at a rate of 0.01 ml/kg/h (dexmedetomidine 0.02 μg/kg/h and esketamine 5 μg/kg/h) from 8 pm in the night before surgery until 8 am in the third morning after surgery.
89192878|NCT05950646|Placebo Comparator|Normal saline|Placebo (normal saline) will be infused at a rate of 0.01 ml/kg/h from 8 pm in the night before surgery until 8 am in the third morning after surgery.
89192879|NCT05949008|Experimental|Metformin Extended Release (ER) Oral Tablets|This is a 24-week, randomized, double-blinded, two arm parallel clinical trial comparing metformin ER vs. placebo in combination with a hypocaloric diet (-500 kcal/day). 150 individuals with obesity and increased waist circumference will be randomized to taking metformin ER with hypocaloric diet or placebo with hypocaloric diet. All patients will receive dietary and exercise counseling with the intent of reducing their average caloric intake by 500 kcal/day.
89413208|NCT02152800|Experimental|Vacyless® 1000 mg|one Vacyless® 1000 mg tablets, 3 times daily for 7days
89413209|NCT02152800|Experimental|Vacyless® 500mg|Two Vacyless® 500mg tablets, 3 times daily for 7 days
89413210|NCT02152800|Active Comparator|Valtrex® 500 mg|Two Valtrex® 500 mg tablets, 3 times daily for 7days
88890609|NCT05961683|Experimental|Infants receiving non invasive ventilation with NIV plus|
88890610|NCT05961618||Uninfected|Subjects who had recovered from SARS-CoV-2 infection
88890611|NCT05961618||Infected|Subjects who had not been infected with SARS-CoV-2.
88890612|NCT05961553|Experimental|Physical Activity Counseling + Pulmonary Rehabilitation|The counseling session on physical activity was carried out individually, six weeks after starting the respiratory rehabilitation program, with an average duration of 30 minutes, based on the guidelines of the Living Well with COPD program. The main objective of the session was: to help the participant and family members to increase physical activity levels and their integration in the long term and as secondary objectives; reinforce the importance and benefits of physical activity in the management of the health condition/symptoms; plan daily/weekly moments of physical activity; define daily goals (physical activity time/sitting time) attainable for each participant; integrate family members/companions into the user's physical activity plan; clarify doubts of the user/relative about the theme.
88890613|NCT05961553|Active Comparator|Pulmonary Rehabilitation|The program comprises a hospital group exercise program, twice a week, on alternate days, for 1h30 to 2h, each session, which included: monitoring of vital signs, peripheral oxygen saturation (SpO2), subjective perception of exertion (RPE), dyspnea and body mass; warm-up phase (10min), with ventilatory control and low-intensity upper and lower limb exercises; continuous aerobic training phase, performed on a treadmill, static cycle ergometer and/or arm ergometer (30-45min), at 60-80% of the maximum Cardiopulmonary Exercise Test load; strength training phase, with free weights, machines (10-20min), at 50-80% of the Maximum Repetition (RM), (8-12 repetitions), 1-2 sets, 8-10 exercises ( upper limbs, trunk and lower limbs); cooling phase (5-10min), with 5 to 8 relaxation, stretching and ventilatory control exercises. The progression of training loads is carried out according to RPE and dyspnea, safeguarding SpO2 values above 88-90% and Heart Rate below the maximum defined for training.
88890614|NCT05961501|Experimental|Study Group|Participants with facial pain and headache of muscular origin which last for more than 3 months. Each of the participants in this group will receive the aqueous solution of CBD and CBN to drink in home every day for 60 days in a specific dose determined by the attending physician
89192880|NCT05949008|Placebo Comparator|Placebo|Patients in the placebo arm will be randomized to placebo with hypocaloric diet. All patients will receive dietary and exercise counseling with the intent of reducing their average caloric intake by 500 kcal/day.
89413211|NCT03543540|Experimental|Nexvax2 (Arm A)|
89413212|NCT03543540|Experimental|Nexvax2 (Arm B)|
89413213|NCT03543540|Placebo Comparator|Nexvax2 Placebo (Arm C)|
89413214|NCT03543540|Placebo Comparator|Nexvax2 Placebo (Arm D)|
89413215|NCT02149758|Experimental|Etoricoxib|Etoricoxib 60 mg once daily
89413216|NCT02149758|Placebo Comparator|matching placebo|matching placebo once daily
89413217|NCT03094546|Experimental|Polyamine supplementation|Intervention: Dietary Supplement (Polyamine supplementation): 750 mg wheat germ extract
89413218|NCT03094546|Placebo Comparator|Placebo|Intervention: Dietary Supplement Placebo: 750 mg cellulose
89413219|NCT03542214|Experimental|Calcium electroporation treatment|Experimental treatment with calcium electroporation for inoperabel colorectal cancer
89413220|NCT03094468|Experimental|P-3058|
89413221|NCT03094468|Placebo Comparator|Vehicle|
89413222|NCT02156388|Experimental|Ia-GW003 50μg/kg|2-3 subjects
89413223|NCT02156388|Experimental|Ia-GW003 150μg/kg|2-3 subjects
89413224|NCT02156388|Experimental|Ia-GW003 300μg/kg|3-6 subjects
89413225|NCT02156388|Experimental|Ia-GW003 400μg/kg|3-6 subjects
88890615|NCT05961501|Placebo Comparator|Control group|Participants with facial pain and headache of muscular origin which last for more than 3 months. Each of the participants in this group will receive the placebo to drink in home every day for 60 days in a specific dose determined by the attending physician
88890616|NCT05961475|Experimental|First product order: order not stated to protect study blinding|Participants will receive each of the 5 study products sequentially in a cross-over design, consuming one study product for one visit, followed by 3-7 day wash-out period before beginning the next product in the sequence
88890617|NCT05961475|Experimental|Second product order: order not stated to protect study blinding|Participants will receive each of the 5 study products sequentially in a cross-over design, consuming one study product for one visit, followed by 3-7 day wash-out period before beginning the next product in the sequence
89413226|NCT02156388|Experimental|Ia-GW003 500μg/kg|3-6 subjects
89413227|NCT02156388|Experimental|Ia-GW003 600μg/kg|3-6 subjects
89413228|NCT02156388|Experimental|Ib-GW003 150μg/kg|6-8 subjects
89413229|NCT02156388|Experimental|Ib-GW003 300μg/kg|6-8 subjects
89413230|NCT05029024|Active Comparator|Intervention group|Patients allocated to the intervention group received standard care plus a guided 30-minute mindful breathing session which consisted of four breathing exercises done consecutively in one-to-one manner. The four exercises included identifying the in-and out-breath, following the entire length of the breath, bringing the mind back to the body and relaxing the whole body. Each exercise lasted 7.5 minutes. Guidance was given by one of the two research assistants, who were medical doctors. They were trained by one of the co-investigators, who was a palliative care physician, certified in mindfulness training.
89413231|NCT05029024|Placebo Comparator|Control group|Patients in the control group received standard care alone.
88890618|NCT05961475|Experimental|Third product order: order not stated to protect study blinding|Participants will receive each of the 5 study products sequentially in a cross-over design, consuming one study product for one visit, followed by 3-7 day wash-out period before beginning the next product in the sequence
89413232|NCT02152878|Active Comparator|Active stimulation|Active stimulation (tDCS) will be used in the dose of 2mA /30 min per day, for 10 days and two extra sessions every other week (total of 12 sessions).
88890619|NCT05961475|Experimental|Fourth product order: order not stated to protect study blinding|Participants will receive each of the 5 study products sequentially in a cross-over design, consuming one study product for one visit, followed by 3-7 day wash-out period before beginning the next product in the sequence
89413233|NCT02152878|Placebo Comparator|Sham stimulation|For Sham Transcranial Direct Current Stimulation, the device is automatically turned off after 30 seconds of stimulation and remains turned off.
89413234|NCT05026216|Experimental|Single-arm study|Using CCH-ases on bilateral buttocks and thigh injections. No placebo being used.
89413235|NCT03542136|Other|Patients receiving chemotherapy treatment with oxaliplatin.|
89192881|NCT05944562|Experimental|Dose De-Escalation Cohort: Tulmimetostat (CPI-0209)|Daily CPI-0209 by mouth for days 1-28 of each 28-day cycle. Dose will depend on dose level assignment of 300 mg daily, 250 mg daily, or 200 mg daily.
89413236|NCT05025982||Group of partecipants|we combined two surgical techniques in the same group of patients
89413237|NCT02156544|Experimental|CKD-519 25mg|CKD-519 25mg or placebo
89413238|NCT02156544|Experimental|CKD-519 50mg|CKD-519 50mg or placebo
89413239|NCT02156544|Experimental|CKD-519 100mg|CKD-519 100mg or placebo
89413240|NCT02156544|Experimental|CKD-519 200mg|CKD-519 200mg or placebo
89413241|NCT02156544|Experimental|CKD-519 400mg|CKD-519 400mg or placebo
89413242|NCT05025904|Experimental|Real-time fMRI neurofeedback (rt-fMRI NFB)|The duration of a session was approximately a half-hour. The course duration was 8 sessions. The preferred frequency was once a week, however, the schedule was flexibly adjusted for patients' convenience.
89413243|NCT05025904|Active Comparator|Сognitive behavioral therapy (CBT)|The duration of a session was approximately an hour/hour and a half. The course duration was 8 individual and 8 group sessions and included home assignments. The preferred frequency was twice a week, however, the schedule was flexibly adjusted for patients' convenience and for improving benefits of the treatment.
89413244|NCT05025904|Active Comparator|EEG neurofeedback (EEG NFB)|"The duration of a session was approximately a half-hour. The course duration was 16 sessions. The preferred frequency was twice a week, however, the schedule was flexibly adjusted for patients' convenience.~Group was preliminarily aborted for lack of time and participants in order to assign more patients to the abovementioned arms."
89413245|NCT03543462|Sham Comparator|Arm A: Chest tube positioning YES|Patients enrolled for chest tube positioning
89413246|NCT03543462|No Intervention|Arm B: Chest tube positioning NO|Patients enrolled for diaphragm closure without chest tube positioning
89413247|NCT03095950|Active Comparator|News with Spin|News items reporting results of RCTs with spin
89413248|NCT03095950|Experimental|News without spin|News items reporting results of RCTs without spin
89413249|NCT05025592||cTACE/DEB-TACE-HAIC+regorafenib±anti-PD1 antibody|patients will receive the combination treatment of cTACE/DEB-TACE plus HAIC and combined with regorafenib and anti-PD1 antibody or not. The anti-PD-1 antibody will be used depended on the contraindications or wishes of patients.
89413250|NCT04467034|Experimental|Receives Stanford tobacco education curriculum|Stanford Tobacco Prevention Toolkit is administered.
89413251|NCT04467034|No Intervention|Does not receive Stanford tobacco education curriculum|Receives another curriculum or no tobacco education.
89413252|NCT02775864||Antipsychotic|Individuals initiating treatment with an antipsychotic medication
88890620|NCT05961475|Experimental|Fifth product order: order not stated to protect study blinding|Participants will receive each of the 5 study products sequentially in a cross-over design, consuming one study product for one visit, followed by 3-7 day wash-out period before beginning the next product in the sequence
88890621|NCT05961449|Experimental|Experimental condition|Participants will complete an experimental exercise that will consist in 25 minutes of cycling between 60-80 Revolution Per Minute (RPM) on a cycle ergometer (CST BX40; Cardiostrong; Germany) at ≥ 70% of the Heart Rate Reserve (HRR).
89413253|NCT02775864||Antidepressant|Individuals initiating treatment with an antidepressant medication
89413254|NCT02775864||Benzodiazepine|Individuals initiating treatment with a benzodiazepine
88890622|NCT05961449|Sham Comparator|Control condition|The control condition will include an exercise design similar to the experimental condition except that the resistance will be kept at 25 W and the RPM below 50. The intensity of the exercise will be kept at minimal levels by ensuring that the heart rate does not increase >25% from baseline
88890623|NCT05961436|Active Comparator|PENG block group|using ultrasound-guided technique, a total of 20ml of 0.25 % bupivacaine will be injected after negative aspiration.
89413255|NCT02775864||Mood stabilizer|Individuals initiating treatment with a mood stabilizer
88890624|NCT05961436|Active Comparator|FN block group|using ultrasound-guided technique, after negative aspiration, 20 mL of 0.25 % bupivacaine will be administered.
88890625|NCT05961423|No Intervention|Laparoscopic surgery|The patients will undergoing laparoscopic surgery for the treatment of locally advanced colorectal cancer
88890626|NCT05961423|Active Comparator|Robotic group|The patients will undergoing robotic surgery for the treatment of locally advanced colorectal cancer
89413256|NCT02156622||Depression Care Manager|All enrolled in AIM 3 received decision support from Depression Care Manager
89413257|NCT03095872|Experimental|Bepanthen/Vaseline|One half of the wound occuring after CO2 laser therapy of photo-damaged skin is treated with Bepanthen and the other half with Vaseline.
89413258|NCT02156700||Liver tumors|Measurement of tumor stiffness by Shear wave elastography - SWE™
89413259|NCT03096184|Experimental|Study Group|Apatinib Mesylate Tablets and Tegafur Gimeracil Oteracil Potassium Capsules administered as a daily oral treatment
89413260|NCT02156778|Active Comparator|Extended Standard Care (Stroke Card)|
89413261|NCT02156778|Active Comparator|Standard Care|
89413262|NCT05028010|Experimental|Training|There will be one arm, intervention group.
88890627|NCT05961358||General anesthesia Patients|Subjects experiencing general anesthesia
88890628|NCT05961345|Experimental|early mobilization (experimental group)|The patients in the experimental group were mobilized at the 4th postoperative hour.
88890629|NCT05961345|No Intervention|control group (late mobilization)|The patients in the control group were mobilized at the 6th hour as in the routine of the clinic.
89413263|NCT02153034||Buruli ulcer patients, no intervention|Buruli ulcer patients administered standard standard care by the attending physician
89413264|NCT02153034||Healthy contacts, no intervention|Healthy volunteers who will be contacts of patients recruited or non-endemic controls. No intervention will be administered
89413265|NCT05027854|Experimental|Stimulation|TMS or tES, depending on experiment
89413266|NCT05027854|Sham Comparator|Sham|Corresponding sham TMS or tES
89413267|NCT03542916|Experimental|CJ-40001|CJ-40001 60ug SC, IV injection
89413268|NCT03542916|Active Comparator|NESP|NESP 60ug SC, IV injection
88890630|NCT05961319||Utilizing Smart Home Monitoring System in a Simulated Home Environment (in Hospital)|The project involves recruiting participants who will reside in a simulated condo environment within the Glenrose Rehabilitation Hospital. These participants will be remotely monitored using various sensors, including ones that track their interactions with appliances and furniture, smart biomechanics devices that assess their physical balance and strength, and a positioning system. By collecting and analyzing data from these sensors, the project aims to gain insights into the participants' daily activities, functional abilities, physical condition, and spatial behaviour.
88890631|NCT05961280||DCIS Mastectomy|Patients who undergo mastectomy with sentinel lymph node biopsy for DCIS at biopsy
88890632|NCT05961267||Patients|Patients with a diagnosis of systemic lupus erythematosus, Gougerot-Sjögren's syndrome, scleroderma, Sharp's syndrome, rheumatoid arthritis or spondyloarthritis, according to current international standards.
89413269|NCT05025202|Experimental|IET|Participants allocated to this arm performed 4 weeks of isometric wall squat exercise training, 3 times per week.
89413270|NCT05025202|Sham Comparator|Sham|Participants allocated to this arm performed 4 weeks of isometric wall squat training, but the training prescription was intentionally provided at an insufficient intensity to achieve any physiology stimulus.
89413271|NCT05025202|No Intervention|No intervention control|Participants allocated to this arm did not perform any exercise and were required to maintain usual daily habits.
89413272|NCT02156856||Hemodynamic optimisation|
89413273|NCT02156856||No hemodynamic optimisation|
89413274|NCT05028088|Experimental|Child-Pugh A|"Diaphragm ultrasound scan before induction of anesthesia.~Anesthesia method: During anesthesia induction, propofol 2.5mg/kg and sufentanil 5μg/kg will be injected intravenously. When the BIS value drops below 60, the muscle relaxation monitor will be calibrated. After T1 and TOF are stable, rocuronium will be injected intravenously at 0.6 mg/kg. During the maintenance stage of anesthesia, the pneumoperitoneum pressure will be at a low level of 8-10mmHg, propofol TCI will be applied to maintain the plasma concentration of 2.5-5.5 μg/mL, remifentanil TCI will be used to keep the plasma concentration of 0.5-5 ng/mL, and rocuronium will be continuously pumped intravenously with 0.3-0.6 mg/kg/h for deep muscle relaxations, with the the post-tetanic twitch count (PTC) value of 1 to 2.~When the TOF value was ≥2%, patients in each group will be given SUG (2mg/kg).~Diaphragm ultrasound scan at the immediate time,10min, 30min and 2h after extubation."
89413275|NCT05028088|Experimental|Child-Pugh B|"Diaphragm ultrasound scan before induction of anesthesia.~Anesthesia method: During anesthesia induction, propofol 2.5mg/kg and sufentanil 5μg/kg will be injected intravenously. When the BIS value drops below 60, the muscle relaxation monitor will be calibrated. After T1 and TOF are stable, rocuronium will be injected intravenously at 0.6 mg/kg. During the maintenance stage of anesthesia, the pneumoperitoneum pressure will be at a low level of 8-10mmHg, propofol TCI will be applied to maintain the plasma concentration of 2.5-5.5 μg/mL, remifentanil TCI will be used to keep the plasma concentration of 0.5-5 ng/mL, and rocuronium will be continuously pumped intravenously with 0.3-0.6 mg/kg/h for deep muscle relaxations, with the the post-tetanic twitch count (PTC) value of 1 to 2.~When the TOF value was ≥2%, patients in each group will be given SUG (2mg/kg).~Diaphragm ultrasound scan at the immediate time,10min, 30min and 2h after extubation."
89413276|NCT05028088|Experimental|Child-Pugh C|"Diaphragm ultrasound scan before induction of anesthesia.~Anesthesia method: During anesthesia induction, propofol 2.5mg/kg and sufentanil 5μg/kg will be injected intravenously. When the BIS value drops below 60, the muscle relaxation monitor will be calibrated. After T1 and TOF are stable, rocuronium will be injected intravenously at 0.6 mg/kg. During the maintenance stage of anesthesia, the pneumoperitoneum pressure will be at a low level of 8-10mmHg, propofol TCI will be applied to maintain the plasma concentration of 2.5-5.5 μg/mL, remifentanil TCI will be used to keep the plasma concentration of 0.5-5 ng/mL, and rocuronium will be continuously pumped intravenously with 0.3-0.6 mg/kg/h for deep muscle relaxations, with the the post-tetanic twitch count (PTC) value of 1 to 2.~When the TOF value was ≥2%, patients in each group will be given SUG (2mg/kg).~Diaphragm ultrasound scan at the immediate time,10min, 30min and 2h after extubation."
88890633|NCT05961228|Other|scoliosis|adolescent age 10-15 with idiopathic scoliosis
88890634|NCT05961202|Experimental|HCQ group|Hydroxychloroquine 200mg bid and Prednisolone 15mg qd for a long time (more than 1 year)
88890635|NCT05961202|Active Comparator|GC group|Prednisolone 15mg qd for a long time (more than 1 year)
88890636|NCT05961137|Active Comparator|After-phase: Incorporation of Rapid Fluid Infusion Device in Prehospital Suspected Sepsis Protocol|Modified protocol specifying intravenous crystalloid infusion Rapid Fluid Infusion Device. The protocol states that for patients meeting the sepsis alert criterion, EMS will provide basic medical care, oxygen, a 12-lead electrocardiogram, attempt placement of an IV catheter and initiate administration of 30mL/kg of fluids.
89192882|NCT05944562|Experimental|Dose Expansion Cohort: Tulmimetostat (CPI-0209)|Daily CPI-0209 by mouth for days 1-28 of each 28-day cycle. Dose will be the maximum-tolerated dose found during the dose de-escalation cohort.
89413277|NCT02156934|Experimental|Muscle derived stem cell|Paraurethral injection of muscle derived stem cell in patients with stress urine incontinency.
88890637|NCT05961137|Active Comparator|Before phase: Conventional Prehospital Suspected Sepsis Protocol|Conventional protocol employing intravenous crystalloid infusion via gravity or pressurized-bag. The protocol states that for patients meeting the sepsis alert criterion, EMS will provide basic medical care, oxygen, a 12-lead electrocardiogram, attempt placement of an IV catheter and initiate administration of 30mL/kg of fluids.
89413278|NCT02157012|Experimental|The condition of rheumatoid arthritis|
88890638|NCT05961111|Experimental|R130 Treatment Group|Every 7-14 days,1-2 ml R130 （concentration of 1x10^8 plaque-forming Units/mL,PFU/mL）will be injected intratumoral or intraperitoneal in patients with advanced solid tumors
88890639|NCT05961072|Experimental|Patients receiving the vibrotactile sensory feedback device|Patients who have undergone a major lower limb amputation and are receiving the vibrotactile sensory feedback device
88890640|NCT05961007|Active Comparator|Aflibercept|only phase II
88890641|NCT05961007|Experimental|IBI302|
88890642|NCT05960981|Experimental|Intervention grup|The work is one-armed. It consists of only those in the intervention group. After the study was announced, informed consent was obtained from those who agreed to participate in the study. Afterwards, the participants filled out the Demographic Data Form, Repetitive Behavior Scale-Revised (RBS-R), Social Communication Checklist-Revised (SCC-R), Child Behavior Checklist-Dysregulation Profile (CBCL-DP) forms before the intervention program started. When the 8-week online group-based parent mediated intervention program was over, they filled out formsRepetitive Behavior Scale-Revised (RBS-R), Social Communication Checklist-Revised (SCC-R), Child Behavior Checklist-Dysregulation Profile (CBCL-DP) again in the first week.
88890643|NCT05960916|Experimental|Densah® bur|Densah is a bur that used for drilling of the alveolar ridge that have low bone density, narrow alveolar ridge, and sinus lifting procedure in dental implant preparation technique.
88890644|NCT05960916|Active Comparator|Conventional bur|Conventional bur is the gold standard bur that used to prepare the osteotomy for dental implant.
88890645|NCT05960838|Experimental|Invervention 1|Immobilization with the Ultrasling® Quadrant shoulder brace after surgical treatment.
88890646|NCT05960838|Active Comparator|Intervention 2 (Control)|Immobilization with the Bledsoe ARC® brace after surgical treatment.
88890647|NCT05960825|Experimental|Group MOPs|Group MOPs : will include 9 patients who willreceive MOPs with maxillary canine retraction that will be performed on intervention sides according to a standardized protocol.
88890648|NCT05960825|No Intervention|Group IMOPS|other side in group which is control group
88890649|NCT05960825|Experimental|Group i-PRF|group i-PRF: will include 9 patients receive i-PRF that will be performed on intervention sides according to a standardized protocol
88890650|NCT05960825|No Intervention|group i-PRF2|other side in group which is control group
88890651|NCT05960799|Experimental|Contiplex C or CON|Patients who will receive a contiplex C block for interscalene nerve block. This catheter also calls Catheter over needle (CON), wich is a catheter that is inserted at the same time that the needle is advancing.
88890652|NCT05960799|Active Comparator|Contiplex or CTN|Patients who will receive a regular contiplex block for interscalene nerve block or also called Catheter throw needle (CTN). This catheter is the gold standard in this centre and the mechanism of insertion is to introduce the catheter throw the needle.
88890653|NCT05960786|Experimental|1. Moderate or Worse (MoW) Arm|Participants will be randomized to use the Otoband as instructed by clinical coordinator per study protocol. There are 4 power levels, these participants will receive the experimental device.
88890654|NCT05960786|Sham Comparator|2. Moderate or Worse (MoW) Arm|Participants will be randomized to use the Otoband as instructed by clinical coordinator per study protocol. There are 4 power levels, these participants will receive the sham device.
88890655|NCT05960786|Experimental|1. Quality of Life (QoL) Arm|Participants will be randomized to use the Otoband as instructed by clinical coordinator per study protocol. There are 4 power levels, these participants will receive the experimental device.
88890656|NCT05960786|Sham Comparator|2. Quality of Life (QoL) Arm|Participants will be randomized to use the Otoband as instructed by clinical coordinator per study protocol. There are 4 power levels, these participants will receive the sham device.
88890657|NCT05960721|Experimental|Low-dose novel oral anti-coagulation (NOAC)-based anti-thrombotic therapy|"HAS-BLED<3: Rivaroxaban 15 mg QD for 3 months, followed by Rivaroxaban 10 mg QD indefinitely~HAS-BLED≥3: Rivaroxaban 10 mg QD for 3 months, followed by Rivaroxaban 2.5 mg bid indefinitely"
88890658|NCT05960721|Active Comparator|Guideline determined medication therapy (GDMT)|"HAS-BLED<3: Rivaroxaban 15 mg QD + Aspirin 100mg QD for 3 months, then Aspirin 100mg QD indefinitely~HAS-BLED≥3: Aspirin 100mg QD + Clopidogrel 75mg QD for 3 months, then Aspirin 100mg QD indefinitely"
89413279|NCT03096028||PMNS cohort|The Pune Maternal Nutrition Study (PMNS) is a preconceptional birth cohort established in 1993 at Diabetes unit KEM hospital research center, Pune. 700 offsprings of the cohort are being followed every 6 years. Maternal vitamin B12 folate level during pregnancy were measured at 18 & 28 weeks.
89413280|NCT02149914|Experimental|PPI treatment|Patients with GERD would be assessed by ANSWatch. Ryodoraku, UGI endoscopy, and GerdQ before taking PPIs and after taking PPI 20mg tablet by mouth everyday for 4 weeks.
89413281|NCT03095794|Experimental|neural mechanisms of decision making|Previous studies on how brain manages a value-based decision have been bounded to individual decisions. The current study will extend the understanding of social dimensions by answering four questions.
88890659|NCT05960669|Experimental|3D model guided SR|A prostate model was 3D printed from preoperative pelvic MRI data and used during surgery to mark a positive surgical margin and guide secondary resection.
89413282|NCT04976218|Experimental|Experimental arm|Enrolled patients in this arm will be administered TGFβR-KO CAR-EGFR T Cells in 3+3 based escalation manner.
89005512|NCT04569760|Placebo Comparator|Placebo Oil - Oral Preparation|"MCT Oil~Dosing will start at 2 mls twice a day for one week and be titrated to 4 mls twice/daily for one week. At the end of Week 2, dose may be titrated to 6 mls twice a day ; then at the end of Week 4, dose may be titrated to 8 mls twice daily (a volume equivalent to the maximum of 800 mg/day total dose of High CBD).~The dose will be titrated in incremental volumes equivalent to 200 mg of active product (4 mls)/day/week if participants are tolerating their current dose, are experiencing no adverse events and have not fully responded so that they may potentially reach the volume equivalent to 800 mg/day/week by Week 4."
89005513|NCT04569565|Experimental|PleurX catheter intervention|Participants will undergo placement and follow up monitoring of PleurX catheter.
89192883|NCT05942911|Experimental|IHL-675A|150 mg CBD, 200 mg HCQ: two soft gel capsules each containing 75 mg CBD and 100 mg HCQ twice per day for a total daily dose of 300 mg CBD and 400 mg HCQ
89192884|NCT05942911|Active Comparator|Cannabidiol|150 mg: two capsules each containing 75 mg CBD twice per day for a total daily dose of 300 mg CBD
89192885|NCT05942911|Active Comparator|Hydroxychloroquine|200 mg: two capsules each containing 100 mg HCQ twice per day for a total daily dose of 400 mg HCQ
89192886|NCT05942911|Placebo Comparator|Placebo|Two capsules twice per day
89535820|NCT02451709|Experimental|Feedback and alarms|"Standard education about importance of inhaled steroids and regular adherence to inhaled steroids after recruitment to study.~Randomized to receive an electronic adherence device ( activated smartinhaler or smartturbo - Nexus 6) with twice daily alarm reminders activated. Patient decides times, different times on weekdays and weekends if required. This device fitted to their regular preventer inhaler, patient aware of its presence and its purpose in the context of the study.~Reviewed in standard asthma clinic every 3 months for 12 months. At each clinic visit, adherence information downloaded from device and data shared with patient and family (feedback of adherence data). Discussion about adherence rates, and action planning for the next 3 months to improve adherence if necessary."
89535821|NCT02451709|Active Comparator|No feedback or alarms|"Standard education about importance of inhaled steroids and regular adherence to inhaled steroids after recruitment to study.~Randomized to receive an electronic adherence device. Deactivated Smartinhaler or Smartturbo.~Device not activated to play reminder alarms. This device fitted to their regular preventer inhaler, patient aware of its presence and its purpose in the context of the study.~Reviewed in standard asthma clinic every 3 months for 12 months. At each clinic visit, adherence information downloaded from device but data not shared with patient, and no adherence discussion."
89535822|NCT02484755|Experimental|gefitinib|gifitinib 250 mg oral administration once daily for a total of 4 weeks.
89535823|NCT03222817|Experimental|HPV Self-sampling|All participants will receive HPV self-sampling. HPV self-sampling allows an individual to screen themselves for cervical cancer in private, using a device that is similar to a tampon.
89535824|NCT03316469|Experimental|Group A: CC & ovulation|AMH level is measured before Clomiphene citrate 100 mg daily for 5 days & detecting Follicular growth assessment by TVU will be performed at day 12 of the menstrual period. Successful and unsuccessful follicular growth will be compared according to the subjects' respective AMH levels.
89535825|NCT03316469|Experimental|Group B: CC & no ovulation|AMH level is measured before Clomiphene citrate 100 mg daily for 5 days & detecting Follicular growth assessment by TVU will be performed at day 12 of the menstrual period. Successful and unsuccessful follicular growth will be compared according to the subjects' respective AMH levels.
89535826|NCT03217903|Experimental|Patients with High-risk MDS With Excess Blasts|
89535827|NCT04992663|Experimental|Intervention group (VR-group)|"The participants randomised into this group are offered the BirthVR intervention during Labour.~The VR group receives a VR information moment during labour and the possibility to exercise with the VR glasses and they receive VR during labour from the moment they are in active labour and use VR as much as they prefer. After labour, participants of the VR-group receive a structured questionnaire in which tolerability, feasibility and satisfaction of VR use is evaluated and participants receive the WDEQ-B questionnaire and PROM and PREM (ICHOM; T3, T4, T5).~As soon as VR does not serve as adequate pain relief during labour and a women requests additional pain medication this will be offered according to local protocol."
89535828|NCT04992663|No Intervention|Care as usual group|Patients randomised to the care as usual group will be offered pain medication during labour according to the local protocol, and on maternal request only. Postpartum participants receive the WDEQ-B questionnaire and PROM and PREM (ICHOM; T3, T4, T5)
89535829|NCT02485067|Experimental|THVD-201|"1. Treatment period(12 weeks)~Double dummy(A+B) A. THVD-201: capsule B. Placebo(For Detrusitol 2mg tablet)~One capsule and One tablet bid on an empty stomach~2. Open-label extension period(An additional 12 weeks)~Regardless of the previous type of arm, all patients only take THVD-201 during this period.~One capsule bid on an empty stomach"
89535830|NCT02485067|Active Comparator|Tolterodine (Detrusitol)|"1. Treatment period(12 weeks)~Double dummy(A+B) A. Placebo(For THVD-201): capsule B. Detrusitol 2mg tablet~One capsule and One tablet bid on an empty stomach~2. Open-label extension period(An additional 12 weeks)~Regardless of the previous type of arm , all patients only take THVD-201 during this period.~One capsule bid on an empty stomach"
89535831|NCT03075813|Experimental|Intervention Cluster|"Surgical surveillance data submitted to the DICON Surgical Database will undergo immediate analysis by optimized SPC methods. If a signal is generated, study personnel in DICON will be notified to adjudicate the signal and determine if further action is required.~Optimized SPC methods include the application of two SPC charts. The investigator determined that when either chart identifies a signal, the study will have approximately 90% sensitivity and 65% specificity to identify important increases in rates of SSI."
89535832|NCT03075813|No Intervention|Control Cluster|Local personnel in clusters randomized to traditional surveillance and feedback will receive bar graph reports and data interpretation per routine DICON surveillance. These reports will be provided every 6 months.
89535833|NCT03203395|Experimental|Heart patients|Screening and counselling
89535834|NCT03203317|Experimental|Insulin-stimulation|2 h insulin-clamp
89535835|NCT03203317|Experimental|Exercise|10 min of maximal exercise
89535836|NCT03316313||Date of birth|Those people born within the years 1945-1965
89413283|NCT02153190|Experimental|HYBRID-OPEN|"Patients are randomized on the schedule; hybrid period and after open period. During the HYBRID Period, the patient will use the AP model when at home, from dinner to wake-up time whereas the patient will self manage glucose control with insulin pump and CGM for the rest of the day.~During the control period called OPEN Period, patient self management of diabetes by insulin pump and CGM will be done at all times. Overall, an increase of time spent in range when using artificial pancreas in the hybrid period should be observed with a reduction of both hypo and hyperglycemia episodes."
89413284|NCT02153190|Experimental|OPEN-HYBRID|"Patients are randomized on the schedule: open period and after hybrid period. During the control period called OPEN Period, patient self management of diabetes by insulin pump and CGM will be done at all times.~During the HYBRID Period, the patient will use the AP model when at home, from dinner to wake-up time whereas the patient will self manage glucose control with insulin pump and CGM for the rest of the day. Overall, an increase of time spent in range when using artificial pancreas in the hybrid period should be observed with a reduction of both hypo and hyperglycemia episodes."
88890660|NCT05960643|Experimental|Breast self-examination group|This group was planned to consist of 51 female students studying at the university. First of all, students will be contacted through their electronically registered contact information. In the pre-test, the researchers will apply the 'Personal Information Form' and the 'Health Belief Model Scale' to the students with the self-report method. Afterwards, students will be given BSE training consisting of two 120-minute sessions. In the first session of the training, theoretical trainings about breast cancer and BSE will be given for 30 minutes. In the second session, BSE application will be shown on the wearable breast model and each student will practice on the model. The practice skills of the participants will be evaluated by the researchers using the 'BSE Practice Skill Evaluation Form'. At the end of the 'Health Belief Model Scale' application, face-to-face and 3 weeks later, online applications will be filled as a post-test.
88890661|NCT05960643|Active Comparator|Control group|No intervention will be made against people in this group.
88890662|NCT05960617|Experimental|Oral administration of Empagliflozin|All subjects will have a baseline assessment and be prospectively followed up for 12 months to examine their outcome after receiving empagliflozin.
88890663|NCT05960591|No Intervention|Control|Participants will receive bore depth measurements with the manual depth gauge, which is the golden standard for bore depth measurements during plate osteosynthesis procedures.
88890664|NCT05960591|Experimental|Intervention|Participants will receive bore depth measurements with the ADEPTH sensor, which is a new sensor technology for bore depth measurements during plate osteosynthesis procedures.
88890665|NCT05960136|Active Comparator|Sinus lift in patients with previous COVID-19 infection|Sinus floor augmentation in the posterior atrophic maxilla with delayed implant placement in patients with positive history of previous COVID-19 infection.
88890666|NCT05960136|Active Comparator|Sinus lift in patients with negative history of previous COVID|Sinus floor augmentation in the posterior atrophic maxilla with delayed implant placement in patients with negative history of COVID-19 infection.
88890667|NCT05959928||Hospital at Home patients|
88890668|NCT05959902|Active Comparator|Forward Walking|"This study ARM will receive following treatment in home program after mesenchymal stem cell treatment.~• Forward Walking"
88890669|NCT05959902|Experimental|Physiotherapy|"This study ARM will be receiving following physiotherapy exercises for knee osteoarthritis after mesenchymal stem cell therapy.~Isometric quadriceps exercise~Straight leg raising (SLR) exercise~Isometric hip adduction exercise~Terminal knee extension exercise~Semi wall squat exercise~Quadriceps drill exercise"
88890670|NCT05959837|Experimental|Single Group Intervention Arm|Exercise intervention with adaptive rower
89192887|NCT05942716|Experimental|Tourette disorder|20 mixt adult patients with TD. Patients will be recruited if a current treatment by aripiprazole (5-15 mg) is already scheduled before the study.
89192888|NCT05942105||ROLL technique|Radioguided occult lesion localization
89192889|NCT05942105||MAGNETIC SEED|Magnetic seed localization
88890671|NCT05959811|Experimental|meridian yoga|60 minutes yoga ,twice a week for 8 weeks
88890672|NCT05959811|No Intervention|usual care group|8 weeks of general care
88890673|NCT05959642|Experimental|Controlled Flow Delivery Dentapen|Controlled Flow Delivery Dentapen - infiltration upper d according to the manufacturer instructions it works with standardised 1.8 ml local anaesthetic carpules . 1)we raise the lip a little 2) we use dentapen for anaesthesia 3) class 1 cavity preparation Articaine hydrochloride 4% with 1:100,000 epinephrine will be injected.The dentist will wait 5 seconds
88890674|NCT05959642|Active Comparator|Traditional metal Syringes|Traditional metal Syringes we raise the lip a little 2) infiltration upper d we use traditional syringes 3)class 1 cavity preparation with composit filling works with standardised 1.8 ml local anaesthetic carpules . we use Articaine hydrochloride 4% with 1:100,000 epinephrine will be injected.The dentist will wait 5 seconds
88890675|NCT05959538|Experimental|Building Regulation in Dual Generations (BRIDGE; DBT + Parenting)|The BRIDGE program is a manualized therapy that provides participants with parenting and DBT skills through video training modules and in-group sessions. Participants in the BRIDGE arm will participate in 16 weeks of 20-30 minute DBT and parenting skills training that will be delivered asynchronously via video (participants will access these by logging onto a password protected website). The BRIDGE condition also includes weekly synchronous 1-hour virtual group therapy sessions as well as DBT and parenting skills worksheets to complete between sessions.
89192890|NCT05942105||WGL technique|Wire guided localization for non-palpable breast lesions
89192891|NCT05942105||CARBON|Carbon dye localization for non-palpable breast lesions
89192892|NCT05942092||ROLL|
89192893|NCT05942092||SEED|
89192894|NCT05940896|Experimental|Dose escalation|DV is given intravenously once every 2 weeks, (dose escalation plan: 1.0mg/kg, 1.5mg/kg, 2.0mg/kg, 2.5mg/kg). DV will be administered at least 2 times during the treatment, and the final DV dose needs to be completed before the last radiotherapy.
88890676|NCT05959538|Active Comparator|Dialectical Behavioural Skills Training (DBT)|Participants in the DBT arm will participate in 16 weeks of DBT skills training through weekly, synchronous 1.5-hour virtual group therapy sessions. Participants will also be asked to complete worksheets on the content between sessions.
88890677|NCT05959538|No Intervention|Services-As-Usual (SAU)|Participants in the SAU arm will receive a list of local mental health and parenting resources, curated by our research team. Participants can access any intervention or resource participants would like throughout the duration of the program.
88890678|NCT05959395|Experimental|VectRx Thermal Therapy|Device performance
88890679|NCT05957900|No Intervention|Control group|Preterm neonates will receive only routine care of the unit.
88890680|NCT05957900|Experimental|Multi-Sensory Stimulation group|"In the present study, it is defined as the application of tactile, visual, vestibular, kinesthetic, olfactory, auditory and oral stimulation to preterm neonates to enhance their development.~The intervention will be provided daily in mourning, quiet alert state of neonate, before feeding for 30 min., 5 days per week for two weeks."
88890681|NCT05957679|Experimental|Diagnostic（MRE, tumor grading of stiffness and adhesion）|Patients undergo a preoperative routine MRI scan and MRE the day before their scheduled surgery. During surgery, the tumor stiffness and adhesion are assessed and recorded by the surgeon according to established evaluation criteria. It is important to note that the surgeon does not have prior knowledge of the tumor's specific stiffness and adhesion before the surgery. This information is typically obtained through intraoperative assessment and observation.
88890682|NCT05955859|Experimental|Patient with clinical suspicion of mycotic sinusitis|Patient with clinical suspicion of mycotic sinusitis will undergo an examination as listed in Detailed Description.
88890683|NCT05955430|Experimental|Exercise, education and PENS|Patients will receive eight face-to-face sessions of therapeutic exercise, four sessions of pain education and eight sessions of percutaneous electrical stimulation (PENS).
88890684|NCT05955430|Active Comparator|Exercise, education and TENS|Patients will receive eight face-to-face sessions of therapeutic exercise, four sessions of pain education and eight sessions of transcutaneous electrical stimulation (TENS).
88890685|NCT05955430|Placebo Comparator|Exercise, education and placebo stimulation|Patients will receive eight face-to-face sessions of therapeutic exercise, four sessions of pain education and eight sessions of placebo stimulation.
88890686|NCT05953818||Maintenance hemodialysis with diabetes group|The patients were given a quiet environment and completed the test within 10 minutes. The cognitive function of the two groups of patients was evaluated and analyzed using the Montreal Cognitive Assessment Scale (MoCA) in Chinese. The patients were given brain magnetic resonance high resolution structural imaging to observe changes in brain structure.
88890687|NCT05953818||Maintenance hemodialysis non diabetic group|The patients were given a quiet environment and completed the test within 10 minutes. The cognitive function of the two groups of patients was evaluated and analyzed using the Montreal Cognitive Assessment Scale (MoCA) in Chinese. The patients were given brain magnetic resonance high resolution structural imaging to observe changes in brain structure.
88890688|NCT05951140|Experimental|Start-Group|The Start-Group starts with the Protein-Application and wereables for 3 Months and afterwards uses only wereables for 6 Weeks.
88890689|NCT05951140|Experimental|Wait-Group|The Wait-Group starts with 6 Weeks of using only wereables and afterwards adds the usage of the Protein-Application.
88890690|NCT05947747|Experimental|Group 1: investigational drug EXO-CD24 at a dose of 10^10|60 patients who will receive a 5-day treatment with the investigational drug EXO-CD24 at a dose of 10^10
88890691|NCT05947747|Placebo Comparator|Group 2: treatment in a clean sterile saline solution (placebo)|30 patients who will receive a 5-day treatment in a clean sterile saline solution (placebo)
88890692|NCT05944159|Experimental|Study Group|Study Group (n= 20) was recieved Temporomandibular joint ve soft tissue techniques. The techniques were applied 30 minutes once a week for 4 weeks by physiotherapist to the study group.
88890693|NCT05944159|Other|Control Group|Control group (n=20) was received routin medication therapy was applied. Both groups were asked to do the home exercise program twice a day consisting of vestibular exercise videos sent over whatss app. It was questioned with a phone call once a week whether the exercises were done or not.
88890694|NCT05942599|Experimental|Single dose intravenous infusion of a banded dose of CAR33+ T Cells/Kg BECAR33|Patients will undergo careful screening to confirm that this treatment is appropriate for them. Patients will receive BE CAR-33 before their scheduled bone marrow transplant. Chemotherapy will be given prior to BE CAR-33 infusion to improve the ability of CAR T-cells to establish and grow. Patients will then receive a single infusion of the BE CAR-33 cells and will be closely monitored in hospital for the next 4 weeks. Patient will start chemotherapy for their scheduled bone marrow transplant 28 days after BE-CAR33 infusion unless their disease is progressing. Patients will be monitored on the study for 1 year after transplant and then long term in routine clinics.
88890695|NCT05939687|Experimental|mesh|In these patients we will do sublay/interoblique repair for prevention of stoma-site hernias using a polypropylene mesh.
88890696|NCT05939687|Active Comparator|non-mesh|In these patients we will close the stoma with standard layered ligature suturing of the abdominal wall without mesh implantation.
88890697|NCT05932680|Experimental|Off Drug Surveillance|Participants will stop receiving teclistamab and will be monitored closely for growth of their multiple myeloma. Participants will restart teclistamab if their multiple myeloma starts to grow.
89192895|NCT05939648|Experimental|SARS-CoV-2 Bivalent mRNA Vaccine|100 μg /1.0 mL/dose, One booster dose 1.0mL IM injection of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021).
89192896|NCT05939648|Placebo Comparator|Saline|One booster dose 1.0mL IM injection of saline.
89192897|NCT05939063|Active Comparator|LRAMPS group|Patients who meet the inclusion and exclusion criteria will undergo laparoscopic radical antegrade modular pancreatosplenectomy (LRAMPS) surgery.
88890698|NCT05931666|Experimental|Gong Mobilization|The subject placed in a side-lying position with the affected shoulder joint facing upward. and abducted at about 90 degrees to maintain the humerus vertical position with elbow in a 90-degree position. The therapist use one hand to keep the subject's elbow joint at 90 degrees, his elbow below the subject's elbow joint, and the other hand to press the humerus head from anterior to posterior. Therapist elevate own body, pulling on the articular capsule of the shoulder joint. This gentle pulling sustained for 10- 15 seconds before relaxing for 5 seconds; the whole manoeuver last roughly 2-3 minutes.
88890699|NCT05931666|Experimental|Kaltenborn Mobilization|Patient lies supine on the table with the arm abducted approximately to 55⁰. The therapist stands facing the lateral side of upper arm. The scapula is fixed using a towel. The therapist's right hand holds around the patients elbow & forearm from the ventral side. Left hand holds around the humeral head with the thumb ventrally just distal to the acromion & the direction of movement is towards caudal assisted by therapist's body. Also anterior and posterior glides are applied with patient positioned similarly in supine lying to improve mobility at the shoulder joint.
88890700|NCT05930145|Experimental|Double stentriever technique|Patients treated with thrombectomy with a proximal balloon guiding catheter using two stentrievers simultaneously (one of 6 mm x 50 mm and another of 6 mm x 50 mm or 4 mm x 35 mm)
88890701|NCT05930145|Active Comparator|Single stentriever technique|Patients treated with thrombectomy with a proximal balloon guiding catheter using one stentriever (6 mm x 50 mm).
88890702|NCT05928611|Active Comparator|Inferior alveolar nerve block|Using 1.8ml of 4% articaine HCL 1:100,000 epinehrine
88890703|NCT05928611|Experimental|Inferior alveolar nerve block with intraligmentary dexamethasone|Using 1.8ml of 4% articaine HCL 1:100,000 epinehrine for inferior alveolar nerve block and 0.4 mL of 8 mg/ 2mLdexamethasone for intraligmentary injection
88890704|NCT05928611|Experimental|Buccal infiltratation with intraligmentary dexamethasone|Using 1.8ml of 4% articaine HCL 1:100,000 epinehrine for buccal infiltratation and 0.4 mL of 8 mg/ 2mLdexamethasone for intraligmentary injection
88890705|NCT05917912|Active Comparator|Sequence A|i)screening and randomization; ii) baseline period (3 weeks); iii) treatment period 1 with placebo(3 weeks); iv) wash-out period (3 weeks); v), treatment period 2 with ATX-01(3 weeks); vi) follow-up visit
88890706|NCT05917912|Active Comparator|Sequence B|i)screening and randomization; ii) baseline period (3 weeks); iii) treatment period 1 with ATX-01(3 weeks); iv) wash-out period (3 weeks); v), treatment period 2 with placebo (3 weeks); vi) follow-up visit
88890707|NCT05913518|Experimental|Active neurofeedback group|
88890708|NCT05913518|Placebo Comparator|Placebo feedback group|
88890709|NCT05913518|No Intervention|Control group|
88890710|NCT05912452|Experimental|Percussion Massage Group|The group to which percussion massage therapy will be applied to the deltoid muscle.
88890711|NCT05912452|Experimental|Kinesiotape Group|The group to which kinesiotaping will be applied to the deltoid muscle.
88890712|NCT05912452|Experimental|Dynamic Stretching Group|The group to which dynamic stretching will be applied to the deltoid muscle.
88890713|NCT05905601|Experimental|NORTH|"Participants in the experimental arm will be provided access to the Full NORTH smartphone application designed to support young adults at risk for psychosis. They will also have access to the research team by phone for technical troubleshooting and support as necessary."
88890714|NCT05905601|Experimental|"NORTH Lite"|"Participants in the control arm will be provided access to the NORTH Lite smartphone application designed to support young adults at risk for psychosis. They will also have access to the research team by phone for technical troubleshooting and support as necessary."
89192898|NCT05939063|Experimental|LDP group|Patients who meet the inclusion and exclusion criteria will undergo laparoscopic distal pancreatosplecnectomy (LDP) surgery.
89192899|NCT05937165|Active Comparator|Standard Dose Freeze-dried Blueberry Powder|Consumption of 24 g of freeze dried blueberry powder for 3 consecutive days.
89192900|NCT05937165|Experimental|Higher Dose Freeze-dried Blueberry Powder|Consumption of 48 g of freeze dried blueberry powder for 3 consecutive days.
89413285|NCT05041738|Experimental|Intraoral Cryotherapy|
89413286|NCT05041738|Active Comparator|Intracanal Cryotherapy|
89413287|NCT02149992|Experimental|Myo-inositol, folic acid|"myo-inositol, oral, 2g, two times per day for 5 total days~folic acid, oral 200 micrograms, two times per day for 7 days~Continuous Glucose Monitoring Surveillance device for 7 days during study period~Capillary glucose monitoring 4 times per day"
89413288|NCT05041660|Experimental|VR ICT|Virtual-reality-based inhibitory control training done daily at home for 6 weeks.
89413289|NCT05041660|Sham Comparator|VR Sham ICT|"Virtual-reality-based sham inhibitory control training (i.e., one that does not include a stop signal and that thus does not truly train inhibitory control) done daily at home for 6 weeks."
89413290|NCT05041660|Active Comparator|Non-VR ICT|Computerized inhibitory control training done daily at home for 6 weeks.
89413291|NCT05041660|Sham Comparator|Non-VR Sham ICT|"Computerized sham inhibitory control training (i.e., one that does not include a stop signal and that thus does not truly train inhibitory control) done daily at home for 6 weeks."
89413292|NCT04833582|Experimental|Combination ZN-c3 with Gemcitabine|
89413293|NCT02157090|Active Comparator|Herpes Patch SOS (Hansaplast®)|
88890715|NCT05905120|Experimental|Toludivenlafaxine hydrochloride sustained-release tablets|80 mg/tablet, 2 tablets each time, once a day, for 4 days
88890716|NCT05904262||Type 2 diabetic patients|Type 2 Diabetes Mellitus. In this prospective study based on face-to-face interview method; body fat (%), skeletal muscle mass (%) (with Omron BF511 Body Composition Monitor), waist and hip circumference, lower extremity muscle strength (for quadriceps and biceps muscles) (with muscle hand held dynamometer), It is planned to measure upper extremity muscle strength (grip strength) (with hand grip dynamometer), functional capacity (with 6 Minute Walk Test), postural stability, stability limits and sensory integration of balance (with Biodex Balance System®). In addition, individuals are expected to answer the questions of the International Physical Activity Questionnaire-Short Form (IPAQ) to evaluate their physical activity levels.
88890717|NCT05895357|Experimental|Music Therapy|The patients were asked about the type of music they wanted to listen to. Especially in the last meta-analyses, it was determined that listening to the music that patients chose was more effective (Witten 2020). For this reason, after the intervention group is asked about the music they want to listen to, the music they want will be played from the music application.
88890718|NCT05895357|No Intervention|No intervention|The patients in the control group will not listen to music, and routine procedures will performed in the clinic without additional intervention. Anxiety, pain, and comfort assessments will made in the control group patients before and after the procedure.
88890719|NCT05891301||questionnaires assessed patient with colorectal cancer after surgery|Patients with colorectal cancer who had a radical resection surgery.
88890720|NCT05887726|Experimental|Zanubrutinib + R-CHOP|
88890721|NCT05886985|Experimental|MatriPlax|Each subject will receive 2x10^7, 4x10^7, or 8x10^7 pcMSCs per administration
88890722|NCT05867550|Active Comparator|Group A ( Rifaximin + Mebeverine )|"Tab. Rifaximin 550mg thrice daily per orally for 2 weeks~Tab. Mebeverine 135mg twice daily per orally for 2 weeks"
88890723|NCT05867550|Active Comparator|Group B ( Rifaximin + Amitriptyline )|"Tab. Rifaximin 550mg thrice daily per orally for 2 weeks~Tab. Amitriptyline 25mg once daily per orally for 2 weeks"
88890724|NCT05867550|Active Comparator|Group C ( Rifaximin + Psyllium Husk )|"Tab. Rifaximin 550mg thrice daily per orally for 2 weeks~Psyllium Husk 15-30mg once daily per orally for 2 weeks"
88890725|NCT05866809|Experimental|HK-660S|Oral administration of HK-660S 100 mg (1 tablet) twice daily before morning and evening meals
88890726|NCT05866809|Placebo Comparator|Placebo|Oral administration of placebo 1 tablet twice daily before morning and evening meals
88890727|NCT05863806|Experimental|Mulligan Mobilzation|"MWM technique was carrying out in flexion, abduction, external and internal rotation directions. For this technique, participants were seated on a stretcher, and the physical therapist is standing opposite of the upper extremity that is treated. The internal hand of the physical therapist stabilizes participants' shoulder girdle and, with the thenar eminence of the other hand, performed a glide of the humeral head (this direction is the most suitable for treating such shoulder limitations).~Participants were asked to flex the affected shoulder until the pain started while the physical therapist sustained the gliding force to the humeral head. The single session of MWM technique was last around 20 minutes, in 3 sets of 10 repetitions with a rest interval of 30 seconds between each sets."
88890728|NCT05863806|Active Comparator|Trasverse Friction Massage|Transverse Friction Massage technique: Patients in the group B were receiving soft tissue massage (deep friction) is made to bend his/ her elbow to 90o and put forearm behind his/ her back, then lean back in half lying position. Thus arm is fixed in adduction and medial rotation. It was given in transverse direction for 10 - 12 minutes. Transverse friction massage was given twice a week with the gap of days for the first 3 week and then the repetition is increased to 3 to 4 times a week for the rest of duration.
88890729|NCT05861583||Lipohypertrophy|Active Comparator Tissue from healthy patients with lipohypertrophy,
89413294|NCT02157090|Active Comparator|Herpes vesicle patch of Compeed®|
89413295|NCT02153268|Experimental|single arm, Liposuction, BonoFill Transplantation|"Liposuction - will be performed on Visit 2 for all eligible subjects~BonoFill Transplantation - will be performed on Visit 6 for all eligible subjects"
89413296|NCT05041582|Experimental|Real tDCS + Citalopram + Rehabilitation|"Real tDCS, 2 mA for 20 mins per session, 10 sessions within 2 weeks~Citalopram 10mg oral intake daily for 3 months, since 2 weeks before tDCS"
89413297|NCT05041582|Sham Comparator|Sham tDCS + Citalopram + Rehabilitation|"Sham tDCS, ramped up over 10 seconds and then reduced to 0mA, 10 sessions within 2 weeks~Citalopram 10mg oral intake daily for 3 months, since 2 weeks before tDCS"
89413298|NCT05041582|Placebo Comparator|Real tDCS + Placebo + Rehabilitation|"Real tDCS, 2 mA for 20 mins per session, 10 sessions within 2 weeks~Placebo oral intake daily for 3 months, since 2 weeks before tDCS"
89413299|NCT05041582|Placebo Comparator|Sham tDCS + Placebo + Rehabilitation|"Sham tDCS, ramped up over 10 seconds and then reduced to 0mA, 10 sessions within 2 weeks~Placebo oral intake daily for 3 months, since 2 weeks before tDCS"
89413300|NCT02157246|Other|Group A, pimonidazole, no CRT|Biopsy, Blood sample, F-MISO PET, pCT, functional MRI, Pimonidazole
88890730|NCT05861583||Lipoedema mild stage|Experimental Tissue from lipoedema patients with mild stage (stage 1)
88890731|NCT05861583||Lipoedema moderate stage|Experimental Tissue from lipoedema patients with moderate stage (stage 2)
88890732|NCT05861583||Lipoedema severe stage|Experimental Tissue from lipoedema patients with severe stage (stage 3)
89413301|NCT02157246|Other|Group B, CRT|Biopsy, Blood sample, F-MISO PET, pCT, functional MRI
89413302|NCT04966156|No Intervention|Usual care group|No change to patient's usual care at Princess Margaret Cancer Centre.
89413303|NCT04966156|Experimental|CaRE-4-allBMT plus usual care|a longitudinal 6-month rehabilitation program that uses a person- centred strategy and a multidimensional approach targeting physical activity, nutrition, psychosocial distress and promoting self-management skills.
89413304|NCT02150070|Experimental|Intravenous ASP2408|
89413305|NCT02150070|Experimental|Subcutaneous ASP2408 low dose|
89413306|NCT02150070|Experimental|Subcutaneous ASP2408 middle dose|
88890733|NCT05859308|Active Comparator|Boxing|Rock Steady Boxing
88890734|NCT05859308|Experimental|Virtual Reality Pixel Plucker|30 minutes of VR engagement
89413307|NCT02150070|Experimental|Subcutaneous ASP2408 high dose|
89413308|NCT02150070|Placebo Comparator|Intravenous Placebo|
89413309|NCT02150070|Placebo Comparator|Subcutaneous Placebo|
89535837|NCT03217513||Forteo|teriparatide 20-microgram once daily available in a 2.4-mL delivery device for subcutaneous injection by the patient
89535838|NCT03217513||Prolia|denosumab 60 mg administered as a single subcutaneous injection every 6 months by the health care provider
88890735|NCT05856591|Active Comparator|Enhanced Usual Care (EUC)|"Participants randomized to EUC will have access to existing usual primary care services. They will also be enrolled in Hypertension Self-Management Education and Support (SMES) class (Hypertension group), which is an existing CDC-endorsed program offered at Eskenazi Health to provide information and skills for managing hypertension (HTN). Classes are led by registered dietitians via Webex."
88890736|NCT05856591|Experimental|Food Resources & Kitchen Skills (FoRKS)|"Participants randomized to FoRKS will attend weekly HTN SMES classes separately from EUC participants. SMES classes will include the EUC curriculum stated above and an introduction to the upcoming FoRKS intervention.~Following HTN SMES completion, FoRKS continues with home-delivered Mediterranean-style ingredient kits, food management lessons, and hands-on cooking classes in one's own kitchen. Classes are led by registered dietitians via Webex. Classes are held twice per week thru Week 12, then only once per week through Week 16."
88890737|NCT05854251|Experimental|Experimental Intervention|Patients receive investigational product
88890738|NCT05854251|Placebo Comparator|Control Intervention|Patients receive placebo
88890739|NCT05849753||T1DM lower SES|Type 1 diabetes of lower SES, including AA and Latino racial/ethnic minorities, who are in suboptimal diabetes control.
88890740|NCT05848947|Other|99mTc-MAA Injection|Patients enrolled in the study will have 3 imaging scans taken after 99mTc-MAA Injection with the final scan occurring 18-24 hours after injection.
88890741|NCT05847426|Experimental|Provision of standard audiological + fNIRS test results|"The treatment arm involves the provision of additional fNIRS sound detection and speech discrimination test results to the audiologists, in addition to standard audiology information. Standard information includes:~At diagnosis: unaided Auditory Brainstem Response results;~After initial hearing aid provision: as a) above plus aided Cortical Evoked Potentials;~After hearing aid program is adjusted to satisfaction: as b) above plus parent observational report, PEACH (2);~After initial cochlear implant programming: behavioural observations."
88890742|NCT05847426|Active Comparator|Provision of standard audiological test results only|"The standard audiology information available to the audiologists includes:~At diagnosis: unaided Auditory Brainstem Response results;~After initial hearing aid provision: as a) above plus aided Cortical Evoked Potentials;~After hearing aid program is adjusted to satisfaction: as b) above plus parent observational report, PEACH (2);~After initial cochlear implant programming: behavioural observations."
88890743|NCT05846932|Experimental|Occupational Therapy Integrating Horses|10 weeks of occupational therapy focused on self-regulation skills, provided while participants are riding horses
88890744|NCT05846932|Active Comparator|Occupational Therapy in a Clinic|10 weeks of occupational therapy focused on self-regulation skills, provided in a traditional clinic environment
88890745|NCT05842733|Active Comparator|Naldebain|Oral Placebo A 650 mg + Naldebain 37.5 mg (0.5 mL oil solution) + Tween 20 and PEG 400 (1 capsule), multiple doses for 3 days. Dosing at 0（2 ± 2 hour after surgery）, 6 ± 2, 14 ± 2, 22 ± 2, 34 ± 2, 46 ± 2, 58 ± 2 and 70 ± 2 hours after the first dose.
88890746|NCT05842733|Active Comparator|SafeTynadol|Oral SafeTynadol 650 mg + Placebo B (0.5 mL oil solution) +Tween 20 and PEG 400 (1 capsule), multiple doses for 3 days. Dosing at 0（2 ± 2 hour after surgery）, 6 ± 2, 14 ± 2, 22 ± 2, 34 ± 2, 46 ± 2, 58 ± 2 and 70 ± 2 hours after the first dose.
88890747|NCT05842733|Active Comparator|Naldebain + SafeTynadol|Oral Naldebain 37.5 mg (0.5 mL oil solution) + SafeTynadol 650 mg + Tween 20 and PEG 400 (1 capsule), multiple doses for 3 days. Dosing at 0（2 ± 2 hour after surgery）, 6 ± 2, 14 ± 2, 22 ± 2, 34 ± 2, 46 ± 2, 58 ± 2 and 70 ± 25 hours after the first dose.
88890748|NCT05842239|Experimental|Hyperbaric Oxygen Therapy active arm|The protocol comprises of 60 consecutive hyperbaric oxygen treatment (HBOT) sessions, 5 sessions per week within a three months' period.
88890749|NCT05841420|Active Comparator|"A: Full dose single agent strategy"|Gemcitabine monotherapy, 1000 mg/m2 weekly on days 1, 8, and 15 every 4 weeks
88890750|NCT05841420|Experimental|"B: Reduced dose (80%) combination-therapy strategy"|Nab-Paclitaxel: 100mg/m2 plus gemcitabine: 800 mg/m2 on day 1, 8 and 15 every 4 weeks
88890751|NCT05838053||Lobectomy with systemic lymph node dissection|lobectomy with hilar and mediastinal lymph node dissection is performed. Systemic or selective lymph node dissection is mandatory, and nodal sampling is not allowed. At least three stations of mediastinal lymph node from 2R, 4R, 7, 8, 9 for the right side and 5, 6, 7, 8, 9 for the left side, respectively.
88890752|NCT05838053||Segmentectomy with systemic lymph node dissection|Segmentectomy with hilar and mediastinal lymph node dissection is performed. If the tumor located at inter-segment plane and without sufficient resection margin distance, a combined segmentectomy will be performed after a comprehensive evaluation. As with lobectomy, systemic or selective lymph node dissection is mandatory, and nodal sampling is not allowed. At least three stations of mediastinal lymph node from 2R, 4R, 7, 8, 9 for the right side and 5, 6, 7, 8, 9 for the left side, respectively. The distance from the dissection margin to the tumor edge must be evaluated in the same manner as with lobectomy.
88890753|NCT05837156|Active Comparator|group cyclophenol|Calculated by body weight (kg), the initial dose of continuous infusion of cyclopophenol is 0.8 mg/kg/h. During the infusion, the researchers adjusted the rate according to the reaction of the subjects, and the adjustment range was 0.4 mg/kg/h-2.4 mg/kg/h.
88890754|NCT05837156|Active Comparator|group heptaflurane|The anesthetic sevoflurane is inhaled for anesthesia maintenance. The initial concentration of sevoflurane is 1.5-2.0%, which can be adjusted to the expected effect according to the subject's reaction.
88890755|NCT05837156|Experimental|group heptaflurane combined cyclophenol|Inhaled anesthetic sevoflurane combined with a small dose of cyclopophenol for anesthesia maintenance. The initial concentration of sevoflurane is 0.5%, and the initial dose of cyclopophenol is 0.4 mg/kg/h.After that, sevoflurane or cyclopophenol (with an adjustment range of 0.2 mg/kg/h-1.2 mg/kg/h) can be adjusted to the expected effect according to the subject's reaction.
89413310|NCT02150148|Experimental|Mentored Gardening Intervention|Participants in this arm will be provided with either a raised bed garden or 4 earthboxes, gardening supplies, and plants and seeds. A master gardener from the Cooperative Extension will mentor them over the course of a year to plant three gardens (spring, summer and fall).
89413311|NCT02150148|Other|Wait-List|Participants in this arm will be provided with the same gardening supplies as the other group, but will receive them one year after enrollment in the study. They also will receive instruction from a master gardener from the Cooperative Extension at this time as well.
89413312|NCT03542838|Experimental|Resiniferatoxin|Resiniferatoxin is administered as a one-time dose, intra-articularly at a dose level of 5ug, 12.5ug, 20ug, 25ug, or 30ug.
89413313|NCT03542838|Placebo Comparator|Saline|Saline is administered as a one-time dose, intra-articularly.
89413314|NCT05027776|Experimental|Experimental: 2-doses Group|Subjects aged 9-14 years, received 2 doses of q-HPV vaccine, which was administered intramuscularly in the deltoid muscle of the non-dominant arm according to a 0, 6-month schedule.
89413315|NCT05027776|Experimental|Experimental: 3-doses Group|Subjects aged 9-19 years, received 3 doses of q-HPV vaccine, which was administered intramuscularly in the deltoid muscle of the non-dominant arm according to a 0, 2，6-month schedule.
89413316|NCT05027776|Active Comparator|Acitve Group|Subjects aged 20-26 years, received 3 doses of q-HPV vaccine, which was administered intramuscularly in the deltoid muscle of the non-dominant arm according to a 0, 2，6-month schedule.
89413317|NCT02150226|Experimental|Experimental: Zirconia monolithic crowns and bridges|Evaluation of Lava Plus zirconia dental crowns and bridges
89413318|NCT02153424||NVAF patients in Mexico treated with Apixaban|All patients with NVAF at the sentinel site for the CNFV in Mexico who received at least 1 dose of Apixaban to reduce the risk of stroke or systemic embolism during the specified 24-month study period
89413319|NCT05025436|Experimental|Acupoint Laser Group|Each subject in the experimental group was given the same main acupoints (5 acupoints) and physique matching acupoints (1-2 acupoints) interventional low-energy laser (Erger laser pen) acupoint stimulation, set wavelength 810nm +/- 10%, power 200mW, select Bahr parameter (B2: 1199 Hz; B3: 2398 Hz) module according to acupoints, treatment time is 30 seconds per acupoint, and the treatment dose is 3 joules per acupoint three times a week. After a period of 4 weeks, pause 2 After two weeks, the two groups crossed over and carried out 4 weeks of intervention.
89413320|NCT05025436|No Intervention|Control Group|Each subject in the control group was given the same main acupoints (5 acupoints) and constitution matching acupoints (1-2 acupoints) without energy acupoint care (therapeutic dose is 0 joules per acupoint), three times a week, after 4 weeks After a two-week suspension, the two groups crossed over for another four-week intervention.
88890756|NCT05835427|Experimental|Fibromyalgia individual|Cervical Extensor Stretch, cervical flexor stretch, cervical lateral flexion stretch, thoracic stretch, pectoral stretch, lumbar extensor stretch, posterior capsule stretch, knee flexor stretch, gastro-soleus stretch, quadriceps stretch, cat-camel exercise, shoulder circles, neck flip- tilting the neck to the right and left, relaxation of the abdominal and back muscles, posterior pelvic tilt.
88890757|NCT05835427|Experimental|Healthy volunteers|Cervical Extensor Stretch, cervical flexor stretch, cervical lateral flexion stretch, thoracic stretch, pectoral stretch, lumbar extensor stretch, posterior capsule stretch, knee flexor stretch, gastro-soleus stretch, quadriceps stretch, cat-camel exercise, shoulder circles, neck flip- tilting the neck to the right and left, relaxation of the abdominal and back muscles, posterior pelvic tilt.
88890758|NCT05834608||Group M|Manual ventilation
88890759|NCT05834608||Group A|AutoFlow mechanical ventilation
88890760|NCT05832723||650 nm low-level red-light|Children who are exposed to the 650 nm low-level red-light will be recruited into the cohort, the exposure factor is red-light irradiation. The study does not give interventions, but only recruit children who received or who is receiving the 650 nm low-level red-light intervention for observation.
88890761|NCT05832060|Experimental|tDCS, tRNS, Sham|"Active left anodal/right cathodal tDCS over TPC~Active tRNS over bilateral TPC~Sham tRNS or tDCS over bilateral TPC"
88890762|NCT05832060|Experimental|tDCS, Sham, tRNS|"Active left anodal/right cathodal tDCS over TPC~Sham tRNS or tDCS over bilateral TPC~Active tRNS over bilateral TPC"
88890763|NCT05832060|Experimental|tRNS, tDCS, Sham|"Active tRNS over bilateral TPC~Active left anodal/right cathodal tDCS over TPC~Sham tRNS or tDCS over bilateral TPC"
89192901|NCT05936736|Experimental|24 Gy in one fraction, urethral sparing HDR like|Patients with localized prostate cancer - negative PSMA PET CT +/- standard staging exams (bone scan, CT, MRI)-enrolled in this study, will be treated to prostate/prostate seminal vesicles (according to the risk group) to a total dose of 24 Gy delivered in 1 fraction, with an urethral sparing HDR like technique. For unfavorable intermediate and high-risk pts, Androgen Deprivation Therapy (ADT) will be prescribed for 6 and 24 months, respectively.
89192902|NCT05933187|Experimental|Sequence 1: A-B-C-D|Participants will receive emraclidine, 30 mg IR tablets, in the treatment sequence A-B-C-D orally, on Day 1 of each 5-day treatment period (up to 26 days)
89413321|NCT02150304||intravenous aminophylline|intravenous aminophylline use during spinal anesthesia
89413322|NCT02150304||no intravenous aminophylline|no use of intravenous aminophylline during spinal anesthesia
88890764|NCT05832060|Experimental|tRNS, Sham, tDCS|"Active tRNS over bilateral TPC~Sham tRNS or tDCS over bilateral TPC~Active left anodal/right cathodal tDCS over TPC"
88890765|NCT05832060|Experimental|Sham, tDCS, tRNS|"Sham tRNS or tDCS over bilateral TPC~Active left anodal/right cathodal tDCS over TPC~Active tRNS over bilateral TPC"
89192903|NCT05933187|Experimental|Sequence 2: B-C-D-A|Participants will receive emraclidine, 30 mg IR tablets, in the treatment sequence B-C-D-A orally, on Day 1 of each 5-day treatment period (up to 26 days)
89413323|NCT02157402|Experimental|Intervention Group|The intervention group will received activities and social events designed according 8 social marketing Benchmark criteria to promote healthy lifestyles.
89413324|NCT02157402|No Intervention|Control Group|The control group will not received any intervention activities and social events to promote healthy lifestyles.
89413325|NCT05027152|Experimental|traditional resistance exercises|The resistance training group will perform traditional resistance exercises with an intensity of 30%-60% of a voluntary repetition maximum and 1 to 2 sets of 10 repetitions each exercise.
89413326|NCT05027152|Experimental|repetitive task training|The repetitive task training group will carry out exercises involving upper and lower limbs.
89413327|NCT04434430|Active Comparator|Gabapentin|Patient will receive preemptive oral gabapentin 600 mg
89413328|NCT04434430|Placebo Comparator|Placebo|Patient will receive oral placebo
89413329|NCT03094156|Experimental|Placebo|Subjects were administered with those investigational products at approximately 8-h intervals, starting in the morning (approximately at 8h00) of Day 1 and finishing in the morning of Day 5 (last dose). On Day 4, concomitantly with the Placebo morning dose, one tablet of Madopar® 250 was administered. On Day 5, concomitantly with the Placebo morning dose, one tablet of Madopar® 250 and one tablet of Comtan® were administered.
89413330|NCT03094156|Experimental|BIA 6-512 25 mg|Subjects were administered with those investigational products at approximately 8-h intervals, starting in the morning (approximately at 8h00) of Day 1 and finishing in the morning of Day 5 (last dose). On Day 4, concomitantly with the BIA 6-512 25 mg morning dose, one tablet of Madopar® 250 was administered. On Day 5, concomitantly with the BIA 6-512 25 mg morning dose, one tablet of Madopar® 250 and one tablet of Comtan® were administered.
89413331|NCT03094156|Experimental|BIA 6-512 50 mg|Subjects were administered with those investigational products at approximately 8-h intervals, starting in the morning (approximately at 8h00) of Day 1 and finishing in the morning of Day 5 (last dose). On Day 4, concomitantly with the BIA 6-512 50 mg morning dose, one tablet of Madopar® 250 was administered. On Day 5, concomitantly with the BIA 6-512 50 mg morning dose, one tablet of Madopar® 250 and one tablet of Comtan® were administered.
88890766|NCT05832060|Experimental|Sham, tRNS, tDCS|"Sham tRNS or tDCS over bilateral TPC~Active tRNS over bilateral TPC~Active left anodal/right cathodal tDCS over TPC"
89413332|NCT03094156|Experimental|BIA 6-512 75 mg|Subjects were administered with those investigational products at approximately 8-h intervals, starting in the morning (approximately at 8h00) of Day 1 and finishing in the morning of Day 5 (last dose). On Day 4, concomitantly with the BIA 6-512 75 mg morning dose, one tablet of Madopar® 250 was administered. On Day 5, concomitantly with the BIA 6-512 75 mg morning dose, one tablet of Madopar® 250 and one tablet of Comtan® were administered.
89413333|NCT03094156|Experimental|BIA 6-512 100 mg|Subjects were administered with those investigational products at approximately 8-h intervals, starting in the morning (approximately at 8h00) of Day 1 and finishing in the morning of Day 5 (last dose). On Day 4, concomitantly with the BIA 6-512 100 mg morning dose, one tablet of Madopar® 250 was administered. On Day 5, concomitantly with the BIA 6-512 100 mg morning dose, one tablet of Madopar® 250 and one tablet of Comtan® were administered.
88890767|NCT05823077|Experimental|Bergamot|In addition to 4 weeks of conventional treatment, Bergamot oil diluted with 1.5% sweet almond oil (4 drops of aromatic oil to 10 cc of sweet almond oil) will be used on the participants. After the oil is diluted, it will be heated up to 36oC. The participant will sit on the stretcher directly opposite the therapist, with the affected knee semi-flexed. The therapist will massage the affected knee for 15 minutes. After the massage, the knees will be wrapped with a towel for 5 minutes.
88890768|NCT05823077|Placebo Comparator|Placebo|In addition to 4 weeks of conventional treatment, Pure sweet almond oil will be used for the participants. Sweet almond oil will be heated to 36oC. The participant will sit on the stretcher directly opposite the therapist, with the affected knee semi-flexed. The therapist will massage the affected knee for 15 minutes. After the massage, the knees will be wrapped with a towel for 5 minutes.
88890769|NCT05823077|No Intervention|Control|4 weeks of conventional treatment.
88890770|NCT05815238||Young Adult|20-35
88890771|NCT05815238||Mild Adults|35-50
89192904|NCT05933187|Experimental|Sequence 3: C-D-A-B|Participants will receive emraclidine, 30 mg IR tablets, in the treatment sequence C-D-A-B orally, on Day 1 of each 5-day treatment period (up to 26 days)
88890772|NCT05815238||Older Adults|50-65
88890773|NCT05813392|Experimental|dCBT-I group|The dCBT-I group will receive full self-help dCBT-I through a smartphone APP for 6 weeks.
88890774|NCT05813392|No Intervention|the wait-list group|The wait-list group will not receive dCBT-I, waiting for treatment.At the end of the 3-month follow-up, the decision whether to receive treatment will be made according to the participants' wishes.
88890775|NCT05813041|Experimental|Investigational Device|Single arm trial - healthy volunteers will all undergo an apheresis procedure using the BioCaptis device. No comparator will be used for this trial.
88922038|NCT05922319||Patients with cognitive impairment taking computerized cognitive training|The exposures and outcomes were measured repeatedly during the training process for each patient. The outcomes were compared to assess the effect of different exposures (computerized cognitive training with different doses). A mixed effects model was built to solve the random effects of patients.
88922039|NCT05921370|Experimental|Silodosin group (the intervention group)|Patients will receive silodosin 8 mg one tablet per day for 3 days before their scheduled retrograde intrarenal surgery.
89413334|NCT02964273|Experimental|Phase A: Tolvaptan|Participants received tolvaptan tablets, orally as a split dose (with the first dose taken upon awakening and the second dose taken approximately 8 hours later), and starting doses based on their weight as per the following specifications: ≥20 to 45 kg: 15/7.5 mg; ≥45 to ≤75 kg: 30/15 mg; >75 kg: 45/15 mg, for 1 week. The starting dose was up-titrated (≥20 to <45 kg: 30/15 mg; ≥45 to ≤75 kg: 45/15 mg; >75 kg: 60/30 mg) after 1 week based upon tolerability and thereafter participants continued the same dose for 12 months. Doses may be titrated down dependent upon participant tolerability.
89413335|NCT02964273|Placebo Comparator|Phase A: Placebo|Participants received matching-placebo tablets, orally as a split-dose (with the first dose taken upon awakening and second dose taken approximately 8 hours later), and starting dose based on their weight as per the following specifications: ≥20 to <45 kg: 15/7.5 mg; ≥45 to ≤75 kg: 30/15 mg; >75 kg: 45/15 mg, for 1 week. The starting dose was up-titrated (≥20 to <45 kg: 30/15 mg; ≥45 to ≤75 kg: 45/15 mg; >75 kg: 60/30 mg) after 1 week based upon tolerability and thereafter participants continued the same dose for 12 months. Doses may be titrated down dependent upon participant tolerability.
89413336|NCT02964273|Experimental|Phase B: Prior Tolvaptan|Qualified participants (defined as those who were willing to continue in the trial and who did not have any adverse events [AEs] that would require investigational medicinal product [IMP] discontinuation) who received tolvaptan and completed Phase A were enrolled in Phase B and received tolvaptan tablets, orally as a split dose (with the first dose taken upon awakening and the second dose taken approximately 8 hours later), and starting dose based on their body weight as per following specifications: ≥20 to <45 kg: 15/7.5 mg; ≥45 to ≤75 kg: 30/15 mg; >75 kg: 45/15 mg, for 1 week. The starting dose was up-titrated (≥20 to <45 kg: 30/15 mg; ≥45 to ≤75 kg: 45/15 mg; >75 kg: 60/30 mg) after 1 week based upon tolerability and thereafter participants continued the same dose for 24 months. Doses may be titrated down dependent upon participant tolerability.
89413337|NCT02964273|Experimental|Phase B: Prior Placebo|Qualified participants (defined as those who were willing to continue in the trial and who did not have any AEs that would require IMP discontinuation) who received matching-placebo and completed Phase A, were enrolled in Phase B and received tolvaptan tablets, orally as a split dose (with the first dose taken upon awakening and the second dose taken approximately 8 hours later), based on their current body weight as per following specifications: ≥20 to <45 kg: 15/7.5 mg; ≥45 to ≤75 kg: 30/15 mg; >75 kg: 45/15 mg, for 1 week. The starting dose was up-titrated (≥20 to <45 kg: 30/15 mg; ≥45 to ≤75 kg: 45/15 mg; >75 kg: 60/30 mg) after 1 week based upon tolerability and thereafter participants continued the same dose for 24 months. Doses may be titrated down dependent upon participant tolerability.
89413338|NCT05025046||Ultrasound findings of thyroid nodules classified as type 3 and 4a of TIRADS|
89413339|NCT02773446|Experimental|Cohort 1 group A|Volunteers will receive 8 logs of E. coli strain B7A after overnight fast
89413340|NCT02773446|Experimental|Cohort 1 group B|Volunteers will receive 9 logs of E. coli strain B7A after 90 minute fast
89413341|NCT02773446|Experimental|Cohort 1 group C|Volunteers will receive 9 logs of E. coli strain B7A after overnight fast
89413342|NCT02773446|Experimental|Cohort 1 group D|Volunteers will receive 10 logs of E. coli strain B7A after 90 minute fast
89413343|NCT02773446|Experimental|Cohort 2 group A|subjects from Cohort 1 who met primary endpoint will receive optimal regimen as determined by analysis after Cohort 1.
88890776|NCT05803733|Experimental|Blood flow restriction (BFR) with low load resistance training|Participants will have the routine rehabilitation protocol and as an addition participants will use a cuff placed proximal to the arm during upper extremity strengthening exercises. The cuff to be used is 175mm wide and 920mm long. After the cuff is placed, it will be inflated to the determined arterial occlusion pressure. The pressure will be adjusted to 50% of the BP in the arm during rest and increased to 60%. Exercises will be performed with the cuff inflated, at approximately 20-30% of 1RM. The first set will be 30 repetitions or at the limit of fatigue (maximum of 4/10), then three sets of 15 repetitions. The cuff will not be deflated for the 30 second rest between sets. A rehabilitation session will be held under the supervision of a physiotherapist. Exercise will be performed for 6 weeks with 3 sessions each week, with 1-2 days break between sessions.
88890777|NCT05803733|Active Comparator|Control Group|Participants only will have the rehabilitation protocol including general physiotherapeutic approaches such as range of motion exercises and strength training which is a daily part of their nursing home services.
89413344|NCT02773446|Experimental|Cohort 2 group B|Naive subjects who will receive optimal regimen as determined by analysis after Cohort 1
89413345|NCT05040724|Experimental|Ivermectin|Ivermectin 3mg, on tablet. As a single dose of 400 µg / kg orally (rounded down to the nearest unit). T+ usual care
89413346|NCT05040724|Placebo Comparator|control|placebo of ivermectin administered in the same manner as the active drug in experimental arm + usual care
89413347|NCT03542058|Experimental|Treatment Group|Study participants will receive carvedilol for a period of 6 month. The initial dosage of carvedilol will be 3.125mg twice daily. Dosage will be titrated up two weekly until the maximum tolerable dose or ceiling dose of 25mg twice daily has been reached.
89413348|NCT03542058|No Intervention|Control Group|Study participant will not receive any cardiac medication, apart from standard cancer care.
89413349|NCT03611439|Active Comparator|ReBuilder Actives|Subjects take one 650 mg capsule by mouth twice a day for 12 months.
89413350|NCT03611439|Placebo Comparator|ReBuilder Placebo|Subjects take one placebo capsule by mouth twice a day for 12 months.
89413351|NCT05040412|Experimental|Diabetic mellitus patients using insulin|The trachea will be intubated by direct laryngoscopy.
88890778|NCT05801341|Experimental|COVID-19 Positive Children|Determined by NP PCR test
89413352|NCT05040412|Experimental|Diabetic patients using oral antidiabetic drug|The trachea will be intubated by direct laryngoscopy.
89413353|NCT03321513|Active Comparator|Aflibercept Group|2.0 mg intravitreous aflibercept
89413354|NCT03321513|Experimental|Bevacizumab + Deferred Aflibercept Group|1.25 mg intravitreous bevacizumab + deferred intravitreous 2.0 mg aflibercept if eye meets switch criteria
89413355|NCT05024110|Experimental|Group I|GI received high-intensity exercise training.
89413356|NCT05024110|Experimental|Group II|GII received moderate-intensity exercise training.
89413357|NCT03093376|Experimental|Effortful Control Camp|"Children will participate in an interactive, child-friendly camp comprised of short, game-like exercises to teach inhibitory and attentional control, as well as visuospatial and working memory skills."
89413358|NCT02032797|Experimental|A: 7 days of progesterone|"Transvaginal ultrasound (US) and hormone analysis for FSH, LH, E2 and P on day 2 of the cycle will be performed. The artificial preparation of the endometrium consists of 7 days oestradiol valerate (Progynova®, Bayer-Schering Pharma AG, Berlin, Germany) 2 mg bid (bi-daily), followed by 6 days oestradiol valerate 2 mg tid (thrice daily). On day 13, the endometrium is measured. If endometrial thickness is more than 7 mm, patients are randomly assigned to group A or B.~Group A receives 7 days of micronized progesterone vaginally (Utrogestan® ((Utrogestan, Besins International), 3x200mg daily), group B receives 5 days of micronized progesterone vaginally. On the 7th (group A) or 5th (group B) day of progesterone supplementation, the cryopreserved-thawed day 5 embryo is transferred."
89413359|NCT02032797|Placebo Comparator|B: 5 days of progesterone|"Transvaginal ultrasound (US) and hormone analysis for FSH, LH, E2 and P on day 2 of the cycle will be performed. The artificial preparation of the endometrium consists of 7 days oestradiol valerate (Progynova®, Bayer-Schering Pharma AG, Berlin, Germany) 2 mg bid (bi-daily), followed by 6 days oestradiol valerate 2 mg tid (thrice daily). On day 13, the endometrium is measured. If endometrial thickness is more than 7 mm, patients are randomly assigned to group A or B.~Group A receives 7 days of micronized progesterone vaginally (Utrogestan® ((Utrogestan, Besins International), 3x200mg daily), group B receives 5 days of micronized progesterone vaginally. On the 7th (group A) or 5th (group B) day of progesterone supplementation, the cryopreserved-thawed day 5 embryo is transferred."
89413360|NCT05024266|Experimental|Tislelizumab + Albumin Paclitaxel + Carboplatin|Tislelizumab 200mg d1, Albumin Paclitaxel 260mg/m2 d1, Carboplatin AUC5 d1, Q3W
89413361|NCT03094078|Active Comparator|News with Spin|News items reporting results of pre-clinical studies with spin
89413362|NCT03094078|Experimental|News without spin|News items reporting results of pre-clinical studies without spin
89413363|NCT03094000|Experimental|Experimental group (CBTE-MIND)|Adding a mindfulness skills intervention to group psychotherapy according to the principles of the Enhanced Cognitive-Behavioral Therapy (CBT-E) for eating disorders (Fairburn, 2008)
88890779|NCT05801315|Experimental|Full mouth ultrasonic debridement plus glycine powder air polishing|Plaque and calculus are firstly removed through full mouth ultrasonic debridement (FMUD) in all sites (both dental and implant). After this procedure an air polishing device (Air-flow Master Piezon®) is used as additional therapy to further debride peri-implant trans-mucosal tract.
89192905|NCT05933187|Experimental|Sequence 4: D-A-B-C|Participants will receive emraclidine, 30 mg IR tablets, in the treatment sequence D-A-B-C orally, on Day 1 of each 5-day treatment period (up to 26 days)
89413364|NCT03094000|Active Comparator|Control group (CBTE)|Group psychotherapy according to the principles of the Enhanced Cognitive-Behavioral Therapy (CBT-E) for eating disorders (Fairburn, 2008), without a mindfulness skills intervention
89413365|NCT05026762|Experimental|Treatment|
89413366|NCT03611283|Experimental|Test group|"Patients had to use:~Mouthwash treatment (250 ml): Aqua, Betaine, Glycerin, PEG-40, Hydrogenated Castor Oil, Propylene Glycol, Xylitol, Aroma, Potassium Phosphate, Diazolidinyl Urea, Allantoin, Olea Europaea Fruit Oil, Sodium Methylparaben, Sodium Propylparaben, Sodium Fluoride, CI75810, Panthenol, Tocopheryl Acetate, Sucralose, Carum Petroselinum Seed Oil, Limonene.~Toothpaste treatment (50 ml): Glycerin, Aqua, Hydrated Silica, Xylitol, Betine, Tetrapotassium Pyrophosphate, Olea Europaea Fruti Oil, Xanthan Gum, Titanium Dioxide, Potassium Phosphate, Aroma, Sodium Fluoride, Diazolidinyl Urea, Papain, Carum Petroselinum Seed Oil, Panthenol, Tocopheryl Acetate, Limonene"
89413367|NCT03611283|Placebo Comparator|Placebo group|"Patients had to use:~Mouthwash placebo(250 ml): Aqua, Glycerin, PEG-40 Hydrogenated Castor Oil, Propylene Glycol, flavoring, Potassium Phospate, Diazolidinyl Urea, Sodium Methylparaben, Sodium Propylparaben, Sodium Fluoride, CI75810, Tocopheryl Acetate, Sucralose, LImonene.~Toothpaste placebo (50 ml): Aqua, Sorbitol, Hydrated Silica, Glycerin, Tetrapotassium Pyrophosphate, Xanthan Gum Titanium Dioxide, Sodium Lauryl Sulphate, Potassium Phosphate, flavoring, Sodium Fluoride, Diazolidinyl Urea, Sucralose, Limonene"
89413368|NCT05040490|Experimental|SUG group|sugammadex as reversal drugs
89413369|NCT05040490|No Intervention|NEO group|neostigmine as reversal drugs
89413370|NCT02773368|Experimental|IDegLira|
89413371|NCT02773368|Active Comparator|IGlar|
89413372|NCT02032563|Experimental|Indocyanine Green|intravenous injection of 0.25mg/kg Indocyanine Green just before surgery
89413373|NCT03093532|No Intervention|Usual Care|The Usual Care group arm will received pre-printed discharge instructions and an outpatient referral. (This group represents standard of care.)
88890780|NCT05801315|Active Comparator|Full mouth ultrasonic debridement|Plaque and calculus are removed through full mouth ultrasonic debridement (FMUD) in all sites (both dental and implant).
88890781|NCT05800678||nulliparous|"inclusion: reproductive age~exclusion: history of gynecological surgery or disorder with possible impact on pelvic floor"
89413374|NCT03093532|Active Comparator|ED SBIRT-HTN|"The ED SBIRT-HTN (The Emergency Department Screening Brief Intervention and Referral for Treatment) arm consists of a series of risk assessment tools (surveys, video, and noninvasive bedside assessments) designed to be efficient, patient-centered and educational for participants in an emergency department setting. Through the intervention, participants will learn more about hypertension management and complications associated with uncontrolled BP. Participants in the ED-SBIRT-HTN group will receive the following interventions:~1) screening (risk assessment/stratification), 2) a limited bedside echocardiogram (looking for evidence of subclinical cardiac disease), and 3) a urine microalbumin test (marker of early cardiovascular disease)."
88890782|NCT05800678||primiparous|"Inclusion: reproductive age, vaginal birth~exclusion:~history of gynecological surgery or disorder with possible impact on pelvic floor~assisted vaginal delivery (forceps, vaccumextraction)~labour induction~pregnancy-related disorders~perineal tear grade III-IV (women with episiotomy were included)~suspicion of LAM avulsion by ultrasound or palpation~Oxford score 4 or 5 after delivery"
88890783|NCT05800444|Experimental|BAY3283142 (low dose)|Participants will receive BAY3283142 as single low dose on Day 1 followed by multiple doses for 7 days from Day 3 to Day 9.
89413375|NCT03093532|Active Comparator|E SBIRT-HTN + PACTH-c|Participants randomized to the SBIRT-HTN +PACHT-c (Post-Acute Care Hypertension Transition Clinic) arm will receive all interventions of the ED SBIRT-HTN arm plus a 48-72 hour follow-up in the Post-Acute Care Hypertension Transition Clinic for repeat blood pressure assessment, review of screening assessments, and secured PCP appointment with a federally qualified health center within the study site's health system.
89413376|NCT02032485|Experimental|Indocyanine Green|Intravenous injection of 0.25 mg/kg Indocyanine Green in patients with peritoneal carcinomatosis from colorectal cancer before the surgery
89413377|NCT05026918|Active Comparator|Group A|all the components of Manual Chest Physiotherapy wer performed on the patients of this group. MCPT was done few hours before meals and it was made sure that nothing was in patient's mouth while doing chest physiotherapy. MCPT includes postural drainage, percussion and vibrations. Chest Physiotherapy was done thrice a day for 30 minutes and there were 21 sessions a week.
89413378|NCT05026918|Experimental|Group B|all the components of Active Cycle of Breathing techniques (ACBT) were performed on the patients of this group. ACBT includes Breathing control techniques, chest expansion exercises and Forced Expiration Technique. These were performed thrice a day for 30 minutes and for 21 sessions a week.
89413379|NCT03093220||community-acquired pneumonia|all adult patients (aged > 16 years) admit to the 4 hospitals between March 2017 and March 2018 with CAP will be enrolled
89413380|NCT05040022|Active Comparator|Group pneumoperitoneum pressure 10|Pneumoperitoneum pressure at 10 mmHg
89413381|NCT05040022|Placebo Comparator|Group neumoperitoneum pressure 14|Pneumoperitoneum pressure at 10 mmHg
89413382|NCT03611205|Experimental|Diagnostic (dPET/CT)|Participants receive radiotracer injection and undergo dPET/CT over 20-75 minutes at baseline, during the 2nd and 4th week of radiotherapy, and 3 months after the completion of chemoradiation therapy.
89413383|NCT03093298|Experimental|Obesity|Enteroscopies with biopsy retrieval and mixed meal tests with blood sampling
89413384|NCT02254902|Experimental|Physical Activity|Participants in the Physical Activity intervention arm of the study receive culturally-modified, materials through participation in 12 weekly 1-.5-hour sessions focused on increasing daily step counts and bouts of moderate intensity physical activity. The group sessions include participation in different forms of physical activity as well as group discussions on the barriers and opportunities for increasing physical activity in daily life.
89413385|NCT02254902|No Intervention|Wait List Control|Participants in the Wait List Control will be offered the program after a 3-month wait period. While waiting for the program, participants are offered to attend monthly sessions on various wellness and prevention topics.
88890784|NCT05800444|Experimental|BAY3283142 (medium dose)|Participants will receive BAY3283142 as single medium dose on Day 1 followed by multiple doses for 7 days from Day 3 to Day 9 (optional arm).
88890785|NCT05800444|Experimental|BAY3283142 (high dose)|Participants will receive BAY3283142 as single high dose on Day 1 followed by multiple doses for 7 days from Day 3 to Day 9.
88890786|NCT05800444|Placebo Comparator|Matching placebo|Participants will receive a BAY3283142 matching placebo as single dose on Day 1 followed by multiple doses for 7 days from Day 3 to Day 9.
88890787|NCT05798403|Experimental|Electroacupuncture group|"Participants will receive electroacupuncture treatment at Shenshu (BL23), Ciliao (BL32), Zhonglvshu (BL29), Huiyang (BL35), Weizhong (BL40), Zhongji (CV3), Dahe (KI12), Shuidao (ST28), Sanyinjiao (SP6). It should be noted that CV3, KI12, ST28, SP6 are used as the group A acupoints and BL23, BL32, BL29, BL35, BL40 as the group B acupoints. Patients will be treated with alternating group A and B acupoints. The frequency of treatment is 3 times a week and each treatment will last for 30 minutes for a total of 12 sessions over the course of four weeks. The follow-up observation will be recorded on week 8 and 16.~At the same time, participants will also receive placebo medication. Oral Solifenacin Succinate placebo will be used and taken once a day for 4 weeks."
89413386|NCT05383443|Experimental|Intervention|"Multidomain non-pharmacological intervention, including cognitive training, physical exercise, nutrition education, capacitation to deal with cognitive decline, and diagnosis and correction of hearing impairment.~The intervention plan includes home training activities of identical intensity for participants with and without access or autonomy to use computer/internet. It will comprise individual and group sessions over three months, possibly extensible up to 12 months.~Caregivers or partners of all participants will be invited to participate in the activities of nutrition education and capacitation to deal with cognitive decline."
88890788|NCT05798403|Active Comparator|Solifenacin Succinate group|"Participants will take Solifenacin Succinate (Wuhan Human well Puracap (Likang) Pharmaceuticals Co., Ltd.) orally before breakfast for 4 consecutive weeks at 5 mg (1 tablet) per day.~At the same time, the participants will receive sham electroacupuncture with a pragmatic placebo needle on sham acupoints. Participants will have the same needle retention time, treatment time, and follow-up time as the electroacupuncture group."
89192906|NCT05930535|Experimental|Parenting for Lifelong Health|"Parenting Program Parenting for Lifelong Health (PLH) for parents and their teens aged 10-14 years old with Helping Adolescents Thrive comics at home"
89413387|NCT05383443|Active Comparator|Control group|"Multidomain non-pharmacological intervention, including cognitive training, physical exercise, nutrition education, capacitation to deal with cognitive decline, and diagnosis and correction of hearing impairment.~It will comprise individual and group sessions, over three months (possibly extensible up to 12 months), conducted with a lower frequency in comparison with the intervention group.~Caregivers or partners of all participants will be invited to participate in the activities of nutrition education and capacitation to deal with cognitive decline."
89413388|NCT05026840||IADPSG|
89413389|NCT05026840||WHO '99|
89413390|NCT02033109|Experimental|PC-1005|"4.00 g dosed once daily for 3 days (safety run-in)~4.00 g dosed once daily for 14 days (main study)"
89413391|NCT02033109|Placebo Comparator|HEC gel|4.00 g dosed once daily for 14 days (main study only)
89413392|NCT02153658|No Intervention|Arm 1|Subjects followed the current hygiene instructions, standard washing in a shower with soap.
89413393|NCT02153658|Active Comparator|Arm 2|Subjects cleaned the foreskin with soapy water using a syringe once a day.
89413394|NCT02153658|Active Comparator|Arm 3|Subjects cleaned the foreskin with diluted chlorhexidine (1%) using a syringe once a day.
89413395|NCT05026294|Experimental|Experimental group I|The experimental group received plyometric training
89413396|NCT05026294|Experimental|Experimental group II|The experimental group received flat feet rehabilitation training
89413397|NCT05026294|No Intervention|Control group|The Control group didn't receive intervention
89413398|NCT04962607||Study Group|"Asymptomatic primary molars with deep carious lesions scheduled for regular treatment.~Exposure of a vital pulp due to caries.~No clinical or radiographic evidence of pulp degeneration, such as spontaneous pain, excessive bleeding from the root canal, internal root resorption, inter-radicular and/or periapical bone destruction, swelling, or sinus tract.~The possibility of proper restoration of the teeth."
89413399|NCT04962607||control group|"Asymptomatic primary molars with deep carious lesions scheduled for regular treatment.~Exposure of a vital pulp due to caries.~No clinical or radiographic evidence of pulp degeneration, such as spontaneous pain, excessive bleeding from the root canal, internal root resorption, inter-radicular and/or periapical bone destruction, swelling, or sinus tract.~The possibility of proper restoration of the teeth."
89413400|NCT05040100|No Intervention|Textbook Cohort|Trainees underwent a 10-minute lecture using two-dimensional (2D) images of the mediastinum selected from standard textbook resources. The lecture carefully reviewed the mediastinal anatomy reflected in the prosected cadaver and provided a variety of 2D axial, coronal, and sagittal images.
89413401|NCT05040100|Experimental|3D Model Cohort|Trainees underwent a 10-minute lecture using two-dimensional (2D) images of the mediastinum selected from standard textbook resources. The lecture carefully reviewed the mediastinal anatomy reflected in the prosected cadaver and provided a variety of 2D axial, coronal, and sagittal images. Upon completion of the didactic session, the 3D model cohort was provided with an additional 10-minute interactive lecture reviewing the same focused mediastinal anatomical structures using the 3D model.
89413402|NCT01336647|Experimental|Group A|Group A Low-Dose Ha44 Gel 0.37% w/w topically administered to head and scalp.Single application for 10 minutes.
89413403|NCT01336647|Experimental|Group B|Group B High-Dose Ha44 Gel 0.74% w/w. Topically administered to hair and scalp. Single application for 10 minutes of duration.
88890789|NCT05783596|Experimental|Obinutuzumab + Glofitamab for Follicular Lymphoma|"Participants will undergo study procedures as outlined:~Imaging scans (CT or PET) at screening and after cycles 3, 7, and 12 of treatment.~Bone marrow biopsy at baseline.~Cycle 1~Days -21, -14, -7, 0 of 36 day cycle: Predetermined dose of Obinutuzumab.~Days 1 and 8 of 36 day cycle: Predetermined dose of Glofitamab. (First dose will be administered in the hospital.)~Cycles 2 - 12:~o Day 1 of 21 day cycle: Predetermined dose of Glofitamab.~Bone marrow biopsy within 2 weeks of end of treatment.~Imaging scans (CT or PET) at 12, 18, and 24 months after treatment initiation.~Follow up visits up to 5 years after treatment completion."
88890790|NCT05783596|Experimental|Obinutuzumab + Glofitamab for Marginal Zone Lymphoma|"Participants will undergo study procedures as outlined:~Imaging scans (CT or PET) at screening and after cycles 3, 7, and 12 of treatment.~Bone marrow biopsy at baseline.~Cycle 1~Days -21, -14, -7, 0 of 36 day cycle: Predetermined dose of Obinutuzumab.~Days 1 and 8 of 36 day cycle: Predetermined dose of Glofitamab. (First dose will be administered in the hospital.)~Cycles 2 - 12:~o Day 1 of 21 day cycle: Predetermined dose of Glofitamab.~Bone marrow biopsy within 2 weeks of end of treatment.~Imaging scans (CT or PET) at 12, 18, and 24 months after treatment initiation.~Follow up visits up to 5 years after treatment completion."
88890791|NCT05783141|Experimental|Experimental formula group|Follow-on formula supplemented with a novel prebiotic combination
88890792|NCT05783141|Placebo Comparator|Control formula group|Follow-on formula not supplemented
88890793|NCT05780853||Typically Developing Children (Control Group)|Typically developing children with no known neurodevelopmental disorder, medical comorbidities, a chronic illness or any additional diagnoses that would impact their ability to complete the game-based assessment.
88890794|NCT05780853||Children with a Diagnosed Neurodevelopmental Disorder (Clinical Group)|Children with a diagnosed neurodevelopmental disorder including: Attention Deficit Hyperactivity Disorder (ADHD), Autism Spectrum Disorder (ASD), Specific Learning Disorder, or a Communication Disorder. Children must also have no known medical comorbidities, a chronic illness or any additional diagnoses that would impact their ability to complete the game-based assessment.
88890795|NCT05776667|Experimental|Hypofractionated Radiation Therapy|
88890796|NCT05772221|Other|Interviewer-Administered|Screening assessments to measure social determinants of health in relation to cardiovascular disease.
88890797|NCT05761873|Active Comparator|Paper audit and feedback only|Provision of A&F reports by email (standard practice in the region) to allocated practices depending on randomisation status.
88890798|NCT05761873|Experimental|Paper and email audit and feedback|Provision of A&F reports by paper via the post (new intervention being trialled) and email (standard practice) to allocated practices depending on randomisation status.
89413404|NCT01336647|Placebo Comparator|Group C|Group C Placebo/ vehicle Ha44 Gel. Topically administered to hair and scalp.Single application for 10 minutes of duration.
89413405|NCT02157558|Experimental|All subjects|All subjects will receive a single oral dose of fexofenadine on Day 1 while fasting. Days 2 to 5 will be Washout days. On Day 6, subjects will begin a 5 day telotristat etiprate regimen. On Day 10 subjects will be given the morning telotristat etiprate dose concomitantly with a single dose of fexofenadine while fasting.
89413406|NCT05018182|Experimental|Neoadjuvant chemotherapy|4 cycles of neoadjuvant chemotherapy with FOLFOXIRI + operation + 5 cycles of adjuvant chemotherapy with XELOX
89413407|NCT01336569|Experimental|DuoTrav|Travoprost 0.004%/timolol maleate 0.5% fixed combination, one drop to the study eye nightly for up to 6 weeks
89413408|NCT05018572|Experimental|"Personalised internet-based treatment I am"|"Personalised internet-based treatment I am."
89413409|NCT05018572|No Intervention|Treatment As Usual|Treatment in primary care / Treatment As Usual (TAU), which is medical treatment
89413410|NCT04899505||Evaluation on appearance of unpleasant body odors|Incidence of the development of unpleasant body odors in AYA oncology patients
89413411|NCT03092986|Active Comparator|chemotherapy with paclitaxel and carboplatin|Intervention: paclitaxel 200 mg/m2 AUC and carboplatin AUC 6 on day 1 every 3 wks for 2 cycles followed by three dimensional conformal radiotherapy on day 42
89413412|NCT03092986|Experimental|chemotherapy with cisplatin and vinblastine|Intervention : cisplatin 100 mg/m2 on day 1 and 29 and vinblastine 5mg/m2 on days 1,8,15,22 and 29 followed by three dimensional conformal radiotherapy on day 50
89413413|NCT04867759||Study group|On outpatient basis, we will take a uterine sample on mid-luteal phase day 21 by Novac curette or pipelle aspirator. Samples of endometrium will be kept in formaline solution and will be sent to National Institute of research and medical sceinces at Alexandria University to be tested for uNK Cells CD56.
89413414|NCT04867759||Control group|On outpatient basis, we will take a uterine sample on mid-luteal phase day 21 by Novac curette or pipelle aspirator. Samples of endometrium will be kept in formaline solution and will be sent to National Institute of research and medical sceinces at Alexandria University to be tested for uNK Cells CD56.
89413415|NCT03092908|Placebo Comparator|Control group|Administer 5 ml placebo (purified water) three times a day.
89005514|NCT04569292||Cancer patients|"confirmation of COVID-19 in the laboratory (RT-PCR techniques);~suspected cases of COVID-19; clinically diagnosed based on symptoms (fever> 37.5 °, decrease in oximeter saturation by at least 5%, cough, diarrhea, otitis, dysgeusia, myalgia, arthralgia, conjunctivitis and rhinorrhea) + close contact a COVID-19 subject positive;~asymptomatic cases; diagnosed based on positive swab results but without symptoms"
89005515|NCT04569370||Scoring Factor|Intervention: Procedure: Laparoscopic cholecystectomy
89413416|NCT03092908|Experimental|Intervention group|Administer 5 ml mature vinegar (Brand: Ninghuafu) three times a day.
89413417|NCT05039398|Active Comparator|Comparison group|
89413418|NCT05039398|Experimental|Telephone D&G|
89413419|NCT05039398|Experimental|Physical meeting D&G|
89413420|NCT02157714|Experimental|PRX002|PRX002
89192907|NCT05930210|Experimental|ENERGI-F703 GEL|ENERGI-F703, topical application, 2 times daily for 16 weeks
88890799|NCT05759182|Experimental|Cerebral Palsy gait training using a pediatric exoskeleton|"ExoAtlet Bambini Outcome, Safety, and Efficacy 8 participants with cerebral palsy will participate in gait training using ExoAtlet Bambini powered exoskeleton.~Intervention: Device: Gait training using ExoAtlet exoskeleton"
89005516|NCT04569370||Difficult criteria|Intervention: Procedure: Laparoscopic cholecystectomy
89192908|NCT05930210|Placebo Comparator|ENERGI-F703 matched vehicle|ENERGI-F703 matched vehicle, topical application, 2 times daily for 16 weeks
89413421|NCT02157714|Placebo Comparator|Placebo|Placebo
89413422|NCT02342665|Experimental|Copanlisib (BAY80-6946)|Dose escalation/safety evaluation cohort and objective tumor response (OR) expansion cohort
89413423|NCT03090724|Experimental|BIA 5-453 (Young)|"Each subject participated in the study for approximately 7 weeks. Participation included the screening evaluations within 28 days before the first administration, phase A (single dose, a 2-day inpatient period followed by 4 ambulatory visits), phase B (multiple-dose during 7 days, 6 ambulatory visits, followed by a 2-day inpatient period and by 5 ambulatory visits) and a follow-up visit 7 to 10 days after the last administration.~Phase A: single-dose on Day 1, followed by a wash out period Phase B: repeated dose from Day 6 to Day 12 (7 days, steady-state)"
89413424|NCT03090724|Experimental|BIA 5-453 (Elderly)|"Each subject participated in the study for approximately 7 weeks. Participation included the screening evaluations within 28 days before the first administration, phase A (single dose, a 2-day inpatient period followed by 4 ambulatory visits), phase B (multiple-dose during 7 days, 6 ambulatory visits, followed by a 2-day inpatient period and by 5 ambulatory visits) and a follow-up visit 7 to 10 days after the last administration.~Phase A: single-dose on Day 1, followed by a wash out period Phase B: repeated dose from Day 6 to Day 12 (7 days, steady-state)"
88890800|NCT05748821|Active Comparator|Autoregulated blood flow restriction|Autoregulated BFR expands as the muscle progresses into the stretch-shortening cycle.
88890801|NCT05748821|Active Comparator|Non-autoregulated blood flow restriction|Non-autoregulated BFR does not expand as the muscle progresses into the stretch-shortening cycle.
88890802|NCT05748821|Active Comparator|No blood flow restriction|This group serves as the control group for this study
88890803|NCT05726461|Experimental|AndroidAPS-rt-CGM|1) AiDEX G7 continuous glucose monitoring (an rt-CGM);2) Equil® insulin patch pump;3) AndroidAPS algorithm implemented in Android smartphone
88890804|NCT05726461|Active Comparator|sensor augmented pump(SAP)|SAP includes only Equil® insulin patch pump and AiDEX G7 continuous glucose monitoring.
88890805|NCT05725291|Experimental|AMT-116 Dose Escalation|
88890806|NCT05712096||EVUSHELD Arm|Individuals given EVUSHELD for pre-exposure prophylaxis
89192909|NCT05927012|Experimental|Part 1 (Initial Titration Strategy)|KER-047(30 mg, 60mg or 80mg) oral tablet daily (or every other day) for up to 24 weeks.
89192910|NCT05927012|Experimental|Part 2 (Cohort Expansion or Alternate Titration Strategy)|The starting dose regimen and titration schedule of KER-047 oral tablet will be based on the SRC (Safety Review Committee) recommendation from Part 1.
89413425|NCT02153892|Other|Multi-center, prospective, single-arm study|To assess the safety and performance of the GDS Accucinch System when used percutaneously to reduce functional mitral regurgitation.
89413426|NCT03090568|Experimental|BIA 5-453 Fasting|BIA 5-453 200 mg in fasting conditions
89413427|NCT03090568|Experimental|BIA 5-453 Fed|BIA 5-453 200 mg in fed conditions
89413428|NCT02157792|Experimental|Part A|This part will be 3 + 3 dose escalation study of M6620 in combination with gemcitabine as well as gemcitabine and cisplatin in participants with advanced solid tumors.
89413429|NCT02157792|Experimental|Part B|This part will be 3 + 3 dose escalation study of M6620 in combination with cisplatin or cisplatin and etoposide in participants with advanced solid tumors.
88890807|NCT05712096||Concurrent Control Arm|Individuals eligible for EVUSHELD pre-exposure prophylaxis but did not receive Evusheld
89413430|NCT02157792|Experimental|Part B2|This part will be 3 + 3 dose escalation study of M6620 in combination with irinotecan in participants with advanced solid tumors.
89413431|NCT02157792|Experimental|Part C1|This will be the expansion part of the study in which participants with advanced non-small cell lung cancer (NSCLC) will be administered M6620 in combination with gemcitabine.
89413432|NCT02157792|Experimental|Part C2|This will be the expansion part of the study in which participants with advanced triple negative breast cancer (TNBC) will be administered M6620 in combination with cisplatin.
88890808|NCT05687825||Clinically relevant postoperative pancreatic fistula|patients who developed clinically relevant postoperative pancreatic fistula after pancreaticoduodenectomy
89413433|NCT02157792|Experimental|Part C3|This will be the expansion part of the study in which participants with platinum-resistant advanced small cell lung cancer (SCLC) will be administered M6620 in combination with cisplatin or carboplatin.
89413434|NCT03095716||elderly patients|Impact of intraperitoneal pressure and warmed, humidified CO2 gas on clinical outcomes after laparoscopic surgery for uterine prolapse in patients aged ˃75 years
89413435|NCT05175391|Active Comparator|Meat based protein, no spice|Test meal will be a chicken salad entree consisting of shredded skinless chicken breast, mayonnaise, lemon juice, celery, salt and pepper, with whole wheat crackers and grapes as side items.
89413436|NCT05175391|Experimental|Meat based protein, spice added|Test meal will be a chicken salad entree consisting of shredded skinless chicken breast, mayonnaise, lemon juice, celery, salt and pepper, onion powder, garlic powder, dill and ground mustard seed, served with whole wheat crackers and grapes as side items.
89413437|NCT05175391|Active Comparator|Plant based protein, no spice|Test meal will be a chick pea and rice salad entree consisting of chick peas, brown rice, mayonnaise, yogurt, lemon juice, celery, soy protein powder, salt and pepper, served with whole wheat crackers and grapes as side items.
89413438|NCT05175391|Experimental|Plant based protein, spice added|Test meal will be a chick pea and rice salad entree consisting of chick peas, brown rice, mayonnaise, yogurt, lemon juice, celery, soy protein powder, salt and pepper, onion powder, garlic powder, cumin, parsley, dill, oregano, ground rosemary and ground mustard seed, served with whole wheat crackers and grapes as side items.
88890809|NCT05687825||No clinically relevant postoperative pancreatic fistula|patients who did not develop clinically relevant postoperative pancreatic fistula after pancreaticoduodenectomy
88890810|NCT05686031||Doctors|Anaesthesiologists
89413439|NCT05023954||A|A longitudinal observational study looking at the pregnancy journey of 200 women Bloods taken for sepsis biomarkers including a genomic sepsis-test throughout the pregnancy journey
89413440|NCT05023954||B|A consecutive collection of data from 100 pregnant women with suspected sepsis Bloods taken for Sepsis Biomarkers including a genomic sepsis-test throughout the sepsis episode
88890811|NCT05686031||Anaesthesia Nurses|
88890812|NCT05676853|Experimental|Pegzilarginase|Weekly subcutaneous dosing of pegzilarginase plus individualized disease management for 52 weeks
88890813|NCT05675306|Experimental|High Dose Frequency|This group will receive treatment 4x/week for 6 weeks
88890814|NCT05675306|Active Comparator|Low Dose Frequency|This group will receive treatment 2x/week for 12 weeks
88890815|NCT05672316|Experimental|Treatment (botensilimab, balstilimab and regorafenib)|Patients receive botensilimab IV, balstilimab IV, and regorafenib PO on study. Patients also undergo CT and collection of blood throughout the study.
89413441|NCT02150538|Active Comparator|Right ventricular stimulation|patients with conventional Right Ventricular Stimulation (only RV) with optimized algorithms for minimization of pacing
89413442|NCT02150538|Experimental|Biventricular Stimulation|Patients with biventricular stimulation (Right Ventricle and Left Ventricle)
89413443|NCT05023798||ATD Cohort 1|The first iteration of the sensor will be tested and results compared to the gold-standard laboratory measuring equipment.
88890816|NCT05671172|Experimental|Group H1|patients will received TAB block with 19 ml bupivacaine 0.25 % plus 1 ml 0.9% normal saline containing 750 IU hyaluronidase as an adjuvant in each side after closing skin.
88890817|NCT05671172|Experimental|Group H2|patients will received TAB block with 19 ml bupivacaine 0.25 % plus 1 ml 0.9% normal saline containing 1500 IU hyaluronidase as an adjuvant in each side after closing skin.
88890818|NCT05671172|Placebo Comparator|Group C|patients will received TAB block with 19 ml bupivacaine 0.25 % plus 1 ml 0.9% normal saline without any adjuvant in each side after closing skin.
88890819|NCT05664646|Sham Comparator|Without stimulation|For study 1, exercise endurance time and heart rate recovery will be measured after arm ergometry without stimulation. For study 2, body core temperature and thermal comfort will be reported without stimulation.
88890820|NCT05664646|Active Comparator|With stimulation|For study 1, exercise endurance time and heart rate recovery will be measured after arm ergometry with stimulation. For study 2, body core temperature and thermal comfort will be reported with stimulation.
89413444|NCT05023798||ATD Cohort 2|The next iteration of the sensor will be tested and results compared to the gold-standard laboratory measuring equipment. The prototype will be tested on a cohort of 3-5 patients.
89413445|NCT05023798||ATD Cohort 3|The next iteration of the sensor will be tested and results compared to the gold-standard laboratory measuring equipment. The prototype will be tested on a cohort of 3-5 patients.
89413446|NCT05023798||ATD Cohort 4|The next iteration of the sensor will be tested and results compared to the gold-standard laboratory measuring equipment. The prototype will be tested on a cohort of 3-5 patients.
88890821|NCT05659719||Recifercept cohort|Achondroplasia patients enrolled in the recifercept phase 2 clinical trial
88890822|NCT05659719||Natural history cohort|Achondroplasia patients enrolled in the achondroplasia natural history study
88890823|NCT05652413|Experimental|Adapted-Engage-PA|Participants will receive two sessions, lasting 60 minutes each, of behavioral intervention strategies to increase daily walking routines and prevent pain flares.
89413447|NCT05023798||ATD Cohort 5|The next iteration of the sensor will be tested and results compared to the gold-standard laboratory measuring equipment. The prototype will be tested on a cohort of 3-5 patients.
89413448|NCT05023798||ATD Cohort 6|The next iteration of the sensor will be tested and results compared to the gold-standard laboratory measuring equipment. The prototype will be tested on a cohort of 3-5 patients.
88890824|NCT05651438||E-Athletes|E-Athletes who are over the age of 18, have participated in professional matches for at least one year, and have an E-sports license were evaluated.
88890825|NCT05650645|Experimental|Incobotulinium toxin A group|Individuals with symptoms of tetanus will receive three serial injections of incobotulinum toxin A into the auricular muscles.
88890826|NCT05650645|Placebo Comparator|Placebo|Individuals with symptoms of tetanus will receive placebo saline injections.
88890827|NCT05650359|Experimental|OrthoPulse|The study population includes a total of 41 patients (based on our sample size calculation), with 21 patients in group 1 and 21 patients in group 2. Eligible study participants are men and women over the age of 18 with permanent dentition who require orthodontic treatment.
88890828|NCT05650359|Active Comparator|Control|The study population includes a total of 41 patients (based on our sample size calculation), with 21 patients in group 1 and 21 patients in group 2. Eligible study participants are men and women over the age of 18 with permanent dentition who require orthodontic treatment.
88890829|NCT05647317|Other|Digital technology-based system for heart failure management|This is a single-arm study to assess the feasibility and preliminary effectiveness of a digital technology-based system for heart failure management
88890830|NCT05645978||Patients who underwent pacemaker insertion during study period|Patients who underwent pacemaker insertion between January 2015 and December 2020
88890831|NCT05645965||Patients who underwent implantable cardioverter-defibrillator (ICD) insertion during study period|Patients who underwent implantable cardioverter-defibrillator (ICD) insertion between January 2015 and December 2020
89192911|NCT05925712|Experimental|Crossover ABA|Group 1 starts using the ventilating suspension system (condition A), group 2 starts using non-ventilating suspension system (condition B) and then they cross-over to the other system, two times.
88890832|NCT05645939||Patients diagnosed with HCMP during study period|Patients newly diagnosed with HCMP between January 2015 and December 2020
88890833|NCT05645926||Patients with MI who underwent revascularization during study period|Patients newly diagnosed with MI and underwent revascularization (PCI or CABG) during study period
88890834|NCT05645913||Atrial fibrillation with oral anticoagulant|patients who were newly receiving an oral anticoagulant for atrial fibrillation during study period
88890835|NCT05636540|Experimental|Cohort A|After undergoing screening assessments and verifying eligibility for study participation subjects will be scheduled to undergo a baseline experimental [18F]FTT PET/CT scan prior to surgery. Patients in Cohort A will undergo surgery with or without additional therapy.
88890836|NCT05636540|Experimental|Cohort B|After undergoing screening assessments and verifying eligibility for study participation subjects will be scheduled to undergo a baseline experimental [18F]FTT PET/CT scan prior to systemic therapy with radionuclide or chemotherapy. Up to 10 patients undergoing systemic therapy may undergo a second (optional) scan that will be performed approximately 1-21 days after therapy has started. The second scan is obtained to evaluate whether the initiation of systemic therapy alters [18F]FTT uptake. As this is a pilot study, only a limited number of patients are sought for the second scan.
88890837|NCT05630326||ESBL UTI|all infants with UTIs caused by ESBL producing organisms
88890838|NCT05630326||Non-ESBL UTI|all infants with UTIs caused by non-ESBL producing organisms
88890839|NCT05630326||ESBL UTI with COVID-19|all infants with UTIs caused by ESBL producing organisms with COVID-19 infection
88890840|NCT05630326||ESBL UTI without COVID-19|all infants with UTIs caused by ESBL producing organisms without COVID-19 infection
88890841|NCT05620901|Experimental|Treatment Arm|Dextenza insert intraoperatively for perioperative ocular inflammation and pain. These patients will not be prescribed topical steroid drops post-operatively
88890842|NCT05620901|Active Comparator|Control Arm|Prednisolone forte 1% steroid drop taper for 28 days post-operatively to treat perioperative ocular inflammation and pain; drops four times per day (QUID) on days 0-7, three times per day (TID) on days 7-14, twice per day (BID) on days 14-21 and once per day (QD) on days 21-28.
88890843|NCT05610995|Experimental|SENSIUM Group|Patients in the experimental group will be discharged with the device after an assessment on Day 1.
88890844|NCT05610995|No Intervention|ERAS standard Group|Patients in the control group will receive the usual ERAS (conventional hospitalization for clinicobiological monitoring).
88890845|NCT05602493|Experimental|test group (n=30) Soludronate® 0.7 mg/ml|"It will be applied on the fresh extraction socket for 15 min and then rinsed with sterile saline 3 time, 1 minute each rinse. After the extraction will be required a CBCT scan. The medication that will be prescribed for the patient will be Enantyum 25 mg (2-3 days) and in case of allergic patient Paracetamol 650 mg (2-3 days).~15 days later (-/+ 2 days), during the follow-up 1 the suture will be removed, the cicatrization of the surgical site evaluated and intraoral photos will be taken. The last follow-up (2) visit, 91 days later (-/+ 2 day) the follow-up 2 will take place. A CBCT scan and intraoral photos will be required."
88890846|NCT05602493|Placebo Comparator|control group (n=30) sterile saline|"It will be applied on the fresh extraction socket for 15 min and then rinsed with sterile saline 3 time, 1 minute each rinse. After the extraction will be required a CBCT scan. The medication that will be prescribed for the patient will be Enantyum 25 mg (2-3 days) and in case of allergic patient Paracetamol 650 mg (2-3 days).~15 days later (-/+ 2 days), during the follow-up 1 the suture will be removed, the cicatrization of the surgical site evaluated and intraoral photos will be taken. The last follow-up (2) visit will be 1,5 months after the intervention and will be optional for those cases showing redness, swelling or pain during the first follow up, 3,5 months later (-/+ 1 week) the end visit will take place. A CBCT scan and intraoral photos will be required at the end visit."
88890847|NCT05602467|Active Comparator|Treatment Group|A total of 32 sessions (2 sets of 16 sessions) of TPS will be delivered, each lasting 30 minutes. Each set includes 3 sessions per week in the first 2 weeks and then 1 session per week in the subsequent 10 weeks.
88890848|NCT05602467|Placebo Comparator|Control Group|The control group will be recruited with the same recruitment criteria. They would receive treatment-as-usual (TAU) in the outpatient clinic without TPS intervention given.
88890849|NCT05587010||Foot drop|Participants living with foot drop in either foot. Orthotic support devices will be compared within this cohort to assess their impact on gait biomechanics and clinical outcomes
88890850|NCT05586789|Experimental|Ranquilon|Study drug Ranquilon, tablets, 1 mg, 2 tablets 3 times a day (daily dose - 6 mg/day), daily, for 28 days
89192912|NCT05925712|Experimental|Crossover BAB|Group 1 starts using the ventilating suspension system (condition A), group 2 starts using non-ventilating suspension system (condition B) and then they cross-over to the other system, two times.
88890851|NCT05586789|Placebo Comparator|Placebo|Placebo, tablets, 2 tablets 3 times a day, daily, for 28 days
88890852|NCT05574127|Experimental|Older Adult Cancer Survivors (OACS) - Behavioral Activation (BA)|Older adult cancer survivors (OACS) will receive a Behavioral Activation intervention
88890853|NCT05574127|Experimental|Older Adult Cancer Survivors (OACS) - Supportive Psychotherapy (SP)|Older adult cancer survivors (OACS) will receive a Supportive Psychotherapy intervention
88890854|NCT05568550|Experimental|Arm 1 - Pembrolizumab and Olaparib|Patients with high-risk prostate cancer receiving combination therapy with Pembrolizumab and Olaparib.
88890855|NCT05568550|Experimental|Arm 2 - Pembrolizumab|Patients with high-risk prostate cancer receiving combination therapy with Pembrolizumab.
88890856|NCT05558956|Experimental|Low Dose|3 mCi dose of 68Ga-PSMA-11 (Illuccix) and a total body PET-CT scan for 4-6 min scan time.
88890857|NCT05558956|Experimental|High dose|7 mCi dose of 68Ga-PSMA-11 (Illuccix) and a total body PET-CT scan for 4-6 min scan time.
88890858|NCT05542849|Experimental|Arm A|
88890859|NCT05542849|Experimental|Arm B|
88890860|NCT05542056||Patients with newly prescribed thiazide or thiazide-like diuretic|As the study population of this observational study shall be as representative as possible all patients with a new thiazide or thiazide-like diuretic regardless of the indication, co-morbidities and co-medication can be included.
88890861|NCT05531552||Group I (control group)|"was collect data without any interference (without clinical pharmacy guidelines).~Subgroup: 10 outpatient, 25 inpatient, 15 patient in CCU."
88890862|NCT05531552||Group II (observation group)|application of clinical pharmacy guidelines and management CAD. Subgroup: 10 outpatient, 25 inpatient, 15 patient in CCU.
88922040|NCT05921370|Placebo Comparator|Placebo group (the control group)|Patients will receive Placebo for 3 days before their scheduled retrograde intrarenal surgery.
89192913|NCT05915546|Experimental|Emraclidine (Fasted then Fed)|Single oral dose of Emraclidine 15 mg tablet under fasted (without food) condition followed by fed condition in treatment period 1 and 2, respectively.
88890863|NCT05525299|Experimental|Intervention|A brief reminiscence-based life review with six themes to recall subjects' memory through the life review reminiscence intervention will be given. A total of six reminiscence chatting sessions (30-60 minutes per session) covering these themes will be conducted weekly.
88890864|NCT05525299|No Intervention|Control|The subjects allocated in the Control group will not receive any intervention.
88890865|NCT05515263|Experimental|Intervention snack|The intervention group will receive a snack food believed to be beneficial for immune function (high content of immunoregulatory nutrients).
88890866|NCT05515263|Placebo Comparator|Control snack|The control group will receive an isocaloric, commercially available snack food (low content of immunoregulatory nutrients).
88890867|NCT05515250|Other|Patient open label intervention arm|
88890868|NCT05510154|Experimental|Brief Advice|Brief Advice involves basic e-cigarette education and advice to switch.
88890869|NCT05510154|Experimental|Single Training|Single Training is the same as Brief Advice but includes one session of real-time training on how to puff on the e-cigarette.
88890870|NCT05510154|Experimental|Training to Competency|Training to Competency is the same as Single Training but includes three real-time training sessions rather than one.
88890871|NCT05508100|Experimental|Part A: IO-108 monotherapy dose confirmation|Patients with advanced or metastatic solid tumors will be enrolled and treated with IO-108, intravenously, every 21 days.
88890872|NCT05508100|Experimental|Part B: IO-108 + anti-PD-1 dose confirmation.|Patients will receive IO-108 in combination with with a fixed dose of pembrolizumab, intravenously, every 21 days; Patients will receive IO-108 in combination with with a fixed dose of tislelizumab, intravenously, every 21 days.
88890873|NCT05508100|Experimental|Part C: Dose expansion|Patients with advanced or metastatic solid tumors who meet the specific criteria will be enrolled into one of the cohorts.
88890874|NCT05505448|Experimental|Cohort 1 Mid IV Dose|Randomized 3:1 for single ascending dose
88890875|NCT05505448|Experimental|Cohort 2 Mid SC Dose|Randomized 3:1 for single ascending dose
88890876|NCT05505448|Experimental|Cohort 3 High IV Dose|Randomized 3:1 for single ascending dose
88890877|NCT05505448|Experimental|Cohort 4 High SC Dose|Randomized 3:1 for single ascending dose
88890878|NCT05505448|Experimental|Cohort 5 Higher IV Dose|Randomized 3:1 for single ascending dose
88890879|NCT05505448|Experimental|Cohort 6 Highest IV Dose|Randomized 3:1 for single ascending dose
88890880|NCT05505448|Experimental|Cohort 7 Low IV Dose|Randomized 3:1 for single ascending dose
88890881|NCT05505448|Experimental|Cohort 8 Low SC Dose|Randomized 3:1 for single ascending dose
88890882|NCT05501327|Experimental|Cohort A|"Injection of SLI-F06 on Treatment Day 0, immediately after wound closure:~Formulation buffer (control)~3.75 mg SLI-F06 total dose per wound (1X)~7.5 mg SLI-F06 total dose per wound (2X)~15 mg SLI-F06 total dose per wound (4X)"
88890883|NCT05501327|Experimental|Cohort B|"Injection of SLI-F06 on Treatment Day 0, immediately after wound closure and on Days 1, 2, 3, 4:~Formulation buffer (control)~3.75 mg SLI-F06 total dose per wound (1X)~7.5 mg SLI-F06 total dose per wound (2X)~15 mg SLI-F06 total dose per wound (4X)"
88890884|NCT05501327|Experimental|Cohort C|"Injection of SLI-F06 on Treatment Day 0, immediately after wound closure and then 3 hours after for wounds dosed twice:~Formulation buffer (control) once~7.5 mg SLI-F06 total dose per wound (2X) once~3.75 mg SLI-F06 dose per wound (1X) twice, total dose 7.5 mg~7.5 mg SLI-F06 total dose per wound (2X), total dose 15 mg"
88890885|NCT05498233|Other|RT-sequence|Group 1 (14 volunteers, RT sequence) will take 2 tablets of Diclectin in Period 1 and 2 tablets of Doxylamine + Pyridoxine in Period 2
88890886|NCT05498233|Other|TR-sequence|Group 2 (14 volunteers, sequence TR) will take 2 tablets of Doxylamine + Pyridoxine in Period 1 and 2 tablets of Diclectin in Period 2.
88890887|NCT05485285||retrospective analysis|A retrospective analysis of disease histories for the period from 2014 to 2021 was carried out. Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury.
88890888|NCT05485285||prospective study|Recruitment of patients for the prospective study was carried out in the period from 02.24.2022 to 05.24.2022
88890889|NCT05484297|Experimental|Treatment|Participants in the treatment arm will receive the intervention post cards
88890890|NCT05484297|Sham Comparator|Control|Participants in the control arm will receive the control post cards
88890891|NCT05476588|Active Comparator|Self-Administration followed by Interviewer-Administered|Screening and validation of assessment tool translated into Spanish
88890892|NCT05476588|Active Comparator|Interviewer-Administered followed by Self-Administration|Screening and validation of assessment tool translated into Spanish
88890893|NCT05476510|Active Comparator|Group M-TAPA = M-TAPA Block Group|Under aseptic conditions, a high-frequency linear probe will be placed on the costochondral angle in the sagittal plane. Then the probe will be slightly angled deeply to visualize the lower view of the perichondrium. We will perform M-TAPA with total of 60 ml (30 ml for each side) of %0,25 bupivacaine.
88890894|NCT05476510|Active Comparator|Group OSTAP = OSTAP Block Group|In the supine position, the transducer is placed in the subcostal region in an oblique plane, and a 15-20 cm needle is first inserted between the rectus abdominis and the transversus abdominis muscle and advanced towards the iliac crest in the interfascial plane. The block location will be confirmed with 5 ml of saline. After the block location is confirmed, a total of 30 ml + 30 ml of 0.25% bupivacaine (total of 60 ml for both sides) will be injected bilaterally.
88890895|NCT05476393|Active Comparator|Erector spinae block (Group ESPB)|ESP block will be applied in Group ESPB. The US probe will be placed longitudinally 2-3 cm lateral to the T5 transverse process. Three muscles from top to bottom; Trapezius at the top, rhomboid major in the middle, and the erector spina muscle at the bottom will be displayed over the hyperechoic transverse process. Using the in plane technique, the block needle will be advanced in the cranio-caudal direction and 5 ml of saline will be injected under the erector spina muscle and the block location will be confirmed. After the block location is confirmed, 40 ml of 0.25% bupivacaine will be administered (20 ml in each side).
88922041|NCT05919069|Experimental|Group 1|Participants with mild hepatic impairment (CP Class A, score of 5 or 6)
88922042|NCT05919069|Experimental|Group 2|Participants with moderate hepatic impairment (CP Class B, score of 7 to 9)
88922043|NCT05919069|Experimental|Group 3|Participants with severe hepatic impairment (CP Class C, score of 10 to 15)
89413449|NCT05023798||ATD Cohort 7|The next iteration of the sensor will be tested and results compared to the gold-standard laboratory measuring equipment. The prototype will be tested on a cohort of 3-5 patients.
89413450|NCT05023798||ATD Cohort 8|The next iteration of the sensor will be tested and results compared to the gold-standard laboratory measuring equipment. The prototype will be tested on a cohort of 3-5 patients.
89413451|NCT05023798||ATD Cohort 9|The next iteration of the sensor will be tested and results compared to the gold-standard laboratory measuring equipment. The prototype will be tested on a cohort of 3-5 patients.
89413452|NCT05023798||ATD Cohort 10|The next iteration of the sensor will be tested and results compared to the gold-standard laboratory measuring equipment. The prototype will be tested on a cohort of 3-5 patients.
89413453|NCT05038774|Experimental|Interventional group|GPs of the Interventional group will receive (1 day) face to face education with structured educational material on strategies of hypertension management by a senior cardiologist.
89413454|NCT05038774|Active Comparator|Control group|GPs of the Control group will receive print version of education material (Structured educational material) on strategies of structured hypertension management.
89413455|NCT02154126|Other|Accuracy assessment|
89413456|NCT05023408|Experimental|Intralesional Bleomycin|Intralesional Bleomycin has been given to palmo plantar warts. Generic name: Bleomycin Dose: 1mg/1ml (0.1%) Frequency: every 2 weekly for 6 weeks.
89413457|NCT05023408|Experimental|Cryotherapy|Cryotherapy has been given to palmo plantar warts. Frequency: every 2 weekly for 6 weeks
89413458|NCT02772978|Active Comparator|tolcapone arm|"This cognitive science study consists of a single arm in which all subjects receive both tolcapone and placebo in randomized, double-blind, counterbalanced, crossover fashion"
88890896|NCT05476393|Active Comparator|Thoracal paravertebral block group (Group TPVB)|After visualizing the T5 spinous process sagittally with the US probe, the probe will be placed 2-3 cm laterally. The ribs and transverse processes will be displayed as hyperechoic structures. Superiorly, the costotransverse ligament and anteriorly the pleura will be visualized. With the in-plane technique, the block needle will be advanced in the cranio-caudal direction until the costotransverse ligament is passed. 5 ml of saline will be injected and the block location will be confirmed. After confirming the location of the needle, negative aspiration is performed, and after observing the absence of CSF, blood and air, 40 ml of 0.25% bupivacaine will be administered, and it will be seen that the pleura is pushed down as the drug is administered (20 ml in each side).
88890897|NCT05473026|Experimental|Gratitude Intervention|"Each participant will receive a gratitude journal (paperback or electronic journal based on preference) for eight weeks and will have the following journaling prompt to complete at least twice a week: There are many things in our lives, both large and small, that we might be grateful about. Think back over the day and write down on the line below all that you are grateful for today (maximum six reasons). The educational goal-setting component will be drawn from the American Cancer Society's Nutrition, Physical Activity, and Cancer toolkit. Participants will be able to choose the order in which they complete the goal-setting modules. Both exercises will be administered daily over eight weeks."
88890898|NCT05473026|No Intervention|Attention Control|"Each participant will receive a journal (paperback or electronic journal based on preference) Participants will receive the following general journaling prompt to complete at least twice a week: What are some memorable events that happened to you today, big, or small (maximum six memories). Write a brief statement about it."
88890899|NCT05472142|Active Comparator|Control Cluster|Clinics in the control group will only be provided with health information technology; they will not participate in the 12-month intervention which incorporates health information technology and practice facilitation.
88890900|NCT05472142|Experimental|Intervention Cluster|Clinics in the intervention group will participate in the 12-month intervention which incorporates health information technology and practice facilitation.
88890901|NCT05472077|Experimental|Participants with COVID-19 Symptom(s)|Participants 4 years old or older with at least one COVID-19 symptom being tested for the virus
88922044|NCT05919069|Experimental|Group 4|Participants with normal hepatic function matched on a group level regarding age, body weight, and sex to the impaired groups
88922045|NCT05916937|Active Comparator|omalizumab 300 mg every six weeks|20 subjects are randomized to receive omalizumab 300 mg every six weeks from week 12 to week 36.
89413459|NCT02772978|Placebo Comparator|placebo arm|"This cognitive science study consists of a single arm in which all subjects receive both tolcapone and placebo in randomized, double-blind, counterbalanced, crossover fashion"
89413460|NCT03090490|Experimental|Intervention group|Antipsychotic treatment discontinuation (DT)
89413461|NCT03090490|Active Comparator|Control group|Maintenance antipsychotic treatment (MT)
89413462|NCT05038696|Experimental|Single arm|Single arm Phase I Clinical Trial
89413463|NCT05300971|Experimental|Heat therapy|Hot water immersion ~3x per week for 12 weeks
89413464|NCT05300971|Sham Comparator|Thermoneutral water immersion|Thermoneutral water immersion ~3x per week for 12 weeks
89413465|NCT03543228||MyoStrain|During standard chemotherapy and/or targeted treatment for breast cancer or lymphoma, MyoStrain will be used during standard cardiac magnetic resonance imaging to evaluate the change in myocardial contraction regionally and globally to detect cardiotoxicity and management of myocardial dysfunction.
89413466|NCT03090334|Experimental|De-escalation|"In this group, investigators will manage the antifungal therapy according to the BG levels as follows:~antifungal therapy will be stopped immediately after the BG response in case of serum BG <80 pg/ml in presence of clinical stability (CS);~antifungal therapy will be continued until further BG determination, both for BG levels between 80-200 pg/ml and for BG <80 pg/ml in patients without CS. In these cases, if the following BG value is <80 pg/ml antifungal therapy will be stopped independently from the CS achievement.~antifungal therapy will be continued until day 10 for BG levels >200 pg/ml"
89413467|NCT03090334|No Intervention|Standard of care|"In this group antifungal treatment will be continued until clinician's decision.~Investigators will be blinded to the BG levels of patients enrolled in this arm, The BG results will be faxed directly to the coordinating center."
89413468|NCT03090178|Experimental|Patients|"Wear a wristband actigraph while sleeping and answer to quality of questionnaires on a smartphone application:~sleep diary~Pruritus~dermatology life quality index"
89413469|NCT03090178|Active Comparator|Healthy Volunteers|"Wear of a wristband actigraph while sleeping and answer to quality of questionnaires on a smartphone application:~sleep diary~Pruritus~dermatology life quality index"
89413470|NCT05290363|Experimental|Patients with axial spondyloarthritis participating in the study|People with axial spondylarthritis (60 participants),
89413471|NCT05290363|Experimental|Patients with peripheral spondyloarthritis participating in the study|People with peripheral spondylarthritis (30 participants).
89413472|NCT03092830||1-arm, 500 participates|Molecular testing of DNA/RNA from skin tumors, SCC/BCC
89413473|NCT00104052|Experimental|PEG-Intron alfa 2b (PEG2b) plus REBETOL (RBV)|PEG2b 1.5 μg/kg/wk given subcutaneously (once weekly) and RBV 400-1200 mg/day by mouth divided in 2 daily doses (administered twice daily with food, dosed 12 hours apart) for 48 weeks. Subjects treated up to 48 weeks and followed for additional 24 weeks after the end of treatment (total of 72 weeks study participation).
89413474|NCT03092596|Experimental|Patient-administered screening tool|Patients will complete a screener for alcohol and drug misuse.
89413475|NCT03092596|Experimental|Patient health navigator-administered screening tool|Patient health navigators will administer a screener for alcohol and drug misuse to patients.
89413476|NCT03092596|Experimental|Patient health navigator-assisted linkage to treatment|Patient health navigators will be trained in motivational interviewing to engage patients about linkage to substance abuse treatment.
89413477|NCT03092596|No Intervention|Treatment as usual|Patients will receive standard care.
89413478|NCT04434508|Active Comparator|laparoscopic right hemicolectomy with CME and central v|laparoscopic right hemicolectomy with CME and central v
88890902|NCT05471336|Experimental|Enteral Feeding during Therapeutic Hypothermia and Rewarming|Trophic feeds of expressed breast milk or donor breast milk at a volume of between 10-15 mL/kg/day will be ordered and administered to the patient via orogastric or nasogastric tube. Trophic feeds will be continued at the same volume for the duration of the hypothermia treatment (72 hours) and the rewarming period (8-12 hours). Once the patient is fully rewarmed, feeds will be advanced as appropriate according to the clinical judgment of the primary medical team as is the current standard of care.
88890903|NCT05467735|Experimental|Interventional: Compression Arm|Patients in the Compression group would be subject to application of standardized lower extremity, thigh-high, elastic compression stockings within 24 hours of admission. Appropriate size of the stockings would be based on calf circumference, thigh circumference and leg length. The compression would be applied throughout the entire duration of hospitalization, provided the patient is able to tolerate it. Daily thorough skin checks for any cutaneous defects or lesions will be performed, and mobilization encouraged.
88890904|NCT05467735|No Intervention|Control Arm|The inflatable sleeves of a sequential compression device would be placed in bilateral lower extremities of patients, but the device would not be turned on, thus no external pressure would be applied.
88890905|NCT05467215|Experimental|Hyperoxia followed by room air|Group 1 will receive oxygen (99%) in Phase 1, and room air (placebo) in Phase 2. Each phase will consist of 2 experiments. In Phase 1, the first experiment will test skin sensation using von Frey Hairs, while the second experiment will test a cutaneous reflex. In Phase 2, the first experiment will test the cutaneous reflex, while the second experiment will test skin sensation with von Frey Hairs. Both high oxygen and room air will be delivered through a face mask. The flow rate will be 10 litres/min for a 2-min period. Participants and experimenters will be blinded to the intervention. Measures will be taken before and after each exposure. In this way, each participant will be involved in four experimental sessions with a minimum of 2-week intervals between every testing session. Each experimental session will take approximately 1.5 to 2 hours. A total duration of involvement in the study is a minimum of 7 weeks.
88890906|NCT05467215|Placebo Comparator|Room air followed by hyperoxia|Group 2 will receive room air (placebo) in Phase 1, and oxygen (99%) in Phase 2. Each phase will consist of 2 experiments. In Phase 1, the first experiment will test the cutaneous reflex, while the second experiment will test skin sensation with von Frey Hairs. In Phase 2, the first experiment will test skin sensation using von Frey Hairs, while the second experiment will test a cutaneous reflex. Both high oxygen and room air will be delivered through a face mask approved by Health Canada. The flow rate will be 10 litres/min for a 2-min period. Participants and experimenters will be blinded to the intervention. Measures will be taken before and after each exposure.In this way, each participant will be involved in four experimental sessions with a minimum of 2-week intervals between every testing session. Each experimental session will take approximately 1.5 to 2 hours. A total duration of involvement in the study is a minimum of 7 weeks.
89192914|NCT05915546|Experimental|Emraclidine (Fed then Fasted)|Single oral dose of Emraclidine 15 mg tablet under fed condition followed by fasted (without food) condition in treatment period 1 and 2, respectively.
89192915|NCT05912283|Experimental|Synthetic Nitrile Condoms (53mm)|53mm width synthetic nitrile condoms
89192916|NCT05912283|Experimental|Synthetic Nitrile Condoms (56mm)|56mm width synthetic nitrile condoms
89413479|NCT04434508|Active Comparator|open right hemicolectomy with CME and central v|open right hemicolectomy with CME and central v
89413480|NCT05038072|Experimental|4 mg Triamcinolone Acetonide (TA)/ Suprachoriodal Injection|Suprachoroidal injection of 4 mg in 100 μL of TA was administered as a single injection.
89413481|NCT02777970|Experimental|Tramadol/Dexketoprofen|"Tramadol Hydrochloride/Dexketoprofen Trometamol 75mg/25mg film-coated tablet oral single dose;~Placebo matching Tramadol Hydrochloride/Paracetamol 75 mg/650mg, as 2 x [37.5mg/325mg] film-coated tablets, oral single dose."
89413482|NCT02777970|Active Comparator|Tramadol/Paracetamol|"Tramadol Hydrochloride/Paracetamol 75 mg/650 mg, as 2 x [37.5mg/325mg] film-coated tablets, oral single dose;~Placebo matching Tramadol Hydrochloride/Dexketoprofen Trometamol 75mg/25mg film-coated tablet oral single dose.~."
89413483|NCT02777970|Placebo Comparator|Placebo|"Placebo matching one film-coated tablet of Tramadol Hydrochloride/Dexketoprofen Trometamol 75mg/25mg oral single dose;~Placebo matching two film-coated tablets of Tramadol Hydrochloride/Paracetamol 37.5mg/325mg oral single dose."
89413484|NCT03037489|Experimental|MIV-711|MIV-711 for a total of 26 weeks
89005517|NCT04569019||Health care workers|The study will be conducted among UCKWUM healthcare professionals, i.e. doctors, nurses, paramedics, laboratory workers, pharmacists, and administration workers. Based on previous research, the group should include at least 200 participants
89005518|NCT04569214|Placebo Comparator|A - Placebo Control|4 tablets of placebo
89005519|NCT04569214|Experimental|B - PAZ320 Low Dose|2 tablets of PAZ320 and 2 tablet of placebo
88812958|NCT03837782|No Intervention|open surgery|"Patients were randomized to undergo open radical resection (laparotomy). Each participating site required accreditation by the trial management committee to ensure proper surgical technique during minimally invasive surgery.~Patients were eligible if they had colorectal adenocarcinoma; had a disease stage of I (T1,T2), IIABC (T3-T4ab) or IIIABC (TanyN1-2) according to the staging system of NCCN; and had an Eastern Cooperative Oncology Group (ECOG) performance-status score of 0 or 1 (on a 5-point scale, with higher values indicating greater disability).~Exclusion criteria included a history of abdominal or pelvic radiotherapy, or evidence of metastatic disease on positron-emission tomography-computed tomography, magnetic resonance imaging, or computed tomography."
88812959|NCT01554371|Experimental|Phase 1b: 1.1 mg/m2 Eribulin Combination w/ Cyclophosphamide (Solid Tumor Escalation Cohort)|Dose escalation cohort will include all patients with solid tumors. Eribulin mesylate 1.1 mg/ m2 on days 1 and 8 followed by cyclophosphamide 600 mg/m2 on day 1 of a 21-day cycle.The highest dose level at which no more than one of six subjects experience DLT defines the MTD
88812960|NCT01554371|Experimental|Phase 1b: 1.4 mg/m2 Eribulin Combination w/ Cyclophosphamide (Solid Tumor Escalation Cohort)|Dose escalation cohort will include all patients with solid tumors. Eribulin mesylate 1.4 mg/ m2 on days 1 and 8 followed by cyclophosphamide 600 mg/ m2 on day 1 of a 21-day cycle.The highest dose level at which no more than one of six subjects experience DLT defines the MTD
88812961|NCT01554371|Experimental|Phase II: Eribulin Combination w/ Cyclophosphamide (Breast Cancer Expansion Cohort)|Dose-expansion cohort will enroll patients with advanced breast cancer only after Phase Ib enrollment has been concluded. The MTD of Eribulin mesylate will be administered on days 1 and 8 followed by cyclophosphamide 600 mg/m2 on day 1 of a 21-day cycle.
88812962|NCT03219398|Active Comparator|8-10 mmHg|Patients receive lower pneumoperitoneum pressure
88812963|NCT03219398|Active Comparator|12-14 mmHg|Patients receive higher pneumoperitoneum pressure
88812964|NCT01450787||diabetics|diabetics
88812965|NCT01450787||non diabetics|non diabetics
88812966|NCT01834352|Active Comparator|Walnut protein flour|Walnut protein flour that is ingested in gradually increasing amounts up to a maintenance dose.
88812967|NCT01834352|Placebo Comparator|Oat flour|Oat flour administered in identical increasing amounts as the active walnut protein flour.
88812968|NCT01451411|Experimental|Conivaptan hydrochloride|
88812969|NCT01451411|Placebo Comparator|Placebo|
88812970|NCT01834430|Experimental|EN group|The EN group gradually restored enteral nutrition, while the PN group continued to receive parenteral nutrition treatment. Both groups received between 20 to 25 kcal/kg/day and 1.5 g/kg/day of protein. Because of the low volume, concentration, and calorie amount, on the first day, tube feeding utilized 500 ml with the speed of 30 ~ 50 ml/h. On the second day, tube feeding utilized 1000 ml with the speed of 60 ~ 80 ml/h. On the third day, tube feeding utilized 1500 ~ 2000 ml with the speed of 100 ~ 120 ml/h. If enteral nutrition could not meet a patient's caloric requirements, PN supplement was started on the fourth day. The required calories and protein for each individual in the two groups was assumed to be achieved after three days of therapy. The PN group continued to receive parenteral nutrition.
88812971|NCT01834430|No Intervention|parenteral nutrient group|
88812972|NCT03837938|Experimental|Levopront® syrup 30 mg/5 ml|Levopront® (levodropropizine) syrup 30 mg/5 ml 10 ml t.i.d. for 7 days The study drugs will be taken t.i.d. (with the interval of not less than 6 hours, between meals) during 7 days.
89413485|NCT02150616|Experimental|Moderate altitude sojourn|Sojourn at moderate altitude (2048 m)
89413486|NCT02150616|Experimental|Low altitude sojourn|Sojourn at low altitude (490 m, baseline)
89413487|NCT02150616|Active Comparator|Oxygen|Oxygen administration via a nasal cannula at a rate of 3 L/min during nights spent at 2048 m
89413488|NCT02150616|Placebo Comparator|Sham oxygen (room air)|Sham oxygen (room air) administration via a nasal cannula at a rate of 3 L/min during nights
89413489|NCT01336023|Experimental|IDeg|
89413490|NCT01336023|Experimental|IDegLira|
89413491|NCT01336023|Experimental|Lira|
89413492|NCT05151445||mHealth dietary app + health coaching intervention|A feasibility study will be utilized to establish the recruitment, retention, and adherence with post-kidney transplant recipients using a consumer-based mHealth dietary app + health coaching.
89413493|NCT02255292|Experimental|cannabidiol (CBD)|Patients with confirmed solid cancer, after progression of all the available standard therapy or unfit to standard therapy according to oncologist's view, measurable disease as determined by RECIST using CT, life expectancy of at least 6 months, Eastern Cooperative Oncology Group (ECOG) performance status < or = 2 and aged 18 years old and more will be included in the current study.
89413494|NCT03092206|Experimental|Group 1|F/TAF ; oral; Dose: 25/200 mg; Frequency: QD
89005520|NCT04569214|Experimental|C - PAZ320 High Dose|4 tablet of PAZ320
89005521|NCT00237978|Active Comparator|1|VIS and wIRA
89192917|NCT05912283|Active Comparator|Control Latex Condom|Commercial natural rubber latex condom
89413495|NCT03092206|Experimental|Group 2|Group 2: E/C/F/TAF; oral; Dose: 150/150/200/10 mg; Frequency: QD
89413496|NCT03092206|Experimental|Group 3|Group 3: R/F/TAF; oral; Dose: 25/200/25 mg; Frequency: QD
88812973|NCT03837938|Active Comparator|Libexin® 100 mg tablets|"Libexin® (prenoxdiazine) 100 mg tablets~1 tablet t.i.d. for 7 days."
88812974|NCT01554683|Active Comparator|High Dose Levetiracetam|Low Dose Levetiracetam administration via IV infusion over 20 min
88812975|NCT01554683|Active Comparator|Low Dose Levetiracetam|High Dose Levetiracetam administration via IV infusion over 20 min
88812976|NCT01554683|Placebo Comparator|Placebo administration|Saline administration via IV infusion over 20 min
88812977|NCT04380584||I|30 patients with type 2 DM with nephropathy
88812978|NCT04380584||II|30 type 2 DM without nephropathy
88812979|NCT04380584||III|30 non DM as control group
89005522|NCT00237978|Active Comparator|2|VIS, wIRA and Adapalen
89413497|NCT02154282|Experimental|ipod games|Administered ipod games with cognitive testing before and after
89413498|NCT05289427|Experimental|TIPS Block|Group TIPS; patients will receive ultrasound guided triple injection peri-sartorius block preoperatively before surgical incision
89413499|NCT05289427|Active Comparator|FNB|Group FNB; patients will receive femoral nerve block (FNB) before surgical incision
89413500|NCT03092440||"Nursing students group"|nursing students
89413501|NCT03092440||"New nurses group"|Nurses with < 2 years experience
89413502|NCT03092440||"Expert nurses group"|Intensive nurses (with ≥ 4 years experience post graduate)
89413503|NCT05017714|Experimental|Active plus SOC|
89413504|NCT05017714|Placebo Comparator|Placebo plus SOC|
88890907|NCT05457881|Experimental|Protein-calorie restriction|Four day dietary intervention immediately before surgery of Scandi-Shake [any of 4 flavors - vanilla, strawberry, banana cream, and caramel] mixed with almond milk (85 grams Scandi-Shake mix to 240 cc almond milk) calculated individually for a total daily volume to achieve 30% caloric restriction and 70% protein restriction, based on gender, age, height, weight, and activity level.
88890908|NCT05457881|No Intervention|Control|Ad libitum diet for four days immediately before surgery
88890909|NCT05445518|Experimental|Jump Start Plus COVID Support (JS+CS) Group|Participants in this group will receive the Jump Start Plus COVID Support intervention for 24 months.
88890910|NCT05445518|Active Comparator|Healthy Caregivers-Healthy Children (HC2) Control Group|Participants in this group will receive the Healthy Caregivers-Healthy Children intervention for 24 months.
88890911|NCT05434000|Other|Children with sickle cell anaemia and abnormal TCD values (200cm/s)|The children identified with abnormal TCD values will be given hydroxyurea and followed for one year
88890912|NCT05433571|Experimental|Myopes - Against the Rule Sequence 1|Eligible subjects that are habitual contact lens wearers will be randomized to the Myope, against-the-rule-astigmatism, (LOW/HIGH DC) sequence and wear two different study lens designs one at a time bilaterally over 2 wear periods.
88890913|NCT05433571|Experimental|Myopes - Against the Rule Sequence 2|Eligible subjects that are habitual contact lens wearers will be randomized to the Myope, against-the-rule-astigmatism, (HIGH/LOW DC) sequence and wear two different study lens designs one at a time bilaterally over 2 wear periods.
88890914|NCT05433571|Experimental|Myopes - With the Rule Sequence 1|Eligible subjects that are habitual contact lens wearers will be randomized to the Myope, with-the-rule-astigmatism, (LOW/HIGH DC) sequence and wear two different study lens designs one at a time bilaterally over 2 wear periods.
88890915|NCT05433571|Experimental|Myopes - With the Rule Sequence 2|Eligible subjects that are habitual contact lens wearers will be randomized to the Myope, with-the-rule-astigmatism, (HIGH/LOW DC) sequence and wear two different study lens designs one at a time bilaterally over 2 wear periods.
88890916|NCT05433571|Experimental|Hyperopes - Against the Rule Sequence 1|Eligible subjects that are habitual contact lens wearers will be randomized to the Hyperope, against-the-rule-astigmatism, (LOW/HIGH DC) sequence and wear two different study lens designs one at a time bilaterally over 2 wear periods.
88890917|NCT05433571|Experimental|Hyperopes - Against the Rule Sequence 2|Eligible subjects that are habitual contact lens wearers will be randomized to the Hyperope, against-the-rule-astigmatism, (HIGH/LOW DC) sequence and wear two different study lens designs one at time bilaterally over 2 wear periods.
88890918|NCT05433571|Experimental|Hyperope - With the Rule Sequence 1|Eligible subjects that are habitual contact lens wearers will be randomized to the Hyperope, with-the-rule-astigmatism, (LOW/HIGH DC) sequence and wear two different study lens designs one at a time bilaterally over 2 wear periods.
88890919|NCT05433571|Experimental|Hyperope - With the Rule Sequence 2|Eligible subjects that are habitual contact lens wearers will be randomized to the Hyperope, with-the-rule-astigmatism, (HIGH/LOW DC) sequence and wear two different study lens designs one at a time bilaterally over 2 wear periods.
88890920|NCT05433480|Experimental|experimental group|Intervention Drug: BPI-16350, Fulvestrant
88890921|NCT05433480|Placebo Comparator|control group|Intervention Drug: Placebo, Fulvestrant
88890922|NCT05432674|Experimental|Digital Fall Prevention|Subjects will participate in Digital Fall Prevention intervention for 12 weeks
88890923|NCT05428735|Active Comparator|Portal Vein Embolization (PVE) alone - (control arm)|Portal Vein Embolization (PVE) alone
88890924|NCT05428735|Experimental|Combined Portal and Hepatic Vein Embolization (PVE/HVE) - (interventional arm)|Combined Portal and Hepatic Vein Embolization (PVE/HVE) - (interventional arm)
88890925|NCT05428215|Active Comparator|PO then SL|Subjects will administer 17-beta-estradiol orally (PO) for Study Day 1-14, followed by administration of 17-beta-estradiol sublingually (SL) for Study Day 15-28.
89005523|NCT00237978|Active Comparator|3|Adapalen
89005524|NCT04568941|Experimental|Preoperative Vacuum-Assisted Biopsy|Preoperative vacuum-assisted biopsy was performed within 10 days before final surgery. The tumor were excised almost.
89413505|NCT02254980|Experimental|Vitamin-E group|Vitamin-E diffused polyethylene
89413506|NCT02254980|Active Comparator|Control group|Standard polyethylene
89413507|NCT00001345||1|Members of families that have had relatives diagnosed with a disease of mineral metabolism. Participants will be asked to give blood samples for DNA extraction.
89413508|NCT05017636|Active Comparator|Treatment groupThorck Shock Wave Ibramed (terapia ESWT)- fat cell death|The shock wave treatment was performed on the left side of the abdomen
89413509|NCT05017636|No Intervention|Without intervention.|no shockwave treatment was performed on the right side of the abdomen, which was specified as a control group no shockwave treatment was performed on the right side of the abdomen, which was specified as a control group without intervention.
89413510|NCT02150694|Experimental|Apelin agonist infusion|Studies to measure change in blood flow in response to apelin agonists (1/10/100nmol) using forearm venous occlusion plethysmography and Aellig hand vein technique.
88890926|NCT05428215|Active Comparator|SL then PO|Subjects will administer 17-beta-estradiol sublingually (SL) for Study Day 1-14, followed by administration of 17-beta-estradiol orally (PO) for Study Day 15-28.
89192918|NCT05900752|Active Comparator|QiMeiYan Probiotics|"1.5g/ sachet, containing the following ingredients:~Bifidobacterium animalis subsp. lactis V9~Lactobacillus casei Zhang~Lactobacillus plantarum P-9~Lactobacillus plantarum CCFM1143~Xylo-oligosaccharide~Maltodextrin~Resistant Dextrin~Blueberry powder"
88890928|NCT05417646|Active Comparator|HNF1A-MODY - SGLT2 inhibition|3-hour hyperglycemic clamp with inhibition of SGLT2 (single-dose empagliflozin 25 mg two hours before clamp)
88890929|NCT05417646|Placebo Comparator|HNF1A-MODY - Placebo|3-hour hyperglycemic clamp without inhibition of SGLT2 (placebo comparator to empagliflozin)
88890930|NCT05417646|Active Comparator|Type 2 Diabetes - SGLT2 inhibition|3-hour hyperglycemic clamp with inhibition of SGLT2 (single-dose empagliflozin 25 mg two hours before clamp)
88890931|NCT05417646|Placebo Comparator|Type 2 Diabetes - Placebo|3-hour hyperglycemic clamp without inhibition of SGLT2 (placebo comparator to empagliflozin)
88890932|NCT05415943|Experimental|Women at high risk of breast cancer|Women with a confirmed diagnosis of breast cancer by thick-needle biopsy and known HER2 receptor expression status, referred for surgical treatment.
88890933|NCT05414903||Children with Normal Hearing|typically developing children with normal hearing (thresholds ≤ 20 dB HL from 0.25 to 8 kHz) age-matched to the children with hearing loss
88890934|NCT05414903||Children with hearing loss and normal vestibular function|Children with hearing loss will have a pure-tone average (PTA) > 65 dB and normal vestibular evaluation.
88890935|NCT05414903||children with hearing loss and vestibular loss|Children with hearing loss will have a pure-tone average (PTA) > 65 dB and and varying degree of vestibular loss (i.e., unilateral or bilateral).
88890936|NCT05412173|Other|RT-sequence|The volunteers will take 1 capsule (200 mg) of Lagevrio (R), 200 mg capsules (Merck Sharp & Dohme (UK) Limited, UK) in Period 1, and 1 capsule (200 mg) of Molnupiravir (T), 200 mg capsules (Valenta Pharm, Russia) in Period 2.
88890937|NCT05412173|Other|TR-sequence|The volunteers will take 1 capsule (200 mg) of the drug Molnupiravir (T), capsules, 200 mg (Valenta Pharm JSC, Russia) in Period 1, and 1 capsule (200 mg) of the drug Lagevrio (R), capsules, 200 mg (Merck Sharp & Dohme (UK) Limited, UK) in Period 2.
88890938|NCT05407337|Experimental|Experimental group|Beneficiaries of NET therapy + standard Sindiane program management.
88890939|NCT05407337|No Intervention|Control group|Beneficiaries of the standard care of the Sindiane program.
88890940|NCT05403268|Sham Comparator|Usual Care|Usual care group. Participants undergo twice daily DeltaScan measurements in addition to usual care. An adapted device is used, that masks the measurement result (it generates a QR-code, that is scanned into the patient data management system). The results will be unblinded one enrollment is complete.
89005525|NCT04568941|Experimental|Preoperative Core Needle Biopsy|Preoperative core needle biopsy was performed within 10 days before final surgery. The needle biopsy were performed with 3 needles.
89413511|NCT02150694|Experimental|Apelin receptor antagonist infusion|Aellig hand vein technique will be used to investigate the change in vein diameter in response to an apelin blocking agent
89413512|NCT02150694|Experimental|Apelin agonist/antagonist co-infusion|Forearm blood flow study to measure blood flow by forearm venous occlusion plethysmography following intraarterial infusion of apelin receptor agonists and antagonist.
89413513|NCT05281003|Experimental|Pembrolizumab + Chemo|"Neoadjuvant setting (Pembrolizumab in combination with chemotherapy): Up to 4 cycles concurrent administrations of (1) Paclitaxel, which are administrated intravenously at 150 mg/m^2 dosage on Day 1 of each 3-week cycle; (2) Cisplatin, which are administrated intravenously at 80 mg/m^2 dosage on Day 1 of each 3-week cycle; (3) Pembrolizumab, which are administrated intravenously at 200 mg dosage on Day 1 of each 3-week cycle.~Adjuvant setting (Pembrolizumab in combination with chemotherapy): All participants who are assessed as ineligible or unnecessary for surgery after neoadjuvant treatment may be eligible for up to an additional 17 cycles (approximately 1 year) of Pembrolizumab treatment in combination with chemotherapy."
89413514|NCT05017792|Other|1- Before vaccination:|"To detect:~COVID-19 IgG/IgM Rapid Test~COVID-19 IgG/IgM by quantitative method(ELISA).~D-dimer"
89413515|NCT05017792|Other|2-7 days after the first dose|Measuring D-dimer
89413516|NCT05017792|Other|3-Before the second dose:|To detect IgG and IgM To detect the level of Covid-19 Ig G antibodies titer in the blood, Quantitative Ig G titer should be measured. To detect the response of the immune system to the vaccine.
89413517|NCT05017792|Other|4-After 3 months from the second dose:|To detect the level ofCovid-19 Ig G antibodies titer in the blood, Quantitative Ig G titer should be measured. To detect the response of the immune system to the vaccine.
89413518|NCT05017792|Other|5-After 6 months from the second dose:|To detect the level ofCovid 19 Ig G antibodies titer in the blood, Quantitative Ig G titer should be measured. To detect the response of the immune system to the vaccine.
89413519|NCT03039283||Nucleus CI532 cochlear implant|
89413520|NCT02150772|Other|Shear Wave Elastography|All included patients have SWE performed
89413521|NCT03089476|Other|High Risk Atopic Infants|Infants, who are at high risk of atopy, which will be determined by a validated questionnaire, will be enrolled. Infants will undergo skin tape stripping (STS), transepidermal water loss assessment (TEWL), bacterial swabs, and parental questionnaires at each visit (3 visits total). At the latter 2 visits, infants will also undergo skin prick testing to evaluate for food sensitization.
89413522|NCT03089476|Other|Atopic Adults|Parents of infants enrolled in the study will undergo skin tape stripping (STS), transepidermal water loss assessment (TEWL), and complete questionnaires at the first visit.
89413523|NCT02158026||infertility without polycystic ovarian syndrome|1000 women with infertility without polycystic ovarian syndrome who are already decided to be treated with ICSI will be recruited
89413524|NCT02158104||Latent trigger point in the upper trapezius muscle|
89413525|NCT05037604||Cases|Patients diagnosed with dermatoporosis. A clinical history, physical examination, and application of a previously validated diagnostic self-questionnaire were performed.
88922046|NCT05916937|Active Comparator|omalizumab 300 mg every four weeks|20 subjects are randomized to receive omalizumab 300 mg every four weeks from week 12 to week 36.
89192919|NCT05900752|Placebo Comparator|Placebo product|"1.5g/sachet, containing the following ingredients:~Maltodextrin~Blueberry powder"
89413526|NCT05037604||Control|Patients not diagnosed with dermatoporosis. A clinical history, physical examination, and application of a previously validated diagnostic self-questionnaire were performed.
89413527|NCT02158182|Experimental|lactulose|
89413528|NCT02158182|Experimental|L-ornithine L-aspartate|
89413529|NCT02158182|Experimental|Rifaximin|
88812980|NCT01452191|Active Comparator|Injury Prevention Briefing and facilitation|Children's Centres will be given an Injury Prevention Briefing which offers guidance on best evidence on reducing fire related injuries in the home, and facilitation by the research team to support implementation of the IPB
88812981|NCT01452191|Active Comparator|Injury Prevention Briefing only|Children's Centres will be given an Injury Prevention Briefing (IPB) , which offers guidance on best evidence on reducing fire related injuries in the home.
88812982|NCT01452191|No Intervention|Usual Care|
88812983|NCT00905060|Experimental|Protein Peptide-Complex (HSPPC-96)|Patients will receive 4 weekly injections of HSPPC-96 followed by a 5th vaccine injection on the same day of the start of maintenance temozolomide administered 2 weeks (+ 4 days) following vaccine administration #4 on the same day of the start of maintenance temozolomide (Day 36). Monthly vaccine injections will then begin on day 21 (+/- 7 days) of the first 28 day temozolomide cycle (Day 56 of the study), 3 weeks following vaccine administration #5 and will continue every 28 days until depletion of vaccine or progression.
88812984|NCT01535573|Active Comparator|Citalopram low dose|Citalopram 20 mg
88812985|NCT01535573|Active Comparator|Citalopram high dose|Citalopram 40 mg
89413530|NCT02158182|Placebo Comparator|Placebo|
89413531|NCT02033187|Experimental|Chlorhexidine bathing|Patients in an ICU randomized to treatment arm 1 will be bathed with single use, no rinse, disposable cloths impregnated with 2% chlorhexidine gluconate solution (Sage® 2% Chlorhexidine Gluconate Cloths). Bathing of the skin of the arms, chest, abdomen, back, both legs, perineum, and buttocks will be performed daily and as needed after patients become soiled. The face and neck will not be bathed in this manner but will be bathed with water-moistened washcloths. All other infection control and cleaning procedures will be performed per the current practice in each intensive care unit.
88812986|NCT01535573|Placebo Comparator|Placebo|Placebo
88812987|NCT01452425|Experimental|Tourniquet|Inflation of a tourniquet
88812988|NCT00905450|Experimental|BOL-303242-X|BOL-303242-X (Mapracorat)
88812989|NCT00905450|Placebo Comparator|Vehicle|Vehicle for BOL-303242-X (Mapracorat)
88812990|NCT01536197||Gastric Bypass|morbidly obese subjects undergoing gastric bypass surgery
88812991|NCT01536197||Gastric banding|morbidly obese subjects undergoing laparoscopic gastric banding surgery
88812992|NCT01536197||Sleeve gastrectomy|morbidly obese subjects undergoing sleeve gastrectomy surgery
88812993|NCT01834508|Other|Treatment group|
88813988|NCT02462928|Experimental|Abicipar Pegol 2 mg (2Q8)|Abicipar pegol 2 mg was administered to the study eye by intravitreal injection on Day 1, Week 4, Week 8 and every 8 weeks (2Q8) thereafter through Week 96. Scheduled visits occurred every 4 weeks. To maintain masking, sham was administered to the study eye at scheduled visits where abicipar was not administered.
89413532|NCT02033187|Active Comparator|Non-chlorhexidine bathing|Patients in an ICU randomized to treatment arm 2 will be bathed with single use, no rinse, disposable cloths that do not contain chlorhexidine gluconate solution (Sage Comfort Bath® Cleansing Washcloths). Bathing of the skin of the arms, chest, abdomen, back, both legs, perineum, and buttocks will be performed daily and as needed after patients become soiled. The face and neck will not be bathed in this manner but will be bathed with water-moistened washcloths. All other infection control and cleaning procedures will be performed per the current protocols in each intensive care unit.
89413533|NCT05037838||Patient undergoing a liver transplantation|Patients undergoing a liver transplantation and able to have a transesopahageal ultrasound
89413534|NCT02154360|Experimental|Aprepitant|"Subjects will add 375 mg daily dosing of aprepitant (Emend®) to their current antiretroviral therapy for 28 days.~6 participants will be receiving an antiretroviral regimen containing atazanavir/ritonavir (300/100 mg) daily plus two other antiretrovirals.~6 participants will be receiving an antiretroviral regimen containing darunavir/ritonavir (800/100 mg) daily plus two other antiretrovirals."
89413535|NCT02740257||Group 1 Artificial Lesions|Photos will be taken of skin lesion markings using a smartphone
89413536|NCT02740257||Group 2 high risk|A convenience sample of patients will be recruited. This population will consist of patients with known high risk to have new/changing lesions, and who fall within the Fitzpatrick skin types I-IV. High risk patients include, but are not limited to, those with dysplastic nevus syndrome, previous history of melanoma/non-melanoma skin cancer, fair skin, >16 nevi, family history of melanoma, and/or immunosuppressed status. The first photography session will be taken by the research team in all 13 projections. After the first visit, the patient will be instructed to take photographs every month for 12 months using the TBDP app on their smart phone or tablet, and have follow-up research appointments every 6 months.
89413537|NCT05017870|Experimental|KSR-001-01|Participants received KSR-001-01 for 6 days.
88890941|NCT05403268|Experimental|Usual Care + DeltaScan|Intervention group. Participants undergo twice daily DeltaScan measurements in addition to usual care. The measurement result is used together with routine delirium screening observations to guide management, according to the local delirium protocol.
88890942|NCT05393830|No Intervention|Normal Sleep|Normal Sleep - Healthy participants are permitted normal nights of polysomnography or actigraphy recorded sleep before participating in an emotion regulation task during functional Magnetic Resonance Imaging (fMRI) scanning
88890943|NCT05393830|Active Comparator|Sleep Restriction|Healthy Participants are sleep restricted to 4 hours of sleep for 3 consecutive days before participating in an emotion regulation task during functional Magnetic Resonance Imaging (fMRI) scanning
88890944|NCT05393830|No Intervention|Patients with Insomnia Disorder|Patients with Insomnia Disorder will also be recruited and will be permitted normal nights of polysomnography or actigraphy recorded sleep before participating in an emotion regulation task during functional Magnetic Resonance Imaging (fMRI) scanning
88890945|NCT05390892|Active Comparator|Sodium-glucose cotransporter-2 inhibitor (SGLT2i)|Therapy with an SGLT2i with proven cardiovascular benefit. This means either canagliflozin, dapagliflozin, or empagliflozin
88890946|NCT05390892|Active Comparator|Glucagon-like peptide-1 receptor agonist (GLP-1 RA)|Therapy with a GLP-1 RA with proven cardiovascular benefit. This means either dulaglutide, liraglutide, or semaglutide.
88890947|NCT05390892|Active Comparator|Combination SGLT2i and GLP-1 RA|Combination therapy with an SLGT2i (canagliflozin, dapagliflozin, or empagliflozin) AND a GLP-1 RA (dulaglutide, liraglutide, or semaglutide)
88890948|NCT05388045|Experimental|Recovery PROM|All study participants will complete the Recovery PROM instrument.
88890949|NCT05384067|Experimental|Mindfulness-based intervention|Participants in this arm will wear a sleep-monitoring device, complete questionnaires and participate in an online mindfulness component each week for the duration of this study.
88890950|NCT05384067|No Intervention|Control|Participants in this arm will only wear a sleep-monitoring device and complete questionnaires.
88890951|NCT05382845|Other|Pregnant women without symptoms of pregnancy related pelvic girdle pain|There is only one arm in this study. The intervention consists of tests to rule out ongoing pelvic pain, manual pain provocation tests, and questionnaire.
88890952|NCT05380089|Experimental|Experimental group|"Over a 4-day period, participants randomly assigned to the experimental group will be instructed to maintain normal solid food choices, but to increase water intake to achieve a total water intake of ≥45ml/kg/day. Prepared bottles of water with the required amount will be given to each participant every morning and collected empty the following day. Instructions to drink small amounts of water every hour be transmitted.~Adherence to instructions regarding water intake will be determined by the return of drinking bottles, analysis of daily food records, assessment of water flux (i.e., collecting urines after subjects being dosed with deuterium), and daily screening questions. These samples will be delivered on a subsequent morning during a daily laboratory visit to collect urine and saliva samples, as well as BI assessment. On the 4th day, participants will perform a neuromuscular function assessment."
88890953|NCT05380089|No Intervention|Control group|Participants randomly assigned to the control group will be instructed to maintain normal solid food choices and water intake based on their average intake reported on the food records. Adherence to instructions regarding water intake will be determined and assessments performed will occur as mentioned previously for the experimental group.
88890954|NCT05376709|Experimental|Short-Term Calorie Reduction(SCR)|To determine the short-term impact of calorie modification on patient outcomes by measuring and comparing the following parameters between two groups a week after starting each R-CHOP cycle: symptoms, hematologic parameters (i.e., erythrocyte-, thrombocytes-, and leucocyte counts), metabolic parameters (i.e., insulin, glucose, insulin growth factor 1), inflammatory response (C-reactive Protein, CRP), and nutrition status (i.e., weight, albumin level, and lean body mass (LBM)).
88890955|NCT05376709|No Intervention|Control|Participated patients will be recruited and randomized to two groups: comparison group who receive standard care and experimental group who receive the SCR intervention. The standard care at NTUH includes encouraging patients to eat healthy and clean diet (e.g., avoid raw or undercooked food). There are no calorie restriction to the comparison group. The next paragraph describes the SCR intervention for experimental group.
89413538|NCT05017870|Experimental|KSR-001-02|Participants received KSR-001-02 for 6 days.
88890957|NCT05366218|Experimental|Tafasitamab|All patients will receive MOR00208 over 2-3 hours i.v. MOR00208 will be administered on a bi-weekly (every fourteen days) basis with infusions on Days 1 and 15 of each 28-day cycle. Additional doses will be administered on Day 4, Day 8 and Day 22 of Cycle 1 as well as Day 8 and Day 22 of Cycle 2 and Cycle 3.
88890958|NCT05351476|Experimental|Resistance Exercise|Participants do regular resistance exercise for 12 weeks.
88890959|NCT05351476|Experimental|Endurance Exercise|Participants do regular endurance exercise for 12 weeks.
88890960|NCT05348421|Experimental|the ultrasound-guided fascia transversalis plane block|The TFPB will be performed while the participant is in the supine position. a high-frequency linear ultrasound probe (5-13 MHz) will be placed transversely in the midaxillary line between the iliac crest and the costal margin. After the external oblique, internal oblique, transversus abdominis muscle, and quadratus lumborum (QL) muscle will be identified.
88890961|NCT05348421|Experimental|The ultrasound guided Pericapsular Nerve Group block|while the participant is in the supine position, a linear ultrasound probe will be initially placed in a transverse plane over the anterior inferior iliac spine (AIIS) and then aligned with the pubic ramus by rotating the probe counterclockwise approximately 45 degrees; In this view, the ilio-pubic eminence (IPE), the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle will be observed.
88890962|NCT05345301|Experimental|Measuring neural activity|While completing hand opening/closing, individuals will have the following measured (1) Neural activity (specifically sensorimotor rhythms) using a EEG cap; (2) muscle activity (specifically finger flexors and extensors) using EMG sensors.
88890963|NCT05336630|Experimental|Forceps Assisted Cannulation|Patients will have a forceps assisted cannulation during their ERCPs.
88890964|NCT05336630|No Intervention|No Forceps Assisted Cannulation|Patients will not have a forceps assisted cannulation during their ERCPs.
88890965|NCT05333276|Experimental|TQB3602 Capsule + AK105 Injection|TQB3602 capsule administered orally on day 1, 8 in 21-day cycle; every three weeks intravenous (IV) for one times of AK105 injection.
88890966|NCT05316324|Experimental|Prepectoral Breast Reconstruction with ADM|
88890967|NCT05316324|Experimental|Prepectoral Breast Reconstruction without ADM|
88890968|NCT05314374|Experimental|Bile Acid Supplement Group|Subjects with obesity and abnormal satiety phenotype will receive ileocolonic-release conjugated bile acid supplements
88890969|NCT05314374|Placebo Comparator|Placebo Group|Subjects with obesity and abnormal satiety phenotype will receive matching-placebo
88890970|NCT05307250|Experimental|Treatment Arm 1|Multiple Family Groups for HIV stigma reduction (MFG-HIVSR) plus FEE
88890971|NCT05307250|Experimental|Treatment Arm 2|Multiple Family Groups for HIV stigma reduction (MFG-HIVSR) plus FEE plus Group-based stigma reduction for educators (GED-HIVSR)
88890972|NCT05307250|Other|Control Arm|Bolstered Standard of Care (BSOC)
88890973|NCT05304403||Chronic Opioid User|Patients identified to have chronic opioid use (identified in chronic pain clinic)
88890974|NCT05304403||Healthy Control|These patients will not be actively recruited in this study. The investigators will use national microbiome dataset as a comparison.
88890975|NCT05304221||Intervention group|Septic patients from 2 sites, who are hospitalized and require empiric antibiotic treatment, whose primary physician was assisted by the Shamir Resistance Calculator.
88890976|NCT05304221||Control group|Septic patients from 2 sites, who are hospitalized and require empiric antibiotic treatment, whose primary physician was not assisted by the Shamir Resistance Calculator.
88890977|NCT05301348|Experimental|Procedure|Subjects will receive PAFC procedure
89005526|NCT04568941|Experimental|Intraoperative Excisional Biopsy|The tumor was excised intraoperatively.
89536906|NCT03307421|Other|debriefing without instructor|Team debriefing without an instructor will be organized as follows. The pairs of participants will be placed in a room with direct access to the video recording of their passage on the simulator. Two documents will be made available to help participants structure their debriefing: one targeting non-technical skills, based on the TEAM Score, and one recalling recommendations on ACR care. Despite its absence at the time of the debriefing, the instructor will be present during the briefing and during the simulation.
88890978|NCT05295121|Experimental|XC221, fasted|Administration of XC221 in fasted state in Dosing Periods 1 and 2 followed by administration of XC221 in fasted state in Dosing Period 3
88890979|NCT05295121|Experimental|XC221, fed|Administration of XC221 in fed state in Dosing Periods 1 and 2 followed by administration of XC221 in fasted state in Dosing Period 3
88890980|NCT05294250|Experimental|XC8, fasted|Administration of XC8 20 mg in fasted state in Dosing Periods 1 and 2 followed by administration of XC8 20 mg in fasted state in Dosing Period 3
88890981|NCT05294250|Experimental|XC8, fed|Administration of XC8 20 mg in fed state in Dosing Periods 1 and 2 followed by administration of XC8 20 mg in fasted state in Dosing Period 3
88890982|NCT05293769||IBS - arm|
88890983|NCT05293769||healthy - arm|
88890984|NCT05292911|Experimental|ALT-801 Dose Level 1|Administered once a week for 12 weeks
88890985|NCT05292911|Experimental|ALT-801 Dose Level 2|Administered once a week for 12 weeks
88890986|NCT05292911|Experimental|ALT-801 Dose Level 3|Administered once a week for 12 weeks
88890987|NCT05292911|Placebo Comparator|Placebo|Administered once a week for 12 weeks
88890988|NCT05291533|Other|Patients using VR Mindfulness Program|Participants are inpatients on any NYP/WCM unit that use VR mindfulness programs; any patient referred for a psychological or neuropsychological evaluation by their treatment team will have the opportunity to complete the VR program. The study is seeking to evaluate the feasibility and preliminary efficacy of the VR mindfulness intervention.
88890989|NCT05289323|Experimental|The Intervention group (N)|0.5 mg ampule (1 ml) will be diluted in 4 ml dextrose 5% to make a solution of 100 μg/ml, 0.2 ml of this solution will be added to 2.5 ml of hyperbaric bupivacaine 0.5 % used for intrathecal injection.
88890990|NCT05289323|Placebo Comparator|The control group (C)|one ml of normal saline 0.9 % will be mixed with 4 ml dextrose 5 % in the five-milliliter syringe. 0.2 ml of this mixture will be added to 2.5 ml of hyperbaric bupivacaine 0.5 % used for intrathecal injection.
88890991|NCT05288556|Experimental|Stoma Site Accessory|Stoma site accessory with enteral tube replacement procedure.
88890992|NCT05283512|Other|IV-hydration group (standard of care according to international guidelines)|"The IV-hydration with isotonic 0.9% NaCl will be initiated three hours prior to the IV CECT and completed four hours after IV CECT (infusion rate of 1-3 mL/kg/hour). Patients are prescribed a fixed volume of 1000 mL, which is equally distributed before and after IV CECT (500 mL before and 500 mL after).~Patients with heart failure (LVEF ≤ 40%) are prescribed a reduced volume of 500 mL, which is also equally distributed before and after IV CECT (250 mL before and 250 mL after)."
88890993|NCT05283512|Active Comparator|Oral hydration group|"The oral hydration regimen will be initiated one-two hours prior to IV CECT and completed within four hours after IV CECT. Patients are prescribed a fixed volume of 1000 mL, which is distributed equally before and after IV CECT (500 mL before and 500 mL after).~Patients with heart failure (LVEF ≤ 40%) are prescribed a reduced volume of 500 mL, which is equally distributed before and after IV CECT (250 mL before and 250 mL after)."
88890994|NCT05281380|Other|Intervention with vitamin supplement|Intervention with vitamin supplement Multi-E and Multi-G
88890995|NCT05275738|Active Comparator|Nicotinamide|Participants will receive 750mg nicotinamide tablets 1+1 per day (1.5g) for 6 weeks and after that 2+2 per day (3.0g).
88890996|NCT05275738|Placebo Comparator|Placebo|Participants will receive 750mg placebo tablets 1+1 per day for 6 weeks and after that 2+2 per day.
88890997|NCT05273619|Experimental|XC8, film-coated tablets, 10 mg|
88890998|NCT05273619|Placebo Comparator|Placebo|
88890999|NCT05272943||Preanesthesia visit measurement|Oxygen saturation will be measured by validated pulse oxymetry and smart electronics in pediatric patients during preanesthesia visit
88891000|NCT05272943||General anesthesia measurement|Oxygen saturation will be measured by validated pulse oxymetry and smart electronics in pediatric patients during general anesthesia
88891001|NCT05272943||PACU measurement|Oxygen saturation will be measured by validated pulse oxymetry and smart electronics in pediatric patients during PACU stay
88891002|NCT05272943||PICU measurement|Oxygen saturation will be measured by validated pulse oxymetry and smart electronics in pediatric patients during PICU stay
88891003|NCT05264389||Poly-Tape Device|Poly-Tape Device for Medial Patellofemoral Ligament (MPFL) Reconstruction
88891004|NCT05264168||Rivaroxaban|Reference group
88891005|NCT05264168||Apixaban|Exposure group
88891006|NCT05262504||EDOF IOL Group|Patients who were implanted with the novel wavefront shaping extended depth of focus IOL
88891007|NCT05262504||Multifocal IOL group|Patients who were implanted with the multifocal IOL
88891008|NCT05258903|Experimental|Ulnar artery|Ulnar artery cannulation under USG-guidance
88891009|NCT05258903|Active Comparator|Radial artery|Radial artery cannulation under USG-guidance
88891010|NCT05257967|Experimental|Experimental arm|ddPCR and BC Cancer NGS panel completed on cerebral spinal fluid and blood circulating tumor DNA
88891011|NCT05257174|Experimental|Jing Si Herbal Tea LIQUID PACKETS|one packet oral twice daily for three months
88891012|NCT05257174|Placebo Comparator|Placebo|one packet oral twice daily for three months
88891013|NCT05256797||Rivaroxaban|Reference group
88891014|NCT05256797||Apixaban|Exposure group
88891015|NCT05227404||COVID19 Assays|All participants enrolled will receive 2 point of care assays, and 1 central lab assay
88891016|NCT05226468|Experimental|NEI-01|Single Arm
88891017|NCT05226195|Experimental|Group 1: Sterile Kinesio tape application|The standard post-surgical protocol and sterile EDF kinesio-taping will be applied to this group. The clinical evaluation will be made on the 15th, 45th and 90th days; functional measurements will be taken. The follow-up period was determined as 3 months.
88891018|NCT05226195|No Intervention|Group 2: Control group|The standard post-surgical protocol applied in our clinic will be applied to Group 2. The clinical evaluation will be made on the 15th, 45th and 90th days; functional measurements will be taken. The follow-up period was determined as 3 months.
89413539|NCT05017870|Experimental|KSR-001-03|Participants received KSR-001-03 for 6 days.
89413540|NCT05017870|Placebo Comparator|KSR-001-04|Participants received KSR-001-04 for 6 days.
89413541|NCT02158260|Experimental|position changing|During the examination, subjects changed position in the following sequence: left lateral head-down position, supine position, prone head-down position, right lateral head-down position, supine position, left lateral position, prone position, prone hip-high position, right lateral position and sitting position.
89413542|NCT02158260|No Intervention|free position|
89413543|NCT02033031|Active Comparator|Lucentis|PRN intravitreal injection of Lucentis
89413544|NCT02033031|Active Comparator|Avastin|PRN intravitreal injection of Lucentis
88891019|NCT05220787|Experimental|Cold stored platelets in 100% plasma stored for 10-14 days|Cold stored apheresis platelets in 100% plasma stored for 10-14 days, maximum of up to three units (3x10^11/unit) from the start of surgery until 24 hours after the end of surgery
88891020|NCT05220787|Active Comparator|Room temperature stored platelets in 100% plasma stored for up to 7 days|Room temperature stored platelets in 100% plasma stored for up to 7 days, maximum of up to three units (3x10^11/unit) from the start of surgery until 24 hours after the end of surgery
88891021|NCT05219994|Experimental|Oral Glucose Tolerance Test|Subjects will consume a 75 g glucose drink within 1-min and monitored for 2 hours.
88891022|NCT05218083|Experimental|REmotely Monitored, Mobile health supported Multidomain Rehabilitation Program with HIIT|Patients will receive our REmotely monitored, Mobile health supported Multidomain Rehabilitation Program with High Intensity Interval Training Program (REMM-HIIT) with iWatch/iPhone.
88891023|NCT05218083|No Intervention|Exercise education without personalized sessions or feedback|Patients will receive an exercise handout and iWatch/iPhone. Patients return home to exercise without personalized instruction and coaching.
88891024|NCT05213650|No Intervention|Invisalign control patients (liquid soap)|Patients who clean their plaques only with liquid soap and toothbrush
88891025|NCT05213650|Experimental|Invisalign non-abrasive toothpaste patients|Patients who clean their plaque with non-abrasive toothpaste and toothbrush
88891026|NCT05213650|Experimental|Invisalign abrasive toothpaste patients|Patients who clean their plaque with abrasive toothpaste and toothbrush
88891027|NCT05213650|Experimental|Invisalign Efferdent patients|Patients who clean their plaques with liquid soap and use Efferdent antibacterial cleaning tablet once a week
88891028|NCT05213650|Experimental|Invisalign Cleaning Crystals patients|Patients who clean their plaques with liquid soap and use Invisalign Cleaning Crystals tablet once a week
88891029|NCT05205746|Experimental|Intramuscular|10 8.0 EID 50/dose intramuscular
88891030|NCT05205746|Experimental|Intranasal|10 8.0 EID 50/dose intranasal
88891031|NCT05205746|Other|Intramuscular Placebo|Physiological saline solution of Sodium Chloride at 0.9% Intramuscular After mask opening ChAdOx-1-S[recombinant]) Intramuscular
88891032|NCT05205746|Other|Intranasal Placebo|Physiological saline solution of Sodium Chloride at 0.9% Intranasal After mask opening ChAdOx-1-S[recombinant]) Intramuscular
88891033|NCT05196750||Normal vaginal delivery|Maternal delivery of delivery via normal vaginal delivery
88891034|NCT05196750||Lower segment Caesarean section (LSCS)|Maternal delivery of delivery via lower segment Caesarean section (LSCS)
88891035|NCT05195905|Experimental|Physician-modified endografts|For this clinical protocol, endografts which are commercially available will be modified in a sterile fashion on a back-table in the operating room.
88891036|NCT05190575|Experimental|TST001|Drug: TST001 IV infusion every 3 weeks until disease progression or other discontinuation criteria.
88891037|NCT05179512||Tiotropium|Reference group
88891038|NCT05179512||Salmeterol/Fluticasone|Exposure group
88891039|NCT05176496||Cohort 1|Women with a continuous observation of 365 days after January 1st, 2000 and before December 31, 2020.
88891040|NCT05176496||Cohort 2|Women diagnosed with HMB.
88891041|NCT05166902|Experimental|Lens A, Then Lens B|Participants will wear lens A for one month and then cross over to wear lens B for one month.
88891042|NCT05166902|Experimental|Lens B, Then Lens A|Participants will wear lens B for one month and then cross over to wear lens A for one month.
88891043|NCT05164926|Experimental|Experimental group, whose perineum was massaged with St. John's Wort oil during labor|St. John's Wort oil will be applied to this group during perineal massage during labor.
89413545|NCT02158338||Asthma|Mothers of children thought to have asthma
89413546|NCT02158338||Non-asthma|Mothers of children without diagnosed respiratory problems
89413547|NCT02033343|Experimental|Real-time tracking & beam adjustment|Prostate cancer radiotherapy using real-time tracking
89413548|NCT05034367|Experimental|Healthy persons|The responses of the healthy subjects are utilized to create reference ranges for a normal cough response to mannitol
89413549|NCT02150850||Registry|Patients who have who have sustained an AFF that consent to participating in the registry only.
89413550|NCT02150850||Cases|Patients who have sustained an AFF that consent to participating in the registry and undergoing EOS® imaging.
89413551|NCT02150850||Controls|For each case we will identify one age- (± 5 years), sex-, height- (± 6 cm) and cumulative bisphosphonate or denosumab exposure ( ±2 years) matched control who has not sustained an AFF to undergo EOS® imaging.
89413552|NCT02033265||Patients with BMI less than 30 kg/m2|Patients with BMI less than 30 kg/m2 undergoing surgical procedures on upper limb (elbow, forearm and hand) scheduled to receive ultrasound-guided axillary brachial plexus block as their primary anesthetic modality at SJHC.
89413553|NCT02033265||Patients with BMI 30 or above|Patients with BMI 30 kg/m2 undergoing surgical procedures on upper limb (elbow, forearm and hand) scheduled to receive ultrasound-guided axillary brachial plexus block as their primary anesthetic modality at SJHC
89413554|NCT02150928|Experimental|Erwinaze / Erwinase|
89413555|NCT03611127|Experimental|early pulmonary rehabilitation (EPR)|early pulmonary rehabilitation started shortly after hospital discharge for COPD exacerbation.
89413556|NCT03611127|No Intervention|Usual care (UC)|No pulmonary rehabilitation for this group
89413557|NCT04964518|Experimental|APG2575 + Azacitidine|200 mg APG2575 dose ramp up +AZA
88891044|NCT05164081|Experimental|Dual antibiotic impregnated cement|Patients treated with a cemented hip hemiarthroplasty using dual antibiotic loaded bone cement (gentamicin+clindamycin) COPAL G+C (Heraeus).
89413558|NCT03543150||Subjects receiving BOTOX|Subjects with a diagnosis of spasmodic dysphonia, for which BOTOX is indicated, will be included.
89413559|NCT03611049|Placebo Comparator|Low dose Vitamin D intervention|intervention includes 800 IU Vitamin D3 replacement
89413560|NCT03611049|Active Comparator|High dose Vitamin D intervention|Intervention includes 5000 IU Vitamin D3 replacement
88812994|NCT01537367|Experimental|Enhanced contact only|"Patients allocated to the Enhanced contact only arm will receive:~HIV information and education~Specific to importance of coming to care regularly~Generic and tailored components~Approximately 10 minutes in length~Enhanced contact over time~Collect locator information~Follow-up contact after medical visit (face-to-face or phone)~Appointment reminders (telephone, e-mail, text message)~Periodic telephone contact across time (support, update locator info, refer any unmet needs to Case Manager)~Attempt to make immediate contact following a missed visit and re-schedule appointment (use locator contact info)"
88812995|NCT01537367|Experimental|Enhanced contact plus behavioral skills|Enhanced contact plus behavioral skills is the longer experimental intervention arm.
88812996|NCT01537367|Active Comparator|Standard of Care|Patients assigned to control arm will receive the standard services offered to all patients at the clinic.
88812997|NCT04380662||COVID+ patients WITH worsening of the disease|COVID+ patients WITH worsening of the disease (case group)
88812998|NCT04380662||COVID+ patients WITHOUT worsening of the disease|COVID+ patients WITHOUT worsening of the disease (control group)
88812999|NCT01537835|No Intervention|Standard Scrubs|Participants will be randomized to one of three types of uniforms. This arm is the standard scrub arm. The participants will wear new standard scrubs.
88813000|NCT01537835|Experimental|Antimicrobial Scrubs 1|Participants will be randomized to one of three types of uniforms. In this arm, the participants will wear one of two types of antimicrobial uniforms. These are commercially available and registered with the Environmental Protective Agency.
88813001|NCT01537835|Experimental|Antimicrobial Scrubs 2|Participants will be randomized to one of three types of uniforms. In this arm, the participants will wear one of two types of antimicrobial uniforms. These are commercially available and registered with the Environmental Protective Agency.
88813002|NCT00906074||Case|Cases will be defined as patients with elective or emergency abdominal surgery who develop severe surgical site infection (deep incisional or organ cavity type; see Center for Disease Control (CDC) criteria for definition in the Appendix), within 0-30 days of surgery.
88813003|NCT00906074||Control|Surgeon-matched controls will be patients with elective or emergency abdominal surgery who are free of surgical site infection (SSI) after 30 days from the surgery.
88813004|NCT01538615|Experimental|HOME Plus Intervention|described below
88813005|NCT01538615|No Intervention|Control|Control participants receive a monthly newsletter for the 10 months of the study with tips on healthy eating. The topics do not overlap the intervention content.
88813006|NCT04380428||Cross section of the student body.|Matriculated students at Portuguese medical and dental faculties.
88813007|NCT03219242|Experimental|Caiman device|Time sparing and post-operative outcome in ovarian cancer including bowel resection for cytoreductive surgery with Caiman device
88813008|NCT04380506|Experimental|Drain removal|Patients that fulfill criteria for surgical drains removal
89413561|NCT05037448|Other|Telehealth|Me & My Wishes videos communicate residents' preferences via personalized video recorded conversations. Me & My Wishes are videos of nursing home residents talking about their preferences for care, and include four sections: About Me, Preferences for Today, Preferences for Medical Intervention and End of Life, and Afterthoughts.
89413562|NCT02151006|Active Comparator|DHEA|women will receive DHEA 6 weeks before starting IVF/ICSI
89413563|NCT02151006|No Intervention|Control|
89413564|NCT03610503|Experimental|Music|Patients listen to music during EMG test
89413565|NCT03610503|No Intervention|Control (Standard Care)|Patients do not listen to music during EMG test (ie. Standard of care)
89413566|NCT03610893|Active Comparator|Perineural dexamethasone|addition of dexamethasone to local anesthetics in infraclavicular brachial plexus block
89413567|NCT03610893|Active Comparator|Perineural dexmedetomidine|addition of dexmedetomidine to local anesthetics in infraclavicular brachial plexus block
89413568|NCT05022940||TBI rehabilitation|All individuals with mild, moderate or severe TBI registered into rehabilitation.
89413569|NCT02032719|Experimental|smartphone assisted lifestyle coaching|6 months of smartphone assisted lifestyle coaching
89413570|NCT02032719|Active Comparator|Lifestyle health coaching|6 months of lifestyle health coaching
89413571|NCT03610425||Post-op evidence based bundle w/ Pre-op education|25 patients undergoing hysterectomy from October 1, 2017 to December 31, 2017 will receive the post-operative evidence based bundle/standard pre-operative education.
89413572|NCT03610425||Standard pre-operative education alone|25 patients undergoing hysterectomy from October 1, 2017 to December 31, 2017 will receive the standard pre-operative education alone.
89413573|NCT05137093||Healthy subjects|Healthy subjects
89413574|NCT05137093||Atopic dermatitis|Atopic dermatitis
89413575|NCT02154438|Experimental|ketamine|ketamine 0.5mg/kg loading dose and followed by 0.5mg/kg/h during operation
89413576|NCT02154438|Placebo Comparator|Placebo|normal saline 0.5mg/kg loading dose and followed by 0.5mg/kg/h during operation
89413577|NCT05022628|Experimental|Therapy arm|donafenib
89413578|NCT02154594|Experimental|Acacia|Rinse with 20 ml of Acacia catechu mouthwash twice daily for 15 days
89413579|NCT02154594|Active Comparator|Chlorhexidine gluconate|Rinse with 10 ml of chlorhexidine mouthwash twice daily for 15 days
88813009|NCT01556633|Experimental|Volunteers on dialysis|
88813010|NCT01556633|Experimental|Volunteers with reduced creatinine clearance|
89413580|NCT02154594|Placebo Comparator|Distilled water|Rinse with 10 ml distilled water twice daily for 15 days.
89413581|NCT03610347|Experimental|Bare metal Stent plus Paclitaxel Balloon|Conventional bare metal Stent plus Paclitaxel Eluting Balloon(Pantera Lux®)
89413582|NCT03610347|Active Comparator|Drug-Eluting Stent (DES)|Sirolimus Eluting Stent (Orsiro®)
89413583|NCT05022706|Experimental|Adolescents living with HIV|"cART directly observed therapy (DOT) for participants at risk of or with a history of non-adherence~monthly home visits by trained health promoters~ongoing support in navigating the health system, including accompaniment to appointments and assistance enrolling in public health insurance~monthly peer support groups"
89413584|NCT02158416||Hematology-oncology|hematology-oncology outpatients requiring platelet transfusion
89413585|NCT03541824|Experimental|Body Acceptance Program|The Body Acceptance Program (BAP) is the active condition. Participants engage in an online intervention during which they complete online and offline activities designed to challenge the appearance-ideal.
89413586|NCT03541824|No Intervention|Waitlist control|Participants in the waitlist control group completed baseline and follow-up assessments with no intervention.
89413587|NCT05016934|Experimental|A vaccine composed of a recombinant S1 antigen 10mcg|Two applications of 10mcg of a vaccine composed of a recombinant S1 antigen 28 days apart
89413588|NCT05016934|Experimental|A vaccine composed of a recombinant S1 antigen 25mcg|Two applications of a vaccine composed of a recombinant S1 antigen 28 days apart
89413589|NCT05016934|Experimental|A vaccine composed of a recombinant S1 antigen 50mcg|Two applications of 50mcg of a vaccine composed of a recombinant S1 antigen 28 days apart
89413590|NCT05016934|Placebo Comparator|Placebo|Two applications of placebo 28 days apart
89413591|NCT02151162|Experimental|Stress management plus omega-3|Thirty participants will be allocated to the arm. These interventions will terminate until 3 months from registration for each participant.
88813011|NCT03218696|Experimental|Cough Syrup for adults and children|CE Marked (authorized) medical device acting by protecting the oropharynx, in a non-pharmacological way, to reduce cough. It contains honey, plantago lanceolata, thymus vulgaris. Dosage form: syrup Dosage: 5 ml. Duration: one night
88813012|NCT03218696|Placebo Comparator|Placebo|The placebo intervention is a similar syrup of taste and colour, with general protective components and other necessary synthetic components which may have an influence on cough, without the specific natural protective components. Dosage form: syrup. Dosage: 5 ml. Duration: one night
88813013|NCT03218774|Other|Home Group|
88813014|NCT03218774|Experimental|Center Group|
88813015|NCT03218852|Experimental|prednisone and cyclophosphamide|"prednisone(0.5mg/kg/day*6 months)~cyclophosphamide(1g intravenous use,per 1 month*6months);~supportive care,including ACE-I or ARBs and blood pressure control"
88813016|NCT03218852|Experimental|prednisone alone|"prednisone(0.5mg/kg/day*6months);~supportive care,including ACE-I or ARBs and blood pressure control"
88813017|NCT01834664|Other|STEM CELL|Transfer of autologous stem cell [MNCs ]intrathecally
88813018|NCT01834742|Experimental|Part A, arm 1|Evening dose 1 plus fixed morning dose
89413592|NCT02151162|Active Comparator|Stress management plus placebo|Thirty participants will be allocated to the arm. These interventions will terminate until 3 months from registration for each participant.
89413593|NCT02151162|Active Comparator|Psychoeducation leaflet plus omega-3|Thirty participants will be allocated to the arm. These interventions will terminate until 3 months from registration for each participant.
89413594|NCT02151162|Active Comparator|Psychoeducation leaflet plus placebo|Thirty participants will be allocated to the arm. These interventions will terminate until 3 months from registration for each participant.
89413595|NCT05016544|Experimental|Inetetamab+Pyrotinib|Dose Escalation and Dose Expansion: Inetetamab in combination with Pyrotinib in HER2 mutant or amplified participants with advanced or metastatic NSCLC
89413596|NCT05016466||Group I. Patients with DLCO <80%.|Patients with DLCO <80% will be followed at baseline and once a year during the study
89413597|NCT05016466||Group II. Patients with DLCO ≥ 80%.|Patients with DLCO ≥80% only will be followed at baseline and year 5.
89413598|NCT05016154|Experimental|Online group CBT intervention|Online group CBT delivered via Microsoft Teams (a secure web-based video conferencing platform) in 10 weekly workshops of 60-75 minutes.
88891045|NCT05164081|Active Comparator|Single antibiotic impregnated cement|Patients treated with a cemented hip hemiarthroplasty using single antibiotic loaded bone cement (gentamicin) Paladins R+G (Heraeus) or Refobacin (Biomet).
88891046|NCT05162183||Glimepiride|Reference Group
88891047|NCT05162183||Liraglutide|Exposure group
89192920|NCT05900362|Experimental|Interventional|All patients receive the VitalCare platform with a tablet computer, an Eko Duo device, a weight scale, a blood pressure cuff, a pulse oximeter
89192921|NCT05895773|Experimental|Treatment group|Nasal and oropharyngeal Povidone Iodine plus Glycyrrhizin sprays will be applied 4 times daily after tooth cleaning with a brush.
89192922|NCT05895773|Placebo Comparator|Placebo group|Nasal and oropharyngeal saline sprays will be applied 4 times daily after teeth cleaning with a brush.
89413599|NCT05016154|Active Comparator|SilverCloud guided|"The SilverCloud app is a set of programs and courses that can be completed on a phone, tablet or computer. Students are also contacted by the SilverCloud support team which offers them guidance and support while using the app.~Silvercloud uses principles borrowed from both a popular type of counseling called Cognitive Behavioral Therapy (CBT) and Mindfulness. Each module takes approximately 40minutes to complete. Students are encouraged to complete at least one module per week."
88891048|NCT05159349||Exposed group|
88891049|NCT05159349||Non-exposed group|
89413600|NCT05016154|Active Comparator|SilverCloud unguided|"The SilverCloud app is a set of programs and courses that can be completed on a phone, tablet or computer. Students are encouraged to use the app as they see fit, although guidelines to using the app are provided.~Silvercloud uses principles borrowed from both a popular type of counseling called Cognitive Behavioral Therapy (CBT) and Mindfulness. Each module takes approximately 40minutes to complete. Students are encouraged to complete at least one module per week."
89413601|NCT05016154|Active Comparator|Mood Flow|The Moodflow app is a mood tracker and journal that helps students figure out what changes their mood. Students are encouraged to use the app as they see fit, although guidelines to using the app are provided.
89413602|NCT03079726||Frail individuals (case)|Individuals classified as frail based on several clinical metrics
89413603|NCT03079726||Non-frail individuals|Individuals failing to meet criteria for frailty based on clinical metrics
88891050|NCT05143749|Experimental|10 assistant doctors who received video training|10 assistant doctors who receive video training will be the intervention arm
88891051|NCT05143749|No Intervention|10 assistant doctors who did not receive video training|10 assistant doctors who did not receive video training will be the control arm
88891052|NCT05142566|Experimental|Ultrasound Closure|Open label, single arm study using ultrasound guidance during MANTA device deployment.
88891053|NCT05134636|Experimental|Treatment Arm|For patients in the intervention arm, symptoms and laboratory results will be assessed using the text-based e-triage 96 hours prior to their intended infusion date. The e-triage will consist of a standardized questionnaire and algorithm to evaluate symptoms and laboratory values. Patients with acceptable labs and minimal or no symptoms can opt to proceed directly to their immunotherapy infusion without an in-person office assessment.
89192923|NCT05894785|Experimental|Study group|
89192924|NCT05894005|Active Comparator|Group A|"VR - Route 1: Students will be first taken to the anesthesia lounge. Here the students will receive VR instructions on how to navigate Route 1 (i.e. they will watch a 360-degree immersive video using Oculus VR headset). Then the students will be assessed with an observed walkthrough of Route 1.~Traditional - Route 2: After completing the Route 1 walkthrough, the same group will be given traditional instructions (2D video) on navigating Route 2, followed by an observed walkthrough of Route 2."
89192925|NCT05894005|Active Comparator|Group B|"Traditional - Route 1: Students will be first taken to the anesthesia lounge. Here the students will receive traditional instructions (2D video) on how to navigate Route 1. Then the students will be assessed with an observed walkthrough of Route 1.~VR - Route 2: After completing the Route 1 walkthrough, the same group will be given VR instructions on how to navigate Route 2, followed by an observed walkthrough of Route 2."
89192926|NCT05891470|Active Comparator|Vaginal Dilatators|Use of vaginal dilatators as standard of care.
89192927|NCT05891470|Experimental|MonaLisa Touch device|Sessions with the MonaLisa Touch device
89413604|NCT05016388|Experimental|Collaborative Multidimensional Model (CMD)|The teams in the CMD group will be composed each of at least a MD, a psychologist, and a social worker. The teams will receive the CMD training and the CMD will be installed in the primary health care (PHC) center. Then, the participants with depression who enter treatment for depression in their respective PHC center, will be enrolled and evaluated by an external team, blind to the interventions at the beginning, three and six months after.
89413605|NCT05016388|Other|Standard Model (SM)|The teams in the SM group will be composed each of at least a MD, a psychologist, and a social worker. The teams will receive the SM training and the SM will be set in the primary health care (PHC) center. Then, the participants with depression who enter treatment for depression in their respective PHC center, will be enrolled and evaluated by an external team, blind to the interventions at the beginning, three and six months after.
89413606|NCT05022160|Experimental|Group P|Patients in this group will receive bilateral pudendal nerve block after spinal anesthesia- before starting the surgery
89413607|NCT05022160|Placebo Comparator|Group C|Patients in this group will only receive spinal anesthesia before starting the surgery
89413608|NCT05009446|Experimental|Preoperative radiotherapy and chemotherapy|Preoperative radiotherapy and chemotherapy plus endoscopic surgery
89413609|NCT01518517|Experimental|GRASPA|"Each patient randomized in GRASPA® group is to receive at least 2 and up to 10 administration of GRASPA® 150 IU/kg, in combination with standard chemotherapy (COOPRALL).~GRASPA® administration takes place as below:~for induction phase: at Day 4 and D18 (F1-F2 induction ) or at D6 if Vanda induction applies (according disease severity)~for consolidation phase: at Day 6 of R2 / R1 blocks, each time block of chemotherapy is given (up to 8 cycles)"
88891054|NCT05134636|No Intervention|Usual Care|Patients in the usual care arm will receive standard of care symptom monitoring including an in-person office assessment prior to their scheduled immunotherapy infusion.
89413610|NCT01518517|Active Comparator|reference L-asparaginase|"For patient randomized in control group, reference L-asparaginase 10,000 IU/m² will be administered every 3 days intravenously, in combination with standard chemotherapy (COOPRALL).~•for induction phase:at Day 4 , D7, D10, D13 (F1 block ) then at Day 18, D21, D24, D27 (of F2 Blocks).~NB: administrations take place at D6, D9, D12 and D15 in case of F1-F2 Induction is replaced by VANDA (according disease severity)~•for consolidation phase: at D6, D9, D12 ofR2/R1 blocks, each time block of chemotherapy is given (up to 8 cycles)."
88891055|NCT05120167|Active Comparator|Endocervical cytology performed by liquid-based cytology|Endocervical sample collected by brushing and preserved in a liquid base, and evaluated as cytology.
88891056|NCT05120167|Active Comparator|Endocervical cell block from a canal sample preserved in a buffered formalin base|"Endocervical sample collected by brushing and preserved in a buffered formalin base for obtaining a cell block, and evaluated similarly as histology."
88891057|NCT05120167|Active Comparator|Endocervical curettage|Endocervical curettage sample preserved in buffered formalin and evaluated by histology.
88891058|NCT05112874||Prospective Cross-Reactive Cohort|"Ages 18-89, Exhibiting symptoms compatible with a viral upper respiratory tract infection at the time of screening.~Lab test confirming~Negative for SARS-CoV-2 (by Polymerase Chain Reaction (PCR) or Antibody detection test)~Respiratory Panel positive for the common seasonal coronaviruses: NL63, 229E, OC43, and HKU1"
88891059|NCT05107466||Individuals with Hearing Loss|60 adults (>18 y/o) with a diagnosis of hearing loss. These participants may use cochlear implant(s), hearing aid(s), or have unaided hearing loss.
88891060|NCT05107466||Individuals with Normal Hearing|40 adults (>18 y/o) without a diagnosis of hearing loss.
88891061|NCT05106361|Experimental|MOSAIC Plus|"Mother AdvocateS In the Community (MOSAIC) Plus intervention to reduce depressive and PTSD symptoms and prevent additional IPV among pregnant women and mothers with children under 5 experiencing IPV. The MOSAIC Plus intervention will integrate IPT principles and skills into the MOSAIC intervention in order to expand it to address consequences of IPV, including depression and PTSD symptoms."
88891062|NCT05106361|Active Comparator|MOSAIC|"Those in the active comparator will receive the Mother AdvocateS In the Community (MOSAIC) Plus intervention to reduce depressive and PTSD symptoms and prevent additional IPV among pregnant women and mothers with children under 5 experiencing IPV."
89413611|NCT02863575|Experimental|Ibuprofen/Caffeine|Ibuprofen 400 mg/ Caffeine 100 mg fixed-dose combination
88891063|NCT05099198||Sitagliptin|Reference group
88891064|NCT05099198||Glimepiride|Exposure group
88891065|NCT05089071|Experimental|CADe group|Endoscopists perform colonoscopy with CADe system
88891066|NCT05089071|No Intervention|Control|Endoscopists perform colonoscopy without CADe system
88891067|NCT05088798|Experimental|18F-Fluoro Dopa Imaging|single arm
88891068|NCT05086172|Experimental|UBA Arm|All subjects in this arm will receive ultrabrief behavioral activation therapy via a single, 90-minute session.
88891069|NCT05086172|No Intervention|Control Arm|All subjects in this arm will complete all study assessment instruments collected in the interventional arm but will not receive an intervention.
88891070|NCT05086081||Prasugrel|Reference group
88891071|NCT05086081||Ticagrelor|Exposure group
88891072|NCT05083949|Experimental|(A): empagliflozin 10mg (R1)+Glifage® 850mg (R2),then (B): FDC 12.5mg empagliflozin/850mg metformin|"On Day 1 of Period 1 subjects received treatment A: Single dose tablet of 10 milligram(mg) empagliflozin film-coated and a 850mg of metformin hydrochloride (HCl) (Glifage®) tablet, orally with 200 milliliter(mL) of water.~On Day 1 of Period 2 subjects received treatment B: Fixed dose combination (FDC) tablet of 12.5mg empagliflozin/850 mg metformin HCl, orally with 200mL of water.~A high-fat, high-calorie meal was served 30 minutes(min) before drug administration. The treatments were separated by a wash-out phase of at least 7 days."
88891073|NCT05083949|Experimental|(B): FDC 12.5mg empagliflozin/850mg metformin,then (A): empagliflozin 10mg(R1) + Glifage® 850mg(R2)|"On Day 1 of Period 1 subjects received treatment B: Fixed dose combination (FDC) tablet containing 12.5 milligram (mg) empagliflozin/850 mg metformin HCl, orally with 200 milliliter (mL) of water.~On Day 1 of Period 2 subjects received treatment A: Single dose tablet of 10mg empagliflozin and 850 mg of metformin hydrochloride (HCl) (Glifage®) tablet, orally with 200mL of water.~A high-fat, high-calorie meal was served 30 minutes (min) before drug administration. The treatments were separated by a wash-out phase of at least 7 days."
88891074|NCT05083455||Enoxaparin|Reference group
88891075|NCT05083455||Rivaroxaban|Exposure group
88891076|NCT05083429||Salmeterol inhaler|Reference group
88891077|NCT05083429||Tiotropium|Exposure group
88891078|NCT05078879|Experimental|Treatment Arm|Patients with GCPC3 will receive daily Empagliflozin for 12 months.
88891079|NCT05078307|Active Comparator|OHR System|Use of the OHR system to perform an operative hysteroscopy by resection of the fibroid.
88891080|NCT05078307|Experimental|OHV System|Use of the OHV system to perform an operative hysteroscopy by vaporization of the fibroid.
88891081|NCT05067816|Active Comparator|Distance Scale-Up Format|10 sites with up to 150 program participants will be randomly assigned to a distance scale-up format where each site implementation team will receive technical assistance individually. All implementation training will occur using a virtual web-based format. Implementation teams will receive 8 hours of web-conferences, 2 hours of online training, and 4 hours of technical assistance.
88891082|NCT05067816|Experimental|Quality Improvement Collaborative Scale-Up Format|10 sites with up to 150 program participants will be randomly assigned to a quality improvement collaborative scale-up format where implementation teams will work collaboratively during training and implementation. All implementation training will occur using a virtual web-based format. Implementation teams will receive 8 hours of web-conferences, 2 hours of online training, and 4 hours of technical assistance.
88891083|NCT05064202|Experimental|Impella 5.5|ADHF-CS patients who are in the experimental arm will be treated with an Impella 5.5 (+/- standard of care)
89192928|NCT05884580|Experimental|Participants receiving treatment with the Neuflo BPH Treatment System.|
89192929|NCT05878665|Experimental|Double low-dose CT|Weight-adjusted low-dose contrast media paired with low-radiation dose abdomen CT
89192930|NCT05871060|Active Comparator|whey concentrate supplement|2,2 grams of whey concentrate dissolved in 100 mL of water
89413612|NCT02863575|Active Comparator|Ibuprofen|Ibuprofen 400 mg
89413613|NCT02863575|Placebo Comparator|Placebo|Placebo comparator
89413614|NCT05021770|Experimental|Phase Ib|"Orelabrutinib dose escalation will occur using a standard 3+3 dose-escalation approach to determined the maximum tolerated dose(MTD) of orelabrutinib dose in combined with thiotepa, beginning at dose level I (150 mg daily) and potentially escalating to dose level 2 (200mg) with rules for escalation and de-escalation. If the dose-limiting toxicity is not found, the dose of 200mg will be used for phase II trial (RP2D).~Orelabrutinib: 150mg or 200mg orally daily. Thiotepa: The dose of thiotepa is fixed as 30 mg/m2 intravenously every 3 weeks (maximum 6 cycle)."
89413615|NCT05021770|Experimental|Phase II|"Participants will receive orelabrutinib and thiotepa at the pre-determined dosage level established in Phase 1b, until progression of the disease (PD), unacceptable toxicity, or patient/investigator discretion. The response will be evaluated every 2 cycles.~Orelabrutinib: RP2D (150 mg or 200 mg qd) Thiotepa:Sintilimab: The dose of thiotepa is fixed as 30 mg/m2 intravenously every 3 weeks (maximum 6 cycle)."
89413616|NCT05008978|Experimental|Test 1|
89413617|NCT05008978|Experimental|Test 2|
89413618|NCT05008978|Experimental|Test 3|
88891084|NCT05064202|Other|Standard of care|ADHF-CS patients who are in the control arm will be treated with escalating doses of inotropes (standard of care)
89413619|NCT05008978|Experimental|Test 4|
89413620|NCT05008978|Experimental|Test 5|
89413621|NCT05021692|Experimental|Intervention|Intervention group: Pregnant women with preeclampsia who receive a web-based support program based on the Health Promotion Model in addition to routine clinical care will form the intervention group.
89413622|NCT05021692|No Intervention|Control|Pregnant women who receive routine clinical care applied to pregnant women with preeclampsia will constitute the control group.
89413623|NCT05009056|Experimental|postsurgical computer guided functional appliance|After achieving ideal condylar poison by computer guided surgery. The distal extension of the final occlusal wafer will be cut and the appliance will be fitted to be utilized as a postsurgical functional appliance for condylar adaptation. Patients will be instructed to wear the splints continuously for 3 months, only being allowed to remove them when eating and brushing their teeth.
89413624|NCT05009056|Active Comparator|Presurgical computer guided functional appliance|Using the software, 3D digitized mandible will be virtually repositioned in ideal centric relation through accurate adjustment of the condyle in its glenoid fossa. Patients' dental casts will be scanned, and digitized into a virtual 3D model and superimposed to the CT cuts into the virtual plan software environment in order to produce preoperative CAD/CAM splint on the adjusted centric occlusion. Patients will be instructed to wear the splints continuously for 3 months, only being allowed to remove them when eating and brushing their teeth.
89413625|NCT03619525|Active Comparator|recruitment group|will receive intermittent lung recruitment during CPB
89413626|NCT03619525|No Intervention|control group|will recieve no intervention
89413627|NCT05230303|Experimental|Caffeine supplementation|Group taking 3 mg/kg of caffeine
89413628|NCT05230303|Placebo Comparator|Placebo treatment|Group taking placebo
89413629|NCT04287790||Health professionals after intervention|Health professionals (physicians, advanced practice providers, pharmacists, social workers, and nurses) who work on the designated general medicine services at Yale New Haven Hospital after implementation intervention (July 2020)
89413630|NCT04287790||Hospitalized patient before intervention|Patients discharged from the general medicine service at Yale New Haven Hospital York street campus following hospitalization for an alcohol related diagnosis 18 months before the start (January 1st 2020) of the implementation intervention
88813019|NCT01834742|Experimental|Part A, arm 2|Evening dose 2 plus fixed morninf does
88813020|NCT01834742|Experimental|Part A, arm 3|Evening dose 3 plus fixed morning dose
88813021|NCT01834742|Active Comparator|Part A, arm 4|Moviprep
88813022|NCT01834742|Experimental|Part B, arm 1|Fixed evening dose plus morning dose 1
88813023|NCT01834742|Experimental|Part B, arm 2|Fixed evening dose plus morning dose 2
88813024|NCT01834742|Experimental|Part B, arm 3|Fixed evening dose plus morning dose 3
88813025|NCT01834742|Experimental|Part B, arm 4|Fixed evening dose plus alternative morning dose
88813026|NCT03836690|Experimental|Donor T cells depleted of CD62L+ cells (CD62L- Tem)|Donors will undergo a steady state apheresis for the collection of T cells. Selection of CD62L- Tem at the required dose will be performed at UCL Centre for Cell, Gene and Tissue Therapeutics (CCGTT). Donor Tem will be infused into patients on day 24-32 following allo-Stem Cell Transplant.
88813027|NCT01834898||Controlled-release oxycodone|Controlled-released oxycodone. First day postoperatively, 40 mg / day divided into 20 mg of 12 in 12 hours and in the second postoperative day, 20 mg / day divided into 10 mg of 12 in 12 hours
88813028|NCT03218462|Experimental|Group 1|Sensory adapted dental environment (SADE) at first exam (visit 1)
88813029|NCT03218462|Experimental|Group 2|Sensory adapted dental environment (SADE) at recall exam (visit 2)
88813030|NCT03218228|Placebo Comparator|implants in healthy individuals|immediate placement of dental implants in individuals with healthy periodontium. the device is dental implants, radiographs, william's periodontal probe
88813031|NCT03218228|Experimental|implants in periodontitis patients|immediate implantation in patients suffering from aggressive periodontitis. the device is the dental implants, radiographs, william's periodontal probe
88813032|NCT03212300|Active Comparator|Aerobic Exercise Training (AET)|20 sessions of AET over a 4 week period just prior to surgery
88813033|NCT03212300|No Intervention|treatment as usual|standard treatment
88813034|NCT03218306|Experimental|SPI guided analgesia|SPI ≤ 10 percentual points over the post-induction/pre-surgical incision value
88813035|NCT03218306|Active Comparator|Clinical Guided Analgesia|No SPI guidance
88891085|NCT05063201|Experimental|Cariprazine|
88891086|NCT05063201|Placebo Comparator|Placebo|
89192931|NCT05871060|Experimental|whey hydrolysate supplement|2,2 grams of whey hydrolysate dissolved in 100 mL of water
89413631|NCT04287790||Health professionals before intervention|Health professionals (physicians, advanced practice providers, pharmacists, social workers, and nurses) who work on the designated general medicine services at Yale New Haven Hospital after implementation intervention (December 2019)
88891087|NCT05062304||Fluticasone furoate-vilanterol|Reference group
88891088|NCT05062304||Fluticasone furoate-umeclidinium-vilanterol|Exposure group
88891089|NCT05058638|Experimental|Aquamin®|
88891090|NCT05057091|Experimental|Lomber Roll techniques group|Direct manipulation will be applied to the lumbar region with the lumbar Roll technique. Painful segment will be determined.
88891091|NCT05057091|Experimental|Posterior- anterior central vertebral manipulation techniques group|Another technique that we will use as a specific vertebral manipulation technique will be Maitland's posterior-anterior central vertebral manipulation and posterior - anterior unilateral central vertebral mobilization technique.
88891092|NCT05045534|Experimental|Cohort 1 Single Dose SD1 (first dose)|Group SD1 a first single dose of TB-840(n=6) or placebo(n=2)
88891093|NCT05045534|Experimental|Cohort 2 Single Dose SD2 (second dose)|Group SD2 a first single dose of TB-840(n=6) or placebo(n=2)
88891094|NCT05045534|Experimental|Cohort 3 Single Dose SD3 (third dose)|Group SD3 a first single dose of TB-840(n=6) or placebo(n=2)
88891095|NCT05045534|Experimental|Cohort 4 Single Dose SD4 (fourth dose)|Group SD4 a first single dose of TB-840(n=6) or placebo(n=2)
88891096|NCT05045534|Experimental|Cohort 5 Single Dose SD5 (fifth dose)|Group SD5 a first single dose of TB-840(n=6) or placebo(n=2)
88891097|NCT05045534|Experimental|Cohort 6 Single Dose SD6 (sixth dose)|Group SD6 a first single dose of TB-840(n=6) or placebo(n=2)
88891098|NCT05045534|Experimental|Cohort 7 Single Dose SD7 (seventh dose)|Group SD7 a first single dose of TB-840(n=6) or placebo(n=2)
88891099|NCT05045534|Experimental|Cohort 8 Single Dose SD8 (eighth dose)|Group SD8 a first single dose of TB-840(n=6) or placebo(n=2)
89413632|NCT04287790||Hospitalized patient after intervention|Patients discharged from the general medicine service at Yale New Haven Hospital York street campus following hospitalization for an alcohol related diagnosis 12 months after the start (January 1st 2020) of the implementation intervention
88891100|NCT05045534|Experimental|Cohort 9 : Mutiple Dose MD1|Group MD1 a first multiple dose of TB-840(n=6) or placebo(n=2)
88891101|NCT05045534|Experimental|Cohort 10 : Mutiple Dose MD2|Group MD2 a first multiple dose of TB-840(n=6) or placebo(n=2)
89192932|NCT05871060|Placebo Comparator|still flavoured water|100 mL of vanilla-flavoured water
89413633|NCT01408615||All Enrolled Participants|Women undergoing COS in combination with a GnRH antagonist for the development of multiple follicles in an ART program.
89413634|NCT04466332|Experimental|Saline ECG with Pilot Tip Location System|PICC insertion using electrocardiographic guidance Pilot Tip Location System (TLS), ECG signal transmission is with saline water
89413635|NCT04466332|Experimental|Guidewire ECG with Sherlock Tip Confirmation System|PICC insertion using electrocardiographic guidance Sherlock 3CG Tip Confirmation System (TCS), ECG signal transmission is with guidewire
88891102|NCT05045534|Experimental|Cohort 11 : Mutiple Dose MD3|Group MD3 a first multiple dose of TB-840(n=6) or placebo(n=2)
88891103|NCT05030324|Experimental|XC221 100 mg|Subjects will receive 1 tablet of XC221, 100 mg tablets orally in the morning (between 7:00 and 11:00) and 1 tablet of placebo in the evening (between 19:00 and 23:00) regardless of food intake for 5 days
88891104|NCT05030324|Experimental|XC221 200 mg|Subjects will receive 1 tablet of XC221, 100 mg tablets orally twice daily, in the morning (between 7:00 and 11:00) and in the evening (between 19:00 and 23:00) regardless of food intake for 5 days
88891105|NCT05030324|Placebo Comparator|Placebo|Subjects will receive 1 tablet of placebo orally twice daily in the morning (between 7:00 and 11:00) and in the evening (between 19:00 and 23:00) regardless of food intake for 5 days
88891106|NCT05029466|Experimental|Immediate treatment|Participants will commence psilocybin treatment immediately upon study enrollment.
88891107|NCT05029466|Experimental|Delayed treatment|Participants will commence psilocybin treatment two weeks after study enrollment.
88891108|NCT05018481|Placebo Comparator|HA35 Placebo Group|24 study participants will receive the standard of care treatment for AH and a 90-day supply of a placebo to take once a day with breakfast.
88891109|NCT05018481|Active Comparator|HA35 Treatment Group|24 study participants will receive the standard of care treatment for AH and a 90-day supply of a HA35 to take once a day with breakfast.
88891110|NCT05017649|Other|Healthy volunteers|volunteers showing no hypercholesterolemia
88891111|NCT05017649|Experimental|Patients with untreated hypercholesterolemia at the time of inclusion|patients presenting hypercholesterolemia with no treatment at the time of inclusion
88891112|NCT05017649|Experimental|Patients with treated hypercholesterolemia at the time of inclusion|patients presenting hypercholesterolemia and treated at the time of inclusion
88891113|NCT05007795|No Intervention|Programmatic MDR TB treatment regimen|Conventional MDR-TB laboratory tests. Sputum culture (and smear microscopy) will be evaluated monthly during the treatment period (and 6 monthly during the follow-up period) for the conventional arm.
89192933|NCT05865457|Experimental|BUFY02|0.3% Sodium Hyaluronate (trometamol buffer) in single-dose containers of 0.45 mL
89413636|NCT05015842|Experimental|Kinesio Tapping plus Conventional Physical Therapy - Experimental Group|"Both groups received conventional physical therapy treatment consisting of therapeutic exercise, heat therapy and manual therapy. All the patients received manual therapy techniques that including joint mobilization and therapeutic exercise that including piriformis stretching as well as bridging exercises to strengthen the core stability muscles (i.e., strengthening of transverses abdominis, erector spinae and lumbar multifidus).~The KT was applied to the back once a week with a treatment duration of 2 weeks. Each KT was applied for continuous three days and the next KT was applied after a break of two days. Each participant in the experimental group was assessed for any allergy reaction of the skin to KT."
89413637|NCT05015842|Other|Conventional Physical Therapy alone - Control Group|Both groups received conventional physical therapy treatment consisting of therapeutic exercise, heat therapy and manual therapy. All the patients received manual therapy techniques that including joint mobilization and therapeutic exercise that including piriformis stretching as well as bridging exercises to strengthen the core stability muscles (i.e., strengthening of transverses abdominis, erector spinae and lumbar multifidus).
89413638|NCT03723967|Experimental|Durvalumab with Carboplatin/Paclitaxel|Combination of Durvalumab with Carboplatin/Paclitaxel as first line treatment in patients with recurrent/metastatic SCCHN not eligible to standard chemotherapy
88891114|NCT05007795|Experimental|Sequence based resistance testing and individualized treatment|Sputum extracted for targeted sequencing and drug resistance profile provided to clinician for individualized treatment.
88891115|NCT05006885|Experimental|ALT-801 Dose Level 1|Administered once a week for 12 weeks
88891116|NCT05006885|Experimental|ALT-801 Dose Level 2|Administered once a week for 12 weeks
88891117|NCT05006885|Experimental|ALT-801 Dose Level 3|Administered once a week for 12 weeks
88891118|NCT05006885|Placebo Comparator|Placebo|Administered once a week for 12 weeks
88891119|NCT05001750|Experimental|continuous antibiotic use until the EVD is removed|continuous antibiotic use until the EVD is removed. Nafcillin 1-2 grams every 6 hours (depending on weight) until the EVD is removed. If penicillin allergic Doxycycline 100mg every 12 hours until the EVD is removed.
88891120|NCT05001750|No Intervention|antibiotics for a total of twenty-four hours|antibiotics for a total of twenty-four hours Nafcillin 1-2 grams every 6 hours (depending on weight) for a total of 24 hours. If penicillin allergic Doxycycline 100mg every 12 hours for a total of 24 hours.
88891121|NCT04994665|Active Comparator|Sleeve gastrectomy|realization of a sleeve gastrectomy alone
88891122|NCT04994665|Experimental|sleeve gastrectomy with omentopexy|realization of a sleeve gastrectomy followed by an omentopexy
88891123|NCT04984473|Sham Comparator|Sham arm|Perform inspiratory muscle training at 2% maximal inspiratory pressure for 12 weeks.
88891124|NCT04984473|Active Comparator|Non-sham arm|Perform inspiratory muscle training at 40% maximal inspiratory pressure for 12 weeks.
88891125|NCT04982575|Experimental|Cagrilintide 2.4 mg and semaglutide 2.4 mg|Participants will receive cagrilintide and semaglutide once a week as injections for 32 weeks.
88891126|NCT04982575|Active Comparator|Cagrilintide 2.4 mg and placebo (semaglutide)|Participants will receive cagrilintide and placebo (semaglutide) once a week as injections for 32 weeks
88891127|NCT04982575|Active Comparator|Semaglutide 2.4 mg and Placebo (cagrilintide)|Participants will receive semaglutide and placebo (cagrilintide) once a week as injections for 32 weeks
88891128|NCT04979884|Experimental|cyclosporine|patients will receive cyclosporine + (standard care treatment (± anticoagulant± antibiotic± antipyretic± steroid) according to Alexandria university hospitals protocol )
88891129|NCT04979884|Active Comparator|Standard of care treatment|patients will receive standard treatment (antiviral ± anticoagulant± antibiotic± antipyretic± steroid± interleukin ) according to Alexandria university hospitals protocol.
88891130|NCT04974463||Persistent Opioid Use at 3 months|Patients who continue to use opioids about 3 months after their joint replacement surgery
88891131|NCT04974463||No Persistent Opioid Use at 3 months|Patients who do not use opioids after about 3 months following joint replacement surgery
88891132|NCT04971304||G-CSF originator receipt|Patients receiving filgrastim (Neupogen) or pegfilgrastim (Neulasta) per Health Care Procedural Coding System (HCPCS) J-codes.
88891133|NCT04971304||G-CSF biosimilar receipt|Patients receiving filgrastim biosimilars (filgrastim-aafi, filgrastim-sndz, tbo-filgrastim) or pegfilgrastim biosimilars (pegfilgrastim-jmdb, pegfilgrastim-bmez, pegfilgrastim-cbqv) per Health Care Procedural Coding System (HCPCS) J-codes.
88891134|NCT04967352||Developed Persistent Opioid Use after 3 months following surgery|
88891135|NCT04967352||Did not develop persistent opioid use after 3 months following surgery|
88891136|NCT04962061|Experimental|Multidomain intervention|The multidomain intervention will combine a cognitive training with aerobic and resistance exercises training, three sessions per week for 46 weeks. Participants will be allowed to perform cognitive and exercise training sessions either home-based or centre-based.
88891137|NCT04962061|Experimental|Physical exercise intervention|The physical exercises intervention will include aerobic and resistance exercises training, three sessions per week for 46 weeks. Participants will be allowed to perform cognitive and exercise training sessions either home-based or centre-based.
88891138|NCT04962061|Active Comparator|Active control intervention|The active control intervention will include stretching and toning exercises, three sessions per week for 46 weeks. Participants will be allowed to perform cognitive and exercise training sessions either home-based or centre-based.
88891139|NCT04951115|Experimental|Radiation + Chemo-Immunotherapy|
89413639|NCT05009212|Experimental|ESt group|Endoscopic stricturotomy
89413640|NCT05009212|Active Comparator|EBD group|Endoscopic balloon dilatation
89413641|NCT05132569|Experimental|SAR442168|Tolebrutinib oral daily dose from baseline until Week 130
88891140|NCT04949503||study group|Patients of study group were all treated with chemoradiotherapy plus nimotuzumab.
88891141|NCT04949503||control group|Patients of control group were only treated with chemoradiotherapy, and were collected at least 3 times as many patients as the study group.
88891142|NCT04944043|Experimental|TQ05105 Tablet|TQ05105 tablet 10mg given orally, twice daily in 28-cycle.
88891143|NCT04940507|Experimental|Tumor cohort|"Intervention 1:~Participants will undergo a partial tumor ablation with MRgFUS using ExAblate Neuro 4000 device (InSightec Ltd, Tirat Carmel, Israel). Blood and CSF samples will be drawn on several timepoints before and after the procedure.~Intervention 2:~Participants will undergo a standard of care tumor biopsy/excision one day after the Intervention 1. Blood samples will be drawn on several timepoints before and after the procedure."
88891144|NCT04940507|Other|Essential tremor cohort|To identify the levels of circulating free DNA release after MRgFUS procedure in non-tumoral patients and to check whether the MRgFUS procedure induce tumoral mutations itself, we will draw blood samples from essential tremor patients before and after standard of care MRgFUS thalamotomy procedure.
88891145|NCT04940182|Experimental|XC221|XC221 100 mg orally. 1 tablet of XC221 100 mg 2 times a day during 14 full days of treatment period
88891146|NCT04940182|Placebo Comparator|Placebo|Placebo orally. 1 tablet of Placebo 2 times a day during 14 full days of treatment period
88891147|NCT04938466||Transition to long-acting growth hormone (LAGH)|Participants in this arm will transition between daily growth hormone treatment and long-acting growth hormone treatment.
88891148|NCT04938466||Consistent daily growth hormone (DGH)|Participants in this group will continue with daily growth hormone treatment.
88891149|NCT04937283|Experimental|Segmentectomy with systemic lymph node dissection|Segmentectomy with hilar and mediastinal lymph node dissection is performed. If the tumor located at inter-segment plane and without sufficient resection margin distance, a combined segmentectomy will be performed after a comprehensive evaluation. As with lobectomy, systemic or selective lymph node dissection is mandatory, and nodal sampling is not allowed. At least three stations of mediastinal lymph node from 2R, 4R, 7, 8, 9 for the right side and 5, 6, 7, 8, 9 for the left side, respectively. The distance from the dissection margin to the tumor edge must be evaluated in the same manner as with lobectomy. When lymph node metastasis is present or resection margin is not cancer-free, the surgical procedure must be converted to a lobectomy.
88891150|NCT04937283|Active Comparator|Lobectomy with systemic lymph node dissection|"lobectomy with hilar and mediastinal lymph node dissection is performed. Systemic or selective lymph node dissection is mandatory, and nodal sampling is not allowed. At least three stations of mediastinal lymph node from 2R, 4R, 7, 8, 9 for the right side and 5, 6, 7, 8, 9 for the left side, respectively.~The distance from the dissection margin to the tumor edge must be evaluated intraoperatively. If the distance is either less than the maximum tumor diameter or ,20 mm, the absence of cancer cells in the resection margin must be histologically or cytologically confirmed before finishing surgery."
88891151|NCT06257303|Active Comparator|Valgus Group|If there is an increase of 10 degrees or more in the frontal plane projection angle while squatting on one leg, the participant will be included in this group.
88891152|NCT06257303|Active Comparator|Control Group|If the frontal plane projection angle is in the normal values while squatting on one leg, the participant will be included in this group.
88891153|NCT06257225|Active Comparator|Patient showing horizontal defect and treated with GBR stabilized with Tacs|Fixation
88891154|NCT06257225|Experimental|Patient showing horizontal defect and treated with GBR stabilized with no Tacs|No Fixation
88891155|NCT06257160|Active Comparator|Surgical infiltration|
88891156|NCT06257160|Experimental|PENG Block ultrasound-guided|
88891157|NCT06257134|Other|Control group|Patients in the control group will complete three HRQoL questionnaires every six months via a digital tablet during their dialysis session.
89192934|NCT05865457|Active Comparator|TRB02|0.3% Sodium Hyaluronate (phosphate buffer) in single-dose containers of 0.45 mL
89192935|NCT05865379|Experimental|BUFY01|0.18% Sodium Hyaluronate (trometamol buffer) in single-dose containers of 0.3 mL
89413642|NCT05132569|Placebo Comparator|Placebo|Matching placebo oral daily dose only for DB period
89413643|NCT05008666|Experimental|L-DEP, Sintinimab+Chidamide, Sintinimab+Azacitidine|"【L-DEP】~L-asparaginase: 2000U/m2 d5, im~Doxorubicin liposome: 25mg/m2 d1, ivd~Etoposide: 100mg/m2 d1, d8, d15, ivd~Methylprednisolone: 15mg/kg/day d1-3, 0.75mg/kg/day, d4-7, 0.25mg/kg/day, d8-14, ivd~【Sintinimab+Chidamide】~Sintinimab: 200mg，d1,ivd,q21d Chidamide：30mg biw, continued oral~【Sintinimab+Azacitidine】~Sintinimab:200mg，d1, ivd, q21d Azacitidine:75mg/m2, d1-d7, ih, q28d"
89413644|NCT03092128||sensitive group; non-sensitive group|sensitive patients were defined as patients reached CR or PR after first month administration,SD after first three months administration. non-sensitive patients were defined as patients reached PD after first month administration and first three months administration.
89413645|NCT05021380||Group|50 generally healthy children diagnosed with dental pain as symptomatic irreversible pulpitis (SIP) or symptomatic apical periodontitis (SAP) aged from 6 to 12 years old will be included to the GROUP.
89413646|NCT03079648|Experimental|Angelica gigas N. extract|capsules (2cap/d, 1,000mg/d) for 12 weeks.
89413647|NCT03079648|Placebo Comparator|Placebo|Placebo for 12 weeks
89413648|NCT03659461|Experimental|low GLP-1 arm|Subjects are required to take oral 100mg Sitagliptin (Januvia) daily before breakfast for 12 weeks. 100mg is the recommended treatment dose. During the treatment with Januvia, subjects are not allowed to take any other medications except metformin
88891158|NCT06257134|Experimental|Experimental group|Every three months, patients in the experimental group will have their symptoms systematically recorded using the IPOS-Renal questionnaire via a digital tablet during their dialysis session.
88891159|NCT06257121|Experimental|SGRT|Patient position will be managed by optical surface management system (OSMS). Equipment for this procedure includes an IMRT board, a long head cushion (with transparent Timo, moldcare, and shim), anatomical markers the cushion (shoulders, under the chin, etc.), a kneefix and arm plates. Every day, prior to treatment, there will be (1) A lateral kilo voltage (kV) image for jaw positioning and (2) a CBCT with standard match (3D column then 3D GTV/PTV). During treatment, patients will undergo real-time monitoring with the VisionRT system (SGRT). A second CBCT will de carried mid-treatment (after the 2nd of 3 arcs) and patient's position will be adjusted if deemed necessary.
88891160|NCT06257108|Experimental|Restorative group|Class II restorations using chlorhexidine-containing bonding agent in Primary molars in children aged between 5-9 years.
88891161|NCT06257108|Active Comparator|Control Group|Class II restorations using standard bonding agent in Primary molars in children aged between 5-9 years.
88891162|NCT06257095|Experimental|Treatment|
89192936|NCT05865379|Active Comparator|SVS20|0.18% Sodium Hyaluronate (phosphate buffer) in single-dose containers of 0.3 mL
88891163|NCT06257095|Active Comparator|Usual Care|
88891164|NCT06257082|Active Comparator|Patient plus Clinician Combined Testimonials|In addition to being randomized for online survey participants, focus groups will view patient plus clinician combined testimonials.
88891165|NCT06257082|Active Comparator|Clinician Only Testimonials|
88891166|NCT06257082|Active Comparator|Patient Only Testimonials|
88891167|NCT06257082|Active Comparator|National Eye Institute video Control|
88891168|NCT06257082|Active Comparator|Pre-video questionnaire-only Control|
88891169|NCT06257030||TARE group|
88891170|NCT06257017|Experimental|Gemcitabine plus cisplatin chemotherapy arm (GC arm)|Patients in this group will receive adjuvant chemotherapy of gemcitabine and cisplatin, prior to radiological progression
88891171|NCT06257017|Other|Standard management arm (SM arm)|Patients in this group will receive chemotherapy of gemcitabine and cisplatin only after radiological progression is observed
88891172|NCT06257004||AMC (Affected Mutation Carrier)|FBN1 mutation (Marfan Syndrome) - Phenotype cardiovascular severe outcome
88891173|NCT06257004||UMC (Unaffected Mutation Carrier)|FBN1 mutation (Marfan Syndrome) - Phenotype cardiovascular mild outcome
88891174|NCT06256978||Critical care patients|
88891175|NCT06256965||patients with present reduced left ventricular ejection fraction|patients with preoperatively shows in echocardiographic parameters LVEF lower 40%.
88891176|NCT06256965||patients with present preserved left ventricular ejection fraction|patients with preoperatively shows in echocardiographic parameters LVEF higher 40%.
88891177|NCT06256952|Experimental|Control (HC) - exclusion first|Healthy participants without SUD Cyberball: Exclusion Day 1; Cyberball: Inclusion Day 2
88891178|NCT06256952|Experimental|Control (HC) - inclusion first|Healthy participants without SUD Cyberball: Inclusion Day 1; Cyberball: Exclusion Day 2
88891179|NCT06256952|Experimental|Moderate to sever alcohol users (AUD) - exclusion first|Participants with alcohol use disorder (moderate to severe if no withdrawal symptoms) and no other substance use disorder (SUD) Cyberball: Exclusion Day 1; Cyberball: Inclusion Day 2
88891180|NCT06256952|Experimental|Moderate to sever alcohol users (AUD) - inclusion first|Participants with alcohol use disorder (moderate to severe if no withdrawal symptoms) and no other substance use disorder (SUD) Cyberball: Inclusion Day 1; Cyberball: Exclusion Day 2
88891181|NCT06256939|Experimental|Intervention Group|The Therapy BRIDGE program is a prospective, longitudinal, non-randomized pilot study for infants diagnosed with IVH and their caregivers. The Therapy BRIDGE program will begin as the infant is nearing discharge from the NICU and continue as the infant transitions to home. It will use a hybrid model including both in-person and telehealth sessions.
88891182|NCT06256939|No Intervention|Control Group|In the instance that a patient is deemed eligible to participate in the Therapy BRIDGE program and the caregiver chooses not to participate, the caregiver will be offered the opportunity to be enrolled in the control arm of our study as part of a monitoring group. This group of patients will continue to receive usual care while admitted to the NICU and any outpatient recommendations will be deferred to the primary NICU therapists caring for the infant based on the patient's individualized needs.
88891183|NCT06256926|Active Comparator|Drug Product|Test Product: Curcuvail® 250 mg capsule
88891184|NCT06256926|Placebo Comparator|Placebo Product|Placebo Product
88891185|NCT06256913||Patients with sarcomeric hypertrophic cardiomyopathy and cardiovascular events|Patients with confirmed sarcomeric hypertrophic cardiomyopathy who experienced cardiovascular events.
88891186|NCT06256913||Patients with sarcomeric hypertrophic cardiomyopathy free of cardiovascular events|Patients with confirmed sarcomeric hypertrophic cardiomyopathy free of cardiovascular events.
88891187|NCT06256900|Experimental|Flow-controlled ventilation|Experimental intervention FCV (EVONE, Ventinova Medical): PEEP and Peak inspiratory pressure titration guided by dynamic compliance.
88891188|NCT06256900|Active Comparator|Pressure-controlled ventilation|Control intervention PCV (Dräger Medical, Atlan A350): lung-protective ventilation to current best practice. Settings determined by the attending anesthesiologist (based on the internal SOP: intraoperative ventilation in robot-assisted laparoscopic surgery).
88891189|NCT06256887||Infants at risk of Cerebral Palsy|N= 20, Infants at risk of Unilateral Cerebral Palsy (UCP); N= 20, Infants at risk of Bilateral Cerebral Palsy (BCP).
89192937|NCT05863442|Active Comparator|Soliris|
88891190|NCT06256887||Infants with diagnosis of SMA1|N=20, Infants with a diagnosis of SMA type 1.
89192938|NCT05863442|Experimental|TUR03|
89413649|NCT03659461|Active Comparator|normal GLP-1 arm|Subjects are required to take oral 100mg Sitagliptin ( Januvia) daily before breakfast for 12 weeks. 100mg is the recommended treatment dose. During the treatment with Januvia, subjects are not allowed to take any other medications except metformin
89413650|NCT03088618|Experimental|Patients with septal deformity|To evaluate the safety and efficacy of surgical material for nasal septoplasty in septal deformity patients with nasal obstruction
89413651|NCT01227187|Experimental|Xigris|Drotrecogin alfa activated (Xigris) used as anticoagulant in patients treated with hemodialysis.
89413652|NCT03088072|Other|Edoxaban Arm|All patients enrolled in the study will receive 6 weeks of edoxaban therapy, at which time a TEE will be performed. If the result is acceptable, edoxaban will be discontinued, and the patient will be treated with dual antiplatelet therapy (aspirin and clopidogrel) until 6 month follow-up. If device thrombus is present at 6 week TEE, patient will be transitioned to aspirin and adjusted-dose warfarin and LAA reassessed by TEE in 6 weeks; further warfarin will be continued according to operator preference. Subjects will have a 6 month follow-up visit prior to study completion. After study completion, patients may be treated with aspirin monotherapy according to the FDA instructions for use for the WATCHMAN device, or according to operator discretion.
89413653|NCT05008042|Active Comparator|Mecobalamine 5 mg/ml|The active substance of vitamin B12 given in the study is Mecobalamin 5mg / ml 2 ml ie 10 mg and is given intramuscularly.
89413654|NCT05008042|Placebo Comparator|NaCl 9mg/ml|Placebo substance given in the study is Sodium Chloride (NaCL) 9 mg / ml 2 ml, isotonic solution for parenteral use (Baxter) given intramuscularly.
88891191|NCT06256887||Infants at very low neurodevelopmental risk (control group)|N=20, Infants born preterm or at term in absence of perinatal neurological complications, therefore a very low neurodevelopmental risk.
88891192|NCT06256796|No Intervention|moderate group controlled patients|
88891193|NCT06256796|Experimental|moderate group study patients|
88891194|NCT06256796|No Intervention|sever controlled group|
88891195|NCT06256796|Experimental|sever study group|
88891196|NCT06256783|Experimental|Treatment group|Once enrolled, participants will be administrated Baozhu Keli and followed by a 3-month medication cycle. The usage of this herbal compound is to take orally twice a day(two sacks per). Add it to about 200ml warm water and take it half an hour before breakfast in the morning and half an hour before bedtime in the evening except menstrual period.
88891197|NCT06256770||scleral contact lenses group|The selected patients were equipped with scleral contact lenses to evaluate their best corrected visual acuity, refraction, ocular surface condition, and fitting status of contact lenses.
88891198|NCT06256770||RGP group|The selected patients were equipped with RGP to evaluate their best corrected visual acuity, refraction, ocular surface condition, and fitting status of contact lenses.
88891199|NCT06256757|Experimental|A（extracorporeal fenestration）|Based on the preoperative CTA reconstructions, the diameter of the aorta and branch vessels, lengths, angles to the arch, clock positions, and related relationships are measured, and a preoperative design for the fenestrations is developed. The outer sheath of the stent graft is then pushed back for several centimeters under sterile conditions, allowing the proximal portion of the stent graft to be released. The length of the released segment should be one to two centimeters distal from the location of fenestration. Using a sterile ruler, the location of the fenestration is determined in accordance with the preoperative plan. The 12 o'clock position is considered to be at the front of the trigger. The position of the stent graft relative to the trigger is also referred to as the 12 o'clock position. If the fenestration must avoid stent struts, then the fenestration is deemed to be at 12 o'clock, as is the position of the trigger relative to the stent graft.
88891200|NCT06256757|Sham Comparator|B（In situ fenestration）|From the left brachial artery (LBA), a 6F angle-adjustable sheath (Lifetech, Inc., Shenzhen, China) is introduced retrogradely until its tip reaches the aortic stent graft. The tip is then adjusted to be as perpendicular as possible to the larger curve of the aortic stent graft. Once the sheath gets to the ideal position, a flexible needle (21 gauge, Futhrough, Lifetech, Inc.) is employed to create the fenestration in the aortic stent graft. Following the puncture, a 0.018-inch guidewire (V-18 ControlWire; Boston Scientific, Natick, MA) is inserted through the needle aperture and into the ascending aorta.
88891201|NCT06256744|Experimental|Protein supplementation|Protein supplementation
88891202|NCT06256731||Single cohort of MS patients with EDSS 1.0-4.5|Confirmed diagnosis of MS with an EDSS score ranging from 1.0 and 4.5.
88891203|NCT06256718|Other|Health services research (PC TEACH)|Primary practice providers sites receive PC TEACH over 3.5 hours for 12 months
88891204|NCT06256640|Experimental|Intervention|
88891205|NCT06256627|Active Comparator|"Analyzing the effect of IFN-α- 1b, il-2, and thalidomide on negative conversion rate of MRD ."|"Analyzing the effect of interference'- α- 1b, interleukin-2, and thalidomide on negative conversion rate of MRD in AML patients who have obtained CR or CRi but are MRD positive after routine induction and consolidation chemotherapy"
88891206|NCT06256627|Active Comparator|"To evaluate whether the ITIVA regimen as maintenance treatment can improveRFS in AML patients"|"To evaluate whether the combination of recombinant human interference'- α- 1b, interleukin-2, and thalidomide, Venentoclax and Azacitidine triple alternative maintenance treatment can improve relapse free survival (RFS) in AML patients who have achieved CR or CRi through conventional induction and consolidation chemotherapy"
88891207|NCT06256588|Experimental|Arm A: Dostarlimab|
88891208|NCT06256588|Placebo Comparator|Arm B: Placebo|
89413655|NCT03619447|Active Comparator|ESP block group|Under general anaesthesia, Ultrasound guided ESP block will perform at the T6 level with15 ml bupivacain+ 5ml lidocaine, bilaterally. Morphine 0.1 mg/kg will administer at last 30 minutes of surgery for postoperative analgesia. Patient controlled analgesia (PCA) with morphine will apply to the all patients. Postoperative pain assessment and morphine consumption will record till the postoperative 24 th hours.
89413656|NCT03619447|Active Comparator|serratus block group|Under general anaesthesia, Ultrasound guided SAP block will perform at the T6 level with15 ml bupivacain+ 5ml lidocaine, bilaterally. Morphine 0.1 mg/kg will administer at last 30 minutes of surgery for postoperative analgesia. Patient controlled analgesia (PCA) with morphine will apply to the all patients. Postoperative pain assessment and morphine consumption will record till the postoperative 24 th hours.
89413657|NCT05015140|Experimental|experiment group|"The first day before the application of music to each of the 15 patients in the experimental group (D-1) 'Patient Identification First evaluation will be made by filling the form and then the Richard Campbell Sleep Questionnaire . The day before transplant (D-1) Starting from 10 days, calm music including nature sounds determined by the music therapist will be played using mp3 player. The Richard Campbell Sleep questionnaire will be filled again on the 10th day (D + 10) after the transplant."
89413658|NCT05015140|No Intervention|control group|"- The day before the transplant (D-1) for each of the 15 patients in the control group, first 'Patient Identification Form' and then 'Richard The first evaluations will be made by filling the Campbell Sleep Questionnaire, and standard treatment and care interventions will be given to the patients in this group.~The sleep questionnaire was filled out again on the tenth day (D + 10) after the transplant without any intervention."
89413659|NCT05021302|Placebo Comparator|Kegel exercises group|20 women in this group
89413660|NCT05021302|Experimental|Electromagnetic stimulation group|20 women in this group
88891210|NCT06256497||DMR Treated Patients|
88891211|NCT06256484|Experimental|ATA3219 Dose Level 1|Participants will receive a single IV infusion of ATA3219 Dose Level 1 on Day 1.
89413661|NCT03079258|Experimental|Exercise|Participants randomized to the exercise intervention group will be required to complete a 24-wk partially supervised exercise programme consisting of 3-4 sessions per week of 15 minutes progressing to 30 minutes over time.
89413662|NCT03079258|No Intervention|Control|Those randomized to the control group will continue with their standard care.
88891212|NCT06256484|Experimental|ATA3219 Dose Level 2|Participants will receive a single IV infusion of ATA3219 Dose Level 2 on Day 1.
88891213|NCT06256484|Experimental|ATA3219 Dose Level 3|Participants will receive a single IV infusion of ATA3219 Dose Level 3 on Day 1.
88891214|NCT06256484|Experimental|ATA3219 Dose Level 4|Participants will receive a single IV infusion of ATA3219 Dose Level 4 on Day 1.
88891215|NCT06256419|Experimental|efficacy difference of GLP-1RA|Responders group and non-responders group
88891216|NCT06256406|Active Comparator|kangaroo care|Kangaroo care Arm subjected to Kangaroo care, a practice involving skin-to-skin contact between the infant and a caregiver.
88891217|NCT06256406|Active Comparator|Music therapy|Music therapy Arm subjected to music therapy, a practise improving perception of newborns
88891218|NCT06256367||Cariprazine|Participants will receive cariprazine as prescribed by their physician in routine clinical practice. The decision to initiate cariprazine should be made prior to, and independently from, the decision to participate in this study.
88891219|NCT06256341||allogeneic HSCT peripheral blood|3, 6, 9, 12, 18 and 24 months after allogeneic HSCT peripheral blood mononuclear cells were isolated from patient blood, stimulated with HHV-6-specific antigen (U54) and cultured for 10 days.
88891220|NCT06256341||healthy blood|One blood sample from a age and sex matched healthy controls without any inflammatory, immunological or infectious disease was taken. mononuclear cells were isolated from patient blood, stimulated with HHV-6-specific antigen (U54) and cultured for 10 days.
88891221|NCT06256328|Experimental|ONO-4578+Nivolumab+chemotherapy|
88891222|NCT06256328|Placebo Comparator|placebo+Nivolumab+chemotherapy|
88891223|NCT06256315|Experimental|Group A:Hyper-ERAS(Length of Postoperative Hospital Stay<48h)|Patients treated with the Hyper-ERAS rehabilitation protocol and discharged within 48 hours were in group A.
88891224|NCT06256315|Experimental|Group B:Hyper-ERAS(LOPS>48h)|Patients treated with the ERAS rehabilitation protocol and discharged in more than 48 hours were in group B.
88891225|NCT06256315|No Intervention|Group C:Control group|Patients eligible but not treated with the Hyper-ERAS rehabilitation protocol during the same period were in group C.
88891226|NCT06256302|Experimental|Transverses abdominis plane block|
88891227|NCT06256302|Active Comparator|Local wound infiltration|
88891228|NCT06256289|Experimental|canagliflozin plus metformin group|canagliflozin 100 mg once daily plus metformin 1000 mg twice daily
88891229|NCT06256289|Active Comparator|metformin group|metformin 1000 mg twice daily
88891230|NCT06256276|Experimental|Whey protein powder and L-carnitine capsules|Subjects will daily consume whey protein powder to supplement normal daily protein intake up to 1.2g protein/kg body weight per day (1 or 2 scoops powder), as well as 2 capsules (1 gram) L-carnitine for 16 weeks.
88891231|NCT06256276|Placebo Comparator|Maltodextrin placebo powder and Psyllium Husk capsules|Subjects will daily consume maltodextrin powder as if to supplement normal daily protein intake up to 1.2g protein/kg body weight per day (1 or 2 scoops powder), as well as 2 capsules (1 gram) psyllium husk for 16 weeks.
88891232|NCT06256263|Active Comparator|stapler repair group|pharyngeal repair after total laryngectomy was done by using a linear stapler
88891233|NCT06256263|Active Comparator|conventional repair group|pharyngeal repair after total laryngectomy was done by the conventional method (stitching).
88891234|NCT06256250|Experimental|group (1): the adaptive xp endo shaper|the root canals of primary molars will be cleaned and shaped in pulpectomy treatment using the adaptive xp endo shaper. it is single file technique saves time and help with patient cooperation.
88891235|NCT06256250|Experimental|group (2): Fanta AF baby file|the root canals of primary molars will be cleaned and shaped in pulpectomy treatment using FANTA AF baby files. it is pediatric rotary system consists of 4 files specialized for primary molars.
88891236|NCT06256250|Active Comparator|group (3): hand k files|the root canals of primary molars will be cleaned and shaped in pulpectomy treatment using hand k files. they are manual files, they are standard for root canal treatment (control group)
88891237|NCT06256237|Experimental|Neoadjuvant Therapy With Toripalimab and JS004 Combined With Etoposide and Platinum Chemotherapy|In this arm, 30 patients with limited-stage small cell lung cancer will receive 4 circles of neoadjuvant toripalimab and JS004 combined with etoposide and platinum chemotherapy. And those resectable after neoadjuvant therapy will be treated with surgery. Postoperative patients receive two cycles of toripalimab and JS004 combined with etoposide and platinum chemotherapy. then patients received maintenance treatment with toripalimab and JS004 until the disease progressed.
88891238|NCT06256224|Experimental|Toripalimab+CCRT|"External beam radiotherapy (EBRT) of 45-50.4Gy was delivered using intensity modulated radiation therapy (IMRT) technique to the pelvic ± para-aortic fields in 25-28 fractions, 5 days a week and was followed by brachytherapy of 24-30Gy in 3-5 fractions, once a week. Concurrent chemotherapy of cisplatin, with a dose of 40 mg/m2 by intravenous infusion, was administered once a week for 5 weeks during EBRT.~Toripalimab 240mg by intravenous infusion was administered every 3 weeks for 6 months and maintained upto 2 years for those whose lesions did not reach complete remission at six-month follow-up."
88891239|NCT06256224|Active Comparator|CCRT|EBRT of 45-50.4Gy was delivered using IMRT technique to the pelvic ± para-aortic fields in 25-28 fractions, 5 days a week and was followed by brachytherapy of 24-30Gy in 3-5 fractions, once a week. Concurrent chemotherapy of cisplatin, with a dose of 40 mg/m2 by intravenous infusion, was administered once a week for 5 weeks during EBRT.
88891240|NCT06256211|Other|Group has treated by Intravenous Paracetamol|"Intravenous paracetamol dose 15 mg/kg body weight every 6 hours for 3 days (12 doses in total).~After the 3-day follow up echocardiogram will be done."
88813036|NCT01557959|Experimental|Treatment (chemo, chemoprotection, antiangiogenesis therapy)|Patients receive docetaxel IV over 1 hour on day 1, cisplatin IV over 1 hour on day 1, and pegfilgrastim subcutaneously on day 2. Treatment repeats every 2 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Beginning 2 weeks after completion of docetaxel, cisplatin, and pegfilgrastim, patients receive oral erlotinib hydrochloride once daily in the absence of disease progression or unacceptable toxicity.
89192939|NCT05858541|Experimental|Music Listening|Music Intervention - Music selection by LUCID The AI-based system for song selection responds to the collected measurement data (video and HRV) and music preference information (like/dislike button, music taste profile) to recommend the playlist for the listener. The songs are selected using 76 different musical features and raw audio information. The system uses these features to recommend and optimize recommendations for the listener. The video is only temporarily streamed from the device to extract a series of facial features to assist in music selection. This data stream is sent to the LUCID cloud platform via encrypted data in transit protocol; the facial features are extracted, and the video is deleted. The facial feature data, even when reconstructed, is not identifiable. No personally identifiable biometric measures are stored in LUCID servers at any time
89192940|NCT05858541|Active Comparator|Audiobooks|Audiobook selection A selection of 40 audiobooks spanning 4 genres (10 each from Literary Classics, Fantasy, Mystery, Non-fiction) will be available. For each session, the participant and their caregiver will be given a prompt to make a genre selection. After making the genre selection, one of the ten stories associated with that genre will be selected at random. All stories were sampled from the Audible audiobook database. Stories had to be 30 minutes in length to align with the length of the music interventions and the selected stories had to have had a 4- or 5-star rating to ensure quality.
89192941|NCT05858112||Patients with suspected MI|
89192942|NCT05855746|Experimental|Colchicine|Participant receive in addition to standard of care therapy, six months of Colchicine
89192943|NCT05855746|Placebo Comparator|Placebo|Participant receive in addition to standard of care therapy, six months of placebo
89192944|NCT05855447||Fibrosing Lung Disease Group|It will consist of 36 patients diagnosed with ILD. The patients whose demographic information such as age, height and weight will be questioned will then be evaluated with a desktop spirometer, peripheral muscle strength measurement with a digital myometer, and functional capacity with a 6MWT. The Moxy device, which is a NIRS, will be attached to the upper leg (the vastus lateralis of the quadriceps muscle) and the rib (intercostal muscles) with a silk patch, and the oxygenation of the muscles here will be measured during the 6MWT. In addition, fatigue status will be evaluated with the Modified Borg Scale.
89437576|NCT03574623|Active Comparator|cNMES|Cyclic Neuromuscular Electrical Stimulation (cNMES) uses an electrical stimulator and surface electrodes over the paretic finger and thumb extensors to deliver electrical stimulation to open the weak hand. The stimulation automatically turns on and off causing the weak hand to open repetitively for several seconds at a time. During the lab visits, participants in the cNMES group will receive occupational therapy task practice. During their home sessions, participants in the cNMES group will use cNMES to perform hand opening exercise.
88813037|NCT03212456|Experimental|Opioid-free|The patients of this group will receive opioid-free anesthesia
88813038|NCT03212456|Active Comparator|Non opioid-free|The patients in this group will receive the same induction and maintenance drugs of the experimental group but with fentanyl 3 - 5 mcg/kg on induction and during the procedure as needed.
88813039|NCT04380272||Brodsky tonsil staging system|An oropharynx examination of all participants will be performed and tonsil size will be evaluated according to the Brodsky staging system. According to this staging system, tonsil sizes will be classified as stage I when the tonsils fill less than 25% of the transverse oropharyngeal space measured between the anterior tonsillar pillars; stage II when they fill between 25% and 50%, stage III when they fill between 50% and 75%, and stage IV when they fill more than 75%.
88813040|NCT04380272||The ultrasonographic data|The submental ultrasonography will be performed on all participants. Ultrasonographic examinations will be performed blinded to the physical examination results. All measurements will be performed by the same radiologist with experience in the field of ultrasonography. A GE LOGIQ E9 (GE Healthcare, Milwaukee, WI, USA) device will be used in the ultrasonography examination. The participants will be viewed using a 2-9 MHz linear probe from the submental region. The examination will be performed while the patient was lying in a supine position with a support placed under the neck.
88813041|NCT03212612||2 groups , control and cases|"Groupe 1: (cases) 45 women who were found to have surgically and histolopathologically -confirmed endometriosis. Endometrial samples(1-2 gram) will be taken by laparoscopy which is the gold standard for definitive diagnosis of endometriosis.~Group2:(control) 45women who were free of endometriosis. Endometrial samples(1-2 gram) will be taken by punch biopsy."
88813042|NCT03218150||bone cement group|patient underwent to cranioplasty reconstruction with customized hydroxyapatite prosthesis
88813043|NCT03218150||titanium mesh group|patient underwent to cranioplasty reconstruction with titanium mesh
88891241|NCT06256211|Other|Group has treated by Rectal Paracetamol|"Rectal paracetamol at a dose of 25 mg/kg body weight with started and then continued at a dose of 15 mg/kg body weight every 8 hours for 3 days (ten doses in total) in neonates weighing more than 1000 gm.~The patient's weight is less than 1000 gm, the initial dose was 15 mg/kg body weight, and the suspense doses are 7.5 mg/kg body weight every 8 hours for 3 days (10 doses in total)."
88891242|NCT06256198||Group S|survivors
89437577|NCT03574623|Active Comparator|Task Oriented Therapy|Task Oriented Therapy (TOT) focuses on practicing using the weak hand to practice activities of daily living tasks. During the clinic visits, participants in the TOT group will receive occupational therapy task practice. During their home sessions, participants in the TOT group will practice using their hand to complete a list of tasks given to them by the therapist to ensure that the participant receives a high dose of task practice.
88891243|NCT06256198||Group M|non survivors
88891244|NCT06256185|Experimental|Arm used for predicting lymph node metastasis|
88891245|NCT06256172|Experimental|Medlink RPM|The 10 Patients enrolled in this arm tested the ue of Medlink in Measuring and reporting their Physiological Paramters in Oder to remotely obtain access to health care for the following diseases: Myasthenia Gravis, Hypertension, Chronic Heart Failure, Diabetes Mellitus, and Chronic Obstruction Pulmonary Disorder.
89192945|NCT05850884||group A|• One hundred stool samples will be collected from patients with intestinal cancer admitted to Sohag Hospital.
88891247|NCT06256133||ANS-Surg-ERAS group|fully implementing ERAS pathway including anesthesiology-related components
88891248|NCT06256133||Surg-ERAS group|preoperative and postoperative ERAS protocol without anesthesiology-related components
88891249|NCT06256133||Conventional group|non-ERAS group
88891250|NCT06256107|Experimental|Intervention|The intervention period will last 4 weeks where participants will be required to use the VR set and document the time of use in a daily diary
88891251|NCT06256094|Experimental|a2 Platinum Premium Infant Formula Stage 1|a2 Platinum Premium Stage 1 (0-6 months) cow's milk based powder infant formula
88891252|NCT06256094|Active Comparator|Frisolac Infant Formula Stage 1 (Dutch Edition)|Dutch Edition of the Frisolac Stage 1 (0-6 months) cow's milk based powder infant formula
88891253|NCT06256081|Active Comparator|Children with hearing loss secondary to glue ear|Children accessing the community audiology NHS services due to concerns about hearing loss who have a diagnosis of glue ear (also known as otitis media with effusion, OME)
88891254|NCT06256081|Sham Comparator|Children with normal hearing|Children accessing the community audiology NHS services due to concerns about hearing loss who do not have a diagnosis of glue ear (also known as otitis media with effusion, OME) and are confirmed as having normal hearing.
88891255|NCT06256068||study group|"Study group: 144 children children >1 year and <5 years from a cancer treatment completion involving cardiotoxicity risk factors and are now in the follow-up observation.~Participants' examination is going to compromise:~exercise capacity test (CPET) to examine the exercise capacity,~extended ALPHA (Assessing Levels of Physical Activity) health-related fitness test battery to assess physical function,~echocardiography to examine cardiac function,~questionnaires: Pediatric Quality of Life Inventory (PedsQL) to assess quality of life, Physical Activity and Leisure Motivation Scale (PALMS) to assess motivation to physical activity and original questionnarie to asses lifestyle, socio-demographic, self-efficacy, anthropogenic factors,~examination with the use of ActiGraph GT3X Accelerometer - a wearable tool on the elastic belt to measure physical activity level, measurement for 14 days."
88891256|NCT06256068||control group|"The control: 144 children who are >1 year and <5 years from a cancer treatment completion without cardiotoxicity risk factors and are now in the follow-up observation.~Participants' examination is going to compromise:~exercise capacity test (CPET) to examine the exercise capacity,~extended ALPHA (Assessing Levels of Physical Activity) health-related fitness test battery to assess physical function,~echocardiography to examine cardiac function,~questionnaires: Pediatric Quality of Life Inventory (PedsQL) to assess quality of life, Physical Activity and Leisure Motivation Scale (PALMS) to assess motivation to physical activity and original questionnarie to asses lifestyle, socio-demographic, self-efficacy, anthropogenic factors,~examination with the use of ActiGraph GT3X Accelerometer - a wearable tool on the elastic belt to measure physical activity level, measurement for 14 days."
89192946|NCT05850884||group B|one hundred stool samples will be collected from the control group of patients who attended outpatient clinics
89413663|NCT05021068||COPD Patients|"The respiratory functions of the participants will be measured in accordance with the ATS-ERS criteria. After measurement; forced expiratory volume in one second (FEV1), forced vital capacity (FVC), FEV1/FVC, total lung capacity (TLC), residual volume (RV), inspiratory capacity (IC), vital capacity (VC) parameters will be recorded.~Spinal structure and mobility will be evaluated with the Spinal Mouse device in the sagittal and frontal planes in standing and sitting positions. For the sagittal plane, the measurements were first in the neutral, then in the maximum flexion and extension positions, for the frontal plane; neutral, right and left lateral flexions will be performed.~Patients will be asked to mark the level of activity that causes dyspnea on the Medical Council Research Scale (MMRC) Dyspnea Score."
89413664|NCT05021068||Control Group|"The respiratory functions of the participants will be measured in accordance with the ATS-ERS criteria. After measurement; forced expiratory volume in one second (FEV1), forced vital capacity (FVC), FEV1/FVC, total lung capacity (TLC), residual volume (RV), inspiratory capacity (IC), vital capacity (VC) parameters will be recorded.~Spinal structure and mobility will be evaluated with the Spinal Mouse device in the sagittal and frontal planes in standing and sitting positions. For the sagittal plane, the measurements were first in the neutral, then in the maximum flexion and extension positions, for the frontal plane; neutral, right and left lateral flexions will be performed.~Patients will be asked to mark the level of activity that causes dyspnea on the Medical Council Research Scale (MMRC) Dyspnea Score."
88891257|NCT06256042|Active Comparator|Arthrocentesis|Delimitation of a corner-tragus line to mark points A (10mm in front of the tragus and 2mm below the CT line) and B (20mm in front of the tragus and 10mm below the CT line); Local intra- and extra-oral antisepsis with aqueous chlorhexidine 0.12% and 0.2%, respectively; Local anesthesia of the auriculotemporal and intra-capsular nerve with mepivacaine 2% + Epinephrine 1:100,000; Insertion of the first 30x0.8 mm needle at point A and injection of 2-3 mL of Lactated Ringer; Insert the second 30x0.8 mm needle into point B Wash with 100-200mL of Ringer Lactate; Removal of the second needle; Injection of 1mL of 20mg Triamcinolone diluted in 0.9% saline solution (1:1) through the needle at point A.
88891258|NCT06256042|Active Comparator|Occlusal splint|A stabilizing maxillary acrylic occlusal splint was made, flat, total and adjusted in central relation (RC).
89413665|NCT05125081|Experimental|LDP group|Liuwei Dihuang Pill (LDP）marketed product in China donated by pharmaceutical company.
89413666|NCT05125081|Placebo Comparator|placebo group|Same smell, color and shape as Liuwei Dihuang Pill (LDP）without herbs in capsules.
89413667|NCT03091972|Experimental|Contact force assisted linear ablation|Left atrial linear ablation performed using the contact force sensing catheter after pulmonary vein isolation
88891259|NCT06256029|Experimental|Experimental group|All participants will undergo the recruitment maneuver. The patients will be divided into non-obese patients (BMI 18.5-24.9 kg/m²) and patients with increased body mass (BMI 25-34.9 kg/m²).
88891260|NCT06255990||NovoSorb® BTM and STSG|Full thickness skin defect qualifying for coverage with the dermal substitute NovoSorb® BTM before transplantation with a split-thickness skin graft (STSG) according to clinical routine
88891261|NCT06255990||STSG alone|Full thickness skin defect qualifying for coverage with split-thickness skin graft (STSG) alone according to clinical routine
88891262|NCT06255977|Placebo Comparator|Placebo Control: placebo|Intravenous infusion with placebo（same volume of saline） every 6 hours, up to a maximum of 13 doses within 72 hours.Each dose of placebo（same volume of saline） will be administered as a slow IV bolus over 30 minutes.
88891263|NCT06255977|Experimental|Experimental: CN-105 peptide for injection 0.1 mg/kg|Intravenous infusion with 0.1 mg/kg CN-105 peptide for injection every 6 hours, up to a maximum of 13 doses within 72 hours.Each dose of CN-105 will be administered as a slow IV bolus over 30 minutes.
89192947|NCT05845307|Experimental|Control Group|Participants you will be randomly assigned to either receive the study drug or be in a control group.
89413668|NCT03091972|Active Comparator|control|Left atrial linear ablation performed using the catheter without contact force sensing after pulmonary vein isolation
89413669|NCT05020834|Experimental|Functional Electrical Stimulation Group|Functional Electrical Stimulation Group received 1.5 hours of conventional physical therapy program /session - 3 sessions weekly - three successive months + 1/2 hour of the gait training program with functional electrical stimulation /session - 3 sessions weekly - three successive months.
89413670|NCT05020834|Experimental|TheraTogs Group|TheraTogs Arm The participating children will wear TheraTogs orthotic undergarment and strapping as preparatory stage without application of any exercise program with gradually increasing the worn time till reaching the 8 hours per day.
89413671|NCT01077817||Esophageal Cancer Cases|Participants with any United Kingdom General Practice Research Database (GPRD) Medical code for esophageal cancer (cases). Cases were confirmed and case onset dates determined by electronic algorithm (based on electronic medical record data) or by medical record review.
89413672|NCT01077817||Comparison Sample (Case-Cohort)|Participants who were matched to cases by age and membership in the GPRD on the case's onset date, and had not experienced any form of esophageal cancer or Paget's Disease and had not received oral or intravenous steroids or chemotherapy or radiotherapy, as indicated by GPRD codes.
89413673|NCT01077817||Non-treated Comparators|Participants who did not initiate treatment of osteoporosis with a study drug
89413674|NCT01077817||Alendronate|Participants initiating treatment for osteoporosis with alendronate
89413675|NCT01077817||Etidronate|Participants initiating treatment for osteoporosis with etidronate
89413676|NCT01077817||Ibandronate|Participants initiating treatment for osteoporosis with ibandronate
89413677|NCT01077817||Risedronate|Participants initiating treatment for osteoporosis with risedronate
88813044|NCT03218150||autologous bone group|patient underwent to cranioplasty reconstruction with autologous bone graft
88813045|NCT02503332|Experimental|Pegcetacoplan 15 mg/100 µL Monthly for 12 months|A single dose of 15 mg pegcetacoplan/100 µL will be administered via intravitreal injection in this study. Subjects will receive an injection every month for 12 consecutive months.
88813046|NCT02503332|Experimental|Pegcetacoplan 15 mg/100 µL EOM for 12 months|A single dose of 15 mg pegcetacoplan/100 µL will be administered via intravitreal injection in this study. Subjects will receive an injection every other month (EOM) for 12 consecutive months.
88813047|NCT02503332|Sham Comparator|Sham Monthly for 12 months|Subjects will receive a Sham procedure every month for 12 consecutive months.
88813048|NCT02503332|Sham Comparator|Sham EOM for 12 months|Subjects will receive a Sham procedure every other month (EOM) for 12 consecutive months.
88813049|NCT03217838|Experimental|Group 1 Arm A (AZD2811 Dose 1)|Participants with AML will receive intevenous (IV) infusion of AZD2811 Dose 1 on Days 1 and 4 of each 28-day cycle until disease progression, unacceptable toxicity, or the decision to discontinue treatment by the participant or the study physician, whichever occurs first.
88813050|NCT03217838|Experimental|Group 1 Arm A (AZD2811 Dose 2)|Participants with AML and myelodysplastic syndrome (MDS) will receive IV infusion of AZD2811 Dose 2 on Days 1 and 4 of each 28-day cycle until disease progression, unacceptable toxicity, or the decision to discontinue treatment by the participant or the study physician, whichever occurs first.
88813051|NCT03217838|Experimental|Group 1 Arm A (AZD2811 Dose 3)|Participants with AML and MDS will receive IV infusion of AZD2811 Dose 3 on Days 1 and 4 of each 28-day cycle until disease progression, unacceptable toxicity, or the decision to discontinue treatment by the participant or the study physician, whichever occurs first.
88813052|NCT03217838|Experimental|Group 1 Arm A (AZD2811 Dose 4)|Participants with AML and MDS will receive IV infusion of AZD2811 Dose 4 on Days 1 and 4 of each 28-day cycle until disease progression, unacceptable toxicity, or the decision to discontinue treatment by the participant or the study physician, whichever occurs first.
88813053|NCT03217838|Experimental|Group 1 Arm A (AZD2811 Dose 5)|Participants with AML will receive IV infusion of AZD2811 Dose 5 on Days 1 and 4 of each 28-day cycle until disease progression, unacceptable toxicity, or the decision to discontinue treatment by the participant or the study physician, whichever occurs first.
88813054|NCT03217838|Experimental|Group 1 Arm B (AZD2811 Dose 2)|Participants with AML will receive IV infusion of AZD2811 Dose 2 on Days 1, 4, 15, and 18 of each 28-day cycle until disease progression, unacceptable toxicity, or the decision to discontinue treatment by the participant or the study physician, whichever occurs first.
88813055|NCT03217838|Experimental|Group 1 Arm B (AZD2811 Dose 6)|Participants with AML will receive IV infusion of AZD2811 Dose 6 on Days 1, 4, 15, and 18 of each 28-day cycle until disease progression, unacceptable toxicity, or the decision to discontinue treatment by the participant or the study physician, whichever occurs first.
88813056|NCT03217838|Experimental|Group 2 Arm A (AZD2811 Dose 3 + Azacitidine 75 mg/m^2)|Participants with AML and MDS will receive Azacitidine 75 mg/m^2 of body surface area (BSA) by subcutaneous (SC) injection or IV infusion prior to the start of AZD2811 infusion on Days 1 through 7 or for 5 consecutive weekdays (Days 1 through 5) with treatment holidays on the 2 weekend days (Days 6 and 7), and the remaining azacitidine dosing will be administered on the first 2 weekdays of the 2nd week (Days 8 and 9) of each 28-day cycle. Participants will receive IV infusion of AZD2811 Dose 3 on Days 1 and 4 of each 28-day cycle. Participants will receive the study treatment until disease progression, unacceptable toxicity, or the decision to discontinue treatment by the participant or the study physician, whichever occurs first.
88891264|NCT06255977|Experimental|Experimental:CN-105 peptide for injection 0.3 mg/kg|Intravenous infusion with 0.3 mg/kg CN-105 peptide for injection every 6 hours, up to a maximum of 13 doses within 72 hours.Each dose of CN-105 will be administered as a slow IV bolus over 30 minutes.
88891265|NCT06255977|Experimental|Experimental: CN-105 peptide for injection 1.0 mg/kg|Intravenous infusion with 1.0 mg/kg CN-105 peptide for injection every 6 hours, up to a maximum of 13 doses within 72 hours.Each dose of CN-105 will be administered as a slow IV bolus over 30 minutes.
88891266|NCT06255964|Other|Phase Ia study|Phase Ia study: for adults with BCG treatment failure or intolerance to BCG, high-risk non muscle invasive bladder cancerPatient, evaluate the safety and tolerability of IAP0971 monotherapy bladder infusion, and determine dose limiting toxicity and/or phase II recommended dose.
88891267|NCT06255964|Experimental|Phase Ib study|Phase Ib study:To evaluate the safety and tolerability of intravesical IAP0971 in combination with BCG in patients with BCG unresponsive high risk non-muscle invasive bladder cancer, and to determine the DLT and RP2D.
89192948|NCT05845307|Experimental|TTI-101|Participants you will be randomly assigned to either receive the study drug or be in a control group.
89192949|NCT05845073|Experimental|Probiotic|Participants in this arm will receive a daily dose of 2x10^9 Colony Forming Units (CFU) of a multi strain probiotic (live bacterium), corresponding to 2 capsules twice daily, for the duration of antibiotic therapy, and 14 days thereafter.
89192950|NCT05845073|Placebo Comparator|Placebo|Participants in this arm will receive an equivalent placebo for the duration of antibiotic therapy, and 14 day thereafter.
89192951|NCT05838170|Experimental|Lotilaner Gel, 2.0% (TP-04)|Participants will be randomized to a 2:1 ratio at baseline to apply Lotilaner Gel, 2.0% (TP-04) on the face BID for 12 weeks.
89413678|NCT01077817||Raloxifene|Participants initiating treatment for osteoporosis with raloxifene
89413679|NCT03087838||delirium group|CAM-ICU is positive within the first 24 hours after operation
88891268|NCT06255964|Experimental|Phase II study|Phase II study:To evaluate the efficacy of intravesical IAP0971 in combination with BCG in patients with BCG unresponsive high risk NMIBC using RP2D as determined in the phase I study.
88891269|NCT06255925|Experimental|Treatment Group|In this arm, participants would participate in in an intervention program that uses character strengths to improve job maintenance skills in young adults.
88891270|NCT06255925|No Intervention|Control Group|In this arm, participants are services as usual and will participate in their regular activities.
88891271|NCT06255899|Active Comparator|Education|All participants will attend an educational training session on the team's Injury Prevention Program (IPP), which will be performed prior to practices and matches throughout the season. All team members, coaching staff, and medical staff will attend the educational session. This session will be administered during the pre-season training period, will last 60-90 minutes, and include a didactic component and a practical component in which all athletes on the team will receive instruction on how to properly perform each component of the IPP program. and have an opportunity to practice performing the IPP on the field. This is an evidence-based program that will be provided to all lacrosse athletes regardless of participation in the research study.
89192952|NCT05838170|Placebo Comparator|Vehicle-Controlled|Participants will be randomized to a 2:1 ratio at baseline to apply vehicle control gel on the face BID for 12 weeks.
89192953|NCT05836064|Experimental|GastroBot-assisted bowel preparation group (GB-group)|Adult patients with no surgical high-risk comorbidities and colonoscopy indications for screening, surveillance, or diagnosis who are undergoing a colonoscopy. GastroBot assisted with the polyethylene glycol bowel preparation: patients will receive the instructions through the WhatsApp application, being guided by the software bot with multiple and personalized alternative instructions according to results.
89192954|NCT05836064|Experimental|Conventional-assisted bowel preparation group (C-group).|Adult patients with no surgical high-risk comorbidities and colonoscopy indications for screening, surveillance, or diagnosis who are undergoing a colonoscopy. The patients received bowel polyethylene glycol bowel preparation instructions in writing without prior personalized advice.
89413680|NCT03087838||non-delirium group|CAM-ICU is negative within the first 24 hours after operation
89413681|NCT03086902|Experimental|Cryo Ablation|PVCs will be mapped and ablated with a Cryo Ablation catheter
89413682|NCT03086902|Active Comparator|Radiofrequency Ablation|In this arm PVCs will be mapped and ablated with a Radiofrequency Ablation catheter
89413683|NCT04433962|Active Comparator|conventional rehabilitation group|the conventional rehabilitation group completed hip joint range of motion and muscle strengthening exercises
89413684|NCT04433962|Experimental|conventional rehabilitation + balance training group|The conventional rehabilitation + balance training group completed hip joint range of motion and muscle strengthening exercises and 12 balance exercises.
88891272|NCT06255899|Experimental|Individualized Feedback + Education|After completing the Education Program, participants assigned to the individualized feedback group will perform the IPP during a strength and conditioning session while a research team member records their performance on a laboratory video camera. The video will be analyzed to identify errors and compensations with movements and a plan for a feedback session to correct movements will be developed. The feedback session will include showing the athlete their video, identifying the error or compensation, and providing verbal, tactile, and visual feedback to correct the error or compensation. Two additional feedback sessions will be scheduled at regular intervals during the season.
89413685|NCT02638012|Experimental|HHT - Floseal|"Once the bleeding has stopped following application of the Floseal® a 50 cc syringe with sterile saline will be used to irrigate the treated nasal cavity to remove any excess Floseal® product as per manufacturer recommendations. This is done with the patient's head tilted downwards at a 30 degree angle so that the irrigation and excess product is removed from the nasal cavity.~If bleeding is not controlled after up to two Floseal applications, the gel and clots will be removed with suction, and the patient will be treated with a standard packing treatment (standard of care)."
89413686|NCT05014906|Active Comparator|minocycline, azelaic acid|minocycline vs minocycline in comination with 15% azelaic acid for treatment of rosacea
89413687|NCT05014906|Experimental|azelaic acid|45 mg oral minocycline vs 45 mg oral minocycline plus 15% azelaic acid in the treatment of facial rosacea
88891273|NCT06255886|Active Comparator|Proton pump inhibitor|Omeprazole 1 mg/ kg and continuing nutrition containing cow's milk protein
88891274|NCT06255886|Active Comparator|Mother or infant diet|Mother on cow milk-protein-free diet if breastfeeding and infant on a hypoallergenic formula if bottle-fed.
88891275|NCT06255886|Placebo Comparator|Placebo|Placebo medicine (appearing substantially like Omeprazole) 1mg/kg and continuing nutrition containing cow's milk protein
88891276|NCT06255860||children with MIS-C|hospitalized children with MIS-C
88891277|NCT06255860||SARS-CoV-2 infection|non hospitalized children infected with SARS-CoV-2 treated by outpatient care
88891278|NCT06255847|Experimental|Reduced-dose pomalidomide/cyclophosphamide/dexamethasone (PCd) regimen group|
88891279|NCT06255834|Experimental|Cohort 1 (SAD - 0.5 mg)|4 subjects in this cohort will receive a single dose of IPG11406 0.5 mg qd and 2 subjects will receive a single dose of placebo 0.5 mg qd orally.
88891280|NCT06255834|Experimental|Cohort 2 (SAD - 2 mg)|4 subjects in this cohort will receive a single dose of IPG11406 2 mg qd and 2 subjects will receive a single dose of placebo 2 mg qd orally.
88891281|NCT06255834|Experimental|Cohort 3 (SAD - 6 mg)|4 subjects in this cohort will receive a single dose of IPG11406 6 mg qd and 2 subjects will receive a single dose of placebo 6 mg qd orally.
89413688|NCT03085420|Experimental|≥30% TBSA burn injury|For patients in Group 1 with ≥30% TBSA, a baseline Echocardiogram (ECHO) will be obtained approximately one week from admission and monthly (+/- 1 week) or at an interval determined by cardiology during the acute inpatient stay. ECHO tests will be discontinued after 3 negative exams or when discontinued by cardiology, whichever comes first.
89413689|NCT03085420|No Intervention|<30% TBSA burn injury|For patients in Group 2 with <30% TBSA and presence of a cardiac abnormality standard clinical care appropriate for the type of arrhythmia will be followed.
89413690|NCT00103506|Active Comparator|VELCADE (bortezomib) monotherapy|Bortezomib (VELCADE) 1.3 milligram per meter square (mg/m^2) by rapid (bolus) i.v. administration given on Days 1, 4, 8, and 11 of each 21-day cycle for up to 8 cycles.
89413691|NCT00103506|Experimental|DOXIL/CAELYX in combination with VELCADE (bortezomib)|Bortezomib (VELCADE) 1.3 mg/m^2 by rapid (bolus) i.v. administration given on Days 1, 4, 8, and 11 of each 21-day cycle for up to 8 cycles. Doxorubicin hydrochloride (DOXIL/CAELYX) 30 mg/m2 by i.v. infusion will be given on Day 4 of every 21-day cycle after the administration of bortezomib (VELCADE) for up to 8 cycles.
89413692|NCT03541746|Experimental|Study Group|Platelet Rich Plasma
89413693|NCT03541746|Active Comparator|Control Group|Intrauterine Foley's Catheter
89437578|NCT03562637|Experimental|Adagloxad simolenin + OBI-821 in conjunction with SOC|"Participants will be administered adagloxad simolenin combined with OBI-821 for up to a total of 21 subcutaneous injections over a period of 100 weeks.~Patient will also receive standard of care (SOC) treatment."
88891282|NCT06255834|Experimental|Cohort 4 (SAD - 20 mg)|6 subjects in this cohort will receive a single dose of IPG11406 20 mg qd and 2 subjects will receive a single dose of placebo 20 mg qd orally.
88891283|NCT06255834|Experimental|Cohort 5 (SAD - 40 mg)|6 subjects in this cohort will receive a single dose of IPG11406 40 mg qd and 2 subjects will receive a single dose of placebo 40 mg qd orally.
88891284|NCT06255834|Experimental|Cohort 6 (SAD - 80 mg)|6 subjects in this cohort will receive a single dose of IPG11406 80 mg qd and 2 subjects will receive a single dose of placebo 80 mg qd orally.
88891285|NCT06255834|Experimental|Cohort 7 (MAD - 10 mg)|6 subjects in this cohort will receive a dose of IPG11406 10 mg qd and 2 subjects will receive a dose of placebo 10 mg qd orally from Day 1 to 10-day.
88891286|NCT06255834|Experimental|Cohort 8 (MAD - 20 mg)|6 subjects in this cohort will receive a dose of IPG11406 20 mg qd and 2 subjects will receive a dose of placebo 20 mg qd orally from Day 1 to 10-day.
89192955|NCT05830578||Cohort 1|Subjects enrolled into Cohort 1 must have no known medical history of AFib and in normal sinus rhythm at the time of screening.
89413694|NCT04992780|Experimental|Hypo-Fractionation|Participants will receive one fraction of radiation therapy a day for 5 days each week for 5 weeks along with weekly chemotherapy with Paclitaxel 45 milligram per meter squared (mg/m2) through intravenous (IV)infusion for 1 hour followed by Carboplatin area under the curve (AUC) 2 IV for 30 minutes for approximately 5 or 6 weeks. Once complete, participant will receive Durvalumab, 1500 mg, IV every 4 weeks for 12 months.
89413695|NCT04992780|Active Comparator|Standard-Fractionation|Participants will receive one fraction of radiation therapy a day for 5 days each week for 6 weeks along with weekly chemotherapy with Paclitaxel 45 milligram per meter squared (mg/m2) through intravenous (IV)infusion for 1 hour followed by Carboplatin AUC 2 IV for 30 minutes for approximately 5 or 6 weeks. Once complete, participant will receive Durvalumab, 1500 mg, IV every 4 weeks for 12 months.
89413696|NCT02158650|Experimental|Video Group|Patients randomized to Group II will be emailed the educational video, pre- and post- knowledge assessments, and patient satisfaction survey with instructions on what order to fill them out. Group II patients will report to the treatment visit and undergo discussion of options and treatment as per standard of care. An additional knowledge assessment survey will be administered to Group II patients after discussion with treating physician.
89413697|NCT02158650|No Intervention|Control Group|Patients randomized to Group I will be come to the clinic for the treatment visit and discuss options and treatment as per standard of care. Pre- and post- discussion knowledge assessments and satisfaction surveys will be administered at the time of the treatment visit.
88891287|NCT06255834|Experimental|Cohort 9 (MAD - 40 mg)|6 subjects in this cohort will receive a dose of IPG11406 40 mg qd and 2 subjects will receive a dose of placebo 40 mg qd orally from Day 1 to 10-day.
88891288|NCT06255808||Ultrasonic group|
88891289|NCT06255795|Experimental|chidamide, anti-PD1 antibody, and pegaspargase group|
88891290|NCT06255795|Active Comparator|DDGP|
88891291|NCT06255782|Experimental|Cohort 1|Participants will receive the Low Dose of ECUR-506 delivered one time via IV Infusion.
88891292|NCT06255782|Experimental|Cohort 2|Participants will receive the High Dose of ECUR-506 delivered one time via IV infusion.
88891293|NCT06255782|Experimental|Expansion Cohort|Participants will receive ECUR-506 at one of the doses evaluated in Cohort 1 or Cohort 2 one time via IV infusion.
89413698|NCT03741738||Non-segmental vitiligo :|"A. Patients aged 19 years or older who were clinically diagnosed with non-segmented leukopenia at Severance Hospital.~B. Patients (36 patients) who experienced worsening symptoms within the last 3 months and 10 patients whose symptoms were stable within 3 months C. Patients with vitiligo lesion at least 3% of the skin"
89413699|NCT03741738||Segmental VT or Focal VT|A. The investigators evaluated patients who were diagnosed as segmental vitiligo clinically on Severance hospital and who were 19 years old or older.
89413700|NCT03741738||Normal control|A. Subjects aged 19 or older who do not have not only vitiligo but also other skin and systemic diseases
89413701|NCT02151240|Experimental|Arm I|Foscarnet Sodium and Sodium Chloride Injection 3g: 250ml, IV; Second administration: Foscarnet Sodium and Sodium Chloride Injection 3g: 250ml, IV
89413702|NCT02151240|Active Comparator|Arm II|First administration: Acyclovir for Injection 0.25g + 0.9% Sodium Chloride Injection 250ml, IV; Acyclovir for Injection 0.25g + 0.9% Sodium Chloride Injection 250ml, IV; Second administration: Acyclovir for Injection 0.25g+ 0.9% Sodium Chloride Injection 250ml, IV
89413703|NCT02154750|Active Comparator|Long, fixed AV delay|Pacemaker will be set to a long, fixed AV delay to minimize ventricular pacing
89413704|NCT02154750|Experimental|Short, optimized AV delay|Pacemaker will be set to the AV delay that produces the greatest cardiac output in echocardiography for each patient enrolled
88891294|NCT06255743|Experimental|case|cases diagnosed systemic lupus erythematosus we measure degree of depression and anxiety and relation to (Anti-Ribosomal P Protein,Anti-U1 RNP, Anti-Nucleosome and Anti-ds DNA Antibodies)
88891295|NCT06255704|Experimental|Zanubrutinib and RCHOP/RDHAP|Patients will receive zanubrutinib and RCHOP alternating with RDHAP for a total of 6 cycles of induction therapy, and patients who achieve complete response after 6 cycles of induction therapy will be eligible to enter a 2-year maintenance treatment period of zanubrutinib in combination with rituximab
88891296|NCT06255678||Patients undergoing PCI|Assessment of ΔvFFR and vFFR after PCI and adverse clinical outcomes, residual angina and quality of life using the validated Seattle Angina Questionnaire (SAQ) and EuroQol 5-level 5-dimensional questionnaire (EQ-5D-5L) in patients with CCS or ACS.
88891297|NCT06255652||Obstetrician and gynaecological procedures|Patients for obstetricians
88891298|NCT06255639||MM patient candidate to vertebroplasty|
88891299|NCT06255561|Experimental|active rTMS treatment|2 sessions with 1800 pulses per session and 50min inter-session interval of active rTMS will deliver to the assigned target.
89413705|NCT02154828||Integrative practices|"Children included in this project are children 3 to 6 years with diagnosis F84.0 F84.1 according to CIM-10.~these children must be supported in care units that meet the criteria defined integrative practices."
88813989|NCT02462928|Experimental|Abicipar Pegol 2 mg (2Q12)|Abicipar pegol 2 mg was administered to the study eye by intravitreal injection on Day 1, Week 4, Week 12, and every 12 weeks (2Q12) thereafter through week 96. Scheduled visits occurred every 4 weeks. To maintain masking, sham was administered to the study eye at scheduled visits where abicipar was not administered.
88813990|NCT02462928|Active Comparator|Ranibizumab 0.5 mg (rQ4)|Ranibizumab (Lucentis®) 0.5 mg was administered to the study eye by intravitreal injection every 4 weeks (rQ4) from Day 1 through Week 96.
88813991|NCT03002831|Experimental|CIK combined chemotherapy|Autologous Cytokine induced killer cells combined Tegafur, Gimeracil and Oteracil Potassium Capsules. After 2 to 4 days of chemotherapy, about 5×10９autologous cytokine induced killer cells are transfused into the vein of the patients in one hour.
89413706|NCT04807530|Active Comparator|Medial/Superior Prefrontal TMS|10 Hz High frequency TMS applied to the mPFC
88813992|NCT03002831|Active Comparator|Chemotherapy|Tegafur,Gimeracil and Oteracil Potassium Capsules 40-60mg, bid, po, D1-14, Q3w
88813993|NCT04375046|Experimental|Experimental: rbACE2 group|0.4 mg/kg IV BID for 7 days (unblinded) + standard of care
88813994|NCT04375046|No Intervention|No Intervention: Control group|Standard of care; no placebo
88813995|NCT03402464|Experimental|Icotinib combined dihydroaremisinin|
89413707|NCT04807530|Placebo Comparator|Posterior Parietal TMS|10 Hz high frequency TMS applied to the posterior parietal cortex
89413708|NCT02159430||HereditaryAngioEdema|Patients from the Eastern Sicily HAE register
89413709|NCT02154984|Experimental|Behavioral (time restricted diet)|Participants follow a time restricted diet, which restricts daily eating to an 8 hour time window between 12:00-8:00 pm. Participants are allowed to consume non-caloric beverages (water, black tea, black coffee, diet soda, etc.) during the fasting hours and required to record daily food consumption in the smartphone app for 6 months. Participants are also coached by telephone over approximately 10-15 minutes weekly for 1 month and then biweekly for 5 months.
89413710|NCT02158962|Experimental|Behavioral - Education|"3 Educational Sessions~Session 1 - Reducing Risk for Intimate Partner Violence (IPV); Session 2 - Reducing risk for Sexually Transmitted Infections including HIV (STI/HIV) Session 3 - A group session which reinforces skills for reducing IPV and STI/ HIV risk reduction."
88813996|NCT05667701|Experimental|Soy isoflavone|Soy isoflavone powder dosed in puree or liquid twice daily
88813997|NCT05667701|Placebo Comparator|Placebo|Matching placebo powder dosed in puree or liquid twice daily
88813998|NCT04375280|Experimental|Cohort 1|Participants will be involved in a long-term evaluation program combining, body composition measures, physical tests as well as self-administered questionnaires. Participants will be followed for 5 years with evaluations taking place at inclusion, 6 months, at 1, 2 and 5 years
88813999|NCT02248337|Active Comparator|4 Liter PEG|Colon preparation for colonoscopy: PEG 4 Liter before endoscopy
88814000|NCT02248337|Experimental|2 Liter PEG plus bisacodil|Colon preparation for colonoscopy: PEG 2 L before endoscopy
89437579|NCT03562637|Active Comparator|Standard of Care treatment|"Study visit intervals will be identical to those in Arm 1.~Patient will receive standard of care (SOC) treatment."
88814001|NCT03402308|Experimental|Schisandra chinensis extract group|This group takes Schisandra chinensis extract for 12 weeks
88814002|NCT03402308|Placebo Comparator|Placebo group|This group takes placebo for 12 weeks
88814003|NCT04526951|Active Comparator|Tenecteplase|The total dose of tenecteplase is 0.25 mg/kg body weight, maximum 25 mg. The total dose will be given as an intravenous bolus
88814004|NCT04526951|Active Comparator|acetylsalicylic acid|one tablet of aspirin 300 mg Other Name: Aspirin
88814005|NCT04374890|Experimental|Experimental|
89413711|NCT02158962|Active Comparator|Behavioral - Education|"3 Educational Sessions~Session 1 - Breast Health Education and Developing A Breast Cancer Risk Reduction Plan Session 2 - Reducing risk for overweight and obesity and Developing a Healthy Eating and Activity Plan Session 3 - A group session which integrates and reinforces skills from Sessions 1 and 2."
89413712|NCT03542604|Experimental|CBT-I + BWL|Cognitive behavioral therapy intervention for insomnia: 6 sessions over 8-week period combining education and behavioral techniques to reduce insomnia. Sleep intervention followed by behavioral weight loss intervention.
89413713|NCT03542604|Placebo Comparator|EDU + BWL|Program will parallel the CBT-I intervention in number and length of sessions. Intended to disseminate basic information about sleep, including behavioral treatment information that is widely available to patients and practitioners.Will be followed by behavioral weight loss intervention.
89413714|NCT02159196|Active Comparator|acetylcysteine and salbutamol|Nebulisation of 3 mL-solution of acetylcysteine (fluimucil 100mg/ml, a mucolytic) and a 2.5 mL solution containing salbutamol (ventolin 2.5 Nebules 2.5mg/2.5 ml, a bronchodilator), administered every 6 hours (i.e., 4 times per day) within 24 hours after initiation of ventilation until tracheal extubation.
89413715|NCT02159196|Experimental|acetylcysteine or salbutamol|"Nebulisation on strict clinical indications; nebulisation of 3 mL-solution of acetylcysteine (fluimucil 100mg/ml, a mucolytic) in case of occurrence of persistent thick and tenacious sputum and only after active humidification is set.~Nebulisation of 2.5 mL solution containing salbutamol (ventolin 2.5 Nebules 2.5mg/2.5 ml, a bronchodilator) in case of occurrence of bronchospasm."
89413716|NCT02765490|Experimental|Group A|AL-335 (800 mg), odalasvir (25 mg) and simeprevir (75 mg) once daily during 6 weeks.
89413717|NCT02765490|Experimental|Group B|AL-335 (800 mg), odalasvir (25 mg) and simeprevir (75 mg) once daily during 8 weeks.
89437580|NCT03554018|Experimental|Acetaminophen|Acetaminophen 500-1000mg every 6 hours for 7 days Participants in this arm will also receive ibuprofen 600mg every 6 hours for 7 days and an educational intervention.
89413718|NCT02159508|No Intervention|Individualised on-demand counselling|Individualized on-demand counselling group was assigned to receive baseline nutritional counselling, that consisted of one dietetic consultation before (chemo)radiotherapy. During (chemo)radiotherapy on-demand counselling group patients received further counselling only on demand.
88891300|NCT06255548|Experimental|Immersive virtual reality group|During the circumcision operation, the IVR group received both routine care and VR game. The children were allowed to play the virtual reality game of their choice. The children in the IVR group had an interactive gaming experience for 10 minutes with the game of their choice, using the remote controls while lying on their backs on the operating table during circumcision.
88891301|NCT06255548|Experimental|Music group|The researcher explained the use of music headphones to the children in the music group. Each child in the music group was allowed to choose the music he wanted to listen to during the circumcision. In the interview with the children in the music group, the type of music they listened to in their daily lives was asked and the music they wanted to listen to during circumcision was determined.
88891302|NCT06255548|No Intervention|Control group|Children in the control group received routine care and no intervention was performed.
88891303|NCT06255535|Experimental|active iTBS group|active iTBS over DLPFC
88891304|NCT06255535|Sham Comparator|Sham group|sham iTBS over DLPFC
88891305|NCT06255522|Experimental|Fully guided implant placement|Through guided surgery implant placement will be performed in maxilla or mandibula in a one stage surgery. The final position will be compare with the initial digital implant planning.
88891306|NCT06255496||Obstetric Patients|Obstetric patient population at risk of experiencing excessive bleeding around the time of delivery
88891307|NCT06255483|Other|Osteoperiosteal clavicular flap|Harvesting of a pedicled osteoperiosteal clavicular flap and clarification of its vascular supply
88891308|NCT06255470|No Intervention|Periodontally Healthy|Periodontally healthy patients received no intervention.
88891309|NCT06255470|Active Comparator|Periodontitis Stage III Grade B|The patients were subjected to quadrant-wise full-mouth subgingival scaling and root planning under local anesthesia by the use of ultrasonic scalers and curettes. The entire non-surgical periodontal treatment of periodontitis groups was completed in a total of 4 sessions in two weeks.
88891310|NCT06255470|Active Comparator|Periodontitis Stage III Grade C|The patients were subjected to quadrant-wise full-mouth subgingival scaling and root planning under local anesthesia by the use of ultrasonic scalers and curettes. The entire non-surgical periodontal treatment of periodontitis groups was completed in a total of 4 sessions in two weeks.
88891311|NCT06255457||Arrhythmogenic mitral valve prolapse versus non-arrhythmogenic mitral valve prolapse|Surgical repair or replacement of the mitral valve due to significant mitral regurgitation according to standard of care.
88891312|NCT06255444||Overweight/Obese BMI|This group consists of overweight and obese patients diagnosed with cervical radiculopathy by a neurosurgeon.
88891313|NCT06255444||Normal BMI|This group consists of patients with normal BMI who were diagnosed with cervical radiculopathy by a neurosurgeon.
88891314|NCT06255431|Active Comparator|Cream Containing Spent Grain Wax Extract, Argan Oil, and Shea Butter (Ezerra Cream)|"Ezerra cream The creams are applied to the face twice daily (0,5 Finger Tip Unit/FTU), immediately after washing.~group A (intervention cream on the right side of the face and control cream on the left side of the face) and group B (intervention cream on the left side of the face and control cream on the right side of the face)."
88891315|NCT06255431|Placebo Comparator|Vehicle cream|Vehicle cream was prepared by the Pharmacy Department of Faculty of Medicine Universitas Indonesia and has similar consistency, color, and scent as the intervention cream. The creams are applied to the face twice daily (0,5 Finger Tip Unit/FTU), immediately after washing.
88891316|NCT06255405|Experimental|Experimental: Intervention group|Dyadic parent-child self-compassion program will be provided.
88891317|NCT06255405|No Intervention|Waitlist control group|Participants in the control group will be instructed to live their lives as usual, no intervention will be imposed during study period. They will be provided with the program after the study.
88891318|NCT06255392|Experimental|Fluzoparib Combined With Apatinib|Fluzoparib combined with Apatinib group: Fluzoparib capsules oral +Apatinib Mesylate oral; each treatment cycle defined as 3 weeks (21 days).
88891319|NCT06255392|Active Comparator|Chemotherapy selected by the investigator|Control group: Control group: patients receive oral Capecitabine tablets, Vinorelbine Tartrate Capsules, or use intravenous Paclitaxel for Injection (Albumin Bound), Gemcitabine Hydrochloride for Injection, or other drugs selected by the investigator.
88891320|NCT06255327|No Intervention|Control group|The participants in the control group were evaluated on the first day after surgery and the day of discharge from clinic by using Pulse Oximetry, Sphygmometer, Spirometry Tests, VAS, MBDS and AMP. Participants in the control group were not given any information or training before or after the operation, and they were on routine hospital care.
88891321|NCT06255327|Experimental|Experimental group|The participants in the experimental group underwent the application of several techniques to reduce pulmonary complications after major abdominal surgeries, defined by the acronym: I COUGH (Incentive spirometry, Coughing/Deep breathing, Oral care, Understanding (Education of patient and family), Getting out of bed, and raising the Head of the bed). Evaluation was conducted on the first day after surgery and the day of discharge of clinic. It was performed using Pulse Oximetry, Sphygmometer, Spirometry Tests, VAS, MBDS, AMP.
88891322|NCT06255314|Experimental|trans abdominal retromusclar laparoscopic ventral hernia repar|
89413719|NCT02159508|Experimental|Intensive nutritional counselling|Intensive nutritional counselling consisted of protocolled counselling given by a dietitian once at baseline and on the 2nd and 4th week of treatment and at the end of chemoradiotherapy.
89413720|NCT02159274||BCS without oncoplastic techniques|BCS without oncoplastic techniques
88814006|NCT03408860|Other|2-week baseline|Patients complete assessment only for a duration of 2-weeks prior to starting the intervention: Countering Emotional Behaviors Module from the Unified Protocol.
88814007|NCT03408860|Other|4-week baseline|Patient complete assessment only for a duration of 4-weeks prior to starting the intervention: Countering Emotional Behaviors Module from the Unified Protocol.
89413721|NCT02159274||BCS with oncoplastic techniques|BCS with oncoplastic techniques.
89413722|NCT02155062|Experimental|Whole grain rye|3-4 portions per day of WG rye containing foods (approximately 20 WG per portion)
89413723|NCT02155062|Experimental|Whole grain wheat|3-4 portions per day of WG wheat containing foods (approximately 20 WG per portion)
89413724|NCT02155062|Placebo Comparator|Refined cereal|No intake of WG wheat or WG rye cereals, only refined cereals or non-AR containing WG cereals (e.g. WG rice or oats)
89413725|NCT02163018|Experimental|HAL-MPE1|Subcutaneous administration of increasing doses of HAL-MPE1.
89413726|NCT02163018|Placebo Comparator|Placebo|Subcutaneous administration of placebo
89413727|NCT02639182|Experimental|AGS-16C3F|Participants received 1.8 milligram per kilogram (mg/kg) of AGS-16C3F once every three weeks by single intravenous (IV) infusion.
89413728|NCT02639182|Active Comparator|Axitinib|Participants received 2 to 10 milligram (mg) of axitinib twice daily by oral administration as defined in the product label and per local institutional guidelines.
88814008|NCT02248415|Experimental|No pump group|Blood cardioplegia administration without roller pump
88814009|NCT02248415|Other|Pump group|Blood cardioplegia administration with roller pump
88891323|NCT06255314|Experimental|enhanced view totally extraperitoneal laparoscopic ventral hernia repair|
89413729|NCT02863419|Experimental|Oral Semaglutide|
89413730|NCT02863419|Active Comparator|Liraglutide|
89413731|NCT02863419|Placebo Comparator|Placebo|
89413732|NCT03541668|Experimental|Group A|Recombinant human urokinase (rhPro-UK)
89413733|NCT03541668|Active Comparator|Group B|Alteplase(rt-PA)
89413734|NCT02155140|Active Comparator|Jejunal feeding|Nutritional supplementation via their jejunostomies for six weeks post hospital discharge, with continued assessment for a further 18 weeks.
89413735|NCT02155140|No Intervention|No jejunal feeding|No jejunal feeding of patients for six weeks following hospital discharge, with continued assessment for a further 18 weeks
89413736|NCT05019898|Experimental|Diagnostic Test: pupillometry|
89413737|NCT02155218|Active Comparator|Standard Injection Rate|Subjects will be given a small amount of contrast (approximately 1 cc test bolus) followed by administration of the remainder of the volume of contrast they are getting for their clinical study. This will be approximately 30-40 cc, depending on patient size, given at an injection rate of 2 - 2.5 cc/second.
89413738|NCT02155218|Experimental|Patient Tailored Injection Rate|"Subjects will be given a small amount of contrast (approximately 1 cc test bolus) followed by administration of the remainder of the volume of contrast they are getting for their clinical study. This will be approximately 30-40 cc, depending on patient size. We will use a mathematical algorithm to rapidly analyze the test bolus and calculate a predicted best way to inject the contrast - likely slower and multi-phasic, meaning different flow rates as the bolus injection evolves. The injection rate will vary from 1 to 3 cc/second."
89437581|NCT03554018|Active Comparator|Placebo|Placebo Participants in this arm will also receive ibuprofen 600mg every 6 hours for 7 days and an educational intervention.
89437582|NCT03534193|Other|Group 1|Participants randomized to Group 1 will receive Standard Diabetic Education with Registered Nurse and Molly Center Diabetes Care Guide (paper-based)
89413739|NCT03079180|Experimental|Aged & strength training at 80% 1RM|"Subjects: 20 subjects aged between 65 and 85 years~Training programs:~Frequency: 3 training sessions per week. Duration: 12 weeks. Intensity: 80% of one repetition maximum (1RM). The 1RM of the participants in each of the 3 exercises performed in the training program will be reviewed every 2 weeks during training. If 1RM increase, the training load will be adjusted accordingly.~Training exercises: A Warm-up will first be performed on a cycle ergometer during 10min. The training intervention will then consist in performing two sets on each one of the two exercises used for Patellar tendon stress: leg extension and leg press. To stress Achilles tendon, the subjects will perform four (4) sets using a calf raise machine. The subjects will perform 4 to 8 repetitions at 80% 1RM.~All training sessions will take place under appropriate supervision in UTC for the duration of the interventions according to the study design."
89413740|NCT03079180|Experimental|Aged & strength training at 55% 1RM|"Subjects: 20 subjects aged between 65 and 85 years~The training program and training exercises in this group are the same as for the Aged & strength training at 80% 1RM arm except for the two following parameters.~Training intensity: Intensity of exercises will be 55% of one repetition maximum (1RM).~The subjects will perform 6 to 12 repetitions at 55% 1RM.~The two training programs (55% or 80% of 1RM) are designed to be equal in volume (resistance x repetitions x sets)."
89413741|NCT03079180|Experimental|Young & strength training at 55% 1RM|"Subjects: 20 subjects aged between 18 and 30 years~The training program and training exercises in this group are the same as for the Aged & strength training at 55% 1RM arm"
89413742|NCT02155296|Experimental|Schools receiving RPI|"This arm contains schools receiving RPI. RPI offers a continuum of practices that range from informal (e.g., using affective statements that communicate feelings) to formal (e.g., hosting a restorative circle where participants are encouraged to express emotions and form emotional bonds). The circles or group meetings that are designed to take place between school staff and students, are the crux of RPI. School staff are encouraged to use the restorative practices to build relationships and resolve staff issues (restorative staff community), as well as when interacting with parents (restorative approach with families). All restorative practices encourage acting with youth and setting high expectations. When a school becomes proficient in all 11 essential practices it is officially recognized as a Restorative Practices School."
89413743|NCT02155296|Experimental|Schools not receiving RPI|This arm is the control arm and consists of schools that are not receiving RPI.
89413744|NCT05020288|Experimental|Orelabrutinib|Orelabrutinib 50mg po qd
89413745|NCT02155374|Active Comparator|Sliding scale insulin|Sliding scale insulin Glucose 7.8-12 mmol/l --> 2 IU insulin, glucose 12.1-17 mmol/l --> 4 IU insulin, glucose ≥17.1 mmol/l --> 6 IU insulin. In case of insufficient control, insulin doses will be increased
89413746|NCT02155374|Experimental|Intermediate acting insulin|Intermediate acting insulin, 0.01 IU / mg prednison / kg body weight with a maximum of 0.5 unit insulin per kg body weight. In case of age > 70 years or diminished renal function (GFR <30ml/min)
89413747|NCT03078712|Active Comparator|Peripheral Perfusion guided resuscitation|Resuscitation will be aimed at normalization of capillary refill time.
89413748|NCT03078712|Active Comparator|Lactate guided resuscitation|Resuscitation will be aimed at normalization or significant decrease in lactate levels.
89413749|NCT02033577|Experimental|Distal gastrojejunal bypass|RYGB with 200 cm BP limb and 150 cm common limb
89413750|NCT02033577|Active Comparator|RYGB|RYGB with 60 cm BP limb and 150 cm alimentary limb
89413751|NCT03542448||Study group|"97 eye of 49 normal Egyptian volunteers were divided into groups according to age, AL, SE of refractive error, minimum corneal thickness (MCT) and mean corneal power as follow:~Age into 3 groups:~Group A: from 18 to 30 years old Group B: from 31 to 40 years old Group C: > 40 years old~Axial length into 3 groups:~Group A: from 22 to less than 24 mm Group B: from 24 to 26 mm Group C: > 26 mm~Spherical equivalent of refractive error into :~Group A : from zero to - 2 D Group B : from - 2 to > - 4 D Group C : from - 4 to > - 6 D Group D: from - 6 to - 8 D~Minimum corneal thickness (MCT) into 3 groups:~Group i: < 500 um Group ii: from 500 to 540 um Group iii: > 540 um~Refractive power of cornea (Mean K) into 3 groups:~Group 1: 41 to less than 44 D Group 2: 44 to 46 D Group 3: > 46 D"
89005527|NCT04568668|Experimental|ADE information transmitted to PharmaNet|Patients in the experimental arm will have standardized adverse drug event information documented in ActionADE transmitted to and stored in PharmaNet, British Columbia's medication dispensing database. The adverse drug event information will become visible to any subsequent healthcare provider who accesses the patient's PharmaNet profile. Community pharmacy software will import the adverse drug event information such that community pharmacists can view the adverse drug event information prior to dispensing medications.
89413752|NCT03610191||Surgery|Patients aged over 18 scheduled for elective cardiac surgery under CPB and general anesthesia. This group will later be divided in to two sub groups based on their neuropsychological battery tests results before surgery and one day before discharge. Blood sample will be collected before, immediately after surgery and at 24h after surgery for serum biomarker tests: MD2, CysC as well as DNA methylation markers of neural system origin.
89413753|NCT03610191||non-surgical control|Age and sex matched volunteers from the community were included for neuropsychological battery tests and set as controls for the diagnosis of POCd in surgical patients.
89413754|NCT04434118||Rheumatoid Arthritis with COVID-19|
89005528|NCT04568668|No Intervention|Standard care (ADE information retained locally)|Patients in the control group will have their adverse drug event information recorded in ActionADE, and their information will be retained locally, as is the current standard of care. This means that their adverse drug event information will not be visible to other providers via PharmaNet.
89413755|NCT04434118||Rheumatoid Arthritis without COVID-19|
89413756|NCT02765100|Experimental|Low CRP|Subjects have CRP > 3
89005529|NCT04568746|Other|patients with qSOFA ≥ 2|adult patients with a qSOFA score ≥ 2 at the screening in the emergency department, will be referred to the emergency vital room
89005530|NCT04568746|Other|patients with qSOFA <2|adult patients with a qSOFA score < 2 at the screening in the emergency department, will be referred to the box
88814010|NCT03409406|Experimental|Caregiver Intervention + ST Intervention|Parents/caregivers receive web-based tablet protocol containing sequenced communication information for working with their child at home in addition to the Standard of Care Intervention.
88814011|NCT03409406|Active Comparator|ST Intervention|This intervention is the once monthly standard of care intervention 30-minutes speech therapy (ST) session that the child receives at the hospital.
88891324|NCT06255314|Experimental|open sublay ventral hernia repair|
88891325|NCT06255288|Experimental|Dialogue, patient information and protein supplement|"Patient will receive:~Structured nutritional dialogue during two visits to the clinic.~Written patient information (pamphlet) during their first visit to the clinic.~Protein supplement drink during two visits to the clinic.~Prescription of protein supplement drink during their first visit to the clinic."
88891326|NCT06255275|Experimental|pedestrian crossing - virtual reality|
88891327|NCT06255262|Experimental|Durvalumab in combination with surufatinib|"Safety introduction phase (6 cases)~Dose expansion phase (24 cases)"
88891328|NCT06255236|Experimental|BIS|The patients will receive both standard frontal and nasal BIS monitoring during general anesthesia.
88891329|NCT06255223|Experimental|Experimental group|For eligible subjects, multimodal radiotherapy will be added to the treatment besides original immunotherapy or combinations of immunotherapy and TKIs after adjustment.
88891330|NCT06255210|Experimental|Induction chemotherapy in different subtypes of olfactory neuroblastoma|"Induction chemotherapy based on pathological molecular subtypes of olfactory neuroblastoma.~① According to the immunohistochemical results of the pathological report, patients with Ki-67 index ≥ 25% were treated with two weeks of gemcitabine+platinum based chemotherapy regimen;~② According to the immunohistochemical results of the pathological report, patients with Ki-67 index <25% were treated with a basic chemotherapy regimen of cyclophosphamide+etoposide+cisplatin (CEP regimen);~According to the progression of the patient's disease, the combination of other chemotherapy/small molecule drugs/targeted drugs can be considered;"
88891331|NCT06255184|Experimental|Serenity GROUP|40 geriatric patients for the serenity group. They will receive the routine care in addition to the serenity therapy which included 8 sessions (1 introductory session, 4 face to face sessions at dialysis unit , and 3 mobile based sessions at home).
89192956|NCT05830578||Cohort 2|Subjects enrolled into Cohort 2 must have a known diagnosis of persistent or permanent AFib and be in AFib at the time of screening.
88891332|NCT06255184|No Intervention|Control group|The control group received only the routine care provided at the dialysis unit with no extra interventions.
89413757|NCT02765100|Experimental|High CRP|Subjects have CRP =/> 3
89413758|NCT02033655|Experimental|Weight loss high protein|Protein supplementation. Subjects follow a calorie-reduction diet for a weight loss of ≥10%, with a high proportion of protein, including substantial amounts of supplemental protein provided as lean beef. Intakes of > 30g of high quality protein will be achieved three times a day by subjects in this group, with all or predominantly all from animal source and 60% of animal protein from pork.
89413759|NCT02033655|Active Comparator|Weight loss control|Diet counseling and group education lessons. Subjects follow a calorie-reduction diet for a weight loss of ≥10%.
88891333|NCT06255171|Other|Nature articles - control 1|Participants will read posts and articles about nature.
88891334|NCT06255171|Experimental|Death by suicide articles|Participants will read posts and articles about death by suicide.
88891335|NCT06255171|Other|Articles about traffic-related deaths - control 2|Participants will read posts and articles about traffic-related deaths.
89413760|NCT02159664|Experimental|didgeridoo practice|
89413761|NCT03091894|Active Comparator|propofol|patients will receive only propofol intravenous infusion for sedation
89413762|NCT03091894|Active Comparator|propofol-dex.|patients will receive dexmedetomidine in addition to propofol intravenous infusion for sedation
89413763|NCT05014594|Active Comparator|Group A (Dapaglifozin)|Group A will receive oral Dapaglifozin (10 mg/day) along with standard medical therapy for 6 months
89413764|NCT05014594|Placebo Comparator|Group B (Placebo)|Group B will receive placebo of Dapaglifozin along with standard medical therapy for 6 months
88891336|NCT06255158|Experimental|INSIGHT Program|"The design of the INSIGHT Program aligns with RNR model, the principles of cognitive behavioral therapy, and schema therapy. The intervention comprises different phases, beginning with an initial individual motivation interview intervention, and followed by a CBT-structured, ST-inspired individual program.~The core of the intervention program consists of a manualized individual program comprising 25 weekly sessions, each lasting approximately 60 minutes."
88891337|NCT06255158|Other|Treatment As Usual Group|TAU in Portuguese prisons is primarily aimed to increase educational and professional qualifications
88891338|NCT06255145|Experimental|Experimental group|In all participants, body composition evaluation was carried out with the Beurer BF 1000 Super Precision device using the Bioelectrical Impedance Analysis principle, fatigue evaluation was carried out with the Fatigue Severity Scale, mobility evaluation was carried out with the Rivermead Mobility Index, and functional status evaluation was carried out with the Functional Independence Scale.
88891339|NCT06255145|Active Comparator|Control Group|In all participants, body composition evaluation was carried out with the Beurer BF 1000 Super Precision device using the Bioelectrical Impedance Analysis principle, fatigue evaluation was carried out with the Fatigue Severity Scale, mobility evaluation was carried out with the Rivermead Mobility Index, and functional status evaluation was carried out with the Functional Independence Scale.
88891340|NCT06255132|Experimental|Patients undergoing open heart surgery|
88891341|NCT06255119|Active Comparator|Active VR Group|Participants received the active virtual therapy intervention.
88891342|NCT06255119|No Intervention|Control Group|A group of patients concurrently on the ATS unit, otherwise eligible to participate in the study who did not enroll, and did not receive an intervention.
88891343|NCT06254339||OAGB cohort|Application of One-anastomosis gastric bypass (OAGB) procedure stated in IFSO/ASMBS.
89413765|NCT03609645|Active Comparator|Fascia iliaca block (FIB)|Group will receive Fascia iliaca block (FIB) with local anesthetic and femoral articular branch block (FAB) with normal saline (Placebo).
89413766|NCT03609645|Experimental|Femoral articular branches block(FAB)|Group will receive Fascia iliaca block (FIB) with normal saline (Placebo) and Femoral AON articular branch block (FAB) with local anesthetic.
89413767|NCT02761980|Experimental|Ibuprofen 250 mg / Acetaminophen 500 mg|Single dose of 2 caplets of Ibuprofen 125 mg / Acetaminophen 250 mg by mouth
89413768|NCT02761980|Active Comparator|Ibuprofen 250 mg|Single dose of 2 caplets of IBU 125 mg by mouth
89413769|NCT02761980|Active Comparator|Acetaminophen 500 mg|Single dose of 1 APAP 500 mg caplet + 1 placebo caplet by mouth
89413770|NCT02761980|Placebo Comparator|Placebo|Single dose of 2 caplets of Placebo by mouth
89437583|NCT03534193|Experimental|Group 2|Participants randomized to Group 2 will receive Molly Center Standard Diabetes Education plus access to Tablet based interactive diabetes education modules
89437584|NCT03532256||Treated Patients|This prospective, observational study includes adult patients (age ≥18) undergoing elective surgical procedures within the departments of orthopedics, sports medicine, and neurosurgery, as well as patients treated for an acute injury and prescribed an opioid from the ED who own a mobile phone and can receive SMS text messaging at the University of Pennsylvania or Penn Presbyterian Medical Center.
89413771|NCT04577157|Experimental|Intervention Arm|"The participants in the intervention group will receive Health@click (seven-item multifaceted educational and reminder module) through WhatsApp. This will be included daily notes for medication reminders, voice messages, Graphics-based Reminders (GBR), Twice-weekly Graphics-based Messages (GBM), and once-weekly lifestyle advice through video in addition to standard care (as being practiced routinely in the hospitals). Besides this, a 24/7 help provision service will be given to the participants. A qualified doctor will be there to provide this educational support. Support will be including the dose of medicine, frequency, mode of action, effects of medicine on current illness, side effects and interaction with different foods, and psychological support to the participants who feel the need."
89413772|NCT04577157|No Intervention|Control Arm|Participants in the control group will receive no intervention except in standard care (as per being practiced routinely in the hospitals).
89413773|NCT05007496|Experimental|AV-COVID-19 (0.1 mcg S-protein)|DCL previously incubated with 0.1 mcg spike protein
89413774|NCT05007496|Experimental|AV-COVID-19 (0.33 mcg S-protein)|DCL previously incubated with 0.33 mcg spike protein
89413775|NCT05007496|Experimental|AV-COVID-19 (1.0 mcg S-protein)|DCL previously incubated with 1.0 mcg spike protein
89413776|NCT03609567|Experimental|Aromatherapy|Aromatherapy using essential oils
89413777|NCT03609567|Placebo Comparator|Placebo|Aromatherapy using odorless placebo
89413778|NCT03609957|Experimental|Aerobic Exercise Training|Moderate intensity (75% heart rate reserve) cycling exercise for 32 minutes, 3 days per week for 5 weeks
89413779|NCT03609957|Experimental|Interval Training|High intensity (95% heart rate reserve) cycling exercise for 20 minutes, 3 days per week for 5 weeks
89413780|NCT03609957|No Intervention|Control|Control (no exercise intervention) group
88891344|NCT06254339||DJB-SG cohort|Application of Duodenojejunal bypass with sleeve gastrectomy (DJB-SG)) procedure stated in IFSO/ASMBS.
89413781|NCT03083938|Experimental|Omental Roll-up|
89413782|NCT03083938|No Intervention|No Omental Roll-up|
89413783|NCT02166684|Experimental|Do-it-yourself devices|All subjects will use do-it-yourself devices for self-monitoring health parameters
89413784|NCT05007184|No Intervention|Control Arm (Arm 1)|Participants will experience an unmodified version of NUSMart, which replicates the traditional shopping experience of online grocery stores.
89413785|NCT05007184|Experimental|Warning Label Arm (Arm 2)|Similar to Arm 1 except that products are labeled with Chilean warning FOP labels.
89413786|NCT05007184|Experimental|Nutri-Score Arm (Arm 3)|Similar to Arm 1 except that products are labeled with NutriScore FOP labels.
89413787|NCT02163096||History of Wheezing, Benign Joint Hypermobility Syndrome|
89413788|NCT02163096||Asthma, Benign Joint Hypermobility Syndrome|
89413789|NCT04570605|Active Comparator|Standard Urotherapy|Patients who meet eligibility criteria who will be counselled on standard recommendations for bladder management.
89413790|NCT04570605|Experimental|Standard Urotherapy + PTENS|Patients who meet eligibility criteria who will be counselled on standard recommendations for bladder management AND use parasacral percutaneous TENS as additional treatment.
89413791|NCT02163174|Active Comparator|Pentoxyfilline arm|Pentoxifylline 5 mg/kg/hr for 6 hours on 6 successive days in addition to antibiotics.
88891345|NCT06254131|Experimental|Ondansetron lozenge (Ondalenz ©)|Patients will receive ondansetron lozenge 4 mg (Ondalenz ©), 2 hours before surgery.
88891346|NCT06254131|Experimental|Ondansetron IV|Patients will receive 4 mg of ondansetron IV approximately 30 minutes before the end of surgery.
88891347|NCT06254131|No Intervention|Control group|Patients will not receive ondansetron as a control group.
88922047|NCT05908812||Sarcopenic obesity|BMI>30, bioelectric impedance positive for sarcopenic obesity (FM% [fat mass percentage] female >43%, male >31% AND SMM/W [skeletal muscle mass/weight] female <28%, male <37%), any one of the physical performance test positive (5-times chair stand test >17 s OR handgrip strength test <35,5 kg for males, <20 kg for females).
89413792|NCT02163174|Placebo Comparator|Placebo arm|Intravenous saline as a Placebo 5 mg/kg/hr for 6 hours on 6 successive days in addition to antibiotics.
89413793|NCT01744912|Experimental|Ublituximab + Lenalidomide|"4 cohorts, with 3 - 6 patients per cohort, as follows:~Cohort 1: Ublituximab 450 mg + Lenalidomide 10 mg Cohort 2: Ublituximab 450 mg + Lenalidomide 15 mg Cohort 3: Ublituximab 600 mg + Lenalidomide 10 mg (escalation to 15 mg permitted after cycle 1) Cohort 4: Ublituximab 900 mg + Lenalidomide 10 mg (escalation to 15 mg permitted after cycle 1) Ublituximab is an IV infusion on days 1, 8, and 15 of cycles 1 & 2 followed by a planned maintenance with a single infusion on day 1 of cycles 3 thru 6.~Lenalidomide is taken orally on days 9 - 28 of cycle 1 followed by daily administration on Days 1 - 28 for cycles 2 thru 6. Non-hodgkins lymphoma patients may have up to a 7 day rest period (Days 21-28) in any cycle."
89413794|NCT03609879|No Intervention|without cervical collar|baseline - without cervical collar
89413795|NCT03609879|Experimental|with cervical collar|scenarios with cervical collars
89413796|NCT03540810|Active Comparator|Hydroxychloroquine|All patients randomised in this arm will receive hydroxychloroquine with their usual treatment, which is antivitamin K anticoagulants
89413797|NCT03540810|Placebo Comparator|Placebo|All patients randomised in this arm will receive a placebo with their usual treatment, which is antivitamin K anticoagulants
89413798|NCT03078400|Experimental|Safety Phase|"Six to 12 subjects~Cohort 1 SPL-108 injection daily + 80 mg/m2 PTX weekly on Days 1, 8, and 15 in 28 day cycles~Cohort 2 SPL-108 BID injection + 80 mg/m2 PTX weekly on Days 1, 8, and 15 in 28 day cycles"
89413799|NCT03078400|Experimental|Exploratory Expansion Phase|"Up to 12 subjects~• Cohort 3: SPL-108 daily dose (to be determined in Arm I) + 80 mg/m2 PTX weekly on Days 1, 8, and 15 in 28 day cycles."
89413800|NCT03609723||MPS® in patients with CABG|Patients undergoing coronary artery bypass grafting with application of a myocardial protection system (MPS ®) and using a minimal extracorporeal circulation system (MiECC)
89413801|NCT03609723||OPCABG in patients with CABG|Patients undergoing coronary artery bypass grafting without use of a minimal extracorporeal circulation system (Off-pump coronary artery bypass grafting = OPCABG)
89413802|NCT02159820|Active Comparator|DTC Arm|Patients are randomly assigned to receive lower-dose decitabine treatment followed by TC regimen (ie, DTC arm).
89413803|NCT02159820|Active Comparator|TC regimen|Patients were randomly assigned to receive carboplatin plus paclitaxel (ie, TC arm).
89413804|NCT05013658|Active Comparator|junior|their anesthesia experiences are between 1 months and 1 year,
89413805|NCT05013658|Active Comparator|senior|Their anesthesia experiences are more than 4 years
89413806|NCT02862171|Experimental|Dapivirine Vaginal Ring-004|Dapivirine Vaginal Ring, 25 mg.Each participant will engage in the screening process for up to 45 days prior to enrolment and will use the monthly Dapivirine Vaginal Ring for a period of up to 12 months. IPM will have the option to extend this trial period.
88891348|NCT06253910|Other|Patient selection|A total of 15 (female) patients, between 31 and 70 years, who were systemically and periodontally healthy and applied to the periodontology clinic for treatment, were included in our study. Criteria for inclusion in the study are having ≥15 permanent teeth excluding third molars, not using any orthodontic appliance, not being pregnant or breastfeeding, not having any uncontrolled chronic and/or auto-immune disease, and not smoking.
88891349|NCT06253910|Other|MARF and FGG tehcniques|Free gingival graft for the treatment of a total of 21 teeth with gingival recession in the lower jaw incisors area, no bone dehiscence, and the amount of attached gingiva being at least 0.5 mm and at most 1.5 mm and modified apically positioned flap methods were randomly selected (coin toss) and applied by a single investigator (MY). Surgical methods were performed on a minimum of 1 and a maximum of 2 teeth in the treated areas.
88891350|NCT06253910|Other|Post-surgical evalution and periodontal measurements|Clinical periodontal parameters (plaque index (PI), pocket probing depth (PPD), bleeding on probing (BOP), gingival recession (GR) and clinical attachment level (CAL)) were recorded and evaluated at baseline, third months, first and second years. Periodontal measurements (keratinized tissue width (KTW), attached gingiva width (AGW)) recorded and evaluated at baseline, third months, first and second years.
88891351|NCT06253884|Experimental|Coronary Artery Disease (CAD) Subjects|Subjects with a of coronary artery disease will undergo computer-controlled gas challenges.
88891352|NCT06253546|Experimental|Olanzapine Dose 1|"Period 1: Participants will receive oral olanzapine daily~Period 2: Participants will receive subcutaneous (sc) injection of TV-44749"
88891353|NCT06253546|Experimental|Olanzapine Dose 2|"Period 1: Participants will receive oral olanzapine daily~Period 2: Participants will receive sc injection of TV-44749"
88891354|NCT06253546|Experimental|Olanzapine Dose 3|"Period 1: Participants will receive oral olanzapine daily~Period 2: Participants will receive sc injection of TV-44749"
89413807|NCT05013814||Children with unilateral cerebral palsy|
89413808|NCT05013814||Typically developed children|
89413809|NCT03083626||Prescription opioid abusers|Patients 21-65 years old taking suboxone or methadone, currently experiencing chronic pain, not taking any opioid analgesic medication for painful condition on a regular basis, not have any current psychiatric or neurological illnesses, not have a history of heart disease in order to be healthy enough to complete the cold pressor test.
89413810|NCT03083626||Healthy control participants|Patients 21-65 years old not taking suboxone or methadone, not experiencing chronic pain, not taking any opioid analgesic medication for painful condition on a regular basis, not have any current psychiatric or neurological illnesses, not have a history of heart disease in order to be healthy enough to complete the cold pressor test.
89413811|NCT04556565||General population|A representative sample of the general adult population (including those tele-working and working outside of home)
89413812|NCT04556565||Cases and contacts|Recently isolated or quarantined COVID-19 cases and close contacts
89413813|NCT04556565||Healthcare workers|Healthcare workers, including medical personnel directly and indirectly involved with patients as well as other personnel (e.g. administrative workers)
89437585|NCT03532256||Treated patients randomized to receive survey|A subset of patients (described above) will receive an automated SMS text message with a link to an online survey. This survey contains the script questions about pain management and opioid use.
89437586|NCT03532256||Treated patients randomized to receive text script|A subset of patients (described above) will receive an automated questionnaire conducted via text message. Questions will be about pain management and opioid use.
89005531|NCT00210899|Active Comparator|Vancomycin plus Ceftazidime|Vancomycin 1g q12h as 1h infusions plus Ceftazidime 1g q8h in 2h-infusions, 7-14d
89005532|NCT00210899|Experimental|Ceftobiprole medocaril|Ceftobiprole medocaril 500mg q8h as 2h infusions, 7-14d
89413814|NCT04405791|Experimental|Active stimulation group|"low intensity transcranial focused ultrasound (tFUS) stimulationThe acoustic intensity output of the FUS transducer was validated at the maximum intensity area using a calibrated needle hydrophone (HNR-500, Onda). The incident acoustic intensity and pressure at the FUS focus were 3W/cm2 spatial-peak pulse-average acoustic intensity (Isppa) and a peak negative pressure (Pr) of 300 kPa. The incident acoustic intensity and pressure at the FUS focus were 3W/cm2, and tone burst duration was 1 ms at 50 % duty cycle (thus, pulse repletion frequency was 500 Hz) for the duration of 300 ms, according to the studies in humans. Each sonication was delivered every 6 s for the duration of 20 min (a total FUS stimulation per each session was therefore 200 times). With a derating factor of 55% reduction in pressure transmission by the human skull, estimated in situ Pr was ~135 kPa with an in situ acoustic intensity of 600 mW/cm2 Isppa ."
89413815|NCT04405791|Sham Comparator|Sham stimluation group|"sham stimulation In case of sham stimulation, the same procedure was repeated without providing actual sonication. No subjects in FUS condition hear/feel any tangible somatosensory phenomena; therefore, the sham condition was indistinguishable."
89413816|NCT03083314|Experimental|SELECTIVE AXILLARY LYMPH NODE DISSECTION (SAD)|
89413817|NCT03083314|Active Comparator|COMPLETE AXILLARY DISSECTION (ALND)|
89413818|NCT05013112|Placebo Comparator|Placebo group|Patients receive no additional therapy.
89192957|NCT05830526|Other|Escape Room|All of the participants were trained in the escape room.
89413819|NCT05013112|Experimental|Metformin group|Patients receive metformin 500mg twice daily from discharge.
89005533|NCT04568785|Experimental|Brief Intervention group|Intervention consisted of a standardized Brief Intervention, which varied depending on the reason the patient had given for refusing the vaccination.
89413820|NCT05013112|Experimental|Empagliflozin|Patients receive Empagliflozin once daily from discharge.
89005534|NCT04568785|Active Comparator|Control group|the control group intervention was the normal advice that professionals used to give their patients
89413821|NCT03082144|Active Comparator|Group 1: RT-Intra-MTX|Intrathecal chemotherapy: MTX 15 mg, plus dexamethasone 5 mg, via lumbar puncture,once per week, 4 weeks in total.
89005535|NCT04568863|Experimental|Melatonin|(12 patients): 7 days of 5 mg per Kg of actual body weight per day of intravenous melatonin every 6 hours. Maximum daily dose 500 mg per day.
89005536|NCT04568863|Placebo Comparator|Placebo|(6 patients): 7 days of 5 mg per Kg of actual body weight per day of intravenous identically-looking placebo every 6 hours.
89005537|NCT02210377|Experimental|Tianjiu (auto-moxibustion)|The participants in the Tianjiu group will be treated with Chinese herbal patches at acupoints on the abdomen and plantar, three times per week, for 4 hours each time during HD.
88891355|NCT06253442|Active Comparator|Patients will receive Supra scapular nerve block and Axillary nerve block.|ultrasound guided suprascapular nerve block combined with ultrasound guided axillary nerve block will be provided to the patient
88891356|NCT06253442|Active Comparator|Patients will receive Interscalene block.|ultrasound guided interscalene brachial plexus block will be provided to the patient
88891357|NCT06253403||clinic|adult women with anorexia nervosa or actual or after stabilization
88891358|NCT06253403||control|health adult women without any psychological or mental illnes
88891359|NCT06252948||MULTIPLE MYELOMA at diagnosis GROUP|Multiple myeloma (before starting chemotherapy, radiation or stem cell transplant
88891360|NCT06252948||Amyloid at diagnosis GROUP|AL amyloidosis (before starting chemotherapy or stem cell transplant)
88891361|NCT06252948||Poems at diagnosis GROUP|POEMS at diagnosis (before starting chemotherapy, radiation, or stem cell transplant
88891362|NCT06252948||Poems in Remission GROUP|POEMS in remission (no chemotherapy, radiation, or stem cell transplant for 2 years
88891363|NCT06252948||MGUS GROUP|MGUS -not treated newly diagnosed
88891364|NCT06252948||Health controls in same household GROUP|household member to be a healthy control (no chemotherapy or gastrointestinal illness to participate)
89413822|NCT03082144|Experimental|Group2: RT-Intra-Ara-C|Intrathecal chemotherapy:Ara-C 50 mg, plus dexamethasone 5 mg, via lumbar puncture, once per week, 4 weeks in total.
89413823|NCT05013034|Placebo Comparator|Placebo (Current Standard of Care)|Current Standard of Care for SARS-CoV2 hypoxemic pulmonary diease
89413824|NCT05013034|Experimental|Basiliximab|Basiliximab in addition to Current Standard of Care for SARS-CoV2 hypoxemic pulmonary diease
89413825|NCT02638948|Placebo Comparator|Placebo|Placebo + Methotrexate dose as specified
89413826|NCT02638948|Experimental|Dose Level 1|BMS-986142 at dose level 1+ Methotrexate as specified
89413827|NCT02638948|Experimental|Dose Level 2|BMS-986142 at dose level 2 + Methotrexate as specified
88891365|NCT06252610||PSC|Population will be consecutive patients with PSC, who will be referred to us by the MGB-affiliated hepatologists.
88891366|NCT06252337|Experimental|Thermafil AH Plus bioceramic test group|Test Group_ A premixed CaSi-containing bioceramic sealer (Ah Plus Bioceramic, Dentsply, Konstanz, Germany) was used in association with a warm carrier-based technique (Thermafil, Dentsply, Konstanz, Germany). AH Plus Bioceramic is mostly composed of zirconium dioxide (50-70%) as a radiopacifier and tricalcium silicate (10-15%) as a bioactive component. Dimethyl sulfoxide and traces of lithium carbonate and thickening agents are also reported by the manufacturer.The sealer was inserted in the canal and the carrier was warmed in a dedicated oven (thermaprep) and inserted within 60 seconds.
88922048|NCT05908812||Non-sarcopenic obesity|BMI>30, bioelectric impedance negative for sarcopenic obesity.
89413828|NCT03091582|Experimental|Cognitive behavioral therapy|The Cognitive-Behavioral Therapy (CBT) intervention will focus on catastrophizing and rumination. CBT emphasizes the role of cognitive factors and behavioral factors on affective distress.
89413829|NCT03091582|Experimental|Behavioral Activation|Behavioral Activation is grounded in learning theory and posits that lack of positive/active engagement of the person with his/her environment contributes to an increase in avoidant or passive behaviors and decreased reinforcement. An empirically validated treatment, behavioral activation reduces depressive symptoms and increase engagement of pleasant events.
89413830|NCT03091426|Experimental|Omiganan 1%|
89413831|NCT03091426|Experimental|Omiganan 1.75%|
89413832|NCT03091426|Experimental|Omiganan 2.5%|
89413833|NCT03091426|Placebo Comparator|Vehicle|
89413834|NCT05020054|Active Comparator|Intervention Tecartherapy|"The procedures will be performed with Tecartherapy equipment, with the equipment Nèartek®- IBRAMED- Industria Brasileira de Equipamentos Eletromédicos.~The treatment will be carried out once a week, totaling 10 sessions, by two dermato-functional physiotherapists. During the sessions, all volunteers will be positioned in dorsal decubitus and the applicator positioned in the abdominal region, the therapy will be dynamic and simultaneously the professional must assess the local temperature.~The parameters used will be:~Area of 300cm², 1MHz, Capacitive Mode: 60mm Disc: Default 100W Time of 10 minutes, keeping temperature at 42°C Resistive Mode: 60mm Disc: Default 110W Time of 10 minutes, keeping temperature at 42ºC. The total treatment time is 20 minutes."
89413835|NCT05020054|Placebo Comparator|Placebo Tecartherapy|the therapy took place with the equipment turned off
89413836|NCT05019820|Active Comparator|Sarcopenia and osteoarthritis group|Women aged 45-65 years diagnosed with sarcopenia and knee osteoarthritis
89413837|NCT05019820|Other|Without osteoarthritis and sarcopenia group|Women aged 45-65 years without a diagnosis of knee osteoarthritis and sarcopenia
89413838|NCT04465864|Other|Insertion visit 4 days prior|Intracanalicular dexamethasone (0.4 mg) insertion four days (+/- 1 day) prior to cataract surgery with intraocular lens (IOL) implant and MIGS (iStent, iStent inject or KDB) insertion. (Patient to use antibiotic three days prior to surgery)
89413839|NCT04465864|Other|Surgical 1 visit day 0|Intracanalicular dexamethasone (0.4 mg) insertion on the day of cataract surgery with intraocular lens (IOL) implant and MIGS (iStent, iStent inject or KDB) insertion. (Patient to use antibiotic three days prior to surgery)
88891367|NCT06252337|Other|Thermafil AH Plus control group|Control Group_ an epoxy resin based sealer (Ah Plus, Dentsply, Konstanz, Germany) was used in association with a warm carrier-based technique (Thermafil, Dentsply, Konstanz, Germany). The sealer was inserted in the canal and the carrier was warmed in a dedicated oven (thermaprep) and inserted within 60 seconds.
88891368|NCT06251804|Experimental|Water exercise program|The treatment program includes in-water exercise program. Participants will be exercised twice a week for six weeks.
88891369|NCT06251804|Active Comparator|Land-based-program|The treatment program includes land-based exercise program. Participants will be exercised twice a week for six weeks.
88891370|NCT06251791|Experimental|Experimental|Experimental: Conventional Physiotherapy In the intensive care unit and who had mechanical ventilation for more than 48 hours and who were extubated. In this group addition to conventional physiotherapy inspiratory muscle training will be performed with the threshold-loaded inspiratory muscle training device, starting at 30% of the maximum inspiratory mouth pressure value, during 5 days, in 2 sessions, 4 sets per day, 6-8 breaths in each set and 2 minutes of rest between sets.
88891371|NCT06251791|Experimental|Conventional|In this group will apply only conventional physiotherapy. Conventional physiotherapy to contain breathing and,thoracal expansion exercises, bronchial hygiene techniques and gradual mobilization. Conventional physiotherapy apply for 5 days after extubation period 1 time a day.
88891372|NCT06251791|No Intervention|Healthy controls|There is no intervention in this group. Baseline measurements are to compare with experimental groups.
88891373|NCT06251271||Pulmonology Ward - 'All Comers'|In the Pulmonology Ward, the cohort will encompass 'All Comers'-any patient referred for PFTs who meets the inclusion criteria. This cross-sectional observational study will screen all eligible patients presenting at the ward, offering a comprehensive snapshot of the diagnostic accuracy of point-of-care ultrasound in this diverse patient population.
88891374|NCT06251089|Experimental|0.07% CPC mouthwash|"Brush your teeth twice a day with fluoride toothpaste, after meals. Then rinse for 1 minute with 15 ml of the test mouthwash for 1 minute. If feasible on the part of the volunteer, they will be asked to do 30 seconds of gargling and 30 seconds of mouthwash.~If the volunteers are unable to rinse, the health professionals who care for them will be asked to perform the application of the product using sterile gauze soaked with the product, passing it through the oral mucous membranes and tongue, twice a day"
89413840|NCT03091504|Experimental|Albuterol via High flow nasal cannula|Enrolled patients inhale bronchodilator (Albuterol Sulfate) with different concentration via High flow nasal cannula, prepared albuterol concentrations are 0.5mg, 1.0mg, 2.0mg and 4.0mg, patients will be assessed by spirometry after each concentration until bronchodilator response is positive and does not improve after the next dose.
89413841|NCT03091270||BOLD-fMRI|Identifying the motor functional cortex in glioma patients with BOLD-fMRI.
89413842|NCT03091270||ZOOMit-fMRI|Identifying the motor functional cortex in glioma patients with ZOOMit-fMRI.
89413843|NCT03091036|Other|Proactive healthcare intervention|Participants who were included before (single-arm pre-post study), now a proactive and integrated intervention program for the health is performed of the complex chronic patient, based in an improvement of the care process.
88891375|NCT06251089|Placebo Comparator|comparator|"Brush your teeth twice a day with fluoride toothpaste, after meals. Then rinse for 1 minute with 15 ml of the control product for 1 minute. If feasible on the part of the volunteer, they will be asked to do 30 seconds of gargling and 30 seconds of mouthwash.~If the volunteers are unable to rinse, the health professionals who care for them will be asked to perform the application of the product using sterile gauze soaked with the product, passing it through the oral mucous membranes and tongue, twice a day"
88891376|NCT06250699|Experimental|no tube|no drainage tube after laparoscopic adrenalectomy
88891377|NCT06250699|Experimental|Drainage tube|tube drainage after laparoscopic adrenalectomy
88891378|NCT06250491|Experimental|Active rTMS|Deep rTMS with H coil targeting the motor cortex bilaterally
88891379|NCT06250491|Placebo Comparator|Sham rTMS|Sham rTMS with H coil targeting the motor cortex bilaterally
88891380|NCT06249854|Experimental|Bojungikkitang & Pembrolizumab combination treatment group|"Pembrolizumab is administered intravenously every 3 weeks for 45 weeks according to standard procedures until disease progression (PD) or unacceptable toxicity occurs.~Bojungikgitang is used in combination with immune checkpoint inhibitor treatment(Pembrolizumab) and is taken 1 bag twice a day before or between meals."
89413844|NCT05019508||High Risk for Gestational Diabetes Mellitus (GDM)|"High risk women screened with HbA1c at initiation of prenatal care who were not diagnosed with Type 2 Diabetes Mellitus or Early GDM.~These women will have Fetal Cardiac Function Parameters at their 20 week anatomy scan (E/A ratio, IVS, MPI). At their 24-28 week routine GDM screening, we will repeat the HbA1c and will repeat the E/A ratio, IVS, MPI. If women have a growth scan for any reason between 32 and 36 weeks, E/A ratio, IVS, and MPI will be repeated at those times."
89413845|NCT05019586||Helicobacter pylori resistance|Patients with treatment resistance to Helicobacter pylori treatment registered at GI-unites from 1990-2012 and included from 2010 to 2012. These patients were treated with a triple therapy of levofloxacin, amoxicillin and proton inhibitor for 10 days
89005538|NCT02210377|Placebo Comparator|Non-Tianjiu (Non auto-MO)|The participants in the control group will be given placebo patches (brown clay patches) on the same sites.
89005539|NCT02210416||LAP repair|patients receiving laparoscopic inguinal hernia repair
89413846|NCT05019586||Newly diagnosed Helicobacter pylori|Patients with newly diagnosed Helicobacter pylori infection from 2010-2012.These patients were treated with a triple therapy of clarithromycin, amoxicillin and proton inhibitor for 10 days
89413847|NCT05019586||Previously eradicated Helicobacter pylori infection|Patients with previously Helicobacter pylori infection included from 2010-2012.
89413848|NCT05019586||Never Helicobacter pylori infection|Patients with previously Helicobacter pylori infection included from 2010-2012.
89413849|NCT03078634|Active Comparator|Multi-Disciplinary clinic|
89413850|NCT03078634|Placebo Comparator|Standard Gastrointestinal clinic|
89413851|NCT03081676|Active Comparator|Glimepiride + GIP|Tablet Glimepiride + infusion of GIP
89413852|NCT03081676|Active Comparator|Placebo + GIP|Placebo tablet + infusion of GIP
89413853|NCT03081676|Active Comparator|Glimepiride + GLP-1|Glimepiride + infusion of GLP-1
89413854|NCT03081676|Active Comparator|Placebo + GLP-1|Placebo tablet + infusion of GLP-1
89413855|NCT03081676|Active Comparator|Glimepiride + Placebo|Glimepiride + infusion of placebo (saline)
89005540|NCT02210416||open repair|patients receiving open flat mesh repair of inguinal hernia
89413856|NCT03081676|Placebo Comparator|Placebo + Placebo|Placebo tablet + infusion of placebo (saline)
89413857|NCT05013268|Experimental|Tislelizumab plus TP regimen as neoadjuvant therapy for local advanced cervical carcinoma|"Experimental:~Tislelizumab, paclitaxel/docetaxel, cisplatin/carboplatin The subjects enrolled in this trial will receive tislelizumab 200mg ivgtt d1, paclitaxel (175mg/m2 ivgtt d1) or docetaxel (75mg/m2 ivgtt d1), cisplatin (75mg/m2 ivgtt d1) or carboplatin (AUC=5 ivgtt d1). The regimen will be repeated every 3 weeks for 3 cycles. Chemotherapy regimen will be selected by investigators.~Subjects will be enrolled serially."
89413858|NCT05005858|Experimental|Autograft|"The filler used in ridge splitting is autologous bone block harvested from mandible~Interventions:~Procedure: ridge splitting~Procedure: bone core biopsy~Device: dental implant placement~Measurement: clinical measurement with Williams probe~Micro-CT analysis~Histomorphometric measurements"
89413859|NCT03081208|Experimental|Nolasiban 900 mg|
89413860|NCT03081208|Placebo Comparator|Placebo|
89413861|NCT00102960|Experimental|Deferred therapy Arm|"Zidovudine: First Line Regimen: Given twice daily at a dose of 240 mg/m^2 of body surface area. Dose was adjusted by age as the children grew older.~Lamivudine: First Line Regimen: 4 mg/kg taken orally twice daily Lopinavir/Ritonavir: First Line Regimen: taken orally twice daily. Dosage depends on age and weight.~Ritonavir: First Line Regimen taken orally twice a day. Started at 250 mg/m^2 Abacavir sulfate: Second Line Regimen: 8 mg/kg taken orally twice daily. Guidelines for switching from first line to second line therapy are available in the protocol.~Didanosine: Second Line Regimen: Either 100 mg/m^2 or 120 mg/m^2 taken orally twice daily. Dosage depends on age.~Efavirenz: Second Line, once daily Nevirapine: Second Line, once daily"
89413862|NCT00102960|Experimental|Early therapy for 40 weeks|"Zidovudine: First Line Regimen: 10 mg/mL taken orally twice per day. Dose was adjusted by age as the children grew older.~Lamivudine: First Line Regimen: 4 mg/kg taken orally twice daily Lopinavir/Ritonavir: First Line Regimen: taken orally twice daily. Dosage depends on age and weight.~Ritonavir: First Line Regimen taken orally twice a day. Started at 250 mg/m^2~Abacavir sulfate: Second Line Regimen: 8 mg/kg taken orally twice daily. Guidelines for switching from first line to second line therapy are available in the protocol.~Didanosine: Second Line Regimen: Either 100 mg/m^2 or 120 mg/m^2 taken orally twice daily. Dosage depends on age.~Efavirenz: Second Line, once daily Nevirapine: Second Line, once daily"
89005541|NCT02278081|Experimental|treatment group|The treatment group will receive 30 mg lansoprazole (prevacid) one capsule per day for three months and mometasone furonate (nasonex) one puff in each nostril per day for three months.
89413863|NCT00102960|Experimental|Early therapy for 96 weeks|"Zidovudine: First Line Regimen: 10 mg/mL taken orally twice per day. Dose was adjusted by age as the children grew older.~Lamivudine: First Line Regimen: 4 mg/kg taken orally twice daily Lopinavir/Ritonavir: First Line Regimen: taken orally twice daily. Dosage depends on age and weight.~Ritonavir: First Line Regimen taken orally twice a day. Started at 250 mg/m^2 Abacavir sulfate: Second Line Regimen: 8 mg/kg taken orally twice daily. Guidelines for switching from first line to second line therapy are available in the protocol.~Didanosine: Second Line Regimen: Either 100 mg/m^2 or 120 mg/m^2 taken orally twice daily. Dosage depends on age.~Efavirenz: Second Line, once daily Nevirapine: Second Line, once daily"
89005542|NCT02278081|Placebo Comparator|placebo group|The placebo group will receive one capsule per day of prevacid placebo for three months and mometasone furonate (nasonex) one puff in each nostril per day for three months.
89005543|NCT02278159||Peritoneal dialysis only|Patient on PD modality 90 days after renal replacement therapy initiation and not transferred to HHD
89005544|NCT02278159||Home hemodialysis only|Patient on HHD 90 days after renal replacement therapy initiation and not transferred to PD
89005545|NCT02278159||PD and HHD|Patient on PD 90 days after RRT initiation and transferred to HHD less than 90 days after PD failure
89005546|NCT02278159||HHD and PD|Patient on HHD after RRT initiation and transferred to PD less than 90 days after HHD failure
89413864|NCT05019118|Experimental|Intervention/treatment|"Dairy foods made with UNICLA milk Participants (n = 45) ingested UNICLA milk and dairy products (yogurt and cheese) for three months.~UNICLA milk is characterised by an improved nutritional composition, obtained by modifying cow's diet, feeeding the dairy cows with a sufficient and balanced ration, which recreates the fatty acid profile of the spring.~This ration includes pastures, high-quality forages and, among other components, a significant amount of flax seeds, which constitute a source of unsaturated fatty acids such as omega-3 and selenised yeast, as a source of organic selenium.~Consequently, UNICLA milk and dairy products are naturally enriched in selenium and ω-3 PUFA.~The daily intake reflects the usual consumption habits, being the recommended amounts of 200 ml of milk and 125 g of yogurt per day and 400g of fresh cheese per week"
89413865|NCT05019118|Placebo Comparator|Conventional milk|"Participants (n = 45) ingest milk and conventional dairy products daily for 3 months.~Daily intake reflects usual dairy consumption habits in real life conditions, without forcing or inducing increased consumption. Therefore, the recommended amounts are 200 ml of milk and 125 g of yogurt per day and 400 g of fresh cheese per week"
89413866|NCT05005702|Experimental|study group|Patients were assigned to inspiratory muscle training (IMT) for 6 weeks. During training, patients were instructed to maintain diaphragmatic breathing, and try to maintain 10-15 breaths, and rested 5-10 between breaths. As soon as the patients managed; they were encouraged to maintain 25-30 breaths at each workload. All patients wore nose-clip during training. The inspiratory load was set at 40% of maximal inspiratory pressure. The training session was supervised at the hospital.
89005547|NCT02278276|Placebo Comparator|0 mg SG1002|Capsules containing 400 mg of placebo will be provided to subjects. Subjects will take two tablets twice each day.
89413867|NCT03078790|Experimental|meditation module|The patients in this arm will be offered the meditation/deep breathing module in the pre-operative area.
89413868|NCT02166762|Experimental|QLV interval measurement|QLV measurements collected during implantation of CRT-D device
89413869|NCT02163252|Active Comparator|Standard|A 12-week internet-based weight loss program that involves weekly video lessons, a self-monitoring platform where participants submit their weight, calorie, and activity information, and weekly automated feedback.
89413870|NCT02163252|Experimental|Early intervention|Participants randomized to Early Intervention will receive the same internet-based weight loss program compared to the Standard group. In addition, Early Intervention participants achieving less than optimal weight loss following several weeks of treatment will be given the opportunity to come to the Weight Control and Diabetes Research Center for an individual visit. At this visit, an interventionist will discuss with the participant any barriers that he or she may be experiencing and recommend alternate strategies to assist in their weight loss. One such strategy would be to recommend the use of meal replacement products or portion controlled meals. In addition to this one-time visit, the interventionist will follow up with the participant via phone weekly, for 2 weeks following this in-person visit.
89413871|NCT05012800|Experimental|COVID-19 Vaccines in older adults|Healthy people between the ages of 60 and 80 inoculated coronavirus vaccine on day 0 and day 21, respectively.
89413872|NCT05012800|Experimental|COVID-19 Vaccines in young adults|Healthy people between the ages of 20 and 59 inoculated coronavirus vaccine on day 0 and day 21, respectively.
89413873|NCT02166840|Experimental|Self expanding metal stent|Patients with self expanding metal stent inserted into bile duct.
89413874|NCT02166840|Active Comparator|Plastic stent|Patients with obstructive jaundice who got a plastic stent inserted into bile duct.
89413875|NCT02858895|Experimental|MDNA55|"Single infusion of MDNA55 via convection enhanced delivery (CED).*~*Subjects may be eligible to receive a second administration of MDNA55."
89413876|NCT04712136|Experimental|Cardiac disease|Children aged of 6 to 18 years old with an inherited cardiac arrhythmia (long QT syndrome, Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia, or arrhythmogenic right ventricular dysplasia), or those with an inherited cardiomyopathy (hypertrophic, dilated, or restrictive cardiomyopathy).
89413877|NCT04712136|Sham Comparator|Control group|Children aged 6 to 18 years old referred to the paediatric cardiology consultation who were classified in the control group after a completely normal check-up, including physical examination, electrocardiogram, and echocardiography.
89005548|NCT02278276|Active Comparator|1600 mg SG1002|Capsules containing 400 mg of sodium polysulthionate (SG1002) will be provided to subjects. Subjects will take two tablets twice each day, providing subjects with 1600 mg SG1002 daily.
89413878|NCT04939714|Experimental|Psychoeducational Intervention|Caregivers receiving the psychoeducational intervention immediately.
89413879|NCT04939714|No Intervention|Waitlist|Caregivers on a waitlist to receive the psychoeducational intervention after a waiting period of 8 weeks.
89413880|NCT05018962|Experimental|Cutting balloon followed by paclitaxel coated balloon|
89413881|NCT02160054||Group 1|patients with kidney transplantation who converted the immunosuppressant from cyclosporine to Graceptor ®
89413882|NCT03078322|Experimental|AV-101|L-4-chlorokynurenine 1440 mg daily for 14 days
89413883|NCT03078322|Placebo Comparator|Placebo|Placebo
89413884|NCT03609489|Experimental|Test Group|Apatinib combined with Capetabine
89413885|NCT03609489|Active Comparator|Control Group|Capecitabine
89413886|NCT02166918||patients with schizophrenia|320 patients with a diagnosis of schizophrenia according to Diagnostic and Statistical Manual IV edition (DSM-IV) criteria, confirmed by the Structured Clinical Interview for DSM-IV - Patient Version (SCID -IP), will be included in the study.
89413887|NCT02166918||unaffected first-degree relatives|240 unaffected first-degree relatives of the recruited patients (120 unaffected parents and 120 unaffected siblings)
89413888|NCT02166918||healthy control|320 healthy control subjects.
89413889|NCT05019196||fMRI，functional reorganization, functional connectivity, functional rating scale|low-grade glioma patients healthy controls
89413890|NCT02033967|Active Comparator|CVP|Central venous pressure-guided vasodilator-induced hypovolemia
89413891|NCT02033967|Experimental|SVV|stroke volume variation-guided vasodilator-induced hypovolemia
89413892|NCT03090802|Experimental|Intervention|The participants of the program arm will have 15 group sessions with mentor mother and up to 2 home visits from 3 weeks-6 months postpartum, which is package as the Mentoring Adolescent Mothers at School (MAMAS) program. Further, adolescent mothers in the intervention arm will receive adolescent-friendly clinical care from 2 weeks-9 months postpartum.
89413893|NCT03090802|No Intervention|Control|Adolescent mothers in the control arm will receive adolescent-friendly clinical care from 2 weeks-9 months postpartum.
89413894|NCT04765956|Experimental|Drug-eluting balloon treatment|Drug-eluting balloon (DEB) treatment of lipid-rich plaque
89413895|NCT03610113|No Intervention|CONSERVATIVE TREATMENT|Conservative treatment is conceived to the use of sling for three weeks, followed by rehabilitation protocol
89413896|NCT03610113|Experimental|REVERSE ARTHROPLASTY TREATMENT|"This group receives a surgical intervention by the use of reverse shoulder arthroplasty through deltopectoral approach and tuberosities reattachment.~It is followed by the same rehabilitation protocol than conservative treatment"
89413897|NCT03081130||Intravenous laser irradiation treatment|We will recruit 30 poor ovarian responders and thin endometrium patients and treat with intravenous laser irradiation of blood (ILIB) via an intravenous catheter for irradiation of the blood under a period of 60 minutes for 10 days.
89413898|NCT03081130||control|We will recruit 30 poor ovarian responders and thin endometrium patients and treat with oral estradiol 8 mg per day and oestrogen gel 4 g per day for 14 days
89413899|NCT02163330|Active Comparator|Acetazolamide|active comparator group will receives 500 mg azetazolamide daily
89413900|NCT02163330|Placebo Comparator|sugar pill|placebo comparator group will receives placebo daily.
89413901|NCT04186845|Experimental|Patients|Single intravenous administration of rhPSMA-7.3 (18F) for PET Scan
89413902|NCT02166996|Active Comparator|A|Suture removal time 7 days.
89413903|NCT02166996|Experimental|B|Suture removal time 14 days.
89413904|NCT03080272||Spinal Surgery|No intervention will take place. Recruiting Autumn 2017 until spring 2018
89413905|NCT03080272||Gastric sleeve|No intervention will take place. Recruiting Autumn 2017 until spring 2018
89413906|NCT03080272||Total knee arthroplasty|No intervention will take place. Recruiting Spring 2018 until Summer 2018
89413907|NCT03080272||Shoulder arthroplasty|No intervention will take place. Recruiting Winter 2017 until Summer 2018
89413908|NCT03080272||Maxillofacial surgery|No intervention will take place. Recruiting 6 march 2017 until Autumn 2017
89413909|NCT03610035|Experimental|Experimental|NPT189
89413910|NCT03610035|Placebo Comparator|Placebo Comparator|Placebo
89413911|NCT02163564|No Intervention|Focus groups|The first part of the study is to conduct focus groups of adolescents with insomnia and depression. The treatment arm is informed by responses provided by teens in the focus group portion.
88891381|NCT06249854|Active Comparator|Pembrolizumab monotherapy group|Pembrolizumab is administered intravenously every 3-week for 45 weeks according to routine practice until disease progression (PD) or unacceptable toxicity occurs.
89413912|NCT02163564|Active Comparator|Treatment|A modified cognitive behavioral therapy for insomnia is the treatment intervention in this treatment arm.
89413913|NCT03609411||Splenectomy|Patients undergoing liver transplantation with simultaneous splenectomy
88891382|NCT06249763|Experimental|High gluten|Participants complete both study arms in a crossover design separated by a washout period.
88891383|NCT06249763|Placebo Comparator|Gluten free|Participants complete both study arms in a crossover design separated by a washout period.
89413914|NCT03609411||Liver transplantation|Patients undergoing liver transplantation only
89413915|NCT02160132|Experimental|A 1-2-3Group|Methylprednisolone 0.5g/d intravenously for 3 consecutive days in the 1st-2nd-3rd month ,and oral methylprednisolone 0.4mg/kg/d on consecutive days for 6 months.
89413916|NCT02160132|Active Comparator|B 1-3-5Group|Methylprednisolone 0.5g/d intravenously for 3 consecutive days in the 1st-3rd-5th month ,and oral methylprednisolone 0.4mg/kg/d on consecutive days for 6 months.
89413917|NCT05005468|Experimental|Camrelizumab Combined With Famitinib|Drug: Camrelizumab Drug: Famitinib
89413918|NCT05005468|No Intervention|Observation|Observation
89413919|NCT02034201|Active Comparator|Lisdexamfetamine|Lisdexamfetamine will be admistered at 140 mg orally daily through week 6 of the protocol.
89413920|NCT02034201|Placebo Comparator|Placebo|Placebo will be administered orally daily through week 6 of the protocol.
89413921|NCT03609333|Experimental|Internal arm|
89413922|NCT02034357|Other|Neurocognitive function|Neurocognitive function assessment (verbal learning and memory) as measured by CVLT and sleep evaluations in Parkinson's disease patients at baseline, and after 4 months and 1 year of CPAP treatment
89413923|NCT03608943||Adrenal insufficiency|"Individuals who are in the process of changing their treatment from:~hydrocortisone to prednisolone or;~prednisolone to hydrocortisone"
89413924|NCT02637856|Experimental|Ocrelizumab|Participants will receive ocrelizumab as an initial dose of two 300-mg IV infusions (600 mg total) separated by 14 days (on Days 1 and 15) followed by one 600-mg IV infusion every 24 weeks for a maximum of 4 doses (up to 96 weeks).
89413925|NCT02637856|Experimental|Ocrelizumab (substudy)|Participants with no serious IRR throughout the main study will be eligible to enroll in an optional substudy and receive one additional shorter infusion of ocrelizumab at the Week 96 visit. Ocrelizumab will be administered IV as a single 600-mg dose at a shorter infusion rate (approximately 2 hours instead of 3.5 hours)
89413926|NCT02858037|Experimental|HIV Open-label Prevention|"Following demonstration of safety and efficacy of the dapivirine vaginal ring in MTN-020, eligible MTN-020 participants will be offered enrollment into MTN-025, a trial designed to obtain additional safety and adherence data in women~MTN-020:NCT01617096 MTN-025: NCT02858037"
89413927|NCT04433884|Experimental|Conventional MAC Laryngoscope|Patients in this group will undergo intubation using conventional macintosh laryngoscope
89413928|NCT04433884|Experimental|C-MAC Video laryngoscope|Patients in this group will undergo intubation using video C-Mac laryngoscope
88891384|NCT06248645|Other|Oxygen followed by placebo|Treatment of each motor attacks by oxygen (gaz) during 15 minutes in the first 5 week-period and placebo (medical air) during 15 minutes in the second 5 week-period.
89413929|NCT03078088|Placebo Comparator|saline|normal saline
89413930|NCT03078088|Experimental|treatment|tham
89413931|NCT05001334|Experimental|Kangaroo care|The mothers of the experimental group who accept to participate in the research are given training on how to make kangaroo care and what to pay attention to.
89413932|NCT05001334|No Intervention|Control group|The mothers of the control group who accept to participate in the research are NOT given any extra training other than routine breastfeeding and care of a newborn.
89413933|NCT05011942|Placebo Comparator|normal saline control arm|ii. normal saline used after initial skin incision prior to coming through fascia, after placement of instrumentation (screws, hooks), prior to placement of bone graft, and after fascial closure iii. Irrigation exposure/soak time to be 1 min for each irrigation time point.
89413934|NCT05011942|Active Comparator|Irrisept irrigation solution|ii. Irrigation (Irrisept vs control of normal saline) used after initial skin inicision prior to coming through fascia, after placement of instrumentation (screws, hooks), prior to placement of bone graft, and after fascial closure iii. Irrigation exposure/soak time to be 1 min for each irrigation time point. iv. 1 bottle (450 mL) Irrisept irrigation to be used during case with normal saline rinse to follow at each irrigation time point in study subjects
89413935|NCT05011786||Open repair group|children with inguinal hernia who were repaired with open high ligation of the hernia sac through an inguinal incision.
89413936|NCT05011786||Laparoscopic repair group|children with inguinal hernia who were repaired laparoscopically by closing the the PPV at the level of internal ring with a purse string suture
89413937|NCT03077932|Other|App Development and Open Pilot|"Phase 1 (app development) will consist of: 1) development of the BetterOFF prototype; and 2) series of usability studies with patients interested in discontinuing opioid medication.~Phase 2 (open pilot) will involve conducting a 12-week open pilot trial (n=20) to test the feasibility and acceptability of the BetterOFF app with patients tapering from opiate medication."
88891385|NCT06248645|Other|Placebo followed by oxygen|Treatment of each motor attacks by placebo (medical air) during 15 minutes, in the first 5 week-period and oxygen (gaz) during 15 minutes in the second 5 week-period.
88891386|NCT06248593|Active Comparator|Phenylephrine|The infusion will have a concentration of Phenylephrine of 25 μg/mL and will be initiated at a rate of 96 mL/hour (1.6 mL/minute), that correspond to a phenylephrine rate infusion of 40 μg/min, then the infusion rate will be manually adjusted within the range 0-144 mL/h : PHE (0-60 μg/min).
89413938|NCT05011630||IAA group|Intraabdominal abscess (IAA) is defined as either a turbid discharge from the intraoperatively placed drain or a postoperative fluid collection managed by CT-guided placement of drains with documental bacteriological culture.
89413939|NCT05011630||Non-IAA group|No IAA formation
89413940|NCT03076528|Experimental|Intervention with game-based exercise|Subjects will be receiving sensor-based interactive ankle & foot exercise program (game-based exercise) during hemo-dialysis, approximately 30 minutes, twice per week and for 4 weeks.
89413941|NCT03076528|Active Comparator|Non-technology foot and ankle exercise program|Subjects will be receiving non-technology foot and ankle exercise program during hemodialysis, approximately 30 minutes, twice per week and for 4 weeks.
89413942|NCT03077854|Experimental|Functional Lung Avoidance-TRT|"Functional Lung Avoidance Thoracic Radiotherapy~The avoidance thoracic radiotherapy treatment plan will be designed to optimize such that radiation dose to functional lung identified by four-dimensional (4D) CT ventilation imaging is as low as reasonably achievable"
89413943|NCT03077854|Active Comparator|Standard-TRT|"Standard Thoracic Radiotherapy~The standard thoracic radiotherapy treatment plan will be designed without reference to the functional lung 4D CT ventilation imaging"
89413944|NCT05005156|Active Comparator|Active vaccine Ad5-nCoV|two dose of active vaccine Ad5-nCoV
89413945|NCT05005156|Placebo Comparator|Placebo for Ad5-nCoV vaccine|one dose of placebo for Ad5-nCoV vaccine
89413946|NCT05010928|Experimental|Tea mouthwash group|
89413947|NCT05010928|No Intervention|Control group|
89413948|NCT05001100|Active Comparator|Traditional rehabilitation|32 subjects will undergo a virtual motor-reality training during the post-surgical rehabilitation period with VRSS
89413949|NCT05001100|Experimental|Rehabilitation with virtual reality|32 subjects with demographic characteristics similar to the subjects of the Vrrs arm will undergo the habitual rehabilitative physiotherapy.
89413950|NCT05001178||Class I horizontal grower|
89413951|NCT05001178||Class I normal grower|
88891387|NCT06248593|Experimental|Norepinephrine|The infusion will have a concentration of Norepinephrine of 4 μg/mL and will be initiated at a rate of 96 mL/hour (1.6 mL/minute), that correspond to norepinephrine rate infusion of 6.4 μg/min, then the infusion rate will be manually adjusted within the range 0-144 mL/h : Norepinephrine (0-9.6 µg/min).
88891388|NCT06247969||Patients intubated under general anesthesia via nasotracheal route.|Patients intubated under general anesthesia via nasotracheal route successfully.
88891389|NCT06247345|Active Comparator|SAD Cohort 1: ADEL Y-01 antibody at a dose of 2.5mg/Kg|This arm represents the group receiving ADEL Y-01 antibody at a dose of 2.5mg/Kg in SAD cohort 1.
88891390|NCT06247345|Placebo Comparator|SAD Cohort 1: Placebo at a dose of 2.5mg/Kg|This arm represents the group receiving placebo at a dose of 2.5mg/Kg in SAD cohort 1.
88891391|NCT06247345|Active Comparator|SAD Cohort 2: ADEL Y-01 antibody at a dose of 7.5mg/Kg|This arm represents the group receiving ADEL Y-01 antibody at a dose of 7.5 mg/Kg in SAD cohort 2.
88891392|NCT06247345|Placebo Comparator|SAD Cohort 2: Placebo at a dose of 7.5mg/Kg|This arm represents the group receiving placebo at a dose of 7.5mg/Kg in SAD cohort 2.
88891393|NCT06247345|Active Comparator|SAD Cohort 3: ADEL Y-01 antibody at a dose of 20mg/Kg|This arm represents the group receiving ADEL Y-01 antibody at a dose of 20mg/Kg in SAD cohort 3.
88891394|NCT06247345|Placebo Comparator|SAD Cohort 3: Placebo at a dose of 20mg/Kg|This arm represents the group receiving placebo at a dose of 20mg/Kg in SAD cohort 3.
88891395|NCT06247345|Active Comparator|SAD Cohort 4: ADEL Y-01 antibody at a dose of 50mg/Kg|This arm represents the group receiving ADEL Y-01 antibody at a dose of 50mg/Kg in SAD cohort 4.
88891396|NCT06247345|Placebo Comparator|SAD Cohort 4: Placebo at a dose of 50mg/Kg|This arm represents the group receiving placebo at a dose of 50mg/Kg in SAD cohort 4.
88891397|NCT06247345|Active Comparator|SAD Cohort 5: ADEL Y-01 antibody at a dose of 100mg/Kg|This arm represents the group receiving ADEL Y-01 antibody at a dose of 100mg/Kg in SAD cohort 5.
88891398|NCT06247345|Placebo Comparator|SAD Cohort 5: Placebo at a dose of 100mg/Kg|This arm represents the group receiving placebo at a dose of 100mg/Kg in SAD cohort 5.
88891399|NCT06247345|Active Comparator|MAD Cohort 1: ADEL Y-01 antibody at a dose of 7.5mg/Kg|This arm represents the group receiving ADEL Y-01 antibody at a dose of 7.5 mg/Kg in MAD cohort 1.
88891400|NCT06247345|Placebo Comparator|MAD Cohort 1: Placebo at a dose of 7.5mg/Kg|This arm represents the group receiving placebo at a dose of 7.5mg/Kg in MAD cohort 1.
88891401|NCT06247345|Active Comparator|MAD Cohort 2: ADEL Y-01 antibody at a dose of 20mg/Kg|This arm represents the group receiving ADEL Y-01 antibody at a dose of 20mg/Kg in MAD cohort 2.
88891402|NCT06247345|Placebo Comparator|MAD Cohort 2: Placebo at a dose of 20mg/Kg|This arm represents the group receiving placebo at a dose of 20mg/Kg in MAD cohort 2.
88891403|NCT06247345|Active Comparator|MAD Cohort 3: ADEL Y-01 antibody at a dose of 50mg/Kg|This arm represents the group receiving ADEL Y-01 antibody at a dose of 50mg/Kg in MAD cohort 3.
88891404|NCT06247345|Placebo Comparator|MAD Cohort 3: Placebo at a dose of 50mg/Kg|This arm represents the group receiving placebo at a dose of 50mg/Kg in MAD cohort 3.
88922049|NCT05902169|Experimental|Experimental Arm: SonoCloud-9 Ultrasound + Carboplatin|The SonoCloud-9 (SC9) device will be implanted in the skull bone window upon completion of tumor resection and routine craniotomy. Carboplatin (CBDCA) will be administered intravenously prior to sonication. The CBDCA/SC9 treatment will be repeated every 3 weeks (depending on patient's tolerability) until disease progression or as clinically indicated. Administration of up to 7 cycles is planned.
89413952|NCT05001178||Class I vertical grower|
89413953|NCT05001178||Class II horizontal grower|
89413954|NCT05001178||Class II normal grower|
89413955|NCT05001178||Class II vertical grower|
89413956|NCT05001178||Class III horizontal grower|
89413957|NCT05001178||Class III normal grower|
89413958|NCT05001178||Class III vertical grower|
89413959|NCT04266340|Placebo Comparator|placebo|no premedication
89413960|NCT04266340|Experimental|oralmidazolam|0.5 mg/kg oral midazolam group
89413961|NCT04266340|Experimental|intravenous midazolam|0.05 mg/kg intravenous injection midazolam group
89413962|NCT04266340|Experimental|dexmedetomidine|2.5µg/kg intranasal dexmedetomidine group
89413963|NCT04338945||Residents in surgical areas|
89413964|NCT03079804|Experimental|Experimental MWM|"Other names:~4 mobilizations - 10 seconds 20 seconds of rest"
89413965|NCT03079804|Active Comparator|Experimental Thrust|"Other names:~1 traction with caudal direction in high speed and low amplitude increasing dorsiflexion."
89413966|NCT03079804|Placebo Comparator|Placebo|"Other names:~It will accurately reproduce the positioning of the hand in the specific treatment condition (Thrust or MWM), however, without applying any movement or force. All interactions, procedures and deadlines will be identical."
89413967|NCT03609255|Active Comparator|Control group (C)|
89413968|NCT03609255|Experimental|Sedentary behavior group (SB)|
89413969|NCT03609255|Experimental|Stress management group (SR)|
88891405|NCT06245564|Experimental|Cream application|This subproject will be conducted in two sessions one week apart. Each session will last approximately 3 hours. In each forearm of the participant, two 4x4 cm areas will be selected as Area of Interest (AOI). In these selected areas, the four different creams will be applied in a randomized position for 1½ hours. After the cream removal, itch will be induced using histamine in one session and cowhage in the other session (the order of histamine and cowhage will be randomized). During the application of the substances, the itch/pain elicited will be monitored for 10 minutes using a VAS (Visual analog scale). After the removal of the substances, measurements of SBP, TP, MEI, MPT, MPS, and thermal sensitivity will be conducted.
88891406|NCT06245369|Experimental|SWITCH tracking healthy nutrients|Participants allocated to this group will be given goals to reach a recommended daily intake of nutrients in which US adults tend to not consume enough. Recommended amounts will be based off of age and sex, in line with the US Dietary Guidelines.
88891407|NCT06245369|Active Comparator|standard SWITCH app|Participants in this group will be given goals to reduce intake of nutrients in which US adults tend to consume too much. Personalized daily intake goals for nutrients will be based on age, weight, sex, and the US Dietary Guidelines.
89413970|NCT03077464|Active Comparator|behavioral nutrition education|Set of curricular nutrition education modules, previously developed and based on Social Cognitive Theory, for the HOP'N After-School program, with additional materials from MyPlate. Materials were employed to increase healthy eating behavioral capability, self-efficacy, attitudes, and enjoyment. Topics included: 1) nutrition label literacy; 2) drinking water; 3) eating colors of the rainbow; 4) healthful snacks; 5) benefits of fruit and vegetable consumption; 6) moving more and sitting less; and 7) taking healthy habits home.
89413971|NCT03077464|Experimental|behavioral nutrition education plus skills|Set of curricular nutrition education modules, previously developed and based on Social Cognitive Theory for the HOP'N After-School program, with additional materials from MyPlate. Materials were employed to increase healthy eating behavioral capability, self-efficacy, attitudes, and enjoyment. Topics included:1) nutrition label literacy;2) drinking water;3) eating colors of the rainbow;4) healthful snacks;5) benefits of fruit and vegetable consumption;6) moving more and sitting less;and 7) taking healthy habits home. Designed to differ from behavioral nutrition education condition by devoting at least 15 minutes of each session to an additional behavioral skills training component. The behavioral skills component was designed to bolster behavioral capability, healthy eating attitudes, self-efficacy, and proxy efficacy with activities such as snack preparation sessions, role-playing games, fruit and vegetable tasting, and playing games that promoted healthier dietary behaviors.
88891410|NCT06244784|Experimental|Intervention Group|Participants in the intervention group will receive the training course on healthy work environment
88891411|NCT06244784|No Intervention|Control Group|
88891412|NCT06242366|Experimental|Intervention group|"In this arm, the participant will receive standard nursing care and the program from an investigator.~The program consisted of 2 phases: 1) Phases I during hospital admission when they are stable will receive a program total 4 times for education about stroke, self-care, rehabilitation, and complication prevention and~2) Phases II following hospital discharge within 24 hours then every 1 week until 4 weeks by Line Application visit. following self-care management, find limit to their self-care.~and Outcomes Assessor will visit to collect data 3 times~In-hospital period~after hospital discharge 4 weeks~after hospital discharge 12 weeks"
88891413|NCT06242366|No Intervention|Control group|"In this arm, the participant will receive only standard nursing care. and Outcomes Assessor will visit to collect data 3 times~In-hospital period~after hospital discharge 4 weeks~after hospital discharge 12 weeks"
88891414|NCT06240702|Experimental|Telerehabilitation Group|Patients in the experimental group will be included in the face-to-face Phase I rehabilitation program until discharge and in the Phase II telerehabilitation program and sleep hygiene training for 3 weeks after discharge. Respiratory exercises will be performed as part of the phase I rehabilitation program until the patients are discharged. In addition, active range of motion and mobility exercises in bed, sitting position and standing, increasing distance walking and stair ascent and descent training will be provided. During the sessions, the patient's vital signs and clinical status will be monitored with a finger pulse oximeter and a blood pressure measuring device according to the patient's perceived degree of difficulty (Borg Scale). As part of the Phase II telerehabilitation program, respiratory exercises, calisthenic exercises and gait training will be performed.
88891415|NCT06240702|No Intervention|Control Group|Patients in the control group will be included in the face-to-face Phase I rehabilitation program until discharge and no intervention will be made after discharge. Until the patients in the control group are discharged, respiratory exercises will be performed as in the experimental group within the scope of the phase I rehabilitation program. In addition, active range of motion and mobility exercises in bed, sitting position and standing, increasing distance walking and stair ascent and descent training will be provided. During the sessions, the patient's vital signs and clinical status will be monitored with a finger pulse oximeter and a blood pressure measuring device according to the patient's perceived degree of difficulty (Borg Scale).
88891416|NCT06239025|Active Comparator|Block + multimodal analgesia|Multimodal analgesia + TTMP block with ropivacaine 0.5 %, 30 mL
88891417|NCT06239025|No Intervention|Multimodal Analgesia|Multimodal Analgesia without a block
88891421|NCT06235723|No Intervention|SOC (A)|SOC = Standard-of-Care
88891422|NCT06235723|Experimental|VR (B)|VR = Virtual Reality
88891423|NCT06234891|Active Comparator|Group 1|NSAID
88891424|NCT06234891|Active Comparator|Group 2|nsaid and physiotherapy
88891425|NCT06229184|Experimental|Control group|Fecal calprotectin samples taken for comparison from healthy adolescents
88891426|NCT06229184|Experimental|Obese group|Fecal calprotectin samples taken from obese adolescents
88891427|NCT06229184|Experimental|Obese + NAFLD group|Fecal calprotectin samples taken from obese adolescents that have NAFLD
88891428|NCT06228521|Experimental|Laser Group|LASEmaR MINI 980 nm
88891429|NCT06228521|Active Comparator|Cryotherapy group:|CryoIQ
89413972|NCT03079960|Experimental|Original patient group (PG-O)|"DBS implantation: patients undergo standard stereotactical neurosurgery for DBS implantation. Decision for DBS treatment has been made prior to inclusion into this study.~Cables and connectors of the macro electrodes will stay externalized for four days for cDBS adjustment procedures. During externalization, patients take part in test stimulation and recording sessions during which they perform short motor tasks.~The externalized connectors of the macroelectrodes allow for simultaneous stimulation of the STN and obtaining LFP recordings with electrophysiological recording and measurement devices from the STN for the fitting of DBS parameters, according to the standard clinical procedure."
88891430|NCT06227858|Experimental|Saffron extract supplementation (15mg, twice daily)|The experimental group will take a single capsule containing: 15mg of of saffron extract (stigma of the flower Crocus sativus), 340mg of Maltodextrin, encapsulated in hydroxypropyl methyl cellulose (HPMC), twice daily (one morning and one evening after the meal).
88891431|NCT06227858|Placebo Comparator|Control group|The Control group will take a single placebo capsule (matched to the experimental intervention in terms of colours and taste, without the active compounds saffron) twice daily (one morning and one evening after the meal).
88891432|NCT06226168|No Intervention|Control group|The control group will not undergo the training program.
89199101|NCT02543307|No Intervention|Standard usual nursing care|Patients in the control group will receive usual nursing care, which is based on the institutional principles and standards of care for surgical patients. Based on the type of surgery and assessment of the nurse the nursing process is used to care for the patients. The nurses will be ending their activities with discharge of the patients.
88891433|NCT06226168|Experimental|Training in normobaric hypoxia|Training performed under normobaric hypoxia (Week I-1600m above sea level; Week II-1800m above sea level; Week III-2200m above sea level; Week IV-2600m above sea level) and thermoneutral conditions (21°C) and constant humidity (40%).
88891434|NCT06226168|Experimental|Training in normoxia|Description: Training performed in normoxia (223 m above sea level) and thermoneutral conditions (21°C) and constant humidity (40%).
88891435|NCT06226168|Experimental|Passive exposure to normobaric hypoxia|Passive exposure to normobaric hypoxia conditions (Week I -1600m above sea level; Week II -1800m above sea level; Week III -2200m above sea level; Week IV-2600m above sea level) and thermoneutral conditions (21°C) and constant humidity (40%).
88891436|NCT06225427|Experimental|Treatment (gilteritinib)|Patients receive gilteritinib PO QD on days 1-21 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo echocardiography at screening and blood sample collection, CT scan and MRI at screening and on study. Additionally, patients may undergo a tumor biopsy pre-treatment and at end of treatment.
88891437|NCT06225024|Active Comparator|BoNT-A|BoNT-A was injected into the affected gastrocnemius muscle under ultrasonography guidance at doses recommended by standard guidelines and appropriate for the patient (50 IU to the medial head, 25 IU to the lateral head). In addition, conventional physical therapy exercises (stretching exercises, range of motion (ROM) exercises, neurophysiologic exercises, and gait exercises) were applied to the patients five days a week for four weeks.
88891438|NCT06225024|Experimental|BoNT-A and ESWT|In addition to the treatments (BoNT-A injection and exercise) in Group 1, one week after the injection, a total of 4 sessions (2 days a week) of ESWT (1000 impulses with an energy density of 0.1 mj/mm2, pressure of 2 bar, and frequency of 4 Hz) were applied to the medial and lateral heads of the gastrocnemius muscle.
88891439|NCT06224647|Experimental|Access to the intervention|"Participants assigned to the intervention group will have full access to the mobile app intervention, namely ROOM app, for the whole duration of the 12-week trial.~As part of the app's onboarding process, participants will receive tips on optimal app usage and can decide to take part in a 21-day challenge where they are encouraged to assess their emotional states on a daily basis and complete one exercise per day. During the onboarding process, participants are encouraged to explore different emotional regulation exercises offered in the app and to save the ones they find most beneficial in their virtual Room, curating a personalized well-being toolkit. While daily notifications prompt regular app engagement, no additional efforts are made to further promote its use."
88891440|NCT06224647|No Intervention|Waitlist control condition|Participants allocated to the control group will be put on a waitlist and granted access to the mobile intervention after the trial concludes. They will then receive the same intervention with the identical onboarding process as the intervention group.
89413973|NCT03079960|No Intervention|Chronic patient group (PG-chronic)|"Patients in this group will take part in one recording session at any desired point in time after they have been implanted with a DBS system as part of their clinical routine treatment. During this session, which will be lasting for approx. 60 minutes, patients will execute different motor tasks while neural activity is recorded non-invasively from cortical areas via surface EEG electrodes.~Recordings are performed while applying different DBS strategies. The different DBS strategies are selected as a set of safe configurations as they are used in clinical routine. The behavioral tests performed for PG-chronic are the same as conducted for PG-O."
88891441|NCT06223958|Experimental|OTX-TKI (axitinib implant)|
88891442|NCT06223958|Other|Control|
88891443|NCT06222346|Experimental|CommonGround Platform|Online Peer Support and Psychoeducational Platform
88891444|NCT06222346|Active Comparator|Control|"National Health Service (NHS) Mental Health webpage(s)"
88891445|NCT06221696|Experimental|Active Fiber Supplement Group|
88891446|NCT06221696|Placebo Comparator|Placebo Group|
88891447|NCT06220188|Experimental|Biochemical recurrent prostate cancer but not radio-morphological local recurrence|Patients with prostate cancer and confirmed biochemical recurrence with PSA of ≥ 0.2 ng/ml after radical prostatectomy or PSA > nadir + 2ng/ml after radiotherapy but not radio-morphological local recurrence after primary therapy with curative intent will receive systemic therapy with [177Lu]Lu-PSMAI&T radioligand therapy
88891448|NCT06216431||Emergency call center workers|This group will consist of individuals working as operators at Izmir 112 Emergency Call Center.
88891449|NCT06216431||Office workers|This group will consist of office workers who work actively at a desk.
88891450|NCT06212986|Experimental|Experimental blended group|The experimental blended group (perform-up group) used the application Perform-UP Tennis on their own and also met up with a professional sports psychologist every 2 weeks for debriefing. Participants were asked to answer a series of questionnaires in two separate phases.
88891451|NCT06212986|No Intervention|Control group|Participants were asked to answer a series of questionnaires in two separate phases, but they only carried out their classic technical training without integrating the mental training program with the app Perform-UP Tennis.
88891452|NCT06211296|Experimental|Shortcut|
88891453|NCT06208618|Experimental|Motivational interviews|"At the beginning of the study, individual face-to-face diabetes education will be provided for each adolescent in the study group on days corresponding to their routine medical appointments in the diabetes education room. The diabetes education will include the following topics:~What is Diabetes?~Treatment in Diabetes~Insulin Therapy~Nutritional Therapy~Physical Activity/Exercise~Acute Complications of Diabetes~Hypoglycemia~Hyperglycemia~Diabetic Ketoacidosis~Diabetes Management in IIlness~The adolescents in the study group will undergo a total of 6 motivational interviews, conducted once a month. Three of these interviews will be face-to-face (at the beginning of the study, at the 3rd month, and at the 6th month), while the remaining three will be conducted remotely using the WhatsApp video call feature (in the 2nd, 4th, and 5th months)."
88891454|NCT06208618|No Intervention|Routine follow-up|The routine follow-up conducted by the diabetes education unit will continue for the study group, and no interventions will be made as part of the research. The study group will undergo a pre-test at the beginning of the study, a follow-up test at the 3rd month, and a post-test at the 6th month as part of the research.
88891455|NCT06203535|Experimental|Aerobic training (group a)|In addition to the standard physical therapy exercise programme (which includes flexibility and balance exercises), twenty individuals with idiopathic chronic fatigue will participate in an aerobic training group and walk for 45 minutes on a treadmill three times a week for two months. The workouts began with a five- to ten-minute warm-up on the treadmill and concluded with an equally extended cool-down. Using the Karvonen method, for exercise intensities ranging from 60 to 75 per cent of heart rate reserve during a 35-minute group cumulative exercise session.
88891456|NCT06203535|Experimental|control group (group B)|twenty participants have idiopathic chronic fatigue will received only traditional physical therapy exercise program (flexibility and balance activities)
88891457|NCT06202443|Experimental|Early Physical Therapy (PT)|PT will be delivered two times a week for 8 weeks by a licensed physical therapist. Participants will start PT approximately 2 weeks after hospital discharge
88891458|NCT06202443|Active Comparator|Delayed Physical Therapy (PT)|PT will be delivered two times a week for 8 weeks by a licensed physical therapist. Participants will start PT approximately 3 months after hospital discharge.
88891459|NCT06198686|Experimental|Sequence 1|A buccal formulation of Nalmefene 16 mg and a 1 mg intravenous dose of nalmefene injection, with a least 7 days washout period between dose
88891460|NCT06198686|Experimental|Sequence 2|A 1 mg intravenous dose of nalmefene injection, and a buccal formulation of Nalmefene 16 mg with a least 7 days washout period between dose
88891461|NCT06187259|Active Comparator|carbide bur group|"carbide burs are extremely hard and can withstand high temperatures. Because of their hardness, carbide burs can maintain a sharp cutting edge and can be used many times without becoming dull. They are best operated at high speeds with light pressure.~Carbide dental bur was designed to, efficiently, remove non-decalcified enamel and dentin, yet, it does not facilitate the differentiation between carious and normal dentin, during cavity preparation."
88891462|NCT06187259|Experimental|polymer bur II group|Polymer bur tools resemble conventional burs in appearance, but they are made of unique polymer material rather than metal. The cutting edges are not spiral, like those of a shovel. The polymer material was designed to be softer than healthy dentin (Knoop hardness 70-90) but harder than carious, softening dentin (Knoop hardness 50-70) (Knoop hardness 0-30). Therefore, it has a knoop hardness of 50 kg/mm2, and its cutting elements effectively remove soft dentin but cannot remove healthy dentin.
88891463|NCT06185933|Active Comparator|lidocaine spray alone|patient in this arm will receive lidocaine spray five puffs of 10 % lidocaine spray (Xylocaine 10 % Spray, Astra Zeneca) (1 puff = 10 mg of lidocaine) 5 minutes before the start of the procedure
88891464|NCT06185933|Active Comparator|receive lidocaine spray + lidocaine viscous solution|patient in this arm will receive lidocaine spray + lidocaine viscous solution five puffs of 10 % lidocaine spray (Xylocaine 10 % Spray, Astra Zeneca) (1 puff = 10 mg of lidocaine) Plus 5 mL of 2 % viscous lidocaine solution (20 mg/mL) (Xylocaine 2 %, Astra Zeneca, London, UK)
88891465|NCT06179043|Sham Comparator|Control labels|Individuals in this trial arm will see neutral control labels on sugar-sweetened beverages.
89192958|NCT05827952|No Intervention|Groups/Cohorts|"The Self-learning group was designed to provide a description of the goals of the course and a reading of the Atomic Habits book. In the first session, the goals of the study were explained, the basic abilities of the caregiver and the case, the games, the relationship, the main problems that the caregiver wanted to change, the Parent Problem Checklist to help assess the caregiver's direction in identifying their own expectations, and the caregiver's perceived barriers and difficulties. The next 8 weeks of the course are based on the parents' self-study progress, and the study provides an online platform or a paper sheet to keep track of the self-study process and to contact the researcher at any time if there are any unexpected situations or problems. The record sheets were returned at the end of the 8-week period, and the self-study group received a face-to-face consultation at the end of the post-test."
89192959|NCT05827952|Experimental|Interventions|Hybrid group used Atomic Habits (20-minute audiobook format), a role structure and a game structure, online schedule reminders more than twice a week and individual counseling sessions (online and physical) for one to two total interventions. The online schedule reminders consisted of four major habits, each with four concepts, to adapt the online audiobook interventions to the caregivers' relationship-building habits with the children A total of 16 sessions are delivered. Parents simply receive the course through digital media and complete the online schedule reminder within the course progress, narrowing down the indicators of habit change and achieving behavioral change through multiple executions.
89192960|NCT05827068|Experimental|mRNA-1011.1|Participants will receive mRNA-1011.1 by intramuscular (IM) injection on Day 1.
89192961|NCT05827068|Experimental|mRNA-1011.2|Participants will receive mRNA-1011.2 by IM injection on Day 1.
89192962|NCT05827068|Experimental|mRNA-1012.1 Dose Level A|Participants will receive mRNA-1012.1 at dose level A by IM injection on Day 1.
89192963|NCT05827068|Experimental|mRNA-1012.1 Dose Level B|Participants will receive mRNA-1012.1 at dose level B by IM injection on Day 1.
89192964|NCT05827068|Active Comparator|mRNA-1010|Participants will receive mRNA-1010 by IM injection on Day 1.
89192965|NCT05827068|Active Comparator|mRNA-1010.2|Participants will receive mRNA-1010.2 by IM injection on Day 1.
89192966|NCT05827068|Active Comparator|mRNA-1010.3|Participants will receive mRNA-1010.3 by IM injection on Day 1.
89192967|NCT05825261||COPD|COPD is defined according to COPD Gold 2023 guidelines.
89192968|NCT05822557|Experimental|Bolus Pouch Feed|A 250 ml feeding pouch containing 400 kcal.
89192969|NCT05822128||Seniors with suspected sleep disorders referred for assessment|Seniors with suspected sleep disorders referred for assessment
89192970|NCT05821933|Experimental|cohort 1 RC108 plus Furmonertinib|phaes 1: RC108 plus Furmonertinib
89192971|NCT05821933|Experimental|cohort 2 RC108 plus Furmonertinib and Toripalimab|phaes 1: RC108 plus Furmonertinib and Toripalimab
89192972|NCT05821933|Experimental|cohort 3 RP2D RC108 plus Furmonertinib|phaes 2: RP2D RC108 plus Furmonertinib
89192973|NCT05821933|Experimental|cohort 4 RP2D RC108 plus Furmonertinib and Toripalimab|phaes 2: RP2D RC108 plus Furmonertinib and Toripalimab
89192974|NCT05819853|Experimental|Metformin + Semaglutide|Participants with PCOS who are currently on metformin and still not having regular menses, will receive 10-months of semaglutide intervention
89192975|NCT05819853|Experimental|Semaglutide|Participants with PCOS who are not on metformin or hormonal therapy, will receive 10-months of semaglutide intervention
89192979|NCT05817825|Experimental|Treatment Group|"The intervention to be developed and tested has two components: 1) the remotely delivered IOP (Smart IOP), and 2) a peer recovery coach to provide support and accountability to the participant."
89192980|NCT05815264|Experimental|Experimental group aged 18-59 years|Subjects in the age group 18-59 years received 1 dose of 0.5 mL 23-valent pneumococcal polysaccharide vaccine
89192981|NCT05815264|Active Comparator|Control group aged 18-59 years|Subjects in the age group 18-59 years received 1 dose of 0.5 mL pneumococcal vaccine polyvalent
89192982|NCT05815264|Experimental|Experimental group aged ≥60 years|Subjects in the age group ≥60 years received 1 dose of 0.5 mL 23-valent pneumococcal polysaccharide vaccine
88891466|NCT06179043|Experimental|Nutrient warning labels|Individuals in this trial arm will see nutrient warning labels on sugar-sweetened beverages.
88891467|NCT06179043|Experimental|Text-only health warning labels|Individuals in this trial arm will see text-only health warning labels on sugar-sweetened beverages.
88891468|NCT06179043|Experimental|Graphic warning labels|Individuals in this trial arm will see graphic health warning labels on sugar-sweetened beverages.
89192983|NCT05815264|Active Comparator|Control group aged ≥60 years|Subjects in the age group ≥60 years received 1 dose of 0.5 mL pneumococcal vaccine polyvalent
89192984|NCT05815264|Experimental|Experimental group aged 2-17 years|Subjects in the age group 2-17 years received 1 dose of 0.5 mL 23-valent pneumococcal polysaccharide vaccine
89192985|NCT05815264|Active Comparator|Control group aged 2-17 years|Subjects in the age group 2-17 years received 1 dose of 0.5 mL pneumococcal vaccine polyvalent
89192986|NCT05813834|Active Comparator|genicular nerve block group|patients will receive genicular nerves block
89192987|NCT05813834|No Intervention|control group|patients will not receive genicular nerves block
89192988|NCT05812963|Active Comparator|Fractional flow reserve-guided PCI|FFR measurement for non-IRA stenosis (>50% visual estimation) will be performed by continuous infusion of adenosine (140~180 ug/kg/min) or intracoronary nicorandil (2 mg bolus) injection. The FFR ≤0.80 will be targeted for PCI. In case of non-IRA stenosis >90%, we will judge FFR value of ≤0.80.
89192989|NCT05812963|Experimental|Intravascular Ultrasound-guided PCI|"In IVUS-guided PCI group, the current trial evaluates clinical outcome following IVUS-guided treatment decision for revascularization of non-IRA stenosis. According to pre-defined criteria, the decision of revascularization will be made.~Revascularization criteria in the IVUS-guided PCI group is 1) minimal lumen area (MLA) ≤ 3mm2 or 2) 3mm2 < MLA ≤4mm2 and plaque burden >70%."
89413974|NCT03079960|No Intervention|Preoperative patient group (PG-pre)|"Patients in this group will take part in one recording session that will take place one week prior to implantation surgery at the earliest, i.e. between day -7 and day 0. Decision for DBS treatment has been made prior to inclusion into this study.~During this recording session, which will be lasting for approx. 60 minutes, patients will execute different motor tasks while neural activity is recorded non-invasively from cortical areas via surface EEG electrodes.~The behavioral tests performed for PG-pre are the same as conducted for PG-O."
89413975|NCT03079882||Living Donor Recipients|Recipients of renal transplants with the transplanted organ originating from living donors
88891472|NCT06175793|Experimental|ASPIRE Intervention Arm|The intervention arm will receive usual care, a free blood pressure cuff in addition to the ASPIRE Components.
88891473|NCT06175793|No Intervention|Control Arm|The control group will receive usual care and a free blood pressure cuff.
88891474|NCT06171022|Experimental|Cherry seed pillow|4 Weeks, 5 days a week, 20 minutes, in addition to the physiotherapy application of the routine, a heated cherry seed pillow will be applied.
88891475|NCT06171022|Active Comparator|Control|4 Weeks, 5 days a week, 20 minutes, in addition to the physiotherapy application of the routine, a hot-pack will be applied.
88891476|NCT06167239|Experimental|Threshold inspiratory muscle trainer|Training of the inspiratory muscles by threshold inspiratory muscle trainer.
88891477|NCT06167239|Experimental|Ventilator pressure setting inspiratory muscle training|Training of the inspiratory muscles by ventilator pressure setting.
88891478|NCT06167239|No Intervention|Traditional treatment|Only prescribed medical treatment programme
88891479|NCT06164678|Experimental|Ottawa Model for Smoking Cessation|"The OMSC group will receive counselling and pharmacotherapy if they choose (specifically NRT) with follow-up calls to support medication titration. Participants will be provided with quit cards, which are pre-loaded with $300 worth of funds that can only be used by the assigned study participant to purchase NRT (if they choose).~For those in the intervention group, the study counsellor who is a trained Nicotine Addiction Treatment Specialist (NATS) will facilitate follow-up, monitor NRT use, and advise participants to titrate NRT dose as required based on their minimum daily nicotine intake. These counselling calls will be conducted at day 3, 7, 14, 21, 30, 60, 90, and 180 as is standard in OMSC for people who smoke and are interested in quitting. A diary will also be provided to the participants to track their usage."
88891480|NCT06164678|No Intervention|Usual Care|The usual care group will receive the initial counselling session but no further follow-up or NRT. They will be able to self-initiate a follow-up call if they choose. Participants will not be excluded if they choose to initiate NRT on their own at their own expense.
88891481|NCT06162949|Experimental|Vonoprazan-based triple therapy|Vonoprazan tablets 20 mg twice daily plus Amoxicillin 50 mg/kg/day capsules or suspension [maximum daily dose 2 g] plus Clarithromycin 20 mg/kg/day tablets or suspension [maximum daily dose 1 g] The triple combination will be given for 14 days
88891482|NCT06162949|Active Comparator|"Proton pump-based triple therapy standard triple therapy"|Esomeprazole tablets [20 mg/day if < 30 kg and 40 mg/daily if ≥ 30 kg] on two divided daily doses plus Amoxicillin 50 mg/kg/day capsules or suspension [maximum daily dose 2 g] plus Clarithromycin 20 mg/kg/day tablets or suspension [maximum daily dose 1 g] The triple combination will be given for 14 days
88891483|NCT06159647|Experimental|Alcohol Messages|Participants view 12 messages: 10 messages related to health topics (2 messages for each of 5 randomly selected health topics from among all health topics) and 2 control messages.
88891484|NCT06158438|Experimental|BTL-754-4 Treatment|Treatment with BTL-754 device with the applicator BTL-754-4 for reduction of facial wrinkles.
88891485|NCT06151158|Active Comparator|Safety Planning Intervention|The SPI is a brief, evidence- based intervention that provides people with an individualized set of steps that can be used progressively to both reduce risk and maintain safety when suicide ideation (SI) emerges. Safety plans are developed collaboratively between providers, at risk youth, and family members when possible. Core SPI components include recognizing warning signs of an imminent suicidal crisis (e.g., changes in mood, thoughts or behaviors); using internal coping skills to reduce distress; using people or places in the individual's support network as a means of distraction from SI; reaching out to family or friends to help manage the crisis; contacting health professionals or emergency services; and reducing access to lethal means. SPI+ includes a brief follow-up component post- discharge that includes contacting the patient for a mood and risk check-in; reviewing and revising the safety plan; and facilitating connection with community mental health services.
88891486|NCT06151158|Active Comparator|Ultra-Brief Crisis IPT-A|Interpersonal Psychotherapy for Adolescents Ultra Short Crisis Intervention (IPT-A SCI) is a scalable, flexible, and extensively examined mental health treatment developed to reduce depressive symptoms and improve interpersonal functioning, and has been adapted for use in adolescents (IPT-A SCI) and shown to be effective in treating depression and reducing associated suicide risk. Interpersonal problems are often at the core of suicidal thinking and behavior in youths including minority youths.
88891487|NCT06146855|Experimental|Tunneling with amnion membrane|
88891488|NCT06146855|Active Comparator|Tunneling with De-epithelialized Free Gingival Graft|
89192990|NCT05808413|Active Comparator|Informational Video|Participants will watch a 1-minute video detailing the impact vaccination has had on the COVID-19 pandemic, where accurate information on vaccination can be found, and the convenience of vaccination.
89192991|NCT05808413|Experimental|Informational + Altruistic Video|Participants will first watch the 1-minute informational video before watching an additional 40-second video eliciting altruistic motivations for vaccination. The purpose of this arm is to test whether altruistic messages are efficacious to increase vaccine intentions beyond providing only vaccine information.
89192992|NCT05808413|Experimental|Informational + Altruistic + Individualistic Video|Participants will watch the 1-minute informational video, the 40-second altruistic video, and an additional 40-second video eliciting individualistic motivations for vaccination. This arm will be used to test if combined altruistic and individualistic messages provide a greater effect than providing only vaccine information.
89005549|NCT02210455|Experimental|The Strongest Families FASD intervention|It is a web-based parent training program with a coach. The program is comprised of 11 sessions, each focusing on a different parenting strategy, delivered using easy to read text, instructional videos and audio clips. One Booster Session is conducted 1 month after completion of Session 11.
88891489|NCT06143514||Breast Milk Collection|Breast milk will be collected of participants with relapsing forms of multiple sclerosis (RMS) who are receiving BRIUMVI™ therapeutically for up to 24 hours to determine concentration of BRIUMVI™ in milk samples.
88891490|NCT06136819|Experimental|RT-310 Cohort 1|Combination Product: RT-310 implant Cohort 1
88891491|NCT06136819|Experimental|RT-310 Cohort 2|Combination Product: RT-310 Implant Cohort 2
88891492|NCT06135220||PE confirmed|Patients admitted with confirmed pulmonary embolism.
88891493|NCT06135220||PE suspected|Patients admitted with suspected, but not confirmed pulmonary embolism.
88891494|NCT06135220||Controls|Healthy controls - same gender and age (within af range of 10 years) as PE patients.
88891495|NCT06133283|Experimental|High intensity endurance exercise and virtual reality (experimental)|The exercise group will perform high intensity interval exercise and VR-based games 3 times a week for 8 weeks.
89192993|NCT05792475|Other|Define Standard of Truth (SOT) by 3 experts|Three experts A, B, and C independently define standard of truth (SOT) about 108 cases.
88891496|NCT06133283|Other|Stretching and virtual reality (control)|The stretching group will perform stretching exercises and VR-based games 3 times a week for 8 weeks.
88891497|NCT06131437|Experimental|CagriSema 2.4 mg/2.4 mg|Participants will receive 2.4 mg cagrilintide and 2.4 mg semaglutide subcutaneously once-weekly (dose escalation period of 16 weeks) for up to 72 weeks.
88891498|NCT06131437|Active Comparator|Tirzepatide 15 mg|Participants will receive 15 mg tirzepatide subcutaneously once-weekly (dose escalation period of 20 weeks) for up to 72 weeks.
88891499|NCT06123195|Experimental|Constipation treatment|A 4-week intervention of constipation treatment with lactulose
88891500|NCT06123195|No Intervention|Control|No constipation treatment except bisacodyl rescue therapy
88891501|NCT06117553||limited|patients adopted limited flushing strategy
88891502|NCT06117553||thorough|Thorough flushing strategy
88891503|NCT06115486|Other|Control Arm / ACSM Guidelines|The control group will follow resistance training guidelines from the American College of Sports Medicine (ACSM) with the goal of promoting hypertrophy
88891504|NCT06115486|Experimental|Experimental Arm / EOC Guidelines|The experimental group will use a regimen that is often used by strength and conditioning coaches to maximize hypertrophy, and is part of the standard regimens at the Exercise Oncology Center (EOC)
88891505|NCT06114186|Active Comparator|control group|anticipate 20 CGM and 5 non-CGM user dyads in the control group
88891506|NCT06114186|Experimental|intervention group|anticipate 20 CGM and 5 non-CGM user dyads in the intervention group
89192994|NCT05788458|Active Comparator|Group A|will receive 20 ml of 0.25 % bupivacaine
89192995|NCT05788458|Active Comparator|Group B|will receive 20 ml of 0.375 % bupivacaine.
89192996|NCT05788458|Active Comparator|Group C|will receive 20 ml of 0.5 % bupivacaine.
89413976|NCT03079882||Deceased Donor Recipients|Recipients of renal transplants with the transplanted organ originating from deceased donors
89413977|NCT05000554|Experimental|Locally advanced gastric cancer|Patients with locally advanced gastric cancer who can receive PD-1 monoclonal antibody combined with neoadjuvant chemotherapy
89413978|NCT02856555|Experimental|Firsocostat 5 mg|Participants will receive firsocostat 1 x 5 mg + 1 x placebo matched to firsocostat 5 mg + 2 x placebo matched to firsocostat 10 mg for 12 weeks.
89413979|NCT02856555|Experimental|Firsocostat 20 mg|Participants will receive firsocostat 2 X 10 mg + 2 x placebo matched to firsocostat 5 mg for 12 weeks.
89413980|NCT02856555|Experimental|Placebo|Participants will receive 2 x placebo matched to firsocostat 5 mg + 2 x placebo matched to firsocostat 10 mg for 12 weeks.
89413981|NCT05000476|Other|Nurse Education and Environmental Regulation|Clinical nurses will be given training on delirium risks, diagnosis, prevention and management. In order to implement the interventions, environmental arrangements will be made in the intensive care units in the light of the training given, and the nurses will record which attempts are made during the day with the daily follow-up form.
89413982|NCT05000476|Experimental|Eye mask and earplugs|"Patients will be monitored for 3 days starting from their hospitalization.~Along with the regulations, each patient will be assisted by the intensive care nurses for 3 days between 23:00 p.m. - 06:00 a.m. for the use of eye mask and earplugs."
89413983|NCT05000476|No Intervention|Control|With the adjustments made, theywill receive the usual care for 3 days.
89413984|NCT03076450|Active Comparator|Maximum Oxygenation|Using PVC to set the initial peep, check ABG real-time, and according to PaO2+PaCO2≥400mmHg whether or not to adjust maintain PEEP.
89413985|NCT03076450|Experimental|Lung Ultrasound Re-aeration Score|Combine POC-LUS with PVC in set the initial peep, and then dynamic record LUS-RAS to feedback regulate PEEP.
89413986|NCT03608787|Experimental|Cohort 1-Early Intervention|Following baseline, participating outlets in this arm will receive the S-STOP program consisting of Pseudo-Intoxicated Mystery Shops (P-I/MS) with performance feedback for 3 months. After 3 months they will receive no further intervention, but will continue to receive Pseudo-Intoxicated Mystery Shops (P-I/MS).
89413987|NCT03608787|Experimental|Cohort 2-Delayed Intervention|Following baseline, participating outlets in this arm will receive receive Pseudo-Intoxicated Mystery Shops (P-I/MS) with no feedback. After 3 months they will receive the S-STOP program consisting of Pseudo-Intoxicated Mystery Shops (P-I/MS) with performance feedback.
88891507|NCT06113016|Active Comparator|Arm A (fisetin, physical activity handout)|Patients receive fisetin PO on days 1-3 of each cycle. Treatment repeats every 14 days for 8 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive handout on the importance of physical activity during baseline. Patients undergo collection of blood samples on study.
88891508|NCT06113016|Experimental|Arm AB (fisetin, tailored exercise training)|Patients receive fisetin PO on days 1-3 of each cycle. Treatment repeats every 14 days for 8 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive individually tailored supervised exercise training consisting of 30-45 minutes of aerobic training and 20-30 minutes of resistance training three times a week over 16 weeks. Patients undergo collection of blood samples on study.
89413988|NCT03076138|Experimental|Test group|Bone grafting with gene-activated matrix (OCP + plasmid DNA with VEGF gene)
89413989|NCT03077308||Rett Syndrome|Auditory and Visual event-related potentials (ERP) and EEG in 60 individuals with Rett syndrome.
89413990|NCT03077308||MECP2 Duplication Syndrome|Auditory and Visual event-related potentials (ERP) and EEG in 18 individuals with MECP2 Duplication syndrome.
89413991|NCT03077308||Rett-related disorders|Auditory and Visual event-related potentials (ERP) and EEG in 18 individuals with CDKL5 syndrome and 14 individuals with FOXG1 syndrome.
89413992|NCT03077308||Controls|Auditory and Visual event-related potentials (ERP) and EEG in 60 Control individuals (30 males and 30 females).
89413993|NCT02237235|Experimental|MMFS-202 -302|"MMFS-202: evening dose~MMFS-302: morning dose"
89413994|NCT02237235|Placebo Comparator|Placebo|Placebo
89413995|NCT03609099|Active Comparator|Moxifloxacin|Active treatment to patients treated during the 5 previous days.
89413996|NCT03609099|Experimental|Placebo|Placebo treatment to patients treated during the 5 previous days.
89005550|NCT02210455|Active Comparator|Psychoeducation|It is a static webpage on IRIS providing FASD information and resources, including recommended book titles, websites and organizations that may be helpful.
89192997|NCT05788237|Experimental|SSA Group 1: Combination|Combination (RSVpreF + qIRV) (Visit 1) followed by placebo (Visit 2). RSVpreF and qIRV are administered as concomitantly but as individual injections.
89192998|NCT05788237|Experimental|SSA Group 2: Sequential|Sequential administration of qIRV (Visit 1) followed by RSVpreF (Visit 2)
89192999|NCT05788237|Experimental|SSB Group 1: Combination (RSVpreF + qIRV) 1.0-mL formulation|RSVpreF lyophilized cake reconstituted with water for injection and mixed with qIRV, yielding an injection volume of 1.0 mL
89413997|NCT03077230|Experimental|Pre/Post Test of a Lung Cancer Screening Decision Aid|
89413998|NCT04463290||Knee Osteoarthritis Patients Group|Patients suffering from primary knee osteoarthritis
89413999|NCT04463290||Control Group|Healthy people without suffering from primary knee osteoarthritis
89414000|NCT05000398|Active Comparator|exercise with a physiotherapist|Participants will exercise with a physiotherapist. 4 times a week for 8 weeks
89414001|NCT05000398|Experimental|home program|The same exercises will be given to the participants as brochures. 4 times a week for 8 weeks
89414002|NCT04925440|Experimental|Probiotic|Probiotic capsules. Participants will consume 2 capsules once a day for 8 weeks.
89414003|NCT04925440|Placebo Comparator|Placebo|Placebo capsules. Participants will consume 2 capsules once a day for 8 weeks
89414004|NCT05000086|Experimental|99Tc methylene diphosphonate|99Tc-MDP was applied as follows: for each course of treatment, 99Tc-MDP 22 mg (5.5mg/set, four sets) was injected intravenously once a day for 7 successive days, one course every 4 weeks until week 24.
89414005|NCT03077074|Experimental|Low carbohydrate consumption|consumption of up to 60 grams of carbohydrate a day for 10 days FMRI will be performed prior and after the intervention during the luteal cycle phase
89414006|NCT05000008|Experimental|Aerobic Exercise Group|Moderate Intensity Aerobic Exercises
89414007|NCT05000008|Experimental|Resistance Exercise Group|Moderate Intensity Resistance Exercises
89414008|NCT05004922||ICSI in upper cavity|Embryo transfer into the upper cavity
89414009|NCT05004922||ICSI in midcavity|Embryo transfer into the midcavity
89414010|NCT05010382|Experimental|Test group|Hybrid surface dental implant
89414011|NCT05010382|Experimental|Control group|moderately rough surface implant
89414012|NCT01242267|Experimental|Phase 1|Phase 1 including Thalidomide Dose Levels of 600, 800, 1000 mg. Three patients will be entered at each dose level sequentially with a maximum of six patients enrolled at the highest dose level that defines dose-limiting toxicity. The starting dose will be 600mg/d x 5 days (dose level 1) given on days -5 to -1 before transplantation. Doses will be escalated in sequential order as listed below through cohorts of patients.
89414013|NCT01242267|Experimental|Phase 2|Phase 2 Thalidomide Dose Level of 1000 mg. The maximum dose to be tested is 1000mg. When the MTD is defined, an additional 40 patients will be enrolled at this level. The first 3 patients of this cohort of 40 patients will be assessed for DLT (2 of 6 patients experiencing DLT at this dose will require dose-de-escalation as described above, and the phase II portion of the study re-initiated at the newly defined MTD).
88891509|NCT06113016|Active Comparator|Arm B (placebo, tailored exercise training)|Patients receive placebo PO on days 1-3 of each cycle. Treatment repeats every 14 days for 8 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive individually tailored supervised exercise training consisting of 30-45 minutes of aerobic training and 20-30 minutes of resistance training three times a week over 16 weeks. Patients undergo collection of blood samples on study.
88922050|NCT05902169|Active Comparator|Control Arm: SoC single agent chemotherapy TMZ or CCNU|"Standard of Care (SoC) treatment with either temozolomide (TMZ) or lomustine (CCNU).~Standard TMZ chemotherapy as a single oral dose every 4 weeks for up to 6 cycles.~Standard CCNU chemotherapy as a single oral dose every 6 weeks for up to 4 cycles."
89414014|NCT03076294|Experimental|MT after rTMS group|High frequency TMS will be applied with an eight-shaped coil angled at zero degrees from the sagittal axis and positioned at the C3 or C4 in accordance with the international 10-20 marking system (JASPER, 1958), which corresponds to the right or left primary motor cortex (M1). Twenty four stimulus trains will be provided at 10 Hz for five seconds each. The interval between the trains will be 25 seconds, totaling 1200 pulses for approximately 12 minutes, with 90% of resting motor threshold (RMT). After TMS, patients will be submitted to 45 minutes of manual therapy protocol.
89414015|NCT03076294|Experimental|rTMS after MT group|Patients will be submitted to 45 minutes of manual therapy protocol. After that, high frequency TMS will be applied with an eight-shaped coil angled at zero degrees from the sagittal axis and positioned at the C3 or C4 in accordance with the international 10-20 marking system (JASPER, 1958), which corresponds to the right or left primary motor cortex (M1). Twenty four stimulus trains will be provided at 10 Hz for five seconds each. The interval between the trains will be 25 seconds, totaling 1200 pulses for approximately 12 minutes, with 90% of resting motor threshold (RMT).
88922051|NCT05892432|Placebo Comparator|Placebo|Participants in this Arm will take a medically inert placebo. To ensure pill equivalence between groups, tablets will be packaged in the same capsule; thus, each participant will take one capsule per day. Participants will be instructed to ingest the capsule orally each morning.
88922052|NCT05892432|Active Comparator|Semaglutide 3 milligrams and 7 milligrams|Participants in this Arm will study medication for a total of 8 weeks - on semaglutide 3 milligrams per day for 4 weeks, then 7 milligrams per day for 4 weeks. To ensure pill equivalence between groups, tablets will be packaged in the same capsule; thus, each participant will take one capsule per day. Participants will be instructed to ingest the capsule orally each morning.
88891510|NCT06113016|Active Comparator|Arm C (placebo, physical activity handout)|Patients receive placebo PO on days 1-3 of each cycle. Treatment repeats every 14 days for 8 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive handout on the importance of physical activity during baseline. Patients undergo collection of blood samples on study.
88891511|NCT06112990|Experimental|Arm 1|Home-based, telehealth resistance training (RT) with creatine monohydrate supplementation (Cr)
88891512|NCT06112990|Placebo Comparator|Arm 2|Home-based, telehealth resistance training (RT) with placebo (PLA)
88891513|NCT06106464|Experimental|Aerobic exercise+6.5 h of prolonged sitting|Participants will sit 6.5 hours after 30 minutes of moderate intensity aerobic exercise.
88891514|NCT06106464|Experimental|Aerobic exercise+2 minutes of walking breaks every 30 minutes|Participants will break prolonged sitting with 2 minutes of walking every 30 minutes after 30 minutes of moderate intensity aerobic exercise.
88891515|NCT06106464|Experimental|Aerobic exercise+4 minutes of walking breaks every 1-h|Participants will break prolonged sitting with 4 minutes of walking every 1-h after 30 minutes of moderate intensity aerobic exercise.
88891516|NCT06106464|Experimental|Aerobic exercise+8 minutes of walking breaks every 2-h|Participants will break prolonged sitting with 8 minutes of walking every 2-h after 30 minutes of moderate intensity aerobic exercise.
88891517|NCT06105866||Patients without Cardiac Disease|Patients between the ages of 18-65 with sinus rhythm, and without valvular disease, pulmonary hypertension, acute myocardial infarction, dilated, and hypertrophic cardiomyopathy will be included in the study.
88891518|NCT06101693||Patients with NTproBNP<125ng/L and clinical suspicion of heart failure in primary care|Expected recruitment of 400 patients (50-60% expected prevalence of obesity, according to population study)
88891519|NCT06101693||Patients with NTproBNP125-399ng/L and clinical suspicion of heart failure in primary care|Expected recruitment of 400 patients (50% expected prevalence of obesity, according to population study)
88891520|NCT06101693||Patients with NTproBNP≥400ng/L and clinical suspicion of heart failure in primary care|Expected recruitment of 400 patients (50% expected prevalence of obesity, according to population study)
88891521|NCT06098911|Experimental|MI varnish (CPP ACP) under glass ionomer in ART group|Application of a thin layer of casein phosphopeptide amorphous calcium phosphate ( CPP ACP ) varnish as indirect pulp capping material under glass-ionomer (Riva Light cure GC company ) in Atraumatic restorative technique.
88891522|NCT06098911|No Intervention|Conventional ART|Placement of glass-ionomer restoration ( Riva Light Cure ) only in Atraumatic restorative technique.
88891523|NCT06094283|Active Comparator|YCT-529|Oral single ascending dose(s)
88891524|NCT06094283|Placebo Comparator|Placebo|Placebo for YCT-529 Capsule
88891525|NCT06079047|Experimental|group Dexamethasone|"adductor canal block with 10 ml of 0.5% bupivacaine + 10 ml of 0.9% saline solution + 2 ml of dexamethasone (8 mg)"
88891526|NCT06079047|Active Comparator|group Controle|"adductor canal block with 10 ml of 0.5% bupivacaine + 10 ml of 0.9% saline solution + 2 ml of 0.9% saline solution"
88891527|NCT06073353|Experimental|THRIVE-M|"Participants will be recruited from the Massachusetts General Hospital Cancer Center and randomized in a 1:1 fashion, stratified by diagnosis type (newly diagnosed versus maintenance versus relapsed), to THRIVE-M versus usual care.~Participants will use THRIVE-M following a diagnosis of multiple myeloma to learn how to cope with physical symptoms, articulate their needs and navigate relationships, and focus on self-care while living with multiple myeloma using an iPad provided by the study team or the participant's own iPad.~Questionnaires (in person, over the computer or telephone, or by mail) will be completed by participants at predetermined days per protocol days."
88891528|NCT06073353|No Intervention|Usual Care|"Participants will be recruited from the Massachusetts General Hospital Cancer Center and randomized in a 1:1 fashion, stratified by diagnosis type (newly diagnosed versus maintenance versus relapsed), to THRIVE-M versus usual care.~Questionnaires (in person, over the computer or telephone, or by mail) will be completed by participants at predetermined days per protocol days.~Participants in the usual care arm will receive their usual care with the multiple myeloma team, including all routine supportive care resources (e.g., support from social work, psychology, or psychiatry) offered by the multiple myeloma team to all patients diagnosed with multiple myeloma.~Patients in both the usual care and THRIVE-M group are permitted to use all supportive care services per usual care. We will track referrals to supportive care services in both groups by reviewing the Electronic Health Record (EHR)."
88891529|NCT06069817|Experimental|High flow nasal cannula group|Treatment with High Flow Nasal Cannula minimum twenty (20) minutes three times a day (one [1] hour a day in total) and up to 10 hours a day in total, according to patient's preferences.
88891530|NCT06069817|Active Comparator|nebulized saline group|Treatment with nebulization of 4-8 cc of normal saline three times daily
88891531|NCT06066788|Other|Feasibility Arm|A 10 sessions over 5 week virtual interaction between an occupational therapist and a person who is post-stroke, engage in meta-cognitive coaching to develop strategies to overcome barriers to daily living experienced in early stages of stroke. Outcomes anticipated are related to the American Heart Association's Healthy 8.
88891532|NCT06066671|Experimental|GCO (Experimental copaiba oil resin gel)|The GCO group will receive the application of an experimental gel based on copaiba oil resin for post tooth bleaching sensitivity
88891533|NCT06066671|Active Comparator|GN (Potassiun nitrate and sodium fluoride gel)|The GN group will receive the application of a potassium and sodium nitrate gel for post tooth bleaching sensitivity
88891534|NCT06066671|Placebo Comparator|GC|The GC group will receive the application of a placebo gel for post tooth bleaching sensitivity
88891535|NCT06065449|Experimental|Arm 1 - Standard Dose|Participants will receive either 1 radiation treatment a day for 3 days in a row (not counting weekends or holidays), or Participants will receive 1 radiation treatment given on 1 day.
88891536|NCT06065449|Experimental|Arm 2 - High Dose|Participants will receive either 1 radiation treatment a day for 5 days, or 1 radiation treatment given on 1 day.
88891537|NCT06064916||Vivity IOL Group|Patients with bilateral implantation of Vivity IOLs.
88891538|NCT06064279|Experimental|Poly-ICLC + IVIG|Patients with stage IV NSCLC will be treated with poly-ICLC + IVIG
88891539|NCT06063486|Experimental|Arm I (C3 Complex/Bioperine)|Patients receive C3 complex/Bioperine PO BID for 12 months in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspiration and biopsy at baseline and follow up, and collection of blood samples throughout the trial.
89193000|NCT05788237|Experimental|SSB Group 2: Combination (RSVpreF +qIRV) 0.5-mL formulation|RSVpreF lyophilized cake reconstituted with qIRV to yield an injection volume of 0.5 mL
88891540|NCT06063486|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID for 12 months in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspiration and biopsy at baseline and follow up, and collection of blood samples throughout the trial.
88891541|NCT06062303|No Intervention|Compartor arm|- Patients allocated to the usual care group will be managed by the clinical staff according to usual practice at their sites including decisions about hemodynamic and perfusion monitoring, and all treatments, but should follow general recommendations of the Surviving Sepsis Campaign to avoid extremes of clinical practice. This includes basic hemodynamic targets such as a MAP >65 mmHg, HR (heart rate) <120 beats per minute (BPM), arterial oxygen saturation (SaO2) >94%, Hb > 7 gr/dl, and the use of NE as the first vasopressor and crystalloids as the fluid of choice.
88922053|NCT05890001|Experimental|BLI5100 Low Dose|Patients will take BLI5100 Low Dose once daily, orally, for up to 29 weeks.
88922054|NCT05890001|Experimental|BLI5100 High Dose|Patients will take BLI5100 High Dose once daily, orally, for up to 29 weeks.
88891542|NCT06062303|Active Comparator|Capillary-refill time and phenotyping group|"Patients w/normal baseline CRT will be periodically monitored. Patients with abnormal CRT and septic shock will be categorized according to pulse pressure (PP). If <40 mmHg, will go to fluid responsiveness (FR) assessment. FR (-) patients will undergo cardiac echo to rule out significant dysfunction. Fluid boluses will be administered in 30 min intervals and repeated as needed if CRT is still abnormal. Patients with PP ≥40 mmHg will proceed according to diastolic pressure (DAP). If ≥50 mmHg will move to FR assessment. If <50 mmHg NE will be increased for MAP >65 mmHg and DAP ≥50 mmHg w/CRT assessed 1 h after. NE will be increased in 0.1 mcg/k/m increments up to 0.5 mcg/k/m.~If CRT is normal, patients will proceed to periodic monitoring. Patients with persistent abnormal CRT or that reached NE safety limit will proceed directly to echo.~Patients that correct CRT with first tier interventions will not be subjected to obligatory echo but will just proceed to periodic monitoring."
88891543|NCT06061328|Experimental|OASIS DA|Half of the sites will be randomized to receive training on the OASIS decision aid.
88891544|NCT06061328|Active Comparator|Current DA Tool|Half of the sites will be randomized to receive training on the current decision aid tool.
88891545|NCT06058728||Part 1 - Oriahnn Exposure Cohort|Participants prescribed Oriahnn for management of heavy menstrual bleeding (HMB) due to uterine fibroids (UF).
88891546|NCT06058728||Part 2 - Nested Hair Loss Cohort|Participants prescribed Oriahnn for management of HMB due to UF, with meaningful hair loss.
88891547|NCT06057831|Experimental|Single Arm|All patients receive total neo-adjuvant therapy (TNT), depending on institutional policy
88891548|NCT06057519|Experimental|Optimized dose rifampicin|1800 mg flat dose
88891549|NCT06057519|Active Comparator|Standard dose rifampicin|450 mg for patients under 50 kg and 600 mg for patients over 50 kg
88891550|NCT06056505|Experimental|Partial kidney nephrectomy with aid of 3D model|The patient information (before intervention) and the surgery (partial nephrectomy) will be performed with the aid of 3D modelling of the kidney.
88891551|NCT06056505|Active Comparator|Partial kidney nephrectomy with aid of 2D model|The patient information (before intervention) and the surgery (partial nephrectomy) will be performed with the aid of 2D modelling of the kidney.
88891552|NCT06051591|Active Comparator|Attention Control|Participants will receive nutrition education and anticipatory guidance to support healthy meal preparation in addition to usual care.
88891553|NCT06051591|Experimental|Food FARMacia intervention|Participants will enroll in the Food FARMacia program and receive groceries twice monthly for 6 months. They will also receive nutrition education and anticipatory guidance to support healthy meal preparation.
88891554|NCT06048822|Experimental|Cancer Survivors|Participation will last approximately 4-6 months. Participants will be encouraged to attend Pickleball sessions at the YMCA at least twice a week. Each session will last 2 hours, and participants will be encouraged to attend at least one hour. Participants will receive a Fitbit to wear continuously 24/7 over 4-6 months to track steps and activity intensity. Participants will also be asked to wear an electronic device (accelerometer) over their right hip during specific time points throughout the study to better understand how pickleball participation contributes to physical activity levels.
88891555|NCT06048822|Experimental|Family or Friend of Cancer Survivors|Participation will last approximately 4-6 months. Participants will be encouraged to attend Pickleball sessions at the YMCA at least twice a week. Each session will last 2 hours, and participants will be encouraged to attend at least one hour. Participants will receive a Fitbit to wear continuously 24/7 over 4-6 months to track steps and activity intensity. Participants will also be asked to wear an electronic device (accelerometer) over their right hip during specific time points throughout the study to better understand how pickleball participation contributes to physical activity levels.
88891556|NCT06048237||Reliability Assessment Arm|This is a single-arm reliability assessment study. Reliability will be assessed by conducting measurements of diaphragm thickness and excursion on the same participants by the same rater (intra-rater reliability) and by different raters (inter-rater reliability) to evaluate measurement consistency.
88891557|NCT06046014|Experimental|Expressive Writing (EW)|four- week, in- home, Body Image (BI)- focused EW intervention
88891558|NCT06046014|Active Comparator|Attention Control|four- week control writing program
88891559|NCT06045325||Myopic -1.00D|Myopic patients with a diopter of at least -1.00
88891560|NCT06042153|Experimental|Arm 1 - Semaglutide|Participants will receive semaglutide as an adjunct to standard-of-care.
88891561|NCT06042153|Placebo Comparator|Arm 2- Placebo|Participants will receive placebo (semaglutide) as an adjunct to standard-of-care.
88891562|NCT06041139||Alcon PanOptix|Patients will have had bilateral implantation of PanOptix IOLs with the toric and/or non-toric models at the time of uncomplicated cataract surgery.
88891563|NCT06041139||Johnson & Johnson Synergy|Patients will have had bilateral implantation of Synergy IOLs with the toric and/or non-toric models at the time of uncomplicated cataract surgery.
88891564|NCT06027671|No Intervention|Care-as-usual (CAU) arm|Per DCS routine, at release, participants will receive a referral letter form the DCS health services and, in most cases, will be provided with a 28-day supply of ART.
88922055|NCT05888571|Active Comparator|prepectoral breast reconstruction with Mesh|Immediate prepectoral breast reconstruction with Mesh
88922056|NCT05888571|Experimental|prepectoral breast reconstruction without Mesh|Immediate prepectoral breast reconstruction without Mesh
88922057|NCT05888311|Experimental|Liquid bandage|Will receive the application of the experimental product (liquid bandage) on the area with activated carbon at the beginning (T0) and at the end of visit 1 (T12).
88922058|NCT05888311|Other|Control area|will not receive the experimental product over activated carbon.
88891565|NCT06027671|Experimental|Group-SPARCS intervention arm|The Group-SPARCS component comprises one individual pre-release session, one individual post-release session, and 12 every-other-week (every two weeks) post-release group sessions extending six months post-release. Each session will be led by two trained individuals: a peer (history of criminal justice involvement and living with HIV) and a social worker.30 Within 14 days of release, participants will have one-on-one contact with a facilitator to update locator information, continue rapport building, review disclosure plans, provide a reminder of SPARCS logistics, and assign or remind the participant to a SPARCS group based on the location of residence and timing of release (depending on whether this occurred pre-release). Each Group-SPARCS meeting lasts approximately 2 hours, and the sessions occur in a private space in a community venue (e.g., community centre or church).
88891566|NCT06027671|Experimental|ART-SPARCS intervention arm|"ART delivery will follow Department of Health (DoH) procedures for differentiated models of care, in particular the Community Adherence Club model. Similar to community adherence clubs, the ART provision in SPARCS will be affiliated with a 'home clinic that will provide ART supplies for the participants. Routine community adherence club activities include:~ART will be provided every two months from correctional facility release to 6 months post-release (months 2, 4, and 6). Participants with less than two months of ART at release will receive a top-off to reach two months. ART will be pre-packaged by the DoH home clinic, collected by the facilitators, and distributed to the participants. At the time of distribution, the facilitators will conduct a standard DoH differentiated care symptom screen. Participants who report specific symptoms will be referred to the home clinic for further assessment per routine with Community Adherence Clubs."
88891567|NCT06027671|Experimental|Full-SPARCS arm|Full-SPARCS combines Group-SPARCS and ART-SPARCS with ART delivery during SPARCS group meetings.
88891568|NCT06017765|Experimental|Immediate Meditation Training group|The Immediate Meditation Training group will immediately receive 8 weekly sessions of Mindfulness Training within 4 weeks after the Baseline visit (V0, during which participants are randomized).
88891569|NCT06017765|Other|Waitlist Control group|The Waitlist Control group will receive the Mindfulness Training after a waiting time of 12 weeks. Participants in this group will not receive any type of intervention before this and will wait till the Immediate Meditation Training group finished all assessment visits (including the follow-up visit in week 12 (V3)).
88891570|NCT06007235|Other|A: CACIPLIQ20 before placebo|Arm A will receive at first CACIPLIQ20 (experimental product) for 1 month, followed by 1-month washout, then 1 month of saline (placebo comparator).
88891571|NCT06007235|Other|B: placebo before CACIPLIQ20|Arm B will receive at first saline (placebo comparator) for 1 month, followed by 1-month washout, then 1 month of CACIPLIQ20 (experimental product).
88891572|NCT06006871|Experimental|The Secret Trail of Moon (MOON): Cognitive training with Serious Video Game|"The Secret Trail of Moon is a therapeutic video game that has been created for the cognitive training of patients with ADHD. Five mechanisms have been designed to work on five cognitive functions that are deficient in ADHD: sustained attention, working memory, reasoning, planning and visuospatial ability. Aspects of rewards and music therapy have been added to this enhanced version of the game.~In this second clinical trial, the impact has been extended to twice a week during 20 sessions. There are two platforms of the same version of the game: computer (7-11 years old) and virtual reality (12-18 years old). Patients have to come to the hospital twice a week for training sessions of about 20-30 minutes duration for 10 weeks. Subsequently, they are given the computer version of the video game on a USB so that they can play it at home for another 10 weeks (twice a week).~Participants are monitored for possible difficulties and/or side effects."
89199102|NCT02543151|Experimental|SpyGlass Choledochoscopy procedure|Any patient referred to endoscopic management for biliary post liver transplant complication without previous treatment will be submitted to SpyGlass (direct visualization system) choledochoscopy procedure.
89005551|NCT00210977||Erythropoietin receptor agonist|Participants with borderline serum anti erythropoietin (EPO) antibody (Ab) titers and who are treated with any erythropoietin receptor agonist (ERA) for any indication, having anti-EPO Ab identified by radioimmunoprecipitation (RIP), who are responding to ERA therapy, will be included in the study.
89005552|NCT02210494|Experimental|Secretrol|
89414016|NCT03076294|Sham Comparator|Control group|In this group, the order of interventions will be randomized. Therefore, the volunteer can start with manual therapy or sham TMS. In manual therapy, patients will be submitted to 45 minutes of a protocol. In addition, with regard to sham TMS, the same parameters will be used, however, it will be performed using two coils, one connected to the magnetic stimulator, away from the patient's scalp and another uncoupled from the stimulator and positioned in the same way as in real stimulation.
89005553|NCT02210611|Active Comparator|36 hours|Intrauterine insemination 36 hours after ovulation induction
89005554|NCT02210611|Active Comparator|42 hours|Intrauterine insemination 42 hours after ovulation induction
89005555|NCT04568512|Placebo Comparator|Control|Brushed biliary samples from a known case of benign biliary stricture were sent for DNA Methylation Biomarker test and cell cytology
89193001|NCT05779761|Experimental|Attention Skills Training|Participants assigned to Attention Skills Training will receive 6-weeks of self-directed, online skills training on attention regulation skills for coping with distress. Six weekly modules will include 10-15 minutes of narrated videos, as well as suggestions for activities and skills practices between modules. Participants will also schedule weekly, 5-10 minute calls with an assigned skills training coach to discuss the participant's experience with the skills training.
89199103|NCT02543229|Experimental|Part 1 Dose escalation - Cohort 1|Dose Level 1 of OPT-302 in combination with Lucentis™
89199104|NCT02543229|Experimental|Part 1 Dose escalation - Cohort 2|Dose Level 2 of OPT-302 in combination with Lucentis™
89414017|NCT03608553|Experimental|ExAblate|ExAblate MR Guided Focused Ultrasound
89414018|NCT01741480|Placebo Comparator|Routine care|General hospital ward patients will receive routine care.
89005556|NCT04568512|Active Comparator|Cholangiocarcinoma|Brushed biliary samples from a known case of cholangiocarcinoma were sent for DNA Methylation Biomarker test and cell cytology
89005557|NCT04568473|Experimental|PRG Barrier Coat (SHOFU Inc., Japan)|"BioSmart Light Cured Protective Shield with bioactive S-PRG (Surface Pre-Reacted Glass ionomer) filler technology.~S-PRG filler possesses a three-layer structure with a stabilized glass-ionomer-like structure surrounding multifunctional glass fillers, and is subsequently protected by a surface modified layer."
89005558|NCT04568473|Experimental|EMBRACE™ Varnish (Pulpdent Corporation, USA)|"Resin-based 5% sodium fluoride with CXP™ (Xylitol-coated Calcium and Phosphate) technology for unsurpassed fluoride release.~The incorporation of CXP™ (xylitol-coated calcium and phosphate) in a permeable resin matrix that does not separate, purportedly drives the sustained, time-released properties of this varnish"
89199105|NCT02543229|Experimental|Part 1 Dose escalation - Cohort 3|Dose Level 3 of OPT-302 in combination with Lucentis™
89414019|NCT01741480|Experimental|Intervention arm|The intervention with early warning system monitoring is to have the rapid response team assess the patients real-time.
89414020|NCT03608085|Experimental|Pharmacist Heart failure MTM training|Community pharmacist who will receive heart failure medication therapy management training
88891573|NCT06006871|Active Comparator|Control Group|"This group corresponds to the control group (n=76). The control group continues with their prescribed pharmacological treatment without any cognitive intervention.~The participants of this group are contacted by telephone once a week to follow up on possible difficulties and/or side effects."
88891574|NCT06001268|Experimental|STRONG-PCS Intervention|Participants will receive an initial in-person consultation with a dietician within 2 weeks of hospital discharge. Then participants will receive individually tailored, bi-weekly nutrition counseling from a dietician via telehealth or in person and remote monitoring through a smart phone app and wearable sensor to allow participants to log food intake while sharing their data with a dietician.
88891575|NCT06001268|Active Comparator|Usual Care|Participants will be referred for nutrition counseling from a dietitian based on clinical discretion.
88891576|NCT05999253||Modified thoracolumbar plane block (mTLIP)|"Modified thoracolumbar plane block (mTLIP): under ultrasound-guided, the lateral compartment of the longissimus muscle and iliocostal muscle muscles are imagined and the block needle is placed in the interfascial plane of these two muscles and local anesthesic solution is appliced.~Patients will be induced with standard general anesthesia and turned to the prone position.~Before the surgical incision, 20 ml of 0.25% bupivacaine 0.25% will be administered bilaterally under ultrasound guidance only once.~20 ml of 0.25% bupivacaine will be used on each side (total of 40 ml of 0.25% bupivacaine will be used)~Plane block applications will be performed by anaesthesiologists with at least 5 years of experience"
88891577|NCT05999253||Erector spinae plane block (ESP)|"Erector spinae plane block (ESP): After determining the vertebral spinal process and trapezius, rhomboid major and erector spinae muscles with ultrasound guidance, the block needle is advanced in the cranio-caudal direction with an in plane approach and local anaesthetic solution is applied to the plane between the erector spinae muscle and the transverse process when the needle rests on the transverse process.~Patients will be induced with standard general anesthesia and turned to the prone position.~Before the surgical incision, 20 ml of 0.25% bupivacaine will be administered bilaterally under ultrasound guidance only once.~20 ml of 0.25% bupivacaine will be used on each side (total of 40 ml of 0.25% bupivacaine will be used)~Plane block applications will be performed by anaesthesiologists with at least 5 years of experience"
89199106|NCT02543229|Experimental|Part 1 Dose escalation - Cohort 4|Dose Level 3 of OPT-302 monotherapy
89414021|NCT03608085|Experimental|Patient Heart failure MTM intervention|Independently living community dwelling subjects who are prescribed at least 1 cardiovascular medication for HF and 3 additional chronic medications after discharge from the Hospital for an MTM consultation by a pharmacist trained in heart failure medication therapy management.
89414022|NCT05004766|Experimental|virtual reality apply|Using the VR system during robot training, the auditory stimulation of VR was applied along with the image of walking of a forest road or coastal road at the same speed as the robot walking speed. The VR programs are a composition of scenic beaty with sounds of nature. Each program is a blend of scenes such as the ocean, desert, forest, flowers, waterfalls, and wildlife.
89414023|NCT05004766|No Intervention|control condition|Each patient participated in the control condition, during which he or she performed RAGT with no distraction for the same amount of time spent doing therapy in VR.
89414024|NCT04066413|No Intervention|Breastfed group|Non-randomized breastfed reference group
89414025|NCT04066413|Placebo Comparator|Control formula|Group receiving standard infant formula
89414026|NCT04066413|Active Comparator|Formula with HMO|Group receiving standard infant formula supplemented with HMO
89414027|NCT02637232||Mirvaso® / Onreltea TM|
89414028|NCT02715375|Experimental|Device: CREON2000A|Children with mild to moderate asthma maintains allergy medicines have an experimental ultra violet device installed in their homes.
89414029|NCT02715375|Sham Comparator|Device: Sham Comparator|Children with mild to moderate asthma maintains allergy medicines have a sham device using a shielded blue light sham lamp that otherwise resembles the experimental device installed in their homes.
89414030|NCT04993690|Experimental|Phase I Dose Escalation|Dose Escalation and determination of MTD; multiple dose levels of LP-168 to be evaluated
89414031|NCT04993690|Experimental|Phase I Dose Expansion A|CLL/SLL patients treated with prior regimens.
89414032|NCT04993690|Experimental|Phase I Dose Expansion B|CLL/SLL patients with no prior therapy.
89414033|NCT04993690|Experimental|Phase I Dose Expansion C|MCL patients treated with prior regimens.
89414034|NCT04993690|Experimental|Phase I Dose Expansion D|WM patients treated with prior regimens.
89414035|NCT04993690|Experimental|Phase I Dose Expansion E|MZL patients treated with prior regimens.
89414036|NCT02855541|Experimental|Cycling intervention|Participants will use a small cycling device (DeskCycle) at their workstation for 15 minutes every hour that they are at work.
88922059|NCT05886504|Active Comparator|Psychiatric intervention group|200 PWID diagnosed with either depression, psychosis or suicidal risk will be proposed to be included in the intervention arm Participants will receive free psychiatric consultation and medication on community-based organization (CBO) sites with full support from CBO members They will receive (together with the control group) linkage to care when needed (HIV, methadone treatment) and harm reduction services.
88922060|NCT05886504|No Intervention|control group free from psychiatric disorder|"200 PWID living with HIV and 200 PWID non-infected with HIV, both free of a diagnosis of depression, psychosis or suicidal risk, will be recruited and proposed a one year follow-up.~They will receive (together with the intervention group) linkage to care when needed (HIV, methadone treatment) and harm reduction services."
89414037|NCT02635984|Placebo Comparator|Triplet Therapy Plus Placebo|All subjects will receive standard triplet antiemetic therapy which consists of ondansetron and dexamethasone on each day of chemotherapy plus fosaprepitant 150 mg IV once per national guidelines for CINV prophylaxis. In addition to those antiemetics, subjects will receive placebo on all chemotherapy days and for three additional days post chemotherapy.
89414038|NCT02635984|Active Comparator|Triplet Therapy Plus Olanzapine|All subjects will receive standard triplet antiemetic therapy which consists of ondansetron and dexamethasone on each day of chemotherapy plus fosaprepitant 150 mg IV once per national guidelines for CINV prophylaxis. In addition to those antiemetics, subjects will receive olanzapine 10mg orally on all chemotherapy days and for three additional days post chemotherapy.
89414039|NCT03076216|Other|OncoSil™ plus SOC Chemotherapy|OncoSil™ implanted with concurrent Standard of Care chemotherapy either gemcitabine or gemcitabine + Abraxane
89414040|NCT03076918|Active Comparator|Conventional PDT|Aktilite® Galderma
89414041|NCT03076918|Experimental|FLEXITHERALIGHT PDT|Light Emitting Textile Device
89414042|NCT03076372|Experimental|MM-310 monotherapy|MM-310 will be administered by IV infusion over 90 minutes on the first day of each 21 day cycle.
89414043|NCT03076060|Experimental|Migraineurs|"Overweighted or Obese migraineurs that refer to a dietician clinic to treat their ponderal condition.~Intervention: 4-week of VLCKD by meal replacements poor in fats and carbohydrates."
88891578|NCT05997771|Experimental|Study Intervention Group|"The study intervention group will be undergoing 3 months of Personalized Nutrition Advisor (PNA)-assisted remote nutritional counselling.The PNA data analysis tool will be used by the dietitians during remote nutritional counselling sessions.The service will be delivered to patients undergoing GLP-1 based obesity treatment as part of their usual care. The study intervention group will report treatment-satisfaction and self-efficacy via questionnaires at baseline, 1.5 - and 3 months.~Patients who expressed their interest in participating in a focus group at the time of study inclusion, will be invited for a 60 min online interview session chaired by an experienced moderator. The focus group will consists of a maximum of 10 participants and address the patient's perspective on the utility of the dietitians' advice, discrepancy from expectations, general feedback and suggestions for PNA improvement using a semi structured discussion guide held in an open and spontaneous format"
88891579|NCT05989828|Experimental|Treatment (A2-ESO-1 TCR-T cells)|Patients undergo leukapheresis on day -28 then receive cyclophosphamide IV over 1 hour on days -7 and -6 followed by fludarabine IV over 30 minutes on days -5 to -1. Patients then receive A2-ESO-1 TCR-T cells IV over 30 minutes on day 0 followed by aldesleukin IV over 15 minutes on days 0 to 2. Patients also undergo blood sample collection and CT scans throughout the study. Additionally, patients may undergo a breast biopsy, a mammogram, breast MRI, and breast US at screening and follow up, and ECHO or MUGA at screening.
89414044|NCT03076060|Sham Comparator|Sham diet migraineurs|"Overweighted or Obese migraineurs that refer to a dietician clinic to treat their ponderal condition.~Intervention: 4-week of non-ketogenic VLCD by meal replacements poor in fats and proteins."
88891580|NCT05989672|Experimental|HSVTI_F1 group|HSV-2 seronegative participants randomized in this group will receive 2 doses of HSVTI Formulation 1 of the study intervention at Day 1 and Day 29.
88891581|NCT05989672|Experimental|HSVTI_F2 group|HSV-2 seronegative participants randomized in this group will receive 2 doses of HSVTI Formulation 2 of the study intervention at Day 1 and Day 29.
88891582|NCT05989672|Placebo Comparator|Placebo group|HSV-2 seronegative participants randomized in this group will receive 2 doses of placebo as control at Day 1 and Day 29.
88891583|NCT05988658||Study cohort|Patients will be identified as high risk based on their AKI risk score (ESTOP- AKI 2.0) being in the top 10% of all hospitalized patients
88891584|NCT05982093|Experimental|Elacestrant|without ovarian function suppression
88891585|NCT05982093|Active Comparator|Elacestrant + Triptorelin|with ovarian function suppression
88891586|NCT05980533|Experimental|Ultrasound|Ultrasound at hospital discharge and at follow up in 7-10 days
88891587|NCT05977907|Experimental|Single Cohort|"Neoadjuvant Pembrolizumab ( 400mg IV infusion x1) + IO102-103 ( Subcutaneous injection weekly x6)~Adjuvant Pembrolizumab ( 400 mg IV infusion Every 6 weeks x8) + IO102-103 ( Subcutaneous injection every 3 week x6 then every 6 weeks x5)"
88891588|NCT05968573|Active Comparator|Persuasive Health Communication Intervention delivered in video format|A video created by the research team will be played to persuade patients to participate in HIV and Hepatitis C (HCV) screening.
88891589|NCT05968573|Active Comparator|Persuasive Health Communication Intervention delivered by Health Educator|Healthcare provider educator getting patients screened for HIV/HCV.
88891590|NCT05966636|Other|Observational Single Arm|All subjects will have scars, quality of life, function assessed pre and post laser treatment
88891591|NCT05964868|Experimental|Liposomal Bupivacaine|This group will receive a one time 5 mL injection of liposomal bupivacaine post-operatively at the surgical site.
88891592|NCT05964868|Active Comparator|Bupivacaine with epinephrine|This group will receive a one-time 5 mL injection of 0.25% bupivacaine with 1:200,000 epinephrine post-operatively at the surgical site.
88922061|NCT05878691|Experimental|GRC 54276|
89414045|NCT03073408|Active Comparator|1: Manual control group|The propofol infusion rate is adjusted manually in a pump by the investigator to maintain BIS between 40 and 60. For this titration it is necessary continuous monitoring, clinical experience, and pharmacokinetic/pharmacodynamic knowledge.
89414046|NCT03073408|Experimental|2: PI +Smith group|The closed loop control automatically adjust propofol infusion rate guided by the feedback of the real value of BIS. The automatic system has to achieve a target BIS of 50 and maintain it between 40 and 60.
88891593|NCT05964868|Placebo Comparator|Saline solution|This group will receive a one-time 5 mL injection of saline post-operatively at the surgical site.
88891594|NCT05963139|Active Comparator|Group 1:10 ml %0,25 bupivacaine ıpack and 15 ml %0,25 bupivacaine adductor block|In this group,US guided IPACK block will be performed with 10 ml %0,25 bupivacaine and adductor block will be performed with 15 ml %0.25 bupivacaine using a 22 gauge 10 mm block needle.
88891595|NCT05963139|Active Comparator|Group 2:15 ml %0,25 bupivacaine ıpack and 15 ml %0,25 bupivacaine adductor block|In this group,US guided IPACK block will be performed with 15 ml %0,25 bupivacaine and adductor block will be performed with 15 ml %0.25 bupivacaine using a 22 gauge 10 mm block needle.
88891596|NCT05963139|Active Comparator|Group 3:20 ml %0,25 bupivacaine ıpack and 15 ml %0,25 bupivacaine adductor block|In this group,US guided IPACK block will be performed with 20 ml %0,25 bupivacaine and adductor block will be performed with 15 ml %0.25 bupivacaine using a 22 gauge 10 mm block needle.
88891597|NCT05963139|Active Comparator|Group 4:15 ml %0,25 bupivacaine adductor block and intravenous patient controlled analgesia|In this group adductor block will be performed with 15 ml %0.25 bupivacaine using a 22 gauge 10 mm block needle and postoperative patient controlled analgesia with morphine will be preferred for postoperative analgesia method.
88891598|NCT05950399|Experimental|Group I (resting and/or stress echocardiography)|Patients choose to undergo either a resting echocardiography performed before and after delivery of a cancer therapeutic agent and months 3, 6, 9 and 12 or up to 5 low intensity stress echocardiography over 25 minutes performed depending on where they are at in the course of their cancer therapy and/or cardiac rehabilitation program at baseline and/or months 3, 6, 9 and 12 after starting cancer therapy.
88891599|NCT05950399|Active Comparator|Group II (stress echocardiography)|Participants undergo low intensity stress echocardiography over 25 minutes at baseline and may undergo a second one at least 24 hours later.
88891600|NCT05948189|Active Comparator|intervention group|a 6-week exercise program
88891601|NCT05948189|No Intervention|Controls|a brochure to read
88891602|NCT05946629|Experimental|SELUTION SLR 014 PTCA DEB|"SELUTION Sustained Limus Release (SLR) 014 Percutaneous Transluminal Coronary Angioplasty (PTCA) Drug Eluting Balloon (DEB)~The SELUTION SLR 014 PTCA DEB is a minimally invasive, single use and sterile Sirolimus coated PTCA balloon catheter.~The SELUTION SLR 014 PTCA DEB is available with balloon diameters from 2.0 to 3.0 mm and lengths of 15 to 40 mm for the purpose of the De Novo IDE trial"
88922062|NCT05878691|Experimental|GRC 54276 with pembrolizumab|
88891603|NCT05946629|Active Comparator|Control Treatment|"any FDA approved limus-based Drug Eluting Stent, as per standard institutional practice"
88891604|NCT05946278||Patients undergoing deformity correction surgery|Patients undergoing deformity correction surgery undergoing a multi-level spinal fusion (i.e. a T10 (or higher) fusion to the pelvis) -OR- a 3 column osteotomy with a corpectomy from for short segment surgeries -OR- a vertebral column resection (VCR) involving a corpectomy -OR- any deformity correction surgery wherein the attending surgeon determines that a large amount of bone containing trabecular elements will be removed and discarded
88891605|NCT05937906|Experimental|Phase I - Level 1|"Mirdametinib 4 mg twice/day for 7 days per cycle for the 4 first cycles + carboplatin/pemetrexed/pembrolizumab.~Pemetrexed/pembrolizumab until progression Number of participants : 3 to 6 patients"
88891606|NCT05937906|Experimental|Phase I - Level 2|"Mirdametinib 4 mg twice/day for 14 days per cycle for the 4 first cycles + carboplatin/pemetrexed/pembrolizumab.~Pemetrexed/pembrolizumab until progression Number of participants : 3 to 6 patients"
88891607|NCT05937906|Experimental|Phase I - Level 3|"Mirdametinib 6 mg twice/day for 7 days per cycle for the 4 first cycles + carboplatin/pemetrexed/pembrolizumab.~Pemetrexed/pembrolizumab until progression Number of participants : 3 to 6 patients"
88891608|NCT05937906|Experimental|Phase I - Level 4|"Mirdametinib 6 mg twice/day for 14 days per cycle for the 4 first cycles + carboplatin/pemetrexed/pembrolizumab.~Pemetrexed/pembrolizumab until progression Number of participants : 3 to 6 patients"
88891609|NCT05937906|No Intervention|Phase II - Standard arm|Carboplatin / Pemetrexed / Pembrolizumab for the first 4 cycles
88891610|NCT05937906|Experimental|Phase II - Experimental arm|Carboplatin / Pemetrexed / Pembrolizumab + mirdametinib for the first 4 cycles
88891611|NCT05937854|Placebo Comparator|Placebo|Encapsulated placebo one or 2 encapsulated tablets po QD
88891612|NCT05937854|Active Comparator|tadalafil|one or 2 encapsulated tablets of encapsulated tadalafil (20MG) po QD
88891613|NCT05925582|Experimental|Group 1|All the participants in Group 1 will receive a 8-week vestibular based exercises program 3 times in a week.
88891614|NCT05925582|Active Comparator|Group 2|All the participants in Group 1 will receive a 8-week calistenic based exercises program 3 times in a week.
88891615|NCT05917249|Experimental|interventional|
88891616|NCT05917119|Experimental|BLT|Bright light therapy delivered via glasses
88891617|NCT05917119|Sham Comparator|s-BLT|Sham Bright light therapy
88891618|NCT05914909|Experimental|Part A: AD-214 in Healthy Volunteers|
88891619|NCT05914909|Placebo Comparator|Part A: Placebo in Healthy Volunteers|
88891620|NCT05914909|Experimental|Part B: AD-214 in patients with ILD or CKD|
88891621|NCT05914909|Placebo Comparator|Part B: Placebo in patients with ILD or CKD|
88891622|NCT05913544|Experimental|SINTYA group|
88891623|NCT05913544|No Intervention|Control|
88891624|NCT05912257|Experimental|NOSH|Multi-Targeted NOSH + Exercise (NOSH Regimen) Arm
88891625|NCT05912257|Active Comparator|Typical Regimen|Typical Regimen Arm
88891626|NCT05907213|Experimental|Loading dose Ketamine|Loading dose of ketamine in 3+3 MTD for 1 hour followed by maintenance 0.05mg/kg/hr ketamine 11-hour infusion.
88891627|NCT05904743|Experimental|Afrezza (Technosphere Insulin) + insulin degludec|The Afrezza-Degludec group will inhale Afrezza at meals and corrections and will inject insulin degludec once a day for the 17 weeks of the RCT Phase. Dexcom CGM will be provided. The Afrezza-Degludec group will continue to use Afrezza and insulin degludec for an additional 13 weeks in the Extension Phase.
88891628|NCT05904743|Active Comparator|Usual Care: Insulin delivery with either MDI, a pump without automation, or an AID system and CGM|The Usual Care group will continue to receive insulin as they did before the study. This could be by injections or by using an insulin pump with or without automation for the 17 weeks of the RCT Phase. Participants will continue to use their personal CGM as they did before the study. The Usual Care group will then use Afrezza and insulin degludec for 13 weeks in the Extension Phase. Dexcom CGM will be provided during the Extension Phase.
88891629|NCT05904522|Experimental|lesional skin|lesional skin of mycosis fungoides stage 1A patients
88891630|NCT05904522|Experimental|non-lesional skin|non-lesional skin of mycosis fungoides stage 1A patients
88891631|NCT05902780|Active Comparator|Group B (25 patients)|In this group, and after induction of general anesthesia, pediatric patients will receive a caudal injection of bupivacaine 0.125 % in a dose of 1ml/kg.
88891632|NCT05902780|Active Comparator|Group D (25 patients)|In this group, and after induction of general anesthesia, pediatric patients will receive a caudal injection of dexmedetomidine in a dose of 1.5 mcg/kg.
88891633|NCT05888831|Experimental|Dose Escalation: BMS-986449 monotherapy|
88891634|NCT05888831|Experimental|Dose Escalation: BMS-986449 + nivolumab|
88891635|NCT05888831|Experimental|Dose Escalation: BMS-986449 monotherapy pharmacodynamic (PD) cohorts|
88891636|NCT05887284|Experimental|Low dose Radiation Therapy|In the test group, patients receive radiotherapy with six fractions of 0.5 Gy each over a period of 3 weeks, with 2 doses applied per week (total dose 3.0 Gy). After the 1st follow-up (3 months after radiotherapy), patients receive the patients in both arms have the option to receive a 2nd series of radiotherapy in consultation with the study physician if no improvement in symptoms has occurred or patients are still not sufficiently satisfied with the outcome (this decision is still made by the physician and patient in a blinded manner). The patients from the test group receive another irradiation series with six fractions of 0.5 Gy each according to the same schedule as before (total dose 3.0 Gy and in sum with the first series 6.0 Gy).
88891637|NCT05887284|Placebo Comparator|Mock Radiation Therapy|In the control group, patients receive sham irradiation with six fractions of 0.0 Gy each over a period of 3 weeks, with 2 treatments per week. After the 1st follow-up (3 months after radiotherapy), patients receive the patients in both arms have the option to receive a 2nd series of radiotherapy in consultation with the study physician if no improvement in symptoms has occurred or patients are still not sufficiently satisfied with the outcome (this decision is still made by the physician and patient in a blinded manner). The patients in the control group, on the other hand, now also receive a radiotherapy with six fractions of 1.0 Gy each over a period of 3 weeks with 2 fractions per week (total dose 6.0 Gy).
88891638|NCT05883410|Experimental|PNF Treatment Group|Hold-relax is a PNF technique will be applied to this group.
88891639|NCT05883410|Active Comparator|Mulligan Mobilization Treatment|The Mobilization with movement (MWM) technique will be applied to this group.
89414047|NCT04993222|Experimental|Sequence TR|6 healthy subjects assigned to the sequence TR were administrated intravenously for 120 mins with the test product of amphotericin B liposome for injection in period 1 and the reference product of AmBisome® in period 2.
89414048|NCT04993222|Experimental|Sequence RT|6 healthy subjects assigned to the sequence RT were administrated intravenously for 120 mins with the reference product of AmBisome® in period 1 and the test product of amphotericin B liposome for injection in period 2.
88922063|NCT05878691|Experimental|GRC 54276 with atezolizumab|
88922064|NCT05878548|Experimental|fixation with Wagner technique and Telescoping nail|corrective osteotomy and intramedullary telescoping nail for deformed femur and Wagner technique to fix NOF fracture
89414049|NCT01147653|Active Comparator|Autologous UCB Reinfusion First,Then Placebo|Subjects receive their autologous umbilical cord blood cells at Baseline, than placebo at Year 1.
89414050|NCT01147653|Placebo Comparator|Placebo First, Then Autologous UCB Reinfusion|Subjects receive placebo at Baseline, then autologous umbilical cord blood cell reinfusion at Year 1.
89414051|NCT04993378||GC patients receiving immunotherapy|
89414052|NCT04065087|Experimental|GX-I7|GX-I7 administered until Progression of Disease
89414053|NCT04065087|Placebo Comparator|Placebo|Placebo administered until Progression of Disease
89414054|NCT03076762|Experimental|Intravesical suburothelial injection|Patients assigned for suburothelial injections received 100 U of onabotulinumtoxinA in 20 sites injected in the bladder body on treatment day and follow-up
89414055|NCT03076762|Active Comparator|Intravesical trigonal injection|Patients assigned trigonal injections will receive 100U of onabotulinumtoxinA at 10 sites injected at the trigonal area (5 injections behind interureteric ridge and 5 inside the trigone) on treatment day and follow-up.
89414056|NCT03073252|Experimental|Normal Protein|Consumption of normal protein (NP) meal
88922065|NCT05876546|Experimental|Liquid bandage|liquid bandage - The liquid bandage will be distributed on a contact test filter paper disc, appropriately identified, in the letter of the alphabet corresponding to the experimental product.
88922066|NCT05876546|Sham Comparator|Saline Solution|saline solution - The sterile saline solution (NaCl 0.9%) will be used as control in another contact test filter paper disc, appropriately identified, in the letter of the alphabet corresponding to the control.
88922067|NCT05876091|Experimental|Vaping -|"Description The order of directed and ad libitum bouts are randomized within participants at each session.~SESSION 1: Participants puff their own brand liquid on study.~SESSIONS 2-5: Participants puff 1 of 4 randomly assigned tobacco flavor formulations at each visit on study.~SESSIONS 6-7: Participants puff 1 of 2 randomly assigned nicotine formulations at each visit on study.~Participants also undergo collection of saliva samples and optionally undergo collection of oral cell and oral rinse samples throughout study."
88922068|NCT05868850|No Intervention|Routine care group|The control group receives routine nursing, including admission education, routine nursing of adverse reactions to chemotherapy, diet guidance for chemotherapy patients, precautions for various examinations, discharge guidance and follow-up.
88922069|NCT05868850|Experimental|Auricular point sticking group|Auricular point sticking therapy is performed on the basis of control group. The acupoint intervention group is established, and the research team consists of 2 graduate students, 1 graduate supervisor, 1 head nurse, 1 chief physician of traditional Chinese medicine, and 1 nursing expert. The nursing expert is responsible for the overall design of the project, and the director of traditional Chinese medicine is responsible for the selection of acupoints and the training of nurses for massage. The supervisor of graduate students and the head nurse are responsible for the overall quality control of the intervention process, while the graduate students are responsible for the preliminary and final screening of research objects, the implementation of intervention programs, the organization, coordination and recording of the entire intervention process and the collection of data.
88922070|NCT05865002|Experimental|AUR107, 5mg to 200mg|Currently, planned dose levels are 5 mg QD, 10 mg QD, 20 mg QD, 40 mg QD, 60 mg QD, 90 mg QD, 135 mg QD, and 200 mg QD
89414057|NCT03073252|Experimental|High Protein|Consumption of high protein (HP) meal
89414058|NCT04993456||POAF group|the patients will have atrial fibrillation following the cardiac surgery
89414059|NCT04993456||non-POAF group|the patients will have no atrial fibrillation following the cardiac surgery
89414060|NCT02747043|Experimental|ABP 798|ABP 798 was administered at a dose of 375 mg/m^2 as an intravenous (IV) infusion once weekly for 4 weeks followed by dosing at weeks 12 and 20.
89414061|NCT02747043|Active Comparator|Rituximab|Rituximab was administered at a dose of 375 mg/m^2 as an IV infusion once weekly for 4 weeks followed by dosing at weeks 12 and 20.
89414062|NCT03075514|Active Comparator|Modified ketogenic diet (MKD)|MKD: 80% fat and 5% carbohydrate (% of total energy requirements per day).
89414063|NCT03075514|Active Comparator|Medium chain triglyceride (MCT) diet|MCT: 75% fat (30% of which is medium chain fatty acids taken as a supplement) and 5% carbohydrate (% of total energy requirements per day).
89414064|NCT05004142|Experimental|FCN-437c with Fulvestrant|FCN-437c 200mg, oral administration under fasting conditions, QD, for 21 days, with 7-day discontinuation, 28 days for 1 cycle; Fulvestrant, C1D1 and C1D15 and Day 1 of each cycle, 500mg/day, intramuscularly.
89414065|NCT05004142|Experimental|FCN-437c in combination with Letrozole + Goserelin|FCN-437c 200mg, oral administration under fasting conditions, QD, for 21 days, with 7-day discontinuation, 28 days for 1 cycle; Letrozole 2.5 mg, QD, for continuous dosing; Goserelin 3.6 mg, subcutaneously, once every 28 days.
89414066|NCT03076684|Experimental|low-fructose diet|Intervention: low-fructose Subjects will consume a four-month diet with the goal of reducing added sugar intake from ≥13% of energy to <5% of energy and keeping their weight stable.
89414067|NCT03076684|Experimental|allopurinol treatment|Subjects participating in the allopurinol treatment arm will begin with an initial dose of drug of 100 mg/d p.o. daily for 2 wks. The dose is then slowly increased over the next 8 wks to achieve a serum uric acid concentration of 6 mg/dL (maximum allopurinol dose is 800 mg/d). Once uric acid reaches 6 mg/dL, the subject stays on this dose and is seen for the interim visit (4 months), at which time all procedures are repeated. After this, drug treatment continues for another 4 months and the subject returns for the final visit at 8 months. The same procedures performed at baseline are repeated at this time. The dose of allopurinol will be taken the morning of the final visit.
89414068|NCT03076684|No Intervention|control arm|After completion of the baseline visit (procedures described above), subjects participating in the control arm are not seen again until the 4-month time point, when the same procedures performed at baseline are repeated, except for the MRI. Following this, they are seen again at 8-months, when all baseline procedures are repeated. Cardiac MRI and labeled water consumption occur at the baseline and final visits.
89414069|NCT02034903|No Intervention|Standard warming|Feeding warmed in water bath
89414070|NCT02034903|Experimental|Commercial warmer|Feedings warmed with a commercial warmer
89414071|NCT04999930|Experimental|Group A|with aerochamber
89414072|NCT04999930|Experimental|Group B|without aerochamber
89414073|NCT03607851|Active Comparator|Conventional titration group|
89414074|NCT03607851|Experimental|Rapid titration group 1|
89005559|NCT04568473|Active Comparator|Duraphat® (Colgate Palmolive Company, New York, NY)|It is attributed to the reactivity of the fluoride by adsorbing to the surface and attracting calcium ions forming loosely-bound calcium fluoride (CaF2)- like reservoir which is also considered responsible for the anticaries mechanism and protection against cariogenic acid attack.
89414075|NCT03607851|Experimental|Rapid titration group 2|
89005560|NCT04568278|Experimental|Intervention Group|a mobile application using the PRO-CTCAE along with usual care
89414076|NCT04999540|Experimental|Tucidinostat + Fulvestrant|"Patients receive 30 mg Chidamide twice per week. Fulvestrant 500mg (2 syringes of Fulvestrant 250mg), Fulvestrant 500 mg i.m. every 28 (+/- 3) days plus an additional 500 mg on day 14 (+/-3) of first month only.~Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity."
89414077|NCT03607773|Active Comparator|Mindfulness Behavioural Intervention (MBI) group|10 one-hour mindfulness sessions
89414078|NCT03607773|No Intervention|Control group|Standard of care.
89414079|NCT03608007|Experimental|X-396 Capsule|Single-arm trial whereby all consented, enrolled, eligible patients receive X-396 capsule, 225 mg once daily.
89414080|NCT02637076|Experimental|narcolepsy with cataplexy|patients given single dose of Xyrem
89199107|NCT02543229|Experimental|Part 2 Dose expansion - Cohort 5|OPT-302 (at Maximum Tolerated Dose [MTD] or highest dose tested in Part 1) in combination with Lucentis™
89005561|NCT04568278|No Intervention|Controlled Group|Usual care
88891641|NCT05877196|Experimental|Moderate Intensity Continuous Training (MICT)|Cycling on recumbent stationary cycle at moderate intensity for 30-50 minutes, 3 times per week for 3-6 months
88891642|NCT05877196|Sham Comparator|Chair-based Stretch|Stretching at low intensity for 30-50 minutes, 3 times per week for 6 months
88891643|NCT05877196|Active Comparator|High-Intensity Interval Training (HIIT)|MICT for 3 months, and then cycling on recumbent stationary cycle at alternate high and moderate intensity for 40 minutes, 3 times per week for 3 months.
88891644|NCT05877196|Active Comparator|Combined Aerobic Resistance Exercise (CARE)|MICT for 3 months, and then cycling on recumbent stationary cycle at moderate intensity for 30 minutes, followed by 20-minute strength-building exercise, 3 times per week for 3 months.
88891645|NCT05869773|Experimental|JZP258|Participants will receive 6 to 9 grams per night of JZP258 (XYWAV) for 6 consecutive weeks.
88891646|NCT05864872|Experimental|Ultrasound group|after blockage of the principal four nerves of the brachial plexus, the needle was redirected, and between 1 and 2 mL of bupivacaine was injected around each visible nerve branch (Intercostobrachial and Medial Brachial Cutaneous ); if the nerve branches were not visible, 5 mL of the local anesthetic was injected (or less volume if the nerves appeared during the injection), in the subcutaneous area located above the brachial fascia, with a posterior direction, toward the latissimus dorsi muscle.
88891647|NCT05864872|Active Comparator|conventional group|after blockage of the principal four nerves of the brachial plexus, 3 to 6 mL of bupivacaine (at the discretion of the anesthesiologist) was infiltrated blindly subcutaneously at the same level of the axilla in the anteroposterior direction prior to complete needle withdrawal
88891648|NCT05862545||COPD patients|Patients with COPD that start BGF treatment (The decision to prescribe BGF must be independent of enrolment into the study, must be determined by the treating physician and should be taken according to the standard of current best medical practice and national guideline)
88891649|NCT05857644|Experimental|Healthy subjects|One time dose of 4 capsules taken orally.
88891650|NCT05857644|Experimental|Mild Hepatic impaired subjects|One time dose of 4 capsules taken orally.
88891651|NCT05857644|Experimental|Moderate hepatic impaired subjects|One time dose of 4 capsules taken orally
88891652|NCT05857644|Experimental|Severe Hepatic Impaired Subjects|One time dose of 4 capsules taken orally.
88891653|NCT05853289|Experimental|Jail staff at pilot jails|Jail staff will be asked to use the implementation resource with guided facilitation to care for pregnant people in and leaving custody.
88891654|NCT05842174|Experimental|Transarterial Embolization with Hydroxychloroquine|Intra-arterial hydroxychloroquine in Lipiodol + transarterial embolization followed by oral hydroxychloroquine
88891655|NCT05842174|Placebo Comparator|Transarterial Embolization without Hydroxychloquine|Intra-arterial Lipiodol + transarterial embolization followed by oral placebo
88891656|NCT05840471|Active Comparator|Tranexamic acid group|This interventional arm will receive tranexamic acid 1 g(10ml) (2 ampules each of 500 mg, 5ML) of tranexamic acid in 20 ml glucose water 5% intravenously twice daily in the acute stage of bleeding for 48 hours. This will be followed by 500 mg tranexamic acid tablets (Trenaxa; Macleods Pharmaceuticals Pvt. Ltd.) three times daily for five days. Participants will be followed up for recurrence of bleeding during pregnancy. The course of treatment will be repeated again if bleeding recurred. The hospital data safety and monitoring board ensured the continued safety of the Participants.
88891657|NCT05840471|Placebo Comparator|Glucose water group|Participants will receive 30 mL of 5% glucose water slowly intravenously immediately during the attack of the bleeding, twice daily for 48 hours. Accompanied with the usual expectant management care.
88891658|NCT05840107|Experimental|GC012F treatment|CAR-T will be infused at a dose of 0.6,1.5,3 x 10^5 CAR-T cells/kg after receiving lymphodepleting chemotherapy. Lenalidomide maintenance therapy will be given post month 6 at physicians' choice.
88891659|NCT05827978|Experimental|mRNA-1010|Participants will receive a single dose of mRNA-1010 by intramuscular (IM) injection on Day 1.
89414081|NCT02637076|Experimental|healthy controls|healthy controls given a single dose of Xyrem
89414082|NCT02034669|Experimental|Treatment with ADSCs transplantation|4 Intervention: laminectomy, intradural space at damage site, intrathecal at lumbar puncture, intravenous
89414083|NCT02034669|No Intervention|Treatment without ADSCs transplantation|Only intervention: laminectomy
89414084|NCT02237391|Experimental|CIPAP Program|Complex Interdisciplinary Pain Assessment Program
89414085|NCT02237391|Other|Treatment as Usual (TAU)|Treatment as usual control group
89414086|NCT03075358|Experimental|Lidocaine spray|
89193002|NCT05779761|Experimental|Attention and Reflective Thought Skills Training|Participants assigned to Attention and Reflective Thought Skills Training will receive 6-weeks of self-directed, online skills training on attention and metacognitive regulation skills for coping with distress. Six weekly modules will include 10-15 minutes of narrated videos, as well as suggestions for activities and skills practices between modules. Participants will also schedule weekly, 5-10 minute calls with an assigned skills training coach to discuss the participant's experience with the skills training.
89414087|NCT03075358|Sham Comparator|Normal saline spray|
89414088|NCT03075358|No Intervention|No spray|
89414089|NCT05003284|Experimental|acupressure wristband|On the day before the surgery, the patients in the experimental groups were introduced to the wristband and given an explanation regarding how it should be used. Approximately 30 minutes before the experimental group patients went to surgery, the PC6 acupressure point was determined for the patients. Immediately after the experimental group patients were taken to the wards after surgery, wristbands were placed on both wrists. İt was stated to the patients that the wristbands should remain on for 24 hours. The wristband was removed at the end of the 24th hour.
89414090|NCT05003284|Placebo Comparator|placebo wristband|On the day before the surgery, the patients in the placebo groups were introduced to the wristband and given an explanation regarding how it should be used. Approximately 30 minutes before the placebo group patients went to surgery, the PC6 acupressure point was determined for the patients. Right after their surgery, patients in the placebo group were fitted with a wristband that looked the same as the acupressure wristband but did not have an acupressure application head. İt was stated to the patients that the wristbands should remain on for 24 hours. The wristband was removed at the end of the 24th hour.
89414091|NCT04999150|Active Comparator|Corticotomy|"A full-thickness labial mucoperiosteal flap was reflected.~Two vertical corticotomies (1 mesial and 1 distal to the canine) were performed . The cortical bone was cut 2 to 3 mm below the alveolar crest towards the apex until bone marrow was exposed.~Cortical-cancellous bone grafts (0.5cc; PuraGraft, Kingwood, TX) were placed at the corticotomy sites.~The mini-screws were placed.~A nickel-titanium (NiTi) closed-coil spring was placed and secured with a 0.014SS ligature wire at the canine and mini-screw. A Dontrix gauge (Orthopli Corp., Philadelphia, PA) was used to measure the force (150g)."
89414092|NCT04999150|Experimental|Micro-Osteoperforation|"MOPs were performed with a stainless-steel manual drill tip that had 1.6mm diameter with an adjustable depth set to 5mm (Excellerator® RT; Propel Orthodontics, Milpitas, CA).~Six perforations were made along 2 parallel vertical lines (each line with 3 holes spaced ~2mm apart) distal to the canine and perpendicular to the buccal cortical bone.~The mini-screws were placed.~A NiTi closed-coil spring was placed and secured with a 0.014SS ligature wire at the canine and mini-screw. A Dontrix gauge was used to measure the force (150g)."
89414093|NCT03073330|Experimental|One Step|The intervention is gestational diabetes screening with 2 hour GTT 75 g load.
89414094|NCT03073330|Active Comparator|Two Step|There is no intervention is this arm as patients will subjected to routine gestational diabetes screening with one hour glucola, 50 g load.
88891660|NCT05827978|Active Comparator|Licensed Quadrivalent Inactivated Seasonal Influenza Vaccine|Participants will receive a single dose of licensed quadrivalent inactivated seasonal influenza vaccine by IM injection on Day 1.
88891661|NCT05818085|Experimental|ABP-671|
88891662|NCT05818085|Active Comparator|Allopurinol|
89414095|NCT02854605|Experimental|GS-9674 30 mg|GS-9674 30 mg + placebo to match GS-9674 100 mg for 24 weeks
88891663|NCT05818085|Placebo Comparator|Placebo|
89414096|NCT02854605|Experimental|GS-9674 100 mg|GS-9674 100 mg + placebo to match GS-9674 30 mg for 24 weeks
89414097|NCT02854605|Placebo Comparator|Placebo|Placebo to match GS-9674 30 mg + placebo to match GS-9674 100 mg for 24 weeks
88891664|NCT05813288|Experimental|150 mg BID|Dexpramipexole 150 mg oral tablet taken twice a day
88891665|NCT05813288|Experimental|75 mg BID|Dexpramipexole 75 mg oral tablet taken twice a day
88891666|NCT05813288|Placebo Comparator|Placebo|Placebo oral tablet taken twice a day
88891667|NCT05790668|Experimental|Evaluation of PIA-Informed Schedule Thinning|The goal of Arm 1 will be to will extend pilot work on the utility of individualizing the starting point for reinforcement schedule thinning based on the results of a progressive-interval assessement (PIA). The investigators will do so by conducting reinforcement schedule thinning using a multielement design in two separate contexts, one informed by the results of a PIA and another not so informed. The criteria for schedule thinning will be identical across both conditions but will be applied to each condition independently. Investigators will determine the efficiency of schedule thinning, reductions of destructive behavior, and durability of functional communication responses across the two conditions.
88891668|NCT05790668|Experimental|Evaluation of Competing Items|The goal of Arm 2 will be to evaluate the utility of competing items (e.g., alternative reinforcement or activities) during schedule thinning. Both conditions will be informed by the PIA, similar to the experimental condition in Arm 1. PIA-informed schedule thinning with competing stimuli will be identical to that of PIA-informed schedule thinning, except (a) the therapist will provide continuous access to the highly competing stimulus identified by that participant's competing stimulus assessment (e.g., providing attention while an iPad is unavailable, playing music while working), and (b) it will occur in the other context (e.g., the yellow context). Investigators will determine the efficiency of schedule thinning, reductions of destructive behavior, the durability of functional communication responses across the two conditions, and resurgence of destructive behavior during prolonged periods of extinction.
88922071|NCT05861947|Experimental|AUR106|25mg to 100 mg, Currently planned dose levels are 25 mg QD, 50 mg QD, 25 mg BID, 50 mg BID, 100 mg BID
89414098|NCT04992910|Experimental|Functional Electrical Stimulation|
89414099|NCT04992910|Active Comparator|Standard Therapy|
89414100|NCT04992988|Experimental|Toripalimab+CCRT|"Cisplatin 100mg/m2(every three weeks),D1,D22,D43 of intensity modulated radiotherapy.~Toripalimab 240mg every 3 weeks with a total of 3 cycles as concurrent anti-PD-1 immunotherapy; Toripalimab240mg every 3 weeks with a total of 9 cycles as adjuvant anti-PD-1 immunotherapy 3 weeks after CCRT"
89414101|NCT03073096|Other|Intervention arm|LVA at time of nodal dissection
89199108|NCT02543229|Experimental|Part 2 Dose expansion - Cohort 6|OPT-302 (at MTD or highest dose tested in Part 1) monotherapy
89199109|NCT02543073|Experimental|MSCs|MSCs will be given the patients in MSCs group. Besides, azithromycin (AZM) and glucocorticoid will also be administered.
89414102|NCT05003596|Experimental|Steroid Group|Patients receive 21 tablets of 4 mg methylprednisolone to be taken by mouth over a 6 week taper. Patients will be advised to not take other anti-inflammatory medications like NSAIDs.
89414103|NCT05003596|Active Comparator|Control Group|Patients will recieve standard treatment that focuses on mobilization and stabilization using common techniques like buddy taping and splinting. Pain control will be managed using non-NSAID medications like Tylenol or opioid narcotics when deemed medically necessary.
89414104|NCT03607929|Experimental|optimal and hydration|Physiological Saline Solution 300 ml/h AND drink freely mineral water during labor
89414105|NCT03607929|Active Comparator|variability and hydration|Other Solutions >o < 300 ml/h AND uncontrolled drink during labor
89005562|NCT04568317|Experimental|Smartwatch group|iCBT intervention 'Space from Depression' with smartwatch as an additional means to self-report data on mood, sleep and physical activity in the 'Space from Depression' program (n=35).
89005563|NCT04568317|Active Comparator|Treatment as usual group|iCBT intervention 'Space from Depression' (n=35).
89005564|NCT04567966|Experimental|Cortical bone plate|A cortical plate was harvested from the external oblique ridge and split in half. Then one plate was fixed at a distance from the atrophied ridge and autogenous bone chips were used to fill the gap between the plate and the ridge.
89414106|NCT04433572|Active Comparator|Temsirolimus|Temsirolimus delivered to adventitia and perivascular tissue after primary revascularization
89414107|NCT04433572|Placebo Comparator|Placebo|Saline placebo delivered to adventitia and perivascular tissue after primary revascularization
89414108|NCT03606135||The Pneumonia Group|Subjects with chest images (x-ray or CT scan) indicating pneumonia.
89414109|NCT03606135||The Control Group|Healthy subjects
89414110|NCT03072940||Patients with idiopathic RBD|
88922072|NCT05861934|Experimental|Distant reiki group|To examine the effect of distant reiki application on pain, functional status and sleep quality in rheumatoid arthritis patients.
89414111|NCT03072940||Healthy volunteers|
89414112|NCT03073018|Experimental|Fosinopril + Pravastatin|Fosinopril (20 mg) + pravastatin (40 mg) once daily for 4 years
89414113|NCT03073018|Active Comparator|Fosinopril + Placebo|Fosinopril (20 mg) + pravastatin placebo once daily for 4 years
89414114|NCT03073018|Active Comparator|Pravastatin + Placebo|Pravastatin (40 mg) + fosinopril placebo once daily for 4 years
88922073|NCT05861934|No Intervention|Control group|Control group; routine care and treatment will be applied.
88922074|NCT05852756|Experimental|Experimental:|pecha kucha will be practiced
88922075|NCT05852756|No Intervention|control|Routine maintenance will be applied.
89414115|NCT03073018|Placebo Comparator|Double Placebo|Fosinopril placebo and pravastatin placebo once daily for 4 years
89414116|NCT03607617||Wedge 1|Five randomized clinics will implement SDH tool.
89414117|NCT03607617||Wedge 2|Five randomized clinics implement SDH tool 24 weeks following prior wedge implementation.
89414118|NCT03607617||Wedge 3|Five randomized clinics implement SDH tool 24 weeks following prior wedge implementation.
89414119|NCT03607617||Wedge 4|Five randomized clinics implement SDH tool 24 weeks following prior wedge implementation.
89414120|NCT03607617||Wedge 5|Five randomized clinics implement SDH tool 24 weeks following prior wedge implementation.
89414121|NCT03607617||Wedge 6|Five randomized clinics implement SDH tool 24 weeks following prior wedge implementation.
89414122|NCT05003206|Experimental|PD,DBS|Patients with idiopathic PD before and after DBS surgery
89414123|NCT03607461|Experimental|Smartphone App Users|Smartphone App Users will receive important information and prescriptive exercise via a smartphone app upon returning home from the hospital following total knee arthroplasty
89414124|NCT03607461|Active Comparator|Home Health Users|Home Health Users will have already undergone traditional home health physical therapy and/or skilled nursing for the purpose of comparing outcomes
89414125|NCT06205277||Patients with pT1 NMIBC who underwent second TURBt|Patients with pT1 NMIBC who underwent second TURBt after a macroscopically completede first TURBt within 6-8 weeks
89414126|NCT06205264|Experimental|Fast Group|"Effect of strength training on executive functions in children.~Strength training sessions will have a frequency of 3 times per week (Monday, Tuesday and Wednesday) for 8 weeks. In addition, each subject is subject to an individualized training program according to the workload in order to progressively increase the intensity of work. The workload will be modified progressively by influencing both the total volume of repetitions and the intensity of the exercises. The multi joint exercises will be controlled movements and not harmful, but at maximum speed during the concentric phase of the exercise."
89414127|NCT06205264|Experimental|Conventional Group|"Effect of strength training on executive functions in children.~Strength training sessions will have a frequency of 3 times per week (Monday, Tuesday and Wednesday) for 8 weeks. In addition, each subject is subject to an individualized training program according to the workload in order to progressively increase the intensity of work. The workload will be modified progressively by influencing both the total volume of repetitions and the intensity of the exercises. This group will perform each phase of the planned exercises at a constant speed."
89414128|NCT06205238|Experimental|Domiciliary CGA|The intervention will consist of domiciliary CGA including nursing, medical and allied health assessment and intervention for frail older adults over age 75 who are discharged from the ED and referred to the CST in Limerick. The bulk of this intervention will be delivered in the patient's own home. Each participant will be required to attend the hub for their medical review where they will access specialist geriatric medical expertise. A domiciliary visit to the older person within 24-48 hours of referral from the ED by a member of the team. This person will act as the case coordinator for the duration of the intervention. During this visit, there will be a detailed assessment of the older adult. Referrals will be made for domiciliary care to the appropriate healthcare professionals based on patient. Interventions prescribed will be individualised based on patient needs. We will use the template proposed by Ellis et al. (2017) to characterise the components of the CGA intervention.
89414129|NCT06205238|Active Comparator|Hub-based CGA|CGA as defined above delivered in an Out-patient setting.
89414130|NCT06205212|Active Comparator|facemask|preoxygenation using a conventional facemask
89414131|NCT06205212|Experimental|high-flow nasal oxygen|preoxygenation using high-flow nasal cannula oxygen
89414132|NCT06205173|No Intervention|Control group|According to the traditional care model, no interventions are applied to the hands and feet.
89414133|NCT06205173|Experimental|Hot compressing group|Temperature control will be maintained within the range of 37-38 degrees Celsius.The application will commence 15 minutes before the administration of Oxaliplatin and conclude 15 minutes after the injection.
89414134|NCT06205173|Experimental|Cold compressing group|Temperature control will be maintained within the range of 12-18 degrees Celsius.The application will commence 15 minutes before the administration of Oxaliplatin and conclude 15 minutes after the injection.
89414135|NCT06205160|Experimental|All subjects|
89414136|NCT06205147|Experimental|Short Falls Efficacy Scale International|The Short Falls Efficacy Scale International (Short FES-I) consists of 7 questions. Scores range from a minimum of 7 points (no fear of falling) to a maximum of 28 points (severe fear of falling). Scores of 7 to 8 points indicate low concern about falling, 9 to 13 points indicate moderate concern about falling, and 14 to 28 points indicate high concern about falling.
89414137|NCT06205147|Experimental|Geriatric Depression Scale, GDS 15|"The assessment will be conducted within one week. Depressive symptoms in the elderly will be evaluated using a binary method, with answers of yes or no. Questions 1, 5, 7, 11, and 13 should be answered with no. Questions 2, 3, 4, 6, 8, 9, 10, 12, 14, and 15 should be answered with yes. Each yes response is assigned 1 point, resulting in a total score of 15 points. Scores ranging from 0 to 6 indicate good emotional adjustment, scores from 7 to 10 indicate moderate emotional distress, and scores above 11 indicate severe emotional distress."
89414138|NCT06205108|Experimental|taVNS stimulation|taVNS is a non-invasive technique to stimulate the auricular branch of the vagus nerve. Transcutaneous electrodes are placed in the cymba concha of the ear and short bursts (20Hz, 1s, 400µs pulse widths) of stimulation are delivered either in parallel to the action or the feedback. Stimulation strength is individually calibrated. Stimulation lasts ~1h in the session.
88814012|NCT02248571|Experimental|Arm A|"Bevacizumab plus Capecitabine (1st treatment phase) followed by Everolimus plus Exemestane (2nd treatment phase)~Dosing (treatment cycle: 21days):~Capecitabine: 1000 mg/m2 orally applied twice daily as combined 150 mg and 500 mg tablets on days 1 to 14 of each 21-day cycle, followed by a seven day rest period (i.e. off-treatment) --- Bevacizumab: 15 mg/kg intravenously applied once every three weeks (i.e. 5 mg/kg/wk dose equivalent)~Everolimus: 10 mg/day orally applied tablet --- Exemestane: 25 mg/day orally applied tablet~Patient questionaires to assess patient reported outcome and patients' preference will be completed at four specific time points during study treatment (two timepoints in each treatment phase)"
88891669|NCT05790668|Experimental|Effects of Competing Items on PIA Outcomes|The goal of Arm 3 will be to examine potential interaction effects between the above two experimental arms by conducting PIAs with no, low, moderate, and high competing stimuli to determine the schedule duration at which schedule thinning should commence with each competing stimulus. All participants will complete this arm prior to enrollment in Arms 1 or 2. The investigators will randomize the sequence of each of the four PIAs (PIA with no competing stimuli, PIA with low competing stimuli, PIA with moderately competing stimuli, PIA with highly competing stimuli) across participants.
88891670|NCT05790005|Experimental|Intervention group|A therapeutic play will be played for 20 minutes after the warm-up play for 10 minutes before the first surgical dressing to be applied after the surgery with children in the 7-12 age groups. There will be 46 children in the intervention group.
88891671|NCT05790005|No Intervention|Control group|Therapeutic play will be not played for 20 minutes after the 10-minute warm-up game before the first surgical dressing to be applied after the surgery with children in the 7-12 age group. The routine procedure applied in the service before the dressing process will be applied. There will be 46 children in the control group.
88891672|NCT05775471|Experimental|Treatment (pembrolizumab, enfortumab vedotin)|Patients receive pembrolizumab IV and enfortumab vedotin IV on study. Patients undergo radical nephroureterectomy and receive pembrolizumab IV on study Patients also undergo MRU imaging and undergo blood, urine and tissue sample collection throughout the study.
88891673|NCT05768347|Experimental|Treatment with Adoptive Cell Therapy|TIL from bladder biopsies will be propagated and cultured with interleukin-2 (IL-2) to a target goal of >30 million cells. These TIL then undergo rapid clonal expansion (REP) by incubation with anti-CD3 monoclonal antibody (mAb), resulting in >500-fold expansion. After 4-6 weeks culture time intravesical TIL will be administered via intravesical infusion, consisting of up to 3.2e8 cells in 40 mL aliquot. Intravesical therapy will be administered for up to 2 hours. This treatment will occur four times (Day 0, Day 7, Day 14 and Day 21).
88891674|NCT05765851|Experimental|Dose Escalation: DS-1103a + T-DXd|Participants with HER2-expressing or HER2-mutant advanced metastatic solid tumors who will receive an intravenous (IV) infusion of DS-1103a (starting dose of 100 mg) every 3 weeks (Q3W) starting on Cycle 1 Day 1. Starting on Cycle 2 Day 1 and on Day 1 of each subsequent cycle, participants will also receive T-DXd Q3W at a dose of 5.4 mg/kg.
88891675|NCT05765851|Experimental|Dose Expansion: DS-1103a + T-DXd|Participants with HER2-low expressing breast cancer who will receive an IV infusion of DS-1103a at the recommended dose for expansion (RDE) in combination with T-DXd 5.4 mg/kg Q3W starting on Cycle 1 Day 1.
88891676|NCT05765318|Experimental|QLB group|"At the end of surgery, before emergence of anesthesia, participants will receive bilateral QLB and intravenous (IV) ketoprofen 100 mg. Ketoprofen 100 mg IV will be repeated every 12 hours.~For breakthrough pain patients will receive an IV bolus of morphine 5 mg. IV bolus can be repeated after 20 min. The maximum is 8 boluses for 4 hours."
88891677|NCT05765318|No Intervention|Control group|"At the end of surgery, before emergence of anesthesia, participants will receive IV ketoprofen 100 mg. Ketoprofen 100 mg IV will be repeated every 12 hours.~For breakthrough pain patients will receive an IV bolus of morphine 5 mg. IV bolus can be repeated after 20 min. The maximum is 8 boluses for 4 hours."
88891678|NCT05763719|Active Comparator|Rabbits for Resilience (RFR) + HIKA|Households randomly selected for RFR + HIKA will consent to one adolescent (age 10-14 years) to participate in RFR, a youth led animal husbandry economic empowerment intervention, where each youth is provided training and mentorship on raising rabbits. Once the adolescent builds the rabbit cage, the adolescent receives a loan of 2 rabbits to raise and breed, once the rabbit produces offspring, the adolescent repays the rabbit loan with 2 rabbits, one to repay the loan and one to repay the interest on the loan. The original rabbits and the remaining offspring are then for the adolescents to continue to raise, breed, sell, or eat with mentorship from the RFR team and other family members. Parents (mother and father) will consent to complete a 22 week couple's curriculum to increase gender equality (e.g. shared decision making, improved communication and reduced partner violence). The curriculum is delivered for 3 hours weekly by trained facilitators with 12 couples per group.
88891679|NCT05763719|Active Comparator|Rabbits for Resilience (RFR) only|Households randomly selected for RFR only will consent to one adolescent (age 10-14 years) to participate in RFR, a youth led animal husbandry economic empowerment intervention, where each youth is provided training and mentorship on raising rabbits. Once the adolescent builds the rabbit cage, the adolescent receives a loan of 2 rabbits to raise and breed, once the rabbit produces offspring, the adolescent repays the rabbit loan with 2 rabbits, one to repay the loan and one to repay the interest on the loan. The original rabbits and the remaining offspring are then for the adolescents to continue to raise, breed, sell, or eat with mentorship from the RFR team and other family members.
88891680|NCT05763719|Active Comparator|HIKA only|Households randomly selected for HIKA, parents (mother and father) will consent to complete a 22 week couple's curriculum to increase gender equality (e.g. shared decision making, improved communication and reduced partner violence). The curriculum is delivered for 3 hours weekly by trained facilitators with 12 couples per group.
88891681|NCT05763329|Experimental|Lemborexant|Patients will receive two treatment sequences. Participants will complete two overnight sleep studies and cross-over with 1-week wash-out period The participants will receive Lemborexant 5 mg per day 5 minutes before lights-out for one dose for the first overnight sleep test of the experiment. After 1 week wash-out period, the participants will cross to the placebo arm and receive placebo 5 minutes before lights-out for one dose for the second overnight sleep test of the experiment.
88891682|NCT05763329|Placebo Comparator|Placebo|Patients will receive two treatment sequences. Participants will complete two overnight sleep studies and cross-over with 1-week wash-out period The participants will receive placebo 5 minutes before lights-out for one dose for the first overnight sleep test of the experiment. After 1 week wash-out period, the participants will cross to the Lemborexant arm and receive Lemborexant 5 mg per day 5 minutes before lights-out for one dose for the second overnight sleep test of the experiment.
88891683|NCT05763121|Experimental|150 mg BID|Dexpramipexole 150 mg oral tablet taken twice a day
88891684|NCT05763121|Experimental|75 mg BID|Dexpramipexole 75 mg oral tablet taken twice a day
88891685|NCT05763121|Placebo Comparator|Placebo|Placebo oral tablet taken twice a day
88891686|NCT05757219|Experimental|Pre-Modulation Treatment|Participants will receive itacitinib 200 mg PO QD beginning at time of apheresis approximately 4-6 weeks prior to CAR-T-cell therapy and will continue until Day 30 (30 Days Post-CAR-T-cell therapy)
88891687|NCT05756582||Health-care workers and students|The study will involve all health-care workers of Fondazione Policlinico Universitario A. Gemelli IRCCS in Rome - a tertiary reference hospital with over 1,500 beds - and all students of all three-year and single-cycle degree courses, master's degree courses, graduate schools of the faculty of Medicine and Surgery of the Catholic University of Sacred Heart in Rome, trained at the Fondazione Policlinico Universitario A. Gemelli IRCCS.
88891688|NCT05754229|Other|AI-assisted colonoscopy|The patients in the intervention group will receive an AI-assisted colonoscopy (AIC) using the computer-aided polyp detection and characterization (CADe and CADx) GI Genius (Medtronic).
88891689|NCT05753436|Active Comparator|Group 1, Curcumin group|Group 1, Curcumin group (n=36): Patients will receive conventional treatment co-administrated with Turmeric Curcumin 500 mg thrice daily for 14 weeks.
88891690|NCT05753436|No Intervention|Group 2, Control group|Group 2, Control group (n= 36): Patients will receive conventional therapy alone for 14 weeks.
88891691|NCT05748600|Experimental|150 mg BID|Dexpramipexole 150 mg oral tablet taken twice a day
88891692|NCT05748600|Experimental|75 mg BID|Dexpramipexole 75 mg oral tablet taken twice a day
89414139|NCT06205108|Sham Comparator|sham stimulation|Stimulation at the earlobe that is not innervated by the vagus nerve with the same parameters (short bursts, 20Hz, 1s, 400µs pulse widths, delivered in parallel to the action or the feedback). Stimulation strength is individually calibrated. Stimulation lasts ~1h throughout the study. Stimulation lasts ~1h in the session.
89414140|NCT06205095|Experimental|pdVWF:FVIII concentrate (Wilate®) Treatment and Standard Care|Wilate® at a dose of 30-60 IU VWF:RCo/kg for the two anticipated heaviest days of bleeding every 24-48 hours within the first 4 days of menstruation will be provided. Additional two optional doses 24-48 hours from the last can be provided. A minimum of 2 doses must be provided.
89414141|NCT06205095|Placebo Comparator|Placebo and Standard Care|Patients randomized to the placebo arm will receive intravenous placebo (normal saline) at the same approximate volume and frequency as the study drug.
88891693|NCT05748600|Placebo Comparator|Placebo|Placebo oral tablet taken twice a day
88891694|NCT05747144||Macular hole|Patients affected by macular hole.
88891695|NCT05747144||Epiretinal membranes|Patients affected by epiretinal membrane.
88891696|NCT05747144||Retinal detachment|Patients affected by retinal detachment.
88891697|NCT05747144||Macular dystrophies|Patients affected by macular dystrophies.
88891698|NCT05740137|No Intervention|Control|Conventional colonoscopy, without AI-assistance.
88891699|NCT05740137|Active Comparator|AI-assisted colonoscopy|AI-assisted colonoscopy (AIC) using a computer-aided polyp detection and characterization (CADe and CADx) system.
88891700|NCT05735639|No Intervention|Compression therapy alone|
88891701|NCT05735639|Experimental|Compression therapy + single dose of low-molecular weight heparin at time of procedure|A single prophylactic dose of low molecular weight heparin (LMWH) (e.g., dalteparin sodium, tinzaparin sodium, enoxaparin sodium) will be prescribed as per standard practice and administered in accordance with the relevant Summary of Product Characteristics (SmPC), manufacturer's recommendations and instructions for use.
88891702|NCT05735639|Experimental|Compression therapy + single dose of LMWH at time of procedure + extended course of LMWH or DOAC|An extended duration of LMWH (e.g., dalteparin sodium, tinzaparin sodium, enoxaparin sodium) or an extended duration of a direct oral anticoagulant (DOAC) (e.g., rivaroxaban, apixaban, dabigatran etexilate) will be prescribed as per current local practice and administered in accordance with the relevant SmPC, manufacturer's recommendations and instructions for use. The duration of this must be at least 7 days, but can be in line with local practice i.e., 7, 10 or 14 days.
88891703|NCT05731544|Experimental|Phase 1 SAD Cohorts|Phase 1 SAD Cohorts with healthy adults randomized 3:1 receiving BMF-219 or placebo.
88891704|NCT05731544|Experimental|Phase 1 single dose food effect sub-study|Phase 1 single dose food effect sub-study with healthy adults randomized 1:1:1:1:1:1 receiving BMF-219 or placebo fasted, with a low-fat meal, and with a high fat meal.
88891705|NCT05731544|Experimental|Phase 1 single dose tablet PK sub-study|Phase 1 single dose x3 PK tablet open-label sub-study with healthy adults randomized 1:1 receiving BMF-219 or placebo fasted, with a low-fat meal, and with a high-fat meal).
89414142|NCT06205069|Active Comparator|Intervention group|"The floss band will be applied to the knee of the dominant lower limb in the intervention group (IG). While the participant will stand and perform a slight knee flexion, the band will be rolled upwards from the tibial tuberosity to 5 cm above the femoral epicondyle. The patella will not be covered. Pressure will be produced by rolling the joint with 50% tension and 50% overlap.~After applying the floss band, passive mobilization will be performed - 20 repetitions of knee flexion and extension and an active movement task - 20 squats. Participants will be instructed to perform knee flexion and extension to their extreme range of motion and to complete the mobility exercises within two minutes. After two minutes, the floss band will be removed and participants will be instructed to stand up and walk for a minute to allow blood to flow back to the foot."
88891706|NCT05731544|Experimental|Phase 2 MAD Cohorts|Phase 2 MAD Cohorts with healthy adults (MAD1) or adults with T2D (MAD 2-8) randomized 3:1 receiving BMF-219 or placebo.
89414143|NCT06205069|No Intervention|Control group|For the CG, after initial assessment, participants without a floss band will perform the same two functional movement tasks (active and passive) with 20 repetitions as the GI for 2 minutes. After two minutes, participants will be instructed to get up and walk for one minute like the intervention group.
89414144|NCT06205056|Experimental|Arm 1: Co-administration: Ad26.Mos4.HIV and CH505 TF chTrimer + ALFQ|"• Arm 1: Dose-consistent injections (5x10^10 vp/0.5 mL) of Ad26.Mos4.HIV in a 0.5 mL injection volume and dose consistent injections of CH505 TF chTrimer (300 µg)+ALFQ (200 µg MPLA/100 µg QS-21) in a 1.1 mL injection volume (20 participants)~OR a 0.5 mL injection and a 1.1 mL injection of Placebo on Study Days 1, 57, and 169 (5 participants)"
89414145|NCT06205056|Experimental|Arm 2: Rapidvax: Ad26.Mos4.HIV and CH505 TF chTrimer + ALFQ|"• Arm 2: A lower dose of Ad26.Mos4.HIV (2.5x10^10 vp/0.25 mL) in a 0.25 mL injection volume and a lower dose of CH505 TF chTrimer (30 µg)+ALFQ (50 µg MPLA/25 µg QS-21) in a 0.5 mL injection volume on Study Day 1; followed by rapid, dose escalating injections of CH505 TF chTrimer (100 µg, 150 µg, and 300 µg)+ALFQ (50 µg MPLA/ 25 µg QS-21) on Study Days 4 (0.5 mL injection volume), 8 (0.5 mL injection volume), and 15 (0.9 mL injection volume); followed by dose consistent injections of Ad26.Mos4.HIV (5x1010 vp/0.5 mL) in a 0.5 mL injection volume and CH505 TF chTrimer (300 µg)+ALFQ (200 µg MPLA/100 µg QS 21) in a 1.1 mL injection volume on Study Days 57 and 169 (20 participants);~OR a 0.25 mL injection and a 0.5 mL injection of Placebo on Study Day 1; followed by 0.5 mL, 0.5 mL, and 0.9 mL injections of Placebo on Study Days 4, 8, and 15, respectively; followed by a 0.5 mL injection and a 1.1 mL injection of Placebo on Study Days 57 and 169 (5 participants)"
89414146|NCT06205017|Experimental|Group A (AFSM)|16 subjects (Group A: intervention group) will take AFSMs in the immediate postoperative period (Appendix A). A weaning period with AFSM nutritional protocol of 4 weeks is planned, the weaning will cover the entire observation period T0 → T1.
89414147|NCT06205017|No Intervention|Group B (protocol in use with homogenized)|16 subjects (Group B: control group) will follow the standard weaning protocol i.e. with homogenized food (Appendix B). A weaning period with nutritional protocol, as per clinical protocol, of 4 weeks is planned, weaning will cover the entire observation period T0 → T1.
89414148|NCT06205004||Young adults in HK|questionnaire based study
89414149|NCT06204991|Experimental|Tumor-infiltrating lymphocytes genemodified with IL-7 gene for IL-7 production upon Ag engagement|"Tumor-infiltrating lymphocytes grown ex-vivo from resected tumor tissue and reapplied to the patient via an intravenous infusion.~Drug: Cyclophosphamide: 2 doses (69 mg/kg) prior to infusion Drug: Fludarabinephosphat 5 doses (25 mg/m2, max. 50 mg) prior to infusion Drug: Proleukin 600.000 IU/kg/dose IL-2 a maximum of 6 doses"
89414150|NCT06204952|Placebo Comparator|Placebo|Take placebo drug 1T tid for 12 weeks.
89414151|NCT06204952|Active Comparator|Test drug|Take Joins®(Clematidis Radix,Trichosanthes Root,Prunella Spike Extract) 1T tid for 12 weeks.
89414152|NCT06204939|Other|Extended Pouch gastric bypass (EPGB)|Classic gastric bypass with 2 anastomoses but with an extended pouch of 12-15cm and a biliary limb of 150cm.
89414153|NCT06204939|Other|One Anastomosis gastric bypass (OAGB)|Gastric bypass with 1 anastomosis and an extended pouch of 12-15cm and a biliary limb of 150cm.
88891707|NCT05731544|Experimental|Phase 2 Expansion Cohort|Phase 2 Expansion Cohort adults with T2D randomized 3:1 ratio receiving BMF-219 or placebo.
89414154|NCT06204913|Experimental|Left, black, icon only, 100% height|Participant will order meals from two menus containing labels next to items high in added sugars (exceeding half the daily value). The label will be on the left of the item, colored black, icon only design, and height that is 100% of size of the menu text height.
89414155|NCT06204913|Experimental|Left, black, icon plus text, 100% height|Participant will order meals from two menus containing labels next to items high in added sugars (exceeding half the daily value). The label will be on the left of the item, colored black, icon plus text design, and height that is 100% of size of the menu text height.
88891710|NCT05723055|Experimental|Treatment: All Patients|"Nivolumab 480 mg IV Q4 weeks Axatilimab (SNDX 6532) dose (3mg/kg IV) Q4 weeks. If DLT criteria are met, Axatilimab dosing will be reduced to 2mg/kg IV Q4W for the remainder of patients on the study.~The combination will be continued until progression/toxicity up to a maximum of 12 cycles."
88891711|NCT05722483|Experimental|Virtual Intensive Outpatient Program|Participants will be treated in a 4 week program involving daily psychotherapy groups, weekly individual therapy and medication management, as well as daily breathalyzer monitoring.
88891712|NCT05720780|Experimental|Usual training with the support of music (MS)|This is the group performing training with the support of the music; it will be the intervention study group (MS)
88891713|NCT05720780|Active Comparator|Usual training without music (C)|This is the usual training group without the support of the music, it will be the control group (C)
88891714|NCT05711576|Placebo Comparator|SRP and no chlorhexidine|Patients received a one-stage full-mouth scaling without chlorhexidine performed in one session of full mouth scaling and root planing.
88891715|NCT05711576|Active Comparator|SRP plus 0.12% chlorhexidine|Patients received a one-stage full-mouth scaling with 0.12% chlorhexidine performed in one session of full mouth scaling and root planing.
88891716|NCT05697874||CNS Sarcoma|Patients diagnosed with Central nervous system (CNS) sarcomas
88891717|NCT05697874||BCOR-altered|Patients diagnosed with tumors characterized by alterations in the BCOR gene.
88891718|NCT05697874||Astroblastoma/MN-1- altered|Patients diagnosed with Astroblastomas/MN-1 alterations
88891719|NCT05697874||Unclassifiable tumors|Patients diagnosed with histologically ambiguous tumors or tumors that fail to classify with the current diagnostic methods.
88891720|NCT05697874||Other Rare Brain tumors|Patients diagnosed with other rare brain tumors that do not meet the criteria for cohorts 1-4.
88891721|NCT05697809|Experimental|A1: OXU-001 / Mid dose|The Oxulumis® device will be used for the administration of OXU-001 (sustained release dexamethasone acetate) via suprachoroidal microcatheterization. A single treatment with dose level 1 (mid dose) will be applied.
88891722|NCT05697809|Experimental|A2: OXU-001 / High Dose|The Oxulumis® device will be used for the administration of OXU-001 (sustained release dexamethasone acetate) via suprachoroidal microcatheterization. A single treatment with dose level 2 (high dose) will be applied.
88891723|NCT05697809|Experimental|B1: OXU-001 / Mid Dose|The Oxulumis® device will be used for the administration of OXU-001 (sustained release dexamethasone acetate) via suprachoroidal microcatheterization. A single treatment with dose level 1 (mid dose) will be applied.
88891724|NCT05697809|Experimental|B2: OXU-001 / High Dose|The Oxulumis® device will be used for the administration of OXU-001 (sustained release dexamethasone acetate) via suprachoroidal microcatheterization. A single treatment with dose level 2 (high dose) will be applied. This dose may be adpated based on the outcome of a Week 6 data review of Part A
88891725|NCT05697809|Active Comparator|B3: Ozurdex®|A single treatment with intravitreal Ozurdex®
88891726|NCT05696561|Experimental|Treatment with a Canaloplasty Device|Canaloplasty Device
88891727|NCT05695950|Experimental|GLPG3667|Participants will receive GLPG3667 dose A orally once daily for 24 weeks.
88891728|NCT05695950|Placebo Comparator|Placebo|Participants will receive placebo matching to GLPG3667 orally once daily for 24 weeks.
88891729|NCT05693935|Experimental|TV-44749 - Dose level 1|Low dose regimen
88891730|NCT05693935|Experimental|TV-44749 - Dose level 2|Medium dose regimen
88891731|NCT05693935|Experimental|TV-44749 - Dose level 3|High dose regimen
88891732|NCT05693935|Placebo Comparator|Placebo|Matching Placebo
88891733|NCT05680077||Positive group|Esophageal carcinoma and high-grade intraepithelial neoplasia patients.
88891734|NCT05680077||Negative group|Patients with other digestive malignancies (including gastric cancer, colorectal cancer, liver cancer, pancreatic cancer,Cholangiocarcinoma, etc.) and patients with non-digestive malignant tumors (including thyroid cancer, lung squamous cell carcinoma, cervix Cancer, endometrial cancer, breast cancer, prostate cancer, etc.), Patients with benign digestive disorders (including esophagitis, gastritis, enteritis, appendicitis, gastric polyps, colorectal polyps, etc.).
88891735|NCT05678075|Active Comparator|Whole food plant-based nutrition education|Providers will receive an educational intervention on whole food plant based nutrition that will last 6 weeks.
88891736|NCT05678075|No Intervention|Delayed intervention|Providers will receive a educational intervention on whole food plant based nutrition that will last 6 weeks.
88891737|NCT05666206|Active Comparator|Fibrin group|Fibrin sealant covered with 2ry dartos flap.
88891738|NCT05666206|Active Comparator|Standard TIP technique|standard TIP technique with second dartos flap and no use of fibrin sealant
88891739|NCT05663580||HIV-positive people virologically suppressed without resistance/failure to NNRTI and INI|Initial administration of two separate intramuscolar injection of cabotegravir 400mg/3mL and rilpivirine 600mg/3mL in opposite gluteal muscles, repeated one month later and then every two months.
88891740|NCT05662293||Patients with arrhythmia-induced cardiomyopathy (retrospective/prospective)|retrospective cohort and case-control study followed by a prospective observational cohort study.
88891741|NCT05657145||Familiar Adenomatous Polyposis|All patient in this group will have the NuView device used to assist in the visualization of the papilla.
88891742|NCT05653349|Experimental|Ianalumab Lower dose|Lower dose of ianalumab administered intravenously with corticosteroids oral or parental (if clinically justified)
88891743|NCT05653349|Experimental|Ianalumab Higher dose|Higher dose of ianalumab administered intravenously with corticosteroids oral or parental (if clinically justified)
88891744|NCT05653349|Placebo Comparator|Placebo|Placebo administered intravenously with corticosteroids oral or parental (if clinically justified)
89536724|NCT02472743|Experimental|Custom-built phototherapy lamp|"Custom-built phototherapy lamp:~All participants will receive light treatment twice weekly for three weeks (or until ulcer/s healing) to one or both hands (both hands if ulcer/s present bilaterally).~The participant will place their hand within the treatment area of the light-based device (total treatment area approximately 15cm2), aiming to centralise the digital ulcer/s to the centre of the treatment region.~At each treatment study visit (visits 1-6 inclusive), the device will undergo a period of (automatic) calibration before use. All three wavelengths (red, infrared and blue) will be delivered simultaneously in combination, with the fluence of the device set at [3J/cm2] (treatment duration approximately 10 to 15 minutes)."
88891749|NCT05645328|Experimental|Intervention Hospital Administrators, Providers, and Data Monitoring Staff|"This is a health-system-level intervention, designed as two-arm intervention trial, where four participating hospitals will be offered support in the areas of training and education, cancer data collection and reporting, quality improvement and clinical peer-to-peer support.~Hospitals that are eligible for the intervention had to be located in an Iowa county classified as non-metropolitan according to rural urban continuum codes (RUCC) 4 through 9 and diagnose or treat at least 100 cancer patients each year. We selected 4 of the 9 rural hospitals meeting this criteria to administer the intervention."
88891750|NCT05645328|No Intervention|Control arm|Hospitals that are eligible for the intervention had to be located in an Iowa county classified as non-metropolitan according to rural urban continuum codes (RUCC) 4 through 9 and diagnose or treat at least 100 cancer patients each year. The remaining 5 hospitals meeting this criteria that were not selected for the intervention will serve as controls.
88891751|NCT05639556||Cohort 1|Forced expiratory volume in 1 second (FEV1) <60% predicted during the 12 months prior to enrollment (>50% of measurements, eliminating periods of exacerbation). If no stable spirometry data are available in the 12 months prior to enrollment, from the prior 24 months will be used.
88891752|NCT05639556||Cohort 2|FEV1 ≥60% predicted during the 12 months prior to enrollment (>50% of measurements, eliminating periods of exacerbation).
88891753|NCT05635500|Experimental|Middle Insertion|Videolaryngoscope is inserted from the middle for endotracheal intubation.
88891754|NCT05635500|No Intervention|Right Insertion|Videolaryngoscope is inserted from the right for endotracheal intubation.
89414156|NCT06204913|Experimental|Left, black, boxed icon, 100% height|Participant will order meals from two menus containing labels next to items high in added sugars (exceeding half the daily value). The label will be on the left of the item, colored black, boxed icon design, and height that is 100% of size of the menu text height.
88891755|NCT05633654|Experimental|Sacituzumab govitecan-hziy (SG) + Pembrolizumab|"Participants will receive SG 10 mg/kg intravenously on Days 1 and 8 of 21-day cycles and pembrolizumab 200 mg intravenously on Day 1 of 21-day cycles for 8 cycles.~Treatment will be administered until a maximum of 8 cycles, local or distant disease recurrence, unacceptable toxicity, physician decision, consent withdrawal, or death."
88922076|NCT05849311|Experimental|Envafolimab with new manufacturing process|80 healthy male subjects with Envafolimab with new manufacturing process
89414157|NCT06204913|Experimental|Right, black, icon only, 100% height|Participant will order meals from two menus containing labels next to items high in added sugars (exceeding half the daily value). The label will be on the right of the item, colored black, icon only design, and height that is 100% of size of the menu text height.
89414158|NCT06204913|Experimental|Right, black, icon plus text, 100% height|Participant will order meals from two menus containing labels next to items high in added sugars (exceeding half the daily value). The label will be on the right of the item, colored black, icon plus text design, and height that is 100% of size of the menu text height.
89414159|NCT06204913|Experimental|Right, black, boxed icon, 100% height|Participant will order meals from two menus containing labels next to items high in added sugars (exceeding half the daily value). The label will be on the right of the item, colored black, boxed icon design, and height that is 100% of size of the menu text height.
89414160|NCT06204913|Experimental|Left, red, icon only, 100% height|Participant will order meals from two menus containing labels next to items high in added sugars (exceeding half the daily value). The label will be on the left of the item, colored red, icon only design, and height that is 100% of size of the menu text height.
89414161|NCT06204913|Experimental|Left, red, icon plus text, 100% height|Participant will order meals from two menus containing labels next to items high in added sugars (exceeding half the daily value). The label will be on the left of the item, colored red, icon plus text design, and height that is 100% of size of the menu text height.
89414162|NCT06204913|Experimental|Left, red, boxed icon, 100% height|Participant will order meals from two menus containing labels next to items high in added sugars (exceeding half the daily value). The label will be on the left of the item, colored red, boxed icon design, and height that is 100% of size of the menu text height.
89414163|NCT06204913|Experimental|Right, red, icon only, 100% height|Participant will order meals from two menus containing labels next to items high in added sugars (exceeding half the daily value). The label will be on the right of the item, colored red, icon only design, and height that is 100% of size of the menu text height.
89414164|NCT06204913|Experimental|Right, red, icon plus text, 100% height|Participant will order meals from two menus containing labels next to items high in added sugars (exceeding half the daily value). The label will be on the right of the item, colored red, icon plus text design, and height that is 100% of size of the menu text height.
89414165|NCT06204913|Experimental|Right, red, boxed icon, 100% height|Participant will order meals from two menus containing labels next to items high in added sugars (exceeding half the daily value). The label will be on the right of the item, colored red, boxed icon design, and height that is 100% of size of the menu text height.
89414166|NCT06204913|Experimental|Left, black, icon only, 150% height|Participant will order meals from two menus containing labels next to items high in added sugars (exceeding half the daily value). The label will be on the left of the item, colored black, icon only design, and height that is 150% of size of the menu text height.
89536725|NCT02472899||Alzheimer's Disease|Blood sample from subjects older than 60 years with a clinical diagnosis of Alzheimer's Disease
88891756|NCT05633654|Active Comparator|Treatment of Physician's Choice (TPC): Pembrolizumab or Pembrolizumab + Capecitabine|"Participants will receive one of the following TPC regimens determined prior to randomization:~Pembrolizumab 200 mg intravenously on Day 1 of 21-day cycles for 8 cycles OR~Pembrolizumab 200 mg intravenously on Day 1 of 21-day cycles and capecitabine 1000 mg/m^2 orally twice daily on Days 1 through 14 of 21-day cycles for 8 cycles.~Treatment will be administered until a maximum of 8 cycles, local or distant disease recurrence, unacceptable toxicity, physician decision, consent withdrawal, or death."
88891757|NCT05629767||Patients with ASCVD|Patients with ASCVD on statins and LDL-C more than 70 mg/dl
88891758|NCT05629676|Experimental|BMT-VR Group|"Participants will complete the BMT-VR intervention during their BMT hospitalization, which contains six sections.~Participants will receive usual transplant care by their BMT team~Participants will complete study questionnaires to assess their quality of life and psychological outcomes~10-20 participants will complete exit interviews to ascertain more feedback on the BMT-VR intervention."
88891759|NCT05629676|No Intervention|Usual care|"Participants will receive usual transplant care by their BMT team~Participants will complete study questionnaires to assess their quality of life and psychological outcomes"
88891760|NCT05629585|Experimental|Dato-DXd in combination with Durvalumab|Arm 1: Dato-DXd 6 mg/kg IV Q3W x 8 cycles + Durvalumab 1120 mg IV Q3W x 9 cycles
88891761|NCT05629585|Experimental|Dato-DXd|Arm 2: Dato-DXd 6 mg/kg IV Q3W x 8 cycles
88891762|NCT05629585|Active Comparator|Investigators Choice Therapy|"Arm 3: Capecitabine (1000 or 1250 mg/m2 oral BID on Days 1 to 14, Q3W) for 8 cycles~Pembrolizumab* (200 mg IV on Day 1, Q3W) for 9 cycles~Capecitabine (1000 or 1250 mg/m2 oral BID on Days 1 to 14, Q3W) for 8 cycles + pembrolizumab* (200 mg IV on Day 1, Q3W) for 9 cycles~* Only participants who have received prior pembrolizumab in the neoadjuvant setting should receive pembrolizumab as part of their adjuvant therapy on Arm 3."
88891763|NCT05626101|Active Comparator|Inravesical BCG|Intravsical induction and maintenance BCG injections.
88891764|NCT05626101|Active Comparator|Inravesical Gemcitabin|Intravsical induction and maintenance gemcitabin injections.
88891765|NCT05624723|Experimental|Group 1: Normal Renal Function|Participants with normal levels of renal function will receive a single oral dose of INCB054707 75 mg on Day 1.
88891766|NCT05624723|Experimental|Group 2: Mild Renal Impairment|Participants with mild levels of renal function will receive a single oral dose of INCB054707 75 mg on Day 1.
88891767|NCT05624723|Experimental|Group 3: Moderate Renal Impairment|Participants with moderate levels of renal function will receive a single oral dose of INCB054707 75 mg on Day 1.
88891768|NCT05624723|Experimental|Group 4: Severe Renal Impairment|Participants with severe levels of renal function will receive a single oral dose of INCB054707 75 mg on Day 1.
88891769|NCT05624723|Experimental|Group 5: Kidney Failure|Group 5 participants with ESRD maintained on HD will receive a single dose of INCB054707 across 2 treatment periods before (Period 1) and after (Period 2) an HD session in order to study the effects of HD on INCB054707.
88891770|NCT05612256||Infants on mechanical ventilation|
88891771|NCT05612256||Infants on non-invasive respiratory support|
88891772|NCT05610345|Experimental|Placenta Blood Drained|Immediately after delayed cord clamping and cutting of the umbilical cord, the cord will be unclamped and blood with be drained until cessation of flow.
88891773|NCT05610345|Active Comparator|Placenta Blood Not Drained|This is the control group. The cord will not be unclamped.
89193003|NCT05779761|Experimental|Health and Wellness Education Training|Participants assigned to Health and Wellness Education Training will receive 6-weeks of self-directed, online skills training on stress-reduction psychoeducation. Six weekly modules will include 10-15 minutes of narrated videos, as well as suggestions for activities and skills practices between modules. Participants will also schedule weekly, 5-10 minute calls with an assigned skills training coach to discuss the participant's experience with the skills training.
89199110|NCT02543073|Active Comparator|Non-MSCs|AZM and glucocorticoid will be given for the patients in Non-MSCs group.
89536726|NCT02472899||Older controls|Blood sample from subjects older than 60 years who are cognitively normal
88891778|NCT05592002|Experimental|Genio® 2.1 System|System Component Genio® System 2.1 Implantable Stimulator (IS) Genio® Implantable Stimulator External Stimulator (ES) Genio® External Stimulator Disposable Patch (DP) Genio® Disposable Patch Activation Chip (AC) Genio® Activation Chip (AC) Model #2364 Charging Unit (CU) Genio® Charging Unit (CU) Model #2238 Sleep Lab Application Genio® Sleep Lab Application Smartphone Application (optional) Genio® Smartphone Application
88891779|NCT05583188|Experimental|Aliya PEF ablation|Pulsed electric field treatment using the Aliya System
88891780|NCT05581030|Experimental|Hyper-CVAD + Calaspargase pegol Treatment|Participants will receive calaspargase pegol administered over 1 hour with each cycle of Hyper-CVAD, mini-CVD, and late intensification, beginning with Cycle 1B. Responding patients will have dose reduction of HyperCVAD for Cycles 2B-4B. Participants with CD20+ ALL will also be given Rituximab once per cycle.
88891781|NCT05579847||Study Participants|Participants with Stage IV Renal Cell Carcinoma will be recruited in the genitourinary medical oncology clinic at Moffitt Cancer Center. Upon consenting, participants will be provided with an mHealth interactive smart phone application.
88891782|NCT05573464|Experimental|BGF MDI HFO 320/14.4/9.6μg|Budesonide, Glycopyrronium, and Formoterol Fumarate (BGF) Delivered by MDI HFO (HFO-1234ze)
88891783|NCT05573464|Active Comparator|BGF MDI HFA 320/14.4/9.6 μg|Budesonide, Glycopyrronium, and Formoterol Fumarate (BGF) Delivered by MDI HFA
88891784|NCT05572073||Retrospective|
88891785|NCT05572073||Prospective|
88891786|NCT05571839|Experimental|SGN-BB228|SGN-BB228 monotherapy
88891787|NCT05569681|Active Comparator|Bemiparin 3500 IU|"Bemiparin sodium 3,500 IU anti Xa/0.2 ml solution for injection in the pre-filled syringe will be provided for each patient in one group; subcutaneously 6 hours after the surgery(orthopedic and non-orthopedic) and then daily for up to 10 days for moderate and high - risk group and for 30 days in very high risk-group patients according to Caprinin risk classification for venous thromboembolism.~Other Name: Hibor; Laboratories Rovi Pharmaceuticals"
89414167|NCT06204913|Experimental|Left, black, icon plus text, 150% height|Participant will order meals from two menus containing labels next to items high in added sugars (exceeding half the daily value). The label will be on the left of the item, colored black, icon plus text design, and height that is 150% of size of the menu text height.
89414168|NCT06204913|Experimental|Right, black, icon only, 150% height|Participant will order meals from two menus containing labels next to items high in added sugars (exceeding half the daily value). The label will be on the right of the item, colored black, icon only design, and height that is 150% of size of the menu text height.
89414169|NCT06204913|Experimental|Right, black, icon plus text, 150% height|Participant will order meals from two menus containing labels next to items high in added sugars (exceeding half the daily value). The label will be on the right of the item, colored black, icon plus text design, and height that is 150% of size of the menu text height.
89005565|NCT04567966|Active Comparator|Cortico-cancellous block graft|A cortico-cancellous block graft was harvested from the symphysis of the mandible and fixed to the atrophied ridge.
89414170|NCT06204913|Experimental|Left, red, icon only, 150% height|Participant will order meals from two menus containing labels next to items high in added sugars (exceeding half the daily value). The label will be on the left of the item, colored red, icon only design, and height that is 150% of size of the menu text height.
89414171|NCT06204913|Experimental|Left, red, icon plus text, 150% height|Participant will order meals from two menus containing labels next to items high in added sugars (exceeding half the daily value). The label will be on the left of the item, colored red, icon plus text design, and height that is 150% of size of the menu text height.
89414172|NCT06204913|Experimental|Right, red, icon only, 150% height|Participant will order meals from two menus containing labels next to items high in added sugars (exceeding half the daily value). The label will be on the right of the item, colored red, icon only design, and height that is 150% of size of the menu text height.
89414173|NCT06204913|Experimental|Right, red, icon plus text, 150% height|Participant will order meals from two menus containing labels next to items high in added sugars (exceeding half the daily value). The label will be on the right of the item, colored red, icon plus text design, and height that is 150% of size of the menu text height.
89414174|NCT06204913|Experimental|Left, red, boxed icon, 150% height|Participant will order meals from two menus containing labels next to items high in added sugars (exceeding half the daily value). The label will be on the left of the item, colored red, boxed icon design, and height that is 150% of size of the menu text height.
89005566|NCT02962011|Experimental|Knotless barbed suture|
89005567|NCT02962011|Active Comparator|polyglactin 910|Vicryl
89199111|NCT00884013||1|Quality Payment and all clinical reminders turned on
89199112|NCT00884013||2|Quality Payment and ABCS measures reminders turned on
89536727|NCT02472899||Younger controls|Blood sample from healthy subjects aged 20 to 30 years who are cognitively normal
89005568|NCT04568356|Experimental|Antigen rapid test for COVID-19|The same group of patients participated in two arms of the study, one arm was for obtaining data on the rapid antigen test for COVID-19, the comparator arm was to obtain data from the RT-PCR
89005569|NCT04567576||Exposed|Patients with underlying rheumatological or autoimmune diseases who have a confirmed infection by 2019-nCoV (COVID-19) who at the time of diagnosis (of infection) receive pharmacological treatment with disease modifying antirheumatic drugs (DMARDs).
89005570|NCT04567576||Un-exposed|Patients with underlying rheumatological or autoimmune diseases who have a confirmed 2019-nCoV (COVID-19) infection who at the time of diagnosis (of infection) are not receiving pharmacological treatment with disease-modifying antirheumatic drugs (DMARDs).
89005571|NCT04568083||Ticagrelor cohort|Patients initiating ticagrelor 60 mg after an MI, with no prescription of ticagrelor 60 mg prior to their qualifying MI. The qualifying MI is defined as the most recent MI occurring before the first ticagrelor 60 mg prescription.
89005572|NCT04568083||Non-ticagrelor cohort|Patients not prescribed ticagrelor 60 mg at a comparable time point after an MI as matched patients in the ticagrelor cohort. Patients may be prescribed another P2Y12 inhibitor or aspirin alone.
89005573|NCT04567459|No Intervention|control group: chemotherapy|No intervention
89005574|NCT04567459|Experimental|experimental group: chemotherapy and nutrition support|Premium amino acids 1pc bid for 6 months
89005575|NCT04567147|Experimental|Probiotic|Formula probiotic contains freeze-dried Lactobacillus casei, Bafidobacterium animals, Bifidobacterium longum, Bifidobacterium bidium and Lactobacillus plantarum, each at a dosage of 3.0E+10 CFU per 2g sachet.
89005576|NCT04567147|Placebo Comparator|Placebo|Placebo made with only the excipients. The placebo sachet was matched to the study probiotic products for taste, color, and size.
89005577|NCT04722380|Experimental|test group|10 infrabony defects treated surgically with Nigella Sativa oil extract Mixed with xenograft
89005578|NCT04722380|Placebo Comparator|control group|10 infrabony defects treated surgically with xenograft alone
89005579|NCT04566952|Experimental|Anlotinib combined With dose-reduced olaparib|Anlotinib-olaparib combination therapy until disease progression
89005580|NCT04567069|Experimental|DC vaccine|Vaccine made from autologous dendritic cells loaded with MG-7 antigen.
89005581|NCT04567069|Experimental|DC vaccine + CTL (cytotoxic lymphocyte)|Cytotoxic lymphocytes are CD3+ T cells co-cultured with DCs.
89005582|NCT04567069|Experimental|DC vaccine + PD-1 monoclonal antibody (Sintilimab Injection)|Sintilimab injection is a type of immunoglobulin G4 monoclonal antibody, which binds to PD-1 molecules on the surface of T-cells, blocks the PD-1/ PD-1 Ligand-1 (PD-L1) pathway and reactivates T-cells to kill cancer cells.
89005583|NCT04566874|Other|Spira-A with HCT/p DBM|Single level Spira-A 3D printed Titanium ALIF Device with HCT/p DBM
89005584|NCT04566874|Active Comparator|Medtronic PEEK ALIF with Infuse|Single level Medtronic Divergent-L/Perimeter PEEK ALIF Device with Recombinant Bone Morphogenic Protein-2 (Infuse)
89005585|NCT04566796|Active Comparator|(Group N)|patients in this group will receive 0.02 mg/kg atropine with neostigmine 0.05 mg/kg IV. to reverse the action of the neuromuscular blocker given.
89005586|NCT04566796|Experimental|(Group S)|the patients will receive Sugammadex 2mg/kg IV. As the reversal agent
89199113|NCT00884013||3|Quality Payment and non-ABCS measures reminders turned on
89199114|NCT00884013||4|Quality Reporting and Recognition with all clinical reminders turned on
89193004|NCT05777720|No Intervention|Control|No intervention will be administered in this arm. Investigators will give families a CO2 monitor to measure average CO2 levels in the home. Investigators will provide a link to the basic CDC isolation guidelines which would be part of standard of care. Investigators will test family members at day 0-1 for baseline testing; and again on day 7 for assessing secondary transmission among susceptible contacts.
89193005|NCT05777720|Experimental|Intervention|Families are provided with one filtration fan unit per room in their home (and one for the index case; if the family lives in a studio, they would receive 2 units). Investigators will advise families on ventilation improvements in their home. Investigators will provide an instructional pamphlet that describes how the fans work and the importance of ventilation. Investigators will follow-up on day 3-4 to check in and run through a checklist to ensure the fans are working and ventilation improvements are being attempted. Investigators will give families a CO2 monitor to measure average CO2 levels in the home. Investigators will test family members at day 0-1 for baseline testing; and again on day 7 for assessing secondary transmission among susceptible contacts.
88891788|NCT05569681|Active Comparator|Bemiparin 5000 IU|"Bemiparin sodium 5000 IU anti Xa/0.2 ml solution for injection in the pre-filled syringe will be provided for each patient in one group; subcutaneously 6 hours after the surgery(orthopedic and non-orthopedic) and then daily for up to 10 days for moderate and high - risk group patients and 30 days in very high-risk group surgical patients according to Caprinin risk classification for venous thromboembolism.~Other Name: Hibor; Laboratories Rovi Pharmaceuticals"
88891789|NCT05564104|Experimental|Participants with normal hepatic function|Participants with normal hepatic function will receive a single subcutaneous (s.c.) dose of 0.9 milligrams (mg) of cagrilintide on Day 1.
88891790|NCT05564104|Experimental|Participants with mild hepatic impairment|Participants with mild hepatic impairment (Child Pugh Grade A) will receive a single subcutaneous (s.c.) dose of 0.9 milligrams (mg) of cagrilintide on Day 1.
88891791|NCT05564104|Experimental|Participants with moderate hepatic impairment|Participants with moderate hepatic impairment (Child-Pugh Grade B) will receive a single subcutaneous (s.c.) dose of 0.9 milligrams (mg) of cagrilintide on Day 1.
88891792|NCT05564104|Experimental|Participants with severe hepatic impairment|Participants with severe hepatic impairment (Child-Pugh Grade C) will receive a single subcutaneous (s.c.) dose of 0.9 milligrams (mg) of cagrilintide on Day 1
88891793|NCT05560451|Experimental|Peer health coach intervention|Participants will receive 20 virtual visits with a trained Veteran peer health coach over 12 months. Coaches will provide participants with brief health education, assist with goal setting and problem solving, enhance social support, and link participants to VA and community resources.
88891794|NCT05560451|No Intervention|Control group/no intervention|Participants will continue to receive their regular, usual primary care.
88891795|NCT05558904|Experimental|Diagnostic (Me-4FDG PET/CT)|Patients receive Me-4FDG tracer IV and then undergo PET/CT over 15 minutes.
88891796|NCT05558475|Experimental|Digital CBTi with Coaching|Virtual Coaching integrated with Digital CBTI. Includes initial enrollment contact, onboarding call, and two follow-up support calls. The coach will be available as resource for technical and other support.
88891797|NCT05558475|No Intervention|Digital CBTi without Coaching (+ initial contact)|The control will be an enhanced treatment as usual condition where participants will receive: 1) provider referral to Digital CBTi; 2) initial enrollment contact and 3) NO virtual coaching contacts. If subjects have a question or need technical support, they will be instructed to contact study staff for assistance.
88891798|NCT05557591|Experimental|Phase 2: Cemiplimab|Arm A: Cemiplimab is administered by IV infusion Q3W
89193006|NCT05768620|Experimental|CAVE|10 immersive virtual reality sessions to train spatial memory
89193007|NCT05768620|Active Comparator|TAU|10 paper and pencil sessions to train spatial memory
88891799|NCT05557591|Experimental|Phase 2: BNT116 + Cemiplimab|Arm B: BNT116 is administered by IV injection. Cemiplimab is administered by IV infusion Q3W.
88891800|NCT05554679|Active Comparator|group A|obese pregnant women who take metformin
88891801|NCT05554679|No Intervention|group B|obese pregnant women who take no metformin
88891802|NCT05553639|Experimental|HB-302/HB-301 Alternating 2-Vector Therapy Intravenously (IV)|HB-302/HB-301 Alternating 2-Vector Therapy Intravenously (IV)
88891803|NCT05550038|Experimental|compression ultrasound|All patients receive a 3-point compression ultrasound followed within 72 hours by a whole-leg ultrasound with Doppler performed by a vascular physician.
88891804|NCT05537571|Experimental|SLN360 Dose 1|SLN360 for subcutaneous injection
89193008|NCT05764616|Experimental|RECTUS group|Patients will receive General Anesthesia combined with bilateral parasternal block and rectus sheath block
89193009|NCT05764616|Active Comparator|CONTROL group|Patients will receive General Anesthesia combined with bilateral parasternal block and infiltration of drainage exits sites with local anesthetic
89536728|NCT02470325|Active Comparator|1 Avidekel|Patients with spasticity and dystonia related to genetic neurodegenerative disease will consume Avidekel oil (6-to-1 ratio of CBD to THC)
88891805|NCT05537571|Experimental|SLN360 Dose 2|SLN360 for subcutaneous injection
88891806|NCT05537571|Experimental|SLN360 Dose 3|SLN360 for subcutaneous injection
88891807|NCT05537571|Placebo Comparator|Placebo Dose 1|Sodium chloride for subcutaneous injection
88891808|NCT05537571|Placebo Comparator|Placebo Dose 2 and 3|Sodium chloride for subcutaneous injection
88891809|NCT05528718||Experimental group|Participants assigned to this intervention arm in the main study will have been administered nitrous oxide at an inspiratory concentration of 50% with concurrent intravenous saline (100mL) for one hour.
88891810|NCT05528718||Placebo group|Participants assigned to this intervention arm in the main study will have been administered 50% oxygen with intravenous midazolam (0.02mg/kg in 100mL) for one hour.
88891811|NCT05528328|Active Comparator|CACIPLIQ20®|CACIPLIQ20® is a medical device used for the treatment of chronic skin ulcers, and contains a molecule belonging to the family of ReGeneraTing Agents (RGTA®). CACIPLIQ20® will be administered topically on the vertical and peri-areolar incisions of one breast for 5 minutes, after subcutaneous plans suture and just before final skin suture.
88891812|NCT05528328|Placebo Comparator|placebo|The placebo solution (saline solution) will be administered on the contralateral side.
88891813|NCT05526989|Experimental|Dostarlimab and Niraparib treatment|Participants will be given 500 mg Dostarlimab IV every 3 weeks for 4 cycles followed by 1000 mg every 6 weeks, along with 200 mg Niraparib by mouth once daily days 1-21 of all cycles.
88891814|NCT05523908|Experimental|High-dose hypofraction Arm|Patients in this arm (High-dose hypofraction Arm) would receive high-dose fractionated radiotherapy with 60-68Gy/15-17f.
88891815|NCT05523908|Experimental|Low-dose hypofraction Arm (Standard BED)|Patients in this arm (Low-dose hypofraction Arm) would receive high-dose fractionated radiotherapy with 48Gy/12f.
88891816|NCT05516485|Experimental|Diagnostic (MRE, tumor grading)|Patients undergo MRE scan over 25 minutes before surgery at the time of standard of care pre-operative MRI scan. On the day of surgery, the surgeon grades and records tumor consistency/stiffness during the operation and afterwards.
89536729|NCT02470325|Active Comparator|2 Enriched Avidekel|Patients with spasticity and dystonia related to genetic neurodegenerative disease will consume Enriched Avidekel oil (20-to-1 ratio of CBD to THC)
88891818|NCT05513547|Other|resting subgroup|Will be allowed to engage in activities that do not require self-luminous displays (e.g., study/read, play boardgames, listen to podcasts) during the three scheduled 7-hour light exposure (LE) conditions. For 'resting' participants, the time they spend under the open sky, in the shade or half-shade, will be matched to what the 'hikers' experience.
88891819|NCT05513547|Other|hiking subgroup|Will have 4 hours of scheduled moderate physical activity (average approx. 70-75% of maximum heart rate during each LE starting 3h after waking up to meet the circadian time when the most pronounced phase-advance is expected. The scheduled 4-hour activity will be a hike in the greater Basel area, which will cover about 12-14 km and a gain in elevation of less than 500 metres. Participants will be instructed to walk at their own speed. During protocol 1, which will take place in the lab, participants in the 'hiking' group will walk on a tiltable treadmill.
88891820|NCT05513027|Experimental|Augmented Whole-body Scanning via Magnifying PET (AWSM-PET)|All enrolled subjects will undergo SOC FDG-PET/CT scan with an AWSM PET device positioned at the far end of the Biograph Vision PET/CT scanner. The patient will receive 10-20 mCi FDG injection according to the SOC FDG-PET/CT protocol dosing schedule. The entire study will require approximately 2 ½ - 3 hours (from the time patient arrives to the completion of the scan).
88922077|NCT05849311|Active Comparator|Envafolimab with old manufacturing process|80 healthy male subjects with Envafolimab with old manufacturing process
89536730|NCT02470325|Active Comparator|3 Avidekel|Patients with spasticity and dystonia due to cerebral palsy will consume Avidekel oil (6-to-1 ratio of CBD to THC)
89536731|NCT02470325|Active Comparator|4 Enriched Avidekel|Patients with spasticity and dystonia due to cerebral palsy will consume Enriched Avidekel oil (20-to-1 ratio of CBD to THC)
88891821|NCT05512962|Experimental|Suprachoroidal Triamcinolone acetonide 2.4mg|The Oxulumis® device will be used for the administration of Triesence® (Triamcinolone acetonide) via suprachoroidal microcatheterization. A single treatment with 2.4mg/60µl Triesence® will be applied.
88891822|NCT05512962|Experimental|Suprachoroidal Triamcinolone acetonide 4.0mg|The Oxulumis® device will be used for the administration of Triesence® (Triamcinolone acetonide) via suprachoroidal microcatheterization. A single treatment with 4.0mg/100µl Triesence® will be applied.
88891823|NCT05510687|Experimental|Glasses to correct presbyopia and digital financial training|The intervention is the provision of glasses to correct presbyopia plus digital financial training to use bKash, a popular mobile banking application that is becoming the preferred mode of transferring payments to the bank accounts of OAA and WA beneficiaries in Bangladesh.
88891824|NCT05510687|No Intervention|Control-No treatment|"Mobile phone with preloaded bank transaction tracking app: Participants will be provided a basic mobile phone handset. The bank transaction tracking application that is being developed to measure the primary outcomes for this trial will be installed on these phones before giving them to the participants. A mobile data pack will also be remotely loaded on the mobile phone to facilitate internet access for mobile banking.~Eyeglasses: These participants will receive a free pair of eyeglasses at the conclusion of the study to correct refractive errors, unless they have obtained such glasses on their own during the study."
88891825|NCT05507307|Experimental|MBSR group|mindfulness-based pregnancy education program group
88891826|NCT05507307|No Intervention|Control group|control group standard care group
88891827|NCT05506059|Other|Healthy Volunteer|Healthy volunteers over the age of 18 who consent to two ultrasounds.
88891828|NCT05506059|Experimental|ED patient with planned heart echocardiogram|Patients in emergency department (ED) who have a heart echocardiogram scheduled as part of their routine clinical care
88891829|NCT05504291|Experimental|Treatment (CVE, melphalan)|See Detailed Description
88891830|NCT05501704|Experimental|Window Phase Arm A: Tamoxifen|Participants will be randomly assigned to receive Tamoxifen 1x daily for 3 weeks (21days).
88891831|NCT05501704|Experimental|Window Phase Arm B: Anastrozole|Participants will be randomly assigned to receive Anastrozole 1x daily for 3 weeks (21days).
88891832|NCT05501704|Experimental|Window Phase Arm C: Anastrozole + Degarelix|Participants will be randomly assigned to receive Anastrozole 1x daily for 3 weeks (21days) and Degarelix on day 1 only.
88891833|NCT05501704|Experimental|Neoadjuvant Phase Arm D: Tamoxifen|Participants will be randomly assigned to receive Tamoxifen 1x daily for 4 cycles (4 months); each study cycle is 28 days.
88891834|NCT05501704|Experimental|Neoadjuvant Phase Arm E: Tamoxifen + Abemaciclib|Participants will be randomly assigned to receive Tamoxifen 1x daily and Abemaciclib 2x daily for 4 cycles (4 months); each study cycle is 28 days.
88891835|NCT05501704|Experimental|Neoadjuvant Phase Arm F: Anastrozole and Degarelix|Participants will be randomly assigned to receive Anastrozole 1x daily and Degarelix on day 1 of each cycle for 4 cycles (4 months); each study cycle is 28 days.
88922078|NCT05847231|Experimental|mandala app|mandala will be aplicated
89414175|NCT06204913|Experimental|Left, black, boxed icon, 150% height|Participant will order meals from two menus containing labels next to items high in added sugars (exceeding half the daily value). The label will be on the left of the item, colored black, boxed icon design, and height that is 150% of size of the menu text height.
89414176|NCT06204913|Experimental|Right, red, boxed icon, 150% height|Participant will order meals from two menus containing labels next to items high in added sugars (exceeding half the daily value). The label will be on the right of the item, colored red, boxed icon design, and height that is 150% of size of the menu text height.
89414177|NCT06204913|Experimental|Right, black, boxed icon, 150% height|Participant will order meals from two menus containing labels next to items high in added sugars (exceeding half the daily value). The label will be on the right of the item, colored black, boxed icon design, and height that is 150% of size of the menu text height.
88891836|NCT05501704|Experimental|Neoadjuvant Phase Arm G: Anastrozole + Degarelix + Abemaciclib|Participants will be randomly assigned to receive Anastrozole 1x daily, Degarelix on day 1 of each cycle and Abemaciclib 2x daily for 4 cycles (4 months); each study cycle is 28 days.
88891837|NCT05492838|Active Comparator|Flapless Surgery|
88891838|NCT05492838|Active Comparator|Surgery With Flap Elevation|
88891839|NCT05489640||HAE Participants|Adult participants with a diagnosis of HAE who are receiving treatment according to routine clinical practice and prescribed all treatments in accordance with the approved marketing authorization will be enrolled in this study. Data will be directly collected from participants via patient reported diaries and paper- based and/or electronic homecare records as appropriate for UK participants using homecare services for icatibant. No study specific intervention will be administered in this study.
88891840|NCT05485766|Experimental|Pembrolizumab+ Paclitaxel + Carboplatin Followed by Pembrolizumab + Olaparib|"Neoadjuvant phase; Treatment 1: Pembrolizumab+ Paclitaxel + Carboplatin (Cycles 1-4) Treatment 2: Pembrolizumab + Olaparib (Cycles 1-4)~Definitive Surgery~Adjuvant phase; Pembrolizumab + Olaparib (1-9 cycles)~Note: each cycle = 3 weeks (Neoadjuvant Treatment 1 and 2, and Adjuvant Treatment)"
88891841|NCT05484999|Experimental|Dual interventions|Receive both interventions: MamaMeals and MamaMatters Interventions
88891842|NCT05484999|Active Comparator|Meals intervention only|MamaMeals
88891843|NCT05484999|Sham Comparator|Control|Wait-list control (received MamaMeals between 16-20 weeks postpartum) (after primary data collection time point)
88891844|NCT05474066||Pre and Post Training|A sample will be recruited from a group of 20 CAF SOF personnel ages 18-65 will be assessed twice: pre and post-special forces military training. All members enrolled in this training will be invited to participate in the study. Testing periods will be about 4 weeks apart, with post training testing within 1 week of conclusion of the exercise. Patients will be recruited from within the Canadian Special Operation Forces community. Recruitment and study will take place starting in September 2022 and continue until complete which is estimated to be approximately 12 months. Participants will be made aware of the study through recruitment letter sent as part of their training package (Appendix A). They will be allowed questions prior to enrollment or at any point during participation.
88891845|NCT05467449||Hematologically normal|Based on immunophenotyping
88891846|NCT05467449||Hematologically abnormal|Based on immunophenotyping
88891847|NCT05447741||Patients with fibromyalgia|Participants will have a quantitative ultrasound examination of the dominant Achilles' tendon, medial collateral ligament at the femoral epicondyle and common extensor tendon at the lateral epicondyle of the elbow.
88891848|NCT05447741||Patients with psoriasis arthritis|Participants will have a quantitative ultrasound examination of the dominant Achilles' tendon, medial collateral ligament at the femoral epicondyle and common extensor tendon at the lateral epicondyle of the elbow.
88891849|NCT05447741||Asymptomatic controls|Participants will have a quantitative ultrasound examination of the dominant Achilles' tendon, medial collateral ligament at the femoral epicondyle and common extensor tendon at the lateral epicondyle of the elbow.
88891850|NCT05447520|Experimental|Montelukast Group|Patients will receive conventional DMARDs plus montelukast 10 mg tablet once daily for 16 weeks.
88922079|NCT05847231|No Intervention|routine maintenance practice|Routine maintenance will be applied.
88891851|NCT05447520|Placebo Comparator|Control Group|Patients will receive conventional DMARDs plus placebo tablet daily for 16 weeks
88891852|NCT05442710|Experimental|ARTICE Treatment Group|Subjects with septic shock treated with immune cell extracorporeal therapy on top of standard of care
88891853|NCT05442710|No Intervention|Control Group|Subjects with septic shock receiving standard of care
89414178|NCT06204900|Experimental|Undergoing a single-level or two-level TLIF between L2-S1|During the surgery, the standard monitoring devices and the EARP monitoring study devices and techniques will be used.
88891854|NCT05438992|Active Comparator|group A|The patients in this group will be administered 15 ml bupivacaine 0.250 % between the popliteal artery and the capsule of the posterior knee.
88891855|NCT05438992|Active Comparator|Group B|The patients in this group will be administered 20 ml bupivacaine 0.250 % between the popliteal artery and the capsule of the posterior knee.
88891856|NCT05438992|Active Comparator|Group C|The patients in this group will be administered 25 ml bupivacaine 0.250 % between the popliteal artery and the capsule of the posterior knee.
88891857|NCT05424484|Experimental|Hernia prevention cohort|single arm study, no control arm
88891858|NCT05419258|Experimental|use of the device during hemodialysis sessions|use of the device during one month during hemodialysis sessions
88891859|NCT05412030|Experimental|Group 1|1 mcg AFX3772 administered intramuscularly 4 times within 12 months
88891860|NCT05412030|Experimental|Group 2|2 mcg AFX3772 administered intramuscularly 4 times within 12 months
88891861|NCT05412030|Experimental|Group 3|5 mcg AFX3772 administered intramuscularly 4 times within 12 months
88891862|NCT05412030|Active Comparator|Group 4|PCV13 administered intramuscularly 4 times within 12 months
88891863|NCT05405387|Experimental|Run-In Phase|Budesonide EC 3 mg three times a day, oral
88891864|NCT05405387|Experimental|Arm 1: Treatment|Budesonide EC 3 mg three times a day, oral
88891865|NCT05405387|Placebo Comparator|Arm 2: Placebo|Placebo 3 mg three times a day, oral
88891866|NCT05405309|Experimental|Phase Ib: Dose Escalation|To assess the MTD of RP-3500 in combination with olaparib
88891867|NCT05405309|Experimental|Phase II: Dose Expansion Enrichment Cohort|All subjects enrolled into the enrichment cohort must have a del(11q) and/or ATM mutation
89536732|NCT03581981|Experimental|Prolonged Exposure for Primary Care (PE-PC)|Brief version of PE provided in 30 minute sessions in PC
88891868|NCT05405309|Experimental|Phase II: Dose Expansion Eligible Subjects Cohort|Cohort will include all other eligible subjects for Dose Expansion.
88891869|NCT05402592|Placebo Comparator|Control Group|Patients will be given 800 ml of water by the blind caregiver until 24:00 at night before the surgery, and 400 ml of water 2-3 hours before the surgery in the morning.Blood samples for plasma glucose, plasma cortisol, and serum insulin levels will be drawn just before the morning dose, 40 minutes and 90 minutes after ingestion of the beverage, and during anesthesia induction. Gastric volume and pH will be evaluated within the first 10 minutes intraoperatively. Vital signs will be evaluated before, during and after surgery. To evaluate the biochemical parameters, blood samples will be taken again preoperatively and at the 6th and 24th hours postoperatively. Postoperative subjective well-being findings of the patients will be evaluated. The SF-36 quality of life scale will be applied to evaluate the quality of life of the patients on the 30th day after surgery.
88891870|NCT05402592|Experimental|Carbonhydrate-rich drink|Patients will be given 800 ml of carbohydrate-containing beverage until 24:00 at night before the surgery by the blind caregiver, and 400 ml of carbohydrate-containing beverage in the morning 2-3 hours before the surgery.Blood samples for plasma glucose, plasma cortisol, and serum insulin levels will be drawn just before the morning dose, 40 minutes and 90 minutes after ingestion of the beverage, and during anesthesia induction. Gastric volume and pH will be evaluated within the first 10 minutes intraoperatively. Vital signs will be evaluated before, during and after surgery. To evaluate the biochemical parameters, blood samples will be taken again preoperatively and at the 6th and 24th hours postoperatively. Postoperative subjective well-being findings of the patients will be evaluated. The SF-36 quality of life scale will be applied to evaluate the quality of life of the patients on the 30th day after surgery.
88891871|NCT05391945||goiter|Patients referred for partial/total thyroidectomy for goiter
88891872|NCT05389995|Active Comparator|Potassium citrate|
88891873|NCT05389995|Active Comparator|Crystal light|
88891874|NCT05389995|Active Comparator|Crystal light + potassium citrate|
88891875|NCT05382637|Experimental|Growth hormone|The participant will receive escalating dose of growth hormone until an IGF-1 level is maintained between the mean and +2 standard deviations.
88891876|NCT05374915|Experimental|REM-001 photodynamic therapy (PDT)|Single arm study. All enrolled patients receive REM-001 therapy
88891877|NCT05369351|Experimental|Standard treatment+mirabegron|In addition to standard treatment, the first dose of mirabegron 50mg/day will be given within 72 hours of symptom onset and continued until the 7th day after onset.
88891878|NCT05369351|Other|Standard treatment|Patients will receive usual care
88891879|NCT05369130||Develop Persistent Postsurgical Pain|Pain present 3 months post-op related to the surgical operation
89536733|NCT03581981|Active Comparator|Treatment as Usual (TAU)|Veterans assigned to PCMHI-TAU will receive standard PCMHI care for PTSD in PC that does not include any PTSD-specific therapy in PCMHI but may include referral for specialty care (including specialty MH), medication management or general supportive contact while awaiting referral. All PTSD care received during the study will be collected and monitored as TAU.
88891880|NCT05369130||Absence of Persistent Postsurgical Pain|Resolution of post-operative pain within the first three months of the operation
88891881|NCT05365347|No Intervention|Treatment as Usual|
88891882|NCT05365347|Experimental|Cognitive enhancement therapy (CET)|Cognitive enhancement therapy with an aim to reduce alcohol consumption
88891883|NCT05362955|Experimental|5-FU Arm|intravaginal 2g 5-fluorouracil cream in every two weeks
88891884|NCT05359861|Experimental|Lead-In|A minimum of 6 patients and up to 30 patients will be enrolled in an open-label Lead-In to assess the preliminary safety and tolerability of SRF388 with atezolizumab plus bevacizumab.
88891885|NCT05359861|Experimental|Arm A: SRF388 in Combination with atezolizumab plus bevacizumab|Patients randomized to Arm A will receive SRF388 with atezolizumab plus bevacizumab.
88891886|NCT05359861|Experimental|Arm B: Placebo in combination with atezolizumab plus bevacizumab|Patients randomized to Arm B will receive placebo with atezolizumab plus bevacizumab.
88891887|NCT05356338|No Intervention|Control|The control group participants in this study will not receive any intervention as is the current standard of clinical care for excess sugary drink consumption. They will receive monthly check-in reminders from research staff to promote engagement and retention and will participate in data collection visits at baseline, 3 and 6 months.
88922080|NCT05846984|Experimental|Learning Skills Together Intervention|Complex care psychoeducation training intervention for family caregivers
88922081|NCT05846984|Active Comparator|Caregiver Healthy Living Intervention|Healthy living intervention for family caregivers
88922082|NCT05843747|Experimental|Sampling|
88891888|NCT05356338|Experimental|Intervention|"Intervention participants will receive a 6-month behavioral intervention with the following components: A water promotion toolkit that includes water bottles, water flavor infusers, stickers to decorate bottles, children's book about water consumption, and instructions for other intervention components (how to view videos, download app, and prepare for calls) Two brief educational videos: a 5-minute video about healthy drink choices for the family and a 3-min video educating residents about local water. Ready, Set Gulp! app for families that will help all family members track their beverage intake, find out how much water and sugar they are consuming, set goals, compete for points, answer quiz questions and create new recipes for flavor infused water. A series of 14 interactive voice response phone calls to parents over 6 months that educate parents on topics relevant to improving family drink choices.~Two counseling sessions by a WIC nutritionist at months 2 and 4"
88891889|NCT05344092|Experimental|VetEd Mobile Application|Participants be provided with the VetEd mobile app, with instructions on how to utilize the app at home over a four-week period.
88891890|NCT05340309|Experimental|Treatment (atezolizumab and recombinant human hyaluronidase)|Patients receive atezolizumab and recombinant human hyaluronidase SC over 3-8 minutes on day 1. Cycles repeat every 3 weeks for 1 year (early-stage lung cancer) or up to 2 years (late-stage lung cancer) in the absence of disease progression or unacceptable toxicity.
88891891|NCT05338671|Active Comparator|2% Lidocaine 1:100,000 epinephrine|Participants in this arm will receive an inferior alveolar nerve block with 1 cartridge (1.8 mL) of 2% Lidocaine 1:100,000 epinephrine following endodontic treatment.
88891892|NCT05338671|Active Comparator|0.5% bupivicaine 1:200,000 epinephrine|Participants in this arm will receive an inferior alveolar nerve block with 1 cartridge (1.8 mL) of 0.5% bupivicaine 1:200,000 epinephrine following endodontic treatment.
88891893|NCT05328973|Other|ELEQUIL|Aromatherapy will be provided using a lavender-peppermint patch called an Aromatab.
88891894|NCT05327868|Experimental|Obese|BMI in Obesity range
88891895|NCT05327868|Experimental|Normal weight (lean)|Normal body weight
88891896|NCT05314088|Experimental|RISE+ Resilience Intervention|Participants in the intervention group will come to the lab for four two-hour weekly sessions in small groups of 3-4. The intervention includes psychoeducational videos and individual written activities on topics such as coping strategies, cognitive appraisals, the responsibility model, and social connections, all integrated into the overarching process of resilience. The intervention will be facilitated by a trained research assistant but as in the pilot study, he/she will be minimally involved (i.e., only administering the videos and explaining the activities) to keep the private reflective nature of the program that participants liked. Upon completion of the program, participants will be given handouts with summaries of the program material. We will gather qualitative and quantitative feedback on the intervention at the one-month posttest.
88922083|NCT05840952|Experimental|ALG-097558|Oral doses of ALG-097558 in Healthy Volunteers, up to 20 doses over 10 days
88922084|NCT05840952|Placebo Comparator|Placebo|Oral doses of placebo in Healthy Volunteers, up to 20 doses over 10 days
89414179|NCT06204874|Experimental|Pulsed Radiofrequency Ablation Arm|18 total subjects in this arm. Subjects will be laid in the prone position. Local anesthesia will be administered. The appropriate spinal interspace will be identified under fluoroscopic guidance and hollow-tip needles will be inserted through the back into the retroperitoneal space adjacent to the superior hypogastric plexus. A microelectrode will be inserted through the hollow needle. A test pulse will be delivered. When proper positioning has been confirmed, 4mL of 1% lidocaine without epinephrine will be administered to reduce discomfort associated with radiofrequency ablation. Pulsed radiofrequency ablation will be performed at a pulse frequency of 2Hz, pulse width of 20ms, temperature of 42 degrees Celsius, total duration 120 seconds. The microelectrode and hollow-tip needle will then be withdrawn.
89414180|NCT06204874|Sham Comparator|Sham Arm|18 total subjects in this arm. Subjects will be laid in the prone position. Local anesthesia will be administered. The appropriate spinal interspace will be identified under fluoroscopic guidance and hollow-tip needles will be inserted through the back into the retroperitoneal space adjacent to the superior hypogastric plexus. A microelectrode will be inserted through the hollow needle. A test pulse will be delivered. Sham pulsed radiofrequency ablation will then be performed with the radiofrequency generator disconnected from the microelectrode. The duration of the sham procedure will be 120 seconds. The microelectrode and hollow-tip needle will then be withdrawn.
89536734|NCT03948347|Active Comparator|active|Active patients will receive liraglutide injections
88891897|NCT05314088|Placebo Comparator|Stress Reduction Control|Control participants will complete an attention-matched internet stress reduction paradigm, which includes an internet navigation protocol and placebo computer games. As with the intervention group, participants in the control group will come to the lab for four two-hour weekly sessions in small groups of 3-4. Facilitator involvement will be the same as the intervention group (e.g., the research assistant will explain computer activities and games but will otherwise not interact with the participant).
88891898|NCT05311384|Experimental|Keys intervention|All participants will receive the Keys CI Therapy protocol over an 8-week intervention period.
88891899|NCT05300048|Experimental|Cohort 1a - Dose Modification without nab-paclitaxel|Subjects with any solid tumor will receive multiple doses of serabelisib administered orally and will consume Insulin Suppressing Diet for up to 12 months
88891900|NCT05300048|Experimental|Cohort 1b - Dose Modification with Nab-Paclitaxel|Subjects with endometrial cancer, ovarian clear cell or ovarian endometriod carcinoma will receive multiple doses of serabelisib administered orally and will consume Insulin Suppressing Diet for up to 12 months. In addition, these subjects will receive nab-paclitaxel intravenously weekly.
88891901|NCT05300048|Experimental|Cohort 2 - Expansion Colorectal Cancer|Subjects will receive dose of serabelisib as determined from Cohort 1a and 1b, and will consume Insulin Suppressing Diet for up to 12 months
89193010|NCT05764343|No Intervention|Routine support/care arm|As the followed routine implementation, this group will be given a brief smoking cessation intervention and will be recommended to apply to smoking cessation outpatient clinics by getting an appointment from quit services.
89199115|NCT00884013||5|Quality Reporting and Recognition with ABCS measures reminders turned on
89199116|NCT00884013||6|Quality Reporting and Recognition with non-ABCS measures reminders turned on
89193011|NCT05764343|Active Comparator|Immediate support arm|Those randomized to this group will have an immediate appointment at the smoking cessation outpatient clinic in addition to the brief smoking cessation intervention.
89193012|NCT05756569|Experimental|Treatment (enfortumab vedotin, pembrolizumab)|Patients receive enfortumab vedotin IV and pembrolizumab IV on study. Patients also undergo CT scan or MRI, and collection of blood throughout the trial.
89199117|NCT02542995|No Intervention|Non-intervention|Usual clinical conditions
89414181|NCT06204835|Experimental|RDCy7 Intraoperative Fluorescence|The patients will receive an injection of fluorophore (RDCy7) before the surgery. Then intraoperative fluorescence imaging will be performed to guide lesion resection.
89414182|NCT06204822||blood pressure measurement|"Participants sit in a comfortable posture with hands naturally placed on the table or thighs, palms facing up without obstruction, facing the camera lens. Rest for 2 minutes.~First blood pressure measurement is taken, and images and data are recorded for 2 minutes.~Participants place both feet on a stool, exerting pressure on the instep (hooking towards the knee) for 1 minute.~Maintain the instep pressure and perform the second blood pressure measurement, recording images and data for 2 minutes.~Participants place both feet flat on the ground, resting for 1 minute.~Third blood pressure measurement is taken, and images and data are recorded for 2 minutes.~The examiner adjusts the program settings, and the participant repeats steps 2 to 6 once."
89414183|NCT06204822||blood oxygen saturation measurement|"Participants sit in a comfortable posture with both hands placed naturally on the table or thighs, palms facing up without obstruction, and facing the camera lens. They rest for 2 minutes.~Participants breathe normally while recording images and data for 1 minute.~Participants hold their breath until discomfort (aiming for at least 40 seconds) while recording images and data for 1 minute.~Participants return to normal breathing, and images and data are recorded for 3 minutes.~The experimenter adjusts program settings, and participants repeat steps 2 to 4 once."
89414184|NCT06204796|Active Comparator|Vitamin D+ Systemic steroids|vitamin D supplement was given as 60,000 IU weekly in conjunction with systemic steroids.
89414185|NCT06204796|Active Comparator|Systemic steroids alone|systemic steroids only
89414186|NCT06204783||Cohort A: Transaortic Valve Implantation (TAVI)|Elective TAVI with biventricular PV loop monitoring (throughout the procedure)
89414187|NCT06204783||Cohort B: Mitral Transcatheter Edge-to-Edge Repair (mitral TEER)|Elective mitral TEER with biventricular PV loop monitoring (throughout the procedure)
89414188|NCT06204783||Cohort C: Tricuspid Transcatheter Edge-to-Edge Repair (tricuspid TEER)|Elective tricuspid TEER with biventricular PV loop monitoring (throughout the procedure)
89414189|NCT06204770|Experimental|groups of infants with CMPA|Administered treatment for 4 weeks during intervention period.
89414190|NCT06204757||women|women who have given birth to a healthy baby
89414191|NCT06204757||midwives|
89414192|NCT06204744|Experimental|Home-based GRASP program|
89414193|NCT06204744|Active Comparator|Conventional occupational therapy home program|
89414194|NCT06204731|No Intervention|Control group|The control group will not undergo the training program.
89414195|NCT06204731|Experimental|LHTL (live high - train low)|Training performed under normoxic conditions (223m), stay and sleep in normobaric hypoxic conditions (3000m) and thermoneutral conditions (21°C) and constant humidity (40%).
89005587|NCT04566913|Experimental|Patients recruited from Cairo University|"After Cone beam CT assessment , The patient is assigned for nonsurgical periodontal phase then an impression is taken for stent formation to facilitate tissue thickness measurement .~> After 2 weeks , the patient is assigned for surgical phase to extract the palatal and apical aspect of the tooth and leave the buccal portion .~Socket preservation is attempted in the socket , using 'genbioss ' bone graft. Modified free gingival graft is done on the pontic site to cover the buccal root shield and the bone graft .~Post operative instructions include :~Analgesics (Prufen 400 mg ) three times for three days~Antibiotic (Augmentin 1gm ) twice daily for one week The patient will be assured to contact the operator of any unexpected complications occured ."
89005588|NCT04566835|Experimental|Education Group|Taking the Health Promotion Program with cartoons and comics for Children with Asthma
89005589|NCT04566835|Other|Control Group|Taking standart care
89414196|NCT06204731|Experimental|LLTH (live low - train high)|"Training performed under normobaric hypoxia conditions (3000m), stay and sleep in normoxic conditions (223m) and thermoneutral conditions (21°C) and constant humidity (40%).~will stay and sleep in normoxic (223m), and train in normobaric hypoxia (3000m)"
89005590|NCT04567030|Experimental|Experimental group A (AI Group: EG-A)|Behavioral: AI intervention For the EG-A, a AI scan box will give to patients that taking mouth image at home once a week until six-month. The AI will send automated message to patients' mobile phone telling about their oral hygiene condition, gum condition, tooth condition.
89005591|NCT04567030|Experimental|Experimental group B (AI with humanized Group: EG-B)|"Behavioral: AI intervention For the EG-B,a AI scan box will give to patients that taking mouth image at home once a week until six-month. The AI will send automated message to patients' mobile phone telling about their oral hygiene condition, gum condition, tooth condition.~The humanized counseling will also send to patients' mobile phone about each patients oral hygiene condition and advises."
89005592|NCT04567030|No Intervention|Control group (CG)|the control group(CG) only have standard oral hygiene education
89005593|NCT00238212|Experimental|Treatment|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89005594|NCT04566757|Experimental|Umbilical Cord Plasma Infusion|Infusion of 50cc of Umbilical Cord Blood Plasma bi-monthly for 6 months
89005595|NCT04566679|Experimental|Butyrate|oral butyrate (500mg) once or twice per day
89005596|NCT04566679|Placebo Comparator|Placebo|oral placebo once or twice per day
89005597|NCT00238251|Active Comparator|Arm I|Patients undergo whole-brain radiotherapy (WBRT) once daily on days 1-5 and 8-12 and receive oral gefitinib once daily on days 1-28. Gefitinib treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity
89005598|NCT00238251|Active Comparator|Arm II|Patients undergo WBRT as in arm I and receive oral temozolomide once daily on days 1-21. Temozolomide treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity
89005599|NCT04566718||Group A|Obese women who have been treated with metformin for one year prior to the study.
89005600|NCT04566718||Group B|Obese women who have been treated with metformin for at least three years prior to the study.
89005601|NCT02210845|Active Comparator|Financially incentivized weight loss|Participants can be assigned to the financially incentivized weight loss group in which they can receive 50 dollars at the end of the month if they achieve their monthly weight loss goal.
89414197|NCT06204731|Experimental|LLTL (live low - train low)|Training performed and stay and sleep in normoxic conditions (223m) and thermoneutral conditions (21°C) and constant humidity (40%).
89414198|NCT06204718|Experimental|Standard pelvic floor exercises|Standard pelvic floor exercises in addition to Global Postural Reeducation training
89414199|NCT06204718|Experimental|Involuntary reflexive pelvic floor exercises|Involuntary reflexive pelvic floor exercises in addition to Global Postural re-education training
89414200|NCT06204705||Veterans with Bipolar Disorders|Veterans with a diagnosis of a bipolar disorder.
89414201|NCT06204705||VA clinicians and administrators|VA clinicians and administrators who provide or oversee clinical care of Veterans with bipolar disorders
89414202|NCT06204692|Other|Computer Guided Dental Implant Surgery.|Computer Guided Dental Implant Surgery
89414203|NCT06204679|Experimental|FDC Fasting|Day 1, Day 7, Day 13
89005602|NCT02210845|Placebo Comparator|Standard of Care|Participants can be assigned to standard of care where they receive no intervention.
89414204|NCT06204679|Experimental|FDC Fed|Day 1, Day 7, Day 13
89414205|NCT06204679|Experimental|Reference Fasting|Day 1, Day 7, Day 13
89414206|NCT06204666|Experimental|High Dose Hemp Fiber Bar|20% hemp hull powder
89414207|NCT06204666|Experimental|Low Dose Hemp Fiber Bar|5% hemp hull powder
89414208|NCT06204666|Placebo Comparator|Placebo|0% hemp hull powder
89414209|NCT06204653|Experimental|High-flow nasal oxygenation group (HFNO group)|
89414210|NCT06204653|Active Comparator|Facemask ventilation group (MV group)|
89414211|NCT06204640|Experimental|spironolactone|
89414212|NCT06204640|No Intervention|standard of care|
89414213|NCT06204627|Active Comparator|Active bipolar TDCS associated with laterality recognition stimuli|Participants will have carbon electrodes positioned, with contact through a 5x7cm sponge moistened in saline solution, with the anode on M1 and the cathode in the supra-orbital region. Individuals with active bipolar TDCS will receive a 2mA stimulus for twenty minutes. Meanwhile, they will use the Regognise hand application to discriminate right/left side of hand images.
89536735|NCT03948347|No Intervention|standard care/no intervention|standard care for stroke as per hospital protocol
89414214|NCT06204627|Active Comparator|Active bipolar TDCS associated with landscape recognition stimuli|"Participants will have carbon electrodes positioned, with contact through a 5x7cm sponge moistened in saline solution, with the anode on M1 and the cathode in the supra-orbital region. Individuals with active bipolar TDCS will receive a 2mA stimulus for twenty minutes.~At the same time, they will be guided to recognize landscapes that do not refer to the recognition of laterality."
89414215|NCT06204627|Active Comparator|TDCS sham associated with laterality recognition stimuli|Participants will have carbon electrodes positioned, with contact through a 5x7cm sponge moistened in saline solution, with the anode on M1 and the cathode in the supra-orbital region. Stimulation will remain inactive for the 20 minutes. Meanwhile, they will use the Regognise hand app to discriminate right/left hand images.
89414216|NCT06204627|Placebo Comparator|TDCS sham and landscape recognition|Participants will have carbon electrodes positioned, with contact through a 5x7cm sponge moistened in saline solution, with the anode on M1 and the cathode in the supra-orbital region. Stimulation will remain inactive for the 20 minutes. At the same time, they will be guided to recognize landscapes that do not refer to the recognition of laterality.
89005603|NCT02210845|Active Comparator|Supervised Exercise|Participants can be assigned to the supervised exercise arm which they will receive supervised professional training once a week.
89005604|NCT02210884|Experimental|Vitamin D|Weekly oral dose of 15,000 IU of Vitamin D3
89414217|NCT06204614|Experimental|DRUG SCREENING USING IMD IN BLADDER CANCER|Study participants placed in arm 1 will be implanted with the microdevice.
89414218|NCT06204601|Experimental|Experimental group|Experimental group
89414219|NCT06204601|No Intervention|Control group|Control group
89414220|NCT06204562|Experimental|one-month imitated laughter practice|The intervention is one-month imitated laughter practice. Each practice session lasts for 3 minutes once a day, giving a total of 21 minutes per week. A brief one-to-one training will be offered and a trained research assistant (RA1). Further in-person demonstration and return demonstration will be conducted until participant is able to demonstrate the Duchenne smile on their own. RA1 will be on-site for two days in the first week and one day in the second week to support the participants.
89414221|NCT06204562|Experimental|waitlist control|The waitlist control group will be under usual care for the first 8 weeks. Then, they will start intervention after the 8 week, and receive two additional outcome assessments.
89414222|NCT06204549|Other|Comorbidities screening and management|
89414223|NCT06204536|Experimental|technology integrated care planning cohort|This cohort will consist of 15 BCBAs that will receive a minimum of 3 technology-based tools (2 proprietary tools and at least 1 non-proprietary tool) for use in conjunction with the standard of care to develop and manage ABA treatment plans for active patients.
89414224|NCT06204536|No Intervention|non-technology integrated care cohort|This cohort will consist of 5 BCBAs that will follow the standard of care that does not involve the use of the tech-based tools to develop and manage ABA treatment plans for active patients receiving ABA.
89414225|NCT06204497|Experimental|Stent-based Diverting Technique|For Stent-based Diverting Technique, the small intestine measuring 15 cm from the ileocecal junction was pulled out through the median incision in the lower abdomen. After a length-wise incision was established in the mesenteric margin of the small intestine, the degradable stent was implanted, and the intestine was sutured. Then, the stent was held in place using an external tie around the bowel. Next, a mushroom-like tube (28 Fr) was placed into the intestine proximal (5-10 cm) to the aforementioned stent. The other side of the mushroom-like tube was inserted through the right lower abdominal wall and connected with a drainage bag. An abdominal drainage tube, or an anal tube, if necessary, was inserted in the proper location prior to the closure of the incision and the abdominal cavity. Abdominal X-ray was routinely performed every week to detect stent degradation, and the mushroom-like tube (28 Fr) was removed two days after stent degradation.
89414226|NCT06204497|Active Comparator|Ileostomy|There will be an ileostomy for the control group. An incision with a diameter of 2 cm will be performed in the lower abdomen, and layers will be separated into the abdominal cavity. The intestine, 20cm to the ileocecal juction under laparoscopic vision, will be pulled out. The anterior sheath of the rectus abdominis and the serous layer of the intestine will be sutured with an absorbable line. Then, the middle point of the mesangial margin of the intestine will be transected, and the intestine will be fixed on the skin. No volvulus or angular formation of the intestine should be confirmed laparoscopically.
89414227|NCT06204484|Active Comparator|MRD-negative standard adjuvant therapy|In MRD-negative standard therapy groups, patients will receive 3-month capecitabine and oxaliplatin (CAPEOX) therapy.
89414228|NCT06204484|Experimental|MRD-negative deferred adjuvant therapy|In MRD- deferred adjuvant therapy group, patients won't get the standard CAPEOX adjuvant therapy at first. When MRD negative status turns to positive status, the 3-month CAPEOX therapy will be arranged.
89414229|NCT06204484|Active Comparator|MRD-positive standard adjuvant therapy|In MRD-positive standard therapy groups, patients will receive 3-month CAPEOX therapy, regardless of the MRD status.
88891902|NCT05300048|Experimental|Cohort 3 - Expansion Endometrial Cancer|Subjects will receive dose of serabelisib as determined from Cohort 1a and 1b, and will consume Insulin Suppressing Diet for up to 12 months. If results from Cohort 1b show a favorable risk-benefit ratio, nab-paclitaxel will be administered intravenously weekly.
88891903|NCT05300048|Experimental|Cohort 4 - Expansion Ovarian Clear Cell or Ovarian Endometrioid Carcinoma|Subjects will receive dose of serabelisib as determined from Cohorts 1a and 1b, and will consume Insulin Suppressing Diet for up to 12 months. If results from Cohort 1b show a favorable risk-benefit ratio, nab-paclitaxel will be administered intravenously weekly.
88891904|NCT05298930|Experimental|Physical activity intervention|"The intervention will take place during the whole isolation phase and will consist of an APA program defined at inclusion, integrating supervised sessions with an APA teacher, as well as unsupervised sessions. The program will be individualized according to the patient's age, physical condition and PA preferences. The sessions will also be adapted to the biological, psychological and social parameters of the patients.~The intervention will be carried out during the entire hospitalization period and for a maximum of 3 months. An connected bike will be installed in the patient's room for the duration of the hospitalization."
88891905|NCT05294471||Healthy participants|70 healthy participants will be recruited, across substudies 1, 2, 4, and 5
88891906|NCT05294471||Participants with known or suspected iron overload|30 Participants with known or suspected iron overload will be recruited, to substudy 3
88891907|NCT05294471||Participants with elevated levels of liver fat|30 participants with elevated levels of liver fat will be recruited, to substudy 3
88891908|NCT05294471||Participants referred for clinical abdominal MRI|60 participants referred for clinical abdominal MRI will be recruited, to substudy 6
88891909|NCT05291507|Experimental|Muse MRgFUS System|Subjects will undergo partial ablation of half (~50%) of their tumor followed by surgical resection approximately 2-3 weeks after ablation.
88891910|NCT05288348|Experimental|DSUVIA (sufentanil)|Subjects will receive a single dose of 30 micrograms DSUVIA (sufentanil) tablet utilizing a sublingual applicator
88891911|NCT05288348|Active Comparator|Standard Care|Subjects will receive standard care pain management
88891912|NCT05286658|Experimental|Healthy Adult Speakers|healthy adult participants across the lifespan in three groups:18-35, 36-55, and 56+
88891913|NCT05280743||MATERNAL cohort|Nursing mothers who underwent Cesarean Delivery and who are receiving oxycodone to treat post-operative pain
88891914|NCT05280743||NEONATE-INFANT cohort|"Neonate encompasses a newborn from the age of birth until <28 days of life. Infant refers to the period of 28 days of life until 1 year of life."
88891915|NCT05260268|No Intervention|Usual Care|"Usual care refers to the normal standard clinical practices immediately post-transplant to the 18 months following. Liver Transplant Recipients at sites have lab values taken weekly for the first 8-10 weeks post-transplant, shifting to every 2-4 weeks for the next 3-4 months, then monthly to every 3 months thereafter depending on clinical needs.~All sites follow a similar schedule of tapering clinic visits ranging from weekly in the first 4 weeks to every 2-4 weeks in months 4-6, every 3-6 months in months 7 12, and every 6 months in months 12-24. All sites assign each patient to a specific transplant coordinator, first paired with a transplant surgeon (first 3-6 months), and then a transplant hepatologist for the remainder of follow-up.~All patients and caregivers receive standard medication teaching prior to hospital discharge and then ad hoc. No routine text message reminders, caregiver reminders, or adherence alerts are used in usual care."
88891916|NCT05260268|Experimental|TEST Intervention|"Clinical activities for Usual Care will also be provided in the TEST arm. The TEST intervention is a technology-enabled strategy to routinely monitor regimen use, adherence, and persistence via a 'low touch', easy to use, online behavioral toolkit - Way to Health . It was developed by University of Pennsylvania researchers to automate behavioral intervention. The TEST approach includes monthly adherence assessments, with tailored adherence support. The following components will be included in the intervention:~Monthly W2H Adherence Assessment & Clinician Alerts~Medication Reminders~Laboratory and Appointment Notifications~Supplemental Self-Management Support"
88891917|NCT05259865||Patients with chronic pain|Patients seen in clinic agreeing to participate in trial by completing clinical questionnaires and genetic testing
88891918|NCT05247788|Experimental|Intoxicated risk awareness training session|Participants will complete an intoxicated risk awareness training session in which they receive a controlled alcohol dose with structured feedback and training to accurately appraise the impairing effects of alcohol and estimate their blood alcohol concentration (BAC).
88891919|NCT05247788|Active Comparator|Alcohol exposure only|Participants assigned to the alcohol-exposure-only condition undergo the same alcohol dose exposures over the session but receive a general body scan and do not receive feedback concerning BAC or performance.
88891920|NCT05242770|Placebo Comparator|Control Arm|Educational pamphlet with resources for sexual dysfunction
88891921|NCT05242770|Experimental|Physical Therapy Arm|Physical therapy for sexual dysfunction.
88891922|NCT05231785|Experimental|Part A: ALN-APP|Participants will be administered a single dose of ALN-APP.
89414230|NCT06204484|Experimental|MRD-positive intensive adjuvant therapy|In the MRD+ intensive standard therapy group, which represents a high risk of recurrence, patients will receive 3-month modified folinic acid, fluorouracil, oxaliplatin and irinotecan (mFOLFOXIRI) intensive therapy, instead of the CAPEOX standard adjuvant therapy.
88891923|NCT05231785|Placebo Comparator|Part A: Placebo|Participants will be administered a single dose of placebo.
88891924|NCT05231785|Experimental|Part B:|Participants will be administered multiple doses of ALN-APP.
88891925|NCT05226351|Active Comparator|Dronabinol PTSD|Donabinol before cognitve testing - PTSD patients
88891926|NCT05226351|Active Comparator|Dronabinol healthy controls|Donabinol before cognitve testing - healthy controls
88891927|NCT05226351|Placebo Comparator|Placebo PTSD|Placebo before cognitve testing - PTSD patients
88891928|NCT05226351|Placebo Comparator|Placebo healthy controls|Placebo before cognitve testing - healthy controls
89414231|NCT06204471|Experimental|Airbag1|Airbag1 worn for two months
88891929|NCT05221320|Experimental|Stage 1 - 5 baskets included, based on primary disease|"Ulixertinib: 450mg twice daily (BID), orally, days 1-28~Hydroxychloroquine: 600mg BID, orally, days 1-28~Cycles repeat every 28 days in absence of disease progression or unacceptable toxicity"
89414232|NCT06204471|Experimental|Airbag2|Airbag2 worn for 2 months
89414233|NCT06204458|Experimental|mild hyperthermia group|For the study, the method of passive whole-body hyperthermia is used. The IRATHERM®1000 system (Von Ardenne Institute for Applied Medical Research/Dresden) is used, in which the entire body is heated to a core body temperature above the physiological 37°C under the application of 10L/min oxygen. The aim is to achieve a core body temperature of 38.5°C within the framework of mild whole-body hyperthermia. After this warm-up phase, a temperature plateau phase of about 60 minutes follows, in which an attempt is made to maintain the core body temperature of 38.5°C. In the temperature plateau phase, a slight increase in the body core temperature is usually observed. The total time required for a session is given as 1.5 to 2 hours, but this depends on the individual constitution and daily condition of the patient and can be subject to fluctuations.
89414234|NCT06204458|Sham Comparator|sham group|"Within the patient information, privacy policy, etc., there is talk of gentle hyperthermia and classic, mild hyperthermia. This serves to introduce the sham intervention as a control group compared to the patient. Lighting conditions, procedures, instructions and explanations are indistinguishable. Within the application, patients of the sham group will receive a hyperthermia application almost without overheating. In order to achieve this, the patients will be positioned on the IRATHERM®1000 in accordance with the Von Ardenne Institute's regulations. Due to the insulating blanket and the natural device and body heat, the patients of the sham group experience a gentle warmth, which is not the same as regular whole-body hyperthermia and an increase in the body core temperature of about 1.5 °C. In the sham setting, the core body temperature increases by about 0.3 to 0.4 °C within a 55-minute session."
89414235|NCT06204445|Experimental|Green (slightly roasted) coffee|Slightly roasted ground Arabica coffee rich in phenolic compounds (hydroxycinnamic acids). Participants will consume 3 cups of freshly brewed coffee daily (breakfast, mid-morning, early afternoon). Black coffee, no milk.
89414236|NCT06204445|Active Comparator|Roasted coffee|Traditional roasted ground coffee (Arabica). Participants will consume 3 cups of freshly brewed coffee daily (breakfast, mid-morning, early afternoon). Black coffee, no milk.
88891930|NCT05221320|Experimental|Stage 2 - basket expansion based on Stage 1|"Ulixertinib: 450mg BID, orally, days 1-28~Hydroxychloroquine: 600mg BID, orally, days 1-28~Cycles repeat every 28 days in absence of disease progression or unacceptable toxicity"
88891931|NCT05204797|Experimental|Robot-assisted UKA|Unicompartmental knee replacement (Journey II UKA, Smith and Nephew, USA) positioned via CORI surgical system (Smith & Nephew, USA).
88891932|NCT05204797|Active Comparator|Standard technique UKA|Unicompartmental knee replacement (Journey II UKA, Smith and Nephew, USA) positioned via standard technique.
88891933|NCT05198076|No Intervention|G1 ( Conventional Physical Therapy Program group)|Patients in (G1) will be treated by a designed physiotherapy program consisted of aerobic exercise on treadmill, stretching exercise, Proprioceptive neuromuscular facilitation (PNF) techniques, Graduated active exercises, gait training, Reciprocal and weight shifting exercises. The treatment will be conducted three sessions per week, day after day for successive four weeks. The session duration was 40min to 1 hour.
88891934|NCT05198076|Experimental|G2 ( High Frequency rTMS group)|Patients in (G2) will be treated by high frequency repetitive transcranial magnetic stimulation (HF-rTMS) in addition to the same physiotherapy program as in G1. The treatment will be conducted three sessions per week, day after day for successive four weeks. The session duration for rTMS will be 20-30 minutes, the physiotherapy session will be 40-45 min.
88891935|NCT05183854|Experimental|Arm I (PCV20, PPSV23)|Patients receive pneumococcal 20-valent conjugate vaccine IM on day 1. PnumoVax23 will be given as an intramuscular injection on Visit 2 (approximately Day 75)
88891936|NCT05183854|Experimental|Arm II (PCV20, PPPSV23)|Patients who have received or are receiving venetoclax therapy, receive pneumococcal 20-valent conjugate vaccine IM at study visit 1 and pneumococcal polyvalent vaccine IM at study visit 2 in the absence of disease progression or unacceptable toxicity.
88891937|NCT05176704||CDR = 0.5|50 Alzheimer's Disease (AD) patients including predominant AD with mixed vascular and MCI due to AD based on their CDR score. Questionable/very mild dementia (CDR = 0.5)
88891938|NCT05176704||CDR = 1|50 Alzheimer's Disease (AD) patients including predominant AD with mixed vascular and MCI due to AD based on their CDR score. Mild dementia/MCI (CDR = 1)
88891939|NCT05176704||CDR = 2|50 Alzheimer's Disease (AD) patients including predominant AD with mixed vascular and MCI due to AD based on their CDR score. Moderate dementia (CDR = 2)
88891940|NCT05176704||CDR = 3|50 Alzheimer's Disease (AD) patients including predominant AD with mixed vascular and MCI due to AD based on their CDR score. Severe dementia (CDR = 3)
88891941|NCT05176704||Healthy Control|50 Participant with no evidence or history of significant neurodegenerative disorder affecting brain function.
88891942|NCT05174884|Experimental|Single Casea S pellet|In Part 1 of this study, four women will each have a single Casea S pellet (22.2 mg ENG) inserted into the inner aspect of the non-dominant upper arm.
88891943|NCT05174884|Experimental|Two Casea S pellets|In Part 2 of this study, eight women will each have two Casea S pellets (44.4 mg ENG) inserted into the inner aspect of the non-dominant upper arm.
88891944|NCT05174884|Experimental|Variable Casea S pellets|Based on PK modeling from Parts 1 and 2, the investigator will select one or more doses of Casea S for Part 3. In Part 3 of this study, approximately 18 women will each have Casea S pellets (range 1-3 pellets) inserted into the inner aspect of the non-dominant upper arm.
88891945|NCT05172687||Nursing home patients of treated study prescribers|Patients attributed to physicians who received overprescribing letters in the primary study who reside in a nursing home.
89414237|NCT06204432|Placebo Comparator|Normal Saline|The Normal Saline arm will use normal saline nasal spray and olfactory training twice a day for 12 weeks.
89414238|NCT06204432|Experimental|Sodium Citrate|The Sodium Citrate arm will use sodium citrate nasal spray and olfactory training twice a day for 12 weeks.
89414239|NCT06204419|Experimental|A (XH-S002)|Participants will receive XH-S002 once or twice daily on scheduled days.
89414240|NCT06204419|Experimental|B (Placebo)|Participants will receive matching placebo once or twice daily on scheduled days.
88891946|NCT05172687||Nursing home patients of control study prescribers|Patients attributed to physicians who received placebo letters in the primary study who reside in a nursing home.
88891947|NCT05172687||Community-dwelling patients of treated study prescribers|Patients attributed to physicians who received overprescribing letters in the primary study who reside in the community.
89005605|NCT02210884|Placebo Comparator|Placebo|Placebo capsule containing no vitamin D
89005606|NCT00238290|Experimental|Arm A|Patients receive trastuzumab (Herceptin®) IV over 30-90 minutes once in weeks 1-3 OR once in week 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients experiencing disease progression after 9 weeks receive trastuzumab as before and oral letrozole once daily in the absence of further disease progression or unacceptable toxicity.
89005607|NCT02895217|Experimental|Cycling exercise in water|The aim of this project is to investigate energetic response (energy expenditure and food intake) of a single bout of cycling exercise in water vs on dryland in normal weight and overweight premenopausal women.
89005608|NCT02895217|Experimental|cycling exercise on dryland|The aim of this project is to investigate energetic response (energy expenditure and food intake) of a single bout of cycling exercise in water vs on dryland in normal weight and overweight premenopausal women.
89005609|NCT02895178|Experimental|Exercise in breast cancer survivors|Combined aerobic and strength exercise training for 12 weeks under supervision
89005610|NCT02895178|No Intervention|No exercise in breast cancer survivors|Lifestyle counseling and standard of care follow up for 12 weeks
89005611|NCT02895178|Sham Comparator|Exercise in healthy subjects|Age-matched healthy subjects. Combined aerobic and strength exercise training for 12 weeks under supervision
89005612|NCT02894944|Experimental|Theragene arm|Patients who were treated with Theragene®,Ad5-yCD/mutTKSR39rep-ADP and chemotherapy
89005613|NCT02894866|Experimental|hyperbaric oxygen|Newborns with hypoxic ischemic encephalopathy treated with intensive care and hyperbaric oxygen
89005614|NCT02894866|No Intervention|control|Newborns with hypoxic ischemic encephalopathy treated with intensive care only
89005615|NCT02894905|Experimental|AL-335 (Cohort 1)|Participants with mild impaired renal function will receive a single oral dose of AL-335 800 milligram (mg) (given as 2*400-mg tablets).
89005616|NCT02894905|Experimental|AL-335 (Cohort 2)|Participants with moderate impaired renal function will receive a single oral dose of AL-335 800 mg (given as 2*400-mg tablets).
89414241|NCT06204406||Patients with non-metastatic upper tract urothelial carcinoma receiving kidney-sparing therapy|The enrolled patients were patients with limited-stage or locally advanced UTUC, who were classified into the following four categories according to the 2022 EAU guidelines as low-risk and high-risk: 1) low-risk patients who were willing to undergo kidney-sparing surgery directly; 2) High-risk patients, with solitary kidney, functional single kidney, bilateral tumors, and absolute kidney-sparing indications; 3) High-risk patients with renal insufficiency, or diseases that lead to renal insufficiency, have relative indications for kidney protection; 4) High-risk patients with good renal function, but a particularly strong willingness to preserve the kidney, willing to accept clinical studies and participate in kidney preservation.
89414242|NCT06204393||COVID-19 has a course of less than 6 days|COVID-19 is mild in hyperthyroidism patients with short course of disease.
89414243|NCT06204393||COVID-19 has a course of 6-9 days|The symptoms and immune level of COVD-19 in this group are in the middle level.
89414244|NCT06204393||COVID-19 has a course of more than 9 days|Theoretically, the symptoms and immune level of COVD-19 in this group are the worst.
89414245|NCT06204354||samples of cervical cancer|fresh samples collected from patients diagnosed with cervical cancer
89414246|NCT06204354||samples of endometrial cancer|fresh samples collected from patients diagnosed with endometrial cancer
89414247|NCT06204354||samples of ovarian cancer|fresh samples collected from patients diagnosed with ovarian cancer
89414248|NCT06204354||samples of vulva cancer|fresh samples collected from patients diagnosed with vulva cancer
89005617|NCT02894905|Experimental|AL-335 (Cohort 3)|Participants with severe impaired renal function will receive a single oral dose of AL-335 800 mg (given as 2*400-mg tablets).
89005618|NCT02894905|Experimental|AL-335 (Cohort 4)|Participants with normal renal function will receive a single oral dose of AL-335 800 mg (given as 2*400-mg tablets).
89005619|NCT02894827||EMS|
89005620|NCT02894827||Control|
89414249|NCT06204354||samples of vaginal cancer|fresh samples collected from patients diagnosed with vaginal cancer
89414250|NCT06204354||samples of rare gynecological cancer|fresh samples collected from patients diagnosed with rare gynecological cancer
89414251|NCT06204341|Experimental|HYPOPRIME treatment|Hypo fractionated pelvic radiotherapy with boost to primary tumour in the prostate with elective lymph node irradiation and minimized androgen deprivation therapy
89414252|NCT06204328|Active Comparator|Benson relaxation technique and mHealth psychoeducation|Intervention Group will receive 6 months mHealth psychoeducation & Benson Relaxation Technique
89414253|NCT06204328|No Intervention|Usual care|The usual care group will follow established and common practices by healthcare providers in these settings.
89414254|NCT06204315|Experimental|Stereotactic Radiosurgery|A non-invasive, non-surgical procedure that precisely delivers radiation to cancer on the spine while avoiding surrounding, healthy tissue.
89005621|NCT02894788||ICU|patients postoperatively admitted to ICU
89005622|NCT02894788||no ICU|patients who didn't required ICU admission postoperatively
89005623|NCT02894749|No Intervention|2D Angiography (2DA)|Standard of care - Patients benefit from a 2D completion angiogram at the end of the procedure, and from a angioCT-scan before discharge. If any technical issues is depicted on the CT-scan, a new intervention needs to be scheduled.
89005624|NCT02894749|Experimental|3D rotational angiography (3DRA)|New strategy - Patients benefit from a 3D rotational acquisition at the end of procedure, which offers CT-like reconstructions. If any technical issues is depicted on the 3DRA, it can be treated during the same operating time. A contrast-enhanced ultrasound is performed for each patient before discharge to confirm that no technical issue was missed by the 3DRA.
89005625|NCT02894593|Other|alcohol essential oils mouthwash|All subjects were instructed to rinse twice a day, in the morning and in the evening, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
89005626|NCT02894593|Active Comparator|0.20% chlorhexidine mouthwash|All subjects were instructed to rinse twice a day, in the morning and in the evening, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
89005627|NCT02894593|Placebo Comparator|Placebo|All subjects were instructed to rinse twice a day, in the morning and in the evening, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
89414255|NCT06204289|Experimental|Nurse-led Supportive Care Group|Nurse-led supportive care was given to family caregivers of patients with lung cancer.
89414256|NCT06204289|No Intervention|Control Group|The control group received only usual care. They did not receive any intervention during the study period.
89414257|NCT06204263|No Intervention|Control Group|Babies in the control group will be given only routine ward care (breast milk or formula via tube without stimulation of the pacifier or mother's finger).
89414258|NCT06204263|Experimental|Experimental Group|The baby will be allowed to suck his father's finger for five minutes three times a day before nasogastric feeding.
89414259|NCT06204211||High myopia|HM participants characterized by AL ≥ 26.00 mm or SE ≤ -6.00 D in at least one eye at the Department of Ophthalmology of the First Affiliated Hospital of Zhengzhou University (Zhengzhou, Henan Province, China) from May 2022 to April 2023 are included as cases.
89414260|NCT06204211||Control|Demographic-matched emmetropic volunteers without consanguinity serve as controls.
89414261|NCT06204185|Active Comparator|1% Metformin|1% Metformin Delivered in biodegradable gel. Frequency- One dose each at baseline, 3 months and 6 months.
89414262|NCT06204185|Placebo Comparator|Control Group|Placebo gel without the active ingredient. Delivered in biodegradable gel. Frequency- One dose each at baseline, 3 months and 6 months.
88891948|NCT05172687||Community-dwelling patients of control study prescribers|Patients attributed to physicians who received placebo letters in the primary study who reside in the community.
88891949|NCT05170646||Participants treated with upadacitinib|
88891950|NCT05162755|Experimental|Dose escalation 1a: S95029|
88891951|NCT05162755|Experimental|Dose escalation 1b: S95029 and Sym021|
88891952|NCT05162755|Experimental|Dose expansion 2a: S095029 and Sym021 and anti-HER2 therapy|
88891953|NCT05162755|Experimental|Dose expansion 2b: S095029 and Sym021 and futuximab/modotuximab|
89005628|NCT02894593|Experimental|alcohol free essential oils mouthwash|All subjects were instructed to rinse twice a day, in the morning and in the evening, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
89414263|NCT06204172|Experimental|Experimental group|patients will receive Neurowave multisensory stimulation with concurrent event-related potential acquisition. This intensive training spans five days a week over four weeks, with each session lasting 45 minutes, summing up to 20 sessions. During each session, participants will encounter personalized visual and auditory stimuli. Neurowave treatment comprises an intensive intervention, presenting emotionally significant audio-visual content linked to the patient's life history. Within Neurowave use, visual stimuli will be complemented by primary auditory stimulation, involving exposure to emotionally charged everyday sounds.
89414264|NCT06204172|Active Comparator|Control group|Participants will receive primary auditory stimulation featuring familiar and emotionally evocative everyday sounds. This involves exposure to audio tapes and sounds related to their daily life, including voices of family and friends, snippets of favorite songs, and sounds associated with past work or leisure activities. The control group will undergo a program called Intensive Sensorial Emotional Stimulation (ISES), matching the frequency, intensity, and session duration of the experimental group but without Neurowave system utilization. Distinctively, the control group will not utilize Neurowave technology. Instead, they will follow a traditional rehabilitation approach incorporating paper materials, live photos, face-to-face interaction with the therapist, and the conventional listening of music tapes. This method aims to replicate an emotionally engaging environment, serving as a comparative reference to the experimental group's Neurowave-assisted experience.
89005629|NCT02894632|Experimental|Healthy volunteers|Volunteers without cardiac, hepatic or renal pathology
89005630|NCT02894554|Placebo Comparator|lamivudine|HBsAg (+) patients received renal transplant and under lamivudine therapy.
89414265|NCT06204146|Experimental|massage|massage was applied to the infants in the experimental group three times daily for 10 days,
89414266|NCT06204146|No Intervention|control|the control group received the usual care
89414267|NCT06204120|Placebo Comparator|Placebo|
89414268|NCT06204120|Active Comparator|morphine hydrochloride injection|
89414269|NCT06204120|Experimental|LPM3480392 injection group 1|
89414270|NCT06204120|Experimental|LPM3480392 injection group 2|
88891954|NCT05160597|Experimental|Diagnostic (68Ga-PSMA-11, image-guided prostate biopsy)|"SCREENING PROCEDURE: Patients receive 68Ga-PSMA-11 IV and 50-100 minutes later, undergo a PET/CT scan. Only patients with 68Ga-PSMA-11 uptake within the prostate proceed to image-guided biopsy.~IMAGE-GUIDED BIOPSY: Patients undergo experimental image-guided prostate biopsy using PET/CT images obtained during screening procedure during a standard of care TRUS."
88891955|NCT05155202||Nicardipine|Major patients hospitalized in intensive care unit, with systolic hypertension, requiring administration of intravenous Nicardipine.
88891956|NCT05155202||Urapidil|Major patients hospitalized in intensive care unit, with systolic hypertension, requiring administration of intravenous Urapidil.
88891957|NCT05144984|Experimental|2.4 mg semaglutide + 2.4 mg NNC0480-0389|subjects will receive once weekly subcutaneous (s.c., under the skin) dose of NNC0480-0389 co-administered with s.c. semaglutide.
88891958|NCT05144984|Placebo Comparator|Placebo (semaglutide) + placebo ( 2.4 mg NNC0480-0389)|subjects will receive once weekly subcutaneous (s.c., under the skin) dose of placebo (NNC0480-0389) co-administered with s.c. placebo (semaglutide).
88891959|NCT05144984|Experimental|2.4 mg semaglutide + 7.2 mg NNC0480-0389|subjects will receive once weekly subcutaneous (s.c., under the skin) dose of NNC0480-0389 co-administered with s.c. semaglutide
89005631|NCT02894554|Active Comparator|telbivudine|HBsAg (+) patients received renal transplant and under lamivudine therapy and then switch to telbivudine 6 months later.
89005632|NCT00238407|Active Comparator|Arm I|Patients receive docetaxel IV over 30-60 minutes and cisplatin IV over 1 hour on days 1, 22, 43, 50, 57, 64, and 71. Beginning on day 43 (week 7) of chemotherapy, patients undergo radiotherapy once daily, 5 days a week, for 7 weeks.
89005633|NCT02894515|Experimental|Test/Reference|Single dose of commercial tablet Treatment A (Test) in period I. Followed by single dose of clinical tablet Treatment B (Reference) in period II. First and second dose administration will be separated by a washout period of at least 7 days
89414271|NCT06204120|Experimental|LPM3480392 injection group 3|
89414272|NCT06204120|Experimental|LPM3480392 injection group 4|
89414273|NCT06204107|Experimental|Group 1|"Phase 1: CKD-379 Test drug~Phase 2: CKD-379 Reference drug"
89414274|NCT06204107|Experimental|Group 2|"Phase 1: CKD-379 Reference drug~Phase 2: CKD-379 Test drug"
89005634|NCT02894515|Experimental|Reference/Test|Single dose of clinical tablet Treatment B (Reference) in period I. Followed by single dose of commercial tablet Treatment A (Test) in period II. First and second dose administration will be separated by a washout period of at least 7 days
89005635|NCT02894671||male under 45y|blood exams performed on males under 45years (in a range of 20-90 years) not wearing articular devices, without fractures, and without these diseases: oncologic, hemochromatosis, hepatic, thalassaemia, diabetes, anemia (Hb<9)
89005636|NCT02894671||male over 45y|blood exams performed on males over 45years (in a range of 20-90 years) not wearing articular devices, without fractures, and without these diseases: oncologic, hemochromatosis, hepatic, thalassaemia, diabetes, anemia (Hb<9)
89005637|NCT02894671||fertile female|blood exams performed on fertile females (in a range of 20-90 years) not wearing articular devices, no pregnant, without fractures, and without these diseases: oncologic, hemochromatosis, hepatic, thalassaemia, diabetes, anemia (Hb<9)
89005638|NCT02894671||infertile female|blood exams performed on infertile females (in a range of 20-90 years) not wearing articular devices, no pregnant, without fractures, and without these diseases: oncologic, hemochromatosis, hepatic, thalassaemia, diabetes, anemia (Hb<9)
89005639|NCT02894710|Experimental|Lidocaine 20mg/ml|Patients in Lidocaine group received an intravenous bolus injection of 1,5 mg/kg lidocaine (0,075mL/kg of Lidocaine 20mg/mL) followed by a continuous lidocaine infusion of 2 mg/kg/hr during surgery (0,1mL/kg/hr of Lidocaine 20mg/mL) and 1 mg/kg/hr in recovery room (0,05mL/kg/hr of Lidocaine 20mg/mL).
89005640|NCT02894710|Placebo Comparator|Glucose 5% (placebo)|Patients in control group received an intravenous bolus injection of 0,075mL/kg of placebo (Glucose 5%) by a continuous lidocaine infusion of 0,1mL/kg/hr of placebo (Glucose 5%) during surgery and 0,05mL/kg/hr of placebo (Glucose 5%) in recovery room.
89414275|NCT06204094|Experimental|Treatment Arm|"Participants will receive 5*5Gy node-sparing short-course radiation (radiation targeting the tumor bed without irradiating surrounding tumor-draining lymph nodes) concurrently with total neoadjuvant CAPOX and sintilimab regimens: Oxaliplatin, 130mg/m2, intravenous infusion,d1 of each cycle; Capecitabine, 1000mg/m2, PO, BID, d1-14 and sintilimab, 200mg intravenous infusion d1 of each cycle. CAPOX and sintilimab are repeated every 3 weeks for 8 cycles. Patients with cCR will be managed with a WW strategy, and patients who did not achieve cCR will receive TME surgery.~Interventions:~Radiation: node-sparing short-course radiation~Drug: PD-1 antibody (Sintilimab)~Drug: Capecitabine~Drug: Oxaliplatin"
89005641|NCT05428189|Experimental|Guided Biofilm Therapy (GBT)|The subjects receive professional oral hygiene guided by plaque a disclosing agent, using air-polishing and a ultrasonic device
89005642|NCT05428189|Active Comparator|Air Polishing and Ultrasonic Debridment|The subject receive professional oral hygiene using air-polishing and a ultrasonic device
89005643|NCT05428111|Active Comparator|control|healthy control individuals
89005644|NCT05428111|Active Comparator|case|Newly diagnosed and under treatment cases of acute lymphoblastic leukemic
89005645|NCT05428072|Experimental|sugar test|Participants will undergo 3 sugar tests followed by
89005646|NCT05427877|Experimental|Heating Device Application|Heating devices will be applied to the trunk and extremities of the body.
89005647|NCT00211562|Active Comparator|Olanzapine|
89005648|NCT00211562|Active Comparator|Omega 3|
89005649|NCT00211562|Active Comparator|Vitamin E +C|
89005650|NCT05427721|Experimental|Group A|Thymol
89005651|NCT05427721|Placebo Comparator|Group B|Calcined magnesia
89005652|NCT05427682|Experimental|Group A (normal liver function)|Each subject will receive a single dose of rongliflozin on Day 1
89005653|NCT05427682|Experimental|Group B (mild liver damage)|Each subject will receive a single dose of rongliflozin on Day 1
89005654|NCT05427682|Experimental|Group C (normal liver function)|Each subject will receive a single dose of rongliflozin on Day 1
89005655|NCT05427682|Experimental|Group D (moderate liver damage)|Each subject will receive a single dose of rongliflozin on Day 1
89414276|NCT06204055|Experimental|Intramuscular Dry-Needling|(IMDN) is a minimally invasive procedure where a solid filament needle is inserted into a myofascial trigger point.
89414277|NCT06204055|Sham Comparator|Sham Intramuscular Dry-Needling|). Park sham acupuncture needles (AcuPrime) will be used to perform sham needling for this group. The sham needle functions by allowing the blunted needle to cause a pricking sensation when pushed against the skin, but does not penetrate. This will allow the patient to perceive that the needle is entering the skin while also maintaining therapist-patient contact and interaction time
89414278|NCT06204003|Experimental|Dose Escalation|When participants start the CBD, they will be started on a low dose of CBD, beginning at 5 mg CBD/kg body mass, and then increased by 5 mg/kg every 2-weeks until 30 mg CBD/kg body mass is taken.
89536736|NCT02723591|Active Comparator|Tacrolimus, Extended Release (Astagraf XL®) Once Daily|Participants received tacrolimus extended release (Astagraf XL) at a starting dose of 0.15 milligram per kilogram (mg/kg), once daily, orally within 48 hours of transplantation (per the treating physician's discretion) for up to 1 year. Dose adjustments were allowed such that participants receiving tacrolimus maintained a minimal trough concentration of 6 nanogram per milliliter (ng/mL) at all times during the study.
89414279|NCT06203951|No Intervention|Standard of Care|In all arms, participants will receive syndromic STI assessment from study nurses at the antenatal clinic per Kenyan national guidelines, which entails a clinician (i.e., nurse, physician, clinical officer) using an algorithm asking whether clients have symptoms of vaginal discharge, lower abdominal pain, or genital ulcers followed by a physical examination for signs that match the self-reported symptoms. Based on clinical presentation, treatment is prescribed. Study nurses will capture information on symptoms, treatment acceptance, and dispensation. All participants will be provided with a study phone number to call at any time free of charge for clarifying questions or concerns with STI medication use.
88891960|NCT05144984|Experimental|2.4 mg semaglutide + 12.0 mg NNC0480-0389|subjects will receive once weekly subcutaneous (s.c., under the skin) dose of NNC0480-0389 co-administered with s.c. semaglutide
88891961|NCT05144984|Experimental|2.4 mg semaglutide + 21.6 mg NNC0480-0389|subjects will receive once weekly subcutaneous (s.c., under the skin) dose of NNC0480-0389 co-administered with s.c. semaglutide
88891962|NCT05144984|Experimental|NNC0480-0389 + placebo (semaglutide)|subjects will receive once weekly subcutaneous (s.c., under the skin) dose of NNC0480-0389 co-administered with s.c. placebo (semaglutide)
88891963|NCT05144984|Placebo Comparator|Placebo (semaglutide) + placebo ( 7.2 mg NNC0480-0389)|subjects will receive once weekly subcutaneous (s.c., under the skin) dose of placebo (NNC0480-0389) co-administered with s.c. placebo (semaglutide).
89414280|NCT06203951|Experimental|Universal Testing|Participants randomized to universal STI testing will be offered Xpert® CT/NG and TV testing regardless of symptoms, and they will receive a standard syndromic STI assessment.
88891964|NCT05144984|Placebo Comparator|Placebo (semaglutide) + placebo ( 12.0 mg NNC0480-0389)|subjects will receive once weekly subcutaneous (s.c., under the skin) dose of placebo (NNC0480-0389) co-administered with s.c. placebo (semaglutide).
88891965|NCT05144984|Placebo Comparator|Placebo (semaglutide) + placebo ( 21.6 mg NNC0480-0389)|subjects will receive once weekly subcutaneous (s.c., under the skin) dose of placebo (NNC0480-0389) co-administered with s.c. placebo (semaglutide).
88891966|NCT05144984|Experimental|Semaglutide 2.4 mg + placebo (NNC0480-0389)|subjects will receive once weekly subcutaneous (s.c., under the skin) dose of placebo (NNC0480-0389) co-administered with s.c. semaglutide.
88891967|NCT05131945|Experimental|Group 1: Standard Suction Thoracentesis|treatment techniques suction is a standard of care and used for draining fluid around the lung.
88891968|NCT05131945|Experimental|Group 2: Gravity Thoracentesis.|treatment techniques (gravity ) is a standard of care and used for draining fluid around the lung.
88891969|NCT05125562|Placebo Comparator|Placebo|100ml normal saline
88891970|NCT05125562|Experimental|10ml ExoFlo|10ml ExoFlo + 90ml normal saline
88891971|NCT05125562|Experimental|15ml ExoFlo|15ml ExoFlo + 85ml normal saline
88891972|NCT05124119||Focus Group One|Participants in Focus Group 1 will be assigned a unique study name or pseudonym and requested to answer a set of three different questionnaires that are described in the study's protocol. This study does not involve any type of intervention. The participants will not be administered any type of medications but only questionnaires. This is an observational (cross-section) type of study and not an experimental or randomized clinical trial.
88891973|NCT05124119||Focus Group Two|Participants in Focus Group 2 will be assigned a unique study name or pseudonym and requested to answer a set of three different questionnaires that are described in the study's protocol. This study does not involve any type of intervention. The participants will not be administered any type of medications but only questionnaires. This is an observational (cross-section) type of study and not an experimental or randomized clinical trial.
88891974|NCT05123326||PVT|Portal Vein Thrombosis (PVT) refers to partial or complete occlusion of the portal vein lumen by a blood clot or its replacement by multiple collateral vessels with the hepato-petal flow, commonly known as 'portal cavernoma.' 240 patients to be recruited
88891975|NCT05123326||HVOTO|Occlusion of two or more hepatic veins. 100 patients
88891976|NCT05121051|Experimental|Group I (broccoli seed and sprout extract)|Patients receive broccoli seed and sprout extract PO QD for 12 weeks in the absence of unacceptable toxicity. Patients undergo the collection of blood and nasal epithelial cell samples at visits 2 and 6 and the collection of buccal cell samples at visits 2, 3, and 6.
88891977|NCT05121051|Active Comparator|Group II (placebo)|Patients receive placebo PO QD for 12 weeks in the absence of unacceptable toxicity. Patients undergo the collection of blood and nasal epithelial cell samples at visits 2 and 6 and the collection of buccal cell samples at visits 2, 3, and 6.
88891978|NCT05117502|Experimental|intermittent Theta Burst Stimulation|Participants will receive 2 treatments of intermittent Theta Burst Stimulation, each two weeks apart. First session will be iTBS alone, the second session will be combined iTBS with APT (Attention processing training).
89414281|NCT06203951|Experimental|Asymptomatic Only Testing|Participants randomized to the asymptomatic only testing will be offered Xpert® CT/NG and TV testing if no signs or symptoms of CT, NG, or TV are identified during STI assessment.
89414282|NCT06203938|Experimental|TILS-treated|Transcranial infrared light stimulation (TILS) will be administered via light-emitting diodes (LEDs), which are a safe and non-invasive form of transcranial photobiomodulation.
89414283|NCT06203938|Sham Comparator|Sham|The sham control group undergoes the same procedure as the treatment group, but without the LEDs turned on.
88891979|NCT05117502|Placebo Comparator|Placebo intermittent Theta Burst Stimulation|Placebo iTBS participants will not receive any stimulation as the coil will be switched to placebo (P) setting. To maintain double-blind in A and P settings, Veterans and researchers wear headphones connected to a sham noise generator. Participants will receive 2 treatments of placebo intermittent Theta Burst Stimulation, each two weeks apart. First session will be iTBS alone, the second session will be combined placebo iTBS with APT (Attention processing training).
89414284|NCT06203925||Primary Study|The study will be a cohort study. Adult SGM living in the metropolitan area of Rio de Janeiro who voluntary want to perform HCV testing ordered through a web-based platform will be eligible for this study. SGM will be defined by gay, bisexual and other cisgender MSM, TGW, transgender men, and gender nonbinary/diverse individuals.
89414285|NCT06203925||Ancillary Study|The study will be a cross-sectional study. Adult MSM or TGW attending a presential visit for PrEP (initiation or follow-up) at INI/FIOCRUZ will be eligible for this study.
88891980|NCT05103839|Experimental|Yoga for Caregivers and Persons With Dementia|Persons With Dementia and their caregivers will participate in up to 20 group yoga classes.
88891981|NCT05098392|No Intervention|Treatment as usual/Sibling interaction|Children with autism will spend time with their typically developing siblings for 20-30 mins at least three times a week
88891982|NCT05098392|Experimental|Sibling-mediated intervention|Children with autism will receive explicit instruction from their typically developing siblings
88891983|NCT05094466|Experimental|Arm I (parent intervention)|Parents receive health coaching sessions over 50-60 minutes monthly for 6 months. Parents also receive navigation sessions with a lay LHW monthly for 6 months and church-based peer support monthly for 6 months.
88891984|NCT05094466|Experimental|Arm II (family intervention)|Family members receive health coaching sessions over 50-60 minutes monthly for 6 months. Family members also receive navigation sessions with a LHW monthly for 6 months and church-based peer support monthly for 6 months.
88891985|NCT05094466|Active Comparator|Arm III (delayed comparison)|Participants receive a handbook that includes core content from the parent and family interventions, but without individual support from coaches, LHWs or the church.
88891986|NCT05092347|Experimental|REGN5459|REGN5459 escalating dose
88891987|NCT05092347|Experimental|REGN5458|REGN5458 escalating dose
88891988|NCT05087095|Experimental|CALM|CALM therapy will be provided via telehealth. Participants will complete surveys (post-session, post-intervention, and 90-day follow-up) via secure email link. Exit interviews will be conducted by phone
88891989|NCT05084391|Experimental|Phase I:|Phase I there will be up to 15 patients treated with SABR and followed for 6 months post-treatment to ensure no significant acute grade 3 or 4 toxicity from SABR treatment.
88891990|NCT05084391|Experimental|Phase II|Phase II portion with 25 patients in each arm assigned to SABR or current practice (standard of care)
88891991|NCT05083338||Observational (questionnaire, pain assessment, biospecimen)|Patients complete questionnaires over 15 minutes and undergo pain assessments prior to surgery and at 3, 6 and 12 months after surgery. Patients also undergo blood sample collection before surgery and optionally at 3, 6 and 12 months after surgery.
88891992|NCT05081245|Experimental|ML-004 (IR)/(ER) tablet|ML-004 is a bilayer immediate-release (IR)/extended-release (ER, gastroretentive) oral tablet formulation. ML-004 is taken orally once daily and provided as a tablet in two dose strengths of 12 mg (3 mg IR/9 mg ER) and 24 mg tablet (6 mg IR/18 mg ER). Dose levels for this study are 12 mg (provided as one 12 mg tablet), 24 mg (one 24 mg tablet), 48 mg (two 24 mg tablets), and 72 mg (three 24 mg tablets).
88891993|NCT05081245|Placebo Comparator|ML-004 Placebo|Matched placebo oral tablets will consist of same excipients as the investigational drug but without any ML-004. Placebo taken orally once daily to match tablet number of ML-004 dose levels for 12 mg (1 tablet), 24 mg (1 tablet), 48 mg (2 tablets), and 72 mg (3 tablets).
88891994|NCT05070871|Active Comparator|Hydrolyzed Collagen type II|10 capsules daily of hydrolyzed collagen (CH) type II is taken per orally. Each capsule contains ~500 mg of CH. Once or twice daily dosing. Duration: 6 months.
88891995|NCT05070871|Placebo Comparator|Maltodextrin|10 capsules daily of maltodextrin is taken per orally. Each capsule contains 500 mg of maltodextrin. Once or twice daily dosing. Duration: 6 months.
88891996|NCT05070871|Experimental|Unhydrolyzed Collagen type II (Salmon bone meal)|10 capsules daily of salmon bone meal enriched with vitamin D3 is taken per orally. Each capsule contains 300 mg of maltodextrin, 200 mg of salmon bone meal (10 capsules = 2000 mg salmon bone meal = 340 mg elemental calcium in the form of microcrystalline hydroxyapatite), and 4 micrograms of vitamin D3 (10 capsules = 40 micrograms of vitamin D3 = 1600 IU).
88891997|NCT05069415|Active Comparator|Emmetropia|The target refraction for both eyes will be emmetropia (± 0.25 D).
89437587|NCT03531099|Experimental|HIFU treatment|"65 patients will receive the immediate treatment with focal HIFU in order to destroy the cancer without causing side effects. HIFU treatment will be conducted with the Focal One® device. The treatment area will be defined using MRI data and 3D biopsies. A safety distance of at least 9 mm will be defined around the tumor. An intraoperative contrast echocardiographic control will be performed to evaluate the necrotic area. If necessary, additional HIFU lesions will be performed during the same session. In case of residual tumor demonstrated during control biopsies, additional treatment of this tumor with focal HIFU may be proposed.~Patients randomized in this arm will also have PSA dosage, MRI exam, questionnaires and prostatic biopsies during their follow up."
88891998|NCT05069415|Experimental|Mini monovision|The target refraction for the dominant eye will be plano (± 0.25 D) and for the non-dominant eye between -0.75D ±0.15.
88891999|NCT05065944||Pre-Anesthesia Evaluation: Telemedicine|Pre-Anesthesia evaluation conducted remotely via video conferencing
88892000|NCT05065944||Pre-Anesthesia Evaluation: In person|Pre-Anesthesia evaluation conducted in person
88892001|NCT05057702|Experimental|Individualized Treatment Recommendation|Participants will receive an individualized treatment recommendation including a combination of up to four FDA-approved drugs within 21 business days of tissue acquisition using the results of real-time high-throughput drug screening, whole exome sequencing (WES), and RNA sequencing.
88892002|NCT05056922|Experimental|Tele-PCIT (Parent-Child Interaction Therapy)|
88892003|NCT05056922|Active Comparator|Treatment as Usual|
88892004|NCT05049837||Specific Aim 1|600 cases: two normal and two tumor formalin-fixed tissue samples
88892005|NCT05049837||Specific Aim 2|600 cases: two normal and two tumor formalin-fixed tissue samples.
88892006|NCT05049837||Specific Aim 3|600 cases, including 150 patients who had received neoadjuvant therapy and 450 patients who had not. Two normal and two tumor formalin-fixed tissue samples.
88892007|NCT05049837||Specific Aim 4|600 cases; including 150 patients who will receive neoadjuvant chemotherapy, 150 patients who received or will receive postoperative adjuvant chemotherapy, and 300 patients who did not receive or will not receive neoadjuvant or adjuvant chemotherapy. Two normal and two tumor formalin-fixed tissue samples
88892008|NCT05049837||Specific Aim 5|600 cases; two normal and two tumor formalin-fixed tissue samples
88892009|NCT05049837||Specific Aim 6|210 cases (of the 600 above), one normal and one tumor formalin-fixed histology sections obtained from formalin-fixed and paraffin- embedded tissue samples.
88892010|NCT05047536|Experimental|KZR-261 with standard therapy: open-label|"Part 1 (Dose Escalation)~The initial dose cohort of the Dose Escalation will receive 1.8 mg/m2 of KZR-261. Subjects will receive 3 doses in a 28-day cycle.~___________________________________________~Part 2 (Dose Expansion)~Following safety review of all Dose Escalation cohorts and determination of the maximum tolerated dose (MTD) or maximum administered dose (MAD), KZR-261 will be evaluated for safety and preliminary efficacy in 4 tumor-specific cohorts and 1 all-tumor cohort to determine the recommended phase 2 dose (RP2D). The 4 tumor-specific cohorts will include:~melanoma (including uveal melanoma)~colorectal cancer~prostate cancer~mesothelioma"
88892011|NCT05037968|Experimental|MagnetOs Flex Matrix|MagnetOs Flex Matrix use in instrumented posterolateral fusion, 7cc-10cc mixed with autograft bone in a 1:1 ratio per spine level at the randomized assigned side
88892012|NCT05037968|Active Comparator|Cell Based Allograft|Cellular Allografts are a cryopreserved, viable cellular allograft containing cancellous bone and demineralized cortical bone designed for surgical use, applied per spine level at the contralateral side.
88892013|NCT05014984|Active Comparator|Telephone Delivered MOVE!|During the baseline visit, Veterans randomized to the control arm will receive only the standard information about MOVE!, diet, and physical activity delivered by the same lay educators. They will not learn the WOOP technique nor receive telephone follow up as detailed below. While we considered having an attention control with the same amount of contact, we decided that the study would be more pragmatic and findings would be more relevant to real-world practice if the control arm followed standard patient education and referral strategies. Data collection during study visits will be at the same timepoints in both arms.
88892014|NCT05014984|Experimental|Mental Contrasting with Implementation Intentions (WOOP) plus MOVE!|At the baseline visit, a lay educator will teach the WOOP technique in-person using protocols adapted from our prior work.12 After, to support WOOP practice, the lay educator will schedule and provide 3 follow-up telephone check-ins with the Veteran. This arm will also receive telephone-delivered MOVE!
88892015|NCT05012579|Experimental|TAPS delivered by Cala device|Two 40-minute TAPS sessions daily for 28 days, recommended as once in the morning and once in the evening.
88892016|NCT05005221|Active Comparator|Unidirectional Text Reminders|"Participants in the unidirectional text reminder arm will receive automated text messages to remind them to collect blood samples 48 hours before, 12 hours before, and the morning of the planned sample collection.~N=15"
88892017|NCT05005221|Experimental|Bidirectional Text Communication|"Participants in the bidirectional text communication arm will also receive automated messages to remind them to collect blood samples 48 hours before, 12 hours before, and the morning of the planned sample collection but they will be asked to confirm the planned day or reschedule. On the day of sample collection participants will also reply with the time the samples are collected to trigger future reminder messages for each of the 4 samples.~N=30"
88892018|NCT04981223|Experimental|ExactVu Imaging|"EV29L transducer will be inserted in the subject's rectum. Cine sweeps will be performed to save images of:~The entire prostate from posterior to anterior (may require 2 sweeps to cover base and apex)~The peripheral zone using the highest zoom setting (30mm depth) on the system (may require 2 sweeps to cover base and apex). Analysis of these images will be performed after surgery but before prostatectomy"
88892019|NCT04956757|Experimental|Intervention Group|"exercise program consists of progressive scapula retraction exercises will be applied three times a week total 24 sessions.~Home exercise program will also advised two times a day."
88892020|NCT04956757|No Intervention|Control Group|Control group will not perform scapula retraction exercises. AHD values of the control group will be compared to intervention groups both retracted and non-retracted conditions.
88892021|NCT04954027||Patients with a use-related disorder weaning for a substance|
88892022|NCT04952688|Experimental|Experimental|"Inclusion~Before Anti-VEGF treatment: opht"
88922085|NCT05840952|Experimental|ALG-097558 and Midazolam|Oral doses of ALG-097558, up to 14 doses over 7 days and oral dose of Midazolam, up to 2 doses, over 2 days, in Healthy Volunteers
88922086|NCT05840952|Experimental|ALG-097558, Placebo, and, Itraconazole|Oral doses of placebo, up to 2 doses over 2 days, followed by ALG-097558, up to 2 doses over 2 days, and itraconazole up to 10 doses over 10 days, in Healthy Volunteers.
88892023|NCT04948450|Experimental|Intervention group|"Physical activity intervention:~Progressive resistance training (PRT) for the physical intervention will be provided at the nursing home.~Cognitive stimulation intervention:~The study subjects will receive cognitive intervention based on Cognitive Stimulation Therapy with rehabilitation experts.~Social intervention:~The social intervention will be combined with physical and cognitive interventions by doing in a group.~Metabolic and vascular risk factors:~Metabolic and vascular risk factors of the intervention group will be evaluated by cardiologists and endocrinologists in the study."
88892024|NCT04948450|No Intervention|Control group|The control group will receive general health advice every 3 months based on their physical examination and blood results. They will be provided information on the vascular risk factors for dementia and will receive instruction and handouts on diet and exercise.
88892025|NCT04941430|Experimental|Diagnostic (7T MRI)|Within 2 weeks of initial standard of care 3T MRI, patients undergo 7T MRI scan with and without contrast over 1-2 hours.
88892026|NCT04929483|Experimental|BIO89-100 - 15 mg QW|
88892027|NCT04929483|Experimental|Experimental: BIO89-100 - 30 mg QW|
88892028|NCT04929483|Experimental|Experimental: BIO89-100 - 44 mg Q2W|
88892029|NCT04929483|Placebo Comparator|Placebo Comparator: Placebo QW|
88892030|NCT04929483|Placebo Comparator|Placebo Comparator: Placebo Q2W|
88892031|NCT04919538||Relapsing Polychondritis Cohort|
89414286|NCT06203899|Experimental|Intervention group|"Participating adolescents receive the preventive group training Op Volle Kracht. It is an altered program for adolescents in the special educational sector, based on the eponymous program for general education. It consists of eight meetings of 45 minutes each and one short follow-up meeting each week to offer repetition. It will take place at school during school hours. A trained psychologist of the STORM approach will facilitate the training with a trained school psychologist.~Participants will undergo a clinical interview at baseline and at 6-month follow-up to detect clinical depression, and will fill in questionnaires at baseline, post-intervention and follow-up at 6 and 12 months after intervention. Assessments will be conducted through a 30-minute self-report questionnaire.~All teachers will be educated on how to recognize and address depressive symptoms and suicidality in adolescents (gatekeeperstraining)."
88892032|NCT04909294|Experimental|stereotaxic external radiation therapy|
88892033|NCT04903717|Experimental|Intervention - Best Practice Alert|Providers randomized to the intervention arm will have a best practice alert appear for each of their eligible patients upon opening of the order entry screen in the patient's medical record which alerts to the presence of HFrEF and the fact that the patient is not currently prescribed an MRA. A link to an order set for MRAs (or to potassium binders should a patient be hyperkalemic) will provided, along with a link to current best practices surrounding the use of MRAs.
88892034|NCT04903717|No Intervention|Usual Care|Providers will not receive a best practice alert for eligible patients and will continue to care for patients as usual.
88892035|NCT04896814|Experimental|Transcutaneous tibial nerve stimulation|The participant will receive an intervention session per week that will be held for a period of 12 weeks. The total application time will be 30 minutes. A symmetrical biphasic current will be applied, with a frequency of 20 Hz in continuous mode and a pulsed frequency of 200 µs.
88892036|NCT04896814|Placebo Comparator|Placebo|The participant will receive one intervention session per week will be performed during a 12 weeks period time. The total application time will be 30 minutes. A discontinuous current at 2Hz frequency and a pulsed frequency of 50 µs, with 2 seconds of work and 10 seconds of pause will be applied in other localization.
88892037|NCT04895579|Experimental|Copanlisib (30-60mg iv)|Patients in the group will receive Durvalumab at 10mg/kg (IV infusion on days 1 and 15, q28 days or 1500mg day 1 q28d). They will also receive Copanlisib ranging from 30mg to 60mg (IV infusion on days 1 and 15, q 28 days).
88892038|NCT04891770|Experimental|Cohort 1: TAF + VIR-2218 + SLGN + Nivolumab|"Nucleos(t)ide(s) (NUC)-suppressed participants with chronic hepatitis B (CHB) will receive:~Tenofovir alafenamide (TAF) 25 mg once daily for 36 weeks (up to 84 weeks).~VIR-2218 200 mg once every 4 weeks for 24 weeks.~At Week 12 the following will be added:~Selgantolimod (SLGN) 3 mg once a week on the same day for 24 weeks.~Nivolumab 0.3 mg/kg once every 4 weeks for up to 24 weeks (Up to protocol amendment 2).~Participants who are on TAF treatment will continue TAF treatment over the duration of study follow-up.~After the implementation of protocol amendment 2, nivolumab treatment was no longer administered."
88892039|NCT04891770|Experimental|Cohort 2 Group A: VIR-2218 + SLGN + Nivolumab|"Viremic participants with CHB will receive:~VIR-2218 200 mg once every 4 weeks for 24 weeks.~At Week 12, the following will be added:~SLGN 3 mg once a week on the same day for 24 weeks~Nivolumab 0.3 mg/kg once every 4 weeks for up to 24 weeks (Up to protocol amendment 2).~Viremic participants who meet criteria to initiate NUC treatment will receive TAF 25 mg once daily for up to 36 weeks during the study.~After the implementation of protocol amendment 2, nivolumab treatment was no longer administered."
88892040|NCT04891770|Experimental|Cohort 2 Group B: SLGN + Nivolumab|"Viremic participants with CHB will receive:~SLGN 3 mg once a week on the same day for 24 weeks.~Nivolumab 0.3 mg/kg once every 4 weeks for up to 24 weeks.~Viremic participants who meet criteria to initiate NUC treatment will receive TAF 25 mg once daily for up to 36 weeks during the study.~Cohort 2 Group B, all treatments were administered up to protocol amendment 2 and after the implementation of protocol amendment 2, the treatments were discontinued based on Sponsor decision due to low likelihood of efficacy."
88892041|NCT04881903|Experimental|MIST intervention followed by MIRA intervention|These are both mobile interventions that use interpretation bias modification (IBM) techniques to reduce cognitive biases. The MIST app targets suicidal cognitions and the MIRA app targets hostile interpretation bias (which contributes to anger). The MIRA application has already been developed, but the MIST application is newly developed based on the same procedures. All participants will complete the MIST intervention and provide feedback so that we can refine it. We will also be collecting EMA data on to examine how changes to suicide cognitions and hostile interpretation bias (by use of the two apps) affects suicidal ideation and functioning.
88922087|NCT05840952|Experimental|ALG-097558 and Carbamazepine|Oral doses of ALG-097558, up to 2 doses over 2 days and oral doses of Carbamazepine, up to 30 doses, over 15 days, in Healthy Volunteers
89005656|NCT05427604|Other|Sequential intervention|"single ingestion of olive oil for assessement of monounsaturated fatty acids peak time in blood (3g)~single ingestion of olive oil for collection of blood sample at peak time (3g)~single ingestion of DHA-rich oil for assessement of polyunsaturated fatty acids peak time in blood (3g)~single ingestion of DHA-rich oil for collection of blood sample at peak time (3g)"
89005657|NCT05427409|Active Comparator|Beta-alanine supplementation|Beta-alanine (4.8 grams) pills (Crown Nutrition, Haro, Spain) in four doses each day during a 4-week supplementation period.
89005658|NCT05427409|Placebo Comparator|Placebo supplementation|Placebo (4.8 grams) pills (Crown Nutrition, Haro, Spain) contain fructose (300mg) and excipients (1200 mg) such as cellulose, calcium phosphate, silicon dioxide and magnesium stearate in four doses each day during a 4-week supplementation period.
89005659|NCT05427331|Experimental|FMT capsule treatment group|drugs use generic name: FMT capsule dosage form: capsule dosage, frequency: 16 capsules once a week duration: 4 weeks
89005660|NCT05427331|Placebo Comparator|Placebo treatment group|drugs use generic name: Placebo dosage form:capsule dosage,frequency:16 capsules once a week duration:4 weeks
89005661|NCT05427175|Active Comparator|Narrowband ultraviolet B|Patients will receive 8 sessions of NB-UVB per month for 3 successive months
89005662|NCT05427175|Active Comparator|Methotrexate|Patients will receive 25 mg/1ml of methotrexate vial per week for 3 successive months
89005663|NCT05427175|No Intervention|healthy individuals as control group|
89005664|NCT05427058|Active Comparator|group 1: superior hypogastric plexus block group|Device: C-arm fluoroscopic device Drug: lidocaine + alcohol
89005665|NCT05427058|Experimental|group 2: ganglion impar block group|Device: C-arm fluoroscopic device Drug: lidocaine + alcohol
89005666|NCT04680091|Experimental|Efavirenz 600 mg + Pyrotinib 400 mg|
89005667|NCT04680091|Active Comparator|Pyrotinib 400 mg|
89005668|NCT04680364|Experimental|participants|to analyze the effects of 6-month ballroom dance (3 times/wk) on physical fitness and reaction time in twenty-four experienced older adults
89005669|NCT04680247|Active Comparator|VA-LCP|Osteosynthesis with a VA-LCP system
89005670|NCT04680247|Active Comparator|NCB-PT|Osteosynthesis with a NCB-PT system
89005671|NCT04680169|Active Comparator|Group A: Bronchoscopic intubation using AuraGain LMA as conduit|A group of 50 patients randomly allocated to bronchoscopic intubation using AuraGain
89005672|NCT04680169|Active Comparator|Group B: Bronchoscopic intubation with I-gel SGA as conduit|A group of 50 patients randomly allocated to bronchoscopic intubation using I-gel
89005673|NCT04680208||Planned ICU admission|Cases who were planned for postoperative ICU admission at the time of preanesthetic check up
89005674|NCT04680208||Unplanned ICU admission|Cases who got admitted to ICU postoperatively without anticipation
89005675|NCT05426824|Experimental|P-GOD|P-GOD (peasparaginase + gemcitabine + oxaliplatin + dexamethasone) ;
89005676|NCT05426824|Experimental|PEMD|PEMD (peaspargase + etocytidine + methotrexate + dexamethasone)
89005677|NCT00211835|Experimental|Treatment Arm 1|Individual psychotherapy focused on identifying and correcting maladaptive cognitions and behaviors with the goal of improving mood. The intervention has adapted CBT specifically to address cognitive deficits associated with TBI, which compound the cognitive distortions typical of depression. CBT therapists embed compensatory strategies within treatment sessions to address cognitive limitations of each participant.
89005678|NCT00211835|Experimental|Treatment Arm 2|A client-centered individual psychotherapy treatment approach designed to address depressive disorders commonly experienced by individuals following a TBI. In line with traditional supportive psychotherapy approaches, the objective of SPT is to improve the individual's ability to deal with problems of daily living more effectively through problem identification, praise, reassurance, encouragement, psychoeducation, advice, anticipatory guidance, and expanding awareness.
89005679|NCT05426590|Active Comparator|Diabetic patient|Patient with diabetes will undergo cataract surgery
89005680|NCT05426590|Active Comparator|Non diabetic patients|Healthy non diabetic patients will undergo cataract surgery
89005681|NCT05426512||Primary Hyperparthyroidism|
89005682|NCT05426512||Postmenopausal women|
89005683|NCT05426317|Other|Metastatic solid tumor treated with first line therapeutic of Immune Checkpoint Inhibitor|"The determinations of soluble PDL1 and serum B2M will be taken by blood sample at diagnosis and then every 3 months for 1 year, during a consultation or treatment in an outpatient hospital.~The measurement of the tumor PDL1 level at diagnosis will be carried out by immunohistochemistry in the anatomopathology department of Clermont Ferrand University Hospital on the tumor sample that allowed the diagnosis, which does not add an additional sample for the patient.~Clinical and imaging examinations will be those conventionally carried out in the context of patient monitoring, the data will only be recorded in the patients' medical files."
89005684|NCT00211874|Experimental|Nurse-management|nurse-led intervention focused on specific management problems
89005685|NCT00211874|No Intervention|Usual Care|Usual care as control group
89005686|NCT05426278|Other|FAW and Bair Hugger Group|Group B, the intervention group (with FAW and Bair Hugger).
89005687|NCT05426278|No Intervention|Control group|Group A, the control group (No FAW or Bair Hugger)
89005688|NCT05426239||Cohort 1|Participants initiating first-line systemic therapy to treat advanced melanoma.
89005689|NCT05426044|Placebo Comparator|Patients will receive oral metformin|twice daily, oral metformin 750mg (i.e. 1500mg/day)
89005690|NCT05426044|Experimental|Patients will receive oral placebo.|twice daily, oral metformin 750mg (i.e. 1500mg/day)
89005691|NCT05425693|Experimental|Hybrid warm-up intervention|
89005692|NCT05425693|Experimental|Dynamic warm-up intervention|
89005693|NCT05425693|Experimental|Stretching warm-up intervention|
89414287|NCT06203899|Active Comparator|Control group|"Participating adolescents will undergo a clinical interview at baseline to detect clinical depression, and will fill in questionnaires at baseline, 12 weeks/'post-intervention' and follow-up at 6 and 12 months 'post-intervention'. Besides, participants will undergo a second clinical interview on depressive symptoms at 6 months follow-up.~All teachers will be educated on how to recognize and address depressive symptoms and suicidality in adolescents (gatekeeperstraining).~Concerning Op Volle Kracht: Adolescents are offered the training after data collection of the study has ended and when the intervention has shown to be effective."
89414288|NCT06203886|Experimental|Test Intervention arm|LumbaCure robotic device
89414289|NCT06203873|Experimental|Biodegradable Occluder Cohort|
89414290|NCT06203873|Active Comparator|Metal Occluder Cohort|
89414291|NCT06203860|Active Comparator|The Cardio-Metabolic Clinic|Comprising specialized, multidisciplinary management of diabetes and cardiovascular disease in a Cardio-Metabolic Clinic.
89414292|NCT06203860|No Intervention|Usual Care|Involving collaboration between the general practitioner, and/or the endocrinology outpatient clinic, and/or cardiology outpatient clinic.
89414293|NCT06203834|Placebo Comparator|placebo|Placebo 200g, without any ingredients of inulin fiber. Eat 200g for once, and once a day.
89414294|NCT06203834|Experimental|I-Fiber Pearl|I-Fiber Pearl 200g, with inulin fiber. Eat 200g for once, and once a day.
89414295|NCT06203795|Experimental|Hemodiafiltration with FX CorAL 800 dialyzer|"Patients are dialyzed three consecutive dialysis sessions with an FX CorAL 800 dialyzer, starting on Saturday.~On Tuesday and Thursday, patients are dialyzed with only a quarter of their regular anticoagulation dose during 4 hours on Tuesday, and 3 hours on Thursday.~Blood is sampled from the arterial and venous blood line at different time points to determine concentrations of different uremic toxins and albumin"
89414296|NCT06203795|Experimental|Hemodiafiltration with FX 800 Cordiax dialyzer|"Patients are dialyzed three consecutive dialysis sessions with an FX 800 Cordiax dialyzer, starting on Saturday.~On Tuesday and Thursday, patients are dialyzed with only a quarter of their regular anticoagulation dose during 4 hours on Tuesday, and 3 hours on Thursday.~Blood is sampled from the arterial and venous blood line at different time points to determine concentrations of different uremic toxins and albumin"
89414297|NCT06203795|Experimental|Hemodiafiltration with Solacea 19H dialyzer|"Patients are dialyzed three consecutive dialysis sessions with a Solacea 19H dialyzer, starting on Saturday.~On Tuesday and Thursday, patients are dialyzed with only a quarter of their regular anticoagulation dose during 4 hours on Tuesday, and 3 hours on Thursday.~Blood is sampled from the arterial and venous blood line at different time points to determine concentrations of different uremic toxins and albumin"
89414298|NCT06203795|Experimental|Hemodiafiltration with Xevonta Hi-20|"Patients are dialyzed three consecutive dialysis sessions with a Xevonta Hi-20 dialyzer, starting on Saturday.~On Tuesday and Thursday, patients are dialyzed with only a quarter of their regular anticoagulation dose during 4 hours on Tuesday, and 3 hours on Thursday.~Blood is sampled from the arterial and venous blood line at different time points to determine concentrations of different uremic toxins and albumin"
89414299|NCT06203782||Experimental Group|In the experimental group, 51 patients underwent endoscopic stricturoplasty. A transparent cap was mounted on the front end of the endoscope, and a needle knife was inserted through the working channel of the endoscope. Under direct visualization, a radial incision was made at the site of the stricture, with an effort to preserve normal mucosal tissue as much as possible. The stricture was gradually incised until the endoscope could smoothly pass through.
89414300|NCT06203782||Control Group|In the control group, 51 patients underwent endoscopic balloon dilation. The endoscope was advanced to the site of the stricture, and a dilation guidewire was inserted. After placing the balloon, it was progressively inflated with pressure, each inflation lasting 1-2 minutes, and this process was repeated 2-3 times until the endoscope and sheath could pass through the narrowed segment and enter the distal colon.
89414301|NCT06203769|Experimental|Experimental group|14-day antibiotic therapy after removal of infected material
88892042|NCT04880824||PG cohort|800 randomized surgical study patients with a frailty syndrome (Pre-frail and frail) of the intervention study PRÄP-GO (PG cohort). 400 study patients receive the intervention and 400 study patients receive standard of care.
89414302|NCT06203769|Active Comparator|control group|28-day antibiotic therapy after removal of infected material
88892043|NCT04880824||NFC cohort|400 non-frail surgical control group (NFC cohort)
88892044|NCT04880824||NO cohort|300 non-operative control group (NO cohort)
88892045|NCT04880824||GB cohort|Skill-Change-Management: a maximum of 30 coworkers and analysis of guiding principle: to a maximum of 35 patients, 30 relatives and 45 coworkers
88892046|NCT04877977||Healthy Volunteers|Individuals who previously signed consent for ETPB research as healthy volunteers
88892047|NCT04877977||Mood Disorder Patients|Individuals with mood disorders who previously signed consent for ETPB research
89005694|NCT05425693|No Intervention|No warm-up intervention|
89414303|NCT06203756|Active Comparator|Femur First, Non Sensor-assisted|Standard robotic surgery cohort with a femur first workflow. Sensor used only to measure final balance achieved with surgeon blinded to measurements.
89414304|NCT06203756|Active Comparator|Femur First, Sensor-assisted|Sensor-assisted robotic surgery cohort with a femur first workflow
89414305|NCT06203756|Active Comparator|Tibia First, Non Sensor-assisted|Standard robotic surgery cohort with a tibia first workflow. Sensor used only to measure final balance achieved with surgeon blinded to measurements.
89414306|NCT06203756|Active Comparator|Tibia First, Sensor-assisted|Sensor-assisted robotic surgery cohort with a tibia first workflow
89414307|NCT06203756|Other|Revision Total Knee Arthroplasty|Sensor-assisted robotic surgery cohort with a tibia first workflow. Revision Total Knee Arthroplasty components.
89414308|NCT06203743|No Intervention|control group|Patients in this group will not undergo any block after LMA. PI, PVI, pulse, saturation, noninvasive arterial pressure values will be recorded before induction, after induction, after LMA, at 0, 5, 10, 15, 20, 25 and 30 minutes after the surgical incision and at the end of anesthesia. PI, PVI will be monitored with Radical-97TM Pulse CO-OximeterTM (Masimo Corp, Irvine, CA, USA) probe.
89414309|NCT06203743|Active Comparator|caudal block group|Patients in this group will receive a caudal block in the lateral decubitus position after LMA with 0.25% Buvasin® 0.5ml/kg. PI, PVI, pulse, saturation, noninvasive arterial pressure values before induction, after induction, after LMA, before applied block, after applied block (after surgical incision) 0., 5., 10., 15., 20., 25. It will be recorded at the 30th and 30th minutes and at the end of anesthesia. PI, PVI will be monitored with Radical-97TM Pulse CO-OximeterTM (Masimo Corp, Irvine, CA, USA) probe.
89414310|NCT06203743|Active Comparator|ilioinguinal-iliohypogastric nerve block group|Patients in this group will undergo an ilioinguinal-iliohypogastric nerve block in the supine position under ultrasound guidance after LMA with 0.25% Buvasin® 0.5ml/kg. PI, PVI, pulse, saturation, noninvasive arterial pressure values before induction, after induction, after LMA, before applied block, after applied block (after surgical incision) 0., 5., 10., 15., 20., 25. It will be recorded at the 30th and 30th minutes and at the end of anesthesia. PI, PVI will be monitored with Radical-97TM Pulse CO-OximeterTM (Masimo Corp, Irvine, CA, USA) probe.
89414311|NCT06203678|Active Comparator|Kinesio taping+exercise|"Kinesio taping will be applied to the bilateral upper trapezius and sternocleidomastoid muscles by an experienced practitioner, once a week for 4 weeks.~Cervical stretching and strengthening exercises home program"
89414312|NCT06203678|Placebo Comparator|Sham taping+exercise|"Sham taping will be applied to the bilateral upper trapezius and sternocleidomastoid muscles once a week for 4 weeks, using patch tape of the same color as kinesio tape.~Cervical stretching and strengthening exercises home program"
89414313|NCT06203678|Other|Exercise|Cervical stretching and strengthening exercises home program
89414314|NCT06203652||All enrolled patients|All patients who are eligible for participation to the study.
89414315|NCT06203574|Experimental|patients with solid tumors|Subjects were recruited from Huashan Hospital of Fudan University.
89414316|NCT06203548|Other|Metabolic dysfunction-associated steatotic liver disease|Adult patients with intrahepatic triglyceride content >=5% by MRI-PDFF
89005695|NCT00238875|Experimental|1|Procedure/Surgery: stereotactic body radiation therapy
89414317|NCT06203509|Experimental|THRIVE Intervention|"THRIVE Intervention~1-month intensive post discharge case management and care coordination"
89414318|NCT06203509|No Intervention|Usual Care|Discharge to home without intensive post-acute case management or care coordination.
89414319|NCT06203470|Experimental|Botox group|"Patients will receive a single intradermal injection of Mesobotox as a monotherapy.~Botulinum toxin injection: Botox injections will be intradermal. Concentration will be 100 U to be diluted with 5-ml sterile physiological sodium chloride solution. Each patient will receive individual injections of 1 U using a grid with points set at a distance of 1 cm apart. Up to two plaques per patient will be selected, whose diameter would not exceed 5-10 cm2. Each patient will receive a single BoNT-A injection"
89414320|NCT06203470|Experimental|Botox and calcipotriol group|Patients will receive a single intradermal injection of Mesobotox of the same dilution followed by topical application of Calcipotriol 0.005% ointment once daily for 3 months.
89414321|NCT06203470|Experimental|calcipotriol group|Patients will apply Calcipotriol (0.005%) as a monotherapeutic control once daily for 3 months
89414322|NCT06203457|Experimental|efgartigimod|Participants will receive efgartigimod IV infusions
89414323|NCT06203444|Experimental|Treatment Arm|Eligible subjects will be enrolled to receive the study drug
89414324|NCT06203431|Experimental|Drug ET-26|
89414325|NCT06203431|Active Comparator|Drug Etomidate|
88892048|NCT04874480|Experimental|Treatment (tegavivint, decitabine)|"PART I: Patients receive tegavivint IV over 4 hours on days 1, 8, 15, and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.~PART II: Patients receive tegavivint IV over 4 hours on days 1, 8, 15, and 22 and decitabine IV over 30-60 minutes on days 1-5. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
88892049|NCT04873713|No Intervention|No Intervention: internal hip rotation|internal hip rotation pre measurement with knee and hip flexion at 90º, internal hip rotation will be performed
88892050|NCT04873713|Experimental|Experimental: internal hip rotation|internal hip rotation post experimental application measurement with Magnetic tape Application with knee and hip flexion at 90º, internal hip rotation will be performed
88892051|NCT04873713|Placebo Comparator|Placebo Comparator: internal hip rotation|internal hip rotation post placebo application measurement with Placebo tape Application with knee and hip flexion at 90o, internal hip rotation will be performed
88892052|NCT04871269|Experimental|Drug: Dronabinol before the trauma film paradigm|
88892053|NCT04871269|Experimental|Drug: Dronabinol after the trauma film paradigm|
88892054|NCT04871269|Placebo Comparator|Placebo before and after the trauma film paradigm|
88892055|NCT04863885|Experimental|Phase 1 Dose Level 1|Participants will be treated at dose level 1: Ipilumumab 3mg/kg + Nivolumab 1mg/kg IV day 1 every 3 weeks for 4 cycles, followed by Nivolumab 360 mg every 3 weeks. Sacituzumab Govitecan 8 mg/kg IV will be administered days 1 and 8 every 3 weeks.
88892056|NCT04863885|Experimental|Phase 1 Dose Level 2|Participants will be treated at dose level 2: Ipilumumab 3mg/kg + Nivolumab 1mg/kg IV day 1 every 3 weeks for 4 cycles, followed by Nivolumab 360 mg every 3 weeks. Sacituzumab Govitecan 10 mg/kg IV will be administered days 1 and 8 every 3 weeks.
88892057|NCT04863885|Experimental|Phase 1 Dose Level -1|If dose reduction is indicated, participants will be treated at dose level -1: Ipilumumab 3mg/kg + Nivolumab 1mg/kg IV day 1 every 3 weeks for 4 cycles, followed by Nivolumab 360 mg every 3 weeks. Sacituzumab Govitecan 6 mg/kg IV will be administered days 1 and 8 every 3 weeks
88892058|NCT04863885|Experimental|Phase 2: Treatment at Maximum Tolerated Dose (MTD)|Participants will be treated at with Ipilumumab 3mg/kg + Nivolumab 1mg/kg IV day 1 every 3 weeks for 4 cycles, followed by Nivolumab 360 mg every 3 weeks plus the maximum tolerated dose of Sacituzumab Govitecan days 1 and 8 every 3 weeks.
88892059|NCT04862156|Experimental|Normothermic Machine Perfusion (NMP)|Following the routine retrieval procedure of the liver, it will be placed on the OrganOx metra for Normothermic Machine Perfusion (NMP) for transport per the Investigational Plan and the Instructions for Use.
88892060|NCT04858490|Experimental|Symptom-triggered diazepam treatment|Participants will be treated for a period of 3 days using a symptom-triggered withdrawal management protocol delivered over telemedicine. Participants who score 10 or above on the modified CIWA-Ar will be advised to take a specific dose of diazepam (either 10 or 20mg, at the clinician's discretion). Participants will be reassessed regularly over the 3-day period.
88892061|NCT04856462|Experimental|Education Support Group|Caregivers receiving structured education and support
88892062|NCT04856462|Active Comparator|Control Group|Caregivers participating in weekly support calls
88892063|NCT04854694|Experimental|All Subjects|"All participants will be fit tested for the masks to ensure that the appropriate size is used. Some participants will wear the FaceView Mask™ (first) for 5 minutes before wearing the conventional surgical N95 respirator for 5 minutes. Others will wear the conventional surgical N95 respirator (first) for 5 minutes before wearing the FaceView Mask™ for 5 minutes.~All subjects will complete the study survey after exposure to the interventions."
88892064|NCT04843800|Experimental|Acupuncture|The acupuncture treatments will consist of one 45-minute session weekly, for 3 consecutive weeks. The acupuncture treatment protocol will be semi standardized according to usual practice. All patients will be treated with a selection of local and distant points, comprising 10 minutes of insertion time, 30 minutes of needle retention and manipulation to achieve de qi (an irradiating feeling) if possible.
88892065|NCT04843800|Experimental|Chiropractic|The chiropractic treatments will consist of one 20-minute session weekly, for 3 consecutive weeks. The Diversified technique is one of the most commonly practiced techniques by chiropractors. In the treatment of low back pain, this technique involves the application of a quick (high-velocity), short (low-amplitude) thrust (adjustment) to the lombo-pelvic area.
88892066|NCT04843800|Experimental|Waiting list and Therapeutic Massage|The therapeutic massage treatments will consist of one 45-minute session weekly, for 3 consecutive weeks. A technique called Fascial Release will be used. Tension related to back pain is believed to be present not only in the back but also in various parts of the body such as the legs, through the connection of fascia, the membrane that surrounds the muscles. The purpose of this treatment is to reduce the tension connected to the lower back.
88892067|NCT04837846||Prospective CCTA Arm|
88892068|NCT04827186|Experimental|highly sensitized patients with either a positive FCXM, or positive CDC cross-match|highly sensitized patients that receive a donor offer and have either a positive FCXM (T or B cell positive) or positive CDC cross-match (B cell positive); a positive CDC cross-match (T cell positive) remains a contraindication at this time.
88892069|NCT04827186|No Intervention|historical cohort of highly sensitized patients with a positive FCXM, or positive CDC cross-match|The control group, as comparison, will be an historical cohort of highly sensitized patients with positive flow (B and T) or positive B standard crossmatch, which received kidney transplant alone or simultaneous kidney and pancreas transplant and followed our standard protocol
88892070|NCT04812743|Experimental|Colorectal Health Research Champion trainees|Colorectal Health Research Champion (CHRC) trainees receive 5 education sessions on colorectal cancer, clinical research, biospecimen donation, ethics, and presentation skills. The CHRCs will invite others in their social networks to present to them this educational information, following the train the trainer model of health education.
88892071|NCT04808323|Experimental|Cohort A|Radiation dose: 64 Gy over 32 fractions, prophylactic nodes treated to 50 Gy over 25 fractions, boost to tumor and radiologically positive nodes to total dose of 64 Gy over 32 total fractions.
88892072|NCT04808323|Experimental|Cohort B|Radiation dose: 68 Gy over approximately 34 fractions, prophylactic nodes treated to 50 Gy over 25 fractions, boost to tumor and radiologically positive nodes to 68 Gy over 34 total fractions.
89414326|NCT06203418|Experimental|Intervention|Multi-Family Therapy
89414327|NCT06203405|Experimental|Titrating sedation targeting both optimal P0.1 and appropriate arousal level|• Sedative drug adjustment to achieve the target of light sedation (RASS 0 to -2) and optimal respiratory drive measured by P0.1 of 1.5 - 3.5 cmH2O
88892073|NCT04808323|Experimental|Cohort C|Radiation dose: 72 Gy over 36 total fractions, prophylactic nodes treated to 50 Gy over 25 fractions, boost to tumor and radiologically positive nodes to 72 Gy over 36 total fractions
88892077|NCT04792775|Experimental|Prolonged Exposure + Emotion Regulation Skills Training|Twelve, 90-minute sessions of Prolonged Exposure (PE) with Dialectical Behavior Therapy (DBT) Emotion Regulation Skills Training.
88892078|NCT04763915|Experimental|GeneSHARE|Access to GeneSHARE, a web-based toolkit including interactive and narrative components to enhance FC of genetic test results.
88892079|NCT04763915|Experimental|LivingLabReport|Access to LivingLabReport, a website containing multiple resources including a summary of the patient's genetic test results, condition-specific information, recommended CRM, and information on accessing CRM services.
88892080|NCT04763915|Active Comparator|Standard-of-care|Receive standard-of-care from their treating healthcare provider.
88892081|NCT04763915|Experimental|Variants of Uncertain Significance (VUS) Pilot Study|Participants are provided access to VUS educational resources including video and written education and assistance for speaking with family members.
88892082|NCT04759131|Experimental|BIVV001: Participants aged <6 Years|Participants aged less than (<) 6 years received BIVV001 at a dose of 50 international units per kilogram (IU/kg) intravenous (IV) injection once-weekly (QW) prophylaxis for 52 weeks.
88892083|NCT04759131|Experimental|BIVV001: Participants aged 6 to <12 Years|Participants aged 6 to <12 years received BIVV001 at a dose of 50 IU/kg IV injection QW prophylaxis for 52 weeks.
88892084|NCT04742400|Experimental|Tolebrutinib (Cohort A)|Tolebrutinib 60 mg/day for 48 weeks, Tolebrutinib 120 mg/day for 96 weeks
88892085|NCT04742400|Experimental|Tolebrutinib (cohort B)|Tolebrutinib 120 mg daily
88892086|NCT04742400|Experimental|tolebrutinib (initial cohort)|Tolebrutinib 60 mg daily
88892087|NCT04737031|No Intervention|Usual Care|Clinicians and patients will receive no further interventions beyond usual practice.
88892088|NCT04737031|Experimental|Clinician Nudge|Clinicians will receive a nudge via Best Practice Alert within the EMR
88892089|NCT04737031|Experimental|Patient Nudge|Patients will receive a message sent through myPennMedicine following establishment of their smoking status.
88892090|NCT04737031|Experimental|Clinician and Patient Nudge|Both strategies described above will be used.
88892091|NCT04728412|Experimental|patients undergoing bronchoscopy under sedation with or at risk of respiratory failure|
88892092|NCT04724369|Experimental|Study Cohort: Subjects with known or presumed neuroblastoma|"Drug: 18F-mFBG Positron-emitting radiopharmaceutical 18F-mFBG as an imaging agent for identification of neuroblastoma.~Other Names:~meta-fluorobenzylguanidine~IRP101"
88892093|NCT04707001|Active Comparator|Ultrasound monitoring group|In the ultrasound group, urinary retention is monitored, according to current practice, with an ultrasound scanner and the patient is catheterized if necessary, if residual urine exceeds 800 ml, or if the patient is symptomatic.
88892094|NCT04707001|Active Comparator|Symptoms alone group|Urination is monitored by asking at regular intervals about the onset of spontaneous urination and the patient is catheterized only on a symptomatic basis.
89193013|NCT05753215|Experimental|omadacycline|Omadacycline will be administered 300 mg orally daily without the loading dose. We chose to omit the loading dose given that many of the enrolled subjects would have received an IV therapy prior to omadacycline initiation and notable gastrointestinal intolerabilities (nausea/vomiting) based on Phase-3 trial data. Subjects receiving omadacycline will be counseled on appropriate timing of administration (fast for 4 hours before dosing and no food for 2 hours after dosing) in light of the known food effects on drug absorption. They will be instructed to avoid use of products containing aluminum, calcium, or magnesium, bismuth subsalicylate, and iron containing preparations such as dairy, antacids, and multivitamins for 4 hours post-dosing.
88892095|NCT04701333|Experimental|Cabergoline|After the completion of the surgical procedure or medical induction for the second-trimester abortion or fetal loss, the participant will be administered cabergoline 1mg orally with juice or water by the clinician or study investigator.
88892096|NCT04701333|Placebo Comparator|Placebo|After the completion of the surgical procedure or medical induction for the second-trimester abortion or fetal loss, the participant will be administered a placebo pill orally with juice or water by the clinician or study investigator.
88892097|NCT04700969|Experimental|A support program to facilitate implementation of EBP for postoperative urinary retention|12- month support program. Multi-professional facilitator-teams will be supported by a 12-month support program including seminars and monthly supervision (e-discussion forum and group teleconferences) to develop an awareness of, and skills in facilitating implementation of evidence/EBP in clinical everyday care.
88892098|NCT04700969|No Intervention|Control-No support program|No support program
88892099|NCT04679896|Experimental|MagnetOs Putty|MagnetOs Putty use in instrumented posterolateral fusion, 7cc-10cc mixed with autograft bone in a 1:1 ratio per spine level at the randomized assigned side.
88892100|NCT04679896|Other|Local autograft|
89414328|NCT06203405|No Intervention|Titrating sedation targeting appropriate arousal level alone|• Sedative drug adjustment to achieve the target of light sedation (RASS 0 to -2) according to the standard clinical practice guidelines for managing pain and agitation for patients receiving mechanical ventilation in the ICU.
89414329|NCT06203366|Experimental|Experimental group|"got the Vojta treatment 30 minutes/session, 3 times/week for 8 weeks~got the ADL and kinetic activities training 30 minutes, 3 times/week for 8 weeks"
89414330|NCT06203366|No Intervention|control group|- got the ADL and kinetic activities training 30 minutes, 3 times/week for 8 weeks
89414331|NCT06203353||weaning success|Patients extubated with no need to non invasive ventilatry support during 48 hours
89414332|NCT06203353||weaning failure|patients requiring reintubation or non invasive ventilation within 48 hours after extubation
89414333|NCT06203314||Zhongshan cohort, Guangdong, China|30-59 years old healthy participants in Zhongshan city.
89414334|NCT06203314||Wuzhou cohort, Guangxi, China|30-69 years old healthy participants in Wuzhou city.
89414335|NCT06203301|No Intervention|control group|No exercise intervention measures will be implemented. The patient will carry out daily life according to his past living habits and continue to be followed for at least one year.
89414336|NCT06203301|Experimental|resistance exercise group|Resistance exercise training begins before the patient undergoes concurrent chemoradiotherapy, radiotherapy, or chemotherapy. The patients were given resistance exercise training for 45 minutes each time, 3 times a week, for 12 consecutive weeks. After that, the patient is asked to regularly perform resistance exercise for at least 1 year.
89414337|NCT06203301|Experimental|walking group|Walking training begins before the patient undergoes simultaneous radiochemotherapy, radiation therapy, or chemotherapy, and requires continuous walking for 15 minutes at least twice a day and at least 5 days a week. Or walk for at least 150 minutes a week and walk for at least 15 minutes continuously each time for 12 consecutive weeks of walking training. After that, ask the patient to walk regularly for at least 1 year.
89414338|NCT06203301|Experimental|resistance exercise and walking group|Before patients receive concurrent chemoradiotherapy, radiotherapy, or chemotherapy, they are given resistance exercise training and walking training for 12 consecutive weeks. After that, the patient is asked to regularly perform resistance exercise and walking for at least 1 year.
89414339|NCT06203275|Placebo Comparator|group 1 (control group)|which will receive metformin based combined oral hypoglycemic plus placebo tablets
89414340|NCT06203275|Active Comparator|group II (intervention group)|which will receive metformin based combined oral hypoglycemic plus 12.5 mg paroxetine daily at morning.
89414341|NCT06203262|Experimental|Ventricular Tachicardia (VCAS-I)|Patients with ventricular tachycardia meeting class II-a/b indications in European guideline for catheter ablation, with a clinical VT event detected by an implanted ICD
89414342|NCT06203262|Experimental|Premature Ventricular Contractions (VCAS-II)|For VCAS-II group, patients with symptomatic frequent unifocal premature ventricular complexes (PVCs) meeting class II-a/b indications based on European guidelines for catheter ablation. For VCAS-II, documentation of frequent PVCs by 24 hours Holter with >11% PVC burden for asymptomatic patients and >5% PVC burden for symptomatic patients within the last 60 days.
89414343|NCT06203236|Active Comparator|Natriuresis-guided group|Natriuresis-guided therapy group receiving diuretic therapy guided by natriuresis measurements.
89414344|NCT06203236|Active Comparator|Control group|Patients with matched age and sex as control group receiving diuretic therapy only.
89414345|NCT06203223|Active Comparator|Ova-max|antioxidant, dietary supplement
89414346|NCT06203223|Placebo Comparator|Placebo|placebo
89414347|NCT06203210|Experimental|Ifinatamab deruxtecan (I-DXd)|Participants randomized to receive 12 mg/kg I-DXd monotherapy on Day 1 of each 21-day cycle until unacceptable toxicity, progressive disease (PD), or withdrawal of consent as specified in the protocol.
89414348|NCT06203210|Active Comparator|Treatment of Physician's Choice (TPC)|Participants randomized to receive topotecan, lurbinectedin, or amrubicin, as per investigator's choice and per locally approved label, until a treatment discontinuation criterion is met as specified in the protocol.
89414349|NCT06203197|No Intervention|control|Patients in the control group will receive routine clinical care after surgery.
88892101|NCT04679844|Experimental|MagnetOs Putty|"Interventions~Procedure: Instrumented posterolateral spine fusion~Device; MagnetOs Putty"
88892102|NCT04679844|Active Comparator|Demineralized Bone Matrix mixed with Autograft Bone|"Interventions~Procedure: Instrumented posterolateral spine fusion~Device: Demineralized Bone Matrix mixed with Autograft Bone"
88892103|NCT04673617|Experimental|Phase 1: Dose confirmation of AB-101 as mono, ritux combo (including DLBCL specific) & BR combo|Phase 1: Dose confirmation of AB-101 as monotherapy, in combination with rituximab (including the DLBCL specific cohort) and in combination with bendamustine and rituximab
88892104|NCT04673617|Experimental|Phase 2: AB-101 given with rituximab or with BR to patients with B-cell NHL at the R2PD|Phase 2: AB-101 given with rituximab or with bendamustine and rituximab to patients with B-cell NHL at the R2PD
89414350|NCT06203197|Experimental|intervention|Patients in the intervention group will use the mobile-based care support application (M-Breast cancer personal care and monitoring system (M-MEKKBİS)) developed within the scope of the research after the surgery.
88892109|NCT04665206|Experimental|VT3989 Dose Escalation|VT3989 dosed orally in 21 or 28 day cycles. Patients will be enrolled into escalating dose levels during the Dose Escalation Phase
88892110|NCT04665206|Experimental|Dose Expansion|VT3989 dosed in 21 or 28 day cycles in patients with refractory metastatic solid tumors or mesothelioma, with or without NF2 mutant tumors.
88892111|NCT04662190|Active Comparator|Control grup|Conventional surgery.
88892112|NCT04662190|Experimental|Intervention group|Surgery planned, simulated and guided by 3D printing.
88892113|NCT04631900|Experimental|Spiritual Intervention Programme|"The intervention is a 8 weeks' programme. The Christianity approach as the framework for spiritual intervention includes use of Bible verses, prayer, hymns singing, sharing and caring for others (mutual support) within the group.~Through these activities, participants have opportunities to re-build and further develop their connectedness to themselves, to others, to their living, their environment, and to larger meaning and purpose."
88892114|NCT04631900|No Intervention|Wait-list Control group|Participants recruited in the waitlist control will be initially tested to generate pre-test scores and will then tested six weeks later which is equivalent to the timespan between the pre-test and post-test for the experimental spiritual programme. In between these two testing sessions, the waitlist control group will not receive any type of spiritual intervention. For ethical reasons, following the second testing session, the participants in the waitlist group will be given the opportunity to participant in the spiritual intervention programme.
88892115|NCT04626635|Experimental|Dose Escalation|Variety of mixed advanced solid tumor types
88892116|NCT04626635|Experimental|Dose Expansion A|Triple Negative Breast Cancer (TNBC)
88892117|NCT04626635|Experimental|Dose Expansion B|Cutaneous Squamous Cell Carcinoma (CSCC)
89193014|NCT05753215|Other|standard of care antibiotic|Standard of care as determined by primary care team
89414351|NCT06203184|Experimental|video game based exercise training|Breathing Games; developed by a company called &amp;amp;Breathing Labs&amp;amp;; allow breathing exercises to be implemented based on video games. Studies have reported that breathing exercises accompanied by visual feedback provide additional benefits, and it has been stated that the virtual reality-based approach is an effective method in this respect.
89414352|NCT06203184|Other|control group|No intervention will be made to the control group.
89414353|NCT06203145|Experimental|BCD-KPD-AutoHSCT|BCD-KPD-AutoHSCT/BCD-AutoHSCT
89414354|NCT06203132|Experimental|Doravirine arm|Doravirine (100 mg) + tenofovir DF (300 mg) + lamivudine (300mg) administered daily
89414355|NCT06203132|Active Comparator|Dolutegravir arm|Dolutegravir (50 mg) + tenofovir DF 300 mg + XTC (300 mg if lamivudine ou 200 mg if emtricitabine) administered daily
89414356|NCT06203119||68Ga-DOTA-BPP|68Ga-DOTA-BPP PET/CT: after intravenous injection of 2.96 MBq/ kg body weight of quality-controlled 68Ga-DOTA-BPP, a Siemens Biograph PET/CT scan will be applied within 1 h-2 h, and the scan range will be from the top of the head to 1/3 of the upper thigh.
89414357|NCT06203119||18F-FGD|18F-FDG PET/CT: after intravenous injection of 2.96 MBq/ kg body weight of quality-controlled 18F-FDG, a Siemens Biograph PET/CT scan will be applied within 1 h, and the scan range will be from the top of the head to 1/3 of the upper thigh.
89414358|NCT06203106||Affected Subjects|Subjects in this group will have a diagnosis and/or medical history of a condition, disease, genetic background, or trait of interest.
89414359|NCT06203106||Healthy Control|Subjects in this group will serve as healthy controls.
89414360|NCT06203093||Charcot-Marie-Tooth Disease|Subjects in this group will have a diagnosis of Charcot-Marie-Tooth Disease.
89414361|NCT06203093||Healthy Control|Subjects in this group will serve as healthy controls.
89414362|NCT06203080|Experimental|Intervention group|An acetic acid thermoreversible gel developed by Shanghai Jinxiang Latex Products Co. will be allocated to the intervention group.
89414363|NCT06203080|Active Comparator|Controlled group|Nonoxinol gel produced by China Pharmaceutical University Pharmacy Co., Ltd will be allocated to the cotrolled group.
89414364|NCT06203015||MDD patients|patients diagnosed with MDD (according to the WHO's [2019] International Classification of Diseases and related health problems categorization of mental disorders), diagnosed by a psychiatrist; ≥18 years old
88892118|NCT04626635|Experimental|Dose Expansion C|Non-Small Cell Lung Cancer (NSCLC)
88892119|NCT04626635|Experimental|Dose Expansion D|Head and Neck Squamous Cell Carcinoma (HNSCC)
88892120|NCT04626635|Experimental|Dose Expansion E|Microsatellite Stable-Colorectal Cancer (MSS-CRC), with Active Liver Metastases and/or Active Peritoneal Metastases
88892121|NCT04626635|Experimental|Dose Expansion F|MSS-CRC with Isolated Lung/Lymph Node Metastases (no active liver and no active peritoneal metastases)
88892122|NCT04626635|Experimental|Dose Expansion G|Epidermal Growth Factor Receptor (EGFR) -mutant NSCLC Post Third Generation tyrosine kinase inhibitor (TKI)
88892123|NCT04626635|Experimental|Dose Expansion H|EGFR-mutant NSCLC Post Third Generation TKI and Post Platinum-Doublet Chemotherapy
88892124|NCT04601064|Experimental|Collaborate Care (CC) Model|For patients randomized to the CC arm, in addition to the provider being alerted to the positive Mental Health and Substance Use Disorder screener, the patient will also be assigned to a peer case manager (P-CM). The P-CM will provide longitudinal care for the patient as part of their care management case load. The collaborative care support team will include the P-CM, a consultant addiction psychiatrist and the patient's HIV provider who will implement a stepped care program consisting of: 1) an initial assessment, determination of and implementation of an individualized care plan to provide; 2) psychosocial and medication adherence support; 3) evidence-based brief intervention incorporating motivational interviewing informed strategies; 4) measurement-based care for Mental Health and Substance Use Disorder provided directly by the HIV primary care provider or in collaboration with specialty Mental Health and Substance Use Disorder services.
88922088|NCT05840952|Experimental|ALG-097558 Bioavailability|Oral doses of ALG-097558, up to 3 doses over 3 days, both solution and tablet formulations dosed in fasted state, and tablet formulation dosed in fed state, in Healthy Volunteers
89193015|NCT05750342|Experimental|Caqui|Subjects will consume two capsules daily. Each capsule will be taken before the two main meals.
89414365|NCT06203015||Control group|Subjects who have not been diagnosed with any mental disorder in the past year; ≥18 years old
89414366|NCT06202989|Experimental|Multiprofen-CC™|Standard care pain medications and topical Multiprofen-CC™ (1g TID) for 3 months after surgery
89414367|NCT06202989|Placebo Comparator|Control|Standard care pain medications and visually identical topical placebo (1g TID) for 3 months after surgery
89193016|NCT05750342|Placebo Comparator|Placebo|The product will have the same characteristics as the experimental product. They will consume two capsules per day, one before the two main meals.
89414368|NCT06202976||Patients|
89414369|NCT06202963|Active Comparator|Group 1|In group 1, hydrodilatation will be performed with intra-articular 40 mg triamcinolone, lidocaine, and physiological saline through a posterior approach to the shoulder, guided by ultrasonographic imaging. Fluid injection will continue until distension is observed in the shoulder joint capsule by ultrasonography. The amount of fluid given will be recorded.
89414370|NCT06202963|Active Comparator|Group 2|The second group will undergo hydrodilatation with intra-articular 40 mg triamcinolone, lidocaine, and physiological saline through a posterior approach to the shoulder, guided by ultrasonographic imaging. The amount of fluid given will be recorded. Additionally, with ultrasonographic evaluation, 2 cc of physiological saline will be injected into the corocohumeral ligament.
89414371|NCT06202937|Experimental|mother baby yoga|Mother-baby yoga will be held with the babies discharged from the neonatal intensive care unit and their mothers
89414372|NCT06202937|Experimental|control|the control group received the usual care
89414373|NCT06202911|Active Comparator|intervention group|preterm neonates with feeding intolerance, pre-Nec., receive the drug
89414374|NCT06202911|Placebo Comparator|control group|preterm neonates
89414375|NCT06202898|Experimental|ENTRUST|The proposed intervention 'ENTRUST' will address structural disparities transgender women encounter by providing skills to aid with economic navigation while simultaneously strengthening and improving social cohesion to increase the odds of them linking to care that is available to them.
89414376|NCT06202898|Active Comparator|Control|Comparison control group.
89414377|NCT06202885||T cell engager|
89414378|NCT06202885||Standard-of-care|
89414379|NCT06202872|Experimental|Active tACS|Gamma (40 Hz) tACS at the precuneus region
89414380|NCT06202872|Sham Comparator|Sham tACS|Sham tACS at the precuneus region
89414381|NCT06202859|Experimental|MIE group|"Manual techniques of secretion drainage~Two sequences separated for 1 min of 6 cycles each of MI-E(Cough Assist E70, Respironics Philips."
89414382|NCT06202859|Active Comparator|Control group|Maintained following national guidelines.
89414383|NCT06202820|Experimental|CV Care Program|"Study procedures will be conducted as follows:~Standard of care androgen deprivation therapy.~4 week standard-of-care follow up visit in clinic with CV care education module completion.~12-week standard-of-care prostate cancer care visit with oncologist.~24-week standard-of-care post-ADT visit in clinic with CV Care module completion, surveys, and exit interview with clinical team members.~The CV Care program will be revised through participant feedback from assessments, surveys, focus groups, and exit-interviews. The revised CV Care Program will be used in the next cohort."
89414384|NCT06202820|Experimental|CV Care Program 2|"Study procedures will be conducted as follows:~Standard of care androgen deprivation therapy.~4 week standard-of-care follow up visit in clinic with CV care education module completion.~12-week standard-of-care prostate cancer care visit with oncologist.~24-week standard-of-care post-ADT visit in clinic with CV Care module completion, surveys, and exit interview with clinical team members.~Participant feedback from surveys, exit-interviews, and possibly focus groups will be collected."
89414385|NCT06202781||Pre-treatment|Advanced gastric cancer patients prior to receiving combined immunotherapy and chemotherapy
89414386|NCT06202781||Post-treatment|Advanced gastric cancer patients who have received 2 to 8 cycles of combined immunotherapy and chemotherapy
89414387|NCT06202781||Response|Advanced gastric cancer patients who have achieved complete response (CR) or partial response (PR) after receiving combined immunotherapy and chemotherapy
89414388|NCT06202781||Non-response|Advanced gastric cancer patients who have achieved stable disease (SD) or progressive disease (PD) after receiving combined immunotherapy and chemotherapy
89414389|NCT06202768||Main population|History of cesarean section Vertex singleton gestation At term (at least 37 weeks of gestation)
89414390|NCT06202651|Experimental|Nd:YAG Laser Interventional Cohort|"Participants include Granular Corneal Dystrophy patients.~On visit 1, participants will undergo visual acuity testing, slit-lamp examination, intra-ocular pressure (IOP) measurement, Scheimpflug tomography, anterior-segment optical coherence tomography (AS-OCT), and slit-lamp photography of the cornea.~On the same visit or on a separate visit within 1 month, the participants will undergo the Nd:YAG Laser treatment. At the investigators' discretion, after the procedure, participants might need to administer generic topical antibiotic eye drops three times daily for a week.~One week post-intervention (visit 2), the participant will repeat visual acuity testing, slit-lamp examination, IOP measurement, Scheimpflug tomography, AS-OCT, and slit-lamp photography of the cornea.~Three months post-intervention (visit 3), the participant will repeat visual acuity testing, slit-lamp examination, IOP measurement, Scheimpflug tomography, AS-OCT, and slit-lamp photography of the cornea."
89414391|NCT06202638||The arterial pressure and HPI course in 7 time-windows cohorts in one-lung ventilated patients|60 consecutive adult patients qualified for open-chest lung resection procedures under general anesthesia with one-lung ventilation will be monitored during the operation using standard invasive hemodynamic monitoring with arterial pressure transducer and concomitantly with HemoSphere monitor with the HPI software attached to the Acumen IQ transducer (Edwards LifeSciences, Irvine, CA, USA). The clinicians will be blinded to the output of the HemoSphere monitor. Hemodynamic waveforms and HPI prediction data will be recorded from the time of arterial cannula insertion until leaving the operation room. HPI values and intraoperative hemodynamic course including intraoperative hypotensive events (IOH) will be recorded at all stages of the procedure.
89414392|NCT06201923|Experimental|Group I (Thyme H)|0.2% thyme honey mouth rinse (20 ml of thyme honey diluted in 100 ml of purified water) 3 times per day.
89414393|NCT06201923|Placebo Comparator|Group II (Saline G)|normal saline oral rinse
89414394|NCT06201871|Experimental|Alcoholic patients|Patients will receive an inferior alveolar nerve block injection using 1.8 mL of 2% lidocaine with 1: 80 000 epinephrine using a direct Halsted approach.
89414395|NCT06201871|Active Comparator|Control patients|Patients will receive an inferior alveolar nerve block injection using 1.8 mL of 2% lidocaine with 1: 80 000 epinephrine using a direct Halsted approach.
89414396|NCT06201845|Experimental|Exercise awareness training|
89414397|NCT06201845|Active Comparator|physical activity awareness training|physical activity awareness training,
89414398|NCT06201546|Active Comparator|TAP block|Transversus Abdominal Plane Block aplied after LSG. In TAP block local anesthetic(%0,25 bupivacaine-20ml)will be administrated the between the transversus abdominis muscle and the internal abdominal muscle fascia.
88922092|NCT05835375|Active Comparator|EQ-778|"capsule to be taken daily after breakfast (in case no URTI episode)~capsules to be taken daily after breakfast (in case of URTI episode)"
88922093|NCT05835375|Placebo Comparator|Placebo|"capsule to be taken daily after breakfast (in case no URTI episode)~capsules to be taken daily after breakfast (in case of URTI episode)"
88922094|NCT05831982|Experimental|Intervention (A)|Intervention focusing on strength training and nutritional optimization.
88922095|NCT05831982|Active Comparator|Control (B)|Usual care. Physiotherapy (type of training decided by the physiotherapist) without nutritional intervention.
89414399|NCT06201546|Active Comparator|m-TAPA block|Modified-Thoracoabdominal Plane Block-pericondrial approach aplied after LSG. In m-TAPA block local anesthetic (0.25% bupivacaine-20ml) will be administrated between the transversus abdominis muscle and the internal abdominal muscle fascia under the costochondrial region.
89414400|NCT06201507|Experimental|Intermediate Risk|Intermediate Risk Patients (Stage IA bulk/E, IB, IIA bulk/E, IIB, IIIA): 4 cycles of chemotherapy
89414401|NCT06201507|Experimental|High Risk|High Risk Patients (Stage IIIA bulk/ E, IIIB, IVA/B): 6 cycles of chemotherapy
88892125|NCT04601064|No Intervention|Usual Care (UC)|For patients randomized to the UC referral arm, the patient's HIV provider will receive an electronic alert of the patient's positive screen for a Mental Health and Substance Use Disorder. The patient will not be contacted by the P-CM. The provider, at their discretion, will initiate referral to the psychiatry service available onsite. For patients with Substance Use Disorder, providers refer to the in-clinic Substance Use Disorder treatment program that is managed by a nurse practitioner with Substance Use Disorder care experience. Once referred, the patient is seen by the nurse practitioner (separate from the HIV provider) who manages prescription of and assessment of adherence to buprenorphine, including monitoring of urine toxicology results with support from an addiction counselor. The Bartlett Clinic runs 2 substance use groups weekly and has processes for referral to a higher level of Substance Use Disorder care at offsite Substance Use Disorder treatment programs.
88892126|NCT04593875|Experimental|Active, then Sham|Active Low intensity focused ultrasound pulsation (LIFUP) will be administered to the internal globus pallidus while participants are in the MRI scanner. Then, 2 weeks later, sham LIFUP will be administered.
88892127|NCT04593875|Experimental|Sham, then Active|Sham low intensity focused ultrasound pulsation (LIFUP) will be administered while participants are in the MRI scanner. Then, 2 weeks later, active LIFUP will be administered to the internal globus pallidus.
88892128|NCT04586244|Experimental|Treatment Group A|epacadostat will be administered in combination with retifanlimab.
88892129|NCT04586244|Experimental|Treatment Group B|retifanlimab will be administered as monotherapy.
88892130|NCT04586244|Experimental|Treatment Group C|epacadostat will be administered as monotherapy.
88892131|NCT04586244|Experimental|Treatment Group D|retifanlimab will be administered in combination with INCAGN02385.
88892132|NCT04586244|Experimental|Treatment Group E|retifanlimab will be administered in combination with INCAGN02385 and INCAGN02390.
88892133|NCT04579692|Experimental|ExAblate Transcranial treatment|The ExAblate Transcranial system will be used to destroy a small cluster of cells that may be causing the study participant's pain . The ExAblate uses ultrasound to heat a small spot in the brain called central lateral thalamic nucleus. Ultrasound passes through the skin and skull and into the brain to focus on this particular spot.
88892134|NCT04570839|Experimental|Dose Escalation Cohorts.|Up to 5 sequential dose escalation cohorts of COM701 in combination with fixed doses of BMS-986207 and nivolumab. All study drugs will be administered IV every 4 weeks until a maximum tolerated dose or recommended dose for expansion is identified.
88892135|NCT04570839|Experimental|Cohort 1 Expansion Cohort A (ovarian cancer)|Single arm: subjects with platinum resistant/refractory epithelial ovarian cancer, primary peritoneal or fallopian tube cancer will be randomized to receive study treatment with COM701 in combination with BMS-986207 and nivolumab. The study drugs will be administered IV every 4 weeks.
88892136|NCT04570839|Experimental|Cohort 2 Expansion Cohort (endometrial cancer).|Single arm: subjects with MSS-endometrial cancer will receive study treatment with COM701 in combination with BMS-986207 and nivolumab. All study drugs will be administered IV every 4 weeks.
88892137|NCT04570839|Experimental|Cohort 3 Expansion Cohort (basket cohort - high PVRL2 tumors).|Single arm: subjects with tumor types with high expression of PVRL2 will receive study treatment with COM701 in combination with BMS-986207 and nivolumab. All study drugs will be administered IV every 4 weeks.
88892138|NCT04570839|Experimental|Cohort 4 Expansion Cohort (Head and Neck cancer).|"Two arms: subjects with head and neck cancer. Equal number of subjects in each of the 2 arms. One arm will enroll subjects who have not previously received treatment with an immune checkpoint inhibitor, the other arm will enroll subjects who have received prior treatment with an immune checkpoint inhibitor.~All subjects will receive study treatment with COM701 in combination with BMS-986207 and nivolumab. All study drugs will be administered IV every 4 weeks."
88892139|NCT04562480|Experimental|Treatment (hypofractionated radiation therapy, resection)|Patients undergo hypofractionated radiation therapy QD (except weekends and holidays) over 3 weeks for a total of 15 fractions. Within 3-6 weeks after completion of radiation therapy, patients undergo surgical resection.
89193017|NCT05749055|Experimental|ENX-102|Four weeks of 2 mg of ENX-102 in capsule form followed by 3 weeks of tapered dose plus 2 weeks of placebo in capsule form (before and/or after the ENX-102 treatment period), taken orally once daily in the evening for a 9-week total treatment period.
88892140|NCT04559074|Experimental|Interventional|Intervention group will receive Amlodipine 1mg/ml Oral Solution; starting dose 1-2mg per day for patients not on amlodipine at entry. Participants will take the prescribed dosage daily. Dosage will be reviewed on a fortnightly basis and adjusted as necessary. The total duration is 3 months.
88922096|NCT05827653|Experimental|Cohort 1_active|Dose 1 NX210c
88922097|NCT05827653|Experimental|Cohort 1_placebo|Placebo
88922098|NCT05827653|Experimental|Cohort 2_active|Dose 2 (TBC) NX210c.
89193018|NCT05749055|Placebo Comparator|Placebo|Nine weeks of placebo in capsule form taken orally once daily in the evening for a 9-week total treatment period.
89193019|NCT05739435|Experimental|ESK-001 Dose Level 1|ESK-001 administered as an oral tablet
89193020|NCT05739435|Experimental|ESK-001 Dose Level 2|ESK-001 administered as an oral tablet
89193021|NCT05732883|Experimental|Dexamethasone group|One dose of 8mg in 2ml Dexamethasone will be given
89193022|NCT05732883|Placebo Comparator|Placebo group|One dose of 2ml 0.9% Normal saline will be given
89414402|NCT06201377|Experimental|Suture with chlorhexidine|At the end of the surgical procedure, the flap will be sutured with an absorbable suture coated with chlorhexidine diacetate (NOVOSYN CHLORHEXIDINE)
89414403|NCT06201377|Active Comparator|Suture without chlorhexidine|At the end of the surgical procedure, the flap will be sutured with an absorbable suture coated without chlorhexidine diacetate (NOVOSYN)
89414404|NCT06201364|Experimental|EOI group|chest wall will be systematically scanned. Initially the probe will be placed in a cephalad to caudad paramedian direction at the anterior axillary line, and the external oblique muscle will be identified at the level ribs 6 and 7 in line with the xiphoid process to confirm correct identification of the external oblique muscle, the probe will be moved in the caudad direction following the external oblique muscle. At the subcostal level, the ultrasound probe will be rotated 90° to see the convergence with the internal oblique and transversus abdominus muscles. The probe will be then moved back to the initial identification point for the external oblique muscle. The EOI plane will be identified deep to the external oblique muscle and superficial to the sixth and seventh ribs and their associated intercostal muscles. Local anesthetic agent will be 20 ml volume (10 ml bupivacaine 0.5% ,10ml saline) will be then injected, this procedure will be done bilaterally.
89414405|NCT06201364|Active Comparator|PVB group|we will be scanning the anatomy of the lateral paravertebral space using a high-frequency linear ultrasound transducer, after identification of the transverse process, internal intercostal membrane (IIM), and pleura at the T3 and T6 levels, an out-of-plane needle guidance technique would be used to perform the PVB with 20 ml volume (10 ml bupivacaine 0.5% ,10ml saline) will be then injected, this procedure will be done bilaterally.
89414406|NCT06201260|Experimental|IPC|a 30 min high-pressure IPC protocol
89414407|NCT06201260|Placebo Comparator|placebo|A 30 min placebo
89414408|NCT06201169|Active Comparator|group I (control)|The bars are fabricated from titanium. the participants received implant supported hybrid prosthesis with CAD/CAM fabricated titanium bars
89414409|NCT06201169|Experimental|group II|The bars are fabricated from PEEK . the participants received implant supported hybrid prosthesis with CAD/CAM fabricated PEEK bars
89414410|NCT06201117|Experimental|Preparatory information|In the experimental group, the participants will rate their anxiety before receiving the 12-minute preparation information video in addition to the usual preparation information on the day they gave consent to participate in the study. The participants will rate their anxiety again 30 minutes after the intervention. The experimental group will receive the preparation video again the second time on the day before surgery. Anxiety and treatment adherence will be measured in the ICU, 48 hours after the surgery.
89414411|NCT06201117|Active Comparator|Usual information|In the comparison group, the participants will rate their anxiety before receiving the usual preoperative information on the day they gave consent to participate in the study. The participants will rate their anxiety again 30 minutes after the usual information. Anxiety and treatment adherence will be measured in the ICU, 48 hours after the surgery.
89414412|NCT06200948|Active Comparator|non-cycling group|patients will receive only complete decongestive treatment
89414413|NCT06200948|Active Comparator|cycling group|patients will receive complete decongestive treatment + cycling ergometry treatment
89414414|NCT06200831|Active Comparator|Staged resection|Resection of the primary colorectal carcinoma and liver metastases in two separate surgeries.
89414415|NCT06200831|Experimental|Simultaneous resection|Resection of both the primary colorectal carcinoma and the liver metastases in one surgical procedure.
89414416|NCT06200727|Experimental|PRF membrane in macular hole|To observe the healing and visual recovery of a macular hole, the macular hole was filled with a PRF membrane. Before the participant went into the operating theatre, a blood sample was taken from the anterior elbow vein using a 5 ml tube without anticoagulants. The middle layer of blood after centrifugation was PRF. After retrobulbar anesthesia and removal of the posterior vitreous cortex. In the PRF group, PRF membrane was utilized to fill the macular hole after the ILM was peeled. Then the eyeball was filled with sterile air after adequate air-liquid exchange. At the end of the operation, tobramycin dexamethasone ophthalmic ointment was applied to the operated eye with pressure, and the participant was instructed to maintain a prone position for 7 days after the operation.
89414417|NCT06200727|Active Comparator|Internal limmiting membrane(ILM) peeling in macular hole|"After retrobulbar anesthesia and removal of the posterior vitreous cortex, the control group underwent the procedure of peeling the ILM. The ILM was completely removed from the retina. Then the eyeballs were filled with sterile air after adequate air-liquid exchange.~At the end of the operation, tobramycin dexamethasone ophthalmic ointment was applied to the operated eye with pressure, and the participant was instructed to maintain a prone position for 7 days after the operation."
89414418|NCT06200727|Experimental|PRF membrane transplantation in pterygium|Following the removal of the pterygium, the prepared PRF was cut to match the size of the exposed scleral surface. It was then placed on the sclera and secured to the surrounding conjunctiva using 3-7 interrupted sutures of 10-0 nylon thread. This was done to ensure that the PRF implant was perfectly aligned with the conjunctiva.
89414419|NCT06200727|Active Comparator|Autologous conjunctival transplantation in pterygium|After the pterygium removal surgery, to restore the eye, participants need to undergo a corneal limbal stem cell transplant. The transplanted stem cells should be the same size as the exposed scleral surface above the temporal part of the eye. When transferring the transplant, ensured that the corneal edge of the grafted conjunctival flap was positioned opposite to the cornea. Closed the flap to the peripheral conjunctiva with 3-7 interrupted sutures using 10-0 nylon thread. Fixed the conjunctival flap to the surrounding conjunctiva with sutures, and covered the sclera with the surrounding bulbar conjunctiva.
88892141|NCT04559074|No Intervention|Observational|This group will record blood pressure readings and data on a daily basis for a total of 3 months. They will not take any medication. They will be reviewed on a monthly basis in consultations.
88892142|NCT04558619|Other|Kōmmour Prenatal|
88892143|NCT04557982||Children aged 3 < 4 years|Children aged 3 < 4 years will be recruited using convenience sampling and meeting the inclusion criteria (child Czech-speaking, able to distinguish between small/medium sized/large toy, willing to cooperate, parent/significant other is present and signs informed consent). The child will be explained the use of the S-COS, and S-FPS and self-reports pain intensity immediately prior to the procedure (Time 0), immediately after the procedure (Time 1) and after 5-10 minutes (Time 2). Furthermore, at Time 0, 1 and 2, the child´s pain level is independently assessed by the attending nurse and by the researcher.
88892144|NCT04557982||Children aged 4 < 5 years|Children aged 4 < 5 years will be recruited using convenience sampling and meeting the inclusion criteria (child Czech-speaking, able to distinguish between small/medium sized/large toy, willing to cooperate, parent/significant other is present and signs informed consent). The child will be explained the use of the S-COS, and S-FPS and self-reports pain intensity immediately prior to the procedure (Time 0), immediately after the procedure (Time 1) and after 5-10 minutes (Time 2). Furthermore, at Time 0, 1 and 2, the child´s pain level is independently assessed by the attending nurse and by the researcher.
88892145|NCT04557982||Children aged 5 < 6 years|Children aged 5 < 6 years will be recruited using convenience sampling and meeting the inclusion criteria (child Czech-speaking, able to distinguish between small/medium sized/large toy, willing to cooperate, parent/significant other is present and signs informed consent). The child will be explained the use of the S-COS, and S-FPS and self-reports pain intensity immediately prior to the procedure (Time 0), immediately after the procedure (Time 1) and after 5-10 minutes (Time 2). Furthermore, at Time 0, 1 and 2, the child´s pain level is independently assessed by the attending nurse and by the researcher.
88892146|NCT04548817||Neurocutaneous Melanocytosis|Participants will have Neurocutaneous Melanocytosis (NCM) Including Cutaneous and CNS Involvement
88892147|NCT04546009|Experimental|Giredestrant + Letrozole-matched Placebo + Palbociclib|
88892148|NCT04546009|Active Comparator|Letrozole + Giredestrant-matched Placebo + Palbociclib|
88892149|NCT04540211|Experimental|Atezolizumab + Tiragolumab + PC|Participants will receive atezolizumab and tiragolumab on Day 1 of each 21-day cycle during the study followed by paclitaxel and cisplatin on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit or unacceptable toxicity, during the induction treatment phase.
88892150|NCT04540211|Placebo Comparator|Placebo + PC|Participants will receive atezolizumab matching placebo and tiragolumab matching placebo on Day 1 of each 21-day cycle during the study followed by paclitaxel and cisplatin on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit or unacceptable toxicity, during the induction treatment phase.
88892151|NCT04533737|Experimental|Arm 1 (brodalumab + dummy 1)|"Participants receive:~Brodalumab 210 mg (1.5 ml) at Weeks 0, 1, 2, and then every 2 weeks.~Dummy 1 (placebo 1.0 ml) at Weeks 0, 4, and then every 8 weeks."
88892152|NCT04533737|Active Comparator|Arm 2 (guselkumab + dummy 2)|"Participants receive:~Guselkumab 100 mg (1.0 ml) at Weeks 0, 4, and then every 8 weeks.~Dummy 2 (placebo 1.5 ml) at Weeks 0, 1, 2, and then every 2 weeks."
88892153|NCT04530552|Experimental|Treatment (apalutamide)|Patients receive apalutamide PO on study. Patients also undergo collection of blood samples throughout the study.
88892154|NCT04529265|Experimental|Methylene Blue group|The first dosage: 2mg/kg MB diluted with normal saline into total 50 ml volume intravenous administration after induction of anesthesia within one hour; The second dosage: 1mg/kg MB diluted with normal saline into total 50 ml volume intravenous administration before the end of surgery within 30 minutes.
88892155|NCT04529265|Placebo Comparator|Control group|The first dosage: normal saline in total 50 ml volume intravenous administration after induction of anesthesia within one hour; The second dosage: normal saline in total 50 ml volume intravenous administration before the end of surgery within 30 minutes.
88892156|NCT04513522|Experimental|Nivolumab + ipilimumab|
88892157|NCT04509765|Experimental|Patients with Hematologic Malgnancies|
88892158|NCT04493372|Experimental|Individuals with spinal cord injury|
88892159|NCT04493372|Experimental|Individuals without spinal cord injury|
88892160|NCT04493242|Placebo Comparator|Placebo|Normal saline 100 mL
88892161|NCT04493242|Experimental|Experimental Dose 1|Normal saline 90 mL and ExoFlo 10 mL
88892162|NCT04493242|Experimental|Experimental Dose 2|Normal saline 85 mL and ExoFlo 15 mL
88892163|NCT04486118|Active Comparator|CA-ACEi|"Enrolled subjects will begin treatment with a low dose of study drug (5 mg) Study drug will then be titrated up as follows, provided the increased dose is tolerated:~Day 3-15 (dosing begins after completion of FIMR Visit 1.1): 5 mg Day 29: 10 mg Day 43: 20 mg Day 57: 40 mg if tolerated Subjects will be required to achieve and maintain a minimum dose of 20 mg daily to ensure adequate dosage of the ACE inhibitor."
89536737|NCT02723591|Active Comparator|Tacrolimus, Immediate Release Twice Daily (BID)|Participants received tacrolimus immediate release as per the institutionally-derived protocol, BID, orally within 48 hours of transplantation (per the treating physician's discretion) for up to 1 year. Dose adjustments were allowed such that participants receiving tacrolimus maintained a minimal trough concentration of 6 ng/mL at all times during the study.
89536738|NCT00705341|Active Comparator|Low dose fluticasone for phase 2|For people with asthma, fluticasone at 250 mcg per day; phase 2 of study
89193025|NCT05727189|Experimental|Part 1 Single Dose|Parallel group comparison, single dose level of 5 forms of the investigational study drug.
89193026|NCT05727189|Experimental|Part 2: Single escalating doses|Parallel group comparison, single p.o. dose escalation (3 dose levels) of 4 forms investigational study drug and placebo administered to two sequential cohorts. Dose Level 1 will be administered to the first cohort. Dose Levels 2 and 3 will be administered to a subsequent cohort. Dose levels in this cohort are separated by a 7-day washout period. Doses to be determined by review of data from Part 1.
89193027|NCT05727189|Experimental|Part 3: Multiple Dose|Parallel group comparison of 4 active treatments dosed p.o. x 4 days. Each active is dosed in a 2-period placebo-controlled crossover separated by a 5-day washout. Doses to be determined by review of data from Part 2.
88922099|NCT05827653|Experimental|Cohort 2_placebo|Placebo
89414420|NCT06200727|Experimental|PRF membrane transplantation in trabeculectomy for glaucoma|The surgical procedure involved the creation of a scleral flap and conjunctiva in the usual manner. The subflap tissue was rinsed with balanced saline and then a small piece of tissue (measuring 1.5mm x 2mm) was removed from the inferior trabecular tissue of the scleral flap. In the corresponding position, peripheral iris excision was performed and the iris was rinsed to remove lost pigment in the vicinity of the incision. Once the orientation was verified, the PRF membrane was placed under the scleral flap.
89414421|NCT06200727|Active Comparator|Amniotic membrane in trabeculectomy for glaucoma|The surgical procedure began with creating the scleral flap and conjunctiva in the usual manner. The sub flap tissue was then rinsed with balanced saline, and a piece of tissue measuring 1.5mm x 2mm was excised from the inferior trabecular tissue of the scleral flap. Next, peripheral iris excision was performed in the corresponding position and the iris was rinsed to remove pigment in the vicinity of the incision. To control the tension of the sutures, the amniotic membrane was placed under the scleral flap, followed by meticulous suturing of the conjunctival flap.
89414422|NCT06200727|Experimental|PRF membrane transplantation in corneal ulcer|The necrotic tissue of the corneal ulcer was cleared to expose the local fresh tissue, and the PRF group prepared PRF membrane and covered the surface of the test eye, and the autologous PRF membrane was continuously sutured to the corresponding surrounding tissues using 10-0 absorbable sutures so that the PRF membrane covered the entire portion of the lesion and was able to be anchored to it.
89414423|NCT06200727|Active Comparator|Amniotic membrane in corneal ulcer|The necrotic tissue of the corneal ulcer was removed to reveal the fresh tissue in the area. After that, the excess amniotic membrane was carefully extracted and placed over the affected eye's surface. The membrane was then attached securely to the surrounding tissue using 10-0 absorbable sutures, covering the entire lesion and holding it in place for proper healing.
89414424|NCT06200441||Developing GVHD|Group of patients who developed GVHD during follow-up in patients who underwent allogeneic hematopoteic stem cell transplantation for AML
89414425|NCT06200441||non-GVHD|Group of patients who did not develop GVHD during follow-up in patients who received allogeneic hematopoteic stem cell transplantation for AML
89414426|NCT06200233|Experimental|single arm|"Rivoceranib 700 mg once daily by mouth. Rivoceranib should be given at the same time each day, with or without meals. Swallow the tablet whole. Do not chew, crush, or split the tablet.~Receive study medication until there is evidence of disease progression, intolerable toxicity, withdrawal of consent by the patient, or in the judgment of the principal investigator that the study cannot continue due to inability to administer.~Tumor response will be assessed according to RECIST v1.1 criteria based on imaging studies (CT or MRI) measured every 8 weeks (±1 week) from C1D1 through 12 months and every 12 weeks (±1 week) after 12 months."
89414427|NCT06200064|Experimental|Self-stretching exercise group|Static neck muscle self-stretching exercises were performed for 30 min. after the TENS procedure. Every muscle in the neck region (head rotator cuff, neck stair muscles, upper part of the trapezius muscle, scapula levator muscle, semiscapular neck muscle, upper oblique head muscle, girdle head and neck muscles, and deep anterior neck flexor muscles) were stretched 3 times for 30 seconds per muscle group. While performing exercises, the subjects applied resistance with their hands. All exercises were performed without causing pain.
89414428|NCT06200064|Experimental|Post-isometric relaxation exercise group|"The investigators used one of the autogenic inhibition techniques - post-isometric relaxation (PIR), known as the muscle contraction-relaxation technique, during which, the subject is lying on his back, he is asked to press his head in the specified direction (50% of the subject's maximum pressure force). to the resistance provided by the therapist. During the press, resistance was provided for 10 seconds and followed by a passive stretch of the muscle in the opposite direction of movement. A total of 5 repetitions are performed for each muscle with a 5-second break. All movements are performed without causing pain of more than moderate intensity."
89414429|NCT06199245|Experimental|emotional freedom technique experimental group|Emotional Freedom Technique was applied to the participants in the experimental group, who had a cesarean section on the first postpartum day and agreed to participate in the study, and their breastfeeding self-efficacy and breastfeeding success were evaluated.
89414430|NCT06199245|No Intervention|control group|Participants in the control group were selected from the same sample group, but no intervention was applied. Breastfeeding self-efficacy and breastfeeding success were evaluated after a routine hospital procedure.
89414431|NCT06198868||Operable group|Early-stage patients with radical surgery or operable patients with neoadjuvant treatment
89414432|NCT06198868||Inoperable group|Advanced-stage patients receive non-surgery therapies.
89414433|NCT06198660|Experimental|positional release|positional release techniques in addition to conventional physical therapy
89414434|NCT06198660|Experimental|cognitive behavioral therapy|cognitive behavioral therapy in addition to conventional physical therapy
89414435|NCT06198660|Active Comparator|conventional physical therapy|conventional physical therapy in control group
89414436|NCT06197035|Experimental|COPCA (Coping With and Caring for Infants With Special Needs) Intervention|"The intervention will be delivered by COPCA coaches who follow the programme's theoretical and practical principles. Caregivers learnt how to stimulate their infant's development by challenging their motor behaviour with trial and error experiences.~This aim to empower the caregivers' competencies to stimulate the infant's daily development, by increasing their motor repertoire.~and enhancing their capacity to adapt movements to situations."
89414437|NCT06197035|Active Comparator|Standard physiotherapy|Standard care will be based on what paediatric physiotherapists generally assume to be useful to promote the development of infants with special needs. Standard care is heterogeneous and eclectic, uses parent training and often includes components of neurodevelopmental treatment with hands-on techniques.
89414438|NCT06196385|Experimental|intensive Cervical Traction for cervical radiculopathy|Using intensive cervical traction through mechanical computerized device
89414439|NCT06196385|Active Comparator|intensive Cervical Traction for healthy matched group|USING TRACTION FOR HEALTHY MATCHED AGE CONTROL GROUP
89414440|NCT06196359|Experimental|Combined Femoral and Popliteal nerve block|Patients who receive a Patients undergoing total knee arthroplasty received a combined femoral and popliteal nerve block (single-shot of each) during the surgical procedure.
89414441|NCT06196359|No Intervention|Control group|Patients undergoing total knee arthroplasty and didn&#39;t receive pain block.
89414442|NCT06195813|Experimental|Asparagus capsule|Participants were randomized to receive an arm. In this arm, participants received asparagus capsule and were asked to consume at 40 mg/kg (1-2 capsule) within 15-30 min after breakfast. Consumption was taken at participants' dwelling.
89414443|NCT06195813|Placebo Comparator|Placebo capsule|Participants were randomized to receive an arm. In this arm, participants received placebo capsule and were asked to consume at 40 mg/kg (1-2 capsule) within 15-30 min after breakfast. Consumption was taken at participants' dwelling.
89414444|NCT06194981||3-4 months CapOx/SOX|"Adjuvant CapOx/SOX 3-4 months after curative surgery:~CapOx: Oxaliplatin: 130 mg/m²/day (day 1) , Capecitabine: 1,000 mg/m², bid (day 1-14), q3W, total 3-4 months (4-6 cycles); SOX: Oxaliplatin: 130 mg/m2/day(day 1) , S-1: 40-60 mg, bid (day 1-14), q3W, total 3-4 months (4-6 cycles)"
89414445|NCT06194981||5-6 months CapOx/SOX|"Adjuvant CapOx/SOX 5-6 months after curative surgery:~CapOx: Oxaliplatin: 130 mg/m²/day (day 1) , Capecitabine: 1,000 mg/m², bid (day 1-14), q3W, total 5-6 months (7-8 cycles); SOX: Oxaliplatin: 130 mg/m2/day(day 1) , S-1: 40-60 mg, bid (day 1-14), q3W, total 5-6 months (7-8 cycles)"
89414446|NCT06194838|No Intervention|Comparator Baseline|The subject will wear the Ossur OFM-2, a passive mechanical knee which is the most commonly used knee for K2 users, for 3 months, as well as in the lab to complete outcome measures.
89414447|NCT06194838|Experimental|Ossur Power Knee|The subject will wear the Ossur Power Knee for 3 months, as well as in the lab to complete outcome measures.
89414448|NCT06194838|Experimental|Reboocon Intuy Knee|The subject will wear the Reboocon Intuy Knee for 3 months, as well as in the lab to complete outcome measures.
89414449|NCT06194045|Experimental|LC-MUFA oil|2x1g capsules containing concentrated marine oil from north atlantic fish
89414450|NCT06194045|Placebo Comparator|Placebo|2x1g capsules containing corn oil
89414451|NCT06193317|Experimental|Active taVNS|TaVNS will be administered by an earset, with conductive eartips placed on the auricular concha of the ears, connected to a stimulator, and during active stimulation, we stimulate both the cymba conchae and external auditory canal of both left and right ears with the following parameters: 30Hertz (Hz), 200-250 us, and with adjustable intensity for 60 min for 16 sessions.
89414452|NCT06193317|Sham Comparator|Sham taVNS|Sham condition will have the same device, with an earset, and conductive eartips placed in the same location of the active stimulation; however during 60 min for 16 sessions there will be no current and the device will be turned off.
89535839|NCT03075735||Metastatic castration resistant patients|The exposition to the primary analysis risk factor (germline deleterious mutation in BRCA1, BRCA2, ATM or PALB2 gene) will be determined after inclusion. Briefly, a NGS targeted-panel based on the majority of genes included in the BROCA panel and additional DNA-repair related genes has been designed based on the available technology. The pathogenicity of germline variants will be determined according to established American College of Medical Genetics and Genomics and Association for Molecular Pathology current consensus at the time of final primary outcome analyses. Variants will also be reviewed against published literature and public databases. According to their mutation-carrier status patients will be classified as: A) Mutation Carriers in BRCA1, BRCA2, ATM and PALB2 genes; B) Mutation carriers in other genes included in the BROCA panel; C) Mutation carriers in others DNA-repair genes D)Non-carriers
89535840|NCT03201289||Cardiac surgery|
89535841|NCT02484131|Experimental|Educational materials/mail|Participants in this group will receive educational materials by mail on the first day of the follow-up period.
89535842|NCT02484131|Experimental|Educational materials/participant choice|Participants in this group will receive educational materials by participant choice on the first day of the follow-up period.
89414457|NCT06191263|Experimental|RVU120 + Venetoclax|RVU120 oral capsule, 125 or 250 mg administered every other day on Days 1-13 of each 21-day cycle of treatment, combined with venetoclax oral tablet, 200 or 400 mg administered once daily on Days 1-14 of each 21-day cycle of treatment
89414458|NCT06190665|Experimental|Visualable microspheres|DEB-TACE with visualable microspheres
89414459|NCT06190665|Active Comparator|PVA microspheres|DEB-TACE with polyvinyl alcohol microspheres
89414460|NCT06188663|Active Comparator|Salt supplementation|Salt supplementation in the form of 1.25g sodium chloride capsules at a dose of 5g/day in two divided doses
89414461|NCT06188663|No Intervention|Usual salt intake (no change in intake)|Usual salt intake (no change in intake)
89414462|NCT06183788|Experimental|Anti-NMDARe patients with remote cognitive rehabilitation|Participants of a prospective cohort in post-acute phase of the Antibody-mediated NMDA Receptor Encephalitis that will received a behavioral treatment.
89414463|NCT06183489|Experimental|Elranatamab|Participant will receive elranatamab subcutaneously (SC) for 24 cycles (28-day cycle)
89414464|NCT06183398|Experimental|Eligible patients|
89437588|NCT03531099|Active Comparator|Active surveillance|"65 patients will be randomized to active surveillance and will have exactly the same follow-up as treated patients excepting the HIFU treatment.~Active surveillance is a therapeutic option that shifts the eventual moment of curative treatment while remaining within a window of curability of the disease.~Patients randomized in this arm will also have PSA dosage, MRI exam, questionnaires and prostatic biopsies during their follow up."
89437589|NCT03530241|Experimental|MRCP positive|
89437590|NCT03530241|Active Comparator|MRCP negative|
89437591|NCT03527017||General Population|Adults living in Germany.
88892164|NCT04486118|Placebo Comparator|nonCA-ACEi|"Enrolled subjects will begin treatment with a low dose of study drug (5 mg) Study drug will then be titrated up as follows, provided the increased dose is tolerated:~Day 3-15 (dosing begins after completion of FIMR Visit 1.1): 5 mg Day 29: 10 mg Day 43: 20 mg Day 57: 40 mg if tolerated Subjects will be required to achieve and maintain a minimum dose of 20 mg daily to ensure adequate dosage of the ACE inhibitor."
89535843|NCT02484131|No Intervention|Control|Participants in this group will not receive any educational materials during hte follow-up period. Educational materials will be sent by mail after the completion of this study.
88892165|NCT04479995|Experimental|Horizon Program|"Eight weekly, audio recorded telehealth videoconferencing sessions. Sessions are 90 minutes.~Questionnaire assessments at 8 and 16 weeks after end of videoconferencing sessions"
88892166|NCT04479995|Experimental|Usual Care|"Standard medical visits to address chronic GVHD, with an additional standardized booklet, in electronic or paper format, containing information on the management of chronic GVHD and stem cell transplant survivorship recommendations.~Questionnaire assessment at 8 weeks and 16 weeks after Horizons Program group starts"
88892167|NCT04476654|No Intervention|Fact Sheet Arm|Komen print materials about genetic counseling and testing will be given to women.
88892168|NCT04476654|Active Comparator|YouTube Video Arm|Participants in this arm will receive the culturally tailored video either via a Youtube link or a DVD.
88892169|NCT04476277|Experimental|Sickle Cell Disease Pre-Transplantation|Autologous cells will be collected in participants with Sickle Cell Disease Pre-Transplantation and biotin-labeled ex vivo and reinfused to measure red cell survival
88892170|NCT04476277|Experimental|Sickle Cell Disease Post-Transplantation|Autologous cells will be collected in participants with Sickle Cell Disease Post-Transplantation and biotin-labeled ex vivo and reinfused to measure red cell survival
88892171|NCT04476277|Experimental|Sickle Cell Trait (HbAS)|Autologous cells will be collected in participants with Sickle Cell Trait (HbAS) and biotin-labeled ex vivo and reinfused to measure red cell survival
88892172|NCT04476277|Experimental|HbAA (Healthy volunteers)|Autologous cells will be collected in participants with HbAA (Healthy volunteers) and biotin-labeled ex vivo and reinfused to measure red cell survival
88892173|NCT04461821||obstructive bronchitis/bronchiolitis|
88892174|NCT04461821||pneumonia|
88892175|NCT04461821||asthma|
88892176|NCT04461821||neurological diseases|
88892177|NCT04461821||type 1 diabetes (T1D)|
88892178|NCT04461821||pharmacotherapy with bronchodilators|
88892179|NCT04461821||pharmacotherapy with antibiotics|
88892180|NCT04461821||pharmacotherapy with antiviral medication|
88892181|NCT04461821||pharmacotherapy with antifungal medication|
88892182|NCT04461821||pharmacotherapy with antiepileptic medication|
88892183|NCT04461821||pharmacotherapy with immuno suppressants and immune-modulati|
88892184|NCT04461821||pharmacotherapy with anesthesia (including sedating, analges|
88892185|NCT04461158|Experimental|Interventional Group|
88892186|NCT04458935||Participants|Participants with retinal hemangioblastoma (RH) managed with trans-scleral cryotherapy at the NIH.
88892187|NCT04439357|Experimental|Treatment (trametinib)|Patients receive trametinib dimethyl sulfoxide PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88892188|NCT04431726|Experimental|Emicizumab|
88892189|NCT04424303||Patients prescribed tofacitinib|Patients with a confirmed diagnosis of moderate to severe ulcerative colitis initiating tofacitinib as per the French summary of product characteristics (SmPC).
88892190|NCT04419480|Experimental|CardioMEMS Implant Group|Following enrollment, patients randomized 1:1 to post-discharge implantation of the CardioMEMS device will receive that device ≤14 days following discharge from the index hospitalization for Cardiogenic Shock, in addition to local standard of care medical therapy.
88892191|NCT04419480|No Intervention|Non-CardioMEMS Implant Group|Following enrollment, patients randomized 1:1 to post-discharge standard of care will be treated according to local standard of care medical therapy following their index hospitalization for Cardiogenic Shock.
88892192|NCT04418271|Experimental|Prehabilitation|Prefrail and frail patients receive prehabilitation (new form of care)
88892193|NCT04418271|No Intervention|Standard of Care|Prefrail and frail patients receive no prehabilitation, but receive standard of care
88892194|NCT04401995|Experimental|Nivolumab and Vidutolimod (CMP-001) Combination with [18F]F-AraG PET/CT|"Prime Phase - Nivolumab 240mg IV, every 2 weeks starting with Cycle 2 (Cycles 2,4,6) for 6 weeks in combination with Vidutolimod 5mg subcutaneous 1st dose, and the remaining injections, 10mg intra-tumorally will be administered Weeks 2-7. [18F]F-AraG PET/CT, single bolus injection of 5 (±10%) mCi IV into a vein, Screening and at Week 2.~Boost Phase - Nivolumab 480mg IV, every 4 weeks and CMP-001 5mg subcutaneous every 4 weeks up to 48 weeks."
88892195|NCT04401995|Experimental|Nivolumab with [18F]F-AraG PET/CT|"Prime Phase - Nivolumab 240mg IV, every 2 weeks starting with Cycle 2 (Cycles 2, 4, 6) for 6 weeks. [18F]F-AraG PET/CT, single bolus injection of 5 (±10%) mCi IV into a vein, Screening and at Week 3.~Boost Phase - Nivolumab 480mg IV, every 4 weeks starting from the time of surgery recovery for up to 48 weeks."
88892196|NCT04358419||PA proven/probable/possible|15 patients with proven, probable or possible PA
88892197|NCT04358419||PA suspected, not confirmed|15 patients as the PA patients, but where the diagnosis of PA is rejected.
88892198|NCT04358419||Healthy controls (PA)|15 subjects of same gender and age as an included patient with proven/probable/possible PA as healthy controls.
88892199|NCT04358419||Pneumocystis pneumonia positive|Four patients with confirmed pneumocystis pneumonia
88892200|NCT04358419||Pneumocystis pneumonia negative|If the diagnosis of pneumocystis pneumonia is not confirmed in a patient with suspected pneumocystis pneumonia, the patient will be included as negative control. Four such patients will be included as healthy controls.
88892201|NCT04358419||Healthy controls (pneumocystis pneumonia)|Four subjects of same gender and age as an included patient with verified pneumocystis pneumonia as healthy controls.
88892202|NCT04356794|Experimental|Medical electroacupuncture(EA)|EA were treated for 4 weeks, 3 times per week.
88892203|NCT04356794|Sham Comparator|Sham electroacupuncture|"Sham acupuncture was performed without stimulation and manipulation to avoid eliciting De Qi sensations.It were treated for 4 weeks, 3 times per week."
88892204|NCT04354246|Experimental|COM902 monotherapy dose escalation.|Monotherapy dose escalation. COM902 monotherapy administered IV every 3 weeks in sequential dose escalation. Up to 7 dose escalation cohorts may be evaluated until a maximum tolerated dose or recommended dose for expansion (RDFE) is identified.
88892205|NCT04354246|Experimental|Dual combination (COM902 + COM701) for evaluation of safety/tolerability (both at RDFE).|COM902 will be combined with COM701 for evaluation of safety and tolerability. All study drugs will be administered IV every 3 weeks.
88892206|NCT04354246|Experimental|COM902 monotherapy cohort expansion at RDFE.|COM902 monotherapy at the RDFE - in subjects with multiple myeloma. COM902 will be administered IV every 3 weeks.
88892207|NCT04354246|Experimental|COM902 + COM701 combination cohort expansion both at RDFE.|COM902 + COM701 (both at the RDFE) evaluated in subjects with select tumor types who have exhausted standard of care treatment: HNSCC, CRC (MSS), NSCLC. All study drugs will be administered IV every 3 weeks.
89193028|NCT05727189|Experimental|Part 4: Food Effects|Two-period single p.o. dose fasted/fed crossover separated by 5-day washout period. Dose to be determined by review of data from Part 2.
89535844|NCT04992351||WALANT group|WALANT was used exclusively as anesthesia method for the operation
88892208|NCT04354246|Experimental|MSS-CRC Triplet combination (COM902 + COM701 + Pembrolizumab).|Triplet combination of COM902 + COM701 + Pembrolizumab evaluated in subjects with MSS-CRC. All study drugs will be administered IV every 3 weeks.
89414465|NCT06181773|Experimental|EPO Feeding program + Usual care (intervention group)|Participants in the intervention group will receive the EPO Feeding program and usual care. EPO Feeding program includes four, weekly group training sessions for parents of preschool children (aged 2-6) led by healthcare professionals. The intervention incorporates lessons and information (i.e., slide shows and handouts), group discussions, motivational interviewing, and other supplementary materials (e.g., stories, key messages, and educational videos) to improve parents' knowledge, skills, and behaviors regarding feeding preschool children. After each module, homework activities will be assigned to participants to help reinforce their knowledge, skills, and behaviors. The motivational interviewing will be conducted by healthcare professionals to provide individual support. Moreover, a WeChat group will be set up to facilitate parental involvement, learning, and communication.
88892209|NCT04354246|Experimental|Platinum resistant ovarian cancer Triplet combination (COM902 + COM701 + Pembrolizumab).|Triplet combination of COM902 + COM701 + Pembrolizumab evaluated in subjects with PROC. All study drugs will be administered IV every 3 weeks.
88892210|NCT04340882|Experimental|Treatment (docetaxel, ramucirumab, pembrolizumab)|Patients receive docetaxel IV over 60 minutes, ramucirumab IV over 60 minutes, and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
88892211|NCT04338204||Patients prescribed tofacitinib|Patients with a confirmed diagnosis of ulcerative colitis with confirmed active disease (biomarker or endoscopy) initiating tofacitinib as per the Swedish summary of product characteristics (SmPC).
88892212|NCT04337931|Experimental|Cohort 1|Sotigalimab administered IV at 0.3 mg/kg every 3 weeks (21 day) treatment cycles
88892213|NCT04337931|Experimental|Cohort 2|Sotigalimab administered IV at 0.3 mg/kg every 2 weeks (14 day) treatment cycles
88892214|NCT04337931|Experimental|Cohort 3|"Metastatic melanoma participants who have failed any number of prior lines of therapy with minimum 3 measurable lesions.~Sotigalimab administered IV at 0.3mg/kg in combination with Stereotactic Body Radiation Therapy (SBRT) every 2 weeks (14-day) treatment cycles up to 16 weeks followed by sotigalimab administered IV at 0.3 mg/kg every 2 weeks (14-day) treatment cycles."
88892215|NCT04309188|Experimental|Stroboscopic Training Group|Treatment group, which will receive stroboscopic training during hitting and fielding drills. The glasses look like sunglasses but have liquid crystal technology that causes a flicker from clear to opaque. The glasses flickering will be controlled on the side of the glasses by the researcher. When the athlete can complete a skill proficiently by catching or hitting during training the level of flickering will be increased to challenge the visual system more.
88892216|NCT04309188|Active Comparator|Standard softball drills|Control group, which will perform normal hitting and fielding drills without stroboscopic training
88892217|NCT04300062|Experimental|Rebiopsy|
88892218|NCT04298437|Experimental|Parent Group Treatment|Families who meet inclusion criteria will participate in the Parent Group Treatment (ADAPT Program).
88892219|NCT04298437|No Intervention|No Treatment|Families who do not meet inclusion criteria will not be invited to participate in the ADAPT Program.
88892220|NCT04295421|Active Comparator|Canal adductor block|ACB was done in the immediate postoperative period under a high-frequency ultrasound guidance in which the adductor canal was identified beneath the sartorius muscle and 20 ml of 0.2% ropivacaine was injected in the canal using a 22-gauge 100-mm short-beveled regional block needle and a catheter was kept for 48H with 4 ml/h ropivacaine 0.2%.
88892221|NCT04295421|Experimental|IPACK block|"IPACK was realized after spinal anesthesia. Patient was placed in a supine position and knee placed in position of 90° flexion. A low-frequency ultrasound probe was positioned in the popliteal crease, and the needle was inserted from medial aspect of the knee from anteromedial to posterolateral direction in a plane between the popliteal artery and the femur. The tip of the needle was placed 1-2 cm beyond the lateral edge of the artery, and 20 ml of 0.2% ropivacaine was injected for each side.~A ACB was done postoperatively with 20 ml ropivacaine 0.2% and a catheter was kept for 48H with 4 ml/h saline"
89437592|NCT03527017||IQOS Users|Adult current IQOS users (at the time of survey) living in Germany who are registered in the Germany IQOS User Database and agreed to be contacted for research purposes at the time of registration.
89437593|NCT03527004||General Population|Survey on use of tobacco products in the general population of adults living in Italy.
89535845|NCT04992351||control|tourniquet with regional or general anesthesia was used for the operation
89535846|NCT03201601|Experimental|550 mg of MYO and 150 mg of DCI|Volunteers will take twice at day for 12 weeks a capsule containing 550 mg of myo-inositol and 150 mg of D-chiro-inositol.
89535847|NCT03201601|Active Comparator|550 mg of MYO and 13.8 mg of DCI|Volunteers will take twice at day for 12 weeks a capsule containing 550 mg of myo-inositol and 13.8 mg of D-chiro-inositol.
89535848|NCT03316157|Experimental|Rehabilitation|Advanced cancer patients will receive an 8 week rehabilitation intervention consisting of physical exercise and nutritional supplementation, along with standard care
88892222|NCT04295408|Placebo Comparator|PLACEBO|Pericapsular Nerve Group block with 40 ml saline
88892223|NCT04295408|Experimental|Pericapsular nerve group block|Pericapsular Nerve Group block with 2 mg.kg-1Ropivacaine in 40 ml of saline
88922100|NCT05821777|Experimental|LB101|"Part 1~Part 1a participants will receive LB101 once every 2 weeks (Q2W) (28-day cycle), with a preliminary plan for 6 sequential dose levels. Part 1b will be a dose optimization and will include >1 dose levels and/or dose schedules that have been deemed safe and tolerable in Part 1a.~Part 2~Dose regimen(s) for participants in Part 2 will be based on the results of Part 1."
89193029|NCT05725226|Active Comparator|Group 1 : 6Fr|Procedure: RIRs/URSL Confirmation of Renal/ Ureteric Stone with CT Urography Preanesthetic Check up and SterileUrine Culture obtained prior to surgery Perioperative Care: Inj. Ceftriaxone 1gm IV stat dose , RIRS/ URSL performed using LASER Holmium lithotripsy 6Fr Double J stent is inserted to maintain the ureteric patency USSQ score obtained on Post operative Day 3, Day 7 and on the day of stone removal (Day 14) USG Abdomen and Pelvis is done on post operative Day 30 to confirm stone clearance.
89414466|NCT06181773|No Intervention|Usual care (control group)|Parents involved in the control group will receive usual care, which is the printed materials of child health-related dietary recommendations published by the Chinese government/Nutrition Society. These materials will also be distributed to the participants in the intervention group. After the final data collection at one-month follow-up, participants from this control group will be offered the complete material package of the EPO Feeding program, their child's weight status measured at the final time point and provided access to pre-recorded modules by healthcare professionals as a incentive.
89414467|NCT06179992|Experimental|Experimental group|The experimental group used the GGED module for 15 days after the first assessment.
89414468|NCT06179992|Active Comparator|Control group|The control group used the GGED module for 15 days after the second assessment.
89414469|NCT06166342|Placebo Comparator|Placebo sachet|consume 1 sachet per day
88892224|NCT04292782|Active Comparator|CAUDAL BLOCK|Sonosite machine (M-Turbo) equipped with a large bandwidth, a multifrequency linear probe (6-19 MHz) and needle of diameter and length respectively between 22G and 25G, 35mm and 40mm according to the child's size (Braun).The patient is positioned laterally with their hips flexed to 90°. The sacral hiatus is forming with the two posterior superior iliac spines an equilateral triangle. The puncture is performed between the two sacral cornuae. The sacrococcygeal ligament gives a perceptible 'pop' when crossed. After crossing the sacro-coccygeal ligament, the needle is redirected 30° to the skin surface, and then advanced a few millimeters into sacral canal. After verifying absence of spontaneous reflux of blood or cerebrospinal fluid, slowly injection of Ropivacaine 0.25% 1ml/ kg
88892225|NCT04292782|Experimental|anterior Quadratus lumborum block|Sonosite machine (M-Turbo) equipped with a large bandwidth, a multifrequency linear probe (6-19 MHz) and a 22G, 50-mm, insulated facet type needle (BBraun Stimuplex Ultra 360°). Patients were placed in the lateral position, a probe was placed transversely to the abdominal flank. The needle was inserted using an in-plane technique and was preceded further into the fascia between the QLM and PM. Following confirmation of the correct space with the administration of 0.5-1 ml local anesthetic, block was induced with 1 ml/kg, 0.25% Ropivacaine,
88892226|NCT04289987|Experimental|CVI-HBV-002|"CVI-HBV-002 1.0mL(20ug/dose)~Intramuscular injection at Baseline, Week 2, 4, 8, 12, 16, 20 / total 7 doses"
88892227|NCT04289987|Placebo Comparator|Normal Saline|"Normal Saline Choonwae Inj. 1.0 mL~Intramuscular injection at Baseline, Week 2, 4, 8, 12, 16, 20 / total 7 doses"
88892228|NCT04285333|Active Comparator|fascial iliaca|: A linear high frequency ultrasound probe (10-15MHz) was placed in a transverse direction over the anterior thigh below the inguinal ligament. We identified the femoral artery and the iliacus muscle lateral to it, covered by the fascia iliaca. The needle was inserted in plane and a 22 gauge, 50 mm needle was advanced until the tips placed underneath the fascia iliaca. Following negative aspiration, the local anesthetic solution was injected in 5mL increments while observing for adequate fluid spread in this plane for a total volume of 20 mL of 1.5% Lidocaine
89005696|NCT05425654|Experimental|RL-MPV + BBC/auto-HCT+ nivolumab|Rituximab, methotrexate (MTX), procarbazine, vincristine and lenalidomide (RL-MPV). The peripheral blood stem cell (PBSC) harvest procedure will be performed after 2nd cycle of RL-MPV. High dose chemotherapy Busulfan, Thiotepa, and Cyclophosphamide. 3 months after auto-HSCT, maintenance therapy with nivolumab 3 mg/kg is started for 6 months every 2 weeks
89193030|NCT05725226|Experimental|Group 2: 4Fr|Procedure: RIRs/URSL Confirmation of Renal/ Ureteric Stone with CT Urography Preanesthetic Check up and SterileUrine Culture obtained prior to surgery Perioperative Care: Inj. Ceftriaxone 1gm IV stat dose , RIRS/ URSL performed using LASER Holmium lithotripsy 4Fr Double J stent is inserted to maintain the ureteric patency USSQ score obtained on Post operative Day 3, Day 7 and on the day of stone removal (Day 14) USG Abdomen and Pelvis is done on post operative Day 30 to confirm stone clearance.
89414470|NCT06166342|Experimental|TCI153 sachet|consume 1 sachet per day
89414471|NCT06165601|Other|Dapagliflozine|For prospective cohort, an additional follow-up at D14 and M1 will be carried out.
89414472|NCT06165354|Placebo Comparator|Control|"Control group receives the routine treatment and uses 0.9% NaCl physiological saline.~The routine treatment regimen at Hanoi Obstetrics and Gynecology Hospital (Hanoi OGH) and Bac Ninh Center for Disease Control and Prevention (Bac Ninh CDC) depends on clinical symptoms, test results of bacterial staining and pathogen detected using multiplex real time PCR assay on day 0."
89414473|NCT06165354|Experimental|X-secret|"X-SECRET group receives the routine treatment and uses NaCl 0.9% plus B. subtilis, B. clausii, and B. coagulans at 5 billion CFU/5 mL (LiveSpo®️ X-SECRET).~The routine treatment regimen at Hanoi OGH and Bac Ninh CDC depends on clinical symptoms, test results of bacterial staining and pathogen detected using multiplex real time PCR assay on day 0."
89414474|NCT06162377|Experimental|Methylnaltrexone|Participants will be given 14 pre-filled syringes of methylnaltrexone. Participants will be instructed how to take the drug as an injection under the skin of your abdominal area.
89414475|NCT06162091||Patients with severe acquired brain injuries|Patients with severe acquired brain injuries admitted at intensive Rehabilitation Units for severe acquired brain injury within 3 months from occurrence
89535849|NCT03316157|No Intervention|Waiting list Control|Standard care alone for the 8 week trial period, followed by participants being offered the rehabilitation programme
89414476|NCT06154707|Experimental|Denosumab Group|Denosumab injection 60mg (1.0ml/ branch, Jiangsu Taikang Biological Medicine Co., LTD., s20233111), once every 6 months, 60mg, subcutaneous injection, at the same time to supplement calcium and vitamin D.
89414477|NCT06154707|Placebo Comparator|Placebo Group|Placebo drug, the main component of normal saline injection (1.0ml/ dose). In addition to the different production batch number, its appearance, character, specification, administration mode and frequency are exactly the same as the experimental group of drugs (different production batch number is convenient for later unblinding reference). Take calcium and vitamin D supplements. The study lasted for 12 months.
89414478|NCT06144476||Airways Disease|Patients with or suspected airways disease including COPD or asthma
88892229|NCT04285333|Experimental|Percapsular nerve group block|A curvilinear low-frequency ultrasound probe (2-5MHz) was initially placed in a transverse plane over the anterior inferior iliac spine (AIIS) and then aligned with the pubic ramus by rotating the probe counterclockwise approximately 45 degrees. In this view, the iliopubic eminence (IPE), the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle were observed. A 22-gauge, 100-mm needle was inserted from lateral to medial in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. Following negative aspiration, the local anesthetic solution was injected in 5 mL increments while observing for adequate fluid spread in this plane for a total volume of 20 mL of 1.5% Lidocaine.
89414479|NCT06144476||Healthy Volunteers|Participants with no significant illness
88892230|NCT04280549||Healthy Subjects|Subjects will have a single visit where a short medical history/list of current medications and single blood draw will be performed.
88892231|NCT04280549||Type 2 Diabetic Subjects|Subjects will have a single visit where a short medical history/list of current medications and single blood draw will be performed.
89414480|NCT06129760|Experimental|Wearing the Apple watch and the associated logging of health data|As part of the monitoring needed for this study, participants will be enrolled for at least 6 months, as this will give enough data to understand how the participant's health changes associate with what is measured by the Apple watch. After this 6 month period, participants may choose to end their participation on the study, or continue if they wish.
88892232|NCT04246086|Experimental|Intravenous (IV) Mosunetuzumab + Lenalidomide (Non-randomized)|Participants will receive treatment with IV mosunetuzumab plus lenalidomide for 12 cycles total (cycle length = 21 days for Cycle 1, 28 days from Cycle 2 onward)
88892233|NCT04246086|Experimental|Subcutaneous (SC) Mosunetuzumab + Lenalidomide (Non-randomized)|Participants will receive treatment with SC mosunetuzumab plus lenalidomide for 12 cycles total (cycle length = 21 days for Cycle 1, 28 days from Cycle 2 onward). Participants that have received complete metabolic response (CMR) or partial metabolic response (PMR) after 12 cycles of induction therapy with mosunetuzumab + lenalidomide will have the option of receiving maintenance therapy with SC mosunetuzumab every 8 weeks (Q8W) for an additional 9 cycles.
88892234|NCT04246086|Experimental|Arm A: IV Mosunetuzumab + Len (Randomized)|Participants will receive treatment with IV mosunetuzumab plus lenalidomide for 12 cycles total (cycle length = 21 days for Cycle 1, 28 days from Cycle 2 onward)
89414481|NCT06121986|Experimental|MKN Adherence Program + Maintenance Opt 1|The M-KN adherence program will consist of 10, 1-hour weekly group meetings, which will take place via HIPAA-compliant Zoom. Sessions will be devoted to providing nutrition information, building group support, identifying participant goals, and working as a group to overcome barriers. Participants will be provided with access to ongoing monthly support groups after the 10-week program ends.
89414482|NCT06121986|Active Comparator|Mediterranean Adherence Program + Maintenance Opt 1|The Mediterranean adherence program will consist of 10, 1-hour weekly group meetings, which will take place via HIPAA-compliant Zoom. Sessions will be devoted to providing nutrition information, building group support, identifying participant goals, and working as a group to overcome barriers. Participants will be provided with access to ongoing monthly support groups after the 10-week program ends.
89414483|NCT06121986|Experimental|MKN Adherence Program + Maintenance Opt 2|The M-KN adherence program will consist of 10, 1-hour weekly group meetings, which will take place via HIPAA-compliant Zoom. Sessions will be devoted to providing nutrition information, building group support, identifying participant goals, and working as a group to overcome barriers. Participants will be provided with two additional booster sessions after the 10-week program ends.
89414484|NCT06121986|Active Comparator|Mediterranean Adherence Program + Maintenance Opt 2|The Mediterranean adherence program will consist of 10, 1-hour weekly group meetings, which will take place via HIPAA-compliant Zoom. Sessions will be devoted to providing nutrition information, building group support, identifying participant goals, and working as a group to overcome barriers. Participants will be provided with two additional booster sessions after the 10-week program ends.
89414485|NCT06115811|Experimental|Radiation Treatment Plan Evaluation Learning Module|"Radiation oncology resident physicians will complete study procedures as below:~Initial survey and pre-module examination.~Learning module.~Post-module survey and examination."
89414486|NCT06114628|Active Comparator|A. Standard TB Regimen. 2HRZE/4HR|24 weeks treatment in both Phase 2B and 2C - 8 weeks Rifampicin, Isoniazid, Pyrazinamide, Ethambutol followed by 16 weeks Rifampicin and Isoniazid.
89414487|NCT06114628|Experimental|Arm B. BDM|Bedaquiline, Delamanid, Moxifloxacin for 16 weeks in Phase 2B
89414488|NCT06114628|Experimental|Arm C. BDM + 656|Bedaquiline, Delamanid, Moxifloxacin and GSK3036656 for 16 weeks in Phase 2B Bedaquiline, Delamanid, Moxifloxacin and GSK3036656 for 8-16 weeks in phase 2C
89414489|NCT06114628|Experimental|Arm D. BDZ + 656|Bedaquiline, Delamanid, Pyrazinamide and GSK3036656 for 16 weeks in Phase 2B Bedaquiline, Delamanid, Pyrazinamide and GSK3036656 for 8-16 weeks in phase 2C
89414490|NCT06114628|Experimental|Arm E. BDL + 656|Bedaquiline, Delamanid, Linezolid and GSK3036656 for 8 weeks followed by 8 weeks Bedaquiline, Delamanid and GSK3036656 in Phase 2B Bedaquiline, Delamanid, Linezolid and GSK3036656 for 8 weeks followed by 0-8 weeks Bedaquiline, Delamanid and GSK3036656 in Phase 2C
89414491|NCT06114628|Experimental|Arm F. BPaM + 656|Bedaquiline, Pretomanid, Moxifloxacin and GSK3036656 for 16 weeks in Phase 2B Bedaquiline, Pretomanid, Moxifloxacin and GSK3036656 for 8-16 weeks in Phase 2C
88892235|NCT04246086|Experimental|Arm B: SC Mosunetuzumab + Len (Randomized)|Participants will receive treatment with SC mosunetuzumab plus lenalidomide for 12 cycles total (cycle length = 21 days for Cycle 1, 28 days from Cycle 2 onward)
88892236|NCT04231968|Experimental|AK0529|Participants who are randomized to the experimental arm will receive AK0529 twice daily for five days .
89414492|NCT06114628|Experimental|Arm G. BDM + BTZ-043|Bedaquiline, Delamanid, Moxifloxacin and BTZ-043 for 16 weeks in Phase 2B Bedaquiline, Delamanid, Moxifloxacin and BTZ-043 for 8-16 weeks in phase 2C
89414493|NCT06114628|Experimental|Arm H. BDZ + BTZ-043|Bedaquiline, Delamanid, Pyrazinamide and BTZ-043 for 16 weeks in Phase 2B Bedaquiline, Delamanid, Pyrazinamide and BTZ-043 for 8-16 weeks in phase 2C
89414494|NCT06114628|Experimental|Arm I. BDL + BTZ-043|Bedaquiline, Delamanid, Linezolid and BTZ-043 for 8 weeks followed by 8 weeks Bedaquiline, Delamanid and BTZ-043 in Phase 2B Bedaquiline, Delamanid, Linezolid and BTZ-043 for 8 weeks followed by 0-8 weeks Bedaquiline, Delamanid and BTZ-043 in Phase 2C
89193031|NCT05710055|Active Comparator|Study product A (Wonderlab wonder4shape)|"2g/bottle, containing the following probiotics total dosage 2.0*10^10 CFU:~CECT7527, CECT7528, CECT7529, B420, HN019~FOS~Polydextrose~IMO"
89193032|NCT05710055|Active Comparator|Study product B (Wonderlab wonder4shape)|"2g/bottle, containing the following probiotics total dosage 2.0*10^10 CFU:~B420, HN019, NCFM~FOS~Polydextrose~IMO"
89414495|NCT06114628|Experimental|Arm J. BPaM + BTZ-043|Bedaquiline, Pretomanid, Moxifloxacin and BTZ-043 for 16 weeks in Phase 2B Bedaquiline, Pretomanid, Moxifloxacin and BTZ-043 for 8-16 weeks in Phase 2C
89414496|NCT06114628|Experimental|Arm K. BMZ + BTZ-043|Bedaquiline, Moxifloxacin, Pyrazinamide and BTZ-043 for 16 weeks in Phase 2B Bedaquiline, Moxifloxacin, Pyrazinamide and BTZ-043 for 8-16 weeks in phase 2C
89414497|NCT06114628|Experimental|Arm L. BD + 656 + BTZ-043|Bedaquiline, Delamanid, GSK3036656 and BTZ-043 for 16 weeks in Phase 2B Bedaquiline, Delamanid, GSK3036656 and BTZ-043 for 8-16 weeks in phase 2C
89437594|NCT03527004||IQOS Users|Survey on use of tobacco products in adult current IQOS Users (at the time of survey) living in Italy who are registered in the Italy IQOS User Database and agreed to be contacted for research purposes at the time of registration.
89437595|NCT03523247|Experimental|Whole Food Plant Based Diet|Single-arm whole-food, plant-based diet will explore the effects on primary prevention in a free-range environment
89536739|NCT00705341|Active Comparator|High dose fluticasone for phase 2|For people with asthma, fluticasone at 1000 mcg per day; phase 2 of study
88892237|NCT04231968|Placebo Comparator|Placebo|Participants in the control arm will be administered placebo at the matching dosage levels of active medications.
88892238|NCT04227067|Active Comparator|TENS|A TENS device consists of an electric pulse generator and pads that are attached to the skin on around the area of maximal pain. We will use the conventional mode, which provides nerve stimulation with a pulse width of 60 microseconds and a pulse rate of 60 pulses per second. The channel intensity will be gradually increased until the intensity is noticeable but not painful.
88892239|NCT04227067|Sham Comparator|SHAM TENS|In the SHAM TENS group the TENS pads will be attached to the pulse generator and the patients skin around the painful area. The investigator will turn the knobs on but the batteries will be removed from the device.
88892240|NCT04222673|Experimental|Peer Specialist|The intervention will last 3-months, a time frame that overlaps with the typical duration of a VA suicide high risk flag. Meetings will be 30-45 minutes and occur primarily in the community, home, or by telephone. Session content will be rooted in Peer Specialists (PSs) offering nonjudgmental empathic support, active listening, and constructive disclosure and role modeling. A primary focus will be helping patients with flags to identify and strengthen connections with informal supports and participation in activities in their community that will enable them to feel more worthwhile as individuals and hopeful about their future.
88892241|NCT04213547|Experimental|Intervention|This will be a single-arm study utilizing a loss-framed incentive intervention to induce increased sleep duration.
88892242|NCT04212117|Other|Arm 1 - Educational Platform, PALS|The Patient Activated Learning System is a free, health education platform written bu trusted MDs.
88892243|NCT04212117|Other|Arm 2 - WebMD|WebMD is a widely used educational platform for health information.
88892244|NCT04201405|Experimental|Haematopoietic stem cell gene therapy for MPS IIIA|Open label
88892245|NCT04199182|Experimental|Exercise|Progressive, multi-component supervised exercise training group.
88892246|NCT04199182|Active Comparator|Healthy Aging Attention Control|A health education program that addresses topics relevant to older adults.
88892247|NCT04198272|Experimental|Facilitated|Schools that are randomized to this arm will be exposed to all of the components in the self-service version in addition to peer facilitation of the CyberRwanda platform at CyberRwanda clubs.
88892248|NCT04198272|Active Comparator|Self-service|"Schools that are randomized to this arm will be exposed to the following components of the intervention:~Self-guided access to the online CyberRwanda platform; and~Promotion of the CyberRwanda program through school launch events."
88892249|NCT04198272|No Intervention|Control|Schools in this arm will not receive any intervention.
88892250|NCT04187170|Experimental|Healthy sedentary subjects exposed to the training program|
88892251|NCT04169841|Experimental|GUIDE2REPAIR patients|olaparib + immunotherapy (durvalumab + tremelimumab) during 4 months followed by durvalumab alone as maintenance in patients with solid cancer and in response or stable after prior molecular target therapy by olaparib based on molecular sequencing.
88892252|NCT04165096|Experimental|Boserolimab + Pembrolizumab|On Day 1 of each 3-week cycle, participants receive pembrolizumab 200 mg intravenously (IV) PLUS boserolimab IV for a maximum of 35 cycles (approximately 2 years). All participants are premedicated 1.5 hours (±30 minutes) before infusion of boserolimab with 50 mg oral (PO) diphenhydramine (or equivalent dose of antihistamine) and 500-1000 mg of acetaminophen PO (or equivalent dose of analgesic).
88892253|NCT04165096|Experimental|Pembrolizumab + MK-4830|On Day 1 of each 3-week cycle, participants receive pembrolizumab 200 mg intravenously (IV) PLUS MK-4830 IV for a maximum of 35 cycles (approximately 2 years).
88892254|NCT04165096|Experimental|Pembrolizumab + MK-0482|On Day 1 of each 3-week cycle, participants receive pembrolizumab 200 mg intravenously (IV) PLUS MK-0482 IV for a maximum of 35 cycles (approximately 2 years).
88892255|NCT04165083|Experimental|Pembrolizumab + MK-4830|On Day 1 of each 3-week cycle, participants receive pembrolizumab 200 mg intravenously (IV) PLUS MK-4830 IV for a maximum of 35 cycles (approximately 2 years)
88892256|NCT04165083|Experimental|Pembrolizumab + MK-0482|On Day 1 of each 3-week cycle, participants receive pembrolizumab 200 mg intravenously (IV) PLUS MK-0482 IV for a maximum of 35 cycles (approximately 2 years)
88892257|NCT04165070|Experimental|Pembrolizumab+Vibostolimab+Carboplatin + Paclitaxel|On Day 1 of each 3-week cycle, participants with squamous NSCLC receive pembrolizumab 200 mg intravenously (IV) PLUS vibostolimab IV PLUS carboplatin Area Under the Concentration-Time Curve (AUC) 6 IV PLUS paclitaxel 200 mg/m^2 IV in Cycles 1-4, followed by maintenance treatment of pembrolizumab 200 mg IV PLUS vibostolimab IV in Cycles 5-35 (total treatment duration: up to approximately 2 years).
88892258|NCT04165070|Experimental|Pembrolizumab+Vibostolimab+Carboplatin + Pemetrexed|On Day 1 of each 3-week cycle, participants with nonsquamous NSCLC receive pembrolizumab 200 mg IV PLUS vibostolimab IV PLUS carboplatin AUC 5 IV PLUS pemetrexed 500 mg/m^2 IV in Cycles 1-4, followed by maintenance treatment of pembrolizumab 200 mg IV PLUS vibostolimab IV PLUS pemetrexed 500 mg/m^2 IV in Cycles 5-35 (total treatment duration: up to approximately 2 years).
88892259|NCT04165070|Experimental|Pembrolizumab+Boserolimab+Carboplatin+Paclitaxel|On Day 1 of each 3-week cycle, participants with squamous NSCLC receive pembrolizumab 200 mg IV PLUS carboplatin AUC 6 IV PLUS paclitaxel 200 mg/m^2 IV PLUS boserolimab IV on Day 1 every 6 weeks (every other 3-week cycle) (Q6W) in Cycles 1-4, followed by maintenance treatment of pembrolizumab 200 mg IV Q3W PLUS boserolimab IV Q6W from Cycles 5 up to Cycle 35 (total treatment duration: up to approximately 2 years).
88892260|NCT04165070|Experimental|Pembrolizumab+Boserolimab+Carboplatin+Pemetrexed|On Day 1 of each 3-week cycle, participants with nonsquamous NSCLC receive pembrolizumab 200 mg IV PLUS carboplatin AUC 5 IV PLUS pemetrexed 500 mg/m^2 IV PLUS boserolimab IV on Day 1 every 6 weeks (every other 3-week cycle) (Q6W) in Cycles 1-4, followed by maintenance treatment of pembrolizumab 200 mg IV Q3W PLUS pemetrexed 500 mg/m^2 IV Q3W PLUS boserolimab IV Q6W from Cycles 5 up to Cycle 35 (total treatment duration: up to approximately 2 years).
88892261|NCT04165070|Experimental|Pembrolizumab+MK-4830+Carboplatin+Paclitaxel|On Day 1 of each 3-week cycle, participants with squamous NSCLC receive pembrolizumab 200 mg IV PLUS MK-4830 IV PLUS carboplatin AUC 6 IV PLUS paclitaxel 200 mg/m^2 IV in Cycles 1-4, followed by maintenance treatment of pembrolizumab 200 mg IV PLUS MK-4830 IV in Cycles 5-35 (total treatment duration: up to approximately 2 years).
88892262|NCT04165070|Experimental|Pembrolizumab+MK-4830+Carboplatin+Pemetrexed|On Day 1 of each 3-week cycle, participants with nonsquamous NSCLC receive pembrolizumab 200 mg IV PLUS MK-4830 IV PLUS carboplatin AUC 5 IV PLUS pemetrexed 500 mg/m^2 IV in Cycles 1-4, followed by maintenance treatment of pembrolizumab 200 mg IV PLUS MK-4830 IV PLUS pemetrexed 500 mg/m^2 IV in Cycles 5-35 (total treatment duration: up to approximately 2 years).
88892263|NCT04165070|Experimental|Pembrolizumab+MK-0482+Carboplatin+Paclitaxel|On Day 1 of each 3-week cycle, participants with squamous NSCLC receive pembrolizumab 200 mg IV PLUS MK-0482 IV PLUS carboplatin AUC 6 IV PLUS paclitaxel 200 mg/m^2 IV in Cycles 1-4, followed by maintenance treatment of pembrolizumab 200 mg IV PLUS MK-0482 IV in Cycles 5-35 (total treatment duration: up to approximately 2 years).
88892264|NCT04165070|Experimental|Pembrolizumab+MK-0482+Carboplatin+Pemetrexed|On Day 1 of each 3-week cycle, participants with nonsquamous NSCLC receive pembrolizumab 200 mg IV PLUS MK-0482 IV PLUS carboplatin AUC 5 IV PLUS pemetrexed 500 mg/m^2 IV in Cycles 1-4, followed by maintenance treatment of pembrolizumab 200 mg IV PLUS MK-0482 IV PLUS pemetrexed 500 mg/m^2 IV in Cycles 5-35 (total treatment duration: up to approximately 2 years).
88892265|NCT04162873|Experimental|Celecoxib Arm|Patients receive celecoxib PO or via feeding tube BID starting 1 to 7 days prior to surgery and continues until the completion of radiation therapy (up to 6 months in total) in the absence of disease progression or unacceptable toxicity.
88892266|NCT04162873|Placebo Comparator|Placebo Arm|Patients receive placebo PO or via feeding tube BID starting 1 to 7 days prior to surgery and continues until the completion of radiation therapy (up to 6 months in total) in the absence of disease progression or unacceptable toxicity.
88892267|NCT04158258||Bevacizumab|Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
88892268|NCT04158258||Trastuzumab|Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
88892269|NCT04158258||Ado-trastuzumab emtamsine|Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
88892270|NCT04158258||Pertuzumab|Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
88892271|NCT04158258||Atezolizumab|Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
88892272|NCT04158258||Capecitabine|Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
88922101|NCT05819697||FIRE Trial Participants|This study only has one group. All participants will receive the same intervention (smart phone app/texting notifications).
89414498|NCT06114108|Experimental|Intervention group: Local consolidative treatment (LAT) & Systemic Therapy|"All patients undergo standard of care (SoC) first-line systemic therapy according to the results of the molecular analysis obtained from the diagnostic biopsy, as per standard of the respective center.~Patients will undergo additional complete surgical resection of the primary tumor with mediastinal lymph node sampling or radical radiotherapy (preferred stereotactic body radiotherapy (SBRT) to the primary tumor. Surgery and/or SBRT to the metastases will be performed before or after the treatment of the primary tumor according to the clinical need. Thereafter, the treatment will be followed by systemic anticancer treatment as SoC."
89414499|NCT06114108|Active Comparator|Control group: Systemic Therapy|Patients of the control group will receive systemic anticancer treatment alone chemotherapy, chemo-immunotherapy, immunotherapy alone, or targeted treatment).
89414500|NCT06112431|Experimental|Telehealth-Based Intervention Arm|Participants randomized to the Telehealth-Based Intervention Arm who require referral to ophthalmology will be teamed up with a Patient Navigator who will provide telehealth-based support with scheduling an in-office glaucoma evaluation at either Columbia University Harkness Eye Institute, Harlem Hospital, or their own eye care provider. Participants will also receive telehealth-based support from a Peer Ambassador, who are individuals from the community with glaucoma or other eye diseases who have expressed interest in sharing their experiences. Each referred participant will receive several telehealth-based calls from a Peer Ambassador over 2 years to discuss their understanding of their new ocular diagnosis and encourage adherence to in-office glaucoma evaluation.
89414501|NCT06112431|No Intervention|Usual Care Arm|Consented participants from community health centers randomized to the Usual Care Arm will receive all the basic level of services including the telehealth-based eye health screening, optometric exam if they fail the screening, and eyeglasses at no charge. Those who require referral to ophthalmology will be scheduled for the initial in-office glaucoma evaluation and their outcomes will be tracked. No additional support from a Patient Navigator or a Peer Ambassador will be provided the Usual Care participants during the study. The Usual Care Arm represents a realistic choice currently available for participants following eye health screening.
89414502|NCT06102824|Experimental|Organoid-guided treatment|Subjects randomized to the organoid-guided treatment (OGT) group will be treated with the drugs predicted to be the most sensitive through PDO drug sensitivity screening. Drugs that the subjects have progressed on before randomization will not be screened. The drugs selected for organoid screening are from the following options: taxane, anthracycline, 5-fluorouracil, gemcitabine, vinorelbine, eribulin, utidelone, carboplatin, sacituzumab govitecan, and trastuzumab deruxtecan (for HER2-low patients).
89414503|NCT06102824|Active Comparator|Treatment of physician's choice|Subjects randomized to the treatment of physician's choice (TPC) group will receive physician-chosen therapy from the following options: taxane, anthracycline, 5-fluorouracil, gemcitabine, vinorelbine, eribulin, utidelone, carboplatin, sacituzumab govitecan, and trastuzumab deruxtecan (for HER2-low patients).
89414504|NCT06097702|Experimental|BX-001N Part 1|Part 1 is SAD with 5 cohorts where each participant will receive single IV bolus following a 8hr fast.
89414505|NCT06097702|Experimental|BX-001N Part 2|Part 2 is MAD with 3 cohorts where each participant will receive 7 sequential daily IV bolus doses following a 8hr fast.
89414506|NCT06097702|Placebo Comparator|Placebo|Matching doses of placebo
89414507|NCT06083454|Experimental|Durvalumab as monotherapy|Two cycles of Durvalumab 1500 mg every 3 weeks, as monotherapy
89414508|NCT06083454|Experimental|Combination of pharmacological ascorbate plus Durvalumab|Combination of pharmacological ascorbate 75 grams intravenously three times a week x 4 weeks plus Durvalumab 1500 mg every 3 weeks for two cycles
89414509|NCT06083454|Active Comparator|Control (no neoadjuvant therapy)|Serve as control and patients will not receive any neoadjuvant therapy before going to surgery. Once randomize, they can go to surgery without any delays.
89414510|NCT06082102|Experimental|Orelabrutinib|
89414511|NCT06082102|Placebo Comparator|Placebo|
89414512|NCT06081049|Experimental|Colchicine|Colchicine 0.5 mg once daily
89414513|NCT06081049|Placebo Comparator|Placebo|Placebo once daily
89414514|NCT06070441|Experimental|Experimental|Home exercise assisted with a chatbot
89414515|NCT06070441|Active Comparator|Control|Home exercise, usual care
89414516|NCT06070428|Active Comparator|PAC Intervention Arm|"Participants randomized to the interventional arm will be given 2 PAC units with HEPA filters inside to be used in the home: one in the room patient sleeps in, the other in the living area of the home. Participants will also be given an air quality monitor. Study staff will educate the patient on use of the filters and monitor.~Patients will be seen in clinic for 30-day and 90-day follow-up visits. Blood pressure, blood draw for biomarker levels, 6-minute walk distance, and questionnaires will be completed.~Patients will be allowed to keep the PAC at the end of the trial and will be informed at that time how to purchase additional filters."
89535850|NCT04992585|Experimental|PTBD with primary metal stent implantation|PTBD with primary metal stent implantation is performed in the same session as a one step-procedure
89535851|NCT04992585|Active Comparator|PTBD with secondary metal stent implantation|PTBD with secondary metal stent implantation is performed as a two step-procedure with metal stent implantation 3 to 7 days after previous percutaneous transhepatic biliary drainage and insertion of a plastic catheter
89193033|NCT05710055|Active Comparator|Study product C (Wonderlab wonder4shape)|"2g/bottle, containing the following probiotics total dosage 2.0*10^10 CFU:~CECT7527, CECT7528, CECT7529, B420, HN019~XOS~Polydextrose~IMO"
89414517|NCT06070428|Sham Comparator|Control non-interventional Arm|"Participants randomized to the non-interventional arm will be given 2 PAC units without HEPA filters inside to be used in the home: one in the room patient sleeps in, the other in the living area of the home. Participants will also be given an air quality monitor. Study staff will educate the patient on use of the filters and monitor.~Patients will be seen in clinic for 30-day and 90-day follow-up visits. Blood pressure, blood draw for biomarker levels, 6-minute walk distance, and questionnaires will be completed.~Patients will be allowed to keep the PAC at the end of the trial and will be informed at that time how to purchase additional filters."
89414518|NCT06063317|Experimental|CF33-CD19 IT Administration Monotherapy|
89414519|NCT06063317|Experimental|CF33-CD19 IV Administration Monotherapy|
89414520|NCT06063317|Experimental|CF33-CD19 IT Administration in Combination with Blinatumomab|
89414521|NCT06063317|Experimental|CF33-CD19 IV Administration in Combination with Blinatumomab|
89193034|NCT05710055|Placebo Comparator|Study product D|"2g/bottle:~MD~Cucumber powder"
89193035|NCT05709288|Experimental|BBM-H901 administration group|Subjects will be administered with single dose intravenous infusion of BBM-H901.
89414522|NCT06061939|No Intervention|Control Group|A control group (CG) that will not undergo treatment, which will be evaluated in the pre and post phase of the study. Participants assigned to this group will receive general advice on the positive effects of regular physical activity, and they will be given the guide of recommendations for the promotion of physical activity.
89414523|NCT06061939|Experimental|Intervention Group|An experimental group (EG) that after an initial evaluation and with their consent, will be subjected to a directed physical training program, based on strength training with blood flow restriction, applied for 12 weeks with 3 weekly sessions (Monday, Wednesday and Friday), with a duration of 30-45 minutes per session. The exercises to be performed will be divided into three different phases: warm-up during the first 10 minutes; the main part with a duration of 15 minutes (where each exercise must be performed doing 4 series with a pattern of 30-15-15-15 repetitions, resting 30-45 seconds between series and 1-2 minutes between exercises); and the return to calm, based above all on stretching exercises with a total duration of 10 minutes.
89414524|NCT06058923|Active Comparator|Minimally Invasive Surgical Technique (MIST)|Double flap minimally invasive surgery for the access of intrabony defects
89414525|NCT06058923|Experimental|Modified Minimally Invasive Surgical Technique (M-MIST)|Single flap minimally invasive surgery for the access of intrabony defects
89414526|NCT06053827||Frozen embryo transfer substituted cycle|In a substituted cycle, estrogen and progesterone are given and a transfer is planned when the endometrium is ready
88892273|NCT04153149|Experimental|Vutrisiran 25 mg|Participants will receive vutrisiran 25 mg administered subcutaneously (SC) once every 3 months (q3M) during the double-blind period.
88892274|NCT04153149|Placebo Comparator|Placebo|Participants will receive placebo during the double-blind period.
89193036|NCT05704036|No Intervention|Observational Study|Participants will complete three study visits (baseline, 6 months, and 12 months) involving DXAs (bone density assessment), x-rays, blood draws, and questionnaires.
89193037|NCT05704036|Experimental|Transdermal Estradiol/Cyclic Progesterone|Participants will apply transdermal estradiol patches (0.1 mg/day) weekly for 12 months following baseline study visits. Participants not already using a progesterone-containing contraceptive will also take progesterone (200 mg) for 10 days per month.
88892275|NCT04143217|Experimental|Open-Label Treatment|SPN-812 Open-Label Treatment 200mg to 600mg SPN-812 once daily for up to 156 weeks
88892276|NCT04141462|Experimental|Patients with a a constitutional genetic alteration|one genetic consultation and one blood test
89414527|NCT06053827||Frozen embryo transfer natural cycle|In a natural cycle no hormones are given and a transfer is planned when there is a dominant follicle apparent at the ultrasound
89414528|NCT06039397|Experimental|"Semi-fowler 30 Right Lateral"|
89414529|NCT06039397|Active Comparator|Conventional care|
89414530|NCT06038812|Other|Group I|patients diagnosed with gingivitis
89414531|NCT06038812|Other|Group II|patients diagnosed with periodontitis
88892277|NCT04133675|Active Comparator|Emsella Chair Active Treatment|Active treatment subjects will be asked to sit on the center of the Emsella chair. The height of the chair will be adjusted until the participant's feet are on the floor. The Emsella chair will be turned on and the setting gradually increased to the subject's sensory threshold; the maximum sensation the subject can tolerate. The setting will then be decreased slightly and stay unchanged for the remainder of the treatment time. The treatment threshold should be increased with every treatment until the subject reaches 100%.
88892278|NCT04133675|Sham Comparator|Emsella Sham Treatment|Sham subjects will be positioned on the device in the same manner as the active treatment group. The sham treatment will be provide some sensation without active HIFEM technology. The programming for the sham treatment will have an amplitude limitation, with the setting below therapeutic level (<10% power).
89414532|NCT06038812|Other|Group III|healthy control
89414533|NCT06037031|Experimental|Cohort 1: Severe Renal Impairment|Participants with severe renal impairment will receive a single oral dose of PF-07923568
89414534|NCT06037031|Experimental|Cohort 2: Normal Renal Function|Participants with normal renal function will receive a single oral dose of PF-07923568
89414535|NCT06037031|Experimental|Cohort 3 (Optional): Moderate Renal Impairment|Participants with moderate renal impairment will receive a single oral dose of PF-07923568
89414536|NCT06034275|Experimental|Dose Escalation of VIP943|Subjects with AML, MDS, and B-ALL with CD123 expression will be administered VIP 943 in sequential ascending doses as a monotherapy via intravenous (IV) administration weekly (QW).
89414537|NCT06030700||Laboratory|Simulated kitchen setting including purchase, prep, eating and cleanout
89414538|NCT06030687||Free-Living|
89414539|NCT06030635|Experimental|CPMX1|Compartment compressibility measurement using the CPMX1 device
88892279|NCT04122768|Experimental|Tele coaching group|Coaching with daily interaction with the coaching application, based on an adaptive physical activity goal
88892280|NCT04122768|Sham Comparator|Sham coaching group|Coaching with fixed physical activity goal and limited interaction with the smartphone application.
88892281|NCT04113707|Experimental|Motor Lab|Group A will receive 20 minutes of motor lab intervention daily.
88892282|NCT04113707|No Intervention|Standard of Care|Group B will receive standard of care which will be 20 minutes of reading per day.
88892283|NCT04111133|Experimental|Carvedilol + Ivabradine|
89414540|NCT06028022|Experimental|Arm I (Reishi mushroom extract, placebo)|Patients receive Reishi mushroom extract PO TID on days 1-28 for weeks 1-4 and then placebo PO TID on days 1-28 for weeks 5-8 in the absence of disease progression or unacceptable toxicity.
89414541|NCT06028022|Experimental|Arm II (placebo, Reishi mushroom extract)|Patients receive placebo PO TID on days 1-28 for weeks 1-4 and Reishi mushroom extract PO TID on days 1-28 for weeks 5-8 in the absence of disease progression or unacceptable toxicity.
89414542|NCT06013176|No Intervention|Usual practice|This arm will consist of encounter-based PRO monitoring, in which patients have an opportunity to complete PRO questionnaires via patient portal in advance of clinical encounters or via tablet during clinical encounters. While clinicians will be encouraged to view and discuss PROs with patients during clinical encounters, they will not be prompted to do so in real-time, nor will there be alerts for escalating symptoms.
88892284|NCT04111133|Active Comparator|Carvedilol|
88892285|NCT04103424|No Intervention|Pre-training Metabolic Study Visit|Participants will first complete a pre-training metabolic study visit.
88892286|NCT04103424|Experimental|Post-training Metabolic Study Visit|Participants will complete a second, identical metabolic study visit following 2-weeks of exercise training.
88892287|NCT04099004|Other|Neural Imaging|Females with PFP attending a single study visit where neural imaging is acquired via MRI.
88892288|NCT04097821|Experimental|Part 1 Arm 1: Ruxolitinib + Siremadlin|Dose escalation of siremadlin added to existing stable dose of ruxolitinib
88892289|NCT04097821|Experimental|Part 1 Arm 2: Ruxolitinib + Crizanlizumab|Safety run-in of crizanlizumab added to existing stable dose of ruxolitinib
88892290|NCT04097821|Experimental|Part 1 Arm 3: Ruxolitinib + Sabatolimab|Safety run-in of Sabatolimab added to existing stable dose of ruxolitinib
88892291|NCT04097821|Experimental|Part 2 Arm 1: Ruxolitinib + Siremadlin|Siremadlin added to existing stable dose of ruxolitinib
89414543|NCT06013176|Experimental|Encounter-based PRO monitoring|Encounter-based PRO monitoring (usual practice) plus patient reminders and triage nurse alerts
89414544|NCT06013176|Experimental|Remote PRO monitoring|Remote PRO monitoring plus patient reminders and triage nurse alerts
89414545|NCT06010758|Experimental|Arm 1: Brush / Listerine Experimental Mouthwash|After brushing for 1 timed minute, participants will rinse full strength for 1 minute with Listerine Experimental Mouthwash twice a day.
89414546|NCT06010758|Experimental|Arm 2: Brush / Listerine Cool Mint Zero|After brushing for 1 timed minute, participants will rinse full strength for 30 seconds with experimental mouthwash twice a day.
89414547|NCT06010758|Experimental|Arm 3: Brush / Listerine Total Care Zero|After brushing for 1 timed minute, participants will rinse full strength for 1 minute with experimental mouthwash twice a day.
89414548|NCT06010758|Other|Arm 4: Brush only|Participants will brush their teeth using a soft bristled toothbrush and Colgate Cavity Protection Toothpaste twice daily for 1 timed minute and then rinse with water for 1 minute.
89414549|NCT06010641|Experimental|Head-down position|head-down position as an adjunct to guideline-based treatment
89414550|NCT06010641|Other|control|guideline-based treatment
89414551|NCT06004856|Experimental|Orelabrutinib|
89414552|NCT06004856|Placebo Comparator|Placebo|
89414553|NCT06001840|Experimental|Experimental: Exclusive cigarette smokers|Exclusive cigarette smokers will be recruited and will be exposed to all of the conditions described in the intervention section.
89536740|NCT00705341|No Intervention|Nonasthmatic controls for phase 1|People without asthma will be enrolled to perform 1 methacholine challenge test in phase 1 of the study
89414554|NCT06001840|Experimental|Experimental: Dual cigarette/ nicotine vaping product users|Dual cigarette and nicotine vaping product users will be recruited and will be exposed to all of the conditions described in the intervention section
89005697|NCT05425381|Experimental|Enhanced version of Interconnected Systems Framework (ISFE)|The ISFE addresses limitations of positive behavioral interventions and supports (PBIS) and school mental health (SMH) and improves the quality of services within the three tiers of multi-tiered systems of support (MTSS) by providing specific guidance on their systematic interconnection. Meaningful interconnection requires effective interdisciplinary collaboration, well-functioning teams, data-based decision making, and effective selection and implementation of evidence-based practices. The original interconnected systems framework (ISF) capitalizes on PBIS' strong implementation infrastructure and universal prevention strategies and combines these elements with SMH enhancements to Tiers 2 and 3 to achieve a comprehensive continuum of evidence-based practices. The ISFE leverages the strengths of PBIS and SMH to create one integrated system of care that achieves synergy and economies of scale.
89005698|NCT05425381|Active Comparator|Positive Behavioral Interventions and Supports with Co-located School Mental Health (PBIS+SMH)|Mental health clinicians will be assigned and can work with MTSS teams (or not). Otherwise, there will be no special guidance. We expect this condition to mimic typical practices in schools, where PBIS and SMH efforts are co-located, but not meaningfully interconnected. In other words, we expect parallel functioning (Splett et al., 2014).
89414555|NCT06000228|Experimental|Shallow vestibule|Miller class III/ RT2 labial gingival recession associated with vestibular depth less than 6mm
88892292|NCT04097821|Experimental|Part 2 Arm 2: Ruxolitinib + Crizanlizumab|Crizanlizumab added to existing stable dose of ruxolitinib
88892293|NCT04097821|Experimental|Part 2 Arm 3: Ruxolitinib + Sabatolimab|Sabatolimab added to existing stable dose of ruxolitinib
88892294|NCT04097821|Active Comparator|Part 2 Arm 6: Ruxolitinib monotherapy|Existing stable dose of ruxolitinib as control for Part 2
88892295|NCT04097821|Experimental|Part 3 Arm 1: Ruxolitinib + Compound X|Compound from Part 2 (to be confirmed) added to existing stable dose of ruxolitinib
89005699|NCT00238914|Active Comparator|CE plus oral naltrexone|Compliance enhancement plus oral naltrexone
89005700|NCT00238914|Active Comparator|BNT plus oral naltrexone|Behavioral naltrexone therapy plus oral naltrexone
89005701|NCT05425342|Experimental|ECG single group|Patients will be instructed how to record an ECG on a smartwatch using the front camera of an iPad. In a second step, a standard ECG will be recorded by medical staff. The ECGs will then be compared by two board certified cardiologists
89005702|NCT04668976|Experimental|Pump Therapy|All patients will undergo surgery to have the Medtronic pump and Codman catheter placed appropriately before HAI therapy can begin.
89005703|NCT00238953|Experimental|EC MPS|
89005704|NCT04669366||Patients in Sweden with metastatic renal cell carcinoma|The cohort of patients with metastatic renal cell carcinoma in Sweden
89005705|NCT04668703|Experimental|combined cataract surgery and intravitreal Conbercept injection|Subjects will receive conbercept injections at a dose of 0.5 mg/eye at the conclusion of cataract surgery.
89005706|NCT04668703|No Intervention|cataract surgery alone|Subjects will undergo cataract surgery by phacoemulsification and intraocular lens implantation.
89005707|NCT04669327||Normal|normal subjects
89005708|NCT04669327||Scoliosis|subjects with moderate idiopathic scoliosis
89005709|NCT04721301|Experimental|Combination immunotherapy|Treatment arm with Nivolumab, Ipilimumab and Maraviroc combination treatment
89005710|NCT04668937||Children who came to the Nancy's Pediatric emergencies during the study period in 2019|
89005711|NCT04668937||Children who came to the Nancy's Pediatric emergencies during the study period in 2020|
89005712|NCT04668625|Experimental|Experimental group|Participate in a massive musical event
89005713|NCT04668625|No Intervention|Control Group|Not participate in a massive musical event
89005714|NCT04668508|Experimental|anlotinib combined with radiation|
89005715|NCT04668430|Other|patients|"Patients for whom orthopedic surgery is indicated and planned among :~Tibial valgus osteotomy~Supra-malleolar osteotomy~Hallux osteotomy for hallux valgus~Total knee arthroplasty~Total ankle arthroplasty~Ankle arthrodesis~Hallux arthrodesis~Rear foot torque arthrodesis~Inverted shoulder prosthesis~Anterior lumbar interbody arthrodesis"
89005716|NCT00556465|Experimental|A, 1,III|in this arm patients took 1200 mg N-acetylcysteine
89005717|NCT00556465|No Intervention|B,2, III|
89005718|NCT04668469|Experimental|Ivermectin plus standard care in Mild/Moderate COVID-19 (Group I)|100 patients with Mild/Moderate COVID-19 (Coronavirus disease) infection received a 4-days course of Ivermectin 400 mcg/kg body weight maximum 4 tablets (6mg / tablet) once daily dose before breakfast plus standard of care as issued by Egyptian protocol of COVID-19 treatment.
89005719|NCT04668469|Active Comparator|hydroxychlorquine plus standard care in Mild/Moderate COVID-19 (Group II)|100 patients with mild/moderate COVID-19 infection received hydroxychlorquine (400 every 12 hours for one day followed by 200 mg every 12 hours for 5 days) plus standard care.
89005720|NCT04668469|Experimental|Ivermectin plus standard care and steroids in Sever COIVD-19 (Group III)|100 patients with severe COVID-19 infection received a 4 days course of Ivermectin 400 mcg/kg body weight maximum 4 tablets (6mg / tablet) once daily dose before breakfast plus standard care and steroids
89005721|NCT04668469|Active Comparator|hydroxychlorquine plus standard care and steroids in Sever COVID-19 (Group IV)|100 patients with Severe COVID-19 infection received hydroxychlorquine (400 mg every 12 hours for one day followed by 200 mg every 12 hours for 9days) plus standard care and steroids
89414556|NCT06000228|Active Comparator|Deep vestibule|Miller class III/ RT2 labial gingival recession associated with vestibular depth more than 6mm
89414557|NCT05999136|Experimental|Pulses Diet (PulD)|Subjects will follow a Pulses-enriched diet for 2 months.
89414558|NCT05999136|Experimental|Plant Proteins Diet (PPD)|Subjects will follow a Plant protein-enriched diet for 2 months.
89414559|NCT05999136|Active Comparator|Habitual Diet (HabD)|Subjects will follow a habitual diet for two months.
89536741|NCT00705341|No Intervention|Asthmatic controls for phase 1|People with asthma will be enrolled to perform 1 methacholine challenge test in phase 1 of the study
88892296|NCT04097821|Experimental|Part 3 Arm 2: Ruxolitinib cessation|Compound from Part 2 added to existing stable dose of ruxolitinib for 3 cycles followed by compound monotherapy
89535852|NCT02450227|Active Comparator|Spinach - Whole leaf (10 mg lutein)|"1-2: Group given whole leaf as first intervention Whole leaf spinach (10 mg lutein) given every second day for a 15 days period.~Followed by:~Minced spinach (10 mg lutein) given every second day for a 15 days period."
89414562|NCT05997615|Experimental|Part 1: AMX-500 Monotherapy Dose Escalation|AMX-500 will be administered as a monotherapy in patients with mCRPC over a 21-day cycle
89414563|NCT05997615|Experimental|Part 2: AMX-500 Monotherapy Dose Expansion|AMX-500 will be administered as a monotherapy in patients with mCRPC over a 21-day cycle
89414564|NCT05997381|Experimental|BioBrace Augment Group|An arthroscopic rotator cuff repair is performed with the BioBrace Implant fixed on top of the repaired tendon using anchors.
89414565|NCT05997381|Sham Comparator|Repair Only Group|An arthroscopic rotator cuff repair is performed using standard surgical procedure.
89414566|NCT05996913|Experimental|Intervention|Imagery rescripting intervention for somatic flashback
89414567|NCT05993559|Experimental|No PMRT|No radiation therapy after neoadjuvant chemotherapy and surgery.
89414568|NCT05993559|Placebo Comparator|PMRT|"Arm Description: Proceed with postoperative radiotherapy, following the guidelines of the respective institution, but advising patients to apply the following points whenever possible.~If radiation therapy is administered, include the chest wall and regional LNs.~If PMRT field to regional LN, include Axillary LN level III, level IV, Internal mammary LN (1-3rd ICS)."
89414569|NCT05989074|Experimental|ALLEGRA|ALLEGRA Delivery System TF will be administered.Patient will receive Anticoagulation medication according to the site-specific standard of care
89414570|NCT05989074|Active Comparator|Balloon-expandable TAVI|Patient will receive any kind of CE-marked balloon-expandable valve, and anticoagulation medication according to the site-specific standard of care
89414571|NCT05988580|Experimental|Experimental group|Subjects will consume a pasta dish with 20-22% of resistant starch
88892297|NCT04097821|Active Comparator|Part 3 Arm 3: Ruxolitinib monotherapy|Existing stable dose of ruxolitinib as control for Part 3
88892298|NCT04097821|Experimental|Part 1 Arm 4: Ruxolitinib + Rineterkib|Dose escalation of Rineterkib added to existing stable dose of ruxolitinib
88892299|NCT04097821|Experimental|Part 1 Arm 5: Ruxolitinib + NIS793|Safety run-in of NIS793 added to existing stable dose of ruxolitinib
88892300|NCT04097821|Experimental|Part 2 Arm 4: Ruxolitinib + Rineterkib|Rineterkib added to existing stable dose of ruxolitinib
88892301|NCT04097821|Experimental|Part 2 Arm 5: Ruxolitinib + NIS793|NIS793 added to existing stable dose of ruxolitinib
88892302|NCT04064437||Individuals with type 1 diabetes|
88892303|NCT04064437||Healthy controls|
88892304|NCT04029857|Active Comparator|Group I (standard of care)|Patients receive standard of care nutritional supplementation.
88892305|NCT04029857|Experimental|Group II (Impact Advanced Recovery)|Patients receive Impact Advanced Recovery PO or via feeding tube BID on days 1-7 for weeks 1, 3, and 5 during chemotherapy and radiation therapy before surgery. Starting 5-7 days before surgery, patients receive Impact Advanced Recovery PO TID until surgery. Within 2 days following surgery, patients may continue to receive Impact Advanced Recovery via feeding tube at the discretion of the treating physician.
88892306|NCT04005638||Autoimmune Cytopenia|
88892307|NCT03995121||Schizophrenia and other psychotic disorders|For each [11C]APP311 PET scan, up to 20 mCi of [11C]APP311 will be administered by infusion pump, followed by up to 120 minutes of dynamic PET data acquisition.
88892308|NCT03995121||Cannabis Use Disorder|For each [11C]APP311 PET scan, up to 20 mCi of [11C]APP311 will be administered by infusion pump, followed by up to 120 minutes of dynamic PET data acquisition.
88892309|NCT03995121||Healthy Control|For each [11C]APP311 PET scan, up to 20 mCi of [11C]APP311 will be administered by infusion pump, followed by up to 120 minutes of dynamic PET data acquisition.
88892310|NCT03976063|Active Comparator|Nifedipine|
89414572|NCT05988580|Placebo Comparator|Control group|Subjects will consume the original version of pasta dish
89414573|NCT05988216|Experimental|BRL-301|Allogeneic CD19-targeted Chimeric AntigenReceptor (CAR) T Cells
89414574|NCT05986864|Experimental|Phase I: Low dose|SKG0106 One-Time Intraocular Injection Dose Level 1
89414575|NCT05986864|Experimental|Phase I: Medium dose|SKG0106 One-Time Intraocular Injection Dose Level 2
89414576|NCT05986864|Experimental|Phase I: High dose|SKG0106 One-Time Intraocular Injection Dose Level 3
89414577|NCT05984680|Other|Aim A - Participants and Providers|Arm A will use the user-centered design process to survey pulmonology content experts, oncology providers, and patients and interview a smaller subset. Specifically, we will measure the perceived efficacy of various components of COPD management using a survey of patients with thoracic cancer and oncology providers.
89414578|NCT05984680|Other|Arm B - Participants only COPD Care Pathway|Investigators will use the COPD care pathway developed by Arm A as the intervention in single-arm pilot study to test its feasibility and other implementation outcomes.
89414579|NCT05978817|Experimental|Damon Ultima brackets|Damon Ultima brackets
89414580|NCT05978817|Experimental|conventional Roth appliance|conventional Roth appliance
89414581|NCT05970978|Experimental|Response to previous biologic therapy|Participants with sPGA0 or 1 score and the body surface area affected with psoriasis lesions <3% at baseline; or PASI-75 was achieved after treated with the previous biologics. 200mg of IBI112 will be administered subcutaneously at week 0, 12, 24 and 36.
89414582|NCT05970978|Experimental|Poor response to previous biologic therapy|Participants with sPGA score ≥2 at baseline, or body surface area affected with psoriasis lesions ≥3% at baseline, o PASI-75 was not reached after treated with previous biologics. 200mg of IBI112 will be administered subcutaneously at week 0, 4, 8, 20 and 32.
88892311|NCT03976063|Placebo Comparator|Placebo|
88892312|NCT03965130|Experimental|Glucagon|Participants will receive glucagon or saline during the PINTA study
88892313|NCT03964259|Active Comparator|Standard Hydration Regimen|In the standard intravenous fluid (IVF) protocol, following completion of HDMTX infusion, post HDMTX IVF will be initiated at 125 mL/m2/hr (no maximum mL/hr total rate).
88892314|NCT03964259|Experimental|Reduced hydration regimen|The reduced intravenous fluid (IVF) protocol, post HDMTX IVF will be initiated at 62.5 mL/m2/hr following completion of HDMTX infusion.
89414583|NCT05970016|Experimental|5mg treatment group|Administered orally once a day (QD)
88892315|NCT03960021|Experimental|Single arm|Each patient is treated with 2 RFA interventions.
89414584|NCT05970016|Experimental|10mg treatment group|Administered orally once a day (QD)
89414585|NCT05970016|Experimental|20mg treatment group|Administered orally once a day (QD)
89414586|NCT05970016|Experimental|40mg treatment group|Administered orally once a day (QD)
89414587|NCT05970016|Experimental|60mg treatment group|Administered orally once a day (QD)
89414588|NCT05970016|Experimental|80mg treatment group|Administered orally once a day (QD)
89414589|NCT05970016|Experimental|100mg treatment group|Administered orally once a day (QD)
89414590|NCT05962827|Experimental|Determine the prevalence of hyperlipoproteinemia (a) in a population of patients with lymphedema|The primary endpoint will be lipoprotein (a) > 30 mg/dL, defining hyperlipoproteinemia (a).
89414591|NCT05961085||Adductor Canal Catheter|Pre-operative adductor canal catheter placement
89414592|NCT05959733|Active Comparator|Repair|This group will undergo a rotator cuff repair procedure.
89414593|NCT05959733|Experimental|Bridging Reconstruction using BioBrace|This experimental group will undergo bridging reconstruction using the bioinductive implant, BioBrace.
89414594|NCT05956964|Experimental|Sleep Restriction (SR)|"The research team will provide participants with a pair of shoes to wear throughout the study. The right shoe will be modified to include a 5cm (approximately 2) rocker-style platform which will keep the left leg suspended during walking. Participants will also be provided with a pair of short crutches to assist with walking. Participants in the SR group will sleep only 5 hours for three consecutive nights."
88892316|NCT03956095||Ensure Surgery Immunonutrition Shake supplements|Participants will be provided with and instructed to drink three Ensure Surgery Immunonutrition Shake supplements per day for seven days prior to their scheduled procedure.
88892317|NCT03941288|Active Comparator|Pharmacodynamics and clinical effects of cannabidiol|"Cannabidiol will be administered orally twice daily in equally divided doses starting at 2.5mg/kg per day and increasing by 2.5 to 5.0mg/kg every other day until the target dose of 20mg/kg is reached.~Cannabidiol and the matching placebo solution (excipients alone) will be provided in identical 100ml amber glass bottles. At the end of the treatment period, the treatment solutions will be tapered (10% volume each day) over 10 days."
89414595|NCT05956964|Active Comparator|Sleep Adequate (SA)|"The research team will provide participants with a pair of shoes to wear throughout the study. The right shoe will be modified to include a 5cm (approximately 2) rocker-style platform which will keep the left leg suspended during walking. Participants will also be provided with a pair of short crutches to assist with walking. Participants in the SA group will sleep for 9 hours for three consecutive nights."
89414596|NCT05956041|Experimental|Experimental|Pembrolizumab 400mg via IV over 30 minutes on Day 1 of each cycle (6 weeks) Mogamulizumab 1mg/kg via IV over a least 60 minutes Cycle 1: Days 1, 8, 15, and 22 Cycle 2+: Days 1, 15, and 29 Each cycle lasts 6 weeks with a maximum of 18 cycles If a subject achieves a complete response (CR) after 3 months of study treatment (2 cycles), they will continue study therapy for an additional 6 months (4 cycles). If a confirmed and persistent CR they may discontinue study treatment and enter an observation period. Subjects who progress during the observation period may be eligible for up to an additional 12 cycles of pembrolizumab and mogamulizumab
88892318|NCT03941288|Placebo Comparator|pharmacodynamics and clinical effects of placebo|"Placebo will be administered orally twice daily in equally divided doses starting at 2.5mg/kg per day and increasing by 2.5 to 5.0mg/kg every other day until the target dose of 20mg/kg is reached.~Cannabidiol and the matching placebo solution (excipients alone) will be provided in identical 100ml amber glass bottles. At the end of the treatment period, the treatment solutions will be tapered (10% volume each day) over 10 days."
88892319|NCT03938870||Experimental: Group 1|30 Young Normal Controls(YNC) ages 18 & Older will enroll to evaluate leucine infusion methods of labeling, vs. the oral method. They will have 5 lumbar punctures (LPs) and the amount of labeled tau in the CSF will be analyzed to obtain tau kinetics in human central nervous system (CNS).
88892320|NCT03938870||Experimental: Group 2|Group 30 CDR > 0. There will be collection of CSF and blood. The participants will either be labeled by intravenous infusion method with leucine or oral method based off the results from the Young Normal Control Group. They will have 5 lumbar punctures (LPs) and the amount of labeled tau in the CSF will be analyzed to obtain tau kinetics in human central nervous system (CNS).
88892321|NCT03938870||Experimental: Group 3|Group of 40 CDR = 0 Age Matched. There will be collection of CSF and blood. The participants will either be labeled by intravenous infusion method with leucine or oral method based off the results from the Young Normal Control Group. They will have 5 lumbar punctures (LPs) and the amount of labeled tau in the CSF will be analyzed to obtain tau kinetics in human central nervous system (CNS).
88892322|NCT03902951|Experimental|Treatment (leuprolide, apalutamide, abiraterone acetate, SBRT)|Patients receive leuprolide SC on day 1, Patients receive a single dose of leuprolide SC on day 1 and apalutamide PO QD and abiraterone acetate PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity. Beginning 2 months of initiation of ADT, patients also receive SBRT over 1, 3, or 5 fractions in the absence of disease progression or unacceptable toxicity.
89437596|NCT03523221|Active Comparator|Dexamethasone arm|All patients will be Urgently treated for anaphylaxis according to guideline protocol. Enrolled patients will be given one of study medication orally, and he /she will observe in the observation room with cardiac monitor and close monitoring by nurse.
88892323|NCT03899844||Cognitively normal|896 of the 1120 enrolled will not exhibit subjective impairment as defined by a brief clinical test. These participants will complete an initial blood collection and cognitive testing, and a subset of participants will be asked to return for a larger blood collection, amyloid (PiB) PET imaging, and MRI.
88892324|NCT03899844||Cognitively impaired|224 of the 1120 enrolled will exhibit subjective impairment as defined by a brief clinical test. These participants will complete an initial blood collection and cognitive testing, and a subset of participants will be asked to return for a larger blood collection, amyloid (PiB) PET imaging, and MRI.
88892325|NCT03896321|Active Comparator|Asprin|Patient will receive dual anti platelet asprin And clopidogrel
88892326|NCT03896321|Active Comparator|Clopidogrel|Patient will receive dual anti platelet asprin And clopidogrel
88892327|NCT03896321|Active Comparator|Warfarin|Patient will receive oral anticoagulation
88892328|NCT03896321|Active Comparator|Novel oral anticoagulant|Patient will receive oral anticoagulation
88892329|NCT03891446|Experimental|Lead-in study 192024-091 or -092 or -095|"Study eye (Eye that received Bimatoprost SR in the lead-in study): No treatment is administered.~Fellow eye (Eye that did not receive Bimatoprost SR in the lead-in study): Fellow eye will receive only standard of care, based on the investigator's judgment."
88892330|NCT03891446|Experimental|Lead-in study 192024-093 Stage 1|"Participants who received 1, 2 or 3 administrations and participants in Stage 2 who received 1 Bimatoprost SR administration due to safety concern or received 2 administrations.~Study eye (Eye that received Bimatoprost SR in the lead-in study): No treatment is administered.~Fellow eye (Eye that did not receive Bimatoprost SR in the lead-in study): Fellow eye will receive only standard of care, based on the investigator's judgment."
88892331|NCT03891446|Experimental|Lead-in study 192024-093 Stage 2|"Participants who received 1 Bimatoprost administration due to sustained efficacy:~Study eye (Eye that received Bimatoprost SR in the lead-in study): 1 additional administration of Bimatoprost SR may be administered through completion of the Month 12 visit, at least 4 months apart from the lead-in study administration. Fellow eye (Eye that did not receive Bimatoprost SR in the lead-in study): Fellow eye will receive only standard of care, based on the investigator's judgment."
88892332|NCT03891446|Experimental|Lead-in study ARGOS|"Study eye (Eye that received Bimatoprost SR first in the lead-in study): 1 additional administration of Bimatoprost SR may be administered through completion of the Month 12 visit, at least 4 months apart from the lead-in study administration.~Treated Fellow eye (Eye that received Bimatoprost SR second in the lead-in study): 1 additional administration of Bimatoprost SR may be administered through completion of the Month 12 visit, at least 4 months apart from the lead-in study administration.~Untreated Fellow eye (Eye that did not receive Bimatoprost SR in the lead-in study): Untreated fellow eye will receive only standard of care, based on the investigator's judgment."
88892333|NCT03873428|Other|FES PET|1 ) inclusion; 2 ) FGD PET / FES PET; 3) Hormone therapy
88892334|NCT03869437|Experimental|Cefiderocol|Participants will receive Cefiderocol 2 grams administered intravenously over 3 hours, every 8 hours for a minium of 5 days and a maximun of 14 days.
88892335|NCT03869437|Active Comparator|Best Available Therapy (BAT)|BAT will be chosen by the investigator and intravenously administered per country-specific guidelines.
89535853|NCT02450227|Experimental|Spinach - Minced (10 mg lutein)|"2-1: Group given minced spinach as first intervention Minced spinach (10 mg lutein) given every second day for a 15 days period.~Followed by:~Whole leaf spinach (10 mg lutein) given every second day for a 15 days period."
88892336|NCT03850782|Experimental|Bimatoprost SR - Dose A|"Study Eye: Participants will receive 1 - 2 Cycles of Bimatoprost SR administrations of Dose A~Fellow Eye: The eye that does not receive Bimatoprost SR treatment will receive standard of care or up to one administration of Bimatoprost SR."
88892337|NCT03850782|Experimental|Bimatoprost SR - Dose B|"Study Eye: Participants received 1 - 3 Cycles of Bimatoprost SR administrations of Dose B~Fellow Eye: The eye that does not receive Bimatoprost SR treatment will receive standard of care or up to one administration of Bimatoprost SR."
88892338|NCT03845283|Experimental|Physical Activity|Participants will receive the core 6-month weight loss program and the tailored intervention to promote structured physical activity.
88892339|NCT03845283|Experimental|Core Program|Participants will receive the core 6-month weight loss program alone. This program includes weekly lessons for the first 12 weeks and monthly lessons for the remaining 12 weeks. Participants will track their intake, physical activity, and weight, input these data into the system, and received tailored feedback.
88892340|NCT03845283|Experimental|Physical Activity & Virtual Meetings|Participants will receive the core 6-month weight loss program, the tailored intervention to promote structured physical activity, and the virtual meetings to support weight loss.
88892341|NCT03845283|Experimental|Virtual Meetings|Participants will receive the core 6-month weight loss program and the virtual meetings to support weight loss.
88892342|NCT03845283|Experimental|Physical Activity & Virtual Reality|Participants will receive the core 6-month weight loss program, the tailored intervention to promote structured physical activity, and access to the virtual reality platform for behavioral weight loss skills training.
88892343|NCT03845283|Experimental|Virtual Reality|Participants will receive the core 6-month weight loss program and access to the virtual reality platform for behavioral weight loss skills training.
88892344|NCT03845283|Experimental|Physical Activity, Virtual Reality, & Virtual Meetings|Participants will receive the core 6-month weight loss program, the tailored intervention to promote structured physical activity, the virtual meetings to support weight loss, and access to the virtual reality platform for behavioral weight loss skills training.
88892345|NCT03845283|Experimental|Virtual Reality & Virtual Meetings|Participants will receive the core 6-month weight loss program, access to the virtual reality platform for behavioral weight loss skills training, and the virtual meetings to support weight loss.
88892346|NCT03845283|Experimental|Physical Activity & Bite Counter|Participants will receive the core 6-month weight loss program, the tailored intervention to promote structured physical activity, and the Bite Counter device to reduce dietary intake.
88892347|NCT03845283|Experimental|Bite Counter|Participants will receive the core 6-month weight loss program and the Bite Counter device to reduce dietary intake.
89535854|NCT02484989||Retinopathy of prematurity|Any baby with ROP who is treated or referred to another unit for treatment either in the form of laser therapy, cryotherapy, antiVEGF agent or vitrectomy/scleral buckling (or a combination of above treatments)
89535855|NCT03216577||Exposed to purpura fulminans|Patients who were admitted in the intensive care unit and survived a purpura fulminans episode
89535856|NCT03216577||Non-exposed to purpura fulminans|Patients admitted in the intensive care unit for a septic shock unrelated to a purpura fulminans, and matched to exposed patients for age, gender, and severity of illness.
89535857|NCT03316079|Active Comparator|Chest physiotherapy techniques|Manual chest physiotherapy techniques applied
88892348|NCT03845283|Experimental|Physical Activity, Bite Counter, & Virtual Meetings|Participants will receive the core 6-month weight loss program, the tailored intervention to promote structured physical activity, the Bite Counter device to reduce dietary intake, and the virtual meetings to support weight loss.
88892349|NCT03845283|Experimental|Bite Counter & Virtual Meetings|Participants will receive the core 6-month weight loss program, the Bite Counter device to reduce dietary intake, and the virtual meetings to support weight loss.
88892350|NCT03845283|Experimental|Physical Activity, Bite Counter, & Virtual Reality|Participants will receive the core 6-month weight loss program, the tailored intervention to promote structured physical activity, the Bite Counter device to reduce dietary intake, and access to the virtual reality platform for behavioral weight loss skills training.
88892351|NCT03845283|Experimental|Bite Counter & Virtual Reality|Participants will receive the core 6-month weight loss program, the Bite Counter device to reduce dietary intake, and access to the virtual reality platform for behavioral weight loss skills training.
88892352|NCT03845283|Experimental|Physical Activity, Bite Counter, Virtual Reality & Meetings|Participants will receive the core 6-month weight loss program, the tailored intervention to promote structured physical activity, the Bite Counter device to reduce dietary intake, access to the virtual reality platform for behavioral weight loss skills training, and the virtual meetings to support weight loss.
88892353|NCT03845283|Experimental|Bite Counter, Virtual Reality, & Virtual Meetings|Participants will receive the core 6-month weight loss program, the Bite Counter device to reduce dietary intake, access to the virtual reality platform for behavioral weight loss skills training, and the virtual meetings to support weight loss.
88892354|NCT03845075|Experimental|active arm|The active medication arm will be given co-administration of 0.5 mg tesofensine/50 mg metoprolol daily for 24 weeks.
88892355|NCT03845075|Placebo Comparator|placebo arm|The placebo arm will receive matching placebo tesofensine and placebo metoprolol.
88892356|NCT03834701|Experimental|EUS guided radiofrequency ablation|Radiofrequency ablation will be performed using a system that consists of an 19-gauge needle electrode (140-cm long), a radiofrequency generator, and an inner cooling system that circulates chilled saline solution during the RFA procedure.
88892357|NCT03830918|Experimental|Arm A (temozolomide, niraparib, atezolizumab)|Patients receive temozolomide PO QD on days 1-5 and niraparib PO QD on days 1-28. Cycles repeats every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive standard of care atezolizumab IV every 3 weeks in the absence of disease progression or unacceptable toxicity.
88892358|NCT03830918|Active Comparator|Arm B (atezolizumab)|Patients receive standard of care atezolizumab IV every 3 weeks in the absence of disease progression or unacceptable toxicity.
88892359|NCT03810196|Other|TBI regimen|Standard of care myeloablative regimens will be used based on disease type and clinical status at time of transplant. Patients with acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma will receive total body irradiation (TBI) regimen (thiotepa, cyclophosphamide, TBI).
88892360|NCT03810196|Other|TBI or busulfan regimen|Standard of care myeloablative regimens will be used based on disease type and clinical status at time of transplant. Patients not diagnosed with ALL or lymphoblastic lymphoma may receive either total body irradiation (TBI) regimen (thiotepa, cyclophosphamide, TBI) or busulfan containing regimen (thiotepa, cyclophosphamide, busulfan).
88892361|NCT03809299|Other|Ad libitum meal timing first|This arm will receive the ad libitum meal timing intervention first, followed by the twice a day feeding intervention.
88892362|NCT03809299|Other|Twice a day meals first|This arm will receive the twice a day feeding intervention first, followed by the ad libitum meal timing intervention.
88892363|NCT03804996|Experimental|TG-1801|Arm Description: TG-1801 will be administered once every 4 weeks (28-day) cycles. Subjects who experience disease progression after completing 6 months of single agent TG-1801 will be eligible for TG-1801 single-agent re-treatment at the discretion of the investigator.
88892364|NCT03804996|Experimental|TG-1101|"Arm Description: TG-1801 and ublituximab will be administered once every 4 weeks (28-day cycle) for up to 6 cycles followed by TG-1801 monotherapy.~To explore the safety of TG-1801 in combination with ublituximab will be explored at doses below and up to the RP2D. TG-1801 intrapatient dose escalation will not be permitted in combination therapy."
88892365|NCT03790267||Hip arthroplasty|
88892366|NCT03790267||Knee arthroplasty|
88892367|NCT03790267||Shoulder arthroplasty|
88892368|NCT03764033|Experimental|Impact of Killing (IOK)|Participants in this arm will receive 10 sessions (60-90 minutes) of a cognitive-behavioral moral injury treatment called IOK .
88892369|NCT03764033|Active Comparator|Present Centered Therapy|Participants in this arm will receive 10 sessions (60-90 minutes) of a PTSD treatment that does not focus on trauma or cognitive restructuring, but rather the functional impact of trauma called Present Center Therapy (PCT)
88892370|NCT03755206|Other|Intervention|Interrupted time series design
88892371|NCT03709758|Experimental|Venetoclax+Daunorubicin+Cytarabine|"Venetoclax administered orally on days 1 to 11 daily~Daunorubicin administered intravenously on days 2-4~Cytarabine administered on days 2-8 by continuous IV infusion"
88892372|NCT03704532||Operative treatment|Patients having undergone an operative treatment of achilles tendon rupture
89193038|NCT05703048|Experimental|dexmedetomidine group|35 patients will be received dexmedetomidine (Precedex; Abbott Laboratories, North Chicago, Illinois, USA) (vial = 2 ml) 100 mcg/ml at bolus dose of 1 mcg /kg slowly infused over 10 min, then continuous infusion by a rate of 0. 5 mcg /kg/h., infused by a syringe pump. infusion stopped immediately upon extubation.
88892373|NCT03704532||Nonoperative treatment|Patients having undergone a nonoperative treatment with functional rehabilitation of achilles tendon rupture
88892374|NCT03696498|Experimental|Partial caries excavation (1 step)|"Patients with radiographical caries within the pulpal ¼ of the dentine with the presence of a radiodense zone separating the pulp from the demineralised dentine is candidates for the treatment. Local anaesthesia shall be used. as this procedure is identical for the two interventions tested in this trial. A partial removal of carious dentine is performed with superficial removal of the outermost infected and necrotic part of the demineralised dentine.~Intervention: A permanent resin restoration is placed on top of the remained caries."
89193039|NCT05703048|Active Comparator|Esmolol group|35 patients will be received i.v. received a loading dose of esmolol 0.5 mg/kg in 30 mL isotonic saline in the IV line, followed by an IV infusion of esmolol 0.05 mg/kg/min. infusion stopped immediately upon extubation.
89414597|NCT05955365|Experimental|Monotherapy strategy|Patients randomized to the monotherapy treatment arm receive any of the commercially available oral P2Y12 inhibitors (clopidogrel, prasugrel oder ticagrelor) and immediately discontinue aspirin and DOAC (or will not re-start DOAC after PCI if treatment was temporarily stopped before). After 1 month, the P2Y12 inhibitor will be stopped and treatment with a commercially available DOAC (at investigator's discretion and dosed according to the instructions for use in patients with atrial fibrillation) will be initiated for the duration of 11 months. After completion of the 12-month study regimen (study visit), the patient will receive antithrombotic therapy according to routine care.
89414598|NCT05955365|Active Comparator|Standard of care strategy|Patients randomized to the standard of care, receive DOAC for at least 12 months. In addition, aspirin is administered for up to 1 month after PCI at investigator's discretion and one of the available P2Y12 inhibitors (clopidogrel, prasugrel oder ticagrelor at investigator's discretion) is administered for a minimum of 6 months and up to 12 months after PCI. After completion of the 12-month control arm regimen (study visit), the patients will be treated according to routine care.
89414599|NCT05954559|Experimental|0.05 mmol/kg Elucirem|a group that receives 0.05 mmol/kg Elucirem
89414600|NCT05954559|Experimental|0.075 mmol/kg Elucirem|A group that receives 0.075 mmol/kg Elucirem
89414601|NCT05948436|Experimental|Clamp|In these patients, we clamped the uterine artery by Darmklemmen clamp after the delivery of the baby before the delivery of placenta. We released the clamp after the suturing of the uterus is finished.
89414602|NCT05948436|No Intervention|Control|Routine Cesarean section is done.
89414603|NCT05943431|Experimental|Paired taVNS|Upper extremity motor rehabilitation training will be paired with taVNS.
89414604|NCT05943431|Active Comparator|Unpaired taVNS|Unpaired transcutaneous vagus nerve stimulation for upper limb motor rehabilitation will be administered.
89414605|NCT05943431|Sham Comparator|Sham taVNS|Upper limb motor rehabilitation training will be paired with sham-stimulation.
89414606|NCT05920083|Experimental|CPAP withdrawal|CPAP withdrawal for 2 weeks
89414607|NCT05915767|Experimental|olive leaf tea|SIBO diagnosed individuals in this group will receive olive leaf tea orally, twice a day after meals for 8 weeks.
88892375|NCT03696498|Active Comparator|Partial caries excavation (2 steps)|"Patients with radiographical caries within the pulpal ¼ of the dentine with the presence of a radiodense zone separating the pulp from the demineralised dentine is candidates for the treatment. Before randomisation, the participants receive the first excavation procedure as this procedure is identical for the two interventions tested in this trial. A partial removal of carious dentine is performed with superficial removal of the outermost infected and necrotic part of the demineralised dentine.~Intervention: After randomisation, a calcium hydroxide containing base material is used and a temporary glass-ionomer restoration is placed in the entire cavity. After 4-6 months, the temporary restoration is removed, final excavation is carried out with hand excavators until firm but stained dentine remains, and a permanent resin restoration is placed."
88892376|NCT03689946|Experimental|Evolocumab, F18-NaF PET, CCTA|Evolocumab self-administration for 18 months. Baseline (pre-treatment) and follow-up 18F-NaF PET and CCTA (possible beta-blocker and nitroglycerin, if medically safe).
88892377|NCT03677882|No Intervention|Treatment as Usual (TAU)|Participants assigned to Treatment As Usual (TAU) will receive the normal standard of care treatment from the Suicide Prevention Team and the Mental Health Service which may include individual therapy, group therapy, and/or medication therapy, all as decided by the individual and his/her doctor. Treatment as usual also includes monitoring by the Suicide Prevention Team.
88892378|NCT03677882|Experimental|Treatment As Usual with Mind-Body Bridging (TAU + MBB)|Participants assigned to TAU + MBB will will receive treatment from the Suicide Prevention Team and the Mental Health Service, AND will be asked to participate in consisting of three to eight 60-minute sessions that will occur consecutively. Each group will be led by a trained MBB facilitator. Participants will receive a workbook at the beginning of the training that contains an explanation of all the major concepts involved in Mind Body Bridging. The workbook has homework assignments to be completed daily between group sessions.
89414608|NCT05915767|No Intervention|Control group|SIBO diagnosed individuals in this group will not receive olive leaf tea or any intervention for 8 weeks.
89414609|NCT05912231|Experimental|Accelerated Proton Beam Radiation Therapy (PBT) Group|"Participants will be randomized 1:1 to XRT group and stratified by receipt of chemotherapy and cardiac risk factors and will complete:~Cardiac MRI and blood tests within 1 month prior to start of radiation therapy.~Radiation therapy 1x daily for 5 days over 1 week.~End of radiation therapy visit with blood tests.~6 month follow up visit with cardiac MRI, blood tests, questionnaires, and photographic imaging.~12 month follow up visit with questionnaires and photographic imaging."
89535858|NCT03316079|Experimental|Chest physiotherapy techniques + Mechanical in-exsufflation|Mechanical insufflation-exsufflation in addition to manual chest physiotherapy techniques
89535859|NCT02637063|Experimental|BlipHub mobile-web app|Mobile web app to promote blood-pressure-reducing diet, physical activity and weight loss.
89535860|NCT02637063|Experimental|BlipHub mobile-web app + health coaching|Telephonic coach-supported mobile web app to promote blood-pressure-reducing diet, physical activity and weight loss.
89193040|NCT05700721|Experimental|Monotherapy|
89193041|NCT05697848|Experimental|Pain Education group|The patients of the experimental group will undergo pain education in addition to individual physiotherapy ( manual therapy and active exercises ).
89437597|NCT03523221|Placebo Comparator|Placebo arm|All patients will be Urgently treated for anaphylaxis according to guideline protocol. Enrolled patients will be given one of study medication orally, and he /she will observe in the observation room with cardiac monitor and close monitoring by nurse.
89437598|NCT03520036|Experimental|MT-7117 low dose|
89437599|NCT03520036|Experimental|MT-7117 high dose|
89437600|NCT03520036|Placebo Comparator|Placebo|
89437601|NCT03514459|No Intervention|Control|Control clinics: Clinics randomized to the control arm will continue usual procedures. Periodic evaluation of cervical cancer screening rates will be examined every 3 months using FP register data.
89005722|NCT04668469|Experimental|Ivermectin plus personal protective measures in COVID-19 prophylaxis (Group V)|100 health care and or household contacts received a prophylactic dose of ivermectin 400 micrograms/kg single oral dose before breakfast to be repeated after one week in addition to Personal Protective Measures ( (hand hygiene, social distancing measures, avoiding touching the eyes, nose and mouth, Masks, respiratory etiquette, and self-isolation)
89005723|NCT04668469|Active Comparator|Personal protective measures in COVID-19 prophylaxis (Group VI)|100 health care and or household contacts received only Personal Protective Measures (hand hygiene, social distancing measures, avoiding touching the eyes, nose and mouth, Masks, respiratory etiquette, and self-isolation)
89005724|NCT04668547|Experimental|Interventional arm|Single arm, no comparison
89005725|NCT00211913|Experimental|vaccine|single dose of StaphVAX®
89005726|NCT00211913|Placebo Comparator|placebo|single dose
89005727|NCT00239031|Experimental|1|
89005728|NCT00212030|Active Comparator|1|
89005729|NCT00212030|Placebo Comparator|2|
89005730|NCT02961777||Time 1|retrospective evaluation of patient record. no intervention
89005731|NCT02961777||Time 2|retrospective evaluation of patient record. no intervention
89005732|NCT02961777||Time 3|retrospective evaluation of patient record. no intervention
89005733|NCT00212108|Experimental|Celecoxib and ZD1839|Celecoxib and ZD1839 will be given twice a day and daily respectively for two consecutive weeks prior to further anti-cancer treatment.
89414610|NCT05912231|Experimental|Accelerated Photon Radiation Therapy (XRT) Group|"Participants will be randomized 1:1 to XRT group and stratified by receipt of chemotherapy and cardiac risk factors and will complete:~Cardiac MRI and blood tests within 1 month prior to start of radiation therapy.~Radiation therapy 1x daily for 5 days over 1 week.~End of radiation therapy visit with blood tests.~6 month follow up visit with cardiac MRI, blood tests, questionnaires, and photographic imaging.~12 month follow up visit with questionnaires and photographic imaging."
89414611|NCT05910411|Experimental|Inelastic compression|Inelastic compression used in the treatment of lymphedema
89005734|NCT00414297|Active Comparator|1 ECP|active ECP Therapy
89005735|NCT00414297|Placebo Comparator|2|Sham ECP Treatment
89005736|NCT00212303|Experimental|Exercise training|Exercise training, 3 times per week, for 6 months.
89005737|NCT00212303|No Intervention|Control|Usual care no active exercise intervention
89005738|NCT00212342|Experimental|Norethisterone,Ethinylestradiol|
89005739|NCT00212342|Placebo Comparator|Sugar pill|
89005740|NCT00414375|Active Comparator|1|Drainage with interval appendectomy
89005741|NCT00414375|Experimental|2|appendectomy on presentation
89005742|NCT00212381|Experimental|oral DIM (Active agent)|2mg/kg/day po of DIM
89005743|NCT00212381|Active Comparator|Red rice bran (Placebo)|this agent is not generally thought to be active but may be
89005744|NCT00414414|Active Comparator|prednisone|
89005745|NCT00414414|Placebo Comparator|placebo|
89535861|NCT02637063|Other|Usual care|No intervention beyond the participants' personal medical care.
89005746|NCT00212459|Experimental|1|Patients are contacted every two weeks after initial counseling to discuss completion of bleeding records.
89005747|NCT00212459|Active Comparator|2|After the initial counseling with regards to bleeding records, there are no more contacts made with the control patients.
89005748|NCT00411593|Experimental|Avastin® + Bortezomib|"Phase I - 3 * 3 design, enrolling patients to receive Avastin® at a fixed dose of 15 mg/kg every 3 weeks and Bortezomib dosed at 1.6 mg/m2 weekly for 2 weeks out of 3.~Phase II - The MTD for Bortezomib from the weekly schedule that is chosen will be combined with Avastin® to estimate the rate of progression-free survival."
89005749|NCT00411827|Active Comparator|1|PRK
89005750|NCT00411827|Active Comparator|2|LASIK
89005751|NCT00212498||TB diagnosis|
89005752|NCT00212576|Experimental|Building Blocks (0-3)|"Randomized at birth to receive Building Blocks Project from birth through 3 years of age.~Note: This arm not followed past 3 years of age; NOT re-randomized to any group at age 3."
89005753|NCT00212576|Experimental|VIP (0-3), VIP (3-5)|"Randomized at birth to receive Video Interaction Project from birth through 3 years of age.~Re-randomized at 3 years to receive Video Interaction Project from 3-5 years of age."
89005754|NCT00212576|Experimental|VIP (0-3), Control (3-5)|"Randomized at birth to receive Video Interaction Project from birth through 3 years of age.~Re-randomized at 3 years to receive care as usual (control) from 3-5 years of age."
89005755|NCT00212576|Experimental|Control (0-3), VIP (3-5)|"Randomized at birth to receive care as usual (control) from birth through 3 years of age.~Re-randomized at 3 years to receive Video Interaction Project from 3-5 years of age."
89005756|NCT00212576|No Intervention|Control (0-3), Control (3-5)|"Randomized at birth to receive care as usual (control) from birth through 3 years of age.~Re-randomized at 3 years to receive receive care as usual (control) from 3-5 years of age."
89005757|NCT00212615|Active Comparator|A|Standard XELOX
89005758|NCT00212615|Active Comparator|B|Chronomodulated XELOX
89005759|NCT00222612|Active Comparator|A or B with 2DI|3 or 4 drug induction plus 2 delayed intensifications
89005760|NCT00222612|Experimental|C plus 2DI|Intensified treatment including Capizzi maintenance
89005761|NCT00222612|Experimental|A or B with 1DI|Reduced intensity treatment
89005762|NCT04709406||obese patients|obese patients underwent bariatric surgery
89005763|NCT00213278|Experimental|1|
89005764|NCT00222846|Active Comparator|A|Attention control
89005765|NCT00222846|Experimental|B|Intervention
89005766|NCT00223002|Experimental|1|PI
89005767|NCT00223002|Experimental|2|Chlorohex
89005768|NCT00223041|No Intervention|A (therapy with fluvastatin 80mg retard)|kidney transplants receive in addition fluvastatin 80mg retard for 3 years
89005769|NCT00223041|Placebo Comparator|B|no therapy with fluvastatin
89005770|NCT00240006|Experimental|1|Shared Solutions®
89005771|NCT00240006|Experimental|2|Shared Solutions® and MS Center/Office Practice Partnership
89535862|NCT02480387|Experimental|Treatment Arm|8 weeks treatment with Ledipasvir/Sofosbuvir FDC
89414612|NCT05909176|Experimental|Start the Conversation Package|The pre-intervention phase will last for 4 months (months 1-4). The only study activity during the pre-intervention phase is the collection of routine PrEP uptake data to establish a baseline for PrEP prescribing at the GYN residency clinics and local PrEP clinics. The implementation of the combined-care model at the LSU GYN residency clinic at UMCNO for 10 months (months 5-14). Then we will add implementation of the social media campaign in the NOLA area for 4 months (months 5-18); implementation of the combined-care model at LSU GYN residency clinic at UMCNO will continue. The layered approach allows for an opportunity to assess the effect of the combined-care model, and subsequently, to what extent the social media campaign additionally engages Black women and builds demand for PrEP.
89414613|NCT05905458|Experimental|Treatment group A: HRS9950 tablets (Low dose)|
89414614|NCT05905458|Experimental|Treatment group B: HRS9950 tablets (High dose)|
88892382|NCT03667716|Experimental|P1a Arm A (Monotherapy Dose Escalation).|COM701 monotherapy sequential dose escalation administered IV every 3 weeks and a Cohort IV every 4 weeks. Up to 8 dose escalation cohorts may be evaluated until a maximum tolerated dose or recommended phase 2 dose is identified.
88892383|NCT03667716|Experimental|P1a Arm B (Combination Dose Escalation).|COM701 sequential dose escalation administered IV every 3 weeks in combination with Opdivo (Nivolumab) 360mg administered IV every 3 weeks and COM701 administered IV every 4 weeks in combination with Opdivo (Nivolumab) 480mg administered IV every 4 weeks.
88892384|NCT03667716|Experimental|P1a Arm A (Monotherapy Expansion).|COM701 monotherapy administered IV every 4 weeks. Cohort expansion in subjects with the following select tumor types (NSCLC, Breast, Ovarian, Endometrial and Colorectal cancer).
88892385|NCT03667716|Experimental|P1b (Combination Cohort Dose Expansion).|COM701 administered IV every 4 weeks in combination with Opdivo (Nivolumab) 480 mg administered IV every 4 weeks. Cohort expansion in subjects with the following select tumor types (Breast, Ovarian, Endometrial and Colorectal cancer).
88892386|NCT03662659|Experimental|BMS-986213 + investigator's choice chemotherapy|BMS-986213 + XELOX or BMS-986213 + FOLFOX or BMS-986213 + SOX
88892387|NCT03662659|Experimental|Nivolumab + investigator's choice chemotherapy|Nivolumab + XELOX or Nivolumab + FOLFOX or Nivolumab + SOX
88892388|NCT03652740|Experimental|Within-Subjects Dose Conditions|Participants are not assigned to different groups/arms. All participants will receive the same drug conditions, but the order in which the participants receive the drug conditions will be different across participants. Thus, comparisons of the drug conditions on mood and choice will be compared within-subjects (e.g., between drug and placebo) and not between arms.
88922102|NCT05815199|Experimental|E-cigarettes (EC)|Adult cigarette smokers with a SMI diagnosis randomized to the EC arm will receive NRT including nicotine patches and lozenges. Participants will also receive telehealth motivational counseling during the intervention period of 8 weeks.
88922103|NCT05815199|Active Comparator|Nicotine Replacement Therapy (NRT)|Adult cigarette smokers with a SMI diagnosis randomized to the NRT arm will receive NRT including nicotine patches and lozenges gum. Participants will also receive telehealth motivational counseling during the intervention period of 8 weeks.
89414615|NCT05905458|Placebo Comparator|Placebo Comparator: Treatment group C|
89414616|NCT05901610|Other|EFT and LIFU|Participants will generate positive future events they are looking forward to at several time points in the future (e.g., 2 weeks, 1 month, 3 months, 1 year, and 5 years). During the LIFU condition, participants will have an ultrasound transducer placed on their head, where brief ultrasound pulses are delivered to the desired brain area using the imaging collected during visit 1. A small amount of ultrasound gel will be placed on the face of the single-element focused ultrasound transducer. The transducer will then be fitted on the scalp over the desired brain area and held in place with a mechanical arm. Brief pulses (0.2 to 2 seconds; duty cycle 10 - 70%; pulse repetition frequency 100 - 1000 Hz) of low-intensity (< 50 W/cm2 Isppa), sub-thermal ultrasound (0.3 - 0.5 MHz) will be delivered in order to determine the area of activation, as well as the patterns of brain activity generated.
89414617|NCT05901610|Other|EFT and Sham LIFU|Participants will generate positive recent past events that have happened to them at several time points in the previous day (e.g., 7pm-10pm, 4pm-7pm, 1pm-4pm, 10am-1pm, and 7am-10am). During Sham LIFU, the device will be set up identically as in real LIFU. However, the device will be turned off.
89414618|NCT05901610|Other|CET ad LIFU|Participants will generate positive recent past events that have happened to them at several time points in the previous day (e.g., 7pm-10pm, 4pm-7pm, 1pm-4pm, 10am-1pm, and 7am-10am). During the LIFU condition, participants will have an ultrasound transducer placed on their head, where brief ultrasound pulses are delivered to the desired brain area using the imaging collected during visit 1.
88892389|NCT03652740|Experimental|Additional Within-Subjects Dose Conditions|"As described previously, all participants will receive the same drug conditions, but the order in which the participants receive the drug conditions will be different across participants. Thus, comparisons of the drug conditions on mood and choice will be compared within-subjects (e.g., between drug and placebo) and not between arms. We have created a second arm in the description of the trial on ClinicalTrials.gov to designate masking - this study involves administration of drug conditions in different dose sequence orders to which participants are randomly assigned."
88892390|NCT03652259|Experimental|Cohort 1: SRP-9003|Participants will receive a single intravenous (IV) infusion of SRP-9003 at a prespecified dose.
89414619|NCT05895292|Experimental|CAD/CAM Milled Methacrylate Complete Removable Dentures based on bone-support concept.|The patient will be provided by a complete removable denture designed according to bone-support concept to restore his missing teeth which will be manufactured by CAD/CAM milling of monolithic methacrylate blanks.
89414620|NCT05895292|Active Comparator|CAD/CAM Milled Methacrylate Complete Removable Dentures based on neutral zone concept.|The patient will be provided with a complete removable denture designed according to the neutral-concept to restore his missing teeth, which will be manufactured by CAD/CAM milling of monolithic methacrylate blanks.
89414621|NCT05888870|Experimental|SCT800 combined with Daratumumab|ITI using low-dose domestic rFVIII (SCT800) (50IU/kg TIW) and treated with Daratumumab 8mg/kg 4-8 times. Other immunosuppressants could be added after 3 months.
89414622|NCT05888870|Active Comparator|SCT800 alone|ITI using low-dose domestic rFVIII (SCT800) (50IU/kg TIW) alone. Other immunosuppressants could be added after 3 months.
89414623|NCT05886400|Experimental|Distracted|Visual and audio distraction via sports video clips or a game will be playing during the testing session.
89414624|NCT05886400|Sham Comparator|Not Distracted|No visual or auditory distractions will be used during testing session. Testing area will be in a controlled environment.
89414625|NCT05885464|Experimental|Fludarabine, cyclophosphamide and alemtuzumab|Lymphodepletion regimen including fludarabine, cyclophosphamide and alemtuzumab
89414626|NCT05885464|Experimental|Fludarabine, cyclophosphamide without alemtuzumab|Lymphodepletion regimen without Alz but consisting of the same dose of Flu/Cy as in the other arm
89414627|NCT05874635|Experimental|Signos digital health app and CGM|For all consented participants, the Signos app will use CGM data to provide recommendations customized to users for promoting general health and wellness.
89414628|NCT05873348|Experimental|FMTgroup|
89414629|NCT05873348|No Intervention|control gtoup|
89414630|NCT05865496|Experimental|611 Dose A|611 300 mg Q2W, subcutaneous (SC) injection.
89414631|NCT05865496|Experimental|611 Dose B|611 450 mg Q4W, subcutaneous (SC) injection.
89414632|NCT05865496|Placebo Comparator|Placebo|Placebo subcutaneous (SC) injection.
89414633|NCT05862571||Mild traumatic brain injury group|Consist of patients who have been diagnosed with mTBI by a doctor at an emergency room or in general practice. The patients must still have symptoms related to their trauma ≥ 2 months and ≤ 24 months after trauma origin. They must not have received any vision therapy from an optometrist in relation to resent mTBI.
89414634|NCT05862571||Non-injured group|The control group will primarily consist of relatives of the individuals with mTBI, preferably a partner or a sibling. The subjects in the control group have to meet the same inclusion and exclusion criteria as the mTBI group, except that they must not be diagnosed with mild traumatic brain injury.
89414635|NCT05860972|Active Comparator|Active group|Active group that will receive 2 treatments with the InMode RF Pro System with the Morpheus8 Applicator (with the 24 pin tip)
89414636|NCT05860972|Sham Comparator|Sham group|Sham group that will receive 2 sham treatments with the same InMode RF Pro System and Morpheus8 Applicator (with a sham 24 pin tip).
89414637|NCT05826990|Experimental|cefepime and enmetazobactam unique study arm|Each study participant will receive a two-hour intravenous administration of cefepime and enmetazobactam every 8 hours, as single drug in fixed dose combination (FDC) formulation at a ratio of 4 to 1.
89414638|NCT05821478|Experimental|Experimental treatment|"a 3-week course of ceftriaxone (Rocephin) IV injection (daily dose 2g/day)~+ oral metronidazole (daily dose 1500mg) followed by a 3-week course of oral rifampicin (Rifadin with 10mg/kg/day) + moxifloxacin (Izilox daily dose 400mg) + metronidazole (daily dose 1500mg) followed by a 6-week course of oral rifampicin (Rifadin with 10mg/kg/day) + moxifloxacin (Izilox daily dose 400mg).~A placebo for lymecycline will also be administered during this intensive treatment phase"
89414639|NCT05821478|Active Comparator|Control|12-week course of oral lymecycline (Tetralysal daily dose 452mg) Placebos for all experimental drugs will also be administered during this intensive treatment phase
89414640|NCT05817786|Experimental|BP PNS (experimental group)|Patients with refractory upper limb neuropathic pain treated by chronic electrical stimulation of the brachial plexus nerve roots
89414641|NCT05817786|Active Comparator|sham stimulation (control group).|Patients with refractory upper limb neuropathic pain treated by sham stimulation
89414642|NCT05800782|Experimental|Memory Training|Participants will perform 6 weeks of face memory training (5 x 40 min sessions/week) that targets enhancing encoding to improve face recollection. As training progresses, the repetition lags (spaces between repeated foil faces) and number of faces will increase.
89414643|NCT05800782|Active Comparator|Perception Training|Participants will perform 6 weeks of face perception training (5 x 40 min sessions/week) that require discriminating faces based on internal features (e.g., eyebrow-eye distance). As training progresses, the faces will become more challenging and the face sizes will vary.
89414644|NCT05800782|Placebo Comparator|Active Control Training|Participants will perform 6 weeks of face perception training (5 x 40 min sessions/week) that require discriminating faces based on external facial features (e.g., hair). As training progresses, the faces will become more challenging and the face sizes will vary.
89414645|NCT05796492|Sham Comparator|LOGIQ E10 Sham|The sham condition will consist of the ultrasound probe placed over the spleen with no energy applied.
89414646|NCT05796492|Active Comparator|LOGIQ E10 ultrasound Active|The intervention condition will receive 10 minutes of splenic ultrasound daily.
89414647|NCT05781399|Experimental|JNT-517 SAD (Part A)|Single dose of JNT-517 or placebo in fasted state.
89414648|NCT05781399|Experimental|JNT-517 MAD (Part B)|JNT-517 or placebo once or twice daily for 14 days, with first daily dose given after an overnight fast.
89414649|NCT05781399|Experimental|JNT-517 Suspension Then Tablet Fasted Then Tablet Fed (Part C)|Single dose of JNT-517 suspension, JNT-517 tablet in a fasted state, and JNT-517 tablet in a fed state in a sequential, open-label manner. Each treatment is separated by a minimum of 5 half-lives.
89414650|NCT05781399|Experimental|JNT-517 Tablet Fasted Then Tablet Fed Then Suspension (Part C)|Single dose of JNT-517 tablet in a fasted state, JNT-517 tablet in a fed state, and JNT-517 suspension in a sequential, open-label manner. Each treatment is separated by a minimum of 5 half-lives.
89414651|NCT05781399|Experimental|JNT-517 Tablet Fed Then Suspension Then Tablet Fasted (Part C)|Single dose of JNT-517 tablet in a fed state, JNT-517 suspension, and JNT-517 tablet in a fasted state in a sequential, open-label manner. Each treatment is separated by a minimum of 5 half-lives.
89414652|NCT05781399|Experimental|JNT-517 PKU (Part D)|JNT-517 or placebo daily for 4 weeks. Dose is based on data from Parts A, B, and C.
89414653|NCT05781009|Active Comparator|patients receiving 300mg PREG|Patients randomly assigned to receive 300mg of pregnenolone (PREG) daily.
89414654|NCT05781009|Placebo Comparator|placebo|Patients randomly assigned to receive a placebo daily.
89414655|NCT05780736||Cohort 1|
89414656|NCT05775380|Active Comparator|Pioglitazone|Research participants will be randomized to receive pioglitazone hydrochloride 45mg/day for 5 days prior to coronary artery bypass surgery.
89414657|NCT05775380|No Intervention|Placebo|Research participants will be randomized to not receive intervention in the days prior to coronary artery bypass graft surgery.
89414658|NCT05759273||Triptorelin 6 Month Formulation|Participants treated with the 6-month triptorelin formulation
89414659|NCT05755568||MLD Participants|Data from medical records of participants diagnosed with late infantile or juvenile MLD at any time from 1 January 2000 to 31 December 2022 will be observed retrospectively.
89414660|NCT05752448|Experimental|Intervention group|Group received care Using POSTCare process
89414661|NCT05752448|No Intervention|Usual Care|Group received usual care
89414662|NCT05751720|Experimental|GLP-1/GIP Arm pre and post intervention|"The adult patients with type 2 diabetes mellitus attending Tawam Hospital Diabetes clinic, who are identified as having fatty liver disease either via ultrasound or biochemical parameter of NFS.~We will aim to include minimum 30 patients fulfilling the selection criteria as below. Informed written consent will be obtained . Intervention group will receive GLP-1 analogues (subcutaneous Tirzepatide or oral semaglutide).~The blood tests will be done at baseline, 3 months of treatment and at 6 months of treatment. Liver imaging (fibroscan and/or MRI fat measurement) will be done at baseline and at 6 months to see if there is any change.The KPa improvement in liver stiffness and total fat estimation pre and post intervention in both groups will assessed"
89414663|NCT05736705|Active Comparator|Monopolar Electrocautery tool|Patients randomized into this group will receive the standard of care monopolar tool for their endoscopic submucosal dissection procedure.
88892391|NCT03652259|Experimental|Cohort 2: SRP-9003|Participants will receive a single IV infusion of SRP-9003. Dose will be determined based on the findings from Cohort 1.
89414664|NCT05736705|Experimental|Bipolar Electrocautery tool|Patients randomized into this group will receive the standard of care bipolar tool for their endoscopic submucosal dissection procedure.
89414665|NCT05727657|Experimental|Satralizumab|Subjects will receive satralizumab 120mg subcutaneous Day 0 and Day 14 after enrollment.
89414666|NCT05725668|Experimental|Dual-task taj ji quan|This intervention includes training of (a) symmetrical postural tai ji quan forms/movements synchronized with breathing, (b) controlled displacement (weight-shifting) of the body's center of mass over the base of support, (c) dynamic eye-hand movements during whole-body motion, (d) multidirectional (anterior-posterior and medial-lateral) stepping, and (e) rotational ankle sway and self-induced reactive postural recovery actions. The training practices are integrated, gradually over time, with a mix of interactive, cognitively stimulating, dual-task exercises that challenge attention control, working memory, verbalization, response inhibition, processing speed, dual tasking, task switching/prioritization, and spatial orientation and postural awareness.
88892392|NCT03649308|Experimental|Negative Pressure Wound Therapy|A negative pressure wound therapy device (PICO) is applied on split-thickness skin graft for 5 to 7 days from surgery in operating theatre. The patient can be mobilized immediately after skin graft procedure.
88892393|NCT03649308|Active Comparator|Conventional treatment|A conventional wound dressing is applied on wound in operating theatre, followed by immobilization for 5 days after split-thickness skin graft procedure.
88892394|NCT03646058|Placebo Comparator|Placebo|2 placebo pills sublingual during 28 days
88892395|NCT03646058|Experimental|0.4mg buprenorphine|1 pill of 0.4 mg buprenorphine + 1 placebo pill per day for 21 days, then 2 placebo pills per day for 1 week, all sublingual.
88892396|NCT03646058|Experimental|0.8mg buprenorphine|1 pill of 0.4 mg buprenorphine + 1 placebo pill per day for 3 days, then 2 pills of 0.4mg buprenorphine per day for 18 days, then 1 pill of 0.4 mg + 1 placebo pill per day for 3 days, then 2 placebo pills per day for 4 days, all sublingual.
89536742|NCT02470013|Experimental|Intervention Group|Nutrition counselling and balanced, energy dense, moderate protein sip feed ('Fortimel Compact, Nutricia GmbH) for 3 months
89536743|NCT02470013|No Intervention|Control Group|Nutrition counselling upon hospital discharge (usual care)
88892397|NCT03641560|Experimental|Enzalutamide group|Participants will receive Enzalutamide once daily in addition to continued androgen deprivation therapy until discontinuation criteria is met
88892398|NCT03628287|Active Comparator|Original Care Coordination Program|Specific intervention components include: 1) outreach for initial case finding and after any missed appointment; 2) case management, including social services and benefits assessments; 3) multidisciplinary care team communication and decision-making via case conferences; 4) patient navigation, including appointment reminders, assistance with scheduling appointments, transportation resources, and accompaniment to primary care visits; 5) antiretroviral treatment adherence support, including directly observed therapy for individuals with greatest need; and 6) structured health promotion, for which clients are assigned to program tracks (determining their frequency of health promotion visits: weekly, monthly or quarterly), depending on their level of assessed need.
88922104|NCT05814133|Experimental|Lithotripsy|Ureteroscopy with lithotripsy using the Thulium Fiber Laser
88922105|NCT05812859|Experimental|Device Use|Patient's will use vaginal orthosis daily from the start of week 2 post-operative to week 12 post-operative.
88892399|NCT03628287|Experimental|Revised Care Coordination Program|"The revised model includes the original intervention components without program track assignments or the three-month induction period of weekly visits. Program additions include a set of tools for assessment and counseling around client HIV self-management capacity; allowance of video chat for delivery of some services; and optional immediate antiretroviral therapy (iART: ensuring the client has a filled prescription within 4 days of enrollment or diagnosis). Other changes include greater guidance on recruiting individuals with unsuppressed VL and a switch from per-member-per-day reimbursement to fee-for-service reimbursement that accounts for resource demands, such as staff travel to clients' homes, and offers higher rates for meeting performance standards."
89414667|NCT05725668|Experimental|Standard tai ji quan|This intervention includes training of tai ji quan forms with synchronized breathing, supplemented by a set of mini-therapeutic exercises. The training involves repeated practice of (a) symmetrical, coordinated, trunk-driven tai ji quan form movements, (b) controlled displacement (weight-shifting) of the body's center of mass over varying sizes of the base of support, (c) dynamic eye-hand movements during whole-body motion, and (d) multidirectional (anterior-posterior and medial-lateral) stepping. As a balance training therapy, movement practices emphasize a dynamic interplay of stabilizing and self-induced destabilizing postural actions and balance exercises that target mobility, stability limits, and sensory integration.
89414668|NCT05725668|Experimental|Stretching exercise|This active control intervention includes light activities that consist of breathing, stretching, and relaxation exercises. Each exercise session encompasses a variety of light and static stretches for joints and muscles, performed in a seated or standing position. Exercise involves the upper body (arms, neck, upper back, shoulder, back, and chest), lower extremities (quadriceps, hamstrings/calfs, and hips), and gentle and slow trunk rotations. Also included are intermittent light walking, deep abdominal breathing exercises that emphasize inhaling and exhaling to maximum capacity, and progressive relaxation of major muscle groups.
89414669|NCT05723653|Experimental|Project nGage Condition|"The Project nGage condition will be delivered by trained Intervention Case Managers to n=300 men (referred to as Index men) and their Support Confidant (SC).~The Project nGage intervention consists of (1) selection and invitation of a SC, (2) a face-to-face intervention between the Intervention Case Manager and the Index and SC, and (3) quarterly interactive mini-booster sessions delivered to the Index and SC via text or telephone, based on participant preference.~At 12 months, Index men in the experimental condition will be re-randomized to either continue receiving quarterly interactive mini-booster sessions or to stop receiving mini-boosters and return to treatment as usual."
89414670|NCT05723653|No Intervention|Treatment as Usual Condition|Treatment as Usual (TAU) is comprehensive and follows Department of Health and Human Services (DHHS) guidelines and local protocols on the provision of HIV primary care, which include scheduling one HIV primary care visit and lab tests (including viral load) once every six months, i.e., two HIV primary care visits per year. In addition, all sites provide standard case management and mental health and psychosocial support services to all patients.
89414671|NCT05719233||Interstitial Lung disease Group|Mini-mental state examination (MMSE) Hamilton Anxiety Rating Scale Hamilton Depression Rating Scale Nerve conduction studies High resolution Chest Computed tomography Pulmonary function Test
89414672|NCT05719233||Control Group|Mini-mental state examination (MMSE) Hamilton Anxiety Rating Scale Hamilton Depression Rating Scale Nerve conduction studies
89414673|NCT05717140|Experimental|Treatment (aerosolized sargramostim, nivolumab)|Patients receive aerosolized sargramostim via inhalation using the Aerogen Solo nebulization device and receive nivolumab IV on study. Patients also undergo collection of blood samples on study and undergo CT or MRI at screening and on study.
89414674|NCT05714059|Experimental|MiniMed™ 780G system with DS5|Subjects with type 1 diabetes wearing the MiniMed™ 780G insulin pump in combination with the DS5 CGM.
89414675|NCT05713955|Active Comparator|study group|For the study group, a unit of autologous BioMatrix OBSiDiAN will be produced. Blood sample (120ml) will be taken after randomization at the ending of the abdominal phase of the surgery. The surgeon will create an esophagogastric anastomosis, after ruling out tension or torsion. Around 1-2ml of autologous BioMatrix OBSiDiAN will be applied on the distal/or proximal resection stump before the stapled anastomose will be created. After firing the standard circular device and creation of a functional anastomosis, a further 2.5-3ml OBSiDiAN must be applied circumferentially on the outside on the anastomosis. Once application is completed, a 30 seconds waiting period is required before putting the esophagus back into the surgical field (study specific). A methylene blue leakage test or other leakage test is performed (standard of care). If there is a leak, the anastomosis will be corrected or the completed procedure has to be done again.
89414676|NCT05713955|No Intervention|standard group|The surgeon will create an esophagogastric anastomosis, after ruling out tension or torsion. A methylene blue leakage test or other leakage test is performed (standard of care). If there is a leak, the anastomosis will be corrected.
89414677|NCT05712889|Experimental|Dose Escalation of VIP236|Investigating VIP236 in a dose escalation cohort in subjects with advanced solid tumor cancer
89414678|NCT05703477|Experimental|FMT Responder|
89414679|NCT05703477|Experimental|FMT non-Responder|
89414680|NCT05702437||MetS Group|it consists of volunteer participants diagnosed with MetS between the ages of 18 and 50. All assessments will be applied to the participants by two different researchers at the same time.
89414681|NCT05702437||Control Group|it will consist of healthy individuals aged 18-50 who do not have any health problems and have volunteered to participate in the study who have undergone a health check within the last 6 months.
89414682|NCT05694650||Focus|Participants will be asked about your previous experiences providing cancer care at MD Anderson and your thoughts on providing hospital care at home
88892400|NCT03625791||radiation-induced sarcomas|
88892401|NCT03625791||radiotherapy for at least 5 years and without sarcomas|
88892402|NCT03625791||primary sarcomas|
88892403|NCT03623373|Experimental|Bendamustine/Rituximab/Acalabrutinib/Cytarabine|"Patients will receive (6) 28 day cycles~Cycles 1-3 will consist of bendamustine on Days 1 and 2, rituximab on Day 1, and acalabrutinib twice per day (BID) on Days 1 through 28.~Cycles 4-6 will consist of rituximab on Day 1, cytarabine every 12 hours on Days 1 and 2, acalabrutinib BID on Days 1 through 7 and 22 through 28 (one week on, two weeks off, one week on), and growth factors as per institutional standard~After Cycle 6, patients will undergo leukapheresis"
89005772|NCT00213590|No Intervention|1|the usual-exposure group, the cyclosporine AUC0-12h target was 4.3 (3.5 to 4.8, range) mg•h/L
89414683|NCT05694650||Interview|Participants will be asked about your previous experiences providing cancer care at MD Anderson and your thoughts on providing hospital care at home
89414684|NCT05689840||0-1 week group|Patients who have been infected with Covid-19 with 0-1 week post-COVID interval before surgery.
89414685|NCT05689840||1-2 weeks group|Patients who have been infected with Covid-19 with 1-2 weeks post-COVID interval before surgery.
89414686|NCT05689840||2-3 weeks group|Patients who have been infected with Covid-19 with 2-3 weeks post-COVID interval before surgery.
89414687|NCT05689840||3-4 weeks group|Patients who have been infected with Covid-19 with 3-4 weeks post-COVID interval before surgery.
89414688|NCT05689840||4-5 weeks group|Patients who have been infected with Covid-19 with 4-5 weeks post-COVID interval before surgery.
89414689|NCT05689840||5-6 weeks group|Patients who have been infected with Covid-19 with 5-6 weeks post-COVID interval before surgery.
89414690|NCT05689840||over 6 weeks group|Patients who have been infected with Covid-19 with over 6 weeks post-COVID interval before surgery.
89414691|NCT05689736|Experimental|Motivational Enhancements + Simplification + Gamification + Low Engagement Nudge|Participants will receive the Core Essentials for Parenting (EFP) intervention and all additional engagement-focused intervention elements: motivational enhancements, simplification, gamification, and low engagement nudges.
89414692|NCT05689736|Experimental|Motivational Enhancements + Simplification + Gamification|Participants will receive the Core EFP intervention and motivational enhancement, simplification, and gamification intervention elements.
89414693|NCT05689736|Experimental|Motivational Enhancements + Simplification + Low Engagement Nudge|Participants will receive the Core EFP intervention and motivational enhancement, simplification, and low engagement nudges as intervention elements.
89414694|NCT05689736|Experimental|Motivational Enhancements + Simplification|Participants will receive the Core EFP intervention and motivational enhancement and simplification as intervention elements.
89414695|NCT05689736|Experimental|Motivational Enhancements + Gamification + Low Engagement Nudge|Participants will receive the Core EFP intervention and motivational enhancement, gamification, and low engagement nudge as intervention elements.
88892404|NCT03601923|Experimental|Niraparib|"Niraparib will be administered orally once daily~Palliative radiation therapy to a small field >1 week prior to Day 1 of study treatment"
88892405|NCT03586258|Experimental|Brain Damaged Subjects|Patients with circumscribed brain injury, developmental pathology or degenerative pathology responsible for selective cognitive disorders
88892406|NCT03586258|Sham Comparator|Healthy Volunteers|Healthy Controls
88892407|NCT03556488||Pediatric CAP|Patients with a clinical diagnosis of CAP and radiographic evidence of lung consolidation, hospitalized in the Pediatric Unit.
88892408|NCT03542682|Active Comparator|Individuals given Standard Bolus first, then quick bolus|Individuals with Type 1 Diabetes (T1D) will receive both Standard and Quick Bolus in a randomized cross-over design.
89414696|NCT05689736|Experimental|Motivational Enhancements + Gamification|Participants will receive the Core EFP intervention and motivational enhancement and gamification as intervention elements.
89414697|NCT05689736|Experimental|Motivational Enhancements + Low Engagement Nudge|Participants will receive the Core EFP intervention and motivational enhancement and low engagement nudge as intervention elements.
89414698|NCT05689736|Experimental|Motivational Enhancements|Participants will receive the Core EFP intervention and motivational enhancement as an additional intervention element.
88892409|NCT03542682|Active Comparator|Individuals given Quick bolus first, then standard bolus|Individuals with Type 1 Diabetes (T1D) will receive both Standard and Quick Bolus in a randomized cross-over design.
89414699|NCT05689736|Experimental|Simplification + Gamification + Low Engagement Nudge|Participants will receive the Core EFP intervention and simplification, gamification, and low engagement nudge as additional intervention elements.
89414700|NCT05689736|Experimental|Simplification + Gamification|Participants will receive the Core EFP intervention and simplification and gamification as additional intervention elements.
89414701|NCT05689736|Experimental|Simplification + Low Engagement Nudge|Participants will receive the Core EFP intervention and simplification and low engagement nudge as intervention elements.
88892410|NCT03522259|Active Comparator|A: Rivaroxaban short arm|7 day prophylactic postop treatment after Bariatric surgery with 10mg Rivaroxaban p.o.
89414702|NCT05689736|Experimental|Simplification|Participants will receive the Core EFP intervention and simplification as an additional intervention element.
89414703|NCT05689736|Experimental|Gamification + Low Engagement Nudge|Participants will receive the Core EFP intervention and gamification and low engagement nudge as additional intervention elements.
89414704|NCT05689736|Experimental|Gamification|Participants will view the Core EFP and will be exposed only to gamification as an additional intervention element.
89414705|NCT05689736|Experimental|Low Engagement Nudge|Participants will receive the Core EFP intervention and low engagement nudge as an additional intervention element.
89414706|NCT05689736|Experimental|EFP Only|Participants will receive the Core EFP intervention and not be exposed to any additional intervention elements.
89414707|NCT05678673|Experimental|XL092 + Nivolumab|Subjects with advanced or metastatic nccRCC will receive XL092 + nivolumab
89414708|NCT05678673|Active Comparator|Sunitinib Malate|Subjects with advanced or metastatic nccRCC will receive an active comparator of sunitinib
89414709|NCT05675631|Experimental|Experimental Group|This group will perform training using suspension elements.
88892411|NCT03522259|Active Comparator|B: Rivaroxaban long arm|"28 day prophylactic postop treatment after Bariatric surgery with 10mg Rivaroxaban p.o.~Subgroup: PK/PD parameters are assessed following the last intake of Rivaroxaban at day 28"
88892412|NCT03485547|Experimental|Venetoclax|"Venetoclax is administered on a daily basis orally.~The investigators will use a modified 3+3 with a de-escalation dose level design to establish the appropriate and tolerable dose of venetoclax."
88892413|NCT03480386|Experimental|Pulmonary Rehabilitation Program Intervention|Subjects will receive 12 weeks home pulmonary rehabilitation (PR) with health coaching.
89414710|NCT05675631|Active Comparator|Control Group|This group will perform training using weights and elastic bands.
89414711|NCT05668403|Experimental|B007:350mg|"B007:350mg Subcutaneous injection was administered on days 1 and 15~B007 matched Placebo Subcutaneous injection was administered on days 1 and 15"
89414712|NCT05668403|Experimental|B007:700mg|"B007: 700mg Subcutaneous injection was administered on days 1 and 15~B007 matched Placebo Subcutaneous injection was administered on days 1 and 15"
89414713|NCT05668403|Experimental|B007:1000mg|"B007: 1000mg Subcutaneous injection was administered on days 1 and 15~B007 matched Placebo Subcutaneous injection was administered on days 1 and 15"
89414714|NCT05668312|Experimental|TELE-pre group|Subjects in the TELE-prehabilitation group receive remote prehabilitation using advanced technologies.
89414715|NCT05668312|Active Comparator|Control group|"The control group is composed by the Con-O (Control Older) group and the Con-Y (Control Young) group. In the Con-O group (n=24) subjects receive home-based prehabilitation using a printed booklet; in the Con-Y group (n=20) subjects do not receive any prehabilitation program.~Subjects in the Con-Y group will be recruited from patients waiting for anterior cruciate ligament reconstruction, thus they will be only assessed with muscular biopsy and blood sampling."
89414716|NCT05666622|Other|Kahramanmaraş Sütçü İmam University|Only routine non-surgical periodontal treatment was applied to the patients.
89414717|NCT05657106|Experimental|Syringe Service Program Plus a Harm Reduction Kiosk Intervention|The intervention to be implemented in the intervention county involves enhancing its existing SSP model with a KyOSK. The intervention county SSP operates identically to the comparison county. As in the comparison county, a card reader will be installed in the intervention county SSP at the beginning of the study to provide objective data on visits and supply access. The KyOSK will resemble a vending machine. The KyOSK will include harm reduction, wound care, hygiene, and other supplies; offer overdose education and other content; a sharps container with a device to obtain data on syringe disposal; and an innovative call-back feature for care navigation by recovery coaches. While the KyOSK is operating, the intervention county will operate its traditional SSP 40 hours/week.
89414718|NCT05657106|No Intervention|Syringe Service Program|The comparison county SSP operates in the local health department and provides syringes, cookers/cottons, naloxone, wound care kits, condoms and lubricant, snacks, drinks, and sharps containers. A peer support specialist is present for consultation with clients upon request during SSP hours. The SSP will expand it hours from 3 hours/week to 40 hours/week at the same time the intervention county receives its KyOSK, to be comparable. SSP clients who enroll in the study will receive a swipe card linked to their SSP client identification. Card readers will be installed in the SSP for clients to swipe upon entry. Staff will provide clients with the same menu of supplies as those in the KyOSK and the same supply/time interval limits will be imposed. SSP clients will receive a resource guide.
89414719|NCT05650554|Experimental|Group 1: Quadrivalent Influenza mRNA Vaccine MRT5413 low dose|participants will receive a single dose of QIV mRNA vaccine (low dose)
89193042|NCT05697848|Active Comparator|Control group|The patients of the control group will undergo individual physiotherapy ( manual therapy and active exercises ).
89193043|NCT05697601||Suspect of Ovarian Cancer|The participant with high suspicion of ovarian cancer and undergo gynaecology and pathology assessment
89193044|NCT05697601||Suspect of Endometrial Cancer|The participant with high suspicion of Endometrial cancer (and or endometrial hyperplasia) and undergo gynaecology and pathology assessment
89193045|NCT05697601||Normal Cohort|The participant with lower suspicion of both types of cancer and undergo gynaecology and pathology assessment
88892414|NCT03480386|No Intervention|Usual Care|Subjects will receive 12 weeks of usual care.
88892415|NCT03476343|Experimental|MRI for Neonates|MRI
88892416|NCT03475134|Experimental|TIL-ACT +/- Nivolumab rescue|Non-myeloablative lymphodepleting chemotherapy (cyclophosphamide and fludarabine), Tumor Infiltrating Lymphocyte (TIL)-Adoptive Cell Therapy (ACT), Interleukin-2 (IL-2), Nivolumab rescue
88892417|NCT03471338|Experimental|Experimental Group|Patients benefit cognitive rehabilitation
88892418|NCT03471338|Sham Comparator|Standard Psychological care|Patients do not benefit cognitive rehabilitation
88892419|NCT03467191|Experimental|Alcohol Beverage|Moderate dose of alcohol (target BAC .08%)
88892420|NCT03467191|Placebo Comparator|Placebo Beverage|
88892421|NCT03447860|Active Comparator|REACH-VA|A cognitive-behavior based multi-component caregiver intervention to reduce caregiver stress.
88892422|NCT03447860|Experimental|PAACC|A mindfulness-based multi-component caregiver intervention to reduce caregiver stress.
88892423|NCT03412591|Other|Open label trial of suvorexant in individuals with opioid use disorder|It is an open label trial to study the efficacy of suvorexant in a group of patients with opioid use disorder.
88892424|NCT03412591|Other|Open label trial of suvorexant in individuals with alcohol use disorder|It is an open label trial to study the efficacy of suvorexant in a group of patients with alcohol use disorder.
88892425|NCT03400332|Experimental|Part 1A: BMS-986253 + nivolumab|
88892426|NCT03400332|Experimental|Part 1B: BMS-986253 + nivolumab|
88892427|NCT03400332|Experimental|Part 1C: BMS-986253 + nivolumab + ipilimumab|
88892428|NCT03400332|Experimental|Part 2A: BMS-986253 + nivolumab + ipilimumab|
88892429|NCT03400332|Placebo Comparator|Part 2B: Placebo + nivolumab + ipilimumab|
88922106|NCT05812859|No Intervention|Standard of Care|Patient's will proceed with normal standard of care post-operative management which is pelvic rest and light acitvity.
88922107|NCT05804227|Experimental|Cohort 1: NF1-muated low-grade glioma|
89193046|NCT05696938|Active Comparator|Wonderlab Nicotinamide Drink|"25ml/bottle, containing the following ingredients per 25ml serving:~Nicotinamide 0.39 mg~Vitamins C 300 mg~Hyaluronic acid 50 mg~Tomato powder 120 mg"
89193047|NCT05696938|Placebo Comparator|Ordinary Drink|"25ml/bottle, containing the following ingredients per 25ml serving:~Litchi juice 0.7 g~Erythritol 2 g~Pectin 0.25 g"
89193048|NCT05690464|Active Comparator|magnesium|magnesium glycinate supplement, 480 mg/day
89193049|NCT05690464|Placebo Comparator|placebo|placebo supplement
89193050|NCT05690243|Experimental|Group therapy delivered via video telehealth|Nine sessions of 60 min each group therapy delivered via telehealth
89193051|NCT05690243|Other|Group therapy delivered via video telehealth - wait list control|Nine sessions of 60 min each group therapy delivered via telehealth after a waiting period.
89193052|NCT05689307|Experimental|SIVA-MVP|Wearable cough detection device with a corresponding smartphone application and charging device.
89193053|NCT05683171|Experimental|Phase 1 Dose Escalation|The dose escalation phase will assess the safety/tolerability of escalating doses of valemetostat and lenalidomide when combined with rituximab
89414720|NCT05650554|Experimental|Group 2: Quadrivalent Influenza mRNA Vaccine MRT5413 medium dose|participants will receive a single dose of QIV mRNA vaccine (medium dose)
89414721|NCT05650554|Experimental|Group 3: Quadrivalent Influenza mRNA Vaccine MRT5413 high dose|participants will receive a single dose of QIV mRNA vaccine (high dose)
89414722|NCT05650554|Active Comparator|Group 4: RIV4|participants will receive a single dose of RIV4 vaccine
89414723|NCT05650554|Active Comparator|Group 5: QIV-SD|participants will receive a single dose of QIV-SD vaccine
89414724|NCT05650554|Active Comparator|Group 6: QIV-HD|participants will receive a single dose of QIV -HD vaccine (for elderly only)
88892430|NCT03389477|Experimental|Cohort 1: 1: palbociclib, 2: Cisplatin & IMRT, 3: palbociclib|"Step 1: Neoadjuvant palbociclib monotherapy (125 mg/day, Days 1-21 of a 28-day cycle for two cycles)~Step 2: Cisplatin 100 mg/m^2 given on Days 1 and 22 with accelerated IMRT 70 Gy to be administered over 6 weeks~Step 3: Adjuvant palbociclib 125 mg/day, days 1-21 of each 28-day cycle for six cycles. Adjuvant palbociclib will begin 16 to 22 weeks following completion of cisplatin & IMRT"
88892431|NCT03389477|Experimental|Cohort 2: 1: palbociclib, 2: Cetuximab & IMRT, 3: palbociclib|"Step 1: Neoadjuvant palbociclib monotherapy (125 mg/day, Days 1-21 of a 28-day cycle for two cycles)~Step 2: Cetuximab given one week before RT and then weekly with accelerated IMRT 70 Gy to be administered over 6 weeks~Step 3: Adjuvant palbociclib 125 mg/day, days 1-21 of each 28-day cycle for six cycles. Adjuvant palbociclib will begin 16 to 22 weeks following completion of cetuximab & IMRT"
88892432|NCT03375216|Active Comparator|taper|participants undergoing a taper as directed by their pain physician. Interventions include sensory testing ( heat, cold, and pressure) and PROMIS surveys.
88892433|NCT03375216|Placebo Comparator|non taper systemic <90|participants on systemic opioids < 90 MEDD (morphine equivalent daily dose) and no taper
88892434|NCT03375216|Placebo Comparator|non taper systemic >90|participants on systemic opioids > 90 MEDD and no taper
88892435|NCT03375216|Placebo Comparator|non taper intrathecal|Participants on intrathecal therapy and no taper
88892436|NCT03375216|Sham Comparator|non opioids|Participants on non-opioid therapy will undergo behavioral tests and PROMIS surveys
88892437|NCT03372291|Experimental|Psychological app|"Psychological intervention consist of four components~Supportive psychotherapy interventions to help patients deal with the initial shock of diagnosis, cope with the loss of independence and abrupt life disruptions, and provide validation and reassurance;~Psychoeducation to manage expectations and enhance preparedness for extended hospitalization and mobilize social supports;~Psychosocial skill-building to promote effective coping strategies and facilitate acceptance while living with uncertainty;~Self-care to promote positive health behaviors and enhance patients' sense of control especially as they transition from the hospital to outpatient care.~The psychological intervention will consist of four sessions (20-25 minutes each) that patients will start during their first week of admission for intensive chemotherapy and continue weekly"
88892438|NCT03372291|Active Comparator|Usual Care|"Participants receiving usual care will not have access to the psychological intervention app. -They will receive usual leukemia care with all the supportive care measures instituted by the leukemia team.~Patients in usual care will also meet with the leukemia social worker based on their request or at the discretion of the treating leukemia team"
88892439|NCT03353584|No Intervention|Standard Care|Participants receive standard care treatment for their vaso-occlusive crisis. Participants will be randomized by age.
88892440|NCT03353584|Active Comparator|Virtual Reality|Participants receive standard care treatment for their vaso-occlusive crisis. In addition, they will have a 15-minute Virtual Reality Therapy session. Participants will be randomized by age.
88892441|NCT03328663|Experimental|CARE intervention|"Six psychological intervention sessions in-person or via video conferencing conducted by a trained psychologist~The CARE intervention contain 3 component~a psychoeducational component to address preparednessmanage expectations, and develop caregiving skills~a psychosocial component focusing on coping strategies, mindfulness, and facilitating acceptance while living with uncertainty~a self-care component to promote caregiver health and well-being"
88892442|NCT03328663|Active Comparator|Standard transplant care|"Standard Transplant Care~Social work consults to help caregivers only upon request"
88922108|NCT05804227|Experimental|Cohort 2: CIC-mutated oligodendroglioma|
89005773|NCT00213590|Experimental|2|the low-exposure group the cyclosporine AUC0-12h target was 50% usual target or 2.2 (2.0 to 2.6, range) mg•h/L
89193054|NCT05675579|Experimental|Sacituzumab Govitecan and Pembrolizumab|"Participants will receive drug on Days 1 and 8 of Cycles 1-4, Participants will receive sacituzumab govitecan by vein.~Participants will receive drug on Days 1, 8, and 15 of each cycle, Participants will receive pembrolizumab by vein."
89193055|NCT05648890||Group 1|Patients above 65 years old undergoing surgery in general or regional anesthesia.
89193056|NCT05646719|Experimental|Nyxol + low dose pilocarpine|
89414725|NCT05650437|Active Comparator|Ultraviolet therapy group|35 women will undergo three weekly sessions of UV therapy in addition to routine aerobic activity and vitamin D supplements (800 IU) daily for three months
89414726|NCT05650437|Active Comparator|Non Ultraviolet therapy group|35 women will undergo three weekly sessions of routine aerobic activity and vitamin D supplements (800 IU) daily for three months
89414727|NCT05644808||Non-small Cell Lung Cancer|
89535863|NCT04999293||The Elderly Undergoing Percutaneous Coronary Intervention|Patients were survivors and treated with DAPT (aspirin [100 mg once daily], cilostazol, or indobufen)combined with a P2Y12 receptor antagonist [clopidogrel (75 mg once daily) or ticagrelor (90 mg twice daily)]) at the time of hospital discharge.All patients were followed for 1 year in the outpatient clinic after hospital discharge.
88892443|NCT03328455|Experimental|Inhibitory control training|"In the inhibitory control training condition, participants will be trained with tasks that involve both response withholding and rule switching. For example, participants will sort polygons based on features (e.g., shape or color) and will be asked to either provide or withhold sorting responses when presented with different cues. Rule-switching is introduced when participants must inhibit the rule used in the previous trial set and change the focus of their attention to a new sorting and/or inhibitory rule. Task difficulty will progressively increase over the course of training based on participants' abilities."
88892444|NCT03328455|Sham Comparator|knowledge-based training|The knowledge-based training condition serves as the control, in which participants will be presented with questions from different categories such as vocabulary, science, or geography and asked to select the correct answer from 4 alternatives within a certain time limit. Task difficulty will progressively increase over the course of training based on participants' abilities.
88892445|NCT03317964||Saliva - cardiomyopathy|Saliva sample for genetic testing from subjects who developed cardiomyopathy
89193057|NCT05646719|Experimental|Nyxol + low dose pilocarpine vehicle|
89193058|NCT05646719|Experimental|Placebo + low dose pilocarpine|
88892446|NCT03317964||Saliva - no cardiomyopathy|Saliva sample for genetic testing from subjects who do not have cariomyopathy
88892447|NCT03316053||Tissue Sample for genetic testing|Biopsy sample
88892448|NCT03310957|Experimental|LV + pembrolizumab|LV + pembrolizumab
88892449|NCT03296371||Ancillary-Correlative (biospecimen collection)|Patients and their parents undergo collection of saliva or buccal mucosa samples for genetic mutational analysis. Germline DNA from saliva or buccal mucosa is evaluated via whole exome sequencing.
88892450|NCT03289039|Experimental|Neratinib|"Neratinib will be administered orally once daily~Neratinib is dosed at 240mg (six 40mg tablets)"
88892451|NCT03289039|Experimental|Neratinib + Fulvestrant|"Neratinib will be administered orally once daily~Neratinib is dosed at 240mg (six 40mg tablets)~Fulvestrant will be administered intramuscular as an injection (shot) on day 1 and 15 of cycle 1, day 1 of cycle 2, and then on day 1 of each subsequent cycle.~Fulvestrant is dosed as 250 mg/5mL (x2) for a total of 500 mg via intramuscular injection (two injections)."
88892452|NCT03275402|Experimental|131I-omburtamab|One treatment cycle of 131I-omburtamab consists of one dosimetry dose (2 mCi ) (for subjects enrolled on Version 1-7 of Protocol 101) and one treatment dose (50 mCi) for up to 2 cycles of length 5 weeks (for subjects enrolled on Version 1-7 of Protocol 101) or 4 weeks (for subject enrolled after Version 7 of Protocol 101). For Japan only, the first cycle consisted of one dosimetry dose (2 mCi ) week 1 one treatment dose (50 mCi) week 2. If eligible a second cycle of 50 mCi 131I-omburtamab was given at week 6. For subjects below 3 and 1 years of age, the treatment dose was reduced by 33% and 50%, respectively.
88892453|NCT03269474||Experimental Group|Blood and tissue specimen will be collected from subjects with an EB diagnosis. Tissue specimen will be collected from blistered and nonblistered skin.
88892454|NCT03269474||Control Group|Blood and tissue specimen will be collected from healthy subjects with non-EB. Tissue specimen will be collected from an inconspicuous skin area.
88892455|NCT03239899|Experimental|HIV Participants|Participants who received 200 mg of Pembrolizumab administered as a one-time intravenous infusion over 30 minutes during the treatment phase of the study.
88892456|NCT03222895||TIGER study cohort|This is the entire patient cohort. Alle patients with resectable esophageal cancer undergoing a transthoracic esophagectomy with at least a 2-field lymphadenectomy
88892457|NCT03195166|Experimental|hemodynamic profile|FloTrac sensor/Vigileo
89193059|NCT05646719|Experimental|Placebo + low dose pilocarpine vehicle|
88892458|NCT03172715|Active Comparator|ORIF (open reduction-internal fixation)|"Osteosynthesis with locking plate(s) will be performed using medial and/or lateral incision, according to morphology of the fracture. Additional osteosynthesis material will be used when necessary. The articular surface will be reduced and bone transplantation or bone substitute used if required.~Postoperatively, touch-down weight bearing will be allowed for 6 weeks, followed by 2 weeks of half-weight-bearing period. A walker or wheelchair will be used when necessary."
88892459|NCT03172715|Experimental|TKR (total knee replacement)|Arthroplasty of the knee will be performed within two weeks after the fracture. Medial parapatellar approach will be used. The minimal possible constraint of the prosthesis (cruciate retaining, posterior cruciate sacrificing or semi-constrained) will be used. A possible insufficient bone stock may be rebuilt with augments. Hinged prosthesis will be used only if stability of the medial collateral ligament is insufficient. A cemented or uncemented tibial stem extender (minimum length 50mm) will be used in all cases. Additional osteosynthesis will be used when necessary. Postoperatively, the patients will be allowed full weight bearing as tolerated.
88892460|NCT03138512|Experimental|Part A, Arm A: nivolumab + ipilimumab|
88892461|NCT03138512|Placebo Comparator|Part A, Arm B: nivolumab placebo + ipilimumab placebo|
88892462|NCT03138512|Experimental|Part B, Arm A: nivolumab + ipilimumab|
89005774|NCT00213629|Other|no arm|no arm
89193060|NCT05644522|Experimental|Group A|Group A receives the intervention Nomad KAFO first; fitting & training will occur with the intervention and will then be used for a 3 month home trial, followed by outcomes testing. Group A then will cross over and train with their own Traditional Assistive Device and will then use their own device for a 3 month home trial, followed by outcomes testing.
89414728|NCT05644418|Experimental|Postcardiac surgery ICU-patients|After postcardiac surgery patients are brought to the ICU and are ventilated on PCV (Pressure Controlled Ventilation). Measurements of the lung volume (by Electrical Impedance Tomography; EIT), the minute volume and Mechanical Power/Dissipated energy are started and continued for the duration of the study. After a few minutes the patient is switched to FCV (Flow Controlled Ventilation) for 90 minutes and afterwards PCV is resumed with the measurements lasting for another 30 minutes (total study time 120 minutes).
89414729|NCT05635227|Experimental|Dexamethasone|The dexamethasone kit will contain 20 mg of dexamethasonphosfat (Dexavit®,Vital Pharma Nordic), 4mg/mL, i.e. 5 mL, which corresponds to 16.67 mg of dexamethasone. Dexamethasone will be administered as an intravenous bolus infusion over 2 minutes after induction of anaesthesia.
89414730|NCT05635227|Placebo Comparator|Placebo (for Dexamethasone)|The placebo kit will contain 5 mL of isotonic (0.9%) normal saline. Placebo will be administered as an intravenous bolus infusion over 2 minutes after induction of anaesthesia.
89414731|NCT05635227|Experimental|Olanzapine|The olanzapine kit will consist of two capsules each containing two 2.5 mg tablets of olanzapine (Olanzapine Stada®, STADA Nordic); i.e. total dose 10mg. The capsules will be delivered to the patient with instruction to take the capsule orally along with other standardized pre-procedure medicine. Patient intake will be recorded.
89414732|NCT05635227|Placebo Comparator|Placebo (for Olanzapine)|The placebo kit will consist of two placebo capsules identical to the capsules containing the olanzapine tablet. The capsules will be delivered to the patient with instruction to take the capsule orally along with other standardized pre-procedure medicine. Patient intake will be recorded.
89530537|NCT03246763|Experimental|Durham County|"The intervention will include nutrition and fitness programming at a community center. The program will be open at least two sessions per week, each session lasting at least 1 hour. The program coordinator will run the programming, which will consist of comprehensive wellness activities. Each session will include at least 60 minutes of exercise and/or active play, and each session will have an additional special theme. For example, one session might include a cardio focused class, and one session might include a yoga class. The number and which sessions the participants attend each week is voluntary; clinic staff will recommend participation in as many sessions per week as possible. Participation is voluntary, and patients may opt-out at any time. Participants will be told that they can indicate to their provider or the program coordinator at any time either by phone or during the clinic appointment that they wish to opt-out of the study and its assessments."
88892463|NCT03138512|Placebo Comparator|Part B, Arm B: nivolumab placebo + ipilimumab placebo|
88892464|NCT03138512|Experimental|Part B, Arm C: nivolumab + ipilimumab placebo|
88892465|NCT03137888|Experimental|sMRI-Guided RT with TMZ|Patients undergo spectroscopic magnetic resonance imaging-guided dose-escalated radiation therapy daily for the first 5 days of every week (Monday - Friday) over 6 weeks. Patients also receive standard of care temozolomide PO daily during radiation therapy for up to 42 days.
88892466|NCT03114306|Experimental|local infiltration analgesia|Patient receive an infiltration of local anaesthetics around the knee to achieve maximal distal block of nerve fibres. Infiltration is performed directly after knee replacement and during weaning of general anaesthesia.
88892467|NCT03114306|Active Comparator|Regional anaesthesia|Patients receive a combined anaesthesia with a regional-anaesthesiological catheter placed close to the distal Nervus saphenus and a single shot anaesthesia of Nervus ischiadicus using local anaesthetics (regional-anaesthesiological catheter analgesia).
88892468|NCT03101319|Experimental|Antipsychotic and Vitamin D3|Subjects randomised to vitamin D3 arm will receive a tablet containing 60,000 IU vitamin D3 starting from the first day of visit and then be taken by mouth on fixed days every week amounting to a total duration of 08 weeks. The subjects will continue to receive antipsychotics as per the decision of the treating team
88892469|NCT03101319|Placebo Comparator|Antipsychotic and B Complex|Subjects randomised to the B Complex arm will receive a tablet of identical size, shape, colour and weight starting from the first day of visit and then be taken by mouth on fixed days every week amounting to a total duration of 08 weeks. The subjects will continue to receive antipsychotics as per the decision of the treating team
88892470|NCT03085524||Surgical Bypass|Subjects in the BEST-CLI trial assigned to surgical revascularization.
88892471|NCT03085524||Endovascular|Subjects in the BEST-CLI trial assigned to endovascular revascularization.
88892472|NCT03076788||Athletes|"Professional and amateur athletes examined during the medical follow-up at the medical sport centre of Caen University Hospital.~The medical examination consists in a clinical exam, an electrocardiogram and an echocardiography."
88892473|NCT03076788||Sedentary controls|"Sedentary patients assessed in the cardiology unit with a normal heart function.~The medical examination consists in a clinical exam, an electrocardiogram and an echocardiography."
88892474|NCT03057106|Active Comparator|Durvalumab and Tremelimumab|Durvalumab q4 weeks until PD + Tremelimumab q 4 wk x 4 doses
88892475|NCT03057106|Active Comparator|Platinum based chemotherapy + Durvalumab + Tremelimumab|"4 cycles platinum plus gem or pem + Durva + Treme (q 3 wk x 4 cycles)~Followed by:~Squamous Cell: Maintenance Durva q 4 wk until PD Non-Squamous Cell: Pemetrexed + Durva q 4 wk until PD"
88892476|NCT03017794||Gleason score 6 or less|Prostate adenocarcinoma with Gleason score 6 or less
89530755|NCT02511041|Experimental|1|This is a prospective exploratory study of nucleoside and monosaccharide supplement-ation and its effect on immunologic parameters in patients with evidence of altered glycosylation and immunologic abnormalities. Up to 50 subjects will receive escalating doses of oralmonosaccharide until a maximum tolerated dose is found and maintained for 6 weeks. Then nucleosidesupplementation will be added and the maximum tolerated dose will continue for 12 weeks. Parameters of interest will be assessed at NIH every 8 weeks. Themaximum participation time for each subject is 252 days. We will begin with PGM3 deficient patients, who will self-administer oral GlcNAc followed by dual supplementation with GlcNAc and Uridine. The remaining subjects will then receive these supplements following the same step-wise approach.
89530756|NCT03233035|Placebo Comparator|placebo group|Intranasal placebo pulverisation
89530757|NCT03233035|Active Comparator|Ketamine group|Intranasal ketamine pulverisation
89193061|NCT05644522|Active Comparator|Group B|Group B receives training in their own Traditional Assistive Device first; training will occur with their own Traditional Assistive Device and will then use their own device for a 3 month home trial, followed by outcomes testing. Group B then will cross over and receive the intervention Nomad KAFO; fitting & training will occur with the intervention and will then be used for a 3 month home trial, followed by outcomes testing.
89193062|NCT05641922|Experimental|BioTrace|Use of the BioTraceIO 360 device for planning, monitoring and assessment of liver tissue ablations
88892477|NCT03017794||Gleason score 7|Prostate adenocarcinoma with Gleason score 7
88892478|NCT03017794||Gleason score 8 -10|Prostate adenocarcinoma with Gleason score 8 -10
88892479|NCT02995330|Experimental|Bone marrow transplantation|"Bone marrow transplantation followed by Cytoxan and testosterone~Day -6 to -1: Subjects will be treated with a standard non-myeloablative conditioning regimen~Day 0: subjects will be infused with non-T-cell depleted bone marrow from a related female donor.~Subjects will receive GVHD prophylaxis consisting of:~Day +3 and +4: Cytoxan (Cy) 50mg/kg IV Day +5 through Day +180: tacrolimus (IV or PO) beginning [dose adjusted to maintain trough level of 5-15 ng/mL] Day +5 through Day +35: Mycophenolate mofetil (MMF) 15 mg/kg PO TID, with a maximum dose of 1g TID.~Day +5: filgrastim (G-CSF) 5 mcg/kg/day, continued until ANC ≥ 1500/mm3.~Day +60, +90, and +120: testosterone cypionate 400 mg IM every 30 days x 3 doses~Subjects will be maintained on continuous LHRH agonist/antagonist therapy (if not previously surgically castrated). Subjects who achieve biochemical CR will stop LHRH agonist/antagonist treatmentat day 180."
88892480|NCT02984566|Experimental|SABR with or without KIM|All patients will receive liver SABR. Kilovoltage Intrafraction Monitoring (KIM) tracking will be trialed during mock treatment. If KIM is successful, it will be used throughout treatment. If unsuccessful, cone beam CT will be used instead.
88892481|NCT02975869|Active Comparator|Standard Leukemia Care|Standard Leukemia care
88892482|NCT02975869|Experimental|Collaborative Palliative and Oncology Care|Collaborative care from Palliative Care and Leukemia will be given
88892483|NCT02935361|Experimental|Treatment (guadecitabine, atezolizumab)|Patients receive guadecitabine SC on days 1-5 and atezolizumab IV over 30-60 minutes on days 8 and 22. Courses repeat every 28 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
88892484|NCT02871726|Experimental|TRUS-Robot and TRUS|TRUS and TRUS-Robot will be used during prostate biopsy
88892485|NCT02871726|Active Comparator|Routine TRUS/Fusion biopsy|Just Uronav will be used during prostate biopsy
89005775|NCT00240045|Experimental|1|
89414733|NCT05635227|Experimental|Flow-targeted hemodynamic management|In the 'flow group', an arterial oxygen delivery (DO2) above 274 mL/min/m2 BSA AND a central venous oxygen saturation (ScvO2) above 70% will be targeted. CPB pump flow will be initiated at a flow rate of 2.4 L/min/m2. If DO2 or ScvO2 are below target, CPB pump flow will be gradually increased until targets are reached up to a maximum CPB pump flow of 3.2 L/min/m2. If DO2 or ScvO2 are below targets despite a maximum CPB pump flow, PaO2 will be gradually increased from an initial target of 15-20 kPa to a maximum of 40 kPa. A haematocrit level equal to or above 21% will be targeted, however, if DO2 or ScvO2 are below target despite a CPB pump flow of 3.2 L/min/m2, the haematocrit target level will be increased to equal to or above 25%. A MAP down to 35 mmHg will be tolerated throughout. The MAP target will be achieved by administration of boluses of phenylephrine up to a total of 2.0 mg, which can be followed by a continuous infusion of norepinephrine up to 0.6 μg per kg per min.
89414734|NCT05635227|Active Comparator|Pressure-targeted hemodynamic management|In the 'pressure group' a MAP between 70 to 80 mmHg will be targeted. The assigned MAP target will be achieved by administration of boluses of phenylephrine up to a total of 2.0 mg, which can be followed by a continuous infusion of norepinephrine up to 0.6 μg per kg per min. CPB pump flow will be fixed at a flow rate of 2.4 L per minute per square meter body surface area. A haematocrit level equal to or above 21% will be targeted throughout. A PaO2 of 15-20 kPa will be targeted throughout.
89414735|NCT05635227|Experimental|Low tidal-volume ventilation|"During initiation of CPB, the 'ventilation' group will receive a tidal volume at 3ml/kg and a set PEEP of 3 cm H2O. The respiratory frequency (RF) will be set at 10, and the inspiratory: expiratory (I:E) ratio will be set to 5:1. Peak pressures (Pmax) will be limited to < 25 cm H2O. FiO2 will be set at 50%. The ventilation strategy will be maintained during CPB.~Any recruitment manoeuvres will be initiated solely at the discretion of the attending anaesthesiologist, and only if the patient's oxygen saturation drops below 88%. All recruitment manoeuvres will be completed by increasing the inspiratory pressure to 20 cmH2O for 10 seconds. The manoeuvre will be repeated three times."
89414736|NCT05635227|Active Comparator|No ventilation|"The 'no-ventilation' group will receive no ventilation or PEEP. The ventilation strategy will be maintained during CPB.~Any recruitment manoeuvres will be initiated solely at the discretion of the attending anaesthesiologist, and only if the patient's oxygen saturation drops below 88%. All recruitment manoeuvres will be completed by increasing the inspiratory pressure to 20 cmH2O for 10 seconds. The manoeuvre will be repeated three times."
89414737|NCT05625867|Experimental|Post-resuscitation interdisciplinary consultation at 4/5 months after discharge from the ICU|
89414738|NCT05625867|Active Comparator|Patient managed under standard practice conditions|
89414739|NCT05625191||Control Group- Without Phonotrauma|Videoendoscopy and acoustic recordings using a head-mounted microphone with a voice-specialized SLP for participants without voice disorders, acoustic recordings will involve the five repetitions of three vowels (/ɑ, i, u/) and a standard reading passage (Rainbow Passage) in three voice conditions (breathy, typical, and pressed). For all participants, high-speed videoendoscopy and simultaneous acoustic recording will occur on one repetition of a sustained /i/ in each requested condition.
89414740|NCT05625191||Patients Diagnosed with Phonotrauma|"Videoendoscopy and acoustic recordings using a head-mounted microphone with a voice-specialized SLP for Participants who have a diagnosis of phonotrauma will be instructed to produce five repetitions of the same three vowels but in only two conditions: typical voice and resonant voice following stimulability assessment and with cues. They will be instructed to maintain relatively consistent volume and pitch across conditions. For all participants, high-speed videoendoscopy and simultaneous acoustic recording will occur on one repetition of a sustained /i/ in each requested condition."
89414741|NCT05624879|Experimental|Accelerated Resolution Therapy Group|Primary caregivers of an immediate family member enrolled in a hospice or palliative care program will receive 4 weekly sessions of accelerated resolution therapy (ART)
89414742|NCT05624879|Active Comparator|Information and Support Group|Primary caregivers of an immediate family member enrolled in a hospice or palliative care program will receive four-time and attention matched sessions of a standardized social work intervention consisting of information and provision of emotional support.
89535864|NCT03316001||cases|patients with a CT scan from January to August 2008 for which mesenteric panniculitis was diagnosed
88892486|NCT02864953|Experimental|BIIB093|BIIB093 administered as a bolus followed by continuous intravenous (IV) infusion over 72 hours.
88892487|NCT02864953|Placebo Comparator|Placebo|Placebo administered as a bolus followed by continuous intravenous (IV) infusion over 72 hours.
88892488|NCT02829918|Experimental|Nivolumab Treatment|This is a single arm study with two stage design using nivolumab in advanced biliary tract cancer (BTC), for participants who have failed or are intolerant to at least one line of therapy and no more than 2 lines of therapy. In the first stage, 18 participants will be accrued. If there is at least one response (or several participants with stable disease based on the study team's discretion), an additional 34 patients will be accrued for a total of 52 patients.
88892489|NCT02791204||Participants with PAD|Subjects will undergo resting perfusion imaging of the feet using two separate SPECT/CT systems. Subjects will be injected with a low dose radioisotope. Heated venous blood sampling will be obtained.
88892490|NCT02791204||Controls|Subjects will undergo resting perfusion imaging of the feet using two separate SPECT/CT systems. Subjects will be injected with a low dose radioisotope. In addition to heated venous blood sampling, arterial blood will be continuously sampled from the radial artery for calculation of a blood input function and K1 values for foot angiosomes.
88892491|NCT02768597|Active Comparator|Large-Diameter Glenosphere +2 mm offset|Primary Reverse Shoulder Arthroplasty using the ReUnion System with a Large-Diameter Glenosphere +2 mm offset
88892492|NCT02768597|Active Comparator|Small-Diameter Glenosphere +2 mm offset|Primary Reverse Shoulder Arthroplasty using the ReUnion System with a Small-Diameter Glenosphere +2 mm offset
88892493|NCT02768597|Active Comparator|Large-Diameter Glenosphere +6 mm offset|Primary Reverse Shoulder Arthroplasty using the ReUnion System with a Large-Diameter Glenosphere +6 mm offset
88892494|NCT02768597|Active Comparator|Small-Diameter Glenosphere +6 mm offset|Primary Reverse Shoulder Arthroplasty using the ReUnion System with a Small-Diameter Glenosphere +6 mm offset
89414743|NCT05607017|Experimental|Radiation Therapy and Losartan|Participants will receive radiation therapy 5x weekly over 1-6 weeks. Participants will receive Losartan 1x daily during radiation therapy and for up to 6 months afterward then be followed for 1 year
88892495|NCT02730923|Experimental|Arm A: AZD2014 plus anastrozole|
89414744|NCT05582889|Experimental|Experimental: Immediate Fitbit Intervention|Participants randomized to this arm receive the 12-week Fitbit intervention; participants then crossover and are observed (no health coaching) for an additional 12-weeks. The Fitbit intervention includes a Fitbit activity tracker, the free Fitbit smartphone app, and 6 Health Coaching calls.
89414745|NCT05582889|Active Comparator|Comparator: Delayed Fitbit Intervention|Wait-listed; participants maintain their usual physical activity for 12-weeks; participants then crossover and receive the full 12-week Fitbit intervention.
89414746|NCT05578612|Experimental|Bridge Plate Removal at 6-8 Weeks Postoperatively|Participants will undergo dorsal spanning bridge plate fixation per standard technique. Patients in the experimental group will return to the operative room for removal of the bridge plate at Week 6-8. Patients will begin the standardized postoperative rehabilitation protocol immediately following bridge plate removal on Week 6-8.
89414747|NCT05578612|Active Comparator|Bridge Plate Removal at 12-14 Weeks Postoperatively|Participants will undergo dorsal spanning bridge plate fixation per standard technique. Patients in the control group will return to the operating room for removal of the bridge plate at Week 12-14. Patients will begin the standardized postoperative rehabilitation protocol immediately following bridge plate removal on Week 12-14.
89535865|NCT03316001||controls|"patients with a CT scan from January to August 2008 for which mesenteric panniculitis wasn't diagnosed and matched by gender and age with cases patients"
88892496|NCT02730923|Active Comparator|Arm B: anastrozole alone|
88892497|NCT02723396||Parkinson|Prospective observation of a cohort of consecutive patients with idiopathic PD in an ecological setting.
88892498|NCT02723396||Healthy|The same assessments will be performed in a subgroup of age- and sex-matched healthy volunteers.
89414751|NCT05544019|Experimental|Dose Escalation|Up to 11 dose levels will be evaluated. Eligible patients will be assigned to a dose level cohort according to an accelerated titration design that will transition to a traditional 3+3 dose escalation.
88892501|NCT02686606|Experimental|Vital 1.5|200ml orally over 30 minutes
88892502|NCT02686606|Active Comparator|Ensure Plus|200ml orally over 30 minutes
88892503|NCT02630589|Experimental|ABI implantation|All 10 patients included in the study will be neurosurgically implanted with the ABI. This is open label, not blinded. The implant is permanent, but can be switched off.
88892504|NCT02542852|Experimental|Open label single arm|Introduction of treatment regimen with atazanavir 300mg qd + ritonavir 100mg qd + dolutegravir 50mg qd
88892505|NCT02517294|Active Comparator|standard nasotracheal tube|Nasotracheal intubation using 'standard' side-beveled nasotracheal tubes
88892506|NCT02517294|Active Comparator|Parker flex-tip nasotracheal tube|Nasotracheal intubation using 'experimental' flex-tip midline-beveled nasotracheal tubes
88892507|NCT02512965|Active Comparator|Standard Conventional Radiotherapy|Standard Conventional Radiotherapy (CRT) 20 Gy in 5 fractions
88892508|NCT02512965|Experimental|Stereotactic Body Radiotherapy|Stereotactic Body Radiotherapy (SBRT) 24 Gy in 2 fractions
88892509|NCT02509520|No Intervention|Mobility-based Physical Rehab (MPR)|ICU control group receiving only mobility based rehabilitation (MPR).
88892510|NCT02509520|Active Comparator|MPR and Neuromuscular Stimulation and HPRO|ICU group receiving mobility based rehabilitation and NMES and High protein supplementation.
88892511|NCT02508324|Other|Cord Blood Unit|"The CBU unit must supply a minimum of 0.5 x 10^7/kg and a maximum of 2.5 x 10^7/kg nucleated cell dose pre-cryopreservation. The unit must match at a minimum of 4 of 6 at HLA-A, -B antigens, -DRB1 alleles with the recipient. Mismatches (0-2) can be at any loci. Although molecular level typing will be available for the patient and the CBU unit, a match is defined at intermediate resolution for HLA-A and -B and at high resolution for -DRB1. The CBU donor will have also undergone HLA typing of the mother, thus allowing determination of the CBU-IPA and NIMA.~CBU grafts in this study will be investigational units that meet all criteria for clinical use. Better matching units will be preferred over less matching units as long as the CBU dose exceeds 0.5 x 10^7 nucleated blood cells/kg."
88892512|NCT02508324|Other|Haploidentical|"Haploidentical healthy related donor (i.e. parent, child, sibling, possibly third degree or farther removed relative like cousin, aunt, nephew etc.).~Collected using standard methods and approximately 3 x10^6 CD34 cells/kg will be infused within 72 hours after completion of treatment."
88892513|NCT02480803|Active Comparator|continuous levodopa infusion|continuous intrajejunal infusion of levodopa-carbidopa
88892514|NCT02480803|Active Comparator|deep brain stimulation|Bilateral deep brain stimulation (DBS) of the subthalamic nucleus (STN)
88892515|NCT02458014|Experimental|Treatment (blinatumomab)|Patients receive blinatumomab IV continuously on days 1-28. Treatment repeats every 6 weeks for up to 5 courses in the absence of disease progression or unacceptable toxicity. Patients who do not proceed with stem cell transplantation may receive blinatumomab IV maintenance therapy with one cycle every 3 months for up to 4 cycles. Patients who remain in MRD remission for 3 months and then become MRD positive again can be retreated following the same treatment plan previously received.
88892516|NCT02456857|Experimental|Treatment (DAE)|Patients receive pegylated liposomal doxorubicin hydrochloride IV over about 3 hours on day 1, bevacizumab IV over 90 minutes on day 1, and everolimus PO QD on days 1-21. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients will not receive bevacizumab during cycle 4 of therapy. Patients then undergo surgery.
89414752|NCT05544019|Experimental|FE/DDI Cohort|Participants will be dosed in a fed (high-fat, high-calorie meal) and fasted state to determine the effect of food on bioavailability of SGR-1505. Participants will be dosed with and without Posaconazole to determine the effect on the exposure of SGR-1505.
89414753|NCT05529316|Experimental|Part 1 Cohort A: Botensilimab|Participants refractory to PD-(L)1 therapy will receive botensilimab intravenously (IV).
89414754|NCT05529316|Experimental|Part 1 Cohort B: Botensilimab|Participants refractory to PD-(L)1 and anti-CTLA-4 therapies will receive botensilimab IV.
89414755|NCT05529316|Experimental|Part 2 Cohort A: Botensilimab + Balstilimab|Participants refractory to PD-(L)1 will receive botensilimab IV in combination with balstilimab IV.
89414756|NCT05529316|Experimental|Part 2 Cohort B: Botensilimab + Balstilimab|Participants refractory to PD-(L)1 and CTLA-4 will receive botensilimab IV in combination with balstilimab IV.
89414757|NCT05527600||assessment of pain in Pediatric Department|2000 children patients admitted in emmergency department
89414758|NCT05523726|Experimental|Preventative Cognitive Behavioral Therapy for Insomnia|Participants in this group will complete daily sleep diary entries for one week, and then have a telehealth pCBT-I session with a nurse coach, where they will receive personalized sleep recommendations to improve sleep quality.
89414759|NCT05523726|No Intervention|Digital Sleep Education Control|Participants in this group will receive digital sleep education, including tips on how to improve your sleep via interactive email. These materials are selected to help prevent chronic insomnia.
88892517|NCT02446444|Experimental|Enzalutamide|Enzalutamide 160 mg daily, by mouth, for 24 months from randomisation. All participants are treated with a LHRHA for 24 months from randomisation and external beam radiation therapy started approximately 16 weeks after randomisation (+/- brachytherapy boost)
88892518|NCT02446444|Active Comparator|Conventional Non-steroidal Anti-androgen (NSAA)|"Conventional Non-steroidal Anti-androgen (NSAA), by mouth, for 6 months from randomisation.~All participants are treated with a LHRHA for 24 months from randomisation and external beam radiation therapy started approximately 16 weeks after randomisation (+/- brachytherapy boost)"
88892519|NCT02435849|Experimental|Single dose of CTL019|Pediatric patients with relapsed or refractory B-cell ALL who were treated with single dose of tisagenlecleucel (CTL019).
88892520|NCT02197234|Experimental|AZD9291 and simvastatin|Sequential treatments of simvastatin alone followed by AZD9291 alone, followed by simvastatin + AZD9291.
88892521|NCT02177292|Experimental|IMRT & IGRT Radiation Therapy|In this study we will deliver a high dose of radiation to the pelvic lymph nodes of 56 Gy (Gy/Gray = measure of amount of radiation) and at the same time give a boost (additional) radiation to the prostate itself (to 70 Gy).
88892522|NCT02168140|Experimental|Treatment (CPI-613 and bendamustine hydrochloride)|Patients receive 6,8-bis(benzylthio)octanoic acid IV over 2 hours on days 1-4 of week 1 and on days 1 and 4 of weeks 2 and 3. Patients also receive bendamustine hydrochloride IV over 30 minutes on days 4 and 5 of week 1. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
88892523|NCT02157051|Experimental|Arm 1 (STEMVAC)|Patients receive CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope plasmid DNA vaccine with rhuGM-CSF as 1 injection ID every 28 days for 3 months. Patients may also receive 2 additional booster STEMVAC vaccines at 3 and 9 months after the third vaccine in the absence of unacceptable toxicity or disease progression.
88892524|NCT02157051|Experimental|Arm 2 (STEMVAC)|Patients receive CD105/Yb-1/SOX2/CDH3/M2-polyepitope plasmid DNA vaccine with rhuGM-CSF as 2 injections ID every 28 days for 3 months. Patients may also receive 2 additional booster STEMVAC vaccines at 3 and 9 months after the third vaccine in the absence of unacceptable toxicity or disease progression.
88892525|NCT02157051|Experimental|Arm 3 (STEMVAC)|Patients receive CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope plasmid DNA vaccine with rhuGM-CSF as 3 injections ID every 28 days for 3 months. Patients may also receive 2 additional booster STEMVAC vaccines at 3 and 9 months after the third vaccine in the absence of unacceptable toxicity or disease progression.
88892526|NCT02157051|Experimental|Arm 4 (STEMVAC)|Patients receive CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope plasmid DNA vaccine with rhuGM-CSF as 2 injections ID every 28 days for 3 months. Patients may also receive 1 additional STEMVAC vaccine at 3 months after the third vaccine in the absence of unacceptable toxicity or disease progression.
88892527|NCT02152631|Experimental|Abemaciclib|200 milligrams (mg) abemaciclib administered, orally, every 12 hours plus best supportive care (BSC) on Days 1 to 28 (28 day cycles).
88892528|NCT02152631|Active Comparator|Erlotinib|150 mg erlotinib administered, orally, every 24 hours plus BSC on Days 1 to 28 (28 day cycles).
88892529|NCT02128802|Experimental|Surgical Gastric Bypass|Patients will undergo surgical gastric bypass according to standard institutional protocols
89414760|NCT05509166|Experimental|LGBTQ-affirmative Cognitive Behavioral Therapy|Individuals assigned to LGBTQ-affirmative cognitive behavioral therapy will receive 10 weekly individually-delivered sessions, directly after baseline assessment, delivered via telehealth. Based on the Unified Protocol, sessions will address minority stress mechanisms underlying sexual minority women's depression, anxiety, and alcohol abuse.
89414761|NCT05509166|Active Comparator|LGBTQ-affirmative Treatment-as-Usual|Individuals assigned to LGBTQ-affirmative Treatment-as-Usual will receive 10 weekly sessions from a therapist at the Institute for Human Identity who will provide their LGBTQ-affirmative therapy services via telehealth.
89414762|NCT05503875|Experimental|treatment|Patients will be treated with adalimumab, secukinumab, ixekizumab, guselkumab, Jak inhibitors or methotrexate.
89414763|NCT05493215|Experimental|Imatinib TDM|Patients with diagnosed gastrointestinal stromal tumor (GIST) who are currently being treated with imatinib.
89414764|NCT05492682|Experimental|open label non-randomized|All patients will follow the same treatment schedule.
89414765|NCT05490329|No Intervention|Standard of Care (Control)|Research staff will provide COVID vaccine materials from the Centers for Disease Control (CDC) to those participants in the Standard of Care (SOC) arm.
89414766|NCT05490329|Experimental|TT-C Intervention|Research staff will provide access to the TT-COVID app for one-month, which will provide knowledge about the COVID-19 vaccine, address mis-information, and include multi-media digital stories from study participant's peers.
89535866|NCT02451241|Sham Comparator|sham acupuncture|group will be submitted to placebo electroacupuncture for 20 minutes, two times a week for 5 weeks. Each session lasts about 40 min.
89535867|NCT02451241|Experimental|acupuncture|group will be submitted to electroacupuncture for 20 minutes, two times a week for 5 weeks. Each session lasts about 40 min.
88892530|NCT02128802|Experimental|Medical Weight Loss Management|Patients will receive best practices medical management for weight loss under current institutional protocols
88892531|NCT02114229|Experimental|(A) Alisertib alone|"Stratum A: Patients with recurrent/progressive AT/RT or extra-CNS malignant rhabdoid tumors (MRT).~Interventions: alisertib, 35 cycles of 3 weeks each (up to 105 weeks). Surgical resection, if indicated."
88892532|NCT02114229|Experimental|(B) Alisertib, chemotherapy, radiation therapy|"Stratum B: Children < 36 months old with newly diagnosed AT/RT. AT/RT those with synchronous extraneural AT/RT (Stratum D1) may also be treated on this arm.~Interventions:~B1 or D1: Induction chemotherapy using methotrexate, vincristine, cisplatin (or carboplatin), cyclophosphamide; followed by focal radiation therapy; followed by induction therapy using alisertib, vincristine, cisplatin (or carboplatin), cyclophosphamide; followed by maintenance alisertib. Those <12 months who are not ready for focal radiation therapy will receive consolidation chemotherapy using alisertib, cyclophosphamide, carboplatin and etoposide while RT is delayed. Surgical resection, if indicated.~B2, B3, D2 or D3: Induction chemotherapy using alisertib, vincristine, cisplatin (or carboplatin), cyclophosphamide; followed by consolidation with topotecan and cyclophosphamide or optional craniospinal irradiation; followed by maintenance alisertib. Surgical resection, if indicated."
88892533|NCT02114229|Experimental|(C) Alisertib, chemotherapy, radiation therapy|"Stratum C: Children ≥36 months old with newly diagnosed AT/RT.~Participants with synchronous extraneural AT/RT (Stratum D4) will also be treated as those assigned to Stratum C.~Interventions: Craniospinal radiation therapy; followed by consolidation chemotherapy using alisertib, vincristine, cisplatin (or carboplatin), cyclophosphamide; followed by maintenance alisertib, surgical resection, if indicated."
88892534|NCT02111681|Experimental|Calypso-based Deep Inspiration Breath Hold (DIBH)|"This trial will investigate the feasibility of implanted anchored Beacon ® electromagnetic lung transponders (Calypso ®) to guide and monitor deep-inspiration breathhold (DIBH) treatments in patients with inoperable thoracic malignancies.~Bronchoscopic Calypso Beacon Implantation, Simulation - Free-breathing scan - 4D CT scan,- DIBH CT scan Radiation - Treatment setup, - Calypso signal recording, - RT treatment with DIBH with or without visual biofeedback Follow-up - 3 and 6 months after RT with diagnostic CT chest"
89530758|NCT02514161|Active Comparator|Inspiratory Muscle Training Group (IMT)|"The IMT program consisted of supervised and domiciliary exercises.~- The supervised exercises was performed in the presence of physiotherapist. This consisted of 30 min 2 days for 4 weeks using the threshold device (Powerbreathe classic level 1, Gaiam Ltd; Southam, Warwickshire, UK). This program involve 5 sets of 5 repetitions with 30 seconds rest between each one. The load of the training was distributed as follow:~First week: 30% Maximum Inspiratory Pressure (MIP)~Second week: 40% MIP~Third week: 50% MIP~Fourth week: 60% MIP~- The domiciliary exercises consisted of Yoga Breathing Exercises (Pranayama) that combines the inspiration and expiration through one or both nostrils, and requires the activation of chest and abdomen"
88892535|NCT02106572|Experimental|abnobaVISCUM 900|intravesical instillation of abnobaVISCUM 900
88892536|NCT02106572|Active Comparator|Mitomycin C|intravesical instillation of Mitomycin C
88892537|NCT02075840|Experimental|Alectinib|Participants will receive alectinib from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death.
88892538|NCT02075840|Active Comparator|Crizotinib|Participants will receive crizotinib from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death.
88892539|NCT02073994|Experimental|AG-120|AG-120 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment with AG-120 until disease progression, development of other unacceptable toxicity or Investigator discretion.
88892540|NCT02048813|Experimental|Arm A (ibrutinib, rituximab)|Patients receive ibrutinib PO QD on days 1-28. Beginning cycle 2, patients also receive rituximab IV over 4 hours on days 1 and 2 of cycle 2, and day 1 of cycles 3-7. Treatment repeats every 28 days for 7 cycles in the absence of unacceptable toxicity. In the absence of disease progression, patients may continue ibrutinib PO QD.
88892541|NCT02048813|Active Comparator|Arm B (rituximab, fludarabine phosphate, cyclophosphamide)|Patients receive rituximab IV over 4 hours on days 1 and 2 of cycle 1, and day 1 of cycles 2-6. Patients also receive fludarabine phosphate IV over 30 minutes and cyclophosphamide IV over 30 minutes on days 1-3. Treatment repeats every 28 days for 6 cycles in the absence of unacceptable toxicity.
88892542|NCT02030860|Experimental|Pre-operative Paricalcitol|Subject will receive gemcitabine/abraxane with preoperatively paricalcitol. Patients randomized to receive paricalcitol pre-operatively will begin treatment with intravenous paricalcitol at 25 μg three times weekly for one cycle beginning day 1 of therapy until the day before surgery (+/- 3 days).
88892543|NCT02030860|Active Comparator|No Pre-operative Paricalcitol|Subject will receive gemcitabine/abraxane without paricalcitol preoperatively.
88892544|NCT02029001|Experimental|Arm A: Maintenance treatment|"Patients will continue targeted treatment matching the molecular alterations identified in their tumor~for a maximum of 136 weeks starting from the date of patient's first study drug intake following inclusion or a discontinuation criteria (unacceptable toxicity, interruption of study drug more than 28 days, documented on-treatment disease progression, patient decision, investigator decision, pregnancy) is met for nilotinib, everolimus, sorafenib, lapatinib, pazopanib, olaparib.~until loss of clinical benefit, or until a permanent study drug discontinuation criteria is met (unacceptable toxicity, interruption of study drug more than 28 days, documented on-treatment disease progression, patient decision, investigator decision, pregnancy) or for up to 2 years duration for patients with CR/PR/SD with the possibility of rechallenge in case of PD after IT cessation for durvalumab + tremelimumab"
88892545|NCT02029001|No Intervention|Arm B:Interruption of targeted treatment|"Targeted treatment received during induction period will be discontinued until a first documented off-treatment disease progression occurs. At progression, treatment reintroduction may be proposed to the patient (left at the investigator's appreciation, and upon patient approval).~Treatment may be continued until on-treatment disease progression, unacceptable toxicity or for a maximum of 136 weeks from the date of patient's first study drug intake following inclusion for nilotinib, everolimus, sorafenib, lapatinib, pazopanib, olaparib or until loss of clinical benefit, or until a permanent study drug discontinuation criteria is met for durvalumab + tremelimumab.~If the investigator considers that the treatment cannot be safely reintroduced (regarding patient's condition and/or laboratory results), the patient will be withdrawn from study."
88892546|NCT02013583||Glucose Transporter Type I Deficiency|No interventions
88892547|NCT01853488||Spinal Cord Injury|Persons with spinal cord injury Osteodensitometry DXA pQCT
88892548|NCT01853488||Reference|Reference population (able-bodied) Osteodensitometry DXA pQCT
88892549|NCT01837225||Control|Patients in the control arm will not receive the fluorescent contrast agent (5-ALA); however, intraoperative fluorescence imaging will still be performed. Patients will receive conventional breast conservation surgery and care independent of the contrast agent dose they receive.
88892550|NCT01837225||Low Dose Contrast Agent|Patients in the low dose arm will receive 15 mg/kg 5-ALA fluorescent contrast agent administered orally 3 hours prior to intraoperative fluorescence imaging. Patients will receive conventional breast conservation surgery and care independent of the contrast agent dose they receive.
88892551|NCT01837225||High Dose Contrast Agent|Patients in the high dose arm will receive 30 mg/kg 5-ALA fluorescent contrast agent administered orally 3 hours prior to intraoperative fluorescence imaging. Patients will receive conventional breast conservation surgery and care independent of the contrast agent dose they receive.
88892552|NCT01837225||Intermediate Dose Contrast Agent|Patients in the intermediate dose arm will receive 20 mg/kg 5-ALA fluorescent contrast agent administered orally 3 hours prior to intraoperative fluorescence imaging. Patients will receive conventional breast conservation surgery and care independent of the contrast agent dose they receive.
88892553|NCT01785719|Experimental|Overweight Women|Regardless of reproductive history, each participant will be provided with six months of the commercial weight loss program, Nutrisystem® D. Nutrisystem® D is a portion-controlled, low calorie, and low glycemic index meal delivery system that provides 1250-1500 kcal/day. It has been proven to help overweight adults achieve real and sustainable weight loss results. When meals and snacks are consumed as instructed, average weight loss is 1-2 lbs per week or 15-20% body weight by the end of six months. Nutrisystem® D offers a balanced meal plan that is consistent with the nutrition recommendations of the USDA for Americans and American Diabetes Association. Each participant will be encouraged to take a daily multivitamin to help meet her micronutrient needs on the program.
88892554|NCT01615731|Active Comparator|Two sets of dilators|Two sets of osmotic dilators inserted 1 and 2 days pre-op
88892555|NCT01615731|Experimental|Mifepristone plus one set of dilators|One set of dilators plus mifepristone
88892556|NCT01589302|Experimental|Treatment (ibrutinib)|Patients will be treated with PCI-32765 capsules administered orally once daily at a dose of 420 mg for 28 day cycles. Weekly monitoring during the first month will occur followed by monthly evaluations for 2 additional months. Monitoring for patients at this point would be every 3 months with monthly CBC(complete blood count)and phone follow-up with a co-investigator on the study. A standard questionnaire will be used in this monthly phone assessment. Patients will continue to receive the study drug indefinitely as long as they are deriving clinical benefit (Complete Response or Partial Response or Stable Disease) and not experiencing any unacceptable toxicity. Subjects with disease progression will be removed from the study. Correlative laboratory samples, quality of life assessment, and immunologic data would be collected over time of therapy.
88892557|NCT01517945||Breast cancer survivors and Rare cancer survivors|This is a Cycle for Survival and Center for Translational Science Center (CTSC)-funded intervention development and pilot clinical trial of a psychosocial intervention to address fear of cancer recurrence in breast cancer survivors (BCS) and rare cancer survivors (RCS). BCS form the largest survivor cohort of any cancer, with approximately 2.5 million living in the United States. About 50 percent of people with cancer have a rare cancer. Even though they account for about half of all cancer diagnoses when combined, research aimed at supporting RCS is sparse, leaving RCS with limited support after treatment.
88892558|NCT01479842|Experimental|Treatment (enzyme inhibitor, chemo, monoclonal antibody)|Patients receive BTK inhibitor PCI-32765 PO QD on days 1-28. Patients also receive rituximab IV on day 1 and bendamustine hydrochloride IV over 30 minutes on days 1-2. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients may continue receiving BTK inhibitor PCI-32765 PO in the absence of disease progression or unacceptable toxicity.
88892559|NCT01477502|Active Comparator|individual homeopathic treatment|participants receive homeopathic treatment in addition to standard prevention measures for UTI
88892560|NCT01477502|Other|standard prophylaxis|
88892561|NCT01349400|Experimental|watchful waiting|"After informed consent and randomization into the watchful waiting group patients will receive standardized verbal information and written instructions on symptoms of acute incarceration. In case of acute symptoms they will be told to visit a physician immediately. On follow-up visits at 1 month, 12 months and 24 months the hernia size will be determined by physical examination, and the pain/ discomfort and the functional status will be monitored.~Control intervention/ reference test:~Open or laparoscopic hernia repair with mesh (non-absorbable or partly-absorbable alloplastic material) or with direct suture repair. For hernias measuring ≥ 3 cm mesh repair is recommended. A wide overlap of the mesh over the fascia margin on each side has to be provided. Divergent types of repair are permitted but have to be documented."
88892562|NCT01349400|Active Comparator|Hernia repair|Intervention: Open or laparoscopic hernia repair with mesh (non-absorbable or partly-absorbable alloplastic material) or with direct suture repair. For hernias measuring ≥ 3 cm mesh repair is recommended. A wide overlap of the mesh over the fascia margin on each side has to be provided. Divergent types of repair are permitted but have to be documented.
88892563|NCT01345136|Experimental|RAD001 Treatment|All subjects will be given RAD001 for 1 year (12 months).
88892564|NCT01299792||one arm; neurogenic bladder dysfunction|evaluation of the clinical utility of bladder wall thickness as a diagnostic tool in patients with spinal cord injury
88892565|NCT00695981|Active Comparator|Rotator cuff repair|Surgery following a 3 months period of active non-operative treatment
88892566|NCT00695981|Active Comparator|Conservative treatment|Physiotherapy according to a standardized protocol following a 3 months period of active non-operative treatment
88892567|NCT00637013|Active Comparator|Acromioplasty|Acromioplasty + physiotherapy according to a standardized protocol following a 3 months period of active non-operative treatment
88892568|NCT00637013|Active Comparator|Physiotherapy|Physiotherapy according to a standardized protocol following a 3 months period of active non-operative treatment
88892569|NCT00521846||1|As part of their routine care, patient's will receive Biomet modular radial head replacement. This study is an observational, prospective study that monitors the patient's pain, functional ability, and patient-reported outcomes.
88892570|NCT00186927|Experimental|Participants|"Participants will be studied in three cohorts:~Healthy seropositive children 3 years up to 6 years~Healthy seropositive toddlers 12 months up to 24 months~Healthy seronegative toddlers 12 months up to 24 months.~Each cohort will receive Sendai virus vaccine."
88892571|NCT04932980|Active Comparator|Aflibercept ® rapid treatment extension (T&E)|Early treat and extend (T&E) with Aflibercept ®. First IVT followed by control after 3 weeks and 2nd IVT after 6 weeks (= shortest treatment interval). Treatment will be adjusted according to morphologic response by adaptation of treatment intervals in +/- two-week increments.
88892572|NCT04932980|Active Comparator|Brolucizumab ® rapid treatment extension (T&E)|Early treat and extend (T&E) with Brolucizumab ®. First IVT followed by control after 3 weeks and 2nd IVT after 6 weeks (= shortest treatment interval). Treatment will be adjusted according to morphologic response by adaptation of treatment intervals in +/- two-week increments.
88892573|NCT04927390|Experimental|Mycophenolate Mofetil (MMF) Arm|Participants will receive mycophenolate mofetil (MMF) for up to 96 weeks, in addition to their background Standard of Care medication for systemic sclerosis related symptoms. They will receive 500mg twice daily over the first 4 weeks following their randomisation, and if tolerated the dose will be increased to a target dose of 1g twice daily starting from week 5 until their Final visit.
88892574|NCT04927390|No Intervention|Control Arm|Standard of Care (no immunosuppression) for systemic sclerosis related symptoms.
88892575|NCT04912336||VV-ECMO|Patients supported because of respiratory failure by Veno-Venous Extra Corporeal Membrane Oxygenator.
88892576|NCT04912336||VA-ECMO|Patients supported because of circulatory failure by Veno-Arterial Extra Corporeal Membrane Oxygenator.
88892577|NCT04910711|Active Comparator|DTG/LNG|Receiving dolutegravir-based antiretroviral therapy and initiating the levonorgestrel implant
88892578|NCT04910711|Other|NEG/LNG|HIV negative, not receiving antiretroviral therapy and initiating the levonorgestrel implant
88892579|NCT04910711|Active Comparator|DTG/MPA|Receiving dolutegravir-based antiretroviral therapy and the depot medroxyprogesterone acetate injection
88892580|NCT04910711|Other|NEG/MPA|HIV negative, not receiving antiretroviral therapy and receiving the depot medroxyprogesterone acetate injection
88892581|NCT04909333|Experimental|Group A (EHH Patients)|Group A will receive a placebo injection (0.9% saline solution) on Day 1 and 10μg Exenatide injection on Day 2.
88892582|NCT04909333|Experimental|Group B (EHH Patients)|Group B will receive a 10μg Exenatide injection on Day 1 and placebo injection (0.9% saline solution) on Day 2.
88892583|NCT04909333|Experimental|Group C (control subjects)|Control subjects without evidence for EHH defined by no glucose levels below 3.0 mmol/l during a 7-day CGFS (Freestyle libre) and matched to EHH patients for age, gender and BMI will receive only on one study day a single intravenous injection of 10μg Exenatide and compared to group A patients on Day 2. They will not receive a Placebo injection.
88892584|NCT04907487||SEP|With Multiple Sclerosis as defined by McDonald's revised clinical or radiological spatial and temporal dissemination criteria
88892585|NCT04907487||NO SEP|For patients with an indication to undergo a brain MRI and at low risk of inflammatory CNS disease
88892586|NCT04903249|Experimental|Affect-regulated exercise prescription|"Participants receive instructions to adjust their pace of exercise so that they feel fairly good or better (i.e., a rating of +1 or higher on the Feeling Scale) while exercising and to avoid any increases in intensity that promote feeling fairly bad or worse. If no intensity of exercise feels at least fairly good participants will be told to exercise at an intensity that feels as positive as possible."
88892587|NCT04902014|Active Comparator|Education|
89414767|NCT05488847|Experimental|Multimodal, Non-Narcotic|This group will be given the preoperative, intraoperative, and discharge meds described below. This group will NOT receive any opioid-containing meds. Preoperative meds: Celecoxib: 400 mg by mouth, Pregabalin: 75 mg by mouth, Tramadol: 50 mg by mouth. Intraoperative meds: Dexamethasone: 10 mg IV, Acetaminophen: 1,000 mg IV, Ropivacaine 5 mg/mL (0.5%): 300 mg local infiltration, Epinephrine 1 mg/mL (1:1000): 1 mg local infiltration, Ketorolac 30 mg/mL: 30 mg local infiltration. Discharge meds: Dexamethasone: 4 mg by mouth twice per day for 4 days (for same day discharge only), 10 mg IV on postoperative day 1 (for overnight patients only), Pregabalin: 75 mg by mouth twice per day for 14 days, Tizanidine: 2 mg by mouth every 6 hours for 14 days, Magnesium: 200 mg by mouth twice per day for 14 days, Ibuprofen: 600 mg by mouth every 6 hours not to exceed 3200 mg per day for 1 month, Acetaminophen: 975 mg by mouth every 8 hours not to exceed 3000 mg per day for 1 month.
88892588|NCT04902014|Experimental|Motivational Interviewing|
88892589|NCT04902014|Experimental|Wearable Fitness Tracker|
88892590|NCT04902014|Experimental|Wearable Fitness Tracker+|
88892591|NCT04900168||ICP monitoring group|patients received ICP monitoring
88892592|NCT04900168||conventional treatment group|patients without ICP monitoring and received conventional treatment
88892593|NCT04897958||Degarelix|Reference group
88892594|NCT04897958||Leuprolide|Exposure group
88892595|NCT04895384||Surgical Cohort|Placement of Edwards ClearSight and Masimo SET on patient intraoperatively.
88892596|NCT04894877||Active Comparator: Invasive Strategy (INV)|Routine invasive strategy with cardiac catheterization followed by revascularization plus optimal medical therapy.
88892597|NCT04894877||Active Comparator: Conservative Strategy|Optimal medical therapy with cardiac catheterization and revascularization reserved for patients with acute coronary syndrome, ischemic heart failure, resuscitated cardiac arrest or refractory symptoms.
88892598|NCT04892758||Formoterol fumarate 10 mcg|Reference Group
88892599|NCT04892758||Mometasone furoate/formoterol fumarate combination MDI 200/10 mcg BID|Exposure Group
88892600|NCT04892732||Budesonide|Reference Group
88892601|NCT04892732||Budesonide-formoterol|Exposure Group
88892602|NCT04882176|Experimental|LM061 Dose Escalation Level 1, 2.5mg|"The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.~first dose: 2.5mg QD, n=1;"
88892603|NCT04882176|Experimental|LM061 Dose Escalation Level 2, 5mg|"The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.~second dose: 5mg QD, n=3;"
88892604|NCT04882176|Experimental|LM061 Dose Escalation Level 3, 10mg|"The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.~third dose: 10mg QD, n=3;"
88892605|NCT04882176|Experimental|LM061 Dose Escalation Level 4, 20mg|"The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.~fourth dose: 20mg, n=3;"
88892606|NCT04882176|Experimental|LM061 Dose Escalation Level 5, 30mg|"The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.~fifth dose: 30mg, n=3;"
89414768|NCT05488847|Active Comparator|Multimodal Plus Narcotic|This group will be given the preop, intraop, and discharge meds described below. They will also be given 35 pills of oxycodone hydrochloride 5mg to be taken every 6 hours as needed at discharge. Preoperative: Celecoxib: 400 mg PO, Pregabalin: 75 mg PO, Tramadol: 50 mg PO. Intraoperative: Dexamethasone: 10 mg IV, Acetaminophen: 1,000 mg IV, Ropivacaine 5 mg/mL (0.5%): 300 mg local infiltration, Epinephrine 1 mg/mL (1:1000): 1 mg local infiltration, Ketorolac 30 mg/mL: 30 mg local infiltration. Discharge: Dexamethasone: 4 mg PO twice per day for 4 days (for same day discharge only), 10 mg IV on postop day 1 (for overnight patients only), Pregabalin: 75 mg PO twice per day for 14 days, Tizanidine: 2 mg PO every 6 hours for 14 days, Magnesium: 200 mg PO twice per day for 14 days, Ibuprofen: 600 mg PO every 6 hours not to exceed 3200 mg per day for 1 month, Acetaminophen: 975 mg PO every 8 hours not to exceed 3000 mg per day for 1 month.
89414769|NCT05485662|Other|MIH-bearing tooth block exposed to HAP toothpaste|A block of molar incisor hypomineralization (MIH) is mounted in an oral appliance and fitted in the subject for testing with the HAP toothpaste
89414770|NCT05485662|Other|MIH-bearing block exposed to Sodium Fluoride toothpaste|A block of molar incisor hypomineralization (MIH) is mounted in an oral appliance and fitted in the subject for testing with the sodium fluoride toothpaste
89414771|NCT05483400|Experimental|Localized Head and Neck Squamous Cell Cancer|three weekly tiragolumab 1200 mg intravenous plus tiragolumab 600 mg intravenous
89414772|NCT05483400|Experimental|Advanced or Metastatic dMMR/MSI Cancer|three weekly tiragolumab 1200 mg intravenous plus tiragolumab 600 mg intravenous
88892607|NCT04882176|Experimental|LM061 Dose Escalation Level 6, 40mg|"The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.~sixth dose: 40mg, n=9;"
88892608|NCT04882176|Experimental|LM061 Dose Escalation Level 7, 60mg|"The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.~seventh dose: 60mg, n=15;"
88892609|NCT04879420||Teriparatide|Reference Group
88892610|NCT04879420||Risedronate|Exposure Group
89193063|NCT05632809|Experimental|NKTR-255 combination (Durvalumab)|"Participants will receive vein over about 30 minutes. Participants receive the first dose within 72 hours (3 days) after you complete CRT and the second dose at 3 weeks after you complete CRT. Then, you will receive NKTR-255 one (1) time every 4 weeks after that for up to 1 year.~Durvalumab Participants will receive durvalumab by vein over about 30 minutes. You will receive the first dose at 3 weeks after you complete CRT therapy. Then, you will receive durvalumab one (1) time every 4 weeks after that for up to 1 year"
89414773|NCT05483400|Experimental|Anti-PD-1 Antibody Resistant Metastatic Melanoma|three weekly tiragolumab 1200 mg intravenous plus tiragolumab 600 mg intravenous
88892611|NCT04875520|Active Comparator|Weekly Screening testing plus symptomatic testing|Among 16 middle and high schools, 8 will be randomized to offer students and staff weekly SARS-CoV-2 testing. Additionally, these schools will offer testing for symptomatic students, staff, household members in all age groups.
88892612|NCT04875520|Active Comparator|Symptomatic testing|All 16 schools will have testing available for individuals that have symptoms or need a test for other reasons.
88892613|NCT04870840|Experimental|Treatment (proton therapy)|Patients undergo radiation therapy QD 5 days a week (Monday through Friday) for the first 18 days and then BID for 15 days in the absence of disease progression or unacceptable toxicity.
88892614|NCT04867408||Main group|Patients with/suspected Inflammatory Bowel Disease attending for an endoscopic procedure
88892615|NCT04867408||Control|Patients without Inflammatory Bowel disease attending for an endoscopic procedure
88892616|NCT04856150|Experimental|Q-1802|Q-1802 dose exploration and Q-1802 dose extension
88892617|NCT04849910|Experimental|Cohort 1|VOR33 infusion followed by Mylotarg Dose Level 1
88892618|NCT04849910|Experimental|Cohort 2|VOR33 infusion followed by Mylotarg Dose Level 2
89414774|NCT05483400|Experimental|Basket|three weekly tiragolumab 1200 mg intravenous plus tiragolumab 600 mg intravenous
89414775|NCT05446376|Experimental|68Ga-citrate PET/CT|
89414776|NCT05443607||Mother infected/newborn not infected|
89414777|NCT05443607||Mother infected/newborn infected|
89414778|NCT05443607||Mother not infected/newborn not infected|
89414779|NCT05443607||Mother not infected/newborn infected|
88892619|NCT04849910|Experimental|Cohort 3|VOR33 infusion followed by Mylotarg Dose Level 3
88892620|NCT04848519|Experimental|Treatment (propranolol hydrochloride, immune checkpoint inhibitor)|The specific ICI that the subject would receive will be dependent on the clinical need and associated FDA approval.
88892621|NCT04848519|Other|Treatment (immune checkpoint inhibitor)|The specific ICI that the subject would receive will be dependent on the clinical need and associated FDA approval.
88892622|NCT04841798|Other|Duloxetine|Assessment of MAO-B distribution volume in the prefrontal cortex before and after duloxetine at 60 mg daily.
88892623|NCT04841798|Other|Rasagiline|Assessment of regional MAO-B distribution volume before and after rasagiline at 1.0 mg daily.
88892624|NCT04841798|Other|Tranylcypromine|Assessment of regional MAO-B distribution volume before and after tranylcypromine at 30 to 60 mg daily.
88892625|NCT04839614|Experimental|CONCURRENT LAPAROSCOPIC HYSTERECTOMY AND WEIGHT LOSS SURGERY|"Upon enrollment in the study at first appointment with gynecologic oncologist, referral to the BWH Center for Metabolic and Bariatric Surgery (CMBS).~Schedule a series of appointments with a bariatric surgeon, nutritionist and psychologist, which is part of the approval process for weight loss surgery.~Hysterectomy and weight loss surgery will then be scheduled on the same day within 8 weeks from first visit with the gynecologic oncologist for endometrial cancer or 12 weeks if you have endometrial pre-cancer.~Series of post-operative visits with the bariatric surgeon and gynecologic oncologic surgeon as well as the nutritionist and psychologist."
88892626|NCT04829188|Active Comparator|Structured Telephone Support (STS)|Post-discharge assessment, education, and medication reconciliation delivered telephonically by a health plan case manager, home care as needed, and follow-up with the primary care provider (PCP) within seven days post-discharge.
89414780|NCT05437510|Experimental|Nirsevimab|1 intramuscular injection at Day 01
89414781|NCT05437510|No Intervention|No preventive intervention for RSV|No intervention
89414782|NCT05435664|Experimental|Intervention Group|During the first interview, the nurses in the intervention group were informed about PGE in a convenient and quiet room within the hospital, face-to-face and face-to-face. Afterwards, the researcher 15 minutes of application was made with the accompaniment. In order for the participants to practice at home, a voice recording containing the PGE steps voiced by the researcher in his own voice was sent to the nurses' phones. Nurses were asked to perform the PGE exercise by listening to the audio recording file for 15 minutes once a day for 4 weeks. In addition, daily reminders were made by creating a group over the WhatsApp application in order to prevent it from being forgotten. They were asked to provide feedback on their compliance with the program. At the beginning of the study, at the beginning of the study, at the 1st, 2nd, 3rd and 4th weeks (at the end of the application), the 'Fatigue Severity Scale' was administered again through face-to-face interviews.
89414783|NCT05435664|No Intervention|Control group|"No intervention was made to the nurses in the control group. In the second and fourth weeks of the study, the Fatigue Severity Scale will be applied again through face-to-face interviews. At the end of the study, nurses will be informed about PGE and a voice recording will be sent to their phones from the WhatsApp application, containing the PGE steps, which the researcher voiced with her voice."
89414784|NCT05432284|Placebo Comparator|Placebo|Placebo (ambient air)
89414785|NCT05432284|Experimental|Vaporized high THC alone|30mg of vaporized pure THC
89414786|NCT05432284|Experimental|Vaporized low THC alone|15mg of vaporized pure THC
89414787|NCT05432284|Experimental|Vaporized low beta-myrcene|2mg of vaporized beta-myrcene
89414788|NCT05432284|Experimental|Vaporized high beta-myrcene|9mg of vaporized beta-myrcene
89414789|NCT05432284|Experimental|Vaporized low THC and low beta-myrcene|15mg vaporized THC with 2mg vaporized beta-myrcene
89414790|NCT05432284|Experimental|Vaporized low THC and high beta-myrcene|15mg vaporized THC with 9mg vaporized beta-myrcene
88892627|NCT04829188|Active Comparator|Low-intensity Remote Patient Monitoring (RPM) + Standard Response Team (RPM-Low, Standard Team)|Questions are pushed to members patients times per week for up to 90 days post-discharge. Questions are limited to those checking vital signs that indicate worsening of infection. Patient answers to RPM questions trigger High or Medium alerts, which trigger a response by members of the intervention care team. RPM alerts are screened by a nurse-staffed call center. Nurses determine whether emergency care is needed. If not, nurses contact the patient and/or the patients' primary care provider (PCP) or specialist to coordinate care and ensure timely follow-up.
88892628|NCT04829188|Active Comparator|High-intensity Remote Patient Monitoring (RPM) plus the Standard Team (RPM-High, Standard Team)|Questions are pushed to patients multiple times per week for up to 90 days post-discharge. Questions include monitoring vital signs for worsening infection but also ask about factors that would indicate worsening of underlying heart or lung conditions, such as weight gain or shortness of breath. Patient answers to RPM questions trigger High or Medium alerts, which trigger a response by members of the intervention care team. RPM alerts are screened by a nurse-staffed call center. Nurses determine whether emergency care is needed. If not, nurses contact the patient and/or the patients' primary care provider (PCP) or specialist to coordinate care and ensure timely follow-up.
88892629|NCT04829188|Active Comparator|Low-intensity Remote Patient Monitoring (RPM) + Enhanced Team (RPM-Low, Enhanced Team)|Questions are pushed to patients multiple times per week for up to 90 days post-discharge. Questions are limited to those checking vital signs that indicate worsening of infection. Patient answers to RPM questions trigger High or Medium alerts, which trigger a response by members of the intervention care team. RPM alerts are screened by a nurse-staffed call center. Nurses determine whether emergency care is needed. If not, the call center alerts a multidisciplinary care team that is led by a certified registered nurse practitioner (CRNP). CRNPs, who operate in a palliative care role, have prescribing authority and can modify care plans. In addition to reacting to RPM triggers, team members (e.g., CRNP, social workers, nurses) meet with the patient in-person or virtually in the week after discharge and at least twice more in the next 90 days, conduct assessments and a pharmacy review, develop care plans, and discuss advance directives).
88892630|NCT04829188|Active Comparator|High-intensity Remote Patient Monitoring (RPM) plus the Enhanced Team (RPM-High, Enhanced Team)|Questions are pushed to patients multiple times per week for up to 90 days post-discharge. Questions include monitoring vital signs for worsening infection but also ask about factors that would indicate worsening of underlying heart or lung conditions, such as weight gain or shortness of breath. Patient answers to RPM questions trigger High or Medium alerts, which trigger a response by members of the intervention care team. RPM alerts are screened by a nurse-staffed call center. Nurses determine whether emergency care is needed. If not, the call center alerts a multidisciplinary care team that is led by a certified registered nurse practitioner (CRNP). CRNPs, who operate in a palliative care role, have prescribing authority and can modify care plans.Team members (e.g., CRNP, social workers, nurses) address RPM triggers, meet with the patient three times, pharmacy review, develop care plans, and discuss advance directives).
88892631|NCT04809506||Patient consulting the Centre for Screening and Prevention of Atherosclerosis|2 additional blood samples (2 x 7ml) at every visit
88892632|NCT04796285|Experimental|Lab Clasp|A finger based device to assay interstitial fluid lactate
89414791|NCT05432284|Experimental|Vaporized high THC and low beta-myrcene|30mg vaporized THC with 2mg vaporized beta-myrcene
89414792|NCT05432284|Experimental|Vaporized high THC and high beta-myrcene|30mg vaporized THC with 9mg vaporized beta-myrcene
89414793|NCT05430035|Experimental|HIPEC|Prophylactic Heated Intra-peritoneal Chemotherapy (HIPEC) 30 mg of mitomycin C (MMC) over the first 60 minutes followed by 10 mg over an additional 30 minutes. Perfusate will be heated to obtain a tissue temperature of 42°.
89414794|NCT05408832|Experimental|Personalized Trial ABCCBA|Participants in Arm 1 will receive a Personalized Trial of the 3 stress management interventions in an ABCCBA treatment order, where A=mindfulness meditation, B=yoga, and C=brisk walking. Participants in this arm will be prompted to complete 30-minute stress management sessions during applicable treatment weeks. A link to the stress management video will be delivered via text 3 times per week to the participant during applicable intervention periods in the personalized trial arms. Participants will be limited to three views of study-provided stress management content each week.
89414795|NCT05408832|Experimental|Personalized Trial CBAABC|Participants in Arm 2 will receive a Personalized Trial of the 3 stress management interventions in a CBAABC treatment order, where A=mindfulness meditation, B=yoga, and C=brisk walking. Participants in this arm will be prompted to complete 30-minute stress management sessions during applicable treatment weeks. A link to the stress management video will be delivered via text 3 times per week to the participant during applicable intervention periods in the personalized trial arms. Participants will be limited to three views of the study-provided stress management content each week.
89414796|NCT05408832|Active Comparator|Standard Care|Participants in Arm 3 will receive Standard Care of the 3 stress management techniques (mindfulness meditation, yoga, and brisk walking). Participants will receive access to the same number of views of the mindfulness meditation, yoga, and brisk walking content given to participants randomized in Arm 1 and Arm 2. However, they will not be prompted to complete any session according to a randomization sequence. A link to the stress management video will be delivered via text 1 time per week to the participant. Participants will be limited to 36 total views of study-provided stress management content (12 total views per stress management technique).
89414797|NCT05403853|Experimental|Monitoring of Diabetes Mellitus|Venous blood draw of up to 24ml and up to 4 fingersticks
89414798|NCT05400200|Other|questionnary with patients Definite diagnosis of PTSD|only patients with diagnosis of PTSD answered questionaries
89414799|NCT05395299|Experimental|Prostatic Arterial Embolization with SQUID (Ethylene Vinyl Alcohol Copolymer )|Injection at the level of the right and left prostate arteries of Squid until a complete occlusion of these arteries, and a filling of their intraprostatic branches
89414800|NCT05382520|Experimental|Explicit sensory retraining for lower extremity in individuals with CIPN|Explicit sensory retraining for lower extremity function (pain, sensory, balance, gait). five one-hour sessions, a week apart: Pre-Post assessment sessions with 3 treatment sessions in between. Home exercise assigned.
89414801|NCT05378100|Experimental|Ketamine-Ketamine|Participants in this arm will receive two infusions of ketamine four weeks apart.
89414802|NCT05378100|Experimental|Ketamine-Midazolam|Participants in this arm will receive one infusion of ketamine followed four weeks later by an infusion of midazolam.
89414803|NCT05378100|Experimental|Midazolam-Ketamine|Participants in this arm will receive one infusion of midazolam followed four weeks later by an infusion of ketamine.
89414804|NCT05375812||GWI|Gulf War Veterans
89414805|NCT05375812||HVC|Healthy Volunteer Controls
89414806|NCT05351593|Experimental|Phase 1 (Tafasitamab, Lenalidomide)|Participants will be given 12mg of Tafasitamab on days 1, 4, 8, 15, and 22 of cycle 1, days 1, 8, 15, and 22 of cycles 2 & 3, and days 1 and 15 for any cycle thereafter. Participants will also be given daily Lenalidomide on days 1-21 of each cycle.
89414807|NCT05351593|Experimental|Phase 2 (Tafasitamab, Lenalidomide)|Participants will be given 12mg of Tafasitamab on days 1, 4, 8, 15, and 22 of cycle 1, days 1, 8, 15, and 22 of cycles 2 & 3, and days 1 and 15 for any cycle thereafter. Participants will also be given daily Lenalidomide on days 1-21 of each cycle at the recommended phase 2 dose.
89414808|NCT05350150|Experimental|Auricular Vagal Nerve Stimulation|Patients will undergo a standard EPS with 4 catheters. Following the standard EPS, patients will be hooked up a Parasym device to provide transcutaneous electrical stimulation to the auricular branch of the vagus nerve, EPS will be repeated.
89414809|NCT05334004|Experimental|Cohort 1: Lopinavir/Ritonavir 200mg/50mg (2 cycles)|Cohort 1 will receive two 5-day cycles of the low dose of the suppository (Lopinavir/Ritonavir (200mg/50mg)) in Weeks 0 and 2
89414810|NCT05334004|Experimental|Cohort 1b: Lopinavir/Ritonavir 200mg/50mg (3 cycles)|Cohort 1b will receive three 5-day cycles of the low dose of the suppository (Lopinavir/Ritonavir (200mg/50mg)) in Weeks 0, 2, and 4 if Cohort 2 has one dose-limiting toxicity (DLT).
89414811|NCT05334004|Experimental|Cohort 2: Lopinavir/Ritonavir 400mg/100mg (2 cycles)|Cohort 2 will receive two 5-day cycles of the higher dose of the suppository (Lopinavir/Ritonavir (400mg/100mg)) in Weeks 0 and 2, if Cohort 1 dose is safe.
89414812|NCT05334004|Experimental|Cohort 2b: Lopinavir/Ritonavir 400mg/100mg (3 cycles)|Cohort 2b will receive three 5-day cycle of the higher dose of the suppository (Lopinavir/Ritonavir (400mg/100mg)) in Weeks 0, 2 and 4 if Cohort 3 has one DLT.
89414813|NCT05334004|Experimental|Cohort 3: Lopinavir/Ritonavir 600mg/150mg (2 cycles)|Cohort 3 will receive two 5-day cycles of the highest dose of the suppository (Lopinavir/Ritonavir (600mg/150mg)) in Weeks 0 and 2, if the Cohort 2 dose is safe.
89414814|NCT05334004|Experimental|Cohort 4: Lopinavir/Ritonavir 600mg/150mg (3 cycles)|Cohort 4 will receive three 5-day cycles of the highest dose of the suppository (Lopinavir/Ritonavir (600mg/150mg)) in Weeks 0, 2, and 4, if the Cohort 3 dose is safe.
89414815|NCT05307094|Experimental|Intervention first|Participants will first be randomly assigned to a parent-mediated social communication intervention. At month 3 participants' social communication will be evaluated. Participants who present with delayed social communication skills will be randomly assigned to 2 additional treatment options: continue, or add video feedback. Participants who do not present with social communication delays will reduce intervention to a weekly phone call.
89414816|NCT05307094|Active Comparator|Developmental monitoring first|Participants will first be assigned to receive monthly monitoring of social communication development. At month 3 participants' social communication will be evaluated. Participants who present with delayed social communication skills will be randomly assigned to 2 additional treatment options: continue, or add video feedback. Participants who do not present with social communication delays will continue to receive developmental monitoring.
89414817|NCT05304442|Experimental|Intravenous Ferric Derisomaltose|One single dose of ferric derisomaltose, 1000 mg Intravenous over at least 20 minutes.
88892633|NCT04793529|Experimental|Cholecalciferol injection|
88892634|NCT06040684||Level of antibodies in kidney transplant recipients|Patients with kidney transplant with a severe acute infection will be enrolled in the study. Levels of antibodies in these patients will be analyzed.
88892635|NCT06040671|Experimental|Lateral canthal hinge surgery patients|Patients undergoing lateral canthal hinge surgery will be enrolled in this group.
88892636|NCT06040671|Experimental|Ptosis surgery patients|Patients undergoing ptosis surgery will be enrolled in this group.
88892637|NCT06040658||Vascular 'hot' clinic.|All adults (aged > 17 years) referred to an urgent-referral, consultant-led, Vascular Surgery outpatient clinic, who have capacity, will be eligible for inclusion in this study.
88892638|NCT06040606||Group 1 (G1)|patients who acquired nosocomial omicron infection after surgery
88892639|NCT06040606||Group 2 (G2)|patients who remained uninfected with omicron during their hospitalization period
88892640|NCT06040580||Patients|Preoperative patients in need of brain surgery for varying brain pathology who require presurgical brain mapping with MRI (fMRI, and dMRI)
88892641|NCT06040554|Experimental|Exercise Program|Participants will participate in a group resistance exercise program for 8 weeks, using elastic bands.
88892642|NCT06040554|No Intervention|Unchanged Activities of Daily Living|Participants will be asked not to change their activities of daily living for the duration of the research.
88892643|NCT06040528||Patients discharged on the Early Discharge Pathway at Barts Heart Centre|This study aims to assess, in a real-world setting, the safety, efficacy and feasibility of further investigations in patients with acute coronary syndrome who are admitted to Barts Heart Centre and are discharged via the early discharge pathway.
88892644|NCT06040515||Symptomatic patients after acute diverticulitis|"Patients aged ≥18 with persistent symptoms at least three months after a radiologic and/or endoscopic documented acute diverticulitis or after six months of surgery for complicated acute diverticulitis.~Therapy with Escherichia coli Nissle 1917 (EcN®) will be prescribed for a global duration of six months with the following assumption schedule: 2 capsules b.i.d. during 4 weeks, followed by 1 capsule o.i.d during 20 days each month for 5 months."
88892645|NCT06040515||Diverticulosis|Patients with asymptomatic diverticulosis. No therapy will be administered. Microbiota assessment will be performed.
88892646|NCT06040515||Asymptomatic patients after acute uncomplicated diverticulitis|Asymptomatic patients assessed three months after an episode of acute uncomplicated diverticulitis. No therapy will be administered. Microbiota assessment will be performed.
88892647|NCT06040515||Asymptomatic patients after acute complicated diverticulitis|Asymptomatic patients assessed six months after an episode of acute complicated diverticulitis submitted to surgery with resection and without stoma . No therapy will be administered. Microbiota assessment will be performed.
88892648|NCT06040489|Experimental|Oral Miltefosine and Pentoxifylline for Cutaneous Leishmaniasis|
88892649|NCT06040489|Experimental|Oral Miltefosine and Pentoxifylline for Mucous Leishmaniasis|
88892650|NCT06040489|Active Comparator|Intravenous Liposomal Amphotericin B for Cutaneous Leishmaniasis|
88892651|NCT06040489|Active Comparator|Intravenous Liposomal Amphotericin B for Mucous Leishmaniasis|
88892652|NCT06040476|Experimental|A group: hUCB treatment|Human cord blood infusion
88892653|NCT06040476|No Intervention|B group: Placebo treatment|Placebo infusion
88892654|NCT06040437|Experimental|Be-Prox intervention|Training in the 6 Be-Prox module
88892655|NCT06040437|No Intervention|Control|Standard care
89414818|NCT05304442|Active Comparator|Oral Iron|ferrous sulfate 65 mg once daily for 42 days.
89414819|NCT05297825|Experimental|Vegan|Participants will be asked to consume a healthy vegan diet.
89414820|NCT05297825|Experimental|Omnivore|Participants will be asked to consume a healthy omnivore diet.
89414821|NCT05286112|Experimental|Mindfulness-Based Cognitive Therapy (MBCT)|MBCT delivered over the course of 10, ~60 minute sessions
89414822|NCT05286112|Active Comparator|Health Education|Health education sessions delivered over the course of 10, ~60 minute sessions
89414823|NCT05282550|Active Comparator|Trazodone First|Trazodone (50 mg at bedtime) and then placebo after a 4-week washout period.
89414824|NCT05282550|Placebo Comparator|Placebo First|Placebo and then Trazodone (50 mg at bedtime) after a 4-week washout period.
88892656|NCT06040411|Experimental|Study Group (experimental)|The order of application was determined by lottery. HT7, LI4 and EX-HN3 points were applied respectively. Before starting the application, the area around to be pressurized was gently rubbed with the palm of the hand for 20-30 seconds. The surrounding tissue was relieved by rubbing gently. After rubbing, pressure was applied to the point determined based on the pain threshold level of each individual with a depth of 1-1.5 cm with the thumb for 5 seconds, rested for 2 seconds and the application was continued for 2 minutes. Acupressure was applied to each point for 2 minutes and the total application time was 15 minutes on average (for 5 points).
88892657|NCT06040411|No Intervention|Standard of care|Standard care was given.
88892658|NCT06040398||TAVR Patients|All outpatients undergoing TAVR and managed through the overnight-model pathway at the Hamilton General Hospital will be eligible for participation.
88892659|NCT06040372|Experimental|LB54640|"5 mg, 25 mg and 200 mg strengths~Subjects will be administered once daily and duration vary per each cohorts.~Single Ascending Dose (SAD) cohorts : 1 day~SAD 1 10mg~SAD 2 25mg~SAD 3 50mg (Food effect cohort)~SAD 4 100mg~SAD 5 200mg~SAD 6 400mg~healthy Multiple Ascending Dose (MAD) cohorts: 28days~MAD 1 10mg~MAD 2 25mg~MAD 3 50mg~MAD 4 100mg~MAD 5 200mg~MAD 6 400mg~MAD 7 600mg"
88892660|NCT06040372|Placebo Comparator|Placebo|matching placebo
88922109|NCT05803018|Experimental|Study treatment|Participants receive BL-B01D1 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
89414825|NCT05272878|Active Comparator|IRBESARTAN|IRBESARTAN will be introduced at 150 mg orally one daily, with a progressive increase to 300 mg a day, at 7 days or 2 months follow-up visit, based on clinical and biological tolerance. Treatment will be continued for 12 months, unless a side effect would occur.
89414826|NCT05272878|Placebo Comparator|Placebo|Placebo will be introduced at 150 mg orally one daily, with a progressive increase to 300 mg a day, at 7 days or 2 months follow-up visit, based on clinical and biological tolerance. Treatment will be continued for 12 months, unless a side effect would occur.
89414827|NCT05268562|Active Comparator|Anesthesia induction with Ketamine|Subjects will receive Ketamine to begin anesthesia for their cardiac surgery.
89414828|NCT05268562|Active Comparator|Anesthesia induction with Propofol|Subjects will receive Propofol to begin anesthesia for their cardiac surgery.
89414829|NCT05256199|Experimental|high-intensity group|The high intensity group receives a personalized, supervised intervention consisting of group meetings and individual sessions.
89414830|NCT05256199|No Intervention|low-intensity group|The low-intensity arm receives online access to general lifestyle-related health information.
89414831|NCT05252832|Active Comparator|Local Infitrate|
89414832|NCT05252832|Experimental|SCPB|
89414833|NCT05242250||Acute SOC Sites with Patients with paroxysmal or persistent atrial fibrillation|Patients with symptomatic, refractory or intolerant to at least one Class I or III AAD, paroxysmal atrial fibrillation (AF episode terminating spontaneously within 7 days) or symptomatic, refractory or intolerant to at least one Class I or III AAD, persistent AF (continuous AF sustained beyond 7-days and less than 1-year) who, in the opinion of the investigator, are candidates for ablation for AF.
89193064|NCT05621460|Experimental|500mL carbonated water first, then 500mL of still water, then 50mL of still water|Participants will undergo this test on three separate days. On each day participants will be asked to drink a glass of water: either a 50mL drink of still water (control condition), a 500mL drink of still (non-carbonated) water, or a 500mL drink of carbonated water. In this arm of the study, participants will receive 500mL carbonated water on the first test day, 500mL still water on the second test day, then 50mL still water on the third day.
89193065|NCT05621460|Experimental|500mL still water first, then 500 mL carbonated water, then 50mL still water|Participants will undergo this test on three separate days. On each day participants will be asked to drink a glass of water: either a 50mL drink of still water (control condition), a 500mL drink of still (non-carbonated) water, or a 500mL drink of carbonated water. In this arm of the study, participants will receive 500mL still water on the first test day, 500mL carbonated water on the second test day, then 50mL still water on the third day.
89414834|NCT05242250||Symptomatic Monitoring SOC Sites with Patients with paroxysmal or persistent atrial fibrillation|Patients with symptomatic, refractory or intolerant to at least one Class I or III AAD, paroxysmal atrial fibrillation (AF episode terminating spontaneously within 7 days) or symptomatic, refractory or intolerant to at least one Class I or III AAD, persistent AF (continuous AF sustained beyond 7-days and less than 1-year) who, in the opinion of the investigator, are candidates for ablation for AF.
89414835|NCT05242250||Full Monitoring SOC Sites with Patients with paroxysmal or persistent atrial fibrillation|Patients with symptomatic, refractory or intolerant to at least one Class I or III AAD, paroxysmal atrial fibrillation (AF episode terminating spontaneously within 7 days) or symptomatic, refractory or intolerant to at least one Class I or III AAD, persistent AF (continuous AF sustained beyond 7-days and less than 1-year) who, in the opinion of the investigator, are candidates for ablation for AF.
89414836|NCT05239039|Experimental|Patients with Generalized Pustular Psoriasis (GPP) presenting with a flare|
89414837|NCT05208125|Experimental|CSSMS|ChAdOx1.HTI at week 0, ConM SOSIP.v7 at weeks 4, 12 and 28, and MVA.HTI at week 22 (CSSMS).
89414838|NCT05208125|Placebo Comparator|PPPPP|Normal saline solution at weeks 0, 4, 12, 22, and 28 (PPPPP).
89414839|NCT05201079|Experimental|MBK-01|Participants will receive MBK-01 capsules of fecal microbiota coming from healthy donors (33 patients).
89414840|NCT05201079|Active Comparator|Fidaxomicin|Participants will receive Fidaxomicin (33 patients).
89414841|NCT05200247|Experimental|Spesolimab|
89536744|NCT02723201|Experimental|Part-1, Period 1: TAK-020 17.5 mg Oral Solution|Single dose 17.5 milligram (mg), on Day 1, followed by 7 days of washout. Dose will be determined from TAK-020 single rising dose (SRD) trial.
88892661|NCT06040359|Experimental|Thriving Mama programme|Nine meetings delivered in either group (5 meetings), individual (1 meeting), or family group (2 meetings) formats over 10 weeks with an additional individual meeting 10-12 weeks postpartum by a trained mother in the community. Each meeting focuses on the girl's physical and mental health, taking care of a newborn, life skills, future-planning and social support and community-based services. Meetings will take place in a mixture of private settings in health facilities, community facilities, and participant homes. Adolescents will also receive usual perinatal care.
88892662|NCT06040359|Active Comparator|Usual perinatal care|"Each visit includes care that is appropriate to the overall condition and stage of pregnancy and should include four main categories of care:~Identification of pre-existing health conditions (e.g., check for weight and nutrition status, anemia, hypertension, syphilis, HIV status);~Early detection of complications arising during pregnancy (e.g., check for pre-eclampsia, gestational diabetes);~Health promotion and disease prevention (e.g., tetanus vaccine, prevention and treatment of malaria, nutrition counseling, micronutrient supplements, family planning counseling); and~Birth preparedness and complication planning (e.g., birth and emergency plan, breastfeeding counseling, antiretrovirals for HIV positive women and reducing mother-to- child transmission of HIV)"
88892663|NCT06040333|Experimental|Dynamic Neuromuscular Stabilisation Exercise|The participants performed DNS exercises addition to standard therapy
88892664|NCT06040333|Other|Standard therapy|Patient education, massage, diaphragmatic breathing, kegel exercise
88892665|NCT06040216||Stage 2 ERM|
88892666|NCT06040216||Stage 3 ERM|
88892667|NCT06040216||Stage 4 ERM|
88892668|NCT06040177|Experimental|SBRT+cardonilizumab+lenvastinib Group|Renvatinib: 8mg (weight <60kg) or 12mg (weight ≥60kg) once a day until disease progression, intolerable toxicity Radiation therapy: Stereotactic radiotherapy (5-8Gy*5F) for portal vein thrombus within 21 days after entry Cadonilimab will be administered within 2 weeks after the completion of the radiotherapy treatment once every 3 weeks (Q3W), for up to 2 years
88892669|NCT06040164||Ob/Pre/H|obesity, prediabetes and healthy mouth
89193066|NCT05621460|Experimental|500mL carbonated water first, then 50mL of still water, then 500mL of still water|Participants will undergo this test on three separate days. On each day participants will be asked to drink a glass of water: either a 50mL drink of still water (control condition), a 500mL drink of still (non-carbonated) water, or a 500mL drink of carbonated water. In this arm of the study, participants will receive 500mL carbonated water on the first test day, 50mL still water on the second test day, then 500mL still water on the third day.
88892670|NCT06040164||Ob/Pre/OCD|obesity, prediabetes and oral cavity disease
88892671|NCT06040164||Ob/Diab/H|obesity, diabetes and healthy mouth
88892672|NCT06040164||Ob/Diab/OCD|obesity, diabetes and oral cavity disease
88892673|NCT06040151||Users of mobile-based medication-reconciliation app|Adult patients (18 years or older) who are asked to complete medication reconciliation before a planned admission to the clinical ward of selected pilot departments in Erasmus Medical Center
88892674|NCT06040112|Experimental|Atelocollagen injection group|Atelocollagen injection
88892675|NCT06040112|Placebo Comparator|Lidocain injection group|Lidocain injection
88892676|NCT06040047|Experimental|PNF plus mobilization|This single group will receive passive mobilization and proprioceptive neuromuscular facilitation for cervical region.
88892677|NCT06040021||EOCRC|Patients aged<50 with colorectal cancer between 2008 and 2018 in Fudan university Shanghai cancer center.
89414842|NCT05197621||Vaccine Arm|Pregnant women who are planning to receive an mRNA COVID vaccine (Pfizer of Moderna), and/or a third booster vaccine, who consent to maternal blood collection before receipt of the vaccine and at 6 time points after receiving the vaccine and/or booster.
88892678|NCT06040021||IOCRC|Patients aged between 50 to 70 with colorectal cancer between 2008 and 2018 in Fudan university Shanghai cancer center.
88892679|NCT06040021||LOCRC|Patients aged between≥70 with colorectal cancer between 2008 and 2018 in Fudan university Shanghai cancer center.
88892680|NCT06040008||healthy volunteers|Healthy status is defined by the absence of evidence of any active or chronic disease at the beginning of the study
88892681|NCT06039969||Cardiac MRI will be performed in patients with heart failure caused by cardiomyopathy.|Cardiac MRI will be performed in patients with heart failure caused by cardiomyopathy. At the same time Collect patient feces.this is a obvertional study ,ther is no intervetion
88892682|NCT06039956|Other|Sentinel Lymph Node Biopsy Arm|"Patients with non-metastatic, biopsy and clipped locally advanced breast cancer will start systemic chemotherapy as per institutional best practices. Patients with a clinical complete response will be consented for SLNB followed by immediate ALND. Patients with persistent suspicious clinical adenopathy will be consented for ALND alone. All patients regardless of response to NAC will undergo ALND as per current institutional practices.~Patients undergoing SLNB followed by ALND will have the procedure performed by study the co-PI at OAUTH who is trained in the performance of SLNB. Histopathologic assessment of the breast and axillary contents will follow a standardized reporting procedure, including the assessment of residual cancer burden in both the breast and the axilla. Presence or absence of residual disease will be reported separately for the SLNB specimens, clipped node and remaining axillary contents."
88892683|NCT06039943|Experimental|All participants|Participants will undergo wheeze monitoring during tidal breathing prior to spirometry and during a spirometry test.
88892684|NCT06039917|Experimental|With automatic surveillance system|Patients were reminded of the surveillance time by an automatic surveillance system after the endoscopic and pathological results were available and before the surveillance time.
88892685|NCT06039917|Experimental|With manual reminder|Patients were reminded of the surveillance time manually after the endoscopic and pathological results were available and before the surveillance time.
88892686|NCT06039917|No Intervention|Normal group|The patients in the control group were observed in the clinical natural state of surveillance without automatic surveillance system or manual reminder.
88892687|NCT06039904|Experimental|Arm A|Arm A was first assigned to Treatment I of natural rubber knee support followed by Treatment II of sponge knee support
88892688|NCT06039904|Experimental|Arm B|Arm B was first assigned to Treatment II of sponge knee support followed by Treatment I of natural rubber knee support
88892689|NCT06039891|Experimental|Nimotuzumab, Tislelizumab group|Subjects will receive Nimotuzumab 400 mg/time, intravenous injection, qw; Tislelizumab 200 mg/time, q3w until disease progression, intolerable toxicity, or 24 months of medication
89414843|NCT05197621||Sample Collection at Delivery Arm|Pregnant patients who have tested positive for COVID during their pregnancy or have a positive COVID test at the time of admission to Labor & Delivery, who consent to collection of maternal blood, cord blood, placenta, and breast milk samples, as well as neonatal blood and stool samples. Patients testing negative for COVID at the time of admission to Labor & Delivery can be enrolled in the study as controls.
88892692|NCT06039839|Active Comparator|first group|Healing of the donor area will be accomplished without the use of collagen matrix
88892693|NCT06039839|Experimental|second group|Closure of the wound defect in the donor area in the region of the maxillary tuberosity will be carried out after CTG harvesting with the use of collagen matrix
88892694|NCT06039748||AngioQFA|
88892695|NCT06039722|Experimental|experimental group|Each subject underwent pulse ablation catheter ablation
88892696|NCT06039696||patients received mNGS test|After enrolment, patients will receive mNGS test.
88892697|NCT06039657|Experimental|SEAS group|The SEAS therapy program comprised a one-year supervised exercise regimen. Supervised sessions were scheduled weekly for the initial month, bi-weekly for the second month, and monthly from the third to the sixth month. Thereafter, sessions were held bimonthly, each lasting one hour. Home exercises were designed to encompass 10-12 distinct exercises, with an approximate duration of 40-45 minutes per session
88892698|NCT06039657|Active Comparator|Standard Care Group|Standard care program aimed to provide patients with basic postural education and exercises in a single session, followed by one year of observation to ensure standard care.
88892699|NCT06039631|Experimental|Organ preservation surgery|In the surgical group, patients will undergo curative surgery for laryngeal/hypopharyngeal cancer along with cervical lymph node dissection. Organ preservation surgery is recommended, and the specific surgical approach will be chosen based on individual case characteristics and the treatment protocols followed at our center. Depending on postoperative pathology results, adjuvant radiotherapy or concurrent radiochemotherapy may be administered as deemed necessary. If postoperative pathology indicates extracapsular invasion of lymph nodes or positive surgical margins, concurrent radiochemotherapy based on cisplatin is recommended. Starting three weeks after the completion of radiotherapy, patients will receive adjuvant immunotherapy using a specific protocol of toripalimab at a dose of 240 mg every 3 weeks for a total of 8 cycles.
88892700|NCT06039631|Other|Concurrent chemoradiation|In the concurrent radiochemotherapy group, patients will undergo target delineation based on the scope before induction chemotherapy. Radiotherapy will be administered at a total dose of 70 Gy over 35 fractions, and concurrent chemotherapy will involve weekly administration of cisplatin. Starting three weeks after the completion of radiotherapy, patients will receive adjuvant immunotherapy using a specific protocol of toripalimab at a dose of 240 mg every 3 weeks for a total of 8 cycles.
88892701|NCT06039592||Modified Drug Therapy Group|Patient in this group will undergo a one-year course of medication, including Captopril(tablet, 0.3mg/kg, tid), Metoprolol(tablet, 0.2mg/kg, bid), Spironolactone(tablet, 2-4mg/kg, bid), Torsemide(tablet, 0.2-0.5mg/ mg, bid), and Potassium Citrate(powder, 0.06g/kg, tid).
88892702|NCT06039592||Traditional Drug Therapy Group|Patient in this group will undergo a one-year course of medication, including Torsemide(tablet, 0.2-0.5mg/mg, bid) and Potassium Citrate(powder, 0.06g/kg, tid).
88892703|NCT06039553||Pulmonary Artery Banding Group|Patient in this group will undergo pulmonary artery banding surgery for congenital heart disease.
88892704|NCT06039540||Modified Drug Therapy Group|Patient in this group will undergo a one-year course of medication, including Captopril(tablet, 0.3mg/kg, tid), Metoprolol(tablet, 0.2mg/kg, bid), Spironolactone(tablet, 2-4mg/kg, bid), Torsemide(tablet, 0.2-0.5mg/ mg, bid), and Potassium Citrate(powder, 0.06g/kg, tid).e Traditional Drug Therapy Group
88892705|NCT06039540||Traditional Drug Therapy Group|Patient in this group will undergo a one-year course of medication, including Torsemide(tablet, 0.2-0.5mg/mg, bid) and Potassium Citrate(powder, 0.06g/kg, tid).
88892706|NCT06039488|Experimental|Exercise|2 days/week of resistance and cardiovascular exercise for 8-weeks
88892707|NCT06039475||Case|Patients with AMS/HACE/HAPE
89414844|NCT05191446|Experimental|Stepped alcohol intervention (SAT) to reduce unhealthy alcohol use|For participants randomized to SAT, consistent with stepped care, treatment will begin with lower intensity services that are stepped up, if necessary, at a predefined time point. Step 1 consists of three motivational interviewing (MI)sessions delivered every 2 weeks. At the 3-month assessment, those with non-response to MI, defined as continued unhealthy alcohol use in the prior 14 days, will be referred to on site physician managed addiction specialty services (Step 2) for higher intensity services.
89414845|NCT05191446|Active Comparator|Usual Care (UC)|UC participants will receive their usual services in hepatology. They will also be given publicly available patient education materials regarding risk associated with unhealthy drinking (mail/email or in-person if desired) and will be asked to follow up with their physician should they have questions about information provided in the handouts. UC participants' hepatology provider will be notified if AUDIT-C scores are greater than 3 at baseline. All UC participants will have access to alcohol and other substance use treatment available to patients at their respective sites.
89414846|NCT05174767|Experimental|Acute DeBakey Type I Dissection|In eligible patients, the ascending aorta is transected and removed in a routine standard of care manner utilizing hypothermic circulatory arrest; the operator will leave at least 10 mm (1.0 cm) aortic tissue proximal to the innominate artery. AMDS is pre-loaded onto the delivery system and is delivered into the true lumen through the open distal aorta and implanted according to the instructions for use.
89414847|NCT05161767||Recovered group|This will group will consists of people who have a remission of their symptoms at 6-months follow-up after whiplash injury.
89414848|NCT05161767||non-recovered group|This will group will consists of people who develop persistent symptoms at 6-months follow-up after whiplash injury.
89414849|NCT05156827|Experimental|TB006|Participants will receive intravenous (IV) 3 infusions of 4000 milligrams (mg) TB006, one every 28 days (Q28D).
89414850|NCT05156827|Placebo Comparator|Placebo|Participants will receive an IV infusion of normal saline 500 milliliters (mL) Q28D.
89414851|NCT05136651|Experimental|Immediate Treatment|Couples assigned to the Immediate Treatment condition will begin the OurRelationship program immediately following random assignment.
89414852|NCT05136651|Other|Waitlist Control|Couples assigned to the Waitlist Control condition will begin the OurRelationship program following a 2-month delay after random assignment.
89414853|NCT05129371|Active Comparator|Breathing Exercise Group|This group will be given breathing exercises in accordance with the determined protocol.
89414854|NCT05129371|Placebo Comparator|Placebo Breathing Group|Normal breathing of this group will be monitored.
89414855|NCT05129371|No Intervention|Control Group|No application will be made to this group.
89414856|NCT05124912|Other|Recurrent Tumor|Receives Laser Interstitial Thermal Therapy (LITT) followed by surveillance or Receives Laser Interstitial Thermal Therapy (LITT) followed by hypofractionated radiation therapy (RT).
89414857|NCT05124912|Other|Radiation Necrosis|Receives Laser Interstitial Thermal Therapy (LITT) and best medical management with steroids or Receives best medical management with steroids.
89414858|NCT05123001|Experimental|Device physiological monitoring|Patients will receive wearable sensor devices (Biostrap arm band)
89414859|NCT05123001|No Intervention|Microsampling|Blood microsamples will be collected at start of conditioning chemotherapy, daily while in the hospital, and after leaving the hospital and outpatient appointments.
89414860|NCT05123001|No Intervention|Biostrap mobile App|Data collection from wearable sensor.
89414861|NCT05114876|No Intervention|Standard of Care|Standard of care
89414862|NCT05114876|Active Comparator|Intervention|Multicomponent delirium-risk prevention bundle
89414863|NCT05107674|Experimental|Phase 1a Dose Escalation of NX-1607 (monotherapy)|Multiple dose levels and dosing regimen of NX-1607 to be evaluated; determination of MTD/Phase 1b recommended dose.
89414864|NCT05107674|Experimental|Phase 1a Food Effect|Impact of food on NX-1607 bioavailability and tolerability to be evaluated
89414865|NCT05107674|Experimental|Phase 1b Dose Expansion in platinum-resistant EOC|Patients with platinum-resistant EOC, including primary peritoneal and fallopian tube carcinoma
89414866|NCT05107674|Experimental|Phase 1b Dose Expansion in advanced gastric/GEJ cancer|Patients with recurrent, locally advanced, or metastatic gastric or GEJ adenocarcinoma
89414867|NCT05107674|Experimental|Phase 1b Dose Expansion in HNSCC|Patients with recurrent, locally advanced, or metastatic HNSCC
89414868|NCT05107674|Experimental|Phase 1b Dose Expansion in recurrent melanoma|Patients with recurrent and either metastatic or unresectable Melanoma
88892708|NCT06039475||Control|Healthy Individuals
88892709|NCT06039462|Other|Children undergoing surgery|
88892710|NCT06039423|Active Comparator|Group (M)|"The M-TAPA block will be combined with general anaesthesia.~:"
88892711|NCT06039423|Placebo Comparator|Group (C)|(control group) conventional general anaesthesia receiving multimodal analgesia.
88892712|NCT06039332|Experimental|Fittig with DSL-BCD|The new way of fitting the audioprocessor
88892713|NCT06039332|Active Comparator|Fitting with DSL v5|The way of fitting the audioprocessor until now
88892714|NCT06039319||Appropriate Growth|Pregnant individuals with normal estimated fetal weight
88892715|NCT06039319||Fetal Growth Restricted|Pregnant individuals with fetal growth restriction
88892716|NCT06039306|Experimental|intervention|Participants will be given 2 servings immunonutrition daily for five (5) days before tentative elective surgery. ERAS protocol will implement and continued 2 servings of immunonutrition for post-operative seven (7) days.
88892717|NCT06039306|No Intervention|conventional|Participants will be on usual diet intake before tentative elective surgery. ERAS protocol will implement and will be prescribed 2 servings of polymeric formula daily only if unable to finish 75% of the diet served in ward.
88892718|NCT06039280|Experimental|NAC+Dexamethasone|"NAC started at 12 hr prior to procedure - (150 mg/kg/hr for 1 hr followed by 12.5 mg/Kg/hr for 4 hr, then continuous infusion of 6.25 mg/h for 48 after the procedure.~Dexamethasone 20 mg in 5 ml NS 1 hour prior to procedure and 8 mg in 5 ml NS at day 2, day 3. Placebo 5 ml NS 1 hr prior to procedure."
88892719|NCT06039280|Active Comparator|NAC+Placebo|NAC started at 12 hr prior to procedure - (150 mg/kg/hr for 1 hr followed by 12.5 mg/Kg/hr for 4 hr, then continuous infusion of 6.25 mg/h for 48 after the procedure.
88892720|NCT06039267||Healthy Controls|Healthy males and females, ages 50-90
88892721|NCT06039267||Mild Cognitive Impairment|Males and females with mild cognitive impairment, ages 50-90
89414869|NCT05107674|Experimental|Phase 1b Dose Expansion in advanced NSCLC|Patients with Stage IV adenocarcinoma NSCLC
89414870|NCT05107674|Experimental|Phase 1b Dose Expansion in mCRPC|Patients with mCRPC who received a minimum of 2 prior lines of therapy in the advanced setting including androgen receptor-directed therapy and a taxane-based chemotherapy and has PSA or radiographic progression
89414871|NCT05107674|Experimental|Phase 1b Dose Expansion in mixed solid tumor cohort|Cohort of mixed solid tumor indications consisting of patients with MPM, TNBC, locally advanced or metastatic urothelial cancer, cervical cancer, or DLBCL/DLBCL-RT
89414872|NCT05107674|Experimental|Phase 1b Dose Expansion in DLBCL including DLBCL-RT|Patients with DLBCL or DLBCL-RT, previously treated with standard, systemic chemotherapy, are not candidates for standard treatment options, or will otherwise be prevented from receiving any standard treatment options.
89414873|NCT05107674|Experimental|Phase 1a Dose Escalation of NX-1607 in combination with Paclitaxel|Indications may include but are not limited to, platinum resistant EOC, gastric/GEJ cancer. HSNCC, NSCLC, TNBC, locally advanced or metastatic urothelial cancer and cervical cancer.
89414874|NCT05107674|Experimental|Phase 1b Dose Expansion of NX-1607 in combination with Paclitaxel|Indications may include but are not limited to, platinum resistant EOC, gastric/GEJ cancer, HSNCC, NSCLC, TNBC, and locally advanced or metastatic urothelial cancer
89414875|NCT05107674|Experimental|Phase 1b Dose Expansion in MSS CRC|Patients with histologically confirmed MSS CRC, known KRAS WT, and must have been previously treated with > 2 lines of systemic therapy including a fluoropyrimidine, irinotecan, and/or oxaliplatin (and EGFR inhibitor if known Ras wild type)
89414876|NCT05104736|Experimental|PT-112|PT-112 will be administered intravenously on Days 1, 8 and 15 of a 28-day cycle at a dose of 360 mg/m2 until disease progression, development of intolerable adverse events, or until 8 years after an individual participant has been on study
89414877|NCT05098132|Experimental|Part A: STK-012 weekly (QW) monotherapy dose escalation|STK-012 will be administered in sequential ascending doses as monotherapy subcutaneously (SC) QW until unacceptable toxicity, disease progression, or withdrawal of consent.
89414878|NCT05098132|Experimental|Part B: STK-012 every three weeks (Q3W) monotherapy dose escalation|STK-012 will be administered in sequential ascending doses as monotherapy SC Q3W until unacceptable toxicity, disease progression, or withdrawal of consent.
89414879|NCT05098132|Experimental|Part C: STK-012 Q3W + pembrolizumab dose escalation|STK-012 will be administered in sequential ascending doses SC Q3W in combination with a fixed dose of pembrolizumab intravenously (IV) Q3W until unacceptable toxicity, disease progression, or withdrawal of consent.
89414880|NCT05098132|Experimental|Part D: Dose expansions|STK-012 will be administered at the RP2D SC as monotherapy and in combination with a fixed dose of pembrolizumab IV Q3W until unacceptable toxicity, disease progression, or withdrawal of consent.
89414881|NCT05095779|Active Comparator|Standard Care|Participants randomized to Standard Care will be offered weekly counseling calls and pharmacotherapy.
89414882|NCT05095779|Experimental|Standard Care + Financial Incentives|Financial Incentives participants will receive standard care for completing counseling calls.
89414883|NCT05092412|Experimental|Low-dose radiotherapy combined with durvalumab, etoposide, and cisplatin/carboplatin|
89414884|NCT05059977|Experimental|TAK-881 0.4 g/kg (in-line warmed)|Participants will receive a single dose of TAK-881 comprising of 0.4 gram per kilogram (g/kg) (in-line warmed) Immune Globulin Subcutaneous (IGSC), 20 percent (%) at progressively increased infusion rates and Recombinant Human Hyaluronidase (rHuPH20) dose of 80 unit per gram (U/g) immunoglobulin G (IgG) on Day 1 of the study treatment period.
89414885|NCT05059977|Experimental|TAK-881 1.0 g/kg (in-line warmed)|Participants will receive a single dose of TAK-881 comprising of 1.0 g/kg (in-line warmed) IGSC, 20% at progressively increased infusion rates and rHuPH20 dose of 80 U/g IgG on Day 1 of the study treatment period.
89414886|NCT05059977|Experimental|TAK-881 1.0 g/kg (un-warmed)|Participants will receive a single dose of TAK-881 comprising of 1.0 g/kg (un-warmed) IGSC, 20% at progressively increased infusion rates and rHuPH20 dose of 80 U/g IgG on Day 1 of the study treatment period.
89414887|NCT05051384|Experimental|Intraocular tumor|New sonographic software technique on ultrasonography to detect low-vascular flow inside intraocular tumors
88892722|NCT06039267||Early Alzheimer's Disease|Males and females with early Alzheimer's disease, ages 50-90
89414888|NCT05037851|Experimental|Opelconazole|14.8 mg opelconazole administered twice daily for 12 weeks
89414889|NCT05037851|Active Comparator|Standard of Care (SoC)|Mold-active SoC prophylaxis/pre-emptive therapy
89414890|NCT05035771|Experimental|Pressure wire measurements|
89414891|NCT05024851||Patients with Psychogenic pruritus|
89414892|NCT05024851||Patients with Neuropathic Pruritus|
89536745|NCT02723201|Experimental|Part-1, Period 2: TAK-020 17.5 mg Co-crystal Tablet (CCT)|Single oral dose 17.5 mg, on Day 1, followed by 7 days of washout. Dose will be the same as Part 1, Period 1.
88892723|NCT06039254|Experimental|Healthy subjects group|
88892724|NCT06039254|Experimental|Mild renal impairment group|
88892725|NCT06039254|Experimental|Moderate renal impairment group|
88892726|NCT06039215|Experimental|Experimental group|Respirator settings are adjusted by nurses according to a pre-established care protocol that complies with international recommendations. The nurse assesses the patient's respiratory status and readjusts the artificial respirator settings if necessary, at least twice a day.
89005776|NCT00240084|Experimental|Nesiritide infusion|Single arm study. 24-hour infusion of B-type Natriuretic Peptide at a dose of 0.01 mcg/kg/minute.
88892727|NCT06039215|No Intervention|Control group|The ventilator settings are adjusted in line with the centre's usual practice. No change from usual management of acute respiratory distress syndrome.
88892728|NCT06039202|Experimental|CA102N plus Trifluridine/tipiracil (TAS-102)|CA102N administered as 0.72 mg/kg of nimesulide equivalents on Days 1 and 15 of each 28-day cycle in combination with TAS-102 at 35 mg/m2/dose orally twice daily (BID) on Days 1 through 5 and Days 8 through 12 of each 28-day cycle. Administration sequence will be CA102N then TAS-102 (IV then oral)
88892729|NCT06039202|Active Comparator|Bevacizumab plus Trifluridine/tipiracil (TAS-102)|bevacizumab 5 mg/kg on Days 1 and 15 of each 28-day cycle in combination with 35 mg/m2 of TAS-102 orally twice daily (BID) on Days 1 through 5 and Days 8 through 12 of each 28-day cycle. Administration sequence will be bevacizumab then TAS-102 (IV then oral)
88892730|NCT06039176||Mayo Clinic|Obtain demographic and clinical data prior to and following implantation of a HeartMate 3 ® device. HeartMate 3® downloaded pump operations data will be obtained at the following scheduled intervals: discharge from the ICU, at the time of discharge from the hospital (or ± 3 days from discharge), 3-months post-implant, 6-months post-implant, and lastly at 12-months post-implant. Downloadable pump operations data will include evaluation of suction events, low flow and other adventitious alarms, PI events and incidence of power cable disconnects beyond 20 seconds. The previously mentioned data will also be collected during any unplanned office visits, any admission regardless of the reason, unplanned ER visits related to equipment problems or any serious adverse event-related ER visits.
88892731|NCT06039176||University of Florida|Obtain demographic and clinical data prior to and following implantation of a HeartMate 3 ® device. HeartMate 3® downloaded pump operations data will be obtained at the following scheduled intervals: discharge from the ICU, at the time of discharge from the hospital (or ± 3 days from discharge), 3-months post-implant, 6-months post-implant, and lastly at 12-months post-implant. Downloadable pump operations data will include evaluation of suction events, low flow and other adventitious alarms, PI events and incidence of power cable disconnects beyond 20 seconds. The previously mentioned data will also be collected during any unplanned office visits, any admission regardless of the reason, unplanned ER visits related to equipment problems or any serious adverse event-related ER visits.
88892732|NCT06039176||University of Utah|Obtain demographic and clinical data prior to and following implantation of a HeartMate 3 ® device. HeartMate 3® downloaded pump operations data will be obtained at the following scheduled intervals: discharge from the ICU, at the time of discharge from the hospital (or ± 3 days from discharge), 3-months post-implant, 6-months post-implant, and lastly at 12-months post-implant. Downloadable pump operations data will include evaluation of suction events, low flow and other adventitious alarms, PI events and incidence of power cable disconnects beyond 20 seconds. The previously mentioned data will also be collected during any unplanned office visits, any admission regardless of the reason, unplanned ER visits related to equipment problems or any serious adverse event-related ER visits.
88892733|NCT06039176||University of California, San Francisco|Obtain demographic and clinical data prior to and following implantation of a HeartMate 3 ® device. HeartMate 3® downloaded pump operations data will be obtained at the following scheduled intervals: discharge from the ICU, at the time of discharge from the hospital (or ± 3 days from discharge), 3-months post-implant, 6-months post-implant, and lastly at 12-months post-implant. Downloadable pump operations data will include evaluation of suction events, low flow and other adventitious alarms, PI events and incidence of power cable disconnects beyond 20 seconds. The previously mentioned data will also be collected during any unplanned office visits, any admission regardless of the reason, unplanned ER visits related to equipment problems or any serious adverse event-related ER visits.
88892734|NCT06039176||Advocate Health|Obtain demographic and clinical data prior to and following implantation of a HeartMate 3 ® device. HeartMate 3® downloaded pump operations data will be obtained at the following scheduled intervals: discharge from the ICU, at the time of discharge from the hospital (or ± 3 days from discharge), 3-months post-implant, 6-months post-implant, and lastly at 12-months post-implant. Downloadable pump operations data will include evaluation of suction events, low flow and other adventitious alarms, PI events and incidence of power cable disconnects beyond 20 seconds. The previously mentioned data will also be collected during any unplanned office visits, any admission regardless of the reason, unplanned ER visits related to equipment problems or any serious adverse event-related ER visits.
88892735|NCT06039176||University of Rochester Medical Center|Obtain demographic and clinical data prior to and following implantation of a HeartMate 3 ® device. HeartMate 3® downloaded pump operations data will be obtained at the following scheduled intervals: discharge from the ICU, at the time of discharge from the hospital (or ± 3 days from discharge), 3-months post-implant, 6-months post-implant, and lastly at 12-months post-implant. Downloadable pump operations data will include evaluation of suction events, low flow and other adventitious alarms, PI events and incidence of power cable disconnects beyond 20 seconds. The previously mentioned data will also be collected during any unplanned office visits, any admission regardless of the reason, unplanned ER visits related to equipment problems or any serious adverse event-related ER visits.
89005777|NCT00243789|Active Comparator|1|Pentoxifylline
89005778|NCT00243789|No Intervention|2|Placebo
89005779|NCT00214175||patients|patients who will receive XRT
89005780|NCT00214175||matched volunteers|Spouse or sibling
89005781|NCT00214253|Experimental|1|Thiazolidinedione therapy
89005782|NCT00214253|No Intervention|2|
89005783|NCT00214331||1|ciprofloxacin
89005784|NCT00214331||2|azithromycin
89005785|NCT00214331||3|gentamicin
89005786|NCT00244023|Experimental|1|Testosterone gel (intervention)
89005787|NCT00244023|Placebo Comparator|2|one sachet of placebo gel once a day, possibly titrated to 2 sachets if insufficient efficacy
89414893|NCT05022472|Experimental|Intervention|We will use a 2-armed randomized controlled trial (RCT) where Latino and AA adults >18 years or older from six participating communities and surrounding community health centers (CHC) will be assigned to the 2 VIDA! intervention (n=3 CHC; N=500 participants) or to the control site (e.g., standard of care) (n=3 CHC; N=500 participants). The two major components of the 2VIDA! intervention are: COVID-19 Individual Awareness and Education, COVID-19 Community Outreach and Health Promotion, COVID-19 Individual Health Education and Linkages to Medical and Supportive Services, and pop-up vaccination stations in Latino and AA communities.
89414894|NCT05022472|No Intervention|Standard of care|The standard of care for vaccine delivery at the control sites. This includes individuals who make an appointment on their own or receive the vaccine at a health center and may receive information about the vaccine from their primary healthcare provider.
89414895|NCT05018416|Experimental|2 REACT injections|Cohort 1 subjects will receive 2 REACT injections in the biopsied and non-biopsied contralateral kidneys 3 months apart (+60 days).
89414896|NCT05018416|Experimental|1 REACT Injection|Cohort 2 subjects will receive 1 REACT injection into the biopsied kidney and if a pre-defined trigger is met, will undergo a second REACT injection into the contralateral kidney.
89414897|NCT05016310|Experimental|High Vit D|High Dose Vitamin D
89414898|NCT05016310|Active Comparator|SOC Vit D|Standard of Care Vitamin D
89414899|NCT05014828|Experimental|Safety Run in Stage and Combination Assessment|lenvatinib + tislelizumab
89193067|NCT05621460|Experimental|500mL still water first, then 50mL still water, then 500 mL carbonated water|Participants will undergo this test on three separate days. On each day participants will be asked to drink a glass of water: either a 50mL drink of still water (control condition), a 500mL drink of still (non-carbonated) water, or a 500mL drink of carbonated water. In this arm of the study, participants will receive 500mL still water on the first test day, 50mL still water on the second test day, then 500mL carbonated water on the third day.
89414900|NCT05013736||Infants|Pre-term and term born infants with corrected gestational age between term age and 24 months with radiologically-confirmed acute unilateral or bilateral brain lesions, including perinatal stroke, neonatal hemorrhagic or thrombotic stroke, involving the motor cortex and/or subcortical structures, and intracranial hemorrhage, involving the motor cortex and/or subcortical white matter, or periventricular leukomalacia. Parents/legal guardians able to attend study visits at the University of Wisconsin-Madison.
89414901|NCT05011123|Experimental|Group 1|1 injection of vYF vaccine at Day 1
89414902|NCT05011123|Active Comparator|Group 2|1 injection of Stamaril vaccine at Day 1
89414903|NCT04985773|Experimental|Lacrosse NSE ALPHA percutaneous coronary intervention (PCI)|Percutaneous coronary intervention (PCI) in which at least one Lacrosse NSE ALPHA device is used.
89414904|NCT04968808|Active Comparator|Staged in-hospital CR (complete revascularization)|Non-infarct related artery (IRA) will be revascularized in other day (during hospitalization) after percutaneous coronary intervention (PCI) for IRA. Non-IRA lesion which have equal or more than 70% diameter stenosis by visual estimation will be revascularized without fractional flow reserve (FFR) evaluation. Non-IRA lesion with diameter stenosis 50-69% by visual estimation will be evaluated using FFR device. In case of FFR value more than 0.8, non-IRA lesion wll be deferred without PCI. If FFR value was equal or less than 0.8, non-IRA lesion will be revascularized.
89414905|NCT04968808|Experimental|Immediate CR (complete revascularization)|Non-infarct related artery (IRA) will be revascularized immediately after percutaneous coronary intervention (PCI) for IRA (during index PCI). Non-IRA lesion which have equal or more than 70% diameter stenosis by visual estimation will be revascularized without fractional flow reserve (FFR) evaluation. Non-IRA lesion with diameter stenosis 50-69% by visual estimation will be evaluated using FFR device. In case of FFR value more than 0.8, non-IRA lesion wll be deferred without PCI. If FFR value was equal or less than 0.8, non-IRA lesion will be revascularized.
89414906|NCT04963413|Experimental|Autologous DCs derived from PBMC loaded with RNA|Autologous DCs derived from PBMC loaded with RNA encoding the human CMV matrix protein pp65-flLAMP plus GM-CSF
89414907|NCT04956640|Experimental|LY3537982 (Dose Escalation)|LY3537982 administered orally.
89414908|NCT04956640|Experimental|LY3537982 (Dose Expansion)|LY3537982 administered orally either alone or with another investigational agent.
89414909|NCT04943536|Experimental|Biolen+Radiation Therapy|Localized single delivery of the Biolen implant (polymer + bicalutamide) with radiation therapy
89414910|NCT04942483||Preschool children with a history of wheeze, aged 1 to 5 years old|"This is a pragmatic, observational study involving preschool children with wheeze aged one to five years old. All treatment and routine monitoring decisions will be at the discretion of their treating general practitioner (GP) or paediatrician (as per usual clinical practice), blinded to the study measurements.~The following three biomarker tests will be performed a) atopic sensitisation, b) blood eosinophil count and c) FeNO (off-line method)."
89414911|NCT04935372||Subjective cognitive decline|Male and female, aged 55 to 80 years with subjective cognitive decline, either cognitively unimpaired or with mild cognitive impairment
89414912|NCT04926922||HONOR TB participants with positive IGRA and/or TST during initial phase|Adult participants who who tested positive on IGRA and or TST during initial phase and meet the study-specific eligibility criteria.
89414913|NCT04925219|Experimental|Remotely supervised exercise|"Best medical therapy including aspirin 75mg od + rivaroxaban 2.5mg bd (if not tolerated clopidogrel 75mg od), atorvastatin 80mg and smoking cessation referral as per NICE guideline for PAD.~Intervention = electronic walking log and fortnightly video/telephone call with physiotherapist for 3 months."
89414914|NCT04925219|Active Comparator|Self-directed exercise|"Best medical therapy including aspirin 75mg od + rivaroxaban 2.5mg bd (if not tolerated clopidogrel 75mg od), atorvastatin 80mg and smoking cessation referral as per NICE guideline for PAD.~Control = electronic walking log and instructions to exercise 4 times per week for 3 months"
89414915|NCT04920812||Mitochondrial diseases|annalysing with methology of multi-OMICS integration we will determined which RNA-Seq data (from muscle or fibroblasts) are the most informative for the interpretation of VUS identified by WES for patients suspected of mitochondrial myopathy.
89414916|NCT04911816|Experimental|Hydroxychloroquine|Hydroxychloroquine sulfate
89535868|NCT03315923|Experimental|Rituximab|Patients in this group will receive 1g of rituximab in 500 cc normal saline serum through intravenous infusion as one treatment course. The treatment course will be repeated in 6 months. Along with rituximab, 100 mg methylprednisolone, 10 mg chlorpheniramine, and 500 mg acetaminophen will also be injected to decrease side effects of rituximab.
89414917|NCT04865133||Observational (biospecimen collection, medical record)|Patients undergo blood sample collection at baseline (prior to first COVID-19 vaccination), prior to second vaccination, 1, 6, and 12 months after the last vaccination. Patients receiving a booster vaccine will undergo blood collection prior to and 1-3 months after vaccination. Patients who receive the types of COVID-19 vaccines that do not require the second injection skip blood sample collection at this time point. This study will collect information regarding the type of COVID-19 vaccine received, date of vaccine injection, and any side effects associated with the COVID-19 vaccine that trial participant encountered. This study will also review the medical record for outcomes and information related to the blood testing.
89414918|NCT04864782|Experimental|QL1604+Chemotherapy|On Day 1 of each 21-day cycle, participants receive an intravenous (IV) infusion of QL1604 200 mg plus Investigator choice of chemotherapy (paclitaxel 175 mg/m^2 plus cisplatin 70 mg/m^2 or paclitaxel 175 mg/m^2 plus carboplatin Area Under the Curve (AUC) 6)
89414919|NCT04862780|Experimental|Part 1A: BLU-945 as monotherapy|Phase 1 dose escalation of BLU-945 as monotherapy at various dose levels
89005788|NCT02962622|Experimental|Hispanic women living with HIV|High intensity interval training (HIIT) on normally active but physically untrained HIV+ Hispanic women, one with (n=15) and other without (n=15) neuro-cognitive impairment (HAND) on antiretroviral therapy (CART) receive 2 weeks, 6 sessions of 8 x 60 seconds cycling bouts eliciting approximately 80% of maximal heart rate with 60 second rest between bouts after which they will receive 4 week, 12 sessions of 10 x 60 seconds cycling bouts eliciting approximately 90% of maximal heart rate with 60 second rest between bouts.
89005789|NCT02962622|Experimental|Hispanic women living without HIV|High intensity interval training (HIIT) on a comparison group of 15 Hispanic women without HIV receive 2 weeks, 6 sessions of 8 x 60 seconds cycling bouts eliciting approximately 80% of maximal heart rate with 60 second rest between bouts after which they will receive 4 week, 12 sessions of 10 x 60 seconds cycling bouts eliciting approximately 90% of maximal heart rate with 60 second rest between bouts.
89414920|NCT04862780|Experimental|Part 1B: BLU-945 with osimertinib|Phase 1 dose escalation of BLU-945 in combination with osimertinib 80 mg tablets for oral administration
89005790|NCT04720950|Experimental|Morning exercise|1 hour of exercise completed between 0800-1000
89005791|NCT04720950|Experimental|Evening exercise|1 hour of exercise completed between 1800-2000
89005792|NCT00414531|Other|SIM|Patients diagnosed to have or not to have Statin induced Myopathy
89005793|NCT00214682|Experimental|Folic acid (400mcg) + Vitamin B12 (100 mcg)|The vitamin intervention was a daily oral dose of one tablet consisting of folic acid 400 mcg + vitamin B12 100 mcg. The folic acid dose of 400 mcg / day was selected as it has been shown to be the dose associated with 90% of the maximal decrease in plasma homocysteine concentration for older individuals. Participants received 1 bottle x 200 tablets in six-month supplies at baseline, 6 months, 12 months, and 18 months. Adherence was monitored by telephone interviews (6 weeks, 6-, 12-, and 24 months) and 10 brief telephone tracking calls (1 - 5 weeks, and 4-, 8-, 13-, 18-, and 22-months).
89005794|NCT00214682|Experimental|Mediated physical activity promotion|Individuals in the Physical Activity Promotion group received a manual designed to promote older individuals' physical activity participation to the level recommended to gain both physical and mental health benefits. The framework of the physical activity manual was informed by social cognitive theory and the transtheoretical model, and comprised five sections that reflect stages of behaviour change, including; precontemplation, contemplation, preparation, action, and maintenance. The manual contained evidence-based strategies and skills to assist people in increasing their physical activity levels. Participants received a pedometer at the commencement of the intervention as pedometry step / minute values are useful as an indicator of moderate to vigorous physical activity with total number of steps for one week recorded during the brief telephone calls at 1-5 weeks, and 4-, 8-, 13-, 18-, and 22- months.
89005795|NCT00214682|Experimental|Mental health literacy|This MHL intervention comprised 10 modules, with nine of these specifically written for older adults. Modules 1 to 5 comprised information on depression and the evidence-based treatment for older adults. The additional MHL modules were booklets addressing evidence-based strategies and treatments for depression. It was delivered in a way to foster support and ensure that participants worked through the material systematically. Modules 1 to 5 were delivered in consecutive weeks as previous research indicates that the maximum impact of MHL on depressive symptoms may occur within the first six weeks of the intervention. Telephone interviewers contacted participants once a week for 5 consecutive weeks to motivate and support participants. There were an additional 5 check-in telephone calls, and Modules 6 to 10 of the MHL material that were delivered via postal mail at 4- (Module 6), 8- (Module 7), 13- (Module 8), 18- (Module 9), and 22- months (Module 10).
89005796|NCT00214682|Placebo Comparator|Placebo tablet|A placebo tablet was the attention control intervention for the folic acid + vitamin B12 intervention group. Participants received 1 bottle x 200 tablets in 6-month supplies at baseline, 6 months, 12 months, and 18 months. Adherence was monitored by telephone interviews (6 weeks, 6-, 12-, and 24 months) and 10 brief telephone tracking calls (1 - 5 weeks, and 4-, 8-, 13-, 18-, and 22-months) during which participants counted their left-over tablets.
89005797|NCT00214682|Active Comparator|Nutrition information|The attention control intervention for the physical activity intervention was printed nutrition literacy and included information concerning the recommended dietary guidelines for older Australians, as well as strategies and additional information to facilitate beneficial dietary behaviours. The same procedure was adhered to as the physical activity intervention to ensure adequate attention control. Participants in the nutrition promotion intervention received 5 brief telephone calls from an interviewer to facilitate adherence to the intervention, and to offer support and clarification of the materials. Participants received five further brief telephone calls as well as nutrition newsletters that were delivered via postal mail at 4-, 8-, 13-, 18-, and 22- months.
89414921|NCT04862780|Experimental|Phase 2, Group 1: BLU-945 as monotherapy|Phase 2 expansion group for BLU-945 as monotherapy at a dose determined during Part 1A in patients with EGFR T790M and C797S mutations
89414922|NCT04862780|Experimental|Phase 2, Group 2: BLU-945 as monotherapy|Phase 2 expansion group for BLU-945 as monotherapy at a dose determined during Part 1A in patients with EGFR T790M mutations
89414923|NCT04862780|Experimental|Phase 2, Group 3: BLU-945 as monotherapy|Phase 2 expansion group for BLU-945 as monotherapy at a dose determined during Part 1A in patients with EGFR C797S mutations
89414924|NCT04862780|Experimental|Phase 2, Group 4: BLU-945 with osimertinib|Phase 2 expansion group for BLU-945 with osimertinib at a dose determined during Part 1B in patients
89005798|NCT00214682|Active Comparator|Pain and arthritis management information|Pain and Arthritis Information was used as the attention control intervention for the MHL intervention and comprised 10 modules. Modules 1 to 5 were contained in an Arthritis Australia consumer guide for arthritis management. Modules 6 to 10 were a series of information pamphlets on pain management, osteoporosis and falls prevention. The delivery of the Pain Information was identical to the MHL intervention with Modules 1 to 5 distributed via postal mail in five consecutive weeks (1-5 weeks), while the remaining intervention modules were delivered at 4- (Module 6), 8- (Module 7), 13- (Module 8), 18- (Module 9), and 22- months (Module 10). Participants also received 10 brief calls from a telephone interviewer that coincided with receiving the print intervention materials.
89005799|NCT00214760|Experimental|PGET|
89005800|NCT00214760|Active Comparator|PMMA|
89005801|NCT00240513|Active Comparator|Minocycline 3 mo|Minocycline 3 mo
89005802|NCT00240513|Experimental|Minocycline plus Tretinoin|Minocycline plus Tretinoin for 3 months
89005803|NCT00240630|Placebo Comparator|Arm 1|placebo to match
89005804|NCT00240630|Experimental|Arm 2|Treximet (sumatriptan/naproxen sodium)
89005805|NCT00244218|Experimental|Treatment Arm|Drug: tetrahydrobiopterin (BH4) Either placebo or BH4, 10mg/kg/day will be given for three months. Then the patient will be given three additional months of open label BH4 at the same rate.
89005806|NCT00244218|Placebo Comparator|Control Arm|Drug: tetrahydrobiopterin (BH4) Either placebo or BH4, 10mg/kg/day will be given for three months. Then the patient will be given three additional months of open label BH4 at the same rate.
89414925|NCT04845958||Pediatric Patients with Unexplained Enlarged Spleen|
89414926|NCT04842331|Experimental|RESP301 + Standard of Care (SOC)|"Treatment arm will receive the study drug RESP301 alongside standard of care (SOC).~RESP301 will be administered for a period of 7 days (i.e. 21 doses) to both index cases and their household members in the treatment arm. Participants will be given the first dose under medical supervision and self-administer at home the remaining 20 doses.~RESP301 is a formulation consisting of 3 agents currently used in clinical practice: mannitol, sodium nitrite and citric acid."
89005807|NCT00215111|Experimental|Low carbohydrate, reduced glycemic load, control diet|
89005808|NCT00244257|Experimental|1|Cohort 1
89005809|NCT00244257|Experimental|2|Cohort 2
89005810|NCT00244257|Experimental|3|Cohort 3
89005811|NCT00244257|Experimental|4|Cohort 4
89005812|NCT00244257|Experimental|5|Cohort 5
89005813|NCT00244335||1|PTSD Subjects
89005814|NCT00244335||2|Trauma Controls: subjects who have experienced a trauma but never developed PTSD
89005815|NCT00215306|Experimental|Lumbar TDR|CHARITÉ Artificial Disc
89005816|NCT00215306|Active Comparator|ALIF|Anterior Interbody Fusion with BAK Cage
89414927|NCT04842331|Active Comparator|Standard of Care (SOC)|SOC
89414928|NCT04835831|Experimental|adapted physical activity + Dietetic advice|
89414929|NCT04835831|No Intervention|Dietetic advice only|
89005817|NCT04709523|Experimental|i-PRF enriched bovine-derived xenograft|Patients treated with i-PRF-enriched bovine-derived xenograft + resorbable membrane
89005818|NCT04709523|Experimental|bovine-derived xenograft|Patients treated with bovine-derived xenograft + resorbable membrane
89005819|NCT04668352|Experimental|Dactolisib 10mg once daily|
89005820|NCT04668352|Placebo Comparator|Placebo|
89005821|NCT04668196||High-flow nasal cannula treatment|
89005822|NCT04668196||Continuous positive airway pressure (CPAP) treatment|
89414930|NCT04829578|Other|Hypnosis|hyspnosis treatment
89414931|NCT04827862|Experimental|Pembrolizumab and Radiation Therapy|pembrolizumab plus low-dose (4 Gy x 5) involved-site radiotherapy
89414932|NCT04804735|Experimental|REV : local anesthesia and virtual reality|Use of virtual reality device in Implanted Venous Access Device (IVAD) procedure under local anesthesia
89414933|NCT04804735|Experimental|MUS : local anesthesia and music therapy|Use of musicotherapy tool in Implanted Venous Access Device (IVAD) procedure under local anesthesia
89005823|NCT04668196||Noninvasive ventilation treatment|
89005824|NCT04668079|Experimental|Modified cross body stretch|modified cross body stretch
89005825|NCT04668079|Experimental|Modified sleeper stretch|modified sleeper stretch
89005826|NCT00215501|Experimental|Group A|Oral capecitabine
89005827|NCT00215501|Experimental|Group B|5-fluorouracil
89005828|NCT04667728|Experimental|intervention group (IGr)|The IGr participants wore a professional continuous glucose monitoring (CGM) sensor (iPro™2) during the first six days of the study. Following this period, IGr participants had a medical consultation for the CGM results and treatment adjustments. Additionally, they received a personalized diet plan from a dietitian. After three months, the IGr participants again wore the CGM sensor for one week. These participants also followed the regular institutional Comprehensive Diabetes Care program care plan.
89005829|NCT04667728|No Intervention|control group (CGr)|The control group followed the regular institutional Comprehensive Diabetes Care program care plan.
89414934|NCT04804735|No Intervention|CONTROL : standard local anesthesia|Implanted Venous Access Device (IVAD) procedure under local anesthesia as standard of care
89005830|NCT04668040|Experimental|Muscle energy technique|Muscle energy technique applied in the lower cross syndrome muscle pattern.
89005831|NCT04668040|Active Comparator|Stretching|Stretching technique applied in the lower cross syndrome muscle pattern.
89005832|NCT04667611||Mild|
89005833|NCT04667611||Moderate|
89414935|NCT04803305|Experimental|Double-Blind PF-06946860 Treatment followed by Open Label PF-06946860 Treatment|subcutaneous injection
89005834|NCT04667611||Severe|
89005835|NCT00556621|Other|gemcitabine, cisplatine, radiotherapy|
89005836|NCT02962583|Experimental|Probiotic|Daily probiotic consumption
89005837|NCT02962583|Placebo Comparator|Placebo|Daily placebo consumption
89005838|NCT00556660|Experimental|1|SPECT imaging
89005839|NCT00556699|Experimental|1|
89005840|NCT00556738|Experimental|nHFPV|Intrapulmonary Percussive Ventilation
89005841|NCT00556738|Active Comparator|nCPAP|Nasal Continuous Positive Airway Pressure ventilation
89414936|NCT04803305|Placebo Comparator|Double-Blind Placebo Treatment followed by Open-Label PF-06946860 Treatment|subcutaneous injection
89414937|NCT04801329||Adults diagnosed with transthyretin-mediated amyloidosis (ATTR-CM)|
89414938|NCT04795908|Experimental|Active rTMS Group|Patients will be seated in a comfortable reclined chair. The neurostimulation protocol will include 1-Hz rTMS over the bilateral SMA at 110% resting motor threshold (RMT). The SMA will be identified as 4 cm anterior to the vertex (Cz in standard 10-20 EEG setup). Each session will consist of 6 trains lasting 5 minutes each (300 pulses per train) with an intertrain interval of 1 minute for a total duration of 35 minutes (1800 pulses). Patients will receive 4 sessions each day on 4 consecutive days for a total of 16 sessions. Daily duration of this study protocol should last approximately 170 minutes including a 10 minute break in between each session.
89005842|NCT00411866|Experimental|Subjects receiving ketoconazole for 8 days|In Session 1, subjects will receive a single oral dose of SB-773812 20 milligrams (mg), followed by 21 days-washout. In Session 2, subjects will receive once daily oral dose of ketoconazole 400 mg repeated for 8 days. On day 5, single oral dose of SB-773812 20 mg will be dosed concomitantly with ketoconazole.
89005843|NCT00411866|Experimental|Subjects receiving ketoconazole for 14 days|In Session 1, subjects will receive a single oral dose of SB-773812 (20mg), followed by 21 days-washout. In Session 2, subjects will receive once daily oral dose of ketoconazole 400 mg repeated for 12 days. On day 5, single oral dose of SB-773812 20 mg will be dosed concomitantly with ketoconazole.
89535869|NCT03315923|Experimental|Glatiramer acetate|Patients in this group will receive 40 mg of glatiramer acetate three times per week through subcutaneous injection.
89535870|NCT02451085|Experimental|remote rehabilitation group|'training with video therapy' a domestic exercise plan through remote rehabilitation system based on short film. (http://videotherapy.co/vt/home.php), the plan will include installation of exercises adapted according to the physical condition of the patient. The content of each exercise is dynamic and variable. The difference between each exercise and the other depends on the feedback that the patient fills at the end of each exercise and sends to the therapist. Before each exercise, it is shown with explanations about the importance of performing it the way of performing. Furthermore, during the training, the patient listens to vocal explanation about the quality and importance of performing the exercise, and a vocal counting is heard and then a positive feedback is given.
89535871|NCT02451085|Other|conventional exercise group|will receive instruction for self-training as accepted today through exercise sheet. The exercises will be suited to the ones provided to the patients in the intervention group. Moreover, a follow-up sheet will be given to the patients to fill in order to receive a feedback at the end of experiment. The training duration will be identical in both groups and will last for 30-45 minutes, three times a week.
89535872|NCT03201133||Patellofemoral pain syndrome with changes in proximal factors|
89535873|NCT03201133||Patellofemoral pain syndrome with changes in local factors|
89535874|NCT03201133||Patellofemoral pain syndrome with changes in distal factors|
89535875|NCT02480075||Chronic pain|Observational ; Adult patients seeking medical treatment that have been diagnosed with chronic pain.
89535876|NCT03201055|Experimental|Non Apnoeic Snorers|Patient's use the Snore Positive airway pressure device for 28 nights.
88892736|NCT06039176||University of Kansas Medical System|Obtain demographic and clinical data prior to and following implantation of a HeartMate 3 ® device. HeartMate 3® downloaded pump operations data will be obtained at the following scheduled intervals: discharge from the ICU, at the time of discharge from the hospital (or ± 3 days from discharge), 3-months post-implant, 6-months post-implant, and lastly at 12-months post-implant. Downloadable pump operations data will include evaluation of suction events, low flow and other adventitious alarms, PI events and incidence of power cable disconnects beyond 20 seconds. The previously mentioned data will also be collected during any unplanned office visits, any admission regardless of the reason, unplanned ER visits related to equipment problems or any serious adverse event-related ER visits.
88892737|NCT06039176||Medical University of South Carolina|Obtain demographic and clinical data prior to and following implantation of a HeartMate 3 ® device. HeartMate 3® downloaded pump operations data will be obtained at the following scheduled intervals: discharge from the ICU, at the time of discharge from the hospital (or ± 3 days from discharge), 3-months post-implant, 6-months post-implant, and lastly at 12-months post-implant. Downloadable pump operations data will include evaluation of suction events, low flow and other adventitious alarms, PI events and incidence of power cable disconnects beyond 20 seconds. The previously mentioned data will also be collected during any unplanned office visits, any admission regardless of the reason, unplanned ER visits related to equipment problems or any serious adverse event-related ER visits.
89414939|NCT04782687|Experimental|Selinexor plus DRd|"Lenalidomide 15 mg orally on Days 1-21 of each 28-day cycle~Dexamethasone 40 mg on Days 1, 8, 15, 22 of each cycle. However, those >75 years old may be administered a weekly dose of 20 mg dexamethasone.~Daratumumab 1800 mg subcutaneous injection once weekly in Cycles 1 and 2, every 2 weeks in cycles 3 to 6, and every 4 weeks thereafter.~Selinexor 60 mg on Days 1, 8, 15, of cycles 1-3, with a planned dose-reduction to 40 mg on Days 1, 8, 15 for cycles beyond 3. If patient was previously dose reduced prior to cycle 4, then at cycle 4 planned dose reduction, you will again decrease dose by 1 level."
89414940|NCT04775472|Experimental|Early left atrial septostomy group|Early left atrial septostomy group will routinely receive left atrial septostomy within 12 hours after VA-ECMO implantation.
89414941|NCT04775472|Active Comparator|Conventional approach group|Conventional approach group will receive left atrial septostomy in cases of deleterious effect of increased LVEDP after VA-ECMO implantation, such as refractory pulmonary edema, abnormal opening of aortic valve, left ventricular dilatation, refractory ventricular tachycardia or fibrillation.
89414942|NCT04765137|Experimental|Atorvastatin 40 mg|Participants receive 40 mg atorvastatin orally daily in the evening.
88892738|NCT06039176||PENDING enrollment for 9th cohort-goal is 10 sites|Obtain demographic and clinical data prior to and following implantation of a HeartMate 3 ® device. HeartMate 3® downloaded pump operations data will be obtained at the following scheduled intervals: discharge from the ICU, at the time of discharge from the hospital (or ± 3 days from discharge), 3-months post-implant, 6-months post-implant, and lastly at 12-months post-implant. Downloadable pump operations data will include evaluation of suction events, low flow and other adventitious alarms, PI events and incidence of power cable disconnects beyond 20 seconds. The previously mentioned data will also be collected during any unplanned office visits, any admission regardless of the reason, unplanned ER visits related to equipment problems or any serious adverse event-related ER visits.
89414943|NCT04760691|Active Comparator|Pre-Exposure Prophylaxis (PrEP) only|Truvada one tablet by mouth daily
89005844|NCT04667182||Combined Diabetes Management Data|Participants with type 1 and type 2 diabetes will use a meal tagging application (app) and fitness tracker. They will upload these data to a web portal where they will be matched with data from their insulin pen and continuous glucose monitor (CGM). Combined data will be used as a complement to standard of care for diabetes management.
89193068|NCT05621460|Experimental|50mL still water first, then 500mL still water, then 500 mL carbonated water|Participants will undergo this test on three separate days. On each day participants will be asked to drink a glass of water: either a 50mL drink of still water (control condition), a 500mL drink of still (non-carbonated) water, or a 500mL drink of carbonated water. In this arm of the study, participants will receive 50mL still water on the first test day, 500mL carbonated water on the second test day, then 500mL carbonated water on the third day.
89193069|NCT05621460|Experimental|50mL still water first, then 500mL carbonated water, then 500 mL still water|Participants will undergo this test on three separate days. On each day participants will be asked to drink a glass of water: either a 50mL drink of still water (control condition), a 500mL drink of still (non-carbonated) water, or a 500mL drink of carbonated water. In this arm of the study, participants will receive 50mL still water on the first test day, 500mL still water on the second test day, then 500mL still water on the third day.
89414944|NCT04760691|Experimental|PrEP plus Gonadotropin Releasing Hormone (GnRH) Agonist|Truvada one tablet by mouth daily Leuprolide 11.25 milligrams (mg) intramuscular (im) injection once
89414945|NCT04760691|Experimental|PrEP plus Low Dose Estrogen|Truvada one tablet by mouth daily Estradiol 1 milligram by mouth daily x 2 weeks
89005845|NCT04667299|Experimental|BMT group|Rabeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid and metronidazole 0.4 g qid for 14 days
89005846|NCT04667299|Active Comparator|BMQ group|Rabeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid, metronidazole 0.4 g qid and amoxicillin 1 g bid for 14 days
89005847|NCT04720794|Other|Subject Self-Collection and Specimen Testing|Subjects will be provided with the Lucira COVID-19 Test Kit and collect one (1) nasal swab according to the QRI and test the sample on the Lucira COVID-19 All-In-One Test. HCP will observe subject during this process and document any observations and deviations from the QRI.
89005848|NCT04667143|Experimental|Retagliptin 100 mg, Henagliflozein 10 mg, plus metformin XR|
89005849|NCT04667143|Experimental|Retagliptin 100 mg, Henagliflozein 5 mg, plus metformin XR|
89005850|NCT04667143|Experimental|Retagliptin placebo, Henagliflozein 10 mg, plus metformin XR|
89005851|NCT04667143|Experimental|Retagliptin placebo, Henagliflozein 5 mg, plus metformin XR|
89005852|NCT04667143|Experimental|Retagliptin 100 mg, Henagliflozein placebo, plus metformin XR|
89005853|NCT04666870||axis length|1007 healthy students with moderate to high myopia (SE ≤ -4.00D) and 894 without myopia (-0.50D ≤ spherical power ≤ +2.00D) were enrolled.
89005854|NCT04666870||gender|male were 54.29% (N=1032), and female were 45.71% (N=869)
89005855|NCT04666753||ImmunoFormulation cohort|"Patients treated* with IMUNO TF® with a combination of nutraceuticals.~*Without restrictions on the adjuvant treatment received."
89005856|NCT04666753||Control cohort|"Control cohort: patients not treated* with IMUNO TF® with a combination of nutraceuticals.~*Without restrictions on the adjuvant treatment received."
89005857|NCT00240825|Experimental|001|Acetaminophen
89005858|NCT00240825|Experimental|002|Ibuprofen
89005859|NCT00240825|Placebo Comparator|003|Placebo
89005860|NCT04666597||Adapted-CCI single-intervention group in children|The single-group intervention will be the adapted-CCI 4D-cycle caries care, with non-AGP and reduced in-office appointments' time. A trained examiner per centre will conduct examinations at baseline, at 5-5.5 months (three months after basic management), 8.5 and 12 months, assessing the child's CCI caries risk and oral-health behaviour, visually staging and assessing caries-lesions severity and activity without air-drying (ICDAS-merged Epi); fillings/sealants; missing/dental-sepsis teeth, and tooth symptoms, synthetizing together with parent and external-trained dental practitioner (DP) the patient- and tooth-surface level diagnoses and personalised care plan. DP will deliver the adapted-CCI caries care. Parents' and dentists' process acceptability will be assessed via Treatment-Evaluation-Inventory questionnaires, and costs in terms of number of appointments and activities. Twenty-one centres in 13 countries will participate.
89005861|NCT04666675|Experimental|Upadacitinib Dose A|Participants will receive Upadacitinib Dose A once daily (QD).
89005862|NCT04666675|Experimental|Upadacitinib Dose B|Participants will receive Upadacitinib Dose B QD.
89005863|NCT04666675|Experimental|Placebo for Upadacitinib Followed by Upadacitinib Dose A|Participants will receive placebo for Upadacitinib followed by Upadacitinib Dose A QD.
89005864|NCT04666675|Experimental|Placebo for Upadacitinib Followed by Upadacitinib Dose B|Participants will receive placebo for Upadacitinib followed by Upadacitinib Dose B QD.
89005865|NCT04666480|Experimental|Single-arm study of PLAR Implant and Delivery System|All enrolled patients will receive the study device
89005866|NCT04666363|Experimental|Lavender oil|On the first day (before intervention), the intensity of needle insertion-related pain was measured. The experimental group inhaled lavender essence (12 consecutive hemodialysis seasons).
89005867|NCT04666363|No Intervention|Control group|The patients will not smell lavender oil.
89005868|NCT00240864|Experimental|001|acetaminophen
89005869|NCT00240864|Experimental|002|ibuprofen
89005870|NCT00240864|Placebo Comparator|003|placebo
89005871|NCT00556816|Active Comparator|Conventional outpatient clinic|Conventional outpatient clinic
89005872|NCT00556816|Experimental|On demand outpatient clinic|On demand outpatient clinic
89005873|NCT00556855|Experimental|A|applied on one hand
89005874|NCT00556855|Placebo Comparator|B|applied on the other hand
89005875|NCT00557011|Experimental|1|NRP104
89005876|NCT00557011|Active Comparator|2|Adderall XR
89005877|NCT00557011|Placebo Comparator|3|Placebo
89005878|NCT00557089|Other|1|This arm will receive the active treatment for 28 days, followed by a 28 day washout period and then the placebo treatment for 28 days.
89005879|NCT00557089|Other|2|This arm will receive the placebo treatment for 28 days, followed by a 28 day washout period and then the active treatment for 28 days.
89005880|NCT04666324|Active Comparator|Simethicone Solution|Treatment with simethicone (Espumisan®, 100 mg/ml, Berlin-Chemie / Menarini Polska Sp z o.o., Warsaw, Poland) for four weeks. Simethicone was administered 3-6 times per day with each treatment comprising 6 drops of the 100 mg/ml emulsion.
89005881|NCT04666324|Experimental|Multilac Baby|Treatment with one stick pack of the multi-strain synbiotic (Multilac® Baby, Vivatrex GmbH, Aachen, Germany) per day for four weeks. Each stick pack of Multilac® Baby contains a total of 10^9 colony forming units (CFU) with equal CFU amounts of the following probiotic bacteria: L. acidophilus LA-14, L. casei R0215; L. paracasei Lpc-3; L. plantarum Lp-115; L. rhamnosus GG, L. salivarius Ls-33, B. lactis Bl-04, B. bifidum R0071, B. longum R0175 and 1.43 g of the prebiotic fructooligosaccharides.
89005882|NCT04720833|Experimental|dried plum (100 g dried plum)|Participants will receive 100 g dried plum daily plus 500 mg calcium and 300 IU vitamin D daily
89005883|NCT04720833|Placebo Comparator|Calcium and vitamin D|Participants will receive 500 mg calcium and 300 IU vitamin D daily
89005884|NCT00215618|Experimental|1|Uterine Balloon Therapy with post procedure curettage
89005885|NCT00215618|Experimental|2|Uterine Balloon Therapy without post-procedure curettage
89414946|NCT04760691|Experimental|PrEP plus High Dose Estrogen|Truvada one tablet by mouth daily Estradiol 6 milligrams (mg) by mouth daily x 2 weeks
89414947|NCT04760691|Experimental|High Dose Estrogen|Estradiol 6 mg by mouth daily x 2 weeks
89414948|NCT04711915|Active Comparator|0.1 mg/kg DMT|0.1 mg/kg DMT administered intravenously
89414949|NCT04711915|Active Comparator|0.3 mg/kg DMT|0.3 mg/kg DMT administered intravenously
89535877|NCT03072693|Active Comparator|Group 1|Home-based remote heart failure management
89535878|NCT03072693|Placebo Comparator|Group 2|Home-based physiological parameter recording only
89005886|NCT04666168|Experimental|Auto CAR-T|Patients will be treated with Auto CAR-T cells
89005887|NCT00215735|Experimental|APC Treatment|wound debridement and treatment with APC
89005888|NCT04665661|Experimental|High-intensity aerobic training (HIAT)|Women will perform treadmill-based aerobic exercise for three days a week, at 70%-85% of MHR for 30 minutes and perceived exertion of 14-16, based on the Borg RPE scale. This range39 is considered to represent HIAT. Aerobic training will be preceded by warm-up exercises for 10 minutes and followed by cool-down exercises for 10 minutes, at a perceived exertion of 11.0 (Borg RPE).
89005889|NCT04665661|Active Comparator|Wait-list control (WLC)|Women in the wait-list control group will be instructed to continue with their usual activities and manage their pain as normal (i.e., with analgesics).
89005890|NCT00215774|No Intervention|No antiarrhythmic treatment|Control group
89005891|NCT00215774|Experimental|B-Flecainide treatment|4 weeks treatment with flecainide
89005892|NCT00215774|Experimental|C-Flecainide treatment|6 months flecainide treatment
89005893|NCT04665778||high risk of hospitalization|
89005894|NCT04665778||not high risk of hospitalization|
89005895|NCT04665466||Group A|QFR≤0.80 vessels with PCI strategy and low PPG index
89005896|NCT04665466||Group B|QFR≤0.80 vessels with PCI strategy and high PPG index
89005897|NCT04665466||Group C|QFR≤0.80 vessels with conservative strategy
89005898|NCT04665544|Experimental|Early-stage endometrial cancer patients|"Histologically proven endometrial cancer (any tumour type).~Apparent early-stage endometrial cancer with intermediate or high risk prognostic factors (deep myometrial invasion or G2/G3 disease or non- endometrioid histological type), no evidence of bulky or suspicious pelvic/para-aortic lymph nodes or distant metastases on preoperative conventional imaging studies; minimum requirement for clinical staging includes expert US or pelvic MRI for local staging and abdominal US or abdominal CT scan or PET CT for distant staging.~Performance status ECOG: 0-1.~Age ≥18, ≤85.~History of second primary cancer only if more than 5 years with no evidence of disease.~Approved and signed informed consent"
89005899|NCT02961816|Experimental|Cohort A: Diffuse Large B-Cell Lymphoma|"Palifermin on Days -13 to -11 and on Days 0, +1, and +2.~Panobinostat daily from Day -9 to -2.~Gemcitabine administered on Days -8 and -3.~Busulfan test dose administered on day -10. Doses of Days -6 and -5 subsequently adjusted to target an AUC of 4,000 microMol.min-1. Busulfan adjusted to target a cumulative AUC of 16000 and may be significantly higher or lower than 4000 on the last 2 days depending on first PK.~Melphalan on Days -3 and -2.~Rituximab on Day -9 for participants with CD20+ tumors.~Dexamethasone twice a day from Day -8 AM to Day -2 PM.~Caphosol oral rinses 30 mL four times a day used from Day -8.~Oral glutamine, 15 g four times a day, swished, gargled and swallowed started on Day -8.~Pyridoxine three times a day from Day -1.~Stem cells administered by vein on Day 0.~G-CSF 1 time each day starting on Day +5 until blood cell levels return to normal."
89005900|NCT02961816|Experimental|Cohort B: Hodgkin's Lymphoma|"Palifermin on Days -13 to -11 and on Days 0, +1, and +2.~Panobinostat daily from Day -9 to -2.~Gemcitabine administered on Days -8 and -3.~Busulfan test dose administered on day -10. Doses of Days -6 and -5 subsequently adjusted to target an AUC of 4,000 microMol.min-1. Busulfan adjusted to target a cumulative AUC of 16000 and may be significantly higher or lower than 4000 on the last 2 days depending on first PK.~Melphalan on Days -3 and -2.~Rituximab on Day -9 for participants with CD20+ tumors.~Dexamethasone twice a day from Day -8 AM to Day -2 PM.~Caphosol oral rinses 30 mL four times a day used from Day -8.~Oral glutamine, 15 g four times a day, swished, gargled and swallowed started on Day -8.~Pyridoxine three times a day from Day -1.~Stem cells administered by vein on Day 0.~G-CSF 1 time each day starting on Day +5 until blood cell levels return to normal."
89005901|NCT02961816|Experimental|Cohort C: T-Cell Lymphoma|"Palifermin on Days -13 to -11 and on Days 0, +1, and +2.~Panobinostat daily from Day -9 to -2.~Gemcitabine administered on Days -8 and -3.~Busulfan test dose administered on day -10. Doses of Days -6 and -5 subsequently adjusted to target an AUC of 4,000 microMol.min-1. Busulfan adjusted to target a cumulative AUC of 16000 and may be significantly higher or lower than 4000 on the last 2 days depending on first PK.~Melphalan on Days -3 and -2.~Rituximab on Day -9 for participants with CD20+ tumors.~Dexamethasone twice a day from Day -8 AM to Day -2 PM.~Caphosol oral rinses 30 mL four times a day used from Day -8.~Oral glutamine, 15 g four times a day, swished, gargled and swallowed started on Day -8.~Pyridoxine three times a day from Day -1.~Stem cells administered by vein on Day 0.~G-CSF 1 time each day starting on Day +5 until blood cell levels return to normal."
89005902|NCT04665427|Other|Patient in whom a bilioenteric anastomosis is performed for any etiology.|Patient in whom a bilioenteric anastomosis is performed for any etiology..
89005903|NCT03454867|Experimental|Hemofiltration (treatment)|Standard acute ischemic stroke treatment + hemofiltration Standard treatment included thrombolytic therapy for eligible candidates (tPA 0,9 mg/kg, max dose 90 mg)
89005904|NCT03454867|Active Comparator|Control|Standard acute ischemic stroke treatment Standard treatment included thrombolytic therapy for eligible candidates (tPA 0,9 mg/kg, max dose 90 mg)
89005905|NCT04665349|Experimental|Pre-op|Nutricia Pre-op, 400 milliliters, per os
89005906|NCT04665349|No Intervention|Control|No intervention
89005907|NCT04665232||Patients affected by autoimmune diseases|Infertile patients suffering from autoimmune diseases to be subjected to IVF in which the luteal phase has been supplemented with 25 mg /die of aqueous subcutaneous progesterone
89005908|NCT04665076|Experimental|Auto CAR-T|Patients will be treated with Auto CAR-T cells
89005909|NCT04665193|Experimental|Abbott Panbio test device|WestJet passengers departing from YVR screened for COVID-19 using Abbott Panbio test device
89005910|NCT00241020|Experimental|Octreotide|
89005911|NCT00216047|Experimental|Single Group Assignment|Trastuzumab + PTK787 for HER2 positive patients
89193070|NCT05621252|Experimental|PLN-74809|160 mg PLN-74809
89193071|NCT05621252|Placebo Comparator|Placebo|Placebo
89535879|NCT02480231|Active Comparator|Babcock tensioning technique|Group for whom the retropubic mid-urethral sling was tensioned using a Babcock clamp.
89535880|NCT02480231|Active Comparator|Scissor spacer technique|Group for whom the retropubic mid-urethral sling was tensioned using a surgical scissor as a spacer.
89414950|NCT04700098|Experimental|Internet-based behavioral treatment for insomnia|Internet version of cognitive-behavioral treatment for insomnia
89414951|NCT04700098|Experimental|Online insomnia patient education|Online insomnia patient education
89414952|NCT04668157|Experimental|TAK-536|TAK-536 granule formulation, orally once daily before or after breakfast. The initial dose of TAK-536 will be 0.1 mg/kg (not exceeding 2.5 mg/day). After the initial dose, TAK-536 will be titrated to 0.2 mg/kg (not exceeding 5 mg/day), 0.4 mg/kg (not exceeding 10 mg/day), and 0.8 mg/kg (not exceeding 20 mg/day) if the subjects do not achieve the target blood pressure and no concerns are found in safety and tolerability.
89414953|NCT04660721|Experimental|sFilm-FS|
89414954|NCT04660721|Active Comparator|TACHOSIL®|
89414955|NCT04617457|Experimental|NAPOX chemotherapy|NAPOX chemotherapy in 14-day cycles with the four IMPs given intravenously in the following order: nal-irinotecan, oxaliplatin, folinic acid and 5-fluouracil.
89414956|NCT04607135|Experimental|Acoustic radiation force impulse (ARFI)|Patients with suspected PCa who are scheduled to undergo an ultrasound fusion-MR prostate biopsy.
89414957|NCT04607135|Active Comparator|MR-ultrasound fusion|Patients with suspected PCa who are scheduled to undergo an ultrasound fusion-MR prostate biopsy.
89414958|NCT04599140|Experimental|Treatment (SX-682, nivolumab)|"MONOTHERAPY STAGE: Patients receive SX-682 orally PO BID on days 1-21 in the absence of disease progression or unacceptable toxicity.~COMBINATION STAGE: Patients receive SX-682 PO BID on days 1-56 and nivolumab IV over 30 minutes on days 1 and 29. Treatment repeat every 56 days weeks for up to 12 cycles in the absence of disease progression or unacceptable toxicity."
89414959|NCT04591093|Active Comparator|CI with FineHearing with 10 more apical electrodes activated then 10 more basal electrodes activated|Cochlear implant with FineHearing Strategy with 10 more apical electrodes activated first during 1 month then FineHearing Strategy with 10 more basal electrodes activated during 1 month
89414960|NCT04591093|Active Comparator|CI with FineHearing with 10 more basal electrodes activated then 10 more apical electrodes activated|Cochlear implant with FineHearing Strategy with 10 more basal electrodes activated first during 1 month then FineHearing Strategy with 10 more apical electrodes activated during 1 month
89414961|NCT04590885|Other|Couple Communication and Support|CCST includes components to assist couples in communicating effectively, decreasing avoidance of important cancer-related issues, and providing each other with support. It includes training in skills for sharing one's thoughts and feelings and listening to one's partner and responding in a supportive manner, and joint problem solving. Participants will be asked to participate inactivities at home between sessions to strengthen skills acquisition.
89414962|NCT04590885|Other|Healthy Lifestyle Informaion|Healthy Lifestyle Information provides couples with health information relevant to cancer in a supportive environment. Sessions focus on the following topics: fatigue, sleep disturbance, nutrition, physical activity, survivorship care plans, and palliative care. Patients and partners are invited to discuss their experiences around the session topics with the therapist and ask questions about the information presented.
88892739|NCT06039176||PENDING enrollment for 10th cohort-goal is 10 sites|Obtain demographic and clinical data prior to and following implantation of a HeartMate 3 ® device. HeartMate 3® downloaded pump operations data will be obtained at the following scheduled intervals: discharge from the ICU, at the time of discharge from the hospital (or ± 3 days from discharge), 3-months post-implant, 6-months post-implant, and lastly at 12-months post-implant. Downloadable pump operations data will include evaluation of suction events, low flow and other adventitious alarms, PI events and incidence of power cable disconnects beyond 20 seconds. The previously mentioned data will also be collected during any unplanned office visits, any admission regardless of the reason, unplanned ER visits related to equipment problems or any serious adverse event-related ER visits.
88892740|NCT06039163|Active Comparator|HH-120|
88892741|NCT06039163|Placebo Comparator|placebo|
88892742|NCT06039150|Experimental|M-TAPA group|The group to be administered 0.025% Bupivacaine by the anesthesiologist bilaterally in M-TAPA block with a maximum dose of 2 mg/kg before extubation.
88892743|NCT06039150|Active Comparator|LAİ group|The group to be divided and administered 0.025% Bupivacaine with a maximum dose of 2 mg/kg by the surgeon to 3 port entry sites before extubation
88892744|NCT06039124||HHT patients previously included in BABH study|Clinical and therapeutic follow-up of HHT patients for one year after the end of a clinical trial using bevacizumab.
88892745|NCT06039111|Experimental|Sequential ICG and Technetium Detection|
88892746|NCT06039059||Receiving PCI with nonintervened coronary lesion|Patients who received PCI with nonintervened coronary lesion.
89414963|NCT04586127|Experimental|Adolescents and Young Adults Needs Assessment & Service Bridge (AYA NA-SB)|Subjects will complete 2 online surveys over the course of 1 month; each should take about 15 minutes to complete.
89414964|NCT04574778|Active Comparator|Group 1: IV acetaminophen and PO placebo|Group 1 will receive 1000 mg of IV acetaminophen approximately 30 minutes prior to skin closure and will receive oral placebo in the holding area prior to surgery
89414965|NCT04574778|Active Comparator|Group 2: PO acetaminophen|Group 2 will receive 1000 mg of PO acetaminophen in the holding area and will not receive an IV placebo.
89414966|NCT04568564|Experimental|Telerehabilitation Group (TG)|Patients diagnosed with lung cancer and underwent thoracotomy
89414967|NCT04568564|Active Comparator|Control group (CG)|Patients diagnosed with lung cancer and underwent thoracotomy
89414968|NCT04567537|Active Comparator|Scars|The entire hypertrophic scar will receive laser treatment only.
89414969|NCT04567537|Active Comparator|Scleroderma|The entire lesion will receive laser treatment.
89414970|NCT04566315|Other|ARTERIAL EMBOLIZATION IN PATIENTS WITH TOTAL KNEE PROSTHESIS|SYMPTOMATIC EFFECTIVENESS OF MICROPARTICLE ARTERIAL EMBOLIZATION IN PATIENTS WITH TOTAL KNEE PROSTHESIS WITH PAIN RESISTANT TO MEDICAL TREATMENT
88892747|NCT06038994||Patients with acute myocardial infarction who experienced CAG|Patients with acute myocardial infarction who experienced coronary angiography
88892748|NCT06038942|Experimental|Formal mindfulness instruction|
88892749|NCT06038942|Experimental|Informal mindfulness instruction|
89414971|NCT04554485|Experimental|Blinatumomab followed by high-dose chemotherapy|Single cycle of blinatumomab followed by high-dose chemotherapy in the induction therapy for Ph-negative acute lymphoblastic leukemia in adults
89414972|NCT04539392||Infertile couple|
89005912|NCT04665310|Active Comparator|Group 1 - Low-Intensity|"All patients will receive standard induction immunosuppression according to institution protocol. TAC will be started when clinically appropriate according to institution protocol.~TAC dosing will be 2 mg twice daily to be reduced by 20% after week 1 and start Envarsus XR once daily.~Target Tacrolimus Trough Concentrations:~Week 0 to Week 4: 8-10 mg/mL Month 1 to Month 3: 6-8 mg/mL"
89005913|NCT04665310|Active Comparator|Group 1 - Moderate-Intensity|"All patients will receive standard induction immunosuppression according to institution protocol. TAC will be started when clinically appropriate according to institution protocol.~TAC dosing will be 3 mg twice daily to be reduced by 20% after week 1 and start Envarsus XR once daily.~Target Tacrolimus Trough Concentrations:~Week 0 to Week 4: 10-12 mg/mL Month 1 to Month 3: 8-10 mg/mL"
89005914|NCT04665310|Active Comparator|Group 1 - High-Intensity|"All patients will receive standard induction immunosuppression according to institution protocol. TAC will be started when clinically appropriate according to institution protocol.~TAC dosing will be 4 mg twice daily to be reduced by 20% after week 1 and start Envarsus XR once daily.~Target Tacrolimus Trough Concentrations:~Week 0 to Week 4: 12-14 mg/mL Month 1 to Month 3: 10-12 mg/mL"
89005915|NCT04665310|Active Comparator|Group 2 - Low-Intensity|"All patients will receive standard induction immunosuppression according to institution protocol. TAC will be started when clinically appropriate according to institution protocol.~TAC dosing will be 2 mg twice daily to be reduced by 20% after week 1 and start Envarsus XR once daily.~Target Tacrolimus Trough Concentrations:~Week 0 to Week 4: 8-10 mg/mL Month 1 to Month 3: 6-8 mg/mL"
89005916|NCT04665310|Active Comparator|Group 2 - Moderate-Intensity|"All patients will receive standard induction immunosuppression according to institution protocol. TAC will be started when clinically appropriate according to institution protocol.~TAC dosing will be 3 mg twice daily to be reduced by 20% after week 1 and start Envarsus XR once daily.~Target Tacrolimus Trough Concentrations:~Week 0 to Week 4: 10-12 mg/mL Month 1 to Month 3: 8-10 mg/mL"
89005917|NCT04665310|Active Comparator|Group 2 - High-Intensity|"All patients will receive standard induction immunosuppression according to institution protocol. TAC will be started when clinically appropriate according to institution protocol.~TAC dosing will be 4 mg twice daily to be reduced by 20% after week 1 and start Envarsus XR once daily.~Target Tacrolimus Trough Concentrations:~Week 0 to Week 4: 12-14 mg/mL Month 1 to Month 3: 10-12 mg/mL"
89005918|NCT04664920||Intervention|Exergame intervention arm.
89005919|NCT00241059|Experimental|EC-MPS arm|
89005920|NCT00216164|Experimental|1|Rituximab + Gemcitabine for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
89005921|NCT04664803|Experimental|Cefecin Tab.|Cefecin Tab./Placebo to Omnicef Cap.
89005922|NCT04664803|Active Comparator|Omnicef Cap.|Omnicef Cap./Placebo to Cefecin Tab.
89005923|NCT04664725|Experimental|SHR3680+ Repaglinide, Bupropion|"Experimental: Repaglinide, Bupropion and SHR3680~Repaglinide and Bupropion QD on Day 1 and Day 21, SHR3680 240 mg once daily (QD) from Study Day 6 - 26"
89005924|NCT04664764|Active Comparator|degludec arm|Group A received insulin degludec,
89005925|NCT04664764|Active Comparator|glargine arm|group B received insulin glargine
89005926|NCT04664764|Active Comparator|NPH group|Group C received NPH insulin
89005927|NCT00244803||HIV Positive FRAM 1 Participant|
89005928|NCT04664686|Active Comparator|AF catheter ablation|
89005929|NCT04664686|Active Comparator|AV node ablation|
89005930|NCT04664374||Mood Disorder|Based on screening questions administered on-line as part of the enrollment process, participants will be divided into two groups: (i) those who screen positive for a history of mood disorders and (ii) all other participants. All outcome measures apply only to the mood disorder group.
89005931|NCT04664374||Other|see above
89005932|NCT04664647||Patients with CCPD|"Inclusion criteria：~Criteria for central nervous system involvement: T2 high-signal intensity lesions in the brain, or spinal cord on MRI, or visual-evoked potentials(VEPs) abnormalities.~Criteria for peripheral nervous system involvement: conduction delay, conduction block, temporal dispersion or F-wave abnormalities, suggesting peripheral demyelinating neuropathy regarding nerve conduction studies (NCS). In the present study, it was compulsory for at least two nerves between the median, ulnar, tibial and peroneal nerves to have abnormal findings indicating demyelination.~Exclusion criterion:~Secondary demyelinating diseases or changes."
89005933|NCT00216281|Active Comparator|clozapine with AZT added|Clozapine augmented with Atomoxitine up to 40mg
89005934|NCT00216281|Placebo Comparator|placebo|Subjects will have a placebo pill added to their clozapine regimen.
89005935|NCT04664296||Children|Hospitalized children, 0 to 17 years of age, 25 subjects, consecutive sample survey
89005936|NCT04664296||Adults|Hospitalized adults, 18 years and above, 50 matched subjects
89005937|NCT04664491|Experimental|Standardized management|Patients will be managed according to recommendations in GOLD guideline and China's guidelines for COPD care.
89005938|NCT04664491|Other|Usual care|Patients will undergo usual care according to current clinical practice in study sites.
89005939|NCT04664530|Placebo Comparator|Control group|
89005940|NCT04664530|Experimental|Treatment group|
89005941|NCT04664218|Experimental|patients with Peritoneal carcinomatosis|Peritoneal carcinomatosis (PC) is a well-known sequel of multiple abdominal malignancies either arising from the gastro-intestinal tract or of gynaecologic origin. On occurrence, PC is mostly considered as a very bad prognostic sign hence it affects the overall survival with very poor response to systemic chemotherapy.
89005942|NCT04663906||Isotretinoin|Test population, prescribed oral isotretinoin between March and October 2020.
89005943|NCT04663906||Control|Background age-matched population, not prescribed oral isotretinoin during March to October 2020
89005944|NCT04663789|Experimental|Staple line plus reinforcement|In this experimental group, a lock stitch will be placed after transecting the pancreas with stapler.
89005945|NCT04663789|Other|staple line with no reinforcement|In this control group, no additional reinforcement is used after transecting the pancreas with stapler.
89414973|NCT04525885|Experimental|Gefapixant 45 mg BID|Participants will receive a gefapixant 45 mg tablet BID during the main study period (24 weeks) and also during the extension period (28 weeks).
89193072|NCT05605912|Experimental|Myosuit intervention|Participants perform Myosuit training sessions. After the clinical Myosuit training program, participants receive the Myosuit at their disposal at home for six weeks and a recommendation for physical activity at home.
89414974|NCT04525885|Experimental|Gefapixant 15 mg BID|Participants will receive a gefapixant 15 mg tablet BID during the main study period (24 weeks) and also during the extension period (28 weeks).
89414975|NCT04525885|Placebo Comparator|Placebo|Participants will receive a matching placebo tablet BID during the 24-week main study period and during the 28-week extension period.
89414976|NCT04517149|Experimental|4D-125 Dose Exploration|"Dose 1 and Dose 2~4D-125 will be administered at the assigned dose level as a single dose, IVT injection on Day 1. The contralateral eye may also be dosed with 4D-125 as a single dose, IVT injection provided the subject is eligible and provides consent."
88892750|NCT06038942|No Intervention|Inactive control|An equal number of university students from all groups will participate in this arm (i.e., those with ADHD, those with a history of nonsuicidal self-injury, and those with self-reported stress). Participants assigned to the inactive control condition will not complete any tasks during the four-week intervention period.
88892751|NCT06038890|Experimental|Holmium laser enculeation of the prostate|veil-sparing Holmium laser enucleation of the prostate
88892752|NCT06038877||Advanced Nephrology Practice Nurses|Advanced Nephrology Practice Nurses in France will be included.
88892753|NCT06038864||Intensive group|Patients with lower limb lymphoedema planned for intensive treatment
88892754|NCT06038864||Maintenance group|Patients with stable lower limb lymphoedema who are in the maintenance phase (at least 3 months)
88892755|NCT06038838|Experimental|Patients with Symptomatic MR (MR>=3+)|Subjects treated with the Tioga TMVR System
88892756|NCT06038786|Experimental|Resilience Training|Participants obtained Resilience Training, a 4 session, 1.5 hour group intervention delivering the following skills: mindfulness, mentalization, and self-compassion.
88892757|NCT06038786|Placebo Comparator|Waitlist|A 4-6 week waitlist during which participants did not receive any treatment. They would then obtain Resilience Training following their waitlist period.
88892758|NCT06038747|Experimental|Individual Psychotherapy + Self-Monitoring|Participants in the intervention group will continue their regular individual psychotherapy sessions. Additionally, after each session, they will complete a brief postsession battery consisting of two scales on the affective reactions of the participants towards their therapist during session and read general feedback encouraging them to discuss their feelings and reflections with their therapist. This questionnaire aims to prompt reflection on the own experience of the therapeutic relationship.
88892759|NCT06038747|Active Comparator|Individual Psychotherapy|Participants in the control group will receive only treatment as usual (i.e., individual psychotherapy) sand and will not complete post-session questionnaires. Additionally, they will not receive any feedback at all encouraging them to discuss their emotional responses with their therapist during the session.
88892760|NCT06038552||IM group|Imatinib(IM)
88892761|NCT06038552||IM combined with HR group|Imatinib(IM) combined with hepatic resection(HR)
88892762|NCT06038552||IM combined with RFA or TACE group|Imatinib(IM) combined with radiofrequency ablation (RFA) or transarterial chemoembolization (TACE)
88892763|NCT06038071|Active Comparator|Control Group|nutrition, IYCF, and WASH education at discharge, followed by regular community-based screenings led by health extension workers, with one final visit scheduled at 6 months after discharge
89414977|NCT04517149|Experimental|4D-125 Dose Expansion|4D-125 will be administered at the assigned dose level as a single dose, IVT injection on Day 1 in both adults and pediatric participants. For adult participants only, the contralateral eye may also be dosed with 4D-125 as a single dose, IVT injection provided the subject is eligible and provides consent.
89414978|NCT04517149|Other|Observational|Natural History
89414979|NCT04496726|Experimental|Cranberry and Quillaja|one 450mg cranberry capsule and one 50mg quillaja capsule in the morning and evening for 14 days.
89414980|NCT04482660|Experimental|PET|
89414981|NCT04473378||FreeStyle Libre sensor cohort|Patients with early stage breast cancer will have their blood glucose levels monitored by the Freestyle libre pro sensor.
89414982|NCT04466527|Experimental|Treatment|Subjects in this arm will undergo laser treatment on their active acne vulgaris lesions. Subjects will serve as their own control.
89414983|NCT04459559|Experimental|Intervention|Using the Tactile Cueing Device
89414984|NCT04446962|Active Comparator|Arm A: R-MPV with Lenalidomide|Lenalidomide in association with R-MPV as a targeted induction treatment
89414985|NCT04446962|Active Comparator|Arm B: R-MPV with Ibrutinib|Ibrutinib in association with R-MPV as a targeted induction treatment
89414986|NCT04431401|Experimental|rTMS treatment group|The participants will be divided into the rTMS treatment group and the sham treatment group by means of randomized methods.The protocol of the treatment is to use rTMS with high frequency 10/20Hz 120%RMT 20 times for one month. The device is Magtism rTMS made in London, UK
89414987|NCT04431401|Sham Comparator|sham treatment group|The control group is to receive sham treatment. The device is the same as the one used in the real treatment group.
89414988|NCT04426006|Other|PRO-SERO-COV|Blood sample and self-administered questionnaire
89414989|NCT04418713|Experimental|exercise group with active video-games|exergaming exercise: A combination of traditional exercise and exercise through active video games performed 3 days a week for one hour during 7 months. As well, it will be including some session about nutritional advice.
89414990|NCT04418713|No Intervention|control group|no physical intevention will be provided, but it will be included some sessions on nutritional advice.
89414991|NCT04413123|Experimental|Cabozantinib|"Eligible patients will be enrolled and receive treatment with~Cycle 1-4 (cycles of 21 days)~Cabozantinib predetermined protocol dosage po daily~Nivolumab predetermined protocol dosage via IV every 3 weeks~Ipilimumab predetermined protocol dosage via IV every 3 weeks~After the first four cycles of therapy,~Cabozantinib determined protocol dosage po daily~Nivolumab predetermined protocol dosage via IV every 3 weeks (cycles of 28 days)"
89414992|NCT04408066|Experimental|Arm A:Suspected COVID-19 patients|Arm A: Suspected COVID-19 Patients - SARS-CoV-2 viral antigen test swab and blood sample for SARS-CoV-2 IgG/IgM
89414993|NCT04408066|Experimental|Arm B: Previously positive COVID-19 patients|Arm B: Previously Positive COVID-19 patients - SARS-CoV-2 IgG/IgM blood sample. Capillary fingerstick samples will additionally be collected in Stage 2.
89414994|NCT04401436||COVID 19 patients|Study participants will be adults who either have COVID-19 or who have recently recovered from the disease(recovered per Centers for Disease Control and Prevention guidelines).
89414995|NCT04343924|Experimental|Diving Group|The subjects of this group daily dive, 5 days per week, for a total of 10 dives at a maximum depth of 6 meters for a maximum duration of 20 minutes in a swimming pool.
89414996|NCT04343924|Active Comparator|Virtual reality Group|The subjects of this group will follow virtual reality sessions recreating the environment in which the submarine diver of the GP+ group operates.
89414997|NCT04343924|No Intervention|Control Group|The subjects of this group will be monitored and treated for PTSD and will not attend the dive discovery course or virtual reality sessions.
89414998|NCT04343313|Experimental|Half Moon TMVr System|The Half Moon Transcatheter Mitral Valve Repair (TMVr) System is designed for transfemoral access and transseptal delivery of a self-expanding implant that restores competency in a regurgitant mitral valve.
89414999|NCT04341350|Active Comparator|Usual sedation|Sedation according to a written, standardized Nurse management protocol using at least one sedative drug (propofol) and one analgesic drug.
89415000|NCT04341350|Experimental|Inhaled sedation|Sedation by inhalation of halogenated gas (Isoflurane) delivered by the Anesthetic-Conserving Device (ACD) system ANACONDA ™ associated with the administration of an analgesic drug.
89415001|NCT04318366||COVID-19 patients|
89415002|NCT04305795|Other|Cohort 1- 1L HNSCC|Recurrent locally advanced and/or metastatic head and neck squamous cell carcinoma
89415003|NCT04305795|Other|Cohort 2- 1L cuSCC|Locally advanced or metastatic cutaneous squamous cell carcinoma
89415004|NCT04305795|Other|Cohort 3- 2L cuSCC|Locally advanced or metastatic cutaneous squamous cell carcinoma
89415005|NCT04296006|Experimental|Active Treatment|Cocaine choice during d-amphetamine maintenance
89415006|NCT04296006|Placebo Comparator|Placebo Treatment|Cocaine choice during placebo maintenance
89535881|NCT03201367|Active Comparator|study group|"acute non-neoplastic PVT, compensated cirrhosis, acute PVT onset within 1 week after initial diagnosis~- treated with rivaroxaban"
89535882|NCT03201367|Placebo Comparator|control group|acute non-neoplastic PVT, compensated cirrhosis, acute PVT onset within 1 week after initial diagnosis receive placebo
88892764|NCT06038071|Active Comparator|scheduled followup|standard of care plus scheduled follow-up visits at 1 month, 3 months, 6 months after discharge
88892765|NCT06038071|Experimental|family MUAC|standard of care plus Family MUAC training for the primary caregiver present at the time of recovery, with one final visit scheduled at 6 months after discharge
88892766|NCT06037811|Active Comparator|Standard of care group|Prednisone 10 mg daily for 2 weeks, then taper by 2.5 mg every 2 weeks until stopped.
88892767|NCT06037811|Active Comparator|Adalimumab group|"Adalimumab 40 mg subcutaneous every 2 weeks for 6 doses (12 weeks)~+ Prednisone 10 mg daily for 2 weeks, tapering by 2.5 mg every 2 weeks until stopped."
88892768|NCT06037616|Active Comparator|gr A: powerpoint and tutor|teaching with powerpoint and tutor
88892769|NCT06037616|Active Comparator|gr B: powerpoint and tutor and video skill|teaching with powerpoint and tutor and video showing skill to perform a skin suture
88892770|NCT06037616|Active Comparator|gr C: powerpoint and tutor and video error|teaching with powerpoint and tutor and video showing errors
88892771|NCT06037616|Active Comparator|gr D: powerpoint and tutor and video skill and error|teaching with powerpoint and tutor and video showing skill to perform a skin suture and errors
88892772|NCT06037447||Standardized Group|Patients in this group will undergo standardized strategy during mitral repair surgeries, including subvalvular apparatus rehabilitation, leaflets repair and annuloplasty.
88892773|NCT06037447||Annuloplasty Group|Patients in this group will undergo annuloplasty only during mitral repair surgeries.
89535883|NCT02479685|Experimental|SORD-BILL|PKS BILL: bipolar laparoscopic loop (a laparoscopic loop using advanced bipolar energy) (Olympus Medical Systems Corp, Tokyo) and PKS PlasmaSORD (Solid Organ Removal Device) for subtotal hysterectomy and uterine morcellation, respectivelly, during sacral colpopexy for Pelvic Organ Prolapse.
89535884|NCT02479685|Active Comparator|STANDARD|Conventional monopolar hook and conventional mechanic morcellator for subtotal hysterectomy and uterine morcellation, respectivelly, during sacral colpopexy for Pelvic Organ Prolapse.
88892774|NCT06037434||Modified Drug Therapy Group|Patient in this group will undergo a one-year course of medication, including Captopril(tablet, 0.3mg/kg, tid), Metoprolol(tablet, 0.2mg/kg, bid), Spironolactone(tablet, 2-4mg/kg, bid), Torsemide(tablet, 0.2-0.5mg/mg, bid), and Potassium Citrate(powder, 0.06g/kg, tid).
88892775|NCT06037434||the Traditional Drug Therapy Group|Patient in this group will undergo a one-year course of medication, including Torsemide(tablet, 0.2-0.5mg/mg, bid) and Potassium Citrate(powder, 0.06g/kg, tid).
88892776|NCT06036433|Active Comparator|Randomized, Placebo Controlled, Double-Blind Clinical Trial Real ( Active) vs. Placebo (Sham)|"The first arm includes the real (active) group (n=30) and the placebo (sham) group (n=30). Both groups will self-administer their at-home photobiomodulation (PBM) therapy with devices that either emit active light energy or emit no light energy, respectively. The 30 minute treatment is completed 3 x per week. The protocol includes abdominal PBM treatment with a hand held infrared device and transcranial PBM treatment with an infrared & red LED helmet. Participants are taught how to administer their own treatment and are provided with weekly follow-up. At the completion of the 24 treatments the devices are returned. Post outcome measurement testing is conducted at baseline and 1 and 4 weeks after the last PBM treatment. An inclusion criteria requires that subjects have been exercising 3 x per week before entering the study and continue the minimum level of exercise throughout the study.~Data from the Real group will be compared with the results from in the Placebo group."
88892777|NCT06036433|Other|Active and Placebo Cross Over|After the first arm of the study is completed and the post treatment assessments administered, participants in the Active and Placebo groups will be offered the option to complete 8 weeks of real (active) at-home PBM treatment of the abdomen and head (transcranial), 3 x per week for a total of 24 treatments. Each treatment takes approximately 30 minutes to complete. The devices are then returned. Outcome measurement testing will be conducted at Weeks 1 and 4 weeks after the last treatment.
88892778|NCT06035523|Other|Subjects with a Wagner Grade 1 or 2 diabetic foot ulcer|Arm receives application of Endoform™ Antibacterial, Endoform™ Natural and Symphony™ and appropriate Off - loading
88892779|NCT06035237|Experimental|Experimental Group|Patients in the experimental group were informed that cold spray would be applied to their arm in a supine position to reduce procedure-related pain. For femoral artery angiography, the central part of the inguinal access area was targeted, and for radial angiography, 2 cm above the styloid process of the radial bone was targeted, and cold spray (Chloroethyl spray) was applied for approximately 3 seconds from a height of 10 cm.
88892780|NCT06035237|No Intervention|Control Group|Pain levels recorded with the VAS were evaluated for patients after the procedure using the state anxiety scale. Pain levels for control group patients were also assessed and recorded within the sheath after intravenous solutions were given. Anxiety levels were recorded after the procedure was completed.
88892781|NCT06031740|Experimental|Sclerotherapy with 1.5% polidocanol.|2mL (3%) polidocanol = 60mg; maximal dose: 1mL/column and 4mL/session.
88892782|NCT06031740|Active Comparator|Foam sclerotherapy|Tessari's technique; 4mL 3% poilidocanol +16mL air; maximal dose: 2mL/column and 20mL/session.
88892783|NCT06029725|Active Comparator|RFMN+Thulium|
88892784|NCT06029725|Active Comparator|RFMN|
88892785|NCT06029218|Experimental|1DB|One daily Beam treatment
88892786|NCT06029218|Active Comparator|2DB|Two daily beam goldstandard
88892787|NCT06013943|Experimental|Envafolimab+Gemox|
88892788|NCT06011239|Experimental|Survey participants|All participants in the study will be in a single arm, divided by clinic.
88892789|NCT06010927|Active Comparator|Group-A; ketamine/midazolam premedication|
88892790|NCT06010927|Active Comparator|Group-B: Ketofol pre-extubation|
88892791|NCT06008444||Post-COVID-19 group|This group will consist of individuals with Parkinson disease who have had COVID-19.
88892792|NCT06008444||Control group|The control group will consist of individuals with Parkinson disease without post-COVID-19.
88892793|NCT06006897||Post-COVID-19 group|This group will consist of individuals with idiopathic scoliosis who have had COVID-19.
88892794|NCT06006897||Control group|The control group will consist of individuals with idiopathic scoliosis without post-COVID-19.
89536746|NCT02723201|Experimental|Part-1, Period 3:TAK-020 17.5 mg Solid Dispersion Tablet (SDT)|Single oral dose 17.5 mg, on Day 1, followed by 7 days of washout. Dose will be the same as Part 1, Period 1.
88892795|NCT05987046|Experimental|Contrast training sessions|Participants will perform three contrast training sessions for a week.
88892796|NCT05982717||Participants With DS or LGS|Participants with a medical record of diagnosis with either DS or LGS that are treated in the participating hospitals and reside in the reference area of these hospitals will be included and data will be retrospectively collected for the period between 01 January 2021 to 31 December 2022.
88892797|NCT05982405|Experimental|Training group|The individuals in the training group will be performed inspiratory muscle training using an inspiratory muscle training device (PowerBreathe®) at 30-50% of the maximal inspiratory pressure.
88892798|NCT05982405|Sham Comparator|Control group|Individuals in the control group will be performed thoracic expansion exercises.
88892799|NCT05958147|Experimental|Probing sites with SPR and C-PRF application|The test group received the C-PRF as adjunct to sacling and root planing
88892800|NCT05958147|No Intervention|Probing sites with SPR alone|
88922110|NCT05797181|Experimental|Dietary and Behavioral Change Group|"The experimental group will be required to adhere to a diet consisting of a 10-15% reduction in carbohydrate and a 1.2-1.4 g/kg body weight/day intake of protein.~The participants will receive 4 times face-to-face meetings (on the first day and on week 1,5 and 9).~Each face-to-face interview will last approximately 30 minutes. During the interview researcher will help the participants to determine their nutritional behaviors, plan and implement the diet."
88922111|NCT05794139|Experimental|Cohort 1|Experimental drug followed by placebo
88922112|NCT05794139|Experimental|Cohort 2|Placebo followed by experimental drug
89415007|NCT04292054|Active Comparator|active group|"The antibiotic prophylaxis will be cefazolin 2 g powder for solution for injection diluted in 50mL of NaCl 0.9%, IV infusion on 30 minutes with syringe pump, in case of absence of colonization to Pseudomonas aeruginosa prior to the surgical procedure.~The dose administer is 2g.~Antibiotic prophylaxis will be piperacilline-tazobactam 4 g powder for solution for injection diluted in 50mL of NaCl 0.9%, IV infusion on 30 minutes with syringe driver in patients with burn wound colonized to Pseudomonas aeruginosa.~The dose administer is 4g."
88892801|NCT05916196|Experimental|Recurrent or metastatic uterine cancer|"Women with known or suspected recurrent or metastatic uterine cancer may be eligible for this study. Patients may participate in this study if they are at least 18 years of age, most participants will be receiving care at the clinical practices of the University of Pennsylvania.~[18F]fluoroestradiol (FES) PET/CT imaging will be used to evaluate estrogen receptor (ER) activity in areas of disease known by standard of care imaging (e.g. CT, MRI, Bone Scan, FDG PET/CT, ultrasound) or clinical exam. For patients starting a new line of therapy, imaging will occur prior to starting new therapy. For patients who completed an initial scan and are starting new therapy, some patients may also undergo a second FES PET/CT scan at the time of suspected progression of disease to compare for changes in FES uptake measures (prior to initiation of next line therapy)."
88892802|NCT05912946|Experimental|Experimental group drug|Generic name: Human interferon a2b injection; Dosage form: solution; Dosage: 1ml: 3 million IU; Frequency and duration: The first 4 weeks were irrigated once a week, a total of 4 times, and the last 4 months were irrigated once a month, a total of 4 times. The total treatment cycle was 5 months, and a total of 8 bladder perfusion treatments were performed.
88892803|NCT05912946|Active Comparator|Sodium Hyaluronate|Generic name: Sterile sodium hyaluronate solution; Dosage form: solution; Dosage: 40mg/50ml; Frequency and duration: The first 4 weeks were irrigated once a week, a total of 4 times, and the last 4 months were irrigated once a month, a total of 4 times. The total treatment cycle was 5 months, and a total of 8 bladder perfusion treatments were performed.
88892804|NCT05912946|Placebo Comparator|Sodium chloride injection|Generic name: Sodium chloride injection; Dosage form: solution; Dosage: 50ml: 0.45g; Frequency and duration: The first 4 weeks were irrigated once a week, a total of 4 times, and the last 4 months were irrigated once a month, a total of 4 times. The total treatment cycle was 5 months, and a total of 8 bladder perfusion treatments were performed.
88892805|NCT05903521||Control group|BMI ≥ 35 kg/m2 without previous bariatric surgery
88892806|NCT05903521||Treatment group|Having had Sleeve Gastrectomy or Roux-en-Y Gastric Bypass more than 12 months ago and without a weight regain of ≥ 15% of nadir weight
88892807|NCT05879523|Experimental|HRS-1893 for single ascending dose (SAD) cohorts|Subjects will be assigned to one of 6 planned dose cohorts and receive single dose of HRS-1893
88892808|NCT05879523|Placebo Comparator|Placebo comparator for SAD cohorts|Subjects will be assigned to one of 6 planned dose cohorts and receive single dose of placebo comparator
88892809|NCT05879523|Experimental|HRS-1893 for multiple ascending dose (MAD) cohorts|Subjects will receive multiple doses of 2-4 planned dose cohorts and receive single dose of placebo comparator for MAD cohorts
88892810|NCT05831475|Experimental|Peer Pairings|Two older adults paired
88892811|NCT05831475|Experimental|Intergenerational Pairings|A younger adult and older adult paired
88892812|NCT05828979|Experimental|UroMems artificial urinary sphincter|Female adults (18+) with urinary incontinence with reduced outlet resistance due to intrinsic sphincter deficiency.
89536747|NCT02723201|Experimental|Part-1, Period 4:TAK-020 17.5 mg Immediate Release Tablet(IRT)|Single oral dose 17.5 mg, on Day 1, followed by 7 days of washout. Dose will be the same as Part 1, Period 1.
88892814|NCT05810649|Experimental|HA35 local injection Group|This clinical study used the 35 kDa low molecular weight HA fragment HA35, which was freshly manufactured by mixing bovine testis-derived hyaluronidase PH20 injection (H31022111) with high-molecular-weight HA injection (H20174089) for 20 minutes at room temperature.
89415008|NCT04292054|Placebo Comparator|Placebo group|The control group will received, as placebo NaCl 0.9% solution for injection diluted in 50mL of NaCl 0.9%, IV infusion on 30 minutes with syringe pump.
89415009|NCT04285372|Experimental|Test group|No intervention on the side branch in the context of percutaneous coronary intervention for the treatment of bifurcation lesion
89415010|NCT04285372|Active Comparator|Control group|Side branch protection: Ballooning or Kissing Balloon Technique, in the context of percutaneous coronary intervention for the treatment of bifurcation lesion
89415011|NCT04279847|Experimental|Part 1 : INCB057643 Monotherapy|INCB057643 dose escalation and dose expansion
89415012|NCT04279847|Experimental|Part 2 : INCB057643 Combination with Ruxolitinib|Combination arm in dose escalation and dose expansion
89415013|NCT04276584|Active Comparator|Positive expiratory pressure|Deep inspiration followed by expiration to a resistance of 10-15 cm of water pressure. Done three times, each time with 10 inspiration/expiration cycles
89415014|NCT04276584|Experimental|Speaking loudly|Speaking loudly during 3 minutes.
89415015|NCT04273022|Experimental|SCT Group|Fifteen SCT subjects will be recruited, consented, screened, and enrolled if they meet inclusion and exclusion criteria. Each subject will undergo a single bout of standardized exercise on a treadmill. Subjects will self-select treadmill speed at 0% grade and begin. After 3 minutes the grade will be increased by 1% every 2 minutes until the target heart rate (70% of heart rate reserve) is reached. Speed and grade will be held constant for 15 minutes, marking the end of the session.
88922113|NCT05790551|Active Comparator|Control|Patients in this arm will undergo standard at-home OUD treatment (n = 20/group) over 30-days.
88922114|NCT05790551|Experimental|Active - App|Patients in this arm will undergo standard at-home OUD treatment in combination with the Addinex dispenser and app (n = 20/group) over 30-days.
89415016|NCT04273022|Active Comparator|Control Group|Five healthy subjects will be recruited, consented, screened, and enrolled if they meet inclusion and exclusion criteria. Each subject will undergo a single bout of standardized exercise on a treadmill. Subjects will self-select treadmill speed at 0% grade and begin. After 3 minutes the grade will be increased by 1% every 2 minutes until the target heart rate (70% of heart rate reserve) is reached. Speed and grade will be held constant for 15 minutes, marking the end of the session.
88892815|NCT05799430|Experimental|Intervention|The intervention group will receive a multidisciplinary medication review and a personalized therapeutic plan in the following 72 hours after hospital discharge. The intervention will be developed by a multidisciplinary team that includes a family physician (FP), a primary care nurse (PCN) and a primary care pharmacist (PCP). PCP is a pharmacist working in a full-time base for the Pharmacy Service in a Primary Care District in Andalusian Public Health Service.
88892816|NCT05799430|Active Comparator|Control group|The control group will receive usual care.
88892817|NCT05799326|Experimental|Levofloxacin group|Levofloxacin 200mg twice per day is administrated.
89415017|NCT04269239|Other|Healthy Habits|This group will meet with a study therapist to discuss strategies to implement healthy habits that may enhance recovery from knee or hip surgery.
88892818|NCT05799326|Placebo Comparator|Levofloxacin simulant group|Levofloxacin simulant 200mg twice per day is administrated.
88892819|NCT05796544|Experimental|Intervention Group|The intervention group will receive a total of four remote educational sessions over 2 months.
88892820|NCT05796544|Active Comparator|Control group|The control group will receive the standard care, consisting of in-person standard education.
88892821|NCT05782010|Experimental|PexyEazy procedure|PexyEazy procedure on patients with hemorrhoidal disease grade II and III. The study is descriptive and non-comparable to evaluate the safety and performance of PexyEazy.
88892822|NCT05775731||shift worker|- shift worker: works at least 60 nights per year Each subject will have blood taken twice (before and after the night-shift), and will answer three questionnaires [Pittsburgh Sleep Quality Index, Generalized Anxiety Disorder-7 (GAD-7) for anxiety disorder and a general health questionnaire]
88892823|NCT05775731||daily worker|- daily worker: does not work at night (from 8 pm to 6 am) Each subject will have blood taken once, and will answer three questionnaires (Pittsburgh Sleep Quality Index, GAD-7 for anxiety disorder and a general health questionnaire)
88892824|NCT05732753|Experimental|Experimental group|An experimental group (GE) that after an initial evaluation and with their consent, will be subjected to a program that includes an intervention based on Mindfulness and an 8-week Education intervention, one day a week with a duration of 120 minutes. The sessions will be divided into two parts, a part of 60' of Mindfulness and another of 60' of Education. In the Mindfulness part, formal Meditation practices and conscious movements based on yoga will be carried out. In the Education part, participants will be instructed in concepts related to the basic neurophysiology of pain.
88892825|NCT05732753|Active Comparator|Control group|The control group (CG) will receive an Education intervention, which will be evaluated in the pre and post phase of the study. Participants assigned to this group will receive 8 sessions, 60' long, with a frequency of one session per week.
88892826|NCT05731024|Experimental|Close-loop synchronization controller|One-hour period where the pressure support of spontaneous effort will be automatically titrated based on pressure and flow waveform analysis obtained from the patient during SPONT mode.
88892827|NCT05731024|Active Comparator|Conventional|One-hour period where the synchronization of pressure support of patient effort during SPONT mode will be manually set.
88892828|NCT05722821|Experimental|Experimental group|An experimental group (GE): that after an initial evaluation will be subjected to a hypopressive abdominal gymnastics program, for 12 weeks with 2 weekly sessions (Tuesday and Thursday, controlling adherence to the sessions through attendance), with a duration of 45 min per session. Once the intervention is finished, you will be subjected to a final evaluation to see if there is a difference or not with the results obtained at the beginning.
89193073|NCT05605912|Active Comparator|Control|Participants perform conventional training sessions. After the clinical training program, participants receive a recommendation for physical activity at home. After the conventional training program the control group will receive the Myosuit intervention.
89193074|NCT05604833|Experimental|experimental|they will November progressive muscle relaxation exercise
89415018|NCT04269239|Other|Sleep Habits|This group will meet with a study therapist to discuss strategies to implement healthy sleep habits that may enhance recovery from knee or hip surgery.
89415019|NCT04258293||Patients|Patients on prolonged corticosteroid therapy (more than three months)
89415020|NCT04257058|Experimental|Electronic educational material|Participants will complete an online pre-test survey via REDCap. One week after the pre-test survey is completed, AYAs will be sent electronic media via email to review on their own. Study staff will confirm receipt and review of material and schedule a post-test survey to be completed in REDCap two weeks after material is reviewed.
88922115|NCT05790551|Experimental|Active - Text Messaging|Patients in this arm will undergo standard at-home OUD treatment in combination with the Addinex dispenser and texting (n = 20/group) over 30-days.
89193075|NCT05604833|No Intervention|no ıntervention|to be followed without exercise
89193076|NCT05604807|Experimental|Dementia course with virtual reality|Dementia course with virtual reality consists of dementia virtual reality activity, intergenerational learning, world café teaching method and community practice
89415021|NCT04253262|Experimental|Dose Level -2|300 mg Rucaparib, 45 mg (day 1 & 15) Copanlisib
89415022|NCT04253262|Experimental|Dose Level -1|400 mg Rucaparib, 45 mg (day 1 & 15) Copanlisib
89415023|NCT04253262|Experimental|Dose Level 1|400 mg Rucaparib, 45 mg Copanlisib
89415024|NCT04253262|Experimental|Dose Level 2|500 mg Rucaparib, 45 mg Copanlisib
88892829|NCT05722821|No Intervention|Control group|A control group (CG): that will not be subjected to treatment, which will be evaluated in the pre and post phase of the study, and a follow-up by telephone contact of adherence to physical activity. The participants assigned to this group will receive general advice on the positive effects of the regular practice of physical activity aimed at preventing urinary incontinence, and they will be given the guide of recommendations for the promotion of physical activity.
88892830|NCT05721560|Experimental|SINEFIX|Rotator cuff repair with the SINEFIX implant, using the SINEFIX instruments
88892831|NCT05720468|Experimental|Exercise|Participants randomized to the exercise group will receive 26 weeks of home-based, combined endurance and resistance training program under guidance and virtual supervision from exercise trainers. Exercise will be performed 5 days per week, with 3 days of endurance training using treadmill and 2 days of resistance training.
88892832|NCT05720468|Placebo Comparator|Waitlist Control Group|The control group will continue usual level of physical activity the participants were doing prior to enrollment in the study. At the end of the 26 week study period, participants will be offered the chance to participate in the same home-based, combined endurance and resistance training program.
88892833|NCT05711602|Experimental|Pilates group|This group receives physical training based on pilates exercises
88892834|NCT05711602|No Intervention|No intervention group|This group does not receive any treatment
88892835|NCT05710783|Experimental|Phase II - Experimental|AVX-COVID/12 Dose: 10^8.0 EID50/ intramuscular dose Study parameters: Safety, Serological response, Cellular response
88892836|NCT05710783|Active Comparator|Phase II - Active Control|ChAdOx-1-S[recombinant]) intramuscular Study parameters: Safety, Serological response, Cellular response
88892837|NCT05710783|Experimental|Phase III - Experimental|AVX-COVID/12 Intramuscular Dose: 10^8.0 EID50/ intramuscular dose Study parameters: Safety, Serological response
88892838|NCT05710783|Active Comparator|Phase III - Active Control|ChAdOx-1-S[recombinant]) intramuscular Study parameters: Safety, Serological response
89415025|NCT04253262|Experimental|Dose Level 3|600 mg Rucaparib, 45 mg Copanlisib
88892839|NCT05710783|Experimental|Phase III - Security|AVX-COVID/12 Intramuscular Dose: 10^8.0 EID50/ intramuscular dose Study parameters: Safety.
88892840|NCT05710783|Experimental|Phase II- Experimental|AVX-COVID/12 Dose: 10^8.0 EID50/ intramuscular dose Study parameters: Safety, Serological response.
88892841|NCT05710783|Active Comparator|Phase II- Active Control|ChAdOx-1-S[recombinant]) intramuscular Study parameters: Safety, Serological response.
88892842|NCT05696847|Experimental|Tirzepatide|Tirzepatide administered subcutaneously (SC)
88892843|NCT05696847|Placebo Comparator|Placebo|Placebo administered SC
88892844|NCT05695469|Experimental|ResuGlove group|Participants in the ResuGlove group will be guided by the audio feedback from the smart resuscitation glove.
88892845|NCT05695469|Active Comparator|Traditional CPR group|Participants in the traditional CPR group will perform chest compressions without guidance from the smart resuscitation glove.
88892846|NCT05679492|Experimental|Meplazumab|First dose: 0.2 mg/kg - Day 1; second dose: 0.2 mg/kg - Day 8
88892847|NCT05679492|Placebo Comparator|Placebo|First dose: control - Day 1; second dose: control - Day 8
88892848|NCT05664087|Experimental|Experimental group|Debridement of tooth extraction sockets was assisted by photodynamic equipment
88892849|NCT05664087|No Intervention|control group|Routine tooth extraction and debridement were performed
88892850|NCT05637177|Experimental|Cognitive behavioral therapy (CBT)|"We used the Aging Wisely program for seniors living in the community, which uses elements of CBT and is specifically designed for older people over the age of 65 living in the community who may be in a worried, anxious or depressed mood. The program focuses on psychoeducation to manage these feelings. Seniors learn to change the ways they think and behave that maintain depression and anxiety. The sessions include education on the process of aging, coping with loneliness, improving sleep, coping with worry and avoidance, coping with loss and death. During the sessions, participants learn to track mood, motivation to change, goal setting, planning pleasant activities, identifying thoughts, working with useless thoughts, and practice techniques to replace useless thoughts. The last two sessions are dedicated to assertiveness and communication, and preventing recurrence of problems."
88892851|NCT05637177|Experimental|Reminiscence therapy|Reminiscence is a method of working with memories. Remembering has an irreplaceable place in every person's life. It is a natural activity that can encourage people, make them aware of their own achievements, different moments in life, point out their value, promote self-esteem and contribute to the development of relationships. Self-remembering is a natural form of cognitive stimulation.
88892852|NCT05637177|Experimental|Music therapy|The aim of music therapy is to optimize the quality of life, and to improve psychological, social, communication, emotional and mental health and well-being. Music therapy brings psychological and physical relaxation, reduces stress, improves mood, alleviates anxiety, improves memory and attention, develops and facilitates communication, enables self-expression. For this purpose, a number of activities are used, such as listening to music, singing, playing simple rhythmic instruments, playing the body and a number of other activities that will be carried out with seniors as part of the intervention.
89415026|NCT04253262|Experimental|Dose Level 4|600 mg Rucaparib, 60 mg Copanlisib
89415027|NCT04251936|Experimental|Exercise training plus smoking cessation group program|
88892853|NCT05637177|Experimental|memory training|"Cognitive training is targeted and structured exercise of cognitive functions (learning, memory, attention, speech, visual-spatial functions, ability to solve problems, plan or manage various tasks and correctly recognize one's surroundings). Regular exercise of cognitive abilities can create a cognitive reserve that can delay the potential aggravation of problems in memory or attention and improve quality of life.~The content of the intervention will be activities developing cognitive functions (primarily memory, attention, imagination, spatial orientation and decision-making speed), practical training and motivation for long-term regular strengthening of cognitive functions using the comprehensive training program MENTEM."
89415028|NCT04251936|Active Comparator|Smoking cessation group program|
89415029|NCT04245150||Ductal Carcinoma In Situ (DCIS) or invasive breast cancer|Participants with DCIS or invasive breast cancer
88892854|NCT05637177|Experimental|creation of educational modules (mental health, neural diseases …)|Educational activities will focus on disease prevention in three main directions - cardiovascular diseases, mental health and neurological diseases. Educational activities will take place within the University of the Third Age LF OU.
88892855|NCT05607784||Adolescent Advisory Board Male|This board consisted of 9 male adolescents recruited from the schools.
88892856|NCT05607784||Adolescent Advisory Board Female|This board consisted of 9 female adolescents recruited from the schools.
89415030|NCT04243837|Experimental|LYT-100 in healthy volunteers|LYT-100, multiple ascending dose
89415031|NCT04243837|Placebo Comparator|Placebo in healthy volunteers|Placebo, multiple administrations
89415032|NCT04243837|Experimental|LYT-100 in healthy volunteers, Fasted|LYT-100, Dose below MTD for 1 dose
89415033|NCT04243837|Placebo Comparator|Placebo in healthy volunteers, Fasted|Placebo, for 1 administration
89415034|NCT04243837|Experimental|LYT-100 in healthy volunteers, Fed|LYT-100, Dose below MTD for 1 dose
89415035|NCT04243837|Placebo Comparator|Placebo in healthy volunteers, Fed|Placebo, for 1 administration
89415036|NCT04243837|Experimental|LYT-100 in patients with BCRL|LYT-100 BID for 6 months
88892857|NCT05607784||Health Education Professionals Panel (HEPP)|This panel consisted of 6 health teachers and other school health professionals such as nurses and counselors. They were recruited at each participating school.
88892858|NCT05606432|Experimental|Group 1|Instructor-led, one-on-one exercise group
88892859|NCT05606432|Active Comparator|Group 2|Self-guided control with virtual fitness membership
89193077|NCT05604807|Active Comparator|Dementia course with no virtual reality|Dementia course with no virtual reality consists of intergenerational learning, world café teaching method and community practice with no dementia virtual reality activity.
89415037|NCT04243837|Placebo Comparator|Placebo in patients with BCRL|Placebo BID for 6 months
89415038|NCT04242147|Experimental|Bi-weekly Monotherapy Dose Escalation (Q2W)|KD033 (SAR445710) will be administered in sequential ascending doses as a monotherapy via intravenous (IV) administration every 2 weeks (Q2W).
89415039|NCT04242147|Experimental|Weekly Monotherapy Dose Escalation (Q1W)|KD033 (SAR445710) will be administered in sequential ascending doses as a monotherapy via intravenous (IV) administration once a week (QW) for 6 weeks and then every 2 week-dosing.
89415040|NCT04242147|Experimental|Dose Expansion|KD033 (SAR445710) will be administered at recommended dose/schedule for expansion
89415041|NCT04215978|Experimental|Phase 1a: BGB-A445 Monotherapy|Dose Escalation Part A: Participants will receive intravenous (IV) infusion of BGB-A445 in sequential cohorts of approximately 8 increasing dose levels on day 1 of each 21-day cycle
89415042|NCT04215978|Experimental|Phase 1a: BGB-A445 + Tislelizumab Combination Therapy|Dose Escalation Part B: Participants will receive IV infusion of BGB-A445 in sequential cohorts of approximately 6 increasing dose levels plus 200mg tislelizumab on day 1 of each 21-day cycle
89415043|NCT04215978|Experimental|Phase 1b:BGB-A445 Monotherapy|Dose Expansion Part A: Participants will receive recommended doses of IV BGB-A445 as determined from Phase 1a Dose Escalation; BGB-A445 will be evaluated in two tumor types
89415044|NCT04215978|Experimental|Phase 1b: BGB-A445 + Tislelizumab and Chemotherapy Combination Therapy|Dose Expansion Part B: Participants will receive recommended dose IV infusion of BGB-A445 plus 200mg tislelizumab and chemotherapy
89415045|NCT04215978|Experimental|Phase 1b: BGB-A445 Monotherapy|Dose Expansion Part C: Participants will receive 1 dose level of BGB-A445
89415046|NCT04185337|Experimental|Diagnostic (ultrasound, ultrasound-guided PAI, FNA, biopsy)|Patients undergo standard of care ultrasound of the lymph nodes, then undergo ultrasound-guided PAI over 3-5 minutes. Patients then undergo standard of care ultrasound-guided FNA or biopsy a suspicious lymph node.
89415047|NCT04178005|Other|Cladribine|"All study participants will receive treatment with cladribine 10 mg tablets at the recommended cumulative dose of 3.5 mg/kg, divided into 2 yearly treatment courses (1.75 mg/kg per treatment course). This regimen corresponds to the recommended dosage as per the USPI.~Each treatment course is divided into 2 treatment cycles:~Administration of first treatment course (year 1 treatment):~First cycle: Starts on Day 1 of the study~Second cycle: Administered 23 to 27 days after the last dose of first cycle.~Administration of second treatment course (year 2 treatment):~First cycle: Administered at least 43 weeks after the last dose of year 1 treatment~Second cycle: Administered 23 to 27 days after the last dose of first cycle of year 2 treatment.~The cycle dosage will be administered as 1 or 2 cladribine 10 mg tablets daily over 4 or 5 consecutive days."
89415048|NCT04174742||A|Subjects 45 years of age or younger
89415049|NCT04174742||B|Subjects over 45 years of age
89415050|NCT04163315|Experimental|dMRI, fMRI and electrocorticography|With this exploratory pilot study, the investigator propose a multimodal evaluation of the structural and functional connectivity of patients with brain tumours, in order to better understand the tumor-induced lesion mechanisms on brain connectivity as well as the brain plasticity mechanisms that the brain develops to maintain a level of overall function neurological. The investigator hope to obtain multimodal brain mapping of locally brain-damaged patients, with a view to improving onco-functional neurosurgical practices.
89415051|NCT04153422|Experimental|Treatment (IVIG)|Patients in the treatment arm will receive 2g/kg IVIG every 4 weeks (over 2 days, 1g/kg dose on Day 1 and 1g/kg dose on Day 2) for 24 weeks (6 doses total).
89415052|NCT04153422|Placebo Comparator|Placebo|Patients in the placebo arm will receive 0.9% NaCl infusions on the same schedule as the active treatment group (Day 1 and Day 2 every 4 weeks for 24 weeks total, (6 doses).
89415053|NCT04137289|Experimental|Phase Ia: BI 905711 - dose escalation|
89415054|NCT04137289|Experimental|Phase Ib: BI 905711 - dose level 1|
89415055|NCT04137289|Experimental|Phase Ib: BI 905711 - dose level 2|
89415056|NCT04137289|Experimental|Phase Ib: BI 905711 - dose level 3|
89415057|NCT04137289|Experimental|Phase Ib: BI 905711 - dose level 4|
89415058|NCT04115033|Experimental|True CES|Veterans with fibromyalgia who meet study criteria and are randomized to the experimental group will receive standard therapy in addition to cranial electrical stimulation (CES), which involves transfer of current from the alpha-stim device using earclip electrodes. The intention of this FDA-approved device is to relieve pain, though data on its effectiveness is still limited. The treatments can be self administered by the participants. The rs-fcMRI evaluation of neural changes and assessment of clinical pain, function, and quality of life will be performed at the beginning and end of the study.
89415059|NCT04115033|Sham Comparator|Sham CES|Veterans with fibromyalgia who meet study criteria and are randomized to the sham comparator group will receive standard therapy in addition to a CES device that does not deliver active electrical stimulation. The intention of this FDA-approved device is to relieve pain, though data on its effectiveness is still limited. The rs-fcMRI evaluation of neural changes and assessment of clinical pain, function, and quality of life will be performed at the beginning and end of the study.
89415060|NCT04105530|Active Comparator|Transcranial direct current stimulation (tDCS) on day 1|"One stimulation will be conducted using Anodal treatment.~The Direct Current Anodal Stimulation will be applied for 20 minutes for each stimulation period. Brief neurocognitive testing will be conducted during each stimulation session."
89415061|NCT04105530|Active Comparator|Transcranial direct current stimulation (tDCS) on day 2|A final stimulation will be conducted using Cathodal stimulation. Direct Current Cathodal Stimulation will be applied for 20 minutes for each stimulation period. Brief neurocognitive testing will be conducted during each stimulation session.
89415062|NCT04105530|Placebo Comparator|Sham treatment|"The sham procedure provides the same small current during ramp up to imitate the intervention, but the current is discontinued after ramping up and no intervention is provided. Sham will be applied for 20 minutes.Stimulation will start 5 minutes before testing and continue throughout completing the NIH Toolbox Cognitive Battery at each trial:"
89415063|NCT04103593|Experimental|exercise group|High-intensity circuit exercise training will be performed 3 times weekly for 12 weeks in a group setting. Circuit training is an exercise modality consisting of a series of exercises at different stations. Exercise training will be delivered by VTEL broadcast from the Salem VAMC to participants at the Atlanta VAMC and Baltimore VAMC. Rooms will be equipped with steps, hand and ankle weights, dumbbells, chairs and bands. No stationary exercise equipment will be used in either AEX or RT.
89415064|NCT04103593|No Intervention|control group|Sedentary activity (confirmed at eligibility no more than 1 structured physical activity/week) will be continued in participants randomized to the control group. Participants have the option after 12-week intervention phase to enter ?delayed? exercise training to assure that all participants can receive exercise training.
89415065|NCT04078997||PCV13-vaccinated,15-24 months of age|"Recruitment for carriage surveillance (primary endpoint) will take place at randomly selected households within each of the catchment areas (zones) of the 20 selected health centers.~Sampling: Random sampling from populations will occur preferentially around the health centers and not from the population on the zonal interfaces. Researchers will designate two geographic sampling areas within each zone around each health center that allows a buffer against zonal borders. If the recruitment target within first sampling area is not met, sampling will move into the second area."
89535885|NCT03202927|Experimental|TPI-120 (PEGFILGRASTIM)|One daily dose of TPI-120 (PEGFILGRASTIM) 6 mg/0.6 ml administered subcutaneously on Day 1 (Study Day 1) of Cycle 1 followed by one daily dose of 6 mg/0.6 ml administered subcutaneously on Day 1 (Study Day 22) of Cycle 2 with a gap of 21 days between two cycles
88892860|NCT05587348|Experimental|1. Best Practice Advisory|Four practices receive a suite of tools intended to increase the rate of referral to DSMES classes for patients with type 2 diabetes. In these four practices, the assigned DCE specialist will have access to a list of eligible patients who have upcoming appointments with their primary care providers. The DCE specialist will message the providers about the eligible patients via the EHR. They will also place a pended order for referral to DSMES class for the eligible patients. The health care provider will be able to either approve or deny the order for the referral Additionally, when an eligible patient presents for an appointment in one of the four intervention clinics, a best practice advisory (BPA) will fire within the EHR and encourage the provider to place a referral for DSMES classes.
89415066|NCT04078997||PCV13-vaccinated, 5-10 years of age|"Six schools will be selected: three located centrally in each of the 3+0 zones, and three in the 2+1 zones.~Sampling: Children will be randomly chosen and recruited from each school. NP swab collection will occur during two surveys, starting 21 and 34 months after the switch to 2+11.~Mapping analysis from our current surveillance activities shows good clustering of recruited children living around the school, suggesting limited movement and thus low risk of contamination between zones with different vaccination schedules."
89415067|NCT04078997||PCV13-unvaccinated HIV-infected adults on ART 18 - 40 years of|"Adults will be recruited from the Queen Elizabeth Central Hospital (QECH), Lighthouse ART clinic in Blantyre.~Sampling: Mapping analysis from current surveillance activities shows good distribution throughout the Blantyre area, suggesting it is possible to achieve balance between those adults residing in 2+1 vs 3+0 areas. Sample collection will be on a rolling basis throughout the study period, starting 18 months after switch to 2+1."
89415068|NCT04078997||PCV13-vaccinated, 9 months of age|"Recruitment will take place at vaccination centers.~Sampling: A convenience sample of NP swabs will be collected at the 9-month (measles-1) visit. Sample collection will occur 9 months after the switch to 2+1 schedule."
89415069|NCT04062812|Experimental|Diluted citrate|"Initial citrate dose 3.5 mmol/L Initial calcium programmed 100% (compensation dose) only dialysis and ratio 1:10 (blood/dialysis) No fluids in the repositioning scale"
89415070|NCT04062812|Active Comparator|Concentrated citrate|Initial citrate dose: 3.5 mmol/L Initial calcium dose: 1.9 mmol/L and 1:20 ratio (blood/dialysis) No convection programmed
89415071|NCT04051619|Experimental|oxytocin|The oxytocin will be formulated at 5mg/0.1mL (5mg/spray) and dispensed as 10-mL nasal spray, twice a day (2 sprays per nostril) for 7 days (total daily dose: 40 international units, IU).
89415072|NCT04051619|Placebo Comparator|matching placebo|The oxytocin-matched placebo will be formulated at 5mg/0.1mL (5mg/spray) and dispensed as 10-mL nasal spray, twice a day (2 sprays per nostril) for 7 days (total daily dose: 40 international units, IU).
88892861|NCT05587348|Placebo Comparator|2. Silent Best Practice Advisory|Two practices will not receive the suite of tools, but the lists and BPA will be created and sent to the research team.
89415073|NCT04042402|Experimental|Open Label|Open label, monthly subcutaneous injection
89415074|NCT04038203||Neonates with UAC placement|Neonates with birth weight less than 1500 grams with UAC placed on admission. Raman measurements will be obtained simultaneously on the right AND left lower extremity for 15 minutes daily in the first week of life.
89415075|NCT04028765|Active Comparator|Oral Misoprostol|
89415076|NCT04028765|Active Comparator|Oxytocin|
89415077|NCT04017520||Mother-infant dyads|"221 mother-infant dyads enrolled at delivery and followed longitudinally at regularly scheduled well child checks (4, 16, 24, and 48- weeks) at a primary care outpatient pediatric clinic affiliated with an academic medical center. Eligible mothers will be those who plan to breast feed for 16 weeks and infants born at term (37-42 weeks). The cohort will be divided post-hoc into atopic and non-atopic groups based on the primary outcome measure (described below).~No intervention will be administered."
89415078|NCT03993054|Active Comparator|Standard CBSM|Participants will receive standard web-based cognitive behavioral stress management (CBSM) over 4 weeks.
89415079|NCT03993054|Experimental|Culturally-tailored CBSM|Participants will receive web-based CBSM that is culturally-tailored for Latino men specifically over 4 weeks.
89415080|NCT03974750|Experimental|intervention|Training on the rehabilitation robot REAplan(R) to learn complex, coordinated bimanual movements
89415081|NCT03974750|Active Comparator|control intervention|Training on the rehabilitation robot REAplan(R) with simple movements
89415082|NCT03960463|Active Comparator|Active|Participants will be provided with a Transcu O2 ® Oxygen delivery system at the surgical site for 4 weeks as supportive care.
89415083|NCT03960463|No Intervention|Control|Participants will be placed in a standard dressing at the surgical site and will be followed for 4 weeks.
89415084|NCT03959241|Active Comparator|Tacrolimus/Methotrexate|Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Methotrexate
89415085|NCT03959241|Experimental|Tacrolimus/MMF/PTCY|Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Mycophenolate Mofetil/Post-Transplant Cyclophosphamide
89415086|NCT03958474|Experimental|Active treatment followed by placebo treatment|Participants complete a gambling task during oxycodone administration and then complete the same gambling task during placebo administration. Participants with a history of IV opioid use can opt to complete a final remifentanil dose-ranging session.
89415087|NCT03958474|Experimental|Placebo treatment followed by active treatment|Participants complete a gambling task during placebo administration and then complete the same gambling task during oxycodone administration. Participants with a history of IV opioid use can opt to complete a final remifentanil dose-ranging session.
89415088|NCT03907488|Experimental|Arm I (chemotherapy, nivolumab, radiation)|Patients receive doxorubicin hydrochloride IV, vinblastine sulfate IV, dacarbazine IV, and nivolumab IV over 30 minutes on days 1 and 15. Patients may receive pegfilgrastim SC on days 2 and 16, or filgrastim SC or IV on days 6-10 and 21-25. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. After completion of cycle 6, patients may receive radiation therapy 5 days per week for approximately 4 weeks at the discretion of the treating physician. Patients also undergo peripheral blood specimen collection and CT, PET/CT and MRI on study.
89415089|NCT03907488|Experimental|Arm II (chemotherapy, brentuximab vedotin, radiation)|Patients receive doxorubicin hydrochloride IV, vinblastine sulfate IV, dacarbazine IV, and brentuximab vedotin IV over 30 minutes on days 1 and 15. Patients may receive pegfilgrastim SC on days 2 and 16, or filgrastim SC or IV on days 6-10 and 21-25. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. After completion of cycle 6, patients may receive radiation therapy 5 days per week for approximately 4 weeks at the discretion of the treating physician. Patients also undergo peripheral blood specimen collection and CT, PET/CT and MRI on study.
89415090|NCT03888950|Experimental|early research PET-CT|The patient will undergo an early research PET-CT after 2 cycles of anti-PD1 (PET1) between the baseline PET-CT and the PET-CT at 3 months of initiation of treatment
89415091|NCT03878485|Experimental|Stereotactic MRI-guided Adaptive Radiotherapy|-Radiotherapy will consist of stereotactic body therapy to the spine, to be given over either a two or five fraction course, delivered once daily or once every other day for a period of one to two weeks, for a total of two or five treatments (depending on whether a 2 or 5 fraction course is selected).
89535886|NCT03202927|Active Comparator|Neulasta (PEGFILGRASTIM)|One daily dose of Neulasta (PEGFILGRASTIM) 6 mg/0.6 ml administered subcutaneously on Day 1 (Study Day 1) of Cycle 1 followed by one daily dose of 6 mg/0.6 ml administered subcutaneously on Day 1 (Study Day 22) of Cycle 2 with a gap of 21 days between two cycles
88892862|NCT05587348|Experimental|3. Peer Support|45 patients in the 6 clinics who are referred to DSMES classes who enroll in the study will be assigned a peer supporter who will work with the participant and encourage attendance to the DSMES classes in addition to the usual support offered by the clinic.
88892863|NCT05587348|Placebo Comparator|4. Usual Care|45 patients in the 6 clinics who are referred to DSMES classes who enroll in the study will receive the usual support offered by the clinic.
88892864|NCT05568381|Experimental|Digital Cognitive Behavioural therapy for insomnia|"Participants will receive a commercially available 6-week, online media-rich course of CBT-I delivered by an animated virtual therapist (Sleepio). Treatment content of this intervention includes behavioural components (sleep restriction, stimulus control, and relaxation), cognitive components (paradoxical intention, cognitive restructuring, mindfulness, positive imagery, and 'putting the day to rest') and educational components (psychoeducation and sleep hygiene). Each of the 6 sessions lasts ~ 30 minutes and incorporates an initial progress review in relation to individualised goals, and exploration of self-reported diary data relating to the participant's current sleep status and pattern. The full program can be accessed via a website or iOS app. Participants will have access to the intervention for up to 12 weeks."
88922116|NCT05785039|Experimental|Study treatment|Participants receive BL-B01D1 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
88922117|NCT05782894|Experimental|Remimazolam besylate|Remimazolam besylate
89199118|NCT02542995|Other|Intevention|"QI interventions and got to see their own survey data - examples include:~Workflow redesign:~Medical Assistant (MA) data entry Improved clinic efficiency projects Assessed workflow with staff Provided time for MAs and RNs to perform tasks Paired MAs and providers Non-physician staff assist with forms~Communication improvement:~Improved teamwork Improved communication between provider groups Routine clinician meetings discussing meaningful topics Survey of providers for wish list of issues Routine emails from leaders Clinicians meeting with leaders~Chronic disease QI projects:~Establishing quality metrics with clinician input Automated Rx refill line Med reconciliation project Screening project for diabetics Screening for depression Improved patient portals"
89415094|NCT03847272|Experimental|Patients|
89415095|NCT03833180|Experimental|Zilovertamab vedotin Schedule 1: Q1/3W|Participants will be administered escalating doses of zilovertamab vedotin at 0.50, 1.00, 1.50, 2.25, 2.50, 2.75, and 3.00 mg/kg IV on Day 1 of repeated 21-day cycles (Q1/3W).
88892865|NCT05568381|Active Comparator|Sleep Health Education wait-list control|"Those in the control group will have access to three modules of the Sleep Health Education package following completion of baseline questionnaires. Each module will be delivered fortnightly with basic information about sleep health (e.g. the impact of sleep on health, creating a sleep-conducive bedroom, sleep and mood). Participants will receive a link to access each module as they are made available.~At trial completion (week 12), control participants will be offered the opportunity to engage with digital CBT-I."
88892866|NCT05549362|Placebo Comparator|ad libitum Control|No treatment control condition.
88892867|NCT05549362|Active Comparator|Traditional CR|A 25% calorie restriction (CR) intervention delivered via traditional in-person sessions.
88892868|NCT05549362|Active Comparator|Adaptive CR|A 25% calorie restriction (CR) intervention delivered via a remote, adaptive, and technology-driven intervention program.
88892869|NCT05549362|Active Comparator|Traditional TRE|An eight-hour time restricted eating (TRE) intervention delivered via traditional in-person sessions.
89415096|NCT03833180|Experimental|Zilovertamab vedotin Schedule 2: Q2/3W|Participants will be administered escalating doses of zilovertamab vedotin at 0.75, 1.00, 1.25, 1.50, 1.75, 2.00, and 2.25 mg/kg IV on Day 1 and 8 of repeated 21-day cycles (Q2/3W).
88892870|NCT05549362|Active Comparator|Adaptive TRE|An eight-hour time restricted eating (TRE) intervention delivered via a remote, adaptive, and technology driven intervention program.
88892871|NCT05548985|Placebo Comparator|control group|oral metoclopramide 10 mg, Metoclopramide tablet was chosen as a placebo because it has the same appearance of midodrine tablet with no cardiovascular effects
88892872|NCT05548985|Active Comparator|Midodrine group|oral midodrine tablet (5 mg)
89415097|NCT03833180|Experimental|Zilovertamab vedotin Schedule 3: Q3/4W|Participants will be administered escalating doses of zilovertamab vedotin at 0.75, 1.00, 1.25, 1.50, 1.75, 2.00, and 2.25 mg/kg IV on Day 1, 8, and 15 of repeated 21-day cycles (Q3/4W).
89415098|NCT03813615|Experimental|"Pilot Proof-of-Concept"|Individualized, progressive aerobic training consisting of treadmill walking for a total of 150 mins/wk delivered over 5 sessions/wk following a linear (breast, prostate, and endometrial) or non-linear (lung) dosing schedule for a minimum of 2 weeks.
89415099|NCT03813615|Experimental|Phase 1a: Dose-Finding / Escalation|Individualized, progressive aerobic training consisting of treadmill walking ranging from a total of 90 mins/wk to 450 mins/wk delivered over 3 to 7 sessions/wk following a linear or non-linear dosing schedule for a minimum of 2 weeks. If a patient is temporarily unable to complete supervised sessions as a result of unforeseen circumstances, patients may be assigned low intensity unsupervised training sessions per EP/PI discretion.
89415100|NCT03805464|Experimental|Knee Joint Effusion|Participants will receive a one-time injection of 60mL of sterile saline into the suprapatellar space of the dominant lower extremity. This injection will be conducted under ultrasound guidance by a board-certified orthopedic surgeon.
89415101|NCT03785262|Sham Comparator|Sham|Inactive uroshield device
89415102|NCT03785262|Experimental|Active Uroshield|Active uroshield device
89415103|NCT03775096|Experimental|carvedilol therapy|The dosage of carvedilol will be gradually increased from the initial recommended starting dose of 3.125 mg twice/daily, the target dose will be 25mg twice daily (50 mg/day) and participants will take 50 mg/day carvedilol for 6 months.Subjects that cannot tolerate the 50 mg daily dose, will be offered to continue at the 25 mg daily dose.
89415104|NCT03769454|Experimental|PP-001 verum - cohort 1|PP-001 verum - cohort 1
89415105|NCT03769454|Placebo Comparator|Placebo - cohort 1|Placebo - cohort 1
89415106|NCT03769454|Experimental|PP-001 verum - cohort 2|PP-001 verum - cohort 2
89415107|NCT03769454|Placebo Comparator|Placebo - cohort 2|Placebo - cohort 2
89415108|NCT03769454|Experimental|PP-001 verum - cohort 3|PP-001 verum - cohort 3
88892874|NCT05540106|Active Comparator|Blank Paper and Pencil|
88892875|NCT05540106|Experimental|Nature Coloring Packet|
88892876|NCT05540106|Experimental|Geometric Shape Coloring Packet|
88892877|NCT05540106|Experimental|Activity Book|
88892878|NCT05535270||Mood Disorder patients|The participants completed a demographic questionnaire, the self-report Oxford Depression Questionnaire (ODQ-C), the Beck Depression Inventory-II(BDI-II), and the Montgomery-Asberg Depression Rating Scale (MADRS).
89415109|NCT03769454|Placebo Comparator|Placebo - cohort 3|Placebo - cohort 3
89415110|NCT03769454|Experimental|PP-001 verum - cohort 4|PP-001 verum - cohort 4
89415111|NCT03769454|Placebo Comparator|Placebo - cohort 4|Placebo - cohort 4
89415112|NCT03752697||Neurological injury|Paper and pencil/computerized assessments of cognitive functioning and metacognitive performance will be administered.
89415113|NCT03752697||Healthy control|Paper and pencil/computerized assessments of cognitive functioning and metacognitive performance will be administered.
89415114|NCT03744910|Active Comparator|Clazakizumab|Clazakizumab is a genetically engineered humanized immunoglobulin G1 (IgG1) mAb that binds to human IL-6 that is administered subcutaneously.
89415115|NCT03744910|Placebo Comparator|Placebo|Physiologic saline solution that is administered subcutaneously.
89415116|NCT03734731|Other|Objective Nerve Conduction testing|Therapy of chronic pain and swelling with Monochromatic Infrared Photo Energy (MIRE) in combination with Transcutaneous Electrical Nerve Stimulation (TENS) and Cannabis or Opioids, to determine which treatment is deemed as the most successful, through objective nerve conduction testing with Neural Scan or AXON-II testing systems. Other types of therapies may be introduced during comparison reviews.
89415117|NCT03720990|Experimental|Cholic acid|Participants will be treated with cholic acid 10 mg/kg body weight.
88892879|NCT05535270||Healthy Controls|The participants completed a demographic questionnaire, Patient Health Questionnaire - 9(PHQ-9), and the first two sections of Oxford Depression Questionnaire (ODQ-20).
88892880|NCT05528315|Experimental|Single dose, ABX-002|Single Dose (solution) dose escalating
88892881|NCT05528315|Experimental|Multiple dose, ABX-002|Multiple Dose (solution) dose escalating
88892882|NCT05528315|Experimental|Formulation Comparison Solution or Capsule|ABX-002 Single Dose TBD - Solution ABX-002 Single Dose TBD - Capsule
88892883|NCT05525091|Experimental|Feeding Assessment|Feeding assessment of High-risk premature infants
88892884|NCT05499962|Other|PrEP-using Black SMM as Recruiters|Recruit 30 PrEP-using Black SMM, including those who use substances, as Recruiters to identify and refer Network Associates to PrEP services. The pilot will occur in six blocks of up to 5 Recruiters to further develop all intervention procedures and enhance the SNS intervention's feasibility and acceptability.
88922118|NCT05782894|Active Comparator|Propofol|Propofol
89415118|NCT03709264|Experimental|Amino Acids infusion|
89415119|NCT03709264|Placebo Comparator|Placebo|
89415120|NCT03705169|Experimental|Arm A: 1 mg/kg SAR441236|Participants continued on non-study-provided ART and received 1 mg/kg of SAR441236, administered as a single intravenous (IV) infusion on Day 0 (Cohort 1).
89415121|NCT03705169|Experimental|Arm A: 3 mg/kg for SAR441236|Experimental: Arm A: 3 mg/kg SAR441236 Participants continued on non-study-provided ART, and received 3 mg/kg of SAR441236, administered as a single IV infusion on Day 0 (Cohort 2).
89415122|NCT03705169|Experimental|Arm A: 10 mg/kg SAR441236|Participants continued non-study-provided ART and received 10 mg/kg of SAR441236, administered as a single IV infusion on Day 0 (Cohort 3).
89415123|NCT03705169|Experimental|Arm A: 30 mg/kg SAR441236|Participants continued non-study-provided ART and received 30 mg/kg of SAR441236, administered as an IV infusion on Day 0 and then every 12 weeks for a total of four doses (Cohort 4).
89415124|NCT03705169|Placebo Comparator|Arm A: 0 mg/kg SAR441236|"Placebo participants were pooled across those receiving:~1 mg/kg dose volume-equivalent administered as a single IV infusion (Cohort 1).~3 mg/kg dose volume-equivalent administered as a single IV infusion (Cohort 2).~10 mg/kg dose volume-equivalent administered as a single IV infusion (Cohort 3)~30 mg/kg dose volume-equivalent administered as an IV infusion on Day 0 and then every 12 weeks for a total of four doses (Cohort 4)~All continued on non-study provided ART."
89415125|NCT03705169|Experimental|Arm B: 1 mg/kg SAR441236|Participants received 1 mg/kg of SAR441236, administered as a single IV infusion on Day 0. Antiretroviral treatment was initiated or re-initiated by Day 28 (Cohort 5).
89415126|NCT03705169|Experimental|Arm B: 30 mg/kg SAR441236|Participants received 30 mg/kg of SAR441236, administered as a single IV infusion on Day 0. Antiretroviral treatment was initiated or re-initiated by Day 28 (Cohort 8).
89415127|NCT03705169|Experimental|Arm C: 0.3 mg/kg SAR441236|Participants continued non-study-provided ART and received 0.3 mg/kg of SAR441236, administered as a subcutaneous (SC) injection(s) on Day 0 (Cohort 10).
88892885|NCT05496959|Active Comparator|Arm 1 (SBRT)|Beginning on day 1, patients undergo SBRT to all lesions for 1, 3, or 5 treatment doses (fractions) over the span of 10-20 days in the absence of disease progression or unacceptable toxicity.
88892886|NCT05496959|Experimental|Arm 2 (177Lu-PNT2002, SBRT)|Patients receive 177Lu-PNT2002 IV over 1-10 minutes on days -112 and -56 in the absence of disease progression or unacceptable toxicity. Beginning on day 1, patients then undergo SBRT to all lesions for 1, 3, or 5 treatment doses (fractions) over the span of 10-20 days in the absence of disease progression or unacceptable toxicity.
88892891|NCT05473741||SGA-LAI|Outpatients with schizophrenia treated with second generation long-acting injectable antipsychotics whose psychotic symptoms have remitted.
88892892|NCT05435300||Schizophrenia/Schizoaffective Disorder|Participants with Schizophrenia/Schizoaffective Disorder and currently enrolled in the tDCS-adherence parent study (REB# 103-2018).
89415128|NCT03705169|Experimental|Arm C: 1 mg/kg SAR441236|Participants continued non-study-provided ART and received 1 mg/kg of SAR441236, administered as an SC injection(s) on Day 0 (Cohort 11).
89415129|NCT03705169|Placebo Comparator|Arm C: 0 mg/kg SAR441236|"Placebo participants were pooled across those receiving:~0.3 mg/kg dose volume-equivalent administered as an SC injection(s) (Cohort 10).~1 mg/kg dose volume-equivalent administered as an SC injection(s) (Cohort 11).~All continued on non-study provided ART."
89415130|NCT03695939|Experimental|Experimental Treatment: realSKIN (skin xenotransplant)|In the experimental arm, patients are treated with the investigational drug, realSKIN®, in a side-by-side comparison to the active comparator, thus, each patient serves as their own control. The designated realSKIN® product size will be placed on the burn wound and secured in place via suturing or stapling. The Investigator will assess the wounds and identify the matched pair of burn sites then the treatments will be randomly assigned to the sites.
88892893|NCT05435053|Experimental|IRE + Nivolumab|IRE on Day 1, followed by Nivolumab on Day 2/3 and then every 2 weeks (q2w) for a maximum of 24 weeks.
88892894|NCT05433116|Experimental|Treatment Arm|combined pembrolizumab (200mg q3w) and lenvatinib treatment (20mg once daily)
88892895|NCT05418998|Experimental|Executive function (EF) training|12 weeks of at-home EF training on a computer or iPad
89415131|NCT03695939|Active Comparator|Active Comparator: Human Allograft Skin|"In the active comparator arm, patients are treated with human cadaver allograft, in a side-by-side comparison to the investigational drug, thus, each patient serves as their own control.~The allograft active comparator will be placed adjacently to the investigational drug, in the same anatomical location, on wound sites following debridement and secured via suture or staples. All other treatment aspects were consistent with the standard of care. The Investigator will assess the wounds and identify the matched pair of burn sites then the treatments will be randomly assigned to the sites."
88892896|NCT05418998|No Intervention|Wait-list control|This will be a comparator arm with no cognitive training. Participants will be given access to the same training program following the conclusion of the study, but no further assessment is planned.
88892897|NCT05379010|Experimental|With L-PRF Block|
88892898|NCT05379010|Active Comparator|No L-PRF Block|
88892899|NCT05377151|Experimental|mobile application (mHealth) intervention only|- the subjects will receive mobile application (mHealth) intervention only
88892900|NCT05377151|Experimental|mobile application (mHealth) intervention and dietitian consultation|- the subjects will receive the information from both mobile application (mHealth) and dietitian consultation
88892901|NCT05377151|No Intervention|standard usual care- dietitian consultation|- the subjects will receive all the related information from the standard usual care- dietitian consultation
89415132|NCT03687957|Experimental|Phase I: rhIL-7-hyFc|"Per standard treatment, patients will receive concurrent RT/TMZ followed by adjuvant TMZ on Days 1-5 of a 28-day cycle for a total of 6 cycles. rhIL-7hyFc will be given by intramuscular injection starting at the end of RT/TMZ (within 7 days after last day of RT/TMZ). The 2nd injection will be administered 3-5 days after the last dose of cycle 3 TMZ treatment (~week 13). The 3rd injection will be given 3-5 days after the last dose of cycle 6 TMZ treatment (~week 25). Note the 2nd and 3rd injections should be administered once between Day 3 through 5 following the last dose of TMZ to achieve the strongest response. The 4th injection (last injection in the study) will be given after completion of monthly TMZ (~Week 37). A total of 4 doses of rhIL-7-hyFc injections are planned~The phase I part will begin with an Accelerated Phase with 1 patient per cohort at the first 2 doses (60 mcg/kg and 120 mcg/kg) followed by a standard 3+3 design on the remaining 4 dose levels"
89415133|NCT03687957|Experimental|Randomized Phase II: Placebo|-Per standard treatment, patients will receive concurrent RT/TMZ followed by adjuvant TMZ on Days 1-5 of a 28-day cycle for a total of 6 cycles. Placebo will be given by intramuscular injection starting at the end of RT/TMZ (within 14 days after last day of RT/TMZ). The 2nd injection will be administered 3-5 days after the last dose of cycle 3 TMZ treatment (~week 13). The 3rd injection will be given 3-5 days after the last dose of cycle 6 TMZ treatment (~week 25). Note the 2nd and 3rd injections should be administered once between Day 3 through 5 following the last dose of TMZ to achieve the strongest response. The 4th injection (last injection in the study) will be given after completion of monthly TMZ (~Week 37). A total of 4 doses of placebo injections are planned.
89415134|NCT03687957|Experimental|Randomized Phase II: rhIL-7-hyFc|Per standard treatment, patients will receive concurrent RT/TMZ followed by adjuvant TMZ on Days 1-5 of a 28-day cycle for a total of 6 cycles. rhIL-7hyFc will be given by intramuscular injection starting at the end of RT/TMZ (within 14 days after last day of RT/TMZ). The 2nd injection will be administered 3-5 days after the last dose of cycle 3 TMZ treatment (~week 13). The 3rd injection will be given 3-5 days after the last dose of cycle 6 TMZ treatment (~week 25). Note the 2nd and 3rd injections should be administered once between Day 3 through 5 following the last dose of TMZ to achieve the strongest response. The 4th injection (last injection in the study) will be given after completion of monthly TMZ (~Week 37). A total of 4 doses of rhIL-7-hyFc injections are planned.
89415135|NCT03687957|Experimental|Phase II Expansion Arm: rhIL-7-hyFc|Per standard treatment, patients will receive concurrent RT/TMZ followed by adjuvant TMZ on Days 1-5 of a 28-day cycle for a total of 6 cycles. rhIL-7hyFc will be given by intramuscular injection starting at the end of RT/TMZ (within 14 days after last day of RT/TMZ). The 2nd injection will be administered 3-5 days after the last dose of cycle 3 TMZ treatment (~week 13). The 3rd injection will be given 3-5 days after the last dose of cycle 6 TMZ treatment (~week 25). Note the 2nd and 3rd injections should be administered once between Day 3 through 5 following the last dose of TMZ to achieve the strongest response. The 4th injection (last injection in the study) will be given after completion of monthly TMZ (~Week 37). A total of 4 doses of rhIL-7-hyFc injections are planned.
89415136|NCT03684109|Experimental|IDH-Mutant Glioma Patients|Patients who have suspected or confirmed gliomas and are scheduled to undergo biopsy or resection of their brain tumors will receive a 3 Tesla (3T) Magnetic Resonance Imaging (MRI) scan of their brain.
89415137|NCT03677037|Experimental|Short-term MBT|The experimental group is short-term mentalization-based therapy. The treatment program includes 20 weeks of mentalization-based group therapy with conjoined individual therapy every second week. The program also includes psychoeducation and individual caseformulations.
89415138|NCT03677037|Active Comparator|Long-term MBT|The control group is long-term mentalization-based therapy. The treatment program includes 14 months of weekly mentalization-based group therapy with combined individual therapy every second week. The program also includes psychoeducation and individual caseformulations.
89415139|NCT03672487|Active Comparator|60/300mg|"The investigators will use a preparation of benznidazole (BZN) that is commercially available in Argentina: Abarax® 100mg and 50mg tablets from ELEA laboratories (Buenos Aires, Argentina). The investigators will purchase the drug at full cost.~Interventions: The standard 60d course will be 300 mg per day, which is similar to the dose used in the second phase of the BENEFIT trial. The drug will be administered orally in two doses per day: the standard course will be one 100mg and one 50mg tablet in the morning and in the evening for 60 days."
89415140|NCT03672487|Experimental|30/150mg|"The investigators will use a preparation of benznidazole (BZN) that is commercially available in Argentina: Abarax® 100mg and 50mg tablets from ELEA laboratories (Buenos Aires, Argentina). ELEA laboratories will prepare the placebo oral tablets, which will be identical to the drug tablets in aspect and taste. The investigators will purchase the drug and placebo at full cost.~Interventions: The BZN short course low dose scheme will be 150 mg per day for 30 days. The drug will be administered orally in two doses per day: the short course treatment will start with the active drug and then placebo oral tablet; one 100 mg tablet and one placebo tablet in the morning and one 50 mg tablet and one placebo tablet in the evening for the first 30 days. The last 30 days will be two placebo tablets in the morning and the evening."
89415141|NCT03656835|Experimental|Diagnostic (ILN biochip testing)|Participants' blood samples undergo ILN biochip testing at diagnosis, before and after every course of chemotherapy, every 3 months for 2 years, and at relapse.
89415142|NCT03655769|Sham Comparator|sham tDCS|tDCS delivered for only 30 sec to replicate tingling sensation and blind subject
89415143|NCT03655769|Experimental|cathodal tDCS|cathodal tDCS, 2 milliamps (mA), delivered to right parietal region
89415144|NCT03590288||TIPS group|Pressure gradient were measured in consecutive cirrhotic patients undergoing TIPS.
89415145|NCT03588260||Idiopathic pulmonary fibrosis|The patients who have agreed to participate in the study from patients diagnosed with idiopathic pulmonary fibrosis referred to the center of pulmonary rehabilitation from the interstitial lung disease polyclinic.
89415146|NCT03588260||Healthy subjects|The healthy adults without additional disease
89415147|NCT03556228|Experimental|VMD-928 300 mg Tablet (ongoing); 100 mg Capsule (complete)|
89415148|NCT03555851||Recipient|Cyclophosphamide
88892902|NCT05373212|Experimental|BC Combo THDB0207 Low dose|Single administration of BC Combo THDB0207 (Low dose)
88892903|NCT05373212|Experimental|BC Combo THDB0207 Medium dose|Single administration of BC Combo THDB0207 (Medium dose)
88892904|NCT05373212|Experimental|BC Combo THDB0207 High dose|Single administration of BC Combo THDB0207 (High dose)
88892905|NCT05373212|Active Comparator|Humalog® Mix25|Single administration of Humalog® Mix25
88892906|NCT05373199|Experimental|BC Combo THDB0207|Single administration of BC Combo THDB0207
88892907|NCT05373199|Active Comparator|Lantus®|Single administration of Lantus®
88892908|NCT05373199|Active Comparator|Humalog®|Single administration of Humalog®
88892909|NCT05359692|Experimental|Part 1: Cohort 1|INCAGN01876 every 2 weeks (Q2W) with retifanlimab every 4 weeks (Q4W).
88892910|NCT05359692|Experimental|Part 1: Cohort 2|INCAGN01876 Q2W with retifanlimab Q4W.
88892911|NCT05359692|Experimental|Part 2 (Expansion): Treatment Group A|INCAGN01876 and retifanlimab combination in participants who have been previously treated with anti-PD-(L)1 therapy.
88892912|NCT05359692|Experimental|Part 2 (Expansion): Treatment Group B|INCAGN01876 and retifanlimab combination in participants who are naive to anti-PD-(L)1 therapy.
88892913|NCT05353361|Experimental|SHR-A1811combined Pyrotinib|
88892914|NCT05353361|Experimental|SHR-A1811Combined Pertuzumab|
88892915|NCT05353361|Experimental|SHR-A1811Combined Adebrelimab|
88892916|NCT05353361|Experimental|SHR-A1811Combined Albumin-bound Paclitaxel|
89415149|NCT03555851||Donor|Specimen collection
89415150|NCT03519971|Experimental|Arm 1: Durvalumab + platinum-based chemotherapy and radiation|"Durvalumab ((MEDI4736) in concurrence with platinum-based chemo-radiation therapy.~All patients will receive 1 of the following platinum-based standard of care chemotherapy options, based on Investigator discretion, in addition to radiation therapy:~cisplatin/etoposide~carboplatin/paclitaxel~pemetrexed/cisplatin~pemetrexed/carboplatin~At the completion of standard of care chemoradiation therapy (SoC CRT), patients with complete response, partial response or stable disease will continue to receive durvalumab as consolidation treatment."
88892917|NCT05352919|Experimental|Litifilimab Low Dose|"Participants who are receiving background nonbiologic lupus standard of care (SOC) therapy and received litifilimab low dose, subcutaneously (SC), every 4 weeks (Q4W) during the parent Phase 3 studies (i.e. studies 230LE303 [NCT04895241] or 230LE304 [NCT04961567]) will continue to receive litifilimab low dose, SC, Q4W from Day 1 up to 152 weeks with an additional dose of litifilimab-matching placebo at Week 2.~Participants who are receiving background nonbiologic lupus SOC therapy and received litifilimab-matching placebo in the parent Phase 3 studies (i.e. studies 230LE303 [NCT04895241] or 230LE304 [NCT04961567]) will be randomized to receive litifilimab low dose, SC, Q4W from Day 1 up to 152 weeks with an additional dose at Week 2."
88892918|NCT05352919|Experimental|Litifilimab High Dose|"Participants who are receiving background nonbiologic lupus SOC therapy and received litifilimab high dose, SC, Q4W during the parent Phase 3 studies (i.e. studies 230LE303 [NCT04895241] or 230LE304 [NCT04961567]) will continue to receive litifilimab high dose, SC, Q4W from Day 1 up to 152 weeks with an additional dose of litifilimab-matching placebo at Week 2.~Participants who are receiving background nonbiologic lupus SOC therapy and received litifilimab-matching placebo in the parent Phase 3 studies (i.e. studies 230LE303 [NCT04895241] or 230LE304 [NCT04961567]) will be randomized to receive litifilimab high dose, SC, Q4W from Day 1 up to 152 weeks with an additional dose at Week 2."
88892919|NCT05344560|Experimental|test/control/control|Eligible subjects that are habitual contact lens wearers will be randomized into the (test/control/control) sequence and will wear two different study lenses one at a time bilaterally over three wear periods.
89415151|NCT03519971|Placebo Comparator|Arm 2: Placebo + platinum-based chemotherapy and radiation|"Placebo in concurrence with platinum-based chemo-radiation therapy.~All patients will receive 1 of the following platinum-based standard of care chemotherapy options, based on Investigator discretion, in addition to radiation therapy:~cisplatin/etoposide~carboplatin/paclitaxel~pemetrexed/cisplatin~pemetrexed/carboplatin~At the completion of standard of care chemoradiation therapy (SoC CRT), patients with complete response, partial response or stable disease will continue to receive placebo as consolidation treatment."
89415152|NCT03493945|Experimental|Arm 1.1|M7824 + N-803
88892920|NCT05344560|Experimental|control/test/test|Eligible subjects that are habitual contact lens wearers will be randomized into the (control/test/test) sequence and will wear two different study lenses one at a time bilaterally over three wear periods.
88892921|NCT05313607|Experimental|conventional group|received conventional physical therapy program
88892922|NCT05313607|Experimental|plyometric group|received a plyometric physical therapy program
89415153|NCT03493945|Experimental|Arm 2.1A|M7824 + BN-Brachyury during phase IIA
89415154|NCT03493945|Experimental|Arm 2.1B|M7824 + BN-Brachyury during phase IIB
89415155|NCT03493945|Experimental|Arm 2.2A|M7824 + BN-Brachyury + N-803 during phase IIA
89415156|NCT03493945|Experimental|Arm 2.2B|M7824 + BN-Brachyury + N-803 during phase IIB
89415157|NCT03493945|Experimental|Arm 2.3A|M7824 + BN-Brachyury + N-803 + Epacadostat during phase IIA
89415158|NCT03493945|Experimental|Arm 2.3B|M7824 + BN-Brachyury + N-803 + Epacadostat during phase IIB
89415159|NCT03484702|Experimental|Administration of JCAR017|
88892923|NCT05287763|Active Comparator|Gelatin Sponge|The palatal wound will be protected with an absorbable gelatin sponge, which will be stabilized by non-resorbable sling sutures.
88892924|NCT05287763|Experimental|Collagen Sponge|The palatal wound will be protected with a collagen sponge, which will be stabilized by non-resorbable sling sutures.
88892925|NCT05284214|Experimental|Sargramostim daily: 14 of 21 days|Sargramostim administered by subcutaneous (SC) injection for 14 consecutive days every 3 weeks, for up to 12 weeks, given in combination with an ipilimumab-containing regimen.
88892926|NCT05284214|Experimental|Sargramostim daily: 5 of 7 days|Sargramostim given by SC injection for 5 consecutive days every week, for up to 12 weeks, given in combination with an ipilimumab-containing regimen for a total of 12 weeks.
88892927|NCT05273476|Experimental|strip|apically repositioned flap+ xenogeneic collagen matrix +free gingival graft
88892928|NCT05221944||Patients on antithrombotic therapy|The study aimed to investigate if perioperative bleeding complications were more common in patients on antithrombotic therapy. We retrospectively reviewed patients with IC/BPS who underwent hydrodistension during January 2010 and May 2021. Patients with and without antithrombotic drugs were identified and grouped and their medical records were reviewed.
88892929|NCT05221944||Patients without antithrombotic therapy|Patients without antithrombotic drugs were identified as controls
88892930|NCT05215197|Experimental|intracochlear prf administration group|intracochlear prf administration group
88892931|NCT05209191|Experimental|Student Athlete Wellness Portal|Web-based intervention that illustrates opioid misuse and diversion resistance strategies.
88892932|NCT05203198|No Intervention|1. No adolescent modules + no parent modules|No adolescent nor parent modules will be offered to the participant.
88892933|NCT05203198|Experimental|2. Adolescent behavioral activation modules only|Adolescent behavioral activation modules only
88892934|NCT05203198|Experimental|3. Adolescent cognitive-behavioral therapy modules only|Adolescent cognitive-behavioral therapy modules only
88892935|NCT05203198|Experimental|4. Adolescent interpersonal therapy modules only|Adolescent interpersonal therapy modules only
89415160|NCT03480061|Active Comparator|Dexmedetomidine Hydrochloride Group|Patients will receive a loading dose of 1 μg/kg dexmedetomidine prior to transfer to CVICU over 20 min immediately postoperative, followed by continuous infusion of 0.1- 1.0 μg/kg/h for up to 24 hours or until patient is ready for discharge from CVICU (whichever is earlier).
89415161|NCT03480061|No Intervention|Standard of Care Group|Standard sedation protocols will be followed at the discretion of the attending physician.
89415162|NCT03440450|Experimental|Cohort 1: Treatment at 1.2 mg/m2|FF-10832 Gemcitabine Liposome Injection, 1.2 mg/m2 administered intravenously (IV) on Days 1 and 15 of each 28-day cycle
89415163|NCT03440450|Experimental|Cohort 2: Treatment at 2.4 mg/m2|FF-10832 Gemcitabine Liposome Injection, 2.4 mg/m2 administered intravenously (IV) on Days 1 and 15 of each 28-day cycle
88892936|NCT05203198|Experimental|5. Adolescent behavioral activation modules + cognitive-behavioral therapy modules|Adolescent behavioral activation modules Adolescent cognitive-behavioral therapy modules
88892937|NCT05203198|Experimental|6. Adolescent behavioral activation modules + interpersonal therapy modules|Adolescent behavioral activation modules Adolescent interpersonal therapy modules
88892938|NCT05203198|Experimental|7. Adolescent cognitive-behavioral therapy modules + interpersonal therapy modules|Adolescent cognitive-behavioral therapy modules Adolescent interpersonal therapy modules
88892939|NCT05203198|Experimental|8. Full Adolescent program only|Adolescent behavioral activation modules Adolescent cognitive-behavioral therapy modules Adolescent interpersonal therapy modules
89415164|NCT03440450|Experimental|Cohort 3: Treatment at 4.8 mg/m2|FF-10832 Gemcitabine Liposome Injection, 4.8 mg/m2 administered intravenously (IV) on Days 1 and 15 of each 28-day cycle
88892940|NCT05203198|Experimental|9. Parent program modules only|Parent program modules
88892941|NCT05203198|Experimental|10. Adolescent behavioral activation modules + parent program modules|Adolescent behavioral activation modules Parent program modules
88892942|NCT05203198|Experimental|11. Adolescent cognitive-behavioral therapy modules + parent program modules|Adolescent cognitive-behavioral therapy modules Parent program modules
88892943|NCT05203198|Experimental|12. Adolescent interpersonal therapy modules + parent program modules|Adolescent interpersonal therapy modules Parent Program
88892944|NCT05203198|Experimental|13. Adolescent behavioral activation + cognitive-behavioral therapy + parent program modules|Adolescent behavioral activation modules Adolescent cognitive-behavioral therapy modules Parent program modules
88892945|NCT05203198|Experimental|14. Adolescent behavioral activation + interpersonal therapy + parent program modules|Adolescent behavioral activation modules Adolescent interpersonal therapy modules Parent program modules
88892946|NCT05203198|Experimental|15. Adolescent cognitive-behavioral therapy + interpersonal therapy + parent program modules|Adolescent cognitive-behavioral therapy modules Adolescent interpersonal therapy modules Parent program modules
89415165|NCT03440450|Experimental|Cohort 4: Treatment at 8 mg/m2|FF-10832 Gemcitabine Liposome Injection, 8 mg/m2 administered intravenously (IV) on Days 1 and 15 of each 28-day cycle
89415166|NCT03440450|Experimental|Expansion Cohort: Treatment at Recommended Phase 2 Dose (RP2D)|For patients with biliary tract cancer: FF-10832 Gemcitabine Liposome Injection, RP2D administered intravenously (IV) on Day 1 of each 21-day cycle
89535887|NCT03215563||Carotid|Patients with carotid artery stenosis who either do not meet surgical criteria (< 50% by NASCET criteria for men, <70% for women), or meet criteria but do not undergo surgery (surgery declined or not offered) and are currently treated with OMT. This cohort will be recruited from the acute TIA clinics and Vascular Laboratory logbooks at Edinburgh Royal Infirmary and Western General Hospital.
88892947|NCT05203198|Active Comparator|16. All adolescent + parent program modules|Adolescent behavioral activation modules Adolescent cognitive-behavioral therapy modules Adolescent interpersonal therapy modules Parent program modules
88892948|NCT05194267|Experimental|Active tDCS|Will be receiving active intensive tDCS treatment
88892949|NCT05188196|Active Comparator|Collagen Membrane|ridge preservation with collagen membrane + collagenated bovine bone mineral
88892950|NCT05188196|Experimental|Collagen Sponge|ridge preservation with collagen sponge + collagenated bovine bone mineral
89193078|NCT05603442|Experimental|Thoracic intervertebral foramen block|The thoracic intervertebral foramen block is performed at second (T2), fifth (T5), ninth (T9), and twelfth (T12) thoracic vertebra. The ultrasonography is performed by using a high-frequency linear-array ultrasound transducer. A Tuohy needle is inserted in-plane to the ultrasound beam in a lateral-to-medial direction gently to contact the spinous process, into the skeletal muscle plane of the erector spinae muscle. Then, the needle tip is moved to reach the angle between the transverse process and spinous process. Subsequently, the needle tip is gently inserted and advanced for 2 mm along with the superior limit of the vertebral pedicle, until losing contact with the bone. Five ml methylene blue 1% dye (MB) are subsequently injected. The anesthetic procedure is bilaterally performed. Two continuous catheter sets were used and threaded 1 cm from the needle tip, for a bilateral continuous block. The catheters are inserted from the caudal to the cephalic direction.
89415167|NCT03435510|Other|Live Donor Champion|The Live Donor Champion program is the sole educational intervention for this trial. LDC consists of 6 monthly sessions of approx. 1 hour each. Each LDC session is led by a transplant physician or clinical coordinator. LDC sessions incorporate formal didactics, active-participant learning, personal stories, moderated group discussions, role-playing, and other skill-building exercises. LDC sessions are as follows: 1) education about ESRD, KT, and LDKT 2) communication skills building 3) Exploring social networks 4) sharing successful donor and recipient stories 5) encouraging candidate self-efficacy 6) Program Recap.
88892951|NCT05168163|Experimental|Arm A (atezolizumab, cabozantinib or lenvatinib)|Patients receive atezolizumab IV over 30-60 minutes on day 1 and cabozantinib PO QD or lenvatinib PO QD on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
88892952|NCT05168163|Active Comparator|Arm B (cabozantinib or lenvatinib)|Patients receive cabozantinib PO QD or lenvatinib PO QD on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89415168|NCT03414684|Experimental|Carboplatin + Nivolumab|"Nivolumab is administered every three weeks intravenously~Nivolumab dosage is 360mg~Carboplatin is administered every three weeks intravenously~Carboplatin dosage is pre-determined by the PI"
89415169|NCT03414684|Active Comparator|Carboplatin|"Carboplatin is administered every three weeks intravenously~Carboplatin dosage is pre-determined by the PI"
89415170|NCT03400085|No Intervention|Standard of Care|The control participants will be instructed to attend required follow-up as is standard of care, and will not receive the mHealth application.
89415171|NCT03400085|Experimental|mHealth application|Participants in the intervention arm will receive the mHealth application at their first post-donation clinic visit. Study personnel will assist participants assigned to the mHealth intervention arm with downloading the application and explain its functioning. Participants will then use the application to complete their required 6-month, 1-year, and 2-year follow-up.
89415172|NCT03374449|Experimental|continuation of the RAS-inhibitors|in the continuation of the RAS-inhibitors arm the treatment will be continued until the morning the day of surgery.
89415173|NCT03374449|Active Comparator|discontinuation of the RAS-inhibitors|In this arm : discontinuation of the RAS-inhibitors 48 hours before surgery Patients won't receive the drug on the morning of the day of the surgery.
89415174|NCT03357536|Experimental|Patients with Listeriosis|"Patients with Listeriosis.~Human biological samples :~Blood sample~Skin biopsy~Saliva"
89415175|NCT03357536|Experimental|Volunteers related with patients with Listeriosis|"Volunteers related with patients with Listeriosis.~Human biological samples :~Blood sample~Skin biopsy~Saliva"
89415176|NCT03346083|Experimental|Cohort 1: Betrixaban 40 mg|Participants received a single, oral dose of betrixaban at 40 mg in a fed state, and had 10 PK blood sampling time points.
89415177|NCT03346083|Experimental|Cohort 2: Betrixaban 80 mg|Participants received a single, oral dose of betrixaban at 80 mg in a fed state, and had 5 PK sampling time points.
89415178|NCT03298451|Experimental|Arm 1|Durvalumab
89415179|NCT03298451|Experimental|Arm 2|Durvalumab in combination with tremelimumab (Regimen 1)
89415180|NCT03298451|Experimental|Arm 3|Durvalumab in combination with tremelimumab (Regimen 2)
89415181|NCT03298451|Active Comparator|Arm 4|Sorafenib
89415182|NCT03279081|Experimental|Cx601|Cx601 eASCs 120 million cells (5 million cells per milliliter [mL]) will be administered once by intralesional injection.
89415183|NCT03279081|Placebo Comparator|Placebo|CX601 placebo-matching eASCs cells will be administered once by intralesional administration.
89415184|NCT03173976|Experimental|Zoledronic Acid|1 cycle of Zoledronic Acid (ZA) at 4mg IVP prior to surgery and a second cycle of ZA at 4 mg IVP 3 weeks after surgery
89415185|NCT03156946|Experimental|Breastfeeding support program|
89415186|NCT03156946|Other|Usual or routine care|
89415187|NCT03073967|Experimental|Part C, Pritelivir|Oral tablets, 100mg/day (400mg loading dose on day 1) for up to 28 days and potential prolongation for up to additional 14 days
89415188|NCT03073967|Active Comparator|Part C,|"Investigator's Choice:~Foscarnet iv, 40 mg/kg tid or 60mg/kg bid or Cidofovir iv, 5 mg/kg body weight given once weekly or Cidofovir 1% or 3%, topically applied 2 to 4 times daily or Imiquimod 5%, topically applied 3 times per week, for up to 28 days and potential prolongation for up to additional 14 days."
89535888|NCT03215563||Non Carotid|Patients with an atherosclerotic disease in the aortic arch including origins of its major branches other than the internal carotid artery treated with OMT. Patients with a cardiac source of embolism will be excluded from the study. This group will be recruited from the acute TIA clinics and inpatients at Edinburgh Royal Infirmary and Western General Hospital.
89535889|NCT03203005|Experimental|IMA970A plus CV8102 and Cyclophosphamide|Investigational treatment with IMA970A, CV8102, Cyclophosphamide
88892953|NCT05122182|Experimental|Interventional Arm|Titratable candesartan with commencing dose 4mg tablets twice daily (daily dose 8 mg) + fixed dose repagermanium one x 120mg immediate release capsule twice daily (total daily dose 240mg). Treatment will continue for 28 days.
88892954|NCT05122182|Placebo Comparator|Control Arm #1|Titratable candesartan with commencing dose 4mg tablets twice daily (daily dose 8 mg) + matched placebo repagermanium one capsule twice daily. Treatment will continue for 28 days.
88892955|NCT05122182|Placebo Comparator|Control Arm #2|Titratable matched placebo candesartan one tablet twice daily + matched placebo repagermanium one capsule twice daily. Treatment will continue for 28 days.
88892956|NCT05113784|Experimental|Meplazumab for Injection|First dose: 0.2 mg/kg - Day 1; Second dose: 0.2 mg/kg - Day 8
88892957|NCT05113784|Placebo Comparator|Placebo|First dose: control - Day 1; Second dose: control -Day 8
88892958|NCT05113186|Experimental|Neoadjuvant and adjuvant therapy with lenvatinib|"Neoadjuvant therapy with lenvatinib to complete a 3-week course, stopping 1 week before the planned date of PA procedure  LENVABLA  protocol, version 1.3 du 25/05/2021 12/55~- Adjuvant therapy with lenvatinib for 3 months starting after the PA evaluation (± 14 days) The daily dose of lenvatinib will be 12 mg (≥60 kg) or 8 mg (<60 kg). Lenvatinib will be taken within 2 hours after a light meal, preferably in the morning."
88892959|NCT05086627|Experimental|Short-course radiotherapy sequential Tislelizumab combined with CapeOX (group A)|"Standard SCRT: A total radiation dose of 25 Gy was delivered in 5 fractions (from day 1 to 5)~Sequential treatment period: After resting for 3-7 days following completion of SCRT, patients were treated with 4 cycles of CapeOX (Oxaliplatin 130 mg/m2 intravenously, day 1; Capecitabine 1000 mg/m2, Bid,days 1-14) and an additional intravenous infusion of 200mg Tislelizumab on the first day of each cycle of CapeOX.~Surgery: After 3 weeks of the completion of neoadjuvant therapy, the TME surgery was performed.~Postoperative adjuvant chemotherapy: Whether postoperative chemotherapy was implemented mainly depended on the patient's wishes, and 2 cycles of CapeOX with or without Tislelizumab will be undergone to these willing cases."
88892960|NCT05086627|Active Comparator|Short-course radiotherapy sequential CapeOX (group B)|"Standard SCRT: A total radiation dose of 25 Gy was delivered in 5 fractions (from day 1 to 5)~Sequential treatment period: After resting for 3-7 days following completion of SCRT, patients were treated with 4 cycles of CapeOX (Oxaliplatin 130 mg/m2 intravenously, day 1; Capecitabine 1000 mg/m2, Bid,days 1-14).~Surgery: After 3 weeks of the completion of neoadjuvant therapy, the TME surgery was performed.~Postoperative adjuvant chemotherapy: Whether postoperative chemotherapy was implemented mainly depended on the patient's wishes, and 2 cycles of CapeOX will be undergone to these willing cases."
88892961|NCT05069597|Experimental|Run-in Period: Creon|Participants will receive Creon daily for 112 days.
88892962|NCT05069597|Experimental|Treatment Period: Creon|Participants will receive Creon daily for 112 days.
88892963|NCT05058391|Experimental|Elaprase 0.5 mg/kg|Participants will receive a single dose of Elaprase 0.5 milligrams per kilogram (mg/kg) body weight, intravenous infusion on Day 1, Week 1 followed by every week up to end of treatment (EOT) (Day 358, Week 52).
89535890|NCT02484209|Experimental|Glimepiride + metformin|Glimepiride (2-4mg twice daily) + metformin (1500 mg daily) (n = 10 in total) Older subjects with moderate frailty will be assigned for 16 weeks to this arm. A subgroup (n=5) will undergo 3 x 72h periods of CBGM
88892964|NCT05052983|Experimental|Nemolizumab|
88892965|NCT05052983|Placebo Comparator|Placebo|
88892966|NCT05048173||Sentinel lymph node group|woman who had sentinel lymph node mapping and biopsy
88892967|NCT05048173||Lymphadenectomy group|woman who underwent traditional pelvic lymphadenectomy without sentinel lymph node mapping
88892968|NCT05044780||Cohort 1/SARS-CoV-2 positive|Participants with molecular testing positive for SARS-CoV-2
88892969|NCT05044780||Cohort 2/SARS-CoV-2 negative|Participants with molecular testing negative for SARS-CoV-2
88892970|NCT05036252||Participants with HER2-positive breast cancer|Participants with HER2-positive breast cancer who have developed mild cardiotoxicity during HER2-targeted therapy, defined by a decline in LVEF > 10% to < 53% without symptoms of clinical heart failure (NYHA class III or IV), will be eligible for participation in this study.
89193079|NCT05601232|Experimental|Boron Neutron Capture Therapy (BNCT)|
89415189|NCT03073967|Experimental|Part D, Pritelivir|Oral tablets, 100mg/day (400mg loading dose on day 1) for up to 28 days and potential prolongation for up to additional 14 days
89415190|NCT03073967|Experimental|Part E, Pritelivir|Oral tablets, 100mg/day (400mg loading dose on day 1) for up to 28 days and potential prolongation for up to additional 14 days
89535891|NCT02484209|Active Comparator|Metformin|Metformin (1500 mg daily) (n = 10 in total) Older subjects with moderate frailty will be assigned for 16 weeks to this arm. A subgroup (n=5) will undergo 3 x 72h periods of CBGM
88892971|NCT05034913|Experimental|Photography to Measure Children's Height, Wrist Circumference, and Abdominal Circumference|Subjects will be given instructions on how to take two photographs at home and submit them securely. Subjects will also be given instructions on how to measure height, wrist circumference, and waist circumference and submit this data to the research team.
88892972|NCT05034822|Experimental|Ruxolitinib cream|ruxolitinib 1.5% cream will be applied twice daily to all areas of the skin affected by AD
88892973|NCT05024058|Experimental|Ligelizumab low dose, symptomatic dermographism group|Ligelizumab low dose subcutaneous injection every 4 weeks in participants with symptomatic dermographism
88892974|NCT05024058|Experimental|Ligelizumab high dose, symptomatic dermographism|Ligelizumab high dose subcutaneous injection every 4 weeks in participants with symptomatic dermographism
88892975|NCT05024058|Placebo Comparator|Placebo SC q4W, symptomatic dermographism|Placebo subcutaneous injection every 4 weeks in participants with symptomatic dermographism
88892976|NCT05024058|Experimental|Ligelizumab low dose, cold urticaria|Ligelizumab low dose subcutaneous injection every 4 weeks in participants with cold urticaria
88892977|NCT05024058|Experimental|Ligelizumab high dose, cold urticaria|Ligelizumab high dose subcutaneous injections every 4 weeks in participants with cold urticaria
88892978|NCT05024058|Placebo Comparator|Placebo SC q4w, cold urticaria|Placebo subcutaneous injection every 4 weeks in participants with cold urticaria
88892979|NCT05024058|Experimental|Ligelizumab high dose, cholinergic urticaria|Ligelizumab high dose subcutaneous injections every 4 weeks in participants with cholinergic urticaria
88892980|NCT05024058|Placebo Comparator|Placebo SC q4w, cholinergic urticaria|Placebo subcutaneous injections every 4 weeks in participants with cholinergic urticaria
88892981|NCT05013008|Experimental|Finerenone|Participants received finerenone 10 mg or 20 mg once daily in addition to standard of care therapy in previous interventional Phase 3 trial FIGARO-DKD. No new intervention was administered in this biomarker study.
88892982|NCT05013008|Placebo Comparator|Placebo|Participants received matching placebo once daily in addition to standard of care therapy in previous interventional Phase 3 trial FIGARO-DKD. No new intervention was administered in this biomarker study.
88892983|NCT05011188|Experimental|Does Escalation|Approximately 3 dose levels of FOR46 will be evaluated. Participants will receive a lead-in treatment period of enzalutamide monotherapy for 14 days (day -14 to day -1), followed by addition of FOR46 on Cycle 1 Day 1. If participants are on enzalutamide at the time of study entry, and remain on continuous dosing at 160 mg daily, the lead-in treatment period will not be required. Prophylactic Pegfilgrastim (G-CSF) will also be administered on Day 2 during all treatment cycles
88892984|NCT05011188|Experimental|Dose Expansion|Participants will receive a lead-in treatment period of enzalutamide monotherapy for 14 days (day -14 to day -1), followed by addition of FOR46 on Cycle 1 Day 1, at the maximum tolerated dose (MTD) as determined in Phase 1b. If participants are on enzalutamide at the time of study entry, and remain on continuous dosing at 160 mg daily, the lead-in treatment period will not be required. Prophylactic Pegfilgrastim (G-CSF) will also be administered on Day 2 during all treatment cycles.
88892985|NCT05002387|Experimental|Unicompartmental OA or equivocal findings in XR|After obtaining informed consent, patients will undergo needle arthroscopy, performed in the operating room prior to undergoing arthroplasty
88892987|NCT04992299|Experimental|Mindfulness-Based Intervention|6-week group intervention, Learning to BREATHE, an adolescent mindfulness-based intervention derived from mindfulness-based stress reduction
88892988|NCT04992299|Active Comparator|Cognitive-Behavioral Therapy|6-week group intervention, the Blues Program, a cognitive-behavioral intervention for adolescents with elevated symptoms of depression
88892989|NCT04992299|Other|Health Education|6-week group program providing didactic information on adolescent health topics
89415191|NCT03073967|Experimental|Part F, Pritelivir|Oral tablets, 100mg/day (400mg loading dose on day 1) for up to 28 days and potential prolongation for up to additional 14 days
89415192|NCT02988375|Experimental|dCBTI|Online access to the digital CBTI program Sleepio
89415193|NCT02988375|Placebo Comparator|Sleep Education|Weekly email messages with sleep hygiene recommendations
89415194|NCT02965950|Experimental|TP53 mutated, LABC|Patients with locally advanced breast cancer, TP53 mutated disease. Dose-dense cyclophosphamide, after taxanes +/- anthracyclines.
89415195|NCT02965950|Experimental|TP53 mutated, MBC, first line|Patients with metastatic breast cancer, TP53 mutated disease. Dose-dense cyclophosphamide first line metastatic disease
88892990|NCT04945486|Experimental|Peer-mentoring|The patients (mentees) are matched with a peer-mentor i.e. a person with a similar life situation or health problem as one self
89415196|NCT02965950|Experimental|TP53 wt, LABC|Patients with locally advanced breast cancer, TP53 wt disease. Dose-dense cyclophosphamide, after taxanes and anthracyclines.
89415197|NCT02965950|Experimental|TP53 wt, MBC|Patients with metastatic breast cancer, TP53 wt disease. Dose-dense cyclophosphamide, after taxanes and anthracyclines.
89415198|NCT02965950|Experimental|TP53 mutated, MBC|Patients with metastatic breast cancer, TP53 mutated disease. Dose-dense cyclophosphamide, after taxanes +/- anthracyclines.
89415199|NCT02876757||5ARI Users|
89415200|NCT02876757||Non 5ARI users|
89415201|NCT02843035|Experimental|Open label (OL) venglustat|Administered once a day orally for up to approximately 8.7 years. Patients will continue their usual dose of Cerezyme during Part 1, Part 2 and Part 3. There is no administration of Cerezyme in Part 4 unless administrated as rescue treatment.
88892991|NCT04945486|No Intervention|Usual care|Usual care provided by professional healthcare workers
88892992|NCT04936022|Other|Control|To receive standard care lifestyle advice only
88892993|NCT04936022|Experimental|Isometric Exercise|To receive standard care lifestyle advice plus 3 sessions of isometric exercise per week
88892994|NCT04935671|Active Comparator|Allopathic + Herbal|"20mg of chamomile and 1 mg saffron in form of teabag for preparation of herbal decoction in dose of two teabags per day for a month as an ADJUVANT THERAPY with standard allopathic treatment for depression."
88892995|NCT04935671|No Intervention|Allopathic only|Only allopathic medication for depression.
88892996|NCT04917861|Experimental|mRNA-1893 Low Dose (2-Dose Regimen)|Participants will receive mRNA-1893 at a low dose level administered as a 2-dose regimen with 28-day (-3/+7 days) interval between vaccinations (administered on Day 1 and Day 29).
88892997|NCT04917861|Experimental|mRNA-1893 High Dose (2-Dose Regimen)|Participants will receive mRNA-1893 at a high dose level administered as a 2-dose regimen with 28-day (-3/+7 days) interval between vaccinations (administered on Day 1 and Day 29).
88892998|NCT04917861|Experimental|mRNA-1893 High Dose (1-Dose Regimen)|Participants will receive placebo matching to mRNA-1893 on Day 1 and mRNA-1893 at a high dose level administered as a 1-dose regimen (administered on Day 29). There will be 28-day (-3/+7 days) interval between vaccinations.
88892999|NCT04917861|Placebo Comparator|Placebo|Participants will receive placebo matching to mRNA-1893 administered as a 2-dose regimen with 28-day (-3/+7 days) interval between vaccinations (administered on Day 1 and Day 29).
89415202|NCT02841930|Experimental|Member|"The member group will be able to join ActionHealth NYC program, where they are assigned a primary care physician and have a standardized fee scale for services obtained in network. Laboratory, diagnostic, and specialty services can be obtained at network H+H locations. They will be offered recommended USPSTF A+B tests/screenings, HIV and TB screening (if indicated), and care coordination. If they are deemed high risk, enhanced care coordination services will be offered."
89415203|NCT02841930|No Intervention|Study|The study group will be counseled on their options to access health care, including at public hospitals and community health centers. They will receive no additional services from the study.
89415204|NCT02728817|Active Comparator|arteriovenous fistula (AVF)|Patient receiving a traditional arteriovenous fistula at the wrist (end-cephalic vein to side-radial artery)
89415205|NCT02728817|Experimental|RADAR|Patient receiving an arteriovenous fistula at the wrist using the Radial Artery Deviation And Reimplantation technique (end-radial artery to side-cephalic vein)
88922119|NCT05782244|Active Comparator|Sildenafil citrate low dose|Sildenafil citrate 20 mg, oral, TID
88922120|NCT05782244|Placebo Comparator|Placebo|Placebo, oral, TID
88922121|NCT05782244|Active Comparator|Sildenafil citrate medium dose|Sildenafil citrate 40 mg, oral, TID
89415206|NCT02723994|Experimental|Ruxolitinib in combination with chemotherapy|
89415207|NCT02685969||18F-Flutemetamol & 18F-FDG PET scans|All study participants will be assessed by PET scan with 18F-Flutemetamol & 18F-FDG PET scans.
89415208|NCT02586857|Experimental|Cohort 1|ACP-196 200 mg administered orally (PO) twice per day (BID)
89415209|NCT02586857|Experimental|Cohort 2|ACP-196 400mg administered orally (PO) once per day (QD).
89415210|NCT02512926|Experimental|Carfilzomib|Carfilzomib in combination with cyclophosphamide and etoposide
89415211|NCT02502318|Experimental|Lobectomy or segmentectomy using video-thoracoscopy|
89415212|NCT02502318|Active Comparator|Lobectomy or segmentectomy using thoracotomy|
89415213|NCT02427451|Experimental|Treatment (obinutuzumab, ibrutinib, Bcl-2 inhibitor GDC-0199)|Patients receive obinutuzumab IV on day 1 (days 1, 2, 8, and 15 for course 1 only) every 28 days for up to 8 courses. Beginning in course 2, patients receive ibrutinib PO QD on days 1-28. Beginning in course 3, patients receive Bcl-2 inhibitor GDC-0199 PO QD on days 1-28. Treatment repeats every 28 days for up to 14 courses in the absence of disease progression or unacceptable toxicity.
89415214|NCT02293980|Experimental|Part 1: MK-3475|Participants with advanced ccRCC receive MK-3475 at an initial dose level of 100mg orally, twice daily (BID) up to approximately 3 weeks. Dose levels will be escalated to identify the maximum tolerated dose (MTD) and/or Recommended Phase 2 Dose (RP2D) for MK-3475. Each escalated dose will be continued for up to approximately 3 weeks before escalating a dose again until a dose limiting toxicity (DLT) is experienced. Thereafter, participants receive RP2D dose of MK-3795 for up to 2 cycles (each cycle length = 28 days) for up to approximately 1 year. Participants may continue to receive MK-3795 beyond 1 year at the discretion of the Sponsor.
89415215|NCT02293980|Experimental|Part 2: MK-3795 + Nivolumab|Participants with advanced ccRCC in the expansion phase receive the RP2D of MK-3795 orally in combination with nivolumab 240mg by IV infusion over ~60 minutes every 2 weeks for up to approximately 1 year (12 cycles; each cycle length = 28 days) or until unequivocal progression or treatment discontinuation, whichever occurs later.
89415216|NCT02293980|Experimental|Part 3: MK-3795 + Cabozantinib|Participants with advanced ccRCC in the expansion phase receive the RP2D of MK-3795 in combination with cabozantinib 20mg up to 60mg orally QD for up to approximately 1 year (12 cycles; each cycle length = 28 days) or until unequivocal progression or treatment discontinuation, whichever occurs later.
89415217|NCT02291848|Experimental|Group A|Patients receiving TAA-specific CTLs as therapy for Myeloma
89415218|NCT02291848|Experimental|Group B|Patients receiving TAA-Specific CTLs as adjunctive therapy following autologous or syngeneic transplant for myeloma
89415219|NCT02291848|Experimental|Group C|Patients with high risk MGUS or smoldering myeloma receiving a fixed dose TAA-Specific CTLs
89415220|NCT02275221||Hepatitis B and C|Hepatitis B and C
89415221|NCT02255799|Active Comparator|Donepezil|Donepezil 5 mg capsules daily for 14 days. Donepezil 10 mg capsules daily for 56 days.
89415222|NCT02255799|Placebo Comparator|Placebo|Placebo capsules once daily for 70 days.
89415223|NCT02244463|Experimental|Phase I: Dose Level 1 (PI DL1)|Phase I Dose Level 1 participants receive MLN0128 3 mg orally, daily for 28 days. Participants are treated until disease progression or withdrawal of consent.
89415224|NCT02244463|Experimental|Phase I: Dose Level 2 (PI DL2)|Phase I Dose Level 3 (dose escalation) participants received MLN0128 5 mg orally, daily for 28 days. Participants are treated until disease progression or withdrawal of consent.
89415225|NCT02244463|Experimental|Phase I: Dose Level 3 (PI DL3)|Phase I Dose Level 3 participants receive MLN0128 5 mg orally, daily for 28 days. Participants are treated until disease progression or withdrawal of consent.
89415226|NCT02244463|Experimental|Phase I: Dose Level 3 (PI DL3) Expansion|Phase I Dose Level 3 participants receive MLN0128 5 mg orally, daily for 28 days. Participants are treated until disease progression or withdrawal of consent.
89415227|NCT02244463|Experimental|Phase II: ATC Cohort|Phase II participants receive MLN0128 at the recommended phase II dose of 5 mg orally, daily for 28 days. Participants are treated until disease progression or withdrawal of consent. All phase I participants treated at the maximum tolerated dose/ recommended phase II dose (DL3) are enrolled in the phase II part of the study according to the appropriate disease cohort.
88922122|NCT05782244|Active Comparator|Sildenafil citrate high dose|Sildenafil citrate 80 mg, oral, TID
89415228|NCT02244463|Experimental|Phase II: DTC Cohort|Phase II participants receive MLN0128 at the recommended phase II dose of 5 mg orally, daily for 28 days. Participants are treated until disease progression or withdrawal of consent. All phase I participants treated at the maximum tolerated dose/ recommended phase II dose (DL3) are enrolled in the phase II part of the study according to the appropriate disease cohort.
89415229|NCT02234388||Registry Participants|All patients who participate in the UCTD Registry will be put into this cohort and observed over approximately 3 years.
89415230|NCT02181257|Other|Newly Diagnosed Bronchiolitis Obliterans (NEW BOS)|"Participants with NEW BOS will be randomized to Early Photopheresis Intervention (EPI) or Control (Standard of Care). EPI patients will receive 24 treatments in a 6-month period and may continue maintenance treatments.~The Control group will receive local Standard of Care for the management of BOS. Therapy will involve changes in immunosuppressive agents."
89415231|NCT02181257|Other|Refractory Bronchiolitis Obliterans Syndrome (REFRACTORY BOS)|Participants with REFRACTORY BOS will be electronically assigned to either ECP treatment or Observation based on the participant's pre-enrollment Forced Expiratory Volume in 1 second (FEV1). Values from pulmonary function tests from the preceding 12 months will be entered into a web-based treatment allocation which will perform an automated calculation. Patients who have a statistically significant rate of decline within the preceding 6 months, and a derived protocol defined slope, will be assigned to the ECP Treatment arm. If a patient does not meet these criteria, the participant will be assigned to the Observation arm.
89415232|NCT02176902|No Intervention|Arm I (control)|Patients receive no intervention.
89415233|NCT02176902|Experimental|Arm II (fish oil)|Patients receive dietary counseling with research dietitian weekly for 1 month and then monthly for 11 months. Patients are given guidelines with recommended meals to follow a low omega-6, high omega-3 fat diet combined with fish oil. Patients also receive 4 fish oil capsules per day PO for 1 year.
89415234|NCT02139397|Experimental|DFMO and Bortezomib|Subjects will take DFMO by mouth 2 times a day for each day of a 21 day cycle and Bortezomib will be given by IV push on days 1, 4, and 8 of each 21 day cycle.
89415235|NCT02038777|Experimental|Monotherapy Cohort|PF-04449913 Monotherapy
89415236|NCT02038777|Experimental|Combination Cohort 1|PF-04449913 in combination with low dose ARA-C (LDAC)
88922123|NCT05773664|Experimental|Arm I (azeliragon, dexamethasone)|Patients receive azeliragon PO and dexamethasone PO or IV throughout the study. Patients also undergo collection of cavity fluid and blood samples, CT scan, and brain MRI with or without contrast throughout the study.
89415237|NCT02038777|Experimental|Combination Cohort 2|PF-04449913 in combination with intensive chemotherapy: PF-04449913 administered continuously for 28 days. Daunorubicin given using 60 mg/m2 for 3-days together with cytarabine 100 mg/m2 on days 1 through 7 followed by cytarabine 1g/m2 on days 1, 3, and 5 during 2-4 cycles of consolidation therapy.
88893000|NCT04905849|Experimental|Adaptive Cognitive Control Trainer (ACCT)|There are three modules within the game, each training a different aspect of cognitive control (attention, goal management, working memory): a visual search task for attention abilities, a spatial span task for working memory, and a task switching paradigm for goal management abilities. There are also 3 different levels of difficulty associated with each module; advancing to the next level delivers an advanced challenge that enhances the difficulty in performing the given cognitive task. Participants advance to the next level of difficulty following 6 training sessions occurring over 2 weeks, with the total training experience being 6 weeks of training (3 days/week), with each training session lasting 36 minutes (not including self-paced breaks).
88893001|NCT04905849|Active Comparator|Active Control Group|An active control application will be used for this arm. The total training experience here will also be for 6 weeks (3 days/week), with each training session lasting ~30 minutes (not including self-paced breaks). Here an app that is matched in terms of expectancy of benefits compared to our training groups will be determined by questioning 100 naïve individuals to predict their expected improvement on each cognitive domain across a multitude of possible applications.
89415238|NCT02038777|Experimental|Azacitidine Combination Cohort|PF-04449913 in combination with azacitidine
89415239|NCT02038777|Experimental|Continuation Cohort|PF-04449913 Monotherapy for one patient rolled-over from another trial in the same project.
89415240|NCT02038777|Experimental|Expansion Cohort of LDAC Combination for Efficacy|PF-04449913 in combination with LDAC to evaluate efficacy
89415241|NCT01991457|Other|Treatment|Fludarabine, Total Body Irradiation (TBI) Fludarabine: 40 mg/m2 X 4 days TBI: TBI 2 Gy 2 times a day X 3 days
89415242|NCT01969344||Smokers without COPD|Current or former smokers with at least a 20 pack-year history with normal lung function based on post-bronchodilator spirometry (n=944).
89415243|NCT01969344||Severe COPD|Current and former smokers with at least a 20 pack-year history with severe COPD based on post-bronchodilator spirometry (n=625).
89415244|NCT01969344||Mild/Moderate COPD|Current and former smokers with at least a 20 pack-year history with mild to moderate COPD based on post-bronchodilator spirometry (n=1210).
89415245|NCT01969344||Non-smokers|Never-smokers with normal lung function on spirometry without use of bronchodilators (n=201).
89415246|NCT01943994|Experimental|Psilocybin-assisted treatment|Participants will receive a 13-week cognitive behavioral intervention for smoking cessation, with a high dose of psilocybin (30mg / 70kg) to be administered on the Target Quit Date in week 5.
89415247|NCT01943994|Active Comparator|Nicotine Replacement Therapy (NRT)|Participants will receive a 13-week cognitive behavioral intervention for smoking cessation, with a standard 8 to 10-week regimen of NRT to be administered beginning on the Target Quit Date in week 5. NRT for this study will be a transdermal nicotine patch administered according to recommended label usage (For individuals who smoke more than 10 cigarettes per day: 21mg daily weeks 1-6, 14mg daily weeks 7-8, 7mg daily weeks 9-10. For individuals who smoke 10 or less cigarettes per day: 14mg daily for weeks 1-6, 7mg daily for weeks 7-8).
89415248|NCT01899989|Experimental|A) >5cm,Chemo eligible (closed to accrual)|Patients will receive five fractions of either 8, 10, or 12 Gy to the gross tumor only. Following SBRT patients will be evaluated by their medical oncologist for consideration of adjuvant chemotherapy, starting 6-8 weeks post-RT. All patients will be followed for one year. Patients will be assessed for toxicity by their radiation oncologist at 4 to 6 weeks post-RT and during chemotherapy by their medical oncologist. Follow up after completion of all treatment will consist of CT chest scans at 6 and 12 months post-SBRT and toxicity assessments every 3 months from the end of SBRT for one year.
89415249|NCT01899989|Experimental|B) 3-5cm OR Chemo ineligible|Using intensity-modulated radiation therapy (IMRT) or volumetric arc therapy (VMAT), the choice of which is determined by the radiation oncologist, patients will be treated in < 5 fractions every other day. The total treatment dose will be between 45 and 54 Gy in < 5 fractions per standard of care. All patients will be followed for one year. Patients will be assessed for toxicity by their radiation oncologist at 4 to 6 weeks post-RT and during chemotherapy at the discretion of their medical oncologist. Follow up after completion of all treatment will consist of CT chest scans at 6 and 12 months post-SBRT and toxicity assessments every 3 months from the end of SBRT for one year. FDG PET/CT scans and Pulmonary Function Tests (PFTs) will be obtained at 3 months and 9 months after SBRT.
89415250|NCT01817166|Placebo Comparator|Placebo|"Patients in this arm will receive a placebo treatment mimicking 100.000 UI of cholecalciferol every 14 days for a maximum of 24 months or until conversion to full multiple sclerosis has occurred.~Intervention: Placebo Intervention: Imaging Intervention: Lumbar puncture Intervention: Blood sampling Intervention: Urine samples"
89415251|NCT01817166|Experimental|Vit D|"Patients in this arm will receive 100.000 UI of cholecalciferol every 14 days for a maximum of 24 months or until conversion to full multiple sclerosis has occurred.~Intervention: Vitamin D Intervention: Imaging Intervention: Lumbar puncture Intervention: Blood sampling Intervention: Urine samples"
89415252|NCT01590862|Active Comparator|Deep Brain Stimulation On|We will assess Reward Motivation behavior with Deep Brain Stimulation on.
89415253|NCT01590862|No Intervention|Deep Brain Stimulation Off|We will assess Reward Motivation behavior with Deep Brain Stimulation off.
89415254|NCT01571986||NIV|All patients with acute respiratory failure treated with non-invasive ventilation who give informed consent about treatment of their clinical data
89415255|NCT01506206||Patients with Deep Brain Stimulators|Patients with deep brain stimulation for either major depressive disorder (MDD) or obsessive compulsive disorder (OCD).
89415256|NCT01506206||Patients with MDD or OCD|Patients with MDD or OCD who do not have a deep brain stimulator.
89415257|NCT00902044|Experimental|Autologous HER2-specific T cells|"THIS ARM IS CLOSED~Dose Level 1: 1x10^4 cells/m2~Dose Level 2: 3x10^4 cells/m2~Dose Level 3: 1x10^5 cells/m2 (NOT BEING USED)~Dose Level 4: 3x10^5 cells/m2 (NOT BEING USED)~Dose Level 5: 1x10^6 cells/m2~Dose Level 6: 3x10^6 cells/m2~Dose Level 7: 1x10^7 cells/m2~Dose Level 8: 3x10^7 cells/m2~Dose Level 9: 1x10^8 cells/m2"
89415258|NCT00902044|Experimental|HER2-specific T cells+fludarabine|"Autologous HER2-specific T cells+fludarabine:~Dose Level 9A: fludarabine followed by 1x10^8 cells/m^2"
89415259|NCT00902044|Experimental|HER2-specific T cells+fludarab.+cycloph.|"Autologous HER2-specific T cells+fludarabine+cyclophosphamide:~Dose Level 9B: fludarabine + cyclophosphamide followed by 1x10^8 cells/m^2"
89415260|NCT00902044|Experimental|CAR Positive cells|Dose Level 9C: fludarabine + cyclophosphamide followed by 1x10^8 cells/m^2 CAR positive cells/m^2
89415261|NCT00659035||IT|Subjects receiving 1-10 mg/day of morphine or its equivalent doses of opioid medications through intrathecal route. Intrathecal medications are administered through a catheter in spinal cord
89415262|NCT00659035||Oral|Subjects receiving oral opioids (morphine, oxycodone, hydrocodone, methadone), but not also receiving anticonvulsants (gabapentin, pregabalin, topiramate), muscle relaxants, benzodiazepines, or diphenylhydramine for at least a week before testing; low dose antidepressants and/or NSAIDs are OK
89415263|NCT00659035||Oral + Anticonvulsant|Subjects receiving oral opioids (morphine, oxycodone, hydrocodone, methadone) and anticonvulsants (gabapentin, pregabalin, topiramate), but not also receiving muscle relaxants, benzodiazepines, or diphenylhydramine for at least a week before testing; low dose antidepressants and/or NSAIDs are OK
89415264|NCT00659035||Control -Pain|Subject not receiving opioid medications, anticonvulsants (gabapentin, pregabalin, topiramate), muscle relaxants, benzodiazepines, or diphenylhydramine for at least a week before testing; low dose antidepressants and/or NSAIDs are OK.
89415265|NCT00659035||Control -No Pain|Age-matched volunteers (NO PAIN) not receiving opioid medications, anticonvulsants (gabapentin, pregabalin, topiramate), muscle relaxants, benzodiazepines, or diphenylhydramine for at least a week before testing; low dose antidepressants and/or NSAIDs are OK.
89415266|NCT00471250||1|Healthy Volunteers
89415267|NCT00471250||2|NIH patients with known or suspected susceptibility to infection.
89415268|NCT04992364||Positive Clinical Performances|Subjects show positive clinical performances regarding burnout syndrome
88893002|NCT04895956|Active Comparator|Intra-sheath injection|In patients randomized to the intra-sheath, corticosteroids will be injected directly into the abductor pollicis longus/ extensor pollicis brevis sheath.
89415269|NCT04992364||Negative Clinical Performances|Subjects show negative clinical performances regarding burnout syndrome
89415270|NCT03608241|Experimental|Treatment sequence 1|Treatment sequence 1 will receive a single dose of an oral contraceptive during the first period of the study (period 1) and then continue to the second period (Period 2) of the study where they will receive PF-06651600 every day for 11 days and a single dose of an oral contraceptive towards the end of the period.
89415271|NCT03608241|Experimental|Treatment Sequence 2|Treatment sequence 2 will receive PF-06651600 every day for 11 days during the first period of the study (period 1) and a single dose of an oral contraceptive towards the end of this period. After completion of Period 1, there will be a washout period of at least 10 days before starting the second period of the study (period 2). During period 2, a single dose of an oral contraceptive will be received.
89415272|NCT03072784|Active Comparator|group S|short time <90 m aortic cross clamping
89415273|NCT03072784|Active Comparator|group L|> 90 minutes aortic cross clamping
89415274|NCT03606057|Experimental|Treatment Group 1: JNJ-64565111+Moxifloxacin Placebo|Participant will receive JNJ-64565111 on days 2, 9, 16, and 23 and moxifloxacin-matching placebo on days 1 and 27.
89415275|NCT03606057|Active Comparator|Treatment Group 2: JNJ-64565111 Matching Placebo+Moxifloxacin|Participant will receive JNJ-64565111-matching placebo on days 2, 9, 16, and 23. Participants will also receive moxifloxacin on day 1 and moxifloxacin-matching placebo on day 27 (sequence 2a) or moxifloxacin-matching placebo on day 1 and moxifloxacin on day 27 (sequence 2b) in a nested crossover manner.
88893003|NCT04895956|Experimental|Extra-sheath injection|In patients randomized to the extra-sheath arm, corticosteroids will be injected surrounding the abductor pollicis longus/ extensor pollicis brevis sheath.
88893004|NCT04888767|No Intervention|Control group|Patients benefiting from the usual re-training sessions
88893005|NCT04888767|Experimental|ITHI Group|Patients benefiting from ITHI re-training sessions
88893006|NCT04883827||RCC with clear cell component|
89415276|NCT03605979||diabetes group|Patient with hypoglycemia unawareness
89415277|NCT04998760|Experimental|ATG-008 + Chemotherapeutics|ATG-008: Oral, 30 mg QD+Paclitaxel: 175 mg/m2, intravenous infusion >3 h, Day 1, Q3W; ATG-008: Oral, 30 mg QD+Carboplatin: AUC = 5, intravenous infusion >1 h, Day 1, Q3W or Cisplatin: 75 mg/m2, intravenous infusion >1h, Day 2, Q3W ; ATG-008: Oral, 30 mg QD+Doxorubicin hydrochloride liposome, 40 mg/m2, Day 1; Q4W;
89415278|NCT04998760|Experimental|ATG-010 + Chemotherapeutics|"perimental: ATG-010 + Chemotherapeutics ATG-010: Oral, 80 mg QW, Day 1/week of treatment cycles +Paclitaxel: 175 mg/m2, intravenous infusion >3 h, Day 1, Q3W; ATG-010: Oral, 80 mg QW, Day~1/week of treatment cycles +Carboplatin: AUC = 5, intravenous infusion >1 h, Day 1, Q3W or Cisplatin: 75 mg/m2, intravenous infusion >1h, Day 2, Q3W ; ATG-010: Oral, 80 mg QW, Day 1/week of treatment cycles +Doxorubicin hydrochloride liposome, 40 mg/ m2, Day 1; Q4W;"
89415279|NCT03607383|Experimental|Red rice yeast group|Red rice yeast based product will be provided under the brand name Molval Fort, one pill a day, for 8 weeks, for a moderate intensity treatment equivalent according the American College of Cardiology/American Heart Association (ACC/AHA) guidelines definitions
88893007|NCT04883827||Healthy Volunteer (no longer recruiting)|
88893008|NCT04826900|Experimental|Robotic Group|Training session included 45 minutes Robotic Therapy, followed by 15-minute functional training. The robotic group will receive 3 sessions per week, for 8 weeks.
88893009|NCT04826900|Experimental|Robotic Mirror Group|Training session included 45 minutes Robotic Mirror Therapy, followed by 15-minute functional training. The robotic group will receive 3 sessions per week, for 8 weeks.
88893010|NCT04819906|Experimental|T-ST-P-M|"Treatment T: Therapeutic E4 dose (20 mg): one E4 20 mg tablet plus four E4 placebo tablets~Treatment ST: Supratherapeutic E4 dose (100 mg): five E4 20 mg tablets~Treatment P: Placebo: five E4 placebo tablets~Treatment M: Moxifloxacin: 1 moxifloxacin 400 mg tablet"
88893011|NCT04819906|Experimental|ST-M-T-P|"Treatment T: Therapeutic E4 dose (20 mg): one E4 20 mg tablet plus four E4 placebo tablets~Treatment ST: Supratherapeutic E4 dose (100 mg): five E4 20 mg tablets~Treatment P: Placebo: five E4 placebo tablets~Treatment M: Moxifloxacin: 1 moxifloxacin 400 mg tablet"
88893012|NCT04819906|Experimental|P-T-M-ST|"Treatment T: Therapeutic E4 dose (20 mg): one E4 20 mg tablet plus four E4 placebo tablets~Treatment ST: Supratherapeutic E4 dose (100 mg): five E4 20 mg tablets~Treatment P: Placebo: five E4 placebo tablets~Treatment M: Moxifloxacin: 1 moxifloxacin 400 mg tablet"
89415280|NCT03607383|Active Comparator|Statin group|Statin choice is done at the discretion of the treating physician for a moderate intensity treatment equivalent according the American College of Cardiology/American Heart Association (ACC/AHA) guidelines definitions, for 8 weeks
89415281|NCT04998526|Experimental|Experimental group|After routine drug treatment is given to hypertension patients, the cold gel pack will be applied to the nape for 3 minutes.
89415282|NCT04998526|Placebo Comparator|Placebo group|After routine drug therapy is given to hypertension patients, the gel pack kept at room temperature will be applied to the nape for 3 minutes.
89415283|NCT04998526|No Intervention|Control group|Routine drug treatment will be given to hypertension patients and no application will be made.
89415284|NCT03607305|Active Comparator|BP limb 70cm|Patients underwent a RYGB with a biliopancreatic limb of 70cm
89415285|NCT03607305|Experimental|BP limb 120cm|Patients underwent a RYGB with a biliopancreatic limb of 120cm
89415286|NCT05002894|Experimental|exercise group|This group included twenty six post-menopausal women. They will participate in Pilates exercise, medical standard care for fatigue and advices to deal with fatigue. The Pilates exercises consisted of a set of 10 movements: bridging; hundred; roll up; one leg circle (both ways); single straight leg stretch; single leg kick; side kick up and down; side kick circles; rest position (stretch and relaxation); and curling ,women were instructed to perform 30 min per session, 3 sessions per week, for 8 weeks.
89415287|NCT05002894|Experimental|standard care group|Each post-menopausal woman in both groups will receive a medical standard care for post-menopausal fatigue.
89415288|NCT02696499|Experimental|PA101B|
89415289|NCT02696499|Placebo Comparator|Placebo|
89415290|NCT03075592||ERCP candidates|ERCP candidates
89415291|NCT05003128|Experimental|LED screen|
89415292|NCT03607227|Active Comparator|Local anesthetic|Levobupivacaine 3.75 mg/ml 15 ml is given as a bolus injection at start of surgery, followed by ropivacaine 2 mg/ml continous infusion 5-8 ml/h from the end of surgery until end of intervention at the fourth to seventh postoperative day.
89415293|NCT03607227|Placebo Comparator|Saline|Saline solution (NaCl 0.9%) is given in equivalent intervals and doses as in the active substance arm.
88893013|NCT04819906|Experimental|M-P-ST-T|"Treatment T: Therapeutic E4 dose (20 mg): one E4 20 mg tablet plus four E4 placebo tablets~Treatment ST: Supratherapeutic E4 dose (100 mg): five E4 20 mg tablets~Treatment P: Placebo: five E4 placebo tablets~Treatment M: Moxifloxacin: 1 moxifloxacin 400 mg tablet"
88893014|NCT04819906|Experimental|ST-P-T-M|"Treatment T: Therapeutic E4 dose (20 mg): one E4 20 mg tablet plus four E4 placebo tablets~Treatment ST: Supratherapeutic E4 dose (100 mg): five E4 20 mg tablets~Treatment P: Placebo: five E4 placebo tablets~Treatment M: Moxifloxacin: 1 moxifloxacin 400 mg tablet"
89415294|NCT05002426||The type and orientation of Rouviere sulcus|"open type, fused type or absent type"
88893015|NCT04819906|Experimental|P-M-ST-T|"Treatment T: Therapeutic E4 dose (20 mg): one E4 20 mg tablet plus four E4 placebo tablets~Treatment ST: Supratherapeutic E4 dose (100 mg): five E4 20 mg tablets~Treatment P: Placebo: five E4 placebo tablets~Treatment M: Moxifloxacin: 1 moxifloxacin 400 mg tablet"
88893016|NCT04819906|Experimental|T-ST-M-P|"Treatment T: Therapeutic E4 dose (20 mg): one E4 20 mg tablet plus four E4 placebo tablets~Treatment ST: Supratherapeutic E4 dose (100 mg): five E4 20 mg tablets~Treatment P: Placebo: five E4 placebo tablets~Treatment M: Moxifloxacin: 1 moxifloxacin 400 mg tablet"
88893017|NCT04819906|Experimental|M-T-P-ST|"Treatment T: Therapeutic E4 dose (20 mg): one E4 20 mg tablet plus four E4 placebo tablets~Treatment ST: Supratherapeutic E4 dose (100 mg): five E4 20 mg tablets~Treatment P: Placebo: five E4 placebo tablets~Treatment M: Moxifloxacin: 1 moxifloxacin 400 mg tablet"
88893018|NCT04819906|Experimental|P-T-ST-M|"Treatment T: Therapeutic E4 dose (20 mg): one E4 20 mg tablet plus four E4 placebo tablets~Treatment ST: Supratherapeutic E4 dose (100 mg): five E4 20 mg tablets~Treatment P: Placebo: five E4 placebo tablets~Treatment M: Moxifloxacin: 1 moxifloxacin 400 mg tablet"
89199119|NCT04037553||Group 1|Patients underwent right ear surgery: After intracuff pressure (ICP) is adjusted to 25 cmH2O at neutral position, lateral neck rotation (approximately 60-70 degrees to the left) was applied to the patients and ICP values were documented following 3 respiration cycles.
89415295|NCT03607149|Active Comparator|STANDARD ARM|Calculation of the dose of pemetrexed as a function of body surface area
89415296|NCT03607149|Experimental|EXPERIMENTAL ARM|Calculation of the pemetrexed dose as a function of the Clearance of creatine (CrCLCG)
89415297|NCT04998292|Experimental|Low level laser therapy|
89415298|NCT04998292|Active Comparator|Control|
89415299|NCT02035293|Other|PEP|No drug and no placebo were used in this study. For all the patients who participated at the study PEP, only following exams must be performed: a clinical probability score (revised Geneva score), plasma D-dimer assay and if necessary, a chest multidetector-row CT angiography and venous ultrasound of the lower limbs
89415300|NCT04998838|Experimental|Tenofovir Disoproxil Fumerate|Pregnant women (&gt;=20 weeks of gestation) will be treated with TDF if clinically eligible; newborns will receive birth dose vaccine (and HBIG if eligible). Non-eligible women will be treated according to normal practices; newborns will still receive birth dose vaccine.
89415301|NCT04998448||Cases|women aged 18 to 50 years, premenopausal, with polycystic ovary syndrome
89415302|NCT04998448||Controls|women aged 18 to 50 years, premenopausal, without polycystic ovary syndrome.
89415303|NCT03607071|Experimental|Prednisolone|The patient who has detected myocardial inflammation from cardiac MRI from baseline is given prednisolone 30 mg/d and taper 5-10 mg per 2 weeks until off at week 24.
89415304|NCT02035215|Experimental|Atorvastatin 20mg, Omega-3-acids ethylesters 90 4g|Atorvastatin calcium 20mg, Omega-3-acids ethylesters 90 4g: po, q.d
89415305|NCT02035215|Placebo Comparator|Atorvastatin 20mg, Placebo|Atorvastatin calcium 20mg, Placebo for Omega-3-acids ethylesters 90 4g: po, q.d
89415306|NCT04992442|Experimental|TAK-935 300 mg + [14C]TAK-935 50 μg + [14C]TAK-935 300 mg|TAK-935 3×100 mg, tablets, orally, once on Day 1, followed by [14C]TAK-935 50 micrograms (μg) [approximately 1 μCi], IV infusion, once on Day 1 of Treatment Period 1, followed by a Washout Period of 7 days, further followed by [14C]TAK-935 300 mg (approximately 100 μCi) solution, orally, once on Day 1 of Treatment Period 2.
89415307|NCT03606993|Experimental|Lucky Iron Fish™ (LIF)|For Mother-infant dyads enrolled into the LIF arm, mother receives a cooking supplement: one ~ 200g iron ingot.
89415308|NCT03606993|No Intervention|Enhanced standard of care (eSOC)|For mother-infant dyads in the eSOC arm, families are not provided iron supplementation (consistent with standard of care) but have additional visits and laboratory monitoring beyond well-child care (enhanced).
89415309|NCT03605589|Experimental|Blinatumomab and Pembrolizumab|"Blinatumomab and Pembrolizumab will be given for 2 cycles (each cycle lasts 35 days).~Blinatumomab administered as a continuous IV infusion. Patient Weight Greater Than or Equal to 45 kg (Fixed dose) Patient Weight Less Than 45 kg (BSA-based dose)~Cycle 1 (Days 1-7):~Patient Weight Greater Than or Equal to 45 kg: 9 mcg/day Patient Weight Less Than 45 kg: 5 mcg/m2/day~Cycle 1(Days 8-28):~Patient Weight Greater Than or Equal to 45 kg: 28 mcg/day Patient Weight Less Than 45 kg: 15 mcg/m2/day~Cycle 2 (Days 1-28):~Patient Weight Greater Than or Equal to 45 kg: 28 mcg/day Patient Weight Less Than 45 kg: 15 mcg/m2/day~Pembrolizumab: 2 mg/kg (max dose 200 mg) administered as a 30 minute IV infusion on day 12 of cycle 1 and day 5 of cycle 2."
89415310|NCT04992130|Experimental|Intervention cohort|Pre-season supplementary neurologic training program
89415311|NCT04992130|No Intervention|Control cohort|Usual pre-season training program
89415312|NCT03072472|Experimental|Endocuff-assisted Flexible Sigmoidoscopy|Patients in this arm will receive their screening sigmoidoscopy with the Endocuff Vision in situ on the scope
89415313|NCT03072472|No Intervention|Standard Flexible Sigmoidoscopy|Patients in this arm will receive their screening sigmoidoscopy without the Endocuff on the scope
89415314|NCT03075436|Experimental|Enhanced demand-side sanitation, hygiene|The intervention group will receive a package of enhanced, demand-side sanitation and hygiene interventions that are informed by formative research and facilitated by local government and Emory Ethiopia partners.
89415315|NCT03075436|Active Comparator|Standard of care|The comparison group will receive the current standard of care, including potential implementation of government-led policies and programs.
89415316|NCT05002582||patients with hematological diseases|to clarify the intestinal carriage rate of carbapenem-resistant Organisms (CRO) in patients with hematological diseases
89415317|NCT03075124|Experimental|External Counter Pulsation group|A standard ECP protocol involves 35 one-hour sessions (once per day, 5 days a week) and continuous for 7 weeks. ECP consists of three sets of pneumatic cuffs attached to each of the patient's legs at the calf and lower and upper thigh. The inflation of the cuffs is triggered by a computer, and timing of the inflation is based on the R wave of the electrocardiogram. The ECP therapist adjusts the inflation and deflation timing to provide optimal blood movement per a finger plethysmogram waveform reading.
89415318|NCT03075124|No Intervention|Control group|Guideline-driven standard medical treatment
89415319|NCT05002036|Active Comparator|HA-GB|eyedrop containing hyaluronic acid and gingko biloba (Trium eyedrops, Sooft srl)
89415320|NCT05002036|No Intervention|No treatment|no treatment for iatrogenic dry-eye
89415321|NCT03074968|Placebo Comparator|control|normal saline
89415322|NCT03074968|Active Comparator|benzydamine hydrochloride|Benzydamine Hydrochloride
89415323|NCT05002348|Experimental|Acupoint Laser Group|In the experimental group, the laser pen was turned on, and the acupoint stimulation was performed for about 3-5 minutes. Each acupoint was performed once a day. The patient wore goggles and observed the patient's vital signs (blood pressure, heartbeat, and blood pressure) with a physiological monitor. Oxygen), if the patient has any discomfort, the procedure will be stopped, and the patient's defecation status will be recorded/evaluated every day for up to 10 days (including Saturdays and Sundays). The post-test questionnaire will be conducted on the day of discharge, and the phone will be followed within one month after discharge. Inquire about the follow-up situation.
89415324|NCT05002348|No Intervention|control group|In the control group, the laser pen does not turn on the energy. The acupoint stimulation is performed for about 3-5 minutes, and each acupoint is performed once a day. The patient wears goggles and observes the patient's vital signs (blood pressure, heartbeat, and blood pressure) with a physiological monitor. Oxygen), if the patient has any discomfort, the procedure will be stopped, and the patient's defecation status will be recorded/evaluated every day for up to 10 days (including Saturdays and Sundays). The post-test questionnaire will be conducted on the day of discharge, and the phone will be followed within one month after discharge. Inquire about the follow-up situation.
89415325|NCT04991584|Experimental|14d concomitant therapy|Patients will receive a 14-day concomitant therapy Option 1:Amoxicillin+Tetracycline+Furazolidone+Vonoprazan fumarate or Esomeprazole Option 2: Amoxicillin+Furazolidone+Levofloxacin+Vonoprazan fumarate or Esomeprazole Option 3: Amoxicillin+Tetracycline+Levofloxacin+Vonoprazan fumarate or Esomeprazole Option 4: Amoxicillin+Clarithromycin+Levofloxacin+Vonoprazan fumarate or Esomeprazole Three options are selected according to the actual situation.
89415326|NCT03072706|Active Comparator|Standard group|2D X-ray templating technology
89415327|NCT03072706|Experimental|Corin OPS™|Corin Optimised Positioning System (OPS) Dynamic Hip Analysis
89415328|NCT04997746||educational pharmaceutical guidelines|Qualified listening of participants; General pharmaceutical educational guidelines on the use of medicines; Manufacture and supply of medicine organizer boxes.
89415329|NCT04997746||Nursing Educational Guidelines|"Nursing educational guidelines; Qualified listening to participants to resolve doubts related to their comorbidities and aging, bringing comfort in relation to their anxieties.~Nursing interventions will occur through verbal educational guidelines given individually and according to the reality of each participant assessed by the research, based on the nursing diagnoses obtained from the North American Nursing Diagnosis Association - NANDA-I (definitions and classification 2018- 2020) 11th edition."
89415330|NCT04997746||Nutritional Educational Guidelines|Obtaining anthropometric measurements (weight, in kilograms, height (in meters), knee height, arm and calf circumference (in centimeters) to trace the participant's nutritional profile and, subsequently, personalized and appropriate nutritional guidelines will be carried out for each situation The calculation of the Body Mass Index (BMI) must be performed by dividing the weight (W) in kilograms (kg) by the square of the height (H) in meters (m) and indicates the individual's nutritional status. The BMI for the elderly (LIPSCHITZ, 1994 apud TAVARES et al., 2015) determines underweight less than or equal to 22kg / m2, adequate or eutrophic weight between 22 and 27kg / m2 and overweight result greater than or equal to 27kg / m2 .
89199120|NCT04037553||Group 2|Patients underwent left ear surgery: After intracuff pressure (ICP) is adjusted to 25 cmH2O at neutral position, lateral neck rotation (approximately 60-70 degrees to the right) was applied to the patients and ICP values were documented following 3 respiration cycles.
89415331|NCT05001412|Experimental|Cohort one|Extensive SCLC patients who are Peripheral type or tumor vascular invasion grade one or less.
89415332|NCT05001412|Experimental|Cohort two|Extensive SCLC patients who are central type or tumor vascular invasion grade two to three.
89415333|NCT04997590|Experimental|Umbilical cord blood mononuclear cells group|Umbilical cord blood mononuclear cells (cell number 1×108/2mL), once every two weeks, 3 times in total.
89415334|NCT04997590|Active Comparator|Staphylococcal Enterotoxin C group|Staphylococcal enterotoxin C (2mL), once every two weeks, 3 times in total.
89415335|NCT04997512|No Intervention|Standard of care|Participants are returned to the care of their usual diabetes care provider following randomisation. They will donate blood and urine samples as well as completing diabetes specific questionnaires at 0 and 6 months. They will also wear a blinded glucose sensor (freestyle Libre PRO) for a two week period at month 6.
89415336|NCT04997512|Experimental|Intervention arm|Participants will be randomised at baseline. They will provide blood and urine samples at months 0 and 6 as well as fill in diabetes specific questionnaires. They will receive education surrounding hypoglycaemia at baseline from a diabetes specialist nurse. They will wear a freestyle libre device which is changed every two weeks for a period of 6 months. At weeks 2,4,12 and 24 they will have their diabetes medication adjusted by the diabetes specialist nurse/diabetes doctor according to their blood glucose profiles, analysed from the data generated by freestyle libre.
89415337|NCT04997122|Experimental|Olive pomace oil|Intake of 45 g/d of olive pomace oil as the only source of oil in the diet
89415338|NCT04997122|Active Comparator|High-oleic sunflower oil|Intake of 45 g/d of high-oleic sunflower oil as the only source of oil in the diet
89415339|NCT04996810|Experimental|PROTOXIN (Phase I/II)|PROTOXIN will be injected to 5 glabellar lines (Each 4U/0.1mL, Total 20U/0.5mL).
89415340|NCT04996810|Active Comparator|Botox® (Phase II)|Botox® will be injected to 5 glabellar lines (Each 4U/0.1mL, Total 20U/0.5mL).
89415341|NCT03072394|Experimental|EMLA anesthetic ointment (AO)|In AO group a layer of 2.5 gr EMLA cream (standard adult dose) is applied to both wrists, 1 cm above the styloid process of the radius 30 minutes before the puncture, by an experienced cathlab nurse.
89415342|NCT03072394|Active Comparator|Local Skin Anesthetic Injection (LA)|In LA group the radial artery is infiltrated with 1-2 mL of 2% lidocaine, using a 26 G needle, 0.5-1 cm proximal to the styloid process one minute before the puncture
89415343|NCT04991428|Experimental|Active trancranial direct current stimulation|Active stimulation for 15 minutes
88893019|NCT04819906|Experimental|T-M-P-ST|"Treatment T: Therapeutic E4 dose (20 mg): one E4 20 mg tablet plus four E4 placebo tablets~Treatment ST: Supratherapeutic E4 dose (100 mg): five E4 20 mg tablets~Treatment P: Placebo: five E4 placebo tablets~Treatment M: Moxifloxacin: 1 moxifloxacin 400 mg tablet"
89005946|NCT04663360|Experimental|Intervention|Intervention to be administered: Adverse Drug Reactions (ADRe) Profile. asks nurses to systematically check patients for the manifestation of itemised adverse side effects or undesirable effects of their primary care medicines, as listed in the BNF and manufacturers' Summaries of Product Characteristics (SmPCs), and seminal texts documenting known ADRs. Nurses are asked to share the identified problems with prescribers and pharmacists overseeing medicines charts.
89415344|NCT04991428|Sham Comparator|Sham stimulation|Similar set-up but no actual stimulation
88893020|NCT04819906|Experimental|ST-P-M-T|"Treatment T: Therapeutic E4 dose (20 mg): one E4 20 mg tablet plus four E4 placebo tablets~Treatment ST: Supratherapeutic E4 dose (100 mg): five E4 20 mg tablets~Treatment P: Placebo: five E4 placebo tablets~Treatment M: Moxifloxacin: 1 moxifloxacin 400 mg tablet"
89005947|NCT04663360|No Intervention|Control|Usual clinical care.
89005948|NCT04663477||Trained nurse-completed CRS|
89415345|NCT03072004|Sham Comparator|Control|"Leprosy patients with focal demyelinating neuropathy in compression sites of the ulnar and common peroneal nerves who will receive application sham LLLT. The laser will be turned off, but the procedure will be the same as with the Low Level Laser Therapy (LLLT) group"
89415346|NCT03072004|Experimental|Low Level Laser Therapy|Leprosy patients with focal demyelinating neuropathy in compression sites of the ulnar and common peroneal nerves who will receive intervention with low-intensity laser therapy (LLLT).
89415347|NCT03072082|Experimental|Danlou Tablet|Danlou 0.3g tablet by mouth, 5 tablets three times daily for 6 months & conventional western medicine (including Aspirin Enteric-coated Tablets, Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet, Atorvastatin Calcium, Isosorbide Mononitrate Tab 20 MG, Metoprolol Tartrate Tab 25 MG, Trimetazidine Dihydrochloride Tablets)
89415348|NCT03072082|Placebo Comparator|Danlou Tablet placebo|Placebo Danlou 0.3g tablet by mouth, 5 tablets three times daily for 6 months & conventional western medicine (including Aspirin Enteric-coated Tablets, Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet, Atorvastatin Calcium, Isosorbide Mononitrate Tab 20 MG, Metoprolol Tartrate Tab 25 MG, Trimetazidine Dihydrochloride Tablets)
89415349|NCT03072316||SSM immediate DIEP|Unilateral skin sparing mastectomy with immediate DIEP
89415350|NCT03072316||SSM immediate DIEP and PMRT|Unilateral skin sparing mastectomy with immediate DIEP flap reconstruction and post mastectomy radiotherapy
89415351|NCT03072316||mastectomy, PMRT, delayed DIEP|simple mastectomy, post mastectomy radiotherapy adn then delayed DIEP reconstruction
89415352|NCT03072316||SSM, temporizing implant, PMRT then DIEP|Unilateral SSM with temporizing implant, PMRT and subsequent
89415353|NCT03076840|Active Comparator|Kinesio tape group|treatment by: application of Kinesio tape in the hamstring muscle by using a 1 strip Y shape of (Kinesio Tex® Tape 5cm) insertion to origin technique to relieve the hamstring tightness while the muscle in stretched position for 15 second (hip flexion and knee extension and then application of the tape) with 25% stretch of the tape
89415354|NCT03076840|Sham Comparator|sham tape group|treatment by: application of Kinesio tape in the hamstring muscle by using a 1 strip I shape of (Kinesio Tex® Tape 5cm) with no stretch in the hamstring musculature and the tape applied perpendicular over the upper third of the hamstring muscle while the muscle in stretched position
89415355|NCT03076840|No Intervention|control group|The student in this group had no treatment in the same position of the previous groups (the hamstring muscle maintained in a stretching position for 15 second)
89005949|NCT04663477||Patient-completed CRS|
89005950|NCT04663438||Arm A|200/Atezolizumab combined with EC regimen Atezolizumab:1200 mg Q3w
89005951|NCT04663438||Arm B|100/Atezolizumab combined with chemotherapy Atezolizumab:1200mg Q3w
89415356|NCT04990960|Active Comparator|Physiotherapist|The Physiotherapist worked on adhered breast scars, stiffness in neck and arm movements and actively worked on AWS cords with gentle extensions and / or energetic detachment maneuvers. No self-treatment methods were offered and required of the subject.
89415357|NCT04990960|Experimental|Self-treatment|The Physiotherapist worked on adhered breast scars, stiffness in neck and arm movements. During each session the patient was also assessed and trained in self-treatment exercises assigned to treat their cords. Subjects were trained to perform self-treatment extension exercises with four exercises selected by the Physiotherapist
89415358|NCT04996732||All Cancers|subgroups according to cancer sites
89415359|NCT03074890|Experimental|Intervention (cases)|Intervention: Massive transfusion protocol resuscitation aiming at ratio 1:1:1 of blood components (RBC:FFP:PLT) and conventional coagulation tests guiding further resuscitation with blood products and procoagulant factors
89415360|NCT03074890|No Intervention|No Intervention (control))|all patients with massive haemorrhage in which the massive transfusion protocol didn´t apply
89415361|NCT04931914||Group c|Patients admitted from June 9, 2020 to june 31, 2021.
89415362|NCT04987450||Study population|Plasma levels of SIRT-1, IL-6, FGF-23, sclerostin, calcium, phosphate, PTH and urine excretion of total protein, albumin, creatinine, calcium and phosphate are measured at baseline. Then the patients receive three intravenous daily pulses of methylprednisolone of 500 mg followed by oral prednisone 0.8-1.0 mg/kg/24h. The same measurements are repeated 4, 7 and 30 days after starting the steroid treatment.
89193080|NCT05601102|Experimental|Intervention group|The programme was a digital movement and music programme with resources from danceSing Care (https://dancesingcare.uk/) and consisted of two movement sessions and one music session each week, each lasting about 20 minutes. Also, the danceSing care resources were designed to suit older adults with physical and cognitive impairments (residents with mobility aids and/or dementia). Movement sessions included chair and standing fitness, which started with a warm-up and finished with stretching exercises. Sessions were managed and supervised by care home activity coordinators.
89415363|NCT03074656|Experimental|Therapeutic drug monitoring|Administration of infliximab according to a treatment strategy based on therapeutic drug monitoring and assessments of anti-drug antibodies
89415364|NCT03074656|Active Comparator|Standard care|Administration of infliximab according to standard clinical care, without knowledge of drug levels or status of anti-drug antibodies
89415365|NCT03074578|Experimental|Night-time desensitization|Watching a video containing verbal and visual violence in the evening, and again in the next morning
89415366|NCT03074578|Sham Comparator|Daytime desensitization|Watching a video containing verbal and visual non-violence in the morning, and then again the evening of the same day
89415367|NCT04996888|Experimental|with AI preoperative automatic reminder system|After receiving regular instructions at the time of their appointment to discuss colonoscopy and education about colonoscopy provided by one nurse, including the importance of bowel preparation, the side effects of the agents used, and the exact preparation instructions, the patients in the experimental group will be sent a message and a phone call by AI system on the day before colonoscopy, which will emphasize the importance of bowel preparation, the directions for use and side effects of purgatives, the proper food type, and the start time.
89415368|NCT04996888|No Intervention|without AI preoperative automatic reminder system|The patients in the control group accept colonoscopy routinely without AI based preoperative automatic reminder system. All patients will receive regular instructions at the time of their appointment to discuss colonoscopy and education about colonoscopy provided by one nurse, including the importance of bowel preparation, the side effects of the agents used, and the exact preparation instructions.
89415369|NCT03071848||Bevacizumab|Participants with advanced cervical cancer (metastatic, recurrent or persistent) who have received treatment with bevacizumab from 01 January 2015 to 01 January 2016 (retrospective and independent from this study) combined with standard chemotherapy (cisplatin/carboplatin or topotecan and paclitaxel) will be observed.
89415370|NCT03070210|Other|EUS-celiac plexus block (EUS-CPB)|"This is the standard technique. In this approach, the needle is passed through the body of the stomach adjacent the celiac artery into the retroperitoneal space in 1 or 2 passes. The injectate (bupivacaine or alcohol) is injected and spreads through the retroperitoneal space, effectively bathing all the ganglia."
89415371|NCT03070210|Active Comparator|EUS-celiac ganglia block (EUS-CGB)|This is a more recent technique which has been often used. In this procedure, the needle is inserted under EUS guidance directly into as many ganglia as possible. For celiac ganglia <1cm in diameter, the solution is injected into the central point; for those ≥1 cm, a needle is advanced to the deepest point into the ganglia and solution is injected as the needle is slowly withdrawn. Injections are continued until an echogenic pattern is produced over the entire celiac ganglia.
89415372|NCT03074422|Experimental|Hypsnosis|During the fixation of the stereotactic frame, a single hypnosis session is performed by a certified senior anesthesiologist. Blood pressure, heart rate and respiratory rate are continuously monitored by the mean of a regular scope. Pain perceived during and after the procedure is quantifies by the mean of the Visual Analogue Scale (VAS) questionnaire. An open, standardized question will be asked to participants concerning feelings and thoughts about the frame fixation. Answers will be audio recorded. A standardized perceived distress questionnaire (PDI-13) will be performed.
89005952|NCT04663516|Experimental|experimental|exercise through video game (Wii)
89005953|NCT04663516|No Intervention|control|children in this group will be given advice about the importance of exercising
89005954|NCT00244959|Experimental|Anastrozole|Anastrozole (1mg, orally, daily) for 12 months as adjuvant therapy for breast cancer
89193081|NCT05601102|No Intervention|Waitlist control group|Waitlist for 12 weeks before participating in the digital movement and music programme with resources from danceSing Care (https://dancesingcare.uk/).
89005955|NCT04663672|Experimental|Exposure Therapy + Exposure Scent Cue During Sleep|Participants will undergo exposure treatment for their target fear while in the presence of a distinctive odor. Exposure will occur in repeated 4-minute trials. Exposure will continue for 40 minutes or until peak fear decreases by at least 35 points on a 100 point scale, compared to peak fear during the initial trial. Participants will subsequently sleep in the presence of the exposure scent.
89193082|NCT05600803||DSOC group|Study subjects are patients who satisfied the inclusion/exclusion criteria and underwent single-operator cholangioscopy.
89415373|NCT03074422|No Intervention|Control|Local anesthesia after clear and complete information of the procedure given the day prior to the surgery. In order to determine the pain perceived during the procedure, a VAS questionnaire will be used, directly after the frame disposal. The rest of the procédure is similar to the hypnosis group.
89415374|NCT03071614|Active Comparator|News with Spin|News items reporting results of animal studies with spin.
89415375|NCT03071614|Experimental|News without spin|News items reporting results of animal studies without spin.
89415376|NCT04991194|Experimental|BIA 5-1058 1200 mg (Part I)|Subjects received 1200 mg of BIA 5-1058 once a day (od), in fasting conditions, for 10 days
89415377|NCT04991194|Experimental|BIA 5-1058 400 mg (Part II)|Subjects received 400 mg of BIA 5-1058 od, in fasting conditions, for 10 days.
89415378|NCT04990648|Experimental|Buzzy group|Buzzy ® was placed on the left arm deltoid muscle site and kept there for 30 seconds. After 30 seconds, Buzzy ® was taken 1 cm up and MMR vaccine injection was administered to the left deltoid muscle site. After the vaccine injection, Buzzy ® was taken to the injection site and kept for another 30 seconds.
89415379|NCT04990648|No Intervention|Control group|MMR vaccine injection was administered to the left deltoid muscle without any intervention or application to the injection site.
89415380|NCT04920058|Experimental|Wellness Program combined with Continuous Glucose Monitoring (CGM)|Continuous Glucose Monitoring (CGM) sensor combined with Levels CGM software that provides real-time visualization, analysis and feedback will be added to a Wellness Program incorporating a low carbohydrate diet (<50 g carbohydrate). Subjects in the group will be manually randomized and listed in a sealed envelope by someone who is not part of the study team
89415381|NCT04920058|Active Comparator|Wellness Program|Wellness Program incorporating a low carbohydrate diet (<50 g carbohydrate). Subjects in the group will be manually randomized and listed in a sealed envelope by someone who is not part of the study team
89415382|NCT02853435|Experimental|Part1a: Gepotidacin 1500 mg-Sequence A-capsules, B-RC, C-HSWG|Subjects will be receive treatment sequence (ABC) which is a single dose of gepotidacin 1500 mg (three tablets of 500 mg) reference capsule (Treatment A) in Period 1, 1500 mg (two tablets of 750 mg) RC tablet (Treatment B) in Period 2 or 1500 mg (two tablets of 750 mg) HSWG tablet (Treatment C) in Period 3, according to randomization. There will be a washout period of at least 3 days between doses.
89415383|NCT02853435|Experimental|Part1a: Gepotidacin 1500 mg-Sequence C-HSWG, A-capsules, B-RC)|Subjects will receive treatment sequence (CAB) to receive a single dose of gepotidacin 1500 mg (two tablets of 750 mg) HSWG tablet (Treatment C) in Period 1, 1500 mg (three tablets of 500 mg) reference capsule (Treatment A) in Period 2 or 1500 mg (two tablets of 750 mg) RC tablet (Treatment B) in Period 3 according to randomization. There will be a washout period of at least 3 days between doses.
89415384|NCT02853435|Experimental|Part1a: Gepotidacin 1500 mg-Sequence B-RC, C-HSWG, A-capsules)|Subjects will receive treatment sequence (BCA) to receive a single dose of gepotidacin 1500 mg (two tablets of 750 mg) RC tablet (Treatment B) in period 1, 1500 mg (two tablets of 750 mg) HSWG tablet (Treatment C) in Period 2, or 1500 mg (three tablets of 500 mg) (Treatment A) in Period 3 reference capsule according to randomization.. There will be a washout period of at least 3 days between doses.
89415385|NCT02853435|Experimental|Part1b: Gepotidacin 1500 mg-Sequence DE-fasted followed by fed|Subjects will receive treatment sequence (DE) according to randomization which is a single 1500 mg (two tablets of 750 mg) dose of gepotidacin tablet (RC or HSWG) selected from Part 1a under fasted condition (Treatment D) in Period 1 followed by fed conditions (Treatment E) in period 2. There will be a washout period of at least 3 days between doses.
89415386|NCT02853435|Experimental|Part1b: Gepotidacin 1500 mg-Sequence ED-fed followed by fasted|Subjects will be receive treatment sequence (ED) according to randomization which is single 1500 mg (two tablets of 750 mg) dose of gepotidacin tablet (RC or HSWG) selected from Part 1a under fed condition (Treatment E) in period 1 followed by fasted conditions (Treatment D) in Period 2. There will be a washout period of at least 3 days between doses.
89415387|NCT02853435|Experimental|Part 2a: Gepotidacin 1500 mg (RC or HSWG)- Japanese subjects|Japanese subjects will receive a single 1500 mg (two tablets of 750 mg) dose of gepotidacin tablet (RC or HSWG) selected from Part 1a.
89415388|NCT02853435|Experimental|Part 2b: Gepotidacin 1500 mg (RC or HSWG)- Chinese subjects|Chinese subjects will receive a single 1500 mg (two tablets of 750 mg) dose of gepotidacin tablet (RC or HSWG) selected from Part 1a.
89415389|NCT04996186||Patients enrolled|Patients with Multiple sclerosis, with an age older than 18 years old and symptoms of fecal incontinence or chronic constipation
89415390|NCT03071770|Experimental|ivosidenib (AG-120)|
89415391|NCT04986982|Experimental|Opicapone|
89415392|NCT04986982|Placebo Comparator|Placebo|Opicapone and placebo capsules will be identical in size, colour, taste and appearance. The packaging and labelling will not allow for any distinction between test and reference drug.
89415393|NCT03071458||Patients with HCC|The cohort is composed of patients with HCC with available tumor and non tumor samples collected retrospectively. These patients have HCC of different stages (localized and advanced stages) It is an observational retrospective study.
89415394|NCT04990570||Pediatric day-case surgical patients, encountered via Virtual clinic from June 2020 till July 2021|"Pediatric patients, with age ranging from 1 month-14 years, with day-case surgical problems, encountered during the era of Covid-19 pandemic.~Telemedicine, in the form of Virtual clinic, was utilized to address this distressing problem, to aid in conveying their concerns and bridge the gap in surgeon-patient relationship & encounter."
89415395|NCT04990570||Control group comprising of patients scheduled to the OPD clinic from June 2019 till June 2020|Cases of office OPD appointments in the period from June 2019 till June 2020 will be included as a control group
89415396|NCT04986826||Healthy master athletes|
89193083|NCT05597189|Experimental|Botanical extracts high dose|Consumption for 84 days. Subjects should consume two capsules half an hour before breakfast.
88893021|NCT04819906|Experimental|M-ST-T-P|"Treatment T: Therapeutic E4 dose (20 mg): one E4 20 mg tablet plus four E4 placebo tablets~Treatment ST: Supratherapeutic E4 dose (100 mg): five E4 20 mg tablets~Treatment P: Placebo: five E4 placebo tablets~Treatment M: Moxifloxacin: 1 moxifloxacin 400 mg tablet"
89193084|NCT05597189|Experimental|Botanical extracts low dose|Consumption for 84 days. Subjects should consume two capsules half an hour before breakfast.
89193085|NCT05597189|Placebo Comparator|Control group|Consumption for 84 days. Subjects should consume two capsules half an hour before breakfast.
89193086|NCT05592249|Experimental|Motor - Cognitive|Motor - Cognitive group will receive motor and cognitive dual task intervention.
88893022|NCT04809766|Experimental|Cohorts I, II, and III (FH-TCR Tᴍsʟɴ)|"LYMPHODEPLETION CHEMOTHERAPY: Patients receive cyclophosphamide IV and fludarabine IV on days -5, -4 and -3 or may optionally receive bendamustine IV on days -4 and -3 prior to the 1st T cell infusion.~T-CELL THERAPY: Patients receive FH-TCR-Tᴍsʟɴ IV over 60-120 minutes on days 0, 21, and 42 in the absence of disease progression or unacceptable toxicity."
88893023|NCT04809766|Experimental|Cohort IV (FH-TCR Tᴍsʟɴ) (Discontinued with amendment 3/28/23)|"LYMPHODEPLETION CHEMOTHERAPY: Patients receive cyclophosphamide IV and fludarabine IV on days -3 to -1.~T-CELL THERAPY: Patients receive FH-TCR-Tᴍsʟɴ IV over 60-120 minutes on days 0, 21, and 42 in the absence of disease progression or unacceptable toxicity."
89193087|NCT05592249|Experimental|Motor - Motor|Motor - Motor group will receive motor and motor dual task intervention.
89193088|NCT05588219|Experimental|Experimental arm|The therapeutic schedule of the experimental arm: External irradiation 45~50Gy/25f+ Brachytherapy 28~30Gy/4~5f; Chemotherapy: DDP 40mg/m2/W, synchronous with radiotherapy, complete at least 4 cycles; Tislelizumab injection[10ml:100mg]: 200mg/3W for 1 year or disease progression or intolerable toxicity, whichever occurs first.
89193089|NCT05585346|Experimental|Laser acupuncture Group|"LA group used a class IV Multiwave Locked System (MLS) laser (Mphi laser, ASA Srl, Vicenza, Italy). MLS laser is a class IV NIR laser with two synchronized sources (905 nm with 75 W peak power, pulsed mode; 808 nm with power 1 W, continuous mode). Both laser beams were synchronized, the locked waves work with the range 1-2000 Hz.~In LA group, based on clinical experience, we choose 5 acupoints on the affected side. It includes ST2(Si Bai), ST4(Di Cang), ST6(Jia Che), GB14(Yang Bai), GB20(Feng chi). We choose 7 acupoints, including LI4 (He Gu), LI11(Qu Chi), ST25 (Tian Shu), ST36 (Zu San Li), SP6 (San Yin Jiao), KI3 (Tai Xi), LR3 (Tai Chong). The acupoints in the limbs and trunk area, were applied bilaterally. Power of laser device is 50%.~Oral vitamin B1."
89193090|NCT05585346|Active Comparator|Control Group|"LA group used a class IV Multiwave Locked System (MLS) laser (Mphi laser, ASA Srl, Vicenza, Italy). MLS laser is a class IV NIR laser with two synchronized sources (905 nm with 75 W peak power, pulsed mode; 808 nm with power 1 W, continuous mode). Both laser beams were synchronized, the locked waves work with the range 1-2000 Hz.~In LA group, based on clinical experience, we choose 5 acupoints on the affected side. It includes ST2(Si Bai), ST4(Di Cang), ST6(Jia Che), GB14(Yang Bai), GB20(Feng chi). We choose 7 acupoints, including LI4 (He Gu), LI11(Qu Chi), ST25 (Tian Shu), ST36 (Zu San Li), SP6 (San Yin Jiao), KI3 (Tai Xi), LR3 (Tai Chong). The acupoints in the limbs and trunk area, were applied bilaterally. Power of laser device is 25%.~Oral vitamin B1."
89193091|NCT05585021|Experimental|Wonderlab Kids instant probiotics|Wonderlab Kids instant probiotics (hawthorn flavor) (4 strains, 20 billion CFU/bottle) 2g/bottle
89193092|NCT05585021|Placebo Comparator|Instant probiotic placebo|Instant probiotic placebo (ET) 2g/bottle
89415397|NCT04986826||Genotype positive phenotype negative transthyretin amyloidosis|
89415398|NCT04986826||Phenotype positive transthyretin amyloidosis|
89415399|NCT03606915||no pain|pain evaluation for patients performed surgery without painful condition (bleeding or others)
89415400|NCT03606915||acute pain|pain evaluation for patients performed surgery with painful condition within several days
89415401|NCT03606915||chronic pain|pain evaluation for patients performed surgery with the painful condition for over months
89415402|NCT03074344|Experimental|XLHA+CoQ10|XLHA+CoQ10 eye drop administered four times a day for 12 weeks (90 days).
89415403|NCT03074344|Active Comparator|Hyaluronic acid (HA)|Hyaluronic acid (HA) eye drop administered four times a day for 12 weeks (90 days).
89415404|NCT03069898|Experimental|TRUE Dads program track|In the TRUE Dads program, fathers and co-parents begin with a Core workshop meeting weekly for 6 weeks. After a check-in, a male-female group leader team focuses on a single topic that represents one of the three main goals of the project as a whole: Co-parenting relationships, Parenting, or Employment and financial stability. From 10 to 18 couples, seated at small tables in a large room, hear mini-lectures, watch videos, and engage in interactive exercises. Fathers then choose to attend one of three intensive workshops focused on couple relationships OR parenting OR economic self-sufficiency meeting 3 hours per week for the next 6 weeks. On an as-needed basis, fathers may be referred for employment programs and fathers and co-parents may be referred for mental health or other services.
89415405|NCT03069898|No Intervention|Control condition study track|Participants (fathers and co-parents) complete intake interview and fill out Baseline survey. They fill out follow-up survey one year later
89415406|NCT02035371|Experimental|FIAsp|Each subject will be randomly allocated to a treatment sequence consisting of 2 dosing visits separated by a wash-out period of 3-12 days
89415407|NCT02035371|Active Comparator|NovoRapid®|Each subject will be randomly allocated to a treatment sequence consisting of 2 dosing visits separated by a wash-out period of 3-12 days
88893024|NCT04794010||Cohort 1|Participants with Metastatic Non-Small Cell Lung Cancer
88893027|NCT04780269|Experimental|Induction of labor with Foley catheter|A Foley catheter will be introduced transcervically in women allocated in this group.
88893028|NCT04780269|Experimental|Induction of labor with PGE2|PGE2 (1mg) will be inserted into the posterior vaginal fornix.
88893029|NCT04769323|Experimental|Group 1|Group 1 use virtual reality.
88893030|NCT04769323|Experimental|Group 2|Group 2 do traditional home exercises.
88893031|NCT04769323|Experimental|Group 3|Group 3 do traditional home exercises and virtual reality.
88893032|NCT04742907|Experimental|TU-100 15 g/day|Subjects will receive a total daily dose of TU-100 5 g TID until hospital discharge or ≤ 10 days (whichever is earlier).
88893033|NCT04742907|Experimental|TU-100 7.5 g/day|Subjects will receive a total daily dose of TU-100 2.5 g TID until hospital discharge or ≤ 10 days (whichever is earlier).
88893034|NCT04742907|Placebo Comparator|Placebo|Subjects will receive placebo TID until hospital discharge or ≤ 10 days (whichever is earlier).
88893035|NCT04735926|Placebo Comparator|Group 1A|Subjects corresponding to Cohort 1 (25-OH-D baseline level > 10 to < 20 ng/mL)
88893036|NCT04735926|Experimental|Group 1B|Subjects corresponding to Cohort 1 (25-OH-D baseline level > 10 to < 20 ng/mL)
88893037|NCT04735926|Experimental|Group 1C|Subjects corresponding to Cohort 1 (25-OH-D baseline level > 10 to < 20 ng/mL)
88893038|NCT04735926|Placebo Comparator|Group 2A|Subjects corresponding to Cohort 2 (25-OH-D baseline level ≤ 10 ng/mL)
88893039|NCT04735926|Experimental|Group 2B|Subjects corresponding to Cohort 2 (25-OH-D baseline level ≤ 10 ng/mL)
88893040|NCT04735926|Experimental|Group 2C|Subjects corresponding to Cohort 2 (25-OH-D baseline level ≤ 10 ng/mL)
88893041|NCT04721158|Other|CGM Arm|Children with type 2 diabetes will wear a continuous glucose monitor for 10 days.
88893042|NCT04693338|Experimental|Supportive care (ICP)|Patients complete surveys for 4 common symptoms: fatigue, hot flashes, insomnia, and sexual dysfunction and receive educational material via mobile app to help with bothersome symptoms. Patients also complete questionnaires.
88893043|NCT04620811|Experimental|3.0 mg/kg of Lirentelimab (AK002)|Subjects in this arm will receive up to 18 monthly doses (3mg/kg) of lirentelimab (AK002)
88893044|NCT04619043|Experimental|Ankle Orthotic|The participant will wear two different ankle orthotics, their currently prescribed orthotic and the experimental orthotic.
88893045|NCT04595825|Experimental|Anti-human CCL24 monoclonal antibody (CM-101)|Anti-human CCL24 monoclonal antibody CM-101 Intravenous Infusion over 60 minutes (±5 minutes)
88893046|NCT04595825|Placebo Comparator|Placebo|Placebo - intravenous infusion
88893047|NCT04595097|Experimental|Intervention Group|The training volume will be 24 sessions. Training frequency will be 3 sessions per week. Duration of training sessions will be around 60min. Patients will perform endurance training or interval training at moderate to high intensities. IMT in both groups will be performed using the PowerBreathe KHP2 device (POWERbreatheKHP2, HaB, International, Southam, UK). Training intensity in the intervention group will be set initially at a load of 50% of patients' maximal inspiratory mouth pressure (MIP). This initial load will be continuously and gradually increased to the highest tolerable intensity during each of the supervised sessions.
88893048|NCT04595097|Active Comparator|Control group|The training volume will be 24 sessions. Training frequency will be 3 sessions per week. Duration of training sessions will be around 60min. Patients will perform endurance training or interval training at moderate to high intensities. Sham IMT will be performed using the PowerBreathe KHP2 device (POWERbreatheKHP2, HaB, International, Southam, UK). Training intensity in the control group will be set at 10% baseline PImax and will be not modified throughout the intervention period.
88893049|NCT04594772|Experimental|Neoadjuvant therapy|All patients will receive Neoadjuvant therapy.
88893050|NCT04561206|Experimental|Treatment (brentuximab vedotin, nivolumab)|Patients receive brentuximab vedotin IV over 30 minutes and nivolumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 16 cycles in the absence of disease progression or unacceptable toxicity.
88922124|NCT05773664|Active Comparator|Arm II (dexamethasone)|Patients receive dexamethasone PO or IV throughout the study. Patients also undergo collection of cavity fluid and blood samples, CT scan, and brain MRI with or without contrast throughout the study.
88893051|NCT04536363|Active Comparator|Standard therapeutic protocol|"Dexamethasone (4mg ampoule, intravenous)~Tocilizumab (8 mg / kg (maximum dose 800 mg) IV, maximum 3)~Empirical Antibiotic Therapy in patients with suspected pneumonia (according to management guidelines)~Enoxaparin (40mg prefilled syringe)~Enoxaparin (20mg, 40mg, 60mg, 80mg prefilled syringe)~Low molecular weight heparin (5000IU prefilled syringe)"
88893052|NCT04536363|Experimental|Standard Therapeutic Protocol + PGE1 Analog|"Analog of PGE1 + Standard therapeutic protocol~Standard medical treatment:~Dexamethasone (4mg ampoule, intravenous)~Tocilizumab (8 mg / kg (maximum dose 800 mg) IV, maximum 3)~Empirical Antibiotic Therapy in patients with suspected pneumonia (according to management guidelines)~Enoxaparin (40mg prefilled syringe)~Enoxaparin (20mg, 40mg, 60mg, 80mg prefilled syringe)~Low molecular weight heparin (5000IU prefilled syringe)"
88893053|NCT04520971|Experimental|780G closed-loop|780 closed-loop insulin delivery system
88893054|NCT04520971|Active Comparator|standard of care|standard of care treatment (continue with current treatment of insulin pump without closed-loop or multiple daily insulin injections).
88893055|NCT04515524||ROP patients from VGFTe-ROP-1920|Retinopathy of prematurity (ROP) who were treated with aflibercept and/or laser photocoagulation in study VGFTe-ROP-1920.
89415408|NCT04996108||Participants with recurrent pericarditis (RP)|Patients aged 16 or over with (1) RP, diagnosed by a clinician, meeting the European Society of Cardiology (ESC) diagnostic criteria, and (2) where the aetiology of the RP is defined as idiopathic (i.e. there is no other aetiology identified, such as infective, malignant, post cardiac injury, as part of an autoimmune condition, as part of another known auto-inflammatory disease).
88893056|NCT04504526|Experimental|68Ga-Pentixafor, PET/CT|PET/CT perform after injecting 68Ga-Pentixafor
88893057|NCT04500912|Active Comparator|Supraflex Cruz stent|Randomization to Supraflex Cruz stent
89415409|NCT04996108||Participants with systemic auto-inflammatory diseases (disease controls)|Patients aged 16 or over with a systemic auto-inflammatory disease, diagnosed by a trained specialist.
89415410|NCT04996108||Healthy volunteers (healthy controls)|Sex, ethnicity and aged matched healthy individuals who do not have a personal history of pericarditis or systemic auto-inflammatory disease.
88893058|NCT04500912|Active Comparator|Ultimaster Tansei stent|Randomization to Ultimaster Tansei stent
88893059|NCT04494334||Healthy Volunteers|These will be age matched healthy volunteers (n=15) who will not undergo bronchoscopy
88893060|NCT04494334||Probable Idiopathic Pulmonary Fibrosis|Patients with probable IPF, who will be having bronchoscopy as part of their clinical diagnostic work up
88893061|NCT04494334||Sarcoidosis,|Patients with sarcoidosis who will be having bronchoscopy as part of their clinical diagnostic work up
88893062|NCT04488419|Experimental|Dosage|Daily subcutaneous (SC) injection of 40mg ATH-1017
88893063|NCT04488419|Placebo Comparator|Placebo|Daily subcutaneous (SC) injection of Placebo
88893064|NCT04481919|Active Comparator|Protocolized spot urine sodium guided diuretic therapy|Patients will have a spot urine sodium and urine creatinine obtained. The urine and creatinine results will be input into the diuretic calculator and the diuretic dose will be chosen based on daily goals for urine output and net negative fluid balance. Performed 3 times per day, diuretic dosing will be individualized based on the proportion of 24-hour diuresis achieved since the prior IV diuretic dose. Every 24 hours new goals for urine output and net negative fluid balance are established based on the study and treatment team's assessment of residual congestion until protocol completion.
88893065|NCT04481919|No Intervention|Guideline-based care|Patients will be placed on guideline-based diuretic dosing consistent with usual practice. The initial dose will be two times their home dose and will be subsequently adjusted by the treating team based on renal function and symptom severity. The treating team can increase or decrease the frequency and dose of diuretic based on urine output and clinical assessment. Patients in this arm also have urine collected 3 times per day by the bedside nurse to mirror the intervention arm.
88893066|NCT04446585|No Intervention|Control sites|"For all 1-1-2 calls with suspected cardiac arrest to the emergency dispatch center will activate a two-tiered response consisting of dispatch of an ambulance with an emergency medical technician, a physician-staffed mobile emergency care unit, and citizen first responders through the Heart Runner app.~The medical dispatcher offers telephone assisted cardiopulmonary resuscitation (CPR) to bystanders. Furthermore, if more than two bystanders are present and an AED is accessible within 1½ minute travel distance (depending on the type of terrain), then one bystander is guided to localize and retrieve the AED."
88893067|NCT04446585|Experimental|Intervention sites|"As a supplement to the standard care as described in the control arm, the following will be supplied:~Strategical deployment of AEDs with 24:7 availability and 1½ minute walking distance to every residence within the area. The AEDs will be registered with the AED network and thus linked to the emergency dispatch center.~The emergency dispatch center will retrieve data from used AEDs.~For each interventional area, approximately 120 residents will receive a course in CPR and AED use and subsequently be recruited as citizen responders so that they can be activated through the HeartRunner app in case of a nearby cardiac arrest."
88893068|NCT04427306|Experimental|Treatment (talimogene laherparepvec)|This study all subject get the research treatment drug (talimogene laherparepvec)
88893069|NCT04421222|Experimental|Part A/Phase 1a: Cohort 1 (Completed)|200 mg EPI-7386
88893070|NCT04421222|Experimental|Part A/Phase 1a: Cohort 2 (Completed)|400 mg EPI-7386
88893071|NCT04421222|Experimental|Part A/Phase 1a: Cohort 3 (Completed)|600 mg EPI-7386
88893072|NCT04421222|Experimental|Part A/Phase 1a: Cohort 4 (Completed)|800 mg EPI-7386
88893073|NCT04421222|Experimental|Part A/Phase 1a: Cohort 5 (Completed)|1000 mg EPI-7386
88893074|NCT04421222|Experimental|Part A/Phase 1a: Cohort 6 (Completed)|800 mg EPI-7386
88893075|NCT04421222|Experimental|Part A/Phase 1a: Cohort 7 (Completed)|1200 mg EPI-7386
88893076|NCT04421222|Experimental|Part A/Phase 1b: Cohort 1 (Completed)|600 mg EPI-7386 BID
88893077|NCT04421222|Experimental|Part A/Phase 1b: Cohort 2|600 mg EPI-7386 QD
88893078|NCT04421222|Experimental|Part B/Cohort 1a|600 mg EPI-7386 + 1000 mg Abiraterone Acetate + Prednisone
88893079|NCT04421222|Experimental|Part B/Cohort 1b|800 mg EPI-7386 + 1000 mg Abiraterone Acetate + Prednisone
88893080|NCT04421222|Experimental|Part B/Cohort 1c|1200 mg EPI-7386 + 1000 mg Abiraterone Acetate + Prednisone
88893081|NCT04421222|Experimental|Part B/Cohort 2a|600 mg EPI-7386 monotherapy for 12 weeks then 600 mg EPI-7386 + 240 mg Apalutamide
88893082|NCT04421222|Experimental|Part B/Cohort 2b|800 mg EPI-7386 monotherapy for 12 weeks then 800 mg EPI-7386 + 240 mg Apalutamide
88893083|NCT04421222|Experimental|Part B/Cohort 2c|1200 mg EPI-7386 monotherapy for 12 weeks then 1200 mg EPI-7386 + 240 mg Apalutamide
88893084|NCT04421079|Placebo Comparator|Placebo|Comparable placebos
88893085|NCT04421079|Active Comparator|Low Dose BDPP|8 oz. Concord grape juice + 450 mg Grape seed polyphenol extract + 150 mg Trans-resveratrol
88893086|NCT04421079|Active Comparator|Medium Dose BDPP|16 oz. Concord grape juice + 900 mg Grape seed polyphenol extract + 300 mg Trans-resveratrol
88893087|NCT04421079|Active Comparator|High Dose BDPP|24 oz. Concord grape juice + 1200mg Grape seed polyphenol extract + 450mg Trans-resveratrol
88893088|NCT04396145||Surgery group|Subjects who will have chronic otitis media surgery will be included in the study.
88893089|NCT04395261||Group 0|Patients were divided into groups according to observation in surgery Empty ear in operation
88893090|NCT04395261||Group 1|Patients were divided into groups according to observation in surgery Serous fluid in operation
88893091|NCT04395261||Group 2|Patients were divided into groups according to observation in surgery Mucoid fluid in operation
88893092|NCT04395261||Group 3|Patients were divided into groups according to observation in surgery Adhesive tympanic membrane in operation
88893093|NCT04395261||Group 4|Control group. Subjects with no otitis media with effusion
88893094|NCT04390724||Patient Group 1: Y90 Standard-of-Care|The first group of patients will be treated with Y90 dose and embolic load as per standard-of-care
88893095|NCT04390724||Patient Group 2: Y90 Dose determined by results from Group 1|The second group of patients will be treated with the optimal Y90 dose and embolic load found in Patient Group 1
89415411|NCT04996108||Relatives of individuals with recurrent pericarditis (familial controls)|First degree relatives of participants meeting the criteria for, and included in the study as, RP cases, who are aged 16 or over.
89415412|NCT03274947|Active Comparator|Hypothesis 2 Protocol 2 Low dose TMS|Low level cerebellar TMS. Delivered once per day for 3 days.
88893096|NCT04328714|Experimental|Adult Population|Study participants aged 18 or older who are having an allogeneic blood and marrow transplant (BMT), to treat leukemia, lymphoma or other cancer of the blood will receive an infusion of mesenchymal stromal cells (MSCs).
88893097|NCT04328714|Experimental|Pediatric Population|Study participants under 18 years of age who are having an allogeneic blood and marrow transplant (BMT), to treat leukemia, lymphoma or other cancer of the blood will receive an infusion of mesenchymal stromal cells (MSCs).
88893098|NCT04298892||hematologic disorder or malignancy|
88893099|NCT04296110|Active Comparator|Control|Participants will receive music relaxation therapy. They will be asked to listen to designated music daily for 12 weeks.
88893100|NCT04296110|Experimental|Biofeedback|Participants will receive a biofeedback intervention. They will be asked to practice breathing at their designated resonance frequency using provided biofeedback device daily for 12 weeks.
88893101|NCT04294771||Myocarditis and other cardiovascular toxicities ICI-related|Case reported in the World Health Organization (WHO)international pharmacovigilance database, or APHP Entrepot de Données de Santé (EDS) and French Système National Des Données de Santé (SNDS) Databases, with a chronology compatible with the drug toxicity
88893102|NCT04294771||Non case|Non-case will be patients exposed to ICI without cardiovascular toxicities
88893103|NCT04263766|Experimental|Healthy Adult Volunteers|The experiment has a within-subject design where each subject will receive TMS to different brain areas. The analysis will involve comparing the effects of TMS to different regions.
89415413|NCT03274947|Active Comparator|Hypothesis 2 Protocol 2 High dose TMS|High level cerebellar TMS. Delivered twice per day for 5 days.
88893104|NCT04250415||Operative Arm|
88893105|NCT04250415||Non-operative Arm|
88893106|NCT04237649|Experimental|Arm A|KAZ954
88893107|NCT04237649|Experimental|Arm B|KAZ954 + PDR001
88893108|NCT04237649|Experimental|Arm C|KAZ954 + NIR178
88893109|NCT04237649|Experimental|Arm D|KAZ954 + NZV930
88893110|NCT04225988|Experimental|Extended-release tacrolimus|Kidney transplant recipients will receive extended-release tacrolimus in addition to standard-dose mycophenolate and prednisone for maintenance immunosuppression.
88893111|NCT04225988|Active Comparator|Immediate-release tacrolimus|Kidney transplant recipients will receive immediate-release tacrolimus in addition to standard-dose mycophenolate and prednisone for maintenance immunosuppression.
88893112|NCT04211155|Experimental|Primary Parent|Participants will be randomly assigned to one of 4 conditions that differ by who is with them in the MRI scanner room: Primary Parent, Close Friend, Experimenter, No Social Partner.
88893113|NCT04211155|Experimental|Close Friend|Participants will be randomly assigned to one of 4 conditions that differ by who is with them in the MRI scanner room: Primary Parent, Close Friend, Experimenter, No Social Partner.
88893114|NCT04211155|Experimental|Experimenter|Participants will be randomly assigned to one of 4 conditions that differ by who is with them in the MRI scanner room: Primary Parent, Close Friend, Experimenter, No Social Partner.
88893115|NCT04211155|Experimental|No Social Partner|Participants will be randomly assigned to one of 4 conditions that differ by who is with them in the MRI scanner room: Primary Parent, Close Friend, Experimenter, No Social Partner.
88893116|NCT04203199|Experimental|First H1 coil, then H7 coil|There will be 1 screening and 2 TMS visits. The procedures will be identical for each TMS visit, except for the type of TMS delivered (H1 or H7 coil). Each participant will be assigned to both coils, with TMS type. Participants assigned to this arm will receive the H1 coil at TMS visit 1, H7 coil at TMS visit 2
88893117|NCT04203199|Experimental|First H7 coil, then H1 coil|There will be 1 screening and 2 TMS visits. The procedures will be identical for each TMS visit, except for the type of TMS delivered (H1 or H7 coil). Each participant will be assigned to both coils, with TMS type. Participants assigned to this arm will receive the H7 coil at TMS visit 1, H1 coil at TMS visit 2.
89415414|NCT03274947|Sham Comparator|Hypothesis 2 Protocol 2 Sham|Sham cerebellar TMS. Delivered twice a day for 5 days.
89415415|NCT03274947|Active Comparator|Hypothesis 2 Protocol 1 Cerebellar TMS|Cerebellar TMS at 10Hz, 250 pulses.
89415416|NCT03274947|Sham Comparator|Hypothesis 2 Protocol 1 Sham|Sham cerebellar TMS
89415417|NCT04990414|Experimental|CBT for voices and dissociation|24 sessions of Cognitive Behavioural Therapy (CBT) over a 6-month period treatment window.
89415418|NCT03069820|Experimental|Study Population|Patients with advanced nasopharyngeal carcinoma scheduled to receive the first line, first cycle TP (docetaxel and cisplatin) chemotherapy
89415419|NCT03605433|Experimental|Oral Anticoagulation+Antiplatelet|Rivaroxaban 2.5 mg twice daily and Aspirin 100 mg once daily.
89415420|NCT03605433|Experimental|Oral Anticoagulation|Rivaroxaban 20 mg once daily
89415421|NCT03605433|Active Comparator|Antiplatet|Aspirin 100 mg once daily
89415422|NCT03071302|Active Comparator|keratoconus|"Evaluation of Visual System Homeobox 1 (VSX1), Superoxide Dismutase (SOD1), Tissue Inhibitors of Metalloproteinases (TIMP3) genes. Keratoconus with fellow eye without topographic and tomographic keratoconous pattern.Evaluation of tomographic datas. Sometimes we picked up the sample of corneal epithelium, and peripheral blood sample from corneal cross linking surgeries, in that case of keratoconus progression.~Group A Keratoconus/ like sound cornea. Group C Keratoconus / Keratoconus~Group C Keratoconus / Keratoconus"
89415423|NCT03071302|Placebo Comparator|sound cornea|"Evaluation of VSX1, SOD1, and TIMP3 genes. To analyze tomographic aspects, we evaluated the patients that underwent to LASIK (Lasei in situ Keratomileusis) with 2 year with follow up without any sign of ectasia To analyze the genes we picked up the sample of corneal epithelium, and peripheral blood sample from PRK (PhotoRefractive Keratectomy) surgeries. These patients showed topographic and tomographic normal pattern.~Group B Sound Cornea / Sound Cornea"
89415424|NCT03606681|Active Comparator|Calcium Hydroxide (Dycal)|Indirect pulp capping treatment with Calcium Hydroxide
89415425|NCT03606681|Experimental|Mineral Trioxide Aggregate (ProRoot MTA)|Indirect pulp capping treatment with Mineral Trioxide Aggregate
89415426|NCT03606681|Experimental|Theracal LC|Indirect pulp capping treatment with Theracal LC
89415427|NCT03071380|Experimental|T test|Test drug (Repatoxaban) 1 tablet contains 10 mg rivaroxaban
88893118|NCT04199351|Experimental|Part A|AMG 171 or placebo, 2 SAD cohorts
89415428|NCT03071380|Active Comparator|B reference|Reference drug (Xarelto) 1 tablet contains 0 mg rivaroxaban
89415429|NCT03070990|Experimental|Arm A: Enfortumab vedotin 1.0 mg/kg|All subjects assigned will receive a single 30 minute intravenous infusion of enfortumab vedotin (ASG-22CE) once weekly for 3 weeks of every 4 weeks (i.e., on Days 1, 8, and 15). A cycle is 28 days.
88893119|NCT04199351|Experimental|Part B|AMG 171 or placebo, 1 MAD cohort
88893120|NCT04199351|Experimental|Part C|AMG 171 or placebo, 3 titration cohorts
88893121|NCT04191733|Experimental|Anterior Approach with KINCISE|Anterior Approach THA using KINCISE(TM) Surgical Automated System
88893122|NCT04191733|Active Comparator|Anterior Approach without KINCISE|Anterior Approach THA with a mallet (without KINCISE)
88893123|NCT04170634||Patients with bone metastases at risk of fracture|Adult patients with tumor osteolytic bone lesions located in proximal femur and/or vertebrae secondary to a myeloma or a breast, lung (NSCL: Non-Small Cell Lung), bladder, thyroid or kidney cancer. The target vertebrae or femur has to be naïve of localized treatment (interventional radiology - cementoplasty, cryotherapy, radiofrequency…). Previous exposure to systemic oncological treatments (chemotherapy, targeted therapy, immunotherapy…) and bone treatments are allowed if administered for less than 3 months.
89415430|NCT03070990|Experimental|Arm B: Enfortumab vedotin 1.25 mg/kg|All subjects assigned will receive a single 30 minute intravenous infusion of enfortumab vedotin (ASG-22CE) once weekly for 3 weeks of every 4 weeks (i.e., on Days 1, 8, and 15). A cycle is 28 days.
89415431|NCT04995718|Experimental|IPET: Intelligent physical exercise training during working hours|Workplace physical exercise
89415432|NCT03605199|Experimental|Denosumab active treatment|Denosumab active treatment
89415433|NCT04986436|Experimental|HS-10360|Either single or multiple doses of varying dose levels
89415434|NCT04986436|Placebo Comparator|Placebo|
89415435|NCT04995250|Experimental|Corrective exercise training for knee Osteoarthritis|
89415436|NCT03606447|Experimental|Single IV administration of [14C]-Uproleselan|
89415437|NCT03074266||Blood coagulation test 1|"Therapeutic: Waste blood from heparinized patients undergoing interventional procedures (standard of care) in different clinical settings will be used to conduct coagulation tests using GEM Hemochron 100 during the course of the procedure before (baseline) and after heparin administration.~There is no drug administration or therapeutic intervention in this study. The interventional procedure (described above) is standard of care and all results of blood coagulation testing using GEM Hemochron 100 performed in this study are not used to influence that care."
89536748|NCT02723201|Experimental|Part 2, Period 1: TAK-020 25 mg CCT|Participants will be randomized to AB or BA crossover where A= Fasted, B =Fed. Sequence I: Single oral dose TAK-020 25 mg, Fasted (A), 7 days washout, single oral dose TAK-020 Fed (B) Sequence II: Single oral dose TAK-020 25 mg, Fed (B), 7 days washout, single oral dose TAK-020 Fasted (A) Dose will be determined from SRD trial and Part 1.
89415438|NCT03074266||Blood coagulation test 2|"Therapeutic: Waste blood from heparinized patients undergoing interventional procedures (standard of care) in different clinical settings will be used to conduct duplicate coagulation tests using Signature Elite during the course of the procedure before (baseline) and after heparin administration.~There is no drug administration or therapeutic intervention conducted in the course of this study. The interventional procedure (described above) is standard of care. The only difference in standard of care is that the blood coagulation test is run in duplicate."
89415439|NCT03605043||Overall cohort|All Persons Living with HIV who enlisted in any one of three high-volume HIV clinics in Tororo District of Eastern Uganda between 2014 and 2017.
89415440|NCT03606369|Experimental|Palonosetron|"Early emesis: Palonosetron 0.25 mg IV + Dexamethasone 12 mg IV + Fosaprepitant 150 mg IV.~Delayed emesis: Dexamethasone 8 mg orally on days 2, 3 and 4."
89415441|NCT03606369|Active Comparator|Ondansetron|"Early emesis: Ondansetron 16 mg IV + Dexamethasone 12 mg IV + Fosaprepitant 150 mg IV.~Delayed emesis: Metoclopramide 10 mg orally every 6 hours + Dexamethasone 8 mg orally every 24 hrs."
89415442|NCT03604965|Experimental|GP+CCRT|GP neoadjuvant chemotherapy followed by cisplatin chemotherapy concurrent combined with intensity-modulated radiation therapy
89415443|NCT03604965|Active Comparator|TPF+CCRT|TPF neoadjuvant chemotherapy followed by cisplatin chemotherapy concurrent combined with intensity-modulated radiation therapy
89415444|NCT02237313|Experimental|prevalent cases|"40 prevalent cases correspond to patients with known pemphigus. Emphasis will be on included patients at different times of the course of their disease.~8 incident cases recruited through the center of Rouen and following an intervention program with psychological support and therapeutic education program"
89415445|NCT02635204|Experimental|DFD-06 Cream|DFD-06 Cream will be applied to subjects with moderate plaque psoriasis twice daily for 14 days.
89415446|NCT02635204|Placebo Comparator|Vehicle Cream|Vehicle Cream will be applied to subjects with moderate plaque psoriasis twice daily for 14 days.
89415447|NCT03604887||study group|All pregnant women who will attend the labor unit during the study period will be invited to participate in the study.
89415448|NCT03074032|Experimental|ONC1-0013B 40 mg|ONC1-0013B 40 mg per os daily
89415449|NCT03074032|Experimental|ONC1-0013B 80 mg|ONC1-0013B 80 mg per os daily
89415450|NCT03074032|Experimental|ONC1-0013B 160 mg|ONC1-0013B 160 mg per os daily
89415451|NCT03074032|Experimental|ONC1-0013B 320 mg|ONC1-0013B 320 mg per os daily
89415452|NCT03606603||Surgical patients|Adult patients after elective major abdominal gastrointestinal surgery with pre-existing malnutrition or who are at significant risk for malnutrition or nutrition-related complications, with indications for nutritional support
89415453|NCT00102804|Experimental|Pemetrexed and Best Supportive Care|
89415454|NCT00102804|Placebo Comparator|Placebo and Best Supportive Care|
88893124|NCT04170335||Bariatric surgery group|Women older than age 40 and younger than age 74 undergoing primary bariatric surgery and having a BMI of ≥35 will be enrolled in this study. Pre operative and postoperative mammograms, inflammatory markers and breast cancer risk scores will be compared.
89415455|NCT04989634|Active Comparator|standard care|In the early pregnancy ( 8-12 weeks of pregnancy ) , a group education on dietary weight management will be carried out according to the current medical system and the regulations of our hospital , followed by routine prenatal examination . According to the corresponding diagnosis and treatment guidelines, examinations and follow-up interventions will be carried out if the metabolic diseases are occurred during pregnancy.
89415456|NCT04989634|Experimental|dietary and weight management|A randomized controlled trial in pregnant women will be initiated at 8-12 weeks of gestation util delivery. The intervention contents included health education , nutritional analysis and individualized dietary guidance combined with mobile medical treatment and face-to-face teaching during the early , middle and late pregnancy stages.
89415457|NCT01814072|Experimental|Condition 1|1) Lifestyle Core; 2) 12 Telephone Coaching Sessions; 3) Report to Primary Care Physician
89536749|NCT02723201|Experimental|Part- 3 Cohort 1: TAK-020 Solid Formulation|Single oral dose on Day 1. Dose will be determined from SRD trial and Parts 1 and 2
89536750|NCT02723201|Experimental|Part 3 Cohort 2: TAK-020 Solid Formulation|Single oral dose on Day 1. Dose will be determined from SRD trial and Parts 1 and 2
88893125|NCT04163640|Experimental|Intervention Group|Patients randomized to this group will receive the intra-ovarian platelet rich plasma injection
88893126|NCT04163640|No Intervention|Control Group|Patients randomized to this group will not receive the intra-ovarian platelet rich plasma injection
89415458|NCT01814072|Experimental|Condition 2|1) Lifestyle Core; 2) 12 telephone sessions; 3) Report to Primary Care Physician; 4) Recommendations to use meal replacements; 5) Buddy training via webinars
89415459|NCT01814072|Experimental|Condition 3|1) Lifestyle Core; 2) 12 telephone sessions; 3) Report to Primary Care Physician; 4) Regular text messages; 5) Buddy training via webinars
89415460|NCT01814072|Experimental|Condition 4|1) Lifestyle Core; 2) 12 telephone sessions; 3) Report to Primary Care Physician; 4) Recommendation to use meal replacements; 5) Regular text messages
89415461|NCT01814072|Experimental|Condition 5|1) Lifestyle Core; 2) 12 telephone sessions; 3) Buddy training via webinars
89415462|NCT01814072|Experimental|Condition 6|1) Lifestyle Core; 2) 12 telephone coaching sessions; 3) Recommendations to use meal replacements
89415463|NCT01814072|Experimental|Condition 7|1) Lifestyle Core; 2) 12 telephone sessions; 3) Regular text messages
89415464|NCT01814072|Experimental|Condition 8|1) Lifestyle Core; 2) 12 telephone sessions; 3) Recommendation to use meal replacements; 4) Regular text messages, 5) Buddy training via webinars
89415465|NCT01814072|Experimental|Condition 9|1) Lifestyle Core; 2) 24 telephone coaching sessions; 3) Report to Primary Care Physician
89415466|NCT01814072|Experimental|Condition 10|1) Lifestyle Core; 2) 24 telephone sessions; 3) Report to Primary Care Physician; 4) Recommendation to use meal replacements; 5) Buddy training via webinars
89415467|NCT01814072|Experimental|Condition 11|1) Lifestyle Core; 2) 24 telephone sessions; 3) Report to Primary Care Physician; 4) Regular text messages; 5) Buddy training via webinars
89536751|NCT03193931|Experimental|Arm A|Pembrolizumab 200 mg q3w i.v. until disease progression or non-tolerable toxicity (maximum 2 years)
88922125|NCT05773053|Experimental|NT 201 Dose 1|Subjects will receive Dose 1.
88922126|NCT05773053|Experimental|NT 201 Dose 2|Subjects will receive Dose 2.
89415468|NCT01814072|Experimental|Condition 12|1) Lifestyle Core; 2) 24 telephone sessions; 3) Report to Primary Care Physician; 4) Recommendation to use meal replacements; 5) Regular text messages
89415469|NCT01814072|Experimental|Condition 13|1) Lifestyle Core; 2) 24 telephone sessions; 3) Buddy training via webinars
89415470|NCT01814072|Experimental|Condition 14|1) Lifestyle Core; 2) 24 telephone coaching sessions; 3) Recommendation to use meal replacements
89415471|NCT01814072|Experimental|Condition 15|1) Lifestyle Core; 2) 24 telephone sessions; 3) Regular text messages
89415472|NCT01814072|Experimental|Condition 16|1) Lifestyle Core; 2) 24 telephone sessions; 3) Recommendation to use meal replacements; 4) Regular text messages, 5) Buddy training via webinars
89415473|NCT01814072|Experimental|Condition 17|1) Lifestyle Core; 2) 12 Telephone Coaching Sessions
89415474|NCT01814072|Experimental|Condition 18|1) Lifestyle Core; 2) 12 telephone sessions; 3) Recommendations to use meal replacements; 4) Buddy training via webinars
89005956|NCT04663672|Placebo Comparator|Exposure Therapy + Novel Scent During Sleep|Participants will undergo exposure treatment for their target fear while in the presence of a distinctive odor. Exposure will occur in repeated 4-minute trials. Exposure will continue for 40 minutes or until peak fear decreases by at least 35 points on a 100 point scale, compared to peak fear during the initial trial. Participants will subsequently sleep in the presence of a novel scent.
89415475|NCT01814072|Experimental|Condition 19|1) Lifestyle Core; 2) 12 telephone sessions; 3) Regular text messages; 4) Buddy training via webinars
89415476|NCT01814072|Experimental|Condition 20|1) Lifestyle Core; 2) 12 telephone sessions; 3) Regular text messages; 4) Recommendation to use meal replacements
89005957|NCT04663672|Sham Comparator|Exposure Therapy + No-Scent Control During Sleep|Participants will undergo exposure treatment for their target fear while in the presence of a distinctive odor. Exposure will occur in repeated 4-minute trials. Exposure will continue for 40 minutes or until peak fear decreases by at least 35 points on a 100 point scale, compared to peak fear during the initial trial. Participants will subsequently sleep in the presence of an odorless control vehicle.
89005958|NCT04663048|Experimental|Protocol A|PiXL treatment with pulsed UV illumination (1.0 sec on /0.8 sec off) in high oxygen in a central ring-shaped 3.5-mm zone of the cornea and total illumination time of 10 min. The area consist of three rings with a central 1.5-mm zone that is left untreated. The illumination area consists of three rings, where the outer and inner ring are thinner than the middle ring. The maximum energy is distributed in the middle ring.
89415477|NCT01814072|Experimental|Condition 21|1) Lifestyle Core; 2) 12 telephone sessions; 3) Report to Primary Care Physician; 4) Buddy training via webinars
89005959|NCT04663048|Active Comparator|Protocol B|PiXL treatment with pulsed (0.5 sec on / 1 sec off) UV illumination in high oxygen in a central ring-shaped 3.5-mm zone of the cornea and total illumination time of 16:40 min. The area consist of three rings with a central 1.5-mm zone that is left untreated. The illumination area consists of three rings, where the outer and inner ring are thinner than the middle ring. The maximum energy is distributed in the middle ring.
89005960|NCT04663009||Mechanical chest compression|Patients recieving LDB CPR
89005961|NCT04663009||Manual chest compressions|Patients recieving manual CPR
89415478|NCT01814072|Experimental|Condition 22|1) Lifestyle Core; 2) 12 telephone coaching sessions; 3) Report to Primary Care Physician; 4) Recommendations to use meal replacements
89005962|NCT04663165|Other|Flap surgery alone|Access flap
89005963|NCT04663165|Other|Flap surgery with adjunctive EMD|Access flap and adjunctive enamel matrix derivative
89005964|NCT04663243|Experimental|Quasi experimental study|Before intervention and after intervention comparison
89005965|NCT00241254|Experimental|1|Cyclophosphamide
89415479|NCT01814072|Experimental|Condition 23|1) Lifestyle Core; 2) 12 telephone sessions; 3) Report to Primary Care Physician; 4) Regular text messages
89415480|NCT01814072|Experimental|Condition 24|1) Lifestyle Core; 2) 12 telephone sessions; 3) Report to Primary Care Physician; 4) Recommendation to use meal replacements; 5) Regular text messages, 6) Buddy training via webinars
89415481|NCT01814072|Experimental|Condition 25|1) Lifestyle Core; 2) 24 telephone coaching sessions
89415482|NCT01814072|Experimental|Condition 26|1) Lifestyle Core; 2) 24 telephone sessions; 3) Recommendation to use meal replacements; 4) Buddy training via webinars
89415483|NCT01814072|Experimental|Condition 27|1) Lifestyle Core; 2) 24 telephone sessions; 3) Regular text messages; 4) Buddy training via webinars
89415484|NCT01814072|Experimental|Condition 28|1) Lifestyle Core; 2) 24 telephone sessions; 3) Regular text messages; 4) Recommendation to use meal replacements
89415485|NCT01814072|Experimental|Condition 29|1) Lifestyle Core; 2) 24 telephone sessions; 3) Report to Primary Care Physician; 4) Buddy training via webinars
89415486|NCT01814072|Experimental|Condition 30|1) Lifestyle Core; 2) 24 telephone coaching sessions; 3) Report to Primary Care Physician; 4) Recommendation to use meal replacements
89415487|NCT01814072|Experimental|Condition 31|1) Lifestyle Core; 2) 24 telephone sessions; 3) Report to Primary Care Physician; 4) Regular text messages
89415488|NCT01814072|Experimental|Condition 32|1) Lifestyle Core; 2) 24 telephone sessions; 3) Report to Primary Care Physician; 4) Recommendation to use meal replacements; 5) Regular text messages, 6) Buddy training via webinars
89415489|NCT04986124||MDD patients|No intervention.
89415490|NCT02167152|Experimental|Ischemic Preconditioning Group|Participants randomized to this group will have a blood pressure cuff placed on each arm, and these cuffs will be inflated one at a time to a pressure calculated based on the person's blood pressure.
89415491|NCT02167152|Active Comparator|Control Group|Participants randomized to this group will have a blood pressure cuff placed on each arm, and these cuffs will be inflated one at a time to a set pressure (30mmHg, or millimeters of mercury on a blood pressure measuring machine).
89415492|NCT03038113|Experimental|Part 1: Single-Ascending Dose (SAD)|Healthy volunteers will be enrolled in up to 8 cohorts with doses starting from 0.1 mg/kg and escalating sequentially after review of safety and pharmacokinetic (PK) data.
89415493|NCT03038113|Experimental|Part 2: Multiple Ascending Dose|Participants with Chronic Hepatitis B will enrolled in Part 2. In Part 2a, participants will receive two monthly injections of either 3 doses equivalent to a multiple of the saturation dose or placebo in a 1:1:1:1 ratio. In Part 2b, a dose selected from Part 2a will be administered to participants randomized into 4 cohorts where they will be dosed weekly (QW) or bi-weekly (Q2W). Each of the cohorts in Part 2b will include participants receiving active drug or placebo in a 3:1 ratio. In Part 2c, NUC-suppressed CHB participants will receive either RO7062931+NUC for up to 24 weeks, or RO7062931+NUC+an immune modulator for up to 48 weeks, at a dose determined from Part 2a and 2b. Part 2c may also enroll treatment-naive immune-active CHB participants.
89415494|NCT02160210|Experimental|Ultrafine Endoscope|The ultrafine endoscope for colonoscopy with water method is performed in screening the colorectal diseases.
89415495|NCT02163642||Non-CF Bronchiectasis|Cyranose® 320
89415496|NCT02163720||Yondelis®-Caelyx®-relapse ovarian cancer|Yondelis®-Caelyx®-relapse ovarian cancer
89415497|NCT04995640||CILCA patients|Subject with a CILCA and a thoracic cardiovascular disease requiring treatment. Both open cardiovascular repair and endovascular treatment (TEVAR) will be included.
89415498|NCT03487952||LDCT screening group|People receive questionnaire administration at baseline, then subsequent yearly chest LDCT scan and follow up.
89415499|NCT02163798|Experimental|Tai Chi Group|Participants in this group received a 12-week instructor-led Tai Chi training program.
89415500|NCT02163798|Experimental|Walking Group|Participants in this group received a 12-week instructor-led brisk walking training program.
88893127|NCT04149249|Experimental|Experimental: Intervention Group (CONNECT)|Patients complete CONNECT, the Video Doctor over 30-45 minutes on an iPad in the waiting room before their lung cancer screening test appointment.
88893128|NCT04149249|Active Comparator|Control Group|"Patients complete CONNECT assessment only over 30-45 minutes on an iPad in the waiting room before their lung cancer screening test appointment.~Individuals who are randomized to the control group will undergo the same assessment questions and all follow up assessments like the intervention group. Instead of viewing and participating in the interactive Video Doctor about Smoking Cessation, they receive a handout containing smoking cessation resources."
89415501|NCT02163798|No Intervention|Control Group|Participants in the control group did not receive intervention during the 12 weeks, and were told that they would be provided two sessions of free health and fitness evaluation with an interval of three months (12 weeks).
88893130|NCT04049097|Experimental|Arimoclomol|248 mg arimoclomol base (equivalent to 400 mg arimoclomol citrate) 3 times daily
89415502|NCT04461002||Cohort|Retrospective cohort
89415503|NCT04985578|Experimental|Dry needling Group|The experimental extremity will be assigned randomly and will receive a single treatment session of TrP dry needling as follows: the therapist will located the TrP that refers the most pain and will apply manual compression until the participant will reported pain. After that, dry needling technique will be performed on the TrP for 60 seconds.
89415504|NCT04985578|Placebo Comparator|Sham dry needling|The experimental extremity will be assigned randomly and will receive a single treatment session of TrP sham dry needling as follows: the therapist will located the TrP that refers the most pain and will apply manual compression until the participant will reported pain. After that, sham dry needling technique will be performed on the TrP for 60 seconds with a needle without tip.
89415505|NCT04985578|No Intervention|Control|No Treatment will be perfomed in this group
89415506|NCT03487874|Experimental|Interscalene block with C8 root block|The 5th to 8th cervical nerve root block under ultrasound guidance using 25 to 30 ml of 0.75% ropivacaine
89415507|NCT03487874|Active Comparator|Conventional interscalene block|The 5th to 7th cervical nerve root block under ultrasound guidance using 25 to 30 ml of 0.75% ropivacaine
89415508|NCT03074110|Active Comparator|Isocapnic hyperventilation|After end of surgery, hyperventilation and administration of a small, precalculated amount of CO2 into the breathing circuit will be performed.
89415509|NCT03074110|No Intervention|Standard procedure|After end of surgery, patients will be subdued to a standard weaning procedure.
89415510|NCT02160366||Biomarker/Molecular Data Collection and Analyzation|Advanced cancer participants
88893131|NCT04033679|Experimental|Active TDCS|In the active condition, a constant current of 2 mA intensity will be applied for 20 min to the parietal regions, using P3 as the cathode and P4 as the anode.
89415511|NCT04989400|Experimental|ulipristal group|received Ulipristal acetate 30mg, starting misoprostol 12 hours later 100µg every 6 hours buccal according to FIGO guidelines 2017,Then women had rest for 24 hours after 5 doses of misoprostol and restarted misoprostol-only in both groups with the same above regimens, repeating the same sequence for two weeks unless there was excessive bleeding or infection or uterine contractions or cervical changes. If failed, patient proceeded to hysterotomy
89415512|NCT04989400|Placebo Comparator|placebo|received placebo tablet of same shape , texture of that of ulipristal then 12 hours later start misoprostol 100µg every 6 hours buccal according to FIGO guidelines 2017. Then women in had rest for 24 hours after 5 doses of misoprostol and restarted misoprostol-only in both groups with the same above regimens, repeating the same sequence for two weeks unless there was excessive bleeding or infection or uterine contractions or cervical changes. If failed, patient proceeded to hysterotomy
89415513|NCT02167230|Experimental|Jailed-balloon technique|Apply jailed-balloon technique to protect the side branch during coronary bifurcation PCI
89415514|NCT02167230|Active Comparator|Jailed-wire technique|Apply jailed-wire technique to protect the side branch during coronary bifurcation PCI
89415515|NCT04989088|Experimental|Left theta/beta and right beta/theta NF training|
89415516|NCT04989088|Placebo Comparator|Sham NF training|
89415517|NCT03485768|Experimental|percutaneous disc decompression with coblation nucleoplasty|PDCN will be performed in patients who are allocated to this group by using the COBLATION Perc-DC SpineWand surgical device (ArthroCare System 2000, ArthroCare corporation, Heredia, Costa Rica, USA)
89415518|NCT03485768|Active Comparator|Manual Therapy|Participants who are allocated to this group will undergo manual therapy treatments containing two kinds: sustained natural apophyseal glides (SNAGs) plus passive joint mobilisations (PJMs)
89415519|NCT02163954|Active Comparator|Clopidogrel|Patients treated with clopidogrel for 14 days
89415520|NCT02163954|Experimental|Ticagrelor|Patients treated with ticagrelor for 14 days
89415521|NCT04985656|Experimental|Pevonedistat 20 mg/m^2 + Decitabine 35 mg + Cedazuridine 100 mg|Pevonedistat 20 mg/m^2, 60-minute intravenous (IV) infusion, once daily, on Days 1, 3, and 5 in each 28-day cycle in combination with decitabine 35 mg and cedazuridine 100 mg tablets, orally, once daily on Days 1 through 5 in each 28-day cycle up to 30 months.
89415522|NCT03485690||COPD|COPD patients with no restrictions. The study protocol does not consider ad-hoc different patient groups. Prospective follow-up will be equally done in all recruited patients
89415523|NCT02167308|Active Comparator|Laser acupuncture group|Subjects will receive 24 activated laser acupuncture treatments. The laser will be applied for 10 seconds to each of the selected acupuncture points.
89415524|NCT02167308|Sham Comparator|Control group|Subjects in the control group will undergo sham laser acupuncture treatment with no laser power output. Acupuncture points, application duration, and total number of treatments will be identical to the Laser acupuncture group.
89415525|NCT03071224|Experimental|[18F]MNI-946|To evaluate [18F]MK-6240 (also known as [18F]MNI-946) a tau targeted radiopharmaceutical.
89415526|NCT04682990|Experimental|Pulmonary TB|"This arm will enroll 80-100 patients older than 18 years old, from the Center of Respiratory Diseases in Douala, with pulmonary TB proved by TB LAMP test.~Interventions:~They will be asked to perform a breath exhalation with a nose clamp.~Medical History: Symptom based Survey, Physical Exam,and HIV status.~Other interventions:~Sputum samples for Ziehl Neelsen smear or Culture in L-J or GeneXpert MTB/RIF;~Chest X-ray Follow Up 5 days after beginning of Tx Follow Up 15 days after beginning of Tx Follow Up 30 days after beginning of Tx"
89415527|NCT04682990|Active Comparator|Non Pulmonary TB|"This arm will enroll 50-100 patients older than 18 years old, from the Center of Respiratory Diseases in Douala, with Negative pulmonary TB status proved by TB LAMP test. These Negative TB patients can be healthy controls or TB suspects.~Interventions:~They will be asked to perform a breath exhalation with a nose clamp. Medical History: Symptom based Survey, and HIV status.~Other interventions:~Sputum samples for Ziehl Neelsen smear or Culture in L-J GeneXpert MTB/RIF;~Chest X-ray."
89415528|NCT02164032|Placebo Comparator|Insulin dilution buffer|"During a subsequent 4-week treatment phase subjects will be randomly assigned to receive intranasal insulin (40 IE) Actrapid (100IE/mL); two 0.1 ml puffs per nostril) or placebo (insulin dilution buffer Novo Nordisk; two 0.1 ml puffs per nostril) four times a day (in total 160 IE Actrapid per day) before each main meal and before going to bed. 40 IE IN insulin enhances insulin concentration in the CSF without any changes in systemic insulin and glucose concentration, and no risk for hypoglycemia.~Ectopic lipid content and heart function will be assessed weekly by non-invasive 1H magnetic resonance spectroscopy."
89415529|NCT02164032|Active Comparator|Intranasal Insulin administration|"During a subsequent 4-week treatment phase subjects will be randomly assigned to receive intranasal insulin (40 IE) Actrapid (100IE/mL); two 0.1 ml puffs per nostril) or placebo (insulin dilution buffer Novo Nordisk; two 0.1 ml puffs per nostril) four times a day (in total 160 IE Actrapid per day) before each main meal and before going to bed. 40 IE IN insulin enhances insulin concentration in the CSF without any changes in systemic insulin and glucose concentration, and no risk for hypoglycemia.~Ectopic lipid content and heart function will be assessed weekly by non-invasive 1H magnetic resonance spectroscopy."
89415530|NCT04985734|Experimental|Patients under diagnostic work-up|
89415531|NCT04682288|Experimental|Levofloxacin Ocular Implant|Biphasic levofloxacin antibiotic implant
89415532|NCT00968149|Experimental|1|Montelukast
89415533|NCT00968149|Placebo Comparator|2|Placebo
89415534|NCT02160444|Experimental|CBT plus Parent as CBT Coach Training|CBT plus Parent as CBT Coach Training
89415535|NCT02160522||Cuffed ETT|Patients that are intubated with a cuffed endotracheal tube.
89415536|NCT02167386|Experimental|Enhanced PrEP Adherence|Enhanced PrEP Adherence: peer navigators, PrEP support group, on-line support group, text message reminders
89415537|NCT02167386|Active Comparator|Standard PrEP Adherence|Standard PrEP Adherence: support groups, case management
89415538|NCT03989882|Experimental|Wheat germ|Wheat germ energy balls containing 30 g of wheat germ, peanut butter, and honey to form 2 energy balls that is approximately 200 kcal. Two energy balls will be consumed daily for 30 days.
89415539|NCT03989882|Placebo Comparator|Control|Control energy ball containing 30 g of cornmeal, peanut butter, and honey to form 2 energy balls that is approximately 200 kcal. Two energy balls will be consumed daily for 30 days.
88922127|NCT05773053|Experimental|NT 201 Dose 3|Subjects will receive Dose 3.
89415540|NCT02164110|Experimental|Euvichol|"Number of doses and intervals: two doses/Weeks 0 and 2~Method of administration: oral administration~Dose of drug to be administered: 1.5 mL/dose"
89415541|NCT02164110|Active Comparator|Shanchol|"Number of doses and intervals: two doses/Weeks 0 and 2~Method of administration: oral administration~Dose of drug to be administered: 1.5 mL/dose"
89415542|NCT03489512|Experimental|A (Chloraprep)|2% chlorhexidine gluconate with 70% isopropyl alcohol with a sterile 3ml single dose applicator. Use for the preparation of the skin before insertion of the central venous catheters and at each dressing change.
89415543|NCT03489512|Active Comparator|B (Clorhexidine 2%)|2% aqueous base chlorhexidine (10 ml single dose containers). Use for the preparation of the skin before insertion of the central venous catheters and at each dressing change.
89415544|NCT02167464|Active Comparator|Aldosterone Antagonist|Prescribe an aldosterone antagonist such as Spironolactone 12.5-25 mg daily as a starting dose with a maximum recommended dose of 50 mg daily.
89415545|NCT02167464|Active Comparator|Referral Hypertension specialist|Referral to a hypertension specialist
89415546|NCT02167464|Active Comparator|Renin treatment-guided therapeutics|Renin treatment-guided therapeutics. A treatment algorithm is provided to guide treatment based upon renin levels.
89415547|NCT02167464|Active Comparator|Renin-guided therapeutics and referral|Renin treatment-guided therapeutics and referral to hypertension specialist. Treatment based upon algorithm for treatment related to renin level in addition to referral to a hypertension specialist.
89415548|NCT03485612||change of the optic nerve sheath diameter|The test group will be male and female patients, aged over 18 and below 90 years of age. Each patient will be operated for urological reasons in the position for lithotomy.
89415549|NCT05200351|Experimental|EAT Intervention|15 sessions of EAT
89415550|NCT02164188|No Intervention|control|Initially this control group will not receive an intervention (wait list). After 8 weeks this goup will receive the Flourishing protocol (cross over).
89415551|NCT02164188|Experimental|Flourishing protocol|This group will receive the intervention Flourishing protocol and after that it will not receive any other intervention (cross over).
89005966|NCT00241254|Active Comparator|2|Methylprednisolone
89415552|NCT03485456|Experimental|Tobramycin|Tobramycin dry powder inhalation with 30, 60 and 90 mg. Nebulisation with 300 mg tobramycin
89415553|NCT03734250||Group Sugammadex HD|Sugammadex used as neuromuscular blocker reverse agent with Vitamin D status equal or above 30ng/ml
89415554|NCT03734250||Group neostigmine HD|Neostigmine used as neuromuscular blocker reverse agent with Vitamin D status equal or above 30 ng/ml
89415555|NCT03734250||Group Sugammadex LD|Sugammadex used as neuromuscular reverse agent with Vitamin D status under 30 ng/ml
89415556|NCT03734250||Group Neostigmine LD|Neostigmine used as neuromuscular reverse agent with Vitamin D status under 30ng/ml
89415557|NCT03487562|Experimental|Sequence 1|Part I: A-B-D-C A: DWP14012 A mg bid B: DWP14012 A mg bid + Clarithromycin 500 mg bid C: DWP14012 A mg bid + Clarithromycin 500 mg bid + Amoxicillin 1 g bid D: Clarithromycin 500 mg bid + Amoxicillin 1 g bid
89005967|NCT04662775|Experimental|Intervention group|This group received the multi-component physical activity intervention (physical activity programme, weekly behaviour change support calls, non-reply text messages)
89005968|NCT04662775|No Intervention|Waitlist control|Participants in the wait-list control group were asked to continue their usual PA habits and received no additional contact from the research team outside of data collection points. Following post-intervention data collection, control group participants were invited to participate in the same intervention as described above.
89005969|NCT04662814|Experimental|shock wave|shock wave for primary dysmenorrhea for study group along side to dietary modification
89005970|NCT04662814|Active Comparator|dietary modification|dietary modification for primary dysmenorrhea for control group
89415558|NCT03487562|Experimental|Sequence 2|Part I: B-C-A-D A: DWP14012 A mg bid B: DWP14012 A mg bid + Clarithromycin 500 mg bid C: DWP14012 A mg bid + Clarithromycin 500 mg bid + Amoxicillin 1 g bid D: Clarithromycin 500 mg bid + Amoxicillin 1 g bid
89415559|NCT03487562|Experimental|Sequence 3|Part I: C-D-B-A A: DWP14012 A mg bid B: DWP14012 A mg bid + Clarithromycin 500 mg bid C: DWP14012 A mg bid + Clarithromycin 500 mg bid + Amoxicillin 1 g bid D: Clarithromycin 500 mg bid + Amoxicillin 1 g bid
89415560|NCT03487562|Experimental|Sequence 4|Part I: D-A-C-B A: DWP14012 A mg bid B: DWP14012 A mg bid + Clarithromycin 500 mg bid C: DWP14012 A mg bid + Clarithromycin 500 mg bid + Amoxicillin 1 g bid D: Clarithromycin 500 mg bid + Amoxicillin 1 g bid
89415561|NCT03487562|Experimental|A|Part II: (DWP14012 B mg + Clarithromycin 500 mg + Amoxicillin 1g) bid
89415562|NCT03487562|Experimental|B|Part II: (DWP14012 A mg + Clarithromycin 500 mg + Amoxicillin 1g) bid
89415563|NCT03487562|Experimental|C|Part II: (Lansoprazole 30 mg + Clarithromycin 500 mg + Amoxicillin 1g) bid
89415564|NCT02160600|Experimental|split bolus|Patients will undergo diagnostic Split bolus DECT scan
89415565|NCT02160600|Experimental|Standard|Patients will undergo routine multiphase diagnostic CT
89005971|NCT04662736||patients having had a BJI/PJI treated with tedizolid as a suppressive antibiotic therapy|
89005972|NCT04662853||Patients with positive results in the fecal occult blood test.|Patients with positive results in the fecal occult blood test in the Program for Early Detection of Colon and Rectal Cancer, undergone by the Consejeria de Salud de la Junta de Andalucia (Spain), were invited to participate in the CCR-microbiome study. This program is screening Andalusian population aged between 50 and 69 years old for colo-rectal cancer presence by fecal occult blood test, and further colonoscopy when positive for this test. Patients included in CCR-microbiome study were recruited between January 2017 and March 2020, at the Reina Sofia University Hospital (Cordoba, Spain) with the consumption of antibiotic within the previous month as exclusion criteria.
89415566|NCT03541434||Healthy|Children with no history of adenotonsillar hypertrophy, recurrent tonsillitis, or middle ear effusion. They presented to the clinic for examination or a scheduled procedure.
89415567|NCT03541434||Recurrent tonsillitis|Children with a history of recurret tonsillitis but no adenotonsillar hypertrophy. Diagnosis was based on physical exam and complete blood count. They presented to the clinic for a sceduled tonsillectomy.
89415568|NCT03541434||Middle ear effusion|Children with chronic middle ear effusion but no adenotonsillar hypertrophy. Diagnosis was based on physical exam and tympanometry. They presented to the clinic for scheduled myringotomy with or without adenoidectomy.
89415569|NCT03541434||Adenotonsillar hypertrophy|Children with tonsillar and/or adenoidal hypertrophy. Diagnosis was based on physical exam and partly on x-ray of nasopharynx or nasopharyngoscopy. They presented to the clinic for scheduled tonsillectomy and/or adenoidectomy.
89415570|NCT05150522|Experimental|BCMA CAR-T|BCMA CAR-T cells infusion
89415571|NCT02167542|Experimental|NPPV group|Patients assigned to noninvasive positive pressure ventilation (NPPV) are connected to the ventilator through a face mask (VBM Endoscopy Mask) that is secured to the patient's face by the investigator.
89415572|NCT02167542|Active Comparator|CPAP valve group|Patients assigned to CPAP valve (Boussignac valve, Vygon, Inc) are connected to this device through a standard face mask that is secured to the patient's face with elastic straps.
88893132|NCT04033679|Sham Comparator|Sham TDCS|In the sham condition, stimulation will be administered using the same parameters at the site of active treatment, but the current will be turned off after 30 seconds.
88893133|NCT04023253|Experimental|mirabegron|Receive mirabegron 2 mg treatment per day
88893134|NCT04023253|Experimental|solifenacin|Receive solifenacin 5 mg treatment per day
88893135|NCT04017793|Active Comparator|Mindfulness Based Stress Reduction Program|
88893136|NCT04017793|Active Comparator|Relaxation Group|
88893137|NCT04007029|Experimental|Treatment (fludarabine, cyclophosphamide, CD19/CD20 T-cells)|"CONDITIONING CHEMOTHERAPY: Patients receive fludarabine phosphate IV over 30 minutes and cyclophosphamide IV over 60 minutes 5, 4, and 3 days before cell infusion.~T-CELL INFUSION: Patients receive CD19/CD20 CAR-T cells IV on day 0. Patients with cytokine release syndrome may also receive tocilizumab IV on day 2 at the discretion of the clinical investigator."
88893138|NCT04003051|Experimental|Supportive Care (Project Prepare website)|Patients use the password-protected Project Prepare website on a computer, tablet, or phone over 10 weeks to view: videos of the swallowing and trismus exercises, tips and stories from former patients, what to expect each week of treatment, recipes and cooking demonstrations, how to take care of their teeth during treatment, strategies for stress relief, and strategies for dry mouth and nausea. This website is designed to reach underserved populations who do not have ready access to specialized preventive care.
88893139|NCT04002310|Experimental|0.3 mg BI 754132 - SRD part|0.3 milligram (mg) BI 754132 powder for solution for injection 60mg/vial with solution of diluent was administered intravitreally as one single injection on Day 1. One patient was dosed first, and when the safety assessments through Day 4 showed no ophthalmological dose limiting events (DLEs) or systemic DLEs, the remaining patients were dosed. Single rising dose (SRD) part.
88893140|NCT04002310|Experimental|1 mg BI 754132 - SRD part|1 mg BI 754132 powder for solution for injection 60mg/vial with solution of diluent was administered intravitreally as one single injection on Day 1. One patient was dosed first, and when the safety assessments through Day 4 showed no ophthalmological dose limiting events (DLEs) or systemic DLEs, the remaining patients were dosed. SRD part.
88893141|NCT04002310|Experimental|3 mg BI 754132 - SRD part|3 mg BI 754132 powder for solution for injection 60mg/vial with solution of diluent was administered intravitreally as one single injection on Day 1. One patient was dosed first, and when the safety assessments through Day 4 showed no ophthalmological dose limiting events (DLEs) or systemic DLEs, the remaining patients were dosed. SRD part.
88893142|NCT04002310|Experimental|6 mg BI 754132 - SRD part|6 mg BI 754132 powder for solution for injection 60mg/vial with solution of diluent was administered intravitreally as one single injection on Day 1. One patient was dosed first, and when the safety assessments through Day 4 showed no ophthalmological dose limiting events (DLEs) or systemic DLEs, the remaining patients were dosed. SRD part.
88893143|NCT04002310|Experimental|6 mg BI 754132 - MD part|6 mg BI 754132 powder for solution for injection 60mg/vial with solution of diluent was administered intravitreally as 3 injections, each separated by 4 weeks (that is, Day 1, Day 29 and Day 57). Multiple dose.
88893144|NCT03982511|Experimental|PCIT-Health|Participants assigned to the PCIT-Health arm will receive the intervention.
88893145|NCT03982511|No Intervention|Wait list control|Participants in the wait list control will receive an invitation to participate in the intervention 10 months after baseline data collection.
88893146|NCT03959631|Experimental|Intervention group|The intervention group will be offered participation for 6 months in a Virtual Communities of practice based on a web 2.0 platform in which there is interaction with other patients and with a multidisciplinary team of professionals. The intervention will be co-designed with a group of patients and a group of primary and specialized care professionals.
89415573|NCT02167620|Placebo Comparator|Metformin|Metformin/ placebo will be dispensed on a biweekly basis, and pill counts conducted at each visit.
89415574|NCT02167620|Placebo Comparator|Placebo|Metformin/ placebo will be dispensed on a biweekly basis, and pill counts conducted at each visit.
89415575|NCT03485300||Patients with chronic liver or kidney diseases|"Patients with chronic liver diseases may affect warfarin therapeutic outcome as liver is the site of metabolism of the drug by cytochrome p 450 enzymes so it decrease warfarin absorption~Kidney diseases also affect the clearance of the drug these patients will undergo liver function tests and kidney function tests"
89415576|NCT03485300||Non compliance of the patient|Missed dose of the warfarin or intermittent drug intake may affect drug therapeutic outcome as well as changing time of drug administration during the day
89415577|NCT03485300||Drugs or food interactions|Administration of other drugs beside warfarin may affect its therapeutic outcome either by inhibition or synergism certain food may also interfere with warfarin especially vitamin k and c rich food so patients will be followed up for drug or food interactions
88893147|NCT03959631|No Intervention|Control group|The control group will not receive any specific intervention. They receive usual care according to actually clinical practice guidelines.
88893148|NCT03905525|Experimental|Cohort 1 /Arm A|CFZ533 dose 1
89193093|NCT05584098|Other|qSOFA and MEWS|Modified Early Warning Score(MEWS) and quick Sequential Organ Failure Assessment(qSOFA) are used in prediction of occurrence of sepsis
89415578|NCT02160756|Active Comparator|Treatment A|Single oral dose of JNJ-56021927 240 milligram (mg) softgel capsule on Day 1.
89415579|NCT02160756|Experimental|Treatment B|Single oral dose of JNJ-56021927 240 mg Tablet Formulation 1 on Day 1.
89415580|NCT02160756|Experimental|Treatment C|Single oral dose of JNJ-56021927 240 mg Tablet Formulation 2 on Day 1.
89415581|NCT02160756|Experimental|Treatment D|Single oral dose of JNJ-56021927 240 mg Tablet Formulation 3 on Day 1.
88893149|NCT03905525|Experimental|Cohort 1/Arm B|CFZ533 dose 2
88893150|NCT03905525|Experimental|Cohort 1/Arm C|CFZ533 dose 3
88893151|NCT03905525|Placebo Comparator|Cohort 1/Arm D|Placebo dose (up to week 24)
88893152|NCT03905525|Experimental|Cohort 1/Arm D1|CFZ533 dose 1 (from week 24)
88893153|NCT03905525|Experimental|Cohort 2/Arm E|CFZ533 dose 1
88893154|NCT03905525|Placebo Comparator|Cohort 2/Arm F|Placebo dose (up to week 24)
88893155|NCT03905525|Experimental|Cohort 2/Arm F1|CFZ533 dose 2 (from week 24)
88893156|NCT03887650|Experimental|Liposomal Bupivacaine 1.3%|10mL Liposomal Bupivacaine 1.3% (133 mg) mixed with 10mL of 0.5% Bupivacaine (total volume 20mL) in single injection interscalene brachial plexus block
88893157|NCT03887650|Active Comparator|Bupivacaine 0.5% with Adjuncts|20mL 0.5% Bupivacaine with 5 mg PF dexamethasone and 5 mcg epinephrine (total volume 20.5mL) in single injection interscalene brachial plexus block
89415582|NCT00963469|Experimental|1|montelukast
89415583|NCT00963469|Active Comparator|2|loratadine
89415584|NCT00963469|Placebo Comparator|3|placebo
89415585|NCT05150366|Experimental|Patient scheduled for percutaneous closure of the left auricle by St Jude AMULET device|
89415586|NCT02160834|Experimental|B-MOBILE smartphone-based intervention (3-min break)|"Participants will receive a smartphone with B-MOBILE app that automatically monitors their sedentary time and prompts them after every 30 continuous sedentary minutes to walk for at least 3 minutes. Participants who meet this goal will receive reinforcing feedback in real time."
88893158|NCT03877341|Active Comparator|PLF|posterolateral fusion
88893159|NCT03877341|Active Comparator|PLIF|posterior lumbar interbody fusion
88893160|NCT03854500|Active Comparator|Tenecteplase|Tenecteplase
88893161|NCT03854500|Active Comparator|Alteplase|Alteplase
88893162|NCT03810924|Active Comparator|Control|Participants reads newspaper before Barlab-Exposure
88893163|NCT03810924|Experimental|Experimental 1 (Distress)|Participants undergo the Trier Social Stress Test before Barlab-Exposure
89415587|NCT02160834|Experimental|B-MOBILE Smartphone-Based Intervention (6-min break)|"Participants will receive a smartphone with B-MOBILE app that automatically monitors their sedentary time and prompts them after every 60 continuous sedentary minutes to walk for at least 6 minutes. Participants who meet this goal will receive reinforcing feedback in real time."
89415588|NCT02160834|No Intervention|Control|
88893164|NCT03810924|Experimental|Experimental 2 (Eustress)|Participants ride an ergometer before Barlab-Exposure
88893165|NCT03783949|Active Comparator|Standard arm (arm A)|Carboplatin (AUC5 d1, q3w i.v.) in combination with Paclitaxel (175 mg/m² d1, q3w i.v.) or Carboplatin (AUC4 d1, q3w i.v.) in combination with Gemcitabine (1000 mg/m² d1, d8, q3w i.v.) followed by maintenance therapy with Niraparib (200/ 300 mg oral daily, q4w)
88893166|NCT03783949|Experimental|First experimental arm (arm B)|Ganetespib (150 mg/m2, d1, q3w) in combination with Carboplatin (AUC5 d1, q3w i.v.) followed by maintenance treatment with Niraparib (200/ 300 mg oral daily, q4w)
88893167|NCT03783949|Experimental|Second experimental arm (arm C)|Ganetespib (150 mg/m² d1, q3w i.v.) plus Carboplatin (AUC5 d1, q3w i.v.) followed by Ganetespib (100 mg/m² d1, d8, d15, d22, q4w i.v.) and Niraparib (200 mg oral daily, q4w)
88893168|NCT03764891||Uphold|Patients who underwent Uphold procedure
88893169|NCT03764891||Perigee|Patients who underwent Perigee procedure
88893170|NCT03755297|Other|Rheumatoid arthritis|Patients responding to ACR/EULAR 2010 criteria and Blood sample analysis of patients treated as standard care
89415589|NCT02160912||Ectoin Mund- & Rachenspray|treatment with Ectoin Mund- & Rachenspray 1%
89415590|NCT02160912||Emser Pastillen|treatment with Emser Pastillen
89415591|NCT03487484||With protective stoma|Patients in which intraoperatively the decision was made to add a protective stoma (following a risk algorithm) to total mesorectal excision. In patients quality of life, the Gastrointestinal Quality of Life Index (GIQLI) questionnaire, Quality of Life Questionnaire for gastrointestinal tract and Faecal Incontinence Score will be applied.
89415592|NCT03487484||No stoma|"Patients in which intraoperatively the decision was made to refrain from adding a protective stoma (following a risk algorithm) to total mesorectal excision.~In patients quality of life, the GIQLI questionnaire (Gastrointestinal Quality of Life Index), Quality of Life Questionnaire for gastrointestinal tract and Faecal Incontinence Score will be applied."
89415593|NCT02164266|Experimental|Part 1: Healthy Volunteers|
89415594|NCT02164266|Experimental|Part 2: Patients with T2D, Group A|Low dose daily oral administration of RO6799477
88893171|NCT03755297|Other|Osteoarthritis|Control patients and Blood sample analysis of patients treated as standard care
89415595|NCT02164266|Experimental|Part 2: Patients with T2D, Group B|High dose daily oral administration of RO6799477
89415596|NCT05150288|Experimental|Formula-fed infants|Infants fed exclusively with experimental formula
89415597|NCT05150288|Experimental|Mixed-fed infants|Infants receiving breastmilk and experimental formula
89415598|NCT05150288|No Intervention|Breast-fed infants|Reference group of exclusively breastfed
89415599|NCT02163876|Experimental|HuCNS-SC cells|Intramedullary transplantation of HuCNS-SC cells in the cervical spine
89415600|NCT02163876|No Intervention|non-surgery arm|non-surgery arm
89415601|NCT00897949|Experimental|Rizatriptan 10 mg|
89415602|NCT00897949|Experimental|Rizatriptan 5 mg|
89415603|NCT00897949|Placebo Comparator|Placebo|
89415604|NCT04260776|Experimental|Phase 1|Participants will be randomly assigned to one of the two text message programs that correspond with the web-based intervention (MyWebQuit): 1) standard, 1-way text messages, or 2) interactive, 2-way text messages
89415605|NCT04260776|Experimental|Phase 2|"For the first 5 weeks after randomization, engagement with the website will be monitored. Participants who continue to engage with the website will continue with the same Phase 1 treatment components until the 3-month follow-up.~Participants who disengage with the website will be randomly assigned to receive one of three re-engagement strategies: 1) interactive, re-engagement text messages, 2) re-engagement email, or 3) no re-engagement strategy"
89415606|NCT03541278|Experimental|IM-SLNB with MIT|The radiotracer was injected with our modified injection technique (MIT) (periareolar intraparenchymal, high volume and ultrasonographic guidance). Internal mammary sentinel lymph node biopsy (IM-SLNB) was performed for patients with internal mammary visualized.
88893172|NCT03755297|Other|Rheumatoid arthritis with JAK/STAT inhibitors|Standard use of JAK/STAT inhibitors and Blood sample analysis of patients treated as standard care
88893173|NCT03722719|Experimental|Group I (the Knack)|
88893174|NCT03722719|Active Comparator|Group II (PFMT)|
88893175|NCT03722719|Active Comparator|Group III (the Knack + PFMT)|
88893176|NCT03699254|Active Comparator|Control|"Control Group (universal prophylaxis + pre-emptive therapy; 6+6): The recommendation of the Spanish Consensus Document will be followed according to the strategy described below:~Universal prophylaxis with valganciclovir (900 mg/24h, corrected for renal function) up to month +6. The use of associated immunotherapy (e.g., anti-CMV hyperimmune immunoglobulin) will depend on each center's clinical practice. During this period, the treatment of blips of viral replication detected during the usual clinical follow-up of patients will depend oneach center's clinical practice.~Pre-emptive therapy guided by viral load from month +6 to month +12. For a viral load above> 38 copies/mL (> 35 IU/mL) and depending on each center's clinical practice, treatment with valganciclovir may be initiated (900 mg/12h, corrected for renal function)."
88893177|NCT03699254|Experimental|Experimental|"Experimental Group (reduced prophylaxis + immuno-guided prophylaxis; 3+9):~Universal prophylaxis with valganciclovir (900 mg/24h, corrected for renal function) up to month +3. The use of associated immunotherapy (e.g., anti-CMV hyperimmune immunoglobulin) will depend oneach center's clinical practice. During this period, the treatment of blips of viral replication detected during the usual clinical follow-up of the patients will depend on the each center's clinical practice.~Immuno-guided prophylaxis. This will consist of a monthly determination of cellular immunity by QF-CMV from month +3 to month +12."
88893178|NCT03680755|Experimental|Tr1 group|Participants assigned to Tr1 will complete the experimental dental anxiety management program, which will be facilitated by a person trained in psychological treatments. This program consists of a series of videos which provide information about dental anxiety, educate about the details of three dental procedures which are anxiety-provoking for the participant, and teach them how to cope better with the dental experience. This program will take about 60 minutes to complete.
89415607|NCT03489200|Experimental|EH301|
89415608|NCT03489200|Placebo Comparator|Placebo|
89415609|NCT03540342|Experimental|One stop strategy group|Percutaneous coronary intervention (PCI) will be performed on the same operating table immediately after the endovascular aortic repair (EVAR)
88893179|NCT03680755|Experimental|Tr2 group|Participants assigned to Tr2 will complete the experimental dental anxiety management program, which will be facilitated by dental staff. This program consists of a series of videos which provide information about dental anxiety, educate about the details of three dental procedures which are anxiety-provoking for the participant, and teach them how to cope better with the dental experience. This program will take about 60 minutes to complete.
88893180|NCT03680755|No Intervention|Active control|Participants assigned to the control group, will not complete the experimental dental anxiety management program at this time. They will complete study paperwork and watch a non-dental video for 45 minutes before their scheduled dental appointment. Immediately after the dental appointment, they will complete a brief interview with the research staff person.
88893181|NCT03634930||EBF exclusive breast fed children at 16 weeks|observation of 24 hours drinking volume, weight, length, body composition, biomarker and satiety cues, as well as eating- and feeding behaviour and nutritional status of exklusiv breastfed children at the age of 8 and 16 weeks, and at 1 and 2 Years
89415610|NCT03540342|No Intervention|Staging strategy group|PCI will be performed several days after EVAR
89415611|NCT04952636|Experimental|Arthroscopic Cuistow|Patients who receive arthroscopic Cuistow procedure
89415612|NCT04952636|Experimental|Open Cuistow|Patients who receive open Cuistow procedure
89415613|NCT03487406|Placebo Comparator|Placebo Ticagrelor & placebo Aspirin|Placebo Ticagrelor 90 mg- one tablet, twice daily. Placebo Aspirin 75 mg- one tablet, once a day.
89415614|NCT03487406|Active Comparator|Aspirin & Placebo Ticagrelor|Aspirin 75mg - one tablet, once a day. Placebo Ticagrelor 90 mg- one tablet, twice daily.
89415615|NCT03487406|Active Comparator|Placebo Aspirin & Ticagrelor|Placebo Aspirin 75 mg - one tablet, once a day. Ticagrelor 90 mg- one tablet, twice daily.
89415616|NCT03487406|Experimental|Aspirin & Ticagrelor|Aspirin 75 mg - one tablet, once a day. Ticagrelor 90 mg- one tablet, twice daily.
89415617|NCT02164344|Experimental|Probiotics|HIV-1 infected patients take daily dietary supplement with probiotics for at least 3 months
89415618|NCT04653571||CASPR2 encephalitis|Cohort of patients with a CASPR2 antibody-associated auto-immune encephalitis.
89415619|NCT02097758|Experimental|transcatheter device closure|Choosing device size using three dimensional image and the formula without sizing balloon
89415620|NCT02760810|Experimental|narafilcon A|Subjects who are new contact lens wearers (neophytes) between the ages of 18-45 will be dispensed the Test Lens and evaluated over a period of 2 weeks.
89415621|NCT04574869|Experimental|Cohort 1|
89415622|NCT04574869|Experimental|Cohort 2|
89415623|NCT04574869|Placebo Comparator|Placebo Cohorts 1 and 2|Placebo will be administered at the same volume and duration of IV infusion corresponding to the cohort dosing schedule.
89415624|NCT04574869|Experimental|Cohort 3|
89415625|NCT04574869|Experimental|Cohort 4|
89415626|NCT04574869|Placebo Comparator|Placebo Cohorts 3 and 4|Placebo will be administered at the same volume and duration of IV infusion corresponding to the cohort dosing schedule.
89415627|NCT04047056|Placebo Comparator|Ergonomic Guidelines Manual|A manual of ergonomic occupational and daily living guidelines will be given to both control and labor kinesiotherapy groups, which is the only approach for the control group initially.
89415628|NCT04047056|Active Comparator|Labor Kinesiotherapy in group|The intervention will be performed by a physical therapist, which will consist of preparatory labor kinesiotherapy, which aims to prepare the workers' osteo-articular system for the beginning of the work activity, acting more specifically on those muscle groups that will be most required during the journey which will be identified in the evaluation. Labor kinesiotherapy will be performed in the workplace before the workday and will last 20 minutes, 3 times a week, for 12 weeks.
89415629|NCT02760654|Experimental|Online Self Management|Participants will interact with an online self management program based on cognitive behavioral principles for 8 weeks as much as they want.
89415630|NCT02760654|No Intervention|Control|Treatment as usual
89415631|NCT00725491|Experimental|1|ganirelix
89005973|NCT00216710|Experimental|Home Visited Mothers|Mothers randomized to the home visited group received AK State-funded home visiting services. Frequency of home visits was determined by home visiting staff based on mothers' needs. Mothers could receive home visiting services until their child turned 3 years old
89415632|NCT00725491|Active Comparator|2|triptorelin
89415633|NCT03487328|Active Comparator|Modified technique for Sacrospinous-Sacrotuberous Fixation|Modified technique for Sacrospinous-Sacrotuberous Fixation
89415634|NCT03487328|Active Comparator|Conventional technique for Sacrospinous-Sacrotuberous Fixation|Modified technique for Sacrospinous-Sacrotuberous Fixation
89415635|NCT00724789||Observational Cohort|Subjects with an ongoing pregnancy after controlled ovarian stimulations with recombinant follicle stimulating hormone/ganirelix followed by in vitro fertilization or intra cytoplasmatic sperm injection.
89415636|NCT00724789||Historical Controls|Subjects with an ongoing pregnancy after controlled ovarian stimulations with recombinant follicle stimulating hormone in a long protocol with a gonadotropin releasing hormone agonist followed by IVF or ICSI
89415637|NCT03485144|Experimental|TV003|Live Attenuated Virus Vaccine-TetraVax-DV
89005974|NCT00216710|No Intervention|Control Mothers|Mothers randomized to the control group did not receive home visiting services, but were offered referrals to other community-based services, as was usual protocol with home visiting agencies were operating at capacity.
89415638|NCT03485144|Placebo Comparator|Placebo for TV003|Placebo
89415639|NCT02164500|Experimental|Ruxolitinib|
89415640|NCT03489356|Experimental|Intervention|Addressing Behavior Change (ABC) intervention delivery method
89415641|NCT03489356|No Intervention|Control|Control
89415642|NCT03925142|Active Comparator|Controlled healthy vegetarian diet|Subjects will be randomized and assigned to consume the controlled Healthy Vegetarian Eeating Pattern for 5 weeks.
89415643|NCT03925142|Experimental|Controlled beef diet|Subjects will be randomized and assigned to consume the beef diet for 5 weeks, which will substitute predominantly starchy vegetables and refined grains with 6 oz. of lean unprocessed beef/day.
89415644|NCT00711607|Experimental|1|Group 1: NOMAC-E2 (days 1-24 and day 35)
89415645|NCT00711607|Placebo Comparator|2|Group 2: NOMAC-E2 (days 1-24) followed by Placebo (day 35)
89415646|NCT03893318|Experimental|Study Group|will receive intravenous lidocaine during and after posterior spinal fusion for AIS
89005975|NCT00216749||Cilostazol|Cilostazol Treatment Patients who were in stable states after the occurrence of cerebral infarction (except cardiogenic cerebral embolism)
89193094|NCT05575908|Experimental|Digital expert team|The participants allocated to this arm will receive personalized advice from an expert team. The participants will have one video meeting with the team and receive a written report.
89193095|NCT05575908|No Intervention|Treatment as usual|The participants will answer a digital questionnaire and will get normal follow-up from his/her general practitioner and labor- and welfare administration (NAV).
89415647|NCT03893318|Placebo Comparator|Control Group|will receive saline placebo during and after surgery.
89415648|NCT03625531|Experimental|Personalized acupuncture|Two sets of acupoints will be selected for the two types. The basic acupoint-prescription includes CV 4, CV 6, CV 12 and SP 6 bilaterally, ST 25 bilaterally, EX-CA 1 bilaterally, ST 40 bilaterally and SP 9 bilaterally. Additional point ST 36 bilaterally and moxibustion as adjuvant therapy will be added for the type of yang deficiency of spleen and kidney, while additional points K 13, LR 3 for the type of yin deficiency of liver and kidney. Besides, flexible modifications of 2-3 acupoints will be performed according to patients special symptoms.
89536752|NCT03193931|Active Comparator|Arm B|Arm B: Methotrexate (MTX) 40 mg/m2 weekly i.v. until disease progression or non-tolerable toxicity (maximum 2 years)
89536753|NCT03846479|Experimental|Itacitinib|Itacitinib 200 mg administered orally daily
89536754|NCT03067259|No Intervention|Control Group|It comprises patients who will not undergo any surgical / anesthetic act
89415649|NCT03625531|Experimental|Fixed acupuncture|Two sets of acupuncture points will be alternated every second treatment. The first set consists of CV 3, CV 6, ST 29 bilaterally, SP 6 bilaterally, SP 9 bilaterally, GV 20 and LI 4 bilaterally. The second set consists of 13 needles: ST 25 bilaterally, ST 29 bilaterally, CV 3, CV 6, SP 6 bilaterally, LR 3 bilaterally, PC 6 bilaterally and GV 20. The following points will be connected to an electrical stimulator: ST 25 bilaterally, ST 29 bilaterally, SP 6 bilaterally, LR 3 bilaterally.
89415650|NCT03625531|Active Comparator|Letrozole|Women in the letrozole group will be given letrozole (Femara, Novartis Pharmaceuticals, Basel, Switzerland) from day 3 to day 7 of the spontaneous menstrual cycle or after a withdrawal bleeding following progestin. The maximum daily dose of letrozole will be 7.5 mg (3 pills) daily for five days.
89415651|NCT03625531|Placebo Comparator|Placebo letrozole|Women will receive placebo letrozole with no acupuncture from day 3 to day 7 of the spontaneous menstrual cycle or after a withdrawal bleeding following progestin. Placebo letrozole will be given in the same way as letrozole.
89415652|NCT02161224|Experimental|1: FG-4592 in subjects with moderate hepatic impairment|
89415653|NCT02161224|Experimental|2: FG-4592 in healthy subjects|
89415654|NCT02167698|Experimental|Airway pressure release ventilation arm|"This group of children would be ventilated using the Airway pressure release ventilation (APRV) mode.~Restrictive fluid therapy, protocolized sedo-analgesia titration, steroid therapy, protocolized supportive care, protocolized early enteral nutrition would be provided to both the groups. Biomarkers would be measured in both groups."
89415655|NCT02167698|Active Comparator|Low-tidal volume ventilation arm|Low-tidal volume ventilation using pressure-regulated volume control mode with target tidal volume of 6 ml/kg or less and other lung-protective strategies. Restrictive fluid therapy, protocolized sedo-analgesia titration, steroid therapy, protocolized supportive care, protocolized early enteral nutrition would be provided to both the groups. Biomarkers would be measured in both groups
89415656|NCT04050943||CRD patients|Patients with chronic pulmonary disease like COPD, asthma, bronchiectasis, and etc.
89415657|NCT02164656|Experimental|mindfulness training|8 week course in mindfulness for smokers
89415658|NCT02634580|Active Comparator|Ezetimibe (Q2W)|Participants received placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for 12 weeks. From week 12 participants received open-label evolocumab 140 mg subcutaneously once every 2 weeks until week 48.
89415659|NCT02634580|Active Comparator|Ezetimibe (QM)|Participants received placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for 12 weeks. From week 12 participants received open-label evolocumab 420 mg subcutaneously once a month until week 48.
89415660|NCT02634580|Experimental|Evolocumab Q2W|Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for 12 weeks. From week 12 participants received open-label evolocumab 140 mg subcutaneously once every 2 weeks until week 48.
89415661|NCT02634580|Experimental|Evolocumab QM|Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for 12 weeks. From week 12 participants received open-label evolocumab 420 mg subcutaneously once a month until week 48.
89415662|NCT02225366|Experimental|Intra-Tumoral Injection of LL37|LL37 administered intratumorally in cutaneous or subcutaneous tumors at least 1 cm in diameter. Patients will receive weekly intratumoral injections of LL37 for up to 8 weeks. The injections will be given every 7 days (+/- 48 hours). Starting dose 250 µg/tumor.
89415663|NCT03540264|Active Comparator|Composite resin|Restoration with composite resin has shown good clinical performance and limited occlusal wear. The Clearfil Majesty will be used in the present study.
89415664|NCT03540264|Active Comparator|Polymer-infiltrated-ceramic-network|This hybrid material seems to be a promising material that imitates natural tooth properties. The VITA-Enamic® will be used in this study.
89415665|NCT00697255|Experimental|corifollitropin alfa + recFSH|Eligible participants will receive a subcutaneous (SC) injection of corifollitropin alfa (Stage 1a: 15mcg, Stage Ib/II: 30 mcg) the first, second, or third day after onset of a progestagen-induced withdrawal bleeding. If the follicle growth is insufficient, the participant will receive a second or third dose of corifollitropin alfa (Stage 1a: 15 mcg, Stage Ib/II: 20 mcg). As soon as the largest follicle reaches a size of ≥12 mm, the participant will start daily SC injections with FSH (Stage 1A: 50 IU, Stage II: 75 IU) the same day. A bolus injection of hCG (5000 IU) will be administered if at least one follicle is ≥18 mm and in total no more than two follicles ≥15 mm are observed.
88893182|NCT03634930||EFF exclusive formula fed children at 16 week|observation of 24 hours drinking volume, weight, length, body composition, biomarker and satiety cues, as well as eating- and feeding behaviour and nutritional status of exklusiv formula fed children at the age of 8 and 16 weeks, and at 1 and 2 Years
88893183|NCT03582449||Elaprase|Participants with Hunter syndrome (Mucopolysaccharydosis II) being treated with Elaprase will be evaluated for this study.
88893184|NCT03559621|No Intervention|control group|Women in the control group will receive follow-up as in normal routine with referral to primary care. They will receive an OGTT after 1 year as part of the trial.
88893185|NCT03559621|Other|intervention group|A mobile-based lifestyle intervention
88893186|NCT03550131|Active Comparator|Standard intervention|"Reducing Disabilities in Alzheimer's Disease (RDAD):~9 60-minute virtual sessions for 6 weeks and 4 15-minute follow-up phone sessions for 4 months"
88893187|NCT03550131|Experimental|Personalized intervention|"Innovations in Dementia Empowerment and Action (IDEA):~9 60-minute virtual sessions for 6 weeks and 4 15-minute follow-up phone sessions for 4 months"
88893188|NCT03522246|Experimental|Arm A|oral rucaparib + intravenous (IV) nivolumab
88893189|NCT03522246|Experimental|Arm B|oral rucaparib+IV placebo
89193096|NCT05575102|Experimental|Walking Football|Walking football intervention for 6-weeks (2-hour per week) at a local sports hall, supervised by a walking football coach with assistance from CB.
88893190|NCT03522246|Experimental|Arm C|oral placebo+ IV nivolumab
88893191|NCT03522246|Placebo Comparator|Arm D|Oral placebo + IV placebo
88893192|NCT03513328|Experimental|Group A--Thiotepa single dose|Fully matched 10/10 subjects with lower risk of graft failure. Subjects will undergo 10/10 HLA (human leukocyte antigen) matched bone marrow and peripheral blood transplant. Subjects receive combination of single daily dose thiotepa (5 mg/kg) added to the backbone of targeted reduced dose IV busulfan, fludarabine and rabbit anti-thymocyte globulin (rATG).
89415666|NCT00697255|Experimental|corifollitropin alfa + hCG|Eligible participants will receive a SC injection of corifollitropin alfa (Stage Ia:15 mcg, Stage Ib/II: 30 mcg) the first, second or third day after onset of a progestagen-induced withdrawal bleeding. If the follicle growth is insufficient the participant will receive a second or third dose of corifollitropin alfa (Stage IA: 15 mcg, stage Ib/II: 20 mcg). As soon as the largest follicle reaches a size of ≥12 mm the participant will start daily SC injections with hCG (Stage Ib/II: 200 IU) the same day. A bolus injection of hCG (5000 IU) will be administered if at least one follicle is ≥18 mm and in total no more than two follicles ≥15 mm are observed.
88893193|NCT03513328|Experimental|Group A--Thiotepa escalated dose|Fully matched 10/10 subjects with lower risk of graft failure. Subjects will undergo 10/10 HLA (human leukocyte antigen) matched bone marrow and peripheral blood transplant. Subjects receive combination of escalated dose of thiotepa (10 mg/kg) added to the backbone of targeted reduced dose IV busulfan, fludarabine and rabbit anti-thymocyte globulin (rATG).
88893194|NCT03513328|Active Comparator|Group B--Thiotepa single dose|Subjects with higher risk of graft failure. Subjects will undergo transplant with <10/10 bone marrow or peripheral blood match, or receiving cord blood transplant. Subjects receive combination of single daily dose thiotepa (5 mg/kg) added to the backbone of targeted reduced dose IV busulfan, fludarabine and rabbit anti-thymocyte globulin (rATG).
88893195|NCT03513328|Active Comparator|Group B--Thiotepa escalated dose|Subjects with higher risk of graft failure. Subjects will undergo transplant with <10/10 bone marrow or peripheral blood match, or receiving cord blood transplant. Subjects receive combination of escalated dose of thiotepa (10 mg/kg)added to the backbone of targeted reduced dose IV busulfan, fludarabine and rabbit anti-thymocyte globulin (rATG).
88893196|NCT03502967|Experimental|Hyperpolarized [1-13C] Pyruvate|Injection with hyperpolarized [1-13C] Pyruvate during MRI.
88893197|NCT03502967|Experimental|Hyperpolarized [2-13C] Pyruvate|Injection with hyperpolarized [2-13C] Pyruvate during MRI.
88922128|NCT05773053|Placebo Comparator|Placebo|Subjects will receive matching placebo.
88922129|NCT05772663|Experimental|personalized program group|people with chronic stroke
88922130|NCT05772663|Active Comparator|routine rehabilitation care group|people with chronic stroke
88922131|NCT05752396||Chronic Pain - Localized|Patients with localized pain conditions (n=140)
89415667|NCT01957748|No Intervention|Standard of Care (SoC)|Subjects randomized to the Standard of Care Arm will receive their HIV clinic's current standard of care retention services.
89536755|NCT03067259|Other|Exposure Group|It comprises those patients that will undergo sedation for diagnostic procedure or some surgical / anesthetic process
89536756|NCT00705263||Patients with chronic hepatitis C|Patients with chronic hepatitis C who are treated with the PegIntron pen plus Rebetol will answer questions on the patient questionnaire.
89415668|NCT01957748|Active Comparator|SoC + ALERT Intervention|Subjects randomized into the ALERT Enhanced Retention Intervention Arm will receive SoC at the HIV clinic where subjects are seen. In addition to SoC, the Intervention arm will receive aggressive engagement efforts by the ALERT specialist to ensure visit continuity and retention into care. The ALERT specialist will also administer an education intervention consisting of 5 retention modules designed to improve HIV knowledge and self-efficacy, and will also monitor health care visits and intervene via methods to track, find, and re-engage patients during the study.
89415669|NCT00548912|Other|1 group - no arms|no arm just error message
88893198|NCT03498716|Experimental|Atezolizumab + Chemotherapy|"Participants will receive atezolizumab (in combination with chemotherapy as described below) every 2 weeks for 10 doses, followed by atezolizumab maintenance therapy every 3 weeks to complete 1 year of treatment from the first dose~Chemotherapy will consist of paclitaxel every week for 12 weeks, followed by dose-dense doxorubicin +cyclophosphamide or dose-dense epirubicin + cyclophosphamide every 2 weeks, for 4 doses supported with Granulocyte Colony-Stimulating Factor (G-CSF) or Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF)"
89415670|NCT02161302|Experimental|Active tDCS|tDCS will be applied in the head of the patients in 20 minute sessions, daily from Monday to Friday for 2 weeks (10 sessions total). The stimulation will be administered with a pair of surface electrodes, sponge coated, soaked in saline. A battery-powered constant current stimulator will be used for this purpose (tDCS device Soterix 1X1). The stimulation is performed by placing the anodal electrode in the primary motor cortex (M1) and the cathodal one in the contralateral supraorbital area, and it will use a 2 mA current.
88893199|NCT03498716|Active Comparator|Chemotherapy|Chemotherapy will consist of paclitaxel every week for 12 weeks, followed by dose-dense doxorubicin +cyclophosphamide or dose-dense epirubicin + cyclophosphamide every 2 weeks, for 4 doses supported with Granulocyte Colony-Stimulating Factor (G-CSF) or Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF)
89193097|NCT05555771|Experimental|Counterpressure Maneuvers|"Participants will receive standard of care treatment (behavioural intervention and avoidance measures, as indicated in Usual Care), alongside training in counter pressure maneuvers. Training in counterpressure maneuvers will be delivered through a handout and video that will show three maneuvers (i.e. arm-tensing, squatting, and leg-crossing) that patients enrolled in the intervention arm can perform when they begin to experience common signs and symptoms of syncope. Patients will be instructed to start with one of the maneuvers and if their symptoms do not go away, move on to a second or third maneuver if needed."
89415671|NCT02161302|Sham Comparator|tDCS Sham|The sham tDCS consists of the same montage of the active tDCS, but the device is turned off 30 seconds after initiating stimulation (without letting the patient notice it). Rest of the montage is kept identical as the active one during the 20 minutes that the session lasts.
88893200|NCT03447119|Experimental|Living Well with a Disability|The parents will work together with the project directors to deliver the adapted curriculum to participating families. With bi-weekly meetings for 10 weeks between parent facilitators and family participants in the home or another desired location. The project directors have already participated in the facilitator training and will serve as mentors to newly trained facilitators. At the end of the online training session, the parent facilitators will be equipped to successfully implement the Living Well curriculum.
88893201|NCT03441295|Experimental|Study 1 Ligamys|Repair Surgery.
88893202|NCT03441295|Experimental|Study 1 Internal Bracing|Repair Surgery.
88893203|NCT03441295|Experimental|Study 2 Internal Bracing|Repair Surgery.
88893204|NCT03441295|Active Comparator|Study 2 Reconstruction|Reconstructive Surgery.
88893205|NCT03430310|Experimental|Low Glycemic Diet|The investigators will use a Low Glycemic Load Diet (LG Diet), which emphasizes low-glycemic sources of carbohydrate, and includes mainly whole foods (vegetables, fruits, whole grains) with minimal highly processed grain products and added sugar. Protein foods will include meat, poultry, fish, eggs, and whey protein supplements if necessary (e.g., for vegetarians). Fat-containing foods will include olive, coconut, and nut oils; butter; tree nuts and nut butters; cheese; cream; coconut milk; avocados; and the fat found in meat. A number of full-fat dairy products will be included. Saturated fat from red meat will be limited to less than 10% of daily caloric intake. Participants will obtain the majority of their fat intake from mono-unsaturated fatty acids (e.g. olive oil), and medium-chain triglycerides (e.g., coconut oil and cream); from nuts and nut butters; and from fresh fish.
88922132|NCT05752396||Chronic Pain - Overlapping|Patients with two or more pain conditions (n=140)
89536757|NCT02470169|Active Comparator|Stimulated IUI|On the 3rd day of menstruation women in group 1 will have a vaginal ultrasound and will receive daily intramuscular 150 IU of human menopausal gonadotropins starting from the 3rd day of menstruation. On day 8 the ultrasound will be repeated and serum E2 will be measured, hMG dose will be adjusted and continued and the frequency of ultrasound scans will be individualized. HMG will be stopped when at least 2 follicles measuring 18 mm are associated with serum E2 of 500-3000 Pg/mL, this was followed by the administration of 10000 IU of human chorionic gonadotropin
88893206|NCT03430310|Placebo Comparator|Control Diet|The Control diet will be compatible with both the American Diabetes Association and The United States Department of Agriculture guidelines. Participants will be given low-fat foods, whole-grain foods, fruits, and vegetables. The meal plans will minimize cholesterol, high-fat foods, high-cholesterol foods, processed starches, and added sugar, and will provide <2300 mg/day sodium. Saturated fat will be limited to less than 10% of total energy, and all dairy products will be fat-free (or low-fat). Although the Control diet will be a healthful diet, it will include a greater amount of carbohydrate foods from such sources as bread, potatoes, and pasta that will distinguish it qualitatively from the LG diet. In addition, it will have quantitatively more total energy from carbohydrate than the LG diet.
88893207|NCT03424161|Other|Secret RF|Treatment with Secret RF for skin quality
88893208|NCT03413189||PREDICT participants|This cohort is obtained from the PREDICT study enrolment (approx. 500) and a review of their medical records will be conducted
88893209|NCT03413189||PREDITCABLE participants|This is a nested cohort of patients recruited into PREDICT (approx. 40) that consent for a physiotherapist home visit to assess their physical and cognitive function and perform and interview to obtain themes regarding recovery
88893210|NCT03404180|Experimental|Peripheral nerve block|"Prospectively evaluate peripheral nerve blocks as a primary anesthetic in the setting of above-the-knee amputations.~All enrollees will be administered Intravenous sedatives using propofol or dexmedetomidine and have ultrasound-guided femoral and sciatic nerve blocks placed per current practice at research site. Single-injection obturator nerve blocks and lateral femoral cutaneous nerve blocks will also be performed."
88893211|NCT03403465|Other|Single arm interventional study|Research FDG-PET scan obtained before radiation therapy; a second research FDG-PET scan is obtained at about 3-5 weeks after treatment has started.
88893212|NCT03390686|Experimental|HD204 (Bevacizumab biosimilar)|HD204 + Carboplatin/Paclitaxel
89193098|NCT05555771|Active Comparator|Usual Care|Participants will receive standard of care treatment for their diagnosis of syncope. This primarily includes behavioural interventions and avoidance measures (e.g., stay hydrated, increase salt intake, avoid hot situations, avoid standing for long periods of time, engage in regular physical activity). Some patients may be prescribed medication (Midodrine, Fludrocortisone) at the discretion of their physician.
88893213|NCT03390686|Active Comparator|Avastin (Bevacizumab)|Avastin® + Carboplatin/Paclitaxel
88893214|NCT03373552||non responder Group|"Platelet function assay:~High platelet reactivity: PRU>208"
88893215|NCT03373552||responder Group|"Platelet function assay:~PRU<208"
88893216|NCT03373201|Experimental|Tasimelteon|
88893217|NCT03373201|Placebo Comparator|Placebo|
88893218|NCT03357926||Observation Group|
88922133|NCT05752396||Healthy Participants|Health Participants without a chronic pain condition (n=140)
88922134|NCT05748405|Experimental|AEF0217|AEF0217 0.1 mg tablet 2 tablets in 10 ml of water per day during 28 days
89415672|NCT04460300|Experimental|Aromatherapy-inhalation group|"In addition to the pharmacological treatment prescribed by the physician to individuals in this group, aromatherapy is carried out through the essential oil inhalation method. Individuals who can distinguish odors in the odor sense test before the application is included in the study. Aromatherapy inhalation is applied for three days and every other day (eg Monday-Wednesday-Friday) determined by the researchers for a week. Intervention is made between 07:00 and 08:00 in the morning hours when the blood cortisol value is maximized and homogeneity is provided.~In this method, 5 drops of lavender oil is dropped directly on a sterile gauze and individuals is allowed to breathe from a distance of 10 cm for 5 minutes."
89415673|NCT04460300|Experimental|Aromatherapy-foot massage group|"In addition to the pharmacological treatment prescribed by the physician to individuals in this group, aromatherapy is applied through foot massage. Swedish massage protocol is followed in foot massage intervention.The foot massage is performed on three days and every other day (eg Monday-Wednesday-Friday) determined by the researchers for a week.The intervention is performed between 07:00 and 08:00 in the morning hours when the blood cortisol value is maximized and homogeneity is provided.~Foot massage is done with 10 drops (5 drops per foot) of lavender for 10 minutes for each foot for 20 minutes. During the intervention, 20 techniques is used and the application time of each technique is 30 seconds (total 10 minutes per foot)."
89415674|NCT04460300|No Intervention|Control group|Interviews is held with the control group while performing the routine treatment and care of the clinic. No intervention is made by the researchers to the control group during the interview.
89415675|NCT05002933|Experimental|Insulin glargine 300 U/ml|Insulin glargine 300 U/ml once daily for 24 weeks. Participants may continue for an additional 12 week extension period or switch to other anti-diabetic treatment, insulin dose will be adjusted according to the recommended dose titration algorithm
89415676|NCT03725826||Acute Myocardial Infarction|Patients (aged 18 and above) with either ST segment elevation or Non-ST segment elevation MI by biomarkers of cardiac injury and symptoms. Cut-off for CPK >2 times and troponin >3 times the upper limit for the lab. Only Patients who undergo coronary revascularization (PCI, CABG), New York Heart Association (NYHA) functional class I-III, and with LVEF < 45% will be enrolled.
89415677|NCT03487250||TenJet System|Percutaneous ultrasound guided medial and lateral tenotomy using the TenJet HydroSurgery System
88893219|NCT03345342|Experimental|PP1M: Transition Phase|Participants who previously have not achieved stability with moderate to higher doses of Paliperidone palmitate 1-month (PP1M) or Paliperidone palmitate 3-month (PP3M) will enter into a transition period of up to 4 months. During transition period participants will receive 1 to 5 injections of PP1M 50 to 100 milligrams equivalent (mg eq.). The participants who achieved stability (stability is defined as at least 3 months of injections with the last 2 doses being the same strength) with PP1M 100 mg eq. will precede from transition phase to maintenance phase.
88893220|NCT03345342|Experimental|PP1M/PP3M: Maintenance Phase|All the participants will receive only 1 dose of PP1M 100 or 150 mg eq. or PP3M 350 or 525 mg eq. The participants will precede from maintenance phase to double-blind phase.
88893221|NCT03345342|Experimental|PP6M or Placebo: Double-Blind Phase|Participants will receive intramuscular injection of PP6M in left gluteal muscle on Day 1 and right gluteal muscle on Day 183 with alternating placebo in right gluteal muscle on Day 92 and left gluteal muscle on Day 274.
88893222|NCT03345342|Experimental|PP3M: Double-Blind Phase|Participants will receive intramuscular injections of PP3M at dose of 350 mg eq. or 525 mg eq. in left gluteal muscle on Day 1 and 274 and right gluteal muscle on Day 92 and 183.
88893223|NCT03290547|Other|arm-1|Cutera enLighten laser treatments that allows the user to choose a wavelength between 640nm to 800nm.
88893224|NCT03270969|Experimental|TDF/FTC|Tenofovir Disoproxil Fumarate/Emtricitabine group HIV-uninfected transgender women receiving feminizing hormone therapy plus tenofovir disoproxil fumarate/emtricitabine
88893225|NCT03264131|Experimental|Open-label, Multicenter, Single-Arm|This is a single-arm intervention where patients will receive concurrent therapy with BV+CHEP [(brentuximab vedotin; 1.8 mg/kg IV, on D1 every 21 days) (cyclophosphamide 750 mg/m^2 on D1; doxorubicin 50 mg/m^2 on D1, etoposide 100 mg/m^2 IV infusion on D1-3; prednisone 100 mg orally once daily on D1-5; cycle length every 21 days)] for 2 to 6 cycles of induction therapy. After 6 cycles of BV + CHEP, responders (CR, PR or SD) who are not eligible for BMT and have CD30-positive ATLL will continue maintenance therapy with BV alone (1.8 mg/kg IV, every 21 days) until disease progression, withdrawal due to toxicity or death.
88922135|NCT05748405|Placebo Comparator|Placebo|Placebo tablet 2 tablets in 10 ml of water per day during 28 days
89415678|NCT03071068|Experimental|THR-317 4mg|anti-PlGF recombinant monoclonal antibody, 4mg dose
89415679|NCT03071068|Experimental|THR-317 8mg|anti-PlGF recombinant monoclonal antibody, 8mg dose
89415680|NCT06161441|Experimental|Arm A|"Randomized 1:1:1~Neoadjuvant period:~placebo + cemiplimab + platinum doublet chemotherapy~Adjuvant period:~placebo + cemiplimab"
88922136|NCT05747495|Experimental|Participants registered in the online training in CPR-AED|"The online training has been designed according to the Catalan Resuscitation Council (CCR) and the European Resuscitation Council (ERC) guidelines. The aim of this training is to provide theoretical and practical knowledge to respond to aid situations (from unconscious people to drowning, both adults and children), as well as the use of the AED.~The contents are available at the link [https://register.magnore.com/registre-curs-de-reanimacio-cardiopulmonar-dea/]."
89415681|NCT06161441|Experimental|Arm B|"Randomized 1:1:1~Neoadjuvant period:~fianlimab high dose + cemiplimab + platinum doublet chemotherapy~Adjuvant period:~fianlimab high dose + cemiplimab"
89415682|NCT06161441|Experimental|Arm C|"Randomized 1:1:1~Neoadjuvant period:~fianlimab low dose + cemiplimab + platinum doublet chemotherapy~Adjuvant Period:~fianlimab low dose + cemiplimab"
89536758|NCT02470169|Active Comparator|Unstimulated IUI|Women in group 2 will be asked to test their morning urine specimen for luteinizing hormone daily starting 4 days before the expected day of ovulation. This will be done using a qualitative kit. IUI will be performed on the day after the surge in urinary excretion of luteinizing hormone.
89193099|NCT05555758|Active Comparator|experimental group|Four ascending dose levels of Aom0319 (n=24) for intravenous injection for once. Dosage day is Day 1.
89536759|NCT02470169|Active Comparator|Control group|Women will be asked to test their urine for luteinizing hormone by the same method as group 2. They will be asked to have an intercourse on the day after the surge in urinary excretion of luteinizing hormone and this will be repeated for 12 months.
89415686|NCT06161389|Experimental|Partially inflated mask|Participants will be invited to administer positive pressure ventilation by using a partially inflated mask in a neonatal manikin
89415687|NCT06161389|Active Comparator|Fully inflated mask|Participants will be invited to administer positive pressure ventilation by using a fully inflated mask in a neonatal manikin
89415688|NCT06161376||multiple sclerosis|Patients diagnosed with MS requiring urodynamic assessment will be recruited during outpatient visits at Toulouse University Hospital. Initial consultations will involve questionnaire completion, 72-hour voiding diaries, and urine sample collection just before urodynamic assessments.
89415689|NCT06161363||The Morisky Medication Adherence Scale (MMAS-8)|The Morisky Medication Adherence Scale completed by the patients
89415690|NCT06161350||Group 1|"Infants who consulted between January 1st 2000 and December 31st 2009 (this is before the implementation of the pre-convention).~Inclusion criteria:~Children consulting a pediatric gastroenterologist for feeding problems in UZB between the 1st of January 2000 and the 31st of December 2009 and receiving the label feeding difficulties.~The infants have a pediatric feeding disorder that prevent them from feeding normally by oral means.~The infants need or have needed (enteral or parenteral) artificial nutrition.~The infants are aged between 0 and 12 years at their first presentation.~The infants are capable of developing normal feeding behavior.~Infants will be excluded from this study if they:~Have no 6-months follow-up available.~Parents refusal to enter a multi-disciplinary approach for the feeding problems of their children."
89415691|NCT06161350||Group 2|"Infants who consulted after the implementation of the pre-convention, who consulted between January 1st 2010 and December 31st 2021.~Inclusion criteria:~Children consulting a pediatric gastroenterologist for feeding problems in UZB between the 1st of January 2010 and the 31st of December 2021 and receiving the label feeding difficulties.~The infants have a pediatric feeding disorder that prevent them from feeding normally by oral means.~The infants need or have needed (enteral or parenteral) artificial nutrition.~The infants are aged between 0 and 12 years at their first presentation.~The infants are capable of developing normal feeding behavior.~Infants will be excluded from this study if they:~Have no 6-months follow-up available.~Parents refusal to enter a multi-disciplinary approach for the feeding problems of their children."
89415692|NCT06161324|Experimental|Tele-rehabilitation group|In the tele-rehabilitation group, participants will use a pelvic floor muscle (superficial) sensor, which will indicate the direction of the pelvic floor muscle (PFM) contraction in the collaborating mobile application. Patient and therapist could communicate either synchronously (i.e. through a video call) or asynchronously (information that stored in the application), regarding the execution of the PFM exercises (direction of the PFM contraction, frequency of the PFM program, duration, statistics etc.). So, the participants of the tele-rehabilitation group, will remotely perform a PFM exercises program at home by using a pelvic floor sensor and at the same time they self-manage their results through the mobile application, under the remote supervision of the physiotherapist.
89415693|NCT06161324|Active Comparator|Traditional treatment group|"In the Traditional (classic) treatment group, participants will follow the usual care treatment of PFMs, based on the pragmatic treatment of incontinence, which is used today in rehabilitation clinics, centers etc. The therapy will include face-to-face meetings weekly, between patient and physiotherapist regarding the progress of the treatment and its smooth transition (intra-vaginally assessment when it needs, correction, encouragement, motivation, etc.). In addition, the patients will be encouraged to do the same exercise program at home based on a printed leaflet that they will receive."
89415694|NCT06161324|Other|Control group|Participants of the control group will be trained in PFM contraction in the 1st meeting assessment and they will receive a comprehensive leaflet, with instructions and PFM exercises at home. In addition, patients will be asked to follow the same PFM exercise protocol (frequency, type of contraction, etc.) as the other two groups at home on their own, without however guidance and supervision.
89415695|NCT06161311|Active Comparator|Myopic RPR group|Patients with myopic relative peripheral refraction
89415696|NCT06161311|Active Comparator|Hyperopic RPR group|Patients with hyperopic relative peripheral refraction
89415697|NCT06161298||Healthy control group|age> 18, without lung disease
89415698|NCT06161298||NSAP group|patients with no stroke pneumonia
89415699|NCT06161298||SAP group|Those diagnosed with stroke-related pneumonia
89415700|NCT06161272|Experimental|Arm1：Fluzoparib|Fluzoparib capsule: oral administration, 3 capsules/dose (150 mg/ dose), twice a day, in the morning and evening, before/after meals can be taken orally, it is recommended to take orally within 0.5h after breakfast and dinner, continuous administration. Every 4 weeks is a treatment cycle.
89415701|NCT06161272|Experimental|Arm2：Fluzoparib + apatinib|"Fluzoparib capsule: oral administration, 2 capsules/dose (100 mg/ dose), twice a day, in the morning and evening, before/after meals can be taken orally, it is recommended to take orally within 0.5h after breakfast and dinner, continuous administration. Every 4 weeks is a treatment cycle.~Apatinib: oral administration, 1 tablet/dose (375 mg/tablet), once a day, it is recommended to take orally within 0.5h after breakfast, continuous administration. Every 4 weeks is a treatment cycle."
89415702|NCT06161259|Experimental|Child-Pugh A|8 participants with mild hepatic impairment (Child-Pugh A) will be given 400mg of Leritrelvir(RAY1216)
89415703|NCT06161259|Experimental|Child-Pugh B|8 participants with mild hepatic impairment (Child-Pugh B) will be given 400mg of Leritrelvir(RAY1216)
89415704|NCT06161259|Experimental|Normal hepatic function|8 participants with normal hepatic function will be given 400mg of Leritrelvir(RAY1216)
89415705|NCT06161246|Experimental|Treatment Group|Subjects will be treated for correction of glabellar lines with Dysport and comfort intervention on one side and Dysport only on the other side depending on pre-determined randomization. Subjects will complete the study assessments and end the study.
89415706|NCT06161220|Experimental|Carbidopa capsule|Dose: 4x 100 mg
89415707|NCT06161220|Active Comparator|Moxifloxacin Tablets, USP|Dose: 400 mg
89415708|NCT06161220|Placebo Comparator|Placebo|
89415709|NCT06161168|Experimental|Baseline Phase (10 or 21 days)|In this study, participants will be randomly allocated to a baseline (A) phase that is further divided into two sub-phases, with different durations of either 10 or 21 days. The allocation to different durations of the baseline phase is randomized in order to mitigate threats to internal validity. During the baseline (A) phase, a representative baseline will be established through repeated measurements of the PQRS. Following the baseline phase (A), the 8-week intervention phase (B) is implemented, followed by a second 3-week (A) phase. There is no separate control group in this study, and all participants receive the same intervention during the intervention phase (B).
89415710|NCT06161142||Persistant hypophosphatasemia|"Patients with persistant hypophosphatasemia are highly suspicious for hypophosphatasia, and as such are the main focus of this study.~In case of persistently low alkaline phosphatase (2nd measurement, 2-4 weeks after the 1st measurement) with normal serum calcium and phosphate values (exclusion of secondary hypophosphatemia due to e.g. rickets or malnutrition) and exclusion of other causes of secondary hypophosphatemia, genetic testing for a pathological ALP gene is performed as part of routine diagnostics.~This study involves the structured recording of specific symptoms, the entire course of the disease since childhood, laboratory parameters and genetic testing."
89415711|NCT06161142||Transient hypophosphatasemia (Control group without hypophosphatasia)|"In patients, in which the initial hypophosphatasemia does not confirm with the second ALP testing, the former suspicion of hypophosphatasia must be discarded. With the exclusion of a hypophosphatasia (characterized by a persistant hypophosphatasemia among other criteria) this group of patients qualifies as a control group of patients without hypophosphatasia.~Data from this control group will be analyzed in order to investigate patient historical, clinical and laboratory features that may help in the discrimination of hypophosphatasia patients against healthy individuals."
89415712|NCT06161129|No Intervention|Control|Group of 50 participants (control) will receive glasses with clear lenses.
89415713|NCT06161129|Active Comparator|FL-41|Group of 50 participants will receive a glasses with an FL-41 filter.
89415714|NCT06161129|Active Comparator|BlueCut|Group of 50 participants will receive glasses with a Blue Cut filter.
89415715|NCT06161129|Active Comparator|500nm|Group of 50 participants will receive glasses with a below 500 nm filter
88922137|NCT05746832|Active Comparator|One session application of (ERCP) in the management of common bile duct stones.|One session application of endoscopic stenting retrograde cholangiopancreatography (ERCP) in the management and clearance of difficult common bile duct stones and assessment of the differences in stone size and the largest CBD diameter before and after stenting in one or two sessions. Stone clearance and complications were also determined with the ERCP, and factors associated with complete clearance were evaluated in patients with difficult CBD stones (a large [≥ 20 mm] or multiple [≥ 3 sized ≥ 15 mm] CBD stones). And also compared the outcomes with conventional procedure of open surgery.
89415716|NCT06161103|Experimental|Experimental: 3D Printed Prefabricated Composite Resin Crown group|(Custom Composite Resin (Custom Resin Solutions, CRSCAM TEKNOLOJİ AŞ., ANTALYA, TURKEY)
89415717|NCT06161103|Experimental|Active Comparator: Prefabricated stainless steel crown group|Stainless Steel Crown (SSC, Kids Crown, Shinghung, Seoul, Korea)
89193100|NCT05555758|Placebo Comparator|placebo group|Four ascending dose levels of placebo (n=8) for intravenous injection for once. Dosage day is Day 1.
89415718|NCT06161090|Experimental|Group 75 mg|CM310 Recombinant Humanized Monoclonal Antibody Injection
89415719|NCT06161090|Experimental|Group 150 mg|CM310 Recombinant Humanized Monoclonal Antibody Injection
89415720|NCT06161090|Experimental|Group 300 mg|CM310 Recombinant Humanized Monoclonal Antibody Injection
89415721|NCT06161090|Experimental|Group 600 mg|CM310 Recombinant Humanized Monoclonal Antibody Injection
89415722|NCT06161090|Placebo Comparator|Placebo|Placebo, Subcutaneous
89415723|NCT06161064|Other|office-based injection laryngoplasty|office-based injection laryngoplasty by using hyaluronic acid
89415724|NCT06161051||Capmatinib|
89415725|NCT06161051||IO monotherapy|
89415726|NCT06161051||Chemotherapy alone|
89415727|NCT06161051||IO + chemotherapy|
89415728|NCT06161038|Active Comparator|Cohort A-A.therapeutic ultrasound group|"Participants: Age between 20-100 years old who diagnosed as myofascial pain syndrome patients and willing to receive treatment.~Intervention: Group A (A) receives 1 MHz therapeutic ultrasound for 5 min at a frequency of 2-3 times per week at the painful upper trapezius muscle."
89415729|NCT06161038|Active Comparator|Cohort A-B.prolotherapy group|"Participants: Age between 20-100 years old who diagnosed as myofascial pain syndrome patients and willing to receive treatment.~Intervention: Group B receives hypertonic prolotherapy at perimysium of upper trapezius muscle. The injectant is 5ml 5% dextrose solution."
89415730|NCT06161038|No Intervention|Cohort B|"Participants: Age between 13-65 years old who diagnosed as idiopathic scoliosis The diagnosis of scoliosis was confirmed by antero-posterior plain Xray with Cobbs angle larger than 10 degrees.~Intervention: None"
89415731|NCT06160947|Active Comparator|Usual Medical Care|This group will consist of eligible, consenting, participants attending centers randomized to ongoing usual medical care.
89415732|NCT06160947|Experimental|Usual Medical Care + Chiropractic Care|This group will consist of eligible, consenting, participants attending centers randomized to ongoing usual medical care plus chiropractic care.
89415733|NCT06160934|Experimental|Intervention Group|The T1D Parent Check-in Group (Intervention Group) will participate in three sessions that will be delivered by a licensed clinical psychologist. In the larger RCT, the intervention will be manualized with training and a treatment protocol that can be delivered by any trained member of the diabetes psychosocial team (e.g., social workers, licensed mental health clinicians, and/or clinical psychologists). The intervention is designed to be both tailored and flexible but with fidelity to a basic structure. Diabetes-specific handouts and videos will be created as part of the intervention and will be provided to families throughout the course of the study.
89536760|NCT02469779|Experimental|ASPIRE Group|Participants complete baseline survey. Participants view the ASPIRE website containing videos, activities, and health information facts about the effects of smoking, the benefits of meditation, and healthy living. This viewing will be videotaped and audio recorded. 3 to 4 sessions will be completed. After each website session, survey will be completed.
89415734|NCT06160934|No Intervention|Treatment as Usual (TAU) Group|Parents assigned to the Treatment As Usual (TAU) group will complete T1-T4 study questionnaires alongside the intervention group. They will also take the Motivation Quiz as part of their T2 questionnaires. Instead of a one-month phone call, these participants will be scheduled for a one-time consultation with a study psychologist after completing their T4 questionnaires. This consultation will entail reviewing the family's specific questionnaire results, discussing challenges/strategies relevant to the family's needs, and providing additional recommendations/referrals as indicated. Families will also be provided access to study resources that will assist with their family's overall adjustment to T1D.
89193101|NCT05555706|Experimental|B013+ Nab-Paclitaxel|"B013 at a fixed dose of 600 milligrams via intravenous (IV) infusion on Days 1 and 15 of the first 28-day cycle, then on Day 1 of each subsequent 28-day cycle.~Nab-Paclitaxel 100 mg/m^2 is administered weekly on Days 1, 8, 15 of each 28-day cycle."
89193102|NCT05545514|Experimental|Verum|"Individualized homeopathy (iHOM):~One out of 140 predefined homeopathic medical products (HMP) in potency C200 or C1000, individually selected as indicated per homeopathic treatment principles. The HMPs are sucrose pillules, impregnated with the specific homeopathic substance and potency and will be administered once at baseline: 5 pillules sublingually. The dosage of the HMP can be repeated or adapted according to the homeopathic treatment principles three times during the course of the study and, in addition, in the event of an acute UTI."
89193103|NCT05545514|Placebo Comparator|Placebo|Non-impregnated sucrose pillules, identical to the HMP (verum) in appearance, taste and size.
89193104|NCT05545384|Experimental|Immediate Azathioprine (1st attack)|"Treatment will be started at 2mg/kg or at 1mg/kg if the patient has a partial activity which would be increased slowly according the 6-TGN activity and clinical and biological tolerance at Week 2 for patient with partial activity or M1 for patient without TPMT activity deficit.~Only for patient with partial deficit and whose 6-TGN activity is low, azathioprine would be increased at 3mg/kg/d at Week 6 and without exceeding a total daily dose of 150 mg."
89415735|NCT06160869|Experimental|ACT Group|Received 90-minutes weekly group sessions of acceptence and commitment therapy plus treatment as usual.
89415736|NCT06160869|Active Comparator|Treatment as usual (TAU) group|Will receive the TAU alone
89415737|NCT06160856||Normal intra-abdominal pressure|
89415738|NCT06160856||Elevated intra-abdominal pressure|
89415739|NCT06160843|Experimental|Study Treatment|Pembrolizumab with Daily Olaparib.
89415740|NCT06160830|Active Comparator|synbiotic|Patients in the synbiotic group will receive, for 10-12 weeks, Two capsules of synbiotic (Zist Takhmir Company) per day, each containing 500 mg of synbiotic. Patients in this group received a multispecies probiotic product (109 CFU/capsule) and fructo oligosaccharid as prebiotics.
89415741|NCT06160830|Placebo Comparator|placebo|Patients in the placebo group will receive Two capsules of placebo containing maltodextrin per day. The placebo powder will comparable in color, texture, and taste to the synbiotics. Supplement packaging will be done by Zist Takhmir Company.
88893226|NCT03233347|Experimental|Treatment (combination chemotherapy, nivolumab)|Patients receive doxorubicin IV over 3-5 minutes, vinblastine IV over 3-5 minutes, and dacarbazine IV over >= 30 minutes, and brentuximab vedotin IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for 3 cycles in the absence of disease progression or unacceptable toxicity. Patients with PET-positive then receive brentuximab vedotin IV over 30 minutes and nivolumab IV over 30 minutes on day 1. Treatment repeats every 2 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity. PET-positive patients then receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 2 weeks for 8 cycles in the absence of disease progression or unacceptable toxicity. PET-negative patients receive nivolumab IV over 30 minutes on day 1 starting after AVD and BV treatment. Treatment repeats every 2 weeks for 8 cycles in the absence of disease progression or unacceptable toxicity.
89415742|NCT06160804|Placebo Comparator|Local standard of care|
89415743|NCT06160804|Active Comparator|Experimental change in care|
89415744|NCT06160791|Experimental|Treatment (ruxolitinib, dexamethasone, etoposide)|During induction therapy, participants receive ruxolitinib orally (PO) twice daily (BID) plus de-intensified HLH-94 induction with dexamethasone PO or intravenously (IV) once daily (QD) or BID for 4 weeks and etoposide IV twice a week (BIW) for 2 weeks and then based on response, once a week (QW) for another 2 weeks in the absence of disease progression or unacceptable toxicity. After induction therapy, participants receive continuation therapy with ruxolitinib PO BID on days 1-28 of each cycle. Treatment repeats every 28 days for a total of up to 6 months after first administration of study drug in the absence of disease progression or unacceptable toxicity.
89415745|NCT06160778|Experimental|Ketorolac Tromethamine|Ketorolac tromethamine, an NSAID belonging to a group of non-opioid analgesics that inhibit the synthesis of prostaglandins and thromboxanes with strong analgesic and anti-inflammatory properties. It is the only non-opioid parenteral non-sedating analgesic available in Canada for use to treat acute pain in the emergency department.
89415746|NCT06160778|Active Comparator|Morphine Sulfate|An intravenous opioid that is commonly used as part of usual care for treament of pain in patients with acute abdominal pain and suspected appendicitis.
89415747|NCT06160765||1.5 kcal/ml High Density Formula|This group consist of patients who are able to consume 300-400 kcal of solid food and given 400 cc High Density Formula 1.5 kcal/ml equivalent to 600 kcal
89415748|NCT06160765||1 kcal/ml High Density Formula|This group consist of patients who are able to consume 500-600 kkal of solid food and given 400 cc High Density Formula 1 kcal/ml equivalent to 400 kcal
88893227|NCT03192176|Placebo Comparator|Placebo|Participants received fezolinetant matching placebo capsules orally, BID for a period of 12 weeks.
88893228|NCT03192176|Experimental|Fezolinetant 15 mg|Participants received fezolinetant 15 mg capsules orally, BID for a period of 12 weeks.
88893229|NCT03192176|Experimental|Fezolinetant 30 mg|Participants received fezolinetant 30 mg capsules orally, BID for a period of 12 weeks.
88893230|NCT03192176|Experimental|Fezolinetant 60 mg|Participants received fezolinetant 60 mg capsules orally, BID for a period of 12 weeks.
88893231|NCT03192176|Experimental|Fezolinetant 90 mg|Participants received fezolinetant 90 mg capsules orally, BID for a period of 12 weeks.
88893232|NCT03192176|Experimental|Fezolinetant 30 mg + Placebo|Participants received fezolinetant 30 mg capsules orally, QD and matching placebo QD for a period of 12 weeks.
88893233|NCT03192176|Experimental|Fezolinetant 60 mg + Placebo|Participants received fezolinetant 60 mg capsules orally, QD and matching placebo QD for a period of 12 weeks.
88893234|NCT03192176|Experimental|Fezolinetant 120 mg + Placebo|Participants received fezolinetant 120 mg capsules orally, QD and matching placebo QD for a period of 12 weeks.
89415749|NCT06160739||group A|microcystic & mixed lymphatic malformation
89415750|NCT06160739||group B|vascular malformation
89415751|NCT06160674||COPD|30 COPD participants, 16 Female and 14 Male.
89415752|NCT06160674||HC|38 HC participants, 20 Female and 18 Male.
88893239|NCT03024333||Healthy subjects|"Healthy subjects are:~Between 19-60 years old~Able to sign the informed consent after the whole study is explained to them~Self-reporting no history of swallowing disorders, neurological deficits and/or cancer of the mouth, neck or brain, or head or neck surgery~Able to sit upright with or without back support of chair~No other diseases affect swallowing function"
88893240|NCT03016013|Placebo Comparator|Placebo plus MTX|Patients received placebo SC plus MTX weekly administered subcutaneously for 24 times.All patients had a foundation MTX therapy, MTX dose should be stable, not to adjust the dose.The researchers evaluated the efficacy of the patient in 12 week.Evaluation of efficacy in patients if not get the ACR20 response, adjust the treatment plan given the test drug.Test group continue to the test drug,placebo group switch to the test drug.
89415753|NCT06160661|Experimental|single arm study|"The purpose of this study was to assess the accuracy of a splint-less approach for mandibular jaw orthognathic surgery. This approach utilized a personalized orthognathic surgical guide (POSG) system, which comprised a set of cutting guides and 3D printed custom titanium fixation plates for bilateral sagittal split osteotomies (BSSOs).~The cutting guides were first used to predrill screw holes and guide osteotomies. The custom plates were then used to reposition and stabilize the bony segments as planned, without the use of surgical splints or any additional tool such as surgical navigation"
89415754|NCT06160648|Experimental|Mechanical Diagnosis and Therapy (MDT)|MDT is a system of examination and intervention based on the patient's response to repeated end range neck movements.
89415755|NCT06160648|Active Comparator|Cervical Spine Clinical Practice Guidelines (CPGs)|The CPGs are guidelines for examination and intervention based on a summary of research conducted on people with neck pain.
88893241|NCT03016013|Experimental|Experimental: RC18 160 mg+MTX|Patients received the test group RC18 160mg plus MTX weekly administered subcutaneously for 24 times. All patients had a foundation MTX therapy, MTX dose should be stable, not to adjust the dose.
88893242|NCT02990130||Study Group|This is a pilot observational study involving patients enrolled in the Seattle VA Bone Marrow Transplant Unit (BMTU) for treatment of their hematologic malignancy. Measurements of patient fitness, body composition, and inflammatory milieu will be performed at visits before HCT, and 30 days (+/- 10 days) after HCT. For patients that continue to receive care at the Seattle VA, additional visits (not exceeding 6 total) may be requested periodically for up to 2 years after HCT.
89193105|NCT05545384|Experimental|Immediate Rituximab (1st attack)|"Once the inclusion criteria are validated, the first injection will be performed according to the injection protocol (Annex 4). Fifteen day later, the second injection will be performed.~The next visit during a consultation with PI or his collaborators will be scheduled 1 week ± 2 days later, and patients will be advised to contact the PI if any neurologic symptoms or symptoms of adverse event occurs in the meantime."
89415756|NCT06160635||Cohort A|Cohort A: Patients chronically infected with HDV. Patients with and without cirrhosis and with and without viremia will be included.
89415757|NCT06160635||Cohort B|Cohort B: Patients chronically infected with HDV and with available historical liver biopsies (5-20 years old biopsies) and clinical follow-up data or current patients willing to receive a core biopsy or fine-needle liver-cell aspirate (FNA). Patients with and without cirrhosis and with and without viremia will be included.
89415758|NCT06160596||PDAC STAGE IV SURVIVORS & CONTROLS|Metastatic pancreatic ductal adenocarcinoma (PDAC) (Other histologies such as adenosquamous carcinoma, hepatoid carcinoma, anaplastic undifferentiated carcinoma and medullary carcinoma, acinar cell carcinoma, neuroendocrine tumors, Solid pseudopapillary neoplasm, Pancreatoblastoma, Serous cystadenocarcinoma are excluded)
89415759|NCT06160596||SMALL CELL LUNG CANCER EXTENSIVE STAGE SURVIVORS & CONTROLS|Extensive small cell lung cancer (SCLC) (Other histologies excluded: combined SCLC with some areas of non-small cell lung cancer (NSCLC), carcinoid tumors, typical and atypical, large cell neuroendocrine carcinoma of the lung).
89415760|NCT06160596||GLIOBLASTOMA SURVIVORS & CONTROLS|Glioblastoma (GBM) (IDH mutated excluded)
89415761|NCT06160570|Active Comparator|IMRT|Intensive Modulated Radiation Therapy
89415762|NCT06160570|Active Comparator|3DCRT|3-Dimension Conformal Radiation Therapy
89415763|NCT06160531|Experimental|CC-42344 Dose 1|Low dose group
89415764|NCT06160531|Experimental|CC-42344 Dose 2|High dose group
89415765|NCT06160531|Placebo Comparator|Placebo|
89415766|NCT06160505||Patients that underwent mastoidectomy alone|This is the control group, consisting of patients that have underwent either canal wall up or canal wall down mastoidectomy for CSOM without mastoid obliteration
89415767|NCT06160505||Patients that underwent mastoidectomy + mastoid obliteration|This is the intervention group, consisting of patients that have underwent either canal wall up or canal wall down mastoidectomy for CSOM followed by obliteration of the mastoid cavity using S53P4 bioactive glass
89415768|NCT06160479|No Intervention|Normal calcium level with no receiving calcium supplement|Pregnant women with normal calcium level in the first half of pregnancy do not receive calcium supplement.
89415769|NCT06160479|Experimental|Normal calcium level with receiving calcium supplement 1g/day|Pregnant women with normal calcium level in the first half of pregnancy receive calcium supplement 1g/day.
89415770|NCT06160479|Experimental|Hypocalcemia with receiving calcium supplement 1g/day|Pregnant women with hypocalcemia in the first half of pregnancy receive calcium supplement 1g/day.
89536761|NCT02469779|Active Comparator|Control Group|Participants complete baseline survey. Participants view the ASPIRE text-based website containing health information facts about smoking, the benefits of meditation, and healthy living. This viewing will be videotaped and audio recorded. 3 to 4 sessions will be completed. After each website session, survey will be completed.
88893245|NCT02940496|Experimental|Arm A (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
88893246|NCT02940496|Experimental|Arm B (pembrolizumab, elbasvir/grazoprevir, ribavirin)|Patients receive pembrolizumab as in arm A. Patients also receive elbasvir/grazoprevir orally PO QD and ribavirin PO QD on days 1-28. Treatment continues for 12-16 weeks in the absence of disease progression or unacceptable toxicity.
88893247|NCT02910492|Experimental|Investigational Enlighten Device|Laser treatment for facial skin rejuvenation with the experimental enLighten Laser
88893248|NCT02897908||liver fibrosis and steatosis|measurements of liver fibrosis and steatosis will be obtained using Vibration controlled transient elastography FDA approved device- FibroScan for the purpose of building a data base of potential subjects for future research.
88893249|NCT02848885|Experimental|Active TDCS|Participants who are randomly assigned to this arm will receive dual hemisphere parietal (P3 cathodal, P4 anodal) stimulation daily for 10 days. Each participant will have two MRI scans and their degree of illness awareness assessed at baseline and after 10 days of tDCS. Illness awareness will be assessed weekly thereafter for 4 weeks.
88893250|NCT02848885|Experimental|Sham TDCS|Participants who are randomly assigned to this arm will receive dual hemisphere sham stimulation with electrodes placed on the parietal lobes (P3 and P4) daily for 10 days. Each participant will have two MRI scans and their degree of illness awareness assessed at baseline and after 10 days of tDCS. Illness awareness will be assessed weekly thereafter for 4 weeks.
88893251|NCT02828761|Experimental|Coronary Calcium Scoring|Coronary calcium scoring by multidetector row computed tomography (MDCT).
88893252|NCT02828761|Active Comparator|Standard Care|Standard evaluation of chest pain patient which often includes immediate non-invasive imaging.
88893253|NCT02823171|Experimental|Sequence I|Sequence I: treatment A/B
88893254|NCT02823171|Experimental|Sequence II|Sequence II: treatment B/A
88893255|NCT02808455|Experimental|Sequence I: A/B|Treatment A: pacritinib 400 mg capsule
88893256|NCT02808455|Experimental|Sequence II: B/A|Treatment B: pacritinib 80 mg solution
88893257|NCT02807207|Experimental|Sequence I|treatment sequence: A/B/C
88893258|NCT02807207|Experimental|Sequence II|treatment sequence: A/C/B
88893259|NCT02807207|Experimental|Sequence III|treatment sequence: B/A/C
88893260|NCT02807207|Experimental|Sequence IV|treatment sequence: B/C/A
88893261|NCT02807207|Experimental|Sequence V|treatment sequence: C/A/B
88893262|NCT02807207|Experimental|Sequence VI|treatment sequence: C/B/A
88893263|NCT02807116|Experimental|Pacritinib and Rifampin|On Day 1, subjects received a single oral 400-mg dose of pacritinib. On Days 8 through 17, following a 7-day washout period, 600-mg oral doses of rifampin were administered QD. It was anticipated that steady-state concentrations of rifampin would be achieved by Day 17. On Day 17, a single oral 400-mg dose of pacritinib was co-administered with the final 600-mg dose of rifampin.
88893264|NCT02704377|Experimental|Supportive care (quality of life, supportive care preferences)|Participants complete questionnaires about quality of life and preferences for supportive care treatment, wear accelerometerundergo heart rate variability(HRV) testing over 10-15 minutes while both lying down and standing, complete a walking test, wear an accelerometer for a period of 1 week, and undergo a single Dual X-ray Absorptiometry (iDXA) scan over 10 minutes. Other interventions include: Laboratory Biomarker Analysis, Quality-of-Life Assessments, and othe Questionnaire Administration.
88893265|NCT02680743|Experimental|Intervention Group|"Patients who fail newborn hearing screen will be screened for CMV by saliva PCR. If positive they will be referred for early hearing screen follow-up and early intervention.~They will also receive a consult with PEdiatric Infectious Disease to evaluate need for treatment.~Intervention:Education of parents to pursue prompt hearing screening."
89415771|NCT06160479|Experimental|Hypocalcemia level with receiving calcium supplement 2g/day|Pregnant women with hypocalcemia in the first half of pregnancy receive calcium supplement 2g/day.
89415772|NCT06160440|Experimental|A single dose SC1011 50mg（A1）|Drug: SC1011 tablet Treatment: No food prior to dosing
89415773|NCT06160440|Placebo Comparator|A single dose SC1011 150mg（A2）|Drug: SC1011 tablet Drug: SC1011-matching placebo tablet Treatment: No food prior to dosing
89415774|NCT06160440|Experimental|A single dose SC1011 150 mg（A3）|Drug: SC1011 tablet Drug: SC1011-matching placebo tablet Treatment: No food prior to dosing
89415775|NCT06160440|Experimental|A single dose SC1011 300mg（A4）|Drug: SC1011 tablet Drug: SC1011-matching placebo tablet Treatment: No food prior to dosing
89415776|NCT06160401|Experimental|Singletine（DC407） ascending dose|Single ascending dose
89415777|NCT06160401|Experimental|Singletine（DC407）food influence group|Food influence group
89415778|NCT06160401|Placebo Comparator|Singletine placebo comparator(Single ascending dose)|Single ascending dose
89415779|NCT06160401|Placebo Comparator|Singletine placebo comparator(food influence group)|Food influence group
89415780|NCT06160388||Patients that underwent mastoidectomy + mastoid obliteration using bioactive glass|This is the intervention group, consisting of patients that have underwent either canal wall up or canal wall down mastoidectomy followed by obliteration of the mastoid cavity using S53P4 bioactive glass for any indication
89415781|NCT06160388||Patients that underwent mastoidectomy alone|This is the control group, consisting of patients that have underwent either canal wall up or canal wall down mastoidectomy without mastoid obliteration for any indication
89415782|NCT06160362|Experimental|double-target CART-19 and 20|Patients will receive a pre-conditioning with cyclophosphamide and fludarabine before infusion of double-target CART-19 and 20 cells. The double-target CART-19 and 20 cells are to be administered on day0.
89415783|NCT06160349||Patient Interviews|Patients with risk factors for maternal sepsis interviewed about pregnancy, labor/delivery, and postpartum via Zoom.
89415784|NCT06160349||Community Stakeholders|Community stakeholders with professional and/or academic backgrounds relevant to maternal health who participate in focus group discussion.
88893266|NCT02603835|Experimental|SSO2 Therapy|Delivery of SSO2 Therapy for 60 minutes selectively into the left main coronary artery (LMCA) using the TherOx DownStream System along with a single use disposable device called the TherOx DownStream Cartridge and a commercially available, qualified SSO2 delivery catheter
88893267|NCT02531594|Experimental|SBIRT|"An assessment form, motivational interviewing, personalized educational materials, immediate access to cessation resources, a 12-week supply of nicotine replacement therapy and weekly booster materials for 12 weeks.~nicotine"
88893268|NCT02531594|Placebo Comparator|HHC|The Healthy Habits Control program has been previously developed and used in the out-patient setting, and will be used as an attention control in which caregivers will receive instruction on healthy lifestyle choices to improve their child's health. Cessation assistance will be offered at the study's conclusion.
88893269|NCT02495311||Women with uterine myoma|Women with uterine myoma
88893270|NCT02495311||Women with adenomyosis|Women with adenomyosis
88893271|NCT02495311||Women without uterine myoma or adenomyosis|Control group
88893272|NCT02465541|Experimental|Arm I (gentle yoga and dietary counseling)|Participants undergo onsite gentle yoga once weekly over 45-60 minutes for 8 weeks and home-based gentle yoga for 6 weeks. Participants also undergo dietary counseling over 8 weeks.
88893273|NCT02465541|Active Comparator|Arm II (enhanced usual care)|Participants undergo enhanced usual care designed to educate on best practices for exercise, diet and lifestyle change once weekly for 14 weeks.
88893274|NCT02370875|Experimental|Real rTMS stimulation|Repetitious transcranial magnetic stimulation (rTMS) will be delivered using the Magstim RapidStim2 over each anterior cingulate cortex, using a figure-of-eight coil. The investigators will apply rTMS with 0.2 Hz frequency to the ACC. 180 stimuli will be delivered with a stimulator output of 100% active motor threshold (AMT). AMT will be assessed at the tibialis anterior muscle with the coil. The AMT will be defined as the lowest stimulation intensity required to evoke a 150 μV potential in the target muscle. To determine the stimulation site for ACC, the coil will be placed over Fz and then moved over the midline of the brain in 0.5-cm steps anteriorly, until the point of maximum motor evoked potential in the orbicularis oculi (OO) muscle. The coil position will be marked on the skin. These rTMS sessions will be repeated daily for 10 days.
88893275|NCT02370875|Sham Comparator|Sham rTMS Stimulation|During sham repetitious transcranial magnetic stimulation (rTMS), subjects will undergo the same procedure for identifying stimulus location as used in patients receiving real rTMS using the sham Magstim RapidStim2 coil. This coil will be placed on the patient's head in an identical manner however will not be connected to the Magstim device. Instead another coil will be connected to provide stimulation sound. In each stimulation condition, the Magstim will be placed behind the patient and not visible to him or her. Placebo sham coil which produces discharge noise and vibration similar to a real coil without stimulating the cerebral cortex. During rTMS, all patients will continue to wear ear plugs as instructed during the real stimulation sessions.
88893276|NCT02365467|Experimental|Treatment with Valiant Mona LSA device|Treatment with Valiant Mona LSA device
89415785|NCT06160323|Active Comparator|EUS-guided coeliac ganglion neurolysis / celiac plexus neurolysis|"Patient would undergo a EUS diagnostic procedure with or without a biopsy. Patient would be blinded to the group they were assigned. The procedure will be performed with a linear array echoendoscope (EUS) under conscious sedation or monitored anaesthesia care.~For cases in which celiac ganglia could not be visualized, EUS-guided coeliac plexus neurolysis (CPN) will be performed."
89415786|NCT06160323|Active Comparator|Conventional step-up approach|"Patient would undergo a EUS diagnostic procedure with or without a biopsy. Patient would be blinded to the group they were assigned. The concept of the conventional step-up approach is to follow ESMO clinical practice guidelines for cancer pain.~In case of inadequate pain control, the analgesics will be stepped up according to the guidelines. After 4 weeks, if patient's VAS score more than 7 or VAS score fails to improve by 20% despite optimal oral analgesics, patients are given the option of EUS-guided CGN/ CPN."
89415787|NCT06160297|Experimental|Modified Otago Exercise Group|MOEG consists of strengthening and balance exercises. Participants were instructed to start the exercises with 5-minute flexibility exercises. The walking component of the original Otago exercises and the stair climbing exercise in the balance exercises were not included in the MOEG. The exercises included 5 strengthening exercises and 11 balance exercises.
89415788|NCT06160297|Experimental|Neuromuscular Exercise Group|Neuromuscular exercises basically consist of four exercise components. These; core stability / postural function, postural orientation, lower extremity muscle strength and functional exercises. Exercises also include 5-minute warm-up and cool-down periods.
89415789|NCT06160297|No Intervention|Control Group|Traditional physiotherapy applications (Hotpack + US (Ultrasound) + TENS (Transcutaneous Electrical Stimulation) were applied to the control group initially, as in every group. After these applications, they were evaluated in terms of basic parameters. A re-evaluation was made after 12 weeks.
89415790|NCT06160245|Experimental|core stability exercise|
89415791|NCT06160245|Active Comparator|traditional exercise|
89415792|NCT06160232|Experimental|high dose psilocybin|31 participants will receive a single administration of 30mg psilocybin provided within the context of a brief standardized psychotherapeutic intervention.
89415793|NCT06160232|Placebo Comparator|low dose psilocybin (active placebo)|31 participants will receive a single administration of a very low dose of psilocybin (active placebo) provided within the context of a brief standardized psychotherapeutic intervention.
89415794|NCT06160219|Active Comparator|Group (OH CO)|Group (OH CO): 30 patients will receive hydroxycobolamin (Cyanokit) 5 gm intravenously(iv) through the central venous catheter as bolus over 15 min reconstituted in 200 ml of NS.
89415795|NCT06160219|Placebo Comparator|Group (C) control|Group (C) control: 30 patients will receive 200ml of NS over 15 min iv.
89415796|NCT06160206|Experimental|Arm A (Retifanlimab, bevacizumab and HFRT)|ARM I: Patients receive retifanlimab IV over 30 minutes on day 1 and bevacizumab IV on day 1 and 15 of each cycle. Treatment repeats every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo HFRT QD, starting in cycle 1 on day 15 for 10 treatments. Patients undergo MRI or CT, as well as blood sample collection throughout the study.
89415797|NCT06160206|Experimental|Arm B (Bevacizumab and radiation)|Patients receive bevacizumab IV on day 1 and 15 of each cycle. Treatment repeats every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo HFRT QD, starting in cycle 1 on day 15 for 10 treatments. Patients undergo MRI or CT, as well as blood sample collection throughout the study.
89415798|NCT06160180|Active Comparator|Drug arm preoperative|receiving pre-operative submucosal dexamethasone 2ml of 4mg/ml solution into buccal vestibule prior to the incision.
89415799|NCT06160180|Active Comparator|Drug arm postoperative|receiving immediately post-operative submucosal dexamethasone 2ml of 4mg/ml solution in the buccal vestibule after placement of last suture.
89415800|NCT06160167||Participants with MM treated with IMiDs|
89415801|NCT06160167||Participants with MM not treated with IMiDs|
89415802|NCT06160167||Participants with MM treated with systemic therapy|
89005976|NCT04662658|Other|Visit 1 UVA|"Visit 1 will last approximately 4 hours, and will include consenting, collection of data, questionnaires, and procedures as follows:~Informed consent~Demographic data~Smoking history~Medical history review~Medication review~Limited physical exam~6-minute walk test~St. George's Respiratory Questionnaire (SGRQ)~Baseline dyspnea index (BDI)~Chronic respiratory questionnaire (CRQ)~PFTs including:~Pre-bronchodilator spirometry/ post bronchodilator spirometry.~Body plethysmography (static lung volumes)~Carbon monoxide diffusion capacity (DLCO)~Collection of peripheral blood (20mL), exhaled breath condensate (EBC), and urine~Hyperpolarized xenon-129 MRI (HXeMRI) if all eligibility criteria are met"
89415803|NCT06160141|Experimental|Training group|The training group performed 48 weeks of resistance training, 3 times per week.
89415804|NCT06160141|No Intervention|Control Group|The control group did not performed any kind of resistance exercises.
89415805|NCT06160102|Other|Framework for safe drug use in people with intellectual and/or developmental disabilities|"Optimizing medication management and medication therapy poses complex challenges related to the different groups, actors, and not least the data systems. To meet these challenges, we have chosen a method where the participants contribute actively in the research: participatory action research (PAR). This method involves both the action and the knowledge production being done in collaboration between all the participants, since neither the researcher nor others have exclusive right to the understanding of reality.~Normalization process theory offers an analytical tool that helps to understand and explain the dynamic processes that occur during the implementation of complex interventions and technological and organizational innovations in health care, which includes institutional and organizational contexts and focuses on what social processes can promote and inhibit it through the integration of new routines and work forms in established social structures."
89415806|NCT06160089|Active Comparator|Gravitational group|Participants will have to perform a 6-week programme based on three exercises: front lunge, side lunge, and front lunge with hand grip pull, that will be the basis of each session. Exercices will be performed with the gravitational device.
89415807|NCT06160089|Experimental|Isoinertial group|Participants will have to perform a 6-week programme based on three exercises: front lunge, side lunge, and front lunge with hand grip pull, that will be the basis of each session. Exercices will be performed with the isoinertial device.
89415808|NCT06160076||Radiofrequency|Patient with atrial fibrillation ablated per radiofrequency
89415809|NCT06160076||Pulsed electric field|Patient with atrial fibrillation ablated per pulsed electric field
89415810|NCT06160063|Experimental|Experimental group|"It is planned to meet with the experimental group 3 times in total. In the first interview, first of all, Diabetes Child Diagnosis Form and Diabetes Health Literacy Scale for Acute Complications in Children will be applied. Then the diabetes health literacy board game will be played. For this, groups of 4 will be formed and care will be taken to ensure that children of similar age groups are together while forming groups. In the clinic, they will be asked to play a diabetes health literacy (DISOY) board game in a quiet, bright room, a room with a table and 4 chairs. DISOY board game averages 45-60 minutes. and the first meeting will end here. Each child will be given one game to play with their parents at least twice at home.~The second interview will be provided 1 month after the first interview. The third interview will be held in the third month. Data collection forms will be filled out again at each interview."
89415811|NCT06160063|No Intervention|control|"control group; It is planned to meet with the control group 3 times in total. In the first, second and third interviews, only the data collection forms will be filled by the children.~After collecting all the data of the experimental group, a board game will be given to the parents and children in the control group."
89415812|NCT06160037|Active Comparator|Arm 1. Transportation and Screening|Free transportation for scheduled prenatal care, developmental screening and referral services for the child at the 6th, 12th, and 24th months of the child's life.
89415813|NCT06160037|Experimental|Arm 2. Transportation, Screening, and Nurse-Visitation during Pregnancy and Infancy|Free transportation for scheduled prenatal care; intensive nurse home-visitation services during pregnancy and through the child's second birthday; and developmental screening and referral services for the child at the 6th, 12th, and 24th months of the child's life.
89415814|NCT06160024|Other|Long-term care facilities|All participating facilities will be offered the same bundle of measures, with core and optional or adaptable components based on the identified needs.
89415815|NCT06160011|Experimental|Intervention Group Electrical Dry Needling amd Physiotherapy|The intervention group will receive a treatment composed by electrical dry needling and conventional physiotherapy treatment
89005977|NCT04662658|Other|Visit 2 Duke University|"Visit 2 will last about 3 hours, and will occur within 2-12 weeks of Visit 1. The purpose of this study visit is to obtain a measure of basic test-retest variability on 6 e-cigarette users and 6 control subjects. Participants will be selected based on age and sex matching needs at the time of enrollment.~During Visit 2, changes in health since Visit 1 will be assessed. In addition, the following will be done in accordance with the parent protocol:~The standard MR compatibility screening form will be completed.~Spirometry will be performed before and after MR imaging.~A limited physical exam~Female subjects who could be pregnant will take a urine pregnancy test prior to imaging.~Xenon MRI will be performed~In addition to the above, the following will be completed:~Carbon monoxide diffusion capacity (DLCO)~Peripheral blood (20mL) and urine"
89005978|NCT04662424|Experimental|MUSIC|music in labor
89005979|NCT04662424|No Intervention|control|no music during labor
89415816|NCT06160011|Active Comparator|Intervention Group Dry Needling amd Physiotherapy|This group will receive a treatment composed by dry needling and conventional physiotherapy treatment
89415817|NCT06160011|Placebo Comparator|Control Group|Control group will receive conventional physiotherapy treatment
89415818|NCT06159985|Active Comparator|Pericardiostomy|The patients who were created with left posterior pericardiotomy during the operation
89415819|NCT06159985|No Intervention|No pericardiostomy|The patients who were not created with left posterior pericardiotomy during the operation
89415820|NCT06159972|Experimental|EndoFLIP|Intraop EndoFLIP measurements
89415821|NCT06159959||Group A: Obese Pregnant Females|About 122 Pregnant women candidate for elective cesarean section suffering from obesity where as Body mass index (BMI) is ≥30 kg/m2
89005980|NCT04662346|Other|patients undergoing robotic pancreatoduodenectomy|patients have pancreatic neoplasm and undergoing robotic pancreatoduodenectomy
89005981|NCT04662385|Experimental|aloe vera toothpaste group|a recently available aloe vera toothpaste for gingival care, offers a completely improved approach for treatment of gingivitis. aloe vera toothpaste was certified as an antibacterial .This innovative toothgel is made using stabilized aloe vera gel from Forever's own plantations and can help you fight plaque as part of a regular brushing routine.
89005982|NCT04662385|Active Comparator|colegate total toothpaste group|Active Ingredient: Stannous fluoride 0.454% (0.15% w/v fluoride ion) Purposes: Anticavity, Antigingivitis, Antisensitivity. Inactive ingredients: Zinc phosphate, Water, Sorbitol, Hydrated silica, Glycerin, PEG-12, Tetras
89005983|NCT04662229|Experimental|Experimental: 10 hz stimulatión|Eco-guided percutaneous electrical stimulation application of low frequency electrical current at 10 hz, 240 microsecond, over the median and ulnar nerve in the arm, for 1 minute on each nerve. The intensity of the current will reach the excitomotor threshold, causing visible but comfortable contractions.
89415822|NCT06159959||Group B: Non-Obese Pregnant Females|About 122 Pregnant women candidate for elective cesarean section and not obese obesity where as Body mass index (BMI) is < 30 kg/m2
89005984|NCT04662229|Sham Comparator|Sham stimulation|Application of the needles only on the median and ulnar nerve of the arm, for 1 minute on each nerve without current intensity and a sound will be applied.
89005985|NCT00557206|Experimental|1|This is a single arm trial.
89005986|NCT04661917|Experimental|BAY2327949|Participants will receive 60 mg of BAY2327949 (2 tablets of 30 mg) once daily for 28 days.
89005987|NCT04661917|Placebo Comparator|Placebo|Participants will receive matching placebo once daily for 28 days.
89005988|NCT04661800|Other|Test de bâton de Sniff|Cohorte
89005989|NCT04661527|Experimental|Sarilumab arm|
89005990|NCT00216944|Active Comparator|1|Premedication with atropine and morphine
89005991|NCT00216944|Active Comparator|2|Premedication with glycopyrronium, thiopental, suxamethonium and remifentanil
89005992|NCT04661488||Children and adolescence|
89005993|NCT00216983||1|"Fasting condition to measure:~quantitative relationships among proline, ornithine and glutamate with an emphasis on evaluating the rate of proline disposal and its conversion to ornithine and glutamate in burn patients~Evaluating the rate of proline de novo synthesis from glutamate or ornithine in burn patients"
89005994|NCT00216983||2|We will study the quantitative relationships among proline, ornithine and glutamate with an emphasis on evaluating the rate of proline disposal and its conversion to ornithine and glutamate in burn patients. When the patients are receiving regular TPN or TPN depleted with proline - arginine - glutamate.
89005995|NCT00216983||3|We wull evaluate the rate of proline de novo synthesis from glutamate or ornithine in burn patients when the patients are receiving regular TPN or TPN depleted proline-arginine-glutamate.
89005996|NCT04661449|Experimental|Lifestyle Intervention|every 3 months within 1 year.
89005997|NCT04661449|No Intervention|control group|Regular follow-up every 6 months within 1 year.
89005998|NCT00241371|Experimental|Clofarabine|4 mg/m2 IV over 1 hour on days 1-5 of each 28 day cycle.
89415823|NCT06159946|Experimental|Spinal cord injury|Each subject was asked to place their hand by the motion sensor (motion control), use a speech speaker (voice control), and then move their eyes up, down, left, and right to activate the eye gaze sensor (eye gaze control) to control water outputs for drinking, rinsing, and grooming. Each subject performed the same task/function three times.
89415824|NCT06159881|Experimental|Personalized cross linking|Participants were treated with personalized energy cross linking according to their thinnest point corneal pachymetry
89005999|NCT04661098|Experimental|Postpubertal patients with imperforate hymen|Formation of an annular hymen in cases of postpubertal imperforate hymen using a laparoscopic trocar (Darwish hymenotomy technique)
89415825|NCT06159855|Other|Control Group: Data Collection|"PRE-TEST~a) Who is decided to have a colonoscopy, using the Patient Information Survey, Procedure Compliance Survey and Beck Anxiety Scale.~ROUTINE APPLICATION~Patients who are planned to undergo colonoscopy and are included in the control group will be trained according to the bowel preparation protocol routinely applied by the clinical nurse.~The Procedure Compliance Survey, which is routinely used as a clinical procedure, is given to the patient/patient's relative after the training of the clinical nurse.~FINAL TEST~Immediately after the procedure, data will be collected again with the Patient Information Survey, Procedure Compliance Survey and Beck Anxiety Scale.~After the procedure, the cleanliness of the intestines will be evaluated by the physician with the Ottawa Bowel Preparation Scale.~The control group will be given training and a booklet after all data collection is completed."
89006000|NCT04661371|Experimental|The experimental group in acute cholecystitis|"inclusion criteria~among patients with mild acute cholecystitis (grade I by Tokyo guidelines) or moderate acute cholecystitis without evidence of gallbladder perforation(grade II)~cholecystitis with a thickness of 4 mm or more on gallbladder in preoperative imaging~Gallbladder with surrounding organs due to gallbladder inflammation~Patients over 19 years of age~normal saline (Isotonic Sodium Chloride Injection Daihan(50mL/bag)) was used before surgery."
89006001|NCT04661371|Experimental|The controled group in acute cholecystitis|"among patients with mild acute cholecystitis (grade I by Tokyo guidelines) or moderate acute cholecystitis without evidence of gallbladder perforation(grade II)~cholecystitis with a thickness of 4 mm or more on gallbladder in preoperative imaging~Gallbladder with surrounding organs due to gallbladder inflammation~Patients over 19 years of age~First-generation cephalosporin (Cefazolin inj., 1g, Cefazolin sodium, Chong-geun-dang pharm.co.) was used before surgery."
89006002|NCT04660630|Experimental|Precision group|The subjects were tested for gene, and the corresponding therapeutic drugs were selected according to the results of gene detection. Regular follow-up was conducted according to the study design to evaluate the efficacy and adverse reactions.
89006003|NCT04660630|Active Comparator|Experience group|The subjects were treated with drugs selected by doctors according to their experience. Follow up was performed at the same frequency as the precision group to evaluate the efficacy and adverse reactions.
89006004|NCT04660630|No Intervention|Observation group|The subjects did not accept any intervention, including follow-up, especially regular evaluation of efficacy and adverse reactions.
89006005|NCT04660786|Active Comparator|intralesional injection of triamcinolone acetonide|5mg/ml) using sterile saline for dilution every 4 weeks for 3 sessions
89006006|NCT04660786|Active Comparator|intralesional injection of vitamin D|(2.5 mg/mL) every 4 weeks for 3 sessions
89006007|NCT00217100|Active Comparator|Multi Vitamin Formulation|
89006008|NCT00217100|Placebo Comparator|Sugar pill|
89006009|NCT04660981|Experimental|İntervention Group|"The women in the intervention group were individually provided with Training Program on Fear of Childbirth Based on Motivational Interview Method once a week, four sessions in total."
89006010|NCT04660981|No Intervention|Control Group|No interventions were made for those in the control group other than routine hospital practices.
89006011|NCT00241410|Experimental|1|4 consecutive groups, dose escalation
89006012|NCT00241410|Placebo Comparator|2|4 consecutive groups
89006013|NCT04660825|Experimental|High intensity resistance band exercise|Randomly assigned as exercise group, exercise intervention. This will be a progressive exercise programme with the aim being to participate three times per week, one in a group session and two in-home sessions.
89006014|NCT04660825|Experimental|Non resistance band exercise|Randomly assigned non-exercise group
89415826|NCT06159842|Experimental|Photodynamic Therapy (Blue light dose 10 J/cm2 at 10 mW/cm2)|20 participants will be enrolled to this arm
89415827|NCT06159829|Experimental|Virtual Reality|Virtual Reality glasses
89415828|NCT06159829|No Intervention|Control|Patients in the control group underwent upper endoscopy following the standard protocol.
89415829|NCT06159803||Patient|"Adult patients with difficult asthma:~To carry out semi-structured interviews with PDA to explore their experiences, beliefs and attitudes to exercise, diet and emotional self-management support.~To carry out semi-structured interviews with PDA that explores the barriers and facilitators to key behaviours that will be targeted in the intervention.~To carry out iterative think aloud with PDA to elicit feedback on drafts of the intervention to optimise the intervention."
89415830|NCT06159803||NHS professionals/Exercise professionals|"NHS professionals working with people living with difficult asthma:~Exercise professionals working with people living with difficult asthma:~To carry out semi-structured interviews with health care and exercise professionals who work with patients living with severe asthma to explore their experiences, beliefs and attitudes to providing exercise, diet and emotional self-management support to this patient group~To carry out semi-structured interviews with health care and exercise professionals who work with patients living with severe asthma that explores the barriers and facilitators to key components that are planned to be included in the intervention.~To carry out iterative think aloud with health care and exercise professionals who work with patients living with severe asthma to elicit feedback on drafts of the intervention to optimise the intervention"
89415831|NCT06159764||Cardioneuroablation|Cardioneuroablation
88893277|NCT02350205|Experimental|Treatment (SASS)|Phase A: All patients will receive both Self assembled skin substitute (SASS) and Split-thickness autograft (paired samples sites A+ B). // Phase B: All patients will receive Self assembled skin subsitute (SASS)
88893278|NCT02284074|Experimental|Nasal LPS spray - placebo|"This is a 5-way crossover, randomised, placebo-controlled study.~Arms consists of the following nasal challenges:~placebo, 1, 10, 30 and 100µg LPS."
88893279|NCT02284074|Experimental|Nasal LPS spray 1µg|"This is a 5-way crossover, randomised, placebo-controlled study.~Arms consists of the following nasal challenges:~placebo, 1, 10, 30 and 100µg LPS."
88893280|NCT02284074|Experimental|Nasal LPS spray 10 µg|"This is a 5-way crossover, randomised, placebo-controlled study.~Arms consists of the following nasal challenges:~placebo, 1, 10, 30 and 100µg LPS."
88893281|NCT02284074|Experimental|Nasal LPS spray 30 µg|"This is a 5-way crossover, randomised, placebo-controlled study.~Arms consists of the following nasal challenges:~placebo, 1, 10, 30 and 100µg LPS."
88893282|NCT02284074|Experimental|Nasal LPS spray 100 µg|"This is a 5-way crossover, randomised, placebo-controlled study.~Arms consists of the following nasal challenges:~placebo, 1, 10, 30 and 100µg LPS."
88893283|NCT02265770|Experimental|Stratum 1 arm A|Conformal radiotherapy followed by 16 weeks of VEC + CDDP.
88893284|NCT02265770|Active Comparator|Stratum 1 arm B|Conformal radiotherapy.
88893285|NCT02265770|Experimental|Stratum 2 arm A|VEC + HD-MTX followed by conformal radiotherapy +/- boost
88893286|NCT02265770|Active Comparator|Stratum 2 arm B|VEC followed by conformal radiotherapy +/- boost
88893287|NCT02265770|Experimental|Stratum 3 arm A|Chemotherapy + Valproate.
88893288|NCT02265770|Active Comparator|Stratum 3 arm B|Chemotherapy
88893289|NCT02140242|Active Comparator|daunorubicin 60 mg/m2|study part 1 - dose daunorubicin standard dose daunorubicin in induction 1 (60 mg/m2) on days 3-5
88893290|NCT02140242|Active Comparator|Double induction|study part 2: induction cycles double induction (only patients with good response)
88893291|NCT02140242|Experimental|Single induction|study part 2: induction cycles single induction (only patients with good response)
88893292|NCT02050906|Experimental|Arm I (diet and exercise intervention)|"EXERCISE COMPONENT: Patients undergo 1 hour of monitored intensive exercise comprising 30 minutes of aerobic exercise and 30 minutes of resistance exercise twice weekly during weeks 1-6, once weekly during weeks 7-8, and independently during weeks 7-12. All patients will complete a comprehensive exercise and quality-of-life assessment at baseline, month 2 and month 3.~BEHAVIORAL ACTIVITY COUNSELING: Patients undergo behavioral activity counseling in small group sessions over 20 minutes once weekly during months 1-2 and individualized activity counseling via telephone calls over 20 minutes every 2 weeks for 3 months. Counseling will include questionnaire administration.~BEHAVIORAL DIETARY INTERVENTION: Patients undergo nutritional counseling over 30 minutes once weekly during months 1-2 and then every 2 weeks via telephone calls during month 3."
88893293|NCT02050906|Active Comparator|Arm II (standard of care)|TELEPHONE BASED COUNSELING: Patients receive standard care and educational literature describing the American Institute of Cancer Research dietary and physical activity guidelines. Patients also receive phone calls over 20 minutes every 2 weeks for 3 months focusing on routine prostate cancer self-management. After 3 months, patients have the option to undergo 2 supervised exercise training and dietary counseling sessions. All patients will complete a comprehensive exercise and quality-of-life assessment at baseline, month 2 and month 3.
88893295|NCT01990196|Active Comparator|AR inhibition only|"AR inhibition only Group 1: degarelix + enzalutamide~Endocrine therapy with degarelix and enzalutamide will continue for a minimum of 6 weeks and a maximum of 8 weeks in all groups prior to the planned prostatectomy."
88893296|NCT01990196|Active Comparator|AR inhibition plus MEK inhibition|"AR inhibition plus MEK inhibition Group 2: trametinib + degarelix + enzalutamide~In Group 2, treatment with trametinib will begin on Day 29 (i.e. four weeks after initiation of androgen deprivation). Thus, trametinib will be administered for no less than two weeks and no more than four weeks."
88893297|NCT01990196|Active Comparator|AR inhibition plus SRC inhibition|"AR inhibition plus SRC inhibition Group 3: dasatinib + degarelix + enzalutamide~In Group 3, treatment with dasatinib will begin on Day 29 (i.e. four weeks after initiation of androgen deprivation). Thus, dasatinib will be administered for no less than two weeks and no more than four weeks."
88893298|NCT01780727|No Intervention|Standard Hemodynamic Management (SHEM)|use of standard hemodynamic management
88893299|NCT01780727|Experimental|EGHEM|use of echocardiography guided hemodynamic management to control fluid and drug therapy.
89006015|NCT04660942||Control|Healthy child
89006016|NCT04660942||Experimental|Patients with developmental delay
89006017|NCT04660513||Morbid obesity|BMI 32.5 kg/m2 and above
89006018|NCT04660513||Non-obese healthy controls|BMI below 25 kg/m2
89415832|NCT06159712|Other|Ocrelizumab|Patients with active multiple sclerosis starting standard treatment with ocrelizumab
89006019|NCT04660591|Active Comparator|standard femoral stem|standard length femoral stem arthroplasty applied for patients with proximal femoral metastasis either impending or pathological fracture
89006020|NCT04660591|Active Comparator|long femoral stem|long femoral stem arthroplasty applied for patients with proximal femoral metastasis either impending or pathological fracture
89415833|NCT06159712|Other|Rituximab|Patients with active multiple sclerosis starting standard treatment with rituximab
89415834|NCT06159712|Other|Ofatumumab|Patients with active multiple sclerosis starting standard treatment with ofatumumab
89415835|NCT06159712|Other|Natalizumab|Patients with active multiple sclerosis starting standard treatment with natalizumab
89415836|NCT06159712|Other|Healthy controls|An age and gender matched healthy control group
89415837|NCT06159608|Other|Healthy Young Women|Young women who do not use e-cigarettes
89415838|NCT06159608|Other|Healthy Young Men|Young men who do not use e-cigarettes
89415839|NCT06159608|Other|Young Women using E-cigarettes|Young women chronically use e-cigarettes
89415840|NCT06159608|Other|Young Men using E-cigarettes|Young men chronically use e-cigarettes
89415841|NCT06159595|Active Comparator|Active Direct electrical stimulation (DES)|Intracranial electrodes will be used for the delivery of invasive brain stimulation.
89415842|NCT06159595|Sham Comparator|Sham Direct electrical stimulation (DES)|Intracranial electrodes will be used for the delivery of invasive brain stimulation.
89415843|NCT06153368|Experimental|Cadonilimab|Drug：Cadonilimab 6 mg/kg，IVD，D1，Q2W Drug：mFOLFIRINOX mFOLFIRINOX（Oxaliplatin 85 mg/m2 IV over 4 hours ; Irinotecan 150 mg/m2 IV over 90 minutes ; Leucovorin(l-LV) 400 mg/m2 IV over 2 hours 5-fluorouracil 2.4 g/m2 for 46 hours continuous infusion.） on days 2 of a 14-day cycle.
88893300|NCT01612351|Experimental|Non-Randomized Single-Arm|All participants will receive induction chemotherapy and transoral surgery. Following surgery, participants will be stratified into a risk category (low, medium, or high). Subjects in the low risk category will receive no further treatment after their transoral surgery. Subjects in the medium risk category will receive ipsilateral radiation concurrent with weekly cisplatin, and subjects in the high risk category will receive cisplatin every three weeks with concurrent bilateral radiation.
88893301|NCT01506856|Active Comparator|Standard treatment: dd-TCiv therapy|Paclitaxel administered by IV infusion weekly plus concurrent carboplatin administered by IV infusion once every 3 weeks
88893302|NCT01506856|Experimental|Study treatment: dd-TCip therapy|Paclitaxel administered by IV infusion weekly plus concurrent carboplatin administered by IP injection once every 3 weeks
88893303|NCT01376505|Experimental|HER-2 Vaccine|"combination of MVF-HER-2 (597-626) and MVF-HER-2 (266-296) emulsified with nor-MDP and ISA 720~This escalation arm has completed. The trial has moved on to the extension arm"
88893304|NCT01376505|Experimental|EXTENSION HER-2 Vaccine at OBD|"Combination of MVF-HER-2 (597-626) and MVF-HER-2 (266-296) emulsified with nor-MDP and ISA 720 at dose level cohort 2~This extension arm is ongoing"
88893305|NCT01336920|Experimental|Treatment (carfilzomib)|Patients receive carfilzomib IV over 30 minutes on days 1, 2, 8, 9, 15, and 16. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
88893306|NCT01256593||Pregabalin (Lyrica) capsule|"Patients administered Pregabalin capsule."
88893307|NCT01215201|Other|Scaling and Root Planing Alone|Control group
88893308|NCT01215201|Experimental|Diode Laser plus Scaling and Root Planing|Diode Laser is used in addition to Scaling and root planing procedure.
88893309|NCT01179009|Experimental|ketamine 100-hour infusion|100-hour infusion of ketamine plus a safener (clonidine)
88893310|NCT01179009|Active Comparator|ketamine 40-minute infusion|40-minute ketamine infusion following a 100-hours +/- placebo (saline) infusion. Participants will also receive a safener (clonidine)
88893311|NCT01000038|Experimental|Wii-Fit Intervention|Intervention: Subjects in this arm participate in Wii-Fit exercises
88893312|NCT01000038|Active Comparator|Walking Intervention|Intervention: Subjects in this arm participate in walking
88893314|NCT00798551|Other|Risk counseling|Risk counseling regarding elevated blood pressure
88893315|NCT00562640|Experimental|WT1-Specific T Cells|This is a phase I dose escalating trial designed to identify tolerable, clinically active doses of Wilms' tumor gene (WT1) peptide sensitized T cells when administered alone or with nonmyelosuppressive chemotherapy in patients with recurrent or persistent, evaluable WT1+ ovarian, primary peritoneal, or fallopian tube carcinomas.
88893316|NCT04791917|Experimental|Delayed Onset Muscle Soreness Induction|Participants will complete an exercise session designed to induce delayed onset muscle soreness in the biceps
88893317|NCT04791917|Sham Comparator|Sham Delayed Onset Muscle Soreness Induction|Participants will complete an exercise session that is unlikely to induce delayed onset muscle soreness in the biceps
88893318|NCT04791384|Experimental|Abemaciclib/Elacestrant|Abemaciclib and Elacestrant combination
88893319|NCT04787302|Experimental|CVL-231|
88893320|NCT04787289|Active Comparator|Higher Standard dosing as per standard regimen|bevacizumab 15mg/kg + chemotherapy
88893321|NCT04787289|Experimental|Lower standard dosing bevacizumab plus chemotherapy|bevacizumab 7.5mg/kg + chemotherapy
88893322|NCT04785417|No Intervention|CONTROL GROUP|received conventional occupational therapy program
88893323|NCT04785417|Experimental|STUDY GROUP|received conventional occupational therapy program in addition to using tablet
88893324|NCT04784221|Experimental|Radiation by protontherapy associated to nanoparticles injection|
88893325|NCT04781361||Isotonic fluid|"Group, received isotonic maintenance fluid containing NaCl between 131 to 154 mmol/L such as:~Dextrose 5% in 0.9% NaCl,~Intravenous fluid containing NaCl between 131 to 154 mmol/L"
88893326|NCT04781361||Hypotonic fluid|"Group, received hypotonic maintenance fluid containing NaCl < 130 mmol/L such as:~Dextrose 5 % in 0.02 % NaCl,~Dextrose 5% in 0.033 % NaCl~Dextrose 5% in 0.045 % NaCl~Intravenous fluid containing NaCl < 130 mmol/L"
88893327|NCT04773587|Experimental|ARQ-151 Cream 0.15%|Active comparator
88893328|NCT04773587|Placebo Comparator|ARQ-151 Vehicle Cream|Placebo comparator
88893329|NCT04767555|Experimental|ILM (inner limiting membrane) peeling|ILM peeling adding to standard vitreous surgery in patients suffering from retinal detachment
88893330|NCT04767555|No Intervention|No Peeling|standard vitreous surgery without ILM peeling in patients suffering from retinal detachment
88893332|NCT04749641|Experimental|Open surgical biopsy|A total of 15 subjects with open surgical biopsy indications will receive microsurgical resection, followed by conformal radiotherapy and administration of the researched vaccine.
88893333|NCT04749641|Experimental|Stereotactic biopsy|A total of 15 subjects without open surgical biopsy indications will receive stereotactic biopsy, followed by conformal radiotherapy and administration of the researched vaccine.
89415844|NCT06152913|Experimental|HANDS-ON treatment with random baselines|Participants are randomly allocated to one of four baseline periods (2.5 weeks, 3 weeks, 3.5 weeks, or 4 weeks). Participants then receive the HANDS-ON treatment. This treatment consists of three phases across nine weeks. After the treatment, there is a follow-up period of 4 weeks.
89415845|NCT06152874|Active Comparator|glucose solution 1|glucose solution prepared dissolving 55 g of monohydrate glucose powder in 250 mL of water
89415846|NCT06152874|Active Comparator|glucose solution 2|glucose solution prepared dissolving 55 g of monohydrate glucose powder in 250 mL of water
89006021|NCT04660552|Experimental|CognilumTM|During the study participants will be wearing the photobiomodulation device Cognilum. The device will administer the stimulation of near infrared light (830nm) to specific areas of the child's brain.
89006022|NCT04660552|Placebo Comparator|Placebo condition|During the study participants will be wearing the photobiomodulation device. The device will not be turned on and therefore no brain stimulation with near infrared light (830nm) will be provided.
89415847|NCT06152874|Experimental|BREAD A|bread made with 95% durum wheat fine semolina (< 400 micrometer)+ 5% of gluten+ 1.2% of yeast + 1% of salt + 59% of water (portion corresponding to 50 g available carbohydrates) +250 mL water
89415848|NCT06152874|Experimental|BREAD B|bread made with 80% durum wheat fine semolina (< 400 micrometer)+ 20% of gluten+ 1.2% of yeast + 1% of salt + 59% of water (portion corresponding to 50 g available carbohydrates) +250 mL water
89415849|NCT06152874|Experimental|BREAD C|bread made with 80% durum wheat coarse semolina (> 500 micrometer)+ 20% of gluten+ 1.2% of yeast + 1% of salt + 59% of water) (portion corresponding to 50 g available carbohydrates) +250 mL water
89415850|NCT06152627||First Year of RTSS-Voice use|These 300 patients from five Voice Centers will receive standard of care voice therapy where their treating clinicians will be trained to use the RTSS-Voice in their documentation.
89415851|NCT06152627||Second Year of RTSS-Voice use|These 300 patients from five Voice Centers will receive standard of care voice therapy where their treating clinicians have already been trained to use the RTSS-Voice in their documentation.
89415852|NCT06151873|Active Comparator|Healthy subjects|control group sample, healthy subjects without musculoskeletal, neurological or vestibular disorders may participate.
89415853|NCT06151873|Experimental|Subjects with neurological damage|Subjects with cerebral palsy/acquired brain damage belonging to the Spanish National Soccer Team with cerebral palsy and acquired brain damage may participate as an experimental group.
89415854|NCT06151613|Active Comparator|Continuous eCTG monitoring|"For the continuous eCTG monitoring, a wireless abdominal electrode patch (measuring fetal heart rate (FHR) and uterine activity (UA)) is used, developed by Nemo Healthcare: The Nemo Fetal Monitoring System (NFMS).~The advantage of the NFMS is that is a safe method for continuous (24/7) fetal monitoring. Furthermore, the patch does not have to be repetitively repositioned during registration, it can be used under the shower and it is wireless giving women more freedom to move around freely. Another benefit of eCTG monitoring is that it is especially suited for women with obesity, where conventional CTG monitoring often fails"
89415855|NCT06151613|No Intervention|Conventional intermittent CTG monitoring|"Conventional intermittent CTG monitoring is performed in Maxima Medical Centre by the use of Philips Avalon FM 30 (Philips Healthcare, Eindhoven, The Netherlands).~This is a combined external measurement method using two transducers placed on the maternal abdomen: one to measure fetal heart rate (FHR) by the use of Doppler ultrasound (DU) and the other at the fundus of the uterus to measure uterine activity (UA) pattern (TOCO), keeping them in place with elastic banding."
89415856|NCT06150768|Active Comparator|Control group Cobalt Chromium Removable Partial Denture|The patient will receive a Cobalt Chromium Removable Partial Denture to restore missing posterior teeth in Kennedy Class II cases. The denture will be fabricated by conventional lost-wax and processing techniques.
89415857|NCT06150768|Experimental|Implant-Supported Porcelain-Fused-to-Metal-Fixed Partial Denture|Two dental implants will be placed to restore missed posterior teeth (second mandibular premolar and second mandibular molar) in Kennedy Class II cases by using a two-stage surgical technique with the help of a radiographic and surgical stent. After a three-month osseointegration period, implants will be loaded with three units of anatomical Implant-Supported Porcelain-Fused-to-Metal-Fixed Partial Denture
89415858|NCT06150768|Experimental|Implant-Supported Zirconia fixed partial denture|Two dental implants will be placed to restore missed posterior teeth (second mandibular premolar and second mandibular molar) in Kennedy Class II cases by using a two-stage surgical technique with the help of a radiographic and surgical stent. After a three-month osseointegration period, implants will be loaded with three units of anatomical implant-supported Zirconia fixed partial dentures
89415859|NCT06149247|Experimental|HyBryte (0.25 % hypericin)|HyBryte (0.25 % hypericin) ointment will be applied to CTCL lesions and treated with visible light 18-24 hours later starting at 6 J/cm^2. Drug application/light session will be done twice a week (at least 2 calendar days apart) for 12 weeks.
89415860|NCT06149247|Active Comparator|Valchlor (mechlorethamine)|Valchlor (0.016% mechlorethamine) gel will be applied to CTCL lesions once daily for 12 weeks.
89415861|NCT06140030|Experimental|Mindfulness training mobile health application|Use of a mindfulness training mobile health application
89536762|NCT02767427|Active Comparator|At-Home Chlorhexidine|Those randomized into the chlorhexidine group will be asked to shower the night before surgery, and to use a standardized pre-packaged Chlorhexidine Wipes (chlorhexidine gluconate wipes) on their surgical site after thoroughly drying those areas. They will be asked to use a second wipe in each area the morning of surgery. Those who forget to use the wipe in the morning were allowed to use the wipe in the pre-operative area and included if this occurs more than one hour before skin prep.
89006023|NCT04660318|Experimental|Experimental: remote photoplethysmography for physiological parameters Monitor Readings|
89006024|NCT04660318|Other|Control: rstandard acquisition system for physiological parameters Monitor Readings|
89006025|NCT00241449|Active Comparator|1|Tamoxifen
89006026|NCT00241449|Experimental|2|Fulvestrant
89006027|NCT04660474||Early reperfusion group|All patients hospitalized and diagnosed as STEMI according to the 4th universal definition of myocardial infarction underwent coronary angiography and PCI treatment. Patients with SO2RT<24 hours were assigned to Early reperfusion group.
89415862|NCT06136793|Experimental|Experimental: Healthy HomeStyles|Online educational intervention
89415863|NCT06136793|Active Comparator|Active Comparator: Safe HomeStyles|Online educational intervention
89415864|NCT06132282|Experimental|Substance Use and Health Risk Intervention (SUHRI)|A technology-based application (administered via tablet) that addresses the interrelated topics of substance use and risky sex practices, within the context of personal relationships.
89006028|NCT04660474||Intermediate reperfusion group|All patients hospitalized and diagnosed as STEMI according to the 4th universal definition of myocardial infarction underwent coronary angiography and PCI treatment. Patients with SO2RT ranging from 24 hours to 7days were assigned to Intermediate reperfusion group.
89006029|NCT04660474||Late reperfusion group|All patients hospitalized and diagnosed as STEMI according to the 4th universal definition of myocardial infarction underwent coronary angiography and PCI treatment. Patients with SO2RT>7days were assigned to Late reperfusion group.
89415865|NCT06121271|Experimental|Bronchial and Thymic Neuroendocrine Tumour|
89415866|NCT06121271|Experimental|Paraganglioma/ Phaeochromocytoma|
89415867|NCT06121271|Experimental|Medullary Thyroid Carcinoma|
89006030|NCT04659889||Patients with clinical features of Long Covid|Patients who have had COVID-19 (PCR proven and/or clinical features of COVID-19) who are currently displaying symptoms of long Covid
89006031|NCT04659889||Patients with no symptoms of Long Covid|Patients who have had COVID-19 (PCR proven and/or clinical features of COVID-19) who are not displaying symptoms of long Covid
89006032|NCT04659733|Experimental|Anlotinib hydrochloride|
89006033|NCT04660006||Control|Patients undergoing uneventful cataract surgery with no retinal vascular disease.
89006034|NCT04660006||Diabetic Retinopathy (DR)|Patients with non-proliferative diabetic retinopathy with no diabetic macular edema treatment in the 6 months prior to uneventful cataract surgery.
89006035|NCT04660006||Diabetic Macular Edema (DME)|Patients with diabetic macular edema undergoing active Anti-VEGF treatment (within the last 3 months) undergoing uneventful cataract surgery.
89006036|NCT04659850|Other|Group 1|Group 1 participants in the young 18 - 30 age group
89006037|NCT04659850|Other|Group 2|Group 2 participants in the older 55 - 75 age group
89006038|NCT04659460|Experimental|Remote Ischemic Conditioning|RIC interventions will be applied to the upper extremity for a total of 20 cumulative minutes of limb ischemia, at a pressure of 250 mmHg.
89006039|NCT04659460|Sham Comparator|Sham Remote Ischemic Conditioning|RIC sham interventions will be applied to the upper extremity for a total of 20 cumulative minutes. For sham, inflation will occur.
89415868|NCT06121271|Experimental|Those Requiring Repeat Peptide Receptor Radionuclide Therapy|
89415869|NCT06119178||EX-PRESS P-50|EX-PRESS P-50 filtration device implanted in one or both eyes during glaucoma surgery
89415870|NCT06119178||EX-PRESS P-200|EX-PRESS P-200 filtration device implanted in one or both eyes during glaucoma surgery
89415871|NCT06097520|Active Comparator|Intervention group|Patients receive a VR headset (Pico G2 4K) for 15 minutes in the time between the 2. and 3. pain assessment and will experience non-interactive videos with different immersive scenarios of nature scenes. Nature sounds, meditation or classical music accompanying the scenarios are played through noise-cancelling headphones. Additionally, a wearable with an optical PPG- and EDA-Sensor (Empatica EmbracePlus) is put on the wrist of each participant in both groups 15 minutes before the inhalation until 15 minutes after the third pain intensity assessment, which enables the tracking of vital signs and monitoring of physiological responses. In both groups the study procedure starts with determining the pain intensity immediately before and after the 15 minutes inhalation procedure which is part of the standard of care. 15 minutes after the second assessment, the pain intensity is determined a third time in both groups.
89006040|NCT04659694|Other|Single arm study|This study only contains one arm
89006041|NCT04659499|Experimental|Nab-paclitaxel in combination with pyrotinib treatment group|Nab-paclitaxel 260mg/m2 every 3 weeks for 12 weeks plus pyrotinib 240mg daily for one year
89006042|NCT00245349||FLT|Study group receiving FLT for imaging
89006043|NCT04659304|Active Comparator|Cohort 1|Single Intravenous (IV) dose of Allocetra-OTS with 5x10^9 cells
89006044|NCT04659304|Active Comparator|Cohort 2|Single Intravenous (IV) dose of Allocetra-OTS with 10x10^9 cells
89415872|NCT06097520|No Intervention|Control group (standard care)|Patients in the control group do not receive any intervention in the time between the second and third pain assessment. Additionally, a wearable with an optical PPG- and EDA-Sensor (Empatica EmbracePlus) is put on the wrist of each participant in both groups 15 minutes before the inhalation until 15 minutes after the third pain intensity assessment, which enables the tracking of vital signs and monitoring of physiological responses. In both groups the study procedure starts with determining the pain intensity using the Numeric Rating Scale (NRS) immediately before and after the 15 minutes inhalation procedure which is part of the standard of care. 15 minutes after the second assessment, the pain intensity is determined a third time in both groups.
89415873|NCT06096090|Active Comparator|Aldesleukin every 4 weeks|
89415874|NCT06096090|Active Comparator|Aldesleukin every 2 weeks|
89006045|NCT04659304|Active Comparator|Cohort 3|Two IV doses of Allocetra-OTS with 10x10^9 cells in each dose
89006046|NCT04659655|Other|surgical aortic valve replacement|n=20 patients with aortic valve pathology and indication for surgical aortic valve replacement
89006047|NCT04659655|Other|surgical mitral valve replacement|n=10 patients with mitral valve pathology and indication for surgical mitral valve replacement
89006048|NCT04649320||cancer patients|adult cancer patients, with solid or hematologic malignancies, neither tested positive nor having COVID19 symptoms
89415875|NCT06096090|Placebo Comparator|Placebo|
89415876|NCT06095141|Experimental|Cisplatin|Cisplatin 25 mg/m2, ivgtt, 30 min, D1, 8.
89415877|NCT06089135|Active Comparator|Intravascular Lithotripsy|
89536763|NCT02767427|Experimental|No At-Home Chlorhexidine|Participants in this group will not use chlorhexidine wipes (no intervention), as is standard of care, prior to their surgical site being cleansed by the surgical team pre-operatively.
89536764|NCT02702687|Experimental|PEF Feedback|This group will have 9 visits across 15 months.
89415878|NCT06089135|Active Comparator|Cutting Balloon|
89415879|NCT06081179|Active Comparator|Psilocybin|40 participants will receive psilocybin
89415880|NCT06081179|Active Comparator|MDMA|40 participants will receive MDMA
89415881|NCT06081179|Active Comparator|Methylphenidate|40 participants will receive methylphenidate
89415882|NCT06061185||Testing populations|All patients with the possibility of acute hemorrhagic stroke and suitable for multimodal CT examination
89415883|NCT06061172|No Intervention|Control group|Care as usual
89415884|NCT06061172|Experimental|Intervention group|GPs in the intervention arm have to use the web application for every patient at least twice (i.e., at least once a quarter), and have to use at least four specific questionnaires at least once, i.e. 1a is required, and either 2a or 2b, and either 3a or 3b, and either 4a or 4b or 4c. Results from the questionnaires need to be discussed between GPs and patients. Additionally, at least one medication review is obligatory.
89415885|NCT06057454|Active Comparator|Active Comparator|R-5280, Taken Twice a day, orally with food for 12 weeks (84 days)
89415886|NCT06057454|Placebo Comparator|Placebo Comparator|Food starch, taken twice a day, orally with food for 12 weeks (84 days)
89415887|NCT06053411|Experimental|Arm 1: diclofenac alone (baseline)|A single dose of diclofenac (25 mg capsule) will be administered by mouth to 5 participants (minimum 2 females) genotyped as extensive metabolizers (Arm 1A) and 5 participants (minimum 2 females) genotyped as poor metabolizers (Arm 1B). Plasma and urine will be collected from 0-12 hours. A washout of at least 3 days will elapse between Arm 1 and Arm 2.
89415888|NCT06053411|Experimental|Arm 2: diclofenac + curcumin|A single oral dose of diclofenac (25 mg capsule) and a single oral dose of curcumin (2,000 mg tablet) will be administered by mouth to the 5 participants genotyped as extensive metabolizers. Plasma and urine will be collected from 0-12 hours.
89415889|NCT06047301|Experimental|Pathways|Pathways focuses on increasing patient hope to support personal goal pursuit during treatment for advanced lung cancer.
89415890|NCT06047301|Active Comparator|Enhanced Usual Care|Enhanced Usual Care focuses on providing patients with education around common lung cancer concerns (e.g., pain and fatigue management) and resources to support them (e.g., supportive services available nationally and at the treating cancer center).
89415891|NCT06040463|Experimental|Remote Glucose Monitoring > Remote Glucose Monitoring (RGM->RGM)|Participant will be randomized into the RGM study arm for the first 6 months. At the 6-month rerandomization point, if the patient is a responder (A1c improved by at least 1 percentage point), patient will remain in the RGM group.
89415892|NCT06040463|Experimental|Remote Glucose Monitoring > Remote Glucose Monitoring+Community Health Worker (RGM->RGM+CHW)|Participant will be randomized into the RGM study arm for the first 6 months. At the 6-month rerandomization point, if the patient is a non-responder (A1c has not improved by at least 1 percentage point), patient will be randomized again with one arm being a continuation of RGM, with the addition of a CHW to provide tailored support.
89415893|NCT06040463|Experimental|Remote Glucose Monitoring > Diabetes Self-Management Training (RGM->DSMT)|Participant will be randomized into the RGM study arm for the first 6 months. At the 6-month rerandomization point, if the patient is a non-responder (A1c has not improved by at least 1 percentage point), patient will be randomized again with one arm being diabetes self-management training (DSMT).
89415894|NCT06040463|Experimental|Diabetes Self-Management Training > Standard of Care (DSMT->SOC)|Participant will be randomized into the DSMT study arm for the first 6 months. At the 6-month rerandomization point, if the patient is a responder (A1c improved by at least 1 percentage point), patient will be directed back to standard of care.
89415895|NCT06040463|Experimental|Diabetes Self-Management Training > Community Health Worker (DSMT->CHW)|Participant will be randomized into the DSMT study arm for the first 6 months. At the 6-month rerandomization point, if the patient is a non-responder (A1c has not improved by at least 1 percentage point), patient will be randomized again with one arm being a CHW to provide tailored support.
89415896|NCT06040463|Experimental|Diabetes Self-Management Training > Remote Glucose Monitoring (DSMT->RGM)|Participant will be randomized into the DSMT study arm for the first 6 months. At the 6-month rerandomization point, if the patient is a non-responder (A1c has not improved by at least 1 percentage point), patient will be randomized again with one arm being RGM.
89415897|NCT06035575|Experimental|Intervention (video)|Educational Video: Participants in this arm will watch an interactive pain management video, sent as a link to their email. Participants will send back answers to the multiple-choice questions posed during the video and/or confirm having watched the video within 5 days (at most) of their acute care visit or discharge from the ED.
89415898|NCT06035575|No Intervention|Usual Care|Participants will receive the typical care provided by medical personnel for their acute pain.
89415899|NCT06034509||TBI Group|Participants in this group will have been identified as sustaining a traumatic brain injury (mild, moderate, severe, or penetrating).
89415900|NCT06034509||High-blast exposed control group|Participants in this group will have no history of traumatic brain injury AND will have a lifetime history of greater than 10 blast exposures.
89415901|NCT06034509||Low-blast exposed control group|Participants in this group will have no history of traumatic brain injury AND will have a lifetime history of less than 10 blast exposures.
89415902|NCT06032156|Placebo Comparator|Placebo|Single dose of a taste-matched calorie-free placebo
89415903|NCT06032156|Experimental|High Dose β-OHB|Single dose of a ketone monoester ([R]-3-hydroxybutyl [R]-3-hydroxybutyrate; 0.6 g β-OHB/kg body weight)
89415904|NCT06032156|Experimental|Low Dose β-OHB|Single dose of a ketone monoester ([R]-3-hydroxybutyl [R]-3-hydroxybutyrate; 0.3 g β-OHB/kg body weight)
89415905|NCT06032000|Active Comparator|LEM-mR203|"Drug: LEM-mR203~An intramuscular single injection prepared by mixing mRNA and DegradaBALL before administration"
89415906|NCT06032000|Placebo Comparator|Placebo|"Drug: 0.9% Sodium Chloride Solution~An intramuscular single injection prepared before administration"
89415907|NCT06027814|No Intervention|Treatment-as-usual (TAU)|TAU will be usual care that the Addiction Consult Service provides. It is comprised of a multidisciplinary team of professionals, including addiction medicine and addiction psychiatry physicians, nurses specializing in the treatment of OUD, substance use disorder counselors, peer recovery supports, and program coordinators.
89415908|NCT06027814|Experimental|PN+mHealth|The intervention is patient navigation and mHealth in addition to treatment-as-usual. The intervention consists of a patient navigator (PN) with the mHealth adherence application facilitating telehealth visits, two-way chats, video-DOT, and delivery of financial incentives via smartphone for adherence and linkage to outpatient treatment within 30 days. Participants will be asked to upload medication adherence videos once a day over the 30 days post discharge from the hospital. Patients will be instructed to continue to take their medication as prescribed in any circumstance where they are unable to upload the video for any reason.
89415909|NCT06025799|Experimental|"Mindfulness-based stress reduction intervention"|patients who will be under routine hospital care as well as Mindfulness-Based Stress Reduction (MBSR) program The Mindfulness-Based Stress Reduction (MBSR) program consists of eight sessions focusing on reducing stress and improving well-being. Participants learn and practice mindfulness techniques such as mindful eating, breathing, body scan, and meditation. The program emphasizes self-responsibility, developing coping strategies, and applying mindfulness daily. Participants engage in formal mindfulness practices, reflect on their experiences, and receive guidance on continuing their mindfulness journey after the program. The goal is to cultivate resilience, enhance well-being, and reduce stress.
89415910|NCT06025799|No Intervention|" routine hospital care"|Female cancer patients who will be under routine hospital care
89415911|NCT06021808|Experimental|LAA clipping group|In this arm, participants are performed thoracoscopic LAA clipping.
89415912|NCT06021808|Active Comparator|NOACs group|Patients randomized to NOAC therapy will begin long-term oral administration of NOACs immediately after enrollment.
89415913|NCT06017973|Other|Possible non-convulsive status epilepticus with ictal-interictal continuum EEG patterns|Patients with a possible non-convulsive status epilepticus, according to American Clinical Neurophysiology Criteria (ACNS) (2021).
89415914|NCT06017973|Other|Healthy control subjects|Healthy control subjects.
89415915|NCT06015685|Experimental|Embedded clinic at Midtown|Using the Emory Clinical Data Warehouse (CDW), all patients of Emory Primary Care Midtown with HbA1c >9% who are not currently under the care of an endocrinologist or the diabetes management program at Emory will be invited to participate in this embedded DM management clinic.
89415916|NCT06015685|Other|Routine Care- Dunwoody Family Medicine Clinic|The control population will be drawn using electronic health record data of diabetes patients at Dunwoody Family Medicine Clinic. Information from the Electronic Health Record will be de-identified after extraction. Control participants will be frequency matched.
89415917|NCT06010420|Experimental|flat sole|Weighted-unweighted in navicular drop test 10 mm or more pronation
89415918|NCT06010420|Experimental|normal base|Weighted-unweighted in navicular drop test difference between measurement 5-9 mm is normal
89415919|NCT06010420|Experimental|high sole|Weighted-unweighted in navicular drop test 4 mm or less is considered supination. are being
89415920|NCT06010394|Active Comparator|control group|commensal physiotherapy will be applied
88893334|NCT04737616|Experimental|CO2 Laser +OCT|Postmenopausal women with genitourinary syndrome of menopause who will receive CO2 vaginal laser treatment
88893335|NCT04737616|Experimental|OCT only|Premenopausal, peri-menopausal and postmenopausal women who will only get one time OCT scan
88893336|NCT04725201|Experimental|Intravenous unfractionated heparin|Administration of intravenous unfractionated heparin according to the Centre hospitalier de l'Université de Montréal (CHUM) deep vein thrombosis (DVT) protocol for 5 days after vascular anastomosis. A bolus will be administered intraoperatively based on the patient's weight. Dosages will be adjusted according to the activated partial thromboplastin time (aim for an APTT of 50-70), which will be measured 6 hours after the start of the protocol and after every dosage adjustment or every morning at 6 a.m. if no adjustments were made in the last 6 hours.
88893337|NCT04725201|Sham Comparator|Control|"No administration of intravenous unfractionated heparin. These patients receive 5000 IU BID of heparin subcutaneously, as a standard post-operative protocol for all in-patients.~The control group receives sham bolus intraoperatively of normal saline and a post-operative normal saline infusion at a fixed dose through an infusion pump to mimic IV heparin infusion."
88893338|NCT04724239|Experimental|The triplet group (sintilimab + chidamide + IBI305)|Every 3 weeks, patients received sintilimab 200 mg and IBI305(bevacizumab) 7.5 mg/kg on day one and chidamide 30 mg orally twice weekly.
88893339|NCT04724239|Active Comparator|The doublet group (sintilimab + chidamide)|Every 3 weeks, patients received sintilimab 200 mg on day one and chidamide 30 mg orally twice weekly.
88893340|NCT04715750|Experimental|Tau deposition in the brains of Alzheimer Disease and Progressive Supranuclear Palsy patients|All patients will receive two administrations of [18F]PI-2620 at a radioactive dose of 185 MBq, one with high specific activity (≤ 5 µg tracer mass dose), another one with low specific activity (40-50 µg tracer mass dose)
88893341|NCT04705727|Experimental|budesonide/formoterol Turbuhaler®|After randomization, patients in the experimental arm will receive budesonide/formoterol Turbuhaler® 100/6 μg, one inhalation every 5 minutes (Maximum 12 inhalations).
88893342|NCT04705727|Active Comparator|nebulisation of terbutaline|0.1 mg/kg nebulized terbutaline 5 mg/2 ml of Terbutaline dilution diluted with 2 ml normal saline delivered by an air compressor nebuliser driven by oxygen at a flow rate of 8l/min. The duration of one dose will be approximately 20 minutes and a total of 3 doses will be administered. In case of an insufficient response, 3 additional doses will be administered for a maximum of 6 nebulisations.
88893343|NCT04677777|Other|Standard of Care|Patients randomized to receive this treatment will receive standard of care appropriate for the condition.
88893344|NCT04677777|Experimental|PP-007|Patients randomized to receive this treatment will receive a single infusion of PP-007
88893345|NCT04674683|Experimental|Test Arm|HBI-8000 30 mg oral BIW + nivolumab IV at specific doses on specific days
88893346|NCT04674683|Placebo Comparator|Control Arm|Placebo oral BIW + nivolumab IV at specific doses on specific days
89415921|NCT06010394|Experimental|exercise group|exercises will be given
89415922|NCT06010394|Experimental|massage group|massage will be done
89415923|NCT06006533|Experimental|kinesio taping|kinesio taping Technique: It is used to provide support to the joint range of motion and tissues. It has a wide range of uses for purposes such as correcting functional disorders, healing, protecting, reducing pain and inflammation. There are differences in cutting shapes according to the applied area and the target to be achieved.
89536765|NCT02702687|Active Comparator|Control Feedback|This group will have 9 visits across 15 months.
89536766|NCT03311009|Experimental|GLPG1972|
89536767|NCT03311009|Placebo Comparator|Placebo|
88893347|NCT04672161|Experimental|Vaccine Education|Patients randomized to the Experimental arm will receive a baseline educational intervention on vaccination following a vaccination history survey. Patients will be followed 6-months after the intervention to record prospective clinical data. Evidence of vaccination-status will be documented. Besides standard of care visits and testing, no additional procedures will be carried out for the purpose of this study.
88893348|NCT04672161|No Intervention|No Vaccine Education|Patients randomized to the No Intervention arm will not receive the Vaccine Education. They will only complete the survey on their vaccination history.
88893349|NCT04662944||Licensed anti-VEGFs|Patients being treated for nAMD with licensed anti-VEGFs
89415924|NCT06006533|Experimental|percussive massage|Percussive Massage Technique: It is one of the instrument-assisted soft tissue mobilization techniques that emerged as a result of combining the effects of traditional massage and vibration therapy. With the mechanical oscillation effect that occurs in the Percussive Massage Technique, the muscle fiber is stimulated and an increase in reflex activity is observed.
88893350|NCT04657822|Experimental|Crizanlizumab|All participants will receive crizanlizumab (SEG101) at the same dose/schedule as in the parent study.
89415925|NCT06006481||1.group|patient area in the children's area
89415926|NCT06006481||2.group|patient area in the field of orthopedics and athletes
88893351|NCT04648410||Members of European Society of Intensive Care|Members of European Society of Intensive Care will obtain an electronic survey considering their routine clinical practice regarding the administration of systemic corticosteroids among patients with COVID-19 ARDS
89415927|NCT06006481||3.group|patient area in neurology and intensive care
89415928|NCT06006481||4.group|general group receiving patients in many fields
89415929|NCT06006481||5.group|physiotherapists working in public health
88893352|NCT04646499|Experimental|Gamma Stimulation Group|This group will receive gamma stimulation
88893353|NCT04635826|Experimental|Adderall/Truth|Participants will be told they are receiving Adderall and will actually be administered Adderall.
88893354|NCT04635826|Experimental|Adderall/Deception|Participants will be told they are receiving Adderall and will actually be administered placebo
88893355|NCT04635826|Placebo Comparator|Placebo/Truth|Participants will be told they are receiving placebo and will actually be administered placebo.
88893356|NCT04635826|Experimental|Placebo/Deception|Participants will be told they are receiving placebo and will actually be administered Adderall
89415930|NCT06006377|Active Comparator|conventional|conventional physiotherapy methods
89415931|NCT06006377|Experimental|backup|Physiotherapy applied with backup device
89415932|NCT06006364||1.Group|Nomophobia Level:none
89415933|NCT06006364||2.Group|Nomophobia Level: mild
89415934|NCT06006364||3.Group|Nomophobia Level: medium
89415935|NCT06006364||4.Group|Nomophobia Level: extreme
89415936|NCT06005948|Active Comparator|control group|No exercise will be given after surgery
89415937|NCT06005948|Experimental|exercise group|Dynamic neuromuscular stabilization exercises will be performed for 8 weeks after surgery.
89415938|NCT06005922|Active Comparator|conventional physiotherapy methods|conventional physiotherapy methods
89415939|NCT06005922|Experimental|temporomandibular joint (TMJ) group|conventional physiotherapy methods and temporomandibular joint mobilization and temporomandibular joint exercises
89415940|NCT06003907|Active Comparator|conventional physiotherapy|traditional and complementary medicine methods will not be used.
89415941|NCT06003907|Experimental|cupping therapy and graston|Complementary methods will be used alongside conventional physiotherapy.
89415942|NCT06002984|Experimental|Using neuromonitoring to find EBSLN|With neuromonitoring of the EBSLN using nerve monitoring system Intervention Device: Neuromonitoring to find EBSLN
89415943|NCT06002984|No Intervention|No using neuromonitoring to find EBSLN|Without neuromonitoring of the EBSLN using nerve monitoring system
89415944|NCT05998330|No Intervention|Usual Hepatology Care|Usual hepatology care
89415945|NCT05998330|Experimental|Usual Hepatology Care with Early Palliative Care|Usual hepatology care with early palliative care
89415946|NCT05992506||Patients at risk of developing POD|"Patients older than 60 years~Scheduled for elective surgery of moderate or high risk (defined as that which requires a subsequent hospitalization of at least 3 days) under general anesthesia.~Signed informed consent."
89415947|NCT05992103|Experimental|Single-Stage Gastric Fundic Ablation plus Endoscopic Sleeve Gastroplasty|Subjects will undergo fundic mucosal ablation followed by endoscopic sleeve gastroplasty in the same endoscopic session
89415948|NCT05989997|Experimental|dose escalation|4 subgroups mass dose escalation.
89415949|NCT05989282||Exposure to structural conditions|Using a survey, we will measure participant exposure to organizational: access policies, transition programs, culture, support for social determinants of health and specialized services.
89415950|NCT05981430|Active Comparator|Fecal microbiota transplant|This group's subject will receive an infusion of 125mL fecal suspension via enema.
89536768|NCT03310931||End and non-END groups|END was denied as NIHSS score increase of 2 or more than 2 within 7 days after admission
88893357|NCT04629781|Experimental|Docetaxel micellar|Trial Treatment with Docetaxel micellar
88893358|NCT04624945||SICU cohort|150 subjects with the admission diagnosis of neurological haemorrhage (e.g. subarachnoid haemorrhage, intracerebral haemorrhage etc), admitted to SICU of National University Hospital, Singapore, who are expected to stay for more than 48 hours, will be recruited and enrolled. Frequency of blood sampling will be stipulated atday 1/2/3/4/5 to draw clinical relevance. An additional 0.5 tablespoonful (7.7ml) of blood will be taken daily from each subject as well as residual blood from routine laboratory test blood samples.
88893359|NCT04614922|Experimental|Acceptance and Commitment Therapy|Participation in a 4 week group program based on Acceptance and Commitment Therapy, individual councelling and home lessions.
88893360|NCT04614922|No Intervention|control group|Standard care, i.e. follow-up as needed, to some degree dependent on current capacity of therapists.
88893361|NCT04608474|Experimental|Evolocumab only|This arm includes subjects who are treated using Evolocumab.
89415951|NCT05981430|Placebo Comparator|Sham fecal microbiota transplant|This group's subject will receive 125mL placebo enema comprised of normal saline with 15% glycerol and brown food colouring 204 (Americolorcorp) as a sham procedure.
89415952|NCT05980091|Other|Group A|Embryo transfer is scheduled on the 6th full day of progesterone administration, following the initial commencement of progesterone (120 hours)
89193106|NCT05545384|Active Comparator|Standard Care: delayed treatment (2nd attack)|"Patients will be treated according to standard of care after their 1st attack. In case of relapse:~before 3 months, IV methylprednisolone (30 mg/kg/j not exceeding 1g/day) will be administered for 3 days. There won't be any change of the initial treatment which will be pursued.~after 3 months, IV methylprednisolone (30 mg/kg/j not exceeding 1g/day) will be administered for 3 days with an oral relay of prednisolone (1mg/kg/day not exceeding 60 mg/day) during 3 months with then a slowly tapered dose (reduction of 25% every week for 4 weeks). Azathioprine or Rituximab might be proposed as per local clinician experience"
89193107|NCT05540054|Experimental|Standard pulmonary rehabilitation group (PR)|Patients diagnosed with COPD and listed for bronchoscopic procedure.
89193108|NCT05540054|Experimental|Inspiratory muscle training group (PR+IMT)|Patients diagnosed with COPD and listed for bronchoscopic procedure.
89193109|NCT05538715|Experimental|Split-thickness group|Following randomization, horizontal guided bone regeneration utilizing Bio-Oss (Geistlich, Wolhusen, Switzerland) and autogenous bone in combination with Bio-Gide membrane (Geistlich, Wolhusen, Switzerland). Surgery is performed with a split-thickness flap design in the posterior maxilla or mandible in partially edentolous patients.
89193110|NCT05538715|Experimental|Full-thickness group|Following randomization, horizontal guided bone regeneration utilizing Bio-Oss (Geistlich, Wolhusen, Switzerland) and autogenous bone in combination with Bio-Gide membrane (Geistlich, Wolhusen, Switzerland). Surgery is performed with a full-thickness flap design in the posterior maxilla or mandible in partially edentolous patients.
89193111|NCT05538702|Experimental|Heated tobacco product with bland taste unit|Nicotine content: 0,5 mg
89193112|NCT05538702|Experimental|Heated tobacco product with menthol taste unit|Nicotine content: 0,5 mg
89193113|NCT05538702|Experimental|Conventional cigarette|Nicotine content: 0,5 mg
89193114|NCT05538702|Placebo Comparator|Heated tobacco product turned off with a bland taste unit|Placebo device
89193115|NCT05529732|Experimental|Application Group|Oral and written consent will be obtained from the patients by face-to-face interview technique at least one day before the surgery. Then, face-to-face interview technique and data collection tools (Personal Information Form and Trait Anxiety Scale) will be applied. It is estimated that the process of obtaining consent and filling out the form will take approximately 5 minutes. The mobile application will be installed on the mobile devices of the patients and the user name and password will be defined by the researcher so that they can log into the mobile application. In the application, a patient warning notification will be sent on the 3rd, 7th and 10th days to remind the patients to fill in the State Anxiety Scale and Daily Living Activities Evaluation and Follow-up Form, which are included in the questionnaires menu and will be active when the day comes.
89193116|NCT05529732|No Intervention|Control Group|Written consent will be obtained from the patients through a face-to-face interview at least one day before the surgery and the data collection form (Personal Information Form and Trait Anxiety Scale) will be filled. During this period, standard care and follow-up protocols will be applied to the patients by the clinic. Patients in the control group will be called by phone on the 3rd, 7th and 10th days of discharge. State Anxiety Scale and Daily Living Activities Evaluation and Follow-up Form will be applied by the researcher. The process is estimated to take 15 minutes.
89193117|NCT05525871|Experimental|Nitrates and Citrulline Malate|Gel elaborated from fruit puree with high polyphenol content, with the addition of nitrates and citrulline malate as study supplements. addition of nitrates and citrulline malate as study supplements.
89193118|NCT05525871|Placebo Comparator|Control product|Consumption of placebo product (Fruit puree)
89193119|NCT05525429|Active Comparator|Nutrition Education|Households in this arm will participate in a multidimensional nutrition education intervention, including (1) didactic training on family nutrition (mothers, fathers, adolescent girls), (2) participatory learning activities (mothers, fathers, adolescent girls), (3) model kitchens (mothers, adolescent girls), and (4) Nutrition Club (adolescent girls).
89193120|NCT05525429|No Intervention|Control|No intervention will be provided. After the research period is complete, the Control group will receive all inputs described above, but no data will be collected during this time period.
89415953|NCT05980091|Other|Group B|Embryo Transfer is scheduled on the 7th full day of progesterone administration, following the initial commencement of progesterone (144 hours)
88893362|NCT04608474|Experimental|Evolocumab plus statin|This arm includes subjects who are treated using a combination of Evolocumab and a statin-based drug.
88893363|NCT04600414|Active Comparator|Collaborative Care for Mental Health Disorders|Collaborative Care Management is an integrated care model that operationalizes the principles of the chronic care model to improve access to evidence-based treatments for mental health disorders.
88893364|NCT04600414|Experimental|Collaborative Care for Opioid Use Disorder|Collaborative Care Management is an integrated care model that operationalizes the principles of the chronic care model to improve access to evidence-based treatments for opioid use disorder.
88893365|NCT04593043||Warfarin|Reference group
88893366|NCT04593043||Dabigatran|Exposure group
88893367|NCT04593030||Warfarin|Reference group
88893368|NCT04593030||Apixaban|Exposure group
88893369|NCT04566302|Experimental|SECM Skin Imaging|The SECM skin imaging procedure will be very similar to that by the FDA approved RCM devices. First, the skin lesion (such as a mole) will be identified on a forearm of the subject. The lesion will be imaged first with a dermatoscope, and then with the SECM device. A dermatoscope is a hand-held device used for the visual observation of the epidermis. It is a superior surface contact microscope used to examine skin lesions.
88893370|NCT04565509|Active Comparator|General Message|In phase 1, three schools will be randomized to a messaging strategy that is developed from focus groups that generally describes COVID-19 and the importance of testing.
88893371|NCT04565509|Active Comparator|Focus/Targeted Message|In phase 1, three schools will be randomized to a messaging strategy that is developed from focus groups that is targeted to address specific concerns of the different communities. Messages may target groups being tested (staff versus students) or sociodemographic or race/ethnicity differences between schools depending on the FG input.
88893372|NCT04565509|Active Comparator|Best Message Alone|In phase 2, the schools will be randomized a second time after data analysis at 5 months to determine which communication strategy is determined to provide the best uptake of testing by students and staff. Three schools will be randomized to receive the best messaging strategy alone to begin at 7 months after testing starts.
89415954|NCT05974475||SBRT Cohort|Radiation: Stereotactic Body Radiotherapy (SBRT)
89415955|NCT05974475||Surgery Cohort|Procedure: Surgery
89415956|NCT05973773|Experimental|Part A (Safety Lead in)|Part A: Safety Lead-In Approximately 6-12 patients will receive zipalertinib administered at an initial dose of zipalertinib PO BID (Dose Level 1) in combination with pemetrexed and carboplatin or cisplatin on a 21-day cycle. Patients may continue to receive study treatment until documentation of progressive disease (PD) or until other withdrawal criteria are met, whichever comes first.
89415957|NCT05973773|Experimental|Part B|"Part B: Phase 3 Enrollment into the Phase 3 portion of the study will begin following completion of Part A.~Approximately 300 patients will be randomized on a 1:1 basis to receive pemetrexed and a platinum agent (either carboplatin or cisplatin) with or without zipalertinib on a 21-day cycle.~Carboplatin or cisplatin will be administered for 4 cycles. Patients may continue to receive zipalertinib (experimental study arm) and pemetrexed (both study arms) until documentation of PD or until other withdrawal criteria are met, whichever comes first."
89415958|NCT05966233|Active Comparator|R-DHAP|R-DHAP x4 + autologous transplant/salvage treatment (based on centrally review response)
89415959|NCT05966233|Experimental|Pola-R-DHAP|Pola-R-DHAP x4 + autologous transplant/salvage treatment (based on centrally review response)
89415960|NCT05954299||Normal|Participants and donor samples without disease (ex: non-cancer)
89415961|NCT05954299||Disease state or condition|Participants and donor samples with known disease or condition (ex: cancer)
89415962|NCT05936385|Experimental|Healthy Lifestyle|Healthy lifestyle counseling and goal setting every month with a team of experts, mobile app with healthy lifestyle resources and goal tracking tool, access to social services and lifestyle programs in the community, and community health worker outreach every month.
89415963|NCT05936385|Active Comparator|Standard of Care|Weight checks and lifestyle counseling with primary care provider every other month.
89415964|NCT05934175|Experimental|Intensive treatment with prolonged exposure|Intensive prolonged exposure delivered for five consecutive days comprising nine individual sessions and five group sessions followed by three individual session one, two and four weeks afterwards.
89415965|NCT05934175|Active Comparator|Weekly delivered prolonged exposure|15 weekly delivered, individual prolonged exposure sessions (gold standard treatment)
89415966|NCT05934162|Experimental|Therapist-supported internet delivered prolonged exposure|Therapist-supported internet delivered prolonged exposure comprising psychoeducation about PTSD, controlled breathing, imaginal exposure including processing, in vivo exposure and relapse prevention. The treatment will be delivered in a digital platform for ten weeks. Participants will have access to a therapist that will guide them through treatment in a text based format.
89415967|NCT05934162|Active Comparator|Therapist-supported CBT|Therapist-supported CBT internet-delivered treatment comprising psychoeducation about PTSD, relaxation techniques and relapse prevention. . The treatment will be delivered in a digital platform for ten weeks. Participants will have access to a therapist that will guide them through treatment in a text based format.
89415968|NCT05929430|Experimental|Mindfulness-Based Health Care Program (MBHC).|Mindfulness skills will take over a 6-week period. Mindfulness skills will deliver in a weekly group format. Participants will be instructed to follow mindfulness practice at home. The program is focused on cultivating mindfulness of present-moment, cultivating a nonreactive, nonjudgmental attitude toward the experience, and includes specific formal and informal practices aimed at cultivating healthy habits and lifestyle (e.g., activities of daily living such as feeding, bathing, or showering and other occupations such as communication management, health management, etc.; and prosocial components (e.g., kindness and compassion).
89415969|NCT05929430|Experimental|Mindfulness-Based Health Care program with virtual reality (MBHC-VR).|This program combines mindfulness practice with immersion in a virtual environment. The content and objectives of MBHC-VR program are the same that MBHC, with the main difference being that all formal practices of each session will be performed using VR.
89415970|NCT05929430|No Intervention|Waiting list control group (WL).|Participants in the WL control group will not receive any intervention during the study. However, for ethical reasons, at the end of the 3-month follow-up assessment, participants of this WL control group will be invited to participate in the MBHC program free of charge.
89415971|NCT05925309|Active Comparator|Antibiotics group|Basic treatment + Prophylactic oral antibiotics
89415972|NCT05925309|Experimental|Non-antibiotics group|Basic treatment
89415973|NCT05921812|Active Comparator|control|apparently healthy individuals with no chronic illness
89415974|NCT05921812|Active Comparator|cases|newly diagnosed Non-Hodgkin's lymphoma patients
89415975|NCT05919693|Experimental|Dose 1|Part 1 MAD Portion Dose 1 - Low Dose
89415976|NCT05919693|Experimental|Dose 2|Part 1 MAD Portion Dose 2 - Low-Mid Dose
89415977|NCT05919693|Experimental|Dose 3|Part 1 MAD Portion Dose 3 - Mid-High Dose
89415978|NCT05919693|Experimental|Dose 4|Part 1 MAD Portion Dose 4 - High Dose
89415979|NCT05919693|Experimental|DME Medium Dose|Part 2 Naïve DME monotherapy Medium Dose
89415980|NCT05919693|Experimental|DME High Dose|Part 2 Naïve DME monotherapy High Dose
89415981|NCT05919693|Experimental|Naïve NVAMD Medium Dose|Part 2 Naïve NVAMD combination therapy Medium Dose
89415982|NCT05919693|Experimental|Naïve NVAMD High Dose|Part 2 Naïve NVAMD combination therapy High Dose
89415983|NCT05919693|Experimental|Experienced NVAMD Medium Dose|Part 2 Experienced NVAMD combination therapy Medium Dose
89415984|NCT05919693|Experimental|Experienced NVAMD High Dose|Part 2 Experienced NVAMD combination therapy High Dose
89415985|NCT05918185||Observational (Surveys, cGA, blood sample, EHR review)|Patients complete surveys and undergo cGA, blood sample collection, and EHR review on study.
89415986|NCT05908669||GBM patients, IDH-wt|
89415987|NCT05905822||Prospectively genotyped participants|These participants will be advertised to in the local area. They will be genotyped for their APOE genotype, and then the stool sample will be collected.
89415988|NCT05905822||Database participants|"Participants from the previously genotyped cohort Early sleep and circadian markers of Alzheimer's disease: the impact of APOE-ε4 on circadian rhythm and sleep-wake homeostasis in humans (Reference: 2017/18-135) who have consented to be contacted will be contacted to collect a stool sample."
89415989|NCT05905536|Experimental|Vitalstream|Device placed on the subject preoperatively in the holding room and continued postoperatively into the Cardiac Intensive Care Unit (ICU).
89415990|NCT05904652|Experimental|SAFEx|Electrical Impedance Tomography recording is commenced 15 minutes prior to planned extubation. High Flow Nasal Therapy (HFNT) is commenced at least 10 minutes prior to planned extubation. At 5 minutes before extubation, the flow rate of HFNT should be established at 60 litres per min (or as high as can be tolerated by the participant) and the fraction of inspired oxygen (FiO2) set at 40 percent. Prior to extubation, endotracheal, infraglottic and supraglottic suctioning are performed. Then, the cuff is let down followed by immediate extubation with simultaneous application of HFNT. 10 minutes after extubation, the FiO2 is weaned in a protocolised manner to 21 percent - or as close to 21 percent as possible over 25 minutes. If the participant is safely weaned onto room air, the flow rate of HFNT is then reduced in a protocolised manner over 120 minutes: 60 minutes at 60 litres per minute (or the highest flow rate tolerated) and then 60 minutes at 30 Litres per minute.
89415991|NCT05904652|Active Comparator|Standard Care|Electrical Impedance Tomography recording commenced 15 minutes prior to planned extubation. Prior to extubation, endotracheal, infraglottic and supraglottic suctioning are performed. Then, the cuff is let down followed by immediate extubation on to low flow conventional oxygen with a fraction of inspired oxygen of up to 40 percent. Then, the participant is weaned at the discretion of their clinician over the next 2 hours and 35 minutes.
89415992|NCT05903170|Active Comparator|360J LifePak Monitor/Defibrillator|"The standardised cardioversion protocol below performed with a 360J shock from a Lifepak Monitor/Defibrillator.~First shock with anteroposterior pad configuration~In event of failure of the above, a second shock with anterolateral pad configuration~In event of failure of the above, a third shock with anteroposterior pad configuration + manual pad pressure"
89415993|NCT05903170|Active Comparator|200J Philips HeartStart MRx Monitor/Defibrillator|"The standardised cardioversion protocol below performed with a 200J shock from a Philips HeartStart MRx Monitor/Defibrillator.~First shock with anteroposterior pad configuration~In event of failure of the above, a second shock with anterolateral pad configuration~In event of failure of the above, a third shock with anteroposterior pad configuration + manual pad pressure~The addition of a fourth 'rescue' shock at 360J using the LifePak Monitor/Defibrillator with pads in the anteroposterior configuration in the event of the first three steps failing to cardiovert to sinus rhythm"
89415994|NCT05897385|Active Comparator|Group L|Intraperitoneal lignocaine 200mg/20mls + epinephrine 1:200,000
89415995|NCT05897385|Placebo Comparator|Group P|Intraperitoneal 20ml of 0.9% normal saline
89415996|NCT05881811|Experimental|A1|Period 1: HSK16149 single dose on D1, 40mg, fasted; Period 2: HSK16149 single dose on D2, 40mg, fasted; Probenecid QID (500mg) on D1~D4. HSK16149 would be administered 2 hours after the first dose of probenecid on D2.
89415997|NCT05881811|Experimental|A2|"Period 1: HSK16149 single dose on D2, 40mg, fasted；probenecid QID (500mg) on D1~D4. HSK16149 would be administered 2 hours after the first dose of Probenecid on D2.~Period 2: HSK16149 single dose on D1, 40mg, fasted;"
89415998|NCT05881811|Experimental|B1|Period 1: HSK16149 single dose on D1, 40mg, fasted; Period 2: HSK16149 single dose on D2, 40mg, fasted; Cimetidine QID (200mg) on D1~D4. HSK16149 would be administered 1 hour after the first dose of Cimetidine on D2.
89415999|NCT05881811|Experimental|B2|"Period 1: HSK16149 single dose on D2, 40mg, fasted; Cimetidine QID (200mg) on D1~D4. HSK16149 would be administered 1 hour after the first dose of Cimetidine on D2.~Period 2: HSK16149 single dose on D1, 40mg, fasted;"
89416000|NCT05878223|Experimental|ESWT to gastrocnemius and soleus|ESWT to gastrocnemius and soleus muscles (2000 shots for each muscle, a total of 4000 shots per session)
89416001|NCT05878223|Active Comparator|ESWT to gastrocnemius|ESWT to gastrocnemius muscle (2000 shots per session)
89416002|NCT05875181|Experimental|VS tFUS/Sham tFUS|VS tFUS (tFUS applied to the ventral striatum) Sham tFUS (go through the motions of applying tFUS to the VS)
89416003|NCT05875181|Experimental|Sham tFUS/VS tFUS|VS tFUS (tFUS applied to the ventral striatum) Sham tFUS (go through the motions of applying tFUS to the VS)
89416004|NCT05871177|Experimental|HiLow hyaluronic acid sodium salt for intralesional penile injection|"Five intralesional injections of HiLow hyaluronic acid sodium salt will be administered in total to men affected by PD every two weeks (for a total period of 2.5 months). Patients will be then followed-up for 3 months.~The following visits are scheduled:~Day 0: basal visit Day 15: injection n.1 Day 30: injection n.2 Day 45: injection n.3 Day 60: injection n.4 Day 75: injection n.5 Day 180: end of follow up"
88893373|NCT04565509|Active Comparator|Best Message + Augmented Message or Implementation Strategy|In phase 2, the schools will be randomized a second time after data analysis at 5 months to determine which communication strategy is determined to provide the best uptake of testing by students and staff. Three schools will be randomized to receive the best messaging strategy plus an augmented messaging or implementation strategy. The augmented messaging and implementation strategies will be informed by the barriers and facilitators identified based on the CFIR domains and results of focus groups and surveys in Aim 2.
88893374|NCT04563741|Experimental|MOVE!+UP (intervention)|usual care enhanced with MOVE!+UP (intervention)
88893375|NCT04563741|Active Comparator|MOVE! (control condition)|usual care enhanced with MOVE! (control condition)
88893376|NCT04554394|Experimental|CellFX Treated Wart|Treated wart with CellFX device intervention
89416005|NCT05863884|Other|CHW Intervention|A six week CHW home-visit behavioral intervention examining changes in diabetes outcomes.
88893377|NCT04554394|No Intervention|Non-treated Wart|Control wart for each enrolled subject without intervention
88893378|NCT04536870|Experimental|STAREE Statin group|Participants in STAREE trial randomised to statin
88893379|NCT04536870|Experimental|STAREE Placebo group|Participants in STAREE trial randomised to placebo
88893380|NCT04532229|Experimental|Experimental|Nimotuzumab+CRT(concurrent IMRT and TMZ)
88893381|NCT04519879|Experimental|Arm IA (white mushroom extract)|Patients receive white button mushroom extract PO BID on day 1. Treatment repeats every 4 weeks for cycles 1-3 then every 12 weeks for cycles 4-6 (36 weeks) in the absence of disease progression or unacceptable toxicity.
88893382|NCT04519879|Active Comparator|Arm IB (clinical observation)|Patients undergo clinical observation for 12 weeks. If PSA continues to increase, patients have the option to receive the white button mushroom extract as in arm IA.
88893383|NCT04519879|Experimental|Arm IIA (white mushroom extract)|Patients receive white mushroom extract PO BID on day 1. Treatment repeats every 12 weeks for 4 cycles (48 weeks) in the absence of disease progression or unacceptable toxicity.
88893384|NCT04519879|Active Comparator|Arm IIB (active surveillance)|Patients undergo active surveillance for 48 weeks.
88893385|NCT04519177|Experimental|Experimental (Early Education)|Firefighters in station randomized to the experimental (early education) will receive the sleep health education program (SHEP) including screening for common sleep disorders. Those found at high risk will be given information about seeking further evaluation, diagnosis and treatment, if necessary.
88893386|NCT04519177|No Intervention|Control (Later education)|Firefighters in station randomized to the control condition will not receive SHEP prior to the data collection.
88893387|NCT04518410|Experimental|Bamlanivimab 7000 mg (Phase 2)|Administered by IV infusion.
88893388|NCT04518410|Placebo Comparator|Bamlanivimab 7000mg Placebo (Phase 2)|Administered by IV infusion
88893389|NCT04518410|Experimental|Bamlanivimab 700mg (Phase 2)|Administered by IV infusion
88893390|NCT04518410|Placebo Comparator|Bamlanivimab 700mg Placebo (Phase 2)|Administered by IV infusion
88893391|NCT04518410|Experimental|Bamlanivimab 700mg (Phase 3)|Administered by IV infusion
88893392|NCT04518410|Experimental|BRII-196+BRII-198 (Pooled Phase 2/3)|Administered by IV infusion
88893393|NCT04518410|Placebo Comparator|BRII-196+BRII-198 Placebo (Pooled Phase 2/3)|Administered by IV infusion
88893394|NCT04518410|Experimental|AZD7442 (IV) (Phase 2)|Administered by IV infusion
88893395|NCT04518410|Placebo Comparator|AZD7442 (IV) Pooled Placebo (Phase 2)|Administered by IV infusion; shared placebo includes AZD7442 (IM) placebo and placebo from other comparator arms in the study.
88893396|NCT04518410|Experimental|AZD7442 (IM) (Phase 2)|Administered by IM injection
88893397|NCT04518410|Placebo Comparator|AZD7442 (IM) Pooled Placebo (Phase 2)|Administered by IM injection; shared placebo includes AZD7442 (IV) placebo and placebo from other comparator arms in the study.
88893398|NCT04518410|Experimental|SNG001 (Phase 2)|Administered by inhalation
88893399|NCT04518410|Placebo Comparator|SNG001 Pooled Placebo (Phase 2)|Administered by inhalation; shared placebo includes placebo from other comparator arms in the study.
88893400|NCT04518410|Experimental|Camostat (Phase 2)|Administered as oral tablets
88893401|NCT04518410|Placebo Comparator|Camostat Pooled Placebo (Phase 2)|Administered as oral tablets; shared placebo includes placebo from other comparator arms in the study.
88893402|NCT04518410|Experimental|SAB-185 (low dose) (Phase 2)|Administered by IV infusion
89416006|NCT05863039|Experimental|Group 1|Strength training associated with blood flow restriction
88893403|NCT04518410|Placebo Comparator|SAB-185 (low dose) Pooled Placebo (Phase 2)|Administered by IV infusion; includes SAB-185 (high dose) placebo and placebo from other comparator arms in the study.
88893404|NCT04518410|Experimental|SAB-185 (low dose) (Phase 3) Non-OMICRON population|"Administered by IV infusion.~The Non-Omicron subpopulation enrolled under Protocol Version 7 was defined as all participants enrolled under Protocol Version 7 excluding those in the Omicron subpopulation.~Omicron/Non-Omicron subpopulation definitions were updated in Version 10.0 of the Primary SAP to be based on the timing of emergence of the Omicron variant within the study population as follows:~Variant information from any sample (i.e., not just from samples obtained on day 0) could be used to assign a participant to the Omicron or non-Omicron Subpopulations.~For participants without variant information, those randomized under Protocol Version 7.0 on or after December 15, 2021 would be assigned to the Omicron Subpopulation, and those randomized on or before December 14, 2021 would be assigned to the Non-Omicron Subpopulation."
88893405|NCT04518410|Active Comparator|Casirivimab and Imdevimab (Phase 3) Non-OMICRON population|"Administered by IV infusion.~The Non-Omicron subpopulation enrolled under Protocol Version 7 was defined as all participants enrolled under Protocol Version 7 excluding those in the Omicron subpopulation.~Omicron/Non-Omicron subpopulation definitions were updated in Version 10.0 of the Primary SAP to be based on the timing of emergence of the Omicron variant within the study population as follows:~Variant information from any sample (i.e., not just from samples obtained on day 0) could be used to assign a participant to the Omicron or non-Omicron Subpopulations.~For participants without variant information, those randomized under Protocol Version 7.0 on or after December 15, 2021 would be assigned to the Omicron Subpopulation, and those randomized on or before December 14, 2021 would be assigned to the Non-Omicron Subpopulation."
88893406|NCT04518410|Experimental|SAB-185 (high dose) (Phase 2)|Administered by IV infusion
88893407|NCT04518410|Placebo Comparator|SAB-185 (high dose) Pooled Placebo (Phase 2)|Administered by IV infusion; includes SAB-185 (low dose) placebo and placebo from other comparator arms in the study.
88893408|NCT04518410|Experimental|BMS 986414+BMS 986413 (Phase 2)|Administered as subcutaneous (SC) injections
88893409|NCT04518410|Placebo Comparator|BMS 986414+BMS 986413 Pooled Placebo (Phase 2)|Administered as subcutaneous (SC) injections; shared placebo includes placebo from other comparator arms in the study.
88922138|NCT05746832|Active Comparator|Two sessions application of (ERCP) in the management of common bile duct stones.|Two sessions application of endoscopic stenting retrograde cholangiopancreatography (ERCP) in the management and clearance of difficult common bile duct stones.and assessment of the differences in stone size and the largest CBD diameter before and after stenting in one or two sessions. Stone clearance and complications were also determined with the ERCP, and factors associated with complete clearance were evaluated in patients with difficult CBD stones (a large [≥ 20 mm] or multiple [≥ 3 sized ≥ 15 mm] CBD stones). And also compared the outcomes with conventional procedure of open surgery.
88922139|NCT05746039|Experimental|Study Drug (semaglutide)|Semaglutide Pen Injector 1.0 mg weekly Once weekly subcutaneous injection Other Name: Wegovy
89193121|NCT05520203||Patient - cohort 1|Patients (and their parents) recruited before introduction of the NP
89193122|NCT05520203||Patient - cohort 2|Patients (and their parents) recruited after introduction of the NP
89416007|NCT05863039|Experimental|Group 2|Conventional strength training using high loads
89416008|NCT05863039|Experimental|Group 3|Conventional strength training using low loads
89416009|NCT05859295|Other|Low-Level Light Therapy|All subjects will receive 3 15-minute treatments of low level light therapy
89416010|NCT05849714|Active Comparator|Usual Care|Patients will receive usual care for their diabetes during their peri-procedural period.
89416011|NCT05849714|Experimental|DIAPI|Patients will receive the care for their diabetes recommended by the DIAPI algorithm during their peri-procedural period.
89416012|NCT05849090|Active Comparator|Standard of care prophylactic antibiotics|"Standard irrigation and IV, cephalosporin, 2-grams, intravenous (IV),~or standard irrigation and IV, clindamycin (900mg) / vancomycin (20mg/kg), intravenous (IV) for patients with cephalosporin allergies."
89416013|NCT05849090|Experimental|Vancomycin and Tobramycin|One-time dosage of topical vancomycin (1 gram) and tobramycin (1.2 grams) powder.
89416014|NCT05847361||P|(P) : Preclamptic women : pregnant women diagnosed with preclampsia
89416015|NCT05847361||N|(N) : normotensive women : pregnant women without any criteria of preeclampsia
89416016|NCT05846646|Experimental|Experimental Arm|PULSAR-ICI + IMSA101
89416017|NCT05846646|Active Comparator|Control Arm|PULSAR-ICI
89416018|NCT05846451|Experimental|Arm 1|"Sixteen non-naive* participants (8 males, 8 females) will be administered a single low dose (2 g) of a well-characterized kratom product by mouth as a tea. Pupil diameter will be measured from 0-12 hours. A washout of at least 10 days will separate Arms 1 and 2.~*Non-naive subjects are defined as intermittent users who consume 2-8 g kratom at least once per month but no more than three times daily within the last six months prior to screening and are willing to abstain for several weeks"
89416019|NCT05846451|Active Comparator|Arm 2|The same 16 participants will be administered a single low dose (10 mg) of immediate-release oxycodone by mouth as a tablet. Plasma, pupil diameter measurements, and urine will be collected from 0-24 hours. A washout of at least 2 days will separate Arms 2 and 3.
88893410|NCT04518410|Experimental|SAB-185 (low dose) (Phase 3) OMICRON population|"Administered by IV infusion The Omicron subpopulation enrolled under Protocol v.7 was defined as (1) all participants randomized under Protocol v.7 infected with the Omicron variant as identified on sequencing of NP sample obtained on day 0, plus (2) all participants randomized under Protocol v.7 on/after December 26, 2021, who do not have variant information available from sample obtained on day 0.~Definitions were updated in Primary SAP v10.0 to be based on timing of emergence of Omicron variant within the study population as follows:~Variant information from any sample (i.e. not just from samples obtained on day 0) could be used to assign a participant to the Omicron or non-Omicron Subpopulations.~For participants without variant information, those randomized under Protocol v7 on or after December 15, 2021 would be assigned to the Omicron Subpopulation, and those randomized on or before December 14, 2021 would be assigned to the Non-Omicron Subpopulation."
89416020|NCT05846451|Experimental|Arm 3|The same 16 participants will be administered a single low dose (2 g) of kratom as a tea. After 15 minutes, the subjects will be administered a single low dose (10 mg) of oxycodone as a tablet by mouth. Plasma, pupil diameter measurements, and urine will be collected from 0-24 hours. A washout of at least 10 days will separate Arms 3 and 4.
89416021|NCT05846451|Experimental|Arm 4|The same 16 participants will self-administer a single low dose (2 g) of kratom as a tea once daily at home. On the fifth day, subjects will return to the research setting, where they will be administered a single low dose (2 g) of kratom, followed 15 minutes later by a single low dose (10 mg) of oxycodone by mouth. Plasma, pupil diameter measurements, and urine will be collected from 0-24 hours.
89416022|NCT05844033||Chronic Lymphocytic Leukemia and Multiple Myeloma Participants|"150 participants will be screened for an antigen-specific antibody profiling biomarker that is associated with an increased risk of any infections.~Study procedures include in-person or virtual appointments every 3 months for 2 years, some of which will also include bloodwork:~In-person or virtual appointments with study staff for months 4, 10, 16, and 22 Day 1.~In-person or virtual appointments with study staff for months 7, 13, 19, and 25 Day 1 with blood tests."
89416023|NCT05837884|Other|First-degree relative of a patient with a plasma cell dyscrasia or another blood cancer.|Individuals will ensure they are eligible by filling out an eligibility questionnaire confirming they meet all eligibility criteria. Individuals will provide informed consent to complete the baseline questionnaire and provide a blood sample that will be used to determine whether they have a monoclonal protein
89416024|NCT05836870|Experimental|Group A-Enhanced Usual Care|Participants will be given general recommendations to increase physical activity and improve nutrition before surgery.
89416025|NCT05836870|Experimental|Group B-Tele-supervised resistance exercises|Participants will take part in a monitored exercise program. The study team will provide more instructions and information about the program
89416026|NCT05832541||Test group (peri-implantitis)|peri-implant tissue specimen will be taken after identification of diseased interproximal implant sites. Following local anesthesia specimen will be taken either by supracrestal incision to remove all diseased soft tissue surrounding the implant or by making 2 parallel incisions, 4 mm apart, with a 15C scalpel blade through the soft tissue until bone contact would be achieved. The 2 incisions will be connected with a perpendicular incision that will be placed at a distance of 4 mm from the proximal surface of implant. The biopsies, including the entire supracrestal soft tissue portion of the diseased site, will be carefully retrieved and prepared for histopathological and immunohistochemical analysis
88922140|NCT05745103|Experimental|The Eleos Health Platform|Therapists in the AI group will use the HIPAA-compliant, secure, password-protected Eleos Health platform. This AI tool was designed for behavioral health to support clinical decision-making and automation of administrative tasks. The platform captures the therapist and patient's utterances during a treatment session, analyzes the data, and offers feedback on the implementation of EBPs. The platform also incorporates a measurement-based care component, wherein standardized assessment scales completed by clients are immediately summarized and graphed for the therapist, who can use these data to inform therapy and share them with the patient. Insights and key indicators from the session data and MBC are summarized into a progress note draft which the therapist can then submit or edit as needed.
89193123|NCT05520203||Healthcare providers|Healthcare providers involved in the process of development, implementation and evaluation as well as all healthcare providers who come into close contact with the Nurse Practitioner
89193124|NCT05519800|Active Comparator|High Glycaemic Index|A diet comprising of High Glycaemic Carbohydrate. Supplemented with a maltodextrin containing beverage.
88893411|NCT04518410|Active Comparator|Casirivimab and Imdevimab (Phase 3) OMICRON population|"Administered by IV infusion The Omicron subpopulation enrolled under Protocol v.7 was defined as (1) all participants randomized under Protocol v.7 infected with the Omicron variant as identified on sequencing of NP sample obtained on day 0, plus (2) all participants randomized under Protocol v.7 on/after December 26, 2021, who do not have variant information available from sample obtained on day 0.~Definitions were updated in Primary SAP v10.0 to be based on timing of emergence of Omicron variant within the study population as follows:~Variant information from any sample (i.e. not just from samples obtained on day 0) could be used to assign a participant to the Omicron or non-Omicron Subpopulations.~For participants without variant information, those randomized under Protocol v7 on or after December 15, 2021 would be assigned to the Omicron Subpopulation, and those randomized on or before December 14, 2021 would be assigned to the Non-Omicron Subpopulation."
88893412|NCT04517864|Experimental|Treatment Arm: PF-06651600|ritlecitinib 200 milligram (mg) once per day (QD) (four 50 mg tablets) for 4 weeks then ritlecitinib 50 mg tablet QD through month 24. At Month 9, participants assigned to this treatment arm will also receive 3 tablets of placebo for 4 weeks to maintain the blind with the other arm. After month 24, participants switch to 50 mg capsules, 1 QD, up to month 60.
89416027|NCT05832541||Control group (clinically healthy)|"tissue sample for control group will be collected from patients undergoing implant surgery. After local anesthesia, a crystal incision will be performed, and a full-thickness flap will be elevated. Following the osteotomy, one or more implants of 4.5-5.0 mm in diameter will be placed. A narrow diameter healing abutment will be screwed in with an insertion torque > 20 NM., and flaps will be repositioned and sutured to obtain optimal adaptation of the mucosa to the titanium abutment.~Sample harvesting will be done after 2 months of healing using circular punch of 4.5-5.0 mm diameter or performing a circular incision by surgical blade by which a 1.5 mm thick collar of peri-implant soft tissue will be harvested and prepared for histopathological and immunohistochemical analysis. A new 4.5-5.0 mm-wide smooth-surfaced healing abutment will be connected to the implant directly after the biopsy sampling."
88893413|NCT04517864|Other|Control Arm (Placebo) followed by active therapy extension|matching comparator: placebo QD (4 tablets x 4 weeks then 1 tablet x 8 months) then ritlecitinib 200 mg QD (four 50 mg tablets) for 4 weeks then ritlecitinib 50 mg tablet QD through month 24. After month 24, participants switch to 50 mg capsules, 1 QD, up to month 60.
88893414|NCT04507204|Experimental|Adhansia XR|Adhansia XR capsules taken orally once daily with or without food.
88893415|NCT04507204|Active Comparator|Concerta|Concerta tablets taken orally once daily in the morning and swallowed whole with the aid of liquids, with or without food.
88893416|NCT04500457|Experimental|Intervention|This arm consists of a 2-week computerized, exposure-based intervention. Treatment sessions are completed every 3 days at home (5 treatment sessions total).
88893417|NCT04500457|No Intervention|Wait-List Control|Participants in this condition will not receive treatment.
88893418|NCT04498052|Experimental|Patients eligible for LDCT lung cancer screening|"This population will consist of patients eligible for, or potentially eligible for, LDCT lung cancer screening according to USPSTF guidelines, who are seen by a pilot user of the intervention. The inclusion criteria are (i) >= 55 years and <= 80 years old at the time of the visit; (ii) does not already have lung cancer; and (iii) meets USPSTF smoking criteria for LDCT screening (30+ pack-year smoking history and current smoker or quit in the past 15 years) or may meet the criteria if a complete smoking history were taken.~USPSTF guidelines may change during the study. In particular, it is anticipated that the guidelines may update during the study whereby the minimum age is reduced to 50 (from 55) and the minimum smoking history is reduced to 20 years (from 30). In the event that the USPSTF guidelines change, the intervention will be updated to match the change to the guidelines. We may also update the study evaluation to match the updated USPSTF guidelines."
88893419|NCT04494048||Endoscopic Bariatric Therapies (EBT).|patients undergoing Endoscopic Bariatric Therapies
88893420|NCT04487574|Experimental|XC221|"XC221 100 mg orally.~1 tablet of XC221 100 mg 2 times a day during 14 days of treatment period."
88893421|NCT04487574|Placebo Comparator|Placebo|"Placebo orally.~1 tablet of Placebo 2 times a day during 14 days of treatment period"
88893422|NCT04486391|Experimental|Tislelizumab|Tislelizumab monotherapy for up to 45 months
88893423|NCT04486391|Experimental|Salvage chemotherapy|Salvage chemotherapy for up to 45 months
88893424|NCT04482855|Experimental|Group 1 (laser group)|Group 1 (laser group): After completion of the baseline measurements, Group 1 participants will be scheduled for LLLT. After completion of LLLT, participants will be scheduled for the 4-week and 8-week follow up data collection.
88893425|NCT04482855|No Intervention|Group 2 (wait-list control group)|Group 2 (wait-list control group): Group 2 participants will not undergo LLLT therapy but will complete all the same study assessments as the laser therapy group, including the baseline, and follow-up assessments. After the 8-week follow-up assessment, participants will be offered the same LLLT as the laser group.
88893426|NCT04481139|Experimental|SHR0302 dose1|SHR0302 dose1 for 24 weeks
88893427|NCT04481139|Experimental|SHR0302 dose2|SHR0302 dose2 for 24 weeks
88893428|NCT04481139|Experimental|SHR0302 dose3|SHR0302 dose3 for 24 weeks
88893429|NCT04481139|Placebo Comparator|Placebo|Placebo for 12 weeks
88893430|NCT04472026|Experimental|Intervention group|Counseling using the electronic conversation aid
88893431|NCT04463667|Experimental|The effects of exercise intervention on fatty liver|The effects of exercise intervention on fatty liver and the improvement of the above-mentioned various metabolic indicators, including improvement of sleep patterns and changes of intestinal microflora.
88893432|NCT04462497|No Intervention|Control Group|Participants will receive the existing method of head support (sponge and towel stack) intraoperatively.
88893433|NCT04462497|Experimental|Study Group|Participants will receive the prototype head and neck support device intraoperatively.
88893434|NCT04458532|Experimental|(A) breast cancer after completion of chemo|300 min/wk for 16 weeks, followed by 16 weeks of usual care.
88893435|NCT04458532|Experimental|(B) breast cancer after completion of chemo|150 min/wk for 32 weeks.
89416028|NCT05824026|Other|main arm|Non comparative - One armed - open labelled Intervention - subjects will wear the test dressing in a two weeks period with planned dressing changes once pr. week.
89416029|NCT05811065|Experimental|OPTIVF predicted drug dosage|This arm will use dosage, trigger predicted by Opt-IVF
89416030|NCT05811065|Active Comparator|Traditional drug treatment|This arm will use doctor specified treatment
89416031|NCT05805085|Experimental|Lens A|Participants will wear Lens A for the first period of 15 minutes.
89416032|NCT05805085|Experimental|Lens B|Participants will wear Lens B for the second period of 15 minutes.
89416033|NCT05805059|Experimental|Control Contact Lens, Then Test Contact Lens|Participants will wear control contact lenses for one week and then crossover to test contact lenses for one week.
89416034|NCT05805059|Experimental|Test Contact Lens, Then Control Contact Lens|Participants will wear test contact lenses for one week and then crossover to control contact lenses for one week.
89416035|NCT05801939|Experimental|Cevostamab|
89416036|NCT05794126|Experimental|Soft Multifocal Hydrogel Contact Lens 1|Participants will wear soft multifocal hydrogel contact lens 1 for the first period of 15 minutes and soft multifocal silicone hydrogel contact lens 2 for the second period of 15 minutes.
89416037|NCT05794126|Experimental|Soft Multifocal Silicone Hydrogel Contact Lens 2|Participants will wear soft multifocal silicone hydrogel contact lens 2 for the second period of 15 minutes.
89416038|NCT05772910|Experimental|EDUcation|The EDU group will assist to an individualized educative program based on intrinsic capacity optimization through lifestyle changes.
89416039|NCT05772910|Experimental|EXERcise|The EXER group will follow a program focused on the specific deficit of muscular power from a simple clinical test such as the STS and, in addition, they will be evaluated to be able to prescribe training individually (evaluation of training)
89416040|NCT05772910|Experimental|EDU-EXER|EDU-EXER group subject develops both interventions together.
89416041|NCT05772910|Active Comparator|CONtrol|CON group will continue the usual clinical treatment and their normal life.
89416042|NCT05766852|Active Comparator|Group A: Breath + Psychoeducation|Participants will be asked to participate in the 3 1.5-hour intervention classes. The pre-intervention and post-intervention assessments will require participants to complete a 20-25-minute online survey via Qualtrics and provide saliva samples.
89416043|NCT05766852|Experimental|Group B: Breath + Movement + Psychoeducation|Participants will be asked to participate in the 3 1.5-hour intervention classes. The pre-intervention and post-intervention assessments will require participants to complete a 20-25-minute online survey via Qualtrics and provide saliva samples.
89416044|NCT05763628|Experimental|Control Contact Lens, Then Test Contact Lens|Participants will wear control contact lenses for two weeks and then crossover to test contact lenses for two weeks.
89416045|NCT05763628|Experimental|Test Contact Lens, Then Control Contact Lens|Participants will wear test contact lenses for two weeks and then crossover to control contact lenses for two weeks.
89193125|NCT05519800|Experimental|Low Glycaemic Index|A diet comprising of Low Glycaemic Carbohydrate. Supplemented with an Isomaltulose containing beverage.
89416046|NCT05754411|Experimental|[14C]STI-1558|
89416047|NCT05753046|Experimental|Early TAP Block|For treatment delivery, subjects will receive 60 mL of 0.25 percent ropivacaine with 4 mg of dexamethasone at the initiation of the procedure (immediately following placement of the robotic / laparoscopic camera port).
89416048|NCT05753046|Experimental|Late TAP Block|For treatment delivery, subjects will receive 60 mL of 0.25 percent ropivacaine with 4 mg of dexamethasone either at the conclusion of the procedure (immediately preceding removal of the robotic / laparoscopic camera port).
89416049|NCT05738603|No Intervention|Standard Therapy Group|The standard therapy group patients will have invasive blood pressure monitoring + standard medical therapy. The therapeutic decision regarding treatment of hypotension, the use of fluids and vasopressors will be determined by the anaesthesia team. The decisions will be based on the information from the standard invasive blood pressure monitoring.
89416050|NCT05738603|Experimental|Hypotension Prediction Index Group|The HPI-group will have the HPI based monitoring with the Acumen IQ sensor (Edwards Lifesciences) and the HPI algorithm connected also to the HemoSphere platform (Edwards Lifesciences). The hemodynamic management will be based on the HPI indications and the specific algorithm, which considers hypovolemia, impaired contractility and vasodilatation. An alert pops up on the monitor screen when the HPI values exceeds 85 and then the clinician needs to make therapeutic decision in order to avoid the hypotensive episode.
89416051|NCT05712694|Experimental|ADIGemDoc|ADI-PEG 20: 36 mg/m2 on Day -7 of Cycle 1, and Days 1, 8, and 15 of each 21-day cycle Gemcitabine: 600 mg/m2 on days 1 and 8 of each 21-day cycle Docetaxel: 60 mg/m2 on day 8 of each 21-day cycle
89416052|NCT05712694|Placebo Comparator|PBOGemDoc|Placebo: matched PBO on Day -7 of Cycle 1, and Days 1, 8, and 15 of each 21-day cycle Gemcitabine: 900 mg/m2 on days 1 and 8 of each 21-day cycle Docetaxel: 75 mg/m2 on day 8 of each 21-day cycle
89416053|NCT05708612|Experimental|Implantation of SimplyFI|Long-term non-active implant
89416054|NCT05706012||Gastro-enterologists and cardiologists|An online survey will be sent to question current clinical practice in long-term antithrombotic management of AMI in SBS patients.
89193126|NCT05514873|Experimental|0.3 mg/kg zilucoplan (RA101495)|Study participants will be treated with subcutaneous zilucoplan (0.3mg/kg/day)
89416055|NCT05705024|Active Comparator|Medium dose of allogenic MSC drops|Dose of allogeneic MSC subconjunctival injection will be assigned 3,000,000 cells/150 µL.
89416056|NCT05705024|Sham Comparator|Control Group|For the control group, 50 µL of the freezing media (vehicle) will be injected.
89416057|NCT05702385|No Intervention|Standard Practice|The control group treats their simulated patients using standard practice and has no introduction to the new diagnostic test.
89416058|NCT05702385|Experimental|Intervention Group 1 - Test Results Given|Intervention Group 1 will receive information regarding the test and will be given the test results, whether selected or not, in Round 2 of CPV administration.
89416059|NCT05702385|Experimental|Intervention Group 2 - Test Results Optional|Intervention Group 2 will receive information regarding the test and will be given the test results if selected in Round 2 of CPV administration.
88893436|NCT04458532|Experimental|(C) breast cancer after completion of chemo|300 min/wk for 32 weeks.
88893437|NCT04458532|Active Comparator|(D) breast cancer after completion of chemo|150 min/wk for 16 weeks, followed by 16 weeks of usual care.
88893438|NCT04448938||optic neuritis|
88893439|NCT04448938||control|
88893440|NCT04442971|Experimental|Music Stimulation|Patients preferred music is presented via headphones.
88893441|NCT04442971|Active Comparator|Alternative Auditory Stimulation|An audio book is presented via headphones.
88893442|NCT04442971|Sham Comparator|No Auditory Stimulation|Silence is presented via headphones.
88893443|NCT04442061|Active Comparator|Active transcranial magnetic stimulation|excitatory TMS will be applied to the right posterior STS
88893444|NCT04442061|Sham Comparator|Sham transcranial magnetic stimulation|The sham TMS follows the same procedure of the active TMS without stimulating cortical tissue
88893445|NCT04417127|Experimental|Microfinance with Integrated Community-based Care|20 microfinance groups with n=450 participants will be randomized to receive the ICB intervention.
88893446|NCT04417127|Active Comparator|Microfinance with Standard of Care|20 microfinance groups with n=450 participants will be randomized to continue to receive standard of care from an AMPATH-supported rural health facility.
88893447|NCT04417127|No Intervention|Standard of Care without Microfinance|n=300 participants who receive care at an AMPATH health facility and who are not involved in microfinance will serve as matched contemporaneous controls. These participants will be actively followed over the 18-months of the trial.
88893448|NCT04414397|Experimental|JUVÉDERM VOLUMA® XC Treatment|Participants received JUVÉDERM VOLUMA® XC injectable gel treatment in both temples followed by an optional touch-up treatment 30 days later.
88893449|NCT04414397|Other|No-treatment control|Participants received no treatment for 3 months and then received an optional delayed treatment with JUVÉDERM VOLUMA® XC and an optional touch-up treatment 30 days later.
89416060|NCT05699018|Other|Diagnostic Test: e-LIFT|only one arm because diagnostic study evaluating blood test using elastometry and liver biopsy as reference
88893450|NCT04404036|Experimental|SinuSonic Device|"Aim 1: SinuSonic device used once a day over a 2 day period.~Aim 2: SinuSonic device used twice daily for 3 minutes in the home setting for 6 weeks.~Aim 3: SinuSonic device used twice daily for 3 minutes in the home setting for 4 weeks."
88893451|NCT04385108|Experimental|hospitalized patients|"very well-defined population of COVID-19 patients with the following outcomes:~Patients with severe disease requiring on admission ICU management for ARDS,~Non-severe hospitalized patients with secondary clinical worsening requiring ICU management,~Non-severe hospitalized patients without clinical worsening requiring ICU management."
88893452|NCT04385108|Experimental|healthcare workers|mildly symptomatic patients among healthcare workers attending outpatient dedicated clinics will be recruited
88893453|NCT04373005||Nasopharyngeal (NP) swabs|"NP swabs:~At the time of consent~3-6 weeks after starting cancer treatment (for patients whose treatment has yet not started) or 3-6 weeks after first swab (for patients already on treatment)~3 months after second swab~6 months after second swab~12 months after second swab"
89193127|NCT05503810|Experimental|Intervention|Six month social support intervention following in hospital cardiac treatment
88893454|NCT04337944|Experimental|Patients with KPro, PPV, and endoscopy|Patients will receive at the same time a Boston keratoprosthesis type 1 (KPro) with a pars plana vitrectomy (PPV) with anterior hyaloid membrane peeling assisted by endoscopy.
89416061|NCT05693493|Experimental|Intervention group|Device: Proprioceptive knee brace Subjects will use proprioceptive knee brace for 6 weeks post-op, in addition to basic management such as physiotherapy.
89416062|NCT05693493|No Intervention|Control group|No device. Subjects will receive basic management such as physiotherapy.
89416063|NCT05685719|Experimental|Part 1: TR|Subjects will take a single dose of test product 200mg/capsule on Day 1 of the study, then reference product 100mg/capsule on Day 8 of the study.
89416064|NCT05685719|Experimental|Part 1: RT|Subjects will take a single dose of reference product 100mg/capsule on Day 1 of the study, then test product 200mg/capsule on Day 8 of the study.
89416065|NCT05685719|Experimental|Part 1: Group 1|Subjects will take a single dose of STI-1558 200mg/capsule on Day 1. Starting from Day 4, subjects will orally take 200mg of itraconazole, q.d, for 6 consecutive days (Day 4 to Day 9). The 5th dose (Day 8) of itraconazole will be co-administered with STI-1558 (200 mg/capsule × 3 capsules) to subjects.
89416066|NCT05685719|Experimental|Part 1: Group 2|Subjects will take a single dose of STI-1558 200mg/capsule on Day 1. Starting from Day 4, subjects will orally take 600mg of rifampin, q.d, for 9 consecutive days (Day 4 to Day 12). The 8th dose (Day 11) of rifampin will be co-administered with STI-1558 (200 mg/capsule × 3 capsules) to subjects.
89416067|NCT05684900||reservoir oxygen mask|During the sedation procedure in the endoscopy unit, patients who used a reservoir oxygen mask will be examined. No premedication will be applied to patients admitted to the endoscopy unit. As a standard, intravenous vascular access will be established with a 22 gauge intraket on the back of the left hand in all patients, 6-10 lt/minute oxygen therapy will be started with a reservoir mask, and peripheral oxygen saturation, end-tidal CO2, blood pressure arterial values will be monitored and recorded. These parameters will be monitored and recorded every five minutes during the procedure. In addition, the sedative agents applied to the patients and their doses will be recorded. After the procedure, all patients will be taken to the recovery room, where they will be observed until the modified aldrete score is 9 or higher. The recovery times of the patients, nausea, vomiting and similar symptoms will be followed and recorded.
89416068|NCT05671055||Main arm|Use of icompanion through will all assessments are performed
89416069|NCT05665751|Experimental|TLC-3595 Dose 1|Oral dose of TLC-3595 Dose 1
89416070|NCT05665751|Experimental|TLC-3595 Dose 2|Oral dose of TLC-3595 Dose 2
89416071|NCT05665751|Placebo Comparator|Placebo|Oral dose of placebo-to-match
89416072|NCT05653427|Experimental|Amivantamab Monotherapy|Participants will receive amivantamab monotherapy intravenously once weekly on Days 1 and 2 in Cycle 1 and on Days 1 and 15 from Cycle 2 onwards based on body weight. Each cycle is of 28 days.
89416073|NCT05650190|Experimental|Test Arm|Single vision, impact resistant spectacle lenses; Test Arm
89416074|NCT05650190|Placebo Comparator|Control Arm|Single vision, impact resistant spectacle lenses; Control Arm
89416075|NCT05649995|Experimental|Pain science education group|the program integrated with pain science education (exercise, walking program and recommendations for reducing sedentary behaviors)
89416076|NCT05649995|Experimental|Biomedical education group|the program integrated with biomedical education (exercise, walking program and recommendations for reducing sedentary behaviors)
89416077|NCT05645380|Active Comparator|High sTILs (≥30%)|Carboplatin (AUC=6) + Docetaxel (75 mg/m2) + Pembrolizumab (200 mg) every 21 days for four cycles.
89416078|NCT05645380|Active Comparator|Intermediate sTILs (5-29%)|Carboplatin (AUC=6) + Docetaxel (75 mg/m2) + Pembrolizumab (200 mg) every 21 days for six cycles.
89416079|NCT05645380|Active Comparator|Low sTILs (<5%)|Carboplatin (AUC=6) + Docetaxel (75 mg/m2) + Pembrolizumab (200 mg) every 21 days for four cycles followed by Doxorubicin (60 mg/m2) + Cyclophosphamide (600 mg/m2) + Pembrolizumab (200 mg) every 14 or 21 days for four cycles.
89416080|NCT05641142|Other|Cohort study|a single arm, the anticoagulant and/or antiplatelet treatment is not conditioned by the study
88893455|NCT04331002|Experimental|Experimental|The experimental group will receive a single 32 mg Zilretta injection approximately 8 weeks after meniscus surgery.
88893456|NCT04331002|Placebo Comparator|Placebo|The placebo group will receive a single 5 mL injection of normal saline approximately 8 weeks after meniscus surgery.
88893457|NCT04320394|Other|Septic shock patients|Patients with septic shock will be taken from an additional tube to analyze their immune response
89530759|NCT02514161|Experimental|IMT + Manual Therapy and Motor Control Exercises|"The protocol for this group is identical to the previous group with the sole difference that is added a manual therapy (MT) and a motor control exercises (MCE). The MT protocol was performed for 15min, whereas the MCE was 10min. Below it described both protocols:~- MT:~Upper cervical region mobilization in flexion~Lower cervical postero-anterior mobilization + maintained traction~Costovertebral joint postero-anterior mobilization~Thoracic vertebral posteroanterior mobilization~Thrust dorsal~- MCE:~Isometric contraction of the deep neck flexors.~Isometric contraction of the neck extensors.~Neural self-mobilization.~Cervical retraction with theraband.~Sphinx.~Scapular adduction exercises in prone.~Scapular adduction exercises in sitting position with theraband."
88893458|NCT04291820|Experimental|Intravenous induction with desflurane maintenance|The EMLA patch will be removed, and intravenous induction with propofol + opioid will be performed. The anaesthesia will be maintained with desflurane according to the levels of Bispectral index (BIS). Neuromuscular blockade is optional based on operator decision.
88893459|NCT04291820|Active Comparator|Inhalation induction with sevoflurane,sevoflurane maintenance|The EMLA patch will be removed, and inhalation induction with the sevoflurane will be performed. After peripheral vein cannulation, the opioid will be administered. The neuromuscular blockade is optional based on operator decision. Anaesthesia will be maintained with sevoflurane according to the set BIS levels.
88893460|NCT04279054|Active Comparator|Group A: 150 mcg morphine|Patients in this group will receive 150mcg of morphine in their neuraxial block
88893461|NCT04279054|Experimental|Group B: 50 mcg morphine|Patients in this group will receive 50mcg of morphine in their neuraxial block
89416081|NCT05633537|Experimental|group 1: zinc oxide-ozonated olive oil|"Group I: 30 primary molars were filled with fresh mix of zinc oxide powder with ozonated olive oil~A single-visit pulpectomy procedure was performed . Standardized preoperative periapical radiograph was obtained to assess tooth condition & proper selection. Teeth were anesthetized & Rubber dam isolation was done, then all caries was removed & access opening was gained. Working length was determined by apex locator. All canals were prepared using Kidzo file system in a lateral brushing motion with an Endo-Mate DT endodontic motor at 350 RPM and 2.5 N/cm torque. EDTA gel 17% will be used before instrumentation & irrigation was done with normal saline. Dryness with paper points size 30 . placement of the root canal filling material (zinc oxide-ozonated olive oil) was applied . Intermediate restorative material was placed, then tooth was restored with stainless-steel crown"
89416082|NCT05633537|Experimental|group 2: zinc oxide- olive oil|"Group 2: 30 primary molars were filled with fresh mix of zinc oxide powder with olive oil~A single-visit pulpectomy procedure was performed . Standardized preoperative periapical radiograph was obtained to assess tooth condition & proper selection. Teeth were anesthetized & Rubber dam isolation was done, then all caries was removed & access opening was gained. Working length was determined by apex locator. All canals were prepared using Kidzo file system in a lateral brushing motion with an Endo-Mate DT endodontic motor at 350 RPM and 2.5 N/cm torque. EDTA gel 17% will be used before instrumentation & irrigation was done with normal saline. Dryness with paper points size 30 . placement of the root canal filling material (zinc oxide- olive oil) was applied . Intermediate restorative material was placed, then tooth was restored with stainless-steel crown"
89416083|NCT05633537|Active Comparator|group 3:zinc oxide- eugenol|"Group 3: 30 primary molars were filled with zinc oxide- eugenol~A single-visit pulpectomy procedure was performed . Standardized preoperative periapical radiograph was obtained to assess tooth condition & proper selection. Teeth were anesthetized & Rubber dam isolation was done, then all caries was removed & access opening was gained. Working length was determined by apex locator. All canals were prepared using Kidzo file system in a lateral brushing motion with an Endo-Mate DT endodontic motor at 350 RPM and 2.5 N/cm torque. EDTA gel 17% will be used before instrumentation & irrigation was done with normal saline. Dryness with paper points size 30 . placement of the root canal filling material (zinc oxide- eugenol) was applied . Intermediate restorative material was placed, then tooth was restored with stainless-steel crown"
89416084|NCT05633121||Patient suffering from uremic calciphylaxis treated with rheopheresis|
89416085|NCT05633121||Patient suffering from uremic calciphylaxis not treated with rheopheresis|
89416086|NCT05627739||Mycophenolate Mofetil therapy Group|An initial dose of 0.5-1.0g bid MMF was orally administered every day, glucocorticoid was started at a dose of 0.5-0.8 mg/kg/day and no more than 60 mg/day.
89416087|NCT05627739||traditional therapy group|Patients were treated with glucocorticoids alone or glucocorticoids combined with Cyclosporine.
89416088|NCT05621980|Experimental|Functional electrical stimulation (FES) + AVK group|This group will use the AVK system in combination with targeted FES to provide training of independent movement of each digit of the paretic hand. This training has two modes: Key Combination and Song. In the Key Combination mode, the subject will attempt to play the discrete key or key combinations specified on the computer screen to practice difficult movements and combinations. In the Song mode, sequential, rhythmic movements will be practiced as the participant is guided to play a series of keys, specified as falling keys, constituting five-note songs. Key Combination will be employed at the beginning and end of each training session to practice discrete movements that proved troubling during the current or previous session. Most of the session will be spent in the Song mode to emphasize the transitions from one movement to the next. In both modes the AVK system will trigger FES for the finger matching the desired key and signal the PneuGlove to resist movement of other digits.
89530760|NCT03236467|Experimental|FM + PTSD|Individuals suffering from Fibromyalgia and PTSD
89530761|NCT03242239|Experimental|ALT02|
89530762|NCT03242239|Active Comparator|EU-licensed Herceptin|
89530763|NCT03242239|Active Comparator|US-licensed Herceptin|
88893462|NCT04273867||Chronic Hypersensitivity Pneumonitis Patients|
88893463|NCT04263051|Experimental|UCPVax + Nivolumab|"UCPVax vaccine (0,5 mg)~Nivolumab (480 mg)"
88893464|NCT04263051|Other|Standard second line chemotherapy|"Standard second line chemotherapy at the choice of the investigator.~This arm will permit to assess the good calibration of the hypothesis on the experimental arm."
88893465|NCT04237935||Clopidogrel 75 mg|Reference group
88893466|NCT04237935||Ticagrelor 90 mg|Exposure group
88893467|NCT04237922||Clopidogrel 75 mg|Reference group
88893468|NCT04237922||Prasugrel 10 mg|Exposure group
88893469|NCT04233021|Experimental|Osimertinib|Osimertinib 80 mg/d
88893470|NCT04228289|Experimental|Oxytocin|40 IU intranasal oxytocin
88893471|NCT04228289|Placebo Comparator|Placebo|intranasal saline spray
88893472|NCT04227821||Hemodynamically instable pediatric patients|Pediatric patients admitted to the pediatric intensive care unit with the need of vasopressor and/or inotrope therapy due to hemodynamic instability
88893473|NCT04215536||DPP4i|Reference group
88893474|NCT04215536||Empagliflozin|Exposure group
88893475|NCT04215523||Dapagliflozin|Exposure group
88893476|NCT04215523||DPP-4 inhibitor|Reference group
88893477|NCT04215081|Experimental|ExoAtlet II Safety and Efficacy|20 participants with paraplegia from SCI will participate in gait training using ExoAtlet II powered exoskeleton.
88922141|NCT05745103|Active Comparator|Treatment as Usual|Participants randomized to the control group will receive the routine services provided in the center. Therapists providing TAU will be permitted to use the strategies they deen would be most successful.
89416089|NCT05621980|Active Comparator|OT Group|An occupational therapist will provide therapy of matching duration to the OT subject group. This will consist of 10 minutes of stretching of the finger muscles, particularly of the extrinsic finger flexors. This stretching will be followed by two 20-minute sessions of therapy focused on active task practice, object manipulation, and individuated movement of the digits. The Canadian Occupational Performance Measure (COPM) will be administered to identify goals that incorporate dexterous use of the paretic hand. Part of each training session will be used to practice these tasks, while the remainder will be used to practice component skills. Active practice will be followed by a final 10 minutes of stretching of muscles of the digits.
89416090|NCT05621148||Full population|LLC patients with prior treatment with BTKi - Underlying tenet: these patients have been treated with a BTKi in at least one of two or more prior lines of therapy and progressed - FULL POPULATION
89416091|NCT05621148||Narrow population|LLC Patients who progressed BTKi and failed VEN (defined as patients who discontinued VEN due to disease progression, intolerability, or failure to achieve an objective response within 3 months of initiating therapy; small patient population) - Tenet: these patients have been treated with both BTKi and VEN in any one of the prior two lines of therapy and progressed
88893478|NCT04210726|Active Comparator|Active Group - 25% Saline Bath|The Active group's patients will separately have an immersion bath in 25% Sea Salt in Water solution (made by adding pure Sodium Chloride in the form of Sea Salt to Tap Water Bath) at a temperature comfortable to every participant (please note that Solubility of Sodium Chloride in Water does not change significantly with change in temperature, therefore the concentration will remain the same regardless of water temperature), whereas the bath solution is in direct contact with the skin, for 30 minutes once daily for 7 consecutive days, in addition to their standard treatments they receive from their health care providers.
88893479|NCT04210726|Placebo Comparator|Control Group - 0.9% Saline Bath|The Control group's patients will separately have a bath in 0.9% Sea Salt in Water (Isotonic solution, made by adding Sodium Chloride in form of Sea Salt to Tap Water) at a comfortable temperature whereas the bath solution is in direct contact with the skin, for 30 minutes once daily for 7 consecutive days, in addition to their standard treatments they receive from their health care providers
89416092|NCT05620342|Experimental|iC9.GD2.CAR.IL-15 T Therapy|Experimental: Single Arm Subjects with extensive stage lung cancer or stage IV non-small cell lung cancer that is platinum-refractory and received PD-1 and/or PD-L1 therapy will receive iC9.GD2.CAR.IL-15 T cells were manufactured from their collected blood sample.
89416093|NCT05619796|Experimental|group 1: Kedo-S Square rotary files|Primary root canals(n=20) were instrumented using rotary P1 Kedo-S Square files (Reeganz Dental Care Pvt. Ltd. India) at 300 rpm and 2.2N cm torque. The rotary files were used with an Endo-Mate DT endodontic motor (NSK, Tokyo, Japan) and EDTA gel 17% (Meta Biomed Co. Ltd, Chungbuk, Korea) was used before instrumentation.
88893480|NCT04202731|Experimental|Sleep Extension|Participants will be asked to extend their time in bed with the goal of improving the total time they sleep each night.
88893481|NCT04169347|Other|Active|This is an open label study single arm
88893482|NCT04165408|Experimental|Device Use|Only one arm
88893483|NCT04135937|Experimental|MESH|Mobile Evidence-Based Smoking Cessation for Veterans Living with HIV is an intervention that is tailored for participants. It can include cognitive behavioral therapy, relapse-prevention text messaging, and/or pharmacotherapy with nicotine replacement therapy, bupropion, or varenicline.
89193128|NCT05503810|No Intervention|Control|Regular follow-up
89193129|NCT05501132|Experimental|tDCS group 1|In the first experimental group, the TDCS intervention protocol consists of 10 sessions of 20 minutes of 1 mA electrical stimulation on 5 consecutive days with two sessions per day.
88893486|NCT04134754|Other|Respiratory physiology testing|Subjects will wear a nosepiece and breathe through a Y-valve that allows switching from room air to two 5-liter rebreathing bags pre-filled with 50% O2, 6% CO2, and balance N2. Ventilation and respiratory gases will be measured using a pneumotachograph and rapid gas analyzers (Ultima PFX pulmonary function/stress testing system, Medical Graphics Corp). In subjects who experience clinical seizure-like activity, we will repeat the HCVR. This repeat test will occur 2 or more hours after a generalized convulsive seizure (GCS). We will repeat the HCVR at least 30 minutes after a non-GCS. Finally, we may repeat the HCVR at least 18 hours after the last seizure (GCS or non-GCS). It is anticipated that some subjects may exhibit frequent seizures that necessitate the adjustment of this schedule. Subjects may also be asked to sniff, hold their breath, and breathe through tubes of different sizes.
88893487|NCT04126070|Experimental|COHORT 1: DNA damage repair defects (DDRD) +/- Inflamed Tumor|"After the screening procedures confirm participation in the research study. The participant will be given a study calendar for this trial.~Androgen Deprivation Therapy: Given per standard care for duration of study~Nivolumab: Given once per every 3 weeks for cycle 1-6 intravenously and then every 4 weeks during subsequent cycles, at predetermined dosage~Docetaxel: Given once every 3 weeks intravenously at pre-determined dosage for cycle 1-6."
88893488|NCT04126070|Experimental|COHORT 2: Inflamed Tumor without DNA repair defects (DDRD)|"After the screening procedures confirm participation in the research study. The participant will be given a study calendar for this trial.~Androgen Deprivation Therapy: Given per standard care for duration of study~Nivolumab: Given once per every 3 weeks for cycle 1-6 intravenously and then every 4 weeks during subsequent cycles, at predetermined dosage~Docetaxel: Given once every 3 weeks intravenously at pre-determined dosage for cycle 1-6."
88893489|NCT04126070|Experimental|COHORT 3: Biomarker Negative|"After the screening procedures confirm participation in the research study. The participant will be given a study calendar for this trial.~Androgen Deprivation Therapy: Given per standard care for duration of study~Nivolumab: Given once per every 3 weeks for cycle 1-6 intravenously and then every 4 weeks during subsequent cycles, at predetermined dosage~Docetaxel: Given once every 3 weeks intravenously at pre-determined dosage for cycle 1-6"
88893490|NCT04120987|Active Comparator|Lifitegrast|One drop of Lifitegrast Ophthalmic Solution 5% will be instilled into each eye twice daily (approximately 12 hours apart) using a single-use conainer.
88893491|NCT04120987|No Intervention|Control|No treatment
89193130|NCT05501132|Experimental|tDCS group 2|In the second experimental group, the TDCS intervention protocol consists of 10 sessions of 20 minutes of 2 mA electrical stimulation on 5 consecutive days with two sessions per day.
89416094|NCT05619796|Experimental|group II: Fanta AFTM-Baby rotary system|Primary root canals(n=20) were instrumented using Fanta AFTM-Baby rotary system (Shanghai Fanta Dental Materials, SUNGO Certification Company Limited, London, England) at 350 rpm and 2 N cm torque. Four files were used sequentially in the following order; open file #17/0.08, #20/0.04 yellow, #25/0.04 red and #30/0.04 blue. The rotary files were used with an Endo-Mate DT endodontic motor (NSK, Tokyo, Japan) and EDTA gel 17% (Meta Biomed Co. Ltd, Chungbuk, Korea) was used before instrumentation.
89416095|NCT05619796|Active Comparator|group III: manual K-files|Primary root canals(n=20) were instrumented using No.15 till 35 size manual K-files (Mani, Inc, Japan) using the quarter-turn-pull technique.
89416096|NCT05617794|Experimental|Treatment 1 - Diffusion Optics Technology (DOT) Pattern|
89416097|NCT05617794|Active Comparator|Treatment 2 - Control Spectacles|
89416098|NCT05611112|No Intervention|Control|Patients in the control group will have unrestricted access to care as usually provided. No restrictions are imposed on the general practitioners (GPs) regarding treatment of patients with mental health problems, as we are interested in assessing the added value of PST in routine clinical practice. In both groups, GPs are recommended to follow the current guidelines.
89416099|NCT05611112|Experimental|Intervention|Patients with type 2 diabetes and/or chronic ischemic heart disease are offered up to seven problem solving therapy sessions within a three-month period from inclusion. In both groups, GPs are recommended to follow the current guidelines.
89416100|NCT05601882|Experimental|Upadacitinib|Participants will receive upadacitinib dose A daily in period 1. Eligible participants will receive upadacitinib dose B daily in period 2.
89416101|NCT05601882|Experimental|Dupilumab followed by Upadacitinib|Participants will receive dupilumab as per its label in period 1. Eligible participants will receive upadacitinib dose A in period 2.
89416102|NCT05597137|Experimental|Experimental Group|During the study period, all subjects were required to avoid a diet high in zinc in order to avoid interference with dietary zinc intake and reduce bias in the weeks 1-2. In the weeks 3-4, all subjects were started to receive zinc supplementation at the normal adult dose (zinc tablets: 1 tablet (10mg) once daily after meals), while maintaining the avoidance of high-zinc foods.
89416103|NCT05590416||adalimumab group|The initial dose of glucocorticoid is 1 mg/kg/day, and gradually stops within 90-180 days. Adalimumab is administered subcutaneously at an initial loading dose of 80 mg, followed by a 40 mg dose every other week (q2w) starting from the second week. Therapy will be continued 6 months after the disappearance of active ocular inflammation. Then, injection will extend for 3 days until withdrawal after 40 days apart.
89416104|NCT05590416||traditional therapy group|Acute VKH patients treatment with only glucocorticosteroid or glucocorticosteroid combined with immunosuppressive agents.
88893492|NCT04118530||Hematopoietic Stem Cell Transplant (HSCT) Patients|- Patients with incidence of AF/AFL in the first 30 days of transplant
88893493|NCT04106102|Active Comparator|Transcramial Direct current stimulation|Implement of Transcramial Direct current stimulation
88893494|NCT04106102|Placebo Comparator|Placebo|
88893495|NCT04060147|Experimental|Cilofexor|Participants will receive escalating doses of cilofexor 30 mg, 60 mg, and 100 mg.
88893496|NCT04038567|Experimental|High dose / therapist attention / introductory call|Will receive high dose intervention content, therapist attention to elevated symptoms, and an introductory call from a therapist.
88893497|NCT04038567|Experimental|High dose / therapist attention / no introductory call|Will receive high dose intervention content, therapist attention to elevated symptoms, and no introductory call from a therapist.
88893498|NCT04038567|Experimental|High dose / app attention / introductory call|Will receive high dose intervention content, app-based attention to elevated symptoms, and an introductory call from a therapist.
89416105|NCT05578287|Experimental|Anti-HER2|Disitamab Vedotin (2mg/kg, once every 2 weeks), Tislelizumab (2mg/kg, once every 2 weeks) combined with low-dose capecitabine 0.5g bid chemotherapy and the COX2 inhibitor celecoxib 200mg bid as salvage therapy
89416106|NCT05567731|Experimental|ultrashort GnRHa|the patients used the ultrashort protocols with GnRH agonist (GnRH-a, and recombinant FSH for controlled ovarian hyperstimulation (COH). Form the second day of menstrual cycle, 0.1 mg/d GnRH agonist will be injected by subcutaneous injection for 3-4 d.
89416107|NCT05567731|Experimental|short GnRHa|Buserelin acetate 100 mg five times daily and FSH will be started on the 2nd day of the menstrual cycle as short application. The dose of gonadotropin hormone will be individualized according to the patient's age and previous stimulation history or response to stimulation. Cycles will be monitored by transvaginal ultrasonography and serum E2 levels.
89416108|NCT05567731|Experimental|long GnRHa|In the long protocol, daily SC injection of Triptorelin :Decapeptyl 0.1 mg (Ferring, Switzerland) 0.1 mg started at day 21 of the cycle prior to stimulation cycle and continued till the day of hCG triggering. Gn stimulation started after fulfilling stimulation start criteria of thin endometrium < 5 mm and low E2 < 50 and LH < 5IU/l with either HMG(Menogon; Ferring, Switzerland) or rFSH (Gonal-f; Merck Serono, Germany) in a starting dose of 150-300 IU/day according to women age, day 3 FSH,AMH and previous gonadotropin response then adjustment of the dose according to ovarian response monitored by serum E2 and ultrasound evaluation. All patients were followed up by Transvaginal ultrasound scan daily or on alternate days according to the ovarian response to treatment starting on treatment cycle day for folliculometry and endometrial thickness and pattern.
88893499|NCT04038567|Experimental|High dose / app attention / no introductory call|Will receive high dose intervention content, app-based attention to elevated symptoms, and no introductory call from a therapist.
88893500|NCT04038567|Experimental|Standard dose / therapist attention / introductory call|Will receive standard dose intervention content, therapist-based attention to elevated symptoms, and an introductory call from a therapist.
89416109|NCT05560230|Experimental|Clonidine|A 100 ml isotonic saline will be mixed with 1 ml clonidine (150 μg). The blinded 100 ml bag including isotonic saline and clonidine 150 μg will be infused over 5-10 min., immediately after intubation.
89416110|NCT05560230|Placebo Comparator|Isotonic saline|A 100 ml isotonic saline will be mixed with 1 ml isotonic saline. The blinded 100 ml bag including isotonic saline will be infused over 5-10 min., immediately after intubation.
89416111|NCT05557552|Experimental|standar thoracic RT dose|Sequential chemo-immunotherapy plus standard dose of thoracic radiotherapy followed by anti-PD-1/PD-L1 maintenance therapy
89416112|NCT05557552|Experimental|decreased thoracic RT dose|Sequential chemo-immunotherapy plus decreased thoracic radiotherapy followed by anti-PD-1/PD-L1 maintenance therapy
89416113|NCT05543213|No Intervention|Control group|Videos of nature will be shown to them, and exercises similar to those in the intervention group will be practiced with them.
89416114|NCT05543213|Active Comparator|Action Observation group|In the intervention group, the same exercises related to balance and walking are practiced after watching videos of the exercises
89416115|NCT05532410|Other|Fundus Camera|
89416116|NCT05526352||IA Patients|Patients with one or more identified intracranial aneurysm, none of which are believed to have ruptured.
89416117|NCT05526352||IA + SAH Patients|Patients with one or more identified intracranial aneurysm, at least one of which has been radiologically or surgically determined to have ruptured.
89416118|NCT05526352||Familiy members|Individuals selected on review of a patient's family tree and contacted by said patient, who agree to be approached for recruitment. In affected families each member will be identified as: proband, affected, unaffected, unknown, or not genetically linked.
89416119|NCT05526352||Healthy Volunteers|Individuals, accompanying or contacted by a patient, or responding to open advertisement, or randomly selected in a defined population who agree to be approached for recruitment.
89416120|NCT05519709||Asymptomatic Adolescent Tennis Players|Adolescent tennis players aged 7-17 years who have been actively attending tennis club for at least 1 year will be form adolescent tennis players groups. The age, body weight (kg) and height (centimeter) of each individual included in the study will record. The assessment form, which includes demographic data such as, training duration(min/day), frequency (times/week) and sport age will record by asking the parents. All measurements will be take before lesson and without warm-up. All measurements will be evaluate by an experienced physiotherapist.
89416121|NCT05518617||SNCA (Alpha-synuclein gene)|PET and SPECT molecular imaging and MRI; Clinical investigation and computerized neuropsychological testing; Collection of blood, urine and CSF biomarkers of PD pathology.
88893501|NCT04038567|Experimental|Standard dose / therapist attention / no introductory call|Will receive standard dose intervention content, therapist-based attention to elevated symptoms, and no introductory call from a therapist.
88893502|NCT04038567|Experimental|Standard dose / app attention / introductory call|Will receive standard dose intervention content, app-based attention to elevated symptoms, and an introductory call from a therapist.
88893503|NCT04038567|Experimental|Standard dose / app attention / no introductory call|Will receive standard dose intervention content, app-based attention to elevated symptoms, and no introductory call from a therapist.
88893504|NCT04031014|Experimental|Active treatment|Treatment with the active treatment protocol of the BTL EMSELLA device twice per week for six treatments total
88893505|NCT04031014|Sham Comparator|Sham treatment|Treatment with the sham protocol of the BTL EMSELLA device twice per week for six treatments total
88893506|NCT04019093|Experimental|Jaw pain patients|Individuals seeking care for jaw pain, including temporomandibular joint and muscle disorder (TMD).
88893507|NCT04019093|Experimental|Healthy controls|Healthy social drinkers without jaw pain recruited as a comparison group.
88893508|NCT04019041|Experimental|bermekimab ew|2 800 mg bermekimab loading dose subcutaneous injections, followed by weekly 400 mg bermekimab injections
88893509|NCT04019041|Experimental|bermekimab eow|2 800 mg loading dose subcutaneous injections, followed by alternating weekly 400 mg bermekimab injections with matching placebo injections
88893510|NCT04019041|Placebo Comparator|placebo ew|2 800 mg placebo loading dose subcutaneous injections, followed by weekly placebo subcutaneous injections
88893511|NCT04018092|Experimental|Active NIR-PBM|"For transcranial stimulation, the study team will use two MedX units (1116 Rehab Console, MedX Health), whereas intranasal stimulation is delivered using the 810 Intranasal device (Vielight Inc). During each lab session, six transcranial LED clusters will be placed on the scalp in two distinct configurations guided by 10-20 EEG system. Total transcranial stimulation time is 40 minutes, 20 min per cluster. Concurrently, two 810 intranasal devices will be placed in each nostril for 25 min of total dose per nostril. For at home sessions, participants will use the standalone 810 Intranasal device only.~Total amount of sessions:~16 sessions of stimulation will occur in the laboratory. Each session will last approximately 90 minutes and will include two 20-minute segments of NIR stimulation.~AND~44 sessions of intranasal stimulation in the home. Each session will last 25 minutes and will occur on weekdays when there is no in-lab session."
88893512|NCT04018092|Sham Comparator|Sham NIR-PBM|"Participants randomized to the Sham control group will undergo identical procedures as the Active group. The only difference is that the sham NIR devices are modified not to deliver stimulation. Because NIR is invisible, participants are unable to detect whether NIR is being delivered."
88893513|NCT04013399|Experimental|Continuous Positive Airway Pressure|Women will receive Continuous Positive Airway Pressure (CPAP) for one month.
89416122|NCT05518617||Parkin (Parkin gene)|PET and SPECT molecular imaging and MRI; Clinical investigation and computerized neuropsychological testing; Collection of blood, urine and CSF biomarkers of PD pathology
89416123|NCT05518617||PINK1 (Phosphatase and Tensin Homolog (PTEN)-Induced Kinase 1 gene)|PET and SPECT molecular imaging and MRI; Clinical investigation and computerized neuropsychological testing; Collection of blood, urine and CSF biomarkers of PD pathology
89416124|NCT05516732||SNCA (Alpha-synuclein gene)|PET and SPECT molecular imaging and MRI; Clinical investigation and computerized neuropsychological testing; Collection of blood, urine and CSF biomarkers of PD pathology
89416125|NCT05516732||Idiopathic Parkinson's Disease|PET and SPECT molecular imaging and MRI; Clinical investigation and computerized neuropsychological testing; Collection of blood, urine and CSF biomarkers of PD pathology
89416126|NCT05516719||SNCA (Alpha-synuclein gene)|PET and SPECT molecular imaging and MRI; Clinical investigation and computerized neuropsychological testing; Collection of blood, urine and CSF biomarkers of PD pathology
89416127|NCT05516719||Idiopathic Parkinson's Disease|PET and SPECT molecular imaging and MRI; Clinical investigation and computerized neuropsychological testing; Collection of blood, urine and CSF biomarkers of PD pathology
88893514|NCT04013399|No Intervention|Control|Women will receive standard prenatal care.
88893515|NCT04011891|Active Comparator|Robotic Partial Nephrectomy|Partial nephrectomy performed using the DaVinci robotic surgical system.
88893516|NCT04011891|Active Comparator|Open Partial Nephrectomy|Partial nephrectomy performed using the open approach.
88893517|NCT04002921||Right colectomy|Patient with scheduled right colectomy and with a documented preoperative scan.
88893518|NCT03988439|Experimental|IDP-118 Lotion|Two cohorts of pediatric participants (1 cohort of participants age 12 to 16 years 11 months and 1 cohort of participants age 4 to 11 years 11 months) will apply IDP-118 Lotion to Investigator identified lesions affecting a minimum of 10% body surface area (BSA) once daily for 8 weeks.
88893519|NCT03975946|Active Comparator|the rheopheresis group|
88893520|NCT03975946|Placebo Comparator|the shamapheresis group|
88893521|NCT03974958|Experimental|AAA patients|Patients with abdominal aortic aneurysm (AAA)
88893522|NCT03974958|Experimental|PAOD patients|patients with peripheral arterial obstructive disease (PAOD)
88893523|NCT03954002|Experimental|TTE and TOE|"A small flexible tube (TOE probe) will be inserted into your oesophagus, or food pipe, to take images of your heart as per routine anaesthetic care for cardiac surgery.~Just before and after general anaesthesia is administered, a short transthoracic echocardiography (TTE scan will be performed to acquire images of your heart. This is an ultrasound scan of your heart using a probe on the outside of the chest. During this period, relevant haemodynamic data such as blood pressure and heart rate will be recorded."
88893524|NCT03938532|Active Comparator|Control Arm|Infant will receive pressure regulated breaths, 40-60 breaths/min, PiP of 20-24cm of water as recommended by 2017 Neonatal Resuscitation Program (NRP) guidelines. Reading of the TV will be blinded from the providers as in routine clinical situations
88893525|NCT03938532|Experimental|Intervention Arm|Infants in the intervention arm will receive VTV following intubation. Peak inspiratory pressure (PiP) provided via T-piece resuscitator will be visible to the providers, and the provider can regulate the PiP to achieve the desired TV goal (4-6 ml/kg), at a rate of 40-60 breaths/min
88893526|NCT03936062||2nd Generation SUs|Reference group
88893527|NCT03936062||Sitagliptin|Exposure group
88893528|NCT03936049||DPP-4 inhibitor|Reference group
89416128|NCT05516719||Healthy Control|PET and SPECT molecular imaging and MRI; Clinical investigation and computerized neuropsychological testing; Collection of blood, urine and CSF biomarkers of PD patholog
89416129|NCT05513352|No Intervention|Experiment 1 - Normal hearing - AAT|Each participant assigned to the normal hearing group will undergo one experimental session during which EEG is recorded while participants perform an auditory attention task (AAT).
88893529|NCT03936049||Liraglutide|Exposure group
88893530|NCT03936036||2nd generation sulfonylureas|Reference group
88893531|NCT03936036||Linagliptin|Exposure group
88893532|NCT03936010||DPP4i|Reference group
88893533|NCT03936010||Canagliflozin|Exposure group
88893534|NCT03930849|Experimental|AIMS Intervention|Participants randomized to the AIMS arm be enrolled in VA's Annie text messaging program and receive the study protocol.
88893535|NCT03930849|No Intervention|No Intervention|Participants randomized to the no intervention arm will not be enrolled in the Annie text messaging program.
88893536|NCT03930849|Experimental|AIMS Intervention Plus|Participants randomized to the AIMS Intervention Plus arm will be enrolled in VA's Annie text messaging program/study protocol and receive a weekly phone call.
88893537|NCT03930381|Experimental|Intervention Arm|This group will download the ASTHMAXcel application and use it for the duration of the study
88893538|NCT03930381|No Intervention|Usual Care Arm|This group will just receive normal provider care
88893539|NCT03921541|Experimental|Pegzilarginase|Weekly IV infusions of pegzilarginase plus individualized disease management for 24 weeks
88893540|NCT03921541|Placebo Comparator|Placebo|Weekly IV infusions of placebo plus individualized disease management for 24 weeks
89416130|NCT05513352|No Intervention|Experiment 1 - Hearing impaired - AAT|Each participant assigned to the normal hearing impaired group will undergo one experimental session during which EEG is recorded while participants perform an auditory attention task (AAT).
89416131|NCT05513352|No Intervention|Experiment 2 - normal hearing _ SAT|Each participant assigned to the normal hearing group will undergo one experimental session in which EEG is used to measure neural speech tracking while participants undergo the selective speech attention task (SAT).
89416132|NCT05513352|No Intervention|Experiment 2 - hearing impaired - SAT|Each participant assigned to the hearing impaired group will undergo one experimental session in which EEG is used to measure neural speech tracking while participants undergo the selective speech attention task (SAT).
89416133|NCT05513352|No Intervention|Experiment 2 - tinnitus - SAT|Each participant assigned to the tinnitus group will undergo one experimental session in which EEG is used to measure neural speech tracking while participants undergo the selective speech attention task (SAT).
89416134|NCT05513352|Experimental|Experiment 3 - normal hearing (tACS) - AAT|"The subjects assigned to the normal hearing group will undertake 20min tACS stimulation applied over the temporo-parietal cortex.~Each session will include the following three phases: (1) pre-stimulation baseline, (2) brain stimulation, and (3) post-stimulation. AAT will be conducted in each phase and concurrent EEG will be recorded."
89416135|NCT05513352|Sham Comparator|Experiment 3 - normal hearing (sham) - AAT|"The subjects assigned to the normal hearing group will undertake 20min sham stimulation applied over the temporo-parietal cortex.~Each session will include the following three phases: (1) pre-stimulation baseline, (2) sham brain stimulation, and (3) post-stimulation. AAT will be conducted in each phase and concurrent EEG will be recorded."
89416136|NCT05513352|Experimental|Experiment 3 - hearing impaired (tACS) - AAT|"The subjects assigned to the hearing impaired group will undertake 20min tACS stimulation applied over the temporo-parietal cortex.~Each session will include the following three phases: (1) pre-stimulation baseline, (2) brain stimulation, and (3) post-stimulation. AAT will be conducted in each phase and concurrent EEG will be recorded."
89416137|NCT05513352|Sham Comparator|Experiment 3 - hearing impaired (sham) - AAT|"The subjects assigned to the hearing impaired group will undertake 20min sham stimulation applied over the temporo-parietal cortex.~Each session will include the following three phases: (1) pre-stimulation baseline, (2) sham brain stimulation, and (3) post-stimulation. AAT will be conducted in each phase and concurrent EEG will be recorded."
89416138|NCT05513352|Experimental|Experiment 3 - tinnitus (tACS) - AAT|"The subjects assigned to the tinnitus group will undertake 20min tACS stimulation applied over the temporo-parietal cortex.~Each session will include the following three phases: (1) pre-stimulation baseline, (2) brain stimulation, and (3) post-stimulation. AAT will be conducted in each phase and concurrent EEG will be recorded."
89416139|NCT05513352|Sham Comparator|Experiment 3 - tinnitus (sham) - AAT|"The subjects assigned to the tinnitus group will undertake 20min sham stimulation applied over the temporo-parietal cortex.~Each session will include the following three phases: (1) pre-stimulation baseline, (2) sham brain stimulation, and (3) post-stimulation. AAT will be conducted in each phase and concurrent EEG will be recorded."
89416140|NCT05513352|Experimental|Experiment 4 - normal hearing (tACS) - SAT|"The subjects assigned to the normal hearing group will undertake 20min tACS stimulation applied over the temporo-parietal cortex.~Each session will include the following three phases: (1) pre-stimulation baseline, (2) brain stimulation, and (3) post-stimulation. SAT will be conducted in each phase and concurrent EEG will be recorded."
89416141|NCT05513352|Sham Comparator|Experiment 4 - normal hearing (sham) - SAT|"The subjects assigned to the normal hearing group will undertake 20min sham stimulation applied over the temporo-parietal cortex.~Each session will include the following three phases: (1) pre-stimulation baseline, (2) sham brain stimulation, and (3) post-stimulation. SAT will be conducted in each phase and concurrent EEG will be recorded."
89416142|NCT05513352|Experimental|Experiment 4 - hearing impaired (tACS) - SAT|"The subjects assigned to the hearing impaired group will undertake 20min tACS stimulation applied over the temporo-parietal cortex.~Each session will include the following three phases: (1) pre-stimulation baseline, (2) brain stimulation, and (3) post-stimulation. SAT will be conducted in each phase and concurrent EEG will be recorded."
89416143|NCT05513352|Sham Comparator|Experiment 4 - hearing impaired (sham) - SAT|"The subjects assigned to the hearing impaired group will undertake 20min sham stimulation applied over the temporo-parietal cortex.~Each session will include the following three phases: (1) pre-stimulation baseline, (2) sham brain stimulation, and (3) post-stimulation. SAT will be conducted in each phase and concurrent EEG will be recorded."
89416144|NCT05513352|Experimental|Experiment 4 - tinnitus (tACS) - SAT|"The subjects assigned to the tinnitus group will undertake 20min tACS stimulation applied over the temporo-parietal cortex.~Each session will include the following three phases: (1) pre-stimulation baseline, (2) brain stimulation, and (3) post-stimulation. SAT will be conducted in each phase and concurrent EEG will be recorded."
89416145|NCT05513352|Sham Comparator|Experiment 4 - tinnitus (sham) - SAT|"The subjects assigned to the tinnitus group will undertake 20min sham stimulation applied over the temporo-parietal cortex.~Each session will include the following three phases: (1) pre-stimulation baseline, (2) sham brain stimulation, and (3) post-stimulation. SAT will be conducted in each phase and concurrent EEG will be recorded."
89416146|NCT05513352|Experimental|Experiment 5 - normal hearing (NF right) - AAT|Each participant of the normal hearing group will undergo the neurofeedback training in which the participants learn to increase alpha power in the right relative to the left parietal cortex. Before and after the NF training, participants will perform the AAT and concurrent EEG will be recorded.
89193131|NCT05501132|Placebo Comparator|Control group|In the placebo group, the TDCS intervention protocol consists of 10 sessions of 20 minutes of sham electrical stimulation on 5 consecutive days with two sessions per day.
89193132|NCT05499780|Experimental|Group A: treatment with Sentinox performed 3 times/day for 21 days|treatment with Investigational Medical Device (IMD) performed 3 times/day for 21 days at 8 am, 2 pm and 8 pm
89416147|NCT05513352|Active Comparator|Experiment 5 - normal hearing (NF left) - AAT|Each participant of the normal hearing group will undergo the neurofeedback training in which the participants learn to increase alpha power in the left relative to the right parietal cortex. Before and after the NF training, participants will perform the AAT and concurrent EEG will be recorded.
89193133|NCT05499780|No Intervention|Group B:no Sentinox treatment|
89193134|NCT05498155|Experimental|Cohort A|Cohort A will consist of a lower-risk population of participants with HER2-negative ER-negative or ER-low defined as having a tumour size >5 mm and ≤20 mm and N0 (T1b-c/N0).
89006049|NCT04648735|Experimental|Drivers with cognitive impairments|The participants firstly completed a questionnaire of driving history and perceived driving competence, followed with a clinical physical and cognitive-perceptual assessment battery conducted by an occupational therapist to note any potential deficits that might affect driving performance. The participants, on a separate visit, completed three practice runs of a closed-circuit standardized course that included 8 driving maneuvers, followed by an on-road driving in the community fir 30 minutes.
89006050|NCT04648735|Active Comparator|drivers with normal cognition|The participants firstly completed a questionnaire of driving history and perceived driving competence, followed with a clinical physical and cognitive-perceptual assessment battery conducted by an occupational therapist to note any potential deficits that might affect driving performance. The participants, on a separate visit, completed three practice runs of a closed-circuit standardized course that included 8 driving maneuvers, followed by an on-road driving in the community fir 30 minutes.
89006051|NCT04648657||acute hypoxemic respiratory failure patients|Mechanically ventilated patients with acute hypoxemic respiratory failure (AHRF) with P/F ratio < 300 with at least PEEP 5 cmH2O)
89006052|NCT00217217|Experimental|Active EEP-MRSI treatment|20 minutes of active treatment with theEcho-Planar Magnetic Resonance Imaging (EP-MRSI)
89006053|NCT00217217|Sham Comparator|Sham comparator EP-MRSI|Sham treatment (20 minutes) with the Echo-Planar Magnetic Resonance Imaging (EP-MRSI).
89006054|NCT04648813|Experimental|tiotropium bromide monohydrate (Spiriva Respimat)|
89006055|NCT04648813|Placebo Comparator|matching placebo|
89006056|NCT04648384|Experimental|Protein Supplementation and Resistance exercise|Protein supplementation composed of 20 gram of whey protein or casein in different proportions (80:20) and fasting state 10 sets of 10 reps at 85% of 1 Maximum repetition
89006057|NCT04648384|Placebo Comparator|Placebo Supplementation|Placebo supplementation composed of 20 gram of Maltodextrin and fasting state 10 sets of 10 reps at 85% of 1 Maximum repetition
89006058|NCT04648384|Experimental|Resistance Training|Resistance Exercise will be performed before supplementation and is composed by 10 sets of 10 repetitions at 85% of 1 Maximum repetition in leg press exercise.
89006059|NCT04648423|Experimental|sodium oxybate|Sodium oxybate solution for oral administration (175 mg/mL). Dose (body weight ≤ 65 kg): 19.0 mL daily, in 3 administrations, for 6 months Dose (body weight > 65 kg): 22.5 mL daily, in 3 administrations, for 6 months
89006060|NCT04648423|Placebo Comparator|placebo|Placebo solution for oral administration. Dose (body weight ≤ 65 kg): 19.0 mL daily, in 3 administrations, for 6 months Dose (body weight > 65 kg): 22.5 mL daily, in 3 administrations, for 6 months
89006061|NCT00558181|Experimental|Rituximab, Methylprednisolone|
89006062|NCT00217256|Experimental|1|Endeavor Drug Eluting Stent
89006063|NCT00217256|Active Comparator|2|Cypher Drug Eluting Stent
89006064|NCT04648618||OSA + DME +|Patients with OSA and DME
89006065|NCT04648618||OSA - DME +|Patients with DME, but no evidence of OSA
89006066|NCT00558220|Experimental|A|Intensive induction followed by high-dose consolidation with stem cell support ± radiotherapy
89006067|NCT04648345|Experimental|Erector spinal plane block group (ESPB group)|After induction of general anesthesia, pre-operative ultrasound-guided bilateral erector spinae plane block will be performed in the ESPB group.
89006068|NCT04648345|Active Comparator|Vertebral side block group (VSB group)|After induction of general anesthesia, pre-operative ultrasound-guided bilateral vertebral side block will be performed in the VSB group.
89006069|NCT04648345|Placebo Comparator|Local block group （LB group）|Local block will be performed at the surgical incisions after the surgery under general anesthesia.
89006070|NCT04648267|Active Comparator|Control group|Patients who have the cast and bolster on for standard 5 days after their radial forearm free flap and 7 days after their fibula free falp
89006071|NCT04648267|Experimental|Experimental group|Patients who have the cast and bolster on for 10-14 days
89006072|NCT00245427|Other|1 All macrolide antibiotics|
89006073|NCT00245427|Other|2 All beta lactam antibiotics|
89006074|NCT04647955|Experimental|Itopride|Oral dose of itopride 100 mg three times daily before the meal for 8 weeks
89006075|NCT04647955|Placebo Comparator|Placebo|Oral dose of placebo three times daily before the meal for 8 weeks
89006076|NCT04647799||forward head position|nerve conduction velocity and f-wave applied to median , ulnar and radial nerve before and after 10,20 and 30 minutes in forward head position while Children will sit on chair with their feet on the ground without any tension, the upper limbs are rested in a table then, the angle between the line passing horizontally from the spinous process of C7 and the line passing between the tragus and spinous process of C7 will be measured by goniometer and goniometer pro application to evaluate the craniovertebral angle recording, we will fix the craniovertebral angle between 40.7° and 43.2°(severe FHP )
89006077|NCT04647799||neutral position|nerve conduction velocity and f-wave applied to median , ulnar and radial nerve before and after 10,20 and 30 minutes while Children will sit on chair with their feet on the ground with head in anatomical position, the upper are rested in a table and used both hand on touch screen of mobile phone
89006078|NCT04647838|Experimental|NSCLC|Tepotinib 500mg (2 tablets of 250mg) per day D1-21 orally, once daily
89006079|NCT04647838|Experimental|Other cancers|Tepotinib 500mg (2 tablets of 250mg) per day D1-21 orally, once daily
89006080|NCT00217373|Experimental|Arm I|"COURSE I: Patients receive recombinant vaccinia-CEA(6D)-TRICOM vaccine SC on day 1. Patients also receive sargramostim (GM-CSF) SC on days 1-4 and IFN-α-2b* SC on days 9, 11, and 13.~COURSES II-IV: Patients receive recombinant fowlpox-CEA(6D)-TRICOM vaccine SC on day 1. Patients also receive GM-CSF as in course 1 and IFN-α-2b* SC on days 1, 3, and 5.~NOTE: *The initial cohort of 6 patients does not receive IFN-α-2b.~Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. After 4 courses, patients who do not have progressive disease or unacceptable toxicity may receive recombinant fowlpox-CEA (6D)-TRICOM vaccine, GM-CSF, and IFN-α-2b every 28 days for 2 more courses and then every 3 months for up to 2 years."
89006081|NCT04647370|Active Comparator|Remote ischemic preconditioning|
88893541|NCT03921541|Experimental|Pegzilarginase Long Term Extension|After completion of 24 weeks DB treatment, weekly IV infusions of pegzilarginase plus individualized disease management for an additional 150 weeks, with the option to receive treatment by SC after 8 weeks of the LTE study.
89416148|NCT05507723|Experimental|Treat-to-target|All participants will have the GoutSMART application installed on their phones, and be offered a management plan including the use of flare prophylaxis and maximum advised dose of allopurinol based on renal function. All Participants in the treat-to-target group will be provided with a BeneCheck hand-held device and taught to perform urate finger prick self-testing. Participants will be prompted to submit urate readings by the GoutSMART app and if urate levels remain above target their allopurinol will be increased incrementally up to the pre-specified maximum dose of allopurinol.
89416149|NCT05507723|Active Comparator|Treat-to-flare|All participants will have the GoutSMART application installed on their phones, and be offered a management plan including the use of flare prophylaxis and maximum advised dose of allopurinol based on renal function. Participants in the treat-to-flare arm of the study will be reviewed every 4 months and allopurinol dose escalated incrementally if they have sustained a gout flare in the preceding 4 months, up to the maximum pre-specified allopurinol dose.
89416150|NCT05490264|Experimental|[68Ga]Ga-NOTA-SNA002|A dose of 1mCi-5mCi of [68Ga]Ga-NOTA-SNA002 between 0.1mg to 0.9mg will be administered intravenously over 5minutes in Day 1 of subject enrollment
89416151|NCT05487040|Experimental|PF-07321332 (nirmatrelvir)/ritonavir participants with severe renal impairment on hemodialysis|Patients with Covid-19 infection and severe renal impairment. Capsule and tablet once a day by mouth.
89416152|NCT05487040|Experimental|PF-07321332 (nirmatrelvir)/ritonavir participants with severe renal impairment not on hemodialysis|Patients with Covid-19 infection and severe renal impairment. Capsule and tablet once a day by mouth.
89416153|NCT05485701||Perinatal women|Women will be recruited in their first trimester of pregnancy and followed-up until 6 months post-partum. This is the 'exposed' group.
89416154|NCT05485701||Non-perinatal women|Non-perinatal women will be recruited as the 'non-exposed' group and followed-up over the same duration as the perinatal group.
88893542|NCT03919448|Active Comparator|Zutrab® (Bevacizumab Richmond)|a single 1 mg/kg IV dose of Bevacizumab
89416155|NCT05461508|Active Comparator|Amoxicillin combined with vonoprazan|The subjects will be given 20mg vonoprazan twice a day and 1000mg amoxicillin three times a day. These two drugs were taken continuously for 14 days
89416156|NCT05461508|Experimental|Amoxicillin combined with vonoprazan and fucoidan|The subjects will be given 20mg vonoprazan twice a day, 1000mg amoxicillin three times a day and fucoidan 1000mg twice a day. These three drugs were taken continuously for 14 days.
88893543|NCT03919448|Active Comparator|Avastin®|a single 1 mg/kg IV dose of Bevacizumab
88893544|NCT03919448|Active Comparator|Cizumab®|a single 1 mg/kg IV dose of Bevacizumab
88893545|NCT03904615|Active Comparator|Whey Protein|30 g of whey protein twice daily during hospitalization and for 30 days after discharge
88893546|NCT03904615|Active Comparator|Collagen Protein|30 g of collagen protein twice daily during hospitalization and for 30 days after discharge
88893547|NCT03904615|Placebo Comparator|Placebo|30 g of maltodextrin twice daily during hospitalization and for 30 days after discharge
89416157|NCT05452902|Experimental|EXCAP Exercise|Exercise for Cancer Patients (EXCAP©®) involves face-to-face instruction and a prescription for an at-home progressive walking and resistance exercise program.
89416158|NCT05452902|Active Comparator|Nutrition Education|Nutrition education involves equal time and attention as the exercise arm, but the content covers nutrition for cancer patients and lacks an exercise prescription.
89416159|NCT05440929||Clinicans|Participants will include: physicians, nurse practitioners, physician assistants, and nurse navigators. Participants will be recruited from the UNC Medical Center breast oncology group as well as other practices identified by the Principal Investigator based on existing professional networks (referring physicians, other UNC oncology entities, collaborative groups).
89416160|NCT05433415|Experimental|Black Girls Move (BGM) Treatment Condition|BGM is guided by the Anti-Racist Public Health Critical Race Praxis with adaptive mechanisms to support Black adolescent females as they navigate a racist society. The BGM treatment condition will include mothers as active participants in all components of the weekly, 12-session intervention to test the impact of actively leveraging the daughter/mother relationship . Participants in our prior research endorsed the importance of daughters and mothers actively engaging in group meetings together on weekends. Participants set PA and diet goals and self-monitor goal attainment. Dyads participate in structured activities designed to facilitate communication, problem solving, role assignment, and relationship quality. Dyads use a variety of videos, role play, discussion, and activities to achieve session outcomes. The sessions are led by trained facilitators who follow a standardized facilitator manual.
89416161|NCT05433415|Active Comparator|Daughters-Only Comparison Condition (DOCC)|The DOCC runs parallel to the BGM intervention and includes daughters-only group meetings. The DOCC incorporates all components of BGM except Family Systems Theory strategies. Daughters in DOCC will receive PA and diet behavior content based on Anti-Racist Public Health Critical Race Praxis and Social Cognitive Theory with daughter-only group activities. DOCC facilitators will lead group meetings and discussions. All DOCC daughters will self-monitor their progress towards PA goals using Fitbit® and progress towards diet goals using Start Simple with My Plate®.
89416162|NCT05433129|Other|Block Testing|Perturbations to the system will be investigated through a series of testing (block design separated by baseline rest): A. transient hyperemic response testing via carotid compression methods, B. orthostatic challenge responses (lying-to-sit, sit-to-stand),8 C. vascular chemo-reactivity via fast and slow breathing exercises and D. impact of neurovascular coupling through cognitive/Stroop testing. Work here will establish areas for improvement in real time.
88893548|NCT03900637|Experimental|Arm I|"MammaPrint high risk :~Neoadjuvant chemotherapy : Adriamycin/Cyclophosphamide #4 followed by Docetaxel #4~MammaPrint low risk :~Premenopausal women : Letrozole 2.5mg PO QD + leuprorelin acetate 3.6mg SQ every 4weeks during 16 weeks (if needed, maximum for 24 weeks)~Postmenopausal women : Letrozole 2.5mg PO QD during 16 weeks (if needed, maximum for 24 weeks)"
89006082|NCT04647370|Sham Comparator|Sham remote ischemic preconditioning|
89416163|NCT05432934|Experimental|Dexamethasone|Dexamethasone 16mg will be added to local anesthetic solution for TAP blocks. 4mg will be injected at 4 anterior abdominal wall sites in a laparoscopically-administered TAP block. This is a single intraoperative dose.
89416164|NCT05432934|No Intervention|Local anesthetic only|Local anesthetic (bupivacaine 0.25) 1mL/kg will be used for TAP blocks.
89416165|NCT05431361|Experimental|Prehabilitation|PREHAB participants will receive a multimodal intervention comprising of exercise, nutrition, and psycho/behavioural/educational support provided by an interprofessional prehab team comprising kinesiologists, dietitians, psychologists, and a previous LLD study partner. To facilitate overall compliance and appropriate adaptation to the home-based intervention components, participants will receive printed material, and a study coordinator will communicate weekly with patients to provide encouragement, monitor adherence, and clarify any questions or concerns.
89416166|NCT05431361|No Intervention|Usual Care|Usual care participants will be instructed to resume typical lifestyle behaviours until the date of the surgery. To standardize exposure to publicly available resources, usual care participants will receive the 24-Hour Movement Guidelines for Adults,33 Canada's Food Guide,27 a list of stress management resources (website, apps, free reading material), and reference to the Smoker's Helpline.
89416167|NCT05429853|Experimental|Sondalis® HP 2 kcal (with or without fibre)|
89416168|NCT05424159|Experimental|Patients with locally advanced unresectable pancreatic cancer|Patients with locally advanced unresectable pancreatic cancer without invasion of the gastrointestinal tract, cT4N0-2M0 Stage III (AJCC/UICC Version 8).
89416169|NCT05423808|Experimental|Intervention group|Patients in the intervention group will be part of a renewed care pathway supported by digital tools.
89416170|NCT05423808|No Intervention|Control group|Patients in the control group will receive standard of care, specific to the hospital where the patient is being treated.
88893549|NCT03893045|Experimental|Ferumoxytol|Each 20 mL single-use vial contains 17 mL of ferumoxytol that consists of iron at a concentration of 30 mg Fe/mL, coated with polyglucose sorbitol carboxymethylether and formulated with mannitol, at a concentration of 44 mg/mL, in a black to reddish brown sterile, aqueous, colloidal, isotonic solution.
88893550|NCT03893045|Active Comparator|Iron sucrose|Each mL contains 20 mg of elemental iron as iron sucrose in water for injection. The 5 mL single-use vial contains 100 mg of iron per 5 mL. The drug product contains approximately 30% sucrose (300 mg/mL)
88893551|NCT03877354||Paediatric patients anaesthesia|Paediatric patients who underwent diagnostic or surgical procedure under general anaesthesia with the need for mechanical ventilation in the selected time period.
88893552|NCT03877354||Paediatric patients intensive care|Paediatric patients admitted to the paediatric intensive care unit with the need for mechanical ventilation in the selected time period
88893553|NCT03867344|Active Comparator|Hypoglycemia|Participants undergo Autonomic Nervous System (ANS) Testing (measurement of Baroreflex Sensitivity using the Modified Oxford test) followed by a functional MRI (fMRI) scan. The next day, participants undergo one 120-minute hypoglycemic hyperinsulinemic clamp procedure (50mg/dL) in the morning followed by ANS Testing and an fMRI scan. Four days later, participants undergo repeat ANS Testing and an fMRI scan.
88893554|NCT03867344|Placebo Comparator|Normoglycemia|Participants undergo Autonomic Nervous System (ANS) Testing (measurement of Baroreflex Sensitivity using the Modified Oxford test) followed by a functional MRI (fMRI) scan. The next day, participants undergo one 120-minute normoglycemic hyperinsulinemic clamp procedure (90mg/dL) in the morning followed by ANS Testing and an fMRI scan. Four days later, participants undergo repeat ANS Testing and an fMRI scan.
88893555|NCT03864562||Black African or Caribbean|Healthy individuals of black African or Caribbean descent
88893556|NCT03864562||White European|Healthy individuals of white European descent
88893557|NCT03837600||Healthy Cohort|Participants who have smoked less than 5 pack-years, have quit smoking for more than 15 years and have no known lung diseases.
88893558|NCT03837600||High-risk Cohort|Participants who are at high risk for lung cancer including current smokers who have smoked for more than 30 pack-years and have not quit within 15 years.
88893559|NCT03837600||Cancer Cohort|Participants who have been diagnosed with lung cancer.
89006083|NCT04646980|Experimental|Biobran/MGN-3|This arm consisted from 20 males and 20 females. Biobran/MGN-3 was orally supplemented at dose of 500 mg per day for 3 months (end of November 2018- end of February 2019).
89416171|NCT05420064|Experimental|Proband-Mediated Cascade Genetic Testing|Control arm- Behavioral: As per standard of care, probands will be given a Family Letter by their genetic counselor that they will be instructed to share with their at-risk relatives (ARR). In addition to the recommendation that ARR undergo genetic counseling and a list of local genetics clinics, this letter will include a link to the eDGP through which control ARR can enroll onto the present study. For these ARR, the eDGP will only be used to obtain study e-consent and to administer study surveys.
89416172|NCT05420064|Experimental|Provider-Facilitated Cascade Genetic Testing|Intervention arm-: Behavioral: Probands will give contact info for their ARR in the eDGP and indicate a date by which they will discuss the familial pathogenic variant with their ARR (can request a delay/halt to outreach). After this date the team will contact the ARR to invite them to review education and e-consent to the study. The study team will facilitate ARR cascade testing through telegenetics pre- and post-test counseling and saliva-based at home testing through MSK or a reference laboratory.
89416173|NCT05400616|Experimental|Intervention|For each nostril, the donated nasal wash sample is quiesced to 15 mls with saline Nasal Microbiota Transplant therapy.
89416174|NCT05400616|Placebo Comparator|Control|For each nostril, 15 mls of saline will be used as the placebo therapy.
89416175|NCT05383417|Experimental|EndoClip|Clip applied to endotracheal tube.
89416176|NCT05383417|No Intervention|No Clip|No clip applied to endotracheal tube.
89416177|NCT05377398|Experimental|1) Intervention group|"Participants in this arm will be offered~a digital individual-level intervention (Bit Habit) &~group-based or individual-level healthy lifestyle and green power intervention~a mini-intervention for substance use if their level of substance use is above certain risk level."
89416178|NCT05377398|No Intervention|2) Control group|"The control group is assumed to continue with current health information and national recommendations for healthy lifestyle and use of services as usual."
89416179|NCT05357950|Active Comparator|PrimeC|2 tablets of PrimeC administered twice daily (4 tablets a day), at a daily dose of 1496 mg
89416180|NCT05357950|Placebo Comparator|Placebo|2 tablets of Placebo administered twice daily (4 tablets a day). Placebo tablets are matched in size, color and taste.
89416181|NCT05356182|Active Comparator|Control Diet Arm|control diet arm (~20% protein content)
89416182|NCT05356182|Active Comparator|Low-Protein Diet Arm|intervention low-protein diet arm (10% protein content)
89416183|NCT05354570|Experimental|Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT)|Radiation will be administered over approximately 6 weeks to 50.4 Gy in 28 fractions with an optional SIB to gross residual disease.
89416184|NCT05350423|Experimental|Thulium Fibre Laser (TFL)|Patients who are randomized to undergo ureteroscopic laser lithotripsy with the Thulium fibre laser (TFL)
89416185|NCT05350423|Experimental|Holmium:Yttrium-Aluminum-Garnet (Ho:YAG)|Patients who are randomized to undergo ureteroscopic laser lithotripsy with the Holmium:Yttrium-Aluminum-Garnet (Ho:YAG) laser
89416186|NCT05334485|Experimental|Pyridostigmine|Patients randomized to this group will be given 60mg of pyridostigmine bromide orally, every 12 hours. Pyridostigmine will be administered from the time of diagnosis of postoperative ileus until the return of bowel function, or for a maximum of 48 hours.
89416187|NCT05334485|Placebo Comparator|Placebo|Patients randomized to this group will be given starch orally, every 12 hours for a maximum of 48 hours.
89416188|NCT05324943|Experimental|FLT201|FLT201 is an advanced therapy investigational medicinal product (ATIMP) administered as a single intravenous infusion.
89416189|NCT05315999|Experimental|Palonosetron Hydrochloride|Palonosetron (500µg): single dose per os 1-2 hours before the start of opioid-therapy (WHO II & III)
89416190|NCT05315999|Placebo Comparator|Placebo|Placebo: single dose per os 1-2 hours before the start of opioid-therapy (WHO II & III)
89416191|NCT05304117|Experimental|Advance Care Planning Experimental|Community Information Session on advance care planning and private one-on-one Sharing Session about advance care planning.
88893560|NCT03832985|Experimental|Receive an adult-onset result|Compare change in psychosocial outcomes and health behaviors of those with a pathogenic variant in a gene associated with adult onset of disease.
88893561|NCT03832985|Experimental|Receive a pediatric-onset result|Compare change in psychosocial outcomes and health behaviors of those with a pathogenic variant in a gene associated with pediatric onset of disease or with risk reduction interventions that begin in childhood.
89416192|NCT05304117|Other|Advance Care Planning Waitlist|Waitlist Group- Baseline control measures will be collected at the same time as Cohort 1 completes their pretest. Six Months after Cohort 1, participants will be pretested again before attending a Community Information Session on advance care planning and an one-on-one Sharing Session about Advance Care Planning.
89416193|NCT05294978||Patients|-Availability of macular optical coherence tomography (OCT)
89416194|NCT05294978||Controls|-Availability of macular optical coherence tomography (OCT)
89416195|NCT05294809|Experimental|PsyPills|"The participants randomized in this condition will receive the mobile health application PsyPills."
89416196|NCT05294809|Experimental|OCAT|"The participants randomized in this condition will receive the mobile health application OCAT."
89416197|NCT05294809|Placebo Comparator|OCAT sham|"The active control group, which consists of the fake version of the OCAT intervention, by offering the same attentional training, without training and feedback on performance."
89416198|NCT05294367|Experimental|Cycle 1|Participants consume magnesium rich foods PO daily for 28 days.
89416199|NCT05294367|Experimental|Cycle 2, Arm I|Participants continue consuming magnesium rich foods PO daily and apply Ancient Minerals Magnesium Lotion topically daily for 28 days.
89416200|NCT05294367|Experimental|Cycle 2, Arm II|Participants continue consuming magnesium rich foods PO daily for 28 days.
89416201|NCT05288452|Experimental|Arm 1|Digital coaching+ Food delivery+ RPM
89416202|NCT05288452|Active Comparator|Arm 2|Digital coaching
89416203|NCT05288452|Active Comparator|Arm 3|Digital coaching+ Food delivery
89416204|NCT05288452|Active Comparator|Arm 4|Digital coaching+ RPM
89416205|NCT05288452|Active Comparator|Arm 5|Food delivery+ RPM
89416206|NCT05288452|Active Comparator|Arm 6|The participant's will not receive any Intervention
89416207|NCT05288452|Active Comparator|Arm 7|Food delivery
89416208|NCT05288452|Active Comparator|Arm 8|RPM
89416209|NCT05282654|No Intervention|Usual Care (Arm 1)|During the 18-month Baseline Period (Arm 1, n=450) patients will be enrolled and receive usual care to develop the initial predictive model.
89416210|NCT05282654|No Intervention|Usual Care (Arm 2)|During the 30-month Main Trial (RCT) Period, patients will be randomized to usual care (Arm 2, n=425). Data collection for post-discharge AE determination will occur during both periods.
89416211|NCT05282654|Experimental|Intervention (Arm 3)|During the 30-month Main Trial (RCT) Period, patients will be randomized to the intervention (Arm 3, n=425). Data collection for post-discharge AE determination will occur during both periods.
89416212|NCT05252988|Experimental|Arm A|"Neratinib 240 mg (six 40mg tablets) orally once daily for 13 cycles (C) (1 C = 28 days), unless patient discontinues earlier.~Mandatory loperamide 4 mg (2 tablets/capsules) orally, 3 times a day (total 12 mg a day) starting Day (D) 1 of neratinib and for the first 14 days. Then, 4 mg (2 tablets/capsules) orally, 2 times a day (total 8 mg a day) until the end of C2 (D56); thereafter, loperamide will be administered PRN (without exceeding 16 mg per day)."
89416213|NCT05252988|Experimental|Arm B|"Neratinib 120 mg for Week 1 (C1D1 - C1D7), followed by 160 mg neratinib for Week 2 (C1D8 - C1D14), followed by 240 mg neratinib for Week 3 and thereafter for 13 cycles inclusive, until cycle 13 day 28 (unless patient discontinues earlier).~Loperamide to be administered PRN only (without exceeding 16 mg per day)."
89416214|NCT05252988|Experimental|Arm C|"Neratinib 240 mg (six 40-mg tablets) orally once daily for 13 C, unless patient discontinues earlier.~Mandatory loperamide 4 mg (2 tablets/capsules) orally, 3 times a day (total 12 mg a day) for the first 14 days. After the first 14 days, 4 mg (2 tablets/capsules) orally, 2 times a day (total 8 mg a day) to complete a total of 28 days.~Mandatory colesevelam 1,875 mg (three 625-mg capsules orally), 2 times a day for the first month (28 days). After day 28, any prophylaxis or treatment for diarrhoea could be administered PRN, if loperamide not to exceed 16 mg per day."
89416215|NCT05251363|Other|Solia S LBB lead|
89416216|NCT05247333|Experimental|Patients presenting with minor ailments or requesting a non-prescription product.|"Community pharmacists working with agreed protocols with primary care physicians respond to all type of patients presenting with minor ailments or requesting a non-prescription product.~Following this consultation, patients are followed up after ten days."
89416217|NCT05243563|Experimental|Fractionated CO2 laser plus topical steroids|3 laser treatments at 6 week intervals for 6 months by a single trained operator
89416218|NCT05243563|Active Comparator|topical steroids alone|self-applied topical steroid therapy using clobetasol propionate 0.05%
88893562|NCT03832985|Active Comparator|Control - No result|Compare change in psychosocial outcomes and health behaviors of those without a genomic result.
88893563|NCT03821272|Experimental|PepCan|Four injections (one every 3 weeks) of PepCan, then three injections (one every 3 months) of PepCan for a total of 7 injections.
88893564|NCT03821272|Placebo Comparator|Placebo|Four injections (one every 3 weeks) of placebo, then three injections (one every 3 months) of placebo for a total of 7 injections.
89416219|NCT05208164|Experimental|Mindfulness Meditation Classes|"8 mindfulness classes: Participants will engage in 8 two-hour mind and body practice classes over 8 weeks in-person or online (during the pandemic). You will receive compensation for your participation and a yoga mat. You will need to wear comfortable clothing. These sessions can be done sitting in chair, sitting on the floor, or standing.~Text messaging., in between classes you will receive text messages to encourage mind and body practices at home. Text messaging may appear as the following:~1.Do you have time to meditate right now? Yes or No. 2.Did you practice your mindfulness today? Yes or no. 3.Remember to wind down this evening and do not drink any caffeinated beverages 4 hours before bed."
89416220|NCT05208164|No Intervention|Usual Care|
89416221|NCT05207462|Experimental|Intensive treatment with prolonged exposure|Intensive treatment with prolonged exposure
89416222|NCT05206279|Experimental|ureteral ICG injection|There is only one arm of the study. All patients will undergo normal laparoscopy. After examining the abdominal structures for presence of endometriosis as well as performing photographic documentation, cystoscopy with intraureteral administration of ICG will be performed, after which intervention the ureters will be examined by laparoscopy. ICG is injected cystoscopy-guided into the ureters (cystoscopy-guided) in a dosage of 5 or 10ml (25mg ICG in 5 or 10ml NaCl) per ureter as a bolus injection.
89416223|NCT05205291||Parkinson's disease patients|18 patients with Parkinson's disease who will undergo clinical assessment, and PET/MR imaging of TSPO using the tracer [11C]PBR28 before and four hours after administration of LPS (1 ng/Kg)
89416224|NCT05205291||Healthy controls|6 healthy controls who will undergo clinical assessment, and PET/MR imaging of TSPO using the tracer [11C]PBR28 before and four hours after administration of LPS (1 ng/Kg)
88893565|NCT03818737|Experimental|Bone Marrow Derived MSCs|Participants randomized to this arm will undergo bone marrow aspiration and then will be further randomized to receive a standard orthobiologic injection into the knee joint of autologous bone marrow concentrate (BMAC).
89193135|NCT05498155|Experimental|Cohort B|Cohort B will consist of a higher-risk population of participants with HER2-negative ER-negative or ER-low defined as having a tumour size of >20 mm but ≤50 mm and N0 (T2/N0), or having a tumour size of >1 mm but ≤20 mm and N1 (T1/N1).
89416225|NCT05200468|Experimental|Ketogenic diet|Weekly menus will be delivered according to diet with the following macronutrient distribution: 25% protein, 10% carbohydrate, 65% fat. Participants will receive a 30-day food menu guide.
89416226|NCT05200468|Experimental|Caloric restriction diet|Weekly menus will be provided according to their usual diet with 500 kcal restriction with the following macronutrient distribution 25-35% protein, 45-55% carbohydrates, 20-30% fat. Participants will receive a 30-day food menu guide.
89416227|NCT05200468|Experimental|Intermittent fasting 16/8|Calorie-restricted menus will be provided with a 16:8 time-restricted feeding. The feeding window will be 8 hours with a fasting time of 16 hours (04.00 pm- 08.00 am or 05.00 pm - 09.00 am), during the fasting window participants will only be allowed to drink water, unsweetened tea, mineral water and coffee without added sugar. Participants will receive a 30-day food menu guide.
89416228|NCT05200468|No Intervention|habitual diet|Participants will be advised to follow their usual diet until the end of the study.
89416229|NCT05197790|Other|Assess device prototype functionality|Everyone will be in the same arm
89416230|NCT05184283||Prospective Cohort|Chart review will be performed for patients who consent to inclusion in the study. Information from routine care will be reviewed and body composition assessment will be done by routine MRI with an additional 6-8 minute scan using AMRA® Profiler 4 Muscle Assessment Score (MAsS) by performing volumetric quantification of fat and water images acquired with 2-point Dixon magnetic resonance imaging (MRI).
89416231|NCT05180695|Experimental|extension part : Soft-tissue sarcomas with MDM2 amplification|"The aim of each extension cohort is to provide preliminary evidence of anti-tumor activity while refining toxicity data, and to gain insight progressive disease activity and exploratory biological analyses. A maximum of 14 patients patients will be enrolled in this cohort  Soft-tissue sarcomas with MDM2 amplification . Both study drugs (pazopanib and HDM201) will be administered as long as the patient experiences clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent."
89416232|NCT05180695|Experimental|extension part : Soft-tissue sarcomas with no MDM2 amplification|"A maximum of 14 patients patients will be enrolled in this cohort  Soft-tissue sarcomas with no MDM2 amplification. Both study drugs (pazopanib and HDM201) will be administered as long as the patient experiences clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent."
89193136|NCT05495230|Other|Usual care|"Practices in the control group provide care as usual, which consists of the SDM programmes according to the national care standards and General Practice guidelines (NHG) for DM2, COPD and CVD. According to these protocolised programmes, patients with COPD, CVD or DM2 visit their general practice at a standard frequency per year (1 - 4 times) and standard monitoring measurements and topics are discussed.~The practices that are randomised to the control group will not receive any additional training related to this study."
89416233|NCT05157672|Experimental|Cinnamon|Arm 1 will consist of administration of a single dose of cinnamon (2 g) with water by mouth to 6 subjects (3 biological men, 3 biological women). Blood will be drawn from 0-48 hours. Urine will be collected from 0-24 hours. The subjects may or may not elect to participate in Arms 2-5. If they do, a washout of at least 7 days will occur between Arm 1 administration of cinnamon and the Arm 2 administration of nicotine.
89416234|NCT05157672|Experimental|Nicotine|Arm 2 will consist of administration of a single dose of nicotine gum (2 mg) to 16 subjects (8 biological men, 8 biological women). If these subjects participated in Arm 1, they will have completed a washout of 7 days since administration of cinnamon before starting Arm 2. Blood and urine will be collected from 0-12 hours relative to nicotine administration. Participants will undergo a washout of at least 4 days before beginning Arm 3.
89416235|NCT05157672|Experimental|Letrozole|Arm 3 will consist of administration of a single oral dose of letrozole (2.5 mg) to the same 16 subjects who participate in Arm 2. Blood and urine will be collected from 0-240 hours and 0-24 hours, respectively, relative to letrozole administration. Participants will undergo a washout of at least 14 days before beginning Arm 4.
89416236|NCT05157672|Experimental|Cinnamon + Nicotine|The same 16 subjects will self-administer the cinnamon product (2 g) three times daily for five consecutive days. On the sixth day, subjects will be administered cinnamon (2 g) and nicotine gum (2 mg). Cinnamon will be administered two additional times. Blood and urine will be collected from 0-12 hours relative to nicotine administration. Participants will undergo a washout of at least 4 days before beginning Arm 5.
89416237|NCT05157672|Experimental|Cinnamon + Letrozole|The same 16 subjects will self-administer the cinnamon product (2 g) three times daily for five consecutive days. On the sixth day, subjects will be administered cinnamon (2 g) and letrozole (2.5 mg). Cinnamon will be administered two additional times. Blood and urine will be collected from 0-240 hours and 0-24 hours, respectively, relative to letrozole administration.
89416238|NCT05152758|No Intervention|Usual Care|Patients will receive the usual care.
89416239|NCT05152758|Experimental|Physical Activity Prescription (PARx)|Patients will be prescribed technology-based physical activity programming.
89416240|NCT05151211||Validity and Reliability Group|In order to evaluate the usability of the 1 MSTS, the validity and reliability of the test will be examined. In order to determine its validity in assessing physical capacity, the correlation of 1 minute sit up and 6 MWT and quadriceps muscle strength; In order to determine its validity in the evaluation of effort-induced desaturation, the correlation between the change in oxygen saturation and heart rate parameters before and after the 6 MWT and the change before and after the 1 MSTS test will be examined. In order to determine the reliability of the 1 MSTS, a re-test will be performed and 1 MSTS will be applied again after 1 week and the intraclass correlation coefficient will be checked.
89536769|NCT03310463|Experimental|Cohort 1, Normal Renal Function|Healthy control participants matched to participants enrolled in Cohort 4 (creatinine clearance ≥90 milliliters per minute [mL/min] estimated by the Cockcroft-Gault equation) will receive ETX2514SUL as a single dose of up to 1000 milligrams (mg) ETX2514 and 1000 mg sulbactam given by concurrent 3-hour intravenous (IV) infusion.
89536770|NCT03310463|Experimental|Cohort 2, Mild Renal Impairment|Participants with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥60 to <90 mL/min/1.73 meters squared [m^2] calculated by the Modified Diet in Renal Disease [MDRD] equation) will receive ETX2514SUL as a single dose of up to 1000 mg ETX2514 and 1000 mg sulbactam given by concurrent 3-hour IV infusion.
89416241|NCT05147454||Trigeminal Neuralgia|Patients with a definite diagnosis of Classical or Idiopathic Trigeminal Neuralgia
89416242|NCT05147454||Persistent Idiopathic Facial Pain|Patients with a definite diagnosis of Persistent Idiopathic Facial Pain
89416243|NCT05147090|Active Comparator|Empagliflozin group|Empagliflozin 10mg daily for 156 weeks
89416244|NCT05147090|Placebo Comparator|Placebo group|Placebo pills (identical in appearance to empagliflozin 10mg) daily for 156 weeks
89416245|NCT05137639|Experimental|PRF group|Participants received platelet-rich fibrin (PRF) prior to free skin grafting
89416246|NCT05137639|No Intervention|non-PRF group|Standard surgical procedure (free skin grafting to reconstruct donor sites without PRF).
89416247|NCT05121012||Group 1|Patients with MSA-P
89416248|NCT05115747|Experimental|"Zero percentage weight off-loading group-A"|This group received the Mild to moderate aerobic exercise training on the Alter-G treadmill with the full weight-bearing for three months.
89416249|NCT05115747|Experimental|"Twenty-five percentage weight off-loading group-B"|"This group received the Mild to moderate aerobic exercise training on the Alter-G treadmill with the twenty-five percentage weight off-loading for three months."
89416250|NCT05115747|Experimental|"Fifty percentage weight off-loading group-C"|"This group received the Mild to moderate aerobic exercise training on the Alter-G treadmill with the fifty percentage weight off-loading for three months."
89416251|NCT05115747|Experimental|"Seventy-five percentage weight off-loading group-D"|"This group received the Mild to moderate aerobic exercise training on the Alter-G treadmill with the seventy-five percentage weight off-loading for three months."
89416252|NCT05115747|No Intervention|Control group-E|Participated no aerobic exercise training.
89416253|NCT05112575||Early imaging: within 36 hours postoperatively.|Patients fulfilling eligibility criteria between 18 and 80 years old who receive MRI or CT follow-up after craniotomy for resection of a space occupying lesion (benign or malignant) or vascular within 36 hours after neurosurgical procedure.
89416254|NCT05112575||Late imaging: between 36 and 72 hours postoperatively|Patients fulfilling eligibility criteria between 18 and 80 years old who receive MRI or CT follow-up after craniotomy for resection of a space occupying lesion (benign or malignant) or vascular between 36 and 72 hours after neurosurgical procedure.
89416255|NCT05104229|Active Comparator|Standard of Care|standard VTE chemoprophylaxis
89416256|NCT05104229|Experimental|Aspirin|Aspirin VTE chemoprophylaxis
89416257|NCT05103436|No Intervention|Control Group|Participants will not receive intervention for the first 2 months. This period will be used for comparison with the intervention group. At the end of the 2-month delay, they will receive TENS (1 hr AM, 1 hr PM/day, 50 Hz, below pain/motor threshold, using an EMS 7500 TENS unit).
89536771|NCT03310463|Experimental|Cohort 3, Moderate Renal Impairment|Participants with moderate renal impairment (eGFR ≥30 to <60 mL/min/1.73 m^2 calculated by the MDRD equation) will receive ETX2514SUL as a single dose of up to 1000 mg ETX2514 and 1000 mg sulbactam given by concurrent 3-hour IV infusion.
88893566|NCT03818737|Experimental|Adipose-derived MSCs|Participants randomized to this arm will undergo small volume lipoplasty, and then will be further randomized to receive an injection into the knee joint of adipose-derived stromal vascular fraction (SVF).
88893567|NCT03818737|Experimental|Umbilical Cord Tissue (UCT) MSCs|Participants randomized to this arm will receive an injection into the knee joint of cryopreserved doses of umbilical cord tissue MSCs.
89199121|NCT04037553||Group 3|Patients underwent left head and neck surgery: After intracuff pressure (ICP) is adjusted to 25 cmH2O at neutral position, gel pillow with the height of 4,5 cm was placed under the shoulders of patients to extend the neck. Following 3 respiration cycles, the ICPs were noted. Then, right or left lateral neck rotation was applied depending on the operation side (approximately 60-70 degree to the opposite site). After 3 respiration cycles, ICPs were documented again.
89199122|NCT00884559|Active Comparator|Technical|Technical Instructions
89199123|NCT00884559|Experimental|Leadership|Leadership-Instructions
89199124|NCT00884637||CNV subjects|
88893568|NCT03818737|Active Comparator|Corticosteroid Injection|Participants randomized to the bone marrow derived MSC, adipose-derived MSC, or umbilical cord tissue MSC study arms will be further randomized within the arm in a 3:1 ratio to receive either MSCs derived from the study arm of the initial randomization or a corticosteroid (CS) injection. Participants randomized to the control group will receive an injection of corticosteroid into the knee joint.
88893569|NCT03801785|Experimental|Children induced to suck pacifiers.|Children will suck a pacifier of identical shape and type and will be allowed other NNS habits.
88893570|NCT03801785|No Intervention|Children induced to stop sucking.|Children will be induced by DDSs to stop sucking and their parents will be advised how to stop their children's NNS habits.
88893571|NCT03795922|Experimental|MT10109L|MT10109L will be injected into the GL: initial double-blind treatment on Day 1, and up to 2 open-label study interventions during the retreatment period.
89416258|NCT05103436|Experimental|Intervention Group|Participants will receive 2 months of TENS (1 hr AM, 1 hr PM/day, 50 Hz, below pain/motor threshold, using an EMS 7500 TENS unit) immediately upon entry to the study.
89416259|NCT05076500||Cervical cancer|Cervical cancer patients receiving standard of care radiotherapy
89416260|NCT05076500||Rectal cancer|Rectal cancer patients receiving standard of care radiotherapy
89416261|NCT05076500||Head and neck cancer|Head and neck cancer patients receiving standard of care radiotherapy
89416262|NCT05076500||nodal non-Hodgkin lymphoma|Patients with nodal NHL receiving standard of care radiotherapy
89416263|NCT05076500||cutaneous lymphoma|Patients with cutaneous lymphoma receiving standard of care radiotherapy
89416264|NCT05076500||cutaneous squamous cell carcinoma and basal cell carcinoma|Patients with cSCC and cBCC receiving standard of care radiotherapy
89416265|NCT05067777|Experimental|Arm I (SMT)|Patients receive SMT over 45 minutes once weekly for 6 weeks.
89416266|NCT05067777|Sham Comparator|Arm II (LT)|Patients receive LT over 45 minutes once weekly for 6 weeks.
89416267|NCT05067777|Active Comparator|Arm III (waitlist)|Patients receive no intervention for 6 weeks.
89416268|NCT05061329||60 Normal individuals|Normal sense of smell and absence of sino-nasal disease, upper airway allergies, and no intranasal medication
89416269|NCT05061329||60 Non-COVID-19 positive patients|with olfactory dysfunction
89416270|NCT05061329||15 COVID-19 positive patients|In the acute phase
89416271|NCT05061329||60 long COVID-19 patients|with olfactory dysfunction persisting for more than 12 weeks
89416272|NCT05061329||60 patients with chronic rhinosinuitis|initiating intranasal glucocorticoids
89416273|NCT05061329||15 patients with chronic rhinosinuitis|initiating biological treatment with either dupilumab or mepolizumab
89416274|NCT05057247|Experimental|Duvelisib plus Docetaxel chemotherapy|"Participants will receive duvelisib by mouth twice daily,dosage per protocol continuously (days 1-21 of a 21-day cycle) with a 7-day lead-in planned prior to the start of taxane therapy.~Docetaxel at via IV will be delivered on day 1 of each 21-day cycle.~Treatment will continue for 24-months or until unacceptable toxicity, progression, or death."
89416275|NCT05055063|Experimental|Belantamab mafodotin|belantamab mafodotin by vein over 30-60 minutes on Day 1 of each 56-day cycle for the first 6 cycles.
89416276|NCT05049096|Experimental|intervention group|In intervention group, participants will receive the whole peri-renal fat modification therapy (including peri-renal fat ultrasonic measurement and localization,focused ultrasound treatment parameters setting and initiating)
88893572|NCT03795922|Placebo Comparator|Placebo|Placebo will be injected into the GL: initial double-blind treatment on Day 1.
88893573|NCT03794089|Experimental|Brief anxiety intervention|Modular anxiety intervention designed for PC-MHI, up to six 30-minute sessions occurring approximately every 2 weeks, patients select modules of interest to them to complete, emphasis on psycho-education and cognitive-behavioral coping strategies for self-management
88893574|NCT03794089|Active Comparator|Usual PC-MHI care|Appointment with PC-MHI provider at local primary care clinic, providers delivers whatever interventions they deem appropriate and collaboratively decides with patients whether and when to meet again as in routine PC-MHI care
88893575|NCT03789149|Experimental|Intraoperative Radiotherapy|Intraoperative Radiotherapy with a mobile device (Intrabeam, Carl Zeiss AG)
88893576|NCT03777982|Experimental|LHRH Agonist or Antagonist|-LHRH agonist or antagonist should be prescribed per standard of care
88893577|NCT03777982|Experimental|Prednisone+Apalutamide+Abiraterone Acetate +LHRH Agonist|"LHRH agonist or antagonist should be prescribed per standard of care~Abiraterone acetate will be taken once daily~Prednisone will be taken twice daily~Apalutamide will be taken once daily"
88893578|NCT03769025|Experimental|Remote Observed Dosing|One group will be assigned to Remote Observed Dosing (ROD) and will have all of their Suboxone® doses remotely observed. The intervention is remote observed dosing
88893579|NCT03769025|Active Comparator|Attention Control|The attention control (AC) group will not have their dosing observed but will send a text message confirming they have taken their study medication to the study team daily matching contact with the study team. Text message confirming that they have taken their study medication is the intervention
88893580|NCT03762473|Experimental|Study Group|Post transplant patients (kidney transplant alone) with standard of care immunosuppression, no prior rejection, prior BK or opportunistic infection, and negative BK screening at month 1, whom have a concentration/dose of < 1 and a steady state therapeutic level will be eligible. Patients will be converted to envarsus at 20% reduction in dose.
88893581|NCT03762473|Active Comparator|Control Group|Post transplant patients (kidney transplant alone) performed between 10-2016 and time of enrollment with standard of care immunosuppression, no prior rejection, prior BK or opportunistic infection, whom had a negative BK screening at month 1 and concentration/dose of < 1 at month 1, and BK data available and month 2,3, 6,9,12.
89416277|NCT05049096|Sham Comparator|sham-control group|In sham control group, participants will receive the sham control therapy(including peri-renal fat ultrasonic measurement and localization,focused ultrasound treatment parameters setting),however,without initiating the focused ultrasound equipment.
89416278|NCT05042479|Experimental|Standard treatment then virtual reality then choice between the two|"Efficiency of VR will be evaluated for each patient across 3 potentially painful care-procedures :~For the first treatment, the child will benefit usual distraction and pain prevention techniques.~For the 2nd, the child will use a VR headset as well as pain prevention techniques (excluding oxygen-nitrous oxide mixtures). The child will choose the application he/she wishes to use according to his/her age and parental agreement.~For the 3rd treatment, the child will choose his/her favorite technique."
89416279|NCT05033184|Experimental|Brief Action Planning Exercise|
89416280|NCT05033184|Active Comparator|Goal Setting Exercise|
89416281|NCT05028075|No Intervention|Usual Care|Participants will complete baseline surveys at enrollment and then complete subsequent surveys (depression, anxiety, well-being, satisfaction with access to care, work productivity, hours of direct patient care, percent of time providing care for patients with COVID-19) at enrollment; 0 months, 6 months, and 9 months.
89416282|NCT05028075|Experimental|Intervention|Participants will complete baseline surveys at enrollment and then complete subsequent surveys (depression, anxiety, well-being, satisfaction with access to care, work productivity) at enrollment; 0 months and then again at 6 months and 9 months. The intervention group receives usual Cobalt plus: 1) monthly automated text messaging reminders and links to Cobalt resources 2) intermittent mental health assessments which triage individuals to an appointment based on their results.
89416283|NCT05018273|Experimental|VB10.NEO 3 mg in combination with Atezolizumab 1200 mg|"VB10.NEO 3 mg will be administered by IM injection for an induction course Q3W (4 doses) followed by maintenance doses Q6W (6 doses) and Q12W (5 doses).~Atezolizumab 1200 mg will be administered by intravenous (IV) infusion on Day 1 of 21 day cycles."
88893582|NCT03760237||Acute Leukemia|Observation only. Patients newly diagnosed with acute leukemia who are scheduled to start treatment with chemotherapy will be enrolled and followed serially with blood collection, echocardiogram, arterial applanation tonometry, and questionnaires for 1 year.
88893583|NCT03745989|Experimental|MK-8353 and Selumetinib Dose Escalation|Participants will receive a combination MK-8353 and selumetinib for 4 days on and 3 days off until disease progression or discontinuation. MK-8353 will be escalated sequentially from 50 mg to 250 mg based on pharmacokinetic and safety data. Selumetinib will be escalated sequentially from 25 mg to 75 mg based on pharmacokinetic and safety data. Doses may be adjusted downward sequentially based on tolerability
88893584|NCT03724552|Experimental|Transcranial LED Therapy (Participants ages 9-17)|Transcranial Laser Emitting Diode (LED) Therapy (TLT) is a noninvasive intervention in which near-infrared light (830nm-850nm) is applied to forebrain.
89416284|NCT05018273|Experimental|VB10.NEO 6 mg in combination with Atezolizumab 1200 mg|"VB10.NEO 6 mg will be administered by IM injection for an induction course Q3W (4 doses) followed by maintenance doses Q6W (6 doses) and Q12W (5 doses).~Atezolizumab 1200 mg will be administered by intravenous (IV) infusion on Day 1 of 21 day cycles."
89416285|NCT05018273|Experimental|VB10.NEO 9 mg in combination with Atezolizumab 1200 mg|"VB10.NEO 9 mg will be administered by IM injection for an induction course Q3W (4 doses) followed by maintenance doses Q6W (6 doses) and Q12W (5 doses).~Atezolizumab 1200 mg will be administered by intravenous (IV) infusion on Day 1 of 21 day cycles."
89416286|NCT05010629|Experimental|9-ING-41 + carboplatin|"Participants will be divided into 2 cohorts: Salivary Gland Cancer with adenoid cystic carcinoma (ACC) and Salivary Gland Cancer without adenoid cystic carcinoma (ACC) and receive:~9-ING-41 2x every 21 day study cycle on Day 1 and Day 4 up to 1 year with option to continue beyond if participant is showing benefit~Carboplatin 1x every 21 day study cycle on Day 1 up to 1 year"
89416287|NCT05010304|Experimental|Pediatric Patients with a history of penicillin allergy|
89416288|NCT05008523|Experimental|Opioids and Police Safety Occupational Risk Reduction Training|Provides occupational risk reduction training for police in 49 slides including 8 filmed videos (police officers, MDs, SSP staff, a person in recovery). The training is delivered online with secure access only for enrolled study participants.
89416289|NCT05008523|Active Comparator|COVID Occupational Risk Reduction Training|The COVID-19 and Police Safety training (Control only) includes 22 slides, also narrated by a professional voice narrator.
89416290|NCT05002608|Experimental|Navigation Intervention|The intervention will be delivered via synchronous videoconferencing (real-time delivery and communication between the navigator and the participant) by a trained patient navigator and will consist of 5, 30-minute sessions delivered every week. The navigation intervention group will also receive an online or mailed copy of the health insurance resource guide.
89416291|NCT05002608|No Intervention|Enhanced Usual Care|Enhanced usual care will consist of an online or mailed health insurance resource guide.
89416292|NCT04992832|Experimental|experimental group|The volunteers of the experimental group will be given peripheral intravenously a dose of 1.0*10^6/kg human umbilical cord mesenchymal stem cells at 0,6,12 week.
89416293|NCT04992832|Placebo Comparator|control group|The control group will be given the same dose of saline containing human albumin.
89416294|NCT04992169|Experimental|Smartphone App with Video Self-Scoring Functionality|In this condition, after parents video-record their delivery of the intervention, they watch their video and are taught to score their own performance/fidelity through question prompts built into the app. When they are finished, the app will offer feedback and follow-up lessons based on the PRT strategies they have not demonstrated consistently.
89416295|NCT04992169|Experimental|Smartphone App without Video Self-Scoring Functionality|In this condition, after parents video-record their delivery of the intervention, they watch their own video but do not score their performance.
89416296|NCT04981470|Experimental|Investigational Device|Subjects implanted with the baroloop device
88893585|NCT03724552|Experimental|Transcranial LED Therapy (Participants ages 18-59)|Transcranial Laser Emitting Diode (LED) Therapy (TLT) is a noninvasive intervention in which near-infrared light (830nm-850nm) is applied to forebrain.
88893586|NCT03721783||children with soft tissue lesions|All children who undergo cryoablation therapy for benign soft tissue lesions
88893587|NCT03674983|Experimental|CEI Group|CEI Group will receive the standard of care (information, prescription, free PrEP) and economic incentives contingent on sufficiently-high adherence to PrEP.
88893588|NCT03674983|No Intervention|SOC Group|SOC Group will receive the standard of care only (information, prescription, free PrEP.)
88893589|NCT03665688|Experimental|Outpatient Dilapan-S|"After Dilapan-S® placement, subjects will be given the option to either return home or to stay in a hotel if transportation is an issue.~Subjects will also be instructed to return to L&D unit 12 hours after insertion, or earlier if any excessive bleeding, rupture of membranes, pain or other concerns (contractions, decreased fetal movement) develop before the 12 hours"
88893590|NCT03665688|Active Comparator|Inpatient Dilapan-S|"After Dilapan-S® placement, subjects will be admitted to L&D unit and standard clinical protocol will be initiated for cervical ripening and labor induction. During the period of 12 hours of cervical ripening subject is to remain nothing per os (NPO), nothing per vagina and undergo continuous fetal heart rate monitoring. No other interventions are to occur during this period of 12 hours, unless clinically indicated."
88893591|NCT03659045|Experimental|Mifegyne® 600MG|Patients assigned to this group will receive three 200 mg tablets of Mifegyne® taken during the consultation Patients will answer to a scale of pain
88893592|NCT03659045|Placebo Comparator|Mifegyne® 200MG|"Patients assigned to this group will receive one 200 mg Mifegyne® tablet and two placebo tablets that will be taken during the consultation.~Patients will answer to a scale of pain"
88893593|NCT03648021|Active Comparator|paracetamol (acetaminophen)|patient will receive1 gramme of paracetamol intravenously
88893594|NCT03648021|Placebo Comparator|Placebo|patient will receive 100 ml of chlorure de sodium 0,9% intravenously
88893595|NCT03646656|Experimental|peer partner|Veterans with at least one CVD risk factor who are interesting in increasing heart healthy behaviors through peer support
88893596|NCT03646656|Other|peer coach|Veterans with at least one CVD risk factor who have made and sustained changes in diet or exercise in the past 3-6 months prior to enrollment. While the investigators will collect data on peer coach participants, their participation is primarily as part of intervention to examine the feasibility and benefit of adding peer coaching to a peer partner intervention.
88893597|NCT03640845|Experimental|experimental group|Patient living in nursing homes a tele-expertise will be performed
88893598|NCT03640845|No Intervention|control group|Patient living in nursing homes will performed a normal care.
89199125|NCT00887133||1|Patients consulting Western Medicine outpatient clinics for a new episode of illness
89416297|NCT04977804|Active Comparator|Eccentric only training|This is the experimental control; where this group will be used as the standard active comparison condition.
89416298|NCT04977804|Experimental|Eccentric plus blood-flow restriction|This is the experimental condition involving the eccentric resistance training with blood flow restriction.
89416299|NCT04969939|Experimental|Semaglutide 2.4 mg and NNC0165-1875 2.0 mg|Participants will receive two doses of NNC0165-1875 as an add on to semaglutide s.c. 2.4 mg
89416300|NCT04969939|Placebo Comparator|Semaglutide 2.4 mg and placebo 2.0 mg(NNC0165-1875 2.0 mg)|Participants will receive placebo as an add on to semaglutide 2.4 mg.
89416301|NCT04969939|Experimental|Semaglutide 2.4 mg and NNC0165-1875 1.0 mg|Participants will receive two doses of NNC0165-1875 as an add on to semaglutide s.c. 2.4 mg
89416302|NCT04969939|Placebo Comparator|Semaglutide 2.4 mg and placebo 1.0 mg(NNC0165-1875 1.0 mg)|Participants will receive placebo as an add on to semaglutide 2.4 mg.
89416303|NCT04967664|Experimental|Qutenza (capsaicin) 8% topical system|Qutenza (capsaicin 8% topical system, containing capsaicin 179 mg or capsaicin 640 µg/cm2 of topical system)
89416304|NCT04967664|Active Comparator|Low-dose capsaicin control|capsaicin 0.04% topical system
89416305|NCT04949841|Experimental|As-needed treatment with delgocitinib|Subjects will be treated with delgocitinib cream 20 mg/g twice daily as needed.
89416306|NCT04947735|Experimental|CYPRESS Extension Test Arm|Single vision, impact resistant spectacle lenses; CYPRESS Test Arm 1 and CYPRESS Test Arm 2 will move into CYPRESS Extension Test Arm
89416307|NCT04947735|Placebo Comparator|CYPRESS Extension Control Arm|Single vision, impact resistant spectacle lenses; CYPRESS Control Arm remains in control lenses as the CYPRESS Extension Control Arm
89416308|NCT04937907|Experimental|Hydroxychloroquine Cohort|Patients in the cohort will receive Hydroxychloroquine(HCQ) throughout the study.Patients administered HCQ by oral at a dose of 6.5mg per kilogram twice a day for 6 months. During treatment with HCQ, patients also received enalapril(5-10mg qd).
89416309|NCT04937907|Sham Comparator|Comparator Cohort|During treatment with HCQ, Patients randomized to Comparator Cohort only received enalapril(5-10mg qd).
89416310|NCT04934475|Experimental|MRD Standard-risk patients (post induction MRD <10-5, MRD SR) (1:1 Randomization) : Arm A|"Arm A: consolidation with 6 additional cycles of Isa-KRD (cycles 7 to 12) 6 cycles of Isatuximab Carfilzomib Lenalidomide Dexamethasone (Isa-KRD) (28-day cycle):~Isatuximab: 10 mg/kg I.V. on days 1 and 15 (cycles 7 to 12)~Carfilzomib: 56 mg/m2 I.V on days 1, 8 and 15 (cycles 7 to 12)~Lenalidomide: 25 mg per day orally from days 1 to 21~Dexamethasone: 40 mg orally on day 1, 8, 15, 22"
88893599|NCT03613792|Active Comparator|Remifentanil and Ketamine Group|Patients in Group 1 will receive remifentanil and ketamine. Remifentanil will be administered initially with a 1mcg/kg IV bolus followed by a continuous infusion, 0.1 to 0.15 mcg/kg/min IV (using ideal body weight) with titration to a maximum dose of 0.2 to 0.4 mcg/kg/min IV. Total dose of ketamine will be titrated from 10 to 40 mg, based on clinical judgment, and it will be recorded. Ketamine will be delivered using 2mL syringes, previously filled with ketamine in normal saline at a 10mg/mL concentration.
88893600|NCT03613792|Active Comparator|Fentanyl and Midazolam|The patients in this group will receive fentanyl doses that range between 0.5 to 2 mcg/kg (25 - 50 mcg) IV bolus in combination with midazolam 1-5 mg bolus over at least 2 minutes as determined by attending anesthesiologist (not to exceed 2.5 mg / 2 min per package insert). Total dosing of fentanyl and midazolam may be titrated, based on clinical judgment, and it will be recorded. Maintenance, additional midazolam doses of 25% of total initial dose required to achieved desired sedation may be administered IV if additional sedation is considered necessary
89199126|NCT00546364|Experimental|Ixabepilone, 40 mg/m^2 + Capecitabine, 1000 mg/m^2|
89199127|NCT00546364|Experimental|Ixabepilone, 32 mg/m^2 + Capecitabine, 1000 mg/m^2|
89416311|NCT04934475|Experimental|MRD Standard-risk patients (post induction MRD <10-5, MRD SR) (1:1 Randomization): Arm B|"Arm B: consolidation with ASCT followed by 2 cycles of Isa-KRD (cycles 7 and 8) Melphalan 200 mg/m2 followed by autologous stem cell transplantation (please refer to section 6.3.2) 2 cycles of Isatuximab Carfilzomib Lenalidomide Dexamethasone (Isa-KRD) (28-day cycle):~Isatuximab: 10 mg/kg I.V. on days 1 and 15 (cycles 7 to 8)~Carfilzomib: 56 mg/m2 I.V on days on days 1, 8 and 15 (cycles 7 to 8)~Lenalidomide: 25 mg per day orally from days 1 to 21~Dexamethasone: 40 mg orally on days 1, 8, 15, 22"
89416312|NCT04934475|Experimental|MRD High-risk patients (post induction MRD >10-5, MRD HR) (1:1 Randomization): Arm C|"Arm C: ASCT followed by 2 cycles of Isa-KRD (cycles 7 and 8) Melphalan 200 mg/m2 followed by autologous stem cell transplantation. 2 cycles of Isatuximab Carfilzomib Lenalidomide Dexamethasone (Isa-KRD) (28-day cycle):~Isatuximab: 10 mg/kg I.V. on days 1 and 15 (cycles 7 to 8)~Carfilzomib: 56 mg/m2 I.V on days on days 1, 8 and 15 (cycle 7 to 8)~Lenalidomide: 25 mg per day orally from day 1 to day 21~Dexamethasone: 40 mg orally on days 1, 8, 15, 22"
89416313|NCT04934475|Experimental|MRD High-risk patients (post induction MRD >10-5, MRD HR) (1:1 Randomization): Arm D|tandem ASCT Melphalan 200 mg/m2 followed by autologous stem cell transplantation.
89416314|NCT04930003|Experimental|Experimental: Phase 1 Adult-vaccine (A Sample, blind study)|Group 1 (phase 1): 22 volunteers aged 18-50 years who will be the QazCoVac-P - COVID-19 twice spaced 21 days apart, intramuscularly, at a dose of 0.5 ml
89416315|NCT04930003|Placebo Comparator|Phase 1 Adult-Placebo (A Sample, blind study)|Group 2 (phase 1): 22 volunteers aged 18-50 years who will be the Placebo twice spaced 21 days apart, intramuscularly, at a dose of 0.5 ml
89416316|NCT04930003|Experimental|Phase 2 Adult-Vaccine, twice vaccination (An Open study)|Group 3 (phase 2): 50 volunteers aged 18-50 years who will be the QazCoVac-P - COVID-19 twice spaced 21 days apart, intramuscularly, at a dose of 0.5 ml
89416317|NCT04930003|Experimental|Phase 2 Elderly-Vaccine, twice vaccination (An Open study)|Group 4 (phase 2): 50 volunteers from 50 years old and elder who will be the QazCoVac-P - COVID-19 twice spaced 21 days apart, intramuscularly, at a dose of 0.5 ml
89416318|NCT04930003|Experimental|Phase 2 Adult-Vaccine, single vaccination (An Open study)|Group 5 (phase 2): 50 volunteers aged 18-50 years who will be the QazCoVac-P - COVID-19 single vaccination, intramuscularly, at a dose of 0.5 ml
89416319|NCT04930003|Experimental|Phase 2 Elderly-Vaccine, single vaccination (An Open study)|Group 6 (phase 2): 50 volunteers from 50 years old and elder who will be the QazCoVac-P - COVID-19 single vaccination, intramuscularly, at a dose of 0.5 ml
89416320|NCT04928235||All Participants|All participants will have thermal imaging of their lower extremities. The temperature values will be shared with the attending physician. The physician will be asked questions about their diagnostic confidence before and after seeing the temperature values.
89416321|NCT04904302|Experimental|Treatment (sitravatinib, nivolumab)|Patients receive sitravatinib PO QD and nivolumab IV over 30 minutes on day 1. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
89416322|NCT04901884|Experimental|One arm / exploratory study|Injection of 18F-FDG.The 18F-FDG cardiac PET-MR scanning visit will take up to 1.5 hours.
89416323|NCT04896385|Experimental|Ruxolitinib cream|Ruxolitinib cream will be administered twice a day (BID) for 24 weeks
88893601|NCT03594734|Experimental|GLB Weight-Loss Intervention|The GLB program, adapted for individuals with TBI, will be delivered to participants over a 12-month period, divided into 22 in-person or virtual, group sessions. The intervention promotes 5-7% weight-loss by reducing calories and increasing exercise (150 minutes of moderate physical activity per week).
88893602|NCT03594734|Active Comparator|Attention Control Group|The attention control group will meet at the same frequency as the GLB-TBI group over a 12-month period. The attention control group will receive education composed of the content from the TBI Model Systems Knowledge Translation Center's factsheets. No education on weight-loss strategies will be provided.
88893603|NCT03575598|Experimental|Sitravatinib and Nivolumab|"Patients will start therapy with sitravatinib within 10 days of study enrollment. Sitravatinib will be given at 120mg once daily on a continuous basis until 48 hours before planned surgery, or for a maximum period of 28 days.~Nivolumab will be given as a single infusion at a dose of 240mg, over a period of 30 minutes on Day 15 of the study."
89416324|NCT04896385|Placebo Comparator|Vehicle Cream|Vehicle cream is matching in appearance to ruxolitinib cream and is to be applied in the same manner as ruxolitinib cream.
89416325|NCT04895735|Experimental|Treatment (pembrolizumab, pemetrexed)|Patients receive pembrolizumab IV over 30 minutes and pemetrexed disodium IV over 10 minutes on day 1. Treatment with pembrolizumab repeats every 21 days for up to 35 cycles (2 years) in the absence of disease progression or unacceptable toxicity. Cycles of pemetrexed disodium repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients who had stable disease, partial response, or complete response after completion of 35 cycles of pembrolizumab, may continue pembrolizumab for an additional 17 cycles (1 year) in the absence of disease progression or unacceptable toxicity.
89416326|NCT04884724|Experimental|Adaptive Dance Exercise Group|"In addition to the routine physiotherapy programs received in the rehabilitation center for children and adolescents with cerebral palsy, an adaptive dance exercise program will be applied 2 days a week in the rehabilitation center for 5 weeks and online for 3 weeks in the presence of a physiotherapist. The duration of each session of the adaptive dance exercises to be applied is planned to be 45-60 minutes. It is planned that the adaptive dance exercises to be applied will be accompanied by the selected song.~Before and after the 8-week exercise program, the participants' trunk stabilization, balance, functional mobility and quality of life will be questioned with determined questionnaires and tests."
88893604|NCT03572166|Experimental|Arginine Infusion|Arginine Stimulation Test
88893605|NCT03572166|Active Comparator|Hypertonic saline infusion|Hypertonic Saline Infusion Test
88893606|NCT03570450|Experimental|Adipose derived Stem Cells - 1.10^6cells/kg|ADSC, single, IV, 1.10^6cells/kg
88893607|NCT03570450|Experimental|Adipose derived Stem Cells - 2.10^6cells/kg|ADSC, single, IV, 2.10^6cells/kg
88893608|NCT03570450|Experimental|Adipose derived Stem Cells - 2,5.10^6cells/kg|ADSC, single, IV, 2,5.10^6cells/kg
88893609|NCT03570450|Experimental|Adipose derived Stem Cells - 3.10^6cells/kg|ADSC, single, IV, 3.10^6cells/kg
88893610|NCT03570450|Placebo Comparator|placebo|Placebo
88893611|NCT03563417|Active Comparator|PCI|
88893612|NCT03563417|Other|OMT|
88893613|NCT03555435|Experimental|On Your Own|Participants in this group will use the online program on their own for 6 weeks.
88893614|NCT03555435|Experimental|Peer Support|Participants in this group will use the online program on their own for 6 weeks with the support of a peer coach. Peer coaching sessions will consist of 6 15-20 minute sessions one time per week. Sessions will be guided by a Moving Forward Peer Support Manual.
88893615|NCT03555435|Placebo Comparator|Wait|Participants in this group will wait 6 weeks.
88893616|NCT03551392|Active Comparator|NIR -Older Adult|Older adult participants receive the Medx Console System and the Vielight 810 intranasal stand alone unit. These interventions occur during 16 lab sessions (1.5 hours each) during an 12 week period, plus daily 25 minute 'at home' intranasal stimulation interventions, 4 days each week.
88893617|NCT03551392|Sham Comparator|No Dose NIR-Older Adult|Older adult participants receive the sham Medx Console System and the sham Vielight 810 intranasal stand alone unit, since the devices deliver no near infrared light. These sham interventions occur during 16 lab sessions (1.5 hours each) during an 12 week period, plus daily 25 minute 'at home' intranasal stimulation interventions, 4 days each week.
88893618|NCT03551392|Active Comparator|NIR -Parkinson|Participants with Parkinson disease receive the Medx Console System and the Vielight 810 intranasal stand alone unit. These interventions occur during 16 lab sessions (1.5 hours each) during an 12 week period, plus daily 25 minute 'at home' intranasal stimulation interventions, 4 days each week.
88893619|NCT03551392|Sham Comparator|No Dose NIR-Parkinson|Participants with Parkinson disease receive the sham Medx Console System and the sham Vielight 810 intranasal stand alone unit, since the devices deliver no near infrared light. These sham interventions occur during 16 lab sessions (1.5 hours each) during an 12 week period, plus daily 25 minute 'at home' intranasal stimulation interventions, 4 days each week.
88893620|NCT03540732|No Intervention|1. Control|"Standard physiotherapy~Empiric formula directed feeding (daily caloric requirement calculated by 25 kcal/kg/day)"
89416327|NCT04884724|No Intervention|Control Group|Children and adolescents diagnosed with Cerebral Palsy will continue their routine physiotherapy and rehabilitation programs in the rehabilitation center. At the beginning of the study and after 8 weeks, the participants' trunk stabilization, balance, functional mobility and quality of life will be questioned with determined questionnaires and tests.
89416328|NCT04879225|Experimental|E-liquid Availability|Flavor availability is manipulated
89416329|NCT04866303|Experimental|Active delivery|For the participants randomized to the active arm will have their home collection kit registered on their behalf by bilingual (Spanish and English) community health workers, who are trusted community members. Home testing kits augmented with study developed materials will direct participants to contact the study team for assistance.
89416330|NCT04866303|Experimental|Passive delivery|Participants randomized to the passive arm will receive a home test kit augmented with instructions on how to self-register their kit online, and will be directed to contact Everlywell for assistance, if needed.
89199128|NCT00546364|Active Comparator|Docetaxel, 75 mg/m^2 + Capecitabine, 1000 mg/m^2|
89199129|NCT00887211|Active Comparator|ProStent|implant ProStent drug-eluting stents
89416331|NCT04865939|Active Comparator|gemcitabine|intravesical instillation of gemcitabine (1 g in 50 mL saline) with dwell time of 1 - 3 hours
89416332|NCT04865939|Experimental|sterile water irrigation|intravesical continuous bladder irrigation with sterile water for 1 - 3 hours and a total instilled volume of approximately 4 - 16 liters
89416333|NCT04864899|Experimental|Recovered COVID-19 patients|
89416334|NCT04864899|Experimental|Recovered non-COVID-19 viral respiratory infections patients|
89416335|NCT04864899|Experimental|Age and gender matched controls|
89416336|NCT04860570||Open Appendectomy (OA) + Double-ring wound-edge protector (2RWEP)|Intervention group: Patients with diagnosis of acute appendicitis treated by open appendectomy using a double-ring wound-edge protector.
89416337|NCT04860570||Laparoscopic Appendectomy (LA)|Control group: Patients with diagnosis of acute appendicitis treated by laparoscopic appendectomy.
89416338|NCT04819737|Experimental|Spinal Cord MRI|
89199130|NCT00887211|Active Comparator|Firebird|implant Firebird drug-eluting stents
89199131|NCT00887367|Placebo Comparator|Placebo to match GSK598809|Placebo to match GSK598809.
89199132|NCT00887367|Placebo Comparator|Placebo to match ethanol infusion|Glucose solution to be given in the same way as ethanol.
89199133|NCT00887445|Experimental|A|
89199134|NCT00887445|Placebo Comparator|B|
89199135|NCT00964288|Other|Period 1|
89199136|NCT00964288|Other|Period 2|
89199137|NCT00964288|Other|Period 3|
89199138|NCT00964288|Other|Period 4|
88893621|NCT03540732|Active Comparator|2. Intervention|"Up to 60 minutes of cycle ergometry daily in addition to standard physiotherapy sessions.~Indirect calorimetry directed feeding (use of indirect calorimetry to calculate daily caloric requirement)"
88893622|NCT03521115|Experimental|Smart Choices 4 Teens|A web-based intervention consisting of 3 main components (Communication, Alcohol, Relationships) provided to both parents and teens was completed by parents and teens individually. At the end of each component, discussion guidelines were given to promote communications and to offer skill building practices between parent and teen regarding the component topic. Both the parent and teen were required to complete the component and discussion before moving to the next component. Numbers are provided for the number of families
88893623|NCT03521115|No Intervention|Control condition|This group was provided with websites where information was available regarding the same topics.
88893624|NCT03520413|Experimental|PRACTICE-DM|PRACTICE-DM is a comprehensive telemedicine intervention that bundles telemonitoring, self-management support, diet/activity support, medication management, and depression support - each of which targets a critical factor underlying PPDM - into a single, comprehensive program specifically developed for practical delivery using existing VHA Home Telehealth (HT) workforce, infrastructure, and technical resources.
89199139|NCT00964522|No Intervention|Standard care|The arm A is the one of standard education and care.
89199140|NCT00964522|Active Comparator|Nurse education and care program|The arm B will receive programmed education and care about the chemotherapy by a nurse of the Medical Oncology service before the beginning of the treatment and in each cycle, in a specific nurse consultation.
88893625|NCT03520413|Active Comparator|Standard VA Home Telehealth|Standard VA HT care coordination and telemonitoring.
88893626|NCT03457415||Healthy Cohort|Healthy Cohort: current non-smoker who has smoked less than 5 pack-years in his or her lifetime, and if smoked, quit more than 15 years ago, and has no known lung disease.
88893627|NCT03457415||High-risk Cohort|High-risk Cohort: individual aged ≥55-74 who is a current smoker with a smoking history of at least 30 pack-years or current non-smoker who has a smoking history of at least 30 pack-years and quit smoking within the past 15 years.
88893628|NCT03457415||Cancer Cohort|Cancer Cohort: individual who has been diagnosed by a physician as highly suspect for having lung cancer, but has not yet undergone a biopsy nor received therapy, and after providing a sputum sample is confirmed to have lung cancer by biopsy.
88893629|NCT03447509|Active Comparator|Experiment 1a|Examine physiological mechanisms contributing to the control of precision and power grip behaviors. To accomplish this aim the investigators propose to complete one main experiment. The investigators will test the hypotheses that there are two fundamentally distinct modes of hand operation after SCI. One involves brainstem pathways, and permits whole-hand 'power grip', while the other involves corticospinal and motor cortical connections, and allows a wide range of fractionated finger movements (precision grip) after SCI. Measurements of corticospinal, reticulospinal, and motoneuron excitability will be tested during index finger abduction, precision and power grip.
88893630|NCT03447509|Active Comparator|Experiment 1b|To accomplish this aim the investigators propose to complete one main experiment. The investigators will use iTMS and/or an acoustic startle stimuli to test the hypothesis that induced-plasticity protocols (iTMS and startle stimuli) will enhance EMG and force output in hand muscles during grasping. In a randomized sham crossover design, SCI and controls will be assigned to two groups: (1) iTMS applied during precision and power grip (two randomized sessions), and (2) startle applied during precision and power grip (two randomized sessions).
88893631|NCT03447509|Active Comparator|Experiment 2|To accomplish this aim the investigators propose to complete one main experiment. The investigators will combine iTMS and/or acoustic startle with precision and power grip training to test the hypothesis that 'precision and power grip training outcomes will be enhanced by iTMS and startle induced plasticity'. In a randomized sham controlled design, SCI and control subjects will be assigned to: training+iTMS and training+sham iTMS and training+startle and training+sham startle.
88893634|NCT03423667|Experimental|N-acetylcysteine|
88893635|NCT03423667|Placebo Comparator|Lactose powder|
88893636|NCT03419897|Experimental|Tislelizumab|200 milligrams once every 3 weeks
88893637|NCT03418129|Experimental|Mobile App Mindfulness|Participants engage in the use of a mobile application on an iPod Touch for a minimum of 10 minutes a day, 4 days a week for a total of 12 weeks.
88893638|NCT03418129|Experimental|Mobile App Neurofeedback|Participants engage in use of a mobile application on an iPod Touch for a minimum of 10 minutes a day, 4 days a week for a total of 12 weeks.
88893639|NCT03418129|Experimental|Mobile App Relaxation|Participants engage in use of a mobile application on an iPod Touch for a minimum of 10 minutes a day, 4 days a week for a total of 12 weeks.
88893640|NCT03411239|Other|Interventional arm|Patients recruited will have OBC inserted under general anaesthesia and various pressure measured
88893641|NCT03378531|Experimental|AEB1102|Each patient may receive AEB1102 administered IV for up to approximately 4 years.
89199141|NCT05955001|Experimental|Tadalafil 5 mg daily after AEEP|those patients will receive Tadalafil 5 mg daily after AEEP
88922142|NCT05744921|Experimental|PNH Transition Patients|Patients with PNH who completed treatment/ protocol requirements (as applicable) in the parent study (R3918-PNH-2021 [NCT05133531]) Note: Dose of pozelimab may be administered intravenously [IV] as needed or as warranted in some circumstances and with sponsor approval for patients who experience breakthrough hemolysis, an increase in lactate dehydrogenase (LDH), a type III hypersensitivity reaction, or reintroduction of study treatment after a period of treatment interruption.
88922143|NCT05744921|Experimental|C5 Polymorphism Patients|Patients who have not been treated in either parent study but who have a documented complement component 5 (C5) variation rendering them refractory to eculizumab/ravulizumab. Note: Loading dose of pozelimab administered IV on Day 1.
89193137|NCT05495230|Experimental|Person-centred integrated care intervention|The core of the person-centered and holistic approach is a cyclical process. The practice nurse in the general practice will act as case manager and can consult the general practitioner or other health providers when necessary. The first step in the intervention is assessing the integral health status of the patient (health across multiple domains, including physiological measurements and symptoms of disease), using a (preferably digital) questionnaire at home and physical measurements. The second step is discussing the results with the patient in a semi-structured way. Personal goals are formulated in the third step. In the fourth step, the healthcare professional and patient will choose through shared-decision making the most appropriate interventions and support to achieve these goals, which are documented in a personal healthcare plan. Next, referrals are made if necessary and the treatment is started. An evaluation is planned and carried out, if necessary multiple times.
89193138|NCT05490290|Active Comparator|Active|In the active intervention the CDSS is implemented with decision support. Physicians are made aware of the referral guidelines and appropriate exams are suggested. Their imaging requests are categorized as appropriate, under certain conditions appropriate, or inappropriate and feedback is provided. Physicians are able to change their request in response to the feedback.
89193139|NCT05490290|No Intervention|Control|The control condition will consist of computerized order entry with structured data entry of the clinical indication and tracking of the imaging exams requested. The CDSS is implemented but without decision support and physicians are blinded to these referral guidelines. Without their knowledge their imaging requests are categorized as appropriate, under certain conditions appropriate, or inappropriate. They receive no feedback to their requests.
89193140|NCT05488808|Active Comparator|Active and then sham rTMS|Deep rTMS is delivered with the Brainsway H7-coil (Brainsway, Jerusalem, Israel) applied via a helmet placed on the head targeting the primary motor cortex of the arm.
89193141|NCT05488808|Sham Comparator|Sham and the active rTMS|Sham stimulation is delivered with a sham coil placed in the helmet encasing the active rTMS coil. Sham rTMS sessions will use exactly the same parameters of stimulation as active rTMS.
89193142|NCT05488054|Experimental|Healthy Individuals|Healthy control patients with no history of knee or hip surgery for comparison of baseline values
89193143|NCT05488054|Experimental|Surgical Patients|Patients who have undergone arthroscopic ACL surgery or arthroscopic hip surgery and are undergoing physical therapy for return to sport
89193144|NCT05485584|Experimental|Healthy subjects(A1)|Each nostril: 2 sprays/time; Pharynx: 4 sprays/time; Once daily
89416339|NCT04805190|Experimental|Pain Catastrophizing Reduction Group|This group will be assigned to a 30-minute, single-session cognitive-behavioral intervention designed to reduce pain catastrophizing.
89193145|NCT05485584|Placebo Comparator|Healthy subjects(A2)|Each nostril: 2 sprays/time; Pharynx: 4 sprays/time; Once daily
89193146|NCT05485584|Experimental|COVID-19 subjects(B1)|Each nostril: 2 sprays/time; Pharynx: 4 sprays/time; Twice daily
89193147|NCT05485584|Placebo Comparator|COVID-19 subjects(B2)|Each nostril: 2 sprays/time; Pharynx: 4 sprays/time; Twice daily
89193148|NCT05482048|No Intervention|Usual Care|In line with current guidelines [4], participants will continue chest physiotherapy as advised by their physiotherapist (at least one session of ACT/day) and continue to undertake exercise and physical activity at their usual levels.
89193149|NCT05482048|Experimental|Exercise as Airway Clearance Therapy (ExACT)|"Arm-2 (ExACT): Participants will be advised to replace routine chest physiotherapy sessions with exercise combined with coughs and huffs - also referred to as forced expiratory techniques (FET) - agreed in our e-Delphi exercise REF and wider PPI discussion as possible alternatives for airway clearance. This intervention we term ExACT*.~The undertaking of ExACT at least once per day is expected of those randomised to Arm 2.~*Although routine chest physiotherapy is being replaced by ExACT, chest physiotherapy is permissible in the event of a chest exacerbation and a protocol deviation will be recorded."
89193150|NCT05477784|Experimental|Group I (enhancing connections-palliative care program)|Patients receive the 5-session EC-PC program bi-weekly with a patient educator about ways to help them talk to and support their child.
89193151|NCT05477784|Active Comparator|Group II (educational material)|Patients receive carefully selected educational booklet that discuss ways to talk about their cancer with their child and a scripted phone call from a trained phone counselor on study.
89193152|NCT05477199|Experimental|Cognitive behavioral principles-based treatment program group|
89193153|NCT05477199|Active Comparator|Control group|
89193154|NCT05468372|Active Comparator|Amphotericin B arm (standard of care)|Intravenous liposomal amphotericin B [5 mg/kg per day] for at least 4 weeks followed by maintenance therapy. Maintenance therapy (after four weeks of treatment initiation) will be continued for at least 12 weeks or longer as decided by the treating physician. The maintenance therapy will be posaconazole. However, if therapeutic drug monitoring is not possible or the participants opt to use isavuconazole or amphotericin, the same will be permitted and noted
89193155|NCT05468372|Experimental|Posaconazole arm|Combination of liposomal amphotericin B (5 mg/kg per day) and posaconazole for first 7 days followed by oral posaconazole only (for induction as well as maintenance therapy). The first four weeks of therapy will be called induction therapy
89199142|NCT05955001|No Intervention|Control group with no Tadalafil|Those patients will not receive Tadalafil after surgery
89416340|NCT04805190|Active Comparator|Pain Education Group|This group will receive general information about the neurobiology of pain and knee OA.
89416341|NCT04766749|Experimental|Experimental|40 minutes before PCI by the nurse to the patient RIPC operation (RIPC is delivered with a standard blood pressure cuff placed on the upper thigh. The cuffs are inflated to 200 mm Hg and keep inflated for 5 minutes,Then deflated to 0 mmHg and keep uninflated for 5 minutes, This cycle is repeated four times), and then do regular PCI operation
89416342|NCT04766749|No Intervention|Control|A standard cuff is placed on the patient's thigh by the nurse 40 minutes before PCI but it is not inflated. PCI is performed 40 minutes later
89416343|NCT04761458|Experimental|Patients scheduled for elective surgery aged 65 and +|
89416344|NCT04757155|Experimental|iCALM Intervention Group|iCALM is a brief, online psychotherapeutic intervention for patients with advanced and metastatic cancer. It consists of one introductory module and four therapeutic modules composed of written psychoeducational material, videos, and exercises. The intervention is designed to be completed in 9 weeks.
89416345|NCT04757155|No Intervention|Care as usual|Participants in the usual care group (UC) will receive routine care. At Princess Margaret Cancer Centre, routine care includes a referral to Psychiatry, Psychology, or Social Work, based on patients' needs.
89416346|NCT04746833|Experimental|SUMMIT|Participants randomized to the experimental intervention will participate in a Motivational Interviewing (MI) session lasting between 30 and 60 minutes with study psychologist. All MI sessions will be audiotaped using a VA-approved digital recorder and transcribed verbatim. Participants will subsequently be shown how to access SUMMIT via a set of unique anonymized login credentials and to navigate the components of SUMMIT on one or more devices, depending on their preference. They will then be trained on how to complete the outcome surveys.
89416347|NCT04746833|Placebo Comparator|control|Participants randomized to the control intervention will use an eHealth comparator: My Pain Diary: Chronic Pain Management (iPhone, Android). This app includes a pain monitoring functioning only, and thus will only minimally overlap, if at all, with SUMMIT's components. Control participants will not participate in a MI session. Participants will download the app and be shown how to use the My Pain Diary app and trained how to complete the outcome surveys
89416348|NCT04745949|Experimental|Treatment (brentuximab vedotin, nivolumab, R-CHP)|Patient will receive an immune lead-in of 2 cycles of Brentuximab vedotin and Nivolumab (A-O) (cycles 1 and 2), which has an appropriate futility rules in place to close early if efficacy targets are not met. At cycle 3 and 4, patients will receive A-O with R-CHP. Patients who will have achieved complete response (CR) at PET/CT before cycle 5 will receive 2 more cycles of A-O-R-CHP (cycle 5 and 6) and A-O only for cycle 7 and 8. If these patients still present CR at PET/CT after cycle 8, they will have completed therapy and will be followed up. In case of stable disease or progressive disease at PET/CT after cycle 4, the patient will be taken off the trial. Patients who present further response but no CR, at PET/CT before cycle 5 will receive 4 more cycles A-O-R-CHP (cycles 5-8). If they reach CR at PET/CT after cycle 8, they will have completed therapy and will be followed up. All patients will receive a total of 8 cycles of A-O. The cycle duration is 21 days.
89416349|NCT04721613||Hypoactive ICU delirium|
89416350|NCT04721613||Hyperactive or mixed ICU delirium|
89416351|NCT04721613||Critically ill patients not suffering form ICU delirium|
89416352|NCT04705935||Term pregnant women without labor contractions or rupture of membranes|Term pregnant women > 37 weeks gestation with a normal pregnancy. One blood sample before a scheduled caesarean section.
89416353|NCT04705935||Term pregnant women with labor contractions|Term pregnant women > 37 weeks gestation with a normal pregnancy. One blood sample when labor contractions, but before spontaneous rupture of membranes.
89416354|NCT04705935||Term pregnant women with spontaneous rupture of membranes|Term pregnant women > 37 weeks gestation with a normal pregnancy. One blood sample after spontaneous rupture of membranes, but without labor contractions.
89416355|NCT04705935||Preterm labor contractions (PLC)|One blood sample when labor contractions before 34 weeks gestation without rupture of membranes.
89416356|NCT04705935||Preterm Prelabor Rupture of the Fetal Membranes (PPROM)|One blood sample when rupture of the fetal membranes before 34 weeks gestation without labor contractions.
89416357|NCT04705935||Control group|Women with normal pregnancies. One blood sample in gestation week 25+0 to 37 matched as controls for PLC and PPROM cases.
88893642|NCT03377049|Experimental|Acetazolamide Challenge|Participants entered into the study as a cohort, will because of their participation, undergo only two additional digital subtraction angiogram (DSA) imaging acquisitions. These will be done in conjunction with their standard diagnostic DSA evaluation and consist of two CBCTPs, one before and one after administration of 1 g acetazolamide through a peripheral IV line. Each CBCTP will require administration of 75-100 mL iodinated contrast medium also through an intravenous line. Neither of these imaging studies will be used for clinical decision making, but would be processed and evaluated at later date for a formal analysis of the results. Following completion of diagnostic imaging subjects will receive the usual standard of care for treatment of their ruptured aneurysm i.e. endovascular embolization or open surgical clipping.
88893643|NCT03355976|Experimental|Arm 1 Nivolumab Ovarian|Nivolumab 240 mg Day 1 Cycle = 2 weeks
88893644|NCT03355976|Experimental|Arm 2 Nivolumab and Ipilimumab Ovarian|Nivolumab 240 mg every 2 weeks Ipilimumab 1mg/kg day 1 Cycle=6 weeks
88893645|NCT03355976|Experimental|Arm 1 Nivolumab Extra-renal|Nivolumab 240 mg Day 1 Cycle = 2 weeks
88893646|NCT03355976|Experimental|Arm 2 Nivolumab and Ipilimumab Extra-renal|Nivolumab 240 mg every 2 weeks Ipilimumab 1mg/kg day 1 Cycle=6 weeks
88893647|NCT03345563|Experimental|Body Mind Training (BMT)|Body mind training
89193156|NCT05468281||Before Period|The before period (12 months) serves as the control period prior to implementation; data will be collected by health records review.
89193157|NCT05468281||After Period|The after period (12 months) will be when patients are prospectively enrolled, and outcomes assessed.
89416358|NCT04705935||Longitudinal cohort during pregnancy|Women with normal pregnancies, where blood samples will be collected at week 12, 20, 28, 34 and 36, as well as at labor.
88893648|NCT03345563|Active Comparator|Body Training (BT)|Body training only
88893649|NCT03345563|Other|Usual care (UC):|Control
88922144|NCT05743062|Experimental|Virtual Reality|Virtual reality intervention will be given 6 times in total and each session will last not more than 60 seconds.
89193158|NCT05466071||TAF group|Patients who take TAF during pregnancy.
89193159|NCT05466071||TDF group|Patients who take TDF during pregnancy.
89416359|NCT04705935||Longitudinal cohort post partum|Women with normal pregnancies, where blood samples will be collected at labor, as well as 2 days, and 4, 8 and 12 weeks after birth.
89416360|NCT04700111|Experimental|Treatment 1 - DOT Pattern|Spectacle lens or treatment 1
89416361|NCT04700111|Active Comparator|Treatment 2 - Control Spectacles|Comparator lens or control arm
89416362|NCT04693793|No Intervention|Control|These providers will complete two rounds of three simulated patient cases (CPVs). Control arm physicians will continue to have access to standard of care diagnostic tools, but not the Janssen test results.
89416363|NCT04693793|Experimental|Educational Materials and Janssen Test Results (Intervention 1)|Participants will care for the same set of CPV patients as the control arm, but will be educated on and will receive the Janssen test results whether they select it or not. Investigators will compare intervention participants' clinical recommendations to those in the control arm.
89416364|NCT04693793|Experimental|Educational Materials and Janssen Test Results when Selected (Intervention 2)|Participants will care for the same set of CPV patients as the control arm, but will be educated on and will receive the Janssen test results only if they select it. Investigators will compare intervention participants' clinical recommendations to those in the control arm.
88893650|NCT03344796|No Intervention|Focus Group|"32 subjects~Focus group: It is expected that each participant will provide comments during the 2 hours of the focus group. It will take about one month to enroll the subjects. The audio files should be transcribed and the analysis completed in 60 days. The analysis will determine enablers and barriers to sun protected outdoor activities and determine strategies for achieving sun protected outdoor activities. Baseline knowledge of sun protection performed prior to and at end of focus group."
88893651|NCT03344796|No Intervention|Usability testing|"10 subjects~Usability test with structured interview: Each participant will use the sensor for 14 days and transmit data with the app installed on their mobile phone. It will take about one month to enroll the subjects. The analysis of the structured interview is completed in one week. Baseline knowledge of sun protection performed prior to and at end of usability test."
88893652|NCT03344796|Active Comparator|Cohort Study 1-Arm 1|"31 subjects~First cohort study: It is expected that melanoma survivors will wear the sensor and transmit data for 21 days in the warm weather months of June-Aug 2019. It will take about 2 months to enroll the subjects. Subjects will receive daily text messages in a sequence starting with behavioral facilitation, outcome expectancies, self-efficacy, and self-regulation. On day 10, participants will receive a text message prompting review and reflection on the prior 10 days of UV exposure. Participants will be randomized in Arm 1 to receive a survey item inviting selection of strategies to achieve sun-protected outdoor activities (structured goal attainment). Baseline knowledge of sun protection performed prior to and at end of intervention."
88893653|NCT03344796|No Intervention|Structured Interviews|20 young adults, ages 18-39 will participate in structured interviews to determine their barriers and enablers of sun exposure and sun protection. Eligible subjects will have at least one hour a day outdoors with 30 minutes of the hour being consecutive. It will take about 3 months to enroll the subjects. The audio files will be transcribed and analysis completed in 60 days. Baseline knowledge of sun protection will be performed prior to and after structured interviews.
88893654|NCT03344796|No Intervention|Cohort Study 2|Second cohort study: 42 young adult participants will recall the number of sunburns experienced in the 28 days prior to enrolling in the study. Then, the same young adult participants will wear the UV sensor daily for 28 summer days. Participants will receive a warning on their mobile phone if the UV dose approaches the dose anticipated to cause sunburn in unprotected skin. Participants will record the number of days in which they get a sunburn. Baseline knowledge of sun protection performed prior to and at end of study.
88893655|NCT03344796|Active Comparator|Cohort Study 1- Arm 2|29 subjects will receive daily text messages in a sequence starting with behavioral facilitation, outcome expectancies, self-efficacy, and self-regulation. On day 10, participants will receive a text message prompting review and reflection on the prior 10 days of UV exposure. Participants will be randomized in Arm 2 to submit a free text description of their strategy (unstructured goal attainment). Baseline knowledge of sun protection performed prior to and at end of intervention.
88893656|NCT03335488|Experimental|RAVICTI -> RAVICTI|Initial Treatment, Maintenance, Safety Extension Periods: RAVICTI, Oral Liquid Product 17.5 mL maximum total daily dose. Dosing will be based on participants disease and treatment status at entry to the study.
88893657|NCT03335488|Active Comparator|NaPBA -> RAVICTI|"Initial Treatment Period: NaPBA dosing based on participants disease and treatment status at entry to the study.~Transition, Maintenance, Safety Extension Periods: RAVICTI, Oral Liquid Product 17.5 mL maximum total daily dose. Dosing will be based on participants disease and treatment status at entry to the study."
88893658|NCT03324802|Experimental|Arm 2 (hypofractionated radiation therapy, 5 fractions)|Within 12 weeks of breast cancer surgery or adjuvant chemotherapy, patients undergo hypofractionated radiation therapy in 5 daily fractions for 5 days.
88893659|NCT03324802|Experimental|Arm I (radiation therapy, 15 fractions)|Within 12 weeks of breast cancer surgery or adjuvant chemotherapy, patients undergo standard radiation therapy in 15 daily fractions for 10 days.
88893660|NCT03323437|Experimental|Patient|Medication-free individuals during first-episode of psychosis who will receive 4 weeks of treatment with risperidone
88893661|NCT03323437|No Intervention|Control|Healthy, psychosis-free controls who will not receive risperidone
88922145|NCT05743062|Other|Control|Participants will serve as their own controls. Participants will not be given any VR intervention at first but they are requested to fill out the survey to collect the baseline data.
88922146|NCT05741229|Active Comparator|Group I (nebulized nitroglycerine)|Patients with persistent pulmonary hypertension (PPHN) and will receive nebulized nitroglycerine as an adjuvant therapy for PPHN
88922147|NCT05741229|Placebo Comparator|Group II (conentional treatment group)|Patients with PPHN and will be treated with conventional regimen for PPHN
89416365|NCT04681625|Active Comparator|Standard silodosin treatment|Peroral treatment with silodosin at a dose of 8 mg daily
89416366|NCT04681625|Experimental|Standard silodosin treatment with PFMT|Peroral treatment with silodosin at a dose of 8 mg daily Intervention: Behavioural: Pelvic floor muscle training (PFMT) with suppressive urgency technique
89416367|NCT04675320||First-line epithelial ovarian cancer (30 patients)|Maintenance treatment of adult patients with newly diagnosed advanced epithelial ovarian, fallopian tube or primary peritoneal cancer (FIGO stages III and IV) with or without BRCA1/2 mutation who have had a partial or complete response to first-line platinum-based chemotherapy.
89416368|NCT04675320||Recurrent epithelial ovarian cancer (20 patients)|Single-agent maintenance treatment of adult patients with primary, recurrent, platinum-sensitive epithelial ovarian, fallopian tube or peritoneal cancer who have responded (completely or partially) to platinum-based chemotherapy.
89416369|NCT04654013|Experimental|Intervention|Workers assigned to the intervention group will receive free spectacles of a design they select, based on the worker's measured refractive power and dispensed one week later at the factory by the study ophthalmic personnel.
89416370|NCT04654013|No Intervention|Control|Workers assigned to the Control group will receive similar free glasses at the end of the study assessment (18 months).
89416371|NCT04650438|Experimental|High-creativity|Here participants are allocated to the high-creativity group. Resting state EEG will be measured pre- and post-TMS and participants' creative performance will be measured by means of a creativity test battery.
89416372|NCT04650438|Experimental|Low-creativity|Here participants are allocated to the low-creativity group. Resting state EEG will be measured pre- and post-TMS and participants' creative performance will be measured by means of a creativity test battery.
89416373|NCT04646902||HTN_OSA|"Patients with hypertension* with obstructive sleep apnea**~* Hypertension will be defined as: i) use of antihypertensive drug(s) and stable dose for at least 2 weeks prior to inclusion; or ii) in untreated patients: office systolic blood pressure values >= 140 mmHg and/ or diastolic blood pressure values >= 90 mmHg.~** OSA will be defined with a polysomnography level 1, 2 or 3 performed within the previous twelve months with:~an apnea-hypopnea index > 5 events per hour (with more than 50% of obstructive events) associated with symptoms (associated sleepiness, fatigue, insomnia, snoring, subjective nocturnal respiratory disturbance or observed apnea) or medical/psychiatric disorder (hypertension, coronary artery disease, atrial fibrillation, congestive heart failure, stroke, diabetes, cognitive dysfunction, or mood disorder), OR~an apnea-hypopnea index > 15 events per hour, AND~no significant changes in health, medications, or lifestyle since the polysomnography."
88893662|NCT03310684||Hypertensive|Clinical data will be collected from the electronic medical record, including height, weight, age, sex, parent-reported race, and past medical and family histories. Antihypertensive medication type and dosage will be recorded. Blood and urine samples will be collected at baseline and yearly for three years. All subjects will receive baseline and yearly echocardiograms. Subjects with overweight/obesity (BMI >=85th percentile for age and sex) will receive baseline and yearly ultrasounds of the liver to evaluate for hepatic fat infiltration. Auscultated, continuous and ambulatory blood pressure will be measured at baseline and yearly.
88893663|NCT03310684||Normotensive with Obesity|"Clinical data will be collected from the electronic medical record, including height, weight, age, sex, parent-reported race, and past medical and family histories. Subjects will receive a baseline ultrasound of the liver to evaluate hepatic fat infiltration as per standard of care.~Blood and urine will be collected at baseline to measure liver function (AST, ALT) and uric acid, angiotensin ll, and angiotensin-(1-7)."
88893664|NCT03310684||Healthy Normotensive|Clinical data will be collected from the electronic medical record, including height, weight, age, sex, parent-reported race, and past medical and family histories. Subjects will have baseline echocardiograms. Blood pressure will be measured at baseline and at one year. Continuous blood pressure and ambulatory blood pressure monitoring will be assessed at baseline. Blood and urine samples will be used to measure uric acid, FGF23, klotho, and albumin, as well as the predictors angiotensin ll and angiotensin-(1-7).
88893665|NCT03306355|Experimental|IOL implantation experimental|hydrophobic, trifocal intraocular lens POD F GF
88893666|NCT03306355|Active Comparator|IOL implantation active comparator|hydrophilic, trifocal intraocular lens POD F
88893667|NCT03300141|Active Comparator|Healthy|Healthy participants will participate in reaching activity using the Looking Glass and Leap motion tracking system
88893668|NCT03300141|Experimental|Chronic Veridical Visual Feedback|Reaching while sitting at the Looking Glass system. The representation of arm movements will directly reflect the participants actual arm movements.
88893669|NCT03300141|Experimental|Chronic Augmented Visual Feedback|Reaching while sitting at the Looking Glass system. The representation of a participant's arm movements will be augmented to encourage different movement patterns and improved movement.
88893670|NCT03300141|Experimental|Acute Veridical Visual Feedback|Reaching while sitting at the Looking Glass system. The representation of arm movements will directly reflect the participants actual arm movements.
88893671|NCT03300141|Experimental|Acute Augmented Visual Feedback|Reaching while sitting at the Looking Glass system. The representation of a participant's arm movements will be augmented to encourage different movement patterns and improved movement.
88893672|NCT03298633|Active Comparator|Intracytoplasmic Sperm Injection|On the day of oocyte retrieval, qualified participants will be randomized into either of two groups. Participants in group A will undergone Intracytoplasmic Sperm Injection (ICSI) procedure, other standard assisted reproductive treatments are similar and parallel between two groups.
88893673|NCT03298633|Active Comparator|Conventional IVF|On the day of oocyte retrieval, qualified participants will be randomized into either of two groups. Participants in this group will undergone Conventional In Vitro Fertilization (IVF) procedure, other standard assisted reproductive treatments are similar and parallel between two groups.
88893674|NCT03273972|Experimental|Alirocumab Treatment Arm|V2: Day 1 - Alirocumab 150mg (subcutaneous injection) V3: Day 15 +/- 3 days - Alirocumab 150mg (subcutaneous injection) plus Atorvastatin 20mg (oral) approx. 14 days prescription.
89199143|NCT05954975||Infants up to 6 months of age|Infants up to six months of age, presenting with systemic illness at the emergency GP post.
89416374|NCT04646902||HTN_NoOSA|Patients with hypertension without obstructive sleep apnea
89416375|NCT04646902||NoHTN_OSA|Patients without hypertension with obstructive sleep apnea
89416376|NCT04646902||NoHTN_NoOSA|Patients without hypertension without obstructive sleep apnea (healthy controls)
89416377|NCT04643002|Active Comparator|Control Arm: isatuximab + pomalidomide + dexamethasone (Substudy 01)|"Isatuximab, intravenous (IV) doseweekly (QW) × 4 weeks (Cycle 1), followed by every two weeks (Q2W) (subsequent cycles).~Pomalidomide dose by mouth daily Day 1 to Day 21.~Dexamethasone dose by mouth QW."
89530764|NCT02514005|Active Comparator|Manual therapy|Overall bilateral manipulation (L5-S1-SI), Hip joint gapping, Stretching the hip rotators with hip and knee flexion, Femorotibial Gapping, Decompression of connective tissue of the patellofemoral region, Internal and external joint line opening in laterality, Mobilization of the base of the fibula, Tibiofibular-talus gapping, and Muscle strengthening.
89530765|NCT02514005|Experimental|Manual therapy and Dry needling|Dry needling is performed in the MTrPs of the vastus lateralis and vastus medialis muscles of the quadriceps.
88893675|NCT03273972|Other|Comparator Treatment Arm|V2: Day 1 - Placebo (subcutaneous injection) V3: Day 15 +/- 3 days - Placebo (subcutaneous injection) plus Atorvastatin 20mg (oral) approx. 14 days prescription.
88893676|NCT03268200|Experimental|Case group|Each segment of colon (right colon, mid-colon, and left colon) was examined twice
88893677|NCT03268200|No Intervention|Control group|Withdrawal time in the each segment of colon (right colon, mid-colon, and left colon) was about 2 minutes.
88893678|NCT03261700|Experimental|RISE|This provider- administered brief- counseling intervention program will increase Women Veteran?s self- efficacy in addressing violence in their current or past relationships. The variable length (up to six- session) modular-based intervention aims at providing resources for WVs in the relevant domains of: 1) safety planning, 2) education on health effects of IPV, 3) improving coping and self- care and red flags, 4) enhancing social support, 5) making difficult decisions, and 5) connecting with resources.
88893679|NCT03261700|Active Comparator|Information and referral condition|This brochure-based intervention includes education about IPV, health effects of IPV, resources and referral options to address a wide-array of health and social issues associated with IPV, and safety planning. Participants randomized to this arm are offered resources and referrals to VA and community resources.
88893680|NCT03244072|Active Comparator|Treatment group|Intracameral injection of moxifloxacin solution after cataract surgery
88893681|NCT03244072|Placebo Comparator|Placebo group|Intracameral injection of placebo after cataract surgery
88893682|NCT03238417|Experimental|Evidence-Based Quality Improvement (EBQI)|EBQI represents a multilevel stakeholder engaged top-down/bottom-up research-clinical partnership approach to systematically improving the design and implementation of local innovations adapted to local contexts. The EBQI contractor will (1) convene facility-level stakeholder meetings, (2) facilitate local facility-level QI team design meetings, (3) provide external practice facilitation through within and across facility QI collaboration calls, (4) provide formative QI data feedback and (5) provide QI training/education to local teams.
88893683|NCT03238417|No Intervention|Waitlist Controls|Waitlist controls will continue naturalistic routine care implementation of VHA directives and other guidance related to comprehensive women's health care.
88893685|NCT03219047|Experimental|Cohort 2 (Co-trial cohort)|Patients receive ibrutinib at standard dose and schedule through an ongoing MD Anderson clinical trial. Patients that respond to ibrutinib but experience relapse or disease progression receive treatment based on the results of the PDX models as in Cohort 1 if they are available. Patients who experience relapse after treatment with ibrutinib are moved to Cohort I if the PDX models are not ready.
88893686|NCT03219047|Experimental|Cohort I (Traditional cohort)|Patients who have previously received ibrutinib, acalabrutinib, PI3K inhibitor ACP-319, or BTK inhibitor BGB-3111 receive treatment through ongoing clinical trials at MD Anderson or standard of care. At the same time, previously collected tissue is used to develop PDX models and suitable drugs/regimens are tested in the PDX models. Patients then receive treatment based on the results of the PDX models through another clinical trial or standard of care.
88893687|NCT03215277|Experimental|Bimekizumab|Subjects will receive several bimekizumab administrations on pre-defined time points. Placebo will be provided in this arm to mask the certolizumab pegol loading dose.
88893688|NCT03215277|Experimental|Certolizumab pegol|Subjects will receive several certolizumab pegol administrations on pre-defined time points.
88893689|NCT03200340|Placebo Comparator|[Part 1] Placebo|Matching placebo
88893690|NCT03200340|Experimental|[Part 1] EC-18 500 mg|1 capsule of EC-18
88893691|NCT03200340|Experimental|[Part 1] EC-18 1000 mg|2 capsules of EC-18 500 mg
88893692|NCT03200340|Experimental|[Part 1] EC-18 2000 mg|4 capsules of EC-18 500 mg
88893693|NCT03200340|Placebo Comparator|[Part 2] Placebo|Placebo 2000mg
88893694|NCT03200340|Experimental|[Part 2] EC-18 2000mg|RP2D: EC-18 2000mg (Part 1 result)
88893695|NCT03185013|Experimental|VGX-3100 + EP|Participants received three IM injections of 6 milligram (mg) (in 1 milliliter [mL]) VGX-3100 followed by EP using the CELLECTRA™-5PSP device on Day 0, Week 4, and Week 12.
88893696|NCT03185013|Placebo Comparator|Placebo + EP|Participants received three IM injections of 1 mL VGX-3100 matching placebo followed by EP using the CELLECTRA™-5PSP device on Day 0, Week 4, and Week 12.
88893697|NCT03182907|Experimental|Bezlotoxumab|Participants receive 10 mg of bezlotoxumab per kg body weight via a single 60-minute (±10 minutes) intravenous (IV) infusion on Day 1. Additionally, participants receive background antibacterial drug treatment (ABD) for 10-21 days per institutional guidelines, at the investigator's discretion. Dose may then be changed based on results from initial 12 participants.
88893698|NCT03182907|Placebo Comparator|Placebo|Participants receive placebo for bezlotoxumab consisting of either 0.9% sodium chloride or 5% dextrose via a single 60-minute (±10 minutes) IV infusion on Day 1. Additionally, participants receive background ABD for 10-21 days per institutional guidelines, at the investigator's discretion.
88893699|NCT03170960|Experimental|Dose Escalation|"Subjects will accrue in cohorts of 3-6 subjects for evaluation of cabozantinib tablet dose of either 20 mg, 40 mg, and 60 mg orally qd in combination with standard dosing regimen of atezolizumab (1200 mg infusion q3w). A standard 3 plus 3 design will be utilized to determine a recommended combination dosing regimen for the Expansion Stage."
88893700|NCT03170960|Experimental|Expansion Cohort 1|RCC subjects with clear cell histology who have not received prior systemic anticancer therapy.
88893701|NCT03170960|Experimental|Expansion Cohort 2|UC subjects (including bladder, renal pelvis, ureter, urethra) who have progressed on or after platinum-containing chemotherapy.
88922148|NCT05732116||Exposure: With PTSD|Surgeons or anesthesiologists with PTSD
89530766|NCT03232957|Experimental|No IT morphine|Spinal block with 0.5% isobaric with no intrathecal morphine
89530767|NCT03232957|Experimental|50 ug IT morphine|Spinal block with 0.5% isobaric with 50 ug intrathecal morphine
89416378|NCT04643002|Experimental|isatuximab + SAR439459 + dexamethasone (Substudy 02)|"SAR439459 in combination with isatuximab and dexamethasone~Part 1:~2 dose levels (DLs) of IV SAR439459:~DL1 SAR439459 dose Q2W.~DL2 SAR439459 dose Q2W.~Isatuximab dose IV QW × 5 weeks (Cycle 1), followed by Q2W administrations (subsequent cycles).~Dexamethasone fixed dose and schedule: QW by mouth In Cycle 1, the first administration of SAR439459 (Day 1) will precede isatuximab by 1 week (first dose of isatuximab will be at Cycle 1 Day 8).~Part 2:~SAR439459 IV dose Q2W.~Isatuximab IV dose QW × 5 weeks (Cycle 1), followed by Q2W administrations (subsequent cycles).~Dexamethasone fixed dose and schedule: QW by mouth. In Cycle 1, the first administration of SAR439459 (Day 1) will precede isatuximab by 1 week (first dose of isatuximab will be at Cycle 1 Day 8)."
89416379|NCT04643002|Experimental|isatuximab + dexamethasone + belantamab mafodotin (Substudy 03)|"Belantamab mafodotin in combination with isatuximab and dexamethasone~Part 1:~1 DL of IV belantamab mafodotin in Part 1 and de-escalation dose DL-1:~DL1 belantamab mafodotin IV dose QW4 or de-escalation dose DL-1 QW8~Isatuximab dose, IV QW × 4 weeks (Cycle 1), followed by Q2W (subsequent cycles).~Dexamethasone fixed dose and schedule: QW by mouth.~Part 2:~Isatuximab IV dose QW × 4 weeks (Cycle 1), followed by Q2W (subsequent cycles).~Belantamab mafodotin IV dose Q4W or Q8W~Dexamethasone fixed dose and schedule: QW by mouth."
89416380|NCT04643002|Experimental|Isatuximab + pegenzileukin (Substudy 04)|"Pegenzileukin in combination with isatuximab~Part 1- dose escalation:~Up to 3 DLs of IV pegenzileukin are planned to be evaluated:~DL1 will explore pegenzileukin at Q2W.~DL2 will explore pegenzileukin at Q2W.~DL3 will explore pegenzileukin at Q2W.~Isatuximab IV dose QW × 4 weeks, followed by Q2W (subsequent cycles).~Part 1 - dose optimization:~Isatuximab IV doseQW × 4 weeks, followed by Q2W (subsequent cycles).~Pegenzileukin at potential doses (DL A and DL B) Q2W.~Part 2 (dose expansion):~Isatuximab IV dose QW × 4 weeks, followed by Q2W (subsequent cycles).~Pegenzileukin IV dose Q2W."
89416381|NCT04643002|Experimental|Experimental: Isatuximab + Dexamethasone + Belumosudil (Substudy 05)|"Isatuximab in combination with belumosudil and dexamethasone Part 1- dose escalation: During the first cycle, belumosudil will be evaluated in monotherapy during 2 to 4 weeks, then isatuximab and dexamethasone will be added, and continued for the subsequent cycles.~Belumosudil by mouth at Dose Level (DL) 1, DL2, DL3, and DL4~Isatuximab IV dose QW × 4 weeks, followed by Q2W (subsequent cycles)~Dexamethasone fixed dose and schedule: QW by mouth~Part 1- dose optimization:~Belumosudil at potential doses (DL A and DL B), daily by mouth~Isatuximab IV dose QW × 4 weeks, followed by Q2W (subsequent cycles)~Dexamethasone fixed dose and schedule: QW by mouth~Part 2- dose expansion:~Belumosudil dose daily, by mouth~Isatuximab IV dose QW × 4 weeks, followed by Q2W (subsequent cycles)~Dexamethasone fixed dose and schedule: QW by mouth"
89416382|NCT04643002|Experimental|Isatuximab + evorpacept + dexamethasone (Substudy 06)|"Isatuximab in combination with evorpacept and dexamethasone~Part 1- dose escalation:~Evorpacept IV dose Q2W~Isatuximab IV dose QW × 4 weeks, followed by Q2W (subsequent cycles)~Dexamethasone fixed dose and schedule: QW by mouth Part 1- dose optimization~Evorpacept IV at potential doses (DL A and DL B), Q2W~Isatuximab IV dose QW × 4 weeks, followed by Q2W (subsequent cycles)~Dexamethasone fixed dose and schedule: QW by mouth~Part 2- dose expansion:~Evorpacept IV dose Q2W~Isatuximab IV dose QW × 4 weeks, followed by Q2W (subsequent cycles)~Dexamethasone fixed dose and schedule: QW by mouth"
89416383|NCT04642261|Experimental|Empagliflozin group|Empagliflozin 10mg daily for 52 weeks
89416384|NCT04642261|Placebo Comparator|Placebo group|Placebo pills (identical in appearance to empagliflozin 10mg) daily for 52 weeks
89416385|NCT04555785|Experimental|Platelet transfusion with Wilate ®|
89416386|NCT04555785|Placebo Comparator|Platelet transfusion with Placebo|
89416387|NCT04551482|Experimental|Oxytocin|Oxytocin nasal spray (24 IU nasal spray, 4 times per day for 12 weeks)
89416388|NCT04551482|Placebo Comparator|Placebo|Placebo nasal spray (24 IU nasal spray, 4 times per day for 12 weeks)
88893702|NCT03170960|Experimental|Expansion Cohort 3|UC subjects (including bladder, renal pelvis, ureter, urethra) who are ineligible for cisplatin-based chemotherapy and have not received prior systemic chemotherapy.
89416389|NCT04541810||Participants receiving Upadacitinib|Participants receiving Upadacitinib as prescribed by their physician per local label.
89530768|NCT03232957|Experimental|100 ug IT morphine|Spinal block with 0.5% isobaric with 100 ug intrathecal morphine
89530769|NCT02513849|Experimental|Tamoxifen treatment|Patients will be administered tamoxifen, 80mg/ day orally for 4 days as a loading dose, followed by 20mg/ day thereafter until gastroscopy and biopsy 4 weeks later.
88893703|NCT03170960|Experimental|Expansion Cohort 4|UC subjects (including bladder, renal pelvis, ureter, urethra) eligible for cisplatin-based chemotherapy and have not received prior systemic chemotherapy.
88893704|NCT03170960|Experimental|Expansion Cohort 5|UC subjects (including renal pelvis, ureter, urinary bladder, urethra) who have radiographically progressed on or after one prior immune check-point inhibitor (ICI) (anti-PD1 or anti-PD-L1) therapy.
88893705|NCT03170960|Experimental|Expansion Cohort 6|CRPC subjects who have radiographically progressed in soft tissue on or after enzalutamide and/or abiraterone acetate for metastatic disease.
88893706|NCT03170960|Experimental|Expansion Cohort 7|Stage IV non-squamous NSCLC subjects who have radiographically progressed on or after treatment with one prior immune checkpoint inhibitor (ICI) (anti-PD-1 or anti-PD-L1) therapy.
88893707|NCT03170960|Experimental|Expansion Cohort 8|Stage IV non-squamous NSCLC subjects with positive PD-L1 expression and without prior systemic anticancer therapy.
88893708|NCT03170960|Experimental|Expansion Cohort 9|Stage IV nonsquamous NSCLC subjects with sensitizing EGFR mutation who have radiographically progressed during or following prior treatment with an EGFR-targeting TKI. Prior treatment with ICIs (anti-PD1 or anti-PD-L1) is allowed if given in combination with chemotherapy.
88893709|NCT03170960|Experimental|Expansion Cohort 10|RCC subjects with non-clear cell histology who have had up to one prior VEGFR-targeting TKI therapy.
89530770|NCT03232879|Experimental|Experimental 1|Motor Imagery
88893710|NCT03170960|Experimental|Expansion Cohort 11|TNBC subjects who have radiographically progressed during or following treatment with at least one prior systemic anticancer therapy. Prior treatment with ICIs (anti-PD1 or anti-PD-L1) is allowed if given in combination with chemotherapy.
88893711|NCT03170960|Experimental|Expansion Cohort 12|OC subjects (including primary peritoneal cancer and fallopian tube cancer) who have platinum-resistant or refractory disease who have had up to two lines of prior systemic anticancer therapy.
88893712|NCT03170960|Experimental|Expansion Cohort 13|EC subjects (serous or endometrioid histology) who have radiographically progressed during or following treatment with at least one prior systemic anticancer therapy.
88893713|NCT03170960|Experimental|Expansion Cohort 14|HCC subjects (Child-Pugh score A) who have not received prior systemic anticancer therapy.
88893714|NCT03170960|Experimental|Expansion Cohort 15|GC/GEJC/LEC subjects who have radiographically progressed during or following platinum-containing or fluoropyrimidine-containing chemotherapy.
88893715|NCT03170960|Experimental|Expansion Cohort 16|CRC subjects who have radiographically progressed during or following systemic chemotherapy that contained fluoropyrimidine in combination with oxaliplatin or irinotecan.
88893716|NCT03170960|Experimental|Expansion Cohort 17|H&N cancer subjects who have radiographically progressed during or following prior platinum-containing chemotherapy. Prior treatment with ICIs (anti-PD1 or anti-PD-L1) is allowed if given in combination with chemotherapy.
88893717|NCT03170960|Experimental|Expansion Cohort 18|DTC subjects (follicular, papillary, and poorly differentiated histologies) who are radioactive iodine (RAI) refractory or deemed ineligible for treatment with RAI.
88893718|NCT03170960|Experimental|Expansion Cohort 19 (SAC)|UC subjects (including renal pelvis, ureter, urinary bladder, urethra) who have radiographically progressed on or after one prior ICI (anti-PD-1 or anti-PD-L1). Subjects may be allowed to receive combination therapy at the Cohort Review Committee recommended dose following radiographic disease progression.
88893719|NCT03170960|Experimental|Expansion Cohort 20 (SAC)|Stage IV non-squamous NSCLC subjects who have radiographically progressed on or after treatment with one prior ICI (anti-PD-1 or anti-PD-L1). Subjects may be allowed to receive combination therapy at the Cohort Review Committee recommended dose following radiographic disease progression.
88893720|NCT03170960|Experimental|Expansion Cohort 21 (SAC)|Metastatic CRPC (mCRPC) subjects who have histologically or cytologically confirmed adenocarcinoma of the prostate without small cell features who have had prior treatment with one, and only one, novel hormonal therapy (NHT) (eg, abiraterone, enzalutamide, apalutamide, daralutamide) for CSPC, mCRPC, or non-metastatic CRPC. Subjects may be allowed to receive combination therapy at the Cohort Review Committee recommended dose following radiographic disease progression.
88893721|NCT03170960|Experimental|Expansion Cohort 22 (SAA)|Metastatic CRPC (mCRPC) subjects who have histologically or cytologically confirmed adenocarcinoma of the prostate without small cell features who have had prior treatment with one, and only one, novel hormonal therapy (NHT) (eg, abiraterone, enzalutamide, apalutamide, daralutamide) for CSPC, mCRPC, or non-metastatic CRPC. Subjects may be allowed to receive combination therapy at the Cohort Review Committee recommended dose following radiographic disease progression.
88893722|NCT03170960|Experimental|Expansion Cohort 23|Metastatic CRPC (mCRPC) subjects who have histologically or cytologically confirmed adenocarcinoma of the prostate without small cell features who have had prior treatment with one, and only one, novel hormonal therapy (NHT) (eg, abiraterone, enzalutamide, apalutamide, daralutamide) for CSPC, mCRPC, or non-metastatic CRPC
88893723|NCT03170960|Experimental|Expansion Cohort 24|Metastatic CRPC (mCRPC) subjects who have histologically or cytologically confirmed adenocarcinoma of the prostate without small cell features who have had prior treatment with at least one NHT and have received docetaxel for mCRPC
88893724|NCT03143673|Experimental|ACURATE TA™|Patient implanted with ACURATE TA™ Bioprosthesis
88893725|NCT03121209||Revascularization Arm (CEA or CAS)|These patients will have been randomized (via the parent trial, CREST-2) to receive intensive medical management as well as either Carotid Endarterectomy (CEA--if they are in the parent study Surgical trial) or Carotid Artery Stenting (CAS--if they are in the parent study Stenting trial).
88893726|NCT03121209||Intensive Medical Management (IMM) Arm|These patients will have been randomized (via the parent trial, CREST-2) to receive medical management only, which includes aspirin. high dose cholesterol lowering agent to a target LDL<70, intensive blood pressure management to target <130/80, smoking cessation, and diabetic control.
88893727|NCT03091725|Experimental|RYGB group|Subjects in this group are scheduled to undergo Roux-en-Y gastric bypass surgery and will be assessed after 16-18% weight-loss
88893728|NCT03091725|Active Comparator|VLCD Group|Subjects in this group will participate in a very low-calorie diet intervention to obtain a 16-18% weight loss.
88893729|NCT03036813|Active Comparator|Dose 1|voxelotor
88893730|NCT03036813|Active Comparator|Dose 2|voxelotor
88893731|NCT03036813|Placebo Comparator|Placebo|Placebo
88893732|NCT03027440||CPP Cohort|offspring born to historic CPP cohort participant mothers between 1959 and 1966 who were known to be alive at age 7 (if still alive at the time of NDI search, ages 50 to 57 years old)
88893733|NCT03027141|Active Comparator|Pre-Transplant Time Point|Participants will be imaged in the Magnetic Resonance Imaging scanner (MRI)
89530771|NCT03232879|Experimental|Experimental 2|Action Observation
89530772|NCT03232879|No Intervention|Control Group|No intervention
88893734|NCT03027141|Experimental|Post-Transplant Time Point|Participants will be imaged in the Magnetic Resonance Imaging scanner (MRI). Patients for whom a pre-transplant fMRI was obtained will undergo functional MRI scanning at three-points post-transplant (approximately 2 and 4 months +/- 2 months post-operation and again at 1 year +/- 3 months post-transplant).
88893735|NCT03007953|Experimental|Intervention|This is a nurse-led telephone-based program integrating palliative care into usual oncologic care for patients diagnosed within 2 months of any type and stage of lung cancer, who will receive therapy other than solely surgical resection. The intervention lasts for the duration of patients' primary lung cancer treatment (usually 3-4 months).
88893736|NCT03007953|No Intervention|Usual Care|Subjects randomized to the usual care arm will receive medical oncology, radiation oncology, pulmonary, CT surgery, as indicated by the type and stage of cancer. At the completion of their primary lung cancer treatment, they will be disenrolled from the study.
88893737|NCT02984163|Experimental|Exercise Intervention|Participant exercise sessions will be conducted in groups of 10-15 under the direct supervision of the community-based exercise specialist. Sessions will be twice a week for 12-weeks. Participants will have the option to continue with the exercise program after the 12-weeks on a fee-for-service basis.
88922149|NCT05732116||Comparator: Without PTSD|Surgeons or anesthesiologists without PTSD
89530773|NCT02513927|Active Comparator|A|To observe the effects of metoprolol (95 mg) on blood pressure variation after 12 weeks of treatment.Then to observe the effects of Nifedipine (30 mg) on blood pressure variation after 12 weeks of treatment.
88893738|NCT02981940|Experimental|Abemaciclib with Surgery|"Abemaciclib will be administered on a continuous twice daily dosing schedule~Patients who require re-operation will receive a short preoperative course of Abemaciclib~Tissue will be used to investigate the ability of Abemaciclib to pass through the blood brain barrier.~After recovery from surgery, participants will resume Abemaciclib. Each cycle lasts 28 days.~NOTE: enrollment to this arm is complete"
88893739|NCT02981940|Experimental|Abemaciclib without Surgery|"Abemaciclib will be administered on a continuous twice daily dosing schedule. Each Cycle last 28 days.~NOTE: enrollment to this arm is complete"
88893740|NCT02981940|Experimental|Cohort 1 Surgery Arm|Participants who require reoperation will be treated with abemaciclib for 10-14 days prior to surgery. Tissue will be used to further investigate the abilities of Abemaciclib. After surgery participants will come off study and pursue standard of care treatments at their treating physician's discretion.
88893741|NCT02930668|Placebo Comparator|Placebo|"The placebo is identical in shape, colour and size to the active comparator with the active ingredient replaced with microcrystalline cellulose.~Subjects will take 2 capsules three times a day, 30 mins before meals."
88893742|NCT02930668|Experimental|Low dose (Glucosanol 350mg)|"Each capsule contains Glucosanol / Phaselite 350mg~Subjects will take 2 capsules three times a day, 30 mins before meals."
88893743|NCT02930668|Experimental|High dose (Glucosanol 500mg)|"Each capsule contains Glucosanol / Phaselite 500mg~Subjects will take 2 capsules three times a day, 30 mins before meals."
88893744|NCT02922192||Rheumatoid arthritis (RA)|With exposure to TNF-α antagonists, non-TNFs, DMARD non-biologics
88893745|NCT02922192||Inflammatory bowel disease (IBD)|With exposure to TNF-α antagonists, non-TNFs, DMARD non-biologics
88893746|NCT02922192||Psoriatic conditions|Patients with a psoriasis, psoriatic arthritis, ankylosing spondylitis with exposure to TNF-α antagonists, non-TNFs, DMARD non-biologics
88893747|NCT02921191||Lung cancer|Lung cancer patients receiving their first cycle of Grade III and IV myelosuppressive chemotherapy regimen treated prophylactically with G-CSF.
88893748|NCT02921191||Breast cancer|Breast cancer patients receiving their first cycle of Grade III and IV myelosuppressive chemotherapy regimen treated prophylactically with G-CSF (filgrastim, TBO-filgrastim or pegfilgrastim)
88893749|NCT02920021|Experimental|Etokimab|Participants received a single dose of 300 milligrams (mg) etokimab administered by 1-hour intravenous (IV) infusion on Day 1.
88893750|NCT02920021|Placebo Comparator|Placebo|Participants received a single dose of placebo administered by 1-hour IV infusion on Day 1.
88893751|NCT02919618|Experimental|stereotactic body radiotherapy (SBRT)|Noninvasive SBRT will be delivered in a single fraction to a region of the heart determined by EP-guidance, using noninvasive electrical mapping combined with anatomic imaging.
88893752|NCT02911701|Experimental|Acetaminophen|Study participants randomized to the acetaminophen group will receive 650mg of acetaminophen orally every 6 hours during their postpartum hospital stay.
88893753|NCT02911701|Active Comparator|Ibuprofen|Study participants randomized to the ibuprofen group will receive 600mg of ibuprofen orally every 6 hours during their postpartum hospital stay.
88893754|NCT02896257|Other|Proactive patient-tailored electronic consult (E-consult)|Primary care clinicians receive patient-tailored guideline concordant treatment recommendations, including orders and rationale to discontinue inhaled corticosteroids.
88893755|NCT02896257|No Intervention|Usual care|Standard practice (usual care). Primary care providers treat their patients as usual.
89536772|NCT03310463|Experimental|Cohort 4, Severe Renal Impairment|Participants with severe renal impairment (eGFR <30 mL/min/1.73 m^2 calculated by the MDRD equation) and not on hemodialysis (HD) will receive ETX2514SUL as a single dose of up to 1000 mg ETX2514 and 1000 mg sulbactam given by concurrent 3-hour IV infusion.
88893756|NCT02881203|Experimental|Breathe Well + RPM|Participants will receive Breathe Well audiovisual feedback in addition to the RPM system
88893757|NCT02881203|Active Comparator|RPM|Varian's RPM system is the current standard of care at Royal North Shore Hospital where this trial is to be run.
88893758|NCT02874742|Experimental|Daratumumab+Lenalidomide+Bortezomib+Dexamethasone (D-RVd)|Participants will receive lenalidomide, bortezomib, dexamethasone and daratumumab.
88893759|NCT02874742|Experimental|Lenalidomide+Bortezomib+Dexamethasone (RVd)|Participants will receive lenalidomide, bortezomib and dexamethasone.
88893760|NCT02840019|Experimental|60 minute research full MRI scan|"Pregnant women who are able to have an MRI are eligible for the 60 minute research full MRI scan. Pregnant women may have a healthy pregnancy, a concern for fetal/placental abnormalities with a clinical fetal MRI ordered by their doctor, or a concern for fetal/placental abnormalities without a clinical fetal MRI ordered by their doctor.~The investigational MRI coil designed for pregnant women and research MRI sequences will be tested during the 60 minute research scan."
88893761|NCT02840019|Experimental|15 minute research add-on MRI scan|"Pregnant women with a concern for fetal/placental abnormalities with a clinical fetal MRI at Boston Children's Hospital are eligible for the 15 minute research add-on MRI scan.~The research MRI sequences will also be tested during the add-on research MRI scan."
88893762|NCT02818842||Pregnant Women|"Medical and personal data will be collected for all the pregnant women who want to participate.~The source of data are :~Primary Health Insurance Fund data~Prenatal Diagnostic Center of Toulouse University Hospital data~Mother and child protection data collection~Medicalisation Program of Information Systems data"
88893763|NCT02805023|Placebo Comparator|Placebo|Intramuscular injection of control medium only
88893764|NCT02805023|Experimental|BGC101|Intramuscular injection of BGC101 (autologous EnEPC preparation)
88893765|NCT02791880||TAVR patients|The group of interest is the patient population with aortic stenosis who are undergoing transcatheter aortic valve replacement (TAVR)
88893766|NCT02749292|Active Comparator|B cell reconstitution|Subjects will not receive their regularly-scheduled every-six-month dose of rituximab and will instead receive rituximab 1000 mg IV x 1 dose once peripheral B cells return ( ≥ 10 B cells/mm3). This cycle will then re-start. Subjects will be seen in clinic every three months. Patients will continue to be dosed with rituximab each time the B cell count rises to 10 cells/mm3. In the unique scenario that the B cells are detectable, but less than the threshold of 10 cells/mm3, subjects will be asked to return in 6 weeks for repeat B cell testing.
89193160|NCT05465083|Experimental|Lungpacer AeroPace Protect System|"The PNS device used for this study will be the most recent AeroPace central venous catheter from Lungpacer Medical Inc (Vancouver, BC). It is an 8.5F 23cm triple lumen central venous catheter with 30 electrodes arranged in two arrays (distal 9 electrodes intended to capture the right phrenic nerve and the 21 proximal to capture the left phrenic nerve). It is inserted via the left internal jugular or left subclavian vein where it is placed in the proximal superior vena cava (SVC) at or above the cavo-atrial junction.~The AeroPace system monitors airway pressure to detect ventilator-triggered controlled mechanical breaths and patient-triggered assisted mechanical breaths. In response to detection of native respiratory efforts the PNS lies quiescent."
89193161|NCT05462873|Experimental|Part 1: Dose escalation|Dose escalation with QEQ278 single agent
89193162|NCT05462873|Experimental|Part 2: Dose expansion|Dose expansion with QEQ278 single agent
89193163|NCT05461859||≥30% HR increase after CNA|Patients in whom ≥30% increase in HR after CNA of RAGP was achieved.
88893767|NCT02749292|Active Comparator|Serologic ANCA flare|Subjects will not receive regularly scheduled every six-month doses of rituximab (1000mg IV) and will instead be seen in clinic for ANCA titer monitoring every 3 months. Re-dosing will occur upon a significant ANCA titer increase. For MPO, a significant rise will be defined as a 5-fold rise in ANCA titer and a level greater than 4 times the cutoff value for the assay. For PR3, a significant rise will be defined as a 4-fold rise in ANCA titer to a level at least twofold above the cutoff for the assay. Subjects who sustain a significant increase in ANCA titer will receive rituximab 1000mg IV x 2 doses, spaced ~2-3 weeks apart. If the ANCA titer remains two-fold above baseline and above a specified threshold (the cutoff value of the assay for PR3 and 4 times the cutoff value for MPO) , subjects will continue to receive rituximab 1000mg IV every 6 months for a maximum of 2 doses, at which time a new baseline ANCA titer will be established and the cycle will re-start.
88893768|NCT02734017|Other|standard course|group not receiving medication review
88893769|NCT02734017|Other|pharmacist-led standardized medication review|"pharmacist-led standardized medication review including :~Medical and pharmaceutical admission medication reconciliation and treatment review~Medical and pharmaceutical medication reconciliation at discharge and treatment review~Medication Liaison Service"
88893770|NCT02715609|Experimental|DSF, Cu, Surgery, RT, TMZ (dose escalation)|"DSF (dose level (DL) 1=125mg, DL 2=250mg, DL 3=375 mg, DL 4=500mg). DSF starts at DL 2 and escalated using the Time-to-Event Continual Reassessment Method~3 day lead-in of oral DSF once daily (QD) prior to surgery (optional)~2 mg Cu gluconate 3 times daily (TID) on days when DSF is given (optional pre-surgery)~Surgery performed per routine clinical care.~After surgery, evaluation to confirm the final pathological diagnosis as GBM (if not the patient will not continue with the 2nd part of the study).~RT 4-6 weeks following surgery at 60 Gy in 30 daily fractions.~TMZ from Day 1 of RT to the last day of RT at a daily oral dose for a maximum of 49 days as per standard clinical care.~DSF QD and Cu TID during chemoradiotherapy as per preoperative dose~4-6 weeks after completion of chemoradiotherapy, adjuvant TMZ may be administered for 6 cycles. TMZ on Days 1-5 of every 28-day cycle. Daily DSF of 500mg will be continued with adjuvant TMZ for up to 6 cycles."
88893771|NCT02715609|Experimental|DSF, Cu, Surgery, RT, TMZ (dose expansion)|"Surgery performed per routine clinical care.~RT 4-6 weeks following surgery at 60 Gy in 30 daily fractions.~TMZ from Day 1 of RT to the last day of RT at a daily oral dose for a maximum of 49 days as per standard clinical care.~DSF QD and Cu TID during chemoradiotherapy as per preoperative dose~4-6 weeks after completion of chemoradiotherapy, adjuvant TMZ may be administered for 6 cycles. TMZ on Days 1-5 of every 28-day cycle. Daily DSF of 500mg will be continued with adjuvant TMZ for up to 6 cycles.~If a patient develops recurrent tumor during follow-up and plans to undergo another resection, he/she may opt for an optional preoperative DSF study prior to salvage surgery."
88893772|NCT02707744||sinus rhythm|patients with heart failure and sinus rhythm
88893773|NCT02707744||atrial fibrillation|patients with heart failure and atrial fibrillation
88893774|NCT02689076|Experimental|HIE Notification plus Care Coordination|VA provider notification of non-VA hospitalization via electronic health information exchange (HIE) plus post-hospital geriatric care transitions intervention
88893775|NCT02689076|Active Comparator|HIE Notification alone|VA provider notification of non-VA hospitalization via electronic health information exchange (HIE) followed by usual post-hospital care
88893776|NCT02689076|No Intervention|Usual Care (No HIE Notification and No Care Coordination)|Absence of VA provider notification of non-VA hospitalization via HIE plus Absence of post-hospital geriatric care transitions intervention [Usual Care]
88893777|NCT02632929||Diabetic Foot Ulcers at Amputation Risk|Patients at high risk for limb amputation from a diabetic foot ulcer will be treated with comprehensive, interdisciplinary approach (usual care) in combination with early application of advanced therapy; dehydrated human amniotic membrane allografts (AMNIOEXCEL®, Derma Science, Princeton, New Jersey).
88893778|NCT02619136|Experimental|Restrictive Transfusion Strategy|We will permit but not require red cell transfusions once a hemoglobin value falls below 80 g/L (required below 70 g/L) during the 30 days following randomization
88893779|NCT02619136|Active Comparator|Liberal Transfusion Strategy|We will transfuse at a transfusion threshold of 100 g/L for up to 30 days after randomization.
88893780|NCT02576990|Experimental|Pembrolizumab: Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)|Participants with rrPMBCL receive pembrolizumab 200 mg every 3 weeks (Q3W), intravenous infusion (IV) on Day 1 of each 3-week cycle for up to a maximum of 35 administrations (approximately 2 years).
89193164|NCT05461859||<30% HR increase after CNA|Patients in whom ≥30% increase in HR after CNA of RAGP was *not* achieved.
88893781|NCT02576990|Experimental|Pembrolizumab: Relapsed or Refractory Richter Syndrome (rrRS)|Participants with rrRS receive pembrolizumab 200 mg Q3W, IV for each 3-week cycle for up to a maximum of 35 administrations (approximately 2 years). Effective with Protocol Amendment 04, enrollment into this cohort was closed.
88893782|NCT02550561|Experimental|Posterior Tibial Nerve Stimulation|PTNS (under the brand name Urgent PC) is an FDA-approved device for the treatment of urinary urgency, urinary frequency and urge incontinence. It is often described as a peripheral form of neuromodulation (as opposed to SNM which is central neuromodulation at the level of the nerve root). PTNS involves 12 weeks of weekly 30 minute office-based treatment sessions with a small electrode placed slightly above the ankle in order to stimulate the S2-4 nerve roots. If benefits are obtained, 12 weeks of treatment is followed by spaced maintenance sessions at timing of provider and patient discretion.
88893783|NCT02524171|Experimental|Moral Reconation Therapy (MRT)|MRT is a group-based cognitive-behavioral intervention to restructure antisocial thinking. Patients will receive two groups per week of this intervention for approximately 12 weeks, in addition to the usual care they receive in the mental health residential rehabilitation treatment program.
88893784|NCT02524171|No Intervention|Usual Care (UC)|Usual care provided by the mental health residential rehabilitation treatment programs, which patients in both groups are in.
88893785|NCT02513225|Experimental|Intervention|The adapted Project EMPWR will be comprised of 2 sessions delivered approximately 7-10 days apart by a trained Apache paraprofessional interventionist. In the first session, interventionists will use curriculum to help participants understand their personal risk factors for STDs including HIV/AIDS (i.e., substance use, mental and emotional health, sexual health, etc.) and develop an achievable personalized risk-reduction plan that emphasizes individual and community-based strengths and resources.The second counseling session will consist of the disclosure of results (if tested) and the provision of social support to help participants develop a longer-term risk-reduction plan. At visit two, participants in both groups will be offered a STD screening protocol test.
88893786|NCT02513225|Other|Control|The comparison condition will consist of Optimized Standard Care (OSC) alone. All participants will receive OSC at the first visit. OSC includes the distribution of educational pamphlets and provision of information on substance use, signs and symptoms of mental health problems, and information about STD screening resources. At visit two, participants in both groups will be offered a STD screening protocol test.
88893787|NCT02511106|Experimental|AZD9291|AZD9291 (80 mg or 40 mg orally, once daily), in accordance with the randomization schedule.
88893788|NCT02511106|Placebo Comparator|Placebo AZD9291|Matching placebo for AZD9291 (80 mg or 40 mg orally, once daily), in accordance with the randomization schedule.
88893789|NCT02500589|Experimental|Mood management enhancement|In the SMK-MM enhanced arm, behavioral mood management will be integrated into the evidence-based smoking cessation counseling.
88893790|NCT02500589|Other|Health education control|"In the contact-equivalent health education condition, participants will receive parallel smoking cessation content on the same schedule as in the MM-enhanced arm; however, health education content will supplant the MM content. The educational content will be based on the VA National Center on Health Promotion and Disease Prevention's Health Living Messages on such topics as being safe, eating wisely, getting recommended immunization and screening tests, and being involved with personal health care. Participants also will receive chronic-disease-specific self-management information."
88893791|NCT02494882|Experimental|Adding Ruxolitinib to Combination of Dasatinib + Dexamethasone|"Steroid Pre-Phase (Days -6 to 0) Prednisone 10 mg/m2/day uptitrated to 60/mg/m2/day oral over seven days (capped at 120 mg/day).~Remission Induction (Days 1 to 84) Dasatinib 140 mg oral once daily. Days 1-84. Dexamethasone 10 mg/m2/day oral (capped at 20 mg/day). Days 1-24. Dexamethasone oral taper 10 mg/m2/day (capped at 20 mg/day) to off. Taper days 25-32. Off day 33.~Ruxolitinib phase I cohort dose oral. Days 1-84. Delivered BID. Delivered per the phase I dose cohort. Methotrexate (MTX) 12 mg Intrathecal (IT) for 4 doses on days 22, 43, 64, 85; +/- 3 days.~Post-Remission Induction Therapy (Starting Day 85) Allogeneic HSCT, at the discretion of the treating physician, at any point post-remission induction.~Or, post-remission induction (consolidation) therapy to be determined per the treating physician"
88893792|NCT02481830|Experimental|Arm A Nivolumab|Nivolumab intravenous infusion as specified
88893793|NCT02481830|Active Comparator|Arm B Chemotherapy Topotecan|Topotecan as specified
88893794|NCT02481830|Active Comparator|Arm B Chemotherapy Amrubicin|Amrubicin intravenous infusion as specified (upon investigator's choice, where locally approved for 2nd line SCLC treatment)
88893795|NCT02478138|Other|Surgical - therapeutic|patients will be enrolled under informed consent based upon their medical diagnosis, planned surgical procedures, and suitability for the procedure. During the study, patients will receive injections of ICG and will be imaged using a commercial NIR imaging system
88893796|NCT02467738|Experimental|Cesium-131 Brachytherapy|Patients undergo brachytherapy using Cesium-131 during surgical resection
88893797|NCT02426814|Sham Comparator|Standard Care with Medication Monitoring|"Patients will be given an inhaler sensor to monitor medication use and a sham version of the mobile app that will not include reminders or incentives.~Intervention: inhaler sensor"
88893798|NCT02426814|Experimental|Medication Monitoring and Mobile App|"Patients will be given an inhaler sensor to monitor medication use and a mobile phone application with reminders to allow self-management of medication use.~Interventions: inhaler sensor and mobile application for asthma adherence"
88893799|NCT02425943|Experimental|Sculptra Aesthetic|
88893800|NCT02416674|Experimental|Transplant recipients|The intervention is transplantatoin of abdominal wall tissues from an organ donor who is deceased to a recipient with a large abdominal wall defect.
88893801|NCT02383173|Active Comparator|Basic Implementation Approach|Basic approach to implementing a Comfort Care Education Intervention utilizing the established infrastructure of Palliative Care Consult Teams
88893802|NCT02383173|Experimental|Enhanced Implementation Approach|Enhanced approach to implementing a Comfort Care Education Intervention utilizing the established infrastructure of Palliative Care Consult Teams
88893803|NCT02380690|Experimental|Peer Coach Assignment|Veteran participants will be assigned to a peer coach, who delivered self-management instruction one-on-one over a 6-month period.
88893804|NCT02380690|No Intervention|Control|"Veteran participants will attend a 2-hour class in pain basics and pain self-management. Veterans will aso be given a set of pamphlets related to pain self-management."
88893805|NCT02368132|No Intervention|Usual Care|Caregivers randomized to UC will be sent general material about VA and community resources for patients with dementia and their CGs. With the exception of this material, individuals in this group will receive usual care and will be contacted again at 3, 6, and 12 months for follow-up research assessments.
88893806|NCT02368132|Active Comparator|Individual Delivered TEP Arm|Two mandatory modules that cover the stages of dementia and provide a brief introduction to problem solving techniques, action plan development, and coping skills, plus a menu of additional modules covering various content areas evaluated during the course of the monthly assessments (e.g., communication skills, behavioral management techniques, stress management and coping skills, longterm planning, etc.). Each individual TEP session will begin with reviewing education related to the selected module. The remainder of each session will involve coaching the caregiver on emotion-focused and problem focused coping strategies. The care manager will also discuss problem solving with the CG to reinforce the action plan and the educational component of the intervention.
88893807|NCT02368132|Active Comparator|Group Delivered TEP Arm|All TEP modules will be in a group format. Each call will take 1.5-2 hours. Each group will be comprised of 5-8 CGs who will call into a teleconference line at a pre-specified time. Groups will include spouse/partner-only or adult child-only CGs. The content of the calls will mirror those in the individual TEP delivered program. In addition to the group calls, they will receive individual care management.
89536773|NCT03310463|Experimental|Cohort 5, ESRD on a Stable HD Regimen|Participants with end-stage renal disease (ESRD) on a stable HD regimen (determined by medical history) will receive ETX2514SUL as a single dose of up to 1000 mg ETX2514 and 1000 mg sulbactam given by concurrent 3-hour IV infusion.
88893808|NCT02362997|Experimental|Diffuse large B cell lymphoma|Pembrolizumab 200mg IV every 3 weeks up to 8 cycles
88893809|NCT02362997|Experimental|Classical Hodgkin lymphoma|Pembrolizumab 200mg IV every 3 weeks up to 8 cycles
88893810|NCT02362997|Experimental|Peripheral T cell lymphoma|Pembrolizumab 200mg IV every 3 weeks up to 8 cycles
88893811|NCT02311673|Experimental|Setmelanotide 0.5 mg|Participants received setmelanotide 0.5 milligrams (mg) once daily as a subcutaneous injection from Day 15 to Day 41 (4-week, double-blind randomized treatment period) and Day 42 to Day 55 (2-week, randomized withdrawal period).
89416390|NCT04514705|Experimental|Intervention Group|The exercises performed will attend the musculoskeletal dimension of the body, which includes the muscular strength / endurance indexes, which is part of the functional-motor dimension of physical fitness related to health. The protocol will be applied in the form of sessions lasting approximately 50 minutes, performed three times a week on alternate days, for a period of 6 weeks, totaling 20 sessions. For aerobic exercises, a treadmill will be used and for anaerobic exercises, four exercises involving muscle mobility / strength in upper and lower limbs will be performed at weight training station.
89416391|NCT04499690||Global CALM Training Program Clinicians|Clinicians engaging in the CALM Training Program.
89416392|NCT04498026|Experimental|Adherus Dural Sealant System|Device: Adherus Dural Sealant, In situ polymerizing sealant
89416393|NCT04498026|Active Comparator|DuraSeal Exact Dural Sealant System|Device: DuraSeal Exact (P080013b)
89416394|NCT04495153|Other|Cohorts|"Cohort 1A and 1B - persistent but stable disease at least 18 weeks after starting ICI treatment~Cohort 2A and 2B - radiographic progressive disease at least 18 weeks after starting ICI treatment~Cohort 3 - refractory disease defined as progressed by imaging at least 9 weeks after starting ICI treatment (CLOSED TO ENROLLMENT)"
89416395|NCT04484181|Experimental|Embryo culture in time lapse technology (TLT)|In the TLT group, the selection for transfer was based on morphological and kinetic criteria (with the use of an algorithm). Embryos will be cultured and selected for fresh transfer.
89416396|NCT04484181|Active Comparator|Embryo culture in conventional incubator|For the standard incubation group, the selection for transfer was based on morphological criteria. Embryos will be cultured and selected for fresh transfer.
89416397|NCT04473469|Experimental|Cystometrogram|The bladder will be filled to different volumes and electrical stimulation will be applied to the pudendal nerve via the implanted neurostimulator.
89193165|NCT05453682|Experimental|Hypo IMRT|in muscle invasive bladder cancer, hypofractionated IMRT with chemotherapy
89193166|NCT05453084|Experimental|Intervention Arm|"The exercise intervention tool will be Fitwalking, which is structured, organized, supervised and administered through a Walking Group"
89193167|NCT05451784|Experimental|PD1+ TILs (NUMARZU-001) product infusion|The treatment administration is divided in NMA-LD chemotherapy(auxiliary medication), TILs product (IMP) and IL-2 (auxiliary medication).
89193168|NCT05444270|Active Comparator|Standard salvage therapy|Subjects will continue to receive current salvage treatment suitable for subjects at the discretion of their doctor, considering the location and size of recurrence, and the patient's comorbidities.
89193169|NCT05444270|Experimental|Standard salvage therapy + SABR|Subjects receive SABR for lesions found in imaging studies. Before or After SABR, standard salvage treatment continues as planned at the discretion of the doctor.
89193170|NCT05443529||Adaptive sports group|Individuals with stroke who regularly, and on a long-term basis, participate in adaptive sports
89193171|NCT05443529||Non adaptive sports group|Individuals with stroke who do not engage in adaptive sports
89193172|NCT05443061|Experimental|Nitroglycerin|Nitroglycerin 5mcg/kg (in 0.5cc) is subcutaneously injected before radial artery cannulation and before removal of the radial arterial catheter.
89193173|NCT05443061|Active Comparator|Control|Normal saline (0.5cc) is subcutaneously injected before radial artery cannulation and before removal of the radial arterial catheter.
89416398|NCT04455620|Experimental|Part 1: BNT151|Monotherapy dose escalation in patients with advanced solid malignancies until the maximum tolerated dose (MTD) and/or RP2D
89416399|NCT04455230|Experimental|Participants who have received gene therapy vector (FLT190)|
89416400|NCT04431752||Healthy Volunteer|10 healthy volunteers to undergo radiographic examinations of the knee joint.
89416401|NCT04431752||Kellgren-Laurence grading I Osteoarthritis Knee|10 patients in Kellgren-Laurence grading I to undergo radiographic examinations of the knee joint.
89416402|NCT04431752||Kellgren-Laurence grading II Osteoarthritis Knee|10 patients in Kellgren-Laurence grading II to undergo radiographic examinations of the knee joint.
89416403|NCT04431752||Kellgren-Laurence grading III Osteoarthritis Knee|10 patients in Kellgren-Laurence grading III to undergo radiographic examinations of the knee joint.
89416404|NCT04431752||Kellgren-Laurence grading IV Osteoarthritis Knee|10 patients in Kellgren-Laurence grading IV to undergo radiographic examinations of the knee joint.
89416405|NCT04417465|Experimental|Monotherapy Dose Escalation|ABBV-CLS-579 will be administered as a monotherapy in subjects with solid tumors
89416406|NCT04417465|Experimental|Combination Dose Escalation with PD-1|ABBV-CLS-579 will be administered in combination with Programmed Cell Death-1 Inhibitor in subjects with solid tumors
89416407|NCT04417465|Experimental|Backfill Cohorts with Monotherapy|ABBV-CLS-579 will be administered as a monotherapy in subjects with solid tumors
89416408|NCT04417465|Experimental|Backfill Cohorts in Combination with PD-1|ABBV-CLS-579 will be administered in combination with Programmed Cell Death-1 Inhibitor in subjects with solid tumors
89536774|NCT05333315|Experimental|Investigation Product 1 (IP1) in softchews form|0,5 g of glucomannan per softchew
89193174|NCT05440149|Active Comparator|The Control group|"If patients received mastectomy, post-mastectomy radiation therapy (PMRT) should be performed.~If patients received breast conserving surgery (BCS), whole breast irradiation (WBI) + Regional radiotherapy (RT) should be performed."
89193175|NCT05440149|Experimental|The Experimental group|"If patients received mastectomy, No PMRT should be performed.~If patients received BCS, WBI alone should be performed."
89193176|NCT05439564|Placebo Comparator|Group morphine|Group morphine (35 patients): patients will be received given 0.5% heavy bupivacaine (3.5 ml) plus 0.1 mg of morphine.
89193177|NCT05439564|Active Comparator|Group morphine-Dex|Group morphine-Dex (35 patients): patients will be received given 0.5% heavy bupivacaine (3.5 ml) plus 0.1 mg of morphine plus 5 mcg of dexmedetomidine.
89193178|NCT05439564|Active Comparator|Group Dex|Group Dex (35 patients): patients will be received given 0.5% heavy bupivacaine (3.5 ml) plus 5 mcg of dexmedetomidine.
89193179|NCT05438875|Active Comparator|Eltrombopag|The initial dose of eltrombopag was 50 mg/time, once a day. According to the clinical standard of eltrombopag dose adjustment in the research protocol set by the research group, the dose was increased when the platelet count was lower than 5×109/L. The highest is 75mg/d, if the dose is higher than 200×109/L, the dose is reduced. When the dose is higher than 400×109/L, the drug is temporarily discontinued, and the drug is repeated according to the platelet count. The treatment course is 12 weeks.
88893812|NCT02311673|Experimental|Setmelanotide 1.5 mg|Participants received setmelanotide 1.5 once daily as a subcutaneous injection from Day 15 to Day 41 (4-week, double-blind randomized treatment period), Day 42 to Day 55 (2-week, randomized withdrawal period), and Day 56 to Day 69 (optional 2-week, open-label extension period).
89530774|NCT02513927|Active Comparator|B|To observe the effects of Nifedipine (30 mg) on blood pressure variation after 12 weeks of treatment. Then to observe the effects of metoprolol (95 mg) on blood pressure variation after 12 weeks of treatment.
88893813|NCT02311673|Experimental|Setmelanotide 2.5 mg|Participants received setmelanotide 2.5 once daily as a subcutaneous injection from Day 15 to Day 41 (4-week, double-blind randomized treatment period), Day 42 to Day 55 (2-week, randomized withdrawal period), and Day 56 to Day 69 (optional 2-week, open-label extension period).
88893814|NCT02311673|Placebo Comparator|Placebo|Participants received placebo matched to setmelanotide once daily as a subcutaneous injection from Day 1 to Day 14 (2-week, single-blind run-in period), Day 15 to Day 41 (4-week, double-blind randomized treatment period), and Day 42 to Day 55 (2-week, randomized withdrawal period).
88893815|NCT02300870||Heart Transplant Rejection|Patients presenting with acute cellular rejection
88893816|NCT02300870||Heart Transplant Control|Patients presenting for routine office visit
88893817|NCT02285725|Experimental|Augmented Microdrilling Surgery|
88893818|NCT02269150|Experimental|Fecal microbiota transplantation with pre-transplant feces|Prior to transplant hospitalization, store feces for testing and possible future use. Patients undergo fecal microbiota transplantation with the subject's stored pre-transplantation feces. The post-engraftment Bacteroidetes testing, randomization, and fecal microbiota transplantation procedure should all be performed within a 28-day window, beginning on the first day of engraftment. In the event that engraftment occurs prior to day +7, the 28-day window will start on day +7. Subjects from both arms will be followed for one year after transplantation for development of CDI, which will be treated by their BMT clinicians per the standards of care at MSKCC. Subjects from both arms will also be assessed for infections and graft-versus-host disease. During the follow-up period, fecal specimens will be collected serially, if feasible, until one year post randomization and analyzed for microbial diversity and composition.
88893819|NCT02269150|Active Comparator|No FMT, routine management|Subjects from both arms will be followed for one year after randomization for development of CDI, which will be treated by their primary BMT clinician per the standards of care at MSKCC. Subjects from both arms will also be assessed by their BMT clinicians for infections and graft-versus-host disease. During the follow-up period, fecal specimens will be collected serially if feasible until one year post randomization and analyzed for microbial diversity and composition.
88893820|NCT02233738|Experimental|Group Motivational Interviewing (GMI)|Group Motivational Interviewing (GMI) participants will receive four structured, back-to-back, 90-min sessions consistent with the central principles and spirit of Motivational Interviewing (MI). GMI, which is based on a manualized protocol, is specifically designed for dually diagnosed Veterans. A focus of the intervention creates awareness of the relationship between the substance use and co-existing psychiatric disorder and the importance of treating both.
88893821|NCT02233738|Active Comparator|Control Treatment Condition (CT)|"Control Treatment Condition (CT): Participants in CT will attend four sessions equal in time and length to Group Motivational Interviewing (GMI) (i.e., 90 minutes) and will involve the following topics: A popular 'box activity': participants will anonymously write evocative questions on slips of paper involving their personal concerns that are placed in a box and, when randomly selected, opened for group discussion (e.g., How do I talk to my family about my alcohol problem?), money management with feedback (2 sessions), and cooking-home maintenance."
88893822|NCT02220426|Other|Xenon inhalation|Inhalation of 5 doses of 750ml of hyperpolarized 129Xe gas
88893823|NCT02123121|Placebo Comparator|Vegetable cellulose|Participants will orally consume one capsule of vegetable cellulose following each of their main meals (i.e. breakfast, lunch, and dinner) for 90 days.
88893824|NCT02123121|Active Comparator|Resveratrol 1000 mg/day|Participants will orally consume one capsule of Resveratrol following each of their main meals (i.e. breakfast, lunch, and dinner) totaling 1000 mg/day for 90 days.
88893825|NCT02123121|Active Comparator|Resveratrol 1500 mg/day|Participants will orally consume one capsule of Resveratrol following each of their main meals (i.e. breakfast, lunch, and dinner) totaling 1500 mg/day for 90 days.
88893826|NCT02009579|Active Comparator|Experimental arm|Nintedanib/vargatef
88893827|NCT02009579|Placebo Comparator|Comparator arm|Placebo
88893828|NCT01959698|Experimental|Treatment (carfilzomib, rituximab, chemotherapy)|Patients receive carfilzomib IV over 10-30 minutes on days 1, 2, 8, and 9; rituximab IV over 3-8 hours on day 3; etoposide IV over 1 hour on days 4-6; carboplatin IV over 1 hour on day 5; and ifosfamide IV over 24 hours on day 5. Treatment repeats every 21-28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
88893829|NCT01790373|Experimental|Suubi+Adherence|"Suubi+Adherence intervention arm provides:~Matched savings accounts/child development accounts (CDAs) for the adolescents held in a local bank.~Financial education and workshops on asset-building, future planning, and protection from risks~Mentorship from a young adult/near-peer~Family-based microenterprise development training~Bolstered Standard of Care: Adherence Counseling Practices~-Four to six counseling sessions to review HIV, ART, resistance, and adherence.~Medical Standard of Care:~-Pediatric ART initiation and monitoring followed by all public clinics, and outlined in National Department of Health Guidelines for pediatric HIV care in Uganda~Psychosocial Standard of Care:~-Psychosocial support provided by lay counselors trained in standardized ART adherence counseling"
88893830|NCT01790373|Active Comparator|Bolstered Standard of Care|"Bolstered Standard of Care: Adherence Counseling Practices~-Four to six counseling sessions to review HIV, ART, resistance, and adherence.~Medical Standard of Care:~-Pediatric ART initiation and monitoring followed by all public clinics, and outlined in National Department of Health Guidelines for pediatric HIV care in Uganda~Psychosocial Standard of Care:~-Psychosocial support provided by lay counselors trained in standardized ART adherence counseling"
88922150|NCT05728944|Experimental|Aceclidine + Brimonidine (LNZ101) dosed bilaterally|LNZ101: Aceclidine + Brimonidine ophthalmic solution
88922151|NCT05728944|Experimental|Aceclidine Ophthalmic Solution (LNZ100) dosed bilaterally|LNZ100: Aceclidine ophthalmic solution
88922152|NCT05728944|Experimental|Vehicle Ophthalmic Solution dosed bilaterally|Vehicle ophthalmic solution
89416409|NCT04417465|Experimental|Combination Expansion with PD-1|ABBV-CLS-579 will be administered at the determined recommended dose in subjects with locally advanced or metastatic, relapsed or refractory head and neck squamous cell carcinoma (HNSCC), relapsed or refractory non-small cell lung cancer (NSCLC), microsatellite instability-high (MSI-H) tumors, and advanced clear cell renal cell carcinoma (ccRCC)
89416410|NCT04417465|Experimental|Combination Expansion with VEGFR TKI|ABBV-CLS-579 will be administered at the determined recommended dose in combination with Vascular Endothelial Growth (VEGFR) Factor Receptor Tyrosine Kinase Inhibitor (TKI) in subjects with advanced ccRCC.
89416411|NCT04405180|Experimental|20 mg Sodium Nitrite TID Arm|Subject is to receive active study drug three times per day during treatment (12 weeks +/- 5 days) period and then after the treatment period (up to 16 weeks total).
89416412|NCT04405180|Placebo Comparator|Placebo Control Arm|Subject is to receive placebo three times per day during treatment period (12 weeks +/- 5 days) and then after the treatment testing period (up to 16 weeks total).
89416413|NCT04376138|Experimental|Motor Imagery|A Brain-Computer Interaction (BCI) based intervention while receiving conventional therapy. Use of motor imagery training, allied with brain-computer interaction, as a solution to promote motor and cognitive gains in stroke survivors.
89416414|NCT04376138|Active Comparator|Conventional Therapy|Extra Occupational Therapy sessions while receiving conventional therapy. Use of conventional therapy techniques and tools for motor rehabilitation, following the original therapeutic intervention plan of the participants.
89416415|NCT04359823|Experimental|Statin/Cholesterol Combination Group|This arm will utilize 2% cholesterol and 2% lovastatin ointment. It will be compounded by a pharmacist. Ointment will be applied on lesional skin with occlusion twice daily for 12 weeks.
89416416|NCT04359823|Experimental|Statin Alone Group|This arm will utilize 2% lovastatin ointment. It will be compounded by a pharmacist. Ointment will be applied on lesional skin with occlusion twice daily for 12 weeks.
89416417|NCT04359680|Active Comparator|Nitazoxanide|Two NTZ 300 mg tablets orally twice daily for 6 weeks.
89416418|NCT04359680|Placebo Comparator|Placebo|Two placebo tablets orally twice daily for 6 weeks.
89416419|NCT04359641|Experimental|CoMET Display|Display of Continuous Monitoring of Event Trajectories (CoMET) predictive monitoring score, with standard CoMET device training.Risk scores will also be presented daily during rounds to members of the care team.
89416420|NCT04359641|No Intervention|No Display|Standard CoMET device training but no display or presentation of predictive monitoring score.
89416421|NCT04353583||ICU patients|Inpatients with COVID-19 requiring ICU care
89416422|NCT04353583||Non-ICU patients|Inpatients with COVID-19 not requiring ICU care
89416423|NCT04345003|Experimental|Myoma elastography|"The standard pre-therapeutic assessment includes a pelvic US to eliminate the presence of calcification of fibroids. If this absence is confirmed, the elasticity of uterine myoma (by ARFI method) will be measured.~The standard pre-therapeutic MRI performed allows to classify and measure the myoma in order to determine if it is accessible for HIFU treatment. MRI elastography sequence with the Resoundant® system will be performed during this exam."
89416424|NCT04333966|Experimental|Interactive PBI|Parents in the interactive PBI condition will receive an interactive web-based SNS PBI with text message prompts aimed to reduce adolescent alcohol use and risky cognitions related to alcohol displays on SNS.
89416425|NCT04333966|Active Comparator|Active Control|Parents in the active control condition will receive an emailed copy of the Surgeon General's Call toAction: A Guide for Families.
89416426|NCT04317846|Active Comparator|Intra-radial group|intra-radial administration of the vasodilatory drugs after sheath insertion (verapamil 2.5 mg + isosorbide dinitrate 0.5 mg)
89416427|NCT04317846|Experimental|Intravenous-post group|intra-venous administration of the vasodilatory drugs after sheath insertion (verapamil 2.5 mg + isosorbide dinitrate 0.5 mg)
89416428|NCT04317846|Experimental|Intravenous-pre group|intra-venous administration of the vasodilatory drugs 5 minutes before sheath insertion (verapamil 2.5 mg + isosorbide dinitrate 0.5 mg)
89416429|NCT04304625|Experimental|Tranexamic acid|After the routine prophylactic IV or IM injection of the uterotonic used in the hospital protocol's -either oxytocin or carbetocin - (as recommended by the 2014 guidelines for prevention and management of postpartum hemorrhage from the CNGOF), the intervention will be the IV administration of a 10-ml blinded ampoule of the study drug (either TXA or placebo according to the randomisation sequence) to the patient within 3 minutes after birth, slowly (over 30-60 seconds), once the cord has been clamped
89416430|NCT04304625|Placebo Comparator|Placebo|After the routine prophylactic IV or IM injection of the uterotonic used in the hospital protocol's -either oxytocin or carbetocin - (as recommended by the 2014 guidelines for prevention and management of postpartum hemorrhage from the CNGOF), the intervention will be the IV administration of a 10-ml blinded ampoule of the study drug (either TXA or placebo according to the randomisation sequence) to the patient within 3 minutes after birth, slowly (over 30-60 seconds), once the cord has been clamped
89416431|NCT04286022|Experimental|Speed Loss 20% Group|The SL20% group will carry out a program based on the limitation of the speed loss, allowing to perform the exercise only until a speed loss of 20% is achieved, following a similar methodology previously published (Pareja-Blanco et al., 2017). The program will consist of a job for 4 weeks, with a frequency of 2 sessions a week. In each session, a 6-series routine with an open number of repetitions will be carried out twice, allowing as many repetitions as possible to perform until a 20% loss of execution speed is reached. The intensity of work will be 70% 1RM, resting 4 minutes between sets. As an only exercise, an elbow flexion (bicep curl) with dumbbell will be performed.
89416432|NCT04286022|Experimental|Reduced Rest Time Group|The RRT group will carry out a program based on the reduction of rest time between series, following a previously published methodology (Stragier et al., 2019). The program will consist of a job for 4 weeks, with a frequency of 2 sessions a week. In each session, a 5 series routine with progressive repetition volume (3 to 7) at 70% 1RM will be performed twice, resting 15 seconds between sets and 150 seconds between each of the 2 blocks. The exercise to be performed will be an elbow flexion (bicep curl) with dumbbell.
89416433|NCT04268550|Experimental|Treatment (selpercatinib)|Patients receive selpercatinib orally PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89530775|NCT03241849|Other|Modified surgical technique for placenta accreta|
89416434|NCT04259632|Experimental|Time Restricted Eating (TRE)|For the TRE group, we will restrict the eating window to 8 hours, where they will eat ad libitum. This is the same interval established by Dr. Panda and by our preliminary data. This interval will be entered into the mCC app and participants will be asked to adhere to this eating window during the intervention. All eating occasions will be logged using the mCC app. Only water and medications will be allowed outside of the eating window.
89416435|NCT04259632|Active Comparator|Caloric Restriction (CR)|Participants randomized to CR will meet with the study dietitian prior to the intervention and be counseled on options to reduce their caloric intake by 15%, while maintaining their eating window. The 15% reduction was selected as our preliminary data and recent literature suggest that TRE with ad libitum intake reduces caloric intake by ~270 to 300 cal/day. The 15% CR is similar to the 11.9% CR achieved by the CALERIE-2 study, which is a 2 year study of CR.26 All eating occasions will be logged using the mCC app. The weekly dietitian review of the mCC information will include maintenance of the eating window and examination of dietary intake to determine compliance with the 15% CR.
89416436|NCT04259632|No Intervention|Unrestricted Eating (non-TRE)|For the unrestricted eating (non-TRE) group, participants will eat ad libitum per their usual habits. They will receive initial counseling about mCC logging. All eating occasions will be logged using the mCC app.
89416437|NCT04255602|Experimental|low dose ticagrelor|After treated with ticagrelor 90mg twice daily and aspirin 100mg once daily for a week,subjects will be treated with ticagrelor 60mg twice daily and aspirin 100mg once daily for until one year after drug eluting stent implantation
89416438|NCT04255602|Active Comparator|standard dose ticagrelor|subjects will be treated with ticagrelor 90mg twice daily and aspirin 100mg once daily for a year since drug eluting stent implantation
88893831|NCT01772420|Experimental|Arm A (lenalidomide, eltrombopag olamine)|"Patients with baseline platelet counts >= 50,000 receive lenalidomide PO daily or QOD on days 1-21. If platelet counts fall below 50,000, patients discontinue lenalidomide and receive eltrombopag olamine PO daily or QOD until platelet count is maintained above 50,000 for 2 weeks. Patients then resume lenalidomide PO daily or QOD. If platelets fall below 50,000 again, patients receive eltrombopag olamine as before. When platelet counts are maintained above 50,000 for 2 weeks, patients resume lenalidomide concurrently with eltrombopag for all subsequent courses.~Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity."
89416439|NCT04240756|Experimental|Parent Stimulant Medication + Child Treatment Strategy|Parent stimulant medication first followed by a child treatment strategy consisting of behavioral parent training followed by a recommendation for child stimulant medication to the primary care provider if the child remains impaired.
89416440|NCT04240756|Active Comparator|Child Treatment Strategy|Child treatment strategy consisting of behavioral parent training followed by a recommendation for child stimulant medication to the primary care provider if the child remains impaired. In this arm, parents do not receive stimulant medication before behavioral parent training.
89416441|NCT04236596|Experimental|Medtronic Interstim II Model 3058 Neurostimulator|
89416442|NCT04229446|Experimental|Receive the music based intervention|After the healthcare workers have accomplished the MBC program the eight week intervention program will be applied by the trained staff at the intervention wards. The intervention (MBC) consists of daily individualized prerecorded music integrated with activity with about 30 minutes duration, combined with a one hour active session in groups twice weekly. The music will be selected based on individualized preferences from the patients or their family. The music will also be adapted to the day rhythm; awakening in the morning, support activities during the day, or for sleep in the evening. The healthcare worker will bring playback equipment e.g. a CD-player to the patient room. In addition will two weekly sessions in groups be performed (each on one hour) with music and movement. The movement will be adapted to their physical capacity.
89416443|NCT04229446|No Intervention|Standard care group|Standard care for participants in this group
89416444|NCT04228263|Other|hydroxychloroquine group|hydroxychloroquine 400 mg preconceptional
89416445|NCT04228263|Other|control group|not receive hydroxychloroquine
88893832|NCT01772420|Experimental|Arm B (eltrombopag olamine, lenalidomide)|"Patients with baseline platelet counts < 50,000 receive eltrombopag olamine PO daily or QOD on days 1-28 until platelet count is maintained above 50,000 for 2 weeks. Patients then receive treatment as in Arm A.~Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity."
89416446|NCT04222634|Other|MDT for oligoprogressive lesions in CRPC|"metastasis-directed therapy:~radiotherapy (SBRT or conventional radiotherapy in case of local recurrence or untreated primary tumor)~metastasectomy~salvage lymphadenectomy~salvage prostatectomy in case of local recurrence or untreated primary tumor"
89416447|NCT04205812|Experimental|INCMGA00012 + chemotherapy (nonsquamous NSCLC)|INCMGA00012 with pemetrexed + cisplatin OR carboplatin followed by INCMGA00012 plus pemetrexed until progression.
89416448|NCT04205812|Active Comparator|Placebo + chemotherapy (nonsquamous NSCLC)|Placebo with pemetrexed + cisplatin OR carboplatin followed by placebo plus pemetrexed until progression. Participants assigned to placebo + chemotherapy will have the option of receiving open-label monotherapy INCMGA00012 in a crossover period after documentation of progressive disease.
89416449|NCT04205812|Experimental|INCMGA00012 + chemotherapy (squamous NSCLC)|INCMGA00012 with carboplatin + paclitaxel OR nab-paclitaxel followed by INCMGA00012 until progression.
89416450|NCT04205812|Active Comparator|Placebo + chemotherapy (squamous NSCLC)|Placebo with carboplatin + paclitaxel OR nab-paclitaxel followed by placebo until progression. Participants assigned to placebo + chemotherapy will have the option of receiving open-label monotherapy INCMGA00012 in a crossover period after documentation of progressive disease.
88893833|NCT01728363|Experimental|Ticarcillin-clavulanate antibiotic|"Cohort Gestational Age (GA) Postnatal Age (PNA) Dose~<30 weeks <14 days: 75 mg/kg Q12 hrs x 6 doses~<30 weeks ≥14 days-45 days 75 mg/kg Q 8 hours x 6 doses~<30 weeks >45 days-90 days 75 mg/kg Q 6 hours x 6 doses~Brand name is Timentin. This drug is an antibiotic used to treat a wide variety of bacterial infections. It is a combination of two drugs & both treat bacterial infections. Ticarcillin is a penicillin-type antibiotic that stops bacterial growth & clavulanate potassium is an enzyme inhibitor that helps the ticarcillin work better."
89416451|NCT04201132|Experimental|Carotid artery stenting|Carotid artery stenting procedure with Neuroguard IEP System
89416452|NCT04198870|Other|Control Arm|Mitral Valve Repair Surgery
89416453|NCT04198870|Experimental|Device Arm|MitraClip™ device implantation
89416454|NCT04175886||Patients with rheumatoid arthritis|Patients with rheumatoid arthritis with an indication for tofacitinib: 5mgx2 per day
89416455|NCT04175886||Healthy subjects|Healthy subjects matched to cases (1:1) on age (±5 years), sex, and menopausal status for women and body mass index (BMI, ±3 kg/m²)
89416456|NCT04151901|Experimental|Male Rehabilitation (M-REHAB)|Disuse + resistance exercise rehabilitation
89416457|NCT04151901|Experimental|Male Control (M-CON)|Disuse + ambulatory control rehabilitation
89416458|NCT04151901|Experimental|Female Rehabilitation (F-REHAB)|Disuse + resistance exercise rehabilitation
89416459|NCT04151901|Experimental|Female Control (F-CON)|Disuse + ambulatory control rehabilitation
89416460|NCT04151082|Experimental|Supportive care (steroid therapy)|Patients receive prednisone PO (or by feeding tube) QD on days 1-5 and then taper off over 2 weeks or methylprednisolone IV over 1 hour on days 1-5 in the absence of disease progression or unacceptable toxicity.
89416461|NCT04139499||Adults with OSA|Adults with obstruction at any or all of the four levels of interest (velopharynx, oropharynx, tongue base, epiglottis) will represent the experimental group.
89416462|NCT04139499||Children with OSA|Children with obstruction at any or all of the four levels of interest (velopharynx, oropharynx, tongue base, epiglottis) will represent the experimental group.
89416463|NCT04139499||Adult control|Adult without any obstruction at four levels of interest (velopharynx, oropharynx, tongue base, epiglottis) will represent a control.
89416464|NCT04139499||Children control|Children exam will be done for all the participants. Subject without obstruction represent a control.
89416465|NCT04135066|Other|Refined grain breakfast|white bread (100g) + milk powder (25g)
89416466|NCT04135066|Other|Whole grain breakfast|plain oats (70g) + milk powder (25g)
89416467|NCT04134884|Experimental|ASTX727 + Talazoparib|
89416468|NCT04133168|Experimental|Cryoablation|Subjects undergoing cardiac ablation procedure with the Boston Scientific Cardiac Cryoablation System
89416469|NCT04132960|Experimental|HER2 status|"Three cohorts of advanced breast cancer patients:~Cohort 1: HER2 over-expressing (HER2 IHC3+ or HER2 IHC2+/ISH+)~Cohort 2: HER2 low-expressing (IHC1+ or IHC2+/ISH-)~Cohort 3: HER2 non-expressing (IHC0+)"
89416470|NCT04111094||HF|Diagnosed heart failure as described by recent guidelines. Inclusion criteria will be applied: i) minimum one symptom typical of HF: positive physical examination (e.g., bilateral oedema, increased jugular pressure) or positive clinical history (e.g., orthopnoea, history of coronary vascular disease, history of arterial hypertension, exposition to cardiotoxic drug/radiation, diuretic use); b-type natriuretic peptide (BNP) or N-terminal pro-BNP levels ≥35 or ≥125 pg/ml, respectively; and iii) classification as New York Heart Association (NYHA) functional class 2 or 3. There is no prespecified inclusion criterion with respect to left ventricular ejection fraction as congestive symptoms and prevalence of kidney dysfunction are comparable in patients with HF across the left ventricular ejection fraction spectrum.
89416471|NCT04111094||Diabetes mellitus/hypertension|Diagnosed diabetes mellitus, with/without treatment
89416472|NCT04111094||Hypertension|Diagnosed hypertension, with/without treatment
89416473|NCT04069793|Active Comparator|Home Trial Condition A|Subject will use a pattern recognition controlled prosthesis that includes a powered wrist rotation, passive wrist flexion/extension, and a single DOF powered hand.
88893834|NCT01728363|Experimental|Rifampin generic antibiotic|"Cohort GA PNA Dose~<32 weeks <14 days 10 mg/kg Q 24 hours x 4 doses~<32 weeks ≥14 days-120 days 15 mg/kg Q 24 hours x 4 doses~≥32 weeks <14 days 15 mg/kg Q 24 hours x 4 doses~≥32 weeks ≥14 days-120 days 20 mg/kg Q 24 hours x 4 doses~The brand name is Rifadin, Rimatane. This drug is an antibiotic and a first line antituberculotic and unlabeled use for infections caused by staphylococcus aureus & staphylococcus epidermis."
88893835|NCT01728363|Experimental|Clindamycin Generic Antibiotic|"Cohort GA PNA Dose~<30 weeks <14 days 10 mg/kg Q 12 hours x 6 doses~<30 weeks ≥14 days-45 days 10 mg/kg Q 8 hours x 6 doses~<30 weeks >45 days-120 days 10 mg/kg Q 6 hours x 6 doses~The brand name is Cleocin. This drug is an antibiotic used to treat a wide variety of bacterial infections and serious infections."
89416474|NCT04069793|Experimental|Home Trial Condition B|Subject will use at pattern recognition controlled prosthesis that includes a powered wrist rotation, powered flexion/extension and a single DOF powered hand.
88922153|NCT05725512|Experimental|Prednisolone|Prednisolone tablets (20 mg daily for 6 weeks, 10 mg daily for 1 week, 5 mg daily for 1 week)
89416475|NCT04063592|Experimental|Intervention|Subjects undergoing the proposed operative intervention. Intervention patients will serve as their own control for all outcome measures
89416476|NCT04057924||CIN 2 women|Non-interventional monocentric prospective study taking place at the Bordeaux University Hospital where women with a CIN2 meeting the eligibility criteria will benefit from abstention from treatment and surveillance for at least 2 years
89416477|NCT04049825|Experimental|Dose Escalation Stage|The dose of OPB-111077 in the first cohort will be 200 mg/day, increasing as appropriate to 400 mg/day in the second cohort and then to 600 mg/day in the third cohort.
89416478|NCT04049825|Experimental|Dose Expansion Stage|4 days on and 3days off of 21-day cycles of OPB-111077 Day 1 of 21-days cycles of rituximab Day 2 and 3 of 21-day cycles of bendamustine
88922154|NCT05725512|Placebo Comparator|Placebo|Identical placebo tablets for 8 weeks
89416479|NCT04046224|Experimental|Sequential dose escalation|"ST-920 is administered as a single infusion:~Cohort 1: 0.5e13 vg/kg~Cohort 2: 1.0e13 vg/kg~Cohort 3: 3.0e13 vg/kg~Cohort 4: 5.0e13 vg/kg"
89416480|NCT04046224|Experimental|Expansion Cohorts|"Anti Alpha-Gal A Antibody Positive Cohort~Anti Alpha-Gal A Antibody Negative Cohort~Female Cohort~Renal Cohort~Cardiac Cohort"
89416481|NCT04040166|Other|PET/MRI scan with 68Ga DOTATATE|PET/MRI scan with 68Ga DOTATATE of carotid arteries in in patients following head and neck radiation therapy
89416482|NCT04040088|Experimental|Cohort A (68Ga-DOTATATE, PET/CT)|Patients with newly diagnosed high-risk neuroendocrine cancer receive 68Ga-DOTATATE intravenously (IV) and undergo PET/CT over 20-30 minutes at diagnosis (before any treatment) and at the time of radiation treatment planning.
89416483|NCT04040088|Experimental|Cohort B (68Ga-DOTATATE, PET/CT)|Patients with previously diagnosed high-risk neuroendocrine cancer receive 68Ga-DOTATATE IV and undergo PET/CT over 20-30 minutes at the time of radiation treatment planning.
89416484|NCT04037228||KneeAlign 2|Those of the group will be adopt KneeAlign 2: accelerometer-based navigation system at total knee arthroplasty.
89416485|NCT04019119|Experimental|Intervention: digital intervention Behaviour Change Technique|The assigned participants will receive an intervention based on gamification and the use of behavior change techniques to reduce sedentary lifestyle. Thus, a new mobile application will be used for 12 weeks that proposes to the user the realization of activities with the aim of reducing their sedentary behavior. The development of the application is based on previous analyzes that propose 6 clusters that encompass 33 factors that influence sedentary behavior. In this way, the application is designed to act on the two accessible: social support and behavior. On the social support, he proposes to the user to share his achievements in social networks or in an internal network of game users. In terms of habit modification, behavior modification strategies proposed in the Michie et al. (2013) taxonomy are applied, such as the following: establishment of personalized goals, rewards and reminders, awareness of achievements achieved, among others
89530776|NCT03242005|Experimental|Pro-set® vs. Quick-set®|Subjects will be randomized to start with one of the study subcutaneous insulin administration sets (MiniMed® Pro-set® or MiniMed® Quick-set®). After completing the first study period,subjects will be placed in the alternative group according to the cross-over study design.
88893836|NCT01614197|Experimental|Dose Level 1|This is the starting dose of temsirolimus at 7.5 mg/m^2 given IV. First dose of temsirolimus will be administered on Day 1, followed immediately by the first dose of IV etoposide and IV cyclophosphamide. Etoposide (100mg/m^2) and cyclophosphamide (440 mg/m^2) are continued for the next four days (Day 1-5). A second dose of temsirolimus is given on Day 8.
88893837|NCT01614197|Experimental|Dose Level 2|If Dose Level 1 is tolerated, the study will escalate to Dose Level 2 following the dose escalation schedule. Dose Level 2 will be administered via IV at 10 mg/m^2. First dose of temsirolimus will be administered on Day 1, followed immediately by the first dose of IV etoposide and IV cyclophosphamide. Etoposide (100mg/m^2) and cyclophosphamide (440 mg/m^2) are continued for the next four days (Day 1-5). A second dose of temsirolimus is given on Day 8.
88893838|NCT01614197|Experimental|Dose Level 3|If Dose Level 2 is tolerated, the study will escalate to Dose Level 3 following the dose escalation schedule. Dose Level 3 will be administered via IV at 15 mg/m^2. First dose of temsirolimus will be administered on Day 1, followed immediately by the first dose of IV etoposide and IV cyclophosphamide. Etoposide (100mg/m^2) and cyclophosphamide (440 mg/m^2) are continued for the next four days (Day 1-5). A second dose of temsirolimus is given on Day 8.
88893839|NCT01614197|Experimental|Dose Level 4|If Dose Level 3 is tolerated, the study will escalate to Dose Level 4 following the dose escalation schedule. Dose Level 4 will be administered via IV at 25 mg/m^2. First dose of temsirolimus will be administered on Day 1, followed immediately by the first dose of IV etoposide and IV cyclophosphamide. Etoposide (100mg/m^2) and cyclophosphamide (440 mg/m^2) are continued for the next four days (Day 1-5). A second dose of temsirolimus is given on Day 8. Temsirolimus will not be escalated beyond Dose Level 4.
88893840|NCT01606826||Asthmatics|Subjects with active asthma.
88893841|NCT01606826||Healthy Controls|Subjects without any known pulmonary disease.
88893842|NCT01584063|No Intervention|Control|These women received general information about pregnancy and the postpartum period and tips for stress management. This information was delivered during 3 group meetings during pregnancy and 1 group meeting postpartum by trained staff from a local community mental health agency.
88893843|NCT01584063|Experimental|MOMs Healthy Lifestyle Intervention|These women received the culturally tailored Healthy MOMs Healthy Lifestyle Intervention, which included social support from Women's Health Advocates (community health workers) and peers, and the Healthy MOMs curriculum. This intervention curriculum covered topics related to healthy eating, physical activity, and stress management during pregnancy and postpartum. General information about pregnancy and the postpartum period were also provided. This intervention was delivered during 10 group meetings and 4 home visits.
88893844|NCT01520701|Active Comparator|Ialuset® application|Arm with application to the skin Ialuset ® cervical during radiotherapy
88893845|NCT01520701|Experimental|bandage skin Hydrosorb|Arm bandage skin hydrogel (Hydrotac®) on the skin cervical during radiotherapy
88893846|NCT01472094||Patients|All patients 65 years old with Stage I to III breast cancer who are beginning adjuvant or neo-adjuvant chemotherapy.
88893847|NCT01422148|Other|Amiodarone|oral amiodarone
88893848|NCT01422148|Experimental|minocycline|intravenous minocycline 100 mg daily x 5 days starting intra-operatively combined with oral amiodarone (400 mg twice daily for 7 days, then 200 mg twice daily for the next 7 days
88893849|NCT01341964|Experimental|Higher dose aspirin group|Clopidogrel 600 mg plus aspirin 325mg
88893850|NCT01341964|Active Comparator|Low dose aspirin group|Clopidogrel 600mg plus aspirin 81mg
88893851|NCT01293214|Experimental|Transplantation|Subjects will undergo single or multiple limb transplantation
88893852|NCT01267812|Experimental|Treatment (bortezomib and rituximab)|Doses of bortezomib given is 1.3 mg/m2 weekly x 4 weeks given every 3 month x 8 cycles. Doses of RITUXAN given is 375 mg/m2 give weekly x 4 weeks given every 6 month for 4 cycles.
88893853|NCT01247974|Experimental|CorMatrix ECM for Pericardial Closure|Pericardial closure with CorMatrix ECM
88893854|NCT01247974|No Intervention|Control|No Pericardial Closure
88893855|NCT01236521|Experimental|Arm 1: Pharmacological (MED)|Subjects in the Pharmacological (MED) arm will receive at least 8 contacts with the nurse care managers (NCM) over the trial period. Participants will have an initial visit at baseline to assess their current and past treatments for chronic lower back pain, pain intensity, and pain-related limitations. Patients' opioids will be adjusted and/or co-analgesics (or adjuvants) will be initiated. During follow-up calls, patients' pain severity, response to treatment, adherence, adverse effects, and desire to change current treatment will be assessed. Follow-up NCM telephone contacts will occur at 2 and 4 weeks after baseline, and months 2, 3, 4, 6, and 9 months. On average, these calls last between 10 to 20 minutes. Detailed logs will be kept of the timing and content of patient contacts.
88922155|NCT05722561|Experimental|Electronic Cigarette|Participants in the Electronic Cigarette (EC) arm will receive telehealth motivational counseling for 5 weeks plus the standardized research e-cigarette (SREC).
88922156|NCT05722561|Active Comparator|Nicotine Replacement Therapy|Participants in the Nicotine Replacement Therapy (NRT) arm will receive telehealth motivational counseling plus combination NRT (patch and lozenge).
88922157|NCT05717114|Placebo Comparator|Group I|received plan bupivacaine1ml/Kg
88922158|NCT05717114|Active Comparator|Group II|received plain bupivacaine 1ml/Kg plus dexmetomedine0.5 µg/Kg
88893856|NCT01236521|Experimental|Arm 2: Behavioral treatment (CBT)|Veterans randomized to behavioral treatment arm (CBT) will receive a series of 8 pain self-management/coping skills training sessions delivered by one of three primary-care based clinical psychologists. Since optimal application of non-pharmacological interventions for pain involves tailoring to patient needs, participants will be introduced to a menu of self-management and coping skills rather than receive a prescribed program. Delivery of the behavioral intervention will employ a flexible approach that is easily adapted to individual preferences and perceived need for learning specific pain coping skills. Tailoring will include the selection of relevant content and skills and assessment of readiness to change behaviors.
88893857|NCT01226797|Placebo Comparator|Placebo|
88893858|NCT01226797|Active Comparator|PF-04136309|
88893859|NCT01142908|Experimental|Arm 1|The pharmacist CVD intervention group - clinical pharmacist-administered intervention which focuses on behavioral and medication management for 12 months.
88893860|NCT01142908|No Intervention|Arm 2|The education control group - these participants will receive educational material about CVD reduction.
88893861|NCT01051895|Experimental|HPV testing|Women randomized to this arm will undergo high risk HPV DNA testing using Hybrid Capture 2®.
89416486|NCT04019119|No Intervention|Control Group|The control group will receive the usual indications about the harms of sedentary lifestyle and the benefits of physical activity, not receiving specific intervention. In case the use of the intervention applied in the experimental group is beneficial, the participants assigned to the control group will be offered the opportunity to receive the intervention outside the study to allow the benefit to be used.
89416487|NCT04007757||1|Participants who have had a hemorrhagic stroke and have been enrolled into the Genetic and Environmental Risk Factors for Hemorrhagic Stroke Study who live in the area of University of Cincinnati, Massachusetts General Hospital, University of Maryland, Duke University, Columbia University and University of Chicago Illinois, age 18 years or greater. Ability of participant or legal representative to provide informed consent. Racial/ethnic category of Caucasian, African American or Hispanic.
88893862|NCT01051895|Active Comparator|Routine colposcopy|Women will be followed in the colposcopy clinic as usual, with no standardized protocol, tests are left at the discretion of the treating physician, in order to document routine proactive. We will document all procedures (biopsies, endocervical curettage, cytology, etc) and their outcome.
88893863|NCT01042379|Active Comparator|Standard Therapy|Paclitaxel, Herceptin followed by Doxorubicin and Cyclophosphamide treatment depending on HR/HER-2 status.
89416488|NCT04000672|Active Comparator|HTO with navigation|High Tibial Osteotomy is offered to patients with symptomatic medial compartment knee osteoarthritis (OA)
89416489|NCT04000672|Experimental|HTO with navigation + PSI jig|"3D printed patient specific metal jigs (PSI jig) are created based on the pre-operative CT image. After that, calibrated osteotome is used to achieve the desired correction with the use of navigation for overall lower limb alignment, which is the same as the Active Comparator group."
88893864|NCT01042379|Experimental|AMG 386 with or without Trastuzumab|Arm is closed.
88893865|NCT01042379|Other|AMG 479 plus Metformin|Arm is closed.
88893866|NCT01042379|Experimental|MK-2206 with or without Trastuzumab|Arm is closed.
88893867|NCT01042379|Experimental|T-DM1 and Pertuzumab|Arm is closed.
89416490|NCT03970304|Experimental|Vaccination, Colonoscopy|Individuals receive immunization with Vivotif typhoid vaccine prior to routine colonoscopy examination. During colonoscopy, small bowel biopsies will be obtained to examine immune responses and microbiota at the mucosal level; brushings will also be obtained.
88893868|NCT01042379|Active Comparator|Pertuzumab and Trastuzumab|Novel Control Investigational Agent. Arm is closed.
88893869|NCT01042379|Experimental|Ganetespib|Arm is closed.
88893870|NCT01042379|Other|ABT-888|Arm is closed.
88893871|NCT01042379|Other|Neratinib|Arm is closed.
88893872|NCT01042379|Experimental|PLX3397|Arm is closed.
88893873|NCT01042379|Experimental|Pembrolizumab 4 cycle|Arm is closed.
89416491|NCT03970304|Experimental|Colonoscopy, Vacciniation, Colonoscopy|Individuals receive immunization with Vivotif typhoid vaccine after initial colonoscopy exam and specimen collection and prior to a routine follow up colonoscopy examination during which additional specimens will be collected.
89536775|NCT05333315|Experimental|Investigation Product 2 (IP2) in powder form|Fiber of light Indian plantain, 7 g; glucomannan, 4,3 g; Inulin 2,5 g; Apple fiber, 1g; Choline, bitartrate 90 mg; Apple pectin,50 mg; Inositol, 40 mg
88893874|NCT01042379|Experimental|Talazoparib plus Irinotecan|Arm is closed.
88893875|NCT01042379|Experimental|Patritumab with or without Trastuzumab|Arm is closed.
88893876|NCT01042379|Experimental|Pembrolizumab 8 cycle|Arm is closed.
88893877|NCT01042379|Experimental|SGN-LIV1A|Arm is closed.
88893878|NCT01042379|Experimental|Durvalumab plus Olaparib|Arm is closed.
88893879|NCT01042379|Experimental|SD-101 + Pembrolizumab|Arm is closed.
88893880|NCT01042379|Experimental|Tucatinib|Arm is closed.
88893881|NCT01042379|Experimental|Cemiplimab|Novel Investigational Agent. Arm is closed.
88893882|NCT01042379|Experimental|Cemiplimab plus REGN3767|Novel Investigational Agent. Arm is closed.
88893883|NCT01042379|Experimental|Trilaciclib with or without trastuzumab + pertuzumab|Novel Investigational Agent. Arm is closed.
88893884|NCT01042379|Experimental|SYD985 ([vic-]trastuzumab duocarmazine)|Novel Investigational Agent. Arm is closed.
88893885|NCT01042379|Experimental|Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab|Novel Investigational Agent. Arm is closed.
88893886|NCT01042379|Experimental|Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab|Novel Investigational Agent. Arm is closed.
88893887|NCT01042379|Experimental|Endocrine Optimization Pilot: Amcenestrant Monotherapy|Novel Investigational Agent. Arm is closed.
88893888|NCT01042379|Experimental|Endocrine Optimization Pilot: Amcenestrant + Abemaciclib|Novel Investigational Agent. Arm is closed.
88893889|NCT01042379|Experimental|Endocrine Optimization Pilot: Amcenestrant + Letrozole|Novel Investigational Agent. Arm is closed.
88893890|NCT01042379|Experimental|ARX788 in Block A and followed by SOC in Block B|Novel investigational Agent followed by SOC
89416492|NCT03970304|No Intervention|Colonoscopy Without Vaccination|Individuals do not receive immunization but consent to collection of specimens during colonoscopy. The specimens to be collected in all three groups include stool, saliva, and small bowel biopsies (terminal ileum).
89416493|NCT03921008|Experimental|Paclitaxel and Radiation|"All patients will receive standard of care induction chemotherapy with 6 weekly cycles of paclitaxel at 80 mg/m^2. They will then receive 6 weekly cycles of paclitaxel at 80 mg/m^2 concurrently with radiation therapy. Patients will be receiving paclitaxel as part of their routine care, but in order to participate in this study, their induction chemotherapy regimen must be paclitaxel. Radiation therapy is 50.4 Gy in 28 fractions delivered within 7 weeks.~Standard of care surgery ideally within 6 weeks after completing concurrent chemotherapy and radiation therapy"
89416494|NCT03915106||Bracing|AIS patients undergoing bracing to control the spinal curve progression
88893891|NCT01042379|Experimental|ARX788 + Cemiplimab in Block A and followed by SOC in Block B|Novel investigational Agent followed by SOC. Arm is closed.
88893892|NCT01042379|Experimental|VSV-IFNβ-NIS (VOYAGER V1™; VV1) + Cemiplimab in Block A and followed by SOC in block B|Novel investigational Agent followed by SOC
88893893|NCT01042379|Experimental|Datopotamab Deruxtecan in Block A and followed by SOC in block B|Novel investigational Agent followed by SOC
88893894|NCT01042379|Experimental|Datopotamab Deruxtecan + Durvalumab in Block A and followed by SOC in block B|Novel investigational Agent followed by SOC
88893895|NCT01042379|Experimental|Zanidatamab in Block A and followed by SOC in block B|Novel investigational Agent followed by SOC
88893896|NCT01042379|Experimental|Endocrine Optimization Pilot: Lasofoxifene|Novel investigational Agent
88893897|NCT01042379|Experimental|Endocrine Optimization Pilot: (Z)-Endoxifen|Novel investigational Agent
88893898|NCT01042379|Experimental|Endocrine Optimization Pilot: ARV-471|Novel investigational Agent
88893899|NCT01042379|Experimental|Endocrine Optimization Pilot: ARV-471 + Letrozole|Novel investigational Agent
88893900|NCT01033188|Active Comparator|Single-bundle technique|Anatomic single-bundle technique
88893901|NCT01033188|Active Comparator|Double-bundle technique|Anatomic double bundle technique
88893902|NCT00687414||adults|male and female with MDS and MPD and AML
88893903|NCT00687414||Healthy|Healthy control group
88893904|NCT00544115|Active Comparator|Regimen I|Patients undergo total body irradiation (TBI) on days -7 to -4 and receive cyclophosphamide IV on days -3 and -2. Alternatively, patients may receive cyclophosphamide on days -7 and -6 and undergo TBI on days -4 to -1.
88893905|NCT00544115|Active Comparator|Regimen II|Patients receive busulfan IV over 2 hours once on day -8 and then every 6 hours on days -7 to -4. Patients also receive cyclophosphamide IV on days -3 and -2.
88893906|NCT00544115|Active Comparator|Regimen III|Patients undergo TBI on days -7 to -4 and receive etoposide IV on day -3.
88893907|NCT00544115|Active Comparator|Regimen IV|Patients receive fludarabine phosphate IV over 30 minutes on days -7 to -3 and melphalan IV on day -2.
88893908|NCT00544115|Active Comparator|Regimen V|Patients receive fludarabine phosphate IV over 30 minutes on days -4 to -2 and undergo TBI on day 0.
89416495|NCT03915106||Surgical|Severe AIS patients requiring surgical intervention to correct the spinal curve
89416496|NCT03901053|Experimental|AB|Participants in this arm will receive the Reaktiv AFO made by FabTech Systems LLC first, then the PhatBrace AFO by Bio-Mechanical Composites Inc. second.
89416497|NCT03901053|Experimental|BA|Participants in this arm will receive the PhatBrace AFO by Bio-Mechanical Composites Inc. first, then the Reaktiv AFO made by FabTech Systems LLC second.
89416498|NCT03889613|Experimental|all patients|All enrolled patients- prospective observation (all patients are followed using videocapsule)
89416499|NCT03880344|Experimental|Vibration Therapy + Normal Out-Patient Physiotherapy|Patients' randomized to this group will receive vibration therapy as a pre-operative rehabilitation programme 3 times a week for 3 months. Regular out-patient department physiotherapy will also be given. They will be assessed 6 weeks and 6 months post operatively.
89416500|NCT03880344|Active Comparator|Normal Out-Patient Department Physiotherapy|Patients randomized to this group will receive regular out-patient department physiotherapy postoperatively for 6 months. They will be assessed 6 weeks and 6 months post operatively.
88893909|NCT00544115|Active Comparator|Regimen VI|Patients receive busulfan IV over 3 hours and fludarabine phosphate IV over 30 minutes on days -5 to -2.
88893910|NCT00150488|Experimental|1|Uracyst® single arm open label Treatment Group
88893911|NCT01455350|Active Comparator|Lidocaine|10 week treatment of daily application of topical lidocaine
89006084|NCT04646980|Placebo Comparator|Placebo|This arm consisted from 20 males and 20 females. Placebo, with the same appearance and taste, was orally supplemented at dose of 500 mg per day for 3 months (end of November 2018- end of February 2019).
88893912|NCT01455350|Experimental|Multimodal physiotherapy|10 weeks of weekly multimodal physiotherapy treatments
88893913|NCT01455636|Experimental|Hand hygiene with Hand Sanitizer (HS)|"To obtain 480 low birth weight infants the entire area of Kaliganj and Norsinghdi will be divided into 48 clusters based on the list of pregnant women identified through a household survey.~24 clusters will be randomized to receive Hand Sanitizer plus nutrition and hygiene education and the remaining 24 will receive only nutrition and hygiene education."
88893914|NCT01455636|Experimental|Hand hygiene with no Hand Sanitizer|"To obtain 480 low birth weight infants the entire area of Kaliganj and Norsinghdi will be divided into 48 clusters based on the list of pregnant women identified through a household survey.~24 clusters will be randomized to receive Hand Sanitizer plus nutrition and hygiene education and the remaining 24 will receive only nutrition and hygiene education."
88893915|NCT01455636|Experimental|Micronutrient Powder|"From 6 months of age, children in randomized clusters will be assigned to receive one sachet of Improved Micronutrient Powder, I-MNP per day for six months with or without hand sanitizer.~Throughout the entire intervention period, mothers/caregivers of the children in all groups will receive simple, standardized, and age and culturally appropriate nutrition and health education that aims to improve feeding and health-seeking behavior and caring practices."
88922159|NCT05717114|Active Comparator|GroupIII|received plain bupivacaine 1ml/Kg plus dexmetomedine1µg/Kg
88893916|NCT01455636|Placebo Comparator|Control|"From 6 months of age, children in randomized clusters will be assigned to receive no hand sanitizer or no micronutrient powder~Throughout the entire intervention period, mothers/caregivers of the children in all groups will receive simple, standardized, and age and culturally appropriate nutrition and health education that aims to improve feeding and health-seeking behavior and caring practices."
88893917|NCT01456026|Experimental|Glycated beta-lactoglobulins|In this randomized, double blind,cross-over study, half of the subjects will receive on one day a beverage with a high AGE content and will be switched after a wash-out of min. 7 days to receive a low-AGE beverage (comparator). The other half will receive the beverages in inverse sequence.
88893918|NCT01456026|Active Comparator|Non-glycated beta-lactoglobulins|In this randomized, double blind,cross-over study, half of the subjects will receive on one day a beverage with a high AGE content and will be switched after a wash-out of min. 7 days to receive a low-AGE beverage (comparator). The other half will receive the beverages in inverse sequence.
88893919|NCT01456078|Experimental|177Lu-DOTA-TATE|
88893920|NCT01456507|Experimental|A|1×40 mg ALO-02 capsule administered with 240 mL of water under fasting conditions.
88893921|NCT01456507|Experimental|B|1×40 mg ALO-02 capsule administered with 240 mL of water under fed conditions (standard high fat breakfast).
88893922|NCT01456507|Experimental|C|1×40 mg ALO-02 with the ALO-02 pellets sprinkled approximately on one table spoon of applesauce, and administered with 240 mL of water under fasting conditions.
88893923|NCT01456520|Experimental|A: single dose Vycavert (Test)|
88893924|NCT01456520|Active Comparator|B: single dose Norco (Reference)|
88893925|NCT01456572|Active Comparator|satiation_obese weight|Obese subjects will receive a complex nutrient drink (Ensure Plus; 17 % protein, 30 % fat and 53 % carbohydrate, 1 kcal/mL). Nutrient intake will be stopped when subjects had reached maximal or unbearable satiation; the time needed to reach the maximal level of satiation (tmax) and the quantity of volume drunk will be recorded and calorie intake calculated.
88893926|NCT01456572|Active Comparator|gastric emptying_obese weight|Obese subjects will receive a standardized meal, consisting of two scrambled eggs (cooked with 10 g butter), placed on two slices of whole wheat bread and 200 mL of milk (in total: 468 kcal). The test meal will be labeled with 100 mg of 13C-octanoic acid for determination of gastric emptying.
88893927|NCT01456572|Placebo Comparator|gastric emptying_normal weight|Normal weight subjects will receive a standardized meal, consisting of two scrambled eggs (cooked with 10 g butter), placed on two slices of whole wheat bread and 200 mL of milk (in total: 468 kcal). The test meal will be labeled with 100 mg of 13C-octanoic acid for determination of gastric emptying.
88893928|NCT01456572|Placebo Comparator|satiation_normal weight|Normal weight subjects will receive a complex nutrient drink (Ensure Plus; 17 % protein, 30 % fat and 53 % carbohydrate, 1 kcal/mL). Nutrient intake will be stopped when subjects had reached maximal or unbearable satiation; the time needed to reach the maximal level of satiation (tmax) and the quantity of volume drunk will be recorded and calorie intake calculated.
88893929|NCT01456572|Active Comparator|hormone profiles_obese weight|Obese subjects will receive 500 mL of a complex nutrient drink (Ensure Plus; 17 % protein, 30 % fat and 53 % carbohydrate). At regular time intervals fasting and post-prandial blood samples will be collected.
88893930|NCT01456572|Placebo Comparator|hormone profiles_normal weight|Normal weight subjects will receive 500 mL of a complex nutrient drink (Ensure Plus; 17 % protein, 30 % fat and 53 % carbohydrate). At regular time intervals fasting and post-prandial blood samples will be collected.
88893931|NCT01456650|Experimental|Glyburide|Patients in which the fasting glucose persisted above the treatment goal (fasting glucose <126 mg/dl) after a 4 week diet period will receive glyburide. The dose of the medication will be adjusted based on the results of fasting glucose values. At each visit patients will return the leftover tablets; counts of the tablets will be the method for measuring the adherence to treatment. The medical study participants who decided to doses of glibenclamide will not know the allele of ABCA1 gene under study.
88893932|NCT01456806|No Intervention|Patients and provider non educated|In this arm neither the patients nor the providers have attended the groupal education courses
88893933|NCT01456806|Active Comparator|Provider educated|Provider attend the interactive group education, while patients do not.
88893934|NCT01456806|Active Comparator|Patients Educated|Patients attend the interactive group education, while providers do not.
88893935|NCT01456806|Active Comparator|Providers/Patients Educated|Provider and Patients both attend the interactive group education.
88893936|NCT01457040|Experimental|Complete Remission (CR)|CR Cohort: high-risk ALL in CR and standard-risk ALL in the status of ≥CR2
88893937|NCT01457040|Experimental|Non-Remission (NR)|NR Cohort: ALL in non-remission
88893938|NCT01457248|Experimental|endotracheal tube with taper-shaped cuff|
88893939|NCT01457248|Active Comparator|Endotracheal tube with cylindrical-shaped cuff|
88893940|NCT01457508|Experimental|Group A|Subjects will receive one single injection of DTPa-HBV-IPV vaccine mixed with Hib vaccine.
88893941|NCT01457508|Active Comparator|Group B|Subjects will receive two separate injections of DTPa-HBV-IPV and Hib vaccine.
88893942|NCT01457534||liver transplantation|
88893943|NCT01457586|Active Comparator|Transfusion|Patient who received blood transfusion in the perioperative period
88893944|NCT01457586|No Intervention|No Transfusion|Patients who did not receive blood transfusion in the perioperative period
88893945|NCT01457794|Other|NewNordicDiet first|Intervention with NND for 3 mo then no intervention for 3 mo
88893946|NCT01457794|Other|NewNordicDiet last|No intervention for 3 mo and then intervention with NND for 3 mo
88893947|NCT01458093||Colonoscopy patients|Consecutive colonoscopy outpatients referred to one of 29 endoscopy units in Italy
88893948|NCT01458145|Experimental|Home visits|
88893949|NCT01458145|No Intervention|routine primary care at community health center|
88893950|NCT01458184|Experimental|PhoneCare system|This arm is evaluating whether utilizing the PhoneCare system aids participants with their complex health care needs.
88893951|NCT01458184|No Intervention|Control Group: without PhoneCare System|Subjects in this arm will receive the usual care. Usual care is defined as receiving regular care from their physicians and no additional care or intervention from the study.
88893952|NCT01458314|Active Comparator|Rehabilitation without NIV|A usual rehabilitative training will be performed in patients using nocturnal NIV, without adoption of daily NIV
89416501|NCT03870919|Other|Palbociclib + locoregional treatment|All patients will receive the standard of care treatment ie Palbociclib + letrozole for 24-26 weeks (a delay of +/- 2 weeks to initiate the locoregional treatment is authorized after the day 1 of cycle 1 of palbociclib plus letrozole). After this period, patient will have the most adapted locoregional treatment ie surgery (conservative or mastectomy) with or without radiotherapy, or radiotherapy. The palbociclib will be continued until progression
89416502|NCT03855800|Experimental|Clinical Follow-up|"Participants not undergoing surgery will be assigned to the Clinical Follow-up study group. Blood, stool, pancreatic juice and cyst fluid collection will be done as per protocol. All participants in the Clinical Follow-up group will be contacted yearly for a telephone interview until they undergo surgery, die, receive a diagnosis that excludes them from the study, or for 5 years, and interval medical records will be obtained and reviewed. During follow-up results of clinically indicated follow-up imaging studies will be abstracted"
89416503|NCT03855800|Other|Surgical|"Participants scheduled for surgical resection after their initial clinical evaluation will be assigned to the Immediate Surgery study group. Blood, stool, pancreatic juice and cyst fluid collection will be done as per protocol. Participants in the Immediate Surgery group will be followed until the surgical pathology of their pancreatic cyst is known."
89416504|NCT03851198|Experimental|Mild Cognitive Impairment patients|Subjects diagnosed with mild cognitive impairment, who will receive the best treatment of clinical practice, will be recruited. They must be more than 60 years old.
88893953|NCT01458314|Experimental|Daily NIV during rehabilitation|Daily NIV will be adopted during the rehabilitation program in patients already using nocturnal NIV
89193180|NCT05438875|Experimental|ATRA and Eltrombopag|ATRA 10 mg, 2 times a day, orally; The initial dose of eltrombopag was 50 mg/time, once a day. According to the clinical standard of eltrombopag dose adjustment in the research protocol set by the research group, the dose was increased when the platelet count was lower than 5×109/L. The maximum dose is 75 mg/d, the dose is reduced if it is higher than 200×109/L, and the drug is temporarily discontinued when it is higher than 400×109/L, and the drug is repeated according to the platelet count. The treatment course is 12 weeks.
88893954|NCT01458353|Experimental|Handsewn ileocolonic anastomosis|Swabs obtained from patients undergoing handsewn ileocolonic anastomosis
88893955|NCT01458353|Experimental|Stapled ileocolonic anastomosis|Swabs obtained for culture in those patients undergoing stapled ileocolonic anastomosis
88893956|NCT01458431|Experimental|Levobupivacaine|Continuous levobupivacaine subfascial infusion
88893957|NCT01458431|Placebo Comparator|NaCl|Continuous NaCl subfascial infusion
88893958|NCT01458678|Active Comparator|Oesophageal Doppler (OD)|Goal directed volume therapy is most often guided by stroke volume measurements by OD.
88893959|NCT01458678|Active Comparator|Pleth Variability Index (PVI)|The Pleth variability index (PVI) is an automated function in pulse oximetry that continuously calculates the dynamic variation between the pulse oximetry pulse variation and its baseline for every breathing circuit. Dynamic indicators are advantageous in predicting a responder to a volume bolus, thus facilitating goal directed volume therapy.
88893960|NCT01458782|Active Comparator|ACI-C|Autologous chondrocyte implantation using collagen membrane (ChondroGide) Please see reference 1 and 2 for details regarding ACI. In this study we are using the collagen membrane instead of periosteum- the other details are exactly the same as in our previous RCT.
88893961|NCT01458782|Active Comparator|AMIC|"Autologous matrix induced chondrogenesis. Microfracture of the defect and covering using the collagen membrane (ChondroGide).~Please see reference 3 for details regarding AMIC"
88893962|NCT01458808|Experimental|Group A|Composed by 21 patients treated with reduction of 2 grams of sodium reduction in their habitual diet.
88893963|NCT01458808|Experimental|Group B|Composed by 20 patients treated by reduction of dialysate concentration from 138 to 135 mEq/L
88893964|NCT01458808|No Intervention|Group C|Composed by 18 patients followed without changes in dialysate sodium concentration or diet sodium amount.
88893965|NCT01459328|Active Comparator|Arm A: Conventional Long Course Chemo-Radiation|Conventional long course chemo-radiation
89193181|NCT05435833|Experimental|Group I (glossopharyngeal nerve block group)|bilateral ultrasound guided GPN block will be performed after induction of anesthesia and pre incisional by an experienced anesthesiologist
88893966|NCT01459328|Experimental|Arm B: Short Course Radiation Followed by Chemotherapy|Experimental short course radiation followed by chemotherapy.
88893967|NCT01459393|Experimental|5-ALA Photodynamic Therapy|Topical application of a 2mm of thickness layer of 20% 5-aminolevulinic acid (5-ALA) associated with 20% dimethyl sulfoxide (DMSO) and 3% ethylene diamine acid (EDTA) emulsion, over the actinic keratosis lesion and over a 0,5 cm margin around it. After a 4 hours interval under light protection with plastic film and aluminum foil, the light protection and the emulsion is removed. Then the lesion is lightened with a red (630 nm) incoherent LED lamp AKTILITE CL 128 (PhotoCure ASA, Oslo, Norway) with a total light dose of 37J/cm2.After that dressings are done and kept for 24H, and removed at patient home.
88893968|NCT01459393|Active Comparator|Cryotherapy with liquid nitrogen|Topical application of liquid nitrogen spray (500ml Cry-ac ® bottle) over the actinic keratosis lesion and over a 0,5 cm margin around it during sufficient time to freeze both the lesion and margin.
88893969|NCT01459445|Other|Metformin+Drospirenone / EE 30µg|
88893970|NCT01459458|Experimental|Clinics trained in brief intervention|Female clients ages 16-29 seeking care in 11 reproductive health clinics in Western Pennsylvania where clinic providers are trained to implement the brief partner violence/reproductive coercion intervention.
88893971|NCT01459458|No Intervention|Control sites providing standard of care|Female clients ages 16-29 seeking care in 14 reproductive health clinics in Western Pennsylvania where clinic providers are providing standard domestic violence screening per usual standard of care.
89193182|NCT05435833|No Intervention|Group II(Control group)|general anesthesia alone (no block)
88893972|NCT01459523|Active Comparator|Imaging technique|In one substudy, subjects will be randomly assigned to either short axis or long axis target ultrasound imaging for perineural catheter insertion. The onset time of sensory anesthesia will be measured following local anesthetic bolus via the catheter.
88893973|NCT01459523|Active Comparator|Catheter location|In another substudy, subjects will be randomly assigned to receive their perineural catheters either proximally or distally along the same target nerve or plexus.
88893974|NCT01459744|Experimental|Communication training for cardiologists|The intervention consists of an educational workshop for heart failure physicians, a reminder system, and a system providing aggregated feedback on their conversations with patients about ICD deactivation.
88893975|NCT01459744|Placebo Comparator|Control arm|Cardiology grand rounds will be held at usual care sites on the importance of advance care planning.
88893976|NCT01459757||Data generated from the past sunitinib A6181036 GIST study|
88893977|NCT01459874||Cardiac Implantable Device recipients|
88893978|NCT01459965|Active Comparator|10 French Stent|10 French biliary plastic stent
88893979|NCT01459965|Active Comparator|11.5 French stent|11.5 French biliary plastic stent
88893980|NCT01460004|No Intervention|patella knee strap|infra patella knee strap- cotton, applied in straight leg
88893981|NCT01460017|Active Comparator|DS arm|Deep sclerectomy surgery will be conduct in this arm
89193183|NCT05427123||Youth with or at clinical high risk for Bipolar Spectrum Disorder|Youth included in the study will have a Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) diagnosis of Bipolar I or II, Cyclothymic Disorder, or Other Specified Bipolar Disorder (per Course and Outcome of Bipolar Youth study definition)
88893982|NCT01460017|Active Comparator|Trab arm|combined Trabeculectomy and Trabeculotomy surgery will be conducted in this arm
88893983|NCT01460030|Experimental|KRN1493|
88893984|NCT01460043|Placebo Comparator|placebo|
88893985|NCT01460043|Experimental|Homeopathy|Individualized symptom based therapy
88893986|NCT01460056||Peritoneal dialysis|
88893987|NCT01460069|Active Comparator|Victoza treatment|
88893988|NCT01460069|Placebo Comparator|Placebo|The placebo pens contain saline and are administered in the same way and volume as Victoza. The placebo pens are specially prepared for this study and will be used in the study only.
88893989|NCT01460082||Exacerbation|The study sample will consist of patients admitted to the hospital because of an acute exacerbation of COPD
88893990|NCT01460095|Experimental|HbA1c measurement and education|3-monthly Hba1c determination with immediate feedback and targeted education delivered to all participants
88893991|NCT01460108|Experimental|AeriSeal System Treatment|Candidates for the trial include patients with advanced non-bullous upper lobe predominant emphysema who have a DLco between 20 and 60% predicted and target sites in at least 1 upper lobe. Eligible and consented patients will undergo evaluation with the Chartis System, and only patients found to have significant collateral ventilation will be enrolled.
88893992|NCT01460121|Experimental|SpotOn's corrective elements|
88893993|NCT01460121|Placebo Comparator|Placebo corrective elements|
88893994|NCT01460134|Experimental|Hematologic Malignancies (Dose Escalation)|B-Cell Enrollment COMPLETED T-Cell Enrollment COMPLETED
89416505|NCT03851198|Active Comparator|Healthy Subjects/ Match control|Healthy subjects of the same age as people with mild cognitive impairment.
88893995|NCT01460134|Experimental|Solid tumors (Dose Escalation; COMPLETED)|
88893996|NCT01460134|Experimental|Solid Tumors (Expansion Phase; COMPLETED)|Several expansion cohorts of up to 15 patients each are planned, including melanoma and renal cell carcinoma.
88893997|NCT01460134|Experimental|Hematologic Malignancies (COMPLETED)|Several expansion cohorts of up to 15 patients each are planned, including Hodgkin lymphoma.
88893998|NCT01460147|Other|DXA scan + MRI|
88893999|NCT01460173|Other|Normal subjects|
88894000|NCT01460173|Other|OSA Patients|
88894001|NCT01460186|Experimental|Blood samples|
88894002|NCT01460199|Placebo Comparator|Placebo|Matching Placebo
88894003|NCT01460199|Experimental|CTP-499|
88894004|NCT01460212|Experimental|Cognitive-Behavior Therapy group|treatment with Cognitive-Behavior Therapy
88894005|NCT01460212|Active Comparator|SSRI antidepressants|treatment by SSRI antidepressant
88894006|NCT01460238||No treatment|No intervention. Each patient will have blood drawn at a standard of care venipuncture.
88894007|NCT01460251|Experimental|Drug:Diapep277|1.0 mg DiaPep277® administered every 3 months.For patients who just completed the 2-year 901 study, a 3-year extended treatment will be offered with 13 administrations; patients who completed the 2-year 910 extension study will be offered a 3rd year of treatment with 5 additional administrations.
88894008|NCT01460277|Experimental|Hydrokinesiotherapy|A 6-week water-based exercise program that focused on balance and weight bearing exercises (3 days a week for 1 hour a session)
88894009|NCT01460277|Active Comparator|Conventional exercise intervention|A 6-week land-based exercise program that focused on balance and weight bearing exercises (3 days a week for 1 hour a session)
88894010|NCT01460316||Conotruncal cardiac defects patients|
88894011|NCT01460316||Mothers of patients|
88894012|NCT01460329||USCOM Cardiac index|
88894013|NCT01460355|Active Comparator|Botulinum toxin plus surgery|Intraoperative injection of 5U (0.1 ml) of Botulinum Toxin will be given to the recessed muscle during surgery
88894014|NCT01460355|Placebo Comparator|Saline solution plus surgery|Saline solution (0,1 ml)will be given to the recessed muscle during surgery procedure
88894015|NCT01460394||Healthy adolescents and young adults|
88894016|NCT01460420|Experimental|Bortezomib + Lenalidomide|After conditioning treatment and graft versus host disease prophylaxis with Bz 1.3 mg/m2 on days +1, +4 and +7 plus sirolimus/rapamycin at a dose of 6 mg po on day -5 and then 4 mg per day in order to maintain serum levels in the range of 6-12 ng /mL, a maintenance therapy with Bz 1.3 mg/m2 on days 1, 8 and 15 in cycles of 56 days up to 6 cycles post-transplant and on day +180 Len will be started at a dose of 5 mg and will be maintained until relapse.
88894017|NCT01460459|Experimental|high frequency of SMBG|Patients are instructed to measure their blood glucose concentrations 4 times per day (pre-prandial and before bedtime) one day weekly in group A.
89199144|NCT05954923|Experimental|Primary arm|This is a single-arm study. Each subject will participate in 6 experimental days in a randomized order. The interventions are equimolar bolus infusions of A) glutamine, B) arginine, C) alanine, D) leucine, E) proline and F) saline (placebo)
88894018|NCT01460459|Experimental|middle frequency of SMBG|Patients are instructed to measure their blood glucose concentrations 4 times per day (pre-prandial and before bedtime) one day per two weeks in group B.
88894019|NCT01460459|Experimental|low frequency of SMBG|Patients are instructed to measure their blood glucose concentrations 4 times per day (pre-prandial and before bedtime) Group C: one day monthly
88894020|NCT01460472|Experimental|Racotumomab plus Best Support Treatment|Patients will receive Racotumomab and Best Support Treatment, which includes any further onco-specific therapy for progressive disease.
88894021|NCT01460472|Active Comparator|Best Support Treatment|Patients will receive best support treatment for advanced NSCLC including onco-specific therapies when disease progresses.
88894022|NCT01460498|Experimental|Dose Escalation Group (AZA)|Azacitidine (AZA) starting dose 50 mg/m2 a day for 3 days subcutaneous or intravenous of 28 day cycle. TKI at dose received during last 6 months.
88894023|NCT01460498|Experimental|Expansion Group (AZA MTD)|Dose Escalation Group plus additional 36 participants for Azacitidine 75 mg/m2 (or Phase I MTD) either subcutaneous or intravenous every day for 3 days of 28 day cycle. TKI at dose received during last 6 months.
89006085|NCT04646863|Experimental|group A|consists of 20 patients received a multiwave locked system laser
89006086|NCT04646863|Experimental|group B|consists of 20 patients received Pilates exercises
89199145|NCT05954897|Experimental|Experimental group|
88894024|NCT01460537|Experimental|Treatment A: Gemcitabine-Copanlisib|The treatment consists of repetitive cycles, each over 28 days. Treatment continues until disease progression or dose limiting toxicity. If gemcitabine is discontinued for toxicity, Copanlisib may be continued at the discretion of the Investigator if a clinical benefit (response or stable disease for 3 months) is noted. - Hour 0 to 0.5: Gemcitabine (1000 mg/m2 as 30-minute IV infusion) on Days 1, 8 and 15 every 28 days - Hour 1.5 to 2.5: BAY80-6946 (starting dose = 0.6 mg/kg as 60-minute IV infusion, starting 1 hour post completion of gemcitabine infusion) on Days 1, 8 and 15 every 28 days
88894025|NCT01460537|Experimental|Treatment B: Cisplatin-Gemcitabine-Copanlisib|Treatment consists of repetitive 21 day cycles for a maximum of 8 cycles. Treatment continues until disease progression, DLT or completion of 8 cycles. After 8 cycles, gemcitabine and Copanlisib, without cisplatin, may continue at the discretion of the Investigator until disease progression or DLT if a clinical benefit is noted (response or stable disease for 3 months). Treatment is administered on Days 1 and 8 every 21 days as follows: - Hour 0 to 1: Cisplatin IV infusion over 60 min (One liter of 0.9% NaCl including 25 mg/m2 cisplatin, 20 mmol of potassium chloride, and 8 mmol of magnesium sulfate) - Hour 1 to 1.5: IV infusion of 500 ml of 0.9% NaCl over 30 min - Hour 1.5 to 2: Gemcitabine (1000 mg/m2 as 30 min IV infusion) - Hour 3 to 4: Copanlisib IV infusion at the MTD determined in Treatment A over 60 min. [If Treatment A MTD is not tolerable, further subject enrollment will begin at one Copanlisib Dose Level lower with the cisplatin-gemcitabine doses remaining constant.]
88894026|NCT01460550|Experimental|gastrointestinal reconstruction|
89193184|NCT05425485|Active Comparator|EducAR strategy|"Healthcare personnel involved in the care of patients with RA in the selected centres will be provided with access to a website and instructed in its use in a videoconference. The website includes a training section for healthcare professionals and another for patients. The former includes explanatory videos on how to manage doctor-patient communication and to facilitate adherence and what not to do, tools to explain treatment options (shared decision aids) and links to key documents. The patient section includes information for patients (downloadable in leaflet format), medication calendars and disease diaries, videos explaining medication administration in RA and links to patient associations, among other tools.~Both access to the website and its materials and to the instruction session will be open to all those involved in the corresponding service, but will not be mandatory."
89193185|NCT05425485|No Intervention|Standard of care|Physicians in the control group will not be instructed and will have no access to the materials included in the physician section of the webpage.
89193186|NCT05424237|No Intervention|Control group|"Sign consent form and baseline assessments~Usual care~Post intervention assessments"
89193187|NCT05424237|Experimental|Interention group|"Sign consent form and baseline assessments~Usual care + app iNATAL~Post intervention assessments"
89193188|NCT05421611|Experimental|SII-YFV|"Live attenuated Yellow Fever Virus (17D-213 Strain) not less than 1000 IU/dose propagated in specific pathogen-free chick embryos~Diluent: 0.5 mL of sterile water for injection"
89193189|NCT05421611|Active Comparator|STAMARIL|"Live attenuated Yellow Fever Virus (17D-204 Strain) not less than 1000 IU/dose produced in specified pathogen-free chick embryos~Solvent: Sodium Chloride 2.0 mg; Water for injections up to 0.5 mL"
89193190|NCT05418816|Experimental|SelfWrap-treated|Treated with SelfWrap Bioabsorbable Perivascular Wrap during AVF creation surgery
89193191|NCT05417711|Experimental|Transcutaneous Vagus Nerve Stimulation Paired with Tailor-Made Notched Music Therapy|The participants receive 30 minutes / time, 4 times / day, continuous 3 months of auditory tVNS combined with TMNMT. The stimulation intensity used in each course was set to the highest level that the patient could tolerate. The participants listen to the tailor-made notched music at the same time.
89193192|NCT05417711|Active Comparator|Tailor-made Notched Music Training|Similarly, 30 minutes / time, 4 times / day, continuous 3 months of TMNMT is received every day. The setting of parameters and the selection of music were the same as those in the experimental group. At the beginning of TMNMT, 10 s of sham stimulation set according to the standard of the experimental group is given.
89193193|NCT05417360|Experimental|Akkermansia muciniphila (A. muciniphila)|After an 8-week low caloric diet (LCD, ~800kcal), participants who have successfully lost 8% of their body weight who are randomized to the intervention group, will receive pasteurized A. muciniphila.
89193194|NCT05417360|Placebo Comparator|Placebo|After an 8-week low caloric diet (LCD, ~800kcal), participants who have successfully lost 8% of their body weight who are randomized to the control group, will receive a placebo.
88894027|NCT01460563|Experimental|Mg_orfil|patients preloaded with sodium valproate receives MgSO4 during the craniotomy.
88894028|NCT01460563|Placebo Comparator|control_orfil|patients preloaded with sodium valproate receives 0.9% saline as placebo.
88894029|NCT01460563|Placebo Comparator|control_no orfil|patients not preloaded with sodium valproate receives 0.9% saline as placebo.
88894030|NCT01460602|Experimental|Part 1: establish MTD|Part 1 consists of dosing to determine maximum tolerated dose (MTD) and dose limiting toxicity (DLT).
88894031|NCT01460602|Experimental|Part 2: The MTD from Part 1|During the Phase 2 part of the study, approximately 24 additional subjects will be enrolled in order to obtain a total of 30 response-evaluable subjects treated at the maximum tolerated dose.
88894032|NCT01460641||CT perfusion|
88894033|NCT01460667|Active Comparator|IV acetaminophen|
88894034|NCT01460667|Placebo Comparator|IV 0.9% normal saline|
88894035|NCT01460680||Fibromyalgia patients|Patients diagnosed as suffering from Fibromyalgia according to the ACR 1990 criteria
88894036|NCT01460680||SLE patients|Patients diagnosed as suffering from Systemic Lupus Erythematosus by the ACR criteria
88894037|NCT01460680||Healthy controls|Healthy controls
88894038|NCT01460693|Active Comparator|Arm A - Imatinib|Imatinib 400mg daily
88894039|NCT01460693|Experimental|Arm B - Dasatinib|Dasatinib 100mg daily
88894040|NCT01460706|Experimental|68Ga-DOTATOC|
88894041|NCT01460758|Experimental|Medial Frontal rTMS Double-Cone-Coil|High frequency rTMS ( Alpine Biomed Mag Pro Option) applied over medial superior frontal cortex (supplementary motor cortex) (Brodmann area 6/8),Double-Cone-water-cooled-Coil (2000 Stimuli of 10 Hz each session), 110% motor threshold.
88894042|NCT01460758|Experimental|Left DLPFC Butterfly Coil|High frequency rTMS ( Alpine Biomed Mag Pro Option): 2000 stimuli of 10 Hz over the left DLPFC (each session), Butterfly-water-cooled-Coil, 110% motor threshold.
88894043|NCT01460758|Sham Comparator|Placebo Stimulation|Sham Stimulation (Conventional butterfly-coil, angled 45°): left DLPFC continuous rTMS, 10 Hz,2000 Stimuli each session, 110% motor threshold
88894044|NCT01460771|Experimental|Treatment|Active Transcranial Direct Current Stimulation (TDCS) at 1mA or highest tolerated current
88894045|NCT01460771|Sham Comparator|sham|inactive Transcranial Direct current stimulation (TDCS) at 0mA
88894046|NCT01460784||N=60|Cross-sectional study of obese young adults who underwent PET/CT after cold exposure to identify active brown fat. No intervention. Enrolled 44 participants.
88894047|NCT01460784||N=600|Cross-sectional study of patients undergoing clinical PET/CT to identify active brown fat. No intervention. Enrolled 405 participants.
88894048|NCT01460784||N=220|Longitudinal observational study of obese adolescents to determine changes in adiposity and adipokines during puberty. No intervention. Enrolled 125 participants.
88894049|NCT01460797|Other|High Glycemic Index|Hypocaloric diet with predominating high glycemic index foods
88894050|NCT01460797|Other|Low Glycemic Index|Hypocaloric diet with predominant low glycemic index foods
88894051|NCT01460797|Other|Low Glycemic Index plus Metformin|Hypocaloric diet with predominant low glycemic index foods plus Metformin (1g/d)
88894052|NCT01460823|Experimental|Use of image guided surgery|
88894053|NCT01460836||Tobramycin Solution|
88894054|NCT01460836||Aztreonam lysine|
88894055|NCT01460888|Experimental|OLA-0 (de-escalation dose)|25mg olaparib twice daily + radiotherapy (50Gy in 25 fractions)
88894056|NCT01460888|Experimental|OLA-1|50mg olaparib twice daily + radiotherapy (50Gy in 25 fractions)
88894057|NCT01460888|Experimental|OLA-2|100mg olaparib twice daily + radiotherapy (50Gy in 25 fractions)
88894058|NCT01460888|Experimental|OLA-3|200mg olaparib twice daily + radiotherapy (50Gy in 25 fractions)
88894059|NCT01460888|Active Comparator|RT alone|
88894060|NCT01460953|Experimental|training intervention|Students participating in didactic training
88894061|NCT01460966|Active Comparator|Filtrap™+ Thrombus aspiration catheter|
88894062|NCT01460966|Active Comparator|Thrombus aspiration catheter|
88894063|NCT01460979|Experimental|Temsirolimus|
88894064|NCT01460992||Pacemaker therapy|Patients with an EVIA/ ENTOVIS pacemaker device. See inclusion and exclusion criteria.
88894065|NCT01461018|Experimental|IgPro20|
88894066|NCT01461070||Breast Cancer Cases|Breast Cancer Cases
88894067|NCT01461070||Controls|Controls
88894068|NCT01461083|Experimental|Assess [18F]MPPF and PET imaging|To assess [18F]MPPF and PET imaging
88894069|NCT01461109|Experimental|Assess [18F] CFPyPB and PET imaging|To assess [18F]CFPyPB and PET imaging
88894070|NCT01461148|Experimental|FSP peptides|Vaccination with three FSP peptides
88894071|NCT01461174|Experimental|Modafinil|200 mg tablet, single dose
88894072|NCT01461174|Experimental|Donepezil|5 mg tablet one per day, 15 days
89193195|NCT05416385||Cardiac outpatients|Subjects referred for outpatient stress echocardiogram (SE).
89193196|NCT05403944|Active Comparator|Standard of Care (SOC)|The SOC rehabilitation group will complete three strength sessions a week. All participants will be provided an educational pamphlet and exercises will be divided into four components - hip abductors, hip extensors, core, and quadriceps muscles. The load magnitude for exercises will be between 60-70% of their 1 repetition max (1RM), with 3 sets of 12 repetitions and a 2-3-minute rest between sets. Time under tension will be prescribed as slow to moderate, with a 2-second concentric phase and 2-second eccentric phase for each exercise. Hip abductor, hip extensor, and core exercises will be initiated during week 1 and continued for the 6-week intervention, while quadriceps focused exercises will be introduced in weeks 3-6.
89193197|NCT05403944|Experimental|Strength Training Rehabilitation Incorporating Power Exercises (STRIPE)|Those in the STRIPE group will complete two power and one strength training sessions a week. All participants will be provided an educational pamphlet and exercises will be divided into four components - hip abductors, hip extensors, core, and quadriceps muscles. The load magnitude will be greater than 60% of the 1RM, with the goal of continually loading against heavy resistance. Participants will complete 4 sets of 6 repetitions, with 3-5 minutes of rest between sets. Time under tension will be prescribed as <1 second for the concentric phase and 1 second for the eccentric phase of the exercise. The strength training sessions will adhere to same parameters as the SOC. Hip abductor, hip extensor, and core exercises will be initiated during week 1 and continued for the 6-week intervention, while quadriceps focused exercises will be introduced in weeks 3-6.
88894073|NCT01461174|Experimental|Memantine|10 mg tablet one per day, 15 days
88894074|NCT01461187|Experimental|exercise in pregnancy|37 pregnant women who performed supervised aerobic physical exercises twice a week
88894075|NCT01461187|No Intervention|Control group|29 pregnant women who had not performed any kind of physical activity during pregnancy
88894076|NCT01461200||Non allergics|
88894077|NCT01461200||allergics|
88894078|NCT01461213|Experimental|Dose 1|Dose 1 = single subretinal injection of vector suspension containing approximately 10e10 rAAV2.REP1 genome particles. Six patients have now received Dose 1.
88894079|NCT01461213|Experimental|Dose 2|Dose 2 = single subretinal injection of vector suspension containing approximately 10e11 rAAV2.REP1 genome particles. Three patients thus far have received Dose 2.
88894080|NCT01461239|Active Comparator|cast post and core|
88894081|NCT01461239|Experimental|fiber post - self-adhesive cement|
88894082|NCT01461239|Experimental|fiber post - conventional cement|
88894083|NCT01461252|Other|Cryoablation combined with radiation|All subjects will have cryoablation combined with radiation on one or two painful metastatic bone tumors.
88894084|NCT01461265|Other|Cryoablation|All subjects will have cryoablation on one or two painful metastatic bone tumors.
88894085|NCT01461330|Experimental|DASH diet|DASH DIET + EXERCISE
89193198|NCT05400603|Experimental|Dose Escalation Phase I cohort|"Subjects will be assigned a cell therapy dose level at time of registration. The entry dose level is Dose Level 1, with escalation up to Dose Level 3 following a 3 + 3 dose escalation design.~If there is no evidence of progression, patients may receive up to a maximum of 4 courses. Each course includes two administrations of γδ T cells, administered one week apart. Toxicity, for deciding dose escalation and defining the MTD, will be evaluated during Course 1. Disease response assessment will be done after Courses 2 and 4. Dinutuximab (17.5 mg/m2), temozolomide (100 mg/m2), irinotecan (50 mg/m2) and zoledronate (0.0125 mg/kg/dose) will be consistent across all dose levels.The same donor for γδ T cell will be used for both cell therapy product infusions per course. Treatment of the first two subjects in each dose escalation cohort will be staggered. The second subject will not be enrolled until the first subject completes the DLT observation interval (minimum of 21 days)."
89193199|NCT05397496|Experimental|PIT565 Group A (dose escalation part)|PIT565 in adult NHL patients for whom two or more lines of chemotherapy have failed and either having progressed (or relapsed) after autologous hematopoietic stem cell transplantation (HSCT), or being ineligible for or not consenting to the procedure
89416506|NCT03850574|Experimental|Part A Dose Escalation|For Part A (tuspetinib as a single agent), dose escalation cohort is planned up to 6 dose levels. If a subject in the dose escalation cohort at any dose level achieves clinical response then the dose level will continue to enroll in Part B. If one DLT or less is observed in the 6 patients (<1/6 DLT observed) in Part A, up to 20 evaluable patients can be enrolled in Part B at that dose level.
89416507|NCT03850574|Experimental|Part B Dose Exploration|For Part B (tuspetinib as a single agent), dose exploration cohort is planned up to 4 dose levels.
89416508|NCT03850574|Experimental|Part C Dose Expansion (tuspetinib as a single agent)|Part C, dose expansion, consists of 2 arms (tuspetinib as a single agent or tuspetinib plus venetoclax). Patients will be randomly assigned to either arm based on the number of slots available. The initial tuspetinib dose for the single arm will be 120mg.
89416509|NCT03850574|Experimental|Part C Dose Expansion (Combination Arm - tuspetinib and venetoclax)|Part C, dose expansion, consists of 2 arms (tuspetinib or tuspetinib plus venetoclax). Patients will be randomly assigned to either arm based on the number of slots available. The initial tuspetinib dose for the combo arm will be 80mg.
89416510|NCT03830320|Active Comparator|Healthy Volunteers|Twenty (20) healthy adult subjects will be injected with [64Cu]FBP8 to establish the safety, whole body distribution, metabolism, pharmacokinetics, and radiation burden of the probe. All subjects will be imaged using PET/MR. Healthy subjects will undergo blood collection before, during, and after the scan. Healthy subjects will also undergo electrocardiogram before and after the scan. An interim review of the data will be conducted after the first six subjects receive the study agent and complete all safety assessments.
89416511|NCT03830320|Experimental|Atrial Fibrillation Patients|Thirty-five (35) patients with LAA thrombus documented by TEE will be injected with [64Cu]FBP8 and imaged for LAA thrombus with MR-PET. The TEE studies in these patients will be part of their routine clinical care. Thirty-five (35) patients with atrial fibrillation and negative TEE will be injected with [64Cu]FBP8 and imaged for LAA thrombus. Forty (40) patients with atrial fibrillation who are scheduled for TEE in the upcoming 14 days will be injected with [64Cu]FBP8 and imaged for LAA thrombus.
89193200|NCT05397496|Experimental|PIT565 Group B (dose escalation part)|PIT565 in adult R/R ALL patients
89193201|NCT05397496|Experimental|PIT565 Group A1 (dose expansion part)|PIT565 in adult R/R large B-cell lymphoma (LBCL) (DLBCL, double/triple hit High-grade B-cell lymphoma (HGBCL), Primary mediastinal large B-cell lymphoma (PMBCL), Follicular lymphoma grade 3B (FL3B)) patients who did not receive CD19-directed CAR-T therapy
89193202|NCT05397496|Experimental|PIT565 Group A2 (dose expansion part)|PIT565 in adult R/R LBCL (DLBCL, double/triple hit HGBCL, PMBCL, FL3B) patients who received CD19-directed CAR-T therapy
89193203|NCT05397496|Experimental|PIT565 Group B1 (dose expansion part)|PIT565 in adult R/R ALL patients
89416512|NCT03830320|Experimental|COVID-19 Patients|Thirty (30) COVID-19 patients will be injected with [64Cu]FBP8 and imaged for thrombi in the body.
89416513|NCT03830320|Experimental|Cancer Patients|Thirty (30) cancer patients will be injected with [64Cu]FBP8 and imaged for thrombi in the body.
89416514|NCT03830320|Experimental|Other Thrombotic Condition Patients|Fifty (50) patients with other thrombotic conditions will be injected with [64Cu]FBP8 and imaged for thrombi in the body.
88894086|NCT01461330|Active Comparator|ADA DIET|DIET ACCORDING AMERICAN DIABETES ASSOCIATION DIETARY RECOMMENDATIONS FOR DIABETES
88894087|NCT01461343|Experimental|pulmonary hypertension|Patients with Group I pulmonary arterial hypertension and exercise-induced pulmonary hypertension to undergo CT imaging, functional PET imaging
88894088|NCT01461343|Active Comparator|healthy controls|healthy adults to serve as controls and to undergo the same study procedures: CT imaging, functional PET imaging
88894089|NCT01461356|Experimental|Minimally Invasive Surgical approach|Minimally invasive surgical approach for total knee replacement.
88894090|NCT01461356|Active Comparator|Medial Parapatellar surgical approach|Standard medial parapateller surgical approach for total knee replacement.
88894091|NCT01461382|Experimental|Phase I|Entered Study May 2008.
88894092|NCT01461382|Experimental|Phase II|Phase II entered 6 months after Phase I. Phase II was a no intervention control for 6 months, then followed an identical intervention protocol to Phase I.
88894093|NCT01461408|Experimental|Beauty Salon #1b|Females ages 18-26
88894094|NCT01461408|Experimental|Beauty Salon #1a|Mothers of 9-18 year old females
88894095|NCT01461408|Experimental|Beauty Salon #2b|Females ages 18-26
89193204|NCT05389553||Patients at term of pregnancy|"We included all full-term pregnancies accepted for delivery that received an accurate ultrasound scan before the birth.~Pregnant women with antepartum hemorrhage, fetal growth restriction, stillbirths, multiple gestations, or congenital abnormalities were excluded."
89193205|NCT05381441|Experimental|SAFE Loop Arm|Nursing units involved in the intervention arm will participate in an iterative educational and quality improvement process that encourages improved reporting of medication safety events deemed important to their individual nursing units.
89193206|NCT05381441|No Intervention|Control Arm|Nurses in this study will continue standard practice protocol.
89193207|NCT05379725|Experimental|Mediterranean diet|Participants will receive diet education on adherence to a Mediterranean dietary pattern.
89193208|NCT05379725|Experimental|Fermented food|Participants will receive diet education on adherence to a high fermented food dietary pattern.
88894096|NCT01461408|Experimental|Beauty Salon #3a|Mothers of 9-18 year old females
88894097|NCT01461408|Experimental|Beauty Salon #3b|Females ages 18-26
88894098|NCT01461408|Experimental|Beauty Salon #4a|Mothers of 9-18 year old females
88894099|NCT01461408|Experimental|Beauty Salon #4b|Females ages 18-26
88894100|NCT01461408|Experimental|Beauty Salon #2a|Mothers of 9-18 year old females
88894101|NCT01461408|Experimental|Beauty Salon #5a|Mothers of 9-18 year old females
88894102|NCT01461408|Experimental|Beauty Salon #5b|Females ages 9-26
88894103|NCT01461408|Experimental|Beauty Salon #6a|Mothers of 9-18 year old females
88894104|NCT01461408|Experimental|Beauty Salon #6b|Females ages 18-26
89416515|NCT03828357||Ellipse VR with Durata|Ellipse VR single-chamber ICD with a Durata defibrillation lead
88894105|NCT01461408|Experimental|Beauty Salon #7a|Mothers of 9-18 year old females
88894106|NCT01461408|Experimental|Beauty Salon #7b|Females ages 18-26
88894107|NCT01461408|Experimental|Beauty Salon #8a|Mothers of 9-18 year old females
88894108|NCT01461408|Experimental|Beauty Salon #8b|Females ages 9-18
88894109|NCT01461421|Active Comparator|Standard Behavioral Treatment|Nutrition education, behavioral weight loss techniques, and standard cognitive strategies for dealing with stress and emotions. Six months weekly, 3 months bi-weekly, 3 months monthly.
88894110|NCT01461421|Experimental|Acceptance Based Behavioral Intervention|Nutrition education, behavioral weight loss techniques, and acceptance based strategies for dealing with stress and emotions. Six months weekly, 3 months bi-weekly, 3 months monthly.
88894111|NCT01461434|Experimental|loop recorder|patients will be implanted with a subcutaneous loop recorder and have regular follow-ups
88894112|NCT01461434|No Intervention|regular follow-up|patients will receive regular follow-ups with standard ECG
88894113|NCT01461447|Experimental|MVA|Volunteers who were primed with 3 HIVIS DNA and further boosted with 2 MVA vaccine will receive a third MVA there shall not be an comparator for this study.
88894114|NCT01461460|Active Comparator|Moxifloxacin 400 mg|
89193209|NCT05378776|Experimental|Sucrose|The experimental arm will receive 1.5 ml/kg of the sucrose solution at triage (once). The composition of the homemade sucrose solution used in our emergency department is 3.5 g of table sugar (sucrose) mixed with 10 ml of diluted juice (see standard arm description) to obtain a solution with the same appearance as the standard arm.
89193210|NCT05378776|Placebo Comparator|Control|This group will receive 1.5 mL/kg of diluted juice composed of juice (apple or orange) and water in equal proportion once at triage. This solution contains 0.05 g/ml of sucrose for a total of 0.075 g/kg of sucrose (eight times less than the intervention arm).
89193211|NCT05373095|Experimental|Adapted Adherence Counseling (PKC) and Conditional Cash Transfers|Eligible and consenting participants randomized to the intervention arm will receive the same standard HIV clinical services according Tanzania's National Guidelines for the Management of HIV as the comparison arm, which includes provision of three, once-monthly, 60-minute nurse-led individual, enhanced adherence counseling sessions adapted for study purposes (PKC sessions). Counseling focuses on the meaning of viral loads and supportive, non-judgmental strategies for adherence and visit attendance. A minimum of three sessions are required. In addition to enhanced adherence counseling, intervention participants will receive the offer of a cash transfer paired with attendance at each of the three enhanced adherence counseling sessions. The first payment will occur at enrollment; the next two cash transfers are payable upon visit attendance and attendance of the two remaining enhanced adherence counseling sessions.
89193212|NCT05373095|No Intervention|Enhanced Adherence Counseling only for those who qualify|Eligible and consenting participants randomized to the control arm will receive standard of care HIV clinical services according to Tanzania's National Guidelines for the Management of HIV. For those who meet clinic eligibility criteria for enhanced adherence counseling, this includes the standard provision of three, once-monthly, 60-minute nurse-led individual, enhanced adherence counseling sessions, starting on the day of a detectable viral load result and for two months after. Counseling focuses on the meaning of viral loads and supportive, non-judgmental strategies for adherence and visit attendance. A minimum of three sessions are required.
88894115|NCT01461460|Experimental|TR-701 FA 1200 mg|
88894116|NCT01461460|Experimental|TR-701 FA 200 mg plus Placebo|
89193213|NCT05372016|Experimental|Experimental: 9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58)|9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52 and 58) Recombinant Vaccine (Hansenula Polymorpha),0.5mL, three doses, 0,2,6 months
89193214|NCT05372016|Active Comparator|GARDASIL ®9|GARDASIL®9 (Types 6, 11, 16, 18, 31, 33, 45, 52 and 58) ,0.5mL, three doses, 0,2,6 months
89193215|NCT05366556|Experimental|Experimental group|Patients in the experimental group will be informed about the using virtual reality glasses during the taking blood. During this process, their anxiety and pain will be assesed. Patients in the study group will be evaluated 2 times, before the intervention and after the intervention, through data collection tools.
88894117|NCT01461460|Placebo Comparator|Placebo|
88894118|NCT01461486|Active Comparator|Continuous Positive Airway Pressure|Intervention group
88894119|NCT01461486|Active Comparator|Oral Appliance (BRD)|Intervention group
88894120|NCT01461486|No Intervention|Hygiene sleep care|Control group
88894121|NCT01461512|Placebo Comparator|Placebo|
88894122|NCT01461512|Experimental|Heme arginate treatment|
88894123|NCT01461525|Experimental|Sphincter preservation surgery|Temporary ileostomy with anal sphincter preservation
88894124|NCT01461525|Experimental|Abdominoperineal Resection|Permanent colostomy with total anal sphincter sacrifice
89416516|NCT03828357||Ellipse DR with Durata & Tendril STS|Ellipse DR dual-chamber ICD with a Durata lead in the right ventricle (RV) and a Tendril STS lead in the right atrium (RA).
89416517|NCT03828357||Ellipse DR with Optisure and Isoflex|Ellipse DR dual-chamber ICD with an Optisure defibrillation lead in the right ventricle (RV) and an Isoflex lead in the right atrium (RA).
89416518|NCT03828357||Quadra Assura MP CRT-D|Quadra Assura MP CRT-D with an Optisure or Durata defibrillation lead in the RV, an Isoflex or Tendril STS lead in the RA, and a Quartet lead in the LV
88894125|NCT01461564|Experimental|Carbon dioxide|Patients insufflated with carbon dioxide during screening colonoscopy
88894126|NCT01461564|Active Comparator|Air|Patients insufflated with air during screening colonoscopy
88894127|NCT01461577|Experimental|insulin glargine|Insulin glargine will be administered once a day, in the morning, at initial dose of 4 units/day. Titration of insulin dose will be performed referred with the median fasting plasma glucose value for the last 3 consecutive days according to the titration algorithm
88894128|NCT01461590|Active Comparator|20ml/kg of whole blood transfusion|Standard care recommended by WHO
88894129|NCT01461590|Experimental|30ml/kg of whole blood|Higher volume than currently recommended
88894130|NCT01461603|Active Comparator|Amino acids|Amino acids compared to saline
88894131|NCT01461603|Active Comparator|3hydroxybutyrat (3OHB)|Ketone body, 3OHB compared to saline
88894132|NCT01461616|Experimental|NPH insulin injection|NPH insulin will be injected in random order in one of three seperated visit days.
88894133|NCT01461616|Experimental|detemir insulin injection|insulin detemir will be injected in random order in one of three seperated visit days.
88894134|NCT01461616|Experimental|glargine insulin injection|insulin glargine will be injected in random order in one of three seperated visit days.
88894135|NCT01461629||heart failure|left systolic heart failure (EF </= 40%)
88894136|NCT01461642|Experimental|Asthma - ICT support.|
88894137|NCT01461642|No Intervention|Asthma, comparator - no ICT support|
88894138|NCT01461681|Experimental|Symptom Management Service for heart failure|Subjects randomized to the SMS-HF group will receive a comprehensive PC consultation by the interdisciplinary PC team at each site consisting of a nurse practitioner, physician, social worker and chaplain with 6 months of follow up. All members of the PC team are experienced PC clinicians. The SMS-HF intervention is based on National Quality Forum preferred practices and the National Consensus Project guidelines for quality PC. The SMS-HF will include assessment and management of symptoms, particularly focused on depression, pain and dyspnea, and a discussion of goals of care.
88894139|NCT01461681|No Intervention|Usual cardiology care|The usual cardiology care group will receive usual care provided by the HF clinic. We will assess symptoms and QoL at enrollment and symptoms, QoL, satisfaction, advance care planning documentation, and resource utilization at follow up 6 months later.
88894140|NCT01461694|Active Comparator|IPL|Half face treated with IPL
88894141|NCT01461694|Active Comparator|Alexandrite Laser|Half face treated with Alexandrite Laser
89193216|NCT05366556|No Intervention|Control group|The control group will receive standard procedure without any intervention
89193217|NCT05359068|Experimental|Stage 1 Arm A|1 SPH3127 tablet，3 SPH3127 matching placebo tablets, 1 valsartan matching placebo capsule, once daily for 12 weeks.
89416519|NCT03820479||Apfel score 1|Female
89416520|NCT03820479||Apfel score 2|Female, non smoker
89416521|NCT03820479||Apfel score 3|Female, non smoker, under 40 years old
89416522|NCT03820479||Apfel score 4|Female, non smoker, under 40 years old, previous history of PONV
89416523|NCT03818880|Experimental|Treatment|Subjects wearing novel spectacle lenses will be assessed
89416524|NCT03800394||HIV only|Adolescents aged 10-19 years with HIV infection
88894142|NCT01461720|Other|Standard medical care|This is the control arm, which is given the best evidence-based standard treatment for the management of acute stroke
88894143|NCT01461720|Experimental|BM-MSCs|Autologous bone marrow-derived mesenchymal stem cells(BM-MSCs)
88894144|NCT01461746|Experimental|Chemotherpay and radiation therapy|Docetaxel plus cisplatin followed by radiation therapy
88894145|NCT01461759|Experimental|Chemotherapy|Docetaxel 70mg/m2BSA + Cisplatin 60mg/m2BSA, q 3 weeks, 8cycles
88894146|NCT01461772|Experimental|CCRT weekly carboplatin|Concurrent chemoradiation therapy with weekly carboplatin
88894147|NCT01461772|Active Comparator|CCRT weekly cisplatin|Concurrent chemoradiation therapy with weekly cisplatin
88894148|NCT01461785|Experimental|GROUP A: PRP +|Group A (16 subjects) will receive lipofilling enriched with 3 ml of autologous PRP ( Platelet rich plasma) with lipofilling
88894149|NCT01461785|Placebo Comparator|GROUP B: PRP -|Group B ( 16 subjects) will receive lipofilling without addition PRP. 27 ml blood will be drawn from the patient, but will be discarded, and not turned into PRP.
88894150|NCT01461798|Experimental|Benecol|In 2009, the dairy Cooperative Colanta Launches Benecol ® yogurt, a product with optimal daily dose of plant stanol, each portion of 100 g containing 3.4 g of Benecol ®, corresponding to 2 g of plant stanol esters . Skim yogurt with Benecol ® is a product made from pasteurized skim milk, sweetened with sucralose homogenized and fermented by the action of specific lactic culture to obtain the optimal characteristics of texture and acidity. With the addition of fruit pulp and supplemented with plant stanol esters (Benecol ®) to help reduce the risk of cardiovascular disease (31). According to Weiss et al, drinkable yogurt with Benecol ® reduces total cholesterol by 5.8% and 9.8% in LDL cholesterol (32).
88894151|NCT01461798|Placebo Comparator|yogurt|Yogurt without plant stanols
89193218|NCT05359068|Experimental|Stage 1 Arm B|2 SPH3127 tablets，2 SPH3127 matching placebo tablets, 1 valsartan matching placebo capsule, once daily for 12 weeks.
89416525|NCT03800394||HIV/TB|Adolescents aged 10-19 years with HIV and TB coinfection
89416526|NCT03800381||Active TB only|Children with clinical diagnosis or acid-fast bacilli (AFB) smear positive TB disease
89416527|NCT03800381||Active TB with HIV Co-infection|Children with clinical diagnosis or AFB smear positive TB disease who test positive for HIV infection
89416528|NCT03798301|Experimental|Treatment Arm|Suspension of CMV-specific T-cells in 10 mL of 0.9% NaCl with 2% HSA. Single dose max. 25,000 T cells/kg body weight (BW) of the recipient delivered via IV bolus injection.
89416529|NCT03785249|Experimental|Phase 1 Dose Exploration|Dose escalation of MRTX849 to determine maximum tolerated dose
89416530|NCT03785249|Experimental|Phase 1b Expansion|Expansion cohort to ensure sufficient safety experience, pharmacokinetic information, and early evidence of clinical activity of MRTX849 to recommend Phase 2 regimens
89416531|NCT03785249|Experimental|Phase 2|Separate cohorts of patients stratified by histological diagnosis, prior treatment history or co-mutation status (e.g., STK11) for evaluation of clinical activity of MRTX849
89416532|NCT03785249|Experimental|Pilot Phase 1b Combination with Pembrolizumab|Phase 1 evaluation of the safety, tolerability, PK and clinical activity of MRTX849 in combination with pembrolizumab in patients with NSCLC
89416533|NCT03785249|Experimental|Pilot Phase 1b Combination with Cetuximab|Phase 1 evaluation of the safety, tolerability, PK and clinical activity of MRTX849 in combination with cetuximab in patients with CRC
89416534|NCT03785249|Experimental|Pilot Phase 1b Combination with Afatinib|Phase 1 evaluation of the safety, tolerability, PK and clinical activity of MRTX849 in combination with afatinib in patients with NSCLC
89416535|NCT03785249|Experimental|Phase 2 Combination with Cetuximab|Phase 2 evaluation of the clinical activity of MRTX849 in combination with cetuximab in patients with CRC
89416536|NCT03785249|Experimental|Pilot Phase 1b Combination with Cetuximab in NSCLC|Phase 1 evaluation of the safety, tolerability, PK and clinical activity of MRTX849 in combination with cetuximab in patients with NSCLC
89416537|NCT03785249|Experimental|Pilot Phase 1b Combination with Cetuximab in PDAC|Phase 1 evaluation of the safety, tolerability, PK and clinical activity of MRTX849 in combination with cetuximab in patients with pancreatic adenocarcinoma (PDAC)
89416538|NCT03773198|Experimental|ERCS Group|
89416539|NCT03773198|Placebo Comparator|Control Group|
89416540|NCT03715946|Experimental|Radiotherapy (RT) + Nivolumab Injection|RT of 45 or 50 Gy in 25 daily fractions, 6 fractions per week. Nivolumab will be administered at 240 mg every 2 weeks during radiotherapy, and at 480 mg every 4 weeks for 6 doses after radiotherapy.
89416541|NCT03702309||LIBERATE|Patients with either histological confirmation of a solid tumor or hematological malignancy, or patients identified as high-risk for cancer (based on identified aberration in cancer predisposition gene or on hormonal and/or family history without known aberration).
89416542|NCT03701763|Experimental|Administration of Apremilast (CC-10004) - 20mg|Apremilast 20mg Twice Daily (BID)
89416543|NCT03701763|Experimental|Administration of Apremilast (CC-10004) - 30mg|Apremilast 30mg Twice Daily (BID)
88894152|NCT01461850|Active Comparator|Primary debulking surgery|All patients with suspicion of advanced ovarian carcinoma (FIGO stage IIIC) will undergo to a diagnostic laparoscopy in order to obtain a laparoscopic score (PIV) based on seven parameters: omental cake, peritoneal and diaphragmatic extensive carcinosis, mesenteric retraction, bowel and stomach infiltration, spleen and/or liver superficial metastasis, as previously published (Fagotti et al, American Journal of Obstetrics and Gynecology, 2008) Patients with PIV ≥ 8 and ≤ 12 randomized in this group will be submitted to an attempt of primary debulking surgery in order to obtain RT < 1 cm, followed by adjuvant chemotherapy.
88894153|NCT01461850|Experimental|Interval debulking surgery|All patients with suspicion of advanced ovarian carcinoma (FIGO stage IIIC) will undergo to a diagnostic laparoscopy in order to obtain a laparoscopic score (PIV) based on seven parameters: omental cake, peritoneal and diaphragmatic extensive carcinosis, mesenteric retraction, bowel and stomach infiltration, spleen and/or liver superficial metastasis, as previously published (Fagotti et al, American Journal of Obstetrics and Gynecology, 2008) Patients with PIV ≥ 8 and ≤ 12 randomized in this group will be submitted only to diagnostic laparoscopy followed by neoadjuvant chemotherapy and subsequent Interval Debulking Surgery, followed by further cycles of chemotherapy.
88894154|NCT01461876||HIV-infected cohort|
88894155|NCT01461876||HIV-uninfected control group|
88894156|NCT01461889|Experimental|High INR|Transfuse plasma to High INR target. Plasma will be transfused to reach a target INR=2.5 for 48 hours while patient is actively bleeding.
88894157|NCT01461889|Active Comparator|Low INR|Transfuse plasma to Low INR target. Plasma will be transfused to reach a target INR=1.8 for 48 hours while patient is actively bleeding.
88894158|NCT01461902||Pediatric Traumatic Brain Injury|Children from 5 days to 15 years of age who have been admitted to the hospital with a traumatic brain injury.
88894159|NCT01461941|Experimental|Drug: 0.2% E6005 ointment|
88894160|NCT01461941|Placebo Comparator|Drug: 0.0% E6005 ointment (vehicle)|
88894161|NCT01461967|Experimental|Part 1a|
88894162|NCT01461967|Placebo Comparator|Part 1b|
88894163|NCT01461967|Experimental|Part 2|
88894164|NCT01462006|Experimental|Sirolimus|
88894165|NCT01462006|Placebo Comparator|Placebo|
88894166|NCT01462019|No Intervention|Control|
88894167|NCT01462019|Experimental|Photobiomodulation|
88894168|NCT01462032|Experimental|Cognitive enhancing games|Children will be introduced to specific games believed to enhance cognitive functioning. Parent will be encouraged to play these games with their children.
89193219|NCT05359068|Experimental|Stage 1 Arm C|4 SPH3127 tablets, 1 valsartan matching placebo capsule, once daily for 12 weeks.
89416544|NCT03701763|Placebo Comparator|Administration of Placebo|Placebo tablet Twice Daily (BID)
89416545|NCT03700541|Active Comparator|Morphine|Morphine-based perioperative analgesia
89416546|NCT03700541|Active Comparator|Piritramid|Piritramid-based perioperative analgesia
89416547|NCT03700411|Active Comparator|Morphine|Morphine-based perioperative analgesia
88894169|NCT01462032|Active Comparator|Parent support and education|Parents will participate in groups designed to provide information about ADHD and support for working with their child.
88894170|NCT01462058|Active Comparator|Vitamin D3|one tablet of vitamin D3 (70µg) per day for 12 weeks.
88894171|NCT01462058|Placebo Comparator|placebo|one tablet of sugar pill per day for 12 weeks.
88894172|NCT01462071||Chronic kidney disease|
88894173|NCT01462123||small polyps patients|Patients with one small polyps at colonoscopy
88894174|NCT01462136|Experimental|ACHN-490 Injection|
88894175|NCT01462149|Experimental|Chemotherapy|Neoadjuvant chemotherapy with docetaxel plus carboplatin
88894176|NCT01462175|Experimental|Schedule A: RO5503781 QW|Participants will receive multiple ascending doses of RO5503781 orally once weekly (QW) x 3 followed by 13 days of rest in a 28 days cycle.
89193220|NCT05359068|Experimental|Stage 1 Arm D|4 SPH3127 matching placebo tablets, 1 valsartan capsule, once daily for 12 weeks.
88894177|NCT01462175|Experimental|Schedule B: RO5503781 QD|Participants will receive multiple ascending doses of RO5503781 orally QD x 5 followed by 13 days of rest in a 28 days cycle.
88894178|NCT01462188|Active Comparator|Immediate stenting|Patients being randomized to the immediate stenting arm will be managed according to the guidelines. Irrespective of TIMI flow at presentation, investigators will be requested to thrombus aspirate immediately after successful wiring of the culprit vessel followed by direct stenting. In cases where insertion of thrombus removal catheter and/or direct stenting is not successful, balloon angioplasty will be allowed.
88894179|NCT01462188|Experimental|Delayed stenting|"Patients being randomized to the delayed/staged stenting arm will be managed with the aim to obtain stable TIMI 3 flow with no considerations given at the percentage of residual stenosis at the culprit lesion.~In patients presenting with TIMI 3 flow, investigators will be left free to wire the vessel and proceed to thrombus aspiration to decrease thrombus burden in the culprit lesion or to leave the vessel untreated at the time of index PCI. Patients presenting with suboptimal TIMI flow (i.e. less than 3), investigators are required to wire the vessel and thrombus aspirate. If stable (persisting for at least 5 minutes) TIMI 3 flow is obtained, investigators are requested to stop the procedure. The goal is to achieve s table TIMI 3 flow with no considerations given to the percentage of residual stenosis. Stenting in this arm will be allowed only on a bail-out strategy."
88894180|NCT01462201|Experimental|Group 1 - Non Invasive Ultrasound|Group 1 3 visits - Measurement of abdominal circumferences 3 visits - Treatment with Ultrashape Contour I VER 3.1 4 visits - Follow up visits The intervention is non invasive ultrasound.
88894181|NCT01462201|Experimental|Group 2 - Non Invasive Ultrasound|Group 2 3 visits - Treatment with Contour I VER 3.1 system 3 visits - Measurements of abdominal circumference 4 visits - Follow Up visits The intervention is non invasive ultrasound.
88894182|NCT01462240||1 - LPS Flex Pororus Femoral Components|Patients suffering from severe knee pain and disability.
88894183|NCT01462331|Other|VitaSugar/VitaFiber-IMO dose-1|A group of 20 subjects (10 male and 10 females) will take IMO dose-1 (12g/dose) powder; three times a day dissolved in a glass of water
88894184|NCT01462331|Other|VitaSugar/VitaFiber-IMO dose-2|A group of 20 subjects (10 male and 10 females) will take IMO dose-2 (18g/dose) powder; three times a day dissolved in a glass of water
88894185|NCT01462331|Placebo Comparator|Placebo|A group of 20 subjects (10 male and 10 females) will take Placebo (12g/dose) powder; three times a day dissolved in a glass of water
88894186|NCT01462396|Experimental|Single Arm|Haploidentical allogeneic stem cell transplant following sub-myeloablative conditioning and cell selection using the Miltenyi Clinimacs device
88894187|NCT01462409|Experimental|heated humidification|
88894188|NCT01462409|Experimental|No Humidification|
88894189|NCT01462409|Experimental|Controlled heated Humidification with heated tube|
88894190|NCT01462422|Other|Primary prevention|
88894191|NCT01462422|Other|Secondary Prevention|
88894192|NCT01462448||Phantom Limb Pain|Subjects will have lower or upper extremity amputation(s) that have resulted in the presence of phantom limb pain.
88894193|NCT01462448||No Phantom Limb Pain|Subjects in the group will have a lower or upper extremity amputation(s) without the presence of phantom limb sensation.
88894194|NCT01462474|Experimental|Drug: Famitinib|
88894195|NCT01462487||Pregnancy outcomes analysis group|Pregnant women evaluated for the following pregnancy outcomes: elective termination, spontaneous abortion (defined as spontaneous fetal loss at < 20 weeks' gestation), fetal death (defined as death of a fetus at > 20 weeks' gestation), premature birth (defined as a birth occurring at < 37 weeks' gestation), and live birth at term
88894196|NCT01462487||Congenital anomalies analysis group|Infants evaluated for congenital anomalies
88894197|NCT01462487||Treatment-emergent diagnoses analysis group|Pregnant women evaluated for treatment-emergent diagnoses
88894198|NCT01462500|Experimental|Miltefosine|Miltefosine PO at a dose of 1.8-2.5 mg/kg/day for 28 days
88894199|NCT01462513|Experimental|L-BLP25|L-BLP25 treatment
88894200|NCT01462513|Placebo Comparator|Placebo|Placebo
88894201|NCT01462526||Control|Participants who do not have glaucoma in either eye
88894202|NCT01462526||Glaucoma|Participants who have glaucoma in one or both eyes
88894203|NCT01462539||OSAS group|
88894204|NCT01462539||Non-OSAS group|
88894205|NCT01462552||Metastatic breast cancer pre-label group|Patients with metastatic breast cancer who initiated lapatanib between January 1, 2007 and December 31, 2007. Follow-up time for this group will continue until June 30, 2008 to allow these patients to have at least six months of follow-up time prior to the label change.
88894206|NCT01462552||Metastatic breast cancer post-label group|Patients with metastatic breast cancer who initiated lapatanib between July 9, 2008 and December 31, 2009. Follow-up time for this group will continue until June 30, 2010 to allow these patients to have at least six month of follow-up.
88894207|NCT01462591|Experimental|L-citrulline|L-citrulline (100mg/kg of body weight per day for 2 weeks)
89193221|NCT05359068|Experimental|Stage 2 Arm A|2 SPH3127 tablets, 1 valsartan matching placebo capsule, once daily for 12 weeks.
88894208|NCT01462591|Placebo Comparator|Maltodextrin|6g/day of placebo (maltodextrin)
88894209|NCT01462604||HER2 overexpressing metastatic or advanced breast cancer pts|
88894210|NCT01462617|Experimental|Pi3K|Experimental
88894211|NCT01462617|Placebo Comparator|Placebo|Placebo Comparator
88894212|NCT01462643|Experimental|variant1|topical ointment, once daily application
88894213|NCT01462643|Experimental|variant 2|topical ointment, once daily application
88894214|NCT01462643|Experimental|variant 3|topical ointment, once daily application
88894215|NCT01462643|Experimental|variant4|topical ointment, once daily application
88894216|NCT01462643|Experimental|variant 5|topical ointment, once daily application
88894217|NCT01462643|Placebo Comparator|variant 6|topical ointment, once daily application
88894218|NCT01462643|Active Comparator|control positive|topical ointment,once daily application
89193222|NCT05359068|Experimental|Stage 2 Arm B|2 SPH3127 matching placebo tablets, 1 valsartan capsule, once daily for 12 weeks.
89193223|NCT05359068|Experimental|Stage 3|2 SPH3127 tablets, once daily for 40 weeks.
89416548|NCT03700411|Active Comparator|Piritramid|Piritramid-based perioperative analgesia
88894219|NCT01462656||Patients with urinary retention|Patients with urinary retention
88894220|NCT01462669|Other|Treatment Period 1|A single 50mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state
88894221|NCT01462669|Other|Treatment Period 2|A single 100mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state
88894222|NCT01462669|Other|Treatment Period 3|A single 200mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state
88894223|NCT01462669|Other|Treatment Period 4|A single 400mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state
88894224|NCT01462708|Experimental|Assess [18F]MK-9470 and PET imaging|To Assess [18F]MK-9470 and PET imaging
88894225|NCT01462721|Other|SVG + eSVS Mesh vs Control SVG|Either the Circumflex Coronary Artery (Cx) or the Right Coronary Artery (RCA) will receive the mesh supported vein graft and the native saphenous vein as second and control graft.
88894226|NCT01462734||human vitreous, human blood serum, PCR|Vitreous and bloodserum samples from macula hole patients without previous ocular or systemic disease
88894227|NCT01462747|Experimental|KULIST|Medical Device, Activated carbon
88894228|NCT01462786|Experimental|ATX-101 in abdomen area|Crossover study in which subjects will receive 2 mg/cm2 ATX-101 in one dosing session in either the submental area or the abdomen crossing over to the alternate area for the second dosing session
88894229|NCT01462786|Experimental|ATX-101 in submental area|Crossover study in which subjects will receive 2 mg/cm2 ATX-101 in one dosing session in either the submental area or the abdomen crossing over to the alternate area for the second dosing session
89416549|NCT03700411|Active Comparator|Epidural|Perioperative epidural analgesia containing an opioid
89416550|NCT03641378|Experimental|Inpatient Palliative Care Intervention|"Patients and Caregivers will complete baseline self-report assessments at the time of obtaining informed consent~Palliative Care Intervention~Therapeutic Relationship~--Develop a strong therapeutic relationship with patients and caregivers~Assessment and Treatment of Patient Symptoms~--Clarify the symptoms the patient will likely experience and offer reassurance about the methods for reporting and treating symptoms~Managing Patients and Caregivers Expectations~--Address early on patients and caregivers' concerns about the trajectory of illness during HCT and treatment side effects~Coping with Illness and HCT --Introduce strategies to help improve adjustment (e.g., behavioral, cognitive, and spiritual approaches; accepting illness while maintaining hope; social support)"
89416551|NCT03641378|Experimental|Transplant Care Alone|"Patients and Caregivers will complete baseline self-report assessments at the time of obtaining informed consent.~Standard Transplant Care"
89416552|NCT03633032|Other|UTE MRI|
89416553|NCT03624101|Experimental|Trikafta|If the participant is not on a current modulator, they will take Trikafta for 28 days followed by a 28 day off period. This cycle will be continued for 168 days
89416554|NCT03624101|Experimental|Symdeko/Trikafta|If the participant currently takes Symdeko , they will take Trikafta for a 28 day period followed by Symdeko for a 28 day period. This cycle will be continued for 168 days
89416555|NCT03624101|Experimental|Ivacaftor/Trikafta|If the participant currently takes Ivacaftor , they will take Trikafta for a 28 day period followed by Ivacaftor for a 28 day period. This cycle will be continued for 168 days
89416556|NCT03623074|Experimental|Test Arm 1|Single vision, impact-resistant spectacle lenses
89416557|NCT03623074|Experimental|Test Arm 2|Single vision, impact-resistant spectacle lenses
88894230|NCT01462799|Experimental|PBL- patient education|Patients will be randomised to PBL in patient education (experiment group)
88894231|NCT01462799|Experimental|Mailed patient information|Patients will be randomised to controlgroup receiving mailed patient information during the year
88894232|NCT01462825|Experimental|tomato ketchup meal|
88894233|NCT01462825|Placebo Comparator|Placebo meal|
88894234|NCT01462838|Experimental|Immunization|P16_37-63 peptide plus Montanide ISA-51 VG
88894235|NCT01462851|Experimental|Dose Escalation|Ascending doses in healthy volunteers
88894236|NCT01462851|Experimental|Part 2: CSF PKPD|Pharmacokinetic and pharmacodynamic cerebrospinal fluid assessment
88894237|NCT01462864|Active Comparator|Intervention|Lifestyle education intervention
88894238|NCT01462864|No Intervention|Control|The control group will receive an information leaflet which is generally distributed in our speciality clinic to patients with diagnosis of PCOS. The leaflet includes general information on PCOS, treatment options and advice on increasing physical activity.
88894239|NCT01462903|Experimental|Drug, T cell immunoterhapy|
88894240|NCT01462916||honey, no honey|
88894241|NCT01462968|Active Comparator|Activated clotting time (ACT) group|heparinization measured as activated clotting time during surgery
88894242|NCT01462968|Experimental|Hepcon group|heparinization measured as heparin concentration in the blood during surgery
88894243|NCT01462994|No Intervention|Single arm|
88894244|NCT01463020|Experimental|Smartphone delivered BA|
88894245|NCT01463020|Active Comparator|Smartphone delivered mindfulness|
88894246|NCT01463046|Experimental|Panobinostat|
88894247|NCT01463085|Placebo Comparator|Control foods|3 servings per day of control foods
88894248|NCT01463085|Experimental|Low-fat dairy|3 servings per day of low-fat dairy products
88894249|NCT01463124|Experimental|Lookin' Good Feelin' Good|Six 30-minute individual student-centered counseling sessions delivered by school nurses during the first two months followed by weekly weigh-ins and monthly visits over the subsequent 6 months, plus an exercise program in the school 3 times a week for the full eight months of the intervention.
88894250|NCT01463124|Active Comparator|Information attention-control|Six individual sessions with school nurse over the first two months followed by monthly visits over the remaining 6 months to check weight and behavior changes and provide a series of pamphlets on weight and weight management.
88894251|NCT01463137|Sham Comparator|Control training with words|Computerized, internet-based control training program. Participant is exposed to a pair of words -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (< or >) in the previous position of ONE of these words and is then asked to press the corresponding arrow button on a keyboard. A total of 192 word pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe follows the more positive word and the more negative word with equal frequency.
88894252|NCT01463137|Sham Comparator|Control training with words + pictures|Computerized, internet-based control training program. Participant is exposed to a pair of words or a pair of faces -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (< or >) in the previous position of ONE of these words or faces and is then asked to press the corresponding arrow button on a keyboard. A total of 96 word pairs and 96 face pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe follows the more positive stimulus and the more negative stimulus with equal frequency.
88894253|NCT01463137|Active Comparator|Positive bias training with words|Computerized, internet-based training program for implicit modification of cognitive bias of attention, variant 1. Participant is exposed to two words -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (< or >) in the previous position of ONE of these words and is then asked to press the corresponding arrow button on a keyboard. A total of 192 word pairs are shown during a session, of one third is the neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe always follows the more positive word.
88894254|NCT01463137|Active Comparator|Positive bias training with words + pictures|Computerized, internet-based training program for implicit modification of cognitive bias of attention, variant 2. Participant is exposed to a pair of words or a pair of faces -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (< or >) in the previous position of ONE of these words or faces and is then asked to press the corresponding arrow button on a keyboard. A total of 96 word pairs and 96 face pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe always follows the more positive word or face.
88922160|NCT05713630|Experimental|Standard care + TXA|Non-surgical patients will be given a single oral or IV loading dose of 1g TXA within three hours of being randomized. For surgical patients, the same loading dose will be administered whenever possible prior to surgery. After 12 hours of the loading dose, patients will be given 500 mg TXA by mouth (or nasogastric tube for those unable to swallow or IV) three times a day, totalling 1500 mg/day, for 45 days.
89416558|NCT03623074|Other|Test Arm 3|Single vision, impact-resistant spectacle lenses
89416559|NCT03586661|Experimental|Treatment (niraparib, copanlisib)|Patients receive niraparib PO daily on days 1-28 and copanlisib IV on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89416560|NCT03575897|Experimental|Intervention Group|Infants randomly assigned to the intervention group will undergo serial measurements of infant body composition during their hospitalization. This information about infant body composition will be known to the clinicians caring for them (including reference data).
89416561|NCT03575897|Active Comparator|Control Group|Infants randomly assigned to the control group will also undergo serial measurements of infant body composition during their hospitalization, but this information will not be available to the clinicians caring for them.
88894255|NCT01463137|Active Comparator|Negative bias training with words|Computerized, internet-based training program for implicit modification of cognitive bias of attention, variant 3. Participant is exposed to two words -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (< or >) in the previous position of ONE of these words and is then asked to press the corresponding arrow button on a keyboard. A total of 192 word pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe always follows the more negative word.
88894256|NCT01463137|Active Comparator|Negative bias training with words + pictures|Computerized, internet-based training program for implicit modification of cognitive bias of attention, variant 4. Participant is exposed to a pair of words or a pair of faces -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (< or >) in the previous position of ONE of these words or faces and is then asked to press the corresponding arrow button on a keyboard. A total of 96 word pairs and 96 face pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe always follows the more negative word or face.
89193224|NCT05357027|Experimental|TC-E202 dose|"This study uses the 3+3 dose escalation method. The initial dose is Dose1, the maximum dose that patients can tolerate is determined as the phase II recommended dose (RPIID), and at least 6 patients are receiving RPIID treatment . If patients develop intolerance in Dose 1 (≥3 subjects with DLT), then the subsequent enrolled patients will receive Dose-1 infusion."
88894257|NCT01463150|Active Comparator|Clopidogrel|Clopidogrel 150mg per day for 15 days
88894258|NCT01463150|Experimental|Prasugrel|Prasugrel 5mg for 15 days
88894259|NCT01463163|Active Comparator|Prasugrel|Prasugrel 60mg LD followed by 10mg MD starting post 24 hours
88894260|NCT01463163|Experimental|Ticagrelor|Ticagrelor 180mg LD followed by 90mg x2 MD starting post 12±6 hours
88894261|NCT01463176|No Intervention|Standard Care|Children in the Standard Care Control group will receive standard care and will be videotaped by the music therapist but will not receive music therapy during their immunization
88894262|NCT01463176|Experimental|Music Therapy|Children in this group will receive live music therapy during their immunization.
88894263|NCT01463189|Experimental|painACTION: Arthritis|
88894264|NCT01463189|No Intervention|treatment as usual|
88894265|NCT01463215|Experimental|Ambroxol|Ambroxol at a dose level of 187.5 or 225 mg/day will be given once daily by mouth for 2 months.
88894266|NCT01463228|Experimental|Treatment Sequence AB|
89193225|NCT05352074|Active Comparator|total colectomy with ileorectal anastomosis|After a complete mobilization of the colon, a resection 2-3 cm proximal to the ileocecal junction is conducted. Use a Pfannestiel incision to perform the anastomosis and to remove the resected colon. The ileorectal anastomosis is performed by introducing the stapler via the anus, with the intention of carrying out a ''cleaner,'' ''tensionless'' procedure.
89193226|NCT05352074|Experimental|subtotal colectomy with cecal-rectal anastomosis|After a complete mobilization of the colon, a resection 2-3cm distal to the ileocecal junction and at the upper part of the rectal ampulla are conducted; the cecum is then lowered into the pelvis, without any rotation, and an antiperistaltic cecorectal anastomosis is performed between the cecal fundus (after appendectomy) and the rectum, after introduction of a stapler through the cecal resection line. Use a Pfannestiel incision to perform the anastomosis and to remove the resected colon. The cecal-rectal anastomosis is performed by introducing the stapler via the anus, with the intention of carrying out a ''cleaner,'' ''tensionless'' procedure.
89193227|NCT05350878|Experimental|Implementation Intervention|Through virtual and in-person meetings, the internal/external facilitation team will support sites in utilizing the multi-component implementation strategy for 7 months
89193228|NCT05350878|No Intervention|Implementation as Usual|In control 'implementation as usual' sites, no facilitation or implementation strategies will be provided. Controls will receive 1) an informational session on the text intervention during grand rounds/staff meetings and 2) flyers to provide patients with intervention enrollment information.
89193229|NCT05347199|Placebo Comparator|Healthy Volunteers Placebo|placebo pill at two time points
89193230|NCT05347199|Active Comparator|Healthy Volunteers Amisulpride|amisulpride pill at two time points
89193231|NCT05347199|Active Comparator|MDD Patients Placebo|placebo pill at two time points
89193232|NCT05347199|Experimental|MDD Patients Amisulpride|amisulpride pill at two time points
89193233|NCT05346588|Active Comparator|Propofol total intravenous anesthesia (TIVA)|No administration of inhaled agent.
89193234|NCT05346588|Active Comparator|Inhaled volatile general anesthesia|Must administer inhaled agent.
88894267|NCT01463228|Experimental|Treatment Sequence BA|
88894268|NCT01463241|Other|BASIC treatment|As an open trial, all participants in this study will receive the BASIC treatment.
88894269|NCT01463254||Surveillance|- a surveillance cohort of 300 women who will report back to the clinic during 12 months after enrolment only if they have complications, medical problems, pregnancy, or want to remove the implant
88894270|NCT01463254||Prospective|a prospective cohort consisting of 300 women who will be followed-up 3 and 12 months after enrollment
88894271|NCT01463280|Experimental|tumescent lidocaine infiltration|Assess Platelet function with respect to dosage of tumescent lidocaine There is only one arm.
88894272|NCT01463319|Experimental|warm water irrigation|warm water irrigation during insertion phase of colonoscopy
88894273|NCT01463319|Experimental|air insufflation|air insufflation during insertion phase of colonoscopy
88894274|NCT01463332|Placebo Comparator|Group NS|Patients were randomly assigned in to three groups of 50 each using a computer-generated table of random numbers. Patients Group NS were injected intravenously with 10 ml of normal saline before injection of propofol.
88894275|NCT01463332|Active Comparator|Group D25|Patients were randomly assigned in to three groups of 50 each using a computer-generated table of random numbers. Patients Group D25 were injected intravenously with 0.25mic/kg of dexmedetomidine diluted with normal saline into 10ml before injection of propofol.
89193235|NCT05340374|Experimental|Treatment Arm|In this single-arm study, patients will receive 7.4 GBq of 177Lu-PSMA-617 on Day 1 of every 6 week Cycle. Cabazitaxel will be administered concurrently on Day 2 and Day 23 of each Cycle (every 3 weeks). The dose of cabazitaxel will vary in dose-escalation. Up to 6 Cycles will be given.
89193236|NCT05335356|Experimental|Bmab1200|Bmab 1200 45 mg Bmab 1200 90 mg
88894276|NCT01463332|Active Comparator|Group D50|Patients were randomly assigned in to three groups of 50 each using a computer-generated table of random numbers. Patients Group D50 were injected intravenously with 0.50mic/kg of dexmedetomidine diluted with normal saline into 10ml before injection of propofol.
88894277|NCT01463345|Experimental|Conservative Transfusion Arm|Subjects in the conservative transfusion arm will receive transfusion only when their hemoglobin levels reach 7.5 g/dl.
89416562|NCT03557957|Experimental|Standard care plus targeted correction of hyponatremia|Diagnosis and treatment of hyponatremia will be standardized according to the European Clinical Practice Guidelines (ECPG). Treatment response and adherence will be evaluated daily and treatment adapted if treatment goals are not reached.Targeted correction of plasma sodium Levels.
89416563|NCT03557957|Active Comparator|Standard care|Diagnosis and treatment of hyponatremia will be solely at the discretion of the attending physicians who are in no way involved in the trial. The study team will not intervene with the treatment in any way. Diagnostic and treatment decisions as well as course of the plasma sodium level will only be recorded after patient is discharged from hospital using the medical records and patient charts. It will be generally recommended to measure plasma sodium levels 3x weekly or more frequently if clinically indicated, at discharge and after 30 days.
89416564|NCT03493048|Experimental|Cetuximab Plus FOLFOXIRI|Cetuximab Plus FOLFOXIRI Patients will receive Cetuximab Plus FOLFOXIRI every 14 days: Cetuximab 500mg/m2 ivd over 90 minutes on Day 1; Oxaliplatin 85 mg/m2 ivd over 3 hours on Day 1; Irinotecan 130 mg/m2 ivd over 90 minutes on Day 1; Leucovorin (l-LV) 200mg/m2 ivd over 2 hours on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion on Day 1.
89416565|NCT03493048|Active Comparator|Cetuximab Plus FOLFOX|Patients will receive Cetuximab Plus FOLFOX every 14 days: Cetuximab 500mg/m2 ivd over 90 minutes on Day 1; Oxaliplatin 85 mg/m2 ivd over 3 hours on Day 1; Leucovorin (l-LV) 200mg/m2 ivd over 2 hours on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion on Day 1.
88894278|NCT01463345|Active Comparator|Liberal Transfusion Arm|Subjects in the liberal transfusion arm will receive transfusion only when their hemoglobin levels reach 9.0 g/dl.
88894279|NCT01463436|Experimental|soy isoflavone 100 mg|the experimental group receiving tablet contain soy isoflavone 100 mg and calcium carbonate 500 mg
88894280|NCT01463436|Placebo Comparator|calcium carbonate 500 mg|The control group receiving a tablet contains calcium carbonate 500 mg for 6 months and 12 months
88894281|NCT01463449||Obese|Obese subjects half with type 2-diabetes. Before and after gastric bypass. Expected reduction in weight 25 %. We expect a reduction in low grade inflammation in adipose tissue after weight loss.
88894282|NCT01463462||Electronic Catheter Stethoscope|
88894283|NCT01463475|Other|Bone Marrow Aspirate|A qualified enrolled donor will have an aspirate bone marrow draw.
88894284|NCT01463488|Experimental|SAR113945 - Dose 1|
88894285|NCT01463488|Experimental|SAR113945 - Dose 2|
88894286|NCT01463488|Experimental|SAR113945 - Dose 3|
88894287|NCT01463488|Placebo Comparator|Placebo|
88894288|NCT01463501|Experimental|Neoadjuvant Treatment|Preoperative chemotherapy/radiotherapy
88894289|NCT01463501|Experimental|Adjuvant Treatment|Postoperative chemotherapy/radiotherapy
89193237|NCT05335356|Active Comparator|Stelara|Stelara 45 mg Stelara 90 mg
89416566|NCT03439748|Experimental|Positive Affect Treatment|15 sessions of psychotherapy designed to augment reward anticipation, reward attainment, and reward learning.
89416567|NCT03439748|Active Comparator|Negative Affect Treatment|15 sessions of psychotherapy designed to decrease threat avoidance, threat appraisal and arousal.
88894290|NCT01463514|Experimental|AIR|"Randomization sequences according to modified catheter protocol.~1. AIR 2. Target Oxygen(88-90%) 3. 100% Oxygen 4. Nitric Oxygen"
88894291|NCT01463514|Experimental|NO|"Randomization sequences according to modified catheter protocol.~1.Nitric Oxygen 2. AIR 3. Target Oxygen(88-90%) 4. 100% Oxygen"
88894292|NCT01463514|Experimental|Oxygen|"Randomization sequences according to modified catheter protocol.~1. 100% Oxygen 2. NO 3. AIR 4. Target Oxygen (88-90%)"
88894293|NCT01463514|Experimental|Target Oxygen|"Randomization sequences according to modified catheter protocol.~1. Target Oxygen (88-90%) 2. 100% Oxygen 3. NO 4. AIR"
88894294|NCT01463540|Active Comparator|Push/pull endoscopic gastrostomy|
88894295|NCT01463540|Experimental|Gastrostomy after gastropexy|
88894296|NCT01463553|No Intervention|wedge resection|
89416568|NCT03433001||Ixazomib + Lenalidomide + Dexamethasone|Participants took ixazomib, lenalidomide, and dexamethasone under conditions of standard medical care in this study. The dosage and administration of ixazomib, lenalidomide, and dexamethasone were not defined by the protocol but according to the package insert of each drug.
89416569|NCT03432078|Active Comparator|Individual hypnotherapy|Treatment given on a individual basis, face to face.
89416570|NCT03432078|Active Comparator|Group hypnotherapy|Treatment given in a group setting, face to face.
89416571|NCT03327428||Patients with Sickle Cell Disease|Patients with any sickling condition, including among others Sickle Cell Anemia, HbSC Disease, HbS-betaThal, excluding Sickle Cell Trait.
89416572|NCT03324893|Experimental|[F18]-FCH PET/MRI|Patients with primary hyperparathyroidism planned for parathyroidectomy
89416573|NCT03314935|Experimental|Treatment Group A|INCB001158 + FOLFOX
88894297|NCT01463553|Experimental|Wedge resection and pleurodosis|
88894298|NCT01463566||1 - Gender Natural Knee|Patients suffering from severe knee pain and disability.
88894299|NCT01463579|Experimental|Exercise programme|
88894300|NCT01463579|Other|Standard Care|
88894301|NCT01463592|Experimental|Group II a|TRIPPLE THERAPY
88894302|NCT01463592|Active Comparator|Group II b|DUAL THERAPY
88894303|NCT01463592|Experimental|Group I|ORAL RENESSANS
88894304|NCT01463605|Other|radiotherapy|It is just a single group assignment
88894305|NCT01463644|Active Comparator|mepolizumab|
88894306|NCT01463644|Placebo Comparator|placebo|
88894307|NCT01463709|Experimental|nanopulse|Administer nano pulse to lesion for varying time intervals.
88894308|NCT01463722|Other|Amniotic fluid Lamellar Body Counting|
88894309|NCT01463748|Experimental|Placebo|starch
89416574|NCT03314935|Experimental|Treatment Group B|INCB001158 + gemcitabine/cisplatin
89416575|NCT03314935|Experimental|Treatment Group C|INCB001158 + paclitaxel
88894310|NCT01463748|Experimental|Graptopetalum paraguayense E. Walther|Graptopetalum paraguayense E. Walther
88894311|NCT01463761||high-level athletes|High-level athlete, enrolled in a Ministry-recognized Pôle
88894312|NCT01463774|Experimental|Treatment Sequence AB|The study consists of 2 treatment periods (A and B). Each treatment period wiill be separated by a washout period of 10-15 days.
88894313|NCT01463774|Experimental|Treatment Sequence BA|The study consists of 2 treatment periods (A and B). Each treatment period wiill be separated by a washout period of 10-15 days.
88894314|NCT01463787|Experimental|inguinal group|
88894315|NCT01463787|Active Comparator|sub-inguinal group|
88894316|NCT01463800|Active Comparator|Structured Exercise training|12 weeks ambulatory low level exercise training
88894317|NCT01463800|No Intervention|Control group|No structured exercise training
88894318|NCT01463813|Placebo Comparator|Placebo|Placebo, no Vitamin D3
88894319|NCT01463813|Experimental|Vitamin D3 80|Vitamin D3 80 micrograms (3200 IU) per day
88894320|NCT01463813|Experimental|Vitamin D3 40|Vitamin D3 40 micrograms (1600 IU) per day
88894321|NCT01463826||Children with bruxism|14 children with bruxism
88894322|NCT01463826||children without bruxism|19 children without bruxism
88894323|NCT01463839||Children 3 to 6|Fifty children (3 to 6 years of age) from a private school in the city of Sao Paulo
88894324|NCT01463852|Experimental|Vincrisitne 2mg|Single Arm study: Vincristine 2mg administered IV by infusion over 5 minutes.
88894325|NCT01463865|Placebo Comparator|Placebo|Sodium chloride
88894326|NCT01463865|Active Comparator|ropivacaine|Naropin
88894327|NCT01462760|Other|First assessment: inclinometer|First assessment: inclinometer Second assessment: actigraph and inclinometer
88894328|NCT01462760|Other|first: Inclinometer and actigraph|first: Inclinometer and actigraph second: inclinometer
88894329|NCT01463904||Morbid obese, diabetics|Patients with morbid obesity or severe metabolic disease
88894330|NCT01463917|Active Comparator|Hypertonic|Use of Hypertonic solution during left marginal branch CABG surgery.
88894331|NCT01463917|Placebo Comparator|Isotonic|Use of Isotonic solution during left marginal branch CABG surgery.
88894332|NCT01463930|Experimental|Audiovisual videodisc and medical verbal information|
89416576|NCT03299530||patients with corneal astigmatism|Patients who had received phacoemulsification surgery with or without implantation of toric IOL are with a certain amount of corneal astigmatism.
88894333|NCT01463930|Active Comparator|Medical verbal information|
88894334|NCT01463943|Experimental|Saccharomyces boulardii capsules (200 mg).|
88894335|NCT01463943|Active Comparator|Floratil®|
88894336|NCT01463943|Experimental|Saccharomyces boulardii powder (200 mg).|
88894337|NCT01463956|Experimental|Boceprevir, Pegylated interferon and Ribavirin|"Lead-in phase (4 week): Pegylated interferon + Ribavirin~Triple therapy regimen for 44 weeks :Boceprevir + Pegylated interferon + Ribavirin~Pegylated interferon + Ribavirin therapy until transplantation (less or equal to 24 weeks)"
88894338|NCT01463969||PCOS patients|
88894339|NCT01463969||Control group|
88894340|NCT01463995||severe neurological diseases|Patients with severe neurological diseases treated on the neurological intensive care unit
88894341|NCT01464008||chronic hepatitis C|
88894342|NCT01464047||Patients with CML or Ph+ ALL|
88894343|NCT01464060|Active Comparator|"Hybrid therapy"|Dual therapy for 7 days: 40 mg omeprazole and 1g amoxicillin every 12h. After dual therapy continue with a quadruple therapy for 7 days: 40 mg omeprazole, 1g amoxicillin, 500 mg metronidazole and 500 mg clarithromycin every 12h.
88894344|NCT01464060|Experimental|"Concomitant therapy"|Quadruple therapy for 14 days: 40 mg omeprazole, 1g amoxicillin, 500 mg metronidazole and 500 mg clarithromycin every 12h
88894345|NCT01464073|Active Comparator|arm 3 : Good Medical Practices|physical exercise at home monitored by telephone (achieving a minimum of 30 minutes per day)
88894346|NCT01464073|Active Comparator|arm 2 : 60% VO2peak|physical exercise at the intensity of 60% of VO2 peak. 4 times a week. duration will be adjusted for arm 1 and arm 2 have the same total energy expenditure by session.
88894347|NCT01464073|Experimental|arm 1 : LIPOXmax|physical exercise at the LIPOXmax intensity during 60 minutes. 4 times a week
88894348|NCT01464086|No Intervention|Standard arm|standard follow-up
88894349|NCT01464086|Experimental|Intensive follow-up|Standard follow-up plus whole body MRI at inclusion, one and two years
88894350|NCT01464099|Active Comparator|Insulin aspart 100U/mL|
88894351|NCT01464099|Experimental|Insulin aspart 200U/mL|
88894352|NCT01464112|Experimental|001|
88894353|NCT01464125|Experimental|Fos-Azi|Open label single arm concurrent administration of fosmidomycin and azithromycin.
88894354|NCT01464138|Experimental|Fosmidomycin-Clindamycin|Single arm study. Co-administration of Fosmidomycin and Clindamycin.
88894355|NCT01464151||Patients with inflammatory bowel disease|patients with a diagnosis of ulcerative colitis, Crohn's colitis or indeterminate colitis between 18 and 70 years of age. Patients should have an indication for surveillance according to the current guidelines, which means a disease duration of at least 8 years and involvement of at least 30% of the colon.
88894356|NCT01464203|Experimental|CT coronary angiography|Patients in this arm will undergo CT coronary angiography to assess the patency of coronary arteries and their clinical management will be decided by the results of CT coronary angiography.
88894357|NCT01464203|Active Comparator|Control Arm|"Patients in this arm will receive the standard of care (SoC). They will undergo either coronary angiography, myocardial perfusion scan or stress echocardiography as decided by the physician in charge, depending on the local availability of individual investigations and the patient's clinical scenario."
88894358|NCT01464242|Experimental|Glucantime® + pentoxifylline|Glucantime® 20mg/kg/day intramuscular injection (IM) daily for 20 days + pentoxifylline 400mg orally 3 times a day for 20 days.
88894359|NCT01464242|Placebo Comparator|Glucantime® + placebo|Glucantime® 20mg/kg/day IM each day for 20 days + placebo 400mg orally 3 times a day for 20 days.
88894360|NCT01464281|Experimental|48-week standard treatment|48-week standard treatment by Peginterferon alfa 2a 180µg/week
88894361|NCT01464281|Active Comparator|96-week prolonged treatment|96-week prolonged treatment by Peginterferon alfa 2a 180µg/week
88894362|NCT01464294||nano-composite|crowns and onlays
88894363|NCT01464294||ceramic|crowns & onlays
88894364|NCT01464320|Experimental|ABT-614|
88894365|NCT01464320|Placebo Comparator|Placebo Comparator|
88894366|NCT01464372|Experimental|Investigational Device|Treatment using electrical field stimulation of peripheral nerves
89193238|NCT05329025|Experimental|Treatment A|Participants with squamous cell carcinoma will receive QL1706, paclitaxel and carboplatin by intravenous (IV) injection on Day 1 of each 21-day cycle for 4 cycles in the induction treatment. In the maintenance phase, participants will be treated with QL1706 until unacceptable toxicity or loss of clinical benefit.
89193239|NCT05329025|Experimental|Treatment B|Participants with non-squamous cell carcinoma will receive QL1706, bevacizumab, pemetrexed, and carboplatin by intravenous (IV) injection on Day 1 of each 21-day cycle for 4 cycles in the induction treatment. In the maintenance phase, participants will be treated with QL1706, bevacizumab and pemetrexed until unacceptable toxicity or loss of clinical benefit.
88894367|NCT01464372|Sham Comparator|Sham Device|Control group using sham device to mimic sound and sensation of investigational device
88894368|NCT01464385|Experimental|Nutritional Beverage #2|Nutritional Beverage with an amino acid Oral 237 ml
88894369|NCT01464385|Experimental|Nutritional Beverage #3|Nutritional Beverage with an amino acid Oral 237 ml
88894370|NCT01464385|Placebo Comparator|Nutritional Beverage #1|Nutritional Beverage Oral 237 ml
88894371|NCT01464398|Active Comparator|Stress reduction|Mindfulness-based stress reduction
88894372|NCT01464398|Active Comparator|Stress reduction with Health education|General stress management and health education
88894373|NCT01464450|Active Comparator|Sequence 1: Treatment A - B - C|Participants will receive a single 20 mg-dose of rivaroxaban as a whole tablet swallowed intact with 70 mL of applesauce and 130 mL of water followed by a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 1 (Treatment A,) followed by a single 20 mg-dose of rivaroxaban crushed and mixed in 70 ml of applesauce, followed by 2 mortar rinses of 65 mL each of water (to ensure delivery of the entire dose) and a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 2 (Treatment B) and followed by 20 mL of water via NG tube (to prime and pre-wet the lumen), followed by a single 20 mg-dose of rivaroxaban crushed and suspended in 50 mL of water given via NG tube, followed by 2 mortar rinses of 65 mL each of water and a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 3 (Treatment C.)
88894374|NCT01464450|Active Comparator|Sequence 2: Treatment A - C - B|Participants will receive a single 20 mg-dose of rivaroxaban as a whole tablet swallowed intact with 70 mL of applesauce and 130 mL of water followed by a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 1 (Treatment A,) followed by 20 mL of water via NG tube (to prime and pre-wet the lumen), followed by a single 20 mg-dose of rivaroxaban crushed and suspended in 50 mL of water given via NG tube, followed by 2 mortar rinses of 65 mL each of water and a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 2 (Treatment C) and followed by a single 20 mg-dose of rivaroxaban crushed and mixed in 70 ml of applesauce, followed by 2 mortar rinses of 65 mL each of water (to ensure delivery of the entire dose) and a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 3 (Treatment B.)
88894375|NCT01464450|Active Comparator|Sequence 3: Treatment B - C - A|Participants will receive a single 20 mg-dose of rivaroxaban crushed and mixed in 70 ml of applesauce, followed by 2 mortar rinses of 65 mL each of water (to ensure delivery of the entire dose) and a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 1 (Treatment B,) followed by a single 20 mg-dose of rivaroxaban crushed and suspended in 50 mL of water given via NG tube, followed by 2 mortar rinses of 65 mL each of water and a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 2 (Treatment C) and followed by a single 20 mg-dose of rivaroxaban as a whole tablet swallowed intact with 70 mL of applesauce and 130 mL of water followed by a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 3 (Treatment A.)
89006087|NCT04646863|Experimental|group C|consists of 20 patients received a multiwave locked system laser and Pilates exercises
89193240|NCT05326568|Experimental|Experimental|Sesame oil was applied by the researcher to the patients assigned to the intervention group. Sesame oil was applied to the 10 cm circumference of the cannula, in the form of 10 drops and 10 minutes.
89193241|NCT05326568|No Intervention|Control|No treatment was applied to the patients assigned to the control group and only standard care was applied.
88894376|NCT01464450|Active Comparator|Sequence 4: Treatment B - A - C|Participants will receive a single 20 mg-dose of rivaroxaban crushed and mixed in 70 ml of applesauce, followed by 2 mortar rinses of 65 mL each of water (to ensure delivery of the entire dose) and a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 1 (Treatment B,) followed by a single 20 mg-dose of rivaroxaban as a whole tablet swallowed intact with 70 mL of applesauce and 130 mL of water followed by a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 2 (Treatment A) and followed by 20 mL of water via NG tube (to prime and pre-wet the lumen), followed by a single 20 mg-dose of rivaroxaban crushed and suspended in 50 mL of water given via NG tube, followed by 2 mortar rinses of 65 mL each of water and a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 3 (Treatment C.)
88894377|NCT01464450|Active Comparator|Sequence 5: Treatment C - A - B|Participants will receive a single 20 mg-dose of rivaroxaban crushed and suspended in 50 mL of water given via NG tube, followed by 2 mortar rinses of 65 mL each of water and a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 1 (Treatment C,) followed by a single 20 mg-dose of rivaroxaban as a whole tablet swallowed intact with 70 mL of applesauce and 130 mL of water followed by a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 2 (Treatment A) and followed by and followed by a single 20 mg-dose of rivaroxaban crushed and mixed in 70 ml of applesauce, followed by 2 mortar rinses of 65 mL each of water (to ensure delivery of the entire dose) and a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 3 (Treatment B.)
88894378|NCT01464450|Active Comparator|Sequence 6: Treatment C - B - A|Participants will receive a single 20 mg-dose of rivaroxaban crushed and suspended in 50 mL of water given via NG tube, followed by 2 mortar rinses of 65 mL each of water and a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 1 (Treatment C,) followed by and followed by a single 20 mg-dose of rivaroxaban crushed and mixed in 70 ml of applesauce, followed by 2 mortar rinses of 65 mL each of water (to ensure delivery of the entire dose) and a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 2 (Treatment B) and followed by a single 20 mg-dose of rivaroxaban as a whole tablet swallowed intact with 70 mL of applesauce and 130 mL of water followed by a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 3 (Treatment A.)
88894379|NCT01464463|Experimental|CBT-active|Patients with Major Depression (N = 50) get a common CBT treatment in combination with physical exercise.
88894380|NCT01464463|Active Comparator|CBT-euthymic|"Patients with Major Depression (N = 50) get the same common CBT treatment as the CBT-active-group, but instead of physical exercise they receive an enjoyment training, which is based on exercises from the Kleine Schule des Genießens (Koppenhöfer, 2004)"
88894381|NCT01464463|Active Comparator|CBASP|Patients with Major Depression (N=50) get a cognitive therapy according to the Cognitive Behavioral Analysis System of Psychotherapy (CBASP).
88894382|NCT01464463|No Intervention|Waiting List|Patients randomized to the waiting list receive psychological treatment after waiting for 4 month.
88894383|NCT01464476|Experimental|Azimilide|Azimilide 75 mg film coated tablets
88894384|NCT01464476|Placebo Comparator|Placebo|
88894385|NCT01464489|Experimental|Control group|Anaesthesia was induced with alfentanil 10 μg.kg-1, propofol 2.5 mg.kg-1 and rocuronium 0.3 mg.kg-1.And receive normal saline for control group
88894386|NCT01464489|Active Comparator|Atropine group|Anaesthesia was induced with alfentanil 10 μg.kg-1, propofol 2.5 mg.kg-1 and rocuronium 0.3 mg.kg-1. And receive atropine (atropine sulfate) 10 μg.kg-1 for atropine group.
88894387|NCT01466608|Experimental|Rosuvastatin|Rosuvastatin 20 mg will be administered once a day for 8 weeks (open-label, one-arm, single-sequence design)
89416577|NCT03263351|Experimental|Cognitive-behavioral therapy group|Six-session cognitive-behavioral therapy group program designed as a prevention of depression intervention for adolescents at-risk for depression. The program is facilitated by a psychologist. Sessions are weekly for 1-hour.
88894388|NCT01463657|Experimental|ELAPR002|Each treatment will consist of up 15 injections in total, each consisting of up to 0.1 ml of product, delivered to the mid to deep dermis of the skin of each NLF using a 27G needle. The needle will be inserted at an approximate angle of 30o parallel to the skin, and the product may be injected by a retrograde injection or by deposition of a bolus. ELAPR and the control may be implanted parallel or perpendicular to the NLF. Exactly the same technique will be used for the treatment of both NLFs for each patient.
88894389|NCT01463657|Active Comparator|Juvéderm® Ultra Plus|Each treatment will consist of up 15 injections in total, each consisting of up to 0.1 ml of product, delivered to the mid to deep dermis of the skin of each NLF using a 27G needle. The needle will be inserted at an approximate angle of 30o parallel to the skin, and the product may be injected by a retrograde injection or by deposition of a bolus. ELAPR and the control may be implanted parallel or perpendicular to the NLF. Exactly the same technique will be used for the treatment of both NLFs for each patient.
88894390|NCT01466621||Previously RV Paced|Patients who were RV paced prior to receiving a cardiac resynchronization therapy device.
88894391|NCT01466621||Non-Previously RV Paced|Patients who received a CRT device without being previously RV paced.
88894392|NCT01466634||permanent polymer DES|
88894393|NCT01466634||bioabsorbable polymer DES|
88894394|NCT01466647|Other|AXL1717 in combination with Gemcitabine HCL and Carboplatin|AXL1717 in combination with Gemcitabine HCL and Carboplatin
88894395|NCT01466712|Experimental|Tiotropium+formoterol/beclomethasone|run-in of 4 weeks with thiotropium cross-over after first treatment period of 4 weeks
88894396|NCT01466712|Sham Comparator|tiotropium+placebo|cross-over cfr arm1
88894397|NCT01466738|Experimental|HRV-16 (100 TCID50)|
88894398|NCT01466738|Experimental|HRV-16 (1000 TCID50)|
88894399|NCT01466777|Active Comparator|traditional laparoscopic surgery type|
88894400|NCT01466777|Experimental|Robotic assisted operation type|
88894401|NCT01466803|Active Comparator|Vorikonazole|The subject will be given vorikonazole twice a day for 5 days prior to the study. The dose will be 400 mg twice a day on day one ans 200 mg twice a day on days 2-5.
88894402|NCT01466803|Placebo Comparator|Placebo|The subjects will be given placebo twice a day for 5 days prior to the study
88894403|NCT01466816|Experimental|Saturated fatty acid test meal|
88894404|NCT01466816|Experimental|Monounsaturated fatty acid meal|
88894405|NCT01466816|Experimental|Polyunsaturated fatty acid meal|
89416578|NCT03263351|Active Comparator|Health education group|Six-session health education group program designed as a health education curriculum for teenagers. The program is facilitated by a psychologist. Sessions are weekly for 1-hour.
89416579|NCT03256773||Notmal|No lung Disease
89006088|NCT04647292|Experimental|Target systolic blood pressure 115-125 mmHg|Recommended target SBP 115-125 millimetres of mercury (mmHg).
89193242|NCT05322096|Experimental|RGH-706|"Part A: Dose A once daily for 6 weeks~Part B: Dose B, Dose C or Dose D once daily (depending on the randomized arm) for 13 weeks"
89193243|NCT05322096|Placebo Comparator|Placebo|"Part A: Placebo once daily for 6 weeks~Part B: Placebo once daily for 13 weeks"
89193244|NCT05320796|Experimental|Solution|Esomeprazol MUT Sandoz® 40mg as a single dose will be dissolved in 10ml tap water to create a solution and then applied per oral
89193245|NCT05320796|Active Comparator|Tablet|Esomeprazo MUT Sandozl® 40mg tablet as a single dose will be given orally
89193246|NCT05318053||2022 Cohort|"Successful completion of screening checklist to indicate one of the following conditions:~recurring, long-standing fantasies that focus on kink, in areas such as: power exchange (Dominant/submissive roles), bondage, sadomasochism, or fetish activities. By fetish, we mean a type of sexual desire in which gratification depends on or is significantly increased by particular objects, clothing items, parts of the body, or types of persons.~OR currently engaging, or have engaged in the past, in consensual kink activities such as power exchange (Dominant/submissive roles), bondage, sadomasochism, or fetish activities.~Age of majority in the legal jurisdiction (geographic location) where the survey is taken (usually age 18)~English-language proficiency sufficient to understand the study instruments~Completion of an electronically signed and dated informed consent form"
89193247|NCT05310487|Experimental|162|The dose-escalation stage will be conducted sequentially at 5 dose levels, which are 100 mg in the pre-test, and 200 mg, 400 mg, 800 mg and 1200 mg in the formal test. Two healthy adult subjects will be enrolled at 100 mg dose level and all given 162. At the start of each level with the exception of 100 mg level which there are only two subjects, two sentinel subjects will be randomized 1:1 to 162 or placebo. The remaining subjects will be randomized 5:1 to receive a single ascending dose of 162 or placebo.
89193248|NCT05310487|Placebo Comparator|placebo|At the start of each level with the exception of 100 mg level which there are only two subjects, two sentinel subjects will be randomized 1:1 to 162 or placebo. The remaining subjects will be randomized 5:1 to receive a single ascending dose of 162 or placebo.
89193249|NCT05295758|Experimental|PAL2 Intervention|Overall study cohort will be enrolled into non-randomized active treatment
89193250|NCT05294107|Experimental|Group Crohn's disease|4 additional biopsies for 30 patients with Crohn's disease
89193251|NCT05294107|Experimental|Group ulcerative colitis|4 additional biopsies for 30 patients with ulcerative colitis
89193252|NCT05294107|Active Comparator|Group No MICI|4 additional biopsies for 30 patients out of Inflammatory Disease Chronic Bowel Disease
89193253|NCT05292404|Experimental|Early PCSK9 inhibitor treatment group|
89193254|NCT05292404|Other|conventional treatment group|
89193255|NCT05292209|Experimental|Active|Riluzole 50mg BID
89193256|NCT05292209|Placebo Comparator|Control|Placebo Matching Double-Dummy Pills
89193257|NCT05281796||healthy patient|Full-mouth clinical periodontal measurements recorded, saliva and GCF obtained
89193258|NCT05281796||gingivitis patient|Full-mouth clinical periodontal measurements recorded, saliva and GCF obtained
89193259|NCT05281796||patients with Stage III periodontitis|Full-mouth clinical periodontal measurements recorded, saliva and GCF obtained
89193260|NCT05281237|Experimental|AVECURE FLEXIBLE MICROWAVE ABLATION PROBE FOR LUNG NODULES|"The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits.~Ablation Procedure- MWA will be used to treat solitary pulmonary nodules up to 3cm.~CT scan will then be performed to evaluate the radiological changes 2 - 4 weeks after the ablation procedure.~Surgery will be performed to remove the lung nodule and the tissue will be evaluated by pathology."
89193261|NCT05275894|Experimental|Non-surgical electrolytic cleaning|"Implant hygiene instructions and removal of the prosthesis~Local anaesthesia~Removal of the granulation tissue and mucosa and bone defect curettage with a steel curette 4R/4L (Hu-Friedy, Chicago, IL, USA)~Removal of supra and submucosal calculus with slim ultrasonic devices (Piezon PS instrument EMS; Nyon, Swiss).~Erythritol air powder-spray system (Air-flow ® master piezon, EMS, Nyon swiss) implant surface treatment. This will be performed by separating the soft tissue with the aim of a periodontal probe (CP 15, Hu-Friedy, Chicago, IL, USA).~Electrolytic cleaning of the implant surface following manufacturer's instructions (GalvoSurge Dental AG, Widnau, Switzerland), with the help of a non-metal periodontal probe to separate the soft tissues and aim the implant surface in all its length.~Antibiotic treatment (Metronidazole 500 mg, every day/ 7 day).~If necessary, modification and polishing of the prosthesis to make it cleanable."
89193262|NCT05273697|Active Comparator|Underwater cold snare polypectomy group|Cold snare polypectomy after complete immersion of the polyp in the water
89416580|NCT03256773||Cystic Fibrosis|cystic fibrosis Lung Disease
88894406|NCT01466829|Placebo Comparator|Control|Control patients treated with placebo.
88894407|NCT01466829|Active Comparator|Intervention|Daily injection with Parathyroid hormone
88894408|NCT01466842|Other|Catheter ablation|
88894409|NCT01466842|No Intervention|Antiarrhythmic drugs|Three months before starting antiarrhythmic drugs, a subcutaneous loop recorder will be implanted.
88894410|NCT01466855|Experimental|Treatment of Retinoblastoma|Study of Intra-Ophthalmic Artery Topotecan infusion for the Treatment of Retinoblastoma.
88894411|NCT01466868|Experimental|MK2206|Treatment is started the day after registration (day 1)until progression according to Cheson international response criteria or documented toxicity.
88894412|NCT01466894|Experimental|IMM 124-E high dose|IMM 124-E 3600 mg per day
88894413|NCT01466894|Experimental|IMM 124-E low dose|IMM 124-E 1800 mg per day
88894414|NCT01466894|Placebo Comparator|Placebo|Placebo tablets
88894415|NCT01466907|Active Comparator|Intervention group|Control of secondary prevention at three months and one year after stroke and referral to physician if medical interventions are needed. Assessment of functional status and self-reports on health outcome. Supportive counselling provided.
88894416|NCT01466907|Other|Control group|Standard care with no outlined follow-up until one year after stroke. Control of secondary prevention after one year after stroke and referral to physician if medical interventions are needed. Follow-up one year after stroke according to the same protocol as the intervention group.
88894417|NCT01466933|Experimental|Community-based|Community trained peer educator delivers parenting sessions to mothers in the village on a monthly basis
89416581|NCT03256773||PCD|Primary Ciliary Dyskinesia
89416582|NCT03256773||COPD|Chronic Obstructive Lung Disease
89416583|NCT03249350|Active Comparator|Standard Contingency Management (CM)|This group will receive standard CM for adolescent substance abuse.
89416584|NCT03249350|Experimental|Enhanced Contingency Management (CM+)|This group will receive an enhanced CM protocol for adolescent substance abuse that targets parenting more intensely.
89416585|NCT03211793|Experimental|MSC injections|Intramuscular injection of mesenchymal stromal cells (50 million allogeneic MSCs in 0.9% NaCl and 10% human serum albumin).
89416586|NCT03211793|Placebo Comparator|Placebo injections|Intramuscular injection of placebo (NaCl 0.9% + 10% human serum albumin)
89416587|NCT03181100|Experimental|Cohort I (vemurafenib, cobimetinib, atezolizumab)|Patients receive vemurafenib PO BID on days 1-21, cobimetinib PO QD on days 1-21, and atezolizumab IV over 30-60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression and unacceptable toxicity.
89416588|NCT03181100|Experimental|Cohort II (atezolizumab, cobimetinib)|Patients receive cobimetinib PO QD on days 1-21 and atezolizumab IV over 30-60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression and unacceptable toxicity.
89416589|NCT03181100|Experimental|Cohort III (atezolizumab, bevacizumab)|Patients receive atezolizumab IV over 30-60 minutes and bevacizumab IV over 60-90 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression and unacceptable toxicity.
89416590|NCT03181100|Experimental|Cohort IV (nab-paclitaxel, atezolizumab, paclitaxel,)|Patients receive nab-paclitaxel IV over 30 minutes on days 1, 8, and 15 and atezolizumab IV on day 1 over 30-60 minutes. Patients may receive paclitaxel IV over 30 minutes on day 1 as a substitute for nab-paclitaxel. Cycles repeat every 21 days in the absence of disease progression and unacceptable toxicity.
89416591|NCT03171818|Experimental|Darbepoetin|Darbepoetin alfa (Aranesp, Amgen)
89416592|NCT03171818|Placebo Comparator|Placebo|Saline
89416593|NCT03169361||Ixazomib 4 mg|The usual adult dosage for oral administration is 4 mg as ixazomib, in the fasting state, once a day, once a week for 3 weeks (Days 1, 8, and 15), with a 13-day washout period (Days 16 through 28). This 4-week cycle will be repeated for 6 cycles. The dose may be reduced appropriately according to the patient's condition. Participants will receive interventions as part of routine medical care.
89416594|NCT03149861|Experimental|No focal biopsy needed|Patients in which PET/MR have found no focal findings, will undergo a systemic biopsy as per standard of care, without specific cores for study purposes (Systemic TRUS guided biopsy)
89416595|NCT03149861|Experimental|Focal biopsy|Patients with a suspicious focal finding on PET/MR, will undergo systemic+focal or focal fusion biopsy (PET/MR-ultrasound guided Fusion biopsy)
89416596|NCT03108703|Experimental|SBRT|RCC patients
89006089|NCT04647292|Active Comparator|Target systolic blood pressure 130-139 mmHg|Target SBP 130-139 mmHg (per American Stroke Association, European Stroke Organisation guidelines).
89416597|NCT03101748|Experimental|Group A (Cohort 1 Phase Ib)|Patients receive neratinib PO QD on days 1-21, paclitaxel IV over 1-3 hours on days 1, 8, and 15, pertuzumab IV over 1 hour on day 1, and trastuzumab IV over 1-2 hours on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients without progression or excessive toxicity with metastatic disease may receive up to 4 additional courses and with locally advanced disease may receive up to 2 additional courses.
89416598|NCT03101748|Experimental|Group B (Cohort 1 Phase II)|Patients receive neratinib, paclitaxel, pertuzumab, and trastuzumab as in Group A. Patients then receive doxorubicin IV and cyclophosphamide IV over 90 minutes on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgery.
89416599|NCT03101748|Experimental|Group C (Cohort 2)|Patients receive neratinib PO QD on days 1-21, paclitaxel IV over 1-3 hours on days 1, 8, and 15. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery/ Patients then receive doxorubicin and cyclophosphamide as in Group B. Patients then undergo standard of care surgery.
89193263|NCT05273697|Active Comparator|Conventional cold snare polypectomy group|Cold snare polypectomy in colon lumen dilated with air
89199146|NCT05954884|Experimental|Intervention|This is a single-arm pilot study and all participants will receive the intervention. Participants will be diagnosed and treated for hypertension at Community Clinic (CC) by a Community Health Care Provider (CHCP) under telemedicine supervision from a Medical Officer at the Upazila Health Complex (UHC).
89416600|NCT03054129|Experimental|Rehabilitation and balance training|"Each patient will attend rehabilitation program for three days per week for six weeks. Patients will receive balance training in addition to supervised rehabilitation program which is including patient education, stretching and strengthening exercises.~Patients will also implement home exercise program. Balance training will be non-supervised program."
89416601|NCT03054129|Active Comparator|Rehabilitation program|"Each patient will attend rehabilitation program for three days per week for six weeks.~Patients will receive supervised rehabilitation program which is including patient education, stretching and strengthening exercises.~Patients will also implement home exercise program."
89416602|NCT03052114||Stroke|Electrical Impedance Tomography with scalp electrodes
89416603|NCT03052114||Head Injury|Electrical Impedance Tomography with scalp electrodes
89416604|NCT03031847|Other|Randomized- Pacemaker (CRT-P)|Cardiac resynchronization therapy Pacemaker
89416605|NCT03031847|Other|Randomized- Defibrillator (CRT-D)|Cardiac resynchronization therapy Defibrillator
89416606|NCT03031847|Other|Observational- Pacemaker (CRT-P)|Cardiac resynchronization therapy Pacemaker (CRT-P): Patients in this arm declined randomization in the trial and elected to participate in the observational registry
89416607|NCT03031847|Other|Observational- Defibrillator (CRT-D)|Cardiac resynchronization therapy Defibrillator (CRT-D): Patients in this arm declined randomization in the trial and elected to participate in the observational registry
88894418|NCT01466933|Active Comparator|Government-based|Government community health workers, trained, deliver the intervention to mothers in the village
88894419|NCT01466933|No Intervention|Control|Mothers receive the standard care which is a visit from the health worker
89416608|NCT02926404||Pediatric patients operated with Patient-specific rods|Patients with patient-specific rods (UNiD Rods) <18Years old
89416609|NCT02926404||Adult patients operated with Patient-specific rods|Patients with patient-specific rods (UNiD Rods) >18Years old
89416610|NCT02831764|Experimental|DTG + 3TC (50 mg+300 mg|Eligible participants will receive one 50 mg tablet of DTG plus one overencapsulated 300 mg 3TC tablet orally once daily upto 96 weeks; thereafter will receive DTG plus 3TC tablet upto Week 148 and will continue to receive this schedule until (i) DTG and 3TC are both locally approved for use as part of a dual regimen, and the single entities of DTG and 3TC are available to patients (e.g. through public health services), or (ii) the DTG/3TC FDC tablet, if required by local regulations, is available, , or (iii) the participant no longer derives clinical benefit, or (iv) the participant meets a protocol defined reason for discontinuation, or (v) development of the DTG plus 3TC dual regimen is terminated.
89416611|NCT02831764|Active Comparator|DTG + TDF/FTC FDC (50 mg+300/200 mg)|Eligible participants will receive one 50 mg tablet of DTG plus one overencapsulated TDF/ FTC FDC (300/200 mg) tablet orally once daily upto 96 weeks; thereafter will receive DTG plus TDF/FTC FDC tablets upto Week 148 (open-label randomised phase).
88894420|NCT01466946||semi-structured interviews|A qualitative study of MSKCC lung cancer patients of Hispanic/Latino descent by collecting retrospective patient narratives to understand the processes that led them to seek medical help when they did, their experiences in seeking and receiving medical guidance, as well as their decisions regarding lung cancer treatment. In addition, we will explore how these patients' representations of lung cancer with its associated risk factors and symptoms affected their treatment decisions.
88894421|NCT01466959|Active Comparator|AD- acetic acid dialysate|AD is a standard bicarbonate based dialysate with a small amount of acetic acid which is the standard of care for dialysis.
89199147|NCT05954858|Experimental|Surgical tissue autograft: TPF flap/pericranial flap|Use of a pedicled autologous piece of tissue called the temporoparietal fascial (TPF) flap or pericranial flap into the resection cavity of newly diagnosed glioblastoma multiforme (GBM) patients
88894422|NCT01466959|Experimental|CD - citrasate dialysate|Dialysis with a citric acid based dialyasate.
88894423|NCT01466998|Experimental|Paced Respiration|Participants will use a small, commercially-available guided-breathing device to practice breathing at a rate slower than 10 breaths per minute. Participants will be instructed to use their devices for at least 15 minutes per day for 12 weeks.
88894424|NCT01466998|Active Comparator|Music Therapy|Participant will use an identical appearing device, programmed to play quiet, relaxing non-rhythmic music while monitoring spontaneous breathing. Participants will be instructed to use their devices for at least 15 minutes per day for 12 weeks.
88894425|NCT01467011||Cases|de novo liver transplant recipients receiving Enteric-coated Mycophenolate Sodium
88894426|NCT01467024||EIA Negative|Blood donor specimens that tested non-reactive by previously licensed HTLV screening assay.
88894427|NCT01467024||EIA Repeat Reactive|Blood donor specimens that tested repeat reactive by previously licensed HTLV screening assay, but are unconfirmed.
88894428|NCT01467024||Known Positive|Blood donor specimens that tested repeat reactive with a licensed HTLV screening assay and have been confirmed through additional, unlicensed supplemental testing.
88894429|NCT01467050|Active Comparator|Application of STOPP/START criteria|
88894430|NCT01467050|No Intervention|Control|
89416612|NCT02772731|Experimental|Shave Margin|After partial mastectomy, patients will be subject to intraoperative randomization to the shave margin group where additional tissue will be resected.
89416613|NCT02772731|Active Comparator|No Shave Margin|After partial mastectomy, patients will be subject to intraoperative randomization to the no shave margin group, where after initial surgery, no further tissue will be removed.
89416614|NCT02754011|Experimental|combination of ribociclib + capecitabine|RIBOCICLIB from 200 to 600mg once daily + CAPECITABINE from 750 to 1000 mg/m² BID, cycles are defined in 21-day periods, 2 weeks on treatment, 1 week off treatment
89416615|NCT02734277||Group 1: Detectable C-peptide by MMTT|"Participants with detectable C-peptide at their:~Last Immune Tolerance Network (ITN) T1DM week 104 study visit,~Last AbATE (NCT00129259) follow-up visit, or~Last ITN066AI T1DES visit~Detectable C-peptide is defined as a value above the lower limit of detection."
89416616|NCT02734277||Group 2:Undetectable C-peptide by MMTT|"Participants without detectable C-peptide at their:~Last ITN T1DM week 104 study visit,~Last AbATE follow-up visit, or last~ITN066AI T1DES visit~Undetectable C-peptide is defined as a value below the lower limit of detection."
89416617|NCT02732860||Triple Negative Breast Cancer|"Triple negative breast cancer patients with residual invasive disease following neoadjuvant chemotherapy (n= up to 15) or with newly diagnosed metastatic disease (n=up to 30).~After the screening procedures confirms patient eligibility:~Molecular Profiling will be performed on clinical sample~pPDX generation for in vivo drug testing~In vitro organoid culture generation (if sufficient fresh tissue available)~Identifying an actionable genomic alteration and drug making a matched treatment therapy recommendation."
89416618|NCT02732860||Colorectal Cancer|"Colorectal cancer patients with metastatic disease undergoing resection of liver metastases, or with lesions amenable to biopsy (n=up to 15).~After the screening procedures confirms patient eligibility:~Molecular Profiling will be performed on clinical sample~pPDX generation for in vivo drug testing~In vitro organoid culture generation (if sufficient fresh tissue available)~Identifying an actionable genomic alteration and drug making a matched treatment therapy recommendation."
89416619|NCT02732860||High Grade Serous Ovarian Cancer|"High grade serous ovarian cancer patients with recurrent disease with a life expectancy of at least 12 months (n=up to 15), or Stage III or IV with residual disease following neoadjuvant chemotherapy, or at risk of high recurrence (n=up to 15).~After the screening procedures confirms patient eligibility:~Molecular Profiling will be performed on clinical sample~pPDX generation for in vivo drug testing~In vitro organoid culture generation (if sufficient fresh tissue available)~Identifying an actionable genomic alteration and drug making a matched treatment therapy recommendation."
89416620|NCT02732860||Other tumor types|"Other selected tumor types at the discretion of the PI (n= up to 30)~After the screening procedures confirms patient eligibility:~Molecular Profiling will be performed on clinical sample~pPDX generation for in vivo drug testing~In vitro organoid culture generation (if sufficient fresh tissue available)~Identifying an actionable genomic alteration and drug making a matched treatment therapy recommendation."
89416621|NCT02719847||EBUS-TBNA|"Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) performed after PET/CT, and before participant receives stereotactic body radiation therapy (SBRT). EBUS-TBNA results compared with the results of PET/CT.~A conventional flexible bronchoscopy performed to examine the tracheobronchial tree, followed by a systematic examination of the accessible intra-thoracic lymph nodes using a linear array ultrasound bronchoscope."
89416622|NCT02702310||Quality of Life/ Grading Skin Findings|Patients' baseline quality of life is established by completion of an initial questionnaire, and skin lesion burden is quantified by physical examination using a recommended system . Following the standard of care radiation therapy, patients' completion of questionnaire, and physical examination is repeated for continued assessment.
89416623|NCT02678962|Active Comparator|SN6AD1 group|Bilateral cataract surgery with implantation of SN6AD1 multifocal IOLs
88894431|NCT01467089||schizophrenia|"Inclusion Criteria: Inpatients and outpatients aged 18-75 years old who have been taking antipsychotics for longer than 6 months in their life time, and that have been compliant for the past week. Patients will be referred by their treating doctors if they have some evidence of movement disorder based on the physician's clinical judgment. We will also include 25% of the sample without any evidence of movement disorder.~Exclusion Criteria: Patients who have medical conditions which make it difficult to perform a physical examination. Patients who are clinically too ill to consent and/or unable to cooperate with the examination procedures."
88894432|NCT01467102||Patients|> 18 years of age
88894433|NCT01467115|Experimental|Treatment|Treatment with induction chemotherapy followed by radiation and cetuximab.
89193264|NCT05269992|Experimental|Real food products|The study products are 1) a 1kcal/ml enteral tube feed provided as a 500ml ready to use enteral tube feed; 2) a 1.5kcal/ml enteral tube feed provided as a 500ml ready to use enteral tube feed, and 3) a 1.5kcal/ml oral nutritional supplement provided in a 200ml ready to drink format. This study is a prospective, longitudinal, 28-day intervention study with a 1-day baseline period aiming to recruit 60 in paediatric patients. During the intervention period, patients will receive one of the three study products (or more if deemed appropriate) for 28 days as a sole source of nutrition or alongside any additional routine nutritional management as required. As such, randomisation was not deemed suitable for this study. The appropriate study product and volume prescribed will be recommended by the investigating dietitian/nurse and agreed with the patient/parent/carer based on their clinical and nutritional requirements.
89193265|NCT05265065|Active Comparator|AstraZeneca (ChAdOx1-S, or Vaxzevria®) - Standard Pfizer-BioNTech booster group|Previously received two doses of AstraZeneca as primary COVID-19 vaccine
89416624|NCT02678962|Active Comparator|SBL-3 group|Bilateral cataract surgery with implantation of SBL-3 multifocal IOLs
89416625|NCT02678962|Active Comparator|LS-313 MF30 group|Bilateral cataract surgery with implantation of LS-313 MF30 multifocal IOLs
89416626|NCT02678962|Active Comparator|AT LISA tri 839 MP group|Bilateral cataract surgery with implantation of AT LISA tri 839 MP multifocal IOLs
89416627|NCT02678962|Active Comparator|ART group|Bilateral cataract surgery with implantation of ART toric multifocal IOLs
89416628|NCT02678962|Active Comparator|LS-313 MF30T group|Bilateral cataract surgery with implantation of LS-313 MF30T toric multifocal IOLs
88894434|NCT01467128|Active Comparator|Structured expert pharmacist review|
88894435|NCT01467128|No Intervention|Normal pharmaceutical care in hospital|
88894436|NCT01467141|Experimental|IAsp|
89416629|NCT02653118||Cohort 1: V503 in the Base Study|Participants received the selected dose formulation of V503 (0.5 mL in a 3-dose regimen) from a Denmark, Norway, or Sweden site in the base study (V503-001, NCT00543543). No study vaccination will be administered in study V503-021.
88894437|NCT01467141|Active Comparator|HI|
88894438|NCT01467154||Control group|
88894439|NCT01467154||NAC group|
88894440|NCT01467167||Baseline|Baseline group in which patients are anesthetized without the use of Smart Pilot View, according to common practice.
88894441|NCT01467167||Smart Pilot View Group|Study group in which patients are anesthetized with the use of Smart Pilot View.
88894442|NCT01467180|Experimental|HCO CVVHD|treatment of rhabdomyolysis pts with septeX dialyzer
88894443|NCT01467180|Active Comparator|HF CVVH|treatment of rhabdomyolysis pts with standard high flux dialyzer
88894444|NCT01467193||1|Endurance trained athletes: minimal >50 mlO2/KG body weight
88894445|NCT01467193||2|Sedentary healthy control subjects: age, BMI, Gender and waist matched (to the growth hormone deficient patients)
88894446|NCT01467193||3|GHD patients without a GH substitution therapy in the last 6 months
88894447|NCT01467206|Experimental|Long term follow up program|
88894448|NCT01467206|Active Comparator|Standard care|
88894449|NCT01467219|Experimental|PET Probe|"Patients will receive an IV injection of approximately 5 MBq/kg body weight of 18F-FDG (Fludeoxyglucose) (up to 550 MBq). Following injection, patients will undergo CT and PET scans. Intraoperatively, a hand held gamma counter will be used to identify hot lymph nodes."
88894450|NCT01467232|Experimental|Autologous CD133+ Stem Cells|Autologous CD133+ stem cells
88894451|NCT01467232|Placebo Comparator|Saline solution containing autologous plasma|Saline solution containing autologous plasma without CD133+ (indistinguishable from the autologous CD133+ stem cells)
88894452|NCT01467258|Experimental|Amantadine|Single dose
89416630|NCT02653118||Cohort 2: GARDASIL in the Base Study|Participants received GARDASIL (0.5 mL in a 3-dose regimen) from a Denmark, Norway, or Sweden site in the base study (V503-001, NCT00543543) and were offered the selected dose formulation of V503 (0.5 mL in a 3-dose regimen) at the conclusion of the base study. V503 vaccination was voluntary and not a condition for inclusion in Cohort 2. No study vaccination will be administered in study V503-021.
89416631|NCT02530034|Experimental|Treatment (Hu8F4)|Patients receive anti-PR1/HLA-A2 monoclonal antibody Hu8F4 IV over 60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89416632|NCT02528175|Experimental|MRg-FU|Hyperthermia via magnetic resonance-guided focused ultrasound will be administered once per week for three weeks concurrent with standard radiation and chemotherapy.
89416633|NCT02396199|Experimental|Endovascular|Endovascular treatment using the Zenith® p-Branch® in combination with the Atrium iCAST™ covered stents
89416634|NCT02339532|Experimental|TOP2A amplified|"If TOP2A amplified: FEC x 3 then THP x 3 3 cycles of FEC 100 administered IV q3w~5-Fluorouracil (5-FU) 500 mg/m²~Epirubicin 100 mg/m²~Cyclophosphamide 500 mg/m²~Followed by 3 cycles of Trastuzumab-Pertuzumab-Docetaxel:~Trastuzumab 8 mg/kg loading dose administered intravenously (IV) followed by 6 mg/kg IV q3w in subsequent cycles.~Pertuzumab 840 mg loading dose administered IV followed by 420 mg IV q3w in subsequent cycles.~DOCETAXEL 75 mg/m² IV escalating at 100 mg/m² IV as tolerated q3w"
89416635|NCT02339532|Experimental|TOP2A not amplified|"If TOP2A not amplified: TCHP x 6 TCHP administered IV q3w for 6 cycles~Trastuzumab 8 mg/kg loading dose administered IV followed by 6 mg/kg IV q3w in subsequent cycles.~Pertuzumab 840 mg loading dose administered IV followed by 420 mg IV q3w in subsequent cycles.~DOCETAXEL 75 mg/m² IV q3w~CARBOPLATIN AUC 6 IV q3w~The Calvert formula will be used to calculate the dose of carboplatin:~Dose (mg) = target AUC (mg/mL x min) x [GFR mL/min + 25] Dose (mg) = 6 x [GFR mL/min + 25] NOTE: the Calvert formula gives the dose in mg, not mg/m². GFR, glomerular filtration rate The maximum dose of CARBOPLATIN must not exceed 900 mg."
89416636|NCT02284919|Experimental|ISO-1 PET/CT|All subjects will receive an [18F]ISO-1 PET/CT scan
89416637|NCT02278848|Experimental|Diagnosis of ICAH|"One arm: patients with chronic adult hydrocephalus.~All patients have: Computerised gait analysis, Ultrasound measurement of cerebral pulsatility, MRI flow, Urinary incontinence scale"
89416638|NCT02101944|Experimental|Treatment (dexamethasone, carfilzomib, Reolysin)|Patients receive dexamethasone intravenously (IV), carfilzomib IV over 30 minutes, and Reolysin IV over 60 minutes on days 1, 2, 8, 9, 15, and 16. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89193266|NCT05265065|Experimental|AstraZeneca (ChAdOx1-S, or Vaxzevria®) - Fractional Pfizer-BioNTech booster group|"Previously received two doses of AstraZeneca as primary COVID-19 vaccine~."
89193267|NCT05265065|Active Comparator|Sinopharm (BBIBP-CorV®)- Standard Pfizer-BioNTech booster group|Previously received two doses of Sinopharm as primary COVID-19 vaccine
89416639|NCT02061345||MCI|Prostate cancer patients having mild cognitive impairment (MCI) attributable to ADT with LHRHa
89416640|NCT02061345||Control|Prostate cancer patients on ADT with LHRHa not having mild cognitive impairment
89416641|NCT02034981|Experimental|CRIZOTINIB|All eligible patients entering the study will receive oral crizotinib as monotherapy
89416642|NCT02003222|Experimental|Arm I (blinatumomab, chemotherapy)|See Detailed Description
89416643|NCT02003222|Active Comparator|Arm II (chemotherapy)|See Detailed Description
89416644|NCT01736748|Experimental|Sensor based PA intervention|Children will be equipped with a heart rate monitor, a GPS receiver and an accelerometer for collection of heart rate, mobility and physical activity free-living data during a 7-day period. This will provide a 'spatio-behavioural diagnosis' using a map-based interactive web application. This data will be used to developed a tailored plan to promote physical activity in the child's every day environment.
89416645|NCT01736748|Other|Traditional PA counseling|In this arm, while children will wear the same sensors as in the intervention arm, the intervention will not rely on data gathered using the wearable sensors. Rather, a traditional physical activity counseling strategy will be adopted in this control group.
89416646|NCT01721343|Experimental|Arm I (enhanced usual care)|Patients undergo enhanced usual care comprising telephonic monitoring with monthly status reports provided to their oncology care teams for 6 months.
89416647|NCT01721343|Experimental|Arm II (enhanced usual care, RCM)|Patients undergo enhanced usual care as in Arm I and participate in an individualized conditioning program delivered telephonically by the Fitness Care Manager (FCM) and adapted, as required, by a local physical therapist for 6 months.
89416648|NCT01721343|Experimental|Arm III (enhanced usual, RCM, PCM)|Patients undergo enhanced usual care as in Arm I, participate in an individualized conditioning program coordinated by the FCM as in Arm II, and receive optimized pain management through a nurse Pain Care Manager (PCM) for 6 months.
89193268|NCT05265065|Experimental|Sinopharm (BBIBP-CorV®)- Fractional Pfizer-BioNTech booster group|Previously received two doses of Sinopharm as primary COVID-19 vaccine
89193269|NCT05265065|Active Comparator|Sputnik V (Gam-COVID-Vac®)- Standard Pfizer-BioNTech booster group|Previously received two doses of Sputnik as primary COVID-19 vaccine
89416649|NCT01661881|Experimental|RB/RC|"Patients received 3 cycles of outpatient RB (rituximab 375 mg/m2 day 1, bendamustine 90 mg/m2 days 1 and 2 of a 4-week cycle), followed by interim CT restaging. Patients with progressive disease (PD) went off study. Those with stable disease (SD) or better went on to receive three cycles of inpatient RC (rituximab 375 mg/m2 day 1, cytarabine 3 g/m2 every 12 h for 4 doses). The cytarabine was dose reduced to:~2 g/m2 for age >60 years old, creatinine 114.9-176.8 lmol/l (for patients ≤60 years old), and pre-existing neurotoxicity;~1.5 g/m2 for age >60 years old AND creatinine 114.9-176.8 lmol/l, or for age >60 years old AND pre-existing neurotoxicity;~1 g/m2 for age > 60 years old AND creatinine 114.9-176.8 lmol/l AND pre-existing neurotoxicity.~Stem cell mobilization and collection, ASCT and post-transplantation supportive care were performed per institutional standard and not as part of this study."
89416650|NCT01640652|Experimental|Low dose vaccine arm|To investigate safety, tolerability and immunogenicity of 25 µg of the serogroup B meningococcal protein vaccine MenPF-1 in healthy adults aged 18 to 50 years of age when given three doses of vaccine with 8 weeks interval.
89416651|NCT01640652|Experimental|High dose vaccine arm|To investigate safety, tolerability and immunogenicity of 50 µg of the serogroup B meningococcal protein vaccine MenPF-1 in healthy adults aged 18 to 50 years of age when given three doses of vaccine with 8 weeks interval.
89416652|NCT01638949|Experimental|Young controls|
89416653|NCT01638949|Experimental|Middle age controls|
88894453|NCT01467284|Experimental|Step Ahead|Promotion of weight gain prevention among teachers and staff in public high schools through Step Ahead, a comprehensive intervention targeting three levels suggested by the ecological framework health behavior change: organizational school level, interpersonal level, and individual level.
89416654|NCT01638949|Experimental|Elderly controls|
89416655|NCT01638949|Experimental|Asymptomatic subjects|Asymptomatic subjects from families carrying a genetic mutation with an autosomal dominant transmission
89416656|NCT01638949|Experimental|Subjectif Cognitive Impariment patients|
89416657|NCT01638949|Experimental|Mild Cognitive Impairment patients|
89416658|NCT01638949|Experimental|Alzheimer Disease patients|
89416659|NCT01638949|Experimental|Non degenerative amnsesic syndrome|
89416660|NCT01582269|Experimental|LY2157299 monohydrate plus lomustine|"300 mg/day LY2157299, given orally for 14 days, followed by 14 days of rest, equaling a 28-day cycle.~First lomustine dose will be given as 100 mg/m2 on day 7 cycle 1. Remaining doses are based on the investigator's discretion and will be given orally once every 6 weeks in capsules to equal 100 to 130 mg/m2."
89416661|NCT01582269|Experimental|LY2157299 monohydrate|300 mg/day LY2157299, given orally for 14 days, followed by 14 days of rest, equaling a 28-day cycle (unblinded)
89416662|NCT01582269|Active Comparator|lomustine plus placebo|"First lomustine dose will be given as 100 mg/m2 on day 7 cycle 1. Remaining doses are based on the investigator's discretion and will be given orally once every 6 weeks in capsules to equal 100 to 130 mg/m2.~LY2157299 monohydrate-matched placebo, given orally as tablets for 14 days, followed by 14 days of rest, equaling a 28-day cycle."
89416663|NCT01550003|Experimental|Certolizumab Pegol|Active treatment with Certolizumab Pegol; dose adjustment is based on weight.
88894454|NCT01467284|Active Comparator|Basic Intervention|Promotion of weight gain prevention among teachers and staff in public high schools through receipt of the workbook print materials and access to website similar to the enhanced intervention.
88894455|NCT01467297|Experimental|ceftidoren|ceftidoren 200 mg bid for 5 days
88894456|NCT01467297|Active Comparator|levofloxacin|levofloxacin 500 mg once daily for 7 days
88894457|NCT01467310|Experimental|GSK1120212|
88894458|NCT01467323|Experimental|A|
89193270|NCT05265065|Experimental|Sputnik V (Gam-COVID-Vac®)- Fractional Pfizer-BioNTech booster group|Previously received two doses of Sputnik as primary COVID-19 vaccine
89193271|NCT05264480|Experimental|Test group|Test patients receive bone augmentation and selective decorticalisation (corticotomy) and 1 week postop. OTM.
89193272|NCT05264480|Active Comparator|Control group|Control subjects receive bone augmentation without decorticalisation (corticotomy) and 1 week postop. OTM.
89416664|NCT01505400||Advanced cancer|Advanced breast, non-small cell lung, colorectal, genitourinary, pancreatobiliary gastrointestinal, upper aerodigestive tract, gynecological, melanoma, unknown primary, and rare carcinomas; as well as patients who are phase I trial candidates
89416665|NCT01474148|Experimental|Neuroprosthesis|Volunteers are evaluated for appropriateness for inclusion in the study on an intent-to-treat basis. Qualifying candidates all receive the implanted neuroprosthesis and participate in post-operative training and follow-up procedures.
88894459|NCT01467323|Active Comparator|B|
88894460|NCT01467336|Other|Passive group|Rehabilitation program is immediate. Active range of motion rehabilitation is started at the sixth week.
88894461|NCT01467336|Other|Immobilization group|No passive Rehabilitation program is started. An active protocol is started after the sixth week
88894462|NCT01467336|Other|Delayed group|Rehabilitation program is delayed to the third week. Active range of motion rehabilitation is started at the sixth week.
88894463|NCT01467349||Raltegravir group|"This study will include subjects who received raltegravir and were previously exposed to NRTIs, NNRTIs, PIs, regardless of the stage of HIV disease at the start of the treatment.~A control group will be used for the evaluation of the primary and secondary objectives in comparison to patients treated with raltegravir (study patients). The control group will be constituted by subjects who never received raltegravir, matched (in a ratio 1:3) with the study subjects by gender, age (± 3 years), CD4+ cells counts (± 50 cells) and HCV co-infection status yes/no). For control patients, the last antiretroviral regimen prescribed will be considered."
88894464|NCT01467362|Experimental|V0034CR01B|
88894465|NCT01467362|Placebo Comparator|Vehicle cream|
88894466|NCT01467375|Experimental|A|
88894467|NCT01467388||phacic|Study patients who still have their own ocular lens
88894468|NCT01467388||pseudophacic|Study patients who have an intraocular lens after cataract surgery
88894469|NCT01467401|Experimental|A|
88894470|NCT01467401|Active Comparator|B|
88894471|NCT01467414|Experimental|NN1250|
88894472|NCT01467440||PGA|Patients under glaucoma treatment with prostaglandines
88894473|NCT01467440||NON-PGA|Patient not recieving prostaglandines to treat their glaucoma
88894474|NCT01467518|Other|Period 1|Subjects will be on individualize stable dose of methdaone for 8 days.
89193273|NCT05261828|Experimental|A|Short multidisciplinary program including education and rehabilitation and a personalized follow-up program
89193274|NCT05261828|Active Comparator|B|Reassuring messages and advices in agreement with the current recommendations.
89193275|NCT05260333|Experimental|Transperineal ultrasound cervical exam followed by Digital (manual) cervical exam|Patients will undergo transperineal cervical exam via Butterfly iQ ultrasound. Patients will then undergo traditional digital cervical exam via examiner's fingers.
88894475|NCT01467518|Other|Period 2|Subjects will be on individualize stable dose of methadone and open label doses of 50mg Dolutegravir (DTG) every 12 hours for 5 days.
88894476|NCT01467531|Experimental|Cohort 1|Period 1 Treatment A = Dolutegravir 50mg q24h x 5 days; Period 2 Treatment B = Rilpivirine 25mg q24h x 11; Period 3 Dolutegravir 50mg q24h + Rilpivirine q24h x 5 days
88894477|NCT01467531|Experimental|Cohort 2|Period 1 Treatment A = GSK1265744 30mg q24h x 12 days; Period 2 Treatment B = Rilpivirine 25mg q24h x 12; Period 3 GSK1265744 30mg q24h + Rilpivirine q24h x 12 days
89193276|NCT05259813|Experimental|JWCAR029 Treatment|Dose-finding for JWCAR029 monotherapy
89416666|NCT01353313|Placebo Comparator|Placebo|Saline placebo
89416667|NCT01353313|Experimental|Hydrocortisone|hydrocortisone sodium succinate for intravenous administration (unpreserved, Solu-Cortef plain, Pfizer®, reconstituted with unpreserved normal saline to avoid exposure to the benzyl alcohol contained in preserved diluents)
89416668|NCT01245712|Experimental|Treatment (APBI)|Within 10 weeks of last breast cancer surgery, patients undergo APBI delivered with proton radiation BID for 5 days.
89416669|NCT01209871|Experimental|Treatment (vaccine therapy)|Patients receive autologous lymphoma immunoglobulin-derived scFV-chemokine DNA vaccine ID at 0, 4, and 8 weeks.
89193277|NCT05255159|Experimental|18F-DOPA PET/CT scan|4 MBq/kg (minimum 100 MBq, maximum 600 MBq) 18F-DOPA injected intravenously with 40 mg furosemide and subsequent whole body PET/CT scan
89535892|NCT04991727||PEEP|The patient was admitted to the operating room, and routine ECG monitoring was performed. The patient was placed in supine position, and ultrasound lung examination was performed. The images of the patient were saved and the score of lung ventilation area was recorded. The induction of general anesthesia was started, and endotracheal intubation was performed after 3min of preoxygenation (100% O2) to establish a safe and effective artificial airway.Mechanical ventilation was performed after endotracheal intubation, and a second time was performed immediately after endotracheal intubation was completed.Pulmonary ultrasound was performed. The PEEPgroup was given the first RM (pulmonary retraction) with pressure maintained at 40cmH2O for 30s, followed by a 7cmH2O PEEP to maintain mechanical ventilation, and the RMS was repeated every 30 minutes until the end of surgery
88894478|NCT01467544|No Intervention|wait list control group|After completing time three data collection, wait-listed participants will be provided with the complete tai chi intervention (8 weeks).
88894479|NCT01467544|Experimental|Tai Chi intervention group|This participant group completes the 8-week tai chi group intervention.
88894480|NCT01467596|Experimental|Elderly population|MEAV50, MEAV95 Onset and duration of sensory and motor blockade
88894481|NCT01467596|Active Comparator|Middle aged population|MEAV50, MEAV95 Onset and duration of sensory and motor blockade
88894482|NCT01467622||Study population|Patients undergoing elective pulmonary wedge resection, anatomic segmentectomy, or lobectomy.
88894483|NCT01467635|Active Comparator|EBUS-TBNA|Sampling using endobronchial ultrasound guided transbronchial needle aspiration
88894484|NCT01467635|Experimental|EBUS-TBNB|Sampling using endobronchial ultrasound guided transbronchial forceps biopsy needle.
88894485|NCT01467648|Experimental|0.5 g by 4 hour infusion|"Blood samples (approximately 2 ml) in group  0.5 g of doripenem with 4 h infusion every 8 h regimen will be obtained by direct venepuncture at the following time: 0, 0.5, 1, 2, 3, 4, 4.5, 5, 6, 7 and 8 h after 7th dose of doripenem."
88894486|NCT01467648|Experimental|0.5 g by 1 hour infusion|"Blood samples (approximately 2 ml) in group  0.5 g of doripenem with 1 h infusion every 8 h regimen will be obtained by direct venepuncture at the following time: 1, 1.5, 2, 4, 5, 6, 7 and 8 h after 7th dose of doripenem."
88894487|NCT01467674||Healthy|
88894488|NCT01467674||Chronic Periodontitis|
88894489|NCT01467674||Better Controlled T2DM|
88894490|NCT01467674||Poor Controlled T2DM|
88894491|NCT01467687|Active Comparator|1|300 mg capsule of Verelan PM or 300 mg verapamil controlled release capsule given orally with food as a single dose with blood collected at 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 24, 30, 36, 48, 60 and 72 hours.
88894492|NCT01467687|Active Comparator|2|300 mg capsule of Verelan PM or 300 mg verapamil controlled release capsule given orally with food as a single dose with blood collected at 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 24, 30, 36, 48, 60 and 72 hours.
88894493|NCT01467726|Experimental|Dose regimen 1|Varied doses
89193278|NCT05253560||Carriers of Gaucher disease|Family of patients with Gaucher disease, sequenced for the GBA1 gene.
89193279|NCT05253560||Gaucher patients|Patients from the Gaucher clinic in Shaare Zedek Medical Center, Jerusalem, Israel
89416670|NCT01083862|Experimental|Educational Intervention - Video & Text|"Educational Intervention - Video & Text describing Living with Coronary Artery Disease."
89416671|NCT01083862|Active Comparator|Educational Intervention - Text Only|"Educational Intervention - Text Only describing Living with Coronary Artery Disease."
89416672|NCT00959452|Experimental|Psychotherapy|
89416673|NCT00682695||1|"Participants who have had a hemorrhagic stroke at University of Maryland, University of Cincinnati, Massachusetts General Hospital, Duke University, Columbia University and University of Chicago Illinois, age 18 years or greater. Ability of the patient or legal representative to provide informed consent. Racial/ethnic category meets one of the following: African American, Caucasian or Hispanic.~Healthy volunteers who are matched to the study cases with hemorrhagic stroke within +/- 5 years of age, same gender and same race."
89416674|NCT00580515|Experimental|1|6 sessions of Family Focused Group Therapy
89416675|NCT00580515|Experimental|2|10 Sessions of Family Focused Group Therapy
89416676|NCT00580515|Active Comparator|3|Standard Care- Social work consultations are routinely provided to the cancer patients, but relatives are only seen during admissions or upon request
89416677|NCT03487172|Other|Right Side Treated|Subjects will be randomized to have their right side treated with PLLA and their left side treated with normal saline.
88894494|NCT01467726|Experimental|Dose regimen 2|Varied doses
88894495|NCT01467726|Experimental|Placebo|Matching placebo
88894496|NCT01467739|Active Comparator|Ambu ® aScope®|
88894497|NCT01467739|Active Comparator|a conventional reusable fiberscope.|
88894498|NCT01467752|Experimental|MCP joint|reconstruction of metacarpophalangeal (MCP) joint
88894499|NCT01467765|Active Comparator|Elemental diet|
88894500|NCT01467765|Placebo Comparator|Liquid nutrient|
88894501|NCT01467778|Active Comparator|ELAPR001|Tropoelastin 0.1ml SC implant
88894502|NCT01467778|Active Comparator|ELAPR002|Tropoelastin 0.1ml SC implant
88894503|NCT01467778|Active Comparator|ELAPR003|Tropoelastin 0.1ml SC implant
88894504|NCT01467778|Placebo Comparator|Saline|Normal Saline 0.9%
88894505|NCT01467791||Patients|All patients with sarcoidosis associated pulmonary hypertension
88894506|NCT01467804|Experimental|Chinese medicine|There are 90 patients with mild to moderate depress in JWXY group, who take the JWXY capsule, and placebo of Sertraline, for 2 months
88894507|NCT01467804|Active Comparator|westen medicine|There are 90 patients with mild to moderate depress in westen medicine group, who take Sertraline, and placebo of the JWXY capsule, for 2 months
88894508|NCT01467817|Experimental|Lifestyle Intervention|This arm will test the combination of 6 months of structured lifestyle intervention incorporating education, exercise, diet, and behavioral support.
89193280|NCT05253560||Healthy controls|Family members of Gaucher patients who are not carriers of Gaucher disease
89193281|NCT05253534|Experimental|Gamma Rhythm Stimulation Group|"Evaluation of the efficacy and safety of GlaucoT in patients with primary open-angle glaucoma (POAG).~In this study, it was planned to investigate the effect of reducing the progression of glaucomatous damage by applying 40 Hz flicker light therapy for 1 hour a day to POAG patients. It is planned to use visual field test, measurements of retinal nerve fiber layer (RNFL) and ganglion cell complex (GCC) layer thicknesses in optical coherence tomography to investigate the effectiveness of the treatment."
89416678|NCT03487172|Other|Left Side Treated|Subjects will be randomized to have their left side treated with PLLA and their right side treated with normal saline.
89416679|NCT02167776|Experimental|Church-based teaching|Teaching about male circumcision provided to church leaders in addition to standard teaching available from Ministry of Health.
89416680|NCT02167776|No Intervention|No church-based teaching|Standard of care. Teaching about male circumcision provided by Ministry of Health.
89416681|NCT04460378|Experimental|Cognitive Behavioral Therapy|Manualized Cognitive Behavioral Therapy starting at the patients' home.
89193282|NCT05253534|No Intervention|Control Group|"This group will be monitored without using the device.The data will be used only for comparison.~Considering the sample size calculations and losses, a total of 60 patients are planned to be included in the study, with 30 patients in each group."
89193283|NCT05241730|Experimental|Low GI|The subjects eat 55-60 E-% carbohydrates with ≥ 65 % from low glycaemic index carbohydrates per day, the other E-% are fats and proteins.
89193284|NCT05241730|Active Comparator|High GI|The subjects eat 55-60 E-% carbohydrates with ≥ 65 % from high glycaemic index carbohydrates per day, the other E-% are fats and proteins.
89416682|NCT03069508|Experimental|200 mg TID|200 mg clemizole hydrochloride will be administered orally thrice a day for 24 weeks.
89416683|NCT03069508|Experimental|300 mg TID|300 mg clemizole hydrochloride will be administered orally thrice a day for 24 weeks.
89416684|NCT03069508|Experimental|400 mg TID|400 mg clemizole hydrochloride will be administered orally thrice a day for 24 weeks.
88894509|NCT01467817|Placebo Comparator|Exercise Control|This arm will test the benefits of exercise alone while controlling for investigator contact.
88894510|NCT01467830|Experimental|absorbable sutures|patients attributed to that arm, undergoing surgery of Open Inguinal Hernia Repair With Mesh Fixation using absorbable sutures.
88894511|NCT01467830|Other|non absorbable sutures|patients attributed to that arm, undergoing surgery of Open Inguinal Hernia Repair With Mesh Fixation using non absorbable sutures,this is the method being considered the standard of care thus far.
88894512|NCT01467843|Active Comparator|Cognitive Behavioral Therapy|Participants randomized to the CBT intervention will attend eight weekly 2 hour sessions.
88894513|NCT01467843|Active Comparator|Mindfulness-Based Stress Reduction|Participants randomized to the MBSR arm will attend eight weekly 2 hour MBSR sessions.
88894514|NCT01467843|No Intervention|Usual Care|Participants randomized to Usual Care will continue to receive care for their low back pain as prescribed by his/her Primary Care Physician.
88894515|NCT01467856||chronic tetraplegia|
88894516|NCT01467908|Experimental|Vegetative state|Patients with the diagnosis of the vegetative state
88894517|NCT01467921|Active Comparator|LV5FU2|leucovorin 200 mg/m2 and 5-fluorouracil 400 mg/m2 intravenously on day 1, followed by a 46-h protracted infusion of 5-fluorouracil 2,400 mg/m2
88894518|NCT01467921|Experimental|FOLFOX|leucovorin 200 mg/m2 and 5-fluorouracil 400 mg/m2 intravenously on day 1, followed by a 46-h protracted infusion of 5-fluorouracil 2,400 mg/m2 oxaliplatin 85 mg/m2 will be given intravenously on day 1 for over 2 h
88894519|NCT01467986|Active Comparator|Irinotecan, Temozolomide|Patients randomized to the control arm receive irinotecan (I) and temozolomide (T) alone.
88894520|NCT01467986|Experimental|Rapamycin, Dasatinib, Temozolomide, Irinotecan|Patients with rNB receive on the study arm the experimental combination of rapamycin (R)- mTOR Inhibitor, dasatinib (D)- protein kinase inhibitor irinotecan (I)- cytostatic topoisomerase-I-inhibitor and temozolomide (T)- Antineoplastic agent
89416685|NCT03069508|Experimental|500 mg TID|500 mg clemizole hydrochloride will be administered orally thrice a day for 24 weeks.
89416686|NCT03481478||Patients with greater tuberosity fractures|If humeral surgical neck fractures can be detected through CT or MRI in such groups.
89416687|NCT03481478||Dislocation patients with greater tuberosity fractures|If humeral surgical neck fractures can be detected through CT or MRI in such groups.
89416688|NCT04995016|Experimental|Locally Advanced Non-metastatic Clear Cell Renal Cell Carcinoma|Neoadjuvant pembrolizumab plus axitinib
88894521|NCT01468025|Active Comparator|Theramine and naproxen|Patients in this group were randomly given active Theramine and active naproxen.
88894522|NCT01468025|Active Comparator|Theramine and placebo|Patients in this group were randomly given active Theramine with placebo representing naproxen.
88894523|NCT01468025|Active Comparator|Naproxen and placebo|Patients in this group were randomly given active naproxen and placebo to represent Theramine.
88894524|NCT01468038|Active Comparator|Active trazodone and placebo|trazodone 50mg with Sentra PM-like placebo
88894525|NCT01468038|Active Comparator|placebo and active Sentra PM|Trazodone-like placebo and Sentra PM
89416689|NCT03485066|Experimental|Training|20 healthy participants, 4 week training of a challenging cognitive task (Tetris) between PET/MR measurements
89416690|NCT03485066|No Intervention|Control|20 healthy participants, no training between PET/MR measurements
88894526|NCT01468038|Active Comparator|Sentra PM and trazodone|Active Sentra PM and active trazodone
88894527|NCT01468038|Placebo Comparator|placebo trazodone and placebo Sentra PM|trazadone-like placebo and Sentra PM-like placebo
88894528|NCT01468051|Experimental|40 μg (2 ml) four doses of Euvax B vaccine|40 μg (2 ml) four doses of Euvax B vaccine (recombinant hepatitis B surface antigen adsorbed on aluminium hydroxide adjuvant- LG Chem, Korea)
88894529|NCT01468051|Experimental|20 μg (1 ml) three doses of Euvax B vaccine|20 μg (1 ml) three doses of Euvax B vaccine (recombinant hepatitis B surface antigen adsorbed on aluminium hydroxide adjuvant- LG Chem, Korea)
88894530|NCT01468064|Experimental|BMSCs group|
89193285|NCT05241730|Experimental|Low Carb High Fat|The subjects eat ≥ 65 E-% fats and a maximum of 50 g carbohydrates per day.
89416691|NCT02764320|Active Comparator|Discontinuation|Migraine prophylactic therapy will be initiated or optimized with the immediate discontinuation of the overused medication(s)
89416692|NCT02764320|Active Comparator|Preventive Therapy Only|Migraine prophylactic therapy will be initiated or optimized without the early discontinuation of the overused medication(s)
89416693|NCT04994860|Experimental|BIA 5-1058|Treatment Period 1: Subjects were admitted to the clinical unit on Day 1. Subjects received a single oral dose of BIA 5 1058 400 mg (4 x 100 mg tablets) on Day 1 after an overnight fast of at least 8 hours and remained fasted for at least 4 hours post-dose. Subjects were discharged from the clinical unit on Day 4 (approximately 72 hours after dosing) barring any medical reasons for an extended clinical stay.
89416694|NCT04994860|Active Comparator|Sildenafil|Treatment Period 2: Subjects were admitted to the clinical unit on Day 1. Subjects received multiple three times a day (t.i.d.) oral doses of sildenafil (Revatio® 1 x 20 mg film coated tablet) approximately 2 hours before or after each meal (breakfast, lunch and dinner) from Days 1 to 5. On Day 6 after an overnight fast of at least 8 hours, subjects received a single morning dose of sildenafil (Revatio® 1 x 20 mg film coated tablet) and remained fasted for at least 2 hours post-dose. Subjects were discharged from the clinical unit on Day 9 (approximately 72 hours after last dosing) barring any medical reasons for an extended clinical stay.
89416695|NCT04994860|Experimental|BIA 5-1058 and Sildenafil|Treatment Period 3: Subjects were admitted to the clinical unit on Day 1. Subjects received multiple t.i.d. oral doses of sildenafil (Revatio® 1 x 20 mg film coated tablet) approximately 2 hours before or after each meal (breakfast, lunch and dinner) from Days 1 to 5. On Day 6 after an overnight fast of at least 8 hours, subjects received a single concomitant dose of BIA 5-1058 400 mg (4 x 100 mg tablets) and sildenafil (Revatio® 1 x 20 mg film coated tablet) and remained fasted for at least 4 hours post-dose. Subjects were discharged from the clinical unit on Day 9 (approximately 72 hours after last dosing) barring any medical reasons for an extended clinical stay.
89416696|NCT03481400|Experimental|Calcitonin gene-related peptide|Calcitonin gene-related peptide infusion (1.5 micrograms/min for 20 mins)
89416697|NCT03481400|Experimental|Placebo|Infusion with placebo (isotonic saline)
89416698|NCT02851407|Experimental|Defibrotide|Defibrotide is administered intravenously at a dose of 25 mg/kg/day in addition to best supportive care on the day before the first day of the conditioning regimen and will continue (for those patients without a VOD diagnosis) for a recommended minimum of 21 days and end no later than Day +30 post HSCT
89416699|NCT02851407|Other|Best Supportive Care|Best supportive care alone (without the addition of defibrotide) according to institutional guidelines and patient need, is administered on the first day of conditioning and will continue until Day +30 post HSCT or hospital discharge, whichever is sooner, or diagnosis of VOD, if applicable
89416700|NCT03481322|Active Comparator|Cooked diet with controlled amount of salt|Patients will receive intervention diet (cooked with controlled amount of salt)
89416701|NCT03481322|Placebo Comparator|Cooked without salt|Patients will receive the standard diet (cooked without salt and 2 grams of salt separated will be added by the patient)
89416702|NCT02167854|Experimental|LJM716, BYL719 AND TRASTUZUMAB|A treatment cycle will consist of 28 days. Treatment doses for trastuzumab and LJM716 will be fixed at trastuzumab 2mg/kg weekly, and LJM716 20mg/kg weekly. The exception to this is if dose de-escalation results in treatment of patients at dose level 1, where LJM will be dosed at 10mg/kg weekly. On Arm A, BYL719 was administered orally once daily continuously at one of 5 dosing levels, beginning with dose level 3, 250mg orally daily. On Arm B, BYL719 will be administered orally once daily during 4 of 7 days in a week, at one of 5 dosing levels, beginning with dose level 3, 250mg orally daily. This means BYL719 will be given to patients on Arm B during days 1-4, 8-11, 15-18, and 22-25 of each cycle. The dose-finding phase will follow a Continuous Reassessment Methods (CRM) phase I biostatistical design.
89416703|NCT03541122||Experimental group|Patients will undergo pelvic X-ray examinations. Measurement indicators will include OFI, MUI, TBOI, CE angle, Sharp angle and AHI of the affected and healthy femoral heads. The investigators will determine the sensitivity and specificity of OFI, MUI and TBOI for the diagnosis of adult acetabular dysplasia, and compare the accuracy of diagnosis between these three indicators and CE angle, sharp angle, and AHI. Further analysis of risk factors for hip function will be implemented.
88894531|NCT01468064|Experimental|EPCs group|
88894532|NCT01468064|Placebo Comparator|Control group|
88894533|NCT01468090||Disease course|562 patients diagnosed with Crohn's disease (209), ulcerative colitis (326) or indeterminant colitis (27) in the period of 1st of January 2003 to 31st of December 2004 in Copenhagen City and County (an area covering 23% of the Danish population).
88894534|NCT01468103|Experimental|PACS|primary angle closure suspects
88894535|NCT01468103|Experimental|PAC|primary angle closure
88894536|NCT01468116||RYGB patients with type 2 diabetes|Morbidly obese patients with type 2 diabetes undergoing gastric bypass surgery
88894537|NCT01468116||RYGB patients without type 2 diabetes|Morbidly obese patients with normal glucose tolerance undergoing gastric bypass surgery
89193286|NCT05239403||Observational (questionnaire, biospecimen collection)|Participants complete questionnaires over 10-15 minutes up to 4 weeks prior to day of vaccination and undergo collection of blood samples up to 4 weeks before or on the day of vaccination and within 3 weeks post vaccination. Patients may also undergo collection of stool samples up to 4 weeks prior to day of vaccination.
89193287|NCT05236374|Experimental|Beef Protein|A beef stew, providing 8.8 mg zinc, 37.9 mg protein (approximately 500 kcal/d energy);
89193288|NCT05236374|Active Comparator|Animal Protein|A control plant protein stew, providing 8.8 mg zinc, 37.9 mg protein (approximately 500 kcal/d energy);
89193289|NCT05235633||Comparison cohort|Children and adolescents at the end of acute treatment for leukemia and non-Hodgkin lymphoma without any exercise intervention
88894538|NCT01468116||Cholecystectomy patients without type 2 diabetes|Patients with normal glucose tolerance undergoing laparoscopically cholecystectomy
88894539|NCT01468129|Active Comparator|Cell Saver|
88894540|NCT01468129|No Intervention|Non Cell Saver|
88894541|NCT01468155|Active Comparator|Dabigatran|Dabigatran will be compared to historical data using other OAC methods for Pulmonary Vein Ablation
88894542|NCT01468168|Experimental|DE-101 Ophthalmic Suspension High Dose|
88894543|NCT01468168|Experimental|DE-101 Ophthalmic Suspension Low Dose|
88894544|NCT01468168|Placebo Comparator|DE-101 Ophthalmic Suspension Vehicle|
89193290|NCT05234983|Experimental|LifeFirst SWASTH brief advice intervention|"Described in the Intervention Description section"
89193291|NCT05234983|No Intervention|Control: Educational pamphlets|In lieu of the intervention, participants will receive a high-quality evidence-based pamphlet tobacco cessation pamphlet created by the NSF team for low-SES audiences in Mumbai. After all data has been collected, community healthcare settings in the control arm will have the opportunity to receive the intervention.
89193292|NCT05233085|Experimental|Cohort 1: AZD4041 Dose Level 1|Participants will receive oral solution of AZD4041 dose level 1 once daily (QD) directly into the mouth using a syringe from Days 1 to 14.
89193293|NCT05233085|Experimental|Cohort 2: AZD4041 Dose Level 2|Participants will receive oral solution of AZD4041 dose level 2 QD directly into the mouth using a syringe from Days 1 to 14.
89416704|NCT02636608||Paritaprevir/Ritonavir + Ombitasvir ± Dasabuvir ± Ribavirin|"Participants in this observational study received treatment with paritaprevir/ritonavir (r) and ombitasvir with or without dasabuvir ± ribavirin (RBV) for 12 or 24 weeks for the treatment of chronic hepatitis C (CHC), according to hepatitis C virus (HCV) genotype/subtype and stage of liver disease.~The prescription of treatment regimen was at the discretion of the physician in accordance with local clinical practice and label, was made independently from this observational study and preceded the decision to offer the patient the opportunity to participate in this study."
89416705|NCT03071146||Bard® LifeStent® 5F Vascular Stent System|Patients with lesion(s) in the infra-inguinal segment (SFA and/or popliteal artery) will be treated with percutaneous transluminal angioplasty (PTA) and the Bard® LifeStent® 5F Vascular Stent System.
89193294|NCT05233085|Experimental|Cohort 3: AZD4041 Dose Level 3|Participants will receive oral solution of AZD4041 dose level 3 QD directly into the mouth using a syringe from Days 1 to 14.
89416706|NCT02759562|Experimental|Andecaliximab 600 mg (Part 1)|Andecaliximab 600 mg weekly for 8 weeks
89416707|NCT02759562|Placebo Comparator|Placebo (Part 1)|Placebo weekly for 8 weeks
89416708|NCT02759562|Experimental|Andecaliximab 300 mg (Part 2)|Andecaliximab 300 mg weekly for 8 weeks
89193295|NCT05233085|Placebo Comparator|Cohorts 1-3: Pooled Placebo|Participants will receive oral solution of placebo equivalent to AZD4041 volume QD directly into the mouth using a syringe from Days 1 to 14.
89416709|NCT02759562|Experimental|Andecaliximab 150 mg (Part 2)|Andecaliximab 150 mg + placebo weekly for 8 weeks
89416710|NCT02759562|Placebo Comparator|Placebo (Part 2)|Placebo weekly for 8 weeks
89416711|NCT02759562|Experimental|Open-Label Extension|(Part 1) Andecaliximab 600 mg weekly for 16 weeks; (Part 2) Andecaliximab 300 mg weekly for 16 weeks
89416712|NCT03074188||pre-dialysis patients|
89193296|NCT05230550||Participants with AGHD (only severe case)|Participants will be treated with commercially available Sogroya® according to routine clinical practice at the discretion of the treating physician. The decision to treat a patient with Sogroya® has been made at the treating physician's discretion and independently from the decision to include the patient in this study.
89199148|NCT05954806||Patients With Hypnale Hypnale Bite receiving Antivenom|Patients With Hypnale Hypnale Bite receiving Antivenom for local or systemic signs of envenomation
89416713|NCT03074188||end stage renal disease|
89416714|NCT03604809|Experimental|OT Guided Cognitive Interventions|Occupational Therapy interventions will be adjusted according to the patient's Richmond Agitation and Sedation Scale (RASS).
89416715|NCT03604809|No Intervention|Usual Care|This will be the standard of care currently provided for delirium prevention within the Department of Critical Care Medicine in Calgary using the ABCDEF bundled approach.
89416716|NCT02167932||Breast Cancer Patients|Breast Cancer patients undergoing chemotherapy will participate in the Walk with Ease program during their treatment.
89199149|NCT05954806||Patients With Hypnale Hypnale Bite not receiving Antivenom|Patients With Hypnale Hypnale Bite not receiving Antivenom for local or systemic signs of envenomation
89416717|NCT04984954|Experimental|Experimental group|This is a multicenter, randomized, double-blind, placebo-controlled clinical trial. Patients were treated with the trial drug or placebo in a 1:1 ratio. The experimental group was treated with MUSK pill (4 pills / day, 3 times / day) on the basis of conventional treatment until the end of follow-up
88894545|NCT01468194|Experimental|Breathing procedure 1|"Walking with breathing procedure 1."
88894546|NCT01468194|Experimental|Breathing procedure 2|"Walking with breathing procedure 2."
89416718|NCT04984954|Placebo Comparator|Placebo group|The control group was given placebo 4 capsules / day, 3 times / day, until the end of follow-up.
89416719|NCT02938377|Active Comparator|No dx of alcohol use disorder, panic or depre|Computerized Brief Intervention (CBI)- a video about alcohol abuse
89416720|NCT02938377|Active Comparator|Risky drinking, no dx of AUD, has panic or depression|Computerized Brief Intervention (CBI)- a video about alcohol abuse, plus 4 sessions of counseling called Motivational Enhancement Therapy
88894547|NCT01468194|No Intervention|Control group|Walking without any reglementation of breathing
88894548|NCT01468220|Placebo Comparator|normoxic training|6 weeks of endurance training under normoxia
88894549|NCT01468220|Active Comparator|hypoxic training|6 weeks of endurance training under hypoxia
88894550|NCT01468259|Experimental|Normal renal function|16 subjects with normal renal function (eGFR greater than 90 mL/min/1.73m²)
89416721|NCT02938377|Active Comparator|Dx of AUD with or without panic or depression|Computerized Brief Intervention (CBI)- a video about alcohol abuse, plus 4 sessions of counseling called Motivational Enhancement Therapy plus a recommendation for Alcohol Pharmacotherapy (APT). The drugs recommended in the APT are all standard of care drugs for alcohol treatment and are not under study in this protocol.
89416722|NCT02161614|Placebo Comparator|Placebo|Patients will use placebo for 30 days
89416723|NCT02161614|Experimental|Estradiol Valerate|patients will use estradiol valerate 1mg/day during 30 days
89416724|NCT04994626|Experimental|Ibrutinib Combined With Rituximab|"Induction therapy: Ibrutinib 560mg administered oral once a day of each 21-day cycle for 6 cycles. Rituximab 375mg/m² administered intravenously (IV) on Day 1 of each 21-day cycle for 6 cycles.~Maintenance therapy: Ibrutinib 560mg administered oral once a day of each 56-day cycle for 6 cycles. Rituximab 375mg/m² administered intravenously (IV) on Day 1 of each 56-day cycle for 6 cycles."
89416725|NCT03604731||Uncomplicated cardiac surgery patients|Patients after schedulled cardiac surgery procedures
89416726|NCT03604731||Complicated cardiac surgery patients|Patients after schedulled cardiac surgery procedures complicated by multiorgan failure
89416727|NCT02168010|Experimental|Experiment|Test Drug Group: 2 times a day; 4 tablets per time (2 tablets of Analgecine and 2 tab. of placebo)
89416728|NCT02168010|Active Comparator|PosCtrl|PosCtrl: Positive Control Group. 2 times a day; 4 tablets / time (2 tab. of Neurotropin and 2 placebo tablets).
89416729|NCT02168010|Placebo Comparator|Placebo|Placebo Group: 2 times a day; 4 tablets / time (4 placebo tablets).
89416730|NCT04994314|Active Comparator|orthodontic primer containing calcium fluoride nanoparticles|Fixed appliance for ten maxillary teeth and the contralateral mandibular teeth will be bonded using orthodontic primer containing calcium fluoride nanoparticles
89416731|NCT04994314|Placebo Comparator|Control primer|Fixed appliance for ten maxillary teeth (contralateral to experimental ten side)and the contralateral mandibular teeth will be bonded using conventional primer (TransbondTM XT orthodontic primers (3M-Unitek, Monrovia, USA)
89416732|NCT02161692|Experimental|High dose chemotherapy|"Characterized by the following sequence:~High dose cyclophosphamide (7 grams/squared meter) x 1 cycle 2 cycles of high-dose etoposide and cisplatin~1 cycle of high dose carboplatin (Area Under the Curve 27) with stem cell rescue"
89416733|NCT02161692|Active Comparator|Conventional dose chemotherapy|Cisplatin, Etoposide, and Bleomycin (PEB) x 4 cycles
89416734|NCT03070756|Other|treatment group (auto-CPAP)|"Participants of this study undergo an diagnostic PSG night. The diagnostic night is followed by an auto-CPAP treatment night.~Interventions:~The treatment night is in line with the routine procedure of the laboratory except the following intervention: the device settings for the treatment night are applied according to the study protocol (minimal intervention)."
89416735|NCT02746575|Experimental|treatment|Postsurgical: 5mg metoprolol, IV, prior to extubation, every 5 minutes to achieve target heart rate of 65/min, up to 15mg; then 25mg metoprolol, oral, every 8 hours for 72 hours.
89416736|NCT02161770|Other|Normal hepatic function|Patients without a history or presence of hepatic disease
89416737|NCT02161770|Other|Mild hepatic impairment|Patients defined by the Child-Pugh classification system to be Child-Pugh A
89416738|NCT02161770|Other|Moderate hepatic impairment|Patients defined by the Child-Pugh classification system to be Child-Pugh B
89416739|NCT03604575|Experimental|Insulin Lispro|Single subcutaneous administration of Insulin Lispro in dose 0.3 IU / kg
89416740|NCT03604575|Active Comparator|Humalog®|Single subcutaneous administration of Humalog® in dose 0.3 IU / kg
89416741|NCT04988932|Experimental|Administration of iNO in SAH patients with severe vasospasm|iNO is started at a dose of 1 parts per million (ppm) and increased stepwise to 2 ppm, 5 ppm, 12 ppm, 25 ppm, until a maximum dose of 40 ppm is reached.
89416742|NCT03602313|Active Comparator|Traditional Gait Training|The Traditional Gait Training group will receive gait training as presently performed without additional modalities.
89416743|NCT03602313|Experimental|Body Weight Support Training|The Body Weight Support group will received body weight support gait training in lieu of traditional gait training.
89416744|NCT03625466|Placebo Comparator|Part 1: Placebo|Participants received placebo matched to LUM/IVA in placebo-controlled period for 48 weeks.
89416745|NCT03625466|Experimental|Part 1: LUM/IVA|Participants weighing less than (<)14 kilograms (kg) at screening received LUM 100 milligrams (mg)/IVA 125 mg fixed-dose combination (FDC) every 12 hours (q12h) in placebo-controlled period for 48 weeks. Participants weighing greater than or equals to (>=)14 kg at screening received LUM 150 mg/IVA 188 mg FDC q12h in placebo-controlled period for 48 weeks.
89416746|NCT03625466|Experimental|Part 2: Overall LUM/IVA|Participants who received either placebo or LUM/IVA in placebo-controlled period administered LUM/IVA (either LUM 100 mg/IVA 125 mg FDC q12h or LUM 150 mg/IVA 188 mg FDC q12h as per their body weight for participants <6 years of age at week 48 and LUM 200 mg/IVA 250 mg FDC q12h regardless of their body weight for participants >=6 years of age at week 48) in open-label period for 48 weeks.
89416747|NCT02168088||Index case|Subjects who have died of sudden unexplained death
89416748|NCT02168088||Biologically related family member|Biologically related family member of the deceased individual
89416749|NCT04989010|Experimental|89Zr-NY005 injection|Patients will receive a tracer (10 mg, IV) dose of Zr-89 (2-3 mCi) labeled anti-CLDN18.2 mAbs (89Zr-NY005)
89416750|NCT03604419|Experimental|PB-119 100 μg|PB-119 100 μg subcutaneous (SC) once weekly (QW) + Metformin oral (p.o.) Glucophage® (stable dosage)
89416751|NCT03604419|Experimental|PB-119 150 μg|PB-119 150 μg SC QW + Metformin oral (p.o.) Glucophage® (stable dosage)
89416752|NCT03604419|Experimental|PB-119 200 μg|PB-119 200 μg SC QW + Metformin oral (p.o.) Glucophage® (stable dosage)
88894551|NCT01468259|Experimental|Mild RD|Eight (8) with mild (60 less than eGFR less than 89 mL/min/1.73m²)
88894552|NCT01468259|Experimental|Moderate RD|Eight with moderate (30 less than eGFR less than 59 mL/min/1.73m²),
88894553|NCT01468259|Experimental|Severe RD|Eight with severe (15 less than eGFR less than 29 mL/min/1.73m²)
89416753|NCT03604419|Placebo Comparator|PB-119 Placebo|PB-119 Placebo SC QW + Metformin oral (p.o.) Glucophage® (stable dosage)
89416754|NCT03540654||Patients with CML discontinuing TKI treatment|
89416755|NCT04994548||Cirrhotic patients or with portal hypertension|Patients with early esophageal cancer
89416756|NCT03484988|Placebo Comparator|Placebo oil|Ingredients: Corn oil, 500mg per capsule
89416757|NCT03484988|Experimental|Echium oil|Ingredients: Echium oil,500mg per capsule
88894554|NCT01468259|Experimental|End Stage Renal Disease|Eight with ESRD (eGFR < 15 mL/min/1.73m² and requiring hemodialysis)
88894555|NCT01468272|Active Comparator|reference treatment|Free combination of Beclomethasone dipropionate DPI and Formoterol fumarate DPI
88894556|NCT01468272|Experimental|CHF 1535 NEXT DPI|CHF 1535 50/6 NEXT DPI
88894557|NCT01468285|Experimental|Treatment arm 1: betahistine dihydrochloride|
88894558|NCT01468285|Placebo Comparator|Treatment arm 2: placebo|
88894559|NCT01468298|Active Comparator|Isostretching|
88894560|NCT01468298|Active Comparator|Global Posture Reeducation|
88894561|NCT01468363|Active Comparator|Group 1|"Overhydration (OH) in liters will be estimated with the BCM (Body Composition Monitor, Fresenius Medical Care, Deutschland GmbH) in order to determine dry weight as needed before a dialysis session.~If OH is positive value, we will try to reach dry weight by ultrafiltration without regard to the level of blood pressure.~If OH is negative value , we will not change dry weight."
88894562|NCT01468363|No Intervention|Group 2|BCM results obtained at the beginning and 12th months will not be given to the treating physicians. Dry weight estimation will be guided by clinical findings, telecardiography, and echocardiography as used to be.
88894563|NCT01468376|Experimental|GLU-01|
88894564|NCT01468376|Experimental|GLU-02|
88894565|NCT01468376|Experimental|GLU-03|
88894566|NCT01468376|Experimental|GLU-04|
88894567|NCT01468376|Experimental|GLU-05|
89416758|NCT03484988|Experimental|Mixed oil|Ingredients:Mixed oil(Echium oil,camelina oil,safflower oil) 500mg per capsule
89416759|NCT02168166|Active Comparator|Executive Function Training|"Two weeks of training of cognitive domain of executive functioning~Using online program (Scientific Brain Training Pro)~Four exercises"
89416760|NCT02168166|Placebo Comparator|Placebo Training|"Two weeks of training with exercises not affecting working memory, information processing speed, or cognitive load~Exercises maintain other traditional progressive aspects to preserve appearance of dynamic titration of difficulty levels~Using online program (Scientific Brain Training Pro)~Four exercises"
89416761|NCT02237547|Experimental|IV and IT UC-MSC and BMMC|Intravenous and intrathecal human umbilical cord tissue-derived mesenchymal stem cells and bone marrow mononuclear cells
89416762|NCT04984720|Experimental|Smart phone based digital app arm|Digital smartphone application which tracks migraine and to offers pill reminders for medication adherence and community blog and disease related educational material for migraineurs will be given to the patients
89416763|NCT04984720|Active Comparator|Paper and pen diary arm|Clinic based education and traditional paper-pen diary will be administered in tracking headache parameters
89416764|NCT02168244|Active Comparator|Ice pack|Pre-treatment with ice - Ice applied to the skin 2-3 minutes before injecting biologic drug injection
89416765|NCT02168244|Active Comparator|Heating Pack|Pre-treatment with heat - Heat applied to the skin 2-3 minutes before injecting biologic drug injection
89416766|NCT02168244|No Intervention|No treatment before injection|No treatment applied to the skin 2-3 minutes before injecting biologic drug injection
88894568|NCT01468376|Experimental|GLU-06|
88894569|NCT01468389|Active Comparator|Taxanes or Platinum in combination with Capecitabine|The patients will received chemotherapy combining capecitabine with platinum or taxanes until progression.
88894570|NCT01468389|Experimental|chemotherapy followed by capecitabine alone|The patients who has received 4 cycle chemotherapy combining capecitabine with platinum or taxanes and the result was SD or CR or PR,will be given capecitabine alone until progression.
88894571|NCT01468402||Magnetic Resonanse Image|The leiomyomas were evaluated individually. MR was used to evaluate morphology: the radiological dimension(s) of the leiomyoma and uterus and the volume. The number of leiomyoma fibroid, and their location in the myometrium was classified. Perfusion and the characterization of the T2 signal were also evaluated.
88894572|NCT01468441|Experimental|GnRH agonist|Administration of GnRH agonist in alternate days, recombinant FSH and hCG microdose for ovarian stimulation.
88894573|NCT01468441|Active Comparator|GnRH antagonist|Daily administration of GnRH antagonist, recombinant FSH and hCG microdose for ovarian stimulation.
88894574|NCT01468467|Experimental|AC220|
88894575|NCT01468480|Experimental|Pro Root MTA- standard method|application of MTA in second group and 24 hour interval before restoration
88894576|NCT01468480|Experimental|Pro Root MTA- single visit|Intervention/Control application of MTA in third group and 15 minute interval before restoration
88894577|NCT01468480|Experimental|MultiCal / LimeLite|application of Multical in forth group
88894578|NCT01468480|Active Comparator|Dycal|application of Dycal in first group as a pulp dressing agent
88894579|NCT01468493||steroid-sensitive FSGS|
88894580|NCT01468493||steroid-dependent and resistant FSGS|
88894581|NCT01468493||Healthy volunteers|
88894582|NCT01468506||Fistula patients|Consecutive patients with autogenous, brachio-cephalic, brachio-basilic or brachio-brachial arterio-venous fistula creation for hemodialysis
88894583|NCT01468519|Experimental|CSII|continuous subcutaneous insulin infusion
88894584|NCT01468519|Active Comparator|MDI|multiple daily insulin injections
88894585|NCT01468545||Group 1|
88894586|NCT01468545||Group 2|
88894587|NCT01468571|Experimental|Spironolactone|Drug: Spironolactone Drug: Placebo
88894588|NCT01468571|Experimental|Placebo|Drug: Placebo Drug: Spironolactone
88894589|NCT01468610|Active Comparator|Workers with MDD|
88894590|NCT01468623|Experimental|OnDose®|Patients will receive FOLFOX6 with or without bevacizumab (Avastin). Patients' 5-FU dose will be optimized by measuring the Area Under the Curve (AUC) of 5-FU by the commercially available OnDose® assay and their dose for subsequent cycles adjusted following a pre-established dose adjustment algorithm.
88894591|NCT01468623|Active Comparator|Body Surface Area (BSA)|Patients will receive FOLFOX6 with or without bevacizumab (Avastin). Patients will receive 5-FU based on traditional BSA calculation and their dose adjusted based on standard clinical practice. OnDose® AUC measurements will be performed for this arm but will not be used for dose adjustment.
89416767|NCT03484832|Experimental|Spray group|Using Walter Ritter Ethyl Chloride Spray and placebo cream
89416768|NCT03484832|Experimental|EMLA group|Using EMLA cream and placebo spray
89416769|NCT03484832|Placebo Comparator|Placebo group|Using placebo cream and placebo spray
88894592|NCT01468636|Active Comparator|Oral Zinc|
88894593|NCT01468636|Placebo Comparator|Placebo|
88894594|NCT01468649|Experimental|Breast Cancer SLN Mapping|Fifty participants consented who will be undergoing standard of care for breast cancer SLN mapping with Tc-99m will be enrolled in this study.
89416770|NCT04985110|Experimental|Cotrimoxazole|The treatment group will receive Cotrimoxazole Forte 960 mg PO q.d. 4 hours before the biopsy procedure.
88894595|NCT01468662||STEMI|
88894596|NCT01468688|Experimental|STI571 (imatinib mesylate) and BKM120|The study will comprise of 2 parts. A dose escalation and a dose expansion part. Patients will receive increasing doses of BKM120 (40, 60, 80, 100 mg) in combination with 400mg imatinib daily until maximum tolerated dose (MTD) and rapid phase 2 dose (RP2D) is determined. 35 patients will enter the expansion phase with 18 patients having a pharmacokinetic (PK) run-in period of 8 days receiving imatinib monotherapy or BKM120 monotherapy.
88894597|NCT01468688|Experimental|STI571+BKM120|BKM120 Monotherapy 8 day run-in followed by STI571 and BKM120 combination therapy
88894598|NCT01468688|Experimental|STI571 monotherapy run-in|STI571 Monotherapy 8 day run-in followed by STI571 and BKM120 combination therapy
88894599|NCT01468727|Experimental|xylitol wipe|
88894600|NCT01468727|Placebo Comparator|placebo wipe|
88894601|NCT01468753|Experimental|Vaginal Insemination|Women will perform vaginal insemination during the fertile period of the menstrual cycle with the collected semen within one hour of collection. Vaginal insemination will occur within one hour of collection 2 days prior to ovulation, on the day of ovulation and 2 days after ovulation for up to 6 months or until conception occurs. For example, if ovulation were on day 14 of a 28 day menstrual cycle, vaginal insemination will occur on days 12, 14 and 16 of the cycle.
88894602|NCT01468766|Active Comparator|Resistance training|
88894603|NCT01468766|Active Comparator|Relaxation training|
88894604|NCT01468779|Placebo Comparator|Sugar pill|The patients submitted to periampullary cancer surgery will receive sugar pills in the preoperative and postoperative period.
89416771|NCT04985110|Placebo Comparator|Placebo|The placebo group will receive placebo q.d. 4 hours before the biopsy procedure.
89416772|NCT02164812|Experimental|Moxifloxacin, Placebo, Efavirenz|Moxifloxacin, Placebo, Efavirenz single dose as specified
89416773|NCT05153798||PerioMonitor Testing|117 Subject to be tested for Oral Inflammatory Load (OIL) with PerioMonitor. Same subjects to be tested for Oral Inflammation with the BOP method.
89416774|NCT04988776|Active Comparator|group A|Patients received ultrasound-guided Intercostobrachial nerve block with 10 ml 0.25% bupivacaine (5 ml 0.5% bupivacaine will be added to 5ml 0.9% normal saline ) supplemental to supraclavicular block with 30 ml 0.25% bupivacaine (15 ml 0.5% bupivacaine will be added to 15 ml of 0.9 %Nacl ) .
89416775|NCT04988776|Active Comparator|group B|patients received ultrasound-guided pectoral nerves block type II with 10 ml 0.25% bupivacaine (5 ml 0.5% bupivacaine will be added to 5ml 0.9% normal saline ) supplemental to supraclavicular block with 30 ml 0.25% bupivacaine (15 ml 0.5% bupivacaine will be added to 15 ml of 0.9 %Nacl )
89416776|NCT02853123|Experimental|Tiotropium + Olodaterol|Patients will receive tiotropium 5mcg + olodaterol 5mcg in a fixed dose combination once daily.
88894605|NCT01468779|Active Comparator|Probiotics|The probiotics pills are given orally in the amount of two pills twice a day as early as two days before surgery until ten days after surgery.
88894606|NCT01468961|Experimental|Internet-based CBT|
88894607|NCT01469026|Active Comparator|Early PET/CT|
88894608|NCT01469026|Active Comparator|Conventional diagnostics including CT|
88894609|NCT01469078|Active Comparator|100 mg Monofer®|
88894610|NCT01469078|Active Comparator|200 mg Monofer®|
89416777|NCT02853123|Active Comparator|Tiotropium|
89416778|NCT02255370|Experimental|CURCUMIN|subjects will be randomized into two arms; they will be given either placebo or curcumin 3g/d per os plus thiopurines during 6 months in a double-blind manner. Rutggerts endoscopic score at 6 months will be the main judgment criteria
89416779|NCT02255370|Placebo Comparator|PLACEBO|subjects will be randomized into two arms; they will be given either placebo or curcumin 3g/d per os plus thiopurines during 6 months in a double-blind manner. Rutggerts endoscopic score at 6 months will be the main judgment criteria
89416780|NCT04459832|Experimental|15 second stretch|Stretching of the hamstring muscles was performed by the primary researcher for 15 seconds. A straight-leg-raising technique was used for this stretch because we believe that it is commonly used in the clinical setting for elderly people. All subjects were supine lying as flat as possible
89416781|NCT04459832|Experimental|30 second stretch|Stretching of the hamstring muscles was performed by the primary researcher for 30 seconds. A straight-leg-raising technique was used for this stretch because we believe that it is commonly used in the clinical setting for elderly people. All subjects were supine lying as flat as possible
89416782|NCT04459832|Experimental|60 second stretch|Stretching of the hamstring muscles was performed by the primary researcher for 60 seconds. A straight-leg-raising technique was used for this stretch because we believe that it is commonly used in the clinical setting for elderly people. All subjects were supine lying as flat as possible
88894611|NCT01469078|Active Comparator|500 mg Monofer®|
88894612|NCT01469091|Active Comparator|Smoking intervention, Nicotine replacement therapy.|
88894613|NCT01469091|No Intervention|Controlgroup|
89416783|NCT04459832|Sham Comparator|control|The control group followed the same procedures except that no stretching force was applied at the end
89416784|NCT02161848||Patients|Patients with verified singe large-scale mtDNA deletions and chronic progressive external ophthalmoplegia.
88894614|NCT01469104|Placebo Comparator|3 day fast|After receiving a standard diet on day 1, subject will fast on days 2, 3, and 4. Water and calorie-fee beverages will be allowed during this 72 hour period.
88894615|NCT01469104|Active Comparator|CHO-free diet|After receiving a standard diet on day 1, a carbohydrate-free diet will be provided on days 2, 3, and 4.
88894616|NCT01469117||Pediatric developmental disabilities|Children aged 1-13 years old with development disabilities, requiring enteral tube feeding for at least 14 days
88894617|NCT01469130|Experimental|MEK162|"MEK162 will be administered orally once on Day 1 of Cycle 1 and continuously on a BID schedule, starting on Day 2 of Cycle 1 and on Day 1 of subsequent cycles. Each cycle will be 28 days in duration. Dose will be escalated and starting dose is 30 mg. Any doses that are missed should be skipped and should not be replaced or made up during the evening dosing or on a subsequent day, whichever applies.~The prescribed BID doses should be taken 12 ± 2 hrs apart."
89416785|NCT02161848||Controls|Healthy controls matched for age and gender.
89416786|NCT02161848||Patient group as Controls|Patients with mitochondrial DNA 3243A>G mutations
89199150|NCT05954780||second line and later lines therapy|Patients enrolled for second line or later lines therapy with selinexor in combination with bortezomib and dexamethasone.
89416787|NCT04984252|Active Comparator|Only Active components|15 minutes, once
89416788|NCT04984252|Sham Comparator|Inactive components|15 minutes, once
89416789|NCT04984252|Placebo Comparator|Distraction group|15 minutes, once
89416790|NCT03481166|Experimental|Education on breastfeeding pain|Both the experimental and control groups will receive usual prenatal education offered through our regional public health program. In addition to usual prenatal education, the experimental group will also receive a one-hour, nurse led (a Registered Nurse specially trained in perinatal care), small group-based education session with specific focus on breastfeeding pain. The goals of this educational intervention are to provide pregnant women with anticipatory guidance around pain which is commonly experienced while breastfeeding in the first two weeks postpartum. Education will include the prevalence, etiology and management of various types of breastfeeding-related pain experienced postpartum.
88894618|NCT01469143|Experimental|NN1218|
88894619|NCT01469143|Active Comparator|insulin aspart|
88894620|NCT01469169|Experimental|Arm 1|
88894621|NCT01469195||Group A - No lead protection|Patients who are admitted for an elective percutaneous coronary intervention procedure ( or stable acute coronary syndrome patients) will be ask to participate in the study and sign an informed consent (see inclusions and exclusions).The Investigators will approach patients in whom a long procedure time and higher radiation exposure are anticipated (like patients with chronic total occlusion, heavily calcified or tortuous coronary arteries). In those, the fluoroscopy time on average, is longer than usual. In group A - no lead protection will be used.
89416791|NCT03481166|No Intervention|Usual prenatal education|Women allocated to the usual prenatal education group will receive prenatal classes through their local public health unit. Women enrolled in classes will receive approximately 12 hours of combined in-class and online prenatal content. Topics include: discomforts of pregnancy, labor and birth, medical interventions, adjustment to parenting, breastfeeding, and caring for the newborn. Breastfeeding-related material includes basic mechanisms of milk production, benefits of breastfeeding, benefits of skin-to-skin, correct breastfeeding latch, breastfeeding positions, timing of feeds, responding to infant cues, and caring for nipples. Women in the usual prenatal education group will not receive education on the prevalence and etiology of nipple pain, nor specific pain management strategies.
88894622|NCT01469195||Group B plus lead protection|Patients who are admitted for an elective percutaneous coronary intervention procedure ( or stable acute coronary syndrome patients) will be ask to participate in the study and sign an informed consent (see inclusions and exclusions).The Investigators will approach patients in whom a long procedure time and higher radiation exposure are anticipated (like patients with chronic total occlusion, heavily calcified or tortuous coronary arteries). In those, the fluoroscopy time on average, is longer than usual. In group B - lead protection will be used from the umbilicus and down.
88894623|NCT01469260|No Intervention|Routine care|ACOG Exercise in Pregnancy pamphlet
88894624|NCT01469260|Experimental|Pedometer|ACOG Exercise in Pregnancy pamphlet, pedometer use, ultimate goal of 10,000 steps per day
88894625|NCT01469273|No Intervention|Control group|Only observation; observation period: 1 year.
88894626|NCT01469273|Experimental|Early Treatment group (E)|1 x 1 ml of EcN suspension/day on 10 consecutive days, application in the morning before feeding/nursing, first application 48h after birth, latest. Observation period: 1 year.
88894627|NCT01469273|Experimental|Late Treatment Group (L)|1 x 1 ml of EcN suspension/day on 10 consecutive days, application in the morning after feeding/nursing, starting on the first day of the 7th month of life. Observation period: 1 year.
88894628|NCT06078462||Group A|Fifty physiotherapist females will participate in this group and will be assessed at the beginning of the study and after 6 months of clinical work.
88894629|NCT06078462||Group B|Fifty dentist females will participate in this group and will be assessed at the beginning of the study and after 6 months of clinical work.
88894630|NCT06078449|Experimental|Injection group|Group (1) the study group, they will receive HA intra-articular injection in addition to 12 sessions of therapeutic ultrasound.
88894631|NCT06078449|Other|Ultrasound group|Group (2) served as the control group, will receive only HA intra-articular knee injection.
88894632|NCT06078423|Experimental|Investigational Vaccine - 5-dose program|Freeze-dried human rabies vaccine (MRC-5 cells), 1.0 ml after reconstitution, with a titer of not less than 5.24 IU, Anhui Zhifeilongkoma Biopharmaceutical Co., Ltd.
89416792|NCT02161926|Experimental|obese men from 60 to 70 years old|Dietary restrictions in obese men (30<Body Mass Index<40 kg/m2)
89416793|NCT02161926|Active Comparator|obese men from 30 to 40 years old|Dietary restrictions in obese men (30<Body Mass Index<40 kg/m2)
89416794|NCT03073642|Active Comparator|Hydrotherapy|"Patients allocated to this group will perform 12 weeks of hydrotherapy treatment, with global exercises. Hydrotherapy sessions will last 45 minutes and will be performed twice a week.~Exercises will involve aerobic exercises (in the pool) with exercises for upper and lower limbs, and trunk."
88894633|NCT06078423|Experimental|Investigational Vaccine - 4-dose program|Freeze-dried human rabies vaccine (MRC-5 cells), 1.0 ml after reconstitution, with a titer of not less than 5.24 IU, Anhui Zhifeilongkoma Biopharmaceutical Co., Ltd.
88894634|NCT06078423|Active Comparator|Control vaccine - 5-dose program|Freeze-dried human rabies vaccine (MRC-5 cells), 1.0 ml after reconstitution, with a titer of not less than 4.57 IU, ,Chengdu Kanghua Biological Products Co., Ltd
88894635|NCT06078423|Active Comparator|Control vaccine - 4-dose program|Freeze-dried human rabies vaccine (MRC-5 cells), 1.0 ml after reconstitution, with a titer of not less than 4.57 IU, ,Chengdu Kanghua Biological Products Co., Ltd
88894636|NCT06078410||TA-BSM|patients received transapical beating-heart septal myectomy
89530777|NCT03236623|Experimental|Menthol Popsicle|The patient will be questioned when the intensity and discomfort of thirst. After randomization, the patient assigned to the experimental group will experience a menthol popsicle. After 20 minutes of the end of the popsicle, will again be questioned as to the intensity and discomfort of thirst. The popsicle will have a support that will assist the patient in the administration of the intervention, giving him autonomy and safety in the application of the intervention.
88894637|NCT06078410||Cardiac surgery involving left heart operation|patients received cardiac surgery involving left heart operation, such as valvuloplasty, valve replacement, repair of auricular septal defect, repair of auricular/ventricular septal defect
88894638|NCT06078371|No Intervention|Opioid pain treatment (Block 1)|Standard of care pain treatment regimen that involves the use of opioids. Discretion of the medical care team and surgeon will be used for specific opioid pain treatment prescription (quantity, frequency) based on standard of care procedures. All forms of treatment are allowed for the standard of care group which may include but are not limited to blocks, opioids, patient-controlled analgesia, NSAIDs, acetaminophen, muscle relaxing agents, sedation medications, and neuropathic pain medications.
88894639|NCT06078371|Experimental|Opioid-Free pain treatment (Block 2)|Pain treatment regiment without the use of opioids. All other pain medication may be used under the discretion of the medical care team and surgeon.
88894640|NCT06078202|Experimental|Part 1, Sequence A|Participants will receive 1 dose of ABBV-903.
88894641|NCT06078202|Experimental|Part 1, Sequence B|Participants will receive 1 dose of ABBV-903.
88894642|NCT06078202|Experimental|Part 1, Sequence C|Participants will receive 1 dose of ABBV-903.
88894643|NCT06078202|Experimental|Part 2, Sequence A|Participants will receive 1 dose of ABBV-903.
88894644|NCT06078202|Experimental|Part 2, Sequence B|Participants will receive 1 dose of ABBV-903.
88894645|NCT06078163|Experimental|Treatment Group|Treatment Group was composed of patients who will undergo daily pharmacological therapy with Alpha Lipoic Acid 600 mg, L-acetylcarnitine 1000 mg, Resvelatrol 50 mg, Vit D3 800UI for 30 consecutive days in combination with a rehabilitation protocol lasting 20 sessions
88894646|NCT06078163|Placebo Comparator|Control Group|Control Group was composed of patients who will only undergo a rehabilitation protocol lasting 20 sessions.
88894647|NCT06078137|Experimental|Intervention Group|Patients randomized to intervention receive both usual Patient reported outcome measure (PROM) and new PROMs strategy (on the technology platform for English speakers and on REDCap/Qualtrix for Spanish Speakers) done after rooming.
88894648|NCT06078137|No Intervention|Control group|Patients go through the registration process which includes PROMs completion using Ipads. Enrolled in the room at the end of the visit.
88894649|NCT06078124|Experimental|Sibling Support for Adolescent Girls in Emergencies (SSAGE)|Participants in this arm will participate in the Sibling Support for Adolescent Girls in Emergencies (SSAGE) intervention, along with three family members, for twelve weeks
88894650|NCT06078124|No Intervention|Control arm|Care as usual
88894651|NCT06078111|Experimental|Prism 10|participants perform rehabilitation activities while wearing 10° visual field deviation prismatic goggles
88894652|NCT06078111|Active Comparator|Neutral Prism|participants perform rehabilitation activities while wearing neutral (no deviation) visual field deviation prismatic goggles
88894653|NCT06078098||AIH patients|AIH population in Italy aged at least 1 year
88894654|NCT06078085|Experimental|Intervention|24 patients that receive a postoperative rehabilitation program to follow after they undergo surgery for abdominal rectus diastasis.
88894655|NCT06078085|No Intervention|Control|24 patients that undergo surgery for abdominal rectus diastasis and can exercise freely after surgery.
88894656|NCT06078059|Experimental|Intervention group|Knee aspiration and the application of UCB-MSCs
88894657|NCT06078059|Active Comparator|Control group|Only knee aspiration, without the application of UCB-MSCs
88894658|NCT06078046|Experimental|Mindful yoga intervention|The intervention, comprising six 90-minute sessions, will be delivered by a trained mindful yoga instructor in group format. The intervention is based on our previously tested mindfulness yoga programme for people with PD (31). Following a universal Hatha Yoga practice, the session comprises mindfulness practice of yoga sequence, breathing exercise, and guided meditation. Both face-to-face and home-based online modes of delivery are available.
88894659|NCT06078046|Experimental|Arts-based therapy intervention|Participants in the six 90-minute sessions in this intervention will be engaged in art-making processes through multiple art modalities such as visual arts, dance/ movement, music, drama, and creative writing. Each section is usually structured with Filling-in - greetings and check-in, Bridging - warm-up, Decentering - arts making and appreciation, Harvesting - sharing and response, and Closure. Both face- to-face and home-based online modes of delivery are available.
88894660|NCT06078007|Experimental|MyMoodCoach Intervention|
88894661|NCT06078007|No Intervention|Treatment-as-usual monitoring control group|
88894662|NCT06077890|Experimental|Digital Intervention Group|This group incorporates the SIMPLI.REHAB digital tool as a complementary strategy for a rehabilitation program, including flexibility exercises and muscle strengthening, manual dexterity and motor coordination training, thermotherapy, and education on joint protection principles.
88894663|NCT06077890|Active Comparator|Conventional Intervention Group|This group follows a conventional rehabilitation program delivered in a more traditional, non-digital manner to serve as a comparison to assess the superiority of the experimental intervention using SIMPLI.REHAB digital tool.
88894664|NCT06077825|Experimental|experimental group|30 patients who underwent total hip arthroplasty surgery took part in the experimental group.
88894665|NCT06077799||supraventricular tachycardia treated with intra-venous adenosine|supraventricular tachycardia treated with intra-venous adenosine
88894666|NCT06077799||supraventricular tachycardia treated with electrical synchronised cardioversion|supraventricular tachycardia treated with electrical synchronised cardioversion
88894667|NCT06077747|Experimental|Coil embolization of lumbar vein|Subjects with confirmed Nutcracker physiology, retrograde lumbar vein flow, and epidural venous plexus congestion with a high pressure headache will have coil embolization of the lumbar vein.
88894668|NCT06077734||Muscle impaired elderly|Elderly scheduled for hip/knee/back surgery with III-IV ASA score, low grip strength and high scoring for sarcopenia
88894669|NCT06077734||Lung cancer cachexia|Non-small cell lung cancer patients stage III with reported cachexia
88894670|NCT06077734||Controls|Elderly scheduled for hip/knee/back surgery without any recorded muscle defects, I-II ASA score, average or high grip strength, low scoring for sarcopenia.
88894671|NCT06077708|Active Comparator|D3K2 with periodontal therapy|Individuals given D3K2 with periodontal therapy were included in the test group.All serum and gingival crevicular fluid samples from individuals who underwent non-surgical periodontal treatment were taken again at 3rd and 6th months, and clinical periodontal measurements were recorded. Glycated hemoglobin A1c (HbA1c), fasting blood glucose (FBG), 25(OH)D3, parathyroid hormone (PTH), calcium (Ca) and magnesium (Mg) values were determined in serum samples. GCF and serum IL-1ß and IL-10 values were analyzed by enzyme-linked immunosorbent analysis (ELISA).
88894672|NCT06077708|Placebo Comparator|Placebo with periodontal therapy|Individuals given placebo with periodontal therapy were included in the control group.All serum and gingival crevicular fluid samples from individuals who underwent non-surgical periodontal treatment were taken again at 3rd and 6th months, and clinical periodontal measurements were recorded. Glycated hemoglobin A1c (HbA1c), fasting blood glucose (FBG), 25(OH)D3, parathyroid hormone (PTH), calcium (Ca) and magnesium (Mg) values were determined in serum samples. GCF and serum IL-1ß and IL-10 values were analyzed by enzyme-linked immunosorbent analysis (ELISA).
88894673|NCT06077682|Active Comparator|Cyclopentolate arm|"To study the effect of cyclopentolate 1% for cycloplegic refractions in pediatric populations with ET:~Firstly, we instilled an anesthetic drop into patients' eyes. Secondly, 2 drops of cyclopentolate 1% (cyclogel) 5 minutes apart were instilled. Autorefraction was taken at 60 minutes after first drop instillation. Primary outcome: spherical equivalent (SE) of cycloplegic refraction at 60 minutes."
88894674|NCT06077682|Active Comparator|Tropicamide arm|"To study the effect of tropicamide 1% for cycloplegic refractions in pediatric populations with ET:~Firstly, we instilled an anesthetic drop into patients' eyes. Secondly, 2 drops of tropicamide 1% (mydriacil) 5 minutes apart were instilled. Autorefraction was taken at 30 minutes after first drop instillation. Primary outcome: spherical equivalent (SE) of cycloplegic refraction at 30 minutes."
88894675|NCT06077617||Diagnostic group|Adult ICU patients submitted to feeding tube placement according to institutional standard operating procedure
88894676|NCT06077604||Patients with a diagnosis of Axial Spondyloarthritis|Patients with a diagnosis of Axial Spondyloarthritis, received in rheumatology consultation/hospitalization over the period 2019-2022 and living in Franche-Comté over the same period
88894677|NCT06077539|Active Comparator|Dexmedetomidine group|25 patients will receive Dexmedetomidine 1 μg/kg bolus over 10 min followed by 0.5 μg/kg/h as maintenance volume-matched 0.9% saline.
88894678|NCT06077539|Active Comparator|Magnesium group|25 patients will receive IV magnesium as a loading dose 15 mg/kg diluted in 0.9% NaCl given over 10 min followed by 10mg/kg/h IV infusion( for Concentration of solution will not exceed 1gm/25 mL (40 mg/ml).
88894679|NCT06077539|Active Comparator|Ketamine group|25 patients will receive intravenous (IV) ketamine 1mg/kg diluted in 0.9% NaCl as a loading dose over 10min then 1mg/kg/h IV infusion
88894680|NCT06077539|Placebo Comparator|Control group|in 25 patients saline will be given as bolus over 10 min then will be infused as maintenance by the same rate of the other groups.
88894681|NCT06077474||PTSD QUESTIONNAIRES|The group is anticipated to consist of in 155 patients who have been exposed to traumatic events.
88894682|NCT06077448||cases|patients with migraine (migraineurs)
89416795|NCT03073642|Experimental|Hydrotherapy and Pain Education|"Patients allocated to this group will perform 12 weeks of hydrotherapy treatment, with global exercises. Hydrotherapy sessions will last 45 minutes and will be performed twice a week.~Exercises will involve aerobic exercises (in the pool) with exercises for upper and lower limbs, and trunk.~During the 12 weeks of hydrotherapy treatment, volunteers will also receive 4 sessions of Pain Therapeutic Education, which is also known as Pain Neuroscience Education, which involves patient education on pain neurophysiology, pain chronification and amplification mechanisms, and chronic pain management. These sessions will be performed in specific dates scheduled according to the volunteers' availability, and with intervals that can last from one to two weeks."
88894683|NCT06077448||controls|healthy individuals
88894684|NCT06077409|Active Comparator|Gentle Human Touch Group|After the mother is dressed in a clean apron, she will be provided to wash and disinfect her hands and heat her hand temperature with a non-contact fire meter device until the measurement value is 34 ºC.Jul. The mother, who was previously informed about the method, will place the fingertips and palm of one hand above the eyebrow line so that it touches the baby's crown part, while placing the other hand on the lower abdomen surrounding the baby's waist and hips (Figure 1). The GHT application will be started 5 minutes before the blood collection procedure, it will be continued during the blood collection procedure and until 5 minutes after the end of the blood collection procedure.
89416796|NCT03487094|Active Comparator|Growth, Tolerance of Infants-Exp|Infant Formula
89416797|NCT03487094|Active Comparator|Growth,Tolerance of Infants-Com|Infant Formula
89416798|NCT03604029||Qualifying Subjects|Qualifying subjects who are high risk for ACS.
89416799|NCT03604029||Qualifying Subjects with ACS|Qualifying subjects who are diagnosed with ACS
89416800|NCT02168322|Experimental|collagen membranes|collagen barrier that help in isolating unwanted tissues in periodontal regneration
89416801|NCT04984408|Experimental|Arm 1: BBIBP-CorV|Study Arms 1 will have two groups: group 1 - HIV-uninfected receiving BBIBP-CorV; group 2 - HIV-infected receiving BBIBP-CorV .
89416802|NCT04984408|Experimental|Arm 2: Flu Quadrivalent|Study Arms 2 will have two groups: group 1 - HIV-uninfected receiving Flu Quadrivalent; group 2 - HIV-infected receiving Flu Quadrivalent. The Flu Quadrivalent is recommended as a single dose for adults, the second and the booster doses for Arm 2 will be placebo.
89416803|NCT04984408|Experimental|Arm 3: BBIBP-CorV and Flu Quadrivalent (Co-administration)|Arm 3 will have 1 group - HIV-uninfected co-administration group receiving both study vaccines.
89416804|NCT03602001|Experimental|attentive eating smartphone app group|Participant's received the intervention 'Attentive eating smartphone application'. This is a smartphone application that encourages a more attentive eating style. Participants also received the 'Standard dietary advice and text tips' intervention. This consists of a standard dietary advice booklet, and weekly dietary advice tips by text message.
89416805|NCT03602001|Active Comparator|control group|Participants received the 'Standard dietary advice and text tips' intervention. This consists of a standard dietary advice booklet, and weekly dietary advice tips by text message.
89416806|NCT02168556|Placebo Comparator|Standard of Care|Patient underwent urodynamic testing by receiving only standard of care with mailed information and during test teaching.
89416807|NCT02168556|Active Comparator|Music|Patient underwent urodynamic testing while listening to music that was 60 beats per minute and received standard of care information and teaching.
88894685|NCT06077409|Active Comparator|Skin to Skin Group|"The temperature of the environment where skin to skin will be carried out will be adjusted between 22-26 degrees C. The mother will be allowed to disinfect her hands and warm them until her hand temperature is at least 34 C. Only the baby's diaper, hat and socks will be left behind, and the baby will be placed face down on the mother's chest, with its head upright and its legs under the breasts in a frog position. The baby's face will be turned towards the mother and eye contact will be made. The baby will be in an upright position between the mother's breasts and skin to skin with the mother.~Skin-to-skin contact will begin 5 minutes before blood collection, continue throughout the procedure, and skin to skin will continue until 5 minutes after the procedure."
89416808|NCT02168556|Active Comparator|Video|Patient watched an informational video prior to urodynamic testing.
89416809|NCT03073564|No Intervention|Incremental cardiopulmonary test|Incremental cardiopulmonary test for upper limbs will be performed only to identify patients who exhibit dynamic hyperinflation during upper limb exercise.
89416810|NCT03073564|Experimental|Endurance test|The endurance test for upper limbs will be performed in two conditions: In the first the patients perform the test in usual breathing, without the use of EPAP. In the second the test will be performed using the EPAP mask.
89416811|NCT03073564|Experimental|Functional test|The functional test for upper limbs will be performed from protocol already published for the 6-min pegboard and ring test (6PBRT). In this stage the patients will perform the 6PBRT in usual breathing and as the use of the EPAP mask.
89416812|NCT03484754|Experimental|corrugator|single injection of 10 Units of botulinum toxina in the corrugator and procerus
89416813|NCT03484754|Active Comparator|orbicularis oculi|single injection of 10 Units of botulinum toxina in the lateral muscle orbicularis oculi (involved in crow's feet wrinkles)
89416814|NCT03601845|Other|MRE-IA (no stimuli)|Additional sequencing only
89416815|NCT03601845|Active Comparator|MRE-IA with stimuli|Visual stimulation while using additional sequencing
89416816|NCT02162004|Experimental|Continuous correction|The insulin pump is set to automatically deliver the patient's usual insulin basal rate. The insulin pump bolus calculator is run every 10 minutes by the attending physician. Bolus calculations are based on glucose sensor values.
89416817|NCT02162004|No Intervention|Control|Regular sensor-augmented pump therapy.
89416818|NCT04459676|Active Comparator|ANG-3777 + SOC|"ANG-3777 Administered IV for 30 min and SOC~Repeat within 24 hours after previous dosing for a total of 4 days"
89416819|NCT04459676|Placebo Comparator|Standard of Care + Placebo|Standard of Care + Placebo
89416820|NCT03603873||Patients|
89416821|NCT03540966|Experimental|Group A|complete Chinese version of the vitiligo life quality index, VLQI-C, conventional therapies plus CapulinTM on-demand treatment period
89416822|NCT03540966|Placebo Comparator|Group B|complete Chinese version of the vitiligo life quality index, VLQI-C, conventional therapies on-demand treatment period
89416823|NCT02162082|Experimental|stent or scaffold|implantation of stents or scaffolds after recanalization of coronary chronic total occlusions
89416824|NCT04984642|Experimental|healty subject|
89416825|NCT02164890|Other|Pharmacokinetics of micafungin|
88894686|NCT06077409|No Intervention|Control Group|The standard procedure of the clinic was applied to preterm infants in the control group. In the standart prosedure of the clinic, the mother was with her baby in the blood collection room and did not perform any procedure.
88894687|NCT06077383|Experimental|Probiotics group|Probiotics group subjects take probiotics every day for 8 weeks.
88894688|NCT06077383|Placebo Comparator|Placebo group|Placebo group subjects take placebo every day for 8 weeks.
88894689|NCT06077370|Active Comparator|dTMS group|dTMS on anterior cingulate cortex and medial prefrontal cortex.
88894690|NCT06077370|Sham Comparator|sham TMS|Sham TMS on anterior cingulate cortex and medial prefrontal cortex.
89416826|NCT03484676|Other|Unilateral Non comminuted zygomatic complex fracture|Patient undergo treatment no control group
89416827|NCT03603561|Active Comparator|Active cTBS|
89416828|NCT03603561|Sham Comparator|Sham cTBS|
89416829|NCT01045226|Experimental|Arm I|Patients undergo proton radiotherapy once daily 5 days a week for approximately 9 weeks in the absence of disease progression or unacceptable toxicity.
89416830|NCT02164968||Obstructive bronchitis|1-5 year old patients who have visited the TAYS emergency room due to obstructive bronchitis and have been instructed to begin a three-month period of inhaled corticosteroid (ICS) treatment as per national guidelines.
89416831|NCT02634346|Experimental|ALKS 3831|Administered as a coated bilayer tablet
89416832|NCT02634346|Active Comparator|Olanzapine|Administered as a coated bilayer tablet
89416833|NCT02634346|Placebo Comparator|Placebo|Administered as a coated bilayer tablet
89416834|NCT00936728|Experimental|Arm A (white wine)|Patients consume white wine twice daily for 3-4 weeks.
89416835|NCT00936728|Active Comparator|Arm B (non-wine nutritional supplement)|Patients receive an oral non-wine nutritional supplement (e.g., Boost or Ensure) twice daily for 3-4 weeks.
89416836|NCT02168634|Experimental|Botulinum toxin|5U Botulinum toxin in 1cc normal saline, administered in one of the two itchy points
89416837|NCT02168634|Placebo Comparator|Normal Saline|1cc normal saline, administered in the other itchy point
89416838|NCT02237781|Experimental|AMH levels|Patients in this group will be stimulated according to a short stimulation protocol with gonadotropins and GnRH antagonists. Levels of AMH will be measured prior and during the ovarian stimulation.
89416839|NCT04459208|Active Comparator|Manta|plug-based vascular closure
89416840|NCT04459208|Active Comparator|ProGlide|suture-based vascular closure
89416841|NCT02168712|Active Comparator|Moderate continuous exercise training|Moderate intensity continuous exercise training
89416842|NCT02168712|Experimental|Interval exercise training|High intensity interval exercise training
88894691|NCT06077357|Active Comparator|COPD Patients|Having COPD. Older than 65 years old and not having any communication problems.
89416843|NCT00849147|Experimental|Haploidentical Bone Marrow Transplant|Participants will receive a human leucocyte antigen (HLA) haploidentical bone marrow transplantation using a non-myeloablative preparative regimen, GVHD prophylaxis.
89416844|NCT00812240|Experimental|Masitinib (7.5)|Participants receive masitinib (7.5 mg/kg/day), given orally twice daily.
89416845|NCT00812240|Experimental|Masitinib (6.0)|Participants receive masitinib (6.0 mg/kg/day), given orally twice daily
89416846|NCT00812240|Active Comparator|Active Comparator (7.5)|Participants receive imatinib at 400 or 600 mg per day
89416847|NCT00812240|Active Comparator|Active Comparator (6.0)|Participants receive imatinib at 400 or 600 mg per day
89416848|NCT02165046|Experimental|SYN006 HFA MDI, 180/10 mcg/dose|SYN006 HFA MDI(Budesonide/Procaterol Hydrochloride, 180/10mcg), Single dose, 4 puffs
89416849|NCT02165046|Active Comparator|Pulmicort pMDI|Budesonide 200mcg, single dose, 4 puffs
89416850|NCT02165046|Active Comparator|Meptin Air 10mcg|Procaterol hydrochloride 10mcg, single dose, 4 puffs
89416851|NCT03070678|Experimental|SAR439954 with or without mefenamic acid|Period 1: single oral dose of 400 mg sotagliflozin Period 2: initial loading dose of 500 mg in the morning of Day 1, followed by 250 mg from Day 1 H6 to Day 7 of mefenamic acid and a single oral dose of sotagliflozin on Day 2
89416852|NCT00101166|Experimental|Vaccine Therapy|Treatment consisted of intradermal vaccine injections at 28-day intervals for a total of 3 immunizations. Injections were performed on Days 1, 29, and 57.
88894692|NCT06077357|Active Comparator|Asymptomatic Patients|Not having a diagnosis of COPD and being over 65 years old and not having any communication problems.
88894693|NCT06077318||Keyhole repair|The keyhole technique involves placing a mesh with a slit in the central hole around the intestinal ring, allowing facilitating the passage of the intestine through the central slit.
88894694|NCT06077318||Sugarbaker repair|The modified Sugarbaker technique uses a mesh to place a patch on the lateralized intestine, effectively preventing herniation of abdominal contents through the stoma.
88894695|NCT06077292|Experimental|15% THC Potency Reduction Group|Participants will be incentivized to use THC products that are at least 15% less potent than baseline
88894696|NCT06077292|Experimental|35% THC Potency Reduction Group|Participants will be incentivized to use THC products that are at least 35% less potent than baseline
88894697|NCT06077279|Experimental|Horticultural Therapy|receive horticulture therapy by seven sessions within two months
88894698|NCT06077279|No Intervention|Routine hospital care|doesn't receive horticulture therapy but receive routine care by hospital within conducting the research
88894699|NCT06077162|Experimental|What Can I Eat Diabetes Nutrition Education Classes Only|Participants will be enrolled in a 3 month, 5 session in-person diabetes nutrition education class, entitled What Can I Eat?, over the course of the 3 month intervention (4 * 90 min in person classes weekly for a month, with 5th class at 3 months from baseline).
89416853|NCT04994236|Experimental|Hepatic Artery Infusion Chemotherapy|Subjects assigned to this arm will receive chemotherapy via catheterizations placed into the hepatic artery.
89416854|NCT03601611|Experimental|Experimental|Tocilizumab 8 mg/kg is to be given as an IV infusion over 60 minutes every 4 weeks (Q4W).
89416855|NCT03597945|Placebo Comparator|Group Placebo|"For patients of this group, the intervention was a femoral nerve block with:~15 ml of lidocaine with epinephrine (300 mg)~and 3 ml of normal saline as adjuvant."
88894700|NCT06077162|Experimental|What Can I Eat Diabetes Nutrition Education Classes + Healthy Food Security Resource|Participants will be enrolled in a 3 month, 5 session in-person diabetes nutrition education class, entitled What Can I Eat?, over the course of the 3 month intervention (4 * 90 min in person classes weekly for a month, with 5th class at 3 months from baseline). Additionally, patients will receive a $30.00 healthy food resource weekly for 12 weeks.
88894701|NCT06077162|Experimental|Healthy Food Security Resource Only|Patients will receive a $30.00 healthy food resource weekly for 12 weeks.
88894702|NCT06077136|Active Comparator|regular physical therapy group|this group will receive regular physical therapy 3 -5 times per week. this program will be designed according to the needs of each child. strength, stretch, facilitation, splinting, coordination, and functional exercises are examples of the components of the programs.
88894703|NCT06077136|Experimental|whole body vibration|"in addition to the regular exercises, selected arm exercises will be performed while the child is under whole-body vibration. using (Galileo® MED 25 TT, Germany; 2021 model) with the following parameters:~WBV session duration: 10 minutes (rest periods can be incorporated~frequency: 12 Hz~Amplitude: 2 (fixed)~duration of each exercise: 2-3 minutes"
88894704|NCT06077110|Experimental|P-OMICs-flow patients|
89416856|NCT03597945|Active Comparator|Group Magnesium|"For patients of this group, the intervention was a femoral nerve block with:~15 ml of lidocaine with epinephrine (300 mg)~and 3 ml of Magnesium sulfate 15% (450 mg) as adjuvant."
88894705|NCT06077084|Active Comparator|Moderate intensity|
88894706|NCT06077084|Active Comparator|High intensity|
88894707|NCT06077058|Experimental|Intervention group|Factorial design with four components/factors: 1) SEE versus none; 2) NRTS versus none; 3) CBIM versus none; and 4) chatbot for smoking cessation versus none, and to 2 x 2 x 2 x 2=16 trial groups. All participants will be randomly and evenly assigned to these 16 intervention groups.
88894708|NCT06077058|No Intervention|Control group|The control group will only provide simple smoking cessation advice with no intervention after recruitment
89416857|NCT02162160|Experimental|Probiotic creme|Women receing probiotic creme
89416858|NCT02162160|Placebo Comparator|placebo|Women receiving a moisturizer
89416859|NCT03486782|Active Comparator|Dual stimulation|i) anodal stimulation of ipsilesional inferior frontal cortex and cathodal stimulation of contralesional supraorbital area ii) anodal stimulation on ipsilesional dorsolateral prefrontal cortex and cathodal stimulation of contralesional supraorbital area
89416860|NCT03486782|Active Comparator|Single stimulation 1|i) anodal stimulation of ipsilesional inferior frontal cortex and cathodal stimulation of contralesional inferior frontal cortex
89416861|NCT03486782|Active Comparator|Single stimulation 2|i) anodal stimulation of ipsilesional inferior frontal cortex and cathodal stimulation of contralesional supraorbital area
89416862|NCT04993846||Pancreatic cancer patients - Explorative phase|Pancreatic cancer patients evaluated at the Pancreatic Surgery Unit of the Pancreas Institute of the University of Verona will be enrolled. Fifteen PC patients per stage will be selected (15 Stage I/II, Stage III, Stage IV). Patients may have been scheduled for surgery or for biopsy for future systemic treatments. An oral microbiota (dental plaque) sample will be collected and a periodontal and dental assessment will be performed, before any therapeutic procedure, together with orthopantomography
89416863|NCT04993846||Healthy controls - Explorative phase|Age-matched (+- 5 years) healthy controls referring to the Odontostomatology Unit for oral procedure according to clinical practice, with a recent (not longer than 12 months) cross-sectional abdominal imaging excluding gastrointestinal cancers.
89416864|NCT04993846||Pancreatic cancer patients - Validation phase|Pancreatic cancer patients evaluated at the Pancreatic Surgery Unit of the Pancreas Institute of the University of Verona will be enrolled. Fifteen PC patients per stage will be selected (15 Stage I/II, Stage III, Stage IV). Patients may have been scheduled for surgery or for biopsy for future systemic treatments.
89416865|NCT04993846||Healthy controls - Validation phase|Age-matched (+- 5 years) healthy controls referring to the Odontostomatology Unit for oral procedure according to clinical practice, with a recent (not longer than 12 months) cross-sectional abdominal imaging excluding gastrointestinal cancers.
89416866|NCT04993846||IPMN patients controls - Validation phase|Patients suffering from IPMNs evaluated at outpatients clinics or scheduled for surgery.
89416867|NCT03730428||pneumonitis group|Patients who developed drug-related pneumonitis after treated with everolims
89416868|NCT03730428||non-pneumonitis group|Patients who didn't develop drug-related pneumonitis after treated with everolims
89416869|NCT03603483|Active Comparator|Patients with sever aortic stenosis 1|Procedure: the patients will undergo aortic valve replacement with aortic root enlargement.
89416870|NCT03603483|Active Comparator|Patients with sever aortic stenosis 2|Procedure: the patients will undergo conventional aortic valve replacement
89416871|NCT04459910||Multidirectional|Arthroscopic lateral ligament repair combined with deltoid arthroscopic ligament repair.
89416872|NCT04984018|Experimental|Chidamide plus Camrelizumab|Pts received 200 mg camrelizumab intravenously every 2 weeks and Chidamide 30mg orally twice (biw) per week for 4 consecutive weeks every 6 weeks until disease progression, unacceptable adverse events (AEs) or withdrawal of consent.
89416873|NCT02162238|Placebo Comparator|purified water|Filtered water Pump water purified by the LSF-filtering device Intervention: Device: LSF-filtering device
89416874|NCT02162238|Experimental|zinc enriched purified water|Zinc water water purified and zinc-enriched by the LSF-filtering device Intervention: Device: LSF-filtering device
89416875|NCT03601533|Other|Phenol|Patients will undergo neurolysis of genicular nerves with 1,5 mL of 7% phenol in each of the genicular nerves (superior, medial and lateral).
89416876|NCT03484598|Experimental|SPEAC Treatment Arm|All study participants will be provided with a SPEAC System to use in their home environment.
89416877|NCT04983784|Experimental|The Effectiveness of Walking on Sleep ,Depression and Quality of Life on intervention|"experimental group:~intervention home-style walking exercises~performed 12 weeks of 30 minutes walking exercise 2-3 times per week~assess on at baseline and 12 weeks"
88894709|NCT06077045||LAIV Vaccinated cohort|All individuals receiving LAIV between 2 and <18 years within a given flu season between 2012 and 2020.
89416878|NCT04983784|Experimental|No intervention group reaction|"control group:~no intervention~Routine care and follow-up~assess on at baseline and 12 weeks"
89416879|NCT02165280|Active Comparator|Guided IMagery (GIM)|If randomized to GIM, they will then be given an audio Compact Disc. Patients will be instructed to listen to the recording least once per day in a calm location during the week leading up to surgery. They will then be seen prior to surgery in the surgical waiting area where they will evaluated for anxiety, preparedness and study compliance.
89530778|NCT03236623|No Intervention|Usual care|The patient will be questioned when the intensity and discomfort of thirst. After randomization, the patient assigned to the control group should receive the usual care consisting of absolute fasting the food and drinks.
88894710|NCT06077045||Unvaccinated cohort|All individuals between 2 and <18 years with no record of influenza vaccinations in a given flu season
88894711|NCT06077019|Experimental|Vilanterol|Participants inhale vilanterol + fluticasone furoat
88894712|NCT06077019|Experimental|Indacaterol|Participants inhale indacaterol + mometasone furoate
88894713|NCT06077019|Placebo Comparator|Placebo|Participants inhale placebo
88894714|NCT06077006||Research|Children between the ages of 6 and 18 years, diagnosed with Migraine, who are under follow-up at the Pediatric Neurology Clinic in Bnei Zion.
88894715|NCT06077006||Control|Children without Migraine, headache or other chronic diseases
88894716|NCT06076993|Experimental|BodyKind programme group|The intervention group will receive the BodyKind body image programme. The four 50 minute lessons of the BodyKind programme will be delivered by teachers at a rate of 1 lesson per week over four consecutive weeks.
88894717|NCT06076993|No Intervention|Waitlist control|The waitlist control group will engage in classes as usual and will receive the BodyKind programme after data is collected.
89416880|NCT02165280|No Intervention|Standard of Care (SOC)|"Each participant will complete a baseline set of questionnaires. The Pelvic Floor Distress Inventory (PFDI) is a 20 question self-administered questionnaire on the presence and both of pelvic floor symptoms .~The Pelvic Organ Prolapse Quantification System (POPQ) measures the topography of the vagina and is considered to be gold standard for quantifying prolapse .~The State-Trait Anxiety Inventory (STAI) has been used extensively in research and clinical practice since its introduction in 1966 and is the most widely cited measure of anxiety.~New measurements at the 6-week follow-up appointment will include the Patient Global Impression of Improvement (PGII), and a postoperative questionnaire eliciting overall satisfaction and development of new pelvic symptoms."
89416881|NCT03486626|Experimental|Patients|
89416882|NCT04983550|Experimental|Group A: SG001 + doxorubicin hydrochloride liposome injection|Two-thirds of the patients will be randomly assigned to group A to receive SG001 240 mg, IV, every 2 weeks (1 cycle every 4 weeks), and doxorubicin hydrochloride liposome injection 40 mg/m^2, IV, every 4 weeks (1 cycle).
89416883|NCT04983550|Active Comparator|Group B: doxorubicin hydrochloride liposome injection|One-third of the patients will be randomly assigned to group B to receive doxorubicin hydrochloride liposome injection 40 mg/m^2, IV, every 4 weeks (1 cycle).
89416884|NCT02255682|Placebo Comparator|Simvastatin and Q10-placebo|Simvastatin 40 mg orally administered daily and Q10-placebo for 8 weeks
89416885|NCT02255682|Active Comparator|Simvastatin and Q10|Simvastatin 40 mg orally administered daily for 8 weeks in combination with Q10 supplementation of 400 mg/daily
89416886|NCT05153486|Experimental|Group A|Circumferential pulmonary vein isolation + linear ablation + bi-atrial mapping + driver ablation
89416887|NCT05153486|Active Comparator|Group B|Circumferential pulmonary vein isolation + linear ablation + vein of Marshall ethanol infusion
88894718|NCT06076967|Experimental|Adapted Mindful Awareness Practices (MAPS)|The Mindful Awareness Practices (MAPs) for ADHD program, an 8-week, group-based mindfulness program for adults with ADHD, has been shown to reduce ADHD, depression, and anxiety symptoms. While promising, it is unknown as to whether the MAPs protocol is feasible, acceptable, and efficacious for college students with ADHD. The current study takes the first step towards enhanced study of mindfulness for college students with ADHD by testing the feasibility, acceptability, and preliminary efficacy of an adapted MAPs protocol delivered within university counseling center settings during the first semester of college.
89193297|NCT05229393|Experimental|Diaphragmatic Manual Therapy Group A|"Experimental: Diaphragmatic Manual Therapy plus Cervical Manual Therapy plus Breathing Reeducation Exercises group.~Cervical manual therapy will be the same as for the Manual Control Group (20 minutes).~Diaphragmatic Manual Therapy (10 minutes) and Breathing Reeducation Exercises (10 minutes). The program will be carried out three times per week lasting four weeks in total. Each session will last about 40 minutes."
89416888|NCT05153486|Active Comparator|Group C|Surgical ablation
89416889|NCT03068572||NERD group|45 GERD patients without obviously abnormality were examined by conventional white-light endoscopy and then followed by Linked Color imaging(LCI) to evaluate minimal change esophagitis and observation agreement of Los Angeles classification system GERD patients with the absence of mucosal breaks at conventional endoscopy,and those patients was given standard or double dose of oral proton pump inhibitor (PPI) for 2 weeks to determine the efficacy of anti-secretory therapy (the so-called PPI test).The response to PPI treatment comprised the NERD group.
88894719|NCT06076967|Active Comparator|Services-As-Usual|Services-As-Usual includes the standard academic support services provided by university disability/accessibility offices.
88894720|NCT06076954|Experimental|Planned therapist feedback iCBT|Participants in the planned therapist feedback iCBT condition will receive the iCBT intervention with planned feedback after each completed module. The therapist may spend a max. of 15 minutes giving feedback per module.
88894721|NCT06076954|Experimental|On-demand therapist feedback iCBT|Participants in the on-demand therapist feedback iCBT condition will receive the intervention with on-demand feedback that is participant-initiated. The therapist may spend a max. of 15 minutes giving feedback per module.
89199151|NCT05954767|Other|Efficacy|Single intravenous injection of IS-001 and ureter visualization and delineation will be compared in white light standard of care and near-infrared (NIR) imaging mode.
88894722|NCT06076941|Experimental|Education|Pregnant women in the experimental group were given oral and dental health education in groups of maximum five, and the forms were filled out before and one month after the education.
88894723|NCT06076941|No Intervention|Control|No intervention was made to the pregnant women in the control group, and the forms were completed before and one month after the training.
88894724|NCT06076928|Sham Comparator|Conventional supervised occupational therapy (CT)|CT consists of standard occupational therapy for hand function which includes but not limited to the following treatment (1) passive and active mobilisation; (2) spasticity management; (3) training with use of various modalities/equipment; (4) gross and fine motor training including reach and grasp/release functions, and object manipulation; (5) grasp training: cylindrical, spherical, intrinsic, 2-finger pincer and 3-finger grip.
88894725|NCT06076928|Active Comparator|HandyRehab (HR) with supervised training by OT|HR training consists of (1) passive and active mobilisation (2) spasticity management (3) gross motor training with HR applied (4) grasp training: cylindrical, spherical, intrinsic, 2-finger pincer and 3-finger grip.
88894726|NCT06076928|Experimental|HandyRehab integrated with BCI (BCI-HR) with supervised training by OT|BCI-HR training consists of (1) passive and active mobilisation (2) spasticity management (3) gross motor training with BCI-HR applied (4) grasp training: cylindrical, spherical, intrinsic, 2-finger pincer and 3-finger grip.
88894727|NCT06076915|Experimental|G1 (Group 1)|"Experimental: Exergame Training, then Usual Daily Work~Participants of G1 first received the Exergame Training (integrated into their working schedule). After 6 weeks, they no longer received exergame training but followed their normal work schedule for another 6 weeks."
89193298|NCT05229393|Sham Comparator|Cervical Manual Therapy Group B|Sham Comparator: Sham Treatment group or Manual Control Group Patients included in this group will receive Cervical Manual Therapy (25 minutes) plus sham Diaphragmatic Manual techniques (15 minutes). The program will be carried out three times per week lasting four weeks in total. Each session will last about 40 minutes.
88894728|NCT06076915|Experimental|G2 (Group 2)|"Experimental: Usual Training Work, then Exergame Training~Participants of G2 first followed their normal work schedule for 6 weeks and then received the Exergame training for another 6 weeks."
89193299|NCT05229393|Active Comparator|Conventional Physiotherapy Program Group C|"Active Comparator: Conventional Treatment group Patients included in this group will receive a conventional physiotherapy program with Transcutaneous Electrical Nerve Stimulation-TENS (15 minutes) plus Microwave pulsed Diathermy (10 minutes), and soft tissue techniques (15 minutes).~The program will be carried out three sessions per week during the four weeks. Each session will last about 40 minutes."
89193300|NCT05222555|Experimental|Treatment (Tafasitamab + Lenalidomide)|"Treatment:~Tafasitamab will be combined with lenalidomide in R/R DLBCL patients.~Dose:~Cohort 1: The dose of tafasitamab will be level 1 high dose in combination with the approved dose~Cohort 2: The dose of tafasitamab will be level 2 high dose in combination with the approved dose~Expansion Cohort: The dose of tafasitamab will be the dose that is deemed safe and tolerable as determined from cohort 1 & cohort 2~Treatment consisting of tafasitamab and lenalidomide combination will be administered until disease progression, unacceptable toxicity, or discontinuation for any other reason, whichever comes first. Lenalidomide can be given for up to 12 cycles in total, after which patients can continue with tafasitamab as monotherapy until progression or unacceptable toxicity."
89193301|NCT05218694|Experimental|CT-guided algorithm (CTGA)|In the CTGA group only the artery suspected of having obstructive coronary disease is examined. Anatomy of the vessel, optimal viewing projections and choice of catheter is determined. A guiding catheter is used as first choice based on the artery involved and the aortic anatomy. Time is recorded according to the ST group, with timepoint 1 after conclusion of the angiogram, timepoint 2 after FFR.
89193302|NCT05218694|No Intervention|Standard treatment (ST)|"ST includes the use of two diagnostic cathers and examination of both coronary arteries by at least 6 different standard projections best optimizing the view of the coronary lesions.~Additional projections may be included if deemed necessary for optimal angiographic evaluation"
89193303|NCT05209685|Experimental|Experimental|Resistance exercise with blood flow restriction
89193304|NCT05209685|Active Comparator|Control|Traditional resistance exercise
89193305|NCT05208411|Experimental|ImPACT group|Group of children at elevated likelihood of ASD who will receive the ImPACT intervention
89193306|NCT05208411|No Intervention|No intervention group|Group of children at elevated likelihood of ASD who won't receive any intervention
89193307|NCT05202080|Experimental|Opioid Counseling and PCS Video Group|This arm of the study will receive the opioid counseling and pain coping skills video 2 weeks prior to their surgery in addition to the conventional information provided to all patients undergoing total joint arthroplasty.
89193308|NCT05202080|No Intervention|Standard of Care Group|This arm of the study will the conventional information provided to all patients undergoing total joint arthroplasty.
89193309|NCT05199324|Experimental|Early step-down to oral antibiotic therapy|The oral antibiotic options are fluoroquinolones (most commonly, ciprofloxacin) or trimethoprim-sulfamethoxazole. The recommended doses for patients with normal renal function would be ciprofloxacin 750 mg twice daily (if body weight ≥70 kg) or ciprofloxacin 500 mg twice daily (if body weight <70 kg) or trimethoprim-sulfamethoxazole 5 mg/kg (for trimethoprim component) every 12 hourly or trimethoprim-sulfamethoxazole (160 mg / 800 mg; double strength) two tablets twice daily. Doses may be adjusted in the setting of renal dysfunction. The recommended treatment duration by the study team is 7 days of active antibiotics (including empiric therapy), although treatment regimen may be longer than 7 days due to regimen extension or requirement for prolonged regimen as clinically indicated.
89193310|NCT05199324|Active Comparator|Continuing intravenous antibiotic therapy|The intravenous antibiotic(s) to be administered will be determined by the treating doctor according to what would be considered standard of care in the hospital site. Commonly used intravenous antibiotics (and doses) for treatment of Gram-negative bacteraemia include ceftriaxone 2 g daily or cefazolin 2 g three times daily. The recommended treatment duration by the study team is 7 days of active antibiotics (including empiric therapy), although treatment regimen may be longer than 7 days due to regimen extension or requirement for prolonged regimen as clinically indicated.
89416890|NCT03068572||Control group|45 control patients were examined by white-light endoscopy and then followed by Linked Color imaging(LCI) to evaluate minimal change esophagitis and observation agreement of Los Angeles classification system,those subjects who had undergone endoscopy solely for the purpose of a health check-up at the same time of the study period
88894729|NCT06076902|Experimental|Treatment group with patch augmentation|Arthroscopic rotator cuff reconstruction using fixation with anchors augmented with a synthetic polyester patch
88894730|NCT06076902|Active Comparator|Comparison group without patch augmentation|Arthroscopic rotator cuff reconstruction using fixation with anchors and no augmentation with a synthetic polyester patch
88894731|NCT06076850|Active Comparator|Standard Care + Active LiESWT|"Tadalafil 5mg daily - to start 5 days before surgery and continued for 12 months after surgery till end of study.~With or without Vacuum Pump~Active LiESWT"
88894732|NCT06076850|Sham Comparator|Standard Care + Sham LiESWT|"Tadalafil 5mg daily - to start 5 days before surgery and continued for 12 months after surgery till end of study.~With or without Vacuum Pump~Sham LiESWT"
88894733|NCT06076837|Experimental|Dose Escalation - Botensilimab + balstilimab + triplet chemotherapy + chloroquine + celecoxib|Botensilimab 50 mg IV D1 of each cycle; Balstilimab 240 mg IV on D 1, 15, and 29 of each cycle; Triplet chemo (nab-paclitaxel 125 mg/m2 + gemcitabine 1000 mg/m2 +cisplatin 25 mg/m2 IV infusion on D 1, 8, 22, and 29 of each cycle; Chloroquine phosphate (Aralen) 500 mg po (300 mg equivalent chloroquine base) on D 1, 8, 15, 22, 29, and 36 of each cycle; Celecoxib 200 mg po twice daily (BID) on D 1 through 5 of each cycle Famotidine 20 mg po BID on D 1 through 5 of each cycle Aspirin 81 mg po every day (QD) thrombotic event prevention
88894734|NCT06076837|Experimental|Expansion Cohort - Botensilimab + balstilimab i+ triplet chemotherapy + chloroquine + celecoxib|Botensilimab (MTD TBD) D1 of each cycle; Balstilimab 240 mg IV on D 1, 15, and 29 of each cycle; Triplet chemo (nab-paclitaxel 125 mg/m2 + gemcitabine 1000 mg/m2 +cisplatin 25 mg/m2 IV infusion on D 1, 8, 22, and 29 of each cycle; Chloroquine phosphate (Aralen) 500 mg po (300 mg equivalent chloroquine base) on D 1, 8, 15, 22, 29, and 36 of each cycle; Celecoxib 200 mg po twice daily (BID) on D 1 through 5 of each cycle Famotidine 20 mg po BID on D 1 through 5 of each cycle Aspirin 81 mg po every day (QD) thrombotic event prevention
89193311|NCT05198258|Experimental|Implementation study - experimental group|Physiotherapists in the experimental group (group A) will receive on-line theoretical education including three hours of practical training by the project leaders. The standardized theoretical education includes three 45 minutes on-line lectures. The theoretical education will be followed by three hours practical training including clinical examination in patients with neck disability and instructions how to perform the neck-specific exercises.To facilitate the implementation process, group A will receive additional support; the physiotherapists can contact the project leader via e-mail, phone, online meetings and/or outreach visits
89193312|NCT05198258|Active Comparator|Implementation study - control group|Physiotherapists in the control group (group B) will receive the same theoretical and practical training as group A but without additional support from the research group or education after the first three theoretical on-line lectures and the three hours practical education.
89193313|NCT05174975|Experimental|App-based Positive Psychological Intervention group|The intervention will be conducted on the app, including 2-week PPI, diabetes-related health education, physical records, and online consultation.
89193314|NCT05174975|No Intervention|control group|usual care which will educated by certificated educators in terms of self-management
89193315|NCT05172271|Sham Comparator|Sham TEST|Anesthesia alone
89193316|NCT05172271|Experimental|Transcranial Electric Stimulation Therapy (TEST)|TEST involves bifrontal electrical brain stimulation at a dose below the seizure threshold, applied in the same manner as standard electroconvulsive therapy (ECT), with scalp electrodes, under anesthesia, using a standard ECT device (modified or unmodified) that can deliver a range of doses below seizure threshold.
89193317|NCT05169866|Experimental|Intravenous Nifekalant|Patients randomized to Nifekalant arm will receive a bolus of 0.3mg/kg IV in the first 5 minutes and a maintenance dose of 0.2-0.4mg/kg/h for 24 hours. If the patient has a recurrence of atrial fibrillation, the maintenance dose can be increased (up to 0.8 mg/kg/h) according to the patient's condition, or receive a bolus of 3mg/kg again at 2 hours intervals. Nifekalant is administered for 24 hours unless meeting the criteria for discontinuation.
89193318|NCT05169866|Active Comparator|Intravenous Amiodarone|Patients randomized to an amiodarone arm will receive a bolus of 150mg IV in the first 10 minutes and a maintenance dose of 0.5-1mg/min for 24 hours. If the patient has a recurrence of atrial fibrillation, the dosage can be adjusted according to the patient's condition, but the total dosage administered within 24 hours should not exceed 2g. Amiodarone is administered for 24 hours unless meeting the criteria for discontinuation.
89193319|NCT05148052|Experimental|Conventional therapy first|Group receiving conventional occupational therapy first and then virtual reality exergames.
89193320|NCT05148052|Experimental|Virtual reality first|Group receiving virtual reality exergames with virtual reality first and then conventional occupational therapy.
89193321|NCT05144191|Other|Insignia uncemented Hip Stem|"The Insignia™ Hip Stem is a collared stem that features a plasma-sprayed Hydroxyapatite (HA) coating over plasma-sprayed titanium in the proximal region and a plasma-sprayed HA coating over grit blast in the distal region and collar underside.~Insignia™ Hip Stems are intended for 'cement less' use only and are intended for total arthroplasty procedures."
88894735|NCT06076824|Experimental|Intervention group (Glucocorticoid treatment)|
88894736|NCT06076824|Placebo Comparator|Control group|Saline solution (0.9%)
88894737|NCT06076772||1|cases developed neutropenia Grade 0-2 with palbociclib administration
88894738|NCT06076772||2|cases developed neutropenia Grade 3-4 with palbociclib administration
89416891|NCT03597711|Active Comparator|IVCannulation 24G non-safety cannula|Peripheral Intravenous cannulation using 24G non-safety cannula
89416892|NCT03597711|Active Comparator|IVCannulation 26G safety cannula|Peripheral Intravenous cannulation using 26G safety cannula
89416893|NCT03597711|Active Comparator|IVCannulation 24G safety cannula|Peripheral Intravenous cannulation using 24G safety cannula
89416894|NCT04607096|Active Comparator|Prediabetic subjects - cluster 3|Presence of a cluster 3 phenotype will be examined according to the parameters described by Wagner et al.(Nat. Med. 2020).
89416895|NCT04607096|Active Comparator|Prediabetic subjects - cluster 5|Presence of a cluster 5 phenotype will be examined according to the parameters described by Wagner et al.(Nat. Med. 2020).
89416896|NCT04607096|Active Comparator|Patients with type 2 diabetes - subphenotype: Severe insulin-deficient diabetes (SIDD)|Presence of a SIDD phenotype will be examined according to the parameters de-scribed Ahlqvist et al. (Lancet Diabetes Endocrinol. 2018 May;6(5):361-369).
89416897|NCT04607096|Active Comparator|Patients with type 2 diabetes - subphenotype: Severe insulin-resistant diabetes (SIRD)|Presence of a SIRD phenotype will be examined according to the parameters de-scribed Ahlqvist et al (Lancet Diabetes Endocrinol. 2018 May;6(5):361-369).
89416898|NCT02261142|Experimental|Multifocal TENS|Multifocal TENS given in the garment Mollii® (Elektrodress) 1 hour every second day together with individualized training exercises. The steering unit counts down 60 minutes visible for the patient
89416899|NCT02261142|Sham Comparator|Sham treatment|Use of the garment Mollii® (Elektrodress) but without the electrical stimulation combined with the individualized training exercises. The steering unit counts down 60 minutes visible for the patient
89416900|NCT03136263|Experimental|Drug order: Oxytocin - placebo|
89416901|NCT03136263|Experimental|Drug order: Placebo - oxytocin|
89416902|NCT04988542|Experimental|Sleep supplement|Circadian Wellness sleep SL strip nightly for 30 days.
89416903|NCT04988542|Placebo Comparator|Control Group|Participants in the control group will have no intervention and no change in their usual daily routine or supplements. They will be asked to not take any sleep aid supplement during the study period.
89416904|NCT03540186|Experimental|Epigenorm Antivir and acupuncture arm|Epigenorm Antivir is a dietary supplement containing extracts of glycyrrhiza roots, hippophae rhamnoides leaves, curcumin, green tea, and vitamin C. Acupuncture involves inserting needles at certain points of the body.
89416905|NCT02035449||McGrath MAC|McGrath MAC is a videolaryngscope
88894739|NCT06076759|Active Comparator|Intrathecal morphine group (Group M):|• Patients in this group will receive intrathecal morphine (0.5 mg diluted in I ml of normal saline) prior to induction of general anesthesia.
88894740|NCT06076759|Active Comparator|Intrathecal dexmedetomidine group (Group D):|• Patients in this group will receive intrathecal dexmedetomidine (5 mcg diluted in 1 ml of normal saline) prior to induction of general anesthesia.
88894741|NCT06076720|Experimental|New head-mounted visual aids|Wearing different head-mounted visual aids
88894742|NCT06076642|Experimental|TAK-881|"Epoch 1: Participants with anti-rHuPH20 antibody titer <1:160 at all-time points during study TAK-881-3001 and study TAK-881-3002 will receive TAK-881 subcutaneous (SC) infusion at the same dose and same treatment interval as at the last infusion in TAK-881-3001 (NCT05755035) at Week 1 and at Weeks 13 and Week 25 of study TAK-881-3002.~Epoch 2: Participants with anti-rHuPH20 antibody titer >=1:160 at any time point during Study TAK-881-3001 (NCT05755035) and/or Study TAK-881-3002 Epoch 1, will continue receiving TAK-881 every 12 weeks for up to Week 121.~After the first TAK-881 infusion in study TAK-881-3002, the interval and/or the dose may be adjusted only at scheduled site visits at the investigator's discretion."
88894743|NCT06076629|Experimental|Low temperature (16#) group|Subjects in exposure group will be exposed to low temperature (16#) for about 2 hours in a chamber.
88894744|NCT06076629|Sham Comparator|Moderate temperature (22#) group|Subjects in exposure group will be exposed to moderate temperature (22#) for about 2 hours in a chamber.
88894745|NCT06076616|Experimental|Prehabilitation/rehabilitation|Patients in this arm follow a lifestyle counseling programme starting from diagnosis up to 6 months postoperatively.
88894746|NCT06076616|No Intervention|Usual care|Patients in this arm follow usual care.
89193322|NCT05131919|Experimental|pembrolizumab|Treatment with pembrolizumab 200 mg.
89416906|NCT04988854|Experimental|Positive Condition|Children were exposed to a video of adult models eating a single piece of raw broccoli whilst showing a positive facial expression (positive video)
89416907|NCT04988854|Experimental|Neutral Condition|Children were exposed to a video of adult models eating a single piece of raw broccoli whilst showing a neutral facial expression (neutral video)
89416908|NCT04988854|Experimental|No-Food Control Condition|Children were exposed to a video of adult models putting pens away whilst showing a neutral facial expression (no-food control video)
89416909|NCT03601377|Experimental|Training away from threat|"Experiment 1 and 2: In the intervention group -training away from threat-, in all angry-neutral faces presentation the probe is presented only after neutral face. Probe type (< or >) is not factorially counterbalanced but there is equal possibility of presentation for each of the following: angry-face location, probe location, or actor.~Experiment 1: received 8 times (2 times per week for 4 weeks) Experiment 2: received 4 times (2 times for 2 weeks)"
89530779|NCT05560841|Experimental|Nailner 2 in 1|"Nailner Brush 2-in-1 (5ml)~Liquid solution in glass bottle with a brush applicator Topical application twice a day during 4 weeks then once a day until 6 months"
89530780|NCT03107221|Experimental|Intervention|"Access to online self-help programme Smart Eating along with usual treatment from a specialist eating disorder service"
89530781|NCT03107221|No Intervention|Control|Usual treatment from a specialist eating disorder service
89530782|NCT02510651|Experimental|ORSHFS|Melanocyte-keratinocyte suspension.
89530783|NCT03236389|Experimental|Collar Wearing|subjects will wear collar during MRI testing
88894747|NCT06076603||Intravenous combined with nebulized polymyxin B|The intravenous combined nebulization patient group was divided into two subgroups based on the different doses received -25mg q12h and 50mg q12h. Patients in the intravenous combination nebulized polymyxin B group received a total medication dose of 1.25 to 1.5mg/kg, of which 25-50mg was used for nebulization and the remaining portion was used for intravenous administration. The specific method of nebulization is to receive nebulized bronchodilator 30 minutes before nebulization, add 25-50mg of polymyxin B to 5ml of physiological saline for dilution, use a vibrating mesh nebulizer to connect to the patient's ventilator pipeline suction tube, do not change the original ventilator parameter settings, and continue nebulization for 30 minutes. After 30 minutes, regardless of whether there is any residue of the nebulized drug, it will be discarded according to general nursing methods.
88894748|NCT06076603||Intravenous polymyxin group B|This group of patients received intravenous injection of polymyxin B alone, with intravenous doses of 1.25-1.5mg/kg of polymyxin B administered every 12 hours.
88894749|NCT06076590|Experimental|multiple electrolytes solution group|Experimental group drugs: Multiple Electrolytes Injection(II) Manufacturer: B.Braun Melsungen AG Dosage Form: Liquid Specification: 500ml/ bag Ingredients: Per 1000ml contains: sodium chloride 6.799g, potassium chloride 0.2984g, calcium chloride 0.3675g, magnesium chloride 0.2033g, sodium acetate 3.266g, L-malic acid 0.671, sodium hydroxide 0.200g Duration :36 months Storage conditions: airtight storage, storage temperature shall not exceed 25, can not be refrigerated or frozen
88894750|NCT06076590|Active Comparator|saline group|Control group drug: Sodium chloride injection Manufacturer: Hua Run Shuang He Pharmaceutical Co., LTD. Dosage Form: Liquid Specification: 500ml:4.5g Ingredients: Per 1000ml contains sodium chloride 9.0g Duration: 36 months Storage conditions: airtight storage
88894751|NCT06076577|No Intervention|Standard of Care Group|
88894752|NCT06076577|Experimental|Prehabilitation Exercise Group|The exercise arm participants will be asked to complete weekly questionnaires which will take around 10 minutes each week and the exercise program which takes 30 minutes each day.
88894753|NCT06076564||Informants|Informants are individuals who knew someone who had a fatal stimulant overdose. Once a decedent is selected, their records will be reviewed to familiarize the interviewer with the situation of their death. Informants will be identified using contacts that the OCME used during their investigation, death records from the state, or emergency contacts from medical records, followed by recommendations from any of those contacts.
88894754|NCT06076564||Living Persons who use Stimulants|To identify resilience factors and risk reduction strategies among living persons who use stimulants, study staff will conduct interviews with up to 60 adults who use either cocaine or methamphetamine.
88894755|NCT06075459||Implanted patients with Intensity IOLs, 12-24 months previously|Men and women who had implantation on both eyes using Hanita Lenses SeeLens SL IOL, for 12 to 24 months post operation.
88894756|NCT06074367|Experimental|GROUP 1 (2g Vitamin C )|
88894757|NCT06074367|Experimental|GROUP 2 (1g Vitamin C )|
88894758|NCT06074367|Placebo Comparator|Control group|
88894759|NCT06074354|Experimental|MY-RIDE group|
88894760|NCT06074354|Active Comparator|Attention-control group|
88894761|NCT06074341|Experimental|Mindfulness-based relapse prevention|"The MBRP condition will be based on an existing rolling group treatment manual, which consists of eight 60-minute sessions. Each session will begin with a brief mindfulness practice and a discussion of what is mindfulness? and the role mindfulness may play in recovery. The themes are repeated every eight sessions, but in every session the participant is bringing a new direct moment experience to the practices in that session. The groups will also consist of people in various stages of recovery and familiarity with the material, which can make for richer discussions of the material led by the group members themselves. Participants who are randomized to receive rolling MBRP treatment will also have access to the Thrive Recovery smart phone app, which includes audio-guided MBRP meditations for participants to practice in daily life."
88894762|NCT06074341|Active Comparator|Referral to online mutual support groups|The referral group will consist of a brief 1:1 meeting with a research team member who will provide an orientation to online mutual support and discuss the SMART Recovery, Alcoholics Anonymous (AA), and other virtual meeting options and to discuss how to access mutual support via these platforms. Individuals will also have an opportunity to review the process of attending online groups, and will discuss technology issues that might arise during groups. The session will be 20-30 minutes in length.
88894763|NCT06074328|No Intervention|No-VR Group|
89193323|NCT05127434|Experimental|mRNA-1345|Single injection of mRNA-1345 on Day 1.
89193324|NCT05127434|Experimental|Placebo|Single injection of mRNA-1345 matching-placebo on Day 1.
89416910|NCT03601377|Experimental|Training towards threat|"Only for Experiment 2: The second ABMT condition -training towards threat- is identical to the first one with the exception that in all angry-neutral face presentations the symbol is presented only after threat face. In addition, at the beginning of every session participants will be informed that a random number of participants will have to repeat their speech. They will also be informed that this instruction will be given right after the dot probe task completion. This will be done in order for the participants to maintain their state anxiety but repetition of the speech task will not actually happen at this stage.~Experiment 2: received 4 times (2 times for 2 weeks)"
89416911|NCT03601377|Placebo Comparator|Placebo|"Experiment 1 and 2: In the placebo group, angry-face location, probe location and actor are fully counterbalanced with regards to their presentation.~Experiment 1: received 8 times (2 times per week for 4 weeks) Experiment 2: received 4 times (2 times for 2 weeks)"
89416912|NCT02165358||Patients|Patients verified with either becker muscular dystrophy or limb-girdle muscular dystrophy type 2I
89416913|NCT02165358||Controls|Healthy controls matched for age and gender.
89416914|NCT03481088|Other|Functional appliance therapy|"All records, including MRI scans will be collected at three stages and will be traced for various angular and linear measurements to document the alterations within the condyle glenoid fossa complex.~Stage- I (pre-treatment),~Stage- II (after pre-functional therapy)~Stage-III (After 6-8 months of functional appliance therapy that is after correction to Class I molar relation)"
89416915|NCT04983706|Experimental|MRI/Ultrasound Fusion Saturation Biopsy|
89416916|NCT02165436|Placebo Comparator|Control|No gum
89416917|NCT02165436|Active Comparator|Chewing Gum|Bubble gum-flavored sugar-free gum - chew for 15-30 minutes 5 times/day
88894764|NCT06074328|Experimental|VR-Group|
88894765|NCT06074276|Experimental|Almonds|Consumption of almonds 5 times per week
88894766|NCT06074276|Placebo Comparator|Control Snack|Consumption of protein and calorie matched non-nut-based food 5 times per week
88894767|NCT06074250|Experimental|Gutopia|Women in this arm will receive dietary modification, fish oil and probiotics from the time of enrollment till completion of last study visit (12 months postpartum). The dietary modification will be conducted by a dietician that will provide feedback on the participants diet at enrollment, ways to improve diet quality to meet pregnancy needs, and increase prebiotic foods. Weekly follow-ups will be conducted by the research team to ensure dietary target is met and to help address challenges in doing so. The initial dietary consult will be 30-45 minutes long with 10-15 minute for each subsequent follow-up.
89416918|NCT03486548|Sham Comparator|control group|adductor canal block with sham block
89416919|NCT03486548|Experimental|sciatic group|adductor canal block with popliteal sciatic nerve block
89416920|NCT03068338|Active Comparator|Conventional therapy|Intermittent pneumatic compression devices are used for prevention of DVT.
88894768|NCT06074250|Experimental|Gutboost|Women in this arm will receive a daily probiotic and fish oil supplement from the time of enrollment till 1 year postpartum.
88894769|NCT06074250|Experimental|Gutless|Women in this arm will receive fish oil and placebo probiotic from the time enrollment till 1 year postpartum .
88894770|NCT06074250|Active Comparator|Gutnone|Women in this arm will only be receiving standard care by their obstetrician, and a one time, 30 minutes consult on how to improve baseline diet quality to meet pregnancy needs will be provided by a dietician at the time of enrollment.
88894771|NCT06074224|Experimental|Clinician with Scores|The patients in the intervention group will include those for whom their clinician was given their sleep questionnaire result before the visit.
88894772|NCT06074224|Active Comparator|Clinician without Scores|The control group will include patients whose clinicians do not view the results, simulating usual care.
88894773|NCT06074172|Placebo Comparator|Placebo (visit 1 drug administration)|246mg Placebo, oral, single-dose (visit 1 drug administration)
88894774|NCT06074172|Active Comparator|Cannabidiol (visit 1 drug administration)|246mg Cannabidiol, oral single-dose (visit 1 drug administration)
89416921|NCT03068338|Experimental|Robotic Sock|Soft robotic actuator used in a sock design technology to perform plantarflexion and dorsiflexion of the foot about the ankle joint.
89416922|NCT02255448|Other|SV1, SV2|SV1 intervention: stroke volume using transthoracic echo SV2 intervention: stroke volume measured using the esCCO device.
89416923|NCT02870816|Active Comparator|Tissue engineered skin substitute|Application of tissue engineered skin substitute with Dressing Application, to be changed weekly following surgical debridement. Patient will practice Offloading. If the ulcer has not closed completely, an additional application of skin substitute will be applied weekly at weeks 2-11.
89416924|NCT02870816|Experimental|Amnionic membrane graft|Application of amnionic membrane graft with Dressing Application, to be changed weekly following surgical debridement. Patient will practice Offloading. If the ulcer has not closed completely, an additional piece of amnionic membrane graft will be applied weekly at weeks 2-11
89416925|NCT03540108|Experimental|Experimental: L. plantarum ECGC 13110402 (LPLDL®)|Lactobacillus plantarum ECGC 13110402 (LPLDL®) equivalent to 4 x10^9 CFU (0.1 g) with the addition of filling carrier (0.12 g; 30% w/v maltodextrin and 5% w/v sucrose) as a capsular format (vegetable) to be consumed once a day, after lunch with 250mL of water.
89193325|NCT05127434|Experimental|mRNA-1345 BD|Single injection of mRNA-1345 on BD Day 1.
89193326|NCT05126888|Experimental|SCI-110|Cannabinoid-based medication consisting of Dronabinol and PEA
89416926|NCT03540108|Placebo Comparator|Placebo Comparator: Maltodextrin|Maltodextrin (an oligosaccharide without prebiotic effect) (0.12 g; 30% w/v maltodextrin and 5% w/v sucrose) as a capsular format (vegetable) to be consumed once a day, after lunch with 250mL of water.
89193327|NCT05126888|Placebo Comparator|Dronabinol|Placebo matched in taste, odour and appearance to SCI-110
89416927|NCT04988230|Experimental|Time Restricted Feeding|Participants will receive a diet of 1500-1800kcal/d for men and 1200-1500kcal/d for women during a window of 8 h/d (8 am to 4 pm).
89416928|NCT04988230|Active Comparator|Continuous Energy Restriction|Participants will follow receive a diet of 1500-1800kcal/ d for men and 1200-1500kcal/d for women, without restriction on feeding time.
88894775|NCT06074159|Other|In-clinic report-back|200 participants receive their personal exposure results from a clinician
89416929|NCT02168790|Experimental|Amniotic membrane ring|Application of amniotic membrane device for 6-7 days.
89416930|NCT04983160|Active Comparator|Allopurinol|
89416931|NCT04983160|Placebo Comparator|Placebo|
89416932|NCT02255526||Healthy Volunteers|Healthy volunteers between the ages of 18 and 80 will wear BodyGuardian remote monitoring system to help validate respiration and activity levels.
88894776|NCT06074159|Other|Online|200 participants receive their personal exposure results from a website online
88894777|NCT06074107|Experimental|BEBT-908 for injection|BEBT-908 for injection, dosage form: injection, specification: 25mg, administration method: the initial dose was 22.5mg/m2, intravenous drip, 3 times a week, 21 days as a cycle, 6 cycles as the total treatment cycle.
88894778|NCT06074094|Experimental|probiotic group|Healthy lifestyle habits and standard diet was recommended for participants ,Probiotic supplementation (Lacteol fort 10 billion) which contains culture medium and lactobacillus LS as active ingredients was administered in the form of oral sachets once daily for 12 weeks.
88894779|NCT06074094|Active Comparator|standard treatment group|Healthy lifestyle habits and standard diet was recommended for participants ,
89199152|NCT05954754|Experimental|Diaphragmatic breathing exercise|Diaphragmatic breathing exercise training was given individually to each pregnant women in the experimental group by one of the trained researchers. Two weeks after the first application, the researcher made the pregnant woman repeat the application 2 days a week via video call. Thus, a total of five diaphragmatic breathing exercises were applied to pregnant women in the experimental group during two weeks. They continued to do breathing exercises for 20-30 minutes a day for ten minutes each day for two weeks as they could tolerate.
89416933|NCT02255526||Heart Failure|Heart failure patients between the ages of 18 and 80 will wear BodyGuardian remote monitoring system to help validate respiration and activity levels.
89416934|NCT04455412|No Intervention|control group|Conventional ICSI procedure was done for first portion of sibling oocytes
89416935|NCT04455412|Experimental|Study group 1|Laser assisted drilling ICSI procedure was done for second portion of sibling oocytes
89416936|NCT04455412|Experimental|Study group 2|Laser assisted thinning ICSI procedure was done for Third portion of sibling oocytes
89416937|NCT03070288||Group 1|Red-green-blue measurements of nasal mucosa images of patients with allergic rhinitis
88894780|NCT06074081|Experimental|motor relearning program|Patients in this group will receive treatment through Motor-relearning programme. Patients will be instructed to perform multiple task like holding object, elbow extension/flexion and multiple movements of shoulder joint. This group will receive MRP for about time duration of 4 weeks,3 days per week,2 hours session per day.
89416938|NCT03070288||Group 2|Red-green-blue measurements of nasal mucosa images of normal healthy individuals
89416939|NCT05635942|Experimental|optimized quadruple therapy (Qo-14)|patients allocated to experimental group receive an optimized quadruple therapy (Qo-14) including 3 grams of Amoxicillin plus standard dose of clarithromycin, metronidazole and esomeprazole for 14 days.
88894781|NCT06074081|Other|mirror therapy|Patient in this group will receive treatment through mirror therapy. Patient will sit in such a way that the mirror will be placed in perpendicular direction on a table. Sound limb will place in front of mirror and affected limb will place behind the mirror. Patient will receive visual feedback from sound limb. This group will receive MT for about 4 weeks, 3 days per week, 2 hours session per day.
89416940|NCT05635942|Active Comparator|standard quadruple therapy (Qs-14)|patients allocated to this group receive standard quadruple therapy (Qs-14) including : amoxicillin 1g twice daily ,clarithromycin 500mg twice daily ,metronidazole 500mg twice daily and esomeprazole 40 mg twice daily for 14 days
89416941|NCT04987684|Other|Standard of Care|
89416942|NCT02759016|Experimental|BI 836826|BI 836826 administered in combination with Standard of Care Ibrutinib
89416943|NCT02169024|Experimental|Expect With Me group prenatal care|receiving prenatal care through an Expect With Me group
89416944|NCT02169024|Active Comparator|Individual Care Only|Standard of Care- individual prenatal care
89416945|NCT02165592||Patients with hemophilia|Patients with hemophilia who meet the inclusion criteria
89006090|NCT00217412|Experimental|Arm I|Group 1 (solid tumor or lymphoma patients): Patients receive oral SAHA once daily on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.Cohorts of 3-6 patients receive escalating doses of SAHA until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. An additional 6 patients may be treated at the MTD.
89006091|NCT00217412|Experimental|Arm II|Group 2 (leukemia patients): Patients receive SAHA as in group 1 at the MTD.
89416946|NCT02169102|Other|Control|
89006092|NCT00217412|Experimental|Arm III|Group 3 (select solid tumor patients): Patients receive oral isotretinoin twice daily on days 1-14. Patients also receive SAHA once daily on days 1-28 OR once on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.The MTD of SAHA is determined as in group 1. An additional 6 patients may be treated at the MTD.
89006093|NCT04646824|Experimental|ahead|A110 mg QD and platinum-based chemotherapy. A 110 mg in combination with pemetrexed (500 mg/m2) plus cisplatin (75 mg/m2) or carboplatin (AUC5) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by A 110mg daily with pemetrexed maintenance (500 mg/m2) every 3 weeks. Dose may be reduced to allow for the management of IP related toxicity.
89416947|NCT02169102|Sham Comparator|Sham Laser|
89193328|NCT05126849|Experimental|Haploidentical allogeneic hematopoietic stem cell transplantation.|"Conditioning regimen Fludarabine (30mg/m2/day i.v: day -6 to day -2), pre-transplant cyclophosphamide (14.5 mg/kg/day i.v: day -6 and day -5), and Total Body Irradiation (2 Gray on day-1)~Stem cell source Bone Marrow~GVHD Prophylaxis Rabbit ATG dosed at 0.5 mg/kg on day -9 and 2 mg/kg on days -8 and -7, Cyclophosphamide 50 mg/Kg/day at D+3 and D+4, Tacrolimus (residual 8-12 microg/L) and mycophenolate (MMF) from D+5. In absence of GvHD, MMF will be stopped at D35 and tacrolimus at day 365.~Prevention of EBV reactivation Rituximab 150mg/m2 intravenously at Day+5 post HSCT, Each infusion of Rituximab will be preceded by administration of anti-pyretic and an antihistaminic, e.g. paracetamol and diphenhydramine."
89416948|NCT02169102|Experimental|Laser 1|Low Power Laser applied at 0.16 Joules/point. 2 points of laser irradiation
89416949|NCT02169102|Experimental|Laser 2|Low Power Laser applied at 16 Joules/point. 2 points of laser irradiation
89416950|NCT02852967|Experimental|Belumosudil 200 mg QD + Placebo|One belumosudil 200 mg tablet and 1 matching placebo tablet in the morning and 1 matching placebo tablet in the evening
89416951|NCT02852967|Experimental|Belumosudil 200 mg BID (Twice Daily) + Placebo|One belumosudil 200 mg tablet and 1 matching placebo tablet in the morning and 1 belumosudil 200 mg tablet in the evening
89416952|NCT02852967|Experimental|Belumosudil 400 mg QD + Placebo|Two belumosudil 200 mg tablets in the morning and 1 matching placebo tablet in the evening
89416953|NCT02852967|Experimental|Belumosudil 600 mg/day|Two belumosudil 200 mg tablets in the morning and 1 belumosudil 200 mg tablet in the evening
89416954|NCT02852967|Placebo Comparator|Placebo|Two matching placebo tablets in the morning and 1 matching placebo tablet in the evening
89416955|NCT02162316|Active Comparator|H.Pylori eradication therapy|A-cillin®, Pantoline® and Clari® is administered with a tablet of placebo (Motilitone®)
89416956|NCT02162316|Experimental|Motilitone®|30 mg is administered with 3 tablets of placebo (Patoline®, Clari® and A-cilin)
89416957|NCT02162394||Referred for Holter monitoring|
89416958|NCT02169180|Experimental|Ibrutinib|Participants will receive ibrutinib capsules 560 milligram (mg) orally, once daily on a 28-day cycle up to 7 cycles or until disease progression (or relapse if the participant achieved a complete response [CR]), unacceptable toxicity, or end of treatment, whichever occurs first.
89416959|NCT03593044|Experimental|One Week Atropine|0.01% concentration atropine drops
89416960|NCT03597087|Experimental|General anesthesia|Group of general anesthesia before transurethral resection of the bladder tumor anesthesia: propopol
89416961|NCT03597087|Experimental|Spinal anesthesia|Group of spinal anesthesia before transurethral resection of the bladder tumor anesthesia: bupibacaine
89416962|NCT02169258|Placebo Comparator|Selective Strategy|non-invasive evaluation of possible myocardial ischemia by using DSE or dTS followed by coronary angiography if the test is positive for ischemia
89416963|NCT02169258|No Intervention|Registry|Clinical decisions are reached by consensus of operators, patients and family as usual care
89416964|NCT02169258|Active Comparator|Systemic Strategy|Routine coronary angiography before PTA without a previous non-invasive stress test
89416965|NCT03603327|Other|Treatment|All subjects will receive a standard of care treatment- Direct acting anti-viral agents Drugs
89416966|NCT05635630|Experimental|ctDNA positive|
89193329|NCT05123482|Experimental|Sub-Study 1 AZD8205 Monotherapy|"Sub-Study 1 has two parts:~Part A : The aim is to determine the safety, tolerability, Recommended Phase 2 Dose(RP2D), and/or the Maximum Tolerated Dose (MTD) of AZD8205.~Part B: The aim of dose expansion is to evaluate anti-tumor activity of AZD8205 as monotherapy in select solid tumors."
89416967|NCT05635630|Experimental|ctDNA negative|
89416968|NCT03596775|Experimental|Dexmedetomidine group|the children received 0.5 μg/kg of intravenous dexmedetomidine over 10 minutes after induction of anesthesia
89416969|NCT03596775|Placebo Comparator|Control Comparator group|the children received 10ml saline over 10 minutes after induction of anesthesia
89416970|NCT03601299|Experimental|Traditional food arm|Traditional food-focused menu
89416971|NCT03601299|No Intervention|Non-intervention arm|Standard RurAL CAP menu
88894782|NCT06074042||tuberculosis-associated COPD|"COPD patient who meets any of the following criteria is diagnosed as tuberculosis-associated COPD:~previously definite pulmonary tuberculosis and ever receiving standard antituberculosis therapy;~previously suspected pulmonary tuberculosis and having typical radiological findings consistent with tuberculosis sequelae;~no definite history of pulmonary tuberculosis but having positive T-SPOT.TB test accompanied with typical radiological findings consistent with tuberculosis sequelae."
88894783|NCT06074042||non-tuberculosis associated COPD|COPD patient in whom neither medical history nor chest CT indicates evidence of pulmonary tuberculosis is diagnosed as non-tuberculosis associated COPD.
88894784|NCT06073990|Experimental|Brief Behavioral Treatment for Insomnia (BBTi)|In the post-intervention group, the investigators collected data at the 1-week, 2-week, and 3-week marks following the intervention.
88894785|NCT06073964|Experimental|TRUST Intervention group|Formerly Internally Displaced Persons living in Lira district, northern Uganda afflicted with primary trauma and experiencing domestic violence will be trained in the community-based utilization of the 'Trauma Resilience & Understanding Self-help Therapy'.
88894786|NCT06073964|No Intervention|Control group|Age and gender cross-matched formerly Internally Displaced Persons living in Lira district, northern Uganda afflicted with primary trauma and experiencing domestic violence will not be trained in the community-based utilization of the 'Trauma Resilience & Understanding Self-help Therapy'.
88894787|NCT06073925|Active Comparator|chronic ITP children with VD level less than 30 ng/ml.|will receive VD 3 50000 IU per week for 3 months beside their treatment for ITP.
88894788|NCT06073925|Active Comparator|chronic ITP children with VD level more than 30 ng/ml.|will receive VD 3 50000 IU per week for 3 months beside their treatment for ITP.
88894789|NCT06073925|No Intervention|Placebo|will receive their treatment for ITP.
88894790|NCT06073912|Experimental|Autogenous corticocancellous block|Autogenous bone graft harvested as a block from the chin area
88894791|NCT06073912|Active Comparator|Mineralized plasmatic matrix|Mix of patient's PRP and autogenous particulate graft
88894792|NCT06073873||Participants with moderate to severe active ulcerative colitis treated with ozanimod|
89416972|NCT03066466|Experimental|Arm A: Atorvastatin|The preventative atorvastatin treatment 40mg daily by mouth for GVHD will start at 14 days prior to transplant & continue until 365 days post-transplant or if significant adverse events occur. Patients will also receive our standard of care for graft versus host disease prevention which consists of two drugs, Methotrexate and Tacrolimus. For all matched unrelated donor allogeneic transplantation patients, the following schedule of Methotrexate 5mg/metered square will be administered IV post-transplant on Days 1, 3 & 6. Tacrolimus will be administered 2 days prior to transplant & continue approximately 180 days post-transplant. Tacrolimus 0.03 mg/kg daily will be administered IV until patient can take it by mouth.
89530784|NCT03121313|Experimental|Maintenance|"Eligible patient will be given maintenance tegafur-uracil for one year.~Dose of tegafur-uracil will be based on patient's body surface area (BSA):~BSA < 1.5 m2: tegafur-uracil 300 mg/day (1 capsule three times a day)~BSA ≥ 1.5 m2: tegafur-uracil 400 mg/day (2 capsules twice a day) Tegafur-uracil will be started after patient has complete the adjuvant radiotherapy and been enrolled into the study."
89530785|NCT03236233|Experimental|Single dose - healthy subjects|
88894793|NCT06073860||Participants with myelodysplastic syndrome or beta thalassemia who will begin luspatercept treatment|
89416973|NCT03066466|Active Comparator|Arm B: Standard of Care|Patients will receive our standard of care for graft versus host disease prevention which consists of two drugs, Methotrexate and Tacrolimus. For all matched unrelated donor allogeneic transplantation patients, the following schedule of Methotrexate 5mg/metered square will be administered IV post-transplant on Days 1, 3 & 6. Tacrolimus will be administered 2 days prior to transplant & continue approximately 180 days post-transplant. Tacrolimus 0.03 mg/kg daily will be administered IV until patient can take it by mouth.
88894794|NCT06073847||Participants with myelofibrosis receiving fedratinib|
88894795|NCT06073808|Experimental|Assess dHACM viability|Implantation of dHACM in patients during Nipple Sparing Mastectomy; test arm. The device will be implanted in one breast per patient during bilateral nipple sparing mastectomy.
88894796|NCT06073808|Active Comparator|Assess dHACM effectiveness against control device|Implantation of control device in patients during Nipple Sparing Mastectomy; control arm. The device will be implanted in one breast per patient during bilateral nipple sparing mastectomy.
88894797|NCT06073795||FL group|Patients will receive FL-guided LSGB with 10 mL of 0.25% bupivacaine.
88894798|NCT06073795||US group|Patients will receive US-assisted LSGB with 10 mL of 0.25% bupivacaine.
88894799|NCT06073769||Participants receiving oral azacitidine maintenance therapy|
88894800|NCT06073756||1|Type 2 diabetes mellitus (T2DM) patients with good glycemic control and have HBA1C <7and ages ranging from ≥18 old.
88894801|NCT06073756||2|Type 2 diabetes mellitus (T2DM) patients with poor glycemic control and have HBA1C ≥7 and ages rang from ≥ 18 years old
88894802|NCT06073730|Experimental|Venetoclax in combination with Decitabine (+-sorafenib)|Venetoclax (VEN) 100mg d1, 200mg d2, 400mg d3-14 Decitabine (DEC) 20mg/m2/q8h, d4-6 (infusion time >2h) Sorafenib 600mg/d, d8-14 (FLT3/ITD mutation positive patients)
89416974|NCT03603249|Experimental|Clopidogrel and Trimetazidine Arm|Patients on DAPT for at least 6 months will be tested for platelet function testing with the P2Y12 VerifyNow assay at baseline. The patients will then undergo at least a 2-week course of Trimetazidine 35 mg/q12h, followed thereafter by platelet function testing.
89416975|NCT03603171||DM2 group|Patients with Myotonic Dystrophy type 2 genetically confirmed, without limitation regarding age or disease onset.
89535893|NCT04991727||ZEEP|"The patient was admitted to the operating room, and routine ECG monitoring was performed. The patient was placed in supine position, and ultrasound lung examination was performed. The images of the patient were saved and the score of lung ventilation area was recorded. The induction of general anesthesia was started, and endotracheal intubation was performed after 3min of preoxygenation (100% O2) to establish a safe and effective artificial airway. Mechanical ventilation was performed after endotracheal intubation, and a second time was performed immediately after endotracheal intubation was completed~On pulmonary ultrasound, patients in the ZEEP group maintained normal mechanical ventilation throughout the operation without PEEP or RMS"
89535894|NCT02484365||single arm study|No treatment or intervention will given to the patients
89535895|NCT03119467|Experimental|Single arm|RP4010 to be administered
89535896|NCT03315767|Other|cirrhosis patients|"ARFI-elastography and portal vein flow measurement: Liver and spleen of patients with a scheduled HVPG-investigation will be examined by an ARFI-elastography-investigation. Additionally the portal vein flow will be assessed.~This examination will be done at d0 before the start of beta-blocker-administration and repeated as monitoring for portal hypertension treated by beta-blocker after 6 and 12 weeks, respectively.~HVPG-measurement: HVPG-values will be assessed at d0, after 6 and after 12 Weeks, respectively."
89535897|NCT04999137|Experimental|Intravenous vitamin C 1.5g + intravenous vitamin B1|intravenous vitamin C (1.5 grams) every 6 hours for 16 doses in combination with intravenous vitamin B1 (200 mg) every 12 hours
89535898|NCT04999137|Experimental|Intravenous Vitamin C 3g + intravenous vitamin B1|Intravenous vitamin C (3 grams) every 6 hours for 16 doses in combination with intravenous vitamin B1 (200 mg) every 12 hours
89535899|NCT04999137|No Intervention|Usual Care|Usual care
89535900|NCT02451163|Active Comparator|polysaccharides from wheat|12.0 g powder containing 10.0 g active ingredient (wheat polysaccharides) as well as 2.0 g filling substance (maltodextrin) stirred in milk or filtered apple juice (200 ml each).
89535901|NCT02451163|Placebo Comparator|control product|12.0 g maltodextrin stirred in milk or filtered apple juice (200 ml each).
89535902|NCT02484053|Experimental|Rheumatologic disease|Rituximab is administered over 120 minutes, 12.5% of the dose will be given over the first 30 minutes and the remaining 87.5% of the dose will be given over 90 minutes.
89535903|NCT02484053|Experimental|Cancer or blood disorder|Rituximab is administered over 90 minutes, 20% of the dose will be given over the first 30 minutes and the remaining 80% of the dose will be given over 60 minutes.
89535904|NCT03200821|Experimental|G17DT|250 µg/0.2 mL administered by intramuscular injection at Weeks 0, 2 and 6. 125 µg booster administered at Week 24.
89535905|NCT03200821|Active Comparator|Gemcitabine|1000 µg/m^2 intravenously administered once weekly for seven weeks starting at Week 0 followed by one week of rest. After, treatments will occur in cycles of 3 weeks of treatment followed by one week of rest.
89535906|NCT02635737|Experimental|Sentimark device placement|Sentimark device placed in women having mastectomy surgery
89535907|NCT03200743||Hpertension|
89535908|NCT03200743||Health|
89535909|NCT03072615||1|receiving TE before and 30 min after TIPS
89535910|NCT03072615||2|receiving SWE before and 7 days, 6 weeks and 3 months after TIPS
89535911|NCT02483897|Experimental|Tetracaine 0.5% ophthalmic drops|0.8 mls. drops provided to be used hourly p.r.n. for pain control
89535912|NCT02483897|Placebo Comparator|placebo (Normal Saline placebo drops)|0.8 mls. drops provided to be used hourly p.r.n. for pain control
89535913|NCT03203083||physically active individuals|subjects who perform sports activities more than 6 hours per week
89535914|NCT03203083||non-physically active individuals|subjects who perform less than 2 hours per week of sport activities
89535915|NCT03200899|Experimental|Memory, Attention, Problem Solving Skills in MS (MAPSS-MS)|Participants randomized to this arm receive the MAPSS-MS intervention. The MAPSS-MS is an an 8 week computer assisted cognitive rehabilitation intervention. The group based component of the intervention emphasizes use of compensatory cognitive strategies as well as lifestyle modifications to enhance cognition. Participants also complete home computer training (minimum 3 times per week for 45 minutes) using a special suite of games designed by Lumosity.
89006094|NCT04646629|Experimental|electroacupuncture treatment|"Participants in the treatment group underwent 60 minutes acupuncture (0.30mm×70mm) at ST36 (Zusanli) and ST37 (Shangjuxu) twice a day for seven days. AfterDeqi,electroacupuncture stimulation apparatus (HANS G6805-2, Huayi Co, Shanghai, China) isconnected and maintained the end of treatment"
89416976|NCT03603171||Healthy controls group|A group of gender and age-matched healthy controls.
89416977|NCT03068260|Active Comparator|Active|"Active bilateral ultrasound-guided transmuscular quadratus lumborum (TQL) block. 60 ml ropivacaine 0,375% single shot.~In both arms, the participants receive 1g Acetaminophen and 400 mg Ibuprofen / 100 mg Celebra. Morphine will be administered IV as part of a PCA-pump regimen or additionally after contact with the nursing staff as it is the standard treatment."
89416978|NCT03068260|Placebo Comparator|Placebo|"Placebo bilateral ultrasound-guided transmuscular quadratus lumborum (TQL) block. 60 ml saline single shot.~In both arms, the participants receive 1g Acetaminophen and 400 mg Ibuprofen / 100 mg Celebra. Morphine will be administered IV as part of a PCA-pump regimen or additionally after contact with the nursing staff as it is the standard treatment."
89416979|NCT02762994|Experimental|BCD-085, 40 mg|Patient will receive 40 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.
89416980|NCT02762994|Experimental|BCD-085, 80 mg|Patient will receive 80 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.
89193330|NCT05121597|Experimental|Videolaryngoscope Group|The group that we will use a videolaryngoscope for nasotracheal intubation.
89416981|NCT02762994|Experimental|BCD-085, 120 mg|Patient will receive 120 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.
89416982|NCT02762994|Placebo Comparator|Placebo|Patient will receive placebo subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.
89416983|NCT05635552||PCS patients|Patients with a COVID-19 infection at least 3 months ago (positive PCR or rapid antibody test) and PCS typical symptoms (e.g. fatigue, breast pain, heart palpitations, cognitive impairment) ongoing for at least 2 months and which cannot be explained by an alternative diagnosis.
89416984|NCT05635552||COVID-19 recovered participants|Participants with Sars-CoV-2 infection at least 3 months ago (positive PCR or positive rapid antibody test) which are fully recovered.
89416985|NCT05635552||COVID-19 infection naïve|"No history of COVID-19 infection (exclusion via measurement of specific antibodies).~Consists of an already established, pre-pandemic healthy cohort and a cohort recruited during the pandemic."
89416986|NCT03603015|Other|Pilot group: urodynamics and cuff test|Single-arm study with all participants undergoing cystometrogram, then cystometrogram with simultaneous penile cuff test, then penile cuff test alone
89416987|NCT02165982||Patients controles|Inpatients suffering from anorexia nervosa at Institut Mutualiste Montsouris
89416988|NCT02165982||Individus sains témoins|Healthy controls selected from the general population
89416989|NCT03070834|Experimental|rIVCF|Randomized to receive insertion of retrievable inferior vena cava filter until chemical anticoagulation can be safely administered.
89416990|NCT03070834|No Intervention|Standard Care|Randomized to not receive insertion of retrievable inferior vena cava filter.
89416991|NCT02165514|Experimental|Lunar iDXA (DEXA) scan|Spinal scans taken by DEXA scanner
89416992|NCT03601065||Routine colonoscopy Cohort|
89416993|NCT02166060|Experimental|Ivabradine|Ivabradine 5 mg twice a day or 7,5 mg twice a day
89193331|NCT05121597|Active Comparator|Control Group|The group that we will use a direct laryngoscope for nasotracheal intubation.
89193332|NCT05120856|Experimental|Active AAT-App|Participants will receive the active AAT-App.
89193333|NCT05120856|Sham Comparator|Minimal AAT-App|Participants will receive the minimal version of AAT-App.
89416994|NCT03305614|Active Comparator|Aphasia therapy and tDCS|combined tDCS and aphasia therapy and the effect of conventional intensive aphasia
89416995|NCT03305614|Sham Comparator|Aphasia therapy and sham-tDCS|computer-based intensive aphasia therapy as measured by specific linguistic tests
88894803|NCT06073730|Active Comparator|Standard dose of Venetoclax + Azacitidine|Venetoclax (VEN) 100mg d1, 200mg d2, 400mg d3-28 Azacitidine (AZA) 75mg/m2/d, d3-9
88894804|NCT06073691|Experimental|Exercise intervention|On each training day, the activity started with a 5-minute stretching and warm-up session; then, a 15-minute walk at 65% of the maximum heart rate (MHR), followed by a 30-second run at 85% MHR, and finally another 15-minute walk at 65% MHR. The running time was gradually increased in individualized and supervised sessions. The exercise intensity was predetermined based on the patient's baseline cardiopulmonary function, and the heart rates (HR) were assessed using a Polar RS300X heart rate monitor.
88894805|NCT06073691|Placebo Comparator|Placebo|The participants might receive an active pharmacological treatment or a matching placebo
88894806|NCT06073678|Experimental|Photobiomodulation|Red laser irradiation on palate wound at the day of the surgery and after 2, 4 and 6 days postoperatively. Protection of wound with surgical dressing during 7 days.
88894807|NCT06073678|Active Comparator|Control|Protection of wound with surgical dressing during 7 days.
88894808|NCT06073639|Experimental|Dentin graft|
88894809|NCT06073639|No Intervention|Conventional|
88894810|NCT06073613||control group|healthy individuals, aged 18 years or older and free of chronic skin diseases, willing to participate in the study
88894811|NCT06073613||Patients with CSDs|Patients with CSDs (psoriasis, atopic dermatitis, autoimmune bullous diseases, or systemic lupus erythematosus,…) were diagnosed by the dermatologists with over 5 years of experience and supportive laboratory tests, aged 18 years or older, and willing to participate in the study
88894812|NCT06073587||ION-682884-CS2 Scintigraphy Subset|Participants randomized in ION-682884-CS2 (NCT04136171) study to receive either eplontersen or placebo with baseline scintigraphy scan with planar and single-photon emission computerized tomography (SPECT) or SPECT with computed tomography (SPECT/CT) images will undergo an optional scintigraphy scan at Weeks 25 or 37, Week 97, and an additional scan at Week 140.
88894813|NCT06073574||Experimental: ION-682884-CS2 MRI Scan Sub-set|Participants enrolled in the parent study ION-682884-CS2 (NCT04136171) to receive either eplontersen or placebo and who consented to participate in this sub-study will undergo cardiac MRI at Baseline, Weeks 25, 49, 97 and 140.
88894814|NCT06073483|Experimental|5G remote gastrectomy|
89193334|NCT05120713||Young Adults|Young Adults aged 18-35
89193335|NCT05120713||Older Adults|Older Adults aged 50-80
88894815|NCT06073392|Experimental|Intervention Group 1 (IG1)|Subjects in IG1 will be given a animation video screening in a specific room. IG1 intervention is on one topic cover only. The animation educational video covers on the topic of effective toothbrushing technique.
88894816|NCT06073392|Experimental|Intervention Group 2 (IG2)|Subjects in IG2 will be given a animation video screening in a specific room. IG2 intervention is on two topics cover only. The animation educational video covers on the topic of effective toothbrushing technique and effects of sugary diet.
88894817|NCT06073392|Experimental|Intervention Group 3 (IG3)|Subjects in IG3 will be given a animation video screening in a specific room. IG3 intervention is on two topics cover only. The animation educational video covers on the topic of effective toothbrushing technique, and dental caries.
88894818|NCT06073392|Experimental|Intervention Group 4 (IG4)|Subjects in IG4 will be given a animation video screening in a specific room. IG4 intervention is on three topics cover. The animation educational video covers on the topic of effective toothbrushing technique, effects of sugary diet, and dental caries.
88894819|NCT06073327|Experimental|Dark Chocolate|Dark chocolate group was provided with 30g of dark chocolate (high in flavanol) for 30 days
88894820|NCT06073327|Sham Comparator|White Chocolate|White chocolate group was provided with30g of white chocolate (0 mg/g of polyphenol) for 30 days
89193336|NCT05117294|Experimental|Bocidelpar (ASP0367): Severe Renal Impairment|Participants with severe renal impairment will receive a single dose of Bocidelpar (ASP0367) under fasting conditions on day 1.
89193337|NCT05117294|Experimental|Bocidelpar (ASP0367): Moderate Renal Impairment|Participants with moderate renal impairment will receive a single dose of Bocidelpar (ASP0367) under fasting conditions on day 1.
89193338|NCT05117294|Experimental|Bocidelpar (ASP0367): Mild Renal Impairment|Participants with mild renal impairment will receive a single dose of Bocidelpar (ASP0367) under fasting conditions on day 1.
89193339|NCT05117294|Experimental|Bocidelpar (ASP0367): Normal Renal Function|Participants with normal renal function will receive a single dose of Bocidelpar (ASP0367) under fasting conditions on day 1.
89193340|NCT05115838|Experimental|Islatravir 47 mg|Participants receive an ISL 47 mg implant for approximately 52 weeks. A subset of participants will receive a second implant for 12 weeks after removal of the first implant.
89530786|NCT03236233|Experimental|Repeat dose - healthy subjects|
89530787|NCT03236233|Experimental|Single dose - subjects with asthma|
89416996|NCT03600987|Experimental|Music and reading lyrics|A single-subject adapted alternating treatment design will be used to compare two music conditions, using music with sung lyrics simultaneously with silent reading of the lyrics, and priming with music and sung lyrics followed by reading of the lyrics, with a control condition using reading materials without music.
89416997|NCT05635474|Experimental|dietary supplement|According to the 2018 statistics of the American Association of Liver Diseases, about 25% of the world's population has non-alcoholic fatty liver disease. Bacillus coagulans does not exist in intestinal microbiota, because it has characteristics of spore production and lactobacillus lactic acid production, and has the ability to maintain the health of intestinal bacteria, acid and alkali resistance, With the advantages of high temperature resistance and high stability, it is currently one of the commonly used probiotic strains. Clinical studies have shown that after intervention of a single Bacillus coagulans strain in patients with non-alcoholic fatty liver disease, the problem of liver fat accumulation and inflammation can be significantly improved, so supplementing Bacillus coagulans TCI711 probiotics isolated from apples may improve Functions of liver and gut microbiota in patients with nonalcoholic fatty liver disease.
88894821|NCT06073288||Crohn's Disease (CD)|"15 CD patients (5 patients/stage: (B1 (more inflammatory, non-structuring), B2 (structuring, non-penetrating) and B3 (structuring and penetrating).~Patient stratification is based on previous classifications done in accordance with the standard of care through TC, RMI or Ecography. For this reason, patients classification is known before surgery."
89193341|NCT05115838|Experimental|Islatravir 52 mg|Participants receive an ISL 52 mg implant for approximately 52 weeks. A subset of participants will receive a second implant for 12 weeks after removal of the first implant.
89416998|NCT05635474|Placebo Comparator|placebo|The placebo was also given in the form of capsules, the main ingredients were maltodextrin, silicon dioxide and magnesium stearate
88894822|NCT06073288||non-Intestinal Bowel Disease patients (no-IBD)|5 patients without IBD-related diseases (ex. diverticulitis)
89416999|NCT02237859|Experimental|Vancomycin|Vancomycin 125 mg PO QD vs Placebo
89530788|NCT02510729|Active Comparator|SPG neurostimulation|Sphenopalatine ganglion (SPG) neurostimulation of 20 Hz
88894823|NCT06073236|Experimental|Intervention group|The intervention group will receive what came out of the co-creation sessions with preschoolers' teachers and parents.
88894824|NCT06073236|No Intervention|Control group|No intervention will be given in the control group, but they will receive the intervention after follow-up. Afterwards, teachers and parents can keep the intervention materials as an incentive.
89530789|NCT02510729|Placebo Comparator|Sham Stimulation|Sham stimulation with amplitude=0
89530790|NCT03235999||Talc pleurodesis|Up to 10 patients who have had talc pleurodesis
89530791|NCT03235999||IPC|Up to 10 patients who have had indwelling pleural catheters (IPC)
89193342|NCT05115838|Experimental|Islatravir 57 mg|Participants receive an ISL 57 mg implant for approximately 52 weeks. A subset of participants will receive a second implant for 12 weeks after removal of the first implant.
89417000|NCT02166138|Experimental|Laser treated Group|Patients in this group will be given the laser treatment with the non-abilative 1540 nm wavelength. Patients will be blinded to this procedure as they will be wearing protective eye wear and noise canceling headphones. These patients will undergo the treatment 3 times, one at day of discharge, second at the 4 week follow up visit, and third at the 8 week follow up visit. After the 8 week follow up visit, patients will be asked to come in for the 3 month follow up visit and 1 year follow up visit for an evaluation. At each visit, the patient's scar will be photograph for evaluation. Each patient will also be asked to fill out the POSAS, and KOOS at each follow up visits. Thus, patients in this group will be getting the Non-Abilative laser treatment.
89417001|NCT02166138|Placebo Comparator|Not Laser treated Group|Patients in this group will be given the laser treatment with the 1540 non-abilative laser device, but the device will not be set to provide treatment. Patients will be blinded to this procedure as they will be wearing protective eye wear and noise canceling headphones. These patients will undergo the treatment 3 times, one at day of discharge, second at the 4 week follow up visit, and third at the 8 week follow up visit. After the 8 week follow up visit, patients will be asked to come in for the 3 month follow up visit and 1 year follow up visit for an evaluation. At each visit, the patient's scar will be photograph for evaluation. Each patient will also be asked to fill out the POSAS, and KOOS at each follow up visits.
89417002|NCT03594825|Experimental|nighttime group|patients with nocturnal hypertension taking valsartan at nighttime
89417003|NCT03594825|Active Comparator|daytime group|patients with nocturnal hypertension taking valsartan at daytime
89417004|NCT05635396|Experimental|Wearable, non invasive sensor for vital signs recording.|All included patients will be provided with a wearable, non invasive sensor for vital signs recording.
89417005|NCT02162550|Experimental|Bydureon|injectable medication Bydureon
89417006|NCT02162550|Placebo Comparator|Placebo|a similar looking injectable
89193343|NCT05115838|Placebo Comparator|Placebo|Participants receive a placebo implant for approximately 52 weeks. A subset of participants will receive a second implant for 12 weeks after removal of the first implant.
89417007|NCT05635318|Placebo Comparator|Group A|Group A including ADHD patients who will be treated according to The American academy of Pediatrics Guidelines with FDA-approved medications
89417008|NCT05635318|Active Comparator|Group B|Group A including ADHD patients who will be treated according to The American academy of Pediatrics Guidelines with FDA-approved medications plus Quantitative EEG Neurofeedback
89417009|NCT02162628||Exair for Total Repair|Total repair with Exair Prolapse Repair System alone or in combination with native tissue repair
89417010|NCT02162628||Total Native Tissue Repair|Total repair with native tissue only
89417011|NCT05306860||Grade B-C stage III-IV periodontitis group|"Grade B-C stage III-IV periodontitis group Grade B: Moderate Moderate bone loss is observed compared to biofilm and % Root Bone Loss/age 0.25 to 1.0 is determined as grade B.~Stage III: Severe Consisted of individuals with interdental AL ≥5 mm, radiographic bone lose extending to middle or apical third of the root, PD≥6 mm and tooth loss due to periodontitis of ≤4.~Grade C: Rapid Rapid bone loss is observed compared to biofilm and % Root Bone Loss/age >1.0 is determined as grade C.~Stage IV:Advanced Consisted of individuals with interdental AL ≥5 mm, radiographic bone lose extending to middle or apical third of the root, PD≥6 mm and tooth loss due to periodontitis of ≥5. Need for complex rehabilition due to: Masticatory dysfunction, Secondary occlusal trauma(tooth mobility degree ≥2) Severe ridge defect,Bite collapse, drifting, flaring. Less than 20 remaining teeth (10 opposing pairs)"
88894825|NCT06073197|Active Comparator|erector spinae plane block|Plane blocks implemented on preoperative course on 35 patients for group.
89417012|NCT05306860||Healthy control group|Consisted of individuals with clinically healthy gingiva on an intact periodontium who had a BOP score less than 10% and PD≤3mm, showed no attachment loss or radiographic bone loss.
88894826|NCT06073197|Active Comparator|combined deep and superficial serratus anterior plane block|Plane blocks implemented on preoperative course on 35 patients for group.
89417013|NCT03539874||Confirmed paternity|Sperm sample from men with confirmed paternity
89417014|NCT03539874||Intrauterine insemination|Sperm sample from men in intrauterine insemination process
89417015|NCT03539874||In vitro fertilization|Sperm sample from men in in vitro fertilization process
88894827|NCT06073171|Other|Cutis Tricolor patient included in trio or duo|Cutis Tricolor patient included in trio (one affected parent, one unaffected parent) or duo (one of the two affected parents)
89193344|NCT05114330||Cohort 1|Systemic (= localized outside the CNS) lymphoma with secondary CNS involvement at initial diagnosis
89193345|NCT05114330||Cohort 2|CNS relapse of previously systemic lymphoma
89535916|NCT03200899|Active Comparator|Usual Care plus Computer games|Participants randomized to this arm receive usual care and are referred to MY BRAIN GAMES web site.
89535917|NCT02636907|Experimental|BI 695501|
89193346|NCT05105100||Participants with Melanoma|Participants will undergo a pre-treatment tumor core biopsy and Peripheral blood mononuclear cell (PBMC) collection. Then, patients will be started on pembrolizumab per standard of care and PBMCs will be collected every 3 weeks (1 cycle)
89417016|NCT02852265|Experimental|COC users or new starts|Subjects will have a etonogestrel contraceptive implant placed at enrollment. Women using COC as method of contraception for at least 1 month will be considered COC users. Women starting a COC or recently started a COC within the past month will be considered new starts.
89417017|NCT02162784|Experimental|Budesonide/procaterol 180/10mcg X1|HFA MDI, oral inhalation, 180/10mcg, one puff
89417018|NCT02162784|Experimental|Budesonide/Procaterol, 180/10mcg X2|HFA MDI, oral inhalation, two puffs
89417019|NCT02162784|Active Comparator|Albuterol HFA MDI 100 mcg X2|HFA MDI, oral inhalation, 100mcg, two puffs
89417020|NCT02166216||Healty subjects|Healthy subjects that participate in a high intensity, endurance bicycle race.
89006095|NCT04646629|Sham Comparator|sham electroacupuncture treatment|"sham electroacupuncture treatment participants in the control group received shallow needling (0.30mm×25mm) at ST36 and ST37(nonacupoints located 1 inch beside acupoints, about 20mm). Specifically, the depth of needle insertion into nonacupoints is 3-5mm and avoided manual stimulation and no Deqi without actual current output."
89417021|NCT03602703||chronic HCV|chronic HCV either treated or not with DAAs.Flow cytometry and Western Blot analysis for each subgroup
89417022|NCT03602703||Liver cirrhosis without HCC|Liver cirrhosis without HCC either received treatment or not.Flow cytometry and Western Blot analysis for each subgroup
89417023|NCT03602703||Liver cirrhosis with HCC|Liver cirrhosis with HCC either received treatment or not.Flow cytometry and Western Blot analysis for each subgroup
89417024|NCT03602703||Control group|Healthy subjects
89417025|NCT02166294|Experimental|NEOX® CORD 1K|Cryopreserved, umbilical cord allograft (NEOX® CORD 1K) with off-loading instructions.
89417026|NCT02166294|Active Comparator|Pressure bandage|Standard of Care Pressure bandage with off-loading instructions
89417027|NCT02166294|Experimental|Standard of Care Cross over to NEOX|Subjects in the Standard of Care (pressure bandage) group that have not healed greater than 50% at the Week 12 visit, or have a wound that is worsening, will be offered participation in the cross-over arm of the trial. The cross-over arm of the study will be treated with NEOX CORD 1K and followed for 12 weeks.
89417028|NCT03600753|Experimental|symptomatic patients|symptomatic patients with viral respiratory infection harboring positive qPCR for respiratory virus (influenza A or B, RSV, rhinovirus, metapneumovirus) A pharyngeal and a nasal swabs will be performed for each patient. Culturomic and metagenomic analyses will be performed
89417029|NCT03600753|Active Comparator|asymptomatic patients|"symptomatic patients with viral respiratory infection with positive qPCR for respiratory virus.~A pharyngeal and a nasal swabs will be performed for each patient. Culturomic and metagenomic analyses will be performed"
89417030|NCT03600753|Other|healthy subjects|Control group of healthy patients. A pharyngeal and a nasal swabs will be performed for each patient. Culturomic and metagenomic analyses will be performed
89417031|NCT02166372||Obese diabetic patients|Diabetic patients with BMI over 25 Age 20 to 67 Diabetes medically controlled at our center for at least six months
89417032|NCT03600675||South Asian Indians|No intervention will be applied for any group
89417033|NCT03600675||Caucasians|No intervention will be applied for any group
89417034|NCT03539718|Experimental|cases|Cases, taurolidine heparin 500 will be used at end of session
89417035|NCT03539718|Active Comparator|control|Controls, Heparin Sodium 5000 will be given at end of session
89417036|NCT02166450||Control group|Denture wearers without clinical signs of denture-related stomatitis confirmed with negative Candida swabs.
89417037|NCT02166450||Denture-related stomatitis group|"Denture wearers with clinical signs of denture-related stomatitis, confirmed with positive Candida swabs.~Treated for fungal infection, with nystatin [100 000 IU every 6 h for 3 weeks, applied on the infected area of the mucous membrane of the palate and cheeks]."
89006096|NCT04646512|Active Comparator|Taurine group and exercise|Intervention with taurine supplementation and physical training.
89006097|NCT04646512|Placebo Comparator|Placebo group and exercise|Intervention with placebo supplementation and physical training.
89006098|NCT04646317|Experimental|Dexmedetomidine|Dexmedetomidine infusion four 50 ml syringes containing 1 microgram per ml dexmedetomidine
89006099|NCT04646317|Placebo Comparator|normaL SALINE 0.9%|Four 50 ml syringes of .9 % Normal SALINE
89417038|NCT03602625||Preterm group|All the live-born infants with gestational age less than 37weeks and more than 20weeks born in the cooperative hospital every day or every two or three days.
89417039|NCT03602625||Term group|The one next-live-born infants with gestational age at 37weeks or more than 37weeks.
89417040|NCT02166528||experiment group|patients with FPFD
89006100|NCT04646161||prostaglandins before iud insertion group|this group will receive 200 mcg prostaglandins in form of misoprostol 2 hrs before mirena iud insertion
89006101|NCT04646161||placebo group|this group will receive placebo tablet before mirena iud insertion
89006102|NCT04645888|Active Comparator|Articaine|"All surgeries were performed by the same surgeon and monitored by the same person. 4 % articaine with 1:200.000 epinephrine was administered to the patients in regional block of the inferior alveolar nerve technique at the first surgery. At the second intervention, patients received the other anesthetic solution which was not used at the first intervention.~1.5 cc of the solution was used to anesthetize the inferior alveolar and lingual nerve and the remaining 0.5 cc was infiltrated to anesthetize the buccal nerve."
89417041|NCT02166528||control group|patients without FPFD
89417042|NCT03600519||AMD Patients|OCT scan
89417043|NCT03540498|Experimental|Probiotics|The volunteers will follow the assigned treatment for 6 weeks (PROBIOTICS_AB-DENTALAC CHEWING GUM. Orally) , which will consist of the consumption of 2 chewing gums a day. The chewing gum should be chewed for at least 15-20 minutes at least 1 hour after the consumption of food. For at least 1 hour after the consumption of chewing gum, volunteers will not be able to consume food, drink (except water) or clean their teeth. Adherence to the treatment will be made by returning the empty containers after 6 weeks.
89417044|NCT03540498|Placebo Comparator|Control|The volunteers will follow the assigned treatment for 6 weeks (PLACEBOS CHEWING GUM. Orally) , which will consist of the consumption of 2 chewing gums a day. The chewing gum should be chewed for at least 15-20 minutes at least 1 hour after the consumption of food. For at least 1 hour after the consumption of chewing gum, volunteers will not be able to consume food, drink (except water) or clean their teeth. Adherence to the treatment will be made by returning the empty containers.
89417045|NCT03600363|Experimental|metformin arm|
89417046|NCT03600363|Placebo Comparator|control arm|
88894828|NCT06073145||Blood flow monitoring in the brain|A group/cohort of 60 participants will be recruited. The group/cohort has a broad range distribution of different physiological parameters, such as age, gender, race, BMI, and etc.
89417047|NCT02162940||patients taking statins|Visual anlogue score vas used to evaluate pain. The SF 36 test was used to evaluate quality of life.
89417048|NCT02162940||patients not taking statins|Visual anlogue score vas used to evaluate pain.The SF 36 test was used to evaluate quality of life.
89193347|NCT05101265|Experimental|Normal Hepatic function cohort|"Patients in the control cohort must meet the following criteria:~Total bilirubin ≤ 1.0 x upper limit of normal (ULN) and no clinical (or histological) evidence of liver disease.~Aspartate aminotransferase (AST) ≤ 1.0 x ULN and alanine aminotransferase (ALT) ≤ 1.0 x ULN.~Albumin ≥ 3.5 g/dL.~The age, weight and CLcr should be within ±10 years, ±15 kg and ±20 mL/min of the mean of pooled HI cohort, respectively; and with a similar male/female ratio."
89193348|NCT05101265|Experimental|Mild Hepatic impairment cohort|"Patients with Mild Hepatic impairment must meet the following additional criteria~Total bilirubin ≤ 1.0 x ULN and AST > 1.0 x ULN, or~Total bilirubin > 1.0 - ≤ 1.5 x ULN and any AST, and~Albumin ≥ 3.0 g/dL"
89193349|NCT05101265|Experimental|Moderate Hepatic impairment cohort|"Patients with Moderate Hepatic impairment must meet the following additional criteria~Total bilirubin >1.5 - ≤ 3.0 x ULN and any AST, and~Albumin ≥ 2.8 g/dL"
89193350|NCT05101265|Experimental|Severe Hepatic impairment cohort|"Patients with Severe Hepatic impairment must meet the following additional criteria:~Total bilirubin >3.0 x ULN and any AST, and~Albumin ≥ 2.5 g/dL"
88894829|NCT06073106||Stroke|Both acutely admitted stroke patients undergoing rehabilitation and chronic recovered stroke outpatients will be recruited.
88894830|NCT06073106||Traumatic Brain Injury|Both acutely admitted TBI patients undergoing rehabilitation and chronic recovered TBI outpatients will be recruited.
88894831|NCT06073106||Breast Cancer|Only recovered breast cancer patients.
88894832|NCT06073106||Knee Osteoarthritis|For patients with chronic knee osteoarthritis.
89193351|NCT05101174|Experimental|Integrated Intervention Group (IIG)|"The IIG attends 150 min exercise per week, which consists of one 90-min trainer-supervised program and multiple online sessions, for 6 months.~Intervention: aerobic exercise, resistance exercise, coordinative exercise, flexibility, social interaction, and meditation."
89417049|NCT03600285|Experimental|TB1-K|TB1-K preservation arm
89417050|NCT03540888|Experimental|Deep Transverse Friction Massage group|Deep transverse friction massage group. Participants were taught by one of the examiners how to sit and perform pre-exercise self-massages on their tested leg musculotendinous junction (MTJ). The procedure consisted of applying friction massage by fingertips transversely to the hamstrings tendon, in a sitting position. The tendon was located over four finger widths proximal to the medial and lateral epicondyles of the femur. One examiner carefully monitored how the technique was performed to assure the precision of the application. This massage technique was applied over a duration of 30 seconds.
89417051|NCT03540888|Active Comparator|Dynamic stretching intervention|The dynamic stretching intervention was included for its positive effects on agility and muscle strength. Participants in this group, swung their tested leg actively into hip flexion while keeping their knee fully extended and their ankle fully plantar flexed until a stretch was felt in the posterior thigh. This was repeated over 30 seconds and included in the participant's warm-up phase.
89417052|NCT03540888|Active Comparator|Static stretching intervention|In the static stretching intervention, all participants laid on the floor in a supine position with both feet pointing upwards, with the tested limb in full knee extension and the foot in a relaxed position. The tested limb was moved up passively to a point of slight pain or discomfort at the posterior aspect of the thigh. This technique puts the hamstrings muscle at its greatest possible length. This position should be held for 30 seconds and was performed three times for a total of one minute and 30 seconds, 15 minutes after a match or training. The contralateral leg was stabilized by means of another collaborator in order to prevent compensation by rotation or elevation of the pelvis.
89417053|NCT03600207|Active Comparator|Control group -complex training|complex training
89417054|NCT03600207|Active Comparator|Experimental group -diaphragm training|diaphragm training
89417055|NCT03600129|Experimental|QLB with 0,375% ropivacaine|
88894833|NCT06073080|Experimental|Protein Nutrition Even|Volunteers will consume 1.6 g protein/kg/d as an even (~0.4/0.4/0.4/0.4 g/kg) distribution across breakfast, lunch, dinner, and a snack.
89417056|NCT03600129|Placebo Comparator|QLB with 0,9% NaCl|
89417057|NCT02169570|Active Comparator|Vitamin D|Vitamin D supplementation Anti Tuberculosis Treatment with 600,000 IU of (I/M) vitamin D3 for 3 doses at 0, 4 and 12 weeks and color and taste matched placebo for calcium for 3 months
88894834|NCT06073080|Active Comparator|Protein Nutrition Skewed|Volunteers will consume 1.6 g protein/kg/d as a skewed (~0.11/0.27/1.15/0.07 g/kg) distribution across breakfast, lunch, dinner, and a snack.
88894835|NCT06073028|Experimental|Rhythmic auditory cueing|"The rhythmic auditory cueing (RAC) is a constant stimulation (bip signal) delivered by a numeric metronome, which is adjusted on 110% of the patient's own cadence."
89193352|NCT05101174|Other|Control Group|"The control group is invited to attend one 60-min online educational course per week for 6 months.~Intervention: 60-min online educational program."
89193353|NCT05091957|Experimental|Community Support Worker|structured review of participant income supports with a trained CSW, to identify financial needs and benefits for which the family is eligible, including assessment of income and food security, affordability of medications, housing and energy insecurity, and dental care. The visits will be conducted in person, by telephone or by videoconferencing, according to participant preference and to ensure adherence to COVID-19 pandemic-related criteria.
89417058|NCT02169570|Placebo Comparator|Placebo|Anti Tuberculosis Treatment with placebo color matched for vitamin D and color and taste matched placebo for calcium
88894836|NCT06073028|Experimental|Adaptive spatial auditory cueing|"Adaptive spatial auditory cueing (ASAC) is a verbal instruction stimulation delivered by an application when the stride length of the patient is less than a predetermined threshold, during two consecutive strides. The instruction is given in the patient's native language, which is French: allongez le pas (i.e. lengthen the step). The predetermined threshold is 110% of the patient's own stride length."
88894837|NCT06073015|Experimental|Experimental group|Esketamine (0.25mg/kg)
88894838|NCT06073015|No Intervention|Control group|the same volume of normal saline
89417059|NCT02169570|Experimental|Vitamin D and Calcium|Vitamin D and Calcium supplementation Anti TuberculosisTreatment with 600,000 IU of (I/M) vitamin D3 for 3 doses at 0, 4 and 12 weeks with daily 1000 mg calcium carbonate for 3 months
89417060|NCT03539640|Active Comparator|PEEP level of 5 cmH2O|During second part of the study (MRI) Diaphragm position
89417061|NCT03539640|Active Comparator|PEEP level of 10 cmH2O|During second part of the study (MRI) Diaphragm position
89193354|NCT05091957|Active Comparator|Usual Care|There is no clear standard of care and potential for practice variation in clinician responses to identified social need. Based on the ethical imperative to provide some support to families who identify unmet social needs, the comparator group will receive Usual Care, defined as: Participants in both groups will receive a written summary of available resources.
89417062|NCT03539640|Active Comparator|PEEP level of 15 cmH2O|During second part of the study (MRI) Diaphragm position
89193355|NCT05083754|Experimental|Arm A- Retifanlimab and Radiation Therapy|Participants will receive Retifanlimab and Radiation Therapy.
89193356|NCT05083754|Experimental|Arm B- Retifanlimab, Radiation Therapy and Temozolomide|Participants will receive Retifanlimab, Radiation Therapy and Temozolomide.
89417063|NCT03913143|Experimental|Group 1: Dose 1 sepofarsen (QR-110)|Initial loading dose, followed by maintenance doses at month 3 and every 6 months there after, administered by intravitreal injection (24 months duration of treatment). After 12 months treatment of the contralateral eye may be initiated
89535918|NCT03200665|Experimental|Ultrasound 35-36 (6 / 7 days weeks)|The patients that are randomized to this group, besides accomplishing the standard of care of national guidelines (third trimester ultrasound at 30-32 (6 / 7 days weeks)) will be submitted to an additional third trimester ultrasound at 35-36 (6 / 7 days weeks).
89535919|NCT03200665|No Intervention|Standard of Care|This is the control group that will be managed in accordance to national guidelines of screening of late fetal growth restriction in low risk pregnancies: third trimester ultrasound at 30-32 (6 / 7 days weeks).
89535920|NCT02450929||Standard Barrel-Cuff ETT|Standard Barrel-Cuff ETT use in surgical patients
89535921|NCT02450929||Taperguard ETT|Taperguard ETT use in surgical patients
89535922|NCT05714189|Other|Intervention group: adherence to Low FODMAP diet|Women could choose to adhere to the low FODMAP diet, over a period of six months. In the first three months, they received extensive guidance by a dietician in training, in addition to supportive materials such as the Monash app, recipes and grocery lists, in the hope of optimal adherence to the diet. After three months, women were asked to continue the diet independently. In addition, women were asked to complete three questionnaires, one every two months. The questionnaires contained the EHP-30, the GIQLI, and self composed questions on their demographics in the first questionnaire, and their strictness of adherence in the second and third questionnaire. The third questionnaire also contained questions on their satisfaction with the dietary guidance and the dietician in training.
89535923|NCT05714189|Other|Intervention group: adherence to endometriosis diet|Women could choose to adhere to the endometriosis diet, over a period of six months. In the first three months, they received extensive guidance by a dietician in training, in addition to supportive materials such as the Monash app, recipes and grocery lists, in the hope of optimal adherence to the diet. After three months, women were asked to continue the diet independently. In addition, women were asked to complete three questionnaires, one every two months. The questionnaires contained the EHP-30, the GIQLI, and self composed questions on their demographics in the first questionnaire, and their strictness of adherence in the second and third questionnaire. The third questionnaire also contained questions on their satisfaction with the dietary guidance and the dietician in training.
89535924|NCT05714189|No Intervention|Control group: no diet adherence|Women were asked to complete three questionnaires, once every two months. These contained the EHP-30 and GIQLI. The first questionnaire contained questions on their demographics, and whether they applied a diet before.
89535925|NCT04998513|Active Comparator|Medical Management Alone Arm|Antibiotics, steroids, fluids
89535926|NCT04998513|Active Comparator|Surgical Arm|Incision and drainage
89535927|NCT03202771|Experimental|Home Biofeedback Therapy|Patients will use home biofeedback device to practice their maneuvers taught by the nurse.
89535928|NCT03202771|Active Comparator|Office Biofeedback Therapy|Patients will get regular office biofeedback therapy with an anal probe inserted while a nurse runs through the exercise session together.
89535929|NCT02483741|Experimental|Manuka Honey|Manuka Honey will be placed in the sockets of the extracted third molars in this group
89535930|NCT02483741|No Intervention|Traditional Extraction|No any special material will be placed in the sockets of the extracted third molars in this group
89535931|NCT01374919|Other|ferumoxytol|IV administration of 1020 mg of ferumoxytol in 15 minutes
89535932|NCT03072381|Active Comparator|Platelet Rich Plasma - Group 1|"Subjects in Group 1 (PRP) will receive a single ultrasound-guided intratendinous (common extensor tendon origin) injection of up to 3 mL autologous PEAK platelet-rich plasma at week 0 (baseline).~If a subject has bilateral elbow common extensor tendon pain, both elbows will be treated in the same study arm."
89535933|NCT03072381|Placebo Comparator|Corticosteroid Control - Group 2|"Subjects in Group 2 (corticosteroid control) will receive a single ultrasound-guided intratendinous injection approximately (may be limited by tendon/soft tissue limitations of the subject) of 2 mL 1% lidocaine + 1mL of him 40mg Kenalog (triamcinolone hexacetonide, 40mg/mL) at week 0.~If a subject has bilateral elbow common extensor tendon pain, both elbows will be treated in the same study arm."
89535934|NCT02483507|Active Comparator|Group T: transversal|Implementation of the vascular catheter with transversal approach under ultrasound guidance
89535935|NCT02483507|Active Comparator|Group L: longitudinal|Implementation of the vascular catheter with longitudinal approach under ultrasound guidance
89535936|NCT02483507|Active Comparator|Group O: oblique|Implementation of the vascular catheter with oblique approach under ultrasound guidance
89193357|NCT05083754|Other|Arm C- Radiation Therapy and Temozolomide|Participants will receive Radiation Therapy and Temozolomide which is the Standard of Care.
89193358|NCT05075759|Experimental|Arm 1 (personalized clinician-led self-management telehealth)|Patients receive a personalized clinician-led self-management telehealth session at baseline and 2 months. Patients with poor response at 3 months are randomized to Arm 2 or 4, otherwise patients receive the same telehealth session at months 4 and 6. Patients may receive 2 additional telehealth sessions after 12 months.
88894839|NCT06072989|Experimental|B4T2-001 CAR T|Single Arm and Open Label study consisting of dose escalation study design followed by dose expansion phase at determined MTD.
88894840|NCT06072976|Experimental|Exclusive human milk|Mothers will consent to providing DHM if MOM is not available. If the infant reaches 100 ml/kg/day of feeds (one feed advancement prior to full feeds) and MOM remains unavailable, they will transition to formula in preparation for discharge. Infants cannot be discharged on donor milk.
88894841|NCT06072976|Experimental|Standard of care|Mothers will consent to providing DHM (if qualifies per hospital policy) or formula if MOM is not available. Infants are only eligible to receive donor milk only if 1) MOM is not available 2) if infant initiates feeds before day 3 of age. The donor milk feed would be stopped on day 5 of age. After day five of age, the infant will receive formula if MOM is not available. This is congruent with the current donor milk policy (see Policy #12785). It is highly unlikely given these infants would receive any donor milk because these infants require surgery and often are waiting return of bowel function . The median age of initiation of feeds is 12 days of age for infants with gastroschisis (PMID: 33647253) which exceeds the days of what the hospital policy says for eligibility which is initiates feed before day 3 of age. If the infant does not qualify for any donor milk and MOM is not available, the infant will receive formula
89193359|NCT05075759|Experimental|Arm 2 (personalized goal setting)|Patients receive personalized goal setting for daily steps and activity (updated weekly) and 3 dietary goals (updated monthly) with social media peer support for 6 months. Patients with poor response at 3 months are randomized to Arms 1 or 4. Patients may receive personalized goal setting for daily steps and activity (updated monthly) and dietary goals (updated every 2 months) after 12 months.
89193360|NCT05075759|Active Comparator|Arm 3 (waitlist)|Patients receive no intervention for 12 months, and then receive their choice of intervention for up to 6 months.
89193361|NCT05075759|Experimental|Arm 4 (remote sessions with a health coach)|Patients receive remote sessions with a health coach every 1-2 weeks for 6 months. Patients may continue to receive remote sessions once a month after 12 months.
89193362|NCT05074849|Experimental|Smart insoles + Education|Participants in this group will receive a 90-minute group session education on foot self-care strategies (daily foot hygiene and cleanliness, foot protection, use of insoles and smart watch)
89193363|NCT05074849|No Intervention|Smart Insoles|Participants in this group will not receive a 90-minute group session education on foot self-care, but will receive foot care supplies, insoles and smart watch
89193364|NCT05074849|No Intervention|Usual Care|Participants will not receive foot self-care education or the use of insoles and smart watch.
89193365|NCT05074238|Experimental|Sunscreen Application|The study participant will be instructed to start applying the sunscreen provided to them to the randomly assigned half of the wound (A or B).
89193366|NCT05074238|Experimental|No Suncreen Application|The study participant will be instructed to not apply the sunscreen provided to them to the randomly assigned half of the wound (A or B).
89193367|NCT05071222|Experimental|ARTEGENE drug product|Autologous purified CD34+ cells transduced with a self-inactivated lentiviral vector, expressing the DCLRE1C gene (alias Artemis)
88894842|NCT06072950||Patient with NRS pain at rest being 4 or higher|Patient with NRS pain at rest being 4 or higher, primarily treated by emergency physician, internist, or surgeon. All patients receive usual care, no interventions are administered.
89193368|NCT05068271|Experimental|Multi-Domain Exercise Program|"Time: 6 months, total of 150 min of exercise per week.~Intervention: aerobic training, muscular fitness training, balance, flexibility, meditation, and social interaction."
88894843|NCT06072937|Experimental|IntelliStent Arm|Single Arm Safety and Effectiveness of the IntelliStent System
88894844|NCT06072924|Experimental|Lingual Endurance Exercise|The experimental exercise group will participate in 3 training sessions per day for 8 weeks. Endurance exercise will include completing isotonic endurance repetitions 3 times a day. Number of repetitions per session will be determined during baseline testing for each participant.
88894845|NCT06072924|Sham Comparator|Sham Exercise|The sham control group will be instructed to press the lingual sensor 30 times at a very low-pressure threshold (1-5 kPa), which will be monitored weekly via device output sent to the study team to avoid use of excessive force that would qualify as exercise (>5 kPa).
89193369|NCT05068271|Other|Control Group|"Time: 6 months, total of 60 min of online educational course per week.~Intervention: educational materials relating to the effects of exercise on cognitive function and aging-related cognitive decline."
89193370|NCT05067335|Experimental|Romosozumab|Subjects randomized to this arm will receive romosozumab during all treatment Periods.
89193371|NCT05067335|Placebo Comparator|Placebo|Subjects randomized to this arm will receive placebo during the Double-Blind-Placebo controlled Period and romosozumab during the Open-Label treatment Period
89193372|NCT05066789|Active Comparator|Biodegradable Polymer DES|"Patients will be randomized to either the polymer-free drug-coated stent (DCS) group or the biodegradable polymer drug-eluting (DES) group with 1:1 ratio.~This group will use Orsiro Mission stent during the index procedure."
89193373|NCT05066789|Active Comparator|12-month DAPT|"Patients will be randomized to either the prasugrel monotherapy group or the 12-month dual antiplatelet therapy (DAPT) group with 1:1 ratio unless patients have additional exclusion criteria for antiplatelet study.~This group will receive 12-month DAPT of aspirin (100mg once daily) plus prasugrel (10mg once daily)."
89193374|NCT05066789|Experimental|Polymer-free DCS|"Patients will be randomized to either the polymer-free drug-coated stent (DCS) group or the biodegradable polymer drug-eluting (DES) group with 1:1 ratio.~This group will use BioFreedom Ultra stent during the index procedure."
89193375|NCT05066789|Experimental|Prasugrel monotherapy|"Patients will be randomized to either the prasugrel monotherapy group or the 12-month dual antiplatelet therapy (DAPT) group with 1:1 ratio unless patients have additional exclusion criteria for antiplatelet study.~This group will receive aspirin (100mg once daily) plus prasugrel (10mg once daily) for 1 month and thereafter prasugrel (10mg once daily) alone."
89193376|NCT05062226|Experimental|GMP-based products|GMP-based nutritional protein substitutes for the dietary management of PKU and TYR
89193377|NCT05060562||Post COVID 19 symptoms Positive|The presence of persistent COVID-related symptoms after being cured.
89193378|NCT05060562||Post COVID 19 symptoms Negative|No persistent COVID-related symptoms after cured
89193379|NCT05058664|No Intervention|Control (standard care)|
89193380|NCT05058664|Experimental|A-F texting component|The A-F texting component will include content consistent with best-practice recommendations for parents to buffer youth against suicide risk.
89193381|NCT05058664|Experimental|A-F texting plus P-F texting component|A-F texting plus P-F texting component arm includes the A-F component, as above, and P-F component. The P-F component includes an embedded micro-randomized trial (MRT) involving two daily randomizations to P-F message vs. no message conditions for the duration of the 6-week intervention. Participants who are randomized to this arm will be randomized twice each day (morning and evening) to either receive or not receive the P-F message at each randomization.
89193382|NCT05052580|Other|COVID-19 Exposure Testing|
89193383|NCT05046418||Hypoallergenic formula containing synbiotics|Infants (aged <13 months) with cow's milk allergy (CMA) who are prescribed a hypoallergenic formula containing synbiotics as part of usual clinical practice for the dietary management of CMA.
89193384|NCT05046314|Experimental|TK216+Vincristin|
89193385|NCT05043337|Experimental|Maternal voice|Recording the maternal voice in reading children's books, and recorded the sound for 13 minutes. When the premature infants undergoing heel lance procedure, the experimental group was explored maternal voice, which starts from 3 minutes before the procedure and ends ten minutes after the heel puncture.
89193386|NCT05043337|Experimental|Lullaby|The Brahms Lullaby recordings are compiled for 13 minutes. When the premature infants undergoing heel lance procedure, the experimental group was explored Brahms Lullaby, which starts from 3 minutes before the procedure and ends ten minutes after the heel puncture.
89193387|NCT05043337|Experimental|Maternal voice combined with lullaby|Recording the maternal voice in reading children's books and giving mother listening to the lullaby at the same time, and recorded the sound for 13 minutes. When the premature infants undergoing heel lance procedure, the experimental group was explored Maternal voice combined with Brahms lullaby, which starts from 3 minutes before the procedure and ends ten minutes after the heel puncture.
89193388|NCT05043337|No Intervention|Control group|When the premature infants undergoing heel lance procedure , the control group was under routine care . Measuring with the Respiration , heart rate , oxygen saturation , and neonatal infant pain scale (NIPS ) were recorded 3 minutes before , during , 1st , 3rd , and 10th minutes after the heel lance puncture .
89193389|NCT05042895|Active Comparator|PCO women|Group A will consist of 100 PCO infertile women
89193390|NCT05042895|Active Comparator|unexplained infertile cases|group B will consist of 50-unexplained infertility.
89193391|NCT05038527|Experimental|ABM/P-15 bone graft|Group A: Bone graft of anorganic bovine bone mineral coated with a bioactive peptide (ABM/P-15)
89417064|NCT03913143|Active Comparator|Group 2: Dose 2 sepofarsen (QR-110)|Initial loading dose, followed by maintenance doses at month 3 and every 6 months there after, administered by intravitreal injection (24 months duration of treatment). After 12 months treatment of the contralateral eye may be initiated
89193392|NCT05038527|No Intervention|Standard treatment|Group B: Standard bone graft which is a mix of locally harvested bone and a morselized femoral head (allogenic)
89193393|NCT05030441|Experimental|Ivosidenib|-Ivosidenib is an oral drug which will be administered on an outpatient basis at a dose of 500 mg daily for up to 17 months (approximately 18 28-day cycles), with each cycle being 28 days.
89193394|NCT05026749|Placebo Comparator|Control Group|
89417065|NCT03913143|Sham Comparator|Group 3: Sham|Sham procedure (no experimental drug administered), Day 1, month 3 and every six months there after. After 12 months cross over to active study drug may be initiated
89417066|NCT02169648|Experimental|ranibizumab|Experimental: Intravitreal injection of Ranibizumab
89417067|NCT02170896|Experimental|Period 1: BIBR1048 MS Capsule A+Pantoprazole|
89417068|NCT02170896|Experimental|Period 1: BIBR1048 MS Capsule B+Pantoprazole|
89417069|NCT02170896|Experimental|Period 1: BIBR1048 MS Capsule C+Pantoprazole|
89417070|NCT02170896|Experimental|Period 1: BIBR1048 MS Capsule D+Pantoprazole|
88894846|NCT06072898|Experimental|Staged Active Treatment Arm (Psilocybin-Psilocybin)|This group will receive psilocybin (25mg) at the first and second treatment visit, along with supportive psychotherapy.
88894847|NCT06072898|Experimental|Placebo to Active Crossover Treatment Arm (Niacin-Psilocybin)|This group will receive niacin (100mg) at the first treatment visit and psilocybin (25mg) at the second treatment visit, along with supportive psychotherapy.
88894848|NCT06072872|No Intervention|No Portable CPAP|Patients continue life as normal without portable CPAP
88894849|NCT06072872|Experimental|Use of portable CPAP|Patients use portable CPAP during periods of exercise
88894850|NCT06072859|Active Comparator|Group 1|Humidified Forest Oils with Limonene
88894851|NCT06072859|Active Comparator|Group 2|Humidified Forest Oils with Limonene & Virtual Reality using a Surface Pro tablet with headphones to experience walking on a forest path and ambient forest sounds.
88894852|NCT06072846|Experimental|enterprise group|Reiki therapy will be applied to the initiative group. Evaluation will be carried out with pre-test and post-test
88894853|NCT06072846|No Intervention|Control group|The control group will not be interfered with. The control group will not be interfered with and will only be evaluated by pre-test and post-test by monitoring.
89417071|NCT02170896|Active Comparator|Period 1: BIBR1048 MS solution+Pantoprazole|
89417072|NCT02170896|Experimental|Period 2: BIBR1048 MS Capsule C|
89417073|NCT02170896|Experimental|Period 2: BIBR1048 MS Capsule D|
89417074|NCT02170896|Active Comparator|Period 2: BIBR1048 MS solution|
89193395|NCT05026749|Active Comparator|AZM 20mg/kg Treatment Group|
89417075|NCT03594513|Active Comparator|MCAF+PR+CTG|The partial restoration of the NCCL will be performed prior the surgeries and will be carried out with composite resin.The surgical procedure for root coverage will be carried out by means modified coronally advanced flap and will be performed by starting with oblique incisions in the interdental areas, which continued with the intrasulcular incision at the recession defects.Each surgical papilla will be dissected in a split-thickness and the envelope flap will be raised with a split-full-split thickness in the coronal-apical direction. Additionally, this group will receive the connective tissue graft harvested from the palate on the recessed area before the sutures.Then, the flap will be coronally positioned and sutured to completely cover the graft.
89535937|NCT05003193|Experimental|Using a pedometer|The pedometer will be given to the intervention group to evaluate the activity level and to encourage a walk , it will be said that their goal is to take 2000 steps in 20 minutes a day after discharge. Patients will be asked to carry the pedometer during physical activity, and to write down the number of steps they take in 20 minutes on the form given to them for 90 days.
88894854|NCT06072820|Other|Research Planning|"Study population will be composed of subject with a confirmed or ruled-out diagnosis of endometriosis. The subject diagnosis could be ascertained through imaging and/or surgery with or without biopsies.~After a first assessment during a routing care visit, the subject will be asked to come back for a day, or half a day depending on the impact of the circadian cycle."
88894855|NCT06072729|Experimental|Magnesuuim Sulphate|"After the initial assessment, the cannula will be removed from the site (if present) the cannulation site will be cleaned with normal saline. A mixture of 100mg magnesium sulfate and glycerin will be applied to a gauze pad (2 × 2). This gauze pad placed on the site of phlebitis induced by peripheral intravenous catheter (PIVC). This will be done three times a day for three consecutive days"
88894856|NCT06072729|Experimental|Cold compression|"After the initial assessment, the cannula will be removed from the site (if present) and the area will be cleaned with normal saline. A gauze pad (2 × 2) soaked in cold water with a temperature below 15 °C will be applied to the phlebitis site for 20 minutes. This will be done three times a day for three consecutive days. The cold water will be stored in the refrigerator in the respective wards one day prior to the dressing. It will be taken from the refrigerator just before the dressing and applied within one minute. After 20 minutes of application, the gauze pad for cold compress will be removed from the phlebitis site. From 1st to 3rd Day daily assessment done through VIP scale, will be conducted in both Group A (magnesium sulphate group) and Group B (cold compression group)"
88894857|NCT06072716|Experimental|interventional|chitosan loaded with miconazole nanoparticles gel
88894858|NCT06072716|Experimental|control|miconazole gel
88894859|NCT06072690||Patients with treatment-naive moderate-to-severe COPD|Patients of any gender aged 40 years and older with newly diagnosed treatment-naive moderate-to-severe chronic obstructive pulmonary disease will have a comprehensive cardiovascular and respiratory examination as well as evaluation of quality of life before the treatment and after 12 weeks of treatment with dual bronchodilation.
88894860|NCT06072677|Experimental|Healthy Minds Program|Participants in this group will begin the Healthy Minds Program immediately following the 4-week baseline period.
88894861|NCT06072677|Other|Waitlist Control|After the 4-week baseline period, participants in the waitlist control condition will wait an additional 4 weeks before starting the Healthy Minds Program.
88894862|NCT06072625|Active Comparator|Olive oil group|Babies who have fully enteral feeding will take oral, 1 ml/kg/day of extra virgin olive-oil
89417076|NCT03594513|Experimental|MCAF+PR+XMD(Mucoderm®)|The partial restoration of the NCCL will be performed prior the surgeries and will be carried out with composite resin.The surgical procedure for root coverage will be carried out by means modified coronally advanced flap and will be performed by starting with oblique incisions in the interdental areas, which continued with the intrasulcular incision at the recession defects.Each surgical papilla will be dissected in a split-thickness and the envelope flap will be raised with a split-full-split thickness in the coronal-apical direction. Additionally, this group will receive a porcine acellular dermal matrix on the recessed area before the sutures. Then, the flap will be coronally positioned and sutured to completely cover the graft.
88894863|NCT06072625|No Intervention|Control group|
88894864|NCT06072573|Experimental|Treatment group|Sublingual spray with maximum application of 16 actuations per day or a maximum daily dose of 17,6mg THC distributed over 4 daily intakes.
88894865|NCT06072573|Placebo Comparator|Control group|Sublingual spray with maximum application of 16 actuations per day distributed over 4 daily intakes.
88894866|NCT06072560|Experimental|Treatment group|
88894867|NCT06072560|Placebo Comparator|Control group|
88894868|NCT06072547|Experimental|Complete flavor profile of on! nicotine pouches|This study arm will provided with access to all varieties of 4mg on! nicotine pouch products throughout the trial.
88894869|NCT06072547|Active Comparator|Non-Flavored on! nicotine pouches only|This study arm will provided with access to non-flavored (i.e., Original) 4mg on! nicotine pouch products throughout the trial.
88894870|NCT06072547|Active Comparator|Non-Flavored then complete flavor on! nicotine pouches|This study arm will provided with access to non-flavored (i.e., Original) 4mg on! nicotine pouch products during the first 3 weeks of the trial and then access to all varieties of 4mg on! nicotine pouch products during the last 3 weeks of the trial.
88894871|NCT06072495|Experimental|child with operated isolated labial cleft|
88894872|NCT06072495|Experimental|child with isolated operated velopalatal cleft with severe VPI ( IIB//IIM) and normal velum anatomy|
88894873|NCT06072495|Experimental|child with isolated operated velopalatal cleft with soft VPI (I/I-II) and abnormal velum anatomy|
88894874|NCT06072495|Experimental|child with isolated operated velopalatal cleft with normal anatomy and soft VPI|
88894875|NCT06072443||CAB-LA PrEP Cohort|Prescribed CAB-LA PrEP as standard of care
88894876|NCT06072443||Oral PrEP Cohort|Prescribed oral PrEP as standard of care
88894877|NCT06072417|Placebo Comparator|Respiratory sleep study at 2840m|Participants will have a respiratory sleep study by polygraphy near their resident altitude at 2840m
88894878|NCT06072417|Experimental|Respiratory sleep study near sea level (0-30m)|Participants will have a respiratory sleep study by polygraphy near sea level (0-30m)
88894879|NCT06072404|Experimental|Group A (OZONE_EXO)|intra-tissutal perialveolar injections of a 15-mL mixture of OxigenOzone (O2O3) with a 26Gx1⁄2 - 0.45x13 mm needle and insufflation of the same mixture in the post-extraction site in patients at risk of medication-induced osteonecrosis of the jaw (ONJ).
89417077|NCT02633800|Experimental|Patritumab|All participants receive patritumab with cetuximab plus platinum-based therapy (cisplatin or carboplatin)
89417078|NCT02633800|Placebo Comparator|Placebo|All participants receive placebo with cetuximab plus platinum-based therapy (cisplatin or carboplatin)
89417079|NCT02169804|Experimental|70 years or older|Non-smoking healthy adult males >or equal to 70 years of age.
89417080|NCT02169804|Experimental|Under 60 years of age|Non-smoking healthy adult males<60 years of age.
88894880|NCT06072404|No Intervention|Group B (NO_OZONE_EXO)|Tooth extraction in patients at risk of medication-induced osteonecrosis of the jaw (ONJ) without the use of ozone application.
88894881|NCT06072365||cystic fibrosis|patient with cystic fibrosis treated with With Elexacaftor/Tezacaftor/Ivacaftor,
88894882|NCT06072352|Experimental|Chlorhexidine acetate solution|
88894883|NCT06072352|Active Comparator|Normal saline|
88894884|NCT06072248|Placebo Comparator|Group A|patients of group A Continue on the conventional way of ventilation and . Microbiological results collected from patients of group A through qualitative sputum.
88922161|NCT05713630|Placebo Comparator|Standard care + placebo|Non-surgical patients will be given a single oral or IV loading dose of 1g placebo within three hours of being randomized. For surgical patients, the same loading dose will be administered whenever possible prior to surgery. After 12 hours of the loading dose, patients will be given 500 mg placebo by mouth (or nasogastric tube for those unable to swallow or IV) three times a day, totalling 1500 mg/day, for 45 days.
89193396|NCT05009992|Experimental|ARM 2: ONC201 (Day -1), Radiation+ONC201, Paxalisib+ONC201|Patients may receive a safety lead in of ONC201. During the trial validation phase, patients without prior biopsy receive ONC201 PO on day -1 prior to standard of care biopsy. During the radiation/re-irradiation phase, patients without prior radiation therapy or have disease progression after radiation therapy undergo weekly radiation therapy and receive ONC201 PO weekly during radiation therapy. During the maintenance phase, patients receive ONC201 PO weekly and paxalisib PO daily (QD). Cycles repeat every 28 days (4 weeks) in the absence of adverse events of unacceptable toxicity
89193397|NCT05009992|Experimental|ARM 4: ONC201 (Day -1,-2), Radiation+ONC201, Paxalisib+ONC201|Patients may receive a safety lead in of ONC201. During the trial validation phase, patients without prior biopsy receive ONC201 PO on days -2 and -1 prior to standard of care biopsy. During the radiation/re-irradiation phase, patients may receive ONC201 PO weekly during radiation therapy. During the maintenance phase, patients receive ONC201 PO weekly and paxalisib PO QD. Cycles repeat every 28 days (4 weeks) in the absence of adverse events or unacceptable toxicity
89193398|NCT05009992|Experimental|ARM 6: Paxalisib (Day -1), Radiation+Paxalisib , Paxalisib+ONC201|Patients may receive a safety lead in of ONC201. During trial validation phase, patients without prior biopsy receive paxalisib PO on day -1 prior to standard of care biopsy. During the radiation/re-irradiation phase, patients without prior radiation therapy or have disease progression after radiation therapy undergo weekly radiation therapy and receive paxalisib PO daily during radiation therapy. During the maintenance phase, patients receive ONC201 PO weekly and paxalisib PO QD. Cycles repeat every 28 days (4 weeks) in the absence of adverse events of unacceptable toxicity
89193399|NCT05002374|Experimental|Experimental Group|
89193400|NCT05002374|Active Comparator|Control Group|
89193401|NCT05001555|Experimental|Group A: Dexketoprofen/Vitamin B (Thiamine mononitrate/Pyridoxine hydrochloride/Cyanocobalamin)|"Group A:~Dexketoprofen/Vitamin B (Thiamine mononitrate/Pyridoxine hydrochloride/Cyanocobalamin), 1 capsule, orally, every 8 hours, for 7 days."
89193402|NCT05001555|Active Comparator|Group B: Dexketoprofen|Group B: Dexketoprofen, 1 tablet, orally, every 8 hours, for 7 days.
89193403|NCT04999345|Experimental|Experimental Group|Provide resistance and aerobic exercise
89193404|NCT04999345|Placebo Comparator|Control Group|Health education and gross range of motion exercise for upper and lower extremities
89193405|NCT04995172||Observational (CT-assisted bronchoscopy, chart review)|Patients undergo RP-EBUS bronchoscopy per standard of care. If the study staff cannot reach the target lesion or is unable to determine a diagnosis, patients undergo bronchoscopy using mobile CT imaging. Patients' medical records are also reviewed for up to 6 months.
89193406|NCT04990596||Age Group 50 to 59|"Inclusion criteria :~age 50-100 years old,~in consultation or hospitalization in one of the participating centres,~treatment with clopidogrel 75 milligrammes per day, for at least 10 days, for primary or secondary prevention of cardiovascular events.~Non-inclusion criteria :~treatment with another antithrombotic drug,~myeloproliferative syndrome,~platelet count < 100 gigas/liter,~acute inflammatory situation: severe sepsis, documented acute infection, chronic systemic inflammatory disease or active cancer,~dialysis."
89193407|NCT04990596||Age Group 60 to 69|"Inclusion criteria :~age 50-100 years old,~in consultation or hospitalization in one of the participating centres,~treatment with clopidogrel 75 milligrammes per day, for at least 10 days, for primary or secondary prevention of cardiovascular events.~Non-inclusion criteria :~treatment with another antithrombotic drug,~myeloproliferative syndrome,~platelet count < 100 gigas/liter,~acute inflammatory situation: severe sepsis, documented acute infection, chronic systemic inflammatory disease or active cancer,~dialysis."
89193408|NCT04990596||Age Group 70 to 79|"Inclusion criteria :~age 50-100 years old,~in consultation or hospitalization in one of the participating centres,~treatment with clopidogrel 75 milligrammes per day, for at least 10 days, for primary or secondary prevention of cardiovascular events.~Non-inclusion criteria :~treatment with another antithrombotic drug,~myeloproliferative syndrome,~platelet count < 100 gigas/liter,~acute inflammatory situation: severe sepsis, documented acute infection, chronic systemic inflammatory disease or active cancer,~dialysis."
88894885|NCT06072248|Active Comparator|Group B|had three times bronchoscopy one at the end of first 5 days, second bronchoscopy at the end of the second 5 days and last one at the end of the studied period to confirm both clinical and bacteriological cure. Bronchoscopy done with the following precautions: we used flexible bronchoscopy Olympus BF-160 adult size, patients kept sedated with both midazolam and fentanyl, 4 syringe of normal isotonic saline used for wash every one 10 ml and suction done immediately after injection, suction of the fluid and small airway secretion after only the first injection of isotonic saline syringe used for BAL and sent for qualitative culture
88894886|NCT06072222|Placebo Comparator|Group A|patients of group A Continue on the conventional way of ventilation and . Microbiological results collected from patients of group A through qualitative sputum.
88894887|NCT06072222|Active Comparator|Group B|had three times bronchoscopy one at the end of first 5 days, second bronchoscopy at the end of the second 5 days and last one at the end of the studied period to confirm both clinical and bacteriological cure. Bronchoscopy done with the following precautions: we used flexible bronchoscopy Olympus BF-160 adult size, patients kept sedated with both midazolam and fentanyl, 4 syringe of normal isotonic saline used for wash every one 10 ml and suction done immediately after injection, suction of the fluid and small airway secretion after only the first injection of isotonic saline syringe used for BAL and sent for qualitative culture
88894888|NCT06072118|Experimental|Adrenomedullin group|
88894889|NCT06072105|Active Comparator|Group 1|Personalized best medical care.
88894890|NCT06072105|Experimental|Group 2|Personalized best medical care PLUS telemedicine
88894891|NCT06072092||Out-of-hospital cardiac arrest adult patients|All patients aged ≥18 years and in out-of-hospital cardiac arrest (OHCA) on arrival at the physician response unit (PRU) in Graz, Austria + surroundings.
88894892|NCT06072066|Experimental|Skin Barrier Oral Supplement|
88894893|NCT06072027|Experimental|cytology|classical cytology will be done, in parallel of VISIOCYT cytology, in order to be compared
88894894|NCT06072014|Experimental|Head-mounted display (HMD)|The HMD system uses a commercially available virtual headset, the Oculus/Meta Quest 2, which allows a user to view a virtual environment in 360 degrees and to interact with the environment using hand-tracking technology (i.e., when a user's hand is projected into the virtual world to be used for interactions and gestures).
88894895|NCT06072014|Experimental|Semi-cave automatic virtual environment (semi-CAVE)|The semi-CAVE system uses projectors and projector screens to provide a 270-degree view of the virtual environment. These projectors are connected to a powerful workstation (desktop computer), which uses HTC Vive trackers and base stations to track user movements and interactions
88894896|NCT06072001|Experimental|Treatment group|Sublingual spray with maximum application of 16 actuations per day or a maximum daily dose of 17,6mg THC distributed over 4 daily intakes.
88894897|NCT06072001|Experimental|Control group|Sublingual spray with maximum application of 16 actuations per day distributed over 4 daily intakes.
88894898|NCT06071988|Experimental|Treatment group|Sublingual spray with maximum application of 16 actuations per day or a maximum daily dose of 17,6mg THC distributed over 4 daily intakes.
89193409|NCT04990596||Age Group 80 to 89|"Inclusion criteria :~age 50-100 years old,~in consultation or hospitalization in one of the participating centres,~treatment with clopidogrel 75 milligrammes per day, for at least 10 days, for primary or secondary prevention of cardiovascular events.~Non-inclusion criteria :~treatment with another antithrombotic drug,~myeloproliferative syndrome,~platelet count < 100 gigas/liter,~acute inflammatory situation: severe sepsis, documented acute infection, chronic systemic inflammatory disease or active cancer,~dialysis."
89193410|NCT04990596||Age Group 90 to 100|"Inclusion criteria :~age 50-100 years old,~in consultation or hospitalization in one of the participating centres,~treatment with clopidogrel 75 milligrammes per day, for at least 10 days, for primary or secondary prevention of cardiovascular events.~Non-inclusion criteria :~treatment with another antithrombotic drug,~myeloproliferative syndrome,~platelet count < 100 gigas/liter,~acute inflammatory situation: severe sepsis, documented acute infection, chronic systemic inflammatory disease or active cancer,~dialysis."
89193411|NCT04984356|Experimental|WU-CART-007|"A CD7-directed chimeric antigen receptor (CAR) T-cell product.~A single IV infusion of WU-CART-007 Cells on Day 1 after Lymphodepletion(LD) Therapy."
89417081|NCT03829657|Experimental|ampreloxetine (Open Label (OL))|Participants will receive ampreloxetine as a single, oral, daily dose of active drug for 16 weeks.
89417082|NCT03829657|Experimental|ampreloxetine|After completing the OL, participants randomized to ampreloxetine will receive single, oral, daily dose of active drug for a further 6 weeks.
89417083|NCT03829657|Placebo Comparator|Placebo|After completing the OL, participants randomized to Placebo will receive single, oral, daily dose of placebo for 6 weeks.
89417084|NCT02170974|Experimental|BIBR 1048 MS polymorph II|
89417085|NCT02170974|Active Comparator|BIBR 1048 MS polymorph I|
88894899|NCT06071988|Experimental|Control group|Sublingual spray with maximum application of 16 actuations per day distributed over 4 daily intakes.
88894900|NCT06071975|Experimental|Treatment group|Sublingual spray with maximum application of 16 actuations per day or a maximum daily dose of 17,6mg THC distributed over 4 daily intakes.
88894901|NCT06071975|Experimental|Control group|Sublingual spray with maximum application of 16 actuations per day distributed over 4 daily intakes.
88894902|NCT06071962|Experimental|Treatment group|Sublingual spray with maximum application of 16 actuations per day or a maximum daily dose of 17,6mg THC distributed over 4 daily intakes.
88894903|NCT06071962|Experimental|Control group|Sublingual spray with maximum application of 16 actuations per day distributed over 4 daily intakes.
88894904|NCT06071949|Experimental|Treatment group|Sublingual spray with maximum application of 16 actuations per day or a maximum daily dose of 17,6mg THC distributed over 4 daily intakes.
88894905|NCT06071949|Experimental|Control group|Sublingual spray with maximum application of 16 actuations per day distributed over 4 daily intakes.
88894906|NCT06071936|Experimental|Treatment group|Sublingual spray with maximum application of 16 actuations per day or a maximum daily dose of 17,6mg THC distributed over 4 daily intakes.
88894907|NCT06071936|Placebo Comparator|Control group|Sublingual spray with maximum application of 16 actuations per day distributed over 4 daily intakes.
88922162|NCT05713370|Placebo Comparator|no exercise, no SR|75 g of glucose will be given at the beginning of the study day (the evening prior there will be no exercise the night before the study day, normal sleep (8 h))
89417086|NCT03594357||Multiple sclerosis|MS patients (EDSS: 0-5,5)
89417087|NCT03594357||Control|Healthy individuals without chronic disease
89417088|NCT03539250|Experimental|IMRT with and without chemotherapy|Subdivision of the PTVnx into regions with different prescribed absorbed doses (PTVsv1,PTVsv2, PTVsv2 is the overlaps between PTVnx and temporal lobe) can be used in cases for which the PTVnx overlaps temporal lobe. When the volume of PTVsv2 is less than 0.2 cubic centimeter (cc), the prescribe dose for PTVsv2 is as the same as that of the PTVsv1, D1cc 63.1Gy, Dmax 72.9Gy for TL (32 fractions). When the volume of PTVsv2 is between 0.2 cc and 0.5cc, the prescribe dose for PTVsv2 is 66Gy, D1cc 63.1Gy, Dmax 72.9Gy for TL (32 fractions). When the volume of PTVsv2 is between 0.5 cc and 1cc, the prescribe dose for PTVsv2 is 66Gy, D1cc 65.8Gy, Dmax 75.2Gy for TL (32 fractions).
88894908|NCT06071897|Experimental|intervention/treatment|"* days of 21 days schedule N5~Vincristine 1,5 mg/m2 i.v., day 1*~Etoposide 100 mg/m2 i.v. , days 1-4*~Cisplatin 100 mg/m2 i.v., days 1-4* N6~Vincristine 1,5 mg/m2 i.v. on days 1, 8*~Dacarbasine 200 mg/m2 i.v., days 1-5*~Ifosphamide 1500 mg/m2 i.v, days 1-5*~Doxorubicin 30 mg/m2 i.v, days 6, 7*~N5Q~N5 (see above)~Dinutuximab beta 10 mg/m2 i.v., days 5-9*~G-CSF (granulocyte colony-stimulating factor) 5 mcg/kg s.c. on day 9 until the ANC is more than 2000 /ml or until counts have recovered for the next cycle of therapy~N6Q~N6 (see above)~Dinutuximab beta 10 mg/m2 i.v., days 6-10*~G-CSF (granulocyte colony- stimulating factor) 5 mcg/kg s.c. on day 10 until the ANC is more than 2000 /ml or until counts have recovered for the next cycle of therapy~Delayed surgery (if needed) will be done after the 4th or 6th course of induction therapy and stem cells apheresis after the 2nd-5th course of induction therapy."
89417089|NCT03593733|Experimental|Cold Water Immersion|Cold Water Immersion
89417090|NCT03593733|Experimental|Photobiomodulation Therapy|Photobiomodulation Therapy
89417091|NCT02174718|Experimental|Daily 4000IU transdermal D patch|Only in the stage 2, Efficacy Study
89417092|NCT02174718|Active Comparator|Daily placebo patch plus oral placebo|Only in the stage 3, non-inferiority Study
89417093|NCT02174718|Active Comparator|Daily placebo patch plus oral vitamin D|Only in the stage 3 Non-inferiority Study
89417094|NCT02174718|Active Comparator|Daily 4000IU topical patch plus oral placebo|Only for the 3rd Stage of the study, Non-inferiority Study
89417095|NCT02174718|Placebo Comparator|Daily transdermal placebo patch|Only in the stage 2, Efficacy Study
89417096|NCT02238171||Chronic Obstructive Pulmonary Disease|
89417097|NCT02174796|Experimental|Surgical treatment group|"patients who chose to undergo a surgical correction (Ravitch or Nuss type intervention).~intervention: surgical correction (Ravitch or Nuss type intervention)."
88922163|NCT05713370|Experimental|no exercise, SR|75 g of glucose will be given at the beginning of the study day (the evening prior there will be no exercise the night before the study day, 4 h of sleep the previous night)
89417098|NCT02174796|Experimental|Orthopedic treatment group|patients who chose an orthopedic treatment by vacuum bell. intervention : orthopedic treatment by vacuum bell.
89417099|NCT03069586|Other|Low pressure pneumoperitoneum|Surgery on low pressure pneumoperitoneum (8 - 10 mmHg).
89199153|NCT05954754|No Intervention|Control|The researchers applied no initiative to the control group, and the women in the control group solely had the routine checks. The women in the control group filled out all pretest forms(Personal Information Form,Revised-Prenatal Coping Inventory (NuPCI), Fetal Health Anxiety Inventory (FHAI)) were re-administered 2 weeks later to women who did not receive any intervention.
89417100|NCT03069586|Active Comparator|low pressure peritoneum and pulmonary recruitment|Surgery on low pressure pneumoperitoneum (8 - 10 mmHg) and at the end of surgery a manual pulmonary recruitment manoeuver (2 x 5sec max 40cmH2O) will be done
89417101|NCT02237703||Post-traumatic stress disorder (PTSD)|Post-traumatic stress disorder (PTSD)
89417102|NCT02237703||Trauma Control (TC)|Trauma Control (TC)
89417103|NCT02237703||Healthy Control (HC)|Healthy Control (HC)
89417104|NCT02169882|Active Comparator|Rifampicin 450 mg (standard dose)|"Twenty patients will receive 1 tablet of 450 mg Rifampicin and 2 tablets of placebo once daily for 30 days.~Unconscious subjects will receive oral drugs via nasogastric tubes (NGT).~After completion of one-month treatment, patients will receive 1 tablet of 450 mg Rifampicin.~Along with study drug and placebo, patients will receive other oral TB drugs (INH, Ethambutol, and Pyrazinamide) and pyridoxin, in accordance to National TB Program guidelines for 6 months.~Patients will also receive dexamethasone in decreasing dose (in 6-8 weeks, according to TBM severity grade on admission)"
89417105|NCT02169882|Experimental|Rifampicin 900 mg per oral|"Twenty patients will receive 2 tablets of 450 mg Rifampicin and 1 tablet of placebo once daily for 30 days.~Unconscious subjects will receive oral drugs via nasogastric tubes (NGT)~After completion of one-month treatment, patients will receive 1 tablet of 450 mg Rifampicin.~Along with study drug and placebo, patients will receive other oral TB drugs (INH, Ethambutol, and Pyrazinamide) and pyridoxin, in accordance to National TB Program guidelines for 6 months.~Patients will also receive dexamethasone in decreasing dose (in 6-8 weeks, according to TBM severity grade on admission)"
89199154|NCT05954689|Experimental|Femoral artery block|An experienced Anesthesiologist will perform the femoral blocks, under ultrasound guidance with a linear probe and a 50mm (millimeters) or 80mm needle. No nerve stimulator will be used during the block. In both groups, femoral nerve block at the nerve sheath will be performed with 20mL (milliliters) 0.5% ropivacaine. In the interventional group, additionally to the previous block, the needle will be retracted and advanced to the antero-medial side of the femoral artery where 10mL 0.5% ropivacaine will be injected after negative aspiration.
89199155|NCT05954689|No Intervention|No intervention|
89417106|NCT02169882|Experimental|Rifampicin 1350 mg per oral|"Twenty patients will receive 3 tablets of 450 mg Rifampicin and 0 tablet of placebo once daily for 30 days.~Unconscious subjects will receive oral drugs via nasogastric tubes (NGT)~After completion of one-month treatment, patients will receive 1 tablet of 450 mg Rifampicin.~Along with study drug and placebo, patients will receive other oral TB drugs (INH, Ethambutol, and Pyrazinamide) and pyridoxin, in accordance to National TB Program guidelines for 6 months.~Patients will also receive dexamethasone in decreasing dose (in 6-8 weeks, according to TBM severity grade on admission)"
89417107|NCT03592173|Experimental|SAS20|The paired stimulation (SAS) will be comprised of patient adjusted subthreshold TMS (80% of resting motor threshold over optimal site for soleus muscle), delivered 20ms prior to a peripheral nerve stimulus in the popliteal fossa and will be repeated at 0.1 Hz for 15 minutes (90 stimuli pairs).
89417108|NCT03592173|Active Comparator|SAS0|The paired stimulation (SAS) will be comprised of patient adjusted subthreshold TMS (80% of resting motor threshold over optimal site for soleus muscle), delivered 0ms prior to a peripheral nerve stimulus in the popliteal fossa and will be repeated at 0.1 Hz for 15 minutes (90 stimuli pairs).
89417109|NCT03592173|Active Comparator|SAS50|The paired stimulation (SAS) will be comprised of patient adjusted subthreshold TMS (80% of resting motor threshold over optimal site for soleus muscle), delivered 50ms prior to a peripheral nerve stimulus in the popliteal fossa and will be repeated at 0.1 Hz for 15 minutes (90 stimuli pairs).
89417110|NCT02174874||Oral Ondansetron|Arm that receive oral solution .8 mgms per ml ondansetron - Apotex Brand DIN 02291967
89417111|NCT02174874||Oral disintegrating tablets|Arm that receives the disintegrating tablets either 4mg or 8 mgs Glaxo Brand 4 mg DIN 02239372, 8 mg DIN 02239373
89417112|NCT03602547|Experimental|CM082 plus JS001|Patients who meet the enrollment criteria will receive CM082 tablets 200mg once daily (qd) orally (taken within half an hour after daily breakfast) in combination with JS001 (3mg/kg, once every 2 weeks, q2w), every 28 days A treatment cycle until the disease progresses, the toxicity is intolerable, the investigator or subject decides to withdraw, loses to follow up, starts using other anti-tumor treatments or dies.
89199156|NCT05954650||Patients in a Minimally Conscious State|"Patients diagnosed as in a Minimally Conscious State Plus and Minus"
89417113|NCT02169960|Active Comparator|Middle School, General|OVK Resiliency Training Program - Cognitive Behavioral Therapy designed to modify negative thoughts and feelings. This program also includes a social problem-solving component.
89417114|NCT02169960|No Intervention|High School, General|No intervention - no Resiliency training, no online intervention for high school students who do not score at risk for development of mental health issues
89417115|NCT02169960|Active Comparator|Middle School, Top 10%|Smart, Positive, Active, Realistic X-factor thoughts (SPARX), Breaking Free, This Way Up online interventions offered to middle school students who score in the Top 10% of their grade for development of mental health issues. OVK Resiliency Training is also provided.
89417116|NCT02169960|Active Comparator|High School, Top 10%|Smart, Positive, Active, Realistic X-factor thoughts (SPARX), Breaking Free, This Way Up online interventions offered to middle school students who score in the Top 10% of their grade for development of mental health issues.
89417117|NCT04277299|Experimental|Intervention group|The participants in the intervention group will receive the routine care plus the ICory-Solution which is the surgical pathway currently practiced in the study hospital. The ICory-Solution has two components: (1) the Buddy Healthcare mobile app (BuddyCare) that provides a comprehensive day-by-day perioperative guide for parents regarding their child's surgery with an interface for health care professionals to monitor parents' and their children's needs as well as communicate with them. (2) The Triumf Health mobile game app that provides emotional support and distraction to children.
89417118|NCT04277299|No Intervention|Control group|Children in the control group will receive routine care provided by the hospital which consists of normal doctor consultant, preoperative preparation, and postoperative care. Parents in this group will receive BuddyCare mobile app which is supposed to be as a normal routine in this hospital.
89417119|NCT03602469|Experimental|Bupivacaine|Ultrasound-guided suprascapular nerve block using bupivacaine will be performed before induction of general anesthesia
88922164|NCT05713370|Experimental|Exercise, no SR|75 g of glucose will be given at the beginning of the study day (the evening prior there will be 45 min of exercise the night before the study day, normal sleep (8 h))
88922165|NCT05713370|Experimental|Exercise, SR|75 g of glucose will be given at the beginning of the study day (the evening prior there will be 45 min of exercise the night before the study day, 4 h of sleep the previous night)
88922166|NCT05712161|Experimental|DurAVR™ THV System|TAVR procedure
89199157|NCT05954611|Experimental|GR2002 injection|GR2002 subcutaneous injection
89417120|NCT03602469|Active Comparator|Bupivacaine-magnesium|Ultrasound-guided suprascapular nerve block using bupivacaine in conjunction of magnesium sulfate will be performed before induction of general anesthesia
89417121|NCT02174952|Experimental|TAU+SH|Families allocated to receive their usual treatment + self-help (TAU+SH) will receive 12 weeks of a self-help version of the New Forest Parenting Programme in addition to the usual treatment they are receiving from their clinician. They will also receive an introductory DVD aimed at highlighting key components of the intervention.
89417122|NCT02174952|No Intervention|TAU|Families in the Treatment as Usual (TAU) condition will receive nothing additional to the treatment offered by their paediatrician or Child & Adolescent Mental Health Services (CAMHS) during the trial phase. Families in the TAU condition will be offered the self-help manual at the end of the trial.
89417123|NCT02170038|Experimental|Arm 1|Healthy premenopausal subjects will receive multiple oral doses of Microgynon for 21days
89417124|NCT02170038|Experimental|Arm 2|Healthy premenopausal subjects will receive a single intramuscular dose of Noristerat
89417125|NCT05001373|Experimental|Study Group 1|eOD-GT8 60mer mRNA Vaccine (100µg)
89417126|NCT05001373|Experimental|Study Group 2|eOD-GT8 60mer mRNA Vaccine (100µg) and Core-g28v2 60mer mRNA Vaccine (100µg)
89417127|NCT05001373|Experimental|Study Group 3|eOD-GT8 60mer mRNA Vaccine (100µg) and Core-g28v2 60mer mRNA Vaccine (100µg)
89417128|NCT05001373|Experimental|Study Group 4|Core-g28v2 60mer mRNA Vaccine (100µg)
89417129|NCT03591939||1|cases of Diabetic type two nephropathy
88894909|NCT06071871|Experimental|Part 1|"Patients whose large B-cell lymphoma has progressed/not responded to previous treatment and are due to start standard CAR-T therapy.~All patients receive 2 cycles of glofitamab and polatuzumab vedotin (Glofit-Pola). Obinutuzumab pre-treatment is given on cycle 1 day 1.~Patients have a PET-CT scan to check the response after cycle 2. If the scan shows a response and patients are still suitable for CAR-T cell therapy, patients will proceed to receive planned CAR-T therapy and will not receive further Glofit-Pola in Part 1. If not, patients can receive 4 more cycles of glofitamab and polatuzumab vedotin, and then 6 cycles of glofitamab."
88894910|NCT06071871|Experimental|Part 2|"Patients whose large B-cell lymphoma has progressed/not responded after standard CAR-T cell therapy.~All patients receive 6 cycles of glofitamab and polatuzumab vedotin (Glofit-Pola), and then 6 cycles of glofitamab alone. Obinutuzumab pre-treatment is given on cycle 1 day 1."
88922167|NCT05706363|Active Comparator|MPFL reconstruction with gracillis graft|MPFL reconstructrion with gracillis graft and screw fixation in femur
89199158|NCT05954611|Placebo Comparator|placebo|placebo subcutaneous injection
89199159|NCT05954598|Experimental|probiotic|The intervention group received 12 weeks of probiotic intervention from the beginning of the study,and at the start of the study at week 13, both groups received 12 consecutive weeks of probiotic intervention
89417130|NCT03591939||2|controls of normal subjects
89417131|NCT02171052|Experimental|Dabigatran etexilate plus digoxin|
89417132|NCT02171052|Active Comparator|Dabigatran etexilate|
89417133|NCT02171052|Active Comparator|Digoxin|
89417134|NCT03675919|Active Comparator|Control group|The control group will be provided a scale, a step counter as well as access to the online portal and will remain in routine care.
89417135|NCT03675919|Experimental|TeLIPro group|The TeLIPro group will be provided a scale, a step counter, a blood glucose meter with test stripes as well as access to the online portal and will get telemedical coaching.
89417136|NCT03591549|Experimental|fulvestrant arm|patients will receive fulvestrant + zoladex intramuscular monthly with an assessment every three months to assess the response and progression
89417137|NCT02261220|Experimental|MEDI4736 + Tremelimumab|Subjects with multiple tumor types.
89417138|NCT02237937|Experimental|Normal dosage|"Selected antidepressants that are substrates of the P-glycoprotein:~Dosage:~paroxetine < 40 mg/d~sertraline < 100 mg/d~citalopram < 40 mg/d~escitalopram < 20 mg/d~venlafaxine < 225 mg/d~amitriptyline < 150 mg/d~amitriptylinoxide < 150 mg/d~nortriptyline < 150 mg/d~trimipramine < 150 mg/d"
89417139|NCT02237937|Experimental|High dosage|"Selected antidepressants that are substrates of the P-glycoprotein:~Dosage:~paroxetine < 80 mg/d~sertraline < 200 mg/d~citalopram < 80 mg/d~escitalopram < 40 mg/d~venlafaxine < 450 mg/d~amitriptyline < 300 mg/d~amitriptylinoxide < 300 mg/d~nortriptyline < 300 mg/d~trimipramine < 300 mg/d"
89417140|NCT02238015||surgery group|patients underwent cataract surgery with 3.0 mm clear corneal incision at 11 o'clock in one eye
89417141|NCT02238015||control group|patients' other eye that did not have surgery
89417142|NCT02238093||Dialysis Patients|End-stage renal disease patients undergoing dialysis at the Hillel Yaffe Medical Center.
88894911|NCT06071832|Experimental|Structured Play Condition|The following describes ONE intervention type with the following rationale. We chose to investigate shared book reading because it is a structured activity that is familiar, emotionally engaging, and supportive of general knowledge and language development. Adults report that shared reading is an important bonding activity that builds adult-child closeness through back- and-forth interactions. Importantly, the joint attention that occurs during shared book reading when adults and children share focus on the book may promote language and social emotional outcomes. Children are responsive and attentive during shared reading over video chat, but it is unknown whether a triadic interaction can be established during reading via video chat.
88922168|NCT05706363|Experimental|MPFL reconstruction with quadriceps graft|MPFL reconstructrion with quadriceps graft and suture anchor fixation in femur
89199160|NCT05954598|Placebo Comparator|placebo|The waiting group received 12 consecutive weeks of placebo intervention from the start of the study, and at the start of the study at week 13, both groups received 12 consecutive weeks of probiotic intervention
89417143|NCT02170116|Experimental|BIBR 1048 MS dose 1|
89417144|NCT02170116|Experimental|BIBR 1048 MS dose 2|
89417145|NCT02170116|Experimental|BIBR 1048 MS dose 3|
89417146|NCT02170116|Experimental|BIBR 1048 MS dose 4|
89417147|NCT02170116|Experimental|BIBR 1048 MS dose 5|
89417148|NCT02170116|Placebo Comparator|Placebo|
89417149|NCT03035227|Active Comparator|Catheter Ablation|Catheter ablation procedure of atrial and/or ventricular arrhythmias.
89417150|NCT03035227|Active Comparator|Medical Therapy|Medical management using antiarrhythmic drugs per standard of care of treating physician.
89417151|NCT03591393|Experimental|Pregnant women|"questionnaire at 1st and 3rd trimester, 10-12 weeks postpartum and 12 months postpartum~pelvic floor ultrasound at 1st trimester and at 3rd trimester"
89417152|NCT02170194|Experimental|Resilience Enhancement Group|The resilience enhancement group will begin with a 90-minute session with the study psychologist, which will include a brief introduction to cognitive behavioral therapy (CBT), but focus primarily on psychoeducational, relaxation techniques and planning positive activities. The majority of the time will be focused on reviewing techniques that promote stress management. Emphasis will be placed on relaxation approaches such as controlled breathing, meditation and yoga. Focus will also be aimed at reviewing how engagement in positive activities may help prevent avoidance, promote social support and wellness. Over the subsequent 6 weeks, daily text messages to all participants will accentuate the positive, including providing recommendations on beneficial activities to engage in, encouraging such activities including in vivo exposure, and fostering behavioral changes.
89417153|NCT02170194|Placebo Comparator|Control Group|"The control group will be provided with an initial informational session providing them with details of where they can get help if they have worsened symptoms over time. In addition, the psychologist will briefly review the apps, but not provide the same pscyhoeducational detail given to the resilience enhancement group. They will receive daily texts with inspirational aphorisms (e.g., Early to bed and early to rise makes a man healthy, wealthy, and wise.) for 6 weeks."
89417154|NCT02170272|Experimental|Home-based Lymphedema Care Program|Home-based Lymphedema Care Program (HBLCP): Participants will undergo one training session with a lymphedema therapist, and then receive a self-care video and educational manual to review at home. After completion of training session, follow-up measures occur at 1, 2, and 3 months.
89417155|NCT02238405|Experimental|Counseling|Intensive anti-smoking counseling
89417156|NCT02238405|No Intervention|Standard Care|Control group will receive current standard of care.
89417157|NCT03539562||Accepted Morphine Sulfate|Patients accepted morphine and promethazine as a method for pain management in early or prodromal labor.
89417158|NCT03539562||Declined Morphine Sulfate|Patients declined morphine and promethazine as a method for pain management in early or prodromal labor.
89417159|NCT02238249||paediatric patients with urticaria|
89417160|NCT03590769|Experimental|PET/MR using FDG-18 radiotracer|Using FDG-18 radiotracer, subject undergoes PET/MR scan which detects the uptake of the tracer.
89417161|NCT03675763|Experimental|Craniosacral therapy|Craniosacral therapy and parent information on how to manage colic.
89417162|NCT03675763|No Intervention|Parent information|Parent information on how to manage colic.
89417163|NCT00394069|Experimental|Montelukast sodium|Participants receive montelukast sodium for 14 days.
88894912|NCT06071832|Experimental|Structured Reading Condition|The following describes ONE intervention type with the following rationale. For our structured play condition, we chose to investigate the activities of playing show and tell, imitating with objects, and drawing because these are common activities derived from lab-based video chat experiments with children, many of which are authored by the PI and Co-I.
88894913|NCT06071832|Experimental|Control Condition|The control families will be asked to do video chat as usual, with no specific instructions.
88894914|NCT06071819||Generalized Anxiety Disorder (GAD)|Patients affected by GAD
88894915|NCT06071819||Panic Disorder (PD)|Patients affected by Panic Disorder
89417164|NCT03598959|Experimental|Treatment|Treated with tofacitinib and chidamide for 4 cycles.
89417165|NCT05634928||TMA|TMA patients
89417166|NCT02238717|Experimental|PF-06372865 (65mg)|
89417167|NCT02238717|Experimental|PF-06372865 (15mg)|
89417168|NCT02238717|Active Comparator|Pregabalin|
89417169|NCT02238717|Placebo Comparator|Placebo|
89417170|NCT03625453|Experimental|ABX-1431|Oral use of hard capsule (10 milligrams), maximum dose per day: 40 milligrams
89417171|NCT03625453|Placebo Comparator|Placebo|Oral use of hard capsule
89417172|NCT03066388|Experimental|Pulse pressure variations|Pulse pressure variations, stroke volume, systemic arterial pressure, heart rate, and respiratory rate are recorded immediately before and after volume expansion (VE), performed as a 30-minute infusion of 500 mL of 4% gelatin. Pulse pressure variations are obtained by noninvasive (ΔPPCNAP) and invasive (ΔPPART) devices.
89417173|NCT03581955|Experimental|Banana Cavendish|240g of fruit plus 150ml of Fresubin ® 2kcal fiber neutral flavor
89417174|NCT03581955|Experimental|Control drink|250ml of Fresubin ® 2kcal fiber neutral flavor
88894916|NCT06071806|Other|surgery/Topical application of fluorouracil|The entire cyst lining radically enucleated with peripheral ostectomy was carried out for all bony walls to remove the microscopic satellite cyst, a sterile radiopaque quarter-inch ribbon gauze coated with 5-FU cream was packed into the surgical wound. Closure of the wound was then done in the usual manner using 3/0 vicryl leaving approximately1 cm of a small distal end of the gauze exposed to allow for easy removal after 24 hours postoperatively
88894917|NCT06071689|Active Comparator|PEEK group|patients receive all-on-4 prostheses constructed from CAD/CAM milled PEEK framework.
88894918|NCT06071689|Active Comparator|Soft metal group|patients receive all-on-4 prostheses constructed from CAD/CAM milled soft metal framework.
88894919|NCT06071689|Active Comparator|selective laser melting group|patients receive all-on-4 prostheses constructed from 3D printed selective laser melting Co-Cr framework.
89417175|NCT03581955|Experimental|Tomato|300g of tomato plus of Fresubin ® 2kcal fiber neutral flavor plus 12g of refined sunflower oil.
89417176|NCT03568123|Experimental|MC polyethylene bearing|Persona Total Knee System with MC polyethylene bearing
89417177|NCT03568123|Active Comparator|CR polyethylene bearing|Persona Total Knee System with a CR polyethylene liner.
89417178|NCT03558217|Experimental|Collared Femoral Implant|Participants will have the Corail collared femoral implant used during their surgery.
89417179|NCT03558217|Active Comparator|Collarless Femoral Implant|Participants will have the Corail collarless femoral implant used during their surgery.
89417180|NCT03587259|Active Comparator|2D mammography|45-46 years old women are invited to attend the usual screening examination (2D mammography). The next year they will be invited to make a 2D mammography, according to screening protocol.
89417181|NCT03587259|Experimental|Tomosynthesis|45-46 years old women are invited to attend the Digital Breast Tomosynthesis (DBT) in adjunct to synthetic mammograms (sDM). The next year they will be invited to make a 2D mammography, according to screening protocol.
89417182|NCT03470311|Active Comparator|Benralizumab|Benralizumab 30mg in 1mL subcutaneously
88894920|NCT06071533||Danshen Injection(DS group)|patients received Danshen Injection
89417183|NCT03470311|Placebo Comparator|Placebo|Matched placebo (1mL) to active Benralizumab subcutaneously
88894921|NCT06071533||Sportive Care group (SC group)|patients received sportive care without Danshen Injection
88894922|NCT06071507||Enteral Stenting|Endoscopic placement of enteral Self-Expandable Metal Stents (SEMS). The procedure implies endoscopic identification of the stricture, placement of a guidewire through the stricture and placement of a SEMS through the stricture under fluoroscopic control.
89417184|NCT04051021|Other|Usual Care|
89417185|NCT04051021|Experimental|Comfort Coach|
89417186|NCT03580707|Active Comparator|Part 1|Compare rapidity of CNS effects of levetiracetam (LEV) & brivaracetam (BRV) within same pt-(randomized, two-way crossover, dbl-blind in total 16 pts w/epilepsy. Pt 1: IV infusion over 15 min BRV will also be administered as 15-min.infusion. BRV vs LEV in randomized double blinded, crossover fashion.
89417187|NCT03580707|Active Comparator|Part 2|Pt 2 Op I:Assuming statistically signify. diff. in rapidity of CNS action has been observed from an analysis of data set in Pt 1,will proceed w/ Pt 2Opt I. Levetiracetam (LEV) or brivaracetam (BRV administered in randomized, two-way crossover, dbl-blind design as IV infusion over 5 min. to another cohort of 8 pts w/photosensitive epilepsy OR Pt 2,Opt II: Assuming no statistically signif. diff. in rapidity of CNS action has been observed from an analysis of data set in Pt 1, will proceed w/Pt 2,Opt II. LEV or BRV will be administered, in randomized, two-way crossover, dbl-blind design as IV infusion over again 15 min. to another cohort of 8 pts w/ photosensitive epilepsy. LEV will be given as 500 mg dose & BRV as 25 mg dose. BRV vs LEV in randomized double blinded, crossover fashion.
89417188|NCT03068026|Experimental|Continuous exercise|Patients will undergo a constant load exercise protocol with gas exchange analysis on a cycle ergometer. The exercise protocol will be consisted of repeated 6-min exercise bouts, separated by 2-min rest periods in between work bouts in order to allow application of the VitaBreath device. During the 1st min of each resting period participants will breathe either via the VitaBreath device or normally adopting the pursed lip breathing technique. During the 2nd min of each resting period participants will breathe normally and perform an IC maneuver to assess the magnitude of dynamic hyperinflation.
89417189|NCT03068026|Experimental|Interval exercise|Patients will undergo an interval exercise protocol with gas exchange analysis on a cycle ergometer. The exercise protocol will consist of repeated 2-min exercise bouts, separated by 2-min resting periods in between work bouts in order to allow application of the VitaBreath device. During the 1st min of each resting period participants will breathe either via the VitaBreath device or normally adopting the pursed lip breathing technique. During the 2nd min of each rest period participants will breathe normally and perform an IC maneuver, to assess the magnitude of dynamic hyperinflation.
89417190|NCT03580005|Active Comparator|Quillichew ERCT|Quillichew ERCT
89417191|NCT03580005|Placebo Comparator|Placebo to match Quillichew ERCT|Placebo to match Quillichew ERCT
89417192|NCT00293995|Other|Laparoscopic repair|Laparoscopic repair, with closure of contralateral patent processus vaginalis
89417193|NCT00293995|Other|Open repair|Open repair
89417194|NCT04412512|Experimental|VATS approach|patients treated by VATS technique.
89417195|NCT04412512|Active Comparator|Thoracotomy approach|patients treated by Thoracotomy technique
89417196|NCT03579927|Experimental|Treatment (CAR transduced CB-NK cells, chemotherapy, ASCT)|Participants receive rituximab IV over 3 hours on days -14 and -8, carmustine IV over 2 hours on day -13, etoposide IV over 3 hours BID on days -12 to -9, cytarabine IV over 1 hour BID on days -12 to -9, melphalan IV over 30 minutes on day -8, CAR.CD19-CD28-zeta-2A-iCasp9-IL15-transduced CB-NK cells IV over 1 hour on day -5. Participants undergo ASCT on day 0. Beginning day 0, participants receive filgrastim SC QD until evidence of an ANC of 0.5 x 10^9/L per 3 consecutive days.
88894923|NCT06071507||EUS-guided Gastrojejunostomy|The procedure implies distention of the jejunal loop and EUS-guided placement of an electrocautery-enhanced (EC) LAMS connecting the stomach to a jejunal loop distal to the stenosis. Any technique for EUS-GE will be allowed, provided that an EC-LAMS >15mm will be used.
88894924|NCT06071507||Surgical Gastrojejunostomy|The procedure implies a surgical anastomosis between gastric wall and a jejunal loop. The procedure can be performed either through laparoscopy or open surgery.
88894925|NCT06071364||chronic nonspecific low back pain patients|Twenty-nine participants experienced chronic non-specific low back pain for over three months without any referred pain in their legs.
88894926|NCT06071364||Asymptomatic subjects|Twenty-nine subjects without symptoms of low back pain
88894927|NCT06071312|Experimental|. Single FMT|Patients enrolled in this arm will receive a single infusion of donor FMT
88894928|NCT06071312|Active Comparator|Sequential FMT|Patients enrolled in this arm will receive sequential infusions of donor FMT
88894929|NCT06071273|Experimental|Home-based exercise|6 months home-based exercise program with continuous monitoring of the cardiovascular response of the participants during exercise via the online platform.
88894930|NCT06071273|Experimental|Community-based exercise|6-month community based (i.e., local community gym) exercise intervention
88894931|NCT06071273|No Intervention|Control group|Control group, no exercise intervention.
88894932|NCT06071208||cases of study|Patients is diabetes whether recently discovered or long standing diabetes
89417197|NCT05180890|Placebo Comparator|Placebo|Placebo infusion, intravenously, administered overnight for approximately 10-hours on Days 1 to 2 in each Treatment Period 1, 2, or 3.
89417198|NCT05180890|Experimental|Danavorexton LD|Danavorexton LD regimen, infusion, intravenously, administered overnight for approximately 10-hours on Days 1 to 2 in each Treatment Period 1, 2, or 3.
89417199|NCT05180890|Experimental|Danavorexton HD|Danavorexton HD regimen, infusion, intravenously, administered overnight for approximately 10-hours on Days 1 to 2 in each Treatment Period 1, 2, or 3.
89417200|NCT03291691||Standard of care: SCI|Patients at Charite, with lower limb surgery undergoing a protective performed ultrasound guided sciatic nerve block. N=15.
89535938|NCT05003193|No Intervention|Not using a pedometer|The control group will not be given a pedometer.Patients in the control group will only be instructed to do physical activity every day and will be asked to record the minutes of physical activity they do for 90 days.
89535939|NCT03202615|Experimental|L (lactoferrin in IDA with pregnancy)|Pregnant women with IDA, in the 2nd trimester are enrolled and treated for 2 months regularly with oral administration of 100 mg bLf granules (Pravotin sachets , Hygint, Egypt) in 1/4 glass of water twice a day before meals in addition to placebo tablets three time per day on an empty stomach.
89535940|NCT03202615|Active Comparator|F (ferrous sulphate with pregnancy)|Pregnant women with IDA, in the 2nd trimester are enrolled and treated for 2 months regularly with oral administration of 150 mg of dried ferrous sulphate capsules (Ferrofol capsules, Eipico, Egypt), one capsule three times daily on an empty stomach, at least 1 hour before or 2 hours after meals, in addition to placebo sachets (starch) twice a day.
89535941|NCT05455853|Experimental|bilateral transcutaneous tibial nerve stimulation,exercise and advices|•They will receive bilateral transcutaneous tibial nerve stimulation three times per week for 4 weeks, in addition to abdominal muscle training and breathing exercise and bowel care advices.
89535942|NCT05455853|Experimental|Exercises and advices|They will perform abdominal muscle training and breathing exercise three times per week, for 4 weeks in addition to bowel care advices.
89535943|NCT03202459|Active Comparator|Active Comparator: Group A - gabapentin|The patient will receive oral 600 mg gabapentin 2 h before surgery
89535944|NCT03202459|Active Comparator|Active Comparator: Group B - pregabalin|The patient will receive oral pregabalin 150 mg 2 h before surgery
89535945|NCT03202459|Placebo Comparator|Placebo Comparator: Group C - placebo|The patient will receive oral placebo 2 h before surgery and ondansetron 8mg intravenous at the end of the surgery
89535946|NCT04991181|Experimental|BIA 5-1058|Capsules; 400 mg; single dose; oral administration.
89535947|NCT03215641|No Intervention|Control|The control group families will participate in the standard Body Works weight loss program. They will fill out brief surveys regarding their physical activity on a weekly basis, but otherwise will receive the standard curriculum. they will receive weekly feedback based on their physical activity surveys.
89535948|NCT03215641|Experimental|Intervention|The intervention group families will be given fitbits on the first day of the Body Works program. They will otherwise receive the same curriculum as the control families. the will fill out the same physical activity surveys as the control families. they will receive weekly feedback based on the objectively measured physical activity.
89535949|NCT02483663||27 Monozygotic Pairs|
89535950|NCT02483663||27 Dizygotic Pairs|
89535951|NCT03118609|Experimental|"Caregivers for Understanding Needs"|"5-8 informal caregiver participants in focus group will discuss current perceived needs.~Up to 150 participants will complete the Understanding Needs survey"
89535952|NCT03118999|Experimental|OM3-FFA|Omega3 linked to free fatty acids
89535953|NCT03118999|Experimental|OM3 -MAG|Omega3 linked to Monoacylglycerol
89535954|NCT03118999|Experimental|OM3-EE|Omega3 linked to ethylester
89535955|NCT04456959||Adult R/R ALL patients who have received InO|Relapsed/refractory ALL patients who are 18 years and over and initiated InO between 1st of June 2016 and date of data collection (to be confirmed). They will have accessed InO treatment via NHS commissioning, via the CUP, or via private purchase and will have at least 3 months follow up from the index date unless death occurs within that time.
89535956|NCT03202693|Experimental|PA-824|[14C]-PA-824 and unlabelled PA-824 oral suspension of 1000 mg unlabeled micronized PA-824 mixed with sufficient [14C]-PA-824 to achieve a final radiolabel dose of approximately 100 µCi/dose.
89535957|NCT05374187|Experimental|Active eTNS|Following screening and determination of eligibility , participants at baseline are randomized to receive 4 weeks nightly treatment with active eTNS. Positive responders will be invited to participate in a 12-month open-label continuation phase.
89535958|NCT05374187|Sham Comparator|Sham eTNS|Following screening and determination of eligibility, participants at baseline are randomize to receive 4 weeks nightly treatment with sham eTNS. At conclusion of the double-blind phase, participants randomized to sham will be provided an opportunity to receive an additional 4 weeks nightly treatment with active eTNS. Positive responders to active eTNS will be invited to participate in a 12-month open-label continuation phase.
89535959|NCT03202381|Experimental|Degarelix|
89535960|NCT05713721||SMC DYT/PARK-TAF1|Symptomatic mutation carriers (SMC) of the TAF1 gene, which is associated with X-linked Dystonia-Parkinsonism, will be examined.
89535961|NCT05713721||AMC DYT/PARK-TAF1|Asymptomatic mutation carriers (AMC) of the TAF1 gene will be examined.
89535962|NCT05713721||SMC DYT/PARK-GCH1|Symptomatic mutation carriers (SMC) of the GCH1 gene, which is associated with dopa-responsive Dystonia, will be examined.
89535963|NCT05713721||AMC DYT/PARK-GCH1|Asymptomatic mutation carriers (AMC) of the GCH1 gene will be examined.
89535964|NCT05713721||SMC PARK-Parkin/PARK-PINK1|Symptomatic mutation carriers (SMC) of the Parkin or PINK1 genes, which is associated with Parkinsonism, will be examined.
89535965|NCT05713721||AMC PARK-Parkin/PARK-PINK1|Asymptomatic mutation carriers (SMC) of the Parkin or PINK1 genes will be examined.
89417201|NCT03291691||Standard of care: FEM|Patients at Charite, with lower limb surgery undergoing a protective performed ultrasound guided femoral nerve block. N=15.
89417202|NCT03291691||Standard of care: ISB|Patients at Charite, with upper limb surgery undergoing a protective performed ultrasound guided interscalene plexus block. N=15.
89417203|NCT03291691||Standard of care: AXP|Patients at Charite, with upper limb surgery undergoing a protective performed ultrasound guided axillary plexus block. N=15.
89417204|NCT00100932|Experimental|1|E7389 28 day cycle
89417205|NCT00100932|Experimental|2|E7389 21 day cycle
89417206|NCT03579849|Experimental|Perfusion SPECT|"Included patients with a diagnosis of acute PE on CTPA and who had a subtraction iodine mapping CT will undergo a SPECT/CT within 24 hours.~Each lung subtraction iodine mapping CT will be interpreted blindly by 3 radiologists. Each of the 20 lung segments will be interpreted as normoperfused or hypoperfused.~Each perfusion SPECT will be interpreted blindly by 3 nuclear medicine physicians. Each of the 20 lung segments will be interpreted as normoperfused or hypoperfused."
89417207|NCT05634772|Active Comparator|the efficacy of dormia basket in management of proximal stent migration|
89417208|NCT05634772|Active Comparator|the efficacy of extraction biliary balloon in management of proximal stent migration|
89417209|NCT03587025|Active Comparator|Amitryptyline|Patients who will be take amitryptyline, 75mg, only use, 30min before surgery.
88894933|NCT06071208||controls of study|prediabetics ,or patients with clinical manifestations of insulin resistance eg acanthosis negricans
88894934|NCT06070506||HFrEF group|Heart failure patients with LVEF persistently ≤40%.
88894935|NCT06070506||HFimpEF group|Heart failure patients with previous LVEF ≤40% and a follow-up LVEF of more than 40%.
88894936|NCT06070415|Experimental|Experimental|Home exercise assisted with a chatbot
88894937|NCT06070415|Active Comparator|Control|Home exercise, usual care
89417210|NCT03587025|Placebo Comparator|Placebo|Patients who will be take placebo 30min before surgery.
88894938|NCT06070181|Other|Control- no adjunctive treatment|One arm is the control: two quadrants per each patient treated with non-surgical periodontal treatment alone. NO adjunctive treatment with emdogain. The two quadrants are randomized.
88894939|NCT06070181|Experimental|Test-adjunctive treatment with Emdogain|The experimental arm is the two quadrants per patient assigned to be treated vid adjunctive Emdogain.
88894940|NCT06069687|Experimental|MELPIDA|A single intrathecal infusion of 10 mL at 1E14 vg/mL for a total dose of 1E15 vg (open-label)
88894941|NCT06069557|No Intervention|Control|There will be no intervention in this group.
89417211|NCT02170350|Experimental|Brief mindful meditation practice|Patients use brief mindful meditation practice (sitting meditation in which the mind is guided to focus in the present, thinking of your existence, and allowing sensations to arise with an openness and curiosity) over 12 minutes daily for 14 days during radiation therapy.
89417212|NCT02238795||Purpura fulminans|Patients diagnosed with Purpura fulminans in association with sepsis
89417213|NCT02171208|Active Comparator|Reference, Test, Reference (RTR)|Doses will be separated by a washout period
89417214|NCT02171208|Active Comparator|Test, Reference, Reference (TRR)|Doses will be separated by a washout period
89417215|NCT03180307|Sham Comparator|no fluorescent imaging|Patient injected with OTL38, but does not undergo fluorescent imaging
89417216|NCT03180307|Experimental|near infrared imaging arm|Patient injected with OTL38 and undergoes near infrared imaging
89417217|NCT05634694||Sun Yat-Sen Memorial Hospital of Sun Yat-sen University|The cohort of Sun Yat-Sen Memorial Hospital of Sun Yat-sen University is the exploration cohort.
89417218|NCT02170428||growth and development|Growth and development of a random sample of healthy Danish infants
89417219|NCT02171286||No Treatment|
89417220|NCT02917213||StudyGroup|"A cohort of 92 patients with first ST elevation acute myocardial infarction (AMI), sinus rhythm, and LV ejection fraction < 45% in the first 24-72 h after symptoms onset.~In the first 24 hours after enrollment a coagulation blood test, a Doppler echocardiogram exam, a Carotid duplex ultrasound exam, a Transcranial Doppler monitoring and a Reveal LINQ insertable cardiac monitoring system will be 1:1 randomly implanted.~A clinical examination (including neuropsiquiatric evaluation), a Doppler echocardiogram exam, a cardiac MRI and a brain MRI will be performed after a week and after 6 months after enrollment."
89417221|NCT02848833||JARDIANCE|T2DM with JARDIANCE
89417222|NCT05634616|Experimental|BCI|The experimental group was trained with BCI-controlled pedaling rehabilitation training system. Patients wore EEG caps and were instructed to imagine upper limb pedaling movements. The greater the patients' movement intention, the higher the Mscore of movement intention index on the monitor and the faster the pedaling speed. In addition, the movements on the monitor are synchronized with the actual movements, and the system provides audio and text feedback according to the patient's performance.
89417223|NCT05634616|Sham Comparator|Sham BCI|In the control group, the training equipment and scenario were the same as in the experimental group, and the patients wore EEG caps and were also instructed to imagine upper limb pedaling movements. However, the system was changed to only record the EEG signal without controlling the pedaling equipment, and the Mscore score and pedaling speed displayed by the equipment in real time were pre-set data of the training performance of the previous pretest patients, i.e., sham neurofeedback.
89417224|NCT02170506|Experimental|submental sensitive transcutaneous electrical stimulation.|Each Healthy subjects will be his own witness. Urostim 2 stimulation Arm
89417225|NCT03539328|Other|Standard treatment|Pegylated Liposomal Doxorubicin 40 mg/mq iv q 28 or Weekly Paclitaxel 80 mg/mq d 1,8,15 q 28 or Gemcitabine 1000 mg/mq d 1,8 q 21 or At physician' discretion
89417226|NCT03539328|Experimental|Pembrolizumab|Pegylated Liposomal Doxorubicin 40 mg/mq iv q 28 or Weekly Paclitaxel 80 mg/mq d 1,8,15 q 28 or Gemcitabine 1000 mg/mq d 1,8 q 21 or At physician' discretion plus Pembrolizumab 200 mg d1 q 21 iv infusion in 30 minutes
89417227|NCT03361189|Experimental|CLS-On|Subjects in this arm will be programmed to CLS-on to received closed loop stimulation-based pacing for 3 months, followed by a standard rate response for 3 months.
89417228|NCT03361189|Active Comparator|CLS-Off|Subjects in this arm, will be placed in a standard rate response for 3 months, followed by CLS-on to received closed loop stimulation-based pacing for 3 months.
89417229|NCT03579537|Experimental|Hemodyalisis patients|group of patients in hemodialysis who performs the exercise program
89417230|NCT02171364|Experimental|virtual simulation|This intervention group is to choose the best effective method operation to patients by simulating 3D atrial computer model which consider patient's heart size and shape.
89417231|NCT02171364|Active Comparator|conventional ablation|The other intervention group is to operate the atrial fibrillation by physician's personal experience, not by virtual simulation.
89417232|NCT03589677||Myotonic dystrophy type 1|"Subjects of both sexes with a diagnosis of Steinert's disease (DM1), de novo or with the previous diagnosis that shows significant worsening detectable during the follow-up foreseen by the normal cure procedure with clinical presentation indicating a CNS compromise will be evaluated for:~quality of life evaluation~exam of neuroimaging~study of myomiRNAs before and after rehabilitation"
88894942|NCT06069557|Experimental|Experimental|An intervention will be made to this group
88894943|NCT06068478|Experimental|Qingzhu Granules|
88894944|NCT06068478|Placebo Comparator|Qingzhu Granules Placebo|
88894945|NCT06068387|Experimental|experimental group|locally advanced cervical cancer treated with surgical staging
89535966|NCT05713721||Control group|A healthy control group will be examined.
89535967|NCT05002647||exposure group|Data from electronic clinical pharmacist records of two infectious disease hospitals
89535968|NCT05002647||Non-exposure group A|Data from medical records of the hospital with no clinical pharmacy.
89535969|NCT05002647||Non-exposure group B|Data from a medical record of the hospital with clinical pharmacy, but the department did not cover by the clinical pharmacy
88894946|NCT06067698|Placebo Comparator|Group (Placebo)|(Placepo group; n=30) which will receive mesalamine 1000 mg three times daily plus placebo once daily
88894947|NCT06067698|Active Comparator|Group (Alpha lipoic acid)|(Alpha-lipoic acid group; n=30) which will receive mesalamine 1000 mg three times daily plus alpha-lipoic acid 600 mg
88894948|NCT06067295||Observational|Patients undergo blood and urine sample collection, complete surveys, and have their medical records reviewed on study.
88894949|NCT06067282|Experimental|Experimental group|The experimental group used microteaching training to cultivate the teaching skills of university students majoring in physical education in China.
88894950|NCT06067282|Active Comparator|Control group|The control group trained the students' teaching skills by conventional training methods.
88894951|NCT06067191|Experimental|Active|spray-dried dispersion (SDD) for Oral Suspension
88894952|NCT06067191|Placebo Comparator|Placebo|spray-dried dispersion (SDD) for Oral Suspension
89535970|NCT03200509|Experimental|Physical Activity Intervention|The participants from both groups will receive a group exercise program, including a combination of general, stabilisation, strengthening and resistance exercises. In addition, the intervention group will receive health coaching sessions and an activity monitor.
89535971|NCT03200509|Sham Comparator|Control group|The participants from both groups will receive a group exercise program, including a combination of general, stabilisation, strengthening and resistance exercises. The participants allocated to the control group will receive sham health coaching and a sham activity monitor, in addition to the exercise program.
88894953|NCT06067100|Experimental|Indacaterol + mometasonefluroate|
88894954|NCT06067100|Placebo Comparator|Placebo|
88894955|NCT06066827|Experimental|Minoxidil|The drug used is minoxidil 5% solutions for topical use, 1 cc, 2 times a day, every day for 12 weeks
89417233|NCT05634460|Active Comparator|Group A|patients in group A treated with 5% potassium hydroxide on every lesion once daily via cotton-tipped applicator for at least two weeks or till inflammatory manifestations
89417234|NCT05634460|Active Comparator|group B|patients in group B treated with10% potassium hydroxide on every lesion once daily via cotton-tipped applicator for at least two weeks or till inflammatory manifestations
89417235|NCT02171442|Experimental|BIBR 953 ZW Intravenously|
89417236|NCT02171442|Active Comparator|BIBR 1048 Oral Solution|
89417237|NCT02035527|Experimental|Treatment (sorafenib tosylate, docetaxel, and cisplatin)|Patients receive sorafenib tosylate PO BID on days 1-14 of course 0. Beginning in course 1, patients receive sorafenib tosylate PO BID on days 1-21, docetaxel IV over 1 hour on day 1, and cisplatin IV over 1 hour on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive sorafenib tosylate PO BID in the absence of disease progression or unacceptable toxicity.Correlative studies will be performed and a total of three biopsies (blood and tumor samples) will be obtained in consenting patients.Pre-treatment biopsy to establish diagnosis and baseline data, Research biopsy obtained at the end of a two week period of sorafenib monotherapy just prior to administration of cycle1 with cisplatin and docetaxel, Research biopsy obtained at the end of two chemotherapy cycles.
89417238|NCT00092131|Experimental|1|Montelukast - Placebo
89417239|NCT00092131|Experimental|2|Placebo - Montelukast
88894956|NCT06066827|Experimental|Secretome from Adipose-Derived Stem Cells|Secretom concentrate of Adipose-Derived Stem Cells (ADSCs) 2cc, injected to the scalp on weeks 0, 4, and 8 of the study
88894957|NCT06066827|Experimental|Minoxidil + Secretome|The subject received both minoxidil and secretome from ADSCs, with the same dosage form, dosage, frequency, and duration
88894958|NCT06065774|Experimental|The Laterally Closed Tunnel Technique with SCTG|"An aseptic field was required for all surgical procedures using povidine iodine. Local anesthesia using 4% articane with 1:100.000 epinephrine was applied.•~Then specially designed tunneling instruments [devmed] were used through the sulcular incision to create a pouch.~A microsurgical blade was used at the inner surface of the pouch till sufficient tissue release was achieved.~Tissue forceps was used to approximate the mesial and distal margin of the gingiva at the pouch margin.~After harvesting the graft, it was placed at the prepared pouch after root surface biomodification using EDTA gel 24% for 2 minutes and copious rinsing with saline solution.~SCTG was pulled using single or mattress sutures and the graft was fixed mesial and distal at the inner part of the pouch using resorbable suture material [Vicryl suture], then the graft was sutured around the neck of the CEJ by sling suture 6/0 polypropylene."
88894959|NCT06065774|Experimental|The Laterally Closed Tunnel Technique with collagen matrix mucograft|"An aseptic field was required for all surgical procedures using povidine iodine. Local anesthesia using 4% articane with 1:100.000 epinephrine was applied.•~Then specially designed tunneling instruments [devmed] were used through the sulcular incision to create a pouch.~A microsurgical blade was used at the inner surface of the pouch till sufficient tissue release was achieved.~Tissue forceps was used to approximate the mesial and distal margin of the gingiva at the pouch margin.~After harvesting the graft, it was placed at the prepared pouch after root surface biomodification using EDTA gel 24% for 2 minutes and copious rinsing with saline solution.~collagen matrix was pulled using single or mattress sutures and the graft was fixed mesial and distal at the inner part of the pouch using resorbable suture material [Vicryl suture], then the graft was sutured around the neck of the CEJ by sling suture 6/0 polypropylene."
88922169|NCT05704634|Experimental|Cohort A : EGFR-mutant cohort|Each cohort is planned for 30 Participants with a total of 60 Participants. Participants who are treated in Run-In safety cohort can also be evaluated for efficacy in the molecularly define cohort A or B.
88922170|NCT05704634|Experimental|Cohort B: LKB1-mutant cohort|Each cohort is planned for 30 Participants with a total of 60 Participants. Participants who are treated in Run-In safety cohort can also be evaluated for efficacy in the molecularly define cohort A or B.
88922171|NCT05701930|Experimental|Experimental:|pecha kucha will be practiced
88922172|NCT05701930|No Intervention|control|Routine maintenance will be applied.
89417240|NCT05729854|Experimental|acupressure group|Acupressure will be performed by the researchers of the main, hand and body parts of the women in the experimental units.In the clinic where the study will be conducted, acupressure application hours were determined considering the analgesic treatment protocol applied. Acupressure will be applied at the 18th and 24th hours postpartum.
89417241|NCT05729854|No Intervention|control group|Acupressure will not be applied to the control group. routine midwifery care.
89417242|NCT02170584|Experimental|BIBR 953 ZW IV|
89417243|NCT02170584|Active Comparator|BIBR 1048 MS oral solution|
89417244|NCT02170584|Experimental|BIBR 1048 MS tablet|
89417245|NCT02170584|Placebo Comparator|BIBR 953 ZW IV Placebo|
88894960|NCT06065774|Experimental|Modified Coronally Advanced Tunnel Technique with SCTG.|"Supraperiosteal incisions was extended to the mucosal level beyond the MGJ to allow sufficient tissue mobility and release.~The tunnel was extended in all directions around the recession defect to create a sufficient pouch for connective tissue graft stabilization.~The interdental papilla tunneling adjacent to the defect was a critical step for technique success.~Then perfect root planning was performed at the denuded root surface to remove the necrotic cementum at the accessible recession defect.~Subsequently palatal anesthesia was given to harvest palatal SCTG using deepitheliailized free gingival graft (FGG) technique.~SCTG was pulled using single or mattress sutures and the graft was fixed mesial and distal at the inner part of the pouch using resorbable suture material [Vicryl suture], then the graft was sutured around the neck of the CEJ by sling suture 6/0 polypropylene."
88894961|NCT06065774|Experimental|Modified Coronally Advanced Tunnel Technique with collagen matrix mucograft|"Supraperiosteal incisions was extended to the mucosal level beyond the MGJ to allow sufficient tissue mobility and release.~The tunnel was extended in all directions around the recession defect to create a sufficient pouch for connective tissue graft stabilization.~The interdental papilla tunneling adjacent to the defect was a critical step for technique success.~Then perfect root planning was performed at the denuded root surface to remove the necrotic cementum at the accessible recession defect.~Subsequently palatal anesthesia was given to harvest palatal SCTG using deepitheliailized free gingival graft (FGG) technique.~collagen matrix was pulled using single or mattress sutures and the graft was fixed mesial and distal at the inner part of the pouch using resorbable suture material [Vicryl suture], then the graft was sutured around the neck of the CEJ by sling suture 6/0 polypropylene."
88894962|NCT06064955|Experimental|Peer Support|Former caregivers will be paired with a current caregivers
88894963|NCT06064864|Experimental|Non-response to SC infliximab at week 30 and switched to infliximab IV 10 mg/kg every 8 weeks|"Patients with moderately to severely active Crohn's disease will be given IV (intravenous) infliximab 5 mg/kg at week 0 and 2. Then, they will be treated with SC (subcutaneous) infliximab every 2 weeks from week 6. At week 30. patients will be allocated to one of 3 arms according to their response to SC infliximab.~[Arm 1] Non-responders at week 30: Switched to infliximab IV 10 mg/kg every 8 weeks"
88894964|NCT06064864|Experimental|Response to SC infliximab at week 30 and then, switched to infliximab IV 5 mg/kg every 8 weeks|"Patients with moderately to severely active Crohn's disease will be given IV (intravenous) infliximab 5 mg/kg at week 0 and 2. Then, they will be treated with SC (subcutaneous) infliximab every 2 weeks from week 6. At week 30. patients will be allocated to one of 3 arms according to their response to SC infliximab.~[Arm 2] Response to SC infliximab at week 30 and then, randomly allocated to infliximab IV 5 mg/kg every 8 weeks"
88894965|NCT06064864|Active Comparator|Response to SC infliximab at week 30 and then, continued infliximab SC 120 mg every 2 weeks|"Patients with moderately to severely active Crohn's disease will be given IV (intravenous) infliximab 5 mg/kg at week 0 and 2. Then, they will be treated with SC (subcutaneous) infliximab every 2 weeks from week 6. At week 30. patients will be allocated to one of 3 arms according to their response to SC infliximab.~[Arm 3] Response to SC infliximab at week 30 and then, randomly allocated to infliximab SC 120 mg every 2 weeks"
88894966|NCT06062095|Experimental|AI arm|AI will be used to diagnose polyps
88894967|NCT06062095|No Intervention|Control arm|Conventional colonoscopy without AI will be perform to diagnose polyps
88894968|NCT06060704|Experimental|triplet combination therapy|Envafolimab Combined With Trifluridine/Tipiracil and Bevacizumab
89417246|NCT03577977||Patients treated with Betaferon|Patients with very early onset of MS, who received at least one injection of interferon beta-1b as prescribed by the treating physician, before the age of 18.
89417247|NCT02175264||Patients and Families with isolated non syndromic CDH cases|
89417248|NCT02668783|Experimental|ENG-E2 125 μg/300 μg|Participants will receive 4 cycles (or 6 cycles if also participating in the extension) of ENG-E2 125 μg/300 μg. Each cycle will consist of 21 days of vaginal ring use followed by 7 ring-free days.
89417249|NCT02668783|Placebo Comparator|Placebo|Participants will receive 4 cycles (or 6 cycles if also participating in the extension) of placebo. Each cycle will consist of 21 days of placebo vaginal ring use followed by 7 ring-free days.
89417250|NCT03577899|Experimental|0.5 mg Conbercept|Subjects received 0.5 mg conbercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every eight weeks thereafter (0.5 mg, q8w) for a total of 92 weeks treatment in the study eye.
89417251|NCT03577899|Experimental|1.0 mg Conbercept|Subjects received 1.0 mg conbercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every twelve weeks thereafter (1.0 mg, q12w) for a total of 92 weeks treatment in the study eye.
89193412|NCT04978584|Experimental|Treatment (uLTRA, CHOP)|"COHORT I (SMART STOP): Patients receive rituximab IV over 4-6 hours on day 1, acalabrutinib PO BID on days 1-21, lenalidomide QD on days 1-10, and tafasitamab IV over 2 hours on days 1, 8, and 15. Treatments repeat every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.~COHORT II (uLTRA-CHOP): Patients who achieve a complete response to the Smart Stop in Cohort I, receive rituximab IV over 4-6 hours on day 1, acalabrutinib PO BID on days 1-21, lenalidomide QD on days 1-10, and tafasitamab IV over 2 hours on days 1, 8, and 15. Treatments repeat every 21 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive cyclophosphamide IV over 1 hour, doxorubicin hydrochloride IV over 15 minutes, vincristine IV over 15 minutes on day 1, and prednisone PO QD on days 1-5. Treatments repeat every 21 days for up to 6 cycles in the absence of disease progr"
89193413|NCT04973163|Experimental|Monotherapy Arm|Each arm consists of three parts (dose escalation (A), dose confirmation (B), and dose expansion (C).
89193414|NCT04973163|Experimental|Combination Therapy Arm|Will be started after confirmation of safety in the Monotherapy Arm. Each arm consists of three parts (dose escalation (A), dose confirmation (B), and dose expansion (C).
89193415|NCT04970576|Experimental|Treatment group|Patients in the intervention group will receive Rivaroxaban 20 mg once a day (OD) for three months
89193416|NCT04970576|Active Comparator|Control group|Patients in the control group will receive usual warfarin therapy dose adjusted as per the target INR of 2 to 3
89193417|NCT04969913||19 + years|Healthy adults over the age of 19 years
89193418|NCT04969913||Ages 11 - 18 years|Healthy children between the ages of 11 and 18 years
89193419|NCT04969913||Ages 5 - 10 years|Healthy children between the ages of 5 and 10 years
89193420|NCT04969913||Ages 6 months - 4 years|Healthy infants between the ages of 6 months and four years
89193421|NCT04968717||HIV elite controllers|"Non-viremic elite controller:~HIV-positive , > 1 year without cART AND with >3 consecutive HIV-RNA < 75 copies/ml spanning >12 months AND stable CD4> 500 cells/uL.(i.e. >75% of measurements)~OR on cART, but before start cART > 1 year without cART AND with >3 consecutive HIV-RNA < 75 copies/ml spanning >12 months AND stable CD4> 500 cells/uL. (i.e. >75% of measurements)~Viremic elite controller:~HIV-positive >5 year without cART AND with always HIV-RNA >50-10.000 copies/ml AND always CD4> 500 cells/uL.~OR on cART, but before start cART >5 year without cART AND with always HIV-RNA >50-10.000 copies/ml AND always CD4> 500 cells/uL"
89193422|NCT04968717||First-degree relatives of HIV elite controllers|
89193423|NCT04968717||cART-treated non-controller HIV patients|
89193424|NCT04968717||First-degree relatives of cART-treated non-controller HIV patients|
89193425|NCT04964739|Other|Cognitive Behavioral Therapy - Men|112 participants identifying as men will be enrolled in 8 weeks of behavioral treatment for cannabis use disorder (CUD). They will receive a motivational interviewing session with a therapist followed by 7 weekly online modules of CBT4CBT with continued monitoring and support from a therapist. Gender and hormonal factors will be examined as predictors of CUD remission and cannabis outcomes.
89193426|NCT04964739|Other|Cognitive Behavioral Therapy - Women|112 participants identifying as women will be enrolled in 8 weeks of behavioral treatment for CUD. They will receive a motivational interviewing session with a therapist followed by 7 weekly online modules of CBT4CBT with continued monitoring and support from a therapist. Gender and hormonal factors will be examined as predictors of CUD remission and cannabis outcomes.
89193427|NCT04961112|Experimental|Experimental - Induced Anxiety|"Participants will be administered a shock procedure in which they are exposed to safe electrical shock that will be gradually increase from (1) 30 milliseconds to (4) 80 milliseconds to an individual threshold that is uncomfortable but not painful. Participants will be told they may receive additional shocks for poor performance during cognitive assessments.~Participants will be administered cranial electrotherapy stimulation with a frequency of .5 Hz and a current of 100 microamps during 30 minutes of cognitive assessments of task switching, inhibition (stroop), working memory (n-back), and processing speed (simple reaction time)."
89199161|NCT05954572||psoriasis patients receiving biologic therapy|A standardized form is going to be used to collect demographic information, and details regarding smoking and alcohol habits. Additional information regarding their treatment regimens will be recorded. Furthermore patients will be evaluated for the presence of acne, rosacea, perioral dermatitis, seborrheic dermatitis, folliculitis, blepharitis, or pityriasis folicullorum, as these conditions have been associated with an increased demodicosis. After that the standardized skin surface biopsy (SSSB) technique will be utilized to assess demodicosis.
89417252|NCT03577899|Active Comparator|Aflibercept|Subjects received 2.0 mg aflibercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every eight weeks thereafter (2.0 mg, q8w) for a total of 92 weeks of treatment in the study eye.
89417253|NCT02175342|Experimental|Tiotropium-1.25 Respimat|Two puffs of tiotropium inhalation solution from a Respimat device, 0.625 mcg/puff
88894969|NCT06058884|Active Comparator|favourbale outcome group|Four hundred fifty-six acute ischemic stroke (AIS) patients who had modified Rankin scale (mRS) two or less after 90 days of ischemic stroke.
88894970|NCT06058884|Active Comparator|unfavourbale outcome group|One hundred thirty-six acute ischemic stroke (AIS) patients who had modified Rankin scale (mRS) three or more after 90 days of ischemic stroke.
88894971|NCT06058520|Experimental|MMT group|patients with HS randomized to receive MTT
88894972|NCT06058520|Placebo Comparator|Placebo group|patients with HS randomized to receive placebo treatment
88894973|NCT06058403|Experimental|Native canola protein|20g of canola protein
88894974|NCT06058403|Experimental|Processed canola protein #1|20g of processed canola #1
88894975|NCT06058403|Experimental|Processed canola protein #2|20g of processed canola #2
88894976|NCT06058403|Active Comparator|Whey protein|20g of whey protein
88894977|NCT06057246|Experimental|Men and post-menopausal women with type 2 diabetes on treatment with diet or diet plus metformin|Each participant will undergo anthropometrics and blood pressure measurements, bioimpedance analysis, indirect calorimetry, administrations of questionnaires for the evaluation of lifestyle habits, 7 days continuous glucose monitoring in parallel with diet, physical activity and sleep monitoring, and standard mixed-nutrient meals at home; a subgroup of 60 participants will undergo venous blood sampling for biochemical determinations before and after a standard mixed-nutrient meal.
88894978|NCT06056739|Experimental|Test Subject|All subjects who are enrolled into the test group and participate in data collection receive the noninvasive Alio platform.
88894979|NCT06056739|No Intervention|Control Subject|All subjects who are enrolled into the control group and participate in data collection will not receive the noninvasive Alio platform.
88894980|NCT06054295||Ancillary-Correlative|Twins with CNS tumors, identified through the Children's Oncology Group's Project:EveryChild (PEC) registry, will have both blood and saliva samples collected at the time of study enrollment.
88894981|NCT06052410|Other|Intervention Group|The group in which the early intervention program was implemented.
88894982|NCT06052410|Other|Control Group|The group where the home program is applied
89417254|NCT02175342|Experimental|Tiotropium-2.5 Respimat|Two puffs of tiotropium inhalation solution from a Respimat device, 1.25 mcg/puff
89417255|NCT02175342|Experimental|Tiotropium-5 Respimat|Two puffs of tiotropium inhalation solution from a Respimat device, 2.5 mcg/puff
89417256|NCT02175342|Experimental|Tiotropium-10 Respimat|Two puffs of tiotropium inhalation solution from a Respimat device, 5 mcg/puff
89417257|NCT02175342|Experimental|Tiotropium-20 Respimat|Two puffs of tiotropium inhalation solution from a Respimat device, 10 mcg/puff
89417258|NCT02175342|Placebo Comparator|Placebo Respimat|
89417259|NCT02175342|Active Comparator|Tiotropium-18 lactose powder Handihaler|
89417260|NCT02175342|Placebo Comparator|Placebo lactose powder Handihaler|
88894983|NCT06050915|Experimental|Single Ascending Dose of DISC-3405|
88894984|NCT06050915|Placebo Comparator|Single Ascending Dose of Placebo|
88894985|NCT06050915|Experimental|Multiple Ascending Dose of DISC-3405|
88894986|NCT06050915|Placebo Comparator|Multiple Ascending Dose of Placebo|
89417261|NCT02504203|Active Comparator|Intervention: BCG and OPV at home visits|Infants randomised to receive vaccines at home visits shortly after birth will receive one 0.05 ml dose of Mycobacterium bovis BCG live attenuated vaccine (BCG-Denmark 1331 (Statens Serum Institute) or BCG Japan (Japan BCG Laboratory) by intradermal injection in the left deltoid region. Dependent on national supply, infants will receive oral polio vaccine (OPV) at the time of BCG vaccination. For all children, the nurse will perform umbilical cord and skin care, encourage skin-to-skin contact to keep the new-born warm, examine and weigh the child at a home visit shortly after birth.
89417262|NCT02504203|No Intervention|Control: No vaccines at home visits|For all children, the nurse will perform umbilical cord and skin care, encourage skin-to-skin contact to keep the new-born warm, examine and weigh the child at a home visit shortly after birth. No vaccines will be administered at these home visits for children in the control arm.
89417263|NCT04236934||All included patients|Patients with recurrent unilateral pleural effusion
89417264|NCT02171520|Experimental|Dabigatran etexilate generation I|
89417265|NCT02171520|Active Comparator|Dabigatran etexilate generation II|
89417266|NCT03069118|Experimental|Treatment|Three-month intervention on the online Workit Health platform
89417267|NCT03069118|Placebo Comparator|Control|A list of online resources/waitlist
89417268|NCT00092053|Placebo Comparator|Placebo|Participants will receive 3 placebo tablets once a month, for 3 months, on the first day of each treatment cycle.
89417269|NCT00092053|Experimental|ibandronate 100 mg|Participants will receive 2 ibandronate 50 mg tablets and 1 placebo tablet once a month, for 3 months, on the first day of each treatment cycle.
89417270|NCT00092053|Experimental|ibandronate 150 mg|Participants will receive 3 ibandronate 50 mg tablets once a month, for 3 months, on the first day of each treatment cycle.
88894987|NCT06050109||OFS continues to use after 5 years|HR-positive premenopausal female patients whose doctors believe that they can benefit from continued use of OFS after 5 years should be included in the trial group.
88894988|NCT06050109||OFS discontinues to use after 5 years|The control group did not need to continue to use OFS, either leuprolide or goserelin
88894989|NCT06049134|Experimental|Arm Group A (PCV20)|Participants will receive 1 dose of the vaccine
88894990|NCT06049134|Experimental|Arm Group B (PCV20)|Participants will receive 2 doses of the vaccine
88894991|NCT06048588|Experimental|YN001|YN001 will be administrated intravenous by single ascending dose, multiple ascending doses weekly or twice a week.
88894992|NCT06048588|Placebo Comparator|Part I-Matching placebo for YN001|Matching placebo for YN001 will be administrated intravenous.
88894993|NCT06048588|Active Comparator|Part II-Rosuvastatin calcium tablets|Rosuvastatin calcium tablets will be given by orally.
88894994|NCT06040450||All subjects with impairments|
88894995|NCT06040450||All subjects without impairments|
88894996|NCT06032598|Experimental|Berry extract 1|Dietary supplement - Berry extract 1
88894997|NCT06032598|Experimental|Berry extract 2|Dietary supplement - Berry extract 2
88894998|NCT06032598|Placebo Comparator|Placebo|Dietary supplement - Placebo
88894999|NCT06028295|Experimental|Wheat Polar Lipid Complex Oil|Dietary supplement - Wheat Polar Lipid Complex (Oil)
88895000|NCT06028295|Experimental|Wheat Polar Lipid Complex Powder|Dietary supplement - Wheat Polar Lipid Complex (Powder)
88895001|NCT06028295|Placebo Comparator|Placebo|Dietary supplement - Placebo
88895002|NCT06025994|No Intervention|STANDARD OF CARE|Patients randomized to the control group will be managed according to current guidelines
88895003|NCT06025994|Experimental|MULTI-DOMAIN LIFESTILE INTERVENTION|"Patients will receive five different kinds of intervention:~i) strict management of CV and metabolic risk factors, ii) tailoring of medical therapy on the basis of the invasive assessment of CMD and coronary vasomotion, iii) dietary counselling, iv) exercise training v) psychological counselling"
88895004|NCT06021938|Active Comparator|Patients starting with RVI|"Patients will begin by wear a virtual reality headset (GAMIDA®) and headphones (Bose®). A tablet (Samsung®) equipped with Healthy Mind software will allow patients to live a 360° visual and auditory 3D experience via Bluetooth connection. After that patients will be handed a smartphone with the Spotify® application to listen to music. Patients will wear headphones."
88895005|NCT06021938|Active Comparator|Patients starting with music therapy|"Patients will begin by handed a smartphone with the Spotify® application to listen to music. Patients will wear headphones. After that patients will wear a virtual reality headset (GAMIDA®) and headphones (Bose®). A tablet (Samsung®) equipped with Healthy Mind software will allow patients to live a 360° visual and auditory 3D experience via Bluetooth connection."
88895006|NCT06020781|Experimental|Bupivacaine and Dexmedetomidine|Patients will receive ultrasound-guided Supraclavicular brachial plexus block with 20 ml bupivacaine 0.5% + 1 μg/kg dexmedetomidine.
88895007|NCT06020781|Active Comparator|20 ml Bupivacaine without additives|Patients will receive ultrasound-guided Supraclavicular brachial plexus block with 20 ml bupivacaine 0.5% without additives.
88895008|NCT06020781|Active Comparator|30 ml bupivacaine without additives|Patients will receive ultrasound-guided Supraclavicular brachial plexus block with 30 ml bupivacaine 0.5% without additives as a control group.
89417271|NCT03068182|Experimental|Arm crank Exercise|Sixty-five participated in an arm crank moderate intensity exercise for 40 minutes.
89417272|NCT03068182|Experimental|Treadmill Exercise|Sixty-five participated in a treadmill moderate intensity exercise for 40 minutes.
89417273|NCT00101010|Experimental|Rituximab - Combination Chemotherapy|Rituximab 375 mg/m^2 intravenous (IV), Cyclophosphamide IV over 1-1½ hours, Pegylated doxorubicin HCl liposome 40 mg/m^2 IV over 1 hour, Vincristine 2 mg IV, day 1, & oral Prednisone 40 mg/m^2 days 1 - 5; Filgrastim (G-CSF) 5 mcg/kg subcutaneously (SC) once daily beginning day 6 continuing until blood counts recover OR Pegfilgrastim 6 mg SC once on day 6 (24 hours after chemotherapy). Treatment repeats every 21 days for up to 8 courses.
89417274|NCT03069040|Experimental|nerve-sparing radical hysterectomy|The patient recived surgury of nerve-sparing radical hysterectomy.
89417275|NCT03069040|Active Comparator|radical hysterectomy|The patient recived surgury of radical hysterectomy.
89417276|NCT03539172|Experimental|Apatinib group|Apatinib Mesylate administered as a daily oral treatment
89417277|NCT05729698|Experimental|polyethylene bag method|polyethylene bag method: preterm babies will be placed in polythene bags after birth
89417278|NCT05729698|Experimental|baby warmer swaddle method|baby warmer swaddle group: preterm babies will be placed in baby warmer swaddle after birth
89417279|NCT02175420|Active Comparator|TFV alone|Typhim Vi
89417280|NCT02175420|Experimental|BCG+TFV|BCG (SSI, Denmark) followed after 14 days by Typhim Vi
89417281|NCT03579381||Immune Controllers|Patients with very low or undetectable levels of viremia without treatment
89417282|NCT03579381||Acute Infection|Early infection, i.e. within 2 weeks of infection
89417283|NCT02170740|Experimental|BIBR 1048 MS|
89417284|NCT02170740|Experimental|BIBR 1048 MS + Pantoprazole|
89417285|NCT02848599|Active Comparator|morphine|The patient-controlled intravenous analgesia with morphine (basal flow of 0.5-2 mg / h, bolus dose of 0.5 mg, lockout interval of 20 minutes, hour limit of 3 doses), which will be carried out 72 hours after the surgery
89417286|NCT02848599|Active Comparator|levobupivacaine|Upon completion of the operation for a period of 72 hours will be implemented continuous epidural local anesthetic through the Patient Controlled Analgesia (PCA) pump (Levobupivacaine 0.125%, basal flow of 6 ml / hour, a bolus dose of 2 ml, lockout interval of 20 minutes, hour limit of 3 doses).
88895009|NCT06017583|Experimental|Experimental arm|The experimental group will receive concurrent simultaneous integrated boost intensity-modulated radiotherapy (SIB-IMRT) and concurrent capecitabine chemotherapy, and complete 2 ~ 4 cycles of XELOX chemotherapy, while receiving full tislelizumab treatment for at least 4 cycles (21 days per cycle).
88895010|NCT06017583|Placebo Comparator|Control arm|The control group received intensity-modulated radiotherapy (IMRT) without tirellizumab, and the other treatment regiments were consistent with the experimental group.
88895011|NCT06008353||Adult patients newly diagnosed with ES-SCLC|The study will include consecutive adult patients newly diagnosed with ES-SCLC (patients with the recurrent limited stage disease are also eligible).
88895012|NCT06007365||Z5m Dental Implants|
88922173|NCT05698381|Experimental|Liquid vinegar|4 tablespoons BID per day (3000 mg acetic acid)
89199162|NCT05954572||treatment-naive or topically treated psoriasis patients|A standardized form is going to be used to collect demographic information, and details regarding smoking and alcohol habits. Additional information regarding their treatment regimens will be recorded. Furthermore patients will be evaluated for the presence of acne, rosacea, perioral dermatitis, seborrheic dermatitis, folliculitis, blepharitis, or pityriasis folicullorum, as these conditions have been associated with an increased demodicosis. After that the standardized skin surface biopsy (SSSB) technique will be utilized to assess demodicosis.
89417287|NCT02175498|Experimental|Homoeopathic medicines|4 pills once a week of the indicated similium for a period of one year
89417288|NCT03069274|Other|Control|Only general nutritional recommendations were given.
89417289|NCT03069274|Experimental|Intervention|General nutritional recommendations, change their drinking habits.
89417290|NCT02171598|Experimental|Fixed sequence 1|multiple-dose, fixed-sequence with 2 periods of 4 days separated by a washout period of at least 14 days. A single dose of 300 mg clopidogrel will be given on top of 75 mg or 150 mg dabigatran in steady state.
89417291|NCT02171598|Experimental|Crossover|clopidogrel + dabigatran / clopidogrel / dabigatran in randomized order
89417292|NCT02171598|Experimental|Fixed sequence 2|intra-individual comparison with the fixed sequence of a single dose of 600mg clopidogrel alone and the combination of dabigatran 150 mg in steady state plus single dose of 600 mg clopidogrel
89417293|NCT03579303|Active Comparator|Homoeopathic remedies in PCOS|Homoeopathic treatment for menstrual disorders in females with PCOS
89417294|NCT03579303|Active Comparator|Homoeopathic remedies and yoga in PCOS|Homoeopathic treatment integrated with yoga therapy for menstrual disorders in females with PCOS
89417295|NCT03068962|Experimental|beetroot juice|Rinse mouth with low nitrate Buxton mineral water followed by holding 10 ml of beetroot juice for 5 min,
89417296|NCT03068962|Experimental|low mineral water (Buxton water)|Rinse mouth with low nitrate Buxton mineral water followed by holding 10 ml of low nitrate mineral water in the mouth for 5 min or
89417297|NCT03068962|Experimental|antiseptic mouthwash then beetroot juice|Rinse with antiseptic mouthwash before holding 10 ml of beetroot juice in the mouth for 5 min
89417298|NCT02171676|Experimental|Docetaxel + BIBW 2992|Dose escalation
89417299|NCT03579225||MATRx plus test|
89417300|NCT02170818|Experimental|Educational Workshop on Speaking-Up|Educational Workshop on Speaking-Up Before Simulated Case
89417301|NCT02170818|Sham Comparator|Unrelated Education|Unrelated Education (CPR) before simulated case (Educational Workshop on Speaking-up after case and debriefing)
89417302|NCT03577743|Experimental|experimental arm|bevacizumab and chemotherapy given every 21 day untill disease progression or unacceptable toxicity
89417303|NCT04794790|No Intervention|Standard Dose|Standard dose induction Visit 1 Day 1 (intake/baseline) Participants will commence induction with a dose of 4mg if COWS is above 7. If COWS is below 7, participant will be instructed to return the next day, so that COWS can be above 7 to start the study.
88895013|NCT06002906|Experimental|Interventional group (with drug)|The interventional group will receive indocyanine green during bariatric surgery inside the operating room before and after making the gastrojejunostomy.
89417304|NCT04794790|Experimental|Macro or High Dose|Macro or High Dosing Visit 1 Day 1 (intake/baseline) Participants will commence induction with a dose of 4mg if COWS is above 7. If COWS is below 7, participant will be instructed to return the next day, so that COWS can be above 7 to start the study. (These participants can still be in the study and will only have to re-do a baseline COW's on the day they come back to the clinic, which will then be considered their day 1).
89417305|NCT04794790|Experimental|Micro or Low Dose|Micro or Low Dose Visit 1 Day 1 (intake/baseline) Participants will commence induction with a dose of 4mg if COWS is above 7. If COWS is below 7, participant will be instructed to return the next day, so that COWS can be above 7 to start the study. (These participants can still be in the study and will only have to re-do a baseline COW's on the day they come back to the clinic, which will then be considered their day 1).
89417306|NCT02178228||Subjects over age 18|Subjects undergoing non-emergent small bowel or large bowel surgery and reconnection of bowel that are over the age of 18
89417307|NCT02178228||Subjects age 15-17|Subjects undergoing non-emergent small bowel or large bowel surgery and reconnection of bowel that are age 15-17 with one permission of one parent.
89417308|NCT02171754|Experimental|BIBW 2992 + Ritonavir|
89417309|NCT02171754|Active Comparator|BIBW 2992|
89417310|NCT02238327||HIV positive normal pulmonary function|HIV positive DLCO percent predicted >=.80 FEV1/FVC percent predicted >=0.70
89417311|NCT02238327||HIV positive with pulmonary dysfuntion|HIV positive DLco percent predicted <=0.80% FEV1/FVC percent predicted<=0.70%
89417312|NCT02995369|Experimental|Cotton Roll Isolation (left), then DryShield Isolation (right)|"Cotton rolls (CRI) will be used to isolate the maxillary and mandibular teeth on the left side of the mouth, followed by sealants placement using Dryshield (DS) on the opposite side.~The four groups are a result of randomizing the side receiving one of the interventions (CRI v. DS) as well as the order of application (first v. second)."
89417313|NCT02995369|Experimental|Cotton Roll Isolation (right), then DryShield Isolation (left)|"Cotton rolls (CRI) will be used to isolate the maxillary and mandibular teeth on the right side of the mouth, followed by sealants placement using DryShield (DS) on the opposite side.~The four groups are a result of randomizing the side receiving one of the interventions (CRI v. DS) as well as the order of application (first v. second)."
89417314|NCT02995369|Experimental|DryShield Isolation (left), then Cotton Roll Isolation (right)|"DryShield (DS) will be used to isolate the maxillary and mandibular teeth on the left side of the mouth, followed by sealants placement using cotton rolls (CRI) on the opposite side.~The four groups are a result of randomizing the side receiving one of the interventions (CRI v. DS) as well as the order of application (first v. second)."
88895014|NCT06002399|Other|Bilateral monofocal intraocular lens|Standard treatment
88895015|NCT06002399|Experimental|Monofocal and contralateral extended depth-of-focus intraocular lens|Experimental treatment
88922174|NCT05698381|Placebo Comparator|Vinegar pill|2 vinegar pills per day (30 mg acetic acid)
88895016|NCT05998317|Experimental|At-night dexamethasone|Patients in the intervention group will receive intravenous 8 mg dexamethasone at night before surgery. The time of dexamethasone administration will be recorded. The dexamethasone ampule will be diluted in a 10 ml syringe and given in at least one minute to avoid unpleasant sensation in injection.
88895017|NCT05998317|Active Comparator|At-induction dexamethasone|Patients in the control group will receive intravenous 8 mg dexamethasone just before or at the induction of anesthesia. The dexamethasone ampule will be diluted in a 10 ml syringe and given in at least one minute to avoid unpleasant sensation in injection.
88895018|NCT05996458||group one|The screening population will undergo gastroscopy, colonoscopy, fecal occult blood test (FIT), Helicobacter pylori (HP) antigen test, ring finger protein 180 (RNF180) and SEPTIN9 gene methylation test, and investigation of risk factors, including past disease history, alcohol drinking history, smoking history, tea drinking history, family history of cancer, marital and reproductive status, and dietary habits.
88895019|NCT05996458||Group one's control（Spouse or sibling of group one )|Only the risk factors will be investigated
88895020|NCT05996458||group two|The screening population will undergo investigation of risk factors, a fecal occult blood test (FIT), and a stool test for Helicobacter pylori (HP) antigen. If a stool occult blood test or H. pylori antigen is positive after testing, RNF180 and SEPTIN9 gene methylation testing will be scheduled. If the gene methylation test is positive, a colonoscopy will be scheduled.
88895021|NCT05996458||group two's control（Spouse or sibling of group two)|Only the risk factors will be investigated
88895022|NCT05996380|Experimental|SHR-3167|
88895023|NCT05996380|Placebo Comparator|SHR-3167 Placebo|
88895024|NCT05996354|Experimental|Intervention arm|Concave Supra-arch Branched stent-graft system
88895025|NCT05984433|Experimental|Electroauricular acupuncture|Immediately after Level 2 sedation is achieved, an enhanced auricular trauma protocol (ATP) will be administered on the ear ipsilateral to the operative side at 8 ear points (Hypothalamus, Amygdala, Hippocampus, Prefrontal Cortex, Point Zero, Shen Men, Insula, Vagus) as described by Cheng (2022). The original ATP was described by Helms (2011). Seirin L 0.2 x 30 mm needles will be placed at Hypothalamus and Shen Men points. Seirin J 0.18 x 15 mm needles will be placed at Amygdala, Hippocampus, Prefrontal Cortex, Point Zero, Vagus, and Insula points. Electrostimulation using an ITO ES 130 microstimulator at 30 HZ with Level 4 intensity, will be applied with the positive lead (red) on Hypothalamus and negative lead (black) at Shen Men for 60 minutes. All needles will be removed 1 hour after insertion.
88895026|NCT05984433|No Intervention|No acupuncture|No acupuncture treatment given
88895027|NCT05984004|Placebo Comparator|Control|Healthy volunteers in Control group receives a nasal spray containing 0.9% NaCl isotonic saline solution.
89417315|NCT02995369|Experimental|DryShield Isolation (right), then Cotton Roll Isolation (left)|"DryShield (DS) will be used to isolate the maxillary and mandibular teeth on the right side of the mouth, followed by sealants placement using cotton rolls (CRI) on the opposite side.~The four groups are a result of randomizing the side receiving one of the interventions (CRI v. DS) as well as the order of application (first v. second)."
88895028|NCT05984004|Experimental|SPEROVID|Healthy volunteers in SPEROVID group receives a nasal spray containing inactivated Bacillus subtilis DSM32444 (postbiotic)
88895029|NCT05982860|No Intervention|Control (n:18)|Players in this group will not be given any nutritional advice/intervention. They will maintain their usual eating habits.
89417316|NCT02171832|Experimental|Mildly liver impaired patients|
89417317|NCT02171832|Experimental|Moderately liver impaired patients|
88922175|NCT05697757|Experimental|Placebo Condition followed by Dynamic Condition|Each lighting condition will last for three weeks (Weeks 2-4 or 5-7). The order of conditions will be randomized. Sleep data will be collected only on the last 7 days of each condition using actigraphy. Light spectrum and intensity will be tracked continuously throughout the waking hours (wearable light tracker). Moreover, caregivers will complete two questionnaires (CSDD and CMAI) every seven days to assess the short and long-term effects of each condition on mood and agitation of older adult participants.
89417318|NCT02171832|Experimental|Healthy volunteers|
89417319|NCT05633524||89 SS patients|The medical records were analyzed retrospectively about the 89 patients with first onset of SS (SS group)
89417320|NCT05633524||89 healthy control subjects|The medical records were analyzed retrospectively about the 89 age- and gender-matched individuals (Control group) who presented with normal control.
89535972|NCT03315611|Active Comparator|AD, sensitized, treated|Allergen challenge chamber and Treatment for 12 day with 'Eucerin AtopiControl Lotion' (for the body) and 'Eucerin AtopiControl facial cream' (for the face): 1,2 g twice daily.
89535973|NCT03315611|Experimental|AD, not sensitized, not treated|Allergen challenge chamber
89535974|NCT03315611|Experimental|AD, sensitized, not treated|Allergen challenge chamber
88895030|NCT05982860|Experimental|MIND diet (n:18)|Players in this group will be asked to include the food groups in the MIND diet in their diet in accordance with their consumption frequency. As a result of the interviews with the coaches and experienced athletes, it was learned that the majority of the athletes did not consume the foods such as wine, berries, and fish included in the MIND diet template. Therefore, these foods, which are the main components of the MIND diet, will be provided by the researcher/project in accordance with the recommended frequencies. However, since wine consumption is not frequently preferred in our country due to religious and socio-cultural reasons, ''hardaliye'', a fermented grape juice (100 mL/day), which is easy to consume and has similar nutritional values to wine (resveratrol and ORAC), will be provided. Berries will be supplied in 2 portions/week, and fish (tons) in 1 portion/week.
88895031|NCT05982548|Experimental|Intervention group|"The VR intervention was created using the Unreal Engine software (Unreal Engine, 2022). The VR intervention includes the scenario of a home.~Participants will view the home as a first person character and experience psychotic phenomena including auditory hallucinations. The intervention will be delivered in one setting and lasts no more than seven minutes. It will be disseminated using smartphone inserted into VR headset equivalent of google cardboard."
89193428|NCT04961112|Experimental|Experimental - No Induced Anxiety|"Participants will be administered a shock procedure in which they are exposed to safe electrical shock that will be gradually increase from (1) 30 milliseconds to (4) 80 milliseconds to an individual threshold that is uncomfortable but not painful. After this procedure, the shock belt will be turned off. Participants will be told they will not receive additional shocks during cognitive assessments.~Participants will be administered cranial electrotherapy stimulation with a frequency of .5 Hz and a current of 100 microamps during 30 minutes of cognitive assessments of task switching, inhibition (stroop), working memory (n-back), and processing speed (simple reaction time)."
89193429|NCT04961112|Sham Comparator|Sham - Induced Anxiety|"Participants will be administered a shock procedure in which they are exposed to safe electrical shock that will be gradually increase from (1) 30 milliseconds to (4) 80 milliseconds to an individual threshold that is uncomfortable but not painful. Participants will be told they may receive additional shocks for poor performance during cognitive assessments.~Participants will be administered sham cranial electrotherapy stimulation with no current during 30 minutes of cognitive assessments of task switching, inhibition (stroop), working memory (n-back), and processing speed (simple reaction time)."
89535975|NCT05002725|Experimental|PENG|An ultrasound guided PENG catheter will be inserted. 20ml of 1.5% lidocaine will be administered.
88895032|NCT05982548|Active Comparator|VR control group|The VR control group will view the scenario of the same home without the simulated visual and auditory hallucinations.
88895033|NCT05982262|Experimental|Patients with hematological conditions|Patients will be referred by the medical or nursing staff of the Hematology Unit at the Bnai Zion Medical Center according to inclusion criteria
88895034|NCT05978713|Experimental|Tirzepatide|A single dose of tirzepatide administered subcutaneously (SC)
88895035|NCT05975385|Experimental|Acupuncture|Group Acupuncture: Points PC 6 bilaterally, LI 4 bilaterally, and Yin Tang will be needled using Seirin L Type 0.25 X 40 mm needles. MH 6 is located 2 cun (a traditional Chinese unit of length) above the wrist crease in between the tendons of palmaris longus and flexor carpi radialis. LI 4 is in the middle of first and second metacarpal bones. Yin Tang is located between the eyebrows. All needles will be removed once skin closure begins, and before emergence and extubation.
88895036|NCT05975385|No Intervention|Control|No acupuncture treatment provided
88895037|NCT05974254|Experimental|Electroauricular acupuncture|Immediately after Level 2 sedation is achieved, an enhanced auricular trauma protocol (ATP) will be administered on the ear ipsilateral to the operative side at 8 ear points (Hypothalamus, Amygdala, Hippocampus, Prefrontal Cortex, Point Zero, Shen Men, Insula, Vagus) as described by Cheng (2022). The original ATP was described by Helms (2011). Seirin L 0.2 x 30 mm needles will be placed at Hypothalamus and Shen Men points. Seirin J 0.18 x 15 mm needles will be placed at Amygdala, Hippocampus, Prefrontal Cortex, Point Zero, Vagus, and Insula points. Electrostimulation using an ITO ES 130 microstimulator at 30 HZ with Level 4 intensity, will be applied with the positive lead (red) on Hypothalamus and negative lead (black) at Shen Men for 60 minutes. All needles will be removed 1 hour after insertion.
88895038|NCT05974254|No Intervention|No acupuncture|No acupuncture treatment given
88895039|NCT05973383||Intervention group- Basic|Subjects with behavioral support from the app LongLife Active®
88895040|NCT05973383||Intervention group- Standard|Subjects with behavioral support from the app LongLife Active® + social support
88895041|NCT05973383||Intervention group- Premium|Subjects with behavioral support from the app LongLife Active® + social support + individual coaching
89193430|NCT04961112|Sham Comparator|Sham - No Induced Anxiety|"Participants will be administered a shock procedure in which they are exposed to safe electrical shock that will be gradually increase from (1) 30 milliseconds to (4) 80 milliseconds to an individual threshold that is uncomfortable but not painful. After this procedure, the shock belt will be turned off. Participants will be told they will not receive additional shocks during cognitive assessments.~Participants will be administered sham cranial electrotherapy stimulation with no current during 30 minutes of cognitive assessments of task switching, inhibition (stroop), working memory (n-back), and processing speed (simple reaction time)."
89193431|NCT04948554|Experimental|Cohort 1: MK-2225|Participants in Cohort 1 will receive MK-2225 at 0.25 mg/kg once every two weeks (Q2W) plus standard of care (SOC) for 12 weeks.
89193432|NCT04948554|Placebo Comparator|Cohort 1: Placebo|Participants in Cohort 1 will receive placebo Q2W plus SOC for 12 weeks.
88895042|NCT05973383||Control group|No exposure
88895043|NCT05970484|Experimental|Intervention|Use of the DrinksRation app with all functionality
88895044|NCT05970484|Active Comparator|Control|Use of the BeAlcoholSmart app with all functionality
88895045|NCT05965895|Active Comparator|US-guided SAP block group|Patients will receive US-guided SAP block with a bolus of 2 mg/kg levobupivacaine made up to a volume of 40 ml followed by an infusion of 0.125% levobupivacaine will be commenced at rate of 8 ml/hr for 48 hr.
89193433|NCT04948554|Experimental|Cohort 2: MK-2225|Participants in Cohort 2 will receive MK-2225 at 0.5 mg/kg (or lower) Q2W plus SOC for 12 weeks.
88895046|NCT05965895|Active Comparator|Dexmedetomidine group|Patients will receive initial loading dose of dexmedetomidine of 1 µg/kg over 30 min followed by a continuous infusion at a rate of 0.5 µg/kg/hr for 48 hr.
88895047|NCT05964400|Experimental|duoABLE|Stroke participant-caregiver duos (dyads) will meet with an occupational therapist 12 times (2x/week for 6 weeks, approximately 30 minutes/session) to apply activity monitoring, activity scheduling, collaborative problem solving, self-assessment, and social interdependence to self-selected activities that aim to increase both dyad members' physical activity levels
88895048|NCT05963425|Experimental|Physical activity: basic physical training (BPT)|"Exercises will target the large muscle groups, with a component/emphasis on the eccentric phase of concentration. The kBox4 Platform (Exxentric AB), a device designed to maximize performance and training outcomes, will be used to enhance the eccentric phase of the exercises.~kBox4 is controlled by a specific program, Kmeter, which records and stores all the information (duration, intensity, repetitions, etc.) of each movement. Exxentric kBox4 will be adapted with special harnesses, insurances on the wall and in front of support bars, according to the needs of the patients. In addition to the major muscle groups, specific attention will be given to the key muscles involved in the gait cycle, such as the tibialis anterior, medial gastrocnemius, rectus femoris, and hamstrings, from a biomechanical perspective."
89193434|NCT04948554|Placebo Comparator|Cohort 2: Placebo|Participants in Cohort 2 will receive placebo Q2W plus SOC for 12 weeks.
88895049|NCT05963425|Experimental|Physical activity: BPT combined with functional exercises|In addition to the BPT program (which includes the transverse focus on strength and resistance exercises), this intervention group will incorporate functional exercises that involve dual task training. The dual task training can encompass both motor-motor and motor-cognitive activities. This means that coordinated exercises will be performed, with cognitive activities introduced at the extremes of the movement. This approach ensures engagement of both physical and cognitive abilities during the PA sessions.
88895050|NCT05963425|Active Comparator|Control|Participants in the control group will maintain their regular daily routines throughout the study period.
89006103|NCT04645888|Active Comparator|Bupivacaine|"All surgeries were performed by the same surgeon and monitored by the same person. % 0.5 bupivacaine without epinephrine was administered to the patients in regional block of the inferior alveolar nerve technique at the first surgery. At the second intervention, patients received the other anesthetic solution which was not used at the first intervention.~1.5 cc of the solution was used to anesthetize the inferior alveolar and lingual nerve and the remaining 0.5 cc was infiltrated to anesthetize the buccal nerve."
89006104|NCT00241722|Experimental|Alvimopan 0.5 mg Twice Daily (BID)|0.5 milligrams (mg) of alvimopan was administered orally twice daily (BID) for 12 months.
89006105|NCT00241722|Placebo Comparator|Placebo|Placebo was administered orally BID for 12 months.
89006106|NCT00558337|Active Comparator|A|
89006107|NCT00558337|Active Comparator|B|
89006108|NCT04646278|Experimental|Hyperemic stimuli|Hyperemic stimuli of coronary flow by adenosine or nicorandil injection
89006109|NCT04645849||"Cohort A or End of treatment"|16 patients recruited at the end of breast cancer treatment and followed during 9 months
89006110|NCT04645849||"Cohort B or Diagnosis"|Patients recruited at breast cancer before any treatment: one blood sample to provide comparative values.
89006111|NCT00558376|Active Comparator|1|Ingestion of 3L polyethylene Glycol
89006112|NCT00558376|Active Comparator|2|Ingestion of 2 doses of sodium phosphate 45 cc
89006113|NCT00217646|Experimental|Arm I|Patients receive oral sorafenib once or twice daily on days 1-5, 8-12, and 15-19.
89006114|NCT00217646|Experimental|Arm II|Patients receive oral sorafenib once or twice daily on days 1-14.
89006115|NCT00558454|Placebo Comparator|1|Placebo
89006116|NCT00558454|Experimental|2|1 mg/kg/day from age 6 weeks to 6 months
89006117|NCT00558454|Experimental|3|2 mg/kg/day from age 6 weeks to 6 months
89006118|NCT00558493|Experimental|1|switching treatment from lamivudine to clevudine
89006119|NCT04645615|Experimental|CURE AF|
89006120|NCT04645537||FinACAF cohort|The study cohort consists of all patients with AF diagnosis (ICD-10 I48) living in Finland during 1.1.2004-31.12.2018. The study cohort is obtained from data of Finnish national registries. Patients with permanent residence in Finland less than 12 months prior to index date and patients with age below 18 years at index date are excluded from the study.
89006121|NCT04645459|Experimental|low phosphorus meal group (LP group)|The proteins of the low phosphorus meal had been removed by an average 20 -30% of the phosphorus through boiling the meats before cooking process.
89006122|NCT04645459|Placebo Comparator|control group|The boiling method did not process for the control meals.
89006123|NCT00558532||Surgical|Those subjects undergoing bariatric surgery or abdominal surgery following a previous bariatric surgery.
89006124|NCT00558532||Control|Volunteers who have dietary habits similar to the subjects.
89006125|NCT00558649|Experimental|1|Low dose flu vaccine delivered intradermally using microneedles
89006126|NCT00558649|Experimental|2|Medium dose flu vaccine delivered intradermally using microneedles
89006127|NCT00558649|Active Comparator|3|Standard dose flu vaccine delivered intramuscularly with a regular needle
89006128|NCT00558805|Active Comparator|1|Usual Care + Family Intervention for Suicide Prevention (FISP)
89006129|NCT00558805|Other|2|Usual Care
89006130|NCT04645303|Experimental|Hyaluronic acid|1mL of hyaluronic acid (20 mg/2 mL; Hyalgan, Fidia, Abano Terme, Italy) infiltration at A1-Pulley under ultrasound guidance after subcutaneous 2% lidocaine without epinephrine infiltration of the skin overlying the A1-pulley.
89006131|NCT04645303|Active Comparator|Triamcinolone acetonide|1 mL of Triamcinolone acetonide 10mg/ml infiltration at A1-Pulley under ultrasound guidance after subcutaneous 2% lidocaine without epinephrine infiltration of the skin overlying the A1 pulley.
89006132|NCT04644835|Experimental|LESW group|The shock wave applicator (Dornier AR2, shock wave device, Dornier MedTech 2010, Wessling, Germany) will be gently placed directly on the ultrasound transmission gel over the skin surface of the suprapubic region above the urinary bladder at the site of the papillary lesion (ultrasound guided) and at other five points. Points 1 and 2 will be at the level of transverse crease 2 cm above the pubic bone and 5 cm from each, points 3 and 4 will 2 cm above points 1 and 2, and point 5 will be centered of points 1-4. A total of 2000 pulses at 0.25 mJ/mm2 will be delivered with a frequency of 3 pulses per second. The position of the shock wave applicator will be changed after every 400 pulses.
89006133|NCT04644835|Sham Comparator|Control group|This group of patients will be exposed to the same therapy head, which will also be fitted with a stand-off without energy transmission.
89006134|NCT04644757|Experimental|Treatment|
89006135|NCT04644718|Experimental|Anodal-tDCS with speech therapy|The participant will complete six consecutive weeks of SLT accompanied with real tDCS. Each session starts with 20 minutes of tDCS followed by the SLT program.
89006136|NCT04644718|Sham Comparator|sham tDCS with speech therapy|The participant will complete six consecutive weeks of SLT accompanied with sham tDCS. Each session starts with 20 minutes of tDCS followed by the SLT program.
89006137|NCT04644562|Experimental|patients undergoing Lower Limb vascular Surgery|Ultrasound-guided lumbar Erector Spinae plane block in patients undergoing Lower Limb vascular Surgery
89006138|NCT00217607|Experimental|Paclitaxel|"Paclitaxel 80 mg/m² Day 1, Day 8 and Day 15. No treatment on Day 22.~1 cycle = 28 days.~Treatment duration: 6 cycles (=6 months)"
89193435|NCT04948554|Experimental|Cohort 3: MK-2225|Participants in Cohort 3 will receive MK-2225 at 1.0 mg/kg (or lower) Q2W plus SOC for 12 weeks.
89193436|NCT04948554|Placebo Comparator|Cohort 3: Placebo|Participants in Cohort 3 will receive placebo Q2W plus SOC for 12 weeks.
89193437|NCT04948554|Experimental|Cohort 4: MK-2225|Participants in Cohort 4 will receive MK-2225 at ≤2.0 mg/kg Q2W if needed plus SOC for 12 weeks.
88895051|NCT05958225|Experimental|Personal agency, leadership and business training|Entrepreneurs will participate in a 3 day residential training (based on SEE Change's Empowered Entrepreneur training) that integrates personal agency with basic business and leadership topics. Participants will also get weekly support messages on their phone for 6 weeks and a check in by a training once a month for 3 months.
88895052|NCT05958225|No Intervention|Control|For this study, the control participants will not receive any intervention.
88895053|NCT05957822|Active Comparator|TXA empirical|Empirical Tranexamic acid (TXA) administration after the anesthesia induction
88895054|NCT05957822|Experimental|TXA TEG6-triggered|When LY30> 3% or MA<54 mm in CRT of TEG6, Tranexamic acid (TXA) is administered
88895055|NCT05957822|Experimental|TXA TEG6-non-triggered|When LY30 ≦ 3% or MA ≥ 54 mm in CRT of TEG6, Tranexamic acid (TXA) is not administered
88895056|NCT05956171|Experimental|Ultrasound Guided Hydrodilatation with corticosteroid injection|"15 ml intra-articular injection to shoulder via anterior approach under ultrasound guidance~Drugs:~betamethasone dipropionate/ betamethasone sodium phosphate(diprospan) (5 mg+2mg/ml) (1 ml)~prilocaine hydrochloride %2 (4 ml)~Sodium chloride %0,9 (10 ml)"
89006139|NCT04644484|Experimental|Experimental Group: SYN023+Rabies Vaccine|"SYN023:~Interventions: are administered by direct injection into the wound or by subcutaneous or intramuscular injection when this is not possible SYN023 is an equal mass mixture of CTB011 and CTB012, two monoclonal antibodies that exhibit a wide spectrum of activity against various wild-type rabies strains in vitro.~Dosage form: 6mg/2mL, liquid; Dosage: 0.3 mg/kg of SYN023; Frequency/duration: at Day 1~Rabies vaccine :~Interventions: should be administered in deltoid muscle Dosage form: >=2.5 IU, freeze-dried vaccine, reconstitute into 0.5 mL before use Dosage: 0.5 mL after reconstitution Frequency/duration: at Day 1, 4, 8, 15, 29"
89006140|NCT04644484|Active Comparator|Control Group: Human Rabies Immune Globulin (HRIG)+Rabies Vaccine|"Human Rabies Immune Globulin (HRIG):~Interventions: are administered by direct injection into the wound or by subcutaneous or intramuscular injection when this is not possible Dosage form: 100 IU/mL, liquid; Dosage: 20 IU/kg; Frequency/duration: at Day 1~Rabies vaccine :~Interventions: should be administered in deltoid muscle Dosage form: >=2.5 IU, freeze-dried vaccine, reconstitute into 0.5 mL before use; Dosage: 0.5 milliliters (mL) after reconstitution; Frequency/duration: at Day 1, 4, 8, 15, 29"
89006141|NCT04644250|Experimental|Arm1|Arm1:preoperative Toripalimab with chemoradiotherapy group Participants will receive carboplatin (AUC=2) VD 30min and paclitaxel liposome (50mg/m²) CIV 24h on day 3,10,17,24,31. And radiotherapy will start from day 1 to 31 of chemotherapy. A total of 41.4 Gy, 23 fractions of 1.8 Gy. Participants will also receive Toripalimab(240mg) VD 30 min on days 3, 24 and 45. After the above neoadjuvant therapy is over, the short-term efficacy evaluation will be performed first, and then a scheduled radical radical resection will be performed from days 59 to 73.
89006142|NCT04644211|Experimental|Ruxolitinib Stage 1|"In stage 1, participants will be divided into two cohorts:~Very low, Low, and Intermediate-risk ETpatients with significant symptom burden and Low-risk PV patients with significant symptom burden~Study cycles are 28 days long, participants in both cohorts will receive:~Ruxolitinib 2x daily for 6 study cycles."
89006143|NCT04644211|Experimental|Ruxolitinib Stage 2|"Stage 2 will commence based on 3 or more participants in Stage 1 showing a predetermined positive response to Ruxolitinib.~In stage 2, participants will be divided into two cohorts:~Very low, Low, and Intermediate-risk ET patients with significant symptom burden and Low-risk PV patients with significant symptom burden~Study cycles are 28 days long, participants in both cohorts will receive:~Ruxolitinib 2x daily for 6 study cycles."
89006144|NCT00217919|Experimental|1|Health-Counselor Mediated Telephone Counseling Intervention
89006145|NCT00217919|No Intervention|2|Usual care
88895057|NCT05956171|Active Comparator|Blind intra-articular corticosteroid injection|"5 ml intra-articular blind injection to shoulder via posterior approach~Drugs:~betamethasone dipropionate/ betamethasone sodium phosphate(diprospan) (5 mg+2mg/ml) (1 ml)~prilocaine hydrochloride %2 (4 ml)"
88895058|NCT05954182|Experimental|Cognitive Intervention|Participants in this group will receive weekly, live, virtual group sessions for 12 weeks
89417321|NCT05225701|Experimental|Transdiagnostic guided internet-delivered intervention with synchronous assistance|Self-applied treatment web system based on transdiagnostic approach for emotional and stress and trauma-derived disorders. The system will contain seven modules. The duration of the intervention program may vary between users; however, the participant will have access permits for a maximum period of 12 weeks. In order to monitor the participant's progress, each user will be assigned an advisor who will be health personnel (psychologists, social workers, and gerontologists) to get an a weekly personalized synchronous assistance and psychological counseling.
89417322|NCT05225701|Active Comparator|Transdiagnostic self-guided internet-delivered intervention|Self-applied treatment web system based on transdiagnostic approach for emotional and stress and trauma-derived disorders. The system will contain seven modules. The duration of the intervention program may vary between users; however, the participant will have access permits for a maximum period of 12 weeks. All modules are sequential, allowing the user to go step by step. This arm does not have personalized online assistance.
89417323|NCT05225701|No Intervention|waiting list|Participants on the waiting list will be assigned to the intervention after 2 months after randomization and will join the Transdiagnostic guided internet-delivered intervention with synchronous assistance.
89417324|NCT02175654|Experimental|Regorafenib|Regorafenib will be administered orally at the initial dosage of 160 mg per day for 3 weeks, followed by one week of rest, according to the 3/1 regimen
88895059|NCT05954182|No Intervention|Control|Participants in this group will NOT receive the group sessions
89417325|NCT05729464||cancer patients with venous thrombosis|
89417326|NCT05729464||cancer patients without venous thrombosis|
89417327|NCT02171910|Active Comparator|Doxapram|Propofol sedation with a doxapram 1mg/kg i.v. bolus at induction and an i.v. infusion 1mg/kg/h) during the procedure
89417328|NCT02171910|Placebo Comparator|Placebo|Propofol sedation with a placebo i.v. bolus at induction and a placebo i.v. infusion during the procedure
89417329|NCT05061355|Experimental|Surgery plus medical therapy|Heart valve surgery will be performed as soon as possible and preferably within 48 hours of randomization in addition to standard medical care for IE.
89417330|NCT05061355|No Intervention|Medical therapy|Only standard medical care for IE.
89417331|NCT02975167|Experimental|Inpatient|"Subjects randomized to this group will receive the same intervention as the outpatient group -- cervical ripening with Foley catheter -- but remain within the hospital. Subjects will be asked to complete a survey assessing their fears, opinions, anxiety, satisfaction and hours of sleep before and after the catheter is placed and removed, respectively.~The intervention: randomization to inpatient cervical ripening"
89535976|NCT05002725|Active Comparator|Femoral Block|An ultrasound guided Femoral Nerve catheter will be inserted. 20ml of 1.5% lidocaine will be administered.
88895060|NCT05945602||Biomarker Optimization - Patients|Veterans currently enrolled for healthcare services at the VA San Diego Healthcare System who have a diagnosis of a chronic psychotic disorder (e.g., schizophrenia or schizoaffective disorder).
88895061|NCT05945602||Biomarker Optimization - Healthy Comparison Subjects|Veterans currently enrolled for healthcare services at the VA San Diego Healthcare System who have no history of mental illness.
89535977|NCT03200041|Other|Low Risk|350 Low risk The only intervention is a 20 ml blood sample will be taken from each participant.
89417332|NCT02975167|Experimental|Outpatient|"Subjects randomized to this group will receive the same intervention as the inpatient group -- cervical ripening with Foley catheter -- but will be discharged home. Subjects will be asked to return to the hospital when the catheter falls out or if 24 hours has elapsed. They will be given detailed instructions and provided a 24 hour phone number to call should they have any concerns. Subjects will be asked to complete a survey assessing their fears, opinions, anxiety, satisfaction and hours of sleep before and after the catheter is placed and removed, respectively.~The intervention: randomization to outpatient cervical ripening"
89417333|NCT03068884|Sham Comparator|Tdcs sham|
89417334|NCT03068884|Placebo Comparator|Placebo|
89417335|NCT03068884|Experimental|Tdcs cathodal|
89417336|NCT03068884|Experimental|Tyrosine|
89417337|NCT02175732|Experimental|KnowIt|Please see the 'KnowIt' intervention description below. Diabetes education, behavioral management
89417338|NCT02175732|Experimental|OnTrack|Please see the 'OnTrack' intervention description below. Diabetes Distress Reduction, Problem Solving Therapy
89417339|NCT04957225|Experimental|Direct intervention|Goal level 60 hours of intensive treatment during 6 weeks. Intensive treatment of aphasia and AOS in ICAP-format (MIRAA).
88895062|NCT05945602||Biomarker Validation in Chronic Psychotic Disorders|Veterans currently enrolled for healthcare services at the VA San Diego Healthcare System with a diagnosis of a chronic psychotic disorder (e.g., schizophrenia or schizoaffective disorder).
88895063|NCT05943626|No Intervention|Control Group|Provided with general health information on diet and physical activity.
89417340|NCT04957225|No Intervention|Waiting group|No intervention during 6 weeks, testing directly before and after the waiting period. After the waiting period the participants receives the same intervention as the direct intervention arm.
89417341|NCT02178306|Experimental|Telmisartan|
89417342|NCT05729386|Experimental|GC2129A + Reference drugs|Period 1: GC2129A, Period 2: Individual Components
89417343|NCT05729386|Experimental|Reference drugs + GC2129A|Period 1: Individual Components, Period 2: GC2129A
89417344|NCT01495741||Asenapine|Participants prescribed asenapine
89417345|NCT01495741||Risperidone Comparator|Participants prescribed risperidone
89417346|NCT01495741||Olanzapine Comparator|Participants prescribed olanzapine
88895064|NCT05943626|Experimental|Intervention Group|Circadian-based intervention focused on timing of light exposure and food intake.
88895065|NCT05939674|Placebo Comparator|Normal saline group|Participants are administered 3mL of 0.9% normal saline at the end of anesthesia
88895066|NCT05939674|Active Comparator|Flumazenil group|Participants are administered 0.3mg(3mL) of flumazenil at the end of anesthesia
89417347|NCT02178384|Experimental|Altered-cast technique|Removable partial dentures will be made using altered-cast technique for free saddles.
89417348|NCT02178384|Active Comparator|Precision attachments|Removable partial dentures will be made using precision attachments which will be located on the distal abutment teeth.
89417349|NCT02178384|Active Comparator|Resilient layer|Removable partial dentures will be made using a resilient-layer on the distal extension of each appliance.
89417350|NCT03068806||Patients with Schizophrenia|Individuals who have been previously diagnosed with schizophrenia and meet our research criteria for symptoms indicative of schizophrenia within their lifetime.
89417351|NCT03068806||Healthy Controls|Individuals who have not met criteria for a psychiatric disorder within their lifetime according to our research criteria for symptoms indicative of a psychiatric disorder.
89417352|NCT05729308|Active Comparator|Group (CE): Patients receiving caudal epidural block|
89417353|NCT05729308|Active Comparator|Group (ESP): Patients receiving bilateral erector spinae plane block.|
89417354|NCT05729308|Active Comparator|Group (C): Control group, patients receiving general anesthesia with intravenous analgesia.|
89417355|NCT00778999|Active Comparator|Oral Contraceptive|Use of oral contraceptive pills prior to controlled ovarian stimulation
89417356|NCT00778999|No Intervention|Non-Oral Contraceptive|No use of oral contraceptive pills prior to controlled ovarian stimulation
89417357|NCT02171988|Active Comparator|Propranolol|Start propranolol 10mg bid, and then dose up to 20mg bid after one month if tolerable
89417358|NCT02171988|Active Comparator|Bisoprolol|Start bisoprolol 2.5mg qd P.O, and then dose up to 5mg qd. if tolerable
89417359|NCT02171988|Active Comparator|Propranolol+pyridostigmine|Start propranolol+pyridostigmine 10mg bid +30mg bid, and then dose up to 20mg bid+30mg bid. if tolerable.
89006146|NCT04644445|No Intervention|Control|Standard bariatric clear liquid diet to be started 4 hours after surgery
89006147|NCT04644445|Experimental|Intervention|Bariatric full liquid diet (clear liquid diet + protein shakes) to be started 4 hours after surgery
89006148|NCT00558883|Active Comparator|1|treatment with Acarbose: 2 weeks 1 x 50mg; 2 weeks 3 x 50mg; 16 weeks 3 x 100mg
89006149|NCT00558883|Placebo Comparator|2|treatment with placebo: 2 weeks 1 x 50mg 2 weeks 3 x 50mg 16 weeks 3 x 100mg
89006150|NCT04643938||Two spontaneous abortions|No intervention
89006151|NCT04643938||three spontaneous abortions|No intervention
89006152|NCT04643938||Four or more spontaneous abortions|No intervention
89535978|NCT03200041|Other|High Risk|150 High Risk going onto invasive diagnostic procedure. The only intervention is a 20 ml blood sample will be taken from each participant.
89006153|NCT04643977|Experimental|mesohyal ARGIBENONE|Name of the investigation medical device: mesohyal ARGIBENONE Code of the MD for the purpose of the clinical investigation: mARG-01-17 GMDN code: 59131 mARG-01-17 is a dermal filler recommended for cutaneous filling, facial wrinkle improvement and general condition of the skin, which is administered by intradermal injections. It encourages repair and restructuring of skin tissue, reducing the signs of aging.
89006154|NCT04643821|Experimental|NAC 25mg/kg, calcitriol 0.05mcg/kg|N-acetylcysteine 25mg/kg iv q 12h, calcitriol 0.05mcg/kg iv q 12h, for 10 days, starting within 6h of birth
89006155|NCT04643821|Experimental|NAC 25mg/kg, calcitriol 0.03mcg/kg|N-acetylcysteine 25mg/kg iv q 12h, calcitriol 0.03mcg/kg iv q 24h, for 10 days, starting within 6h of birth
89006156|NCT04643821|Experimental|NAC 40mg/kg, calcitriol 0.03mcg/kg|N-acetylcysteine 40mg/kg iv q 12h, calcitriol 0.03mcg/kg iv q 24h, for 10 days, starting within 6h of birth
89006157|NCT04643509||cardiac surgery|patients benefiting from pulmonary arterial catheter monitoring after cardiac surgery
89006158|NCT04643665||No grade 3 Pulmonary graft dysfunction at postoperative day 3|patients having not a grade 3 Pulmonary graft dysfunction at postoperative day 3
89006159|NCT04643665||Grade 3 Pulmonary graft dysfunction at postoperative day 3|patients having a grade 3 Pulmonary graft dysfunction at postoperative day 3
89006160|NCT04643392||Patients with Lipedema|Participants who were diagnosed with upper extremity lipedema by a lymphologist.
89006161|NCT04643236|Experimental|periodontal health educational group (test)|25 subjects diagnosed with gingivitis received periodontal health education session
89006162|NCT04643236|Active Comparator|oral hygiene motivation group (control)|25 subjects diagnosed with gingivitis received standard oral hygiene motivation session
89193438|NCT04948554|Placebo Comparator|Cohort 4: Placebo|Participants in Cohort 4 will receive placebo Q2W plus SOC for 12 weeks.
89193439|NCT04948554|Experimental|Cohort 5: MK-2225|Participants in Cohort 5 will receive MK-2225 (no more frequent than Q2W) ≤2.25 mg/kg Q2W or ≤4.5 mg/kg Q4W if needed plus SOC for 12 weeks.
89535979|NCT03075345|Active Comparator|Treatment as usual (weight management intervention)|6 session weight management programme (over 12 weeks).
89006163|NCT00559000|No Intervention|Waitinglist Control|
89006164|NCT00559000|Experimental|KIDNET|
89006165|NCT00414570|Experimental|[18]F-FLT PET scan|Radioactive dose of 2.59 MBq/kg (range 100 - 350 MBq) [18]F-FLT per injection prior to Positron Emission Tomography (PET) imaging. [18]F-FLT PET scans at baseline/pre-treatment and at disease progression, up to a maximum of two separate [18]F-FLT PET scans per participant.
89006166|NCT00218114|Experimental|1|Divalproex sodium (Depakote). This is a parallel groups design lasting a total of six weeks. Participants will be on a fixed-flexible dosing schedule. The dose of depakote will be raised to 750mgs or 1000mgs, depending on weight, in two weeks to achieve blood levels between 50-130 micrograms per milliliter. If a patient does not achieve this blood level on 750mgs or 1000 mgs, the dose may be raised during the second week.
89006167|NCT00218114|Placebo Comparator|2|This is a parallel groups design lasting a total of six weeks. Participants will be on matching placebo for 250 mgs divalproex sodium (Depakote).
89006168|NCT00559078||CAH|Women diagnosed with CAH (either simple virilizing or salt-losing)
89006169|NCT00559117|Experimental|Cohort|
89193440|NCT04948554|Placebo Comparator|Cohort 5: Placebo|Participants in Cohort 5 will receive (no more frequent than Q2W) placebo plus SOC for 12 weeks.
89535980|NCT03075345|Experimental|Treatment as usual plus acceptance and commitment therapy|6 session weight management programme (over 12 weeks) plus a 4 session acceptance and commitment therapy (ACT) programme. The ACT part will commence straight after the conclusion of the weight management programme.
89417360|NCT02171988|Active Comparator|Bisoprolol+pyridostgmine|start bisoprolol+pyridostgmine 2.5mg qd+30mg bid, and then, dose up to 5mg qd+30mg bid. if tolerable
88895067|NCT05939427|Experimental|NGAGE tool group|Will have access to the NGAGE tool to learn about engaging in care and to request engagement activities.
89417361|NCT00725413|Experimental|Arm 1|Healthy premenopausal women requiring a long-term method of contraception
89417362|NCT02178462||Primary ovarian cancer patients|Intervention will not be administered.
89417363|NCT02178462||Primary endometrial cancer patients|Intervention will not be administered.
89417364|NCT02178462||Benign gynecological disease patients|Intervention will not be administered.
89417365|NCT02178462||Healthy controls|Intervention will not be administered.
88895068|NCT05939427|No Intervention|Non-Intervention|Will receive usual care standards.
88895069|NCT05937308|Other|NEUROMARK Treatment|Interventional registry to collect real world data - Subjects will undergo treatment with the NEUROMARK System.
88895070|NCT05936047|Experimental|Experimental|The clotted vertebral bone marrow aspirate (vBMA) will be obtained from vertebral bone marrow aspirate.The vBMA clot contain mesenchymal stem cells (MSCs), growth factors, platelet and osteogenic and anti-inflammatory mediators.
88895071|NCT05934838|Experimental|Tazemetostat and CAR T-Cell Therapy|Tazemetostat is being administered prior to, and following, standard of care CAR T cell therapy. The use of tazemetostat in this way is investigational.
88895072|NCT05930678|Active Comparator|Without ventilation|No ventilation sequence during the intubation period and without face mask ventilation during the apnea period
88895073|NCT05930678|Experimental|With ventilation|"Sequence with ventilation during the apnea period with face mask ventilation"
88895074|NCT05926219|Experimental|Fatigue|Volunteers will perform one-legged knee extension exercise until fatigue while seated on an ergometer. Volunteers will then undergo bilateral skeletal muscle biopsies of the vastus lateralis muscle in their thigh.
88895075|NCT05921487|Experimental|Time Restricted Eating|This is a single-arm study in a convenience sample of Veterans with thoracic paraplegia and obesity. The intervention will test adherence of participants to a TRE window with a self-selected start time. The duration of the eating window will initially be 12 hours, then transition to 10 hours at the end of week 2, maintained through study's end (end of week 6).
88895076|NCT05910736|Experimental|Medicare AWV Toolkit|Practice-tailored intervention combining EHR tools with practice redesign workflows and templates for completing AWVs
88895077|NCT05910216|Experimental|Group Dance & Music (Online)|Social Telerehabilitation with Dance & Music (Online): The dance intervention will be instructed by a physiotherapist and dance professional, who will follow a structure based on the materials of the Dance for Parkinson's (USA) ® method
88895078|NCT05910216|Active Comparator|Group Multimodal Therapeutic Exercise & Music (Online)|Social Telerehabilitation with Multimodal Therapeutic Exercise & Music (Online): The intervention with multimodal therapeutic exercise will be instructed by a physiotherapist, who will follow a structure based on a previous study and Physical Therapy Guidelines for People with PD
88895079|NCT05900466|Active Comparator|1: Metformin Treatment|500 mg metformin ER tablets once daily in the morning with a glass of water for 8 weeks.
88895080|NCT05900466|Placebo Comparator|2: Placebo|Matching metformin ER placebo tablets once daily in the morning with a glass of water for 8 weeks.
88895081|NCT05895929|Experimental|Mepolizumab treatment arm|Nasal epithelial cells will be exposed in vitro to mepolizumab in culture.
88895082|NCT05895929|No Intervention|Control arm|Nasal epithelial cells will be exposed in vitro to media without mepolizumab in culture
88895083|NCT05891626|Experimental|Group intervention|Six comparable general clinics (2 for pediatric care and 4 for adult primary care) from all MultiCare facilities will be selected to participate in the study. Half of the clinics will be in the Puget Sound Region and others in the Eastern Washington Areas. Allocation to the intervention will be based on randomization: one pediatric and two adult (Internal Medicine or Family Medicine) clinics will get the comprehensive intervention.
88895084|NCT05891626|No Intervention|Standard care|The other three facilities will stay as the control under routine care. The three control group sites will have no additional interventional activities regarding vaccination, except for MultiCare's usual vaccine promotion practices (which the interventional clinics will have also).
88895085|NCT05891483|Experimental|Treatment group A: SHR-1905 Injection（dose 1）|
88895086|NCT05891483|Experimental|Treatment group B: SHR-1905 Injection（dose 2）|
88895087|NCT05891483|Experimental|Treatment group C: SHR-1905 Injection（dose 3）|
88895088|NCT05891483|Placebo Comparator|Placebo Group|
88895089|NCT05890833||Neuromuscular disorders|
88895090|NCT05888519|Other|FID123300/FID123301/FID122505|FID123300 ocular lubricant in Period 1, followed by FID12330 ocular lubricant in Period 2, followed by FID122505 ocular lubricant in Period 3, as randomized. For each period, the subject will receive one drop in each eye for one day. A 1-4 day washout will separate each period.
88895091|NCT05888519|Other|FID123301/FID122505/FID123300|FID123301 ocular lubricant in Period 1, followed by FID122505 ocular lubricant in Period 2, followed by FID123300 ocular lubricant in Period 3, as randomized. For each period, the subject will receive one drop in each eye for one day. A 1-4 day washout will separate each period.
88895092|NCT05888519|Other|FID122505/FID123300/FID123301|FID122505 ocular lubricant in Period 1, followed by FID123300 ocular lubricant in Period 2, followed by FID123301 ocular lubricant in Period 3, as randomized. For each period, the subject will receive one drop in each eye for one day. A 1-4 day washout will separate each period.
88895093|NCT05880004|Experimental|Food Pantries receiving SAFPAS intervention|Food Pantries in this arm will receive access to all functions of the SAFPAS application
88895094|NCT05880004|No Intervention|Food Pantries not receiving SAFPAS intervention|Food Pantries in the arm will not receive access to the SAFPAS application
89417366|NCT02172066|Experimental|Narrative Exposure Therapy (NET)|During NET, the client, with the assistance of the therapist, constructs a chronological narrative of his or her entire life with a focus on exposure to traumatic stress. Empathic understanding, active listening, congruency and unconditional positive regard are key components of the therapist's behavior. The therapist asks in detail for emotions, cognitions, sensory information, and physiological reactions to link the traumatic events to an autobiographical context, namely time and place. In total the Individuals receive 6 sessions of NET, every session lasting between 1,5 and 2 hr depending on the needs of the participant.
89417367|NCT02172066|No Intervention|No treatment control|
89417368|NCT02631850|Active Comparator|Traditional CI Therapy|"Participants will receive a 35-hour dose of CI therapy. Treatment will consist of 35 therapist/client contact hours in the clinic, 10 weekdays, over 3 weeks. To promote carry-over of motor gains to daily activities, participants will complete: (1) a treatment contract, (2) daily self-report of arm use, and (3) problem-solving to overcome barriers to use of the more affected upper extremity. In addition, the client will agree to wear a padded restraint mitt on the less affected hand for the majority of waking hours to encourage use of the weaker hand for daily activities. Finally, the participant will agree to 30 minutes per day of individualized task-practice outside the clinic (in addition to training in the clinic) focused on functional activities catered towards accomplishing the person's therapeutic goals."
89417369|NCT02631850|Active Comparator|Gaming CI Therapy|15 hours of progressive massed motor practice will occur through in-home video game play over 15 consecutive weekdays. Participants will play the game during times of their choosing. The participant will wear an activity monitor biofeedback device for the majority of waking hours. As with traditional CI therapy, the client will agree to an additional 30 minutes per day of individualized task-practice. Five therapist/client contact hours will occur in the clinic on approximate treatment days 1, 3, 6, and 11 and will focus on treatment elements that cannot be readily addressed through the game, such as problem-solving to help the participant carry over motor gains to daily life.
89417370|NCT02631850|Active Comparator|Gaming CI Therapy with Additional Contact via Video Conference|This group will receive treatment that is identical to Group 2, but will receive an additional 2.6 hours video conference consultation throughout the treatment period.
89417371|NCT02631850|Active Comparator|Traditional Occupational Therapy/Physical Therapy|Five therapist/client contact hours will occur on approximate treatment days 1, 3, 6, and 11 (same schedule as gaming CI therapy). 1 hour progressive resistance exercise to establish and progress an upper extremity home exercise program, 2 hours of neuromuscular reeducation, and 2 hours functional practice on activities of daily living (ADLs) with verbal encouragement to use the more affected upper extremity to the largest extent possible. Home practice consists of strengthening exercises, designed to increase range of motion, prescribed twice daily. After completing their participation in the standard OT condition (6 months), participants will be crossed-over to a CI therapy gaming only condition. This condition will be identical to that described above, excluding therapist contact throughout the intervention. Rather, participants will receive a DVD explaining the intervention and guiding them through use of the system.
89417372|NCT00103038|Experimental|Diagnostic (ferumoxytol, gadolinium, DCE-MRI, DSC-MRI)|"Study patients: adult patients with high grade primary malignant brain tumors or with known or suspected brain metastases from histologically confirmed primary cancer~Study procedures: patients will receive IV ferumoxytol (maximum dose 4 mg/kg, over at least 15 minutes) beginning approximately 15 seconds after start of 3T DSC-MRI and GBCA IV approximately 1 minute and 50 seconds after start of 3T DCE-MRI on day 1. Patients will also undergo MRI without contrast at baseline (before and on day 2. Imaging with ferumoxytol, GBCA and without contrast repeats every 3 weeks for a total of 6 more imaging sessions over up to 5 years.~3 Tesla Magnetic Resonance Imaging: Undergo 3T MRI~Dynamic Contrast-Enhanced Magnetic Resonance Imaging: Undergo 3T DCE-MRI~Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging: Undergo 3T DSC-MRI~Ferumoxytol: Given IV~Gadolinium: Given IV~MRI-Based Angiogram: Undergo MRA"
88895095|NCT05879159|Experimental|Accelerated Recovery Protocol|"Accelerated Recovery after Minimally Invasive Hepatic Surgery (ARAMIS-Hep)~Participants randomized to this arm will undergo a recovery pathway that potentially allows for discharge on the day of surgery (post-operative day 0).~You will receive a clear liquid diet, be encouraged to ambulate independently, and opioid use will be minimized in the recovery unit.~You will be assessed in the post-operative recovery unit. If you meet discharge criteria, you will be discharged the afternoon/evening of surgery. If you do not, you will be admitted for overnight observation.~You will have a telehealth video visit on post-operative days 1 and 2~You will have in-person clinic visit within 14 days of discharge.~You will fill out about 14 questionnaires over a 30-day period to assess how you are feeling regarding your recovery"
88895096|NCT05879159|Experimental|Comparison/Control Arm|"Standard Post-operative recovery pathway after minimally invasive hepatic surgery.~Participants randomized to this arm will undergo our institution's standard recovery pathway for minimally invasive liver surgery.~You will be transferred to the Transitional PACU for overnight observation.~Your diet will be advanced to gastrointestinal first food diet on Post-operative Day 1, with opioid weaning and frequent ambulation.~You will be discharged once criteria are met.~You will have an in-person clinic visit within 14 days of discharge.~You will fill out about 14 questionnaires over a 30-day period to assess how you are feeling regarding your recovery."
88895097|NCT05877612||Burst stimulation|Patients treated by Spinal Cord Stimulation in Burst Mode for their Complex Regional Pain Syndromes (CRPS) Type 1 of the Upper Limbs
88895098|NCT05875961|Experimental|Group A|Eligible subjects who have been randomized to receive two intramuscular vaccinations (3 weeks apart) of low dose A/H2N3c + standard dose MF59 adjuvant
88895099|NCT05875961|Experimental|Group B|Eligible subjects who have been randomized to receive two intramuscular vaccinations (3 weeks apart) of intermediate dose A/H2N3c + standard dose MF59 adjuvant
89193441|NCT04948554|Experimental|Cohort 6: MK-2225|Participants in Cohort 6 will receive MK-2225 (no more frequent than Q2W) ≤2.25 mg/kg Q2W or ≤4.5 mg/kg Q4W if needed plus SOC for 12 weeks.
89193442|NCT04948554|Placebo Comparator|Cohort 6: Placebo|Participants in Cohort 6 will receive (no more frequent than Q2W) placebo plus SOC for 12 weeks.
89193443|NCT04943744||String Test|Participants in the COMBINE study will have an EST performed at pre- specified timepoints (screening, week 8, and week 32) and as needed depending on GI symptoms.
89417373|NCT00620035|Experimental|Radiopaque Etonogestrel Implant|"Radiopaque Etonogestrel Implant (drug) inserted with the Next Generation Applicator (NGA)~The Radiopaque Implant is a single rod contraceptive implant of 4 cm length and~2 mm in diameter which is placed at the inner side of the non-dominant upper-arm~about 8-10 cm above the medial epicondyle. The Radiopaque Implant contains~approximately 68 mg etonogestrel (ENG) dispersed in a matrix of ethylene vinyl acetate (EVA) copolymer and barium sulfate, surrounded by an EVA membrane. The barium-sulfate provides radio-opacity and allows detection by X-ray.~The ENG dose released from the implant amounts to about 60-70 mcg/day shortly after insertion and decreases to about 40 mcg/day at the start of the second year, and to about 25-30 mcg/day at the end of the third year."
89193444|NCT04941716|Experimental|Treatment (acalabrutinib, venetoclax)|Patients receive acalabrutinib PO BID and venetoclax PO QD on days 1-28. Patients receive acalabrutinib alone for the first three 28 day cycles. Venetoclax is added beginning with Cycle 4. Treatment repeats every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity.
89193445|NCT04940780|Active Comparator|Patient Preference Arm|patients who specify their preference for either acupuncture or touch therapy
89193446|NCT04940780|Active Comparator|Randomized Treatment Arm|with no preference, to be randomly allocated to either the acupuncture or touch-therapy subgroup
89417374|NCT03068728|Other|All Study Participants|"Participants received hemostatic packing agent in one nasal cavity and no packing in the other.~Participants were randomized to one of three hemostatic packing agents (Arista, Nexfoam, Nasopore) through sealed envelope, chosen by surgeon prior to placement, with packing agent allocation and sidedness."
89417375|NCT02175888|Experimental|Oral iron supplement every day for 14 days|Daily administration of 60 mg iron in form of ferrous sulphate capsules for 14 consecutive days
89193447|NCT04933331||Curodont Repair Fluoride Plus (Curodont) cohort|The effectiveness of Curodont treatment in this group will be compared to other treatment options and cohorts. Curodont will be professionally applied in the dental clinic. The treatment time takes about 5 minutes. Patients receive one professional dose application and be provided with homecare instructions and will be instructed to return for regular dental visits and exams according to the frequency determined by their dental team, usually every 6 months.
89199163|NCT05954429|Experimental|Serplulimab+Fruquintinib|Participants will receive serplulimab 300 mg every 3 weeks (Q3W) concurrently with fruquintinib regimen: 5mg (QD) orally for 2 weeks, 1 week off, repeated every 3 weeks. Treatment repeats every 3 weeks until disease progression or intolerable toxicity.
89417376|NCT02175888|Active Comparator|Oral iron supplement every second day for 28 days|Administrations of 60 mg iron in form of ferrous sulphate capsules on every second day for 28 days
89417377|NCT05577637|Active Comparator|group A topical tacrolimus 0.03% with uvb phototherapy|Group A :contain 30 patients who have been treated with topical 0.03% tacrolimus twice daily at night and then received uvb phototherapy thrice weekly for 12 weeks
88895100|NCT05875961|Experimental|Group C|Eligible subjects who have been randomized to receive two intramuscular vaccinations (3 weeks apart) of high dose A/H2N3c + standard dose MF59 adjuvant
88895101|NCT05875961|Experimental|Group D|Eligible subjects who have been randomized to receive two intramuscular vaccinations (3 weeks apart) of high dose A/H2N3c non-adjuvanted
88895102|NCT05875961|Experimental|Group E|Eligible subjects who have been randomized to receive two intramuscular vaccinations (3 weeks apart) of lowest dose A/H2N3c + high dose MF59 adjuvant
88895103|NCT05875961|Experimental|Group F|Eligible subjects who have been randomized to receive two intramuscular vaccinations (3 weeks apart) of low dose A/H2N3c + high dose MF59 adjuvant
89417378|NCT05577637|Active Comparator|Group B topical placebo twice daily with uvb phototherapy thrice weekly|Group B :contain 30 patients received uvb phototherapy only thrice weekly for 12 weeks
88895104|NCT05868408|Active Comparator|Control formula|CTRL, an infant formula with minimum protein content of 1.8g intact protein/100kcal
88895105|NCT05868408|Experimental|Experimental formula 1|EXPL1, an infant formula with minimum protein content of 1.9g hydrolyzed protein/100kcal
89417379|NCT02176044|Placebo Comparator|Glucose infusion|Placebo infusion of sterile 5% glucose - 500ml infused over 4 hours.
89417380|NCT02176044|Active Comparator|Sodium Nitroprusside infusion|Sodium nitroprusside dissolved in 5% glucose solution. Infused at 0.5mcg/kg/min for 4 hours.
89417381|NCT03067870|Experimental|Stem Cells|Autologous bone marrow-derived stem cell transplantation.
89417382|NCT05054491|Experimental|Group ANC|Intervention period in stepped wedge design where women are receiving antenatal care in a group setting
88895106|NCT05868408|Experimental|Experimental formula 2|EXPL2, an infant formula identical to EXPL1 but manufactured using a different partially hydrolyzed milk protein base
89417383|NCT05054491|No Intervention|Individual ANC (routine)|Pre-intervention time period (control period) where the intervention is not being implemented yet (women are receiving individual antenatal care as is currently offered)
89417384|NCT02176122|Active Comparator|Meropenem|Meropenem 1g adm every 8 hours IV up to study day 4.
89417385|NCT02176122|Experimental|Piperacillin-tazobactam combination product|Piperacillin/tazobactam 4.5g adm every 6 hours IV up to study day 4.
89193448|NCT04933331||Other tooth-specific initial lesion interventional treatments cohort(s)|"Silver Diamine Fluoride (SDF). The treatment time is about 2 minutes.~Glass Ionomer Sealants: The treatment time takes about 5 minutes per sealant. Typically four sealants are completed in one visit.~All patients will be provided with homecare instructions and will be instructed to return for regular dental visits and exams according to the frequency determined by their dental team, usually every 6 months."
89417386|NCT04887064|Experimental|Normal Hepatic Function|
89193449|NCT04933331||Control cohort, no tooth-specific treatment or whole mouth treatment.|If a patient or their caregivers choose no tooth-specific treatment, they will be included in the control cohort. This group includes patients who chose to receive no treatment at all, as well as those who choose whole mouth treatments such as: 2.26% fluoride varnish, 1.23% fluoride foam, and 5000 ppm fluoride prescription toothpaste.
89417387|NCT04887064|Experimental|Moderate Hepatic Impairment|
89417388|NCT04887064|Experimental|Severe Hepatic Impairment|
89417389|NCT02967757||liraglutide 3.0 mg / liraglutide 1.2 mg/1.8 mg|
89417390|NCT05632276|Other|ConvaFoam dressings|Participants wounds will be assessed and will be allocated ConvaFoam Border, Silicone or Non-Adhesive dressing based upon the investigator's clinical judgment. participants will receive a dressing as part of a protocol of care for up to a period of 4 weeks
89417391|NCT02261298|Experimental|ONO-4538 1mg/kg|ONO-4538 water-soluble injection, 100 mg/vial, 1mg/kg, 3 times once every 2 weeks in each 6-week cycle
88895107|NCT05860881|Experimental|Topical Sirolimus|Topical 1% sirolimus cream applied daily to the face for 6 months
88895108|NCT05860881|Placebo Comparator|Placebo|Topical placebo cream applied daily to the face for 6 months
88895109|NCT05847244|No Intervention|control|Lifestyle counseling plus standard evidence based therapy
88895110|NCT05847244|Experimental|intervention (metformin)|Lifestyle counseling plus standard evidence based therapy and metformin (target dose 1000 mg bid)
88895111|NCT05830929|Experimental|Ovarian tissue freezing and subsequent auto-transplantation after thawing|Ovarian tissue freezing and subsequent auto-transplantation after thawing
88895112|NCT05824182|Experimental|Intervention Group|Intervention group: FACE self-help app with guidance
88895113|NCT05824182|No Intervention|control group|Waiting list control group with questionnaires and EMA
88895114|NCT05820698|Experimental|The Mediterranean style diet|Participants in the Mediterranean style diet arm (n = 12) will receive dietary advice to follow a Mediterranean style diet by the Research Nutritionist.
88895115|NCT05820698|Experimental|The Mediterranean style diet with time-restricted eating|Participants in the Mediterranean style diet with time-restricted eating arm (n = 12) will receive dietary advice to follow a Mediterranean style diet combined with time-restricted eating by the Research Nutritionist.
88895116|NCT05820698|Active Comparator|The UK diet with time-restricted eating|Participants in the UK diet with time-restricted eating arm (n = 12) will receive dietary advice to follow a UK diet combined with time-restricted eating by the Research Nutritionist.
89193450|NCT04933331||Orthodontic cohort|Patients in active orthodontic care will be analyzed separately from other patients to account for the impact of orthodontic appliances on treatment outcomes. Orthodontic appliances are recognized by the American Dental Association Caries Risk Assessment as a risk factor for caries because they create dental plaque stagnation areas that are difficult to clean. Initial caries lesions are very frequently seen immediately surrounding orthodontic brackets (braces), yet continued plaque stagnation over the treated areas may heavily influence the success of any treatment. All groups/cohorts above will be represented in the orthodontic cohort in parallel.
89199164|NCT05954390|Active Comparator|Active Therapy|The active comparator intervention is a solution containing undenatured beta-glucans
89417392|NCT02261298|Experimental|ONO-4538 3mg/kg|ONO-4538 water-soluble injection, 100 mg/vial, 3mg/kg, 3 times once every 2 weeks in each 6-week cycle
89417393|NCT02261298|Experimental|ONO-4538 10mg/kg|ONO-4538 water-soluble injection, 100 mg/vial, 10mg/kg, 3 times once every 2 weeks in each 6-week cycle
89417394|NCT02178618|Active Comparator|Partially covered biliary self expandable metal stent|
89417395|NCT02178618|Active Comparator|Uncovered biliary self expandable metal stent|
89417396|NCT02176200|Experimental|Berodual® Respimat®|
89417397|NCT02176200|Active Comparator|Berodual® HFA-MDI|
89417398|NCT03577665|Experimental|curative proton therapy|Patients who meet the selection criteria are selected, signed for consent, and treated with proton therapy alone at 7200 cGy / 15 fractions, 5 times a week for 3 weeks
88895119|NCT05817318|Other|Pre-to-post renal denervation treatment|Pre-to-post treatment comparison
88895120|NCT05816148||Disabled persons|Members or users of APF France handicap
89417399|NCT03537612|Experimental|Opt-Clonidine|Intrathecal Clonidine 1 mcg/kg (up to 75 mcg) immediately post-op; Clonidine pill TID Post-op Day 1-5 (liquid version available if subject cannot swallow capsule)
89417400|NCT03537612|Experimental|Sub-opt-Clonidine|Intrathecal Clonidine 1 mcg/kg (up to 75 mcg) immediately post-op; Clonidine pill TID Post-op Day 1-5 (liquid version available if subject cannot swallow capsule)
89417401|NCT03537612|Active Comparator|Opt-Morphine|Intrathecal spinal morphine (5 mcg / kg) immediately post-op; Placebo pill TID Post-op Day 1-5 (liquid version available if subject cannot swallow capsule)
89417402|NCT03537612|Active Comparator|Sub-opt-Morphine|Intrathecal spinal morphine (5 mcg / kg) immediately post-op; Placebo pill TID Post-op Day 1-5 (liquid version available if subject cannot swallow capsule)
89417403|NCT03579147|Experimental|Treatment Group|Treatment with the investigational device BTL EMSCULPT.
89417404|NCT02172144|Experimental|BI 1744 CL|
89417405|NCT02172144|Placebo Comparator|Placebo|
89417406|NCT02172144|Active Comparator|Moxifloxacin (Avalox®)|
89417407|NCT02178774||parturients|tissue oxymetry
89417408|NCT03579069||Ductus venosus Doppler realized|Ductus venosus Doppler realized
89417409|NCT03579069||Ductus venosus Doppler unrealized|Ductus venosus Doppler unrealized
89417410|NCT05729074|Experimental|Part A-1(SAD1)|IN-A002 Ointment 0.3% or Placebo Ointment, single dose
89417411|NCT05729074|Experimental|Part A-1(SAD2)|IN-A002 Ointment 0.5% or Placebo Ointment, single dose
89417412|NCT05729074|Experimental|Part A-1(SAD3)|IN-A002 Ointment 1% or Placebo Ointment, single dose
89417413|NCT05729074|Experimental|Part A-1(SAD4)|IN-A002 Ointment 3% or Placebo Ointment, single dose
89193451|NCT04906746|Experimental|Dosing Regimen for Ruxolitinib|"Level 0: Ruxolitinib 0 MG po bid for 1 month (Month 1)~Level 1: Ruxolitinib 10 MG po bid for 1 month (Month 2)~Level 2: Ruxolitinib 15 MG po bid for 1 month (Month 3)"
89417414|NCT05729074|Experimental|Part A-1(SAD5)|IN-A002 Ointment 5% or Placebo Ointment, single dose
89417415|NCT05729074|Experimental|Part A-2(MAD1)|IN-A002 Ointment 1% or Placebo Ointment, Twice daily (BID), multiple topical applications for 14 days
89417416|NCT05729074|Experimental|Part A-2(MAD2)|IN-A002 Ointment 3% or Placebo Ointment, Twice daily (BID), multiple topical applications for 14 days
89417417|NCT05729074|Experimental|Part A-2(MAD3)|IN-A002 Ointment 5% or Placebo Ointment, Twice daily (BID), multiple topical applications for 14 days
89417418|NCT05729074|Experimental|Part B(MAD1)|IN-A002 Ointment 1%, Twice daily (BID), multiple topical applications for 28 days
89417419|NCT05729074|Experimental|Part B(MAD2)|IN-A002 Ointment 3%, Twice daily (BID), multiple topical applications for 28 days
89417420|NCT05729074|Active Comparator|Part B|"Part B(MAD1), (MAD2):~Elidel Cream 1% (pimecrolimus), Twice daily (BID), multiple topical applications for 28 days"
89417421|NCT02176512|Experimental|Sequence 1|"four treatment periods:~Treatment A~Treatment B~Treatment B~Treatment A"
89417422|NCT02176512|Active Comparator|Sequence 2|"four treatment periods:~Treatment B~Treatment A~Treatment A~Treatment B"
89006170|NCT04643275|Experimental|Non-invasive lipolysis of the upper arms|The treatment administration phase consists of four (4) treatment visits, delivered 5- 10 - days apart. Each therapy session will last 30 minutes. Follow-ups visits at 1 month and 3 months after the final treatment will be held.
89006171|NCT04642924|Experimental|Locally Advanced Rectal Cancer|Patients included with locally advanced rectal cancer SGM-101 10mg, 3-5 days prior to surgery
89006172|NCT04642924|Experimental|Recurrent rectal cancer|Patients included with (locally) recurrent rectal cancer SGM-101 10mg, 3-5 days prior to surgery
89417423|NCT02238561||Elective major abdominal surgery|Patients undergoing elective major open or laparoscopic abdominal surgery at Plymouth Hospitals National Health Service (NHS) Trust (PHNT)
89417424|NCT05728996||Group 1|"standard: only routine diagnostic procedures are performed"
89417425|NCT05728996||Group 2A|"less invasive: in addition to routine monitoring, patients also undergo semen sampling"
89006173|NCT04643119|Active Comparator|Cruciate-Retaining Insert|
89006174|NCT04643119|Experimental|Medial-Congruent Insert|
89006175|NCT00241878|Experimental|1|Teacher-Delivered Weight Control Intervention
89006176|NCT00241878|Other|2|Teacher-Delivered General Health Intervention
89006177|NCT04643197|Experimental|Experimental arm|Abdominal fascia will be closed with barbed suture.
89006178|NCT04643197|Active Comparator|Control|Abdominal fascia will be closed with non-barbed suture.
89199165|NCT05954390|Placebo Comparator|Placebo|The placebo comparator intervention is the same solution used in the active comparator intervention except it does not contain any beta-glucans
89199166|NCT05954234|Active Comparator|pelvic floor rehabilitation and postural re-education|
89199167|NCT05954234|Active Comparator|pelvic floor rehabilitation and spinal mobilization|
89417426|NCT05728996||Group 2B|"less invasive: in addition to routine monitoring, patients undergo semen sampling and/or leukapheresis."
89417427|NCT05728996||Group 3|"extended: patients undergo (in addition to routine sampling) semen sampling, invasive tissue sampling (GALT and/or lumbar puncture) and leukapheresis."
89417428|NCT03578991|No Intervention|Arm 1|"Control group - Treatment as usual:~Type 2 diabetic patients with mild cognitive impairment who will receive the standard clinical treatment recommended by their primary care physician/endocrinologist."
89417429|NCT03578991|Experimental|Arm 2|"Intervention - Smart pillbox:~Type 2 diabetic patients with mild cognitive impairment receiving the standard clinical treatment recommended by their primary care physician/endocrinologist, plus the use of a smart pillbox."
89006179|NCT04643314|Experimental|Guided video-based self-evaluation|"In addition to their usual residency training, participants randomized to this group will undergo the following interventions:~The participants will be asked to review their own operating room recordings (of each of the 5 consecutive submitted laparoscopic cholecystectomy cases that the participant acted as the primary operator) and to assess themselves (within 72 hours (3 days) of the procedure) using validated intra-operative assessment tools. The completion of the self-evaluations is to guide and document video-based self-reflection. The duration of self-assessment/reflection session will be up do the participant. Residents in this group will have unlimited access to their recordings through the web-based platform. On the other hand, they will not be able to access the battery of assessment forms after the third day following the procedure."
89006180|NCT04643314|No Intervention|Traditional intraoperative teaching|"Subjects randomized to this group will undergo their usual residency training.~The recordings of the 5 submitted consecutive laparoscopic cholecystectomy procedures performed by the participant as the primary operator will be stored. However participants in this arm of the study will not have access to the uploaded videos until the end of the study."
89006181|NCT04643080|No Intervention|Control|Subjects were asked to avoid consuming fermented foods for 12 weeks.
89006182|NCT04643080|Experimental|Yogurt|Subjects were asked to consume 6 oz. of yogurt daily for 12 weeks.
88895121|NCT05801913|Experimental|Treatment (CMV-specific CD19-CAR T cells, triplex vaccine)|Patients undergo leukapheresis on day -30 and receive lymphodepleting chemotherapy on days -10 to -3 per SOC on study. Patients then receive CMV-specific CD19-CAR T cells IV on day 0 and CMV-MVA triplex vaccine IM on days 28 and 56 in the absence of unacceptable toxicity on study. Patients also undergo x-ray during screening and on study, as well as PET, CT, MRI, blood sample collection, and bone marrow biopsy on study and during follow-up.
89417430|NCT03578991|Experimental|Arm 3|"Intervention - Smart pillbox & Interactive digital platform:~Description: Type 2 diabetic patients with mild cognitive impairment receiving the standard clinical treatment recommended by their primary care physician/endocrinologist, plus the use of a smart pillbox and an interactive digital platform."
89417431|NCT03538236|Active Comparator|Lifestyle intervention alone|All patients included in the study will undergo an evaluation by a nutritionist and will undergo diet and lifestyle intervention.
88895122|NCT05791435|Experimental|Biofeedback group|This group will receive biofeedback to assist with breathing
88895123|NCT05791435|Experimental|Non-Biofeedback group|This group will only have their breathing monitored after instruction
88895124|NCT05791279|Experimental|Interventional arm|"The participants in the intervention group will receive information about their ECG-based Heart-Age and the Heart Age. The estimated Heart Age and Heart Age Gap will be presented in writing to the participants in the experimental arm within 2 weeks after the baseline visit. The presentation will include a brief and easy-to-understand description on how the Heart Age has been estimated. In addition, patients will receive information about general advice on how to improve blood pressure levels and reduce the risk of future cardiovascular disease by adopting a healthy lifestyle and adhering to the prescribed medication. This information will be the same for participants in the two study arms, and is based on recommendations from the European Society of Cardiology.~For patients in the intervention group the ordinary primary care physicians will also be informed about the ECG-based Heart-Age."
88895125|NCT05791279|No Intervention|Control arm|The control group will receive standard care according to routine care at the individual primary health care center, and receive the same general advice, on how to improve blood pressure levels and/or to reduce risks of future cardiovascular disease, as the participants in the intervention group.
88895126|NCT05789303|Experimental|Cohort 1: No Prior CAR T-Cell Therapy|This cohort will consist of 19 participants who have not had CAR T-Cell Therapy. Participants will receive belantamab mafodotin, carfilzomib, pomalidomide and dexamethasone.
88895127|NCT05789303|Experimental|Cohort 2: Prior CAR T-Cell Therapy|This cohort will consist of 64 participants who have had prior CAR T-Cell Therapy. Participants will receive belantamab mafodotin, carfilzomib, pomalidomide and dexamethasone.
88895128|NCT05788484|Experimental|CDX-585|"Dose-escalation phase: Eligible patients will receive treatment, based on cohort assigned, in 2-week cycles until progression or intolerance.~Expansion phase: Patients enrolled in the expansion phase of the study will receive CDX-585 at the dose level chosen during the escalation phase."
88895129|NCT05788328|Active Comparator|Period 1|Participants will receive dabagatrin etexilate (DE) as a single dose
88895130|NCT05788328|Active Comparator|Period 2|Participants will receive rosuvastatin as a single dose
88895131|NCT05788328|Active Comparator|Period 3|Participants will receive PF-07081532 daily titrated
89417432|NCT03538236|Experimental|Intragastric balloon with lifestyle|Patients who do not reach the 10% weight loss with lifestyle intervention alone after 6 months will be offered to have intragastric balloon insertion for 6 months. Regardless of whether an intragastric balloon is inserted, all patients will continue with the same lifestyle changes described above for another 6 months.
88895132|NCT05788328|Experimental|Period 4|Participants will receive PF-07081532 daily and DE as a single dose
88895133|NCT05788328|Experimental|Period 5|Participants will receive PF-07081532 daily and rosuvastatin as a single dose
88895134|NCT05788328|Active Comparator|Period 6|Participants will receive PF-07081532 daily titrated
89417433|NCT02238873|Active Comparator|Pegfilgrastim +1|Pegfilgrastim will be given 24 hours (day +1) after completion of salvage chemotherapy
89417434|NCT02238873|Experimental|Pegfilgrastim +3|Pegfilgrastim will be given 72 hours (day +3) after completion of salvage chemotherapy
89417435|NCT05141994|Experimental|2.5mg of BAT5906|Specification: 10mg/0.2ml/piece; route: intravitreal injection; dose: 2.5mg/eye/time, 50μl; medication duration: about once every 4 weeks, taking 3 times after continuous use, effective observation to Week 48.
89417436|NCT05141994|Experimental|4.0mg of BAT5906|16mg/0.2ml/piece; route of administration: intravitreal injection; dose: 4.0mg/eye/time, 50μl; duration of administration: once every 4 weeks, 3 times after continuous administration , The effectiveness was observed to the 48th week.
89417437|NCT02238951|Experimental|Mobile Health (mHealth)|Care coordination using mHealth technology enhancements
89417438|NCT02238951|Active Comparator|No mHealth|Care coordination without mHealth enhancements
89417439|NCT03034057|Other|sayana press|single arm
88895135|NCT05788328|Experimental|Period 7|Participants will receive PF-07081532 daily and DE as a single dose
88895136|NCT05788328|Experimental|Period 8|Participants will receive PF-07081532 daily and rosuvastatin as a single dose
88895137|NCT05787249|No Intervention|Usual care (no nudge)|Usual standard of care, no nudging.
88895138|NCT05787249|Experimental|Provider nudge only|Nudge sent to provider through EHR.
88895139|NCT05787249|Experimental|Patient nudge only|Nudge sent to the patient through text messaging.
88895140|NCT05787249|Experimental|Patient and provider nudge|Nudge sent to both provider through EHR, and to patient through text messaging.
88895141|NCT05784311|Experimental|Perioperative plus prolonged antibiotic prophylaxis|Prolonged prophylaxis: a single dose of 5-7mg/kg gentamicin followed by 2gr IV cefazolin and 500mg IV metronidazole every 4 hours of surgery (perioperative prophylaxis) followed by five days of 1500mg IV cefuroxime and 500mg IV metronidazole thrice daily
88895142|NCT05784311|No Intervention|Only perioperative prophylaxis|Perioperative prophylaxis: a single dose of 5-7mg/kg gentamicin followed by 2gr IV cefazolin and 500mg IV metronidazole every 4 hours of surgery.
89417440|NCT04630366|Experimental|NST-1024|NST-1024 capsules given once daily for up to 14 days
89417441|NCT04630366|Placebo Comparator|Placebo|Matching placebo capsules to NST-1024 given once daily for up to 14 days
89417442|NCT03578913|Active Comparator|porcelain fused to metal crown|Although metal free restorations are gained popularity recently, PFM restorations, whether they are tooth-supported or implant-supported are still considered as the gold standard due to their excellent biocompatibility, consistent esthetics, superior strength, and marginal adaptation.2 PFM restorations are also considered durable and long-lasting
89417443|NCT03578913|Experimental|PEEK crown|The main concern of dental implants is their lack of elasticity, therefore with the use of PFM, all ceramic or zirconia crowns; the load is directly transferred to bone. That is why up till now researchers are in quest of different materials to enhance soft and hard tissue reaction around implant supported restorations. Recently the use of PEEK as a final restoration on dental implants has wide acceptance, due to its excellent biocompatibility and exceptional physical and chemical properties regarding toughness, hardness and elasticity. In term of load cushioning capacity of the prosthetic elements, PEEK has a comparable modulus of elasticity (4GPa) to that of bone (4.2GPa). Thus, the bone could allow bone stimulation favoring its remodeling without overloading
89417444|NCT05628844||Healthy subjects|Healthy persons ≥ 18 yrs of age
89417445|NCT05628844||Critically ill patients|Critically ill patients ≥ 18 yrs of age admitted to the ICU
89417446|NCT05728684|Experimental|CM310|CM310, subcutaneous
88895143|NCT05779852|Experimental|self-hypnosis and care|
88895144|NCT05779852|Other|care|
88895145|NCT05779228|Experimental|Color Contrast|Test patch is surrounded spatially by different colors
88895146|NCT05779228|Experimental|Color Adaptation|Test patch is surrounded temporally (preceded) by different colors
88895147|NCT05779228|Experimental|Neuroimaging|Functional MRI and Electroencephelography data are acquired for multiple test colors
88895148|NCT05779228|Experimental|Red Room|Participants are tested in a red-illuminated room
88895149|NCT05779228|Experimental|Dark Room|Participants are tested in a completely darkened room
88895150|NCT05779228|Experimental|Gradual Change|Participants view a gradual change in tint, presented on a head-mounted display
88895151|NCT05778851|No Intervention|A1 Control|6 Virtual patient cases with GERD and similar BE risk factors as the cases in intervention arm A2 but without an EsoGuard result and in a different order.
88895152|NCT05778851|Active Comparator|A2 Intervention|"6 Virtual patient cases with GERD and similar BE risk factors as the cases in the control arm A1 with an EsoGuard result.~5 EsoGuard negative cases (same cases for all intervention questionnaires) and 1 positive EsoGuard case (different for questionnaire A/B/C)."
88895153|NCT05778851|No Intervention|B1 Control|6 Virtual patient cases with GERD and similar BE risk factors as the cases in intervention arm B2 but without an EsoGuard result and in a different order.
88895154|NCT05778851|Active Comparator|B2 Intervention|"6 Virtual patient cases with GERD and similar BE risk factors as the cases in the control arm B1 with an EsoGuard result.~5 EsoGuard negative cases (same cases for all intervention questionnaires) and 1 positive EsoGuard case (different for questionnaire A/B/C)."
88895155|NCT05778851|No Intervention|C1 Control|6 Virtual patient cases with GERD and similar BE risk factors as the cases in intervention arm C2 but without an EsoGuard result and in a different order.
88895156|NCT05778851|Active Comparator|C2 Intervention|"6 Virtual patient cases with GERD and similar BE risk factors as the cases in the control arm C1 with an EsoGuard result.~5 EsoGuard negative cases (same cases for all intervention questionnaires) and 1 positive EsoGuard case (different for questionnaire A/B/C)."
88895157|NCT05777824|No Intervention|low-risk and PCR|Observation
88895158|NCT05777824|Experimental|low-risk and MPR|immunotherapy maintenance
88895159|NCT05777824|Experimental|low-risk and IPR|postoperative radiotherapy (50 Gy) and immunotherapy maintenance
88895160|NCT05777824|Experimental|high-risk and PCR|postoperative radiotherapy (50 Gy) and immunotherapy maintenance
88895161|NCT05777824|Experimental|high-risk and MPR|postoperative radiotherapy (60 Gy) and immunotherapy maintenance
88895162|NCT05777824|Experimental|high-risk and IPR|postoperative concurrent chemoradiotherapy (60 Gy) and immunotherapy maintenance
88895163|NCT05767086|Experimental|Gonadotropin-releasing hormone (GnRH) antagonist|Cetrotide® (0.25 mg, MerckSerono Pharmaceuticals, Darmstadt, Germany)
89006183|NCT04642846|Experimental|one application of SDF|
89006184|NCT04642846|Experimental|two application of SDF one month apart|
89006185|NCT04642612||Treatment Arm|Patients ages 18-85 years old presenting with orthopedic shoulder surgery with indication to receive preoperative insertion of interscalene nerve block.
89006186|NCT04642768|Experimental|3-Hydroxybutyrate treatment|KetoneAid Ketone Ester 0,5g/kg (max. 50g) bolus
89006187|NCT04642768|Placebo Comparator|Placebo Treatment|Maltodextrin-base isocaloric placebo
89006188|NCT00241917|Experimental|Video|
89417447|NCT05616286|Experimental|Mindfulness-SOS|Mindfulness-SOS for Refugees is a brief internet-based mobile-supported intervention program which is a mobile health adaptation of MBTR-R, mindfulness- and compassion-based, trauma-sensitive, and socio-culturally adapted group intervention program designed for FDPs. Mindfulness-SOS for Refugees entails 8 brief sessions and 9 mindfulness meditation practice exercises - delivered via audio recordings using participants' smartphones. Mid-intervention, 3-weeks following randomization, all participants will be re-assessed. Participants initially randomized to MG-Mindfulness-SOS will be identified as either responders or non-responders. Responders will be assigned to continue MG-Mindfulness-SOS. Non-responders will be re-randomized to either Intensified-Guidance Mindfulness-SOS (IG-Mindfulness-SOS), an adaptive intervention sequence condition, or to continue with the MG-Mindfulness-SOS, a non-adaptive intervention sequence condition.
89006189|NCT00241917|No Intervention|Control|
89006190|NCT04642495||Human subjects aged 4 and above|Human volunteers aged 4 and above.
89006191|NCT04642456|Other|Control group|"Healthy subjects or volunteers~Intervention:~Balance Assesment Scale Trunk strength measurement with EMG MRI spine/pelvis EOS stereoradiographic full body exam"
89006192|NCT04642456|Other|ASD group|"Patient group with ASD~Intervention:~Balance Assesment Scale Trunk strength measurement with EMG MRI spine/pelvis 2 EOS stereoradiographic full body exam Balance Assesment Scale 2 Trunk strength measurement with EMG 2"
89006193|NCT04642339|Experimental|Vaccine Gam-COVID-Vac|Gam-COVID-Vac combined vector vaccine against the SARS-CoV-2 infection
89006194|NCT04642339|Placebo Comparator|Placebo|Placebo
89006195|NCT04642300|Active Comparator|Holmich Protocol|Treatment will be administered three times a week (on even or odd days). The duration of each session was about 90 min for module 1 (first two weeks) and 120 min for module 2 (from the third week). From the third week, the athletes were asked to perform exercises from module 1 every other day, between the treatment sessions
89006196|NCT04642300|Active Comparator|Myofascial Release Technique|Treatment wiil be given twice a week as individual treatment by the physiotherapist. The duration of treatment is about 30 min.
89006197|NCT00245895|Active Comparator|1|Aranesp
89006198|NCT04642144|Experimental|Yerba mate and carbohydrate|Consumption of yerba mate infusion and carbohydrate-based meal.
89006199|NCT04642144|Active Comparator|Yerba mate and fasting|Consumption of yerba mate infusion and stay in a fasting state.
89006200|NCT04642144|Active Comparator|Carbohydrate and water|Carbohydrate meal consumption and water intake.
89006201|NCT00218231|Experimental|1|300 mg/day bupropion-sr
89417448|NCT05616286|No Intervention|Waitlist-Control|Following the 7-week waitlist period and another assessment, participants randomized to waitlist-control will be assigned to Minimally-Guided Mindfulness-SOS (MG-Mindfulness-SOS) and then re-assessed following 3-weeks and, as described above, assigned to either continue in the MG-Mindfulness-SOS group or to move to the Intensified-Guidance Mindfulness-SOS (IG-Mindfulness-SOS).
89417449|NCT02757768|Experimental|Mirabegron|Participants received initial dose of 25 mg of mirabegron which was increased to 50 mg after 4 weeks. In addition to mirabegron participants received 0.4 mg of oral tamsulosin hydrochloride daily throughout the study.
89006202|NCT00218231|Placebo Comparator|2|0 mg bupropion-sr
89006203|NCT04641754|Experimental|WX-0593 Tablets|60 mg of WX-0593 tablets, once daily for 7 days, followed by 180 mg of WX-0593 tablets, once daily in a 21-days cycle.
89006204|NCT04641676|Other|Foundation medicine NGS in parallel with local NGS|The patient will have in parallel FMI NGS test and Local reimbursed NGS test.
89006205|NCT04641676|Other|Foundation Medicine NGS|The patient will have only FMI NGS test.
89006206|NCT04641676|Experimental|LB Foundation Medicine NGS test|The patient do not have enough biopsy material or have tumor not accessible for a biopsy will have a liquid biopsy Foundation Medicine test.
89006207|NCT00218270|Experimental|1|Reduction of tobacco use by substituting tobacco free snuff.
89006208|NCT00218270|Placebo Comparator|2|Reduction of tobacco use by using behavioral techniques.
89006209|NCT04641793|Experimental|SCI|
89006210|NCT04641793|Experimental|STROKE|
89006211|NCT04641793|Experimental|UNIMPAIRED|
89006212|NCT04641598|Experimental|Endometrial scratch|A speculum will be inserted into the vagina and the cervix cleansed with betadine (or alternative if allergy). The cervix will be grasped with a single tooth tenaculum and an endometrial biopsy pipelle inserted into the uterine cavity to the depth of the uterine fundus. Suction will be applied and the pipelle will be completely withdrawn in a single pass. All instruments will be removed from the vagina after hemostasis is ensured.
89006213|NCT04641598|Sham Comparator|Sham procedure|A speculum will be inserted into the vagina and the cervix cleansed with betadine (or alternative if allergy). The motions of grasping the cervix with a single tooth tenaculum and inserting the biopsy pipelle will be simulated, but not actually performed. All instruments will then be removed from the vagina.
89006214|NCT04641364|Placebo Comparator|Control: placebo|Subjects received 0.9% sodium chloride injection.
89006215|NCT04641364|Active Comparator|Control: Human Serum Albumin(HSA)|Subjects received Human Serum Albumin, 10 g for each day, three days for a cycle, and totally three cycles.
89006216|NCT04641364|Experimental|Experimental:recombinant human albumin|Subjects received recombinant Human Serum Albumin, 1.25g, 5g, 10g, 20g, 30 g for the single dose study. For the multiple dose study, subjects received recombinant Human Serum Albumin, 10 g for each day, three days for a cycle, and totally three cycles.
89006217|NCT04641481|Experimental|Study vaccine|BBV152B (6µg-Algel-IMDG)
89006218|NCT04641481|Placebo Comparator|Placebo|Phosphate buffered saline with Alum (without antigen)
89006219|NCT04720638|Experimental|Short fiber reinforced flowable resin composite restorations|(everX Flow, GC Europe) + (Gaenial posterior, GC Europe
89006220|NCT04720638|Active Comparator|Conventional resin composite restoration.|(Gaenial posterior, GC Europe)
89006221|NCT04641013||People with HIV over the age of 55 years|
89006222|NCT04641013||People without HIV over the age of 55 years|
89006223|NCT04641130|Experimental|Exposure to birch pollen|"Step 1: dose validation 16 subjects are exposed for 2 consecutive days (D1 + D2), to the same aerial concentration of Bet v1.~The main objective is achieved if the Abelson score is ≥ 5 on J1 or J2. If the main objective is achieved for the 60 ng/m3 concentration, 8 responder subjects will directly perform step 2.~If the main objective is not achieved for the 60 ng/m3 concentration, the subjects will be exposed between 7 to 10 days after exposure 1, to an allergen concentration of 120 ng/m3 (Exposure 2: D1 + D2).~Step 2: reproducibility Once the allergen concentration has been determined (step 1), 8 of the responder subjects from step 1 are exposed again to this same concentration, during 2 additional exposures (Exposure 3: D1 + D2 and Exposure 4: D1 + D2), at least 7 days apart.~A wash-out period of at least 7 days is observed between step 1 and 2. The duration of allergen exposure will be a maximum of 4 hours for all exposures."
89006224|NCT00246051|Other|Sleep Hygiene Education|
89006225|NCT00246051|Other|Expert-Led Sleep Disorders Screening and Treatment|
89006226|NCT00246051|Other|Online Sleep Disorders Screening|
89006227|NCT00559312|Experimental|FSC 250/50|fluticasone 250μg/salmeterol 50μg combination
89006228|NCT00559312|Placebo Comparator|Placebo|matched placebo inhaler
89006229|NCT00559351|Active Comparator|S|esophagectomy
89006230|NCT00559351|Experimental|CHTS|neoadjuvant chemotherapy followed by esophagectomy
89006231|NCT00559351|Experimental|CHRTS|neoadjuvant chemoradiotherapy followed by esophagectomy
89417450|NCT02757768|Placebo Comparator|Placebo|Participants received matching placebo in addition to oral tamsulosin hydrochloride daily throughout the study.
89417451|NCT05615662|Experimental|Meru Health Program|This group of participants will receive the app-based 12-Week Meru Health Program as their study intervention.
89417452|NCT05615662|Active Comparator|Treatment as Usual|"This group of participants will receive Treatment as Usual mental health services under the direction and referral of their Primary Care Physician."
88895164|NCT05767086|Experimental|Medroxyprogesterone acetate|Tarlusal® (5 mg, Deva Pharma, Istanbul, Turkey)
88895165|NCT05767086|Experimental|Dydrogesterone|Duphaston® (10mg, Abbott Laboratories, Chicago, Illinois, ABD)
88895166|NCT05766748|Experimental|Treatment Group|"Azeliragon will be orally administered to 3 groups of 6 subjects, with escalation of dosing occurring with each subsequent group.~Dose Level 1 consists of a loading dose of 15mg once daily for 6 days, followed by a continuous dose of 5mg once daily for the remainder of the study.~Dose Level 2 consists of a loading dose of 15mg twice daily for 6 days, followed by a continuous dose of 10mg once daily for the remainder of the study.~Dose Level 3 consists of a loading dose of 30mg twice daily for 6 days, followed by a continuous dose of 20mg once daily for the remainder of the study.~Escalation will continue until stopping rules are met or the highest defined dose level is reached. The trial will be closed to accrual if the first dose level is deemed intolerable."
88895167|NCT05765890||Hepatologists|Recruited via email through online panel companies with which respondents have provided permission to be contacted for research purposes
88895168|NCT05765890||Metabolically-Focused HCPs|Recruited via email through online panel companies with which respondents have provided permission to be contacted for research purposes
88895169|NCT05762250|Experimental|Auricular Acupuncture|"Intervention group: Ear acupressure is performed on both ears with permanent pellets according to the NADA (National Acupuncture Detoxification Association) protocol over a period of 8 weeks (presentation at the study center 1x/week, application of the acupressure patches there; these remain on both ears for 5 days and should be massaged 3x/day by the patients themselves according to the instructions provided).~In addition, patients receive a 30-minute psychoeducational talk at the first treatment appointment to promote their own health competence."
88895170|NCT05762250|No Intervention|Waitlist|Control group: standard treatment / waiting list Patients in the control group will also receive a one-time 30-minute psychoeducational interview at baseline.
88895171|NCT05759286|Experimental|aromatherapy group|Children in this group will receive IANB injection with a nasal mask (similar to a nitrous oxide mask), the way the mask work is by putting on its circular hole a 3d printed perforated box containing cotton balls loaded with lavender-neroli oils blend
88895172|NCT05759286|Experimental|music group|children in this group will receive IANB injections by listening to music as background from a recorder.
88895173|NCT05759286|Experimental|combination group music and aromatherapy|children in this group will receive aromatherapy using the nasal mask with an aromatherapy box as well as music for 5 minutes and through the injection
88895174|NCT05759286|Placebo Comparator|control group|children in this group will receive IANB injections with behavioral management techniques l
88895175|NCT05750745|Experimental|Test Dentifrice|Participants will be instructed to brush the two test teeth first, then the whole mouth (all teeth) for 1-timed minute, twice daily (morning and evening) with Sensodyne Sensitivity & Gum. After brushing, participants will be instructed to rinse once with 10 milliliters (mL) of water using the measuring cup provided.
89417453|NCT05728606|Experimental|Robot-assisted D2 distal gastrectomy|Robot-assisted D2 distal gastrectomy after 3-Cycle SOX neoadjuvant chemotherapy
89193452|NCT04903561|Experimental|Intervention|In the experimental arms, the woman will be asked to collect a vaginal sample with the Evalyn® Brush or a urine sample with the Colli-PeeTM. Women shall receive this self-sampling device directly from the GP or shall pick it up at a close by pharmacist with a prescription of the GP. In four GP practices (1, 2, 5, 6) the patient has to collect the SS preferentially in the GP practice (at home if the GP practice is not well equipped) whereas in the other four GP practices (3, 4, 7, 8), the patient has to collect the SS at home and send it to the laboratory by using a prepaid envelope.
89193453|NCT04903561|No Intervention|control|Women in the control group will receive an oral recommendation given by the GP with a reminder of the current screening policy to have a cervical sample taken by a physician chosen by the woman. This clinician-taken cervical sample will be sent to a laboratory for processing with the usual screening test. Today the usual screening test still is cytology, but this will change in the future (date to be defined) to an HPV test.
89193454|NCT04900155|Active Comparator|Atorvastatin 80 mg|Initially, hypolipidemic treatment with atorvastatin at a dose of 80 mg / day is prescribed from the first 24-96 hours of myocardial infarction in addition to standard therapy for the disease.
89417454|NCT05225389|Experimental|CT1812|Investigational Drug
89417455|NCT05552833|Experimental|COPD patients|This arm will consist of only COPD patients.
89417456|NCT05552833|Experimental|Healthy controls|This arm will consist of age and BMI matched healthy controls.
89193455|NCT04900155|Active Comparator|Atorvastatin-Ezetimibe|In the absence of reaching the target level of LDL-C ≤1.4 mmol / L and ≥50% of the initial level after 4-6 weeks from the onset of myocardial infarction, patients additionally receive ezetimibe at a dose of 10 mg 1 time / day.
89193456|NCT04897893|Experimental|Experimental Treatment|All subjects enrolled in the study will receive an identical dose of 2g/day (4 capsules of MAG-EPA) which will be taken by the subject at home. The duration of treatment should not be prolonged in the event of missed doses, that is, treatment should end on the 84th day as planned. A deviation of ± 3 days is acceptable, which means that treatment can be stopped from day 81 to day 87 of subject's participation.
89417457|NCT03066076|Active Comparator|Thyroidectomy|Total thyroidectomy
89417458|NCT03066076|Active Comparator|Antithyroid drug|Thiamazol, Propylthiouracil
89417459|NCT05225077|Active Comparator|Dapagliflozin 10mg group|Dapagliflozin 10 mg once a day for 1 month after the procedure.
89417460|NCT05225077|No Intervention|Non-intervention group|No intervention.
89417461|NCT05577286|Other|control group|15 Children with type 1 Diabetes mellitus in this group will receive the regular medical treatment without change of their daily activity routine
89417462|NCT05577286|Experimental|plyometric group|15 Children with type 1 Diabetes mellitus in this group will receive the regular medical treatment as in control group in addition to a designed plyometric training program for 30 minutes, three times a week for two successive months.
88895176|NCT05750745|Active Comparator|Negative Control|Participants will be instructed to brush the whole mouth (all teeth) for 1-timed minute, twice daily (morning and evening) with Crest Cavity Protection Fresh Lime. After brushing, participants will be instructed to rinse once with 10 mL of water using the measuring cup provided.
88895177|NCT05750745|Active Comparator|Positive Control|Participants will be instructed to brush the whole mouth (all teeth) for 1-timed minute, twice daily (morning and evening) with Sensodyne Repair and Protect. After brushing, participants will be instructed to rinse once with 10 mL of water using the measuring cup provided.
88895178|NCT05749887|Other|salvage sugery|Salvage surgery for patients diagnosed locally advanced cervical cancr with residual tumor after standard chemoradiation (Pelvic EBRT/Extended-field EBRT + concurrent platinum-containing chemotherapy+ brachytherapy)
88895179|NCT05746546|Experimental|Transdermal Nicotine Patch|Participants will wear nicotine transdermal patches daily for 12-15 weeks. Participants will apply a study patch each morning and remove at bedtime. Active dose will titrate up from 3.5mg to 7mg, and then can optionally be further titrated to a maximum dose of 14mg. After week12, the dose will be slowly tapered over 2-3 weeks.
88895180|NCT05746273|Experimental|Transdermal Nicotine Patch|Participants will be randomized to apply nicotine transdermal patches during waking hours. Active dose will titrate up from 3.5mg to 7mg in the first 3 weeks. Doses can be optionally titrated to a maximum of 14mg over 12 weeks, based on tolerability and perceived benefit. After 12 weeks, the patch dose will be tapered over 2-3 weeks.
88895181|NCT05746273|Placebo Comparator|Transdermal Placebo Patch|Participants will be randomized to apply placebo transdermal patches during waking hours. Placebo patch titration will mirror the active arm, increasing the dose will titrate up from 3.5mg to 7mg in the first 3 weeks. Doses can be optionally titrated to a maximum of 14mg over 12 weeks, based on tolerability and perceived benefit. After 12 weeks, the patch dose will be tapered over 2-3 weeks.
88895182|NCT05744700|Active Comparator|Inulinase|Total 2,000 INU inulinase per day for 28 days
88895183|NCT05744700|Placebo Comparator|Placebo|Maltodextrin for 28 days
88895184|NCT05742295|Experimental|Intervention group|vitamin K is used as a prophylactic dose to prevent cefoperazone/sulbactam coagulopathy.
88895185|NCT05742295|No Intervention|Control group|
88895186|NCT05741216|Experimental|OTF Test 1|One application of ocular lubricant to each eye at night for 5 consecutive nights
88895187|NCT05741216|Experimental|OTF Test 2|One application of ocular lubricant to each eye at night for 5 consecutive nights
88895188|NCT05741216|Experimental|OTF Test 3|One application of ocular lubricant to each eye at night for 5 consecutive nights
88895189|NCT05741216|Active Comparator|Ocular lubricant|One drop of ocular lubricant applied to each eye at night for 5 consecutive nights
88895190|NCT05740956|Experimental|HS-10502|HS-10502 Tablets，PO，QD
88895191|NCT05736939||Men with long COVID-19 syndrome|Patients were male adults (>18 years), with persistent symptoms more than 3 months since the acute phase of the COVID-19.
88895192|NCT05736939||Women with long COVID-19 syndrome|Patients were women adults (>18 years), with persistent symptoms more than 3 months since the acute phase of the COVID-19.
88895193|NCT05733364|Experimental|Investigational Product (Capsules with B vitamins & taurine)|IP will be administered orally once daily in capsule form, ideally between conventional mealtimes (i.e., breakfast, lunch, supper).
88895194|NCT05733364|Placebo Comparator|Microcrystalline cellulose placebo|Placebo will be administered orally once daily in identical capsule form as the IP, ideally between conventional mealtimes (i.e., breakfast, lunch, supper).
88895195|NCT05728372|Experimental|Treatment (64CDP PET)|Patients receive standard of care pembrolizumab IV at baseline. Patients then receive 64CDP IV days 1 and 29 on study. Patients undergo PET scan on days 2 and 30 on study. Patients also undergo standard of care SBRT days 8-18.
88895196|NCT05727007|Experimental|MRI in colon cancer|All prospectively included patients with colon cancer will be preoperatively submitted to MRI for staging. The evaluation of the diagnostic accuracy will be based on the cross-examination with the CT scan and the pathology results
88895197|NCT05717907|No Intervention|Control group|conventional nasotracheal intubation procedure
88895198|NCT05717907|Experimental|Guided group|use suction catheter guided endotracheal tube through the nasal passage
88895199|NCT05717179|No Intervention|Clinical decision strategy|All patients receive a TNF-alpha blocker while continuing background csDMARD(s) therapy. If a CDAI ≤10 is not achieved after 12 weeks, patients are switched to a bDMARD or tsDMARD. The decision on which b/tsDMARD to use at week 12 is at the discretion of the investigator.
88895200|NCT05717179|Experimental|Clinical plus ultrasound-based decision strategy|All patients in this group will be evaluated by ultrasound at 44 joints. In case of clinically-verified plus ultrasound verified inflammation, patients will receive a TNF-alpha blocker while continuing background csDMARD(s) therapy. If a CDAI ≤10 is not achieved after 12 weeks, patients are again evaluated by ultrasound at 44 joints. In case clinically-verified plus ultrasound-verified inflammation is present, patients are switched to a bDMARD or tsDMARD. The decision on which b/tsDMARD to use is at the discretion of the investigator. In case clinically-verified plus ultrasound-verified inflammation is absent, patients receive step-up pain therapy while background csDMARD(s) will be continued.
88895201|NCT05714020|Active Comparator|Real rTMS|The active rTMS protocol is a 15-minute 10Hz stimulation, 10 seconds on, 20 seconds off, at 90% RMT, for a total of 3000 pulses using a real TMS coil. The target is the primary motor cortex.
89006232|NCT00559390||Pre-PCOS|First degree relatives, either sisters or daughters, of women with Polycystic Ovary Syndrome.
89417463|NCT04942093|Experimental|With diet|A low-calorie, high-protein diet will be prescribed to the patient for a period of 4 weeks. The diet will be done the 4 weeks before the bariatric surgery
89006233|NCT00559390||Controls|Sisters and daughters of women who do not have PCOS
89417464|NCT04942093|Other|Without diet|A low-calorie, high-protein diet will not be prescribed to the patient for a period of 4 weeks.
89417465|NCT03067558||Accuracy evaulation|Three age groups (young infants 0 to <2 months, children 2 to <12 months and 12 to 59 months) will participate in the accuracy evaluation. Participants will be enrolled in a ratio 3:1 fast to normal breathers, by age group. Respiratory rate evaluations will be done using the ARIDA test device and the MK2 ARI timer (standard practice).
89417466|NCT03067558||Consistency evaluation|Two age groups (children 2 to <12 months and 12 to 59 months) will participate in the consistency evaluation. Participants will be enrolled in a ratio 3:1 fast to normal breathers, by age group. Respiratory rate evaluations will be done using the ARIDA test device and the MK2 ARI timer (standard practice).
89417467|NCT03067558||Respiratory rate fluctuation evaulation|Two age groups (children 2 to <12 months and 12 to 59 months) will participate in the respiratory rate fluctuation evaluation. All participants will be normal breathers.Respiratory rate evaluations will be done using the MK2 ARI timer (standard practice). The ARIDA test device will be strapped to the child during the manual RR count with MK2 ARI timer (standard practice).
89417468|NCT04909567|Experimental|Intervention arm|"Optimisation:~Diet, organised exercise, psychosocial support"
89006234|NCT00559429|Active Comparator|C1|
89006235|NCT00559429|Active Comparator|C2|
89417469|NCT04909567|No Intervention|Control arm|Current standard preparation before surgery
89006236|NCT00559429|Active Comparator|C3|
89006237|NCT00559429|Active Comparator|C4|
89193457|NCT04896164|Experimental|Investigational arm|Patients in the investigational arm will receive curcumin lozenges (4 gm BD containing 400 mg curcumin BD) as prophylaxis from two days prior to receiving high dose chemotherapy .
89193458|NCT04896164|Placebo Comparator|Control arm|patients in the control arm will receive matching placebo lozenges from two days prior to receiving high dose chemotherapy
89417470|NCT03067792|Active Comparator|FOLFIRI|2nd palliative chemotherapy with FOLFIRI regimen,In FOLFIRI group, patients received irinotecan 180 mg/m2 and 5- fluorouracil 400mg/m2 intravenously bolus injection on days 1 and leucovorin 200mg/m2 for 2 hours and 5-fluorouracil 600mg/m2 for 22 hours intravenously infusion on day 2 of a 14-day cycle. Response evaluation would be done after 3 cycle of chemotherapy in DP group
89417471|NCT03067792|Active Comparator|DP|2nd palliative chemotherapy with Docetaxel/cisplatin regimen, In DP group, patients received docetaxel 75 mg/m2 and cisplatin 75mg/m2 intravenously on days 1 of a 21-day cycle. Response evaluation would be done after 2 cycle of chemotherapy in DP group
89417472|NCT05224999|Experimental|nivolumab|
89417473|NCT03066154|Experimental|N15DOP|Chemoradiation with ModraDoc/r and radiotherapy of the prostate in dose escalation design, followed by maintenance treatment.
88895202|NCT05714020|Sham Comparator|Sham rTMS|The sham rTMS protocol is performed by a sham coil. The sham rTMS protocol is a 15-minute 10Hz stimulation, 10 seconds on, 20 seconds off, at 90% RMT, for a total of 3000 pulses. The target is the primary motor cortex.
88895203|NCT05700045|Experimental|dexmedetomidine + ropivacaine|each side dexmedetomidine 0.5ug/kg+0.25% ropivacaine 20ml TAP block
88895204|NCT05700045|No Intervention|ropivacaine|each side 0.25% ropivacaine 20ml TAP block
88895205|NCT05699941|Experimental|treatment arm|"Ectoin® Containing Inhalation Solution (EIL07) (Class-IIa MDD legacy medical device).~Taken twice daily over the period of 3 weeks (treatment) Inhalation of the content of EIL07 single dose (2.5 mL) by using a mesh nebulizer device."
88895206|NCT05696834||sclerotherapy and bone marrow|Sclerotherapy With Adjuvant Bone Marrow Injection In Management of Aneurysmal Bone Cyst
88895207|NCT05695261|Experimental|antibiotic / MTT|"Study subjects randomized to the experimental arm will receive oral antibiotics for 7 days as a way to modulate the composition of the gastrointestinal microbiota.~Upon completion of oral antibiotics, subjects randomized to the experimental arm will be administeredf MTT under medical supervision. Subjects will be monitored and then discharged. Subjects will be instructed to take MTT capsules daily for 27 days."
88895208|NCT05695261|Active Comparator|placebo / placebo|"Study subjects randomized to the placebo arm will receive oral placebo capsules instead of oral antibiotics, for 7 days, at the same frequency and capsule amount per dose.~Upon completion of 7 days of placebo (matching the antibiotics given in the experimental arm), subjects randomized to the placebo arm will be administered capsules of placebo (matching the MTT capsules given in the experimental arm) under medical supervision. Subjects will be monitored and then discharged. Subjects will be instructed to take placebo capsules daily for 27 days."
88895209|NCT05695183|Experimental|Emergency Department Nurses|Registered nurses will use the IV SafeLock Device on patients during care in the emergency department.
88895210|NCT05684692|Experimental|Sub-study A: Siltuximab|"The treatment period includes a double-blind treatment period (days 1-84) and an open-label treatment period (days 85-168).~All participants will receive siltuximab during this drug sub-study. Twenty (20) participants will be randomized to receive either Siltuximab or matching placebo during the double-blind treatment period. All participants will receive siltuximab during the open-label treatment period. Participants will complete study procedures as outlined:~Double-Blind Treatment period: Administration of Siltuximab versus matching placebo in pre-determined dose once every 21 days (for 4 cycles).~Open-Label Treatment period: Administration of Siltuximab in pre-determined dose once every 21 days (for 4 cycles)."
89006238|NCT04641403|No Intervention|Group 1 (Standard IV analgesia group (SA), n=40):|In this group, the block will be administered with normal saline (NS) and all port sites will be infiltrated with NS.
89006239|NCT04641403|Active Comparator|Group 2 (Local analgesia group (LA), n=40):|In this group, the block wiil be administered with NS and local anesthetic will be administered to the port sites.
89006240|NCT04641403|Experimental|Group 3 (two qudrant-Laparoscopic-assisted transversus abdominis plane block (LTAP) group, n=40)|After the infiltration of all ports sites with NS, right sided two-quadrant block will be performed using bupivacaine.
89193459|NCT04894825|Experimental|Dose Escalation Cohort|"Monotherapy: Five dose levels of M108 will be tested according to an accelerated titration method followed by a conventional 3 + 3 study design.~Combined with chemotherapy: Three dose levels of M108 will be tested by a conventional 3 + 3 study design.~The dose-limiting toxicity (DLT) will be assessed from the first administration to the end of the first cycle (21 days)."
89193460|NCT04894825|Experimental|Dose Expansion Cohort|Once the effective dose has been determined, 1~2 expansion cohorts will be opened to evaluate the efficacy and safety of the selected dose.
89193461|NCT04893226|No Intervention|Control|Participants in this group will have baseline and post-study data collected, including food timing, activity/sleep data, and metabolic parameters (OGTT, body composition, anthropometric measurements, lipid panel, inflammatory markers). There will be no intervention.
89193462|NCT04893226|Experimental|Time-Restricted Feeding (TRF) Group|Participants in this group will have baseline and post-study data collected, including food timing, activity/sleep data, and metabolic parameters (OGTT, body composition, anthropometric measurements, lipid panel, inflammatory markers). Subjects in this group will be educated about the health benefits of time-restricted feeding (TRF). Then each subject in the TRF group will self-select a 10-h window during which she will consume all daily calories for 16 weeks.
89193463|NCT04890730||Southern Medical University of Nanfang Hospital|Southern Medical University of Nanfang Hospital
89193464|NCT04890730||Tongji Hospital Affiliated to Tongji University|Tongji Hospital Affiliated to Tongji University
89193465|NCT04890730||The Second Affiliated Hospital Of Nanchang University|The Second Affiliated Hospital Of Nanchang University
89193466|NCT04885036|Active Comparator|Treatment As Usual|This group will receive treatment as usual within the family unit
89193467|NCT04885036|Experimental|EFST intervention|This group will receive an EFST stand alone treatment consisting of a two days EFST course and 6 individual parental guidance sessions
89417474|NCT05224687||Daptomycin are dosed solely by pharmacists|Daptomycin at two institutions are dosed solely by pharmacists
89417475|NCT05224687||daptomycin protocol is not used and dose by the provider|daptomycin PTD is optional or not utilized at the other institutions.
89006241|NCT04641403|Experimental|roup 4 (Four qudrant-Laparoscopic-assisted transversus abdominis plane block (LTAP) group, n=40)|After the infiltration of all ports sites with NS, bilateral four-quadrant block will be performed using bupivacaine.
89006242|NCT00218582|Experimental|1|Dual focus 12 step mutual aid groups for persons with co-occurring disorders (psychiatric and substance use disorders), provided within the context of standard psychiatric day treatment
89006243|NCT00218582|Active Comparator|2|Standard psychiatric day treatment
89006244|NCT04640740|Experimental|anterolateral approach (ALA)|anterolateral surgical approach of total hip arthroplasty
89006245|NCT04640740|Experimental|posterior approach (PA)|posterior surgical approach of total hip arthroplasty.
89193468|NCT04882514|Experimental|Vaccine p*17-K4S2 (50 µg/mL) Vaccine|To evaluate the safety and immunogenicity of p*17-CRM197 (25µg) + K4S2-CRM197 (6.25µg): TOTAL 31.25 µg
89193469|NCT04882514|Experimental|J8-K4S2 (100 µg/mL ) Vaccine|To evaluate the safety and immunogenicity J8-CRM197 (50µg) + K4S2-CRM197 (6.25µg): TOTAL 56.25 µg
89193470|NCT04882514|Sham Comparator|Rabavert Vaccine|Comparator vaccine (RABAVERT)
89193471|NCT04881825|Experimental|once-weekly glepaglutide|All participants will receive 10 mg of glepaglutide as once-weekly injections under the skin (subcutaneous, s.c.)
89417476|NCT02753946|Experimental|ZTI-01|6 g ZTI-01 (IV fosfomycin) intravenously administered every 8 hours (18g total daily dose for 7-14 calendar days)
89006246|NCT00218660|Experimental|1|Nal + BRENDA
89006247|NCT00218660|Placebo Comparator|2|Placebo + BRENDA
89417477|NCT02753946|Active Comparator|piperacillin tazobactam|4.5 g piperacillin/tazobactam (4 g piperacillin/0.5 g tazobactam) intravenously administered every 8 hours (13.5g total daily dose for 7-14 calendar days)
89006248|NCT00218660|Experimental|3|Nal + CBT
89006249|NCT00218660|Placebo Comparator|4|Placebo + CBT
89006250|NCT04640389||Urban|Urban adolescents living in Moshi District, Tanzania, who are between 10-14 years of age.
89006251|NCT04640389||Rural|Rural adolescents living in Kilosa District, Tanzania, who are between 10-14 years of age.
89006252|NCT04640467||Pregnant women|Women with uncomplicated singleton pregnancy who are planning a vaginal delivery, gestational age from 36 ± 0/7 weeks until onset of active labor (cervical dilatation ≤ 4cm) and cephalic presentation
89006253|NCT04640233|Experimental|Primary Group|Gam-COVID-Vac combined vector vaccine, 0.5 ml/dose + 0.5 ml/dose prime-boost immunization on day 1 (component I rAd26-S) and on day 21 (component II rAd5-S)
89006254|NCT04640233|Placebo Comparator|Control Group|Placebo, 0.5 ml/dose + 0.5 ml/dose immunization on days 1 and 21
89193472|NCT04867616|Experimental|Dose level 1 bepranemab|Participants randomized to this arm will receive pre-specified doses (Dose level 1) of bepranemab during the Double-blind Treatment Period and the Open-label Extension Period.
89193473|NCT04867616|Experimental|Dose level 2 bepranemab|Participants randomized to this arm will receive pre-specified doses (Dose level 2) of bepranemab during the Double-blind Treatment Period and the Open-label Extension Period.
89193474|NCT04867616|Placebo Comparator|Placebo Arm|Participants randomized to this arm will receive Placebo to maintain the blinding during the Double-blind Treatment Period and will re-randomized during the Open-label Extension Period to receive pre-specified doses of bepranemab.
89193475|NCT04852068|Experimental|Investigational Vaccine - 5-dose program|Freeze-dried human rabies vaccine (Vero cells), 0.5ml after reconstitution, with a titer of not less than 2.5IU, Anhui Zhifeilongkoma Biopharmaceutical Co., Ltd.
89193476|NCT04852068|Experimental|Investigational Vaccine - 4-dose program|Freeze-dried human rabies vaccine (Vero cells), 0.5ml after reconstitution, with a titer of not less than 2.5IU, Anhui Zhifeilongkoma Biopharmaceutical Co., Ltd.
89193477|NCT04852068|Active Comparator|Control vaccine - 5-dose program|Freeze-dried human rabies vaccine (Vero cells), 0.5ml after reconstitution, titer not less than 2.5IU, Liaoning Chengda Biological Co., Ltd.
89193478|NCT04852068|Active Comparator|Control vaccine - 4-dose program|Freeze-dried human rabies vaccine (Vero cells), 0.5ml after reconstitution, titer not less than 2.5IU, Liaoning Chengda Biological Co., Ltd.
89193479|NCT04840927|Experimental|Cohort 1: E7386 40 mg|"Participants will be randomized to one of the 3 treatment sequences:~Treatment sequence 1: Participants will receive Regimen A on Day 1 of treatment period 1 then Regimen B on Day 1 of treatment period 2 then Regimen C on Day 1 of treatment period 3 and an optional Regimen D on Day 1 of an optional treatment period 4.~Treatment sequence 2: Participants will receive Regimen B on Day 1 of treatment period 1 then Regimen C on Day 1 of treatment period 2 then Regimen A on Day 1 of treatment period 3 and an optional Regimen D on Day 1 of an optional treatment period 4.~Treatment sequence 3: Participants will receive Regimen C on Day 1 of treatment period 1 then Regimen A on Day 1 of treatment period 2 then Regimen B on Day 1 of treatment period 3 and an optional Regimen D on Day 1 of an optional treatment period 4.~A maximum wash out period of 10 days will be maintained between treatment periods 1, 2 and 3."
89536776|NCT05333315|Experimental|Investigation Product 3 (IP3) in powder form and capsules form|POWDER: Plantain fibre 10 g; Inulin, 2 g; Apple fibre, 1,5 g; Root of pellitory, 500 mg; Apple pectin, 450 mg CAPSULE: Pumpkin seed extract, 300 mg; Garlic extract odourless, 300 mg; Artichoke leaf extract, 150 mg; Cumin seed extract, 150 mg; Peppermint leaf extract, 150 mg; Anise seed extract, 150 mg; Curcuma rhizome extract, 150 mg; Vitamin C, 42 mg; Zinc (in gluconate),10 mg; Vitamin B6, 1,5 mg
89536777|NCT05333315|Experimental|Investigation Product 4 (IP4) in liquid form|LIQUID: Arabinogalactan, 700 mg; Inulin, 700 mg; Beta-glucans, 30 mg
88895211|NCT05684692|Experimental|Sub-study B: Erenumab-Aooe|"The treatment period includes a single-blind treatment period (days 1-84) and an open-label treatment period (days 85-168).~All participants will receive erenumab-aooe during this drug sub-study. Twenty (20) participants will receive a randomization assignment to receive either Erenumab-Aooe or matching placebo during the single-blind treatment period. All participants will receive erenumab-aooe during the open-label treatment period. Participants will complete study procedures as outlined:~Single-Blind treatment period (days 1 - 84): Administration of Erenumab-Aooe versus matching placebo in pre-determined dose once every 28 days (for 3 cycles).~Open-Label Treatment period (days 85-168): Administration of Erenumab-Aooe in pre-determined dose once every 28 days (for 3 cycles)."
88895212|NCT05671146|Experimental|Graded weight-bearing exercise|participants will perform exercises using an anti-gravity treadmill
88895213|NCT05671146|Active Comparator|Closed kinetic chain exercise|Exercises will be achieved in a weight-bearing position, with or without support, besides other exercises to improve knee flexors and extensors strength.
88895214|NCT05671146|Sham Comparator|open kinetic chain exercise|Exercises including stretching and strengthening exercises for knee flexors and extensors
88895215|NCT05669027|Experimental|Experimental Condition|Mobile Neurofeedback intervention arm
88895216|NCT05669027|Placebo Comparator|Control Condition|Sham-control arm
88895217|NCT05658146|Experimental|Sequence 1|
88895218|NCT05658146|Experimental|Sequence 2|
88895219|NCT05658146|Experimental|Sequence 3|
88895220|NCT05658146|Experimental|Sequence 4|
88895221|NCT05658146|Experimental|Sequence 5|
88895222|NCT05658146|Experimental|Sequence 6|
88895223|NCT05646602|Experimental|Collagenase Clostridium Histolyticum with LiSWT for PD Group|Subjects being treated for Peyronie's disease (PD) will have Collagenase Clostridium Histolyticum (CCH) intralesional injection with focused low-intensity shockwave therapy (LiSWT).
88895224|NCT05646602|Active Comparator|Collagenase Clostridium Histolyticum for PD Group|Subjects being treated for Peyronie's disease (PD) will have Collagenase Clostridium Histolyticum (CCH) intralesional injection
88895225|NCT05646602|Active Comparator|Radial Shockwave Therapy for ED Group|Subjects being treated for erectile dysfunction (ED) will have radial shockwave therapy.
88895226|NCT05646602|Experimental|Linear Shockwave Therapy for ED Group|Subjects being treated for erectile dysfunction (ED) will have linear shockwave therapy
88895227|NCT05646199|Active Comparator|Metformin|Participants in this group will be given metformin
88895228|NCT05646199|Active Comparator|Semaglutide|Participants in this group with receive Semaglutide
88895229|NCT05643690||Clinical Validation Group|Patients with suspected bladder cancer (including hematuria, inflammatory bladder, suspicious ultrasound results)
88895230|NCT05641649|Experimental|Test formulation group of volunteers|"Sixteen healthy subjects aged between 18 and 60 years who satisfy the inclusion/ exclusion criteria will be enrolled in the study. Volunteers will be assigned to take particular formulation by a method of randomization on the first study day.~Half of the volunteers falling in the test formulation arm will be given a tablet of test formulation with 200 ml of water in an empty stomach on the first study day. In the second study day, these volunteers will be exchanging the formulations."
88895231|NCT05641649|Experimental|Innovator formulation group of volunteers|"Sixteen healthy subjects aged between 18 and 60 years who satisfy the inclusion/ exclusion criteria will be enrolled. Volunteers will be assigned to take particular formulation by a method of randomization on the first study day.~Half of the volunteers falling in the innovator formulation arm will be given a tablet of innovator formulation with 200 ml of water in an empty stomach on the first study day. In the second study day, these volunteers will be exchanging the formulations."
88895232|NCT05640115|Experimental|Group A (Ureteral Stenting)|Group A: Participants in this group will receive a standard of care ureteral stenting performed by a urologist.
88895233|NCT05640115|Experimental|Group B (Percutaneous Nephrostomy)|Participants in this group will receive a standard of care percutaneous nephrostomy tube placement performed by an interventional radiologist.
88895234|NCT05639972|Experimental|Conditioning, E7 TCR-T cells, and aldesleukin|Participants will receive a conditioning regimen consisting of cyclophosphamide and fludarabine followed by E7 TCR-T cells cells IV x 1 dose, followed by aldesleukin every 8 hours for up to 3 doses.
89417478|NCT04959487|No Intervention|Standard of care|Control participants will receive standard of care as offered by clinical partners to all T2DM patients, including referral to nutritional counseling, T2DM support groups, and participation in local diabetes self-management programs. Control participants are also often provided referral information for locally available food support services in the region that provide diabetes-appropriate foods. At the end of follow up, the control arm will receive similar services from POH to what the intervention arm received during the intervention, regardless POH eligibility criteria (6 months of DM-tailored food support to meet 67% of their daily requirements, video recording of the 4 CHEFS-DM education classes, and access to a POH dietitian at their request).
88895235|NCT05638776|Experimental|REGEND001 Autologous Therapy Product|Transplantation of REGEND001 Autologous Therapy Product
88895236|NCT05638776|Placebo Comparator|Placebo|Transplantation of Placebo
89535981|NCT03215251|Experimental|EXPERIMENTAL GROUP|Intervention bundle consisted of sterile cold wet oral swab wipes and sterile ice cold water sprays administered in two sessions of 15 minutes each. First session was given in 15 minutes, patients received cold wet oral swab wipes in oral cavity 2 to 3 times and mouth spray with 5 to 6 sprays. A maximum of 9 wipes and 18 sprays of sterile water. After administration of intervention bundle, Posttest 1 was taken after 15 minutes observation with the same tools. Then researcher waited for 15 minutes after post test1 and session two was administered in 15 minutes with a maximum of 9 wipes and 18 sprays of sterile water. Post test 2 was taken after 15 minutes of session two.
88895237|NCT05632523||adult patients with renal transplant|Conversion from anticalcineurin to belatacept
88895238|NCT05632211|Experimental|AVT05 50mg s.c.|Single dose Pre-filled syringe to be injected subcutaneously into thigh or abdomen
88895239|NCT05632211|Active Comparator|EU Simponi 50mg s.c.|Single dose Pre-filled syringe to be injected subcutaneously into thigh or abdomen
88895240|NCT05632211|Active Comparator|US Simponi 50mg s.c.|Single dose Pre-filled syringe to be injected subcutaneously into thigh or abdomen
88895241|NCT05629091|Experimental|FibDex|FibDex® is a CE-marked NFC wound dressing intended to come into contact with injured skin and specifically split-thickness skin graft wounds, which have breached the dermis.
88895242|NCT05629091|Active Comparator|Epicite hydro|Epicitehydro is composed of biotechnology derived cellulose and is indicated for treatment of superficial and deep partial thermal and chemical burn wounds (1st and 2nd degree), scalds, skin graft donor sites, abrasions and lacerations
88895243|NCT05629091|Active Comparator|Epiprotect|Epiprotect is composed of biosynthetic cellulose. It contains a minimum of 95% isotonic saline solution. Epiprotect is intended for treatment of partial thickness wounds. It can also be used as a temporary coverage for full thickness wounds prior to transplantation or other surgical intervention.
88895244|NCT05625438|Experimental|Bedside Telerehabilitation|"Participants will be assigned 45-minute therapy training exercises each day for 5 days per week.~Participants will use the HandyMotion device to interact with the telerehabilitation program displayed on the TV set in the patient room."
88895245|NCT05623449|Experimental|combination of face-to-face and teleconsultation hypnosis consultation|The first and the last hypnosis sessions in face-to-face, and the other 3 intermediate sessions being conducted by teleconsultation.
88895246|NCT05623449|Active Comparator|face-to-face hypnosis consultation|5 face-to-face hypnosis sessions
89535982|NCT03215251|No Intervention|CONTROL GROUP|No Intervention administered. Thirst and Dry mouth scores were assessed only. Usual care was continued.
89535983|NCT03315533|Experimental|Duloxetine 30 milligrams (mg)|
89535984|NCT03315533|Placebo Comparator|Placebo|
89535985|NCT03315533|Experimental|Duloxetine 60 milligrams (mg)|
88895255|NCT05606757|Experimental|Cohort 1, BOTOX Dose A|Participants will receive BOTOX Dose A
89417479|NCT04959487|Experimental|Food support and nutrition education|The intervention entails two components: 1) food support that consists of weekly medically tailored meals and healthy groceries that on average covers 75% of daily energy requirements from baseline to six months and 2) diabetes-tailored nutritional education that consists of two individual counseling sessions with a Registered dietitian and four group education sessions.
88895256|NCT05606757|Experimental|Cohort 1, BOTOX Dose B|Participants will receive BOTOX Dose B.
88895257|NCT05606757|Placebo Comparator|Cohort 1, Placebo|Participants will receive placebo for BOTOX.
88895258|NCT05606757|Experimental|Cohort 2, BOTOX Dose A|Participants will receive BOTOX Dose A
88895259|NCT05606757|Experimental|Cohort 2, BOTOX Dose B|Participants will receive BOTOX Dose B
88895260|NCT05606757|Experimental|Cohort 2, BOTOX Dose C|Participants will receive BOTOX Dose C
88895261|NCT05606757|Placebo Comparator|Cohort 2, Placebo|Participants will receive placebo for BOTOX
88895262|NCT05606757|Experimental|Cohort 3, BOTOX Dose A|Participants will receive BOTOX Dose A
88895263|NCT05606757|Experimental|Cohort 3, BOTOX Dose B|Participants will receive BOTOX Dose B.
88895264|NCT05606757|Experimental|Cohort 3, BOTOX Dose C|Participants will receive BOTOX Dose C.
88895265|NCT05606757|Experimental|Cohort 3, Placebo|Participants will receive placebo for BOTOX.
88895266|NCT05605470|Experimental|Part A: Arm 1 (1 dose of ChulaCov19 BNA159 vaccine)|Participants will be randomized to receive ChulaCov19 BNA159 vaccine (50 mcg) given by IM (n=55)
88895267|NCT05605470|Active Comparator|Part A: Arm 2 (one dose of active comparator vaccine)|Participants will be randomized to receive Comirnaty® (Pfizer/BNT) vaccine (30 mcg) given by IM (n=25)
88895268|NCT05605470|Experimental|Part B: Arm 3 (one dose of COMVIGEN vaccine)|Participants will be randomized to receive ChulaCov19 BNA159.2 (COMVIGEN) vaccine (50 mcg) given by IM (n=70)
89417480|NCT00431431|Experimental|1|tibolone
88895269|NCT05601804||Food Insecure Women with Obesity|4 focus groups with 6-8 participants each
88895270|NCT05601804||Food Secure Women with Obesity|3 focus groups with 6-8 participants each
88895271|NCT05589038|Experimental|Baby Wash/Shampoo|Parent participant will bathe the baby participants using baby wash/shampoo at least 3 times per week, but no more than once daily, up to 4 weeks.
88895272|NCT05589038|Experimental|Baby Wash/Shampoo + Baby Lotion|Parent participant will bathe the baby participants using baby wash/shampoo at least 3 times per week, but no more than once daily, and apply lotion at least once daily after bathing, for 4 weeks.
88895273|NCT05586308|Other|Active control|Participants in this arm will receive an evidence-based text-messaging support.
88895274|NCT05586308|Active Comparator|Media literacy|Participants will receive media literacy e-learning lessons and an evidence-based text-messaging support.
88895275|NCT05586308|Active Comparator|Financial incentive|Participants will receive financial incentive intervention and an evidence-based text-messaging support.
88895276|NCT05586308|Experimental|Combined|Participants will receive media literacy e-learning lessons, financial incentive, and an evidence-based text-messaging support program.
88895277|NCT05585411|Experimental|LBBAP group|In this arm, a left bundle branch area pacing(LBBAP) lead will be attempted to be placed.
88895278|NCT05585411|Active Comparator|RVP group|In this arm, a Right ventricular pacing (RVP) lead will be attempted to be placed.
88895279|NCT05580289|No Intervention|control group|Routine care of the patient will be done and the level of pain will be determined with McGill pain scale questionnaire short form
88895280|NCT05580289|Experimental|detrimental group|Warm half shower + dry hot application will be applied to the experimental group in the early postoperative period.mplementation Phase: After mobilizing the patients in the experimental group, who have regained their muscle strength and can be mobilized, their legs will be washed with 40-45oC warm tap water for 5 minutes (down from the hip level) until their legs are up to the femur acetabulum level, and then the patient will be taken to the bed for 20 minutes. Dry hot application will be done over the bladder. Palpation and bladder examination will be performed every hour to understand bladder filling in patients who will be expected to urinate within 6-8 hours after surgery.
88895281|NCT05575531|Experimental|Experimental Group|"MEWSS and Nursing Guide Application will be used in the study group. MEWSS: The Modified Early Warning Score (MEWS) consists of a simple to use algorithm based on physiological parameters such as heart rate, respiratory rate, systolic blood pressure, temperature and level of consciousness.~Nursing Guide Application (NGA): According to the follow-up carried out in this study: If the patient's MEWSS is 4 or below, a ten-minute follow-up was performed. If the MEWSS is five, then five-minute follow-up is passed, and if the score has not changed as a result of the follow-ups, five-minute follow-ups are continued. If the score decreased to four or less, ten-minute follow-up was started, if the score increased, five-minute follow-ups were continued, and the emergency team was informed and the patient was evaluated (the emergency team was informed about the study)."
88895282|NCT05575531|No Intervention|Control Group|In the control group, the patients followed according to the Modified Early Warning Scoring System received routine care in the clinic.
88895283|NCT05569148|Experimental|Faricimab PFS Configuration|
88895284|NCT05565092|Experimental|ALXN1820 300 mg once weekly|Participants will receive 300 milligrams (mg) once weekly (QW).
88895285|NCT05565092|Experimental|ALXN1820 600 mg once every 4 weeks|Participants will receive 600 mg once every 4 weeks (Q4W).
88895286|NCT05565092|Experimental|ALXN1820 300 mg once every 2 weeks (Optional cohort)|Participants will receive 300 mg once every 2 weeks (Q2W).
88895287|NCT05560802|Experimental|Labour care guide|According to WHO guidelines
88895288|NCT05560802|No Intervention|Standard care|Standard delivery care in Sweden
88895289|NCT05558124|Experimental|Dose Escalation|Dose escalation to determine the maximum tolerated dose (MTD) of CPX-351 in combination with Gemtuzumab Ozogamicin in participants with newly diagnosed acute myeloid leukemia. Participants will be treated in cohorts of size three to six and the dosage will be escalated if the clinical toxicity is acceptable. A total of 3 dose levels will be used.
88895290|NCT05557513|Active Comparator|Ag-RDT (arm 1)|Symptomatic /suspected COVID-19 participant or close contact/family members of COVID-19 patient will be tested with Ag RDT and also involve in awareness-raising campaign with mask distribution.
89417481|NCT00431431|Active Comparator|2|raloxifene
89417482|NCT05566210|Active Comparator|Acupuncture group|Acupuncture was performed 2-3 times a week for 30 minutes each time for 3 months, starting from the 5th day of menstruation (spontaneous menstruation or drug withdrawal hemorrhaging menstruation)
89417483|NCT05566210|Placebo Comparator|Sham acupuncture group|Sham acupuncture was performed 2-3 times a week for 30 minutes each time for 3 months, starting from the 5th day of menstruation (spontaneous menstruation or drug withdrawal hemorrhaging menstruation)
89535986|NCT05002491|Experimental|High protein feeding|Two isocaloric feeding phases of 2 weeks followed by an ad-libitum feeding phase of 3 months
89417484|NCT04945057|Experimental|Intervention group|"All participants will use the Mindpax mobile application, wear the wrist accelerometer and fill in weekly self-assessments. All participants will obtain weekly health tips (general psychoeducation) and additional individualized targeted tips when the system detects deviation from individual mood, activity and sleep patterns.~Participants, who did not participate in the previous AKTIBIPO study (DeNovo) will complete additional 3 months of actigraphy and self-evaluation monitoring with research version of the Mindpax application, providing limited feedback and no health tips."
89417485|NCT03067480|Experimental|3-Month iPro2 Professional CGM|Professional CGM measures interstitial glucose every 5 minutes via a glucose-oxidase-impregnated membrane during a 3 day period. The patient wearing professional CGM is blinded to the repeated measurements and the data is stored for retrospective analysis.
89417486|NCT03067480|Experimental|6-Month iPro2 Professional CGM|Professional CGM measures interstitial glucose every 5 minutes via a glucose-oxidase-impregnated membrane during a 3 day period. The patient wearing professional CGM is blinded to the repeated measurements and the data is stored for retrospective analysis.
89417487|NCT02172222|Experimental|Sequence ABC|"Treatment A: BI 10773 once daily from day 1 to 5~Treatment B: BI10773 and linagliptin once daily from day 1 to 7~Treatment C: Linagliptin once daily from day 1 to 7"
89417488|NCT02172222|Experimental|Sequence CAB|"Treatment C: Linagliptin once daily from day 1 to 7~Treatment A: BI 10773 once daily from day 1 to 5~Treatment B: BI10773 and linagliptin once daily from day 1 to 7"
89417489|NCT03625219|Active Comparator|Prednisone|Cohort B only: Subjects will take 40 mg (8 x 5mg tablets) for three consecutive days, then 30 mg (6 x 5mg tablets), 20 mg (4 x 5 mg tablets), 10 mg (2 x 5 mg tablets) and 5 mg (1 x 5 mg tablet) daily for two consecutive days for each dose level for a total of 11 days of treatment.
89417490|NCT03625219|Placebo Comparator|Placebo|Cohort B only: 8 tablets for 3 consecutive days; then 6 tablets, 4 tablets, 2 tablets, and 1 tablet daily for 2 consecutive days for each tablet count for a total of 11 days
89199168|NCT05954221|Experimental|Red cell lysis buffer (RCLB) group|Patients assigned to this group will receive EUS-FNB as routine. The obtained tissue will be processed with red cell lysis buffer and underwent histological evaluation.
89417491|NCT02176590|Experimental|Power PATH|Classroom PATHS Social Emotional Learning Curriculum (for preschool classrooms) plus Coping Power parent intervention (teaches parents what children are learning in the classroom PATHS program and also provides parents with mental health intervention and parenting topics to promote family well-being)
89417492|NCT02176590|Active Comparator|Head Start as usual|Head Start as usual (will measure the effects of Head Start programming as usual on the primary outcomes)
89417493|NCT02255916|No Intervention|Controll|No sound-bed intervention
89417494|NCT02255916|Experimental|Music|live sound-bed music intervention
88895291|NCT05557513|No Intervention|No Ag-RDT (arm 2)|No community based Ag RDT testing but there has routine ATK or RT-PCR test by Thai health authorities if local health volunteer finds symptomatic or suspected COVID-19 or close contact with positive cases in their villages. The participant also involves in awareness-raising campaign with mask distribution.
88895292|NCT05549765|Experimental|Pharmacopucture on suboccipital muscles|"The Pharmacopucture group will recieve 3 sessions of Pharmacopucture on suboccipital muscles; on second, third, fourth day after hospitalization. A trained doctor of Korean medicine with at least 3 years of clinical experience are going to conduct the pharmacopucture.~The Pharmacopucture group will also be treated with other Korean medical treatment everyday: acupuncture, chuna and Korean herbal medicine."
88895293|NCT05549765|Active Comparator|Korean medical treatment|The control group will be received Korean medical treatment everyday after hospitalization: acupuncture(except on suboccipital parts), chuna, pharmacoacupuncture and Korean herbal medicine
88895294|NCT05548114|Active Comparator|EUS-guided gastrojejunostomy|EUS-guided gastrojejunostomy is performed using a lumen-apposing metal stent
88895295|NCT05548114|Active Comparator|Surgical gastrojejunostomy|A surgical gastrojejunostomy will be created via laparoscopic or open technique, as clinically appropriate.
88895296|NCT05547698|Active Comparator|Off-Pump Bilateral Lung Transplantation|Subjects will receive 'off-pump' technique for lung transplantation as part of standard of care
88895297|NCT05547698|Active Comparator|Venoarterial Extra Corporeal Membrane Oxygenation (VA ECMO) Bilateral Lung Transplantation|Subjects will receive VA ECMO technique for lung transplantation as part of standard of care
88895298|NCT05540418|Experimental|Experimental group|"Pre-procedural information form, state-trait anxiety scale, and comfort scale were applied to patients who had planned colonoscopy.~Two drops of lavender (2%) essential oil was dripped onto a 2 x 2 cm cotton gauze cloth attached to the front of the clothes of the experimental group patients, approximately 12 inches below their noses.~They were asked to inhale 2% lavender essential oil for 20 minutes. They were directed to breathe normally after inhalation.~Vital signs of the patients were checked before and after the procedure. After the process, the forms were filled again, the final test process was completed."
88895299|NCT05540418|No Intervention|Control Group|"Pre-procedural information form, state-trait anxiety scale, and comfort scale were applied to patients who had planned colonoscopy. Lavender aromatherapy was not applied to the patients in this group, but routine care was applied.~After the process, the forms were filled again, the final test process was completed. The data took about 15-20 minutes with face-to-face interview method."
88895300|NCT05536492|No Intervention|G1-Control group|normal socket healing after extraction without intervention
88895301|NCT05536492|Experimental|G2|SOCKET AUGMENTATION WITH A-PRF ALONE
88895302|NCT05536492|Experimental|G3|SOCKET AUGMENTATION WITH A-PRF + ALLOGRAFT
88895303|NCT05535049|No Intervention|Periodontally healthy group|24 participants were included in this group.
88895304|NCT05535049|Active Comparator|Periodontitis group|24 participants were included in this group.
88895305|NCT05534412|Experimental|Practice-Based Intervention|The intervention will include physician education, electronic decision support, implementation of an electronic referral system, and patient education/co-management by an advance practice provider.
89199169|NCT05954221|Active Comparator|conventional group|Patients assigned to this group will receive EUS-FNB as routine. The obtained tissue will be fixed with formalin as usual and underwent histological evaluation.
89199170|NCT05954208|Experimental|VAGT-WHCM|Vısual Arts Group Therapy Based On Watson's Human Care Model
89199171|NCT05954208|Active Comparator|Control group|Routine follow-up, treatment in the institution
89199172|NCT05954195|Active Comparator|HIIT group|The group who received high intensity interval training
89199173|NCT05954195|Placebo Comparator|control/comparator group|control group that might be placebo group, standard care group or no intervention group
89199174|NCT05954156|Experimental|injectable restorative resin composite material used for cementation|Highly filled injectable composites display properties in a manner similar to resin cements due to their unique viscosities. This with the added benefits of higher filler content, thus improved mechanical and physical properties with the easy placement and handling properties which can improve clinical performance and durability of indirect restorations. (Fugimoto et al., 2019)
89417495|NCT02178852|Experimental|TNS-active|TRIGEMINAL NERVE STIMULATION (TNS)
88895306|NCT05534412|No Intervention|Control|"Offices in this group will not receive the four-pronged intervention. However, after the study trial, there will be a validation phase in which the initial control group will then receive the intervention. This cross-over deign will then allow all 60 offices to receive the intervention. Data from the cross-over intervention group will be analyzed as a separate cohort to confirm improvements in patient care and outcomes as measured in the intervention group under the study trial can be duplicated."
88895307|NCT05510843|Experimental|THB001 Dose Level A|
88895308|NCT05510843|Experimental|THB001 Dose Level B|
88895309|NCT05510843|Experimental|THB001 Dose Level C|
88895310|NCT05509660|Experimental|Therapist-guided internet-based CBT treatment with increased therapist support|"Intervention/treatment: Behavioral: 'PUMA+'~8-week transdiagnostic CBT with therapist-support. One psychoeducation module followed by two transdiagnostic modules tailored to primary depression or anxiety symptoms, followed by three participant-choice modules, and ending with two transdiagnostic modules (acceptance; maintenance of skills learned). From mid-treatment onwards, participants will be offered increased therapist support."
88895311|NCT05509660|Active Comparator|Therapist-guided internet-based CBT treatment with standard therapist-support|"Intervention/treatment: Behavioral: 'PUMA' Intervention/treatment: Behavioral: 'PUMA'~8-week transdiagnostic CBT with therapist support. One psychoeducation module followed by two transdiagnostic modules tailored to primary depression or anxiety symptoms, followed by three participant-choice modules, and ending with two transdiagnostic modules (acceptance; maintenance of skills learned)."
88895312|NCT05508022|Experimental|Breathing Exercise|Breathing exercises will be applied to the participants in the experimental group.
88895313|NCT05493722|Experimental|Stimulation Group A|Participants with already implanted DBS will receive stimulation order 1. PS, OS, OS.
88895314|NCT05493722|Experimental|Stimulation Group B|Participants with already implanted DBS will receive stimulation order 1. OS, PS, OS.
88895315|NCT05493722|Experimental|Stimulation Group C|Participants with already implanted DBS will receive stimulation order 1. OS, OS, PS.
88895316|NCT05493007|Experimental|Sandbag motion style acupuncture treatment|"The MSAT group will recieve 3 sessions of MSAT; on second, third, fourth day after hospitalization.~A trained doctor of Korean medicine with at least 3 years of clinical experience will conduct the MSAT.~The MSAT group will be also treated with other Korean medical treatment everyday: acupuncture, chuna, pharmacoacupuncture and Korean herbal medicine."
88895317|NCT05493007|Active Comparator|Korean medical treatment|The control group will be received Korean medical treatment everyday after hospitalization: acupuncture, chuna, pharmacoacupuncture and Korean herbal medicine
88895318|NCT05491681|Experimental|Low dose|Experimental: Cohort 1 Low dose, 20M cells, 3 patients
88895319|NCT05491681|Experimental|Medium dose|Experimental: Cohort 2 Med dose, 100M cells, 3 patients
88895320|NCT05491681|Experimental|High dose|Experimental: Cohort 3 High dose, 200M cells, 3 patients
88895321|NCT05487378|Other|1st PKU GOLIKE 2nd AA protein substitute|7 days with usual protein substitute and PKU GOLIKE as their last dose of protein substitute for the day (at least one sachet with15g PE) in an amount equivalent to their usual protein substitute PE followed by a 2-week washout period on their usual protein substitute, and then 7 days with AA protein substitute for all daily doses.
88895322|NCT05487378|Other|1st AA protein substitute 2nd PKU GOLIKE|7 days with AA protein substitute for all daily doses followed by a 2-week washout period on their usual protein substitute, and then 7 days with usual protein substitute and PKU GOLIKE as their last dose of protein substitute for the day (at least one sachet with15g PE) in an amount equivalent to their usual protein substitute PE
88895323|NCT05487196|Experimental|Clonidine|"Bolus dose at epidural initiation, through the epidural catheter:~10 ml Ropivacaine 0.1 % combined with a single dose of Clonidine 60 mcg"
88895324|NCT05487196|Experimental|Dexmedetomidine|"Bolus dose at epidural initiation, through the epidural catheter:~10 ml Ropivacaine 0.1 % combined with a single dose of Dexmedetomidine 30 mcg"
88895325|NCT05487196|Active Comparator|Ropivacaine + Fentanyl|"Bolus dose at epidural initiation, through the epidural catheter:~10 ml Ropivacaine 0.1 % combined with a single dose of Fentanyl 100mcg"
89417496|NCT02178852|Placebo Comparator|TNS-sham|TRIGEMINAL NERVE STIMULATION (TNS) - sham
89417497|NCT05553964|Experimental|Study Groups|"Positives: Symptomatic vs. Asymptomatic Negatives: Symptomatic vs. Asymptomatic~Each broken down by age groups:~2-14 years old 15-24 years old 25-64 years old 65+ years old"
88895326|NCT05482828|Experimental|JGT group|Treatment group: JGT (Jaeumgeonbi-Tang) tablet. 8 g t.i.d. for 28 days
88895327|NCT05482828|Placebo Comparator|Placebo group|Placebo group: Corn starch tablet, 8 g t.i.d. for 28 days
88895328|NCT05480579|Experimental|Cohort 1: treated with different doses of single intravenous injection of IBI311|
88895329|NCT05480579|Placebo Comparator|Cohort 1: placebo group|
88895330|NCT05479968||Tissue Spectrometry group|The experimental group is subjected to testing the Specrocor Investigational Device.
88895331|NCT05471700|Experimental|Azacitidine combined with Venetoclax|"Each course is 28 days long. Subjects with newly diagnosed AML receive Venetoclax once daily by oral. The doses of Venetoclax is 100 mg on Day 1, 200 mg on Day 2, reaching a target dose of 400 mg on Day 3 and continuing through Day 28. If concomitantly receiving azoles, the dose of Venetoclax will be adjusted according to the instructions. At the same time patients will receive Azacitidine 75mg/m2 subcutaneous on Days 1-7.The induction therapy includes 1-2 cycle until subjects get remission.~Once complete remission, subjects will receive consolidation. Azacitidine combined with Venetoclax or middle to high dose of arabinoside based chemotherapy would be given at the discretion of the physician."
88895332|NCT05469178|Experimental|Phase 1b Cohort 1: Bemcentinib Dose 1|Participants with previously untreated locally advanced (Stage IIIb/IIIc)/metastatic (Stage IV) non-squamous NSCLC without actionable mutations will receive bemcentinib dose 1 once daily until a reason for discontinuation has been met or for up to 2 years, whichever occurs first along with CIT (Pembrolizumab infusion followed by pemetrexed and carboplatin).
88895333|NCT05469178|Experimental|Phase 1b Cohort 2: Bemcentinib Dose 2|Participants with previously untreated locally advanced (Stage IIIb/IIIc)/metastatic (Stage IV) non-squamous NSCLC without actionable mutations will receive bemcentinib dose 2 once daily until a reason for discontinuation has been met or for up to 2 years, whichever occurs first along with CIT (Pembrolizumab infusion followed by pemetrexed and carboplatin).
88895334|NCT05469178|Experimental|Phase 1b Cohort 3: Bemcentinib Dose 3|Participants with previously untreated locally advanced (Stage IIIb/IIIc)/metastatic (Stage IV) non-squamous NSCLC without actionable mutations will receive bemcentinib dose 3 once daily until a reason for discontinuation has been met or for up to 2 years, whichever occurs first along with CIT (Pembrolizumab infusion followed by pemetrexed and carboplatin).
88895335|NCT05469178|Experimental|Phase 2a Expansion Cohort: Bemcentinib (at 2 doses as determined from Phase 1b)|Participants with previously untreated advanced (Stage IIIb/IIIc)/metastatic (Stage IV) non-squamous NSCLC having a serine/threonine kinase 11 (STK11) mutation as identified by Next Generation Sequencing (NGS) and without actionable mutations will receive bemcentinib, at RP2D identified in Phase 1b, once daily until a reason for discontinuation has been met or for up to 2 years, whichever occurs first along with CIT (Pembrolizumab infusion followed by pemetrexed and carboplatin).
88895336|NCT05461378||Outpatients|Outpatients who have not yet received EVUSHELD but who plan on receiving it in the future.
89193480|NCT04840927|Experimental|Cohort 2: E7386 40 mg|"Participants will be randomized to one of the 3 treatment sequences:~Treatment sequence 4: Participants will receive Regimen C on Day 1 of treatment period 1 then Regimen B on Day 1 of treatment period 2 then Regimen A on Day 1 of treatment period 3 and an optional Regimen D on Day 1 of an optional treatment period 4.~Treatment sequence 5: Participants will receive Regimen A on Day 1 of treatment period 1 then Regimen C on Day 1 of treatment period 2 then Regimen B on Day 1 of treatment period 3 and an optional Regimen D on Day 1 of an optional treatment period 4.~Treatment sequence 6: Participants will receive Regimen B on Day 1 of treatment period 1 then Regimen A on Day 1 of treatment period 2 then Regimen C on Day 1 of treatment period 3 and an optional Regimen D on Day 1 of an optional treatment period 4.~A maximum wash out period of 10 days will be maintained between treatment periods 1, 2 and 3."
89193481|NCT04839081||RA patients|RA patients diagnosed according to the 1987 ACR Criteria
89193482|NCT04839081||Control|Age- and sex-matched control subjects with nociceptive/mechanical pain complaint other than in hand, lasting more than three months
89193483|NCT04835766||Symptomatic group|These patients had bladder injury during PAS surgery and had Lower urinary tract symptoms
89193484|NCT04835766||Asymptomatic group|These patients had bladder injury during PAS surgery and had no Lower urinary tract symptoms
89193485|NCT04829448|Experimental|Protein Intervention Group|Patients who receive the protein nutritional supplement as part of their prescribed exercise-based rehabilitation program.
89193486|NCT04829448|No Intervention|Control Group|Patients who receive the prescribed exercise-based rehabilitation program, without protein supplement.
89193487|NCT04825834||Individuals eligible for Lung Cancer screening with Lung Cancer diagnosis|
89193488|NCT04825834||Individuals eligible for Lung Cancer screening with no cancer diagnosis|
89193489|NCT04825834||Individuals eligible for Lung Cancer screening with Non-Lung Cancer diagnosis|
89193490|NCT04822064|Experimental|intranasal dexmedetomdine and kemtaine|Additional intranasal administration of dexmedetomidine (2mcg/kg) and ketamine (3mg/kg) to induce rescue sedation (pediatric sedation state scale = 1,2,3) after failed sedation attempt (PSSS=4,5) with oral chloral hydrate (50mg/kg)
89193491|NCT04822064|Active Comparator|oral chloral hydrate|Additional oral chloral hydrate (50mg/kg) administration to induce rescue sedation (pediatric sedation state scale = 1,2,3) after failed sedation attempt (PSSS=4,5) with oral chloral hydrate (50mg/kg)
89193492|NCT04821843|Experimental|(Neoadjuvant chemotherapy) nCT|This arm received chemotherapy with or without immunotherapy/targeting agents as neoadjuvant treatment.
89193493|NCT04821843|Placebo Comparator|(Neoadjuvant Chemoradiation) nCRT|This arm received chemoradiotherapy with or without immunotherapy/targeting agents as neoadjuvant treatment.
89193494|NCT04821817|Placebo Comparator|Group C (Control group)|Patients in this group will receive peribulbar anesthesia with 10 ml local anesthetic mixture composed of 4 ml of plain bupivacaine 0.5%, 4 ml of lidocaine 2% containing 50 IU, and 2 ml normal saline.
89193495|NCT04821817|Experimental|Group R (rocuronium group)|Patients in this group will receive peribulbar anesthesia with 10 ml local anesthetic mixture composed of 4 ml of plain bupivacaine 0.5%, 4 ml of lidocaine 2% containing 50 IU, and 0.06 mg/kg of rocuronium in 2 ml normal saline.
89193496|NCT04816955|Experimental|Nutrient-based recommendations|Participants in this group will be given nutrient-based recommendations to reduce free sugar intakes.
88895337|NCT05461378||Select inpatients (SOT/HCT/CAR-T)|Newly transplanted adult solid organ transplant and HCT recipients, as well as CAR-T-cell therapy recipients, during their hospitalization to undergo SOT/HCT/CAR-T-cell therapy
88895338|NCT05461378||Individuals who have received EVUSHELD|Individuals who have received EVUSHELD within 9 months of enrollment.
88895339|NCT05460988|Experimental|Non surgical re-instrumentation|The sites showing remaining pockets (PD>4mm), in the sextants allocated to re-instrumentation group, will be treated with subgingival debridement. The subgingival debridement will be performed after the administration of local oral anaesthesia (Articaine 1:100000) using a periodontal tip on ultrasonic instrument (EMS) and Gracey's curettes.
88895340|NCT05460988|Active Comparator|Flap surgery|All the sites showing a residual pocket in a sextant allocated to surgery group will receive flap surgery. After the administration of oral local anaesthesia (Articaine 1:100000) an intrasulcular flap will be raised. In order to preserve interdental tissue the flaps will be designed accordingly the principles of papillary preservation flap. Toot root will be carefully debrided using both ultrasonic instruments and Grecey's curettes. Bone recontouring and ostectomy/osteoplasty will be avoided. Single simple sutures will be used to close the flap (Vicryl 5-0).
88895341|NCT05452642|Active Comparator|DASH diet|12-month DASH diet intervention with psychological support
88895342|NCT05452642|Experimental|Very low-carbohydrate diet|12-month very low-carbohydrate diet intervention with psychological support
88895343|NCT05446766|Experimental|Self-guided Exposure-based Digital Intervention for Health Anxiety|Eight weeks of self-guided exposure-based intervention delivered digitally, via the Internet.
88895344|NCT05442112|Experimental|Wellness Smartphrase|This arm will receive a secure message after the conclusion of their standard clinic visit providing a set script containing information on a number of wellness-related topics in MS (sleep, diet, exercise).
88895345|NCT05442112|No Intervention|No Intervention|This arm will not receive a secure message after their appointment, and will instead receive their standard care with their provider.
88895346|NCT05439226|Experimental|CMNT diet|The CMNT group was instructed to consumed the provided CMNT diet consisting of 6 cycles of 5 consecutive days followed by 10 days of ad libitum food consumption. Participants received a 917 kcal/day preprepared human CMNT diet (44.75% carbohydrate, 9.1% protein and 46.15% fat) for 5 consecutive days per cycle
88895347|NCT05439226|No Intervention|Usual Care|Dietary recommendations based on the Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition) as the control group
88895348|NCT05433220|Experimental|Alert when provider is entering orders|
88895349|NCT05433220|No Intervention|No alert, usual care|
88895350|NCT05427006||Z5-BL Dental Implants|
88895351|NCT05427006||Z5-TL Dental Implants|
88895352|NCT05415514|Other|Instrumented assessment of muscle function|During the instrumented evaluations, the investigators will evaluate the possibility of measuring the passive and active function of the muscle using: - an isokinetic dynamometer, an ultrasound and elastography device, an electrical stimulation of the calf nerve
88895353|NCT05412914|Experimental|Remimazolam|remimazolam infusion
88895354|NCT05412914|Active Comparator|Propofol|propofol infusion
88895355|NCT05408195|Experimental|CHATBOT users|patients downloading and using the CHATBOT
88895356|NCT05407389|Experimental|KT-301 (formerly US-APR2020)|
88895357|NCT05407038|Experimental|Supportive care (remote monitoring with health coaching)|Patients undergo routine exercise using a remote monitoring system (Garmin Vívofit activity monitor, Nonin 3150 WristOx2 pulse oximeter, and an Android tablet) over 30 minutes at least 6 days per week and complete daily questionnaires over 20 minutes for 12 weeks. Patients also receive health coaching telephone calls over 5-20 minutes once a week for 12 weeks. At the end of the 12 weeks, patients complete an audio taped telephone interview.
88895358|NCT05406856|Active Comparator|IMRT/VMAT group|This group receives standard of care curative treatment with primary external beam radiation therapy (IMRT/VMAT), combined with chemotherapy, followed by 3D image (MRI)-guided adaptive brachytherapy.
88895359|NCT05406856|Experimental|IMPT group|This group receives curative treatment with primary external beam radiation therapy (IMPT), combined with chemotherapy, followed by 3D image (MRI)-guided adaptive brachytherapy.
89193497|NCT04816955|Experimental|Nutrient- and food-based recommendations|Participants in this group will be given nutrient- and food-based recommendations to reduce free sugar intakes.
89193498|NCT04816955|Experimental|Nutrient- and food-based recommendations with food swaps|Participants in this group will be given nutrient- and food-based recommendations and advice on food swaps to reduce free sugar intakes.
89193499|NCT04816955|Placebo Comparator|Control|Participants in this group will not be given any recommendations to reduce free sugar intakes.
89193500|NCT04811716|Experimental|Pozelimab Q4W + Cemdisiran|
88895360|NCT05356572|Active Comparator|Investigational Skin Preparation Device versus Disposable Dermal Curette|
88895361|NCT05356572|Active Comparator|Investigational Skin Preparation Device versus Abrasive Pad for Skin Preparation|
88895362|NCT05354726||CKD group|"Inclusion Criteria for Volunteers (Inclusion Criteria):~6-18 age range,~According to the Chronic Kidney Disease Assessment and Classification Guide prepared by the National Kidney Foundation- Kidney Disease Outcomes Quality Initiative (NKF-KDOQI); Stage 2, glomerular filtration rate 60-89 ml/min/1.73 m2, Stage 3, glomerular filtration rate 30-59 ml/min/1.73 m2, Stage 4, glomerular filtration rate 15-29 ml/min/1.73 m2,~Presence of kidney transplantation was determined as inclusion criteria.~Exclusion Criteria for Volunteers:~acute infection,~Ongoing dialysis,~Congenital heart disease,~Hypertension that cannot be controlled with dual antihypertensive medication,~Neurological and/or genetic musculoskeletal disease,~The presence of orthopedic and cognitive problems that prevented the tests from being performed were determined as exclusion criteria."
88895363|NCT05354726||Control Group|"Inclusion Criteria for Control Volunteers:~Not have cardiovascular, neurological and/or genetic musculoskeletal disease~Not having orthopedic and cognitive problems that prevent testing~The patient's and/or family's willingness to participate in the study"
88895364|NCT05352971||Patients with multiple sclerosis|
88895365|NCT05351294|Experimental|Arm 1|All enrolled patients will receive standard oncologic care at the discretion of the treating physicians, but will also complete the EORTC QLQ-C30, EQ-5D-5L, PTPQ, FAMCARE-P16 at baseline before randomization. Follow-up assessment using EORTC QLQ-C30, PTPQ, FAMCARE-P16 will occur every 3 months, and using EQ-5D-5L will occur every 1 month, for a total of 12 months. These will be administered during standard-of-care clinic or infusion center visits.
88895366|NCT05351294|Experimental|Arm 2|Patients enrolled in Arm 2 will also be seen be a radiation oncologist during the course of the study. The RO will review the patient's most recently completed EQ 5D-5L questionnaires and perform a complete History and Physical evaluation to determine if there is any immediate role for PRT. Based on the patient's type of cancer and areas of spread, the RO will also discuss types of symptoms that could develop in the future, and give instructions and educational materials to the patient so he/she can better identify those symptoms early on.
88895367|NCT05350163|Experimental|HLA Matched Cohort I|5 x 10^5/kg at 6-7 weeks post-transplant (Group A), 4-5 weeks post-transplant (Group B), or 2-3 weeks post-transplant (Group C)
88895368|NCT05350163|Experimental|HLA Matched Cohort II|5 x 10^5/kg starting time point X (whichever was safest as determined by Matched Cohort I), 1 x 10^6/kg 3-4 weeks after first dose, and 1 x 10^6/kg 3-4 weeks after second dose
88895369|NCT05350163|Experimental|HLA Matched Cohort III|5 x 10^5/kg starting time point X (whichever was safest as determined by Matched Cohort I), 1 x 10^6/kg 3-4 weeks after first dose, and 2 x 10^6/kg 3-4 weeks after second dose
89193501|NCT04811716|Experimental|Pozelimab Q2W + Cemdisiran|
89193502|NCT04809324|Experimental|Gross examination|measurement of the surgical margins will be done by the surgeon in the operating room using sterile scale after resection of the primary tumor .
89193503|NCT04809324|Active Comparator|Frozen section|frozen section examination of surgical margins will be done by the pathologist.
89193504|NCT04809168||AS patients|AS patients diagnosed according to the modified New York criteria
89193505|NCT04809168||Control|Age- and sex-matched control subjects with nociceptive/mechanical pain complaint lasting more than three months
89193506|NCT04797481|Experimental|Novel Intervention|Novel Intervention Exercise group.
89193507|NCT04797481|Active Comparator|Control|Self-managed Exercise group.
89193508|NCT04796324|Experimental|Ixabepilone|Ixabepilone 40 mg/m2 is administered as a 3-h intravenous infusion Day 1 in a 3-week cycle
89193509|NCT04794543||e-cigarettes and/or e-liquid vaping smokers|actively use e-cigarettes or e-liquid vaping
89193510|NCT04794543||cigarette smokers|actively use burning leaf tobacco cigarettes or inhaled burning leaf marijuana (cannabis)
89193511|NCT04794543||Non-smokers|no use of e-cigarettes or vape or active smoking in the past 5 years (and less than a total of 10 pack-years lifetime use)
89193512|NCT04787341|Active Comparator|Panitumumab followed by Regorafenib|
89193513|NCT04787341|Experimental|Regorafenib followed by Panitumumab|
89193514|NCT04786275||Tetanic stimulation|Single arm study
89193515|NCT04782284|Experimental|Comprehensive swallowing rehabilitation|
89193516|NCT04782284|Active Comparator|Swallowing education|
89193517|NCT04748874|Experimental|Immediate mNC-FET|In the immediate arm, patients undergo mNC-FET in the menstrual cycle immediately following oocyte retrieval and failed fresh embryo transfer or freeze-all.
89193518|NCT04748874|No Intervention|Postponed mNC-FET|Standard procedure where mNC-FET is performed at least one full menstrual cycle after failed fresh embryo transfer or freeze-all cycle.
89193519|NCT04741009|Experimental|CI632 Slim Modiolar Electrode|
89193520|NCT04738786|Active Comparator|Wide surgical safety margin|1.5 cm safety margin surgery for cT1-2N0 oral tongue cancer
89193521|NCT04738786|Active Comparator|Narrow surgical safety margin|1.0 cm safety margin surgery for cT1-2N0 oral tongue cancer
89193522|NCT04738734|Experimental|CellFX Procedure|CellFX device using pre-defined energy protocols
89193523|NCT04738734|Active Comparator|Cryosurgical Procedure|Cryosurgery will be standardized across all investigational sites. Investigators will perform the Cryosurgical procedure using the Brymill Cry-Ac B700 Liquid Nitrogen Sprayer.
89193524|NCT04738695||Nursing home residents/staff members|Follow-up of seroprevalence
89193525|NCT04733768|Experimental|18F-PSMA-1007 PET/CT scan|Single Arm study - all enrolled patients will undergo an experimental 18F-PSMA-1007 PET/CT scan
89193526|NCT04728932|Experimental|Levosimendan|A continuous infusion of Levosimendan will be administered over 24 h, with no initial bolus. The starting infusion rate will be 0.15 µg/kg/min and will be increased to 0.20 µg/kg/min after 2 hours in the absence of rate-limiting side effects
89006255|NCT02961621|Experimental|Stress Reduction Training Group|This group will complete a 7-week online mindfulness-based resiliency training: Stress Reduction Training for 9-1-1 Telecommunicators
89193527|NCT04728932|Placebo Comparator|Placebo|A continuous infusion of Placebo will be administered over 24 h, with no initial bolus. The starting infusion rate will be 0.15 µg/kg/min and will be increased to 0.20 µg/kg/min after 2 hours in the absence of rate-limiting side effects
89193528|NCT04718883|Experimental|JWCAR029 treatment|JWCAR029 be administrated at dose level: 1 x 10^8 CAR+T cells
88895370|NCT05350163|Experimental|HLA Mismatched Cohort I|1 x 10^5/kg at 6-7 weeks post-transplant (Group A), 4-5 weeks post-transplant (Group B), or 2-3 weeks post-transplant (Group C)
88895371|NCT05350163|Experimental|HLA Mismatched Cohort II|1 x 10^5/kg starting time point Y (whichever was safest as determined by Mismatched Cohort I), 5 x 10^5/kg 3-4 weeks after first dose, and 5 x 10^5/kg 3-4 weeks after second dose
88895372|NCT05350163|Experimental|HLA Mismatched Cohort III|1 x 10^5/kg starting time point Y (whichever was safest as determined by Mismatched Cohort I), 5 x 10^5/kg 3-4 weeks after first dose, and 1 x 10^6/kg 3-4 weeks after second dose
88895373|NCT05330195|Experimental|Treatment Group|Home exercise program Children will be given a home program including stretching, breathing, normal joint movement, body weight and mildly resistant exercises, and children will be asked to do these for 3 to 5 days a week. Also, aerobic training will be performed 3 days a week for 12 weeks at 60% of their maximum hearth rate with 40 minutes total duration consisting of 5 min warm up and 5 min cool down period to children in treatment group
89193529|NCT04718129|Experimental|Mindfulness|Internet-based, coached Mindfulness Program. Nine weekly coached sessions with practice exercises between sessions.
89193530|NCT04718129|No Intervention|Control|Participants in this arm are randomly assigned to an assessment-only, no intervention control condition.
89193531|NCT04716400|Experimental|Intervention group|"Stop sexual harassment"
89193532|NCT04716400|No Intervention|Control group|No intervention
89193533|NCT04712643|Experimental|Arm A: atezolizumab + bevacizumab + TACE|Participants will receive atezolizumab plus bevacizumab on Day 1 of a 21-Day cycle, after every on-demand transarterial chemoembolization procedure.
89193534|NCT04712643|Active Comparator|Arm B: TACE alone|Participants will receive on-demand transarterial chemoembolization.
89193535|NCT04710641|Experimental|MTL-CEBPA in combination with sorafenib|Intravenous infusion of MTL-CEBPA 130mg/m2 given once every 3 weeks. Oral sorafenib 400mg twice a day will commence C1D8.
89193536|NCT04710641|Active Comparator|Sorafenib alone|Oral sorafenib 400mg twice a day commencing Day1
89193537|NCT04707599|No Intervention|OFF intervention|No reminder plus (telephone reminder from therapist) but standard test message reminder (SMS) from second admission
89193538|NCT04707599|Experimental|ON intervention|Reminder plus (telephone reminder from therapist) AND standard test message reminder (SMS) from second admission
89193539|NCT04707196|Experimental|Abemaciclib + NSAI or Fulvestrant|Participants received abemaciclib 150 milligram (mg) orally twice daily, on days 1 through 28 of a 28-day cycle, for up to 6 cycles or less in case of disease progression, or any other discontinuation criterion is met, plus either NSAI (nonsteroidal aromatase inhibitors - anastrozole or letrozole) administered orally as per standard of care or fulvestrant administered intramuscularly as per standard of care.
89193540|NCT04693858|Experimental|Child Anxiety Learning Modules (CALM)|Children randomly assigned to this condition will receive the CALM intervention.
89193541|NCT04693858|Active Comparator|Child Anxiety Learning Modules--Relaxation (CALM-R)|Children randomly assigned to this condition will receive the CALM-R intervention.
89417498|NCT02255994|Experimental|UGYTEX|Patients in this arm received the UGYTEX mesh in the pro-cure 1 study (see NCT00153257)
89417499|NCT02255994|Active Comparator|No MESH|Patients in this arm had subvesical plication without reinforcement.
89535987|NCT03214861||Nurses Health Study|The Nurses' Health Study (NHS) was initiated in 1976 as a prospective cohort study, where 121,701 female registered nurses between the ages of 30 and 55 years were recruited from 11 US states.
89535988|NCT03214861||Health Professionals Follow-Up Study|The Health Professionals Follow-up Study (HPFS) was initiated in 1986 and recruited 51,529 US men between the ages of 40-75.
88895374|NCT05330195|Active Comparator|Control Group|Home Based Exercise Group Children will be given a home program including stretching, breathing, normal joint movement, body weight and mildly resistant exercises, and children will be asked to do this program for 3-5 days a week.
88895375|NCT05325307|Experimental|Acupressure Group (experimental)|The experimental group will be given acupressure.
88895376|NCT05325307|Placebo Comparator|Placebo Acupressure Group (control)|The placebo group will be given placebo acupressure
89417500|NCT03065842|Experimental|Abortion- and contraceptive-use stigma reduction program|Four sessions (à 120 min), every week in 1 month.
89417501|NCT03065842|Active Comparator|Usual standards|Usual standards
89417502|NCT04939519|Active Comparator|Text-Messaging (TM)|Population health management intervention that analyzes electronic health record data to automatically identify participants who are eligible for the COVID-19 vaccine and proactively reach those participants for vaccine scheduling. This is a bi-directional text messaging system.
89417503|NCT04939519|Active Comparator|Text-Messaging plus Patient Navigation|Population health management intervention that includes the same bi-directional text-messaging system as Arm 1 (the text messaging condition) with the addition of patient navigation. Patient navigation includes real-time assistance from a community health worker to address barriers, provide motivation, and assist with logistics of COIVD vaccination.
89417504|NCT02176746|Placebo Comparator|non-cancer stem cell vaccine|This is no cancer stem cells vaccine in this group
89417505|NCT02176746|Experimental|giving low dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
89417506|NCT02176746|Experimental|giving middle dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
89417507|NCT02176746|Experimental|giving high dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
89417508|NCT05551546|Active Comparator|Functional Medicine Health Coaching for Elimination Diet|"Participants randomized into the Functional Medicine Health Coaching for Elimination Diet arm will receive five remote health coaching sessions over 10 weeks in support of their progress through an elimination diet. All study arms will receive written elimination diet support materials."
89417509|NCT05551546|Other|Self-guided Elimination Diet|"Participants randomized into the Self-guided Elimination Diet group will engage with the elimination diet without health coaching. All study arms will receive written elimination diet support materials."
89417510|NCT02178930|Other|Integrated self management support|The intervention involves the introduction of an interactive chronic disease support platform into doctor-patient consultations, in addition to a self-management support program. Specifically, the intervention comprises the following interlinked components: within consultation engagement; at home exploration; phone and web-based health coaching.
88895379|NCT05307198|Experimental|Rectal Artery Infusion Chemotherapy|Patients receive 2 cycles of Capecitabine and Oxaliplatin (CapeOx) chemotherapy and evaluated with rectum Magnetic Resonance Imaging (MRI). Patients with more than 20% regression of maximum diameter of rectal tumor in MRI image will entry into next step of rectal artery infusion of Oxaliplatin and oral Capecitabine（1000mg/㎡）with anti-PD1 antibody（200mg）every 3 weeks for 2 cycles.Then those patients will receive rectectomy including anterior resection or abdominoperineal resection by open or laparoscopy with TME.
88895380|NCT05304104|Experimental|Telehealth Cognitive Behavioral Therapy (teleCBT)|About one-half of participants will be randomly assigned to Telehealth Cognitive Behavioral Therapy (teleCBT), a virtual Cognitive Behavioral Therapy (CBT) for binge eating disorders delivered via an Office of Information and Technology (OI&T)-approved video platform, by a master's-level research clinician. TeleCBT will be administered in 8 to 10 hourly individual sessions over a three-month treatment period.
88895381|NCT05304104|Active Comparator|Self-Help Cognitive Behavioral Therapy (shCBT)|About one-half of participants will be randomly assigned to Self-Help Cognitive Behavioral Therapy (shCBT), a Self-Help CBT for binge eating disorders initiated by a research assistant via telephone and then continued by the participant at home. These materials are the same exact ones provided to participants in TeleCBT (i.e., treatments are matched for materials), and will be mailed to participants. They will be instructed to work independently through one chapter per week for the following 12 weeks (i.e., treatment length is matched to TeleCBT).
89417511|NCT02178930|No Intervention|Usual care|The control group will receive usual care from study sites until all study participants have completed 12 months of follow up from their Baseline Visits. At this point access to the study intervention will be expanded to include control sites.
89417512|NCT02179008|Experimental|DE-117 Low Dose ophthalmic solution|One drop Low Dose DE-117 in each eye QD for 90 days
88895382|NCT05293938||OCA Treatment Group|PBC patients with a history of UDCA failure who initiated OCA in the study window (01 Jun 2015 to 31 Dec 2021)
88895383|NCT05293938||Control Group|PBC patients with a history of UDCA failure who were eligible but were not treated with OCA (or off-label fibrates) in the study window (01 Jun 2015 to 31 Dec 2021)
89417513|NCT02179008|Experimental|DE-117 Low/Middle Dose ophthalmic solution|One drop DE-117 Low/Middle Dose ophthalmic solution in each eye QD for 90 days
89417514|NCT02179008|Experimental|DE-117 Middle Dose ophthalmic solution|One drop Middle Dose DE-117 in each eye QD for 90 days
89417515|NCT02179008|Experimental|DE-117 Middle/High Dose ophthalmic solution|One drop Middle/High Dose DE-117 in each eye QD for 90 days
89417516|NCT02179008|Experimental|DE-117 High Dose ophthalmic solution|One drop High Dose DE-117 in each eye QD for 90 days
88895384|NCT05290493|Active Comparator|NB-001|Active drug product, NB-001: Two (2) 100 mg capsules will be administered orally BID with liquids or, if the subject is unable to swallow a capsule whole, capsules may be opened, and the contents sprinkled on applesauce; total daily dose: 400 mg.
88895385|NCT05290493|Placebo Comparator|Placebo|Placebo: Two (2) capsules (matching NB-001) will be administered orally BID with liquids or, if the subject is unable to swallow a capsule whole, capsules may be opened, and the contents sprinkled on applesauce.
88895386|NCT05287100|Experimental|Midodrine|Midodrine starting at 0.25mg/kg/day in 2-3 divided doses, increased to 0.5mg/kg/day after 7 days if MAP does not increase by >10% ; Midodrine dosage will be decreased by 25% in case of arterial hypertension (>95th centile BP for the age). Also Standard medical therapy as per departmental protocol will be continued
88895387|NCT05287100|Active Comparator|Standard medical therapy|Standard medical therapy as per departmental protocol
88895388|NCT05285670|Experimental|Digital counseling plus interactive two-way SMS dialogue|Participants will receive initial counseling on a tablet followed by automated SMS messages with prompts to reply. They will have the ability to both respond to and initiate SMS dialogue. Trained Study Nurses will monitor and respond to participant messages.
88895389|NCT05285670|No Intervention|Control|Control receiving standard of care.
88895390|NCT05279014|Active Comparator|Exercise in a fed-state|12-weeks of exercise training, 50-minutes, 3 days per week performed 1.5-3 hours after a high-carbohydrate meal (1 g/kg body mass).
88895391|NCT05279014|Experimental|Exercise in a fasted-state|12-weeks of exercise training, 50-minutes, 3 days per week performed after at least an 8-hour fast. A high-carbohydrate meal (1 g/kg body mass) will be consumed after exercise.
88895392|NCT05275426|Experimental|Ewing sarcoma|Participants have a diagnosis of Ewing sarcoma as molecularly defined by an EWSR1 fusion with an ETS-transcription factor family member including FLI1, ERG, ETV1, ETV4, and FEV
88895393|NCT05271903|Experimental|Intervention|The MAMA intervention, which is a simulation training intervention for labor and delivery prviders.
88895394|NCT05262907|Experimental|Ventripoint 3D Echocardiogram|Ventripoint 3D Echo performed on subject to validate technology for use in single ventricle patients.
88895395|NCT05262907|Active Comparator|Transthoracic Echocardiogram or Cardiac MRI|Non-invasive imaging of the heart to evaluate structure and function.
88895396|NCT05259917|Placebo Comparator|Placebo|
88895397|NCT05259917|Experimental|KVD900 600 mg|
88895398|NCT05259917|Experimental|KVD900 300 mg|
88895399|NCT05251324||Participants With Hot Flushes (at least 3 per day)|"At Visit 1, participants will complete informed consent, questionnaires regarding medical history, physical activity levels, stress and anxiety, menopause symptoms and a hot flush behavior scale. Visit one will be completed remotely using a HIPAA-compliant online platform or over the phone.~At Visit 2, baseline measurements will be recorded for two hours and spontaneous hot flushes will be detected. Participants will then have a temperature-controlled, water-circulating heating pad at a consistent temperature of 107˚F placed on their torso for 30 min, followed by five min of recovery. This will be followed by a blood draw to measure sex hormones. At either Visit 2 or a separate visit, participants will have a dual energy x-ray absorptiometry scan for a body composition assessment. For participants taking prescribed MHT, a standard protocol for enrollment and they may complete up to six study visits."
89006256|NCT02961621|No Intervention|Control Group|This group is a wait-list control and will be offered the training after all data collection has been completed.
89006257|NCT04640116|Experimental|TIPS combined with microwave ablation|
89006258|NCT00242112|Other|MRI - pathology|
89006259|NCT00559546|Active Comparator|1|3 weeks of Montelukast and 3 weeks of placebo treatment
89417517|NCT02179008|Active Comparator|latanoprost ophthalmic solution 0.005%|One drop latanaprost in each eye QD for 90 days
89417518|NCT05545150|Experimental|Diagnostic (Volumetric Specimen Imager Device)|Patients undergo breast conservation surgery (lumpectomy or partial mastectomy) per standard care, and VSI intraoperative imaging is captured on the day of surgery.
89417519|NCT02172300|Experimental|Tiotropium|Tiotropium inhalation capsules via HandiHaler
89417520|NCT02172300|Placebo Comparator|Placebo|Placebo inhalation capsules via HandiHaler
89417521|NCT05223907|Experimental|Group Etomidate|Etomidate will be used for general anesthesia
89417522|NCT05223907|Experimental|Group Propofol|Propofol will be used for general anesthesia
89417523|NCT03537456|Experimental|mRDX-02-17|"mRDX-02-17 is a dermal filler recommended for correction and treatment of wrinkles and dermal depressions, which are administered by intradermal injections. It encourages repair and restructuring of skin tissue, reducing the signs of aging and has the following indications:~Hypotrophic tissues~Tissue hypotonicity~Crow's feet~Glogau III - IV~Fiztpatrick I - VI~WSRS (Wrinkle Severity Ranking Scale): 2-5"
89417524|NCT04799353|Experimental|Group 1: Placebo SC + Placebo IV|Participants will receive Subcutaneous (SC) Placebo, followed by Intravenous (IV) Placebo.
89417525|NCT04799353|Experimental|Group 2: Budigalimab (SC) + Placebo IV|Participants will receive Subcutaneous (SC) Budigalimab, followed by Intravenous (IV) Placebo.
89417526|NCT04799353|Experimental|Group 3: Budigalimab SC + Placebo IV|Participants will receive Subcutaneous (SC) Budigalimab, followed by Intravenous (IV) Placebo.
89417527|NCT04799353|Experimental|Group 4: Placebo SC + Budigalimab IV|Participants will receive Subcutaneous (SC) Placebo, followed by IV Budigalimab.
89417528|NCT03065998|Active Comparator|Drug-A|opripramol 150 mg per day (3*50) Opipramol is a selective agonist for sigma-1 receptor. It is clinically used as an antidepressant and anxiolytic agent.
89417529|NCT03065998|Active Comparator|Drug-B|baclofen 90 mg per day (3*30) Baclofen is a GABAb-1 antagonist and has shown partial efficacy in suppressing withdrawal symptoms in alcohol addicts and cocaine.
89417530|NCT02172378|Experimental|Tiotropium inhalation capsules|
89417531|NCT02172378|Placebo Comparator|Placebo inhalation capsules|
89417532|NCT05728528|Experimental|PK-guided EHL FVIII concentrates prophylaxis with moderate intensity physical activities|PK-guided EHL FVIII concentrates prophylaxis with moderate intensity physical activities
89417533|NCT05728528|Active Comparator|PK-guided EHL FVIII concentrates prophylaxis alone|PK-guided EHL FVIII concentrates prophylaxis alone
89417534|NCT03625375|Experimental|Treatment Group|Individuals will perform exercises 3 times a week.
89417535|NCT03625375|No Intervention|Control Group|Individuals will not perform exercises
89417536|NCT02176824|Experimental|Triple Chronotherapy|Total Sleep Deprivation, Sleep phase advance, and Bright Light Therapy. Carex Health Brands Day-Light Classic 10,000 Lux
89006260|NCT00559546|Active Comparator|2|3 weeks of placebo and 3 weeks of montelukast treatment
89006261|NCT04639921|Experimental|active - placebo|intake of socalled gluten bars two daily for seven days, followed by one week wash-out, and then placebo bars for seven days
89417537|NCT02176824|Sham Comparator|Sham Triple Chronotherapy|Total sleep deprivation, Three day fixed wake schedule, and sham light therapy.
89417538|NCT02176824|Active Comparator|Treatment As Usual|Normal inpatient care including pharmacotherapy, psychotherapy, milieu therapy, and social work interventions.
89417539|NCT05728450|Experimental|Study group|This group includes 15 burned patients who will receive laser puncture for one month (3 times/week) in addition to their physical therapy program (splinting, stretching ex. and ROM ex.) and medical treatment.
89417540|NCT05728450|No Intervention|Control group|This group includes 15 burned patients who will receive their physical therapy program (splinting, stretching ex., strengthening ex. and ROM ex.) and medical treatment.
89417541|NCT03625297|No Intervention|Shelter cat adoption control group|Families of children with autism will complete a control period with no intervention, then adopt a shelter cat after completion of the control period
89417542|NCT03625297|Experimental|shelter cat adoption|Families of children with autism will adopt a shelter cat
89417543|NCT02256228|Active Comparator|Group R|Ropivacaine is instillated through one multi-hole catheter wich would be inserted percutaneously in all patients and tunnelled about 1-2 cm lateral to the abdominal incision and the tip of the catheter placed in the intra-peritoneal cavity. The catheter would not be ligated and fixed in situ intra-peritoneally. Twenty ml of Ropivacaine would be injected subcutaneously along both sides of the incision prior to skin closure. Additionally, 20 ml of Ropivacaine (1mg/mL) would be injected every hour by an automatic pump via the intra-peritoneal catheter into the abdomen.
89417544|NCT02256228|Placebo Comparator|Group P|Saline is instillated through one multi-hole catheter wich would be inserted percutaneously in all patients and tunnelled about 1-2 cm lateral to the abdominal incision and the tip of the catheter placed in the intra-peritoneal cavity. The catheter would not be ligated and fixed in situ intra-peritoneally. Twenty ml of Saline would be injected subcutaneously along both sides of the incision prior to skin closure. Additionally, 20 ml of Saline would be injected every hour by an automatic pump via the intra-peritoneal catheter into the abdomen.
89535989|NCT02483351|Experimental|Liberal RBC Transfusion Strategy|
89535990|NCT02483351|Active Comparator|Restrictive RBC Transfusion Strategy|
88895400|NCT05251324||Participants Without Hot Flushes|"At Visit 1, participants will complete informed consent, questionnaires regarding medical history, physical activity levels, stress and anxiety, menopause symptoms and a hot flush behavior scale. Visit one will be completed remotely using a HIPAA-compliant online platform or over the phone.~At Visit 2, baseline measurements will be recorded for two hours and spontaneous hot flushes will be detected. Participants will then have a temperature-controlled, water-circulating heating pad at a consistent temperature of 107˚F placed on their torso for 30 min, followed by five min of recovery. This will be followed by a blood draw to measure sex hormones. At either Visit 2 or a separate visit, participants will have a dual energy x-ray absorptiometry scan for a body composition assessment. For participants taking prescribed MHT, a standard protocol for enrollment and they may complete up to six study visits."
88895401|NCT05242731|Active Comparator|Study group|Studygroup: Working with MSmonitor and video calling. Complete research questionnaires every 3 months in the Case Report Form, Researchmanager.
88895402|NCT05242731|Active Comparator|Controlgroup|Became care as usual (CAU), not working with MSmonitor or video calling. Complete research questionnaires every 3 months in the Case Report Form, researchmanager.
88895403|NCT05242276||uterine manipulator cohort|Patients with early-stage endometrial cancer who have performed a hysterectomy with a uterine manipulator to mobilize the uterus during the surgery.
88895404|NCT05242276||no uterine manipulator cohort|Patients with early-stage endometrial cancer who have performed a hysterectomy without a uterine manipulator to mobilize the uterus during the surgery.
88895405|NCT05224141|Experimental|Pembrolizumab/Vibostolimab|Participants will receive 4 cycles (each cycle is 3 weeks) of a fixed-dose coformulation of 200 mg pembrolizumab and 200 mg vibostolimab (MK-7684A) every 3 weeks (Q3W), in combination with 100 mg/m^2 etoposide, and platinum (Area Under the Curve (AUC) 5 mg/mL/min carboplatin or 75 mg/m^2 cisplatin) chemotherapy Q3W for a total of approximately 12 weeks. This will be followed by additional cycles of MK-7684A Q3W until any of the conditions for discontinuation are met. To maintain the blinding, saline placebo will be administered on cycle 1 day 1 and then Q3W as needed beyond cycle 1.
88895406|NCT05224141|Active Comparator|Atezolizumab|Participants will receive 4 cycles (each cycle is 3 weeks) of 1200 mg atezolizumab Q3W, in combination with 100 mg/m^2 etoposide and platinum (AUC 5 mg/mL/min carboplatin or 75 mg/m^2 cisplatin) chemotherapy Q3W for a total of approximately 12 weeks. This will be followed by additional cycles of atezolizumab Q3W until any of the conditions for discontinuation are met. To maintain the blinding, saline placebo will be administered on cycle 1 day 1 and then Q3W as needed beyond cycle 1.
88895407|NCT05222178|Experimental|Low Dose Cohort|HMI-103 delivered IV one time
88895408|NCT05222178|Experimental|Intermediate Dose Cohort|HMI-103 delivered IV one time
89417545|NCT03067168|Active Comparator|Bupivacaine Arm|The subjects of this arm will receive an injection of 5mL of 0.5% bupivacaine, 1-2 cm deep to the surface of the vaginal epithelium into the levator ani muscle, puborectalis. A second injection of 5mL of 0.5% bupivacaine, 1-2 cm deep to the surface of the vaginal epithelium will be repeated on the same side, approximately 2-3 cm cephalad of the first injection at the iliococcygeus muscle. These 2 injections will then be repeated on the contralateral side.
89417546|NCT03067168|Placebo Comparator|Placebo Arm|The subjects of this arm will receive an injection of 5mL of 0.9% normal saline, 1-2 cm deep to the surface of the vaginal epithelium into the levator ani muscle, puborectalis. A second injection of 0.9% normal saline, 1-2 cm deep to the surface of the vaginal epithelium will be repeated on the same side, approximately 2-3 cm cephalic from first injection at the iliococcygeus muscle. These 2 injections will then be repeated on the contralateral side.
89417547|NCT04051177|Experimental|parents living with HIV intervention group|Parents living with HIV in this group received five two-hour parent HIV disclosure intervention, delivered one session per week for five weeks in the clinics where the parents are recruited. The intervention curriculum is modeled after the TRACK program with supplemental materials from TALC.
89417548|NCT04051177|Other|Parents living with HIV control group|"Parents living with HIV in this group received five two-hour nutrition education curriculum in same delivery way. The nutrition curriculum is modeled after the Simply Good Eating: curriculum developed at University of Minnesota."
88895409|NCT05222178|Experimental|High Dose Cohort|HMI-103 delivered IV one time
88895410|NCT05215977|Experimental|MW031|MW031 injection(60 mg) was administered subcutaneously once every 6 months for a maximum of 2 consecutive doses throughout the trial, according to the investigator's assessment.
88895411|NCT05215977|Placebo Comparator|placebo|Placebo was administered subcutaneously once every 6 months for a maximum of 2 consecutive doses throughout the trial.
88895412|NCT05212766||Vaccinated or unvaccinated uninfected South Asian ethnicity|Participants will have not experienced infection (positive test) - we will aim to recruit both vaccinated and unvaccinated individuals although the latter may be harder to recruit. They will identify as of South Asian ethnicity. Uninfected subjects, will be recruited by advertisement within KCL or social media, from non-COVID in-patients or outpatients or attending A&E at GSTT and at SARS-CoV2 antigen testing centres and vaccination centres and at PIC sites.
89006262|NCT04639921|Placebo Comparator|placebo - active|intake of placebo bars two daily, followoed by wash-out for one week, and gluten bars (experimental) for seven days.
89417549|NCT02176980|Active Comparator|Medical provider (MP) brief alcohol counseling & referral|"Screening of HCV-infected patients for alcohol use using the 10-item Alcohol Use Disorders Identification Test (AUDIT).~Patients self-administer the AUDIT.~HCV providers review the AUDIT with the patient.~If the patient is using any alcohol, the HCV provider conducts brief alcohol counseling using the FRAMES model, based on the evidence-based Screening, Brief Intervention, and Referral to Treatment (SBIRT) method.~Medical provider will explain the importance of alcohol abstinence in the presence of HCV infection.~Patient is referred to an alcohol treatment programs outside the liver clinic. Typical counseling will take the form of individual and group therapy."
89417550|NCT02176980|Experimental|Brief alcohol counseling & 6 months of HCV-alcohol treatment|"Steps 1 through 5 as described in comparator arm above.~6 months of group therapy, offered weekly.~6 months of individual therapy, in person or by phone, offered every two weeks.~Therapy content emphasizes interplay between alcohol use and liver health/HCV.~Informal collaboration between HCV providers and addictions therapists.~Shared EMR charting.~Referral to study-provided psychiatry as needed."
89417551|NCT04774237|Experimental|BRIMOCHOL™|A single drop in each eye at a visit.
88895413|NCT05212766||Asymptomatic / mild infected South Asian ethnicity|Participants will have experienced asymptomatic or mild infection (positive test). They will identify as of South Asian ethnicity. Volunteers or subjects attending SARS-CoV2 testing centres who are found to be antigen positive or In-patients who have positive Covid tests and designated as asymptomatic/mild but admitted for non-covid reasons or those attending A&E with COVID but designated as mild/asymptomatic
88895414|NCT05212766||Symptomatic infected South Asian ethnicity|Participants will have experienced moderate or severe symptomatic infection (positive test, admission). They will identify as of South Asian ethnicity. Patients either seen at GSTT or admitted as in-patients to GSTT or KCH and found to be SARS-CoV2 positive by RT-PCR in nasopharyngeal samples and designated as moderate/severe on the NIH/NIMR COVID severity scale.
89006263|NCT04639882|Experimental|Control-Remote-$0|"In this condition, Participants:~receive attention control feedback~complete the baseline and intervention procedure remotely~are compensated $0 for completing the baseline and intervention procedure"
89006264|NCT04639882|Experimental|Control-Remote-$30|"In this condition, Participants:~receive attention control feedback~complete the baseline and intervention procedure remotely~are compensated $30 for completing the baseline and intervention procedure"
89417552|NCT04774237|Experimental|BRIMOCHOL™ F|A single drop in each eye at a visit.
89417553|NCT04774237|Active Comparator|Carbachol|A single drop in each eye at a visit.
89417554|NCT02172456|Experimental|Tiotropium|
89417555|NCT05223595|Experimental|dose escalation|Gentuximab at a dose of 8 mg/kg or 12 mg/kg based on body weight + Almonertinib at a dose of 110mg for one 28-day cycle
88895415|NCT05212766||Infected recovered South Asian ethnicity|Participants will have experienced moderate or severe symptomatic infection (positive test, admission) and recovered. They will identify as of South Asian ethnicity.
89417556|NCT03067246|Active Comparator|VBM Intubating Laryngeal Tube|Device: VBM Intubating Laryngeal Tube Intervention: VBM Intubating Laryngeal Tube insertion, seal pressure, endotracheal intubation
89417557|NCT03067246|Active Comparator|I-Gel|Device: I-Gel Intervention: I-Gel insertion, seal pressure, endotracheal intubation
89417558|NCT02030184|Experimental|Topotecan and Rhenium Re 188 P2045|In the phase II portion of this study, patients will be screened using Technicium Tc99m. Eligible, consented patients will receive Topotecan treatment for three days, at doses of either 1.0 mg/m2 or 1.5 mg/m2. They will then receive a single dose of Rhenium Re 188-P2045, at one of the following dosage levels based on the Phase I Maximum Tolerated Dose (MTD): 40% of MTD; 50% of MTD; 75% of MTD; 85% of MTD or 100% of MTD.
89193542|NCT04693858|No Intervention|Waitlist control|Within each nurse, 20% (1 in 5) children will be randomly assigned to wait a period of eight weeks prior to starting the intervention with their school nurse. During this period, the child is not prevented from seeing the school nurse, nor are they prevented from continuing to utilize stable doses of community treatment (i.e., therapy outside of school or medication); nurses are simply asked to provide normal support and avoid using techniques specific to CALM or CALM-R. After the 8 weeks, youth are re-evaluated and nurses begin delivering the intervention to the student.
89417559|NCT04235998||Systematic lung ultrasound|Patients with unilateral pleural effusion of unknown course
89417560|NCT02172534|Experimental|Tiotropium bromide low|Single dose: 2.5 µg Tiotropium
89417561|NCT02172534|Experimental|Tiotropium bromide medium|Single dose: 5 µg Tiotropium
89417562|NCT02172534|Experimental|Tiotropium bromide high|Single dose: 10 µg Tiotropium
89417563|NCT02172534|Experimental|Tiotropium bromide low (28 days)|multiple dose: 2.5 µg Tiotropium
89417564|NCT02172534|Experimental|Tiotropium bromide medium (28 days)|Multiple dose: 5 µg Tiotropium
89417565|NCT02172534|Placebo Comparator|Placebo|single or multiple dose of Placebo
89417566|NCT02256306|Experimental|Young Donor Plasma|Subjects will receive 1 unit of plasma, once weekly for 4 weeks.
89417567|NCT04713631|Active Comparator|Artesunate and Curcumin|Artesunate 200 mg PO once a day x 2 weeks. Curcumin 2 gm PO once a day x 13 weeks.
89417568|NCT04713631|Active Comparator|Artesunate and Placebo C|Artesunate 200 mg PO once a day x 2 weeks. Placebo C x 13 weeks.
89417569|NCT04713631|Active Comparator|Curcumin and Placebo A|Placebo A x 2 weeks. Curcumin 2 gm PO once a day x 13 weeks.
89417570|NCT04713631|Placebo Comparator|Placebo A and Placebo C|Placebo A x 2 weeks. Placebo C x 13 weeks.
88895416|NCT05212766||Vaccinated or unvaccinated uninfected Caucasian ethnicity|Participants will have not experienced infection (positive test) - we will aim to recruit both vaccinated and unvaccinated individuals although the latter may be harder to recruit. They will identify as of Caucasian ethnicity. Uninfected subjects, will be recruited by advertisement within KCL or social media, from non-COVID in-patients or outpatients or attending A&E at GSTT and at SARS-CoV2 antigen testing centres and vaccination centres and at PIC sites.
89193543|NCT04691518|Active Comparator|Acute Intermittent Hypoxia (AIH)|Undergoing Acute Intermittent Hypoxia sessions
89417571|NCT04459078|Experimental|Camrelizumab combined with Albumin Paclitacxel and Apatinib.|Participants are given intravenous administration of Camrelizumab (200mg/3w) in addition with intravenous administration of Albumin Paclitacxel (135mg/m2, d1, d8/3w, 4-6 cycles) and Apatinib (250mg Qd po for 5 days,, take rest for 2 days every week). Treatment terminates when disease progression, death or unacceptable toxicity.
89417572|NCT02179242|No Intervention|Control arm|This arm will receive routine care following their heart failure which includes no cardiac rehab intervention.
89417573|NCT02179242|Experimental|Cardiac rehab|This arm will receive cardiac rehab intervention 3 times per week for 4 weeks following discharge.
89417574|NCT04693195|Experimental|BLU-5937 oral tablet|Eligible participants will receive BLU-5937 twice a day (BID) orally for 4 weeks.
89417575|NCT04693195|Placebo Comparator|Placebo oral tablet|Eligible participants will receive matching Placebo BID orally for 4 weeks.
88895417|NCT05212766||Asymptomatic / mild infected Caucasian ethnicity|Participants will have experienced asymptomatic or mild infection (positive test). They will identify as of Caucasian ethnicity. Volunteers or subjects attending SARS-CoV2 testing centres who are found to be antigen positive or In-patients who have positive Covid tests and designated as asymptomatic/mild but admitted for non-covid reasons or those attending A&E with COVID but designated as mild/asymptomatic
88895418|NCT05212766||Symptomatic infected Caucasian ethnicity|Participants will have experienced moderate or severe symptomatic infection (positive test, admission). They will identify as of Caucasian ethnicity. Patients either seen at GSTT or admitted as in-patients to GSTT or KCH and found to be SARS-CoV2 positive by RT-PCR in nasopharyngeal samples and designated as moderate/severe on the NIH/NIMR COVID severity scale.
88895419|NCT05212766||Infected recovered Caucasian ethnicity|Participants will have experienced moderate or severe symptomatic infection (positive test, admission) and recovered. They will identify as of Caucasian ethnicity
88895420|NCT05211570|Experimental|AB8939|AB8939 administered as a single agent
88895421|NCT05211570|Experimental|AB8939 plus azacitidine|AB8939 administered in combination with azacitidine
88895422|NCT05206435|Active Comparator|Electronic Cigarettes|Participants in this arm are randomized to receive electronic cigarettes for the 6-week study period.
88895423|NCT05206435|Active Comparator|Nicotine Lozenges|Participants in this arm are randomized to receive nicotine lozenge for the 6-week study period.
88895424|NCT05204472|Experimental|Burst DBS first, Tonic DBS second|10 days of Burst-stimulation followed by 10 days of active tonic stimulation (Burst-DBS -> tonic-DBS)
88895425|NCT05204472|Active Comparator|Tonic DBS first, Burst DBS second|10 days of active tonic stimulation followed by 10 days of Burst-stimulation (tonic-DBS -> Burst-DBS)
88895426|NCT05203614|Other|Household Contribution|Do something thoughtful or nice for your caregiver that would provide them with tangible support
88895427|NCT05203614|Other|Outside Contribution|Do something outside your home/household that contributes to the larger society
88895428|NCT05203614|Other|Control|Keep track of your daily activities
88895429|NCT05198570||Intravenous Aciclovir|Patients receiving intravenous aciclovir for prophylaxis or treatment of herpes virus infections
88895430|NCT05198570||Oral Aciclovir|Patients receiving oral aciclovir/valaciclovir for prophylaxis or treatment of herpes virus infections
88895431|NCT05198479|Experimental|Arm 177 Lu-DOTA0-Tyr3-Octreotate|Treatment with 177Lu-DOTATATE consist of a cumulative dose of 23.68 - 29.6 GBq (640 - 800 mCi) 177Lu-DOTA0-Tyr3-Octreotate; Four administrations of 5.92 - 7.4 GBq (160 - 200 mCi) 177Lu-DOTA0-Tyr3-Octreotate; Concomitant amino acids will be given with each administration for kidney protection; 177Lu-DOTA0-Tyr3-Octreotate will be administered at 8±1-week intervals, which can be extended up to 16 weeks to accommodate resolving acute toxicity.
88895432|NCT05196308|Experimental|Xeomin® receivers|Patients will receive Xeomin®.
88895433|NCT05196308|Placebo Comparator|Placebo receivers|Patients will receive placebo injection instead of Xeomin®.
88895434|NCT05192330|Experimental|Virtual Reality Glasses|"After obtaining written informed consent, the data collection form, Spielberger State Anxiety Scale and visual analogue scale(pain and nursing satisfaction) scoring scale will apply to both groups by face to face interview during the day giving appointment for intrauterine insemination. Immediately after the questionnaires were applied, the nurse gave Virtual Reality Glasses for 30 minutes.~Glasses will be given put on before the process starts and training will be given to continue watching the video while wearing the glasses.The women include in the Virtual reality application group will be shown a video with a nature view during the procedure.~Every woman will be shown the same video."
88895435|NCT05192330|Experimental|Therapeutic Touch|"Applied therapeutic touch intervention on their hands for 30 minutes to help patients feel comfortable during the procedure.The researcher started the application by taking an appropriate hand of the patient between his hands and held it for 30 minutes. The researcher's fingers are closed, not clasped, and his hand is placed on the participant's hand.~The researcher held her hand steady without touching or rubbing it. In addition, the researcher is not use gloves."
88895436|NCT05192330|No Intervention|control group|Participants in the control group received standard care (verbal information about procedure and a short written information about the procedure) and no intervention (virtual reality or Therapeutic Touch) was performed. Both groups were re-evaluated using the same scales after the intrauterine insemination. Within 5 minutes of completing the procedure, participants will asked to evaluate their pain in order to characterize pain intensity using the visual analogue scale, anxiety scale and satisfaction scale.
89417576|NCT03067090|Experimental|Intra-articular Aquamid Reconstruction|Intra-articular injection of 3 ml aquamid reconstruction (AR) to the knee. A second injection of 3 ml will take place after 1 month (+/- 2 weeks).
89417577|NCT03068494||Coronary Bifurcation Lesion|
88895437|NCT05187377|Experimental|Growth Hormone then Saline|12 weeks in each treatment phase (rhGH then placebo) and a four week wash-out period between phases.
88895438|NCT05187377|Placebo Comparator|Placebo (saline) then Growth Hormone|12 weeks in each treatment phase (placebo then rhGH) and a four week wash-out period between phases.
88895439|NCT05186688|Experimental|Physical activity|Patients are encouraged to participate in physical exercise at the psychiatric unit
88895440|NCT05186636||ICU patients receiving renal replacement therapy|All patients in participating ICU's receiving CRRT or IRRT during the study period
88895441|NCT05184478|Experimental|Group A (MC then placebo)|Group A will receive medicinal cannabis during Treatment Period 1 (70 days), followed by a 7 day dose reduction and 21 day wash-out period, then will receive placebo during Treatment Period 2 (70 days).
89193544|NCT04691518|Placebo Comparator|Sham AIH|Undergoing Sham AIH sessions
88895442|NCT05184478|Experimental|Group B (placebo then MC)|Group B will receive placebo during Treatment Period 1 (70 days), followed by a 7 day dose reduction and 21 day wash-out period, then will receive medicinal cannabis during Treatment Period 2 (70 days).
88895443|NCT05182749|Placebo Comparator|Placebo|Dose is 1mL of placebo given orally three times a day for 7 days (Phase 1) or 6 days (Phase 2a)
88895444|NCT05182749|Experimental|Bacteriophage|Dose is 1mL of bacteriophage preparation given orally three times a day for 7 days (Phase 1) or 6 days (Phase 2a)
88895445|NCT05178030||GALLOP-11|Patients with a proven KIT exon 11 mutated GIST covered by our in-house designed ddPCR assay.
88895446|NCT05169359|Other|Intervention|The study is a type 2 hybrid Effectiveness Implementation trial. The study uses a stepped wedge design. Patients are in a usual care phase until their clinic begins active implementation. Once active implementation begins, patients will view the Speak Up! Video intervention prior to their visit. The 10-minute video program will be provided to patients for viewing on an iPad (or other modality such as a portable DVD player, computer, or TV as appropriate to the site based on PDSA activities during implementation planning).
88895447|NCT05168618|Experimental|Treatment (cabozantinib, atezolizumab)|Patients receive cabozantinib PO QD on days 1-21 and atezolizumab IV over 30-60 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
88895448|NCT05166512|Active Comparator|Standard DPP|Standard DPP (over 12 months)
88895449|NCT05166512|Experimental|DPP Cooks|Standard DPP plus DPP Cooks (over 12 months, with 6 active cooking sessions during the first 4 months)
88895450|NCT05143255|Experimental|KNOW Intervention|
88895451|NCT05138380|Experimental|Foot orthoses|
88895452|NCT05138380|Sham Comparator|Flat shoe insert|
89417578|NCT02756832||Alogliptin Benzoate|Participants with diabetes mellitus type 2 (T2DM) who received alogliptin benzoate tablets, orally, as prescribed by physician according to Russian summary of product characteristics (SmPC) were observed for approximately 6 months.
88895454|NCT05131113|No Intervention|Control group|The control group will receive the usual care and hygiene recommendations of the movement
88895455|NCT05131113|Experimental|Interventionist group|The interventional group will add an individualized physical exercise program to the usual care.
88895456|NCT05122988||age 18|target sample 2500
89193545|NCT04691206|Other|standardized step-wise operative curriculum|"General surgery residents at Mayo Clinic will complete surveys measuring resident autonomy, performance, confidence and case complexity at baseline and postoperatively following laparoscopic cholecystectomy to serve as a pre-intervention baseline.~A standardized step-wise operative curriculum will then be implemented Residents will follow and graduate through this curriculum by initiating a perioperative model of briefing objectives, intraoperative teaching, and debriefing feedback (BID). The effectiveness of the intervention will then be measured by comparing survey results pre and post intervention."
88895457|NCT05122988||age 19|target sample 626
88895458|NCT05122988||age 20|target sample 626
88895459|NCT05122988||age 21|target sample 1250
88895460|NCT05120375|Experimental|A/ Accelerated titration|1mg of BAT6021
88895461|NCT05120375|Experimental|B/ Accelerated titration|3mg of BAT6021
88895462|NCT05120375|Experimental|C/ Accelerated titration|10mg of BAT6021
88895463|NCT05120375|Experimental|"D/standard 3 + 3"|30mg of BAT6021
88895464|NCT05120375|Experimental|"E/standard 3 + 3"|100mg of BAT6021
88895465|NCT05120375|Experimental|"F/standard 3 + 3"|300mg of BAT6021
88895466|NCT05120375|Experimental|"G/standard 3 + 3"|600mg of BAT6021
88895467|NCT05120375|Experimental|"H/standard 3 + 3"|900mg of BAT6021
88895468|NCT05117788||TB suspects|"Sputum specimens will be collected from TB suspects enrolled in the study. The specimens will be tested with~Bioneer Accupower Q-FRIA assay using the Iron q-PCR instrument (investigational product)~Xpert MTB/RIF Ultra and Xpert MTB/XDR (comparators products)"
88895469|NCT05115695|Active Comparator|PNF/Interventional|Upper extremity and scapular patern of PNF exercise approach will be applied to the first group for 6 weeks, 3 days a week, 30 minutes a day.
88895470|NCT05115695|Experimental|NDT/Experimental|Upper extremity strengthening exercises consisting of Neurodevelopmental Therapy (NGT-Bobath) approaches will be applied to the second group for 45 minutes, 3 days a week for 6 weeks.
88895471|NCT05104866|Experimental|Dato-DXd|Arm 1: Dato-DXd
88895472|NCT05104866|Active Comparator|Investigators Choice of Chemotherapy (ICC)|"Arm 2: ICC~Capecitabine~Gemcitabine~Eribulin mesylate~Vinorelbine"
88895473|NCT05098769||Acute pulmonary embolism|an age of ≥ 18 years and a PE diagnosis based on CT pulmonary angiography
88895474|NCT05089409|Experimental|A (ATB1651, 2 mg/mL)|"The planned ATB1651 dose level of 2 mg/mL.~Six participants are expected to be enrolled in each arm."
88895475|NCT05089409|Experimental|B (ATB1651, 5 mg/mL)|"The planned ATB1651 dose level of 5 mg/mL.~Six participants are expected to be enrolled in each arm."
88895476|NCT05089409|Experimental|C (ATB1651, 10 mg/mL)|"The planned ATB1651 dose level of 10 mg/mL.~Six participants are expected to be enrolled in each arm."
88895477|NCT05089409|Experimental|D (ATB1651, 20 mg/mL)|"The planned ATB1651 dose level of 20 mg/mL.~Six participants are expected to be enrolled in each arm."
89417579|NCT05728216||NEPHROCT cohort|Patients > 18 years of age with suspected acute kidney injury or chronic kidney disease requiring biopsy in the nephrology department
88895478|NCT05089409|Placebo Comparator|E (ATB1651, 30 mg/mL)|"The planned ATB1651 dose level of 30 mg/mL.~Six participants are expected to be enrolled in each arm."
88895479|NCT05089409|Placebo Comparator|F (placebo)|"The participants will apply placebo for 28 days.~Six participants are expected to be enrolled in each arm."
88895480|NCT05086796|Active Comparator|Substance Use Treatment and Recovery Team (START)|The intervention is administered to participants in this arm. Participants in this arm will work with the Substance Use Treatment and Recovery Team (START), a collaborative care team for inpatients with opioid use disorder.
89193546|NCT04675164|Active Comparator|LAISS group|Viable immotile testicular sperms will be selected before ICSI using laser assisted immotile sperm selection (study group).
89193547|NCT04675164|Active Comparator|HOST group|Viable immotile testicular sperms will be selected before ICSI using hypo-osmotic swelling test (control group).
89417580|NCT04449406||Individuals at risk of developing PDAC|"Symptomatic participants (via direct recruitment to UroPanc and via study/tissue bank(s) i.e. UCL ADEPTs study)~Asymptomatic participants (via study/tissue bank(s) i.e. University of Liverpool EUROPAC registry)~Medical history, demographic information and concomitant medications information will be collected at baseline, together with blood and urine samples. Urinary biomarkers and plasma CA19-9 will be measured and the results compared with imaging data (and pathology, if it becomes available)."
89417581|NCT00108810|Experimental|Transdermal Ketoprofen Patch with CHADD|
89417582|NCT00108810|Placebo Comparator|Placebo patch and a dummy heating unit|
88895481|NCT05086796|No Intervention|Usual Care|Usual care for people with opioid use disorder.
88895482|NCT05085574|Experimental|Group 1 (Study Product)|Subjects will receive 80 mg famotidine (PO) QID and 400 mg celecoxib as a first dose, followed by 200 mg (PO) BID celecoxib, for 5 days. Following this 5-day period, subjects will continue their famotidine treatment for an additional 9 days.
88895483|NCT05085574|Placebo Comparator|Group 2 (Reference Therapy)|Subjects will receive matching placebos QID and BID, for 5 days. Following this 5-day period, subjects will continue to receive matching famotidine placebo, QID, for an additional 9 days.
88895484|NCT05084729||Imagio OA/US|Imagio optoacoustic
88895485|NCT05084248|Active Comparator|Low-dose|400 IU Per Orem
88895486|NCT05084248|Experimental|High-dose|4000 IU Per Orem
88895487|NCT05081687|Experimental|Total neoadjuvant therapy (TNT)|"4 cycles of mFOLFIRINOX every 14 days:~Oxaliplatin 85 mg/m2~Irinotecan 150mg/m2~5-FU 2.400mg/m2~Dexamethasone 12mg~Atropine 0.5mg~Netupitant/palonosetron"
88895488|NCT05081687|No Intervention|Standard of care|Standard post-radiation care
88895489|NCT05081674|Active Comparator|ALK-translocated|"st line Alectinib~nd line Carboplatin pemetrexed~rd line Docetaxel"
88895490|NCT05081674|Active Comparator|EGFR-mutant|"st line Erlotinib~nd line Carboplatin pemetrexed~rd line Docetaxel"
88895491|NCT05081674|Active Comparator|PD-L1 >= 50%|"st line Pembrolizumab~nd line Carboplatin pemetrexed~rd line Docetaxel"
88895492|NCT05081674|Active Comparator|PD-L1< 50%|"st line Carboplatin pemetrexed~nd line nivolumab~rd line Docetaxel"
89193548|NCT04667663|Experimental|CPD-DARA|"Drug: Daratumumab Other Name: Darzalex~Drug: Cyclophosphamide~Drug: Pomalidomide Other Name: Pomalyst/ Imnovid~Drug: Dexamethasone"
89417583|NCT02172612|Experimental|Arm 1 - Intervention|Those included in the intervention group will undergo an educational session with the study pharmacist and one of the licensed prescribers from Sanders-Brown to discuss recommended changes in their treatment plan. If changes in medications are indicated by the pharmacist-prescriber team, and accepted by the patient, new prescriptions will be provided and a letter will be sent to the primary care physicians detailing the changes made and the rationale behind such changes.
89417584|NCT02172612|No Intervention|Arm 2 - Control|Those included in the control group will receive a generic brochure about medication safety and inappropriate medication use in the elderly.
89417585|NCT03067402|Other|Observation|Patient receives standard observation, i.e. only do a nuclear imaging stress test if symptoms present themselves over the course of 3 years.
88895493|NCT05077332|Experimental|Group 1 (Study Product)|Participants will receive 80 mg famotidine (PO) QID and 400 mg celecoxib as a first dose, followed by 200 mg (PO) BID celecoxib, for 5 days. Following this 5-day period, participants will continue their famotidine treatment for an additional 9 days.
88895494|NCT05077332|Placebo Comparator|Group 2 (Reference Therapy)|Participants will receive matching placebos QID and BID, for 5 days. Following this 5-day period, subjects will continue to receive matching famotidine placebo, QID, for an additional 9 days.
88895495|NCT05076006|Placebo Comparator|Placebo|Tablets without active ingredients
88895496|NCT05076006|Experimental|PF-06700841|tablets containing active drug (a combined TYK/JAK inhibitor)
88895497|NCT05073484|Experimental|10 mg of BAT6021|BAT6021 100mg/vial，10mg Ⅳ infusions
88895498|NCT05073484|Experimental|30 mg of BAT6021|BAT6021 100mg/vial，30mg Ⅳ infusions
89193549|NCT04657354|Active Comparator|Fast track|Study subjects in Fast Track arm will get an MRI done on the same day. If the MRI shows concordant findings of herniated disc, the subject will be referred to a spine surgeon to be seen within one week. If the surgeon and subject decide on discectomy, the surgery is scheduled within the same week. Total timespan from first interview to surgery will be no longer than 2 weeks.
89417586|NCT03067402|Experimental|Nuclear Perfusion Imaging Stress Test|Patient receives routine nuclear image perfusion stress test
88895499|NCT05073484|Experimental|100 mg of BAT6021|BAT6021 100mg/vial，100mg Ⅳ infusions
89417587|NCT00106080|Experimental|Intervention|Audit and Feedback
89417588|NCT00106080|No Intervention|Control|Usual care
89417589|NCT02177214||ventral hernia|Adult patients scheduled for elective laparoscopic repair of ventral hernia, with inclusion of primary and incisional hernias. Visualization of the mesh surface observed with MRI scan at 3 weeks and 13 months after ventral hernia repair with a visible IPOM prosthesis (Dynamesh®)
89417590|NCT05588284|Experimental|Pharmacomechanical Catheter-directed Thrombolysis for acute DVT|AngioJet, Boston Scientific
89417591|NCT05588284|Placebo Comparator|anticoagulation alone for acute DVT|anticoagulation alone for acute DVT
89417592|NCT02256150|Experimental|Mizoribine (MZR)|Oral administration, daily dose of 150mg (50mg/tablet, t.i.d) All study subjects will receive standard steroid therapies during the study.
89417593|NCT02256150|Active Comparator|Cyclophosphamide (CTX)|"Intravenous injection with between 0.5 to 1.0 g/m2 body surface area each time (the maximum dose is 1.0 g/day each time).~All study subjects will receive standard steroid therapies during the study."
89417594|NCT02179320|Active Comparator|Dry needling|Dry needling for myofascial pain syndrome, in the trapezius muscle.
88895500|NCT05073484|Experimental|300 mg of BAT6021|BAT6021 100mg/vial，300mg Ⅳ infusions
88895501|NCT05073484|Experimental|600 mg of BAT6021|BAT6021 100mg/vial，600mg Ⅳ infusions
88895502|NCT05073484|Experimental|900 mg of BAT6021|BAT6021 100mg/vial，900mg Ⅳ infusions
88895503|NCT05073484|Experimental|100mg BAT6021+300mg BAT1308|BAT6021 100mg/vial，BAT1308 100mg/vial ; BAT6021 100mg+BAT1308 300mg Ⅳ infusions
88895504|NCT05073484|Experimental|300mg BAT6021+300mg BAT1308|BAT6021 100mg/vial，BAT1308 100mg/vial ; BAT6021 300mg+BAT1308 300mg Ⅳ infusions
88895505|NCT05073484|Experimental|600mg BAT6021+300mg BAT1308|BAT6021 100mg/vial，BAT1308 100mg/vial ; BAT6021 600mg+BAT1308 300mg Ⅳ infusions
88895506|NCT05073224|Experimental|Postpartum|Participants who are six months postpartum will complete 2 experimental sessions, separated by 7-10 days. Participants will complete multiple questionnaires, maximal voluntary contractions of the lower extremity muscles, clinical tests of lumbopelvic neuromuscular control/posterior pelvic pain provocation, and fatiguing lower extremity/trunk muscle exercise. Ultrasound imaging will be performed to measure inter-recti distance. Wireless Electromyography (EMG) sensors will be used to record EMG and limb steadiness (via Inertial Measurement Units (IMU). Physical activity will be measured by questionnaire and accelerometer.
88895507|NCT05073224|Active Comparator|Nulligravid|Participants who have never been pregnant will complete 2 experimental sessions, separated by 7-10 days. Participants will complete multiple questionnaires, maximal voluntary contractions of the lower extremity muscles, clinical tests of lumbopelvic neuromuscular control/posterior pelvic pain provocation, and fatiguing lower extremity/trunk muscle exercise. Ultrasound imaging will be performed to measure inter-recti distance. Wireless EMG sensors will be used to record EMG and limb steadiness (via IMUs). Physical activity will be measured by questionnaire and accelerometer.
88895508|NCT05067998||IV Vitamin Therapy Treatments|IV vitamin infusion therapy involves inserting an IV line into a vein in your arm to administer a high concentration of liquid vitamins, antioxidants, amino acids, and minerals into your bloodstream. The therapy may be for only one vitamin or a cocktail of nutrients.
89006265|NCT04639882|Experimental|Control-InPerson-$0|"In this condition, Participants:~receive attention control feedback~complete the baseline and intervention procedure in the research lab~are compensated $0 for completing the baseline and intervention procedure"
89417595|NCT02179320|Sham Comparator|Sham needling|Superficial dry needling in the trapezius muscle
89417596|NCT02177370|Experimental|Fenoterol metered dose inhaler (MDI)|
89417597|NCT02177370|Active Comparator|DSCG MDI|
89417598|NCT03538080|Experimental|ACCUVEIN plus ultrasound|Patients referred for marking of saphenous veins before varicose vein surgery or for saphenectomy for vascular or coronary artery bypass grafting will have marking with Accuvein and ultrasound
89417599|NCT03538080|Sham Comparator|Ultrasound only|Patients referred for marking of saphenous veins before varicose vein surgery or for saphenectomy for vascular or coronary artery bypass grafting will have marking with ultrasound only.
89417600|NCT02030106||Prior Preterm Birth Patients|All obstetrical patients eligible for the study that have had a prior preterm birth.
89417601|NCT02030106||Term Birth Patients|All obstetrical patients eligible for the study that have not had a prior preterm birth.
89417602|NCT02172690|Experimental|Laparoscopic Staging|For Patients diagnosed as Locally Advanced Gastric Cancer(cT2+NanyM0)by CT and EUS, undergo laparoscopic staging.
89417603|NCT03538704|Experimental|BMI≥25 group with metformin|Patients with BMI≥25kg/m2 in the experimental group are treated with medroxyprogesterone acetate (MPA) 0.25g/d plus metformin and are followed-up of baseline data, hormone levels,
89417604|NCT03538704|No Intervention|BMI≥25 group without metformin|Patients with BMI≥25kg/m2 in the none intervention group are treated with MPA 0.25g/d alone and are followed-up of baseline data, hormone levels, and endometrial pathology every 3 months until 12 months.
89417605|NCT03538548|Experimental|Treatment|Participants receive a standard 12-week course of Cognitive Behavioral Therapy for Relapse Prevention (CBT-RP; Carroll, 1998). The treatment protocol will be implemented over 12 weeks, with two 1-hour sessions per week for the first two weeks and one 1-hour session per week thereafter (i.e., a total of 14 sessions).
89417606|NCT02633020|Experimental|AMG 714|Participants were administered 8 mg/kg AMG 714 via intravenous infusion on day 0, day 7 and every 2 weeks thereafter through week 10.
89417607|NCT02633020|Placebo Comparator|Placebo|Participants were administered placebo via intravenous infusion on day 0, day 7 and every 2 weeks thereafter through week 10.
89417608|NCT02172768|Experimental|alternate dosing|treatment for 8 days with intravenous micafungin twice weekly
89417609|NCT02172768|Active Comparator|daily dosing|micafungin daily for 8 days
88895509|NCT05067998||Herbal Medicine, Tincture (Liquid Vitamins)|Tinctures are concentrated herbal extracts made by soaking the bark, berries, leaves (dried or fresh), or roots from one or more plants in alcohol or vinegar. The alcohol or vinegar pulls out the active ingredients in the plant parts, concentrating them as a liquid. Examples of common herbal health products and supplements include black cohosh, echinacea, garlic, ginkgo, saw palmetto, and St. John's wort. Herbal Medicine is type of medicine that uses roots, stems, leaves, flowers, or seeds of plants to improve health, prevent disease, and treat illness.
88895510|NCT05067998||Supplements|Dietary supplements are substances you might use to add nutrients to your diet or to lower your risk of health problems such as osteoporosis or arthritis. Dietary supplements come in the form of pills, capsules, powders, gel capsules and tablets, extracts, or liquids. Dietary supplements come in a variety of forms, including tablets, capsules, gummies, and powders, as well as drinks and energy bars. Popular supplements include vitamins D and B12; minerals like calcium and iron; herbs such as echinacea and garlic; and products like glucosamine, probiotics, and fish oils.
88895511|NCT05067998||Vitamins (Orally)|Vitamins are substances that our bodies need to develop and function normally. They include vitamins A, C, D, E, and K, choline, and the B vitamins (thiamin, riboflavin, niacin, pantothenic acid, biotin, vitamin B6, vitamin B12, and folate/folic acid). Vitamins are essential nutrients that enable your body to work properly and to stay healthy. Most vitamins can be found in the food that we eat or from vitamin supplements.
88895512|NCT05062317|Experimental|ctDNA (Low Risk)|Will receive less intense chemotherapy, such as capecitabine or 5-fluorouracil.
88895513|NCT05062317|Experimental|ctDNA (High Risk)|Will receive more intense chemotherapy. This may include resuming the chemotherapy you received before surgery (for example, FOLFOX [5-fluorouracil, leucovorin and oxaliplatin] or FOLFIRI [5-fluorouracil, leucovorin and irinotecan] with or without bevacizumab)
88895514|NCT05055271||Delphi panel|The Delphi panel will include 10 international experts in sleep and respiratory medicine. Two panelists will serve as co-chairs and eight panelists will serve as section leads for the major topic areas throughout the process. A series of planning sessions will be conducted with the co-chairs and section leads prior to implementation of the survey.
88895515|NCT05055258|Experimental|300 mg KVD824|300 mg KVD824 twice a day for 12 weeks
88895516|NCT05055258|Experimental|600 mg KVD824|Two 300 mg KVD824 tablets twice a day for 12 weeks
88895517|NCT05055258|Experimental|900 mg KVD824|Three 300 mg KVD824 tablets twice a day for 12 weeks
89417610|NCT02172846|Experimental|Treatment (PBT, paclitaxel, and carboplatin)|"CHEMORADIATION THERAPY:~PBT daily 5 days a week over 3 weeks for a total of 15 fractions~Paclitaxel intravenously (IV) over 1 hour weekly for 3 weeks~Carboplatin intravenously (IV) over 30 minutes weekly for 3 weeks.~CONSOLIDATION CHEMOTHERAPY (B=beginning 4-6 weeks after completion of radiation therapy, patients may receive):~Paclitaxel IV over 1 hour on day 1~Carboplatin IV over 30 minutes on day 1~At the discretion of the treating physician~Treatment repeats every 3 weeks for 2 courses in the absence of disease progression or unacceptable toxicity."
89417611|NCT02172924|Active Comparator|Early Decidual Stromal Cells|Patients with therapy-refractory GVHD and on calcineurin inhibitor and high dose corticosteroids since no more than 7 days will be given Decidual Stromal Cell therapy.
89417612|NCT02172924|Active Comparator|Late Decidual Stromal Cells|Patients with therapy-refractory GVHD and on calcineurin inhibitor and high dose corticosteroids for longer than 7 days will be given Decidual Stromal Cell therapy.
89417613|NCT02173002|Active Comparator|Standard care|Standard care
89417614|NCT02173002|Experimental|myIBDcoach|myIBDcoach
88895518|NCT05055258|Placebo Comparator|Placebo to KVD824|One, two or three placebo tablets to be taken twice a day for 12 weeks
88895519|NCT05049577|Placebo Comparator|Control group|To maintain blinding, in the control group, the remifentanil infusion was replaced with 50 ml of normal saline in 50 ml syringe. The remifentanil (or saline) infusion was run until the pump indicated the target Ce had been achieved. Pharmacokinetic model for remifentanil was the Minto model (Height, Weight, and Age) Anesthesia in all patients was induced using 2 mg/kg of 2% propofol. The attending anesthesiologist asked the patients how they felt pain to evaluate pain severity of PIP while half -dose of propofol was administered. After the rest of the propofol was administered, the attending anesthesiologists asked the same question.
88895520|NCT05049577|Experimental|Remifentanil group|Remifentanil 1 mg was diluted into 50 ml of normal saline. A commercial TCI pump (Orchestra Base Primea, Fresenius Vial, France) was used for the effect-site TCI of remifentanil. The study groups received remifentanil to a target Ce of 4 ng/ ml. Pharmacokinetic model for remifentanil was the Minto model (Height, Weight, and Age) Anesthesia induction and the evaluation of pain were same as control group
88895521|NCT05048979|Experimental|Exercise|Prospective pre-post pilot study design. (N=54)
88895522|NCT05048979|No Intervention|No exercise|Prospective cohort study design. (N=100)
88895523|NCT05033821|Experimental|Intervention|Participants who receive the FOY+ImPACT intervention
88895524|NCT05033821|No Intervention|Control|Participants who receive standard library programing, but not the FOY+ImPACT intervention.
88895525|NCT05030675|Experimental|Treatment (fostamatinib)|Patients receive fostamatinib PO BID on days 1-28. Treatment repeats every 28 days for up to 6 cycles (week 24) in the absence of disease progression or unacceptable toxicity.
88895526|NCT05027490|Experimental|patients receiving CANUT support (guide + dietary interviews)|"Patients included in this arm will have following interventions :~CANUT support : patients will receive the CANUT guide (food guide) to help them deal with eating disorders encountered during their chemotherapy treatment ; the CANUT support includes calls from a dietician between chemotherapy cycles for support and advice.~anthropometric measures~Prehension strength measurement~food quality of life questionnaire (Qualité de Vie Alimentaire QVA)~Quality of Life Questionnaire Core 30 (QLQ C30)~Scratch & Snif Test~Taste Strip Test~Nutrition interview~24 H feed back questionnaire~condiment questionnaire~tobacco questionnaire"
89417615|NCT00106626|Experimental|1|vorinostat (Suberoylanilide Hydroxamic Acid [SAHA])
89417616|NCT02179476|Experimental|Glyder|Glyder Facet Restoration Device
89417617|NCT03538470|Experimental|Spa treatment|Mineral water cares in Contrexéville thermal cure center, massage, cataplasm.
89417618|NCT02179554||cardiopulmonary bypass|Patients undergoing elective surgery requiring cardiopulmonary bypass
88895527|NCT05027490|Active Comparator|patients not receiving canut support (guide + dietary interviews)|"Patients included in this arm will have following interventions :~anthropometric measures~Prehension strength measurement~food quality of life questionnaire (Qualité de Vie Alimentaire QVA)~Quality of Life Questionnaire Core 30 (QLQ C30)~Scratch & Snif Test~Taste Strip Test~Nutrition interview~24 H feed back questionnaire~condiment questionnaire~tobacco questionnaire"
88895528|NCT05017688|Other|Patient population|"The population of the study will be adult patients with GI-aGVHD grade III to IV undergoing MaaT013 treatment through named-patient use program ATUn (Early Access Program).~Blood and stool samples will be collected at each visit to analyse the gut microbiota and the immune cells."
89417619|NCT03537378|Experimental|Hybrid APC Therapy Group|1) Patients are diagnosed as early central lung neoplasms (severe dysplasia, carcinoma in situ, microinvasive carcinoma，mucoepidermoid carcinoma.etc.) by inquiry of the first doctor, CT test, endoscopy and histopathology. Patients who meet inclusion/exclusion criteria are not suitable for or refuse surgery.
89417620|NCT03538392||PAD|
89417621|NCT03538392||AV Fistula|
89417622|NCT03538392||AV Graft|
89417623|NCT02177448|Experimental|BIBR277 and placebo matching enalapril|
88895529|NCT05011890|Other|Single-arm|Participants will be assigned to the single-arm involving weekly monitoring of their patient-reported outcomes using Moovcare®.
88895530|NCT05005819|Experimental|[18F]APN-1607|Participants will receive an IV bolus injection of [18F]APN-1607, followed by PET brain imaging.
88895531|NCT04988282|Active Comparator|Steroid|"Methylprednisolone, oral, 0.5 mg/kg/day, 4 weeks; followed by a gradual reduction of 25% every 2 weeks.~Total Duration:12-16 weeks"
88895532|NCT04988282|Other|control|standard symptom-relief therapy (since there is no current standard therapy for post-COVID Interstitial Lung Disease, patients in this arm will be commenced symptom-relief therapies including bronchodilators, inhaled corticosteroids, non-steroid anti-inflammatories, cough relievers, and long-term oxygen if the patient has respiratory failure)
88895533|NCT04985513|No Intervention|Group N|Stopping ventilation during cardiopulmonary bypass
89417624|NCT02177448|Active Comparator|Enalapril and placebo matching BIBR277|
88895534|NCT04985513|Active Comparator|Group V|Ventilation was performed using an inhaled oxygen fraction of 20% and a tidal volume of 5ml/kg at the time of cardiopulmonary bypass.
88895535|NCT04983654|Experimental|Patients with limb ulcer|Patients with sickle cell disease and suffering from limb ulcer
88895536|NCT04983654|Experimental|Patients without limb ulcer|Patients with sickle cell disease without any limb ulcer
88895537|NCT04962932|Experimental|Internet-delivered exposure-focused CBT|Internet-delivered CBT over 10 weeks The CBT treatment lasts for 10 weeks and includes the following: Education on the role of anxiety on cardiac function and the effects of symptom preoccupation and avoidance QoL and depression in AF, creating a vicious cycle; exposure to physical sensations that are similar to AF symptoms (e.g.,palpitations due to physical activity or stress) to reduce fear of these symptoms; exposure to situations or activities previously avoided and abolishment of behaviors that aim to control symptoms; and behavioral activation aiming to increase social and physical activity and reduce depressive symptoms. Therapist support is provided at least once weekly through the platform developed for the purpose. Therapists are trained CBT-psychologists.
89006266|NCT04639882|Experimental|Control-InPerson-$30|"In this condition, Participants:~receive attention control feedback~complete the baseline and intervention procedure in the research lab~are compensated $30 for completing the baseline and intervention procedure"
89417625|NCT02177526|Other|Imaging - CT and MRI examinations|Abdominal and pelvic CT and pelvic MRI imaging will be performed in 30 patients.
89417626|NCT02179632|Experimental|Disclosure intervention zero|Treatment Group 1: This group will be directed to ProPublica's Dollars For Docs physician payment disclosure registry for State of Massachusetts, and be asked to search for Dr. A. Participants will be asked to complete a worksheet reporting the total dollar amount listed for Dr. A, according to manufacturer, in 2012. Dr. A will be a physician the researchers have chosen who does not appear on the website and therefore did not receive any payments in 2012. Participants should report $0/not listed as the response. Following this stage, participants will be told that Dr. A does not appear on the website and therefore did not receive any payments.
89417627|NCT02179632|Experimental|Disclosure intervention low|"Treatment Group 2: This group will be directed to ProPublica's Dollars For Docs physician payment disclosure registry for State of Massachusetts, and be asked to search for Dr. B. Participants will be asked to complete a worksheet reporting the total dollar amount listed for Dr. B, according to manufacturer, in 2012. Dr. B will be a physician the researchers have chosen who received an aggregate amount that is a low payment (below $100) in 2012. Participants should report the dollar amount listed as the response. Following this stage, participants will be told the exact dollar amount for payments received by Dr. B in 2012."
89417628|NCT02179632|Experimental|Disclosure intervention high|"Treatment Group 3: This group will be directed to ProPublica's Dollars For Docs physician payment disclosure registry for State of Massachusetts, and be asked to search for Dr. C. Participants will be asked to complete a worksheet reporting the total dollar amount listed for Dr. C, according to manufacturer, in 2012. Dr. C will be a physician the researchers have chosen who received an aggregate amount that is a high payment (above $250) in 2012. Participants should report the dollar amount listed as the response. Following this stage, participants will be told the exact dollar amount for payments received by Dr. C in 2012."
89417629|NCT02179632|No Intervention|Control group|Control Group: The control group will not be exposed to the disclosure website, but will participate in another online information-seeking task. These participants will visit the Farmer's Almanac website and be asked to search for temperature reports.
88895538|NCT04962932|Active Comparator|Internet-delivered stress management treatment|Stress management treatment for 10 weeks Participants randomized to The Stress Management Treatment will receive 10 weeks of stress managemen including relaxation technics, standard life style advice regarding physical activity, sleep and and standardized AF-information in line with current guidelines for AF. Therapist support is provided at least once weekly through the platform developed for the purpose. Therapists are trained CBT-psychologists.
89417630|NCT02177604|Experimental|Wingate HIT|7 days of high-fat overfeeding (50% excess calories) in conjunction 3 supervised sessions of Wingate High-intensity Interval Training.
89417631|NCT02177604|Experimental|Modified HIT|7 days of high-fat overfeeding (50% excess calories) in conjunction with 3 supervised sessions of Modified High-Intensity Interval Training
88895539|NCT04962230|Experimental|Period 1|PF-07321332/ritonavir orally as a single dose
88895540|NCT04962230|Experimental|Period 2|Carbamazepine + PF-07321332/ritonavir orally.
88895541|NCT04947150|Experimental|LOCATION TRIGGERED MESSAGING|Weekly message is triggered when arriving at grocery store.
88895542|NCT04947150|Experimental|COACH MONITORING|Coaches view grocery purchases via web portal, send weekly messages about purchases they observe, and conduct three brief phone calls to discuss purchases.
89417632|NCT02177604|Active Comparator|No Exercise Control|7 days of high-fat overfeeding (50% excess calories) with no supervised exercise
89417633|NCT02173236|Experimental|platform-switched implants|platform-switched implants vs. platform-matched implants
88895543|NCT04947150|Experimental|BENEFITS OF CHANGE|Attend an extra workshop session and three phone calls to identify and reflect on benefits of dietary change. Content added to standard weekly messages about benefits of change.
89417634|NCT02173236|Active Comparator|platform-matched implants|platform-switched implants vs. platform-matched implants
89417635|NCT03537300|Experimental|experimental group|
89417636|NCT03537300|Active Comparator|control group|
89193550|NCT04657354|No Intervention|Usual care|"Study subjects in Usual Care will be treated following the Danish National Guidelines in which a conservative approach for the first 4-6 weeks with focus on pain relief by pain-relief medication, exercises and encouragement to resume normal activities as much as possible. Patients in this arm will be scheduled 2 and 4 week follow-up appointments as per national guidelines.~If the symptoms have not resolved after this period, then a referral to a multidisciplinary spine care department is made. However, if symptoms are still present at 8-12 weeks first then a referral for a spine surgeon assesment can be done."
89417637|NCT03537144|Active Comparator|Indomethacin|Indomethacin as drug to treat PDA.
88895544|NCT04947150|Experimental|HOUSEHOLD SUPPORT|An adult household member attends one workshop session and three phone calls with the index participant. This household member receives weekly text messages for 20 weeks about program goals and ways to support the index participant.
88895545|NCT04943445|Experimental|Treatment: Single Arm|"Induction chemo-immunotherapy:~Carboplatin AUC of 6, paclitaxel 175 mg/m2, and pembrolizumab 200 mg, i.v. on day 1, every 21 days for 3 cycles. Patients without disease progression will proceed to the concurrent radioimmunotherapy phase of the trial.~Concurrent radio-immunotherapy:~Radiation therapy given concurrently with pembrolizumab 200 mg i.v. on day 1, every 21 days for 3 cycles. Patients without disease progression will proceed to the consolidation immunotherapy phase of the trial.~Consolidation immunotherapy:~Pembrolizumab 200 mg i.v. on day 1, every 21 days for 11 doses."
88895546|NCT04939883|Experimental|Intervention Group|Patients allocated to the intervention group will receive carvedilol 6.25 mg twice daily, then increased to 12.5 mg twice daily, until maximum dose of 25 mg twice daily according to the patients' tolerance; The dosis increments will occur every 5 days. If after the increment the patient develops bradycardia or hypotension, the dose will be reduced to the maximum tolerated dose. Carvedilol will ideally be maintained for up to 30 days after the end of chemotherapy.
88895547|NCT04939883|Placebo Comparator|Control Group|Patients allocated to this group will receive placebo in a presumably staggered and progressive manner similar to the group intervention. The placebo will ideally be maintained for up to 30 days after the end of chemotherapy.
88895548|NCT04935528|Other|vaccined salaried staff (group 1)|"vaccined salaried staff group (Distinction between~Employees vaccinated with two doses of vaccine (2 Pfizer doses or 2 Astra doses or 1 Pfizer dose + 1 Astra dose) and never infected with SARS-CoV-2~And employees vaccinated with one dose of Pfizer or Astra vaccine and previously infected with SARS-CoV-2"
89417638|NCT03537144|Experimental|Acetaminophen|Acetaminophen as drug to treat PDA.
89417639|NCT02632786|Experimental|NEOD001|Study Drug given IV every 28 days at 24mg/kg
89417640|NCT02632786|Placebo Comparator|Placebo|Placebo
89417641|NCT02173314|Experimental|Treatment|
89417642|NCT02173314|No Intervention|Comparison|
89417643|NCT02173470|No Intervention|Control|Routine clinical care (which includes a conventional chest X-ray).
89417644|NCT02173470|Experimental|CT scan|Routine clinical care, which includes a chest x-ray, with an additional ultra low-dose non contrast enhanced chest CT with IR (performed preoperatively).
89417645|NCT02173626|Other|GSH Medical Staff|Volunteers from the Good Samaritan Hospital medical staff were included on a first come first serve basis
89417646|NCT03067012|Experimental|Oncometabolic reconstruction|Patients undergoing oncometablic surgery
89417647|NCT02177682|Experimental|Afuresertib|"Three subjects will be enrolled and given afuresertib 125 mg orally and monitored for toxicity. After completion of PK sampling in 3 days (Cycle 0), daily repeated dose of 125 mg will be given for 21 days (Cycle 1). If no DLT event is found after 21 days of repeated dosing, up to 6 subjects will be enrolled and given afuresertib 150 mg. If afuresertib 150 mg is assessed to be tolerable, up to 6 subjects can be enrolled and given afuresertib 200 mg. If afuresertib 200 mg is assessed to be intolerable, up to 6 subjects will be enrolled and given afuresertib 150mg or 175 mg. In any Dose levels, if DLT occurs in more than 2 subjects, that Dose level will be considered as intolerable."
89417648|NCT03066934||NIV Failure Group|NIV Failure Group consisted of children who failed their noninvasive ventilation session and required intubation or re-intubation
88895549|NCT04935528|Other|non vaccined salaried staff (group 2 - witnesses)|non vaccined salaried staff group wtih positive SARS-CoV-2
88895550|NCT04935528|Other|vaccined patients (group 3)|vaccined patient group
88895551|NCT04933695|Experimental|Sotorasib: 960 mg Daily|Participants with metastatic non-small cell lung cancer (NSCLC) with Kirsten rat sarcoma (KRAS) p.G12C mutation whose tumors express < 1% programmed death-ligand 1 (PD-L1) and/or serine/threonine kinase 11 (STK11) mutation in need of first line treatment will be administered sotorasib 960 mg daily. Participants will be stratified by known presence of STK11 mutation.
88895552|NCT04933695|Experimental|Sotorasib: 240 mg Daily|Participants with metastatic non-small cell lung cancer (NSCLC) with Kirsten rat sarcoma (KRAS) p.G12C mutation whose tumors express < 1% programmed death-ligand 1 (PD-L1) and/or serine/threonine kinase 11 (STK11) mutation in need of first line treatment will be administered sotorasib 240 mg daily. Participants will be stratified by known presence of STK11 mutation.
88895553|NCT04931732||Diagnosis|
88895554|NCT04931732||Relapse|
89417649|NCT03066934||NIV success group|Children who successfully managed their noninvasive ventilation therapy
89417650|NCT03065764|Other|Patients|For the first 3 patients, PET scans will be obtained at 1, 72 and 120 hours post tracer injection to determine the optimal scan time point and to perform biodistribution measurements and dosimetry. All subsequent 7 patients receive only 1 PET scan post-injection (i.e. two PET scans).
88895555|NCT04923126|Experimental|Phase I: Recurrent and/or progressive low-grade glioma without prior exposure to MEK inhibitors|Participants will receive mirdametinib at one of the dose levels twice daily days 1-28. For the first cycle of treatment, participants will take mirdametinib tablets dissolved in water. After the first cycle of treatment, participants may receive the medicine the same way (dissolved in water) or may receive capsules. Treatment repeats every 28 days for up to 26 cycles of treatment (24 months) in the absence of disease progression or unacceptable toxicity.
88895556|NCT04923126|Experimental|Phase 2, Cohort 1: Newly diagnosed and/or previously untreated (except surgery)|Participants will receive the RP2D of mirdametinib. Therapy will be administered in cycles of 28 days and may be continued for up to 24 months (26 cycles) in absence of disease progression or unacceptable toxicity.
88895557|NCT04923126|Experimental|Phase 2, Cohort 2: Recurrent and/or Progressive without prior exposure to MEK inhibitors|Participants will receive the RP2D of mirdametinib. Participants may take mirdametinib tablets dissolved in water, or receive capsules. Therapy will be administered in cycles of 28 days and may be continued for up to 24 months (26 cycles) in absence of disease progression or unacceptable toxicity.
88895558|NCT04923126|Experimental|Phase 2, Cohort 3a:|Participants with recurrent and/or progressive low-grade glioma who previously received ≥ 6 courses MEK inhibitor (including mirdametinib) and did not progress while on active MEKi therapy. Participants will receive the RP2D of mirdametinib. Participants with previous exposure to mirdametinib may receive a starting dose lower than the RP2D, depending on the dose they tolerated during their previous exposure. Participants may take mirdametinib tablets dissolved in water, or receive capsules. Therapy will be administered in cycles of 28 days and may be continued for up to 24 months (26 cycles) in absence of disease progression or unacceptable toxicity.
88895559|NCT04923126|Experimental|Phase 2, Cohort 3b:|Participants with recurrent and/or progressive low-grade glioma who previously received ≥ 6 courses MEK inhibitor (including mirdametinib) and did not progress while on active MEKi therapy. Participants will receive the RP2D of mirdametinib. Participants may take mirdametinib tablets dissolved in water, or receive capsules. Therapy will be administered in cycles of 28 days and may be continued for up to 24 months (26 cycles) in absence of disease progression or unacceptable toxicity.
88895560|NCT04920422||Metastatic colorectal cancer patients.|Medical history data of all patients with at least 1 treatment with regorafenib will be collected retrospectively.
88895561|NCT04919317|Placebo Comparator|Control|Control group patients received 29mL bupivacaine plus 1mL 0.9% saline. Like the experimental group, 20mL of the mixture was injected into the fascial plane between the pectoralis minor and the serratus anterior muscles at the level of the third rib, while the remaining 10mL of the mixture was then injected into the fascial plane between the pectoralis major and pectoralis minor muscles during the same needlestick.
88895562|NCT04919317|Experimental|Experimental|Experimental group patients received 29mL bupivacaine plus 1mL of 4mg/mL dexamethasone. Like the control group, 20mL of the mixture was injected into the fascial plane between the pectoralis minor and the serratus anterior muscles at the level of the third rib, while the remaining 10mL of the mixture was then injected into the fascial plane between the pectoralis major and pectoralis minor muscles during the same needlestick.
89006267|NCT04639882|Experimental|PNF-Remote-$0|"In this condition, Participants:~receive personalized normative feedback~complete the baseline and intervention procedure remotely~are compensated $0 for completing the baseline and intervention procedure"
89417651|NCT02755818||control|heparin at 50unit/kg of body weight having glomerular filtration rate (GFR) of greater than 60
89417652|NCT02755818||chronic renal disease (CKD3b)|heparin at 50unit/kg of body weight having glomerular filtration rate (GFR) of 30-45
89417653|NCT02755818||chronic renal disease (CKD4)|heparin at 50unit/kg of body weight having glomerular filtration rate (GFR) of 15-30
89417654|NCT02755818||chronic renal disease (CKD5)|heparin at 50unit/kg of body weight having glomerular filtration rate (GFR) of less than 15, or on hemodialysis
89417655|NCT02177760|Experimental|Sirolimus|Sirolimus (0.05 mg/kg/day) day -5 for aGVHD prophylaxis through day +100 or until T-regulatory cells >9% of CD4 effector cells; whichever comes first.
89417656|NCT02179710||Motivational Interviewing|Review of adherence dashboard by the investigator with the patient to facilitate and engage intrinsic motivation within the client in order to change behavior.
89417657|NCT02173782|Experimental|Berodual® Respimat ® high dose|
89417658|NCT02173782|Active Comparator|Berodual® MDI|
89417659|NCT02173782|Experimental|Berodual® Respimat® low dose|
89417660|NCT02173782|Placebo Comparator|Placebo|
89417661|NCT02179866|Experimental|[14C]-labeled RO5285119|Single oral dose - drinking solution
88895563|NCT04915248|Experimental|All patients registered in the DALYA trial|"Treatment consists of an induction phase (every 21 days) planning one course (cycle 1) of daratumumab as single agent followed by 8 courses (cycles 2-9) of daratumumab in combination with bortezomib and dexamethasone (DVd regimen).~Patients achieving at least a SD after induction will be addressed to the maintenance phase (every 28 days), planning a maximum of 6 cycles (cycles 10-15) of daratumumab as single agent until disease progression, unacceptable toxicity, withdrawal of consent and/or the investigator decision."
88895564|NCT04910841|Experimental|Connect|
89417662|NCT05719948|Active Comparator|Flouroscopic guidance cervical medial branch continous RF ablation|"After the patient lying prone we obtaining the posterior approach with PA view then lateral 15 degrees the C shaped edge of the cervical vertebrae were appeared and then we advance the needle till reaching this C shaped till hitting the bone then slipping the active tip slightly therafter we obtaining lateral view to determine the depth of the needle over the cervical pedicle.~patients in the continous radiofrequency group will be underwent continous radiofrequency at 80°C for 90 seconds for 2 cycles"
88895565|NCT04905706||3D laparoscopic adrenalectomy|Operations are done with an high definition 3D laparoscopic system (Olympus, Tokyo, Japan); all personnel wear polarized glasses to achieve stereoscopic imaging in the operating room. Dissection is realized using a hybrid energy system (Thunderbeat, Olympus Europe Se & Co, Hamburg, Germany).
89417663|NCT05719948|Active Comparator|Flouroscopic guidance cervical medial branch combined pulsed and continous RF ablation|"After the patient lying prone we obtaining the posterior approach with PA view then lateral 15 degrees the C shaped edge of the cervical vertebrae were appeared and then we advance the needle till reaching this C shaped till hitting the bone then slipping the active tip slightly therafter we obtaining lateral view to determine the depth of the needle over the cervical pedicle.~patients in the continous and pulsed group will be underwent continous and pulsed radiofrequency at 80°C for 90 seconds for 1 cycle followed by pulsed radiofrequency at 42°C for 120 seconds for 1 cycle"
89417664|NCT02030262|Experimental|Air|The participant will undergo epiretinal membrane peeling with fluid-air exchange. The remaining of the surgery is the same in all arms.
89417665|NCT02030262|Active Comparator|Sulfur hexafluoride (SF6)|The participant will undergo epiretinal membrane peeling with fluid-SF6 exchange. The remaining of the surgery will stay the same.
89417666|NCT02177916|Experimental|Traditional teaching|
89417667|NCT02177916|Experimental|DVD|
89417668|NCT02179944||Participants|
89417669|NCT03537846||Osteoporosis and women|Patient women over thirty years old
89417670|NCT02173860|Active Comparator|FFR-guided revascularization|Patients with valvular heart disease scheduled for elective cardiac surgery and concomitant significant coronary artery disease will have FFR measured with a St. Jude Medical coronary pressure wire across all lesions in vessels pre-specified as suitable for surgical revascularization. If the FFR is ≤0.80, then CABG will be performed. If the FFR is >0.80 then no graft will be placed in that particular vessel. Patients in whom FFR of a particular lesion is not possible can be included if at least one additional lesion is suitable for FFR measurement and grafting.
89417671|NCT02173860|Active Comparator|Angio-guided revascularization|Concomitant CABG will be performed as per clinical routine in all vessels with at least one stenosis > 50%. The vessel should be pre-specified as suitable for surgical revascularization before randomization. An internal mammary graft to the LAD should be attempted in all cases, if possible. Further revascularization strategy is left to the discretion of each center.
89417672|NCT04210336|Experimental|PAPILOCARE|"Randomized patients will receive two different guidelines depending on the time of randomization:~Guideline A (from patient 1 to 100 in order of randomization): guideline of 1 cannula per day x 21 days + 7 days rest during the 1st month + 1 cannula / alternate days until completing 6 months (except for menstruation days ).~Guideline B (from patient 101 to 200 in order of randomization): pattern of 1 cannula per day x 21 days + 7 days rest for 3 months + 1 cannula / alternate days until completing 6 months (except for menstruation days) ."
88895566|NCT04902326|Active Comparator|Enhanced Usual Care (EUC)|Receives one intervention: automated educational text messages
88895567|NCT04902326|Experimental|Financial Incentives|Receives two interventions: automated educational text messages and financial incentives.
88895568|NCT04902326|Experimental|Tailored Messages|Receives two interventions: autonomy-supportive automated educational text messages and tailored text messages.
89193551|NCT04655573||Patient Derived Micro-Organospheres (PDMO)|Subjects will undergo image-guided biopsy as a standard of care clinical biopsy from which extra tissue is taken for research purposes. Following the biopsy, a PDMO will be generated and they will receive a chemotherapy regimen as determined by their treating physician. PDMO are successfully generated, and the patient begins treatment with a hemotherapy backbone. A patient will be considered evaluable if pathology results are available from the biopsy.
88895569|NCT04902326|Experimental|Combo Arm-Financial Incentives Plus Tailored Messages Arm|Receives three interventions: autonomy-supportive automated educational text messages, tailored text messages, and financial incentives.
88895570|NCT04901494||SSRI for at least one year prior to the diagnosis of MCI|subjects with an initial diagnosis of MCI who were treated with an SSRI for at least one year prior to the diagnosis of MCI
88895571|NCT04901494||SSRI at the time of diagnosis and treated with it for at least 6 months after the diagnosis of MCI|SSRI at the time of diagnosis and treated with it for at least 6 months after the diagnosis of MCI
88895572|NCT04901494||Subjects without SSRI use|Subjects without SSRI use
88895573|NCT04892199|Active Comparator|Semaglutide injection once-weekly|
88895574|NCT04892199|Placebo Comparator|Semaglutide-Placebo injection once-weekly|
88895575|NCT04888702|Experimental|SMA patients|Patients with type 2 or 3 spinal muscular atrophy undergoing Spinraza° or risdiplam treatment.
89193552|NCT04653948||Cohort Study|Women greater than or equal (≥) to 18 years of age and emancipated minors aged between 14 and 17 years of age seeking antenatal care at Kawempe National Referral Hospital in their first and second trimesters of pregnancy will be invited to participate in the study until a sample size of at least 4000 women is achieved. They will be followed-up along with their liveborn infants until a minimum of 14 weeks post-delivery.
89193553|NCT04653948||EMR Cohort|Anonymised data from the entire maternal and infant population that attend Kawempe Hospital for antenatal and/or delivery +/- post-partum care during the two-year study period will be analysed to describe maternal, obstetric and neonatal outcomes.
88895576|NCT04888689|Experimental|MS patients|Ambulant patients with multiple sclerosis
88895577|NCT04887129|Experimental|Students and staff at Mary Cariola Center|All students enrolled at the Mary Cariola Center in Rochester, NY. All staff working at the Mary Cariola Center in Rochester, NY.
88895578|NCT04882891|Experimental|MS patients|Ambulant patients with multiple sclerosis
88895579|NCT04876456|Experimental|Cabozantinib|Patients will be treated with Cabozantinib 60mg orally daily continuously until disease progression, unacceptable toxicity, or trial closure.
88895580|NCT04871594|Experimental|Nivolumab monotherapy|Day 1: nivolumab 240 mg Day 22: nivolumab 240 mg Day 43: nivolumab 240 mg
88895581|NCT04866147||Surgery patients|Patients who undergo various common surgical procedures
89193554|NCT04652076|Other|Arm A: Standard Chemotherapy alone (Paclitaxel + Carboplatin)|Standard Chemotherapy will be adminitred in 2 independant cohorts: Endometrial carcinoma or Cervix Carcinoma
89193555|NCT04652076|Other|Arm B: Experimental double combination [Standard Chemotherapy +NP137]|Experimental double combination [Standard Chemotherapy +NP137] will be administred in 2 independant cohorts: Endometrial carcinoma or Cervix Carcinoma
89193556|NCT04652076|Other|Arm C: Experimental double combination [Pembrolizumab +NP137]|Experimental double combination [Pembrolizumab +NP137] will be administred in 2 independant cohorts: Endometrial carcinoma or Cervix Carcinoma
89193557|NCT04652076|Other|Arm D: Experimental triple therapeutical combination [Pembrolizumab+ Standard Chemotherapy + NP137]|Experimental triple combination [Pembrolizumab+ Standard Chemotherapy + NP137] will be administred in 2 independant cohorts: Endometrial carcinoma or Cervix Carcinoma
89193558|NCT04640480|Experimental|Cohort 1|SNB-101 5/8mg/m2 Q2W IV
89193559|NCT04640480|Experimental|Cohort 2|SNB-101 10/16mg/m2 Q2W IV
89193560|NCT04640480|Experimental|Cohort 3|SNB-101 20/32mg/m2 Q2W IV
89417673|NCT04210336|Placebo Comparator|PLACEBO|"Randomized patients will receive two different guidelines depending on the time of randomization:~Guideline A (from patient 1 to 100 in order of randomization): guideline of 1 cannula per day x 21 days + 7 days rest during the 1st month + 1 cannula / alternate days until completing 6 months (except for menstruation days ).~Guideline B (from patient 101 to 200 in order of randomization): pattern of 1 cannula per day x 21 days + 7 days rest for 3 months + 1 cannula / alternate days until completing 6 months (except for menstruation days) ."
89417674|NCT02173938||Treatment seekers|
89417675|NCT02180022|Placebo Comparator|Placebo|Patients treated with placebo for 12 weeks
89417676|NCT02180022|Experimental|Onion peel extract|Patients treated with onion peel extract for 14 days
89417677|NCT05717374|Active Comparator|Group Dexamethasone|will receive 0.5 ml/kg volume (bupivacaine 0.25 % + dexamethasone 0.1mg/kg) for caudal block
89417678|NCT05717374|Experimental|Group Methylprednisolone|will receive 0.5 ml/kg volume (bupivacaine 0.25% + methylprednisolone 0.5mg/kg) for caudal block
89417679|NCT03537768|Active Comparator|UPA 30mg|
88895582|NCT04858867|Other|Cohort 1|"Study procedures~Lenvatinib during week 1-12~rhTSH-stimulated I-124 dosimetry at week 0, 6 and 12~rhTSH-stimulated I-131 therapy at week 13 (if eligible)~Intra-therapeutic I-131 dosimetry at week 13 (if eligible)~Biopsy at week 0 and 6~F-18 FDG PET/CT at week 0, 6, 12, 24 and 36~Tg levels at week 0, 6, 12, 24 and 36~QoL assessment at week 0, 6, 12, 24 and 36"
88895583|NCT04858867|Other|Cohort 2|"Study procedures (in case of 12-wk lenvatinib):~Lenvatinib during week 1-12~rhTSH-stimulated I-124 dosimetry at week 0 and 12~rhTSH-stimulated I-131 therapy at week 13 (if eligible)~Intra-therapeutic I-131 dosimetry at week 13 (if eligible)~Biopsy at week 0 and 6~F-18 FDG PET/CT at week 0, 12, 24 and 36~Tg levels at week 0, 6, 12, 24 and 36~QoL assessment at week 0, 6, 12, 24 and 36~Study procedures (in case of 6-wk lenvatinib)~Lenvatinib during week 1-6~rhTSH-stimulated I-124 dosimetry at week 0 and 6~rhTSH-stimulated I-131 therapy at week 13 (if eligible)~Intra-therapeutic I-131 dosimetry at week 13 (if eligible)~Biopsy at week 0 and 6~F-18 FDG PET/CT at week 0, 6, 12, 24, 30 and 36~Tg levels at week 0, 6, 12, 24, 30 and 36~QoL assessment at week 0, 6, 12, 24, 30 and 36"
88895584|NCT04852471|Active Comparator|Standard Post-Operative Counseling + FACT-G (Control Arm)|Patients will receive the standard postoperative counseling at discharge, discharge instructions, and the link to website with postoperative instructions. Patients will complete the Functional Assessment of Cancer Therapy - General (FACT-G).
88895585|NCT04852471|Experimental|Standard Post-Operative Counseling + PROM survey + FACT-G (Intervention Arm)|Patients will receive the standard postoperative counseling at discharge, discharge instructions, and the link to website with postoperative instructions. The intervention arm will receive and complete the Patient-Reported Outcome Measure (PROM) survey via the SMS text messaging service on a set schedule. Patients will complete the FACT-G.
88895586|NCT04848857|Experimental|Treatment Group|colchicine (0.5mg), one pill a day, oral intake
88895587|NCT04848857|Placebo Comparator|Control Group|placebo, one pill a day, oral intake
88895588|NCT04846556||venous thromboembolic event related to cancer|Patients admitted for a venous thromboembolic event related to their cancer will be included A data collection will be realized. Patients admitted between 2017 and 2019 at Saint-Etienne University Hospital, Louis-Mourier Hospital (AP-HP) and Amiens University Hospital.
88895589|NCT04826562|Experimental|dolutegravir/lamivudine|dolutegravir/lamivudine
88895590|NCT04823689|Sham Comparator|Dorsal decubitus|The dorsal decubitus reduction consists in placing the patient in the dorsal position and achieving reduction by traction maneuvers on the luxated upper limb. This maneuver generally requires procedural sedation. A mild traction of the traumatized limb in the axis is performed, with slight external rotation and progressive abduction. In the absence of reduction at this stage, this gesture is completed by a flexion adduction of the limb. A counterweight is then made by a rolled sheet and passed under the armpit of the patient.
88895591|NCT04823689|Experimental|Ventral decubitus|The ventral decubitus reduction consists in placing the patient in the ventral position. The luxated limb is positioned in pendulum and the line of contact with the stretcher must pass through the mid-clavicular line. The humeral head is brought to the scapula.
88895592|NCT04817540|Experimental|Single arm, Herzuma arm|
89006268|NCT04639882|Experimental|PNF-Remote-$30|"In this condition, Participants:~receive personalized normative feedback~complete the baseline and intervention procedure remotely~are compensated $30 for completing the baseline and intervention procedure"
89417680|NCT03537768|Active Comparator|LNG 1.5 mg|
89417681|NCT03537768|Active Comparator|LNG 3.0|
89417682|NCT02180256|Experimental|Endoscratching, non-RIF|Endometrial scratching. Women with no more than 1 previous unsuccessful embryo transfer. Pipelle in the first seven days of the menstrual cycle, just before starting controlled ovarian stimulation.
89193561|NCT04640480|Experimental|Cohort 4|SNB-101 30/48mg/m2 Q2W IV
89193562|NCT04640480|Experimental|Cohort 5|SNB-101 40/64mg/m2 Q2W IV
89417683|NCT02180256|No Intervention|Control, non-RIF|No intervention. Women with no more than 1 previous unsuccessful embryo transfer.
89417684|NCT02180256|Experimental|Endoscratching, RIF|Endometrial scratching. Women with 2 or more previous unsuccessful embryo transfers. Pipelle in the first seven days of the menstrual cycle, just before starting controlled ovarian stimulation.
89417685|NCT02180256|No Intervention|Control, RIF|No intervention. Women with 2 or more previous unsuccessful embryo transfers.
89417686|NCT02174094|Experimental|Clobazam|Clobazam - 1.0, 1.5 or 2.0 mg/kg/day (maximum 60 or 80 mg/day) twice daily (BID); Clobazam oral suspension 2.5 mg/mL, clobazam scored tablets 10 mg, orally
89417687|NCT02174094|Placebo Comparator|Placebo|Placebo to clobazam oral suspension 2.5 mg/mL and placebo to clobazam scored tablets 10 mg, orally
89417688|NCT02174172|Experimental|Arm A: Atezolizumab with Ipilimumab|Participants will receive atezolizumab along with ipilimumab.
89417689|NCT02174172|Experimental|Arm B: Atezolizumab with Interferon alfa-2b|Participants will receive atezolizumab along with Interferon alfa-2b.
89417690|NCT02174172|Experimental|Arm C: Atezolizumab with PEG- interferon alfa-2a|Participants will receive atezolizumab along with PEG- interferon alfa-2a.
89417691|NCT02174172|Experimental|Arm D:Atezolizumab with PEG-interferon alfa-2a and Bevacizumab|Participants will receive atezolizumab along with PEG- interferon alfa-2a and bevacizumab.
89193563|NCT04640480|Experimental|Cohort 6|SNB-101 45/72mg/m2 Q2W IV
89193564|NCT04640480|Experimental|Cohort 7|SNB-101 50/80mg/m2 Q2W IV
89417692|NCT02174172|Experimental|Arm E: Atezolizumab with Obinutuzumab|Participants will receive atezolizumab along with obinutuzumab or atezolizumab alone.
89417693|NCT02180334|Experimental|Mosapride|"Mosapride citrate 5 mg (Gasmotin®): 1 tablet (5 mg) will be administered 1 hour before MMTT.~Linagliptin 5 mg (Trajenta®): 1 tablet (5 mg) per day should be taken for 7 days during run-in period. 1 tablet (5 mg) will be administered 1 hour before MMTT.~Acetaminophen 500 mg (Tylenol®): 3 tablets (1500 mg) will be administered at once with the mixed meal for calculating gastric emptying time."
89417694|NCT02180334|Placebo Comparator|Control|"Placebo drug: 1 tablet will be administered 1 hour before MMTT.~Linagliptin 5 mg (Trajenta®): 1 tablet (5 mg) per day should be taken for 7 days during run-in period. 1 tablet (5 mg) will be administered 1 hour before MMTT.~Acetaminophen 500 mg (Tylenol®): 3 tablets (1500 mg) will be administered at once with the mixed meal for calculating gastric emptying time."
89417695|NCT03033745|Experimental|IgPro20 (Pump-Assisted Volume Cohort)|Weekly volumes per injection site of 25 mL up to 50 mL administered subcutaneously.
89417696|NCT03033745|Experimental|IgPro20 (Pump Assisted Flow Rate Cohort)|Weekly flow rates per injection site of 25 mL/hour up to 100 mL/hour administered subcutaneously.
89417697|NCT03033745|Experimental|IgPro20 (Manual Push Flow Rate Cohort)|Frequent (ie, 2 to 7 times per week) flow rates per injection site of 25 to 30 mL/hour up to 120 mL/hour (equivalent of approximately 0.5 mL/minute up to 2 mL/minute) administered subcutaneously.
89417698|NCT02174250|Experimental|Istradefylline 40mg|Period 1: Day 1, istradefylline 40mg then crossover to Period 2
89417699|NCT02174250|Experimental|Rifampin 300mg BID + istradefylline 40mg|Period 2: Days 1-20 rifampin 300mg BID + istradefylline 40mg Day 8 only
89417700|NCT01672294|Experimental|treatment|three facilitator-led end-of-life preparation and completion sessions with a facilitator with both patient and caregiver
89417701|NCT01672294|Active Comparator|attention control|three facilitator led sessions of listening to a relaxation CD.
89417702|NCT02174328|Experimental|acetylsalicylic acid|This group will receive 1 tablet of acetylsalicylic acid (100 mg) orally daily from 5-10 weeks gestation until the end of gestation, about week 36
89417703|NCT02174328|Placebo Comparator|Placebo|This group will receive 1 tablet of placebo orally each day from 5-10 weeks gestation until the end of gestation, about week 36
89417704|NCT02174484||Pacemaker recipients|Patients implanted with a single or dual pacemaker and with Home-Monitoring system activated and periodic IEGM activated
89417705|NCT02177994|Experimental|Group A ceftriaxone after cord clamping|"165 patients pregnant at 37weeks or more undergoing elective cesarean section randomly distributed to receive~1 gm. ceftriaxone via l intravenous infusion single dose after cord clamping."
89006269|NCT04639882|Experimental|PNF-Inperson-$0|"In this condition, Participants:~receive personalized normative feedback~complete the baseline and intervention procedure in the research lab~are compensated $0 for completing the baseline and intervention procedure"
89417706|NCT02177994|Active Comparator|Group B ceftriaxone before skin incision|"165 patients pregnant at 37weeks or more undergoing elective cesarean section randomly distributed to receive~1 gm. ceftriaxone vial intravenous infusion single dose 30-60 minutes before skin incision."
89417707|NCT02755116|Experimental|Olanzapine|10mg pill
89417708|NCT02755116|Placebo Comparator|Placebo|
89417709|NCT02178150|Active Comparator|Magnesium Oxide|magnesium tablets, 250 milligram magnesium, 8 weeks, every day 1 tablet
89417710|NCT02178150|Placebo Comparator|Placebo|Placebo tablets, the same in color, odor and appearance with magnesium tablets, 8 weeks, one tablet every day
89417711|NCT04411030|Experimental|Part 1|Oral administration of ASTX660 and itraconazole at specific time points.
89417712|NCT04411030|Experimental|Part 2|Oral administration of ASTX660 and midazolam at specific time points.
89417713|NCT03066856|Experimental|Intervention|After baseline examinations, participants are randomized to an active dietary intervention group.The intervention group is invited to attend six full days of life-style intervention activities over the next six months. These activities include six cookery courses followed by lunch, six physical activity sessions (walking for 45 minutes) and six conferences. The intervention and control groups both complete questionnaires on adherence to the Mediterranean diet (MEDAS) at baseline and at the end of the study, and are asked for at least two 24-hour recalls of the previous day's food intake, and details of their physical exercise during the six-month intervention.
89006270|NCT04639882|Experimental|PNF-Inperson-$30|"In this condition, Participants:~receive personalized normative feedback~complete the baseline and intervention procedure in the research lab~are compensated $30 for completing the baseline and intervention procedure"
89417714|NCT03066856|No Intervention|Control|All participants receive general recommendations for the dietary prevention of cancer. After baseline examinations, women randomized in the control group carry on following the baseline recommendations.
89417715|NCT02754492|Experimental|Single Platelet Product|Healthy adult volunteer blood donors that qualify for a single unit platelet collection will undergo plateletpheresis on the Trima Accel® Automated Blood Collection System (Trima Accel System with Version 7.0 Software). Concurrent plasma will be collected in 25% of the collections.
89006271|NCT00218816|Experimental|1|
89006272|NCT00218816|Other|2|
89006273|NCT04639804|Active Comparator|Tegoprazan 50 mg|Multiple doses of tegoprazan alone once daily (QD) for 7 days
89006274|NCT04639804|Active Comparator|NSAIDs|Multiple doses of NSAIDs alone twice daily (BID) for 7 days
89193565|NCT04637698|Experimental|Dose expansion|OH2 injection will be administered at 1E+07 CCID50/mL .
88895593|NCT04810884||Living kidney donors|"Aim 1: A survey about fractures and general bone health will be sent to 3000 prior living kidney donors.~Aim 2: Out of these 3000 subjects, 200 prior living kidney donors who are ≥10 years post kidney donation will be invited to Mayo Clinic Rochester for an assessment of bone health. Each subject will undergo lateral DXA with vertebral fracture assessment (VFA), bone density assessment of each hip, radius and spine by DXA scan, bone structure assessment by HRpQCT of the distal radius and tibia, finite element assessment (µFEA), skin AGEs measurement, and blood collection to measure markers of bone formation and resorption."
88895594|NCT04810884||Matched Controls|"Aim 1: A survey about fractures and general bone health will be sent to 3000 age, sex, race, and comorbidity-matched subjects who would have been eligible to donate but did not donate a kidney.~Aim 2: Out of these 3000 subjects, 200 control subjects who would be eligible to donate, but have not donated, and are matched by age, sex, race, and comorbidity to donors at the time of donation will be invited to Mayo Clinic Rochester for an assessment of bone health. Each subject will undergo lateral DXA with vertebral fracture assessment (VFA), bone density assessment of each hip, radius and spine by DXA scan, bone structure assessment by HRpQCT of the distal radius and tibia, finite element assessment (µFEA), skin AGEs measurement, and blood collection to measure markers of bone formation and resorption."
88895595|NCT04806165|Experimental|Repeated Administration|
88895596|NCT04806165|Experimental|Personalized Recommendation|
88895597|NCT04806165|Experimental|Motivational Interviewing|
88895598|NCT04806165|Experimental|Core Modules Only|
88895599|NCT04806165|Experimental|Motivational Interviewing, Personalized Recommendation, Repeated Administration|
88895600|NCT04806165|Experimental|Motivational Interviewing, Repeated Administration|
88895601|NCT04806165|Experimental|Motivational Interviewing, Personalized Recommendation|
88895602|NCT04806165|Experimental|Personalized Recommendation, Repeated Administration|
88895603|NCT04806165|Experimental|Psychoeducation|
88895604|NCT04806165|Experimental|Psychoeducation, Repeated Administration|
88895605|NCT04806165|Experimental|Psychoeducation, Personalized Recommendation|
88895606|NCT04806165|Experimental|Psychoeducation, Motivational Interviewing|
88895607|NCT04806165|Experimental|Psychoeducation, Motivational Interviewing, Personalized Recommendation|
88895608|NCT04806165|Experimental|Psychoeducation, Personalized Recommendation, Repeated Administration|
88895609|NCT04806165|Experimental|Psychoeducation, Motivational Interviewing, Repeated Administration|
88895610|NCT04806165|Experimental|Psychoeducation, Motivational Interviewing, Personalized Recommendation, Repeated Administration|
88895611|NCT04800783|Other|Swallowing disorders cohort|All included patients will undergo an ultrasound assessment of the oral and laryngeal structures involved in the swallowing process.
88895612|NCT04799899|Experimental|Virtual MBCT Intervention|Participants will participate in 8 weekly virtual group sessions of MBCT. Participants will be asked to complete a brief survey following each session. Within one week before and after the intervention and 3-months post-intervention participants will be asked to complete a series of questionnaires and provide self-collected blood samples. Upon completion of the intervention participants will complete an audio-or video recorded exit interview (approximately 30-60 minutes).
88895613|NCT04799899|Experimental|Virtual Health Enhancement Control|Participants will participate in 8 weekly virtual group sessions that focus on cardiac health and depression education. Participants will be asked to complete a brief survey following each session. Within one week before and after the intervention and 3-months post-intervention participants will be asked to complete a series of questionnaires and provide self-collected blood samples. Upon completion of the intervention participants will complete an audio-or video recorded exit interview (approximately 30-60 minutes).
88895614|NCT04795232|No Intervention|Control|Participants in this arm will receive no intervention
89193566|NCT04632758|Experimental|WX-0593 Tablets|Eligible patients with ALK+ NSCLC will receive WX-0593 tablets without food until documented disease progression or unacceptable toxicity. 60 mg of WX-0593 tablets, once daily for 7 days, followed by 180 mg of WX-0593 tablets, once daily in a 28-days cycle.
89193567|NCT04632758|Active Comparator|crizotinib|Eligible patients with ALK+ NSCLC will receive oral crizotinib at 250mg BID without food until documented disease progression or unacceptable toxicity.
89193568|NCT04629209|Experimental|Arm A: ONC201 with Surgical Resection in Glioblastoma|Patients must be eligible for salvage surgical resection as deemed by the site Investigator. ONC201 will be administered orally, twice a week (2 consecutive days on and 5 days off per week) schedule at a dose of 625mg.
89193569|NCT04629209|Experimental|Arm B: ONC201 in Glioblastoma|Unequivocal evidence of recurrence (progressive disease) on contrast-enhanced brain CT or MRI as defined by RANO criteria, or have documented recurrent glioma on diagnostic biopsy. ONC201 will be administered orally, twice a week (2 consecutive days on and 5 days off per week) schedule at a dose of 625mg.
89193570|NCT04627285|Experimental|Lacosamide|Subjects in this arm will receive various single doses of lacosamide
89193571|NCT04618315|Active Comparator|Audiology-Based Best Practice|Hearing aids will be fit using current best practices used by audiologists to fit hearing aids.
89193572|NCT04618315|Experimental|Consumer Decides|Hearing aids will be self fit by patients using an interactive application on a tablet computer. Patients will choose their preferred hearing aid settings after comparing four settings with varying loudness levels.
89193573|NCT04618315|Experimental|Efficient Fitting|Hearing aids will be self fit by patients using an interactive application on a tablet computer. Patients will choose their preferred hearing aid settings after comparing four settings with varying base and treble settings.
89193574|NCT04600362|Experimental|Dupilumab|Patients randomized to this arm will receive two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by single 300 mg injection of Dupilumab every 2 weeks (q2w) from week 2 to week 16.
89417716|NCT02754492|Experimental|Double Platelet Product|Healthy adult volunteer blood donors that qualify for a double unit platelet collection will undergo plateletpheresis on the Trima Accel® Automated Blood Collection System (Trima Accel System with Version 7.0 Software). Concurrent plasma will be collected in 25% of the collections.
88895615|NCT04795232|Experimental|COD45|Participants in this arm will participate in a COD training session consisted of 45 degrees changes of direction
89417717|NCT02754492|Experimental|Triple Platelet Product|Healthy adult volunteer blood donors that qualify for a triple unit platelet collection will undergo plateletpheresis on the Trima Accel® Automated Blood Collection System (Trima Accel System with Version 7.0 Software). Concurrent plasma will be collected in 25% of the collections
89417718|NCT04068688|Experimental|Caregiver-Child Dyads with ASD (Autism Spectrum Disorder)|Participants in this arm will be caregivers of and children with ASD.
89417719|NCT04068688|No Intervention|Children with typical development|Participants in this arm will be children with typical development.
88895616|NCT04795232|Experimental|COD90|Participants in this arm will participate in a COD training session consisted of 90 degrees changes of direction
88895617|NCT04789577|Active Comparator|FLU-Q-PAN H7N9 Formulation 1_B Group|Healthy male and female participants who received two doses of FLU-Q-PAN H7N9 Formulation 1 vaccine and AS03B adjuvant. Participants received the first dose at Day 1 and the second dose at Day 22.
88895618|NCT04789577|Active Comparator|FLU-Q-PAN H7N9 Formulation 1_A Group|Healthy male and female participants who received two doses of FLU-Q-PAN H7N9 Formulation 1 vaccine and AS03A adjuvant. Participants received the first dose at Day 1 and the second dose at Day 22.
88895619|NCT04789577|Active Comparator|FLU-Q-PAN H7N9 Formulation 2_B Group|Healthy male and female participants who received two doses of FLU-Q-PAN H7N9 Formulation 2 vaccine and AS03B adjuvant. Participants received the first dose at Day 1 and the second dose at Day 22.
88895620|NCT04789577|Active Comparator|FLU-Q-PAN H7N9 Formulation 2_A Group|Healthy male and female participants who received two doses of FLU-Q-PAN H7N9 Formulation 2 vaccine and AS03A adjuvant. Participants received the first dose at Day 1 and the second dose at Day 22.
88895621|NCT04789577|Active Comparator|FLU-Q-PAN H7N9 Formulation 3_B Group|Healthy male and female participants who received two doses of FLU-Q-PAN H7N9 Formulation 3 vaccine and AS03B adjuvant. Participants received the first dose at Day 1 and the second dose at Day 22.
88895622|NCT04789577|Active Comparator|FLU-Q-PAN H7N9 Formulation 3_A Group|Healthy male and female participants who received two doses of FLU-Q-PAN H7N9 Formulation 3 vaccine and AS03A adjuvant. Participants received the first dose at Day 1 and the second dose at Day 22.
88895623|NCT04789577|Placebo Comparator|Placebo Group|Healthy male and female participants who received two doses of placebo, the first dose at Day 1 and the second dose at Day 22.
88895624|NCT04772456|Experimental|metabolic MRI|Single-arm study in patients who have Glioma Perform metabolic magnetic resonance imaging on patient have a Glioma cancer to understand if metabolic MRI can be safely performed on this population
89417720|NCT04068688|No Intervention|Children with developmental delay|Participants in this arm will be children with developmental delay.
89417721|NCT04068688|Experimental|Caregiver-Child Dyads with ASD (Autism Spectrum Disorder) Telehealth Adaptation|Participants in this arm will be caregivers of and children with ASD receiving telehealth intervention (adaptation due to COVID-19 restrictions).
88895625|NCT04756609|Experimental|Systematic offer of nurse-driven SARS-CoV-2 screening + usual practice|Systematic offer of nurse-driven SARS-CoV-2 screening combined with usual practice
88895626|NCT04756609|Active Comparator|Control group: Usual emergency department practice|Usual emergency department practice with physician-directed diagnostic testing
88895627|NCT04749368|Experimental|Cohort A|Participants will receive BRII-835 (VIR-2218) for 32 weeks
88895628|NCT04749368|Experimental|Cohort B|Participants will receive BRII-835 (VIR-2218) and BRII-179 (VBI-2601) with IFN-α up to Week 40
88895629|NCT04749368|Experimental|Cohort C|Participant will receive BRII-835 (VIR-2218) and BRII-179 (VBI-2601) up to Week 40
88895630|NCT04737382|Other|Biopsy and blood|A histological core biopsy of a tumor lesion and a blood sample for ctDNA analysis will be collected
88895631|NCT04733183|Experimental|Arm1: DTIC + L19TNF|Patients will receive Dacarbazine (DTIC) on Day 1 and L19TNF on Days 1, 3 and 5 every 21 days.
88895632|NCT04733183|Active Comparator|Arm 2: DTIC|Patients will receive Dacarbazine (DTIC) on Day 1 every 21-day cycle .
88895633|NCT04732884|Experimental|Weight sensor with biofeedback|Activation of the feedback function of the weight-bearing sensor as mean to possibly enhance compliance to weight-bearing instructions postoperative.
89417722|NCT04068688|No Intervention|Early Childhood Development (ECD) Practitioners and ECD Practitioner School Supervisors|The ECD worker and/or school supervisor are 1) employed by our participating recruitment partners (Western Cape Education Department Schools) and 2) involved in delivery of the caregiver coaching sessions, either in person or remotely.
89417723|NCT04068688|No Intervention|Early Start Denver Model (ESDM) Supervisors|The local supervisors are 1) trained ESDM therapist, 2) supervise weekly coaching sessions in the schools, and/or 3) supervise remote intervention delivery sessions.
88895634|NCT04732884|Experimental|Weight sensor without biofeedback|Standard patient education considering postoperative weight-bearing parameters and measurement of actual weight-bearing with the sensor.
89417724|NCT02174640|Active Comparator|Coffee|Coffee Beverage
89417725|NCT02174640|Placebo Comparator|Water|Water
88895635|NCT04732624|Experimental|Enteral-based Protocolized Resuscitation|Administration of Enteral-based Resuscitation using Oral Rehydration Solution (ORS) either by mouth of via naso-enteric access for moderate sized burn injuries (20-40% TBSA) per resuscitation protocol for burn-injured patients. Resuscitation will be administered in the acute resuscitation phase of burn injury (24-72 hours post injury). Patients will receive supplemental Intravenous Fluid (IV Fluid) resuscitation using Lactated Ringer's solution as needed per protocol.
88895636|NCT04732624|Active Comparator|Intravenous Fluid Protocolized Resuscitation|Administration of Intravenous Fluid using Lactated Ringer's solution per standard of care resuscitation protocol for patients with moderate sized burn injuries (20-40% TBSA).
89417726|NCT04437654|Experimental|Anticoagulation group(Apixaban group)|Apixaban 5mg twice daily (2.5mg twice daily if meets dose-reduction criteria) for 2 years
88895637|NCT04722133|Experimental|HERZUMA+mFOLFOX|
88895638|NCT04702958||Torsemide|Patients enrolled in the TRANSFORM-HF study randomized to Torsemide, or patients prescribed Torsemide at hospital discharge
88895639|NCT04702958||Furosemide|Patients enrolled in the TRANSFORM-HF study randomized to Furosemide, or patients prescribed Furosemide at hospital discharge
89417727|NCT04437654|No Intervention|Nonanticoagulation group|Standard treatment except anticoagulant for 2 years
89417728|NCT05526508|Experimental|Rebound once-weekly|This group will undergo 12 weeks of rebound exercise training once weekly, for 30 minutes per session.
89417729|NCT05526508|Experimental|Rebound twice-weekly|This group will undergo 12 weeks of rebound exercise training twice weekly, for 30 minutes per session.
89417730|NCT02185638|Experimental|A20-50|"A20-50 (2 capsules). Each capsule contains:~Yerba Mate (Ilex paraguariensis), Guarana seed (Paullinia cupana), Magnesium Oxide , Caffeine , Damiana (Turnera microphylla), Green tea (Camellia sinensis), Ginger (Zingiber Officinale), Kola nut (Cola acuminate or nitida), Pyridoxine Hydrochloride, Tibetan Ginseng root (Rhodiola crenulata), Schisandra (Schisandra Chinensis), Jujube (Ziziphus Jujuba) , Cocoa nut (Theobroma cacao), Chinese Skullcap (Scutellaria Baicalensis), Black tea leaf (Thea sinensis), Rice flour (to fill)~Dose = 2 capsules have a total of 200 mg of caffeine"
89417731|NCT02185638|Active Comparator|YGD|"YGD blend (2 capsules). Each capsule contains:~Yerba Maté (leaf) , Guarana (seed) , Damiana (leaf) , Rice flour: to fill ,~The 2 capsules of the YGD blend contain about 40 mg xanthines (caffeine and caffeine-like stimulants)."
89417732|NCT02185638|Placebo Comparator|Placebo|"Placebo (2 capsules). Each capsule contains:~Rice Flour"
89417733|NCT02185716|Active Comparator|local infiltration|Group L (n=25) will be given total 30 ml 0.25 % levobupivacaine infiltration around trocar-site with injector in sterilized conditions without administering TAP block at the end of the operation
89417734|NCT02185716|No Intervention|Control|Only routine general anesthesia will be applied
89417735|NCT02185716|Experimental|TAP|Group T (n=25) will be given bilateral total 30 ml 0.25 % levobupivacaine administering TAP block under the guidance of ultrasound at the preoperative period.
89193575|NCT04600362|Placebo Comparator|Placebo|Patients randomized to this arm will receive identically matching doses of placebo. Two subcutaneous injections of placebo as a loading dose (to mimic the experimental Dupilumab arm) on Day 1 followed by a single injection q2w from Week 2 to Week 16.
89417736|NCT01671748|Active Comparator|Standard Care|Standard treatment for VLUs is administered once a week, i.e. compression bandaging and non-adherent dressing, with debridement if required.
88895640|NCT04701437|Experimental|Peer-enhanced intervention|Those randomized to the peer-enhanced intervention group will be contacted by a peer mentor within 72 hours of enrollment to discuss the early release period, readiness for HCV treatment, and identify ancillary needs. Individuals randomized to this arm will be provided a study cell phone.
88895641|NCT04701437|Placebo Comparator|Standard of care|If randomized to the standard of care intervention, the participant will only receive passive referral to HCV-care.
88895642|NCT04700046|Active Comparator|Mexiletine|Mexiletine 167 mg (equivalent to mexiletine HCl 200 mg)
89417737|NCT01671748|Experimental|MIST and Standard Care|MIST ultrasound therapy is applied for between 3 and 12 minutes (depending on wound size) 3 times a week in combination with standard treatment for VLUs of compression bandaging and non-adherent dressing change 3 times a week, with debridement as required.
88895643|NCT04700046|Placebo Comparator|Placebo|The placebo capsules contain the same ingredients as the active formulation with the exception of mexiletine
89417738|NCT02182050|Experimental|BIBF 1120 ES low dose|
88895644|NCT04687956|Experimental|LYMPHA|LYMPHA procedure is performed in which the lymphatic vessels drained from the arm and the axillary vein are micro-bonded to the side branches.
89193576|NCT04597658|Active Comparator|Conventional rehabilitation|
89417739|NCT02182050|Experimental|BIBF 1120 ES high dose|
89417740|NCT02182050|Placebo Comparator|Placebo|
88895645|NCT04687956|Active Comparator|Control|No LYMPHA procedure is performed
89193577|NCT04597658|Experimental|Body weightsupported treadmill training|
89417741|NCT02182128|Experimental|BIBF 1120|
89417742|NCT02182206|Experimental|BIBF 1120|
89417743|NCT02180490|Experimental|UHAC 62 XX tablet|
89417744|NCT02180490|Active Comparator|UHAC 62 XX capsule|
89417745|NCT02180568|Experimental|Lipiodol|Lipiodol-guided lung localization technique
89417746|NCT02180568|Active Comparator|Hookwire|Hookwire-guided lung localization technique
89417747|NCT02657889|Experimental|niraparib plus pembrolizumab|"Phase 1: Dose-escalation: ascending doses of niraparib up to 300mg/day orally (PO) on Days 1-21 and pembrolizumab 200mg intravenously (IV) on Day 1 of each 21-day cycle~Phase 2: niraparib (recommended Phase 2 dose) in combination with pembrolizumab 200mg IV on Day 1 of each 21-day cycle"
89417748|NCT02182284|Experimental|BI 201335 NA - low dose|
89417749|NCT02182284|Experimental|BI 201335 NA - high dose|
89530792|NCT02513693|Experimental|Standard Neuromuscular Blockade|"Drug: rocuronium + neostigmine~Administration of rocuronium 0,6 mg/kg iv, top-ups 5-10 mg iv to target value of Train-of-Four (TOF) count = 1-2, TOF-count measurement every 1 min. Neuromuscular blockade reversal at the end of anesthesia: neostigmine 0.03 mg/kg iv + atropine 0.5-1.0 mg iv Induction of anesthesia: midazolam 1-2 mg iv, sufentanil 10-30 mcg iv, propofol 1.5-2.5 mg/kg iv Anesthesia: sevoflurane in air to target 1.2-1.5 minimal alveolar concentration (MAC). Rescue medication: sevoflurane, propofol 20-40 mg iv Extubation when patient is conscious and attained the recovery from neuromuscular blockade to a TOF-ratio of at least 0,9."
88895646|NCT04664829|Experimental|Bexarotene and Capecitabine|
88895647|NCT04651400||COVID-19 patients who had received treatment with ATIII|Patient records of patients hospitalised for severe COVID-19 infection until 01.06.2020 that required oxygen therapy will be used to retrospectively gather baseline demographic data (age, gender, height, weight, ethnicity/race, blood group, rhesus factor) and comorbidities. Records will also be used to retrospectively gather information on routine coagulation and laboratory parameters measured as per local protocols (including where available: AT, aPTT, PT, Quick, INR, , fibrinogen, D-dimers, haemoglobin levels, and platelet count), and thromboembolic complications and bleeding events that occurred during the individual observational treatment period. Patients will be grouped into 2 cohorts; those that received treatment with ATIII and those that did not. ATIII was administered as per local guidelines at each institute.
89006275|NCT04639804|Active Comparator|Tegoprazan 50 mg + NSAIDs|Multiple doses of tegoprazan QD in combination with NSAIDs BID for 7 days
89006276|NCT00559663|Active Comparator|GT|The green tea group is given initially green tea treatment and then after a washout period of four weeks switched to the dark chocolate treatment.
89417750|NCT03536286|Experimental|Encouragement Zone 3|"Encouragement households will be randomly sampled based on location, and a team of 2 local community champions/data collectors (hired from within the community) will visit each of the encouragement arm homes. Community champions will be responsible for visiting each home, going door-to-door and speaking with each family individually in order to avoid contamination/cross-over with control households.~The Asili intervention involves membership into a program; households have the option to opt in or out at any time, without consequence to themselves or the study. The intervention itself involves access to clean water and health clinics. No drugs or medication are administered to individuals through this intervention."
89006277|NCT00559663|Active Comparator|DC|The dark chocolate group is given initially dark chocolate treatment and then after a washout period of four weeks switched to the green tea treatment.
89006278|NCT04639570|Experimental|KneuroKnits group|Participants in the KneuroKnits group
89417751|NCT03536286|No Intervention|Control Zone 3|Control households will still have equal access to the Asili intervention and can gain membership into a program at any time. Regardless of membership status, households have the option to opt in or out at any time, without consequence to themselves or the study. The intervention itself involves access to clean water and health clinics. No drugs or medication are administered to individuals through this intervention.
89417752|NCT03536286|Experimental|Encouragement Zone 4|"Encouragement households will be randomly sampled based on location, and a team of 2 local community champions/data collectors (hired from within the community) will visit each of the encouragement arm homes. Community champions will be responsible for visiting each home, going door-to-door and speaking with each family individually in order to avoid contamination/cross-over with control households.~The Asili intervention involves membership into a program; households have the option to opt in or out at any time, without consequence to themselves or the study. The intervention itself involves access to clean water and health clinics. No drugs or medication are administered to individuals through this intervention."
89417753|NCT03536286|No Intervention|Control Zone 4|Control households will still have equal access to the Asili intervention and can gain membership into a program at any time. Regardless of membership status, households have the option to opt in or out at any time, without consequence to themselves or the study. The intervention itself involves access to clean water and health clinics. No drugs or medication are administered to individuals through this intervention.
89417754|NCT03536208|Experimental|Warfarin|Patients will be assigned to warfarin by mouth daily on an outpatient basis. Dose level will increase after 5 patients enrolled. Dose 1 = 1 mg warfarin; Dose 2 = 2 mg warfarin; Dose 3 = 2.5 mg warfarin; Dose 4 = 4 mg warfarin and Dose 5 = 5 mg warfarin
89417755|NCT03034915|Experimental|UMEC/VI 62.5/25 mcg via ELLIPTA + placebo via DISKUS|Subjects will be instructed to self-administer one dose of UMEC/VI 62.5/25 mcg inhalation powder each morning via ELLIPTA DPI and placebo twice daily (morning and evening) via DISKUS DPI.
89417756|NCT03034915|Experimental|UMEC 62.5 mcg via ELLIPTA + placebo via DISKUS|Subjects will be instructed to self-administer one dose of UMEC 62.5 mcg inhalation powder each morning via ELLIPTA DPI and placebo twice daily (morning and evening) via DISKUS DPI.
89417757|NCT03034915|Experimental|Salmeterol 50 mcg via DISKUS + placebo via ELLIPTA|Subjects will be instructed to self-administer one dose of salmeterol 50 mcg twice daily (morning and evening) via DISKUS DPI and placebo once daily morning via ELLIPTA DPI.
89417758|NCT02182362|Experimental|BI 201335 NA in rising doses|single dose of BI 201335 NA on day 1, multiple dosing days 4-24
89006279|NCT04639687|Experimental|Immediate intervention|If randomized to this group, household of child and participating caregiver receives 12 weekly deliveries of vegetables plus added whole grains, along with text messages containing links to cooking instruction videos
89417759|NCT02182362|Placebo Comparator|Placebo|
89006280|NCT04639687|Other|Wait list control (delayed intervention)|If randomized to this group, participants do not get any intervention activities for the first 12 weeks, and their outcome data at V2 contribute as controls. For ethical reasons, this low-income population ultimately gets the intervention (food)later, and data after they receive the intervention contributes to follow-up data only.
89417760|NCT02182362|Experimental|BI 201335 NA|highest tolerated dose of BI 201335 on day 1-28 in patients with Gilbert's syndrome
89417761|NCT05373459||Health care workers without third COVID-19 booster|Health care workers received less than 3 doses of COVID-19 vaccine
89417762|NCT05373459||HCWs with third COVID-19 booster|Health care workers received at least 3 doses of COVID-19 vaccine
89417763|NCT02180802|Experimental|motivational intervieing group|The behavioral intervention targets were improved eating and physical activity behavior in order to reduce obesity levels. Each adolescent was encouraged to eat a variety of foods from each of the four major food groups and low-fat alternatives . Moreover, each adolescent was encouraged to achieve at least 60 minutes of moderate-to-vigorous intensity physical activity daily as recommended by the World Health Organization
89417764|NCT02180802|Experimental|motivational interviewi group with parental involvement|an additional single session with parents or guardians over 60 minutes in the clinic
89417765|NCT02180802|Active Comparator|Control|The patients received routine care
89417766|NCT03578835||Multi-center BSI cohort|Patients from six German study centers suffering from bloodstream infection caused by specific target organisms.
89006281|NCT00218855|Placebo Comparator|A|
89006282|NCT00218855|Active Comparator|B|
89006283|NCT04639609|Experimental|Group 1 : Patients|
89006284|NCT04639609|Other|Group 2 : healthy volunteers|
89006285|NCT04639726|Active Comparator|Whey Protein|
89006286|NCT04639726|Placebo Comparator|Placebo|
89006287|NCT04639765|No Intervention|No video|This condition involves no video presentation.
89006288|NCT04639765|Experimental|CBT without Personalization|Video provides information about cognitive behavioral therapy.
89006289|NCT04639765|Experimental|CBT with Personalization|Video provides information about cognitive behavioral therapy and describes how treatment can be personalized.
89417767|NCT05141136|Experimental|Ultrasound probe sagittal group|A thoracic 2 paravertebra block is performed with the ultrasound probe placed sagittal and the needle in plane with respect to the probe.
89417768|NCT05141136|Active Comparator|Ultrasound probe transverse group|A thoracic 2 paravertebra block is performed with the ultrasound probe placed transverse and the needle in plane with respect to the probe.
89417769|NCT03578757|Experimental|intervention group|stress management program and the same usual practice (restrictive diet, physical activity and thermal spa treatment)
89417770|NCT03578757|Active Comparator|usual practice group|Both groups will benefit of a 21-day residential program at the thermal spa resort combining corrections of eating disorders
89417771|NCT03577509|Experimental|ABCD|Group1: 0.5mg/kg Group2: 1.0mg/kg Group3: 1.5mg/kg
89417772|NCT00301119||lung cancer screening cohort|observational only. no intervention. current, former and never smokers over age 50 without history of cancer, except for non melanoma skin cancer, no previous treatment with chemotherapy.
89417773|NCT00301119||r/o lung cancer|observational only. no intervention. patients with CT findings suspicious for lung cancer who are undergoing bronchoscopy and/or surgery.
89417774|NCT02631538|Placebo Comparator|Placebo|Subjects will receive belimumab placebo weekly subcutaneous injections to Week 52 and rituximab placebo infusions at Weeks 8 and 10.
89417775|NCT02631538|Experimental|Belimumab monotherapy|Subjects will receive 200 mg weekly subcutaneous injections of belimumab to Week 52 and placebo rituximab infusions at Weeks 8 and 10.
89417776|NCT02631538|Experimental|Belimumab and Rituximab co-administration therapy|Subjects will receive belimumab 200 mg SC weekly for 24 weeks followed by weekly placebo belimumab injections to Week 52 with rituximab 1000 mg intravenously at Weeks 8 and 10.
89417777|NCT02631538|Active Comparator|Rituximab monotherapy|Subjects will receive 1000 mg IV rituximab infusions at Weeks 8 and 10 and weekly subcutaneous injections of placebo belimumab to Week 52.
89417778|NCT03577353|Experimental|experimental-DTW|The intervention of the experimental group was based on dual-task treadmill walking while using the Virtual Reality (VR) tool.
89417779|NCT03577353|Active Comparator|Control- TMW|The intervention of the control group was based on single-task treadmill walking.
88895648|NCT04651400||COVID-19 patients who had not received treatment with ATIII|Patient records of patients hospitalised for severe COVID-19 infection until 01.06.2020 that required oxygen therapy will be used to retrospectively gather baseline demographic data (age, gender, height, weight, ethnicity/race, blood group, rhesus factor) and comorbidities. Records will also be used to retrospectively gather information on routine coagulation and laboratory parameters measured as per local protocols (including where available: AT, aPTT, PT, Quick, INR, , fibrinogen, D-dimers, haemoglobin levels, and platelet count), and thromboembolic complications and bleeding events that occurred during the individual observational treatment period. Patients will be grouped into 2 cohorts; those that received treatment with ATIII and those that did not. ATIII was administered as per local guidelines at each institute.
88895649|NCT04651400||Non-COVID-19 patients who had received treatment with ATIII|"A control group will be used to gather comparative data in non-COVID-19 patients.~Data will be gathered retrospectively from patient records for severely ill patients who received oxygen therapy for non-COVID-19 infection until end 2019 (31.12.2019). Control group will also be grouped into 2 cohorts for those having received/ having not received ATIII treatment."
89417780|NCT03584061|Experimental|Fat grafting/fat transplant.|Each patient receives fat grafting to the site of dermal pain. Fat is to be harvested for either the abdomen or the thigh.
89417781|NCT03578679|Experimental|HEGOR/AZICUR shampoo solution|At D1, shampoo AZICUR liquid formulation in infested persons aged 0 to 6 years and / or less than 15 kg, also apply the combination HEGOR / AZICUR solution shampoo in women pregnant or lactating women not eligible for treatment with Ivermectin, to prevent them from contaminate treated participants who are very close to them or share the same bed or same bench table at school.
89006290|NCT04639765|Experimental|ADM without Personalization|Video provides information about antidepressant medications.
89417782|NCT03583281|Active Comparator|Flax oil|Participants will consume capsules containing flax oil (4 grams alpha-linolenic acid [ALA] per day) for 4 weeks
89417783|NCT03583281|Active Comparator|Fish oil|Participants will consume capsules containing DHA-enriched fish oil (4 grams DHA per day + 0.8 grams EPA per day) for 4 weeks
89417784|NCT05479981|Experimental|AOC 1001|AOC 1001 will be administered quarterly. On Day 43 patients will receive an additional dose. Treatment assignment will be based on treatment received in AOC 1001-CS1. If participant did not receive AOC 1001 on Day 43 in AOC 1001-CS1, participant will receive AOC 1001 treatment on Day 43 in AOC 1001-CS2.
89417785|NCT05479981|Experimental|AOC 1001 (with Placebo at Day 43)|AOC 1001 will be administered quarterly. On Day 43 patients will receive an additional dose. Treatment assignment will be based on treatment received in AOC 1001-CS1. If participant received AOC 1001 on Day 43 in AOC 1001-CS1, participant will receive blinded placebo treatment on Day 43 in AOC 1001-CS2.
89417786|NCT03583203|Experimental|Experimental Group|This group will include personalized information about lung damage. After evaluating their COPD, the patients will be informed about its existence it so and staging. Depending on the damage found, the generation of motivation will focus on the different prevention methods. Likewise, after the motivation level is set, the patients will be offered the option of treatment and regular follow-up. The intervention will be strengthened by motivational messages, half of which are linked to the possibilities of preventing respiratory damage, sent to the patient's mobile phone via SMS during the 3 months after the face-to-face intervention. Patients without mobile phones will receive a call on their phone to convey the same messages.
89417787|NCT03583203|No Intervention|Control Group|The control intervention lasts 30 minutes and will be structured around the 5 A's technique (Ask, Advice, Assess, Assist and Arrange).
89417788|NCT05474287|Experimental|Supraglottic jet oxygenation and ventilation|Supraglottic jet oxygenation and ventilation is conducted for the participants during sedation.
89417789|NCT05474287|Active Comparator|High-flow nasal oxygen therapy|High-flow nasal oxygen therapy is conducted for the participants during sedation.
89417790|NCT05661214|No Intervention|Control Group 1|This group is the control group 1 (one) that will be taught using structured standard teaching content. Before teaching, participants will be applied pre tests. After teaching, they will be applied post tests.
89417791|NCT05661214|Experimental|Intervention Group 1|This group is the intervention group 1 (one) that will be taught using model-based structured teaching content. In this teaching content, researchers will teach pressure injury risk factors; after teaching, participants will plan nursing interventions with Clinical Decision Support System (CDSS) integrated software. Before teaching, participants will be applied pre tests. After teaching, they will be applied post tests.
89417792|NCT05661214|No Intervention|Control Group 2|This group is the control group 2 (two) that will be taught using structured standard teaching content. After teaching, they will be applied post tests. This group has no pre-test and will be created to increase internal validity, only.
89417793|NCT05661214|Experimental|Intervention Group 2|This group is the intervention group 2 (two) that will be taught using model-based structured teaching content. In this teaching content, researchers will teach pressure injury risk factors; after teaching, participants will plan nursing interventions with Clinical Decision Support System (CDSS) integrated software. After teaching, they will be applied post tests. This group has no pre-test and will be created to increase internal validity, only.
89417794|NCT02035605|Active Comparator|ALN-AT3SC|
89417795|NCT02035605|Placebo Comparator|Sterile Normal Saline (0.9% NaCl)|
88895650|NCT04651400||Non-COVID-19 patients who had not received treatment with ATIII|"A control group will be used to gather comparative data in non-COVID-19 patients.~Data will be gathered retrospectively from patient records for severely ill patients who received oxygen therapy for non-COVID-19 infection until end 2019 (31.12.2019). Control group will also be grouped into 2 cohorts for those having received/ having not received ATIII treatment."
89417796|NCT03619369|Active Comparator|Early Circumcision|
89417797|NCT03619369|Placebo Comparator|Routine Circumcision|
89417798|NCT03619369|Active Comparator|Delayed Circumcision|
89417799|NCT03578601||Thyroid surgery|Patient undergoing thyroid surgery
89417800|NCT04421508|Active Comparator|Inhaled Nitric Oxide (iNO)|Pulsed inhaled iNO 125 mcg/kg IBW/hour
89417801|NCT04421508|Sham Comparator|Placebo|Pulsed inhaled N2, 99.999% gas
89417802|NCT03578523||Chronic Kidney Disease|"CKD stage 3-4 eGFR 59-20mls/min/1.73 '3 Tesla multiparametric MR: Renal MRI Scan to assess blood flow, perfusion, oxygenation and microstructure (MR T1 relaxation time and diffusion).~Each patient will have 3 renal MRI scans. renal histopathology scoring: Blinded fibrosis scoring of renal histopathology (If biopsy performed for clinical indication) Iohexol clearance test: Blood and urine sampling around scan sessions; this will include routine patient care biochemistry and haematology panel.~urine protein and albumin measurements, stored plasma/serum/urine for subsequent analysis.~Iohexol clearance to measure GFR within 1 week of the scan session"
88895651|NCT04651374|Experimental|Geko Device|Confirmed Covid-19 positive patients will be randomized to either applying the Geko device arm or the no device arm.
89417803|NCT03578523||Acute Kidney Injury|"AKI stage 2-3 '3 Tesla multiparametric MR: Renal MRI Scan to assess blood flow, perfusion, oxygenation and microstructure (MR T1 relaxation time and diffusion).~Each patient will have 3 renal MRI scans. Iohexol clearance test: Blood and urine sampling around scan sessions; this will include routine patient care biochemistry and haematology panel.~renal histopathology scoring: Blinded fibrosis scoring of renal histopathology (If biopsy performed for clinical indication) urine protein and albumin measurements, stored plasma/serum/urine for subsequent analysis.~Iohexol clearance to measure GFR within 1 week of the scan session"
89417804|NCT03578445|Experimental|Patients with a pancreatic cystic lesion|
89417805|NCT02185872|Active Comparator|Aerobic and Resistance Training|Participants completed 24 exercise sessions based on current guidelines. Aerobic exercise (50 min) was performed on machines every session and resistance training (20 min) was performed on machines two sessions per week. Aerobic intensity was prescribed at 40-50% of heart rate reserve (HRR) Weeks 1-4 and 50-60% HRR Weeks 5-8. Resistance training was supervised by an ACE certified personal trainer. One-repetition maximums (1-RM) were assessed Week 1 (i.e., seated bicep curl, military press, seated lat pulldown, seated leg extension, triceps pulldown, bench press, reverse leg curl, seated leg press). For Weeks 2-3 participants completed, 3 sets of 15 reps at 50% 1-RM; Weeks 4-5, 3 sets of 12 reps at 60% 1-RM; Weeks 6-7, 3 sets of 10 reps at 70% 1-RM; Week 8, 3 sets of 8 reps at 75% 1-RM. Three sets of 15 unweighted crunches were completed each day. One minute of rest was taken between each set and each exercise.
89417806|NCT02185872|Experimental|High-intensity functional training|Participants completed a total of 24 sessions that were pre-programmed and led by a certified instructor (CrossFit Level 2), which lasted up to 60 minutes in duration. The first two class periods were structured as an introduction to common movements used in high-intensity functional training (HIFT; e.g., squats, deadlift, press, jerks, barbell, dumbbell, and medicine ball cleans, pullups, kettlebell swings, among others). No scheduled workouts were given on days 1 and 2. Beginning on day 3 each HIFT class consisted of 10-15 minutes of stretching and warmup, 10-20 minutes of instruction and practicing techniques and movements, and 5-30 minutes for the workout of the day, performed at vigorous intensity, relative to each person's ability and fitness level. All weights and movements were individually prescribed and recorded for each participant.
88895652|NCT04651374|No Intervention|No Device|Confirmed Covid-19 positive patients will be randomized to either applying the Geko device arm or the no device arm.
88895653|NCT04650984|Active Comparator|Arm 1|Patients will receive 75 mg/m2 doxorubicin once every 3 weeks (reference treatment).
88895654|NCT04650984|Experimental|Arm 2|Patients will receive 13 µg/kg L19TNF on days 1, 3 and 5 every 3 weeks in combination with 60 mg/m2 doxorubicin (once every 3 weeks).
88895655|NCT04649502|Experimental|Metformin combined with doxycycline|
88895656|NCT04649502|Placebo Comparator|Doxycyline combined with placebo|
89417807|NCT02256462|Experimental|Interventional|Adalimumab levels and antibodies will be obtained with every laboratory examination (every 2 months, except for the first 2 visits). Dose or interval adjustment will be performed as followed:when trough levels results taken prior to ADA injection are above 5 µg/ml no change in dosing is required. Detectable levels below 5 µg/ml will result in interval decrease to every week. If levels are still below 5 µg/ml dose will be increased to 40 mg (in patients receiving less than 40 mg). Undetectable levels below 0.3µg/ml will be followed by antibodies (ATAs) measurement. If ATAs are persistently above 8 µg/ml the patient will discontinue the study. If ATAs are below 8 µg/ml ADA intervals will be decreased to every week.
88895657|NCT04637087|Experimental|Atrial Fibrillation Risk Estimation Tool|For eligible patients presenting with an acute ischemic stroke, a clinical atrial fibrillation risk estimation tool will be displayed in the patient's electronic health record through a best practice alert (BPA). The alert will display for the stroke neurologist caring for the patient when they first open the patient's chart. The neurologist may accept the automatically generated atrial fibrillation risk score displayed in the BPA, may modify some of the inputs of the score based on the patient's personal medical history and re-calculate, or may choose to dismiss the BPA.
88895658|NCT04632576|Experimental|transcutaneous electrical acupoint stimulation|transcutaneous electrical acupoint stimulation is one of the many forms of acupuncture, and is a distinctive part of Chinese medicine that has been practiced in China for thousands of years. It is employed by placing electrodes on acupoint and electrical stimulation is given after anesthetic induction to the end of the surgery.
88895659|NCT04632576|No Intervention|Control|"Electrodes are placed on same acupoints as the experimental group, and will receive the optimal intensity test before the anesthesia induction, but no electrical stimulation is given during the operation."
88895660|NCT04629651|Experimental|Captopril|"In phase I, Cohorts of 3 patients each will receive doses of captopril with a goal dose of 150mg total by mouth (PO) daily. Initial dose per patient will start at 12.5 mg daily, which will then be increased on weekly intervals as tolerated. To be administered per the intra-patient dose escalation scheme below~Phase I:~Day 0: 12.5mg/day Day 7: 12.5mg twice daily Day 14: 12.5mg three times daily Day 21: 25mg three times daily Day 28: 50mg three times daily~Phase II: The efficacy of captopril will be assessed in the Phase II portion. Captopril given at Maximum Tolerated Dose - bone marrow evaluation to be done at 6 months"
88895661|NCT04614103|Experimental|Cohort 1|Patients whose tumors did not express programmed cell death-ligand 1 (PD-L1), i.e., tumor proportion score (TPS) < 1% prior to ICI treatment and Patients with no available historical TPS for PD-L1 expression
88895662|NCT04614103|Experimental|Cohort 2|Patients whose tumors expressed PD-L1 TPS ≥1% prior to ICI treatment
88895663|NCT04614103|Experimental|Cohort 3|Patients, regardless of tumor PD-L1 TPS prior to ICI treatment, who are unable to safely undergo a surgical tumor resection for TIL generation
88895664|NCT04614103|Experimental|Cohort 4|Patients, regardless of tumor PD-L1 expression status prior to ICI treatment, who have meet all inclusion/exclusion criteria except the requirement to have documented disease progression may elect to have the tumor harvest procedure and TIL production prior to disease progression on their current anticancer treatment. Documentation of progressive disease and identification of a target lesion for RECIST v1.1 assessment is required at Baseline for these patients.
88895665|NCT04614103|Experimental|Retreatment Cohort|Patients who were previously treated with LN-145 in Cohort 1, 2, 3, or 4.
88895666|NCT04614025|Experimental|PLX-PAD Treatment|"PLX-PAD 300 million cells (20 million/mL) administered via 15 IM injections (1 mL each).~Single administration in addition to best standard medical care."
88895667|NCT04614025|No Intervention|Control Group|Best standard medical care
88895668|NCT04604444|Experimental|Multimodal Intensive Rehabilitation of Aphasia/AOS (MIRAA)|A minimum of 3 hour speech-language training daily during 10 days.
88895669|NCT04601857|Experimental|futibatinib and pembrolizumab (Cohort A)|Patients with UC and FGFR3 mutation or FGFR1-4 fusion/rearrangement.
88895670|NCT04601857|Experimental|futibatinib and pembrolizumab (Cohort B)|All other patients than in Cohort A with UC (including patients with other FGFR or non-FGFR genetic aberrations and patients with wild-type [non-mutated] tumors).
88895671|NCT04601415||GP Referrals|Patients with HF referred by GP to echo department
88895672|NCT04601415||Echo patients|Non-selected patients attending echo department in hospital
88895673|NCT04591951|Active Comparator|I2-ART Group|I2-ART intervention will be modeled based on the Parent Empowerment Program model. It will use methods of adult learning, direct instruction to share knowledge or techniques for practice, group support, modeling, vicarious learning, and practice opportunities (i.e., role rehearsals). I2-ART training includes 40 hours of didactic and interactive sessions (10 sessions of 4 hours each) covering the following areas: 1) conceptual framework, 2) listening, engagement, and boundary-setting skills; 3) ADHD psychoeducation (e.g., diagnosis, treatment, shared decision-making tools), and 4) service options. The caregivers in the I2-ART group will receive the intervention for 3 months. The I2-ART will be implemented by the family navigators and will include a 2-hour face-to-face meeting, at least three monthly in-person meetings, and intermittent contact between in-person meetings by phone calls, texts or emails, as determined by the family navigator-caregiver dyad.
88895674|NCT04591951|Placebo Comparator|Control Group|"The caregivers in the control group will receive usual care."
88895675|NCT04591405|Experimental|Attenuated Mumps vaccine (KMB-17) in phase II and III|≥4.3logCCID50/ml Attenuated Mumps vaccine (KMB-17)[≥4.3 logCCID50/ml] in 360 children (5-11 years old) on 0 day
88895676|NCT04591405|Placebo Comparator|Placebo in phase II|Freeze-dried stabilizer and diluent without mumps virus antigen in 360 children (5-11 years old) on 0 day
89417808|NCT02256462|No Intervention|Clinical|"Adalimumab levels and antibodies will be requested based on physician judgment when there are signs of loss of response (LOR). Dose and interval adjustment will be performed according to clinical measures: Following physician decision trough levels and ATAs will be collected and further adjustment may be considered according to results. Interval adjustment will be performed as described for the interventional arm.~LOR is defined as PCDAI equal or higher than 10 or CRP higher than 0.5 mg/dl (5mg/l) and/or Fecal calprotectin higher than 150 mcg/gr (If lower than 150 at randomization)."
89417809|NCT04587271|Experimental|Lactating Mothers (Moringa)|Lactating mothers.
89417810|NCT04587271|Experimental|Breastfeeding Infants (Moringa)|Breastfeeding infants from lactating mothers
89417811|NCT04587271|Experimental|Children (Moringa)|Children from 6-59 months of age.
89417812|NCT04587271|Placebo Comparator|Lactating Mothers (placebo)|Lactating mothers.
89417813|NCT04587271|Placebo Comparator|Breastfeeding Infants (placebo)|Breastfeeding infants from lactating mothers
89417814|NCT04587271|Placebo Comparator|Children (placebo)|Children from 6-59 months of age.
89417815|NCT02631148|Experimental|Melatonin|Circadin, controlled release melatonin tablet 2mg by mouth each day before bedtime for 6 weeks
89417816|NCT02631148|Placebo Comparator|Placebo|Placebo tablet identical to Circadin by mouth each day before bedtime for 6 weeks
88895677|NCT04591405|Experimental|Attenuated Mumps vaccine (KMB-17) in phase III|≥4.3logCCID50/ml Attenuated Mumps vaccine (KMB-17)[≥4.3 logCCID50/ml] in 5640 children (5-11 years old) on 0 day
88895678|NCT04591405|Placebo Comparator|Placebo in phase III|Freeze-dried stabilizer and diluent without mumps virus antigen in 5640 children (5-11 years old) on 0 day
88895679|NCT04585243|Experimental|Self-Sampling Kit|Participants will be mailed a Self-Sampling kit (Evalyn Brush) to collect samples for analysis for HPV/Cervical cancer screening.
88895680|NCT04583878||Participants with Pulmonary Embolism|The target accrual is based on the primary endpoint (exercise intolerance and dyspnea on exertion). To achieve adequate power and precision in the primary analysis, the target enrollment is 80 children. Both males and females of all races and ethnic groups are eligible for this study.
88895681|NCT04583878||Control Group|A positive control group that has not had pulmonary embolism (PE) but is prescribed physical activity restrictions expected to produce a similar deconditioning effect as patients with PE will be enrolled from UT Southwestern only (cohort 1) or children who are no prescribed physical activity restrictions and are otherwise considered healthy (cohort 2). The target accrual of the positive control group is based on feasibility and availability of funds and will be limited to 25 controls.
88895682|NCT04578327|Experimental|Aim 1|Data from Specific Aim 1 will be used to test the following hypotheses: H1a. The body-powered prosthetic devices are embodied more than passive and myoelectric prosthetic devices. H1b. Passive cosmetic devices are embodied less than actuated cosmetic devices (agency). H1c. Body-powered terminal devices are embodied less than myoelectric terminal devices (agency).
88895683|NCT04578327|Experimental|Aim 3|Data from Specific Aim 3 will be used to test the following hypotheses: H3a. The maximum number of channels elicits more embodiment than the minimum number. H3b. The sensory feedback from passive spatial locations of the hand increases the embodiment compared to sensory feedback just from the grasping spatial locations.
88895684|NCT04571502|Experimental|Full Intervention|TRIADs (caregiver, PWD, and provider) randomly assigned to the experimental arm will have access to use CareHeroes AND the newly developed AAC app. Provider will receive information via the AAC app.
88895685|NCT04571502|Active Comparator|Minimal Intervention|TRIADs (caregiver, PWD, and provider) randomly assigned to the minimal intervention arm will have access to use CareHeroes but only a paper version of the newly developed AAC app.
88895686|NCT04558931|Experimental|A - Isatuximab/CellProtect|"Isatuximab will be given intravenously (IV) at the dose of 10 mg/kg on Days 1, 8, 15, 22 (cycle 1), 36, 50 (cycle 2), 64, 78 (cycle 3) and monthly thereafter (cycles 4-36).~CellProtect will be given IV infusion at the dose of 3x10^7 cells/kg day 29 , 43 and 3-10x10^7 on day 57.~Each cycle will be 28 days, after completion of third cycles, patients will continue with Isatuximab alone until disease progression, unacceptable AE, death, completion of 3 years of treatment or patient's decision to discontinue, whichever occurs first."
88895687|NCT04558931|Active Comparator|B - Isatuximab|"Isatuximab will be given intravenously (IV) at the dose of 10 mg/kg on Days 1, 8, 15, 22 (cycle 1), 36, 50 (cycle 2), 64, 78 (cycle 3) and monthly thereafter (cycles 4-36).~Each cycle will be 28 days, after completion of third cycles, patients will continue with Isatuximab alone until disease progression, unacceptable AE, death, completion of 3 years of treatment or patient's decision to discontinue, whichever occurs first."
88895688|NCT04557085|Placebo Comparator|Placebo|Placebo
89417817|NCT02030496|Active Comparator|Closed reduction and plaster|Closed reduction will be performed and after adequate reduction has been confirmed, the wrist will be immobilised according to Dutch guidelines: a splint for one week followed by a circular cast for another four weeks.
89417818|NCT02030496|Active Comparator|open reduction and internal fixation|The intervention group will be treated with open reduction and internal fixation with a volar locking plate.
89417819|NCT02239107|Experimental|N-Acetyl cysteine|Laparoscopic ovarian drilling followed by NAC 1200mg daily in two divided doses for five days starting cycle day 2 for 6 month
89417820|NCT02239107|Active Comparator|laparoscopic drilling group|laparoscopic drilling only will be done
89417821|NCT02182518|Experimental|Epinastine + Pseudoephedrine|
89417822|NCT02182518|Experimental|Epinastine|
89417823|NCT04339621||Treatment Naive|20 patients with AIH will be recruited that will be treatment naive at the time of recruitment.
89417824|NCT04339621||Treatment cessation review|77 AIH patients will be recruited who will have been on treatment for the past 18-24 months and will be coming in to meet their physician to review treatment cessation options
89417825|NCT02239185|Other|Hernial sac ligation in continuity|laparoscopic closure of hernia sac in continuity using 3 - 0 non-absorbable purse-string suture. Two 3-mm.needle holders are used for intracorporeal insertion of purse string suture around the opened IIR with intracorporeal knot tying.
89417826|NCT02239185|Other|Hernial sac disconnection|circumferential incision on the peritoneum at internal inguinal ring (IIR) with separation of hernia sac from the peritoneum. The proximal part of the sac will be sutured using non-absorbable 3-0 prolene on round body needle.
89417827|NCT05486182|Experimental|Prospective population|
89417828|NCT03574935|Experimental|External Chinese medicine|"External Chinese medicine include 3 kinds of formula，including:~Qin, Hua and Bu will be applied to cover the participants' lesions in wet dressing form. Dosage form:5g/ml; frequency:qd; duration:2months."
88895689|NCT04557085|Experimental|Cenobamate 100 mg/day|Cenobamate 100 mg/day
88895690|NCT04557085|Experimental|Cenobamate 200 mg/day|Cenobamate 200 mg/day
88895691|NCT04557085|Experimental|Cenobamate 400 mg/day|Cenobamate 400 mg/day
88895692|NCT04555694|Active Comparator|Restasis and Lotemax|10 subjects will be receiving Restasis ophthalmic solution twice a day in both eyes and Lotemax ophthalmic solution twice a day in both eyes.
88895693|NCT04555694|Active Comparator|Restasis and Dextenza|10 subjects will be receiving Restasis ophthalmic solution twice a day in both eyes, as well as receiving Dextenza insertion in both lower lids.
88895694|NCT04555694|Active Comparator|Restasis|10 subjects will be receiving Restasis ophthalmic solution twice a day in both eyes
88895695|NCT04541667|Active Comparator|Air for luminal inflation|Patients randomized into this arm will have luminal inflation using air.
89193578|NCT04596384|Experimental|Group I (telemonitoring program, actigraph, TapCloud)|Before surgery, patients complete a functional and nutritional assessment. The home environment of patients will also be assessed. Based on findings, patients undergo personalized prehabilitation. Patients also wear an actigraph throughout the study to measure and record daily steps taken and sedentary time. Patients use the TapCloud app on a smart device (phone, tablet) or home computer to collect, track, and report their symptoms. Based on patient input in the TapCloud app, a real-time alert is sent to an RN when predetermined thresholds are met. RNs then contact the patient via the TapCloud app and further phone calls if necessary. Patients, caregivers and surgeons may also participate in a focus group in-person, via telephone, or videoconferencing.
89417829|NCT03574935|Active Comparator|External Western medicine|Ethacridine Lactate Solution, 1% Sulfadiazine Silver Cream and rb-bFGF will be applied to cover the participants' lesions. Dosage form:3g/ml; frequency:qd; duration: 2months.
89417830|NCT02239029|Active Comparator|Platelet rich plasma|"Platelet rich plasma (PRP) is a new and potential treatment for patients with kinds of musculoskeletal disorders.~Patients with bilaetral knee osteoarthritis randomized receive on dose of PRP in one knee and placebo with normal saline in the other side."
89417831|NCT02239029|Placebo Comparator|normal saline|Normal saline was injected into the other side of knee as the control group.
88895696|NCT04541667|Active Comparator|Carbon Dioxide for luminal inflation|Patients randomized into this arm will have luminal inflation using carbon dioxide.
88895697|NCT04537871||Observational (physical assessment)|Patients undergo echocardiogram to assess cardiac function and mechanics, cardiopulmonary exercise test, pulmonary function test, musculoskeletal ultrasound, bioelectrical impedance analysis to measure total lean body mass and percent body fat), physical function tests, and collection of blood samples within 45 days from the start of conditioning therapy, and at 6 months, 1 year, and 2 years post-transplant.
88895698|NCT04527003|Placebo Comparator|Group A - Placebo|Norethindrone acetate (5mg daily) + Placebo
88895699|NCT04527003|Active Comparator|Group B - Low Dose CBD|Norethindrone acetate (5mg daily) + Low dose CBD (10mg sublingual daily)
88895700|NCT04527003|Active Comparator|Group C - High Dose CBD|Norethindrone acetate (5mg daily) + High dose CBD (20mg sublingual daily)
88895701|NCT04515797|Experimental|Treatment with Direct Acting Antiviral for HCV|4 week treatment period with glecaprevir and pibrentasvir (G/P) within 24 hours of transplant
88895702|NCT04511026|Experimental|Lymphoseek/SPECT-CT/Indocyanine|The subject will receive f 0.5 mL each Lymphoseek into the uterine cervix prior to surgery and subsequent SPECT/CT imaging preoperatively. Intraoperatively, following anesthesia induction, Indocyanine Green (0.5 mL) will be injected into the uterine cervix. Using near-infrared imaging, efferent lymphatic vessels and lymph nodes will be visualized and confirmed by detected radioactivity using a laparoscopic gamma counter. The preoperatively obtained SPECT/CT images will help guide the surgery.
89417832|NCT03578289|Experimental|Experimental Group (telemental health_|The experimental group will received cognitive behavioral therapy (CBT) via TMH for 8 sessions.
89417833|NCT03578289|Experimental|Waiting Control Group (usual care)|Participants randomly assigned to the control group will receive routine care for three months followed by the 8-week CBT intervention
89417834|NCT03574857|Active Comparator|Metolazone|Metolazone 5 mg by mouth once daily for 2 days
89417835|NCT03574857|Active Comparator|Chlorothiazide|Chlorothiazide 500 mg IV once daily for 2 days
89417836|NCT02753400|Experimental|Emixustat hydrochloride|"Week 1- Four tablets (2 placebo, 2 emixustat HCl Strength A)~Week 2- Four tablets (2 placebo, 2 emixustat HCl Strength B)~Week 3- Four tablets (2 placebo, 2 emixustat HCl Strength C)~Week 4- Four emixustat HCl tablets (Strength C)~All tablets are administered orally once daily. After week 4, all subjects will be held at a stable dose for the remainder of the 12-week dosing regimen."
88895703|NCT04510051|Experimental|Treatment (chemotherapy, IL13(EQ)BBzeta/CD19t+ T cells)|Patients receive cyclophosphamide intravenously IV on days -5 and -4, and fludarabine IV on days -5 to -2. Patients then receive autologous IL13(EQ)BBzeta/CD19t+ T cells intraventricularly over 5 minutes QW on day 0. Treatment with autologous IL13(EQ)BBzeta/CD19t+ T cells repeats every 7 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients may receive additional cycles of IL13(EQ)BBzeta/CD19t+ T cells as long as they continue to meet eligibility criteria and have doses available for infusion.
88895704|NCT04501185||UTS Stem|The subjects who received UTS Stem in total hip arthroplasty.
89417837|NCT02753400|Placebo Comparator|Placebo|Four placebo tablets are administered orally once daily for 12 weeks; Subjects in the placebo group will be mock-titrated on the same schedule as those in the active arm.
89417838|NCT03578055|Active Comparator|BDD with UDCA|Postoperative BDD with UDCA treatment
89417839|NCT03578055|Placebo Comparator|Placebo|Placebo
89417840|NCT02185950|Experimental|Ultrasound group|Therapeutic ultrasound, 3 MHz, continuous with intensity 1W/cm2 will be applied to the selected region (burn scar deep 2nd degree or 3rd degree, grafted) with exposure time of 2 minutes for each effective radiation area head (ERA), a total of 4 minutes of application in an area of 9X5 cm, and the application parameters with a matched control side of the patient, in a region with contralateral uninjured skin.
89417841|NCT02185950|Experimental|Group paraffin|Paraffin therapy is heated with thermostat own equipment, being applied to the selected region (burn scar deep 2nd degree or 3rd degree, grafted) and control (uninjured), with a length of 9X5 cm, at a temperature of 38 ° C with appropriate brush in layers (4 layers), remaining for 20 minutes. After the period of application of paraffin will be removed and discarded, with no reuse.
88895705|NCT04501185||UTF-reduced Stem|The subjects who received UTF-reduced Stem in total hip arthroplasty.
88895706|NCT04498208|Experimental|Personalized prehabilitation|Patients will participate in a personalized health optimization program combining one-on-one coaching, tailored to each patient's physical, nutritional, well-being and cognitive status baseline. Prehabilitation will last from a minimum of 14 days to a maximum of 42 days before surgery
88895707|NCT04498208|No Intervention|Standard prehabilitation|Patients in the control group will be provided with standard instructions in a hard-copy form specific to prehabilitation before surgery associating physical, nutritional, stress-reduction and cognitive recommendations without any personalized coaching for at least 14 days prior to surgery.
88895708|NCT04480463|Experimental|SCD411|
88895709|NCT04480463|Active Comparator|Aflibercept|
88895710|NCT04470609|Experimental|Low dosage vaccine on a 0- and 28-day schedule|Two doses of low dosage Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0, 28
88895711|NCT04470609|Experimental|Medium dosage vaccine on a 0- and 28-day schedule|Two doses of medium dosage Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0, 28
89193579|NCT04596384|Active Comparator|Group II (surgeon-only perioperative care program)|Patients and their families meet with the surgeon at least once before surgery. After surgery, patients are managed daily during post-operative care. Patients may receive a referral for functional and nutritional prehabilitation at the discretion of the surgeon/surgical team. Patients and their families receive instructions to follow the standard procedures for reporting problems between clinic visits, including contacting their surgical team if symptoms become severe and physical function worsens; and the use of the hospital call line to report problems. Patients, caregivers and surgeons may receive the opportunity to participate in focus group in-person, via telephone, or videoconferencing.
89193580|NCT04587531|Active Comparator|Active CES Therapy|Group receives active treatment for 6 weeks. The intervention used will be cranial electrotherapy stimulation from and Alpha-Stim AID.
89535991|NCT03075189|Experimental|Protein supplement|"During hospitalization the intervention group will receive a protein enriched snack/meal in the morning and before bedtime. They will be given 15 gr of protein every morning, and the meal before bedtime will vary in protein content according to the individual needs. Diet registration will be carried out every day during hospitalization. At discharge, participants in the intervention will be instructed and advised with focus on consuming more protein at home.~Diet registration and testing at baseline, discharge and follow-up."
88895712|NCT04470609|Experimental|High dosage vaccine on a 0- and 28-day schedule|Two doses of high dosage Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0, 28
88895713|NCT04470609|Placebo Comparator|Placebo on a 0- and 28-day schedule|Two doses of placebo at the vaccination schedule of day 0, 28
88895714|NCT04464759|Experimental|Phase 1a: Nivolumab and Hydroxychloroquine (HCQ)|"Dose escalation:~Dose Level 1: HCQ 400 mg orally every 12 hours and nivolumab 480 mg IV every 4 weeks~Dose Level 2: HCQ 600 mg orally every 12 hours and nivolumab 480 mg IV every 4 weeks~Continue protocol treatment for up to 24 months until disease progression, unacceptable toxicity, withdrawal of consent, or other protocol-mandated study removal."
88895715|NCT04464759|Experimental|Phase 2: Nivolumab and Hydroxychloroquine (HCQ)|"HCQ 400-600 mg (maximum tolerated dose from Phase 1a) orally every 12 hours and nivolumab 480 mg IV every 4 weeks~Continue protocol treatment for up to 24 months until disease progression, unacceptable toxicity, withdrawal of consent, or other protocol-mandated study removal."
89006291|NCT04639765|Experimental|ADM with Personalization|Video provides information about antidepressant medications and describes how treatment can be personalized.
89417842|NCT02185950|Experimental|Ultrasound group + endermotherapy|Therapeutic ultrasound, 3 MHz, continuous with intensity 1W/cm2 will be applied to the selected region (burn scar deep 2nd degree or 3rd degree, grafted) with exposure time of 2 minutes for each effective radiation area head (ERA), a total of 4 minutes of application in an area of 9X5 cm. The application of endermotherapy will be held shortly after the therapeutic ultrasound in a timely manner across the surface of the scar, for about 2 seconds per head area with a negative pressure between 100-200 mmHg, a total of 4 minutes application in an area of 9 x 5 cm. The same application parameters will be performed with one hand matched control patient, in a region with contralateral uninjured skin.
89535992|NCT03075189|No Intervention|Standard treatment|"The control group are having the ordinary hospital diet and are following normal guidelines. They are not offered the protein focused counseling at discharge.~Diet registration and testing at baseline, discharge and follow-up."
89535993|NCT05437835|Experimental|Diffusion length and anesthetic effect|diffusion length of local anesthetics in the subparaneural space could predict anesthetic effect and duration of analgesia
89535994|NCT03075033|Active Comparator|SOS gruop|Use of The Shikani Optical Stylet In Patients At Risk Of Secondary Cervical Spine Injury
89417843|NCT02185950|Experimental|Group paraffin + endermotherapy|Paraffin therapy is heated with thermostat own equipment, being applied to the selected region (burn scar deep 2nd degree or 3rd degree, grafted) and control (uninjured), with a length of 9X5 cm, at a temperature of 38 ° C with appropriate brush in layers (4 layers), remaining for 20 minutes. After the period of application of paraffin will be removed and discarded, with no reuse.The application of endermotherapy will be held shortly after the paraffin therapy in a timely manner across the surface of the scar, for about 2 seconds per head area with a negative pressure between 100-200 mmHg, a total of 4 minutes application in an area of 9 x 5 cm. The same application parameters will be performed with one hand matched control patient, in a region with contralateral uninjured skin.
89417844|NCT02238639|Experimental|Active search for pulmonary embolism|All included patients will undergo D-dimer testing. A negative plasma highly sensitive D-dimer value (defined as a D-dimer level below the manufacturers assay threshold) will rule out pulmonary embolism, and no further examination will be performed. For patients with a positive D-dimer value, a multidetector computed tomographic pulmonary angiography (MDCT) will be performed.
88895716|NCT04464759|Experimental|Phase 1b: Nivolumab + Ipilimumab +Hydroxychloroquine (HCQ)|"HCQ 400-600 mg orally every 12 hours and nivolumab 3 mg/kg IV plus ipilimumab 1 mg/kg IV every 3 weeks x4 cycles~Then 6 weeks after the last dose of ipilimumab/nivolumab begin maintenance nivolumab 480 mg IV every 4 weeks~Continue protocol treatment for up to 24 months until disease progression, unacceptable toxicity, withdrawal of consent, or other protocol-mandated study removal."
89417845|NCT02238639|No Intervention|Standard management|All included patients will undergo standard clinical management of their exacerbations, as deemed appropriate by the attending physician.
89417846|NCT02186028|Experimental|Vitamin D 400 IU|"Vitamin D-400IU/ml- 1ml daily~Neonates will be administered Vitamin D 400 IU orally daily by the mother or other caregiver for a period of six months. The neonates will be followed up for compliance at 2 weeks, 6, 10 and 14 weeks and thereafter at 6 months of age."
89417847|NCT02186028|Active Comparator|Vitamin D 200IU|"Vitamin D 400IU/ml : 0.5ml daily~Neonates will be administered Vitamin D 200 IU orally daily by the mother or other caregiver for a period of six months. The neonates will be followed up for compliance at 2 weeks, 6, 10 and 14 weeks and thereafter at 6 months of age."
89417848|NCT02182596|Experimental|DAUNORUBICINE - ARACYTINE - MYLOTARG -|"Adaptive Bayesian method for dose-finding in phase I/II clinical trials based on treatment efficacy and toxicity (Thall, Russel, 1998), with successive patients cohorts and three combined dose levels:~DNR 45 mg/m2 IV days 1 to 3 + AraC 100 mg/m2 CI days 1 to 7 + Mylotarg 3mg/m2 IV days 1, 4, 7.~DNR 60 mg/m2 IV days 1 to 3 + AraC 100 mg/m2 CI days 1 to 7 + Mylotarg 3mg/m2 IV days 1, 4, 7.~DNR 60 mg/m2 IV days 1 to 3 + AraC 200 mg/m2 CI days 1 to 7 + Mylotarg 3mg/m2 IV days 1, 4, 7.~Two consolidation courses for CR patients:~Amsacrine: 90 mg/m2 IV Day 1 Cytarabine: 1g/m2 twice a day IV Days 1 to 4 Mylotarg: 3 mg/m2 IV Day 1."
89417849|NCT03574701|Experimental|A: Vitamin A and Olfactory Retraining|Group A: This study group will receive intranasal vitamin A at 10,000 I.U. per day and olfactory retraining using scented oils in addition to their standard of care.
89417850|NCT03574701|Experimental|B: Vitamin A|Group B: This study group will receive Vitamin A in addition to their standard of care. They will not receive olfactory retraining.
89417851|NCT03574701|No Intervention|C: Standard of Care|Group C: This study group will receive only standard of care .
89417852|NCT02180880|Experimental|Pregabalin and Oxcarbazpepine|Pregabalin and Oxcarbazepine
89417853|NCT05471440|Active Comparator|Direct boost mRNA|Participants will be randomised into a direct boost group (DB; i.e end of August) or a post-poned boost group (PPB; i.e 3-4 months later) group after stratification for priming (mRNA versus Janssen). The immune response will be measured at start of the study (visit 1, all participants) and 0, 7, 28 and 84 days after boost.
89417854|NCT05471440|Active Comparator|Direct boost adeno|Participants will be randomised into a direct boost group (DB; i.e end of August) or a post-poned boost group (PPB; i.e 3-4 months later) group after stratification for priming (mRNA versus Janssen). The immune response will be measured at start of the study (visit 1, all participants) and 0, 7, 28 and 84 days after boost.
89417855|NCT05471440|Active Comparator|Post-poned boost mRNA|Participants will be randomised into a direct boost group (DB; i.e end of August) or a post-poned boost group (PPB; i.e 3-4 months later) group after stratification for priming (mRNA versus Janssen). The immune response will be measured at start of the study (visit 1, all participants) and 0, 7, 28 and 84 days after boost.
89417856|NCT05471440|Active Comparator|Post-poned boost adeno|Participants will be randomised into a direct boost group (DB; i.e end of August) or a post-poned boost group (PPB; i.e 3-4 months later) group after stratification for priming (mRNA versus Janssen). The immune response will be measured at start of the study (visit 1, all participants) and 0, 7, 28 and 84 days after boost.
88895717|NCT04462601||Patients with Sjögren Syndrome|
89417857|NCT02186106|Experimental|Loading dose substitution|Substituted with a highdose of cholecalciferol at study start
89417858|NCT02186106|No Intervention|Historic controls|Control subjects from journal archive
88895718|NCT04443010|Experimental|Phase 1 part: Dose Finding|Patients will be treated in cohorts according to a 3+3 study design with standard treatment (consisting of radiotherapy of 60 Gy/30 fractions for 6 weeks plus 75 mg/m2 TMZ (temozolomide) daily (chemoradiotherapy), followed by 4 weeks of treatment break, followed by maintenance treatment with 6 maintenance cycles of TMZ 150-200 mg/m2 on Days 1 to 5 q28) combined with L19TNF at different dose levels on Day 1, 3, 5, 22, 24 and 26 of chemoradiotherapy and on Day 1, 3 and 5 of each 28-day chemotherapy maintenance cycle.
88895719|NCT04443010|Experimental|Phase 2 part: Signal Seeking|32 patients will receive standard chemoradiotherapy and L19TNF at RD and with the administration scheme established in phase I part of the study.
88895720|NCT04443010|Active Comparator|Phase 2b part: Activity Evaluation_control arm|"Patients will be randomized 1:1 and treated with either standard chemoradiotherapy and L19TNF as established in phase I part and the phase II part of this study or only chemoradiotherapy (control).~- Arm 2: Patients will receive radiotherapy and TMZ (temozolomide)."
89417859|NCT02181036|Experimental|family work shop|2 to 3 hours per session, one session per week, for a total of 6 weeks of family work shop
89417860|NCT02239419|Experimental|CO2-Enriched Tap Water (Carbothera)|CO2-enriched tap water (CO2 concentration, 1000-1200 ppm) maintained at a temperature of 37˚C. Tap water will be enriched with CO2 by the investigational Carbothera device.
89417861|NCT02239419|Placebo Comparator|Non-CO2-Enriched Tap Water|Non-CO2-enriched tap water (i.e. normal tap water) maintained at a temperature of 37˚C.
88895721|NCT04443010|Experimental|Phase IIb part: Activity Evaluation_treatment arm|"Patients will be randomized 1:1 and treated with either standard chemoradiotherapy and L19TNF as established in phase I part and the phase II part of this study or only chemoradiotherapy (control).~- Arm 1: Patients will receive radiotherapy, TMZ (temozolomide) and L19TNF."
88895722|NCT04423237||Severe Iron Overload (SIO)|Children affected by Severe Iron Overload who received DEFERASIROX
88895723|NCT04423237||Severe Iron Overload + Ductopenia (SIO+D)|Children affected by Severe Iron Overload + Ductopenia who received DEFERASIROX
88895724|NCT04416750|Experimental|Treatment|Open label; Imatinib tablets administered once daily; Dosage: in the range of 100mg-400mg; Group evaluated: adults with PAH
88895725|NCT04412538|Experimental|Low dosage vaccine on a 0- and 28-day schedule|Two doses of low dosage Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0, 28
88895726|NCT04412538|Experimental|Low dosage vaccine on a 0- and 14-day schedule|Two doses of low dosage Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0, 14
88895727|NCT04412538|Experimental|Medium dosage vaccine on a 0- and 28-day schedule|Two doses of medium dosage Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0, 28
88895728|NCT04412538|Experimental|Medium dosage vaccine on a 0- and 14-day schedule|Two doses of medium dosage Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0, 14
88895729|NCT04412538|Experimental|High dosage vaccine on a 0- and 28-day schedule|Two doses of high dosage Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0, 28
88895730|NCT04412538|Experimental|High dosage vaccine on a 0- and 14-day schedule|Two doses of high dosage Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0, 14
88895731|NCT04412538|Placebo Comparator|Placebo on a 0- and 28-day schedule|Two doses of placebo at the vaccination schedule of day 0, 28
88895732|NCT04412538|Placebo Comparator|Placebo on a 0- and 14-day schedule|Two doses of placebo at the vaccination schedule of day 0, 14
88895733|NCT04411732||patients with neuromuscular disorder|cohort of patients with neuromuscular disorder
88895734|NCT04411732||healthy controls|cohort of healthy controls
88895735|NCT04411199|Experimental|D-PLEX+SoC|D-PLEX is provided to suitable and willing study subjects as an adjunct to the SoC treatment
88895736|NCT04411199|Other|Standard of Care|The SoC for prophylactic antibiotic treatment is based on international guidelines
89417862|NCT03943147|Experimental|BMS-986165 Dose 1|Specified Dose on Specified Days
89417863|NCT03943147|Experimental|BMS-986165 Dose 2|Specified Dose on Specified Days
89417864|NCT03943147|Placebo Comparator|Placebo for BMS-986165|Specified Dose on Specified Days
89417865|NCT03943147|Experimental|Mycophenolate Mofetil (MMF)|Specified Dose on Specified Days
89417866|NCT03536130|Experimental|Electronic chest drainage system|Patients in the intervention arm are connected to Drentech Palm Evo with single standard chest tube (28 Ch) immediately after closure of the chest. Patients with digital devices are managed by setting the pump to -20 cmH2O until the morning of postoperative day (POD) 1 and then setting the pump on physiologic mode (0 cmH2O) thereafter.
89417867|NCT03536130|No Intervention|Traditional device|Patients in the no intervention (traditional) arm are connected to traditional drain system with single standard chest tube (28 Ch) immediately after closure of the chest. Patients with traditional devices (requiring connection to wall suction) are managed by applying suction (-20 cmH2O) until the morning of POD 1 and are subsequently disconnected from suction thereafter.
89417868|NCT03617133|Other|Standard arm|General and specific aims of EMBRACEII as well as the multiple quantitative hypotheses are based on technical data, dose volume parameters and clinical results of the prospective observational study EMBRACEI (NCT00920920, 3 year data 2015) and the retrospective RetroEMBRACE (3/5 year data 2015). The performance of EMBRACE II interventions and clinical outcome in terms of disease- (local, nodal, systemic control, OS, CSS) and morbidity-outcome (various organs and endpoints) is thus based on recent clinical evidence with radiochemotherapy and image guided adaptive brachytherapy. The expected effect of EMBRACE II interventions on clinical outcome is estimated from comparative analyses of interventions in subgroups of Retro-/EMBRACE (partly published). Based on the Retro-/EMBRACE benchmark, the estimated outcome including a confidence interval is quantified for each clinical endpoint in the overall cohort as well as different subgroups for an overall expected patient number of 1000.
88895737|NCT04407247|Active Comparator|Arm I (infliximab)|Patients receive infliximab IV over 1 hour once at week 0, 2, 6 for a total of 3 doses in the absence of disease progression or unacceptable toxicity.
88895738|NCT04407247|Experimental|Arm II (vedolizumab)|Patients receive vedolizumab IV over 1 hour at week 0, 2, 6 for a total of 3 doses in the absence of disease progression or unacceptable toxicity.
89417869|NCT02182674|Experimental|Combivent HFA|
88895739|NCT04402216|No Intervention|Current standard of care, no formal preparation|Participants in this group will receive the standard of care with no formal preparation. MRI technologist will meet patient prior to scan introducing role of patient, role of MRI technician, and give verbal discussion of MRI process. MRI technologist will offer opportunity for patient to watch a movie as alternative focus/distraction during MRI scan. The child life specialist will not meet with the caregiver or child during their visit.
89417870|NCT02182674|Active Comparator|Combivent (CFC)|
88895740|NCT04402216|Experimental|Child Life-led preparation|Participants will meet with a child life specialist who will provide psychological preparation utilizing photos, MRI sounds, verbal discussion of MRI process, and discuss various coping strategies such as deep breathing or stress ball and option to watch a movie for alternative focus/distraction during the scan.
88895741|NCT04402216|Experimental|MRI preparation video|Participants will be shown an MRI preparation video by the research coordinator in the MRI dressing room prior to MRI scan. The MRI preparation video will walk the patient through the MRI experience with a mock patient explaining all the steps of MRI process from check in to discharge. The child life specialist will not meet with the caregiver or child during their visit.
88895742|NCT04402216|Experimental|Child Life preparation with VR|Participants will be provided MRI preparation with a child life specialist using the Kind VR device. The VR (virtual reality) session will consist of an audio and visual MRI experience designed to serve as an opportunity for the patient to practice their scan prior to MRI. The VR session will take place once during the Radiology admission and will be approximately 15 minutes in duration. The VR software was developed by Kind VR and was designed specifically for the purpose of preparation for brain MRI. The interactive VR experience walks patients through each step of an MRI. Patients can practice holding still for the MRI and will get feedback from the VR headset when they are moving their head. Along with VR practice session CCLS will discuss various coping strategies such as deep breathing and/or stress ball and option to watch a movie for alternative focus/distraction during the scan.
88895743|NCT04398680|Experimental|Part 1, Group 1: Participants with normal hepatic function|Participants with normal hepatic function (Serum bilirubin and Aspartate aminotransferase [AST] less than or equal to [<=] Upper limit of normal [ULN]) will be administered with Belantamab mafodotin
88895744|NCT04398680|Experimental|Part 1, Group 2: Participants with moderate hepatic impairment|Participants with moderate hepatic impairment (Serum bilirubin greater than >1.5 - 3 times ULN and any AST) will be administered with Belantamab mafodotin
88895745|NCT04398680|Experimental|Part 2,Group 3: Participants with severe hepatic impairment|Participants with severe hepatic impairment (Serum bilirubin >3 times ULN and any AST) will be administered with Belantamab mafodotin
88895746|NCT04389450|Experimental|PLX-PAD interval high dose|PLX-PAD will be administered via 15 IM injections (1 mL each). Each subject will be treated twice, with an interval of 1 week between treatments.
88895747|NCT04389450|Experimental|PLX-PAD low dose|PLX-PAD 300, single administration, second administration of placebo after 1 week.
88895748|NCT04389450|Placebo Comparator|Control Group A|Placebo, two administrations, 1 week apart
88895749|NCT04389450|Experimental|PLX-PAD high dose|PLX-PAD, single administration
88895750|NCT04389450|Placebo Comparator|Control Group B|Placebo, single administration
88895751|NCT04364230|Experimental|All Participants|6MHP (200mcg of each peptide) and 300mcg of NeoAg-mBRAF will be co-administered locally with 0.9mg of polyICLC and CDX-1140. There will be a dose escalation of CDX-1140 (50mcg, 200mcg, 800mcg, 3.0mg). A vaccine containing all of these components will be given on days 1, 22, 43, and 64. The vaccine will be given subcutaneously/intradermally.
89006292|NCT04639765|Experimental|Combined Treatment without Personalization|Video provides information on the combined treatment of cognitive behavioral therapy with antidepressant medications.
89006293|NCT04639765|Experimental|Combined Treatment with Personalization|Video provides information on the combined treatment of cognitive behavioral therapy with antidepressant medications and describes how treatment can be personalized.
89006294|NCT00218894||post cataract surgery|
89417871|NCT02182752|Active Comparator|Ropivacaine - Tramadol|
89417872|NCT02182752|Active Comparator|Ropivacaine|
89417873|NCT03703258|Experimental|Intervention|"The THRIVE app involves 3 weeks of daily activities. Day 1 involves identification of activities to add to a self-care activity list with guidance around selecting activities that increase social contact, reduce alcohol use, and reduce avoidance. They will also complete an active-learning exercise about cognitive distortions and create a stuck point to-do list consisting of their cognitive distortions. In subsequent days, participants will be prompted to complete activities from both lists. They will also have access optional activities on topics such as asking for help, preventing isolation, deciding whether to disclose an assault, coping with negative reactions to disclosure, and thinking in helpful ways about social support. They will be prompted to complete brief daily surveys in the app, which will populate a symptom tracker. Participants in will have brief weekly phone contact with a coach to monitor safety and troubleshoot issues with app use."
89417874|NCT03703258|No Intervention|Assessment-only control|The assessment-only control condition will involve access to a version of the app that includes daily surveys and a symptom tracker populated by these surveys, but without any of the other exercises included in the experimental version of the app. Participants in the control condition will have brief weekly phone contact with a coach to monitor safety and troubleshoot issues with app use.
89417875|NCT02186184|Experimental|Orthokeratology in the first year|The participants would wear orthokeratology in the first year and then switch to spectacle in the second year
89417876|NCT02186184|Active Comparator|Spectacle in the first year|The participants would wear spectacle in the first year and then changed to orthokeratology in the second year
88895752|NCT04362722|Experimental|Single arm|"40 patients will be enrolled and treated with a mixture of 6.5 Mio IU (~1.08 mg) L19IL2 and 200 µg L19TNF once weekly for 4 consecutive weeks. The dose will be distributed among the lesions via multiple intralesional injections.~New lesions occurring during the treatment phase will also be treated as described but the treatment period for new lesions will not be extended beyond the previously defined 4 weeks treatment period with clock-start at the time of the first intralesional L19IL2/L19TNF injection.~After the Tumor Assessment/Safety visit, patients may receive surgery in a curative intention within 6 weeks, in order to assess the pathological response with estimation of percent of residual viable tumor cells."
88895753|NCT04350866||Pre-Implementation (0-, 6-, 12-, or 18-months)|Following training in BBTI, all sites (except site 1) will enter the pre-implementation phase for 6-, 12-, or 18-months. During this phase, sites will not receive any access to or support for the implementation strategies. They will deliver and implement BBTI as they see fit. Qualitative interviews will be conducted at the end of this phase.
88922176|NCT05697757|Experimental|Dynamic Condition followed by Placebo Condition|Each lighting condition will last for three weeks (Weeks 2-4 or 5-7). The order of conditions will be randomized. Sleep data will be collected only on the last 7 days of each condition using actigraphy. Light spectrum and intensity will be tracked continuously throughout the waking hours (wearable light tracker). Moreover, caregivers will complete two questionnaires (CSDD and CMAI) every seven days to assess the short and long-term effects of each condition on mood and agitation of older adult participants.
89417877|NCT03572439|Active Comparator|Cephalad to caudal|Sensory block level check using ice, moving from cephalad to caudal
89417878|NCT03572439|Active Comparator|Caudal to cephalad|Sensory block level check using ice, moving from caudal to cephalad
89417879|NCT03572361|Experimental|V3-MOMMO|Oral once daily pill of tableted vaccine (V3-MOMMO) containing pooled breast cancer antigens administered for 3 months in 20 volunteers with breast cancer
89417880|NCT03730987|Experimental|HoMBRES Intervention Group - Father|Four sessions (2 sessions per week, approximately 1.5 hours each) with the fathers, in which facilitators conduct educational sessions; During the period of social distancing, interventions were remotely facilitated via a well-tested video platform accessible by a link sent to the participants' telephone, computer, tablet or IPad (approximately 1.5 hours each session. Intervention videos were followed up with a telephone call to respond to any questions participants may have had about the sessions and clarify (if needed) the material covered in the videos via telephone or videoconferences. Only fathers were included in this group.
88922177|NCT05695638||Intention-to-treat cohort|All patients included
89417881|NCT03730987|Active Comparator|Diabetes Prevention Intervention Group - Father|One session of 1.5 hours held once per week. Session content will focus on the importance of physical activity, healthy eating, and maintaining a healthy weight. Only fathers were included in this group.
89417882|NCT03730987|No Intervention|HoMBRES Intervention Group - Adolescent|The adolescent received no intervention.
89417883|NCT03730987|No Intervention|Diabetes Prevention Intervention Group - Adolescent|The adolescent received no intervention.
89417884|NCT02186262||Primary gliomas, Recurrent gliomas|
89417885|NCT02186340|Experimental|Inspiratory muscle training|
89417886|NCT03572205|Experimental|CC genotype LA|4-week study diet will be isocaloric following the habitual diet of the participants with a supplement of 30-50 ml (5-6 % of energy intake) of sunflower oil (source of LA: linoleic acid) daily, depending on body weight. The same diet will be instructed for both genotypes.
89417887|NCT03572205|Experimental|TT genotype LA|4-week study diet will be isocaloric following the habitual diet of the participants with a supplement of 30-50 ml (5-6 % of energy intake) of sunflower oil (source of LA: linoleic acid) daily, depending on body weight. The same diet will be instructed for both genotypes.
89417888|NCT03572205|Experimental|CC genotype ALA|4-week study diet will be isocaloric following the habitual diet of the participants with a supplement of 30-50 ml (5-6 % of energy intake) of camelina oil (source of alpha-linolenic acid: ALA) daily, depending on body weight. The same diet will be instructed for both genotypes.
89417889|NCT03572205|Experimental|TT genotype ALA|4-week study diet will be isocaloric following the habitual diet of the participants with a supplement of 30-50 ml (5-6 % of energy intake) of camelina oil (source of alpha-linolenic acid: ALA) daily, depending on body weight. The same diet will be instructed for both genotypes.
89417890|NCT02181192|Experimental|delayed radiotherapy|PET/CT and Radiotherapy after achievement of PSA marginal value Additive imaging
88895754|NCT04350866||Implementation (12-months)|After the pre-implementation phase, all sites will enter a 12-month implementation phase (except site 1, which will begin implementation following BBTI training). During this phase, sites will receive access to and support for the bundle of implementation strategies, both from the hub site and their local champion/internal facilitator. During this phase, PCMHI clinicians trained in BBTI will receive feedback as necessary regarding their BBTI skills from their local champion/internal facilitator. During this phase, PCMHI clinicians will also complete quarterly surveys regarding implementation strategies they are using and which strategies are/are not helpful. Qualitative interviews will be conducted at the end of this phase.
88895755|NCT04350866||Post-Implementation (6-months)|Following the 12-month implementation phase, each site will have access to and support for the implementation strategies removed and similar to the pre-implementation phase, will deliver and implement BBTI as they see fit. During this 6-month phase, PCMHI clinicians will also complete quarterly surveys regarding implementation strategies they are using and which strategies are/are not helpful. Qualitative interviews will be conducted at the end of this phase.
88895756|NCT04344626|Experimental|Brain tonometry|Participants undergoing intra-operative brain tissue stiffness measurements using a digital tonometer. Evaluated brain tissue is both presumed normal and abnormal based on results of pre-operative evaluations.
88895757|NCT04332341|Experimental|Nicotinamide riboside (NR)|
88895758|NCT04325659|Active Comparator|Lofexidine/Sham Bridge Device|Lofexidine (Lucemyra) encapsulated
88895759|NCT04325659|Placebo Comparator|Sham Bridge Device /Placebo Study Drug|Inactive Bridge Device and placebo study drug
88895760|NCT04325659|Experimental|Active Bridge Device/ Placebo Study Drug|Active Bridge Device and placebo study drug
88895761|NCT04314375|Experimental|Low Dose Budesonide|
88895762|NCT04314375|Experimental|High Dose Budesonide|
88895763|NCT04314375|Placebo Comparator|Placebo|
88895764|NCT04308278|Experimental|2LEBV® / 2LXFS®|6 months of treatment
89193581|NCT04587531|Sham Comparator|Sham CES Therapy|Group receives treatment using sham cranial electrotherapy stimulation devices for 6 weeks. No actual treatment will be received. This group will not receive any treatment interventions. The same outcome measures will be used as the treatment group.
89193582|NCT04586257|Experimental|Group I|patients in this group will receive Erector spinae plane block after induction of general anesthesia.
89193583|NCT04586257|Experimental|Group II|patients in this group will receive thoracolumbar interfascial plane block after induction of general anesthesia
89417891|NCT02181192|Active Comparator|instant radiotherapy|Instant Radiotherapy according to guidelines
89417892|NCT03536598|Experimental|Test|Amlodipine 10mg + Valsartan 160mg + Rosuvastatin 20mg
89417893|NCT03536598|Active Comparator|Reference 1|Amlodipine 10mg + Valsartan 160mg
89417894|NCT03536598|Active Comparator|Reference 2|Valsartan 160mg + Rosuvastatin 20mg
89417895|NCT03574467||Bobath Approach Applied to Patient with Brain Tumors|
89417896|NCT03574467||Bobath Approach Applied to Patient with Stroke|
89417897|NCT05462314||Gastrointestinal Malignancies (pancreatic, colorectal, gastroesophageal, and hepatobiliary)|Individuals with a gastrointestinal malignancy including pancreatic, colorectal, gastroesophageal, or hepatobiliary malignancies.
89417898|NCT03065608||Study Group|The study group included 36 patients with pain form of dysfunction.
89417899|NCT03065608||Control Group|The control group consisted of 36 patients with painless form of disorder.
88895765|NCT04308278|Placebo Comparator|Placebo|6 months of treatment
88895766|NCT04304963||T1DM and intact awareness of hypoglycaemia|200 participants with T1DM and intact awareness of hypoglycaemia
89417900|NCT03536988|Experimental|TAMIS-IPAA|In TAMIS-IPAA group, transanal minimally invasive surgery of proctectomy with IPAA will be performed.
88895767|NCT04304963||T1Dm and impaired awareness of hypoglycaemia|50 participants with T1Dm and impaired awareness of hypoglycaemia
88895768|NCT04304963||insulin treated T2DM|350 participants with insulin treated T2DM ( > 1 injections / day)
88895769|NCT04303403|Experimental|Dose Escalation and Expansion|"Dose Escalation:~Trametinib 2mg daily monotherapy for 14 days. Followed by combination oral trametinb (2mg starting dose) daily and oral ruxolitinib (5mg starting dose) twice daily at assigned doses.~Dose Expansion:~Combination oral trametinb daily and oral ruxolitinib twice daily at the maximum tolerated dose (MTD) established at the Dose Escalation phase.~A cycle of therapy will comprise of 28 days of combination trametinib and ruxolitinib treatment."
88895770|NCT04302103|Experimental|RC18 160mg|Patients received the test group RC18 160mg weekly administered subcutaneously for 24 times.
88895771|NCT04302103|Experimental|RC18 240 mg|Patients received the test group RC18 240mg weekly administered subcutaneously for 24 times.
88895772|NCT04289571|Experimental|Participants|Participants with retinal disease, healthy volunteers
88895773|NCT04285853|Experimental|Oxycodone Arm|"Patients in this opioid group will receive 15 oral opioid tablets (5 mg oxycodone) Patients will also receive 8 rescue medications, in the Oxycodone arm will be placebo rescue medications.~All participants will also receive the following as part of standard of care:~Oral non-opioid (1000 mg acetaminophen), every 8 hours.~Prescription of non-opioid non-steroidal anti-inflammatory medication (naproxen 500 mg) to be used 2x/day post-surgery.~Standardized multimodal intra- and post-operative protocols, including an adductor canal peripheral nerve block.~Intraoperative education on post-surgical pain management."
89193584|NCT04573738|Experimental|Robotic transanal surgery|Robotic assisted transanal total mesorectal excision for rectal cancer patients
89193585|NCT04573738|Active Comparator|Laparoscopic transanal surgery|Laparoscopic transanal total mesorectal excision for rectal cancer patients
89193586|NCT04570709|No Intervention|Control|Patients in the control arm will receive standard of care and no intervention.
89193587|NCT04570709|Experimental|Intervention|Patients in the intervention arm will receive the PACT intervention provided by a multidisciplinary team of RNs, OTs, and PTs.
89193588|NCT04568369|Experimental|Treatment group|Patients will engage in a four-week treatment protocol (20 treatments). This was chosen as it is the midpoint between typical depression and migraine protocol durations. A standardized atlas brain with Montreal neurologic institute (MNI) coordinates will be used for navigation. The DLPFC will be located through MNI coordinates (-50, 30, 36). The intensity of the rTMS will be 100-120% of resting motor threshold amplitude, with a frequency of 10 Hz, 10 trains of 60 pulses/train (total of 600 pulses) and an inter-train interval of 45s.
89193589|NCT04568369|Sham Comparator|Sham group|In the sham condition, a sham coil will be applied to the scalp after the resting motor threshold is determined. Patients will be able to hear the sound and feel the vibration of sham coil, but will not experience any effective stimulation. Previous sham studies have demonstrated efficacy of the blinding method.
89193590|NCT04564339|Experimental|Ravulizumab: LN Cohort|Eligible participants will receive ravulizumab IV infusion in combination with background therapy during both the Initial Evaluation Period (26 weeks) and Extension Period (24 weeks). During the Follow-up Period (36 weeks) participants will receive background therapy according to the standard of care.
89193591|NCT04564339|Placebo Comparator|Placebo: LN Cohort|Eligible participants will receive placebo IV infusion in combination with background therapy during both the Initial Evaluation Period (26 weeks) and Extension Period (24 weeks). During the Follow-up Period (36 weeks) participants will receive background therapy according to the standard of care.
89535995|NCT03075033|Active Comparator|Awake Fiberoptic Intubation|Use of Awake Fiberoptic Intubation In Patients At Risk Of Secondary Cervical Spine Injury
89535996|NCT03107143|Experimental|Treatment Group|Trial subjects have Q2 System installed on their beds in addition to receiving standard care of pressure ulcer prevention according to study hospital's policy and protocol.
88895774|NCT04285853|Placebo Comparator|Placebo Arm|"Patients in placebo group will receive 15 placebo tablets. All patients will also receive 8 rescue medications: Patients who randomize to the non-opioid arm will receive 5mg oxycodone rescue tablets.~All participants will also receive the following as part of standard of care:~Oral non-opioid (1000 mg acetaminophen), every 8 hours.~Prescription of non-opioid non-steroidal anti-inflammatory medication (naproxen 500 mg) to be used 2x/day post-surgery.~Standardized multimodal intra- and post-operative protocols, including an adductor canal peripheral nerve block.~Intraoperative education on post-surgical pain management."
88895775|NCT04271007|Active Comparator|Group I|Use of the drug Topison on one side of the upper limb and Mometasone Furoate 1mg /g Sanofi, Medley on the opposite side
88895776|NCT04271007|Active Comparator|Group II|Use of the drug Topison on one side of the upper limb and Mometasone Furoate 1mg /g Aché on the opposite side
88895777|NCT04252547|Experimental|Grup 1|"-During the Procedure Group 1 The preprocedural measurements(weight, heart rate and oxygen saturation ) will be applied to the infants in Group 1 before the first feeding hour when they are included in the study and then they will be held on their mothers' chest for skin-to-skin kangaroo care for half an hour. Their heart rate and oxygen saturation will be recorded for half an hour. At the end of the kangaroo care, the infant will be breastfed by his/her mother.~During the second feeding hour, his/her heart rate and oxygen saturation will begin to be recorded ten minutes before the feeding hour. The data will be recorded for ten minutes and then the infant will be taken out of the incubator and weight is measured only in his/her clean diaper. He/she will be handed over to the mother to breastfeed."
88895778|NCT04252547|Experimental|Grup 2|"- During the Procedure Group 2 The preprocedural measurements will be applied to the infants in Group 2 before the first feeding hour when they are included in the study and then they will be breastfed by their mothers.~The preprocedural measurements (weight, heart rate and oxygen saturation) will be applied to the infant during the second feeding hour and then he/she will be held on his/her mothers' chest for skin-to-skin kangaroo care for half an hour. Their heart rate and oxygen saturation will be recorded for half an hour. At the end of the kangaroo care, the infant will be breastfed by his/her mother."
88895779|NCT04243473||Prostate Biopsy, Urine sample and Blood sample|For purposes of exploratory analyses, blood (whole blood, serum, plasma) and urine samples will be collected pre-IR treatment, 1-month post-implant, 6 month follow-up and 2 years follow-up. Patients will be asked to opt-in on the consent form specifically for the 2-year biopsy, otherwise they have the choice to opt out.
88895780|NCT04239963||Healthy Controls|Subjects who have no history of clinical depression or other psychological disorder
88895781|NCT04239963||Current MDD|Subjects experiencing a current episode of Major Depressive Disorder.
88895782|NCT04239911|Active Comparator|Enhanced usual care|Home health aides in the enhanced usual care arm will receive a virtual heart failure training course.
88895783|NCT04239911|Experimental|Intervention arm|Home health aides in the intervention arm will receive a virtual heart failure training course and a communication-based messaging app.
88895784|NCT04235322|Experimental|2LHERP® arm|2LHERP® treatment (6 months of treatment)
88895785|NCT04235322|Placebo Comparator|Placebo arm|Placebo treatment (6 months of treatment)
88895786|NCT04230395|Experimental|CAP (Counseling on Alcohol Problems)|The CAP intervention is an up to 4-session alcohol reduction intervention that uses a combination of Motivational Enhancement Therapy and Cognitive Behavioral Therapy. The intervention will also include 3 booster sessions.
88895787|NCT04230395|Other|Usual Care|Provider advice to reduce alcohol use per recommended standard of clinical care, and referral to treatment as indicated
88895788|NCT04224519|Experimental|Batch 1 of sIPV|The first commercial batch of sIPV
88895789|NCT04224519|Experimental|Batch 2 of sIPV|The second commercial batch of sIPV
88895790|NCT04224519|Experimental|Batch 3 of sIPV|The third commercial batch of sIPV
88895791|NCT04220515|Experimental|Inactivated Poliomyelitis Vaccine Made From Sabin Strain|Primary 3-dose of sIPV and booster 1 dose of sIPV
88895792|NCT04219332|Experimental|Subserosal injection of indocyanine green tracer group|Subserosal injection of indocyanine green, with a concentration of 0.5 mg /ml, 6 points along the lesser and greater curvature of the stomach, 1.5 ml for each point.
88895793|NCT04219332|Active Comparator|Submucosal injection of indocyanine green tracer group|Submucosal injection of indocyanine green, with a concentration of 1.25mg /ml, four points around the primary tumor, each point 0.5 ml.
88895794|NCT04211649|Experimental|3 days of antibiotherapy|The patient viewed for the first time at the hospital and suspected of leptospirosis received a probabilistic antibiotherapy
89193592|NCT04564339|Experimental|Ravulizumab: IgAN Cohort|Eligible participants will receive ravulizumab IV infusion in combination with background therapy during both the Initial Evaluation Period (26 weeks) and Extension Period (24 weeks). During the Follow-up Period (36 weeks) participants will receive background therapy according to the standard of care.
88895795|NCT04211649|No Intervention|7 days of antibiotherapy (Amoxycilline or Doxycycline)|When the leptospirosis is confirmed ( PCR Leptospirosis positive) the pobabilistic antibiotherapy is switched to a prophylactic antibiotherapy with Amoxicillin or Doxycycline.
88895796|NCT04204616|Experimental|Nemolizumab|Participants weighing less than (<) 90kilogram (kg) will receive 30 milligram (mg) nemolizumab every 4 weeks (Q4W) and participants weighing greater than or equal to (>=) 90 kg will receive 60 mg nemolizumab (two 30-mg injections) Q4W.
88895797|NCT04199767|Experimental|20 IU Insulin first, then 40 IU Insulin|Participants will be randomly assigned to receive regular insulin (U100, 20 IU) administered with an intranasal nebulizer-like device. Participants in this arm will then receive regular insulin (U100, 40 IU) at visit 3 during second intervention period.
88895798|NCT04199767|Experimental|40 IU Insulin first, then 20 IU Insulin|Participants will be randomly assigned to receive regular insulin (U100, 40 IU) administered with an intranasal nebulizer-like device. Participants in this arm will then receive regular insulin (U100, 20 IU) at visit 3 during second intervention period.
89193593|NCT04564339|Placebo Comparator|Placebo: IgAN Cohort|Eligible participants will receive placebo IV infusion in combination with background therapy during the Initial Evaluation Period (26 weeks) and will switch to ravulizumab for the Extension Period (24 weeks). During the Follow-up Period (36 weeks) participants will receive background therapy according to the standard of care.
89417901|NCT03536988|Active Comparator|Lap-IPAA|In Lap-IPAA group, transabdominal minimally invasive surgery of proctectomy with IPAA will be performed.
89006295|NCT04639375|Experimental|Vaccinated with polio vaccine (IPV)|All subjects will receive polio vaccine: IPV as manufactured by Sanofi Pasteur for distribution in the United States
89006296|NCT04639492|Experimental|MBS oral solution|fermented soybean extract-MBS
89006297|NCT04639453||Stroke|Individuals with post-stroke hemiparesis in subacute phase will be included in the study.
89006298|NCT00218933|Active Comparator|moderate exercise training|
89006299|NCT00218933|Experimental|high intensity exercise training|
89006300|NCT00218933|No Intervention|controls|
89006301|NCT04638985|Experimental|group 1 (sIPV+DTaP+MMR)|150 subjects; simultaneously administration of sIPV+DTaP+MMR as booster immunization at the age of 18 months old, 0.5 ml each, respectively
89006302|NCT04638985|Active Comparator|group 2 (sIPV)|150 subjects; vaccination of 0.5 ml sIPV as booster immunization at the age of 18 months old
89006303|NCT04638985|Active Comparator|group 3 (DTaP)|150 subjects; vaccination of 0.5 ml DTaP as booster immunization at the age of 18 months old
89006304|NCT04638985|Active Comparator|group 4 (MMR)|150 subjects; vaccination of 0.5 ml MMR as booster immunization at the age of 18 months old
89006305|NCT04638907||Observational study group|Consenting adult male patients undergoing elective robot-assisted prostatectomy. No further selection or randomisation. Enrollment as availability for the study.
89006306|NCT04709718||churgery of geant liver hemangioma|
89006307|NCT04628884|Active Comparator|Protamine dosing according the total heparin administrated|The protamine dose will be calculated according to the total heparin administered including the heparin dose add during the pump purge, 1 mg of protamine for each 100 IU of heparin
89006308|NCT04628884|Experimental|Protamine dosing according the residual heparin determined by a pharmacokinetic model|The protamine dose will be calculated according to the residual heparin estimated before the separation of the cardiopulmonary bypass using a pharmacokinetic model, 1 mg of protamine for each 100 IU of residual heparin
89006309|NCT04629157|Experimental|All patients|All patients entering the study will undergo paired testing of a lateral flow device using an anterior nasal swab and an RT-PCR using a nose and throat swab.
89006310|NCT00561301|No Intervention|1|
89006311|NCT00412334|Experimental|1|
89006312|NCT00412334|Experimental|2|
89006313|NCT00412334|Experimental|3|
89006314|NCT00412334|Experimental|4|
89006315|NCT00561379|Active Comparator|1|
89006316|NCT00561379|Active Comparator|2|
89006317|NCT04629118||Selution SLR™ 018 Drug Eluting Balloon|Subjects will undergo fistuloplasty with the study device - Selution SLR™ 018 Drug Eluting Balloon
89006318|NCT00561496|Other|Twice daily|Tenofovir gel intravaginal twice daily for 14 days
89006319|NCT00561496|Other|Once daily|Tenofovir gel intravaginal once daily for 14 days
89006320|NCT00218972|Active Comparator|AIT: aerobic interval training|High intensity interval training on treadmill at > 90% of maximal HR for four bouts of four minutes with warm up, active pauses and cool down, three times per week for 12 weeks.
89006321|NCT00218972|Active Comparator|MIT, moderate intensity training|Moderate intensity treadmill continuous exercise at 70% of maximum heart rate for 47 minutes (in order to ensure isocaloric training amount), three times per week for 12 weeks.
89006322|NCT00218972|Active Comparator|Recommendation of regular exercise|No training intervention, general advice as prescribed in guidelines.
89006323|NCT00561535|Experimental|A|Lactobacillus FARCIMINIS
89006324|NCT00561535|Placebo Comparator|B|Placebo
89006325|NCT03454672|Experimental|Tixel|Tixel Treatment.
89006326|NCT03454672|Active Comparator|Laser|Laser Treatment.
89006327|NCT03454633|Experimental|Mild hypothermia|Initiation of circulatory arrest using the cardiopulmonary bypass at temperature 28.1 - 34 degrees Celsius
89006328|NCT03454633|Active Comparator|Moderate hypothermia|Initiation of circulatory arrest using the cardiopulmonary bypass at temperature 20.1 - 28 degrees Celsius
89006329|NCT04628923|Experimental|QLB|"With the patient in the lateral decubitus and the block side independent, a curvilinear ultrasound transducer (2-5 MHz) will be directed caudally in a sagittal plane 3-4 cm lateral to the lumbar spinous process of L4, which is almost opposite to the iliac crest, producing a longitudinal scan of the lumbar paravertebral region; and thus identifying the transverse processes of L3 and L4, with PM muscle in-between and erector spinae muscle posteriorly.~The probe is shifted slowly to the lateral side until the transverse processes disappear and the QL muscle is evident in its long axis attached caudally to the iliac crest with a characteristic sonographic image of three muscle layers appearing from posterior to anterior as: erector spinae, QL, and PM muscles respectively."
89006330|NCT04628611|Active Comparator|Video laryngoscopy Group (V) using Storz c-mac laryngoscope|video laryngoscope without a channel used for endotracheal intubation, the device used to obtain a view of the larynx, and the endotracheal tube is passed through the vocal cords independent of the device. The device is connected to the monitor via connecting cable
89006331|NCT04628611|Active Comparator|The flexible intubating laryngoscopy Group (F) using Storz flexible intubation video endoscope set|The flexible intubating scope is used to locate the vocal cords and acts as a stylet for the endotracheal tube once the scope is placed into the trachea.This device consists of a flexible insertion cord that contains a small camera at the tip, used to transmit images to camera head. The cord includes a channel for a light source, a working channel for suction or administration of oxygen or local anesthetic, and a cable that allows the operator to flex the tip of the scope. The cord attaches to a handle with a light source,camera head control lever for flexion/extension of the tip, and a working channel port. The device is connected to the monitor via connecting table
89006332|NCT04628845|Placebo Comparator|SRP and endontic treatment without laser 940nm|Periodontal pockets's treatment of scaling, root debridement and endodontic treatment of root canals without using laser 940nm.
89006333|NCT04628845|Active Comparator|SRP and endodontic treatment with laser 940nm|Periodontal pockets's treatment of scaling, root debridement and endodontic treatment of root canals with using laser 940nm.
89006334|NCT04628806||HSP70CTC|Isolation of circulating tumor cells by HSP70
89006335|NCT04628689|Active Comparator|Group 0.25% bupivacaine|30 ml 0.25% bupivacaine
89006336|NCT04628689|Active Comparator|Group 0.375% bupivacaine|0.375% bupivacaine
89006337|NCT04628455|Other|Inversion and Snaring|needlescopic inversion, snaring, and excision of the hernia sac using two Suture Grasper Sevice of Mediflex Company and a home made snare
89417902|NCT03576963|Experimental|Treatment (guadecitabine, nivolumab)|This study consists of an initial dose escalation followed by an expansion cohort. Dose escalation of guadecitabine starts from 30 mg/m^2 given SC on days 1-5 every 28 days in combination with fixed dose of nivolumab at 240 mg given IV on days 8 and 22 every 28 days. Dose escalation will continue until the maximum tolerated dose is reached or all planned doses are administered.
89006338|NCT00246363|Experimental|Silymarin|Silymarin
89417903|NCT02186496|Experimental|Candesartan and Amlodipine|Candesartan 8mg and Amlodipine 5mg, PO, 1days or 22days
89417904|NCT02186496|Experimental|CKD-330|CKD-330 8/5mg, PO, 1days or 22days
89417905|NCT05615194|Placebo Comparator|Placebo|Normal saline in volume equivalent of dexmedetomidine dose according to patient weight ; Administered via infusion pump (Smith Medical Medfusion® 4000 Syringe Infusion Pump) so that the full dose is delivered over 10 minutes during induction of general anesthesia
89417906|NCT05615194|Active Comparator|Dexmedetomidine|Dexmedetomidine 0.6 mcg/kg (adjusted body weight) ; Administered via infusion pump (Smith Medical Medfusion® 4000 Syringe Infusion Pump) so that the full dose is delivered over 10 minutes during induction of general anesthesia
89417907|NCT03572127|Experimental|Non-animal derived diet|High protein diet derived from non-animal sources.
89417908|NCT03572127|Active Comparator|Animal derived diet|High protein diet derived from animal sources.
89417909|NCT02186574|Active Comparator|Pre-emptive tenofovir|Tenofovir disoproxil
89417910|NCT02186574|Placebo Comparator|Placebo|Placebo
89417911|NCT04974268|Experimental|Exercise and nutritional program|Intervention group that receives supervised exercise and weight loss program based on individual and group intervention with Mediterranean diet and substitute for a daily meal (non-mandatory), manual lymphatic drainage and compression garment if there is more than 600 ml of excess volume in the limb affected.
89417912|NCT04974268|No Intervention|Control Group|Control group will receive recommendations for aerobic unsupervised exercise 150 min per week, standard dietary recommendations (Mediterranean diet pattern and 1800 Kcal diet), manual lymphatic drainage and compression garment if there is more than 600 ml of excess volume in the limb affected.
88895799|NCT04189939||subjects with treatment-resistant depression|approximately 48 subjects with treatment-resistant depression will undergo (1) clinical assessments, (2) perform a computer-based decision-making task while (3) their brain activity is monitored using a 3T MRI scanner.
88895800|NCT04189939||healthy subjects|approximately 48 healthy subjects will undergo (1) clinical assessments, (2) perform a computer-based decision-making task while (3) their brain activity is monitored using a 3T MRI scanner.
88895801|NCT04189939||subjects with non treatment-resistant depression|approximately 48 subjects with non-treatment-resistant depression will undergo (1) clinical assessments, (2) perform a computer-based decision-making task while (3) their brain activity is monitored using a 3T MRI scanner.
88895802|NCT04182776||Pelvis fracture type II to IV|All treatments will remain the standard (routine) care procedures based on individual clinician's judgment and the patient characteristics. The registry does not dictate any specific treatment.
88895803|NCT04159506|Experimental|The Equus Effect (TEE)|TEE is a 4-session intervention. Each session is 4 hours and includes: 1) mindfulness-based activities; 2) didactics about emotion regulation and interpersonal skills; and 3) experiential learning activities with horses that provide opportunities to practice emotion regulation and interpersonal skills. At the end of each session, Veterans debrief about what they learned and identify how they might apply this knowledge to manage their mental health concerns and function better socially.
88895804|NCT04159506|Active Comparator|Attention Control (AC)|AC will exclude equine-related activities or discussions but maintain mindfulness-based activities, emotion regulation and interpersonal skills didactics, and experiential learning activities with between-session application. Instead of experiential equine activities, AC will rely on team-building activities, which aim to enhance social relations by involving participants in collaborative tasks and providing opportunities for emotion regulation and interpersonal skills practice.
88895805|NCT04148066|Other|Osimertinib and Crizotinib|"Osimertinib will be administered according to label: 80 mg once daily.~Crizotinib will only be prescribed upon detection of MET amplification using ctDNA. Crizotinib will be administered according to label: 250 mg bi-daily."
89535997|NCT03107143|No Intervention|Control Group|Control subjects receive only standard care of pressure ulcer prevention according to study hospital's policy and protocol without Q2 System
89536778|NCT05333315|Experimental|Investigation Product 5 (IP5) in two capsules form|CAPSULE 1:L-arginine, 100 mg; Choline bitartrate, 100 mg; L-carnosine, 100 mg; L-taurine, 100 mg; Soy lecithin, 50 mg; R-alfa lipoic acid,10 mg; Vitamin B6,2 mg; Folic acid, 200 µg; Vitamin D3, 5 µg; Vitamin B12, 2 µg CAPSULE 2: Schisandra fruit extract, 400 mg; Milk thistle fruit extract associated with phospholipids, 200 mg; Grape seed extract associated with phospholipids, 50 mg; Grape seed extract (Vitis vinifera),50 mg
88895806|NCT04144231|No Intervention|Treatment-as-usual (TAU)|Treatment-as-usual (TAU) delivered by psychiatrists and psychiatric nurses in HUS Psychiatry Outpatient Clinic for Psychosis. Participants who randomized to TAU -group, may receive medication for insomnia, but they will not received CBT-I. Treatment-as-usual is included in all intervention groups.
88922178|NCT05695274|Experimental|Experimental group|To examine the effects of progressive muscle relaxation exercises on pain, kinesiophobia and functional status in fibromyalgia patients.
88922179|NCT05695274|No Intervention|Control group|Control group; routine care and treatment will be applied.
89536779|NCT03310385|Experimental|High-dose GHX02 group(1,920mg/day)|4 tablets of the GHX02, three times daily for 7 days
88922180|NCT05688345|Active Comparator|Remimazolam|Maintenance doses of remimazolam is administered for sedation
88895807|NCT04144231|Experimental|Internet-Based Cognitive Behavioral Therapy for Insomnia|"TAU and Internet-Based Cognitive Behavioral Therapy for Insomnia (iCBT-I) with the support of a therapist, delivered by mobile application (HUS iCBT-I): There will be seven manualized sessions, conducted at intervals of either every one or two weeks.~HUS iCBT-I, is based on the same theoretical model of insomnia as described in Morin 2003 and Edinger 2015- and involves the same interventions as ordinary CBT-I: a structured treatment focusing on education, behaviors and cognitions. iCBT-I consists of psychoeducation about sleep, sleep restriction therapy, stimulus control, relaxation techniques, and challenging beliefs and perception of sleep.~During the therapy, the therapist monitors progress at least once a week, sends messages to the participant, and answers any treatment-related questions. The aim of the feedback is to comment on exercises, clarify intervention and motivate the patient to persist the in carrying out the treatment and the requested behavioral changes."
88895808|NCT04144231|Experimental|Cognitive Behavioral Group Therapy for Insomnia|TAU and Cognitive Behavioral Group Therapy for Insomnia (GCBT-I): There will be six 90-minute manualized sessions, conducted at intervals of either one or two weeks. One booster session will be conducted one month after the treatment. Each group will have 4-8 people. The content of the CBT-I group is based on CBT for insomnia (as described above) and a previously published insomnia treatment manual for psychotic patients (Waters 2017).To ensuring the rights, safety and wellbeing of participants during the COVID-19 (Coronavirus) pandemic, we produce GCBT-I via internet.
88895809|NCT04142476|Experimental|Pharmaceutical Interview|Pharmaceutical Interview to motivate patient in his hormonotherapy's compliance
88895810|NCT04141358||Study group|Patients with end-stage renal disease who will undergo arteriovenous fistula (AVF) surgery will be recruited and follow-up them up to 6 weeks or until the AVF become suitable for hemodialysis.
88895811|NCT04125914|Experimental|Prevention (weight management, health behavior intervention)|Participants undergo weight management and health behavior intervention with a combination of 4 components for 16 weeks. TELEPHONE COACHING: Participants receive 1 phone call each week from a coach over 30-45 minutes to discuss diet, physical activity and goal setting. EMAIL COACHING: Participants receive 1 phone call to discuss the process over 10-15 minutes and then receive 1 email each week for 16 weeks. NO COACHING: Participants receive 1 phone call the first week over 10-15 minutes to discuss the process. TEXT MESSAGING: Participants receive 7-12 text messages comprising information about diet and physical activity each week for 16 weeks. SELF-MONITORING: Participants record their food intake and weight directly into the Fitbit website or application 4-7 days each week or 1 day each week for 16 weeks. FAMILY TEAM INTERVENTION: Participants receive 2 group phone calls and join a Facebook group that is monitored by research staff where they can interact with each other and coaches.
89417913|NCT02181270|Experimental|high intensity exercise|High-intensity interval exercise (HIIE): Subjects will perform 5-10 minute warm-up (50% VO2peak). Subjects will then exercise at an exercise intensity that corresponds to 90% HRmax, for 4 minutes. This will be followed by 3 min of exercise at 55% HRmax. Four of these exercise intervals/recovery periods will be completed. The total exercise commitment will be ~45 minutes
89417914|NCT02181270|Experimental|Continuous moderate exercise group|Continuous moderate exercise group (CME): Subjects will perform a 5-10 minute warm-up at 50% VO2peak. Thereafter, the intensity of exercise will be increased to 70% VO2peak by increasing the speed and incline of the treadmill. Subjects will exercise at this intensity for 60 minutes.
88895812|NCT04102579|Experimental|Valbenazine|Capsule, administered orally once daily for 12 weeks.
88895813|NCT04102579|Placebo Comparator|Placebo|Capsule, administered orally once daily for 12 weeks.
88895814|NCT04093921|Experimental|Intervention|Receive motivational enhancement training based, telehealth-delivered 6-8 session intervention aimed at increasing readiness to engage in pain self-management, in addition to all recommended outpatient treatments.
88895815|NCT04093921|Active Comparator|Standard Care|Participate in all recommended outpatient pain treatments while awaiting PPRC admission.
88895816|NCT04093362|Experimental|TAS-120|TAS-120 tablets, oral; 21-day cycle
88922181|NCT05688345|Active Comparator|Propofol|Propofol is administered for sedation through target-controlled infusion
88922182|NCT05688345|Active Comparator|Dexmedetomidine|Loading and maintenance doses of dexmedetomidine are administered for sedation
89417915|NCT03066700||Hemospray application|The patients with GI bleeding from tumor and received Hemospray as a hemostasis method.
89417916|NCT02240901|Experimental|Laryngeal mask airway|Laryngeal mask airway（LMA） is used to maintain mechanical ventilation during intra-operative
89417917|NCT02240901|Experimental|Endotracheal intubation group（ETI）|Endotracheal intubation group（ETI）is used to maintain mechanical ventilation during intra-operative
89417918|NCT03066544|Active Comparator|bupivacaine (Exparel)|subjects assigned by clinician's judgment - standard care choice A
89417919|NCT03066544|Active Comparator|naratriptan pill (Amerge)|subjects assigned by clinician's judgment - standard care choice B
89417920|NCT03066544|Active Comparator|dexamethasone tablet (Decadron)|subjects assigned by clinician's judgment - standard care choice C
89417921|NCT03066544|Active Comparator|ketorolac (Toradol)|subjects assigned by clinician's judgment - standard care choice D
88895817|NCT04093362|Active Comparator|Cisplatin/Gemcitabine|"• On Days 1 and 8 of a 21-day cycle, patients will receive:~Cisplatin 25 mg/m2 in 1000 mL 0.9% saline by intravenous (I.V.) infusion over 1 hour, followed by 500 mL 0.9% saline over 30 minutes; and~Gemcitabine 1000 mg/m2 in 250-500 mL 0.9% saline by I.V. infusion over 30 minutes, beginning after completion of the cisplatin and saline infusions."
88895818|NCT04077164||Individuals with Chronic Pain|Individuals who identify as having a chronic musculoskeletal pain condition.
88895819|NCT04077164||Partners|Partners (e.g., life partner, spouse, or significant other) of the individual with the chronic musculoskeletal pain condition.
88895820|NCT04073420||Surgical Valve Replacement and/or Repair Patients|
88895821|NCT04070027|Active Comparator|Total Hip Arthroplasty|A standard fast-track multimodal surgical program comprising patient information, optimised pain management, and early mobilisation. Total hip arthroplasty (THA) will be performed by experienced orthopaedic surgeons in accordance with the standard posterior surgical approach. Patients will receive standard postoperative rehabilitation consisting of either a standard leaflet with a hospital-specific home-based exercise program aimed at increasing hip muscle strength and range of motion or, if considered necessary, a referral to supervised hip-specific exercise therapy delivered at private physiotherapist clinics or municipal rehabilitation. Furthermore, postsurgical procedures will follow hospital-specific procedures ranging from no postsurgical control to postsurgical assessment of the hip and rehabilitation at the physiotherapy department (after six-weeks).
88895822|NCT04070027|Active Comparator|Progressive Resistance Training|"A 12-week supervised explosive-type progressive resistance training (PRT) program with two training sessions a week. All training sessions will be conducted in municipal rehabilitation centres with one-to-one supervision and ≥48 hours of rest in between sessions. The standardised PRT program will consist of warm-up on a stationary bicycle (10 min) followed by four lower extremity exercises (50 min). Exercises will be performed unilaterally with as full range of motion as possible in sets of three separated by 60 sec of rest in the following order: leg press, hip extension, hip flexion, and hip abduction. Patients will be instructed to complete the concentric phase of each repetition as fast as possible, maintain full extension for 1 sec, and perform the eccentric phase in 2-3 sec. Hip-related pain up to 5 rated on a Numerical Rating Scale (0-10) is considered acceptable during exercises. After the 12-weeks, patients will be offered three-months of optional unsupervised PRT."
88895823|NCT04061239|Experimental|CPX-351 Arm|"CPX-351 is a liposomal formulation with a fixed 5:1 molar ratio of cytarabine and daunorubicin. It will be administered as a 90-minute intravenous infusion.~The treatment includes up to 2 cycles of induction as follows:~1 x CPX-351 1st induction: daunorubicin 44 mg/m² and cytarabine 100 mg/m² in liposomes on days 1, 3, and 5~1 x CPX-351 2nd induction: daunorubicin 44 mg/m² and cytarabine 100 mg/m² in liposomes on days 1 and 3~Each induction cycle will last 28 days. Depending on the type and extent of response as well as toxicity, the patient may continue on to consolidation therapy after induction or be discontinued from the treatment phase and transferred directly to alloHCT, if applicable. CPX-351 consolidation is with daunorubicin 29 mg/m² and cytarabine 65 mg/m² in liposomes on days 1 and 3. For patients < 60 years up to 3 consolidation cycles and for patients ≥ 60 years up to 2 consolidation cycles are allowed."
88895824|NCT04061239|Other|CCR Arm|"The conventional care regimens (CCR) arm has 2 options according to the discretion of the investigator:~conventional 7+3 cytarabine/daunorubicin chemotherapy regimen~treatment with s.c. Azacitidine"
88895825|NCT04053452|Experimental|GBS Patients|
88895826|NCT04053452|Active Comparator|Controls|
88895827|NCT04052191|Experimental|Low Dose|Low Dose of MCRcI® stem cells.
88895828|NCT04052191|Experimental|Intermediate Dose|Intermediate Dose of MCRcI® stem cells.
88895829|NCT04052191|Experimental|High Dose|High Dose of MCRcI® stem cells.
88895833|NCT04037709|Placebo Comparator|scaling and root planing (SRP) + PDT placebo|"17 patients will receive periodontal treatment (scaling and root planing - SRP) with the ultrasound. The SRP will be done in one session. SRP will be performed by only one experienced researcher. Periodontal reassessment will be performed after 30 days.~The PDT placebo wil be done using an agent with the same vehicle as that of the methylene blue to mimic irrigation with the photosensitizer; the laser will be switched off at the time of application."
89417922|NCT03574311|Experimental|Ferric carboxymaltose|Preoperative 1000 mg intravenous single dose as 30 minute infusion
89417923|NCT03574311|Placebo Comparator|Placebo|Preoperative 100 ml saline as 30 minute infusion
89417924|NCT02844543|Experimental|Athletes|Participants will be evaluated using the EYE-SYNC eye-tracking device, Desktop Eye-Tracker, and Sport Concussion Assessment Tool (SCAT-3) tool.
89417925|NCT03063424|Other|Healthy subjects|
89417926|NCT03063424|Other|Asthmatics with EIB|
89417927|NCT03576807|Experimental|CD20 CAR-T cells|Experimental: CD20 CAR-T cells
89417928|NCT03182179|Experimental|O-P sequence|Patients will receive of oral Ondansetron 4mg BD for 28 days followed by 28 days of placebo. It will be one week of washout between the two treatments.
88895834|NCT04037709|Experimental|scaling and root planing (SRP) + PDT|"17 patients will receive the same scaling and root planing treatment that placebo group.~However the PDT will be done only on one side of the mouth using methylene blue 0.005% - Chimiolux 5, DMC - purified water and methylene blue.The red laser diode (λ = 660 nm) will be applied with an output power of 100mW . The laser head will be positioned in direct contact with the pseudo periodontal pocket."
88922183|NCT05684445|Experimental|Distant reiki group|According to Classical Usui Reiki, Reiki II. Remote Reiki will be practiced every day for 10 days by researchers who have completed the Phase 1 training. The time of remote reiki application will be planned by talking with the patient.
89417929|NCT03182179|Experimental|P-O sequence|Patients will receive oral placebo for 28 days followed by Ondansetron 4mg BD for 28 days. It will be one week of washout between the two treatments.
89417930|NCT03576729||Hurler syndrome participants|Participants who have MPS IH, also called Hurler syndrome
89417931|NCT03576729||Hurler-Scheie/Scheie participants|Participants who have either MPS IHS or MPS IS. MPS IHS is also called Hurler-Scheie syndrome. MPS IS is also called Scheie syndrome.
89417932|NCT03576729||Healthy Controls|Age-matched healthy controls
89417933|NCT03576651|Experimental|JHL1149|
89417934|NCT03576651|Active Comparator|US-sourced-Avastin™|
89417935|NCT03576651|Active Comparator|EU-sourced Avastin™|
89417936|NCT03574233||patients who are ready to wean ventilator off|
89417937|NCT03064906|Other|Meal Performance and/or Exercise|"This study is a two-part, multi-center, observational clinical trial being conducted in a Clinical Research Center (CRC) setting using the Insulet AP (artificial pancreas) system.~Subjects may participate in hybrid closed-loop session Option A - Meal Performance and/or Option B - Exercise, but are not required to participate in both. If participating in both, Option A and Option B must be conducted in separate sessions."
89417938|NCT03034135|Experimental|DSF-Cu|Disulfiram/copper (oral capsules) dosed 80 mg/1.5 mg three times a day for approximately 6 months.
89417939|NCT05411458|Experimental|Experimental group|"Experimental group consists of 15 Type-2 DM patients who applied for routine outpatient follow-up in the internal medicine clinic, whose diabetes tests and treatments were arranged by an internist, who had COVID-19 at least 3 months ago.~12-week treatment program; A - 6 weeks of aerobic exercise (AE) (outdoor walking program) 6 week program B - Jacobson Progressive Relaxation Exercises (JIGE) (done by patients at home). The 6-week B program (JIGE) was applied in addition to the aerobic exercise (AE) program.~An exercise program is 30-45 minutes, and the applications are done every other day and 3 days a week.The treatment programs started with the evaluation of the cases by the physiotherapist and are followed up using the Telerehabilitation method. At the beginning of each week, the patients were called and checked, and their exercise treatments were completed at the end of 12 weeks."
89417940|NCT05411458|Other|Control Group|"Control group consists of 15 Type-2 DM patients without COVID-19, who applied to the internal medicine outpatient clinic for routine outpatient follow-up, whose diabetes examinations and treatments were arranged by an internist.~12-week treatment program; A - 6 weeks of aerobic exercise (AE) (outdoor walking program) 6 week program B - Jacobson Progressive Relaxation Exercises (JIGE) (done by patients at home). The 6-week B program (JIGE) was applied in addition to the aerobic exercise (AE) program.~An exercise program is 30-45 minutes, and the applications are done every other day and 3 days a week.The treatment programs started with the evaluation of the cases by the physiotherapist and are followed up using the Telerehabilitation method. At the beginning of each week, the patients were called and checked, and their exercise treatments were completed at the end of 12 weeks."
89417941|NCT03574155|No Intervention|Control- group|"It is composed of patients scheduled for surgical treatment by tumors of the uterine cervix, vulva, ovary or endometrium, who will receive preoperative and postoperative guidelines according to the usual routine for the perioperative period of the present institution. Patients and their followers of the control group will participate in a preoperative consultation with the surgeon to discuss the indication of the procedure and its risks, benefits and alternatives to the procedure being indicated, if any.~Pre-operative Counseling and Education Application of the questionnaire (ESAS) and (HADS)"
89417942|NCT03574155|Experimental|Experimental Group|"Composed of patients scheduled for surgical treatment by tumors of the uterine cervix, vulva, ovary or endometrium who will receive preoperative counseling and education through a pre-defined protocol after preoperative consultation with the surgeon. The counseling session will take place with at least one companion. The purpose of this session is to supplement, re-emphasize and strengthen the perioperative guidelines. An illustration (explanatory folder) will be used to demonstrate the location of the surgery, how the scar will be and on which sites of the abdomen and organs the surgery will cover. All this counseling and education will be applied at the same time to the patient and her companion. At the end of the intervention, a space will be left open for both the patient and the companion to ask questions and questions.~Pre-operative Counseling and Education Application of the questionnaire (ESAS) and (HADS)"
89417943|NCT02239731|Experimental|FDX104 (4% Doxycycline)|Active ingredient: Doxycycline Concentration: 4% Route: Topical Dosage schedule: Twice daily, morning and evening. Prophylactic treatment to prevent the rash associated with EGFRI treatment. patients will apply a thin layer of the drug twice daily for five weeks to one half of face
89417944|NCT02239731|Placebo Comparator|Placebo foam|Active ingredient: None Route: Topical Dosage schedule: Twice daily, morning and evening. Patients will apply a thin layer of the placebo twice daily for five weeks to the opposite half of the face of which they received active treatment.
89417945|NCT03571893|Experimental|Weight Watchers Freestyle (Flex)|Participate in Commercially Available behavioral weight loss program delivered by Weight Watchers International in the community
89417946|NCT03571893|Active Comparator|DIY Personal Plan|Receive informational resources for healthy lifestyle change to promote weight loss
89417947|NCT03064828|Active Comparator|CT colonoscopy(normal dose)|Perform CT colonoscopy with full bowel preparation and inflated colon, CT Scans on subjects with normal-dose protocol by setting scanning parameters as 120-140 kilovolts peak (kVp), 100-200mA
89417948|NCT03064828|Experimental|CT colonoscopy(low dose)|Perform CT colonoscopy with full bowel preparation and inflated colon, CT Scans on subjects with normal-dose protocol by setting scanning parameters as 120-140 kVp, 20-100mA
89417949|NCT02035683|Other|Advanced NSCLC patients undergoing first-line chemotherapy|single cohort
89417950|NCT03064594||cornuostomy|cornuostomy
89417951|NCT03064594||wedge resection|wedge resection
89417952|NCT02239809|Active Comparator|Active Stimulation|Patients assigned to active stimulation arm will receive electrical stimulation during the study.
89417953|NCT02239809|Placebo Comparator|Placebo Stimulation|Patients assigned to the placebo arm did not receive stimulation electrical stimulation for 24 weeks. After this period the participants randomized to sham stimulation will be moved to the active stimulation and will be followed until study completion.
89417954|NCT03571815|Experimental|fluoride varnish application|intervention; fluoride varnish application (with 5% Sodium fluoride varnish application on teeth)
89417955|NCT03571815|Placebo Comparator|control group|application of water on teeth in the control group
89417956|NCT04050358|Active Comparator|1X dose of NRPT|
89417957|NCT04050358|Placebo Comparator|Placebo|
89006339|NCT00246363|Placebo Comparator|Placebo|Placebo
89006340|NCT04628533|Experimental|Four Month Duration|Participants will meet weekly online via video chat with an experienced behavioral weight loss counselor in a synchronous 1-hour chat session for 16 weeks in a well-established behavioral weight loss program.
89006341|NCT04628533|Active Comparator|Six Month Duration|Participants will meet weekly online via video chat with an experienced behavioral weight loss counselor in a synchronous 1-hour chat session for 24 weeks in a well-established behavioral weight loss program.
89006342|NCT04628299|Placebo Comparator|Sham Laser|A non-emission laser will be applied in plantar fascia
89006343|NCT04628299|Experimental|Experimental group Myofascial Induction|Myofascial Induction in plantar fascia
89006344|NCT00561613|Placebo Comparator|1|SILCS with K-Y Jelly
89006345|NCT00561613|Active Comparator|2|SILCS with N-9
89006346|NCT00561769||A|poor responder
89006347|NCT04628143|No Intervention|Standard of Care|Standard of Care Treatment for COVID-19 Infection
89006348|NCT04628143|Experimental|Nafamostat + Standard of Care|Nafamostat mesylate on top of standard of care
89006349|NCT04627792|Other|Waitlist Group|We will use a switching replication design in which fifty guardians will be randomly assigned using a lottery to receive the intervention and fifty will be assigned to a group who will receive the intervention at a later time point
89006350|NCT04627987||Main study|Patients with severe, symptomatic aortic stenosis will be recruited and followed up with primary outcome of heart failure death and hospitalisation (n=192). Of these, 170 will have an implantable cardiac monitor placed to detect presence and burden of non-sustained VT.
89006351|NCT04627909||Group under Robot treatment|Interaction with the Humanoid Robot for 15 minutes
89006352|NCT04627909||Group involved with medical personnel|Interaction with medical personnel for 15 minutes
89006353|NCT04627909||Control group|Exclusive interaction with the caregiver for 15 minutes
89417958|NCT02985073|Experimental|Veritas® mesh|Use of Veritas mesh in conjunction with immediate breast reconstruction on one side
89417959|NCT02985073|Experimental|TIGR® mesh|Use of TIGR® mesh in conjunction with immediate breast reconstruction on one side
89417960|NCT02239887||WaveCrest LAA occlusion device|Left Atrial Occlusion
89536780|NCT03310385|Experimental|Standard-dose GHX02 group(960mg/day)|2 tablets of the GHX02 and 2 tablets of the placebo, three times daily for 7 days
89536781|NCT03310385|Placebo Comparator|Placebo control|4 tablets of the placebo, three times daily for 7 days
89536782|NCT03310307|Active Comparator|vitamin D3|50,000 IU
89006354|NCT04627519|No Intervention|SoC alone|Standard of Care alone (days 1 to 9)
89006355|NCT04627519|Experimental|Rhea Health Tone®|Rhea Health Tone® 2 ml twice daily after meal (every 12 hours) for 9 days to be provided together with Standard of Care.
89006356|NCT04627636|Experimental|study group|which treated with MTrPs release combined with shockwave therapy and conventional program
89006357|NCT04627636|Experimental|control group|which treated with conventional physical therapy program
89006358|NCT04627480|Experimental|Experiment Arm|Active Fisher Wallace device for full 8 weeks
88895835|NCT04036227|Experimental|GS-248|"Part I (SAD): Single doses of 1 mg, 5 mg, 25 mg, 75 mg, 225 mg and 450 mg (planned doses)~Part II (MAD): Multiple ascending doses for 10 days in four cohorts with planned doses of 25 mg, 75 mg, 225 mg and 450 mg. The doses will be finally selected based on results from Part I."
88895836|NCT04036227|Placebo Comparator|Placebo|Matching placebo oral solution
88895837|NCT04036136|Experimental|Behavioral Activation|Treatment will consist of 15 weekly 45-minute sessions. Session 1 provides orientation and psychoeducation on anhedonia, and activity monitoring is introduced. Sessions 2-3 include structured values assessments of 10 life areas to enhance motivation for sustained behavior change and to clarify goals. Following goals clarification, an activity hierarchy is developed, establishing a set of idiographic behavioral targets across life areas prioritized by ease of implementation to scaffold task engagement during the course of treatment.
88895838|NCT04036136|Active Comparator|Mindfulness Treatment|BATA will be compared to mindfulness based cognitive therapy (MBCT), chosen because its mechanisms of action are hypothesized to impact different brain mechanisms than BATA. Mindfulness is nonjudgmentally bringing awareness and acceptance to one's present-moment experience. MBCT will be administered in an individual format. The MBCT protocol will be modeled on the session outlines presented in Wahbeh et al., 2014. Treatment will be compromised of 15 weekly 45-minute sessions.
88895839|NCT04034004|Experimental|Meditation|"Subjects will participate in four sessions (20 min/session) of mindfulness training. Participants will be taught that perceived sensory events are momentary and fleeting and require no further evaluation."
88895840|NCT04034004|Experimental|meditation|"Subjects will participate in four sessions (20 min/session) of mindfulness training. Participants will be taught that perceived sensory events are momentary and fleeting and require no further evaluation."
88895841|NCT04033029||Patients under CVVHDF with high adsorption membrane|Continuous venovenous hemodiafiltration mode (CVVHDF) using PrismafleX eXeed™ system and high adsorbent polyethyleneimide membrane (oXiris®). Filtration parameters will be determined following the local protocol (dose of 25-30 ml/kg/h).
89417961|NCT04096378|Experimental|EMBRace Intervention Group|Over 13 weeks, participants will engage in a pretest (week 1) 5 weekly sessions (weeks 2-6), a posttest (week 7) and a follow-up (week 13). The intervention (Engaging, Managing, and Bonding through Race: EMBRace) seeks to reduce racial trauma for both youth and caregivers and increase family functioning via psychoeducation and therapy.
88895842|NCT04026503|Experimental|Live Long Walk Strong|8 week rehabilitation program
88895843|NCT04026503|Active Comparator|8 week wait list control|8 week wait list then followed by 8 weeks of the Live Long Walk Strong rehabilitation program
88895844|NCT04022746|Experimental|Diagnostic (MRI/MRE)|Patients undergo standard of care MRI and MRE over 30-90 minutes within 5 days of liver biopsy before receiving any medical treatment for HCC, at 6 weeks after medical treatment for HCC, and then every 12 weeks for up to 24 months.
88895845|NCT04020185|Experimental|Ph I Monotherapy|"Dose escalation design in which administered dose levels of IMSA101 as monotherapy will be escalated stepwise in successive cohorts of 3 to 6 patients per dose group (using a standard 3+3 study design) of IMSA101 until the RP2D or maximum tolerated dose (MTD) level is identified.~The first patient enrolled in each dose level must complete the first two weeks of Cycle 1 prior to enrolling the second and third patients.~Dose levels to be evaluated include (although not necessarily limited to) 100 µg (representing 1/60th of the pre-clinical Highest Non-Severely Toxic Dose [HNSTD] dose), 200 µg, 400 µg, 800 µg, and 1,200 µg."
88922184|NCT05682781|Active Comparator|Dietary Counseling|
88922185|NCT05682781|Experimental|Dietary Counseling + Oral Nutritional Supplement|
88922186|NCT05678712|No Intervention|Standard treatment|"After a two weeks run-in baseline period (blinded CGM) some of the participants (1:1) were randomly assigned to six weeks of standard treatment, i.e. self monitoring of blood glucose (the last two weeks with blinded CGM → 2 weeks wash-out (baseline for next period) (blinded CGM) → six weeks with non-blinded CGM with data available for the patient himself/herself and dialysis staff"
89006359|NCT04627480|Sham Comparator|Sham Arm|Sham Fisher Wallace device for 4 weeks, then cross over at 4 weeks to active device.
89417962|NCT04096378|Other|EMBRace Waitlist Group|Participants will wait for thirteen weeks without receiving EMBRace or alternative therapeutic sessions. The waitlist group will subsequently become the intervention group with the opportunity to participate in the EMBRace intervention protocol above.
88895846|NCT04020185|Experimental|Ph I Combination Therapy|"Ph I combination dosing of IMSA101 shall be evaluated upon satisfaction of the following criteria:~A given dose level (combo dose level 1) has been confirmed as safe for monotherapy dosing (i.e. 2/6 patients experience Cycle 1 DLT).~The next higher dose level (combo dose level 2) has been confirmed as safe for monotherapy dosing (i.e. 2/6 patients experience Cycle 1 DLT).~The dose level (combo dose level 1) is found to demonstrate adequate IMSA101 pharmacodynamic (PD) activity based on exploratory endpoints.~Eligible patients shall have demonstrated RECIST stable disease through ≥ 4 consecutive cycles of an approved PD-1/PD-L1-targeted ICI with no Grade ≥ 3 CTCAE events considered to be drug-related.~Safety evaluations and dose escalation of IMSA101 administered in combination with current therapy shall proceed in a manner consistent with monotherapy escalation and shall proceed independently of monotherapy dose escalation."
88895847|NCT04020185|Experimental|Ph II Monotherapy (Arm A)|"This dose-expansion arm of 20 patients is intended to confirm the tolerability of the RP2D and identify provocative signals of IMSA101 anti-tumor activity when administered as monotherapy~Tumor type to be evaluated will be identified prior to Phase IIA commencement and will be documented in a protocol amendment."
88895848|NCT04020185|Experimental|Ph II Combination Therapy (Arm B)|"This dose-expansion arm of 20 patients is intended to confirm the tolerability of the RP2D and identify provocative signals of IMSA101 anti-tumor activity when administered as combination therapy with PD-1/PD-L1 targeted immune checkpoint inhibitors.~This arm shall include a safety run-in of 5-10 patients.~Tumor type and corresponding treatment combination will be identified prior to Phase IIA commencement and documented in a protocol amendment."
88895849|NCT04020185|Experimental|Ph II Combination Therapy (Arm C)|"This dose-expansion arm of 20 patients is intended to confirm the tolerability of the RP2D and identify provocative signals of IMSA101 anti-tumor activity when administered as combination therapy with non-PD-1/PD-L1-targeted immuno-oncology (IO) drugs approved by the FDA.~This arm shall include a safety run-in of 5-10 patients.~Tumor type and corresponding treatment combination will be identified prior to Phase IIA commencement and documented in a protocol amendment.."
88895850|NCT04007380|Other|CPAP-therapy arm|This single-arm clinical trial will examine the effects of 4-month period CPAP therapy in individuals living with SCI. The CPAP will be adjusted according to the results of the auto-titrating CPAP testing for each participant.
88895851|NCT03998579|Experimental|Individualized exercise|The intervention group get a referral to physiotherapist in Primary Health Care in Stockholm County Council, close to where they live. Within the third week after discharge, the patients begin twelve weeks of biweekly exercise. The physical exercise is individually targeted aerobic and strength exercises, based on international recommendations for persons with cancer disease. The program is approved by resposible surgeons.
88895852|NCT03998579|Active Comparator|Active control group|Oral and written information of a home-based exercise programme and information of supportive techniques to improve physical activity
88895853|NCT03995641|No Intervention|Surgery Alone|Patient will receive sacrospinous ligament suspension surgery without any additional interventions
89417963|NCT03701815|Experimental|Post-stroke|Patients will receive a 12-week lifestyle medicine program.
89417964|NCT02239965||Anaesthesia personnel|Anaesthesiologists and nurse anaesthetists
89417965|NCT03064672|Experimental|induction by transcervical Balloon Catheters insertion|
89417966|NCT03064672|No Intervention|induction without transcervical Balloon Catheters|
89417967|NCT03571659||two subthreshold parameters|5% and 15% duty cycle (DC)
89417968|NCT03571659||standard ETDRS|early treatment of diabetic retinopathy study
89417969|NCT03705013||Baseline Cologuard positive and negative colonoscopy|Those whose Cologuard T0 result was positive and colonoscopy result was negative.
89417970|NCT03705013||Baseline Cologuard positive and no colonoscopy|Those whose Cologuard T0 result was positive and subject declined to complete a colonoscopy per protocol.
89417971|NCT03705013||3-year follow-up Cologuard positive and negative colonoscopy|Those whose Cologuard result at T3 was positive and colonoscopy result at T3 was negative.
89417972|NCT03705013||3-year follow-up Cologuard positive and no colonoscopy|Those whose Cologuard result at T3 was positive and subject declined to complete a colonoscopy per protocol.
89417973|NCT03576339|Sham Comparator|Sham Group - Free Gingival Graft + Sham Electric Stimulation|With the aim to ridge preservation after condemned tooth extraction, the socket will be sealed with a free gingival graft removed from the palate. The tooth will be extracted through the use of appropriate instruments in order to obtain a minimally traumatic exodontia. After the exodontia, curettage and irrigation of the dental socket will be performed. The free gingival graft will be removed from the donor palatal area with a circular incision of 9 mm and 2 mm thickness. After free gingival graft removal from palate, it will be adjusted to the entrance of the socket and sutured. Patient randomized to the SHAW Group will receive the simulation of the electrical stimulation process, thus non current will be applied.
89417974|NCT03576339|Experimental|Test Group - Free Gingival Graft + Electric Stimulation|With the aim to ridge preservation after condemned tooth extraction, the socket will be sealed with a free gingival graft removed from the palate. The tooth will be extracted through the use of appropriate instruments in order to obtain a minimally traumatic exodontia. After the exodontia, curettage and irrigation of the dental socket will be performed. The free gingival graft will be removed from the donor palatal area with a circular incision of 9 mm and 2 mm thickness. After free gingival graft removal from palate, it will be adjusted to the entrance of the socket and sutured. Conductive electrodes for electrical current application will be applied to the palatal donor area on each side of the wound at a distance of 3 mm from the wound edge. An alternating current of 100 microamperes (μA) at 9 kilohertz (kHz), will be distributed in order to traverse the operated area. A single application of electrical stimulation will be given for 120 seconds, five consecutive days.
89417975|NCT03571503||Integrative Korean medicine treatment|Herniated lumbar disc (HLD) patients with radiating leg pain in the integrative Korean medicine treatment group will be administered integrative Korean medicine treatment consisting of 2 sessions/day of acupuncture, and herbal medicine, Chuna manual therapy, bee venom pharmacopuncture and pharmacopuncture, electroacupuncture, cupping, and other interventions, as needed.
89417976|NCT03571503||Doin with integrative Korean medicine|Herniated lumbar disc (HLD) patients with radiating leg pain in the Doin (conduction exercise) with integrative Korean medicine treatment group will be administered integrative Korean medicine treatment consisting of 2 sessions/day of acupuncture, and herbal medicine, Chuna manual therapy, bee venom pharmacopuncture and pharmacopuncture, electroacupuncture, cupping, and other interventions, as needed, plus Doin (conduction exercise) for 1 session of the 2 sessions/day of acupuncture.
89417977|NCT03574077|Experimental|Instant messaging|AWARD advice + NRT sampling + Active referral + Instant Messaging (IM)
89417978|NCT03574077|Active Comparator|SMS messaging|AWARD advice + NRT sampling + Active referral + SMS messaging
89417979|NCT03064516|Experimental|Endocrown|Restorations with ceramic endocrown in endodontically treated teeth
89417980|NCT03064516|Active Comparator|Onlay and fiber pin|Restorations with onlay ceramic and glass fiber pin in endodontically treated teeth
89417981|NCT03573999|Active Comparator|Mannitol 20%|Mannitol 20% (4.6ml/kg) will be administered 20 minutes before dura matter opening.
89417982|NCT03573999|Experimental|Hypertonic saline 7.5%|Hypertonic saline 7.5% (2ml/kg) will be administered 20 minutes before dura matter opening
89417983|NCT04863703||One group with HBV/HDV coinfection|Measurement of HVPG before antiviral treatment of HBV/HDV coinfection and one year after treatment initiation with Bulevirtide. Administration of Bulevirtide and HVPG measurement is independent from this study.
89417984|NCT03571425|Placebo Comparator|Oral Placebo|Placebo drink
89417985|NCT03571425|Active Comparator|Oral Protein|Protein drink, ingested orally
89417986|NCT03571425|Active Comparator|Enteral Protein|Protein drink, administered via enteral tube
89417987|NCT03063190|Placebo Comparator|Hyperparathyroidism_0|Chronic Kidney Disease patients with parathyroid hormone higher than 300pg/ml
89417988|NCT03063190|Active Comparator|Hyperparathyroidism_1|Chronic Kidney Disease patients with parathyroid hormone higher than 300pg/ml
89417989|NCT03063190|Placebo Comparator|Adynamic_0|Chronic Kidney Disease patients with parathyroid hormone lower than 150pg/ml
89417990|NCT03063190|Active Comparator|Adynamic_1|Chronic Kidney Disease patients with parathyroid hormone lower than 150pg/ml
89417991|NCT03065452||Patients who underwent open decompression surgery|Observational study on patients who underwent open decompression surgery
89417992|NCT03992638|Experimental|L-PRF membrane|Periodontal plastic surgical procedures (coronally advanced flap, CAF) in combination with a double layer autologous leucocyte and platelet-rich fibrin (L-PRF) membrane.
89417993|NCT03992638|Active Comparator|Control|CAF
89417994|NCT03573843|Placebo Comparator|Control|Patients who meet the inclusion / exclusion criteria will be randomly assigned to the Control group: They will continue to receive the standard prevention measures: delirium detection, treatment health team education and the patient's family, sleep hygiene plan, early mobilization , resolve sensorial deterioration, and delivery of information of temporal-spatial reorientation in a continuous manner, plus the use of a mobile device without installed delirium prevention software (placebo).
89417995|NCT03573843|Experimental|Experimental|Patients who meet the inclusion / exclusion criteria will be randomly assigned to the experimental group:They will continue to receive standard prevention measures: Detection of delirium, education of health care team and the patient's family, sleep hygiene plan, early mobilization, resolve sensory impairments, and delivery of information of temporal-spatial reorientation in continuously, plus the use of software installed on a mobile device designed to support the prevention of delirium (Prevention software).
89417996|NCT03573687|Experimental|RT on Fat Metabolism|Determine the extent to which a full-body acute RT protocol will affect intra-RT and post-RT SCAAT lipolytic rate, and post-RT whole-body substrate utilization in RT women compared to baseline measures (independent of Aims 2 and 3).
89417997|NCT03573687|Experimental|PRO Timing on Fat Metabolism|Assess the differences in overnight and next morning SCAAT lipolytic rate and next-morning whole-body substrate utilization compared to baseline between acute NP and DP consumption trials after a RT bout in RT women.
88895854|NCT03995641|Experimental|Surgery Plus Trigger Point Injection|Patient will have sacrospinous ligament suspension procedure with addition of a trigger point injection (9cc of 0.5% marcaine and 1 cc kenalog) over area of suture placement
88895855|NCT03977753|Experimental|2LVERU®/2LVERU® JUNIOR|Group N°1: 2LVERU® or 2LVERU® JUNIOR treatment (6 months of treatment)
88895856|NCT03977753|Placebo Comparator|Placebo|Group N°2: Placebo treatment (6 months of treatment)
88895857|NCT03969706|Experimental|Single Arm|Abemaciclib 200mg tablet PO twice daily administered on 28-day cycles Subjects remain on treatment until tumor progression or unacceptable toxicity.
88895858|NCT03957473||Single Arm|Single Arm - Use of Indigo Aspiration System with CAT RX Aspiration Catheter (mechanical thrombectomy) in high thrombus burden acute coronary vessel occlusions
88895859|NCT03952962|Experimental|Randomized Discontinuation Period: OFF then ON DBS|"Subjects randomized to this arm are initially OFF DBS after the open label period then gradually decreased in their optimized setting's amplitude for 8 weeks and then ON DBS for 8 weeks."
89193594|NCT04559932|Experimental|Intervention|The knowledge and self-efficacy pre-tests will be completed at the start of the course and the post-test will be completed after the course at the end of the day. Study participants will complete tests independently using paper and pencil. Six weeks and six months post course completion, the knowledge and self-efficacy tests will be completed using REDcap (Research Electronic Data Capture), a secure web application for building and managing online surveys and databases or via telephone as per participant preference. Study participants will be sent a link to complete the tests online for the subsequent study visits. Study participants will receive 2 reminder emails (1 week apart) and 1 reminder phone call after the email reminders (if applicable) to complete the tests. Monthly telephone calls by the RA will be made to review the HCP experience logs.
89193595|NCT04559932|No Intervention|Control|Study participants in the control arm will be offered complementary attendance in the Health Tech Junior enterostomy and vascular access competency based training course while awaiting their session. This is being done to minimize the potential confound of generalized improvements in self-efficacy that may occur as a result of participating in an 8 hour learning opportunity at SickKids. The control group will also complete the tracheostomy course during session 3 and 4 but this will occur outside the window of data collection for the study procedures. Data collection intervals as described above for the intervention group will be followed for the control group.
88895860|NCT03952962|Experimental|Randomized Discontinuation Period: ON then OFF DBS|"Subjects randomized to this arm are initially ON DBS with optimized stimulation settings for 8 weeks after the open label period and then OFF DBS with gradually decreasing amplitude for 8 weeks."
88895861|NCT03926312|Experimental|Smart device-based rehabilitation|One month after myocardial infarction, patients will receive a smart band and a cellphone in order to transmit data on physical activity to electronic health record. A study nurse will periodically check compliance with recommended physical activity and intervene in the case of non-compliance.
89193596|NCT04558073|Experimental|Body Project (BP)|The BP intervention includes four one-hour sessions given over a month by two facilitators. The sessions will be held on a collaborative platform in groups of six people.
89193597|NCT04558073|Experimental|Healthy Weight Program (HW)|The HW intervention includes four one-hour sessions given over a month by two facilitators. The sessions will be held on a collaborative platform in groups of six people.
89193598|NCT04558073|No Intervention|Waiting-list (WL)|The waiting list will consist of two assessments each separated by a one-month interval. Following this waiting time, participants will receive the BP intervention.
89417998|NCT03573687|Experimental|PRO Timing on Markers of Fat Metabolism|Assess the differences in overnight and next morning metabolic biomarkers of fat metabolism compared to baseline between acute nighttime PRO (NP) consumption versus daytime PRO (DP) consumption trials after a RT bout in RT women.
88895862|NCT03926312|No Intervention|Control group|Patients will receive a guideline directed recommendation to increase physical activity to 30 minutes of moderate physical activity a week.
89417999|NCT03576027|Experimental|Hyperbaric oxygen therapy|
89418000|NCT03571269|Experimental|OCT-guided group|Detailed methods of OCT examination are the same as above. Whether stenting or not will be decided by the operators according to the underlying mechanisms of culprit lesions. If stenting, OCT will be used to guide and optimize the whole process of PCI. Patients will be treated with dual antiplatelet therapy (aspirin+ticagrelor or aspirin+clopidogrel) for at least 12 months.
88895863|NCT03922984|Experimental|Glioblastoma Patients|Patients with histologically proven glioblastoma will undergo enhanced MRI with arterial spin labeling at weeks 0, 3, 6, 10, 18, 26, and 34 after beginning standard of care treatment.
88895864|NCT03900520||Pneumonia group (PREVAIL-Pneumo)|Children aged 1-35 months with pneumonia or lower respiratory tract infection hospitalized or recommended for hospitalization
88895865|NCT03900520||Community group (PREVAIL-Community)|Children aged 1-35 years living in the community with no known systemic illness
88895866|NCT03900520||Economic group (PREVAIL-Econ)|PREVAIL-Pneumo-enrolled children hospitalized for pneumonia
88895867|NCT03891784|Experimental|Treatment (abemaciclib)|Patients receive abemaciclib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88895868|NCT03868410|Active Comparator|cPMD rTMS + Training|New Approach
88895869|NCT03868410|Active Comparator|iM1 rTMS + Training|Conventional Approach
88895870|NCT03866954|Experimental|Intravenous administration of EE-TP|Intravenous administration of EE-TP. The starting dose will be Dose Level 1, with potential subsequent dose levels of Dose Level 2 and Dose Level 3 dependent on whether metabolic correction is achieved or not.
88895871|NCT03862950|Placebo Comparator|Placebo Medication|The placebo will be dosed in a weight-dependent manner. For participants under 50kg at baseline, the initial dose will be 250mg once per day, and if this dose is well tolerated, they will increase each week by 250mg until a maximum dose of 1000mg daily is reached. For participants at and above 50kg at baseline, the initial dose will be 500mg once per day, and if this dose is well tolerated, they will increase each week by 500mg until a maximum dose of 2000mg daily is reached. After the 4-week titration period, each participant will continue dosing at his or her maximum tolerated dose daily for the remaining 12 weeks of the study.
88895872|NCT03862950|Active Comparator|Active Metformin Medication|The active metformin medication will be dosed in a weight-dependent manner. For participants under 50kg at baseline, the initial dose will be 250mg once per day, and if this dose is well tolerated, they will increase each week by 250mg until a maximum dose of 1000mg daily is reached. For participants at and above 50kg at baseline, the initial dose will be 500mg once per day, and if this dose is well tolerated, they will increase each week by 500mg until a maximum dose of 2000mg daily is reached. After the 4-week titration period, each participant will continue dosing at his or her maximum tolerated dose daily for the remaining 12 weeks of the study.
88895873|NCT03846830|Active Comparator|IVE/VPT 6 week Crossover|Subjects will randomly be placed in one of two groups (IVE or VPT) involving daily exercise for 5 weeks, 6 weeks washout, and then crossover into the other group for a final 5 weeks. The Incremental Velocity Error (IVE) group uses a device worn on the head that delivers a moving target during head motion; while Traditional Vestibular Rehabilitation (VPT) uses the traditional eye and head turning rehabilitation exercises. Gait and balance training offered throughout each of the 5 weeks epochs of training.
88895874|NCT03846830|Experimental|IVE/VPT 3 week Crossover|Subjects will randomly be placed in one of two groups (IVE or VPT) involving daily exercise for 3 weeks, 3 weeks washout, and then crossover into the other group for a final 3 weeks. The Incremental Velocity Error (IVE) group uses a device worn on the head that delivers a moving target during head motion; while Traditional Vestibular Rehabilitation (VPT) uses the traditional eye and head turning rehabilitation exercises. Gait and balance training will not start until the washout period.
88895875|NCT03846830|Active Comparator|IVE/VPT 3 week crossover|Subjects will randomly be placed in one of two groups (IVE or VPT) involving every other day exercise for 3 weeks, 3 weeks washout, and then crossover into the other group for a final 3 weeks. The Incremental Velocity Error (IVE) group uses a device worn on the head that delivers a moving target during head motion; while Traditional Vestibular Rehabilitation (VPT) uses the traditional eye and head turning rehabilitation exercises. Gait and balance training offered throughout the 3 weeks of exercise.
89193599|NCT04554368||IA-CEFDCT group|95 patients who underwent IA-CEFDCT and MT for acute anterior stroke.
89418001|NCT03571269|No Intervention|Angiography-guided group|Detailed methods of angiography examination are the same as above. Whether stenting or not and the whole process of PCI will be decided by the operators according to the current treatment standard of angiography. Patients will be treated with dual antiplatelet therapy (aspirin+ticagrelor or aspirin+clopidogrel) for at least 12 months.
89418002|NCT01671280||Azithromycin IV|Subjects who are treated with Azithromycin IV
89418003|NCT03573531||Donor Human Milk|Donor Human Milk (processed by a human milk bank) Sampled at two different neonatal units in the United Kingdom Collection of 5 ml of otherwise routinely discarded donor human milk
89418004|NCT03573531||Preterm Milk|Preterm transitional or mature breast milk Sampled from healthy mothers of preterm babies (born , 37 weeks gestational age) at a neonatal unit in the United Kingdom Collection of 5 ml at a time point of routine expression
89418005|NCT03573531||Term Milk|Term mature breast milk Sampled from healthy mothers of term babies in the community (e.g. Baby Cafes). Collection of 5 ml expressed for this study
89418006|NCT01405963|Placebo Comparator|Placebo|Participants received placebo to tezepelumab administered by intravenous infusion on study days 1, 29, and 57.
89418007|NCT01405963|Experimental|Tezepelumab 700 mg|Participants received 700 mg tezepelumab administered by intravenous infusion on study days 1, 29, and 57.
89418008|NCT03571113||Development|The study population was divided into two parts by random: development dataset (5,775) and validation dataset (1,457)
89418009|NCT03571113||Validation|The study population was divided into two parts by random: development dataset (5,775) and validation dataset (1,457)
89418010|NCT03575715|Experimental|EBUS group|EBUS and guide sheath (GS) are inserted into bronchi in the assistance of navigation bronchoscopy. The EBUS probe and GS are confirmed to reach the lesion by EBUS images, cytologic and pathologic specimens are obtained with or without fluoroscopic guidance.
89418011|NCT03065374|Experimental|Treatment arm A|IMM-529, 1000 mg three times daily, orally
89418012|NCT03065374|Placebo Comparator|Treatment arm B|Matching Placebo, three times daily, orally
89418013|NCT03575637|Experimental|Olanzapine intervention group|Patients who have failed first-line treatment of advanced gastric cancer receive second-line treatment with paclitaxel regimen and olanzapine 5 mg QD.
89418014|NCT03575637|No Intervention|Control group|Patients who have failed first-line treatment of advanced gastric cancer receive second-line treatment with paclitaxel regimen.
89006360|NCT04627363|Experimental|HAIC plus Bevacizumab and Toripalimab|Hepatic arterial infusion of oxaliplatin , fluorouracil, and leucovorin every 6 weeks. Lenvatinib 12 mg (or 8 mg) once daily (QD) oral dosing. Toripalimab, 240 mg intravenously every 3 weeks. Bevacizumab 15 mg/kg intravenously every 3 weeks.
89418015|NCT03573219|Experimental|Healthy participant|Healthy volunteers that fulfill the inclusion criteria. Intervention: Short-wave diathermy (Radiation)
89418016|NCT04852198|Active Comparator|OAGB|149 patients receiving one anastomosis gastric bypass (OAGB) with a Biliopancreatic-limb of 150cm
89418017|NCT04852198|Active Comparator|RYGB|149 patients receiving Roux-en-Y gastric bypass (RYGB) with a Biliopancreatic-limb of 150cm
89418018|NCT04792255|Experimental|Group A: Reduced contrast media dose group|"Reduced contrast media protocol: extracranial carotid artery intervention (2-4 fps according to the institutional protocol).~Contrast administration with an automatic contrast injector: angiographic image acquisitions will be performed with 6 ml of 50% contrast media (3 ml iodined contrast media, 3 ml physiologic saline) with a 3 ml/s flow rate.~DSA and DVA images will be calculated; DVA images will be used for diagnosis and interventions."
89006361|NCT04627207|Experimental|Reference-Reference-Test|Sequence 1
89418019|NCT04792255|Active Comparator|Group B: Standard contrast media dose group|"Standard contrast media protocol: extracranial carotid artery intervention (2-4 fps according to the institutional protocol).~Contrast administration with an automatic contrast injector: angiographic image acquisitions will be performed with 6 ml iodined contrast media with a 3 ml/s flow rate.~DSA and DVA images will be calculated; DSA images will be used for diagnosis and interventions."
89418020|NCT03575559|Experimental|Individual planning|An education and general motivational treatment is provided to each participant. Afterwards, participants are filling in the planning forms, referring to their individual physical activity. Both members of the dyad form up to three own individual plans. They are not allowed to speak to each other. The following behavior change techniques (BCT) are included in the planning intervention protocol: action planning, barrier identification, problem solving (coping planning). Interventions: Behavioral: Individual planning. Behavioral: Education and motivation. Active Comparator: No planning intervention, individual distraction task.
89418021|NCT03575559|Experimental|Collaborative planning|An education and general motivational treatment is provided to each participant. Afterwards, participants are filling in the planning forms together, referring to their joint physical activity. The friendship dyad forms up to three joint plans about engaging in PA together. The following behavior change techniques (BCT) are included in the planning intervention protocol: action planning, barrier identification, problem solving (coping planning). Interventions: Behavioral: Collaborative planning. Behavioral: Education and motivation. Active Comparator: No planning intervention, collaborative distraction task.
89418022|NCT03575559|Active Comparator|Individual distraction task|An education and general motivational treatment is provided to each participant. Afterwards, participants have to interpret a short video showing scenes of two different superhero movies. Several questions will be asked about characteristics of the two super heroes in the movie and whether these heroes are comparable. Each participant watches the movie alone and answers all questions by him/herself. Both members of the dyad are not allowed to speak to each other.
89418023|NCT03575559|Active Comparator|Collaborative distraction task|An education and general motivational treatment is provided to each participant. Afterwards, participants have to interpret a short video showing scenes of two different superhero movies together. Several questions ask about the characteristics of the two super heroes in the movie and whether these heroes are comparable. Both members of the dyad watch the movie together and answer the questions conjointly.
89418024|NCT03062956|Experimental|Single oral dose of MYK-491|single-dose, oral suspension
89418025|NCT03062956|Placebo Comparator|Single oral dose of placebo|single-dose, oral suspension
89418026|NCT03704779|Experimental|Multimodal Mindfulness Activity Program|Students assigned to the intervention will receive 8 weeks of the mindfulness activity intervention.
89006362|NCT04627207|Experimental|Reference-Test-Reference|Sequence 2
89418027|NCT03704779|No Intervention|Control Group|Students assigned to the control group will not receive any intervention.
89536783|NCT03310307|Placebo Comparator|Placebo|Similar in size, shape and color to vitamin D3
89006363|NCT04627207|Experimental|Test-Reference-Reference|Sequence 3
89006364|NCT00242424|Placebo Comparator|1|0.25 ml normal saline placebo given as injection to infants at 2 and 3 months of age
89006365|NCT00242424|Experimental|2|2005-6 Fluzone, pediatric formulation of trivalent inactivated influenza vaccine (sanofi pasteur) administered to infants at 2 and 3 months of age
89006366|NCT04627324|Experimental|The smart toothbrush and smart mirror (STM) system toothbrushing instruction (TBI)|Participants received using the STM system TBI. The plaque indexes were evaluated at baseline, immediately after TBI (day 0), 1 week, 1 month and 10 month (1st study only) after TBI.
89418028|NCT03062800|Experimental|P+Cisplatin/Carboplatin+T|"Induction therapy (Platinum based chemotherapy combined with antiangiogenic therapy 4-6 cycles):~Pemetrexed + Platinum + Thalidomide [pemetrexed (500mg/m^2)+cisplatin(75mg/m^2)or carboplatin(AUC=5) on day 1 of 21-days cycle, ivgtt +thalidomide 100-200mg/d ,oral, qn ]~Continue maintenance therapy (It is defined when a drug included in the induction treatment is used as maintenance .Patients who had not progressed during induction phase will be in this phase):~Thalidomide 100mg/d ,oral, qn, until either disease progression or unacceptable toxicity."
89418029|NCT03062800|Experimental|P+Cisplatin/Carboplatin|"Induction therapy ( Platinum based chemotherapy 4-6 cycles):~Pemetrexed + Platinum [pemetrexed (500mg/m^2)+cisplatin(75mg/m^2)or carboplatin(AUC=5) on day 1 of 21-days cycle,ivgtt ]~Maintenance therapy (It is defined when a drug included in the induction treatment is used as maintenance .Patients who had not progressed during induction phase will be in this phase):~Pemetrexed (500mg/m^2) on day 1 of 21-days cycle, ivgtt.until either disease progression or unacceptable toxicity"
88895876|NCT03844750|Experimental|Treatment (vactosertib, pembrolizumab, surgery)|"Neoadjuvant pembrolizumab will be administered at a fixed dose of 200 mg (IV) for 1 cycle plus 200 mg vactosertib (PO QD, 5 days per week x 2 weeks).~Adjuvant pembrolizumab (400 mg IV) + vactosertib (200 mg PO QD Cycle 1, 5 days per week, Cycles 2 and beyond (200 mg BID, 5 days per week) will be administered for up to eight 6-week cycles"
88895877|NCT03806803|Active Comparator|LFMT|Lyophilized fecal microbiota transplant capsules
88895878|NCT03806803|Experimental|LSFF|Lyophilized sterile fecal filtrate capsules
88895879|NCT03806166|Experimental|Shorter Systemic Antibiotics|Participants will receive local antibiotic therapy at the time of surgery, followed by one week or less of systemic antibiotic therapy, for bone and joint infection.
88895880|NCT03806166|Active Comparator|Long Systemic Antibiotics|Participants will receive local antibiotic therapy at the time of surgery, followed by four weeks or more of systemic antibiotic therapy (standard treatment recommended by international guidelines), for bone and joint infection.
88895881|NCT03792867|Experimental|Radical Resection and HIPEC|
88895882|NCT03765918|Experimental|Pembro Neoadjuvant+Pembro SOC Adjuvant|Participants receive 200 mg pembrolizumab by intravenous (IV) infusion administered on Day 1 of a 21-day cycle for 2 cycles as a neoadjuvant prior to surgery. Following surgical resection, high risk participants receive 200 mg pembrolizumab by IV infusion administered on Day 1 every 3 weeks (Q3W) for fifteen 21-day cycles plus standard of care radiotherapy plus cisplatin 100 mg/m^2 by IV infusion on Day 1 Q3W for three 21-day cycles as adjuvant therapy. Following surgical resection, low risk participants receive 200 mg pembrolizumab by IV infusion administered on Day 1 Q3W for fifteen 21-day cycles plus standard of care radiotherapy as adjuvant therapy.
88895883|NCT03765918|Active Comparator|No Neoadjuvant+SOC Adjuvant|Participants receive no neoadjuvant prior to surgery. Following surgical resection, high risk participants receive standard of care radiotherapy plus cisplatin 100 mg/m^2 by IV infusion on Day 1 Q3W for three 21-day cycles as adjuvant therapy. Following surgical resection, low risk participants receive standard of care radiotherapy as adjuvant therapy.
88895884|NCT03741764|Other|Vivosorb|Only arm in study
89193600|NCT04553497|Active Comparator|Rehabilitation and interferential current therapy|Flipping a coin was used for simple randomization (tails - interferential current). In this arm, interferential current therapy was applied to the patients in addition to the rehabilitation program.
88895886|NCT03737669|Experimental|Mirasol-treated Fresh Whole Blood|Standard Fresh Whole Blood, treated with Mirasol Pathogen Reduction Technology
88895887|NCT03737669|Placebo Comparator|Standard Fresh Whole Blood|Standard-issue fresh whole blood
88895888|NCT03716128||Low turnover bone disease|PTH<150 pg/ml
88895889|NCT03716128||High turnover bone disease|PTH>300 pg/ml
88895890|NCT03716128||Normal renal function|Patients under examination for prostate cancer
88895891|NCT03683225|Experimental|CTC-413|Pramipexole with/with out aprepitant orally once daily
88895892|NCT03678389|Experimental|1|ENDOSPHENOIDAL COIL
88895893|NCT03642964|Experimental|treatment|CTC-501 (pramipexole IR, given with ondansetron) given orally twice daily
88895894|NCT03642964|Placebo Comparator|placebo|generic placebo tablets given orally twice daily
88895895|NCT03638999|Active Comparator|Intervention Group - Ketorlac (NSAID)|Subjects will receive a one-time intravenous injection of 1 ml of Ketorlac 30 mg/ml prior to the start of the ureteroscopic procedure. After consent and during screening visit demographic information, medical/surgical history, and height and weight will be collected. On Day 0 subject will be randomized to NSAID or Saline using inclusion/exclusion criteria and the procedure data will be collected. On Day 1 subject will receive a follow up phone call and complete AUA Symptom Score, USS Questionnaire 1 and USS Questionnaire 2 and any adverse events will be assessed. These questionnaires will again be administered on the day of stent removal and again 1 to 2 months post stent removal.
88895896|NCT03638999|Placebo Comparator|Placebo Group - Normal Saline|Subjects in the control group will receive a one-time 1 ml of 0.9% injectable normal saline prior to the start of the ureteroscopic procedure. After consent and during screening visit demographic information, medical/surgical history, and height and weight will be collected. On Day 0 subject will be randomized to NSAID or Saline using inclusion/exclusion criteria and the procedure data will be collected. On Day 1 subject will receive a follow up phone call and complete AUA Symptom Score, USS Questionnaire 1 and USS Questionnaire 2 and any adverse events will be assessed. These questionnaires will again be administered on the day of stent removal and again 1 to 2 months post stent removal.
88895897|NCT03635892|Experimental|Cohort 1: Unclassified, papillary, and HL RCC|Cohort 1 is designed as a single stage study with a total sample size of 20. This design discriminates between ORR rates of 10 and 35%.
88895898|NCT03635892|Experimental|Cohort 2: Chromophobe RCC|Cohort 2 is designed as a Simon's optimal two-stage design with a total possible sample size of 17. This design discriminates between ORR rates of 5 and 25%.
88895899|NCT03635892|Experimental|Cohort 3: Unclassified, papillary, and HL RCC|Cohort 3 is designed as an expansion cohort of Cohort 1 with 20 additional patients to obtain a more precise estimate of the ORR and clinical outcomes
89193601|NCT04553497|Sham Comparator|Rehabilitation and sham therapy|Flipping a coin was used for simple randomization (heads - sham). In this arm, sham therapy was applied to the patients in addition to the rehabilitation program.
89193602|NCT04552288|Experimental|Participants with eosinophil-related cutaneous events|Study participants will have grade 2/3 eosinophil-related cutaneous adverse events
88895900|NCT03635892|Experimental|Cohort 4: Unclassified, papillary, and HL RCC|Cohort 4 is an expansion of Cohorts 1+3, which will accure an additional 40 patients
89193603|NCT04551963|Experimental|Arm A: Zanubrutinib with or without Moderate CYP3A|"Cycle 1 (30 days): Participants were administered zanubrutinib at a dose of 320 mg once a day from Day 1 to Day 3; From Day 4 to Day 10, fluconazole was administered once a day at a dose of 400 mg with zanubrutinib at a reduced dose of 80 mg twice a day; On Day 11 and Day 12, zanubrutinib monotherapy was administered at 80 mg twice a day, followed by 320 mg once a day from Day 13 to Day 21; From Day 22 to Day 28, diltiazem was administered once a day at a dose of 180 mg with 80 mg zanubrutinib twice a day; On Day 29 and Day 30, zanubrutinib monotherapy was administered 80 mg twice a day.~Cycles 2 to 6 (28 days each cycle): Zanubrutinib 160 mg twice a day or 320 mg once a day."
89193604|NCT04551963|Experimental|Arm B: Zanubrutinib with or without Strong CYP3A|"Cycle 1 (30 days): Participants were administered zanubrutinib at a dose of 320 mg once a day from Day 1 to Day 3; From Day 4 to Day 10, voriconazole was administered twice a day at a dose of 200 mg (total daily dose of 400 mg) with zanubrutinib at a reduced dose of 80 mg once a day; On Day 11 and Day 12, zanubrutinib monotherapy was administered at 80 mg once a day, followed by 320 mg once a day from Day 13 to Day 21; From Day 22 to Day 28, clarithromycin was administered twice a day at a dose of 250 mg (total daily dose of 500 mg) with 80 mg zanubrutinib once a day; On Day 29 and Day 30, zanubrutinib monotherapy was administered 80 mg once a day.~Cycles 2 to 6 (28 days each cycle): Zanubrutinib 160 mg twice a day or 320 mg once a day."
89193605|NCT04527107|Experimental|THR-149 dose level 1|
89193606|NCT04527107|Experimental|THR-149 dose level 2|
89536784|NCT00704405|Experimental|24-wk Vaniprevir 600 mg + Peg-IFN/RBV|Vaniprevir 600 mg (total daily dose) and RBV (1000 mg or 1200 mg total daily dose based on body weight) twice daily (b.i.d.) and Peg-IFN 180 mcg injection once weekly for 24 weeks.
88895901|NCT03629223|Experimental|Part A: First Tepotinib TF2 then TF3|Participants received a single oral dose of 500 milligrams (mg) Tepotinib tablet formulation 2 (TF2, reference treatment) on Day 1 of treatment period 1 followed by a single oral dose of 500 mg (2 x 250 mg) Tepotinib tablet formulation 3 (TF3, test treatment) on Day 1 of treatment period 2 under fasting conditions. The washout period was 21 days between Day 1 of each period.
88895902|NCT03629223|Experimental|Part A: First Tepotinib TF3 then TF2|Participants received a single oral dose of 500 mg (2 x 250 mg) Tepotinib TF3 (test treatment) on Day 1 of treatment period 1 followed by a single oral dose of 500 mg Tepotinib TF2 (reference treatment) on Day 1 of treatment period 2 under fasting conditions. The washout period was 21 days between Day 1 of each period.
89418030|NCT05709015|Other|1|Based on a randomisation table, each participant will use either a mouthwash containing neutral electrolyzed water, placebo, or chlorhexidine digluconate twice a day instead of tooth brushing and flossing for 4 days. Each subject will receive each mouthwash type only once during the study period (he/she will receive a different mouthwash type in every arm of the study based on a randomisation table).
88895903|NCT03629223|Experimental|Part B: First Tepotinib TF2 Fasted then TF2 Fed|Participants received a single oral dose of 500 mg Tepotinib TF2 (reference treatment) on Day 1 of treatment period 1 under fasting conditions followed by a single oral dose of 500 mg Tepotinib TF2 (reference treatment) on Day 1 of treatment period 2 under fed conditions. The washout period was 21 days between Day 1 of each period.
89418031|NCT05709015|Other|2|Based on a randomisation table, each participant will use either a mouthwash containing neutral electrolyzed water, placebo, or chlorhexidine digluconate twice a day instead of tooth brushing and flossing for 4 days. Each subject will receive each mouthwash type only once during the study period (he/she will receive a different mouthwash type in every arm of the study based on a randomisation table).
88895904|NCT03629223|Experimental|Part B: First Tepotinib TF2 Fed then TF2 Fasted|Participants received a single oral dose of 500 mg Tepotinib TF2 (reference treatment) on Day 1 of treatment period 1 under fed conditions followed by a single oral dose of 500 mg Tepotinib TF2 (reference treatment) on Day 1 of treatment period 2 under fasting conditions. The washout period was 21 days between Day 1 of each period.
88895905|NCT03629223|Experimental|Part C: First Tepotinib TF3 Fasted then TF3 Fed|Participants received a single oral dose of 500 mg (2 x 250 mg) Tepotinib TF3 (test treatment) on Day 1 of treatment period 1 under fasting conditions followed by a single oral dose of 500 mg (2 x 250 mg) Tepotinib TF3 (test treatment) on Day 1 of treatment period 2 under fed conditions. The washout period was 21 days between Day 1 of each period.
88895906|NCT03629223|Experimental|Part C: First Tepotinib TF3 Fed then TF3 Fasted|Participants received a single oral dose of 500 mg (2 x 250 mg) Tepotinib TF3 (test treatment) on Day 1 of treatment period 1 under fed conditions followed by a single oral dose of 500 mg (2 x 250 mg) Tepotinib TF3 (test treatment) on Day 1 of treatment period 2 under fasting conditions. The washout period was 21 days between Day 1 of each period.
89418032|NCT05709015|Other|3|Based on a randomisation table, each participant will use either a mouthwash containing neutral electrolyzed water, placebo, or chlorhexidine digluconate twice a day instead of tooth brushing and flossing for 4 days. Each subject will receive each mouthwash type only once during the study period (he/she will receive a different mouthwash type in every arm of the study based on a randomisation table).
89418033|NCT02524041|Experimental|secondary hyperparathyroidism|Blood specimen and HR-pQCT for measure bone quality and quantity
89418034|NCT03573141||Knee OA patients receiving Physical Therapy|Only 1 group was included in this study. Subject's physical activity and sleep quality were assessed at baseline, prior to treatment. Follow up data was collected immediately after a course of physical therapy then again 8 weeks later.
89418035|NCT03573063|Other|Androgen metabolism after starvation|Metabolism changes after 48 hours starvation in healthy women
89418036|NCT03571035|Experimental|Example|Mandibular movements recordings by a mono vision system.
89418037|NCT03570957|Experimental|MT-2990, Low dose|Single intravenous dose
89418038|NCT03570957|Experimental|MT-2990, Low-middle dose|Single intravenous dose
89418039|NCT03570957|Experimental|MT-2990, High-middle dose|Single intravenous dose
89418040|NCT03570957|Experimental|MT-2990, High dose|Single intravenous dose
89418041|NCT03570957|Placebo Comparator|Placebo|Single intravenous dose
89418042|NCT04050631||L&D team|the first responders on L&D floor including : anesthesia, nurses and OBGYN
89418043|NCT03575481||Post stroke patients|
89418044|NCT03572829|Experimental|Aprepitant|Aprepitant combined with ondansetron and dexamethasone
89418045|NCT04050787|Experimental|D2 Lymphadenectomy including No. 10|lymphadenectomy including spleen-preserving No. 10 lymph node dissection will be performed for the treatment of patients assigned to this group
89418046|NCT04050787|Active Comparator|D2 lymphadenectomy excluding No. 10|Laparoscopic total gastrectomy with D2 lymphadenectomy but without No. 10 lymph node dissection will be performed for the treatment of patients assigned to this group
89418047|NCT03570879||Power morcellation|Women that underwent laparoscopic myomectomy with subsequent power morcellation of the surgical specimens.
89418048|NCT03570879||Transvaginal extraction|Women that underwent laparoscopic myomectomy with subsequent transvaginal extraction of the surgical specimens.
89418049|NCT04050475|Experimental|PSY-FMD|Subjects randomized in the PSY-FMD group carried out the Functional Therapy protocol over 20 individual sessions, which were scheduled twice a week for the first two months and once a week for the last month (three months total). The treatment program was specifically manualized for treating depression with the aim to increase mood, self-esteem and quality of life. Furthermore, patients followed a Fasting Mimicking Diet (FMD) protocol consisting of 3 cycles of 5 days a month each: the first day of the diet provided 1090 kcal (10% protein, 56% fat, 34% carbohydrate), the days 2-5 were identical in the formulation and provided 725 kcal (9-10% protein, 44-56% fat, 34-47% carbohydrate). Between cycles of FMD the subjects stuck to a free diet. At the end of the treatment all patients were re-tested through the same assessment protocol and the same things was realized at the follow-up (three months later the end of the treatment).
88895907|NCT03625765|Experimental|SmartGoggles|The prototype system offers real time stereoscopic fluorescence imaging along with in vivo handheld microscopy. Investigators have found that the system can detect fluorescent targets with as low as 1.2 picomoles ICG (60 nanomolar (nM) concentration). The hand-held microscopy module has a resolution of 25 micron. The prototype system has 2 complementary metal-oxide-semiconductor (CMOS) imaging sensors housed on a printed circuit board (PCB) with imaging lenses and emission filters optimized for ICG dye. The light source provides concurrent excitation centered at 780 nm and white light illumination with optical density (OD) 6 level cut-off. The SmartGoggles is a non-invasive imaging system that does not require contact with patients.
88922187|NCT05678712|Experimental|Intervention (access to CGM data)|"After a two weeks run-in baseline period (blinded CGM) some of the participants (1:1) were randomly assigned to six weeks with non-blinded CGM with data available for the patient himself/herself and dialysis staff → 2 weeks wash-out (baseline for next period) (blinded CGM) → Six weeks of standard treatment, i.e. self monitoring of blood glucose (the last two weeks with blinded CGM"
89418050|NCT04050475|No Intervention|PSY|Subjects randomized into the control group (PSY) completed the same Functional Therapy program without practicing any diet. Specifically, at the end of the nutritional consultation the nutritionist suggested them to keep a food diary without changing their habitual diet style.
89418051|NCT05367921|Experimental|CPM#1|Compartment compressibility ratio measurement using the CPM#1 device
89418052|NCT02239497|Experimental|femoral block by US and NE and intravenous analgesia|preincisional femoral block by ultrasound and neurostimulation, with 20 ml bupivacaine 0,5% and epinephrine. ketoprofen, dipyrone and dexamethasone IV. Morphine IV to rescue analgesia
89418053|NCT02239497|Experimental|Intravenous analgesia|Intravenous analgesia with ketoprofen, dipyrone and morphine. IV morphine to rescue analgesia
89418054|NCT03572751||Vascular surgical patients|"Patient subjects are recruited from patients referred for vascular surgical procedure in Tampere University Hospital.~Bed-, wrist- and ECG-sensor monitoring"
89418055|NCT03572751||Healthy volunteers|"Healthy volunteer subjects will be recruited mainly from the students of Tampere University of Technology.~Bed-, wrist- and ECG-sensor monitoring"
89418056|NCT03705403|Active Comparator|Control|Standard of Care (SOC) according to the local and national guidelines: (wait and see or surgery and/or chemotherapy and/or standard (symptomatic) radiation therapy and/or SABR (oligometastatic disease)
89418057|NCT03705403|Experimental|Experimental treatment|Standard of Care (SOC SABR (oligometastatic disease) or radiation therapy (diffuse disease) + L19-IL2 up to 6 cycles (Darleukin)
89418058|NCT02239653|Experimental|Physician communication|"The Milk. Water. Period intervention comprises brochures, posters, and key talking points for use by primary pediatricians to use in discussion with the parent about the child's beverages consumption."
89418059|NCT02239653|No Intervention|Usual care|
89418060|NCT03705325|Experimental|Spirobank smart spirometer with VitalFlo mobile app|In this single arm study, all participants will be receive the spirometer and an iPhone 5S (without SIM card) loaded with the VitalFlo app.
89418061|NCT03572673|Active Comparator|Flexima 3S|Flexima 3S is a 2-piece ostomy appliance composed with an adhesive base plate and a drainable pouch for collecting stools (1 base plate for 5 days and 1 pouch for 5 days)
88895908|NCT03614702|Experimental|1-dose cIPV + 2-doses bOPV (Candy)|"cIPV: Inactivated Poliomyelitis Vaccine Made from Wild Polio Strains Produced by Sanofi Pasteur Co., Ltd. 0.5ml/dose~bOPV (Candy): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 in Dragee Candy (Human Diploid Cell) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences . 1g/pill,10 pills/pach,one pill each time; each pill containing polio virus≥5.92 lgCCID50 including type1 polio virus≥5.8 lgCCID50，type 3 polio virus ≥5.3lgCCID50."
88895909|NCT03614702|Experimental|1-dose sIPV + 2-doses bOPV (Candy)|"sIPV: Inactivated Poliomyelitis Vaccine Made from Sabin Strains Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences 0.5ml/dose~bOPV (Candy): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 in Dragee Candy (Human Diploid Cell) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 1g/pill,10 pills/pach,one pill each time;each pill containing polio virus≥5.92 lgCCID50 including type1 polio virus≥5.8 lgCCID50，type 3 polio virus ≥5.3lgCCID50."
88895910|NCT03614702|Experimental|2-doses cIPV + 1-dose bOPV (Candy)|"cIPV: Inactivated Poliomyelitis Vaccine Made from Wild Polio Strains Produced by Sanofi Pasteur Co., Ltd. 0.5ml/dose~bOPV (Candy): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 in Dragee Candy (Human Diploid Cell) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 1g/pill,10 pills/pach,one pill each time; each pill containing polio virus≥5.92 lgCCID50 including type1 polio virus≥5.8 lgCCID50，type 3 polio virus ≥5.3lgCCID50"
88895911|NCT03614702|Experimental|2-doses sIPV + 1-dose bOPV (Candy)|"sIPV: Inactivated Poliomyelitis Vaccine Made from Sabin Strains Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 0.5ml/dose~bOPV (Candy): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 in Dragee Candy (Human Diploid Cell) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 1g/pill,10 pills/pach,one pill each time; each pill containing polio virus≥5.92 lgCCID50 including type1 polio virus≥5.8 lgCCID50，type 3 polio virus ≥5.3lgCCID50"
88895912|NCT03614702|Experimental|2-doses cIPV + 1-dose tOPV (Candy)|"cIPV: Inactivated Poliomyelitis Vaccine（Vero） Made from Wild Polio Strains Produced by Sanofi Pasteur Co., Ltd. 0.5ml/dose~tOPV (Candy): Trivalent oral attenuated live poliomyelitis vaccine against type 1, type 2 and type 3 in Dragee Candy (Human Diploid Cell) Produced by Beijing Tiantan Biological Products Co., Ltd. 1g/pill,10 pills/pach;each pill containing polio virus≥5.95 lgCCID50 including type1 polio virus≥5.8 lgCCID50，type 2 polio virus ≥4.8lgCCID50，type 3 polio virus ≥5.3lgCCID50"
89193607|NCT04527107|Experimental|THR-149 dose level 3|
88895913|NCT03614702|Experimental|2-doses sIPV + 1-dose tOPV (Candy)|"sIPV: Inactivated Poliomyelitis Vaccine Made from Sabin Strains Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences 0.5ml/dose~tOPV (Candy): Trivalent oral attenuated live poliomyelitis vaccine against type 1, type 2 and type 3 in Dragee Candy (Human Diploid Cell) Produced by Beijing Tiantan Biological Products Co., Ltd.1g/pill,10 pills/pach,one pills each time;each pill containing polio virus≥5.95 lgCCID50 including type1 polio virus≥5.8 lgCCID50，type 2 polio virus ≥4.8lgCCID50，type 3 polio virus ≥5.3lgCCID50"
88895914|NCT03614702|Experimental|1-dose cIPV + 2-doses bOPV (Liquid)|"cIPV: Inactivated Poliomyelitis Vaccine（Vero） Made from Wild Polio Strains Produced by Sanofi Pasteur Co., Ltd. 0.5ml/dose~bOPV (Liquid): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 (Human Diploid Cell) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 0.5ml or 1.0ml each bottle;total content of polio virus≥7.12lgCCID50/ml，type1 polio virus≥7.0 lgCCID50/ml，type 3 polio virus ≥6.5lgCCID50/ml.(2 drops per person;be be equivalent to 0.1ml each person )"
88895915|NCT03614702|Experimental|1-dose sIPV + 2-doses bOPV (Liquid)|"sIPV: Inactivated Poliomyelitis Vaccine Made from Sabin Strains Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 0.5ml/dose~bOPV (Liquid): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 (Human Diploid Cell) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 0.5ml or 1.0ml each bottle;total content of polio virus≥7.12lgCCID50/ml，type1 polio virus≥7.0 lgCCID50/ml，type 3 polio virus ≥6.5lgCCID50/ml.(2 drops per person;be be equivalent to 0.1ml each person )"
88922188|NCT05666362|Active Comparator|Group 1 : ( benoxinate hydrochloride 0.4% group )|They will receive benoxinate hydrochloride 0.4% immediately before fundus examination .
88922189|NCT05666362|Placebo Comparator|Group 2 : ( control group )|They will receive saline drops instead of benoxinate hydrochloride 0.4%. Randomization: simple randomization sampling using sealed envelope technique.
89193608|NCT04527107|Experimental|THR-149 + sham|
89193609|NCT04527107|Experimental|THR-149 + aflibercept flip-over|
89193610|NCT04527107|Active Comparator|Aflibercept + THR-149 flip-over|
89193611|NCT04527107|Active Comparator|Aflibercept + sham|
89193612|NCT04515342||Participants|This is a cross-sectional study involving approximately 150 patients. They undergo a physical examination, fill out a questionnaire, have blood samples drawn, undergo a Dual Energy X-ray Absorptiometry (DXA) scan and different physical procedures to assess muscle strength and muscle function.
89193613|NCT04512287|Experimental|Experimental: Autologous PRP followed by Placebo Group|Participants in this group will receive the autologous intervention first, followed by the placebo intervention 3 months later.
89193614|NCT04512287|Experimental|Experimental: Placebo followed by Autologous PRP Group|Participants in this group will receive the placebo intervention first, followed by the Autologous PRP intervention 3 months later.
89193615|NCT04502381|Experimental|Intervention arm|The study participants in the intervention arm will receive nebulization with amphotericin B deoxycholate (10 mg twice a day every alternate day, as described below) along with intravenous liposomal amphotericin B (3 to 5 mg/kg body weight)
89193616|NCT04502381|Active Comparator|Conventional arm|Participants will receive treatment with only intravenous liposomal amphotericin B (3 to 5 mg/kg body weight)
89193617|NCT04489719||Observational (biospecimen collection)|Patients receive standard of care radium Ra 223 dichloride given by IV bolus every 4 weeks for up to 6 cycles. Patients undergo collection of blood every 1-3 months during radium Ra 223 dichloride treatment.
89193618|NCT04472910|Experimental|Neo-adjuvant mFFX|Neo-adjuvant mFFX up to 6 cycles, surgery, adjuvant chemotherapy for up tp 6 cycles, follow up
89193619|NCT04468113||US-guided core biopsy and clip placement|Female patients with sonographically suspicious, intramammary foci, scheduled for ultrasound-guided core biopsy and marking of the lesion with the Tumark® Vision Clip
89193620|NCT04466566|Placebo Comparator|Saline|Saline will be infused during the study
88895916|NCT03614702|Experimental|2-doses cIPV + 1-dose bOPV (Liquid)|"cIPV: Inactivated Poliomyelitis Vaccine Made from Wild Polio Strains Produced by Sanofi Pasteur Co., Ltd. 0.5ml/dose~bOPV (Liquid): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 (Human Diploid Cell) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 0.5ml or 1.0ml each bottle;total content of polio virus≥7.12lgCCID50/ml，type1 polio virus≥7.0 lgCCID50/ml，type 3 polio virus ≥6.5lgCCID50/ml.(2 drops per person;be be equivalent to 0.1ml each person )"
88895917|NCT03614702|Experimental|2-doses sIPV + 1-dose bOPV (Liquid)|"sIPV: Inactivated Poliomyelitis Vaccine Made from Sabin Strains Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 0.5ml/dose~bOPV (Liquid): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 (Human Diploid Cell) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 0.5ml or 1.0ml each bottle,total content of polio virus≥7.12lgCCID50/ml，type1 polio virus≥7.0 lgCCID50/ml，type 3 polio virus ≥6.5lgCCID50/ml.(2 drops per person;be be equivalent to 0.1ml each person )"
89006367|NCT04627324|Active Comparator|conventional toothbrushing instruction (TBI)|Participants received using conventional TBI. The plaque indexes were evaluated at baseline, immediately after TBI (day 0), 1 week, 1 month and 10 month (1st study only) after TBI.
89006368|NCT04627402|Experimental|Injection combo agents|Intravitreous injection of triamcinolone acetonide (TA) and conbercept.
89006369|NCT04627402|Active Comparator|Injection single agent|Intravitreous injection of conbercept only.
89193621|NCT04466566|Active Comparator|Exendin-9,39|Exendin-9,39 will be infused during the study
89193622|NCT04454697|Experimental|Intervention|Patient receive personalized 3D-printed GWR
89193623|NCT04454697|Active Comparator|Control|Patient receive standardized radiation protection tooth splints
89193624|NCT04451135|Experimental|Patients with Treatment-Resistant Depression|
89193625|NCT04432597|Experimental|1/Arm 1A|Human Papillomavirus Vaccine (HPV) vaccine at 1x10(11) Viral Particles (VP) Dose Level 1 (DL1) and at 5x10(11) VP Dose Level 2 (DL2)
89193626|NCT04432597|Experimental|2/Arm 1B|Human Papillomavirus Vaccine (HPV) vaccine at recommended phase 2 dose (RP2D) plus M7824 at 1200 mg.
89193627|NCT04432597|Experimental|3/Arm 2A|Human Papillomavirus Vaccine (HPV) vaccine at recommended phase 2 dose (RP2D) given as neoadjuvant or induction therapy.
89193628|NCT04432597|Experimental|4/Arm 2B|Human Papillomavirus Vaccine (HPV) vaccine at recommended phase 2 dose (RP2D) plus M7824 at 1200 mg given as neoadjuvant or induction therapy.
89193629|NCT04416555|Placebo Comparator|VR googles using exposure sham program|The study groups will receive VR googles and the sham program
89193630|NCT04416555|Active Comparator|VR googles and the real VR program experience.|The study group will receive the VR googles and the real VR program experience.
89193631|NCT04408612||Dyspnea in stable coronary artery disease|Stable patients with dyspnea and coronary artery disease
89193632|NCT04400708|Sham Comparator|control group|normal saline injection
89193633|NCT04400708|Experimental|test group|0.5% ropivacaine injection
89193634|NCT04396483|Experimental|"Tubal sterilization Pomeroy's method"|
89193635|NCT04396483|Active Comparator|Salpingectomy|
89193636|NCT04390971|Experimental|ET-01|BCL11A Enhancer modified Autologous Hematopoietic Stem Cells.
89193637|NCT04390308||Intervention|The cortex of selected ovary will be punctured up to ten times. In the surgical report, the surgeon will state how many punctures have been done.
89193638|NCT04390308||Control|No intervention
89193639|NCT04389203|Experimental|Study group|Unilateral tubal disconnection and waiting for pregnancy for 2 years after laparoscopy
89193640|NCT04389203|Experimental|Control group|Unilateral tubal disconnection and ICSI
89193641|NCT04379765||Grup 1: Exercise and physical therapy programme|30 patients with lumbar spinal stenosis will receive hot pack, transcutaneous electrical nerve stimulation and deep warming as a physical therapy modality , and lumber flexion and strengthening exercises were performed for 7 times/week for 3 weeks.
89193642|NCT04379765||Grup 2: Surgical procedure programme|30 patients with lumbar spinal stenosis underwent decompression operation of the relevant level.
89193643|NCT04372914|Experimental|BRB Lozenges|Oral lozenges that contain 1 gram of BRB freeze-dried powder
89193644|NCT04370704|Experimental|Phase 1 Part 1|Part 1 will confirm the safety of INCAGN02385 and INCAGN02390 when used in combination. INCAGN02385 will be administered first intravenously followed by INCAGN02390.
89193645|NCT04370704|Experimental|Phase 1 Part 2|Part 2 will confirm the safety of the triple combination of INCAGN02385 + INCAGN02390 + INCMGA00012, following confirmation of the safety of the doublet in Part 1. INCAGN02385 will be administered first intravenously followed by INCAGN02390 and INCMGA00012.
89193646|NCT04370704|Experimental|Phase 2 Cohort A|Phase 2 will determine preliminary efficacy and proof of concept for the combination of INCAGN02385 + INCAGN02390 + INCMGA00012. INCAGN02385 will be administered first intravenously followed by INCAGN02390 and INCMGA00012
89193647|NCT04370704|Experimental|Phase 2 Cohort B|Phase 2 will determine preliminary efficacy and proof of concept for the combination of INCAGN02385 + INCAGN02390 + INCMGA00012. INCAGN02385 will be administered first intravenously followed by INCAGN02390 and INCMGA00012
89193648|NCT04370704|Experimental|Phase 1 Part 3|Part 1 will confirm the safety of INCAGN02385 + INCAGN02390 + INCMGA00012 when used in combination.
89193649|NCT04370704|Experimental|Phase 1 Part 4|Part 1 will confirm the safety of INCAGN02385 + INCAGN02390 + INCMGA00012 in combination.
89193650|NCT04356638|Active Comparator|The sedative pre-medication oral Midazolam|
89193651|NCT04356638|Active Comparator|The sedative pre-medication intranasal Dexmedetomidine|
89193652|NCT04356638|Placebo Comparator|Placebo|
89193653|NCT04356638|No Intervention|No Sedative Pre-medication|
89193654|NCT04347434|Experimental|Atorvastatin 80 mg|"Treatment with atorvastatin is prescribed at a dose of 80 mg / day from the first 24-96 hours of AMI in addition to the standard therapy.~If there is no achievement of the target level of LDL-C, ≤1.5 mmol / L after 5-6 weeks from the AMI onset, patients additionally receive ezetimibe at a dose of 10 mg 1 time / day."
88895918|NCT03614702|Experimental|2-doses cIPV + 1-dose tOPV (Liquid)|"cIPV: Inactivated Poliomyelitis Vaccine Made from Wild Polio Strains Produced by Sanofi Pasteur Co., Ltd. 0.5ml/dose~tOPV(Liquid) Trivalent oral attenuated live poliomyelitis vaccine against type 1, type 2 and type 3 in Dragee Candy (Vero) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 1.0ml each bottle,total content of polio virus≥7.15lgCCID50/ml，type1 polio virus≥ 7.0 lgCCID50/ml，type2 polio virus ≥ 6.0lgCCID50/ml，type 3 polio virus≥ 6.5lgCCID50/ml.(2 drops per person;be be equivalent to 0.1ml each person )"
88895919|NCT03614702|Experimental|2-doses sIPV + 1-dose tOPV (Liquid)|"sIPV: Inactivated Poliomyelitis Vaccine Made from Sabin Strains Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences.0.5ml/dose~Trivalent oral attenuated live poliomyelitis vaccine against type 1, type 2 and type 3 in Dragee Candy (vero) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 1.0ml each bottle,total content of polio virus≥7.15lgCCID50/ml，type1 polio virus≥7.0 lgCCID50/ml，type 2 polio virus ≥ 6.0lgCCID50/ml，type 3 polio virus ≥ 6.5lgCCID50/ml.(2 drops per person;be be equivalent to 0.1ml each person )"
88895920|NCT03568383|Experimental|Arm A: Delamanid (DLM)|HHCs will receive delamanid (DLM) for 26 weeks.
88895921|NCT03568383|Experimental|Arm B: Isoniazid (INH)|HHCs will receive isoniazid (INH) and pyridoxine (vitamin B6) for 26 weeks.
88895922|NCT03567473|Experimental|Active Intervention Arm|Oral dexamethasone and nebulized epinephrine OR Oral dexamethasone and inhaled epinephrine given by MDI
88895923|NCT03567473|Placebo Comparator|Control Arm|"Oral placebo (OraBlendTM in Canada and a compounded oral placebo solution at New Zealand/Australia sites) and nebulized saline.~OR Oral placebo (OraBlendTM in Canada and a compounded oral placebo solution at New Zealand/Australia sites) and inhaled placebo given by MDI."
89006370|NCT04627051|Experimental|Dysfunction AV graft|Dysfunctional AV graft stenosis treated with atherectomy and drug coated balloon angioplasty
89006371|NCT00219362|Experimental|ALVAC-HIV 4 injections|Arm A: injection of ALVAC-HIV(vCP1452) for a total of 4 injections (W0, W4, W8, W20)
89193655|NCT04347434|Active Comparator|Atorvastatin-Ezetimibe|In the absence of reaching the target level of LDL-C of ≤1.4 mmol / L and a decrease in the indicator by ≥50% after 5-6 weeks from the onset of AMI, patients additionally receive ezetimibe at a dose of 10 mg 1 time / day.
89193656|NCT04343170|Placebo Comparator|control group|Patients of this group received placebo treatment consisted of two subcutaneous injections of 1 mL saline and an oral placebo.
89193657|NCT04343170|Experimental|ultra-short-term treatment|Patients of this group received Combination treatment consisted of a slow (30 min) intravenous infusion of 20 mg/kg ferric carboxymaltose (maximum of 1000 mg), 40 000 U subcutaneous α erythropoietin,1 mg subcutaneous vitamin B12(, and 5 mg oral folic acid (acidum folicum)
89193658|NCT04342026||Parent of patient with cryptorchidism|parent exposition of endocrine disruptors
89193659|NCT04342026||Parent of patient without cryptorchidism|Parent exposition of endocrine disruptors
89193660|NCT04338152|Experimental|FFT-CHR|Family-Focused Therapy for Clinical High-Risk Individuals
89193661|NCT04338152|Active Comparator|Enhanced Care|Enhanced Care Psychoeducation for Clinical High-Risk Individuals
89193662|NCT04337242|Experimental|Blended Dynamic Interpersonal Therapy (B-DIT)|B-DIT is based on the same treatment principles as face-to-face Dynamic Interpersonal Therapy (DIT) and has the same structure of treatment consisting of three phases: (a) an exploration and engagement phase, (b) a middle or working through phase, and (c) an ending phase. B-DIT consists of 8 online modules that are alternated with up to 8 fortnightly face-to-face sessions.
89193663|NCT04337242|Experimental|Blended Cognitive Behavioral Therapy (B-CBT)|B-CBT is based on the same treatment principles as face-to-face Cognitive Behavioral Therapy (CBT). These include (a) psycho-education about depression, (b) cognitive restructuring (i.e., identifying and challenging maladaptive thoughts and beliefs, fostering problem solving capacities), (c) mindfulness and acceptance based approaches, and (d) relapse prevention. B-CBT in this trial consists of 8 online modules that are alternated with up to 8 fortnightly face-to-face sessions.
89193664|NCT04337242|Active Comparator|Dynamic Interpersonal Therapy (DIT)|DIT is a short-term, integrative psychodynamic, 16 weekly sessions individual therapy for depression. DIT formulates the presenting symptoms of depression as responses to interpersonal difficulties or perceived threats to attachments (loss/separation) and hence also as threats to the self.
89193665|NCT04337242|Active Comparator|Cognitive Behavioral Therapy (CBT)|CBT is a brief talking therapy that consists of a maximum of 16 sessions, offered over 4 to 6 months. CBT is based on the assumption that depression is directly related to patterns of thinking. Specifically, dysfunctional and often automatic patterns of thinking are assumed to be related to the onset and maintenance of depression.
89193666|NCT04336111|No Intervention|control group|will receive sham bilateral bilevel ultrasounded guided retrolaminar block at T4 and T10 after induction of anaesthesia in prone position.
89193667|NCT04336111|Experimental|retrolaminar block|will receive real bilateral bilevel ultrasounded guided retrolaminar block at T4 and T10 after induction of anaesthesia in prone position. The total desired volume used in the whole injection will be 40 ml containing 3mg / kg bupivacaine with adrenaline 2.5 2 µg/ml. The total 40 ml volume will be divided into 10 ml for each injection.
89193668|NCT04336046|Sham Comparator|control group|will receive sham bilateral ultrasounded guided erector spinae block using 1 mg /kg normal saline in a total volume of 20 ml for each side after induction of anaesthesia in prone position after induction of anaesthesia in prone position.
89193669|NCT04336046|Experimental|erector spinae block|will receive real bilateral ultrasounded guided erector spinae block by bupivacaine at 1 mg /kg in a total volume of 20 ml for each side after induction of anaesthesia in prone position
89193670|NCT04335994|Active Comparator|Standard of Care|Patients receive standard of care for diagnosing obstructive sleep apnea, which is in-laboratory polysomnography.
89418062|NCT03572673|Experimental|New 2-piece ostomy appliance|New 2-piece appliance is a 2-piece ostomy appliance composed with an adhesive base plate and a drainable pouch for collecting stools (1 base plate for 5 days and 1 pouch for 5 days)
89418063|NCT03575091|No Intervention|control group|The infants will receive the standard care at the ward.
89418064|NCT03575091|Experimental|Non-individualized|The parents will be guided manually by the nursing staff and receive written information about how to change body positions of their child regularly throughout the hospital stay.
89418065|NCT03575091|Experimental|Individualized|The infant will receive frequent changes of body positions, stimulation to physical activity, and stimulation to deep breathing while bouncing on a large ball in the arms of an adult. Additional light chest compressions and inhalations may be given. A physiotherapist will perform the intervention at least once daily, and the parents will be manually guided and receive written information about how to change body positions of their child regularly in a similar way throughout the hospital stay.
89418066|NCT03704623|Active Comparator|Paracetamol|Patients will receive IV 1 g of Paracetamol
89418067|NCT03704623|Active Comparator|Parecoxib|Patients will receive 40 mg of Parecoxib IV
89418068|NCT03570723|Active Comparator|stepwise uterine devascularization|"Uterine hemostatic sutures, through examination of the placental bed, may use some hemostasis at the placental bed,overswing was commenced using endo-uterine sutures. If there is still significant bleeding, bilateral uterine artery ligation, and internal iliac artery ligation when needed.BUAL started immediately through blunt dissection downwards and laterally of the peritoneum covering the uterine isthmus and cervix. The peritoneum is mobilized freely at the uterine angles to expose both uterine arteries and avoid inclusion of the ureters in the ligation. The uterine artery pulsations were palpated digitally at the level of the internal os."
89418069|NCT03570723|Experimental|A glove-loaded Foley's catheter|A glove-loaded Foley's catheter tamponade, the internal os of the cervix was identified and a double-way 20 Fr Foley's catheter with a 30-50-ml balloon was inserted through the cervix to be handled by an assistant through the vagina and fixed to the patient's lower limb after inflation of the catheter balloon by 300 ml warm saline and pulling it against the lower uterine segment between the two transverse sutures. Only one glove-loaded Foley's catheter was used for tamponade.
89418070|NCT03701659|Experimental|TUPKRP+MAB Group|These patient will be treated by TUPKRP and MAB.
89418071|NCT03701659|Active Comparator|MAB Group|These patient will be treated by MAB only.
89418072|NCT03065296|Experimental|Musculoskeletal (MSK) Exercise Prescription|"Phase I: Residents will be surveyed as to their knowledge and confidence in both diagnosing specific musculoskeletal (MSK) issues and prescribing the correct home rehabilitation regimen.~In between phase 1 and phase 2 there will be a series of didactic lectures to educate resident on home exercise prescription and get them familiarized with the handouts.~Phase II: Residents will be surveyed again in May 2017 with the same multiple choice questions and Likert style confidence scales from phase 1~The survey will consist of multiple choice and short essay questions, focused on the most common musculoskeletal (MSK) injuries seen in the primary care setting."
89418073|NCT03572595||Staging|Patients with pathologically proven colorectal cancer presented for pre-operative staging, underwent standard routine conventional radiological imaging i.e MRI , then will be subjected to be imaged by F-18 FDG-PET/CT from skullbase to midthigh, then interpretating the results of the hybrid PET/CT by two nuclear physicians then comparing with other conventional images.
89418074|NCT03572595||Recurrent|"Patients with treated colorectal cancer, suspecting of recurrence , will be subjected to be imaged by F-18 FDG-PET/CT from skull base to midthigh, interpretating the results of the hybrid PET/CT by two nuclear physicians.~Then refer back to the treating physicians , another biopsy will be taken from the suspected recurrence and then results will be compared with hybrid PET/CT images.~comparing the results with histopathology ."
89418075|NCT03572517|Active Comparator|Subarachnoid block|"Subarachnoid block with hyperbaric bupivacaine 0,5% 3ml associate with morphine 50 mcg.~A general anesthetic with fentanyl 3 mcg / kg + propofol 2 mg / kg + rocuronium 0.6 mg / kg will be performed.~Anesthesia will be maintained with remifentanil (ng / ml) through Minto's pharmacokinetic model (BBraun infusion syringe - Perfusor® Space model) and desflurane (Fe%)."
89418076|NCT03572517|Active Comparator|Spinal morphine|"Spinal morphine with morphine 50 mcg. A general anesthetic with fentanyl 3 mcg / kg + propofol 2 mg / kg + rocuronium 0.6 mg / kg will be performed.~Anesthesia will be maintained with remifentanil (ng / ml) through Minto's pharmacokinetic model (BBraun infusion syringe - Perfusor® Space model) and desflurane (Fe%)."
89418077|NCT03952546|Experimental|Treatment Arm|Saline-coupled bipolar sealer
89418078|NCT03952546|Active Comparator|Control Arm|Unipolar electrocautery
89418079|NCT03570645|Experimental|dexmedetomidine group|thoracic paravertebral blocks using a combination of ropivacaine and dexmedetomidine 100 ug every time
89418080|NCT03570645|Experimental|dexamethasone Group|thoracic paravertebral blocks using a combination of ropivacaine and dexamethasone 10 mg every time
89418081|NCT03570645|Sham Comparator|control group|thoracic paravertebral blocks using only ropivacaine
89418082|NCT05354037|Active Comparator|Group A|EMD + M-MIST approach
89418083|NCT05354037|Experimental|Group B|EMD with flapless approach
89418084|NCT03705091||Transplant|Incident patients receiving a kidney transplant for end stage kidney disease. Patients will undergo functional magnetic resonance imaging at 2 months, 6 months and 12 months following transplantation.
89418085|NCT03567135||Experimental 1|concurrent chemoradiotherapy（Temozolomide+apatinib） maintenance therapy（Temozolomide）
89006372|NCT00219362|Experimental|ALVAC-HIV 3 injections|Arm B: injection of ALVAC-HIV(vCP1452) for a total of injections (W4, W8, W20)
89006373|NCT00219362|Placebo Comparator|Placebo - 4 injections|Arm C1: injection of placebo for a total of 4 injections (W0, W4, W8, W20)
89418086|NCT03567135||control|concurrent chemoradiotherapy（Temozolomide） maintenance therapy（Temozolomide）
89418087|NCT03567135||Experimental 2|concurrent chemoradiotherapy（Temozolomide+apatinib） maintenance therapy（Temozolomide+apatinib）
89418088|NCT03570567|Other|Piranha Treatment|The food impaction will be treated using the Piranha endoscopic device.
89418089|NCT03624439|Experimental|Normal airway|normal airway. the language has not been inflated. the instructor assessed the difficulty of intubation based on the Cormack - Lehane scale to the first degree
89418090|NCT03624439|Experimental|Difficult airway|dofficult airway. Difficult airways were obtained by means of language inflation using a simulator control panel, so as to obtain the degree of intubation difficulty assessed by an independent anesthesiologist to the third degree according to the Cormack-Lehane scale
89193671|NCT04335994|Experimental|Home Sleep Apnea Test|Patients will undergo assessment for obstructive sleep apnea using a home sleep apnea test.
89535998|NCT03200197|Experimental|menthol chewing gum|Allocation concealment was performed through the use of individual opaque envelopes numbered externally in sequence, containing the randomly defined group information.This step was performed by a researcher who did not participate in the data collection. The intensity of the initial thirst was measured by means of the Verbal Numerical Scale (VNS), which ranged from 0 (no thirst) to 10 (very intense thirst) and the discomfort of the initial thirst was measured through the Perioperative Thirst Discomfort Scale (PTDS), which is composed of 7 attributes and ranges from 0 to 14. After using the intervention (menthol chewing gum) for 10 minutes, chewing at a natural rhythm and swallowing the saliva produced, the intensity and final discomfort were measured using the same scales.
88895924|NCT03519685|Experimental|Contraceptive Training and Education|Colleges assigned to this arm receive a one-day UCSF Continuing Medical Education (CME # MMC18087) accredited training on contraceptives and technical assistance. The training is for staff at the student health center and local health centers where they refer for contraceptive services. Students attending colleges assigned to this arm receive education about contraceptive methods and how to access services.
88895925|NCT03519685|Placebo Comparator|Nutrition Education|Students attending colleges assigned to this arm receive nutrition education about the impacts of sugar on health.
88895926|NCT03517579|Experimental|Pilot Project|It is a Pilot study of 10 persons
88895927|NCT03510104|Experimental|MRX-2843|MRX-2843: Dose Escalation Successive dose escalation cohorts to determine MTD
88895928|NCT03469674|Experimental|Molecular profile based treatment|Determination of the integrated clinicopathological and molecular profile to determine adjuvant treatment: observation for favourable profile; vaginal brachytherapy for intermediate profile; external beam radiotherapy for unfavourable profile
88895929|NCT03469674|Active Comparator|Vaginal brachytherapy|Adjuvant vaginal brachytherapy (standard treatment)
88895930|NCT03464760|Placebo Comparator|Placebo|
88895931|NCT03464760|Experimental|Spirulina-Silicon supplementation|
88895932|NCT03455608|Active Comparator|RE-ACTIVE|Reactive intervention started promptly if/when dysphagia is identified (RE-ACTIVE)
89193672|NCT04331418|No Intervention|control group|"On arrival to operating room, Noninvasive monitors, such as electrocardiography, noninvasive blood pressure (NIBP), oxygen saturation (SpO2), will be attached and baseline parameters such as heart rate, mean arterial pressure, and peripheral oxygen saturation will be recorded .~General anesthesia will be induced with O2/sevo (FiO2 = 1 /sevoflurane 8% MAC), cis-atracurium 0.1 mg/kg iv, +/- fentanyl 1 mcg/kg iv. Trachea will be intubated with an appropriate sized, endotracheal tube and maintenance of anesthesia by O2/Air (FiO2 = 0.4), sevoflurane 2% MAC.~Dexamethasone 0.15 mg/kg iv will be given as PONV prophylaxis. Increments of fentanyl 0.5 mcg/kg iv and cis-atracurium 0.03 mg/kg iv will be given according to hemodynamics and capnography."
89193673|NCT04331418|Experimental|caudal group|After negative aspiration of blood or cerebrospinal fluid, 2 mg/ kg of bupivacaine at concentration of 0.5% (volume 0.5ml/kg) was given as per the group assigned, then the site of injection was dressed, and the patient was turned supine.
89193674|NCT04331418|Experimental|dexmetomidine group|Children in this group will be received (1 mcg/kg IV over 10 minutes followed by 0.5 mcg/kg/hr) with a suggested maximum dose of 2 mcg/kg.of dexmedetomidine is available in a 100 mcg/mL concentration in a 2 mL preservative-free vial. It may be prepared as a 2 to 4 mcg/mL solution using normal saline
89193675|NCT04317859|Experimental|Behavioural Activation (Intervention)|Originally a component of Cognitive Therapy, Behavioural Activation is the use of strategies such as activity scheduling, master/pleasure ratings, and graded task assignments to modify one's perception of specific situations. Behavioural Activation involves the use of activities to improve life situations and mood symptoms.
89193676|NCT04317859|No Intervention|Waitlist (Control)|The Control group (waitlist) will receive treatment as usual while waiting to receive BA intervention (at the end of intervention group therapy time, which will consist of 18 sessions over an 14 week period). This group will be assessed by clinical staff that offer treatment as usual for mood symptoms and quality of life measures during the waiting time.
89193677|NCT04307511|Experimental|low dose DAPT therapy|treated with ticagrelor 60mg plus aspirin 100 mg for 11 months after one month standard DAPT(ticagrelor 90mg plus aspirin 100 mg )treatment
89193678|NCT04307511|Active Comparator|standard dose DAPT therapy|treated with ticagrelor 90mg and aspirin 100mg after PCI for 12 months as the standard group
89193679|NCT04304183||slow transit constipation|patients diagnosed with slow transit constipation had undergone surgery.
89193680|NCT04301011|Experimental|Arm A: TBio-6517 alone|Dose escalation of TBio-6517 alone administered by direct injection into tumor(s) x 4. Booster injections of TBio-6517 are permitted for up to 24 months.
89193681|NCT04301011|Experimental|Arm B: TBio-6517 and Pembrolizumab|Dose escalation of TBio-6517 administered in combination with pembrolizumab. TBio-6517 will be directly injected into tumor(s) x 4. Booster injections of TBio-6517 are permitted for up to 24 months. Pembrolizumab will be administered beginning at Day 9 via intravenous (IV) infusion every 3 weeks for up to 24 months.
89193682|NCT04301011|Experimental|TBio-6517 and Pembrolizumab in MSS-CRC|Doses of TBio-6517 will be administered by direct injection into tumor(s) x 4 in combination with pembrolizumab beginning at Day 9 given every 3 weeks for up to 24 months in patients with microsatellite stable colorectal carcinoma (MSS-CRC). Booster injections of TBio-6517 are permitted for up to 24 months.
88895933|NCT03455608|Active Comparator|PRO-ACTIVE EAT|Early low intensity proactive intervention started before RT commences
88895934|NCT03455608|Active Comparator|PRO-ACTIVE EAT + EXERCISE|Early high intensity proactive intervention started before RT commences
88895935|NCT03435250|Experimental|AG-270|AG-270 will be administered on Days 1 to 28 of each 28-day cycle. Treatment will continue until disease progression or unacceptable toxicity.
88895936|NCT03435250|Experimental|AG-270/docetaxel|AG-270 will be administered daily, starting 1 week prior to docetaxel infusion. Starting on Cycle 1 Day 1, docetaxel (by intravenous infusion [IV]) will be administered once during each 21-day cycle. Treatment with AG-270 and docetaxel will continue until disease progression or unacceptable toxicity.
88895937|NCT03435250|Experimental|AG-270/nab-paclitaxel/gemcitabine|AG-270 will be administered daily, starting 1 week prior to nab-paclitaxel and gemcitabine infusion. Starting on Cycle 1 Day 1, nab-paclitaxel and gemcitabine IV will be administered on Days 1,8, and 15 during each 28-day cycle. Treatment with AG-270, nab-paclitaxel, and gemcitabine will continue until disease progression or unacceptable toxicity.
89193683|NCT04301011|Experimental|TBio-6517 and Pembrolizumab in cutaneous melanoma|Doses of TBio-6517 will be administered by direct injection into tumor(s) x 4 in combination with pembrolizumab beginning at Day 9 given every 3 weeks for up to 24 months in patients with malignant melanoma of the skin. Booster injections of TBio-6517 are permitted for up to 24 months.
89193684|NCT04301011|Experimental|TBio-6517 and Pembrolizumab in cutaneous squamous cell carcinoma of the skin|Doses of TBio-6517 will be administered by direct injection into tumor(s) x 4 in combination with pembrolizumab beginning at Day 8 given every 3 weeks for up to 24 months in patients with cSCC. Booster injections of TBio-6517 are permitted for up to 24 months.
89193685|NCT04301011|Experimental|TBio-6517 and Pembrolizumab in HPV positive head and neck cancer|Doses of TBio-6517 will be administered by direct injection into tumor(s) x 4 in combination with pembrolizumab beginning at Day 9 given every 3 weeks for up to 24 months in patients with HPV associated oropharyngeal cancer. Booster injections of TBio-6517 are permitted for up to 24 months.
89193686|NCT04301011|Experimental|Arm C: TBio-6517 intravenous|Dose escalation of TBio-6517 alone administered by intravenous infusion x 4. Booster infusions of TBio-6517 are permitted for up to 24 months.
89193687|NCT04301011|Experimental|Arm D: TBio-6517 intravenous and Pembrolizumab|Dose escalation of TBio-6517 administered in combination with pembrolizumab. Dose escalation of TBio-6517 alone administered by intravenous infusion x 4. Booster infusions of TBio-6517 are permitted for up to 24 months. Pembrolizumab will be administered beginning at Day 9 via intravenous (IV) infusion every 3 weeks for up to 24 months.
89193688|NCT04227483|Active Comparator|Prednisolone|Prednisolone 0.5 mg/kg/day for 4 weeks; 0.25 mg/kg/day for 4 weeks; 0.125 mg/kg/day for 4 weeks. Then taper by 5 mg every 2 weeks and discontinue. All doses will be rounded off to the nearest 5 mg (maximum duration of therapy, 4 months)
89193689|NCT04227483|Experimental|Deflazacort|Deflazacort 0.75 mg/kg/day for 4 weeks; 0.375 mg/kg/day for 4 weeks; 0.1875 mg/kg/day for 4 weeks. Then taper by 6 mg every 2 weeks and discontinue. All doses will be rounded off to the nearest 6 mg (maximum duration of therapy, 4 months)
89193690|NCT04219254|Experimental|BI-1206 + Pembrolizumab 25mg/mL (MK-3475)|BI-1206 administrated either IV or SC + Pembrolizumab 200mg administered IV every third week as a fixed dose will be used.
89193693|NCT04195633|Experimental|Arm A (high dose treosulfan)|Patients receive high dose treosulfan IV over 120 minutes on days -6 to -4 and fludarabine IV over 60 minutes on days -6 to -2. Patients then undergo total-body irradiation on day -1 and allogeneic hematopoietic stem cell transplantation on day 0. Patients then receive cyclophosphamide IV over 1-2 hours on days 3-4. Beginning on day 5, patients receive cyclosporine IV BID or TID over 1-2 hours or PO (after 3 months, in the absence of GVHD, cyclosporine tapering will start by 5-10% per week, until drug withdrawal at 6 months post-transplant). Beginning on day 5, patients also receive mycophenolate sodium PO TID or mycophenolate mofetil IV or PO TID until day 35 (may be continued if active GVHD is present). Beginning on day 5, patients also receive filgrastim until the absolute neutrophil count is > 1,000/uL for 3 consecutive days.
89193694|NCT04195633|Experimental|Arm B (low dose treosulfan)|Patients receive low dose treosulfan IV over 120 minutes on days -6 to -4 and fludarabine IV over 60 minutes on days -6 to -2. Patients then undergo total-body irradiation and allogeneic hematopoietic stem cell transplantation, and receive cyclophosphamide, cyclosporine, mycophenolate sodium or mycophenolate mofetil, and filgrastim as in Arm A.
89193695|NCT04190823|Experimental|RC98|
89193696|NCT04189783|Active Comparator|Arm I (liposomal bupivacaine)|Patients receive standard of care liposomal bupivacaine injection before and during surgery and standard of care non-opioids and opioids at days 0-3 after surgery in the absence of unacceptable toxicity.
89418091|NCT05708937|Experimental|Experimental group|Experimental group participants used the mindfulness mobile application. Then, the psychosocial status of the participants was measured with scales.
89418092|NCT05708937|No Intervention|Control group|The control group participants did not receive any intervention. Classical care was applied. Then, the psychosocial status of the participants was measured with scales.
89418093|NCT03698383|Experimental|Herzuma plus Gedatolisib|
89418094|NCT04760782|Experimental|Treatment group|Daily self-administered injection of 80 mcg abaloparatide (8 weeks) + hard collar immobilization (12 weeks)
89418095|NCT04760782|Active Comparator|Historical control group|Patients who received only 12 weeks of hard collar immobilization
89006374|NCT00219362|Placebo Comparator|Placebo - 3 injections|Arm C2: injection of placebo for a total of 3 injections (W4, W8, W20)
89006375|NCT04626895|Other|Scalp Cooling|Patients who be will using the scalp cooling device during chemotherapy will be enrolled in tis arm
89006376|NCT04626895|No Intervention|Non Scalp-Cooling|Patients who do not use scalp cooling device during chemotherapy will be enrolled in this arm.
89006377|NCT04626817|Active Comparator|Isotretinoin receiving group|Isotretinoin receiving group for acne vulgaris
89006378|NCT04626817|Placebo Comparator|Local treatment receiving group|Local treatment receiving group for acne vulgaris
89006379|NCT04626739|Experimental|volunteers|The patient voluntarily signs the informed consent, and the patient meets the entry criteria to diagnose patients with Relapsed Refractory (R/R) non-Hodgkin lymphoma
89006380|NCT00219401|Experimental|Neonatal 7vPCV|Receive study vaccine (Prevnar) at birth, 1 and 2 months
89006381|NCT00219401|Experimental|Infant 7vPCV|Receive the study vaccine (Prevnar) at 1, 2 and 3 months
89006382|NCT00219401|Placebo Comparator|Control|Do not receive study vaccine (Prevnar)
89006383|NCT04627129|Experimental|SHR2554+Itraconazole|SHR2554 50 mg QD on Day 1 and Day 8, Itraconazole 200 mg once daily (QD) from Study Day 4 - 12
89006384|NCT04626856|Experimental|Low dosage in adults|Low dosage Inactivated Rotavirus vaccine (Vero cell) in adults aged 18-49 years old on day 0, 28
89006385|NCT04626856|Experimental|Medium dosage in adults|Medium dosage Inactivated Rotavirus vaccine (Vero cell) in adults aged 18-49 years old on day 0, 28
89193697|NCT04189783|Experimental|Arm II (liposomal bupivacaine)|Patients receive standard of care liposomal bupivacaine injection before and during surgery and standard of care non-opioids and opioids at days 0-3 after surgery in the absence of unacceptable toxicity. Patients then receive a second liposomal bupivacaine injection on day 4 after surgery.
89418096|NCT03698305|Experimental|ASP5354 Dose Escalation (5 Dose Levels)|Healthy male and female subjects will be assigned to Cohorts 1-5. In each cohort, 4 subjects will be randomized to receive escalated doses of ASP5354. Each subject will receive a single intravenous bolus injection under fasting conditions.
89006386|NCT04626856|Experimental|High dosage in adults|High dosage Inactivated Rotavirus vaccine (Vero cell) in adults aged 18-49 years old on day 0, 28
89006387|NCT04626856|Experimental|Low dosage in adolescents|Low dosage Inactivated Rotavirus vaccine (Vero cell) in adolescents aged 6-17 years old on day 0, 28
89006388|NCT04626856|Experimental|Medium dosage in adolescents|Medium dosage Inactivated Rotavirus vaccine (Vero cell) in adolescents aged 6-17 years old on day 0, 28
89006389|NCT04626856|Experimental|High dosage in adolescents|High dosage Inactivated Rotavirus vaccine (Vero cell) in adolescents aged 6-17 years old on day 0, 28
89006390|NCT04626856|Experimental|Low dosage in infants (7-71 months old)|Low dosage Inactivated Rotavirus vaccine (Vero cell) in infants aged 7-71 months old on day 0, 28
89006391|NCT04626856|Experimental|Medium dosage in infants (7-71 months old)|Medium dosage Inactivated Rotavirus vaccine (Vero cell) in infants aged 7-71 months old on day 0, 28
89006392|NCT04626856|Experimental|High dosage in infants (7-71 months old)|High dosage Inactivated Rotavirus vaccine (Vero cell) in infants aged 7-71 months old on day 0, 28
89006393|NCT04626856|Experimental|Low dosage in infants (2-6 months old, two-dose)|Low dosage Inactivated Rotavirus vaccine (Vero cell) in infants aged 2-6 months old on day 0, 28
89006394|NCT04626856|Experimental|Medium dosage in infants (2-6 months old, two-dose)|Medium dosage Inactivated Rotavirus vaccine (Vero cell) in infants aged 2-6 months old on day 0, 28
89006395|NCT04626856|Experimental|High dosage in infants (2-6 months old, two-dose)|High dosage Inactivated Rotavirus vaccine (Vero cell) in infants aged 2-6 months old on day 0, 28
89418097|NCT03698305|Placebo Comparator|Placebo Dose Escalation (5 Dose Levels)|Healthy male and female subjects will be assigned to Cohorts 1-5. In each cohort, two subjects will be randomized to receive placebo.
89006396|NCT04626856|Experimental|Low dosage in infants (2-6 months old, three-dose)|Low dosage Inactivated Rotavirus vaccine (Vero cell) in infants aged 2-6 months old on day 0, 28, 56
89006397|NCT04626856|Experimental|Medium dosage in infants (2-6 months old, three-dose)|Medium dosage Inactivated Rotavirus vaccine (Vero cell) in infants aged 2-6 months old on day 0, 28, 56
89193698|NCT04188600|Experimental|treatment group|"The treatment group will be treated with Libicare for three month (2 tablets/day). After the first three months (12 weeks) of treatment, the treatment group will be classified into two populations:~Responding patients: this population, defined by FSFI score > 26.55, will be randomized (1:1) into 2 groups: one of them will take Libicare® for further 12 weeks (total period on treatment: 24 weeks) and the other group will remain under observation with no treatment for further 12 weeks (total period on treatment: 12 weeks).~Non-responding patients: this population, defined by FSFI score ≤ 26.55, will intake Libicare® for further 12 weeks (total period on treatment: 24 weeks)."
89193699|NCT04188600|Active Comparator|active control group|The active control group will be treated with a Selenium and vitamins B complex for three month (2tablets/day). After the first three months (12 weeks) of treatment, patients of the active-control group will cross over the treatment to Libicare® for three months (12 weeks)
89193700|NCT04188327|Sham Comparator|Control group(Group I)|Patients will receive sham stellate ganglion block weekly for three times
89006398|NCT04626856|Experimental|High dosage in infants (2-6 months old, three-dose)|High dosage Inactivated Rotavirus vaccine (Vero cell) in infants aged 2-6 months old on day 0, 28, 56
89006399|NCT04626856|Placebo Comparator|Placebo on day 0, 28|Two doses of placebo at the vaccination schedule of day 0,28
89006400|NCT04626856|Placebo Comparator|Placebo on day 0, 28, 56|Three doses of placebo at the vaccination schedule of day 0, 28,56
89193701|NCT04188327|Experimental|Stellate Ganglion block group (Group II)|Patients will receive stellate ganglion block weekly for three times with injection of 6ml bupivicain 0.25%+ 1 ml methylpredinosolone 40mg
89193702|NCT04187352|Experimental|CS1001+ Fluorouracil+Cisplatin|
89193703|NCT04187352|Active Comparator|Placebo+ Fluorouracil+Cisplatin|
89193704|NCT04186078||obstructive sleep apnea (OSA)|5 or more predominantly obstructive respiratory events [obstructive and mixed apneas, hypopneas or respiratory effort-related arousals (RERAs)] per hour of sleep during a PSG or per hour of monitoring (respiratory polygraphy)
89193705|NCT04186078||central sleep apnea (CSA)|"PSG shows all of the following:~5 or more central apneas and/or central hypopneas per hour of sleep.~The number of central and/or central hypopneas is > 50% of the total number of apneas and hypopneas."
89193706|NCT04186078||control|apnea-hypopnea index < 5 per hour of sleep during a PSG or per hour of monitoring (respiratory polygraphy)
89193707|NCT04185701|Experimental|Eye examination by expert and SiVIEW software|Eye examination by an expert and by a technician with the SiVIEW system.
89193708|NCT04164940||Age 21-30|Patients aged 21-30 when admitted to hospital and receiving brief alcohol intervention
89193709|NCT04164940||Age 31-40|Patients aged 31-40 when admitted to hospital and receiving brief alcohol intervention
89193710|NCT04164940||Age 41-50|Patients aged 41-50 when admitted to hospital and receiving brief alcohol intervention
89193711|NCT04164940||Age 51-60|Patients aged 51-60 when admitted to hospital and receiving brief alcohol intervention
89536785|NCT00704405|Experimental|24-wk Vaniprevir 600 mg + 24-wk PBO + Peg-IFN/RBV|Vaniprevir 600 mg (total daily dose) and RBV (1000 mg or 1200 mg total daily dose based on body weight) b.i.d. and Peg-IFN 180 mcg injection once weekly for 24 weeks, followed by PBO and RBV (1000 mg or 1200 mg total daily dose based on body weight) b.i.d. and Peg-IFN 180 mcg injection once weekly for an additional 24 weeks.
89006401|NCT00246636|Active Comparator|OM5/LOV111859 (double-blind study) - Antara|Antara (fenofibrate) + placebo
89193712|NCT04164940||Age 61-70|Patients aged 61-70 when admitted to hospital and receiving brief alcohol intervention
89193713|NCT04164940||Age 71-80|Patients aged 71-80 when admitted to hospital and receiving brief alcohol intervention
89193714|NCT04164940||Age 81 and older|Patients aged 81 and older when admitted to hospital and receiving brief alcohol intervention
89193715|NCT04135300|Experimental|Arm of BBM-H901|Subjects will be dosed with single dose of BBM-H901 at 5x10·12 vg/kg via intravenous infusion.
89193716|NCT04122469|Experimental|Oligo-Progression; GU|Receiving SBRT.
89193717|NCT04122469|Experimental|Oligo-metastatic Breast Cancer|Receiving SBRT.
89193718|NCT04120636|Experimental|Phase I open label study|"Drug: Episcleral Celecoxib~Other Names:~Sequestered, Transscleral, Controlled-Release Celecoxib~Sustained Release Transscleral Celecoxib"
89193719|NCT04120311|Experimental|Phase I open label study|"Drug: Episcleral Dexamethasone Sequestered Transscleral, Controlled-Release Dexamethasone~Other Names:~• Sustained Release Transscleral Dexamethasone"
89193720|NCT04116528|Other|Ketamine|Every eligible participant will receive 0.5mg/kg IV given over 40 minutes
89193721|NCT04116528|Active Comparator|Buprenorphine or Placebo|Buprenorphine or placebo once daily for 4 weeks
89193722|NCT04107883|Experimental|control group|perform artificial colloidal solution transfusion during anhapetic phase.
89193723|NCT04107883|Experimental|anhapetic group|Perform plasma transfusion during anhapetic phase.
89193724|NCT04103476|Experimental|BZA/CE|Oral bazedoxifene 20 mg / conjugated estrogens 0.45 mg
89193725|NCT04103476|Placebo Comparator|Placebo|Oral matching placebo
89193726|NCT04102007|Other|Risankizumab|Participants receive Risankizumab following suboptimal response to secukinumab or ixekizumab
89193727|NCT04100213|Experimental|TSST|
89193728|NCT04089215|Experimental|JWCAR029 treatment|JWCAR029 be administrated in two dose level
89193729|NCT04072978||Intraocular lens implantation: AC IOL|"Patients who are scheduled to undergo AC IOL (anterior chamber intraocular lens) implantation for any of the following indications:~primary or secondary aphakia~primary or secondary lens subluxation or dislocation"
89193730|NCT04072978||Intraocular lens implantation: SF IOL|"Patients who are scheduled to undergo SF IOL (scleral fixated intraocular lens) implantation for any of the following indications:~primary or secondary aphakia~primary or secondary lens subluxation or dislocation"
89193731|NCT04054401|Experimental|DRG Neurostimulation with Spinal Fusion|
89193732|NCT04052555|Experimental|Treatment (berzosertib, radiation therapy)|Patients receive berzosertib IV over 60 minutes BIW for 5 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo RT 5 days a week for 5-6 weeks depending on the type of surgery undergone. Patients also undergo a collection of blood on study.
89006402|NCT00246636|Experimental|OM5X/LOV111860 (extension study) - Open-Label Antara + Lovaza|Open-label Antara (fenofibrate) + Lovaza (omega-3-acid ethyl esters) [formerly known as Omacor]
89418098|NCT03566901|Experimental|Robot-Assisted Stair Climbing Training|Each session will consist of the G-EO System training and stretching exercises. Total net treatment time/session: 50 minutes. Physiotherapists will alter constraints to grade tasks according to patient ability. The training complexity will be increased, as the patient will improve in performance (i.e. increasing gait speed, reducing body weight support, increasing the number of repetition). Heart rate during training sessions will be monitored using a Polar V800. Heart rate will not exceed the threshold of 120 bpm.
89418099|NCT03566901|Active Comparator|Conventional Physiotherapy|50 min of overground walking training and stair climbing up/down and lower limb mobilization and stretching exercise.
89418100|NCT04743232|No Intervention|Standard practice|Standard practice concerning advanced care directives; care as usual
89418101|NCT04743232|Experimental|Decision aid implementation|Stepped-wedge implementation of the intervention
89418102|NCT03704389|Experimental|Clinical decision support intervention|Participating clinicians will receive any of three clinical decision support nudges within the electronic health record when all eligibility criteria are met within a patient's chart.
89418103|NCT03064282|Placebo Comparator|Placebo|Drug free base as placebo
89418104|NCT03064282|Experimental|group two- papaverine arm|papaverine in a suitable base
89418105|NCT02628418|Experimental|Gloreha Group|"The patients in the Gloreha Group underwent to following interventions:~General Rehabilitation~Specific hand rehabilitation by Gloreha device"
89418106|NCT02628418|Other|Control Group|"The patients in the Control Group underwent to following interventions:~General Rehabilitation~Specific hand rehabilitation performed by physiotherapist"
89418107|NCT03027609|Experimental|AR-105|One intravenous infusion of AR-105 20mg/'kg
89418108|NCT03027609|Placebo Comparator|Control|Matching placebo
89418109|NCT03704311|Experimental|Single|Evaluation of mitochondrial function after muscle biopsy and follow-up for surgical complications.
89418110|NCT03063112|Active Comparator|Group 1( radiofrequency group )|Bilateral thoracic splanchnic nerves block will be performed by radiofrequency thermocoagulation at two level of vertebra T10 and T11 by using radiofrequency generator device and lidocaine 2% before thermal lesion
89418111|NCT03063112|Placebo Comparator|Group 2 ( alcohol group )|Bilateral thoracic splanchnic nerves block will be performed by ethyl alcohol at one level of vertebraT11 by using of C arm fluoroscopic device.
89418112|NCT03701503|Experimental|Obese|"Women age 20-40, with BMI ≥ 25-35 kg/m2 Given a balanced breakfast (Protein 12,4%, carbohydrate 68,2%, fat 22,6%) with calories according to their energy requirement,which is calculated by adding basal metabolic rate (BMR) with additional energy from physical activity.~Participants' blood was taken before intervention, and 15, 60, 120, and 180 minutes after intervention, then examined in laboratory to measure every outcome. After 4 hours, participants were given ad libitum meal. After the participants done eating, the calorie in meal taken by participants was measured."
89536786|NCT00704405|Experimental|48-wk Vaniprevir 300 mg + Peg-IFN/RBV|Vaniprevir 300 mg (total daily dose, taken once daily [q.d.]) and RBV (1000 mg or 1200 mg total daily dose based on body weight) b.i.d. and Peg-IFN 180 mcg injection once weekly for 48 weeks.
89006403|NCT00246636|Experimental|OM5/LOV111859 (double-blind study) - Antara + Lovaza|Antara (fenofibrate) + Lovaza (omega-3-acid ethyl esters) [formerly known as Omacor]
89006404|NCT00219440|Experimental|A|ACTOS plus standard diet
89193733|NCT04045301|Experimental|Omalizumab 16 mg/kg|"Participants will receive omalizumab 16 mg/kg monthly doses for 12 weeks, followed by omalizumab 8 mg/kg monthly for 4 weeks and then omalizumab 4 mg/kg monthly for 4 weeks.~Multi-food oral immunotherapy following a symptom-driven schedule will begin 8 weeks after starting study drug."
89193734|NCT04045301|Experimental|Omalizumab 8 mg/kg|"Participants will receive omalizumab 8 mg/kg monthly doses for 12 weeks, followed by omalizumab 4 mg/kg monthly for 4 weeks and then omalizumab 2 mg/kg monthly for 4 weeks.~Multi-food oral immunotherapy following a symptom-driven schedule will begin 8 weeks after starting study drug."
89193735|NCT04045301|Placebo Comparator|Placebo|"Participants will receive placebo doses for 20 weeks. The doses will be injected every 2 or 4 weeks depending on the weight of the participant.~Multi-food oral immunotherapy following a symptom-driven schedule will begin 8 weeks after starting study drug."
89193736|NCT04044404||A on C group|Acute on Chronic Kidney Disease patients
89193737|NCT04044404||functional delayed graft function group|patients with functional delayed graft function(fDGF) after kidney transplantation
89193738|NCT04044404||Normal|without functional kidney injury
89193739|NCT04017650|Experimental|Treatment (encorafenib, cetuximab, nivolumab)|Patients receive encorafenib PO QD on days 1-28, cetuximab IV over 1 hour on days 1 and 15, and nivolumab IV over 30 minutes on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89193740|NCT04005430|Experimental|Phase 1|Phase I open label study
89193741|NCT04002830|Experimental|Taliglucerase Alpha|Intravenous infusion of Taligluucerase alfa (Elelyso) in treatment-naive patients with type 3 Gaucher disease
89193742|NCT03978507|Experimental|DeFOG group|feedback number of steps + cueing
89193743|NCT03978507|Active Comparator|Control group|feedback number of steps
89193744|NCT03967379|Experimental|Mobile app plus enhanced standard care|"Patients will received enhanced standard care in addition to access to the sexual health mobile app.~The app will also prompt patients to engage their partners with specific exercises."
89193745|NCT03967379|Other|Enhanced Standard Care|"Patients will receive Enhanced Standard Care~Patients will meet with a transplant clinician for a brief medical examination to assess the need for medications for erectile dysfunction, vaginal atrophy, or vulvovaginal GVHD~Patients will not have access to the sexual health mobile app"
89193746|NCT03966183||UVFP patients post thyroplasty|Patients in this group are adults who have undergone type I medialization thyroplasty (with Montgomery implant, silicone implant, follow-up of more than 3 months) as a definitive procedure following unilateral vocal fold paralysis.
89193747|NCT03966183||Control participants|The people in this group are control subjects of the same age, sex and manual laterality as the patients.
89193748|NCT03958721|Experimental|Concurrent Adjuvant Capecitabine and Radiotherapy|
89193749|NCT03938649|Experimental|Conventional IMRT|"RapidArc IMRT to prostate and pelvic nodes. 76Gy to prostate, 70Gy to proximal 2/3 of seminal vesicles, and 50Gy to pelvic nodes (up to bifurcation of common iliac nodes).~38 fractions of daily treatment, Monday to Friday"
89193750|NCT03938649|Experimental|SBRT|"RapidArc IMRT to prostate and pelvic nodes. 40Gy to prostate, 36.25Gy to proximal 2/3 of seminal vesicles, and 25Gy to pelvic nodes (up to bifurcation of common iliac nodes)~5 fractions of weekly treatment. Once fraction per week."
89193751|NCT03937700|Experimental|CPWalker Robotic-Assisted Gait Training|Each subject will participate in 16-24 gait training sessions in the CPWalker over the course of 8 weeks with each session lasting up to 2 hours
89193752|NCT03937349||sPTx group|Patients underwent subtotal parathyroidectomy due to severe secondary hyperparathyroidism
89193753|NCT03937349||TPTx+AT group|Patients underwent total parathyroidectomy with immediate autotransplantation of parathyroid tissue due to severe secondary hyperparathyroidism
89536787|NCT00704405|Experimental|48-wk Vaniprevir 600 mg + Peg-IFN/RBV|Vaniprevir 600 mg and RBV (1000 mg or 1200 mg based on body weight) b.i.d. and Peg-IFN 180 mcg injection once weekly for 48 weeks.
89006405|NCT00219440|Experimental|B|Actos plus structured diet
89193754|NCT03937349||Control group|Patients with severe SHPT on conservative treatment (calcimimetics, active vitamin D analogues, phosphate-binders) who are likely to undergo surgery in a period of 12 months
88895938|NCT03425669|Active Comparator|Placebo medication and sham stimulation|Patients will be randomly chosen to the group who will get a combination of placebo and sham stimulation.
88895939|NCT03425669|Active Comparator|Active medication|Patients are randomly chosen to the group who will get active medication without stimulation.
88895940|NCT03425669|Sham Comparator|Active stimulation|Patients are randomly chosen to the group who will get acitive stimulation without taking medicine.
88895941|NCT03425669|Active Comparator|Controls with sham stimulation|Controls without ADHD are randomly chosen to the group who will get sham stimulation.
88895942|NCT03425669|Sham Comparator|Controls with active stimulation|Controls without ADHD are randomly chosen to the group who will get active stimulation.
88895943|NCT03420014|Active Comparator|Arm 1: Doxorubicin|Patients will receive a fixed dose doxorubicin, administered as a 15 ± 5 minutes i.v. infusion.
88895944|NCT03420014|Experimental|Arm 2: L19TNF plus doxorubicin|"Patients will receive a fixed dose of L19TNF in combination with a fixed dose doxorubicin.~Doxorubicin will be administered as a 15 ± 5 minutes i.v. infusion on day 1 of each 21-day cycle followed by at least 30 minutes pause before starting infusion of L19TNF."
88895945|NCT03395405|Experimental|Nitazoxanide Arm|500 mg (one tablet) nitazoxanide by mouth twice daily with food for 56 consecutive doses. N=80
88895946|NCT03395405|Placebo Comparator|Placebo Arm|Placebo (one tablet) by mouth twice daily with food for 56 consecutive doses. N=80
88895947|NCT03393520|Placebo Comparator|Placebo|Participants will be assigned to treatment with placebo capsules administered twice a day over a 12-week period.
88895948|NCT03393520|Experimental|AVP-786; Dose 1|Participants will receive AVP-786 (Dose 1) capsules administered twice a day over a 12-week period.
88895949|NCT03393520|Experimental|AVP-786; Dose 2|Participants will receive AVP-786 (Dose 2) capsules administered twice a day over a 12-week period.
88895950|NCT03385707||CGM and Microbiota|Participants will wear a Dexcom continuous glucose monitor (CGM) and activity monitor for two weeks. They will not be aware of sensor glucose values. A stool sample will be collected. The investigators will evaluate relationships between patterns of postprandial glycemia, recorded by CGM, food intake, and microbiome composition.
88895951|NCT03385005|Active Comparator|Healthy Volunteers|This arm consists of healthy volunteers receiving electrical stimulation of the muscles within the forearm via an investigational (not FDA approved) neuromuscular stimulator.
89193755|NCT03930056|Experimental|C-Brace II Group|Subjects will be assigned a C-Brace II orthotic for use.
89193756|NCT03930056|Active Comparator|Traditional Group|Subjects will continue with their own KAFO (non C-Brace II) use.
88895952|NCT03385005|Active Comparator|Spinal Cord Injury Participants|This arm consists of spinal cord injury participants receiving electrical stimulation of the muscles within the forearm via an investigational (not FDA approved) neuromuscular stimulator.
89193757|NCT03906877|Experimental|Injection laryngoplasty group (IL)|The patients in the first group will receive an IL of hyaluronic acid in the paralyzed vocal fold within a maximum of three months after the onset of symptoms. The Ear-Noise-Throat (ENT) physician will perform the injection in office, under topical anaesthesia.
89536788|NCT00704405|Placebo Comparator|48-wk PBO + Peg-IFN/RBV|PBO and RBV (1000 mg or 1200 mg based on body weight) b.i.d. and Peg-IFN 180 mcg injection once weekly for 48 weeks.
89006406|NCT00219440|Experimental|C|Metformin plus standard diet
88895953|NCT03381248|Experimental|Cooled Radiofrequency|Cooled radiofrequency energy will be delivered to study subjects' knees to ablate culprit sensory nerves and reduce knee pain. Subjects in this group will be followed for 12 months post-procedure.
88895954|NCT03381248|Active Comparator|Hyaluronic Acid, then Cooled Radiofrequency|Hyaluronic acid injections will be administered to study subjects' knees to reduce knee pain. Subjects in this group will have the option to crossover to receive cooled radiofrequency after 6-months. Crossover subjects will be followed for an additional 6 months post-procedure. Non-crossover subjects will continue to be followed until the 12-month timepoint.
88895955|NCT03368625|Other|Arm 1|Neoadjuvant SRS
88895956|NCT03359109||Stainless Steel Devices|10 patients with stainless steel devices implanted
88895957|NCT03359109||Titanium or Titanium-alloy Based Devices|30 patients with titanium or titanium-alloy implanted devices
88895958|NCT03359109||De Novo Titanium Implant|10 patients undergoing de novo titanium implant placement who have had no previous orthopedic procedures
89006407|NCT04626700|Experimental|iNAP|
89006408|NCT04626700|Active Comparator|CPAP|
89193758|NCT03906877|Experimental|Voice therapy group (VT)|Patients from the second group will be involved in 15 sessions of thirty minutes of voice therapy, twice a week, and will have to do home practice. Patients will have to record these training sessions. Initiation of this intervention should also take place within the first three months after the onset of symptoms. They will also receive an injection of physiological saline under the skin of the neck (sham of injection).
89193759|NCT03906877|Sham Comparator|Sham group|The patients of the third group will be treated following the traditional wait-and-see policy. They will receive an injection of physiological saline under the skin of the neck and will be seen during 15 sessions of 30 minutes, twice a week. Therefore, this will be a sham procedure for both IL and VT.
89193760|NCT03905707|Experimental|Glepaglutide SC injections twice weekly|"Glucagon-Like Peptide-2 (GLP-2) analog, 10 mg subcutaneous injection twice weekly.~In this long term safety study, there is no placebo arm."
89193761|NCT03905707|Experimental|Glepaglutide SC injections once weekly and placebo once weekly|"Glucagon-Like Peptide-2 (GLP-2) analog, 10 mg subcutaneous injection once weekly and placebo once weekly.~In this long term safety study, there is no placebo arm."
89193762|NCT03904043|Experimental|Radiation + FOLFOX|"Pelvic radiotherapy 5GY x 5 fractions once daily~Radiation to extra-mesorectal node 7 Gy x 5 fractions once daily~FOLFOX should begin 2-4 weeks after completion of radiotherapy and will consist of FOLFOX x 8 cycles (16 weeks).~Oxaliplatin day 1 every 14 days~Leucovorin day 1 every 14 days. Levoleucovorin may be substituted if leucovorin is not available.~5-FU bolus day 1 every 14 days~5-FU infusion day 1 every 14 days over 46 hours~Alternatively CAPOX (capecitabine and oxaliplatin) may be given for 5 cycles over 15 weeks.~An optional simultaneous integrated boost of 30 Gy in 5 fractions to the primary tumor is permitted"
89193763|NCT03901001|Active Comparator|oseltamivir and adjunctive sirolimus|Sirolimus 1 mg daily and oseltamivir 75 mg bid for 5 days, both given orally. Extension of dosing to 10 days for oseltamivir and the study drug is allowed if there is slow recovery, lack of improvement, or deterioration.
89193764|NCT03901001|Placebo Comparator|oseltamivir alone|oral oseltamivir 75 mg bid alone for 5 days. Extension of dosing to 10 days for oseltamivir and the study drug is allowed if there is slow recovery, lack of improvement, or deterioration.
89193765|NCT03900988|Active Comparator|intravenous N-acetylcysteine (NAC) and oseltamivir|
89193766|NCT03900988|Placebo Comparator|intravenous 5% dextrose and oseltamivir|
89193767|NCT03900377|Experimental|Lg-B-NHL or MCL|For previously untreated patients with Lg-B-NHL or MCL, rituximab will be intravenously administered at 375 mg/m^2 on Day 0 (the day before Day 1 only in Cycle 1), and SyB L-0501RI will be intravenously administered at 90 mg/m^2/day on Day 1 and Day 2 of each 28-day cycle with up to 6 cycles.
89193768|NCT03900377|Experimental|DLBCL|For patients with recurrent or refractory DLBCL, rituximab will be intravenously administered at 375 mg/m^2 on Day 1, and SyB L-0501RI will be intravenously administered at 120 mg/m^2/day on Day 2 and Day 3 of each 21-day cycle with up to 6 cycles.
89193769|NCT03898960||Mechanical Thrombectomy|NIMBUS Device
89193770|NCT03895489|Experimental|Journey II|Smith and Nephew Richards (SNR) Journey II Knee prosthesis
89193771|NCT03895489|Active Comparator|Stryker|Stryker Triathlon Total Knee prosthesis
89193772|NCT03895489|Active Comparator|Zimmer|Zimmer Persona® The Personalized Knee prosthesis
89193773|NCT03874104|Experimental|Study product|Extensively Hydrolysed Formula containing Pre- and Probiotics
89193774|NCT03863093|Experimental|An erythritol powder|An erythritol powder will be used by Electro Medical Systems AIRFLOW® and then Electro Medical Systems Piezo will be used for supra- and subgingival ultrasonic instrumentation
89193775|NCT03863093|Active Comparator|ultrasonic instrumentation|Electro Medical Systems Piezo will be used for supra- and subgingival ultrasonic instrumentation
89193776|NCT03853616|Experimental|Phase I: DL 0: 1x10e5 MB-CART19.1 cells|In each dose level of each of the three cohorts three 3 + 3 patients will be treated. A particular dose level will be expanded to 6 patients if one patient out of 3 patients treated at that particular dose level develops DLT. Once this occurs, further dose-escalations are halted until the dose has proven to be safe in the expanded cohort. If 2 or more in a cohort of 6 patients develop DLT no further dose escalation is allowed, and the next lower dose level will be expanded to 6 patients in total. The highest dose among the dose levels tested at which no more than one out of six patients experiences DLT will be considered the MTD.
89418113|NCT03701503|Active Comparator|Non Obese|"Women age 20-40, with BMI 18,5-23 kg/m2 Given a balanced breakfast (Protein 12,4%, carbohydrate 68,2%, fat 22,6%) with calories according to their energy requirement,which is calculated by adding basal metabolic rate (BMR) with additional energy from physical activity.~Participants' blood was taken before intervention, and 15, 60, 120, and 180 minutes after intervention, then examined in laboratory to measure every outcome. After 4 hours, participants were given ad libitum meal. After the participants done eating, the calorie in meal taken by participants was measured."
88895959|NCT03357757|Experimental|Avelumab with VPA|Valproic Acid (VPA, 12.5 mg/kg) once per day and Avelumab (10 mg/kg IV) every 2 weeks for up to 2 years.
88895960|NCT03354663|Experimental|TactiCath SE|Catheter ablation with the TactiCath SE ablation catheter to achieve pulmonary vein isolation.
88895961|NCT03344458|Experimental|TransCon hGH|Once weekly subcutaneous injection of TransCon hGH
88895962|NCT03312465||AS Domelock System Subjects|Subjects that receive the Anatomical Shoulder Domelock System
88895963|NCT03305419|Experimental|Subjects receiving treatment sequence ABC in cohort 1: Part A|Eligible subjects will be randomized to receive treatment sequence ABC in Part A; A= GSK2982772 120 mg TID, B= GSK2982772 240 mg TID, and C= GSK2982772 360 mg BID. Subjects will receive oral capsule of GSK2982772 or placebo on Day 1 in each of the 3 treatment periods followed by a wash-out period of at least 7 days between dosing regimens.
88895964|NCT03305419|Experimental|Subjects receiving treatment sequence ABP in cohort 1: Part A|Eligible subjects will be randomized to receive treatment sequence ABP in Part A; A= GSK2982772 120 mg TID, B= GSK2982772 240 mg TID, and P= Placebo. Subjects will receive oral capsule of GSK2982772 or placebo on Day 1 in each of the 3 treatment periods followed by a wash-out period of at least 7 days between dosing regimens.
89418114|NCT03704233||Cryobiopsy|Transbronchial cryobiopsy is performed in patients with undefined diffuse parenchymal lung diseases, and assess the diagnostic yield and safety.
89418115|NCT02752776|Experimental|Secukinumab|All patients are received s.c. injections of secukinumab 300 mg at Week 0, 1, 2 and 3 during the first 4 weeks followed by monthly maintenance dosing of 300 mg secukinumab starting at Week 4 until Week 48. Consideration was given to discontinuing treatment in patients who showed no response up to 16 weeks of treatment (e.g. patients who did not achieve a PASI 50 response). If discontinued, patients completed the end of study visit assessments. Some patients with an initially partial response (e.g. patients who achieved a PASI 50 response but not a PASI 75 response) subsequently improved with continued treatment beyond 16 weeks.
89418116|NCT03704155|Experimental|Experimental group (EG)|The EG was treated with Botulinum toxin type A and physiotherapy (stretching, balancing training, functional walking training).
89418117|NCT03704155|Active Comparator|Control group (CG)|GC was treated with physiotherapy (stretching, balancing training, functional walking training).
89418118|NCT03698227|Experimental|Study treatment|"Olaratumab 20 mg/kg IV on day 1 and day 8 of cycle 1 and 15 mg/kg olaratumab IV on day 1 and day 8 of cycles 2-8.~Plus dexrazoxane at a dose equal to 10 times the doxorubicin dose (mg/m2) IV on day 1 of each 21 day cycle for 8 cycles~Plus doxorubicin 75 mg/m2 IV on day 1 of each 21 day cycle for 8 cycles~Beginning with cycle 9, olaratumab maintenance monotherapy at 15 mg/kg IV on day 1 and day 8 of each subsequent 21 day cycle"
89418119|NCT03697915|Experimental|Experimental group|Experimental group, in which a physical therapy programme supplemented by the James lift system was applied
89418120|NCT03697915|Placebo Comparator|Control|Control group, in which a conventional physical therapy programme was applied.
89418121|NCT03697837|Experimental|Parent Management Training|Parents will receive a web-based parenting intervention for tantrums and disruptive behavior in young children
89536789|NCT01534481|Active Comparator|Donor Milk|Donor milk provided by the Human Milk Banking Association of North America
88895965|NCT03305419|Experimental|Subjects receiving treatment sequence APC in cohort 1: Part A|Eligible subjects will be randomized to receive treatment sequence APC in Part A; A= GSK2982772 120 mg TID, P= Placebo and C= GSK2982772 360 mg BID. Subjects will receive oral capsule of GSK2982772 or placebo on Day 1 in each of the 3 treatment periods followed by a wash-out period of at least 7 days between dosing regimens.
88895966|NCT03305419|Experimental|Subjects receiving treatment sequence PBC in cohort 1: Part A|Eligible subjects will be randomized to receive treatment sequence PBC in Part A; P= Placebo, B= GSK2982772 240 mg TID and C= GSK2982772 360 mg BID. Subjects will receive oral capsule of GSK2982772 or placebo on Day 1 in each of the 3 treatment periods followed by a wash-out period of at least 7 days between dosing regimens.
88895967|NCT03305419|Experimental|Subjects receiving GSK2982772 120 mg TID in cohort 2 : Part B|Eligible subjects will receive GSK2982772 oral capsule with a dose of 120 mg TID for 14 days in Part B.
88895968|NCT03305419|Experimental|Subjects receiving GSK2982772 120 mg TID in cohort 3 : Part B|Eligible subjects will receive GSK2982772 oral capsule with a dose of 120 mg TID for 14 days in Part B.
88895969|NCT03305419|Experimental|Subjects receiving GSK2982772 240 mg TID in cohort 4: Part B|Eligible subjects will receive GSK2982772 oral capsule with a dose of 240 mg TID for 14 days in Part B.
88895970|NCT03305419|Experimental|Subjects receiving GSK2982772 360 mg BID in cohort 5: Part B|Eligible subjects will receive GSK2982772 oral capsule with a dose of 360 mg BID for 14 days in Part B.
88895971|NCT03305419|Placebo Comparator|Subjects receiving placebo in cohort 2 : Part B|Subjects will receive placebo oral capsule for 14 days in Part B.
88895972|NCT03305419|Placebo Comparator|Subjects receiving placebo in cohort 3 : Part B|Subjects will receive placebo oral capsule for 14 days in Part B.
88895973|NCT03305419|Placebo Comparator|Subjects receiving placebo in cohort 4 : Part B|Subjects will receive placebo oral capsule for 14 days in Part B.
88895974|NCT03305419|Placebo Comparator|Subjects receiving placebo in cohort 5: Part B|Subjects will receive placebo oral capsule for 14 days in Part B.
88895975|NCT03288103|Experimental|Growth Hormone Treatment for Participants with ACAN Deficiency|Pre-pubertal children with ACAN deficiency on daily growth hormone (Norditropin) regimen for a 3 year period.
89418122|NCT02186730|Experimental|Stressbsuters|"Computerised Cognitive Behaviour package consisting of eight 30-45 minute sessions of CBT designed for 12-18 year olds. Each Stressbusters session is an interactive presentation featuring narration synchronised with videos, animations, graphics and printouts.~The programme has a narrator guiding individuals through each of the eight sessions in a linear progression. Each session builds on the knowledge gained in previous sessions and on tasks carried out at home. Sessions contain flexible add-ons such as written fact sheets (for example about bullying, sleep problems) which can be printed out and taken away together with home practice related handouts from the programme (for example mood diary sheets). Session topics include getting activated, relapse prevention, challenging negative thoughts and problem solving"
88895976|NCT03273881|Active Comparator|glucose solution and insulin|Participants will receive intravenous saline solution boosted with 5% glucose + 8 units regular insulin in a rate of 125 mL/h.
88895977|NCT03273881|Active Comparator|glucose solution only|Participants will receive intravenous saline solution boosted with 5% glucose in a rate of 125 mL/h.
88895978|NCT03245242||Enhanced Recovery After Surgery|Prospectively enrolled group to receive standardized care under a set ERAS protocol/pathway.
88895979|NCT03245242||Historical usual surgical care|Recent historical patients (5 years prior to start of ERAS) that will be propensity-matched to ERAS patients to be used as controls for comparison of outcomes.
88895980|NCT03237494||Participants at risk for hATTR and participants diagnosed with hATTR|Participants 18 years of age or older
88895981|NCT03233152|Experimental|ipilimumab + nivolumab|"Only one study cohort will be predefined in this phase I clinical trial; a classical phase I 3+3 patient recruitment design will be used to guide patient recruitment.~Ipilimumab (YervoyTM, 50 mg/10 mL) will be administered by at the end of the neurosurgical resection procedure at a dose of injection of 10 mg (2 ml of YervoyTM, 50 mg/10mL vial).~First administration of 10 mg Nivolumab (OpdivoTM, 40 mg/4mL solution) by the intravenous route will be administered within 24 hours prior to the planned neurosurgical resection. The following administrations of 10 mg nivolumab will be by a 15 minutes intravenous infusion on days 15, 29, 43, 57, and 71 (or up to ± 3 days before or after the scheduled date if necessary)."
89536790|NCT01534481|Placebo Comparator|Preterm Formula|Preterm formula determined by center practice
88895982|NCT03190967|Experimental|1/Phase I: Ado-trastuzumab (T-DMI) + Temozolomide (TMZ) Dose Escalation|T-DM1 + TMZ in dose escalation
88895983|NCT03190967|Active Comparator|2A /Phase II: Arm A, Ado-trastuzumab (T-DMI) Alone|T-DM1
88895984|NCT03190967|Experimental|2B/Phase II /Arm B, Ado-trastuzumab (T-DMI) + Temozolomide (TMZ)|T-DM1 + TMZ at recommended phase 2 dose (RP2D)
88895985|NCT03188965|Experimental|Part A: single-agent dose-escalation|Patients with histologically confirmed solid tumors or non-Hodgkin's lymphoma (NHL) receive BAY1895344 in a 21-day cycle.
88895986|NCT03188965|Experimental|Part A.1: Single-agent dose escalation with alternative dosing schedule|Patients with histologically confirmed solid tumors or NHL known to be positive for ATM loss and/or ATM deleterious mutations receive BAY1895344 in a 28-day cycle.
88895987|NCT03188965|Experimental|J-arm of Part A: dose escalation cohort in Japanese patients|Japanese patients with histologically confirmed solid tumors receive BAY1895344 at two dose levels: MTD-1 and MTD.
89006409|NCT00246675|Other|Standard Care|Patients will only receive frusemide as per the treating physicians treatment
89006410|NCT00246675|Other|Intervention|Patients will be given frusemide to achieve a study specified urine output target of 1-2mls/kg/hour
89006411|NCT04626778|Active Comparator|Peroxyl|1.5% Hydrogen Peroxide mouthwash
89006412|NCT04626778|Placebo Comparator|placebo mouthwash|0.0% Hydrogen peroxide mouthwash
89006413|NCT04626973|Experimental|Intensive-targeting group|
89193777|NCT03853616|Experimental|Phase I: DL 1: 5x10e5 MB-CART19.1 cells|Dose evaluation will start in Cohorts 1 and 2 with Dose Level 1. In each dose level of each of the three cohorts three 3 + 3 patients will be treated. A particular dose level will be expanded to 6 patients if one patient out of 3 patients treated at that particular dose level develops DLT. Once this occurs, further dose-escalations are halted until the dose has proven to be safe in the expanded cohort. If 2 or more in a cohort of 6 patients develop DLT no further dose escalation is allowed, and the next lower dose level will be expanded to 6 patients in total. The highest dose among the dose levels tested at which no more than one out of six patients experiences DLT will be considered the MTD.
89193778|NCT03853616|Experimental|Phase I: DL 2: 1x10e6 MB-CART19.1 cells|Dose evaluation will start in Cohort 3 with Dose Level 2, sparing Dose Level 1. If Dose Level 2 is not tolerated, Dose Level 1 will be tested. In each dose level of each of the three cohorts three 3 + 3 patients will be treated. A particular dose level will be expanded to 6 patients if one patient out of 3 patients treated at that particular dose level develops DLT. Once this occurs, further dose-escalations are halted until the dose has proven to be safe in the expanded cohort. If 2 or more in a cohort of 6 patients develop DLT no further dose escalation is allowed, and the next lower dose level will be expanded to 6 patients in total. The highest dose among the dose levels tested at which no more than one out of six patients experiences DLT will be considered the MTD.
89193779|NCT03853616|Experimental|Phase I: DL 3: 3x10e6 MB-CART19.1 cells|In each dose level of each of the three cohorts three 3 + 3 patients will be treated. A particular dose level will be expanded to 6 patients if one patient out of 3 patients treated at that particular dose level develops DLT. Once this occurs, further dose-escalations are halted until the dose has proven to be safe in the expanded cohort. If 2 or more in a cohort of 6 patients develop DLT no further dose escalation is allowed, and the next lower dose level will be expanded to 6 patients in total. The highest dose among the dose levels tested at which no more than one out of six patients experiences DLT will be considered the MTD. In Dose Level 3, three additional patients will be treated, if no DLT occurred. Dose Level 0 will be tested only if Dose Level 1 is not tolerable.
89193780|NCT03853616|Experimental|Phase II - Recommended dose MB-CART19.1|Phase II will evaluate the efficacy and safety in patients treated with the recommended dose in Cohorts 1 to 3, respectively.
89193781|NCT03843385|Experimental|faecal microbiota filtrate|Encapsulated faecal microbiota filtrate . 2×5 frozen capsules by mouth on 5 consecutive days per week (5 days on and 2 days off; week 1 - week 12) with water or cool drink.
89193782|NCT03843385|Active Comparator|faecal microbiota|Encapsulated faecal microbiota. 2×5 frozen capsules by mouth on 5 consecutive days per week (5 days on and 2 days off; week 1 - week 12) with water or cool drink.
89193783|NCT03843385|Sham Comparator|Placebo|Placebo: Encapsulated sterile saline. 2×5 frozen capsules by mouth on 5 consecutive days per week (5 days on and 2 days off; week 1 - week 12) with water or cool drink.
89193784|NCT03824327|Experimental|Treatment (BOLD fMRI, papaverine hydrochloride, SBRT)|Patients undergo BOLD fMRI and receive papaverine hydrochloride IV on day 1. Within 30-90 minutes, patients undergo a second BOLD fMRI. Patients then receive papaverine hydrochloride IV and within 30-90 minutes after dose undergo SBRT for a up to 4-5 sessions over 2 weeks.
89006414|NCT04626973|Active Comparator|Conventional-targeting group|
89006415|NCT00242463|Experimental|nandrolone|Patients receive weekly injections of nandrolone
88895988|NCT03188965|Experimental|Part B: single-agent expansion|Patients with a) DDR deficiency biomarker-positive advanced solid tumors: castration-resistant prostate cancer (CRPC), HER2-negative breast cancer (BC), colorectal cancer (CRC), and gynecological tumors; OR b) histologically confirmed advanced cancer and loss of ATM regardless of the cancer type receive BAY1895344 at MTD determined at the end of dose escalation.
88895989|NCT03188965|Experimental|Part B.1: single-agent expansion with alternative dosing schedule|Patients with histologically confirmed relapsed or refractory MCL receive BAY1895344 at a dose determined after evaluation of multiple BAY1895344 doses in Part A.1
88895990|NCT03184571|Experimental|Bemcentinib + pembrolizumab|"Cohort A enrols participants who received a maximum of 1 prior line of platinum-containing chemotherapy and no prior immunotherapy of any kind to receive bemcentinib (BGB324) in combination with pembrolizumab.~Cohort B enrolls participants who received a maximum of one prior line of an anti-PD-(L)1 therapy (monotherapy) to receive bemcentinib (BGB324) in combination with pembrolizumab.~Cohort C enrolls participants who received a maximum of one prior line of therapy with an anti-PD-(L)1 therapy in combination with a platinum-containing chemotherapy.~Bemcentinib capsules are administered at 400mg for days 1-3, and 200mg thereafter. Pembrolizumab is an IV infusion, administered at a dose of 200mg every 3 weeks."
88895992|NCT03108196|Experimental|sigmoid|"Use 15 cm detaenial sigmoid colon to reconstructed a U shape neobladder after radical cystectomy."
88895993|NCT03108196|Experimental|ileal|"Use 70 cm distal ileal segment to reconstructed a spherical shape neobladder after radical cystectomy."
88895994|NCT03097939|Experimental|Nivolumab and Ipilimumab|
89193785|NCT03822728|No Intervention|Without 3D-DESS MRI|As for deep seated tumors in preoperative CT or US (or tumors in both superficial and deep parotid glands), the patients will undergo surgery without 3D-DESS MRI (currently routine practice).
89193786|NCT03822728|Experimental|With 3D-DESS MRI|As for deep seated tumors in preoperative CT or US (or tumors in both superficial and deep parotid glands), preoperative 3D-DESS MRI will be additionally performed to delineate the intra-parotid facial nerve.
88895995|NCT03097874|Experimental|Family Based Treatment|Family Based Treatment of adolescent Anorexia Nervosa
88895996|NCT03097874|Experimental|Family Based Treatment + Intensive Parental Coaching|Family Based Treatment plus Intensive Parental Coaching if weight milestones are not met by session 4.
88895997|NCT03096782|Experimental|Chemotherapy and Cord blood transfusion|"All patients received Busulfan as per standard of care. Busulfan test dose can be administered either as an outpatient prior to admission or as an inpatient on Day -10.~Busulfan pharmacokinetics will be performed with the test dose and the first dose on Day -7 per standard of care. The doses of Days -6, -5, and -4 will be subsequently adjusted to target an AUC of 4,000 microMol.min-1. In the event that PK adjusting were not possible a dose of busulfan of 130 mg/m2 will be administered.~GVHD PROPHYLAXIS: All patients also receive mycofenolate mofetil IV over 2 hours or PO BID on days -3 with a taper beginning on day 100 in the absence of GVHD, tacrolimus IV or PO starting on day -2 for 6 months in the absence of GVHD, and filgrastim-sndz SC QD starting on day 0 until white blood count begins to recover."
88895998|NCT03093831|Experimental|Ibrutinib|
88895999|NCT03088189||Vitamin B12 group|Mothers in the group are receiving vitamin B12 2µg supplements daily
88896000|NCT03088189||Multiple micronutrient group|mothers in this group are receiving vitamin B12 2µg plus multiple micronutrients (MMN) plus 20g of milk powder
88896001|NCT03088189||Placebo|Mothers are receiving placebo
89006416|NCT00242463|Placebo Comparator|Placebo|
89006417|NCT00561808|Experimental|Observational|
89418123|NCT02186730|Active Comparator|Websites|Any individuals randomised to arm 2 of the trial will spend the equivalent time accessing currently available self help websites that provide information about low mood/depression. These four websites will be the same as those used in our initial feasibility study of which, based on our preliminary data, there is evidence for their usefulness.
89006418|NCT00561886|Experimental|1|Patients with COPD receiving once 24 µg formoterol
89006419|NCT04626622||ARVI and influenza prophylaxis with Kagocel (n=50)|"Prophylaxis according to routine practice and instructions for medical use of Kagocel.~Group of patients receiving Kagocel for prevention of ARVI and influenza"
89006420|NCT04626622||ARVI and influenza prophylaxis without any antiviral medicines (n=25)|Group of patients receiving no any antiviral medicines for prevention of ARVI and influenza
89418124|NCT01342965|Experimental|Erlotinib|Participants received erlotinib 150 mg orally once daily until progressive disease or unacceptable toxicity.
89418125|NCT01342965|Active Comparator|Chemotherapy|Participants received gemcitabine 1250 mg/m^2 intravenously (IV) on Days 1 and 8 and cisplatin 75 mg/m^2 IV on Day 1 of every 3 week cycle until disease progression, unacceptable toxicity, or a total of 4 cycles, whichever came first.
89418126|NCT02181348|Active Comparator|Intervention (Vitamin E supplementation)|Vitamin E 400 mg once daily for 3 months
89418127|NCT02181348|Placebo Comparator|placebo (edible oil)|
89418128|NCT02186886|Other|Golimumab|Golimumab: Patients with body weight less than 80 kg initial dose of 200 mg, followed by 100 mg at week 2, then 50 mg every 4 weeks, thereafter // Patients with body weight greater than or equal to 80 kg initial dose of 200 mg, followed by 100 mg at week 2, then 100 mg every 4 weeks, thereafter
89418129|NCT02186964|Experimental|tension free primary closure|patients treated by tension free primary closure
89006421|NCT00561964|Experimental|1|
89193787|NCT03815825|Experimental|IONIS-FB-LRx|Stage 1 participants will receive IONIS-FB-LRx randomized to 1 of 3 dose levels, administered subcutaneously every 4 weeks, completing the treatment period at Week 45. Stage 2 will expand 2 of the dosing cohorts in a new randomized group of participants based on the Stage 1 interim analysis. Participants will be randomized to 1 of 2 of the expanded cohorts, administered subcutaneously every 4 weeks, completing the treatment period at Week 45.
89006422|NCT00561964|Placebo Comparator|2|
89006423|NCT04626193|Experimental|Doxycyclien|Measure eradication rate of Helicobacter pylori infection with Doxycycline,Levofloxacien,tinadizole
89006424|NCT04626193|Active Comparator|Levofloxacine|Measure eradication rate of Helicobacter pylori infection with Livofloxacine and tinadizole,amoxicilline
89006425|NCT04626232|Experimental|N SLEEVE|Monocentric, randomized, single-blind controlled trial, with 2 parallel arms (experimental technique versus surgical reference technique).
89006426|NCT04626232|Other|SLEEVE|The conventional sleeve gastrectomy technique consists of reducing the gastric capacity by removing 2/3 of the stomach by a vertical transection.
89418130|NCT02186964|Experimental|karydakis|patients treated by Karydakis method
89418131|NCT02186964|Experimental|Limberg flap|patients treated by Limberg flap procedure
89418132|NCT02182908|Other|Non surgical aneurysm of abdominal aorta|PET-Scan
89418133|NCT02245893|Active Comparator|Screw|"In the SCREW Group (standard surgery technique), surgical treatment will be by closed reduction utilizing intraoperative fluoroscopy to visualize the reduction and percutaneous syndesmosis screw insertion. Intraoperative fluoroscopic stress and non-stress views will be obtained as per standard of care.~'open reduction internal fixation (ORIF)"
89418134|NCT02245893|Active Comparator|Anatomic repair technique (ART)|"In the ART group (study group) surgical treatment will be by open reduction and internal fixation. In order to stabilize the syndesmosis, direct visual anatomic alignment will be conducted and a syndesmotic screw inserted. In addition, fixation of the anterior ligament will be performed with use of a 2.7 to 4.0 mm suture anchor. Repair of the intact portion of the ligament will be made using a modified Mason -Allen repair. Intraoperative fluoroscopic stress and non-stress views will be obtained as per standard of care.~'open reduction internal fixation (ORIF)"
89418135|NCT02182986||Subjects Enrolled Pre-Transplant|"Subjects (N=approximately 357) Enrolled Pre-Transplant~Subjects with evidence of EBV infection prior to transplant~Subjects without evidence of EBV infection prior to transplant, who are at risk of developing EBV infection after transplant"
89418136|NCT02182986||Subjects Enrolled Post-Transplant|"Subjects (N=approximately 588) Enrolled 3 Yrs Post-Transplant~Subjects with evidence of EBV infection prior to transplant~Subjects without evidence of EBV infection prior to transplant, who are at risk of developing EBV infection after transplant"
89006427|NCT00562042||1|Patients diagnosed with acute pulmonary embolism were enrolled in this study.
89006428|NCT00242541|Experimental|Octreotide acetate|
89006429|NCT04625998|Experimental|Intervention|Elementary schools and Head Start centers in the intervention catchment areas implemented (1) an enhanced Coordinated Approach To Child Health (CATCH) program for elementary schools using the CATCH Coordination Guide (Enhanced CATCH Elementary School Program), and (2) CATCH Early Childhood program for Head Start Centers.
89006430|NCT04625998|No Intervention|Comparison|Elementary schools and Head Start centers in the comparison catchment area used their regular school and early care and education (ECE) nutrition and physical activity programs. Elementary schools were required by law to implement a coordinated school health program.
89006431|NCT04625842|Experimental|Patient focus group|Patients who received radiation treatment
89006432|NCT04625842|Experimental|Family focus group|Family of patients who received radiation treatment
89006433|NCT04625686||Inpatient Treatment|Inpatient psychiatric treatment
89006434|NCT04625686||OCIC Treatment|In-person outpatient crisis intervention
89006435|NCT04625686||Telehealth Therapy Treatment|Virtual outpatient therapy
89006436|NCT04625686||No Show Group|Participant who do not attend recommended treatment
89006437|NCT04625920|Experimental|Virtual reality|women allocated to undergo hysteroscopy with Vr System
89006438|NCT04625920|Experimental|Standart care|women allocated to undergo hysteroscopy without VR
89006439|NCT00219674|Active Comparator|2|Group II
89006440|NCT00219674|Active Comparator|3|
89006441|NCT00219674|Active Comparator|4|
89006442|NCT00219674|Active Comparator|1|Group I
89006443|NCT04625881|Active Comparator|Active product|A powder containing 20 g of apple derived fiber will be consumed daily
89006444|NCT04625881|Placebo Comparator|Placebo|A rice derived placebo devoid of fiber and aromatized with apple fragancy will be provided
89006445|NCT04625608|Other|Standard care|Participants in this arm shall receive 3.6 ml/kg of water a minimum of 1 hour prior to the induction of general anaesthesia. This is standard practice in the 2 participating institutions.
89006446|NCT04625608|Experimental|Paracetamol arm|Participants in this arm shall receive 3 ml/kg of water plus 15 mg/kg of oral paracetamol suspension a minimum of 1 hour prior to the induction of general anaesthesia.
89193788|NCT03815825|Experimental|Placebo|Stage 1 participants will receive a placebo matching solution, administered subcutaneously every 4 weeks, completing the treatment period at Week 45. Stage 2 participants will receive a placebo matching solution, administered subcutaneously every 4 weeks, completing the treatment period at Week 45.
89193789|NCT03809013|Experimental|RC48-ADC|Participants will be treated with RC48-ADC 2.0 mg/kg, once every 2 weeks (Q2W) until investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or participant's decision to withdraw from therapy, or death (whichever occurs first).
89193790|NCT03802240|Experimental|Sintilimab +IBI305+Pemetrexed+Cisplatin|"Drug: Sintilimab 200mg IV Q3W Other Name: IBI308~Drug: IBI305 15mg/kg IV Q3W~Drug: Pemetrexed 500mg/m2 IV Q3W~Drug: Cisplatin 75mg/m2 IV Q3W"
89193791|NCT03802240|Experimental|Sintilimab +Placebo2+Pemetrexed+Cisplatin|"Drug: Sintilimab 200mg IV Q3W Other Name: IBI308~Drug: Pemetrexed 500mg/m2 IV Q3W~Drug: Cisplatin 75mg/m2 IV Q3W~Drug: Placebo2 Placebo2 IV Q3W"
89006447|NCT04625491||Location on lower limb|Proximal (thigh) Medium (leg) Distal (ankle and foot)
89006448|NCT04625335|Experimental|Group 1: Intervention First|Adult, healthy volunteers will receive the intervention (prophylactic therapeutic massage) before completing the Cold Pressor Test. Following the crossover, these participants will then complete the Cold Pressor Test without prior massage.
89006449|NCT04625335|Experimental|Group 2: Intervention Last|Adult, healthy volunteers will complete the Cold Pressor Test without prior massage. After crossover, they will receive the intervention (prophylactic therapeutic massage) before completing the Cold Pressor Test.
89006450|NCT04625452|Experimental|BBCC+5A's+GS|Brief behavior change counseling using 5A's + Guiding style (from motivational interviewing) + Printed education materials ( at baseline, 12 weeks, 24 weeks)
89006451|NCT04625452|No Intervention|Normal care|They will receive the normal care: simple advice on changing lifestyle risk factors + medications for diabetes or hypertension ( at baseline, 12 weeks, 24 weeks)
89006452|NCT04625179|Experimental|Melatonin and hyaluronic acid and sinus membrane elevation|melatonin and hyaluronic acid will be placed after maxillary sinus membrane elevation and simultaneous dental implants placement
89006453|NCT04625179|Active Comparator|sinus membrane elevation without any materials|no materials will be placed after maxillary sinus membrane elevation and simultaneous dental implants.
89006454|NCT04624789||GM1-Gangliosidosis - Sialidosis|"Confirmed diagnosis of:~GM1-Gangliosidosis Morquio B Variant~Sialidosis~Galactosialidosis"
89006455|NCT04624789||GM2-Gangliosidoses|"Confirmed diagnosis of:~Tay-Sachs Disease, incl. B1-Variante~Sandhoff Disease~GM2-Activator-Deficiency"
89006456|NCT04624867|Experimental|HP-1050 patch|HP-1050 and Xulane will be administered simultaneously.
89006457|NCT04624516|Experimental|Intervention group|The group received training in self-structured foot exercise and they were encouraged to do self-structure foot exercise 3 times a week. They received usual care
89006458|NCT04624516|No Intervention|Control Group|the group received usual care
89006459|NCT02962232|Experimental|LEGFLOW OTW group|in the LEGFLOW OTW group the subject will be treated by the Paclitaxel Releasing Peripheral Balloon Dilatation Catheter (LEGFLOW)
89006460|NCT02962232|Active Comparator|AMPHIRION DEEP group|in the AMPHIRION DEEP group the subject will be treated by PTA catheter (AMPHIRION DEEP)
89006461|NCT04624711|Experimental|Eribulin Mesylate Combined With Anlotinib|Patients receive eribulin mesylate plus anlotinib.
89006462|NCT04624594|Experimental|Artificial Intelligence (AI) Group|"To determine baseline ability and serve as their own control, participants in both groups performed 10 bodyweight squat control repetitions without feedback followed by one minute of rest. Those in the AI group then performed 10 more practice repetitions with real-time audiovisual feedback from the app followed by one minute of rest. The AI's design provided one piece of feedback, if necessary, with a vocal statement and on-screen video per repetition (e.g. when a participant performed a squat repetition with their neck flexed downward, AI suggested keeping their head up with on-screen instruction). Participants in both groups then performed 10 test repetitions without feedback followed by one minute of rest."
89006463|NCT04624594|Active Comparator|Physical Therapist Group|"To determine baseline ability and serve as their own control, participants in both groups performed 10 bodyweight squat control repetitions without feedback followed by one minute of rest. Those in the PT group (n=15) also performed 10 practice repetitions with one piece of feedback per repetition, if necessary, from the PT followed by one minute of rest. Participants in both groups then performed 10 test repetitions without feedback followed by one minute of rest."
89006464|NCT04624477||Active Surveillance|Patients under active surveillance choose to not have immediate thyroid surgery. Patients are closely monitored with respect to clinical status, ultrasound imaging, biochemical indices (thyroid function, thyroglobulin, and thyroglobulin antibodies) and any thyroid cancer-related treatments (if received). Active surveillance is conducted at a participating study site. Criteria defining disease progression are established, and if such criteria are met, thyroid surgery is recommended to the patient. However, patients are free to choose to have thyroid surgery at any time, in the absence of disease progression. Thyroid cancer clinical and treatment outcomes are tracked by the study team.
89006465|NCT04624477||Immediate Thyroid Surgery (total or partial thyroidectomy)|Patients who choose surgery, undergo thyroidectomy, as per current standards of care, by a surgeon of their choice in an institution of their choice. The treating surgeon, in discussion with the patient, will choose the extent of thyroid surgery that may be appropriate for the individual case. Post-surgical follow-up is per the discretion of the treating surgeon, endocrinologist, or other healthcare providers involved in the patient's thyroid cancer care. Thyroid cancer clinical and treatment outcomes are tracked by the study team.
89006466|NCT04624282||Patients with chronic superficial gastritis|Patients with chronic superficial gastritis
89006467|NCT04624282||Patients with chronic atrophic gastritis|Patients with chronic atrophic gastritis
89006468|NCT04624282||Patients with gastric carcinoma|Patients with gastric carcinoma
89006469|NCT04624360|Experimental|Study Drug A|Dexamethasone 8mg intravenous administration stat dose post clamping of the umbilical cord
89006470|NCT04624360|Placebo Comparator|Study Drug B|Normal saline 2cc intravenous stat dose administered after clamping of the umbilical cord
89006471|NCT04624438|Experimental|Electromyostimulation - EMS|Experimental group comprised of healthy young adults that undergoes unilateral isometric training using electromyostimulation over quadriceps femoris
89006472|NCT04624438|Experimental|Voluntary activation - VOLUNTARY|Experimental group comprised of healthy young adults that undergoes unilateral isometric training based on voluntary activation of quadriceps femoris
89006473|NCT04624438|Experimental|Combination of EMS and VOLUNTARY - COMBINED|Experimental group comprised of healthy young adults that undergoes unilateral isometric training that combines electromyostimulation and voluntary activation of quadriceps femoris.
89193792|NCT03802240|Active Comparator|Placebo1+Placebo2+Pemetrexed+Cisplatin|"Drug: Pemetrexed 500mg/m2 IV Q3W~Drug: Cisplatin 75mg/m2 IV Q3W~Drug: Placebo1 Placebo1 IV Q3W~Drug: Placebo2 Placebo2 IV Q3W"
89418137|NCT03570411||HCT Recipient|"All participants who meet eligibility criteria and consent to enrollment on study.~Blood specimens will be collected for the T-SPOT.CMV blood test from HCT recipients over the course of 6 months, starting weekly at Day +1, biweekly starting at Day +45, and monthly starting at day +120.~The amount of blood collected at each visit will be based on age."
89418138|NCT03570411||HCT Donor|"Approved allogeneic HCT donor for a HCT recipient enrolled on the SPOTCMV protocol~A blood sample for the T-SPOT.CMV blood test will be collected from the HCT donor prior to transplant"
89418139|NCT03536910|Other|General anesthesia|
88896002|NCT03055013|Experimental|Arm I (nivolumab, nephrectomy)|"Patients receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 14 days for 2 cycles. Patients then undergo partial or radical nephrectomy 7-28 days later. Patients then receive nivolumab over 30 IV on day 1. Treatment repeats every 14 days for 6 cycles, and then every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity.~Patients enrolled after Amendment 4 receive nivolumab IV over 30 minutes on day 1. Patients then undergo partial or radical nephrectomy 7-28 days later. Patient then receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 4 weeks for up to 9 cycles in the absence of disease progression or unacceptable toxicity."
88896003|NCT03055013|Active Comparator|Arm II (nephrectomy)|Patients undergo partial or radical nephrectomy within 8 weeks after registration followed by observation.
88896004|NCT03052049|Experimental|Prostate Artery Embolization|There is only one arm of this study where patients receive Prostate Artery Embolization
88896005|NCT03036657|Experimental|Manual Acupuncture|"Device:~Sterile single-use MAC acupuncture needles - 0.22 x 25 mm, TianJin Haing Lim Sou Won Medical Equipment Co, Ltd, South Korea~Used for Intervention:~Manual Acupuncture to PC3, PC5 or HT3, HT4 for 20 min"
88896006|NCT03036657|Experimental|Low-Frequency Electroacupuncture|"Device:~Electrostimulator 6c.Pro, Pantheon Research, Venice, CA~Used for Intervention:~Low-frequency Continuous Electroacupuncture (2Hz) to PC3, PC5 or HT3, HT4 for 20 min"
88896007|NCT03036657|Experimental|High-Frequency Electroacupuncture|"Device:~Electrostimulator 6c.Pro, Pantheon Research, Venice, CA~Used for Intervention:~High-frequency Continuous Electroacupuncture (100 Hz) to PC3, PC5 or HT3, HT4 for 20 min"
88896008|NCT03033446|Experimental|Y90-Radioembolization and Nivolumab|
88896009|NCT03019536|Experimental|70 mg LY3303560|70 milligram (mg) LY3303560 administered intravenously (IV) every 4 weeks for 25 weeks with the option of continuing treatment up to 49 weeks (up to 6 further doses), followed by a 16-week follow-up period.
88896010|NCT03019536|Experimental|210 mg LY3303560|210 mg LY3303560 administered IV every 4 weeks for 25 weeks with the option of continuing treatment up to 49 weeks (up to 6 further doses), followed by a 16-week follow-up period.
88896011|NCT03019536|Experimental|Placebo IV|Placebo administered intravenously (IV) every 4 weeks for 25 weeks with the option of continuing treatment up to 49 weeks (up to 6 further doses),, followed by a 16-week follow-up period.
88896012|NCT02966665|Experimental|Healthy Young Volunteers (18-30 years)|Healthy volunteers between the ages of 18 and 30 years with no diseases or conditions that would affect their participation in the study, administered various treatments to assess their effect on blood flow and metabolic demand of tissues under wide-ranging conditions, including Maximum Exercise Tests, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid, L-Ascorbate, BQ-123, Fexofenadine, Ranitidine, Angiotensin-II, Valsartan, Acetylcholine, Sodium Nitroprusside, Norepinephrine, Phentolamine and MitoQ.
88896013|NCT02966665|Experimental|Healthy Older Controls (over 65 years)|Healthy volunteers 65 years of age or older with no diseases or conditions that would affect their participation in the study, administered various treatments to assess their effect on blood flow and metabolic demand of tissues under wide-ranging conditions, including Maximum Exercise Tests, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid, L-Ascorbate, BQ-123, Fexofenadine, Ranitidine, Angiotensin-II, Valsartan, Acetylcholine, Sodium Nitroprusside, Norepinephrine, Phentolamine and MitoQ.
88896014|NCT02966665|Experimental|Coronary Angiography patients|Patients undergoing routine coronary angiography, but who do not require intracoronary procedures or have history of myocardial disease, administered various treatments to assess their effect on blood flow and metabolic demand of tissues under wide-ranging conditions, including Maximum Exercise Tests, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid, L-Ascorbate, BQ-123, Fexofenadine, Ranitidine, Angiotensin-II, Valsartan, Acetylcholine, Sodium Nitroprusside, Norepinephrine, Phentolamine and MitoQ.
88896015|NCT02966665|Experimental|Chronic Obstructive Pulmonary Disease patients|Patients diagnosed with mild to moderate COPD, but not severe COPD patients, administered various treatments to assess their effect on blood flow and metabolic demand of tissues under wide-ranging conditions, including Maximum Exercise Tests, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid, L-Ascorbate, BQ-123, Fexofenadine, Ranitidine, Angiotensin-II, Valsartan, Acetylcholine, Sodium Nitroprusside, Norepinephrine, Phentolamine and MitoQ.
88896016|NCT02966665|Experimental|Pulmonary Arterial Hypertension patients|Patients with idiopathic or heritable Group 1 pulmonary arterial hypertension, administered various treatments to assess their effect on blood flow and metabolic demand of tissues under wide-ranging conditions, including Maximum Exercise Tests, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid, L-Ascorbate, BQ-123, Fexofenadine, Ranitidine, Angiotensin-II, Valsartan, Acetylcholine, Sodium Nitroprusside, Norepinephrine, Phentolamine and MitoQ.
88896017|NCT02966665|Experimental|Heart Failure patients|Patients with Class I - III New York Heart Association symptoms of Heart Failure who are not anemic or taking medications that affect blood clotting, administered various treatments to assess their effect on blood flow and metabolic demand of tissues under wide-ranging conditions, including Maximum Exercise Tests, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid, L-Ascorbate, BQ-123, Fexofenadine, Ranitidine, Angiotensin-II, Valsartan, Acetylcholine, Sodium Nitroprusside, Norepinephrine, Phentolamine and MitoQ.
88896018|NCT02966665|Experimental|Hypertension patients|Patients with chronic high blood pressure, but with less than severe hypertension, administered various treatments to assess their effect on blood flow and metabolic demand of tissues under wide-ranging conditions, including Maximum Exercise Tests, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid, L-Ascorbate, BQ-123, Fexofenadine, Ranitidine, Angiotensin-II, Valsartan, Acetylcholine, Sodium Nitroprusside, Norepinephrine, Phentolamine and MitoQ.
89006474|NCT04624438|No Intervention|Control group - CONTROL|Group of healthy young adults who received no intervention.
89418140|NCT03536910|Other|Spinal anesthesia|
89418141|NCT05354817|Other|mFolfirinox|
89418142|NCT02181582|Experimental|Emapunil Administration|Single Arm Study
88896019|NCT02945241|Experimental|Cystatin C-guided vancomycin dosing algorithm|Cystatin C is an endogenous cysteine proteinase inhibitor produced by all nucleated cells and a biomarker used routinely to estimate glomerular filtration rate either alone or in combination with creatinine. This new dosing algorithm includes patient weight, individualized goal trough concentration, and glomerular filtration rate (expressed with the CKD-EPI creatinine-cystatin C equation in mL/min) to determine dose and frequency.
88896020|NCT02945241|Other|Creatinine clearance guided vancomycin dosing|Historical controls for the quality improvement project had doses based on weight and interval established with the creatinine clearance using the Cockcroft-Gault equation.
88896021|NCT02938299|Experimental|Arm 1: neoadjuvant + surgery|"Patients in Arm 1 will receive multiple intratumoral administrations into all injectable cutaneous, subcutaneous, and nodal tumors of a mixture of L19IL2 and L19TNF once weekly for up to 4 weeks (or until all injectable tumors have disappeared, or intolerance to study treatment or in the opinion of the investigator immediate surgical resection or any other treatment for melanoma is warranted, whichever occurs first).~Newly occurring injectable melanoma lesions within the 4 weeks treatment period will also be treated as described. Surgical resection of all existing metastases will follow within 4 weeks after end of treatment. Surgery will be performed after the safety evaluation carried out at week 5 and, if indicated, may be carried out on the same day of the safety evaluation."
88896022|NCT02938299|Active Comparator|Arm 2: surgery alone|Patients in Arm 2 will receive directly surgical resection of melanoma tumor lesions within 4 weeks after randomization.
88896023|NCT02934568|Experimental|LEE011|All patients in all combinations with LEE011 will be entered in one arm.
88896024|NCT02924818|Experimental|Chronic Obstructive Pulmonary disease (COPD)|
88896025|NCT02924818|Experimental|Cystic Fibrosis (CF)|
88896026|NCT02924818|Experimental|bronchiectasis|
89418143|NCT05354739||Emla Group|"Emla Cream~1 gm of EMLA cream contains lidocaine 25 mg, prilocaine 25 mg, and macrogol glycerol hydroxy stearate. Act as a surface anesthetic of the skin. Will apply ½ tube (approximately 2 gram) per 10 square cm and covered with occlusive dressing. Applied for 30-45 minutes for children needing IV catheter placement or blood extraction based on the treating physician decision depending on the patient's need"
89418144|NCT05354739||Buzzy Device Group|"Buzzy Device~The vibration cold device (BUZZY) is 8.4 cm X 5.3 cm X 2.9 cm dimensions, exist in different but the investigators will choose the most attractive color, and can be handled by the child prior the procedure~It composed of two parts:~The main body which can be operated by a switch. It generates vibration using two AAA batteries.~Removable ice wings. The ice wings are reusable for about 100 times, both wings weighing 18 grams. It stays frozen at room temperature for around 10 minutes. The research nurse will follow the manufactures recommendations (MMJ labs, Atlanta, Georgia, USA)."
89418145|NCT02181660|Experimental|Dose Escalation Cohort|ASP2215
89418146|NCT03566745||Study group|Patients with mutation in AhR gene - presumed low Blood for protein activity
89418147|NCT03566745||Control|Patients without mutation in AhR gene - presumed normal Blood for protein activity
89418148|NCT03697759|Experimental|Usual care + selfBACK|Participants will use the selfBACK system and app
89418149|NCT03566589|Experimental|PS128|daily ingestion of Lactobacillus plantarum PS128 capsules
89418150|NCT03536832|Active Comparator|cesarean section with Vicryl|Women undergoing cesarean section with low transverse skin incisions will be closed with 3-0 Vicryl.
89418151|NCT03536832|Active Comparator|cesarean section with prolene|Women undergoing cesarean section with low transverse skin incisions will be closed with 3-0 Prolen.
89418152|NCT03697681|Experimental|Glutamine|Intravenous glutamine infusion perioperatively for 18 hours (8 hours before surgery and 10 hours after induction of anesthesia)
89418153|NCT03697681|Placebo Comparator|Placebo|placebo
89418154|NCT03566355|Experimental|curative proton therapy|Patients who meet the selection criteria are selected, signed for consent, and treated with proton therapy alone at 7200 cGy / 15 fractions, 5 times a week for 3 weeks
89418155|NCT02187276||Alzheimer disease or mixed dementia|Patients were evaluated four times. In the first consultation, without taking cholinesterase inhibitors (ChEI), after three, six and 12 months taking ChEI.
89418156|NCT03697525|Experimental|Vibration Group (VG)|VG participants undergo rMV treatment, carried out for three consecutive days by 2 trained physiatrists; each daily session consists of three 10-minute treatment (for each treated limb), interspersed with a 5-minute break. During the rMV, subjects are required to make a voluntary isometric contraction of the treated muscle
89418157|NCT03697525|Sham Comparator|Control Group (CG)|CG participants undergo the sham rMV by positioning the vibrator close to the tendon but without touching the skin. In this condition, patients were only subject to the faint buzzing sound of the vibrator. Sham rMV treatment is carried out for three consecutive days by 2 trained physiatrists; each daily session consists of three 10-minute treatment (for each treated limb), interspersed with a 5-minute break. During the rMV, subjects are required to make a voluntary isometric contraction of the treated muscle
89418158|NCT02183064|Experimental|Meloxicam|
89418159|NCT02183064|Active Comparator|Usual care prescription NSAID|
89418160|NCT03624907|Other|Consecutive Daily Treatment|Participant will receive daily stereotactic body radiotherapy at a dose of 48-50 Gy in 4-5 fractions with treatment occurring over 4-5 days
89418161|NCT03624907|Other|Non-Consecutive Daily Treatment|Participant will receive non-daily stereotactic body radiotherapy at a dose of 48-50 Gy in 4-5 fractions with treatment occurring over 8-12 days
89418162|NCT02181894||Orally intubated infants|Subjects will be <72 hours of age and orally intubated. Following consent, four measures will be reported (i.e. body weight, nasal to tragus length, suprasternal notch to xyphoid process and shoulder to elbow length). Measures will be compared against a chest x-ray and placement of ETT at the subjects lip to identify the most accurate method to place endotracheal tubes in the newborn.
89418163|NCT03704077|Experimental|Cohort A: relatlimab + nivolumab + paclitaxel|
89418164|NCT03704077|Experimental|Cohort A: nivolumab + paclitaxel|
88896027|NCT02924818|Experimental|Interstitial lung disease (ILD)|
88896028|NCT02924818|Experimental|controls|
88896029|NCT02877316|Experimental|MYPLAN app|MYPLAN app (safety plan) as part of treatment
89193793|NCT03799328|Experimental|multi-OIT|Low dose OIT with multiple allergens
89193794|NCT03796572|Experimental|Infraclavicular Regional Block|This group is given ropivacaine 0.5% up to a max of .5 ml/kg until appropriate ultrasound guided spread is achieved.
88896030|NCT02877316|Active Comparator|Safety plan on paper|Safety plan on paper as part of treatment
88896031|NCT02847468|Experimental|FDG and FCH PET|Patients will performed a TEP with 2 different radiotracer before treatment is started and 1 month after treatment has been started.
89193795|NCT03796572|Sham Comparator|Puncture Wound|This group is given the same puncture wound and dressing given to the experimental group.
88896032|NCT02804087|Experimental|MobiusHD Implantation|
88896033|NCT02804087|Sham Comparator|Sham Implantation|Sham
89193796|NCT03787693|No Intervention|Stroke Symmetric Non-VR|In this control arm, stroke survivors who walk symmetrically will walk on a split-belt treadmill in a non-virtual reality environment.
89193797|NCT03787693|Experimental|Stroke Symmetric VR|In this experimental arm, stroke survivors who walk symmetrically will walk on a split-belt treadmill in a VR - virtual reality environment.
89193798|NCT03787693|No Intervention|Stroke Asymmetric Non-VR|In this control arm, stroke survivors who walk asymmetrically will walk on a split-belt treadmill in a non-virtual reality environment.
89193799|NCT03787693|Experimental|Stroke Asymmetric VR|In this experimental arm, stroke survivors who walk asymmetrically will walk on a split-belt treadmill in a VR - virtual reality environment.
89193800|NCT03786237|Experimental|Treatment Oral Capsules / Intravenous|
89193801|NCT03780322|Experimental|Armeo Spring Pediatric|This group will receive training with Armeo Spring Pediatric in 45 minute sessions, 3 times a week, for a total of 15 sessions
89418165|NCT03704077|Active Comparator|Cohort A: ramucirumab + paclitaxel|Standard-of-care
88896034|NCT02763033|Experimental|Bob's Red Mill®|"Patients will follow the standard BMT (bone marrow transplant) diet and add potato-starch produced by Bob's Red Mill® beginning on day -7 and continuing through day +100.Patients will consume 20 g of Bob's Red Mill®, Potato-based dietary starch, orally twice daily.~Initially, subjects will take 20g daily for first three days prior to increasing dose to 20 g BID."
88896035|NCT02763033|Placebo Comparator|Starch Placebo|Patients will receive an iso-caloric, non-resistant starch placebo.
88896036|NCT02750397||HIV D+/R+|HIV+ recipients who receive an organ transplant from an HIV+ donor
89418166|NCT03704077|Experimental|Cohort B: relatlimab + nivolumab|
89418167|NCT03704077|Active Comparator|Cohort B: nivolumab|Standard-of-care
89418168|NCT03704077|Experimental|Cohort C: relatlimab + nivolumab|
89418169|NCT02256618|Experimental|Cell therapy|Infants who are born at the study sites, have moderate to severe encephalopathy, and have cord blood available for infusion
89418170|NCT04433416||hypertension|After admission, two or more of the three blood pressure measurements under the same period of calm state that met hypertension, and the patient reported that he had a history of hypertension and that the blood pressure reached the standard of hypertension in the previous non-medication state was included in the hypertension group
89418171|NCT04433416||non-hypertension|Patients who denied the history of hypertension and were not taking antihypertensive drugs after admission and had normal blood pressure measurements were included in the non-hypertensive group
89418172|NCT02183142|Active Comparator|Mobic Germany|
89418173|NCT02183142|Experimental|Mobic China|
89418174|NCT03568773|Experimental|High-intensity interval training|"The HIIT protocol is being performed with the cycling mode. The program consists of repeated intense explosions alternating with recovery intervals.~The adaptation period consists of 4 shots of 20 seconds interspersed by 180 seconds interval (active recovery). From the first to the fourth week the volunteers performed from four to six race shots from 30 to 45s with intervals from 180s to 120s. From the fifth week until the end of the intervention, training takes place with six shots of 60s with a 120s interval between running shots. The work intensity for all sessions is above 95% of VO2max, with 30W of recovery. In addition, participants refer to number 19 on the Borg Scale. Sessions range from 12 to 36 minutes without heating and recovery. In total there are 12 weeks of training."
89418175|NCT03568773|Experimental|Aerobic exercise moderate intensity|The training protocol was started, with the sessions held in the open air. From the first to the fourth week, the volunteers gave sessions of 40 to 60 minutes, intensity in L1, three sessions / week. In the fifth week, the intensity was increased to the midpoint between L1 and half of L2, maintaining 60 minutes per session and frequency three times per week. From the sixth week, the weekly frequency increased to five days, with three supervised sessions and two unsupervised sessions, but with a smartphone application that recorded distance traveled and intensity. From the ninth week on, the weekly frequency was maintained and the intensity increased for L2. In supervised sessions, training intensity is also monitored by heart rate using a Polar heart rate monitor.
89418176|NCT03568773|Experimental|Control Group|The control group attends stretching classes once a week and sessions lasting 60 minutes. At the end of the fifteen weeks (three weeks of adaptation and twelve weeks of training) of the study, these volunteers will be invited to engage in the aerobic training program regardless of their participation in the research.
89418177|NCT02187432||ADPKD|EuroCYST is and observational trail aiming to investigate disease progression across the different stages of disease and stage specific morbidity and mortality factors in a longitudinal observational multi center study and to evaluate the levels of and associations between the impacts of patients reported disease outcome (quality of life (QoL), pain, self-estimated health status, health burden).
89418178|NCT03703999||type 1 diabetic patients freestyle Libre|group of type 1 diabetic patients that will be selected to use Freestyle libre on the basis of clinicians decisions and reimbursement criteria
89418179|NCT03701425|Experimental|Mediterranean diet and exercise plan|"Random assignment, through software, to 4 groups of treatment: consume the Mediterranean diet: according to the definition, with the distribution of macronutrients: Protein contribution 0.8-1.2 gram, Carbon Hydrates 45-50% Lipids 30% An exercise plan: The classic exercise program who they will carry out a 5-minute warm-up program with active mobilizations. After that, they will perform intervals of 5 min with resistance to maintain the heart rate prescribed, with active breaks of 1 - 2 min, 4 repetitions. At the end, there will be a return to calm The program of high-intensity anaerobic exercise will consist of a 5-minute warm-up , followed by 5 sets of isokinetic exercise with protocol November 20, rest of 90 s between series. The program will be done 3 times per week for 12 weeks."
89418180|NCT03701425|Experimental|Mediterranean diet|Random assignment, through software, to 4 groups of treatment: consume the Mediterranean diet: according to the definition, with the following distribution of macro nutrients: Protein contribution 0.8-1.2 gram Carbon Hydrates 45-50% Lipids 30%
88896037|NCT02750397||HIV D-/R+|HIV+ recipients who receive an organ transplant from an HIV- donor
88896038|NCT02681211|Experimental|Auricular Acupuncture|If assigned to the auricular acupuncture arm, efficacious ear points will be located by a needle contact test and/or an electrical point finder which emits an acoustic alarm when a change in electrical resistance is detected signifying a potential active auricular acupoint.
88896039|NCT02681211|Active Comparator|Medication and Fluid|"If assigned to receive intravenous medications and fluid the subject will be treated with the ED standard of care medications which include:~Ketorolac 0.5mg/kg, max 30mg~Metoclopramide 0.1 mg/kg, max 10mg~Diphenhydramine 1mg/kg, max 50mg~Normal saline fluid bolus 20mL/kg, max 1000mL"
88896040|NCT02673775|Placebo Comparator|Clean Air|Subjects will be exposed to clean air for 3 hours.
89193802|NCT03780322|Active Comparator|Conventional physical and occupational therapy|This group will receive combined physical and occupational therapy in 45 minute sessions, 3 times a week, for a total of 15 sessions.
88896041|NCT02673775|Experimental|Ozone|Subjects will be exposed to 0.2 ppm ozone for 3 hours.
89418181|NCT03701425|Active Comparator|Only exercise|"An exercise plan: The classic exercise program who they will carry out a 5-minute warm-up program with active mobilizations. After that, they will perform intervals of 5 min with resistance to maintain the heart rate prescribed, with active breaks of 1 - 2 min, 4 repetitions. At the end, there will be a return to calm The program of high-intensity anaerobic exercise will consist of a 5-minute warm-up , followed by 5 sets of isokinetic exercise with protocol November 20, rest of 90 s between series. The program will be done 3 times per week for 12 weeks."
89418182|NCT03701425|Active Comparator|Low standard low fat diet|Random assignment, through software, to 4 groups of treatment: consume the low standard low fat diet: according to the definition, with the following distribution of macro nutrients:Protein contribution 0.8-1.2 Carbon Hydrates 45-50% Lipids 20%
89418183|NCT03566277|Experimental|Single-arm trial|All participants will undergo each of three conditions during the study.
89418184|NCT02181972|Experimental|Gingko biloba|
89418185|NCT02181972|Placebo Comparator|Placebo|
89418186|NCT05708781|Experimental|CSE Group|in addition to Conventional treatment, core strengthening exercise were given
89418187|NCT05708781|Experimental|IDBE Group|in addition to Conventional treatment, intensive dynamic back exercise were given
89418188|NCT05708781|Active Comparator|Control Group|Conventional Treatment
89418189|NCT02187510|Experimental|Umbilical cord milking|Once the preterm is born keep the baby from the mother's thighs. The obstetrician cord milking three times (2seconds/milking) taking the cord from the base 20cm respect towards the baby. Then clamp de cord.
89418190|NCT02187510|Active Comparator|Delayed cord clamping|Once the preterm is born the neonatologist keep the baby beside the mother at level of the operating table during 30 seconds without cord clamping. The baby is covered with a polythene bag and put a cap on his head. Then the obstetritian clamp the cord.
89418191|NCT03697369||Observation group|Individuals with T1D ages 0-20 years who switched management modality from MDI to pump as part of their clinical care and were followed up prospectively in the next 12 months.
89418192|NCT03568695|Other|Detected patients|If they agree to participate in the study, the patients detected for one or the other of the STIs (Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium) on one site, will have on day of result return, two new samples on each of the three sites (pharynx, rectum, urine) which will make it possible to compare the difference of sensitivity between real-time multiplex PCR from pools of 3 samples and the usual technique .
89418193|NCT02183220|Experimental|Metamizol high & Placebo|
89418194|NCT02183220|Experimental|Metamizol low & Placebo|
89418195|NCT02183220|Active Comparator|Acetylsalicylic acid & Placebo|
89418196|NCT02183220|Placebo Comparator|Placebo|
88896042|NCT02666768|Experimental|gamma interferon-1b|Gamma interferon-1b 100 mcg subcutaneous (SC) 3 times weekly for 12 months
88922190|NCT05662280|Experimental|Active intermittent Theta Burst Stimulation|"In a 2x2 factorial double-blind design, researchers will randomize a sample of adolescents with WM deficits to intermittent theta burst stimulation (iTBS) at the left dorsolateral prefrontal cortex (DLPFC) or inferior parietal lobule (IPL), based on each participant's structural brain MRI.~Participants in both arms will complete an active iTBS session and a sham iTBS session. The primary outcome will be theta-gamma coupling during WM demands, as measured via electroencephalography (EEG) during a Sternberg spatial WM task (SWMT) immediately before and after iTBS."
89418197|NCT03701347|Active Comparator|Reeve's model|After introduction of Loop excision electrosurgical procedure through video, participants will undergo Reeve's simulators
89418198|NCT03701347|Active Comparator|Hefler's model|After introduction of Loop excision electrosurgical procedure through video, participants will undergo Hefler's simulators
89418199|NCT03701347|Experimental|Ida's Model|After introduction of Loop excision electrosurgical procedure through video, participants will undergo Ida's simulators
89418200|NCT03566121|Other|Continent women|Women with ICI-Q=0 Pelvic ultrasound / Urodynamic ultrasound
89418201|NCT03566121|Experimental|Incontinent women|Women with ICI-Q≥1 Pelvic ultrasound / Urodynamic ultrasound
89418202|NCT02190084|Active Comparator|transcranial magnetic stimulator|Neurostar repetitive transcranial magnetic stimulator. The active procedure will stimulate at 120% motor threshold for 4 seconds at a frequency of 10 Hz, with an inter-train interval of 26 seconds for a total of 3,000 pulses. 20 treatment sessions are given over a four week period.
89418203|NCT02190084|Sham Comparator|Sham coil treatment|Neurostar repetitive transcranial magnetic stimulator. 20 treatments identical in duration will be administered over a four week period.
89418204|NCT03697291|Experimental|PS wire|self-invented iECG wire
89418205|NCT03697291|Active Comparator|Certodyn|Commercially available iECG system - Certodyn
89418206|NCT03565965|Experimental|Experimental Group (EG)|The Experimental training (ET) consists of 10 sessions with 4 blocks of MP (GMP) intercalated with 4 blocks of gait physical practice (GPP), under single (ST) and dual-task (DT) conditions.
89418207|NCT03565965|Active Comparator|Control Group (CG)|The Control training (CT) consists of 10 sessions with 4 blocks of MP (nGMP) intercalated with 4 blocks of gait physical practice (GPP), under single (ST) and dual-task (DT) conditions.
89418208|NCT03703843|Experimental|Active|ARTUS MONO
89418209|NCT02187588|Experimental|Eschscholtzia Californica - low dose|
89418210|NCT02187588|Experimental|Eschscholtzia Californica - high dose|
89418211|NCT02187588|Active Comparator|Ibuprofen|
89418212|NCT02187588|Placebo Comparator|Placebo|
89418213|NCT03568617|Experimental|rTMS group|
89418214|NCT03697213||General Practitioners|Registered General Practitioners in one of the six participating countries.
89418215|NCT02187666||Lumbar|Patients undergoing lumbar spinal surgery
89418216|NCT02187666||Cervical|Patients undergoing cervical spine surgery
89418217|NCT05364489|Experimental|Bevacizumab combined with Oxaliplatin and TAS-102|Efficacy, safety and exploratory clinical study of Bevacizumab combined with Oxaliplatin and TAS-102 in first-line treatment of advanced colorectal cancer
89193803|NCT03779217||group A|In this group there are women in that the mammography shows a breast represented by 80% of adipose tissue and less than 20% by fibro-glandular tissue.
89418218|NCT02183298|Experimental|BI 1356 BS - single rising dose|
89006475|NCT04624048||University population|Survey to analyze the impact of COVID-19.
89006476|NCT01580605||Users of somatropin|
89193804|NCT03779217||group B|In this group there are women in that the mammography shows a breast represented by adipose tissue in the range of 50-75% and for the rest by fibro-glandular tissue
89193805|NCT03779217||group C|In this group there are women in that the mammography shows a breast represented by adipose tissue in the range 25-50% and the rest is from fibro-glandular tissue.
89193806|NCT03779217||group D|In this group there are women in that the mammography shows a breast represented by almost entirely fibro-ghiandular tissue.
89418219|NCT02183298|Placebo Comparator|Placebo|
89418220|NCT03569943|Experimental|Robotol|
89418221|NCT03697135||Seed Contacts|Initial participants who will invite previous injecting contacts to take a hepatitis C test using a respondent driven sampling method
89418222|NCT03697135||Initial Nominations for Testing|Contacts of initial participants who consent to be tested and enrol in the study using a respondent driven sampling method
89418223|NCT03697135||Second Level Nominations for testing|Contacts of wave one participants who consent to be tested and enrol in the study using a respondent driven sampling method
89418224|NCT02190162|Active Comparator|Tantum Verde® mouthwash|solution of Tantum Verde
89418225|NCT02190162|Placebo Comparator|placebo mouthwash|saline with mint flavor
89006477|NCT04623970|Experimental|Propofol sedation group|Patients in this experimental group received propofol sedation agent.
89006478|NCT04623970|Experimental|Ketofol 1:3 sedation group|Patients in this experimental group received ketofol sedation agent as a 1:3 mixture.
89006479|NCT04623970|Experimental|Ketofol 1:4 sedation group|Patients in this experimental group received ketofol sedation agent as a 1:4 mixture.
89193807|NCT03776552|Active Comparator|Rapid weight loss (RWL) program|16-week rapid weight loss (RWL) program [8-week LED (<1000 kcal/day) - followed by an 8-week gradual increase in energy intake (4 weeks <1300 kcal/day and 4 weeks <1500 kcal/day)] followed by a 36-weight loss maintenance program.
89193808|NCT03776552|Active Comparator|Gradual weight loss (GWL) program|16-week GWL-program (estimated total energy expenditure minus 800-1000 kcal/day) followed by a 36-weight loss maintenance program.
89193809|NCT03760328|Active Comparator|therapeutic stimulation|Therapeutic Stimulation: optimal therapy setting for home use
89418226|NCT03565809||Case : ADRS group|"Incidence analysis in ADRS group defined by the first recording of one of the following criteria: (i) LTD registration for ADRS (ICD-10 codes: F00-F03, G30, or G31), (ii) hospital stay reporting a diagnosis code of ADRS (similar ICD-10 codes) or (iii) reimbursement for at least one acetylcholinesterase inhibitor (rivastigmine, galantamine or donepezil) or memantine."
89418227|NCT03565809||Control : non ADRS Group|Incidence analysis in non ADRS group. Each incident ADRS case was paired (1:1) to a beneficiary without any ADRS criteria, matched on age (same birth year), sex, residence area (based on of the 100 administrative 'départements') and insurance scheme.
88896043|NCT02632708|Experimental|AG-120 with cytarabine and daunorubicin|Daily AG-120 administered orally in combination with standard Induction therapy and consolidation therapy. After 1 cycle of induction therapy, participants may undergo a second induction cycle given as per institutional practice. Participants who achieve an adequate response at the end of induction therapy will go on to receive consolidation therapy (mitoxantrone/etoposide or up to 4 cycles of cytarabine) in combination with AG-120. Participants who complete consolidation therapy and are in complete response (CR) or complete remission with incomplete hematologic recovery (CRi) (including CR with incomplete platelet recovery [CRp]) may continue on maintenance therapy and receive daily treatment with AG-120.
88896044|NCT02632708|Experimental|AG-120 with cytarabine and idarubicin|Daily AG-120 administered orally in combination with standard Induction therapy and consolidation therapy. After 1 cycle of induction therapy, participants may undergo a second induction cycle given as per institutional practice. Participants who achieve an adequate response at the end of induction therapy will go on to receive consolidation therapy (mitoxantrone/etoposide or up to 4 cycles of cytarabine) in combination with AG-120. Participants who complete consolidation therapy and are in CR or CRi (including CRp) may continue on maintenance therapy and receive daily treatment with AG-120.
88896045|NCT02632708|Experimental|AG-221 with cytarabine and daunorubicin|Daily AG-221 administered orally in combination with standard Induction therapy and consolidation therapy. After 1 cycle of induction therapy, participants may undergo a second induction cycle given as per institutional practice. Participants who achieve an adequate response at the end of induction therapy will go on to receive consolidation therapy (mitoxantrone/etoposide or up to 4 cycles of cytarabine) in combination with AG-221. Participants who complete consolidation therapy and are in CR or CRi (including CRp) may continue on maintenance therapy and receive daily treatment with AG-221.
88896046|NCT02632708|Experimental|AG-221 with cytarabine and idarubicin|Daily AG-221 administered orally in combination with standard Induction therapy and consolidation therapy. After 1 cycle of induction therapy, participants may undergo a second induction cycle given as per institutional practice. Participants who achieve an adequate response at the end of induction therapy will go on to receive consolidation therapy (mitoxantrone/etoposide or up to 4 cycles of cytarabine) in combination with AG-221. Participants who complete consolidation therapy and are in CR or CRi (including CRp) may continue on maintenance therapy and receive daily treatment with AG-221.
88896047|NCT02632708|Experimental|AG-221 (starting on Day 8) with cytarabine and daunorubicin|Daily AG-221 administered orally starting on Day 8 of induction cycle 1 in combination with standard Induction therapy and consolidation therapy. After 1 cycle of induction therapy, participants may undergo a second induction cycle given as per institutional practice. Participants who achieve an adequate response at the end of induction therapy will go on to receive consolidation therapy (mitoxantrone/etoposide or up to 4 cycles of cytarabine) in combination with AG-221. Participants who complete consolidation therapy and are in CR or CRi (including CRp) may continue on maintenance therapy and receive daily treatment with AG-221.
89006480|NCT00219947||high risk|Blood draw from individuals known to be or at high risk for HIV-infection
89006481|NCT00219947||diagnosed|Blood draw f rom individuals diagnosed with HIV infection
89006482|NCT04623892|Experimental|TQB2618|TQB2618 administered intravenously (IV) on Day 1 of each 21-day.
89193810|NCT03760328|Sham Comparator|sham stimulation|Sham Stimulation (Control Group): stimulation voltage programmed at 0.1 volts
89418228|NCT03697057||patients|Patients scheduled for elective ambulatory gynaecological surgery, which was performed under standardised general anaesthesia
89006483|NCT00562081|Placebo Comparator|1|Patient does not have 24/7 access to a Certified Asthma Educator.
89006484|NCT00562081|Active Comparator|2|Patient has 24/7 access to a Certified Asthma Educator.
89418229|NCT03697057||healthy volunteers|Female healthy volunteers matched to the patient group regarding the age
89418230|NCT03701191|Experimental|Grpup A (Test group)|Inverted periosteal pedicle flap will be carried out
89418231|NCT03701191|Active Comparator|Group B (Control group)|Coronally advanced flap with subepithelial connective tissue graft
89418232|NCT02183376|Experimental|BI 1356 - healthy subjects|
89418233|NCT02183376|Experimental|BI 1356 - mild liver impairment|
89006485|NCT04623658||Sacrococcygeal teratoma|Fetuses and infants diagnosed with sacrococcygeal teratoma and cared for between 2007 and 2017 in the main Parisian fetal medicine and pediatric surgery units: Necker-Enfants Malades Hospital, Antoine Béclère Hospital, Armand Trousseau Hospital, Robert Debré Hospital and Le Kremlin-Bicêtre Hospital.
89006486|NCT04623619|Experimental|Acetyl L-Carnitine|Acetyl L-Carnitine
89006487|NCT04623619|No Intervention|Standard of care|Standard of care
89006488|NCT00562198|Experimental|1|Investigational drug Stalevo 200
89006489|NCT00220025|Experimental|NBUVB|
89006490|NCT03454594|Experimental|low level laser hemotherapy|Watch laser acupuncture and nasal irradiation
89006491|NCT03454594|No Intervention|control|all the participants in this group did not receive low level laser irradiation during the study period
89006492|NCT04623463|Other|Exercise intervention|Participants included in the present study will benefit from a 4-week physical activity intervention. Upon the initial visit, a physical activity prescription will be defined and they will be equipped with a physical activity monitor that allows feedback. Participants will then exercise one day per week on-site and 4 days/week on their own. Weekly physical activity will be reviewed weekly with the participant during their on-site visit.
89006493|NCT04623814|Experimental|Food effect|HEC113995 20mg will be administered fasted, with regular meal or with high-fat meal for once.
89418234|NCT02183376|Experimental|BI 1356 - moderate liver impairment|
89418235|NCT02183376|Experimental|BI 1356 - severe liver impairment|
89418236|NCT03696979|Active Comparator|myofascial induction|Twice a week for 8 weeks. Lumbar interfacial field stroke application, Lumbar interfacial field to deep application, Lumbar region cross-hands induction technique, Hip flexor region induction.
89418237|NCT03696979|Active Comparator|Therapeutic Pain education|Pain education,twice a week for 8 weeks. The mechanism of pain,Pain processing in the center, How sensitive the central nervous system is in chronic pain, Pain becomes chronic with the contribution of factors, Problems related to fear of pain will be explained in detail.
89418238|NCT03565731|Experimental|ACT-PA Intervention|The primary goal of the intervention is to increase values-based autonomous motivation to increase bout-related MVPA using a single workshop. Participants will engage in basic and advanced values clarification exercise to help clarify (1) the relative importance of major values domains (e.g. social, vocational, recreational), and (2) the potential role of PA in empowering functioning in these domains. Participants will generate their own activity goals and additional values-based goals. In addition, acceptance strategies will be taught to reduce cognitive and emotional barriers to meeting values-based goals. Participants will be asked to report progress on goals each week via an automated email survey from a secure project website. Upon completing the survey, participants will receive standardized responses via email. Monthly phone calls will be brief, semi-structured, and designed to review key principles and trouble-shoot specific barriers identified by the participant.
89418239|NCT02187822|Experimental|Dose Escalation + Dose Expansion|"Dose Escalation followed by Dose Expansion.~Dose Escalation Phase: The maximum tolerated dose (MTD) for TPI 287 given concurrently with Fractionated Stereotactic Radiotherapy (FSRT) will be determined using the standard 3+3 study design.~Dose Expansion Phase: Participants will be treated with TPI 287 at MTD given concurrently with FSRT to further assess toxicity and tumor response."
89418240|NCT03696901||use of Xydalba, >18 years|Male and female patients, ≥18 years of age at the time of receipt of Xydalba. Patients who received at least one Xydalba administration in Germany
89418241|NCT03063034|Active Comparator|PD21864AA, PD21864AB|Subjects will use PD21864AA for 1 week and then PD21864AB for 1 week.
89418242|NCT03063034|Active Comparator|PD21864AB, PD21864AA|Subjects will use PD21864AB for 1 week and then PD21864AA for 1 week.
89006494|NCT04623814|Experimental|Multiple Ascending Doses-HEC113995 10mg|HEC113995 10mg will be administered fasted for 10 days
89006495|NCT04623814|Experimental|Multiple Ascending Doses-HEC113995 20mg|HEC113995 20mg will be administered with food for 10 days
89006496|NCT04623814|Experimental|Multiple Ascending Doses-HEC113995 40mg|HEC113995 40mg will be administered with food for 10 days
89006497|NCT04623814|Placebo Comparator|Multiple Ascending Doses-placebo|Placebo arms will be administered fasted or with food for 10 days
89006498|NCT01580644|Experimental|Period 1: formulation 1 oral solution|
89006499|NCT01580644|Experimental|Period 2: formulation 2 capsule|
89006500|NCT01580644|Experimental|Period 3: Selected formulation + food|
89006501|NCT01580644|Experimental|Period 4: Selected formulation at higher dose|
89006502|NCT04623151|Experimental|Online leaflet in narrative format|
88896048|NCT02632708|Experimental|AG-221 (starting on Day 8) with cytarabine and idarubicin|Daily AG-221 administered orally starting on Day 8 of induction cycle 1 in combination with standard Induction therapy and consolidation therapy. After 1 cycle of induction therapy, participants may undergo a second induction cycle given as per institutional practice. Participants who achieve an adequate response at the end of induction therapy will go on to receive consolidation therapy (mitoxantrone/etoposide or up to 4 cycles of cytarabine) in combination with AG-221. Participants who complete consolidation therapy and are in CR or CRi (including CRp) may continue on maintenance therapy and receive daily treatment with AG-221.
88896049|NCT02617277|Experimental|Dose Schedule A|In Schedule A, patients will receive MEDI4736 (durvalumab) by intravenous on Day 1, and AZD1775 (adavosertib) twice daily orally on Days 1-5 and Days 15-19 of a 28-day cycle. In all dose schedules, dexamethasone will be administered as an anti-emetic on the first day of the AZD1775 (adavosertib).
88896050|NCT02617277|Experimental|Dose Schedule B|In Schedule B, patients will receive MEDI4736 (durvalumab) by intravenous on Day 1, and AZD1775 (adavosertib) twice daily orally on Days 15-17 and Days 22-24 of a 28-day cycle. In Schedule B there will be a 7-day AZD1775 (adavosertib) lead-in to enable serial PK measurements prior to initiating MEDI4736 on Day 1. In all dose schedules, dexamethasone will be administered as an anti-emetic on the first day of the AZD1775 (adavosertib) consecutive dosing day blocks including the lead-in portion of Schedules B, C, and D. Additional alternative dose levels and/or schedules may also be explored if emerging data suggest these would be more appropriate.
88896051|NCT02617277|Experimental|Dose Schedule C|In Schedule C, patients will receive MEDI4736 (durvalumab) by intravenous on Day 1, and AZD1775 (adavosertib) twice daily orally on Days 8-10, Days 15-17, and Days 22-24 of a 28-day cycle. In Schedule C there will be a 7-day AZD1775 (adavosertib) lead-in to enable serial PK measurements prior to initiating MEDI4736 (durvalumab) on Day 1. In all dose schedules, dexamethasone will be administered as an anti-emetic on the first day of the AZD1775 (adavosertib) consecutive dosing day blocks including the lead-in portion of Schedules B, C, and D. Additional alternative dose levels and/or schedules may also be explored if emerging data suggest these would be more appropriate.
88896052|NCT02617277|Experimental|Dose Schedule D|In Schedule D, patients will receive MEDI4736 (durvalumab) by intravenous on Day 1, and AZD1775 (adavosertib) one time per day orally on Days 15-19, and Days 22-26 of a 28-day cycle. In Schedule D there will be a 9-day lead-in period with AZD1775 (adavosertib) being dosed on Days -9 to -5 to enable serial PK measurements prior to initiating MEDI4736 (durvalumab) on Day 1. In all dose schedules, dexamethasone will be administered as an anti-emetic on the first day of the AZD1775 (adavosertib) consecutive dosing day blocks including the lead-in portion of Schedules B, C, and D. Additional alternative dose levels and/or schedules may also be explored if emerging data suggest these would be more appropriate.
88896053|NCT02611570||Non-smokers at risk for lung cancer|"Non-smoking subjects with lung cancer family history~Non-smoking subjects with a given lung cancer risk other than lung cancer family history"
88896054|NCT02548546|Active Comparator|Surveillance|No Surgery with ECHO and ECG-gated MRA imaging.
88896055|NCT02548546|Active Comparator|Surgery-Open|Open Surgery with ECHO and ECG-gated MRA imaging.
89193811|NCT03758118|Active Comparator|NAION patients OS-Citicoline treated|In a group of patients with NAION, OS-Citicoline will be administered (500 mg/day) for 6 months followed by three months of suspension
88896056|NCT02548546|Active Comparator|Surgery-EVAR|EVAR with ECHO and ECG-gated MRA imaging.
88896057|NCT02489617|Experimental|Pathologic evaluation of excised tissue|"Patient diagnosed with intraductal papilloma without atypia (IPWA) or flat epithelial atypia (FEA).~-- Pathologic evaluation of excised tissue"
88896058|NCT02471144|Experimental|Secukinumab low dose|Secukinumab
88896059|NCT02471144|Experimental|Secukinumab high dose|Secukinumab
88896060|NCT02471144|Placebo Comparator|Placebo|Placebo
88896061|NCT02471144|Active Comparator|Etanercept Comparator|Etanercept
89193812|NCT03758118|No Intervention|NAION patients untreated|In one group of patients with NAION no type of treatment will be performed during 9 months of observation
89006503|NCT04623151|Active Comparator|Online leaflet in non-narrative format|
89193813|NCT03740490|Experimental|Smart-T + NRT|Smart-T provides content during the pre-quit and post-quit periods to prepare and support participants during their quit attempt. The Smart-T app contains multiple components including an EMA delivery and data transfer system, automated messages based upon EMA responses, and on-demand content. All participants will receive free nicotine replacement therapy (NRT).
89193814|NCT03740490|Active Comparator|NCI QuitGuide + NRT|The National Cancer Institute's QuitGuide app is a free smartphone app and is one of few apps that includes many of the recommendations detailed in the Clinical Practice Guideline. The QuitGuide app aims to help smokers understand their smoking patterns and develop the skills needed to quit smoking. QuitGuide provides content during the pre-quit and post-quit periods to prepare and support participants during their quit attempt. All participants will receive free nicotine replacement therapy (NRT).
89193815|NCT03734237|Active Comparator|Egg based influenza vaccines|Quadrivalent egg-based vaccines, which contain an inactivated form of the virus. Vaccines will be given to the participant in accordance with standard clinical practices for those in the US military. All egg-based vaccines are FDA licensed for use in the United States.
89418243|NCT03565653|Experimental|High dietary salt|For 10 days each, participants will be asked to eat a recommended sodium diets (2300 mg Na+/d) while taking unmarked pills containing uniodized table salt. On the 10th day, participants will report to the lab to complete 60 minutes of cycling exercise. Following exercise, participants will rest for 60 minutes while undergoing serial blood pressure measurements. Participants will then be outfitted with ambulatory blood pressure cuffs for assessment of blood pressure over the following 24 hours.
88896062|NCT02448420|Experimental|Arm A: HER2-positive/Hormone receptor-negative (Recruitment Closed)|"Patients with hormone receptor-negative, HER2 positive breast cancer, who received trastuzumab + palbociclib.~Palbociclib: oral, 200 mg/day for 2 weeks, followed by 1 week off. Trastuzumab: intravenous trastuzumab loading dose of 8mg/kg followed by 6 mg/kg once every 3 weeks; or subcutaneous trastuzumab 600mg every 3 weeks."
88896063|NCT02448420|Experimental|Arm B1: HER2+/Hormone receptor-positive (Recruitment Closed)|"Patients with hormone receptor-positive, HER2 positive breast cancer, who received trastuzumab + palbociclib.~Palbociclib: oral, 200 mg/day for 2 weeks, followed by 1 week off. Trastuzumab: intravenous trastuzumab loading dose of 8mg/kg followed by 6 mg/kg once every 3 weeks; or subcutaneous trastuzumab 600mg every 3 weeks."
89418244|NCT03565653|Experimental|Placebo|For 10 days each, participants will be asked to eat a recommended sodium diets (2300 mg Na+/d) while taking unmarked pills containing a placebo (dextrose). Participants will complete both interventions in random order. On the 10th day, participants will report to the lab to complete 60 minutes of cycling exercise. Following exercise, participants will rest for 60 minutes while undergoing serial blood pressure measurements. Participants will then be outfitted with ambulatory blood pressure cuffs for assessment of blood pressure over the following 24 hours.
89418245|NCT02187900|Experimental|TWH for the treatment of IgAN|Interventions :The dosage of 40 mg of Multi-glycoside of Tripterygium Wilfordii HOOK. f. was divided into 2 equal doses at 12-hour intervals for 6 months.
89418246|NCT02187900|Active Comparator|MMF for IgAN|MMF for the treatment of IgAN for 6 months
89418247|NCT03062644|Experimental|MR308 100 mg bid|Tramadol/Celecoxib)
89418248|NCT03062644|Experimental|MR308 150 mg bid|Tramadol/Celecoxib
89418249|NCT03062644|Experimental|MR308 200 mg bid|Tramadol/Celecoxib
89418250|NCT03062644|Active Comparator|Tramadol 100 mg qid|Tramadol
89418251|NCT03062644|Active Comparator|Celecoxib 100 mg bid|Celecoxib
89418252|NCT03062644|Placebo Comparator|Placebo|Placebo
89418253|NCT04749355|Experimental|BST-236|BST-236 Intravenous, 4.5 g/m^2/d or 2.3 g/m^2/d, for 6 days
89418254|NCT02190318|Experimental|Losartan|Losartan is taken orally 100mg/d
89418255|NCT02190318|Experimental|spirolactone|spirolactone is taken orally 20mg/d
89418256|NCT02190318|Experimental|losartan in combination with spirolactone|Losartan is taken orally 100mg/d and spirolactone is taken orally 20mg/d
89418257|NCT02190318|Sham Comparator|blank control|patients with antihypertensives besides ACEI/ARBs and spirolactone.
89418258|NCT02246361|No Intervention|Phase 1 (without PIL)|No particular intervention during consultation for the patient
89418259|NCT02246361|Experimental|Phase 2|Patient Information Leaflet is given to the patient during the consultation
89418260|NCT03701113|Active Comparator|Milk-based protein matrix (MBPM)|Intervention: Dietary Supplement : Test Product Intervention: Diagnostic Test : Aerial Bone Mineral Density (BMD) Intervention: Diagnostic Test : Bone Turnover Composition of Test Product - 25g of milk-based proteins + 1000mg dairy-based calcium fortified with 40ug Vit D flavoured and textured supplied food grade and product tested by Dairygold Co-operative Society, Mitchelstown, Ireland.
89418261|NCT03701113|Other|CONTROL|Intervention: Habitual dietary behaviour Intervention: Diagnostic Test : Aerial Bone Mineral Density (BMD) Intervention: Diagnostic Test : Bone Turnover
89418262|NCT03062722|Experimental|keyhole approach|open minimally invasive approach
89418263|NCT03703687|Experimental|Gratitude intervention|"The intervention will be proposed to both the patient and the caregiver and consists of two steps: the gratitude letter and the gratitude visit. In the gratitude letter, the individual writes about his feelings of gratitude through a letter, based on a written instruction. The gratitude visit consists of an extension of the gratitude letter where the writer of the letter (i) either personally reads the letter to the beneficent or (ii) gives it to him and asks him to read it in his presence or later in his absence."
89418264|NCT03503968|Experimental|Phase I - 3 disease entities|MDG1011 administration of escalating doses
89418265|NCT03503968|Experimental|Phase II - HLA*02:01 - disease entity 1|MDG1011 administration of Phase II recommended dose
89418266|NCT03503968|Active Comparator|Phase II - HLA*other - disease entity 1|Investigator Choice therapy
89418267|NCT03503968|Experimental|Phase II - HLA*02:01 - disease entity 2|MDG1011 administration of Phase II recommended dose
89418268|NCT03503968|Active Comparator|Phase II - HLA*other - disease entity 2|Investigator Choice therapy
89418269|NCT02246829|Other|Aflibercept 2mg Intravitreal injection|2 mg intravitreal Aflibercept initiated with one injection every 4 weeks for three consecutive doses (loading dose) The duration of the follow-up is 12 weeks. This means 3 injections per patient should be given over the study period
89418270|NCT02190396||Group 1|Placental calcification of Grade 3
89418271|NCT02190396||Group 2|No placental calcification noted, the control group.
89006504|NCT04623151|No Intervention|No leaflet (control)|
89193816|NCT03734237|Active Comparator|Recombinant influenza vaccines|FluBlok, recombinant HA influenza vaccine. Vaccines will be given to the participant in accordance with standard clinical practices for those in the US military. Flublok Quadrivalent is a quadrivalent recombinant influenza vaccine that has been licensed by the FDA for use in the United States.
89418272|NCT02183532|Experimental|BI 1356 BS|
89418273|NCT03536442||Intervention (CBT)|"As there is only one arm in this trial, this will be described in intervention."
89418274|NCT03569787||Patients with hyperprolactinaemia|Patients undergoing subfertility studies with at least one high prolactin reading (>500mU/L).
89418275|NCT04741477|Experimental|Topical CBD Product with low level of THC|Participants will topically apply a high CBD-product that also contains low levels of THC.
89418276|NCT04741477|Placebo Comparator|Placebo topical product|Participants will topically apply a placebo product that does not contain cannabinoids.
89418277|NCT03569709|Active Comparator|Aerobic Exercise|Sub-threshold aerobic exercise.
89418278|NCT03569709|Placebo Comparator|Stretching|Stretching program that will not raise heart rate.
89418279|NCT03569709|Placebo Comparator|Rest|Relative rest. Avoid all structured exercise.
89006505|NCT04623073||Patients who underwent DAA THA|Patients who underwent DAA THA by a single surgeon who routinely documents the distance from the should of the stem to the upper end of the EO footprint
89006506|NCT04623307||Brain damage patients|Brain damage patients were monitored the human brain activity by the non-contact DCS-Speckle multi-parameter imager.
89006507|NCT04623307||Brain edema patients|Brain edema patients were monitored the human brain activity by the non-contact DCS-Speckle multi-parameter imager.
89006508|NCT04623307||Healthy subjects|Healthy subjects were monitored the human brain activity by the non-contact DCS-Speckle multi-parameter imager.
89006509|NCT00562237|Placebo Comparator|1|
89006510|NCT00562237|Experimental|2|
89006511|NCT00562237|Experimental|3|
89006512|NCT00562237|Experimental|4|
89006513|NCT00562237|Experimental|5|
89006514|NCT00562237|Experimental|6|
89006515|NCT00562237|Experimental|7|
89006516|NCT00562276|Experimental|1|Immediate IUD insertion following suction aspiration between 5 and 12 weeks gestation
89006517|NCT00562276|No Intervention|2|Delayed IUD insertion 2-6 weeks following suction aspiration between 5 and 12 weeks gestation
89006518|NCT01580683|Experimental|Ascorbic acid|
89006519|NCT01580683|Placebo Comparator|Placebo|
89006520|NCT04623229|Experimental|MCS|
89006521|NCT04623229|Experimental|ReLACS Early|
89006522|NCT04623229|Experimental|ReLACS Standard|
89006523|NCT04623112|Other|FC Deactivated|Frequency Compression feature on hearing aids is deactivated for 4 weeks
89006524|NCT04623112|Experimental|FC activated & set to default|Frequency compression feature activated on hearing aids and set to default software settings for 4 weeks.
89006525|NCT04623112|Experimental|FC activated and set to hearing loss|Frequency Compression feature activated on hearing aids and set to hearing loss cut-off for 4 weeks
89006526|NCT04623385|Active Comparator|Aerosolized 13 cis retinoic acid plus Inhalation Inhaled testosterone|"The infected patients will receive Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days~The infected patients will be treated with a single dose of testosterone (0.1, 0.2, or 0.3 mg) by inhalation for 14 days"
89006527|NCT04623385|Sham Comparator|The standard therapy|infected patients will receive the standard therapy for COVID-19 for 14 days
89418280|NCT03569631|Experimental|BPN14770|25mg BPN14770 capsules, one capsule taken twice daily for 12 weeks
89006528|NCT04623346||Weber B-type Ankle fractures in prepandemic period|Patients with AO Weber B-type ankle fracture in prepandemic period
89006529|NCT04623346||Weber B-type Ankle fractures in pandemic period|Patients with AO Weber B-type ankle fracture in pandemic period
89006530|NCT04623346||Wrist fractures in prepandemic period|Patients with extraarticular distal radius fracture in prepandemic period
89006531|NCT04623346||Wrist fractures in pandemic period|Patients with extraarticular distal radius fracture in pandemic period
89006532|NCT04623346||Proximal humerus fractures in prepandemic period|Patients with 2-part,3-part and 4-part fractures in prepandemic period
89006533|NCT04623346||Proximal humerus fractures in pandemic period|Patients with 2-part,3-part and 4-part fractures in pandemic period
89006534|NCT04623034|Experimental|400 mg MSI-195 - SAD|400 mg MSI-195 (within Stage 1, single ascending dose)
89006535|NCT04623034|Experimental|800 mg MSI-195 - SAD|800 mg MSI-195 (within Stage 1, single ascending dose)
89418281|NCT03569631|Placebo Comparator|Placebo|Matching placebo capsules, one capsule taken twice daily for 12 weeks
89006536|NCT04623034|Experimental|1600 mg MSI-195 -SAD|1600 mg MSI-195 (within Stage 1, single ascending dose)
89006537|NCT04623034|Experimental|800 mg MSI-195 - fasted|800 mg MSI-195 fed (within Stage 2, cross-over comparison)
89006538|NCT04623034|Experimental|1600 mg SAM-e Complete TM - fasted|1600 mg SAM-e Complete (within Stage 2, cross-over comparison)
89193817|NCT03734237|Active Comparator|Cell-culture based influenza vaccines|Flucelvax, Madin-Darby canine kidney (MDCK)-cell-culture based inactivated influenza vaccine. Vaccines will be given to the participant in accordance with standard clinical practices for those in the US military. Flucelvax quadrivalent, the only cell-based flu vaccine FDA licensed for use in the United States.
89193818|NCT03733990|Experimental|FP-1305 (bexmarilimab) 0.3 mg/kg|Part I, Dose-escalation FP-1305 0.3 mg/kg is administered in Q3W intervals
89006539|NCT04623034|Experimental|800 mg MSI-195 - fed|800 mg MSI-195- fed (within Stage 2, fed arm)
89006540|NCT04622800|Other|Individuals applied with proprioceptive neuromuscular fasilition techniques|No exercise intervention was made.
89006541|NCT04622878|Other|acute lower limb ischemia patients|patients with no palpable pulsations or audible signals in the lower limb
89006542|NCT04622956|Experimental|Experimental|GVHD prophylaxis will consist of high-dose PTCy (50 mg/kg i.v. on days +3 and +4) with mesna, cyclosporine (initiated on day +5) and methotrexate i.v (see doses on the right). Cyclosporine will be dosed with a target trough of 200 to 250 ng/mL and discontinued without taper at D+60 (if bone marrow graft) or until D+90 (is peripheral blood graft), unless acute GVHD is present. Filgrastim will be administered from day +5 until neutrophil recovery to ≥ 1,000/mcL for 3 days.
89006543|NCT04622956|No Intervention|Control Group|GVHD prophylaxis will consist of high-dose PTCy (50 mg/kg i.v. on days +3 and +4) with mesna, cyclosporine (initiated on day +5) and mycophenolate mofetil (15 mg/kg/dose p.o. t.i.d. initiated on day +5). Cyclosporine will be dosed with a target trough of 200 to 250 ng/mL and discontinued without taper at D+60 (if bone marrow graft) or until D+90 (is peripheral blood graft), unless acute GVHD is present.
89006544|NCT00242892|Experimental|1|Intra coronary measures of pressure
89006545|NCT04622566|Experimental|Lenvatinib and Pembrolizumab in Resectable mucosal Melanoma.|
89006546|NCT04622488|Active Comparator|Diclofenac Potassium|In the form of insitu gel can be applied as solution or suspension that undergoes gelation after administration.
89006547|NCT04622488|Experimental|Calcium Hydroxide|
89006548|NCT00220298|Experimental|Arm 1|
89006549|NCT04622761|No Intervention|control|Immediate surgery (radical prostatectomy) (standard care)
89193819|NCT03733990|Experimental|FP-1305 (bexmarilimab) 1 mg/kg|Part I and II, Dose-escalation FP-1305 1 mg/kg is administered in Q3W, Q2W or Q1W intervals
89193820|NCT03733990|Experimental|FP-1305 (bexmarilimab) 3 mg/kg|Part I and II, Dose-escalation FP-1305 3 mg/kg is administered in Q3W, Q2W or Q1W intervals
88896064|NCT02448420|Experimental|Arm B2:HER+/HR+: trastuzumab + palbociclib +letrozole (Recruitment Closed)|"Patients with hormone receptor-positive, HER2 positive breast cancer, who received trastuzumab + palbociclib + letrozole Palbociclib: oral, 200 mg/day for 2 weeks, followed by 1 week off. Trastuzumab: intravenous trastuzumab loading dose of 8mg/kg followed by 6 mg/kg once every 3 weeks; or subcutaneous trastuzumab 600mg every 3 weeks.~Letrozole: daily oral dose of 2.5 mg."
88896065|NCT02448420|Experimental|Arm C1: Palbociclib, trastuzumab and endocrine therapy|"HR-positive, HER2 positive, Luminal intrinsic subtype determined by PAM50 who will receive trastuzumab + palbociclib + endocrine therapy~Trastuzumab: intravenous trastuzumab loading dose of 8mg/kg followed by 6 mg/kg once every 3 weeks; or subcutaneous trastuzumab 600mg every 3 weeks.~Palbociclib: oral, 125 mg/d for 3 weeks, followed by one week off, in 4-week cycles.~Endocrine therapy: either an Aromatase Inhibitor, Fulvestrant, or Tamoxifen."
88896066|NCT02448420|Active Comparator|Arm C2: Treatment based of physician's choice|HR-positive, HER2 positive, Luminal intrinsic subtype determined by PAM50 who will receive treatment based on physician's choice from the following options: TDM1 or chemotherapy (gemcitabine, vinorelbine, capecitabine, eribulin or a taxane) in combination with trastuzumab or endocrine therapy (Aromatase Inhibitor, Fulvestrant or Tamoxifen) in combination with trastuzumab.
88896067|NCT02438306|Experimental|CardiAMP cell therapy|Placement of an introducer guidewire, performance of a left ventriculogram, and treatment with autologous cell therapy.
88896068|NCT02438306|Sham Comparator|Sham Comparator|Placement of an introducer guidewire and performance of a left ventriculogram with no autologous cell therapy treatment.
88896069|NCT02420002|Active Comparator|Usual care (MEOPA)|"Patients randomized to this arm will receive usual care, including MEOPA inhalation during local anesthetic injection and suturing.~Intervention: Use of MEOPA during suturing Intervention: Stitch removal"
88896070|NCT02420002|Experimental|Experimental arm (Hypnosis)|"Patients randomized to this arm will receive usual care as in the other arm, but before MEOPA inhalation is started, hypnosis will be tried. The local anesthetic injection and suturing will therefore take place under hypnosis (and MEOPA if necessary).~Intervention: Use of Hypnosis during suturing Intervention: Stitch removal"
88896071|NCT02408471|Other|Ascension® MCP Finger Implant|Single arm study, patient treated with Ascension® PyroCarbon MCP implant.
88896072|NCT02403674|Experimental|Doravirine, Tenofovir, Lamivudine|Treatment-naive HIV-infected participants will receive doravirine, tenofovir, lamivudine, a single-tablet FDC containing doravirine 100 mg + lamivudine 300 mg + tenofovir disoproxil fumarate 300 mg, q.d. by mouth for 96 weeks. Participants will also take 1 placebo tablet matched to ATRIPLA™ q.d. by mouth for 96 weeks in order to maintain blinding.
88896073|NCT02403674|Active Comparator|ATRIPLA™|Treatment-naive HIV-infected participants will receive ATRIPLA™, a single-tablet FDC containing efavirenz 600 mg + emtricitabine 200 mg + tenofovir disoproxil fumarate 300 mg (equivalent to 245 mg tenofovir disoproxil), q.d. by mouth for 96 weeks. Participants will also take 1 placebo tablet matched to doravirine, tenofovir, lamivudine q.d. by mouth for 96 weeks in order to maintain blinding.
88896074|NCT02375802|Experimental|Experimental|Liposuction will be done to extract 50-100 cc of adipose tissue which will be processed to obtain the stromal cells. The adipose-derived stromal cells will be injected into a fibrin sealant applicator and applied to the wound (intervention), Patients will receive 5.0x106 ASCs per cubic centimeter of wound area. The wound will be dressed with an occlusive dressing and soft silicone dressing. The dressing will remain in place for one week (minimally, 3 days). Follow-up will occur weekly for 6 weeks.
88896075|NCT02354781|Experimental|Experimental|The vector will be delivered to both limbs via multiple, direct intramuscular injections of rAAV1.CMV.huFollistin344; the number of injections per muscle will depend on the size of the patient. A total dose of 2.4E12 vg/kg (1.2E12vg/kg/limb) will be delivered to the lower limbs of 6 DMD subjects
89193821|NCT03733990|Experimental|FP-1305 (bexmarilimab) 10 mg/kg|Part I and II, Dose-escalation FP-1305 10 mg/kg is administered in Q3W, Q2W or Q1W intervals
88896076|NCT02352948|Experimental|MEDI4736 (durvalumab) monotherapy in Sub-study A|MEDI4736 (durvalumab) by intravenous infusion. Sub-study A for patients with PD-L1 positive tumors.
88896077|NCT02352948|Active Comparator|Standard of Care in Sub-study A|Investigator choice from Vinorelbine, Gemcitabine and Erlotinib. Sub-study A for patients with PD-L1 positive tumors.
89193822|NCT03733990|Experimental|FP-1305 (bexmarilimab) 0.1 mg/kg|Part I Dose-escalation FP-1305 0.1 mg/kg is administered in three-week intervals
89193823|NCT03733990|Experimental|FP-1305 (bexmarilimab) 30 mg/kg|Part II Dose-escalation FP-1305 30 mg/kg is administered in Q3W, Q2W or Q1W intervals
89418282|NCT03696745|Placebo Comparator|Placebo|preterm infants with severe hypoxic ischemic encephalopathy receive only 0.9% Sodium-chloride
89418283|NCT03696745|Experimental|infusion|preterm infants with severe hypoxic ischemic encephalopathy will receive up to 4 infusions of their own volume reduced cord blood stem cells. The number of doses will be determined by the amount of available cord blood stem cells. The dose for each infusion is 5x107 cells/kg
88896078|NCT02352948|Experimental|MEDI4736 (durvalumab) + tremelimumab in Sub-study B|MEDI4736 (durvalumab) by intravenous infusion and tremelimumab by intravenous infusion. Sub-study B for patients with PD-L1 negative tumors.
88896079|NCT02352948|Active Comparator|Standard of Care in Sub-study B|Investigator choice from Vinorelbine, Gemcitabine and Erlotinib. Sub-study B for patients with PD-L1 negative tumors.
89193824|NCT03729765|Experimental|hemoperfusion|The patients in the simultaneous hemoperfusion arm will receive hemoperfusion when extracorporeal membrane oxygenation (ECMO) is commenced. veno-arterial extracorporeal membrane oxygenation (VA-ECMO) patients treat with hemoperfusion three times in a row，each time for 6 hours.
89193825|NCT03729765|No Intervention|standard care|The patients in the standard care arm will not receive hemoperfusion when lextracorporeal membrane oxygenation (ECMO) is commenced.
89193826|NCT03693872|Other|Apomorphine|Withdrawal of dopaminergic agonists at pump initiation
89193827|NCT03693872|Other|Dopaminergic Agonist + Apomorphine|Continuation of dopaminergic agonists at pump initiation
89193828|NCT03686696|No Intervention|No Beta blocker and no ACEI/ARB|No Beta blocker and no ACEI/ARB
88896080|NCT02352948|Experimental|MEDI4736 (durvalumab) monotherapy in Sub-study B|MEDI4736 (durvalumab) by intravenous infusion. Sub-study B for patients with PD-L1 negative tumors.
88896081|NCT02352948|Experimental|tremelimumab in Sub-study B|tremelimumab by intravenous infusion. Sub-study B for patients with PD-L1 negative tumors.
88896082|NCT02337452||Observational (family outreach program)|Patients communicate with at-risk family members to share genetic test results and other relevant information, as well as to learn more about their disease via family outreach program website. At risk family members are then contacted by a study coordinator or genetic counselor for further follow up. At-risk relatives receive resources to facilitate understanding of their at-risk status and to facilitate predictive testing.
88896083|NCT02331914||Gastro-intestinal stromal tumors|"A bio-databank consisting of TKI drug level and serum for analysis of mutations in circulating tumor DNA will be set up. This bio-databank will be used to study whether changes in the amount of the primary KIT mutation is an early predictor of treatment response and/of failure. Moreover, secondary TKI resistant mutations in circulating tumor DNA will be assessed.~To be able to assess those mutations, a tumor biopsy will be performed at the time of radiologic progressive disease. Vena puncture for blood collection will be performed at routine out patient visits."
88896084|NCT02315326|Experimental|Arm A: Participants with refractory/recurrent PCNSL or refractory/recurrent SCNSL|This is an open-label, non-randomized, single center, dose escalation, phase I/II study to establish the maximum-tolerated dose (MTD) of ibrutinib as a single agent in patients with refractory/recurrent PCNSL or refractory/recurrent SCNSL (Arm A).
88896085|NCT02315326|Experimental|Arm B: Participants with refractory/recurrent PCNSL or refractory/recurrent SCNSL|The defined MTD from Arm A will then be used in an expansion cohort to further assess toxicity and clinical activity
88896086|NCT02315326|Experimental|Arm C: Participants with refractory/recurrent PCNSL or refractory/recurrent SCNSL|Arm C will investigate the MTD of ibrutinib in combination with HD-MTX and to determine the safety and tolerability of the ibrutinib/HD-MTX combination regimen in PCNSL and SCNSL patients. To minimize drug-drug interaction between HD-MTX and Ibrutinib, Ibrutinib will not be administered concurrently with HD-MTX.
88896087|NCT02315326|Experimental|Arm D: Participants with refractory/recurrent PCNSL or refractory/recurrent SCNSL|THIS IS ONLY ARM RECRUITING In Arm D, patients will be treated with 4 cycles of therapy. Methotrexate (3.5 g/m2) will be given at Dday 1 and Dday 15 of each cycle. Rituximab (500 mg/m2) will be given at Dday 0 and Dday 15 of each cycle. Vincristine (1.4mg/m2) will be given at Dday 1 and 15 of cycle 1 and 2 only. Procarbazine (100mg/m2) will be given of Day 1 of each cycle. Ibrutinib will be dosed at 560 mg daily. Arm D will have a safety lead-in of 6 patients. If more than 1 of 6 subjects develop a dose limiting toxicity (DLT) within the first 28 days of therapy (cycle 1), ibrutinib will be reduced to 420 mg daily dosing, and 6 additional patients will be enrolled. If more than 1 of 6 subjects develop a DLT, additional enrollment will be stopped.
88896088|NCT02303431|Experimental|Cohort 1a|12 to < 18 years of age: edoxaban low dose group
88896089|NCT02303431|Experimental|Cohort 1b|12 to < 18 years of age: edoxaban high dose group
88896090|NCT02303431|Experimental|Cohort 2a|6 to < 12 years of age: edoxaban low dose group
88896091|NCT02303431|Experimental|Cohort 2b|6 to < 12 years of age: edoxaban high dose group
88896092|NCT02303431|Experimental|Cohort 3a|2 to < 6 years of age: edoxaban low dose group
88896093|NCT02303431|Experimental|Cohort 3b|2 to < 6 years of age: edoxaban high dose group
88896094|NCT02303431|Experimental|Cohort 4a|6 months to <2 years of age: edoxaban low dose group
88896095|NCT02303431|Experimental|Cohort 4b|6 months to <2 years of age: edoxaban high dose group
88896096|NCT02303431|Experimental|Cohort 5a|0 to 6 months of age: edoxaban low dose group
88896097|NCT02303431|Experimental|Cohort 5b|0 to 6 months: edoxaban high dose group
88896098|NCT02248597|Experimental|Treatment (stem cell transplant with GVHD prophylaxis)|"PREPARATIVE REGIMEN: Patients receive fludarabine phosphate IV QD on days -6 to -2. Patients receiving myeloablative conditioning receive busulfan IV every 6 hours for 16 doses on days -7 to -4 and patients receiving reduced intensity conditioning receive busulfan IV every 6 hours for 8 doses on days -5 to -4. Patients also receive cyclophosphamide IV QD on days -3 and -2~TRANSPLANT: Patients undergo stem cell transplant on day 0.~GVHD PROPHYLAXIS: Patients receive cyclophosphamide QD on days 3 and 4, tacrolimus on days 5-180, and mycophenolate mofetil on days 5-35. Allogeneic hematopoietic stem cell transplantation"
89193829|NCT03686696|Experimental|Beta blocker and ACEI/ARB|Beta blocker and either ACE inhibitor or Angiotensin receptor blocker
88896099|NCT02227823|Experimental|significant decrement|Patients with significant decrement at electromyogram will be treated by pyridostigmine bromide 60mg 3 times a day for patients older than 18 and 1.5mg/kg 3 times a day for children less than 40kg
88896100|NCT02227823|No Intervention|no decrement|Patient without significant decrement will not receive any treatment and will be the control group
88896101|NCT02129543||Arm A: Treatment for Malignancy/Failure Group|Participants in this group will be those who are undergoing treatment for hematologic malignancy or bone marrow failure state.
89193830|NCT03686696|Experimental|Beta blocker alone|Beta blocker alone
89193831|NCT03686696|Experimental|ACEI/ARB alone|Either ACE inhibitor or Angiotensin receptor blocker alone
89193832|NCT03679650|Experimental|AML Patient who are undergoing allogeneic transplantation|"Patients will be vaccinated with DC/AML fusion cells~Four days of GM-CSF given subcutaneously at the site of vaccination~Patients will receive 2 vaccines, 3 weeks apart, with the potential for a booster vaccine~Patients will be treated with 5 days of decitabine in the post-transplant setting"
89193833|NCT03679650|Experimental|AML Patient who are undergoing transplantation|"Patients will be vaccinated with DC/AML fusion cells~Four days of GM-CSF given subcutaneously at the site of vaccination~Patients will receive 2 vaccines, 3 weeks apart, with the potential for a booster vaccine"
89418284|NCT03568227|Experimental|Healthy Subjects|"The study has a 2 (Intervention: Hypnosis, Control) x 2 (State: 1 & 2) factorial within-subjects design, resulting in a total of 4 conditions. All volunteers participate at the 4 conditions in the same session.The order of the interventions is counterbalanced resulting in two possible sequences:~Sequence 1: Hypnosis State 1, Hypnosis State 2, Control State 1, Control State 2~Sequence 2: Control State 1, Control State2, Hypnosis State 1, Hypnosis State 2~Volunteers will be randomly allocated to the two sequence types."
89418285|NCT03700957|Experimental|Docosahexaenoic Acid Group|participants will recieve 100 milligrams of Docosahexaenoic Acid per day for 14 days
89418286|NCT03700957|Placebo Comparator|Control Group|participants will recieve placebo
89418287|NCT03565419|No Intervention|Control|Participants conduct the ultrasound-guided peripheral cannulation while they confirm real-time images displayed on the viewer next to the phantom.
89418288|NCT03565419|Experimental|Intervention|Participants conduct the ultrasound-guided peripheral cannulation wearing smart glasses. They confirm real-time images displayed on the viewer of smart glasses.
88896102|NCT02129543||Arm B: Standard-of-Care SCT Group|Participants in this group will be cancer participants being treated with standard of care stem cell therapy
88896103|NCT02129543||Arm C: Adoptive T Cell Therapy Group|Participants in this group will be participants being treated with adoptive T cell therapy.
88896104|NCT02129543||Arm D: Control Group|Participants without cancer for studies of immunophenotype and immunologic function.
88896105|NCT02125461|Experimental|MEDI4736|MEDI4736 (intravenous infusion)
88896106|NCT02125461|Placebo Comparator|PLACEBO|Placebo (matching placebo for intravenous infusion)
88896107|NCT02102529||bowel endometriosis|laparoscopic colonic resection
88896108|NCT02096042|Experimental|Brentuximab Vedotin|Pilot Phase: Starting dose of Brentuximab Vedotin 1.2 mg/kg intravenous (IV) infusion over approximately 30 minutes on days 1, 8, and 15 of each 28-day cycle (+/- 3 days).
89418289|NCT03568149||Group A: endometriosis|assessment of pain symptoms at first medical examination; assessment of pelvic vascular insufficiency signs.
89418290|NCT03568149||Group B: no endometriosis|assessment of pain symptoms at first medical examination; assessment of pelvic vascular insufficiency signs.
89418291|NCT03568071|Experimental|Cohort A - dose regimen A|MOR106 will be administered as IV infusion. Subjects will receive repeated doses of MOR106 over a 12-week treatment period. A loading dose (dose regimen A) will be administered on Day 1.
89418292|NCT03568071|Experimental|Cohort B - dose regimen B|MOR106 will be administered as IV infusion. Subjects will receive repeated doses of MOR106 over a 12-week treatment period. A loading dose (dose regimen B) will be administered on Day 1.
89418293|NCT03568071|Experimental|Cohort C - dose regimen C|MOR106 will be administered as IV infusion. Subjects will receive repeated doses of MOR106 over a 12-week treatment period. A loading dose (dose regimen C) will be administered on Day 1.
89418294|NCT03568071|Experimental|Cohort D - dose regimen D|MOR106 will be administered as IV infusion. Subjects will receive alternating repeated doses of MOR106 or placebo over a 12-week treatment period. A loading dose (dose regimen D) will be administered on Day 1.
89418295|NCT03568071|Experimental|Cohort E - dose regimen E|MOR106 will be administered as IV infusion.Subjects will receive alternating repeated doses of MOR106 or placebo over a 12-week treatment period. A loading dose (dose regimen E) will be administered on Day 1.
89418296|NCT03568071|Placebo Comparator|Placebo|Subjects will receive repeated doses of placebo over a 12-week treatment period.
89418297|NCT02629822|Experimental|DOR/3TC/TDF|Treatment-naïve HIV-1 infected participants with NNRTI transmitted resistance-associated mutations were treated with open-label MK-1439A (DOR/3TC/TDF 100mg/300mg/300mg) as a FDC tablet taken once daily by mouth for 96 weeks in the Base Study. In addition, eligible participants continued to receive the same MK-1439A regimen from Week 96 to Week 192 during the Extension Study.
89418298|NCT02247297||Pregnant Women|Healthy pregnant women and women with preeclampsia, HELLP syndrom, amniotic infection syndrome, or preterm premature rupture of membranes
89418299|NCT04433104|Experimental|Treatment (UC-MSC trasnplatation)|1 x 10^6 umbilical Cord Mesenchymal Stem Cells per body kg will transplant via the intravenous at baseline, and the second transplantation will be performed 3 months after the first transplantation and combination with Vietnames MOH procedure
89418300|NCT04433104|Other|control arm|drug therapy according to Vietnamese MOHS procedure
89418301|NCT03565341|Experimental|Melasma|Treatment of Melasma Using PiQo4 Laser System
89418302|NCT03696667|Active Comparator|Affective BCI training|15 participants in the intervention group will undergo 24 sessions of BCI-based emotion regulation training over an 8-week period. Each session will take about 30-minute to complete where participants will listen to music with audio feedback to regulate emotions toward positive affect.
89418303|NCT03696667|No Intervention|Control group|15 participants in the control group will take part in 24 music sessions (with no audio feedback) over an 8-week period. Each session will take about 30-minute to complete.
88896109|NCT02096042|Experimental|Brentuximab Vedotin + 5-Azacytidine|"Phase I Dose-Escalation Phase: Starting dose of Brentuximab Vedotin 1.0 mg/kg IV (starting dose level 1), or one-dose level lower than the established MTD if the pilot portion of the study establishes a lower MTD, infusion over approximately 30 minutes on days 1, 8, and 15 of each 28-day cycle. All patients receive 5-azacytidine at 75 mg/m2/day by vein or subcutaneously on days 1-7 every 28 days.~Phase II Dose-Expansion Phase: Patients receive Brentuximab Vedotin at MTD from dose-escalation phase by vein on Days 1, 8, and 15 of each 28-day cycle. Patients receive 5-Azacytidine at 75 mg/m2/day by vein or subcutaneously on days 1-7 every 28 days. Patients can receive up to a total of 12 cycles of treatment (weekly + monthly combined)."
88896110|NCT02087033|Experimental|ritmonutra|ritmonutra 2 tablets/day by mouth for 4 weeks sugar pill manufatured to simulate ritmonutra: 2 tablets/day by mouth for 4 weeks
88896111|NCT02087033|Placebo Comparator|placebo|placebo
89418304|NCT03700723|Experimental|Resusix|The experimental drug (Resusix) will be administered intravenously to subjects enrolled in this arm of the study. Subjects may receive doses of 1-4 units during the blinded intervention period.
89418305|NCT03700723|Active Comparator|FP24 (Frozen Plasma)|The active comparator FP24 will be administered intravenously to subjects enrolled in this arm of the study. Subjects may receive doses of 1-4 units during the blinded intervention period.
88896112|NCT02036931||Metal on Polyethylene articulation|G7 cup with Metal on Polyethylene articulation (MOP)
88896113|NCT02036931||Ceramic on Polyethylene articulation|G7 cup with Ceramic on Polyethylene articulation (COP)
88896114|NCT02036931||Ceramic on Ceramic articulation|G7 cup with Ceramic on Ceramic articulation (COC)
88896115|NCT02027233|Experimental|Nasopharyngeal sample|Rapid completion of nasopharyngeal within 24 hours after hospitalization without exceeding 7 days after the onset
88896116|NCT02019628|Experimental|BRM4 at a dosage level of 1 gram/day|60-day trial of Rice Bran Arabinoxylan Compound (RBAC) at a dosage level of 1 gram/day.
88896117|NCT02019628|Experimental|BRM4 at a dosage level of 3 grams/day|60-day trial of Rice Bran Arabinoxylan Compound (RBAC) at a dosage level of 3 grams/day.
88896118|NCT01940471|Experimental|TAF 25 mg|TAF + TDF placebo for 96 weeks (per amendment 1 & 2) or 144 weeks (per amendment 3).
88896119|NCT01940471|Active Comparator|TDF 300 mg|TDF + TAF placebo for 96 weeks (per amendment 1 & 2) or 144 weeks (per amendment 3).
88896120|NCT01940471|Experimental|Open-label TAF|"All participants who complete the double-blind period (96 weeks or 144 weeks) will be eligible to receive open-label TAF until Week 384 of the study.~After the end of study treatment, participants can either switch to commercially available anti-HBV treatments in their country or will be followed every 4 weeks, for up to 24 weeks off treatment (treatment-free follow-up (TFFU)) for safety assessment."
88896121|NCT01902693||HIV & chemotherapy|"Participants will be aged ≥ 18 years, aware of their HIV status and the diagnosis of malignancy, have a plasma viral load of < 50 HIV-1 RNA copies/ml (on suppressive HAART) at enrolment and be designated to receive cytotoxic chemotherapy including one or more of the following agents: R-CHOP, ABVD, Liposomal doxorubicin (Caelyx) or liposomal daunorubicin (Daunoxome) or Paclitaxel.~There is no intervention for this study. Blood samples will be taken and if available from routine care surplus cerebrospinal fluid."
88896122|NCT01860456||CML Imatinib/Nilotinib|Patients affected by chronic myeloid leukemia and treated with imatinib or nilotinib
88896123|NCT01848639|Active Comparator|Spironolactone|After a month in run-in period under 25 mg per 2 days of spironolactone administered per os in practice after dialysis session three times a week, patients will be randomized to spironolactone. The dose should be increased to 25 mg once daily and could be adjusted in using an algorithm used in the EPHESUS and EMPHASIS-HF trials.
88896124|NCT01848639|Placebo Comparator|Placebo|After a month in run-in period under 25 mg per 2 days of spironolactone administered per os in practice after dialysis session three times a week, patients will be randomized to placebo. The dose should be increased to 25 mg once daily and could be adjusted in using an algorithm used in the EPHESUS and EMPHASIS-HF trials.
88896125|NCT01809080||2020|
88896126|NCT01809080||2019|
88896127|NCT01809080||2018|
88896128|NCT01809080||2017|
88896129|NCT01809080||2016|
88896130|NCT01809080||2015|
88896131|NCT01809080||2014|
89418306|NCT03696511|Active Comparator|group 1:maxillary insertion|Orthodontic miniscrew insertion; maxillary insertion. buccal
89418307|NCT03696511|Active Comparator|group 2: mandible insertion|Orthodontic miniscrew insertion; mandible insertion.
89418308|NCT03696511|Active Comparator|group 3: palatal insertion|Orthodontic miniscrew insertion; palatal insertion
89418309|NCT03565263||FGID-IBD|"Patients aged 9-18 years~with inflammatory bowel disease (Crohns, ulcerative colitis or indeterminate colitis)~in remission (defined as: Physician's global assessment = remission, no nocturnal stools, no blood in stools, < or = 3 stools/day, C-reactive-protein < 10 mg/L, Erythrocyte sedimentation rate < 20 mm, no flare of disease or change of treatment in the last 3 months, no ongoing corticosteroid therapy~followed for IBD for at least 1 year~with at least one Functional Gastrointestinal disorder according to the Fr-qPGS questionnaire (Rome III criteria)"
89418310|NCT03565263||No FGID-IBD|"Patients aged 9-18 years~with inflammatory bowel disease (Crohns, ulcerative colitis or indeterminate colitis)~in remission (defined as: Physician's global assessment = remission, no nocturnal stools, no blood in stools, < or = 3 stools/day, C-reactive-protein < 10 mg/L, Erythrocyte sedimentation rate < 20 mm, no flare of disease or change of treatment in the last 3 months, no ongoing corticosteroid therapy~followed for IBD for at least 1 year~not a single Functional Gastrointestinal disorder according to the Fr-qPGS questionnaire (Rome III criteria)"
89418311|NCT03700645|No Intervention|PCI and standard medical treatment|Patients diagnosed with multi vessel disease that after Heart team discussion underwent intervention by PCI and receive standard medical treatment according to practice guidelines.
89418312|NCT03700645|Active Comparator|PCI, standard treatment and Allopurinol|Patients diagnosed with multi vessel disease that after Heart team discussion underwent intervention by PCI and in addition to standard medical treatment, receive treatment with allopurinol.
89418313|NCT03700645|No Intervention|CABG and standard medical treatment|Patients diagnosed with multi vessel disease that after Heart team discussion underwent intervention by CABG and receive standard medical treatment according to practice guidelines.
89418314|NCT03700645|Active Comparator|CABG standard treatment and Allopurinol|Patients diagnosed with multi vessel disease that after Heart team discussion underwent intervention by CABG and in addition to standard medical treatment, receive treatment with allopurinol.
88896132|NCT01809080||2013|
89418315|NCT03569319|Experimental|"Group 1: THINK-MED resource (baseline)"|"The THINK-MED resource contains an information booklet, recipe books, menu plan cards, shopping list cards and goal setting cards. Participants will receive this resource on one occasion at baseline (n=10)"
89418316|NCT03569319|Experimental|"Group 2: THINK-MED resource (staged)"|"This group of participants will receive the THINK-MED resource at monthly intervals for 5 months accompanied by telephone feedback from the research dietitian (n=10)"
89418317|NCT03569319|Placebo Comparator|Group 3: Control|"Participants will receive the THINK-MED resource after their final 6 month study visit (i.e. delayed intervention) (n=10)"
89418318|NCT03567915||Rice|Group that healthy volunteers eat rice.
89418319|NCT03567915||Noodle|Group that healthy volunteers eat noodle.
89193834|NCT03679078|Experimental|IDDSI nutritional supplement drink|Single arm designed, 28day on IDDSI nutritional supplement drink
89193835|NCT03654898|Active Comparator|VITAL Start|VITAL Start: Video-based pre-ART counseling
89418320|NCT03624673|Experimental|endoscopic robot-assisted simple enucleation|Simple enucleation consists of excising the tumor by blunt dissection following the natural cleavage plane between the peritumoral capsule and the renal parenchyma without removing a visible rim of healthy renal tissue.
89418321|NCT03624673|Active Comparator|standard robot-assisted partial nephrectomy|Standard partial nephrectomy is defined as the excision of the tumor and of an additional margin of healthy peritumor renal parenchyma.
89193836|NCT03654898|Placebo Comparator|Standard of Care|pre-ART education as conducted via routine facility methods
89418322|NCT03064360||Biomarker Testing, PROs, PRIs|Biomarker testing for cardiac biomarkers, B-type natriuretic peptide (BNP) and Troponin I (Tnl), symptom and quality of life questionnaires, and patient metrics (activity, sleep, heart rate, heart rate variability).
89418323|NCT03565185|Active Comparator|End-effector|"For stroke rehabilitation 5 days a week in addition to conventional treatment methods robot-assisted gait training(end-effector type-Lokohelp) will be taken with 45 minutes a day for 3 days a week for 4 weeks.~Patients will be assessed with PASS, Rivermead mobility index, 10-meter walking test, 6-minute walking test, Barthel index, and FAC in terms of baseline and ending for posture, mobility, walking velocity, walking capacity, daily life activities and ambulance level."
89418324|NCT03565185|Active Comparator|Exoskeleton|"For stroke rehabilitation 5 days a week in addition to conventional treatment methods robot-assisted gait training (exoskeleton type-Robogait) will be taken with 45 minutes a day for 3 days a week for 4 weeks.~Patients will be assessed with PASS, Rivermead mobility index, 10-meter walking test, 6-minute walking test, Barthel index, and FAC in terms of baseline and ending for posture, mobility, walking velocity, walking capacity, daily life activities and ambulance level."
89418325|NCT03565185|Placebo Comparator|conventional treatment|conventional treatment methods for stroke rehabilitation 5 days a week Patients will be assessed with PASS, Rivermead mobility index, 10-meter walking test, 6-minute walking test, Barthel index, and FAC in terms of baseline and ending for posture, mobility, walking velocity, walking capacity, daily life activities and ambulance level.
89418326|NCT03703531||Patients resuscitated in Istria county|Cardiopulmonary resuscitation performed for OHCA
89418327|NCT03564951|Active Comparator|Control|ablation of Atrial fibrillation using spatio-temporal dispersion
89418328|NCT03564951|Experimental|Isochrone|ablation of concordance zones using isochrone and voltage maps
89418329|NCT04499053|Experimental|durvalumab (MEDI4736) and tremelimumab|Durvalumab in combination with tremelimumab and platinum-based doublet chemotherapy. Only subjects who achieve stable disease or better radiological response after 4 cycles of induction treatment will be eligible to continue study treatment with durvalumab in maintenance.
89418330|NCT05353413|Experimental|Various types of optic neuropathies|Patients with various types of optic neuropathy.
89418331|NCT05353413|Other|Healthy volunteers|Healthy volunteers
89418332|NCT03567681|Experimental|Extended release oxcarbazepine|Six week of open treatment with extended release oxcarbazepine (Oxtellar XR)
89418333|NCT03567681|Experimental|Immediate release oxcarbazepine|Six week of open treatment with Immediate release oxcarbazepine ( Trileptal)
89418334|NCT03462706|Experimental|Cold Snare|Polyps sized 6mm to 15mm found during colonoscopy will be removed using cold snare techniques.
89418335|NCT03462706|Experimental|Hot Snare|Polyps sized 6mm to 15mm found during colonoscopy will be removed using hot snare techniques.
89418336|NCT03462706|Experimental|Cold EMR|Polyps sized 6mm to 15mm found during colonoscopy will be removed using cold EMR techniques.
89418337|NCT03462706|Experimental|Hot EMR|Polyps sized 6mm to 15mm found during colonoscopy will be removed using hot EMR techniques.
89418338|NCT02840253|Experimental|NIRS|Non-invasive near infrared spectroscopy to assess changes in tissue and cerebral oxygenation.
88896133|NCT01809080||2012|
88896134|NCT01809080||2011|
88896135|NCT01809080||2010|
88896136|NCT01809080||2009|
88896137|NCT01809080||2008|
88896138|NCT01809080||2007|
88896139|NCT01809080||2021|
88896140|NCT01809080||2022|
88896141|NCT01809080||2023|
88896142|NCT01809080||2024|
88896143|NCT01809080||2025|
88896144|NCT01809080||2026|
88896145|NCT01765400|Active Comparator|Prasugrel|Prasugrel oral 10 mg once daily for 2 weeks
88896146|NCT01765400|Active Comparator|Clopidogrel|Clopidogrel oral 75 mg once daily for 2 weeks
88896147|NCT01751906|Experimental|Absorb BVS|Subjects receiving Absorb BVS
88896148|NCT01751906|Active Comparator|XIENCE|Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
88896149|NCT01730937|Active Comparator|Sorafenib Alone|400 mg sorafenib twice a day for 28-day cycle. Continue up to 5 years in the absence of disease progression or unacceptable toxicity.
88896150|NCT01730937|Experimental|SBRT followed by Sorafenib|27.5 Gy to 50 Gy stereotactic body radiation therapy (SBRT) in 5 fractions 24-72 hours apart over 5-15 days followed within 1-5 days by one cycle of 200 mg sorafenib twice a day. Starting with second cycle, if tolerable, increase to 400 mg sorafenib twice a day. Continue up to 5 years in the absence of disease progression or unacceptable toxicity.
89418339|NCT03567447|Experimental|Treatment group|This group will receive droxidopa 100mg to 600mg three times a day (TID) titration for 2 weeks and then maintenance dosage for 4 additional weeks. We will assess participants two times over the 4-week intervention. Each assessment will be the same as the baseline assessment, including the Orthostatic Hypotension Symptom Assessment (OHSA), postural, and gait assessments, and will be administered during the 2nd and 4th weeks following onset of stable treatment phase.
89418340|NCT03567447|Placebo Comparator|Non treatment group|This group will receive placebo appearing to be 100mg to 600mg three times a day (TID) titration for 2 weeks and then maintenance dosage for 4 additional weeks. We will assess participants two times over the 4-week intervention. Each assessment will be the same as the baseline assessment, including the Orthostatic Hypotension Symptom Assessment (OHSA), postural, and gait assessments, and will be administered during the 2nd and 4th weeks following onset of stable treatment phase.
89418341|NCT03567369|Experimental|Dexamethasone|Dexamethasone 4,0 mg / mL
89418342|NCT03567369|Experimental|Traumeel S|Traumeel 2,2 mg / mL
89418343|NCT03397654|Experimental|TACE followed by pembrolizumab|Trans-arterial chemoembolization (TACE) using doxorubicin solution (60 mg dose) and gelatin sponge particles; followed, at least 30 or 45 days later, by pembrolizumab solution (200 mg dose) every 3 weeks for a maximum of 1 year
89418344|NCT05354271|Experimental|High-intensity interval training|Patients will cycle or walk/run four intervals of four-min at high intensity with the aim to reach 80-90% of peak oxygen consumption, 90-95% of peak heart rate, 15-17 Borg scale, shortness of breath). Each interval is separated by a three-min active recovery, at 50-60% of peak oxygen consumption or 70-75% of peak heart rate. Total exercise time will be 38 min including the warm-up and cool-down.
89418345|NCT05354271|Active Comparator|Moderate-intensity continuous training|Patients will cycle or walk/run continuously at moderate intensity (50-60% of peak oxygen consumption, 70-75% of peak heart rate) for 37 min. Total exercise time will be 47 min for the moderate-intensity continuous training group including warm-up and cool-down (isoenergetic compared to high-intensity interval training).
89418346|NCT05354271|No Intervention|Control|The control group will continue their habits without increasing the level of physical activity nor participate to any supervised exercise training.
89418347|NCT03266146|Experimental|36 Weeks Methylprednisolone|Participants in 36 weeks of glucocorticoid treatment group will receive methylprednisolone, 48mg/d for the 1st week, 32mg/d for the 2nd week, 24mg/d for the next two weeks, followed by 16mg/d for 20 weeks and reduction in doses of methylprednisolone by 4 mg per 4 weeks until drug withdrawal. Participants in 36 weeks of glucocorticoid treatment group also will receive standard treatment including reduced glutathione, glycyrrhizin, ademetionine, alprostadil, or ursodeoxycholic acid (UDCA). Participants will then be followed for 24 weeks.
89418348|NCT03266146|Experimental|48 Weeks Methylprednisolone|Participants in 48 weeks of glucocorticoid treatment group will receive methylprednisolone, 48mg/d for the 1st week, 32mg/d for the 2nd week, 24mg/d for the next two weeks, followed by 16mg/d for 32 weeks and reduction in doses of methylprednisolone by 4 mg per 4 weeks until drug withdrawal. Participants in glucocorticoid 48 weeks of treatment group also will receive standard treatment including reduced glutathione, glycyrrhizin, ademetionine, alprostadil, or ursodeoxycholic acid (UDCA). Participants will then be followed for 24 weeks.
89418349|NCT03703453|Experimental|REBOA|Patients undergoing REBOA for medical cardiac arrest
89418350|NCT03700489|Experimental|patients take titanium dioxide denture|patients will receive titanium dioxide denture (made from conventional acrylic resin modified by titanium dioxide nanoparticles ) for 1 month in the initial phase of the trial then in the later phase after one month they will receive( rapid heat cured acrylic resin)denture
89418351|NCT03700489|Placebo Comparator|patients take rapid heat denture|patients will receive rapid heat denture for 1 month in the initial phase of the trial then in the later phase patients will receive titanium dioxide denture (made from conventional acrylic resin modified by titanium dioxide nanoparticles )
89418352|NCT03695965||study group|patients with history of ankle trauma or chronic lateral ankle pain
89418353|NCT02800941||Oral anticoagulant treatment|Patients with pulmonary hypertension are treated with oral anticoagulants according to the usual practice. Patients have follow-up at 3, 6 and 12 months.
89418354|NCT03695887|Experimental|Nitrous Oxide Inhalant Product|Nitrous oxide
89418355|NCT03695887|Placebo Comparator|Placebo|placebo comparator
89418356|NCT04432714|Experimental|R2-DA-EPOCH|
89418357|NCT02752074|Experimental|Pembrolizumab + Epacadostat|Pembrolizumab + Epacadostat
89418358|NCT02752074|Active Comparator|Pembrolizumab + Placebo|Pembrolizumab + Placebo
89418359|NCT03564795|Experimental|KeraStat Gel|Each enrolled subject will have at least one eligible burn randomized to the KeraStat Gel arm. This burn will be dressed with KeraStat Gel and covered by a secondary dressing. Subjects will be instructed to change the dressing and re-apply the KeraStat Gel per the instructions for use (at least every 3 days).
89418360|NCT03564795|Active Comparator|Silver Sulfadiazine|Each enrolled subject will have at least one eligible burn randomized to the Silver Sulfadiazine arm. This burn will be dressed with the Silver Sulfadiazine and covered by a secondary dressing. Subjects will be instructed to change the dressing and re-apply the Silver Sulfadiazine per the institution's Standard of Care instructions.
89418361|NCT03624595|Experimental|Dexmedetomidine group|Dexmedetomidine infusion is administered from 16:00 to 08:00 during the night of surgery; and will repeated for a maximum of 5 consecutive nights. For patients with mechanical ventilation, the infusion rate is 0.2-0.7 ug/kg/h; for those without mechanical ventilation, the infusion rate is 0.05-0.2 ug/kg/h. The target depth of sedation is Richmond Agitation-Sedation Scale (RASS) -1.
89418362|NCT03624595|Placebo Comparator|Placebo group|Placebo (normal saline) infusion is administered from 16:00 to 08:00 in the same speed for the same duration as in the dexmedetomidine group. The conventional sedation is provided when necessary with propofol and/or midazolam by intravenous infusion/injection. The target depth of sedation depth is RASS -1.
89418363|NCT03063970|Experimental|Experimental Group|Wear of the tailor made Dynamic Lycra Orthosis for up to eight hours every day for eight weeks Usual rehabilitation
89418364|NCT03063970|Active Comparator|Comparison Group|Usual rehabilitation
89418365|NCT03564717|Experimental|Segmented Three dimensionally printed transfer tray|
89418366|NCT03564717|No Intervention|Full arch three dimensionally printed transfer tray|
89418367|NCT03063892|Placebo Comparator|Control Arm|Will receive intravenous Saline solution placebo bolus dose in the Emergency Center over 10 minutes. The subject will also receive intravenous Saline solution over 8 hours prior to surgery. Another dose will be administered at the time of incision and the final dose three hours later.
89418368|NCT03063892|Experimental|Experimental Arm|Will receive intravenous Tranexamic Acid (TXA) 15mg/kg (maximum 1 gram) bolus dose over 10 minutes in the Emergency Center. The subject will also receive an intravenous dose of Tranexamic Acid (TXA) 15mg/kg over 8 hours prior to surgery. Another 15mg/kg dose of Tranexamic Acid (TXA) will be administered over 10 minutes at the time of incision and the final dose (15mg/kg) of Tranexamic Acid (TXA) intravenously over 10 minutes three hours later.
89418369|NCT05708313|Experimental|Cardiac Rehabilitation|people recruited for the trial will participate in the Intensive cardiac rehabilitation arm.
89418370|NCT03063736|Experimental|Td vaccine with entolimod|Td vaccine (4 ug) + Entolimod (1 ug) (n=25)
89418371|NCT03063736|Placebo Comparator|Td vaccine only|Td vaccine (4 ug) (n=15)
89418372|NCT03695731|Experimental|Patients without Neuropathy|activation of cold induced brown adipose tissue
89418373|NCT03695731|Experimental|Patients with Neuropathy|activation of cold induced brown adipose tissue
89418374|NCT03564639||Injection drug users with HCV|People who inject drugs who were confirmed positive for HCV and initiated treatment in the parent study beginning in September 2017.
89418375|NCT03063814|Experimental|APP|In the APP group, a video sequence of each exercise, supported by short written descriptions (in accordance to 'Get set - Train smarter', (9) on how to perform the exercise correctly, was shown to the participants on an iPad. The video-recorded exercises were performed by the same physiotherapist who supervised PHY participants. If required, the participants in the APP group were allowed to watch the video and description several times between trials of the same exercise. The participants approved their own trials when they believed that the exercises had been performed as described.
89418376|NCT03063814|Active Comparator|PHY|In PHY, a physiotherapist demonstrated and explained the focus areas of each of the five exercises before the participant performed the exercises. If needed, verbal feedback was given between trials to correct the performance of the exercise. The physiotherapist approved trials that were performed with proper technique.
89418377|NCT02190474|Experimental|Mindfulness Group|These adolescents will be invited to participate in a group mindfulness meditation program based on a protocol refined by the investigative team. The weekly group meetings will be taught by an MBSR teacher at the Yale School of Medicine, with experience teaching mindfulness interventions to adults, children, and adolescents.
89418378|NCT03703219||Mother Touch Program|Forty days of rest period of the mother after delivery, Full body massage, diet and belly binding methods were administered by trained carer.
89418379|NCT03703219||Usual care Program|comparison cohort were followed in usual care under the supervision of health professionals.
89418380|NCT05353179|Experimental|Meperizumab injection|Subcutaneous injection of meperizumab once
89418381|NCT05353179|Active Comparator|NUCALA®|Subcutaneous injection of NUCALA® once
89418382|NCT03063580|Experimental|SAR439954 with or without rifampicin|Period 1: single oral dose of 400 mg sotagliflozinon Day 1 morning Period 2: once-daily oral doses of 600 mg rifampicin from Days 1 to 10 and a single oral dose of 400 mg sotagliflozin
89418383|NCT03700255|Experimental|Group A|Group A will undergo the PickUpSimTM simulation training program
89418384|NCT03700255|No Intervention|Group B|Group B will only have the classic training with no simulation.
89418385|NCT02187978|Experimental|Early total enteral feeding (ETEF)|"Feeding will be initiated on D1 with 80ml/kg/day of expressed breast milk or LBW formula milk.~No intravenous fluid will be provided. Feeds will be advanced till 150ml/kg/day is attained."
89418386|NCT02187978|Active Comparator|Conventional enteral feeding (CEF)|"Feeding will be initiated on D1of life with 20ml/kg of expressed breast milk or LBW formula milk.~Remaining requirement as intravenous fluids. Feeds advanced by 20ml/kg/day for next 2 days and then 30ml/kg/day for the next three days until 150ml/kg/day is reached."
89418387|NCT05353101|Experimental|Cyclosporine 0.05% eye drops group|The patients with VKC will receive Cyclosporine 0.05% eye drops or Loteprednol Etabonate 0.5% and Tobramycin Eye Drops 0.3% effect of Cyclosporine 0.05% eye drops would be evaluated during the follow-up visits.
89193837|NCT03654742|Active Comparator|ECTE/Electrosurgery|Extracapsular tonsillectomy (ECTE) with monopolar electrosurgery
89193838|NCT03654742|Experimental|ICTE/Microdebrider|Intracapsular tonsillectomy (ICTE) with microdebrider
89418388|NCT03700333|Experimental|S-1 Group|Stage IIIB or IV non-small-cell lung cancer (NSCLC) population treated by Tegafur,Gimeracil and Oteracil Potassium Capsules (S-1)
89418389|NCT03700333|Active Comparator|Pemetrexed Group|Stage IIIB or IV non-small-cell lung cancer (NSCLC) population treated by Pemetrexed
89418390|NCT03703141|Experimental|Sucralose 48 mg|Sucralose 48 mg in 60 ml of water O.D. for ten weeks
89418391|NCT03703141|Experimental|Sucralose 96 mg|sucralose 96 mg in 60 ml of water O.D. for ten weeks
89418392|NCT03703141|Placebo Comparator|Placebo|60 ml of water as placebo O.D. for ten weeks
89418393|NCT02190630|Active Comparator|Part time (12hour) wear|the' Modified Clark Twin Block' will be worn part time
89418394|NCT02190630|Active Comparator|Full time (24hour) wear|the ' Modified Clark Twin Block' will be worn full time
89418395|NCT05352555|Experimental|Robotic Maneuvering System (RMS)|"BPPV subtype diagnosis and corresponding treatment will be performed using automated RMS chair and recorded with video frenzel goggle.~In cases of posterior canal involvement, Epley's maneuver will be used for canalithiasis and cupulolithiasis. Semont maneuver will be used as a second-line treatment for cupulolithiasis, in cases of initial failure.~In cases of horizontal canal involvement, Barbecue (Lempert) maneuver will be used. If canalithiasis or cupulolithiasis is diagnosed, Gufoni's maneuver will be performed.~In cases of anterior canal involvement, Yacovino's maneuver will be used."
89193839|NCT03654742|Experimental|ICTE/Coblator|Intrapsular tonsillectomy (ICTE) with coblator
89193840|NCT03651648|Experimental|SENSITACT System ON|As soon as the early signs of an apnea-bradycardia are detected, the SENSITACT controller sends a trigger signal to the PASITHEA stimulator that immediately activates kinesthetic stimulation
89193841|NCT03651648|Sham Comparator|SENSITACT System OFF|The SENSITACT controller doesnt send any trigger signal to the PASITHEA stimulator even if an early sign of an apnea-bradycardia is detected.
88896151|NCT01569581|Experimental|100U/0.5ml in 6-11 months old infants|inactivated EV71 vaccine (KMB-17) of 100U/0.5ml (320Eu/0.5ml) in 1750 infants aged 6-11 months old on day 0, 28
88896152|NCT01569581|Experimental|100U/0.5ml in 12-23 months old infants|inactivated EV71 vaccine (KMB-17) of 100U/0.5ml (320Eu/0.5ml) in 1750 infants aged 12-23 months old on day 0, 28
89193842|NCT03644277|Experimental|Massed practice training with dAIH|"Seek to address gross upper extremity movements, grip and pinch strength, and coordination.The ultimate goal of the session is to achieve a total of 300 repetitions during training.~Once fitted with the mask, initial recordings of heart rate, blood pressure, and arterial oxygen saturation (SpO2) will be taken. The sequence of hypoxia will consist of 60- 90 seconds of 9-10% O2 (FiO2 0.09), alternating with 60- 90 seconds of 21% O2 (normoxic air FiO2 0.21). The delivery of hypoxia and normoxic air mixtures will be repeated up to 18 times per session each, for a total of up to 45 minutes, to maintain SpO2 at 80-90%."
89418396|NCT05352555|Active Comparator|Canalith Reposition Maneuver|"BPPV subtype diagnosis and corresponding treatment will be performed with manual repositioning maneuvers and recorded with video frenzel goggle.~In cases of posterior canal involvement, Epley's maneuver will be used. In cases of horizontal canal involvement, Log roll maneuver will be used. In cases of anterior canal involvement, Yacovino's maneuver will be used."
89418397|NCT03252340||Drug: ADSTEM Inj.|Participants in Phase I clinical trials treated with ADSTEM Inj.
89418398|NCT03695653|Active Comparator|Drink Tracking (MA) Condition|Ps will receive weekly mobile assessment trick tracking described above for six months in addition to the guidelines on safe drinking.
89418399|NCT03695653|Experimental|TA Intervention|The TA intervention is tailored but will adapt over time too
89418400|NCT03695653|Experimental|Tailored Content Only (TO)|The TO treatment arm includes tailored text messages sent at 6pm daily based on the baseline assessment.
89418401|NCT05708391|Experimental|Experimental arm: Radiotherapy, Realgar-Indigo naturalis formula|
89418402|NCT02188134||65 and older|No intervention will be administered
89418403|NCT03700177|Active Comparator|ropivacaine + dexamethasone|Every participant receives general anesthesia and a modified pectoral nerve block for breast surgery. Participants of this arm receive single-shot ropivacaine (0,2%, 30ml) plus 2ml dexamethasone (8mg).
89193843|NCT03644277|Experimental|Massed practice training with Sham dAIH|"Seek to address gross upper extremity movements, grip and pinch strength, and coordination.The ultimate goal of the session is to achieve a total of 300 repetitions during training.~Once fitted with the mask, initial recordings of heart rate, blood pressure, and arterial oxygen saturation (SpO2) will be taken. The sequence of hypoxia will consist of 60- 90 seconds of 9-10% O2 (FiO2 0.09), alternating with 60- 90 seconds of 21% O2 (normoxic air FiO2 0.21). The delivery of hypoxia and normoxic air mixtures will be repeated up to 18 times per session each, for a total of up to 45 minutes, to maintain SpO2 at 80-90%."
89418404|NCT03700177|Placebo Comparator|ropivacaine + placebo|Every participant receives general anesthesia and a modified pectoral nerve block for breast surgery. Participants of this arm receive single-shot ropivacaine (0,2%, 30ml) plus 2ml placebo (NaCl 0,9%).
89418405|NCT05353023||ICU ADMISSION|All patients admitted in a French intensive care unit over a 7-year period (2013 to 2019) using the French National Uniform Hospital Discharge Database (PMSI)
89418406|NCT02183610|Experimental|[14C] BI 1356 as oral (p.o.) solution|
89418407|NCT02183610|Experimental|[14C] BI 1356 solution for i.v. infusion|
88896153|NCT01569581|Experimental|100U/0.5ml in 24-35 months old children|inactivated EV71 vaccine (KMB-17) of 100U/0.5ml (320Eu/0.5ml) in 1500 children aged 24-35 months old on day 0, 28
88896154|NCT01569581|Experimental|100U/0.5ml in 36-71 months old children|inactivated EV71 vaccine (KMB-17) of 100U/0.5ml (320Eu/0.5ml) in 1000 children aged 36-71 months old on day 0, 28
88896155|NCT01569581|No Intervention|0U/0.5ml in infants (6-11 months old)|0U/0.5ml (0Eu/0.5ml) placebo in 1750 infants aged 6-11 months old on day 0, 28
88896156|NCT01569581|No Intervention|0U/0.5ml in infants (12-23 months old)|0U/0.5ml (0Eu/0.5ml) placebo in 1750 infants aged 12-23 months old on day 0, 28
88896157|NCT01569581|No Intervention|0U/0.5ml in children (24-35 months old)|0U/0.5ml (0Eu/0.5ml) placebo in 1500 children aged 24-35 months old on day 0, 28
88896158|NCT01569581|No Intervention|0U/0.5ml in children (36-71 months old)|0U/0.5ml (0Eu/0.5ml) placebo in 1000 children aged 36-71 months old on day 0, 28
88896159|NCT01560416|Active Comparator|ARM A - Fulvestrant|Fulvestrant: 500 mg administered by intramuscular injection on days 1 and 15 of cycle 1, day 1 of cycle 2 and each subsequent cycle; cycle duration is 28 days Eligible participants on Arm A were allowed to crossover to Arm B upon disease progression. Treatment continued for Arm A participants until 2nd disease progression.
88896160|NCT01560416|Active Comparator|Arm B - Fulvestrant+Ganetespib|"Fulvestrant: 500 mg administered by intramuscular injection on days 1 and 15 of cycle 1, day 1 of cycle 2 and each subsequent cycle; cycle duration is 28 days Ganetespib: 200 mg/m2 administered intravenously on days 1, 8 and 15 of each 28 day cycle~Arm B participants whose disease was at a minimum stable could elect to discontinue ganetespib after 6 cycles or stay on combination treatment until disease progression. Otherwise, Arm B participants taken off ganetespib for toxicity were to remain on single agent fulvestrant until disease progression."
89418408|NCT04434352|Active Comparator|Baseline Erectile Dysfunction|The first arm of the study will be those men with erectile dysfunction as defined by IIEF score. These men will either have PDE5i refractory or responsive erectile dysfunction. Subjects will receive either Sham treatment (no ultrasound energy delivered via a Sham probe) or LiSWT for erectile dysfunction. Follow up will occur at 1 month, 3 months, and 6 months following the end of treatment. Effectiveness will be measured by change in IIEF/SHIM score and EHS score. Each questionnaire is described in the trial description with a higher score indicating improved function.
89418409|NCT04434352|Active Comparator|Erectile Dysfunction-Penile Rehabilitation|The second population of patients will be those who are planning to undergo treatment for prostate cancer. In a similar manner, men will be randomized to either the Sham or active treatment groups. Men will be treated prior to undergoing definitive treatment for prostate cancer to assess the effectiveness in LiSWT as a means of erectile preservation prior to prostate cancer treatment.
89418410|NCT04434352|Active Comparator|Erectile Dysfunction Post-Prostate Cancer Treatment|The third population of patients will be those who have undergone treatment for prostate cancer. The investigators will compare IIEF scores and EHS scores in men who have undergone prostatectomy or radiation therapy. Again, there will be a sham and treatment group.
88896161|NCT01551823|Experimental|Team 1|Influenza Virus Vaccine(no Preservative) 2×0.25ml intramuscular injections
88896162|NCT01551823|Experimental|Team 2|Influenza Virus Vaccine(contains Preservative)2×0.25ml intramuscular injections
88896163|NCT01551810|Experimental|Influenza Virus Vaccine|Influenza Virus Vaccine（no Preservative ) 0.5ml intramuscular injections
88896164|NCT01551810|Experimental|Influenza Virus Vaccine(Preservative)|Influenza Virus Vaccine（add Preservative ) 0.5ml intramuscular injections
88896165|NCT01512706|Experimental|160Eu/0.5ml in infants (6-11 months old)|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 60 infants aged 6-11 months old on day 0, 28
89418411|NCT03699943|Active Comparator|CaverStem 1.0 - Low|Intra-cavernosal injection of autologous bone marrow concentrate for the treatment of Erectile Dysfunction. low dose 30 cc
89418412|NCT03699943|Active Comparator|CaverStem 1.0 - High|Intra-cavernosal injection of autologous bone marrow concentrate for the treatment of Erectile Dysfunction. high dose 60 cc
89418413|NCT03699943|Active Comparator|Caverstem 2.0 - Clinical Registry|Intra-cavernosal injection of autologous bone marrow concentrate for the treatment of Erectile Dysfunction. 20 cc
88896166|NCT01512706|Experimental|320Eu/0.5ml in infants (6-11 months old)|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 60 infants aged 6-11 months old on day 0, 28
89418414|NCT02183688|Experimental|ASA + paracetamol + caffeine|
89418415|NCT02183688|Active Comparator|ASA + paracetamol|
89418416|NCT02183688|Active Comparator|ASA|
88896167|NCT01512706|Experimental|640Eu/0.5ml in infants (6-11 months old)|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 40 infants aged 6-11 months old on day 0, 28
89418417|NCT02183688|Active Comparator|Paracetamol|
89418418|NCT02183688|Active Comparator|Caffeine|
89418419|NCT02183688|Placebo Comparator|Placebo|
89418420|NCT03695575|Other|Study sample|A repeated-measures model will be used. This means that participants in a single arm will be tested in all conditions. Speech recognition and listening effort outcomes will be measured in two conditions: with and without a bone-conduction headset.
89418421|NCT02190708|Experimental|PQ912 & Midazolam & Omeprazole|day2 - day6 800mg PQ912 twice per day po day1 / day6 2.5 mg Midazolam once per day day1 / day6 20 mg Omeprazole once per day
89418422|NCT02835495|Experimental|Lifestyle Weight Loss|"Behavioral: HELP Vets Intervention~Lifestyle intervention consisting of 24 weekly group meetings led by a Veteran community health worker and 3 individual sessions with a nutritionist/diabetes educator"
89418423|NCT02835495|Active Comparator|Enhanced Usual Care|"Behavioral: Individual Education Program~Standard care consisting of 2 individual sessions with a nutritionist/diabetes educator and a monthly newsletter"
89418424|NCT02190786|Experimental|KUX-1151, Low dose|
89418425|NCT02190786|Experimental|KUX-1151, Middle dose|
89418426|NCT02190786|Experimental|KUX-1151, High dose|
89418427|NCT04864132||Subjects survived from COVID-19|The subjects who had confirmed COVID-19 infection aged between 18-30/years
89418428|NCT04864132||Subjects never had COVID-19|"The subjects aged between 18-30/years who have not been diagnosed with COVID-19 as of March 11of 2020 and who have not been in contact and risky according to the Life Fits Into Home application"
89418429|NCT03695341||Fulvestrant|Fulvestrant 500mg per month (D1, D28, q28d), with a loading dose 500mg of first dose at D15
89418430|NCT03695341||Everolimus plus Exemestane|Everolimys 10 mg or 5 mg daily; Exemestane 25mg per day
89418431|NCT05338983|Active Comparator|Control: Traditional local anesthesia|After proper isolation and drying of the injection site, the topical anesthetic gel (20% benzocaine) will be applied to the injection site using sterile cotton tipped applicator for 60 seconds, then the anesthesia (2% mepivacaine hcl with 1:100000 epinephrine) will be administere
89418432|NCT05338983|Experimental|Group A (Warm group)|The topical anesthetic gel (20% benzocaine) will be applied to the injection site using sterile cotton tipped applicator for 60 seconds. The cartridge of anesthetic solution will be placed in the baby bottle warmer in 300 ml of cold water (21°C). The anesthetic fluid will be warmed to reach 37°C (98.6°F) ,then the local anesthesia((2% mepivacaine hcl with 1:100000 epinephrine) will be administered
88896168|NCT01512706|Experimental|1280Eu/0.5ml in infants (6-11 months old)|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 40 infants aged 6-11 months old on day 0, 28
88896169|NCT01512706|Placebo Comparator|0Eu/0.5ml in infants (6-11 months old)|0Eu/0.5ml placebo in 80 infants aged 6-11 months old on day 0, 28
88896170|NCT01512706|Experimental|160Eu/0.5ml in infants (12-23 months old)|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 30 infants aged 12-23 months old on day 0, 28
88896171|NCT01512706|Experimental|320Eu/0.5ml in infants (12-23 months old)|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 30 infants aged 12-23 months old on day 0, 28
88896172|NCT01512706|Experimental|640Eu/0.5ml in infants (12-23 months old)|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 40 infants aged 12-23 months old on day 0, 28
89418433|NCT05338983|Experimental|Group B (Buffered group)|The topical anesthetic gel (20% benzocaine) will be applied to the injection site for 60 seconds,0.1ml of 8.4% of sodium bicarbonate will be removed from the 50 ml vial by one ml insulin syringe and directly injected into the local anesthetic cartridge. The cartridge will be shacked 5 times to mix the solution, then the local anesthesia(2% mepivacaine hcl with 1:100000 epinephrine) will be administered.
89418434|NCT05338983|Experimental|Group C (Buzzy group)|After the child setting on the dental chair,(20% benzocaine) topical anesthetic gel will be applied to the injection site for 60 seconds. He will be familiar with the Buzzy device by explaining how it works in simple words. The wings of the device will be kept in the freezer. Once the child is ready, the frozen wings will be attached to the device and Buzzy will be placed extra-orally above the area/cheek where local anesthetic will be delivered. Once Buzzy is being held in place by hand, press the button or switch on the top of Buzzy, then the anesthesia (2% mepivacaine hcl with 1:100000 epinephrine) will be administered.
89418435|NCT02183766|Placebo Comparator|Maltodextrin|6 mL once a day diluted in juice during 30 days.
89418436|NCT02183766|Active Comparator|Galactooligosaccharide prebiotic|6 mL once a day diluted in juice during 30 days.
89418437|NCT03063658|Active Comparator|Paracetamol|Paracetamol (Paracerol) 1 gram will be administered intravenously. The first dose will be infused for 10 minutes after the induction of anesthesia and before the first surgical incision. The remaining three doses will be administered every 6 hours for postoperative 24 hours.
88896173|NCT01512706|Experimental|1280Eu/0.5ml in infants (12-23 months old)|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 40 infants aged 12-23 months old on day 0, 28
88896174|NCT01512706|Placebo Comparator|0Eu/0.5ml in infants (12-23 months old)|0Eu/0.5ml placebo in 50 infants aged 12-23 months old on day 0, 28
89418438|NCT03063658|Active Comparator|Ibuprofen|Ibuprofen (Intrafen) 800 mg will be administered intravenously. The first dose will be infused for 10 minutes after the induction of anesthesia and before the first surgical incision. The remaining three doses will be administered every 6 hours for postoperative 24 hours.
89418439|NCT03695263|Experimental|N-of-1 Trial|Multiple crossovers between one of the available intervention options (mindfulness meditation, gratitude journaling, physical activity, laughter therapy, or random acts of kindness) and usual activities
89418440|NCT03535896|Experimental|HSR and injection|HSR and corticosteroid injection
89418441|NCT04488562||Patients with COVID-19|Patients with proven COVID-19 and abnormalities on chest X-Ray/HRCT, admitted at the hospital. Patients are included around the time of discharge from the hospital or at their regular outpatient clinic visit 6 weeks after discharge, depending on the clinical status of the patient at time of discharge.
89418442|NCT03695107||XBDP1-|
89418443|NCT03695107||XBDP2-|
89418444|NCT02835339|Active Comparator|MgSO4 4g load, 1g/hr infusion|Once their obstetrician prescribes magnesium sulfate, participant will be assigned by 50/50 chance to one of two treatment regimens. Participant will be assigned to either a dose of 4 g at the start, followed by 1g every hour; or a dose of 6 g at the start, followed by 2g every hour until treatment for preeclampsia is complete.
89418445|NCT02835339|Experimental|MgSO4 6g load, 2g/hr infusion|Once their obstetrician prescribes magnesium sulfate, participant will be assigned by 50/50 chance to one of two treatment regimens. Participant will be assigned to either a dose of 4 g at the start, followed by 1g every hour; or a dose of 6 g at the start, followed by 2g every hour until treatment for preeclampsia is complete.
89418446|NCT03695029|Experimental|treatment group|Pregnant women receiving tenofovir alafenamide 25 mg per day since 26-32 weeks of pregnancy to 2-4 weeks postpartum.
89418447|NCT03695029|No Intervention|control group|control group receive no drug, only follow-up
89418448|NCT02259855|Experimental|Mild hepatic insufficiency|
89418449|NCT02259855|Experimental|Moderate hepatic insufficiency|
89418450|NCT02259855|Experimental|Healthy subjects|
89418451|NCT04465084|Other|Case|Relapsing-Remitting Multiple Sclerosis and Secondary Progressive Multiple Sclerosis.
89418452|NCT04465084|Other|Witness|"Person matched to a case on age (+/-3 years) and education level"
89418453|NCT02188212|Other|NobelProcera Crown Shaded Zirconia|NobelProcera Crown Shaded Zirconia molar
88896175|NCT01512706|Experimental|160Eu/0.5ml in children (24 months-5 years old)|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 30 children aged 24 months-5 years months old on day 0, 28
89418454|NCT03703063|Experimental|Resectable patients|Gemcitabine and Nab-Paclitaxel Participants received albumin-bound paclitaxel 125 mg/m^2 followed by gemcitabine 1000 mg/m^2 by intravenous infusion (IV) on Days 1, 8 and 15 of each 28 day cycle. Followed by nal-IRI (ONIVYDE®) 70 mg/m^2 followed by leucovorin 400 mg/m^2 followed by 5FU 2400 mg/m^2 on days 1, 15 of the 28 day cycle.
89418455|NCT03703063|Experimental|Borderline resectable patients|Gemcitabine and Nab-Paclitaxel Participants received albumin-bound paclitaxel 125 mg/m^2 followed by gemcitabine 1000 mg/m^2 by intravenous infusion (IV) on Days 1, 8 and 15 of each 28 day cycle. Followed by nal-IRI (ONIVYDE®) 70 mg/m^2 followed by leucovorin 400 mg/m^2 followed by 5FU 2400 mg/m^2 on days 1, 15 of the 28 day cycle.
88896176|NCT01512706|Experimental|320Eu/0.5ml in children (24 months-5 years old)|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 30 children aged 24 months-5 years months old on day 0, 28
88896177|NCT01512706|Experimental|640Eu/0.5ml in children (24 months-5 years old)|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 40 children aged 24 months-5 years months old on day 0, 28
88896178|NCT01512706|Experimental|1280Eu/0.5ml in children (24 months-5 years old)|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 40 children aged 24 months-5 years months old on day 0, 28
88896179|NCT01512706|Placebo Comparator|0Eu/0.5ml in children (24 months-5 years old)|0Eu/0.5ml placebo in 50 children aged 24 months-5 years old on day 0, 28
88896180|NCT01510366|Experimental|Cohort 1|Inactivated Poliomyelitis Vaccine (Sabin strains) 3 x 0.5ml intramuscular injections.
89418456|NCT04094337|Experimental|Internet-assisted treatment|The intervention group will receive internet-assisted treatment comprising six web-based sessions, comprising information, exposure to physical activity, how worry can excess pain, physical reactions to pain and worry, consequences of avoidance, and specific panic treatment. The first session will be done at the hospital before discharge, the others at home. Between sessions there will be a brief telephone contact with a project worker.
89418457|NCT04094337|No Intervention|Control group|The control group will receive treatment as usual, which is no specific treatment. The control group can however use the general health system as they like.
89418458|NCT02183844|Experimental|Psychosocial Weight Intervention|Weekly group intervention for diet and exercise, designed specifically for individuals with serious mental illness and the cognitive deficits that accompany those illnesses
89418459|NCT03564249|Experimental|Group 1 Young patients with constipation|25 young patients that present at secondary or tertiary care with intractable constipation. They will undergo the new MRI gastrointestinal transit test (MiniCap) once before standard treatment for constipation and once after the treatment.
89418460|NCT03564249|Experimental|Group 2 Healthy participants|25 young healthy controls matched for gender. They will undergo the new MRI gastrointestinal transit test (MiniCap) once.
89418461|NCT03702985|Active Comparator|Capecitabine and Irinotecan without Amifostine|"Concurrent Chemoradiotherapy:~Radiation: 50Gy/25Fx; Capecitabine: 625mg/m2 bid Monday-Friday per week; Irinotecan: 80mg/m2 (UGT1A1*28 6/6) or 65mg/m2 (UGT1A1*28 6/7)~Chemotherapy in Interval Between CRT and Surgery:~Capecitabine: 1000mg/m2 bid d1-14; Irinotecan: 200mg/m2 d1~Surgery:~Scheduled 6-8 weeks after the completion of CRT Adjuvant Chemotherapy: depends on patients pathological review."
89418462|NCT03702985|Experimental|Capecitabine and Irinotecan with Amifostine|"Concurrent Chemoradiotherapy:~Radiation: 50Gy/25Fx; Capecitabine: 625mg/m2 bid Monday-Friday per week; Irinotecan: 80mg/m2 (UGT1A1*28 6/6) or 65mg/m2 (UGT1A1*28 6/7) Amifostine: 400mg/m2 per week~Chemotherapy in Interval Between CRT and Surgery:~Capecitabine: 1000mg/m2 bid d1-14; Irinotecan: 200mg/m2 d1~Surgery:~Scheduled 6-8 weeks after the completion of CRT Adjuvant Chemotherapy: depends on patients pathological review."
89418463|NCT02188290||HAPLO group|Control group of all eligible patients who received an HSCT from a haploidentical donor without ATIR administration between 1 January 2006 and 30 June 2013
89418464|NCT02188290||MUD group|Control group of eligible patients who received an HSCT from a fully matched unrelated donor between 1 January 2010 and 31 December 2012
88896181|NCT01510366|Experimental|Cohort 2:|Inactivated Poliomyelitis Vaccine (Salk strains) 3 x 0.5ml intramuscular injections.
88896182|NCT01354002||Protocol Participants|All participants enrolled on protocols
88896183|NCT01345539|Experimental|Stereotactic Body Radiotherapy (SBRT) with/without chemotherapy|"Sequence of therapy: SRS/SBRT will be used for all sites of metastatic disease in close approximation to initiation of treatment for the primary disease site (within 6 weeks). Ideally, SRS/SBRT would occur first followed by treatment to primary site. However, in some circumstances surgical resection of the primary site could precede SRS/SBRT, especially if surgical resection is required for pathological confirmation of disease.~Chemotherapy choice of agents is at the discretion of the treating medical oncologist; chemotherapy may be initiated after stereotactic radiosurgery treatment of the primary disease site has been completed."
88896184|NCT01288066|Other|Hemiarthroplasty|Patients are treated with hemi shoulder arthroplasty with CE marked medical devices of the Epoca system.
88896185|NCT01288066|Other|Total arthroplasty|Patients are treated with total shoulder arthroplasty with CE marked medical devices of the Epoca system.
88896186|NCT01279850||Pregabalin (Lyrica) capsule|"Patients administered Pregabalin capsule."
88896187|NCT01278875||Acute Coronary Syndrome|Subjects with ACS within 72 hours of clinical presentation
88896188|NCT01278875||Stable CAD subjects|Patients with stable, chronic CAD
88896189|NCT01278875||Control subjects|Healthy individuals
88896190|NCT01257269||1|Patients with confirmed hereditary TTP due to congenital ADAMTS13 deficiency
88896191|NCT01257269||2|Family members of patients with confirmed hereditary TTP
88896192|NCT01217281|No Intervention|Control|"Full mouth supra-gingival debridement using hand instruments and ultrasonic scalers, in one session. Patient motivation and oral hygiene instructions Review and prophylaxis at 1 month, 3 months and 6 months after initial treatment session.~Full mouth periodontal therapy provided at the end of the 6month period (supra and sub- gingival full mouth scaling)"
89418465|NCT02188290||MMUD group|Control group of eligible patients who received an HSCT from a 1-locus mismatched unrelated donor between 1 January 2010 and 31 December 2012
89418466|NCT02188290||UCB group|Control group of eligible patients who received a double umbilical cord blood transplantation between 1 January 2010 and 31 December 2012
89418467|NCT03702907||Normal Cognition|No diagnosis of a cognitive disorder
89418468|NCT03702907||Cognitive Disorder|Diagnosed with a cognitive disorder such as :Mild Cognitive Impairment, Alzheimer's disease, Frontotemporal Dementia, Lewy Body Dementia, Vascular Dementia, or other neurodegenerative condition.
89418469|NCT02256930|Experimental|M518101|M518101 will be applied 9 times for 21 days on the infrascapular area of the back under occlusive patch conditions.
89418470|NCT02256930|Placebo Comparator|M518101 Vehicle|M518101 Vehicle will be applied 9 times for 21 days on the infrascapular area of the back under occlusive patch conditions.
89418471|NCT02256930|Active Comparator|Sodium lauryl sulfate|The sodium lauryl sulfate will be applied 9 times for 21 days on the infrascapular area of the back under occlusive patch conditions.
88896193|NCT01217281|Active Comparator|Test/ Non-surgical Periodontal Therapy|"Full mouth periodontal therapy (sub and supra- gingival debridement) provided under local anaesthesia in two half-mouth sessions.~Review and prophylaxis 1 month, 3 months and 6 months after the end of the initial therapy."
88896194|NCT01068327|Experimental|Treatment (SRT, radiosensitizer, and chemotherapy)|See Detailed Description
88896195|NCT01035463|Experimental|Treatment (stem cell transplantation)|"PRE-CONDITIONING (patients with CD20+ NHL): Patients receive rituximab IV per standard of care.~PREPARATIVE REGIMEN: Patients receive carmustine IV on day -6, etoposide IV BID and cytarabine IV BID on days -5 through -2, and melphalan IV on day -1.~AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION: Patients undergo stem cell infusion on day 0.~MAINTENANCE THERAPY: Beginning approximately 100 days post-transplant, patients receive lenalidomide PO on days 1-21. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity."
88896196|NCT00937586||Newly diagnosed patients|Patients with newly diagnosed prostate cancer.
88896197|NCT00936390|Active Comparator|Dose-Escalated Radiation Therapy Alone|Radiation therapy consists of 79.2 Gy EBRT only or 45 Gy EBRT followed by low- or high-dose rate brachytherapy. EBRT is delivered in 1.8 Gy daily fractions.
89418472|NCT02256930|Sham Comparator|Saline|The saline will be applied 9 times for 21 days on the infrascapular area of the back under occlusive patch conditions.
89418473|NCT04056351|Other|Cohort of 50 enrolled patients|The following visits will be performed: direct post-OP, 3 weeks, 6 weeks, 3 months and 6 months after surgery. Surgical details will be assessed from the surgical notes. Medical images will be collected according to the standard of care. A post-OP CT scan will also be acquired when the treating surgeon requests it as per standard of care, or additionally, as a study specific imaging procedure for the rest of the participants. Patient activity will be estimated based on various factors, including questionnaires on demographics, activity level, comorbidity score and contralateral grip strength. The actual post-OP shoulder activity will be measured by motion tracking by means of sensors attached to upper arm of the treated side and on the chest for 6 weeks and by grip strength assessed at the treated arm at week 6. Fixation failure status will be determined 6 months post-OP. Imaging and details regarding the fixation failure event will be sent to ARI.
89418474|NCT02183922|Placebo Comparator|light fruit jam|The placebo group received light fruit jam (15 g/day) during 12 weeks.
89418475|NCT02183922|Experimental|microencapsulated fish oil|The microencapsulated fish oil group received light fruit jam with microencapsulated fish oil (3 g/day) during 12 weeks.
89418476|NCT02183922|Experimental|microencapsulated conjugated linoleic acid|The microencapsulated conjugated linoleic acid group received light fruit jam with microencapsulated conjugated linoleic acid (3 g/day) during 12 weeks.
88896198|NCT00936390|Experimental|Dose-Escalated Radiation Therapy and Short-Term Androgen-Deprivation|"Radiation therapy consists of 79.2 Gy EBRT only or 45 Gy EBRT followed by low- or high-dose rate brachytherapy. EBRT is delivered in 1.8 Gy daily fractions.~Six months of androgen-deprivation therapy starts 8 weeks prior to start of radiation therapy and consists of luteinizing-hormone releasing-hormone (LHRH) agonist (antagonist) therapy (leuprolide, goserelin, buserelin. triptorelin, or degarelix) and anti-androgen therapy (bicalutamide or flutamide)."
88896199|NCT00572234|Experimental|Receiving Bupropion SR|receiving bupropion SR 12 week course of bupropion SR 150 mg, BID (twice a day)
88896200|NCT00572234|No Intervention|Treatment as Usual|Not receiving bupropion
88896201|NCT00497926|Experimental|Living Kidney Allograft|Recipients with the need for a living kidney allograft are treated with an enriched hematopoietic stem cell infusion from the same living donor
88896202|NCT00411138|Active Comparator|Radiation Therapy|Pelvic Radiotherapy alone
88896203|NCT00411138|Experimental|Radiation Therapy and Chemotherapy|Pelvic Radiation plus 2 concurrent cycles cisplatin followed by 4 adjuvant cycles carboplatin and paclitaxel
88896204|NCT00149149|Experimental|Indomethacin treated volunteers|5d of indomethacin treatment (50 mg t.i.d) with ZnC (37.5 mg b.i.d) coadministration.
88896205|NCT00149149|Placebo Comparator|Placebo treated volunteers|5 days of indomethacin treatment (50 mg t.i.d) with placebo coadministration.
88896206|NCT01469312|Placebo Comparator|Control|The control arm consists of the traditional pasta.
89418477|NCT03699787|Experimental|Graphomotor intervention program|The experimental group (EG) intervention comprises a graphomotor intervention program according to a psychomotor approach. The program integrates two group sessions (6-8 children)/week of 30 minutes for 8 weeks (16 sessions).
89418478|NCT03699787|No Intervention|Control Group|The control group (CG) participants will maintain their normal classroom activities. After the study, control group participants will be offered the opportunity to integrate a similar graphomotor intervention program.
89418479|NCT03564405|Experimental|UNI-DEB|
89418480|NCT02190942||Vasculitis Contact Registry Patients|Consent will be obtained from at least 20 randomly selected patients with each of the following self-identified diagnoses in the VCRC Patient Contact Registry: Behçet's disease, EGPA, GCA, GPA, MPA, PAN and TAK that have already completed the VCRC Diagnostic Questionnaires. Permission will be obtained to contact subjects' primary vasculitis care providers to request that the providers complete an online version of this questionnaire (or print copy, if they prefer), and request specific chart items from their office to further verify the data.
88896207|NCT01469312|Active Comparator|Modified pasta|Dreamfields, Miracle Noodles
88896208|NCT01469325|Active Comparator|Repetitive Transcranial Magnetic Stimulation|We deliver rTMS to the left prefrontal cortex at 120% motor threshold (10 Hz, 4-second train duration, and 26-second intertrain interval) for 37.5 minutes (3000 pulses per session) using a figure-eight solid-core coil.
88896209|NCT01469325|Sham Comparator|Sham rTMS|Sham rTMS using a similar coil with a metal insert blocking the magnetic field and scalp electrodes that delivered matched somatosensory sensations.
88896210|NCT01469338|Experimental|Supportive care (management of therapy complications)|Patients receive cabazitaxel IV over 1 hour on day 1, prednisone PO QD, and octreotide pamoate IM on day 1. Patients also receive octreotide acetate SC TID on days 1-14 of course 1 only. Treatment with cabazitaxel repeats every 21 days and treatment with prednisone and octreotide pamoate repeats every 4 weeks for up to 10 courses in the absence of disease progression or unacceptable toxicity.
88896211|NCT01469351|Active Comparator|Drug|the GLP-1 receptor analog liraglutide is the active drug. The dose is 1.8mg daily
88896212|NCT01469351|Placebo Comparator|placebo|non active intervention
88896213|NCT01469403|No Intervention|control group|Standard procedure for knee arthroplasty
88896214|NCT01469403|Active Comparator|Weight loss program|The intervention program consists of 8 weeks of low-diet, using formula foods, and dietary counseling before surgery. When using formula foods the patients can achieve a quicker weight reduction and a greater reduction in fat mass than using conventional dietetic hypo caloric diet.
88896215|NCT01469416|Active Comparator|Rosuvastatin|
88896216|NCT01469416|Experimental|Rosuvastatin + clopidogrel|
88896217|NCT01469429|Placebo Comparator|Arm I (Lozenge placebo)|Patients receive lozenge placebo PO QID.
88896218|NCT01469429|Experimental|Arm II (LBR lozenge)|Patients receive lyophilized black raspberries lozenge PO (8gms/day)
88896219|NCT01469429|Placebo Comparator|Arm III (Saliva Substitute placebo)|Patients receive Saliva Substitute placebo PO QID.
88896220|NCT01469429|Experimental|Arm IV (LBR Saliva Substitute)|Patients receive lyophilized black raspberries Saliva Substitute PO (8gms/day).
88896221|NCT01469442|Experimental|external biliary duct stent|'External Biliary duct stent in the bile duct by cystic way'
88896222|NCT01469442|No Intervention|without external biliary duct stent|
89418481|NCT02184000||1. the control group healthy adult volunteers|
89418482|NCT02184000||2. patients with chronic hepatitis B or C|
89418483|NCT02184000||3. pacients with liver cirrhosis type B or C|
89418484|NCT03702829|Experimental|Experimental Drug|Inotersen, a transthyretin (TTR) antisense oligonucleotide. Administered subcutaneously weekly. Each dose shall contain 300 mg of active drug. Subsequent visits will occur at 3, 6, 12, 18 and 24 months. Every 2 weeks, blood will be monitored for renal function and platelet count and urine will be tested by dipstick for proteinuria.
89418485|NCT03064984|Active Comparator|CBS eyedrops|Eyedrops prepared from CBS (Cord Blood Serum), and administered 1 drop/each eye/8 times per day, for 30 days
89418486|NCT03064984|Active Comparator|PBS eyedrops|Eyedrops prepared from PBS (Peripheral Blood Serum) from adult donor subjects, administered 1 drop/each eye/8 times per day, for 30 days
89418487|NCT02184078|Experimental|single group|"Nevirapine:~Study days 15-28 dose given once a day (q.d.) Study days 29-42 dose given twice a day (b.i.d.)~Rifabutin:~Study Days 0 to 42"
89418488|NCT03702673|Experimental|Treatment A|K-877 CR Tablet A
88896223|NCT01469455|Experimental|DT01|
89418489|NCT03702673|Experimental|Treatment B|K-877 CR Tablet B
89418490|NCT03702673|Experimental|Treatment C|K-877 CR Tablet E
89418491|NCT03702673|Experimental|Treatment D|K-877 IR Tablet
89418492|NCT03694951|Experimental|Intervention Group|The intervention group will receive a pedometer and HAPA behavioural counseling with the aim of reducing their daily sedentary behaviour to <7 hours per day, over a one week period. Counseling strategies will be grounded in the HAPA model - specifically, creating an action plan and coping strategies for reducing their daily sedentary behaviour. Strategies may include: setting an alarm while studying to break up sedentary behaviour, to stand rather than sit on transit, and/or to achieve an active step profile (i.e., ≥10,000 steps a day) through pedometer self-monitoring.
89418493|NCT03694951|No Intervention|Control Group|The control group will not receive any behavioural intervention.
89418494|NCT03694873|Experimental|tramadol|one tablet of Tramadol 100 mg (Tramaw, Global Napi, Giza,Egypt) administered orally immediately, 12 h and 24 h after randomization.
89418495|NCT03694873|Active Comparator|celecoxib|one tablet of Celecoxib 200 mg (Celebrex® 200, Pﬁzer,USA) administered orally immediately, 12 h and 24 h after randomization.
89418496|NCT02188446|Experimental|Smoking and alcohol cessation education|
89418497|NCT02188446|No Intervention|Standard treatment|Standard treatment is information about benefits of stopping drinking and smoking before surgery and if wanted, advice about who to contact to get support.
89418498|NCT02191020|Experimental|Total glucosides of paeony & Acitretin Capsules|During the first week，0.6g，oral，b.i.d.During the other weeks，0.6g，oral，t.i.d
89418499|NCT02191020|Active Comparator|Acitretin Capsules|20mg/day oral,when subject's weight less than 70kg;otherwise,30mg/day oral.
89418500|NCT02832063|Active Comparator|B244 arm|B244 dose administered in a 1:1 (active vs placebo) ratio
89418501|NCT02832063|Placebo Comparator|Placebo arm|Placebo dose administered in a 1:1 (active vs placebo) ratio
89418502|NCT02188524|No Intervention|Control Group|No exercise program
89418503|NCT02188524|Experimental|Exercise Group|exercise program
88896224|NCT01469468|Experimental|Single arm, fixed sequence dosing|
88896225|NCT01469481|Experimental|1|
88896226|NCT01469494|Active Comparator|DIEP flap group|The standard of care for the patient population is the DIEP or SIEA flap breast reconstruction. Currently the single operating surgeon in the study will always try to perform a SIEA flap reconstruction. If the anatomy does not allow it he will convert to a DIEP flap. The majority of breast surgeons in North America will generally perform a DIEP flap initially. The proposed study does not alter the standard of care received.
89418504|NCT03694717||Patients|The patients will receive a 500 ml fluid expansion over a standardized 10 minutes period
89193844|NCT03644277|Experimental|Rapael glove with dAIH|"The Rapael Smart Glove is a virtual reality hand exoskeleton rehabilitation device. The tasks selected will address gross movement, hand function, and dexterity. Tasks utilized will include, but are not limited to: fly swat, throwing darts, squeezing an orange, catching a baseball, and floating fish. The number of total repetitions and activity outcomes will be recorded.~Once fitted with the mask, initial recordings of heart rate, blood pressure, and arterial oxygen saturation (SpO2) will be taken. The sequence of hypoxia will consist of 60- 90 seconds of 9-10% O2 (FiO2 0.09), alternating with 60- 90 seconds of 21% O2 (normoxic air FiO2 0.21). The delivery of hypoxia and normoxic air mixtures will be repeated up to 18 times per session each, for a total of up to 45 minutes, to maintain SpO2 at 80-90%."
88896227|NCT01469494|Active Comparator|SIEA flap group|The standard of care for the patient population is the DIEP or SIEA flap breast reconstruction. Currently the single operating surgeon in the study will always try to perform a SIEA flap reconstruction. If the anatomy does not allow it he will convert to a DIEP flap. The majority of breast surgeons in North America will generally perform a DIEP flap initially. The proposed study does not alter the standard of care received.
88896228|NCT01469507|Experimental|V0220|
89193845|NCT03644277|Active Comparator|Rapael glove with Sham dAIH|"The Rapael Smart Glove is a virtual reality hand exoskeleton rehabilitation device. The tasks selected will address gross movement, hand function, and dexterity. Tasks utilized will include, but are not limited to: fly swat, throwing darts, squeezing an orange, catching a baseball, and floating fish. The number of total repetitions and activity outcomes will be recorded.~Once fitted with the mask, initial recordings of heart rate, blood pressure, and arterial oxygen saturation (SpO2) will be taken. The sequence of hypoxia will consist of 60- 90 seconds of 9-10% O2 (FiO2 0.09), alternating with 60- 90 seconds of 21% O2 (normoxic air FiO2 0.21). The delivery of hypoxia and normoxic air mixtures will be repeated up to 18 times per session each, for a total of up to 45 minutes, to maintain SpO2 at 80-90%."
88896229|NCT01469507|Active Comparator|Hyaluronan|
89193846|NCT03644277|Placebo Comparator|No training with dAIH|"Once fitted with the mask, initial recordings of heart rate, blood pressure, and arterial oxygen saturation (SpO2) will be taken. The sequence of hypoxia will consist of 60- 90 seconds of 9-10% O2 (FiO2 0.09), alternating with 60- 90 seconds of 21% O2 (normoxic air FiO2 0.21). The delivery of hypoxia and normoxic air mixtures will be repeated up to 18 times per session each, for a total of up to 45 minutes, to maintain SpO2 at 80-90%.~Hearth rate and pulse oximetry will be continuously monitored throughout, and recording will be taken at each alteration in sequence. Blood pressure will be taken upon completion of the total sequence"
89193847|NCT03643770|No Intervention|Acute Intermittent Hypoxia (AIH) treatment|The mask will first provide a normoxic air (room air) mixture (FiO2 = 0.21) via the mask. The mask is designed to couple with a universal mask circuit connecting to the air mixture system. The purpose of the mask will be to minimize room air entrainment.
89193848|NCT03643770|Active Comparator|AIH in combination with upper extremity training|The mask will first provide a normoxic air (room air) mixture (FiO2 = 0.21) via the mask. The mask is designed to couple with a universal mask circuit connecting to the air mixture system. The purpose of the mask will be to minimize room air entrainment. In addition to this upper extremity training will be given using an upper-limb robotic rehabilitation device.
89418505|NCT02184234|Experimental|Antistax film coated tablets|
88896230|NCT01469520|Active Comparator|Reference|Co-administered liquid mixture of Epivir® (lamivudine) solution, Retrovir® (zidovudine)and Viramune® (nevirapine)
88896231|NCT01469520|Active Comparator|Test product|Fixed dose combination of lamivudine, zidovudine and nevirapine reconstitutable suspension
88896232|NCT01469520|Active Comparator|Test Product|Fixed dose combination combination (Lamivudine, Zidovudine and Nevirapine)tablet
88896233|NCT01469533|Experimental|experimental group|The experimental group receives the real spinal mechanical manipulation.
88896234|NCT01469533|Sham Comparator|control group|The control group receives the sham-manipulation procedure.
88896235|NCT01469559|Active Comparator|Novolin Toronto insulin|
88896236|NCT01469559|Placebo Comparator|Normal saline|
88896237|NCT01469572|Experimental|Sir-sphere radioembolization|Everolimus, Pasireotide and Sir-sphere radioembolization
88896238|NCT01469598|Experimental|Gemcitabine/Docetaxel|Gemcitabine 1000 mg/m2 IV over 10 mg/m2/min Docetaxel 35 mg/m2 IV over 1hr every 21 days
88896239|NCT01469611|Experimental|JX-594|Infusion Procedure:JX-594 will be administered on the designated treatment days at a dose of either 1 x 106, 1 x 107 or 3 x 107 pfu per kg. Virus infusion should occur over 60 minutes (+/- 5 minutes). The final infusion volume of virus plus diluent will be approximately 250 mL.
88896240|NCT01469624|Experimental|Test group|This group receives pentoxifylline
88896241|NCT01469624|No Intervention|Control group|
88896242|NCT01469663||Healthy Control|Healthy participants without borderline personality or depression
88896243|NCT01469663||Major Depression, No Borderline Personality Disorder|With major depression and no borderline personality
88896244|NCT01469663||Major Depression + Borderline Personality Disorder|With major depression and borderline personality disorder
88896245|NCT01469663||No Major Depression, Borderline Personality Disorder|With no major depression, but with borderline personality disorder
88896246|NCT01469676|No Intervention|Control group|In the Control group, a standard arterial line filter was inserted on CPB circuit.
88896247|NCT01469676|Experimental|Filtering Group|In the Filtering group, a leukocyte filter was inserted in the arterial line circuit.
88896248|NCT01469689|Experimental|Google Adwords only|In these areas,the investigators will display online adverts using Google Adwords, with links to the investigators' project website, and from there to four other websites for depression.
88896249|NCT01469689|Experimental|Local organisation websites|In these areas, the investigators will try to place adverts on the websites of local organizations, with links to the investigators' project website, and from there to four other websites for depression.
88896250|NCT01469689|Experimental|Google Ads and local websites|In these areas, the investigators will place Google Adwords and also try to place adverts on the websites of local organizations, with links to the investigators' project website, and from there to four other websites for depression.
88896251|NCT01469689|No Intervention|Control|Control areas. No Intervention
89418506|NCT03694639|No Intervention|Pregabaline group|where patients received pregabaline 150 mg twice daily.
89193849|NCT03643770|Active Comparator|Sham AIH therapy in combination with upper extremity training|Sham hypoxia followed by upper extremity training will be given using an upper-limb robotic rehabilitation device (Armeo Spring®, Hocoma AG, Switzerland). Armeo Spring is a gravity support system based on an ergonomic arm exoskeleton with integrated springs.
89536791|NCT03310151|Experimental|Intervention|Group follows usual care plus imagined movements in a home exercise plan. The exercises will be taught to the subject by reading through an exercise booklet with them, this ensures the advice is standardised. The imagined movement programme will consist of imagined wrist movement in all planes. The frequency of approximately 10-15 minutes, four times a day has been selected as a practical compromise of previous investigations, (Moseley, 2004 and Frenkel et al., 2014), and mirrors routine advice.
88896252|NCT01469728|Experimental|Awake VATS|Thoracoscopic talc pleurodesis performed in awake patients through sole thoracic epidural anesthesia.
88896253|NCT01469728|Active Comparator|Non-awake VATS talc pleurodesis|Thoracoscopic talc pleurodesis performed through sole general anesthesia and one-lung ventilation
88896254|NCT01469754||Lymphoma Survivors|
89193850|NCT03643770|No Intervention|Sham AIH therapy|Sham hypoxia
89193851|NCT03631173|Active Comparator|Patient with microdialysis|Intervention group - Patients will receive an intraperitoneal microdialysis catheter and will be monitored consecutively by microdialysis. The surgeon is familiar with the current microdialysis results at any time during the study period. The surgeon may intervene based on traditional symptoms and signs plus predetermined values of the microdialysis results.
89418507|NCT03694639|Active Comparator|Pregabaline plus ganglion impar block group|where patients received pregabaline 150 mg twice daily plus ganglion impar block using 5 ml bupivacaine 5% with 14 mg/2 ml betamethasone.
89418508|NCT03564327||Patients with sinus rhythm|
89418509|NCT03564327||patients with atrial fibrillation|
89418510|NCT05014854|Other|Intervention|"Finger and tip pressures are assessed in two phases (A/B). Baseline measurements (A) are collected in the 1st and 2nd therapy session after inclusion. First, data is collected via SEMS (from 2nd grade) or via a sheet with standard forms (1st grade), followed by the recording of a standard sentence (from SEMS) or a standard form at the end of the session. The 2nd session is started and ended with the writing of the chosen standard set. Phase-A-measurements are recorded without feedback.~From the 3rd therapy session on SensoGrip is used with activated feedback (B). At the end of each session, the same standard set used in Phase A is written twice - once with and once without feedback. This order changes each time to minimize possible bias due to habitation to writing with SensoGrip. Data is recorded in both forms. Children can take SensoGrip home from the 4th session on and use it in daily life.~In the last session, SEMS or the standard forms are re-executed as initially applied."
89418511|NCT04476199|Experimental|Treatment with VEN-DEC|Venetoclax will be given with a 3-day ramp up beginning with 100 mg dose on Day 1, with 200mg on Day 2, to reach the final dose of 400 mg on Day 3 of Cycle 1. Venetoclax will be continued at 400 mg daily. Tumor lysis prophylaxis will be administered from day -4, cycle 1 (oral uric acid reducing agent and hydration with at least 1.5 L/day).Decitabine will be administered at the dose of 20 mg/sqm intravenously from day 1 to day 5 every 28 days (VEN-DEC) for 2 cycles.
89418512|NCT02188680|Active Comparator|Low FODMAPS diet and positive breath testing for fructose|Patients with breath testing positive have a low FODMAPS diet. The test will be considered as positive if we observe an increase of more than 20 ppm of H2 and/or CH4 on a sample with regard to the basal concentration
89418513|NCT02188680|Sham Comparator|negative breath testing for fructose|patients with negative breath test have a low FODMAPS diet
89418514|NCT03702595|Experimental|Interventional group|Hip flexors stretching protocol
89418515|NCT02191098|Experimental|ALT-803|ALT-803
89418516|NCT02188758||Adults - CFPE Treatment|Other: CF Pulmonary Exacerbation (CFPE) Treatment
89418517|NCT02030340||Testing Lower urinary tract dysfunction|All patients with lower urinary tract dysfunction where urodynamic diagnosis is required according to standards and (international) practice guidelines will have a synchronous double system (combination of air-charged and water filled) urodynamic test.
89418518|NCT02191176|Experimental|Dextromethorphan syrup - low dose|
89418519|NCT02191176|Experimental|Dextromethorphan syrup - high dose|
89418520|NCT02191176|Placebo Comparator|Placebo|
88896255|NCT01469793|Experimental|DMOT4039A Q3W: Dose Escalation|Participants in different cohorts will receive DMOT4039A at various escalating dose levels, starting with 0.2 milligrams per kilogram (mg/kg), as intravenous infusion every 3 weeks (Q3W) to determine the maximum tolerated dose (MTD) of DMOT4039A for until disease progression, loss of clinical benefit or unacceptable toxicity, whichever occurred first (up to approximately 2.5 years).
88896256|NCT01469793|Experimental|DMOT4039A Q3W: Dose Expansion|Participants will receive DMOT4039A at recommended phase 2 dose (RP2D) for Q3W dosing schedule as intravenous infusion Q3W until disease progression, loss of clinical benefit or unacceptable toxicity, whichever occurred first (up to approximately 2.5 years).
89193852|NCT03631173|No Intervention|Patient without microdialysis|The control group - The patients will not receive a microdialysis catheter. The patients are monitored according to current standards of care and the surgeon may intervene based only on traditional symptoms and signs.
88896257|NCT01469793|Experimental|DMOT4039A Q1W: Dose Escalation|Participants in different cohorts will receive DMOT4039A at various escalating dose levels, starting with a dose 33% of MTD for Q3W dosing schedule, as intravenous infusion every week (Q1W) to determine the MTD of DMOT4039A for until disease progression, loss of clinical benefit or unacceptable toxicity, whichever occurred first (up to approximately 2.5 years).
89193853|NCT03598894||Case NDHT|Healthy non-dipping hypertensives 'NDHT' (24h mean wake SBP >145mmHg at baseline and a decline of <10% between mean day time and night time systolic pressures)
89418521|NCT03694093||Patients with Hyperhidrosis|Subjects with Primary Hyperhidrosis will be followed in this study. Because this study is observational, there will be no intervention.
89418522|NCT02191254|Experimental|Antistax®|1 tablet per day for 12 weeks
89418523|NCT02191254|Placebo Comparator|Placebo|
89418524|NCT02184312|Experimental|Nevirapine XR low dose|
89418525|NCT02184312|Experimental|Nevirapine XR medium dose|
89418526|NCT02184312|Active Comparator|Nevirapine XR high dose|
89418527|NCT02184312|Active Comparator|Nevirapine (VIRAMUNE®)|commercial product
89418528|NCT02184390|Experimental|tutorial|Parents who receive access to the tutorial immediately
88896258|NCT01469793|Experimental|DMOT4039A Q1W: Dose Expansion|Participants will receive DMOT4039A at RP2D for Q1W dosing schedule as intravenous infusion Q1W until disease progression, loss of clinical benefit or unacceptable toxicity, whichever occurred first (up to approximately 2.5 years).
89418529|NCT02184390|No Intervention|wait list control|Parents who are assessed at the same time points as the intervention arm, but do no receive access to the tutorial
88896259|NCT01469806||1 - PFJ|Patients who require primary partial knee arthroplasty of the patello-femoral joint.
89418530|NCT02184468|Other|Dual dispatch|Simultaneously dispatching of EMS, firefighters and/or police in OHCA
89418531|NCT02188914||Inhalant use disorder group|Subjects must have a diagnosis of inhalant use disorder, according to the DSM-5, who are under a treatment program for addictive disorders.
88896260|NCT01469845|Active Comparator|hypertonic saline and usual care|
88896261|NCT01469845|Active Comparator|usual care (oxygen therapy)|
88896262|NCT01469858|Experimental|study group|fMRI
89418532|NCT02188914||Normal control group|Normal control without a history of drug abuse or dependency.
89418533|NCT04050241|Experimental|Videolaryngoscope|Anesthetists performing intubation with the Glidescope videolaryngoscope.
89418534|NCT04050241|Experimental|Direct laryngoscope|Anesthetists performing intubation with the Mcintosh laryngoscope.
89418535|NCT02191332||Viramune|
89418536|NCT03702361|Experimental|Rapid infusion of Vpriv|Rapid intravenous infusion of velaglucerase alfa (VPRIV) in treatment-naive patients with type 1 Gaucher disease
89536792|NCT03310151|No Intervention|control|Follows usual care
88896263|NCT01469871|Active Comparator|Hypafix Transparent dressing|The Hypafix Transparent dressing, a stretchable dressing, will be used to treat the patients in this group
88896264|NCT01469871|Active Comparator|Mepore Pro dressing|The Mepore Pro dressing, a self-adhesive perforated dressing, will be used to treat the patients in this group
88896265|NCT01469871|Active Comparator|Mepilex Border dressing|The Mepilex Border dressing, a self-adherent soft silicone dressing, will be used to treat the patients in this group
88896266|NCT01469884|Experimental|Certican®|Arm1(conversion):Certican®+mycophenolate+prednisone
89418537|NCT02191410|Active Comparator|High Frequency Positive Pressure Ventilation|
89418538|NCT02191410|Placebo Comparator|Continuous Positive Airway Pressure|
89418539|NCT03699085|Experimental|ED-LINC Intervention Condition|Patients in this arm will receive the ED-LINC intervention. Elements of ED-LINC are based on evidence-based treatments and are central components of collaborative care. ED-LINC will be supported by a novel Emergency Department Information Exchange (EDIE) technology platform that allows for the creation of ED care plans and electronic alerts and will assist in care coordination of this complex population.
89418540|NCT03699085|No Intervention|Usual Care Condition|Patients in this arm may receive a spectrum of consulting services visits including social work services, psychiatric consultation, inpatient psychiatry consult, rehabilitation psychology consultation, addiction intervention services, pain team consultation services that include MD psychiatric and PhD psychologist providers, spiritual care or other consulting services which shall count as usual care.
89418541|NCT02188992||Cohort 1|Patients with sepsis syndrome, without criteria for severe sepsis/septic shock. These patients are recruited from the emergency department.
89418542|NCT02188992||Cohort 2|Patients with community acquired sepsis syndrome REQUIRING critical care admission due to severity of sepsis. These patients are recruited from the critical care areas (ICU/HDU).
89418543|NCT02188992||Cohort 3|Patients without sepsis syndrome. Age and gender matched to cohort 1, and recruited from Emergency Department.
89418544|NCT02191644|Placebo Comparator|Refined rice|
89418545|NCT02191644|Experimental|Whole grains and legumes|
89418546|NCT02184702||shoulder arthroscopy|
89418547|NCT02189070||Responders|Responding participants
89418548|NCT02189070||Non-responders|Non-responding participants
89418549|NCT02189148||Cohort|"Each participant will :~give consent~provide a blood sample (10 ml)~be measured (weight and height for BMI calculation)~undergo a blood pressure measurement~have an ultrasound exam (uterine arteries Doppler, placental volume, thickness of the placenta)~answer to a short questionnaire (5 pages)"
89418550|NCT02189226|Experimental|probe-based confocal laser endomicroscopy (pCLE) group|
89418551|NCT02189226|Active Comparator|chromoendoscopy (CE) group|
89418552|NCT03698929|Active Comparator|Dietary Effect of Cholesterol - Egg Phase|In a randomized, 9-week crossover trial, we will test the effects of dietary cholesterol in individuals without baseline cholesterol intake through two 4-week dietary intervention periods, using baked goods containing egg yolks or egg-free baked goods. During the egg phase participants will consume two egg yolks a day for four weeks. Each week, participants will be given a week's worth of baked goods containing two egg yolks each.
89418553|NCT03698929|Placebo Comparator|Dietary Effect of Cholesterol - No-Egg Phase|In a randomized, 9-week crossover trial, we will test the effects of dietary cholesterol in individuals without baseline cholesterol intake through two 4-week dietary intervention periods, using baked goods containing egg yolks or egg-free baked goods. During the no-egg phase participants will consume an egg-free product for four weeks. Each week participants will be given a week's worth of egg-free baked goods.
88896267|NCT01469884|Active Comparator|Tacrolimus or Cyclosporine|Arm2(maintained):Tacrolimus or Cyclosporine+mycophenolate+prednisone
89418554|NCT02256774|Experimental|Combivir® plus BILR 355/Ritonavir|
89418555|NCT02256774|Experimental|BILR 355/Ritonavir|
89418556|NCT04597164||Artificial liver support system group|100 patients in this group will receive treatment of double plasma molecular adsorption system, low volume plasma exchange, and comprehensive internal medical treatment
89418557|NCT04597164||Comprehensive medical treatment group|100 patients in this group will receive comprehensive internal medical treatment.
89418558|NCT02191722|Experimental|JIA patients|All participants will be evaluated before and after reading the comics booklet
88896268|NCT01469286|Active Comparator|TEA|Needleless electroacupuncture at ST36 and PC6
88896269|NCT01469286|Placebo Comparator|Sham-TEA|Needleless acupuncture at sham-points
88896270|NCT01469910|Experimental|Simotinib|
88896271|NCT01469910|Placebo Comparator|Placebo|
88896272|NCT01469923|Active Comparator|AZD2820|AZD2820 multiple injections
88896273|NCT01469923|Placebo Comparator|Placebo for AZD2820|Placebo for AZD2820 multiple injections
88896274|NCT01469936|Experimental|PERMEAPROTECT|
88896275|NCT01469936|Placebo Comparator|PLACEBO|
88896276|NCT01469949||Kinesthetic Imagery group|Subjects receiving Kinesthetic Imagery
88896277|NCT01469949||Visual Imagery Group|Subjects receiving visual imagery
88896278|NCT01469949||Control group|Subjects receiving measurement with intervention
88896279|NCT01469962||obese patients|
88896280|NCT01469975|Experimental|Arm A: Dose level 1|1.5 mg of OTSA101-DTPA radiolabelled with 370MBq of 90Y
88896281|NCT01469975|Experimental|Arm B: Dose level 2|1.5 mg of OTSA101-DTPA radiolabelled with 1110 MBq of 90Y
88896282|NCT01469975|Experimental|Arm C: Dose level 3|3 mg of OTSA101-DTPA radiolabelled with 2220 MBq of 90Y
88896283|NCT01469988|Experimental|Testosterone|
89418559|NCT03693859|Experimental|Behavioral Weight Loss + Gaming|Treatment will consist of 12-weekly, one-hour group sessions of approximately 15 participants per group. Participants will provide logs of serious gaming (intervention).
88896284|NCT01469988|Placebo Comparator|Placebo|
89193854|NCT03598894||Control NT|matched healthy normotensives 'NT' (24h mean wake SBP <120mmHg)
89418560|NCT03693859|Active Comparator|Behavioral Weight Loss + Health Segments|Control participants will be asked to spend 30 minutes watching health segments online, five days per week, for 8 weeks. Participants will provide logs of video segment watching (control).
89193855|NCT03598894||Control DHT|matched dipping hypertensives 'DHT' (24h mean wake SBP >145mmHg and a decline of >10% between mean day time and night time systolic pressures)
89418561|NCT02184780||GUSTO Neurocognitive Cohort|This study involves retrospective analysis of data from an existing cohort of 600 infants who were enrolled in the neurocognitve arm of the GUSTO study (Growing up in Singapore Towards Healthy Outcomes). GUSTO is a prospective observational cohort study done in Singapore, where subjects were followed up from in-utero up to 36 months of age and beyond. The infants have already undergone a rigorous battery of neurocognitive tests at 6, 18, 24 and 36 months of age and their detailed demographic and medical information are available.
89418562|NCT02256852|Experimental|QBKPN SSI|Individualized maintenance dose administered subcutaneously for 12 weeks
89418563|NCT02189304|Experimental|PT010|PT010; Budesonide, Glycopyrrolate, and Formoterol Fumarate Inhalation Aerosol. Administered as 2 inhalations
89418564|NCT02189304|Experimental|PT009|PT009; Budesonide and Formoterol Fumarate Inhalation Aerosol. Administered as 2 inhalations
89193856|NCT03584464|Other|Bifurcation Cohort|Subjects receiving stents 2.0 mm - 5.0 mm in diameter will be included in the Bifurcation Cohort.
89418565|NCT02189304|Active Comparator|Symbicort Turbohaler|Symbicort Turbohaler; Budesonide and Formoterol Fumarate Inhalation Powder taken as 2 inhalations
89418566|NCT02184858|Experimental|lisinopril|dose titration of investigational product (lisinopril) dependant on blood pressure, levels of renin and aldosterone and on adverse events.
89418567|NCT02191956|Active Comparator|Behavioral Parent Training|Standard of care intervention
89418568|NCT02191956|Experimental|Behavioral Parent Training - Enhanced|Standard of Care Behavioral Parent Training plus new delivery methods
88896285|NCT01470014||IVNC|
88896286|NCT01470014||differential diagnosis to IVNC|
88896287|NCT01470040|Experimental|discontinuation of aspirin therapy|
88896288|NCT01470040|Sham Comparator|continuation of aspirin therapy|patients will continue their pre-injury dose of low-dose aspirin therapy per previous medical indication
88896289|NCT01470053|Experimental|mometasone furoate + azelastin HCl|opaque suspension, four times each naris per day
88896290|NCT01470053|Active Comparator|mometasone furoate|opaque suspension, four times each naris per day
88896291|NCT01470053|Active Comparator|azelastine HCl|lucidus colorless liquid, two times each naris per day
88896292|NCT01470092|Active Comparator|Tibolone|Subjects will take 2.5mg of oral Tibolone daily for the duration of the 12 week trial either alone or in adjunct to currently prescribed anti-depressant medication.
88896293|NCT01470092|No Intervention|Placebo|Subjects will take oral placebo tablets packaged daily for the duration of the 12 week trial either alone or in adjunct to currently prescribed antidepressant medication.
88896294|NCT01470157|Experimental|Ketamine|Oral Ketamine in addition to oral midazolam
88896295|NCT01470157|Placebo Comparator|Placebo|Normal saline (placebo) in addition to oral midazolam
88896296|NCT01470183||Lupus Nephritis Patients|"Male or female subjects age 18 and older~Must have confirmed diagnosis of Class III or Class IV lupus nephritis by biopsy~Must have stable disease on medication at time of enrollment"
88896297|NCT01470183||Control Patients|Any patient with an idiopathic glomerular disease who does not have lupus nephritis. This includes patients with minimal change disease, membranous nephropathy, focal segmental glomerulosclerosis, and IgA nephropathy.
88896298|NCT01470209|Experimental|Combination of BKM120 and everolimus|
88896299|NCT01470222|Experimental|Intervention Group|"Monthly, all-worksite activities will be implemented to raise awareness of healthy nutrition for weight control throughout the worksite. The purpose of the all-worksite activities is: a) to create a supportive worksite-wide atmosphere for the individuals enrolling in the weight loss support group, and b) to provide low-level weight loss support for individuals who wish to prevent weight gain.~Individuals with eligible weight (defined as BMI ≥ 25 kg/m2) without medical contradictions to weight loss, who wish to join a support group to lose weight, may enroll in the worksite weight control support group that will meet weekly for the first 10 weeks and then monthly until the end of the 6-month intervention"
88896300|NCT01470222|Experimental|Control Group (delayed intervention)|At the end of the study period, subjects will receive a 2-month structured intervention that will provide all of the resources and materials given to the intervention worksite as well as weight control support groups for employees interested in losing weight.
89193858|NCT03567824|Experimental|Open label phase|MLD10 (magnesium l-lactate dihydrate) 10mEq extended release caplets BID for three months, all subjects.
89418569|NCT02030652|Experimental|SNIPPV Group|Synchronized nasal intermittent positive pressure using NAVA ( Intermittent nasal positive pressure positive ventilation.)
89418570|NCT02030652|Active Comparator|CPAP Group|Nasal CPAP group without intermittent ventilation.
89418571|NCT03535662|Experimental|Orvepitant|Orvepitant single 20mg dose
89418572|NCT03535662|Experimental|Orvepitant and itraconazole|Orvepitant single 20mg dose in combination with repeat dose itraconazole
89536793|NCT01470755|Other|salbutamol - dose 1|Metered dose inhaler, 100µg+300µg per puff, administered one day
89536794|NCT01470755|Other|Salbutamol - dose2|Metered dose inhaler, 100µg+500µg per puff, administered one day
89418573|NCT02192034|Experimental|Navigation Group|This group will receive standard clinic instructions for the colonoscopy and two additional phone calls from the patient navigator to discuss the purpose, preparation, and additional information regarding the colonoscopy procedure.
89418574|NCT02192034|Placebo Comparator|Control|This group will receive only clinic instructions without intervention from the patient navigator.
88896301|NCT01470235||Ovarian Cancer|"Women treated for ovarian cancer at the departments of obstetrics and gynecology, Aarhus University Hospital and Rigshospitalet, Copenhagen.~Expected recruitment: 200"
88896302|NCT01470235||Control patients|"Women referred to the departments of obstetrics and gynecology in Aarhus University Hospital and Rigshospitalet, Copenhagen on benign indication.~Expected recruitment: 200."
89418575|NCT03702205|Experimental|Betaine supplementation|The experimental procedure for each athlete includes a 3-week betaine supplementation either 2.5 g or 5 g daily. Betaine will be administered in the form of capsules containing either 0.5 or 1 g betaine. The capsules will be ingested with at least 250 mL of water. Each athlete will ingest 5 betaine capsules a day. On training days the supplements will be taken in the morning (2 capsules), in the evening (2 capsules) and 1.5 hours before training session (1 capsule). On rest days the supplements will be taken in the morning (2 capsules), in the afternoon (1 capsule) and in the evening (2 capsules).
89535999|NCT03200197|Active Comparator|Usual care (maintenance of fasting)|Allocation concealment was performed through the use of individual opaque envelopes numbered externally in sequence, containing the randomly defined group information.This step was performed by a researcher who did not participate in the data collection.The intensity of the initial thirst was measured by means of the Verbal Numerical Scale (VNS), which ranged from 0 (no thirst) to 10 (very intense thirst) and the discomfort of the initial thirst was measured through the Perioperative Thirst Discomfort Scale (PTDS), which is composed of 7 attributes and ranges from 0 to 14. After maintaining the usual care, that is, reaffirming the need for fasting for 10 minutes, the intensity and final discomfort were measured using the same scales.
89193859|NCT03567824|Other|Random off phase|MLD10 (magnesium l-lactate dihydrate) 10mEq extended release caplets BID for three months or Placebo
89193860|NCT03565159|Active Comparator|Prevenar 13|A volume of 0.5ml will be drawn up into a syringe and labelled with an Annex 13 label.
89193861|NCT03565159|Placebo Comparator|Sodium chloride 0.9%|A volume of 0.5ml will be drawn up into a syringe and labelled with an Annex 13 label.
89418576|NCT03702205|Experimental|Placebo treatment|The experimental procedure for each athlete included a 3-week placebo administration. Placebo will be capsules with starch. Placebo will be ingested with at least 250 mL of water. Each athlete will ingest 5 placebo capsules a day. On training days the supplements will be taken in the morning (2 capsules), in the evening (2 capsules) and 1.5 hours before training session (1 capsule). On rest days the supplements will be taken in the morning (2 capsules), in the afternoon (1 capsule) and in the evening (2 capsules).
89418577|NCT03624829||Exp: Patients of GPs with shared care|All patients 16-65 years old who during 12 months have been in contact with a GP in any of the three GP centers that are randomized to shared care before the 12 months.
89418578|NCT03624829||Con: Patients of GPs without shared care|All patients 16-65 years old who during 12 months have been in contact with a GP in any of the three GP centers that are not randomized to shared care before the 12 months, and all patients 16-65 years old who during 12 months have been in contact with a GP in any of the six GP center before the randomization and implementation of shared care.
89418579|NCT02189460||Healthy adults|20 young adults aged between 30 and 50 years old. 20 middle aged adults aged between 50 and 70 years old. 20 older adults of 70 years old and more.
89418580|NCT02189538|Experimental|ω-3 PUFA|Modular low fat diet (18%) including 9% as ω-3 PUFA
89418581|NCT02189538|Active Comparator|Low fat enteral diet|Modular low fat (18%)
89418582|NCT02184936||acute ischemic stroke|
89418583|NCT02192268|Active Comparator|HFOO|Children of the HFOO group will be subjected to two daily sessions of this resource which should be the same throughout her hospitalization with Shaker equipment.
89418584|NCT02192268|Active Comparator|Assisted Coughing|The children in the control group will be subjected to two daily sessions of assisted coughing.
89418585|NCT02192268|Active Comparator|PEP|The children will be subjected to PEP group two daily sessions of this resource which should be the same throughout her hospitalization with facial mask and valve Spring load with expiratory pressure of 10cmH2O.
89418586|NCT02185092|Placebo Comparator|Sugar Pill|1 pill orally daily
89418587|NCT02185092|Active Comparator|Lactobacillus GG|1 pill (2 x 10x 9 CFU) daily orally
89418588|NCT02189616|Other|regular care group|receive regular care which contains filling a paper asthma diary daily.
89418589|NCT02189616|Experimental|SMS reminder group|receive weekly mobile phone short message reminders for 3 months
89418590|NCT02189616|Experimental|SMS reminder and SMS consultation group|receive weekly mobile phone short message reminders and can consult asthma nurse by mobile phone short message when needed for 3 months
89418591|NCT03693703|Experimental|bi-parametric MRI|Patients will undergo axial T2-weighted and diffusion-weighted imaging (no contrast agent injection)
89418592|NCT03693703|Active Comparator|multi-parametric MRI|Patients will undergo multiparametric MRI including morphological study (T2- and T1-weighted imaging) and functional acquisitions (diffusion-weighted and dynamic contrast-enhanced imaging)
88896303|NCT01470235||HBOC/HNPCC|"Patients registered in the large Danish Register of HBOC( hereditary breast and ovarian cancer) and HNPCC (hereditary nonpolyposis colorectal cancer).~Expected recruitment: 200."
89418593|NCT02189694|Active Comparator|Insulin pump therapy|Glucose levels will be controlled for 3 consecutive nights using insulin pump therapy. Subjects will carry on with their normal conventional insulin pump therapy and will be allowed to freely implement therapeutic adjustments..
89418594|NCT02189694|Active Comparator|Single-hormone closed-loop strategy|Glucose levels will be controlled by single-hormone closed-loop strategy for 3 consecutive nights. A member of the research team will be present at the diabetic camp to ensure protocol implementation and patient's safety. Glucose levels will be controlled by single-hormone closed-loop strategy between 22:00 until 7:00 next morning. Glucose sensor reading will be entered manually into the computer every 10 minutes. The computer will generate a recommendation for the basal rates of insulin delivery. Pump's parameters will then be changed manually to implement the computer generated recommendations.
89418595|NCT02189694|Active Comparator|Dual-hormone closed-loop strategy|Glucose levels will be controlled by dual-hormone closed-loop strategy for 3 consecutive nights. A member of the research team will be present at the diabetic camp to ensure protocol implementation and patient's safety. Glucose levels will be controlled by dual-hormone closed-loop strategy between 22:00 until 7:00 next morning. Glucose sensor readings will be entered manually into the computer every 10 minutes. The computer will generate a recommendation for the basal rates of insulin delivery and glucagon mini-boluses. Pumps' parameters will then be changed manually to implement the computer generated recommendations.
89418596|NCT04277377||DSA in patients with kidney failure|Patients on kidney transplantation waiting list with DSA detected by Luminex (and mean fluorescence intensity (MFI) > 1000) in their blood.
89418597|NCT02189772|Experimental|MDX (metadoxine extended release)|"Route of administration: oral~The dose of MDX (approximately 14-22 mg/kg) will be determined by the subject's weight at the baseline visit as follows:~40-49 kg 700 mg consisting of a 700 mg tablet~50-64 kg 1050 mg consisting of a 700 mg tablet, a 350 mg tablet~65-100 kg 1400 mg consisting of two 700 mg tablets"
89418598|NCT02189772|Placebo Comparator|placebo|Placebo tablets will be similar in appearance (color and size) to the investigational product
89418599|NCT02192346|Experimental|2.4 mg/kg α-TEA|Patients will receive oral α-TEA 2.4 mg/kg daily for the first 14 days of a 28 day cycle.
89418600|NCT02192346|Experimental|4.8 mg/kg α-TEA|Patients will receive oral α-TEA 4.8 mg/kg daily for the first 14 days of a 28 day cycle.
88896304|NCT01470261||ADHD medicated|Children aged 5-17 years with clinical diagnosis of ADHD and not previously treated with methylphenidate who have an agreement with their physician to begin treatment with methylphenidate.
88896305|NCT01470261||ADHD unmedicated controls|Children aged between 5-17 years with clinical diagnosis and not previously treated with methylphenidate who have an agreement with their physician NOT to treat with methylphenidate
89193862|NCT03550040|Active Comparator|Robot assisted prostatectomy.|Intervention: radical prostatectomy
89418601|NCT02192346|Experimental|8.0 mg/kg α-TEA|Patients will receive oral α-TEA 8.0 mg/kg daily for the first 14 days of a 28 day cycle.
89418602|NCT02192346|Experimental|9.6 mg/kg α-TEA|Patients will receive oral α-TEA 9.6 mg/kg daily for the first 14 days of a 28 day cycle.
89418603|NCT02192346|Experimental|12 mg/kg α-TEA|Patients will receive oral α-TEA 12 mg/kg daily for the first 14 days of a 28 day cycle.
89418604|NCT02192346|Experimental|16.8 mg/kg α-TEA|Patients will receive oral α-TEA 16.8 mg/kg daily for the first 14 days of a 28 day cycle.
89418605|NCT02192346|Experimental|19.2 mg/kg α-TEA|Patients will receive oral α-TEA 19.2 mg/kg daily for the first 14 days of a 28 day cycle.
89418606|NCT02192346|Experimental|22.3 mg/kg α-TEA|Patients will receive oral α-TEA 22.3 mg/kg daily for the first 14 days of a 28 day cycle.
89418607|NCT02192346|Experimental|26.8 mg/kg α-TEA|Patients will receive oral α-TEA 26.8 mg/kg daily for the first 14 days of a 28 day cycle.
89193863|NCT03550040|Experimental|3D laparoscopic prostatectomy|Intervention: radical prostatectomy
89418608|NCT04319068||Healthy|Eligible participants from the Biobank cohort at the National Heart Centre, Singapore, will be screened will be recruited for the study over a period of 3 years.
89418609|NCT04319068||Hypertensive|Eligible participants from the Biobank cohort at the National Heart Centre, Singapore, will be screened will be recruited for the study over a period of 3 years
89418610|NCT03698773|Active Comparator|Baseline Group|Access to existing educational materials about labor/delivery pain relief options, as well as an opportunity to ask physicians, nurses, and other relevant personnel for more information.
89418611|NCT03698773|Experimental|Website Group|Access to a tablet computer set to display an educational website (thepainlesspush.com) with information about labor/delivery pain relief options, as well as an opportunity to ask physicians, nurses, and other relevant personnel for more information.
89193864|NCT03531320|Experimental|Part 1:Dose-Escalation Phase|40 mg D07001-softgel capsules 60 mg D07001-softgel capsules 80 mg D07001-softgel capsules 120 mg D07001-softgel capsules 160 mg D07001-softgel capsules
89193865|NCT03531320|Experimental|Part 2: Dose-Expansion Phase (Phase 2)|higher dose-expansion of D07001-softgel capsules lower dose-expansion of D07001-softgel capsules
89193866|NCT03529201|Experimental|QLB|At the end of surgery, QLB with ropivacaine will be done on the side of the operation.
89418612|NCT02185170|Experimental|Fluorescence assesment|"All patients undergo a transurethral resection.~There are four different steps in the study:~the first step: fresh prostatic tissue of 30 subjects will be use to asses the fluorescence signal and the entire chain,~the second step: fresh prostatic tissue of 10 subjects will be used to asses the immunolabelling protocol,~the third step: fresh prostatic tissue of 20 subjects will be used to asses the use of the FEMTO-ST institute medical device,~the four step: the fresh prostatic tissue from the 10 subjects of the second step will be evaluated to verify the preservation of morphological structure with the use of the Light-CT scanner."
89418613|NCT03693469|Experimental|Virtual Reality|Participants are distracted by wearing the virtual reality headset and watching a roller coaster app during immunization.
89006550|NCT04622761|Experimental|treatment|"14 days prior to starting Cabazitaxel patients will take 50mg Bicalutamide once daily for 21 days.~7 days prior to starting Cabazitaxel patients will be given 3 months LHRH treatment via injection. The entire dose will be administered via one injection 7 days prior to starting Cabazitaxel. This may be either leuprorelin or goserelin acetate and should be given as per local practice.~At least 30 minutes prior to each administration of Cabazitaxel, patients will be administered IV premedication consisting of:~50mg Ranitidine 10mg Chlorphenamine 8mg Dexamethasone Daily from Day 1 until end of Cabazitaxel treatment patients will take 10mg Prednisolone once daily from Day 1 until end of Cabazitaxel treatment Day 1 of each cycle - Patients will receive Cabazitaxel 25 mg/m2 intravenously over one hour every 21 days (on Day 1 of each cycle). Treatment will be continued for 4 cycles."
89006551|NCT04622371|Experimental|moderate exercises group|Patients received 30 minutes of aerobic exercise at 40-60% of maximum heart rate
89418614|NCT03693469|No Intervention|Control (Standard-of-Care)|Participants are distracted with Standard-of-Care by doctors, nurses, nurse practitioners, child life specialists and/or parents.
89418615|NCT02192424|Active Comparator|Metformin alone|After a 3-week course of intensive insulin therapy, participants will be treated with ongoing metformin monotherapy. Metformin will be initiated at 500mg twice a day for the first 2 weeks, before progressing to 1000mg twice a day for the duration of the trial (24 months).
89418616|NCT02192424|Experimental|Metformin + Intermittent Insulin Therapy|After a 3-week course of intensive insulin therapy, participants will be treated with ongoing metformin monotherapy, initiated at 500mg twice a day for the first 2 weeks, before progressing to 1000mg twice a day for the duration of the trial (24 months). Participants will stop their metformin for 2 weeks every 3 months, during which time they will receive intermittent intensive insulin therapy for 2 weeks. The 2-week course of insulin therapy will be repeated at 3-, 6-, 9-, 12-, 15-,18- and 21-months, with final outcome measurement performed at 24-months.
89418617|NCT04276597|Experimental|Lu177 DOTATOC treatment|4 doses of 200mCi 177Lu- DOTATOC PRRT
89418618|NCT02257008|Experimental|Single rising dose of BILR 355 BS with grapefruit juice|
89006552|NCT04622371|Experimental|Light exercises group|Patients treated by walking30 minutes daily divided into 5minutes every 2 hours to break sedentary position for 12 hours daily.
89006553|NCT04622215|Other|ICIQ questionnaire|
89006554|NCT04622137|No Intervention|Arm sling only group (group S)|Participants used only arm sling for clavicula fracture
89193867|NCT03529201|Experimental|Control|Standard care. No regional blocks.
89418619|NCT02257008|Experimental|Single rising dose of BILR 355 BS with nelfinavir|
89418620|NCT02257008|Experimental|Single dose of BILR 355 BS with atazanavir|
89418621|NCT02257008|Experimental|Single dose of BILR 355 BS with atazanavir, ritonavir|
89418622|NCT04432948||Maternal Group|Pregnant women administered into a maternity public hospital in labour (vaginal delivery, caesarean section)
89536000|NCT05002179|Experimental|Treatment group|"Treatment group, 3 x 2 Echinaforce chewable tablets (EC, 3x800mg) daily during prevention and 5 x 2 EC (5x800mg) during acute viral Respiratory tract infection vRTIs"
89193868|NCT03510208|Experimental|Cohort 1 -50mg panitumumab-IRDye800|A panitumumab-IRDye800 dose of 50mg (Cohort 1) with or without a 100 mg loading dose of unlabeled panitumumab will be injected 1 to 5 days before the planed standard of care surgery. Participants then undergo NIR imaging during standard of care surgery 1-5 days after receiving panitumumab-IRDye800.
89193869|NCT03510208|Experimental|Cohort 2 -100mg panitumumab-IRDye800|A panitumumab-IRDye800 dose of 100mg (Cohort 2) with or without a 100 mg loading dose of unlabeled panitumumab will be injected 1 to 5 days before the planed standard of care surgery. Participants then undergo NIR imaging during standard of care surgery 1-5 days after receiving panitumumab-IRDye800.
88896306|NCT01470261||Non-ADHD controls|Any child, including siblings of a child in either the ADHD-medicated or ADHD-unmedicated control group, who is 5-17 years old. These children must have a low rating (<1.5) on the clinician-rated Swanson Nolan and Pelham IV Rating scale (SNAP IV) and not be medicated with with either dexamfetamine or atomoxetine.
88896307|NCT01470287|Experimental|Arm 1|
88896308|NCT01470300|Experimental|Standard ED|100% energy density
89193870|NCT03510208|Experimental|Cohort 3 -100mg panitumumab-IRDye800|Cohort 3 dose will be determined based on Cohort 1 and Cohort 2, with or without a 100 mg loading dose of unlabeled panitumumab will be injected 1 to 5 days before the planed standard of care surgery
88896309|NCT01470300|Experimental|Reduced ED - F/V|80% energy density by adding fruit and vegetables
88896310|NCT01470300|Experimental|Reduced ED - Fat|80% energy density by decreasing fat
88896311|NCT01470300|Experimental|Reduced ED - Plain water|80% energy density by adding plain water
88896312|NCT01470313|Experimental|PD-0360324|
89536001|NCT05002179|No Intervention|Control Group|"No treatment Comparison group. Participants are free to take none or any preventive measure. Participants are requested not to take any Echinacea products"
88896313|NCT01470313|Placebo Comparator|Placebo|
88896314|NCT01470326||Bazedoxifene Tablets|Subjects taking Bazedoxifene Tablets
88896315|NCT01470339|Placebo Comparator|placebo|migraine patients to receive placebo treatment
88896316|NCT01470339|Active Comparator|duloxetine|migraine patients to receive duloxetine
88896317|NCT01470352|Placebo Comparator|Placebo|
89193871|NCT03496623|Experimental|Inhaled Treprostinil|Inhaled treprostinil delivered via an ultrasonic nebulizer with a target dosing regimen of 12 breaths (72 micrograms [mcg]) 4 times daily (QID)
88896318|NCT01470352|Active Comparator|treatment|Duloxetine will be given in a daily dose of 30 mg for 5 weeks
88896319|NCT01470365|Experimental|Treatment (radiation therapy)|Patients undergo 3-dimensional CRT or IMRT QD, 5 days a week for 10-30 days. Treatment continues in the absence of disease progression or unacceptable toxicity.
89193872|NCT03496623|Placebo Comparator|Placebo|Placebo delivered via an ultrasonic nebulizer for QID administration
88896320|NCT01470378|Active Comparator|Control Group|This group will not be undergoing to manual lymphatic drainage
88896321|NCT01470378|Active Comparator|Study Group|This group will be undergoing to manual lymphatic drainage
88896322|NCT01470391|Experimental|Adductor-Canal-Blockade|
88896323|NCT01470391|Active Comparator|Femoral Nerve Block|
88896324|NCT01470404||adjuvant chemotherapy|Patients enrolled on to the adjuvant XP trial + patients who received adjuvant chemotherapy following curative resection of gastric cancer
88896325|NCT01470430||ROP infants treated with intravitreal anti-VEGF agents|
89193873|NCT03473561|Experimental|Racecadotril plus standard treatment oral rehydration solution|Racecadotril Infants Granules for Oral Suspension 10 mg (in addition to standard treatment i.e. oral rehydration solution) Racecadotril Children Granules for Oral Suspension 30 mg (in addition to standard treatment i.e. oral rehydration solution)
89193874|NCT03471260|Experimental|Treatment (venetoclax, ivosidenib, azacitidine)|Patients receive venetoclax PO daily on days 1-14. Patients also receive ivosidenib PO daily on days 15-28 of cycle 1 and days 1-28 of subsequent cycles. Patients may also receive azacitidine IV over 30-60 minutes or SC on days 1-7. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89536002|NCT03107299|Other|Control|
89193876|NCT03459820|Experimental|18F-DCFPyL PET/CT|18F-DCFPyL PET/CT Scan
89536003|NCT03107299|Other|Send sms to patients|
89536004|NCT03107299|Other|pharmaceutical maintenance following medical consultation|
89536005|NCT04997967|Experimental|Ketofol group|Patients undergoing urgent therapeutic ERCP for severe cholangitis, with American Society of Anaesthesiologist (ASA) Grade II - III. Will receive Ketofol (ketamine: propofol concentration 1:4) prepared in 50 ml syringe containing dextrose 5% (each ml contained 8 mg propofol and 2 mg ketamine), administered as following; 5 ml of ketofol as loading then infusion titrated till targeted RSS score.
88896326|NCT01470430||ROP infants treated with retinal laser photocoagulation|
88896327|NCT01470443|Active Comparator|GEMOX|"Gemcitabine 1,000 mg/㎡, day 1 and 8, every 3 weeks~Oxaliplatin 100 mg/㎡, day 1, every 3 weeks"
89536795|NCT01470755|Other|Salbutamol - dose3|Metered dose inhaler, 200µg+600µg per puff, administered one day
88896328|NCT01470443|Experimental|XELOX|Xeloda, 1000mg/㎡ bid, day 1-15, every 3 weeks Oxaliplatin 130mg/㎡, day 1, every 3 weeks
88896329|NCT01470456|Experimental|SAR3419 + Rituximab|Combined therapy will be administered intravenously for 8 doses in the absence of unacceptable toxicity, disease progression or withdrawal of consent.
88896330|NCT01470482|Other|No Tourniquet|We compare tourniquet or not in knee surgery
88896331|NCT01470482|Active Comparator|Tourniquet|We compare tourniquet or not in knee surgery
88896332|NCT01470495|Experimental|RFA+Sorafenib|to treat recurrent HCC both with RFA and Sorafenib
88896333|NCT01470495|Active Comparator|RFA group|To treat recurrent HCC with RFA
88896334|NCT01470508|Experimental|Family Enhancement|PAS is a 27-week program consisting of 25 sessions, 50 minutes in length, between an individual and a therapist. During six (6) family sessions, a family member will accompany the individual to therapy and will take an active role during the session. In this program, individuals and their family members will learn about ways to communicate about their relationship in the context of experiencing an eating disorder. PAS focuses on family-specific skills such as communication skills and problem solving skills while also incorporating eating disorders psychoeducation.
88896335|NCT01470508|Active Comparator|Cognitive Behavioral Therapy|Individuals meet their therapist once a week for 25 sessions, 50 minutes in length, for a period of 27 weeks for therapy.
88896336|NCT01470521|Experimental|Hookworm larvae (Necator americanus)|Participants will receive 25 live hookworm larvae
88896337|NCT01470521|Placebo Comparator|Placebo|Participant will receive pharmacopoeial grade water
88896338|NCT01470534|Experimental|Normal body weight|
88896339|NCT01470534|Experimental|Obese|
89418623|NCT03693391|Experimental|Cohort 1: JNJ-64140284|Participants in cohort 1 will receive single oral dose of JNJ-64140284 at a starting dose of 0.5 milligram (mg) under fasted conditions. The dose levels of JNJ-64140284 will be escalated sequentially based on the decisions of an independent Data Review Committee (iDRC), the clinical team and the investigator. First 3 participants will also receive an intravenous (IV) bolus injection of [18F]JNJ-64511070 at a dose of 185 megaBecquerel (MBq). Participants with no measurable brain receptor occupancy will receive second (escalated) dosing with JNJ-64140284 and subsequent positron emission tomography-computed tomography (PET-CT) scan.
89418624|NCT03693391|Experimental|Cohort 2: JNJ-64140284|Participants in cohort 2 will receive next dose level of JNJ-64140284 based upon the data-review from the previous cohort and on the decisions of an iDRC, the clinical team and the investigator. At least 3 participants will receive an IV bolus injection of [18F]JNJ-64511070 at a dose of 185 MBq. Participants with no measurable brain receptor occupancy will receive second (escalated) dosing with JNJ-64140284 and subsequent PET-CT scan.
89418625|NCT03693391|Experimental|Cohort 3: JNJ-64140284|Participants in cohort 3 will receive next dose level of JNJ-64140284 based upon the data-review from the previous cohort and on the decisions of an iDRC, the clinical team and the investigator. At least 3 participants will receive an IV bolus injection of [18F]JNJ-64511070 at a dose of 185 MBq. Participants with no measurable brain receptor occupancy will receive second (escalated) dosing with JNJ-64140284 and subsequent PET-CT scan.
89418626|NCT03693391|Experimental|Cohort 4: JNJ-64140284|Participants in cohort 4 will receive next dose level of JNJ-64140284 based upon the data-review from the previous cohort and on the decisions of an iDRC, the clinical team and the investigator. At least 3 participants will receive an IV bolus injection of [18F]JNJ-64511070 at a dose of 185 MBq. Participants with no measurable brain receptor occupancy will receive second (escalated) dosing with JNJ-64140284 and subsequent PET-CT scan.
89418627|NCT02185248|No Intervention|Control Group|General clinical counseling in regards to child's BMI category and necessary changes to diet and activity regimen.
89418628|NCT02185248|Experimental|Wellness Plan|Received a wellness action plan. The plan included a color-coded BMI chart to help parents understand their child's weight category as well as a brief action planning worksheet to help families create personalized plans around healthy diet and activity changes.
89418629|NCT04433806|Experimental|Intervention|25 subjects, all referred to community based program for weight loss at ExercisAbilities
89418630|NCT03693313|Experimental|CrossFit KAMP Group 1|14 weeks of CrossFit Kids exercise program
89418631|NCT03693313|Active Comparator|CrossFit KAMP Wait-list Group|Waitlist group that waits 14 weeks while group 1 does exercise program. After first 14 weeks will then participate in 14 weeks of CrossFit Kids exercise program
89418632|NCT02189928|Experimental|With per-CID protocol|Usual care patients (thrombolysis or not ) with remote ischemic per-conditioning using an electronic tourniquet .
89418633|NCT02189928|Other|Without per-CID protocol|Usual care patients (thrombolysis or not).
89418634|NCT04433650|Experimental|Group 1|"The child will firstly undergo phase A without the digital reporting and communication tool.~The child will secondly undergo phase B with the digital reporting and communication tool (i.e., A, B)."
88896340|NCT01470534|Placebo Comparator|Normal Body Weight placebo|Participants of mormal body weight given placebo
88896341|NCT01470534|Placebo Comparator|Obese placebo|Participants who are obese given placebo
88896342|NCT01470560|Sham Comparator|Sham Yoga Group Treatment|Sham yoga group (control group) will attend 8 weekly sessions for 1-2 hours and will be lead by a certified yoga instructor. The yoga class will be based on Pantajali's Eight Fold Path which is the basis of Yoga. Emphasis will be placed on healthy alignment and ways to pace and adjust poses to make them safe and productive for the body.
88896343|NCT01470560|Active Comparator|MBSR Group Treatment|Mindfulness-Based Stress Reduction (MBSR) was developed by Jon Kabat-Zinn in 1979. MBSR is a group-based intervention, typically provided to up to 30 participants, in a class-based format of eight weekly two hour sessions.
88896344|NCT01470573|Experimental|Progenitor Autologous Cells|Progenitor Autologous Cells of Sclerocorneal Limbus Amplified ex Vivo
88896345|NCT01470586|Other|Surgery for colorectal cancer|Colorectal cancer patients
88896346|NCT01470586|No Intervention|Controls|Controls
88896347|NCT01470625|Other|LCP Program|The LCP Program is continuous quality improvement program of end-of-life care implemented in hospice
88896348|NCT01470690|Active Comparator|boceprevir|Boceprevir 800 mg TID for 4 consecutive days + a single dose of 800 mg on Day 5 (BOC alone)
88896349|NCT01470690|Active Comparator|omeprazole|Omeprazole 40 mg QD for 5 consecutive days (OME alone)
88896350|NCT01470690|Experimental|boceprevir+omeprazole|Omeprazole 40 mg QD for 5 consecutive days combined with boceprevir 800 mg TID for 4 consecutive days + a single dose of 800 mg on Day 5 (BOC+OME)
88896351|NCT01470703|Experimental|ECMO arm|
88896352|NCT01470703|Active Comparator|conventional arm|
88896353|NCT01470729||Spinocerebellar Ataxia type 1 (SCA1)|Spinocerebellar Ataxia type 1 (SCA1)
88896354|NCT01470729||Spinocerebellar Ataxia type 2 (SCA2)|Spinocerebellar Ataxia type 2 (SCA2)
88896355|NCT01470729||Spinocerebellar Ataxia type 3 (SCA3)|Spinocerebellar Ataxia type 3 (SCA3)
88896356|NCT01470729||Spinocerebellar Ataxia type 7 (SCA7)|Spinocerebellar Ataxia type 7 (SCA7)
88896357|NCT01470742|Active Comparator|XELODA|Capecitabine 1000mg/m2 bid D1-14 every 3weeks
88896358|NCT01470742|Experimental|XELOX|D1-14 Capecitabine 1000mg/m2 bid D1 Oxaliplatin 110mg/m2 + D5W 250ml over 2hr every 3weeks
88896359|NCT01470768|Other|Arm 1 - AA Formula with DHA and ARA|Marketed AA formula with Docosahexanoic Acid (DHA) and Arachidonic Acid (ARA)
88896360|NCT01470768|Other|Arm 2 - AA Formula with alternative levels of DHA and ARA|
88896361|NCT01470794|Experimental|Single Arm|Toca 511 vector/Toca FC prodrug
88896362|NCT01470807|Experimental|portable artificial pancreas system with CTR algorithms|This is the only arm of the study and concerns all patients.
88896363|NCT01470820|Active Comparator|Distance 20 cm|The infants were randomized by sealed and opaque envelopes to one of four phototherapy regimens. Either with distance from the phototherapy device to the mattress of 20, 29, 38 or 47 cm measured by a wood stick for each infant, corresponding to the distances to the infants of averagely 12, 21, 30 and 39 cm, respectively.
88896364|NCT01470820|Active Comparator|Distance 29 cm|
89006555|NCT04622137|Active Comparator|Arm sling with kinesiotaping therapy group (group K).|Participants used arm sling and the investigators applied kinesiotheraphy for clavicula fracture
89006556|NCT04622449||Chronic liver disease with anemia|All patients with anemia as diagnosed by WHO criteria in patients with liver disease of any etiology.
89006557|NCT00412412|Experimental|A|Patients with HER2- Breast Cancer
89006558|NCT00412412|Experimental|B|Patients with HER2+ Breast Cancer
89006559|NCT00242931|Experimental|Fludarabine, TBI, Cyclosporine, MMF|"Fludarabine 30 mg/m2/day x 3, day -4 to day -2 TBI 200 cGy x 1, day 0 For related donors: cyclosporine (CSP) 5 mg/kg p.o. bid, day -3 to day +56, then taper by 20% every 5 days to be completed by day +81 For related donors: mycophenolate mofetil (MMF) 15 mg/kg p.o. q 12 hours, day 0 to day +27, then stop~For unrelated donors: cyclosporine (CSP) 5 mg/kg p.o. bid, day -3 to day +56, then taper by 20% every 5 days to be completed by day +81 For unrelated donors: mycophenolate mofetil (MMF) 15 mg/kg tid day +0 to day +29, 15 mg/kg bid day +30 to day +149, and then taper by 25% per week from day +150 to day +180. Discontinue by day +181."
89006560|NCT04622098||patients with SEL|"Any patient with detected sub-epithelial lesion during upper endoscopy either symptomatized or accidently discovered.~Patients diagnosed by EUS, CT scan or surgically removed lesions."
89006561|NCT00412490||Smoking Behavior Group|Individuals Having Surgery for Oral Cavity Cancer.
89006562|NCT00247182|Other|Step 1|Minimal Intervention
89006563|NCT00247182|Active Comparator|Step 2-A|Brief motivational intervention (BMI)
89006564|NCT00247182|Active Comparator|Step 2-B|Assessment-only control
89006565|NCT04622059|Experimental|acoustic stimulation|Fetuses in the group A (n=105) received an acoustic stimulation
89006566|NCT04622059|No Intervention|no acoustic stimulation|Fetuses in the group B (n=105) no intervention was performed
89006567|NCT04621903|Experimental|Ayurveda|
89006568|NCT04621942|Experimental|Training group|12 women after mastectomy. Inertial rehabilitation was performed twice a week (Monday and Thursday, between 5:00 and 8:00 PM) for 6 weeks using Cyklotren device (Inerion, Poland). Moreover, women from training group participated in rehabilitation gymnastics twice a week.
89006569|NCT04621942|Active Comparator|Control group|12 women after mastectomy. All women participated in rehabilitation gymnastics twice a week.
89006570|NCT04621591|Experimental|Saneso 360° gastroscope|Subjects will have a clinically indicated per standard of care EGD procedure performed using the Saneso 360° gastroscope. Immediately thereafter Patients will then have an EGD procedure using a standard Gastroscope (Olympus GIF 180) performed by a second endoscopist.
89006571|NCT00412568|Active Comparator|1|PRK control group
89006572|NCT04621669|Experimental|digoxin, Rosuvastatin calcium,SHR3680|
89006573|NCT04621669|Experimental|metformin hydrochloride ,SHR3680|
89006574|NCT00247221|Experimental|1) MI/Family Check-Up|Brief integrated individual and family intervention -- the experimental intervention integrates an individual Motivational Interview (MI) for the adolescent with a brief family intervention, the Family Check-Up
89006575|NCT00247221|Active Comparator|2) MI only|
89006576|NCT00562393|Experimental|Overfeeding|4 weeks of 1250 kcal added daily
89006577|NCT00562432|Experimental|Plexisyl-AF|Plexisyl-AF implants
89006578|NCT00562432|Sham Comparator|No Treatment|Surgery without experimental treatment
89006579|NCT00562471|Experimental|1|Adhesion Prevention Gel Arm
89006580|NCT00562471|Other|2|Standard of Care Comparator Arm (standard of care for post-operative adhesion prevention included irrigation of tissues and lavage of all fluids with Ringers Lactate solution following surgery and 300 to 500mL of solultion left in the pelvic cavity immediately prior to wound closure)
89006581|NCT00562510|Experimental|Raltegravir|
89006582|NCT00562510|Placebo Comparator|Raltegravir matching placebo|
89006583|NCT00562666|Experimental|1|Single hepatic intra arterial administration of 500 millions T gamma delta lymphocytes
89418635|NCT04433650|Experimental|Group 2|"The child will firstly undergo phase B with the digital reporting and communication tool.~The child will secondly undergo phase A without the digital reporting and communication tool (i.e., B, A)."
89006584|NCT00562666|Experimental|2|Single hepatic intra arterial administration of 1000 millions T gamma delta lymphocytes
89006585|NCT00562666|Experimental|3|Single hepatic intra arterial administration of 2000 millions T gamma delta lymphocytes
89006586|NCT00562666|Experimental|4|Single hepatic intra arterial administration of 4000 millions T gamma delta lymphocytes
89006587|NCT04621396||Next Generation Cohort|We will follow the children from mothers who either have T2D, GDM, or are controls.
89006588|NCT04621513|Experimental|Collaborative Care Model of TCM and WM|Traditional Chinese Medicine(TCM):laser acupuncture and massage education. Western Medicine (WM):intra-nasal corticosteroid with singulair
89006589|NCT04621513|Active Comparator|Western medicine|Western Medicine (WM):intra-nasal corticosteroid with singulair
89006590|NCT00562705|Experimental|1|Growth hormone and nutritional intervention
89006591|NCT00562705|Active Comparator|2|growth hormone
89006592|NCT04621162|Experimental|Positive Expectations (initial)|
89006593|NCT04621162|Experimental|Negative Expectations (initial)|
89006594|NCT04621162|Placebo Comparator|Neutral Expectations (initial)|
89006595|NCT04621162|Experimental|Positive Expectations (during intervention)|
89006596|NCT04621162|Experimental|Negative Expectations (during intervention)|
89006597|NCT04621162|Placebo Comparator|Neutral Expectations (during intervention)|
89006598|NCT04621357|Experimental|Patient with intracerebral haemorrhage|Patients will be screened at admission in the stroke units right after brain MRI demonstrating the presence of blood in the brain parenchyma.
89006599|NCT04621123|Experimental|Experimental group|Subjects randomized to convalescent anti-SARS-CoV-2 MBT plasma plus SMT will receive one infusion of 200 to 300 ml of ABO-compatible convalescent plasma obtained from a convalescent donor.
89006600|NCT04621123|Placebo Comparator|Control Group|Subjects randomized to placebo plus SMT will receive one infusion of 200 to 300 ml of sterile saline solution 0.9%.
89006601|NCT04621240|Experimental|Online SMART Intervention & Stress Solutions|Strategic Memory Advanced Reasoning Training (SMART) teaches meta-cognitive strategies for individuals to apply to their daily lives for improved performance
89418636|NCT02190006||Polycystic ovarian syndrome|Women with polycystic ovarian syndrome undergoing ICSI
88896365|NCT01470820|Active Comparator|Distance 38 cm|
88896366|NCT01470820|Active Comparator|Distance 47 cm|
88896367|NCT01470833|No Intervention|Non-weight-bearing|"The group of non-weightbearing is instructed as follows:~Week 1 to 6 No weightbearing. Crutches are obligatory. Week 7 to 8 Full weightbearing is allowed.~Dynamic rehabilitation From day 15 patients of both groups must do ankle exercises. Minimum 5 times a day the patient must take of the orthosis. Sitting at a table with the leg hanging freely over the edge a series of 25 active dorsal flexion and passive plantar flexion exercises must be made."
88896368|NCT01470833|Experimental|Early weight-bearing|"The group allowed early weight-bearing is instructed as follows:~Week 1 to 2 Weightbearing is allowed with in pain limit. Crutches are recommended.~Week 3 to 4 Full weightbearing is allowed. Week 5 to 8 Full weightbearing is allowed. Crutches should be avoided."
88896369|NCT01470846|Experimental|APD|patient with epidural analgesia
88896370|NCT01470846|Active Comparator|PCA|Patient with morphine analgesia
88896371|NCT01470885||glucose value|glucose value
88896372|NCT01470898|Experimental|anesthesia monitoring|Bispectral Index Monitoring (BIS) has been proven to be effective in preventing awareness. Optimizing anesthesia level using BIS monitoring, neither to light nor to deep will probably help to shorten recovery time and reduce drug consumption. A BIS sensor was applied to patient's forehead before induction of anesthesia and connected to A-2000 BIS monitor (Aspect Medical Systems, Newton, MA, USA). It records the electroencephalogram from 4 electrodes and after processing it with mathematic algorithms it generates a number from 0 to 100. When the BIS value is lower than 40, the patient is in deep anesthesia state, when the value is over 80, the patient is under light sedation.
88896373|NCT01470898|Experimental|no bispectral index monitoring|At the induction of anesthesia, and every 15 minutes during operation following parameters were recorded: heart rate (HR), systolic blood pressure (BP), end-tidal CO2 (etCO2) and BIS level. Also, operation time and extubation time were recorded. Finally, all patients were visited on the first postoperative day and interviewed about intraoperative recall.
88896374|NCT01470911|Experimental|SB010|The drug SB010 is administered in phosphate-buffered saline solution, inhaled via a controlled breathing system over a 5 to 10 min.
88896375|NCT01470911|Placebo Comparator|Placebo|The placebo (phosphate-buffered saline) is administered as a solution inhaled via a controlled breathing system over a 5 to 10 min.
88896376|NCT01470937|Experimental|Acarbose|acarbose 100 mg once daily
88896377|NCT01470937|Placebo Comparator|Placebo|Matched placebo was administered for acarbose 100 mg once daily
88896378|NCT01470950|Experimental|MotionMaker Training|Device description: MotionMaker™ is a stationary robotic system for the active mobilization of the lower limbs. With its proprietary 'Closed-Loop' technology, it is a novel and exciting development that offers a truly interactive patient training system Training 3 times a week with MotionMaker device together with conventional treatment
88896379|NCT01470963|Experimental|Referral template|Implementation of the referral templates at the GP office
88896380|NCT01470963|No Intervention|Control|Normal referral pattern
88896381|NCT01470976|Active Comparator|Goal-directed Therapy (GDT) Protocol|
88896382|NCT01470976|Active Comparator|Standard Protocol|
88896383|NCT01471002|Experimental|Renal cancer without nephrectomy|patients with renal cancer that cannot be offered a partial nephrectomy
88896384|NCT01471067|Experimental|Fludarabine/Clofarabine/Busulfan/Rituximab/TBI|Myeloablative Regimen: Rituxan 375 mg/m^2 (B cell malignancy) by vein (IV) on Day -10; Busulfan AUC 4,000 IV either as an outpatient prior to admission or as an inpatient on Day -9; Clofarabine 30 mg/m^2 IV Day -7 to Day -4; ATG 1.25 mg/Kg by vein on Day -4 and 1.75 mg/Kg by vein on Day -3; Fludarabine 10 mg/m^2 IV on Days -7 to -4; Total Body Irradiation (TBI) 2 Gy on Day -3; with Cord Blood infusions on Day 0.
88896385|NCT01471067|Experimental|Fludarabine + Melphalan|Reduced Intensity: Fludarabine 40 mg/m^2 IV on Days -5 to -2; Melphalan 140 mg/m^2 IV on Day -2; ATG 1.25 mg/Kg by vein on Day -4 and 1.75 mg/Kg by vein on Day -3; with Cord Blood infusions on Day 0.
88896386|NCT01471080|Experimental|RFA group|using RFA to treat cavernous hemangiomas
88896387|NCT01471080|Active Comparator|hepatectomy group|using laparoscopic hepatectomy to treat cavernous hemangiomas of the liver
88896388|NCT01471119|Experimental|Dermatophagoides Farinae Drops Group 1|Dermatophagoides Farinae Drops Group 1 is the group with maintenance dose of 2 drops of grade 5 Dermatophagoides Farinae and 1 drop of placebo.
88896389|NCT01471119|Experimental|Dermatophagoides Farinae Drops Group 2|Dermatophagoides Farinae Drops Group 2 is the group with maintenance dose of one drop of grade 5 Dermatophagoides Farinae and 2 drops of placebo.
88896390|NCT01471119|Experimental|Dermatophagoides Farinae Drops Group 3|Dermatophagoides Farinae Drops Group 3 is the group with maintenance dose of 3 drops of grade 4 Dermatophagoides Farinae.
88896391|NCT01471119|Experimental|Placebo|Placebo Group is the group with maintenance dose of 3 drops of placebo.
88896392|NCT01471132|Experimental|HIPEC|
88896393|NCT01471145|Experimental|Depot Naltrexone|
89536796|NCT01470755|Other|salbutamol - dose4|Metered dose inhaler, 200µg+200µg per puff, administered one day
89418637|NCT02192580|Active Comparator|Omega-3|omega-3 (DHA+EPA) in divided 3 times/day in addition to standard regimens: Children less than 18 kg:26 mg/kg EPA and 11 mg/kg DHA Children 18-24 kg:504 mg EPA and 216 mg DHA Children 25-32 kg:672 mg EPA and 288 mg DHA Children 33-41 kg:840 mg EPA and 360 mg DHA Children 5-15 years:1000 mg EPA and 878 mg DHA omega-3 in divided 3 times/day in addition to standard regimens
89418638|NCT02192580|No Intervention|Control|control group received just standard regimens without omega-3
89418639|NCT02193594|Experimental|CCRT group|The patient in CCRT group will receive the preoperative concurrent chemoradiotherapy for 5 weeks and sequential radical D2 total gastrectomy and postoperative adjuvant chemotherapy of 6 cycles.
89418640|NCT02193594|Active Comparator|CT group|The patient in CT group will receive radical D2 total gastrectomy and postoperative adjuvant chemotherapy of 8 cycles.
89418641|NCT02185326|Experimental|Microflare and growth hormone|the patients in this group were given oral contraceptive pills (OCPs) for 28 days, this was followed by 2 days free. Triptorelin (Decapeptyl Ferring Pharmaceuticals, Germany) 0.05 mg/day S.C. was then started daily followed by human menopausal gonadotropin IM daily (HMG 75 IU, Merional, IBSA) 3 days later. Growth hormone (Norditropin, Novo nordisk) was administrated on day 6 of HMG stimulation daily in a dose of 2.5 mg S.C. till the day of hCG administration.
89418642|NCT02185326|No Intervention|Microflare protocol alone|the patients in this group were given oral contraceptive pills (OCPs) for 28 days, this was followed by 2 days free. Triptorelin (Decapeptyl Ferring Pharmaceuticals, Germany) 0.05 mg/day S.C. was then started daily followed by human menopausal gonadotropin IM daily (HMG 75 IU, Merional, IBSA) 3 days later
89418643|NCT02185482|Experimental|Physician Supported Care|The intervention is an individualized, stepped-care depression treatment program provided by a depression clinical specialist primary care physician.
89418644|NCT02185482|Other|Usual care|Usual care patients will be advised to consult with their primary care physician regarding depression. Primary care physicians prescribe antidepressant medication and can refer patients to the Mental Health Services.
89418645|NCT02192658||People with Disability (PWD) (N= 850)|"PWD will be identified thanks to the disability screening tool developped by the Washington Group (WG). This tool is based on the WHO International Classification of Functionning (ICF).~A stratified cluster sampling in 2 steps will be used in both, Yaounde and Ouagadougou. Each city will be divided in enumeration areas (EAs). First step : EAs will be drawn randomly with probability proportional to their size in number of households. Second step: in each EA, 30 households will be randomly drawn and each person living in these households will be screened for disability with the WG tool, according to the inclusion and exclusion criteria."
88896394|NCT01471158|Active Comparator|Azarga/Cosopt|Following administration of the baseline dose (each intervention instilled in one eye in a contralateral fashion to establish baseline ocular comfort for each medication), Azarga will be instilled one drop in each eye on Day One, after which Cosopt will be administered one drop in each eye on Day Two.
88896395|NCT01471158|Active Comparator|Cosopt/Azarga|Following administration of the baseline dose (each intervention instilled in one eye in a contralateral fashion to establish baseline ocular comfort for each medication), Cosopt will be administered one drop in each eye on Day One, after which Azarga will be administered one drop in each eye on Day Two.
88896396|NCT01471184|Experimental|Ectoin® Eye Drops/Nasal Spray|Eye Drops/Nasal Spray
88896397|NCT01471184|Placebo Comparator|Placebo Eye Drops/Nasal Spray|
88896398|NCT01471210|Experimental|Part 1 : Urelumab (BMS-663513) Dose escalation|Urelumab (BMS-663513) solution administered intravenously on specified days
89193877|NCT03455517|Experimental|Veritas|"Step 1. All patients: venetoclax 5-weeks dose-titration phase with weekly increases in the dose of venetoclax.~Step 2. All patients will receive 6 courses of the VR combination.~Step 3. After 6 courses of VR combination:~3a. Patients with no response will be off treatment; 3b. Patients with clinical response (CR or PR) after 6 courses of VR combination will receive venetoclax as a single agent for 6 months. Then, patients will be observed clinically until disease progression or until month 36."
89193878|NCT03431168|Active Comparator|Azithromycin/TMPS|"Azithromycin 1 gm po daily x 3 days at enrollment and at each 4 week follow up visit.~TMPS double strength 1 tablet po daily."
88896399|NCT01471210|Experimental|Part 2 : Urelumab (BMS-663513) Cohort Expansion|Urelumab (BMS-663513) solution administered intravenously on specified days
88896400|NCT01471210|Experimental|Part 3:Urelumab (BMS-663513) Tumor-specific Cohort Expansions|Enrollment of subjects of three specific tumor types [(colorectal cancer (CRC), head and neck squamous cell carcinoma (SCCHN), and B-Cell non-Hodgkin's lymphoma (B-NHL)] who will be treated at the Maximum Tolerated Dose (MTD) (or highest dose tested)
88896401|NCT01471210|Experimental|Part 4:Urelumab (BMS-663513) Cohort Expansion in B-NHL|Arm A and Arm B: Urelumab (BMS-663513) liquid administered intravenously on specified days exploring q3w and q6w dosing regimen
88896402|NCT01471223||Patients receiving Belatacept in CTS|Patients receiving a 1st kidney-only transplant at a center participating in the CTS and receiving Belatacept at the time of transplantation
88896403|NCT01471223||Patients receiving CNI in CTS|Patients receiving a 1st kidney-only transplant at a center participating in the CTS and receiving CNI at the time of transplantation
88896404|NCT01471236|Experimental|Agili-c bi-phasic implant|mini-arthrotomy
89193879|NCT03431168|Placebo Comparator|Placebo/TMPS|"Azithromycin placebo 1 gm po daily x 3 days at enrollment and at each 4 week follow up visit.~TMPS double strength 1 tablet po daily."
89193880|NCT03419481|Experimental|pembrolizumab|
89193881|NCT03412630|Experimental|Diagnostic (computed tomography perfusion imaging)|Patients undergo computed tomography perfusion imaging at baseline and on day 15 after initiation of standard of care bevacizumab treatment and before the second dose.
88896405|NCT01471262||Elderly|Patients more or equal to 70 years old
88896406|NCT01471262||Young|Patients less than 70 years old
88896407|NCT01471275|Experimental|Jiangtangtiaozhi decoction|
88896408|NCT01471275|Active Comparator|metformin|
88896409|NCT01471314||Spontaneous migraine|
88896410|NCT01471327|Experimental|SB-240563, 10mg|IV, single dose at Day 1
88896411|NCT01471327|Experimental|Placebo|Saline IV, single dose at Day 1
88896412|NCT01471327|Experimental|SB-240563, 75mg|IV, single dose at Day 1
89418646|NCT02192658||Non-Disabled People (control group) (N= 850)|For each PWD, 1 non-disabled control person will be randomly chosen from the census list of the same enumeration area. Control will also be matched on age and sex.
89418647|NCT03536364|Experimental|Prediabetes|manipulation of food order during a meal on postprandial in subjects with prediabetes
89418648|NCT02192736|Other|Intra-nasal infusion of MTF|Trophic factors from umbilical cord mesenchymal stem cells administered intra-nasally
89418649|NCT03535428||VENOUS exploration|
89418650|NCT02192892|Experimental|CSB drum dried + α-amylase|CSB drum dried + α-amylase: Porridge from Corn Soy Blend drum dried with α-amylase
89418651|NCT02192892|Placebo Comparator|CSB drum dried - α-amylase|CSB drum dried - α-amylase: Porridge from Corn Soy Blend drum dried without α-amylase
89418652|NCT02192892|Experimental|CSB + α-amylase|CSB + α-amylase: Porridge from Corn Soy Blend with α-amylase
89418653|NCT02192892|Placebo Comparator|CSB - α-amylase|CSB - α-amylase: Porridge from Corn Soy Blend without α-amylase
89418654|NCT02192892|Experimental|RSB + α-amylase|RSB + α-amylase: Porridge from Rice Soy Blend with α-amylase
89418655|NCT02192892|Placebo Comparator|RSB - α-amylase|RSB - α-amylase: Porridge from Rice Soy Blend without α-amylase
89418656|NCT02192892|Active Comparator|WSB + α-amylase|WSB + α-amylase: Porridge from Wheat Soy Blend with α-amylase
89418657|NCT02192892|Active Comparator|Commercial porridge flour|Porridge from commercial porridge flour
89418658|NCT02192892|Active Comparator|Commercial porridge bar|Porridge from commercial porridge bar
89418659|NCT02192892|Experimental|CSB PLUS drum dried + α-amylase|CSB PLUS drum dried + α-amylase: Porridge from Corn Soy Blend PLUS drum dried with α-amylase
89418660|NCT02192892|Placebo Comparator|CSB PLUS drum dried - α-amylase|CSB PLUS drum dried - α-amylase: Porridge from Corn Soy Blend PLUS drum dried without α-amylase
88896413|NCT01471327|Experimental|SB-240563, 250mg|IV, single dose at Day 1
88896414|NCT01471327|Experimental|SB-240563, 750mg|IV, single dose at Day 1
88896415|NCT01471366|Active Comparator|Frozen capsule|Two frozen fish oil capsules (300 mg EPA/DHA per capsule) by mouth three times daily with 8 ounces of water without food or dairy products
88896416|NCT01471366|Active Comparator|Capsule with food|Two room temperature fish oil capsules (300 mg EPA/DHA per capsule) by mouth three times daily with 8 ounces of water with food but no dairy products
88896417|NCT01471366|Active Comparator|Capsule without food|Two room temperature fish oil capsules (300 mg EPA/DHA per capsule) by mouth three times daily with 8 ounces of water with no food or dairy products
88896418|NCT01471366|Active Comparator|Capsule with milk|Two room temperature fish oil capsules (300 mg EPA/DHA per capsule) by mouth three times daily with 8 ounces of milk with no food or additional dairy products
88896419|NCT01471392|Experimental|Identigene STD Test Kit Arm|Single-Arm trial where the group will complete the Identigene STD Test Kit at home and these results will be compared with the results from testing in the clinic with the Gen-Probe APTIMA kit. The subject will only be informed of the results from the approved test (Gen-Probe APTIMA) that is done in the clinic.
88896420|NCT01471418|Experimental|Disease population|
88896421|NCT01471431|Experimental|Spontaneous breathing trial|The spontaneous breathing trial will determine the extubation readiness of the subject.
88896422|NCT01471431|No Intervention|Usual care|Subjects will be extubated using usual care, without the use of the spontaneous breathing trial.
88896423|NCT01471470|Experimental|neoadjuvant|
88896424|NCT01471496|Experimental|prophylactic injection therapy group|In addition to medical therapy which included 2x 30 mg Pantoprazole and intravenous fluids this group of the patients recieved injection therapy.
88896425|NCT01471496|No Intervention|control group|This group of the patients recieved medical therapy only.
88896426|NCT01471509|Placebo Comparator|Control|240 ml water
88896427|NCT01471509|Active Comparator|glucose|50 g glucose
88896428|NCT01471509|Active Comparator|Amino acid|1 mmol amino acid/kg lean body mass
88896429|NCT01471509|Active Comparator|amino acid plus glucose|50 g glucose plus 1 mmol amino acid/kg lean body mass
88896430|NCT01471535|Experimental|peginterferon alpha 2a|the inactive chronic HBsAg carriers were treated with peginterferon alpha 2a for 72 weeks and followed for 24 weeks.
88896431|NCT01471548|Experimental|TKI258|dose escalation
88896432|NCT01471587||Patients with COPD|
88896433|NCT01471600|No Intervention|No intervention|Group overnight fasting
88896434|NCT01471600|Active Comparator|Group drink|Glucose drink (200 ml of fruit juice without pulp, ± 200ml coffee or tea, 2 at 4 hours before induction of anaesthesia)
88896435|NCT01471613|Experimental|Group C - Cord blood cell|Conventional treatment, cord blood cell transplant and placebo
88896436|NCT01471613|Placebo Comparator|Group A - Control|Conventional treatment and placebo
88896437|NCT01471613|Experimental|Group B - Lithium Carbonate|Conventional treatment and lithium carbonate
88896438|NCT01471613|Experimental|Group D - Combination Therapy|Conventional treatment, cell transplant and 6-weeks course of lithium carbonate
88896439|NCT01471652|Active Comparator|Nutraceuticals|Subjects will receive a combination of 4 nutraceuticals (CoEnzyme Q10, acetyl-L-carnitine, alpha-lipoic acid, docosahexaenoic acid (DHA)) and a multivitamin.
88896440|NCT01471652|Placebo Comparator|Placebo|
88896441|NCT01471665|Experimental|GSK2190915 100mg|This is a crossover study so patients will receive 100mg of GSK2190915 once daily for up to 16 days followed by a wash out period of at least 14 days before they cross over onto the placebo arm of the study.
88896442|NCT01471665|Placebo Comparator|Placebo|This is a crossover study so patients will receive placebo once daily for up to 16 days followed by a wash out period of at least 14 days before they cross over onto the GSK2190915 100mg arm of the study.
88896443|NCT01471678|Experimental|Fixed dose combination product|Fixed Dose Combination capsule containing dutasteride 0.5mg and tamsulosin 0.2 mg
88896444|NCT01471678|Experimental|Dutasteride (0.5mg)|Commercial formulation of dutasteride
88896445|NCT01471678|Experimental|Harnal-D Tablets and Harnal capsules|Commercial formulations of Harnal-D Tablets and Harnal Capsules both comprising 0.2mg tamsulosin HCl
89193882|NCT03404908|Experimental|TAP|Ultrasound-guided transversus abdominis plane block at the end of cesarean section
89193883|NCT03404908|Experimental|QLB|Ultrasound-guided quadratus lumborum block at the end of cesarean section
89193884|NCT03399032||Caspofungin|Each patient will receive: caspofungin i.v. once daily ( 70 mg on the first day, 50 mg on the 2 and 3 day
88896446|NCT01471704|Experimental|INX-08189 50 mg|Study Day 0: Single 50 mg dose of INX-08189 in the morning
88896447|NCT01471704|Active Comparator|240 mg verapamil HCL ER|Study Days 6 to 11: 240 mg verapamil HCL ER once daily (QD) in the morning
88896448|NCT01471704|Active Comparator|INX-08189 50 mg & verapamil HCLER 240 mg|Study Day 12: Co-administration of single 50 mg dose of INX-08189 and 240 mg verapamil HCL ER in the morning
88896449|NCT01471288|Active Comparator|Group3|Normal controls
88896450|NCT01471288|Placebo Comparator|Group4|Normal controls
88896451|NCT01471288|Active Comparator|Group 1|Hypothyroid patients taking levothyroxin.
88896452|NCT01471288|Placebo Comparator|Group2|Hypothyroid patients taking levothyroxin
89193885|NCT03386617|Experimental|NEPA|"Day 1 of each chemotherapy cycle:~1 tablet of NEPA (NETU 300 mg/ PALO 0.50 mg) 1 hour prior to the start of chemotherapy with dexamethasone 12 mg administered orally 30 minutes prior to chemotherapy Days 2 to 3 Dexamethasone. The time and date of intake will be recorded."
88896453|NCT01471717|Experimental|C 1:INX-08189 50 mg qd X 5 days|Cohort 1: Subjects will begin administration of INX-08189 50 mg every day (QD) on Study Day 0. Dosing will occur each morning for 5 days after a fast of at least 8 hours prior to each dose on Study Days 0 through 4. INX-08189 will be administered with water, and subjects will remain fasting for 2 hours following each dose.
88896454|NCT01471717|Active Comparator|C1: INX-08189 / Victrelis 800 mg TID X 3 days|Cohort 1:INX-08189 50 mg QD will be administered concurrently with Victrelis 800 mg three times a day (TID) for 3 additional days
88896455|NCT01471717|Active Comparator|C2: Victrelis 800 mg TID x 3 days|Cohort 2: Subjects will begin administration of Victrelis 800 mg three times a day (TID) on the morning of Study Day 0. Victrelis will be administered with water and food with doses at least 7 hours apart. Victrelis 800 mg TID will be administered for a total of 3 days
88896456|NCT01471717|Active Comparator|C 2:Victrelis 800 mg TID with INX-08189 50 mg QD|Cohort 2: Victrelis 800 mg TID will be administered concurrently with INX-08189 50 mg QD for 5 additional days
88896457|NCT01471717|Placebo Comparator|C1: Placebo with Victrelis 800 mg|Cohort 1: Placebo QD will be administered concurrently with Victrelis 800 mg TID for 3 additional days
88896458|NCT01471717|Placebo Comparator|C 2: Victrelis 800 mg with Placebo|Cohort 2: Victrelis 800 mg TID will be administered concurrently with Placebo QD for 5 additional days
88896459|NCT01471730|Placebo Comparator|Saline solution|
88896460|NCT01471730|Active Comparator|Fibrinogen|
88896461|NCT01471730|Active Comparator|Prothrombin complex|
89193886|NCT03366272|Active Comparator|(R)-GemOx|eight cycles of (R)-GemOx (Gemcitabine 1000 mg/m2, d1, Oxaliplatin 100 mg/m2, d1, Rituximab 375 mg/m2 in case of B-cell lymphoma disease, repeated every 2 wks)
89193887|NCT03366272|Experimental|Nivo-(R)-GemOx|eight cycles of nivolumab (240 mg flatdose) plus (R)-GemOx in 2-wk intervals followed by additional 9 infusions of Nivolumab (480 mg flatdose) in 4-wk intervals as consolidation or up to progression or unacceptable toxicity, whatever occurs first
89418661|NCT02192892|Experimental|CSB PLUS + α-amylase|CSB PLUS + α-amylase: Porridge from Corn Soy Blend PLUS with α-amylase
89418662|NCT02192892|Placebo Comparator|CSB PLUS - α-amylase|CSB PLUS - α-amylase: Porridge from Corn Soy Blend PLUS without α-amylase
89418663|NCT02192892|Experimental|RSB PLUS + α-amylase|RSB PLUS + α-amylase: Porridge from Rice Soy Blend PLUS with α-amylase
89418664|NCT02192892|Placebo Comparator|RSB PLUS - α-amylase|RSB PLUS - α-amylase: Porridge from Rice Soy Blend PLUS without α-amylase
89418665|NCT02192892|Experimental|WSB PLUS + α-amylase|WSB PLUS + α-amylase: Porridge from Wheat Soy Blend PLUS with α-amylase
89418666|NCT02192892|Placebo Comparator|WSB PLUS - α-amylase|WSB PLUS - α-amylase: Porridge from Wheat Soy Blend PLUS without α-amylase
89418667|NCT02192892|Active Comparator|Commercial MSB + α-amylase|Commercial MSB + α-amylase: Commercial porridge from Mais Soy Blend with α-amylase
88896462|NCT01471743|Experimental|Impact Advance Recovery (R)|3 supplements per day for 5 days pre-operatively
88896463|NCT01471743|Active Comparator|Standard Supplement|3 supplement per day for 5 days pre-operatively
88896464|NCT01471756|Experimental|iSnare with Gonak solution|
88896465|NCT01471756|Experimental|Snaremaster braided snare with Gonak solution|
88896466|NCT01471756|Experimental|iSnare with saline solution|
88896467|NCT01471756|Experimental|Snaremaster braided snare with saline solution|
88896468|NCT01471769|Experimental|pain management video|Experimental
88896469|NCT01471769|Placebo Comparator|falls prevention video|placebo
88896470|NCT01471795||Study Population|150 subjects with end-stage heart failure who have been scheduled to undergo device implantation with a VAD, either as a bridge to cardiac transplantation or for destination therapy.
88896471|NCT01471808|Active Comparator|CSII|continuous subcutaneous insulin infusion
88896472|NCT01471808|Active Comparator|Metformin & Pioglitazone|CSII combined with metformin and pioglitazone
88896473|NCT01471808|Active Comparator|Sitagliptin|CSII combined with sitagliptin 100mg/d
88896474|NCT01471821|Experimental|simplification|Lopinavir/ritonavir (400/100 BID) plus lamivudine (300 QD)
88896475|NCT01471821|Active Comparator|Continue with current treatment|
88896476|NCT01471847|Experimental|BEZ235 + Trastuzumab (Phase l /Phase ll)|"Phase l: Eligible patients will receive increasing doses of oral BEZ235 administered on a continuous twice daily (BID) schedule + weekly trastuzumab at a fixed dose of 2 mg/kg. Treatment will be organized into cycles of 28 days.~Phase ll: Eligible patients will receive weekly trastuzumab (2 mg/kg) + oral BEZ235 on a continuous twice daily (BID schedule) at the MTD or RP2D.~Treatment will be organized into cycles of 21 days."
88896477|NCT01471847|Active Comparator|Lapatinib + Capecitabine (Phase II)|Eligible patients will receive lapatinib (1250 mg given orally once daily on days 1 through 21) in combination with capecitabine (2000 mg/m2/day administered orally in 2 doses approximately 12 hours apart on days 1 through 14). Treatment will be organized into cycles of 21 days .
88896478|NCT01471860|Experimental|Device and Medical Management|"Medical Management, to be determined by the participant's physician, described as:~Optimal pharmacological therapy: Prescribed to a beta blocker, a diuretic, and an ACE (Angiotensin-converting-enzyme) inhibitor or ARB (Angiotensin Receptor Blocker) unless contraindicated or not tolerated. These drugs must be used in a manner consistent with their labeling.~Stable pharmacological therapy: No more than a 50% increase or a 50% decrease of the dosage of any one medication, and post titration of all heart failure medications.~Participants should remain on their prescribed heart failure medications and same dosing schedule for the duration of the study unless investigators determine medically necessary changes are needed. Additionally, every effort should be made to maintain adequate rate control for subjects with atrial fibrillation throughout the duration of the study."
88896479|NCT01471873||Keratoconus Group (KG)|Keratoconus group (KG) included patients with progressive keratoconus.
88896480|NCT01471873||Collagen-Cross-linking group (CXLG)|Collagen-Cross-linking group (CXLG) included keratoconus patients that had been treated with uneventful corneal collagen cross-linking (CXL) at least on year prior to their enrolment in the study.
88896481|NCT01471886|Active Comparator|Naproxen|Every 8 hours for 4 days.
88896482|NCT01471886|Experimental|Ketorolac Tromethamine|Every 8 hours for 4 days
88896483|NCT01471899|Active Comparator|Naproxen|2 tablets every 8 hours for 4 days.
88896484|NCT01471899|Experimental|Ketorolac Tromethamine|10 drops every 8 hours for 4 days
88896485|NCT01471925|Experimental|Esomeprazole (40mg) + Sodium Bicarbonate (721mg)|
88896486|NCT01471925|Active Comparator|Nexium®|
89193888|NCT03363217|Experimental|Neurofibromatosis Type 1 (NF1) with low-grade glioma|Patients presenting with Neurofibromatosis Type 1 (NF1) and a progressing/refractory low-grade glioma.
89193889|NCT03363217|Experimental|Neurofibromatosis Type 1 (NF1) with Plexiform Neurofibroma|Patients presenting with Neurofibromatosis Type 1 (NF1) and a plexiform neurofibroma
89193890|NCT03363217|Experimental|Progressing/refractory low grade-glioma, KIAA1549-BRAF fusion|Patients presenting with a progressing/refractory low-grade glioma with a KIAA1549-BRAF fusion.
89193891|NCT03363217|Experimental|Progressing/Refractory central nervous system (CNS) glioma.|Patients presenting with a progressing/refractory central nervous system glioma with an activation of the MAPK/ERK pathway who do not meet criteria for inclusion in other study groups.
89193892|NCT03334708||Locally Advanced or Metastatic Pancreatic Cancer Cohort|For patients with locally advanced or metastatic PDAC, blood will be collected pre-treatment initiation (baseline), after first chemotherapy cycle, every 8-12 weeks while under treatment to coincide with restaging CT scan and at time of disease progression.
89193893|NCT03334708||Acute Benign Pancreatic Pathology Control Cohort|For patients with acute pancreatitis, blood specimens will be drawn at the time of acute pancreatitis and every 6-12 months thereafter
88896487|NCT01471938||Caucasians|31 healthy adults in an age range of 18 to 65 years with a BMI of 18.5 to 35 kg/m2 are planned to be recruited.
88896488|NCT01471938||Afro Americans|31 healthy adults in an age range of 18 to 65 years with a BMI of 18.5 to 35 kg/m2 are planned to be recruited.
88896489|NCT01471938||East and Southeast Asian|31 healthy adults in an age range of 18 to 65 years with a BMI of 18.5 to 35 kg/m2 are planned to be recruited.
89193894|NCT03334708||Chronic Benign Pancreatic Path,IPMC & Pancreatic Cyst Ctrl|For patients with chronic pancreatitis, IPMN, or cysts, blood specimens will be drawn every 6-12 months.
89193895|NCT03334708||Healthy Control|For normal controls, blood specimens will be drawn once at study baseline.
88896490|NCT01471938||Hispanics|31 healthy adults in an age range of 18 to 65 years with a BMI of 18.5 to 35 kg/m2 are planned to be recruited.
89193896|NCT03330418|Experimental|Placebo Comparator|Participants received placebo weekly administered subcutaneously for 48 times in the double-blind treatment period.Once the participants relapse,they should advance to the open phase.All participants were treated with the test drugs.
88896491|NCT01471951|Experimental|single embryo transfer|
88896492|NCT01471964|Experimental|MLN8237 and Erlotinib|"Phase I Erlotinib 100 mg PO daily* + MLN8237 30 mg PO BID (days 1 - 7), escalating to Erlotinib 150mg PO daily + MLN8237 starting at 30mg PO BID days 1-7, escalating to 40mg BID (days 1 - 7) , then 50mg BID (days 1 - 7).~Phase II Erlotinib 150mg PO daily + MLN8237 at MTD from phase I."
88896493|NCT01471977|Experimental|education, counselling, default tracer|
89193897|NCT03330418|Experimental|RC18 160 mg|Patients received the test group RC18 160mg weekly administered subcutaneously for 48 times.Starting with the forty-ninth dose,the trial went into the open phase . All participants were treated with the test drugs.
89193898|NCT03319797|Other|Treatment with NOVOCART® Inject plus|Treatment with NOVOCART® Inject plus (Autologous chondrocyte transplantation)
89193899|NCT03314805|Placebo Comparator|Control|Placebo
89193900|NCT03314805|Experimental|Treatment|Astragalus polysaccharides 500 mg
89193901|NCT03313804|Experimental|Immune Checkpoint Inhibitor + Radiation|Immune checkpoint inhibitor (Nivolumab OR Pembrolizumab OR Atezolizumab) PLUS Radiation Therapy (Stereotactic Body Radiation Therapy OR fractionated radiation therapy)
89418668|NCT04762212|Active Comparator|Hip with the greatest limitation in flexion range of motion|Participants that have limited hip flexion of less than 101 degrees will be randomly assigned to one of two groups: one intervention group will receive Mobilization with Movement and home program of stretching with over-pressure one group will receive only a home program of stretching with over-pressure.
89418669|NCT04762212|Active Comparator|Hip with the least limitation in flexion range of motion|Participants least limited hip in flexion range of motion will serve as the control group. This limb will not receive an intervention.
89193902|NCT03283033|Experimental|Experimental 3|Introduction of a new salad bar and marketing conditions during second semester of school year
89418670|NCT04412707|Active Comparator|Arm A|Melflufen 40 mg iv Day 1 of each 28 day cycle. Dexamethasone 40 mg po Day 1,8, 15 and 22 of each 28 day cycle, if > 75 years of age 20 mg. Cycle 1 will be administered via a Peripheral Venous Catheter (PVC) and cycle 2 and onwards melflufen will be administered via a Central Venous Catheter (CVC).
89418671|NCT04412707|Active Comparator|Arm B|Melflufen 40 mg iv Day 1 of each 28 day cycle. Dexamethasone 40 mg po Day 1,8, 15 and 22 of each 28 day cycle, if > 75 years of age 20 mg. Cycle 1 will be administered via a Central Venous Catheter (CVC) and cycle 2 will be administered via a Peripheral Venous Catheter (PVC). From cycle 3 and onwards melflufen will be administered via CVC.
88896494|NCT01471990|Active Comparator|PACAP38|
88896495|NCT01471990|Active Comparator|VIP|
89193903|NCT03283033|Experimental|Experimental 2|Introduction of marketing conditions during second semester of school year
89418672|NCT03534882|Experimental|Washout|Discontinuation of topical prostaglandin analogue therapy: Participants are asked to discontinue (washout) their prostaglandin analogue for 42 days. As the experimental group, the purpose of this arm is to determine the lingering IOP-reducing effects following discontinuation of chronic prostaglandin analogue therapy, and to determine if IOP rises back to baseline (pre-treatment values).
89418673|NCT03534882|No Intervention|Control|Patients are asked to remain on their prostaglandin analogues and continue treatment as prescribed by their ophthalmologist. The purpose of this arm is to minimize bias in intraocular pressure readings.
89418674|NCT02930850|Experimental|Test subjects|All subjects are enrolled and receive Rad-67 Pulse oximeter sensor for measurement of hemoglobin.
89418675|NCT02193672|Experimental|PET/CT + [18F]Fluciclatide|"At baseline: Participants have PET/CT imaging within 7 days prior to initiation of chemotherapy treatment. Participants monitored at 24 hours post scan via telephone.~On treatment: Participants have PET/CT imaging at end of the first cycle and prior to the initiation of the second cycle of chemotherapy. Participants assessed at 24 hours post scan via telephone call.~Baseline and on treatment PET/CT imaging performed with agent [18F] Fluciclatide."
89418676|NCT03698695|Experimental|THN201|THN201: Donepezil 5mg capsule and Mefloquine 10mg capsule once daily for 15 days
89418677|NCT03698695|Active Comparator|Donepezil|Donepezil 5mg capsule and Mefloquine placebo capsule once daily for 15 days
89418678|NCT03698695|Placebo Comparator|Placebo|Donepezil placebo capsule and Mefloquine placebo capsule once daily for 15 days
89418679|NCT03693235|Experimental|70 degrees|During tracheal intubation using a lightwand, the tracheal tube combined with a lightwand will be bent by 70 degrees.
88896496|NCT01472003|Experimental|ABT-806 Arm|Subjects with advanced solid tumors
88896497|NCT01472003|Experimental|ABT-806i Arm|Subjects with advanced solid tumors
88896498|NCT01472016|Experimental|Cohort A|ABT-700 will be administered by intravenous infusion at escalating dose levels in 21-day dosing cycles. Additional subjects will be enrolled in an expansion cohort that will further evaluate ABT-700.
89193904|NCT03283033|Experimental|Experimental 1|Introduction of a new salad bar during second semester of school year
89193905|NCT03283033|No Intervention|Control|No introduction of a new salad bar and no introduction of marketing conditions
89193906|NCT03269981|Experimental|Whole breast irradiation|Post-lumpectomy radiotherapy to the whole breast alone.
89193907|NCT03269981|Active Comparator|Whole breast and nodal irradiation|Post-lumpectomy radiotherapy to the whole breast and regional lymph node.
89193908|NCT03241537|No Intervention|Hormonal therapy alone|total androgen ablation or antiandrogen therapy alone for 2-3 years
89193909|NCT03241537|Active Comparator|Hormonal therapy with radiotherapy|total androgen ablation or antiandrogen therapy for 2-3 years combined with radiotherapy on whole pelvis
89418680|NCT03693235|Experimental|80 degrees|During tracheal intubation using a lightwand, the tracheal tube combined with a lightwand will be bent by 80 degrees.
88896499|NCT01472016|Experimental|Cohort B|ABT-700 plus docetaxel.
88896500|NCT01472016|Experimental|Cohort C|ABT-700 plus FOLFIRI/cetuximab
88896501|NCT01472016|Experimental|Cohort D|ABT-700 plus erlotinib
88896502|NCT01472029|Experimental|5-FU, leucovorin, docetaxel, oxaliplatin (FLOT), trastuzumab|
88896503|NCT01472042||Sports induced concussion|Exposure to sports induced concussion
88896504|NCT01472042||Routine Athletic Exertion|Exposure to routine athletic exertion (non-concussion control)
88896505|NCT01472042||Other Non-Penetrating Trauma to the Head|Exposure to other non-penetrating trauma to the head that is witnessed or self-reported
88896506|NCT01472055|Experimental|Fludarabine|Analysis of the pharmacokinetics of fludarabine for hematopoietic stem cell transplantation in pediatric patients
88896507|NCT01472068|Experimental|Inko RS device|30 minutes of treatment with the Inko RS device, five days each week, for 12 weeks.
88896508|NCT01472120||P and C|"P: NAFLD patients~C: Healthy controls"
88896509|NCT01472133||Young Healthy Volunteers|Healthy volunteers under the age of 40
88896510|NCT01472133||Older healthy volunteers|Healthy volunteers over the age of 70
88896511|NCT01472133||Patients with atrial fibrillation|Patients with permanent AF
88896512|NCT01472133||Patients with a pacemaker|Patients who have an implanted pacemaker that is continually pacing
89418681|NCT03693235|Experimental|90 degrees|During tracheal intubation using a lightwand, the tracheal tube combined with a lightwand will be bent by 90 degrees.
88896513|NCT01472133||Patients with restricted chest movement|Patients whose chest expansion is less than 2.5cm
89193910|NCT03239626|Experimental|POHIM-RT|adjuvant hypofractionated IMRT for cervical cancer patients
88896514|NCT01472146|Experimental|Zometa neoadjuvant HER2 breast cancer|"Zo-Nantax arm - Neoadjuvant chemotherapy with association of zoledronic acid and standard treatment with anthracycline followed taxane plus trastuzumab in locally advanced breast cancer HER2 positive HR positive/negative.~Drug:Cyclophosphamide Drug:Adriamycin Drug:Docetaxel Drug:Trastuzumab Drug:Zolendronic acid"
88896515|NCT01472159|No Intervention|CGM-Usual Care|Routine CGM education
89193911|NCT03239613|Other|POHIM-CCRT|postoperative adjuvant concurrent chemotherapy with hypofractionated IMRT (2.5 Gy/fraction, 16 fractions, once a day)
89418682|NCT02030808|Placebo Comparator|Muscle Relaxants (MR) group|Cisatracurium will be administered
88896516|NCT01472159|Experimental|CGM-Teamwork|"Routine CGM education~CGM Family Teamwork Intervention"
89418683|NCT02030808|Active Comparator|Non- Muscle Relaxants (NMR) group|No cisatracurium will be administered
89418684|NCT03702049|Experimental|RN/CHW TBI|Nurse-led Community Health Worker TBI (RN/CHW TBI) program
89418685|NCT04729296|Experimental|Golimumab|Golimumab for subcutaneous use
88896517|NCT01472172|Experimental|Cryobiopsy|Biopsies will be obtained by flexible autoclavable cryoprobe 20416-032 (Erbokryo CA, ERBE, Germany) with 2.4 mm in diameter. The tip of the probe is cooled to -890C with nitrous oxide within seconds after footswitch activation. The biopsy sample will by extracted by gently pulling of the probe.
88896518|NCT01472211|Experimental|intervention filter|children consuming purified and zinc enriched water delivered by a household-based water filter
88896519|NCT01472211|Placebo Comparator|placebo filter|children consuming purified water delivered by a household-based water filter
88896520|NCT01472211|Active Comparator|disinfection tablets|children will consume water treated with government promoted disinfection tablets (aquatabs)
88896521|NCT01472237|Active Comparator|Nutritional intervention|It will last 6 months. Will be conducted by a physician nutrition specialist assisted by a technician in diet and nutrition. The first visit will take place during admission. The patient receives dietary advice and a customized diet designed to optimize energy intake and macro/micro-nutrients needs.
88896522|NCT01472237|Placebo Comparator|Care as usual|The patients are referred to their cardiologyst and primary care physicians
88896523|NCT01472250||chemotherapy|Eligible patients will accept generalized chemotherapy according to the investigator's assessment.
88896524|NCT01472263|Experimental|Pentoxifylline|
88896525|NCT01472263|Placebo Comparator|Placebo|
88896526|NCT01472276|No Intervention|Control|
88896527|NCT01472276|Active Comparator|Web-based program|
89418686|NCT04729296|Placebo Comparator|Placebo|Placebo syringes and vials matching active drug
89418687|NCT03698617|Experimental|HSK3486|"Dose Escalation Cohort:~0.1 mg/kg, 0.2 mg/kg, 0.3mg/kg 0.4 mg/kg 0.5 mg/kg, 0.6 mg/kg, 0.7mg/kg, 0.8 mg/kg Dose Expansion Cohort: 0.3 mg/kg and 0.5 mg/kg."
89418688|NCT03698617|Active Comparator|Propofol|Dose Escalation Cohorts:2.0mg/kg and 2.5mg/kg; Dose Expansion Cohorts: 2.0mg/kg
89418689|NCT02193750|Placebo Comparator|Placebo|1 placebo muesli bars and 1 serving placebo muesli per day (0.55 g total fructans/GOS)
89418690|NCT02193750|Experimental|Moderate Oligosaccharide Group|1 placebo muesli bar and 1 serving intervention muesli per day (3.25 g total fructans/GOS)
89418691|NCT02193750|Experimental|High Oligosaccharide Group|1 intervention muesli bar and 1 serving intervention muesli per day (5.43 total fructans/GOS)
89418692|NCT02193126|Experimental|Treatment|
89418693|NCT02193126|No Intervention|Comparison|
89536797|NCT03310073|Experimental|bOPV (bivalent OPV Bio Farma)|"bOPV one dose corresponds to 2 drops (0.1ml). The vaccine shall be given orally.~The subject received bOPV, Pentabio and IPV according to the study schedule."
88896528|NCT01472302|Experimental|ASV|Adaptive Support Ventilation
88896529|NCT01472302|Active Comparator|PCV|Pressure Controlled Ventilation
88896530|NCT01472315|Active Comparator|medroxyprogesterone acetate|
88896531|NCT01472315|Placebo Comparator|Placebo|Placebo pills taken in the same way as the active comparator
88896532|NCT01472354|No Intervention|Standard of care referral to specialist|Subjects are referred for education, counseling and evaluation for HCV treatment to a specialty health care provider
89418694|NCT02194374|Experimental|ROR1R-CAR-T Cells|"Peripheral blood mononuclear cells (PBMC) collected via venipuncture and/or steady state leukapheresis at discretion of PI. Participants receive a cycle of lympho-depleting chemotherapy as chosen by treating physician 4 to 5 days before ROR1R-CAR-T cell infusion : Fludarabine, Cyclophosphamide, and Rituximab (FCR), Bendamustine and Rituximab (BR), or Fludarabine, Bendamustine, and Rituximab (FBR).~Dose Escalation Cohort starting dose level of ROR1R-CAR-T cells/kg: 105 cell/kg infused via central venous catheter or by vein on Day 1.~Dose Expansion Cohort starting dose level of ROR1R-CAR-T cells/kg: MTD from Dose Escalation Cohort."
89418695|NCT03693079|Experimental|Wet Cupping|wet cupping therapy will be applied to all participants
89418696|NCT02193204|Experimental|Social Drinkers Depressive Symptoms|30 non-dependent light socially drinking (SD) smokers with depressive symptoms will be recruited to participate in two laboratory sessions (Stress and Neutral / Relaxing). This arm will be exposed to both the personal stress imagery and neutral imagery interventions.
89418697|NCT02193204|Experimental|Social Drinkers No Depressive Symptoms|30 non-dependent light socially drinking (SD) smokers without depressive symptoms will be recruited to participate in two laboratory sessions (Stress and Neutral / Relaxing). This arm will be exposed to both the personal stress imagery and neutral imagery interventions.
89418698|NCT02193204|Experimental|Alcohol Dependent, Non-Depressive|30 treatment-engaged 28-day abstinent, alcohol dependent (AD) smokers, without Depressive symptoms. All AD subjects will either be admitted to the Clinical Neuroscience Research Unit (CNRU) of the Connecticut Mental Health Center for five weeks of inpatient stay and study participation (inpatient), or they will be scheduled for a two night stay on the CNRU following 3 weeks of abstinence (outpatient). This arm will be exposed to both the personal stress imagery and neutral imagery interventions.
89418699|NCT02193204|Experimental|Alchohol Dependent Depressive Symptoms|30 treatment-engaged 28-day abstinent, alcohol dependent smokers with depressive symptoms. All AD subjects will either be admitted to the Clinical Neuroscience Research Unit (CNRU) of the Connecticut Mental Health Center for five weeks of inpatient stay and study participation (inpatient), or they will be scheduled for a two night stay on the CNRU following 3 weeks of abstinence (outpatient). This arm will be exposed to both the personal stress imagery and neutral imagery interventions.
89418700|NCT03693001|Experimental|IC/FM Patients|All patients had been diagnosed with fibromyalgia and were suffering from IC by standard criteria.
89418701|NCT02193906|Experimental|Intervention group|Cognitive training.
89418702|NCT02193906|Placebo Comparator|Placebo group|Placebo task.
89418703|NCT03692923|No Intervention|control group|participants received ordinary prenatal care.
89418704|NCT03692923|Experimental|virtual community group|participants were invited to join a virtual community to interact with peers in addition to their ordinary prenatal care.
89418705|NCT02193360|Experimental|Single arm Dose Escalation|
89418706|NCT03688321|Active Comparator|Probiotic capsule GR-1 and RC-14|The intervention for study group is taking 2 capsules containing probiotic strains GR-1 and RC-14 before sleep for 18 weeks after being confirmed as GBS positive on 28th week gestation
89418707|NCT03688321|Placebo Comparator|Placebo capsule|The intervention for placebo group is taking 2 capsules not containing probiotic strains GR-1 and RC-14 before sleep for 18 weeks after being confirmed as GBS positive on 28th week gestation
89418708|NCT03692845|Other|O-TLIF group|Spinal fusion ,Transforaminal lumbar interbody fusion procedure will be performed through open surgery.
89418709|NCT03692845|Other|MI-TLIF group|Spinal fusion,Transforaminal lumbar interbody fusion procedure will be performed through minimally invasive surgery using a tubular retractor.
89193912|NCT03229200|Experimental|Ibrutinib|Treatment with Ibrutinib, once daily until disease progression or unacceptable toxicity.
89193913|NCT03224507|Experimental|KRdD followed by auto-HCT|Cycle 1-Dexamethasone 40mg orally days 1/8/15/22; Lenalidomide 25mg orally days 1-21; Carfilzomib 20mg/m2 days 8/9 then 36mg/m2 venous days 15/16; Daratumumab 16mg/kg venous days 1/8/15/22 (KRd-Dara). Cycle 2 the same except Carfilzomib 36mg/m2 venous days 1/2/8/9/15/16. Cycles 3,4 the same but no Daratumumab Days 8 and 22. Dosage adjusted for last tolerated dose (LTD). Following induction therapy, auto-HCT is done (consolidation 1), then up to two 4-cycle blocks of KRd-Dara consolidation (consolidations 2 and 3). Minimum residual disease (MRD) checked after each phase. Patients with confirmed MRD(-) at or after consolidation 1 will not undergo maintenance and will be actively monitored for resurgence of MRD or clinical relapse. After consolidation if MRD+ patients will undergo standard of care lenalidomide maintenance.
89418710|NCT02194452|Experimental|Diagnostic (gallium Ga 68-edotreotide PET/CT)|"Patients undergo gallium Ga 68-edotreotide PET/CT at baseline and 1-30 days after surgery.~Interventions: gallium Ga 68-edotreotide, positron emission tomography, computed tomography, laboratory biomarker analysis"
89418711|NCT04243213|Experimental|Vibration Group|Intervention group I receives a unit of 10 minutes daily on the vibrating plate with an upright posture of 15 ° postoperatively from the 2nd to the 7th day
89418712|NCT04243213|Experimental|15° Tilt Group|Intervention group II is positioned postoperatively from day 2 to day 7 for 15 minutes at 15 degrees, but without vibration
89418713|NCT04243213|Placebo Comparator|Control Group|The control group only receives standard physiotherapy and no further treatments
89418714|NCT02193438|Active Comparator|Spice 1|Red chili pepper extract
89418715|NCT02193438|Active Comparator|Spice 2|Cinnamon extract
89418716|NCT02193438|Active Comparator|Spice 3|Refreshing agent
89418717|NCT02193438|Placebo Comparator|Placebo|Tomato juice
89418718|NCT01358721|Experimental|Arm 1: BMS-936558|
89418719|NCT01358721|Experimental|Arm 2: BMS-936558|
89418720|NCT01358721|Experimental|Arm 3: BMS-936558|
89418721|NCT01358721|Experimental|Arm 4: BMS-936558|(treatment naive)
89418722|NCT02257164|Active Comparator|femoral nerve block|20 ml injection of 2 mg/ml ropivacaine in femoral nerve
89418723|NCT02257164|Experimental|obturator nerve block and intraarticular injection|10 ml injection of 2 mg/ml ropivacaine in obturator nerve intraarticular injection : 10 ml of chlorhydrate ropivacaine (2 mg/ml) and 10ml of magnesium sulfate
89418724|NCT02193984|Experimental|Peer support|Study participants are assigned a volunteer peer supporter who has been trained to offer support on diabetes management.
89418725|NCT02193984|No Intervention|Control|No intervention
89418726|NCT02194608|Experimental|Telemedicine system|Participants will self-test blood glucose level, weight, and blood pressure and results will be uploaded and transmitted directly via a hometelehealth system to a central location (HUB). Blood draws will be administered at baseline and follow-up visits.
89418727|NCT02194608|No Intervention|Usual care|Participants will self-record their blood glucose levels, blood pressure and weight in a diary. Blood draws will be administered at baseline and follow-up visits.
89418728|NCT02195856|Active Comparator|Diseased condition|Crossover design where participants will start in the Beetroot juice condition, and after a washout period, move into the other condition.
89418729|NCT02195856|Placebo Comparator|Placebo|Crossover design where participants will start in the placebo condition, and after a washout period, move into the other condition.
89418730|NCT02195934|Other|Standard orange juice (OJ) followed by blood OJ|This randomized 2-way cross over study will compare the effect of blood orange juice with that of a standard (blonde) orange juice consumed daily for 28 days, on markers of cardiovascular disease, with a 3 week washout period in between.
89418731|NCT02195934|Other|Blood orange juice followed by standard OJ|This randomized 2-way cross over study will compare the effect of blood orange juice with that of a standard (blonde) orange juice consumed daily for 28 days, on markers of cardiovascular disease, with a 3 week washout period in between.
89418732|NCT02194686|Active Comparator|Cilostazol|One tablet (100 mg) twice per day for 12 weeks
89418733|NCT02194686|Placebo Comparator|Dummy Placebo|One tablet twice per day for 12 weeks
89418734|NCT04633681|Experimental|Cake matrix|3 phases of 2-week daily consumption of cake product containing 1) sucrose, 2) Neotame 1, 3) Stevia Reb M. Randomised cross-over with 2-week wash-out between phases.
89418735|NCT04633681|Experimental|Biscuit matrix|3 phases of 2-week daily consumption of biscuit product containing 1) sucrose, 2) Neotame 1, 3) Stevia Reb M. Randomised cross-over with 2-week wash-out between phases.
89418736|NCT04633681|Experimental|Yoghurt matrix|3 phases of 2-week daily consumption of yoghurt product containing 1) sucrose, 2) sweetener blend 1, 3) sweetener blend 2. Randomised cross-over with 2-week wash-out between phases.
89418737|NCT04633681|Experimental|Chocolate matrix|3 phases of 2-week daily consumption of chocolate product containing 1) sucrose, 2) sweetener blend 1, 3) sweetener blend 2. Randomised cross-over with 2-week wash-out between phases.
89418738|NCT04633681|Experimental|Cereal matrix|3 phases of 2-week daily consumption of cereal product containing 1) sucrose, 2) sweetener blend 1, 3) sweetener blend 2. Randomised cross-over with 2-week wash-out between phases.
89418739|NCT04633681|Experimental|Universal Eating Monitor study|A sub-group of the yoghurt matrix will be selected for assessment of eating rate and microstructure of feeding using Universal Eating Monitors.
89418740|NCT04633681|Experimental|fMRI study|A sub-group of the chocolate matrix will be selected for assessment of neural activation to images of food using fMRI.
89418741|NCT03692767|Experimental|Anti-CD22 CAR NK cells|Total dose of 50-600 thousand /kg Anti-CD22 CAR NK cells will be administered at day0
89418742|NCT03535038|Experimental|Inferior vena cava (IVC) diameter|subjects underwent IVC diameter measurement after VPW measurement
89418743|NCT03535038|Active Comparator|Vascular pedicle width (VPW)|Supine chest x ray was done and the VPW is assessed by radiologists.
89418744|NCT04622995||Exposed|Patients prescribed opiate replacement therapy plus a benzodiazepine.
89418745|NCT04622995||Unexposed|Patients prescribed opiate replacement therapy with no benzodiazepine prescribing.
89418746|NCT01341639|Experimental|PR5I|V419 + RotaTeq + Prevenar 13 + ProQuad
89418747|NCT01341639|Active Comparator|INFANRIX™ hexa|INFANRIX™ hexa + RotaTeq + Prevenar 13 + ProQuad
89418748|NCT03534960|Other|High Flow Nasal Oxygen Therapy|Patients are randomized to the high flow nasal oxygen therapy group
89418749|NCT03534960|Other|Nasal CPAP|Patients are randomized to the nasal continuous positive airway pressure treatment group
89418750|NCT02196012|Experimental|Lifestyle counseling|The intervention condition will contain multiple components: nutrition education, physical activity, social support, social media (Pinterest and Facebook), and smartphone applications for self-monitoring. Students in this condition will have access to the private study website, which will be the central platform for delivery of the program materials and social support. The website, developed using Wordpress.com, will include nutrition materials, exercise videos, a forum, and links to the study's Facebook and Pinterest pages
89536006|NCT04997967|Active Comparator|Propofol group|Patients undergoing urgent therapeutic ERCP for severe cholangitis, with American Society of Anaesthesiologist (ASA) Grade II - III. Sedation was initially started by bolus dose of 0.5 mg/kg propofol IV over 3 minutes then, infusion was started at the rate of 50 µg /kg/min till RSS score of 5.
88896533|NCT01472354|Experimental|LEAP-C Group Intervention|4-week group intervention to help HIV/HCV co-infected patients reframe negative appraisals associated with HCV treatment to decrease decisional conflict, increase HCV knowledge, improve communication
89193914|NCT03224507|Experimental|KRdD only|Cycle 1-Dexamethasone 40mg orally days 1/8/15/22; Lenalidomide 25mg orally days 1-21; Carfilzomib 20mg/m2 days 8/9 then @ 36mg/m2 venous days 15/16; Daratumumab 16mg/kg venous days 1/8/15/22. Cycle 2 the same except Carfilzomib 36mg/m2 venous days 1/2/8/9/15/16. Cycles 3,4 the same but no Daratumumab Day 22. Dosage adjusted for last tolerated dose (LTD). Following induction therapy, Following induction therapy, patients will receive up to three 4-cycle blocks of KRd-Dara consolidation (consolidations 1, 2 and 3). Minimum residual disease (MRD) checked after each phase. Patients with confirmed MRD(-) at or after consolidation 1 will not undergo maintenance and will be actively monitored for resurgence of MRD or clinical relapse. After consolidation if MRD+ patients will undergo standard of care lenalidomide maintenance.
89193915|NCT03215030|Experimental|Part 1 (Dose Escalation) Schedule A: Modakafusp alfa 0.001 Up to 14 mg/kg|Modakafusp alfa 0.001 up to 14 milligram per kilogram (mg/kg), infusion, intravenously (IV), once every week (Q1W) on Days 1, 8, 15 and 22 of each 28-day treatment cycle up to 2 cycles, followed by once on Days 1 and 15 of each 28-day treatment cycle up to 4 cycles, followed by once on Day 1 of each 28-day treatment cycle until treatment discontinuation.
88896534|NCT01472393|Experimental|Creatine supplementation|
89193916|NCT03215030|Experimental|Part 1 (Dose Escalation) Schedule B: Modakafusp alfa TBD|Modakafusp alfa TBD, infusion, IV, once every 2 weeks (Q2W) on Days 1 and 15 of each 28-day treatment cycle until treatment discontinuation. The starting dose will be decided by the investigators and sponsor representatives based on all available clinical information.
89193917|NCT03215030|Experimental|Part 1 (Dose Escalation) Schedule C: Modakafusp alfa TBD|Modakafusp alfa TBD, infusion, IV, once every 3 weeks (Q3W) on Day 1 of each 21-day treatment cycle until treatment discontinuation. The starting dose will be decided by the investigators and sponsor representatives based on all available clinical information.
89193918|NCT03215030|Experimental|Part 1 (Dose Escalation) Schedule D: Modakafusp alfa TBD|Modakafusp alfa TBD, infusion, IV, once every 4 weeks (Q4W) on Day 1 of each 28-day treatment cycle until treatment discontinuation. The starting dose will be decided by the investigators and sponsor representatives based on all available clinical information.
89193919|NCT03215030|Experimental|Part 2 (Dose Expansion): Modakafusp alfa TBD + Dexamethasone 40 mg|Dose(s) for Phase 2 will be based on safety and tolerability results from the preceding Phase 1 dose escalation cohorts. Participants in Phase 2 cohorts will receive modakafusp alfa TBD as a single agent. Participants in at least 1 cohort will receive modakafusp alfa TBD and modakafusp alfa TBD and dexamethasone 40 mg, orally, once weekly of each 28-day treatment cycle until treatment discontinuation.
89193920|NCT03215030|Experimental|Part 3 (Dose Extension): Modakafusp alfa 120 mg|Participants will receive modakafusp alfa 120 mg, infusion, IV, Q4W, for each 28-day treatment cycle until disease progression or treatment discontinuation.
89193921|NCT03215030|Experimental|Part 3 (Dose Extension): Modakafusp alfa 240 mg|Participants will receive modakafusp alfa 240 mg, infusion, IV, Q4W, for each 28-day treatment cycle until disease progression or treatment discontinuation.
89193922|NCT03193190|Active Comparator|Cohort 1: Control (Nab-Paclitaxel and Gemcitabine)|"Cohort 1: Participants will receive Nab-Paclitaxel 125 mg/m^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle; and Gemcitabine 1000 mg/m^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle.~Participants in the Cohort 1 control arm who experience disease progression will be given the option of enrolling into Cohort 2 (if open for enrollment), provided they meet eligibility criteria."
89193923|NCT03193190|Experimental|Cohort 1: Atezolizumab + Chemotherapy + Selicrelumab|Cohort 1: Participants will receive Atezolizumab 840 mg IV infusion on Days 1 and 15 of each 28 day cycle; Nab-paclitaxel 125 mg/m^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle; Gemcitabine 1000 mg/m^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle; and Selicrelumab 16 mg subcutaneous injection on Day 1 of Cycles 1-4 and every third cycle thereafter (i.e. Cycles 7, 10, 13 etc.) of each 28-day cycle.
89193924|NCT03193190|Experimental|Cohort 1: Atezolizumab + Chemotherapy + Bevacizumab|Cohort 1: Participants will receive Atezolizumab 840 mg IV infusion on Days 1 and 15 of each 28 day cycle; Bevacizumab 10 mg/kg IV infusion on Days 1 and 15 of each 28 day cycle; Nab-paclitaxel 125 mg/m^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle; Gemcitabine 1000 mg/m^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle.
89418751|NCT02196012|Active Comparator|attention control condition|Students randomized to the attention control condition will receive educational emails three times per week. Nutrition materials will be sent once a week, and links to the YouTube exercise videos will be sent twice a week. At the start of the program, students will be emailed a link to the Pandora workout station. The materials sent to the control group will be the same materials posted on the website for the intervention group. Participants will access the emailed lessons and videos each week at their own convenience. Individuals in the attention control condition will not have access to the study website or social media pages.
89418752|NCT02628028|Experimental|Part A 5 mg LY3337641|Given once a day for 4 weeks.
89418753|NCT02628028|Experimental|Part A 10 mg LY3337641|Given once a day for 4 weeks.
88896535|NCT01472393|Placebo Comparator|Placebo|
88896536|NCT01472406|Experimental|Closed-loop session|The study consists of an evaluation of the Sansum Closed-loop Artificial Pancreas Device, insulin infusion pump, Continuous Glucose Monitor, zone-Model Predictive Control algorithm, and a Safety Health Monitoring System. during a 24-hour closed-loop in a clinic environment (Sansum Diabetes Research Institute, Santa Barbara, CA).
88896537|NCT01472458|Active Comparator|Active Intervention|This stepped-wedge cluster randomized evaluation will randomly allocate 18 hospitals into 4 groups to receive our active intervention at different sequential time points according to the randomly assigned stepped-wedge schedule. Hospitals will function as control hospitals until it is their turn to receive the active intervention, according to the stepped wedge schedule. Each wedge consists of 4-5 hospitals and will last 5 months.
88896538|NCT01472458|No Intervention|Control Hospitals|This stepped-wedge cluster randomized evaluation will randomly allocate 18 hospitals into 4 groups to receive our active intervention at different sequential time points according to the randomly assigned stepped-wedge schedule. Hospitals will function as control hospitals until it is their turn to receive the active intervention, according to the stepped wedge schedule. Each wedge consists of 4-5 hospitals and will last 5 months.
88896539|NCT01472471||acute asthmatic children|Children hospitalized with a diagnosis of acute asthma exacerbation
88896540|NCT01472471||stable asthmatic children|Children with a history of asthma currently asymptomatic
88896541|NCT01472484|Experimental|lpa with high polyphenol|
89418754|NCT02628028|Experimental|Part A 30 mg LY3337641|Given once a day for 4 weeks.
89418755|NCT02628028|Placebo Comparator|Part A Placebo|Given once a day for 4 weeks.
88896542|NCT01472484|Experimental|lpa with low polyphenol|
88896543|NCT01472484|Experimental|control bean with low polyphenol|
88896544|NCT01472484|Experimental|control bean with high polyphenol|
88896545|NCT01472497|Experimental|glymepiride|
88896546|NCT01472510|Active Comparator|Arm 1:The PRN Group|You will receive 6 monthly intravitreal injections of 0.5% Ranibizumab administered about every 28 days. It is possible you may receive additional injections into the study eye for the next six months if certain criteria is met.
88896547|NCT01472510|Active Comparator|arm 2:The Monthly Group:|You will receive 12 monthly intravitreal injections of 0.5% Ranibizumab administered every 28 days.
88896548|NCT01472523||Controls|
88896549|NCT01472523||Aneuploidy|T13, 18, 21 and other chromosomal abnormalities yet to be determined
88896550|NCT01472536|Experimental|3-day sequestration|Students will be sequestered within their residence hall room for 3 days following influenza like illness symptoms
88896551|NCT01472536|No Intervention|Control|No intervention
88896552|NCT01472575||Pre- rotavirus vaccination introduction|Children aged 0-less than 6 years of age admitted to hospital in South Australia with ICD10-AM separation codes consistent with rotaviral infection or gastroenteritis of any cause during the period 01May2005-30Apr2007 (pre vaccine introduction)
88896553|NCT01472575||post rotavirus vaccine introduction|Children aged 0-less than 6 years of age admitted to hospital in South Australia with ICD10-AM separation codes consistent with rotaviral infection or gastroenteritis of any cause during the period 01May2009-30Apr2011 (post vaccine introduction)
88896554|NCT01472601||FOLFOX_6|Oxaliplatin : 85 mg/m2/day D1 Leucovorin : 200 mg/m2/day D1 5-FU : 400 mg/m2/day D1 5-FU : 2,400 mg/m2/day D1 over 46 hrs Every 2 weeks, first 6 cycles, then Leucovorin : 200 mg/m2/day D1 5-FU : 400 mg/m2/day D1 5-FU : 2,400 mg/m2/day D1 over 46 hrs Every 2 weeks, 6 cycles
88896555|NCT01472601||FOLFOX_12|Oxaliplatin : 85 mg/m2/day D1 Leucovorin : 200 mg/m2/day D1 5-FU : 400 mg/m2/day D1 5-FU : 2,400 mg/m2/day D1 over 46 hrs Every 2 weeks, total of 12 cycles
88896556|NCT01472614|Experimental|DLBS3233|
88896557|NCT01472627||Bortezomib treatment|Subjects receiving standard of care regimen including Bortezomib
89418756|NCT02628028|Experimental|Part B 5 mg LY3337641|Given once a day for 12 weeks and an additional 52 weeks for Long-term extension (LTE) period.
89418757|NCT02628028|Experimental|Part B 10 mg LY3337641|Given once a day for 12 weeks and an additional 52 weeks for Long-term extension (LTE) period.
88896558|NCT01472640|Active Comparator|Liraglutid|Liraglutid
88896559|NCT01472640|Placebo Comparator|Placebo|Placebo
88896560|NCT01472666|Experimental|Fat rich in MC-SFA|63 gram milk fat with high content of MC-SFA (C6-C12=8.5 g) incorporated in rolls, muffin and as butter.
88896561|NCT01472666|Experimental|Fat low on MC-SFA|63 gram milkfat with low content of MC-SFA (C6-C12=6.9 g) incorporated in rolls, muffin and as butter
88896562|NCT01472666|Experimental|Casein protein|60 gram casein protein (Miprodan 30) ingested twice daily with 600 ml water.
88896563|NCT01472666|Experimental|Whey protein|60 gram whey protein (Lacprodan DI-9224) ingested twice daily with 600 ml water.
88896564|NCT01472705||everolimus-eluting stents (EES)|Second-generation everolimus-eluting stents (EES) have been shown to be superior to the first-generation paclitaxel eluting stents (PES) in terms of safety and efficacy.
88896565|NCT01472705||biolimus-eluting stents (BES)|Third generation biolimus-eluting stents (BES) have been shown to be superior to the PES and non inferior to first-generation sirolimus eluting stents in terms of safety and efficacy.
88896566|NCT01472731|Experimental|GC1008 imaging and treatment|"Part 1: Feasibility of 89Zr-GC1008 PET imaging in patients with suspicion of a malignant glioma to assess if GC1008 penetrates into the brain tumor and to quantify its uptake.~Part 2: 89Zr-GC1008 PET imaging in patients with relapsed malignant glioma and phase II extension study with therapeutic GC1008 in these patients"
88896567|NCT01472744|Experimental|Dance|Participants will be instructed in various forms of dances such as ballroom, swing, waltz, folk, and English country.
88896568|NCT01472744|Active Comparator|Strengthening, Stability, Stretching|Participants will be instructed in various forms of strength, stretching (flexibility) and stability (balance)exercises.
88896569|NCT01472744|Experimental|Walking|Participants in this moderate aerobic conditioning exercise program will be instructed in a walking program that focuses on having them walk within their target heart rate.
88896570|NCT01472744|Experimental|Walking + Nutritional Supplement|Participants in this moderate aerobic conditioning exercise program will be instructed in a walking program that focuses on having them walk within their target heart rate. These participants will also be provided with a daily nutritionally balanced liquid, milk-based formula.
88896571|NCT01472783|Experimental|Veliparib|
88896572|NCT01472796|Active Comparator|Tekturna (Aliskirin) with vit. D supplementation|Tekturna (Aliskiren) 300mg daily and vitamin D supplementation (50,000 IU)every other week.
88896573|NCT01472796|Placebo Comparator|Tekturna (Aliskiren) with placebo|Tekturna (Aliskiren) 300mg per day supplemented with placebo (vitamin D)
88896574|NCT01472809|Placebo Comparator|Placebo|Placebo tablets
88896575|NCT01472809|Experimental|ZYGK1|"ZYGK1 tablets; 0.125, 0.25, 0.5, 1, 2, ... mg.~Dose escalation will continue till single AE occurs in any block of 3 volunteers on ZYGK1 or pharmacokinetic (dose linearity) saturation is reached or desired PK/PD effect is achieved"
88896576|NCT01472848|Experimental|Cohort 1|
88896577|NCT01472848|Experimental|Cohort 2|
88896578|NCT01472848|Experimental|Cohort 3|
89418758|NCT02628028|Experimental|Part B 30 mg LY3337641|Given once a day for 12 weeks and an additional 52 weeks for Long-term extension (LTE) period.
89418759|NCT02628028|Placebo Comparator|Part B Placebo|Given once a day for 12 weeks.
89418760|NCT03688087|Placebo Comparator|placebo|"Smartphone application placebo"
89418761|NCT03688087|Active Comparator|"Bouge"|"Smartphone equipped with the application Bouge"
89418762|NCT02194764|Experimental|Expirimental Formulation|Participants will be administered a single encapsulated dose of the test formulation (Model Naltrexone 50mg containing 2-butanol). Breath samples will be taken over 90 minutes (-5, 0, 5, 10, 20, 40, 60, 90). Subjects will then be randomly crossed over to the four interventions (Formulation 1, Formulation 2, Formulation 3, Formulation-free positive control) three formulations from the first part of the study and a control administration (a capsule-in-capsule design).
89418763|NCT03692689|Experimental|SCT200|Initially, 6.0mg/kg of SCT200 will be administered once a week for a maximum of 6 cycles. After 6 cycles, 8.0mg/kg of SCT200 will be administered every two weeks until disease progression.
88896579|NCT01472848|Experimental|Cohort 4|
89193925|NCT03193190|Experimental|Cohort 1: Atezolizumab + Chemotherapy + AB928|Cohort 1: Participant will receive AB928 150 mg orally once daily on Days 1 to 28 of each 28 day cycle; Atezolizumab 840 mg IV infusion on Days 1 and 15 of each 28 day cycle; Nab-paclitaxel 125 mg/m^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle; Gemcitabine 1000 mg/m^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle.
88896580|NCT01472848|Experimental|Cohort 5|
88896581|NCT01472848|Active Comparator|Cohort 6|
88896582|NCT01472861|Placebo Comparator|No AECC|Routine procedures without AECC
88896583|NCT01472861|Experimental|AECC|Endometrial biopsy and Autologous endometrial coculture
88896584|NCT01472900|Experimental|Er:YAG laser|
88896585|NCT01472900|Active Comparator|BP gel|
89418764|NCT02196090|Experimental|Single arm|Study uses the single case series design with only one arm. All participants in the one arm will have procedures with treatment as usual (Exposure and Response Prevention) alternating with procedures including the vagal maneuver (Cold Face Gel Mask).
89418765|NCT04619719|Experimental|Hyperbaric Oxygen|Hyperbaric Oxygen Therapy (HBOT) + Standard of Care (SOC) as defined by current best practice treatments for COVID-19
89418766|NCT04619719|No Intervention|Standard of Care|Standard of Care (SOC) as defined by current best practice treatments for COVID-19
89418767|NCT03534414||Intervention|A Portfolio Dietary Pattern involving a combination of 4 cholesterol lowering foods, namely: plant sterols, viscous fibre, plant protein, and nuts.
88896586|NCT01472913|Active Comparator|Fibrin Sealent|
88896587|NCT01472913|Placebo Comparator|Saline water|
88896588|NCT01472926|Experimental|Tenecteplase 0.25 mg/kg|Intravenous tenecteplase 0.25 mg/kg (single bolus, maximum 25 mg)
88896589|NCT01472926|Active Comparator|Alteplase 0.9 mg/kg|Intravenous alteplase 0.9 mg/kg (10% bolus and 90% as IV infusion over 1 hour, maximum 90 mg)
88896590|NCT01472978|Active Comparator|Immediate antibiotic treatment|Patients will be treated with an antibiotic as soon as the aspirate obtained at the colonoscopy is found to be positive for C. diff.
88896591|NCT01472978|Sham Comparator|Delayed treatment with an antibiotic|Treatment will be started after a delay after the aspirate obtained at the colonoscopy is found to be C. diff positive.
88896592|NCT01473017|Experimental|CBT-based guided self-help|Providing a guided self-help booklet to patients with anxiety/depression meeting criteria, with two telephone calls by a clinician to provide support with this.
88896593|NCT01473017|No Intervention|No CBT intervention|Control group in comparison to CBT guided self-help group
88896594|NCT01473030||Dutasteride|No PCa at Year 2 or Year 4
88896595|NCT01473030||Placebo|No PCa at Year 2 or Year 4
88896596|NCT01473056|Experimental|Dose 1 JTK-853|
88896597|NCT01473056|Experimental|Dose 2 JTK-853|
88896598|NCT01473056|Experimental|Dose 3 JTK-853|
88896599|NCT01473056|Experimental|Dose 4 JTK-853|
88896600|NCT01473056|Placebo Comparator|Placebo|
88896601|NCT01473069|Experimental|Dose 1 JTK-853, 400 mg ketoconazole|
88896602|NCT01473069|Experimental|Dose 2 JTK-853|
88896603|NCT01473069|Experimental|Dose 3 JTK-853|
88896604|NCT01473069|Experimental|Dose 4 JTK-853|
88896605|NCT01473069|Placebo Comparator|Placebo|
88896606|NCT01473082|Active Comparator|PFNA|Proximal Femoral Nail Antirotation (PFNA Synthes)
88896607|NCT01473082|Active Comparator|PFNA Augmentation|Proximal Femoral Nail Antirotation PFNA Augmentation (Synthes) with Traumacem V+ Synthes
88896608|NCT01473121||Group 1|
88896609|NCT01473147|Active Comparator|GLP-1|
88896610|NCT01473147|Placebo Comparator|Normal saline|
88896611|NCT01473173|Experimental|CJ-12420 50mg|"Single dose~8 volunteers will be administered CJ-12420 50mg or placebo comparators.(CJ-12420:placebo=6:2)"
88896612|NCT01473173|Experimental|CJ-12420 100mg|"Single dose~8 volunteers will be administered CJ-12420 100mg or placebo comparators.(CJ-12420:placebo=6:2)"
88896613|NCT01473173|Experimental|CJ-12420 200mg|"Single dose~8 volunteers will be administered CJ-12420 200mg or placebo comparators.(CJ-12420:placebo=6:2)"
88896614|NCT01473173|Experimental|CJ-12420 400mg|"Single dose~8 volunteers will be administered CJ-12420 400mg or placebo comparators.(CJ-12420:placebo=6:2)"
89193926|NCT03193190|Experimental|Cohort 1: Atezolizumab + Chemotherapy + Tiragolumab|Cohort 1: Participants will receive Atezolizumab 840 mg IV infusion on Days 1 and 15 of each 28 day cycle; Tiragolumab 420 mg IV infusion on Days 1 and 15 of each 28 day cycle; Nab-paclitaxel 125 mg/m^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle; Gemcitabine 1000 mg/m^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle.
89418768|NCT03534414||Control|A National Cholesterol Education Program (NCEP) based diet, a diet low in saturated fat and cholesterol.
88896615|NCT01473173|Experimental|CJ-12420 100mg (repeated dose)|"Repeat doses~100mg is the anticipated dose~8 volunteers will be administered CJ-12420 100mg or placebo comparator.(CJ-12420:placebo=6:2)"
89418769|NCT03534336|No Intervention|Control|"Participants are enrolled in a 12-week, self-administered online weight loss program. The program is delivered through 12 weekly sessions; each includes educational videos and a health literacy quiz. Each quiz contains 10 questions, and a quiz is considered passed when at least 7 questions are answered correctly. All participants are encouraged to follow the program, take the quizzes, and lose 5% of their baseline body weight by the end of the program.~No financial incentives are given for losing weight or passing quizzes."
89418770|NCT03534336|Experimental|Incentive for Education|"Same 12-week, self-administered online weight loss program as in the Control arm.~Each participant is also given a $150 Incentive for Education for passing at least nine quizzes by the end of the program."
89418771|NCT03534336|Experimental|Incentive for Weight Loss|"Same 12-week, self-administered online weight loss program as in the Control arm.~Each participant is also given a $150 Incentive for Weight Loss for losing 5% of their baseline body weight."
89418772|NCT02967640|Experimental|Ketalar|ketalar injection, subacromial
89418773|NCT02967640|Placebo Comparator|Placebo|physiological sodium chloride (NaCl 9%) injection, subacromial
89418774|NCT03692533|Active Comparator|Group A|Group (A) [study cases] Adult patients who will undergo radical or partial nephrectomy.for primary renal cell carcinoma.
89418775|NCT03692533|Active Comparator|Group B|Group (B) [control cases] Adult patients who will undergo simple nephrectomy for benign causes
88896616|NCT01473173|Experimental|CJ-12420 200mg (repeated dose)|"Repeat doses~200mg is the anticipated dose~8 volunteers will be administered CJ-12420 200mg or placebo comparator.(CJ-12420:placebo=6:2)"
88896617|NCT01473173|Active Comparator|Esomeprazole 40mg|8 volunteers will be administered Esomeprazole 40mg
88896618|NCT01473225|Experimental|Calorie label|
88896619|NCT01473225|Active Comparator|No calorie label|
88896620|NCT01473238|Active Comparator|Desktop PC|Conventional institutional Desktop Personal Computers will be used to collect data of patients via a password protected encrypted interface.
88896621|NCT01473238|Experimental|Mobile|Novel Mobile Clinical Trial Management System on iPads will be used to collect data of patients via a password protected encrypted interface.
88896622|NCT01473251|Active Comparator|Avastin for Diabetic Macular Edema|1.25 mg avastin monthly for 4 months
88896623|NCT01473251|Active Comparator|Avastin for Exudative Macular Degeneration|1.25 mg Avastin monthly for 4 months
88896624|NCT01473251|Active Comparator|Lucentis for Exudative Macular Degeneration|0.5 mg Lucentis monthly for 4 months
88896625|NCT01473264|Placebo Comparator|Control|
88896626|NCT01473264|Experimental|High dose rhCC10|5 mg/kg study drug (rhCC10)
88896627|NCT01473264|Experimental|Low Dose rhCC10|1.5 mg/kg study drug (rhCC10)
88896628|NCT01473277|Active Comparator|BT-A (Dysport 500U)|
88896629|NCT01473277|Active Comparator|Triamcinolone acetonide|
88896630|NCT01473290|Experimental|Arm I|Patients receive live freeze-dried lactic acid bacteria probiotic (VSL#3®) orally (PO) 3 times a day during RT (5-8 weeks) and for 2 weeks after completion of RT.
88896631|NCT01473290|Placebo Comparator|Arm II|Patients receive placebo PO 3 times a day during RT (5-8 weeks) and for 2 weeks after completion of RT.
88896632|NCT01473303|Experimental|Arm I|Patients receive oxaliplatin IV over 2 hours, irinotecan hydrochloride IV over 90 minutes, and leucovorin calcium IV over 2 hours on day 1 and fluorouracil IV over 48 hours beginning on day 2 (mFOLFIRINOX) and ganitumab IV over 30-60 minutes on day 1. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity.
88896633|NCT01473303|Experimental|Arm II|Patients receive mFOLFIRINOX as in arm I and placebo IV over 30-60 minutes on day 1.
88896634|NCT01473316|Experimental|A|
88896635|NCT01473329|Experimental|Structured Diabetes education|The intervention group received a structured DSME course. The course was composed by weekly 2 hour meetings for five weeks total hours group of 10 patient and reinforcement meetings every 4 months, for one year
89418776|NCT02943928|Experimental|laryngoscope and chest CT image|First,the operator calculate the distance between the carina and the glottis by CT image and make s marker on the double lumen endotracheal tube. Then the operator when inserted into the double lumen tube under the visualof laryngoscope until see marker just at the glottis.
89418777|NCT02943928|Experimental|Traditional method by experience|Operator inserted the double lumen tube by experience
89418778|NCT02194920||Parathyroid reimplantation|
89418779|NCT04855552|Experimental|Single-Arms Longitudinal Group|Behavioral weight-loss program via telehealth (video conferencing). Participants will receive weekly group sessions of lifestyle counseling for the first 20-weeks, followed by every other week sessions in weeks 22 and 24, for a total of 6-months of intervention.
89418780|NCT03701971|Experimental|Music Therapy|"a medical examination~Before and after music therapy, patients will have to answer questionnaires :~Before :~Questionnaire 5D itch scale Itchy Quality of Life Pruritus assessment on the digital scale Questionnaire State-Trait Anxiety Inventory (STAI Y-A)~After :~Pruritus assessment on the digital scale Questionnaire State-Trait Anxiety Inventory (STAI Y-A) PGIC~• Patients will then benefit from a balneotherapy session the next morning. Patients will have to answer questionnaires before and after balneotherapy :~Before :~Pruritus assessment on the digital scale Questionnaire State-Trait Anxiety Inventory (STAI Y-A)~After :~Pruritus assessment on the digital scale Questionnaire State-Trait Anxiety Inventory (STAI Y-A) PGIC"
89418781|NCT03701971|Active Comparator|Emollient cream|"a medical examination~Before and after music therapy, patients will have to answer questionnaires :~Before :~Questionnaire 5D itch scale~Itchy Quality of Life~Pruritus assessment on the digital scale~Questionnaire State-Trait Anxiety Inventory (STAI Y-A)~After :~Pruritus assessment on the digital scale~Questionnaire State-Trait Anxiety Inventory (STAI Y-A)~PGIC~Patients will then benefit from a balneotherapy session the next morning. Patients will have to answer questionnaires before and after balneotherapy :~Before :~Pruritus assessment on the digital scale~Questionnaire State-Trait Anxiety Inventory (STAI Y-A)~After :~Pruritus assessment on the digital scale~Questionnaire State-Trait Anxiety Inventory (STAI Y-A)~PGIC"
89418782|NCT02194140|Other|oral contrast|oral iodinated contrast material
89418783|NCT03534648|Experimental|Effect of PF-05221304 on PF-06865571 PK|
89418784|NCT03534648|Experimental|Effect of PF-06865571 on PF-05221304 PK|
89418785|NCT03701893|Experimental|Lactobacillus PS11610|Lactobacillus PS11610 for couples with genital dysbiosis and infertility. Each dose contains 1*10E9 colony forming unit (CFU) of Lactobacillus PS11610.Two daily doses for her and one daily dose for him until pregnancy or end of study period (6 months).
88896636|NCT01473342|Other|Control & Intervention Phases|The control phase will run for 8 weeks, including survey completion and accelerometer wear during Week 1 and Week 8. The intervention phase will run for the 9 weeks following the control phase; where participants are assigned a smartphone to interact with the Mila Blooms gaming app and integrated social network & receive weekly supportive coaching phone calls from study staff for 8 weeks (Week 9 - Week 16) followed by accelerometer wear & survey completion during the 9th and final week (Week 17).
88896637|NCT01473433|Other|Control|Patients in which the non-revascularizable area will be left untouched and the revascularizable area will be treated normally.
88896638|NCT01473433|Experimental|adiFLAP|Patients in which the non-revascularizable area will be covered by the adiFLAP and the revascularizable area will be treated with the normal procedure.
88896639|NCT01473446|No Intervention|Control|Standard monitoring. Initial optimization of fluid status is performed by pulse, BP and anaesthesiologist assessment with Ringer acetate. Followed by an infusion of 10ml/kg/t Ringer acetate. Urinary output and blood pressure is used as a surrogate parameter: the infusion rate is increased by a fall in blood pressure or urine output <0.5ml/kg/t. Bleeding replaced with HES 1:1, otherwise see table for fluid therapy page 9. Vasoactive agents (noradrenaline / phenylephrine) is given if the anesthesiologist considers this necessary. Postoperative give 1000ml Glucose 5%. HES or Ringer when low blood pressure, eventually noradrenaline as vasoactive agent.
88896640|NCT01473446|Experimental|Goal directed fluid therapy|
88896641|NCT01473459|Active Comparator|IVM Treatment|
88896642|NCT01473459|Active Comparator|Antagonist Protocol|
88896643|NCT01473472|Active Comparator|Truvada|associated with an overall offer of prevention (counselling, STD screening, condoms, HAV and HBV vaccinations, treatment post-exposure to the HIV infection)
89193927|NCT03193190|Experimental|Cohort 2: Atezolizumab + Cobimetinib|"Cohort 2: Participants will receive Cobimetinib 60 milligrams (mg) once daily orally on Days 1-21 of each 28-day cycle; and Atezolizumab 840 mg IV infusion on Days 1 and 15 of each 28-day cycle.~Participants who progressed on treatment may have the option of receiving Atezolizumab + RO6874281 treatment, provided they meet the eligibility criteria and the arm is open for enrollment."
89193928|NCT03193190|Experimental|Cohort 2: Atezolizumab + PEGPH20|"Cohort 2: Participants will receive PEGPH20 3 micrograms per kilogram (mcg/kg) IV infusion on Days 1, 8 and 15 of each 21-day cycle; and Atezolizumab 1200 mg IV infusion on Day 1 of each 21-day cycle.~Participants who progressed on treatment, may have the option of receiving Atezolizumab + Cobimetinib or Atezolizumab + RO6874281 treatment, provided they meet the eligibility criteria and the arms are open for enrollment."
88896644|NCT01473472|Placebo Comparator|Placebo of Truvada|associated with an overall offer of prevention (counselling, STD screening, condoms, HAV and HBV vaccinations, treatment post-exposure to the HIV infection)
88896645|NCT01473485|Experimental|ExAblate Transcranial Device|
89193929|NCT03193190|Experimental|Cohort 2: Atezolizumab + BL-8040|"Cohort 2: Participants will receive BL-8040 1.25 milligrams per kilogram (mg/kg) subcutaneously (SC) on Days 1-5 of the first week, followed by combination treatment consisting of BL-8040 1.25 mg/kg SC three times a week on non-consecutive days and Atezolizumab 1200 mg IV infusion on Day 1 of each 21-day cycle.~Participants who progressed on treatment may have the option of receiving Atezolizumab + Cobimetinib or Atezolizumab + RO6874281 treatment, provided they meet the eligibility criteria and the arms are open for enrollment."
89418786|NCT02196402||study population|"Consecutive adult (18-80 yrs) outpatients undergoing colonoscopy for routine indications (screening, symptoms, surveillance).~Exclusion criteria:~patients with CRC history or hereditary polyposis syndromes or hereditary non-polyposis colorectal cancer~patients with inadequate bowel preparation~patients in which cecal intubation was not achieved or scheduled for partial examinations~polyps could not be resected due to ongoing anticoagulation or could not be retrieved for pathologic assessment"
89418787|NCT02194218|Experimental|Nevirapine XR 4 doses|
89418788|NCT02194218|Active Comparator|Nevirapine XR 2 doses|
88896646|NCT01473498|Experimental|Test group|"Patients will be treated with fluid and norepinephrine to achieve and maintain a mean arterial pressure of 65 mm Hg. Then they will be randomized in two groups.~In the first group (study group, n=30), mean arterial pressure will be increased to 85 mm Hg for 72 hours by increasing the dose of norepinephrine in patients (A maximum dose of 1.2 mcg / kg / min is not exceeded). Key details, e.g., for drugs include dosage form, dosage, frequency and duration."
88896647|NCT01473498|Active Comparator|Control group|"Patients will be treated with fluid and norepinephrine to achieve and maintain a mean arterial pressure of 65 mm Hg. Then they will be randomized in two groups.~In this group (control group, n=30), mean arterial pressure will be maintained at 65 mm Hg."
89418789|NCT02194296|Experimental|Ambroxol hydrochloride - lozenge|
89418790|NCT02194296|Active Comparator|Ambroxol hydrochloride - syrup|Mucosolvan®
89418791|NCT02195076||Breast Cancer patients|
89418792|NCT02195076||Lung cancer patients|
89418793|NCT02195076||Healthy controls|
89418794|NCT02196480|No Intervention|Methotrexate|JIA patients on stable dose of methotrexate vaccinated with PPV23
89418795|NCT02196480|Experimental|anti-TNF|JIA patients refractory to methotrexate immediately before the association of anti-TNF vaccinated with PPV23
89418796|NCT03977701|Experimental|Mono-morphemic Singleton PD|Speech sound treatment on mono-morphemic singleton consonants for children with PD.
89418797|NCT03977701|Experimental|Mono-morphemic Singleton PD-SLI|Speech sound treatment on mono-morphemic singleton consonants for children with PD-SLI.
89418798|NCT03977701|Experimental|Mono-morphemic Cluster PD|Speech sound treatment on mono-morphemic consonant clusters for children with PD.
88896648|NCT01473511|Experimental|Strongest Families Program + Usual care|50% randomized to receive Strongest Families intervention immediately as well as the usual care services available via the referring agency for the 22 month study period.
89418799|NCT03977701|Experimental|Mono-morphemic Cluster PD-SLI|Speech sound treatment on mono-morphemic consonant clusters for children with PD-SLI.
89418800|NCT03977701|Experimental|Bi-morphemic Singleton PD|Treatment on singletons in bi-morphemic contexts for children with PD.
89418801|NCT03977701|Experimental|Bi-morphemic Singleton PD-SLI|Treatment on singletons in bi-morphemic contexts for children with PD-SLI.
89418802|NCT03977701|Experimental|Bi-morphemic Cluster PD|Treatment on bi-morphemic consonant clusters for children with PD.
89418803|NCT03977701|Experimental|Bi-morphemic Cluster PD-SLI|Treatment on bi-morphemic consonant clusters for children with PD-SLI.
89418804|NCT03977701|Experimental|Bi-morphemic Singleton SLI|Treatment on singletons in bi-morphemic contexts for children with SLI.
89418805|NCT03977701|Experimental|Bi-morphemic Cluster SLI|Treatment on bi-morphemic consonant clusters for children with SLI.
89418806|NCT04224220|Active Comparator|Adult Medical Care Coordination|This group will receive adult medical care coordination following discharge from a recent hospitalization.
89418807|NCT04224220|Active Comparator|Remote Patient Monitoring|This group will receive remote patient monitoring following discharge from a recent hospitalization.
89418808|NCT04224220|No Intervention|Usual Care|The usual care group will not receive additional supportive care following discharge from a recent hospitalization beyond what is typically offered through their primary care team.
89418809|NCT02197026|Experimental|Synvisc group|injection of Synvisc® at day 1, day 8 and day 15; in the mean time it will be recommended to decrease or stop all other OA treatments
89418810|NCT02197026|Active Comparator|Osteoarthritis standard treatment group|Treatment will be left to the discretion of the investigator who could prescribe any therapies, except viscosupplementation product
89418811|NCT02197104|Experimental|Citocoline|The intervention will be 1000mg of citicoline in capsule form once daily.
89418812|NCT03975595|Active Comparator|Meditation Group A|"A brief meditation intervention involving guided breathing and/or attention exercises (further information withheld to preserve blinding).~Meditation Group A is the Savoring Meditation Condition. Participants in this condition were trained to generate positive emotions through savoring a pleasant autobiographical memory in a multi-sensory manner."
89418813|NCT03975595|Active Comparator|Meditation Group B|"A brief meditation intervention involving guided breathing and/or attention exercises (further information withheld to preserve blinding).~Meditation Group B is the Breathing Meditation Condition. Participants in this condition were trained to relax and body and take deep breaths in a self-directed manner."
89418814|NCT02197182|Experimental|LUXSOL Cream|LUXSOL Cream is a copper containing cream to be administered intravaginally before bedtime for 10 consecutive nights.
89418815|NCT02197182|Active Comparator|Metronidazole cream|Metronidazole cream is the active comparator drug to be self-administered intravaginally each night before bedtime for 10 consecutive nights. Dosage is per package insert.
89418816|NCT03692455|Experimental|BPG Group|Patients will be submitted to Roux-en-Y Bypass Gastric Surgery.
89418817|NCT03692455|Experimental|Sleeve Group|Patients will be submitted to Vertical Sleeve Gastrectomy Surgery.
89193930|NCT03193190|Experimental|Cohort 2: Atezolizumab + RO6874281 every 2 weeks|"Cohort 2: Participants will receive Atezolizumab 840 mg IV infusion on days 1 and 15 of each 28 day cycle; RO6874281 will be administered 10 mg by IV infusion on day 1 and 15 mg on days 8, 15, and 22 for cycle 1 (28 day cycle). RO6874281 will be administered 15 mg by IV infusion on days 1 and 15 of each subsequent 28 day cycle.~Participants who progressed on treatment may have the option of receiving Atezolizumab + Cobimetinib, provided they meet the eligibility criteria and the arm is open for enrollment."
89193931|NCT03193190|Experimental|Cohort 2: Atezolizumab + RO6874281 every 3 weeks|"Cohort 2: Participants will receive Atezolizumab 1200 mg IV infusion on Day 1 of each 21 day cycle; and RO6874281 10 mg by IV infusion on day 1 of each 21 day cycle.~Participants who progressed on treatment may have the option of receiving Atezolizumab + Cobimetinib, provided they meet the eligibility criteria and the arm is open for enrollment."
89199175|NCT05954156|Active Comparator|dual cured resin cement|Dual cured resin cement is chosen as a comparator (gold standard )for the cementation of indirect restorations. (Sadighpour et al., 2018) Resin cement is insoluble and has superior mechanical and physical properties, compared with other previous luting materials. The clinical advantages of resin cement include high resistance to compression forces, low thermal expansion coefficients, high flexural strengths, and hardness. In addition, resin cement is characterized by adhesion to many materials, the ability to modify shade and color, high retention, resistance to wear at the margin of the restoration, and low marginal permeability. Resin cement provides optimal bond with resin composite indirect restorations and evenly distributes the compression force along all contact surfaces. (Gurdal et al., 2018
89418818|NCT02197260|Experimental|Protocol A|Antibiotics (3/d 500 mg metronidazole plus 375 mg amoxicillin for 7 days) during the first, non-surgical phase of periodontal therapy (T1), and placebo during the second, surgical phase (T2)
89418819|NCT02197260|Active Comparator|Protocol B|Placebo during the first, non-surgical phase of periodontal therapy (T1), and antibiotics (3/d 500 mg metronidazole plus 375 mg amoxicillin for 7 days) during the second, surgical phase (T2)
89418820|NCT03688009|Experimental|Mindfulness-Based Family Psycho-Education (MBFBE)|A programme focuses on non-judgmental attitudes, collaborative inquiry and self-care, including components of understanding early psychosis, medication, treatment management, mental health service collaboration, attention to caregiver's experiences and distress, strategies for improving communication and problem-solving, and crisis planning.
89418821|NCT03688009|Active Comparator|Family Psycho-Education (FPE)|A programme focuses on information giving, problem-solving and mutual support, including components of understanding early psychosis, medication, treatment management, mental health service collaboration, attention to caregiver's experiences and distress, strategies for improving communication and problem-solving, and crisis planning.
89199176|NCT05954130|Experimental|Mobile Application Support Specific to Sexual Health in Pregnancy|The training module will consist of 3 sessions. The first session will last 1 hour, with 45 minutes of interactive lecture and 15 minutes of question and answer. The second and third sessions will last 1 hour, with 45 minutes of interactive narration and 15 minutes of qualitative interviews. Module sessions will have a dynamic structure that takes into account the needs of the pregnant woman in her trimester. The content of the training sessions will be structured on the following topics.
88896649|NCT01473511|No Intervention|Usual care|50% randomized will not receive Strongest Families Intervention during the 22 month study phase, but will receive the usual care services available via the referring agency. At the end of the 22 month study period study participants will be offered the Strongest Families Intervention services.
88896650|NCT01473537|Active Comparator|calcium lactate solution 75 mM|
88896651|NCT01473537|Active Comparator|calcium lactate solution 150 mM|
88896652|NCT01473537|Placebo Comparator|placebo|
88896653|NCT01473550|Experimental|Early Intervention|At Phase 1 (first 3 months of project), the 200 participants in Group 1 will be provided with a Personal Health Record (PHR) through TELUS Health Space, as well as they will be introduced to smart phone technology to ready them for deployment of the prompts and reminders. Two months later, they will be provided with a smart phone.
88896654|NCT01473550|Experimental|Later Intervention|A delayed implementation plan will be used (but will have no effect on the standard of care for the remaining 200 participants), so the remaining 200 participants in Group 2 will initially act as a control group, but at Phase 2 (six months later - approximately June 2012) the remaining 200 participants will be introduced to the technology in the same order (PHR -> Smart Phone). Group 2 will have the benefit of any enhancements made during Phase 1 of the project.
88896655|NCT01473576|Experimental|Nitrate|Sodium nitrate ingestion prior to ingesting intrinsically labeled protein
88896656|NCT01473576|Placebo Comparator|Sodium chloride|Sodium chloride placebo group
88896657|NCT01473615|Experimental|Treatment As Usual + Mindfulness Based Cognitive Therapy|Subjects randomized into the intervention group will receive, a manualized 8-week MBCT group skills program with sessions that each last 2 hours, in addition to their treatment as usual (TAU).
88896658|NCT01473615|No Intervention|Treatment As Usual|Patients randomized into the TAU group will continue to receive their care as usual and be put on a waitlist. They will be offered the MBCT treatment after the completion of the study.
88896659|NCT01473641||New users of Nexplanon|
88896660|NCT01473654|Experimental|ADAPT tool|prediabetes counseling using ADAPT tool
88896661|NCT01473654|No Intervention|Control|
88896662|NCT01473667|Active Comparator|Superficial Cervical Plexus Block|
88896663|NCT01473667|Active Comparator|Local Infiltration|
88896664|NCT01473680||Patients who will receive chemo|This study is an assessment of individuals' cognitive functioning through administration of NP and psychological instruments and EEG. These assessments do not require manipulation of a participant's environment to elicit change in behavior or treatment outcome. NP and psychological instruments.
88896665|NCT01473680||Patients who will not receive chemo|This study is an assessment of individuals' cognitive functioning through administration of NP and psychological instruments and EEG. These assessments do not require manipulation of a participant's environment to elicit change in behavior or treatment outcome. NP and psychological instruments.
88896666|NCT01473680||Healthy Controls|This study is an assessment of individuals' cognitive functioning through administration of NP and psychological instruments and EEG. These assessments do not require manipulation of a participant's environment to elicit change in behavior or treatment outcome. NP and psychological instruments.
88896667|NCT01473693||surgery-only group|This will be a prospective study to investigate chemotherapy related structural brain changes in individuals undergoing anatomic lung resection for non-small cell carcinoma with and without, induction systemic chemotherapy treatment.
89418822|NCT02197338|Experimental|Short Wire, Small Tome|Short wire system, small sized sphincterotome will be used to perform the Intervention of Bile Duct Cannulation.
89418823|NCT02197338|Active Comparator|Short Wire, Standard Tome|Short wire system, standard sized sphincterotome will be used to perform the Intervention of Bile Duct Cannulation.
89418824|NCT02197338|Active Comparator|Long Wire, Small Tome|Long wire system, small sized sphincterotome will be used to perform the Intervention of Bile Duct Cannulation.
89418825|NCT02197338|Active Comparator|Long Wire, Standard Tome|Long wire system, standard sized sphincterotome will be used to perform the Intervention of Bile Duct Cannulation.
88896668|NCT01473693||induction chemotherapy group|This will be a prospective study to investigate chemotherapy related structural brain changes in individuals undergoing anatomic lung resection for non-small cell carcinoma with and without induction systemic chemotherapy treatment.
88896669|NCT01473706||Consumers|Adults aged ≥ 65 years; Employed part-time, unemployed, retired, full-time or a homemaker; English speaking
88896670|NCT01473706||Caregivers of Consumers|Family, relative, friend, professional caregiver of an individual age ≥ 65 years; Lives with individual aged ≥ 65 years OR Visits individual aged ≥ 65 years five or more days a week; Makes decisions or has strong influence on the individual aged ≥ 65 years' diet and medical needs; English speaking
88896671|NCT01473719|Active Comparator|motivational intervention|7-session individual motivationally-based intervention
88896672|NCT01473719|Placebo Comparator|health education|7-session individual session focusing on health education
89199177|NCT05954130|No Intervention|control|No training will be given to the pregnant women in the control group who accepted to participate in the study.
89199178|NCT05954117|Experimental|Interventional|patients with esophageal or gastroesophageal adenocarcinoma included to evaluate the energy expenditure before and after chemotherapy and evaluate parameters of cachexia
88896673|NCT01473771|Experimental|Caring Letter Condition (CL)|"In the Caring Letters (CL) group, participants will be emailed letters for two years on a planned schedule. The emailed letters are simple expressions of care and include standard contact information for available health care services."
88896674|NCT01473771|No Intervention|Usual Care (UC)|The participants in the Usual Care (UC) group will not receive the emails.
88896675|NCT01473797|Experimental|cladribine|
88896676|NCT01473810|Experimental|Vacc-4x low dose|80 µg Vacc-4x (20 µg pr. peptide) in 300 µl Endocine divided into two administrations, one for each nose cavity
88896677|NCT01473810|Experimental|Vacc-4x medium dose|400 µg Vacc-4x (100 µg pr. peptide) in 300 µl Endocine divided into two administrations, one for each nose cavity
88896678|NCT01473810|Experimental|Vacc-4x high dose|1200 µg Vacc-4x (300 µg pr. peptide) in 300 µl Endocine divided into two administrations, one for each nose cavity
88896679|NCT01473810|Placebo Comparator|Zero dose|Adjuvant only, i.e. 300 µl Endocine divided into two administrations, one for each nose cavity
88896680|NCT01473823|Placebo Comparator|Placebo oil|Canola oil with high oleic acid content flavored with lemon supplied as 5 ml daily.
88896681|NCT01473823|Active Comparator|Omega-3 LCPUFA|"The omega-3 LCPUFA supplementation comprises of 5 ml daily of Möller's Tran flavored with lemon. This dose provides the child with 1200 mg of omega-3 fatty acid of which 600 mg is DHA and 400 mg is EPA."
89199179|NCT05954091|Experimental|OH2 Injection|Subjects will get OH2 injection every two weeks, and up to 8mL for each treatment. There will have three virus titers: 1×10^6 CCID50/mL, 5×10^6 CCID50/mL, 1×10^7 CCID50/mL.
89418826|NCT03687931|Experimental|Arm 1|Dexamethasone suspension dose level 1
89418827|NCT03687931|Experimental|Arm 2|Dexamethasone suspension dose level 2
89418828|NCT02814526|Experimental|Aerobic|Moderate/high intensity aerobic exercise will involve training at 70-80% heart rate reserve for 30 min, with an additional 10 minutes for warm-up and 5 minutes for cool-down, 4 times per week, for 12 months while supervised twice per week by a study-certified trainer at a participating YMCA .
89418829|NCT02814526|Active Comparator|Stretching/balance/range of motion|The stretching/balance/range of motion program will involve exercise at or below 35% heart rate reserve for 30 min, with an additional 10 minutes for warm up and 5 minutes for cool-down, 4 times per week, for 12 months while supervised twice per week by a study-certified trainer at a participating YMCA.
89418830|NCT04214574|Experimental|Real time ultrasound-guided Parasagittal oblique technique|
89418831|NCT04214574|Experimental|Real time ultrasound-guided paramedian tranverse technique|
89536007|NCT02479607|Experimental|Intervention group|Use of an application for a smartphone or tablet for daily reporting symptoms and access to self-care advice and health care professionals in real time in combination with standard care according to the clinic´s routines
89536008|NCT02479607|No Intervention|Control group|Standard care according to the clinic's routines.
88896682|NCT01473888|Other|T89|
89193932|NCT03193190|Active Comparator|Cohort 2: Control (Nab-Paclitaxel and Gemcitabine or mFOLFOX6)|"Cohort 2: Participants who progressed on a prior fluoropyrimidine-based regimen will receive Nab-paclitaxel 125 mg/m^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle; and Gemcitabine 1000 mg/m^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle.~Participants who progressed on a prior gemcitabine-based regimen will receive 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6). Participants will receive Oxaliplatin 85 mg/m^2 IV on Days 1 and 15 of each 28 day cycle; Leucovorin 400 mg/m^2 IV on Days 1 and 15 of each 28 day cycle; Fluorouracil 400 mg/m^2 IV push on Days 1 and 15 of each 28 day cycle; and Fluorouracil 2400 mg/m^2 IV continuous infusion over 46 hours on Days 1 and 2 and on Days 15 and 16 of each 28 day cycle.~Participants who progressed on treatment, may have the option of receiving Atezolizumab + Cobimetinib or Atezolizumab + RO6874281 treatment, provided they meet the eligibility criteria and the arms are open for enrollment."
89193933|NCT03193190|Experimental|Cohort 1: Atezolizumab + Chemotherapy + Tocilizumab|Cohort 1: Participants will receive Tocilizumab 8 mg/kg IV infusion on Day 1 of each 28 day cycle; Atezolizumab 1680 mg IV infusion on Day 1 of each 28 day cycle; Nab-paclitaxel 125 mg/m^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle; and Gemcitabine 1000 mg/m^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle.
88896683|NCT01473901|Experimental|BKM120 + Temozolomide (Concomitant Phase)|Cranial radiation: Days 1 - 5 every 7 days for 42 days60 Gy in 30 fractions; Temozolomide: 75 mg/m2 Daily, orally; BKM120: 0, or 40, or 60, or 80 mg/d Daily, orally or Days 1-5 every 7 days, orally
88896684|NCT01473901|Experimental|BKM120 + temozolomide with/without radiotherapy|"Adjuvant phase cycle 1:~Temozolomide 150 mg/m2 - Days 1 - 5 every 28 days Daily; BKM120 60, or 80, or 100 mg/d;~Adjuvant phase cycle 2+:~Temozolomide 200* mg/m2 - Day 1 ~ 5 every 28 days Daily BKM120 0, or 40, or 60, or 80 or 100 mg/d"
88896685|NCT01473914|Experimental|Low dose|"Standard renal vitamin plus low dose zinc and selenium plus vitamin E~1 capsule p.o, daily"
88896686|NCT01473914|Experimental|Medium dose|"Standard renal vitamin plus medium doses of zinc and selenium plus vitamin E~1 capsule p.o, daily"
88896687|NCT01473914|Active Comparator|Standard treatment|"Standard renal vitamin~1 capsule p.o, daily"
88896688|NCT01473927||1|Crohn's Disease patients
88896689|NCT01473927||2|Ulcerative colitis patients
88896690|NCT01473966|No Intervention|standard of care|patients receive standard care
89193934|NCT03169985|Active Comparator|Rosuvastatin plus ezetimibe arm|In patients who have moderate stenosis(30-70%) in coronary artery and deferred to medical treatment by intracoronary physiologic or radiologic test, this arm will be received rosuvastatin 10 mg plus ezetimibe 10 mg qd during 12 months after randomization.
89199180|NCT05954078|Experimental|mFOLFIRINOX adjuvant chemotherapy|Patients will receive mFOLFIRINOX once every two weeks for 6 cycles as adjuvant chemotherapy
89536798|NCT03309995|Experimental|Zinc lozenges|Each lozenge contains 13 mg elemental zinc as zinc acetate. The instruction for common cold patients is to dissolve slowly 6 lozenges per day in their mouth, which totals to 78 mg/day of elemental zinc, at most for 5 days, as early as possible from the start of the cold symptoms.
89536799|NCT03309995|Placebo Comparator|Placebo lozenges|The placebo lozenges contain sucrose octaacetate, and they are similar with the zinc lozenges in visual appearance and in taste.
88896691|NCT01473966|Experimental|Coffee orally|patients will receive standard of care plus coffee orally
88896692|NCT01473966|Experimental|coffee rectally|patients receive standard of care plus coffee rectally
88896693|NCT01473979|Active Comparator|Arm A) Secondary closure with the vacuum-assisted system (VAC|"after the diagnosis of the poststernotomy wound infection is established the clinical procedure is obtained as follows: firstly the empiric antibiotic therapy with vancomycin is induced. The lab samples including bacteriology test are obtained. Surgical debridement is made until occurrence of tissue bleeding. Finally VAC sponge is implanted wit the negative suction pressure of 75 mmHg.~The patients are obtained 5 to 7 times to the surgical procedures in time intervals of 48/72 hours. Subsequently when the last three bacteriology samples are negative a delayed primary closure or rectus abdominal muscle flap may be done."
88896694|NCT01473979|Active Comparator|Arm B) Surgical procedure by delayed primary closure|In the first step, after the diagnosis of the infection was done, and the empiric antibiotic therapy is induced with vancomycin in the first surgical intervention the sternal wires will be removed, the mediastinum is explored and extensive surgical debridement is performed until occurrence of tissue bleeding.The patients will receive treatment delivered through the VAC system in the first 48 hours following the first surgical intervention, subsequently the wound is closed.
89418832|NCT02195154|Experimental|18F-DTBZ for Vascular Parkinsonism|This neuroimaging study includes the 18F-FP-(+)-DTBZ PET, MRI structure images, diffusion tensor imaging, susceptibility weighted imaging, resting state and gait-related imagery task functional MRI. Each evaluable subject involved in this study must fulfill all the inclusion and exclusion criteria according the subject group, each subject will have 3 visits in this study. Safety measurement for 18F-FP-(+)-DTBZ will be evaluated by medical history, vital signs, physical examinations, laboratory examinations and collecting of adverse events.
89418833|NCT02196636|Experimental|Part 1: Single Ascending Dose (SAD)|Adaptive model per protocol
88896695|NCT01474031||20 DAA subjects|20 DAA subjects: THA with a Deltamotion articulating surface utilizing the Direct Anterior Approach
88896696|NCT01474031||Control group|healthy volunteers
88896697|NCT01474044|Placebo Comparator|Placebo|
88896698|NCT01474044|Active Comparator|Gastropyloric Complex Capsules|
88896699|NCT01474057|Experimental|DESTRESS-PC|A brief, nurse-assisted, Internet-based online self-management tool for PTSD (DESTRESS-PC), based on empirically valid cognitive-behavioral therapy (CBT) strategies and designed for implementation in a primary care setting. DESTRESS-PC stands for DElivery of Self-TRaining and Education for Stressful Situations for Primary Care.
88896700|NCT01474057|Active Comparator|OUC|Optimized Usual Care (OUC) for PTSD--usual PTSD treatment offered within the primary care setting, optimized by training PC providers in PTSD identification and treatment and providing basic care management including phone check-ins to monitor symptoms and feedback to providers.
88896701|NCT01474096|Experimental|implementation strategy|determining whether the use of implementation strategy (including training session, information distribution, an opinion leader) of Breastfeeding CPG in primary care is more effective than the usual practice of mere circulation.
88896702|NCT01474096|No Intervention|Conventional intervention|
88896703|NCT01474161|Placebo Comparator|Matching placebo|
88896704|NCT01474161|Active Comparator|GFT505 20mg - old formulation|Study Part I : dose level = 120mg
88896705|NCT01474161|Experimental|GFT505 60mg - new formulation|Study Part I : dose level = 120mg ; Study Part II : dose level = 180mg, 240mg and 300mg ; Study Part III : dose level = 120mg, 180mg and 240mg ; Study Part IV : dose level = 120mg or 180mg.
88896706|NCT01474174||Supportive care (vaccine therapy)|Patients receive trivalent influenza vaccine IM on day 0.
88896707|NCT01474187|Experimental|Irinotecan|irinotecan dose initial from 50mg/m2/week, increased by 15mg/mg/week
88896708|NCT01474226|Experimental|Lysine Amino Acid|
88896709|NCT01474252|Experimental|RSI technique|"Intubation with RSI technique. RSI technique includes the administration of inductive and neuromuscular blocking agents to facilitate an intubation.~In this study, we have no restriction of medication use. Physicians can chose any of medication as an individual judgement."
88896710|NCT01474252|No Intervention|Non-RSI|Intubation without RSI technique. No any medication use during intubation period.
88896711|NCT01474265|Placebo Comparator|varenicline placebo|
88896712|NCT01474265|Active Comparator|varenicline|
88896713|NCT01474265|Active Comparator|Nicorette TX|
88896714|NCT01474265|Active Comparator|Nicorette TX optional|
88896715|NCT01474265|No Intervention|control group smokers|
88896716|NCT01474278|Experimental|1|
88896717|NCT01474278|Placebo Comparator|2|
88896718|NCT01474304|Active Comparator|Acetaminophen|Craniotomy patients will receive a 1000 mg dose of intravenous (IV) acetaminophen before incision and a second 1000 mg dose of IV acetaminophen 6 hours later.
88896719|NCT01474304|No Intervention|No acetaminophen|Patients will receive standard of care with no intraoperative doses of acetaminophen.
88896720|NCT01474330|Experimental|0.5-mg Pomalidomide or placebo (Cohort A)|A single 0.5-mg pomalidomide capsule or matching placebo administered once daily for 5 days under fasted conditions
88896721|NCT01474330|Experimental|1-mg Pomalidomide or placebo (Cohort B)|This arm may be initiated pending a safety review of Cohort A. A single 1-mg pomalidomide capsule or matching placebo administered once daily for 5 days under fasted conditions.
88896722|NCT01474330|Experimental|2-mg Pomalidomide or placebo (Cohort C)|This arm may be initiated pending a safety review of Cohort B. A single 2-mg pomalidomide capsule or matching placebo administered once daily for 5 days under fasted conditions.
88896723|NCT01474343|Experimental|SAF-301|
88896724|NCT01474356|No Intervention|BT (brachytherapy)|Cervical cancer patients after the treatment with external beam radiotherapy combined with chemotherapy. In this group of patients, interstitial brachytherapy only was performed.
88896725|NCT01474356|Experimental|BTHT (brachytherapy and hyperthermia)|Cervical cancer patients after the treatment with external beam radiotherapy combined with chemotherapy. In this group of patients, interstitial brachytherapy with interstitial hyperthermia was performed.
88896726|NCT01474369|Experimental|TAK-438 10 mg QD|
88896727|NCT01474369|Experimental|TAK-438 20 mg QD|
88896728|NCT01474369|Placebo Comparator|Placebo QD|
89418834|NCT02196636|Experimental|Part 2: Food Effect (FE)|Fasted versus Fed
89418835|NCT03534024|Active Comparator|nanomicielle curcumin|
89418836|NCT03534024|Placebo Comparator|plecebo|
89418837|NCT04175574|Experimental|Intervention group|The intervention consist of the patients in the experimental group listening to pre-recorded music played through a set of noise cancelling Sony headphones which are padded for extra comfort from a Sony Digital Walkman. The duration of the intervention is 30 minutes without interruption, such as eating, talking and being on their mobile phones.
89418838|NCT04175574|No Intervention|Control group|Whereas, patients in the control group will be given similar headphones but without any music. They will also be briefed not to eat, talk and being on their mobile phones.
89418839|NCT02753686||Cohort 1: Endocrine Therapy (ET)|HR+ HER2- male, female pre/postmenopausal advanced breast cancer patients being treated with endocrine therapy
89418840|NCT02753686||Cohort 2: Endocrine Therapy (ET) plus Targeted Therapy (TT)|HR+ HER2- male, female pre/ postmenopausal advanced breast cancer patients being treated with endocrine therapy in combination with targeted therapy including CDK4/6 inhibitor therapy
89418841|NCT02195388||CR with AH|Patients after ACS with arterial hypertension treat with comprehensive cardiac rehabilitation
89418842|NCT02195388||N-CR with AH|Patients after ACS with arterial hypertension don't treat with comprehensive cardiac rehabilitation.
88896729|NCT01474382|Experimental|OraVerse|OraVerse in doses of either 1/4, 1/2 or 1 cartridge (1.8mL)
88896730|NCT01474382|Sham Comparator|Sham injection|Dentist simulates injection with dental syringe
88896731|NCT01474395|Experimental|D-serine 60 mg/kg|double blind dose of d-serine
88896732|NCT01474395|Placebo Comparator|Placebo D-serine|
88896733|NCT01474408|Experimental|interval training|4 x 4 minutes exercise at 90 - 95 % of peak heart rate separated with 3 minutes at 70 % of peaks heart rate
88896734|NCT01474408|Active Comparator|moderate exercise|moderate continuous exercise at 70 % of peak heart rate on venous function.
88896735|NCT01474408|Other|control|routine measurements, no exercise
88896736|NCT01474447|Experimental|Grinberg Method|
88896737|NCT01474460|Placebo Comparator|Control group|The control group only receiving warfarin therapy (individualized therapy, hence no specific form, dosage, frequency and duration is applicable here - i.e. 5mg daily everyday for 6 months may be applicable to one patient but not all researched patients).
88896738|NCT01474460|Experimental|Phytonadione|Patients receiving 200mcg of phytonadione.
88896739|NCT01474473|Experimental|CACIPLIQ20 and Cast Boot|This arm receives treatment by CACIPLIQ20 application every 3 to 4 days and the wounded leg is held with a nonremovable, windowed, fiberglass Cast Boot.
88896740|NCT01474473|Placebo Comparator|Placebo and Cast Boot|This arm receives a placebo (saline solution) every 3 to 4 days and the wounded leg is held with a nonremovable, windowed, fiberglass Cast Boot.
88896741|NCT01474499|Experimental|Docusate sodium and sorbitol rectal solution|
88896742|NCT01474499|Active Comparator|Glycerine|
88896743|NCT01474525|Experimental|Telemonitoring|
88896744|NCT01474525|Active Comparator|Usual Care|
88896745|NCT01474564||Pts with Pancreatic Adenocarcinoma|This is an observational study to assess the feasibility of 1) isolating and enriching circulating tumorigenic cells from the peripheral blood of eligible pancreatic cancer patients and 2) successful gene expression profiling of these circulating tumorigenic cells.
88896746|NCT01474577||pts who have had Rb-82 PET myocardial perfusion imaging|Eligible patients will have had Rb-82 PET myocardial perfusion imaging at MSKCC, 2008 - 2011. Patients will complete one questionnaire over the phone.
88896747|NCT01474603||1|overweight or obese diabetic
88896748|NCT01474616|Other|Sit-to-Stand Activity|
88896749|NCT01474629|Active Comparator|probiotic-based dietary supplement|
88896750|NCT01474629|Placebo Comparator|placebo|
88896751|NCT01474642|Active Comparator|Capecitabine/Cisplatin(XP)|Capecitabine AND Cisplatin
88896752|NCT01474642|Active Comparator|Capecitabine/Paditaxel(XG)|Capecitabine + Paditaxel(genexol)
88896753|NCT01474668|Experimental|A|Experimental
88896754|NCT01474707|Experimental|Group one|Group1 will view the knowledge-based video only
88896755|NCT01474707|Experimental|Group two|Group two will view the motivational video only
88896756|NCT01474707|Experimental|Group three|Group three will view both knowledge-based and motivational videos
88896757|NCT01474707|Experimental|Group four|Group four will view the printed educational pamphlet and will not view either video
88896758|NCT01474720|Experimental|SLE patients|Subjects with mild SLE over age 50 years will receive open-label Zostavax vaccine.
88896759|NCT01474720|Active Comparator|Healthy subjects|Healthy subjects aged 50 years and older without any history of autoimmune disease will receive zostavax vaccine. Immune responses to varicella zoster virus and adverse events will be compared to those seen in SLE patients
88896760|NCT01474733|Experimental|educational intervention|participants undergo a series of educational interventions over 3 years
88896761|NCT01474759|Experimental|Portion size instruction|Advice on diet, physical activity, and behavior change. Instruction in food portion size.
88896762|NCT01474759|Experimental|Pre-portioned foods|Advice on diet, physical activity, and behavior change. Provision of pre-portioned foods.
88896763|NCT01474759|Active Comparator|Comparison|Advice on diet, physical activity, and behavior change. Advice on healthy eating for weight loss.
89418843|NCT02195388||CR without AH|Patients after ACS without arterial hypertension treat with comprehensive cardiac rehabilitation
89418844|NCT04216927|Experimental|Nitric Oxide|Intraoperative NO entrained at 20 ppm into the oxygenator of the CPB circuit with standard care
89418845|NCT04216927|Placebo Comparator|Oxygen|Standard CPB without NO administered at any point intraoperatively
89418846|NCT02329834|Experimental|Treatment Sequence 1|Furosemide Injection Solution for subcutaneous administration (80mg) over 5 hours followed by i.v. Furosemide Injection, USP (80 mg)by i.v. bolus in second period
89418847|NCT02329834|Experimental|Treatment Sequence 2|Furosemide Injection, USP (80 mg) by i.v. bolus, followed by Furosemide Injection Solution for subcutaneous administration (80mg) over 5 hours in second period.
89418848|NCT02195466|Experimental|TPV + RTV + FCZ|
89418849|NCT03692377||Children Aged 2-6|Children 2 to 6 years of age who are arriving with a guardian to the Emergency Department with a low acuity condition (Canadian Triage scale (CTAS) 4 or 5) and are waiting to be seen by the doctor, or are waiting for test results.
89418850|NCT02195544||Synvisc®|
89418851|NCT03687853|Experimental|Intrahepatic Arterial Infusion chemotherapy|chemotherapy through intrahepatic arterial Infusion is one of the most widely used liver tumor treatments.
89418852|NCT03687853|No Intervention|control|chemotherapy through Peripheral venous is one of the regularly used method.
89418853|NCT02197494|Experimental|Test|Valsartan Tablets USP 320 mg DIVIS
88896764|NCT01474785|Experimental|RYGB|Roux-en-Y gastric bypass surgery (RYGB) subjects to undergo hyperinsulinemic-euglycemic clamp with human ghrelin infusion pre-operatively and post-operatively.
88896765|NCT01474785|Experimental|VSG|Vertical sleeve gastrectomy (VSG) subjects to undergo hyperinsulinemic-euglycemic clamp pre-operatively and post-operatively.
89418854|NCT02197494|Active Comparator|Reference|Diovan® (Valsartan) 320 Tablets
88896766|NCT01474785|Experimental|Low Calorie Diet|Subjects will receive very low calorie diet prescribed for RYGB patients and undergo hyperinsulinemic-euglycemic before and after diet.
88896767|NCT01474837|Experimental|Exercise with motivational interviewing|Young people with depression exposed to exercise with motivational interviewing
88896768|NCT01474837|No Intervention|Treatment as usual|Young people with depression receiving treatment as usual
88896769|NCT01474850|Active Comparator|open lung|The lung recruitment maneuver (RM) immediately after intubation using pressure controlled ventilation, increase in peak inspiratory pressure up to 30 cm H2O during tidal ventilation, respiratory rate 4/min and positive end expiratory pressure (PEEP) 15 cm H20. PEEP 7 cm H2O until extubation. Inspiratory oxygen concentration (FiO2) 40% during recovery from anesthesia.
88896770|NCT01474850|No Intervention|control|No recruitment maneuver is performed. PEEP 0 cm H2O. Inspiratory oxygen concentration (FiO2) 100 % during recovery from anesthesia.
88896771|NCT01474902|Experimental|Treatment group|"The initial enoxaparin dose will be: 1.75 mg/kg/dose SC q12h for patients ≤ 2 months old or~1 mg/kg/dose SC q12h for patients > 2 months old~Adjust the dose of enoxaparin according to the following monogram. Depending on the Enoxaparin Anti-factor Xa level achieved, successive actions are indicated, including whether to hold the next scheduled dose, whether any dose change is indicated and when the next anti-factor Xa level should be drawn."
88896772|NCT01474902|No Intervention|No-treatment|
88896773|NCT01474928|Experimental|Group 2: community video group|In each community intervention group two subject viewed the patient role played community video
88896774|NCT01474928|Experimental|Group three: both videos group|In each community intervention group three subject viewed two videos (the patient role played community and physician-led knowledge videos)
88896775|NCT01474928|Active Comparator|Group four: pamphlet group|In each community intervention group four subject read an educational pamphlet only - act as active comparator group
88896776|NCT01474928|Experimental|Group one: knowledge video group|In each community intervention group one subject viewed the physician-led knowledge video
89193935|NCT03169985|Active Comparator|High-dose rosuvastatin monotherapy arm|In patients who have moderate stenosis(30-70%) in coronary artery and deferred to medical treatment by intracoronary physiologic or radiologic test, this arm will be received rosuvastatin 20 mg qd during 12 months after randomization.
89418855|NCT02710474|Active Comparator|Standard Care|Preterm infants will receive current Standard Care (SC) in the NICU.
89418856|NCT02710474|Experimental|Intervention|Preterm infants will receive Family Nurture Intervention (FNI) in addition to current Standard Care (SC) in the NICU. Specifically, staff will support the parents and facilitate contact between mother and infant during the NICU stay.
89418857|NCT02710474|Active Comparator|Term Controls|Full term infants will receive current Standard Care (SC) in the NICU. Term Controls (TC)
89418858|NCT02710474|Active Comparator|Chart Review|Chart review will be conducted to acquire a comparison group to determine if our study participants differ from the non-study population.
88896777|NCT01474941|Experimental|5 mg QD PF-04620110 or Placebo|
88896778|NCT01474941|Experimental|5 mg BID PF-04620110 or Placebo|
88896779|NCT01474941|Experimental|Optional Arm, PF-04620110 or Placebo|
88896780|NCT01474967|Experimental|Lower metformin dose group|500 mg metformin daily with breakfast for 1 week 500 mg metformin per 12 hours with breakfast and dinner for 23 weeks
88896781|NCT01474967|Active Comparator|Higher metformin dose group|500 mg metfomin daily with breakfast for 1 week 500 mg metformin per 12 hours with breakfast and dinner for 1 week 500 mg metformin with breakfast and 1000 mg with dinner for 22 weeks
88896782|NCT01475006|Experimental|Part I Dose Exploration|Pre-specified nominal doses are proposed in the dose exploration. Intermediate doses may also be used if required based on the CRM design.
88896783|NCT01475006|Experimental|Part II Dose Expansion|Dose selected from Part 1 dose exploration
88896784|NCT01475019|Experimental|PCOS obese Orlistat|Obese PCOS women treated with Orlistat, diet and physical exercise
88896785|NCT01475019|Experimental|Obese Orlistat|Obese women (non PCOS) treated with Orlistat, diet and physical exercise
88896786|NCT01475019|Experimental|PCOS obese diet|Obese PCOS women treated with diet and physical exercise
88896787|NCT01475019|Experimental|PCOS obese Sibutramine|Obese PCOS women treated with Sibutramine, diet and physical exercise
88896788|NCT01475032|Experimental|CHF 1535|CHF 1535 (BDP/FF) for 12 weeks
88896789|NCT01475032|Active Comparator|BDP|BDP for 12 weeks
88896790|NCT01475032|Active Comparator|BDP+FF|free combo BDP+FF for 12 weeks
88896791|NCT01475045||Turbuhaler inhaler use|
88896792|NCT01475045||Discus inhaler use|
88896793|NCT01475045||Elpenhaler inhaler use|
89193936|NCT03153527|Placebo Comparator|Placebo arm (intervention arm)|Stop glucocorticoid treatment; administer placebo matching the verum preparation in weekly intervals.
89418859|NCT03683017|Experimental|I-OP2.0|Patients receive Invisalign orthodontic treatment, with 3.5 day Aligner changes, by the qualified Principal Investigator (PI). Patients receive OrthoPulse 2.0 device.
88896794|NCT01475084|Experimental|Cryobiopsy, forceps biopsy|"Cryoiopsies will be obtained by flexible autoclavable cryoprobe 20416-032 (Erbokryo CA, ERBE, Germany) with 2.4 mm in diameter. The tip of the probe is cooled to -890C with nitrous oxide within seconds after footswitch activation.~Forceps biopsies will be obtained by flexible FB-55CD-1 Olympus forceps."
88896795|NCT01475149||aPL positive - group 1|aPL positive with APS, receiving HCQ
88896796|NCT01475149||aPL positive - group 2|aPL positive with APS and SLE, receiving HCQ
88896797|NCT01475149||aPL positive - group 3|aPL positive without APS but with SLE, receiving HCQ
88896798|NCT01475149||aPL positive - group 4|aPL positive without APS or SLE, receiving HCQ
88896799|NCT01475149||aPL negative - group 1|aPL negative with SLE, receiving HCQ
88896800|NCT01475149||aPL negative - group 2|aPL negative with SLE, not receiving HCQ
88896801|NCT01475188|Placebo Comparator|placebo|20 patients with intermittent allergic rhinitis sensitized to grass pollen allergens
88896802|NCT01475188|Active Comparator|Specific subcutaneous immunotherapy|21 symptomatic patients with intermittent allergic rhinitis sensitized to grass pollen allergens
88896803|NCT01475201|Experimental|Step Count Prescription Arm|The active trial arm intervention consists of usual care plus step count prescription delivered by the treating doctor, over a one-year period.
88896804|NCT01475201|Active Comparator|Usual care arm|The control trial arm will receive usual care alone, over a one-year period (i.e. no step count prescription but, in accordance with guidelines, including advice to engage in 30-60 minutes of activity on most days of the week). Consistent with clinical practice guidelines, our collaborating doctors have indicated that the usual care of the target population requires clinic visits at roughly three-month intervals to ensure vascular risk factor monitoring and management.
88896805|NCT01475227|Experimental|Arm A- early Solvazinc group|Zinc sulphate 125mg (1 Solvazinc tablet) once daily orally after dissolution in water, day 2 to day 15
88896806|NCT01475227|Experimental|Arm B- late Solvazinc group|Zinc sulphate 125mg (1 Solvazinc tablet) once daily orally after dissolution in water, day 15 to day 28
88896807|NCT01475240||Group 1: Controls|HIV-infected patients on stable > 6 months on TDF/FTC or ABC/3TC plus PI/r based ARV regimen with normal bilirubin
88896808|NCT01475240||Group 2: Cases|HIV-infected patients on stable >6 months on TDF/FTC or ABC/3TC plus PI/r based ARV regimen with HBR (>2.5 X upper limit)
88896809|NCT01475266|Experimental|EO9 (Apaziquone)|
88896810|NCT01475266|Placebo Comparator|Placebo|
88896811|NCT01475292|Experimental|RV568 treatment group low dose|
88896812|NCT01475292|Experimental|RV568 treatment group high dose|
88896813|NCT01475292|Placebo Comparator|Placebo treatment group|
88896814|NCT01475318|Experimental|misoprostol + mifepristone + letrozole|
88896815|NCT01475344|Active Comparator|Human Fibrinogen Concentrate|"Fibrinogen Concentrate will be administrated over 5 min/vial:~Body Weight: < 30 kg / 30-60 kg / 60 - 90 kg / > 90 kg~No. of vials: 1 vial (100 ml) / 2 vials (200 ml) / 3 vials (300 ml) / 4 vials (400 ml)~Fibrinogen: 1.5 g / 3 g / 4.5 g / 6 g~Immediately after admission to hospital, the patient's parameters including blood collection (see below) will be measured for the second time (T2), if applicable, after the end of administration of the study drug. Additional measurements will be made 3 hours (T3), 9 hours (T4), and 24 hours (T5), 48 hours (T6) and one week after admission (T7). 30 days after inclusion in the study, a final investigation is planned (T8)."
88896816|NCT01475344|Placebo Comparator|Placebo|"Placebo administrated over 5 min/vial:~Body Weight: < 30 kg / 30-60 kg / 60 - 90 kg / > 90 kg~No. of vials: 1 vial (100 ml) / 2 vials (200 ml) / 3 vials (300 ml) / 4 vials (400 ml)~Placebo: 1.5 g / 3 g / 4.5 g / 6 g~Immediately after admission to hospital, the patient's parameters including blood collection (see below) will be measured for the second time (T2), if applicable, after the end of administration of the study drug. Additional measurements will be made 3 hours (T3), 9 hours (T4), and 24 hours (T5), 48 hours (T6) and one week after admission (T7). 30 days after inclusion in the study, a final investigation is planned (T8)."
88896817|NCT01475357|Other|Arm 1: NPO pre-operative|1) Current care - NPO (nothing by mouth) postnatal intestinal function of neonates with complex CHD who receive enteral trophic breastmilk (10cc/kg/day) feeds (intervention) vs NPO (nothing by mouth) in the pre-operative period.
88896818|NCT01475357|Active Comparator|Arm 2: Fresh Breast Milk pre-operative|2) Intervention - Trophic mother's own fresh (non-frozen) breastmilk gavage feeds via nasogastric tube every 3 hours at 10 cc/kg/day
88896819|NCT01475383|Active Comparator|PF-03654746|Subjects are randomized to either active drug or placebo in Period 1; in Period 2 the sequence is reversed.
88896820|NCT01475383|Placebo Comparator|Placebo|Subjects are randomized to either active drug or placebo in Period 1; in Period 2 the sequence is reversed.
88896821|NCT01475396|Experimental|Aerobic Exercise|
88896822|NCT01475396|Experimental|Anaerobic Exercise|
88896823|NCT01475396|No Intervention|Unchanged condition|
88896824|NCT01475409|Experimental|QuantiFERON-TB Gold In-Tube (QFT-GIT)|Patients were randomized to undergo, on the same day, tuberculin skin test (TST) and QFT-GIT by means of a randomization list to generate the order by which the 2 tests had to be executed. QFT-GIT was repeated after 3 and 6 months since TNF antagonist onset.
88896825|NCT01475422|Experimental|Conversation Maps Diabetes Education|
88896826|NCT01475422|Active Comparator|Usual Care|
88896827|NCT01475435|Active Comparator|chronic periodontitis|Saliva and GCF samples will be evaluated before and after treatment from patients treated of chronic periodontitis.
88896828|NCT01475435|Placebo Comparator|periodontally healthy individuals|Saliva and GCF samples will be evaluated from periodontally healthy individuals at baseline.
89418860|NCT03683017|Experimental|I-OP2.1|Patients receive Invisalign orthodontic treatment, with 3.5 day Aligner changes, by the qualified Principal Investigator (PI). Patients receive OrthoPulse 2.1 device.
89418861|NCT03683017|Experimental|F-OP2.0|Patients receive fixed appliance orthodontic treatment by the qualified Principal Investigator (PI). Patients receive OrthoPulse 2.0 device.
89418862|NCT01340937|Experimental|V419 Lot A|V419 (Lot A) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 month of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age
89418863|NCT01340937|Experimental|V419 Lot B|V419 (Lot B) 0.5 mL IM at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 month of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age
89193937|NCT03153527|Active Comparator|Verum group (control/standard arm)|If patient is on > 7.5 mg prednisone-equivalent daily: administer 7.5 mg q.d. for 7 days, then 5 mg q.d. for 7 days, then 2.5 mg q.d. for 7 days, then 2.5 mg q.d. every second day, then stop. If patient on 7.5 mg q.d.: maintain for 7 days, then taper as above.
89418864|NCT01340937|Experimental|V419 Lot C|V419 (Lot C) 0.5 mL IM at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 month of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age
89418865|NCT01340937|Active Comparator|Control|Pentacel™ 0.5 mL IM at 2, 4, 6, and 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age; and Recombivax HB vaccine 0.5 mL IM at 2 and 6 months of age
89418866|NCT02303470|Experimental|Vigorous Exercise|High-intensity interval training for 15 minutes daily, 5 days per week for 8 weeks
89418867|NCT02303470|Experimental|Moderate Exercise|Brisk walking for 30 minutes daily, 5 days per week for 8 weeks
89418868|NCT03692299|Active Comparator|Saccaromyces boulardii oral tablet|Saccharomyces boulardii Oral Tablet 200 mg b.i.d. during 2 weeks, followed by a 2-week rest period and then again 200 mg b.i.d. during 2 consecutive months.
89418869|NCT03692299|Active Comparator|Metronidazole plus S. boulardii|Metronidazole 500 mg b.i.d during 1 week, followed by a 3-week rest period and then again 500 mg b.i.d during 2 consecutive months.
89418870|NCT03692299|Active Comparator|Metronidazole|Metronidazole 500 mg b.i.d during 1 week, plus Saccharomyces boulardii 200 mg b.i.d. during 1 week, follow for only Saccharomyces 200 mg b.i.d. for one another week, 2-week rest period and then this regimen is repeated for two consecutive months.
89418871|NCT03682939|Experimental|Single arm|Single arm, open-label, all participants will receive both Bexsero® (meningitis B vaccine) and Menveo® (meningitis ACWY vaccine) vaccines.
89418872|NCT02927184|Placebo Comparator|Placebo|Placebo capsule
89418873|NCT02927184|Experimental|VK2809 (5mg)|5mg VK2809 capsule
89418874|NCT02927184|Experimental|VK2809 (10mg)|10mg VK2809 capsule
89418875|NCT02927184|Experimental|VK2809 (10mg QOD)|10mg VK2809 capsule
88896829|NCT01475435|Active Comparator|chronic periodontitis with diabetes type 2|Saliva and GCF samples will be evaluated before and after treatment from patients with diabetes type 2 treated of chronic periodontitis
88896830|NCT01475435|Placebo Comparator|periodontally healthy individuals with diabetes type 2|Saliva and GCF samples will be evaluated from periodontally healthy individuals with diabetes type 2 at baseline
88896831|NCT01475448|Experimental|Sedentary older adults - running|Sedentary older adults (60 years old or more) recruited from local community
89193938|NCT03151278|Experimental|Zero-fluoroscopy ablation|Atrial arrhythmias will be mapped and ablated under the guidance of three-dimensional mapping system without fluoroscopy.
89193939|NCT03151278|Active Comparator|Conventional fluoroscopy ablation|Atrial arrhythmias will be mapped and ablated under fluoroscopic guidance plus three-dimensional mapping system.
89193940|NCT03148054||Study group|Patients undergoing elective left sided colon surgery
89199181|NCT05954078|Active Comparator|mFOLFOX6/XELOX adjuvant chemotherapy|Patients will receive mFOLFOX6 once every two weeks for 12 cycles or XELOX once every three weeks for 8 cycles as adjuvant chemotherapy
89418876|NCT02201992|Experimental|Arm A (crizotinib)|Patients receive crizotinib PO BID on days 1-21. Treatment repeats every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
89418877|NCT02201992|Active Comparator|Arm B (observation)|Patients undergo observation.
89418878|NCT03687775||DSG-Stabi|The group consists of patients with primary trapeziometacarpal osteoarthritis and an indication for trapeziectomy alone or in combination with the resection-suspension-interposition arthroplasty.
89418879|NCT03534492|Experimental|Durvalumab plus Olaparib|Durvalumab 1500 mg every 4 weeks for up to a maximum of 2 months (up to 2 doses/cycles) plus Olaparib 300 mg b.i.d. up to 56 days (2 cycles of 28 days each cycle).
89418880|NCT03687697|Experimental|Global vs. G-TL Media|Global medium will be compared with G-TL (Time-Lapse) medium.
88896832|NCT01475448|Active Comparator|Sedentary older adults - walking|Sedentary older adults (60 years old or more) recruited from local community
88896833|NCT01475526|Experimental|Intervention|El Valor de Nuestra Salud Store Intervention
89418881|NCT03687697|Experimental|Global vs. Cornell's C3 Media|Global medium will be compared with Cornell's C3 single step medium.
88896834|NCT01475526|No Intervention|Control|No intervention. Business as usual
89418882|NCT03687697|Experimental|Global vs. Cornell's sequential Media|Global medium will be compared with Cornell's C1/C2 sequential medium.
89418883|NCT03624283|Experimental|Group A|Group A will be provided with Exercise-based vestibular rehabilitation (VR) twice per day for a period of 4 weeks;
89418884|NCT03624283|Experimental|Group B|Group B will be prescribed with Betahistine 12mg, twice daily for 7 days;
89418885|NCT03624283|Experimental|Group C|Group C will receive an combination of Exercise-based VR plus Betahistine.
89006602|NCT00243126|Experimental|Family-Based Risk Reduction Intervention|The intervention will be delivered in five, two-hour, small group sessions, across five weeks (group will meet once per week). Each of the 5 modules consists of 3 sessions: a one-hour session for the daughters meeting together with each other, a one-hour session for the mothers meeting together with each other; and a one-hour session in which the daughters and mothers meet together. Therefore, each week, the daughters will meet as a group for one hour of each module, while the mothers meet as a group for one hour, and for one hour the mothers and daughters will all meet together.
89006603|NCT00243126|No Intervention|No Treatment Control Group Condition|A no treatment control group condition will be utilized for this preliminary feasibility study. Participants in this condition, both mothers and adolescents will be assessed at baseline, immediate post-intervention, at 3-month follow-up and at 6-month follow-up.
89006604|NCT04620967|Experimental|Iasp-Fiasp|First period: Insulin pump with Iasp Second period: Insulin pump with Fiasp
89006605|NCT04620967|Experimental|Fiasp-Iasp|First period: Insulin pump with Fiasp Second period: Insulin pump with Iasp
89006606|NCT04620655|Experimental|RD13-01 cell infusion|
89006607|NCT04620616|Experimental|Product Use Sequence 1|"Products use sequence:~Period 1 - RELX ENDS tobacco flavor Period 2 - RELX ENDS menthol flavor Period 3 - Usual Brand ENDS"
89006608|NCT04620616|Experimental|Product Use Sequence 2|"Products use sequence:~Period 1 - RELX ENDS menthol flavor Period 2 - Usual Brand ENDS Period 3 - RELX ENDS tobacco flavor"
89006609|NCT04620616|Experimental|Product Use Sequence 3|"Products use sequence:~Period 1 - Usual Brand ENDS Period 2 - RELX ENDS tobacco flavor Period 3 - RELX ENDS menthol flavor"
89006610|NCT04620616|Experimental|Product Use Sequence 4|"Products use sequence:~Period 1 - Usual Brand ENDS Period 2 - RELX ENDS menthol flavor Period 3 - RELX ENDS tobacco flavor"
89006611|NCT04620616|Experimental|Product Use Sequence 5|"Products use sequence:~Period 1 - RELX ENDS tobacco flavor Period 2 - Usual Brand ENDS Period 3 - RELX ENDS menthol flavor"
89006612|NCT04620616|Experimental|Product Use Sequence 6|"Products use sequence:~Period 1 - RELX ENDS menthol flavor Period 2 - RELX ENDS tobacco flavor Period 3 - Usual Brand ENDS"
89006613|NCT04620694||Radial artery cannulation|Patients whom radial artery was cannulated at the beginning of the surgery.
89006614|NCT04620694||Aortic cannulation (brachial or femoral artery)|"Patients whom femoral or brachial artery was cannulated at the beginning of the surgery.~Active comparator"
89006615|NCT04620499|Experimental|Experimental|EEG-guided drug prescription
89006616|NCT04620499|No Intervention|Control|Will receive EEG, but drugs will be prescribed as usual
89006617|NCT04620772|Experimental|Cyclophosphamide arm|Participants randomized to the cyclophosphamide arm will be administered 750 mg/m2 body weight (rounded off to the nearest 50 mg above the calculated value) of cyclophosphamide diluted in normal saline every month (Total 6 months) along with equal dose of mesna 50% administered prior to infusion and 50% after the infusion of cyclophosphamide
89006618|NCT04620772|Other|Placebo arm|Participants randomized to the placebo group will be given similar quantity of normal saline and mesna as described above
89006619|NCT04620421|Experimental|Training group (Rhythm-based multitask training)|Randomized to participate in the rhythm-based multitask training intervention
89006620|NCT04620421|No Intervention|Control group (Continuation of regular activity schedule)|Randomized to the control group who is encouraged to continue their regular everyday routines, which may include self-administrated training exercises.
89006621|NCT04620577||Antibiotic group|Infusion of ceftriaxone sodium needle (2g, solvent 100ml normal saline) within 1h before and 12h after PTCD.
89006622|NCT04620577||No-antibiotic group|Infusion of Normal saline within 1h before and 12h after PTCD.
89006623|NCT04620850|Experimental|Acupressure|Acupressure after cesarean section 3 hr and then next 3 hr (duration 10 min per time) Acupressure at below knee the point ai locate about4 finger spcae below patella on the lateral side of tibia bone
89006624|NCT04620850|No Intervention|No acupressure|Standard post-operative care
89006625|NCT00562744|Experimental|SIM|Participants complete training and assessment of performance in PALS scenarios using high-fidelity simulator
89006626|NCT00562744|No Intervention|MAN|Participants complete training and assessment of performance in PALS scenarios using mannequin
89006627|NCT04620460|Active Comparator|LIFUS-left DLPFC|20 patients will be treated with active LIFUS for 3 weeks on the left DLPFC.
88896835|NCT01475539|Experimental|Group A (Sequential 1): IPV-OPV-OPV|Participants will receive 1 dose of Sanofi Pasteur's injectable Inactivated Poliovirus Vaccine (IPV) followed by 2 doses of a commercially available Oral Poliovirus Vaccine (OPV)
89418886|NCT03687619|Experimental|CO-OP|Cognitive Orientation to daily Occupational Performance (CO-OP) is a top-down approach. This programme will be conducted as a small group. Each group will averagely have 5 children. The primary investigator will conduct the programmes. It will be one hour session, twice a week, 12 weeks.
89418887|NCT03687619|Experimental|Conductive Education|Conductive Education is a down-top approach. This programme will be conducted as a small group. Each group will averagely have 5 children. The primary investigator will conduct the programmes. It will be one hour session, twice a week, 12 weeks.
89418888|NCT02195778||Young, 18 to 30|
89418889|NCT02195778||Middle, 31 to 50|
88896836|NCT01475539|Experimental|Group B (Sequential 2): IPV-IPV-OPV|Participants will receive 2 doses of Sanofi Pasteur's injectable Inactivated Poliovirus Vaccine (IPV) followed by 1 dose of a commercially available Oral Poliovirus Vaccine (OPV)
88896837|NCT01475539|Experimental|Group C (Reference): OPV-OPV-OPV|Participants will receive 3 doses of a commercially available Oral Poliovirus Vaccine (OPV)
88896838|NCT01475552|Experimental|abciximab|
88896839|NCT01475552|Active Comparator|control|
88896840|NCT01475565||African-American women|Observational study--no intervention
88896841|NCT01475565||Caucasian women|Observational study--no intervention
89193941|NCT03119012|Active Comparator|P2Y12 receptor inhibitor monotherapy arm|In patients who do not occur a MACCE until 12-month after BRS implantation, P2Y12 receptor inhibitor monotherapy arm will be received clopidogrel 75mg qd or ticagrelor 60mg bid during follow-up period (24 months after randomization).
89418890|NCT02195778||Older, 51 to 70|
89418891|NCT02197728|Active Comparator|Hohl uterine manipulator ®|Total laparoscopic hysterectomy is performed using the Hohl uterine manipulator ®
89418892|NCT02197728|Active Comparator|Colpo-Probe™ Vaginal Fornix Delineator|Total laparoscopic hysterectomy is performed using the Colpo-Probe™ Vaginal Fornix Delineator
89418893|NCT03687385|Active Comparator|ASA I / LFNO|Low-flow nasal oxygenation (LFNO) O2 flow 5L/min, FiO2 40%
89418894|NCT03687385|Active Comparator|ASA II / LFNO|Low-flow nasal oxygenation (LFNO) O2 flow 5L/min, FiO2 40%
89418895|NCT03687385|Active Comparator|ASA III / LFNO|Low-flow nasal oxygenation (LFNO) O2 flow 5L/min, FiO2 40%
89418896|NCT03687385|Experimental|ASA I / HFNO|High-flow nasal oxygenation (HFNO) O2 flow 40L/min, FiO2 40%
89418897|NCT03687385|Experimental|ASA II/ HFNO|High-flow nasal oxygenation (HFNO) O2 flow 40L/min, FiO2 40%
88896842|NCT01475578|Experimental|STA-1|"STA-1 capsule (Cistanche tubulosa), 2 capsules/time, 3 times/day, orally~Dummy Ergoloid Mesylates tablet (Placebo), 2 tablets/time, 3 times/day, orally"
88896843|NCT01475578|Active Comparator|Ergoloid Mesylates|"Ergoloid Mesylates tablet, 2 tablets/time, 3 times/day, orally before meal~Dummy STA-1 capsule (Placebo), 2 capsules/time, 3 times/day, orally"
88896844|NCT01475591|No Intervention|Multimodal rehabilitation|The arm intervention is just multimodal rehabilitation.
88896845|NCT01475604|Active Comparator|Targeted pulsed electromagnetic field|
89418898|NCT03687385|Experimental|ASA III/ HFNO|High-flow nasal oxygenation (HFNO) O2 flow 40L/min, FiO2 40%
89418899|NCT02031198|Experimental|AADvac1|"Patients who have received 6 doses in the previous trial will be administered 1-2 booster doses of AADvac1 (2 if their antibody titers decline below those achieved in the previous trial).~Patients who have received 3 doses in the previous trial will be administered another 3 doses, then vaccinated with booster doses as above."
89418900|NCT03682861|Placebo Comparator|Placebo|Placebo flavored drink similar to treatments but with no energy will be ingested post glycogen lowering exercise, followed by a 20 km time trial intervention
89418901|NCT03682861|Experimental|Carbohydrate drinks|Sweet corn derived starch mixed in water at three different concentrations (6%, 12% and 18%) will be ingested post glycogen lowering exercise, followed by a 20 km time trial intervention
89418902|NCT03682783||Fundus Image|Glaucomatous and Non-glaucomatous fundus images that have been taken from the last 5 years in Shanghai General hospital.
88896846|NCT01475604|Sham Comparator|Sham|
88896847|NCT01475617|Experimental|Novel Multivitamin/Mineral Supplement|These subjects will be given a novel multivitamin/mineral supplement post RYGB bariatric surgery for 6 months duration.
88896848|NCT01475617|Active Comparator|Standard of care supplement|These subjects will be given the standard recommended regimen at Johns Hopkins Bayview Medical Center post RYGB bariatric surgery for 6 months duration.
88896849|NCT01475630|Other|control|information, avoiding parafunctions
88896850|NCT01475630|Experimental|physical therapy|mobilisation, exercises ,..
88896851|NCT01475656||Levetiracetam as first line|Babies who receive levetiracetam as a first line drug for seizures
88896852|NCT01475656||Phenobarbital as first line|Babies who receive phenobarbital as a first line drug for seizures and levetiracetam as a second line drug
88896853|NCT01475669|Experimental|Fibrinogen Concentrate (Human)|
88896854|NCT01475669|Placebo Comparator|Placebo|
88896855|NCT01475682||1|"167 subjects recruited from our previous OSA and metabolic syndrome (OSAMS) cohort from October 2002 to June 2007 will be invited to be reassessed at this time point."
88896856|NCT01475695|Experimental|Single cohort|14C GSK2251052
88896857|NCT01475708||no symptoms|patients with erythema migrans and no additional newly onset symptoms treated with doxycycline
88896858|NCT01475708||mild symptoms|patients with erythema migrans and mild unspecific newly onset symptoms treated with doxycycline
88896859|NCT01475708||severe symptoms-lumbar puncture|"patients with erythema migrans and newly onset intense neurologic symptoms with lumbar puncture performed, treated with doxycycline"
88896860|NCT01475747||Observational - SPRINT trial subjects|Subjects in the Systolic Pressure Intervention Trial (SPRINT) observed to examine factors that affect atherosclerosis in chronic kidney disease
88896861|NCT01475760|Active Comparator|K2CG chewing gum (20 mg chitosan)|
88896862|NCT01475760|Active Comparator|K2CG chewing gum (60 mg chitosan)|
88896863|NCT01475760|No Intervention|Standard of Care|
88896864|NCT01475773||Adults (starting from age 17)|adults seeking orthodontic treatment at the university of Leuven
88896865|NCT01475799|Experimental|Percutaneous Aortic Valve 18F System|Evaluation of the Direct Flow Medical Percutaneous Aortic Valve 18F System for the Treatment of Patients with Severe Aortic Stenosis.
88896866|NCT01475812||COPD hyperinflation|
88896867|NCT01475864||Incomplete biliary stone extraction.|
89418903|NCT02196948|Experimental|Electrolysis Percutaneous Therapeutic (EPTE)|Electrolysis Percutaneous Therapeutic (EPTE) consists of the application of a galvanic electrical current with an acupuncture needle in the soft tissue, in this case the supraspinatus tendon, to initiate a local inflammatory process allowing phagocytosis and repair of the affected tissue. The technique is pain-free since the electrical intensity is adapted to each patient. In addition, patients will be asked to perform an eccentric loading exercise program for the shoulder musculature, particularly the supraspinatus and infraspinatus muscles, to be performed on an individual basis twice every day. The therapeutic protocol will be applied for 4 weeks.
88896868|NCT01475877||Nepafenac|
88896869|NCT01475890|Active Comparator|7000IU/day|29 subjects will be randomized to receive 7000IU/day of vitamin D3.
88896870|NCT01475890|Placebo Comparator|Placebo|29 subjects will be randomized to receive placebo.
88896871|NCT01475903||sleeve gastrectomy|
88896872|NCT01475929|Active Comparator|Probiotic low|Lower dose of probiotic supplement
88896873|NCT01475929|Placebo Comparator|Placebo|
88896874|NCT01475929|Active Comparator|Probiotic high|Higher dose of probiotic supplement
88896875|NCT01475942|Active Comparator|Probiotic|Lactobacillus
88896876|NCT01475942|Placebo Comparator|Placebo|Sucrose
88896877|NCT01475968|Active Comparator|Ultrafine Air Pollution Particulate Matter|<2.5 microns concentrated from outside ambient air
88896878|NCT01475968|Sham Comparator|Filtered Air|Filtered Air
88896879|NCT01475981|Experimental|Dose 1 JTK-853 (fasted condition)|
88896880|NCT01475981|Experimental|Dose 2 JTK-853 (fasted condition)|
88896881|NCT01475981|Experimental|Dose 3 JTK-853 (fasted condition)|
88896882|NCT01475981|Experimental|Dose 2 JTK-853 (fed condition)|
88896883|NCT01475981|Experimental|Dose 3 JTK-853 (fed condition)|
88896884|NCT01475981|Experimental|Dose 4 JTK-853 (fed condition)|
88896885|NCT01475981|Experimental|Dose 5 JTK-853 (fed condition)|
88896886|NCT01475981|Experimental|Dose 6 JTK-853 (fed condition)|
88896887|NCT01475981|Experimental|Dose 7 JTK-853 (fed condition)|
88896888|NCT01475981|Experimental|Dose 5 JTK-853 (high-fat fed condition)|
88896889|NCT01475981|Placebo Comparator|Placebo|
88896890|NCT01475994|Experimental|Challenge with grass pollen|
88896891|NCT01475994|Placebo Comparator|Challenge with clean air|
88896892|NCT01476007|Experimental|oral Cobalamin (vitamin B12)|oral Cobalamin (vitamin B12)
88896893|NCT01476007|Experimental|intramuscular Cobalamin (vitamin B12)|intramuscular Cobalamin (vitamin B12)
88896894|NCT01476020||no clopidogrel 6 months after DES|Patients with a single treatment antiplatelet therapy (aspirin) 6 months after drug-eluting stent implantation (Xience V Abbott company), including a 12-, 24- and 36-month follow-up analysis.
88896895|NCT01476020||2 antiplatelet therapy 2 years after DES|patients with dual antiplatelet therapy with clopidogrel and aspirin 24 months after drug-eluting stent implantation, including a 12-, 24- and 36-month follow-up analysis.
88896896|NCT01476033|Active Comparator|fruit, berry and vegetable concentrate|20 ladies receive an encapsulated, powdered fruit, berry and vegetable concentrate for 8 weeks
88896897|NCT01476033|Placebo Comparator|20 women with placebo|placebo for 8 weeks
88896898|NCT01476046|Experimental|GSK1995057|Single intravenous dose
88896899|NCT01476046|Placebo Comparator|Placebo|Single intravenous dose
89006628|NCT04620460|Sham Comparator|LIFUS-SHAM|20 patients will be treated with sham LIFUS for 3 weeks on the left DLPFC.
89418904|NCT02196948|Experimental|Eccentric exercise|Patients will be asked to perform an eccentric loading exercise program for the shoulder musculature, particularly the supraspinatus and infraspinatus muscles, to be performed on an individual basis twice every day. The therapeutic protocol will be applied for 4 weeks.
88896900|NCT01476059|Other|telephone follow-up|Asthmatic children being treated, who will be given medical guidance and therapeutic guidance through telephone calls at every fifteen days to the parents or guardians, performed by trained professionals.
88896901|NCT01476059|Other|No telephone follow-up|Asthmatic children being treated, who will be given medical guidance without telephone follow-up calls to parents or guardians.
88896902|NCT01476072|No Intervention|no treatment|MRI scans only
88896903|NCT01476085|No Intervention|no treatment|no treatment
88896904|NCT01476098|Placebo Comparator|Arm 1|incremental doses capsaicin
89418905|NCT03692143||teriparatide group|The group of postmenopausal women who diagnosis with osteoporotic fractures treated with teriparatide
88896905|NCT01476098|Active Comparator|Arm 2|incremenrtal doses casaicin
88896906|NCT01476111||Group 1|Patients with primary invasive breast cancer
88896907|NCT01476124|Experimental|Regimen A|Morphine placebo + GEn 600 mg
89193942|NCT03119012|Active Comparator|Extended DAPT arm|In patients who do not occur a MACCE until 12-month after BRS implantation, Extended DAPT arm will be received aspirin 100mg qd plus P2Y12 receptor inhibitor (clopidogrel 75mg qd or ticagrelor 60mg bid) during follow-up period (24 months after randomization).
89193943|NCT03117036||Lymphoma|Patients are diagnosed with aggressive lymphoma including Hodgkin and non-Hodgkin lymphoma. All patients should receive systemic chemotherapy. Newly diagnosed or relapsed/refractory patients can be enrolled.
89193944|NCT03117010||Hemophagocytosis|"Subjects should fulfill the following criteria~Subjects should have at least one of the following problems~Presence of hemophagocytosis in tissue or bone marrow~Presence of at least 3 conditions among 8 conditions of HLH diagnostic criteria~Age > 18 years~Written informed consents~Subjects receive steroids and etoposide"
89193945|NCT03116763|Experimental|iPeer2Peer Mentorship|In addition to standard care, youth in the experimental group will receive the iPeer2Peer program, a peer mentorship program that will provide modeling and reinforcement of self-management by pre-screened and trained peer mentors (young adults with JIA aged 18-22 years who have learned to function successfully with their disease). Mentors will encourage participants to develop and engage in self-management skills and provide social support.
89193946|NCT03116763|Active Comparator|Control Group|The control group will receive standard care but without the iPeer2Peer program.
89199182|NCT05954052|Experimental|Glutathione Oral Supplementation|Glutathione will be the only study medication dispensed to subjects for this study. Subjects will be told to take the first dose of study medication after breakfast each day and the second dose in the evening after dinner. The proposed dose range for Glutathione in this study will be 1000mg-3000mg/day based on the subject's weight.
89199183|NCT05954039|Experimental|Wheat Polar Lipid Complex|Dietary supplement - Wheat Polar Lipid Complex
89199184|NCT05954039|Placebo Comparator|Placebo|Dietary supplement - Placebo
88896908|NCT01476124|Experimental|Regimen B|Morphine Extended release (60 mg) + GEn placebo
88896909|NCT01476124|Experimental|Regimen C|Morphine Extended release (60mg) + GEn 600 mg
89418906|NCT03692143||PVP group plus alendronate|The group of postmenopausal women who diagnosis with osteoporotic fractures treated with vertebroplasty. Then alendronate was prescribed.
89418907|NCT03692143||teriparatide and PVP group|The group of postmenopausal women who diagnosis with osteoporotic fractures treated with teriparatide after vertebroplasty
89418908|NCT02201004|Experimental|tofogliflozin|Tofogliflozin administered once daily for 52 weeks. Insulin administered as base treatment.
89418909|NCT02201004|Placebo Comparator|placebo|Placebo administered once daily for 16 weeks. After 16-weeks, Tofogliflozin administered once daily for 36 weeks. Insulin administered as base treatment.
88896910|NCT01476137|Experimental|Part 2A and 2B: GSK1120212 + GSK2110183 Dose Combination 1|One of two dose combination levels (GSK1120212+GSK2110183) based on data from Part 1 of the trial
88896911|NCT01476137|Experimental|Part 2A and 2B: GSK1120212 + GSK2110183 Dose Combination 2|One of two dose combination levels (GSK1120212+GSK2110183) based on data from Part 1 of the trial
88896912|NCT01476137|Experimental|Part 1: Cohort 1|GSK1120212 1.5mg + GSK2110183 50mg
88896913|NCT01476137|Experimental|Part 1: Cohort 2|GSK1120212 1.5mg + GSK2110183 100mg
88896914|NCT01476137|Experimental|Part 1: Cohort 3a|GSK1120212 2mg + GSK2110183 100mg
88896915|NCT01476137|Experimental|Part 1: Cohort 3b|GSK1120212 1.5mg + GSK2110183 125mg
88896916|NCT01476137|Experimental|Part 1: Cohort 4a|GSK1120212 2mg + GSK2110183 125mg
88896917|NCT01476137|Experimental|Part 2A: GSK1120212 2mg|Maximum tolerated dose of GSK1120212 as determined in prior single-agent trials
88896918|NCT01476137|Experimental|Part 2A; GSK2110183 125mg|GSK2110183 125mg
88896919|NCT01476137|Experimental|Part 2A: GSK2110183 MTD|Maximum tolerated dose (MTD) as determined in ongoing single agent trial PKB115340
88896920|NCT01476150||Dongcheng|
88896921|NCT01476150||Haidian|
88896922|NCT01476150||Xicheng|
88896923|NCT01476150||Chaoyang|
88896924|NCT01476150||Chongwen|
88896925|NCT01476150||Tongzhou|
88896926|NCT01476150||Fengtai|
88896927|NCT01476150||Xuanwu|
88896928|NCT01476176|Experimental|Experimental paracetamol formulation|experimental formulation
89418910|NCT02197884|Experimental|Itraconazole + JNJ-54861911 (Part 1)|Single dose of JNJ-54861911, 25 milligram (mg) tablet orally on Day 1 and Day 9 along with itraconazole 200 mg (2*100 mg capsule) orally once daily from Day 5 to Day 12.
89418911|NCT02197884|Experimental|Clarithromycin + JNJ-54861911 (Part 2)|Single dose of JNJ-54861911, 25 mg tablet orally on Day 1 and Day 9 along with clarithromycin 500 mg immediate release tablet orally twice daily from Day 5 to Day 12.
89418912|NCT02198586||No treatment|The population of this study is 45 to 75 years old at the time of inclusion in the parent study (ClinicalTrials.gov ID: NCT01835717).
89418913|NCT02201082|Experimental|Nebulization and airway clearance technique|nebulization combined to airway clearance
89418914|NCT02201082|Active Comparator|Nebulization|nebulization
89418915|NCT02201160|Active Comparator|omega 3|The subjects will take 4 capsules/day during 6 months. Each capsule of the active n-3 PUFA supplement contained 500 mg of fish oil (each capsule provides 300 mg of n-3 PUFA (EPA+DHA) with 3.75 U vitamin E to prevent peroxidation).
89418916|NCT02201160|Placebo Comparator|Sun Flower|The subjects will take 4 capsules/day during 6 months. The placebo capsule contained 500 mg of sunflower oil with 3.75 U vitamin E.
89418917|NCT03687229||Patient|"Chronic HCV patients before treatment & 3 months after starting of treatment. not known to be:~Cirrhosis~Diabetes Mellitus.~Hemochromatosis~HBV~HIV.~Hepatocellular carcinoma (HCC)~Chemotherapy~Organ transplantation"
89418918|NCT03687229||Control|Apparently healthy individuals
89418919|NCT05085054|Experimental|targeted therapy+salvage surgery|"Participants treated with targeted therapy without progression and radiological confirmation of tumor downstaging (≤stage IIIA) by PET-CT followed by salvage surgery were enrolled into the group of targeted therapy plus salvage surgery.~The molecular targeted agents used in our study included osimertinib (80 mg, once a day) . Salvage surgery was defined as surgical intervention based on standard operation (lobectomy plus lymphadenectomy) of NSCLC for advanced patients who initially had no surgical indications, but achieved significant downstaging (≤stage IIIA) without progression after targeted therapy.~Targeted therapy was continued after salvage surgery until progression."
89418920|NCT03687151||patients with a diagnosis of invasive or in situ cancer|patients with a diagnosis of invasive or in situ cancer living in the French Region Sud-Provence-Alpes-Côte d'Azur since 2005
88896929|NCT01476176|Active Comparator|paracetamol marketed formulation|Paracetamol marketed formulation
88896930|NCT01476189|Experimental|Experimental paracetamol formulation|test formulation
88896931|NCT01476189|Active Comparator|Marketed paracetamol|Marketed paracetamol
89199185|NCT05954013|Experimental|PD_Pal intervention|Participants with Parkinson's disease receive usual care from their established neurology and/or home care team + the PD_Pal intervention.
89418921|NCT02257320|Other|Feasibility|Assessing EMG activity with Bruxoff(TM) device
89418922|NCT03969121|Active Comparator|Placebo + Endocrine therapy|Endocrine therapy for 16 weeks plus placebo
88896932|NCT01476189|Active Comparator|Higher dose marketed paracetamol|higher dose marketed paracetamol
88896933|NCT01476215|Experimental|Fast dissolution suspension|
89418923|NCT03969121|Active Comparator|Palbociclib + Endocrine therapy|Endocrine therapy for 16 weeks plus Palbociclib
89418924|NCT02201238|Experimental|Diclofenac sodium/menthol gel (in tube)|1% diclofenac sodium plus 3% menthol gel (in 30g aluminium tube). Dose given- 4g applied topically to a 400cm2 (20cm x 20cm) area of the skin, four times daily for three consecutive days with 5h between adjacent doses on the same day
89418925|NCT02201238|Experimental|Diclofenac sodium/menthol gel (in roll-on device)|1% diclofenac sodium plus 3% menthol gel (in roll-on applicator device supplied in 30g plastic bottles). Dose given- 4g applied topically to a 400cm2 (20cm x 20cm) area of the skin, four times daily for three consecutive days with 5h between adjacent doses on the same day
88896934|NCT01476215|Experimental|Medium dissolution suspension|
88896935|NCT01476215|Experimental|Slow dissolution suspension|
88896936|NCT01476215|Active Comparator|Marketed suspension|
88896937|NCT01476228|Experimental|study group|EEG recording
88896938|NCT01476241||EarNoseThroatGroup|a cohort of patients that had undergone PEG tube placement from October 2008 until October 2010 at the Department of Otorhinolaryngology - Head and Neck Surgery
88896939|NCT01476241||SurgeryGroup|a historic cohort group of patients with the PEG tube placed in the Department of Surgery from September 2005 until September 2009
88896940|NCT01476254||Cholecystectomy|Women scheduled for laparoscopic cholecystectomy
88896941|NCT01476254||Hysterectomy|Women scheduled for laparoscopic hysterectomy
88896942|NCT01476280|Sham Comparator|Palonosetron|
88896943|NCT01476280|Sham Comparator|Ramosetron|
89418926|NCT02201238|Active Comparator|Diclofenac sodium tablets|50mg diclofenac sodium tablets administered orally, three times daily for three consecutive days with 6h between adjacent doses on the same day
89418927|NCT02201238|Active Comparator|Voltaren gel|Voltaren gel supplied in 100g aluminium tube. Dose given- 4g applied topically to a 400cm2 (20cm x 20cm) area of the skin, four times daily for three consecutive days with 5h between adjacent doses on the same day
89418928|NCT03682627|Active Comparator|preventive fenestration|Fenestration is performed at the time of kidney transplantation
89418929|NCT03682627|Experimental|preventive fenestration and clipping|Fenestration and clipping of the edges are performed at the time of kidney transplantation
88896944|NCT01476306|Placebo Comparator|In-patient care|
88896945|NCT01476306|Experimental|Telemedicine care|
88896946|NCT01476319|No Intervention|control|
88896947|NCT01476319|Experimental|video|
88896948|NCT01476332|Experimental|Group 1: Cis-UCA 0.5% eye drops|
88896949|NCT01476332|Experimental|Group 2: Cis-UCA 2.5% eye drops|
88896950|NCT01476332|Placebo Comparator|Group 3: Placebo for cis-UCA, eye drops|
89006629|NCT04620031|Experimental|HSK3486|HSK3486 for Sedation
88896951|NCT01476358|Active Comparator|Vitamin A|Capsule containing oil vehicle with Vitamin A (retinyl palmitate). Capsules are prepared by the manufacturer (Strides Arcolab Limited, India) and assigned blinded codes by World Health Organization officials.
88896952|NCT01476358|Placebo Comparator|Placebo|Capsule containing oil vehicle withOUT Vitamin A (retinyl palmitate). Capsules are prepared by the manufacturer (Strides Arcolab Limited, India) and assigned blinded codes by World Health Organization officials.
88896953|NCT01476371|Experimental|Mindfulness-based group treatment|8 group mindfulness sessions (1 per week), complemented by home mindfulness exercises
88896954|NCT01476371|No Intervention|Treatment as usual|Treatment as usual (including individual CBT and medication)
88896955|NCT01476384|Experimental|Glucose drink|75 gram glucose, dissolved in 250 ml water
88896956|NCT01476384|Placebo Comparator|Placebo|250 ml water
88896957|NCT01476410|Experimental|Treatment (antibody-drug conjugate and combination chemo)|"LEAD-IN: Patients receive brentuximab vedotin IV over 30 minutes on day 1. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.~AVD CHEMOTHERAPY: Patients then receive doxorubicin hydrochloride IV, vinblastine IV, and dacarbazine IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Patients achieving CR receive brentuximab vedotin IV over 30 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity."
88896958|NCT01476423||A|
88896959|NCT01476436|Experimental|LCHF diet|Advice of a diet low in carbohydrate
88896960|NCT01476436|Active Comparator|Usual diet|Subjects shall continue to eat their usual daily diet with no low carbohydrate intervention
88896961|NCT01476462||ALL diagnosed 1980-2007|Cases of childhood acute lymphoblastic leukemia (ALL) diagnosed between 1980 and 2007 and included in the clinical trials of the participating ALL study groups
89418930|NCT02257398|Experimental|Sequence ABDC|Subjects will be administered treatments in Sequence ABDC where, A= GSK2140944 1000 mg IV infusion over 120 minutes and single dose of moxifloxacin placebo administered orally in morning; B= GSK2140944 1800 mg IV infusion over 120 minutes and single dose of moxifloxacin placebo administered orally in morning; C= GSK2140944 placebo IV infusion over 120 minutes and single dose of moxifloxacin placebo administered orally in morning and D= Moxifloxacin 400 mg administered orally in morning and GSK2140944 placebo administered as IV infusion over 120 minutes
88896962|NCT01476488|No Intervention|Advagraf|single group, conversion of prograf to advagraf
88896963|NCT01476514|Experimental|1|"In the setting of comparing patients with a genetic mutation and healthy volunteers blinding of the PI would demand a substantial increase in co-workers (i.e. recruitment, selection of age-and sex matched volunteers), reason why no blinding was chosen.~Affected patients will be compared to age and sex matched volunteers, recruited after completion of testing 23 hyperekplexia patients."
88896964|NCT01476527|Experimental|Deep Brain Stimulation|Deep Brain Stimulation (DBS) is a neurosurgical procedure involving the implantation of deep brain electrodes, connected via a subcutaneous extension wire, to an implantable pulse generator (IPG, or 'battery') that is implanted below the collarbone
88896965|NCT01476540|Experimental|Deep Brain Stimulation|Deep Brain Stimulation
88896966|NCT01476553|Experimental|Intervention arm|Extensive Intraperitoneal Lavage (EIPL)
88896967|NCT01476579|Other|Non-invasive CT coronary angiography|This study is evaluating diagnostic accuracy of non-invasive CT coronary angiography with invasive coronary angiography.
88896968|NCT01476592|Experimental|Resveratrol|5 gm/day of resveratrol orally, in two divided doses of 2.5 gm each without a break in therapy for a total of three cycles.
88896969|NCT01476605|Active Comparator|PrT-DMS|1.0 mL 5% morrhuate sodium + 1.5 mL 50% dextrose, 1 mL 2% lidocaine and 3.5 mL normal saline.
88896970|NCT01476605|Experimental|PrT-D|PrT-D solution is 4 mL 50% dextrose, 3 mL normal saline, and 2 mL 2% lidocaine
88896971|NCT01476605|No Intervention|Waitlist|
88896972|NCT01476605|Active Comparator|Platelet rich plasma|
88896973|NCT01476618||Denver VA OIF/OEF and mental health providers|Denver VA OIF/OEF and mental health providers
88896974|NCT01476631|Experimental|Arm A: 30 minutes walking|First Step program with 30 minutes of walking and 10,000 steps per day for 3 months.
88896975|NCT01476631|Experimental|Arm B: 60 minutes walking|First Step program with 60 minutes of walking and 13,000 steps per day for 3 months.
88896976|NCT01476657|Experimental|IPI-145|IPI-145 is administered orally as a capsule formulation. The IPI-145 drug product is supplied as 1 mg, 5 mg, 25 mg, and 100 mg formulated capsules. IPI-145 will be administered orally daily during each 28-day cycle. Patients will be evaluated for DLTs in the dose escalation portion of the study during Cycle 1 (28 days), after which treatment may continue for additional cycles.
88896977|NCT01476670||Posterior fossa tumor|Patients with posterior fossa tumor scheduled for elective surgery will be enrolled in the study.
88896978|NCT01476683|Experimental|FCT|A single 2 x100 mg dose of an experimental Racecadotril Film-coated tablet (FCT) administered orally with 240 ml of water, with a 7- day washout between visits.
89006630|NCT04620031|Active Comparator|Propofol|Propofol for Sedation
89418931|NCT02257398|Experimental|Sequence BCAD|Subjects will be administered treatments in Sequence BCAD where, A= GSK2140944 1000 mg IV infusion over 120 minutes and single dose of moxifloxacin placebo administered orally in morning; B= GSK2140944 1800 mg IV infusion over 120 minutes and single dose of moxifloxacin placebo administered orally in morning; C= GSK2140944 placebo IV infusion over 120 minutes and single dose of moxifloxacin placebo administered orally in morning and D= Moxifloxacin 400 mg administered orally in morning and GSK2140944 placebo administered as IV infusion over 120 minutes
89418932|NCT02257398|Experimental|Sequence CDBA|Subjects will be administered treatments in Sequence CDBA where, A= GSK2140944 1000 mg IV infusion over 120 minutes and single dose of moxifloxacin placebo administered orally in morning; B= GSK2140944 1800 mg IV infusion over 120 minutes and single dose of moxifloxacin placebo administered orally in morning; C= GSK2140944 placebo IV infusion over 120 minutes and single dose of moxifloxacin placebo administered orally in morning and D= Moxifloxacin 400 mg administered orally in morning and GSK2140944 placebo administered as IV infusion over 120 minutes
89418933|NCT02257398|Experimental|Sequence DACB|Subjects will be administered treatments in Sequence DACB where, A= GSK2140944 1000 mg IV infusion over 120 minutes and single dose of moxifloxacin placebo administered orally in morning; B= GSK2140944 1800 mg IV infusion over 120 minutes and single dose of moxifloxacin placebo administered orally in morning; C= GSK2140944 placebo IV infusion over 120 minutes and single dose of moxifloxacin placebo administered orally in morning and D= Moxifloxacin 400 mg administered orally in morning and GSK2140944 placebo administered as IV infusion over 120 minutes
89199186|NCT05954013|No Intervention|Control group|Participants with Parkinson's disease receive usual care from their established neurology and/or home care team.
89418934|NCT03533868|No Intervention|Standard of Care (SOC)|Patients in this arm will have their viral load monitored using the standard of care method, using the Roche Cobas TaqMan HIV-1® v2 (Roche) assay.
89418935|NCT03533868|Experimental|Point-of-care (POC)|Patients in this arm will have their follow-up viral loads (after baseline) monitored using a Point-of-care viral load monitoring test, the Cepheid Xpert HIV-1 Viral Load assay.
89418936|NCT02198742|Active Comparator|Miller blade|Subjects must have >500 intubations in order to participate in this study. There is no placebo group, and each subject wil be his or her own control.
89418937|NCT02198742|Active Comparator|Truview PCD|Subjects were given a quick guide of the Truview PCD supplied by the manufacturer with step by step instructions for use. They were also given time to practice with the device on a normal model until they felt comfortable. There is no placebo group, and each subject wil be his or her own control.
88896979|NCT01476683|Experimental|RPB|A single 2 x100 mg dose of an experimental Racecadotril Powder Blend administered orally with 240 ml of water, with a 7- day washout between visits.
88896980|NCT01476683|Active Comparator|TFT|A single 2 x 100 mg dose of a marketed Tiorfast® capsule administered orally with 240 ml of water, with a 7-day washout between visits.
88896981|NCT01476683|Active Comparator|TFR|A single 175 mg dose of a marketed Tiorfanor® 175 mg FCT administered orally with 240 ml of water, with a 7-day washout between visits.
88896982|NCT01476735|Active Comparator|split-dose polyethylene glycol solution|first dose (1,5 l) of polyethylene glycol solution taken at 6-7.00 in the evening before colonoscopy, second dose (1,5 l) taken at 5.30-6.00 in the morning of a day of colonoscopy; additional bisacodyl taken at 12.00 at the day before colonoscopy
88896983|NCT01476735|Active Comparator|Individual preparation for colonoscopy|
88896984|NCT01476761|Active Comparator|MicroCutter Stapling Device|Patients undergoing surgical treatment with the MicroCutter Stapling Device
88896985|NCT01476774|Active Comparator|Buprenorphine Transdermal System|
88896986|NCT01476774|Active Comparator|Tramadol CR|
88896987|NCT01476800|Experimental|YM178 OCAS alone|
88896988|NCT01476800|Active Comparator|Ketoconazole alone|
88896989|NCT01476800|Experimental|YM178 OCAS and ketoconazole|
88896990|NCT01476813|Experimental|Glyco 25|BDP/FF (400/24 daily)+ Glyco 25µg daily
88896991|NCT01476813|Experimental|Glyco 50|BDP/FF (400/24 daily)+ Glyco 50 µg daily
88896992|NCT01476813|Experimental|Glyco 100|BDP/FF (400/24 daily)+ Glyco 100µg daily
88896993|NCT01476813|Active Comparator|BDP/FF 400/24|BDP/FF 400/24
88896994|NCT01476865||Healthy|normal, healthy people
88896995|NCT01476865||RA|rheumatoid arthritis patients
88896996|NCT01476878|Experimental|Open Arm|Each study patient will receive high dose, single treatment radiation using a plastic mask instead of a head frame that pins into a patient's skull.
88896997|NCT01476891|Active Comparator|Wait-List|Wait-list Control Group. The control group will receive the next available online MBSR program.
88896998|NCT01476891|Active Comparator|Immediate MBSR|Immediate Online MBSR Group. Participation in a standardized manual-based 8-week online MBSR program.
88896999|NCT01476917|Experimental|Treatment|Subjects that completed the ATLAST Study
88897000|NCT01476930|Experimental|cupping serkangabin|migraine cases treated by cupping and serkangabin syrup
88897001|NCT01476930|Active Comparator|conventional|migraine cases treated by conventional drug treatment protocols
88897002|NCT01476943||Patient treated with Belatacept at the time of transplantation|Patients undergoing solid organ transplantation, whose transplant center participates in CTS and who are treated with Belatacept at the time of transplantation
88897003|NCT01476943||Patient treated with CNI at the time of transplantation|Patients undergoing solid organ transplantation, whose transplant center participates in CTS and who are treated with a Calcineurin inhibitor (CNI) based regimen at the time of transplantation
88897004|NCT01476956||Rheumatoid Arthritis|
88897005|NCT01476969|Experimental|Manual Tourniquet|
88897006|NCT01476982||Emergency Department Patients|Patients presenting to the Emergency Department complaining of chest pain.
89006631|NCT00243282|No Intervention|1|Control (Support Group)
88897007|NCT01476995||Controls|Men and women ages 18-85 lacking any medical diagnosis (as defined in the protocol) of one or more of the following systems/organs: cardiovascular system; gastrointestinal system; kidneys; liver; lungs.
89418938|NCT02198742|Active Comparator|Glidescope Cobolt|Subjects were required to watch a instructional video provided by the manufacterer. Subjects were then allowed to practice on a normal model until they felt comfortable before beginning the study. There is no placebo group, and each subject wil be his or her own control.
88897008|NCT01476995||Five Diagnosis Group|Men and women ages 18-85 with at least one active medical diagnosis (as defined in the protocol) of one or more of the following systems/organs: cardiovascular system; gastrointestinal system; kidneys; liver; lungs.
88897009|NCT01477021|Experimental|Treatment (NY-ESO-1 specific CD8+ T cells)|Patients receive cyclophosphamide IV on days -3 and -2. Patients receive NY-ESO-1-specific T cells IV on day 0.
88897010|NCT01477034|Experimental|2,000 IU/day vitamin D3 x 6 months|Subjects will take a 2,000 IU daily vitamin D3 supplement for 6 months.
88897011|NCT01477034|Experimental|4,000 IU/day vitamin D3 x 6 months|Subjects will take a 4,000 IU daily vitamin D3 supplement for 6 months.
88897012|NCT01477034|Experimental|2,000 IU/day vitamin D3 x 3 months|Subjects will take a 2,000 IU daily vitamin D3 supplement for 3 months.
88897013|NCT01477034|Experimental|4,000 IU/day vitamin D3 x 3 months|Subjects will take a 4,000 IU daily vitamin D3 supplement for 3 months.
88897014|NCT01477047||Patients receiving primary hip or knee arthoplasty|
88897015|NCT01477060|Other|ARM A - Lapatinib|hormonal therapy + lapatinib (1250mg/die) until disease progression or extraordinary medical circumstances occur or intolerable toxicities occur or the patient withdraws consent.
88897016|NCT01477060|Other|ARM B - Metformin|Hormonal therapy + metformin until disease progression or extraordinary medical circumstances occur or intolerable toxicities occur or the patient withdraws consent.
88897017|NCT01477060|Other|ARM C - Lapatinib + Metformin|Hormonal therapy + lapatinib + metformin until disease progression or extraordinary medical circumstances occur or intolerable toxicities occur or the patient withdraws consent.
88897018|NCT01477073|Experimental|FSH-GEX 75 IU|follitropin epsilon 75 IU QD
88897019|NCT01477073|Experimental|FSH-GEX 150 IU|follitropin epsilon 150 IU QD
88897020|NCT01477073|Experimental|FSH-GEX 150 IU QAD|follitropin epsilon 150 IU QAD
88897021|NCT01477073|Active Comparator|recombinant FSH|Gonal-f 150 IU QD
88897022|NCT01477073|Active Comparator|urinary FSH|Bravelle 150 IU QD
88897023|NCT01477073|Placebo Comparator|Placebo|Placebo QD
88897024|NCT01477086||Hip fracture|We included patients with traumatic hip fracture, with surgery and who are admitted for rehabilitation
89418939|NCT02201316|Experimental|Sequence 1 (ABC)|Subjects will receive treatments in the sequence ACB where, A=Single dose of reference mosapride citrate 5mg (GASMOTIN); B= Single dose of formulation 1 GR107719B 5mg (mosapride citrate); C= Single dose of formulation 2 GR107719B 5mg (mosapride citrate). All treatments will be administered orally in fasted state. Each treatment will be separated by a washout period of at least 7 days and no more than 14 days.
88897025|NCT01477099|Experimental|Toothbrushing with a manual brush|Toothbrushing with a manual brush
88897026|NCT01477099|No Intervention|No toothbrushing|no toothbrushing
88897027|NCT01477112|Experimental|Supplemented Diabetics (DB)|Diabetics supplemented with betacarotene for 45 days
88897028|NCT01477112|Experimental|Unsupplemented Diabetics (DS)|Diabetics without betacarotene supplementation
88897029|NCT01477112|Active Comparator|Supplemented Controls (CB)|Controls supplemented with betacarotene for 45 days
88897030|NCT01477112|Active Comparator|Unsupplemented Controls (CS)|Controls without betacarotene supplementation
88897031|NCT01476397|Active Comparator|control infant formula|partially hydrolyzed whey infant formula
88897032|NCT01476397|Experimental|test infant formula|partially hydrolyzed whey infant formula with probiotic
88897033|NCT01477125|Experimental|Flex working memory training|30-40 minutes of working memory training, 5 days a week for 5 weeks
88897034|NCT01477125|Placebo Comparator|Control version of Flex|30-40 minutes of training with a control version of Flex, 5 days a week for 5 weeks.
88897035|NCT01477138||DDD(R)|SSS. PM programmed to DDD(R) mode with ventricular pacing on the right ventricular septum.
88897036|NCT01477138||AAI(R)<=>DDD(R)|SSS, PM-mode programmed for minimizing right ventricular pacing on the right interventricular septum
88897037|NCT01477151|Active Comparator|sevoflurane|These patients will receive sevoflurane as the volatile anesthetic pre-, during-, and post-cardiopulmonary bypass at a targeted dose of 0.5-2.0 MAC.
88897038|NCT01477151|Experimental|isoflurane|These patients will receive isoflurane as the volatile anesthetic pre-, during-, and post-cardiopulmonary bypass at a targeted dose of 0.5-2.0 MAC.
88897039|NCT01477164|Experimental|Aerobic Exercise Training|Participants will perform 12-weeks of high intensity aerobic training.
88897040|NCT01477164|Active Comparator|Combined|The combined group will have 12-weeks of no exercise followed by 12-weeks of combined aerobic and resistance exercise training. Assessments will be made at three time points: baseline, after 12-weeks of no training, and after 12-weeks of combined training.
88897041|NCT01477164|Experimental|Resistance Exercise Training|Participants will perform 12-weeks of resistance exercise training.
88897042|NCT01477190|Experimental|Spinal group|Isobaric bupivacaine 0.5% 10 mg together with preservative-free morphine was injected. The dose of morphine was based on patient's age, with 200 μg in patients aged ≤ 75 years and 150 μg in patients aged > 75 years.
88897043|NCT01477190|Active Comparator|PCA group|PCA Morphine is set to the patient for 48 hours postoperative. 2 mg. of morphine is given to a patient as much as patient requires, maximum at every 7 minutes.
88897044|NCT01477203|Active Comparator|Escitalopram|50 Major Depressive Disorder Patients and 50 Anxiety Disorder Patients will receive Escitalopram as medication
88897045|NCT01477203|No Intervention|Remitted Patients|
88897046|NCT01477203|No Intervention|Healthy Controls|
88897047|NCT01477216|Experimental|Measuring method|To compare glycemic responses and GI values from capillary and venous blood and to compare glucose solution with white bread as the reference food and to study the effect of the number of reference tests on GI values.
89006632|NCT00243282|Other|2|Intervention (Mindfulness Based Breathing Therapy)
88897048|NCT01477216|Experimental|Mixed meals|To examine the glycaemic and insulinaemic responses of a mashed potato-based meal when a high fat food (rapeseed oil) or a high protein food (chicken breast) or fat, protein and salad together were added to the meal. Furthermore, we studied how the predicted and measured GI values of the mixed meal differed from each other.
88897049|NCT01477216|Experimental|Coffee|To examine the effects of two different coffee portions with glucose and caffeine-containing soft drinks on postprandial glucose and insulin responses. Further objectives were to study how coffee and different accompaniments affect glucose and insulin responses.
88897050|NCT01477216|Experimental|Snacks|To measure GI and II values for Finnish snack foods
88897051|NCT01477216|Experimental|Berries|To study the effects of berries on glycemic and insulinemic responses
88897052|NCT01477216|Experimental|GIs of low-carbs|To measure glycemic and insulinemic responses to low-carbohydrates foods
88897053|NCT01477216|Experimental|Glucose metabolism and BMI|To examine the effects of overweight and glucose tolerance on the glucose, insulin and lipid responses to an HGI meal and an LGI meal. Furthermore, the second aim was to study the effect of BMI and glucose tolerance on the GI measured.
88897054|NCT01477216|Experimental|Insulin measurement|To compare how methodological choices affect measured insulin values
88897055|NCT01477216|Experimental|Alcohol|To investigate the effect of alcohol on postprandial glucose and insulin responses, and to determine glycemic and insulinemic indices values for beer and non-alcoholic beer.
88897056|NCT01477242|Experimental|Ondansetron|Ondansetron use group
89418940|NCT02201316|Experimental|Sequence 2 (ACB)|Subjects will receive treatments in the sequence ACB where, A=Single dose of reference mosapride citrate 5mg (GASMOTIN); B= Single dose of formulation 1 GR107719B 5mg (mosapride citrate); C= Single dose of formulation 2 GR107719B 5mg (mosapride citrate). All treatments will be administered orally in fasted state. Each treatment will be separated by a washout period of at least 7 days and no more than 14 days.
88897057|NCT01477242|Placebo Comparator|Placebo|Placebo group
88897058|NCT01477255||Cancer patient|Patient participants will include children and adolescents between the ages of 8-17 years who have been recently diagnosed with cancer. They will use an iPad as a diary to track their daily experiences. They will use an iPad as a diary to track their daily experiences.
88897059|NCT01477255||Control|For each pediatric patient enrolled, a child without a history of a serious medical illness will be recruited from the larger community who is matched on variables of age, race/ethnicity, gender, and socioeconomic status. They will use an iPad as a diary to track their daily experiences. They will use an iPad as a diary to track their daily experiences.
88897060|NCT01477268|Other|zoloft|Both arms of the study will include zoloft. However, the treatment response to zoloft will be compared in two different subgroups.
88897061|NCT01477281|Experimental|Venafon (Diosmin and Hesperidin)|Administer one tablet 2 times daily (oral), the main meals (lunch and dinner).
88897062|NCT01477281|Active Comparator|Daflon|Administer one tablet 2 times daily (oral), the main meals (lunch and dinner).
88897063|NCT01477294|Experimental|Caffeine|Intervention with Caffeine in a random order
88897064|NCT01477294|Placebo Comparator|Placebo|Placebo (malt dextrin) administered in a random order
88897065|NCT01477307||hypocaloric diet|The included patients are assigned to a hypocaloric standardized diet for 3 weeks.
88897066|NCT01477346|Other|Nurse intervention|Nurse led package of care based on current recommended best practice.
88897067|NCT01477346|Other|Standard care|Continuing standard general practitioner led care
88897068|NCT01477359||CS screened as underlying etiology|"Patients with active Clinically Manifest CS~Patients diagnosed with extra-cardiac sarcoidosis and being screened for CS"
89418941|NCT02201316|Experimental|Sequence 3 (BAC)|Subjects will receive treatments in the sequence BAC where, A=Single dose of reference mosapride citrate 5mg (GASMOTIN); B= Single dose of formulation 1 GR107719B 5mg (mosapride citrate); C= Single dose of formulation 2 GR107719B 5mg (mosapride citrate). All treatments will be administered orally in fasted state. Each treatment will be separated by a washout period of at least 7 days and no more than 14 days.
89418942|NCT02201316|Experimental|Sequence 4 (BCA)|Subjects will receive treatments in the sequence BCA where, A=Single dose of reference mosapride citrate 5mg (GASMOTIN); B= Single dose of formulation 1 GR107719B 5mg (mosapride citrate); C= Single dose of formulation 2 GR107719B 5mg (mosapride citrate). All treatments will be administered orally in fasted state. Each treatment will be separated by a washout period of at least 7 days and no more than 14 days.
88897069|NCT01477372|Experimental|Exercise group|Supervised exercise program
88897070|NCT01477372|No Intervention|Control|Sedentary pregnant woman
88897071|NCT01477385|Active Comparator|Resin Infiltration|Resin Infiltration 30% Silver Diammine Fluoride Placebo Dental Flossing
88897072|NCT01477385|Experimental|30% Silver Diammine Fluoride|30% Silver Diammine Fluoride Resin Infiltration Placebo Dental Flossing
88897073|NCT01477385|Active Comparator|Oral Hygiene|Dental Flossing 30% Silver Diammine Fluoride Placebo Resin Infiltration Placebo
88897074|NCT01477398|Active Comparator|inspired CO2|Inspired CO2
88897075|NCT01477398|No Intervention|No intervention: Standard of Care|tidal volume and respiratory rate are not changed during recovery from anesthesia
88897076|NCT01477411|Experimental|PA21 and Digoxin with food|The maximum dose of PA21 will be 15.0 g/day. The maximum dose of Digoxin will be 0.5 mg/day
88897077|NCT01477411|Experimental|No PA21; Digoxin with food|The maximum dosage of Digoxin will be 0.5 mg/day
88897078|NCT01477411|Experimental|PA21 with food and Digoxin 2hrs later|The maximum dose of PA21 will be 15 g/day. The maximum dose of Digoxin will be 0.5 mg/day
88897079|NCT01477424|Experimental|PA21 and Warfarin with food|The maximum dose of PA21 will be 15.0 g/day. The maximum dose of Warfarin will be 10 mg/day
88897080|NCT01477424|Experimental|No PA21; Warfarin with food|The maximum dosage of Warfarin will be 10 mg/day
88897081|NCT01477424|Experimental|PA21 with food and Warfarin 2hrs later|The maximum dose of PA21 will be 15 g/day. The maximum dose of Warfarin will be 10 mg/day
88897082|NCT01477437|Experimental|Intervention (experimental) Group|
88897083|NCT01477437|No Intervention|Control group|
88897084|NCT01477476|Active Comparator|Active Treatment|14 subjects with receive active treatment with Anakinra.
88897085|NCT01477476|Placebo Comparator|Placebo|7 subjects will receive the placebo comparator.
88897086|NCT01477489|Experimental|Treatment|
88897087|NCT01477515||End stage renal disease patient|
88897088|NCT01477515||Matched controls|
88897089|NCT01477541|Experimental|PM/ON integration arm|Health centers where professional midwives or obstetric nurses are integrated into clinic staff and delivering services.
88897090|NCT01477541|No Intervention|Control|
88897091|NCT01477554|No Intervention|Control|Hospitals randomized to the control arm do not receive any intervention.
88897092|NCT01477554|Experimental|PRONTO training|PRONTO training is delivered to medical teams at hospitals randomized to this arm.
88897093|NCT01477580|Experimental|Low-dose V180 with low-dose ISCOMATRIX™ adjuvant|
88897094|NCT01477580|Experimental|Low-dose V180 with medium-dose ISCOMATRIX™ adjuvant|
88897095|NCT01477580|Experimental|Medium-dose Non-adjuvanted V180|
88897096|NCT01477580|Experimental|Medium-dose V180 with low-dose ISCOMATRIX™ adjuvant|
88897097|NCT01477580|Experimental|Medium-dose V180 with medium-dose ISCOMATRIX™ adjuvant|
88897098|NCT01477580|Experimental|Medium-Dose V180 with Alhydrogel™ adjuvant|
88897099|NCT01477580|Experimental|High-dose Non-adjuvanted V180|
89418943|NCT02201316|Experimental|Sequence 5 (CAB)|Subjects will receive treatments in the sequence CAB where, A=Single dose of reference mosapride citrate 5mg (GASMOTIN); B= Single dose of formulation 1 GR107719B 5mg (mosapride citrate); C= Single dose of formulation 2 GR107719B 5mg (mosapride citrate). All treatments will be administered orally in fasted state. Each treatment will be separated by a washout period of at least 7 days and no more than 14 days.
89418944|NCT02201316|Experimental|Sequence 6 (CBA)|Subjects will receive treatments in the sequence CBA where, A=Single dose of reference mosapride citrate 5mg (GASMOTIN); B= Single dose of formulation 1 GR107719B 5mg (mosapride citrate); C= Single dose of formulation 2 GR107719B 5mg (mosapride citrate). All treatments will be administered orally in fasted state. Each treatment will be separated by a washout period of at least 7 days and no more than 14 days.
89418945|NCT03682549||HCV positive Patients|"patients will be recruited from the outpatient's viral hepatitis clinic~The patients will be diagnosed as HCV positive through (antiHCV-Ab) and (HCV-PCR) tests"
89418946|NCT03682549||Successfully treated former HCV patients|Patients formerly diagnosed as HCV positive who received DAA treatment successfully.
89418947|NCT03682549||Normal Individuals|healthy volunteers recruited from the outpatient clinic of the Faculty of Dentistry- Cairo University
89418948|NCT02197962|Experimental|Extracorporeal radial shockwaves|Patients will receive 2,000 impulses of extracorporeal radial shockwave per week, with pressure of 2.5bar to 4.0bar, at the frequency of 8Hz. The impulses will be applied at the most painful site of the knee joint interface on manual palpation, for three consecutive weeks.
89418949|NCT02197962|Placebo Comparator|Placebo Radial Shockwaves|Patients will receive 2,000 impulses of placebo radial shockwave per week, without any energy flow intensity. Frequency of 8Hz will appear in the screen. The impulses will be applied at the most painful site of the knee joint interface on manual palpation, for three consecutive weeks.
89418950|NCT02201550||Liraglutide|Patients with type 2 diabetes undertaking treatment with liraglutide
89418951|NCT03533790|Experimental|DEP-Ru|doxorubicin (doxorubicin hydrochloride liposome injection) 25 mg/m2 day 1; etoposide 100 mg/m2 was administered day1; methylprednisolone 2 mg/kg days 1 to 5,then gradually reduce; ruxolitinib 0.3mg/kg/d。This regimen was repeated after 2 weeks.
89418952|NCT02198118|No Intervention|Control Group|Control group (CG) subjected only to evaluations and to no exercises.
89006633|NCT04620109|Placebo Comparator|SDE Placebo|Subjects will receive placebo (drops without drug).
89006634|NCT04620109|Active Comparator|SDE 0.03 mg/eye|Actual dose is 0.03 mg/eye by 60μL KDR2-2 eyedrops of a concentration of 0.5 mg/mL for 1 time.
89418953|NCT02198118|Experimental|Study Group|Study group (SG) instructed to perform domiciliary exercises for the upper limbs
89418954|NCT02201706|Experimental|Multi-electrocoagulation retinectomy|Retinal re-detachment in eyes with silicone oil filled,a modified surgery named Multi-electrocoagulation retinectomy will be used to re-attach the retina.
89418955|NCT02198196|Experimental|Weight Talk-Mindfulness|WT-M retain the evidence-based elements of WT-S (control condition), including the DASH diet, physical activity components, and an emphasis on self-monitoring. However, each call in WT-M will include an emphasis on mindfulness and stress management that will not be included in the control condition.
89418956|NCT02198196|No Intervention|Weight Talk-Standard|Weight Talk-Standard is a phone and web-based weight loss intervention offered by employers as a benefit to their employees. Weight Talk is based on the NIH Clinical Guidelines on Identification, Evaluation and Treatment of Overweight and Obesity in Adults and utilizes the curriculum developed for the Diabetes Prevention Program. Weight Talk-S contains no additional stress management techniques.
89418957|NCT02198820||General|All patients included who underwent surgery with general anesthesia
89418958|NCT02198820||Loco Regional|All patients included who underwent surgery with loco regional anesthesia
89418959|NCT02201862||Euploid Subjects|Subject's with fetal euploidy confirmed by chromosome analysis
89418960|NCT02201862||Aneuploid Subjects|Subject's with fetal aneuploidy confirmed by chromosome analysis
89418961|NCT02257476|Experimental|Carfilzomib|Patients will receive single agent carfilzomib on a weekly dosing schedule (days 1, 8, 15) in a 21 day cycle. The initial dose will be 20 mg/m² for cycle 1, day 1. Dose escalation will proceed in a standard 3+3 fashion with the requirement that dose escalation to the next level can only proceed if 0 of 3 or ≤ 1 of 6 patients experience a dose limiting toxicity (DLT). Dexamethasone 8 mg PO/IV will be administered prior to all carfilzomib doses.
89418962|NCT02202018|Experimental|Active KT Intervention|CKD clinics receiving the active knowledge translation intervention.
89418963|NCT02202018|No Intervention|Usual standard of care|Clinics will continue their standard of care education and approach to use of home dialysis.
89418964|NCT02198898|No Intervention|GUARDIX|no guadix
89418965|NCT02198898|Experimental|guadix|guadix treatment
88897100|NCT01477580|Experimental|High-dose V180 with low-dose ISCOMATRIX™ adjuvant|
89418966|NCT03691753|Experimental|Experimental arm|Patients will be treated with Fitaya Vena Cava Filter System.
88897101|NCT01477580|Experimental|High-dose V180 with medium-dose ISCOMATRIX™ adjuvant|
88897102|NCT01477580|Experimental|Low-dose V180 with high-dose ISCOMATRIX™ adjuvant|
88897103|NCT01477580|Experimental|Medium-dose V180 with high-dose ISCOMATRIX™ adjuvant|
88897104|NCT01477580|Experimental|High-dose V180 with high-dose ISCOMATRIX™ adjuvant|
88897105|NCT01477580|Placebo Comparator|Placebo|
88897106|NCT01477593|Experimental|Group I|
88897107|NCT01477593|Active Comparator|Group II|
88897108|NCT01477593|Active Comparator|Group III|
88897109|NCT01477606|Experimental|Midostaurin|
88897110|NCT01477619|Experimental|Smokers|Split into BMI categories
88897111|NCT01477619|Experimental|Non-Smokers|Gender, age, and BMI matched to Smokers
88897112|NCT01477619|Experimental|Elderly|
88897113|NCT01477632|Experimental|A|
88897114|NCT01477632|Experimental|B|
88897115|NCT01477632|Active Comparator|C|
88897116|NCT01477645||Leaded ammunition|
88897117|NCT01477645||Non-leaded ammunition|
88897118|NCT01477645||Modified non-leaded ammunition|
88897119|NCT01477658||Congenital AV Block|Patients diagnosed with Congenital Complete Atrioventricular Heart Block
88897120|NCT01477658||Postoperative AV Block|Patients diagnosed with postoperative AV block
88897121|NCT01477671||Study Group|Participants aged between 5 and 10 year-old on day of inclusion.
88897122|NCT01477697|Active Comparator|Omega-3|50 mg/kg per day of omega-3 fatty acids (DHA Omega-3, Martek Biosciences, Columbia, MD)
88897123|NCT01477697|Placebo Comparator|Placebo|50 mg/kg per day of vehicle
88897124|NCT01477723|Experimental|Experimental Oral Nutrition Supplement|Experimental ONS orally Two 8 fl oz servings/day
88897125|NCT01477723|No Intervention|No Product|
88897126|NCT01477736|Active Comparator|Botulinum toxin A|
88897127|NCT01477736|Active Comparator|oxybutynin|
89418967|NCT03691753|Active Comparator|Control arm|Patients will be treated with Aegisy Vena Cava Filter.
89418968|NCT02198274|Experimental|BIBH 1|
88897128|NCT01477775|Active Comparator|Standard of Care|The treating physician will be left free to give the oral P2Y12 receptor blocker, including clopidogrel,prasugrel or ticagrelor, which according to his/her clinical judgement is most appropriate for the individual patient.
88897129|NCT01477775|Experimental|Customized choice of the oral P2Y12 receptor blocker|The choice of the oral P2Y12 receptor blocker will be based on an algorithm which integrates phenotype information, including but not limited to residual on-treatment platelet reactivity assessed via Verifynow P2Y12 assay.
88897130|NCT01477788||women, sonographic ovarian mass|women that will arrive to the sonographic unit of the gynecological department with the sonographic diagnosis of ovarian mass
88897131|NCT01477801|Experimental|CHOLECALCIFEROL|
88897132|NCT01477801|Placebo Comparator|PLACEBO|
88897133|NCT01477814|Active Comparator|physician chart reminder|either a paper or an electronic reminder placed on the subject's medical record to remind the physician to screen for colorectal cancer
88897134|NCT01477814|Active Comparator|chart reminder, educational mat'ls, FIT|physician chart reminder plus mailed educational materials, including the Centers for Disease Control CRC Screen for Life, the ACS DVD on CRC screening, a fecal immunochemical test with postage-paid return mailer, a magnet reminding individuals to get screened, and a CRC screening preference sheet where subjects could indicate their preferred CRC test
88897135|NCT01477814|Active Comparator|CR, ed mat'ls, FIT, phone call|physician chart reminder (CR) plus mailed educational materials, including the Centers for Disease Control CRC Screen for Life, the ACS DVD on CRC screening, a fecal immunochemical test with postage-paid return mailer, a magnet reminding individuals to get screened, and a CRC screening preference sheet where subjects could indicate their preferred CRC test, and a motivational telephone call designed to elicit barriers and preferences and motivate individuals to complete a CRC screening test.
88897136|NCT01477827||Healthy volunteers|Healthy adolescents aged 12-15 years
88897137|NCT01477840|Experimental|Misoprostol|
88897138|NCT01477866|Experimental|citogenex|citogenex + conventional therapy
88897139|NCT01477866|Active Comparator|conventional therapy|conventional therapy
88897140|NCT01477879|Active Comparator|Versabase/20% S. purpurea extract|
88897141|NCT01477879|Placebo Comparator|placebo (versabase gel only)|placebo used will be versabase gel alone
88897142|NCT01477931|Experimental|Wellbutrin XL|
88897143|NCT01477983|Active Comparator|ATP guide additional ablation - AAD|UNDER-ATP trial: ATP guide additional ablation, EAST-AF trial: AAD for 90 days
88897144|NCT01477983|Active Comparator|Control - AAD|UNDER-ATP trial: Control, EAST-AF trial: AAD for 90 days
88897145|NCT01477983|Active Comparator|ATP guide additinal ablation - Control|UNDER-ATP trial: ATP guide additional ablation, EAST-AF trial: Control
88897146|NCT01477983|Active Comparator|Control - Control|UNDER-ATP trial: Control, EAST-AF trial: Control
88897147|NCT01477996|Active Comparator|Group 1|27-gauge needle
88897148|NCT01477996|Active Comparator|Group 2|30-gauge needle
89418969|NCT02202096|Experimental|Intervention (plus usual care)|Patient education: One-on-one visit Discharge planning: Assessment of barriers to discharge Medication reconciliation: Patient medication review Appointment before discharge: Additional measure to ensure awareness of next clinic visit Transition coach Patient-centered discharge instructions: Enhanced Provider continuity: Specific surgeons responsible for coordinating care with medical/radiation oncology Timely follow-up: Barriers to clinic follow-up visits will be discussed Timely PCP communication Follow-up telephone call Patient hotline: 24 hour follow-up following call to Ask My Nurse number
89418970|NCT02202096|No Intervention|Usual Care|Usual care-Standard of care that all colorectal cancer patients normally receive
89418971|NCT02202174||Supraglottic Airway Device|Patients will receive a supraglottic airway device as a primary means of ventilation. The following devices may be used: LMA Unique, LMA ProSeal, LMA Supreme, LMA Flexible, Ambu Aura-I, Ambu Aura Once, Air-Q, I-Gel, or other supraglottic airway device. Choice of the device will be clinician dependent and based on the patients body weight per manufacturer guidelines
89418972|NCT03943927|Experimental|Pharmacogenetic-guided metoprolol management|
89418973|NCT03691675|Experimental|Drug coated balloon|Patients with de novo lesion whose radiography showed that target lesion diameter stenosis is ≥50%, reference diameter is ≥2.75mm and who agreed with the Drug coated balloon dilatation therapy
89418974|NCT03533166|Experimental|Chlorhexidine|Mechanical treatment + 0.03% chlorhexidine + 0.05% CPC mouthrinse
89418975|NCT03533166|Placebo Comparator|Placebo|Mechanical treatment + Placebo mouth rinse
89418976|NCT03937453||New-Onset Diabetes Mellitus|Diabetes Mellitus diagnosed within the past 12 months
89418977|NCT03937453||Deteriorating Diabetes Mellitus|History of Diabetes Mellitus with recent deteriorating within the past 6 months confirmed with repeat testing and not associated with weight gain or diabetes medication non-compliance
89418978|NCT02199132||Nasopharyngeal Carcinoma|
89418979|NCT03687073|Experimental|Single-dose PK study|Subjects will take the assigned dose of I3C, Sil, or I3C + Sil once at the study center. Ten mL of blood will be collected at the time points described in Section 9.14. Concurrently, urine will also be collected for 24 hours after the first dose of I3C, Sil or I3C + Sil, divided into the time intervals.
89418980|NCT03687073|Experimental|Multi-dose PK Study|Subjects will take the assigned dose of I3C, Sil, or I3C + Sil for 8 weeks. Ten mL of blood will be collected at the time points described in Section 9.14. Concurrently, urine will be collected for 24 hours after the first dose of I3C, Sil or I3C + Sil, divided into the time intervals.
89418981|NCT03687073|Experimental|Safety Study|Safety data will be generated during the multi-dose PK and PD study, as DLT is not anticipated in the single-dose PK study. Enrollment into dose cohorts 1 and 2 can occur on a continuous basis. Enrollment for dose cohorts 3 and 4 will be done sequentially using a modified 3+3 design (see Section 8.2). The first three subjects enrolled into a dose cohort must complete at least 21 days of the multi-dose PK/PD study without a DLT before the remaining 4 subjects in the cohort can be enrolled.
89193947|NCT03085147|Experimental|Fluorescent PARPi Binding Imaging Agent PARPi-FL|In the phase I of the study, increasing concentrations of PARPi-FL will be used in up to 12 patients with OSCC to determine concentration that results in the highest contrast between tumor and normal mucosa. Dose escalation will be performed in groups of three patients until image contrast decreases, side effects are noted or the concentration of PARPi-FL exceeds 1μM. Imaging will be performed in the Department of Surgery during a presurgical visit including clinical examination of the oral cavity. In the phase II part of the study the concentration of PARPi-FL determined in phase I will be used to image 18 patients with OSCC on the day of surgery. Imaging findings will be correlated with histopathologic findings in the surgically resected specimens.
88897149|NCT01478022|Active Comparator|Isosorbide Dinitrate 20 mg|Isosorbide Dinitrate 10 mg b.i.d
88897150|NCT01478022|Active Comparator|Ibuprofen 200 mg|Ibuprofen 200 mg daily, capsule
88897151|NCT01478022|Experimental|Isosorbide dinitrate and Ibuprofen|Isosorbide dinitrate 20 mg daily and Ibuprofen 200 mg daily
88897152|NCT01478061|Active Comparator|anastomoses in blood vessels and grafts|
88897153|NCT01478074|Experimental|FLAG + NK Cells + ALT-801|
88897154|NCT01478126|Experimental|Glutamine|Intravenous glutamine infusion perioperatively and 24 hours after surgery
88897155|NCT01478126|Placebo Comparator|Placebo|
88897156|NCT01478139|Experimental|LIFT|Subjects randomized to this arm will receive the ligation of the intersphincteric fistula track (LIFT) procedure
88897157|NCT01478139|Experimental|LIFT-plug|Subjects randomized to this arm will receive the ligation of the intersphincteric fistula track and plug (LIFT-plug) procedure
89193948|NCT03074305|Active Comparator|DEB strategy|"DEB procedure will be standardized in order to maximize drug delivery into target segment. Commercially available DEB will be used (Sequent Please, B Braun, Germany or Pantera Lux, Biotronik, German). The below requirements will be mandatorily recommended.~Residual stenosis after lesion preparation : %DS <20%~Delivery time : < 30 seconds~Total inflation time : > at least 1 minute~Previous BVS : DEB diameter ratio : > 1.0:1~Maximum inflation pressure : at least above nominal pressure of DEB"
89193949|NCT03074305|Active Comparator|DES strategy|The implantation of 2nd generation DES will be performed as universally recommended. In the DES group, the newest version of 2nd generation everolimus-eluting stent (Xience Alpine, Abbott Vascular, USA) will be recommended.
88897158|NCT01478152|Experimental|Ectoin Inhalation Solution|"After baseline visit subjects will receive 0.9% saline inhalation solution for placebo. Patients will be instructed to inhale once daily with the AKITA2® APIXNEB® inhalation system for 5 - 7 days.~The treatment phase with low dose of Ectoin® will follow subsequently without any washout phase. This treatment phase will be repeated for medium and a high Ectoin® dose. All doses of Ectoin® inhalation solution will be administered for 5 - 7 days without any washout phase. Sputum inductions will be conducted on the last but one day of placebo treatment phase and on the last but one day of treatment phase with the highest Ectoin® dose."
88897159|NCT01478165|Placebo Comparator|Tiva group (Group T)|
88897160|NCT01478165|Active Comparator|TIVA plus palonosetron group (Group T+P)|
88897161|NCT01478230|Experimental|N1/3-I5|5 mg Inhalation during 10 minutes every hour for 11 hours with a puff frequency of four puffs per minute, with a 36-hour washout between visits
88897162|NCT01478230|Active Comparator|NX-I10|10 mg Inhalation during 10 minutes every hour for 11 hours with a puff frequency of four puffs per minute, with a 36-hour washout between visits.
88897163|NCT01478269||Cases of aggressive B-cell lymphoma|Cases of aggressive B-cell lymphoma diagnosed between 2001 to 2007 in Italy
88897164|NCT01478282|Active Comparator|Rivaroxaban|Healthy donors subjected to 20mg/day for 5 days
89193950|NCT03046862|Experimental|Durvalumab/Tremelimumab+chemotherapy|Durvalumab and Tremelimumab in combination with gemcitabine/cisplatin.
88897165|NCT01478282|Active Comparator|Dabigatran|Healthy volunteers subjected to 150 mg/12hours for 5 days
88897166|NCT01478295|Experimental|CuidaCare Intervention|Regular care in consultation or home and Structured nursing care (CuidaCare intervention): improved strategies for coping, health education on self-care and dependent care and emotional support. 10 visits are structured, with a periodicity of approximately 2 visits per month and last for 30 to 40 minutes each
88897167|NCT01478295|Active Comparator|Control Group/Usual Care|Usual care in consultation or home, which is to respond to the specific demands of care of the caregiver, using the resources of the nursing discipline.
88897168|NCT01478334|Experimental|Exercise then control|
88897169|NCT01478334|Experimental|Control then exercise|
88897170|NCT01478386|Other|Viscosupplementation injections|Control group will receive a series of three viscosupplementation injections into the affected knee
88897171|NCT01478386|Experimental|Off-loading knee brace|
88897172|NCT01478386|Experimental|Viscosupplementation and knee brace|
89418982|NCT03687073|Experimental|Cohort 4 PD Study|The effect of I3C, Sil, or I3C + Sil on the pharmacodynamic endpoints listed under the Secondary Objectives in Section 1.2 will be characterized. This PD study will be done concurrently with the multi-dose PK study. Subjects will take the assigned dose of I3C, Sil, or I3C + Sil for 8 weeks. Nasal epithelium, oral cavity cells, buccal cells, blood, and urine will be collected at the time points described in the study calendar in Section 4.0.
89418983|NCT03691597|Active Comparator|Adhesive resin cement|type of cement used for cementation of crowns have a good adhesion bond
89418984|NCT03691597|Experimental|Bioactive cement|recent cement improve the marginal integrity
88897173|NCT01478399|Experimental|Impaired Renal Function|Subjects have impaired renal function matched to subjects with normal renal function by age and weight.
88897174|NCT01478399|Experimental|Normal Renal Function|Subjects have normal renal function matched to subjects with impaired renal function by age and weight.
88897175|NCT01478412||Males with prostate adenocarcinoma|English speaking males with histologically confirmed prostate adenocarcinoma and diagnosis of low risk or intermediate risk prostate cancer.
88897176|NCT01478425|Experimental|Active|Lipidic Microemulsion
88897177|NCT01478425|Placebo Comparator|Control|Saline nose-spray device
88897178|NCT01478438|Experimental|Treat and Excise|All subjects will be treated with Interstitial Laser Therapy (ILT) followed by excision no later than 28 days post ablation.
88897179|NCT01478451|Experimental|Massage|massage will be provided for 10 minutes at the left or right trapezius (randomized)
88897180|NCT01478451|Experimental|Exercise|exercise (shoulder shrugs with elastic resistance) will be performed for 10 minutes at the left or right trapezius (randomized)
88897181|NCT01478451|No Intervention|Control|control shoulder (randomized)
88897182|NCT01478464|No Intervention|Control group|Control group, does not receive any intervention
88897183|NCT01478464|Experimental|Massage group|Massage will be performed on the left or right hamstring muscle (randomized) for ten minutes with a massage roller. The contralateral leg will not be massaged, but serve as a non-massaged control leg to assess possible cross-over effects from the massaged leg
88897184|NCT01478490|Experimental|Treatment Arm 1A|mirabegron, poor metabolizers
88897185|NCT01478490|Experimental|Treatment Arm 1B|mirabegron, extensive metabolizers
88897186|NCT01478490|Experimental|Treatment Arm 2|mirabegron/metoprolol
88897187|NCT01478503|Experimental|Treatment Arm A|mirabegron
88897188|NCT01478503|Placebo Comparator|Treatment Arm B|matching placebo
88897189|NCT01478516|Experimental|Plasmin|eyes with macular edema
88897190|NCT01478529|Experimental|Treatment Arm A|low dose of mirabegron
88897191|NCT01478529|Experimental|Treatment Arm B|high dose of mirabegron
89193951|NCT03042078|Experimental|Zero-fluoroscopic ablation|Paroxysmal supraventricular tachycardia will be ablated under the guidance of Ensite NavX and without the use of fluoroscopy.
88897192|NCT01478568|Experimental|mirabegron / desipramine|
88897193|NCT01478607|Experimental|1. Qutenza 30 minutes + SOC|
88897194|NCT01478607|Experimental|2. Qutenza 60 minutes + SOC|
88897195|NCT01478607|No Intervention|3. SOC|Subjects randomized to this group will receive treatment optimized for them on an individual basis. The investigator will be free to provide whatever pharmacological or other treatment is considered optimal for management of the subject's pain.
89193952|NCT03042078|Active Comparator|Conventional fluoroscopic ablation|Paroxysmal supraventricular tachycardia will be ablated under the guidance of Ensite NavX plus fluoroscopy.
89418985|NCT02199210|Experimental|Prompting forethought|"A demographic questionnaire will be filled out by each participant. After randomization, participants will be presented with the background information of the simulated scenario.Subsequently:~participants forethought will be prompted and each participant will be asked to report his/her forethought,~participants then will be asked to manage a simulated massive transfusion scenario,~at completion of the scenario, each participant will undergo individualized debriefing and a syllabus on massive transfusion will be briefly discussed with them and also provided as a reading material for learning."
88897196|NCT01478633|Experimental|Galantamine|
88897197|NCT01478646|Experimental|Conventional breathing therapy|first: conventional breathing therapy, second: reflectory breathing therapy
88897198|NCT01478646|Experimental|Reflectory breathing therapy|first: reflectory breathing therapy second: conventional breathing therapy
88897199|NCT01478659|Active Comparator|Control bar and yogurt|
88897200|NCT01478659|Experimental|Fiber bar and yogurt|
89418986|NCT02199210|No Intervention|No prompting|"A demographic questionnaire will be filled out by each participants. After randomization, participants will be presented with the background information of the simulated scenario.Subsequently:~participants will sit and wait for a predetermined time before entering into the simulator,~participants then will be asked to manage a simulated massive transfusion scenario,~at completion of the scenario, each participant will be interviewed about their thought process before entering to the simulation room,~each participant will undergo individualized debriefing and a syllabus on massive transfusion will be briefly discussed with them and also provided as a reading material for learning."
88897201|NCT01478672|No Intervention|Standard care|
88897202|NCT01478672|Experimental|Health coaching and and Life-long Monitoring|
88897203|NCT01478685|Experimental|Arm A: CC-486 plus Carboplatin|CC-486 will be administered orally at doses between 100-300 mg daily for either 14 or 21 days depending on tolerability. Carboplatin will be given by intravenous (IV) infusion once every 21 Days at a dosage of AUC x 4.
88897204|NCT01478685|Experimental|Arm B: CC-486 plus ABI-007|"CC-486 will be administered orally at doses between 100-300 mg daily for either 14 or 21 days depending on tolerability~ABI-007 will be administered by intravenous (IV) infusion on two of every three weeks at a dosage of 100 mg/m^2"
89418987|NCT03686917||CHAT-P|Survey
88897205|NCT01478685|Experimental|Arm C: CC-486|CC-486 will be administered orally at doses between 100-300 mg daily for either 14 or 21 days depending on tolerability
88897206|NCT01478711|Active Comparator|Intervention|A clinical decision support tool for the care and management of premature infants will be embedded into the electronic health record.
88897207|NCT01478711|No Intervention|No Intervention|No intervention, No clinical decision support tool will be used for non-intervention sites.
88897208|NCT01478724|Placebo Comparator|Placebo|Animal proteins
88897209|NCT01478724|Experimental|Milk protein fraction dose 1|
89418988|NCT02031354|Experimental|Lysine Chloride|
89418989|NCT03682471||Deoxycholic Acid Injection, 5 mg/mL|Non-treatment observational follow-up study: Participants were previously treated with deoxycholic acid injection, 5 mg/mL in studies ATX-101-10-16 or ATX-101-10-17.
89418990|NCT03682471||Deoxycholic Acid Injection, 10 mg/mL|Non-treatment observational follow-up study: Participants were previously treated with deoxycholic acid injection, 10 mg/mL in studies ATX-101-10-16 or ATX-101-10-17.
89418991|NCT03682471||Placebo|Non-treatment observational follow-up study: Participants were previously treated with placebo in studies ATX-101-10-16 or ATX-101-10-17.
88897210|NCT01478724|Experimental|Milk protein fraction dose 2|
88897211|NCT01478750|Experimental|emulsified fat, orally|At 09:00, subjects will ingest the test load, consisting of 460 water and 40 ml sunflower oil, well emulsified with Tween-80
88897212|NCT01478750|Experimental|intragastric administration of fat|At 09:00, subjects will receive the load, consisting of 460 water and 40 ml sunflower oil, well emulsified with Tween-80 intragastrically
88897213|NCT01478750|Experimental|intraduodenal administration of fat|At 09:00, subjects will receive the load, consisting of 460 water and 40 ml sunflower oil, well emulsified with Tween-80 intraduodenally
88897214|NCT01478750|Experimental|intragastric, non-emulsified fat|At 09:00, subjects will receive the load, consisting of 460 water and 40 ml sunflower oil, non emulsified, intragastrically
88897215|NCT01478776|Active Comparator|diabetes, omega-3|patient with type 2 diabetes who receive 4gr/day omega-3
88897216|NCT01478776|Placebo Comparator|placebo, diabetes|patient with type 2 diabetes who receive 4 cap of placebo/day
88897217|NCT01478789|Experimental|Water dispersible Plant Sterol (WD-PS)|WD-PS dairy product (a novel formulation for dispersible free sterols in aqueous media produced)2g/d of free plant sterol
88897218|NCT01478789|Experimental|Esterified plant sterol (PS-Ester)|PS-Ester enriched dairy product (2g/d free plant sterol)
88897219|NCT01478789|Placebo Comparator|placebo|100 g/d yogurt with no added plant sterol
88897220|NCT01478802|Active Comparator|CMV Arm|Patients with moderate-to-severe Acute Respiratory Distress Syndrome treated solely with lung protective, low volume high positive end-expiratory pressure conventional mechanical ventilation (CMV) and recruitment maneuvers, as specified in detail in the Detailed Description section.
88897221|NCT01478802|Experimental|HFO-RMs Arm|Patients with moderte-to-severe Acute Respiratory Distress Syndrome treated initially with a 96-hour-lasting session (session duration modifiable according to oxygenation criteria) of High-frequency oscillation (HFO)-Recruitment Maneuvers (RMs), and then with lung protective CMV interspersed to additional HFO-RMs sessions (if required according to study protocol). The protocolized use of HFO-RMs may extend until day 10 post-randomization, according to pre-specified oxygenation criteria. Full details are provided in the Detailed Description Section.
89418992|NCT02198352|Experimental|BIBN 4096 BS - in single rising doses|
89418993|NCT02198352|Placebo Comparator|Placebo|
89418994|NCT03533088|Experimental|Hospitalized rehabilitation|Patients in this group will recieve rehabilitation program twice in a week at our clinic after the surgical procedure until post-operative 12 weeks.
88897222|NCT01478815|Placebo Comparator|Standard Care|
88897223|NCT01478815|Experimental|Contingency management for abstinence from drugs|
88897224|NCT01478841|Experimental|Polyphenols|9 weeks of supplementation with polyphenols(D56) and during the last week supplementation with polyphenols associated with a fructose load during the last 6 days (D63).
88897225|NCT01478841|Placebo Comparator|placebo|9 weeks of supplementation with placebo (D56) and during the last week supplementation with placebo associated with a fructose load during the last 6 days (D63).
88897226|NCT01478867||Celiac patients|
88897227|NCT01478880|Experimental|cTBS|
88897228|NCT01478880|Sham Comparator|Sham cTBS|
88897229|NCT01478893|Experimental|SEL-068|
88897230|NCT01478893|Placebo Comparator|Saline|
88897231|NCT01477905|Experimental|Remi50 no prime|For using experimental target control infusion device (TCIs), targeting an effect-site concentration (Ceff) of 4.0 ng/ml, were randomly performed using 50 μg/ml (Remi50) of remifentanil, and without PRIMING,
88897232|NCT01477905|Experimental|Remi20 no prmie|For using experimental TCIs, targeting an effect-site concentration (Ceff) of 4.0 ng/ml, was 20 μg/ml (Remi20) of remifentanil, and without PRIMING
88897233|NCT01478906||elderly ,adult|
88897234|NCT01478945|Active Comparator|Dermfix 1000 active 311 nm NB-UVB|"Active hand held NB-UVB unit:~Manual device administering NB-UVB"
88897235|NCT01478945|Active Comparator|Waldmann active 311 nm NB-UVB|"Active hand held NB-UVB unit:~Manual device administering NB-UVB (Waldmann)"
88897236|NCT01478945|Sham Comparator|Dermfix 1000 placebo|Manual placebo hand held NB-UVB unit
88897237|NCT01478984|Active Comparator|one staged PCI|the patient randomized to this arms complete the myocardial revascularization in one stage PCI, the investigators treat all lesions.
88897238|NCT01478984|Active Comparator|multistaged PCI|the patients randomized to this arms in the first stage the investigators treat only the culprit lesion and in second stage the investigators treat the other vessels
88897239|NCT01478997|Experimental|Flexsure Capsules|Investigational Product
89193953|NCT03034174||tigecycline|"Each patient will receive: tigecycline (200 mg q 12 hours i.v.), meropenem (2 g q 8 hours i.v). In each case CVVHD will be started.~Blood samples (3 mL) will be collected 2, 4, 8 and 12 hours after each dose of tigecycline for 3 consecutive days."
88897240|NCT01478997|Placebo Comparator|Carboxy Methyl Cellulose Capsules|Placebo
88897241|NCT01479023|Experimental|Cohort 1|"64Cu-DOTA-U3-1287 at a radiotracer dosage of 8-15 mCI and ≤ 0.2 mg of DOTA-U3-1287 on Day 1.~Patient will have option to continue to Part 2 (extension phase)."
88897242|NCT01479023|Experimental|Cohort 2|"64Cu-DOTA-U3-1287 at the radiotracer dosage defined by Cohort 1 and ≤ 0.2 mg of DOTA-U3-1287 on Day 1.~9.0 mg/kg unlabeled U3-1287 followed by a second dose of ≤ 0.2 mg 64Cu-DOTA-U3-1287 on Day 8.~Patient will have option to continue to Part 2 (extension phase)."
88897243|NCT01479023|Experimental|Cohort 3|"64Cu-DOTA-U3-1287 at the radiotracer dosage defined by Cohort 1 and ≤ 0.2 mg of DOTA-U3-1287 on Day 1.~12.0 mg/kg unlabeled U3-1287 followed by a second dose of ≤ 0.2 mg 64Cu-DOTA-U3-1287 on Day 8.~Patient will have option to continue to Part 2 (extension phase)."
88897244|NCT01479023|Experimental|Cohort 3a|"64Cu-DOTA-U3-1287 at the radiotracer dosage defined by Cohort 1 and ≤ 0.2 mg of DOTA-U3-1287 on Day 1.~15.0 mg/kg unlabeled U3-1287 followed by a second dose of ≤ 0.2 mg 64Cu-DOTA-U3-1287 on Day 8.~Patient will have option to continue to Part 2 (extension phase)."
88897245|NCT01479023|Experimental|Cohort 4|"64Cu-DOTA-U3-1287 at the radiotracer dosage defined by Cohort 1 and ≤ 0.2 mg of DOTA-U3-1287 on Day 1.~18.0 mg/kg unlabeled U3-1287 followed by a second dose of ≤ 0.2 mg 64Cu-DOTA-U3-1287 on Day 8.~Patient will have option to continue to Part 2 (extension phase)."
88897246|NCT01479023|Experimental|Cohort 5|"64Cu-DOTA-U3-1287 at the radiotracer dosage defined by Cohort 1 and ≤ 0.2 mg of DOTA-U3-1287 on Day 1.~TBD (to be determined) mg/kg unlabeled U3-1287 followed by a second dose of ≤ 0.2 mg 64Cu-DOTA-U3-1287 on Day 8.~Patient will have option to continue to Part 2 (extension phase)."
89193954|NCT03031626|Experimental|Arm A: Medical air followed by oxygen|
89193955|NCT03031626|Experimental|Arm B: Oxygen followed by medical air|
89193956|NCT03031210|Experimental|Twice a day regimen|Patients will received a prescription of amoxicillin (90mg/kg/day) divided in two doses daily.
89193957|NCT03031210|Active Comparator|Thrice a day regimen|Patients will received a prescription of amoxicillin (90mg/kg/day) divided in three doses daily.
89193958|NCT03025984|Active Comparator|Texting|"Patients in the Texting group will receive reminders based on their individual disease treatment. A text message shall be sent one day (12 to 36 hours) before appointments to remind about the appointment and with instructions to bring glucose and food records to the appointment. If medication changes are made at the appointment, the patient will receive a text message reminder the day after her appointment to reinforce the regimen. Postpartum patients who had GDM will receive a text message reminder to complete their glucose tolerance test. A reminder will be sent at 2 weeks postpartum followed by a reminder at 6 weeks and 10 weeks postpartum if the testing is not completed."
89193959|NCT03025984|No Intervention|No texting|Patients in the contact control group will be enrolled in the text4baby program with assistance from a healthcare provider. As the study will conclude upon the patient's postpartum visit, she will be offered the option of discontinuing messages, which otherwise would continue through the infant's first year of life.
89193960|NCT03025932||Patient cohort|Patients who underwent laparoscopic hernia repair of giant hiatal hernia with mesh and received anterior fundoplication
89193961|NCT03018262||Healthy Volunteers - Sub-study 1|Healthy Volunteers
89193962|NCT03018262||Healthy Volunteers - Sub-study 2|Healthy Volunteers
89193963|NCT03018262||Healthy Volunteers - Sub-study 3|Healthy Volunteers
89193964|NCT03017586|Experimental|STN|DBS target with Subthalamic Nucleus (STN).
89193965|NCT03017586|Experimental|GPi|DBS target with Globus Pallidus Internus (GPi).
89193966|NCT03001869|Experimental|68Ga-PSMA PET/CT|68Ga-HBED-CC-PSMA PET/CT
89193967|NCT02996877||Guideline Directed Medical Therapy|Patients who have an initial treatment strategy of using guideline-directed medical therapy only.
89193968|NCT02996877||Percutaneous Coronary Intervention|Patients who will have a Percutaneous Coronary Intervention as the initial treatment strategy along with guideline directed medical therapy.
89193969|NCT02988921|Experimental|Esophageal or esophagogastric cancer|
89193970|NCT02986672|Active Comparator|Calanus oil|Children receiving omega-3 in form om calanus oil in capsule form
89193971|NCT02986672|Placebo Comparator|Placebo|Children receiving medical paraffin in capsule form (2 ml volume per day)
89193972|NCT02983565|No Intervention|Sleep study on usual long-term oxygen therapy flow rate|Participants will have a sleep study on their usual LTOT flow rate.
89193973|NCT02983565|Experimental|Sleep study on the intelligent oxygen therapy system|Participants will have a sleep study on the intelligent oxygen therapy system. This system will supply variable flow oxygen to match a pre-set oxygen saturation target of 93% during sleep.
88897247|NCT01479023|Experimental|Part 2 (extension phase)|Loading dose of 18.0 mg/kg unlabeled U3-1287 followed by 9.0 mg/kg unlabeled U3-1287 every 3 weeks.
88897248|NCT01479036|Active Comparator|docetaxel and epirubicin|DE chemotherapy alone
88897249|NCT01479036|Experimental|docetaxel and epirubicin plus endostatin|chemotherapy plus endostatin
88897250|NCT01479049|Experimental|MP group|Hearts are arrested with cold blood cardioplegia with moderate potassium concentration (K+, 10mmol/L) during cardiac surgery.
88897251|NCT01479049|Active Comparator|HP group|Hearts were arrested with cold blood cardioplegia with high potassium concentration (K+, 20mmol/L) during cardiac operation
88897252|NCT01479062|Experimental|participation in Alive-PD|Alive-PD lifestyle intervention with multi-channel delivery
88897253|NCT01479062|Placebo Comparator|Control|Usual care
88897254|NCT01479088|Experimental|cinacalcet tab or extemporaneous solution po added to SoC|"Subjects who meet all inclusion/exclusion criteria at baseline will be given cinacalcet 30mg film-coated tablet, for oral use added to phosphate binders and vitamin D analogue.~For subjects receiving a cinacalcet dose <30mg, commercially available cinacalcet 30mg tab will be ground and diluted with a 5% dextrose solution. Then, an aliquot of this solution corresponding to the individually prescribed dose will be administered as indicated.~Initial dosing of cinacalcet will be 0.5-0.75mg/kg or 30 mg po once daily (OD) each evening with food.~During the cinacalcet dose-titration 6-month period for efficacy assessment, the dose will be increased on monthly basis by 0.5 mg/kg or by 30mg OD to achieve the target iPTH value <180 pg/mL, as tolerated by the subject, up to maximum of 180mg OD in absence of signs of hypocalcemia, according to the current summary of product characteristics."
88897255|NCT01479101||MammaPrint, BluePrint, neo-adj CT or HT|All patients receive the MammaPrint and BluePrint gene expression profile. Treatment at the discretion of the physician while adhering to NCCN guidelines.
88897256|NCT01479114|No Intervention|control group|
88897257|NCT01479114|Experimental|G-CSF group|
88897258|NCT01479114|No Intervention|Non-GCSF group|
88897259|NCT01479153|Active Comparator|Subclavian catheterization|
88897260|NCT01479153|Active Comparator|Internal Jugular catheterization|
88897261|NCT01479153|Active Comparator|Femoral Catheterization|
88897262|NCT01479166||affected patients with small airway disease (SAD)|20 patients suffering from mild cystic fibrosis and involvement of small airways
88897263|NCT01479166||affected patients without small airway disease (SAD)|20 patients suffering from mild cystic fibrosis without SAD
88897264|NCT01479166||non-affected patients|20 matched controls not suffering from cystic fibrosis
89193974|NCT02981615|Experimental|treatment arm|Subjects allocated to the treatment arm of the study will be administrated Levofloxacin 500mg/d given p.o. once a day, starting on day 10 from beginning of each cycle until day 28 on an ambulatory basis. Levofloxacin will be continued in the first 4 Azacytidine cycles.
89193975|NCT02981615|Placebo Comparator|placebo|Subject allocated to the placebo arm will be treated with placebo once a day, starting on day 10 from beginning until day 28 of each of the first 4 cycles.
89193976|NCT02963363|Experimental|Interventional|"Home-Based Adapted Physical Activity intervention during neoadjuvant chemotherapy :~150 minutes per week of aerobic and muscle strengthening exercises during 18 weeks"
89193977|NCT02944799|Active Comparator|Alendronate|Continues treatment with alendronate, 70mgs oral tablet once every week
89193978|NCT02944799|Placebo Comparator|Placebo|Placebo tablets, one every week
88897265|NCT01479179|Experimental|AMG 479 + Trastuzumab|AMG 479 18 mg/kg or 12 mg/kg intravenously (IV) 30 minutes after trastuzumab. Trastuzumab loading dose (Week 1) 8 mg/kg IV over 90 minutes; maintenance dose 6 mg/kg IV over 30 minutes every 3 weeks.
88897266|NCT01479192|Experimental|Fenretinide|100mg: 2cps/day for 5 years followed by
88897267|NCT01479192|Placebo Comparator|Placebo|matched placebo 2 cps/day for 5 years
88897268|NCT01479205||mite allergic patients without SIT|patients suffering from allergic asthma/ rhino-conjunctivitis denying specific immunotherapy
88897269|NCT01479205||mite allergic patients with SIT|patients suffering from allergic asthma/ rhino-conjunctivitis undergoing mite specific immunotherapy
88897270|NCT01479231|Experimental|dexlansoprazole|
88897271|NCT01479244|Experimental|NeuVax™|NeuVax™ in WFI solution with Leukine®
88897272|NCT01479244|Active Comparator|Leukine®|Leukine® with WFI
88897273|NCT01479257||Bilingual Latinos|Bilingual Houston area Latinos surveyed for 7 continuous days with objective and subjective assessments using accelerometer and smart phone.
88897274|NCT01479283|Active Comparator|Short-Arm Antibiotic Regimen|"Intervention: 24-Hour Prophylactic Cefazolin* Antibiotic Regimen~*or another cephalosporin with equivalent gram-positive coverage in centers where cefazolin is not routinely used or not approved for use"
88897275|NCT01479283|Experimental|Long-Arm Antibiotic Regimen|"Intervention: 5-Days Prophylactic Cefazolin* Antibiotic Regimen~*or another cephalosporin with equivalent gram-positive coverage in centers where cefazolin is not routinely used or not approved for use"
88897276|NCT01479296|Experimental|Group 1: rAd5 Plus Placebo|Participants will receive the VRC rAd5 gag-pol/env A/B/C vaccine injection in their right arm (1×10^10 PU), and placebo vaccine injections in their left arm, right thigh, and left thigh.
89006635|NCT04620109|Active Comparator|SDE 0.06 mg/eye|Actual dose is 0.06 mg/eye by 60μL KDR2-2 eyedrops of a concentration of 1.0 mg/mL for 1 time.
89193979|NCT02940951|Other|Usual home care provided by clinicians|Usual care provided by the home health clinicians. This may or may not include use of some standardized forms of quality of life assessment that were in place prior to the study beginning.
89193980|NCT02940951|Experimental|Use of QPSS by home health clinicians|Usual home care plus the use of the Quality of Life Assessment and Practice Support System (QPSS) to document, monitor and address the quality of life concerns of patients and family caregivers.
89193981|NCT02923947|Experimental|Normal renal function|For inclusion in the study as a patient with normal renal function, patients must have creatinine clearance ≥90 mL/min.
89418995|NCT03533088|Experimental|Home-based rehabilitation|Patients in his groups will performed home-based rehabilitation in the early stages of the post-op period. They will com to our clinic once in a two weeks and the recieve the exercise program to perform at home until the 6. weeks of the post-operative period. After the 6. week they will come to our clinic once in a week until the post-operative 12. week.
89418996|NCT02202408|Experimental|SKI2670|"Single-dose escalation/ Subjects received an oral single dose of SKI2670 capsule by dosing group~-Dosing Group 1, Dosing Group 2, Dosing Group 3, Dosing Group 4"
89418997|NCT02202408|Placebo Comparator|Placebo|Subjects received an oral single dose of placebo capsule matched to the SKI2670 dose (Placebo for SKI2670)
89418998|NCT02202486||Migraine with aura|Brain MRI
89418999|NCT02202486||Migraine without aura|Brain MRI
88897277|NCT01479296|Experimental|Group 2: Separated Vaccine Components|Participants will receive the rAd5 gag-pol vaccine injection in their right arm (0.5×10^10 PU), the rAd5 env A vaccine injection in their left arm (0.17×10^10 PU), the rAd5 env B vaccine injection in their right thigh (0.17×10^10 PU), and the rAd5 env C vaccine injection in their left thigh (0.17×10^10 PU).
88897278|NCT01479296|Experimental|Group 3: Divided Dose rAd5|Participants will receive the VRC rAd5 gag-pol/env A/B/C vaccine injection divided into fourths, with one fourth of the total dose given in each of 4 sites: right arm, left arm, right thigh, and left thigh (each at 0.25×10^10 PU).
88897279|NCT01479387||Group 1|
88897280|NCT01479400||infants who were exposed to antipsychotics as fetus|
88897281|NCT01479400||infants who were not exposed to antipsychotics as fetus|
88897282|NCT01479413||Schizophrenia|
88897283|NCT01479452|Other|Bariatric surgery|Bariatric surgery
89419000|NCT02202486||Chronic migraine|Brain MRI
89419001|NCT02202564|Experimental|LT+ADV-TK|Liver transplantation and double-dose ADV-TK/ganciclovir administration The first ADV-TK dose was administered before closing the peritoneal layer; the second ADV-TK dose was administered 2 months after LT; ganciclovir was slowly administered 36 hours after LT and twice daily for 14 days.
89419002|NCT02202564|Active Comparator|LT|Orthotopic liver transplantation
89419003|NCT02202642|Experimental|limbal stem cells|"Using collagenase to isolate limbal stem cells and improve the technique of ex vivo expansion of limbal stem cells for the treatment of patients suffering from unilateral limbal stem cell insufficiency based on the concept of limbal stem cells need special cell-cell contact and cell-extracellular matrix interaction to support their survival"
89419004|NCT02198508|Active Comparator|DFX single treatment|a single oral dose of DFX 30 mg/kg once daily, (Exjade®, Novartis Pharmaceuticals Corporation, USA )
89419005|NCT02198508|Active Comparator|DFP single treatment|single oral dose of DFP 40 mg/kg/day twice a day, (Kelfer®, Cipla Ltd., India)
89419006|NCT02198508|Experimental|combination treatment|sequential oral doses of DFX 30 mg/kg/d, DFP 40 mg/kg/d and DFP 40 mg/kg/d (dosing interval: seven hours).
89419007|NCT03533634|Experimental|superior group|this group with midshaft clavicle fracture were treated with superior reconstruction plate
89419008|NCT03533634|Experimental|anteroinferior group|this group with midshaft clavicle fracture were treated with anteroinferior reconstruction plate
89419009|NCT02202720|Experimental|sevoflurane|
89419010|NCT02206308|Experimental|single arm|Three escalating single-dose groups of chimeric anti-CD20 monoclonal antibody(SCT400) : 250 mg/m2 , 375 mg/m2，500 mg/m2, once a week for 4 doses;
89419011|NCT03686839|Experimental|SMR neurofeedback training to MCI|"Sensorimotor rhythm neurofeedback protocol consisted of 20 individual sessions, twice a week, during 11 weeks maximum. For each subject MCI, NF was planned and conducted by a neuropsychologist experienced in neurophysiology and neurofeedback. Each session lasted 1h10-15min and was conducted as follows:~Preparation and installation of the electrodes, verification of the impedance, adjustment of the calibration and thresholds (15 minutes).~NF training (tasks and video described below) (45 minutes).~Feedback and debriefing about the session (15 minutes)."
89419012|NCT02202798||Syringe device|Endotracheal tube cuff pressure measured by 2 new syringe devices.
89419013|NCT02202876|Active Comparator|Aim 1: Children with Cystic Fibrosis|Cystic Fibrosis children aged 1 to 9 years with normal glucose tolerance receiving Oral Glucose Tolerance Test
88897284|NCT01479452|Other|Controls|Usual care
88897285|NCT01479491||Case Group|Children aged < 12 months presenting with IS and covered by the Japan Medical Data Centre Company Limited (JMDC), Tokyo referred to as the JMDC Medical Data Bank (JMDC-MDB).
88897286|NCT01479504|Experimental|1A(nedaplatin and IMRT)|neoadjuvant chemotherapy using nedaplatin plus docetaxel followed by concurrent chemotherapy using nedaplatin and Intensity-modulated Radiation Therapy(IMRT)
88897287|NCT01479504|Active Comparator|1B(cisplatin and IMRT)|neoadjuvant chemotherapy using cisplatin plus docetaxel followed by concurrent chemotherapy using cisplatin and Intensity-modulated Radiation Therapy(IMRT)
88897288|NCT01479504|Experimental|2A(nedaplatin and CRT)|neoadjuvant chemotherapy using nedaplatin plus docetaxel followed by concurrent chemotherapy using nedaplatin and conventional fractionation radiotherapy(CRT)
88897289|NCT01479504|Active Comparator|2B((cisplatin and CRT))|neoadjuvant chemotherapy using cisplatin plus docetaxel followed by concurrent chemotherapy using cisplatin and conventional fractionation radiotherapy(CRT)
88897290|NCT01479556|Placebo Comparator|Placebo|Study subjects wil be randomized to the Placebo arm following a stratification procedure based on AIS scale (A-E), neurological level of injury (cervical or thoracic), and presence of at-level neuropathic pain before or after 3 months from the time of spinal cord injury.
88897291|NCT01479556|Active Comparator|Pregabalin|Study subjects wil be randomized to the Pregabalin arm following a stratification procedure based on AIS scale (A-E), neurological level of injury (cervical or thoracic), and presence of at-level neuropathic pain before or after 3 months from the time of spinal cord injury.
88897292|NCT01479634|Active Comparator|Arm A|Treatment for HIV in participants with CD4+ cell counts 250-350 cells/uL
88897293|NCT01479634|Active Comparator|Arm B|Treatment for HIV in participants with CD4+ cell counts >350 cells/uL
88897294|NCT01479647|Experimental|PH-797804 1 mg Fasted|Subjects will receive a single 1 mg dose in the fasted state
88897295|NCT01479647|Experimental|PH-797804 1 mg Fed|Subjects will receive a single 1 mg dose following a high-fat meal
88897296|NCT01479647|Experimental|PH-797804 10 mg Fasted|Subjects will receive a single 10 mg dose in the fasted state
88897297|NCT01479647|Experimental|PH-797804 10 mg Fed|Subjects will receive a single 10 mg dose following a high-fat meal
88897298|NCT01479647|Experimental|PH-797804 24 mg Fed|Subjects will receive a single 24 mg dose following a high-fat meal
88897299|NCT01479660|Placebo Comparator|Control|
88897300|NCT01479660|Experimental|Probiotic|
88897301|NCT01479673|No Intervention|Control group|"Patients in this group will receive enteral nutrition/parenteral nutrition or combination of enteral and parenteral nutrition according to the liberal  regimen, i.e. according to local practice."
88897302|NCT01479673|Experimental|Indirect Calorimetry|Study group: Indirect Calorimetry (IC) Patients in this group will receive enteral nutrition/parenteral nutrition or combination of enteral and parenteral nutrition according to the individual energy requirements calculated by Indirect Calorimetry measurement of Resting Energy Expenditure (REE).
88897303|NCT01479686|Active Comparator|conventional neuronavigation|conventional neuronavigation guided resection in adults with glioma
89419014|NCT02202876|Active Comparator|Aim 1: Control Children|Children with out Cystic Fibrosis aged 1 to 9 years controls with normal glucose tolerance receiving Oral Glucose Tolerance Test
89419015|NCT02202876|Active Comparator|Aim 2a: Teens with Cystic Fibrosis - High Glycemic Meal|Cystic Fibrosis subjects 12 years of age or older with normal glucose tolerance eating High Glycemic Index Meal
88897304|NCT01479686|Experimental|intraoperative MRI|iMRI guided resection in adults with glioma
88897305|NCT01479699|Placebo Comparator|Placebo capsule|Four placebo capsules containing safflower oil only
88897306|NCT01479699|Active Comparator|Olive leaf extract capsule|Four olive leaf capsules. Each containing 4mg oleuropein plus safflower oil.
88897307|NCT01479712|Active Comparator|Irrigation|This is the arm that will receive irrigation.
88897308|NCT01479712|No Intervention|No Irrigation|This is the arm that will not receive irrigation.
89419016|NCT02202876|Active Comparator|Aim 2a: Teens with Cystic Fibrosis - Low Glycemic Meal|Cystic Fibrosis subjects 12 years of age or older with normal glucose tolerance eating Low Glycemic Index Meal
88897309|NCT01479738|Experimental|Capitate bone grafting|18 patients with PIP joint defects were included in the study. There were 13 male and 5 female patients with a mean age of 31 years (range, 18-47 years). The injury occurred in the right hand in 11 patients and on the left hand in 7. The injured PIP joints were in the index finger (n=7), long finger (n=9), and ring finger (n=2).
88897310|NCT01479751|Experimental|ketamine|Patients receive ketamine 0.5 mg/kg 2 min before Roc injection.
88897311|NCT01479751|Experimental|priming|Patients receive Roc 0.06 mg/ kg as a priming dose 3 min before injection of Roc 0.54 mg/kg.
88897312|NCT01479751|No Intervention|Roc 0.9|Patients receive Roc 0.9 mg/kg as an induction dose.
88897313|NCT01479751|No Intervention|Control|Patients receive Roc 0.6 mg/kg without any pretreatments of Mg, ketamine, or priming.
88897314|NCT01479751|Experimental|Mg|Patients receive magnesium sulfate (MgSO4) 50 mg/kg over 10 min before Roc injection.
88897315|NCT01479790|No Intervention|Visante AS-OCT and Cirrus AS-OCT|The tear meniscus is the thin concave strip of the tear film near the eyelid margins. During the acquisition the participants place their chins on a chin rest and look at a fixation light/target. This whole procedure should not take more than 5 minutes. The patients are allowed to blink freely except for during the acquisition time of less than 5 seconds. The procedure will be repeated for the upper and lower tear meniscus of both eyes.
88897316|NCT01479790|Experimental|Thermography measurement|"In total, four pairs of thermographic sequences on the ocluar surface temperature from volunteers will be taken.~A thermographic sequence will be captured from each eye.~After 20 minutes, a second pair of thermographic sequences will be captured.~An eye mask with a temperature of not more than 40 deg C (will be worn by the volunteer for 5 minutes and a third pair of thermographic sequences will be captured immediately after mask removal.~A fourth pair of thermographic sequences will be captured 1 hour after mask removal."
88897317|NCT01479803|Active Comparator|EchoTip HD ProCore 22 Gauge|first passage in the pancreatic tumor with the EchoTip HD ProCore 22 Gauge then with the EchoTip 22 Gauge
88897318|NCT01479803|Active Comparator|Echo Tip 22 Gauge|First passage through the tumor with the EchoTip 22 Gauge then with Echotip HD ProCore 22 Gauge
88897319|NCT01479829|Active Comparator|ESC + CBX|Escitalopram 10 mg twice day plus Celecoxib 200 mg twice daily.
88897320|NCT01479829|Placebo Comparator|ESC + PBO.|Escitalopram 10 mg twice day plus placebo administered twice daily.
88897321|NCT01479855||Patients|Patients referred to a memory clinic due to memory problems and their healthy spouse
88897322|NCT01479881|Experimental|001|a single 100-mg dose of cyclosporine, and after a wash out period of at least 10 days, TMC435 150 mg once daily (q.d.) for 10 days on Days 1 to 10, coadministered with a single 100-mg dose of cyclosporine on Day 7.
89193982|NCT02923947|Experimental|Severe renal impairment|For inclusion in the study as a patient with severe renal impairment, patients must have stable severe renal impairment (creatinine clearance <30 mL/min), as defined by the Cockcroft Gault equation, for at least 2 months prior to Day 1.
88897323|NCT01479881|Experimental|002|TMC435 150 mg once daily (q.d.) for 10 days on Days 1 to 10, coadministered with a single 100-mg dose of cyclosporine on Day 7 and after a wash out period of at least 10 days, a single 100-mg dose of cyclosporine.
88897324|NCT01479881|Experimental|003|a single 2-mg dose of tacrolimus on Day 1. After a wash out period of at least 10 days, participants will receive TMC435 150 mg q.d. for 12 days on Days 1 to 12, coadministered with a single 2-mg dose of tacrolimus on Day 7.
88897325|NCT01479881|Experimental|004|TMC435 150 mg q.d. for 12 days on Days 1 to 12, coadministered with a single 2-mg dose of tacrolimus on Day 7. After a wash out period of at least 10 days, participants receive a single 2-mg dose of tacrolimus.
88897326|NCT01479894||Sample Collection|This is an exploratory study utilizing archived tumor specimens and demographic and pathologic characteristics derived from the patient's medical charts. As such, all eligible patients must have a stored tumor specimen which can be accessed for analysis.
88897327|NCT01479907|Active Comparator|Synbiotics|"A specific multistrain/multifi ber synbiotic composition of prebiotics and probiotics (Synbiotic Forte™, IONIA Pharmaceuticals, Athens, Greece) was administered at the active comparator arm of the study. It contained 10 [11] of each of four lactic acid bacteria (LAB): Pediococcus pentosaceus 5-33:3, Leuconostoc mesenteroides 32-77:1, Lactobacillus paracasei ssp. paracasei 19, and Lactobacillus plantarum 2362, and 2.5 g of each of the four fermentable fibers (prebiotics): b-glucan, inulin, pectin and resistant starch. The synbiotics were delivered in sachets and then mixed with water (12 g in 250 mLof water once daily). Th e treatment started on the day patients tolerated per os liquid intake (2nd-4th POD). The intervention period lasted 15 days."
88897328|NCT01479907|Placebo Comparator|Placebo|The patients belonging to the placebo comparator arm received only the 4 fi bers and no LAB (12 gin 250 mLof water once daily for 15 days). All the subjects were interviewed by a dedicated research fellow (KP) and reactions to the product, and any adverse events occurring in the 15-day period were recorded.
88897329|NCT01479920|Active Comparator|DCEAS|"Dense cranial electroacupuncture stimulation (DCEAS)~For those who were currently under antidepressant treatment, they would continue the existing treatment regimens. For those who were not medicated at the time of trial, fluoxetine (FLX) was given at an initiate dose of 10 mg/day and escalated to an optimal dose within one week, based on individual response, but the maximum dose was set at 40 mg/day."
88897330|NCT01479920|Sham Comparator|n-CEA|"Non-invasive cranial electroacupuncture (n-CEA)~For those who were currently under antidepressant treatment, they would continue the existing treatment regimens. For those who were not medicated at the time of trial, fluoxetine (FLX) was given at an initiate dose of 10 mg/day and escalated to an optimal dose within one week, based on individual response, but the maximum dose was set at 40 mg/day."
88897331|NCT01479933|Experimental|Vitamin D 40|Vitamin D3 40 micrograms (1600 IU) per day
88897332|NCT01479933|Experimental|Vitamin D 80|Vitamin D3 80 micrograms (3200 IU) per day
88897333|NCT01479933|Placebo Comparator|Placebo|
88897334|NCT01479946|Experimental|Early Electrochemotherapy|Electrochemotherapy is given as early as possible after the discovery of skin metastases
88897335|NCT01479946|No Intervention|Delayed or no Electrochemotherapy|patients are to be treated for their breast cancer according to clinical routine with electrochemotherapy as an option only after 6 months from randomization
88897336|NCT01479959|Active Comparator|No PEEP level|protocol conducted while no PEEP is applied
88897337|NCT01479959|Active Comparator|effective PEEP level (PEEPeff)|PEEP level allowing the entire expiratory volume to go through the upper airways during quiet breathing
88897338|NCT01479959|Active Comparator|intermediate PEEP level (PEEP50)|50% of PEEPeff
88897339|NCT01479972|Experimental|VPM1002|
88897340|NCT01479972|Active Comparator|BCG|
89193983|NCT02914535|Experimental|Filgotinib 200 mg (blinded dosing)|Filgotinib 200 mg + placebo to match filgotinib 100 mg for up to 336 weeks
89419017|NCT02202876|Active Comparator|Aim 2b: Cystic Fibrosis Consuming Test Soda|Participants with Cystic Fibrosis 12 years of age or older with normal glucose tolerance or impaired glucose tolerance consuming a test beverage of a test soda. A week later these participants will have an Oral Glucose Tolerance Test.
89419018|NCT02202876|Active Comparator|Aim 2b: Cystic Fibrosis Consuming Fruit Juice|Participants with Cystic Fibrosis 12 years of age or older with normal glucose tolerance or impaired glucose tolerance consuming a test beverage of fruit juice. A week later these participants will have an Oral Glucose Tolerance Test.
89419019|NCT03686761|Experimental|Study|A Involvement with the osteotomy site of the surgery, osteotomy was performed then GCF were collected from teeth neighboring the
89419020|NCT03686761|Active Comparator|Control|Involvement with the osteotomy site of the surgery, surgical osteotomy was performed then GCF were collected from teeth away from the osteotomy site
89419021|NCT02206386|Experimental|MentalHealthTraining-Net|MHTraining-Net is an implementation strategy that uses a web-based platform with several long distance tools (e.g. e-learning modules, consultation, telephone calls, toolkits, and discussion boards) to deliver four types of implementation activities: infrastructure development, training and education, quality improvement, and social networking.
89419022|NCT02206386|Active Comparator|Enhanced Support|Nurses in agencies randomized to Enhanced Support have full access to the study protocol and to recorded trainings in the use of the protocol and depression screening posted by Brightree.
89419023|NCT03028129|Experimental|Treatment|Each subject received two oral supervised weekly doses of isoniazid 900 milligrams.
88897341|NCT01479998|Active Comparator|Standard care and nicotine replacement therapy|standard care is 4 counseling sessions and nicotine replacement therapy
88897342|NCT01479998|Experimental|standard care plus NRT plus contingency management|standard care is 4 counseling sessions and nicotine replacement therapy plus 3 weekly meetings with positive reinforcers
88897343|NCT01480011|Experimental|lactobacillus lozenges|The study drug contains not less than 2x109 (2 billion) viable cells of Lactobacillus CD2 as active ingredient
88897344|NCT01480037||Elderly|Individuals between 60 and 70 years-old
88897345|NCT01480037||Long-lived|Individuals above 85 years-old
88897346|NCT01480037||Young|Individuals between 20 and 30 years-old
88897347|NCT01480050|Experimental|Dose Finding and Dose Expansion|"DOSE FINDING 4 Levels~For all Levels:~Cycle 1 Mibefradil QID dosing, Days 1-8 (to accommodate PKs) (*2 doses on Days 1 and 8) Temozolomide daily at 150-200 mg/m2, Days 9-13;~Cycles 2+ Mibefradil QID, Days 1-7 Temozolomide daily at 150-200 mg/m2, Days 8-12~DOSE EXPANSION 28-day cycles FLT PET scans, Baseline x2, Day 7 Mibefradil MTD determined at Dose Finding QID, Days 1-7 Temozolomide daily at 150-200 mg/m2, Days 8-12"
88897348|NCT01480063||Fampyra|Fampyra administered as prescribed in routine clinical practice.
88897349|NCT01480102|Placebo Comparator|Group B- No Block|Participants randodmized to this arm will have a local anesthetic injection and pressure applied to the paravertebral space. A paravertebral injection will not be conducted.
88897350|NCT01480102|Active Comparator|Group A- Paravertebral block|Participants randodmized to this arm will have a local anesthetic (Bupivicaine 0.5% without epinephrine) injection and will be given a paravetebral block into the T10 paravertebral space..
88897351|NCT01480141|Experimental|Single Arm Study|Single arm trial where all patients will be treated with afatinib until the day of surgery and for a minimum of two weeks. Patients will receive treatment with afatinib 40mg orally daily.
88897352|NCT01480167|Active Comparator|RF-TVA with STABILIT Vertebral Augmentation System|All RadioFrequency-Targeted Vertebral Augmentation (RF-TVA) arm participants will be treated with the StabiliT Vertebral Augmentation System. This system is a commercially available device in the United States designed to perform percutaneous vertebral augmentation (also known as kyphoplasty).
88897353|NCT01480167|Active Comparator|Non Operative Management|All non-operative management (NOM) arm participants will receive non-operative standard of care management, which can include: analgesics, bed rest, back braces, physiotherapy, rehabilitation programs, and walking aids according to standard practices of participating institutions.
88897354|NCT01480180|Experimental|Prophylaxis|
89419024|NCT03028129|Placebo Comparator|Control|Each subject received two oral supervised weekly doses of placebo (oral tablet, without the active ingredient, similar in size, weight, color, taste and odor).
89419025|NCT02202954|Active Comparator|Guided Self-rehabilitation Contract|"In Guided Self-rehabilitation Contracts, the therapist acts as a coach, in the sports' sense, providing double guidance: technical, selecting and teaching the required exercises to the patient using infrequent thorough visits, for example every month; Psychological, binding with the patient on the contract.~The patient agrees to perform the prescribed daily stretch postures and rapid alternating movements over the long term and to document this work in a written diary."
89419026|NCT02202954|No Intervention|Conventional rehabilitation|conventional therapy in the community
88897355|NCT01480180|Experimental|On-demand|
88897356|NCT01480193|Active Comparator|Sound Based and Educational Therapies|The SBE program will consist of two hour-long individual counseling and sound therapy sessions based on the Department of Veterans Affairs Progressive Audiologic Tinnitus Management approach. SBE treatment incorporates the use of education, counseling, increased relaxation and decreased stress, along with the integration of sound therapy to better manage the impact of tinnitus.
88897357|NCT01480193|Experimental|Integrative Medicine Therapies and SBE|2 Sound Based and Educational Sessions 3 Cognitive Based Therapy Sessions 9 Telephonic Health Coaching Sessions 5 Acupuncture Sessions Group-Based 8 week Mindfulness Based Stress Reduction
88897358|NCT01480245|Experimental|Continuous Dosing|GSK2402968 6mg/kg/week
88897359|NCT01480245|Experimental|Intermittent Dosing|GSK2402968 6mg/kg/week
88897360|NCT01480245|No Intervention|Natural History Observation|The objective of this arm will be to explore DMD disease progression in a naturalistic setting once discontinuing active treatment
88897361|NCT01480271|Experimental|Part 1 Cohort 1 GSK2445053|2ng GSK2245053
88897362|NCT01480271|Placebo Comparator|Part 1 Cohort 1 Placebo|Placebo
89419027|NCT03660384|Experimental|SO|Subjects receive 1,000 centistoke silicone oil tamponade during vitrectomy
89419028|NCT03660384|Experimental|C3F8|Subjects receive 16% C3F8 gas tamponade during vitrectomy
88897363|NCT01480271|Experimental|Part 1 Cohort 2 GSK2445053|20ng GSK2445053
89419029|NCT04178317||Venetoclax Participants|Participants receiving venetoclax for chronic lymphocytic leukemia according to the approved local label, and the decision to prescribe Venetoclax is independent from the enrollment into the study.
88897364|NCT01480271|Placebo Comparator|Part 1 Cohort 2 Placebo|Placebo
88897365|NCT01480271|Experimental|Part 1 Cohort 3 GSK2245053|100ng GSK2445053
88897366|NCT01480271|Placebo Comparator|Part 1 Cohort 3 Placebo|Placebo
88897367|NCT01480271|Experimental|Part 1 Cohort 4 GSK2445053|200ng GSK2445053
88897368|NCT01480271|Placebo Comparator|Part 1 Cohort 4 Placebo|Placebo
88897369|NCT01480271|Experimental|Part 1 Cohort 5 GSK245053|400ng GSK2445053
88897370|NCT01480271|Placebo Comparator|Part 1 Cohort 5 Placebo|Placebo
88897371|NCT01480271|Experimental|Part 1 Cohort 6 GSK2445053|1000ng GSK2245053
89419030|NCT02206464|Experimental|Group 1|H7 DNA vaccine on Day 0 and H7N9 MIV at StudyWeek 16
88897372|NCT01480271|Placebo Comparator|Part 1 Cohort 6 Placebo|Placebo
88897373|NCT01480271|Experimental|Part 1 Cohort 7 GSK2445053|2000ng GSK2445053
88897374|NCT01480271|Placebo Comparator|Part 1 Cohort 7 Placebo|Placebo
88897375|NCT01480271|Experimental|Part 1 Cohort 8 GSK2445053|4000ng GSK2445053
88897376|NCT01480271|Placebo Comparator|Part 1 Cohort 8 Placebo|Placebo
88897377|NCT01480310|Experimental|A|
88897378|NCT01480310|Experimental|B|
88897379|NCT01480323|Experimental|Ipilimumab|Ipilimumab i.v. + Interleukin-2 intratumoral
88897380|NCT01480336|Placebo Comparator|Amiodarone with Placebo|
88897381|NCT01480336|Active Comparator|Amiodarone with Ranolazine|
88897382|NCT01480362|Experimental|Negative Pressure Wound Therapy|The therapy involves the controlled application of sub-atmospheric pressure to the local wound environment,using a sealed wound dressing connected to a vacuum pump.
88897383|NCT01480362|Active Comparator|Standard Wound Therapy|Standard wound therapy according to current evidence-based guideline(basic and advanced methods of wound treatment)
88897384|NCT01480375|Experimental|Navigo™ and Smartbx™ system.|all biopsy cores were handled using the Smartbx™ system. part of the procedures were performed with both Navigo™ and Smartbx™ system.
88897385|NCT01480375|No Intervention|standard method|all biopsy cores were handled using standard method - shaking the biopsy needle into formalin vial. no navigation system.
88897386|NCT01480388|Placebo Comparator|Placebo|
88897387|NCT01480388|Experimental|JNJ-39758979 (10 mg/d)|
88897388|NCT01480388|Experimental|JNJ-39758979 (30 mg/d)|
88897389|NCT01480388|Experimental|JNJ-39758979 (100 mg/d)|
88897390|NCT01480388|Experimental|JNJ-39758979 (300 mg/d)|
88897391|NCT01480414|Experimental|4times injection|the patients with ischemic lower limb ulcer who underwent 4times stem cell injection.
88897392|NCT01480414|Experimental|one injection|Patients with peripheral artery disease underwent cell transplantation just one time.
88897393|NCT01480453||Trabecular Metal Humeral Stem|Patients requiring primary, total or hemi shoulder arthroplasty who receive the Trabecular Metal Humeral Stem.
88897394|NCT01480466|Experimental|Obesity tools in electronic health record|This arm will consist of a new set of tools within the electronic health record to help primary care clinicians address overweight and obesity with their patients.
88897395|NCT01480466|No Intervention|Standard care|This arm is standard care for overweight/obesity.
88897396|NCT01480492|No Intervention|therapy|
88897397|NCT01480505||High myopic eye|Persons with high Myopia suffered from Rhegmatogenous Retinal detachment
88897398|NCT01480544|No Intervention|Mothers at endline|Data collected on new mothers (up to three weeks after childbirth) in 180 clusters with 100 mothers in each cluster at endline.
88897399|NCT01480544|Experimental|Treatment 1|Data collected on new mothers (up to three weeks after childbirth) and on providers with incentives for clinical improvements in quality of maternity care in the providers' patient populations and the catchment areas served by the providers.
88897400|NCT01480544|Experimental|Treatment 2|Data collected on new mothers (up to three weeks after childbirth) and on providers with incentives for improvement in maternal and infant health outcomes in the providers' patient populations and in the catchment areas served by the providers.
88897401|NCT01480544|No Intervention|Control|Data collected on new mothers (up to three weeks after childbirth) and providers with no incentives
88897402|NCT01480557|Active Comparator|Liquefaction group|Subjects that were operated for cataract using liquefaction technology
88897403|NCT01480557|Active Comparator|Torsional ip group|Subjects that were operated for cataract using torsional ip technology
88897404|NCT01480609|Active Comparator|Dose-Dialysis|Subjects will be dosed with study drug followed by a scheduled dialysis session
88897405|NCT01480609|Active Comparator|Dialysis-Dose|Subjects will be dosed following the completion of their scheduled dialysis session
88897406|NCT01480622|Experimental|TDF tablets|Tenofovir disoproxil fumarate tablets
88897407|NCT01480635||Incomplete Colonoscopy|
88897408|NCT01480648|Experimental|BI144807|Subjects receive a single oral dose of BI144807solution
88897409|NCT01480648|Placebo Comparator|Placebo|Subjects receive a single oral dose of placebo solution
88897410|NCT01480661|Active Comparator|Roflumilast|
88897411|NCT01480661|Placebo Comparator|Placebo|
88897412|NCT01480687|Experimental|Omega-3 fatty acid|
88897413|NCT01480687|Active Comparator|Ciprofibrate|
88897414|NCT01480700|Experimental|rich-eggs|subjects consume 2 eggs rich in lutein/zeaxanthin and DHA per day during 4 months
88897415|NCT01480700|Active Comparator|standard eggs|subjects consume 2 standard eggs per day
88897416|NCT01480713|Experimental|Monotherapy with IPs+ Raltegravir 400 mg|Lopinavir/r 400/100 mg every 12 hours + Raltegravir 400 mg every 12 hours or Darunavir/rit 800/100 mg every 24 hours + Raltegravir 400 mg every 12 hours
88897417|NCT01480726||Open vein harvest|Conventional open vein harvest from the lower leg
88897418|NCT01480726||Endoscopic vein harvest|Endoscopic vein harvest from the calf
89419031|NCT02206464|Experimental|Group 2|H7 DNA and H7N9 MIV administered on Day 0 and H7N9 MIV boost at Study Week 16
88897419|NCT01480739|Experimental|1|AZD5069 100 mg capsules (50 mg BD) for 7 days
88897420|NCT01480739|Experimental|2|Placebo twice daily for 7 days
88897421|NCT01480752|Active Comparator|Lornoxicam|
88897422|NCT01480752|Placebo Comparator|normal saline|
88897423|NCT01480752|Placebo Comparator|no injection|
88897424|NCT01480765|Placebo Comparator|Control: Placebo + Placebo|Placebo capsules and Placebo infusion
88897425|NCT01480765|Active Comparator|Pregabalin and Placebo infusion|Pregabalin capsules and Placebo infusion
88897426|NCT01480765|Active Comparator|Pregabalin + Ketamine infusion|Pregabalin capsules + Ketamine infusion
88897427|NCT01480778|Experimental|LNG+EE2|pill test contained levonorgestrel 0,15 mg and ethynil estradiol 0,03 mg per day over 21 days
88897428|NCT01480778|Active Comparator|Nordette|pill comparator contained levonorgestrel 0,15 mg and ethynil estradiol 0,03 mg per day over 21 days
88897429|NCT01480791|Active Comparator|Hydrochlorothiazide|Treatment of patients with hydrochlorothiazide and effect on small arteries
88897430|NCT01480791|Experimental|Aliskiren|Treatment of patients with aliskiren and effect on small arteries
88897431|NCT01480791|No Intervention|Normotensive non diabetic subjects|A comparator non intervention normotensive non diabetic group of healthy subjects will be used for baseline comparison of primary and secondary endpoints
88897432|NCT01480804|Experimental|Geriatric diabetes team intervention group|The subjects in this group underwent evaluation for barriers to self care by a diabetes educators well versed with age specific barriers. After consideration of patients clinical, functional, and psychosocial background a geriatric diabetes team devised strategy to help patients cope respective barriers. A care manager then implemented the coping strategies by educating patients and caregivers. She also made home visits to assess any safety issues not know to clinic based geriatric team. She helped the patients and caregivers with all aspects of care coordination. Patients in this group received phone contact from care managers as many times as needed over the six month intervention period.
88897433|NCT01480804|No Intervention|Attention Control Group|The subjects in the group received similar, in person, contact as the intervention group. An educator, separate from the one involved in the intervention team, called patents in this group for a total of eleven time within the first six months. The phone calls were forces toward general discussion without any diabetes related advice.
88897434|NCT01480817|Active Comparator|Sorafenib|Sorafenib 400mg po bid
89006636|NCT04620109|Active Comparator|SDE 0.12 mg/eye|Actual dose is 0.12 mg/eye by 60μL KDR2-2 eyedrops of a concentration of 2.0 mg/mL for 1 time.
89006637|NCT04620109|Active Comparator|SDE 0.24 mg/eye|Actual dose is 0.24 mg/eye by 60μL KDR2-2 eyedrops of a concentration of 4 mg/mL for 1 time.
89419032|NCT02206464|Experimental|Group 3|H7N9 MIV on Day 0 and H7N9 MIV at Study Week 16
89419033|NCT02203188|Experimental|Lid debridgement scaling|Perform lid debridgement scaling
89419034|NCT02203188|No Intervention|Control|No Treatment
89419035|NCT04059679|Active Comparator|EC aspirin (81mg qd)|
89419036|NCT04059679|Experimental|EC aspirin (81mg qd) plus rivaroxaban (2.5 mg bid)|
89419037|NCT02206542|Experimental|Robot-assisted group|Electroacupuncture, physical therapy and upper limb rehabilitation robot
89419038|NCT02206542|Active Comparator|Control group|Electroacupuncture and physical therapy
88897435|NCT01480817|Experimental|TACE for HCC with portal vein invasion|Antineoplastic agents are directly injected into the hepatic artery, allowing high intratumoral concentrations of drugs and thereby reducing systemic side effects. The mixture of chemotherapeutic agents and iodized oil is almost completely retained in neoplastic nodules and can remain in HCC tissue for a long time. Subsequent mechanical embolization of the artery feeding the neoplasm causes ischemic damage to the tumor and prolongs the duration of the effects of chemotherapeutic agents.
88897436|NCT01480830|No Intervention|Standard colonoscopy|
88897437|NCT01480830|Experimental|Magnetic endoscopic imaging colonoscopy|
88897438|NCT01480856|Active Comparator|Cobedding|Newborn twins are settled in a single bed : this is cobedding
88897439|NCT01480856|Placebo Comparator|Single -bedding|Newborn twins are settled in two beds : this is single-bedding
88897440|NCT01480869|Active Comparator|Conventional vitamin D and calcium supplementation|Conventional vitamin D and calcium supplementation with 2 daily OROCAL VITAMINE D3® (500 mg calcium/200 IU cholecalciferol) tablets.
88897441|NCT01480869|Experimental|vitamin D supplementation tailored to vitamin D deficiency|"Conventional calcium supplementation with 2 daily OROCAL 500® (500 mg calcium) tablets to suck + vitamin D3 supplementation (UVÉDOSE®, cholecalciferol, 100 000 IU drinkable solution, 2 ml vial) whose schedule of administration depends on vitamin deficiency level:~100 000 IU of vitamin D3 at D1, D15, D28 and D43 if 25OHD level < 10 ng/mL~100 000 IU of vitamin D3 at D1, D15, D28 if 10 ng/mL ≤ 25OHD level < 20 ng/mL~100 000 IU of vitamin D3 at D1 if 20 ng/mL ≤ 25OHD level < 30 ng/mL"
88897442|NCT01480882|Active Comparator|Conventional Chest PhysioTherapy|Conventional Chest Physiotherapy (CCPT) is delivered by professional physiotherapist for 15 minutes.
88897443|NCT01480882|Experimental|Mechanical percussion|"Mechanical percussion will be delivered by a device called LEGA for 15 minutes"
88897444|NCT01480895|No Intervention|Post GDM follow-up group.|
88897445|NCT01480895|Experimental|lifestyle intervention group.|The women in this group had participated in lifestyle intervention by diet instructions and physical exercise program.
88897446|NCT01480908|Experimental|VSD, +Right bundle branch block|Patients undergone surgical closure of ventricular septal defect and have a postoperative right bundle branch block, about 20 patients
88897447|NCT01480908|Experimental|VSD, -Right bundle branch block|Patients undergone surgical closure of ventricular septal defect and does not have a postoperative right bundle branch block, about 20 patients
88897448|NCT01480908|Experimental|Control|Healthy control subjects, about 20 patients
88897449|NCT01480921|Experimental|home based exercise training|
88897450|NCT01480921|Active Comparator|supervised exercise training|
88897451|NCT01480934||Group:A-cases-Patients with a history of Diabetes Mellitus|(N=75 eyes). The inclusion criteria for group A: Diabetes mellitus was defined as glycosylated haemoglobin (Hb A1c ) levels of 6% or more , use of diabetic medication (oral hypoglycemic agents, insulin injection or diet restriction), or a physician's diagnosis of diabetes.
88897452|NCT01480934||Group - B:controls|Patients with uncomplicated age-related cataract who were otherwise healthy constituted the controls(Group:)B (n=75 eyes).
88897453|NCT01480947|Experimental|Bio-Three|add-on treatment of the probiotics (Bio-three)
88897454|NCT01480947|No Intervention|control treatment|control treatment (intravenous fluid, oral rice and half strength milk formula)
88897455|NCT01480960|Active Comparator|Whole body vibration training|Whole body vibration training in addition to pulmonary rehabilitation
88897456|NCT01480960|No Intervention|No whole body vibration training|Pulmonary rehabilitation without whole body vibration training
88897457|NCT01480973|Experimental|MRI post lung SBRT|Feasibility of MRI to differentiate between benign and malignant changes seen after lung SBRT.
88897458|NCT01480986|Experimental|Treatment arm|This is a single arm trial. The patient will enter phase one and will continue to phase two once the disease progresses in phase one or the phase one has been completed.
89419039|NCT03691363|Experimental|M-STEP|Mobile exercise intervention
88897459|NCT01480999||Laparotomy (open surgery)|
88897460|NCT01480999||Laparoscopic surgery|
88897461|NCT01480999||Robotic assisted surgery|
88897462|NCT01481012||Group I: Cardiopulmonary Bypass + Heart Transplantation|CPB for orthotopic heart transplantation (excluding any patients with VADs)
88897463|NCT01481012||Group II: Cardiopulmonary Bypass + Pulsatile LVAD|CPB for implantation of a Thoratec HeartMate I LVAD (for destination therapy or bridge to transplantation).
88897464|NCT01481012||Group III: Cardiopulmonary Bypass + Continuous Flow LVAD|CPB for implantation of an axial flow or centrifugal flow LVAD (for destination therapy or bridge to transplantation) (e.g. HeartMate II, DeBakey VAD or VentraAssist LVAS)
89419040|NCT02202330|Placebo Comparator|Standard Care, Organized Discharge|Stroke patients are given instructions before discharge regarding diet, need for rehabilitation, possible complications, medication use and information booklets are also handed out. This information is imparted by a multidisciplinary team consisting of a neuro physician, a stroke nurse, a dietitian and a physiotherapist. These are verbal instructions and handouts are written in English. On the day of discharge, or 24 hours prior to discharge, a discharge coordinator details the skills learnt . A detailed written discharge summary is given out detailing all aspects of care, follow-up, medications and test results.
89193984|NCT02914535|Experimental|Filgotinib 100 mg (blinded dosing)|Filgotinib 100 mg + placebo to match filgotinib 200 mg for up to 336 weeks
88897465|NCT01481012||Group IV: Cardiopulmonary Bypass + CABG Surgery|CPB for CABG surgery
88897466|NCT01481025|Experimental|Cimicifuga+Hiperico|80 + 450 mg / tablet
88897467|NCT01481025|Active Comparator|Cimicifuga Herbarium|80 mg / caps
88897468|NCT01481025|Active Comparator|Aplause®|20 mg / tablet
88897469|NCT01481038||Group dialysis patients|Patient on hemodialysis with central venous catheter
88897470|NCT01481038||Group hematology patients|Patients with hemato-oncologic underlying disease (plus/minus hematopoietic stem cell transplantation HSCT) and central venous catheter
88897471|NCT01481064|Active Comparator|Multifaceted approach|After baseline measurement a multifaceted approach will start for 1 year, including audit and feedback, an educational outreach visit, and patient-mediated interventions.
88897472|NCT01481064|No Intervention|Usual care|After baseline measurement no intervention will occur in these hospitals.
88897473|NCT01481090|Active Comparator|Electro-Acupuncture|Group will receive 4 acupuncture treatments over 14 days during hormone treatment
88897474|NCT01481090|No Intervention|Control|Group will not receive acupuncture.
88897475|NCT01481103|Active Comparator|Acupuncture group|Participants will keep a headache diary for 4weeks and then attend eight weekly acupuncture sessions. Acupuncture will be done by a licensed acupuncturist and will last approximately 25 minutes. Following the acupuncture sessions, participants will keep a headache diary for an additional 4 weeks
88897476|NCT01481103|No Intervention|Control group|participants will be asked to maintain a daily diary of headache occurrences and OTC medication use for 16 weeks.
88897477|NCT01481142|Experimental|Adacolumn|
88897478|NCT01481168|Active Comparator|"Pacemaker on"|DDD+/-R pacing
88897479|NCT01481168|Placebo Comparator|"Pacemaker off"|ODO pacing
88897480|NCT01481168|Experimental|Implantable Loop Recorder|Implantable loop recorder in adenosine test negative patients
88897481|NCT01481181|Experimental|zinc enriched water|zinc enriched purified water at 2-6mg/l per day
88897482|NCT01481181|No Intervention|purified water only|non zinc enriched, purified drinking water
88897483|NCT01481181|No Intervention|control group|group of households receiving hygiene practice recommendations and water guard (water purifying solution)
88897484|NCT01481194|Experimental|ACVDL|ACVDL is a combination of doxorubicin, cyclophosphamide, bortezomib, dexamethasone, and lenalidomide
88897485|NCT01481207||neonates with perinatal asphyxia|neonates with suspected perinatal asphyxia (HIE)
89193985|NCT02914535|Placebo Comparator|Placebo (blinded dosing)|Placebo to match filgotinib 200 mg + placebo to match filgotinib 100 mg for up to 336 weeks
89193986|NCT02914535|Experimental|Filgotinib 200 mg (open-label)|Filgotinib 200 mg for up to 336 weeks
89193987|NCT02914535|Experimental|Filgotinib 100 mg (open-label)|Filgotinib 100 mg for up to 336 weeks
88897486|NCT01481220|Experimental|Azacitidine + Eltrombopag|
88897487|NCT01481233|Experimental|Single arm|Colchicine 0.5 mg BID x 21 days
88897488|NCT01481259|Experimental|Immunotherapy|Subjects receive autologous cytokine-induced killer cell infusion every 21 days
88897489|NCT01481259|Active Comparator|Pemetrexed|Subjects receive pemetrexed infusion at a dose of 500mg/m2 every 21 days
88897490|NCT01481285||healthy adults|The study will cover 992 healthy adults. 496 men and 496 women in an age range of 18 to 65 years are planned to be recruited.
88897491|NCT01481298||LVNC|12 patients with left ventricular non-compaction cardiomyopathy
89193988|NCT02903680|Active Comparator|Dexamethasone group|Dexamethasone 0.6 mg/kg IV (max 15 mg) before departure from the ED.
89193989|NCT02903680|Placebo Comparator|Placebo group|The control group received a similar looking placebo (NaCl 0,9% IV) with the same volume.
88897492|NCT01481298||HCM|10 patients with hypertrophic cardiomyopathy
88897493|NCT01481298||DCM|11 patients with dilatative cardiomyopathy
88897494|NCT01481298||controls|24 healthy controls
88897495|NCT01481311||Patients before dialysis treatment|
88897496|NCT01481311||Patients after dialysis treatment|
88897497|NCT01481337||Polypectomy or mucosal endoscopic resection under aspirin|
88897498|NCT01481350|Experimental|Sildenafil|All patient will be treat with a intravenous administration of the drug from the beginning of the intervention, for a maximum of 72 hours.
88897499|NCT01481363|Active Comparator|Treatment as usual|Half of participants recruited will be randomly assigned to the control group to receive treatment as usual. This is will be based on a single one hour consultation which will include communication advice and information.
88897500|NCT01481363|Experimental|The Talking Sense treatment|Half of carer participants recruited will be randomly assigned to receive the Talking Sense treatment. This will be conducted one to one and individualised over 3 sessions and no more than 4.5 hours during no more than 8 weeks.
88897501|NCT01481389|Active Comparator|Theobromine drink|
88897502|NCT01481389|Active Comparator|Cocoa drink|
88897503|NCT01481389|Placebo Comparator|Placebo drink|
88897504|NCT01481389|Active Comparator|Cocoa and theobromine drink|
89193990|NCT02864004|Experimental|APO group|An apomorphine pump will be installed and adjusted. The target dose corresponds to the patient's individual optimized dose :maximum dose of 10 mg/hour for 16 hours
89193991|NCT02864004|Active Comparator|Control group|Patients will be optimally treated with oral dopaminergic therapy to obtain the best medical treatment (BMT) defined as the most efficient single treatment options or their combination.
89193992|NCT02842424|Experimental|Ramipril Treatment|6 months treatment with the medication Ramipril
89193993|NCT02834364|Experimental|single arm|Encorafenib 450 mg. p.o.once daily and Binimetinib 45 mg p.o. twice daily until disease progression or toxicity requiring discontinuation of treatment. 1 cycle is defined as 28 days.
88897505|NCT01481402|Placebo Comparator|Placebo-liothyronine|3 months of placebo followed by 3 months of Liothyronine treatment.
89193994|NCT02823041|Experimental|Cognitive Training & Exercise|This arm involves a combination of systematic computerized cognitive training plus 150 minutes per week of aerobic exercise. All participants will also receive individual case management and supportive psychotherapy as well as Individual Placement and Support.
88897506|NCT01481402|Other|Liothyronine-Placebo|3 months of Liothyronine treatment followed by 3 months of Placebo treatment.
89193995|NCT02823041|Active Comparator|Cognitive Training|This arm includes the same systematic computerized cognitive training as the experimental condition, but without the additional aerobic exercise. All participants will also receive individual case management and supportive psychotherapy as well as and Individual Placement and Support.
88897507|NCT01481441|Other|SonoVue|Ultrasound Contrast Agent
88897508|NCT01481454|Experimental|Group 1: QIV Lot 1|Participants will receive the Quadrivalent Influenza Vaccine (QIV) from Lot 1.
88897509|NCT01481454|Experimental|Group 2: QIV Lot 2|Participants will receive the Quadrivalent Influenza Vaccine (QIV) from Lot 2.
88897510|NCT01481454|Experimental|Group 3: QIV Lot 3|Participants will receive the Quadrivalent Influenza Vaccine (QIV) from Lot 3.
88897511|NCT01481454|Active Comparator|Group 4: TIV|Participants will receive the Trivalent Influenza Vaccine (TIV).
88897512|NCT01481467|Experimental|Intervention|Influenza vaccination implementation strategy applied.
88897513|NCT01481467|No Intervention|Control|Usual care.
88897514|NCT01481480|Experimental|Latissimus dorsi tendon transfer|A Latissimus dorsi tendon transfer is performed
88897515|NCT01481480|Active Comparator|Arthroscopic repair|An arthroscopic repair is performed
88897516|NCT01481493|Experimental|Active Treatment|BT061 monoclonal antibody (subcutaneous)
88897517|NCT01481493|Placebo Comparator|Placebo|subcutaneous injection of placebo
88897518|NCT01481506|Experimental|Telemonitoring|
88897519|NCT01481506|No Intervention|Usual care|
88897520|NCT01481519|Active Comparator|dexamethasone 0.1%/povidone-iodine 0.4%|Patients were instructed to put one drop into each symptomatic eye four times daily for 7 days.
88897521|NCT01481519|Placebo Comparator|artificial tears|Patients were instructed to put one drop into each symptomatic eye four times daily for 7 days.
88897522|NCT01481584|Experimental|Canola protein|Canola protein (Brassica juncea; incorporated in a drink)
88897523|NCT01481584|Active Comparator|Reference protein|Reference Protein (soy protein isolate; incorporated in a drink)
88897524|NCT01481584|No Intervention|Wash out|Wash out (four weeks without any intervention between interventional periods)
88897525|NCT01481584|No Intervention|Run-in|Run-in period (three days before intervention, defined diet)
88897526|NCT01481597|Experimental|deuteporfin 1mg/kg|
88897527|NCT01481597|Active Comparator|deuteporfin 2.5mg/kg|
88897528|NCT01481597|Active Comparator|deuteporfin 5mg/kg|
88897529|NCT01481597|Active Comparator|deuteporfin 7.5mg/kg|
88897530|NCT01481597|Placebo Comparator|placebo|
88897531|NCT01481610|Experimental|Lumiracoxib group|Patients in this group will receive a standard fixed dose of lumiracoxib PO (200 mg/day) for a period of maximum 10 days, but no shorter than 7 days.
88897532|NCT01481610|Active Comparator|Diclofenac group|Patients in this group will receive a standard fixed dose of diclofenac PO (100 mg/day) for a period no longer than 10 days but no shorter than 7 days.
88897533|NCT01481623|Other|Gene identification and phenotyping|Identification of patients (probands), questionnaire and informed consent of patients and their families, biological sampling, DNA and RNA extraction, genetic study for gene identification, re-contact of family members and relatives (with consent) for metabolic study of mutation carriers, and complementary studies of homozygous patients in some cases
89419041|NCT02202330|Experimental|Video Arm, Standard Discharge|"Intervention is as follows:~5 minute videos, on various stroke related topics/ themes delivered in one session before discharge from the hospital (list topics on which videos have to made)~Discussion and questions and answers after viewing video to ensure that core message has been understood and there are no lacunae in understanding the message of video.~Phone card - a memory chip installed in the cell phones of intervention team that ensures that the videos can be replayed at home to refresh memory of some details that may not have been captured in the mandatory viewing sessions."
88897534|NCT01481636||No treatment, OSA (AHI >15)|Patients with OSA recruited prior to receiving NHS treatment.
89193998|NCT02720302|Experimental|SOFT|"All Children have their first and their last consultation at The Child Obesity Unit.~The investigators use Standardized Obesity Family Therapy SOFT as described by Nowicka & Flodmark (1-3). The intervention use psychological techniques developed in systemic family therapy applied on advice regarding exercise and diet as well as behavioural Life style Changes.~At each consultation with the overweight child and his/her biological parents there are two therapists present."
89193999|NCT02720302|Experimental|TeleSOFT|"The same method Lifestyle intervention SOFT is used. The only difference is that the communication in the second, third (and fourth) visit is made by use of video on distance. The investigators use Standardized Obesity Family Therapy SOFT as described by Nowicka & Flodmark (1-3)."
89194000|NCT02716012|Experimental|MTL-CEBPA Monotherapy|MTL-CEBPA administered weekly, twice weekly or thrice weekly over 3 weeks followed by 1 week of rest defining a 28-day cycle.
89194001|NCT02716012|Experimental|MTL-CEBPA & Sorafenib (combination)|MTL-CEBPA is administered weekly or twice weekly in combination with sorafenib over 3 weeks followed by 1 week of rest defining a 28-day cycle.
89194002|NCT02716012|Experimental|MTL-CEBPA & Sorafenib (sequential)|MTL-CEBPA is administered weekly or twice weekly for 2 cycles (28-day cycle) followed by 2 cycles of sorafenib
89194003|NCT02715518|Active Comparator|FFR-guided strategy arm|"FFR measurement for non-IRA stenosis (>50% visual estimation) will be performed by continuous infusion of adenosine (140~180ug/kg/min) or intracoronary nicorandil (2mg bolus) injection. The FFR ≤ 0.80 will be targeted for PCI using 2nd generation drug-eluting stent. In case of non-IRA stenosis > 90%, we will judge FFR value of ≤ 0.80.~The evaluation of non-IRA stenosis by FFR will be recommended to perform during same intervention with primary PCI for IRA. However, exceptions can be made for complex lesions including ACC/AHA classification B2/C lesion where the operator estimates that the revascularization procedure will require significant contrast overload which may lead to deterioration of cardiac and renal function of the patient. Such procedures can be performed in a staged procedure during the same hospitalization."
89194004|NCT02715518|Active Comparator|Angiography-guided strategy arm|"Non-IRA stenosis with > 50% stenosis will be the target of PCI using 2nd generation drug-eluting stent.~As for the angiography-guided strategy arm, PCI for non-IRA stenosis will be recommended during same procedure. However, exceptions can be made for complex lesions including ACC/AHA classification B2/C lesion where the operator estimates that the revascularization procedure will require significant contrast overload which may lead to deterioration of cardiac and renal function of the patient. Such procedures can be performed in a staged procedure during the same hospitalization."
89194005|NCT02695498|Experimental|Mindfulness Based Stress Reduction|Mindfulness Based Stress Reduction (MBSR) is a standardized course in mindfulness mediation and yoga.
89194006|NCT02695498|Experimental|Migraine/stress Education|This course will educate participants about migraine pathophysiology, headache triggers, stress, gentle stretches, and daily migraine readings.
89419042|NCT02199288||Cohort|
89419043|NCT03682315|Active Comparator|Biphasic phycogenic biomaterial|Biphasic phycogenic biomaterial and Autogenous cortical bone
89419044|NCT03682315|Experimental|Xenograft bovine hydroxyapatite|Xenograft bovine hydroxyapatite and Autogenous cortical bone
89419045|NCT02257710||Orsiro|All subjects requiring coronary revascularization with Drug Eluting Stents (DES)
89419046|NCT03682237|No Intervention|A) Standard diabetes training (control)|"More specifically, group training in general diabetes health issues, how to do experienced based dosing, how to handle sick days, exercise etc. in general terms. The group will not be taught in carbohydrate counting or bolus calculation. They will be encouraged to measure SMBG at least 4 times daily with patients own preferred glucose meter.~Patients will be offered 6 months treatment with FGM after study end."
88897535|NCT01481649||HBsAg-negative, anti-HBc-positive|HBsAg-negative, anti-HBc-positive subjects undergoing hematopoietic stem cell transplantation (HSCT)
89419047|NCT03682237|Active Comparator|B) Carbohydrate counting, automated bolus calculation|
88897536|NCT01481662||retrospective|cases retrospectively reported the last 20 years
88897537|NCT01481662||Prospective|"Diffusion tensor magnetic resonance imaging of the brain:~new cases prospectively reported"
88897538|NCT01481675||BPDLL group|Patients subjected to the Biliopancreatic Diversion Long Limbs surgical operation will undergo an oral glucose tolerance preoperatively and 12 months after the operation
88897539|NCT01481675||LSG group|Patients subjected to laparoscopic sleeve gastrectomy will undergo an oral glucose tolerance test preoperatively and 12 months postoperatively
88897540|NCT01481688|No Intervention|Control|Routine haemodialysis sessions as per usual
89419048|NCT03682237|Active Comparator|C) Flash glucose monitoring (FGM)|Group training with same content as for group A.
88897541|NCT01481688|Experimental|Intradialytic exercise|One hour of exercise completed during haemodialysis.
88897542|NCT01481688|Active Comparator|Extra time|30 minutes extra dialysis time.
89194007|NCT02688777|Experimental|Immediate Backward Walking Training|Individuals will participate in 18 sessions of Backward Walking training immediately following baseline assessment.
89194008|NCT02688777|Active Comparator|Delayed Backward Walking Training|Individuals will participate in 18 sessions of Backward Walking training at 1-year post-strokeD
89194009|NCT02648334|Active Comparator|IN.PACT drug coated balloon|IN.PACT drug coated balloon
89194010|NCT02648334|Experimental|Lutonix drug coated balloon|Lutonix drug coated balloon
89194011|NCT02646618|Active Comparator|Get Social|"Get Social participants will receive a weight loss intervention in a protected Twitter group. The intervention content will be structured to deliver in an online context. The online coaches will post daily content, respond to questions, address concerns, and encourage engagement. The weight loss intervention is based on the Diabetes Prevention Program (DPP), an evidence-based weight loss program focused on lifestyle changes. The goals for the intervention are 175 minutes of moderate physical activity per week and an overall weight loss of 7%. Each participant will get an individualized calorie goal that would facilitate a 1-2 lbs. weight loss weekly. Participants will also be encouraged to use an app such as MyFitnessPal to track daily diet."
89194012|NCT02646618|Active Comparator|Traditional|Participants will attend weight loss groups weekly for 8 weeks, then biweekly for 16 weeks, then monthly between months 6 and 12. The weight loss intervention is based on the Diabetes Prevention Program (DPP), an evidence-based weight loss program focused on lifestyle changes. The goals for the intervention are 175 minutes of moderate physical activity per week and an overall weight loss of 7%. Each participant will get an individualized calorie goal that would facilitate a 1-2 lbs. weight loss weekly. Participants will also be encouraged to use an app such as MyFitnessPal to track daily diet.
89194013|NCT02617186|Active Comparator|Thoracoscopic Lobectomy|
89194014|NCT02617186|Active Comparator|Robotic Lobectomy|
89194015|NCT02609425||STRATAFIX|Anastomosis of esophagus to stomach
89194016|NCT02607722||Nintedanib|Patients with IPF
89194017|NCT02567253|Experimental|low dose, normothermic|CRS + normothermic (37°C) intraoperative intraperitoneal chemoperfusion, with 75mg/m² Cisplatin during 90min + adjuvant chemotherapy
88897543|NCT01481701|Experimental|intravenous chemotherapy|treatment of ovarian carcinoma in relapse
88897544|NCT01481714|Active Comparator|Sodium Picosulphate preparation the day before|"Preparation the day before of the procedure using sodium picosulphate:~A sachet mixed with 250 mL of water at 18:00 pm~A sachet mixed with 250 mL of water at 21:00 pm~A minimum of 4 litres of fluid were recommended throughout the preparation"
88897545|NCT01481714|Experimental|Split-dose sodium picosulphate preparation|"The day before the procedure:~- A sachet mixed with 250 mL of water at 18:00 pm, followed by 2 litres of clear liquids~The day of the procedure:~A sachet administered at 5:45 am, followed by 1,5 litres of fluid intake up to 7 am for colonoscopies scheduled from 9 to 11 am.~A sachet administered at 6:45 am, followed by 1,5 litres of fluid intake up to 8 for colonoscopies scheduled after 11 am."
88897546|NCT01481727|Placebo Comparator|cpap sham|non invasive mechanical ventilation type cpap sham manoeuver
88897547|NCT01481727|Active Comparator|high-intensity NIMV|Non-invasive mechanical ventilation, biPAP modality, with high-intensity IPAP (>18cmH2O)
88897548|NCT01481753|Active Comparator|Braun arm|patients received Braun enteroenterostomy
88897549|NCT01481753|Active Comparator|Non Braun Arm|Patients do not receive a Braun enteroenterostomy
88897550|NCT01481766|Experimental|Iron plus dietary counseling (Non-anemic iron deficiency)|
88897551|NCT01481766|Placebo Comparator|Placebo plus dietary counseling (Non-anemic iron deficiency)|
88897552|NCT01481766|No Intervention|Iron sufficient|From the screening cohort of it is anticipated that 25 children will have iron deficiency anemia and an equal number of randomly selected children with iron sufficiency (n=25) will be sampled. These children will be compared to the children with non-anemic iron deficiency.
88897553|NCT01481766|Active Comparator|Iron deficiency anemia|From the screening cohort of it is anticipated that 25 children will have iron deficiency anemia and an equal number of randomly selected children with iron sufficiency (n=25) will be sampled. These children will be compared to the children with non-anemic iron deficiency.
88897554|NCT01481805||Hepatocellular carcinoma patients treated with sorafenib|
88897555|NCT01481818|Experimental|radioprotector|
88897556|NCT01481831|Active Comparator|H PALO day 1|Highly Emetogenic Arm, Palonosetron 0.25mg IV*1 dose on day 1
88897557|NCT01481831|Experimental|H PALO day 1,3,5|Highly Emetogenic Arm, Palonosetron 0.25mg IV*3 doses on days 1,3 and 5
88897558|NCT01481831|Active Comparator|M PALO day 1|Moderately Emetogenic Arm, Palonosetron 0.25mg IV*1 dose on day 1
88897559|NCT01481831|Experimental|M PALO day 1,3,5|Moderately Emetogenic Arm, Palonosetron 0.25mg IV*3 doses on days 1,3 and 5
88897560|NCT01481844|Experimental|sequential treatment|1.drugs experimental-Sequential -PPI( Lansoprazole 30mg x2/day) + amoxicillin 1gx2/day for 5days, followed by 5 days of PPI(Lansoprazole 30mg x2/day) + ( Clarithromycin500mg x2/day and Tinidazole 500mg x2/day )
88897561|NCT01481844|Active Comparator|quadruple therapy|Quadruple drug regimen (i.e.-14 days of PPI (Lansoprazole 30mg x2/day) + Bismuth Subsalicylate 525mg X4/day + Metronidazole 500mg x3/day + Tetracycline 500mg x4/day )-is standard of care as second line treatment in eradication of H pylori
88897562|NCT01481857|Experimental|Thoracolumbar proprioception|
88897563|NCT01481857|Experimental|Segmental Stabilization|
88897564|NCT01481870|Active Comparator|Sorafenib-sunitinib|Sorafenib is first line treatment followed by sunitinib.
88897565|NCT01481870|Active Comparator|Sunitinib-sorafenib|Sunitinib is first line treatment followed by sorafenib.
88897566|NCT01481909|Placebo Comparator|Sugar Pill|All patients included in this study will be subjected at the screening visit to a standardized provocation of Darier's sign by a device for standardized provocation testing (Hartmann and Siebenhaar 2009). Patients that exhibit positive skin test reactions will be enrolled, provided that they meet all inclusion criteria and none of the exclusion criteria and that they give informed consent. Study patients will receive treatment for 28 days (minimal 25, maximal 30 days) before visit 1 and visit 2 including the same day before the provocation test (RUP 20mg/day or placebo according to randomization). All patients will receive antihistaminic rescue medication immediately after completing the testing when necessary.
89419049|NCT03682237|Active Comparator|D) Carbohydrate counting, automated bolus calculation, FGM|Group training as group B. A more sophisticated education concept will be developed for how FGM should be used to adjust settings and suggestions from the automated bolus calculator (MySugr app).
89419050|NCT02203266|Experimental|Feedback|Feedback on the patient's own inhaler use, with personalized information on the patients technique and timing of use of the diskus inhaler as recorded on the INCA device will be provided to patients in the feedback group after 1,2 and 6 months.
89419051|NCT02203266|Active Comparator|Demonstration|Current best practice - inhaler technique education
89419052|NCT02203266|No Intervention|Control|Usual care in the community pharmacy setting
89419053|NCT03686527||Echocardiography|
89419054|NCT03686527||MRI Fibrosis|
89419055|NCT03691285|Experimental|Single-implant mandibular overdenture|Participants allocated to this group will have an implant placed in the mandibular midline and after 3 weeks (healing period - early loading) an attachment system will be tightened and a retention matrix will be incorporated to the mandibular denture.
89419056|NCT03691285|Active Comparator|Two-implant mandibular overdenture|Participants allocated to this group will have two implants placed in the inter-foraminal region after 3 weeks (healing period - early loading) an attachment system will be tightened and a retention matrix will be incorporated to the mandibular denture.
89194018|NCT02567253|Experimental|high dose, normothermic|CRS + normothermic (37°C) intraoperative intraperitoneal chemoperfusion, with 100mg/m² Cisplatin during 90min + adjuvant chemotherapy
89419057|NCT02206854|Experimental|R-flurbiprofen|200 mg R-flurbiprofen in gelatine capsules once
89419058|NCT02206932|Other|Sofosbuvir + Simeprevir|Subjects will be enrolled and treated with simeprevir 150 mg and sofosbuvir 400 mg once daily for 12 weeks
89419059|NCT03686449|Experimental|study group 1|Non-cultured Autologous Keratinocyte Suspension
89419060|NCT03686449|Experimental|study group 2|Adipose-Derived Stem cell-Keratinocyte Suspension
89419061|NCT03686449|Active Comparator|Control group|Split skin graft
89419062|NCT02207010|Experimental|AZD1775|Patients will receive a single dose (either 100 mg, 200 mg or 400 mg) of AZD1775, an oral agent, prior to surgery for resection of GBM
89419063|NCT02203344||Light sedation|Light sedation is defined as RASS of +1 to -2.
89419064|NCT02203344||Deep sedation|Deep sedation is defined as RASS of -3 to -5
89419065|NCT03686293|Experimental|Paracetamol and breakfast|One tablet of paracetamol (500 mg) and a standardized breakfast will be consumed within 15 minutes one morning upon 10 hours of fasting
89419066|NCT05261724||Patients with primary brain tumors|
89419067|NCT05261724||Patients with secondary brain tumors|
89194019|NCT02567253|Experimental|low dose, hyperthermic|CRS + hyperthermic (41°C) intraoperative intraperitoneal chemoperfusion, with 75mg/m² Cisplatin during 90min + adjuvant chemotherapy
89419068|NCT03686137||Institut Paoli-Calmettes patients undergoing liver surgery|
89419069|NCT02203422|Experimental|combination treatment group|60 enrolled patients are randomly picked up to take cyclosporin A in combination with rhTPO at the indicated dose.
89419070|NCT02203422|Active Comparator|single treatment group|60 enrolled patients are randomly picked up to take cyclosporin A at the indicated dose.
89419071|NCT03686059|Experimental|punctal plug|SOFT PLUG® Preloaded Silicone Plugs by OASIS®
89419072|NCT03686059|Experimental|Combined|SOFT PLUG® Preloaded Silicone Plugs by OASIS® plus Daily intake of DHA (docosahexaenoic acid)
89419073|NCT03686059|No Intervention|control|no medication was given
89419074|NCT03682159|No Intervention|control|
89419075|NCT03682159|Experimental|intervention|
89419076|NCT03532854|Experimental|Sequence A|Ezetimibe/Rosuvastatin -> Valsartan -> Valsartan and Ezetimibe/Rosuvastatin
89419077|NCT03532854|Experimental|Sequence B|Valsartan -> Valsartan and Ezetimibe/Rosuvastatin-> Ezetimibe/Rosuvastatin
89419078|NCT03532854|Experimental|Sequence C|Valsartan and Ezetimibe/Rosuvastatin -> Ezetimibe/Rosuvastatin -> Valsartan
89419079|NCT03532854|Experimental|Sequence D|Ezetimibe/Rosuvastatin -> Valsartan and Ezetimibe/Rosuvastatin-> Valsartan
89419080|NCT03532854|Experimental|Sequence E|Valsartan -> Ezetimibe/Rosuvastatin -> Valsartan and Ezetimibe/Rosuvastatin
89419081|NCT03532854|Experimental|Sequence F|Valsartan and Ezetimibe/Rosuvastatin -> Valsartan -> Ezetimibe/Rosuvastatin
88897567|NCT01481909|Active Comparator|Rupafin|All patients included in this study will be subjected at the screening visit to a standardized provocation of Darier's sign by a device for standardized provocation testing (Hartmann and Siebenhaar 2009). Patients that exhibit positive skin test reactions will be enrolled, provided that they meet all inclusion criteria and none of the exclusion criteria and that they give informed consent. Study patients will receive treatment for 28 days (minimal 25, maximal 30 days) before visit 1 and visit 2 including the same day before the provocation test (RUP 20mg/day or placebo according to randomization). All patients will receive antihistaminic rescue medication immediately after completing the testing when necessary.
88897568|NCT01481922|Active Comparator|Whitacre 22 gauge|lumbar puncture performed with a Whitacre 22 gauge (BD)
88897569|NCT01481922|Experimental|Whitacre 24 gauge|lumbar puncture performed with a Whitacre 24 gauge (BD)
89419082|NCT03591822|Other|Arm AB : Intervention under study x Control intervention|Subjects receive intervention A during which they will benefit from a systemic pain assessment and from the PARO robot as a therapeutic mediator, followed by intervention B during which patients will benefit from a systemic pain assessment without the PARO robot.
89419083|NCT03591822|Other|Arm BA: Control intervention x Intervention under study|Subjects receive intervention B during which they will benefit from a systemic pain assessment without the PARO robot, followed by intervention A during which patients will benefit from a systemic pain assessment and from the PARO robot as a therapeutic mediator.
89419084|NCT03690973|Active Comparator|Alveolar socket preservation with graft and flap surgery|
89419085|NCT03690973|Experimental|Immediate implant placement with bone using flapless surgery|
88897570|NCT01481948|Experimental|story plus behaviorial procedures|The girls randomized to this arm of the study will view an interactive story about 6 8-10 year old African American girls who seek to find clues to solve a mystery about the town in which they live. The episodes will contain information about healthy nutrition and physical activity, as well as basic information about physical activity and kitchen safety tips, developmentally appropriate recipes, and portion sizes. Girls randomized to this arm of the study will also engage in key behavior change procedures, such as goal setting, problem solving, and self monitoring.
88897571|NCT01481948|Active Comparator|story only|The girls randomized to this arm of the study will view an interactive story about 6 8-10 year old African American girls who seek to find clues to solve a mystery about the town in which they live. The episodes will contain information about healthy nutrition and physical activity, as well as basic information about physical activity and kitchen safety tips, developmentally appropriate recipes, and portion sizes. Girls randomized to this arm of the study will not engage in key behavior change procedures, such as goal setting, problem solving, and self monitoring.
88897572|NCT01481948|No Intervention|Wait list control|This group will participate in data collection only; after the 3rd data collection point, they will be given access to the intervention
88897573|NCT01481961|Experimental|rTMS arm|
88897574|NCT01481987|Experimental|Epiretinal Membrane|The investigators prospectively included 49 eyes of 49 patients with idiopathic ERM for which surgical treatment had been planned.
88897575|NCT01481987|No Intervention|Control|Subjects with normal visual acuity and OCT profile
88897576|NCT01482000|Experimental|Pulmonary daoyin therapy of China|The intervention group will perform a 3 months pulmonary daoyin of China therapy program which consists of training and patient education. They will be evaluated with some tests for the study.
88897577|NCT01482000|Active Comparator|Control|The control group will get the usual care with some additional tests for the study.
88897578|NCT01482013|Experimental|HPP854|Oral HPP854 once a day for 28 days.
88897579|NCT01482013|Placebo Comparator|Placebo|Oral, placebo once a day for 28 days.
88897580|NCT01482026|Experimental|Treated patients|Patients for whom ADHD treatment is introduced at enrolment. Evolution of the ADHD Rating Scale-IV inattention subscore
88897581|NCT01482026|Experimental|Non treated patients|Patients for whom no ADHD treatment is required at enrolment. Evolution of the ADHD Rating Scale-IV inattention subscore
88897582|NCT01482039|No Intervention|Standard Ultrasound|Current standard of care - one abdominal view of the cervix to rule out placenta previa
88897583|NCT01482039|Experimental|Sequential Screen|Start with 3 abdominal views of the cervix with measurement. If 3 adequate views cannot be obtained, or if measurement is less than 3cm, then will perform transvaginal scan for measurement.
88897584|NCT01482039|Experimental|Screening Transvaginal Ultrasound|Obtain 3 adequate cervical length measurements using transvaginal ultrasound
88897585|NCT01482052|Experimental|Test Vaccine|NmVac4-A/C/Y/W-135-DT™ conjugate vaccine
88897586|NCT01482052|Active Comparator|US Licensed Vaccine|Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine
89419086|NCT03690973|Experimental|Immediate implant placement with bone and flap surgery|
89419087|NCT03690973|Experimental|Alveolar socket preservation with graft and flapless surgery|
89419088|NCT02207166||user group|volunteers who are willing to receive 40 minutes video monitoring and questionnaires while operation a electronic blood pressure measuring machines.
89419089|NCT04059289||Intraocular lens type I|Tecnis EYHANCE IOL (Johnson & Johnson, New Brunswick/USA)
89419090|NCT04059289||Intraocular lens type II|Clareon IOL (Alcon Pharma. Freiburg/FRG)
89419091|NCT02203500|Experimental|Lacidipine|
89419092|NCT02203500|Experimental|Telmisartan|
89419093|NCT02203500|Experimental|Lacidipine + Telmisartan|
88897587|NCT01482078||Receive MgSO4 infusion|Parturients who present to the hospital at less than 34 weeks gestational age with potential pre-term labor, pre-term rupture of membranes or intrauterine growth restriction
88897588|NCT01482078||Do not receive MgSO4 infusion|"We will approach a control group of subjects: i.e. parturients undergoing cesarean section (elective or emergency) with neuraxial anesthesia.~We will seek to ensure that the control group is similar to the study group with respect to the following parameters:~Number of singleton or multiple pregnancy~Parity of parturients~Anesthetic technique (spinal or epidural)~Time of cesarean section (08:00-19:59 or 20:00 to 07:59) Once informed consent is obtained these subjects will be treated identically to the study group in terms of anesthetic management and data collection."
88897589|NCT01482104|Experimental|MAL-PDT re-treatment|1 treatment of MAL-PDT with re-treatment of non-complete responders
88897590|NCT01482104|Active Comparator|usual MAL-PDT|2 MAL-PDT treatments 1 week apart
88897591|NCT01482117|Active Comparator|Clopidogrel|single oral administration of 300mg of clopidogrel
88897592|NCT01482117|Active Comparator|Cilostarole|single oral administration of 100mg of cilostazole
88897593|NCT01482117|Active Comparator|Clopidogrel/Cilostazol|single oral administration of 300mg clopidogrel and 100mg cilostazol
88897594|NCT01482130|Experimental|Training group|All participants in the training group will pursue a 12 weeks of strength training.
88897595|NCT01482130|Other|Controls|The control group will be encouraged to follow a training program according to recommended exercise guidelines
88897596|NCT01482143|Experimental|All Study subjects|
88897597|NCT01482156|Experimental|RAD001 + BEZ235|Patients will receive first dose of RAD001 at 2.5mg/5mg/10 mg weekly or 2.5mg/5mg daily in combination of BEZ235 at 50 mg/100 mg/200 mg/300 mg/400 mg twice a day. In the initial cohort of the dose finding phase, patients will receive a single 2.5 mg dose of RAD001 on Cycle 1 Day 1 and the combination therapy of RAD001 2.5 mg/week and BEZ235 200 mg bid starting on Cycle 1 Day 8. Dose escalation phase: patients will start RAD001 and BEZ235 on Cycle 1 Day 1 with both study drugs being administered at the center. Dose expansion phase: the first 15 patients enrolled at selected sites will take RAD001 as monotherapy from Day 1 to Day 7 (for PK sampling). The combination therapy of RAD001 and BEZ235 will start on Day 8. All remaining patients will receive the combination therapy of RAD001 and BEZ235 starting on Cycle 1 Day 1.
89419094|NCT03681925|Experimental|Intervention|Dietitians randomized to the intervention arm will have access to their participating patients' Nutrition Literacy Assessment Instrument (NLit) scores, and base their intervention on these results.
89419095|NCT03681925|No Intervention|Control|Dietitians randomized to the control arm will not have access to their participating patients' Nutrition Literacy Assessment Instrument (NLit) scores, and will provide the standard-of-care intervention for their patients.
89419096|NCT03681847|Active Comparator|normal saline|Patients will receive normal saline 0.9% 15 ml/kg over 15-20 minutes.
89419097|NCT03681847|Active Comparator|Hydroxyethyl starch|Patients will receive hydroxyethyl starch 130/0.4 in 0.9 % sodium chloride 5 ml/kg over 15-20 minutes.
89419098|NCT03681847|Active Comparator|Hypertonic saline|Patients will receive hypertonic saline 3% (7ml/kg) over 15-20 minutes.
89419099|NCT03533478|Experimental|Group I|32 patients with mild or moderate diabetic macular edema.
89419100|NCT03533478|Placebo Comparator|Group II|32 patients with mild or moderate diabetic macular edema
89419101|NCT02203656|Placebo Comparator|Placebo Supplement|Daily placebo supplement for 30 days after discharge.
89419102|NCT02203656|Experimental|Nutritional Supplement|Daily nutritional supplement for 30 days after discharge.
89419103|NCT02203656|Experimental|In-home exercise + placebo|in-home exercise 3 times a week and daily placebo supplement for 30 days after discharge.
89419104|NCT02203656|Experimental|In-home exercise + nutrition|in-home exercise 3 times a week and daily nutritional supplement for 30 days after discharge.
89419105|NCT02203656|Experimental|Testosterone|Single testosterone injection within 24 hours of hospital discharge.
89419106|NCT04436146|Other|laryngeal manual therapies|The laryngeal manual therapy incorporates massaging the laryngeal muscles thus reducing excessive tension in the laryngeal and perilaryngeal musculature in patients with globus .
89419107|NCT02203734|Experimental|Moderate Pressure Massage|Moderate Pressure Massage Therapy
88897598|NCT01482234|Experimental|pedometers only|Participants randomized to this arm will receive pedometers only. They will participate in baseline and 3 months data collection.
88897599|NCT01482234|Experimental|pedometers + prompts|Participants randomized to this arm will receive pedometers plus a weekly prompt to set a step goal. They will participate in baseline and 3 months data collection.
88897600|NCT01482234|Experimental|pedometer + prompt + messages|Participants randomized to this arm will receive pedometers, weekly prompts, and 6 motivational text messages a week. They will participate in baseline and 3 months data collection.
88897601|NCT01482234|No Intervention|Control|Participants randomized to this group will participate in data collection only; they will not receive an intervention.
88897602|NCT01482247|Active Comparator|L-arginine|
88897603|NCT01482247|Placebo Comparator|Placebo Supplement|
88897604|NCT01482260||Primary Cutaneous Malignant Melanoma|
88897605|NCT01482260||Cutaneous Malignant Melanoma Metastases|
88897606|NCT01482260||Benign Melanocytic Nevi|
88897607|NCT01482273|Active Comparator|CDT+US group|CDT using the EkoSonic Endovascular System with intravascular high-frequency, low-power ultrasound for 15 hours.
88897608|NCT01482273|Active Comparator|CDT-US group|CDT using the EkoSonic Endovascular System without intravascular high-frequency, low-power ultrasound for 15 hours.
88897609|NCT01482299|Experimental|RAD001 (everolimus)|
88897610|NCT01482338|Experimental|DSG|The low-dose oral contraceptive pill which one consists of 20 microgram ethinyl estradiol and 150 mg desogestrel were taken orally by participants every day beginning Day1 to Day 3 of the first menstrual cycle until complete 24 days and continued with free-hormone pills for 4 days. The next cycle has to continue in the same way until complete 6 cycles.
88897611|NCT01482338|Active Comparator|DRSP|The other low-dose oral contraceptive pill which consists of 20 microgram ethinyl estradiol and 3 mg drospirenone were taken orally by participants every day beginning Day1 to Day 3 of the first menstrual cycle until complete 24 days and continued with free-hormone pills for 4 days. The next cycle has to continue in the same way until complete 6 cycles.
88897612|NCT01482364|Experimental|HOTMAN-driven therapeutic approach arm|"Hotman-driven therapeutic approach arm(group IHM) will receive treatment according to the results of the HOTMAN® System."
88897613|NCT01482364|Placebo Comparator|Control arm|Control arm will receive usual antihypertensive care according to the 2007 ESH Guidelines.
88897614|NCT01482377|Experimental|Part A: RO5479599 Dose Escalation|Participants will receive a dose of 100 milligrams (mg) RO5479599 followed by dose escalation from Day 1 of Cycle 1. RO5479599 dose will be escalated as monotherapy in approximately 6 cohorts with dose increments between cohorts of up to 100 percent (%) until MTD.
88897615|NCT01482377|Experimental|Part B: RO5479599 Dose Escalation + Cetuximab|Participants will receive RO5479599 in combination with cetuximab. Escalation of RO5479599 in combination with cetuximab will start in a standard 3+3 design until MTD/OBD is reached. If the initial combination is not tolerated, further cohorts will be dosed with the same dose of cetuximab and lower doses of RO5479599.
88897616|NCT01482377|Experimental|Part C: RO5479599 Dose Escalation + Erlotinib|Participants will receive RO5479599 in combination with erlotinib. Escalation of RO5479599 in combination with erlotinib will start in a standard 3+3 design until MTD/OBD is reached. If the initial combination is not tolerated, further cohorts will be dosed with the same dose of erlotinib and lower doses of RO5479599.
88897617|NCT01482377|Experimental|Imaging (IMG) Substudy|RO5479599 will be administered with zirconium- 89-labeled RO5479599.
88897618|NCT01482416|Experimental|Estrogen use|climacteric women will use conjugated equine estrogens
88897619|NCT01482416|Placebo Comparator|use of Placebo|climacteric women will use placebo
88897620|NCT01482442|Active Comparator|sorafenib group|Patients will receive continuous oral treatment with 800 mg of sorafenib daily (Nexavar, Bayer HealthCare Pharmaceuticals-Onyx Pharmaceuticals). Treatment interruptions and dose reductions (to 400 mg once daily) will be permitted for drug-related adverse effects. At the discretion of the investigator, the dose may be re-escalated to after the resolution of the adverse event.
88897621|NCT01482442|Active Comparator|radioembolization group|The first step will check patient eligibility and prepare conditioning by performing selective mesenteric and hepatic angiography (to document the arterial tumor supply and to occlude extrahepatic vessels) and 99mTc-macroaggregated albumin scintigraphy. The second step is RADIOEMBOLIZATION therapy. One to two weeks after patient eligibility and conditioning, treatment is performed with SIR-Sphere (SIRTEX Medical Ltd.,Lane Cove,Australia).
88897622|NCT01482468|Active Comparator|continuous infusion|continuous infusion of palonosetron added to prophylactic single injection of palonosetron
88897623|NCT01482468|Placebo Comparator|singel injection|continuous infusion of normal saline added to prophylactic single injection of palonosetron
89419108|NCT02203734|Sham Comparator|Light Pressure Massage|Light Pressure Massage Therapy
89419109|NCT02203812|Experimental|Probiotic Arm|L. brevis CD2 Lozenges (4 lozenges per day - 1 lozenge in the morning, 1 lozenge in the afternoon and 2 lozenges in the night). Each lozenge contains at least 1 billion colony forming units of Lactobacillus brevis CD2.
89419110|NCT02203812|Placebo Comparator|Placebo Arm|Placebo lozenges (4 lozenges per day - 1 lozenge in the morning, 1 lozenge in the afternoon and 2 lozenges in the night). The placebo lozenge contains all ingredients except the active constituent (probiotic, Lactobacillus brevis CD2).
88897624|NCT01482494||Pompe suspected patients|"Patients who go to an Internal Medicine clinic for examination of a limb-girdle myopathy.~Patients with asymptomatic hyper-CK-emia. Patients with a prior diagnosis of polymyositis. Patients with a myopathy of uncertain origin and respiratory insufficiency. Patients with polymyositis unresponsive to steroid therapy"
88897625|NCT01482520||Renal cell carcinoma|
88897626|NCT01482520||Hepatocellular carcinoma patients|
89419111|NCT02199444|Experimental|Sevelamer|The dose of Sev was 2400 mg (800 mg three times a day) in all patients.
88897627|NCT01482533||Revision Total Hip Arthroplasty|
88897628|NCT01482533||Revision Total Knee Arthroplasty|
88897629|NCT01482546||Water Colonoscopy Method|As first described by Dr. Felix W. Leung, the maneuvers can be summarized as warm water infusion in lieu of air insufflation combined with suction removal of all residual colonic air and residual feces by water exchange. The air pump will be turned off before insertion of the colonoscope into the rectum to avoid accidental insufflation of air. Warm water (at 36-37ºC) maintained using a water bath and heat saver envelop will be infused intermittently. The minimum amount of water needed to distend the colon and open the lumen will be used during scope insertion. Cecal intubation will be suggested by appropriate movement of the endoscopic image on the monitor screen when the right lower quadrant is palpated or the appendiceal orifice visualized under water. The cecum will then be distended by air to confirm visualization of the ileocecal valve and appendiceal orifice. No specific limit will be set for the volume of water to be used.
88897630|NCT01482546||Air Colonoscopy Method|The minimal amount of air will be used during insertion to open the lumen. Minimal amounts of water (10 to 50 mL) at room temperature will be used for washing of residual feces. If insertion is hindered by scope looping, attempts at loop reduction will be made. If advancement does not occur within 3 to 5 minutes, an assistant will provide abdominal compression, followed by changing the patient's position to facilitate passage of the colonoscope. Cecal intubation will be suggested by identification of the appendiceal orifice and ileocecal valve or intubation of the terminal ileum.
88897631|NCT01482559|Placebo Comparator|dextrose 5%|IV Infusion
89419112|NCT02199444|Placebo Comparator|Placebo|The patients received placebo three times a day
88897632|NCT01482559|Experimental|Dopamine Hydrochloride|IV Infusion
88897633|NCT01482572||Gene profiling Success|
89006638|NCT04620109|Active Comparator|RDE 0.06 mg/eye|The actual dosage is 0.06 mg/eye given 4 times a day for a maximum daily dosage of 0.24mg (60μL KDR2-2 eyedrops concentration of 1.0 mg/mL), which will continues for 6 days plus 1 administration of 0.06 mg/eye in the morning of Day 7. That cohort only started after safety proof from SDE 0.24 mg/eye cohort.
89419113|NCT02199522|Experimental|titration induction of propofol|titration induction of propofol by Fresenius pump at the speed of 1 mg•kg-1•min-1
88897634|NCT01482585||early stage lung adenocarcinoma|
88897635|NCT01482611|Experimental|Panel 1: Caucasian|10, 75 and 300 mg JNJ-47910382 or placebo
88897636|NCT01482611|Experimental|Panel 2: Caucasian|30, 150, 600 mg JNJ-47910382 or placebo
88897637|NCT01482611|Experimental|Panel 3: Japanese|Session VIII and X: Doses of JNJ-47910382 or placebo to be determined
88897638|NCT01482611|Experimental|Panel 4: Japanese|Session IX: Dose of JNJ-47910382 or placebo to be determined
88897639|NCT01482624|Active Comparator|VISCOSEAL® SYRINGE|
88897640|NCT01482624|Other|Standard arthroscopic meniscal surgery|
88897641|NCT01482650|Experimental|Baska mask|
88897642|NCT01482650|Active Comparator|single use laryngeal mask airway (LMA)|
88897643|NCT01482663|No Intervention|Chronic hand eczema patients|Written information sheets and a 14-minutes DVD about hand eczema handed out by the dermatologist
88897644|NCT01482663|Experimental|Behavioral: Healthy Skin Clinic|1-2 counselling sessions with a nurse, tailored according to individual risks and resources and user access to a website comprising a self-monitoring log, a patients' forum and the possibility of communication with the intervention team of nurses
88897645|NCT01482676||1|controls (normal bladder function)
88897646|NCT01482676||2|acontractile bladder
88897647|NCT01482676||3|overactive bladder
88897648|NCT01482676||4|bladder pain syndrome
88897649|NCT01482689|Experimental|Fish oil capsule|
88897650|NCT01482689|Experimental|Multivitamin tablet|
88897651|NCT01482702|Experimental|weight loss intervention|Behavioral weight loss intervention
88897652|NCT01482702|Experimental|Weight Loss plus Resistance Training|Behavioral weight loss intervention with the addition of resistance training
88897653|NCT01482702|Active Comparator|Comparator|Group of women who did not receive chemotherapy
88897654|NCT01482741||Pts undergoing chemotherapy for Stage IV colorectal carcinoma|Six focus groups of 7-9 participants each will be conducted for approximately 90 minutes according to the established methodology of Krueger and Casey. Focus group sessions are semi-structured group interviews in which previously chosen, open-ended questions about topics of interest are posed to participants by a trained moderator.
89419114|NCT02199522|No Intervention|convention induction of propofol|propofol 2mg•kg-1 intravenously by Fresenius pump at the speed of 250mg•min-1
89419115|NCT03532698||osimertinib and aspirin|Osimertinib and Aspirin starting at a dose of 80 mg and 100mg once a day, orally with meals. Aspirin treatment will be initiated one week before beginning TKI therapy, if possible, but TKI therapy will not be delayed for Aspirin loading. Drug: Osimertinib and Aspirin will be administered once every day. If subject has complete response, partial response, stable disease, or unacceptable toxicity.
89419116|NCT03532698||osimertinib|Osimertinib starting at a dose of 80 mg once a day, orally with meals. Drug: Osimertinib will be administered once every day. If subject has complete response, partial response, stable disease, or unacceptable toxicity.
89419117|NCT03685981|Experimental|Incentives information provided|
89419118|NCT03685981|No Intervention|No incentives information provided|
89419119|NCT02203890||Apparently Healthy|Apparently healthy preschool children who attend 3 daycare centers of the Secretariat of Beneficials Works of the First Lady in Guatemalan Western Highlands
88897655|NCT01482741||Parents of pediatric patients stage 1-3 neuroblastoma|within the preceding 6 months. Six focus groups of 7-9 participants each will be conducted for approximately 90 minutes according to the established methodology of Krueger and Casey. Focus group sessions are semi-structured group interviews in which previously chosen, open-ended questions about topics of interest are posed to participants by a trained moderator.
88897656|NCT01482741||Women who have undergone tx for early stage breast cancer|within the preceding 6 months. Six focus groups of 7-9 participants each will be conducted for approximately 90 minutes according to the established methodology of Krueger and Casey. Focus group sessions are semi-structured group interviews in which previously chosen, open-ended questions about topics of interest are posed to participants by a trained moderator.
88897657|NCT01482741||Men undergoing surveillance imaging after tx for testicular ca|Six focus groups of 7-9 participants each will be conducted for approximately 90 minutes according to the established methodology of Krueger and Casey. Focus group sessions are semi-structured group interviews in which previously chosen, open-ended questions about topics of interest are posed to participants by a trained moderator.
89419120|NCT02207790|Experimental|E2609 low-dose and placebo in healthy Japanese subjects|Cohort 1 will consist of Japanese subjects randomized to a low-dose of E2609 as an orally administered tablet along with subjects receiving matching placebo tablets (matched in number and appearance).
89419121|NCT02207790|Experimental|E2609 mid-dose and placebo in healthy Japanese subjects|Cohort 2 will consist of Japanese subjects randomized to a mid-dose of E2609 as an orally administered tablet along with subjects receiving matching placebo tablets (matched in number and appearance).
89419122|NCT02207790|Experimental|E2609 high-dose and placebo in healthy Japanese subjects|Cohort 3 will consist of Japanese subjects randomized to a high-dose of E2609 as an orally administered tablet along with subjects receiving matching placebo tablets (matched in number and appearance).
89419123|NCT02207790|Experimental|E2609 mid-dose and placebo in healthy White subjects|Cohort 4 will consist of White subjects randomized to a mid-dose of E2609 as an orally administered tablet along with subjects receiving matching placebo tablets (matched in number and appearance).
88897658|NCT01482741||Men & women enrolled in the MSKCC lung ca screening program|Six focus groups of 7-9 participants each will be conducted for approximately 90 minutes according to the established methodology of Krueger and Casey. Focus group sessions are semi-structured group interviews in which previously chosen, open-ended questions about topics of interest are posed to participants by a trained moderator.
89006639|NCT04620109|Active Comparator|RDE 0.12 mg/eye|The actual dosage is 0.12 mg/eye given 4 times a day for a maximum daily dosage of 0.48mg (60μL KDR2-2 eyedrops concentration of 2.0 mg/mL), which will continues for 6 days plus 1 administration of 0.12 mg/eye in the morning of Day 7. That cohort might be optional based on emerging data from this study.
89419124|NCT02207868||no treatment|
89419125|NCT03685903|Experimental|CapsoCam® Plus (SV-3) capsule endoscope|Endoscope Capsule
89419126|NCT02203968|Placebo Comparator|Normal saline|Placebo (normal saline) will be administered intravenously as a single 300ml rapid infusion (less than 3min) via level I automated pressure pump within one hour of hospital admission.
89419127|NCT02203968|Active Comparator|Fibrinogen concentrate|Fibrinogen concentrate (RiaSTAP™) is a freeze-dried lyophilised plasma product presented in powdered form. The powder is reconstituted with water for intravenous injection at a concentration of 20 mg fibrinogen per ml. The concentrate is formulated with human albumin, L-arginine, sodium citrate and sodium chloride. RiaSTAP™ is supplied as a purified lyophilisate in a 1g dosage form and is reconstituted in 50 ml of sterile water. The final volume of RiaSTAP™ to be infused in this study will therefore be 300 ml.
89419128|NCT03690895||Cases|
89419129|NCT02010424|Experimental|Individual culture|standard IVF protocol: half of the fertilized oocytes of the patient will be cultured individually in drops of 25 µl Cook cleavage medium till day 3 after fertilization and subsequently in drops of 25 µl Cook blastocyst medium till day 5 after fertilization
89419130|NCT02010424|Experimental|WOW|Half of the fertilized oocytes of the patient will be cultured in group in a WOW dish, each in a separate microwell but covered with one drop of 30 µl of Cook cleavage medium till day 3 after fertilization and subsequently all the embryos will be transferred to a new WOW dish (in the exactly the same position) covered with 30 µl of Cook blastocyst medium till day 5 after fertilization
89419131|NCT02204046|Experimental|BIWA 4|"Generic Name: Bivatuzumab~186Re-labelled humanised monoclonal antibody BIWA 4"
89419132|NCT03063346|Experimental|Protein hydrolysate high dose|
89419133|NCT03063346|Experimental|Protein hydrolysate low dose|
89419134|NCT03063346|Placebo Comparator|Placebo|
89194020|NCT02567253|Experimental|high dose, hyperthermic|CRS + hyperthermic (41°C) intraoperative intraperitoneal chemoperfusion, with 100mg/m² Cisplatin during 90min + adjuvant chemotherapy
89419135|NCT03690817||Bilateral vestibulopathy|Patients with bilateral vestibulopathy, according to the Barany Criteria (2017, Strupp).
89194021|NCT02564068|Experimental|Control|"These 8 subjects will undergo an in the sleep-lab diagnostic polysomnography that would be identical to the one they had for standard of care medical guidelines if they were diagnosed with OSA in the sleep-lab."
89419136|NCT03690817||Healthy controls|Subjects without vestibular or neurological diseases (DHI<5), and with normal hearing thresholds according to their age.
89419137|NCT03623971|Experimental|Artificial Intelligence|A universal diagnostic system. An artificial intelligence to make comprehensive evaluation and treatment decision of cataract.
89419138|NCT03063268|Experimental|Trust-Enhanced Messaged with Interactive Features on E-Consent|Messaging with trust-enhanced modification to the language that the research team has identified as beneficial additional knowledge to provide to participants. This messaging was reviewed by participants from Phase I and edited as suggested.
89419139|NCT03063268|Experimental|Interactive Features on E-Consent|Interactive hyperlinks to open up to further information for key words that participants from Phase I and prototype design and testing have identified as gaps in subject knowledge and provision of information to subjects.
89419140|NCT03063268|Active Comparator|Standard E-Consent|Standardized text currently used by the University of Florida (UF) IRB with no trust-enhanced messaging or interactive hyperlinks that provide further information for subjects.
89419141|NCT02208180|Experimental|Return of genomic results on cardiovascular disease risk|Participants will receive genomic cardiovascular disease risk information.
89419142|NCT02208180|Active Comparator|Return of lifestyle results on cardiovascular disease risk|Participants will receive lifestyle cardiovascular disease risk information. Genomic risk information will be returned after the conclusion of the study.
89419143|NCT03690739|Active Comparator|platinum-based chemotherapy|According to the investigator's discretion
89419144|NCT03690739|Active Comparator|PLD + Trabectedin|PLD 30 mg/m² + Trabectedin 1.1 mg/m² q21
89419145|NCT01983748|Experimental|A|Biological/Vaccine; Autologous Dendritic Cells loaded with autologous Tumor RNA
89419146|NCT01983748|No Intervention|B|Control, Standard of care, which is clinical control every 3 months
89419147|NCT03623815|Other|Sham tDCS followed by active tDCS|Within subjects design. This group received sham (placebo) transcranial direct current stimulation (tDCS) for 20 minutes in session one. At least one month later this group received 2mA of active tDCS for 20 minutes in session two.
88897659|NCT01482741||Men and women enrolled in the thoracic survivorship|Six focus groups of 7-9 participants each will be conducted for approximately 90 minutes according to the established methodology of Krueger and Casey. Focus group sessions are semi-structured group interviews in which previously chosen, open-ended questions about topics of interest are posed to participants by a trained moderator.
88897660|NCT01482754|Experimental|Rituximab Infusion at 90-minutes|
88897661|NCT01482780|Experimental|PICSO|PICSO (pressure controlled intermittent coronary sinus occlusion), a special coronary sinus catheter will be introduced after induction of anaesthesia until going on bypass.
89194022|NCT02564068|Experimental|Oxytocin|"These subjects will undergo another in the sleep-lab diagnostic polysomnography that is identical to the one that they had for standard of care to diagnose OSA. Within one hour prior to the research polysomnography the subjects will be given oxytocin (40 IU) intranasally. Outcome measures will be assessed."
89419148|NCT03623815|Other|Active tDCS followed by sham tDCS|Within subjects design. This group received 2mA of active transcranial direct current stimulation (tDCS) for 20 minutes in session one. At least one month later this group received sham (placebo) tDCS for 20 minutes in session two.
89419149|NCT02208336||Observational (electronic medical record review)|Patients' electronic medical records are reviewed for adherence, severe myelosuppression, and patient morbidity retrospectively and prospectively.
89419150|NCT02208414|Experimental|Crab or shrimp|Intervention: treated with crab and shrimp energy signature vial using NAET
89419151|NCT02208414|Placebo Comparator|Placebo|Treated with water vial
89419152|NCT03921229|Experimental|Intervention|6-months of 11 web-based intervention (tele-coaching) sessions (9 biweekly sessions and 2 monthly sessions) of approximately 30 minutes each; continued use of eTrack nebulizer and vest monitor photo capture as measures of adherence.
89419153|NCT02199678|Placebo Comparator|Placebo|Placebo
89419154|NCT02199678|Active Comparator|ketamine 25 mg|ketamine
89419155|NCT02199678|Active Comparator|ketamine 35 mg|ketamine
89419156|NCT02199678|Active Comparator|ketamine 50 mg|ketamine
89419157|NCT03681613|Experimental|Exercise Therapy With CNS Treatment|NEMEX program combined with a CNS-focused protocol
89419158|NCT03681613|Experimental|Exercise Therapy alone|NEMEX program alone
89419159|NCT02199756||Cesarean section|Women with cesarean section
88897662|NCT01482780|No Intervention|Control|normal procedure of preparing Bypass grafts. Equivalent time before going on Bypass is determined as control period
88897663|NCT01482793|Active Comparator|AVAMAX|Avamax vertebroplasty kits provided by Care Fusion
88897664|NCT01482793|No Intervention|Simulated injection procedure|Patient will be unaware as to whether the control procedure or vertebroplasty had been performed since full sterile preparation, sedation and simulated injection procedure will be used.
89419160|NCT02199834|Experimental|Peer group|24 patients who have good glycemic control and self-care will be trained as peer supporters to deliver peer support to this group under supervision by a program manager. Peer supporters will call their peers at least 12 times a year to provide both informational and emotional support. Half of the patients in this group will be randomized to receive a personalized feedback report displaying trends of metabolic control of A1c, BP, LDL-C, and body weight, with automated decision support based on their own attained values every 4 months through mails.
88897665|NCT01482806|Experimental|Computerized CBT + Internet Support Group|Guided patient access to Beating the Blues plus access to a moderated ISG where patients will be able to communicate confidentially to receive and provide advice and peer-support from other study participants (CCBT+ISG; N=300).
88897666|NCT01482806|Experimental|Computerized CBT Alone|Guided patient access to Beating the Blues, a proven-effective, on-line 8-session CCBT program approved for use in the United Kingdom (CCBT-alone; N=300).
88897667|NCT01482806|No Intervention|Usual Care|"Primary care physicians' usual care for mood and anxiety disorders (UC; N=100)."
88897668|NCT01482832|Experimental|Experimental|Behavioral: Interpersonal therapy-based treatment Participants assigned to receive interpersonal therapy-based treatment will focus on the psychological aspects of pregnancy and factors that may play a role in the development of postpartum depression in teenage mothers, such as poor social support, role transitions, and life stressors. Both groups will attend 5 weekly sessions and have a brief booster session postpartum.
88897669|NCT01482832|Active Comparator|Control|Behavioral: Standard care Participants assigned to receive standard care will focus on prenatal education including issues associated with pregnancy and postpartum. Both groups will attend 5 weekly sessions and have a brief booster session postpartum.
89419161|NCT02199834|Other|Refused peer group|Patients who fit the criteria of peers but refuse to be contacted by peer supporters will be signed as refused group. Half of the patients in this group will be randomized to receive a personalized feedback report displaying trends of metabolic control of A1c, BP, LDL-C, and body weight, with automated decision support based on their own attained values every 4 months through mails.
89419162|NCT02199834|Experimental|Report group|Patients in this group will receive a personalized feedback report displaying trends of metabolic control of A1c, BP, LDL-C, and body weight, with automated decision support based on their own attained values twice a year through mails.
88897670|NCT01482845|Experimental|Group 1|
88897671|NCT01482845|Experimental|Group 2|
88897672|NCT01482871|Experimental|Arm 1.5 mg ALG-1001|Group Using 1.5 mg per 100 ul of ALG-1001
88897673|NCT01482871|Experimental|Arm 2.5 mg ALG-1001|Group Using 2.5 mg per 100 ul of ALG-1001
88897674|NCT01482871|Experimental|Arm 5.0 mg ALG-1001|Group Using 5.0 mg per 100 ul of ALG-1001
88897675|NCT01482871|Experimental|Arm 7.5 mg ALG-1001|Group Using 7.5 mg per 100 ul of ALG-1001
89419163|NCT02199834|No Intervention|Usual care|Patients will receive standard usual care with clinicians' follow-up and referral with education to diabetes nurses if deemed necessary at in-charge clinicians' discretion.
89419164|NCT03690583|Experimental|Zinc group|Zinc sulfate 10 mg in children younger than 1 year old, 20 mg in children older than 1 year old
89419165|NCT03690583|Placebo Comparator|Placebo group|Glucose
89419166|NCT03685669||Lung nodule group|
89419167|NCT03685669||Healthy Control group|
88897676|NCT01482897|Experimental|corticoïd|anesthetic bloc (10 ml of xylocaïne 1%) immediately followed with corticoid (125mg in.5 ml)
88897677|NCT01482897|Placebo Comparator|physiological solution|anesthetic bloc (10 ml of xylocaïne 1%) immediately followed with physiological solution (20 ml)
88897678|NCT01482897|Sham Comparator|feigning of peridural infiltration|feigning of peridural infiltration : anesthetic bloc (10 ml of xylocaïne 1%) immediately followed with placement of empty syringe in peridural.
89419168|NCT03685513|Active Comparator|Metal ceramic single posterior crowns|Metal copings veneered with feldspathic porcelain
89419169|NCT03685513|Experimental|BioHPP PEEK-based single posterior crowns|BioHPP PEEK copings veneered with composite resin
89419170|NCT03685435||Non-fasting patients|We will examine non-fasting patients using bedside ultrasound. First we examine the gaster in a supine position. Then we repeat the procedure in a right lateral position.
89419171|NCT03533400|Active Comparator|Group 1|Group 1 (control group) will be given the standard Jamboxx musical device. They will be trained to use the device during two 20 minute training session with a respiratory therapist, and will be instructed to play the device for a minimum of 30 minutes, 3 times a week. The Jamboxx musical device is a hands-free breath controlled musical device designed for people with quadriplegia. The mouthpiece acts as a transducer, changing air pressure created by the user's lungs to a joystick signal to the computer via a differential pressure sensor. The Jamboxx can produce musical sounds of many instruments (trumpet, drums, etc.) in many different scales and in any key.
89419172|NCT03533400|Experimental|Group 2|Group 2 (treatment group) will be given the Jamboxx musical device plus the Jamboxx respiratory therapy device. The respiratory therapy device is similar to the music device, but with specially designed games that guide the user through breathing exercises intended to strengthen the lungs.
89419173|NCT03026257|Experimental|AOHG|Lotrafilcon B contact lenses with added wetting agent, worn bilaterally (in both eyes) for 30 days in a daily wear modality and cared for with either a hydrogen peroxide-based contact lens solution with added wetting agent or a POLYQUAD/ALDOX-preserved contact lens solution with added wetting agent, as randomized
89419174|NCT03026257|Active Comparator|Habitual|Habitual silicone hydrogel contact lenses worn bilaterally for 30 days in a daily wear modality and cared for with participant's habitual multi-purpose solution (MPS)
89419175|NCT02199912|Experimental|Patients with colorectal surgery|
89419176|NCT03681457|Other|Group 1 - Normal Hepatic Function|Normal hepatic function - Control - control group
89419177|NCT03681457|Experimental|Group 2 - Mild Hepatic Impairment|Mild hepatic impairment - Child-Pugh A (Score 5-6)
89419178|NCT03681457|Experimental|Group 3 - Moderate Hepatic Impairment|Moderate hepatic impairment - Child-Pugh B (Score 7-9)
89419179|NCT03681457|Experimental|Group 4 - Severe Hepatic Impairment|Severe hepatic impairment - Child-Pugh C (score 10-15)
89419180|NCT02200068|Active Comparator|PHR Group|This group will have access to a personal health record website SANOIA in addition to all resources they use or find online
88897679|NCT01482897|No Intervention|no intervention|natural evolution of discal sciatica
88897680|NCT01482923||Treatment As Usual (TAU)|This study is a pilot intervention trial examining the feasibility of a motivational smoking cessation intervention using respiratory biomarker feedback in low income PLWHA. The plan is to recruit a pilot sample of 50 eligible and consented participants, randomized at a 1:1 ratio into either the Treatment As Usual (TAU) condition or the experimental (Aspiration, Inspiration Respiration, or AIR) intervention condition.
88897681|NCT01482923||Aspiration, Inspiration Respiration, or AIR|This study is a pilot intervention trial examining the feasibility of a motivational smoking cessation intervention using respiratory biomarker feedback in low income PLWHA. The plan is to recruit a pilot sample of 50 eligible and consented participants, randomized at a 1:1 ratio into either the Treatment As Usual (TAU) condition or the experimental (Aspiration, Inspiration Respiration, or AIR) intervention condition.
88897682|NCT01482936|Experimental|Oxycodone (OxyNorm®) Injection|The subjects will be randomized to receive a single dose of OxyNorm® 2.5, 5, and 10mg
88897683|NCT01482949|Experimental|AGS-003 in combination with sunitinib|Subjects will undergo Induction (AGS-003 every 3 weeks until 5 doses are administered) followed by Booster (AGS-003 at 3 month intervals). Subjects that will begin sunitinib therapy will be on this arm.
88897684|NCT01482975|Experimental|Smoking and Alcohol Prevention|TTM expert system
88897685|NCT01482975|Active Comparator|Diet and Exercise|TTM expert system
88897686|NCT01482988||Critical care patients antipated to stay more than 72 hours|
88897687|NCT01483001|Experimental|Sensitivity Assay|Patients treated with a treatment chosen by sensitivity assay in vitro
88897688|NCT01483014|Experimental|imatinib|
88897689|NCT01483053|Active Comparator|Agomelatine|Participants who are randomly assigned to the agomelatine group will be treated with agomelatine oral tablets for twelve weeks. Participants will begin their agomelatine treatment at 25mg/day dosage, increasing to 50mg/day as clinically indicated.
88897690|NCT01483053|Active Comparator|Escitalopram|Participants who are randomly assigned to the escitalopram group will be treated with escitalopram oral tablets for twelve weeks. Participants will begin their escitalopram treatment at 10mg/day dosage, increasing to 20mg/day as clinically indicated.
89419181|NCT02200068|No Intervention|Non-PHR Group|This group will not be informed of the Personal Health Record Website and will use Internet as they usually do.
89419182|NCT04974502|Experimental|Non-smoker group|
89419183|NCT04974502|Experimental|Smoker group|
89419184|NCT03690505|Other|Assessment|Assessment of the Knowledge and Needs of Patients With AMD Before a Therapeutic Patient Education Program is Put in Place
89419185|NCT03685357||Idiopathic Parkinson's|"Oral glucose tolerance test~The Unified Parkinson's Disease Rating Scale (UDPRS)."
89419186|NCT03685357||Diabetics receive sulphonylurea group|"Record RBDSQ (Rapid eye movement Sleep Behavior Disorder Screening Questionnaire) total score"
89419187|NCT03685357||Diabetics on sulphonylurea and metformin|"Record RBDSQ (Rapid eye movement Sleep Behavior Disorder Screening Questionnaire) total score"
89419188|NCT03685357||Healthy|"Record RBDSQ (Rapid eye movement Sleep Behavior Disorder Screening Questionnaire) total score~Oral glucose tolerance test"
89419189|NCT02200146|Active Comparator|Prednisone|Prednisone per os 0,5 mg/kg/die once/day for 3 months. After 3 months, between responders, prednisone was slowly tapered (5 mg/week maintaining the new reduced dose for one week) to 0,2 mg/kg/die for further 6 months.
89419190|NCT02200146|Experimental|Hydroxychloroquine + Prednisone|Hydroxychloroquine per os 200 mg/die (or adjusted for body weight if less than 61 kg), twice/day + prednisone 0,15 mg/kg per os daily, once/day for 3 months, than for further 6 months between responders.
89419191|NCT04974190|Active Comparator|Patients treated with actual device with actual solution|
89419192|NCT04974190|Placebo Comparator|Patients treated with actual device with placebo solution|
88897691|NCT01483066|Experimental|ShapeMatch Instrumentation|
88897692|NCT01483066|Active Comparator|Usual Instrumentation|
88897693|NCT01483092|Experimental|inulin|
88897694|NCT01483092|Placebo Comparator|maltodextrin|
88897695|NCT01483131|Experimental|Low intensity resistance training|
88897696|NCT01483131|Experimental|High intensity resistance training|
88897697|NCT01483131|Experimental|Low intensity resistance training with vascular occlusion|
89419193|NCT03690349||Skin test in severe asthma exacerbation|Skin test in asthmatic children hospitalized due to severe asthma exacerbation in a preceding year
88897698|NCT01483157|Experimental|low intensity with vascular occlusion|
88897699|NCT01483157|Experimental|high intensity resistance training|
88897700|NCT01483157|No Intervention|no exercise training|
88897701|NCT01483170|Experimental|Fexinidazole|
88897702|NCT01483170|Placebo Comparator|Placebo fexinidazole|
89419194|NCT03690349||skin test in outpatient|Skin test in asthmatic children without severe asthma exacerbation in a preceding year
88897703|NCT01483196|Experimental|Diagnostic (TCD)|Patients undergo TCD examination including bilateral evaluation of standard intracranial arterial segments including the M1 and M2 segments of the MCA, the ACA and PCA, via the transtemporal acoustic windows, the ICA siphon via transorbital approach, and the vertebral and basilar arteries (proximal, mid, and distal) via the suboccipital approach. Patients also undergo MRI. All tests occur between 21 days after completion of surgery and up to 30 days prior to adjuvant chemotherapy and between 20-60 days after completion of adjuvant chemotherapy.
89194023|NCT02563600|Experimental|Pre-letter telephone call|A brief 10 min telephone call to patients on waiting list prior to receipt of appointment invitation letter.
89419195|NCT02200224|Experimental|Rapid Testing/Treatment Group|All subjects enrolled in the rapid testing group will receive rapid CT/NG and TV testing in addition to the CT/NG Nucleic Acid Amplification Test (NAAT) and wet mount testing that is currently used in the ED.
89419196|NCT02200224|No Intervention|Control|All subjects enrolled in the control group will receive CT/NG and TV testing according to the current standard of care for Johns Hopkins ED.
89419197|NCT03685279|Experimental|NHA Group|"Six-week, online intervention with weekly, sequential, content knowledge and skills practice. Each week included recorded, slide presentations (narrated by the developer of the NHA, Howard Glasser); readings from The Transforming the Intense Child Workbook by Howard Glasser with Melissa Lowenstein; participants' skills practice, web postings, and live sessions with Howard Glasser and Advanced NHA Trainers."
88897704|NCT01483222|Experimental|QUIKDRAW Pro|Wearing an inelastic lumbar support for 6 months
88897705|NCT01483222|Experimental|MUELLER 4581|Wearing an elastic lumbar support for 6 months
88897706|NCT01483222|No Intervention|Blank Control|Receiving no intervention
88897707|NCT01483235|Experimental|Reduced cardiac rehabilitation (rCRP)|The rCRP is the intervention group, compared to the standard cardiac rehabilitation program group (sCRP). The rCRP will have the core elements of the sCRP, that is, in-hospital exercise sessions, dietary counseling, educational sessions, follow-up with the cardiologist, dietician and exercise specialist. The only difference will be the number of in-hospital exercise sessions (10 sessions for the rCRP v/s 32 sessions for the sCRP). Patients from rCRP will receive individual exercise guidelines, an educational package with questions of the week and a diary to record their exercise sessions (logbook), that will serve as a self-monitoring system.
88897708|NCT01483235|Active Comparator|Standard cardiac rehabilitation (sCRP)|The standard cardiac rehabilitation (sCRP) follows the standard cardiac rehabilitation program model of a four-month period. Patients receive an initial intake evaluation by a cardiologist, nurse, exercise specialist and dietitian before starting the program. The program consists of 32, twice weekly in-hospital exercise sessions, educational sessions, nutritional counseling, medical care, psychological screening and smoking cessation if needed.
89194024|NCT02563600|Experimental|Post-letter telephone call|A brief 10 min telephone call to patients on waiting list prior to receipt of appointment invitation letter.
88897709|NCT01483248|Experimental|Intervention|Conventional therapy plus MenSCs treatment
88897710|NCT01483248|Active Comparator|No intervention|"Conventional therapy plus placebo treatment:~Oral or intravenous administration"
88897711|NCT01483261|Experimental|Trauma-Focused Cognitive Behavioral Therapy|
89194025|NCT02563600|No Intervention|No telephone call|No telephone call made to patient.
89194026|NCT02521493|Experimental|Arm A (standard risk)|"INDUCTION II: Patients receive cytarabine IV continuously over 96 hours, daunorubicin hydrochloride IV over 1-15 minutes, and thioguanine PO BID on days 1-4. Induction II continues for a minimum of 28 days.~INDUCTION III: Patients receive cytarabine, daunorubicin hydrochloride, and thioguanine as in Induction II. Induction III continues for a minimum of 28 days.~INTENSIFICATION I: Patients receive cytarabine IV continuously over 168 hours on days 1-7 and etoposide IV over 60-120 minutes on days 1-3. Intensification I continues for a minimum of 28 days.~INTENSIFICATION II: Patients receive cytarabine and etoposide as in Intensification I. Intensification II continues for a minimum of 28 days.~(This arm is closed to accrual and treatment with amendment #4A 01/07/2019)"
89194027|NCT02521493|Experimental|Arm B (high risk)|"INDUCTION II: Patients receive high dose cytarabine IV over 1-3 hours Q12 hours on days 1-4 and mitoxantrone hydrochloride IV over 15-30 minutes on days 3-6. Induction II continues for a minimum of 28 days.~INTENSIFICATION I: Patients receive high dose cytarabine IV over 1-3 hours Q12 hours and etoposide IV over 90-120 minutes on days 1-5. Intensification I continues for a minimum of 28 days.~INTENSIFICATION II: Patients receive high dose cytarabine IV over 3 hours Q12 hours on days 1, 2, 8, and 9. Patients also receive asparaginase or asparaginase Erwinia chrysanthemi IM or IV over 30 minutes on days 2 and 9. Intensification II continues for a minimum of 28 days."
89194028|NCT02517749|Active Comparator|Usual Care Group|Patients in this group will be managed as per the British Thoracic Society guideline for management of malignant pleural effusions. They will undergo chest tube insertion and undergo Talc pleurodesis with 4g of SteriTalc
89194029|NCT02517749|Active Comparator|Indwelling Pleural Catheter Group|Patients in this group will undergo Indwelling Pleural Catheter (IPC) insertion. This will be inserted as per standard practice. They will undergo Talc pleurodesis via the IPC with 4g SteriTalc
89194030|NCT02419495|Experimental|Arm A (selinexor, carboplatin) (ARM CLOSED)|Patients receive selinexor PO on days 1, 8, and 15 and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. After 6 cycles, patients can continue single agent selinexor until disease progression.
89194031|NCT02419495|Experimental|Arm B (selinexor, paclitaxel)|Patients receive selinexor PO twice weekly (e.g. Monday/Wednesday or Tuesday/Thursday or Wednesday/Friday or Thursday/Saturday or Friday/Sunday) on days 1-14. Patients then receive selinexor PO on days 1, 3, 8 and 10 and paclitaxel IV over 3 hours on days 1 and 8. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity. After 8 cycles of combination treatment, patients can continue single agent selinexor until disease progression.
89194032|NCT02419495|Experimental|Arm C (selinexor, eribulin)|Patients receive selinexor PO on days 1, 8, and 15 and eribulin IV over 1 hour on days 1 and 8. Combination treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. After 6 cycles, patients can continue single agent selinexor until disease progression.
89194033|NCT02419495|Experimental|Arm D (selinexor, doxorubicin, cyclophosphamide) (ARM CLOSED)|Patients receive selinexor PO on days 1, 8, and 15, doxorubicin IV over 90 minutes and cyclophosphamide IV over 30 minutes on day 1. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. After 6 cycles, patients can continue single agent selinexor until disease progression.
89194034|NCT02419495|Experimental|Arm E (selinexor, carboplatin, paclitaxel) (ARM CLOSED)|Patients receive selinexor PO on days 1, 8, and 15 and carboplatin IV over 30 minutes and paclitaxel IV over 3 hours on day 1. Treatment repeats every 21 days for up to 8 cycles depending con cancer type (6 cycles for non-small cell lung cancer, up to 8 cycles for ovarian cancer and other histological malignancies) in the absence of disease progression or unacceptable toxicity. After 6 to 8 cycles, patients can continue single agent selinexor until disease progression.
89194035|NCT02419495|Experimental|Arm F (selinexor, carboplatin, pemetrexed) (ARM CLOSED)|Patients receive selinexor PO on days 1, 8, and 15 and carboplatin IV over 30 minutes and pemetrexed disodium IV over 10 minutes on day 1. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. After 6 cycles, patients can continue single agent selinexor until disease progression.
88897712|NCT01483261|No Intervention|Waiting List Control|
88897713|NCT01483274|Experimental|Safety|Decitabine and donor lymphocyte infused dendritic cell (DC).
88897714|NCT01483274|Active Comparator|Vaccine|Decitabine and Dendritic cell (DC) pulsed with MAGE-A1, MAGE-A3, NY-ESO-1 Peptides
88897715|NCT01483287|Active Comparator|Enzyme|Capsules with alpha-galactosidase (enzyme) (400 GaIU x 3) are ingested at breakfast, lunch and dinner.
88897716|NCT01483287|Placebo Comparator|Placebo|3 capsules with a non-active substance are ingested at breakfast, lunch and dinner
88897717|NCT01483300|Experimental|lobaplatin|gemcitabine plus lobaplatin
88897718|NCT01483300|Active Comparator|cisplatin|gemcitabine plus cisplatin
88897719|NCT01483326||Cohort|
88897720|NCT01483339|Experimental|Metacognitive Therapy|
88897721|NCT01483339|Experimental|Exposure and Response Prevention|
89194036|NCT02419495|Experimental|Arm G (selinexor, topotecan hydrochloride) (ARM CLOSED)|Patients receive selinexor PO on days 1, 8, and 15 and topotecan hydrochloride IV over 30 minutes on days 1-5. Treatment repeats every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity. After 8 cycles, patients can continue single agent selinexor until disease progression.
89419198|NCT03685279|Other|Control Group|The Control Group received the same intervention after the collection of NHA Group post-intervention surveys.
89419199|NCT02208492|Experimental|Levetiracetam|
89419200|NCT02208492|Active Comparator|Carabamazepine|
88897722|NCT01483391|Active Comparator|Enhanced Care|Three sessions of family education and three sessions of individual support over 4 months.
88897723|NCT01483391|Experimental|Family-Focused Treatment|12 therapy sessions involving the at-risk child or adolescent, parents, and available siblings. Therapy will include psychoeducation about mood disorders, communication enhancement training, and problem-solving skills training.
89419201|NCT03685201|Active Comparator|Orange Juice1|100% orange juice
88897724|NCT01483404||Patient with fracture of femural neck|All patient with fracture of the femural neck in the listed period of time
88897725|NCT01483417|Experimental|SILS|Laparoscopic hysterectomy including LAVH, LH(a), and TLH using SILS port
88897726|NCT01483417|Active Comparator|Conventional multi-port laparoscopic hysterectomy|3-4 ports laparoscopic hysterectomy including LAVH, LH(a), or TLH
88897727|NCT01483430|Placebo Comparator|Placebo|
88897728|NCT01483430|Experimental|Ginseol Kg1, high dose|
88897729|NCT01483430|Experimental|Ginseol Kg1, low dose|
88897730|NCT01483443|Experimental|Oophrectomy group|Patient undergone oophrectomy along with primary tumor
88897731|NCT01483443|No Intervention|without oophrectomy|Patient group without oophrectomy
88897732|NCT01483456|Other|Usual care|
88897733|NCT01483469|Active Comparator|Concept Proof|
88897734|NCT01483469|Experimental|Receptor Occupancy|
88897735|NCT01483482|Other|Conservative treatment|"The group allocated to conservative treatment is treated with a simple sling. The sling is removed when the patient is pain free.~The first 6 weeks max 1 kg of weight-bearing is allowed and the patient is instructed to restrict movement of the arm to the level of the shoulder."
88897736|NCT01483482|Other|Surgical treatment|"Patients allocated to surgical treatment are operated with a superior locking plate.~The first 6 weeks max 1 kg of weight-bearing is allowed and the patient is instructed to restrict movement of the arm to the level of the shoulder."
88897737|NCT01483508|Active Comparator|Flavanol and procyanidins|
88897738|NCT01483508|Experimental|Flavanols only|
88897739|NCT01483508|Experimental|Procyanidins only|
88897740|NCT01483521|Experimental|Waitlist families|"Experimental arm consisted of randomized waitlist families who received home visitation where mothers were taught to play with their children in a developmentally appropriate manner and also engaged in a co-construction task.~Control arm families did not get any active intervention. Parents from both arm types completed pre and post questionnaires to measure child's externalizing behaviors and parenting stress.~Parents from experimental group were encouraged to keep a diary of their play record."
88897741|NCT01483534|Experimental|Targeted Lung Denervation|Targeted Lung Denervation
88897742|NCT01483547||Neurosurgical|
88897743|NCT01483547||Non-neurosurgical|
88897744|NCT01483573|Experimental|straight leg raise|stretch the muscle
88897745|NCT01483573|Experimental|neural mobilization|stretch the nerve
88897746|NCT01483586|Experimental|KLTc high dose|6 KLTc gelcaps taken four times a day
88897747|NCT01483586|Experimental|KLTc low dose|3 KLTc gelcaps taken four times a day
88897748|NCT01483638|Experimental|Experimental|axitinib
88897749|NCT01483638|Placebo Comparator|control|placebo
88897750|NCT01483677|Experimental|Nintendo Wii|Subjects in this arm of the study play a game (Boomblox) on the Nintendo Wii for 30 minutes.
88897751|NCT01483677|Active Comparator|Playstation2|Subjects in this arm of the study play a game (Time Crisis 2) on the Playstation 2 for 30 minutes.
88897752|NCT01483716|No Intervention|Control|NIV alone
88897753|NCT01483716|Experimental|Intervention|Rehabilitation arm
88897754|NCT01483729|Active Comparator|Part 1 A|
88897755|NCT01483729|Experimental|Part 1 B|
88897756|NCT01483729|Experimental|Part 1 C|
88897757|NCT01483729|Active Comparator|Part 2 D|
88897758|NCT01483729|Experimental|Part 2 E|
88897759|NCT01483729|Experimental|Part 2 F|
88897760|NCT01483755|Experimental|Postconditionned|36 postconditionned patients
88897761|NCT01483755|Sham Comparator|Conventional intervention|36 control patients with conventional primary percutaneaous intervention (PCI)
88897762|NCT01483768|Experimental|Arm A:|Sleeve gastrectomy for morbid obesity
88897763|NCT01483781|Experimental|Canagliflozin|
88897764|NCT01483781|Placebo Comparator|Placebo|
89419202|NCT03685201|Experimental|Orange Juice2|100% Orange Juice with enzyme-treated orange pomace fiber
89419203|NCT03685201|Placebo Comparator|Raw Orange|raw orange
89419204|NCT01670188|Active Comparator|Pneumatic SCD|Use of pneumatic SCD (VenaFlow System - DJO Global) on upper extremity with PICC line inserted.
89419205|NCT01670188|No Intervention|Non-SCD group|Standard care
89419206|NCT02208570|Experimental|P(+)V(+)|PPV>14% before anesthesia induction, HES 6ml/kg infused
89419207|NCT02208570|Experimental|P(+)V(-)|PPV>14% before anesthesia induction, no additional volume infused
89419208|NCT02208570|Experimental|P(-)V(+)|PPV<14% before anesthesia induction, HES 6ml/kg infused
89419209|NCT02208570|Experimental|P(-)V(-)|PPV<14% before anesthesia induction, no additional volume infused
89419210|NCT03685123|Experimental|PA-REC|This group will participate in an OPTIFAST weight loss program. After achieving clinically significant weight loss, participants will exercise at the minimum physical activity recommendations
89419211|NCT03685123|Experimental|WM-REC|This group will participate in an OPTIFAST weight loss program. After achieving clinically significant weight loss, participants will exercise at the weight maintenance recommendations
89419212|NCT04982536|Experimental|VMCore Biopsy System|The VMCore biopsy needle will used to collect up to 10 tissue samples.
89419213|NCT04982536|Active Comparator|Standard of Care Biopsy Needle|The urologist will use his/her standard biopsy needle to collect up to 15 tissue samples.
89419214|NCT02208648||Deceased|"Peri-operative mortality (within 90 days). Pairs of CT scans (deceased plus matched control) will be anonymised and stored on a secure server. Abbreviated Calcium scores will be generated for all patients in the trial by a trained radiologist using a calcium scoring method. The radiologist will be blinded to the group that the patient belongs to, to minimise bias. Scans (deceased patients and matched controls) will be analysed in batches of 30 pairs. Radiologist (s) will be blinded to group allocation. Scans will not be paired at the time of reading."
89419215|NCT02208648||Matched control|"Patients who survived beyond 90 days peri-operatively. Pairs of CT scans (deceased plus matched control) will be anonymised and stored on a secure server. Abbreviated Calcium scores will be generated for all patients in the trial by a trained radiologist using a calcium scoring method. The radiologist will be blinded to the group that the patient belongs to, to minimise bias. Scans (deceased patients and matched controls) will be analysed in batches of 30 pairs. Radiologist (s) will be blinded to group allocation. Scans will not be paired at the time of reading."
88897765|NCT01483794||Genital warts treated|Patients that have had treatment on their genital warts
88897766|NCT01483794||Genital warts on treatment|Patients currently being treated for genital warts
88897767|NCT01483833|Active Comparator|Iferanserin|Iferanserin administration intra-anally twice daily for 14 days
88897768|NCT01483833|Placebo Comparator|Placebo|Placebo administration intra-anally twice daily for 14 days
88897769|NCT01483846|Experimental|AV-101|"Subjects will be randomized into one of three dose cohorts (360, 1,080, and 1,440 mg) to receive a daily oral dose for 14 consecutive days. Each cohort will have 12 subjects on active drug and 4 subjects on placebo.~--------------------------------------------------------------------------------"
88897770|NCT01483846|Placebo Comparator|microcrystalline cellulose|Subjects will be randomized into one of three cohorts (360, 1,080, and 1,440 mg) to receive a daily oral dose for 14 consecutive days. Each cohort will have 12 subjects on active drug and 4 subjects on placebo.
88897771|NCT01483859|Other|right hepatectomy with preoperative LSM|patients undergoing right hepatectomy with preoperative LSM between August 2007 and July 2011
88897772|NCT01483885|Experimental|TENS 4Hz|
88897773|NCT01483885|Experimental|Interferential Current 4Hz|
88897774|NCT01483885|Placebo Comparator|TENS|
88897775|NCT01483885|Placebo Comparator|Interferential Current|
88897776|NCT01483885|Experimental|Manual Acupuncture|
88897777|NCT01483885|Experimental|TENS 100 Hz|
89419216|NCT03690271||Groupe 5-5|"Patients for whom the clinician has prescribed local anesthetics in the epidural:~fixed dose administered every hour in a systematic way : 5 ml~dose to be administered every hour by the patient : 5 ml"
89419217|NCT03690271||groupe 6-6|"Patients for whom the clinician has prescribed local anesthetics in the epidural:~fixed dose administered every hour in a systematic way : 6 ml~dose to be administered every hour by the patient : 6 ml"
88897778|NCT01483885|Experimental|Interferential Current 100Hz|
89419218|NCT03690271||groupe 7-7|"Patients for whom the clinician has prescribed local anesthetics in the epidural:~fixed dose administered every hour in a systematic way :7 ml~dose to be administered every hour by the patient :7 ml"
89419219|NCT02208726|Placebo Comparator|Sucrose pillules|Unmedicated sucrose pillules will be taken once daily, in the morning, 30 minutes after breakfast, for 14 days, up to 7 days before the first academic examination.
89419220|NCT02208726|Experimental|Homeopathic homaccord|Sucrose pillules medicated with Picricum acidum and Phosphoricum acidum in potencies of 6CH, 30CH and 200CH. Pillules will be taken once daily, in the morning, 30 minutes after breakfast, for 14 days, up to 7 days before the first academic examination.
88897779|NCT01483911|Experimental|ALX-0171|
88897780|NCT01483911|Placebo Comparator|Placebo|
88897781|NCT01483950||Patients with hypercholesterolaemia|
88897782|NCT01483976|Active Comparator|Oral medical nutritional supplement without AN777|orally over a three hour period
88897783|NCT01483976|Experimental|Experimental oral medical nutritional supplement with AN777|orally over a three hour period
88897784|NCT01483989|Experimental|SYSTANE® Gel Drops Lubricant eye gel|SYSTANE Gel Drops Lubricant Eye gel dosed (bilaterally) 3 times per day for the 28 day period.
88897785|NCT01484002||Crosslinked polyethylene liners|Polyethylene liners from joint replacements that were crosslinked and heat treated to eliminate free radicals.
88897786|NCT01484002||Conventional polyethylene liners|Polyethylene liners from joint replacements that manufactured from conventional UHMWPE and terminally sterilized by methods that did not involve gamma-irradiation.
89419221|NCT03690193|Experimental|Ketogenic Diet Arm|All participants will be assigned to the 3-month ketogenic diet intervention. Study partners will be instructed to assist participants in adherence to a 1:1 ketogenic diet (approximately 70% fat, <10% carbohydrate, and 20% protein). Participants will be provided medium chain triglyceride oil with a target intake of 1-2 tablespoons per day and micronutrient supplements consisting of multivitamin, vitamin D, calcium, and phosphorus. After the 3-month ketogenic diet, participants will complete a 1-month washout period in which they halt adherence to the ketogenic diet and resume their normal diet.
89419222|NCT02208804|Experimental|Surefire Infusion System|Hepatic arterial administrations using the Surefire Infusion System
89419223|NCT02208804|Active Comparator|Standard End-hole Microcatheter|Hepatic arterial administrations using the standard end-hole microcatheter
89419224|NCT03684967|Experimental|fruquintinib|Fruquintinib treatment: administration for 3 weeks followed by 1 week break, and administration every day for the first 21 days.
89419225|NCT01933048|Other|Healthcare Worker Administration|FluMist administered by a Healthcare Worker
89419226|NCT01933048|Experimental|Self-Administration|FluMist self-administered by subject
89419227|NCT02258100||Paper|Patients receiving care documented via paper anesthesia record.
88897787|NCT01484015|Experimental|Arm I (standard infusion)|Patients receive cefepime hydrochloride IV over 30 minutes.
89419228|NCT02258100||AIMS|Patients receiving care documented via electronic anesthesia record.
89419229|NCT04059367|Experimental|NNC9204-1177 and cocktail of approved drugs|
88897788|NCT01484015|Experimental|Arm II (prolonged infusion)|Patients receive cefepime hydrochloride IV over 3 hours. Treatment repeats every 8 hours.
88897789|NCT01484067|Experimental|Patch|At onset of signs/symptoms, subjects will apply assigned patch, and return to study center within 24 hours. Patch will be worn continuously, being replaced as needed.
88897790|NCT01484067|No Intervention|No Patch|No treatment will be initiated at onset of signs and symptoms although subject is still required to return to study center with 24 hours of onset of signs/symptoms.
88897791|NCT01484080|Experimental|Arm I: BIBF1120+Paclitaxel|2 weeks run-in of BIBF 1120 alone followed by paclitaxel + BIBF 1120 combination
88897792|NCT01484080|Active Comparator|Arm II: Paclitaxel|Paclitaxel monotherapy treatment will start within 2 weeks after randomization.
88897793|NCT01484106|Experimental|Treatment group|"Patients will be randomized (1:1, stratified by site, in permutation blocks of 4) to the Treatment or Standard Care arms."
88897794|NCT01484106|Active Comparator|Control|Standard of Care
88897795|NCT01484145|Active Comparator|6 mA.min, 20 mins|
88897796|NCT01484145|Experimental|6 mA/min, 20 mins, clamping|
88897797|NCT01484145|Experimental|6 mA/min, 20 mins, debridement, clamping|
88897798|NCT01484145|Experimental|15 mA/min, 30 mins, clamping|
88897799|NCT01484145|Experimental|15 mA/min, 50 mins, debridement, clamping|
88897800|NCT01484158||Myocardial Infarction|Patients with myocardial infarction
88897801|NCT01484171|Active Comparator|idarubicin|The patients will receive induction chemotherapy containing standard dose of idarubicin in combination with cytarabine.
88897802|NCT01484171|Experimental|microtransplantation|The patients will receive induction chemotherapy containing high dose of idarubicin in combination with cytarabine and follow by infusioning granulocyte colony-stimulating factor-mobilized HLA-mismatched donor peripheral blood stem cells
88897803|NCT01484184|Active Comparator|buspirone or levodopa/carbidopa|Another 2-arm design will be tested composed of 16 subjects receiving drug A or drug B at MTD dose of the combined study drug as identified in the previous 2-arm groups.
88897804|NCT01484184|Placebo Comparator|Placebo|First, a 2-arm design will be used, the first arm being composed of 3 subjects receiving the lowest dose of SPINALON, the second arm being composed of 1 subject receiving a placebo. This 2-arm design will be repeated consecutively with increasing doses, as long as the dose is well tolerated. Six (6) groups are expected to be tested with this 2-arm design.
88897805|NCT01484223|Experimental|Experimental Group|Intervention group: Structured nursing intervention
89419230|NCT02208882|Experimental|Panel 1: BMS-986120 or Placebo|BMS-986120 or Placebo multiple dose by mouth as specified
89419231|NCT02208882|Experimental|Panel 2: BMS-986120 or Placebo|BMS-986120 or Placebo multiple dose by mouth as specified
89419232|NCT02208882|Experimental|Panel 3: BMS-986120 or Placebo + Midazolam|BMS-986120 or Placebo (multiple dose) + Midazolam (single dose) by mouth as specified
88897806|NCT01484223|No Intervention|No intervention|Control group: conventional intervention or non_support
88897807|NCT01484262||Liraglutide|
88897808|NCT01484262||Any insulin|
88897809|NCT01484353|Experimental|Intervention group|This is the only arm in the study. They will be compared before and after
88897810|NCT01484366|Active Comparator|intramedullary nailing and plating|intramedullary nailing of the ulna and plating of the radius in the treatment of both bone forearm fractures
88897811|NCT01484366|Active Comparator|plating|plating of both the radius and ulna in the treatment of both bone forearm fractures
89419233|NCT02208882|Experimental|Panel 4: BMS-986120 or Placebo|BMS-986120 or Placebo multiple dose by mouth as specified
89419234|NCT04432246|Experimental|bilateral SMA|Continuous theta burst stimulation (cTBS) stimulation will be applied over the bilateral SMA once a day, 5 days/week, for 4 weeks.
89419235|NCT03681301|Experimental|Interventional|Additional self-directed learning and practice using virtual reality simulator, after conventional training session
89419236|NCT03681301|No Intervention|Control|Conventional training session which includes didactic teaching and low-fidelity simulation session involving trainer's demonstration, followed by hands-on practice
89419237|NCT02208960|Experimental|Neonatal Kit|Mothers in the neonatal kit clusters will receive a neonatal kit and training on how to use the kit components during their third trimester of pregnancy. The kit will contain a clean birth kit to be used at the time of delivery either at home or in a facility, 4% chlorhexidine (CHX) lotion, sunflower oil emollient, ThermoSpot, a Mylar infant sleeve, and a reusable, non-electric, heating device. Community Health Workers will be equipped with a hand-held battery operated scale to identify low birth weight newborns.
89419238|NCT02208960|Experimental|Neonatal Stimulation|During home visits in the 3rd trimester, mothers in the neonatal stimulation clusters will be taught 3 core messages pertaining to neonatal stimulation. First, mothers will be taught how to make eye contact and talk to their child. This type of interaction encourages social inclusion, attachment, and development of social-communication skills. Second, mothers will be taught techniques to foster responsive feeding and caregiving. Finally, mothers will be encouraged to sing songs and nursery rhymes, including those with gentle touch in order to support the development of communication skills, and introduce a tactile component to caregiving. These messages will be reiterated at subsequent home visits by the CHW after the baby is born.
89419239|NCT02208960|Experimental|Neonatal Kit and Neonatal Stimulation|Participants in this arm of the study will receive both a neonatal kit (described in Arm 1) and neonatal stimulation (described in Arm 2).
89419240|NCT02208960|No Intervention|Control (Standard Care)|"In control clusters, CHWs will visit the home according to the regular schedule (same as in the intervention clusters) and deliver the standard CHW post-natal care that consists of talking to mothers about:~Exclusive breastfeeding and proper nutrition for both the mother and the baby.~Ensuring warmth to the baby.~Full immunization and growth monitoring of newborn.~Hygiene and sanitation practices.~Family Planning and promote the proper use of Insecticides Treated Nets.~Identifying any danger sign/complication for both mothers and new-borns and refer for prompt treatment (within 24 hours) for management and treatment.~Promoting the use of services such as birth registration.~Giving advice on proper care of the umbilical cord."
89419241|NCT04974112||General Surgery|This study was conducted in parallel in many Class-A hospitals across the country. Special researchers were assigned by the research unit to collect patient information using SGA and NRS2002 and other data measurement tools.
89419242|NCT04974112||Thoracic Surgery|This study was conducted in parallel in many Class-A hospitals across the country. Special researchers were assigned by the research unit to collect patient information using SGA and NRS2002 and other data measurement tools.
89419243|NCT04974112||orthopedics|This study was conducted in parallel in many Class-A hospitals across the country. Special researchers were assigned by the research unit to collect patient information using SGA and NRS2002 and other data measurement tools.
89419244|NCT04974112||Gastroenterology|This study was conducted in parallel in many Class-A hospitals across the country. Special researchers were assigned by the research unit to collect patient information using SGA and NRS2002 and other data measurement tools.
89536009|NCT03200275||HOSPITALISED PNEUMONIA PATIENTS|"All patients of more than 18 years of age, hospitalized consecutively for pneumonia irrespective of it being community or hospital acquired. All the patients included in this study will need to have acute symptoms of less than 2 weeks and radiological features which are compatible to pneumonia.~They will undergo testing for Legionella pneumophila serogroup 1 urine antigen using a qualitative rapid assay following manufacturer's instructions at baseline. The diagnosis of Legionella pneumonia is made if the Immunocatch™ Legionella Urine Antigen Test is positive."
89536010|NCT02479295|Active Comparator|Straight Tenckhoff catheter|Tenckhoff catheter with straight intra-abdominal part
89536011|NCT02479295|Active Comparator|Coiled Tenckhoff catheter|Tenckhoff catheter with coiled intra-abdominal part
88897812|NCT01484379|Experimental|unilateral neck exploration|unilateral neck exploration of elderly with primary hyperparathyroidism
88897813|NCT01484405|Other|anterolateral approach|surgical intervention THA anterolateral approach
88897814|NCT01484405|Other|posterior approach|surgical intervention THA posterior approach
88897815|NCT01484418|Experimental|A Exposure long|Exposure in vivo for fear avoidant chronic low back pain patients. This treatment means that the individual is exposed to movements and tasks that have been avoided due to fear of (re)injury. The treatment begins after three educational lessons including the rational and developing a fear hierarchy. Exposure phase includes 10 exposures sessions which are highly individualized. Behavioral experiments can be included to correct catastrophic misinterpretations. The main purpose of this intervention type is to reduce pain related disability via diminishing fear avoidance.
88897816|NCT01484418|Experimental|B Exposure short|See above exposure long. This treatment comprises 5 exposure sessions.
88897817|NCT01484418|Active Comparator|C Cognitive behavioural psychotherapy|Cognitive behavioural psychotherapy for fear avoidant chronic low back patients. The therapy is modularized in three main parts. The educational lesson is followed by the module graded activity which represents the behavioral part of the program. The second module comprises relaxation. And the last part contains cognitive interventions. Cognitive behavioural intervention techniques are employed to support the patient in the process of coping with chronic pain: i.e. reduction of disability and improving functional ability.
88897818|NCT01484444||gastrointestinal cancer|
88897819|NCT01484457|Experimental|Closed-loop control system|"The objective of this study is to automate glucose control in subjects with type 1 diabetes using a computer control algorithm in a controlled in-clinic research setting.~The controller will be evaluated under two conditions:~restoring euglycemia (80-140 mg/dL) when the controller is initiated during a period when the subject's glucose is above the euglycemic range;~restoring euglycemia (80-140 mg/dL) when the controller is challenged with a small unannounced meal (~25 g CHO)."
88897820|NCT01484470|No Intervention|Unmanipulated arm|Participants that do not meet criteria for StemEx®, will be registered into the unmanipulated UCB arm and receive the standard conditioning regimen.
88897821|NCT01484470|Experimental|Stemx Arm|StemEx is a stem/progenitor cell-based product of ex-vivo expanded allogeneic UCB, which is administered to the subject in combination with the non-manipulated portion of the same cord blood unit (CBU). The CBU must be cryopreserved in two portions of which the larger (or equal) CBU portion contains at least 1.5 x 107 total nucleated cells (TNC)/Kg. This portion remains unmanipulated and is transplanted on Day 0. StemEx is derived from the smaller (or equal) CBU portion, which is expanded ex vivo for 21 days starting pre-transplant in the presence of cytokines TPO, IL-6, Flt-3L and SCF at a concentration of 50ng/ml and 5μM tetraethylenepentamine (TEPA)
88897822|NCT01484483||Cohort|
88897823|NCT01484509||Intermittent claudication|
88897824|NCT01484522||Group A|Influenza A 2009 Monovalent vaccine
88897825|NCT01484522||Group B|Influenza A 2009 monovalent vaccine
88897826|NCT01484522||Group C|Influenza A 2009 monovalent vaccine
88897827|NCT01484535|Other|Ankle aspiration|ankle aspiration
88897828|NCT01484535|Placebo Comparator|placebo procedure|placebo procedure
88897829|NCT01484548|Experimental|Vaccine: 20 ug LEISH-F3 + 2 ug GLA-SE|Low dose of adjuvant.
88897830|NCT01484548|Experimental|Vaccine: 20 ug LEISH-F3 + 5 ug GLA-SE|Higher dose of adjuvant.
88897831|NCT01484548|Active Comparator|20 ug LEISH-F3 alone|20 ug of LEISH-F3 antigen alone. 3 injections at Days 0, 28, and 56.
88897832|NCT01484574|Experimental|Low dose|Stempeucel - CLI will be administered at the lowest dose
88897833|NCT01484574|Experimental|Intermediate dose|Stempeucel - CLI will be administered at intermediate dose
88897834|NCT01484574|No Intervention|Control arm|Standard protocol of care alone
88897835|NCT01484587|Experimental|001|
88897836|NCT01484587|Placebo Comparator|002|
88897837|NCT01484600|Experimental|Group 1|
88897838|NCT01484600|Experimental|Group 2|
88897839|NCT01484613||Quadripolar lead|All participants receive a CRT-D system with quadripolar lead
88897840|NCT01484639|Active Comparator|Restrictive transfusion triggers|"Patients allocated to a restrictive transfusion group will receive a red cell transfusion if their hemoglobin is 75 g/L or less intraoperatively and postoperatively."
88897841|NCT01484639|Active Comparator|Liberal transfusion triggers|"Patients allocated to a liberal transfusion strategy will receive red cell transfusion if their hemoglobin concentration is 95 g/L or less intraoperatively and postoperatively in the intensive care unit, and less than 85 g/L on the ward."
88897842|NCT01484665|Experimental|Participants (Males, age 50-75 yrs)|Eligible men will be identified from the administrative database and electronic medical record at the University of Minnesota (EMR) at least 24 hours prior to the clinic visit. They will be asked to complete the PROCASE Decision-Aid.
88897843|NCT01484704||No treatment|
88897844|NCT01484704||MRI|
88897845|NCT01484717|Active Comparator|Standard Care|Telephone counseling plus nicotine patch
88897846|NCT01484717|Experimental|Contingency management for abstinence from cigarettes|Telephone counseling and nicotine patch plus contingency management
88897847|NCT01484743||Patients with parastomal hernia repair|Patients registered in the Danish Ventral Hernia database
88897848|NCT01484756|Placebo Comparator|calcium carbonate 500 mg|Control group received one daily tablet of calcium carbonate 500 mg for 6 months
88897849|NCT01484756|Experimental|daily multi micronutrient supplement|Experimental group received one daily multi micro-nutrient supplement tablet for 6 months
88897850|NCT01484782|Experimental|Interactive Voice Response (IVR) calls|Weekly automated telephone assessment and behavior change calls focused on blood pressure management. The experimental group will receive a weekly 10-minute automated phone call to their telephone for disease assessment and self-care support for 6 weeks. In-home blood pressure cuffs were provided for measurement of blood pressure throughout the study.
88897851|NCT01484782|No Intervention|Usual care|This group received results of blood pressure readings. PCP referrals. Educational materials about hypertension and self-management. At follow-up, patients received home blood pressure monitoring cuffs.
89194037|NCT02419495|Experimental|Arm H (selinexor, FOLFIRI) (ARM CLOSED)|Patients receive selinexor PO on days 1, 8, 15 and 22, irinotecan hydrochloride IV over 90 minutes, fluorouracil IV continuously over 48 hours and leucovorin calcium IV over 2 hours on days 1 and 15. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. After 6 cycles, patients can continue single agent selinexor until disease progression.
89194038|NCT02419495|Experimental|Arm I (selinexor, irinotecan hydrochloride) (ARM CLOSED)|Patients receive selinexor PO on days 1, 8 and 15 and irinotecan hydrochloride IV over 90 minutes on days 1 and 8. Treatment repeats every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity. After 8 cycles, patients can continue single agent selinexor until disease progression.
89194039|NCT02419495|Experimental|Arm J (selinexor, capecitabine, oxaliplatin) (ARM CLOSED)|Patients receive selinexor PO on days 1, 8 and 15, capecitabine PO twice daily (BID) on days 1-14 and oxaliplatin IV over 2 hours on day 1. Treatment repeats every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity. After 8 cycles, patients can continue single agent selinexor until disease progression.
89194040|NCT02419495|Experimental|Arm K (selinexor, olaparib) (ARM CLOSED)|Patients receive selinexor PO on days 1, 8, 15, and 22 and olaparib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89194041|NCT02419495|Experimental|Arm L (selinexor, pembrolizumab)|Patients receive selinexor PO twice weekly (e.g. Monday/Wednesday or Tuesday/Thursday or Wednesday/Friday or Thursday/Saturday or Friday/Sunday) and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89194042|NCT02419495|Experimental|Arm M (selinexor, nivolumab|Patients receive selinexor PO twice weekly (e.g. Monday/Wednesday or Tuesday/Thursday or Wednesday/Friday or Thursday/Saturday or Friday/Sunday) and nivolumab IV over 30 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89194043|NCT02419495|Experimental|Arm P (selinexor, nivolumab, ipilimumab)|Patients receive selinexor PO on days 1, 8, 15, 22, 29, and 36, nivolumab IV over 30 minutes on days 1, 15, and 29, and ipilimumab PO QD on day 1. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
89194044|NCT02419495|Experimental|Arms N and O (selinexor, nivolumab, ipilimumab)|Patients receive selinexor PO on days 1, 8, and 15, nivolumab IV over 30 minutes on day 1, and ipilimumab PO QD on day 1. Cycles repeat every 3 weeks for 4 cycles. Starting cycle 5, patients receive selinexor PO on days 1, 8, 15, and 22 and nivolumab IV over 30 minutes on day 1. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
89194045|NCT02385617|Experimental|Esophagectomy|Double blind single dose placebo-octreotide crossover
89194046|NCT02385617|Experimental|Total gastrectomy|Double blind single dose placebo-octreotide crossover
89194047|NCT02385617|Active Comparator|Control - no surgery|Double blind single dose placebo-octreotide crossover
89194048|NCT02385617|Experimental|Pancreaticoduodenectomy|Double blind single dose placebo-octreotide crossover
89194049|NCT02381249|Experimental|Esophagectomy|Double-blind single dose octreotide-placebo crossover
89194050|NCT02381249|Experimental|Gastrectomy|Double-blind single dose octreotide-placebo crossover
89194051|NCT02381249|Active Comparator|Unoperated healthy control|Double-blind single dose octreotide-placebo crossover
89194052|NCT02381249|Experimental|Pancreaticoduodenectomy|Double-blind single dose octreotide-placebo crossover
89194053|NCT02347930||Confirmed acute kidney injury|Confirmed acute kidney injury
89194054|NCT02339922|Experimental|Treatment (ixazomib citrate, rituximab)|Patients receive ixazomib citrate orally (PO) on days 1, 8 ,15, and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Upon completion of 6 cycles of ixazomib citrate therapy, patients also receive rituximab intravenously (IV) once weekly for 4 doses total, followed by ixazomib citrate alone, until disease progression or unacceptable toxicity.
89194055|NCT02332356|Active Comparator|step up|Procedure: MREC patients receive therapeutic step up
89194056|NCT02332356|No Intervention|observation step up|
89194057|NCT02332356|Active Comparator|step down|Procedure: MREC patients receive therapeutic step down
89194058|NCT02332356|No Intervention|observation step down|
89194059|NCT02299596|Experimental|Pre and postoperative exercise|"The intervention is prehabilitation preoperatively and physical training postoperatively. During the hospital stay both groups will be treated in the same manner.~Preoperative intervention:~One half hour of exercise daily added to the existing daily exercise routine. The level of exercise should produce shortness of breath but the patient should be able to talk without much effort.~Inspiratory muscle training. Thirty breaths x two twice daily. Postoperative intervention is mainly the same as preoperatively."
89194060|NCT02299596|No Intervention|Control|Standard treatment with one exception, patients will fill in a physical activity diary
88897852|NCT01484795|Experimental|Continuous positive airway pressure|
88897853|NCT01484795|Experimental|BILEVEL|
88897854|NCT01484821|Active Comparator|Arm A|Volunteers (18 -30 years)
89419245|NCT04974112||Respiratory|This study was conducted in parallel in many Class-A hospitals across the country. Special researchers were assigned by the research unit to collect patient information using SGA and NRS2002 and other data measurement tools.
89419246|NCT04974112||Neurology|This study was conducted in parallel in many Class-A hospitals across the country. Special researchers were assigned by the research unit to collect patient information using SGA and NRS2002 and other data measurement tools.
89419247|NCT02209038|Experimental|Expanded AD Choice|"Would you like to complete an advance directive with the assistance of any person(s) you choose?~4 answer choices:~Yes, I would like to complete a comprehensive version of an advance directive.~Yes, I would like to complete an expanded version of an advance directive.~Yes, I would like to complete a brief version of an advance directive.~No, I do not wish to complete an advance directive."
89419248|NCT02209038|No Intervention|Standard AD Choice|"Would you like to complete an advance directive with the assistance of any person(s) you choose?~2 answer choices:~Yes, I would like to complete an AD.~No, I do not wish to complete an advance directive."
89419249|NCT02209038|Experimental|Expanded Life-sustaining therapy Choice|"For each hypothetical illness state described in the living will:~4 answer choices:~No, I would not want life support.~Yes, I would want life support.~I would want life support if my doctor believes it could help, but I want to stop receiving life support if at any time my doctor believes it is only delaying the moment of my death.~I do not wish to specify a preference at this time."
89419250|NCT02209038|No Intervention|Standard Life-sustaining Therapy Choice|"For each hypothetical illness state described in the living will:~3 answer choices:~No, I would not want life support.~Yes, I would want life support.~I do not wish to specify a preference at this time."
88897855|NCT01484821|Active Comparator|Arm B|Volunteers (70 years or older)
89419251|NCT03681067|Experimental|GSK10708060|Humanised antibody GSK1070806
89419252|NCT03681067|Placebo Comparator|Placebo - sodium chloride|Placebo
88897856|NCT01484821|Experimental|Arm C|70 years patient or older with curative cares for cancer
88897857|NCT01484847|Experimental|PF-00299804|Patients with locally advanced head and neck squamous cell carcinoma will be treated with a single dose (45mg) of PF-00299804 via G-Tube on an empty stomach
89419253|NCT03061708|Experimental|AZD2014 50mg BD continuous schedule of a 28 day cycle|AZD2014 50mg BD continuous schedule of a 28 day cycle
89419254|NCT03680989|Placebo Comparator|Natural Light|"Participants will use a therapy light that provides ~500 lux at 22 for 30 minutes each morning beginning 30 minutes after waking."
89419255|NCT03680989|Active Comparator|Bright Light|"Participants will receive Bright Light Exposure using a therapy light that provides ~10,000 lux at 22 for 30 minutes each morning beginning 30 minutes after waking."
88897858|NCT01484860|Experimental|AUY922|AUY922 will be administered as a weekly infusion at a dose of 70 mg/m2 based on the recommended phase II dose from the phase I study or alternate dose based on the phase I study final results.The drug will be continued until disease progression or unacceptable toxicity. One cycle will be defined as 4 weeks of treatment.
88897859|NCT01484886|Experimental|Restrictive transfusion strategy|RBC will be transfused if the hemoglobin level falls below 7 for bi-ventricular repairs and under 9.0 for single ventricle palliations.
88897860|NCT01484886|Experimental|Liberal RBC transfusion strategy|RBCs will be transfused for Hemoglobin under 9.5 for biventricular repairs and under 12 for single ventricle palliations.
89194061|NCT02285114|Experimental|F/TAF+3rd ARV agent (Cohort 1)|Participants between 12 to < 18 years of age and ≥ 35 kg in body weight will switch their current 2-NRTI containing regimen to F/TAF (200/25 mg for unboosted 3rd agent and 200/10 mg for boosted 3rd agent) while continuing on their 3rd ARV agent for 48 weeks.
89194062|NCT02285114|Experimental|F/TAF+3rd ARV agent (Cohort 2, Group 1, Part A)|Participants between 6 to < 12 years of age and ≥ 25 kg in body weight must be on a boosted protease inhibitor (PI) as their 3rd ARV agent and will switch their current 2-NRTI regimen to F/TAF 200/25 mg while continuing on their boosted PI for 48 weeks.
88897861|NCT01484899||PAH|Patients with pulmonary arterial hypertension (PH). PH defined as mean pulmonary artery pressure >25mmHg with a pulmonary capillary occlusion pressure ≤ 15mmHg
88897862|NCT01484899||CTEPH|Patients with chronic thromboembolic pulmonary hypertension. CTEPH defined as mean pulmonary artery pressure >25mmHg with a pulmonary capillary occlusion pressure ≤ 15mmHg.
88897863|NCT01484899||Controll group|Data from 16322 (10336 females) participants of the Swiss health survey (SHS) 2007 will serve as control. The SHS was performed in 2007, a representative sample of 30000 Swiss citizens were asked to participate, 66% answered per telephone to detailed health question.
89419256|NCT03062410|Other|Electronic PRO|All patients diagnosed with mRCC initiating TKI anti-VEGF treatment (Sunitinib or Pazopanib) will be invited to complete the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 cancer specific questionnaire and the EQ-5D before each visit with the physician. Questionnaires completion will be done by patients on tablets and/or computer terminals via the CHES software (Computer-based Health Evaluation System) at hospital before consultation or at home via secured portal. Physician will immediately have access to a visual summary of HRQOL evaluation.
88897864|NCT01484925||With Barrett's Esophagus|Patients who have been diagnosed in the past with Barrett's Esophagus
88897865|NCT01484925||Without Barrett's Esophagus|Patients without Barrett's Esophagus will be asked to take part so that comparison can be made with patients' tissue for those with the condition and those without the condition.
88897866|NCT01484964|Experimental|Treatment A|ASP015K Formulation 1 with moderate-fat meal
88897867|NCT01484964|Experimental|Treatment B|ASP015K Formulation 2 under fasting conditions
88897868|NCT01484964|Experimental|Treatment C|ASP015K Formulation 2 with moderate-fat meal
88897869|NCT01484990|Experimental|1|
88897870|NCT01485016||ambulatory epilepsy subjects|
88897871|NCT01485029|Experimental|NP children|Nasopharyngeal (NP) aspirate with a small flexible canule to obtain NP swabs
88897872|NCT01485042|Experimental|Dose Escalation|This is a Phase 1 dose escalation with an expanded cohort that will enroll at MTD.
89194063|NCT02285114|Experimental|F/TAF+3rd ARV agent (Cohort 2, Group 2, Part A)|Participants between 2 to < 12 years of age and between 17 kg to < 25 kg in body weight must be on a boosted protocol specified 3rd ARV agent and will switch their current 2-NRTI containing regimen to F/TAF 120/15 mg while continuing their 3rd ARV agent for 48 weeks.
89194064|NCT02285114|Experimental|FTC/TAF+3rd ARV agent (Cohort 3, Part A)|Participants between 2 to < 6 years of age will receive F/TAF plus a 3rd ARV agent through 48 weeks.
89194065|NCT02285114|Experimental|FTC/TAF+3rd ARV agent (Cohort 4, Part A)|Participants between 1 month to < 2 years of age will receive F/TAF plus a 3rd ARV agent through 48 weeks.
89419257|NCT02204202||Grade A0|Double-lung transplant recipients with no evidence of rejection who undergo both [18F]FDG and [18F]ISO-1 PET imaging scans
89419258|NCT02204202||Grades A2-3|Double-lung transplant recipients with mild to moderate rejection who undergo both [18F]FDG and [18F]ISO-1 PET imaging scans
89419259|NCT02209116|Active Comparator|QB Open|Participants and their clinician will receive results of the Qb Test
88897873|NCT01485068|Experimental|Danubio|
88897874|NCT01485081|Experimental|Danubio|
88897875|NCT01485107|Experimental|Ultherapy™ treatment on the décolleté|All enrolled subjects will receive the study treatment.
88897876|NCT01485133||Air colonoscopy|Colonoscopy will be performed without medications and with judicious air insufflation during colonoscope insertion.
88897877|NCT01485133||Water colonoscopy|Colonoscopy will be performed without medications and aided by water infusion in-lieu of air insufflation during insertion of the colonoscope. The water infusion involves putting warm sterile water into the colon to open up the colon for advancement of the colonoscope until the end of the colon (cecum) is reached. The water is delivered via a needle adaptor or the built-in scope irrigation channel by an infusion pump equipped with a foot switch which will be controlled by the endoscopist. Infused water used to cleanse residual fecal matter will be suctioned as needed to clear the colonic lumen.
89194066|NCT02285114|Experimental|F/TAF+3rd ARV agent (Cohort 2, Group 1, Part B)|Screening will be initiated for Part B following confirmation of TAF dose in Part A. Approximately 10 additional total participants will be enrolled across all Part B cohorts and will receive F/TAF while continuing their 3rd ARV agent through 48 weeks.
89194067|NCT02285114|Experimental|F/TAF+3rd ARV agent (Cohort 2, Group 2, Part B)|Screening will be initiated for Part B following confirmation of TAF dose in Part A. Approximately 10 additional total participants will be enrolled across all Part B cohorts and will receive F/TAF while continuing their 3rd ARV agent through 48 weeks.
89194068|NCT02285114|Experimental|FTC/TAF+3rd ARV agent (Cohort 3, Part B)|Screening will be initiated for Part B following confirmation of TAF dose in Part A. Approximately 10 additional total participants will be enrolled across all Part B cohorts and will receive F/TAF while continuing their 3rd ARV agent through 48 weeks.
89194069|NCT02285114|Experimental|FTC/TAF+3rd ARV agent (Cohort 4, Part B)|Screening will be initiated for Part B following confirmation of TAF dose in Part A. Approximately 10 additional total participants will be enrolled across all Part B cohorts and will receive F/TAF while continuing their 3rd ARV agent through 48 weeks.
89194070|NCT02285114|Experimental|FTC/TAF +3rd ARV agent (Extension Phase)|After completion of 48 weeks, all participants will be given the option to participate in an extension phase of the study. Gilead will provide F/TAF until a) the participant turns 18 and F/TAF is commercially available for use in adults in the country in which the participant is enrolled or, b) F/TAF becomes commercially available for pediatric use in the country in which the participant is enrolled or, c) Gilead Sciences elects to terminate development of F/TAF in the applicable country.
89194071|NCT02252250|Active Comparator|conventional laparoscopic|conventional laparoscopic total mesentery excision surgery for rectal cancer.
89194072|NCT02252250|Experimental|Transanal hybrid-laparoscopic|Transanal hybrid-laparoscopic total mesentery excision surgery for rectal cancer.
89194073|NCT02250131|No Intervention|Control|Routine cardiopulmonary bypass technique. Flow adjusted on BSA and temperature
89194074|NCT02250131|Active Comparator|Goal Directed Perfusion|Perfusion targeted at oxygen delivery
89194075|NCT02193620|Placebo Comparator|Placebo group|Placebo soft capsules
89194076|NCT02193620|Experimental|Study group|PHN131 soft capsule with Nalbuphine HCl 60 mg/cap
89194077|NCT02187848|Experimental|SAR408701 Main Dose Escalation Cohort|Dose escalation administered intravenously, once every two weeks
88897878|NCT01485146|Experimental|Cohort 1|8 Healthy Subjects in Phase I Unit
89194078|NCT02187848|Experimental|SAR408701 Expansion Cohort colorectal cancer (CRC)|Administered intravenously at the maximum tolerated dose (MTD), once every 2 weeks, to patients with colorectal cancer
89194079|NCT02187848|Experimental|SAR408701 Expansion Cohort non-squamous NSCLC|Administered intravenously at the MTD, once every 2 weeks, to patients with carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) expressing non-squamous non-small cell lung cancer (NSCLC) of at least 50% of tumor cells at or above 2+ intensity
89194080|NCT02187848|Experimental|SAR408701 Expansion Cohort gastric adenocarcinoma|Administered intravenously at the MTD, once every 2 weeks, to patients with CEACAM5 expressing gastric adenocarcinoma
89194081|NCT02187848|Experimental|SAR408701 Loading Dose Escalation cohorts (Escalation bis)|Loading dose escalation administered intravenously at first cycle, followed by MTD, once every 2 weeks
89419260|NCT02209116|Other|Qb Blind|Participants and their clinician will be blind to the results of the Qb test
89419261|NCT02204280||Type 2 Diabetic|Patiens with type 2 diabetic which conform to the WHO in 1999 diabetes diagnostic criteria.
89419262|NCT02204280||Diabetic With macro-or Microalbuminuria|Patients with diabetic with macro-or microalbuminuria.
89419263|NCT02204280||proteinuria,nondiabetic renal disease|Patients with proteinuria due to nondiabetic renal disease,such as IgA nephropathy,FSGS,Hypertensive renal damage and MN.
89419264|NCT02204280||healthy controls|Healthy person.
89419265|NCT04982380|Experimental|Experimental group|Patients will be instructed to continue current antidiabetic treatment, which should be kept unchanged throughout the trial, and start treatment with Bifidobacterium, Lactobacillus, Enterococcus and Bacillus Cereus Tablets, Live (Siliankang) 3 tablets p.o. tid for 12 weeks.
89419266|NCT04982380|Placebo Comparator|Control group|Patients will be instructed to continue current antidiabetic treatment, which should be kept unchanged throughout the trial, and start treatment with Siliankang simulative tablets 3 tablets p.o. tid for 12 weeks.
89419267|NCT02204358|Experimental|autologous bone marrow stem cells|Using collagen scaffold loaded with autologous bone marrow stem cells to treat severe intrauterine adhesions or endometrial dysplasia.
89419268|NCT04973644|Experimental|Internet + Digital Hospital-remote home management mode|Remote monitoring devices+Internet management platform, dietary recommendations, exercise supervision, web education, information pushing, doctor-patient interaction.
89419269|NCT04973644|No Intervention|the traditional management mode|Routine dietary and exercise recommendations, education as well as monitor in the clinic.
88897879|NCT01485146|Experimental|Cohort 2|8 Healthy Subjects in Phase I Unit
88897880|NCT01485146|Experimental|Cohort 3|8 Healthy Subjects in Phase I Unit
88897881|NCT01485159||All|All subjects enrolled in the study
88897882|NCT01485185|Experimental|Gabapentin lower dose alone|low dose
88897883|NCT01485185|Active Comparator|Gabapentin higher dose alone|higher dose
88897884|NCT01485185|Experimental|Gabapentin in combination with donepezil|Gabapentin lower dose and donepezil
88897885|NCT01485185|Placebo Comparator|Placebo|Placebo
88897886|NCT01485198|Active Comparator|Control|Patients treated with Acetaminophen
89419270|NCT02209194||Aortoiliac Aneurysms Iliac Aneurysms|Endovascular repair of aortoiliac or iliac aneurysms
89419271|NCT02204436|Other|Emulsion and gel|A fixed similar quantity of both emulsion and gel were applied consequentially on the hand twice a day, in the morning and in the evening (preferentially always at the same hour), with a mild massage, until complete absorption, for 8 weeks.
88897887|NCT01485198|Experimental|Experimental|Patients who underwent a BMASC extraction and joint infusion
88897888|NCT01485211|Experimental|crosslinking with hypoosmolar riboflavin|Riboflavin and UVA-induced corneal cross-linking increases the stability of keratoconic corneas. The current inclusion criteria require a minimum stromal thickness of 400 µm. Hypo-osmolar riboflavin solution increases the stromal thickness before CXL in cases with preoperatively thin corneas.
89419272|NCT03680833|Other|prospective cohort study|"Prospective cohort study with detection of sentinel lymph nodes followed by a full pelvic lymphadenectomy. Patients will act as their own controls.~The intervention is the detection and removal of sentinel lymph nodes"
89419273|NCT02209350|Active Comparator|Group 1|Operations technique on the abdominal aorta. Aorta-femoral bypass. Medication: after surgery all patients are prescribed long-term aspirin (100 mg daily) and clopidogrel for 3 months (75 mg daily).
89419274|NCT02209350|Active Comparator|Group 2|Standard endovascular treatment (stenting) in patients with the iliac segment occlusive disease. Medication: after stenting all patients are prescribed long-term aspirin (100 mg daily) and clopidogrel for 3 months (75 mg daily).
89419275|NCT05263128||Boston carpal tunnel syndrome questionnaire|
89419276|NCT05263128||Hand-20 questionnaire|
89419277|NCT02200692||plasma transfusion|Patients receiving plasma transfusion.
88897889|NCT01485224|Experimental|Thalidomide|"Single arm study:~Eligible patients will receive thalidomide at a starting dose of 50 mg/day by mouth at bedtime for 4 weeks. In the event of unsatisfactory/no response, thalidomide dosage will be progressively increased by 50 mg/day every 4 weeks until complete or partial response, to a maximum dose of 200 mg/day.~Treatment will be continued until one of the following criteria is met:~8 additional weeks of treatment after the achievement of complete response~16 additional weeks of treatment after the achievement of partial response~24 weeks of treatment completed without response~unacceptable toxicity. Then, patients will be followed off of thalidomide for 24 weeks."
88897890|NCT01485237||Severe H1N1 pneumonia in adult patients|Severe adult H1N1 pneumonia patients undergoing antiviral and oxygen therapy, mechanical ventilation and support with pulmonary rescue therapies ( nitric oxide, ECMO, HFO)in Winnipeg
88897891|NCT01485237||Severe pneumonia in adults not H1N1|Patients admitted to the hospital and/or ICU with viral pneumonia, bacterial pneumonia, septic shock, ARDS in Winnipeg
88897892|NCT01485289||Investigational Stabilimax|
89419278|NCT02204514||Surgery for external snapping hip|
89419279|NCT03680599|Experimental|Connection to Health for Smokers|Participants in this arm will participate in the Connection to Health for Smokers Arm of the study, wherein an electronic survey will be administered and participants will be guided through an evidence-based action planning sequence, taking into account each patient's unique social environment, health related behaviors, and behavioral health status, with multimodal follow up.
89419280|NCT03680599|Active Comparator|Enhanced Standard of Care|Participants in this arm will participate in Enhanced Standard Care, wherein participants will receive a brief electronic survey and receive standard smoking cessation program that does not include formal action planning and multimodal follow up.
89419281|NCT02209428|Active Comparator|IDH wild type|Patients with IDH wild type, according to the result of genetic sequencing of their surgical resected specimens. Intervention: oral temozolomide, 75 mg/m2/day for 21 days repeated every 4 weeks, 6 cycles.
89419282|NCT02209428|Experimental|IDH mutation|Patients with IDH mutations, according to the result of genetic sequencing of their surgical resected specimens. Intervention: oral temozolomide, 75 mg/m2/day for 21 days repeated every 4 weeks, 6 cycles.
89419283|NCT03684733||Arm 1: Cohort 1 - Retrospective Analysis|Participants attending MRI & XRM for a clinical indication with at least one normal breast
89419284|NCT03684733||Arm 2: Cohort 2 - Retrospective Analysis|"BRCA1 or BRCA2 mutation carriers attending MRI & XRM for breast screening:~Genetic risk of breast cancer"
89419285|NCT03684733||Arm 2: Cohort 3 - Retrospective Analysis|"Participants attending MRI & XRM for breast screening post mantle radiotherapy:~Environmental risk of breast cancer"
89419286|NCT03684733||Arm 2: Cohort 4 - Prospective|"General population attending XRM for breast investigation:~Population risk of breast cancer MRI"
88897893|NCT01485289||Control, Posterolateral Fusion|
88897894|NCT01485302|Experimental|Cohort 1|Dose 1 IV infusion
88897895|NCT01485302|Experimental|Cohort 2|Dose 2 IV infusion
88897896|NCT01485302|Experimental|Cohort 3|Dose 3 IV infusion
88897897|NCT01485302|Experimental|Cohort 4|Dose 4 IV infusion
88897898|NCT01485302|Experimental|Cohort 5|Dose 1 SC injection
88897899|NCT01485302|Experimental|Cohort 6|Dose 2 SC injection
88897900|NCT01485315|Active Comparator|Liberal blood transfusion|Blood transfusion at haemoglobin 9.0 g/dl (5.6 mM) or less
88897901|NCT01485315|Active Comparator|Restrictive blood transfusion|Blood transfusion at haemoglobin 7.0 g/dl (4.3 mM) or less
88897902|NCT01485328|Active Comparator|AMARGOL|per oral solution 40 mL single dose
88897903|NCT01485328|Placebo Comparator|Vehicle without active principles|per oral solution 40 mL single dose
88897904|NCT01485341|Active Comparator|gluten|gluten is administered blindly versus placebo for 15 days at 10 g/day
88897905|NCT01485341|Placebo Comparator|rice starch|placebo (rice starch) will be administered blindly versus gluten for 15 days at 10 g/day
88897906|NCT01485367|Active Comparator|Adapalene gel 0.3%|All odd numbered subjects will receive treatment to the left arm. The untreated arm will serve as an intrapatient control and will be evaluated separately from the treated arm for signs of purpura.
88897907|NCT01485367|Active Comparator|Adapalene gel 0.3 %|All even numbered subjects will receive treatment to the right arm. The untreated arm will serve as an intrapatient control and will be evaluated separately from the treated arm for signs of purpura.
88897908|NCT01485406|Experimental|Pn Group|Toddlers 12-23 months of age receiving GSK2830930A vaccine.
88897909|NCT01485406|Active Comparator|Control Group|Toddlers 12-23 months of age receiving Synflorix.
88897910|NCT01485432||P group|Group P: Fluid Management according to measurements with PiCCO®
88897911|NCT01485432||C group|Group C: Conventional fluid management
88897912|NCT01485445|Experimental|Fluticasone Furoate (single strip configuration)|400mcg, administered as 2 inhalations of 200mcg
88897913|NCT01485445|Experimental|Fluticasone Furoate (two strip configuration)|400mcg, administered as 2 inhalations of 200mcg. Second strip contains lactose and magnesium stearate
88897914|NCT01485445|Experimental|Fluticasone Furoate/Vilanterol|400/50mcg, administered as 2 inhalations of 200/25mcg
88897915|NCT01485458|Experimental|Early surgery|
88897916|NCT01485458|Active Comparator|Delayed surgery|
88897917|NCT01485510|Experimental|Glasgow Infant and Family Team (GIFT)|A service developed by Charles Zeanah and colleagues in New Orleans, that aims to improve the mental health of maltreated infants.
88897918|NCT01485510|Active Comparator|Family Assessment & Contact Service|A social-work based service that aims to assess maltreated children and make recommendations about their future care.
88897919|NCT01485523||Patients|A = Patients with allergic rhinitis sensitized to dust mites
88897920|NCT01485523||Control Subjects|B = control subjects with allergic rhinitis not sensitized to dust mites C = control subjects without allergic rhinitis
88897921|NCT01485549||MSA Patients|Patients suffering from Multiple system atrophy (MSA)
88897922|NCT01485549||Controls|Patients requiring spinal tap without being affected by a neurodegenerative disorder.
88897923|NCT01485562|Active Comparator|Misoprostol|women who experience a PPH will be randomized to receive 800 misoprostol (four tablets of 200 mcg administered sublingually)
88897924|NCT01485562|Placebo Comparator|placebo|women who experience a PPH will be randomized to receive 4 placebo tablets administered sublingually
88897925|NCT01485575||Filter use during vitrectomy|
88897926|NCT01485653|Experimental|Mepivacaine, Ultrasound Axillary Block|Group 1) 20mL 1.5% mepivacaine Group 2) 30mL 1.5% mepivacaine
88897927|NCT01485679|Experimental|positrons emission tomography|
88897928|NCT01485692|Active Comparator|ziprasidone injection|ziprasidone injection after baseline measures of agitation, could be repeated twice, if necessary, between the 90 minutes of the observation
88897929|NCT01485692|Active Comparator|haloperidol + midazolam, injection|Haloperidol plus midazolam injection, after baseline measures of agitation,allowed to be repeated twice over the 90 minutes period of observation
88897930|NCT01485692|Active Comparator|haloperidol + promethazine, injection|haloperidol + promethazine injection after baseline measures of agitation, could be repeated after 30 minutes, and once more, if necessary, in the 90 minutes period of observation
88897931|NCT01485692|Active Comparator|olanzapine, injection|olanzapine, 10mg, intramuscular injection after baseline measures of agitation, could be repeated twice if necessary, between the 90 minutes of observation
88897932|NCT01485718|Active Comparator|Glucomannan|Participants in the glucomannan arm will receive glucomannan 2 capsules 30 minutes before the three largest meals of the day.
88897933|NCT01485718|Placebo Comparator|Placebo|Participants in the placebo arm will receive placebo 2 capsules 30 minutes before the three largest meals of the day.
88897934|NCT01485731|Experimental|Nelfinavir + Cisplatin + Pelvic Radiation Therapy|Nelfinavir in combination with Cisplatin and Pelvic Radiation Therapy
88897935|NCT01485744|Experimental|LDE225; Fluorouracil; Leucovorin; Oxaliplatin; Irinotecan|
88897936|NCT01485757|Experimental|L-arginine|
88897937|NCT01485822||TRAVATAN|As prescribed by physician for the treatment of open-angle glaucoma and dosed for at least two years
88897938|NCT01485822||Treatment Naive|No prior exposure (or less than 1 month) to any topical, ocular prostaglandin analogue
88897939|NCT01485835|Experimental|Ganetespib + Bortezomib + Dexamethasone|"Ganetespib: IV; days 1, 4, 8, 11; every 3 weeks~Cohort 1: 100 mg/m²~Cohort 2: 100 mg/m²~Cohort 3: 120 mg/m²~Cohort 4: 144 mg/m²~Cohort 5: 173 mg/m²~Bortezomib: IV or subcutaneous; days 1, 4, 8, 11; every 3 weeks~Cohort 1: 1.0 mg/m²~Cohort 2, 3, 4, 5: 1.3 mg/m²~Dexamethasone: Oral prior to bortezomib~Cohort 1, 2, 3, 4, 5: 20 + 20 mg~Day of and following bortezomib"
88897940|NCT01485848|Active Comparator|Paclitaxel|A single 1 hour intravenous infusion every week for 6 cycles (each cycle is 4 weeks)
88897941|NCT01485848|Experimental|Paclitaxel + EP-100|Paclitaxel every week plus EP-100 twice weekly by 1 hour intravenous infusion for the first 3 weeks of each 4 week cycle for 6 cycles (each cycle is 4 weeks)
88897942|NCT01485900|Experimental|Cohort 1|Dose 1: 20 days 3-step uptitration with doses A, B, and C of SAR407899 vs. placebo
88897943|NCT01485900|Experimental|Cohort 2|Dose 2: 20 days 3-step uptitration with doses B, C and D of SAR407899 vs. placebo
88897944|NCT01485913|Experimental|Lifestyle counseling|"The group subjected to educations will follow the whole process of peer education described in Part 1 of this Protocol.~The control group will perform these classic individual consultations but will not follow the whole process of peer education.~The classical management in diabetes consultations consists of:~A counselling session~A measure of blood glucose~A measurement of blood pressure~A measure of weight and size~A complete clinical examination~A prescription or a renewal of treatment (diabetes pills, insulin, IEC, statins etc ...)"
88897945|NCT01485913|No Intervention|No Lifestyle counseling|"The group subjected to educations will follow the whole process of peer education described in Part 1 of this Protocol.~The control group will perform these classic individual consultations but will not follow the whole process of peer education.~The classical management in diabetes consultations consists of:~A counselling session~A measure of blood glucose~A measurement of blood pressure~A measure of weight and size~A complete clinical examination~A prescription or a renewal of treatment (diabetes pills, insulin, IEC, statins etc ...)"
88897946|NCT01485926|Experimental|Docetaxel, Carboplatin and Trastuzumab|Arm A- 6 cycles q3weekly Docetaxel (75mg/m²) + Carboplatin (AUC 6) + Trastuzumab 8 mg/kg on day 1 (loading dose) and 6mg/kg for subsequent cycles, q3weekly thereafter. Patients will be scheduled for surgery and will continue to receive Trastuzumab post-operatively 6 mg/kg for one year from 1st dose of Trastuzumab.
88897947|NCT01485926|Experimental|Docetaxel, Carboplatin, Trastuzumab and Lapatinib|Arm B - 6 cycles q3weekly Docetaxel (75mg/m²) + Carboplatin (AUC 6) + Trastuzumab (8 mg/kg on day 1 (loading dose) and 6mg/kg for subsequent cycles, q3weekly thereafter.) + Lapatinib (1000mg daily) until 1 week prior to surgery. Patients will be scheduled for surgery and will continue to receive Trastuzumab post-operatively 6 mg/kg for one year from 1st dose of Trastuzumab.
88897948|NCT01485939|Placebo Comparator|placebo patch|
88897949|NCT01485939|Active Comparator|lidocaine patch|
88897950|NCT01485952|Experimental|SEN0014196 (Low Dose)|10 mg, once daily administration (immediate release capsule)
88897951|NCT01485952|Experimental|SEN0014196 (High dose)|100 mg, once daily administration (immediate release capsule)
88897952|NCT01485952|Placebo Comparator|Placebo|Once daily (immediate release capsule)
88897953|NCT01485965|Experimental|Fasted condition|Subjects in the Fasted group will take study drug after an overnight fast (since at least midnight). Additionally, on PK assessment days, no food will be allowed for at least 4 hours after study drug administration.
88897954|NCT01485965|Experimental|Fed condition|Subjects in the Fed group will take study drug within 30 minutes after starting breakfast; these subjects will otherwise maintain their normal eating schedule.
88897955|NCT01485978|Active Comparator|Ramipril blinded|oral treatment with 1 to 6 mg per body surface area ramipril once daily for 3 years
88897956|NCT01485978|Placebo Comparator|placebo to ramipril|Oral placebo treatment to ramipril once daily for 3 years or until progress to next disease level. After progression to next disease level, patients will be unblinded, and ramipril treatment will be initiated.
88897957|NCT01485978|Other|open label ramipril|Open label treatment with ramipril as per protocol, if randomization is refused.
88897958|NCT01486004|Experimental|001|35 µg ethinylestradiol and 1 mg norethindrone once daily for first 21 days in each OC cycle (2 OC cycles in total) + 150 mg capsule once daily for 10 days (Day12 till and including Day21) in 2nd OC cycle
88897959|NCT01486017|Experimental|Treatment A|ASP015K oral dose low strength
88897960|NCT01486017|Experimental|Treatment B|ASP015K oral dose medium strength
88897961|NCT01486017|Experimental|Treatment C|ASP015K oral dose high strength
89194082|NCT02187848|Experimental|SAR408701 Expansion Cohort non-squamous NSCLC (Lung bis)|Administered intravenously at the MTD, once every 2 weeks, to patients with CEACAM5 expressing non-squamous NSCLC of at least 1% but below 50% of tumor cells at or above 2+ intensity
89194083|NCT02187848|Experimental|SAR408701 Expansion Cohort colorectal cancer (CRC-L)|Loading dose of determined MTD-L administered intravenously at first cycle, followed by MTD, once every 2 weeks
89194084|NCT02187848|Experimental|SAR408701 Expansion Cohort small cell lung cancer (SCLC)|Administered intravenously at the MTD, once every 2 weeks, to patients with CEACAM5 expressing SCLC
89194085|NCT02187848|Experimental|SAR408701 Dose Escalation every 3 weeks cohort|Dose escalation administered intravenously, once every three weeks
89194086|NCT02183168|Experimental|Meloxicam suppository|
89194087|NCT02183168|Experimental|Meloxicam tablet|
89194088|NCT02183168|Active Comparator|Indomethacin suppository|
89194089|NCT02183129|Experimental|Meloxicam|
89194090|NCT02183129|Active Comparator|Diclofenac|
89194091|NCT02176967|Experimental|Group A (clinical observation)|Patients undergo clinical observation for 96 weeks in the absence of disease progression. Patients also undergo CT, MRI, and/or ultrasound throughout the trial.
89194092|NCT02176967|Experimental|Group B (clinical observation, first-line chemotherapy)|Patients undergo clinical observation for 3 years in the absence of disease progression. Upon disease progression, patients undergo surgery or receive first-line chemotherapy comprising carboplatin IV over 1 hour on day 1 (courses 1, 2, 4, 6, and 7), etoposide IV over 1 hour on days 1-3 (courses 1, 3, 4, 5, and 7), cyclophosphamide IV over 1 hour on day 1 (courses 2, 3, 5, 6, and 8), and doxorubicin hydrochloride IV over 15 minutes on day 1 (courses 2, 4, 6 and 8). Treatment with chemotherapy repeats every 21 days for 2-8 courses in the absence of disease progression or unacceptable toxicity. Once a PR or better is achieved, patients undergo clinical observation for 3 years. Patients also undergo CT, MRI, and/or ultrasound throughout the trial and undergo bone marrow aspiration, bone marrow biopsy, and tumor biopsy at screening and time of progression.
89194093|NCT02176967|Experimental|Group C (clinical observation, first-line chemotherapy)|Patients at high risk for deterioration and a poor outcome immediately receive first-line chemotherapy as in Group B. All other patients undergo clinical observation for 3 years in the absence of disease progression. Upon disease progression, patients receive first-line chemotherapy as in Group B. Once a PR or better is achieved, patients undergo clinical observation for 3 years. Patients also undergo CT, MRI, and/or ultrasound throughout the trial and undergo bone marrow aspiration, bone marrow biopsy, and tumor biopsy at screening and time of progression.
89194094|NCT02137850|Experimental|50 EDs (exposure days)|
89536012|NCT03214705||Patients with poor outcome|Follow up of patients is done for 21 days by combined clinical and radiological examination. Poor clinical outcome is associated with vasospasm leading to permanent neurological deficit, stroke or death.
89194099|NCT02077621|Experimental|PG2|"Treatment Group:~PG2 (500 mg in 500 ml saline), 1 dose a day before surgery and 1 dose a day for 3 days after surgery"
89194100|NCT02077621|Placebo Comparator|Placebo|"Control group:~Placebo (500 ml saline), 1 dose a day before surgery and 1 dose a day for 3 days after surgery"
89194101|NCT02065011|Other|Long-term follow up|Long-term follow up of patients who received SAR421869 in a previous study TDU13600
89194102|NCT01994499|Experimental|videothoracoscopy drainage|videothoracoscopy drainage of pleural effusion
89194103|NCT01994499|Active Comparator|Medical pleural drainage|Medical drainage
89194104|NCT01960244||hypercholesterolemia|familial hypercholesterolemia
89194105|NCT01952366||Depressed patients|Patients admitted to specialist health care service of old age psychiatry
89194106|NCT01920100||Memory clinic|People visiting a memory clinic at Ullevål University Hospital, St Olav Hospital or Innlandet Hospital Trust (n=400). The patients will be assessed three times over a three-year follow-up. Baseline inclusion started in January 2010. The final assessments will take place in spring 2014.
89194107|NCT01920100||Nursing homes|People admitted to a nursing home recruited from municipalities in Hedmark, Oppland, Nord-Trøndelag and Bergen (n=1000). Baseline assessments take place when the person is admitted to the nursing home. The patients will be assessed every six months over a three-year follow-up period. The first participant was included in March 2012, and baseline inclusion will be completed in December 2013.
89194108|NCT01920100||In-home care|People 70 years of age or older receiving in-home care recruited from municipalities in Hedmark, Oppland, Oslo, Østfold and Buskerud (n=995). The patients will be assessed three times over a three-year follow-up period. Baseline inclusion started in April 2009 and the final assessments will take place in December 2013.
89194109|NCT01920100||People without dementia|"People without dementia recruited from Nord-Trøndelag, Drammen and Oslo (n=400).~The participants will be assessed three times over a three-year follow-up period. Baseline inclusion will take place in autumn 2012 and the last follow-up will take place in autumn 2015."
89194110|NCT01915511||Subjects with a new IPF diagnosis|Subjects with a new diagnosis of IPF established at the time of enrollment in the registry
89194111|NCT01915511||Subjects with a non-IPF ILD diagnosis|Subjects with a diagnosis of a non-IPF ILD of any duration, including, but not limited to Idiopathic Non-Specific Interstitial Pneumonia (iNSIP), Unclassifiable Idiopathic Interstitial Pneumonias (IIPs), Interstitial Pneumonia with Autoimmune Features (IPAF), Autoimmune ILDs such as Rheumatoid Arthritis (RA-ILD) and Systemic Sclerosis (SSc-ILD), Chronic Hypersensitivity Pneumonitis (HP), Sarcoidosis or Exposure-related ILDs such as asbestosis with progressive phenotype
89194112|NCT01843530|Experimental|Group 1|Cortisone, Clemastin + BERINERT
89194113|NCT01843530|Placebo Comparator|Group 2|Cortinsone, Clemastin + NaCl
89419287|NCT03684577|Experimental|Hypnotherapy for Agoraphobia|A total of 8-12 individual sessions of hypnotherapy over 12 weeks will be delivered. Hypnotherapy consists of hypnotic activation and reinforcement of the patient's own resources, the use of relevant positive and negative experiences from the biography, and the development of positive solution imagery. The central technique is the work with a symptom regression and the resolution of old and actual experiences. Furthermore, formal trance induction, utilisation techniques, indirect techniques such as the use of metaphors or the representative technique, or work with time progression will be used.
89419288|NCT03684577|No Intervention|Wait-list control group|Patients in the wait-list control group will receive 8-12 sessions of individual hypnotherapy after a waiting period for 12 weeks.
89419289|NCT03684499|Other|study group (1)|The subjects will be divided into two equal groups Study group and control group by randomization. The study group will be given IV fluid supplementation with 0.5% normal saline in dextrose 5%for period of 24hours . The volume of supplementation included a presumed deficit of 50 ml/kg (equivalent to mild dehydration), half of daily maintenance fluid for 24 hours in accordance to standard norms and extra 20 ml/kg per day as a phototherapy allowance. In addition, they will continue breastfeeding. The control group will be continued on breast feeding , before the randomization procedure. All the infants will get phototherapy by standard method. Phototherapy will be discontinued when the bilirubin level will be <15 mg/dl.
89419290|NCT03684499|No Intervention|control group( 2)|The subjects will be divided into two equal groups Study group and control group by randomization. The study group will be given IV fluid supplementation with 0.5% normal saline in dextrose 5%for period of 24hours . The volume of supplementation included a presumed deficit of 50 ml/kg (equivalent to mild dehydration), half of daily maintenance fluid for 24 hours in accordance to standard norms and extra 20 ml/kg per day as a phototherapy allowance. In addition, they will continue breastfeeding. The control group will be continued on breast feeding , before the randomization procedure. All the infants will get phototherapy by standard method. Phototherapy will be discontinued when the bilirubin level will be <15 mg/dl.
89419291|NCT02200848|Experimental|Lenalidomide, Ibrutinib, Rituximab|Rituximab on day 1, lenalidomide days 1-21 and ibrutinib continuously for 6 cycles or until disease progression or intolerance to the combination. Single agent ibrutinib will then be continued until disease progression or intolerance.
89419292|NCT03684421||Long Antagonist Protocol|Clinical pregnancy rate and live birth rates of patients who followed Long Antagonist Protocol for COS
89419293|NCT03684421||Classical Antagonist Protocol|Clinical pregnancy rate and live birth rates of patients who followed Classical Antagonist Protocol for COS
89419294|NCT02204670||Overweight Adolescents Performing Resistance Training|Overweight adolescents that meet pre-specified enrollment criteria will all undergo supervised resistance exercise for a 6-week period. Prior to training, all participants will undergo a single bout of resistance training to determine the acute release of Irisin with resistance training. This will be the primary exposure variable. After the acute session, all participants will perform resistance training three times per week for a period of 4 weeks. During each session participants will perform 3 sets of 8-12 repetitions (60-85% of 1RM) for major muscle groups (quadriceps, shoulders, and pectoral).
89419295|NCT02204826|Experimental|V + KRG group (n = 20)|three capsules of KRG (500 mg/dose) daily and varicocelectomy.
89419296|NCT02204826|Active Comparator|non-V + KRG group|three capsules of KRG (500 mg/dose) daily
89419297|NCT02204826|Active Comparator|V + P group (n = 20)|placebo capsules and varicocelectomy
89419298|NCT02204826|Placebo Comparator|non-V + P group|non-V + P group (n = 20) placebo capsules
89419299|NCT02200926|Experimental|Placebo|The breathing was performed normally in this groups.
89536013|NCT03214705||Patients without poor outcome|Patients who do not develop delayed cerebral ischemia or stroke, confirmed by combined clinical and radiological examination.
89536014|NCT04991415|Experimental|Treatment|30 minutes of manual therapy three times a week for two weeks (six total sessions).
88897962|NCT01486056||healthy patients, may have epilepsy|Subjects at least 12 years old and in general good health for Phase I, and at least 18 years old and in general good health for Phase II. It is desired, but not required, for subjects to have epilepsy and taking at least 1 antiepileptic medication.
88897963|NCT01486069||Dentofacial Deformity|Patients with dentofacial deformities candidate to orthognathic surgery
88897964|NCT01486082||Empirical OCA|This group will be treated with omeprazole, amoxicillin and clarithromycin without having a previous antibiogram.
88897965|NCT01486082||OCA after antibiogram|This group will be treated with omeprazole, clarithromycin and amoxicillin after an antibiotic susceptibility confirmation.
88897966|NCT01486095|Experimental|AXXESS + Biomatrix|After mandatory predilatation, a self-expanding, conically shaped nickel-titanium AXXESS biolimus A9-eluting stent is placed at the level of the carina. The device is available in 3.0 and 3.5 mm calibre and 11 and 14 mm length. Depending on the lesion anatomy, additional Biomatrix™ Drug Eluting Coronary Stent Systems are placed distally if necessary. The procedure is completed with kissing balloon postdilatation using non-compliant balloons sized to the reference vessel diameter of the distal branches. Before this kissing balloon inflation, consecutive high pressure inflations should be performed in both branches.
89006640|NCT04620109|Active Comparator|RDE 0.24 mg/eye|The actual dosage is 0.24 mg/eye given 4 times a day for a maximum daily dosage of 0.96mg (60μL KDR2-2 eyedrops concentration of 4.0 mg/mL), which will continues for 6 days plus 1 administration of 0.24 mg/eye in the morning of Day 7. That cohort might be optional based on emerging data from this study.
89194114|NCT01720563|Placebo Comparator|Control|Placebo
89006641|NCT04620109|Placebo Comparator|RDE Placebo|Subjects will receive placebo (drops without drug).
89006642|NCT04620265|Experimental|Treadmill training 100%|This group received antigravity treadmill training 100% weight bearing and conventional exercise program.
89194115|NCT01720563|Experimental|Treatment|Astragalus polysaccharides 500 mg
89194116|NCT01720550|Experimental|PG2 High Dose|Astragalus Polysaccharides 500 mg
89194117|NCT01720550|Experimental|PG2 Low Dose|Astragalus Polysaccharides 250 mg
89194118|NCT01696565|Experimental|125 mg/day Treatment Arm|125 mg/day PG2 treatment continuously for 7 days
89194119|NCT01696565|Experimental|250 mg/day Treatment Arm|250 mg/day PG2 treatment continuously for 7 days
89194120|NCT01696565|Experimental|500 mg/day Treatment Arm|500 mg/day PG2 treatment continuously for 7 days
89194121|NCT01670383||Postresuscitation group|Adults (age over 16 years old) who have survived from nontraumatic cardiac arrest and admitted to ICU.
89536015|NCT04991415|No Intervention|Control|No intervention
89536016|NCT02483273||Brain dead patients|Brain dead patients certified by cerebral angiography.
89194122|NCT01670383||Sepsis group|Adults (age over 16 years old) who satisfy the sepsis criteria (SIRS>=2 and infection is suspected for a cause) and admitted to the ICU.
89194123|NCT01656902|Experimental|N3D plus|NOVOCART® 3D plus (Autologous Chondrocyte Transplantation System)
89194124|NCT01656902|Active Comparator|Microfracture|Microfracture is the standard care surgery.
89194125|NCT01626079|Experimental|MitraClip System|Percutaneous mitral valve repair using MitraClip System
89194126|NCT01626079|No Intervention|Control Group|Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.
89194127|NCT01626079|Experimental|COAPT CAS Group|Percutaneous mitral valve repair using MitraClip System
89194128|NCT01560182|Experimental|OTL-200 Gene Therapy|CD34+ cells transduced ex vivo with lentiviral vector encoding ARSA cDNA
89194129|NCT01502280|Experimental|5-ALA/Gliolan® /5-Aminolevulinic acid|Within 3 hours prior to surgery, patient will orally ingest [or be given via Nasogastric (NG), Orogastric (OG), or Gastric tube (G-tube)] 5-ALA/Gliolan®/5-Aminolevulinic acid mixed with sterile water (20mg/kg)
89194130|NCT01502280|Placebo Comparator|Placebo - ascorbic acid|Within 3 hours prior to surgery, patient will orally ingest [or be given via Nasogastric (NG), Orogastric (OG), or Gastric tube (G-tube)] 1.5 Gm. placebo - ascorbic acid in 50 ml sterile water.
89194131|NCT01485809|Experimental|Gefitinib|
89194132|NCT01420237|Other|Restoration ADM X3 Device|Restoration ADM X3 Device in total hip replacement.
89194133|NCT01413100|Experimental|Treatment (HDIT autologous PBSCT)|"STEM CELL MOBILIZATION AND PREPARATION: Patients receive filgrastim SC on mobilization days 1-4 followed by apheresis until a target dose of CD34+ cells >= 2.5 x 10^6/kg are collected. Patients difficult to mobilize with filgrastim alone receive cyclophosphamide IV or *plerixafor SC on mobilization days 1-2 and filgrastim SC on mobilization days 5-7.~HDIT CONDITIONING: Patients receive high-dose cyclophosphamide IV over 1-2 hours on days -5 to -2 and anti-thymocyte globulin IV on days -5, -3, -1, 1, 3, and 5.~TRANSPLANTATION: Patients undergo autologous PBSCT on day 0.~MAINTENANCE THERAPY: Beginning 2-3 months after transplant, patients receive mycophenolate mofetil PO BID for 2 years."
89194134|NCT01349959|Experimental|Treatment (entinostat and azacitidine)|Patients receive azacitidine SC on days 1-5 and 8-10, and entinostat PO on days 3 and 10. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with progressive disease may continue azacitidine and entinostat in combination with hormonal therapy, at treating physician discretion, or undergo event monitoring.
89194135|NCT01331681|Experimental|Intravitreal Aflibercept Injection 2Q4|Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks (2Q4).
89194136|NCT01331681|Experimental|Intravitreal Aflibercept Injection 2Q8|Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks for 5 visits followed by injections every 8 weeks (2Q8).
89194137|NCT01331681|Active Comparator|Macular Laser Photocoagulation (Control)|Participants received laser treatment at baseline and as needed at visits at which laser retreatment criteria were met, but no more frequently than every 12 weeks.
89006643|NCT04620265|Experimental|Treadmill training 75%|This group received antigravity treadmill training 75% weight bearing and conventional exercise program.
89194138|NCT01325233|Experimental|PG2 Injection|Powder for Injection, 500 mg PG2/500 ml normal saline, tiw, 2 weeks
89194139|NCT01325233|Placebo Comparator|Placebo|Powder for Injection, 500 ml normal saline, tiw, 2 weeks
89194140|NCT01286272|Experimental|Arm A (ofatumumab, bendamustine hydrochloride)|"INDUCTION: Patients receive ofatumumab IV over 2-8 hours on day 1 and bendamustine hydrochloride IV over 30-60 minutes on days 1 and 2. Treatment repeats every 35 days for up to 6 courses. Patients without disease progression continue on to maintenance therapy.~MAINTENANCE: Beginning 8 weeks after the start of induction course 6, patients receive ofatumumab IV over 2-8 hours on day 1. Treatment repeats every 56 days for up to 4 courses."
89194141|NCT01286272|Experimental|Arm B (ofatumumab, bendamustine hydrochloride, bortezomib)|"INDUCTION: Patients receive ofatumumab IV over 2-8 hours on day 1, bendamustine hydrochloride IV over 30-60 minutes on days 1 and 2, and bortezomib IV over 3-5 seconds or SC on days 1, 8, 15, and 22. Treatment repeats every 35 days for up to 6 courses. Patients without disease progression continue on to maintenance therapy.~MAINTENANCE: Beginning 8 weeks after the start of induction course 6, patients receive ofatumumab IV over 2-8 hours on day 1 and bortezomib IV over 3-5 seconds or SC on days 1, 8, 15, and 22. Treatment repeats every 56 days for up to 4 courses."
89194142|NCT01215136|Active Comparator|Cohort 1|Single-agent everolimus (enrollment limited to patients with patients with creatinine clearance < 60 ml/min AND Karnofsky performance status of 60-70%)
89194143|NCT01215136|Active Comparator|Cohort 2|Everolimus plus paclitaxel (enrollment limited to patients with creatinine clearance < 60 ml/min OR Karnofsky performance status of 60-70%)
89536017|NCT02483273||Healthy volunteers|Any person with no known cerebral pathology.
89536018|NCT03214471|No Intervention|Usual Care|usual care provided by the NHS for patients undergoing bariatric surgery.
89536019|NCT03214471|Experimental|Intervention|usual care + BARI-LIFESTYLE intervention
89536020|NCT04990947||Bariatric surgery (Roux-en-Y Gastric Bypass)|Patients who are eligible for RYGB
89536021|NCT04990947||Lifestyle group|Patients with a BMI > 30 who will start a lifestyle program
88897967|NCT01486095|Active Comparator|Culotte technique: Xience V/Prime|The culotte technique consists of stenting one of both branches of the bifurcation lesion first, and after balloon dilatation of the stent meshes, stenting the uncovered branch through the first stent and leaving the main vessel covered with two overlapped stents. The procedure is terminated by kissing balloon dilatation of both branches using non-compliant balloons sized to the reference vessel diameter of the distal branches. Before this kissing balloon inflation, consecutive high pressure inflations should be performed in both branches.
88897968|NCT01486108|Experimental|Tonic|5 hz stimulation at an amplitude that the patient find bearable (+/- 1.5 mA)
88897969|NCT01486108|Experimental|Sham|no stimulation, patient receive a sham stimulation (actually the IPG is not running)
88897970|NCT01486108|Experimental|burst|500 hz burst at 5 hz stimulation
88897971|NCT01486121|Other|S.O.S.-V|
88897972|NCT01486121|No Intervention|Standard|
88897973|NCT01486134|Experimental|procedure|
89194144|NCT01177774||Recent-onset tics that will persist|Children between 5 to 10 years of age with recent-onset tics (first tic occurred within the past 9 months) who, when reassessed at 1 year after the first tic began (i.e. 6-12 months after study enrollment) will turn out to meet criteria for a chronic tic disorder (including Tourette syndrome). Scheduled follow-up visits will include children over age 10 (initially enrolled at age 5-10).
89194145|NCT01177774||Recent-onset tics that will remit|Children between 5 to 10 years of age with recent-onset tics (first tic occurred within the past 9 months) who will no longer have tics when reassessed 1 year after the first tic began (6 to 12 months after study enrollment). Scheduled follow-up visits will include children over age 10 (initially enrolled at age 5-10).
89194146|NCT01177774||Tic-free control subjects|Children with no current or past tic disorder of similar age, sex and handedness as the children in the recent-onset tics groups.
89194147|NCT01177774||Existing TS/CTD|Children with current tics whose first tics were more than 12 months ago (DSM-5 Tourette's Disorder or Persistent [Chronic] Motor or Phonic Tic Disorder), of similar age, sex and handedness as the children in the recent-onset tics groups.
89194148|NCT01142401|Experimental|Arm A (fulvestrant)|Patients receive fulvestrant IM on day 1 (days -14, 1, and 15 of course 1 only). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with progressive disease may crossover to arm C.
89194149|NCT01142401|Experimental|Arm B (fulvestrant, bortezomib)|Patients receive fulvestrant as in arm A and bortezomib IV on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89194150|NCT01142401|Experimental|Arm C (fulvestrant, bortezomib)|Patients receive fulvestrant IV on day 1 and bortezomib IM on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89194151|NCT01021098||Natural History Study|The core Natural History Study of ILI is an observational, longitudinal cohort study using data from clinical findings, medical chart review, and diagnostic, virologic and immunologic laboratories to describe the epidemiology and immunology of ILI. This study aims to describe the clinical history of influenza and other viral respiratory pathogens in a population of US military active duty members and their dependents. The primary focus will be the etiology, natural history and immunology of ILI in otherwise healthy adults and children. We will recruit subjects with ILI in both the outpatient and inpatient setting, and will serially collect biological specimens (e.g. nasal/throat swabs, blood, rectal swabs) over a 28-day period. In addition, we will collect a single buccal (cheek) swab.
89194152|NCT01021098||HIV-Positive Cohort|In addition, given a number of human immunodeficiency virus (HIV)-infected subjects who serve in the active duty force, we will also examine a subset of HIV-positive military beneficiaries as part of this consortium. An additional objective of the study will be to descriptively examine the clinical and laboratory characteristics of ILI events among HIV-infected persons using the military's substantial experience in following a stable HIV-infected population. We will recruit subjects with ILI in both the outpatient and inpatient setting, and will serially collect biological specimens (e.g. nasal/throat swabs, blood, rectal swabs) over a 28-day period. In addition, we will collect a single buccal (cheek) swab.
89194153|NCT00960401||cardiac counseling|10 left sided breast cancer patients 10 right sided breast cancer patients
89194154|NCT00960401||coronary artery evaluation|10 left sided breast cancer 10 right sided breast cancer
89194155|NCT00860600|Experimental|1. PG2 Treatment: 5 days/week|Powder for Injection, 500 mg PG2/500 ml normal saline, 5 days/week, 2 to 4 weeks
89194156|NCT00860600|Experimental|2. PG2 Treatment: 3 days/week|Powder for Injection, 500 mg PG2/500 ml normal saline, 3 days/week, 2 to 4 weeks
89194157|NCT00633828|Experimental|A Intervention group|Increased physical education in primary school (daily)
89194158|NCT00633828|No Intervention|B Control group|Normal physical education in primary school (typically once per week)
89194159|NCT00584532|Placebo Comparator|A|A=Placebo ARM of Study
89194160|NCT00584532|Active Comparator|B|B=GCP Capsules. Ten 500 mg capsules per day for a total of 5 grams a day.
89194161|NCT00525759|Active Comparator|A|Neoadjuvant chemotherapy alone
89194162|NCT00525759|Experimental|B|Neoadjuvant chemotherapy + zoledronic acid
89194163|NCT00523107|Experimental|PG2|PG2 500 mg / 500 ml normal saline will be given t.i.w for 8 weeks.
89194164|NCT00523107|Placebo Comparator|Placebo|500 ml normal saline will be given t.i.w 1-4 weeks, then PG2 500 mg / 500 ml normal saline will be given 5-8 weeks.
89536022|NCT02483195|Active Comparator|Combination Group|This group will use a mixed combination of 5% Minoxidil and 200mg Spironolactone for 12 months to be used once daily.
88897974|NCT01486147|Experimental|Visual|Group provided with nutrition information using visual nutrient profiling tool
88897975|NCT01486147|Other|Table|Group provided nutrition information using table format
88897976|NCT01486160||nursing home residents|participants in this group are nursing home residents
88897977|NCT01486160||Nursing home employees|Participants in this group are health care workers, employees at the nursing home
88897978|NCT01486173||Premature infants with a GA < 32 Weeks|
88897979|NCT01486173||New born with a GA > 37Weeks|
88897980|NCT01486186|Experimental|traditional chinese medicine|The experimental group will receive three type of TCM, they are Baofei granule, Bufeijianpi granule and Bufeiyishen granule.
88897981|NCT01486186|Placebo Comparator|placebo|placebo chinese medicine in addition to best care according to clinical guidelines for COPD patients
88897982|NCT01486212||Healthy volunteers.|Male aged 18-40 years. Non-smokers. No known familiar disposition to vascular/heart diseases. No intake of prescription medicine.
88897983|NCT01486225|Other|Innothera's brand Stokings|Innothera's branded grip-top silicone band stokingc
88897984|NCT01486225|Other|Other than Innothera's brand|
88897985|NCT01486251|Experimental|experimental|"axitinib will be given BID orally. One cycle is defined as a 14-day period (7 days ON / 7 days OFF). The 3 dose levels tested will be: 1st cycle: 5 mg BID; 2nd cycle: 7 mg BID; 3rd cycle: 10 mg BID.~Patients will receive a first cycle of single agent axitinib at the starting dose with DCE-US assessment. If no study treatment-related adverse event (AE) of grade > 1 is observed during this cycle, intrapatient dose escalation will be performed for the second cycle. The same dose escalation method wil apply between the 2d and 3d cycles."
88897986|NCT01486290|Experimental|Geriatric Diabetes Team Intervention|The subjects in this group underwent evaluation for barriers to self care by a diabetes educator well versed with age specific barriers. After consideration of patient clinical, function, and psychosocial background, a geriatric diabetes team devised strategy to help patients cope with respective barriers. An office based diabetes diabetes educator conveyed the strategy to patient and caregivers viz phone calls. the educator called study participants up wot eleven times over a sex month period.
88897987|NCT01486290|No Intervention|Atention Control Arm|The subjects in the group received similar, in person contact, as the intervention group. an educator, separate from the one involved in the intervention team, called patients in this group for a total of eleven times within the first six months. The Phone calls were focused toward general discussion without any diabetes related advice.
88897988|NCT01486303|Experimental|Facial Cosmetic Acupuncture|28 Patients with grade III to IV wrinkling on the face, according to the Glogau classification system, were treated with Facial Cosmetic Acupuncture.
88897989|NCT01486329|Experimental|VXM01|Investigational anti-angiogenic live cancer vaccine
88897990|NCT01486329|Placebo Comparator|Placebo|Placebo control
88897991|NCT01486342||Group 1|Mechanically ventilated patients without acute lung injury and lung injury prediction score < 4
88897992|NCT01486355|Experimental|Early measles vaccine|Receives an early measles vaccine in addition to the standard measles vaccine at 9 months of age
88897993|NCT01486355|No Intervention|No early measles vaccine|Receives only the standard measles vaccine at 9 months of age
88897994|NCT01486381|Experimental|BIAsp 30|
88897995|NCT01486394|Experimental|Focused sonography|Intervention group: After the primary evaluation by a physician in the emergency department, focused sonography of the patients heart, lungs and deep veins in the legs are performed. Hereafter the further examinations and treatment are done according to hospital guidelines.
88897996|NCT01486394|No Intervention|Usual treatment and diagnostic work-up|Control group: After the primary evaluation by a physician in the emergency department. Hereafter the further examinations and treatment are done according to hospital guidelines.
88897997|NCT01486407||Intravenous (IV) drug delivery|patients on whom intravenous vascular access has been established for the purpose of rapid sequence intubation drug delivery.
88897998|NCT01486407||Intraosseous (IO) drug delivery|Patients on whom intraosseous vascular access has been established for rapid sequence intubation drug delivery.
88897999|NCT01486420|Active Comparator|Open surgery|
88898000|NCT01486420|Active Comparator|Corticosteroid Injection|
88898001|NCT01486433|Experimental|Epanova and Simvastatin|
88898002|NCT01486433|Active Comparator|Simvastatin|
88898003|NCT01486459|Experimental|PCI with lithium|Prophylactic cranial irradiation Lithicarb® tablets 250mg/day for 6 weeks. Initial dosing will be 250mg given once daily, and increased by 250 - 500 mg increments depending on plasma levels.
88898004|NCT01486459|No Intervention|Standard|Prophylactic cranial irradiation alone.
88898005|NCT01486472||GC patients receiving adjuvant S-1 chemotherapy|
88898006|NCT01486485|Experimental|heparinized saline priming group|Experimental group : heparinized saline priming group
88898007|NCT01486485|Active Comparator|nafamostat infusion group after heparinized saline priming|active comparator : nafamostat infusion group after heparinized saline priming
88898008|NCT01486511||Liver resection patients|All patients that underwent elective liver resection for both malignant and benign diseases.
88898009|NCT01486524||DrotAA Treatment Group|Patients with severe sepsis at high risk of death (INDICATED patients) who received treatment with drotrecogin alfa (activated (DrotAA) as part of standard care in ICU. The standard dosing regimen for DrotAA is 96 hours of continuous infusion at a dose of 24 ug/kg/hour. DrotAA is also known as recombinant human activated protein C.
89419300|NCT02200926|Experimental|Loaded breathing training|subjects will trained to inspire deeply against the resistance setting by using BreathMAX® at the loaded of 18 cmH2O with breathing frequency control at 6 breaths/minute. Breathing pattern will be controlled at duty cycle of 0.4 (inspiratory time = 4 sec and total respiratory time = 10 sec). The training program will be performed at home for 30 minutes/day, 7 days/week for 8 weeks.
89419301|NCT02200926|Experimental|Unloaded breathing training|subjects will trained to inspire deeply (no resistance) with breathing frequency control at 6 breaths/minute. Breathing pattern will be controlled at duty cycle of 0.4 (inspiratory time = 4 sec and total respiratory time = 10 sec). The training program will be performed at home for 30 minutes/day, 7 days/week for 8 weeks.
89419302|NCT03684031|Experimental|Cognitive Control Training|Participants in this arm will complete a computer-based training program two times in the lab. Participants will complete the first training session in the lab during their initial visit and they will return to the lab one week later to complete the second session.
89419303|NCT03684031|Sham Comparator|Sham Cognitive Control Training Program|Participants in this arm will complete a sham training program two times in the lab. The program will look similar in length and design to the experimental training program, but the content of the program will remain affectively neutral. As in the experimental condition, participants will complete the first training session in the lab during their initial visit and they will return to the lab one week later to complete the second session.
89419304|NCT02751450|Experimental|Stannous Fluoride dentifice|Participants will apply (under supervision) a pea-sized dose of experimental dentifrice containing 0.454% w/w stannous fluoride (1100ppm) to each of the two qualifying teeth using their finger by direct application and gently rubbing into the tooth's cervical margin for the allocated time. No rinsing will be permitted
89419305|NCT02751450|Other|Sodium Monofluorophosphate dentifrice|Participants will apply (under supervision) a pea-sized dose of dentifrice containing Dentifrice containing 0.76% sodium monofluorophosphate (1000ppm fluoride)to each of the two qualifying teeth using their finger by direct application and gently rubbing into the tooth's cervical margin for the allocated time. No rinsing will be permitted.
89419306|NCT02204904||Allo-HSCT prospective|Subjects who will be consented before they received an allo-HSC infusion. They will be consented and enrolled on the study during the Screening Period.
89419307|NCT02204904||Allo-HSCT partial prospective/retrospective|Subjects who will be consented after they received an allo-HSC infusion but before they reach 24 months post-infusion on study. Subjects in this cohort will participate prospectively in at least the Month 24 Visit in order to obtain prospective on-study data for this and all visits after Month 24
89419308|NCT02204904||Allo-HSCT retrospective|Subjects who received an allo-HSC infusion on or after January 1, 2013 and died before study data collection.
89419309|NCT02209662|Experimental|APIC-PRP and Standard of Care|APIC-PRP
89419310|NCT02209662|Placebo Comparator|Placebo, Saline plus standard of care|Placebo, Saline plus standard of care
89419311|NCT03689881|Experimental|Tomosynthesis|Tomosynthesis of SI joints
89419312|NCT03689803|Active Comparator|Lipidemia|
89419313|NCT02209740||Tenofovir switch|Patients switched tenofovir to different antiretroviral regimen according to physicians decision
89006644|NCT04620265|Experimental|Treadmill training 50%|This group received antigravity treadmill training 50% weight bearing and conventional exercise program.
89419314|NCT02205138|Experimental|ALLOB® cells with ceramic scaffold|ALLOB® cells with ceramic scaffold Implantation
89419315|NCT02257788|Active Comparator|Treatment Arm 1|PRO 140: one SC dose, 350 mg (day 1), followed by two single SC doses, 350 mg each (days 8 and 15) Intervention: Drug: PRO 140 (humanized monoclonal antibody to CCR5)
89419316|NCT02257788|Active Comparator|Treatment Arm 2|PRO 140: one SC loading dose, 700 mg (day 1), followed by two single SC doses, 350 mg each (days 8 and 15) Intervention: Drug: PRO 140 (humanized monoclonal antibody to CCR5)
89419317|NCT02257788|Active Comparator|Treatment Arm 3|PRO 140: one SC loading dose, 700 mg (day 1), followed by one single SC dose 350 mg (day 15) Intervention: Drug: PRO 140 (humanized monoclonal antibody to CCR5)
89419318|NCT02257788|Active Comparator|Treatment Arm 4|PRO 140: one SC dose, 700 mg (day 1) Intervention: Drug: PRO 140 (humanized monoclonal antibody to CCR5)
89419319|NCT02220660|Active Comparator|Free dose combination|
88898010|NCT01486524||Control Group (non-DrotAA treated)|Patients with severe sepsis at high risk of death (INDICATED patients) who did not receive DrotAA treatment as part of their standard care in an ICU. The Control group patients will be selected to match the DrotAA-treated patients based on numerous clinical covariates, including propensity score (for DrotAA treatment).
89419320|NCT02220660|Experimental|Fixed dose combination|
89419321|NCT02209818|Experimental|Laser Irradiation One Dose|Laser irradiation will be applied in one dose for patients in this group, but only on one side of the jaw. The other side of the jaw will receive a placebo procedure (i.e. a red light beam will be emitted on the gingival tissues as if they are irradiated by a laser beam).
89419322|NCT02209818|Experimental|Laser Irradiation Two doses|Laser irradiation will be applied in two doses for patients in this group, but only on one side of the jaw. The second dose will be given after 24 hour of the first one. The other side of the jaw will receive a placebo procedure (i.e. a red light beam will be emitted on the gingival tissues as if they are irradiated by a laser beam).
89419323|NCT02257944|Experimental|Motivational Interviewing|Receive brief hospital-based intervention
89419324|NCT02257944|Other|Treatment as Usual|Treatment as Usual
89419325|NCT02220738|Experimental|ABT-957|ABT-957 administered twice-daily for 7 days
89419326|NCT02220738|Placebo Comparator|Placebo|Placebo administered twice-daily for 7 days
89419327|NCT03689725|Experimental|Preterm music group|Music exposure with headphones
89419328|NCT03689725|No Intervention|Preterm control group|headphones without music
89419329|NCT03689725|No Intervention|Full-term control group|
89419330|NCT04981990|Active Comparator|Single lung ventilation|Using double lumen endotracheal tube and lung isolation
89419331|NCT04981990|Active Comparator|Two lung ventilation|Using conventional single lumen endotracheal tube and intermittent two lung ventilation
88898011|NCT01486550|Active Comparator|Voluven (Hydroxyethyl starch 130/0,4)|Patients undergoing laparoscopic nephrectomy will receive either fluid therapy with active comparator (Voluven) or placebo (Sodium Chloride)
88898012|NCT01486550|Placebo Comparator|Sodium Chloride 9mg/ml|Patients undergoing laparoscopic nephrectomy will receive either fluid therapy with active comparator (Voluven) or placebo (Sodium Chloride)
88898013|NCT01486563|Active Comparator|Voluven (Hydroxyethyl starch 130/0,4)|Patients undergoing radical prostatectomy will receive either fluid therapy with active comparator (Voluven) or placebo (Sodium Chloride)
88898014|NCT01486563|Placebo Comparator|Sodium Chloride 9 mg/ml|Patients undergoing radical prostatectomy will receive either fluid therapy with active comparator (Voluven) or placebo (Sodium Chloride)
88898015|NCT01486576|Active Comparator|Voluven (Hydroxyethyl starch 130/0,4)|Patients undergoing hip replacement surgery will receive either fluid therapy with active comparator (Voluven) or placebo (Sodium Chloride. Patients will receive minimum 7,5 ml/kg in the first hour of the surgery and 5 ml/kg in the subsequent hours.
88898016|NCT01486576|Placebo Comparator|Sodium Chloride 9 mg/ml|Patients undergoing hip replacement surgery will receive either fluid therapy with active comparator (Voluven) or placebo (Sodium Chloride. Patients will receive minimum 7,5 ml/kg in the first hour of the surgery and 5 ml/kg in the subsequent hours.
88898017|NCT01486602|Experimental|Concurrent therapy + consolidation therapy|"Concurrent Therapy (1 cycle = 14 days, Cycles 1-3): Patients will receive paclitaxel 45 mg/m^2 by IV over 1 hour weekly followed by carboplatin AUC 2 by IV over 30-60 minutes for 4 weeks (there will be no chemotherapy during Cycle 3). Patients will receive radiotherapy concurrently for up to 5.5 weeks, depending on the cohorts the patient is registered defined per the protocol.~Consolidation Therapy (1 cycle = 21 days, Cycles 4-5): Four weeks following the end of radiotherapy patients will receive paclitaxel 200 mg/m^2 by IV over 3 hours followed by carboplatin AUC 6 by IV over 30-60 minutes on day 1 of each 21 day cycle for a total of 2 cycles (days 1 and 22)."
88898018|NCT01486641|Active Comparator|Anterolateral approach|"Patients with a displaced femoral neck fracture operated through the anterolateral approach to the hip arthroplasty.~Lubinus total hip arthroplasty or varikopf hemiarthroplasty."
88898019|NCT01486641|No Intervention|Posterolateral approach|"Patients with a displaced femoral neck fracture operated through the posterolateral approach to the hip arthroplasty.~Lubinus total hip arthroplasty or varikopf hemiarthroplasty."
89419332|NCT02205216|Active Comparator|Active tDCS|Active tDCS combined with a rehabilitative intervention consisting of cognitive training and sensory cueing.
89419333|NCT02205216|Sham Comparator|Sham tDCS|Sham tDCS combined with a rehabilitative intervention consisting of cognitive training and sensory cueing.
89419334|NCT03683953|Placebo Comparator|Placebo|0.9% sodium chloride intratracheal instillate on 14 days after birth
89419335|NCT03683953|Experimental|mesenchymal stem cells|mesenchymal stem cells intratracheal instillate on 14 days after birth ,dose is 25 million cells/kg
89419336|NCT03061396|Experimental|Electroacupuncture Single point|Single point PC6 means there is only one acupoint to be chosen: Neiguan(PC6)
89419337|NCT03061396|Experimental|Electroacupuncture Matching points|There are three acupoints to be chosen:Bilateral Neiguan(PC6)and Zhongwan(CV12)
89419338|NCT02209896|Experimental|BlueWind Reprieve System|The Reprieve implant will be implanted for eligible patients. Implant parameters settings will be set according to patient's sensations.
89419339|NCT05262894|Experimental|Breathing in the snow|Breathing in the snow using a specially designed apparatus and measuring the respiratory gases distribution in snow.
89419340|NCT03689647|Experimental|Single Group Experimental|Each participant will act as their own control with variables of interest measured while walking without the assistive device and while walking with the assistive device.
89419341|NCT04973722|Experimental|LY06006|60 mg/1 ml, once every 6 months administered subcutaneously
89419342|NCT04973722|Active Comparator|Prolia|60 mg/1 ml, once every 6 months administered subcutaneously
88898020|NCT01486654|Active Comparator|Anodal stimulation|
89419343|NCT01358175|Experimental|Secukinumab 10 mg/kg i.v. / 75 mg s.c.|Three i.v. infusions: at Baseline and weeks 2 and 4, followed by one s.c. injection every four weeks until the end of the study.
89419344|NCT01358175|Experimental|Secukinumab 10 mg/kg i.v. / 150 mg s.c.|Three i.v. infusions: at Baseline and weeks 2 and 4, followed by one s.c. injection every four weeks until the end of the study.
89419345|NCT01358175|Placebo Comparator|Placebo|Three i.v. infusions: at Baseline and weeks 2 and 4, followed by one s.c. injection every four weeks until the end of the study.
89419346|NCT03689569|Experimental|Exercise|Exercise only: Patients randomized to this group will receive a placebo (corn starch) and be given 16 weeks of personal training.
89419347|NCT03689569|Experimental|Resistant Starch|Resistant starch only: Patients randomized to this group will receive 30 g of resistant starch daily for 16 weeks. They will not be given an exercise training
89419348|NCT03689569|Experimental|Exercise & Resistant Starch|Exercise & resistant starch: Patients assigned to this group will do 16 weeks of personal training and they will be supplemented with 30 g of resistant starch daily for the 16 week period
89419349|NCT03689569|Placebo Comparator|Starch|Corn starch only: Patients assigned to this group will not be given and exercise program and they will receive the placebo for 16 weeks
89419350|NCT03683797|Experimental|Post-discharge call|Patients in this arm will receive a call from a clinical care coordinator after they have been discharged from NYU Langone Health.
88898021|NCT01486654|Active Comparator|Cathodal stimulation|
88898022|NCT01486654|Placebo Comparator|Sham stimulation|
89419351|NCT03683797|No Intervention|No post-discharge call|Patients in this arm will not receive a call from a clinical care coordinator after they have been discharged from NYU Langone Health.
88898023|NCT01486667|Placebo Comparator|sugar pill|
88898024|NCT01486667|Active Comparator|Levothyroxine|Eligible patients will be randomized and be given 25 mcg of levothyroxine or identical placebo tablet at the beginning of the enrollment. The dosage of levothyroxine will subsequently be individualized for each patients. Serum levels of TSH and FT4 will be checked initially and then every 6 weeks until the end of the study. The investigators will attempt to maintain TSH levels between (0.25-2.5) mU/l which is the lower half of normal range. Advice given to patient regarding whether to increase or decrease the dose of medications will be based on patient TSH level according to study protocol.
88898025|NCT01486680|Active Comparator|Laparoscopic Silastic Ring Roux-en-Y Gastric Bypass|
89419352|NCT02209974|Placebo Comparator|Inhaled Placebo|Inhaled placebo administered to healthy (n=7) and to a half (n=8) of COPD patients
88898026|NCT01486680|Active Comparator|Laparoscopic Sleeve Gastrectomy|
88898027|NCT01486706|Experimental|Gabapentin|Two to three months of behavioral therapy prior to start of Gabapentin 100mg/capsule, initially 1 capsule once a day for 1 week then titrate dosage according to symptoms until maximum dose of 1500mg/day Placebo tablet of Solifenacin Succinate will titrate dose same as Solifenacin arm according to symptoms of patient
88898028|NCT01486706|Active Comparator|Solifenacin Succinate|Two to three months of behavioral therapy prior to Solifenacin Succinate 5mg/tablet initially 1 tablet once a day then titrate dosage according to symptoms upto maximum dose of 10mg/day Placebo form of Gabapentin will titrate dosage same as Gabapentin group according to symptoms of patient
88898029|NCT01486706|Placebo Comparator|Placebo|Two to three months of behavioral therapy prior to Placebo form of Gabapentin and Solifenacin and titrate accordingly same as the treatment arms
88898030|NCT01486732|Experimental|Umbilical Cord Blood & Rehabilitation|Allogeneic umbilical cord blood infusion and active rehabilitation
88898031|NCT01486732|Active Comparator|Placebo Umbilical Cord Blood & Rehabilitation|Placebo Umbilical Cord Blood infusion and active rehabilitation
88898032|NCT01486745||Normal colonoscopy|
88898033|NCT01486745||Colonic polyps|
88898034|NCT01486745||Colorectal cancer patients|
88898035|NCT01486745||Breast & Prostate Cancer patients|
88898036|NCT01486771|Experimental|IV Macugen Q6|Will receive 3 intravitreal pegaptanib injections at 6-week intervals, then 3 additional injections at 12-week intervals
88898037|NCT01486771|Experimental|IV Mac Q6 Arm|Will Selective Laser Photocoagulation after 3 intravitreal pegaptanib injections
89419353|NCT02209974|Experimental|Inhaled corticosteroids (Fluticasone, 0.5 mg)|Inhaled corticosteroids administered to the other half (n=8) of COPD patients
89419354|NCT03689413|Experimental|1 mg/kg|"For '1 mg/kg' group, sugammadex of 1 mg/kg (ex. 60 mg for 60 kg patient) will be administered to the assigned patient for this group after tracheal intubation.~We will use Sugammadex 200 MG in 2 ML Injection for this."
89419355|NCT03689413|Active Comparator|2 mg/kg|"For '2 mg/kg' group, sugammadex of 2 mg/kg (ex. 120 mg for 60 kg patient) will be administered to the assigned patient for this group after tracheal intubation.~We will use Sugammadex 200 MG in 2 ML Injection for this."
89419356|NCT02220816|Experimental|Competitive Training|The patients will receive only competitive activities designed to restore attention abilities. These include pencil-and-paper tasks completed under competitive circumstances and competitive virtual games specifically designed to treat different aspects of attention (divided, selective, sustained, etc).
88898038|NCT01486771|Experimental|Pan Retinal Photocoagulation|Will act as the control group, thus subjects in this group will receive standard PRP (modified ETDRS protocol)
88898039|NCT01486797|Experimental|NOX-A12|
88898040|NCT01486823|Experimental|Cohort A|
88898041|NCT01486823|Experimental|Cohort B|
88898042|NCT01486836||ICD therapy|
88898043|NCT01486875||BIAsp 30|
88898044|NCT01486888|Experimental|Formulation A|
88898045|NCT01486888|Active Comparator|Formulation B|
89419357|NCT02220816|Active Comparator|Non-Competitive Training|The patients will receive conventional attentional training. Pencil and paper tasks focused on different aspects of attention (divided, selective, sustained, etc.) will be completed by all participant under individual or group-therapy sessions. No competitive training will be allowed.
89419358|NCT03683641|Active Comparator|Shock Wave group|Applying shock wave to patient's Achilles tendon insertion
88898046|NCT01486901|Experimental|Formulation A|
88898047|NCT01486901|Active Comparator|Formulation B|
88898048|NCT01486914|Experimental|NN2000|
88898049|NCT01486914|Active Comparator|IAsp|
88898050|NCT01486940|Experimental|Basal/bolus regimen 1|
88898051|NCT01486940|Active Comparator|Basal/bolus regimen 2|
88898052|NCT01486953|Active Comparator|sevoflurane|Anesthesia with sevoflurane
88898053|NCT01486953|Experimental|Desflurane|Anesthesia with desflurane
88898054|NCT01486979|Experimental|Low dose|
88898055|NCT01486979|Active Comparator|High dose|
88898056|NCT01486992|Experimental|Nimotuzumab|irinotecan 180mg/m2，iv ，d1，LV 200 mg/m2 ，2h，d1，5-FU 400 mg/m2， iv，d1 5-FU 2400mg/m2，CIV，46h，q2w Nimotuzumab 200mg，iv，qw
88898057|NCT01487005||elderly subjects|Healthy
88898058|NCT01487018|Experimental|Navigation Surgery|To evaluate the feasibility and accuracy of a new method for planning and realizing zygomatic osteotomies in cases of established post-traumatic deformities using computer assisted navigation.
88898059|NCT01487018|Active Comparator|Traditional Surgery|To compare with the experimental arm.
89006645|NCT04620265|Experimental|Treadmill training 25%|This group received antigravity treadmill training 25% weight bearing and conventional exercise program.
89419359|NCT03683641|Sham Comparator|Sham Control group|Applying sham shock wave to patient's Achilles tendon insertion
88898060|NCT01487031|Experimental|Music Therapy|Patients randomized to receive music therapy will receive 2 sessions of live music therapy, at least 48 hours apart, from a Music Therapist-Board Certified (MT-BC, certified through the Certification Board for Music Therapists) in their room.
88898061|NCT01487031|Active Comparator|No music therapy|Those patients randomized to standard therapy (no music therapy) are allowed to listen to music; however they will not receive interactive music therapy from a certified therapist.
88898062|NCT01487057||Thyroid cancer, lipids, LT4 withdrawal|
88898063|NCT01487057||Thyroid cancer, Lipids, LT4 substitution|
88898064|NCT01487070|Experimental|Macugen (Pegaptanib Sodium)|Open-label, single-center trial. Subjects will recieve intravitreous injections of Macugen 7-14 days before Vitrectomy.
88898065|NCT01487096|Placebo Comparator|Placebo|"Placebo (for teriflunomide),~two tablets once daily for 1 week then,~one tablet once daily for 35 weeks."
88898066|NCT01487096|Experimental|Teriflunomide 7 mg|"Teriflunomide 7 mg:~two tablets once daily for 1 week then,~one tablet once daily for 35 weeks."
88898067|NCT01487096|Experimental|Teriflunomide 14 mg|"Teriflunomide 14 mg:~two tablets once daily for 1 week then,~one tablet once daily for 35 weeks."
88898068|NCT01487122|Experimental|Continuous Microwave|
88898069|NCT01487122|Experimental|Pulsed Microwaves|
88898070|NCT01487122|Sham Comparator|sham microwaves|
88898071|NCT01487135|Experimental|EVP-6124|A single low dose of 8-mg EVP-6124 and A single high dose of 80-mg EVP-6124
88898072|NCT01487135|Placebo Comparator|Placebo|Cranberry juice (180 mL)
88898073|NCT01487135|Active Comparator|Moxifloxacin|A single dose of 400-mg Moxifloxacin
88898074|NCT01487187|Active Comparator|immediate umbilical cord clamping|The control group will receive immediate cord clamping at birth which is the standard of care in our institution
88898075|NCT01487187|Experimental|Milking the umbilical cord at birth|Infants in the cord-milked group will be placed at or below the level of the placenta, and about 20 cm of the umbilical cord (or the length of cord that is accessible if less than 20 cm) will be vigorously milked towards the umbilicus three times before clamping the cord.
88898076|NCT01487213|No Intervention|Controls|Routine follow-up at the clinic 2-3 weeks after the treatment
88898077|NCT01487213|Other|Home self test|Intervention
88898078|NCT01487239|Experimental|A|[14C]-GDC-0980 administered as a 10-mg oral dose
88898079|NCT01487252|Active Comparator|Healthy Controls|
88898080|NCT01487252|Active Comparator|Delayed Sleep Phase Disorder|
88898081|NCT01487278|Experimental|Misoprostol|600 mcg oral misoprostol administered during the third stage of labor
88898082|NCT01487278|Experimental|UnijectTM|10 IU oxytocin delivered IM with UnijectTM during he third stage of labor
88898083|NCT01487291||Psychotic patients|Inpatients and outpatients followed at Instituto de Psiquiatria da Universidade Federal do Rio de Janeiro, Brazil
89419360|NCT05262816|Experimental|sanyinjiao group|Perpendicular insertion about 0.8-1.2cun at bilateral sanyinjiao(SP6) acupoint.Then,bilateral SP6 were connected with Electronic Acupuncture Treatment Instrument (KWD-808-I,Yingdi, China). The frequency of the pulse was 20 Hz with a pulse duration of 200 us.Intensity of stimulus was depending on patient's tolerance.
89419361|NCT05262816|Active Comparator|guanyuan group|Perpendicular insertion about 0.8-1.2cun at bilateral Guanyuan(CV4), Zhongji (CV3) acupoints.Then,the two acupoints were connected with Electronic Acupuncture Treatment Instrument (KWD-808-I,Yingdi, China). The frequency of the pulse was 20 Hz with a pulse duration of 200 us.Intensity of stimulus was depending on patient's tolerance.
89419362|NCT02207049|Active Comparator|Three Meals (TM)|Preschoolers will be provided their caloric needs within three meals.
89419363|NCT02207049|Active Comparator|Meal plus Snack (M+S)|Preschoolers will be provided three meals and two snacks, with total amount of food provided in the day the same as the Three Meal (TM) arm.
88898084|NCT01487304||Low dose HRT|
88898085|NCT01487317|Experimental|Rivastigmine transdermal patch|
88898086|NCT01487317|Placebo Comparator|placebo|
88898087|NCT01487330|Experimental|Subjects receiving TAVI valve|
88898088|NCT01487343||breast or gastrointestinal cancer pts taking capecitabine|This is a mixed-methodology pilot study of patients currently taking oral chemotherapy for breast or gastrointestinal cancer. The quantitative portion of the study consists of self-report questionnaires assessing adherence, beliefs about medications, side effect experience, self-efficacy, and satisfaction with patient education; the qualitative portion is an interview guided by two open-ended questions.
88898089|NCT01487356||Patients undergoing colonoscopy|Data was collected on all adult patients undergoing outpatient colonoscopy at St. Paul's Hospital from May 2008 to June 2009. Exclusion criteria were prior colon resection and repeat colonoscopy for the purpose of endoscopic therapy for known lesions.
88898090|NCT01487369||Insulin Aspart|
88898091|NCT01487382||Insulin Aspart|
88898092|NCT01487395|Active Comparator|Donepezil|Donepezil will be administered OS as of 5 mg- Orally Disintegrating Tablets one per day in the morning over 15 days.
88898093|NCT01487395|Placebo Comparator|Placebo|The placebo will be presented as tablet comparable to ARICEPT
88898094|NCT01487408||Insulin Aspart|
88898095|NCT01487421||SIT|
88898096|NCT01487434|Experimental|Check & Connect|Check and Connect Structured Mentoring and Case Management
88898097|NCT01487447|Experimental|Intervention|
88898098|NCT01487447|Active Comparator|Control|
88898099|NCT01487460|Experimental|TAP311 in Healthy Volunteers|
88898100|NCT01487460|Placebo Comparator|Matching Placebo|Healthy Volunteers and Patients will be treated in Placebo group.
88898101|NCT01487460|Experimental|TAP311 and Simvastatin|
88898102|NCT01487460|Experimental|TAP311 in Patients|
88898103|NCT01487473|Active Comparator|Mindfulness-Based Stress Reduction|
88898104|NCT01487473|No Intervention|Waitlist Control|
88898105|NCT01487486||Normal patients|Women with infertility diagnosis of male factor only or women who are oocyte donors
88898106|NCT01487486||Polycystic Ovary Syndrome, High BMI|Women with Polycystic Ovary Syndrome with a BMI between 30-35
89194165|NCT00482807|Experimental|Docetaxel, intensity-modulated radiation therapy and hormone therapy|This phase I trial is studying the side effects and best dose of docetaxel when given together with intensity-modulated radiation therapy and hormone therapy in treating patients with high-risk locally advanced prostate cancer with pelvic lymph node metastasis.
89194166|NCT00474604|Active Comparator|Participants without breast cancer|
89194167|NCT00474604|Experimental|Participants with breast cancer|
89194168|NCT00871312|Active Comparator|Topical Wound Oxygen Therapy|Subjects will receive four 90 minute treatments of two2 therapy per week
88898107|NCT01487486||Polycystic Ovary Syndrome, Low BMI|Women with Polycustic Ovary Syndrom with a BMI between 20 & 25
89194169|NCT00871312|Placebo Comparator|Placebo Therapy|Subjects will receive four 90 minute treatments of Placebo two2 therapy per week
88898108|NCT01487512|Experimental|Sequence 1: Treatment A-D-B-C|The study consists of 4 single-dose treatment periods. Successive drug administrations will be separated by a washout period of at least 7 and no more than 14 days.
88898109|NCT01487512|Experimental|Sequence 2: Treatment B-A-C-D|The study consists of 4 single-dose treatment periods. Successive drug administrations will be separated by a washout period of at least 7 and no more than 14 days.
89419364|NCT02207049|Active Comparator|Three Meal plus Snack (TM+S)|Preschoolers will be provided three meals and two snacks with total amount provided in the meals equal to the Three Meal (TM) arm and total amount provided in the snacks equal to Meal plus Snacks (M+S) arm.
89419365|NCT02205372|Experimental|MT-3995|
88898110|NCT01487512|Experimental|Sequence 3: Treatment C-B-D-A|The study consists of 4 single-dose treatment periods. Successive drug administrations will be separated by a washout period of at least 7 and no more than 14 days.
88898111|NCT01487512|Experimental|Sequence 4: Treatment D-C-A-B|The study consists of 4 single-dose treatment periods. Successive drug administrations will be separated by a washout period of at least 7 and no more than 14 days.
88898112|NCT01487551|Experimental|paquinimod|
88898113|NCT01487564|Experimental|Hydromorphone 16 mg|
88898114|NCT01487590|Active Comparator|Acupuncture moxibustion|Six interventions with acupuncture moxibustion, stimulating point BL67, during 20 minutes each, 48 hours apart.
88898115|NCT01487590|Placebo Comparator|Placebo|Six interventions with placebo (inactivated laser), stimulating point BL67, during 20 minutes each, 48 hours apart
88898116|NCT01487616||Women with previous preterm birth|Women with history of preterm birth (birth of a baby of less than 37 weeks gestational age, where labour was spontaneous) regardless of past pregnancy history.
88898117|NCT01487616||Women with previous miscarriage|Women with history of miscarriage (spontaneous pregnancy loss before 24 weeks of gestation), regardless of past pregnancy history.
88898118|NCT01487616||Women with previous term births|Women with previous term births (37 or more weeks of gestation)
88898119|NCT01487629|Experimental|Bevacizumab|Treatment of macular edema with intravitreal Bevacizumab
88898120|NCT01487629|Experimental|Ranibizumab|Treatment of macular edema with intravitreal Ranibizumab
89419366|NCT02205372|Placebo Comparator|Placebo|
89419367|NCT02678793|Other|Subjects who have completed Study 4975-MN-202 will be eligible|Subjects who have completed Study 4975-MN-202 will be eligible to receive open-label treatment with CNTX-4975 200 μg in Study 4975-MN-203 if they meet the inclusion/exclusion criteria.
89419368|NCT02210442|Experimental|Educaguia intervention|Implementation of practice clinical guidelines with educational games
89419369|NCT02210442|Active Comparator|Control group|Implementation of clinical practice guidelines with standard practice care
88898121|NCT01487642|Experimental|Telephone counselling|
88898122|NCT01487642|Experimental|Proactive telephone counselling|
89419370|NCT04116229|Active Comparator|Normal-weight|Participants who have a body mass index within the normal-weight category.
89419371|NCT04116229|Active Comparator|Obese|Participants who have a body mass index within the obese category.
89419372|NCT05262660||SAAE group|Patients who were diagnosed with primary aldosteronism choice SAAE at our institution
89419373|NCT05262660||MRA group|Patients who were diagnosed with primary aldosteronism choice medical treatment(mineralocorticoid receptor antagonists, MRA)) at our institution
89419374|NCT02210832|Experimental|Best practices for pregnant smokers|Five As plus referral to pregnancy-specific tobacco quit line
88898123|NCT01487642|Experimental|web-based smoking cessation programme|
88898124|NCT01487642|Active Comparator|Self-help material|
88898125|NCT01487655||healthy age matched controls|
88898126|NCT01487655||normal tension glaucoma patients|
88898127|NCT01487655||primary open angle glaucoma patients|
88898128|NCT01487681||Invasive cervical cancer|
88898129|NCT01487681||Cervical intraepithelial neoplasia 2/3|
88898130|NCT01487681||Cervical intraepithelial neoplasia 1|
88898131|NCT01487694|Experimental|Cimicifuga racemosa|patients receive cimicifuga racemosa rhizome and root extract 40 mg/day (equivalent to triterpene glycosides 12.3 mg)
88898132|NCT01487694|Placebo Comparator|Placebo|Placebo containing no active ingredient which match the drug in bottle, shape, color and smell
88898133|NCT01487707|Experimental|Voluntary Health Worker (VHW) Program|
88898134|NCT01487707|Experimental|VHW program plus Safe Birth Kit|
88898135|NCT01487707|Experimental|VHW program plus Folk Media Activities|
88898136|NCT01487720|Experimental|GEMOX|GEMOX treatment
88898137|NCT01487746||treatment|Stroke patients
88898138|NCT01487746||Controls|healthy controls
88898139|NCT01487759|Active Comparator|Prebiotic|
88898140|NCT01487759|Placebo Comparator|Placebo|
88898141|NCT01487772||Hip-fracture patients|Hip-fracture patients admitted to Orthopaedic Department of Danderyd Hospital
88898142|NCT01487785|Experimental|LDE225+gemcitabine|Increasing doses of LDE225 (from 400 mg) once a day + 1000 mg/m2 of gemcitabine on days 1, 8 and 15 of every 28 day cycle.
88898143|NCT01487798|Experimental|Treatment period 1|
89419375|NCT02210832|Experimental|Best practices plus financial incentives|Best practices plus providing financial incentives contingent on biochemically verified abstinence. Incentives are in the form of vouchers exchangeable for retail items and available through 12-weeks postpartum.
88898144|NCT01487798|Active Comparator|Treatment period 2|
88898145|NCT01487811|Experimental|Formulation 1|
89419376|NCT02210832|No Intervention|Never-smoker comparison condition|We will follow a group of never-smoker pregnant women matched to smokers on key sociodemographic and obstetrical characteristics for purposes of comparisons in birth/health outcomes at delivery and through 1 year postpartum
88898146|NCT01487811|Active Comparator|Formulation 2|
89419377|NCT04981600|Active Comparator|Laser Group|Grade II-III hemorrhoids present a special challenge to surgeons since aggressive surgery exposes the patient to several per- and postoperative complications. Therefore new techniques have been developed and one of the most popular contemporary technique is laser hemorrhoidectomy. By this technique a laser probe is inserted above the dentate line and advanced to the apex of the cushion and several shots are delivered while pulling out the probe gradually. The idea is to compromise the vascular flow of corpus cavernosum recti, hence shrinking the hemorrhoidal cushion.
88898147|NCT01487824||Preterm-born Young Adults|
88898148|NCT01487824||Term-born Young Adults|
88898149|NCT01487837|Active Comparator|Fibrinogen if FibTEM < 8 mm|Administration of fibrinogen concentrate if ROTEM FibTEM revealed MCF < 8 mm
88898150|NCT01487837|Experimental|Fibrinogen if FibTEM < 13 mm|Administration of fibrinogen concentrate if ROTEM FibTEM revealed MCF < 13 mm
88898151|NCT01487876|Experimental|LAM+DNA vaccine|lamivudine (LAM) chemotherapy and DNA vaccine
88898152|NCT01487876|Placebo Comparator|LAM+Placebo|"Each volunteer received 4 injections of 4 mg placebo scheduled by a prime and 3 boosts at intervals of 4, 8, 12 weeks.~lamivudine (LAM) chemotherapy and Placebo"
89419378|NCT04981600|Active Comparator|RF (Radiofrequency) Group|Another recent and similar method is radiofrequency coagulation which depends on transmitting radiofrequency waves to tissue. This transmission results in conversion of radiofrequency waves into heat and causes coagulation necrosis in corpus cavernosum recti. The necrosis leads to fibrosis of the surrounding vessels and consequently cushion shrinkage is achieved.
89419379|NCT02212392|No Intervention|control|This arm was not given any prophylactic antibiotics. Patients were managed in the surgical ward by post graduate residents under the supervision of consultants
89419380|NCT02212392|Experimental|Antibiotics|this arm was given IV antibiotics, prophylactically, right from the day of admission. They were given intravenous broad spectrum (MEROPENEM) twice daily at 12 hours interval for 7-10 days
88898153|NCT01487889|Experimental|Rapeseed oil|Study group receive commercial vegetable-potato-meat-meals containing rapeseed oil as part of complementary food
88898154|NCT01487889|Experimental|Fatty fish|Study group receive 2 times per week a vegetable-potato-meat-meals as part of complementary food.
88898155|NCT01487889|Active Comparator|Corn oil|Study group receive commercial vegetable-potato-meat-meals containing corn oil as part of complementary food
89194170|NCT00740012|Active Comparator|Even, low numbers|They start with a alarm- clock night. No venous blood drawing.
89194171|NCT00740012|Active Comparator|Even, high numbers|They start with a nurse performing blood glucose determination. No venous blood drawing.
88898156|NCT01487902|Experimental|ADT arm|Concomitant androgen deprivation treatment
88898157|NCT01487902|Active Comparator|No ADT arm|No concomitant androgen deprivation treatment arm
88898158|NCT01487915|Active Comparator|GCb|Gemcitabine plus Carboplatin
88898159|NCT01487915|Experimental|GemOx|Gemcitabine plus Oxaliplatin
88898160|NCT01487967|Experimental|Intervention|Families in the intervention arm will receive culturally appropriate educational material, complete the Preference and Goal Instrument at the study start, use the results to inform decision making about ADHD treatment, have their preferences/goals tracked in the electronic health record, and have their progress toward their goals assessed at 3 months and 6 months (approximately).
88898161|NCT01487967|No Intervention|Control|Parents will receive education on ADHD and its treatment, and otherwise receive standard care.
88898162|NCT01487980|Active Comparator|Early cord clamping|Within 30 seconds after birth.
89419381|NCT02833077|Experimental|JUVÉDERM VOLUMA® XC|JUVÉDERM VOLUMA® XC was injected into the chin at a volume determined by the investigator on Day 0. Participants were eligible to receive touch-up treatment 30 days later, if applicable. The maximum total volume administered was up to 4 milliliters (mL) for both treatments combined.
89419382|NCT02833077|Other|No Treatment then JUVÉDERM VOLUMA® XC|No treatment for 6 months followed by optional treatment with JUVÉDERM VOLUMA® XC injected into the chin at a volume determined by the investigator on Month 6. Participants were eligible to receive touch-up treatment 30 days later, if applicable. The maximum total volume administered was up to 4 mL for both treatments combined.
89419383|NCT03679897|Experimental|Ropivacaine group|BPB with 0.375% ropivacaine solution
89419384|NCT03679897|Active Comparator|Levobupivacaine group|BPB with 0.25% levobupivacaine solution
89419385|NCT03060070|Placebo Comparator|control group,|saline in the same volume will be added to the local anesthetic for TAP block in patients undergoing abdominal cancer surgery
89419386|NCT03060070|Active Comparator|ketamine group,|ketamine in a dose of 0.5mg/kg will be added to the local anesthetic for TAP block in patients undergoing abdominal cancer surgery
89419387|NCT03060070|Active Comparator|dexmedetomidine group|dexmedetomidine in a dose of 1ug/kg will be added to the local anesthetic for TAP block in patients undergoing abdominal cancer surgery
89419388|NCT02212470|Active Comparator|Drug Eluting Balloon|Admiral In.Pact Drug Eluting Balloon
89419389|NCT02212470|Active Comparator|Nitinol Stent|Complete SE Self-expandible Nitinol stent
89419390|NCT03683563|Active Comparator|4% citrate|dialysis catheter locked with 4% sodium citrate
88898163|NCT01487980|Experimental|Delayed cord clamping|Between 2 and 3 minutes after birth
88898164|NCT01487993|Active Comparator|Metformin|Metformin with lifestyle intervention during 18 months
88898165|NCT01487993|Placebo Comparator|Placebo|Placebo and lifestyle intervention during 18 months
88898166|NCT01488006||Bigliani/Flatow Shoulder System|Other than the Bigliani/Flatow device, there will be no difference in treatment between those patients undergoing arthroplasty with the Bigliani / Flatow prosthesis and those who previously received other prosthesis. APatients who decide to participate in the study will complete various forms prior to surgery (The Informed Consent, Contact Information Form, Demographics Module, and standard outcomes forms such as American Shoulder and Elbow Surgeon Score form, Constant's Score form, and the Simple Shoulder Test, EuroQOL and SF-36). The patient will also complete forms postoperatively at 3-month, 6-month, 1-year, 2-year, 3-year, 4-year and 5-year intervals (American Shoulder and Elbow Surgeon Score form, Constant's Score form, Simple Shoulder Test, EuroQOL and SF-36).
88898167|NCT01488032||high-tension glaucoma|subjects with IOP>22 mmHg without eyedrops and signs of glaucomatous optic nerve damage
88898168|NCT01488032||low-tension glaucoma|subjects with IOP<22 mmHg without eyedrops and signs of glaucomatous optic nerve damage
89419391|NCT03683563|Experimental|30% citrate|dialysis catheter locked with 30% sodium citrate
89419392|NCT03563625|Active Comparator|Caudal block|Caudal block with 1mg/kg bupivacaine 0.25%.
89419393|NCT03563625|Active Comparator|Wound infiltration|Local wound infiltration with 1mg/kg bupivacaine 0.25%.
89419394|NCT04973488|Experimental|Treatment arm|In the treatment arm, Therapeutic plasma exchange will be conducted in the first 24 hours after being admitted into the intensive care unit, after which convalescent plasma from donors that have had COVID-19 will be transfused
89419395|NCT04973488|No Intervention|Control arm|In the control arm, patients will receive standard COVID-19 treatment
88898169|NCT01488058|Other|Group 2|Waitlist control
88898170|NCT01488058|Experimental|Group 1|CBM intervention (OxIGen) plus Internet based Cognitive Behavioural Therapy for depression
88898171|NCT01488084|Experimental|"Pedicled no-touch SVG harvesting"|Saphenous vein harvested with a pedicle of surrounding fat and distension with heparinized blood at arterial pressure. No manual distention.
88898172|NCT01488084|Active Comparator|Conventional open SVG harvesting|Saphenous vein is harvested with an open technique, stripped of adventitia, and manually distended with crystalloid solution.
88898173|NCT01488110|Experimental|Migraine medical device|Treatment with an active nasal probe
89419396|NCT02213016|Sham Comparator|Transcranial magnetic stimulation|Sham repetitive Transcranial magnetic stimulation, 5 Hz, 5 sessions per week for three weeks: Total of 15 sessions.
89419397|NCT02213016|Active Comparator|Transcraneal magnetic stimulation|Active repetitive Transcranial magnetic stimulation, 5 Hz, 5 sessions per week for three weeks: Total of 15 sessions.
89419398|NCT02213016|Sham Comparator|Sham Comparator|Sham repetitive Transcranial magnetic stimulation, 5 Hz, 2 sessions per week for 7 1/2 weeks: Total of 15 sessions.
89419399|NCT02213016|Active Comparator|Active Comparator|Active repetitive Transcranial magnetic stimulation, 5 Hz, 2 sessions per week for 7 1/2 weeks: Total of 15 sessions.
89419400|NCT03683485|Experimental|long duration EPBD group|Balloon dilation was performed using wire-guided hydrostatic balloon catheters. An 8-mm dilatation balloon was used for EPBD. Balloons were gradually inflated to maximum pressure for 3 minute, and complete inflation was verified by fluoroscopy. Stones were removed by standard techniques, including balloon or basket catheters.
89419401|NCT03683485|Active Comparator|endoscopic sphincterotomy (EST) group|After deep cannulation was achieved, a complete sphincterotomy was performed with a 25-mm pull-type sphincterotome (Clever Cut 3; KD-V411M, Olympus, Tokyo, Japan) and the sphincter was divided up to the transverse duodenal fold. A complete sphincterotomy was defined by the free passage of a fully bowed sphincterotome and the presence of spontaneous bile drainage. A complete sphincterotomy was defined by the free passage of a fully bowed sphincterotome and the presence of spontaneous bile drainage.
89419402|NCT04973878|Experimental|Group A|EGD performed before the Colonoscopy
89419403|NCT04973878|Experimental|Group B|Colonoscopy performed before the EGD
88898174|NCT01488110|Placebo Comparator|Inactive migraine medical device|Treatment with an inactive nasal probe.
88898175|NCT01488123|Experimental|Ayurvedic Intervention|
88898176|NCT01488136|Active Comparator|Diazoxide|Oral diazoxide 7 mg/kg
88898177|NCT01488136|Placebo Comparator|Placebo|Matched placebo
89419404|NCT02258178||1, Flucelvax|Flucelvax exposure in pregnancy
88898178|NCT01488162||Cohort|
88898179|NCT01488175|Active Comparator|with tourniquet|
88898180|NCT01488175|Placebo Comparator|without tourniquet|
88898181|NCT01488201|Experimental|KHK4827|
88898182|NCT01488201|Placebo Comparator|Placebo|
88898183|NCT01488214|Experimental|Scleroderma patient|Evaluation of Scleroderma patient
88898184|NCT01488214|Placebo Comparator|Healthy subjects|Evaluation of healthy subjects
88898185|NCT01488227|Experimental|Vitamin D|Vitamin D
88898186|NCT01488227|Placebo Comparator|Oil pill|Contains vegetable and soybean oil supplied by Nature Made by Pharmavite LLC located in Northridge, CA and is United States Pharmacopeia (USP) certified.
88898187|NCT01488253|Experimental|acute GVHD prevention by sirolimus based regimen|The investigators will evaluated the primary endpoint and secondary endpoints comparing with historical control, that is used tacrolimus/methotrexate as a GVHD prophylaxis after HLA-matched, related PBSCT.
88898188|NCT01488266|Experimental|aripiprazole augmentation|
88898189|NCT01488266|Active Comparator|different class of antidepressant|
88898190|NCT01488292|Experimental|RECAP social skills and reading program|
88898191|NCT01488292|No Intervention|Control group (services as usual)|Control Group (services as usual)
88898192|NCT01488305|No Intervention|Only government regular program|One arm is control arm, in this arm no additional program is added in government regular program
88898193|NCT01488305|Experimental|AAMA arm (HFP and IYCF BCC)|Second arm is AAMA project intervention which includes HFP activities, ENA and BCC activities
88898194|NCT01488305|Experimental|MNP added in AAMA|It is actually a intervention arm
88898195|NCT01488331||Cohort|
88898196|NCT01488344|Experimental|BIBF 1120|
88898197|NCT01488357||Early stage breast cancer patients receiving mastectomy|
88898198|NCT01488383|Experimental|Stevioside capsules 200mg|Capsules of 200mg Stevioside
88898199|NCT01488383|Active Comparator|Sodium Saccharin 250 capsules|Capsules of 250mg Saccharin
88898200|NCT01488396|Experimental|0.05%cyclosporin eye drop|
88898201|NCT01488422|Active Comparator|Group 1|Both groups will receive stress reduction materials. We expect both groups to achieve similar amounts of stress reduction, but to use different brain regions to do so.
88898202|NCT01488422|Active Comparator|Group 2|Both groups will receive stress reduction materials. We expect both groups to achieve similar amounts of stress reduction, but to use different brain regions to do so.
88898203|NCT01488435|Placebo Comparator|Cow's Milk|Powdered whole cow's milk
88898204|NCT01488435|Experimental|Follow-On Formula|Powdered Follow-On Formula with added long-chain Polyunsaturated fatty acid, prebiotics, and polysaccharide
88898205|NCT01488461||patients ataxic|
88898206|NCT01488474||Diabetes Mellitus (DM)|Patients with diagnosed diabetes mellitus type 1 or 2 undergoing surgery of the lower limb and are receiving regional anesthesia with peripheral nerve stimulation
88898207|NCT01488474||Control (C)|Patients with no history of diabetes mellitus Type 1 or 2 undergoing surgery of the lower limb and are receiving regional anesthesia with peripheral nerve stimulation
88898208|NCT01488500|Experimental|Filtered air exposure|3 hour exposure to filtered air with intermittent exercise
88898209|NCT01488500|Experimental|Wood smoke exposure|3 hour exposure to dilute wood smoke generated from incomplete combustion in a wood burning stove at approximately 300 mcg/m3
88898210|NCT01488500|Experimental|Wood pellet smoke emission|3 hour exposure to dilute wood smoke generated from wood pellets during incomplete combustion during intermittent exercise at approximately 300 mcg/m3
88898211|NCT01488513|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive sphingosine kinase-2 inhibitor ABC294640 PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88898212|NCT01488526|No Intervention|Control arm: HBIG & vaccine for infants|Provide standard of care to mothers and standard immunoprophylaxis to their infants
88898213|NCT01488526|Experimental|TDF treatment arm|tenofovir from 30-32 weeks of pregnancy to the week 4 of postpartum for mothers and standard immunoprophylaxis to their infants
88898214|NCT01488552|Experimental|Gemcitabine & Abraxane Pancreatic Cancer|Gemcitabine+Nab-paclitaxel, FOLFIRINOX, Immunohistochemistry (IHC) Analysis, Metformin and Folfiri
88898215|NCT01488565|Experimental|Azacitidine and Eltrombopag|Vidaza (azacitidine) Revolade (eltrombopag)
88898216|NCT01488604|Experimental|PNS|2 sprays of experimental nasal spray per nostril 4 times per day for 7 days
88898217|NCT01488604|Sham Comparator|SNS|2 sprays of sham nasal spray per nostril 4 times per day for 7 days
88898218|NCT01488630|No Intervention|Treatment as Usual|Chart review only.
88898219|NCT01488630|Experimental|STaRS|Patients asked to participate in follow-up study to get information on whether they went to referral recommended by their provider through the STaRS system.
88898220|NCT01488643||OBESITY PATIENTS|PATIENTS WITH BMI >35
88898221|NCT01488643||CONTROL TEAM BMI <35|
88898222|NCT01488656|Placebo Comparator|Placebo dietary supplements|Visually identical inactive dietary supplement pack
88898223|NCT01488656|Experimental|Active dietary supplements|Combination of antioxidants, minerals, fish oil, proflavanol and vitamin D
88898224|NCT01488669|Experimental|Robotic neck dissection|Robotic neck dissection was performed via modified face lift or retroauricular approach using the robotic arms, while conventional neck dissection was conducted after transverse skin incision from the mastoid tip to the midline.
88898225|NCT01488669|Active Comparator|Conventional neck dissection|Neck dissection is performed after an external transverse skin incision.
88898226|NCT01488682|Experimental|Harmonic scalpel|Harmonic Focus® Curved Shears (Ethicon Endo-Surgery, Cincinnati, OH) was used for vascular control of the surgery regardless of vessel diameter, except when hand-tied or suture ligation was needed for IJV ligation or in case bleeding was not controlled with electrocoagulation
88898227|NCT01488682|Active Comparator|conventional hand tie ligation|electrocautery was used to control the small vessels and conventional hand-tied ligation was used for large sized arterial, venous, or lymphatic vessels.
88898228|NCT01488695|Experimental|GlideScope Groove|Patient will be intubated using the GlideScope Groove device.
88898229|NCT01488695|Active Comparator|Control|Control Group: Macintosh Blade
88898230|NCT01488721||General Newborn Population-Prospective|Specimens prospectively collected in the course of routine newborn screening originating from hospitals, birthing centers, and/or clinics.
88898231|NCT01488721||Newborn Specimens-Confirmed Positive|Banked confirmed positive specimens that were originally collected as part of the newborn screening program, but when found to screen positive for a disease, were followed up clinically to definitively diagnose the subject with the disease (CF, CAH or CH). Follow up results were reported to the sites by the treating clinicians.
89194172|NCT00740012|Active Comparator|Uneven, low numbers|They start with an alarm- clock night and have venous blood drawing.
89194173|NCT00740012|Active Comparator|Uneven, high numbers|They start with a nurse performing blood glucose determination and have venous blood drawing.
89194174|NCT04064268|Experimental|Healthy + Whey|Healthy conditions (overnight fast)
89194175|NCT04064268|Experimental|Catabolic + Whey|Catabolic conditions (36-hour fast, bed rest and inflammation (LPS))
89194176|NCT04064268|Experimental|Catabolic + 3-OHB / Whey|Catabolic conditions (36-hour fast, bed rest and inflammation (LPS))
89194177|NCT00738660|Experimental|A|single experimental arm cross over of patients, addition of Ramipril onto Telmisartan.
89194178|NCT00740168||TG|Bevacizumab treatment group with metastasized cancer
89194179|NCT05225974|Experimental|Liraglutide injection|
89194180|NCT05225974|Active Comparator|Liraglutide injection(Victoza®)|
89194181|NCT00729638|Experimental|Single arm|Single arm phase I study
89194182|NCT00734682|Experimental|Nanoliposomal CPT-11|All patients are treated with nanoliposomal CPT-11
89194183|NCT00876538|Experimental|TRO19622|2 capsules of TRO19622 (330mg) once day with the noon meal
89194184|NCT00876538|Placebo Comparator|Control|2 capsules of placebo once day with the noon meal
89194185|NCT00732108|Experimental|topiramate|topiramate 50mg orally for 2 weeks, then 100mg orally for 6 weeks
89194186|NCT00732108|Placebo Comparator|2|1 placebo pill orally for 2 weeks, then 2 placebo pills orally for 6 weeks
89194187|NCT00735800|Active Comparator|Supportive Counseling|
89194188|NCT00735800|Experimental|Problem-Solving|
89194189|NCT00876616|Experimental|Tacrolimus+Mycophenolate mofetil|FK506 4mg/d+MMF 1.0g/d
89194190|NCT00876616|Active Comparator|Cyclophosphamide|CTX iv 0.75 g/m2 body surface area (BSA)
89194191|NCT04064502||volunteers|273 adult volunteers ranging from 18-78 years old
89194192|NCT00729716|Experimental|A|BioCart™II treatment
89194193|NCT00729716|Active Comparator|B|Microfracture procedure
89194194|NCT00863200||Telephone Intervention Group|
89194195|NCT00863200||Standard Care Group|
88898232|NCT01488734|Experimental|Mushroom with 600 IU vitamin D2|Mushroom with 600 IU of vitamin D2 daily and placebo tablet
89194196|NCT00734760|Experimental|A|a tailored, face-to-face education and counseling intervention with a nurse lasting approximately 45 minutes, followed by a telephonic reinforcement in 30 days
89194197|NCT00734760|No Intervention|B|care-as-usual with data collection at the same time points as the experimental group
89194198|NCT00740324|Active Comparator|N|
89194199|NCT00740324|Active Comparator|B|
89194200|NCT00740324|Active Comparator|G|
89194201|NCT00871468|Active Comparator|superior plate|Clavicle plate on the superior surface of the bone
89194202|NCT00871468|Experimental|anterior inferior plate|plate placed on anterior inferior surface of bone
89194203|NCT04040998|Experimental|CCT+TAU group|The participants in CCT+TAU group received compensatory cognitive training plus treatment as usual. The CCT intervention consisted of two 50-minute sessions each week for 10 weeks
89194204|NCT04040998|No Intervention|TAU group|The participants in TAU group received usual treatment at the same time as CCT+TAU group.
89194205|NCT05575440||Observational (18F-TFB PET/CT)|Patients receive fluorine F18 tetrafluoroborate IV and undergo PET/CT scan on study.
89194206|NCT00863278|Active Comparator|Arm A|"All patients will be treated by stabilized Kligman's trio with daily application during 4 months.~After one month, the left side of the face will be treated with pulsed dye laser at the rate of 3 sessions (one every weeks).~Applications of cream will be stopped on both side of the face for the 3 days following each laser session. Final visit will be scheduled 1 month after the end of applications of stabilized Kligman's trio.~All the patients will used a sunscreen indication 50 + for the duration of the entire study.~The patient is her own witness. They compare the hemiface treated without laser and the hemiface treated with the laser."
89194207|NCT00863278|Active Comparator|Arm B|"All patients will be treated by stabilized Kligman's trio at the rate of application in the evening during 4 months.~After one month, the side of the right face will be treated by pulsed dye laser at the rase of 3 sessions spaced out by 3 weeks each.~Applications will be stopped in the 3 days which will follow every session by laser with blown colouring agent. The patients will be seen again 1 month after the stopping of applications of stabilized Kligman's trio~All patients will be used a sunscreen indication 50 + for the duration of study.~The patient is her own witness. They compare the cheek treated without laser and the cheek treated with the laser."
89194208|NCT00740558|Active Comparator|1|Two groups received a traditional chiropractic adjustment of the lumbar 5 and the other group received a manually assisted mechanical force adjustment of the lumbar 5.
89194209|NCT00740558|Sham Comparator|2|The investigators had two groups, one for each chiropractic technique used in the research project and we had a control group
89536023|NCT02483195|Active Comparator|Single Group|This group will use a mixed combination of 5mg Finasteride with placebo topical preparation for 12 months to be used once daily.
89536024|NCT03071991||Study group|Preincisional bupivacain will be used
89536025|NCT03071991||Control group|No preincisional anesthetic drug will be used
88898233|NCT01488734|Experimental|Mushroom with 4000 IU Vitamin D2|Mushroom with 4000 IU of Vitamin D2 daily and placebo tablet
88898234|NCT01488734|Active Comparator|600 IU Vitamin D3 and untreated mushroom|Commercially available tablets with 600 IU/day of Vitamin D3 and untreated mushroom
88898235|NCT01488734|Active Comparator|4000 IU Vitamin D3 and untreated mushroom|Commercially available tablets with 4000 IU/day of Vitamin D3 and untreated mushroom
88898236|NCT01488747|Experimental|Coromega Omega-3 Squeeze|5.03 g
88898237|NCT01488747|Experimental|Coromega Nectar|12.22 g
88898238|NCT01488747|Experimental|Barleans Swirl|17.45 g
88898239|NCT01488747|Active Comparator|Nordic Omega-3 Softgel|4 softgels
88898240|NCT01488760||Nineteen women with low back pain|
88898241|NCT01488760||Twenty pain-free women|
88898242|NCT01488773||ICS + salmeterol|"Patients treated with both inhaled glucocorticosteroid (ICS) and salmeterol (long-acting β2-agonist).~90 patients met the inclusion criteria for this group."
88898243|NCT01488773||ICS + montelukast|"Patients treated with both inhaled glucocorticosteroid (ICS) and montelukast (leukotriene receptor antagonist).~42 patients met the inclusion criteria for this group."
88898244|NCT01488786|Experimental|BrainPort Vision Device|Single Arm
88898245|NCT01488799|Active Comparator|MI-CBT|
88898246|NCT01488799|Active Comparator|CBT alone|
88898247|NCT01488812||Hip-fracture patients|All the hip-fracture patients admitted to the Orthopaedic Depart of Danderyd Hospital between 1st June 2007- 1st June 2008 who fulfilled the inclusion criteria of the study.
88898248|NCT01488825|No Intervention|Wait-list control group|The wait-list control group received no intervention, or instruction and they were observed with their usual care for 12-weeks intervention period. Upon completion of the study, this group received 12 weeks of yoga intervention.
88898249|NCT01488825|Experimental|Yoga Intervention Group|The yoga sessions developed specifically for study participant consisted of 12 weekly 60-minute designed to benefit in episodic tension type headache.
88898250|NCT01488838|Experimental|Arm 1:|Radiation: 60-66 Gy in 2 Gy daily fractions Cisplatin: 40 mg/m2 weekly during radiation for 7 doses
88898251|NCT01488838|Active Comparator|Arm 2:|Radiation: 60-66 Gy in 2 Gy daily fractions
88898252|NCT01488864|Experimental|Applied Relaxation (AR)|
88898253|NCT01488864|No Intervention|Untreated Control Group (CG)|The women assigned to CG will be told to act as an untreated control group i.e. not to use hormonal treatment, other alternative medication, natural remedies for hot flashes and even not acupuncture, mind-body therapies or intensive physical activity.
88898254|NCT01488903||Premenopausal Women|600 health premenopausal Women
88898255|NCT01488903||Postmenopausal women|600 healthy postmenopausal women
88898256|NCT01488916||Vitamin D deficiency|patients with serum vitamin D levels of the lower tertile
88898257|NCT01488916||Vitamin D inadequacy|patients with serum vitamin D levels of the middle tertile
88898258|NCT01488916||Reference group|patients with serum vitamin D levels of the upper tertile
88898259|NCT01488942|Experimental|monetary reinforcer|Subjects randomized to this arm will receive an escalating reinforcer initially for attendance at each clinic visit (until month 6 after starting HAART) and subsequently (until month 12 after starting HAART) will receive an escalating variable reinforcer for each month in which a viral load at or below 100 copies/mL is maintained
88898260|NCT01488942|No Intervention|no reinforcer|All subjects will receive HAART and standard medical care, but subjects in the control arm will not receive monetary reinforcers.
88898261|NCT01488955|Experimental|Ibuprofen|Ibuprofen 400 mg oral once daily from day 0 for 3 days, placebo granulate oral day 0
88898262|NCT01488955|Experimental|Fosfomycin-Trometamol|Fosfomycin-Trometamol (Monuril) 3 g granulate oral at day 0, placebo to Ibuprofen once a day from day 0 for 3 days
88898263|NCT01488968|Active Comparator|Standard|Standard Radiation Treatment
88898264|NCT01488968|Experimental|Hypofractionated|Hypofractionated
88898265|NCT01489007||Vegetarian Children|"Self-described lacto-ovo vegetarians for the past 6 months (Subjects who include a small amount of fish or chicken in the diet (not more than 2 servings total/week of both combined) will be allowed to participate in this study as these are not major iron contributors to the diet. Subjects must not have eaten any red meat however for 6 months.) Control subjects will be non-vegetarians."
88898266|NCT01489033|Experimental|Group A active|"6 administrations and 5 weeks duration~Vial 2: 0.1 ml, 0.2 ml and 0.5 ml at 1 week intervals~Vial 3: 0.1 ml, 0.2 ml and 0.5 ml at 1 week intervals."
88898267|NCT01489033|Placebo Comparator|Group A placebo|"6 administrations and 5 weeks duration~Vial 2: 0.1 ml, 0.2 ml and 0.5 ml at 1 week intervals~Vial 3: 0.1 ml, 0.2 ml and 0.5 ml at 1 week intervals."
88898268|NCT01489033|Experimental|Group B active|"8 administrations and 7 weeks duration~Vial 1: 0.2 ml at 1 week intervals~Vial 2: 0.1 ml, 0.2 ml, 0.4 ml at 1 week intervals~Vial 3: 0.1 ml, 0.2 ml, 0.4 ml and 0.5 ml at 1 week intervals"
88898269|NCT01489033|Placebo Comparator|Group B placebo|"8 administrations and 7 weeks duration~Vial 1: 0.2 ml at 1 week intervals~Vial 2: 0.1 ml, 0.2 ml, 0.4 ml at 1 week intervals~Vial 3: 0.1 ml, 0.2 ml, 0.4 ml and 0.5 ml at 1 week intervals"
88898270|NCT01489033|Experimental|Group C active|"8 administrations, 2 administrations in the same day. 1 week interval between 2 doses, during 3 weeks.~Week 1: vial 2 - 2 administrations of 0.1 ml with 30 minute interval~Week 2: vial 2 - 0.2 ml and 0.3 ml with 30 minute interval~Week 3: vial 3 - 2 dose of 0.1 ml with 30 minute interval~Week 4: vial 3 - 0.2 ml and 0.3 ml with 30 minute interval"
88898271|NCT01489033|Placebo Comparator|Group C placebo|"8 administrations, 2 administrations in the same day. 1 week interval between 2 doses, during 3 weeks.~Week 1: vial 2 - 2 administrations of 0.1 ml with 30 minute interval~Week 2: vial 2 - 0.2 ml and 0.3 ml with 30 minute interval~Week 3: vial 3 - 2 dose of 0.1 ml with 30 minute interval~Week 4: vial 3 - 0.2 ml and 0.3 ml with 30 minute interval"
88898272|NCT01489059|Experimental|Part 1 - Arm 1: BMS-982470 (Daily x 5) + Ipilimumab|Dose Escalation
89419405|NCT01355679|Experimental|Guided therapy|A total of 14 eligible neuroblastoma patients who are refractory or relapsed on conventional therapy will be treated. Guided therapy will allow the use of any therapeutic combination (up to 4 agents) provided it includes medications contained in the study report. All patients will be followed for survival, disease response, progression and safety. All patients will be treated according to the discretion of the treating oncologist and study committee (minimum 3 oncologists and one pharmacist). Extent of disease will be measured and assessed for changes throughout the course of the study and at 6-8 week intervals (every 2 cycles).
89419406|NCT03062566||Severe TBI patients|GCS 3-8
89419407|NCT02220972|Experimental|Arm A: First on Perampanel with a crossover to Placebo|Treatment Arm A will initially receive perampanel 2 mg QD titrated up to 4 mg QD and finally to 6 mg QD with a crossover to placebo.
89419408|NCT02220972|Experimental|Arm B: First on Placebo with a crossover to Perampanel|Treatment Arm B will initially receive placebo with a crossover to perampanel 2 mg QD titrated up to 4 mg QD and finally to 6 mg QD.
89419409|NCT02205606|Active Comparator|HGP0816 5mg|
88898273|NCT01489059|Experimental|Part 1 - Arm 2: BMS-982470 (Weekly) + Ipilimumab|Dose Escalation
88898274|NCT01489059|Experimental|Part 2 - Arm 1: BMS-982470 (Daily x 5) + Ipilimumab|Cohort Expansion
88898275|NCT01489059|Experimental|Part 2 - Arm 2: BMS-982470 (Weekly) + Ipilimumab|Cohort Expansion
88898276|NCT01489059|Active Comparator|Part 2 - Arm 3: Ipilimumab monotherapy|Cohort Expansion
89419410|NCT02205606|Active Comparator|HGP0816 10mg|
89419411|NCT02205606|Active Comparator|HGP0816 20mg|
89419412|NCT02205606|Experimental|HCP1306 5/10mg|
89419413|NCT02205606|Experimental|HCP1306 10/10mg|
89419414|NCT02205606|Experimental|HCP1306 20/10mg|
88898277|NCT01489072|Experimental|Remifentanil 0.25 mcg/kg|Administration of a bolus dose of remifentanil 0.25 mcg/kg before emergence of a desflurane-based anesthesia
88898278|NCT01489072|Active Comparator|Remifentanil 0.5 mcg/kg|Administration of a bolus dose of remifentanil 0.5 mcg/kg before emergence of a desflurane-based anesthesia
88898279|NCT01489098||Breast Fed reference group|3 and 5 year olds from the above group
88898280|NCT01489098||Infant formula - protein level 1|3 ad 5 year olds from the above group
88898281|NCT01489098||Infant formula - protein level 2|3 and 5 year olds from the above group
88898282|NCT01489124|Experimental|0.5 g of imipenem by 0.5-hr infusion|0.5 g of imipenem every 6 hrs administrated by 0.5-hr infusion for 3 days
88898283|NCT01489124|Experimental|0.5 g of imipenem by 2-hr infusion|0.5 g of imipenem every 6 hrs administrated by 2-hr infusion for 3 days
88898284|NCT01489124|Experimental|1 g of imipenem by 2-hr infusion|1 g of imipenem every 6 hrs administrated by 2-hr infusion for 3 days
88898285|NCT01489137|Experimental|neurosurgery with fixation|
88898286|NCT01489163|Experimental|Lifestyle Counseling|
88898287|NCT01489163|No Intervention|Control|
89419415|NCT02832375|Experimental|Experimental: stannous fluoride|Participants will be instructed to dose a dry toothbrush containing 0.454% w/w of stannous fluoride (1000 parts per million [ppm] fluoride) with a full strip (1 inch) of toothpaste. Participants will then brush each of the two selected sensitive test teeth first followed by the whole mouth thoroughly for at least 1 minute.
88898288|NCT01489202|Active Comparator|platinum chromium EES|Patients undergoing PCI with stenting will have implantation of platinum chromium everolimus-eluting stents
88898289|NCT01489202|Active Comparator|cobalt chromium everolimus-eluting stent|Patients undergoing PCI with stenting will have implantation of cobalt chromium everolimus-eluting stents
88898290|NCT01489215|Experimental|"Clinical group-presence intervention"|"The Presence intervention is based on based on the principles of graduated extinction, which has been defined has been defined as effective and recommended therapy in the treatment of bedtime problems and night wakings by the Standard of Practice Committee of the American Academy of Sleep Medicine."
89006646|NCT04620265|Sham Comparator|Conventional program|This group received the conventional exercise program only.
89419416|NCT02832375|Active Comparator|Standard: sodium monofluorophosphate|Participants will be instructed to dose a dry toothbrush containing 0.76% w/w sodium monofluorophosphate (1000ppm fluoride) with a full strip (1 inch) of toothpaste. Participants will then brush each of the two selected sensitive test teeth first followed by the whole mouth thoroughly for at least 1 minute.
89419417|NCT03059680|Experimental|High potassium diet group|Individuals in this arm were asked to increase dietary potassium intake over a 4 week period. This was achieved through an increase in consumption of fruits and vegetables.
88898291|NCT01489215|Experimental|"Clinical group-checking intervention"|"The Checking training is based on the principles of graduated extinction, which has been defined has been defined as effective and recommended therapy in the treatment of bedtime problems and night wakings by the Standard of Practice Committee of the American Academy of Sleep Medicine"
88898292|NCT01489215|No Intervention|Control Group|
88898293|NCT01489228|Experimental|High Dose E1224|High Dose (HD - 8weeks) Group
88898294|NCT01489228|Experimental|Low Dose E1224|Low Dose (LD - 8 weeks) Group
88898295|NCT01489228|Experimental|Short Dose E1224|Short Dose (SD - 4 weeks) Group
88898296|NCT01489228|Placebo Comparator|Placebo|Placebo (8 weeks) Group
88898297|NCT01489228|Active Comparator|Benznidazol|BZN (Laboratório do Estado de Pernambuco -LAFEPE, tablet 100mg), 5 mg/Kg/day PO divided in two daily doses, for 60 days
88898298|NCT01489241|No Intervention|Usual care|Patients in the control group receive usual care and visit the outpatient department at 4 and at 12 weeks after discharge when pulse rate, oxygen saturation and spirometry is performed. In the case of clinical deterioration during the study, the patients contact as usual their general practitioner. Usual care of COPD patients consists of regular visits to the specialist or primary care clinics every time a medication change is made or a medical examination is needed
88898299|NCT01489241|Experimental|Telemonitoring|
88898300|NCT01489267|No Intervention|Control group|Ten patients in the group only receive nerve functional evaluation and electrophysiology examination before and 1,3,6,12 months after recruit. They will not accept cell therapy.
88898301|NCT01489267|Experimental|Stem cell transplantation|10 patients in the group accept stem cell transplantation.
89419418|NCT03059680|No Intervention|Usual diet group|Individuals in this group were asked to continue habitual dietary intake
89419419|NCT04964752|Other|the upper arm group on Day 2|The upper arm group to perform Visit 3 venous blood glucose measurement on Day 2.
88898302|NCT01489293||atopic subjects|Patients with one atopic disease or more (atopic dermatitis,rhinitis, asthma, food allergy)
88898303|NCT01489293||non-atopic subjects|Control group without atopic diseases.
88898304|NCT01489306|Experimental|MDT-637|Active formulation
88898305|NCT01489306|Placebo Comparator|Placebo|Matched Placebo Comparator
88898306|NCT01489319|Experimental|Nl Wt PCOS - Nl Abdominal Adiposity|10 normal weight women with PCOS who have normal abdominal adiposity established by DEXA
88898307|NCT01489319|Experimental|Nl Wt PCOS - Increased Abdominal Adiposity|10 normal weight women with PCOS who have increased abdominal adiposity established by DEXA
88898308|NCT01489319|No Intervention|Obese PCOS|10 obese women with PCOS
88898309|NCT01489319|No Intervention|Nl Wt Controls - Nl Abdominal Adiposity|10 normal weight ovulatory women serving as controls who have normal abdominal adiposity established by DEXA
88898310|NCT01489319|No Intervention|Nl Wt Controls - Increased Abdominal Adiposity|10 normal weight ovulatory women serving as controls who have increased abdominal adiposity established by DEXA
88898311|NCT01489319|No Intervention|Obese Controls|10 obese ovulatory women serving as controls
88898312|NCT01489345|Experimental|Arm 1: Experimental|
88898313|NCT01489345|Placebo Comparator|Arm 2: Placebo Comparator|
88898314|NCT01489371|Experimental|Treatment (EGEN-001, pegylated liposomal doxorubicin)|Patients receive pegylated liposomal doxorubicin hydrochloride IV over 60 minutes on day 1 and EGEN-001 IP over 30-60 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88898315|NCT01489384||3 months: Discontinue vs continue DMARDS|At 3 months those patients who achieved a change in DAS28 of 1.2 or greater will be randomized to discontinue versus continue DMARDs and will be followed for an additional 15 months
88898316|NCT01489384||6 months: discontinue vs continue DMARDs|(Protocol amendment 4.0)At 6 months, those patients still on Cimzia and DMARD therapy who were not randomized at month 3 AND achieve a change in DAS28> 1.2 will be randomized to discontinue versus continue DMARDs and will be followed for an additional 12 months.
88898317|NCT01489384||6 months: D/C vs Cont'd DMARDs if change in DAS28|(Protocol amendment 4.0)At 6 months, if the change in DAS28 is at least 0.6 and there is a decision to continue Cimzia, then the patients will be randomized to discontinue versus continue DMARDs with Cimzia and will be followed for an additional 12 months.
88898318|NCT01489384||3 or 6 months: stop CIMZIA and treat as per SOC|(Protocol amendment 4.0)If a change in DAS28 of <0.6 occurs at 6 months (at 3 months for protocol amendment 6.1)in patients not randomized at month 3 then the patient will stop Cimzia and treatment will be standard of care. However, patient will still be followed until the end of study.
88898319|NCT01489397|Experimental|Gastric intestinal metaplasia|
88898320|NCT01489397|Placebo Comparator|Normal|
88898321|NCT01489410|Active Comparator|Drug-Eluting Beads with Doxorubicin|Drug-Eluting Beads (DEB) with Doxorubicin is administered via beads that release it to the liver through a groin puncture site and delivered via catheter through the vessels that feed the liver.
88898322|NCT01489410|Active Comparator|Lipiodol Ethanol Mixture (LEM)|Lipiodol Ethanol Mixture (LEM) is administered to the liver through a groin puncture site and delivered via catheter through the vessels that feed the liver.
88898323|NCT01489436|Active Comparator|Single port cholecystectomy|In brief, a flexible, multi-sleeve 15-mm trocar designed specifically for single-port cholecystectomy will be inserted at the umbilicus via a 15-mm single incision. An additional 2-mm grasping device may be introduced in the right upper quadrant for retraction if necessary; this device is placed percutaneously without the need for a trocar. A 5-mm laparoscopic clip applier will be introduced through the periumbilical trocar to ligate the cystic artery and the cystic duct. The gallbladder will be removed through the umbilical port, adequate hemostasis is ensured, the umbilical trocar removed, and the single operative site will be closed and sterile dressings applied (four Band-Aids).
88898324|NCT01489436|Active Comparator|Four-port laparoscopic cholecystectomy|The control procedure for the research practicum is a four-trocar laparoscopic cholecystectomy, the current gold-standard operation. This approach utilizes a 10-mm trocar placed at the umbilicus via a 15-mm incision and three separate subcostal 5-mm trocars placed via separate 5-mm incisions. The gallbladder will be removed through the umbilical trocar site. On occasion, this incision needs to be enlarged to accommodate removal of the gallbladder. Trocar sites will be closed and sterile dressings applied (four Band-Aids).
88898325|NCT01489462|Experimental|High Intensity Strength Training|The strength-training intervention will consist of 5-min warm-up, 40-min training, and 15-min cool-down. The 60-min sessions will be conducted 3 times/wk for 18 months. Every 2 weeks the load lifted will be adjusted so that the participants in this group are lifting 3 sets of each exercise at 75-90% of 1RM.
88898326|NCT01489462|Experimental|Low Intensity Strength Training|The strength-training intervention will consist of 5-min warm-up, 40-min training, and 15-min cool-down. The 60-min sessions will be conducted 3 times/wk for 18 months. Every 2 weeks the load lifted will be adjusted so that the participants are lifting 3 sets of 15 repetitions at 30-40% of 1RM.
88898327|NCT01489462|Active Comparator|Attention Control|Participants in the control group will attend 60-min organized workshops 2 times/month for the first 6 months and then 1 time/month for months 7-18. Over the 18 months interactive presentations will cover such topics as foot care, nutrition, managing medication, and sleep practices, and experts will give wide-ranging lectures.
88898328|NCT01489488|Experimental|Arm 1|
88898329|NCT01489488|Experimental|Arm 2|
88898330|NCT01489488|Experimental|Arm 3|
88898331|NCT01489488|Experimental|Arm 4|
88898332|NCT01489488|Experimental|Arm 5|
88898333|NCT01489501|Experimental|only one arm available|Caomecs transplantation on eye cornea.
88898334|NCT01489514||Peanut allergic subjects|
88898335|NCT01489540|Active Comparator|new diagnostic strategy|Combination of laser Doppler imaging and clinical assessment of burn depth
88898336|NCT01489540|No Intervention|current diagnostic strategy|Clinical assessment of burn depth
88898337|NCT01489566|Active Comparator|Tyroserleutide for injection|the Tyroserleutide for injection at the dosage of 6mg/d
88898338|NCT01489566|Placebo Comparator|the placebo|
88898339|NCT01489592|Experimental|curcumin|oral administration of 6g of curcumin
88898340|NCT01489592|Placebo Comparator|placebo|oral administration of 12 sugar pill
88898341|NCT01489605|Experimental|GlideScope Groove|Patients will be intubated using the GlideScope Groove device. (Verathon)
88898342|NCT01489605|Active Comparator|Control: Standard GlideScope|Control: Patients will be intubated using standard practice, a standard GlideScope (Verathon)
88898343|NCT01489618|Active Comparator|PPS|Group 1: patients will a single administration of the PPS (one dose at W4). 25 patients will be randomised in this group.
88898344|NCT01489618|Experimental|PnCJ PPS|Group 2: patients will receive a first boost with the PnCj (one dose at W0) and then one administration of the PPS vaccines (one dose at W4). 47 patients will be randomised in this group.
89006647|NCT00243321|Experimental|HDR brachytherapy -> IMRT|Radiotherapy
89419420|NCT04964752|Other|the upper arm group on Day 15±1 day|The upper arm group to perform Visit 3 venous blood glucose measurement on Day 15±1 day.
89419421|NCT04964752|Other|the upper arm group on Day 29±1 day|The upper arm group to perform Visit 3 venous blood glucose measurement on Day 29±1 day.
89419422|NCT04964752|Other|the abdomen group on Day 2|The abdomen group to perform Visit 3 venous blood glucose measurement on Day 2.
89419423|NCT04964752|Other|the abdomen group on Day 15±1|The abdomen group to perform Visit 3 venous blood glucose measurement on Day 15±1.
89419424|NCT04964752|Other|the abdomen group on Day 29±1|The abdomen group to perform Visit 3 venous blood glucose measurement on Day 29±1.
89419425|NCT02205684|Experimental|Physical activity|Aerobic High Intensity Training (HIT)
89419426|NCT02205684|Active Comparator|Computer game skills training|Playing Nintendo Wii Sports
89419427|NCT03563781|Other|SENTINEL NODE|Patients with ovarian cancer will receive sentinel node identification and they will be then submitted to complete pelvic and para-aortic lymphadenectomy (as per the present guidelines)
88898345|NCT01489631|Active Comparator|epidural analgesia|The first group will be treated with epidural analgesia. Before surgery the epidural catheter will be placed according to local guidelines. After the operation epidural infiltration with bupivacaine and sufentanil will be commenced.
89419428|NCT03062332||Bipolar disorder,mania|The group includes subjects who are diagnosed to mania episode of bipolar disorder.
89419429|NCT03062332||Bipolar disorder,depressive|The group includes subjects who are diagnosed to depression episode of bipolar disorder.
89419430|NCT03062332||Bipolar disorder,mixed|The group includes subjects who are diagnosed to mixed episode of bipolar disorder.
89419431|NCT03062332||First episode major depression|The group includes subjects who are diagnosed to first episode of major depression.
89419432|NCT03062332||major depression，recurrent|The group includes subjects who are diagnosed to recurrent episode of major depression.
88898346|NCT01489631|Active Comparator|local infiltration|The second group will receive local infiltration with ropivacaine of the knee during surgery.
88898347|NCT01489631|Active Comparator|local infiltration and gabapentin|The third group will receive local infiltration with ropivacaine of the knee during surgery and will additionally be treated with gabapentin.
89419433|NCT03062332||Healthy control|The group includes subjects who are Healthy control.
89419434|NCT02925403|Active Comparator|Group 1|10μg R21/Matrix-M1 on days 0, 28, and 56.
89419435|NCT02925403|Active Comparator|Group 2|50μg R21/Matrix-M1 on days 0, 28, and 56.
89419436|NCT02925403|Placebo Comparator|Group 3|Saline injection on days 0, 28, and 56.
89419437|NCT02213640|Experimental|Arm A Anodal tDCS and prismatic adaptation|anodal tDCS over the primary motor cortex : stimulation intensity of 1mA during 20 minutes (5 consecutive sessions during one week).
89419438|NCT02213640|Placebo Comparator|Arm B: control|Prismatic adaptation with placebo stimulation
88898348|NCT01489644|Experimental|Treatment period 1|
88898349|NCT01489644|Experimental|Treatment period 2|
88898350|NCT01489644|Experimental|Treatment period 3|
89419439|NCT04973176|Active Comparator|Endotracheal intubation with C-MAC D Blade Videolaryngoscopy and Standard Bougie|Patients randomised to standard bougie will be intubated using standard bougie (Frova® airway intubation catheter )
89419440|NCT04973176|Active Comparator|Endotracheal intubation with C-MAC D Blade Videolaryngoscopy and Flexi-tip Bougie|Patients randomised to Flexi-tio bougie will be intubated using Flexi-tip bougie (P3 medical Ltd, Bristol, UK)
89419441|NCT04108741|Experimental|treadmill training with augmented reality dual tasking|
89419442|NCT04108741|Experimental|treadmill training with random number generation dual tasking|
89419443|NCT04108741|Active Comparator|treadmill training|
89419444|NCT02205918||Sham TMS|"Participants in this group will receive one, 30 minute session of inactive (sham) TMS."
89419445|NCT02205918||Active TMS|Participants in this group will receive one, 30 minute session of 1hz TMS.
89419446|NCT03059836|Experimental|n3 PUFA|Intervention: n3 PUFA (3000mg of Eicosapentaenoic acid per day and 1800mg of Docosahexaenoic acid per day)
88898351|NCT01489644|Active Comparator|Treatment period 4|
88898352|NCT01489683|Experimental|control|3 ml of normal saline was instilled to larynx and trachea
89419447|NCT03059836|Placebo Comparator|Placebo|Intervention: Organic Sunflower Oil 5000mg per day
88898353|NCT01489683|Active Comparator|lidocaine|3 ml of 4% lidocaine was instilled to larynx and trachea before endotracheal intubation
88898354|NCT01489696|Experimental|Treatment Arm 1|tamsulosin singles doses; mirabegron multiple dose
89419448|NCT03679819||HR-TRUS|HR-TRUS for the detection of prostate cancer in men scheduled for radical prostatectomy for localized prostate cancer
89419449|NCT02216370||Cryptogenic Stroke or TIA|
89419450|NCT02216370||Healthy Volunteers|Healthy Volunteers as comparative group adjusted to investigated group by age and gender
89419451|NCT02626780|Experimental|SVF Injection|Liposuction of a small amount of adipose tissue will be taken from each subject. Stromal Vascular Fraction (SVF) will be disassociated within the GID SVF-2 from the autologous adipose tissue to be injected into a small (approximately 2x2cm) area of the scalp in men or women with androgenic alopecia.
89419452|NCT03683407||Chemotherapy Group|All participants are advanced NSCLC without druggable gene mutation (EGFR, ALK, ROS-1, Met, Ret. BRAF, etc), who would receive platinum-based chemotherapy.
89419453|NCT02221206|Active Comparator|Treatment|mini-screw implant anchorage-assisted retraction of maxillary incisors
89419454|NCT02221206|No Intervention|Control|regular maximum anchorage
89419455|NCT03683329|Experimental|Antibiotic de-escalation|"According to the results of the antibiogram of the suspected causative bacteria, the ''pivotal'' antibiotic (antipseudomonal betalactam) used for empirical treatment is switched to an antibiotic with a spectrum as narrow as possible according to the targeted pathogens,~Stop the companion antibiotic (aminoglycoside, fluoroquinolone, macrolide) between day 2 and day 3 of antibiotic treatment as much as possible,~Stop the empirical antibiotic directed against methicillin-resistant staphylococcus aureus (MRSA) or an enterococcus in the absence of these bacteria in the culture."
89419456|NCT03683329|Active Comparator|Standard treatment without de-escalation|"The companion antibiotic is stopped between day 3 and day 5 of antibiotic treatment as much as possible and according to the local prescription,~Empirical antibiotics directed against MRSA or enterococcus were used according to local prescription and/or international guidelines,~The pivotal antibiotic of the empirical treatment is continued for the entire duration of the treatment, independently of microbiological results. For prolonged treatment, the physician has the choice of de-escalating after 8-15 days of treatment."
89419457|NCT02221362||Observational|No interventions
89419458|NCT05262192|Experimental|study group|Nutrition education will be given to the experimental group.
89419459|NCT05262192|No Intervention|control group|No intervention will be applied to the control group.
89419460|NCT04981054||cystocele with repairment|women with ≥ stage II cystocele who visited the urogynecological department of a medical center for cystocele repair
89419461|NCT04972864|Active Comparator|Exercise training group|Individuals in the treatment group were given respiratory exercises (diaphragmatic breathing, thoracic expansion, exercises to increase chest compliance with respiratory control with exercise band and leg strengthening exercises) and inspiratory muscle training with the Threshold IMT (T-IMT) device. Inspiratory muscle training was applied for 30 minutes, 3 times a day, 7 days a week for 6 weeks.
89419462|NCT04972864|Placebo Comparator|Control training group|Breathing exercises (diaphragmatic breathing, thoracic expansion, exercises to increase chest compliance with respiratory control with exercise band and leg strengthening exercises) were taught in the control group and only the exercise link containing these exercises was sent.
89419463|NCT03677557|Other|Cutaquig Intervention|Participants with primary or secondary immunodeficiency disease who are currently on subcutaneous immunoglobulin treatment but have developed adverse events including allergic reaction and are willing to change the treatment product to 16.5% Cutaquig.
89419464|NCT01363401|Experimental|Test group|Treatment group with HYNR-CS inj.
89419465|NCT01363401|Experimental|Control group|No treatment with HYNR-CS inj.
88898355|NCT01489696|Experimental|Treatment Arm 2|mirabegron single doses; tamsulosin multiple dose
88898356|NCT01489709||Vesicare group|Who receive vesicare
88898357|NCT01489722|Experimental|AZD1208|Single ascending dose escalation of 3 - 6 patient cohorts until maximum tolerated dose (MTD) is established. Up to 12 patients may be included at any dose not determined to be intolerable. Safety expansion using MTD in up to 44 Acute myelogenous leukemia (AML) patients.
88898358|NCT01489735||1|
88898359|NCT01489761|Active Comparator|zotarolimus-eluting stent|Resolute Integrity or Resolute Onyx stent
88898360|NCT01489761|Experimental|everolimus-eluting stent|Xience Prime or Xience Xpedition or Xience Alpine stent
88898361|NCT01489774|Placebo Comparator|Placebo|
88898362|NCT01489774|Experimental|CJ-12406|CJ-12406 Tablet, daily for 1 day or bid for 10 days
88898363|NCT01489787|Experimental|Phase I : HIFU|
88898364|NCT01489787|Experimental|Phase IIa : HIFU|
88898365|NCT01489787|Experimental|Phase IIb : HIFU|
89419466|NCT03673020|Experimental|ASV® AGEN2017|ASV® AGEN2017 + QS-21 Stimulon® Adjuvant Vaccine
88898366|NCT01489800|Experimental|Early Feeding|Introduction of clear liquid diet 24 hours after extubation with advancement to regular diet 24 hours thereafter if there is no significant nausea or vomiting.
88898367|NCT01489800|No Intervention|Control Feeding|Standard of care with introduction of clear liquid diet at time of return of bowel function as determined by flatus. Advancement to full diet 24 later if clear diet well tolerated.
88898368|NCT01489839||Periodontal diseased|Subjects with periodontal disease will be enrolled. Subjects with mild disease will have at least 4 teeth with at least 1 site with pocketing of 5 mm or more and concomitant attachment greater than or equal to 2 mm, and radiographic evidence of mesial or distal alveolar bone loss around at least 2 of the affected teeth. Subjects with severe disease will have at least 8 teeth with a site having >5mm pocketing and loss of 3 mm attachment with evidence of alveolar bone loss in 2 teeth.
88898369|NCT01489839||Periodontally healthy|Periodontally healthy subjects have no teeth with pocketing of 4 mm or greater and attachment loss, with the exception of the distal of the second molars where a pocket of 4 mm and concomitant attachment of up to 2 mm will be acceptable. Healthy subjects can have up to 3 sites with gingival recession and no radiographic evidence of alveolar bone loss.
88898370|NCT01489852|Active Comparator|Estrogen pre-treatment|
88898371|NCT01489852|No Intervention|Control|The control group did not receive any pre-treatment.
88898372|NCT01489865|Experimental|ABT-888 and mFOLFOX-6|ABT-888 orally at escalating does in Phase I and then at recommended phase II dose with standard mFOLFOX-6
88898373|NCT01489878||β-lactams|amoxicillin-clavulanate or penicillins M
88898374|NCT01489878||macrolides|
88898375|NCT01489878||fluoroquinolones|
88898376|NCT01489878||synergistins|
88898377|NCT01489904|Experimental|Botulinum Toxin|Botulinum Toxin type-A
88898378|NCT01489904|No Intervention|Control Treatment|No intervention
88898379|NCT01489917|No Intervention|Compression without adjustment|TR band (Terumo medical) applied. The TR band is then deflated gradually till pulsatile bleeding is observed under the transparent plastic inflatable chamber and then 1-2 cc of air is placed back in the TR band chamber to stop bleeding. The band is left in place for 2 hours and not adjusted further unless patient complained of symptoms or bleeding occurred.
88898380|NCT01489917|Experimental|Patent hemostasis & heparin|TR-band is placed and positioned similarly to the other study arm. However, in theses cases, patency is evaluated at the time of application of the TR-band, and monitored every 15 minutes afterwards till the band is removed and hemostasis completed. After TR-band placement, if maintenance of radial artery patency is obtained, no heparin is administered and TR band is left in place for 1-hour. If radial artery patency is not maintained, a bolus of heparin 50 U/kg or a maximum of 5000 units is administered and the band is left in place for 2 hours.
88898381|NCT01489930|Experimental|Endurance Exercise|Participants will perform 8-weeks of moderate intensity endurance (cycling) exercise
88898382|NCT01489930|Experimental|Resistance Exercise|Participants will perform 8-weeks of whole-body resistance exercise training.
89006648|NCT04620148|Experimental|TAK-242|Patients will be administered TAK-242 as a continuous IV infusion with standard care starting with a loading dose of 0.9 mg/kg administered over 30 minutes, followed by a continuous, constant rate infusion of 1.8 mg/kg/day for 7 days
89006649|NCT04620148|Placebo Comparator|Placebo|Patients will be administered placebo as a continuous IV infusion with standard care starting with a loading dose of 0.9 mg/kg administered over 30 minutes, followed by a continuous, constant rate infusion of 1.8 mg/kg/day for 7 days
89419467|NCT04980508|Active Comparator|Patients that had COVID-19 and were treated as outpatients|Patients underwent diagnostic evaluation including IIEF-5 form, penile color Doppler ultrasonography, corpus cavernosum electromyography, and fasting serum levels of testosterone, luteinizing hormone, follicle stimulating hormone, and prolactin measured in the morning (07-11 am). The relaxation degrees of cavernosal smooth muscles were calculated from the corpus cavernosum electromyography results.
89419468|NCT04980508|Active Comparator|Patients who were hospitalized due to COVID-19|Patients underwent diagnostic evaluation including IIEF-5 form, penile color Doppler ultrasonography, corpus cavernosum electromyography, and fasting serum levels of testosterone, luteinizing hormone, follicle stimulating hormone, and prolactin measured in the morning (07-11 am). The relaxation degrees of cavernosal smooth muscles were calculated from the corpus cavernosum electromyography results.
89419469|NCT04980508|Active Comparator|Patients who did not have COVID-19|Patients underwent diagnostic evaluation including IIEF-5 form, penile color Doppler ultrasonography, corpus cavernosum electromyography, and fasting serum levels of testosterone, luteinizing hormone, follicle stimulating hormone, and prolactin measured in the morning (07-11 am). The relaxation degrees of cavernosal smooth muscles were calculated from the corpus cavernosum electromyography results.
89419470|NCT03679663|No Intervention|Palpation|Anesthesia performed without ultrasound
89006650|NCT04619641|Active Comparator|High flow nasal cannula (HFNC)|HFNC will be applied by means of a dedicated device (AIRVO2, Fisher & Paykel Healthcare, Auckland, New Zealand). Gas flow will be set at 50 L/min, and humidification chamber will be set at 31°C.
89006651|NCT04619641|Active Comparator|Continuous Positive Airway Pressure (CPAP)|"CPAP will be delivered through a helmet (Castar Next, Intersurgical S.p.A., Mirandola, Italy), with an adjustable Positive End-Expiratory Pressure (PEEP) valve (2.5-20 cmH2O) set at 10 cmH2O (Intersurgical S.p.A., Mirandola, Italy). The helmet will be connected to a turbine-driven ventilator (Monnal T60, Air Liquide Medical Systems, Antony, France) set to deliver oxygen-air admixture at a continuous flow rate of 60 L/min, in order to improve CO2 wash out. No heated humidification will be applied to avoid the fog effect in the helmet."
89006652|NCT04619641|Active Comparator|HFNC+CPAP|"HFNC+CPAP consists in the contemporaneous application of HFNC and CPAP through helmet. HFNC will be set at 30 L/min, with a temperature at 31° C and 100% of relative humidity, while CPAP will be delivered through a helmet (Castar Next, Intersurgical S.p.A., Mirandola, Italy), with an adjustable Positive End-Expiratory Pressure (PEEP) valve (2.5-20 cmH2O) set at 10 cmH2O (Intersurgical S.p.A., Mirandola, Italy). The helmet will be connected to a turbine-driven ventilator (Monnal T60, Air Liquide Medical Systems, Antony, France) set to deliver oxygen-air admixture at a continuous flow rate of 60 L/min, in order to improve CO2 wash out. No heated humidification will be applied to avoid the fog effect in the helmet"
89006653|NCT04619758|Experimental|Emollient Group|Mothers of the neonates in group A will be advised massage with sunflower oil.
89006654|NCT04619758|No Intervention|Non-Emollient Group|Mothers of the neonates in group B will be advised massage without any emollient.
89006655|NCT04619914|Experimental|Group A (clomiphene citrate & estradiol group)|included 35 anovulatory PCO patients who received clomiphene citrate (Clomid; Aventis pharma S.AE, Global Napi pharmaceuticals, Cairo, Egypt) 100 mg daily from cycle day 3 to 7 with estradiol valerate 4-mg (two white tablets of cyclopregynova) from cycle day 8 to 14
89006656|NCT04619914|Experimental|Group B (Letrozole group)|included 35 anovulatory PCO patients who received letrozole (Femara; Novartis pharma AG, Basle, Switzerland) 5 mg daily from cycle day 3 to day 7.
89006657|NCT00220766|Experimental|Group 1|Infusion #1 (Week 0)Dextrose (0.14 mL/kg/min), then IGIV-C, 10% (0.08 mL/kg/min) ; Infusion #2 (Week 3-4)Dextrose (0.08 mL/kg/min), then IGIV-C, 10% (0.14 mL/kg/min)
89419471|NCT03679663|Experimental|Ultrasound|Anesthesia performed after ultrasound
89419472|NCT02218476|Other|APS Patient|
89006658|NCT00220766|Experimental|Group 2|Infusion #1 (Week 0)Dextrose (0.08 mL/kg/min), then IGIV-C, 10% (0.14 mL/kg/min); Infusion #2 Dextrose (0.14 mL/kg/min), then IGIV-C, 10% (0.08 mL/kg/min)
89006659|NCT04619875|Other|Lactulose|
89006660|NCT04619875|Other|KB5|
89006661|NCT04619875|Other|SG1|
89006662|NCT04619290|Experimental|Methylene blue treated group|Patients will be included in this group with the following symptoms: with at least one of the following symptoms: headache, nausea, dyspnea, myalgia, vomiting. Also that they meet the inclusion criteria
89006663|NCT04619290|Active Comparator|Conventionally treated group|Patients will be included in this group with the following symptoms: with at least one of the following symptoms: headache, nausea, dyspnea, myalgia, vomiting. Also that they meet the inclusion criteria
89006664|NCT04619563|Experimental|Anlotinib hydrochloride plus Docetaxel|Paticipants receive 4 to 6 cycles (21 days per cycle) combined administration period of Anlotinib Hydrochloride and Docetaxel, and then Anlotinib Hydrochloride maintenance treatment.
89006665|NCT04619329|Experimental|GSMs-TACE+ Surgical Resection Group|After TACE using Lobaplatin and GSMs (150-350μm, 350-560μm, 560-710μm or 710-1000μm), patients will receive surgical resection 15-30 days later, as specified per protocol.
89006666|NCT04619329|Active Comparator|Surgical Resection Group|Patients will receive surgical resection, as specified per protocol.
89006667|NCT00220844|Experimental|Nortriptyline|
89006668|NCT00220844|Experimental|Placebo|
89419473|NCT03679507|Active Comparator|Group A|The first patient group will receive Low Intensity Ultrasound Therapy on the affected knee joint, using the CPI-LIPUS Device
89419474|NCT03679507|Placebo Comparator|Group B|"Will be treated with an identical device whose ultrasound emitting capabilities has been nullified. This device appears to operate, including illumination of the operating light."
89419475|NCT03679507|Active Comparator|Group B1|The first patient group will receive high CBD oil applied topically to the affected knee joint.
89419476|NCT03679507|No Intervention|Group B2|This group of patients will not receive high CBD oil to the affected joint.
88898383|NCT01489930|Experimental|Control / Combined Training|Participants will perform 8-weeks of no exercise, followed by an additional 8-weeks of combined endurance plus resistance exercise training.
89419477|NCT04972708||Bipolar Disorder|100 patients after COVID-19 infection 100 patients without COVID-19 infection
89419478|NCT04972708||Healthy controls|100 controls after COVID-19 infection 100 controls without COVID-19 infection
89419479|NCT02221440|Placebo Comparator|air, second stage of labor|"Patients randomized to the group will receive sham administered by nasal catheter.~The therapy will continue until after delivery"
89419480|NCT02221440|Experimental|oxygen, second stage of labor|"Patients randomized to the group will receive oxygen administered by low flow nasal oxygen at a flow rate of 2 L/min.~The therapy will continue until after delivery"
89419481|NCT04963582|Experimental|Acupuncture Group|Bilateral LI4 acupuncture is administered before IUD insertion. Pain perception is evaluated by 10 points rated VAS after completion of the procedure.
89419482|NCT04963582|No Intervention|Control Group|IUD insertion is proceeded without any intervention. Pain perception is evaluated by 10 points rated VAS after completion of the procedure.
89419483|NCT02218632|Active Comparator|lactose-free diet|lactose-free diet (standard therapy) vs. lactose-free diet plus temporary oral galactose supplements
89419484|NCT02218632|Active Comparator|lactose free diet|lactose-free diet (standard therapy)
89419485|NCT02205996|Active Comparator|Controls|Weight-matched healthy controls. Euglycaemic Hypoglycaemic insulin clamp. Using hyperinsulinaemic clamps, blood glucose levels were stabilised over 1 hour to reach 5 mmol/L and maintained at that level for 1 hour, then gradually reduced over 1 hour to 2.8 mmol/L and maintained at that level for 1 hour. Blood samples were collected at times 0 (baseline), 2 hours (euglycaemia), 4 hours (hypoglycaemia) and at 24 hours after the clamp studies.
89419486|NCT02205996|Active Comparator|Type 2 diabetes|People with a known diagnosis of type 2 diabetes. Euglycaemic Hypoglycaemic Insulin clamp. Using hyperinsulinaemic clamps, blood glucose levels were stabilised over 1 hour to reach 5 mmol/L and maintained at that level for 1 hour, then gradually reduced over 1 hour to 2.8 mmol/L and maintained at that level for 1 hour. Blood samples were collected at times 0 (baseline), 2 hours (euglycaemia), 4 hours (hypoglycaemia) and at 24 hours after the clamp studies.
89419487|NCT04980586||Non-OSA Groups|Participants with apnea-hypopnea index < 5 events per hour of sleep.
89419488|NCT04980586||Mild OSA Group|Participants with apnea-hypopnea index > 5 < 15 events per hour of sleep.
88898384|NCT01489943|Experimental|All subjects receiving treatment|During the treatment subjects will receive Midazolam 3 mg on Day 1, Pioglitazone 15 mg on Day 2, Omeprazole 40 mg on Day 3, Rosuvastatin 10 mg on Day 4, GSK1605786 500 mg twice daily (BID) from Day 5 to 10, GSK1605786 500 mg BID + Midazolam 3 mg on Day 11, GSK1605786 500 mg BID + Pioglitazone 15 mg on Day 12, GSK1605786 500 mg BID + Omeprazole 40 mg on Day 12, GSK1605786 500 mg BID + Rosuvastatin 10 mg on Day 14 as single sequence.
88898385|NCT01489982|Experimental|Light therapy|For patients who have sleep maintenance insomnia light therapy will be administered daily. If patients suffer only from sleep onset insomnia, this light therapy will be given upon awakening in the morning. Light boxes will be provided by Litebook company. In the active therapy group, the intensity of the light will be set at 10,000 lux with a head-to-light distance of 20cm. Patients will be instructed to let the light shine indirectly on their eyes (i.e. they do not look directly at the light). Patients can be reading, eating, watching TV, etc., during the time of light therapy.
88898386|NCT01489982|Experimental|CBT and sleep hygiene training|This will involve education about sleep in general, giving techniques related to sleep and relaxation, tips on stress management, etc.. This will take place at the Lady Davis Institute of the Jewish General Hospital. There will be 6 weekly sessions totalling 90 minutes - most of the time this will be in a group setting, with a maximum of 6 patients per group. Light therapy will also be part of this treatment strategy. There will be separate gropus for English and French-speaking patients
88898387|NCT01489982|Experimental|Insomnia medications|Pharmacologic treatment will be individualized depending on patient characteristics and initial response. It will consist of two potential treatments - Doxepin or Zopiclone. Both of these agents are currently used commonly in the general population and also in PD patients. The agents will be prescribed exactly as any other medical prescription (i.e. patients will fill their own prescriptions at their own pharmacy).The decision for which agent to use will be as follows: a)If patients suffer from sleep onset insomnia (with or without sleep maintenance insomnia), or if doxepin is contraindicated, Zopiclone will be prescribedb) or b)If patients suffer from sleep maintenance insomnia only (or if Zopiclone is contraindicated), Doxepin will be the first choice agent.
88898388|NCT01489982|Placebo Comparator|Placebo intervention of light therapy|The inactive/placebo intervention will be 30 minutes of light therapy, using red light below the threshold required to entrain light cycles. This therefore functions as a placebo condition for the active light therapy protocol. Patients be informed that some forms of light therapy will be expected to be less active, but we will not disclose what type of condition is inactive.
88898389|NCT01489995|Experimental|Reference|Fasted
88898390|NCT01489995|Experimental|Glucose Drink|Fed
88898391|NCT01489995|Experimental|Before High Fat Meal|Fed
88898392|NCT01489995|Experimental|Before Light Meal|Fed
88898393|NCT01489995|Experimental|After Light Meal|Fed
88898394|NCT01490008|Experimental|Veregen|Veregen® (sinecatechins) Ointment, 15%, local application of 250 mg corresponding to 0.5 cm strand of ointment, 3 times daily (total dose of 750 mg/d)
89419489|NCT04980586||Moderate OSA group|Participants with apnea-hypopnea index > 15 < 30 events per hour of sleep.
89419490|NCT04980586||Severe OSA Group|Participants with apnea-hypopnea index > 30 events per hour of sleep.
89419491|NCT03059914|Experimental|InterOss|Maxillary sinus augmentation using ABBM Inteross ( Xenograft)
89419492|NCT03059914|Active Comparator|Bio-oss|Maxillary sinus augmentation using ABBM Bio-oss ( Xenograft)
89419493|NCT04972474|No Intervention|RADAR-MDD Questionnaire App as Usual|The RADAR-MDD questionnaire app as usual asks participants to complete 3x active tasks per week, with one reminder notification at 9am on a day that a questionnaire is due. The notification reads 'Questionnaire Time. Won't usually take longer than 3 minutes'. The participant is not able to view any data progress, aside from through the Fitbit app, which was present in the original RADAR-MDD study.
89419494|NCT04972474|Experimental|RADAR-MDD Adapted Questionnaire App|"The following components are also present:~Notifications: The notification will alternate between the phrases 'Questionnaire Time. Symptom tracking might increase self-awareness of your emotions (Bakker & Rickard, 2018)', 'Questionnaire Time. Symptom tracking is a technique often used in treatment to increase insight into your symptoms (Kramer et al., 2014)', and 'Questionnaire Time. Tracking your symptoms through a smartphone and Fitbit might help research to better understand health conditions'.~Progress visualisation: Participants will be able to view their questionnaire completion progress as a visualisation through the app, in the form of a graph.~Additional components: An additional text on the home screen of the active app will read 'You can contact your research team between 9am-5pm Mon-Fri if you have questions, onradar-engage@kcl.ac.uk'."
89419495|NCT02221518|Experimental|Patients with OCD|Behavioral: Exposure & Response Prevention (EX/RP)
89419496|NCT02206074|Active Comparator|T2DM|Crossover design where participants will start in the Beetroot juice condition, and after a washout period, move into the other condition.
89419497|NCT02206074|Placebo Comparator|Placebo|Crossover design where participants will start in the placebo condition, and after a washout period, move into the other condition.
89419498|NCT04972084|Experimental|Powerscope group|Class II patients which will receive treatment using Powerscope appliance
89419499|NCT02219802|Active Comparator|Drug-eluting stent|Treatment of infarct related laesion with a drug-eluting stent
89419500|NCT02219802|Experimental|Drug-coated balloon|After treatment of the infarct related artery with a drug-coated ballon, an additional BMS is advised to be used in case of residual stenosis > 50% or coronary artery dissection type > B.
89419501|NCT04980664|Experimental|Integrated intervention strategies|
89419502|NCT04972006|Experimental|One week baseline|Participants randomized to baseline one will go through a one-week baseline period before beginning the treatment.
89419503|NCT04972006|Experimental|Two week baseline|Participants randomized to baseline two will go through a two-week baseline period before beginning the treatment.
89419504|NCT04972006|Experimental|Three week baseline|Participants randomized to baseline three will go through a three-week baseline period before beginning the treatment.
89419505|NCT02220036|Active Comparator|Magnesium Oxide|magnesium tablets, 250 milligram magnesium, 12 weeks, every day 1 tablet
89419506|NCT02220036|Placebo Comparator|Placebo|Placebo tablets, the same in color, odor and appearance with magnesium tablets, 12 weeks, one tablet every day
88898395|NCT01490008|Active Comparator|Tea|"Lipton® Green Limone, a green tea beverage; oral intake of 500 mL green tea, 3 times daily (total dose on 1500 mL/d)"
88898396|NCT01490021|Experimental|rTMS/Active TBS|A continuous Theta-Burst Stimulation (TBS) protocol will be applied over the left dorsolateral prefrontal cortex. Three stimuli at 50Hz, 80% of individual Motor Threshold will be repeated every 200ms for 40sec (Galea et al., 2010; Oberman and Pascual-Leone, 2009).
88898397|NCT01490021|Placebo Comparator|rTMS/Placebo TBS|rTMS/Placebo TBS
88898398|NCT01490034|Experimental|Energy dense beverage|Metabolic effects of consuming energy dense beverages before and after regular consumption
88898399|NCT01490034|Experimental|Energy dense solid food form|Metabolic effects of consuming energy dense solid foods before and after regular exposure.
88898400|NCT01490034|Experimental|Eenergy dilute beverages|Metabolic effects of consumption of energy dilute beverages on a regular basis.
88898401|NCT01490034|Experimental|Energy dilute solid food form|Metabolic effects of consuming energy dilute sold foods before and after regular exposure.
88898402|NCT01490047|Experimental|rhTNF-α 25 µg/m² + Caelyx 40 mg/m²|Cohort 2: rhTNF-α 25 µg/m² + Caelyx 40 mg/m²
88898403|NCT01490047|Experimental|rhTNF-α 50 µg/m² + Caelyx 40 mg/m²|Cohort 3: rhTNF-α 50 µg/m² + Caelyx 40 mg/m²
89419507|NCT02220114|Other|Vigabatrin: Vigabatrin new ST formulation then Sabril®|"Sabril®: sachet for oral solution 500 mg, 50 to 100mg/Kg/day, twice a day, 14 days.~Vigabatrin new ST formulation: Soluble tablets 100 or 500 mg, 50 to 100mg/Kg/day, twice a day, 12 weeks."
89419508|NCT04972240|Active Comparator|Customized PEEK abutment/ crown on a Ti base.|
89419509|NCT04972240|No Intervention|Prefabricated titanium abutment, supporting ceramometal separate crown.|
89419510|NCT02221596|Experimental|vitamin D + aerobic training|vitamin D capsules every weekday (10,000IU/day) and exercise
89419511|NCT02221596|Active Comparator|vitamin D + no aerobic training|vitamin D capsules every weekday (10,000IU/day) and no exercise
88898404|NCT01490047|Experimental|rhTNF-α 100 µg/m² + Caelyx 40 mg/m²|Cohort 4: rhTNF-α 100 µg/m² + Caelyx 40 mg/m²
88898405|NCT01490047|Experimental|rhTNF-α 150 µg/m² + Caelyx 40 mg/m²|Cohort 5: rhTNF-α 150 µg/m² + Caelyx 40 mg/m²
88898406|NCT01490047|Experimental|rhTNF-α 200 µg/m² + Caelyx 40 mg/m²|Cohort 6: rhTNF-α 200 µg/m² + Caelyx 40 mg/m²
88898407|NCT01490047|Experimental|rhTNF-α 250 µg/m² + Caelyx 40 mg/m²|Cohort 7: rhTNF-α 250 µg/m² + Caelyx 40 mg/m²
88898408|NCT01490047|Experimental|rhTNF-α 25 µg/m² + Caelyx 30 mg/m²|Cohort 1 rhTNF-α 25 µg/m² + Caelyx 30 mg/m²
88898409|NCT01490099|Experimental|Treatment period 1|
88898410|NCT01490099|Active Comparator|Treatment period 2|
88898411|NCT01490112||IAsp|
88898412|NCT01490164||scoliosis|young adults requiring surgical correction
88898413|NCT01490177|Experimental|One|
88898414|NCT01490203||Group 1: HCC resection/RFA|Patients who will undergo resection of at least two hepatic segments for HCC or radiofrequency ablation (RFA) for HCC and underwent gadoxetic acid (Gd-EOB-DTPA)-enhanced MRI
88898415|NCT01490203||Group 2: Potential liver donor|Potential liver donors with normal hepatic function and and underwent gadoxetic acid (Gd-EOB-DTPA)-enhanced MRI
88898416|NCT01490216|Other|lisdexamfetamine|open label
88898417|NCT01490229|Active Comparator|Ezetimibe|Patients assigned to ezetimibe will receive for 1 year ezetimibe (10 mg/day)
88898418|NCT01490229|Active Comparator|Nutraceuticals|Patients assigned to nutraceuticals will receive for 1 year 1 capsule/day containing red yeast rice 200 mg, policosanol 10 mg, and berberine 500 mg
88898419|NCT01490255|Active Comparator|Ranolazine|Patients will receive ranolazine (750 mg bid) for 15 days
88898420|NCT01490255|Active Comparator|Amlodipine|Patients will receive amlodipine (10 mg once daily) for 15 days
88898421|NCT01490268|Active Comparator|Sufentanil Group 1|Sufentanil Low Titration
88898422|NCT01490268|Active Comparator|Sufentanil Group 2|Sufentanil High Titration
88898423|NCT01490281|Experimental|water-based exercise intervention|
88898424|NCT01490281|Experimental|land-based exercise intervention|
88898425|NCT01490281|No Intervention|Control group|
88898426|NCT01490307|Experimental|FCU offered|
88898427|NCT01490307|No Intervention|No feedback or services offered|
88898428|NCT01490320|Placebo Comparator|Control|Parents in control group experienced a routine primary care visit.
88898429|NCT01490320|Experimental|Handout intervention|"Caregivers assigned to the hand-out group were instructed to read the AAP hand-out Pulling the Plug On TV Violence. This 2 page hand-out emphasizes the negative effect that television has on children's behavior and makes recommendations about limiting media. The RA did not supervise the reading of the handout."
88898430|NCT01490320|Experimental|Multimedia intervention|"Caregivers assigned to the multimedia group were instructed to watch Recommendation 3: Decrease Exposure to Violence from the Play Nicely program, a 5 minute video in English and Spanish that teaches caregivers about the negative impact of violent media and instructs parents about the importance of limiting media. The intervention was presented to the parents on a mobile laptop computer."
88898431|NCT01490333|Experimental|2500 IU Vitamin D3|
88898432|NCT01490333|Active Comparator|400 IU Vitamin D3|
88898433|NCT01490346||ART treated individuals|
88898434|NCT01490372||GDM offspring|Children born from gestational diabetes mellitus pregnancy
88898435|NCT01490372||No-GDM offspring|Children born from a normal pregnancy
88898436|NCT01490398|Experimental|Rosuvastatin|Rosuvastatin 10mg qd for 12 months.
88898437|NCT01490411|Placebo Comparator|Placebo|Placebo was given the same way as a subcutaneous (just under the skin) injection. Patients received at least 10 injections of Placebo or rBet v1-FV.
88898438|NCT01490411|Experimental|20 µg rBet v1-FV Immunotherapy|The drug tested in this study (rBet v1-FV) was given as a subcutaneous (just under the skin) injection. Patients received at least 10 injections of Placebo or rBet v1-FV, administered in increasing doses weekly for 10 weeks, up to one of the maximum concentrations.
88898439|NCT01490411|Experimental|80 µg rBet v1-FV Immunotherapy|The drug tested in this study (rBet v1-FV) was given as a subcutaneous (just under the skin) injection. Patients received at least 10 injections of Placebo or rBet v1-FV, administered in increasing doses weekly for 10 weeks, up to one of the maximum concentrations.
88898440|NCT01490411|Experimental|160 µg rBet v1-FV Immunotherapy|The drug tested in this study (rBet v1-FV) was given as a subcutaneous (just under the skin) injection. Patients received at least 10 injections of Placebo or rBet v1-FV, administered in increasing doses weekly for 10 weeks, up to one of the maximum concentrations.
88898441|NCT01490411|Experimental|320 µg rBet v1-FV Immunotherapy|The drug tested in this study (rBet v1-FV) was given as a subcutaneous (just under the skin) injection. Patients received at least 10 injections of Placebo or rBet v1-FV, administered in increasing doses weekly for 10 weeks, up to one of the maximum concentrations.
88898442|NCT01490424||sepsis|SIRS plus inflammation
88898443|NCT01490424||Control|normal person under medical examination
88898444|NCT01490437|Experimental|PemCis|Pemetrexed plus Cisplatin
88898445|NCT01490476|Experimental|RAD001|Patient with Neurofibromatosis Type 2 and Vestibular Schwannoma treated with RAD001.
88898446|NCT01490489|Other|Pregnent women with blood sample|
88898447|NCT01490515|Active Comparator|Morphology embryo evaluation|To compare non-invasive metabolomic profiling and the traditional method of morphology assessment for embryo selection in terms of implantation and pregnancy rates in a clinical IVF program.
88898448|NCT01490515|Experimental|non-invasive metabolomic profiling|To compare non-invasive metabolomic profiling and the traditional method of morphology assessment for embryo selection in terms of implantation and pregnancy rates in a clinical IVF program.
88898449|NCT01490541||Gastric intestinal metaplasia patient|
88898450|NCT01490554|Experimental|autologous fibroblast grafts|autologous fibroblast grafts
88898451|NCT01490567|Placebo Comparator|placebo|Subjects will be given with a dose of 5mg/day placebo. All drugs will be administered orally.
88898452|NCT01490567|Active Comparator|donepezil|Subjects will be given with a dose of 5 mg/day donepezil. All drugs will be administered orally.
88898453|NCT01490593||Patients with Eye Injuries|The database is being established to record the number and types of eye injuries occurring in Canada. Thus there is only one cohort group, individuals who have sustained an eye injury.
88898454|NCT01490606|Experimental|knee OA project|12 sessions of PT, 6 INDIVIDUAL AND 6 GROUP TREATMENTS
88898455|NCT01490606|No Intervention|conventional PT|
88898456|NCT01490619|Experimental|Healthy Thinking in Teens|Group-based, manualized program, based on cognitive behavioral therapy techniques.
88898457|NCT01490619|Active Comparator|Advanced Diabetes Education|Group-based, manualized program designed to provide diabetes education, focused on adolescent-specific topics.
88898458|NCT01490645||one group (all patients)|
88898459|NCT01490658|Experimental|Treatment period 1|
88898460|NCT01490658|Experimental|Treatment period 2|
88898461|NCT01490658|Active Comparator|Treatment period 3|
88898462|NCT01490671|Experimental|Group 1a (tenofovir gel)|Group 1a will include women with a gestational age range of 36 0/7 to 37 6/7 weeks; they will receive 1% tenofovir gel
88898463|NCT01490671|Placebo Comparator|Group 1b (placebo gel)|Group 1b will include women with a gestational age range of 36 0/7 to 37 6/7 weeks; they will receive placebo gel.
89419512|NCT02221596|Active Comparator|placebo + aerobic training|placebo capsule every weekday and exercise
88898464|NCT01490671|Experimental|Group 2a (tenofovir gel)|Group 2a will include women with a gestational age range of 28 0/7 to 32 6/7 weeks; they will receive 1% tenofovir gel.
88898465|NCT01490671|Placebo Comparator|Group 2b (placebo gel)|Group 2b will include women with a gestational age range of 28 0/7 to 32 6/7 weeks; they will receive placebo gel.
88898466|NCT01490671|Experimental|Group 3a (tenofovir gel)|Group 3a will include women with a gestational age range of 20 0/7 to 24 6/7 weeks; they will receive 1% tenofovir gel.
88898467|NCT01490671|Placebo Comparator|Group 3b (placebo gel)|Group 3b will include women with a gestational age range of 20 0/7 to 24 6/7 weeks; they will receive placebo gel.
88898468|NCT01490671|Experimental|Group 4a (tenofovir gel)|Group 4a will include women with a gestational age range of 12 0/7 to 16 6/7 weeks; they will receive 1% tenofovir gel.
88898469|NCT01490671|Placebo Comparator|Group 4b (placebo gel)|Group 4b will include women with a gestational age range of 12 0/7 to 16 6/7 weeks; they will receive placebo gel.
88898470|NCT01490736|Experimental|LTS/Vehicle|Within subject control study
88898471|NCT01490749|Experimental|XELOX/Radiation/Carboplatin/RAD001|Patients receive XELOX comprising oxaliplatin intravenously (IV) over 120 minutes on day 1 and capecitabine orally (PO) twice daily (BID) on days 1-14. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo radiotherapy (RT) 5 days a week for up to 6 weeks. Patients also receive carboplatin IV over 15 minutes to 24 hours once weekly for 5-6 weeks and RAD001 PO every other day (QOD) or once daily (QD) for 5-6 weeks during radiation therapy (RT). Patients with resectable disease undergo surgery.
88898472|NCT01490762|Active Comparator|Regular Human Insulin|Subcutaneous injection
88898473|NCT01490762|Experimental|TI and Regular Human Insulin|All subjects have 4 clamp procedures with 10, 30, 60,80 units of TI and 1 clamp with 15 IU Regular Human Insulin
88898474|NCT01490775|Experimental|eMedonline access|patients will be followed for 3 months with access to eMedonline
88898475|NCT01490775|Active Comparator|no access to eMedonline|patients will be followed for 3 months with no access to eMedonline
88898476|NCT01490827||Argus II Retinal Prosthesis|Patients implanted with an Argus II Retinal Prosthesis
88898477|NCT01490853||CML and interpheron alpha|Adult Ph+CML pts in CCgR after IFN alpha.
88898478|NCT01490879|Experimental|Nexagon® Low Dose|Twice weekly applications of Nexagon® low dose in addition to off-loading using a Removable Cast Walker
89419513|NCT02221596|No Intervention|placebo + no aerobic training|placebo capsule every weekday and no exercise
89419514|NCT04971616||Group 1: Patients with shoulder, neck and lower back discomfort|Patients with shoulder, neck and lower back discomfort.
89419515|NCT02224794||Fast-Track Group|includes subjects who complete the Fast-Track EVAR protocol
89419516|NCT02224794||Standard P-EVAR Group|includes subjects who do not complete the Fast-Track EVAR protocol, and their procedures are completed with bilateral percutaneous access
88898479|NCT01490879|Experimental|Nexagon® Medium Dose|Twice weekly applications of Nexagon® medium dose in addition to off-loading using a Removable Cast Walker
88898480|NCT01490879|Experimental|Nexagon® High Dose|Twice weekly applications of Nexagon® high dose in addition to off-loading using a Removable Cast Walker
88898481|NCT01490879|Placebo Comparator|Nexagon® vehicle|Twice weekly applications of Nexagon® vehicle in addition to off-loading using a Removable Cast Walker
88898482|NCT01490905|Active Comparator|Theramine active and ibuprofen placebo|2 capsules Theramine twice daily with one ibuprofen-like placebo once daily.
88898483|NCT01490905|Active Comparator|Theramine and Ibuprofen (Theraprofen)|Two capsules Theramine twice daily with Ibuprofen 400mg once daily.
88898484|NCT01490905|Active Comparator|Theramine placebo and Ibuprofen|Two Theramine-like placebo twice daily and one ibuprofen 400mg.
88898485|NCT01490944|Active Comparator|Iron and Folic Acid|
88898486|NCT01490944|Experimental|Iron, Folic acid and cyanocobalamin|
88898487|NCT01490983|Experimental|eMedonline access|patients will have access to eMedonline access for 3 months
88898488|NCT01490983|Other|no access to eMedonline|patients will be followed for 3 months with no access to eMedonline
88898489|NCT01490996|Active Comparator|Chemotherapy only|Patients receiving up to 12 cycles of therapy. Standard care pathway management.
88898490|NCT01490996|Experimental|Chemotherapy plus curcumin|Patients taking daily oral curcumin for up to 12 cycles of therapy. Standard care pathway management.
88898491|NCT01491048|Active Comparator|THA Physiotherapy|Physiotherapy care during the period of hospitalization after THA.
88898492|NCT01491048|Active Comparator|No physiotherapy after THA|No Physiotherapy care during the period of hospitalization after THA.
88898493|NCT01491061|Active Comparator|Ranolazine|Administration of two preprocedural doses of Ranolazine 12 hours apart (1,000 mg the night before PCI and 1,000 mg prior to PCI)
88898494|NCT01491061|Placebo Comparator|Placebo|Placebo
88898495|NCT01491074|Placebo Comparator|NaCl 0.9% 100 ml|
88898496|NCT01491074|Experimental|Tocilizumab 280 mg|Intravenous infusion, 280 mg Tocilizumab (14 ml) added to 86 ml of 0.9% NaCl
88898497|NCT01491087|Experimental|PENTAXIM® vaccine group|
88898498|NCT01490385|Active Comparator|LED Phototherapy|LED phototherapy will be delivered transdermally via an extra-oral device and in a split mouth manner (half of the dental arch).
89194210|NCT00729794|Experimental|Study Group|Patients with refractory, inhospital cardiac arrest, i.e., with asystole, pulseless electrical activity, or ventricular fibrillation/pulseless ventricular tachycardia not responsive to two attempts at defibrillation.
89419517|NCT02224794||Standard EVAR Group|includes subjects who do not complete the Fast-Track EVAR protocol, and their procedures are not completed with bilateral percutaneous access (i.e. converted to femoral cutdown or open surgical repair)
89419518|NCT02221752|Experimental|Folic acid|Mothers randomized to receive 2 capsules per day: one with placebo and one with 0.40 mg folic acid from enrollment to delivery.
89419519|NCT02221752|Experimental|Ferrous Sulfate + folic acid|Mothers randomized to receive 2 capsules per day: one with iron (300 mg ferrous sulfate [60 mg elemental iron]) and the other with 0.40 mg folic acid from enrollment to delivery.
88898499|NCT01490385|No Intervention|Control: conventional orthodontic tooth movement|
89194211|NCT00729794|Placebo Comparator|Control Group|Patients with refractory, inhospital cardiac arrest, i.e., with asystole, pulseless electrical activity, or ventricular fibrillation/pulseless ventricular tachycardia not responsive to two attempts at defibrillation.
89194212|NCT00871546|Experimental|Participants with MCL randomized to SCH 727965|
89194213|NCT00871546|Active Comparator|Participants with MCL randomized to bortezomib|
89194214|NCT00871546|Experimental|MCL treated w/SCH 727965 after progression on bortezomib|
89194215|NCT00871546|Experimental|Participants with B-CLL randomized to SCH 727965|
89194216|NCT00871546|Active Comparator|Participants with B-CLL randomized to alemtuzumab|
89194217|NCT00871546|Experimental|B-CLL treated w/ SCH 727965 after progression on alemtuzumab|
89194218|NCT00732186|Experimental|Group 1 and Group 2|
89194219|NCT04064996|Active Comparator|Group A|Routine rehabilitation program patient education
89194220|NCT04064996|Experimental|Group B|Routine rehabilitation program + foot exercise training
89194221|NCT00729872|Experimental|1|AG011: low dose
89194222|NCT00729872|Placebo Comparator|2|Placebo: low dose
89194223|NCT00729872|Experimental|3|AG011: mid dose
89194224|NCT00729872|Placebo Comparator|4|Placebo: mid dose
89194225|NCT00729872|Experimental|5|AG011: high dose
89194226|NCT00729872|Placebo Comparator|6|Placebo: high dose
89194227|NCT03902964||women treated for breast cancer in 2017 (cohort A)|all patients who completed breast cancer treatment between January 1 and May 31, 2017. Withdrawal of men, metastatic patients from the outset, patients with a history of breast cancer or any other location, selection of 20 patients with breast cancer in situ at random
89194228|NCT03902964||women treated for breast cancer in 2015 (cohorte B)|all patients who completed breast cancer treatment between January 1 and 31 May 2015. Withdrawal of men, metastatic patients from the outset, patients with a history of breast cancer or any other location, selection of 20 patients with breast cancer in situ at random
89194229|NCT04039828|Experimental|Stratum|"Stratum 1: From 3 months to <18 months= 175 Stratum 2: From 18 months to 59 months= 175~In total, 350 participants will be enrolled"
89194230|NCT00616018|Experimental|A|all subjects receive 4 g/day of acetaminophen for 10 consecutive days in this open-label study
89194231|NCT04064970||PASS Cohort|
89194232|NCT00740948|Experimental|1|Rituximab
89194233|NCT00740948|Placebo Comparator|2|Placebo
89194234|NCT00871702|Experimental|Donor lymphocyte infusion|CD34-TK75 transduced T lymphocytes from donors matched at a 5/6 or 6/6 antigen level at a dose of 1.0 x 105 cells/kg recipient weight.
89194235|NCT00732342|No Intervention|1|Standard Treatment
89194236|NCT00732342|Experimental|2|Standard Treatment with Contingency Management for 12 weeks with a 0.5 probability of winning prizes for each negative sample submitted
88898500|NCT01491100||Group 1|
88898501|NCT01491126||examinees undergoing bidirectional endoscopy|Study population will include sequential examinees undergoing bidirectional endoscopy, age> 18 years
89194237|NCT00732342|Experimental|3|Standard Treatment with Contingency Management for 24 weeks with a 0.34 probability of winning prizes for each negative sample submitted
89194238|NCT00732342|Experimental|4|Standard Treatment with Contingency Management for 24 weeks with a 0.5 probability of winning prizes for each negative sample submitted
89194239|NCT00876850|Experimental|PTK 0796|PTK 0796 100mg for injection; PTK 0796 tablet 150mg
89194240|NCT00876850|Active Comparator|Linezolid|For gram positive treatment: Linezolid 600 mg tablets and pre-mixed 600mg IV infusion solution; For gram negative treatment: Moxifloxacin 400 mg tablets and pre-mixed 400mg IV infusion solution
89194241|NCT00734916|Active Comparator|1|Omegaven 10%
89194242|NCT00734916|Active Comparator|2|Intralipid 10%
89194243|NCT00734916|Placebo Comparator|3|Placebo
89194244|NCT00872092||Breath test|Subjects with suspected SBBO
89194245|NCT00738816|Other|Intervention|Systematic medication review
89194246|NCT00877084|Experimental|1|Resistance training: series of 3x8 repetitions will be performed for the quadriceps muscle at 70% of the 1 Repetition Maximum determined as the weight the patient can lift once over the full range of motion. The weight can be applied using free weights or using a classical multi-gym device or a quadriceps chair.
89194247|NCT00877084|Placebo Comparator|2|Usual care according to clinical pathway for COPD exacerbations + NO training
89194248|NCT00735150||1|25 female and 5 male BRCA carriers
89194249|NCT05157412|Experimental|Steroids + Doxycycline|Systemic Prednisolone in decreasing doses (40 mg/d on days 1-7, 20 mg/d on days 8-14, and 10 mg/d on days 15-21) along with Doxycycline (200 mg as a loading dose on the 1st day, followed by 100 mg once daily one hour before meal as a maintenance dose) for 3 weeks.
89194250|NCT05157412|Active Comparator|Steroids Only|Systemic Prednisolone in decreasing doses (40 mg/d on days 1-7, 20 mg/d on days 8-14, and 10 mg/d on days 15-21) for 3 weeks.
89194251|NCT00732420|Experimental|Treatment Arm A|Daily oral pazopanib in combination with weekly oral topotecan. Initially rising dose to determine the maximum tolerated dose: finally an expanded cohort treated at the maximum tolerated dose.
89194252|NCT00732420|Experimental|Treatment Arm B|Daily oral pazopanib in combination with oral topotecan given for 5 consecutive days every 21 days. Initially rising dose to determine the maximum tolerated dose; finally an additional cohort of patients treated at the maximum tolerated dose.
88898502|NCT01491139|Experimental|single arm|"All patients will receive induction chemotherapy (cisplatin and 5-FU), followed by cisplatin chemotherapy and radiotherapy in addition to oral olaparib.~Induction chemotherapy (21 day cycle)~Drug: cisplatin 80mg/m2 (day 1)~Drug: 5-FU (fluorouracil) 1000mg/m2/day (day 1-4 continuous infusion)~olaparib plus chemoradiotherapy (8 weeks)~Drug: olaparib~Drug: Cisplatin~Radiation"
88898503|NCT01491152|Experimental|WBV Training|
88898504|NCT01491152|No Intervention|Control|No WBV Training. Standard of Care.
88898505|NCT01491165|Experimental|stem cell transplantation therapy|umbilical cord mesenchyma stem cell transplantation through interventional procedures do in liver cirrhosis patients.
88898506|NCT01491191|Experimental|PEA|Administration of PEA from 8 days before surgical operation until 30 days after surgery.
88898507|NCT01491191|Active Comparator|Sugar pill|Administration of placebo from 8 days before surgical operation until 30 days after surgery.
88898508|NCT01491204|Experimental|paclitaxel +HM30181|
88898509|NCT01491230||25 autologous/25 allogeneic patients|
88898510|NCT01491243|Active Comparator|Intensive treatment group|Patients will receive high concentration sodium bicarbonate (3 ml/kg/h for 1 hour, then 1 ml/kg/h for 7 h) followed by i.v. saline for 48 h after PCI in case of abnormal NGAL findings
88898511|NCT01491243|Active Comparator|Standard treament group|Patients will receive i.v. 1 ml/kg/h saline infusion for 48 h after PCI in case of abnormal NGAL findings
88898512|NCT01491256|Active Comparator|High dose Atorvastatin|Arm of pre-procedural high dose atorvastatin loading
88898513|NCT01491256|Placebo Comparator|Control|No pre-procedural high dose atorvastatin loading
88898514|NCT01491282||No treatment|
88898515|NCT01491295|Active Comparator|Lamivudine plus adefovir|Continue lamivudine/adefovir add on treatment (standard treatment)
88898516|NCT01491295|Experimental|Tenofovir|Switch from lamivudine/adefovir add on threatment to tenofovir monotherapy
88898517|NCT01491308|Active Comparator|Restrictive|Hemoglobin concentrations will be maintained in the range of 7.5 to 9.0 g per deciliter, with a transfusion given when the hemoglobin concentration is below 7.5 g per deciliter.
88898518|NCT01491308|Active Comparator|Liberal|Hemoglobin concentrations will be maintained in the range of 10.0 to 12.0 g per deciliter, with a transfusion given when the hemoglobin concentration is below 10.0 g per deciliter.
88898519|NCT01491321|Experimental|Bee Venom Acupuncture & Loxoprofen|
88898520|NCT01491321|Placebo Comparator|Sham Bee Venom Acupuncture & Loxoprofen|
88898521|NCT01491334||Asymptomatic|Asymptomatic women presenting at various ages without prolapse condition.
88898522|NCT01491334||Symptomatic|Symptomatic women presenting with prolapse conditions with no prior surgeries and women presenting with surgery scheduled with or without prior surgery.
88898523|NCT01491347||alcohol dependent|
88898524|NCT01491360|Experimental|LaserACE(R) procedure performed|The LaserACE(R) procedure (partial depth scleral micro-excisions with an Er:YAG laser in a specified pattern) will be performed.
88898525|NCT01491373|Experimental|rhBMP-2/ACS|
88898526|NCT01491373|Active Comparator|Autograft|
88898527|NCT01491412||Acute psychotic episode in schizophrenia|Subjects suffering from schizophrenia being discharged from the hospital following hospitalisation due to acute psychotic episode
88898528|NCT01491438|Experimental|PRGF and conventional treatment|PRGF once a week (day 1) and conventional treatment twice a week (days 1 and 4)
88898529|NCT01491438|Active Comparator|Conventional treatment alone|Conventional treatment (cleaning, debridement of the wound and application of the corresponding dressing and using of antibiotics if necessary) twice a week (days 1 and 4).
88898530|NCT01491477|Experimental|INFUSE™ Bone Graft|
88898531|NCT01491477|Active Comparator|Autogenous bone|
88898532|NCT01491503|Experimental|Montelukast and levocetirizine|
88898533|NCT01491503|Active Comparator|Montelukast|
88898534|NCT01491503|Active Comparator|Levocetirizine|
88898535|NCT01491555||DMD patients|35 boys ages 2 through 30 with DMD
88898536|NCT01491555||Control Group|35 healthy boys ages 2 through 30
88898537|NCT01491581|Experimental|micronutrient enriched bar|bar enriched with micronutrients
88898538|NCT01491581|Placebo Comparator|control arm|normal bar
88898539|NCT01491646||Pulmonary Hypertension|Previous diagnosis of PH by right heart catheterization
88898540|NCT01491646||Healthy Controls|Healthy controls without lung/heart conditions
88898541|NCT01491659|Active Comparator|Amoxicillin/clavulanate/Idoform Plus|
88898542|NCT01491659|Placebo Comparator|Amoxicillin/clavulanate/Placebo|
88898543|NCT01491685||Pregnant|
88898544|NCT01491685||Non- Pregnant|
88898545|NCT01491698|Experimental|pts undergoing Roux-en-Y pouch reconstruction (RYP)|This is a pilot randomized controlled trial comparing changes in health-related quality of life (HRQOL) in patients undergoing Roux-en-Y pouch reconstruction (RYP) with patients undergoing conventional Roux-en-Y reconstruction (RYC) following total gastrectomy for adenocarcinoma.
89006669|NCT04619407||teacher|"Employed in a school in Mecklenburg-Vorpommern~Age between 18 to 67 years~Willing and able to provide informed consent~Over 5 months: Monthly nasopharyngeal swabs for SARS-CoV-2 PCR, additionally blood samples for SARS-CoV-2 antibody testing will be taken at the beginning and at the end of the study"
88898546|NCT01491698|Active Comparator|pts undergoing conventional Roux-en-Y reconstruction (RYC)|This is a pilot randomized controlled trial comparing change in health-related quality of life (HRQOL) in patients undergoing Roux-en-Y pouch reconstruction (RYP) with patients undergoing conventional Roux-en-Y reconstruction (RYC) following total gastrectomy for adenocarcinoma.
88898547|NCT01491711|Active Comparator|Fractionated 5-ALA HCl 20% gel PDT|Twice on day 1
88898548|NCT01491711|Active Comparator|Methylaminolevulinate PDT in 2 sessions|On day 1 and 8
88898549|NCT01491724||pCLE images|
88898550|NCT01491750|Experimental|GUIDED IMAGERY|
88898551|NCT01491750|Placebo Comparator|AUDIO BOOK|
88898552|NCT01491867|Experimental|Travoprost arm|All individuals receive travoprost 0.003% 1/day in both eyes after 6 weeks wash-out for 3 months
89194253|NCT00877162|Experimental|1|Providing parents with a group teaching intervention (2 hours long). The teaching session is followed by 2 weeks of phone calls twice a week to offer parents support for their use of the strategies described in the teaching session and to clarify any questions about the teaching session content. The arm will have baseline data collected one week prior to the teaching session. Follow-up data will be collected at 6 and 24 weeks post intervention. A pamphlet on infant safety will be distributed to the intervention arm following the 6 week data collection point. A pamphlet on managing behavioural sleep problems will distributed to the control group following the 6 week data collection point.
89194254|NCT00877240|Other|Lifestyle counseling|
89194255|NCT00863590|Experimental|A|Panel A
89194256|NCT00863590|Experimental|B|Panel B
89194257|NCT00863590|Experimental|C|Panel C
89194258|NCT00863590|Experimental|D|Panel D
89194259|NCT00735228|Active Comparator|1|Perioperative blood glucose was controlled within the normal levels (80-110 mg/dL) by artificial pancreas.
89194260|NCT00735228|Active Comparator|2|Perioperative blood glucose concentration was controlled within the range from 140 to 160 mg/dL by artificial pancreas.
89194261|NCT00739128|Active Comparator|1|celiac patients who did not respond to initial hepatitis B vaccine series , will receive repeat hep B vaccine via intramuscular route
89194262|NCT00739128|Active Comparator|2|celiac patients who did not respond to initial hepatitis B vaccine series , will receive repeat hep B vaccine via intradermal route
89194263|NCT00863668|Active Comparator|Efavirenz|
89194264|NCT00863668|Experimental|Raltegravir|
89194265|NCT00739206|Experimental|Cohort 1|Adult patients with uncomplicated malaria
89194266|NCT00739206|Experimental|Cohort 2|Pediatric patients with uncomplicated malaria
89194267|NCT00739206|Experimental|Cohort 3|Pediatric patients with severe malaria
89194268|NCT00735540||A|Acute organic diseases
89194269|NCT00735540||B|Patients with chronic diseases
89194270|NCT00735540||C|Patients with psychiatric diagnosis
89194271|NCT00872248|Experimental|1|Parturients received spinal anesthesia
89194272|NCT00872248|Active Comparator|2|Parturients received epidural anesthesia
89194273|NCT00732576|Active Comparator|1|9 fish oil capsules, equivalent to 3 gram per day of n-3 polyunsaturated fatty acids (PUFA)
89194274|NCT00732576|Active Comparator|2|9 fish oil capsules, equivalent to 3 gram per day of n-3 polyunsaturated fatty acids (PUFA) including 1 capsule of menaquinone-7 per day (10 µg)
89194275|NCT00732576|Active Comparator|3|9 fish oil capsules, equivalent to 3 gram per day of n-3 polyunsaturated fatty acids (PUFA) including 2 capsules of menaquinone-7 per day (20 µg per day)
89194276|NCT00732576|Active Comparator|4|9 fish oil capsules, equivalent to 3 gram per day of n-3 polyunsaturated fatty acids (PUFA) including 1 capsule of menaquinone-7 per day (45 µg per day)
89194277|NCT00732576|Active Comparator|5|9 krill oil capsules, equivalent to 1,5 gram per day of n-3 polyunsaturated fatty acids (PUFA)
89194278|NCT00732576|Active Comparator|6|9 krill oil capsules, equivalent to 1,5 gram per day of n-3 polyunsaturated fatty acids (PUFA) including 1 capsule of menaquinone-7 per day (10 µg)
89194279|NCT00732576|Active Comparator|7|9 krill oil capsules, equivalent to 1,5 gram per day of n-3 polyunsaturated fatty acids (PUFA) including 2 capsules of menaquinone-7 per day (20 µg per day)
89194280|NCT00732576|Active Comparator|8|9 krill oil capsules, equivalent to 1,5 gram per day of n-3 polyunsaturated fatty acids (PUFA) including 1 capsule of menaquinone-7 per day (45 µg per day)
89194281|NCT00863902|Experimental|Cetirizine Hydrochloride|Cetirizine Hydrochloride 10 mg tablets, single dose
89194282|NCT00863902|Active Comparator|Zyrtec|Zyrtec® 10 mg tablets, single dose
89194283|NCT03903042||Group 1|Center 1: Traditional camera(Canon) vs Aurora camera
88898553|NCT01491880|Experimental|Child Anxiety Program by Telephone|The child anxiety program by telephone is an adaptation of Ron Rapee's Cool Kids Outreach Program (Lyneham and Rapee, 2006) for child anxiety, with appropriate adaptations made to meet the needs of rural Latino families (including a Spanish translation). This is a parent mediated program, where parents are taught how all the skills of cognitive behavior therapy (CBT) and how to apply these skills to these children's anxieties. Children are also expected to participate, however all direct contact that a therapist may have, is with the parent only.
89194284|NCT03903042||Group 2|Center 2: Traditional camera(Zeiss) vs Aurora camera
89194285|NCT03903042||Group 3|Center 3: Traditional camera(Topcon) vs Aurora camera
89194286|NCT00732732|Experimental|Green banana|Subjects receiving green banana powder.
89194287|NCT00732732|Placebo Comparator|Placebo|Microcrystalline cellulose given as placebo
89194288|NCT00732810|Experimental|Breast cancer randomized to SCH 727965|
89194289|NCT00732810|Active Comparator|Breast cancer randomized to capecitabine|
89194290|NCT00732810|Experimental|SCH 727965 in breast cancer after progression on capecitabine|
89194291|NCT00732810|Experimental|NSCLC randomized to SCH 727965|Note: Enrollment of participants with NSCLC was completed per protocol as of 26 JAN 2010
89194292|NCT00732810|Active Comparator|NSCLC randomized to erlotinib|Note: Enrollment of participants with NSCLC was completed per protocol as of 26 JAN 2010
89194293|NCT00732810|Experimental|SCH 727965 in NSCLC after progression on erlotinib|Note: Crossover to SCH 727965 after progression on erlotinib was completed per protocol as of 26 JAN 2010
89419520|NCT04971382|Experimental|curcumin combined with particulate xenograft.|"Curcumin will be used in combination with xenograft after ridge splitting surgery~Curcumin is widely used in medicine due to medicinal properties, cost-effectiveness, and simple extraction from a turmeric plant that grows in different regions in the world. Recent evidences have shown that curcumin possesses multiple biological activities and pharmacological properties including anti-inflammation , antioxidation , anticancer , antimicrobial , and free radical scavenger effects"
89419521|NCT04971382|Active Comparator|alveolar ridge splitting with use of particulate xenograft alone.|xenograft will be used alone after ridge splitting
89419522|NCT02220192|Experimental|Focal LEEP|All patients will undergo focal treatment of high-grade cervical intraepithelial neoplasia using LEEP. A two-week follow-up assessment will evaluate the side effects of the treatment and any unusual symptoms. This will be done through a phone survey. At six months a clinic visit is required to assess whether there are any precancerous cells of the patient's cervix.
89419523|NCT04728906|Experimental|Heart patch + cardiomyocytes - hAESC|Patients who undergo bypass (CABG) surgery are given heart patch in areas where grafting (bypass) is not feasible
89419524|NCT02220270||patient with PDA or ASD|
88898554|NCT01491880|Experimental|Child Anxiety Program- Self Help|Families randomized to the Self-Help CBT condition will receive program materials along with instructions for completing weekly assignments. Specifically, they will receive the same materials as families in the telephone-based condition however in the self-help group, parents and children are expected to read the materials for that week and complete the workbook activities without planned therapist involvement. Instead they will be given the option to initiate a telephone call to the therapist, if they have questions or need extra support.
89419525|NCT03061162|Experimental|Study Arm|Gastric cancer patients with peritoneal metastasis undergo pulsed low dose rate 3-dimensional conformal radiation therapy, QD, 5 days a week for 25 days. Treatment continues in the absence of disease progression or unacceptable toxicity.
88898555|NCT01491906|Experimental|Text-Messaging|The group that receives the behavioral counseling and text messaging lifestyle intervention
88898556|NCT01491906|No Intervention|Usual Care|This group will receive usual care
89419526|NCT02220348|Experimental|linaclotide|Linaclotide 72μg, 145 μg, or 290 μg capsules, once daily for 3 days, oral administration
89419527|NCT04151680||Intermittent anticoagulation|Patients receiving anticoagulation only if continuous electrocardiographic monitoring detects an atrial fibrillation episode
89419528|NCT04151680||Chronic anticoagulation|Patients receiving chronic oral anticoagulation regardless findings at continuous electrocardiographic monitoring
89419529|NCT02221830|Placebo Comparator|Placebo|Normal Saline (standard of care)
89419530|NCT02221830|Experimental|Treatment|normal saline + oxytocin
89419531|NCT02221908||Patients brought to Hahnemann Hospital ED|
89419532|NCT04151446|Experimental|Laser Scleral Microporation procedure|Patients suffering from presbyopia will receive bilateral Laser Scleral Microporation procedure.
89006670|NCT04619407||pupils|"Attending school in Mecklenburg-Vorpommern~Age between 6 to 17 years~Agreement to participate~Legal representative willing and able to provide informed consent~Over 5 months: Monthly nasopharyngeal swabs for SARS-CoV-2 PCR"
89419533|NCT02224950|Placebo Comparator|Control|"Non-medicated Emollient with no Clothing Covering Upper Limb - Baseline/Control Cells"
89419534|NCT02224950|Active Comparator|Sleeve 2|Non-medicated Emollient plus Lyocell/Chitosan Sleeve
89419535|NCT02224950|Placebo Comparator|Placebo Sleeve|Non-medicated Emollient plus Cotton Sleeve
89419536|NCT04970524|Experimental|control group(conventional free gingival graft)|Conventional free gingival grafts are applied to the areas of the patients determined by randomization as suggested by Sullivan and Atkins.
89419537|NCT04970524|Experimental|test group(Partially de-epithelialized free gingival graft)|Partial free gingival graft is applied to the areas of the patients determined by randomization. Unlike the control group, the epithelium on the graft was partially epithelialized.
89419538|NCT04970758||study group|Athletes /strength exercise
89419539|NCT04970758||control group|
89419540|NCT03039114|Experimental|Parsaclisib + Hexal and Gazyvaro|
89419541|NCT04970602|Experimental|MB group|This group will be given 2mg/kg methylene blue infusion within 20 minutes, 2 hours later followed by 0.5mg/kg/h for 4 hours.
89419542|NCT04970602|No Intervention|control group|This group will be given conventional vasopressors, except methylene blue, based on the attending doctor's decision.
89419543|NCT02221986|Experimental|Interdisciplinary rehabilitation|"The intervention consists of 6 weeks intensive outpatient physiotherapy in conjunction with 0-6 weeks of occupational therapy if need is indicated. The physical intervention contains supervised group exercise of 90 minutes three times a week in groups up to four patients included continuously.~The occupational therapy intervention consists of individual training 60 minutes twice a week for patients having deficits in activity or participation levels measured by the Assessment of Motor and Process Skills (AMPS)."
89419544|NCT02221986|No Intervention|Care as usual|The control group receives usual standard of care (e.g. no training, individual training or group training in the municipality). The amount of training in this group is based on a questionnaire at the follow-up trials.
89419545|NCT02225028|Active Comparator|Physical Activity Counseling|Participants who are randomized to the physical activity counseling intervention group will work with a physical activity coach over the course of 6 months to come up with a physical activity program that works for each individual. Participants will have 16 phone calls and discuss goals and values, track physical activity, troubleshoot barriers, and work on keeping exercise interesting and motivating. Participants will also learn strategies for managing stress and battling unhelpful thoughts that may get in the way of activity. By the end of the intervention, the goal is to be regularly doing 150 minutes of physical activity each week. The physical activity coach will work with participants to ensure that they are increasing activity safely in order to prevent injuries.
89419546|NCT02225028|No Intervention|Usual Care|Participants randomized to the usual care control group will receive a packet of exercise related-information at the end of the baseline assessment as well as a letter from study staff informing them of their randomization status and their test results. The letter will provide information on biological markers that are in the at-risk range, advice to seek medical advice regarding lifestyle changes such as diet and exercise and information on how to contact study staff regarding test results. We will offer to forward test results to their health care provider provided they furnish written release of information We will emphasize our interest in providing them with a follow-up assessment in 6 months.
89419547|NCT04963114|Experimental|Art therapy|art therapy in the form of a one-hour guided tour of art works followed by a two-hour guided creative painting workshop on specific themes such as beauty and wonder and colors and emotions
89419548|NCT04963348||convolutional neural network (CNN)|a classical deep convolutional neural network (CNN) called Inception-V3 was applied to the image sets and validated the classification performance of the trained models
89419549|NCT02831673|Experimental|DTG + 3TC (50 mg+300 mg)|Eligible participants will receive one 50 mg tablet of DTG plus one overencapsulated 300 mg 3TC tablet orally once daily upto 96 weeks; thereafter will receive DTG plus 3TC tablet upto Week 148 and will continue to receive this schedule until (i) DTG and 3TC are both locally approved for use as part of a dual regimen, and the single entities of DTG and 3TC are available to patients (e.g. through public health services), or (ii) the DTG/3TC FDC tablet, if required by local regulations, is available, , or (iii) the participant no longer derives clinical benefit, or (iv) the participant meets a protocol defined reason for discontinuation, or (v) development of the DTG plus 3TC dual regimen is terminated.
89419550|NCT02831673|Active Comparator|DTG + TDF/FTC FDC (50 mg+300/200 mg)|Eligible participants will receive one 50 mg tablet of DTG plus one overencapsulated TDF/ FTC FDC (300/200 mg) tablet orally once daily upto 96 weeks; thereafter will receive DTG plus TDF/FTC FDC tablets upto Week 148 (open-label randomised phase).
89419551|NCT04962802|Experimental|Manhood 2.0|Manhood 2.0 is a group-level intervention, delivered in 7 sessions over 13 hours, and is based on social cognitive theory, social norm theory, theory of gender and power, and the theory of reasoned action. Sessions were delivered twice a week, for approximately 3.5 weeks. For the final session, participants received one hour of content and were administered the immediate post-intervention survey. The intervention takes a holistic, gender-transformative approach, includes reproductive health knowledge, healthy relationships, altering gender norms and stereotypes which drive reproductive health behavior, and explicit and proactive support of female partner contraceptive use. Activities are designed to engage young men in critical reflection and dialogue about gender norms, and then apply these discussions to a range of key issues including intimate relationships, gender-based violence, substance abuse, STIs, and early pregnancy.
89419552|NCT04962802|Placebo Comparator|Post-High School Readiness|The Post-High School Readiness Program helped youth build skills around identifying colleges or programs of interest, completing applications for programs, writing resumes and increasing financial literacy. The post-high school readiness curriculum was delivered by LAYC staff members and the content was delivered twice a week, for approximately 3.5 weeks (as with the intervention). For the final session, participants did not receive content and were administered the immediate post-intervention survey.
89419553|NCT02220504|Experimental|Intervention group|Antipsychotic treatment discontinuation (DT)
89419554|NCT02220504|Active Comparator|Control group|Maintenance antipsychotic treatment (MT)
89419555|NCT04962958|Experimental|HAIC+Donafenib|Donafenib combined with Hepatic arterial infusion chemotherapy with Folfox Protocol
88898557|NCT01491997|Active Comparator|Mind Body Medicine Course 1|The subject of each course is Mind/Body medicine. One course is learning about the mind and the body through experiences. The other is learning about the mind and the body through experiences. Both courses will follow the same format, meeting once every week, for a total of 8 weeks, for roughly 2 hours per class. You will be provided with a schedule of the weekly classes, which will occur on the same day every week, at the same time. Weekly sessions will be run by a teacher and will include other participants in the class. . You will also be given homework assignments that are intended to reinforce what you learn in the program. The assignments will require up to 45 minutes, 6 days/week. Following the 6th class, and before the 7th class, there is a voluntary ½ day Saturday program. Participation in this program is optional. You are expected to continue to incorporate what you learned in the class in your daily routine after you are done with the classes.
88898558|NCT01491997|Active Comparator|Mind/Body Medicine Course 2|The subject of the course is Mind/Body medicine. This course is learning about the mind and the body through lectures. The course will meet once every week, for a total of 8 weeks, for roughly 2 hours per class. You will be provided with a schedule of the weekly classes, which will occur on the same day every week, at the same time. Weekly sessions will be run by a teacher and will include other participants in the class. You will also be given homework assignments that are intended to reinforce what you learn in the program. The assignments will require up to 45 minutes, 6 days/week. Following the 6th class, and before the 7th class, there is a voluntary all day Saturday program. Participation in this program is optional. You are expected to continue to incorporate what you learned in the class in your daily routine after you are done with the classes.
89194294|NCT00732888|Other|1|On an 18-day schedule, calcium supplement (Tums Ultra 1000®) once daily on day 15; and Tasigna® once daily on days 1 and 15 (i.e., Tasigna® alone on day 1, and combination of Tasigna® and calcium supplement on day 15).
89419556|NCT02031510|Active Comparator|bupivacaine-dexmedetomidine|transversus abdominis plane block with bupivacaine 0.25% with dexmedetomidine 1 µg Kg-1
89419557|NCT02031510|Active Comparator|bupivacaine|transversus abdominis plane block with bupivacaine 0.25%
89419558|NCT02031510|Placebo Comparator|placebo|Transversus abdominis block with saline 0.9%
88898559|NCT01492010|Experimental|25 g protein|25 g whey protein
89194295|NCT00732888|Other|2|On an 18-day schedule, calcium supplement (Tums Ultra 1000®) once daily on day 1; and Tasigna® once daily on days 1 and 15 (i.e., combination of Tasigna® and calcium supplement on day 1, Tasigna® alone on day 15).
89194296|NCT00732966|Experimental|1|Hypertensive patients will be treated with losartan for one months
89419559|NCT03059758|Experimental|Brain activity during reasoning and measure of math skill|Brain activity during reasoning and measure of math skill
89419560|NCT02230878|Experimental|JNJ-42847922, 5 milligram (mg) and Placebo|Participants will be receive either 5 mg of JNJ-42847922 from Day 1 up to Day 10 or matching placebo from Day 1 up to Day 10.
89194297|NCT00732966|Experimental|2|Hypertensive patients will be treated with valsartan
89194298|NCT00739440|Experimental|I|Patients 15 to 60 years with scorpion sting, will receive serum antiscorpion elaborated by Birmex
89419561|NCT02230878|Experimental|JNJ-42847922, 10 mg and Placebo|Participants will be receive either 10 mg of JNJ-42847922 from Day 1 up to Day 10 or matching placebo from Day 1 up to Day 10.
89419562|NCT02230878|Experimental|JNJ-42847922, 20 mg and Placebo|Participants will be receive either 20 mg of JNJ-42847922 from Day 1 up to Day 10 or matching placebo from Day 1 up to Day 10.
89419563|NCT02230878|Experimental|JNJ-42847922, 40 mg and Placebo|Participants will be receive either 40mg of JNJ-42847922 from Day 1 up to Day 10 or matching placebo from Day 1 up to Day 10.
89419564|NCT03059602||Knee group|Caregivers who will be the primary source of assistance (medical, rehabilitative, daily living, etc) after surgery for patients undergoing total knee arthroplasty.
89419565|NCT03059602||Hip group|Caregivers who will be the primary source of assistance (medical, rehabilitative, daily living, etc) after surgery for patients undergoing total hip arthroplasty.
89419566|NCT03059602||Spine group|Caregivers who will be the primary source of assistance (medical, rehabilitative, daily living, etc) after surgery for patients undergoing Cervical/Thoracic Lumbar Spine Surgery (Discectomy, Foraminotomy, Laminectomy, Fusion, Nerve Root Decompression)
89419567|NCT02222064|Experimental|Mindfulness|8 week self-managed mindfulness based intervention
89419568|NCT04961788|Experimental|Gemox combined PD1 antibody|"Toripalimab (240mg) intravenously, the administration time is 60 (+15) minutes, Q3W is administered once.~Gemox chemotherapy D1: oxaliplatin 85mg/m2, gemcitabine 1g/m2 D8: Gemcitabine 1g/m2 Three weeks is a course of treatment, a total of 6-8 courses."
88898560|NCT01492010|Experimental|6.25 g protein supplemented with leucine|6.25 g protein supplemented with leucine
88898561|NCT01492010|Experimental|6.25 g whey protein with EAA|6.25 g protein supplemented with a mixture of essential amino acids devoid of leucine
88898562|NCT01492023||control|control group: no intervention
88898563|NCT01492023||neuropsychological rehabilitation|intervention group: neuropsychological rehabilitation (13 times 60 minutes, once per week, during 13 weeks) control group: no intervention
88898564|NCT01492049|Experimental|Patient Decision Aid (PtDA)|Participants view Patient decision aid (PtDA) video.
88898565|NCT01492049|Active Comparator|Control|Participants view a video on Essential Hypertension.
88898566|NCT01492062|Experimental|closed-loop control|Multiple Model Predictive Controller
89194299|NCT00739440|Experimental|II|Patients 15 to 60 years with scorpion sting, will receive other commercial serum antiscorpion (Alacramyn)
89194300|NCT00735774|Experimental|11C-ORM-13070|
88898567|NCT01492075|Active Comparator|Continuous infusion|Continuous infusion of LA intraabdominally
88898568|NCT01492075|Experimental|PCRA (Intermittent injection)|Patient controlled LA intraabdominally
88898569|NCT01492114|Experimental|Resveratrol first|"Subjects in the group resveratrol first will be submitted to: 30 days of treatment with Transmax (resveratrol, 500 mg, Biotivia Bioceuticals LLC), one tablet/day in the morning at fasting; then to 30 days of wash-out (no supplementation), and then to 30 days of treatment with placebo (one tablet/day in the morning at fasting)."
89194301|NCT00739518|Experimental|MRI scan - new technology|The patient's clinical MRI scan will also utilize some new technology, such as a change in software or additional MRI sequences
89194302|NCT00733044|Experimental|Specialized Care|Stepped-care cognitive behavioural approach with elements from tinnitus retraining therapy
89419569|NCT02222142||Isoflurane group|Isoflurane inhalational anesthesia during OPCAB
89419570|NCT02222142||Propofol group|Total intravenous anesthesia with propofol during OPCAB
89194303|NCT00733044|Active Comparator|Usual Care|Audiological diagnostics and intervention and, if necessary, one or more consultations with a social worker with a maximum of ten one hour session
89419571|NCT04961710|Experimental|Hetrombopag Olamine|
89419572|NCT04961710|Placebo Comparator|Placebo|
89194304|NCT00735930|Experimental|Treatment (alvocidib, lenalidomide)|Patients receive alvocidib IV over 4.5 hours on days 1, 8, and 15 in course 1 followed by a week of rest. Beginning in course 2 and all subsequent courses, patients receive lenalidomide PO QD on days 1-21 and alvocidib IV over 4.5 hours on days 3, 10, and 17. Treatment repeats every 35 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
89419573|NCT02225262|Experimental|CyberKnife Radiosurgery|
89419574|NCT04961866|Active Comparator|Group A|patients received 1 g/ kg of protein
88898570|NCT01492114|Active Comparator|Placebo first|"Subjects in the group Placebo first will be submitted to: 30 days of treatment with placebo, one tablet/day in the morning at fasting; than to 30 days of wash-out (no supplementation), and then to 30 days of treatment with Transmax (resveratrol, 500 mg) (one tablet/day in the morning at fasting)."
89194305|NCT00736008||A|Patients with thromboembolic events
89419575|NCT04961866|Active Comparator|Group B|patients received 2 g/ kg of protein
89419576|NCT02225340||Controls|
89419577|NCT02225340||Familial hypercholesterolemia|
89419578|NCT02830893|Experimental|The LARA Therapy|The LARA arm of this study will use the LARA system while study participants are staying at the acute rehabilitation unit of UC Irvine Douglas Hospital. LARA is a system that facilitates patients to perform high amounts of arm movement with the affected upper extremity. Study participants are able to actively propel themselves in the unit.
89419579|NCT02830893|Active Comparator|The Standard Therapy|The control arm of this study will use a standard wheelchair while study participants are staying at the acute rehabilitation unit of UC Irvine Douglas Hospital. Study participants will have no exposure to LARA and they will use a standard wheelchair. They will use their unaffected upper and lower extremities to propel themselves in the unit.
89419580|NCT02231112|Experimental|Prone position whole breast RT|
89419581|NCT04425382||Darunavir/Cobicistat|Patients received Darunavir/Cobicistat (Rezolsta®) as part of the treatment regimen for COVID-19 pneumonia
89419582|NCT04425382||Lopinavir/Ritonavir|Patient received Lopinavir/Ritonavir (Kaletra®) as part of the treatment regimen for COVID-19 pneumonia
89419583|NCT02231190|Experimental|GSK1278863|Subjects will be given five oral doses of GSK1278863 100 mg (5mg if a low dose is elected for subjects enrolled after interim analysis). The first dose will be administered immediately after completion of eccentric exercise, and then at 4, 8, 24, and 48 hours
89419584|NCT02231190|Placebo Comparator|Placebo|Subjects will be given five oral doses of Placebo. The first dose will be administered immediately after completion of eccentric exercise, and then at 4, 8, 24, and 48 hours
89419585|NCT03563937||Phenprocoumon|Patients with NVAF who initiated the treatment of Phenprocoumon.
89419586|NCT03563937||Apixaban|Patients with NVAF who initiated the treatment of Apixaban.
89419587|NCT03563937||Rivaroxaban (Xarelto, BAY59-7939)|Patients with NVAF who initiated the treatment of Rivaroxaban.
89419588|NCT03563937||Edoxaban|Patients with NVAF who initiated the treatment of Edoxaban.
89419589|NCT04424992||Covid19 infection related patients|The patients enrolled in the study are all patients with clinical and microbiological diagnosis of COVID-19 infection hospitalized since February 23, 2020 at San Gerardo Hospital (ASST-Monza).
89419590|NCT02231268||Depressive patients|
89419591|NCT04961476||GrM0|GrM0 - without supplementation
89419592|NCT04961476||GrM1|GrM1 - with 1-MNA supplementation
89419593|NCT02231346||chronic obstructive pulmonary disease patients|
89419594|NCT02225418|Sham Comparator|Placebo TQL block|30 ml single shot TQL block with saline 0,9%
89419595|NCT02225418|Active Comparator|Active TQL block|30 ml single shot TQL block with ropivacaine 0,75%
89419596|NCT04431856|Experimental|Immediate Condition|Participants in the Immediate Condition group will receive a total of 4 sessions of Unified Protocol for COVID-19 Parenting Stress (UP-COVID) intervention
89419597|NCT04431856|Active Comparator|Delayed Condition|Participants in the Delayed Condition group will receive the Self Help Guide (SHG) by the National Child Traumatic Stress Network (NCTSN). They will then receive the UP-COVID intervention following their week 6 assessment
89419598|NCT03679429||Control group|Patients from the control group will be examined using a CF-HQ 190 EVIS Exera III Advanced Diagnostic Video Colonoscope. If colon polyps are detected optical diagnosis will be determined WITHOUT using the NBI function of the scope.
89419599|NCT03679429||Intervention|Patients from the control group will be examined using a CF-HQ 190 EVIS Exera III Advanced Diagnostic Video Colonoscope. If colon polyps are detected optical diagnosis will be determined by using the NBI function of the scope.
89419600|NCT02231424||chronic obstructive respiratory tract disease patients|
89419601|NCT04960852|Experimental|a single shade structurally colored universal resin composite|Cavities will be prepared. one shade universal composite (Omnichroma) a will be applied according to the manufacturer.
89419602|NCT04431934|No Intervention|CONTROL|No intervention arm
88898571|NCT01492127|No Intervention|Blood test|Blood test :carcinoma in cirrhotic patients
88898572|NCT01492153||NovoLet® device|
89194306|NCT00736086||1|Subjects who are ambulated early post-percutaneous, cardiac or peripheral vascular, diagnostic catheterization procedures with the use of StarClose® Vascular Closure System in the femoral artery after diagnostic catheterization procedure.
89419603|NCT04431934|Active Comparator|PROBIOTIC|
89419604|NCT04431934|Active Comparator|FMT REGIMEN|
89419605|NCT04717128|Experimental|Baby doll with user remote controlled jaw|In this arm, standardized patients will use the Newborn Oral Assessment and Latch Simulator (NORALSim) to demonstrate and teach newborn positioning and attachment in the breastfeeding skills workshop.
89419606|NCT04717128|Active Comparator|Baby doll with hand controlled jaw|In this arm, standardized patients will use a cloth baby doll with a puppet-style mouth to demonstrate and teach newborn positioning and attachment in the breastfeeding skills workshop.
89419607|NCT02231502|Experimental|Vegetable-based convenience food|"One time ingestion of a vegetable-based convenience product. Dietary restrictions will be observed (i.e. avoidance of some vegetables) for 3 days prior to the bioavailability assessment (a list of foods to avoid will be provided).~At least 7 days wash-out between each assessment visit."
89419608|NCT02231502|Active Comparator|Vegetable meal|"One time ingestion of a minimally processed vegetable meal. Dietary restrictions will be observed (i.e. avoidance of some vegetables) for 3 days prior to the bioavailability assessment (a list of foods to avoid will be provided).~At least 7 days wash-out between each assessment visit."
89419609|NCT04960774||Control group|Patients with non-severe periodontitis or healthy people who were treated in our department in the same period were included as the control group.
89419610|NCT04960774||Severe periodontitis group|Severe periodontitis patients who meet the inclusion and exclusion criteria in the Department of Stomatology, the second affiliated Hospital of Medical College of Zhejiang University
89419611|NCT02225496|Experimental|Transoral Robotic Surgery (TORS)|Transoral robotic surgery performed utilizing Intuitive Surgical da Vinci Surgical System. Utilizing robotic surgical system, tumor excised with wide surgical margins of 0.5-1 cm. Functional assessment performed at pre-treatment, within 1-4 weeks post-op from TORS (before adjuvant therapy), and after completion of treatment at the following time points: 6 months (±2 months), 12 months (±2 months), and 24 months (±6 months). Functional measures include video-fluoroscopic examination of swallowing (modified barium swallow [MBS] study) with administration of the Performance Status Scale-Head and Neck (PSS-HN) and MD Anderson Dysphagia Inventory (MDADI) questionnaire.
89419612|NCT04960696||primary school/78 subjects|Determining the negative effects of distance education on eye symptoms during the pandemic period.
89419613|NCT04960696||middle school/78 subjects|Determining the negative effects of distance education on eye symptoms during the pandemic period.
89419614|NCT04960696||high school/78 subjects|Determining the negative effects of distance education on eye symptoms during the pandemic period.
89419615|NCT04960696||university/81 subjects|Determining the negative effects of distance education on eye symptoms during the pandemic period.
89419616|NCT05057130|Experimental|Three-component chemotherapy|Doxorubicin 25 mg / m2 IV on days 1-3, Cisplatin 120 mg / m2 IV on day 1 against the background of hyperhydration. G-CSF support from 4 to 13 days. Methotrexate 12 g / m2 at 28 and 35 days IV with leucovorin 60 mg / m2 in the first 5 days after each administration of methotrexate. The interval between cycles is 42 days
88898573|NCT01492166||Novolet®|
88898574|NCT01492179|Active Comparator|Intravenous Lidocaine|Intravenous lidocaine would be administered as an infusion for pain management both intra- and post-operatively.
88898575|NCT01492179|Active Comparator|Intra-abdominal Lidocaine|Lidocaine would be administered intermittently, once each hour intra-abdominally for postoperative pain management.
88898576|NCT01492179|Placebo Comparator|Normal saline|Normal saline would be administered intra-abdominally and intravenously in the same patient. Rescue analgesia in the form of morphine (PCA) would be used for pain management.
88898577|NCT01492192|Experimental|RCC Patients Antiangiogenic treatment|
88898578|NCT01492205||Human insulin|
88898579|NCT01492218||NovoLet®|
89419617|NCT05057130|Active Comparator|Two-component chemotherapy|Doxorubicin 25 mg / m2 IV on days 1-3, Cisplatin 120 mg / m2 IV on day 1 against the background of hyperhydration. G-CSF support from 4 to 13 days. The interval between cycles is 28 days
89419618|NCT04961008|Experimental|Bottle-PEP|Bottle-PEP
89419619|NCT04961008|Active Comparator|Routine physiotherapy|v
88898580|NCT01492244||Patients with knee pain and a known diagnosis|
88898581|NCT01492257|No Intervention|SDM Control|The control arm will consist of usual care, patients will receive existing educational materials.
88898582|NCT01492257|Experimental|SDM Intervention|RCT intervention will include a package of decision and communication aids question-asking, and information recall. The intervention includes digital video discs and booklets produced by the Foundation for Informed Medical Decision Making and Health Dialog; a question-prompting phone call with a trained health coach; audio-recordings of the patient-surgeon consultation; and a copy of the surgeon's dictated note.
88898583|NCT01492283||NAFLD|Non alcoholic fatty liver disease without type 2 diabetes
88898584|NCT01492283||NAFLD+T2D|Non alcoholic fatty liver disease with type 2 diabetes
88898585|NCT01492283||T2D|Type 2 diabetics without non alcoholic fatty liver disease
88898586|NCT01492283||cirrhosis|Patients with liver cirrhosis
88898587|NCT01492283||Kontrol groups|Healthy control subjects
88898588|NCT01492296|Active Comparator|conventional fasting|patients were evaluated after fasting for 8 hours
88898589|NCT01492296|Experimental|Short fasting|patients who were evaluated with endoscopy after fasting for two hours
88898590|NCT01492322||Sated and withdrawal group|To determine differences in TRODAT binding to the DAT between a smoker when sated and when in withdrawal
88898591|NCT01492335|Experimental|Cognitive Report|Primary care physicians in the Cognitive Report group receive the results of their patients cognitive testing together with clinical diagnosis (Normal, Mild Cognitive Impairment, Dementia) and treatment recommendations.
88898592|NCT01492335|Experimental|Treatment As Usual|Physicians in the Treatment As Usual Group do not receive the results of their patients cognitive assessment, they do not receive treatment recommendations, nor are they told of the patients diagnosis (Normal, Mild Cognitive Impairment, Dementia)
88898593|NCT01492348|Experimental|STEPS UP Intervention|STEPS UP is a centrally assisted stepped collaborative telecare management program within primary care. The STEPS UP intervention added to Optimized Usual Care (PCMH-BH; formerly RESPECT-Mil) in 4 ways: (1) care management enhancements; (2) stepped psychosocial treatment options (web, phone, in person); (3) electronic symptom registry for measurement-based treatment planning (symptoms are measured at regular intervals and care is intensified for patients with recurrent or persistent PTSD and/or depressive) and for telecare manager caseload and site performance monitoring; and (4) routine assisted review of patient, telecare manager, and site performance by a central psychiatrist and psychologist.
88898594|NCT01492348|Active Comparator|Optimized Usual Care (OUC)|Service members randomized to Optimized Usual Care (OUC) will get usual treatment at the site. OUC is RESPECT-Mil, a voluntary, primary care-based implementation program where, with the assistance and collaboration of a psychiatrist and an on-site nurse-level care manager, service members with symptoms of PTSD and depression are screened, tracked, and treated within the primary care system.
88898595|NCT01492374|Experimental|Arm 1: BMS-241027 (0.003 mg/kg)|
88898596|NCT01492374|Experimental|Arm 2: BMS-241027 (0.01 mg/kg)|
88898597|NCT01492374|Experimental|Arm 3: BMS-241027 (0.03 mg/kg)|
88898598|NCT01492374|Experimental|Arm 4: Placebo matching BMS-241027|
88898599|NCT01492387|No Intervention|Local standard of care|Patients randomized to this arm will be treated for the duration of therapy dictated by the primary care physician.
88898600|NCT01492387|Experimental|Individualized arm|Patients randomized to this arm will be treated according to clinical response: antibiotic therapy will be discontinued 48 hours after the day that the patient reaches clinical stability, with at least 5 days of total antibiotic treatment.
88898601|NCT01492413|Experimental|Online basic lifestyle counseling (OBLI)|Subjects receive one online informational class.
89419620|NCT03677479|Experimental|socket preservation with camelline bone|natural hydroxyapatite derived from camels prepared by investigator
88898602|NCT01492413|Experimental|Online lifestyle counseling (OLC)|Subjects receive 12 weekly online classes with a focus on behavior modification for weight loss.
88898603|NCT01492413|Experimental|OBLI intervention plus a fortified diet beverage (BEV)|Subjects receive online basic lifestyle information (OBLI) plus a fortified diet beverage.
88898604|NCT01492413|Experimental|OLC plus fortified diet beverage (BEV)|Subjects receive OLC plus diet beverage (BEV).
88898605|NCT01492452|No Intervention|guidelines|22 parents in the intervention group were randomized and received standardized guidelines for nursing:The guidelines took around an hour and involved pre-operative care such as bathing with detergent solution, pre-anesthetic administration (as prescribed), preoperative fasting (as prescribed), clothing, hygiene care and nail oral. They were also provided information on the endotracheal tube, tubes, catheters, epicardial pacemaker wires and electrodes to be used in the perioperative period and which remain for some period after surgery, as well as possible complications.
88898606|NCT01492465|Active Comparator|AMG 876|
88898607|NCT01492465|Placebo Comparator|Placebo|
89419621|NCT03677479|Active Comparator|socket preservation with bovine bone|natural hydroxyapatite derived from cows (Bio-Oss)
89419622|NCT02222220|Placebo Comparator|metoclopramide|61 participating subjects were randomized into 2 groups: 30 received metoclopramide up to 30 mg/day and 31 received placebo, each for 4 weeks in a double-blind mode
89419623|NCT02222220|Experimental|metocliopramide|61 participating subjects were randomized into 2 groups: 30 received metoclopramide up to 30 mg/day and 31 received placebo, each for 4 weeks in a double-blind mode
89536026|NCT02479373|Experimental|Resistance Exercise (RE)|Those assigned to RE will complete baseline and post-testing assessments and participate in 12 weeks of individually-supervised resistance exercise, which will take place in the exercise facility on the Johns Hopkins Bayview Medical Center Campus. Exercises will be performed on Ren-Ex Machines. This equipment is suitable for the proposed study because it provides ultra-low friction movement which creates a personalized resistance profile, which minimizes force on joints and thereby reduces the risk of joint trauma and injury.
89419624|NCT03059290|Active Comparator|protaper next file|the PROTAPER NEXT™ X1 (017/04) file, in one or more passes until the working length is reached. Use PROTAPER NEXT X2 (025/06), exactly as described for PROTAPER NEXT X1 file, until the working length is passively reached. Gauge the foramen with a size 025 hand file and, if this file binds at length, the canal is shaped and ready for disinfection. If the size 025 hand file is loose at length, then continue shaping with the PROTAPER NEXT X3 (30/07) and, when necessary, the PROTAPER NEXT X4 (040/06) or PROTAPER NEXT X5 (050/06), gauging after each instrument with the 030, 040 or 050 hand files, respectively. During canal shaping, irrigate, recapitulate with a small-sized hand file after each sequential PROTAPER NEXT instrument, then re-irrigate. in an endodontic motor according to the manufacturer instructions (X-Smart, Dentsply Maillefer, USA.), with torque 2.0 N.cm and speed 300 rpm.
89419625|NCT03677323|Experimental|Virtual reality|The virtual reality device will consist of the virtual reality headset and headphones for full immersion.
88898608|NCT01492491|No Intervention|standard HFR therapy|standard HFR hemodiafiltration therapy
88898609|NCT01492491|Active Comparator|SUPRA-HFR therapy|SUPRA-HFR hemodiafiltration therapy
88898610|NCT01492504||Subjects with chronic hepatitis C|Subjects who participated in a clinical trial in which Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) was administered for the treatment of chronic hepatitis C
89194307|NCT00617734|Experimental|IMC-A12 (cixutumumab)|
89194308|NCT00617734|Experimental|IMC-A12 (cixutumumab) + cetuximab|
89419626|NCT03677323|Active Comparator|Drug sedation|The sedation group will benefit from drug sedation used in current practice, that is to say an association of Sufentanil, Droleptan and Propofol.
89419627|NCT02225574|Experimental|Advanced CML + Philadelphia positive Acute Leukemia-Group 1|"Phase 1 Starting dose of MEK-162: 30 mg by mouth twice a day of a 28 day cycle.~Phase 1 Starting dose of Nilotinib: 400 mg by mouth twice a day of a 28 day cycle.~Questionnaires completed and the end of cycle 1, 2, 3, 6, 9, and 12.~Phase 2 Starting dose of MEK-162: MTD from Phase 1 to be taken by mouth twice a day starting on Day 1 of a 28 day cycle.~Phase 2 Starting dose of Nilotinib: MTD from Phase 1 to be taken by mouth twice a day starting on Day 2 of a 28 day cycle."
89419628|NCT02225574|Experimental|Chronic Phase CML - Group 2|"Phase 1 Starting dose of MEK-162: 30 mg by mouth twice a day of a 28 day cycle.~Phase 1 Starting dose of Nilotinib: 400 mg by mouth twice a day of a 28 day cycle.~Questionnaires completed and the end of cycle 1, 2, 3, 6, 9, and 12.~Phase 2 Starting Dose of Nilotinib: MTD from Phase 1 by mouth twice a day starting on Day 1 of a 28 day cycle.~Phase 2 Starting Dose of MEK-162: MTD from Phase 1 by mouth twice a day starting on Day 8 of a 28 day cycle."
89419629|NCT02625922|Experimental|Serelaxin followed by Placebo|On Day 1 of treatment period 1, Serelaxin will be administered as a continuous i.v. infusion according to a weight-range adjusted dosing regimen The routine exercise assessment will commence at minute 120. In treatment period 2, on day 15 ± 1-day washout, matching placebo will be administered as a continuous i.v. infusion according to a weight-range adjusted dosing regimen.
89419630|NCT02625922|Experimental|Placebo followed by Serelaxin|On Day 1 of treatment period 1, matching placebo will be administered as a continuous i.v. infusion according to a weight-range adjusted dosing regimen The routine exercise assessment will commence at minute 120. In treatment period 2, on day 15 ± 1-day washout, Serelaxin will be administered as a continuous i.v. infusion according to a weight-range adjusted dosing regimen.
89419631|NCT03679273|Experimental|Abound supplement|The participant will take the supplementation drink containing 79 kcal, 7 g L-arginine, 7 g L-glutamine and 1.5 g calcium β-hydroxy-β-methylbutyrate (Abound; Abbott Nutrition, Columbus, OH, USA). The subjects will be instructed to drink the entire packet dissolved in 250 ml of water twice per day for 21 days.
89419632|NCT03679273|No Intervention|Traditional supplement|The participant will take traditional diabetes-specific formula as provided by dietitians.
89419633|NCT02259192|Experimental|Open-label|Cochlear Implant
89419634|NCT03619291|Experimental|High-intensity functional training|all-out exercise
89194309|NCT00733122|Experimental|A|GARDASIL, Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
88898611|NCT01492517|Sham Comparator|Clean air exposure|Exposure to clean air will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus. Each subject will be exposed to clean air for 2 hours. Subjects will begin exercising on an exercise bike. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/m2/BSA followed by a 15 minute rest period. The exposure atmosphere will be at approximately 40 + 10% RH and approximately 22 + 2 oC.
88898612|NCT01492517|Other|Ozone exposure|Exposure to 0.3ppm ozone will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus. Each subject will be exposed for 2 hours. Subjects will begin exercising on an exercise bike. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/m2/BSA followed by a 15 minute rest period. The exposure atmosphere will be at approximately 40 + 10% RH and approximately 22 + 2 oC. Ozone exposures will be conducted in a (6 ft x 6 ft x 8 ft) stainless steel chamber with a continuous supply of exposure medium. Ozone will be monitored continuously.
89419635|NCT03619291|Active Comparator|Aerobic exercise|walking
89419636|NCT03619291|Sham Comparator|control|sitting
89419637|NCT02259270||ASTRA-1|"All patients discharged from the participating hospitals between July 2012 and July 2013.~Determination of long term use of AST before, during and after hospitalisation based on dispensing data, no record review."
89419638|NCT02259270||ASTRA-2|Random selected subset of patients in ASTRA-1 with startup of AST in the hospital and AST at discharge. Record review for appropriateness of indication of startup of AST.
89419639|NCT03059212|Experimental|High frequency rTMS|Real rTMS, one session per day, for 10 days
89419640|NCT03059212|Experimental|High frequency rTMS with cognitive training|Real rTMS and cognitive training, one session per day, for 10 days
89419641|NCT03059212|Sham Comparator|Sham rTMS|Sham rTMS, one session per day, for 10 days
89419642|NCT03688477|Experimental|iovera°|Patients will receive iovera° prior to stand of care ACL
89419643|NCT03688477|No Intervention|Standard of Care|Patients will receive standard of care ACL procedure without iovera° treatment.
89419644|NCT02225652|Experimental|FEC + filgrastim x 3 cycles q 14-21 days and Weekly Paclitaxel|"FEC (FLUOROURACIL 500 mg/m2 IV infusion of 30 minutes + EPIRUBICIN 60 mg/m2 IV infusion of 1 hour + CYCLOPHOSPHAMIDE 500 mg/m2 IV infusion of 30 minutes).~From day 7 until hematological recovery = Filgrastim 300 microg s.c. After 21 days from the last FEC cycle = Paclitaxel 100 mg/m2 IV infusion of 1hour (weekly for 8 cycles, at day 1)."
89419645|NCT03059524||patients with multiple organ failure|
89419646|NCT03059524||patients without multiple organ failure|
89419647|NCT03059524||normal subjects|
89419648|NCT02222298|Experimental|VAAPS group|patients undergoing video assisted ablation of pilonidal sinus
89419649|NCT02222298|Active Comparator|conventional treatment group|patients undergoing conventional off-midline Bascom cleft lift procedure
89419650|NCT03059368|Experimental|new bone fixation plate with screw|Fracture ends and injured posterior cruciate ligament will be exposed in twenty patients with tibial avulsion fracture of posterior cruciate ligament of knee through posterior approach. Open reduction will be conducted. The posterior cruciate ligament will be reconstructed with a new bone fixation plate with screw(cancellous bone screw).
89419651|NCT03461653|Other|Telemedicine counselling|intervention group Women who will receive telemedicine counselling
89419652|NCT03461653|No Intervention|Standard care|Women who will receive standard face-to-face counselling
88922191|NCT05662280|Experimental|Sham intermittent Theta Burst Stimulation|"In a 2x2 factorial double-blind design, researchers will randomize a sample of adolescents with WM deficits to intermittent theta burst stimulation (iTBS) at the left dorsolateral prefrontal cortex (DLPFC) or inferior parietal lobule (IPL), based on each participant's structural brain MRI.~Participants in both arms will complete an active iTBS session and a sham iTBS session. The primary outcome will be theta-gamma coupling during WM demands, as measured via electroencephalography (EEG) during a Sternberg spatial WM task (SWMT) immediately before and after iTBS."
89419653|NCT04960462||the treatment of sacral cysts in patients with sacral cysts by using nerve root sleeve reinforcement|The clinical data of patients with sacral cysts treated with nerve root sleeve reinforcement and reconstruction of the sacral canal cyst were summarized and followed up from 3 to 6 months after the operation to form a case summary and report.
89419654|NCT02222376|Active Comparator|Conventional treatment|Weekly ulcer debridement and daily cleansing
89419655|NCT02222376|Experimental|Pirfenidone|Weekly ulcer debridement, daily cleansing, plus twice a day topical pirfenidone application
89419656|NCT03672799|Experimental|Rehabilitation Planning Consult (RPC)|"The RPC is a trans-disciplinary, consultative intervention. In the RPC, individualized rehabilitation needs are established, goals are set, strategies to achieve the goals are developed, and follow-through with strategies and goal attainment is facilitated by a rehabilitation professional who consults and collaborates with the survivor. The Rehabilitation Consultant does not provide hands-on treatment, but rather determines the survivors' priority individualized rehabilitation goals, and then helps devise a plan for the survivor to meet those goals independently.~Participants allocated to RPC will receive a 1 hour consultation with the Rehabilitation Consultant and second consultation 2 to 12 weeks later."
89419657|NCT03672799|Active Comparator|Wait list control (WLC)|"There is no standard rehabilitation care for survivors of head and neck cancer at the Princess Margaret Cancer Centre.~Participants allocated to WLC will enter a 12 week waiting period after which they will crossover to the RPC group."
89419658|NCT04960540||impaired speech comprehension processing in ALS|Brain functional network mechanism of impaired speech comprehension processing in ALS
89419659|NCT04960540||language use processing injury in ALS|Brain functional network mechanism of language use processing injury in ALS
89419660|NCT04960540||motor executive processing injury in ALS|Brain functional network mechanism of motor executive processing injury in ALS
89419661|NCT04960540||anguage cognitive impairment in ALS|Brain structural network mechanism of language cognitive impairment in ALS
89419662|NCT02231658|Experimental|Liraglutide|The highest injected once daily dose will be 1.8 mg s.c. for liraglutide.
88922192|NCT05662202|Experimental|BF-200 ALA|"Topical application of BF-200 ALA containing 7.8% 5-ALA (5-aminolevulinic acid).~Red light photodynamic therapy (PDT)"
89419663|NCT02231658|Experimental|Lixisenatide|The highest injected once daily dose will be 20µg s.c. for lixisenatide.
89419664|NCT03677167|Experimental|walking on a treadmill barefoot group|26 Patients in this group will walk barefoot on the treadmill and will be asked to walk barefoot at home and report the time of barefoot walking at home
89419665|NCT03677167|Active Comparator|Walking on a treadmill with shoes group|26 Patients in this group will walk with shoes on the treadmill
89419666|NCT04959682|Experimental|Intervention group|Patients in the intervention group will receive 30 minutes of patient-tailored instrumental music in the beginning of one weekly hemodialysis treatment for a period of six weeks
89419667|NCT04959682|No Intervention|Control group|The procedure in the control group is the same as in the intervention group, except that they don't listen to music
89419668|NCT04542408|Experimental|Intensive anticoagulation strategy|In-hospital (ICU & normal ward): weight-adapted LMWH, high dose/ therapeutic dose (according to respective SmPC) After discharge and in ambulatory patients: Edoxaban according to SmPC
89419669|NCT04542408|Other|Moderate anticoagulation strategy|In-hospital (ICU & normal ward): LMWH, prophylactic dose as part of SOC After discharge and in ambulatory patients: Administration of oral placebo according to the dosing rules for Edoxaban
89419670|NCT03623581|Experimental|GB226 3mg/kg every 2 weeks|Geptanolimab Injection, 3mg/kg every 2 weeks
89419671|NCT03059134|Experimental|Mirabegron 25mg for 12 weeks|Mirabegron 25mg once-daily for 4 weeks, and continue the same dose of mirabegron for another 8 weeks
89419672|NCT03059134|Active Comparator|Mirabegron 25mg followed by 50mg|Mirabegron 25mg once-daily for 4 weeks, and increase the dose to 50mg for another 8 weeks
89419673|NCT03059134|Active Comparator|Mirabegron 25mg followed by solifenacin|Mirabegron 25mg once-daily for 4 weeks, and shift to solifenacin 5mg for another 8 weeks
89419674|NCT03059134|Active Comparator|Mirabegron 25mg add-on solifenacin|Mirabegron 25mg once-daily for 4 weeks, and add-on solifenacin 5mg for another 8 weeks,
89419675|NCT04959136|Experimental|Ambulatory Monitoring Solution|The evaluable device (Ambulatory Monitoring Solution and its parts) is a secondary monitoring device and no decisions/diagnosis will be made from these devices.
89419676|NCT04959214|Experimental|intervention: progressive relaxation exercise practice group|intervention: progressive relaxation exercise practice group: A group of 30 intensive care nurses who will practice the progressive relaxation exercise at home 3 days a week for 1 month.
89419677|NCT04959214|No Intervention|control: uninterrupted group|control: A group of 30 intensive care nurses who did not intervene for 1 month
89419678|NCT03672721|Experimental|IA Carbo + radiation|Intraarterial carboplatin + radiation
89419679|NCT02225808|Experimental|CBT for anxiety in autism|Cognitive-behavioral therapy (CBT) teaches skills for coping with anxiety and consist of 12 weekly sessions. CBT is conducted with child and parent.
89419680|NCT04959370|Experimental|Dynamic hip screw (DHS)|
89419681|NCT04959370|Active Comparator|Cannulated compression screw (CCS)|
89419682|NCT02941237|Other|Healthcare worker measurement of SpO2|Measurement of SpO2 using the Lifebox pulse oximeter probe in children of different ages, stratified by age: 0-1 months, 2-11 months, 12-23 months and 24-59 months
89419683|NCT02941237|Other|Expert measurement of SpO2|Measurement of SpO2 using the Lifebox pulse oximeter probe and Masimo oximeter probe in children of different ages, stratified by age: 0-1 months, 2-11 months, 12-23 months and 24-59 months
89419684|NCT02222454|Experimental|KLOX BioPhotonic System|Treatment with KLOX BioPhotonic System in adjunction to Standard Of Care for pressure ulcers.
88898613|NCT01492517|Other|Diesel exhaust exposure|Exposure to diesel exhaust will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus. Each subject will be exposed to diesel exhaust (up to 300 ug/m3). Subjects will begin exercising on an exercise bike. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/m2/BSA followed by a 15 minute rest period. The exposure atmosphere will be at approximately 40 + 10% RH and approximately 22 + 2 oC. The DE will be generated from a diesel generator used to power a load bank that is located outside the Human Studies Facility, and subsequently introduced into the exposure chamber after different dilutions with clean HEPA and charcoal filtered and humidified air to give a chamber concentration of up to 300 μg/m3.
88898614|NCT01492517|Other|18Ozone|Exposure to ozone generated using the heavy non-radioactive isotope of oxygen (18O). Exposure to 0.3ppm 18O will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus. Each subject will be exposed for 2 hours. Subjects will begin exercising on an exercise bike. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/m2/BSA followed by a 15 minute rest period. The exposure atmosphere will be at approximately 40 + 10% RH and approximately 22 + 2 oC. Ozone exposures will be conducted in a (6 ft x 6 ft x 8 ft) stainless steel chamber with a continuous supply of exposure medium. Ozone will be monitored continuously.
88898615|NCT01492530|Experimental|6-session, small group|Men of African American Legacy Empowering Self (MAALES) Intervention, a six-session, theoretically grounded, small-group intervention held over 3 weeks. Includes an additional 2 booster sessions at 6 and 18 weeks following Session 6.
88898616|NCT01492530|Active Comparator|HIV Education & Risk Reduction Session|20-30 minute standard, client-centered HIV education and risk-reduction session administered over the phone or in person. Similar to that received during pre-test counseling for HIV testing.
88898617|NCT01492543|Experimental|Aiyi®|Tegafur Gimeracil Oteracil Potassium Capsule
88898618|NCT01492556|Experimental|Etoposide|Etoposide Capsules
88898619|NCT01492569|Experimental|Arm I (TAPS at the P6 point)|Patients undergo TAPS at the true acupuncture point (P6) 30 minutes prior to first chemotherapy infusion and then four times a day for 20 minutes every 2 hours at 8am, 10am, 12pm, and 2pm. Patients then crossover to Arm II for the second course of chemotherapy.
88922193|NCT05662202|Placebo Comparator|Vehicle|Topical application of vehicle to BF-200 ALA containing no active ingredient. Red light photodynamic therapy (PDT)
88922194|NCT05658835||Patient suffering from ischemic stroke|
89419685|NCT04959292||Meniscus regeneration|Reconstruction of the anterior cruciate ligament, total or partial meniscus resection was performed in our hospital, and two years after the operation, the meniscus regeneration was found under secondary arthroscopy.
89419686|NCT04959292||Meniscus without regeneration|Anterior cruciate ligament reconstruction, total or partial meniscus resection was performed in our hospital, and two years after the operation, no meniscus regeneration was found under secondary arthroscopy.
89419687|NCT02928991|Experimental|Acquired Aplastic Anemia (AA)|Patients with severe or very severe acquired aplastic anemia (AA). Patients will receive a matched related donor bone marrow transplant following reduced intensity conditioning (RIC) including thymoglobulin (ATG), fludarabine and dose-reduced cyclophosphamide.
89419688|NCT02928991|Experimental|Inherited Bone Marrow Failure Syndrome + Trilineage Aplasia|Patients with inherited bone marrow failure (iBMF) syndromes with trilineage aplasia includes those with diagnoses of Fanconi Anemia, Dyskeratosis Congenita, and related conditions. Patients will receive a matched related donor bone marrow transplant following conditioning with fludarabine, cyclophosphamide, thymoglobulin.
89419689|NCT02928991|Experimental|Inherited Bone Marrow Failure Syndrome no Trilineage Aplasia|Patients with inherited bone marrow failure (iBMF) syndromes without trilineage aplasia includes those with diagnoses of Severe Congenital Neutropenia, Diamond-Blackfan Anemia, and related conditions. Patients will receive a matched related donor bone marrow transplant following conditioning with thymoglobulin, busulfan and fludarabine.
89419690|NCT04958980|No Intervention|Placebo|The control group will be evaluated in 2 stages: at the beginning and at the end of the study and will be accompanied only with scheduled medical consultations (also simulating the reality of basic health units with a traditional model of care) and the intervention group will undergo evaluations with the multiprofessional team on two occasions (at the beginning and at the end of the study)
89419691|NCT04958980|Active Comparator|Specific and educational guidelines on pathology care (diabetes mellitus)|"Multiprofessional educational guidelines and analysis of the following exams:~Periodontal record, bleeding rate on and visible plaque;~Body mass index (BMI): weight (kg) divided by height squared (m²);~Serum glucose values;~Glycated hemoglobin;~Blood count: hemoglobin;~Urea: male:~Creatinine male;~Uric acid;~Oxalacetic glutamic transaminase;~Glutamic pyruvic transaminase;~Total cholesterol and fractions: Cholesterol, Non HDL, LDL, VLDL;~Triglycerides;~Type I urine;~Vitamin D3 25OH;~Microalbuminuria;~Blood pressure: systolic;~Abdominal circumference."
89419692|NCT02222532|Experimental|Tetronine|Oral T3 (Tetronine) is given 1 mcg/kg every 6 hourly through naso-gastric tube since induction of anesthesia for 60 hours
89419693|NCT02222532|Placebo Comparator|Placebo|Placebo (saccharin lactic) is given every 6 hourly through naso-gastric tube since induction of anesthesia for 60 hours
89419694|NCT04959058|Other|Volunteer|This study has only one arm for the brachial plexus evaluation with ultrasound
89419695|NCT02231736||Type 2 diabetes, HbA1c>7.5|
89419696|NCT02231736||Type 2 diabetes, HbA1c<7.5|
89419697|NCT04958590||1 （asymptomatic）|the middle-aged and elderly Chinese asymptomatic population who underwent the whole spine X-ray in standing and sitting positions.
89419698|NCT04958590||2 （patients）|the patients who underwent posterior lumbar fusion surgery for lumbar degenerative disease has been followed up for three months.
89419699|NCT02225964||aMCIp,aMCIs|progressive aMCI,stable aMCI
89419700|NCT04958824|Experimental|Immediate return of results|The intervention for this study is the delivery of genetic test results that reflect pharmacokinetic and pharmacodynamic effects of specified genetic markers. We will use the Sanford panel being promoted by the VA through a clinical project entitled PHASER. The results are returned to the patient and provider approximately 1 week from randomization.
89419701|NCT04958824|No Intervention|Delayed return of results|In the control arm the genetic test results are not returned until 12 weeks when the main outcome is assessed.
89419702|NCT02226042|Experimental|Mindfulness-based Cognitive Therapy|Individuals currently in remission from depression will choose to enter the Mindfulness-based Cognitive Therapy (MBCT) arm and undergo the 8 week MBCT group programme
89419703|NCT02226042|No Intervention|Non-MBCT arm|Individuals currently in remission from depression will choose not to undergo the 8 week MBCT group programme
89419704|NCT02226042|No Intervention|Healthy volunteers|Individuals who have never experienced major depression
88898620|NCT01492569|Sham Comparator|Arm II (TAPS at a non-P6 point)|Patients undergo TAPS at a sham non-acupuncture point 30 minutes prior to first chemotherapy infusion and then four times a day for 20 minutes every 2 hours at 8am, 10am, 12pm, and 2pm. Patients then crossover to Arm I for the second course of chemotherapy.
88898621|NCT01492608|Active Comparator|Magnesium sulphate|Magnesium sulphate will be given as a loading dose of 5 g infused for 20-30 minutes, followed by a maintenance dose of 1 g per hour. Placebo will be given in identical appearing doses. The maintenance infusion will be continued until delivery appears, or for 24 hours if delivery does not occur or no longer is considered imminent. The infusion will be resumed when delivery is considered imminent again. Another loading dose of 5 g will be given if at least 6 hours has passed after infusion was stopped. The doses that are used in this project are similar to those used for prevention of eclampsia among women with severe preeclampsia.
88898622|NCT01492608|Placebo Comparator|Natriumchlorid|Placebo and the active drug (Magnesium sulphate) will be administered identically (same loading and maintenance dose for the same period of time).
88898623|NCT01492647|Experimental|JNJ 10229570-AAA 1.2%|
88898624|NCT01492647|Experimental|JNJ 10229570-AAA 3.6%|
88898625|NCT01492660|Experimental|Echogenic needle and catheter|The echogenic needle will be positioned using ultrasonography and neurostimulation with an end point of plantar or dorsiflexion with 0.6mA of current strength. The catheter will be inserted using ultrasonography alone. 20 Ml of 2% mepivacaine will be inserted using the catheter. The distribution of drug will be evaluated using short axis and long axis views. Sensory motor block evaluation every 5 minutes for 30 minutes. Duration of block procedure, number of passes and success will be evaluated
88898626|NCT01492660|Active Comparator|Neurostimulation|The non echogenic needle will be positioned using ultrasonography and neurostimulation with plantar or dorsiflexion as the end point with 0.6mA current.The catheter will be positioned using neurostimulation with plantar or dorsiflexion with 0.6-1.5mA current.
88898627|NCT01492699|Experimental|PRX-03140|PRX-03140 for the treatment of PTSD
89419705|NCT03672565|Active Comparator|Hospital setting|ERPs may be conducted in various settings on hospital grounds (e.g., cafeteria, hallways) but will not be conducted off property.
89419706|NCT03672565|Active Comparator|Community setting|Community ERP sessions will be conducted locations deemed most relevant to the child's symptom presentation such as in the home or at other community locations (e.g., church, downtown).
89419707|NCT02258646|Experimental|Telerehabilitation|Exercise training at home, telemonitoring, and education/self-management
89419708|NCT02258646|Experimental|Unsupervised exercise training at home|Unsupervised exercise training at home
89419709|NCT02258646|No Intervention|Usual care|Usual care
89419710|NCT02919163|Experimental|Visible light exposure Red 30 lux|The participants will be exposed to incandescent light with a red color filter at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
89419711|NCT02919163|Experimental|Visible light exposure Red 120 lux|The participants will be exposed to incandescent light with a red color filter at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
89419712|NCT02919163|Experimental|Visible light exposure Blue 30 lux|The participants will be exposed to incandescent light with a blue color filter at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
89419713|NCT02919163|Experimental|Visible light exposure Blue 120 lux|The participants will be exposed to incandescent light with a blue color filter at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
89419714|NCT02919163|Experimental|Visible light exposure Green 30 lux|The participants will be exposed to incandescent light with a green color filter at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
88898628|NCT01492712|Experimental|Low-high-low blood target concentration|Patients in the low-high-low group will receive an infusion of propofol with an initial blood target concentration of 2 mcg/ml. After 15 minutes the target will be increased to 5 mcg/ml and after a further 15 minutes the target will be reduced back to 2 mcg/ml for a further 15 to 30 minutes.
88898629|NCT01492712|Experimental|High-low-high target blood concentration|Patients in the high-low-high group will receive an infusion of propofol with an initial blood target concentration of 5 mcg/ml. After 15 minutes the target will be reduced to 2 mcg/ml and after a further 15 minutes the target will be increased back to 5 mcg/ml for a further 15 to 30 minutes.
88898630|NCT01492725|Experimental|Intra-arterial Clot Retrieval after iv tPA|
88898631|NCT01492725|Active Comparator|Standard care iv tPA|
88898632|NCT01492738|No Intervention|Control Group|Participants will be asked to make themselves comfortable lying on a massage table for 20 minutes.
88898633|NCT01492738|Active Comparator|Acupuncture group|Acupuncture group will receive one acupuncture treatment for twenty minutes.
88898634|NCT01492751||Spanish Multicentric Clinically Localized Prostate Cancer|A consecutive sample of clinically localized prostate cancer patients treated with radical prostatectomy, external beam radiotherapy and prostate brachytherapy in 10 Spanish hospitals.
89419715|NCT02919163|Experimental|Visible light exposure Green 120 lux|The participants will be exposed to incandescent light with a green color filter at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
89419716|NCT02919163|Experimental|Visible light exposure White 30 lux|The participants will be exposed to incandescent light with no color filter at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
89419717|NCT02919163|Experimental|Visible light exposure White 120 lux|The participants will be exposed to incandescent light with no color filter at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
89419718|NCT04958356||Children with increased risk for T1D and/or CeD|The participants carrying HLA-conferred susceptibility to type 1 diabetes will be screened annually for four diabetes predictive autoantibodies and followed up to 1-3 years of age. The participants carrying HLA-conferred susceptibility to celiac disease are screened for tissue transglutaminase antibodies (tTGA) at the age of 1 and 3 years. If a child tests positive for such autoantibodies, endomysial antibodies will be analyzed.
89419719|NCT02231970|Experimental|Endoscopic sleeve gastroplasty|The intervention is an endoscopic procedure: to perform endoscopic sleeve gastroplasty we used a cap-based flexible endoscopic suturing system (OverStitch™, Apollo, Inc. Austin, Texas) mounted on a double-channel endoscope (GIF-2T160; Olympus Medical Systems Corporation, Tokyo, Japan) to achieve full-thickness, running sutures through the gastric wall from antrum to fundus.
89419720|NCT03623425|Experimental|68Ga-PSMA-11 PET before 18F-FCH PET|Crossover design
89419721|NCT03623425|Experimental|18F-FCH PET before 68Ga-PSMA-11 PET|Crossover design
89419722|NCT02232048||Corticosteroid Treatment|Patients in the internal medicine department who are being treated with corticosteroids will undergo Transthoracic Echocardiogram to determine change in heart function.
89419723|NCT04958512|Other|blank control group|
89419724|NCT04958512|Experimental|treatment group(Yangxue Qingnao pill)|
89419725|NCT04958512|Active Comparator|control group(hidezhen)|
89419726|NCT03672409|Other|Intervention in knowledge|All participants will be offered learning sessions to improve knowledge in diabetes
89419727|NCT02222766|Experimental|Parents and Tots Together Program|9-week group-based parenting program
89419728|NCT02222766|Active Comparator|Control|Minimal attention control- weekly mailed information on general child development for 9 weeks
89419729|NCT04957888||training group|the observational group to find out the potential biomarker
89419730|NCT04957888||validation group|the validation group to validate the parameters used for early diagnosis
89419731|NCT03678961||Group N|Neutral position
89419732|NCT03678961||Group E|External rotation of leg by 45 degrees
89419733|NCT03678961||Group EF45|External rotation of leg by 45 degrees, hip flexion by 45 degrees, and knee flexion by 45 degrees
89419734|NCT03678961||Group EF15|External rotation of leg by 45 degrees, hip flexion by 15 degrees, and knee flexion by 15 degrees
89419735|NCT04957576|Sham Comparator|Asynchronous Stimulation|The right and the left disown hands will be stimulated with a tactile stimulation (paintbrush) in an asynchronous way, i.e. with a time-delay between one hand-touch and the other
89419736|NCT04957576|Experimental|Synchronous Stimulation|The right and the left disown hands will be stimulated with a tactile stimulation (paintbrush) in synchronously, i.e. without a time-delay between one hand-touch and the other
89419737|NCT03672253|Experimental|CAR-T Re-treatment group|Patients will be treated with CAR-T cells targeting BCMA (Different epitope with the previous CAR-T cell treatment they had been used) with a escalation approach, 0.5x10^6- 2.0x10^6 CAR-T cells/kg.
88898635|NCT01492764||Active Group|This group will receive brief ablation at localized sources (Focal Impulse and Rotor Modulation, FIRM)
88898636|NCT01492764||Control Group|This group receives traditional ablation for this disorder
88898637|NCT01492790|Experimental|Cholecystectomy first|Patients enrolled in this arm will undergo emergency cholecystectomy first without any common bile duct imaging
88898638|NCT01492790|Active Comparator|Sequential common bile duct imaging/cholecystectomy|Patients enrolled in this arm will undergo common bile duct imaging and, if needed, ERCP first followed by emergency cholecystectomy
88898639|NCT01492803|Placebo Comparator|Placebo|Subjects randomized to the placebo arm.
88898640|NCT01492803|Experimental|Probiotics|The probiotics use in the study contains two strains of Lactobacillus plantarum. Each dose of the active study agent contains contains 1 g maltodextrin plus the probiotic bacteria Lp299v (5 x 109 cfu) and Lp299 (5 x 109 cfu).
88898641|NCT01492816|Experimental|Intervention Group|Community members who become engaged in the coalitions and in the broader mobilization effort. A subset of community members.
88898642|NCT01492842||Youth with behaviorally-acquired HIV who enrolled in ATN 106|Behaviorally-acquired HIV-infected adolescents and young adults, ages 12-24, inclusive, who have enrolled in ATN 106.
88898643|NCT01492855|Experimental|Operative treatment|
88898644|NCT01492855|Experimental|Conservative treatment|
88898645|NCT01492881|Experimental|Vorinostat, Bortezomib, Doxil|"Induction therapy will consist of up to 8 cycles of vorinostat, bortezomib, and doxil. One cycle is defined as 21 days.~Maintenance therapy will consist of Vorinostat and bortezomib. One maintenance cycle is 28 days and repeated for up to 1 year."
88898646|NCT01492894|Active Comparator|50% decrease in calcineurin inhibitor|
88898647|NCT01492894|Active Comparator|Rapamune|
88898648|NCT01492907|Active Comparator|Healthy Control Participants|age/sex matched normal controls - the subject will swallow a capsule with a dietary relevant dose of MeIQx
88898649|NCT01492907|Active Comparator|Pancreatic Cancer Patients|Patients with operable pancreatic cancer scheduled for a pancreatectomy at the University of Minnesota Medical Center.
88898650|NCT01492920|Experimental|Arm I (acetyl-L-carnitine hydrochloride)|Patients receive ALC PO BID on days 1-21 (during chemotherapy treatment).
88898651|NCT01492920|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID on days 1-21 (during chemotherapy treatment) (maximum of 8 courses).
88898652|NCT01492946||Elective surgical patients|Elective surgical patients in the Charité University Berlin Campus Charité Mitte
88898653|NCT01492959||Insulin human|
88898654|NCT01492985|Placebo Comparator|Vaccine placebos|Vaccine placebos corresponding to the dilutant of these vaccines
88898655|NCT01492985|Experimental|Vaccine arm|
88898656|NCT01492998|Experimental|Guggulsterone|One arm of 15 chronically HCV genotype one infected patients
88898657|NCT01493011|Experimental|chemotherapy & WBH|Standard chemotherapy protocol combined with whole body hyperthermia
89419738|NCT04957810|No Intervention|Patients who are given regular home functional exercises and discharged from the hospital|Discharge guidance using regular home function exercises, that is, existing regular missions and paper-based brochures
88898658|NCT01493011|No Intervention|chemotherapy|standard chemotherapy protocol for advanced NSCLC
88898659|NCT01493037|Other|PICSO|PICSO treatment for 90 minutes
88898660|NCT01493050|Experimental|Sevelamer Carbonate|1600 mg (two 800 mg in the form of tablets or powder to be diluted in water) TID with meals for 26 weeks
88898661|NCT01493050|Active Comparator|calcium carbonate|1200 mg of calcium carbonate TID with meals for 26 weeks
88898662|NCT01493076||Baby-S group|The baby-sphincterotome was in patients in whom biliary sphincterotomy was clinically indicated but in whom after standard techniques to gain biliary access had failed (study population).
88898663|NCT01493102|Active Comparator|Vasopressin|Vasopressin will be reduced first (0.01 U/hour)
88898664|NCT01493102|Active Comparator|Norepinephrine|Norepinephrine: Norepinephrine will be reduced first (0.1 microgram/kg/hour)
88898665|NCT01493115|Experimental|Sequence 1|Reference (insulin glargine) - Test1 (insulin glargine - new formulation dose 1) - Test2 (insulin glargine - new formulation dose 2)
88898666|NCT01493115|Experimental|Sequence 2|Test1 (insulin glargine - new formulation dose 1) - Test2 (insulin glargine - new formulation dose 2) - Reference (insulin glargine)
88898667|NCT01493115|Experimental|Sequence 3|Test2 (insulin glargine - new formulation dose 2) - Reference (insulin glargine) - Test1 (insulin glargine - new formulation dose 1)
88898668|NCT01493128||stable sinus rhythm|
88898669|NCT01493128||permanent atrial fibrillation|
88898670|NCT01493128||paroxysmal atrial fibrillation|
88898671|NCT01493141||MOMHR|Patients who have had metal-on metal hip resurfacing (MOMHR)
88898672|NCT01493141||THA|Patients who have had metal-on-polyethylene or ceramic total hip arthroplasty (THA)
88898673|NCT01493154|Experimental|Cohort 1 - DNA Vaccine (Dose 0.5 mg/dose)|pNGVL-4a-CRT/E7 (detox) DNA Vaccine (Dose 0.5 mg/dose) + Cyclophosphamide (200 mg/m2)
88898674|NCT01493154|Experimental|Cohort 2 - DNA Vaccine (Dose 1.0 mg/dose)|pNGVL-4a-CRT/E7 (detox) DNA Vaccine (Dose 1.0 mg/dose) + Cyclophosphamide (200 mg/m2)
88898675|NCT01493154|Experimental|Cohort 3 - DNA Vaccine (Dose 2.0 mg/dose)|pNGVL-4a-CRT/E7 (detox) DNA Vaccine (Dose 2.0 mg/dose) + Cyclophosphamide (200 mg/m2)
89419739|NCT04957810|Active Comparator|Patients who are guided by conventional discharge guidance and the optimized WeChat official account|Use regular discharge guidance and optimized WeChat public account guidance
89419740|NCT02226354|Active Comparator|Flaxseed oil|9.73ml Flaxseed oil once daily, for 28 days
89419741|NCT02226354|Experimental|Ahiflower oil|9.73ml Ahiflower oil once daily, for 28 days
89419742|NCT04957654|Experimental|VST with collagen plug soaked in blood|
89419743|NCT04957654|Active Comparator|VST with Allograft Demineralized bone matrix Grafton|
89419744|NCT04957654|Active Comparator|VST with autogenous cortical chips and bovine deprotinzed particles|
89419745|NCT02223000|Active Comparator|BIBV 308 SE solution|
89419746|NCT02223000|Experimental|BIBV 308 SE capsule 1|
89419747|NCT02223000|Experimental|BIBV 308 SE capsule 2|
89419748|NCT04957420||Neupro gruop|Patients using Neupro according to the standard clinical practice of therapists
89419749|NCT03350035|Experimental|IV Ganaxolone active|Ganaxolone IV loading dose with continuous infusion (maintenance dose) for 2-4 days followed by an 18-hour taper.
89419750|NCT03350035|Placebo Comparator|IV Placebo, non-active|Placebo IV loading dose with continuous infusion (maintenance dose) for 2-4 days followed by an 18-hour taper.
89419751|NCT02223078|Experimental|G17DT|Three 250 µg injections over a six week period (weeks 0,2 and 6)
89419752|NCT02223078|Placebo Comparator|Placebo|Three 250 µg injections of a placebo over a six week period (weeks 0,2 and 6)
89419753|NCT04957108||All cardiac implantable devices|Assessed separately by Pacemaker ID app and cardia-x algorithm
89419754|NCT02905188|Experimental|GLYCAR T cells + Fludarabine and Cytoxan|GPC3-CAR (GLYCAR T cells) along with lymphodepleting chemotherapy (Cytoxan and Fludarabine) will be administered to patients with hepatocellular carcinoma.
89419755|NCT03676933|Experimental|DS107E and Steroid|First 7 days: Steroid taken topically once a day and DS107E taken once a day Next 56 days: DS107E taken topically twice a day
89419756|NCT03676933|Placebo Comparator|Vehicle and Steroid|First 7 days: Steroid taken topically once a day and DS107E taken once a day Next 56 days: DS107E taken topically twice a day
89419757|NCT04957030|Experimental|ULDCT group|underwent ultralow-dose chest CT(ULDCT)
89419758|NCT04957030|No Intervention|LDCT group|underwent conventional chest CT(LDCT)
89419759|NCT02232204|Active Comparator|CBT for Insomnia in ICD Patients (CBT-I-ICD)|Participants will complete 4 weekly therapy sessions focused on improving sleep and reducing ICD-related stress. A multicomponent CBT-I-ICD (Cognitive Behavioral Therapy for Insomnia in ICD Patients) protocol will involve: sleep hygiene, stimulus control, sleep restriction, relaxation, cognitive restructuring, ICD education and recall information, shock planning, and quality of life-improvement recommendations.
89419760|NCT02232204|No Intervention|Waitlist Control (WLC)|Participants in the WLC group will not receive any treatment between the baseline and post-treatment assessments. After the final follow-up assessment, they will be offered the opportunity to receive CBT-I-ICD.
89419761|NCT03671941|Active Comparator|Group A|D578 Tab. 1T
89419762|NCT03671941|Experimental|Group B|CKD-357 Tab. 1T
89419763|NCT03058900|Experimental|Fecal microbiota transplantation (FMT)|
89419764|NCT03058900|Sham Comparator|Placebo (saline)|
89419765|NCT02226510|Placebo Comparator|Placebo|Placebo capsules (with an identical appearance to the active drug) and containing only microcrystalline cellulose PhEur
89419766|NCT02226510|Active Comparator|Metformin XL|In the active arm, the added therapy will be metformin XL in an initial dose of 1000mg/day (metformin XL 500mg x2/day). They will continue on Metformin XL 500mg x2/day for two weeks and after safety blood checks the metformin XL dose will be increased to 2000 mg/day. If the higher dose cannot be tolerated the dose will be reduced to 1000mg/day (and stopped if this cannot be tolerated).
89419767|NCT03676855|Active Comparator|bladder dissection before uterine incision|
89419768|NCT03676855|Experimental|bladder dissection after uterine incision|
88898676|NCT01493154|Experimental|Cohort 4 - DNA Vaccine (Dose 4.0 mg/dose)|pNGVL-4a-CRT/E7 (detox) DNA Vaccine (Dose 4.0 mg/dose) + Cyclophosphamide (200 mg/m2)
88898677|NCT01493193|Active Comparator|Endurance training with constant work load|
88898678|NCT01493193|Experimental|Pyramid-Training|
88898679|NCT01493193|Experimental|High-intensity interval training|
88898680|NCT01493206|Experimental|intraoperative radiotherapy|
88898681|NCT01493232|Experimental|Denture, edentulous patient, treatment|Dentures with different type of occlusion
88898682|NCT01493232|Experimental|Denture, Edentulous patient, treatment|Dentures with different type of occlusion
88898683|NCT01493245|Experimental|JNS020QD|
88898684|NCT01493258|No Intervention|Control Group|The study participants randomized to the Group 2 will serve as a control. At the beginning of the study, they will receive a CERSG brochure printed from the AHRQ site. They will be asked to study it to the best of their ability throughout the day.
88898685|NCT01493258|Experimental|iCOPE Intervention group|iCOPE intervention group will receive a CERSG brochure via the iCOPE system.
88898686|NCT01493297|Other|Retinyl palmitate|Labeled iron as FeSO4 (4 mg) added to a test meal with or without retinyl palmitate (1000 RE)
88898687|NCT01493297|Other|Beta-carotene|Labeled iron as FeSO4 (4 mg) added to a test meal with or without beta-carotene (1000 RE)
89419769|NCT04956874|Experimental|Experimental Group|Participants will complete the FL-REACH annualized caregiver intervention.
88898688|NCT01493310|Experimental|Arm A (hormone therapy, chemotherapy)|Patients will receive mifepristone and nab-paclitaxel in 28-day treatment cycles. Patients receive mifepristone once a day by mouth on days 0, 1, 7, 8, 14, and 15 and nab-paclitaxel by intravenous infusion (IV) on days 1, 8, and 15. Treatment cycles are repeated every 28 days in the absence of disease progression or unacceptable side effects.
88898689|NCT01493310|Active Comparator|Arm B (chemotherapy)|"Patients will receive nab-paclitaxel and placebo for a 28-day treatment cycle (Cycle 1).~Patients receive placebo once a day by mouth on days 0, 1, 7, 8, 14, and 15 and nab-paclitaxel by intravenous infusion (IV) on days 1, 8, and 15. Patients then cross-over to Arm A after completion of the first treatment cycle."
89419770|NCT04956874|No Intervention|Control Group|No-intervention control group
89419771|NCT03676777||Infection|Patients admitted or developed bacterial/fungal infection while hospitalization
89419772|NCT03676777||Non-infection|Patients without bacterial/fungal infection
89419773|NCT04956562||Vaccinated with sinovac|Vaccinated COVID-19 patients over 65 years consisted the study group
89419774|NCT04956562||Unvaccinated|Unvaccinated patients over 65 years composed the control group
89419775|NCT02223156||MediYoga|
89419776|NCT02223156||Music relaxation|
89419777|NCT02223156||No treatment|
89419778|NCT02225886|Experimental|Ascorbic acid|Patients will receive a 300 mg intravenous ascorbic acid, 3 times a week, postdialysis, except for the dialysis sessions when iv iron is administered.
89419779|NCT02225886|Placebo Comparator|Control group|Patients will receive 100 mL saline solution, 3 times a week, with associated medication, except but the dialysis sessions when iv iron is administered.
89419780|NCT04956328|Experimental|OCA Tablets 5-10 mg|OCA 5 mg once daily in combination with UDCA for 24 weeks and then titrating up to 10 mg based on tolerability and response for remainder of double-blind period.
89419781|NCT04956328|Placebo Comparator|Placebo|Placebo once daily in combination with UDCA for 48 weeks.
89419782|NCT02223234|Active Comparator|Control|Control- monthly mailed information on children's health
88898690|NCT01493323|Experimental|Control|
88898691|NCT01493323|Experimental|Depressive attempters|
88898692|NCT01493336|Experimental|Capecitabine RTD|
88898693|NCT01493336|Active Comparator|Xeloda|
88898694|NCT01493349||Controls|No diverticular disease or other gastrointestinal and liver diseases
88898695|NCT01493349||Uncomplicated diverticular disease|
88898696|NCT01493349||History of complicated diverticular disease|
88898697|NCT01493349||Current complicated diverticular disease|
89419783|NCT02223234|Experimental|Email and 4 Home Visits|Weekly emails and 4 home visits with a health educator
89419784|NCT02223234|Experimental|Email and 2 Home Visits|Weekly emails and 2 home visits
89419785|NCT03671863||Infants who are treated for clubfoot|Infants who are treated for clubfoot in the reference reeducation center
88898698|NCT01493362||1|Participants with Bulimia Nervosa
89419786|NCT02223312|Experimental|TAPA-pulsed DC vaccine|The subject will take low-dose cyclophosphamide by mouth for 5 days starting 7 days prior to the vaccine cycle. The vaccine contains 1 x 10^7 TAPA-pulsed dendritic cells and is administered SQ with low-dose GM-CSF following the low-dose cyclophosphamide cycle. A total of six (6) cycles of cyclophosphamide and six (6) DC vaccines cycles will be administered alternating every 14 days.
88898699|NCT01493362||2|Participants who are healthy controls
88898700|NCT01493388||A|
88898701|NCT01493401|Experimental|Midurethral sling|Currently available midurethral procedures for stress urinary incontinence can be used.
88898702|NCT01493440|Other|Atosiban|
89419787|NCT04426656|No Intervention|Part 2 Standard of Care|Participants will receive written HIV prevention materials including basic facts of PrEP, recommendations for HIV/STI(sexually transmitted infections) testing and referrals to local HIV/STI testing sites and prevention services.
88898703|NCT01493466||Normal|normal person under physical examination
88898704|NCT01493466||SIRS|"temperature >38 ℃ or <36℃;~pulse rate>90 beats/min;~ventilatory rate>20 breaths/min or hyperventilation with partial pressure of arterial carbon dioxide (PaCO2)<32mmHg;~white blood cell count>12,000μL-1 or <4000μL-1 or >10% immature cells"
88898705|NCT01493466||spesis|sepsis is defined as SIRS plus confirmed infection.
88898706|NCT01493466||severe sepsis|"severe sepsis: sepsis associated with organ dysfunction, hypoperfusion, or hypotension;~septic shock: sepsis with arterial hypotension, despite adequate ﬂuid resuscitation."
88898707|NCT01493466||death|sepsis patients within 48 hours before death
88898708|NCT01493479|Experimental|Fractionated Initial Zevalin|
88898709|NCT01493492||SIRS|"temperature >38 ℃ or <36℃;~pulse rate>90 beats/min;~ventilatory rate>20 breaths/min or hyperventilation with partial pressure of arterial carbon dioxide (PaCO2)<32mmHg;~white blood cell count>12,000μL-1 or <4000μL-1 or >10% immature cells"
88898710|NCT01493492||sepsis|"Sepsis~sepsis: SIRS plus infection;~severe sepsis: sepsis associated with organ dysfunction, hypoperfusion, or hypotension;~septic shock: sepsis with arterial hypotension, despite adequate ﬂuid resuscitation."
88898711|NCT01493492||non-survivors with sepsis|sepsis patients who died within 28 days
88898712|NCT01493518|Placebo Comparator|PLACEBO|
88898713|NCT01493518|Experimental|AMG 557|
88898714|NCT01493583||severely obese women|
88898715|NCT01493583||Women after Roux-en Y gastric bypass surgery|Women recruited for this group had undergone Roux-en Y gastric bypass surgery at least one year before. In this women measurement of brain activity and gastrointestinal and metabolic response took place between 13 and 106 month after surgery.
88898716|NCT01493583||lean women|
88898717|NCT01493609|No Intervention|Waitlist Control|
89419788|NCT04426656|Experimental|Part 2 mini-app|In addition to the standard of care, participants in the mini-app arm will have access to the mini-app (i.e. the intervention) during the whole study period.
88898718|NCT01493609|Experimental|Click-East app|Participants will receive a copy of the game immediately following recruitment and assessment.
88898719|NCT01493622|Placebo Comparator|placebo|Subjects will be given with 200mg/day placebo(100mg,bid) and variable dose SGA. All drugs will be administered orally.
88898720|NCT01493622|Active Comparator|minocycline|Subjects will be given with 200mg/day minocycline (100mg,bid)and variable dose SGA.All drugs will be administered orally.
88898721|NCT01493635|Active Comparator|Standard 3 Step approach.|Standard 3 Step approach of the WHO analgesic ladder (Step 1 - Step 2 - Step 3).
88898722|NCT01493635|Experimental|2 Step approach.|2 Step approach of the WHO analgesic ladder (Step 1 - Step 3).
88898723|NCT01493648|Experimental|Vitamin D|
88898724|NCT01493648|Placebo Comparator|Placebo|
89419789|NCT04955782||62-84 hours of abstinence|samples will be analyzed for semen volume, pH, count, concentration, motility, morphology and viability
88898725|NCT01493661||Group 1|Men with Total Sleep Time ≤ 6h that will undergo 25 percent of chronic sleep restriction of their TST
88898726|NCT01493661||Group 2|Men with Total Sleep Time (range 7-8h)that will undergo 25 percent of chronic sleep restriction of their TST
88898727|NCT01493661||Group 3|Men with Total Sleep Time ≥ 9h that will undergo 25 percent of chronic sleep restriction of their TST
88898728|NCT01493674|No Intervention|placebo tablets|two identical tablets, but composed of crystalline cellulose, lactose and colouring
88898729|NCT01493674|Experimental|a suplemented group|two 5-mg tablets of folic acid
88898730|NCT01493700|Experimental|control|use routine respiratory circuit during mechanical ventilation of anesthetic machine during shoulder arthroscopy
88898731|NCT01493700|Active Comparator|electrically heated circuit|use routine respiratory circuit during mechanical ventilation of anesthetic machine during shoulder arthroscopy
88898732|NCT01493713|Experimental|Bevacizumab, XELOX|Bevacizumab in combination with XELOX
88898733|NCT01493726|Experimental|ALKS 9072, Low dose|
88898734|NCT01493726|Experimental|ALKS 9072, Med dose|
88898735|NCT01493726|Experimental|ALKS 9072, High dose|
88898736|NCT01493726|Placebo Comparator|Placebo|
88898737|NCT01493739||lymphadenopathy|
88898738|NCT01493752|Active Comparator|Nitrate-rich beetroot juice|Six weeks once daily dose of nitrate rich beetroot juice
88898739|NCT01493752|Placebo Comparator|Nitrate deplete beetroot juice|six weeks daily dose beetroot juice (nitrate deplete)
88898740|NCT01493765||Benchmarking|All resident study subjects will drill virtual temporal bones within the computer based system. The performance data will be used to validate the rating metrics and computer scoring process.
89419790|NCT04955782||1-3 hours of abstinence|samples will be analyzed for semen volume, pH, count, concentration, motility, morphology and viability
89419791|NCT03058822|Experimental|Prefilled Syringe Upper Arm|Single subcutaneous dose from prefilled syringe into upper arm of BMS-931699
88898741|NCT01493817||Basic science (biomarker analysis)|Paraffin-embedded specimens are analyzed for macrophage markers. Results of each sample are then compared with patient's tumor stage, presence of vascular invasion, tumor progression, and survival.
89419792|NCT03058822|Experimental|Prefilled Syringe Thigh|Single subcutaneous dose from prefilled syringe into thigh of BMS-931699
89419793|NCT03058822|Experimental|Prefilled Syringe Abdomen|Single subcutaneous dose from prefilled syringe into abdomen of BMS-931699
89419794|NCT03058822|Experimental|Drug in Vial Upper Arm|Single subcutaneous dose from drug in vial into upper arm of BMS-931699
88898742|NCT01493843|Experimental|Arm A: 340 mg pictilisib + CP|Participants with advanced (Stage IV) or recurrent squamous NSCLC will be administered 340 mg pictilisib plus carboplatin (C) plus paclitaxel (P).
88898743|NCT01493843|Placebo Comparator|Arm B: Placebo + CP|Participants with advanced (Stage IV) or recurrent squamous NSCLC will be administered placebo corresponding to 340 mg pictilisib plus carboplatin (C) plus paclitaxel (P). Participants with investigator assessed radiographic progression of NSCLC per RECIST 1.1 will be allowed to cross over to Arm A during the first 4 cycles with carboplatin + paclitaxel or after chemotherapy has been completed (Cycle >/= 5).
88898744|NCT01493843|Experimental|Arm C: 340 mg pictilisib + CPB|Participants with advanced (Stage IV) or recurrent non-squamous NSCLC will be administered 340 mg pictilisib plus carboplatin (C) plus paclitaxel (P) plus bevacizumab (B).
88898745|NCT01493843|Placebo Comparator|Arm D: Placebo + CPB|Participants with advanced (Stage IV) or recurrent non-squamous NSCLC will be administered placebo corresponding to 340 mg pictilisib plus carboplatin (C) plus paclitaxel (P). Participants with investigator assessed radiographic progression of NSCLC per RECIST 1.1 will be allowed to cross over to Arm C during the first 4 cycles with carboplatin + paclitaxel + bevacizumab or after chemotherapy has been completed (Cycle >/= 5).
88898746|NCT01493843|Experimental|Arm E: 260 mg pictilisib + CPB|Participants with advanced (Stage IV) or recurrent non-squamous NSCLC will be administered 260 mg pictilisib plus carboplatin (C) plus paclitaxel (P) plus bevacizumab (B).
88898747|NCT01493843|Placebo Comparator|Arm F: Placebo + CPB|Participants with advanced (Stage IV) or recurrent non-squamous NSCLC will be administered placebo corresponding to 260 mg pictilisib plus carboplatin (C) plus paclitaxel (P). Participants with investigator assessed radiographic progression of NSCLC per RECIST 1.1 will be allowed to cross over to Arm E during the first 4 cycles with carboplatin + paclitaxel + bevacizumab or after chemotherapy has been completed (Cycle >/= 5).
88898748|NCT01493856|Active Comparator|Rosuvastatin+Olmesartan|single dose of Rosuvastatin 20mg and olmesartan medoxomil(CS-866) 40mg
88898749|NCT01493856|Experimental|DWJ1276|Single dose of DWJ1276
88898750|NCT01493869|Experimental|Group 1|Subjects with normal hepatic function: healthy normal adult subjects
88898751|NCT01493869|Experimental|Group 2|Subjects with mild hepatic impairment: adult subjects with a Child-Pugh grade A (score 5-6).
88898752|NCT01493869|Experimental|Group 3|Moderate hepatic impairment: adult subjects with a Child-Pugh grade B (score 7-9).
88898753|NCT01493869|Experimental|Group 4|Severe hepatic impairment: adult subjects with a Child-Pugh grade C (score 10-15).
88898754|NCT01493882|Placebo Comparator|Placebo|
88898755|NCT01493882|Experimental|JNJ-39758979 30 mg/d|
88898756|NCT01493882|Experimental|JNJ-39758979 100 mg/d|
89419795|NCT03058822|Experimental|Drug in Vial Thigh|Single subcutaneous dose from drug in vial into thigh of BMS-931699
89419796|NCT03058822|Experimental|Drug in Vial Abdomen|Single subcutaneous dose from drug in vial into abdomen of BMS-931699
89419797|NCT03671707|Experimental|Intervention group|Brief AWARD advice + Nicotine replacement therapy sampling + Active referral
89419798|NCT03671707|Active Comparator|Control group|Very brief advice (VBA) + Leaflet
88898757|NCT01493882|Experimental|JNJ-39758979 300 mg/d|
88898758|NCT01493895|Active Comparator|control group,|The control group will be treated with a sham B-cure laser machine, emitting only green indicator light and no 808nm laser.
88898759|NCT01493895|Experimental|study, LLLT-808 B-cure laser machine|The study group will be treated with the LLLT-808 B-cure laser machine, emitting the 808nm laser beam together with a green indicator light.
88898760|NCT01493908|Active Comparator|High price|
88898761|NCT01493908|Active Comparator|Low price|
88898762|NCT01493908|Active Comparator|Low price participants aware paying part|
88898763|NCT01493908|Active Comparator|No price|
88898764|NCT01493908|Active Comparator|Free of charge|
89419799|NCT02226588|Experimental|Secondary prevention|Single sublingual dose of 800mcg (4 tablets) misoprostol administered to women with 350-500mL postpartum blood loss as estimated using a blood absorption mat or due to deteriorating postpartum condition of the woman as determined by provider's clinical judgment
89419800|NCT02226588|Active Comparator|Universal prophylaxis|Single oral prophylactic dose of 600mcg (3 tablets) misoprostol administered to all women within 1 minute of deliver of baby
89419801|NCT04955548|Experimental|arthroscopic microfracture with autologous adipose gel|The experimental group will be treated with arthroscopic microfracture with autologous adipose gel.
89419802|NCT04955548|Active Comparator|arthroscopic microfracture|The control group will be treated with arthroscopic microfracture.
88898765|NCT01493921|Experimental|SR-T100 gel|Patient group receiving medication SR-T100 gel with active ingredient under investigation, enrolled subjects randomly assigned to this group to accurately depict statistical significance of the measured outcome.
88898766|NCT01493921|Active Comparator|Vehicle gel|Patients given placebo with non-SR-T100 ingredients as they are being administered to patients, subjects are under random assignments from patient pool to depict statistically significant outcome measurement.
88898767|NCT01493934|Active Comparator|Healthy volunteers|First injection in human, on 6 healthy volunteers, sequentially : volunteer number1, then volunteers n°2 to n° 6, before infusion in type 2 diabetic patients.
88898768|NCT01493934|Experimental|type 2 diabetic patients|After completion of the study for the 6 healthy volunteers, infusion in 6 type 2 diabetic patients.
88898769|NCT01493973|Experimental|Epoetin alfa|Patients will be treated with Epoetin alfa 1200 IU/Kg s.c. every 12 weeks
89419803|NCT03676621|Experimental|study group|patients will receive buccal misoprostol
89419804|NCT03676621|Active Comparator|control group|patients will receive intravenous oxytocin
88898770|NCT01493973|Placebo Comparator|Placebo|Placebo 1200 IU/Kg s.c. every 12 weeks
88898771|NCT01493999|Active Comparator|Prasugrel arm|A loading dose of 60 mg prasugrel in patients with HPR after 600 mg clopidogrel.
88898772|NCT01493999|Active Comparator|Clopidogrel reloading|A maximum of three adjusted loading doses of 600 mg clopidogrel until normal platelet reactivity is achieved in patients with HPR after the first 600 mg clopidogrel.
89419805|NCT02226666||Patients having MRI with Eovist|Subjects having a clinically ordered MRI with Eovist. Patients consenting for the study will be monitored before and after getting MRI contrast. For the study oxygen saturation (amount of oxygen level in the blood) and breathing will be monitored during the can. Breathing will be measured with a non-invasive respiratory monitoring device attached to the MR scanner. Each patient will answer survey questions after the scan about their experiences concerning MRI contrast.
89419806|NCT02226666||Patients having MRI with Multihance|Subjects having a clinically ordered MRI with Multihance. Patients consenting for the study will be monitored before and after getting MRI contrast. For the study oxygen saturation (amount of oxygen level in the blood) and breathing will be monitored during the scan. Breathing will be measured with a non-invasive respiratory monitoring device attached to the MR scanner. Each patient will answer survey questions after the scan about their experiences concerning MRI contrast.
88898773|NCT01494012|Experimental|Treatment (SBRT)|Patients undergo SBRT 5 days a week for approximately 1 week in the absence of disease progression or unacceptable toxicity.
88898774|NCT01494025|Experimental|Diet and Exercise|
88898775|NCT01494064||Retrospective|Included patients have been no specific nursing practice.
89419807|NCT03678649|Experimental|the treatment arm|"1000-1250 mg/m2 orally twice daily for 14 days followed by a 1-week rest period, given as 3- week cycles for a total of 6 cycles .~it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent"
89419808|NCT03678649|No Intervention|the control arm|clinical observation
89419809|NCT04955860||Study Group|Individuals with bilateral posterior crossbite will be included.
89419810|NCT04955860||Control Group|Individuals with no anterior and/or posterior crossbite and transversal malocclusion will be included.
89419811|NCT02886156|Experimental|CPAP plus BSC|Participants in the CPAP plus BSC group will receive CPAP treatment plus the aforementioned BSC intervention. CPAP treatment (LOTUS AUTO; Curative Medical Technology Inc., Beijing, China) will be initiated using standard clinical practice at each center.
89419812|NCT02886156|Active Comparator|BSC intervention|Participants in the BSC only group will receive advice regarding lifestyle modification, sleep hygiene, naps, exercise, caffeine, and diet, and avoiding alcohol consumption, but no specific weight loss program, diet, or salt restriction will be suggested.
89419813|NCT03678571|Experimental|Latrunculin A supplemented vitrification medium|
89419814|NCT03678571|No Intervention|Vitrification medium with no supplementation|
89419815|NCT04955392|Experimental|Intervention group|Group of patients that will receive the 4 techniques proposed to evaluate the changes on sleep quality
88898776|NCT01494064||Prospective|Standardization of nursing supervision of included patients using a grid of appropriate surveillance for the prevention of complications in the ICU
88898777|NCT01494077||EUS-FNA of Pancreatic Cyst|Patients who have a pancreatic cyst requiring standard of care EUS-FNA that yields 2.25 ML (or greater) of fluid will be included in the study.
89419816|NCT04955392|Sham Comparator|Control group|Group of patients that will receive a sham technique
89419817|NCT02226744|Active Comparator|Focused breathing|Focused deep breathing techniques used to produce specific physiological and psychological states
89419818|NCT02226744|Active Comparator|Focused breathing 2|Focused deep breathing techniques used to produce specific physiological and psychological states
89419819|NCT03671629|Experimental|Intervention group|In addition to a standard medication review at the hospital, this group also receives an enhanced clinical pharmacist service during 180 days after discharge from the hospital.
89419820|NCT03671629|No Intervention|Control group|This group receives standard care, which might include a medication review at the hospital.
89419821|NCT02226822||Adult patients with documented T2DM|Adult patients with documented history of type 2 diabetes mellitus who are initiating their second line oral or parenteral anti-diabetics medication after first line oral diabetic therapy
89419822|NCT02845297|Experimental|Safety Run In Phase (only Cohort 1):|The treatment of relapsed and refractory AML patients.
89419823|NCT02845297|Experimental|Cohort 2|The treatment of newly diagnosed AML patients (≥ 65 years) who are not candidates for intensive induction chemotherapy.
89419824|NCT04954534|Experimental|NEUROSTEM (hUCB-MSCs) - high dose|human umbilical cord blood-derived mesenchymal stem cells High dose: 3 x 10^7 cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4-week intervals
89419825|NCT03678415|Experimental|Control|In the control arm, the community healthcare providers serve usual health education like counseling as they provided in perinatal period of enrolled mothers regular follow up basis. This health education is different from developed intervention. But service provider does not know. The investigators select community clinic before provide training regarding training manual. For this, the investigators selected 11 cluster randomly among the 23 community clinics' in the primary health care in study area and provide common health education instructions to the enrolled mothers. But service providers does not know the intervention package services that will provide in intervention arm's service providers.
88898778|NCT01494090|Active Comparator|Rosuvastatin|
88898779|NCT01494090|Placebo Comparator|placebo|
88898780|NCT01494116|Experimental|10 mL syringe size|
88898781|NCT01494116|Experimental|20 mL syringe size|
88898782|NCT01494116|Experimental|30 mL syringe size|
88898783|NCT01494116|Experimental|60 mL syringe size|
89419826|NCT02223468||CASE-CONTROL|CASE: Liver transplant recipients (n=20) CONTROL: A healthy person with a similar age (±10 years) to the control selected from the same family setting (n=20)
89419827|NCT03671551||Psychomotor/psychological evaluation|Children in the study aged 6 to 30 months followed or referred to CHIC for oral disorders will have a psychomotor assessment and a psychological interview. Questionnaires on eating behavior will also be proposed.
89419828|NCT04954924|No Intervention|Control group - standardized physiotherapy program|The standardized physiotherapy program was designed on the basis of S. van Grinsven et al.'s (2010) rehabilitation protocol - was applied 4 weeks, 3 times per week, the duration of the procedure was 60 minutes.
89419829|NCT04954924|Experimental|Experimental group - standardized physiotherapy program and Kinesio tape|The standardized physiotherapy program was designed on the basis of S. van Grinsven et al.'s (2010) rehabilitation protocol - was applied 4 weeks, 3 times per week, the duration of the procedure was 60 minutes. The Kinesio tape (KT) technique was chosen on the basis of K. Kase et al.'s (2003) recommendations. KT (Japan) was applied to the injured leg using muscular and functional-corrective techniques on the quadriceps femoris and the hamstring muscle. There were 6 KT procedures per participant in the experimental group. The CON group received KT only during the baseline and final assessment to assess short-term effect of KT.
89419830|NCT04954378||Positive lymph node metastasis|pathological diagnosis :Positive lymph node metastasis
89419831|NCT04954378||Negative lymph node metastasis|pathological diagnosis :Negative lymph node metastasis
88898784|NCT01494142||ADEH-Staph+|Atopic Dermatitis without a history of Eczema Herpeticum and with S. aureus skin colonization. A minimum of 1100 participants will be enrolled; we will target 500 Non-Hispanic Caucasian, 300 Non-Hispanic African American, and 300 Mexican American Caucasian ADEH-Staph+ participants. Although we will target these three groups, no racial/ethnic groups will be excluded.
89419832|NCT03676387|No Intervention|Aged based group (group AB) (n = 27)|ETT size was determined according to age
89419833|NCT03676387|Active Comparator|Ultrasound based group (group UB) (n = 27): ETT was determined|ETT was determined according to the subglottic transverse diameter that was estimated with ultrasonography.
89419834|NCT02226900|Experimental|Hybrid Revascularization|The hybrid myocardial revascularization group will be accomplished by a two-step scheme, comprised by off-pump LIMA-to-left anterior descending grafting, followed by percutaneous coronary interventions with Promus Element (everolimus second generation drug eluting stent) for the remaining coronary lesions.
89419835|NCT02226900|Other|Conventional Surgical Coronary Bypass Grafting|Conventional Coronary Artery Bypass Grafts with in pump technique.
89419836|NCT04954456|Experimental|QLS31901|"Part 1 (Dose escalation): QLS31901will be administered in sequential cohorts each receiving 1 of 6 doses of QLS31901 on day 1 of every 21-day cycle (3 weeks) via IV infusion. Dose escalation will continue until an MTD is reached.~Part 2 (Dose Expansion): The PK parameters of QLS31901 will be tested at 2-3 doses determined during the dose-escalation phase in subjects with advanced malignant tumor cohorts."
89419837|NCT02232360|Experimental|Rosuvastatin and fenofibrate|Combination therapy: rosuvastatin 10 mg and fenofibrate 160 mg per day
89419838|NCT02232360|Active Comparator|Rosuvastatin alone|Rosuvastatin 10 mg per day
89419839|NCT03676309|Placebo Comparator|placebo|placebo tablet twice a day twenty minutes before main meals, for 12 weeks,
89419840|NCT03676309|Active Comparator|nutraceutical oral capsule|nutraceutical oral capsule 920 mg twice a day for 12 weeks
89419841|NCT04954144|Experimental|Leap Motion Sensor|The Leap Motion Sensor is an optical hand tracking module that captures the movements of hands with unparalleled accuracy.
89419842|NCT04954144|Experimental|Neurodevelopmental Treatment Approach|Neurodevelopment treatment approach is used to influence the quality of the motor response and is carefully matched to the patient's abilities to use sensory information and adapt movements.
89419843|NCT02232438|Experimental|Behavioral activation therapy|Patients treated with Behavioral activation therapy will improve in mood and anxiety symptoms and psychosocial functioning at the end of the 6 weeks of treatment.
89419844|NCT03678337||Observational cohort with plasma samples|
89419845|NCT04953676|Other|Control Group|round tunnel
89419846|NCT04953676|Experimental|Experimental group|flat tunnel
89419847|NCT02226978|Experimental|TPV/r with valaciclovir|VAL 2 days (on days 1 and 13), TPV/r 12 days (on days 2 to 13)
89419848|NCT02831959|Experimental|NovoTTF-200M device|"NovoTTF-200M device Patients undergo SRS followed by continuous TTFields treatment using the NovoTTF-200M device. TTFields treatment will consist of wearing four electrically insulated electrode arrays on the head.~The treatment enables the patient to maintain regular daily routine."
89419849|NCT02831959|Active Comparator|Best Standard of Care|Patients will undergo SRS alone and be treated with the best known standard of care for Non-Small Cell Lung Cancer metastatic to the brain.
89419850|NCT04953832|Experimental|Cognitive Training + exposure|Participants will complete adaptive computerized cognitive training plus a series of speech tasks
89419851|NCT04953832|Active Comparator|No training + exposure|Participants will complete a low-dose computerized cognitive program plus a series of speech tasks
89419852|NCT04953520|Experimental|Ultrasound-CT fusion imaging guidance|The patient undergoes lumbar nerve root block guided puncture needle placement under the guidance of ultrasound-CT fusion imaging
88898785|NCT01494142||ADEH-Staph-|Atopic Dermatitis without a history of Eczema Herpeticum and without S. aureus skin colonization. A minimum of 1100 participants will be enrolled; we will target 500 Non-Hispanic Caucasian, 300 Non-Hispanic African American, and 300 Mexican American Caucasian ADEH-Staph- participants. Although we will target these three groups, no racial/ethnic groups will be excluded.
89419853|NCT04953520|Active Comparator|Pure ultrasound guidance|The patient undergoes lumbar nerve root block guided puncture needle placement under the guidance of pure ultrasound guidance
88898786|NCT01494142||ADEH+|Atopic Dermatitis with previous or current Eczema Herpeticum.We will try to include a minimum of 150 Non-Hispanic Caucasian ADEH+ participants. ADEH+ participants of other racial/ethnic groups will not be excluded
88898787|NCT01494142||ADEV+|Atopic Dermatitis with previous or current Eczema Vaccinatum. ADEV+ sub-phenotype is very rare so all eligible participants will be enrolled.
88898788|NCT01494142||Non-atopic|Non-atopic healthy participants. A minimum of 250 non-atopic participants will be enrolled. Non-atopic participants will serve as a control group for the genetic, biomarker, Staph characterization, and microbiome studies.
89419854|NCT04359030||Freestyle group|Patients treated with a Freestyle aortic valve bioprosthesis
89419855|NCT04359030||Perimount group|Patients treated with a Perimount aortic valve bioprosthesis
88898789|NCT01494155|Experimental|Hydroxychloroquine|Hydroxychloroquine with chemoradiation
88898790|NCT01494194|Placebo Comparator|placebo for food challenge|
88898791|NCT01494194|Experimental|ASP Skin prick solution|
88898792|NCT01494194|Experimental|ASP sorbet|
88898793|NCT01494207|Experimental|Lifestyle intervention|Participants will receive the intervention (counseling) or usual care (control group)
88898794|NCT01494220||Living donor liver transplantation|Patients undergoing living donor liver transplantation in the Mansoura University Liver Transplantation Program from 2007 to 2010
88898795|NCT01494246|Experimental|electronic mail|
88898796|NCT01494246|No Intervention|brief advise|
88922195|NCT05658575|Experimental|Dapansutrile|An initial loading dose of 2000 mg dapansutrile on Day 1 followed by a maintenance regimen of 1000 mg dapansutrile twice daily starting 12 hours later through the second dose on Day 7, inclusive.
88922196|NCT05658575|Placebo Comparator|Placebo Tablet|An initial loading dose of matching placebo (to mimic dapansutrile dosing) on Day 1 followed by a maintenance regimen of matching placebo twice daily starting 12 hours later through the second dose on Day 7, inclusive.
88922197|NCT05658237|Experimental|therapeutic group|
89419856|NCT04953988|Experimental|Robotic surgery group|
89419857|NCT04953988|Active Comparator|Manual operation group|
89419858|NCT01358331|Experimental|MK-8353 100 mg twice daily (BID)|100 mg capsules administered orally twice daily for 28 days for each cycle
89419859|NCT01358331|Experimental|MK-8353 200 mg BID|200 mg capsules administered orally twice daily for 28 days for each cycle
89419860|NCT01358331|Experimental|MK-6353 300 mg BID|300 mg capsules administered orally twice daily for 28 days for each cycle
89419861|NCT01358331|Experimental|MK-8353 350 mg BID|350 mg capsules administered orally twice daily for 28 days for each cycle
89419862|NCT01358331|Experimental|MK-8353 400 mg BID|400 mg capsules administered orally twice daily for 28 days for each cycle
89419863|NCT01358331|Experimental|MK-8353 800 mg BID|800 mg capsules administered orally twice daily for 28 days for each cycle
89419864|NCT04953598||acetabular labrum tears|Patients with clinically diagnosed acetabular labrum tears
89419865|NCT04953598||Patients with non-hip injuries|For non-hip joint reasons, come to the ultrasound department of our hospital to diagnose patients at the same time, and exclude other past and current hip diseases
89419866|NCT03676231|Experimental|High-dose SGM-1019|
89419867|NCT03676231|Experimental|Low-dose SGM-1019|
89419868|NCT03676231|Placebo Comparator|Placebo|
89419869|NCT04937010|Active Comparator|Industry standard stimulation|Standard sub threshold stimulation parameters
89419870|NCT04937010|Sham Comparator|Experimental stimulation|Sham stimulation
89419871|NCT04952818||RANK/RANKL low expression|
89419872|NCT04952818||RANK/RANKL high expression|
88898797|NCT01494259|Experimental|Bupivacaine (Treatment) Group|The Symbios GOPump is the Food and Drug Administration-approved delivery device used to infuse the bupivacaine. The pump is attached to catheters placed in the patient's breast reconstruction site. A 10cm long 16-guage needle is provided to aid insertion of the catheter into the patient. The entire catheter will pass through the bore of the introducer needle. A 60cc syringe is used to fill the Symbios GOPump through the fill port. After filling the 60cc syringe with up to 300cc of 0.5% bupivacaine, the syringe is attached to the port and the medication injected into the infusion pump. The steady-flow pressure regulator maintains a constant 6 psi pressure in the outflow chamber ensuring a uniform flow of medication through each catheter inserted into the Symbios GOPump.
88898798|NCT01494259|Placebo Comparator|Saline (Placebo) Group|The Symbios GOPump is the Food and Drug Administration-approved delivery device used to infuse the saline. The pump is attached to catheters placed in the patient's breast reconstruction site. A 10cm long 16-guage needle is provided to aid insertion of the catheter into the patient. The entire catheter will pass through the bore of the introducer needle. A 60cc syringe is used to fill the Symbios GOPump through the fill port. After filling the 60cc syringe with up to 300cc of normal saline, the syringe is attached to the port and the medication injected into the infusion pump. The steady-flow pressure regulator maintains a constant 6 psi pressure in the outflow chamber ensuring a uniform flow of medication through each catheter inserted into the Symbios GOPump.
88898799|NCT01494272||Group CB (Caudal Before-study group)|This group will receive caudal ropivacaine and epinephrine after induction of general anesthesia prior to surgical incision
89419873|NCT03623503||first group|Observational study of 25 newborn with a likely EOS
89419874|NCT03623503||second group|Observational study of v33 newborn with a possible EOS
88898800|NCT01494272||Caudal After (CA)-control group|This group will receive caudal ropivacaine with epinephrine after completion of surgery but before emergence from anesthesia
88898801|NCT01494272||Local Infiltration After (LIA) control group|This group will receive local infiltration of ropivacaine around the surgery site at the conclusion of surgery but before emergence from anesthesia
88898802|NCT01494285|Experimental|ARK-E021 5% foam|
88898803|NCT01494285|Experimental|ARK-E021 10% foam|
88898804|NCT01494285|Placebo Comparator|Placebo foam|
89419875|NCT02227056|Experimental|Methylphenidate treatment|On three different days each participant will receive Methylphenidate in a dosage of 0.3 milligram/kilo rounded to the nearest full milligram dosage
89419876|NCT02227056|No Intervention|Control|On three different days each participant will be re-evaluated without recieveing Methylphenidate.
89419877|NCT05708157||Active group|Patients with perennial allergic rhinitis who receive concomitant intranasal antihistamine and corticosteroid.
89419878|NCT03671317|Experimental|Intervention group|This arm will receive a medical clowning intervention in addition to pre and post surveys about the blood draw process.
89419879|NCT03671317|No Intervention|Non-intervention group|This arm will continue usual care with no intervention from medical clowns. They will be asked to complete pre and post surveys about the blood draw process.
89419880|NCT04350840|Experimental|Feedback|Participating endoscopists will make high confidence diagnosis according to their judgment time
88898805|NCT01494311|Active Comparator|Placebo patch and lidocaine injection|Fourty-five patients were randomly assigned to receive a placebo patch, looking identically to the Rapydan patch and subsequent subcutaneous injection of 0.5 ml of lidocaine 1%.
88898806|NCT01494311|Experimental|Lidocaine/tetracaine patch|Fourty-five patients were randomly assigned to receive a lidocaine/tetracaine patch, followed by subcutaneous injection 0.5 ml of normal saline solution.
88898807|NCT01494337|Active Comparator|HOLEP|HOLEP In the first arm, holmium laser enucleation of the prostate will be done
88898808|NCT01494337|Active Comparator|PVEP/XPS|PVEP/XPS green light photoselective Vapo-Enucleation of prostate using XPS 180W machine will be used in the second arm
88898809|NCT01494389||SIRS|(1) temperature > 38oC or < 36oC; (2) pulse rate > 90 beats/min; (3) ventilation rate > 20 breaths/min or hyperventilation with a partial pressure of arterial carbon dioxide (PaCO2) < 32 mmHg; (4) white blood cell (WBC) count >1 2,000μL-1 or < 4000 μL-1 , or > 10% immature cells.
88898810|NCT01494389||sepsis|SIRS + infection
88898811|NCT01494389||Normal|not SIRS and have no infection
88898812|NCT01494402|Experimental|D961S|2 way crossover
88898813|NCT01494402|Experimental|esomeprazole + buffered acetylsalicylic acid|2 way crossover
88898814|NCT01494415|Experimental|chemoradiotherapy|This is a single arm study with patients receiving nab-paclitaxel, carboplatin and thoracic radiotherapy.
88898815|NCT01494480|Experimental|stem cell transplantation|After stem cell prepared, the patients accepted 4 times stem cell transplantations through lumbar puncture, the time is 3-5days between two treatments. The patient would have to be in the bed at least 6 hours and removed the pillow.
88898816|NCT01494519|Active Comparator|Treament Arm 1|Definitive fixation with an external ring fixator.
88898817|NCT01494519|Active Comparator|Treatment arm 2|Definitive fixation with a locked IM nail or plate
88898818|NCT01494558|Active Comparator|PE concurrent chemotherapy|Radiotherapy concurrently with PE chemotherapy
88898819|NCT01494558|Active Comparator|PC concurrent chemotherapy|Radiotherapy concurrently with PC chemotherapy
88898820|NCT01494571||90 pediatric, 7 to 14 year old subjects|
88898821|NCT01494571||30 pediatric, 5 to 6 year old subjects|
88898822|NCT01494571||30 pediatric, 3 to 4 year old subjects|
88898823|NCT01494571||30 pediatric, 1 to 2 year old subjects|
88898824|NCT01494571||30 pediatric, 6 to 12 month old subjects|
88898825|NCT01494571||30 pediatric, 4 to 6 month old subjects|
88898826|NCT01494571||30 pediatric, 2 to 4 month old subjects|
88898827|NCT01494597|Experimental|Isavuconazole and cyclosporine|Isavuconazole three times per day (TID) for two days followed by once a day (QD) for 6 days. Cyclosporine single doses on Days 1 and 15.
88898828|NCT01494623|Active Comparator|Active rTMS|Active treatment will be delivered at an intensity that is 90% of the RMT. Stimulation will be delivered at either 20 Hz or 10 Hz, depending on the patients' tolerance to the stimulation, with 50 stimulation trains of 30 stimuli each (i.e., 1500 stimuli) and an intertrain interval of 30 sec. 25 trains will be applied to to the left or right hemisphere followed by the other hemisphere.
88898829|NCT01494623|Sham Comparator|Sham rTMS|Sham stimulation will be delivered using the same stimulation parameters and at the site of active treatment, but with only the side-edge resting on the scalp. The coil will be angled 45 degrees away from the skull in a single-wing tilt position. This method produces sound and some somatic sensation (e.g., contraction of scalp muscles) similar to those of active stimulation, but with minimal direct brain effects.
88898830|NCT01494636|Experimental|GSK2339345 (solution) (part A)|Part A
88898831|NCT01494636|Experimental|GSK2339345/ Placebo/ Lidocaine (nebulised) (part B)|Part B
89419881|NCT03058744|Experimental|IDP-118 Lotion|8 Weeks
89419882|NCT03058744|Experimental|HP Monad Lotion|8 Weeks
89419883|NCT03058744|Active Comparator|Ultravate Cream|2 Weeks
89419884|NCT03058744|Active Comparator|Tazorac Cream|4 Weeks
89419885|NCT02734537|Experimental|Arm A (IMRT)|Patients undergo IMRT QD 5 days a week for 6 weeks in the absence of disease progression or unacceptable toxicity.
89419886|NCT02734537|Experimental|Arm B (IMRT, cisplatin)|Patients undergo IMRT QD 5 days a week and receive cisplatin IV over 1-2 hours weekly for 6 weeks in the absence of disease progression or unacceptable toxicity.
89419887|NCT03059056|Experimental|pharmacokinetic evaluation|Empagliflozin 25 mg
89419888|NCT02227134|Other|Difficult Airway|Children with a history of difficult airway intubation.
89419889|NCT02227134|Other|Obstructive Sleep Apnea|Children with a history of obstructive sleep apnea.
89419890|NCT00951639|Experimental|5g Cassia cinnamon|Experimental treatment group
89419891|NCT00951639|Active Comparator|50 minutes endurnace exercise|Endurance exercise treatment known to influence blood glucose
88898832|NCT01494688|Experimental|Part 1 - Dose Escalation: RO5509554|Participants will receive a single, low dose of 100 milligrams (mg) RO5509554 in 7-day PK run-in period (Cycle 0), followed by dose escalation from Day 1 of Cycle 1. RO5509554 will be escalated as monotherapy in approximately 6 cohorts with dose increments between cohorts of up to 100 percent (%). The doses will be escalated further until MTD/OBD as single agent is reached.
89419892|NCT00951639|Placebo Comparator|5g Cellulose|Placebo equivalent in weight and appearance to experimental treatment
89419893|NCT03058666|Experimental|Aerosolized Calfactant|"NICU Patients with a clinical diagnosis of RDS~Inspired oxygen ≥21% to maintain adequate oxygen saturation~Not Intubated~Requiring Nasal continuous positive airway pressure"
89419894|NCT03058666|No Intervention|Usual Care|There will be no protocol driven interventions in the usual care group.
88898833|NCT01494688|Experimental|Part 1 - Dose Escalation: RO5509554 + Paclitaxel|RO5509554 will be administered in combination with a fixed dose of weekly (QW) paclitaxel (80 milligrams per square meter [mg/m^2]). The starting dose for RO5509554 in combination with paclitaxel will be 2 dose levels below to that of the highest dose of monotherapy RO5509554. Escalation of RO5509554 in combination with QW paclitaxel will start in a standard 3 + 3 design until MTD/OBD as combination dose is reached. If the initial combination is not tolerated, further cohorts will be dosed with the same dose of paclitaxel and lower dose of RO5509554. If insufficient safety, pharmacokinetic or pharmacodynamic data have been collected at the MTD/OBD, up to an additional 4 participants may be enrolled at that dose level.
88898834|NCT01494688|Experimental|Part 2 - Expansion Cohort: RO5509554|Participants will receive RO5509554 1000 mg Q2W, Q3W or initial biweekly followed by monthly maintenance.
88898835|NCT01494688|Experimental|Part 2 - Expansion Cohort: RO5509554 + Paclitaxel|Participants will receive RO5509554 1000 mg Q2W in combination with a fixed dose of QW paclitaxel (80 mg/m^2).
88898836|NCT01494701|Experimental|Cohort 1 (n=6)|
88898837|NCT01494701|Experimental|Cohort 2 (n=6)|
88898838|NCT01494701|Experimental|Cohort 3 (n=6)|
88898839|NCT01494701|Experimental|Cohort 4 (n=10)|
88898840|NCT01494714|Experimental|Closed-patch test|
88898841|NCT01494727|Experimental|CJ Amlodipine/Valsartan 10/160mg|
88898842|NCT01494727|Active Comparator|Novartis Exforge 10/160mg|
88898843|NCT01494740|Experimental|split-virion, non-adjuvanted vaccine of 7.5 μg|split-virion, non-adjuvanted H1N1 vaccine of 7.5 μg.
88898844|NCT01494740|Experimental|split-virion, non-adjuvanted vaccine of 15 μg|split-virion, non-adjuvanted H1N1 vaccine of 15 μg.
88898845|NCT01494740|Placebo Comparator|split-virion, non-adjuvanted vaccine of seasonal influenza|split-virion, non-adjuvanted H1N1 vaccine of seasonal influenza.
88898846|NCT01494766|Other|Tyrosine|"Dietary Supplement: L-Tyrosine~Other Names:~NOW Brand L-Tyrosine 750 mg Tablets~-Tyrosine 750 mg PO every day for 7 days, then increase to 1500 mg PO every day for 7 days, then increase to 2250 mg PO every day for 7 days, then increase to 3000 mg PO every day for remainder of the study."
89419895|NCT02223624|Experimental|eccentric aerobic exercise group|Eccentric aerobic exercise group: Participants in this group will participate in an eccentric aerobic exercise rehabilitation program for a total of eight weeks, two sessions per week. Outcome measurements will be taken post exercise program and also after a 3 month follow-up period. Each session will be approximately 60 minutes in duration and include approximately 10 minutes of warm up (stretches), eccentric stepper aiming for 20 minutes, walking and light weights, followed by a five minute cool-down period.
89419896|NCT02223624|Active Comparator|Concentric aerobic exercise group|"Concentric aerobic exercise group (usual care): The length of the concentric aerobic exercise based rehabilitation program will be the same as the study group- twice weekly exercise sessions for 8 weeks. Outcome measurements will also be taken after a 3-month follow-up period.~Participants in the concentric aerobic exercise group will participate in the same warm-up and cool down period as the eccentric group. They will also complete walking and light weights. To replace the 20 minutes of eccentric exercise, concentric participants will complete approximately 20 minutes of exercise bike, stair climbing and rowing as able with required rests."
89536027|NCT02479373|Other|Control Group (CG)|Those assigned to the CG will complete baseline and post-testing assessments and will also be given JIA educational materials, including physical activity and exercise recommendations from the American Academy of Pediatrics (AAP) Council on Sports Medicine and Fitness (COSMF).
88898847|NCT01494779|Experimental|Somatropin Test|Somatropin of Blausiegel Indústria e Comércio Ltda.
88898848|NCT01494779|Active Comparator|Saizen|Somatropin of Merck Serono
88898849|NCT01494805|Experimental|Low Dose rAAV.sFlt-1|
88898850|NCT01494805|Experimental|High Dose rAAV.sFlt-1|
88898851|NCT01494805|Active Comparator|Control - ranibizumab only|
88898852|NCT01494831|Experimental|TF-CBT|
88898853|NCT01494831|No Intervention|Waiting List control|
88898854|NCT01494844|Other|Device interface comfort assessment|Single group rates one noninvasive respiratory monitoring interface and then another.
88898855|NCT01494857|Experimental|Adalimumab|Adalimumab 40 mg
88898856|NCT01494883|No Intervention|Treatment as usual|
88898857|NCT01494883|Experimental|Mindfulnes Based Stress Reduction|A weekly training of eight session lasting two and a half hours.
88898858|NCT01494909|Experimental|Ensure plus|Ensure sip feeds during 6 hours. After 2 hours pancreatic intake
88898859|NCT01494935|Experimental|Normal glycemic diet|COntrol diet with fat and glycemic index similar to typical American diet.
88898860|NCT01494935|Experimental|High-fat, high-glycemic diet|High-fat, high-glycemic diet
88898861|NCT01494948|Placebo Comparator|placebo|skin test negative
88898862|NCT01494948|Active Comparator|allergic|Skin test positive
88898863|NCT01494961|Experimental|Couple-oriented post-test HIV counseling|Women received couple-oriented post-test HIV counseling
88898864|NCT01494961|No Intervention|Standard post-test HIV counseling|Women received post-test HIV counseling as per standard site protocol
88898865|NCT01494974|Active Comparator|FP7 implant|
88898866|NCT01494974|Active Comparator|FP8 implant|
88898867|NCT01495026|Experimental|Fixed dose combination product|Fixed dose combination capsule containing dutasteride 0.5mg and tamsulosin 0.2mg
88898868|NCT01495026|Experimental|Dutasteride|Commercial formulation of Dutasteride 0.5mg
89419897|NCT02223624|No Intervention|Waiting list control|Waiting list (no exercise): Participants assigned to this group will not receive any intervention during the study period. They will be assessed like other participants at baseline and after eight weeks, but not at three-month follow-up due to ethical concerns around withholding care known to be effective. Given that there is a waiting list for the current exercise program of 4-12 weeks, it is felt that delaying care for a set period of eight weeks is not of ethical concern. Following the completion of assessments, waiting list participants will be able to complete the traditional exercise program as usual but not as participants of the study's experimental groups.
89419898|NCT03563547|Active Comparator|Fat modified diet|Subjects in this arm had been instructed to achieve specific daily maximum intakes in total fat (≤ 30% of total energy intake), saturated fatty acids (≤10% of total fat intake) and cholesterol (≤ 300 mg). Furthermore the participating families had been trained to replace as many visible fat sources as possible with rapeseed oil due to its favorable composition of polyunsaturated fatty acids.
89419899|NCT03563547|Experimental|Fat modifed diet enriched with soy protein|"Subjects in this arm had been instructed to achieve specific daily maximum intakes in total fat (≤ 30% of total energy intake), saturated fatty acids (≤10% of total fat intake) and cholesterol (≤ 300 mg). Furthermore the participating families had been trained to replace as many visible fat sources as possible with rapeseed oil due to its favorable composition of polyunsaturated fatty acids.~Subjects in this arm were additionally instructed to consume at least 0.25 g of soy protein per kg bodyweight per day and were provided with recipes and practical advice on how to achieve this goal. Example provided: a child with a bodyweight of 30kg would have to consume the equivalent of approx. 50g of Tofu per day to meet the treatment target."
88898869|NCT01495026|Experimental|Harnal-D Tablets|Commercial formulation of Harna--D Tablets comprising 0.2mg Tamsulosin Hydrochloride
88898870|NCT01495039|Active Comparator|Nystatin|surgical patients admitted to our ICU older than 18 years of age and expected to require invasive mechanical ventilation for more than 48 h.Patients were allocated to receive systematic nystatin prophylaxis (2 x 106 U per day administered three times daily in the naso-gastric tube)
88898871|NCT01495039|Placebo Comparator|Control|surgical patients admitted to our ICU older than 18 years of age and expected to require invasive mechanical ventilation for more than 48 h.
88898872|NCT01495052|No Intervention|Usual care group|The usual care group was used as control group and didn't receive any intervention except standard health advice at the beginning and the end of the study.
88898873|NCT01495052|No Intervention|diet group|This group received systematic education about nutrition and diabetes combined with a structured dietary intervention.
89419900|NCT03058510||Stable CAD Patients|Stable CAD patients with calcified bifurcation lesion
88898874|NCT01495052|Experimental|50g-ONOG plus diet group|This group received systematic education about nutrition and diabetes combined with a structured dietary intervention. Participants in the 50g-ONOG plus diet groups were asked to replace their customarily used staple food with oat porridge containing 50g ONOG.
88898875|NCT01495052|Experimental|100g-ONOG plus diet group|This group received systematic education about nutrition and diabetes combined with a structured dietary intervention. Participants in the 100g-ONOG plus diet groups were asked to replace their customarily used staple food with oat porridge containing 100g ONOG.
88898876|NCT01495065|Experimental|Part A|Japanese subjects in cohort 1 and 2 will receive treatments A, B and C. Caucasian subjects in cohort 3 will receive treatment B and C.
88898877|NCT01495065|Experimental|Part B|Subjects in cohort 4 and 5 will receive repeat doses of IV GSK2251052 for 10 days.
88898878|NCT01495078|Experimental|Telemonitoring|Patients with follow-up telemonitoring
88898879|NCT01495078|No Intervention|Non - telemonitoring|Patients with usual face follow-up
88898880|NCT01495104|Experimental|Single Arm|
88898881|NCT01495117|Active Comparator|Povidone Iodine|7.5% povidone iodine soaping 10% povidone iodine painting
88898882|NCT01495117|Active Comparator|Chlorhexidine Gluconate|4% chlorhexidine gluconate soaping 2% chlorhexidine gluconate painting
88898883|NCT01495130|Experimental|Diagnostic (TRUS)|Patients undergo TRUS during RALP.
88898884|NCT01495143|Active Comparator|Healthy group|Eight healthy volunteers (five males and three females) with a body mass index of 23.8 and without chronic metabolic disease or low back pain. They are all non-smokers and non-medicated.
88898885|NCT01495143|Experimental|Surgery group|"Two MD catheters is placed in the paraspinal muscle at the level of midpoint of incision bilaterally.~A reference catheter is placed in the deltoid muscle."
88898886|NCT01495156|Experimental|Lithium/Adjunctive SGA|
88898887|NCT01495156|Placebo Comparator|Placebo/Adjunctive SGA|
88898888|NCT01495169|Experimental|Iloperidone|Part A (dose-escalation and fixed dose): Eligible patients receive iloperidone 2mg/day (1 mg BID) on day 1, then escalated every day for up to 12days utilizing a forced titration regimen to achieve a maximum dose of 12, 16, 20 or 24 mg/day given BID. Part B (optional extension phase): Patients who successfully complete Part A of the study are eligible to continue treatment with iloperidone for an additional 26 weeks
88898889|NCT01495182|Experimental|Dietary Fiber - Dose 1|Dietary fiber will be added to study foods
88898890|NCT01495182|Experimental|Dietary Fiber - Dose 2|Dietary fiber will be added to study foods
88898891|NCT01495182|Active Comparator|Control|Study foods with no added fiber will be given
88898892|NCT01495195|Experimental|Donepezil, high-dose|Titration of donepezil to 22.5 mg daily
88898893|NCT01495195|Experimental|Selegiline & low-dose donepezil|Low-Dose Donepezil [titrated to 10 mg daily] and transdermal selegiline [6 mg daily]
88898894|NCT01495195|Experimental|Selegiline & high-dose donepezil|High-Dose Donepezil [titrated to 22.5 mg daily] and transdermal selegiline [6 mg daily]
88898895|NCT01495195|Placebo Comparator|Sugar pill|Inert pill for comparison
88898896|NCT01495208|Experimental|aflibercept|
88898897|NCT01495260|Experimental|N-acetylcysteine, lipoic acid and vitamin E|Two Dose titration design
88898898|NCT01495273|Experimental|Nerve stimulator|Experimental group; will undergo transtracheal injection with needle connected to nerve stimulator.
88898899|NCT01495273|Active Comparator|Standard needle/syringe|Control group; will undergo transtracheal injection with standard needle/syringe assembly.
88898900|NCT01495299||cataract patients with glaucoma|
88898901|NCT01495312|Experimental|SLT|
88898902|NCT01495325|Sham Comparator|Filtered Air Exposure|1 hour exposure to filtered air during intermittent exercise
88898903|NCT01495325|Active Comparator|Woodsmoke Exposure|1 hour exposure to dilute woodsmoke at a concentration of 1000µg/m3 during intermittent exercise
89419901|NCT02227212|Experimental|Insulin glargine U300|Once daily subcutaneous injection for 4 weeks
88898904|NCT01495338|Experimental|AC-170 0.17%|
88898905|NCT01495338|Experimental|AC-170 0.24% (Formulation 1)|
88898906|NCT01495338|Experimental|AC-170 0.24% (Formulation 2)|
88898907|NCT01495338|Placebo Comparator|Olopatadine hydrochloride 0.2%/Tears Naturale II|
88898908|NCT01495351|Experimental|ABT-888/Bortezomib|Patients will be on a treatment schedule including twice daily oral dosing for 14 days followed by 1 week rest in combination with standard dosing of Bortezomib and Dexamethasone in a 21 days cycle for a total of 14 cycles.
88898909|NCT01495364|Experimental|NBS10|active treatment - CD34+ cells
88898910|NCT01495364|Placebo Comparator|placebo|matching placebo
88898911|NCT01495377|Active Comparator|Remifentanil|
88898912|NCT01495377|Placebo Comparator|Placebo|
88898913|NCT01495377|Experimental|Technetium|
88898914|NCT01495377|Experimental|Dynamometer|
88898915|NCT01495429|Experimental|PICC line (Peripherally)|placement of a picc line
88898916|NCT01495429|Active Comparator|CICVC (central insertion)|placement of a centrally inserted central venous catheter
88898917|NCT01495442|Active Comparator|modified Handihaler DPI|
88898918|NCT01495442|Placebo Comparator|standard Handihaler DPI|
88898919|NCT01495455||Knee osteoarthritis|
88898920|NCT01495455||No knee pain/osteoarthritis|
88898921|NCT01495494|Active Comparator|Marketed nasal strip|Marketed nasal strip
88898922|NCT01495494|Experimental|Prototype nasal dilator|Prototype nasal dilator
89419902|NCT00303849|Experimental|Treatment (etoposide, mannitol, melphalan, carboplatin, STS)|Patients receive etoposide phosphate IV over 10 minutes, mannitol IA over 30 seconds, melphalan IA over 10 minutes, and carboplatin IA over 10 minutes on days 1 and 2. Patients then receive sodium thiosulfate IV over 15 minutes at 4 and 8 hours after carboplatin. Courses repeat every 4 to 6 weeks for up to 12 months.
89419903|NCT04863846||Clinical standard (first study phase)|Current clinical standard, non-algorithm-based decision-making (prior to implementation of the algorithm)
89419904|NCT04863846||Algorithm-based allocation (second study phase)|New algorithm-based allocation to an intubation technique (after implementation of the algorithm)
89419905|NCT03058432|Experimental|Intensity-modulated Radiotherapy|Radiotherapy alone was given.
89419906|NCT03058432|Active Comparator|Concurrent chemoradiotherapy|Concurrent cisplatin-based radiotherapy was given.
89419907|NCT04649112|Experimental|Dose Level 1|"In this study, PBCAR19B, allogeneic anti-CD19 CAR T Cells, is used to treat participants with relapsed or refractory (r/r) Non-Hodgkin Lymphoma (NHL).~Route of Administration: Intravenous injection/infusion."
89419908|NCT04649112|Experimental|Dose Level 2|"In this study, PBCAR19B, allogeneic anti-CD19 CAR T Cells, is used to treat participants with relapsed or refractory (r/r) Non-Hodgkin Lymphoma (NHL).~Route of Administration: Intravenous injection/infusion."
89419909|NCT04649112|Experimental|Dose Level 3|"In this study, PBCAR19B, allogeneic anti-CD19 CAR T Cells, is used to treat participants with relapsed or refractory (r/r) Non-Hodgkin Lymphoma (NHL).~Route of Administration: Intravenous injection/infusion."
89419910|NCT04952740|Experimental|Ischemic postconditioning|Routine PCI operations (including thrombus aspiration, stent injection, application of GPIIb/IIIa, etc.) + immediate post-ischemic adaptation: 30 seconds balloon inflation and 30 seconds deflation for 3 cycles
89419911|NCT04952740|Active Comparator|No Ischemic postconditioning|Routine PCI operations (including thrombus aspiration, stent injection, application of GPIIb/IIIa, etc.)
89419912|NCT04316832|Experimental|Intervention/treatment|The mindfulness based cognitive training will be delivered in one session and will include short mindfulness exercises.
89419913|NCT04316832|Placebo Comparator|No intervention|Control exercise, participants will listen to the first chapter of the audiobook The Hobbit, JRR Tolkien.
89419914|NCT02828241|Experimental|DFD-04 Ointment|DFD-04 (Itraconazole) Ointment
89419915|NCT02828241|Placebo Comparator|Placebo Ointment|Placebo Ointment
89419916|NCT04952428||Peri-implant group|It is based on clinical and radiographic bone loss. Implants should have clinical inflammation in combination with bleeding on probing and/or suppuration, also progressive bone loss when compared with baseline radiograph shall be demonstrable, as well as an increase in probing pocket depth (PPD) from the baseline examination (Baseline record are referred to those obtained after definitive prosthesis delivery). In those cases where no baseline records were available, marginal bone loss > 3mm and probing > 6mm were stated as requirements (2).
89419917|NCT04952428||Peri-implant mucositis group|The case definition of peri-implant mucositis it is based on clinical inflammation in combination with profuse bleeding on probing and/or suppuration with increasing of probing pocket depths and absence of bone loss beyond crestal bone level (initial remodelling) (2).
89419918|NCT04952428||Healthy patients group|The case definition of peri-implant health was based on absence of clinical inflammation, lack of bleeding on probing and absence of bone loss following initial healing (< 2mm) (2).
89419919|NCT04641858|Active Comparator|BCG-Denmark|Participants that are randomized in the active arm will receive an adult 0.1 ml dose of BCG vaccine (BCG-Denmark, AJ Vaccines) in the skin covering the right upper deltoid muscle. Each 0.1 ml vaccine contains between 200000 to 800000 colony forming units of the live attenuated strain of Mycobacterium bovis (BCG), Danish strain 1331.
89419920|NCT04641858|Placebo Comparator|Control|Placebo will be 0.1 ml sterile 0.9 % NaCl, which has a similar color and appearance as the resuspended BCG vaccine.
89419921|NCT03563703|Experimental|Ultrasound imaging|Ultrasonography offers visual information about the size and depth of blood vessels, potentially facilitating intravenous placement of the needle in real time.
89419922|NCT03563703|Experimental|Near-infrared imaging|Near-infrared imaging devices project near-infrared light onto the skin, which is absorbed by deoxygenated hemoglobin. The invisible image of the underlying vascular pattern is captured by the device, processed and projected, in real time, back onto the patient's skin using visible green light. This technology allows hands-free visualization of a vascular map to guide catheter placement.
89419923|NCT04295928|Experimental|Intervention|Implementation of a personalized pharmaceutical plan with a view to increasing the patient's therapeutic education in the hospital and in the community (entrance and discharge reconciliation, 3 pharmaceutical interviews in the hospital, strengthening of the community-hospital link , 3 outpatient pharmaceutical consultations)
89419924|NCT04295928|No Intervention|Usual care period|No changes to usual center practices
89419925|NCT04952116|Other|Eyelid reconstruction|Direct eyelid closure will be done in small defects after periocular defects with or without canthyolysis , Larger defects will be reconstructed with anterior and posterior lamella reconstruction using grafts and flaps
89419926|NCT02227524|Experimental|No Device|Assistive device conditions
89419927|NCT02227524|Experimental|Single Point Cane|Assistive device condition
89419928|NCT02227524|Experimental|Four-Point Cane|Assistive device condition
89419929|NCT02227524|Experimental|Trekking Pole|Assistive device condition
89419930|NCT04951960|Other|A group from higher PEEP to lower PEEP|Patient allocated for this arm are received from higher to lower PEEP setting.
89419931|NCT04951960|Other|A group from lower PEEP to higher PEEP|Patient allocated for this arm are received from lower to higher PEEP setting.
89419932|NCT02223780|Placebo Comparator|control|standard management
89419933|NCT02223780|Active Comparator|early palliative care|early palliative care
89419934|NCT04951882|Placebo Comparator|hUC-MSCs treatment|Patients of acute lung injury will be treated by suspention of hUC-MSCs and albumin combined with standard therapies.
89419935|NCT04951882|No Intervention|non-cell therapy|Patients of acute lung injury will be treated by vehicle (albumin) combined with standard therapies.
89419936|NCT01355523|Active Comparator|Melatonin|6 mg oral melatonin daily
89194310|NCT01033513||Literature Only (Control)|The participants on this arm served as the control group. Five types of literature were mailed to the participants in the literature only arm. A letter was included with the materials thanking participants for their participation, requesting that the participants read the literature, and encouraging them to contact the RDs with any questions. The Clinical Study Manager's telephone number was provided for questions about diet or lifestyle changes. The RDs documented all contacts with participants on a phone summary. Other than the delivery of literature and responses to specific questions asked by the participant or the participant's primary caregiver through telephone calls, the RDs had no further interaction with the participant until the conclusion of the participant's trial period.
89419937|NCT01355523|Placebo Comparator|Placebo|6 mg oral placebo daily
89419938|NCT02223936|Other|children with Prenatal enlarged nuchal transluce|
89419939|NCT02223936|Other|Control|
89419940|NCT04952038||ALS patients with sleep disorder|
89419941|NCT04952038||ALS patients without sleep disorder|
89419942|NCT02227602|Experimental|Mango|Mango polyphenolics
89419943|NCT04951414||ICF|
89419944|NCT04951414||Control|
89419945|NCT02227680|Active Comparator|Music Therapy|Patients randomized to the music therapy group will receive 1-3 10-40 minute music therapy sessions during each of the days of their stay on the inpatient unit. Each participant randomized to the music therapy intervention will be given a personalized CD and one portable CD player with headphones which they may keep after the study has ended.
89419946|NCT02227680|Active Comparator|Massage Therapy|Patients randomized to the massage therapy group will receive 1-3 10-40 minute massage treatments during each of the days of their stay on the inpatient unit.
89419947|NCT02227680|No Intervention|Usual Care|The control group will continue to receive usual care while on the Family Medicine Inpatient Unit.
89419948|NCT04951648|Experimental|Almonertinib|
89419949|NCT04951648|Active Comparator|Platinum-based doublet chemotherapy|
89419950|NCT04185246|Experimental|Single arm|"Subjects will be enrolled with sequential allocation to 1 of 3 cohorts with the following intravenous (IV) doses of NH002: 2.5 µl/kg, 5.0 µl/kg, or 10.0 µl/kg.~Each patient will undergo an unenhanced ultrasound examination and a NH002 contrast-enhanced examination on the same day"
89419951|NCT04164888|Experimental|CIVI 007, Dose A|Subcutaneous (SC) injection of a PCSK9 inhibitor- low dose given twice
89419952|NCT04164888|Experimental|CIVI 007, Dose B|SC injection of PCSK9 inhibitor- dose titration
89419953|NCT04164888|Experimental|CIVI 007, Dose C|SC injection of PCSK9 inhibitor- high dose given twice
89419954|NCT04164888|Placebo Comparator|Placebo|Placebo SC injection matching PCSK9 inhibitor given twice
89419955|NCT04951258|Experimental|Multicomponent exercise group|
89419956|NCT04951258|Active Comparator|Video home exercise group|
89419957|NCT02227914|Experimental|Oprozomib with Sorafenib|"Phase 1b:~Oprozomib doses will be escalated in sequential groups of at least 2 subjects. Study subjects will receive oprozomib at dose levels of 90, 120, 150, 180, 210, or 240 mg + sorafenib to reach the dose levels of 600 or 800 mg total daily dose until the maximum tolerated dose (MTD) is reached.~Phase 2:~Study subjects who meet the entry criteria will receive oprozomib + sorafenib at the RP2D (recommended Phase 2 dose) established in the Phase 1b portion of the study."
89419958|NCT02227914|Active Comparator|Sorafenib|"Phase 2:~Study subjects who meet the entry criteria will receive sorafenib 400 mg twice a day (800 mg total daily dose)."
89419959|NCT04161456|Experimental|Apremilast|Apremilast twice daily 30 mg
89419960|NCT04951024|Experimental|Thoracolumbar interfacial plane (TLIP) Block|Thoracolumbar interfacial plane (TLIP) Block will be performed after induction of anesthesia by anesthesiologist who is not part of investigators for this study. Bilateral 20 ml 0.25 % Bupivacaine injected between multifidus and longissimus muscle with Ultrasound guidance.
89419961|NCT04951024|Active Comparator|Erector Spinae Plane (ESP) Block|Erector Spinae Plane (ESP) Block will be performed after induction of anesthesia by anesthesiologist who is not part of investigators for this study. Bilateral 20 ml 0.25 % Bupivacaine injected between the erector spinae muscles and transverse process with Ultrasound guidance
89419962|NCT04950790|Experimental|Test group|Shuxuening injection + basic treatment
89419963|NCT04950790|Placebo Comparator|Control group|placebo (sterilized water for injection) + basic treatment
89419964|NCT04951180||Group 1|Femoral acetabular impingement syndrome (FAIS) patients with gluteus medius lesions
89419965|NCT04950478|Experimental|Virtual Reality|The children wore the virtual reality headset and game was started one minute before the venipuncture. The children took off the virtual reality headset after the venipuncture ended.
88898923|NCT01495507||Patellofemoral Instability|Patients with diagnosis of patellofemoral instability receiving MPFL-reconstruction as part of the clinical routine
88898924|NCT01495520|Active Comparator|Ranolazine|Patients will receive ranolazine 750 mg bid for 30 days
88898925|NCT01495520|Placebo Comparator|Placebo|Patients will receive placebo for 30 days
88898926|NCT01495546|Experimental|Early loading|
88898927|NCT01495546|Active Comparator|late loading|
88898928|NCT01495624|Placebo Comparator|Ropivacaine with perineural dexamethasone|30 ml 0.5% ropivacaine plus dexamethasone 8 mg (2 ml) mixed with the local anesthetic with 2 ml normal saline given intravenously (systemic placebo);
88898929|NCT01495624|Active Comparator|Ropivacaine with systemic steroid|30 ml 0.5% ropivacaine for interscalene block mixed with 2 ml normal saline (perineural placebo) plus dexamethasone 8 mg (2 ml) administered systemically.
88898930|NCT01495650|Experimental|Intervention arm|
88898931|NCT01495650|No Intervention|Control arm|Routine practice
88898932|NCT01495663|Other|Single Group|I-131-CLR1404
89419966|NCT04950478|No Intervention|Control Group|No intervention was performed to reduce pain in the control group
89419967|NCT04950556|Experimental|Exercise group|Fast and slow contractions will be taught in PFMT. For fast contractions, they will be asked to contract and relax the pelvic floor muscles quickly. For slow contractions, they will be asked to contract the pelvic floor muscles slowly, keep them at maximum contraction and relax slowly. Ten slow contractions in addition to 10 fast contractions will be considered as 1 set of exercises. For the first week, they will be asked to do 5 sets of exercises per day, every day. Then, the number of sets will be increased by 5 each week and the number of sets will reach 30 in the 6th week. PFMT will be applied by the patients as a home program every day of the week for 6 weeks.
88898933|NCT01495715|Experimental|Idebenone|
88898934|NCT01495715|Placebo Comparator|Placebo|
88898935|NCT01495728|Experimental|Thrust Manipulation -Thoracic Spine|Mid and Upper Thoracic Spine
88898936|NCT01495728|Placebo Comparator|Sham Manipulation|Mid and Upper Thoracic Spine
88898937|NCT01495754|Experimental|coffee3|
88898938|NCT01495754|Experimental|coffee6|
88898939|NCT01495754|Placebo Comparator|water|
88898940|NCT01495767||females, males|females: patients of female sex males: patients of male sex
88898941|NCT01495780|Experimental|Remote Health Monitoring|Subjects assigned to this arm will conduct daily at-home health monitoring using several electronic devices that will transmit data back to the study team. Everyday, subjects will measure pulse oximetry (SpO2) using a finger clip, answer questions about symptoms and medication use, answer a quality of life questionnaire, perform breathing tests, and record physical activity (using a physical activity monitor that will be mailed to the study team). Wearing the activity monitor is optional and will only occur during months 1, 6, and 12.
88898942|NCT01495806|Experimental|Glucomannan|5 g 2x 10 day
88898943|NCT01495806|Placebo Comparator|Placebo|
89419968|NCT04950556|Other|Control group|Waiting list will included in control group.
89419969|NCT02224014||Lendormin D tablets|
89419970|NCT02224092|Active Comparator|Active|Active is a multivitamin multimineral with phytonutrient product.
89419971|NCT02224092|Placebo Comparator|Placebo|Placebo is a sugar pill.
89419972|NCT03671161|Experimental|Patients with poorly controlled diabetes type 1|Adults with type 1 diabetes, HbA1c >9% (75 mmol/mol), multi daily insulin injections ( MDI) and who perform less than 2 SMBG /day swithced to Insulin Pump and flash glucose monitoring
89419973|NCT02258802|Experimental|Psychoeducational intervention|Participants will be receiving a cooking lesson in their community every 2 weeks for 1 year.
89419974|NCT02258802|No Intervention|Usual food practices|These are participants from the communities where the intervention is active but are not attending the cooking lessons.
89419975|NCT03671083||Injured and Matched Control Subject Pool|Injured subjects consist of subjects who are head injured and meet the inclusion/exclusion criteria. Injured subjects will be tested within 72 hours (3 days) of injury and at specified time points post injury. Matched control subjects will be tested at the same time intervals as the injured subject. BrainScope Battery will be performed at each time point and consists of the following components: brain electrical activity (EEG), neurocognitive performance assessment, ocular motor assessment, and clinical symptoms/assessments.
89419976|NCT03671083||Healthy Volunteer Subject Pool|This subject pool will consist of uninjured (not head injured) subjects and will be tested at a single time point. These subjects will perform the same BrainScope Battery as the injured and matched control subjects.
89419977|NCT04950088|Active Comparator|Game|"Patients will be assigned into a Video Game group or a No Video Game group. All patients on any particular day will be assigned into the same group. This is done to prevent one patient from feeling disappointed after seeing another patient with a video game, and then learning they may not have one. Group assignment will alternate each day."
89419978|NCT04950088|Active Comparator|no game|"Patients will be assigned into a Video Game group or a No Video Game group. All patients on any particular day will be assigned into the same group. This is done to prevent one patient from feeling disappointed after seeing another patient with a video game, and then learning they may not have one. Group assignment will alternate each day."
89419979|NCT03675997||Autografted patients|Patients hospitalized in the hematological department of the Institute will complete the first day of conditioning and then weekly HAD (Hospital Anxiety and Depression) scale.
89419980|NCT04950400|Experimental|Carrelizumab + chemotherapy + apatinib|
89419981|NCT02228070|Experimental|strabismus video goggles|
89419982|NCT02625220|Experimental|Prototype toric lens senofilcon A|Subjects will wear the senofilcon A prototype toric contact lens bilaterally for 6-8 days as a daily disposable modality.
89419983|NCT04046484|Active Comparator|Normal Saline (Dose: Equal volume) + Standard of care|Patients will receive the best available standard of care. In control group, 3 doses of equal volume of normal saline will be administered as an IV bolus over 1 minutes every 3 hours ± 1 hour on day 1, 3 and day 6 post randomization.
89419984|NCT04046484|Experimental|PMZ-1620 + Standard of care|Patients will receive the best available standard of care. In PMZ group, 3 doses of PMZ-1620, at 0.3 μg/kg body weight will be administered as an intravenous bolus over 1 minute every 3 hours ± 1 hour on day 1, 3, and day 6 (total dose/day: 0.9 µg/kg body weight).
89419985|NCT03670927||Cases|Cases (incident patients with a diagnosis of primary sarcoma and histologically confirmed by an expert pathologist of the RRePS or ResOs networks in the 15 districts of France participating to this study) Environmental, occupational and lifestyle-related exposures
88898944|NCT01495832|Experimental|Pulse Group|The pulse group will consume pulse-enriched foods designed to deliver ½ cup of pulses per day for 12 weeks.
88898945|NCT01495832|Active Comparator|Control Group|The control group will consume comparator foods for 12 weeks.
88898946|NCT01495871|Active Comparator|Amino acids|Amino acid supplementation for 6 weeks
88898947|NCT01495871|Placebo Comparator|Placebo|Supplementation of placebo (inert components)for 6 weeks
88898948|NCT01495871|Active Comparator|Valine|Valine supplementation for 6 weeks
89419986|NCT03670927||Controls|"Subjects never diagnosed with a primary sarcoma and individually-matched by sex, age (5-years group), and districts of residence and randomly selected from electoral list.~Environmental, occupational and lifestyle-related exposures"
89419987|NCT04949932|Experimental|Intervention Arm|Poly herbal powder (PHP)
89419988|NCT04949932|Placebo Comparator|Placebo Arm|Powder of Cicer arietinum
89419989|NCT02826603|Experimental|Secukinumab|Secukinumab
89419990|NCT02826603|Active Comparator|Ustekinumab|Ustekinumab
88898949|NCT01495884|Experimental|Lapatinib (Tyverb™) and (Myocet™)|
88898950|NCT01495897|Other|Healthy|Healthy volunteers
88898951|NCT01495897|Experimental|Dystonia|patients with Primary Dystonia
88898952|NCT01495897|Experimental|Parkinson|patients with Parkinson's disease
88898953|NCT01495897|Experimental|Essential tremor|patients with essential tremor with or without deep brain stimulation
88898954|NCT01495910|Experimental|Abiraterone acetate|Abiraterone acetate oral suspension administered daily from study Day 1 to study Day 6 of each treatment period: the first dose level is 100 mg with escalating doses of 250 mg and 500 mg in subsequent treatment periods.
88898955|NCT01495936|Active Comparator|Continuous Positive Airway Pressure|"After 20 minutes ventilation on one lung (during anesthesia) the patient will be randomly assigned to the study arm Continuous Positive Airway Pressure (CPAP). CPAP will be applied for 20 minutes to the non-ventilated lung at a pressure of 5cmH20 using the disposable Mallinckrodt Bronchocath CPAP system."
88898956|NCT01495936|Active Comparator|RM + Positive End Expiratory Pressure|"After 20 minutes of ventilation on one lung (during anesthesia) the patient will be randomly assigned to the study arm RM + Positive End Expiratory pressure which is a Recruitment Maneuver (RM) followed by Positive End Expiratory Pressure (RM-PEEP) which will be applied to the ventilating lung at a pressure of 5cmH2O."
88898957|NCT01495949|Active Comparator|etomidate|
89419991|NCT02224170|Experimental|Lidocaine group|
89419992|NCT02224170|Active Comparator|Dexamethasone group|
89419993|NCT03058120|No Intervention|Stress testing|Patient with chest pain, low risk by modified HEART score, undergoes whatever admission and stress testing plan is determined by ED and inheriting decision unit physicians.
89419994|NCT03058120|Active Comparator|Early discharge|Patient with chest pain, low risk by modified HEART score, is discharged from the emergency room without admission nor stress testing.
89419995|NCT02224248|Experimental|Health checks with fitness testing|
89419996|NCT02224248|Active Comparator|Health checks without fitness testing|
89419997|NCT02228148|Experimental|NFS|Cochlear Nucleus Fitting Software
89419998|NCT02228148|Active Comparator|CSS|Cochlear Nucleus Custom SoundTM Suite
89419999|NCT04949698||No TMA|parturients without thrombotic microangiopathies
89420000|NCT04949698||TMA with plasma exchange|parturients with thrombotic microangiopathies, and treated with plasma exchange
88898958|NCT01495949|Active Comparator|thiopentone|
88898959|NCT01495962|Active Comparator|Botulinum Toxin A injection|
88898960|NCT01495962|Placebo Comparator|Placebo (Normal Saline) injection|
88898961|NCT01496001|Experimental|Cohort|
88898962|NCT01496027||term newborns|
88898963|NCT01496027||Preterm Newborns (32-37 GA)|
88898964|NCT01496040|Experimental|rAAV2/4.hRPE65|"3 cohortes of 3 patients each.~All the patients enrolled in the study will receive a single subretinal injection in one eye. The eye, that will be injected, will be the eye with the poorest visual acuity."
88898965|NCT01496053|Active Comparator|AndoSan|AndoSan given to IBD patients
88898966|NCT01496053|Sham Comparator|Sugar extract|Sugar extract to IBD patients
88898967|NCT01496079||Inactivated influenza vaccine in pregnancy|Healthy pregnant women who elect to receive inactivated influenza vaccine in early pregnancy (< 20 weeks gestation) and their infants
88898968|NCT01496079||No inactivated influenza vaccine during pregnancy|Healthy pregnant women who decline inactivated influenza vaccine in pregnancy and their infants
88898969|NCT01496092|Experimental|Keto Acid supplemented with usual protein diet|
88898970|NCT01496092|No Intervention|usual protein diet|
88898971|NCT01496105|Active Comparator|lidocaine spray 10%|
88898972|NCT01496105|Placebo Comparator|Saline|
88898973|NCT01496144|Experimental|Manual therapy and active exercises|Spinal manipulation /mobilisation
88898974|NCT01496144|Placebo Comparator|Detuned ultrasound and active exercises|
88898975|NCT01496170|Experimental|Treatment A: MK-8931 12 mg|Participants receiving 12 mg MK-8931 for 7 days
88898976|NCT01496170|Experimental|Treatment B: MK-8931 40 mg|Participants receiving MK-8931 40 mg for 7 days
88898977|NCT01496170|Placebo Comparator|Treatment C: Placebo matching MK-8931 12 mg or 40 mg|Participants receiving placebo matching MK-8931 12 mg or 40 mg for 7 days
88898978|NCT01496170|Experimental|Treatment D: MK-8931 60 mg|Participant receiving MK-8931 60 mg for 7 days
88898979|NCT01496170|Placebo Comparator|Treatment E: Placebo matching MK-8931 60 mg|Participants receiving placebo matching MK-8931 60 mg for 7 days
88898980|NCT01496196|Active Comparator|tranexamic acid-500 mg/5 ml 3-4 times a day|tranexamic acid arm: inhalations of tranexamic acid 500 mg/5 ml 3-4 times a day
88898981|NCT01496196|Placebo Comparator|tranexamic|placebo arm
88898982|NCT01496209|Sham Comparator|Placebo control|
88898983|NCT01496209|Experimental|Group: Cardiosphere Treatment|Biological: Allogeneic Human Cardiospheres (allogeneic CSps or alloCSps), a 3D micro-tissue heart-derived cell therapy product. Subjects will receive 150 million cell-equivalents of alloCSps via endomyocardial injection (10 million per site at 15 peri-infarct sites)
88898984|NCT01496235|Active Comparator|Dark chocolate|Presence of 70% cocoa solids
88898985|NCT01496235|Placebo Comparator|White chocolate|
88898986|NCT01496261|Active Comparator|Clopidogrel and Aspirin|
88898987|NCT01496261|Experimental|Coprigerl|
88898988|NCT01496300|Sham Comparator|Manual|Manual Implantation of THA
88898989|NCT01496300|Experimental|Navigated|Navigated Implantation of THA
88898990|NCT01496326|Experimental|Ibuprofen|
88898991|NCT01496326|Placebo Comparator|Placebo|
88898992|NCT01496339|Active Comparator|Traditional therapy control|
88898993|NCT01496339|Experimental|Stem cell infusion|
88898994|NCT01496378|Experimental|Problem-Solving Skills Training|In addition to standard medical care, parents in the problem-solving skills training group will receive 8 sessions (1 hour each) of individual problem-solving therapy over 8 weeks. Caregivers will be asked to complete the first training session and at least 3 subsequent sessions in person at their local treatment facility (Seattle Children's Hospital or Oregon Health and Science University). Remaining sessions will be completed via telephone.
88898995|NCT01496378|No Intervention|Standard Care|Parents and children in the Standard Care group will continue with the care that has been prescribed for their child's pain problem by their treating physician, which may include medications, physical therapy, and mental health intervention.
89420001|NCT04949698||TMA without plasma exchange|parturients with thrombotic microangiopathies, but not treated with plasma exchange
89420002|NCT02258568|Experimental|Smoking abstinence counseling|Telephone motivational counseling sessions supporting smoking abstinence
89420003|NCT02258568|No Intervention|Control|Do not receive telephone motivational counseling sessions supporting smoking abstinence
89420004|NCT04949308||Genetic diagnosis|Genetic: Genetic diagnosis No Intervention foreseen, but genetically confirmed diagnosis of PCD (bi-allelic mutations in a gene, known to cause PCD) with typical clinical symptoms of PCD and at least one other method confirming PCD-diagnosis is needed
89420005|NCT02228226||MG-1treated group|MG-1treated group: Patients those who underwent arthroscopic Bankart repair for glenohumeral instability using MG-1
89420006|NCT05956847||Gastric precancerous lesions，Normal gastric mucosal tissue and gastric cancer tissues|Normal gastric mucosal tissue Gastric precancerous lesions:Atrophic gastritis, non Atrophic gastritis, intestinal metaplasia, dysplasia gastric cancer tissues
88898996|NCT01496391||Healthy Participants|eGFR ≥60 ml/min/1.73m^2, healthy prospective kidney donor
88898997|NCT01496391||Moderate Renal Function Impairment|eGFR 30-59 ml/minute/1.73m^2
88898998|NCT01496391||Severe Renal Function Impairment|eGFR <30 mL/minute/1.73m^2
88898999|NCT01496404|Experimental|Electrocautery|Epidermis and dermis incised with cutting setting of electrocautery.
88899000|NCT01496404|Active Comparator|Scalpel|Control, incision of epidermis and dermis with scalpel.
88899001|NCT01496417|Experimental|Belatacept therapy|20 Patients receiving belatacept based immunosuppressive protocol for 12 months post-transplantation.
88899002|NCT01496443|Experimental|TAK-875 & Glimepiride QD|TAK-875 50 mg, tablets, orally and glimepiride 2 mg, capsules, orally and glimepiride placebo matching capsules, orally, once daily on dosing days for up to 19 days.
88899003|NCT01496482||Patients without dry eye symptoms|Patients without dry eye symptoms as measured by standard questionnaire.
88899004|NCT01496482||Patients with dry eye symptoms|Patients with dry eye symptoms as measured by standard questionnaire.
88899005|NCT01496495|Experimental|ARRY-614|
88899006|NCT01496508|Experimental|HFOV|A SLE5000 infant ventilator was used as the high-frequency ventilator.HFOV setting were as follows: initial frequency was set between 11 and 15Hz; pressure amplitude of oscillation was initially adjusted to provide adequate chest wall movement and was subsequently titrated to maintain the PaCO2 between 40 and 55 mmHg.Extubation was considered when the patient's condition was stable for 12-24h, while adequate oxygenation could be maintained with an FIO2 <0.3 and respiratory rate <25/min.
88899007|NCT01496508|Experimental|CV|A Servo-i-Maquet will be used as the conventional mechanical ventilator. CV settings were: exhaled tidal volumes set at 5-6 mL/kg, initial peak inspiratory pressure (PIP) of 15-25 cmH2O; positive expiratory end pressure (PEEP) set to 4-6 cmH2O; inspiratory times of 0.25-0.40s; rates set to <60/min. The weaning process was initiated when the following parameters were achieved: PIP <18 cmH2O, PEEP <4 cmH2O, and FIO2 <0.4. Extubation was considered when the patient's condition was stable for 12-24h, while adequate oxygenation could be maintained with an FIO2 <0.3 and respiratory rate <25/min. All infants extubated onto nasal continuous positive airway pressure (Infant Flow, Electro Medical Equipment) and then weaned to a nasal cannula, and then to room air.
88899008|NCT01496521|Experimental|Aspirin|
88899009|NCT01496521|Experimental|Tea Polyphenols|
88899010|NCT01496521|No Intervention|Control|
88899011|NCT01496534|Active Comparator|Cisplatin|Gemcitabine 1000 mg/m2 IV on days 1 + 8 Cisplatin 70 mg/m2 IV day 1 Dovitinib given orally on days 1-5, 8-12 and 15-19. Treatment will be recycled every 21-days. The dose of dovitinib will be escalated in successive cohorts.
88899012|NCT01496534|Active Comparator|Carboplatin|Gemcitabine 1000 mg/m2 IV on days 1 + 8 Carboplatin AUC 5 IV day 1 Dovitinib given orally on days 1-5, 8-12 and 15-19. Treatment will be recycled every 21-days. The dose of dovitinib will be escalated in successive cohorts.
88899013|NCT01496547|Experimental|intensive chemo - RIC preparation|The intensive chemotherapy is composed of Fludarabine 35mg/m2 D1-5, high-dose cytarabine 2g/m2 D1-5 + idarubicin (12mg/m2) D5-7. The reduced intensity preparation regimen will start 7 days after the chemotherapy with fludarabine 35mg/m2 for 5 days + iv busulfan 3.2mg/kg/day for 3 days followed by stem cell infusion 2 days later.
88899014|NCT01496573||Basic science (biomarker analysis)|Archived tumor tissue samples are analyzed for CRKL expression.
88899015|NCT01496638|Experimental|"No side branch treatment group"|Implantation of coronary stent in bifurcation lesion
88899016|NCT01496638|Experimental|"Stenting of main vessel and side branch group"|Implantation of coronary stent in bifurcation lesion
88899017|NCT01496651|Active Comparator|Percutaneous coronary intervention|Coronary Artery Bypass Grafting Versus Drug Eluting Stent Percutaneous Coronary Angioplasty in the Treatment of Unprotected Left Main Stenosis
88899018|NCT01496651|Active Comparator|Coronary artery bypass graft operation|Coronary Artery Bypass Grafting Versus Drug Eluting Stent Percutaneous Coronary Angioplasty in the Treatment of Unprotected Left Main Stenosis
88899019|NCT01496677|Experimental|Elderly subjects (65 or older)|
89420007|NCT05956782|Active Comparator|Attention Control|"Education: Each survivor will receive a copy of Facing Forward; Life After Cancer Treatment (No. 18-2424, March 2018). Each family member or friend will receive When Someone You Love is Being Treated for Cancer (No. 14-5726, May 2014). Specific parts of booklets will be reviewed during the 15-minute/per participant telephone chat.~Telephone Chats: The primary purpose is study retention. After the first 12-week period ends the weekly chats will be tapered for 12 weeks.~One text message delivered weekly by telephone is a reminder of the day and time of the chat(s).~Tobacco Use Reduction: Many survivors of lung cancer struggle with nicotine addiction; smoking cessation and relapse prevention content will be made available to current smokers (The FOREVER FREE program - a free, twelve short booklet evidence-based resource created by the H. Lee Moffitt Cancer Center & Research Institute at the University of South Florida)."
88899020|NCT01496677|Experimental|Younger adults (18-45 years old)|
88899021|NCT01496690|Active Comparator|pregabalin|The pregabalin dose is 75 mg daily the first week followed by 7 weeks of flexible daily dosing (150, 300, 450 or 600 mg.) depending on tolerability and response.
88899022|NCT01496690|Placebo Comparator|Pregabalin Placebo Capsules|
88899023|NCT01496703||renal transplantation with MMF from day 1|
88899024|NCT01496716||Hip Osteoarthritis|
88899025|NCT01496729|Active Comparator|Transversus abdominis plane (TAP) block with ropivacaine|A Transversus abdominis plane (TAP) block with ropivacaine, a local anesthetic, will be performed at the end of the surgical procedure
88899026|NCT01496729|Sham Comparator|Sham TAP block with normal saline|A sham TAP block with normal saline will be performed at the end of the surgical procedure.
88899027|NCT01496742|Experimental|Bevacizumab+MetMAb|
88899028|NCT01496742|Active Comparator|Bevacizumab+Placebo|
88899029|NCT01496742|Experimental|Pemetrexed+MetMAb|
88899030|NCT01496742|Active Comparator|Pemetrexed+Placebo|
88899031|NCT01496755|Placebo Comparator|Placebo|
88899032|NCT01496755|Experimental|RG7667|
88899033|NCT01496768|Experimental|Leucine|
88899034|NCT01496768|Placebo Comparator|Alanine|
88899035|NCT01496781|Experimental|EndoClot|This arm is designed to observe if the Endoclot treatment can achieve comparable hemostasis efficacy compared with hemoclip.
88899036|NCT01496781|Active Comparator|Hemoclip|This arm is used as a control treatment group to compare with Endoclot treatment.
88899037|NCT01496794||Endophthalmitis cultures|
88899038|NCT01496820|Experimental|GO2KA1|
88899039|NCT01496820|Placebo Comparator|Placebo|
88899040|NCT01496833|Experimental|Endovascular|Total endovascular arch reconstruction
88899041|NCT01496859|Experimental|Baska|
88899042|NCT01496911|Experimental|Levocetirizine (5 mg)|
88899043|NCT01496911|Active Comparator|Hydroxyzine (50 mg)|
88899044|NCT01496911|Placebo Comparator|Placebo|
88899045|NCT01496924|Other|speech therapy group|All dysphagic patients will be submitted to speech therapy
88899046|NCT01496937|Experimental|GLPG0974 oral solution|GLPG0974 oral solution
88899047|NCT01496937|Placebo Comparator|Placebo oral solution|Placebo oral solution
88899048|NCT01496950|Active Comparator|Active Comparator: Active rTMS|10Hz active rTMS delivered to the left dorsolateral prefrontal cortex
88899049|NCT01496950|Placebo Comparator|Placebo|10Hz placebo rTMS delivered to the vertex
88899050|NCT01496989|Experimental|Group 1: HIV-MAG followed by Ad35-GRIN/ENV|HIV-MAG (IM/EP) at Months 0,1,2 followed by Ad35-GRIN/ENV (IM) at Month 6. (Vaccine:Placebo = 12/3)
88899051|NCT01496989|Experimental|Group 2: HIV-MAG+GENEVAX® IL-12 followed by Ad35-GRIN/ENV|HIV-MAG + GENEVAX® IL-12 (IM/EP) at Months 0,1,2 followed by Ad35-GRIN/ENV (IM) at Month 6. (Vaccine:Placebo=12/3)
88899052|NCT01496989|Experimental|Group 3: HIV-MAG+GENEVAX® IL-12 followed by Ad35-GRIN/ENV|HIV-MAG + GENEVAX® IL-12 (IM/EP) at Months 0,1,2 followed by Ad35-GRIN/ENV (IM) at Month 6. (Vaccine:Placebo= 12/3)
88899053|NCT01496989|Experimental|Group 4: HIV-MAG+GENEVAX® IL-12 followed by Ad35-GRIN/ENV|HIV-MAG + GENEVAX® IL-12 (IM/EP) at Month 0 followed by Ad35-GRIN/ENV (IM) at Month 4. (Vaccine:Placebo=12/3)
88899054|NCT01496989|Experimental|Group 5: Ad35-GRIN/ENV followed by HIV-MAG+GENEVAX® IL-12|Ad35-GRIN/ENV (IM) at Month 0 followed by HIV-MAG + GENEVAX® IL-12 (IM/EP) at Month 4. (Vaccine:Placebo=12/3)
88899055|NCT01497002|Active Comparator|standard arm|standard treatment arm
88899056|NCT01497002|Experimental|OSHO - intensified consolidation|Intermediate dose AraC
88899057|NCT01497002|Experimental|OSHO - allografting as consolidation|allogeneic stem cell Transplantation versus no transplantation
89420008|NCT05956782|Experimental|BE Intervention Group|"The BE Manual is an educational resource for Managing Stress, Increasing Physical Activity (PA) and Stopping Smoking and Staying Smoke free.~A timed, weekly telephone counseling session (60 min./dyad max) will be recorded. The purpose is to provide social support with SMART goal setting, adherence monitoring, encouragement..~Breathing Exercises and Meditations are incorporated into the BE Manual and sent by a link via text messages.~A Texting Library provides additional education, support, and encouragement daily. There are 5 story lines: BE Active, BE Kind to Yourself, BE Supportive and BE Smoke free (offered to current smokers only). Stay Smoke free will be instituted once tobacco use has stopped.~Weekly Logs for tracking goals and progress with behavior changes (PA, breathing practices and meditations) and a pedometer are provided. After 12 weeks, the calls and texts will be tapered."
89420009|NCT05956743|Active Comparator|intervention group|"Intervention Group: A total of 6 weeks of planning will be made with the working group.~1 week : Patients included in the study group and meeting the research criteria will be informed about the research. Pre-test data forms for each patient who accepted to participate in the study, Patient Identification Form, Pittsburgh Sleep Quality Index (PUKI) within 30 minutes will be collected.~2.,3.,4.,5. week: Patients will practice a total of 12 progressive relaxation exercise sessions for 30 minutes, 3 times a week (Monday, Wednesday, Friday) for 4 weeks, accompanied by the training booklet and music player.~6 week: In the last week of the application, individuals will be called to the hospital and in the Diabetes Polyclinic training room.A final test will be made by the researcher. The Pittsburgh Sleep Quality Index (PUKI) will be reapplied."
89420010|NCT05956743|Sham Comparator|Sham group|"1 week: After informing Sham group patients about the research at the first interview, Patient Information Form, Pittsburgh Sleep Quality Index (PUKI) will be applied.~In the 6th week of the study, individuals will be called to the hospital and the post-test Pittsburgh Sleep Quality Index (PUKI) will be re-administered by the researcher in the diabetes polyclinic training room.~6 week: Since the study was terminated after the 6th week, a booklet and music player will be given to the patients. In addition, progressive relaxation exercise training will be given to the patients and the importance of using it in their lives will be explained."
89420011|NCT05956717||Experimental Group|Subjects wore orthokeratology lenses
89420012|NCT05956717||Control group|Subjects wore single-vision glasses group
89420013|NCT05956704|Experimental|Experimental Group|
89420014|NCT05956704|Active Comparator|Control group|
89420015|NCT05956704|No Intervention|Blank control group|
89420016|NCT05956678|Experimental|Standard TranS-C|Standard TranS-C is modularized and delivered across eight 50-minute, weekly, individual sessions. It is comprised of 4 cross-cutting interventions featured in every session; 4 core modules that apply to the vast majority of patients; and 7 optional modules used less commonly, depending on the presentation.
88899058|NCT01497028||Plicated Gastric Banding|
88899059|NCT01497028||Standard Gastric Banding|
88899060|NCT01497080||1|
88899061|NCT01497080||activity level|
88899062|NCT01497080||no treatment|
88899063|NCT01497093|Experimental|Pomalidomide/Bortezomib/Dexamethasone|1, 2, 3 or 4 mg of pomalidomide will be taken orally on Days 1-14 of a 21-day cycle along with 1 or 1.3 mg/m2 of bortezomib administered intravenously or subcutaneously on Days 1, 4, 8 and 11 of 21 days for cycles 1 -8 and on days 1, 8 of 21 days for cycle 9 and onward until disease progression, and dexamethasone 20 mg/day [≤ 75 years old] or 10 mg/day [> 75 years old] orally on days 1, 2, 4, 5, 8, 9, 11, 12 of 21 days for cycles 1-8 and on days 1, 2, 8, 9 of 21 days for cycles 9 and onward until disease progression
88899064|NCT01497106|Experimental|Calorie restriction|Participants will work with the CRU dietetics staff to plan a diet that will result in their losing 1-2 pounds per week over 16 weeks.
88899065|NCT01497106|Active Comparator|Control|Participants will continue their normal living for entire time of the study, totaling 16 weeks.
88899066|NCT01497119|Experimental|JNJ-39758979, 300 mg|
88899067|NCT01497119|Experimental|JNJ-39758979, 100 mg|
88899068|NCT01497119|Placebo Comparator|Placebo|
88899069|NCT01497132|Experimental|Vitamin D3|
88899070|NCT01497132|Placebo Comparator|Placebo|
88899071|NCT01497158|Active Comparator|Control Group|Participants who received only self-help brochure regarding environmental tobacco smoking (ETS) exposure in the home.
88899072|NCT01497158|Active Comparator|Active Group|Participants who received self-help brochure regarding environmental tobacco smoking (ETS) exposure in the home and biomarker feedback from the urine of cohabitating adult non-smoker in the home.
88899073|NCT01497223|Experimental|MGCD290 and Fluconazole|Oral Administration of MGCD290 and Fluconazole
88899074|NCT01497223|No Intervention|Fluconazole|This is an Active Comparator: Oral Administration of Fluconazole with Placebo
88899075|NCT01497236|Experimental|Experimental: Ready to Use Terapeutic Food (RUTF)|
88899076|NCT01497236|Experimental|Multi Micronutrient Powder (MNP)|
88899077|NCT01497236|No Intervention|no supplement|
88899078|NCT01497249|Placebo Comparator|Placebo|Placebo Beverage
88899079|NCT01497249|Active Comparator|A dietary fiber (FCHO)|15g/BID
88899080|NCT01497288|Experimental|Sequence 1 (A-B-C)|"A: single dose of 200 μg INFS (100 μL) (Instanyl®), administered on Day 1~B: single dose of 400 μg INFS (100 μL), administered 4 hours after the first treatment~C: two single doses of 400 μg INFS (100 μL) (10 min apart), administered 24 hours after the first treatment (Day 2)"
88899081|NCT01497288|Experimental|Sequence 2 (A-C-B)|"A: single dose of 200 μg INFS (100 μL) (Instanyl®), administered on Day 1~C: two single doses of 400 μg INFS (100 μL) (10 min apart), administered 4 hours after the first treatment~B: single dose of 400 μg INFS (100 μL), administered 24 hours after the first treatment (Day 2)"
88899082|NCT01497301|No Intervention|Standard Individual Medical Appointment|
88899083|NCT01497301|Active Comparator|Group Visits|
88899084|NCT01497314|Other|Low Lactose Infant Formula|
88899085|NCT01497327|Experimental|PSI-352938 Group A|Mild (Child-Pugh Class A; 5-6) hepatic impairment
88899086|NCT01497327|Experimental|PSI-352938 Group B|Moderate (Child-Pugh Class B; 7-9) hepatic impairment
88899087|NCT01497327|Experimental|PSI-352938 Group C|Severe (Child-Pugh Class C; 10-15) hepatic impairment
88899088|NCT01497327|Experimental|PSI-7977 Group A|Mild (Child-Pugh Class A; 5-6) hepatic impairment
88899089|NCT01497327|Experimental|PSI-7977 Group B|Moderate (Child-Pugh Class B; 7-9) hepatic impairment
88899090|NCT01497327|Experimental|PSI-7977 Group C|Severe (Child-Pugh Class C; 10-15) hepatic impairment
89420017|NCT05956678|Experimental|Adapted TranS-C|The process for developing Adapted TranS-C has been iterative and grounded in theory, data and stakeholder feedback. The core elements of the evidence-based theory of change underpinning TranS-C have been retained. Adapted TranS-C is delivered in four 20-minute, weekly, individual sessions and is comprised of 4 cross-cutting interventions featured in every session, 5 modules that apply to the vast majority of patients, and 1 optional module used less commonly, depending on the presentation.
88899091|NCT01497340|Active Comparator|Position at introitus level|The newborn will be held by the neonatologist at the level of the introitus, the cord will be clamped at 2 minutes after birth with a plastic clamp placed at 1 cm from its cutaneous insertion.
89194311|NCT01033513||Meals Only|Participants in the meals only arm received a pre-intervention assessment (but no nutrition counseling). The RDs gave the participants in the meals only arm a phone number and encouraged them to phone with questions or problems, especially problems associated with the meals. Subsequently, the meals only participants received seven diagnosis-appropriate therapeutic meals a week, delivered once per week. The meals were specially designed to address the participants' medical diagnoses. They were developed using the ADA MNT protocols for caloric and nutrient content requirements for individuals with the specified diagnoses, in addition to meeting AoA Nutrition Program dietary requirements. The meals were provided primarily in frozen form. However, some shelf-stable and refrigerated components were also included. In conformance with AoA regulations, appropriate meals were also offered to the spouse of any participant receiving a therapeutic meal.
89420018|NCT05956639|Experimental|6-month course of Rezvilutamide|6-month course of Rezvilutamide with ADT and chemotherapy
88899092|NCT01497340|Experimental|position at Maternal Abdomen|The newborn will be placed on the abdomen and of the mother immediately after the first weight measurement. The cord will be clamped at 2 minutes after birth .
88899093|NCT01497353|Active Comparator|Position at introitus level|The newborn will be held by the neonatologist at the level of the introitus, the cord will be clamped at 2 minutes after birth. New weigh will be obtained after that.
88899094|NCT01497353|Experimental|Position at Maternal Abdomen|The newborn will be placed on the abdomen and of the mother immediately after the first weigh measurement. The cord will be clamped at 2 minutes after birth .
88899095|NCT01497379|Experimental|intra-individual implant ON|intra-individual implant activation
88899096|NCT01497379|Placebo Comparator|intra-individual implant OFF|intra-individual implant deactivation
88899097|NCT01497405|Active Comparator|Test, Treat, Retain(TTR) only|Participants in this group will be screened for HIV. HIV positive women will be given post-test counseling and referrals for prompt medical evaluation.
88899098|NCT01497405|Experimental|Test, Treat, Retain(TTR) + Women's Health CoOp (WHC)|TTR +WHC: Participants in this group will be screened for HIV. HIV positive women, will be given post-test counseling and referrals for prompt medical evaluation and assessment. Both HIV negative and positive participants in this group will participate in 2 individual behavioral counseling sessions focusing on reducing HIV risk behaviours, alcohol and other drug use, and risk of violent victimization. It also adds case management to increase follow through with referrals and risk reduction plans and activities. This intervention is an adaptation of the evidence-based Women's CoOp(PI: Dr. Wendee M. Wechsberg).
88899099|NCT01497431|Experimental|Arm I (Se-methyl-seleno L-cysteine)|Participants receive Se-methyl-seleno L-cysteine on days 1-84.
88899100|NCT01497431|Experimental|Arm II (selenomethionine)|Participants receive selenomethionine PO on days 1-84.
88899101|NCT01497431|Placebo Comparator|Arm III (placebo)|Participants receive placebo PO on days 1-84.
88899102|NCT01497444|Experimental|sorafenib and TH-302|Patients will be administered sorafenib tablets to take twice daily by mouth, every day of each cycle. Patients will also be given TH-302 intravenously (IV) on days 8, 15 and 22 of each cycle. A cycle is 28 days.
89420019|NCT05956639|Active Comparator|Long-term course of Rezvilutamide|Long-term course of Rezvilutamide with ADT and chemotherapy
88899103|NCT01497457|Experimental|MR saline peritoneography|Patients that will undergo MR saline peritoneography
88899104|NCT01497470|Experimental|Paclitaxel/carboplatin with custirsen|Custirsen added to standard paclitaxel/carboplatin chemotherapy
88899105|NCT01497483|Active Comparator|Pravastatin alone|Subjects will be dosed with Pravastatin alone (40 mg)
89420020|NCT05956613|No Intervention|Control: conventional root canal treatment|
89420021|NCT05956613|Other|Test: partial pulpotomy|Partial pulpotomy using bioceramic putty
89420022|NCT05956600|Other|Amisulpride|Amisulpride administered orally. Dose range 50 to 1200 mg daily
89420023|NCT05956574|Experimental|Nutrigenomix|Participants in this group will be asked to complete an oral swab at baseline. This swab will indicate their dietary needs based on their genetic composition. These personalized dietary needs will be shared with the participant; the participant will be encouraged to follow their dietary plan for the duration of the study. Participants in this group will also gradually increase their physical activity up to 300 min/week at 6 months.
89420024|NCT05956574|Active Comparator|Control|Participants in this group will receive a standard care dietary plan. They will also be asked to gradually increase their activity up to 300 min/week by 6 months.
89420025|NCT05956561||only one group|all patients seeking delayed dental implant placement above 18 years and medical free, no previous augmentation or sinus lifting
88899106|NCT01497483|Experimental|Pravastatin and Cyclosporine|Subjects will be dosed with pravastatin and cyclosporine.
88899107|NCT01497522|Experimental|Vildagliptin|In addition to their stable dose of metformin monotherapy, patients should take vildagliptin 50 mg twice daily.
88899108|NCT01497522|Placebo Comparator|Placebo|In addition to their stable dose of metformin monotherapy, patients should take vildagliptin matching placebo.
88899109|NCT01497535|Experimental|Insulin detemir|
88899110|NCT01497535|Active Comparator|Insulin glargine|
88899111|NCT01497548|Experimental|Methylphenidate add on to Mirtazapine|Methylphenidate add on to the usual treatment (Mirtazapine)
88899112|NCT01497548|Placebo Comparator|Placebo add on to Mirtazapine|Non active compund add on to the usual treatment (Mirtazapine)
88899113|NCT01497561|Experimental|insulin detemir|
88899114|NCT01497561|Active Comparator|insulin NPH|
88899115|NCT01497574|Experimental|Insulin detemir|
88899116|NCT01497574|Active Comparator|Insulin glargine|
88899117|NCT01497587|Experimental|Insulin detemir|
88899118|NCT01497600|Experimental|insulin detemir|
88899119|NCT01497600|Active Comparator|insulin NPH|
88899120|NCT01497626|Experimental|Bortezomib plus lapatinib|Combination treatment with lapatinib and bortezomib
88899121|NCT01497639|Active Comparator|Process 1|"Visit 1: Baseline evaluation (maximum 1 week before operation)~Visit 2: Testing of electrodes and subsequent initiation of interleaving stimulation mode (4th postoperative week).~Visit 3 Evaluation and cross-over to double-monopolar stimulation mode (16th postoperative week).~Visit 4 Final evaluation. (28th postoperative week)."
88899122|NCT01497639|Active Comparator|Process 2|"Visit 1: Baseline evaluation (maximum 1 week before operation)~Visit 2: Testing of electrodes and subsequent initiation of double-monopolar stimulation mode (4th postoperative week).~Visit 3 Evaluation and cross-over to interleaving stimulation mode (16th postoperative week).~Visit 4 Final evaluation. (28th postoperative week)."
88899123|NCT01497652|Active Comparator|Treatment Group|Treatment group will receive Rasagiline (Azilect) 1mg daily
88899124|NCT01497652|Placebo Comparator|Placebo Group|will receive placebo daily
88899125|NCT01497678|Other|Extracellular Matrix|Implantation of Extracellular Matrix
88899126|NCT01497691|Other|Control|This group will receive all standard of care therapies as per the pediatric ED Asthma Severity Protocol.
88899127|NCT01497691|Sham Comparator|Sham NIPPV|This group will receive all standard of care therapies as per the pediatric ED Asthma Severity Protocol. All nebulized treatments will be given via the NIPPV/BiPAP machine. The pressure settings will be fixed at a positive end-expiratory pressure (PEEP) of 5-8 cm H2O.
88899128|NCT01497691|Active Comparator|BiPAP|This group will receive all standard of care therapies as per the pediatric ED Asthma Severity Protocol. All nebulized treatments will be given via the NIPPV/BiPAP machine. Settings will be adjusted based on the age and clinical presentation of the child.
88899129|NCT01497717|Experimental|Adalimumab, Behcet with arthritis|
88899130|NCT01497730||CR FB|Subjects receiving a Cruciate Retaining Fixed Bearing implant configuration
89420026|NCT05956522|Experimental|Test/reference|Subjects first receive a single-dose of 25 mg/5 mg test Empagliflozin And Linagliptin tablet (T, produced by Qilu Pharmaceutical (Hainan) Co., Ltd ) in the first treatment period and to receive the reference (R, Boehringer Ingelheim International GmbH & Co. KG )in the second treatment period.
89420027|NCT05956522|Experimental|Reference/test|Subjects first receive a single-dose of 25 mg/5 mg reference Empagliflozin And Linagliptin tablet (R, Boehringer Ingelheim International GmbH & Co. KG) in the first treatment period and to receive test tablet (T, produced by Qilu Pharmaceutical (Hainan) Co., Ltd) in the second treatment period.
89420028|NCT05956483||Rapid Mood Screener (RMS)|Participants with Unipolar Major Depressive Disorder and Bipolar 1 Depression will be evaluated with RMS questionnaire and MINI interview.
89420029|NCT05956470|Experimental|SKY intervention group|Meditation and breath program: includes gentle stretches (office yoga' in a sitting position) and three different types of specific breathing exercises. 3x1,5 hours. Daily practice thereafter for about 30 minutes for 8 weeks. In addition, there are weekly one-hour sessions for group practice and discussion.
89420030|NCT05956470|Active Comparator|Control group|Group discussion-based viewing of online educational videos that demonstrate ways to mitigate psychological distress, including the use of cognitive coping techniques. 3x1,5 hours. It includes weekly online meetings with group discussions, experience sharing, and watching brief videos on the key elements of the program for 8 weeks.
89420031|NCT05956457|Experimental|Single Arm Cohort Receiving Digital Health Coaching|All study participants will be enrolled in a 3-month digital health coaching program. They will also receive a Fitbit device to be worn daily for the capture of physical activity data.
89420032|NCT05956444|Experimental|Treatment Group|Treated with both the treatment programs determined on the basis of the NDT and conventional physiotherapy. Programs prepared specifically for each child, in a 45-minute single session, 2 days a week, for 8 weeks in total. Each child was given a treatment program tailored to their needs.
89420033|NCT05956444|Active Comparator|Control Group|Treated with only the treatment programs determined on the basis of conventional physiotherapy.
89420034|NCT05956431|Experimental|Levosimendan group|The administration scheme of Levosimendan is continuous intravenous infusion at the rate of 0.05-0.2 μg/kg/min for 24 hours, and no load is given to reduce the risk of Hypotension.
89420035|NCT05956431|Placebo Comparator|Placebo group|The placebo group received continuous intravenous infusion of physiological saline at the rate of 0.05-0.2 μg/kg/min for 24 hours, while also receiving comprehensive cluster therapy with PCAS.
89420036|NCT05956418|Experimental|Centhaquine (Dose: 0.01 mg/kg) + Standard of care|Centhaquine will be administered intravenously after enrollment to hypovolemic shock patients with systolic arterial blood pressure ≤ 90 mmHg at presentation and continue to receive standard shock treatment. Centhaquine will be administered at a dose of 0.01 mg/kg of body weight, as an intravenous (IV) infusion over 1 hour in 100 mL of normal saline. Second dose of centhaquine will be administered if SBP falls below or remains below or equal to 90 mmHg but not before 4 hours of the previous dose and total doses per day (in 24 hours) will not exceed 3 doses. Centhaquine administration if needed will continue for two days post-enrollment. A minimum of 1 dose or maximum of 6 doses of centhaquine will be administered within first 48 hours post-enrollment. Each patient will be monitored closely throughout his/her hospitalization and will be followed until discharge or day 7 (whichever is earlier) from enrollment.
89420037|NCT05956392|Experimental|Screen-use reduction + Sleep extension|For the intervention group, participants are required to follow an agreed schedule where one hour of their daily screen-use time during school days will be repurposed for additional sleep during the two-week manipulation period.
89420038|NCT05956392|No Intervention|Free-living control|For the control group, participants will remain under free-living conditions (no restrictions on their screen-use time or sleep time) during the two weeks.
89420039|NCT05956379|Experimental|Exercise group|Physical therapists will provide personalized aerobic exercise program prescriptions in the preparatory period based on the results of exercise-related assessments, and the training intensity is based on the results of the maximum exercise test, with moderate intensity for 24 weeks, >=3 cardio workouts per week.
89420040|NCT05956379|No Intervention|Control group|No change in exercise habits and maintaining baseline physical activity.
89420041|NCT05956366||Anorexia nervosa|Children and adolescents presenting for treatment for anorexia nervosa typica or atypica (ICD-10: F50.0 or F50.1)
89420042|NCT05956366||Bulimia nervosa|Children and adolescents presenting for treatment for bulimia nervosa typica or atypica (ICD-10: F50.2 or F50.3)
89420043|NCT05956366||Other eating disorders|Children and adolescents presenting for treatment for other eating disorders (ICD-10: F50.8)
89420044|NCT05956301|Active Comparator|Group I|Conventional Oxygen Therapy
88899131|NCT01497730||PS FB|Subjects Receiving a Posterior Stabilized Fixed Bearing implant configuration
89420045|NCT05956301|Experimental|Group II|High-flow nasal oxygen
89420046|NCT05956301|Experimental|Group III|Supraglottic jet oxygenation and ventilation
89006671|NCT04619407||childcare educators|"Employed in a kindergarten in Mecklenburg-Vorpommern~Age between 18 to 67 years~Willing and able to provide informed consent~Over 5 months: Monthly nasopharyngeal swabs for SARS-CoV-2 PCR, additionally blood samples for SARS-CoV-2 antibody testing will be taken at the beginning and at the end of the study"
89006672|NCT04619407||preschoolers|"Attending kindergarten in Mecklenburg-Vorpommern~Age between 3 to 6 years~Agreement to participate~Legal representative willing and able to provide informed consent~Over 5 months: Monthly nasopharyngeal swabs for SARS-CoV-2 PCR"
89006673|NCT00243399|Experimental|Oxandrolone|
89006674|NCT00562822|Active Comparator|Arthroscopic Surgery|Arthroscopic surgery optimized with physical and medical therapy
89006675|NCT00562822|Active Comparator|Physical and medical therapy|treatment with physical and medical therapy alone
89006676|NCT04618861||Control Group|"This cohort involved the volunteers who had no known acute, subacute or chronic disease history, who did not suffer from any infection in the last fortnight, who were not on a particular medication, who presented to the ED with reasons other than infectious complaints, and who gave their written consent to participate in the study.~The exclusion criteria consisted of diagnosis of kidney and liver failure, acute pulmonary embolism, chronic inflammatory disease history (rheumatological disease, autoimmune disease), pregnancy, presence of any cancer diagnosis, chronic obstructive pulmonary disease, asthma disease, and history of cerebrovascular disease. In addition, the patients whose CT imagings were compatible with Covid-19 pneumonia but whose PCR tests were negative were also excluded from the study."
89006677|NCT04618861||CT (+), PCR (-) Covid-19 Suspected Pneumonia Group|"This group consisted of patients who applied to the emergency department with symptoms of Covid-19, whose thorax CT according to RSNAEC criteria showed typical Covid-19 pneumonia findings, but whose RT-PCR test was negative in the swab sample taken in the emergency room.~The exclusion criteria consisted of diagnosis of kidney and liver failure, acute pulmonary embolism, chronic inflammatory disease history (rheumatological disease, autoimmune disease), pregnancy, presence of any cancer diagnosis, chronic obstructive pulmonary disease, asthma disease, and history of cerebrovascular disease. In addition, the patients whose CT imagings were compatible with Covid-19 pneumonia but whose PCR tests were negative were also excluded from the study."
89006678|NCT04618861||CT (+), Covid-19 Pneumonia Group|"This cohort consisted of the patients (a) who applied to the emergency department with SARS-CoV-2 symptoms and was diagnosed with SARS-CoV-2 infection according to WHO guideline (13) (b) whose CT imagings were compatible with SARS-CoV-2 pneumonia in accordance with the Radiological Society of North America Expert Consensus (RSNAEC) criteria (14), (c) whose nasopharyngeal swab samples taken in the ED were positive for RT-PCR, and (d) who gave their informed consent to participate in the study.~The exclusion criteria consisted of diagnosis of kidney and liver failure, acute pulmonary embolism, chronic inflammatory disease history (rheumatological disease, autoimmune disease), pregnancy, presence of any cancer diagnosis, chronic obstructive pulmonary disease, asthma disease, and history of cerebrovascular disease. In addition, the patients whose CT imagings were compatible with Covid-19 pneumonia but whose PCR tests were negative were also excluded from the study."
89006679|NCT04618861||CT (-), PCR (+) Covid-19 infection group|"This cohort included the patients (a) who presented to the Covid-19 outpatient polyclinic of the ED with pneumonia symptoms, (b) whose CT imaging's were compatible with Covid-19 pneumonia in accordance with the RSNAEC criteria and whose PCR tests were positive, (c) whose SARS-CoV-2 PCR tests were positive as a result of contact tracing, and (d) who presented to the ED for further examination.~The exclusion criteria consisted of diagnosis of kidney and liver failure, acute pulmonary embolism, chronic inflammatory disease history (rheumatological disease, autoimmune disease), pregnancy, presence of any cancer diagnosis, chronic obstructive pulmonary disease, asthma disease, and history of cerebrovascular disease. In addition, the patients whose CT imagings were compatible with Covid-19 pneumonia but whose PCR tests were negative were also excluded from the study."
89006680|NCT00220922|Experimental|1|injection site reactions with the use of alcohol wipes prior to performing the patients' daily Copaxone® injection
89420047|NCT05956288|Experimental|Blood flow restriction (BFR) with low load resistance training|A single BFR exercise (Biceps curl with dumbell) will be perform. The initial resistance load for performing the above exercise will correspond to 5% of the body weight of each participant (±0.250 kg). Participants will be asked to perform 4 sets of bicep curls. The first set will consist of repetitions until failure (inability to follow the rhythm or inability to perform an additional contraction) followed by 3 sets of 15 repetitions with 30 seconds rest between sets. In case that for any of the participants will not be able to complete all the repetitions, or they are unable to follow the pace of the metronome, the resistance load will be reduced by 0.5 kg. Vascular Occlusion Pressure will be set at 50-60% of the complete occlusion pressure for the intervention group .Five minutes after the execution of the biceps curl exercise, each participant will receive a specific training which will consist of six therapeutic exercises targeting in loading the rotator cuff and scapula muscles
89006681|NCT00220922|Experimental|2|injection site reactions without the use of alcohol wipes prior to performing the patients' daily Copaxone® injection
89420048|NCT05956288|Placebo Comparator|Sham-Blood flow restriction (sham-BFR) with low load resistance training|Same procedure as experimental . The only difference between the two groups regarding the intervention will be the percentage of blood flow restriction cuff pressure. In the sham BFR group, as much pressure as 2 fingers can penetrate the cuff will be automatically applied via MADUP®, where based on the literature seems not to promote adaptations related to the use of the method.
89006682|NCT00243438||1|Patients who have received a Vision stent and who have diabetes and/or complex lesions.
89006683|NCT04618939|Experimental|BR-TD-1001|Randomized subjects were assigned to receive a single dose of BR-TD-1001
88899132|NCT01497730||CR RP|Subjects receiving a Cruciate Retaining Rotating Platform implant configuration
88899133|NCT01497730||PS RP|Subjects receiving a Posterior Stabilized Rotating Platform implant configuration
88899134|NCT01497743|Placebo Comparator|placebo|Subjects will be randomized into either the probiotic or placebo arm of the study at a 1:1 ratio. All randomized subjects will receive probiotic or matching placebo: 1 capsule orally twice daily, with meals) for the first 4 weeks. There will be a 6-week washout period, followed by 4 weeks of the alternate treatment. The subject will not be on study medication during this washout period.
88899135|NCT01497743|Active Comparator|Probiotic|Subjects will be randomized into either the probiotic or placebo arm of the study at a 1:1 ratio. All randomized subjects will receive probiotic or matching placebo: 1 capsule orally twice daily, with meals) for the first 4 weeks. There will be a 6-week washout period, followed by 4 weeks of the alternate treatment. The subject will not be on study medication during this washout period.
88899136|NCT01497769|Experimental|Group 1|Aerosol inhaled MVA85A and intradermal saline placebo
88899137|NCT01497769|Experimental|Group 2|Intradermal MVA85A and inhaled aerosol saline placebo
88899138|NCT01497782|Experimental|Instructor feedback|Intervention group who receives up to three sessions of instructor feedback during completion of a predefined proficiency level on a laparoscopic virtual reality simulator.
88899139|NCT01497782|No Intervention|No instructor feedback|Control group who did not receive instructor feedback during completion of a predefined proficiency level on a laparoscopic virtual reality simulator.
88899140|NCT01497821|Experimental|Dose exploration|Pre-specified nominal doses are proposed in the dose exploration at two dosing frequencies: every two weeks and every three weeks. Intermediate doses may also be used if required based on the Continuous Reassessment Method (CRM) design.
88899141|NCT01497821|Experimental|Dose expansion|Dose and dosing frequency selected from Part 1 dose exploration.
88899142|NCT01497210|Experimental|EASH|
88899143|NCT01497847||travelers to tropical destinations|
88899144|NCT01497873|Experimental|Belotecan|Camtobell Injection
88899145|NCT01497873|Active Comparator|Topotecan|Hycamtin Injection
88899146|NCT01497886|Active Comparator|Hip Hop Stroke educational program|Hip Hop Stroke is a school-based educational program that incorporates educational hip hop music and two cartoons to communicate stroke knowledge to children.
88899147|NCT01497886|Placebo Comparator|Nutrition Education program|"The investigators will use what they will refer to as a usual care control. For this purpose the investigators have selected nutrition, physical activity, and obesity education. A trained facilitator will conduct the control program in the school auditorium. The investigators will use this control method to control for attention, i.e., having a facilitator come to the classroom for the same amount of time as in the intervention that is, 1-hour sessions on three consecutive days. The facilitator will provide focused lectures on relevant topics, and show two short, 4-minute animated films on nutrition, and physical activity. The investigator will conduct parallel pretests and post-tests on the children (same as intervention testing sequence)."
88899148|NCT01497912|Active Comparator|Atorvastatin|Atorvastatin 80mg once daily
88899149|NCT01497912|Placebo Comparator|Placebo|Matched placebo tablets
88899150|NCT01497925|Experimental|ADI-PEG 20|
88899151|NCT01497951|Experimental|Aminolaevulinic acid|
88899152|NCT01497951|Placebo Comparator|Placebo|
88899153|NCT01497964|Experimental|Cabazitaxel|Cabazitaxel, several dosages
88899154|NCT01497977|Experimental|soya phytoestrogens|
88899155|NCT01497977|Experimental|red clover phytoestrogens|
88899156|NCT01497977|No Intervention|No drugs|
88899157|NCT01497990|Experimental|Ertapenem|The patient received two injections of ertapenem, at a dose of 1g.j-1 by intravenous injection of 30 minutes, separated by 24 h.
88899158|NCT01498003|Placebo Comparator|Control group|normal saline was applied to those randomized to control group, with same use as tirofiban
88899159|NCT01498003|Experimental|Tirofiban group|after angioram, and before guiding catheter engagement: 10μg/kg bolus followed by 0.15μg/kg/min maintenance infusion
88899160|NCT01498016|Experimental|Iv-Busulfan|iv busulfan 1.6mg/kg given q12h
88899161|NCT01498029|Active Comparator|Randomized to Microfracture|This group of patients who have been randomised to receive microfracture procedure will be the control group for this study
88899162|NCT01498029|Experimental|Randomized to CAIS|This group of patients who have been randomised to receive the CAIS procedure will be the experimental group for this study
88899163|NCT01498055||CIK therapy group|
88899164|NCT01498055||control group|
88899165|NCT01498081|Experimental|Single dose of AZD2115 25 µg|
88899166|NCT01498081|Experimental|Single dose of AZD2115 80 µg|
88899167|NCT01498081|Experimental|Single dose of AZD2115 240 µg|
88899168|NCT01498081|Placebo Comparator|Single doses of placebo|
88899169|NCT01498081|Active Comparator|Single dose of indacaterol 150 µg|
88899170|NCT01498081|Active Comparator|Single dose of indacaterol 150 µg + tiotropium 18 µg|
88899171|NCT01498094|Active Comparator|Control|Standard low-flow oxygen therapy.
88899172|NCT01498094|Experimental|Intervention|High Flow Nasal Cannula Oxygen Therapy
88899173|NCT01498133|Experimental|skin-to-skin contact|Newborns in the study group had skin-to-skin contact with their mothers in the NICU, twice a day (morning and evening) for 60 minutes, for seven days (including weekends).
88899174|NCT01498133|No Intervention|control group|The control group (n = 49) received routine care without skin-to-skin contact.
88899175|NCT01498159|Experimental|Pharmacist + Health Promoter|Participants in this group will receive support from both a pharmacist and health promoter. Number of sessions will be determined by the study team member and patient.
88899176|NCT01498159|Active Comparator|Pharmacist|Participants will receive support from pharmacist.
88899177|NCT01498172|Experimental|NMIBC at intermediate risk of progression|
88899178|NCT01498172|Experimental|NMIBC at high risk of progression|
88899179|NCT01498172|Experimental|NMIBC at low risk of progression|
88899180|NCT01498198|Experimental|Expedited Surgery|Participants will have surgery within 3 months
89420049|NCT05956275|Active Comparator|adductor canal block and infiltration popliteal artery capsule knee block|Adductor canal block and infiltration popliteal artery capsule knee block were performed accompanied by USG, Bupivacaine and 10 mL of 0.9% NaCl were applied in each block application.
89420050|NCT05956275|Sham Comparator|Control|No block performed
88819874|NCT01461668|Experimental|Retapamulin|Participants in this arm will be instructed to complete a decolonization regimen that will involve a 5-day application of retapamulin with follow up bilateral nares swab one week following completion of therapy (~D12) to assess clearance. If follow up swabs are positive for MRSA, patients will be given a second course of the same agent (retapamulin) to begin one week following swab collection (~D19-23) so that up to two decolonization attempts will be made. A final set of bilateral nares swabs will be obtained from all subjects six weeks from the completion of initial treatment (~D47).
88899181|NCT01498198|Experimental|Non Operative Management|Participants will undergo non operative care for as long as they are improving, and will return to the surgeon when no progression is reached.
89420051|NCT05956262|Experimental|AR group|Student in AR group received a two-time repeated AR-based training for 30 minutes at two-week intervals.
88899182|NCT01498211|Experimental|Biopsy|
89420052|NCT05956262|Experimental|traditional group|Students in the traditional group received a two-time repeated 10-minute lesson regarding proper toothbrushing skills in the classroom at two-week intervals.
88899183|NCT01498224|Active Comparator|Suture|Suture application
88899184|NCT01498224|Experimental|ReSure Sealant|Sealant application
89420053|NCT05956249|Experimental|Intervention Group: Online group therapy|"Online group therapy for the treatment of depression, anxiety and improvement of emotional well-being.The intervention will be carried out in 6 groups of 6 participants.~All meetings will be weekly, in groups and will last an average of 1 hour. After the end of the intervention, a scientific initiation fellow will contact the study participants, from both groups, to reapply the scales."
89420054|NCT05956249|Active Comparator|Control Group: Without online group therapy|The control group will only receive the intervention after the reassessment of the scales by the scholarship holder, who is blind to the groups.
89420055|NCT05956197||Acute Decompensation of Cirrhosis|Acute Decompensation of Cirrhosis
89420056|NCT05956145|Experimental|Intervention group|Colchicine 0.5 mg QD
89420057|NCT05956145|Placebo Comparator|Placebo group|Placebo
89420058|NCT05956080|Other|Allergy testing|
89420059|NCT05956067|Experimental|Equal energy white stimulus|Equal energy white light at 500 lux. The International Commission on Illumination (CIE) coordinates of this light are (x=y=0.33), indicating that the stimulus appears uniformly white which means that the activation of each of the three classes of photoreceptors are equivalent, thus silencing any chromatic opponency. The stimulus will be delivered by a portable battery-operated ganzfeld light stimulation device for 2 hours per day for 5 consecutive days.
89420060|NCT05956067|Experimental|Green light stimulus|Green light at 500 lux. Participants will view 545 nm green light delivered via a portable battery-operated ganzfeld light stimulation device for 2 hours per day for 5 consecutive days.
89420061|NCT05956067|Experimental|S-cone modulating white light|The S-cone modulating light stimulus will alternate between two light conditions at 500 lux that will activate the S-cones by about 100x differentially between the two conditions while maintaining the L- an M-cones at constant activation between the two alternating conditions using 427 nm versus 545 nm light. The stimulus will be delivered by a portable battery-operated ganzfeld light stimulation device for 2 hours per day for 5 consecutive days.
89420062|NCT05956054|Active Comparator|S1 transforaminal injection with a straight needle|
89420063|NCT05956054|Experimental|S1 transforaminal injection with a curved needle|
89420064|NCT05956028|Experimental|(group S)|receive ultrasound guided subclavian vein cannulation
89420065|NCT05956028|Active Comparator|(group I)|receive ultrasound guided internal jugular vein cannulation
89420066|NCT05955989|Active Comparator|Complete denture fabricated from Conventional heat curing|The patients in this group will receive complete dentures fabricated by conventional heat curing method. and they will receive soft lining of the complete dentures after one year.
89420067|NCT05955989|Active Comparator|complete denture fabricated by CAD/CAM milled technology|The patients in this group will receive complete dentures fabricated by CAD/CAM ( Computer aided design/ Computer aided manufacture) method. and they will receive soft lining of the complete dentures after one year.
89420068|NCT05955989|Active Comparator|complete denture fabricated by CAD/CAM 3D Printed technology|The patients in this group will receive complete dentures fabricated by 3D printing ( three dimension) method. and they will receive soft lining of the complete dentures after one year.
89420069|NCT05955963|Experimental|paediatric inflammatory bowel disease|
89420070|NCT05955950|Experimental|Gratitude List|Participants must to write 3-5 words a day for 14 days about aspects of their daily experience that they are grateful for.
89420071|NCT05955950|Active Comparator|List of any event|Participants must to write 3-5 words a day for 14 days about events of your own choosing that impressed the participant during the day, whether positive or negative.
88899185|NCT01498237|Experimental|Photoacoustic endoscopy|This is a one-arm, feasibility study to determine how well the experimental procedure photoacoustic endoscopy will evaluate the human endometrial cavity in vivo.
88899186|NCT01498250||basal cell carcinoma|
89420072|NCT05955833|Experimental|89Zr-DFO*-trastuzumab PET|Patients undergoing the 89Zr-DFO*-trastuzumab PET-scans
89420073|NCT05955820|Experimental|Conventional exercises for impingement syndrome|Four exercises (prone extension, side-lying external rotation, side-lying forward flexion, prone horizontal abduction with external rotation) will be performed for three sets of 10 repetitions
88899187|NCT01498250||non-lesional skin|
89420074|NCT05955820|Experimental|Suspension system exercises for impingement syndrome|Four exercises (Kneeling shoulder extension, Supine/ standing / kneeling row, sitting press up, kneeling push up) will be performed for 3-6 sets of 10 repetitions
89420075|NCT05955794|Other|patient group|500 (400 syndromic patients plus 100 non-syndromic controls matched for gender and age)
89420076|NCT05955794|Other|control group|500 (400 syndromic patients plus 100 non-syndromic controls matched for gender and age)
88899188|NCT01498315||Women following hysterecomy|
88899189|NCT01498354|Experimental|2-D high definition TEO (transanal endoscopic operation)|
88899190|NCT01498354|Active Comparator|Transanal endoscopic microsurgery (TEM)|Transanal endoscopic microsurgery (TEM), 3-D vision system using a rectoscope, which allows access to rectal tumors located up to 20 cm from the anal verge
88899191|NCT01498367|No Intervention|Usual care|Participants in the control group receive usual care. Usual care consists of regular visits to the specialist when required. In the occasion of the visit, HbA1c and glucose measurements are performed and the current oral or insulin therapy is modified if necessary. Patients also receive basic education in the management of diabetes.
88922198|NCT05656027|Experimental|Aceclidine + Brimonidine (LNZ101) dosed bilaterally|LNZ101 (Aceclidine /Brimonidine) ophthalmic solution
88922199|NCT05656027|Experimental|Aceclidine Ophthalmic Solution (LNZ100) dosed bilaterally|LNZ100 (Aceclidine) ophthalmic solution
89420077|NCT05955781|Experimental|Group A|Spinal Mobilization with Leg Movement (SMWLM) will be given as intervention to experimental group. Participants will be given Hot pack for 15 minutes, TENS for 10 minutes.
89420078|NCT05955781|Active Comparator|Group B|The patients will be given Spinal mobilization (transverse glide) on the effected spinous process. The total time duration will be 25-30 minutes. Participants will be given Hot pack for 15 minutes, TENS for 10 minutes.
89420079|NCT05955742|Experimental|Control|Glide path preparation with hand files.
89420080|NCT05955742|Experimental|ProGlider|Glide path preparation using rotational NiTi file.
88899192|NCT01498367|Experimental|Telemonitoring of diabetes 2 patients|Patients will have one educational visit to set up the system and explain how it works. Patients will download their measurements from their tele-glucose meter to their mobile phone and the data will be transferred to the regional database. The care team (a nurse specially trained and the allocated physician) will regularly access the patient's home diary, and will provide the appropriate counselling and medication changes as frequently as necessary. In addition to blood glucose measurements, routine questions about symptoms and eventual difficulties related to diabetes as well as diabetic management will be routinely captured and reported.
88899193|NCT01498380|Experimental|Dexmedetomidine Rapid Bolus|All subjects will receive a rapid bolus of dexmedetomidine following induction of anesthesia with propofol and remifentanil and placement of laryngeal mask airway.
89420081|NCT05955742|Experimental|WaveOne Gold Glider|Glide path was preparation using reciprocating NiTi file.
89420082|NCT05955716|Experimental|Virtual reality glasses|During the episiotomy incision and repair, women in this group watched a relaxation video with virtual reality glasses.
88899194|NCT01498406|Experimental|high dose vitamin D3|4,000 IU of vitamin D3 daily for 8 months
88899195|NCT01498406|Active Comparator|low dose vitamin D3|400 IU of vitamin D3
89420083|NCT05955716|No Intervention|Control Group|Women in this group received routine care in the hospital.
89420084|NCT05955703|Experimental|Using the experimental group as a result of the training based on PPM|"The training sessions planned within the scope of PPM were applied to the patients, who were divided into groups of six according to the bed order, for 15-20 minutes for eight weeks, when the patients felt well, through training booklets and power point presentations. When the trainings started, the posters prepared were hung in the waiting room while the intervention group was undergoing hemodialysis. The person providing the care of the patient was included in each training. During the trainings, it was requested that the training booklets be with the patients and the power point presentations continued in parallel with the training booklets.~Post-test was applied to intervention group~three months after the post-test application, follow-up test was applied to the intervention group in order to evaluate the impact."
89420085|NCT05955703|No Intervention|Using the control group as a result of the training based on PPM|After the follow-up test, training was given to the patients in the control group and a model-based training booklet was distributed.
88899196|NCT01498432|Experimental|Heliox21|
88899197|NCT01498432|Active Comparator|Air O2|
88899198|NCT01498497||PR-021 Eosinophilic Esophagitis (EoE) Subjects|Subjects who received study drug and completed PR-021 study
88899199|NCT01498510|No Intervention|treatment-as-usual (TAU)|The standard medical treatment provided to chronic pain patients at the study site pain specialty practice
88899200|NCT01498510|Experimental|TAU plus web-based intervention|An interactive, web-based intervention, based on principles of cognitive behavior therapy (CBT), that teaches chronic pain patients with aberrant behavior self-management skills to reduce pain severity and medication misuse and improve functioning
88899201|NCT01498523|Experimental|raw camel milk|
88899202|NCT01498523|Experimental|camel milk powder solution|
88899203|NCT01498523|Active Comparator|raw cow milk|
88899204|NCT01498523|Active Comparator|Glucose solution|
88899205|NCT01498562|Experimental|Gefitinib plus Nimotuzumab|Combination therapy group: Gefitinib(250mg daily) and Nimotuzumab (200mg weekly)
88899206|NCT01498562|Active Comparator|Gefitinib alone|Mono-therapy group: Gefitinib(250mg daily)
88899207|NCT01498614|Experimental|Affect school|Affect school is an educational intervention which includes 8 group sessions followed by 10 individual meetings with therapist
88899208|NCT01498614|Active Comparator|Basal body awareness|Basal body awareness is an educational method with 9 group sessions followed by 6 individual meetings
88899209|NCT01498627||Case Group|Subjects in this group are incident cases (i.e. newly diagnosed subjects) reported as having occurred in the previous twelve months before the recruitment consultation.
88899210|NCT01498627||Control Group|Subjects selected from the pool of potential referents reported by physicians in general practice, who meet the same general inclusion and exclusion criteria as the cases.
88899211|NCT01498666|Experimental|L. reuteri protectis tablets|one tablet a day for 4 weeks
88899212|NCT01498666|Placebo Comparator|Placebo tablet|one tablet a day for 4 weeks
88899213|NCT01498705||Hemmorhagic Stroke|"Hospitalization for an admitting diagnosis of hemorrhagic stroke admitted to the neurosurgical intensive care unit~Age greater than 18 years~No evidence of ischemic cerebrovascular injury"
88899214|NCT01498718|Experimental|Group 1A (18-50 yrs): DNA vaccine + TIV|HA DNA Vaccine (VRC-FLUDNA061-00-VP) at Day 0 and licensed TIV at Week 36
89420086|NCT05955677|Experimental|[68Ga]Ga-PSMA-D5 and [68Ga]Ga-PSMA-11 PET/ CT scan|Subjects PET/CT imaging: On any two days for two consecutive weeks, each subject underwent a PET/ CT scan after intravenous injection of [68Ga]Ga-PSMA-D5 and [68Ga]Ga-PSMA-11.
88899215|NCT01498718|Experimental|Group 2A (51-70 yrs): DNA vaccine + TIV|HA DNA Vaccine (VRC-FLUDNA061-00-VP) at Day 0 and licensed TIV at Week 36
88899216|NCT01498718|Placebo Comparator|Group 1B (18-50 yrs): TIV only|Phosphate buffered saline (PBS) on Day 0 + TIV at Week 36
88899217|NCT01498718|Placebo Comparator|Group 2B (51-70 yrs): TIV only|Phosphate buffered saline (PBS) on Day 0 + TIV at Week 36
88899218|NCT01498731|Experimental|Copeptin|"Patients who test negative for Copeptin at admission will be considered low-risk and will be discharged home without further interventions.~To secure the patients safety they will be transferred into our co-operating network of resident cardiologists using the software Praxis-connect i.e. these patients will be discharged with an electronically booked appointment to see a cardiologist preferably the next day (but latest within the next three days). In case of any findings suggestive of acute coronary syndrome or worsening of the patient's condition, the patient will immediately be re-admitted to our Emergency Room.~Patients who test positive for Copeptin will be treated as by standard practise."
88899219|NCT01498731|No Intervention|Standard|Patients will be managed as by standard practice abiding current guidelines for the management of patients with suspected ACS.The copeptin result will not be available for the treating physician.
88899220|NCT01498757||Patients treated with Taxane/5-FU/platinum based chemo.|
88899221|NCT01498783|Experimental|Treatment|"Participants meeting the eligibility requirements.~Intervention: 5-fluorouracil"
88899222|NCT01498796|Experimental|Ketorolac|
89194312|NCT01033513||MNT Only|The participants in this arm received MNT from the project RDs, who employed the Hyperlipidemia Medical Nutrition Therapy MNT Protocol, developed by ADA (2002). Because ADA had not finalized MNT protocols for hypertension, the RDs followed the protocol for hyperlipidemia for participants diagnosed with either hyperlipidemia or hypertension, with adjustments, as appropriate, to benefit those individuals who were diagnosed with hypertension.All MNT sessions were in the participants' homes, and if a caregiver was required for the individual to participate in the project, every effort was made to include this person in the MNT sessions. The MNT intervention took place over at least three sessions, and, in conformance with the ADA protocol, each participant received individualized counseling and education.
89194313|NCT01033513||Meals and MNT|The participants assigned to the MNT plus meals arm received both of the interventions, as described above.
89194314|NCT00733200|No Intervention|Control group|
89194315|NCT00877318|No Intervention|Control|Program of cardiac rehabilitation introduced in complete hospitalization pursued in day hospital during 3 months
89194316|NCT00877318|Experimental|telemedicine|Program of cardiac rehabilitation introduced in complete hospitalization pursued at home via a terminal during 3 months
89194317|NCT00577460|Active Comparator|Pramipexole|Patients to receive Pramipexole ER 0.375 - 4.5 mg in tablet form daily
89194318|NCT00577460|Placebo Comparator|Placebo|Patients to receive placebo tablets identical to Pramipexole ER tablets only during transfer phase
89194319|NCT00877396|Experimental|Influenza|Inactivated Influenza vaccination
89194320|NCT00877396|Placebo Comparator|Control|Hepatitis A vaccine
89194321|NCT00877474|Experimental|Arm 1|PM01183 administered i.v. over one hour, on Day 1, every three weeks, at a starting dose of 20 µg/m2.
89194322|NCT00872326|Experimental|Autologous Bone Marrow Mononuclear Cells|Consecutive inclusion among diabetic patients with critical limb ischemia. Intraarterial infusion of autologous bone marrow mononuclear cells
89194323|NCT00877552||Control|Typically developing
89194324|NCT00877552||Mild ventriculomegaly (MVM)|Fetal isolated mild ventriculomegaly
89194325|NCT00877552||Schizophrenia High Risk|Offspring of mothers with schizophrenia
89420087|NCT05955664|Placebo Comparator|MRI including DTI|"MR imaging will be performed on 3T MRI scanner (Skyra, Avanto) in supine position with no rectal contrast. The patients will undergo pelvic MRI with additional diffusion tensor (DTI) sequences dedicated for assessment of the fibres in the pelvic floor muscles.~DTI will be processed with the use of special software. The images will be assessed separately by two clinicians who will not know patients' symptoms or results of the US."
88899223|NCT01498796|Placebo Comparator|Placebo|
88899224|NCT01498835|Experimental|Combined Sunitinib and irradiation|Patients with locally advanced or recurrent soft tissue sarcoma will receive Sunitinib and irradiation as neoadjuvant treatment. Restaging and tumor resection will be performed 6 weeks after completion of sunitinib and irradiation.
88899225|NCT01498848|Active Comparator|Soybean oil|Families were given soybean oil for cooking during 4 weeks
88899226|NCT01498848|Active Comparator|Sunflower oil|Families were given sunflower oil for cooking during 4 weeks
88899227|NCT01498861|Other|Run-In Period|Ortho-Cyclen for 21 days. Only for subjects who are not already taking Ortho-Cyclen prior to the study
88899228|NCT01498861|Experimental|Sequence AB|Subjects will take Ortho-Cyclen once a day from Day 1-21 of their menstrual cycle. In addition they will take dolutegravir 50 mg twice a day from Days 1-10 and placebo twice a day from Day 12-21
88899229|NCT01498861|Experimental|Sequence BA|Subjects will take Ortho-Cyclen once a day from Day 1-21 of their menstrual cycle. In addition they will take placebo twice a day from Days 1-10 and dolutegravir 50 mg twice a day from Day 12-21
88899230|NCT01498874|Placebo Comparator|Placebo|
88899231|NCT01498874|Experimental|low dose gevokizumab|
88899232|NCT01498874|Experimental|high dose gevokizumab|
88899233|NCT01498900||Repaglinide|
88899234|NCT01498913||Repaglinide|
88899235|NCT01498926|Experimental|Glycerol|
89194326|NCT00877552||Bipolar High Risk|Offspring of mothers with schizophrenia
89420088|NCT05955664|Active Comparator|Pelvic floor ultrasound.|"Internal pelvic floor ultrasound will be performed with the use of high-frequency transducers with automatic 3D image acquisition by one of the Consultant Radiologists involved in the study.~No preparation is required. No vaginal or rectal contrast is used. The patient will be scanned in a supine position and the probe is inserted into the vagina in the neutral position to avoid excessive pressure on surrounding structures to avoid distortion of the anatomy. The 3D data automatic acquisition takes approximately 70 seconds.~The analysis of the ultrasound images will be performed on the Trust computers by Radiologists experienced in pelvic floor ultrasound."
89420089|NCT05955599|Experimental|Pre-adolescent Intervention|11-13 year old female handball players complete a supervised ACL injury prevention program twice a week (2 x 15 minutes) for a duration of 8 weeks. The ACL injury prevention training consists of three tracks focusing on 1) hamstring and hip external rotation strength; 2) medial hamstring activation; 3) single leg landing technique training with a special focus on knee control. The training is integrated in the players/team's normal handball practice.
89420090|NCT05955599|Other|Pre-adolescent Control|11-13 year old female handball players complete a supervised shoulder injury prevention program twice a week (2 x 15 minutes) for a duration of 8 weeks. The shoulder injury prevention training consists of three tracks focusing on 1) external rotator cuff strength; 2) scapula stability; 3) core strength and trunk rotation. The training is integrated in the players/team's normal handball practice.
89420091|NCT05955599|Experimental|Adult Intervention|Adult (≥18 year old) female handball players complete a supervised ACL injury prevention program twice a week (2 x 15 minutes) for a duration of 8 weeks. The ACL injury prevention training consists of three tracks focusing on 1) hamstring and hip external rotation strength; 2) medial hamstring activation; 3) single leg landing technique training with a special focus on knee control. The training is integrated in the players/team's normal handball practice.
89420092|NCT05955599|Other|Adult Control|Adult (≥18 year old) female handball players completed a supervised shoulder injury prevention program twice a week (2 x 15 minutes) for a duration of 8 weeks. The shoulder injury prevention training consists of three tracks focusing on 1) external rotator cuff strength; 2) scapula stability; 3) core strength and trunk rotation. The training is integrated in the players/team's normal handball practice.
89420093|NCT05955560|Other|Treatment Sequence 1|PureWick™ Male External Catheter is used first, followed by cross-over to Sage PrimoFit.
89420094|NCT05955560|Other|Treatment Sequence 2|The Sage PrimoFit™ is used first, followed by cross-over to PureWick MEC.
89420095|NCT05955547||APACHE-II|
89420096|NCT05955547||APACHE-Inf|
89420097|NCT05955521|Experimental|CtDNA/Exosome evaluation|
89420098|NCT05955404|Experimental|Kangaroo mother care|This study uses the Kangaroo mother care as a non-pharmacological strategy to alleviate the pain that preterm infants experience in the NICU.
89420099|NCT05955391|Experimental|Experimental: TGRX-326|Subjects to be treated with the investigational drug TGRX-326 at 60 mg once day in 21-day cycles.
89420100|NCT05955378|Experimental|DSR Ankle|The DSR Ankle is a novel microprocessor-controlled ankle prosthesis that is able to provide enhanced mobility and stability to individuals with lower limb amputation. It interfaces to the user by attaching to their socket via an industry-standard pyramid connector.
89420101|NCT05955378|Active Comparator|Predicate Ankle|The predicate ankle is the user's prescribed prosthesis worn for the activities of daily living.
89420102|NCT05955313|Experimental|Naltrexone|NALTREXONE HYDROCHLORIDE 4,5 mg, coated oral tablets, 1xd. for 4 months
89420103|NCT05955313|Placebo Comparator|Placebo|Placebo, coated oral tablets, 1xd.
89420104|NCT05955287|Experimental|Couple Intervention|"Patients will receive usual care. In addition, they will participate in virtual OSA support groups led by an African American peer-motivator patient with long-standing OSA and their bed partner. Peer-motivator couples will be trained and certified as competent prior to interacting with study participants. They will share their experiences with managing OSA including coping strategies to maximize CPAP adherence.~Telemonitoring. Patients and bed partners will receive text messages encouraging CPAP adherence."
89420105|NCT05955287|Active Comparator|Control|Patients with CPAP technical difficulties will be encouraged to contact the sleep technologist for assistance. Patients will also attend a 90-minute virtual webinar and question-answer session on hypertension management (1 month), cancer screening (3 months), and weight management (6 months) led by African American physicians with expertise in each topic.
89194327|NCT00736112|Experimental|BMT and food allergy|trial subjects will receive food allergy testing and management in conjunction with BMT (Bilateral Myringotomy with Tympanostomy Tubes). Food allergy management involves parental education on how to avoid the specific offending foods.
89420106|NCT05955274|Active Comparator|mBPT only|
89420107|NCT05955274|Experimental|mBPT and just-in-time adaptive intervention|
89420108|NCT05955248|Placebo Comparator|Control (CTRL)|Participants will be treated following Enhanced Recovery After Surgery (ERAS) protocols + placebo supplements containing maltodextrin and sunflower oil
89420109|NCT05955248|Active Comparator|Mixed-nutriend supplement (NUT)|Mixed nutrient supplement containing whey protein, leucine, vitamin D and omega 3 fatty acids
89420110|NCT05955248|Active Comparator|Multi-modal intervention (MM)|Multimodal prehabilitation including structured exercise (1 supervised exercise session per week + home-based exercise program), nutritional optimization with dietician, NUT intervention, and relaxation strategies.
88899236|NCT01498926|Active Comparator|Mannitol|
89420111|NCT05955209|Experimental|Disitamab Vedotin(RC48-ADC)|Disitamab Vedotin(RC48-ADC) :2.0mg/kg，Q2W
89420112|NCT05955144|Other|Repeatable bilirubin measurement independent of phone|all subjects will receive bilirubin measurement from 4 different smartphones and a transcutaneous device to ensure that the measurement of bilirubin is not affected by phone camera
88899237|NCT01498939|Experimental|IDet 0.2 U/kg|
89194328|NCT00736112|Experimental|BMT and adenoidectomy|"involves BMT (Bilateral Myringotomy with Tympanostomy Tubes), adenoidectomy, and food allergy testing and management.~Food allergy management involves parental education on how to avoid the specific offending foods."
89194329|NCT00736112|Active Comparator|BMT alone|The standard protocol for children presenting with initial Chronic OME is to perform a BMT (Bilateral Myringotomy with Tympanostomy Tubes).
89194330|NCT00863980|Experimental|Telmisartan|Treatment with Telmisartan
89194331|NCT00863980|Active Comparator|Candesartan|Treatment with Candesartan
88899238|NCT01498939|Experimental|IDet 0.4 U/kg|
89194332|NCT00415519|Experimental|1|
88899239|NCT01498939|Experimental|IDet 0.8 U/kg|
88899240|NCT01499004|Experimental|Treatment A|tofacitinib (CP-690,550) modified-release formulation A-Fed
88899241|NCT01499004|Experimental|Treatment B|tofacitinib (CP-690,550) modified-release formulation B1-Fed
88899242|NCT01499004|Experimental|Treatment C|tofacitinib (CP-690,550) modified-release formulation A-Fasted
88899243|NCT01499004|Experimental|Treatment D|tofacitinib (CP-690,550) modified-release formulation B1-Fasted
88899244|NCT01499004|Experimental|Treatment E|tofacitinib (CP-690,550) modified-release formulation B2-Fasted
88899245|NCT01499004|Experimental|Treatment F|tofacitinib (CP-690,550) immediate-release formulation-Fasted
88899246|NCT01499017|Experimental|Cohort A|Each subjects in Cohort A will receive 3 single doses of PF-06291874 and 1 placebo dose in random order in Periods 1-4.
89194333|NCT00415519|Placebo Comparator|2|
89420113|NCT05955131|Other|Control Bread|Subjects will eat control bread, in an amount containing 50g of carbohydrates
89420114|NCT05955131|Experimental|Bread Supplemented with Chilean Beans|Subjects will eat bread supplemented with Chilean native beans at 30% w/w, in an amount containing 50g of carbohydrates
89420115|NCT05955131|Other|Glucose control|Subjects will drink glucose, in an amount containing 50g of carbohydrates
89420116|NCT05955118||Open Angle Glaucoma|Subjects with mild to moderate open angle glaucoma undergoing bilateral combined cataract surgery & Hydrus Microstent implantation.
89420117|NCT05955105|Experimental|Treatment Arm|Subjects will receive ILB-2109 tablets and Toripalimab injection
89420118|NCT05955079||Endometrial Cancer|Patients over 18 years old with a biopsy-proven endometrial cancer, at FIGO stage I to IV, and amenable and undergoing surgical treatment
89420119|NCT05955027|Experimental|80mg group|D1, two 40mg tablets and two placebo tablets
89420120|NCT05955027|Experimental|160mg group|D1, four 40mg tablets
89420121|NCT05955027|Placebo Comparator|Placebo group|D1, 4 placebo tablets
89420122|NCT05954663||Patients who underwent venous recanalization by angioplasty-stenting|Patients who underwent venous recanalization by angioplasty-stenting for post-thrombotic iliofemoral syndromes from June 2014 to June 2021.
89006684|NCT04618939|Active Comparator|Td-pur inj|Randomized subjects were assigned to receive a single dose of Td-pur inj
89006685|NCT00562900|Active Comparator|A, robotic|
89006686|NCT00562900|Active Comparator|B, laparoscopic|
89006687|NCT04618900|Experimental|Osteotome-mediated sinus floor elevation with Bio-Oss collagen|Sinus floor elevation with a grafting material (Bio-Oss collagen)
89006688|NCT04618900|Placebo Comparator|Osteotome-mediated sinus floor elevation with no grafting material|Sinus floor elevation with no grafting material
89420123|NCT05952440||RA in remission who performed synovial biopsy before treatment change|
89420124|NCT05952440||RA in remission eligible to synovial biopsy before treatment change|
89420125|NCT05952440||Subjects asymptomatic for joint inflammation without ACPA/RF positivity|
89420126|NCT05952349|Active Comparator|Combination Therapy Group|ARM# 1 OLIVE OIL 5ML/5MG (BD) NUTRITIONAL SACHET 2100MG (BD)
89420127|NCT05952349|Other|Standard Therapy Group|ARM # 2 METFORMIN 1000MG (BD)
89006689|NCT04619134|Experimental|NCSR Program|Non Pain Contingent Spinal Rehabilitation
89006690|NCT04619134|Active Comparator|Conventional Physical therapy|Conventional Physical Therapy
89006691|NCT00243477|Active Comparator|Treatment|Escitalopram given
89006692|NCT00243477|Placebo Comparator|Placebo|Placebo given
89420128|NCT05952310|Experimental|Allogeneic Natural Killer cells|Low doses (1x106/UI/m2) of subcutaneous interleukin-2 (IL-2) will be administered every 48h for a maximum of 6 doses, in conjunction with the NK cell infusion, to favor the expansion and antitumor effect of the NK cells.
89420129|NCT05951920|Experimental|Lymph node aspiration / Blood sampling|
89420130|NCT05951504|Active Comparator|Solumedrol 1 Dose|Patients with an odontogenic cervicofacial infection were treated with one dose of Solumedrol 125mg intravenous at time of surgery. Remainder of management was as per protocol.
89420131|NCT05951504|Active Comparator|Solumedrol 4 Dose|Patients with an odontogenic cervicofacial infection were treated with one dose of Solumedrol 125mg intravenous at time of surgery, as well as three consecutive doses of Solumedrol 125mg intravenous every six hours post-operatively. Remainder of management was as per protocol.
89420132|NCT05951348|No Intervention|Immediate cord clamping|this arm where the patient didn't receive any special maneuver and immediate cord clamping after delivery of the fetus is done
89420133|NCT05951348|Experimental|Delayed cord clamping|this arm where the patient receive a delay in cord clamping for 30 seconds after delivery of the fetus
89420134|NCT05951348|Experimental|Umbilical cord milking|this arm where the patient receive stripping of the umbilical cord in the direction of the fetus 10 times in a time frame 10-15 seconds after delivery of the fetus
89420135|NCT05950386||The control group|The invited non-lead-exposed workers live in Yangzhou, Jiangsu, China
89420136|NCT05950386||The lead exposure group|The invited chronic-lead exposed workers live in Yangzhou, Jiangsu, China
88899247|NCT01499017|Experimental|Cohort B|Each subjects in Cohort B will receive 2 single doses of PF-06291874 and 1 placebo dose in random order in Periods 1-3; in addition, 1 dose of PF-06291874 will be administered in Period 4 in the fed state.
89420137|NCT05950178|Other|Clinical brain death|The protocol is based on performing two consecutive apnea tests on a patient in clinical brain death in intensive care unit. The first apnea test will be conducted under standard oxygen therapy and confirms clinical brain death (standard procedure). The second apnea test (for the study) will be conducted under high-flow oxygen therapy. Only patients whose apnea test is initially validated under standard oxygen therapy will have the second apnea test under high-flow oxygen therapy.
88899248|NCT01499056|Experimental|hip osteoarthritis|The patients with hip joint osteoarthritis who underwent cell injection
88899249|NCT01499069|Experimental|Antimuscarinic agents|
88899250|NCT01499108|Experimental|Liraglutide|single-group study were participants recieve Liraglutide
88899251|NCT01499121|Other|Sunitinib|Starting dose/schedule of Sunitinib 50 mg/28 days on, 14 days off. The intent is to maximize dose intensity of Sunitinib and minimize time off therapy based on individual tolerability using dose modification criteria.
88899252|NCT01499186|No Intervention|Control group|There will be no participation in a training program. The control group will perform all measurements.
88899253|NCT01499186|Experimental|Intervention group|The subjects of the vibration group will be subjected to local vibration training by the use of custom-made cylindrical vibrators. These subjects will perform all measurements.
89194334|NCT03841162||Patients with suspected sepsis|Patients for whom blood cultures are drawn at the Emergency Department or the department of Infectious Diseases/Nephrology
89420138|NCT05946200|Active Comparator|Low flow|It will be used low-flow (0.75 l/min) to manage the general anesthesia.
89420139|NCT05946200|Sham Comparator|Normal flow|It will be used normal-flow (1.5 l/min) to manage the general anesthesia.
89420140|NCT05940688|Experimental|Digital Health Intervention|This group will receive routine prenatal care services. Additionally, those randomized to this arm will receive a DHI intervention. A modified DHI will be utilized that was developed by Memora Health in conjunction with EQUATE partners at UPenn and feedback from the POPPY Study Team and Community Advisory Board. All content is designed for 7th grade Flesch-Kincaid level or lower.
89420141|NCT05940688|Experimental|Community health worker (CHW)|"Individuals randomized to this group will receive routine prenatal care services. Additionally, they will receive a CHW intervention. The CHW intervention will be adapted from an ongoing CHW program in Jefferson County, AL called From Day One (FDO), a comprehensive patient-centered program designed to educate and provide non-clinical, psychosocial, emotional support to expectant mothers from the 1st trimester of pregnancy through their child's first year of life. The intervention has been modified by the POPPY Study Team and Community Advisory Board."
89420142|NCT05940688|Experimental|DHI Plus CHW|This group will receive routine prenatal care services. Additionally, this group will receive both DHI and CHW interventions.
88899254|NCT01499212|Experimental|I:E ratio 1:1|
88899255|NCT01499225|Experimental|YH14642 A-I|
88899256|NCT01499225|Experimental|YH14642 A-II|
88899257|NCT01499225|Experimental|YH14642 A-III|
88899258|NCT01499225|Active Comparator|Active Comparator B|
88899259|NCT01499225|Active Comparator|Active Comparator C|
88899260|NCT01499225|Placebo Comparator|Placebo|
88899261|NCT01499238|Active Comparator|nasal SIMV|rate: 30-50/min, PIP: 16, PEEP: 4-6, fİO2: 40%
88899262|NCT01499238|Active Comparator|nasal CPAP|PEEP: 4-6 mmHg, Fio2: 40%
88899263|NCT01499251|Experimental|Macitentan|Macitentan in combination with dose-dense temozolomide
88899264|NCT01499264|Experimental|MySkin patch|Hydrogel e polyurethane film
88899265|NCT01499264|Active Comparator|Traditional Dressing|
88899266|NCT01499316|Experimental|High Flow oxygen|10 minute of 10/L min of inhaled oxygen with reservoir bag.
88899267|NCT01499316|Experimental|Room Air|
88899268|NCT01499329||Patient receiving stent therapy|
88899269|NCT01499381||Routine prostate biopsy patients|
88899270|NCT01499394||Normal|"Donor samples reflective of a normal non-disease state"
89194335|NCT00736268|Experimental|CST|Telephone-based Enhanced Coping Skills Training (CST)
89194336|NCT00736268|Other|UMC|Usual Medical Care and COPD education and symptom monitoring (UMC)
89194337|NCT01323907|Experimental|Omegaven|Omegaven IV lipid emulsion administration for infants with life threatening parenteral nutrition associated liver disease
89194338|NCT01323985|Experimental|GSK2315698|Intravenous infusion single dose
88899271|NCT01499394||Disease state or condition|Donor samples reflective of a known disease state or condition
88899272|NCT01499407|Active Comparator|Standard abciximab bolus|
88899273|NCT01499407|Experimental|ClearWay-infused abciximab|
88899274|NCT01499407|Experimental|Thrombectomy plus ClearWay-infused abciximab|
88899275|NCT01499407|Active Comparator|Thrombectomy plus standard abciximab bolus|
88899276|NCT01499433|Experimental|caspofungin|
88899277|NCT01499446|Experimental|GW685698X (fluticasone furoate) 100mcg Morning|
88899278|NCT01499446|Experimental|GW685698X (fluticasone furoate) 100mcg Evening|
88899279|NCT01499446|Experimental|GW685698X (fluticasone furoate) 250mcg Evening|
88899280|NCT01499446|Placebo Comparator|Placebo|
88899281|NCT01499459|Experimental|autologous mesenchymal stem cell transplantation|
88899282|NCT01499472|Active Comparator|shock wave therapy, shortened wound healing time|
88899283|NCT01499472|Other|normal wound care|standard of care intervention
88899284|NCT01499485|Experimental|Acetazolamide|
88899285|NCT01499485|Placebo Comparator|placebo|
88899286|NCT01499537|Active Comparator|Percutaneous Drainage|Percutaneous Transhepatic Biliary Drainage (PTBD)
88899287|NCT01499537|Experimental|EUS-guided drainage|endoscopic ultrasonography guided biliary drainage through the duodenal or the gastric wall
88899288|NCT01499550|Experimental|TNI application|In this study arm the patient is treated with humidified transnasal high flow (TNI) plus oxygen (result flow: 20 L/min).
88899289|NCT01499550|Active Comparator|Oxygen treatment|Long term oxygen treatment (LOT) is the routine treatment in patients suffering from COPD. In this study arm the patient is treated with his individual oxygen flow rate.
89420143|NCT05940688|No Intervention|Usual Care|This group will receive routine prenatal care services.
88899290|NCT01499589||RA in block room|Performing regional anesthesia in the block room
88899291|NCT01499589||RA inside OR|Performing regional anesthesia inside the main orthopedic operating room
88899292|NCT01499602|Experimental|LNG-IUS|Release rate of 20µg Levonorgestrel(Mirena, Bayer Schering Pharma Oy, Finland) per day with one year follow up.
88899293|NCT01499602|Active Comparator|Norethisterone Acetate|Norethisterone Acetate tablets at a dose of 5 mg three times daily (15mg/day) for 3 weeks over three months.With persistence of endometrial hyperplasia, the treatment is repeated for another 3 months
88899294|NCT01499615||children undergoing general anesthesia|The intervention was the application of 4 ekg electrodes so as to non-invasivly measure cardiac output
88899295|NCT01499641|Active Comparator|Epidural steroid|1.0 mL methylprednisolone acetate 40 mg/mL instilled at the decompressed nerve root
88899296|NCT01499641|Experimental|None epidural steroid|
88899297|NCT01499680||NV in XLIF|This group will have the XLIF procedure done using NV.
88899298|NCT01499693|Experimental|Magnesium Pantoprazole 20mg|
88899299|NCT01499693|Active Comparator|Magnesium Pantoprazole 40mg|
88899300|NCT01499706|No Intervention|Standard of Care Control|Participants will receive standard sexual risk reduction services available to them through medical and community-based organizations
88899301|NCT01499706|Experimental|1-session motivational interviewing|Participants will receive a single session of motivational interviewing delivered over the telephone
88899302|NCT01499706|Experimental|4-session motivational interviewing|Participants will receive four weekly sessions of motivational interviewing delivered over the telephone.
88899303|NCT01499719||Surgical checklist|Compliance for surgical checklist
88899304|NCT01499732||Early Rheumatoid Arthritis|Subjects currently experiencing active early rheumatoid arthritis (duration of symptoms < or = 2 years) according to the 2010 ACR/EULAR criteria for the diagnosis of RA at screening. Must be drug naive (no prior treatment with traditional disease-modifying antirrheumatic drugs (DMARDs), or biologic response modifying agents)
88899305|NCT01499732||Healthy subjects without rheumatoid arthritis|Healthy subjects without rheumatoid arthritis
88899306|NCT01499732||Established Rheumatoid Arthritis|Subjects currently experiencing active established rheumatoid arthritis (duration fo symptoms > or = 2 years) according to the 2010 ACR/EULAR criteria at screening. Subjects with active established RA currently receiving methotrexate, must have received it for at least 12 weeks, and at a stable dose (> or = 15 mg/week) for at least 6 weeks prior to screening. They must be biologic naive, and must recieve at least 5mg oral folic acid weekly
89420144|NCT05939297||people with coronary heart disease|In order to measure the self-management and self-efficacy levels of the patients,Heart Health Self-efficacy and Self-Management Scale , Self-Care Management Scale in Chronic Diseases, general self-efficacy scales will be applied to the patients.
89420145|NCT05937477||Neoadjuvant, Adjuvant Chemotherapy Arm|Patients diagnosed with lung, head and neck, or esophageal cancer and undergoing Neoadjuvant, Adjuvant chemotherapy.
89420146|NCT05937477||Palliative Chemotherapy Arm|Patients diagnosed with lung, head and neck, or esophageal cancer and undergoing Palliative chemotherapy.
89420147|NCT05932758|Other|no excisional biopsy|Patients in this arm underwent to an initial sequence of sampling (less than 4 g of tissue sampled)
89420148|NCT05932758|Experimental|excisional biosy|Patients in this arm will undergo a second sequence of biopsy samples (at least 4g sampled)
89420149|NCT05927753|Experimental|Test lens. Deseyne Daily Disposable Contact Lens|Test contact lens to be worn as a daily disposable soft (hydrophilic) contact lens, to be discarded daily. Individual new lens placed daily for a period of 90 consecutive days, bilaterally. Follow-up visits are 1 week, 1 month, 2 months, and 3 months after dispensing.
89420150|NCT05927753|Active Comparator|Control lens. 1-Day Acuvue Moist Daily Disposable Contact Lens|Control lens to be worn as a daily disposable soft (hydrophilic) contact lens, to be discarded daily, Individual new lens placed daily for a period of 90 consecutive days, bilaterally. Follow-up visits are 1 week, 1 month, 2 months, and 3 months after dispensing.
89420151|NCT05925166|Experimental|rhTNFR-Fc|Subjects will be administered rhTNFR-Fc 50 mg subcutaneously
89420152|NCT05925166|Active Comparator|Triamcinolone acetonide|Subjects will be administered triamcinolone acetonide 40 mg intramuscularly
88922200|NCT05656027|Experimental|Brimonidine ophthalmic solution dosed bilaterally|Brimonidine ophthalmic solution
88922201|NCT05655351|Experimental|Patients vaccinated with the anti-SARS-Cov-2 vaccination|These patients will receive the anti-SARS-Cov-2 vaccination and their blood will be regularly monitored.
89006693|NCT04619173|Experimental|Thoracic manipulation|additional thoracic manipulation along with hotpack, transcutaneous electrical nerve stimulation ,serratus anterior,pectoralis major,minor, posterior capsular stretches..
89420153|NCT05917795|Experimental|kidney transplant candidates with obesity (BMI > 35 kg/m2)|Subjects with an indication to kidney transplantation that are not listed because of a high BMI according to the policy of the transplant Centre (cut-off 35 kg/m2)
89420154|NCT05916404|Experimental|Training Group|The training group will receive upper extremity high-intensity interval aerobic exercise training on an arm ergometer accompanied by a physiotherapist for 6 weeks.
89420155|NCT05916404|Sham Comparator|Control Group|The control group will not be given any training for 6 weeks during the study period.
89420156|NCT05914155|Active Comparator|Rituximab group in double-blind phase|
89420157|NCT05914155|Placebo Comparator|Placebo group in double-blind phase|
89420158|NCT05914155|Other|Rituximab group in open-label phase|
89420159|NCT05910463|Experimental|AXOMOVE Therapy|Use of a web and mobile application for remote monitoring and rehabilitation
89420160|NCT05910463|No Intervention|Routine care|Current rehabilitation support care
89420161|NCT05907395|Experimental|PF-07293893 and Placebo (Cohort 1)|Single dose administration of PF-07293893 and placebo; Within a cohort, participants will receive up to 4 doses of PF-07293893 and up to 2 doses of placebo.
89420162|NCT05907395|Experimental|PF-07293893 and Placebo (Cohort 2)|Single dose administration of PF-07293893 and placebo; Within a cohort, participants will receive up to 4 doses of PF-07293893 and up to 2 doses of placebo.
89420163|NCT05907395|Experimental|PF-07293893 and Placebo (Cohort 3)|Single dose administration of PF-07293893 and placebo; Within a cohort, participants will receive up to 4 doses of PF-07293893 and up to 2 doses of placebo.
89194339|NCT02568176|Experimental|Cohort 1|Participants will receive single oral dose of midazolam 6 milligram (mg) on Day 1 and 17. Participants will self-administer esketamine intranasally thrice per day on morning of Day 2, 5, 9, 12 and 16 (84 mg).
89194340|NCT02568176|Experimental|Cohort 2|Participants will receive single oral dose of bupropion 150 mg on Day 1 and 19. Participants will self-administer esketamine intranasally thrice per day on morning of Day 4, 7, 11, 14 and 18 (84 mg).
89194341|NCT01033591|Experimental|Exercise|Supervised exercise + Optimized treatment according to the European Society of Cardiology guidelines
89194342|NCT01033591|Other|Control|Optimized treatment according to the European Society of Cardiology guidelines
89194343|NCT00741182|Experimental|Femur PTH(1-34)|24 participants with trochanteric fractures will be assigned to Forsteo (PTH(1-34)) treatment
89194344|NCT00741182|No Intervention|Femur Control|"24 participants with trochanteric fractures will be assigned to no treatment"
89194345|NCT00741182|Experimental|Humerus PTH(1-34)|24 participants with collum chirurgicum fracture will be assigned to Forsteo (PTH(1-34)) treatment
89194346|NCT00741182|No Intervention|Humerus Control|"24 participants with collum chirurgicum fracture will be assigned to no treatment."
89194347|NCT00872404|Experimental|1|CP-751,871 will be administered as an open-label intravenous solution. Patients will remain under clinical observation for one hour post-infusion
89194348|NCT00423943|Experimental|D|modafinil
89194349|NCT00423943|Placebo Comparator|Placebo|placebo
89194350|NCT00877630||1:endoscopic group|patients underwent endoscopic thyroidectomy
89194351|NCT00877630||2:conventional group|patients underwent open thyroidectomy
89194352|NCT00736346|Active Comparator|1|
89194353|NCT00736346|Active Comparator|2|
89194354|NCT00736346|Active Comparator|3|
89194355|NCT00736346|No Intervention|4|
89194356|NCT00864058|Experimental|A|Gabapentin 400 mg capsules
89194357|NCT00864058|Active Comparator|B|Neurontin 400 mg capsules
89194358|NCT00741416||Case|Those with a diagnosis of Coronary Artery Disease
89194359|NCT00741416||Control|Those who do not have Coronary Artery Disease (are healthy) but are matched to a Case participant by age, gender, and ethnicity.
89194360|NCT00864136||Group 1|
89194361|NCT00864136||Group 2|
89194362|NCT00864136||Group 3|
89194363|NCT05742308|Experimental|Experimental: Laughter yoga|The intervention group received laughter yoga twice a week for three weeks.
89194364|NCT05742308|No Intervention|No Intervention: Control group|The control group did not take part in the laughter yoga program.
89420164|NCT05896293|Experimental|kisspeptin pump|SC administration of kisspeptin for two weeks (pulsatile, every 60-240 minutes)
89194365|NCT00864214|Experimental|1|Estrogen is the Biest 2.0 mg bioidentical cream; the placebo is the transdermal patch; the progesterone is compounded progesterone-100 mg
89420165|NCT05887388|Experimental|Intervention|Connect-Home Plus will be delivered in the skilled nursing facility and via telephone after discharge.
89420166|NCT05886374|Experimental|HMPL-415S1|HMPL-415S1 will be administered orally once daily in 28 days treatment cycles
89420167|NCT05882006||cases|IBD patients (including Crohn's disease and Ulcerative colitis)
89420168|NCT05882006||controls|Age, sex, and calendar-year matched controls sampled from non-IBD patients to be a round number of at least four times the number of cases
89420169|NCT05881928|Other|50 epileptic patients receive SV for 6 months , for whom add lamotrigine for 6 month|50 epileptic patients receive SV for 6 months at dose 30 mg.kg.day, for whom add lamotrigine for 6 month at dose 0.5 mg.kg.day then add 0.5 mg.kg.day every 2 weeks
89420170|NCT05872893|Experimental|ondansetron + dexamethasone, continuous infusion|Patients will receive a continuous infusion of age-adjusted doses of first-generation 5-HT3 receptor antagonist ondansetron in combination with dexamethasone
89420171|NCT05872893|Active Comparator|ondansetron + dexamethasone, push injection|Patients will receive standard i/v push injections of first-generation 5-HT3 receptor antagonist ondansetron and dexamethasone
89420172|NCT05869747|Active Comparator|Blood Donation|
89420173|NCT05869747|Active Comparator|Plasma Donation|
89420174|NCT05869747|Placebo Comparator|Blood/Plasma Control|
89420175|NCT05869747|Active Comparator|Zone 2 Training|
89420176|NCT05869747|Active Comparator|Intermittent Fasting|
89420177|NCT05869747|Placebo Comparator|Zone 2 Control|
89420178|NCT05869747|Placebo Comparator|Intermittent Fasting Control|
89420179|NCT05869539|Experimental|Tumor-infiltrating lymphocyte transfer combined with ANV419|"Patients have excisional biopsy/surgical resection of tumor lesion(s) (tumor collection) and TILs are expanded from this lesion/these lesions (TIL expansion).~The transplant product will be produced in the Good Manufacturing Practice (GMP) facility of the University Hospital in Basel. TIL transfer to patient and first administration of ANV419 at day 0."
89420180|NCT05863026|Experimental|iDEAL group|School cluster randomization will be used to ensure administrative efficacy, lessened risk of experimental contamination, and enhancement of subject compliance. 20 standard 4 classrooms and 20 form 4 classrooms from primary and secondary school, then will be divided randomly into intervention and control group. The unit of randomization will be on a 1:1 basis in either the control or intervention group.
89420181|NCT05863026|No Intervention|Control|School cluster randomization will be used to ensure administrative efficacy, lessened risk of experimental contamination, and enhancement of subject compliance. 20 standard 4 classrooms and 20 form 4 classrooms from primary and secondary school, then will be divided randomly into intervention and control group. The unit of randomization will be on a 1:1 basis in either the control or intervention group.
89420182|NCT05858359|Experimental|ImPACT program|The ImPACT program consists of 8 weekly 1-hour sessions with homework between sessions.
89420183|NCT05858359|No Intervention|Waitlist|Waitlist control
89420184|NCT05855226|No Intervention|Care as usual|Care as usual, consist of GR rehabilitation when a patient is back at home.
89420185|NCT05855226|Experimental|OTHER-intervention|The OTHER-intervention is part of the OT care. Start during inpatient GR rehabilitation and goes on 12 weeks afte discharge when a patient is home. The OT will coach a patient and use a activity monitoring system. Also videoconferencing will be used.
89420186|NCT05826288|Experimental|Post BMT or CAR-T patients receiving care at UCHealth|"Participants will be recruited for this study from among three discrete patient populations:~Allogeneic BMT patients receiving care at UCHealth who are planning to reside in the Denver metro area within 45 minutes of the Anschutz Medical Campus (AMC) for at least 90 days post-transplant.~Autologous BMT patients receiving care at UCHealth who are planning to reside in the Denver metro Area within 45 minutes of the AMC for at least 30 days post-transplant.~CAR-T patients receiving care at UCHealth who are planning to reside in the Denver metro area within 45 minutes of the AMC for at least 30 days post treatment."
89420187|NCT05826275|Experimental|Dose Escalation|To determine the MTD in patients with HPV-associated cancers
89420188|NCT05826275|Experimental|Dose Expansion|Dose Expansion Phase, in parallel one dose level lower than the highest dose deemed safe in Dose escalation with a PD-1 checkpoint blockade.
88899307|NCT01499745|Active Comparator|Exercise Training at Pulmonary Rehabilitation Program|Exercise Training at Pulmonary Rehabilitation Program 2 weekly sessions of 60 min for 12 weeks
88899308|NCT01499745|Placebo Comparator|Standard Treatment for IPF|Continue for normal live with standard treatment
88899309|NCT01499758|Experimental|1|Atorvastatin Calcium Tablets of OHM Laboratories Inc.
88899310|NCT01499758|Active Comparator|2|LIPITOR® Tablets 80mg of Pfizer Ireland Pharmaceuticals
88899311|NCT01499771|Experimental|1|Atorvastatin Calcium Tablets of OHM Laboratories Inc.
88899312|NCT01499771|Active Comparator|2|LIPITOR® Tablets 80mg of Pfizer Ireland Pharmaceuticals
88899313|NCT01499784|Experimental|Pelvic Floor muscle Training|educational class for behavioral modification and group exercise class for pelvic floor muscle training
88899314|NCT01499797|No Intervention|regular medical care|Identified community dwelling frail elderly people receiving regular medical care in their primary care setting
88899315|NCT01499797|Experimental|The CareWell programme|Identified community dwelling frail elderly people receiving care in line with the CareWell programme
88899316|NCT01499823||Patients with high-grade glioma|Patients with high-grade glioma (glioblastoma multiforme or anaplastic astrocytoma), who receive concurrent chemoradiation (CCRT) with temozolomide
88899317|NCT01499836|Experimental|general anesthesia and PVB|general anesthetics consisting of propofol, cisatracurium and fentanyl for endotracheal intubation and deaflurane for maintenance will be given. After intubation, paravertebral injections will be performed under ultrasound guidance.
88899318|NCT01499836|Experimental|sedation and PVB|After sedation with midazolam and fentanyl, the patients in sedation and PVB group will receive PVB. paravertebral injections will be performed under ultrasound guidance.Intraoperative sedation will be provided with propofol titrated to moderate sedation.
88899319|NCT01499836|Active Comparator|general anesthesia|general anesthetics consisting of propofol, cisatracurium and fentanyl for endotracheal intubation and deaflurane for maintenance will be given.
88899320|NCT01499875|Other|Phenoxymethylpenicillin|It is a descriptive trial to find out about the pharmacokinetics
88899321|NCT01499901|Experimental|sequential|implantation bilateral sequential
88899322|NCT01499901|Experimental|simultaneous|implantation bilateral simultaneous
88899323|NCT01499914|Experimental|Influenza vaccination|Influenza vaccination in patients with cystic fibrosis
88899324|NCT01499927|Active Comparator|electronic reminders|Behavioral: Early switching from intravenous to oral antiinfective agents due to electronic reminders
88899325|NCT01499927|No Intervention|no electronic reminders|Behavioral: Early switching from intravenous to oral antiinfective agents without computerized decision support
88899326|NCT01499966|Experimental|group POP|PLASTER OF PARIS
88899327|NCT01499966|Experimental|TG|TUBIGRIP
88899328|NCT01499979|No Intervention|Vascular inflow occlusion|Patients that will receive intermittent vascular inflow occlusion, the standard method for vascular occlusion at our institution, during liver resection.
88899329|NCT01499979|Experimental|Hypothermic perfusion|Patients will receive in situ hypothermic perfusion of the future remnant liver during liver resection.
88899330|NCT01499992|Experimental|aquatic physical therapy|aquatic physical therapy program which will be conducted twice weekly for 10 weeks and will include a 40-50 minute hydrotherapy session emphasizing range of motion and light resistive exercises of the arm, primarily focussing on the shoulder.
88899331|NCT01499992|No Intervention|standard care|
88899332|NCT01500005|Experimental|vitamin D|Baby D3 drops
88899333|NCT01500018|Experimental|Crossover Treatment Sequence 1|Period 1: Placebo, Period 2: Phentermine 45 mg, Period 3: Phentermine 90 mg, Period 4: Ketamine 100 mg, Period 5: TC-5214 2 mg, Period 6: TC-5214 8 mg, Period 7: TC-5214 16 mg
88899334|NCT01500018|Experimental|Crossover Treatment Sequence 2|Period 1: Phentermine 45 mg, Period 2: Ketamine 100 mg , Period 3: Placebo, Period 4: TC-5214 8 mg , Period 5: Phentermine 90 mg, Period 6: TC-5214 16 mg, Period 7: TC-5214 2 mg
88899335|NCT01500018|Experimental|Crossover Treatment Sequence 3|Period 1: Ketamine 100 mg, Period 2: TC-5214 8 mg, Period 3: Phentermine 45 mg, Period 4: TC-5214 16 mg, Period 5: Placebo, Period 6: TC-5214 2 mg, Period 7: Phentermine 90 mg
88899336|NCT01500018|Experimental|Crossover Treatment Sequence 4|Period 1: TC-5214 8 mg, Period 2: TC-5214 16 mg, Period 3: Ketamine 100 mg, Period 4: TC-5214 2 mg, Period 5: Phentermine 45 mg , Period 6: Phentermine 90 mg, Period 7: Placebo
88899337|NCT01500018|Experimental|Crossover Treatment Sequence 5|Period 1: TC-5214 16 mg, Period 2: TC-5214 2 mg, Period 3: TC-5214 8 mg, Period 4: Phentermine 90 mg, Period 5: Ketamine 100 mg, Period 6: Placebo , Period 7: Phentermine 45 mg
88899338|NCT01500018|Experimental|Crossover Treatment Sequence 6|Period 1: TC-5214 2 mg, Period 2: Phentermine 90 mg, Period 3: TC-5214 16 mg, Period 4: Placebo, Period 5: TC-5214 8 mg, Period 6:Phentermine 45 mg , Period 7: Ketamine 100 mg
88899339|NCT01500018|Experimental|Crossover Treatment Sequence 7|Period 1: Phentermine 90 mg, Period 2: Placebo, Period 3: TC-5214 2 mg, Period 4: Phentermine 45 mg, Period 5: TC-5214 16 mg, Period 6: Ketamine 100 mg, Period 7: TC-5214 8 mg
88899340|NCT01500018|Experimental|Crossover Treatment Sequence 8|Period 1: TC-5214 16 mg, Period 2: TC-5214 8 mg, Period 3: TC-5214 2 mg, Period 4: Ketamine 100 mg, Period 5: Phentermine 90 mg, Period 6: Phentermine 45 mg, Period 7: Placebo
88899341|NCT01500018|Experimental|Crossover Treatment Sequence 9|"Period 1: TC-5214 2 mg, Period 2: TC-5214 16 mg, Period 3: Phentermine 90 mg, Period 4: TC-5214 8 mg, Period 5: Placebo, Period 6: Ketamine 100 mg, Period 7:~Phentermine 45 mg"
89420189|NCT05824637|Other|Skin Prick Test|Study participants will receive a skin prick test by the skin prick automated test device on the right arm and manually by a health care provider on the left arm.
89420190|NCT05818345|No Intervention|Control|Participants will receive a standard menu with the existing pricing structure of the restaurant
89420191|NCT05818345|Experimental|Pricing Intervention|Participants will receive a menu where lower kcal dishes are discounted by 30%
89420192|NCT05790343||BAPHYC|Parents of children, aged 5-12 years, who have anxiety problems.
89420193|NCT05774249|Active Comparator|Ultrasound guided pectointercostal fascial plane block group|using 20 mL of 0.25% bupivacaine with adrenaline 1:400,000
89420194|NCT05774249|Placebo Comparator|control group|using 20 mL of normal saline 0.9%
89420195|NCT05767398|Experimental|Sequence 1|Zanubrutinib will be administered as a single dose of treatment (tablet) or reference (capsule) on separate occasions.
89420196|NCT05767398|Experimental|Sequence 2|Zanubrutinib will be administered as a single dose of treatment (tablet) or reference (capsule) on separate occasions.
89420197|NCT05759819|Experimental|CLZ-BM3D group|"The cilostazol-coated BioMimics 3D stent on the delivery system is implanted into the target lesion and self-expands to maintain the vessel lumen diameter. Post-dilatation is performed as needed.~- CLZ is released from the surface of the implanted stent."
89420198|NCT05756855|Experimental|behavioral intervention|This will involve conducting a 12-week open pilot trial (up to n=16 dyads of EIS clinicians-EIS participants) to test the feasibility and acceptability of the adapted Psychological Interventions for Coping with Anger and Schizophrenia: a study of outcomes (PICASSO) intervention in the OnTrackNY setting.
89420199|NCT05754541|Experimental|WeFlow-Tribranch Aortic Arch Stent Graft System|
89420200|NCT05748444||Children with cystic fibrosis|Voluntary children with cystic fibrosis aged 6-18 years with normal glucose tolerance will be included in the study.
89420201|NCT05732792||Anesth-CIPS|The survey is endorsed by the European Society of Anaesthesiology and Intensive Care (ESAIC) and will be distributed from February 2023 onwards to its members for a period of 6 months.
89420202|NCT05726188||Stage I colon cancer|Patients aged 18 years or above with pT1 or pT2 N0 colon cancer (up to the recto-sigmoid junction) who underwent curative resection between January 2010 and December 2019
89420203|NCT05725005|Experimental|Group 1|Group 1 will receive 10 mg once-daily (QD) doses of ASN51, by mouth, for 14 days.
89420204|NCT05725005|Experimental|Group 2|Group 2 will receive 20 mg once-daily (QD) doses of ASN51, by mouth, for 14 days.
89420205|NCT05719844|Experimental|Neuropsychological tests|The neuropsychological tests are computerized (TAP battery) or paper-and-pencil tests. They assess processing speed, short-term memory and auditory-verbal working memory capacity, episodic memory and selective attention.
89420206|NCT05717647||Paediatric patients with severe traumatic brain injury undergoing multimodality monitoring|"Patients admitted with brain injury requiring ventilation and ICP monitoring~Age group: 3 years and 16 years (children under the age of three years are excluded as the triple bolt for multimodality monitoring is not currently used for this age group)"
89420207|NCT05715138|Experimental|GPi-DBS|The DBS electrodes are implanted into posteroventral GPi bilaterally.
89420208|NCT05715138|Experimental|STN-DBS|The DBS electrodes are implanted into dorsolateral STN bilaterally.
88899342|NCT01500018|Experimental|Crossover Treatment Sequence 10|Period 1: Phentermine 90 mg, Period 2: TC-5214 2 mg, Period 3: Placebo, Period 4: TC-5214 16 mg Ketamine 100 mg, Period 5: Phentermine 45 mg, Period 6: TC-5214 8 mg, Period 7: TC-5214 2 mg
89006694|NCT04619173|Active Comparator|Conventional Physical Therapy Program|hot pack transcutaneous electrical nerve stimulation, serratus,anterior,pectoralis major, minor, posterior capsular stretches.
89420209|NCT05709535||Experimental: [18F]PSMA-1007 Injection|A single intravenous dose of 3 - 4 MBq/kg (up to a maximum of 400 MBq) of [18F]PSMA-1007 Injection will be administered followed by PET/CT imaging.
88899343|NCT01500018|Experimental|Crossover Treatment Sequence 11|Period 1: Placebo, Period 2: Phentermine 90 mg, Period 3:Phentermine 45 mg, Period 4: TC-5214 2 mg, Period 5: Ketamine 100 mg, Period 6: TC-5214 16 mg, Period 7: TC-5214 8 mg
88899344|NCT01500018|Experimental|Crossover Treatment Sequence 12|Period 1: Phentermine 45 mg, Period 2: Placebo, Period 3: Ketamine 100 mg, Period 4:Phentermine 90 mg, Period 5: TC-5214 8 mg, Period 6: TC-5214 2 mg, Period 7: TC-5214 16 mg
89006695|NCT04618783|Experimental|Low-dosage experimental group|Three doses of low-dosage investigational sIPV, vaccinated within one-month interval between doses
89420210|NCT05688059|Experimental|Absorbable Suture|Absorbable suture for sacrospinous ligament suspension
89420211|NCT05688059|Experimental|Permanent Suture|Permanent suture for sacrospinous ligament suspension
89420212|NCT05678582||HBV with hepatic steatosis|HBV with hepatic steatosis on liver biopsy
89006696|NCT04618783|Experimental|Medium-dosage experimental group|Three doses of medium-dosage investigational sIPV, vaccinated within one-month interval between doses
89006697|NCT04618783|Experimental|High-dosage experimental group|Three doses of high-dosage investigational sIPV, vaccinated within one-month interval between doses
89006698|NCT04618783|Active Comparator|Control wIPV group|Three doses of control wIPV, vaccinated within one-month interval between doses
89420213|NCT05678582||HBV without hepatic steatosis|HBV without hepatic steatosis on liver biopsy
89006699|NCT04618783|Active Comparator|Control sIPV group|Three doses of control sIPV, vaccinated within one-month interval between doses
89006700|NCT00221039|Experimental|DRUG+ECP|UVVADEX +ECP will be administered to patients with CTCL.Duration of Treatment: The study will consist of 2 treatment periods, a 6-month initial period and a 6-month follow-up period where photopheresis therapy may continue.
89006701|NCT00562939|Experimental|A|1 mg CpG 7909 + pneumococcal vaccines
89006702|NCT00562939|Placebo Comparator|B|Pneumococcal vaccines
89006703|NCT04618510|Experimental|SEED 1-dayPure EDOF soft contact lens|The participant will be requested to wear the daily disposable lens 8-10 hours per day and replaced daily. All participants will be followed for 12 months (followup visit schedule; 3 months, 6 months, 12 months) post-contact lens wear.
89006704|NCT04618510|Sham Comparator|Single vision spectacle lens|The participant will be requested to wear the spectacle lens daily. All participants will be followed for 12 months (follow up visit schedule; 3 months, 6 months, 12 months) post spectacle lens wear.
89420214|NCT05678491|Experimental|Endoscopic mucosal band ligation|All 12 patients with GERD will undergo the same procedure. Multiple rubber bands will be used to ligate mucosa in the gastroesophageal junction and cardia in 3/4 of the circumference.
89420215|NCT05673668|Experimental|The endovascular denervation (EDN) group|Receive endovascular denervation (EDN) treatment
89420216|NCT05650281||Patients|Patients with RRMS (2017 Mc Donald criteria) treated with highly active treatment in the first 5 years of symptoms onset, at least 1 year, with an EDSS below 4
89420217|NCT05635812||Participants Autism Spectrum Disorders (ASD)|ASD according to DSM-5 criteria
89420218|NCT05635812||Participants 22q11.2|Participants with a genetic syndrome diagnosed by FISH or CGH-array
89420219|NCT05635812||Neurotypical participants|Neurotypical development
89420220|NCT05634174|Experimental|Obese Group|Single dose, 100mg oral mirabegron in Obese Insulin Resistant adults
89420221|NCT05634174|Experimental|Non-Obese Group|Single dose, 100mg oral mirabegron in Non-Obese adults
89420222|NCT05632354|Experimental|Treatment|open-label GBT021601
88899345|NCT01500018|Experimental|Crossover Treatment Sequence 13|Period 1: Ketamine 100 mg, Period 2: Phentermine 45 mg, Period 3: TC-5214 8 mg, Period 4: Placebo, Period 5: TC-5214 16 mg, Period 6: Phentermine 90 mg, Period 7: TC-5214 2 mg
88899346|NCT01500018|Experimental|Crossover Treatment Sequence 14|Period 1: TC-5214 8 mg, Period 2: Ketamine 100 mg, Period 3: TC-5214 16 mg, Period 4: Phentermine 45 mg, Period 5: TC-5214 2 mg, Period 6: Placebo, Period 7: Phentermine 90 mg
88899347|NCT01500070|Experimental|Drug-eluting stent|Patients implanted with the PROMUS ELEMENT Everolimus-Eluting Stent System (Boston Scientific) or the PROMUS ELEMENT PLUS Everolimus-Eluting Stent System (Boston Scientific).
88899348|NCT01500148|Experimental|Intevention-PMVr Procedure|
88899349|NCT01500161|Experimental|Single Arm|The following conditioning regimens will be used, depending on the underlying hematologic malignancies. Conditioning regimens with Busulfan/clofarabine and with fludarabine/melphalan will be used for all patients except those with Non-Hodgkin's lymphoma when the conditioning regimen of BCNU, Etoposide, ARA-C and Melphalan will be used.
88899350|NCT01500174|Experimental|active UVC device|Three times per week irradiation of wound base and periwound skin
88899351|NCT01500174|Placebo Comparator|Placebo UVC device|Three times per week irradiation of wound base and periwound skin
88899352|NCT01500265||Patient naive|Patient with hepatitis B virus naive untreated
88899353|NCT01500265||Patient with TDF|Patient with hepatits B treated with Tenofovir
88899354|NCT01500265||Patient with ETV|Patient with hepatitis B virus treated with Entecavir
88899355|NCT01500291||Anesthesiologist|
88899356|NCT01500291||Nurse anesthetist|
88899357|NCT01500304|Experimental|Minimally invasive surgery|Minimally invasive inguinal lymph node dissection is a 10-step technique to provide novel inguinal lymph node staging and treatment.
88899358|NCT01500330|Experimental|cupping massage|12 weeks home use of cupping massage (delivered by the partner or friend) twice a week for 20 minutes
88899359|NCT01500330|Active Comparator|control group|progressive muscle relaxation twice a week for 20 minutes
88899360|NCT01500343|Experimental|Saccharomyces boulardii|
88899361|NCT01500343|Placebo Comparator|Placebo|
88899362|NCT01500356|Experimental|Diet alone|Weight loss intervention that focuses only on reducing energy intake of the diet.
88899363|NCT01500356|Experimental|Diet plus Moderate Exercise|Weight loss intervention that involve an energy restricted diet (identical to the Diet Alone arm) plus the inclusion of 150 minutes per week of moderate-intensity exercise.
88899364|NCT01500356|Experimental|Diet Plus High Exercise|Weight loss intervention that involve an energy restricted diet (identical to the Diet Alone arm) plus the inclusion of 250-300 minutes per week of moderate-intensity exercise.
88899365|NCT01500369|Active Comparator|remote ischemic conditiong|"Patients in the treatment group will receive three sequential sphygmomanometer cuff inflations on their right upper arm after induction of anesthesia in the operating room. The cuff will be inflated by the OR nurse up to 200 mmHg for five minutes each occasion, with five minutes deflation in between inflations. Following this pre-conditioning phase, routine anesthesia procedures will be implemented. The entire pre-conditioning phase will last 30 minutes."
88899366|NCT01500369|Placebo Comparator|Standard Care|Patients in the control group will have the sphygmomanometer cuff placed on their right upper arm, but the cuff will not be inflated. Similar to patients in the treatment group, patients in the control group will undergo the same 30 minute delay before induction of anesthesia and surgery
88899367|NCT01500395||Stent Graft and open surgery|Hybrid Operations including debranching technique+Thoracic Endovascular Aortic Repair (TEVAR), Frozen elephant trunk technique, aortic arch replacement with concommitant TEVAR, et al.
88899368|NCT01500408|Other|Commercial INFB followed by Investigational INFB|Process A (currently-approved manufacturing process involving FBS) first, then Process B (new serum-free manufacturing process, without FBS)
88899369|NCT01500408|Other|Investigational INFB followed by Commercial INFB|Process B (new serum-free manufacturing process, without FBS) first, then Process A (currently-approved manufacturing process involving FBS)
88899370|NCT01500421|Experimental|TH - Endovacular alone|Patients randomized to this arm are cooled to a bodytemperature of 33 degrees with an endovascular groin catheter (Copenhagen only).
88899371|NCT01500421|Experimental|TH - Endovascular + nasopharyngeal induction|Patients randomized to this arm are cooled to a bodytemperature of 33 degrees with endovascular catheter along with nasopharyngeal induction (Copenhagen only).
88899372|NCT01500421|No Intervention|Standard Treatment|Patients are treated with standard care in the stroke ward.
88899373|NCT01500421|Experimental|TH - Surface Cooling|Patients randomized to this arm are cooled to a bodytemperature of 33 degrees with cold saline infusion followed by surface cooling with Arctic Sun Cooling system, Medivance, USA (Malmø only)
88899374|NCT01500486||PenMate device|
88899375|NCT01500512||Observation (observe patients undergoing SLN dissection)|Patients receive standard therapy including sentinel lymph node dissection. Patients are then observed to collect information about treatment and outcomes every 2 months for 2 years.
88899376|NCT01500538|Experimental|Eltrombopag and vorinostat combination therapy|Daily oral intake of 400mg vorinostat if necessary with combination therapy eltrombopag commencing at 50mg per day increasing to a maximum of 200mg per day
88899377|NCT01500564|Sham Comparator|Sham tDCS and motor training: sham comparator|"Participants will receive sham tDCS over the primary motor cortex of the ipsilesional hemisphere during 20 minutes of motor training (10 consecutive sessions Monday-Friday during two weeks).~Intervention: placebo tDCS Other: Motor Training"
88899378|NCT01500564|Experimental|Anodal tDCS and motor training: experimental|"Participants will receive anodal tDCS over the primary motor cortex of the ipsilesional hemisphere. The following parameters will be used: stimulation intensity of 1mA during 20 minutes of motor training (10 consecutive sessions Monday-Friday during two weeks).~Interventions:~Device: anodal tDCS~Other: motor Training during physiotherapy"
88899379|NCT01500577|Experimental|Nimesulide|Nimesulide 100 mg (capsules), 100mg/die every day for 1 year. Oral administration
88899380|NCT01500577|Experimental|Simvastatin|Simvastatin 20 mg (capsules). 20mg/die every day for 1 year. Oral administration
88899381|NCT01500577|Placebo Comparator|Placebo|Placebo (capsules). 1 cps/die every day for 1 year. Oral administration
89006705|NCT04618549|Active Comparator|Direct anterior approach|Patients with a femoral neck fracture, treated by hemiarthroplasty by direct anterior approach, using a regular OR table, without hip hyperextension.
89420223|NCT05619705|Experimental|Healthy for Two-Health Coaching (H42)|Those assigned to the intervention group will receive the 8 to 11 month H42 health coaching intervention in addition to usual home visiting and usual prenatal and postpartum care clinical services. Intervention duration will depend on the participant's gestational age at the of enrollment. Participants can be enrolled as early in pregnancy as 20 weeks gestation and as late as 33 weeks gestation. All participants would be enrolled for 6 months postpartum. Therefore, the minimum time in the intervention would be 8 months and maximum would be 11 months.
89420224|NCT05619705|Active Comparator|Maintain Health in Pregnancy and Postpartum (mHIPP)|"Those assigned to the usual home visiting plus comparison group, called maintain health in pregnancy and postpartum (mHIPP), will receive the typical, evidence-based experience in participants' home visiting program in addition to the participants' usual prenatal and postpartum care clinical services. In addition, the investigators will provide a brief (less than 5 minutes) maternal warning signs educational video that is available in English or Spanish. The video was developed for a home visiting client audience and is publicly available, https://mdmom.org/warningsigns."
89420225|NCT05604859|Active Comparator|non-intervening group|conventional treatment，including symptomatic and supportive treatment, antiviral treatment etc.
89420226|NCT05604859|Experimental|intervention group|"Part A group: Patients received methylprednisolone 1-2mg/kg/d（or other glucocorticoid equivalent to methylprednisolone 1-2mg/kg/d) + IVIG 0.2g-0.4g/kg/d for a total of 3-5 days. If the disease progressed after treatment, the patients were given the dose of rescue therapy (methylprednisolone > 2mg/kg/d or other glucocorticoid equivalent to methylprednisolone > 2mg/kg/d + IVIG 0.4g/kg/d) for another 3-5 days.~Part B group: Patients received tocilizumab 4mg/kg once.~Part C group: Patients received low molecular weight heparin 100U/kg, qd or q12h IH for 4-7 days.~All patients received conventional treatment. All patients were followed up from the end of treatment to day 28 after completion of treatment."
89420227|NCT05595486|No Intervention|Usual Care|As a pragmatic trial, usual care will be defined by contemporary clinical standards. For maternal care, this includes a comprehensive medical visit between 4-12 weeks postpartum. This visit includes utilization of a validated screen for postpartum depression and, if that screen is positive, a clinical assessment and initiation of treatment (e.g. pharmacotherapy or referral for psychotherapy). In addition, this visit includes a discussion of contraception as well as supportive education on breastfeeding. For paternal care, clinical standards are gleaned from the AAP, ACOG, and USPSTF reports outlining mental health screening, reproductive health, and vaccine uptake. For infant care, standard pediatric care from the AAP and Bright Futures periodicity timeline and guidelines will be used. In addition, assignment in this arm will be given surveys at baseline, 1M, 2M, 4M, 6M, and 12M.
89420228|NCT05595486|Experimental|Baby2Home Intervention|Families randomized to the intervention arm will receive the B2H services. B2H is a novel digitized CC-based intervention delivered via a smartphone app available on iOS or Android phones, built by combining two successful programs: NICU2Home+ app and CC services. Using the UCD methodologies, AI-based communication within the app will include education for mothers and fathers on the standard of care regarding self-care and newborn care after hospital discharge as well as education, reminders and scheduling for recommended preventative healthcare services for themselves and their new infant.
89420229|NCT05590234|Active Comparator|Dexmedetomidine combined with bupivacaine group (DB group)|patients received 1ug/kg dexmedetomidine plus 20 mL of bupivacaine 0.25%,
89006706|NCT04618549|Active Comparator|Mini Posterior Approach|Patients with a femoral neck fracture, treated by hemiarthroplasty by a mini posterior approach.
89006707|NCT04618549|Active Comparator|Lateral approach|Patients with a femoral neck fracture, treated by hemiarthroplasty by a lateral (Hardinge) approach.
89006708|NCT04618588|Experimental|"Sinus elevation using Low Window Sinus Lift technique"|
89006709|NCT04618159|Other|Helipyl|helipyl wil be given to 10 children with asymptomatical helicobacter pylori infection
89194366|NCT00864214|Experimental|2|Estrogen is the Biest 2.5 mg bioidentical cream; the placebo is the transdermal patch; the progesterone is compounded progesterone-100 mg
89194367|NCT00864214|Experimental|3|Estrogen is the Biest 3.0 mg bioidentical cream; the placebo is the transdermal patch; the progesterone is compounded progesterone-100 mg
88899382|NCT01500590|Experimental|renin-angiotensin system blockers|Those eligible patients will be randomized into 2 groups. One group use renin-angiotensin systems (RAS) blockers to control their blood pressure, the other group will use other types of anti-hypertensive agents other than RAS blockers
88899383|NCT01500590|Active Comparator|non-renin angiotensin system blockers|"These includes norvasc adalat retard natrilix betaloc aldomet~amlodipine 2.5 to 10 mg once daily nifedipine retard 20mg once daily to 40mg twice daily indapamide 2.5mg once daily metoprolol 25mg to 100mg daily methyldopa 125 mg once daily to 500mg twice daily"
88899384|NCT01500603|Experimental|Experimental|Patients will receive AdvanceXP retrourethral male sling implantation under general or loco-regional anaesthesia, by perineal approach. The sling is placed via transobturator route
88899385|NCT01500603|Active Comparator|Active comparator|Patients will receive Pro-ACT balloons implantation under general or loco-regional anaesthesia, by perineal approach. The balloons are placed under X-ray control laterally to the urethra, under the bladder neck. The extremity of the device (titanium port), linked to the balloon, is located subcutaneously in the scrotum. During post-operative visits, readjustments of the volume of the balloons will be made under local anaesthesia. The volume will be increased or decreased according to the patients symptoms.
88899386|NCT01500616|Experimental|open label telaprevir|Depending on the patient's HAART regimen, 750 or 1125 mg telaprevir every 8 hours for 12 weeks in combination with pegylated interferon alfa and ribavirin for 48 weeks.
88899387|NCT01500044|Active Comparator|Conventional Rehabilitation Program|The conventional program consists in cervicothoracic mobilizations and stabilization exercises. This program is based on the intervention used in clinical practice, and on programs proposed in two RCTs evaluating individuals with neck and arm pain that do not include any specific mobilization or exercise leading to the opening of the intervertebral foramen. Four mobilisation techniques will be executed at each treatment session. However, the therapists will not be allowed to use techniques that specifically open the intervertebral foramen of the affected segment, two segments above and two segments below.
88899388|NCT01500044|Experimental|Program targeting the opening of foramen|"The same interventions as for the conventional rehabilitation program will be applied, except:~Of the four mobilisation techniques, there will be two mandatory techniques targeting the opening of the intervertebral foramen on the same side and at the same level as the radiculopathy: global contralateral rotation mobilisation and ipsilateral lateral shearing in a flexion position. The therapist, according to the biomechanical evaluation results, will choose the two other mobilisation techniques."
88899389|NCT01500642|Active Comparator|sublingual immunotherapy|15 patients treated with sublingual immunotherapy (SLIT One, ALK Abello) administered at standard dose (200 STU / dose) from June to August 2001
88899390|NCT01500642|Active Comparator|vestibular immunotherapy|15 patients treated with vestibular immunotherapy (SLIT One, ALK Abello) administered at standard dose (200 STU / dose) from June to August 2001
88899391|NCT01500642|Active Comparator|sublingual doubled immunotherapy|15 patients treated with sublingual immunotherapy (SLIT One, ALK Abello) administered at doubled dose (400 STU / dose) from June to August 2001
88899392|NCT01500655|Experimental|Catheter|An ultrasound guided block of the LFCN is performed, followed by the placement of a catheter underneath the fascia iliaca.
88899393|NCT01500655|Experimental|Ultrasound guided LFCN block|An ultrasound guided regional nerve block --using ropivacaine 0.2%-- will be performed around the lateral femoral cutaneous nerve (LFCN).
88899394|NCT01500655|No Intervention|Control|This group gets the current standard of care--the donor site is infiltrated with 0.25% bupivacaine.
88899395|NCT01500668|Active Comparator|Treatment|Injection of 200 units of Botulinum Toxin A (BOTOX) to a treated limb. Each limb will be divided to two levels - arterial arch and digital arteries (near MCP/MTP) levels. In each level 100 units of Botox will be injected in 6 injection points in the proximity of the arteries.
88899396|NCT01500668|Placebo Comparator|Control|Injection of 0.5cc of normal saline (0.9% NaCl) to each injection site as in the Active drug arm.
88899397|NCT01500707|Experimental|SCH 900800|Participants receiving a single dose of SCH 900800
88899398|NCT01500785|Active Comparator|levosimendan|
88899399|NCT01500785|Placebo Comparator|placebo|
88899400|NCT01500811|Experimental|chondrocyte|Patients with sever hip osteoarthritis who underwent intra articular cell injection.
88899401|NCT01500824|Experimental|Crizotinib|
88899402|NCT01500837|Active Comparator|RIFAMPIN|CLINDAMYCIN + RIFAMPIN
88899403|NCT01500837|Active Comparator|LEVOFLOXACIN|CLINDAMYCIN + LEVOFLOXACIN
88899404|NCT01500850|Active Comparator|NPH insulin + insulin glulisine|Patients will be randomized to be treated with NPH insulin + Insulin Glulisine for 24 weeks.
88899405|NCT01500850|Active Comparator|NPH insulin + human insulin|Patients will be randomized to be treated with NPH insulin + human insulin for 24 weeks.
88899406|NCT01500850|Experimental|Insulin glargine + insulin glulisine|Patients will be randomized to be treated with insulin glargine + insulin glulisine for 24 weeks.
88899407|NCT01500850|Experimental|Insulin Glargine + Human insulin|Patients will be randomized to be treated with insulin glargine + human insulin for 24 weeks.
88899408|NCT01500863|Active Comparator|hCG|
88899409|NCT01500863|Experimental|Triptorelin 0.2mg s.c.|
88899410|NCT01500863|Experimental|0.2mg triptorelin plus estradiol/progesterone|
88899411|NCT01500863|Experimental|0.2mg tripoterlin plus single bolus hCG 1500 IU|
88899412|NCT01500863|Experimental|0.2mg tripoterlin plus multiple boluses hCG 500 IU|
88899413|NCT01500863|Experimental|0.2mg tripoterlin plus multiple doses recLH|
88899414|NCT01500876|Experimental|Study Arm|Single Arm
89420230|NCT05590234|Active Comparator|bupivacaine 0.25%,|patients received 20 ml of bupivacaine 0.25%
89420231|NCT05590234|Placebo Comparator|control group (S group)|patients received 20 ml of normal saline 0.9%.
89420232|NCT05584332|Placebo Comparator|Placebo|
89420233|NCT05584332|Experimental|4vHPV Vaccine|
88899415|NCT01500889|Active Comparator|CLI sphincterotomy|Conventional Lateral internal sphincterotomy LIS was performed in the lithotomy position by a standard open technique, briefly; a 5-mm incision was made into the perianal skin along the intersphinteric groove. The internal anal sphincter was then dissected and a segment withdrawn with a pair of artery forces and divided with diathermy to the level of the dentate line. Figures 5, 6, 7 and 8 illustrate the procedure.
88899416|NCT01500889|Active Comparator|GroupII: V-Y advancement flap|The V-Y advancement flap was performed by making a V-shaped incision from the edges of the fissure extending about 4 cm from the anal verge and away from the midline. The V-shaped flap formed of skin and subcutaneous fat was mobilized sufficiently to allow advancement into the anal canal to cover the fissure defect. Care was taken to preserve enough pedicles to ensure adequate blood supply. The base of flap was sutured to the lower anal mucosa with interrupted 000 Vicryl Rapide. Figures 1, 2, 3 and 4 illustrate the procedure.
89194368|NCT00864214|Experimental|4|Estrogen is the Vivelle-Dot patch 0.05 mg; the placebo is the transdermal cream; the progesterone is micronized progesterone-100 mg
89194369|NCT05742230|Experimental|Henagliflozin 10 mg|Single 10 mg tablet, administered orally once daily for 12 weeks
89420234|NCT05564208|Experimental|Elafibranor Fasting then Elafibranor fed|Participants will receive Elafibranor 80 mg in Fasting State on Day 1 of Period 1 followed by a washout period of a maximum of 28 days. Participants will then receive Elafibranor 80 mg in Fed State on Day 1 of Period 2.
89420235|NCT05564208|Experimental|Elafibranor Fed then Elafibranor fasting|Participants will receive Elafibranor 80 mg in Fed State on Day 1 of Period 1 followed by a washout period of a maximum of 28 days. Participants will then receive Elafibranor 80 mg in Fasting State on Day 1 of Period 2.
89420236|NCT05562635|Experimental|5 % polymers with CBD application|Bilateral application of 5% polymer gel with CBD intraorally, on the masseter muscle
89420237|NCT05562635|Experimental|10 % polymers with CBD application|Bilateral application of 10% polymer gel with CBD intraorally, on the masseter muscle
89420238|NCT05562635|Placebo Comparator|Placebo group|Application of polymers without CBD on the masseter muscles, bilaterally
89420239|NCT05540223|Experimental|DREAMS 3G RMS|Intervention with a DREAMS 3G Sirolimus Eluting Resorbable Coronary Magnesium Scaffold System
89420240|NCT05540223|Active Comparator|Xience DES|Intervention with a Xience Everolimus Eluting Stent System
89420241|NCT05508230|Experimental|Experimental|
89420242|NCT05477238|Experimental|Cerebrovascular Accident|Stroke patients will perform 2 walking tests indoors and outdoors wearing a gas exchange analyzer, an accelerometer and a heart rate monitor meter
89420243|NCT05477238|Other|healthy volunteer|Healthy volunteers patients will perform 2 walking tests indoors and outdoors wearing a gas exchange analyzer, an accelerometer and a heart rate monitor meter
89420244|NCT05476172|Active Comparator|Dienogest|Patients with endometriosis are prescribed dienogest for treatment.
89420245|NCT05476172|Active Comparator|Norethindrone Acetate|Patients with endometriosis are prescribed Norethindrone Acetate for treatment.
89420246|NCT05444985|Experimental|External Oblique Intercostal Block Group|While patients are still under general anesthesia, external oblique intercostal block (EOIB) will be performed bilaterally according to appropriate asepsis/antisepsis rules before awakening.
89420247|NCT05444985|Active Comparator|Control|Patients in the control group will not have any intervention concerning regional anesthesia.
89420248|NCT05444062|No Intervention|Control Arm: CVD|"Patients diagnosed with mild to severe CAC and not on first line guideline recommended therapy.~Coronary artery Calcification (CAC) score obtained from lung cancer screening CT Scan images"
89420249|NCT05444062|Other|Intervention Arm: CVD|"Patients diagnosed with mild to severe CAC and not on first line guideline recommended therapy.~CAC score obtained from lung cancer screening CT Scan images"
89420250|NCT05444062|No Intervention|Control Arm: COPD|Patients with untreated COPD or not on first line guideline recommended therapy.
89420251|NCT05444062|Other|Intervention Arm: COPD|Patients with untreated COPD or not on first line guideline recommended therapy.
89420252|NCT05433155|Active Comparator|Videolaryngoscopy|Nasotracheal intubation performed with the Storz C-Mac Video Laryngoscope
89420253|NCT05433155|Active Comparator|Direct Laryngoscopy|Nasotracheal Intubation performed with the standard clinical direct blades
89420254|NCT05432518|Experimental|Treatment|"Patients will receive one of the 5 study drugs based on their recurrent tumor mutation profile and their recurrent organoid response to these drugs:~Afatinib~Dasatinib~Palbociclib~Everolimus~Olaparib"
89420255|NCT05428709|Experimental|Acute exercise|Participants will be asked to walk or jog on a treadmill for a maximal exercise test.
89420256|NCT05426759|Experimental|GP Ablation|Single arm study with GP ablations performed during open-chest surgery
89420257|NCT05422976|Experimental|EVI-01 treatment|EVI-01 should be injected within the synovial cavity using standard procedures for intra-articular (IA) injections by a physician skilled in performing IA injections.
89420258|NCT05413096|Placebo Comparator|placebo tube|neutral material without any biological effects
89420259|NCT05413096|Active Comparator|Combination of diclofenac potassium and propolis|active agents combination of diclofenac potassium 3% (10 mg/g, 60 g, EMS) and Propolis 5% gel
89420260|NCT05375994|Experimental|avutometinib(VS-6766)+adagrasib|To determine the recommended phase 2 dose (RP2D) for VS-6766 in combination with adagrasib in G12C inhibitor exposed patients
89420261|NCT05375994|Experimental|avutometinib (VS-6766)+adagrasib RP2D|To determine the efficacy of the RP2D identified from Part A in G12C inhibitor exposed patients
89420262|NCT05346523|Experimental|Usual Care + CDDS usage|Patients presenting to the ER and included in the study during the ER's intervention period will be treated and diagnosed by the ER physicians as usual but with support of the CDDS.
89420263|NCT05346523|No Intervention|Usual Care|Patients presenting to the ER and included in the study during the ER's intervention period will be treated and diagnosed by the ER physicians as usual without support of the CDDS.
89420264|NCT05345223||TGCV|Patients who have been confirmed as TGCV by a cardiologist.
89420265|NCT05327465|Experimental|Aerobic and resistance exercise|"Virtually supervised 16-week aerobic and resistance exercise performed at home via Zoom.~The exercises will be performed three times per week for 16 weeks, and virtually supervised by a professional exercise trainer."
88899417|NCT01500889|Active Comparator|TLIS with VY anoplasty|Tailored lateral sphincterotomy was performed in the lithotomy position by a standard open technique, briefly; a 5-mm incision was made into the perianal skin along the intersphinteric groove. The internal anal sphincter was then dissected and a segment withdrawn with a pair of artery forces and divided with diathermy, the extent of sphincterotomy was done to be more or less equal to the length of the fissure. Then the V-Y advancement flap was performed.
89420266|NCT05327465|Active Comparator|Usual care|Maintenance of baseline exercise levels for 16 weeks with an offer to perform the same exercise program after 16 weeks.
89420267|NCT05309109|Experimental|MCO-HD group|Hemodialysis sessions using the Theranova 500™ (Baxter healthcare Corporation Deerfield, USA; surface area 2 m², ultrafiltration coefficient: 59 ml/h/mmHg)
89420268|NCT05309109|Experimental|HF-HD group|Hemodialysis sessions using the Elisio 21H™ (Nipro Europe, Zaventen Belgium; surface area 2.1 m², ultrafiltration coefficient: 82 ml/h/mmHg)
89420269|NCT05303558||Participants With High-risk Localized Prostate Cancer|Adult participants from Japan, South Korea, and Taiwan with high-risk localized prostate cancer (HR LPC) who received radical prostatectomy (RP) and perioperative (neoadjuvant and/ or adjuvant) hormonal therapy will be observed from the date of confirmed HR LPC diagnosis until death, lost to follow-up (last known visit), or end of study period, whichever comes first. This study will utilize data from electronic medical records (EMR) in South Korea and Taiwan, and data from chart reviews in Japan. Data will be analyzed retrospectively from 1 January 2015 to 30 June 2017, with a follow-up till 30 June 2022.
88899418|NCT01500902|Other|vascular testing|We are assessing vascular testing in patients presenting with acute coronary syndrome to determine if this type of testing will help identify which patients are more likely at risk to have another heart attack.
88899419|NCT01500915|Experimental|ranibizumab|
88899420|NCT01500941|Active Comparator|probiotics|
88899421|NCT01500941|Placebo Comparator|maltodextrin|
88899422|NCT01500954||squamous cell carcinoma|
88899423|NCT01500954||non-lesional skin|
88899424|NCT01500967|Active Comparator|Traction|6kg to 10kg, 3 times a week, once the other day（except the weekends）,20 minutes, 2 weeks.
88899425|NCT01500967|Experimental|Manipulations|Shi-style manipulations is a cervical manipulation for cervical radiculopathy.This manipulation is a kind of traditional Chinese massage and it can dredge the meridians. Patients are treated every day for 30 minutes. Seven times as one course and totally there are two courses. 3 times a week, once the other day（except the weekends）,30 minutes, 2 weeks.
88899426|NCT01500980|Experimental|Pilot Phase|Pilot phase will include 6 subjects and will investigate the timing of PQ dosing relative to parasite exposure.
88899427|NCT01500980|Experimental|Chloroquine, ITV, primaquine, malaria challenge|
88899428|NCT01500980|Active Comparator|Sporozoite negative vaccine|
88899429|NCT01500980|Active Comparator|Primaquine placebo|
88899430|NCT01500980|No Intervention|malaria challenge|
88899431|NCT01500993|Active Comparator|5-Fluorouracil (5-FU)|Drug - 5FU based chemoradiotherapy and chemotherapy
88899432|NCT01500993|Experimental|Capecitabine|Drug - Capecitabine-based radiochemotherapy and chemotherapy
88899433|NCT01501006||Patient Roles|Physician communication styles will be evaluated with different patient roles.
88899434|NCT01501019|No Intervention|Sjogren and Myositis Control (no control for takayasu's)|
88899435|NCT01501019|Experimental|Sjogren, Myositis and Takayasu's Trained|
89420270|NCT05302973|Active Comparator|Conventional rehabilitation|Inpatient rehabilitation - person-centred and tailored to individual participant needs - which take into account the different sequelae associated with the severity of COVID-19, the prolonged stay of people in the acute hospital or in the intensive care unit, and the pre-existing comorbidities.
89420271|NCT05302973|Active Comparator|Aerobic exercise|Addition of aerobic exercise to conventional inpatient rehabilitation treatment for people wtih post-COVID-19.
89420272|NCT05277077|Experimental|Experimental Group|In addition to the conservative treatment, the experimental group will follow PNE sessions (one session per week over six consecutive weeks). Each session will take between 45 min and 1 h. The physiotherapist with 6 years of clinical and PNE experience will conduct all sessions. PNE will be conducted in line with international guidelines and covered the neurophysiology of pain, transition from acute to chronic pain, and the nervous system ability to modulate the pain experience. The theoretical information will be complemented with pictures and diagrams based on previous procedures. A booklet with the contents of each session and containing a mixture of text, figures, and activities to perform between sessions will be developed for the purpose of this study and given to participants. Time devoted to PNE will decrease from session 1 (60 min) to session 6 (15 min).
89194370|NCT05742230|Other|blank control|standard treatment
89420273|NCT05277077|Active Comparator|Control Group|"The control group will follow a conservative treatment. The 90-minute-long training sessions will be held 5 days per week. The training program will include the following exercises: cold-pack for 20 minutes; 20 minutes of Conventional TENS; 3 minutes of soft tissue massage for deltoid and biceps muscles; scapula and glenohumeral joint mobilizations; towel sliding and duster slide exercises on the wall; wand-assisted bilateral shoulder elevation; external rotation in increasing abduction angles, internal rotation in abduction, horizontal adduction and functional internal rotation exercises; strengthening exercises; finger ladder exercises; activation of deltoid, rotator cuff, and scapular muscles at chest level as the degree of active elevation increases; anterior elevation using an elastic band; strength training in Full Can position; closed kinetic chain trainings; isometric exercises of the periscapular muscles, deltoid and trapezius; and posterior capsule stretching."
89420274|NCT05276063|Placebo Comparator|Placebo|Placebo Arm
89420275|NCT05276063|Active Comparator|Low Dose|Active Arm Low Dose Linsitinib
89420276|NCT05276063|Active Comparator|High Dose|Active Arm High Dose Linsitinib
89420277|NCT05270460|Experimental|PCS12852 0.1mg|PCS12852 0.1mg tablet
88899436|NCT01501032|Experimental|Closed Loop Control- MD-Logic|The MD-Logic artificial pancreas system will be used in conjunction with continuous glucose monitoring and insulin pump delivery to manage the subject's blood glucose.
88899437|NCT01501045|Experimental|healthy subjects|healthy subjects
88899438|NCT01501045|Experimental|pain patients|Migraine and muscle headache patients
88899439|NCT01501058|Experimental|case group|
89194371|NCT00872482|Experimental|1|Nimotuzumab (200 mg fixed dose) will be administered by the intravenous route weekly during WBRT and following WBRT. Radiotherapy will consist of 30 Gy, in 10 fractions of 3 Gy/day.
89420278|NCT05270460|Experimental|PCS12852 0.5mg|PCS12852 0.5mg tablet
89420279|NCT05270460|Placebo Comparator|Placebo|Similar in appearance to active study drug
88899440|NCT01501058|Other|waitlist control group|For this group, same intervention with the Experimental group will be provided after waiting for 14 weeks.
88899441|NCT01501071|Experimental|esophageal calibration|Esophageal calibration tube was applied to this group of patients during laparoscopic Nissen fundoplication operation
88899442|NCT01501071|No Intervention|Control|Standard Laparoscopic Nissen fundoplication without esophageal calibration
88899443|NCT01501084|Active Comparator|Exenatide|Exenatide injection 10 mcg subcutaneous
89194372|NCT00872482|Placebo Comparator|2|"A placebo will be administered by the intravenous route weekly during WBRT and following WBRT.~Radiotherapy will consist of 30 Gy, in 10 fractions of 3 Gy/day."
89420280|NCT05269862|Experimental|In-Clinic Cohort|Subjects who are implanted with Abbott Infinity DBS systems with the Neuosphere Virtual Clinic feature, and receive programming for their DBS system in-clinic only.
89420281|NCT05269862|Active Comparator|Virtual Clinic Cohort|Subjects who are implanted with Abbott Infinity DBS systems with the Neuosphere Virtual Clinic feature, and receive programming for their DBS system with Virtual Clinic and in-clinic sessions.
89420282|NCT05260918|Active Comparator|Flotation-REST|Float-REST therapy uses sensory deprivation tanks that consist of a very large warm water enclosure with a high concentration of Epsom salt to create a completely buoyant environment. This, along with a combination of temperature that is kept equal to skin temperature (94 degrees), allows the participant to eliminate the gravitational effects on the body, and along with lack of sound and low to no light (depending on comfort) allows the brain and body to completely relax for augmented physical and mental recovery. The room will contain an intercom that allows participants to communicate with study personnel in the event the participant needs assistance. Participants will undergo 60 minute sessions twice a week for 3 weeks.
88899444|NCT01501084|Placebo Comparator|Saline|.2cc SC injection of sterile normal saline
88899445|NCT01501097|No Intervention|Control group|
88899446|NCT01501097|Experimental|early HV-crrt|
88899447|NCT01501123|Experimental|Haloperidol|IM Haloperidol
88899448|NCT01501123|Active Comparator|IM Midazolam|
88899449|NCT01501136|Experimental|sequential trial,DDGP, radiotherapy|sequential DDGP(gemcitabine,pegaspargase,cisplatin,dexamethasone) regiment followed by radiotherapy
88899450|NCT01501136|Experimental|sequential trial,VIPD, radiotherapy|sequential VIPD（cisplatin，Etoposide,Ifosfamide,dexamethasone，Mesna） regiment followed by radiotherapy
88899451|NCT01501136|Experimental|sequential trial, radiotherapy,DDGP|sequential radiotherapy followed by DDGP(gemcitabine,pegaspargase,cisplatin,dexamethasone) regiment
88899452|NCT01501136|Experimental|sequential trial,radiotherapy, VIPD|sequential radiotherapy followed by VIPD（cisplatin,Etoposide,Ifosfamide,dexamethasone,Mesna）regiment chemotherapy
88899453|NCT01501136|Experimental|Radiotherapy|Suitable type intensity-modulated radiation therapy (IMRT) 50GY
88899454|NCT01501149|Experimental|DDGP regiment|DDGP(gemcitabine,pegaspargase,cisplatin,dexamethasone) regiment
88899455|NCT01501149|Experimental|SMILE Regiment|Modified SMILE （methotrexate，hexadecadrol，Ifosfamide，L-AsparaginaseL，Etoposide，Mesna）Regiment
88899456|NCT01501175||patients with suspected SVT|patients with suspected SVT and inhabitants of the Saint Etienne region
88899457|NCT01501188|Experimental|Kinesio taping|Specific type of muscle and joint taping
88899458|NCT01501188|Placebo Comparator|Kinesio taping placebo|Kinesio taping placebo
88899459|NCT01501214|Active Comparator|Atosiban|
88899460|NCT01501214|Placebo Comparator|Placebo|Normal saline
88899461|NCT01501227|Active Comparator|Taper Guard Endotracheal Tube|Patients in the test group will be intubated with the Taper Guard Endotracheal Tube. The incidence of VAP, the length of ventilation, the length of intensive care stay, the length of hospital stay and the mortality rate will be monitored.
88899462|NCT01501227|Sham Comparator|conventional endotracheal tube|Patients in the placebo comparator group will be intubated with the conventional Endotracheal Tube. The incidence of VAP, the length of ventilation, the length of intensive care stay, the length of hospital stay and the mortality rate will be monitored.
88899463|NCT01501240||liver cirrhosis, liver transplantation|Patients with known liver cirrhosis and planned to undergo liver transplantation within 1 month will be eligible population in the study
88899464|NCT01501253|Experimental|CKD-828 2.5/40mg|CKD-828 2.5/40mg
88899465|NCT01501253|Experimental|CKD-828 2.5/80mg|CKD-828 2.5/80mg
88899466|NCT01501253|Active Comparator|S-Amlodipine 2.5mg|S-Amlodipine 2.5mg
89420283|NCT05260918|Placebo Comparator|Nappod|Participants in this arm will be asked to lie comfortably in a special recliner called a Metro Nappod for the duration of a 60 minute session twice a week for 3 weeks. The chair is located in a quiet and dimly lit room to minimize interruptions. The pod is equipped with a privacy visor, built-in speaker, and a timer with an alarm.
89420284|NCT05260801|Experimental|Bright lighting followed by Placebo lighting|Each lighting condition will last for two weeks (Weeks 2-3 or 4-5), be limited to the 10 workdays, and be active for 8 hours per day. The order of conditions will be randomized.
89420285|NCT05260801|Experimental|Placebo lighting followed by bright lighting|Each lighting condition will last for two weeks (Weeks 2-3 or 4-5), be limited to the 10 workdays, and be active for 8 hours per day. The order of conditions will be randomized.
89420286|NCT05260073||Tirbanibulin (Klisyri®)|Participants will receive tirbanibulin ointment 2.5 mg in 250 mg (single dose packet). The participants will be observed for 24 weeks to gather participant reported outcomes (PROs) and clinical profile.
89420287|NCT05252676||Patients|Patients with ground glass opacity featured lung adenocarcinoma who are candidates for surgery.
88899467|NCT01501266||Faslodex|
88899468|NCT01501279|Experimental|pudendal nerve block|USG guided pudendal nerve block performed under general anesthesia
88899469|NCT01501279|No Intervention|no nerve block|Control group without nerve block
89420288|NCT05250713|Experimental|tDCS|Patients receiving tDCS during SEEG investigation
89420289|NCT05250713|Experimental|tACS|Patients receiving tACS during SEEG intervention
89420290|NCT05249192|Experimental|Immediate UC removal|Urinary catheter removal immediately after the end of the surgical procedure before exiting the operating room.
89420291|NCT05249192|Active Comparator|Early UC removal|Urinary catheter removal on first postoperative day (6 a.m.) as per standard protocol
89420292|NCT05230199|Active Comparator|Monitored standard of care|At the study site, much like other contemporary NICUs, parents are encouraged to be present 24 hours per day, with significant variability in the amount, types and timing of parent engagement. Infant holding is supported, provided the infant can maintain physiological stability during handling. Parents can hold infants on mechanical ventilation, but holding is not encouraged during times when the infant is on oscillatory ventilation and/or when chest tubes are in place. Holding time may be restricted in infants <32 weeks due to temperature instability. Nurses and therapists foster parent participation through instruction on caregiving and developmentally appropriate interactions, but these are balanced with other priorities of care. With standard of care, there is no targeted and set amount of positive sensory exposure, and practices vary based on the comfort level of nurses, the medical team, and the parents.
89420293|NCT05230199|Experimental|SENSE multisensory program|The SENSE program includes the provision of specific types and amounts of evidence-based tactile, auditory, visual, vestibular/kinesthetic, and olfactory interventions to be conducted by parents with their preterm infants, with a specific amount defined for each day of hospitalization. The program changes across PMA and an infant's tolerance of the prescribed activities. A sensory support team can fill in the gaps in intervention for infants in the SENSE group when parents are not available. The parent education materials identify specific doses of sensory inputs at each PMA. Feasibility has been established, with provision of an average of 155 hours of sensory exposures across NICU hospitalization.
89420294|NCT05214287|Experimental|Intermittent with 5x5-minutes, FiO2 0.163|Delivered intermittently, with FiO2 0.163 and room-air, each 5 minutes, for 5 cycles/session
89420295|NCT05214287|Experimental|Intermittent with 5x5-minutes, FiO2 0.127 or 0.133|Delivered intermittently, with FiO2 0.127 or 0.133 (depending on SaO2 during screening procedure at FiO2 0.127, see study procedures) and room-air, each 5 minutes, for 5 cycles/session
89420296|NCT05214287|Experimental|Continuous for 45 minutes, FiO2 0.163|Delivered via the hypoxicator
89420297|NCT05214287|Experimental|Continuous for 45 minutes, FiO2 0.127 or 0.133|FiO2 0.127 or 0.133 (depending on SaO2 during screening procedure at FiO2 0.127, see study procedures)
89420298|NCT05214287|Placebo Comparator|Continuous for 45 minutes, FiO2 0.209|Delivered via an open three-way valve in the circuitry from hypoxicator to the participant
89420299|NCT05183282|Experimental|Tarsus Patch Group|All subjects will receive the Tarsus Patch to be worn and evaluated by the investigator in the clinic and to also be worn at home for 3 nights.
89420300|NCT05182931|Experimental|BRAFv600E mutant radioiodine refractory thyroid cancer|"Prior to commencing interventional treatment, participants will commence a low iodine diet and undergo thyroxine withdrawal and commence T3 replacement from day -27. On day -5 they will receive an oral dose of 124I (40MBq/1.08 mCi) with imaging at 24 hours (+/-6) post dose and a second imaging assessment within 120 hours.~Participants will receive Dabrafenib (oral, 150mg BD) and Trametinib (oral, 2mg OD) from day 1-30.~A second oral dose of I124 will be administered at day 24 followed by imaging at the same interval as baseline.~Participants achieving >20Gy tumour uptake of I124 will be administered 6GBq (3.3Gy/GBq) 131I, I131 wb scan and SPECT/CT will be performed within 24 hours and at hospital discharge.~Participants who do not achieve >20Gy tumour update of I-124 will move into follow up.~Follow up will occur every 12 weeks for 12 months."
89420301|NCT05182931|Experimental|RAS mutant radioiodine refractory thyroid cancer|"Prior to commencing interventional treatment, participants will commence a low iodine diet and undergo thyroxine withdrawal and commence T3 replacement from day -27. On day -5 they will receive an oral dose of 124I (40MBq/1.08 mCi) with imaging at 24 hours (+/-6) post dose and a second imaging assessment within 120 hours.~Participants will receive Trametinib (oral, 2mg OD) from day 1-30.~A second oral dose of I124 will be administered at day 24 followed by imaging at the same interval as baseline.~Participants achieving >20Gy tumour uptake of I124 will be administered 6GBq (3.3Gy/GBq) 131I, I131 wb scan and SPECT/CT will be performed within 24 hours and at hospital discharge.~Participants who do not achieve >20Gy tumour update of I-124 will move into follow up.~Follow up will occur every 12 weeks for 12 months."
89420302|NCT05163067|Experimental|Combined aerobic exercise and cognitive training program|
88899470|NCT01501292||Immature oocytes (GV, M-I)|
88899471|NCT01501292||Mature oocytes (M-II)|
88899472|NCT01501305|Placebo Comparator|Placebo|Mineral rehydration solution
88899473|NCT01501305|Active Comparator|Carob powder|Carob powder and probiotics
88899474|NCT01501318|Active Comparator|Personalized feedback plus education|Participants receive the personalized feedback report plus education. This is the currently implemented service approach.Treatment as usual with participants receiving a personalized feedback report about the risks associated with their current substance use behaviors and a brief (5-15 minute) motivational interviewing based education session provided by a trained health coach.
88899475|NCT01501318|Experimental|Personalized feedback report alone|Provision of the personalized feedback report alone.
89420303|NCT05163067|No Intervention|Standard health counseling at baseline|
89420304|NCT05156476|Active Comparator|Genicular nerve block-iPACK group|"Genicular nerve block-iPACK group (performed by anaesthesiologist) Method: Ultrasound and nerve stimulation guided injection Genicular nerve block will be performed on the the superomedial, the superolateral, the inferomedial and inferolateral genicular nerve.~Drug: a total of 30 ml of ropivacaine 0.5% (150 mg) will be used for this treatment arm."
89420305|NCT05156476|Active Comparator|Femoral triangle block-iPACK group|Femoral triangle block-iPACK group (performed by anaesthesiologist) Method: Ultrasound and nerve stimulation guided injection Drug: a total of 30 ml of ropivacaine 0.5% (150 mg) will be used for this treatment arm
89420306|NCT05156476|Active Comparator|Local Infiltration Analgesia (LIA)|LIA (performed by surgeon) Method: Blind injection Drug: a total of 200 ml of 0.2% ropivacaine will be used (400 mg). Of this, 150 ml of ropivacaine 0.2% will be mixed with 1 mg of adrenaline.
89420307|NCT05154370||MS/CIS|Diagnosis of MS and CIS based on the 2017 McDonald MS diagnostic criteria.
89420308|NCT05154370||ADEM|Diagnosis of ADEM based on the 2012 IPMSSG diagnostic criteria for ADEM
89420309|NCT05154370||MOGAD|Diagnosis of MOGAD based on the 2020 Chinese Expert Consensus.
89420310|NCT05154370||NMOSD|diagnosis of NMOSD according to 2015 International Panel for Neuromyelitis Optica Diagnosis criteria.
89420311|NCT05139680||Patients with mixed phenotype ATTRv-CM|Hereditary ATTR-CM patients presenting with mixed phenotype
88899476|NCT01501331||RRT diagnostic tool|Patients implanted with an Energen device or successor.
88899477|NCT01501357|Experimental|multilevel filaments toothbrush|Children will brush with anteroposterior toothbrushing and a modified toothbrush (multilevel filaments)
88899478|NCT01501357|Active Comparator|cross toothbrushing|Children will brush with cross toothbrushing.
88899479|NCT01501370|Experimental|ZLd|"Patients, who are receiving Lenalidomide maintenance treatment with or without prednisone, will be randomized to receive:~Cohort 1: ZLd association:~Lenalidomide orally at the dose of 25 mg/day for 21 days every 28 days~Vorinostat orally at the dose of 400 mg/day on days 1-7 and 15- 21 on a 28-day cycle.~Dexamethasone orally at the dose of 40 mg day 1,8, 15, 22 every 28 days."
88899480|NCT01501370|Active Comparator|Ld|"Patients, who are receiving Lenalidomide maintenance treatment with or without prednisone, will be randomized to receive: Lenalidomide orally at the dose of 25 mg/day for 21 days every 28 days~• Dexamethasone orally at the dose of 40 mg day 1,8, 15, 22 every 28 days."
88899481|NCT01501396|Experimental|Arm A (megestrol alone)|Megestrol acetate 800 mg PO daily x 8 weeks
88899482|NCT01501396|Experimental|Arm B (megestrol plus mirtazapine)|"Megestrol acetate 800 mg PO daily x 8 weeks~Mirtazapine 15 mg PO at bedtime x 1 week followed by 30 mg PO at bedtime x 7 weeks"
88899483|NCT01501409|Experimental|Group I|
88899484|NCT01501409|Active Comparator|Group II|
88899485|NCT01501409|Active Comparator|Group III|
88899486|NCT01501422|Experimental|Estrogen|Use estrogen patch for 8 weeks
88899487|NCT01501422|Experimental|Placebo|Use placebo patch for 8 weeks
88899488|NCT01501435|Experimental|CJ-30039|Incrementally Modified Drugs of fenofibric acid
88899489|NCT01501435|Active Comparator|fenofibric acid|Greencross Lipidil Supra 160mg
88899490|NCT01501448|Active Comparator|OCP|
89420312|NCT05135728|Experimental|Unstuck and On Target-Preschool|"UOT-P is based on the foundational principles of UOT for improving EF as well as evidence-based teaching methods (e.g., positive behavior supports, visual aids). Through this program, children, teachers and parents develop a shared self-regulatory vocabulary that enables children to improve EF at home and school through adult modeling and gradual scaffolding. The self-regulatory vocabulary (e.g., Flexible, Make a New Plan, Unstuck) becomes a contagious common language. We hypothesize this is the mechanism of change by which children will show improved EF skills, leading to increased academic readiness, improved social competence and reduced externalizing behaviors."
88899491|NCT01501448|Active Comparator|Oral estradiol valerate|
88899492|NCT01501474||CholangioFlex and Fluorescent in situ Hybridization(FISH)|
88899493|NCT01501487|Active Comparator|HER2 negative patients|"In order to provide some consistency in management and have a treatment policy in place only recommended therapy with several well accepted and presumed equivalent chemotherapy regimens will be used. The proposed neo-adjuvant chemotherapy regimens for HER2 negative patients include:~TAC chemotherapy~TC chemotherapy~Dose Dense AC or FEC100 followed by paclitaxel or docetaxel chemotherapy"
88899494|NCT01501487|Active Comparator|Her2 positive patients|The proposed neo-adjuvant chemotherapy regimens for HER2 negative patients is TCH chemotherapy.
88899495|NCT01501500|Active Comparator|botulinum toxin type A. HV angle|intramuscular injection of BTA into target muscle
88899496|NCT01501500|Placebo Comparator|Normal saline, HV angle|intramuscular injection of normal saline into target muscle
88899497|NCT01501539|No Intervention|Standard postop gastrostomy tube care|At the completion of the operative procedure for gastrostomy tube placement, the surgical incisions and the gastrostomy tube will be covered with dermabond, steristrips, and/or tegaderm dressings, according to surgeon preference. Standard postop gastrostomy tube care. Insertion site cleaned with soap and water. No dressing added.
88899498|NCT01501539|Experimental|Standard hydrocolloid dressing|At the completion of the operative procedure for gastrostomy tube placement, the surgical incisions will be covered with dermabond, steristrips, and/or tegaderm dressings, according to the surgeons preference. The gastrostomy tube will have a thin layer of hydrocolloid dressing (HD) placed around the gastrostomy tube. The HD will be changed once every other day fo the first 30 days after gastrostomy tube placement. After 30 days, care will revert to standard care.
88899499|NCT01501539|Experimental|Silver hydrocolloid dressing|At the completion of the operative procedure for gastrostomy tube placement, the surgical incisions will be covered with dermabond, steristrips, and/or tegaderm dressings, according to surgeon preference. The gastrostomy tube will have a thin layer of silver hydrocolloid dressing (HD) placed around the gastrostomy tube. The silver HD will be changed once every other day for the first 30 days after gastrostomy tube placement. After 30 days, care will revert to standard care.
88899500|NCT01501552|No Intervention|Treatment as usual|In the no-intervention treatment as usual group, a package, containing a summary card of the national guideline recommendation, will be delivered to each provider unit without demonstration. In Poland, the summary card will be adapted from the PHEPA guidelines (ref) for the purposes of this trial. The treatment as usual group will be requested to screen and offer person-to-person SBI at the PHCU.
88899501|NCT01501552|Experimental|Training & support (T&S)|The T&S only group will be offered two face-to-face educational meetings of at least one hour and a maximum of 2 hours, and one telephone support call of at least ten minutes and a maximum of 30 minutes. The telephone call will be offered to one of the GPs ('leader'). Depending on the needs of the PHCU, one additional face to face training (1 to 2 hours) may be offered. The time interval between meetings will be on average 2 weeks. The training sessions will address improving knowledge, skills, attitudes, and perceived barriers and facilitators by combining theory and practice-based training.
88899502|NCT01501552|Experimental|Financial incentive|The financial incentive only group will receive a financial incentive depending on their screening and brief intervention activities. They will be paid for the performance, with the country dependent system of pay (fee for item or fee for achieving set rates) and based on normal practices and financial rates for financial incentives for clinical preventive activities.
88899503|NCT01501552|Experimental|E-SBI|The e-SBI (online screening and brief intervention)only group are expected to refer identified at-risk patients to an approved e-SBI programme, which will be either country specific (where these exist) or based on the WHO e-SBI programme (Poland).
89420313|NCT05135728|Active Comparator|Waitlist Control|Children at clinic sites beginning in Year 4 will be placed in Arm 2, in which a waitlist control model will be used. Assessment of participants on outcome measures will occur at pre-intervention, followed by a 16-week waitlist period, again at baseline, followed by a 16-week intervention, and then finally at endpoint. All participants in Arm 2 will receive UOT-P as their intervention (see Experimental Arm).
88899504|NCT01501552|Experimental|T&S and financial incentive|The T&S and financial incentive group will be offered two face-to-face educational meetings of at least one hour and a maximum of 2 hours, and one telephone support call of at least ten minutes and a maximum of 30 minutes. Also, they will receive a financial incentive depending on their screening and brief intervention activities. They will be paid for the performance, with the country dependent system of pay (fee for item or fee for achieving set rates) and based on normal practices and financial rates for financial incentives for clinical preventive activities.
88899505|NCT01501552|Experimental|T&S and e-SBI|The T&S and e-SBI group will be offered two face-to-face educational meetings of at least one hour and a maximum of 2 hours, and one telephone support call of at least ten minutes and a maximum of 30 minutes. The telephone call was offered to one of the GPs ('leader'). Depending on the needs of the PHCU, one additional face to face training (1 to 2 hours) was offered. Also this group is expected to refer identified at-risk patients to an approved e-SBI (online screening and brief intervention) programme, which will either be country specific (where these exist) or based on the WHO e-SBI programme (Poland).
88899506|NCT01501552|Experimental|Financial incentive and e-SBI|The financial incentive and e-SBI (online screening and brief intervention) group will be paid for screening and referral performance instead of actual delivery of e-SBI by themselves as in line with the e-SBI only group, with the country dependent system of pay (fee for item or fee for achieving set rates) and based on normal practices and financial rates for financial incentives for clinical preventive activities.
89420314|NCT05128383|Experimental|Dupilumab Subcutaneous Injection|"600 mg at initial visit and 300mg every 2 weeks until week 22~Each subject will receive 600mg of Dupilumab at baseline visit and 300mg of Dupilumab as a subcutaneous injection every 2 weeks for a total of 9 doses over 22 weeks."
89420315|NCT05126836|Other|Cilostazol|"First week, Cilostazol 100mg twice a day~Second week, Placebo twice a day~Third week, Cilostazol 100mg twice a day~Forth week, Placebo twice a day"
89420316|NCT05126836|Other|Placebo|"First week, Placebo twice a day~Second week, Cilostazol 100mg twice a day~Third week, Placebo twice a day~Forth week, Cilostazol 100mg twice a day"
89420317|NCT05109338|Experimental|Ben-Guard user|Participants will wear the garment for up to 18 months while needing a central line catheter.
88819875|NCT01461668|Placebo Comparator|Placebo|Participants in this arm will be instructed to complete a decolonization regimen that will involve a 5-day application of a placebo with follow up bilateral nares swab one week following completion of therapy (~D12) to assess clearance. If follow up swabs are positive for MRSA, patients will be given a second course of the same agent (placebo) to begin one week following swab collection (~D19-23) so that up to two decolonization attempts will be made. A final set of bilateral nares swabs will be obtained from all subjects six weeks from the completion of initial treatment (~D47).
88819876|NCT04998825|Experimental|Proteoglycan F group|"Taking Proteoglycan F~Dosage of Proteoglycan F: 50mg/day~Used time: 24 weeks"
88819877|NCT04998825|Placebo Comparator|Control group|"Taking Placebo (Dextrin)~Dosage of Placebo: 50mg/day~Used time: 24 weeks"
88819878|NCT00372177|Active Comparator|EP1645|Single-Dose
88819879|NCT04980339||ASO group|All participants with TGA/TBA after ASO
88819880|NCT01461824|Active Comparator|150 mg DMPA|Depot medroxyprogesterone acetate (DMPA) 150 mg every 12 weeks IM
88819881|NCT01461824|Experimental|104mg DMPA|Depot medroxyprogesterone acetate (DMPA) 104 mg every 12 weeks IM
88819882|NCT01461824|Experimental|75mg DMPA|Depot medroxyprogesterone acetate (DMPA) 75 mg every 12 weeks IM
89420318|NCT05109338|No Intervention|Retrospective match control|Matched historical control for intervention group based on age, gender and duration of use of a central venous catheter.
89420319|NCT05089227|Experimental|"intervention group"|
88899507|NCT01501552|Experimental|T&S, financial incentive and e-SBI|The T&S, financial incentive and e-SBI (online screening and brief intervention) group will be offered two face-to-face educational meetings of at least one hour and a maximum of 2 hours, and one telephone support call of at least ten minutes and a maximum of 30 minutes. The telephone call will be offered to one of the GPs ('leader'). Also, they are expected to offer screening at the PHCU and to refer screen positive patients to e-SBI programmes. Additionally, they will be paid for screening and referral performance, with the country dependent system of pay (fee for item or fee for achieving set rates) and based on normal practices and financial rates for financial incentives for clinical preventive activities.
88899508|NCT01501565|No Intervention|Control|Standard analgesic therapy: iv Metamizol 2 g q8h
88899509|NCT01501565|Experimental|TAP|"Transverse abdominal plain (TAP) blockade with local anesthetic: Bupivacaine chlorhydrate 0.25% adjusted by weight and type of surgery. Maximum dose: 150 mg of bupivacaine.~Two approaches are done: 1)Posterior TAP: the needle insertion point is cephalad to the iliac crest, behind the midaxillary line. The needle is inserted under ultrasound guidance in plane. Local anesthetics is deposited between the internal oblique and transversus abdominis muscles, 2)Subcostal TAP: the needle is inserted ultrasound guided perpendicularly to abdominal wall, directed parallel to the costal margin but oblique to the sagittal plane. Local anesthestic is deposited between transversus abdominis and the rectus abdominis muscles."
88899510|NCT01501578||telomerase mutation|Patients with interstitial lung disease and telomerase mutation
88899511|NCT01501578||control|Patients with idiopathic pulmonary fibrosis and without telomerase mutation
88899512|NCT01501591|Other|Hydroxyzine|This group will receive a first generation H-1 receptor antagonist, hydroxyzine (25 mg) twice on two days; on one day described by the investigator as hydroxyzine and on the other day described by the investigator as placebo, in a randomized balanced crossover design.
88899513|NCT01501591|Other|Placebo|This group will receive a placebo twice on two days; on one day described by the investigator as hydroxyzine and on the other day described by the investigator as placebo, in a randomized balanced crossover design.
88899514|NCT01501591|Other|Hydroxyzine/placebo|This group will receive hydroxyzine and placebo in a randomized double-blind placebo-controled crossover design.
88899515|NCT01501617|Experimental|HSC- Hair Stimulating Complex|Hair Stimulating Complex will be injected intradermally into the scalp of the test subject at 2 timepoints (Baseline and 6 Weeks after Baseline) using sterile syringes with 30 gauge needles at a volume of 0.1 mL per injection. A total of 8 injections (about 3mm apart) will be administered into one of the the 2 randomized sites (left or right) of the subject's scalp. Six weeks after the Baseline injection, the same treatment site will receive a repeat dose (the same volume and number of injections as used in the baseline) with no crossover.
89420320|NCT05089227|Active Comparator|"standard group"|
89420321|NCT05075005|Active Comparator|Treatment Cohort|Treatment Cohort: Will utilize a minimalist shoe (Vibram® Fivefingers) and follow the training protocol described below for training on natural terrain.
89420322|NCT05075005|Experimental|Control Cohort|Control Cohort: Will utilize the same minimalist shoe and follow the same training schedule as the treatment group, with the modification of training on hardscapes.
89420323|NCT05050357|Active Comparator|hormonal intrauterine device arm|
89420324|NCT05050357|Active Comparator|progestin arm|
89420325|NCT05032430|Experimental|Calma, Conversa, y Cría (CCC)|Mindfulness-based parental stress reduction intervention
89420326|NCT05032430|Active Comparator|Enhanced Usual Care|Comparator group designed to influence health and well-being that does not include mindfulness as an active ingredient.
89420327|NCT05008809|Experimental|Treatment|Active treatment with mFOLFOXIRI or mFOLFOX6 q2w up to six months followed by structured Follow-up for up to five years after randomization
89420328|NCT05008809|No Intervention|Control|Structured Follow-up for up to five years after randomization
89420329|NCT04986917|Experimental|Su2ura® approximation device - study device group|Patients with a primary umbilical hernia will be recruited to the study and the hernia will be repaired using the Su2ura® approximation device
89420330|NCT04976179|Experimental|FCM - Intravenous Ferric carboxymaltose|Intravenous Ferric Carboxymatlose administered in a single dose of 20mg/Kg to a maximum of 1000mg in 200mls of infusion given over minimum of 15 - 20 minutes at enrollment.
89420331|NCT04976179|Active Comparator|FS -Oral Ferrous sulphate|Oral Ferrous Sulphate (containing 65mg of elemental iron) to be taken as one 200mg tablet 3 times a day until delivery.
88899516|NCT01501617|Placebo Comparator|Dulbecco's Modified Eagle Medium, DMEM|Dulbecco's Modified Eagle Medium (DMEM) will be administered the same way as described above into treatment zone of the test subject's scalp not treated with HSC.
88899517|NCT01501630||PET/CT and MRI|all patients will benefit from PET/CT and MRI
88899518|NCT01501643|Active Comparator|Spirometry|Spirometry
88899519|NCT01501643|Experimental|Non invasive positive pressure ventilation|Non invasive positive pressure ventilation
88899520|NCT01501669|No Intervention|Capecitabine alone arm|X arm
88899521|NCT01501669|Experimental|Irinotecan plus capecitabine arm|
88899522|NCT01501682||primary suture|operated with primary suture
88899523|NCT01501682||other mesh|operated with insertion of another mesh
88899524|NCT01501682||ventralex|operated with insertion of ventralex mesh
88899525|NCT01501695|Experimental|5LGr, granule and placebo tablet|"Drug:5LGr; Dosage form:Granule;Strength:5 gram/sack;Mimic Tablet:0 mg/tablet. Dosage: 5LGr Granule: 1 sack, t.i.d. for patients less than 12 yrs,whereas 1.5 sacks, t.i.d. for patients 13-18 yrs.~Mimic tablet:For patients 5-12 yrs: 0.5 tablet, b.i.d for first 2 weeks, then 1 tablet, bid for next 6 weeks; for patients 13-18 yrs: tablet b.i.d for first 2 weeks, then 2 tablets b.i.d for next 6 weeks.~Duration: 8 weeks."
88899526|NCT01501695|Active Comparator|tiapride tabletand mimic 5LGr granule|"Tiapride are 100 mg scored tablets. Mimic 5LGr granule are preparation that contain no active ingredient, and act as placebo.~Dosage: Tiaptride tablet: For patients 5-12 yrs: 50mg bid for first 2 weeks, then 100 mg, bid for next 6 weeks; for patients 13-18 yrs:100mg bid for first 2 weeks, then 200 mg bid for next 6 weeks.~Mimic 5LGr Granule:Strength:0 gram/sack.Dosage:1 sack for patients less than 12 yrs,while 1.5 sacks for patients 13-18 yrs.Frequency: T.i.d.~Duration: 8 weeks."
88899527|NCT01501695|Placebo Comparator|placebo, granule and tablet|"This arm includes mimic preparation of 5LGr granule and tiapride tablets , which doesn't contain active ingredients.~Dosage form: Mimic Granule:Strength:0 gram/sack Dosage:1 sack, t.i.d for patients less than 12 yrs,while 1.5 sacks, t.i.d for patients 13-18 yrs.~Mimic tablet:Strength:0 mg/tablet.For patients 5-12 yrs: 0.5 tablets b.i.d for first 2 weeks, then 1 tablet,b.i.d for next 6 weeks; for patients 13-18 yrs:1 tablet b.i.d for first 2 weeks, then 2 tablets b.i.d for next 6 weeks.~Duration: 8 weeks."
88899528|NCT01501708|Experimental|Caspofugin based combination therapy|"Caspofugin based combination therapy:~Patients will recieve caspofungin with voriconazole or amphotericin B"
88899529|NCT01501721|Experimental|Exercise|Home-based exercise program
88899530|NCT01501721|Experimental|Nutritional counseling|Nutrition counseling aiming to reduce suggar intake
88899531|NCT01501734|Experimental|all patients with symptomatic CHF|"Single arm prospective study~Study population will include all patients referred to our outpatient clinic for congestive heart failure for a two-year period, who will be screened for sleep apnea and found to have sleep disordering breathing (SDB).~200 patients will visit the outpatient clinic for congestive heart failure.~Approximately 30% will be eligible for this study."
88899532|NCT01501747|Active Comparator|overt drug|The study has 4 sub-parts (one for each of 4 drugs), each sub-part has a crossover design. In this arm, the volunteer will be given one oral dose of 300 mg caffeine, 500 mg paracetamol, 500 mg cephalexin, or 400 mg ibuprofen and will be told that they are receiving such medication.
88899533|NCT01501747|Placebo Comparator|Placebo (Covert drug)|The study has 4 sub-parts (one for each of 4 drugs), each sub-part has a crossover design. In this arm, the volunteer will be given one oral dose of 300 mg caffeine, 500 mg paracetamol, 500 mg cephalexin, or 400 mg ibuprofen and will be told that they are receiving a placebo.
88899534|NCT01501760|Experimental|bevacizumab|Three subconjunctival injections of 0.5 ml of bevacizumab at inclusion, 1 month, 2 month.
88899535|NCT01501760|Placebo Comparator|Placebo|Three subconjunctival injections of 0.5 ml of Nacl at inclusion, 1 month, 2 month.
88899536|NCT01501773|Experimental|Autologous bone marrow stem cell|
88899537|NCT01501773|No Intervention|Control|
88899538|NCT01501786|Sham Comparator|control|propofol and saline are administered
88899539|NCT01501786|Experimental|Ket10|ketamine is co-administered with propofol
88899540|NCT01501786|Experimental|Ket20|ketamine is co-administered with porpofol
88899541|NCT01501799|Experimental|Adapalene 0.1% and benzoyl peroxide 2.5% topical gel|
88899542|NCT01501799|Active Comparator|EPIDUO™ (adapalene 0.1% and benzoyl peroxide 2.5%) Gel|
88899543|NCT01501799|Placebo Comparator|Vehicle Gel|
88899544|NCT01501812||Schizophrenia|Subjects who are suffering from Schizophrenia or Schizoaffective disorder acording to the DSM-IV-R criteria
88899545|NCT01501812||Control|Healthy subjects without any mental ilness in axis I or II.
88899546|NCT01501812||Bipolar|Subjects who are suffering from bipolar I or 2 disorder acording to the DSM-IV-R criteria
88899547|NCT01501812||MDD|Subjects who are suffering from Major Depressive disorder acording to the DSM-IV-R criteria
88899548|NCT01501812||Anxiety|Subjects who are suffering from Panic disorder or from Generalized Anxiety disorder acording to the DSM-IV-R criteria
88899549|NCT01501812||PTSD|Subjects who are suffering from Post Traumatic Stress Disorder acording to the DSM-IV-R criteria
88899550|NCT01501825|Active Comparator|single channel|Single Channel with a coil placed over the left PFC (10 Hz).
88899551|NCT01501825|Experimental|four channels|"Four channels:~10 Hz over the left PFC.~1 Hz over the right PFC.~10 Hz over the left parietal cortex.~1 Hz over the right parietal cortex."
88899552|NCT01501864|Experimental|School Support Group|School Support Intervention
89420332|NCT04966104|Experimental|ODYSSEE-vCHAT|"ODYSSEE-vCHAT consisted of:~Automated digital counselling resources (educational pages, videos, tools, and trackers)~Chatrooms available 24/7~Weekly 30-minute webcasts led by a healthcare professional or patient representative~Each aspect was informed by a rotating schedule of 7 weekly self-care themes. Webcasts were recorded and streamed to our private YouTube channel, and associated hyperlinks were shared on the program. Subjects had the option of submitting photographs depicting heart-healthy lifestyles and activities (with no identifying, sensitive, or personal information) to the Gallery Wall.~Subjects were invited by email to access the resources available to them. They logged on to the program using password-protected personal accounts. Each participant's total number of logins and login time (with timestamps) were recorded. Assessments occurred online at baseline, months 4, 8, and 12, and trial completion (median = 8.5 months, range = 2 to 15 months)."
88899553|NCT01501864|No Intervention|Control|No school support
89420333|NCT04966104|No Intervention|eUC|eUC provided educational HF self-care resources that are available to the public on professional heart health websites (e.g., Heart Failure Society of Canada, American Heart Association, European Society of Cardiology, Health Canada). Patients were provided with unlimited access to these resources. Subjects were invited by weekly emails to partake in these resources. Self-reported assessments are administered at baseline, months 4, 8, and 12, and trial completion (median = 8.5 months, range = 2 to 15 months).
89420334|NCT04964843|Experimental|N-acetylcysteine|25 participants randomly selected to receive 1500 milligrams of oral n-acetylcysteine twice daily for 7 weeks.
88899554|NCT01501877|Experimental|Distress Tolerance|Acceptance and Commitment Therapy based Distress Tolerance (DT) smoking cessation intervention delivered in 7 2-hour group, 1 50-minute individual, and 2 10-minute phone sessions and 8 weeks of transdermal nicotine patch.
88899555|NCT01501877|Active Comparator|Standard Smoking Cessation|Standard smoking cessation intervention delivered in 7 2-hour group, 1 50-minute individual, and 2 10-minute phone sessions and 8 weeks of transdermal nicotine patch.
88899556|NCT01501890|Active Comparator|Progesterone|Women attending the Gynecological Emergency Unit due to first trimester vaginal bleeding, with a viable singleton pregnancy at a gestational age of 6-13 completed weeks of gestation
88899557|NCT01501890|Placebo Comparator|Placebo|Women attending the Gynecological Emergency Unit due to first trimester vaginal bleeding, with a viable singleton pregnancy at a gestational age of 6-13 completed weeks of gestation.
88899558|NCT01501903|Active Comparator|Standard|Biopsy using standard technique of FNA
88899559|NCT01501903|Other|Fanning|Biopsy using fanning technique
88899560|NCT01501916|Experimental|vitamin d|
88899561|NCT01501916|Placebo Comparator|Placebo|
88899562|NCT01501942|Experimental|Active|The active drug product is an oral solution of AIM-102 in phosphate buffered saline at a concentration of 35.0 mg/ml.
88899563|NCT01501942|Placebo Comparator|Inactive product|The matching placebo is an oral solution of phosphate buffered saline
88899564|NCT01501968|Active Comparator|Colistin|Colistimethate sodium 2.5-5mg/kg iv
88899565|NCT01501968|Experimental|Colistin + Ascorbic acid|Colistimethate sodium 2.5-5mg/kg iv and ascorbic acid 2 grams iv every 12 hours
89420335|NCT04964843|Placebo Comparator|Placebo|25 participants randomly selected to receive placebo twice daily for 7 weeks.
89420336|NCT04950803|Active Comparator|Active arm|Subjects will take microbiome immunity formula (SIM01) daily for 6 months
89420337|NCT04950803|Placebo Comparator|Placebo arm|Subjects will take active vitamin daily for 6 months
89420338|NCT04946825|Experimental|Quit cigarettes, but continue using e-cigarettes, with nicotine replacement therapy and text support|Participants in this arm will be instructed to quit tobacco cigarettes with nicotine replacement therapy (patches and lozenges) and text message support. In addition, these participants will be encouraged to continue using electronic cigarettes to help them quit smoking tobacco cigarettes.
89420339|NCT04946825|Experimental|Quit cigarettes and quit e-cigarettes with nicotine replacement therapy and text support.|Participants in this arm will be instructed to quit tobacco cigarettes and quit electronic cigarettes with nicotine replacement therapy (patches and lozenges) and text message support.
88899566|NCT01501994|Experimental|Walking workstation, counseling, accelerometry feedback|2 week baseline: accelerometer with no feedback 12 experimental: Use of the walking workstation, counseling on increasing activity levels, feedback from the accelerometer 12 week crossover: Feedback from accelerometer, no counseling or walking workstation
88899567|NCT01501994|Other|Control then crossover|2 week baseline: accelerometer with no feedback 12 week control period: accelerometer with no feedback 12 week crossover period: accelerometer with feedback, counseling on increasing activity, and use of a walking workstation
88899568|NCT01502007|Experimental|Accelerometer feedback and lifestyle counseling|The accelerometer, Fitbit, will be worn continuously. Fitbit can provide feedback to subjects about their physical activity. Subjects will wear the Fitbit for two weeks (without feedback) to obtain baseline activity data. The experimental group will then be instructed on use of the fitbit. Subjects will meet with the exercise counselor who will use accelerometer data to provide feedback and counseling to help the user increase their activity by at least 20% each day. In subjects who achieve an increase of 20%, the counseling will focus either on maintaining activity levels or increasing activity further depending on the desire of the subject. Counseling will be provided once weekly by phone and in person at least once a month. Following the 26th week the experimental subjects will continue to wear the Fitbit and receive feedback about their activity levels for an additional 24 weeks, but they will no longer receive counseling.
88899569|NCT01502007|Experimental|Accelerometer without Feedback|The accelerometer, Fitbit, will be worn continuously. Subjects will wear the Fitbit for two weeks (without feedback) to obtain baseline activity data. The control group will continue to wear the fitbit for the next 24 weeks without any feedback or activity counseling. Following the 26th week of the study, the subjects in the control group will complete the same program given to the experimental group in weeks 2 through 26.
88899570|NCT01502020|Active Comparator|Zyclara™|
88899571|NCT01502020|Experimental|Generic Imiquimod Cream, 3.75%|
88899572|NCT01502020|Placebo Comparator|Vehicle Cream|
89420340|NCT04946825|Experimental|Quit cigarettes, but continue using e-cigarettes, with text support.|Participants in this arm will be instructed to quit tobacco cigarettes with text message support. In addition, these participants will be encouraged to continue using electronic cigarettes to help them quit smoking tobacco cigarettes.
89420341|NCT04946825|Experimental|Quit cigarettes and quit e-cigarettes with text support.|Participants in this arm will be instructed to quit tobacco cigarettes and quit electronic cigarettes with text message support.
89420342|NCT04907656|Experimental|dCBT Condition|The dCBT used in this study (Daylight) was selected due to its noted efficacy in treating GAD. 25 interventions will be provided in four modules, with an average duration of 20 minutes. Sessions are unlocked weekly, and completion of an initial assessment drives an algorithm to personalize the program. Individuals may progress through treatment at a slower pace than weekly sessions; 10 weeks is allowed for treatment completion. Treatment is based on principles of applied relaxation, stimulus control, cognitive restructuring, and imaginal exposure. Participants schedule a time for each session and receive prompts if they miss the appointment. All interventions are aided by the use of an animated therapist.
88899573|NCT01502046|Experimental|Sativex|
88899574|NCT01502046|Placebo Comparator|Placebo|
88899575|NCT01502059|Experimental|Pilates Group|This group keep their usual treatment and did a Pilates treatment twice a week (one hour each class) during 90 days.
88899576|NCT01502059|No Intervention|Control Groups|This group keep their usual treatment and can do the Pilates training after the end of the study.
88899577|NCT01502098|Active Comparator|Early passive motion|Pendulum exercises starting on the first postoperative day. The patients are instructed to commence passive range-of-motion exercises in the plane of the scapula with the assistance with the contralateral limb. Active motion exercises were not permitted until four weeks after surgery.
88899578|NCT01502098|No Intervention|Immobilization|Immobilization with sling during a month. Pendulum exercises starting on the fourth postoperative week. The patients are instructed to commence passive range-of-motion exercises in the plane of the scapula with the assistance with the contralateral limb. Active motion exercises.
88899579|NCT01502111||Airway management|Patients receiving advanced airway management in physician manned helicopter emergency medical services over a 12-month period.
88899580|NCT01502124|Active Comparator|Lyophilized|
88899581|NCT01502124|Experimental|Liquid|
88899582|NCT01502137|Experimental|ESRD patients|
88899583|NCT01502137|Experimental|Healthy subjects|
88899584|NCT01502150||Pediatric Proton Therapy Patients|Data collection of MDACC patients under the age of 18 treated with proton radiotherapy. Proton dosimetry data collection, corresponding radiation dose distribution and imaging data in order to correlate normal tissue response with dose distribution.
88899585|NCT01502163|No Intervention|Control|"No prewarming~Intraoperative forced air warming (Thermoflect™/Mistral Air™) (after induction of anaesthesia, before surgery starting)~Passive insulation with Thermoflect™ material.~All fluids administrated intraoperative will be warmed."
89420343|NCT04907656|No Intervention|Waitlist (control) Condition|Participants allocated to the waitlist (control) condition will not receive an active intervention during the study. Participants will still complete all scheduled study assessments. They will receive access to the dCBT after completion of all study assessments.
89006710|NCT04618120|Experimental|Virtual Reality-based Exercise Group|"Virtual reality-based exercises, breathing exercises and patient education on general considerations.~Virtual reality-based exercises were done using the Microsoft Xbox 360 Kinect system. Among the 'Kinect Sports' games, especially tennis, table tennis, boxing and bowling games including upper extremity movements were selected. These games require all-directional and repetitive motion of the shoulder and elbow joint. Patients played the games using the operated / affected side arms. Between games, the patient was rested in a chair. In the meantime, deep breathing exercises were done.~The patients participated in virtual reality-based exercises 3 days a week (15-18 sessions in total) during the radiotherapy treatment continued (5-6 weeks). Each exercise session was set to last 30-40 minutes in total."
89420344|NCT04901390|Experimental|Yogurt with B. lactis and added cane sugar|Participants will consume yogurt with B. lactis and added cane sugar twice daily for 14 days.
89420345|NCT04898387|Experimental|T4030 Group|
89420346|NCT04898387|Active Comparator|Ganfort Group|
89006711|NCT04618120|Experimental|Exercise Group|"Stretching exercises, range of motion exercises, posture exercises, breathing exercises and patient education on general considerations.~11 different exercises consisting of shoulder range of motion in all directions, stretching exercises, posture exercises and breathing exercises were performed in the presence of a physiotherapist.The patients participated in this exercise program 3 days a week (15-18 sessions in total) during the radiotherapy treatment continued (5-6 weeks). One session of the exercises was completed in an average of 30-40 minutes. The same exercises were repeated in each session."
89420347|NCT04874532|Experimental|Community Paramedic (CP) program and Education Materials|Subjects will receive CP home visits and telephone calls for 1 month, along with printed diabetes education materials and a resource guide for contacting their diabetes care team in addition to usual care.
89420348|NCT04874532|Active Comparator|Usual Care and Education Materials|Subjects will receive printed diabetes education materials and a resource guide for contacting their diabetes care team in addition to usual care.
89420349|NCT04869189|Other|High Sphere|Subjects with a spherical refraction between -1.75 DS and -6.00 DS
89420350|NCT04869189|Other|Low Sphere|Subjects with a spherical refraction between -1.50 DS and +1.00 DS
89006712|NCT04618120|No Intervention|Control Group|Only patient education on general considerations.
89006713|NCT04618276|Experimental|Arm A (MAL group)|"Skin swab for culture in the groin for baseline~PDT with 5% topical methyl aminolevulinate (MAL) as the prodrug for the photosensitizer Pp IX~Skin swab for culture~Skin antisepsis~Skin swab for culture"
89006714|NCT04618276|Experimental|Arm B (Methylene Blue group)|"Skin swab for culture in the groin for baseline~PDT with 0.01% methylene blue based photosensitizer (NF-031)~Skin swab for culture~Skin antisepsis~Skin swab for culture"
89006715|NCT04618276|No Intervention|Control group|"Skin swab for culture in the groin for baseline~NO PDT~Skin antisepsis~Skin swab for culture"
89006716|NCT04618042|Experimental|FX06|
89006717|NCT04618042|Placebo Comparator|Placebo|
89006718|NCT04618003||Athletes with Spinal Cord Injury|Group of athletes with spinal cord injury that was assessed at rest and during a physical activity in virtual reality.
89006719|NCT04618003||Non-athletes with spinal cord injury|Group of non-athletes with spinal cord injury that was assessed at rest and during a physical activity in virtual reality.
89006720|NCT04618003||Able-bodied control group|Group of non-athletes able-bodied control subjects that was assessed at rest and during a physical activity in virtual reality.
89006721|NCT04617691|Experimental|Group 1: Guselkumab PFS-U|Participants will receive single intravenous (IV) guselkumab formulation using UltraSafe Plus Passive Needle Guards (PFS-U) to create the IV solution.
89006722|NCT04617691|Experimental|Group 2: Guselkumab FVP|Participants will receive single IV guselkumab formulation using Final Vialed Product (FVP) to create the IV solution.
89006723|NCT04617613|Active Comparator|Standard triple therapy|Standard triple therapy group received omeprazole 20 mg, amoxicillin 1 g and clarithromycin 500 mg twice daily for 14 days.
89006724|NCT04617613|Experimental|Quadruple therapy group|Quadruple therapy group received omeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg twice daily after meals for 14 days.
89006725|NCT04617652|Active Comparator|Group M|Magnesium group
89006726|NCT04617652|Placebo Comparator|Group C|Control group
89420351|NCT04848753|Active Comparator|Experimental Group|Toripalimab combined with cisplatin and paclitaxel
89420352|NCT04848753|Placebo Comparator|Control Group|Placebo combined with cisplatin and paclitaxel
89006727|NCT02961738|Active Comparator|Full-CAT|Participants in this arm receive an intervention of a full 8-session course of cognitive analytic therapy (CAT). This means that they are assessed then then receive a narrative reformulation, that then leads onto a sequential diagrammatic reformulation and then the change methods and completion.
89006728|NCT02961738|Experimental|An 8-session CAT without narrative reformulation (CAT-NR)|Participants in this arm receive an intervention of a full 8-session course of cognitive analytic therapy (as described above), but crucially with the narrative reformulation (NR) aspect removed. All other aspects of treatment remain the same.
89006729|NCT04617730|Active Comparator|Control arm|
89006730|NCT04617730|Experimental|Interventional arm|
89006731|NCT04617223|Other|Treatment|
89006732|NCT04617184||Inflammatory Bowel Disease|any patient with IBD will be included in the registry
89420353|NCT04833816|Experimental|Ketamin|Patient will get a bolus of ketamine at 0.1 mg / kg followed by a continuous infusion of ketamine at a dose of 0.15 mg / kg / hour
89420354|NCT04833816|Placebo Comparator|Placebo|Patient will get a bolus of NaCL at 0.1 mg / kg followed by a continuous infusion of NaCl at a dose of 0.15 mg / kg / hour
89420355|NCT04825561|Active Comparator|Active Comparator|AD-208 and Placebo of AD-2081
89420356|NCT04825561|Placebo Comparator|Placebo Comparator|Placebo of AD-208 and Placebo of AD-2081
89420357|NCT04825561|Experimental|Experimental Comparator|Placebo of AD-208 and AD-2081
89420358|NCT04823247||Tildrakizumab|Patients diagnosed with moderate-to-severe plaque psoriasis who require systemic biologic therapy and qualify for treatment with an IL-23p19 inhibitor in real-world clinical practice, following the routine clinical practice on each patient country, will be observed for 24 months.
89420359|NCT04814329||effective group|After treatment, tumor achieved complete response or partial response and the progression-free survival time was ≥6 months.
88899586|NCT01502163|Active Comparator|Group passive prewarming|"Passive prewarming / insulation on nursery ward before transport to the OR (Thermoflect TSCI, Amersfoort, NL)~Intraoperative forced air warming (Thermoflect™ / Mistral Air ™) The forced air warming will be applied after induction of anaesthesia.~All fluids administrated intraoperative will be warmed."
88899587|NCT01502163|Active Comparator|Group Active prewarming|"Active prewarming on nursery ward before transport to the OR (Thermoflect™/Mistral Air™, TSCI, Amersfoort, NL)~Intraoperative forced air warming (Thermoflect™ / Mistral Air ™) The forced air warming will be applied after induction of anaesthesia.~All fluids administrated intraoperative will be warmed."
88899588|NCT01502176||Atrial fibrillation patients|All patients discharged from hospital with a diagnose of atrial fibrillation
88899589|NCT01502189|Experimental|Representational approach|The Representational approach as described in the detailed description.
88899590|NCT01502202|Active Comparator|Study arm|Pemetrexed plus Cisplatin plus Gefitinib
88899591|NCT01502202|Placebo Comparator|Placebo arm|Pemetrexed plus Cisplatin plus Placebo
88899592|NCT01502215|Active Comparator|Liberal Transfusion Strategy|Liberal Group - transfusion when hemoglobin is lower than 9 g/dL. Intervention: Other: Red blood cell transfusion
88899593|NCT01502215|Active Comparator|Restrictive Transfusion Strategy|Restrictive Group - transfusion when hemoglobin is lower than 7 g/dL Intervention: Other: Red blood cell transfusion
88899594|NCT01502241|Active Comparator|Radiotherapy|6 weeks standard partial brain treatment.
88899595|NCT01502241|Experimental|Temozolomide|Temozolomide in a one week on/one week off schedule per Wick et al. 2004 and A. Wick et al. 2007
88899596|NCT01502254|Experimental|Copy of audio recording|Patients receive a copy of the audio recorded information about the clinical trial directly after the clinical visit. This makes it possible to repeat the information before a decision is made to participate in the clinical trial or not.
88899597|NCT01502254|No Intervention|No copy of audio recording|Patients in the control arm receive no copy of the audio recording.
88899598|NCT01502267|No Intervention|Group 1|This group will not receive IVIG and B cell depleting agents
88899599|NCT01502267|Experimental|Group 2|This group will receive IVIG and B cell depleting agents
88899600|NCT01502319||All subjects|Group/Cohort label is not applicable to this umbrella protocol. The Consortium funds specific research teams who will determine the number of group(s)/cohort(s) relevant to their study.
88899601|NCT01502345|Experimental|PUUV DNA Vaccine|This group will receive Puumala Virus DNA Vaccine only
88899602|NCT01502345|Experimental|HTNV + PUUV|This group will receive a 1:1 mixture of HTNV and PUUV DNA Vaccines
88899603|NCT01502345|Experimental|HTNV DNA Vaccine|This group will receive Hantaan Virus DNA Vaccine only
88899604|NCT01502358|Experimental|Tetravalent Dengue Vaccine (TVDV)|low dose (no adjuvant)
88899605|NCT01502358|Experimental|Tetravalent Dengue Vaccine (TVDV) with Vaxfectin® (low-dose)|low dose (with adjuvant)
88899606|NCT01502358|Experimental|Tetravalent dengue Vaccine (TVDV) with Vaxfectin® (high-dose)|high dose (with adjuvant)
88899607|NCT01502384||healthy relatives|healthy 1st degree relatives of PD patients
88899608|NCT01502397||HBsAg-negative, anti-HBc-positive|HBsAg-negative, anti-HBc-positive subjects undergoing rituximab-containing chemotherapy
88899609|NCT01502449|Experimental|DESTRESS-T|Usual primary care PTSD treatment, plus a telephone care management program over 8 weeks that includes: four outreach calls, feedback to the treating primary care provider, and care coordination
88899610|NCT01502449|Active Comparator|Optimized Usual Care (OUC)|Optimized Usual Care is usual primary care PTSD treatment, plus a telephone care management program that includes: four outreach calls, feedback to the treating primary care provider (PCP), and care coordination.
88899611|NCT01502475||Veteran Attitudes toward CAM|
88899612|NCT01502527|Experimental|Treatment with Femarelle|An open labeled , twice daily treatment with Femarelle
88899613|NCT01502553|Experimental|Blood Pressure, Heart Rate, Monitor|"Device Comparison Test DUT: Transtek Blood Pressure Monitor, LS-802 Refrence Device: Yuyue Medical Blood Pressure Meter, YYBP-212, accuracy: ±1mmHg and range: 0-300mmHg.~Groups/Cohorts: Blood Pressure & Heart Rate Monitor"
88899614|NCT01502566|Experimental|Educational Intervention|Children/mothers allocated to this arm will receive an pamphlet with key information on dental caries prevention, together with oral instructions about how to avoid dental caries. This intervention will be applied at the Brazilian National Vaccination Day
88899615|NCT01502566|No Intervention|Control group|This group will receive no intervention
88899616|NCT01502592|Experimental|Cryoablation alone|This is a pilot study evaluating the safety and tolerability of pre-operative, single-dose ipilimumab and/or cryoablation in patients with early stage/resectable breast cancer.
88899617|NCT01502592|Experimental|Ipilimumab alone|This is a pilot study evaluating the safety and tolerability of pre-operative, single-dose ipilimumab and/or cryoablation in patients with early stage/resectable breast cancer.
88899618|NCT01502592|Experimental|Ipilimumab & Cryoablation|This is a pilot study evaluating the safety and tolerability of pre-operative, single-dose ipilimumab and/or cryoablation in patients with early stage/resectable breast cancer.
88899619|NCT01502605|Experimental|5-ALA|This arm will receive the investigational agent, 5-ALA.
88899620|NCT01502618|Experimental|Focus Group|The focus group participants for this study will be Black Young Men who have Sex with Men (B-YMSM) ages 16-24 years (inclusive) who are diagnosed as HIV-positive and receive medical care at one of the two participating AMTUs or their community partners.
88899621|NCT01502670|Experimental|Lung Nodule|
88899622|NCT01502683|Experimental|Off-pump No Clamp|Off-pump coronary artery bypass patients randomized to no clamp for proximal anastomoses.
88899623|NCT01502683|Experimental|Off-pump Partial Occluding Clamp|Off-pump coronary artery bypass patients randomized to partial occluding clamp for proximal anastomoses.
89420360|NCT04814329||stable group|After treatment, tumor remains stable and the progression-free survival time was more than 1 month and less than 6 months.
89420361|NCT04814329||Early progressed group|After treatment, tumor got progressed and the progression-free survival time was no more than 1 month.
89420362|NCT04795830|Active Comparator|Control group with Stainless Steel Crown (SSC)|"After pulpotomy and hemostasis, MTA powder and liquid will be mixed according to the manufacturer's instructions and applied via MTA applicator to cover the amputated pulp stumps.~Using a glass ionomer gun, a capsule of GC Corporation's EQUIA Forte High Translucency glass ionomer restorative (GC EQUIA Forte HT Fil Capsule) will be injected to fill the pulp chamber.~Finally, the tooth will be restored with a stainless steel crown."
89420363|NCT04795830|Active Comparator|Control group with Restoration|"After pulpotomy and hemostasis, MTA powder and liquid will be mixed according to the manufacturer's instructions and applied via MTA applicator to cover the amputated pulp stumps.~Using a glass ionomer gun, a capsule of glass ionomer restorative GC EQUIA Forte HT Fil Capsule will be injected to fill the pulp chamber and restore the tooth."
89420364|NCT04795830|Experimental|Study group with Restoration|"After pulpotomy and hemostasis, BC RRM Fast setting putty will be applied from the manufacturer's syringe using a plastic instrument to cover the amputated pulp stumps.~Using a glass ionomer gun, a capsule of glass ionomer restorative GC EQUIA Forte HT Fil Capsule will be injected to fill the pulp chamber and restore the tooth."
89420365|NCT04795830|Experimental|Study group with Stainless Steel Crown (SSC)|"After pulpotomy and hemostasis, BC RRM Fast setting putty will be applied from the manufacturer's syringe using a plastic instrument to cover the amputated pulp stumps.~Using a glass ionomer gun, a capsule of glass ionomer restorative GC EQUIA Forte HT Fil Capsule will be injected to fill the pulp chamber.~Finally, the tooth will be restored with a stainless steel crown."
89420366|NCT04793373|Experimental|EpiFaith® group|Study subject will have the epidural placement with an EpiFaith® syringe.
89420367|NCT04793373|Active Comparator|Conventional group|Study subject will have the epidural placement with a conventional glass syringe.
89420368|NCT04772222|Experimental|Dexmedetomidine (DMT)|Subjects randomized to DMT arm in a 1:1 ratio. A loading dose of 1 mcg/kg will be given followed by 0.1 to 0.5 mcg/kg/h continuous infusion. The Neonatal Pain, Agitation, and Sedation Scale (N-PASS) will be used to determine infusion rate.
89420369|NCT04772222|Active Comparator|Morphine|Subjects randomized to morphine in a 1:1 ratio. Intermittent dosing every 3-4 hours of 0.02-0.05 mg/kg/dose or continuous infusion of 0.005 to 0.01 mg/kg/hr. The N-PASS will be used to determine dosing and frequency.
88899624|NCT01502683|Experimental|On-pump Single Cross Clamp|On-pump coronary artery bypass patients randomized to single cross clamp for cardioplegic arrest and proximal anastomoses.
88899625|NCT01502683|Experimental|On-pump Double Clamp|On-pump coronary artery bypass patients randomized to cross-clamp for cardioplegic arrest and partial-occluding clamp for proximal anastomoses. This strategy involves the application of two clamps.
88899626|NCT01502696|Experimental|PEG IFN alfa-2b|
88899627|NCT01502696|No Intervention|Observation|
89420370|NCT04766021|Placebo Comparator|Placebo|Given once, followed by observation for 6 hours in a 20 degree Celsius (68 degree Fahrenheit) room
89420371|NCT04766021|Experimental|100 mg Mirabegron|Given once, followed by observation for 6 hours in a 20 degree Celsius (68 degree Fahrenheit) room
89420372|NCT04766021|Experimental|150 mg Mirabegron|Given once, followed by observation for 6 hours in a 20 degree Celsius (68 degree Fahrenheit) room
89420373|NCT04766021|Experimental|200 mg Mirabegron|Given once, followed by observation for 6 hours in a 20 degree Celsius (68 degree Fahrenheit) room
89420374|NCT04764370|Experimental|WeFlow-Arch Moduler Embedded Branch Stent Graft System|
89420375|NCT04752644|Experimental|Group1: MVA-BN-RSV|"Participants will receive one intramuscular injection of MVA-BN-RSV (nominal titre 5 x 10*8 Inf.U per 0.5 mL) given on day -28 before RSV challenge on day 0.~On day 0, intranasal challenge with RSV-A (Memphis 37b strain) virus will occur for all participants"
89420376|NCT04752644|Placebo Comparator|Group 2: Placebo|"Participants will receive one intramuscular injection of Tris-Buffered-Saline (0.5 mL) given on day -28 before RSV challenge on day 0.~On day 0, intranasal challenge with RSV-A (Memphis 37b strain) virus will occur for all participants"
88899628|NCT01502722|Experimental|Group 1 - Crossover|This group will drink water in the 1st study.
88899629|NCT01502722|Experimental|Group 2 - Crossover|This group will drink Pineapple Soda in the 1st study
88899630|NCT01502722|Experimental|Group 3 - Crossover|This group will drink Pineapple Diet Soda in the 3rd study
88899631|NCT01502735|Experimental|DENV-1 PIV (high dose)|
88899632|NCT01502735|Experimental|DENV-1 PIV (low dose)|
88899633|NCT01502748|Experimental|Endovascular Sampling|Paired sampling from the distal arterial(endovascular catheter) and peripheral venous (femoral sheath) locations in acute stroke patients undergoing endovascular recanalization who received intravenous Magnesium Sulfate as a part of the FAST-MAG study
88899634|NCT01502774|Experimental|Cyclosporin|Injection of Cyclosporin A : one single intravenous bolus injection of 2.5 mg/Kg Echocardiography
88899635|NCT01502774|Placebo Comparator|Control|one single intravenous bolus injection of Placebo Echocardiography
88899636|NCT01502800|Experimental|Part 1 (ARQ 761)|"ARQ 761 (beta lapachone) will be given once a week. The same dose of ARQ761 each week for 4 weeks (1 cycle = 28 days). The total infusion time will be one (1) hour.~Beginning dose level will be 195 mg/m2 and will increase until the maximum tolerated dose is defined. Seven dose levels that may be administered:~1-195 mg/m2 2-390 mg/m2 3-450 mg/m2 4-550 mg/m2 5-660 mg/m2 6-800 mg/m2 7-1000 mg/m2"
88899637|NCT01502800|Experimental|Part 2 Arm A|"The same dose of ARQ761 will be given each week for 8 weeks. The total infusion time will be 2 or 3 hours.~Beginning dose level will be 390 mg/m2."
88899638|NCT01502800|Experimental|Part 2 Arm B|"ARQ 761 (beta lapachone) will be given bi-weekly for 8 weeks. The total infusion time may be either 2 or 3 hours.~The beginning dose level will be 390 mg/m2."
88899639|NCT01502800|Experimental|Part 2 Arm C|"ARQ 761 (beta lapachone) will be given 2 consecutive weeks followed by one week of rest for 6 weeks. The total infusion time will be 2 or 3 hours.~The beginning dose level will be 390 mg/m2."
88899640|NCT01502826||Group A|less insulin-resistant
88899641|NCT01502826||Group B|severely insulin-resistant
88899642|NCT01502839||OEF/OIF Veterans|Operation Enduring Freedom (OEF)/Operation Iraqi Freedom (OIF) Veterans
89420377|NCT04749511|Other|DIG-PROMs-h|Patients who underwent THA are given conventional and digital surveys of the WOMAC index. Patients adhesion to both surveys will be compared.
89420378|NCT04748380|Experimental|CRC DA|Stratifying by sex, 30 participants will be randomized to receive the CRC DA pamphlet.
89420379|NCT04748380|Other|Home Safety Pamphlet|Stratifying by sex, 30 will be randomized to receive the home safety information at the visit.
89420380|NCT04730336|Experimental|Tixel Treatment|Tixel Treatment 3 Tixel treatment sessions, 2 weeks apart follow by 2 Follow up sessions
89420381|NCT04728360|Experimental|BAT2206|"Patients who weigh ≤ 100 kg: BAT2206 45 mg (1 injection of 45 mg/0.5 mL) by SC injection via PFS.~Patients who weigh > 100 kg: EU-sourced Stelara 90 mg (2 injections of 45 mg/0.5 mL each) by SC injection via PFS."
89420382|NCT04728360|Active Comparator|Stelara (EU-sourced)|"Patients who weigh ≤ 100 kg: EU-sourced Stelara 45 mg (1 injection of 45 mg/0.5 mL) by SC injection via PFS.~Patients who weigh > 100 kg: EU-sourced Stelara 90 mg (2 injections of 45 mg/0.5 mL each) by SC injection via PFS."
89420383|NCT04724499|Experimental|High-Intensity Intervals Training|"Participants will be randomized into one of two groups: High-Intensity Intervals Training (HIIT) or Attention Control~Participants assigned to the exercise group (HIIT), will receive an exercise bike and have 3 weekly supervised exercise training sessions for four (4) months/16weeks.~Participants can choose to participate in the exercise sessions at home via zoom or in clinic.~Participants will have two (2) baseline tests, one (1) midpoint test, two (2) post High-Intensity Intervals Training (HIIT) tests and four (4) month follow up test and receive 3 MRIs over the span of 9 months."
89420384|NCT04724499|Active Comparator|Attention Control|"Participants will be randomized into one of two groups: High-Intensity Intervals Training (HIIT) or Attention Control~Participants assigned to the Attention Control group, will receive instruction on a 16 week home-based stretching program.~Participants will have two (2) baseline tests, one (1) midpoint test, two (2) post home-based stretching program tests and receive 3 MRIs over the span of 9 months.~At the end of the 16-week home-based stretching program, participants will be provided the option to participate in the High-Intensity Intervals Training (HIIT) program."
89420385|NCT04682925|Experimental|skin care arm of where evidence-based practices in the implementation guide|Participants in this arm will be given evidence-based skin care interventions, which are included in the guidelines to prevent medical device-related pressure injuries, and are implemented by the researcher nurse. After the nasogastric tube is inserted by the patient's physician.
89420386|NCT04682925|Experimental|hydrocolloid (Convatec Granuflex-extra thin) dressing|Patients in this arm will be applied a translucent hydrocolloid cover, which is compatible with the sensitive skin structure, can be applied to all body surfaces and nasal mucosa, and allows the underlying mucosa and skin to be observed after the nasogastric tube is inserted by the patient's physician. This cover will be applied to the nasal mucosa and nasal wing under the nasogastric tube.
89420387|NCT04682925|Other|control|Participants in the control group will be given no intervention , these patients will receive the routine clinical care(dressing change and nasal skin cleaning once a day) applied in the intensive care unit.
89420388|NCT04678167|Experimental|Boarding ring glasses|"Realization of the following examinations WITH Boarding ring glasses :~caloric tests,~measurement of the speed of Nystagmus,~angle of deviation in Fukuda,~Alexander's degree of nystagmus,~EHTEV and EEV questionnaires,~anxiety VAS"
89420389|NCT04678167|Placebo Comparator|Placebo glasses|"Realization of the following examinations WITH Placebo glasses :~caloric tests,~measurement of the speed of Nystagmus,~angle of deviation in Fukuda,~Alexander's degree of nystagmus,~EHTEV and EEV questionnaires,~anxiety VAS"
89420390|NCT04678167|Other|No glasses|"Realization of the following examinations WITHOUT glasses :~caloric tests,~measurement of the speed of Nystagmus,~angle of deviation in Fukuda,~Alexander's degree of nystagmus,~EHTEV and EEV questionnaires,~anxiety VAS"
89420391|NCT04648969|Experimental|Experimental: kisspeptin, GnRH|• Intravenous administration of kisspeptin 112-121; 20 boluses in a 40-hour period. Intravenous administration of GnRH; one bolus.
89420392|NCT04622592|Experimental|QVLP15+Full AS03|Participants received one intramuscular (IM) injection (total volume 0.7 mL) of 15 μg/strain of the Quadrivalent virus-like particle (VLP) Influenza Vaccine adjuvanted with full dose of AS03 on Day 0 into the deltoid region of the non-dominant arm (if possible).
89420393|NCT04622592|Experimental|QVLP15+Half AS03|Participants received one IM injection (total volume 0.7 mL) of 15 μg/strain of the Quadrivalent VLP Influenza Vaccine adjuvanted with half dose of AS03 on Day 0 into the deltoid region of the non-dominant arm (if possible).
89420394|NCT04622592|Experimental|QVLP30+Full AS03|Participants received one IM injection (total volume 0.7 mL) of 30 μg/strain of the Quadrivalent VLP Influenza Vaccine adjuvanted with full dose of AS03 on Day 0into the deltoid region of the non-dominant arm (if possible).
88899643|NCT01502852||OEF/OIF Veterans with TBI|
88899644|NCT01502852||Family Members and Friends|Family Members and Friends of OEF/OIF Veterans with TBI
88899645|NCT01502852||Community Mental Health Center Providers|Community Mental Health Center providers working with OEF/OIF Veterans with TBI
88899646|NCT01502878|Active Comparator|Nut challenge|Double-blind placebo controlled oral challenge 5-50-200-1000 mg peanut or hazelnut protein, or placebo administered with 30 min intervals and 2 hour-follow-up after the last dose.
88899647|NCT01502878|Placebo Comparator|Nut challenge: Placebo|See intervention
88899648|NCT01502878|Experimental|Nut oral desensitization|Patients who have moderate to severe immediate allergic reaction at peanut challenge and who enter the oral desensitization program receive peanut protein daily, from 0,1 mg to 800 mg peanut protein, maintenance dose 800 mg.
88899649|NCT01502891|Active Comparator|Decision aid|DEPRESSION CHOICE decision aid is provided to clinician to share with patient
88899650|NCT01502891|No Intervention|Normal care|
88899651|NCT01502904|Active Comparator|Cypher group|
88899652|NCT01502904|Experimental|Nobori group|
88899653|NCT01502904|Active Comparator|Pravastatin group|
88899654|NCT01502904|Active Comparator|Pitivastatin group|
88899655|NCT01502904|Active Comparator|Non-ARB group|
88899656|NCT01502904|Experimental|ARB group|
88899657|NCT01502930|Experimental|IRT|Imagery Rehearsal Therapy
88899658|NCT01502930|Active Comparator|CONT|Stress reduction and positive imagery
88899659|NCT01502930|No Intervention|REG|Registration only
88899660|NCT01502943|Experimental|Phlegm and blood stasis Syndrome G|
88899661|NCT01502943|Placebo Comparator|Phlegm and blood stasis control G|
89420395|NCT04622592|Experimental|QVLP30+Half AS03|Participants received one IM injection (total volume 0.7 mL) of 30 μg/strain of the Quadrivalent VLP Influenza Vaccine adjuvanted with half dose of AS03 on Day 0 into the deltoid region of the non-dominant arm (if possible).
88899662|NCT01502943|Experimental|Qi deficiency and blood stasis G|
88899663|NCT01502943|Placebo Comparator|Qi deficiency and blood stasis control G|
88899664|NCT01502969|Placebo Comparator|Placebo|Children receiving placebo (cell culture medium in absence of virus)
88899665|NCT01502969|Active Comparator|Rotavirus vaccine|Rotavin-M1, 10e6.3ffu/dose, 2 doses
88899666|NCT01502982|Experimental|Chemoimmunotherapy|
88899667|NCT01502995|Active Comparator|With laser light|Trial of walking tasks using laser light on walker.
88899668|NCT01502995|Active Comparator|Without laser light|Trial of walking task without laser light on walker.
88899669|NCT01503008|Experimental|Sustained Behavior Change system support|
88899670|NCT01503008|Active Comparator|Control|
88899671|NCT01503034||Study cohort|This cohort is made up of pregnant women with a breast cancer diagnosed between 2000 and 2014.
88899672|NCT01503034||Compared cohort|This cohort is made up of non-pregnant women with a breast cancer diagnosed between 2000 and 2009.
88899673|NCT01503047|Experimental|CLA group|Treatment consisted of exchanging the normal milk product consumed at breakfast for 200 ml of a skimmed milk with a lipid composition of 0.42 g saturated fatty acids (SFAs) and 0.72 g oleic acid, enriched with 3 g of a 1:1 mix of c9-t11 and t10-c12 (Tonalin®) (CLA group)
88899674|NCT01503047|Placebo Comparator|Placebo group|Treatment consisted of exchanging the normal milk product consumed at breakfast for 200 ml of a skimmed milk with a lipid composition of 0.42 g saturated fatty acids (SFAs) and 0.72 g oleic acid, enriched with 3 g oleic acid (placebo, P group.
88899675|NCT01503060|Placebo Comparator|Group 1|"Visit 1-4 (2,4,6,12 month vaccinations): Patients will receive standard care~Visit 5 (15 month vaccination): At the last visit all 4 groups will receive all three active interventions."
88899676|NCT01503060|Active Comparator|Group 2|"Visit 1-4 (2,4,6,12 month vaccinations): Parents will be taught about managing pain~Visit 5 (15 month vaccination): At the last visit all 4 groups will receive all three active interventions."
88899677|NCT01503060|Active Comparator|Group 3|"Visit 1-4 (2,4,6,12 month vaccinations): Parents will be taught about managing pain and their infant will be given sugar~Visit 5 (15 month vaccination): At the last visit all 4 groups will receive all three active interventions."
88899678|NCT01503060|Active Comparator|Group 4|"Visit 1-4 (2,4,6,12 month vaccinations): Parents will be taught about managing pain and their infant will be given sugar water and a topical anesthetic~Visit 5 (15 month vaccination): At the last visit all 4 groups will receive all three active interventions."
88899679|NCT01503099||Active ITB|Patients with active intestinal tuberculosis (ITB)
88899680|NCT01503099||Controls India|Healthy subjects serving as controls
89420396|NCT04622592|Experimental|QVLP45+Full AS03|Participants received one IM injection (total volume 0.7 mL) of 45 μg/strain of the Quadrivalent VLP Influenza Vaccine adjuvanted with full dose of AS03 on Day 0 into the deltoid region of the non-dominant arm (if possible).
89420397|NCT04622592|Experimental|QVLP45+Half AS03|Participants received one IM injection (total volume 0.7 mL) of 45 μg/strain of the Quadrivalent VLP Influenza Vaccine adjuvanted with half dose of AS03 on Day 0 into the deltoid region of the non-dominant arm (if possible).
88899681|NCT01503099||CD India|Patients with active Crohn's Disease (CD) in India
88899682|NCT01503099||Active PTB|Patients with active pulmonary tuberculosis (PTB)
88899683|NCT01503099||CD Norway|Patients with active Crohn's Disease (CD) in Norway
88899684|NCT01503099||Controls Norway|Healthy subjects serving as controls in Norway
88899685|NCT01503112||Patients starting incretin treatments|Patients starting GLP-1 agonists or DPPIV inhibitors as part of their normal clinical care.
88899686|NCT01503138|Experimental|Purpose-built intervention|A purpose-built intervention consists of: (i) Empowerment; (ii) Parenting workshops; and (iii) Telephone social support and Peer support.
88899687|NCT01503138|No Intervention|Standard community health education program|The community health education programme consists of two group sessions with one on the topic of osteoporosis and one on dietary therapy based on the concepts of Chinese medicine.
88899688|NCT01503151|Placebo Comparator|Placebo|repeated trials of a dot-probe task and repeated trials of an interpretation task, both not intended to change threat-related biases patterns.
88899689|NCT01503151|Experimental|Attention Bias Modification (ABM)|Attention training via repeated trials of a dot-probe task intended to direct attention away from threat stimuli.
88899690|NCT01503151|Experimental|Interpretation Bias Modification (IBM)|Interpretation training intended to facilitating a more benign interpretation bias
88899691|NCT01503151|Experimental|Attention and interpretation biases modification|Attention and interpretation training intended to direct cognitive biases away from threat stimulus.
88899692|NCT01503177|Experimental|Treatment (viral therapy)|Patients receive MV-NIS intrapleurally on day 1. Treatment repeats every 28 days for up to 6 courses in absence of disease progression or unacceptable toxicity.
88899693|NCT01503203|Experimental|Wii Group|This group will do the same training of the Prime Group. However will do also Physical Virtual Training using Nintendo Wii and Wii Balance Board. The physical virtual training going to applied during thirty minutes.
88899694|NCT01503203|Active Comparator|Prime Group|This group will do strength exercises and core training.
88899695|NCT01503216|Experimental|cholecalciferol|Human volunteers receiving cholecalciferol (vitamin D3) for 8 weeks
88899696|NCT01503216|Experimental|Ergocalciferol|Ergocalciferol 2000 IU per day for 8 weeks
88899697|NCT01503216|Placebo Comparator|Placebo|Placebo for 8 weeks
88899698|NCT01503242|Experimental|Treatment (monoclonal antibody, chemo, TBI, transplant)|Patients receive 90Y-BC8 Ab IV on day -12 and fludarabine phosphate IV on days -4 to -2. Patients undergo TBI and allogeneic peripheral blood stem cell transplant on day 0. Patients also receive graft-vs-host disease prophylaxis comprising cyclosporine PO BID on days -3 to 56 with taper to day 180 or on days -3 to 100 with taper to 180; and mycophenolate mofetil IV or PO BID on days 0-27, or 0-40 with taper to 96.
88899699|NCT01503255|Experimental|cognitive behavioral group therapy|
88899700|NCT01503255|Active Comparator|health education group|
88899701|NCT01503268|Active Comparator|Percutaneous ablation|
88899702|NCT01503268|Active Comparator|Surgical ablation|
88899703|NCT01503268|Active Comparator|DCCV|Direct current cardioversion
88899704|NCT01503281|Experimental|Hospital-based exercise program|Exercise monitored at the hospital
88899705|NCT01503281|Experimental|Home-based exercise program|Participants perform exercise at home
88899706|NCT01503281|No Intervention|Control|Control Group participants maintained their usual levels of daily activity, with no additional exercise components.
88899707|NCT01503307||Prenatal/Postpartum CHD Diagnosis|parent of a baby (prenatal or postpartum)who was recently found to have a heart defect.
88899708|NCT01503320|Experimental|Enteral glutamine|
88899709|NCT01503320|Placebo Comparator|Placebo|
88899710|NCT01503346|Experimental|herbal medicine|"Intervention group~1. 2 grams of DaHuang abstract powder and 0.5 grams GanTsao abstract powder are mixed and separated into four packages;~2. each package was given to each patient four times a day (three time after meal and one time before sleep);~3. each patient received the usual medication of the hospice ward at the same time;~4. record the patients' score of pre-test, mid-test and after-test of QIPCTP at the 1st day, the 3rd day and the 6th day;~5. record the patients' score of EORTC QLQ-C30 V3.0 and ECOG (Eastern Cooperative Oncology Group Performance Status) at the 1st day and the 6th day."
88899711|NCT01503359|Experimental|Dietary Supplement: Sarcosine|Sarcosine Group
88899712|NCT01503359|Placebo Comparator|Placebo|Control Group
88899713|NCT01503372|Experimental|Arm A: FLO + Pazopanib|
88899714|NCT01503372|Active Comparator|Arm B: FLO|
88899715|NCT01503385|Experimental|Celecoxib|"Combination of and concurrent radiotherapy Cisplatin/etoposide with or without Celecoxib.~Intervention: Drug: Celecoxib"
88899716|NCT01503398|Experimental|Olanzapine Tablets, 5 mg|Olanzapine Tablets, 5 mg of Dr. Reddy's Laboratories Limited
89006733|NCT04617301||Group 1. Internal root resorption (IRR)|Internal root resorption is the progressive destruction of intraradicular dentin and dentinal tubules along the middle and apical thirds of the canal walls as a result of clastic activities. It is seen as a radiolucent area around the pulpal cavity, usually of incisors and mandibular molars. The various etiological factors suggested for internal root resorption include traumatic injury; infection and orthodontic treatment.
88899717|NCT01503398|Active Comparator|Zyprexa|Zyprexa Tablets, 5 mg of Eli Lilly and company
88899718|NCT01503424|Experimental|Olanzapine Tablets, 5 mg|Olanzapine Tablets, 5 mg of Dr. Reddy's Laboratories Limited
88899719|NCT01503424|Active Comparator|Zyprexa|Zyprexa Tablets, 5 mg of Eli Lilly and company
88899720|NCT01503437|Experimental|Olanzapine OD Tablets 5 mg|Olanzapine OD Tablets 5 mg of Dr. Reddy's Laboratories Limited
88899721|NCT01503437|Active Comparator|Zyprexa Zydis 5 mg Tablets|Zyprexa Zydis 5 mg Tablets of Cardinal Health, UK
88899722|NCT01503450|Experimental|Olanzapine OD Tablets 5 mg|Olanzapine OD Tablets 5 mg of Dr. Reddy's Laboratories Limited
88899723|NCT01503450|Active Comparator|Zyprexa Zydis 5 mg Tablets|Zyprexa Zydis 5 mg Tablets of Cardinal Health, UK
88899724|NCT01503463|No Intervention|Usual Care|Patients in the control group receive usual care delivered by their primary care physicians and cardiologists. Usual care consists of regular visits to the specialist or primary care clinics every time a medication change is required, or a medical examination is needed.
88899725|NCT01503463|Experimental|Home telemonitoring of patients with CHF|
88899726|NCT01503476|Experimental|Healthy volunteers|healthy volunteers
88899727|NCT01503476|Experimental|symptomatic patients|symptomatic patients with known or suspected gastro esophageal reflux disease
88899728|NCT01503502|Experimental|flumatinib 400mg qd|
88899729|NCT01503502|Experimental|flumatinib 600 mg qd|
88899730|NCT01503502|Active Comparator|imatinib|
88899731|NCT01503528|Active Comparator|Motor Sparing Nerve Block|Motor sparing knee block (60mL of 0.5% ropivacaine with 10 mg Morphine, 30 mg Ketorolac and 150 mcg of epinephrine as the initial bolus) initiated in the preoperative period in the block room as per the standard practice and continued until discharge. Spinal anesthetic with 15 mg of hyperbaric bupivacaine. Patients will be connected to an Ambit infusion pump in the postoperative period set to deliver ropivacaine 0.2% at a basal infusion rate of 7 mL/Hr with patient controlled boluses of 5mL every hour for breakthrough pain. Patients will be discharged home following removal of the anaesthetic catheter and fulfilling criteria for discharge.
88899732|NCT01503528|Experimental|Peri-Articular Catheters|3 peri-articular catheters inserted at the end of surgery followed by peri-articular infiltration with ropivacaine 0.2% and wound infusions will be continued until discharge using elastomeric devices. Spinal anesthetic with 15 mg of hyperbaric bupivacaine. Patients will be discharged home following removal of the anaesthetic catheter and fulfilling criteria for discharge.
88899733|NCT01503554|Experimental|Social Worker + Pharmacist Intervention|Intervention arm offering enhanced services from a social worker and a pharmacist post-discharge
88899734|NCT01503554|Experimental|Usual Care|Patients receiving usual care will have a medication reconciliation performed by a physician or nurse during their hospital stay. No further support or interventions are provided post discharge.
88899735|NCT01503567||Subjects 6 to 18 years old without inhibitors|
88899736|NCT01503567||Subjects 6 to 18 years old with inhibitors|
88899737|NCT01503567||Subjects above18 years old without inhibitors|
88899738|NCT01503567||Subjects above 18 years old with inhibitors|
88899739|NCT01503580|Experimental|antimuscarinic drug|
88899740|NCT01503593|No Intervention|Alveolar ridge dimensions|Control group - Only extraction teeth
88899741|NCT01503593|Experimental|Alverolar ridge dimension|Extraction of teeth and implant a bone substitute
88899742|NCT01503619||Basic science (biomarker analysis)|DNA isolated from archived tumor tissue and blood samples are analyzed for genetic mutations and gene expression profiling using Illumina exome sequencing. Results are compared with transcriptome of tumors (or cell lines) with and without the specific mutation. Cell culture studies overexpressing or inhibiting the genes of interest are also performed in a mouse model to identified potential drivers of small cell lung cancer.
88899743|NCT01503658|Experimental|Clopidogrel+Aspirin|Clopidogrel on Day 1, Aspirin on Day 2 - Day 14, Clopidogrel + Aspirin Day 15, Aspirin on Day 16 - Day 28, Clopidogrel + Aspirin Day 29
88899744|NCT01503671|Experimental|Atorvastatin|Atorvastatin 40 mg/day for high inflammation CAPD patient
88899745|NCT01503671|No Intervention|No intervention arm|Placebo arm without intervention
88899746|NCT01503684||Patients with sepsis|Patients who are admitted to ICU with the diagnosis of sepsis
88899747|NCT01503723||Patients with acute lung injury|Patients who are admitted to ICU with the diagnosis of acute hypoxemic respiratory failure
88899748|NCT01503736|Placebo Comparator|Placebo|
88899749|NCT01503736|Experimental|4g/day|Ferric Citrate for a total daily dose of 4g
88899750|NCT01503736|Experimental|6g/day|Ferric Citrate for a total daily dose of 6g
88899751|NCT01503762|Experimental|Mirror Therapy Group|Mirror Therapy Group
88899752|NCT01503762|Sham Comparator|Control Group|Control Group receive classical rehabilitation techniques including splinting, tendon gliding, ...
88899753|NCT01503775||TRUFILL® DCS Orbit Galaxy|
89420398|NCT04622592|Active Comparator|QVLP30 unadjuvanted|Participants received one IM injection of 0.7 mL of 30 μg/strain of the Quadrivalent VLP Influenza Vaccine unadjuvanted on Day 0 into the deltoid region of the non-dominant arm (if possible).
88899754|NCT01503788|Active Comparator|periprocedural sedation with midazolam|periprocedural sedation with IV midazolam 5-10 minutes before diagnostic lumbar puncture
88899755|NCT01503788|No Intervention|No intervention|Participants will undergo the diagnostic lumbar puncture as routinely practiced
88899756|NCT01503801|Experimental|inhaled nitric oxide|The preterm infants in the experimental group inhaled nitric oxide
88899757|NCT01503801|Active Comparator|oxygen|The preterm infants enrolled but subjected to routine respiratory support.
89420399|NCT04622592|Active Comparator|Fluzone HD Quad|Participants received one IM injection of 0.7 mL of 60 μg/strain of the Fluzone high dose (HD) Quadrivalent Influenza Vaccine on Day 0 into the deltoid region of the non-dominant arm (if possible).
89420400|NCT04604093||SMBG, self-monitoring of blood glucose|Subjects will be randomized to continue use traditional SMBG, self-monitoring of blood glucose, to manage their diabetes.
89420401|NCT04604093||FreeStyle Libre 2|Subjects will be randomized to use the FreeStyle Libre 2 Flash Glucose Monitoring System to manage their diabetes.
89420402|NCT04558775||Observational Cohort|
89420403|NCT04545866|Experimental|budesonide with surfactant|Infants randomized to the intervention arm receive a dose of surfactant (poractant alfa; Curosurf) mixed with budesonide (Pulmicort nebulizing suspension) within 50 hours of birth and administered via endotracheal tube.
88899758|NCT01503814|No Intervention|Control (Usual Care)|Control
89420404|NCT04545866|Active Comparator|surfactant alone|Infants randomized to the active control arm receive a dose of surfactant (poractant alfa; Curosurf).
88899759|NCT01503814|Experimental|Intervention|"Use of a simplified guideline-based CVD prevention and management scheme by village doctors targeting high risk individuals focusing on a2+2model: 2 therapeutic lifestyle recommendations (smoking cessation and salt consumption reduction) plus prescription of 2 low-cost drugs (aspirin and low-dose diuretics) when applicable"
89420405|NCT04529993|Experimental|Interstitial pulmonary fibrosis|
89420406|NCT04529993|Experimental|Chronic obstructive pulmonary disease|
88899760|NCT01503827|Experimental|WBRT|Patients will receive WBRT after local treatment. A minimum of 30 Gy in 10 fractions given as one fraction per day within 4 weeks of randomisation
88899761|NCT01503827|No Intervention|Observation|No Intervention
89420407|NCT04529993|Experimental|Healthy volunteers|
89420408|NCT04523220|Experimental|BAY1213790 low dose|Participants will receive Osocimab (BAY1213790) 105 mg single loading dose as subcutaneous abdominal injection, followed by monthly maintenance doses of 52.5 mg until the end of the extension treatment period.
89420409|NCT04523220|Placebo Comparator|Placebo low dose|Placebo will be administered subcutaneously in the same manner as Osocimab.
89420410|NCT04523220|Experimental|BAY1213790 high dose|Participants will receive Osocimab (BAY1213790) 210 mg single loading dose as subcutaneous abdominal injection, followed by monthly maintenance doses of 105 mg until the end of the extension treatment period.
88899762|NCT01503840|Active Comparator|Sugammadex|
89420411|NCT04523220|Experimental|Placebo high dose|Placebo will be administered subcutaneously in the same manner as Osocimab.
88899763|NCT01503840|Placebo Comparator|Sodium chloride solution|
88899764|NCT01503892|Placebo Comparator|Placebo|The control group will receive placebo pill twice daily for twelve months.
88899765|NCT01503892|Active Comparator|Metanx|Metanx group will receive one pill twice daily for twelve months.
88899766|NCT01503905|Active Comparator|Docetaxel plus epirubicin|
88899767|NCT01503905|Active Comparator|docetaxel plus epirubicin plus cyclophosphamide|
88899768|NCT01503918|Experimental|Valaciclovir/Aciclovir|
88899769|NCT01503918|Experimental|Valganciclovir/Ganciclovir|
88899770|NCT01503918|No Intervention|control|
88899771|NCT01503931||Alcohol-dependent patients|"men and women, aged 18 to 75~legally effective, written informed consent for participation within the study~right handedness~no other psychiatric disorder according to ICD 10~no psychotropic substances within the last 7 days"
88899772|NCT01503931||Healthy control subjects|"men and women, aged 18 to 75~legally effective, written informed consent for participation within the study~right handedness~no psychiatric disorder according to ICD 10~no psychotropic substances within the last 7 days"
88899773|NCT01503957|Placebo Comparator|Saline solution|Nasal spray
88899774|NCT01503957|Experimental|Nasya|Thixotropic nasal spray suspension
88899775|NCT01503970|Experimental|Chondrocyte implantation|
88899776|NCT01503983|Experimental|Trastuzumab+Oxaliplatine+capecitabine|Patient takes Trastuzumab (initial dose 8 mg/kg and a maintenance dose 6 mg/kg) anda oxaliplatin (dose 130mg/m2) during the first day os cycle and them Capecitabine (dose 2000 mg/m2)during 14 days in cycle of 21 days.
89420412|NCT04468906|Experimental|"Biceps self-locking T tenotomy"|
89420413|NCT04468906|Active Comparator|Biceps tenodesis (control)|
89420414|NCT04456491||Asthma|Patients with Asthma
89420415|NCT04456491||COPD|Patients with COPD
89420416|NCT04456491||Control group|Healthy volunteers
89420417|NCT04446260|Experimental|Part 1 Dose escalation|
89420418|NCT04446260|Experimental|Part 2 Indication expansion|
89420419|NCT04444583||HFpEF|HF patients with preserved ejection fraction (HFpEF)
89420420|NCT04444583||HFrEF|HF patients with reduced ejection fraction (HFrEF)
89420421|NCT04407442|Experimental|Treatment (azacitidine, dexamethasone, daratumumab)|"PRE-INDUCTION (CYCLE 0): Patients receive azacitidine IV on days -7 to -3 in absence of disease progression or unacceptable toxicity.~INDUCTION (CYCLES 1-2): Patients receive azacitidine IV on days 22-26, dexamethasone IV or orally (PO), and daratumumab subcutaneously (SC) over 3-5 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity~CONSOLIDATION (CYCLES 3-6): Patients receive azacitidine IV on days 22-26 of cycle 3 and on days 1-5 of cycles 5-6, dexamethasone IV or PO, and daratumumab SC over 3-5 minutes on days 1 and 15. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity~MAINTENANCE (CYCLES 7+): Patients receive azacitidine IV on days 1-5, dexamethasone IV or PO, and daratumumab SC over 3-5 minutes on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity"
89420422|NCT04372615|Active Comparator|Inebilizumab|"Approximately 58 patients will receive Inebilizumab in addition to first line immunotherapy.~(Approximately 116 participants will be randomized in a 1:1 ratio to 2 treatment groups; approximately 58 participants to each treatment group).~All participants will also receive a 3 day course of IVIg."
89420423|NCT04372615|Placebo Comparator|Placebo|"Approximately 58 patients will receive placebo in addition to first line immunotherapy.~(Approximately 116 participants will be randomized in a 1:1 ratio to 2 treatment groups; approximately 58 participants to each treatment group).~All participants will also receive a 3 day course of IVIg."
89420424|NCT04345796|Active Comparator|carvedilol+empagliflozin|Patients will receive carvedilol SR 16mg and empagliflozin 10mg qd.
89420425|NCT04345796|Active Comparator|carvedilol alone|Patients will receive carvedilol SR 16mg alone.
89420426|NCT04345796|Active Comparator|empagliflozin alone|Patients will receive empagliflozin 10mg and matching placebo of carvedilol.
89420427|NCT04345796|Placebo Comparator|placebo|Patients will receive matching placebo of carvedilol.
89420428|NCT04336306|Experimental|Evaluation of chronic hemodynamic and autonomic repercussions|Participants in a cardiovascular rehabilitation program will be randomly allocated to CR + VRBT interventions. This group will hold 3 weekly sessions (one for VRBT and two for CR) for 12 weeks. In the first, sixth and last week, chronic hemodynamic data and autonomic data will be evaluated.Furthermore,at the end of 12 weeks, a focus group with therapists and a focus group with patients will be held to identify qualitative aspects in relation to the insertion of VRBT. And in all eligible patients of CR wiil be applied the Questionnaire of barriers identification in frequenters of Cardiovascular Rehabilitation.
89420429|NCT04310267|Active Comparator|classic occlusal level, low point of force application|the point of force application for maxillary protraction is at the level of the occlusal plane.
89420430|NCT04310267|Active Comparator|Nasal level, Medium point of force application|the point of force application for maxillary protraction is at 20 mm from the occlusal plane (Nasal floor).
89420431|NCT04310267|Active Comparator|Infrorbital level, High level|the point of force application for maxillary protraction is at the level of the infraorbital foramen
89420432|NCT04288479|Experimental|Doing a single HIT session in gestational week 22-36|
89420433|NCT04265612|Experimental|Negative Pressure dressing|"Pico® negative pressure dressing that will be placed in the operating room in both sternal wound and saphenectomy. This dressing will remain in place for 7 days without getting up, unless it has become saturated, in which case, only the dressing will be changed."
88899777|NCT01503996||glaucoma|hospitalized glaucoma patients
89420434|NCT04265612|Active Comparator|Aquacel hydrogel dressing|"Aquacel Surgical® hydrogel dressing that will be placed in the operating room in both sternal wound and saphenectomy. This dressing will remain in place for 7 days without getting up, unless it has become saturated, in which case, only the dressing will be changed."
89420435|NCT04258319|Experimental|Affected (Lymphedema)|Subjects affected lymphedema extremity will have elastic and viscoelastic parameters collected by ultrasound procedure
89420436|NCT04258319|Active Comparator|Unaffected (Control)|Subjects unaffected extremity will have elastic and viscoelastic parameters collected by ultrasound procedure
89420437|NCT04257877||Diabetes type 1|Patients= diabetes type1
89420438|NCT04257877||Healthy participants|Healthy participants = Control group
89420439|NCT04233671|Experimental|Mindfulness based relapse prevention and peer mentoring|MiMP is a twelve week program, meeting once per week for 12 weeks for approximately two hours. Eight weeks are facilitated by a licensed counselor, and four weeks are facilitated by a peer mentor.
89420440|NCT04233671|No Intervention|12 Step Treatment Program Control|The control group will meet for 12 weeks for standard 12 Step Facilitation meetings.
89420441|NCT04227145|No Intervention|Usual Care|We will recruit up to 85 women with substance abuse disorder (or opioid abuse disorder) from recovery centers. Eligible women will complete a baseline survey and study staff will provide a referral for participants to seek more information on contraception and services. Study staff will record whether the participant accepted the referral. Follow-up will occur via phone call at 2-weeks, 1-month and 3-months post-enrollment to determine if they accessed contraceptive referral services if they initiated any contraceptive method, and if so: if they continued, changed, or discontinued this contraception method. We will recruit, complete baseline and usual care referral at recovery sites on a timely rotation that mirrors the intervention period (e.g., every fourth Friday morning at Site 1), in order to increase the chance of recruiting a comparable population.
88899778|NCT01503996||controls|hospitalized patients without glaucoma
88899779|NCT01504009|Experimental|Muscle strength|
88899780|NCT01504022|No Intervention|Control group.|Control group.
88899781|NCT01504022|Experimental|Telecare, self monitoring, lifestyle counseling|Patients in the intervention group will measure their blood pressure with home blood pressure monitor which is linked to a secured website. Patients will measure as recommended in the European guidelines of hypertension. This includes 2 measurements in the morning and two times in the evening on 7 consecutive days every month. The measurements of the first day will be discarded. These measurements will be forwarded to the web-based system, which will be managed by the nurse practitioner and the research doctor. At least every month patients are contacted about the state of their condition. If needed, antihypertensive medication is added of adjusted by the nurse practitioner or research doctor under the supervision of one consultant physician. Tailored lifestyle advices are given every month.
88899782|NCT01504035|Experimental|Hemostatic putty plus Lidocaine (Orthostat-L)|
88899783|NCT01504035|Active Comparator|Hemostatic putty (Orthostat)|
88899784|NCT01504048|Experimental|Chromoendoscopy|
88899785|NCT01504061|Experimental|Mederma Ultra Gel|
88899786|NCT01504061|Active Comparator|Mederma N&I|
88899787|NCT01504074||Patients suffering on CME secondary to cataract surgery|
88899788|NCT01504087||patinet with deep venous thrombosis|patient with deep venous thrombosis by ultrasonography as case; patient with no deep venous thrombosis by ultrasonography as control
88899789|NCT01504087||patient without deep venous thrombosis|
88899790|NCT01504100||femoral internal rotation|
88899791|NCT01504100||no femoral internal rotation|
88899792|NCT01504113||Study 1 goup|Patients who are planned to receive targeted agents
88899793|NCT01504113||Study 2 case group|Patients who have received targeted therapy
88899794|NCT01504113||study 2 control group|Psoriasis patients without target therapy
88899795|NCT01504126|Experimental|Treatment (propranolol hydrochloride)|Patients receive propranolol hydrochloride PO BID beginning 48-72 hours before treatment. Patients undergoing surgery resume propranolol hydrochloride post-operatively once oral drugs are tolerated and continue until completion of 6 cycles of chemotherapy. Patients undergoing neoadjuvant chemotherapy continue propranolol hydrochloride PO BID during 3 chemotherapy cycles pre-surgery and 3 cycles post-surgery. Treatment repeats every 3 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
88899796|NCT01504139|Experimental|hCG in the late follicular phase + luteal phase|
88899797|NCT01504139|Experimental|hCG in the follicular phase + luteal phase|
89194373|NCT00428389|Experimental|Immediate Switch|Patients randomized to the immediate switch group continued treatment with donepezil through the evening prior to Day 8 of the study. On Day 8, all patients began open-label treatment with 5 cm^2 rivastigmine patch formulation. A new patch was applied daily for 4 weeks. Patients who completed the core phase had the option of entering the extension phase, in which they received open-label treatment with rivastigmine patch formulation for an additional 20 weeks. In the absence of any dose-limiting adverse events (AEs), the dose was increased to 10 cm^2 patch, and it remained the same through Week 25. Patients who experienced dose-limiting AEs had their dose reduced to 5 cm^2 patch and continued on their best tolerated dose for the remainder of the study.
88899798|NCT01504139|Experimental|LH in the luteal phase|
88899799|NCT01504139|Active Comparator|vaginal progesterone and estradiol in the luteal phase|
88899800|NCT01504152||patients who received HSCT at MSKCC between 2005-2010|A self-administered patient questionnaire will be used to collect data that will assess the prevalence of international travel after HSCT and travel related morbidity and exposure risks among HSCT recipients.
88899801|NCT01504165|Experimental|Group 1|Healthy volunteers: matched subjects with normal renal function
88899802|NCT01504165|Experimental|Group 2|Mild renal impaired subjects
88899803|NCT01504165|Experimental|Group 3|Moderate renal impaired subjects
88899804|NCT01504165|Experimental|Group 4a|First group of Severe renal impaired subjects
88899805|NCT01504165|Experimental|Group 4b|Second group of severe renal impaired subjects
89420442|NCT04227145|Experimental|SexHealth Mobile|We will train Swope providers in contraceptive counseling before intervention. We will recruit up to 85 women with substance abuse disorder (or opioid abuse disorder) from recovery centers. Eligible women will complete a baseline survey. Study staff will provide a referral for participants to seek more information on contraception and services. Women will have direct access to contraceptive counseling and services on-site via the mobile medical unit if they choose to use it. Counseling will focus on presenting the most effective contraceptive methods first (i.e., LARC). If women participate in contraceptive counseling, study staff will record the uptake of contraceptive medication and clinic referral at the time of enrollment and conduct follow-up surveys at 2-weeks, 1-month, and 3-months post-enrollment. If the participant refuses contraceptive counseling on MMU, a referral will be given.
88899806|NCT01504178|Experimental|duloxetine|The first group (12 patients) will receive, after 28 days of duloxetine treatment, one duloxetine dose, an injection of apomorphine and a placebo of L-Dopa.
88899807|NCT01504178|Placebo Comparator|positive control (L-Dopa)|The second group (12 patients) will receive, after 28 days of placebo treatment, one placebo dose of duloxetine, an injection of apomorphine and injection of placebo of L-Dopa.
88899808|NCT01504178|Placebo Comparator|negative control|The third group will receive, after 28 days of placebo treatment, one placebo of duloxetine, an injection of placebo of apomorphine and a dose of L-Dopa.
88899809|NCT01504191|Experimental|Internet-based CBT|Randomized patients with symptoms of anxiety and/or depression after MI will participate in an Internet-based CBT-program.
88899810|NCT01504191|No Intervention|Treatment as usual (TAU)|"Control: After randomization patients with symptoms of anxiety and/or depression after MI will participate in the treatment as usual (TAU).~Reference: A reference group without depressive or anxiety symptoms will participate in the treatment as usual (TAU)."
88899811|NCT01504230||health older adults|
88899812|NCT01504230||Osteoporosis participants|
88899813|NCT01504243||Control|normal person under medical examination
88899814|NCT01504243||sepsis|SIRS plus inflammation
88899815|NCT01504256|Experimental|catumaxomab|"this arm was stopped. the antibody previously used as a study drug is not available at this time. patients will be randomized only into the standard arm~[Catumaxomab: 4 intraperitoneal infusions of catumaxomab at an escalating dose of 10µg (d0), 20µg (d3), 50µg (d7), and 150µg (d10) and 7 days after the last catumaxomab infusion FLOT; 6 cycles q2w: Fluorouracil 2600 mg/m² as 24h infusion (d1) , leucovorin 200mg/m² (d1), oxaliplatin 85 mg{m² (d1), docetaxel 50 mg/m² (d1))"
88899816|NCT01504256|Active Comparator|standard therapy|"FLOT; 6 cycles q2w:~Fluorouracil 2600 mg/m² as 24h infusion (d1) leucovorin 200mg/m² (d1) oxaliplatin 85 mg{m² (d1) docetaxel 50 mg/m² (d1)"
88899817|NCT01504282|Active Comparator|MMC group|One eye of each patient was randomly assigned to receive intraoperative topical 0.02% MMC for 5 seconds.
88899818|NCT01504282|Placebo Comparator|BSS group|One eye of each patient was randomly assigned to receive balanced salt solution (BSS) with the same manner.
88899819|NCT01504295|Experimental|Metadoxine|Metadoxine 500mg tablet t.i.d.for 12 weeks
88899820|NCT01504295|Placebo Comparator|Sugar pill|Placebo group
88899821|NCT01504308|Experimental|MR-HIFU treatment|Patients receiving MR-HIFU treatment
88899822|NCT01504308|Sham Comparator|Sham Treatment|Patients receiving sham treatment
88899823|NCT01504321|Active Comparator|Active|
88899824|NCT01504321|Placebo Comparator|Placebo|
88899825|NCT01504334|Experimental|Pirfenidone(200mg)|Pirfenidone（200mg）tablets will be taken 3 times a day during the whole study process. For the first week, 1 tablet will be taken each time. For the second week, 2 tablets will be taken each time. From the third week to the 48th week, 3 tablets will be taken each time. Base drug Acetyl Cysteine Tablets（600mg）will be taken once a day, 1 tablet each time from the first to the 48th week.
88899826|NCT01504334|Placebo Comparator|Placebo (without active ingredient)|
88899827|NCT01504347|Experimental|Primary vaccination in seronegative subjects|
88899828|NCT01504347|Experimental|Booster vaccination in seronegative subjects|
88899829|NCT01504347|Experimental|Primary + booster vacc. (seronegative + seropositive subjects)|
88899830|NCT01504360|Experimental|sarcoma group|patient suffering form radiation-induced sarcoma
88899831|NCT01504360|Active Comparator|free from sarcoma group|patient without sarcoma 5 years after radiation therapy
88899832|NCT01504386|Experimental|TAP block|TAP block with ropivacaine
88899833|NCT01504386|Placebo Comparator|Placebo TAP block|Sham block with saline
88899834|NCT01504399||Microscopic:|Microscopic (single nostril, direct endonasal with nasal speculum)transsphenoidal nasal surgery
88899835|NCT01504399||Endoscopic|Fully endoscopic: (bi-nostril, no nasal speculum) transsphenoidal pituitary surgery
88899836|NCT01504438|Other|Salto Talaris Total Ankle Replacement|
88899837|NCT01504438|Other|STAR Total Ankle Replacement|
88899838|NCT01504451|Active Comparator|Biosense Webster ablation|Biosense Webster irrigated multi-electrode phased radiofrequency AF ablation
88899839|NCT01504451|Active Comparator|Surgical ablation|Minimally invasive thoracoscopic surgical AF ablation
88899840|NCT01504451|Active Comparator|Medtronic ablation|Medtronic multi-electrode phased radiofrequency AF ablation
88899841|NCT01504464|Experimental|mesenchymal stem cell|Patients with knee joint osteoarthritis who underwent intra articular mesenchymal stem cell injection.
88899842|NCT01504464|Experimental|placebo|The patients who are in control group and underwent placebo injection.
88899843|NCT01504490|Experimental|CS-7017 and Bexarotene|Combination of CS-7017 and Bexarotene
88899844|NCT01504503|Experimental|Donepezil Hydrochloride10 mg Tablets|Donepezil Hydrochloride 10 mg Tablets of Dr. Reddy's Laboratories Limited
88899845|NCT01504503|Active Comparator|Aricept 10 mg Tablets|Aricept 10 mgTablets of Pfizer Inc
88899846|NCT01504516|Experimental|Donepezil Hydrochloride10 mg Tablets|Donepezil Hydrochloride 10 mg Tablets of Dr. Reddy's Laboratories Limited
88899847|NCT01504516|Active Comparator|Aricept 10 mg Tablets|Aricept 10 mgTablets of Pfizer Inc
88899848|NCT01504529||Neupro Treatment|Data from patients with advanced PD who have been treated with Rotigotine (Neupro®) for at least the previous 6 months as prescribed by physicians according to usual clinical practice in Spain, will be retrospectively collected.
88899849|NCT01504542|Experimental|Low-dose HS-110|2,000,000 cells/0.5mls + erlotinib 150mg orally once daily
88899850|NCT01504542|Experimental|High dose HS110|10,000,000 HS110 cells/0.5ml + erlotinib 150mg orally once daily.
88899851|NCT01504542|Placebo Comparator|Placebo vaccine + erlotinib 150mg orally once daily|Placebo vaccine buffered saline solution + erlotinib 150mg orally once daily
88899852|NCT01504555||Patients under investigation for hypercortisolism|Patients undergoing routine evaluation for hypercortisolism at Haukeland University Hospital, Bergen, Norway, will be asked to participate.
88899853|NCT01504568|Other|Prophylactic Antibotics|Amoxicillin/clavulanic acid
88899854|NCT01504568|No Intervention|Non Treatment|Subjects will be followed without the use of antibiotics.
88899855|NCT01504581|Experimental|HM10660A|
88899856|NCT01504581|Active Comparator|Pegasys|
88899857|NCT01504581|Placebo Comparator|HM10660A Placebo|
88899858|NCT01504594|Experimental|Patients|Children which meet eligibility criteria and after being assessed, are stimulated with G-CSF, undergo bone marrow extraction and then have them applied directly to the coronary arteries through cardiac catheterization.
88899859|NCT01504607||Congenital cataract surgery with IOL implantation|Congenital cataract surgery was performed with or without anterior vitrectomy, followed by in the bag IOL implantation
88899860|NCT01504620|Other|Sugar infusion|Diagnostic assessment of blood glucose by means of different devices
88899861|NCT01504620|Experimental|insulin infusion|infusion of insulin to achieve low glucose levels
88899862|NCT01504633|Experimental|DHA+EPA Group|DHA/EPA capsule (100mg DHA + 20mg) and placebo syrup per day
88899863|NCT01504633|Experimental|Fe Group|Placebo capsule and Fe syrup (16mg elemental iron) per day
88899864|NCT01504633|Experimental|DHA/EPA+Fe Group|DHA/EPA capsule (100mg DHA + 20mg) and Fe syrup (16mg elemental iron) per day
88899865|NCT01504633|Experimental|Placebo Group|Placebo capsule and placebo syrup
88899866|NCT01504646|Placebo Comparator|Olive Oil Capsule|Ten subjects will take eight placebo olive oil capsules per day for three weeks.
88899867|NCT01504646|Experimental|Lyprinol|Ten subjects will take eight Lyprinol capsules per day for three weeks.
88899868|NCT01504659|Active Comparator|Bipolar-Ketalar|Children with a diagnosis of BP-I, BP-II or BP-NOS will receive 4 administrations of intranasal ketalar
88899869|NCT01504659|Placebo Comparator|Bipolar-Placebo|Children with a diagnosis of BP-I, BP-II or BP-NOS will receive 4 administrations of placebo
88899870|NCT01504685|Active Comparator|Unbanded laparoscopic gastric bypass|Laparoscopic Roux- en-Y gastric bypass without any band around de gastric reservoir
88899871|NCT01504685|Active Comparator|Banded laparoscopic gastric bypass|Placement of a premeasured band or ring around the gastric reservoir, adjacent to the gastroenterostomy.
88899872|NCT01504698|Experimental|Treatment with manipulation|
88899873|NCT01504698|Active Comparator|Treatment without manipulation|
88899874|NCT01504724|Experimental|IVB group|Patients were treated with IVB injections approximately within 1 week before the first PRP. Then patients had PRP, which was done in three sessions at weeks 0, 1, and 2 according to ETDRS guidelines. The superior, inferior, and nasal and temporal areas were treated sequentially.
88899875|NCT01504724|No Intervention|only PRP group|Patients had PRP, which was done in three sessions at weeks 0, 1, and 2 according to ETDRS guidelines. The superior, inferior, and nasal and temporal areas were treated sequentially.
88899876|NCT01504737|Experimental|Supervised Exercise Training|12 weeks of 40 min aerobic bicycle ergometer exercise 3 times per week.
88899877|NCT01504737|Active Comparator|Physical Activity Recommendations|Written and verbal information on minimal level of physical activity recommended.
88899878|NCT01504750|Experimental|lighting room|In the ceiling, luminaires are installed that offer the basic lighting in the patient room that will automatically and gradually change in light level (100-300 lux) and color temperature (3000-4000 K). This so called daily rhythm light meets the EN12464-1 standard for patient rooms in hospitals.
88899879|NCT01504750|No Intervention|control room|Normal lighted patient room
88899880|NCT01504763|Experimental|Massage|Chair massage for 15 minutes once a week for 10 weeks.
88899881|NCT01504776|Experimental|Open Label Drug Therapy|Single arm
88899882|NCT01504802||Growth hormone deficient|Children with short stature, a peak growth hormone response on stimulation testing of less than 7 ng/ml, and no other identifiable cause of short stature
88899883|NCT01504802||Idiopathic short stature|Children with short stature, a peak growth hormone response on stimulation testing of greater than or equal to 7 ng/ml, and no identifiable cause for the short stature
88899884|NCT01504828|Experimental|Ramipril|Those who are 40 years and older receive an ACE inhibitor to determine if this reduces age-related changes in left ventricular energetics and function
88899885|NCT01504906|Experimental|A|cyclosporine 600 mg+ a single oral dose of 180 mg ticagrelor
88899886|NCT01504906|Experimental|B|single dose cyclosporine 600 mg
88899887|NCT01504906|Experimental|C|single dose 180 mg ticagrelor
88899888|NCT01504932|Experimental|Arm I: BRB Lozenge|"Former oral cancer patients receive lozenges containing freeze-dried black raspberry (BRB) powder. They will take the lozenges four times each day (QID) by mouth (PO) for up to 6 months.~Patients will be asked to complete a baseline survey documenting any family history of cancer, tobacco, alcohol, and mouthwash use, a Head and Neck Cancer Inventory Survey (HNCI), an Insomnia Severity Index (ISI) Survey, and a Brief Fatigue Inventory (BFI) Survey.~They will receive a trial-specific logbook to record their usages.~Intervention: Black Raspberry (BRB) Lozenge Intervention: Survey Administration Intervention: Laboratory Biomarker Analysis"
89420443|NCT04222088||Patients detected with Plasmodium falciparum (Artemether-lumefantrine)|Patients with mono-infection of Plasmodium falciparum with 1,000-100,000 asexual forms per µl
88899889|NCT01504932|Other|Arm II: Biomarker Control|"Former oral cancer patients will not receive lozenges containing freeze-dried black raspberry (BRB) powder.~Patients will be asked to complete a baseline survey documenting any family history of cancer, tobacco, alcohol, and mouthwash use, a Head and Neck Cancer Inventory Survey (HNCI), an Insomnia Severity Index (ISI) Survey, and a Brief Fatigue Inventory (BFI) Survey.~They will receive a trial-specific logbook to record their usages.~Intervention: Survey Administration Intervention: Laboratory Biomarker Analysis"
88899890|NCT01504945|Active Comparator|RBC transfusion|
88899891|NCT01504945|Placebo Comparator|Normal saline infusion|
88899892|NCT01504984|Experimental|SYO-1126|Imatinib 400mg/tablet, PO, 1 tablet once daily for I&II D1(crossover)
88899893|NCT01504984|Active Comparator|Glivec film coated tab 4T(400mg)|100mg/tablet, po, 4 tablets once daily for period I&II D1(crossover)
88899894|NCT01505023|Active Comparator|Partial meal replacement|
88899895|NCT01505023|Experimental|Partial meal replacement with inulin|
88899896|NCT01505023|Active Comparator|Inulin|
88899897|NCT01505023|No Intervention|No intervention|
88899898|NCT01505036|Experimental|SMARTCARE service|U-Health service
88899899|NCT01505036|No Intervention|Usual care|Usual care
88899900|NCT01505049||Previously received all three doses of HPV vaccine|This group will consist of 78 women ages 18 to 30 who have received their third dose of vaccine three or more years ago. Recruitment of this group was completed in Sept 2012.
88899901|NCT01505049||Previously received two doses of HPV vaccine|This group will consist of 78 women ages 18 to 30 who have received two doses of the HPV vaccine. The second dose must have been received six or more months ago.
88899902|NCT01505049||Unvaccinated Cohort|This group will consist of 45 women who have not received their HPV vaccination. Women ages 18-26 are eligible for this cohort. Recruitment for this group was completed in January 2013.
88899903|NCT01505075|Experimental|Hypofractionated radiation|40 Gy in 5 fractions over 29 to prostate; 30 Gy in 5 fractions over 29 days to seminal vesicles
88899904|NCT01505088|Experimental|Iontophoretic Dexamethasone Phosphate Ophthalmic Solution|Dexamethasone phosphate (40 mg/mL) solution delivered by iontophoresis treatment consisting of 4.0 mA-min at 1.5 mA on Day 0 and Day 7 with accompanying placebo eyedrops (saline solution) for up to 28 days.
88899905|NCT01505088|Active Comparator|Prednisolone Acetate Ophthalmic Suspension (1%)|Placebo (100 mM sodium citrate buffer solution) iontophoresis treatment consisting of 4.0 mA-min at 1.5 mA on Day 0 and Day 7 with accompanying prednisolone acetate ophthalmic suspension (1%) (positive control) eyedrops for up to 28 days.
88899906|NCT01505101|Experimental|Mindfulness-Oriented Recovery Enhancement|
88899907|NCT01505101|Active Comparator|Conventional Support Group (SG)|
88899908|NCT01505127|Experimental|TAK-438 20 mg BID|"TAK-438 20 mg, tablets, orally, twice daily for 1 week~Lansoprazole placebo-matching capsules, orally, twice daily for 1 week~Amoxicillin 750 mg, capsules, orally, twice daily for 1 week~Clarithromycin 200 or 400 mg, tablets, orally, twice daily for 1 week"
88899909|NCT01505127|Experimental|Lansoprazole 30 mg BID|"TAK-438 placebo-matching tablets, orally, twice daily for 1 week~Lansoprazole 30 mg, capsules, orally, twice daily for 1 week~Amoxicillin 750 mg, capsules, orally, twice daily for 1 week~Clarithromycin 200 or 400 mg, tablets, orally, twice daily for 1 week"
88899910|NCT01505140|No Intervention|Usual Western style diet|Participants will consume their usual Western style diet avoiding tree nuts
88899911|NCT01505140|Experimental|Whole walnuts|Participants will consume usual Western style diet adding 75 gm whole walnuts per day
88899912|NCT01505153|Experimental|pbi-shRNA STMN1 LP|pbi-shRNA™ STMN1 LP administered by a single intratumoral (IT) injection.
88899913|NCT01505218|Active Comparator|Propofol sedation by nurse anaesthetist|Nurse anaesthetists managed infusion of propofol 10 mg/ml at doses of 0.2 - 0.8 ml/kg during ERCP. The target of moderate sedation was achieved within 5 minutes from start of the sedation.
88899914|NCT01505218|Active Comparator|Patient-controlled propofol sedation|"Self-administration of propofol via patient-controlled sedation pump (CME...). No programmed lock-out period, no dose limit or background infusion. 5 mg propofol/effectuated demand from the patients. Capacity of the pump was 6 possible doses per minute.~Before start of ERCP the patients were allowed to sedate themselves to a sense of heavy tiredness."
88899915|NCT01505218|No Intervention|Midazolam sedation by the ERCP-team|Midazolam doses for sedation during ERCP. Initial dose of 2-3 mg and after ERCP start, 1-2 mg as additional doses. Maximum total dose 6-8 mg. ERCP performing doctor is responsible for dose ordination.
88899916|NCT01505231|Active Comparator|Norepinephrine group|Blinded norepinephrine
88899917|NCT01505231|Active Comparator|Vasopressin Group|Blinded vasopressin
88899918|NCT01505244|Experimental|Physical Activity|Before-school moderate to vigorous physical activity 3 days/week
88899919|NCT01505257|Experimental|END-DSD Intervention|
88899920|NCT01505257|No Intervention|Control|
88899921|NCT01505270||Autistic Children|
88899922|NCT01505283|Placebo Comparator|Group Saline|Epidural administration of saline
88899923|NCT01505283|Experimental|Group Sufentanil|Epidural administration of sufentanil
88899924|NCT01505283|Experimental|Group Lidocaine|Epidural administration of lidocaine
88899925|NCT01505296|Active Comparator|Antiarrhythmic drug|Class I or III antiarrhythmic drug
88899926|NCT01505296|Experimental|Catheter ablation|Pulmonary vein isolation
88899927|NCT01505309|Experimental|Stent Graft|TEVAR procedure using devices include Medtronic Stent Graft（Medtronic Medtronic, Inc., US） Microport Stent Graft（Microport Co.,LTD.，Shanghai, China） Ankura Stent Graft（Lifetech Scientific Co.,LTD.，Shenzhen, China）.
88899928|NCT01505322||Thoracic surgery|Lung cancer patients
88899929|NCT01505335||Implant osteotomy measurements|Drilled implant locations
88899930|NCT01505348|Experimental|Fasting|Overnight fast
88899931|NCT01505348|No Intervention|Feeding|Normal breakfast
88899932|NCT01505361|Experimental|Probiotic|Pregnant women at 30 week of pregnancy(n=50) receiving Lactobacillus salivarius PS2(9 log per day, until birth)
88899933|NCT01505361|Placebo Comparator|Placebo|Pregnant women at 30 week of pregnancy(n=50) receiving the excipient (once a day, until birth)
88899934|NCT01505413|Experimental|Tarceva, Gemcitabine, Oxaliplatin|"Erlotinib 100 mg po qd daily AND~Gemcitabine 1000 mg/m² with 150mL of normal saline intravenously infusion over 100min on Day 1~Oxaliplatin 100 mg/m2 with 500mL of 5DW intravenously a 2-hour infusion on D2 Every 2 weeks~Each two weeks is a cycle. If at end of 12 cycles response continues, will administer Gemcitabine and erlotinib until progression."
88899935|NCT01505426|Experimental|ASP1941 group|ASP1941 + metformin
88899936|NCT01505426|Placebo Comparator|placebo group|placebo + metformin
88899937|NCT01505439|Experimental|Solifenacin group|Once daily
88899938|NCT01505478||Patients admitted with infection|All consecutive ED patients during the study period that have been admitted and identified to have a suspected infection at ED disposition using a data collection tool
88899939|NCT01505517||individuals with low back pain|
88899940|NCT01505517||healthy controls|
89420444|NCT04222088||Patients detected with Plasmodium vivax (Chloroquine)|Patients with mono-infection of Plasmodium falciparum with ≥ 250 per µl
89420445|NCT04196543|Experimental|écho-doppler with ultrasonar Sonovue® injection|
88899941|NCT01505543||chronic obstructive pulmonary disease|
88899942|NCT01505543||healthy matched controls|
88899943|NCT01505556||Diaphragm paresis|
88899944|NCT01505556||Healthy controls|
88899945|NCT01505582|Experimental|Inspiratory muscle training|
88899946|NCT01505582|Sham Comparator|Sham inspiratory muscle training|
88899947|NCT01505595|Experimental|Proprioceptive training|
89194374|NCT00428389|Experimental|Delayed Switch|Patients randomized to the delayed switch group were switched to 5 cm^2 rivastigmine patch formulation on Day 8, following a 7-day withdrawal period from donepezil. A new patch was applied daily for 4 weeks. Patients who completed the core phase had the option of entering the extension phase, in which they received open-label treatment with rivastigmine patch formulation for an additional 20 weeks. In the absence of any dose-limiting adverse events (AEs), the dose was increased to 10 cm^2 patch, and it remained the same through Week 25. Patients who experienced dose-limiting AEs had their dose reduced to 5 cm^2 patch and continued on their best tolerated dose for the remainder of the study.
89194375|NCT00736424||1|Have received bilateral AN stimulation of the anterior nucleus (AN) of the thalamus for epilepsy or are receiving it at the time of enrollment
88899948|NCT01505595|Sham Comparator|Sham proprioceptive training|
88899949|NCT01505621||Young|Healthy adults 18-30 years old
88899950|NCT01505621||Elderly|Healthy adults greater than 65 years old
89194376|NCT00616642|Experimental|Group 1 (ACTH-secreting adenomas)|Patients receive 4 mg oral rosiglitazone maleate once daily in week 1 and then 8 mg once daily beginning in week 2 and continuing for up to 6 months in the absence of disease progression or unacceptable toxicity.
89194377|NCT00616642|Experimental|Group 2 (non-secreting macroadenomas)|Patients receive 4 mg oral rosiglitazone maleate once daily in week 1 and then 8 mg once daily beginning in week 2 and continuing for up to 12 months in the absence of disease progression or unacceptable toxicity.
89194378|NCT02568488|Experimental|metformin|PCOS women receiving metformin 850 mg orally twice daily over a period of 6 months
89194379|NCT00923624|Active Comparator|staff emails|Attention control that includes staff sending emails with information about using health information technology system.
89194380|NCT00923624|Experimental|study nurse messages|A series of 6 proactive secure messages and 3 proactive booster messages (for a total of 9 secure and personalized messages) sent by the study nurse via the EMR patient web portal.
89420446|NCT04187950|Placebo Comparator|Yogurt with inactivated B. lactis and added cane sugar|Participants will consume yogurt with heat inactivated B. lactis and added cane sugar twice daily for 14 days.
89420447|NCT04187950|Experimental|Yogurt with B. lactis and added honey|Participants will consume yogurt with B. lactis and added honey twice daily for 14 days.
89420448|NCT04165759||patients|Patients with lung cancer who are candidates for surgery.
88899951|NCT01505660|No Intervention|Usual Care|Patients not randomized to the intervention will receive usual care which includes a patient reported outcomes assessment every 6 months as part of routine clinical procedures and patient-initiated interactions with case managers.
88899952|NCT01505660|Experimental|Care management|The intervention will include frequent healthcare delivery team notification of PROs including medication adherence and adherence barriers such as depression symptoms along with tailored intervention recommendations and targeted care management using a stepped care approach.
88899953|NCT01505686|Experimental|study group|All patients in this study have MRI scan prior to hernia repair surgery. If inflammatory changes are present, the scan is repeated 6 months after surgery. If not, the scan is performed only if the patient has pain problems at 6 months.
88899954|NCT01505738||bacterial cultures|Bacterial samples are collected preoperatively from urine, nose and possible lower limb ischaemic wounds, perioperatively from inguinal area and wound edges, and twice postoperatively. In addition, in case of a wound infection, bacterial samples are taken for diagnosis as usual.
88899955|NCT01505751||cervical cancer|
88899956|NCT01505777|Experimental|Probiotics(Medirac) 10/mosapride 10mg|
88899957|NCT01505777|Experimental|Probiotics(Medirac) 15/mosapride 10mg|
88899958|NCT01505777|Experimental|Probiotics(Medirac) 15/mosapride 15mg|
88899959|NCT01505777|Experimental|Probiotics(Medirac) 30/mosapride 15mg|
88899960|NCT01505777|Placebo Comparator|Probiotics(Medirac) placebo/mosapride placebo|
88899961|NCT01505790|Experimental|CLOPIDOGREL GROUP|
88899962|NCT01505790|Active Comparator|PRASUGREL GROUP|
88899963|NCT01505803|Active Comparator|Zinc supplement|
88899964|NCT01505803|Active Comparator|Omega 3 supplement|
88899965|NCT01505803|Active Comparator|Zinc and omega 3 supplements|
88899966|NCT01505803|Placebo Comparator|Placebo supplement|
88899967|NCT01505816|No Intervention|Toric|Multifocal Toric IOL implantation
89194381|NCT00864292||HIV-infected, no dementia|Patients with HIV-infection but no dementia
89194382|NCT00864292||HIV-infected, dementia|Patients with HIV-infection and dementia
89194383|NCT03994549|Active Comparator|ZP7570|Single subcutaneous injection
89194384|NCT03994549|Placebo Comparator|Placebo|Single subcutaneous injection
89194385|NCT00736658|Experimental|AZD1386|4 groups receiving a specified volume of the active component AZD1386 at different points of time.
89420449|NCT04136340|Active Comparator|In-person follow-up|Due to the COVID-19 pandemic, patients originally randomized to the in-person group received telemedicine visits. Thus, the researchers will expand our sample for these interviews to include patients who have completed at least 2 telemedicine follow-up visits whether they were originally randomized to the in-person group or the home telemedicine group.
89420450|NCT04136340|Experimental|Home Telemedicine follow-up|
89420451|NCT04112953||Upcoming cardiac surgery|Subjects in this group will have an upcoming cardiac surgery with the use of cardiopulmonary bypass and no pre-existing renal insufficiency or failure
89420452|NCT04105777||Standard Low Glucose Parenteral Nutrition using Eurotubes®|Patients receive standard PN reduced in glucose in Eurotubes®.
89420453|NCT04105777||Standard Parenteral Nutrition using Eurotubes®.|Patients receive standard PN in Eurotubes®.
89420454|NCT04105777||Standard Parenteral Nutrition using 2/3-chamber bags|Patients receive PN according to the routine used by the participating site.
89420455|NCT04063722|Experimental|Modified Benelli Procedure|point x refers to the point where the nipple areola complex should be placed at 18 cm from the mid clavicular line. line A is marked above and medial to the areola and a second radial line above it and parallel to it passing in the point (X) was made and named line B. The ends of this line is curved to approximate and connect to both ends of the line A . two incisions were made on the lines A and B . Next, the whole thickness of the excess skin between line A and the line B was excised (Simon classification 2A, 2B and 3) and subcutaneous mastectomy was done and sent to histopathology. Later on, bleeding control was done by good hemostasis and suction drain was put in its proper site. Finally subcuticular suturing was done by approximation of two incisions using Nylon 3/0. Lastly, sterile pressure dressing was placed.
89420456|NCT04063722|Active Comparator|webester procedure|periareolar incision with excision of the breast tissue
89420457|NCT04020458|Active Comparator|Periodontitis, no kidney disease|"Dental intervention i. Full mouth intraoral X-rays (FMX)~ii. Full periodontal exam, diagnosis, Oral hygiene instructions (OHI)~iii. RX: 7 days of p.o. metronidazole (250mg)/amoxicillin (500mg) T.I.D., combined with local chlorhexidine rinses (not for subjects with Kidney transplant).~iv. Single visit intensive scaling and root planning (SRP) (full mouth)~v. Re-evaluation after 4-6 weeks (referral for definitive treatment)~vi. Extraction of teeth deemed hopeless based on periodontal, endodontic or restorative considerations~vii. Caries control, sedative dressing (palliative), referral to endodontic dentist for root canal treatment (RCT)"
89420458|NCT04020458|Active Comparator|Experimental- chronic kidney disease|"Dental intervention i. Full mouth intraoral X-rays (FMX)~ii. Full periodontal exam, diagnosis, Oral hygiene instructions (OHI)~iii. RX: 7 days of p.o. metronidazole (250mg)/amoxicillin (500mg) T.I.D., combined with local chlorhexidine rinses (not for subjects with Kidney transplant).~iv. Single visit intensive scaling and root planning (SRP) (full mouth)~v. Re-evaluation after 4-6 weeks (referral for definitive treatment)~vi. Extraction of teeth deemed hopeless based on periodontal, endodontic or restorative considerations~vii. Caries control, sedative dressing (palliative), referral to endodontic dentist for root canal treatment (RCT)"
89420459|NCT04020458|No Intervention|Control- no Periodontitis or kidney disease.|Only regular dental cleaning
89420460|NCT03978520|Placebo Comparator|Elsubrutinib placebo/upadacitinib placebo|Placebo capsule for elsubrutinib once a day by mouth for up to 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for up to 48 weeks
89420461|NCT03978520|Experimental|ABBV-599 High Dose (Elsubrutinib 60 mg/upadacitinib 30 mg)|60 mg elsubrutinib capsule once a day by mouth for up to 48 weeks; 30 mg upadacitinib film-coated tablet once a day by mouth for up to 48 weeks
89420462|NCT03978520|Experimental|Elsubrutinib placebo/upadacitinib 30 mg|Placebo capsule for elsubrutinib once a day by mouth for up to 48 weeks; 30 mg upadacitinib film-coated tablet once a day by mouth for up to 48 weeks
89420463|NCT03978520|Experimental|ABBV-599 Low Dose (Elsubrutinib 60 mg/upadacitinib 15 mg)|60 mg elsubrutinib capsule once a day by mouth for up to 24 weeks; 15 mg upadacitinib film-coated tablet once a day by mouth for up to 24 weeks
89420464|NCT03978520|Experimental|Elsubrutinib 60 mg/upadacitinib placebo|60 mg elsubrutinib capsule once a day by mouth for up to 24 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for up to 24 weeks
89420465|NCT03968328||Observational (interview, survey)|Patients respond to a survey and participate in an interview with study staff about their fever and when they started feeling unwell.
89420466|NCT03962127||First time ischemic stroke|Patients with a first event of ischemic stroke admitted to hospitals in Central Norway.
89420467|NCT03947957|Other|collection of expectoration, stools and blood|
89420468|NCT03941743|Experimental|Prevention (fingolimod hydrochloride)|Patients receive fingolimod hydrochloride PO QD starting the day before chemotherapy, the day of chemotherapy, and 1 day after chemotherapy for 12 weeks.
89420469|NCT03929393|Experimental|Mindful Movement|8, 90-minute, in-person, group sessions over 8 weeks
89420470|NCT03929393|Active Comparator|Keys to Health & Wellbeing|8, 90-minute, in-person, group sessions over 8 weeks
89420471|NCT03921398||Patients with ESRD|Patients with history of biopsy-proven lupus nephritis (all classes of lupus nephritis)
89420472|NCT03921398||Patients with active lupus prior to treatment and no ESRD|Patients with biopsy-proven ACTIVE lupus nephritis
89420473|NCT03921398||Healthy individuals|Healthy individuals
88899968|NCT01505829||Biological validation cohort 1|
88899969|NCT01505829||Response assessment cohort 2|
88899970|NCT01505842|Experimental|Colonoscopy with chromoendoscopy|Colonoscopy with chromoendoscopy using 0.2-0.5% Indigo-Carmine solution sprayed in the whole colon and rectum plus 32 random biopsies plus biopsies from suspicious areas
88899971|NCT01505842|Active Comparator|Conventional colonoscopy|White light colonoscopy plus 32 random biopsies plus biopsies from suspicious areas
88899972|NCT01505855|Experimental|anti-TNF only|Crohn's disease, on an anti-TNF agent [infliximab or adalimumab] only
88899973|NCT01505855|Experimental|Combined immunosuppression|Crohn's disease, on combined immunosuppression (both anti-TNF agent and immunomodulator [azathioprine or 6-MP])
88899974|NCT01505855|Experimental|Immunomodulator only|Crohn's disease, on an immunomodulator only
88899975|NCT01505855|Experimental|Non-immunosuppression|Crohn's disease, not on immunosuppressive medications (5-ASA only: control arm)
88899976|NCT01505907|Experimental|CXB909 15mg|CXB909 15mg
88899977|NCT01505907|Experimental|CXB909 30mg|
88899978|NCT01505907|Experimental|CXB909 60mg|
88899979|NCT01505907|Experimental|CXB909 120mg|Dose
88899980|NCT01505907|Experimental|CXB909 250mg|
88899981|NCT01505920|Experimental|Lidocaine spray|10% lidocaine spray 40 mg applied directly to the cervix, 3 minutes before starting cervical excision
88899982|NCT01505920|Active Comparator|Lidocaine submucosal injection|2% lidocaine with 1:100,000 adrenaline 2 ml injected submucosally to the four quadrant of the cervix, 3 minutes before starting cervical excision
88899983|NCT01505946||LOW RESPONDERS|Documented low anamnestic response after FVIII exposure (FVIII inhibitors titre >0.6 and < 5 BU/ml tested by Bethesda assay, Nijmegen modification). Patients who have never been submitted to ITI and also those patients who have completed ITI with partial success (defined as inhibitors titre >0.6 and < 5 BU/ml and no increase in the INH titer > 5 BU over treatment with FVIII)
88899984|NCT01505946||HIGH RESPONDERS|Patients who documented high response after FVIII exposure (FVIII inhibitors titre > 5 BU/ml tested by Bethesda assay, Nijmegen modification) and who are potential candidates to a first or rescue ITI
88899985|NCT01505959|Experimental|Conventional|
88899986|NCT01505959|Active Comparator|Telemedicine|
88899987|NCT01505985|Experimental|Specialized Oral Nutritional Supplement|
88899988|NCT01505985|Placebo Comparator|Placebo|
88899989|NCT01505998|Experimental|Amlodipine Besylate/Benazepril HCl|Amlodipine Besylate/Benazepril HCl 10 mg/40 mg capsules of Dr. Reddy's Laboratories Ltd.
88899990|NCT01505998|Active Comparator|Lotrel|Lotrel® Amlodipine Besylate/Benazepril HCl 10 mg/40 mg capsules of Novartis Pharmaceuticals
88899991|NCT01506011|Experimental|Amlodipine Besylate/Benazepril HCl|Amlodipine Besylate/Benazepril HCl 10 mg/40 mg capsules of Dr. Reddy's Laboratories Ltd.
88899992|NCT01506011|Active Comparator|Lotrel|Lotrel® Amlodipine Besylate/Benazepril HCl 10 mg/40 mg capsules of Novartis Pharmaceuticals
88899993|NCT01506024|Active Comparator|THA Direct lateral|Total hip arthroplasty (THA) carried out by direct lateral approach (DLA)
88899994|NCT01506024|Experimental|THA Posterior|Total hip arthroplasty (THA) carried out by posterior approach (DLA)
88899995|NCT01506024|Experimental|THA Anterior|Total hip arthroplasty (THA) carried out by anterior approach (DLA)
88899996|NCT01506037|Experimental|Desloratadine OD tablets 5 mg|Desloratadine OD tablets 5 mg of Dr. Reddy's Laboratories Limited
88899997|NCT01506037|Active Comparator|Clarinex|Clarinex 5 mg of Schering Corporation Inc USA
88899998|NCT01506050|Experimental|Desloratadine OD tablets 5 mg|Desloratadine OD tablets 5 mg of Dr. Reddy's Laboratories Limited
88899999|NCT01506050|Active Comparator|Clarinex|Clarinex 5 mg of Schering Corporation Inc USA
88900000|NCT01506063|Experimental|Levocetirizine DiHCl Tablets, 5 mg|Levocetirizine DiHCl Tablets, 5 mg of Dr. Reddy's Laboratories Ltd.
88900001|NCT01506063|Active Comparator|XYZAL|XYZAL Tablets 5 mg of UCB Farchim S.A.
88900002|NCT01506076|Experimental|Levocetirizine DiHCl Tablets, 5 mg|Levocetirizine DiHCl Tablets, 5 mg of Dr. Reddy's Laboratories Ltd.
88900003|NCT01506076|Active Comparator|XYZAL|XYZAL Tablets 5 mg of UCB Farchim S.A.
89194386|NCT00736658|Placebo Comparator|Placebo|Included in each dose group
89420474|NCT03899259|Experimental|4 Milligram (mg) Baricitinib|Participants received one 4 mg Baricitinib tablet administered orally, every day (QD) one placebo tablet administered orally QD to maintain blind.
88900004|NCT01506089|Experimental|36 degree group|36 degrees Celsius for the incubators is the experimental condition in this study.
88900005|NCT01506089|No Intervention|37 degree group|37 degrees Celsius is the standard incubator temperature for the culture of embryos.
88900006|NCT01506115|Experimental|HCC with bile duct invasion|Photodynamic therapy with biliary drainage in patients with bile duct invasion of unresectable HCC
88900007|NCT01506128||HPV|Premenopausal women with HSIL in Pap test or high-risk HPV
88900008|NCT01506154|Placebo Comparator|Placebo|Therapy with placebo
88900009|NCT01506154|Experimental|MRX-7EAT|Therapy with experimental drug
88900010|NCT01506167||Bevacizumab and Capecitabine/Oxaliplatin|Participants who receive bevacizumab in combination with capecitabine/oxaliplatin
88900011|NCT01506167||Bevacizumab and Fluorouracil/Folinic Acid/Oxaliplatin|Participants who receive bevacizumab in combination with fluorouracil/folinic acid/oxaliplatin
88900012|NCT01506167||Bevacizumab and Capecitabine|Participants who receive bevacizumab in combination with capecitabine
88900013|NCT01506167||Bevacizumab and Fluorouracil/Folinic Acid/Irinotecan|Participants who receive bevacizumab in combination with fluorouracil/folinic acid/irinotecan
88900014|NCT01506167||Bevacizumab and Capecitabine/Irinotecan|Participants who receive bevacizumab in combination with capecitabine/irinotecan
88900015|NCT01506167||Bevacizumab and Fluorouracil +/- Folinic Acid|Participants who receive bevacizumab in combination with fluorouracil +/- folinic acid
88900016|NCT01506167||Other|Participants who receive bevacizumab in combination with other first-line chemotherapy regimens
88900017|NCT01506180||Patients admitted to Geriatric Department|The patients receive comprehensive geriatric assessment
88900018|NCT01506180||Patients admitted to general medical departments|This group do not receive comprehensive geriatric assessment
88900019|NCT01506219|Experimental|Geriatrician-performed CGC|Geriatrician-performed CGC in addition to the usual care at Community Rehabilitation Unit.
88900020|NCT01506219|No Intervention|Usual care|Usual services at Community Rehabilitation Unit.
88900021|NCT01506232||ADHD|Youth diagnosed with ADHD.
88900022|NCT01506232||ASD|Youth diagnosed with an Autism Spectrum Disorder (ASD).
88900023|NCT01506232||BPD|Youth diagnosed with Bipolar Disorder.
88900024|NCT01506232||Healthy Controls|Youth not diagnosed with any psychiatric/psychological disorder.
88900025|NCT01506245|No Intervention|Control|
88900026|NCT01506245|Experimental|Family-based behavioral therapy|Family-based behavioural therapy either in group or in individual setting. Parents can choose between the 2 types of therapy.
88900027|NCT01506258|No Intervention|Patients not infused with stem cells|Historic Controls
88900028|NCT01506258|Experimental|Patients infused with stem cells|
88900029|NCT01506284||Anesthetized patients ASA I-II|ASA classification I-II, scheduled for elective surgery requiring general anesthesia.
88900030|NCT01506310|No Intervention|Diet alone|
88900031|NCT01506310|Experimental|Behavioral therapy|
88900032|NCT01506310|Experimental|Exercise|
88900033|NCT01506310|Experimental|Behavioral therapy and exercise|
88900034|NCT01506336|Experimental|masitinib|masitinib 12 mg/kg/day
88900035|NCT01506336|Active Comparator|sunitinib|sunitinib 50 mg/day
88900036|NCT01506349|Experimental|Crossover Group 1|"Group 1 will consume 4 grams of gluten before neurocognitive testing at Visit 2.~Group 1 will consume placebo before neurocognitive testing at Visit 3."
88900037|NCT01506349|Experimental|Crossover Group 2|"Group 2 will consume placebo before neurocognitive testing at Visit 2.~Group 2 will consume 4 grams of gluten before neurocognitive testing at Visit 3."
88900038|NCT01506375|Experimental|gpASIT|grass pollen peptides alone
88900039|NCT01506375|Experimental|gpASIT/adjuvant|grass pollen peptides + adjuvant
88900040|NCT01506388|Experimental|folye catheter plus vaginal IMN|intracervical foley catheter plus vaginal IMN
88900041|NCT01506388|Active Comparator|Misoprostol vaginally|intravaginal misoprostol
88900042|NCT01506401|Active Comparator|Conventional Ventilation|Low tidal volumes, relatively high PEEP.
88900043|NCT01506401|Experimental|High Frequency Oscillation|Open-lung strategy for high frequency oscillation.
88900044|NCT01506414|Experimental|combination treatment|
88900045|NCT01506427|Experimental|[F-18] HX4|
89194387|NCT05225896||DNER ataxia|Patients with well-characterized DNER antibodies.
89194388|NCT04645394|Placebo Comparator|Placebo|The participants are receiving 1 dose of each in the stated order.
89420475|NCT03899259|Experimental|2 mg Baricitinib|Participants received one 2 mg Baricitinib tablet administered orally QD, and one placebo tablet administered orally QD to maintain blind.
89420476|NCT03899259|Placebo Comparator|Placebo|Participants received two placebo tablets administered orally QD to maintain the blind.
89420477|NCT03899259|Experimental|4 mg Baricitinib Maximum Extended Enrollment (MEE)|Participants received one 4 mg Baricitinib tablet administered orally, every day (QD) one placebo tablet administered orally QD to maintain blind.
89420478|NCT03899259|Experimental|2 mg Baricitinib MEE|Participants received one 2 mg Baricitinib tablet administered orally QD, and one placebo tablet administered orally QD to maintain blind.
89420479|NCT03899259|Placebo Comparator|Placebo MEE|Participants received two placebo tablets administered orally QD to maintain the blind.
89420480|NCT03896685|Experimental|endTB-Q: BeDeCLi 24 or 39 weeks|endTB-Q regimen: bedaquiline-delamanid-linezolid-clofazimine (BeDeCLi). Subjects who are randomized to this arm will be assigned to duration of 24 or 39 weeks , according to the participant's extent-of-TB-disease phenotype. Participants may take as long as 32 weeks to complete all doses of a 24-week treatment regimen, and up to 47 weeks to complete all doses of a 39-week treatment regimen. Dosing of the experimental regimens will be oral and weight based.
89420481|NCT03896685|Active Comparator|endTB-Q: Control arm|endTB-Q is the control regimen, designed according to latest World Health Organization guidelines.
89420482|NCT03874715|Experimental|Switching: NovoLog/SAR341402|Participants self-administered subcutaneous (SC) injection daily prior to the start of a meal during the 16-week treatment period, starting with NovoLog (100 units per milliliters [U/mL]) for the first 4 weeks, then SAR341402 (100 U/mL) for 4 weeks, followed by NovoLog (at same dose) for 4 weeks and then SAR341402 (at same dose) for the last 4 weeks on top of mandatory background therapy with Lantus (Insulin glargine, 100 U/mL) as basal insulin.
89420483|NCT03874715|Active Comparator|Non-Switching: NovoLog|Participants self-administered SC injection of NovoLog (100 U/mL) daily prior to the start of a meal during the 16-week treatment period on top of mandatory background therapy with Lantus (Insulin glargine, 100 U/mL) as basal insulin.
89420484|NCT03801863||Ultrasound-guided Erector Spinae Block|Patients will then be randomized into one of the two groups above. One group will receive a lumbar erector spinae block at L4 with 30ml of 0.375% ropivacaine with 50 mcg of dexmedetomidine before the procedure using ultrasound guidance. The second group will receive no peripheral nerve block to serve as the control. All patients receiving nerve blocks will have a printed image of the block thus to confirm proper spread of local anesthetic both cranially and caudally.
89420485|NCT03801863||No Ultrasound-guided Erector Spinae Block|Patients with no peripheral nerve block to serve as the control.
89420486|NCT03801356|Other|Selective Nerve Root Block|Patient will receive a Selective Nerve Root Block injection at the target level prior to surgical intervention.
89420487|NCT03786003|Experimental|VATS|Video-assisted thoracoscopic surgery
89420488|NCT03786003|Active Comparator|Thoracotomy|Open surgery
89420489|NCT03664037|Active Comparator|D group, (n=55)|
89420490|NCT03664037|Placebo Comparator|C group, (n=55)|
89420491|NCT03659981|Experimental|MS Patients|Multiple sclerosis patients MRI 7T will be performed
89420492|NCT03600779|Experimental|experimental group 1.5T|Population of patients with myelin syndrome (MS) at the the disease onset with active lesions inhomogeneous Magnetisation Transfer (ihMT) sequence will be performed.
89420493|NCT03600779|Active Comparator|control group 1.5 T|healthy volunteers matched in sex and age inhomogeneous Magnetisation Transfer (ihMT) sequence will be performed.
89420494|NCT03600779|Experimental|experimental group 3T|Population of patients with myelin syndrome (MS) at the the disease onset with active lesions inhomogeneous Magnetisation Transfer (ihMT) sequence at 3T will be performed.
89420495|NCT03600779|Active Comparator|control group 3T|inhomogeneous Magnetisation Transfer (ihMT) sequence will be performed. inhomogeneous Magnetisation Transfer (ihMT) sequence at 3T will be performed.
89420496|NCT03567356|No Intervention|Treatment as Usual|TAU will contain patients who will be receiving treatment for opioid use disorder through their usual venues without the family engagement, assertive outreach, and home delivery of XRNTX doses.
89420497|NCT03567356|Experimental|MAT-Plus Intervention|"The intervention group will receive the multi-component MAT-PLUS treatment: 1) Significant other engagement through the Helping Hands approach empowers designated concerned helpers, providing concrete guidance for monitoring, supervision, and improving adherence for their loved one in treatment; 2) Care coordination and case management by counselors to enhance adherence to XRNTX ; 3) Assertive outreach incorporates frequent multi-channel outreach with the goal of achieving XRNTX dosing."
89420498|NCT03514485|Active Comparator|P+S- (Partner School)|This arm includes children who attend one of the partnering schools and who are randomized to receive the primary care intervention Yes We Can Children's Asthma Program.
89420499|NCT03514485|Active Comparator|P-S+ (Partner School)|This arm includes children who attend one of the partnering schools and who are randomized to receive the school intervention Open Airways for Schools Plus.
89420500|NCT03514485|Active Comparator|P+S+ (Partner School)|This arm includes children who attend one of the partnering schools and who are randomized to receive the enhanced school intervention Open Airways for Schools Plus, School-Based Asthma Therapy and the primary care intervention Yes We Can Children's Asthma Program.
89420501|NCT03514485|No Intervention|P-S- (Partner School)|This arm includes children who attend one of the partnering schools, and are randomized to the control group (no primary care or school intervention).
88900046|NCT01506440||Supportive Care (cognitive assessment)|Patients complete cognitive assessments, comprising HVLT-R, TMT-A, TMT-B, DSC, Animals, MoCA, and DST. Patients also complete the Beck Depression Inventory. Assessments are administered on day 1 of chemotherapy and at 6-8 weeks and 12-16 weeks after day 1 of chemotherapy.
88900047|NCT01506466|Other|additional examinations/measurements|
88900048|NCT01506492|No Intervention|Usual Care|Usual care includes routine screening for depression and other distress in oncology outpatient clinics, communication of screening information to the medical treatment team, and referral as needed.
88900049|NCT01506492|Experimental|CALM|Patients assigned to the intervention arm will receive 3-6 CALM therapy sessions over 3-6 months delivered by a trained therapist at our center.
88900050|NCT01506505|Experimental|Polypill in the morning|Cardiovascular agents in a polypill used from 05.00-11.00 in the morning (acetylsalicylic acid 75 mg, simvastatin 40 mg, lisinopril 10 mg, hydrochlorothiazide 12,5 mg)
88900051|NCT01506505|Experimental|Polypill in the evening|Cardiovascular agents in a polypill used from 18.00-00.00 in the evening (acetylsalicylic acid 75 mg, simvastatin 40 mg, lisinopril 10 mg, hydrochlorothiazide 12,5 mg)
88900052|NCT01506505|Active Comparator|Individual agents of the polypill)|"Cardiovascular agents in as acetylsalicylic acid 75 mg, lisinopril 10 mg, hydrochlorothiazide 12,5 mg used 05.00-11.00 in the morning.~Simvastatin 40 mg used 18.00-00.00 in the evening."
88900053|NCT01506518||Duchenne muscular dystrophy and age 5-6 years|Boys diagnosed with Duchenne muscular dystrophy and age 5-6 years at enrollment.
88900054|NCT01506518||Duchenne muscular dystrophy and age 7-8 years|Boys diagnosed with Duchenne muscular dystrophy and age 7-8 years at enrollment.
88900055|NCT01506518||Duchenne muscular dystrophy and age 9-10 years|Boys diagnosed with Duchenne muscular dystrophy and age 9-10 years at enrollment.
88900056|NCT01506518||No known neuromuscular disorders and age 5-14 years|Volunteer boys ages 5-14 years with no known neuromuscular disorders to serve as controls.
88900057|NCT01506531|Active Comparator|primary closure of gastroschisis|Attempt primary skin closure of gastroschisis shortly after birth
88900058|NCT01506531|Active Comparator|silo for gastroschisis|Surgical placement of silo over gastroschisis shortly after birth
88900059|NCT01506544|Experimental|Arm 1 Pharmacokinetic study|This will be a single dose study where participants will receive 20mg/kg or the participant's usual dose as a liquid containing hydroxyurea 100mg/mL. For a subset of participants (n= at least 6), a multiple-dose, steady state (i.e. at least 4 consecutive days of dosing) study will be performed.
88900060|NCT01506544|Active Comparator|Arm 2: Relative bioavailability study|This will be a single dose study. Participants will receive each of the two following treatments of HU in a randomized, crossover fashion: Either approximately 20 mg/kg/day (rounded to the nearest 200mg and no greater than 30 mg/kg) or the participant's usual daily dose as: 1) a liquid containing 100 mg/mL of hydroxyurea, or 2) Droxia® 200 mg capsules administered orally.
88900061|NCT01506557|Experimental|choecalciferol|
88900062|NCT01506557|Placebo Comparator|placebo|
88900063|NCT01506570|Experimental|TetraVax-DV Vaccine - Admixture TV003|Participants will receive one SC injection of the TetraVax-DV Vaccine - Admixture TV003 in their upper arm at Day 0 and Day 180.
88900064|NCT01506570|Experimental|TetraVax-DV Vaccine - Admixture TV005|Participants will receive one SC injection of the TetraVax-DV Vaccine - Admixture TV005 in their upper arm at Day 0 and Day 180.
88900065|NCT01506570|Placebo Comparator|Placebo|Participants will receive one SC injection of placebo in their upper arm at Day 0 and Day 180.
88900066|NCT01506583||General population|This group of participants is primarily an out-patient population.
88900067|NCT01506583||In-patient population|This group of participants is primarily an in-patient population.
88900068|NCT01506583||Pediatric Group|Participants in this group are children 18 years or younger.
88900069|NCT01506622|Active Comparator|Propofol group|intravenous administration of propofol 1 mg/kg at the end of anesthesia
88900070|NCT01506622|Active Comparator|Fentanyl group|intravenous administration of fentanyl 1 mcg/kg at the end of anesthesia
88900071|NCT01506622|Active Comparator|Control group|intravenous administration of saline at the end of anesthesia
88900072|NCT01506635|Placebo Comparator|Control group|included patients who received artificial tear twice a day as control group.
88900073|NCT01506635|Experimental|Timolol group|included the patients with myopic regression who received timolol 0.5% eye drop twice a day
88900074|NCT01506661|Experimental|Rheumatoid Arthritis|10 subjects with mild rheumatoid arthritis aged 50 years and older will be enrolled and will receive a single dose of Zostavax vaccine.
88900075|NCT01506661|Active Comparator|Healthy Subjects|10 healthy subjects aged 50 years or older who have not been previously immunized, will receive a single injection of Zostavax.
88900076|NCT01506687|Experimental|Navigator intervention|
88900077|NCT01506687|Active Comparator|Usual Care Control|Usual care
88900078|NCT01506713|Experimental|Clopidogrel|Clopidogrel tablets 75 mg of Dr. Reddy's Laboratories Limited
88900079|NCT01506713|Active Comparator|Plavix|Clopidogrel Tablet 75 mg
88900080|NCT01506739|Active Comparator|1|
88900081|NCT01506739|Active Comparator|2|
88900082|NCT01506739|Active Comparator|3|
88900083|NCT01506752|Active Comparator|E2020 improved 10 mg without water|
88900084|NCT01506752|Active Comparator|E2020 current 10 mg without water|
88900085|NCT01506752|Active Comparator|E2020 improved 10 mg with water|
88900086|NCT01506752|Active Comparator|E2020 current 10 mg with water|
88900087|NCT01506765|Active Comparator|patients who receive NAC first|this group will receive 2g/day of NAC (2 caps of 0.5g twice day)for a duration of 8 weeks first, and after this 8 weeks their receive placebo for 8 weeks.
88900088|NCT01506765|Placebo Comparator|patients who receive placebo first|this patients will receive first placebo for a duration of 8 weeks, and after this 8 weeks their receive NAC for 8 weeks
88900089|NCT01506778|Active Comparator|Group 1(With Tenaculum)|This group consisted of the patients whose had been applied tenaculum at cervix during the endometrial sampling procedure
88900090|NCT01506778|No Intervention|Group 2 (Without Tenaculum)|This group consisted of the patients whose had been not applied tenaculum during the endometrial sampling procedure.
88900091|NCT01506791|Experimental|Desloratadine and pseudoephedrine ER tablets 5/240 mg|Desloratadine and pseudoephedrine ER tablets 5/240 mg of Dr. Reddy's Laboratories Limited
88900092|NCT01506791|Active Comparator|Clarinex D 24-hour|Clarinex D-24 of Schering Corporation Inc USA
88900093|NCT01506804|Experimental|Training of painful shoulder|Steroid injection X 2 and 10 weeks exercise program of painful shoulder
88900094|NCT01506804|Placebo Comparator|Contralateral training|Steroid injection X 2 and 10 weeks exercise program of asymptomatic shoulder
88900095|NCT01506817||Fibromyalgia|patients with fibromyalgia fulfilling the 1990-ACR research criteria and with pain in the hands as a prominent clinical feature
88900096|NCT01506817||Controls|healthy aged matched pain-free controls
88900097|NCT01506830|Active Comparator|Absolute isolation|Absolute isolation of the operatory field with rubber dam: Moisture control is provided by a rubber dam and a gingival retraction clamp placed in the cervical area of the tooth.
88900098|NCT01506830|Experimental|Relative isolation|Relative isolation of the operatory field with cotton rolls: Moisture control was provided using a labial retractor, cotton rolls and gingival retraction cord placed into the gingival sulcus
88900099|NCT01506843|Active Comparator|mite allergen drop|Children with allergic rhinitis sensitized with dust mites will receive progressive doses of allergen drops comparing those receiving placebo.
88900100|NCT01506843|Active Comparator|mite plus bacterial extracts|Vaccine constituted with mite and bacterial extracts will be compared to placebo.
88900101|NCT01506843|Placebo Comparator|Placebo|Placebo will be constituted by the same solution used to make dilution of the allergen extracts.
88900102|NCT01505972|Experimental|Six and three time schedule|
88900103|NCT01505972|Experimental|Four and two time schedule|
88900104|NCT01506869||Type 2 diabetes|
88900105|NCT01506869||Prediabetes|
88900106|NCT01506869||Normal glucose regulation|
88900107|NCT01506895|Experimental|darapladib|darapladib dosed at 160 mg once daily
88900108|NCT01506895|Placebo Comparator|placebo|Placebo to match once daily
88900109|NCT01506921|Active Comparator|Racemic ketamine|
88900110|NCT01506921|Active Comparator|S-ketamine|All subjects receive both study drugs in a cross- over design. Equipotent doses are used. 0,6 mg/kg racemic ketamine equals 0,3 mg/kg s-ketamine
88900111|NCT01506934|Experimental|linifanib|Single Doses
88900112|NCT01506999||Stable phase of ischemic heart disease|patients with history of angina pectoris, or myocardial infarction
88900113|NCT01506999||acute phase of ischemic heart disease|patients with unstable angina or acute myocardial infarction
88900114|NCT01506999||control group|subjects without ischemic heart disease (IHD)
88900115|NCT01507012|Experimental|Powdered berryfruit extract|Powdered berry extract containing 500mg of polyphenols
88900116|NCT01507012|Placebo Comparator|Placebo|
88900117|NCT01507012|Experimental|Berryfruit juice|Berryfruit juice containing 500mg polyphenols
88900118|NCT01507025||horizontal flap|patients were scheduled to undergo LASIK and with horizontal flaps(nasal- or temporal-hinge)
88900119|NCT01507025||vertical flap|patients were scheduled to undergo LASIK and with vertical flaps(superior- hinge)
88900120|NCT01507038|Experimental|Group A|
88900121|NCT01507038|Experimental|Group B|
88900122|NCT01507038|Experimental|Group C|
88900123|NCT01507038|Placebo Comparator|Group D|
88900124|NCT01507064|Active Comparator|Group A|Patients who undergo to LA without sorafenib pretreatment
88900125|NCT01507064|Experimental|Group B|Patients who are treated with sorafenib before LA
88900126|NCT01507077|Placebo Comparator|ZGN-440 sterile diluent|
88900127|NCT01507077|Experimental|ZGN-440|
88900128|NCT01507116||People with Diabetes|
88900129|NCT01507116||Family Members|
88900130|NCT01507116||Healthcare Professionals|
88900131|NCT01507142||cART-unresponsive AIDS|HIV-positive, AIDS diagnosis, cART for >18 months, <200 CD4 Tcells/mm3 and Viral Load >5000 copies/ml
88900132|NCT01507142||cART-responsive AIDS|HIV-positive, AIDS diagnosis, cART for >18 months, >350 CD4 Tcells/mm3 and Viral Load<50 copies/ml
88900133|NCT01507142||Acute or early HIV infection|Acute HIV: Acute retroviral syndrome, Negative or positive HIV antibody, Positive HIV p24gag, viral load or NAAT / Early HIV: HIV antibody and viral load positive currently, negative in last 12 months, No clinical or immunological evidence of advanced HIV disease
88900134|NCT01507142||HIV-negative Hepatitis B|Negative HIV antibody and viral load, Positive HBV antibody, Positive or Negative HBV surface antigen, Negative or Positive HBV viral load
88900135|NCT01507168|Placebo Comparator|Placebo|
88900136|NCT01507168|Experimental|GC33 (RO5137382)|
88900137|NCT01507194|Active Comparator|Ondansetron 4 mg|
88900138|NCT01507194|Experimental|Vestipitant 6 mg|
88900139|NCT01507194|Experimental|Vestipitant 12 mg|
88900140|NCT01507194|Experimental|Vestipitant 18 mg|
88900141|NCT01507194|Experimental|Vestipitant 24 mg|
88900142|NCT01507194|Experimental|Vestipitant 36 mg|
88900143|NCT01507259||100 g containing 70% or 34% cocoa|Healthy controls
88900144|NCT01507272|Experimental|NNC 90-1170 (liraglutide)|
88900145|NCT01507272|Placebo Comparator|Placebo|
88900146|NCT01507311|Experimental|NNC 90-1170|
88900147|NCT01507311|Placebo Comparator|Placebo|
88900148|NCT01507337|Experimental|Elderly|
88900149|NCT01507337|Experimental|Young|
88900150|NCT01507363|Active Comparator|"Gabapentin high"|Tables with Gabapentin (1300 mg/day) for 7 days, starting on the day of surgery
88900151|NCT01507363|Active Comparator|"Gabapentin intermediate"|Tables with Gabapentin for 7 days (900 mg/day), starting on the day of surgery
88900152|NCT01507363|Placebo Comparator|Placebo|Placebo tablets for 7 days, starting on the day of surgery
88900153|NCT01507376|Experimental|A: recombinant hCG(250 µg Ovitrell)|1- Group A consisted of 60 infertile women who received recombinant hCG(250 µg Ovitrelle)
89194389|NCT04645394|Active Comparator|Fermented aronia high dose|The participants are receiving 1 dose of each in the stated order.
89194390|NCT04645394|Active Comparator|Fermented aronia low dose|The participants are receiving 1 dose of each in the stated order.
89194391|NCT04645394|Active Comparator|Aronia|The participants are receiving 1 dose of each in the stated order.
89194392|NCT01589029|Other|CANAKINUMAB (ILARIS®)|
89194393|NCT00877786|Active Comparator|Face-to-face group therapy|
89194394|NCT00877786|Active Comparator|Online chat group therapy|
89194395|NCT02568332|Experimental|Group 1|"Interventions: AdCh3NSmut1, MVA-NSmut. Administration schedule: 1 dose AdCh3NSmut1 2.5 x 10^10 vp at week 0 and 1 dose MVA-NSmut 2 x 10^8 pfu at week 8.~Subjects: 20 HIV seropositive individuals"
89194396|NCT01033669||Dry Powder Inhalers|
89194397|NCT00872638|Active Comparator|1|
89420502|NCT03514485|Active Comparator|P+ (Non-Partner School)|This arm includes children who do not attend one of the partnering schools and who are randomized to receive the primary care intervention Yes We Can Children's Asthma Program.
88900154|NCT01507376|Experimental|B: recombinant hCG(500 µg Ovitrell)|2- Group B consisted of 60 infertile women who received recombinant hCG(500 µg Ovitrelle)
88900155|NCT01507376|Experimental|C: urinary hCG|3- Group C consisted of 60 infertile patients received 10,000 IU urinary hCG
88900156|NCT01507389|Experimental|Mild|
88900157|NCT01507389|Experimental|Moderate|
88900158|NCT01507389|Experimental|Severe|
89194398|NCT00872638|Active Comparator|2|
89194399|NCT00877864|Active Comparator|High volume combined aerobic/resistance exercise|
89194400|NCT00877864|Active Comparator|Low volume combined aerobic/resistance exercise|Low volume combined aerobic/resistance exercise
89194401|NCT00877864|Active Comparator|High volume combined A/R exercise, printouts, pedometers|High volume combined aerobic/resistance exercise, printouts, pedometers
89194402|NCT00877864|Active Comparator|Low volume combined A/R exercise, printouts, pedometers|Low volume combined aerobic/resistance exercise, printouts, pedometers
89194403|NCT00877864|Active Comparator|Printed PA information, pedometers and step log group|Printed physical activity information, pedometers and step log group
89194404|NCT00877864|Placebo Comparator|Control|
89194405|NCT00877942||1|Typically developing children drawn from the general population
89194406|NCT00877942||2|Children with Turner Syndrome
89194407|NCT00736736|Active Comparator|Leg Press|Leg Press exercise for 3 times/week and sustain for 8 weeks.
89194408|NCT00736736|Experimental|Hip Exercise|Additional hip abductor and hip external rotator strength training to leg press exercise for people in this group. All participants received exercise for 3 times per week for 8 weeks.
88900159|NCT01507389|Experimental|Normal|
88900160|NCT01507402|Experimental|Cohort 1|Dose regimen 1 (Participants 18 to ≤ 65 yrs old)
88900161|NCT01507402|Experimental|Cohort 2|Dose regimen 2 (Participants 18 to ≤ 65 yrs old)
88900162|NCT01507402|Experimental|Cohort 3|Dose regimen 3 (Participants 18 to ≤ 65 yrs old)
88900163|NCT01507402|Experimental|Cohort 4|Dose regimen 4 (Participants 18 to ≤ 65 yrs old)
89194409|NCT00736736|No Intervention|Control|Education was given during 8 weeks of study period. After 8 weeks of study, exercise was given as compensation.
89194410|NCT00864448|Experimental|A|Ramipril10 mg Capsules, single dose
89194411|NCT00864448|Active Comparator|B|Atlace® 10 mg capsules, single dose
89194412|NCT00406315|Other|A1|atypical antipsychotic for the treatment of schizophrenia
89194413|NCT00872716|Experimental|Quetiapine XR|100 mg single-dose Quetiapine XR
89194414|NCT00872716|Placebo Comparator|Placebo|
89194415|NCT05740826||Study group|People with temporomandibular disorder which was determined based on one of the following factors observed during the examination: acoustic symptoms, present temporomandibular joint pain, problems with opening the mouth, deviation of the jaw during abduction, or reported locking of the jaw.
89194416|NCT05740826||Control group|People without temporomandibular disorder.
89194417|NCT00864526|Experimental|A|Oxycodone HCl 5 mg / Ibuprofen 400 mg tablets, single dose
89194418|NCT00864526|Active Comparator|B|COMBONOX® tablets, single dose
89194419|NCT02568410||CABG on CPB|Patients undergoing elective coronary artery bypass grafting using cardiopulmonary bypass. No study interventions beyond the standard clinical practice for these surgeries at Duke University Medical Center. No study drug administration.
89194420|NCT00864604|Experimental|A|Nabumetone 750 mg tablets, single dose
89194421|NCT00864604|Active Comparator|B|Nabumetone 750 mg tablets, single dose
89194422|NCT04064138|Active Comparator|Peritoneal block|patients will receive peritoneal block as an adjuvant analgesic technique.
89194423|NCT04064138|Active Comparator|Ultrasound guided erector spinae plane block|Patients will receive ultrasound guided erector spinae plane block
89194424|NCT01323751|Experimental|Treat Regimen|ACY-1215 Bortezomib Dexamethasone
88819883|NCT04080843|Experimental|Group A|"Patients in the study group will receive the following treatment:~21 days as a treatment cycle, Anlotinib 12 mg/day, Orally(D1-D14); Capecitabine 850 mg/m2,Orally(D1-D14), Bid; Oxaliplatin 130 mg/m2, iv(D1).~If anlotinib is not tolerated(except Hand-foot skin reaction), the dose can be reduced to 10mg or 8mg ,until un-tolerable toxicity again. After 6 cycles of combined therapy, patients will receive capecitabine and anlotinib as maintenance therapy until tumor progression."
88900164|NCT01507402|Experimental|Cohort 5|Dose regimen 5 (Participants 18 to ≤ 65 yrs old)
89194425|NCT00878020|Active Comparator|Arm 1|BMS-830216 (10 mg)
89194426|NCT00878020|Active Comparator|Arm 2|BMS-830216 (30 mg)
88819884|NCT04076397|Other|lipofilling group|"Patient will conduct a total of 4 visits: D15, M1, M3, M6 during which they will have: a clinical examination as well as the following evaluations:~Make EVA (evaluation of the pain),~Complete DASH questionnaire~Complete DN4 questionnaire~Patients in the lipofilling group will also have:~the repair of the last dressing during the consultation at J15~Ablation of any threads~Control of the digital and abdominal scar~Making a photo of their finger at V1 and M6"
88819885|NCT04076397|Other|desensitization group|"Patient will conduct a total of 4 visits: D15, M1, M3, M6 during which they will have: a clinical examination as well as the following evaluations:~Make EVA (evaluation of the pain),~Complete DASH questionnaire~Complete DN4 questionnaire"
88819886|NCT05141253|Experimental|RD133 treatment group|"Administration of RD133 Three dose groups of 1.0×10^6 CAR-T/kg, 3.0×10^6 CAR-T/kg, and 6.0×10^6 CAR-T/kg RD133 are designed in this study. 3 to 6 subjects are expected to be enrolled in each dose group according to observed DLT.~RD133 will be intravenously infused at least 24 hours after lymphodepletion preconditioning. According to the assigned dose group, the designated dose of RD133 will be infused in a single infusion within 30 minutes on day 0."
88819887|NCT05457309|Experimental|malignant fungating wounds care regimen|malignant fungating wounds care regimen based on the evidences, expert consultation, pre-experiment and final determination
88819888|NCT04334265|Experimental|Anluohuaxian combined with regular treatment group|Anluohuaxian: 6g each time, twice a day
88819889|NCT04334265|No Intervention|regular treatment group|
88819890|NCT05457231|Experimental|CST-SF group|The feedback process was as follows. Feedback was given after each interview, including brief feedback and SF. Brief feedback was provided by the clinical instructor based on the Gap-Kalamazoo Communication Skills Assessment Form immediately after each interview. Within two weeks after the first and second interviews, the interns received SF from experts and clinical instructors based on the Communication Skills Measure for Therapist. The SF of the third interview could not be completed because the internship had ended.
88819891|NCT04866849||STUDY GROUP|"patient diagnosed with bruxism The presence of bruxism was based on self-reported bruxism and examination. Self reported bruxism was recorded as yes or no . Participants were examined for the existence of four clinical signs of bruxism: (I) abnormal tooth wear, (II) impressions of teeth in the buccal area, (III) impressions of teeth on the tongue, and (IV) hypertrophy of the masseter muscle. In this study, clinical signs of bruxism were considered present if one of the four items was answered yes."
88819892|NCT04866849||CONTROL GROUP|healthy volunteers
88819893|NCT05457153|Experimental|Technology-Based Well-Being Process Program|"WEBEPROP will be conducted for 8 weeks. The program for the intervention group is included the modüls. In the program, the modules of Self-Knowledge, Inner Communication and Awareness of Perceptions, Emotion and Thought Management will be completed in 8 weeks (each model two weeks) . The other module will not be accessible and cannot be switched before the prevous module is completed."
88819894|NCT05457153|Active Comparator|Control Group|After the first follow-ups have been made to the control group, they will continue to receive standard care. After the monitoring of the initiative group within the scope of the program is completed, the website of the well-being process program will be made available to the control group. Children and adolescents will benefit from the modules by promoting the website.
88819895|NCT04737837||children|Children aged 4~16 years with focal onset seizures
88819896|NCT04737837||Adult|Adults aged >16 years with focal onset seizures
88819897|NCT05456919||BRCA Mutated and no RRS|
88819898|NCT05456919||BRCA Mutated and RRS|
88819899|NCT05456919||BRCA Mutated and oncological diagnosis|
88819900|NCT05456919||BRCA Wildtype without oncological diagnosis|
88819901|NCT04737447|Active Comparator|Group A (Control Group)|20 participants treated with standardized urophysiotherapy twice a week, once for 45 Minutes and then for 15 Minutes. Urophysiotherapy is a well manifested and standardized therapy in the treatment für children's incontinence after the age of five years.
88819902|NCT04737447|Active Comparator|Group B (Study Group)|20 participants treated with standardized urophysiotherapy and Whole Body Vibration training (WBVT). These patients are treated with the standardized urophysiotherapy once a week and furthermore they train with WBVT twice a week for each time 15 minutes. Criteria for modifying the device utilization are based on participant's age and therapy progress. The utilized frequency of the device is individually adapted to the participant. Older patients (> ten years old) are allowed to higher frequency standards than younger participants (< 10 years old). The amplitude (0.5 mm - 2 mm) is alternated to the participant's age and height. If side effects occur (e.g. dizziness), frequency can be alternated. The intended frequency level is between 10 an 20 Hz.
88819903|NCT04774809|Active Comparator|SHR0302 Low Dose|Drug: SHR0302 SHR0302 Ointment BID Low Dose
88819904|NCT04774809|Active Comparator|SHR0302 High Dose|Drug: SHR0302 SHR0302 Ointment BID High Dose
88819905|NCT04774809|Placebo Comparator|Placebo Comparator: Vehicle|Drug: vehicle Vehicle BID Placebo
88819906|NCT05456763|Experimental|group A|150 mg sodium butyrate twice a day for 12 weeks
88819907|NCT05456763|Placebo Comparator|group B|placebo capsules twice a day for 12 weeks
88819908|NCT02958657|Experimental|Exercise Training|Patients randomized to the training group will start the supervised regular training program 01 month after the myocardial infarction, and it will last for three months.
88819909|NCT02958657|No Intervention|Control Group|Patients in the control group will receive general instructions regarding rehabilitation post-acute myocardial infarction and will be followed for four months after the myocardial infarction.
88819910|NCT05456451|Experimental|Parkinson group(pre and post treatment)|5 participants will be evaluated for tremor and autonomic dysfunction at pre and post treatment
88900165|NCT01507402|Experimental|Cohort 6|Dose regimen 6 (Participants 18 to ≤ 65 yrs old)
88900166|NCT01507402|Experimental|Cohort 7|Dose regimen 7 (Participants 18 to ≤ 65 yrs old)
88900167|NCT01507402|Experimental|Cohort 8|Dose regimen 3 (Participants > 65 to ≤ 85 yrs old)
88900168|NCT01507402|Experimental|Cohort 9|Dose regimen 9 (Participants 18 to ≤ 65 yrs old)
88900169|NCT01507415||Exacerbation|Patients with Chronic Obstructive Pulmonary Disease (COPD)
88900170|NCT01507428|Active Comparator|Arm I (standard chemoradiotherapy)|Patients undergo radiotherapy QD 5 days a week for 30 fractions. Patients also receive paclitaxel IV over 1 hour and carboplatin IV over 30 minutes once weekly for 6 weeks. Patients undergo FDG-PET/CT imaging between fractions 18 and 19.
88900171|NCT01507428|Experimental|Arm II (experimental chemoradiotherapy)|Patients undergo an individualized dose of image-guided radiotherapy QD 5 days a week for 30 fractions and undergo 18 F FDG-PET/CT between fractions 18 and 19. Based on the scan results, patients undergo individualized adaptive radiotherapy for the final 9 fractions. Patients also receive paclitaxel and carboplatin as in Arm I.
88900172|NCT01507454||Local treatment|
88900173|NCT01507467|Active Comparator|Accl. RT|Accelerated Radiotherapy 66-70 Gy, 2Gy/fx, 6fx/week
88900174|NCT01507467|Experimental|Accl. RT + Nimorazole|Accelerated Radiotherapy 66-70 Gy, 2Gy/fx, 6fx/week + Nimorazole
88900175|NCT01507480|Experimental|Bevacizumab|This study is to be carried out sequentially (dose escalation) on 5 groups of 8 patients. Each group is made up of 6 verum and 2 placebos.
88900176|NCT01507506|Active Comparator|Conventional arm|3-dimensional conformal radiotherapy + Temozolomide
88900177|NCT01507506|Experimental|Experimental arm|simultaneous-integrated boost with intensity-modulated radiotherapy guided by magnetic resonance spectroscopic imaging + Temozolomide
88900178|NCT01507519|Experimental|BioMime™|BioMime™ DES
88900179|NCT01507532|Other|Ceftazidime|pharmacokinetic monitoring
88900180|NCT01507558|Experimental|Intervention|Perivascular administration of dexamethasone following endovascular superficial femoral and popliteal artery angioplasty or atherectomy.
88900181|NCT01507571|Experimental|Dignity Therapy|
88900182|NCT01507597|Other|Healthy Subjects|
88900183|NCT01507597|Other|T2DM|
88900184|NCT01507597|Other|T1DM|
88900185|NCT01507623|Experimental|With Capnograpy|Intervention group with the addition of capnography to standard monitoring (non-invasive blood pressure, pulse, pulse oximetry, clinical observation of respiration, electrocardiography (ECG) and respiratory frequency measured by the ECG)
88900186|NCT01507623|No Intervention|No Capnography|Control group without the addition of capnography to standard monitoring (non-invasive blood pressure, pulse, pulse oximetry, clinical observation of respiration, electrocardiography (ECG) and respiratory frequency measured by the ECG)
88900187|NCT01507636|Active Comparator|Group 1|Occupational therapy using a special arm function training.
88900188|NCT01507636|Active Comparator|Group 2|Physical therapy using the Theraband for training of force.
88900189|NCT01507649|No Intervention|Control|
89194427|NCT00878020|Active Comparator|Arm 3|BMS-830216 (100 mg)
89194428|NCT00878020|Active Comparator|Arm 4|BMS-830216 (300 mg)
88900190|NCT01507649|Experimental|Telephone-based intervention|
88900191|NCT01507675||Military Veterans|Participants will be recruited from the Denver VA Medical Center (DVAMC), regardless of clinic.
88900192|NCT01507701|Experimental|Clonidine|
88900193|NCT01507714|No Intervention|control arm|vaginal wall repair surgery will be done to women in this arm, with no treatment for stress incontinence
88900194|NCT01507714|Active Comparator|TVT-O arm|the women in this arm will have a TVT-O procedure in addition to the vaginal wall repair
88900195|NCT01507727|Experimental|Drug: Tolvaptan|
88900196|NCT01507727|Placebo Comparator|Drug: Placebo|
88900197|NCT01507740||1|Control group n=20
88900198|NCT01507740||2|investigational group (cancer patients) n=40 patients treated with antiangiogenic agent
88900199|NCT01507753|Placebo Comparator|Placebo Supplement and No PEP|Will receive two capsules by mouth, two times daily matched for odor and appearance with the active intervention.
88900200|NCT01507753|Experimental|Omega-3 and PEP|"Omega-3 Supplementation will receive 1000 mg Ω3 (two 500 mg capsules, each containing 350 mg EPA: 50 mg DHA; 100 other Ω3)by mouth, two times daily.~Psychoeducational Psychotherapy (PEP)Therapy sessions occur twice a week for up to 24 sessions of manualized treatment."
88900201|NCT01507753|Experimental|Omega-3 and No PEP|Omega-3 Supplementation will receive 1000 mg Ω3 (two 500 mg capsules, each containing 350 mg EPA: 50 mg DHA; 100 other Ω3)by mouth, two times daily.
88900202|NCT01507753|Experimental|Placebo Supplement and PEP|"Placebo Supplement will receive two capsules by mouth, two times daily matched for odor and appearance with the active intervention.~Psychoeducational Psychotherapy (PEP)Therapy sessions occur twice a week for up to 24 sessions of manualized treatment."
88900203|NCT01507766|Experimental|Early enteral nutrition|The enteral nutrition was started within 48h after admission
88900204|NCT01507766|Active Comparator|Delayed enteral nutrition|The enteral nutrition was started at the 8th day after admission
88900205|NCT01507805|Experimental|EA preconditioning|electroacupuncture five days pre-operation
88900206|NCT01507805|Sham Comparator|Sham EA preconditioning|Patients treated with sham EA preconditioning Intervention
88900207|NCT01507818|Active Comparator|Ivivi Torino II|Active treatment with Non-thermal Pulsed Radio Frequency device
88900208|NCT01507818|Sham Comparator|Inactive Sham|Sham treatment
88900209|NCT01507844|Sham Comparator|ventilation|
88900210|NCT01507857|Experimental|400U /0.5ml in infants|inactivated vaccine(vero cell) against EV71 of 400U /0.5ml in 5000 infants aged 6-35 months old on day0,28
88900211|NCT01507857|Placebo Comparator|0/0.5ml placebo in infants|0/0.5ml placebo in 5000 infants aged 6-35 months old on day0,28
88900212|NCT01507870|Active Comparator|prophylactic onlay mesh|
88900213|NCT01507870|No Intervention|continuous running suture|continuous running suture of the linea alba
88900214|NCT01507883||human oocytes/embryos|Sibling oocytes cultured in single or sequential media until day6
89194429|NCT00878020|Active Comparator|Arm 5|BMS-830216 (600 mg)
89194430|NCT00878020|Active Comparator|Arm 6|BMS-830216 (1200 mg)
89420503|NCT03514485|No Intervention|P- (Non-Partner School)|This arm includes children who do not attend one of the partnering schools and who are randomized to the control group (no primary care intervention and ineligible for the school intervention).
89420504|NCT03502200|Experimental|E-cigarette|5% nicotine JUUL e-cigarette (Tobacco or Menthol flavor). Will also receive counseling.
89420505|NCT03502200|Active Comparator|Treatment As Usual|Nicotine Replacement Therapy consisting of nicotine patches and lozenge along with standard assessments. Will also receive counseling.
89420506|NCT03336242|Experimental|Cohort 1: Cannabidiol Oral Solution 20 mg/kg/day|Treatment Period: Cannabidiol Oral Solution 20 milligrams per kilogram per day (mg/kg/day) divided twice daily (BID) for 4 weeks.
89420507|NCT03336242|Experimental|Cohort 2: Cannabidiol Oral Solution 30 mg/kg/day|"Titration Period: Cannabidiol Oral Solution 20 mg/kg/day divided BID for 5 days.~Treatment Period: Cannabidiol Oral Solution 30 mg/kg/day divided BID for 4 weeks."
89420508|NCT03336242|Experimental|Cohort 3: Cannabidiol Oral Solution 10 mg/kg/day|Treatment Period: Cannabidiol Oral Solution 10 mg/kg/day divided BID for 4 weeks.
89420509|NCT03334435|Placebo Comparator|Responders and Partial Responders (RPR)-Placebo|Responders or partial responders (RPR) [Investigator's Global Assessment (IGA) of (0,1, or 2) at entry to study JAHN and never rescued in originating study] participants from previous Baricitinib monotherapy studies-JAHL and JAHM and combination therapy study-JAIY were assigned to remain in this arm to receive placebo orally.
89420510|NCT03334435|Experimental|RPR-Bari 1-milligram (mg)|RPR participants from previous Baricitinib monotherapy studies-JAHL and JAHM were assigned to remain in this arm to receive Baricitinib 1 mg orally.
89420511|NCT03334435|Experimental|RPR-Bari 2-mg|RPR participants from previous Baricitinib monotherapy studies-JAHL and JAHM and combination therapy study-JAIY were assigned to remain in this arm to receive Baricitinib 2 mg orally.
89420512|NCT03334435|Experimental|RPR-Bari 4-mg|RPR participants from previous Baricitinib monotherapy studies-JAHL and JAHM and combination therapy study-JAIY were assigned to remain in this arm to receive Baricitinib 4 mg orally.
89420513|NCT03334435|Experimental|Non-responders (NR): Bari 1 mg to 2 mg|Non-responder (NR) [those not meeting definition of RPR] participants from previous Baricitinib monotherapy studies-JAHL and JAHM who received Baricitinib 1 mg and were re-randomized to this arm to receive Baricitinib 2 mg orally.
89420514|NCT03334435|Experimental|NR: Bari 1 mg to 4 mg|NR participants from previous Baricitinib monotherapy studies-JAHL and JAHM who received Baricitinib 1 mg and were re-randomized to this arm to receive Baricitinib 4 mg orally.
89420515|NCT03334435|Experimental|NR: Bari 2 mg to 2 mg|NR participants from previous Baricitinib monotherapy studies-JAHL and JAHM and combination therapy study-JAIY who received Baricitinib 2 mg and were re-randomized to this arm to receive Baricitinib 2 mg orally.
89420516|NCT03334435|Experimental|NR: Bari 2 mg to 4 mg|NR participants from previous Baricitinib monotherapy studies-JAHL and JAHM and combination therapy study-JAIY who received Baricitinib 2 mg and were re-randomized to this arm to receive Baricitinib 4 mg orally.
89420517|NCT03334435|Experimental|NR: Bari 4 mg to 4 mg|NR participants from previous Baricitinib monotherapy studies-JAHL and JAHM and combination therapy study-JAIY who received Baricitinib 4 mg and were re-randomized to this arm to receive Baricitinib 4 mg orally.
89420518|NCT03334435|Experimental|NR: Placebo to Bari 2 mg|NR participants from previous Baricitinib monotherapy studies-JAHL and JAHM and combination therapy study-JAIY who received placebo and were re-randomized to this arm to receive Baricitinib 2 mg orally.
89420519|NCT03334435|Experimental|NR: Placebo to Bari 4 mg|NR participants from previous Baricitinib monotherapy studies-JAHL and JAHM and combination therapy study-JAIY who received placebo and were re-randomized to this arm to receive Baricitinib 4 mg orally.
89420520|NCT03334435|Placebo Comparator|Placebo|Participants from previous Baricitinib monotherapy studies (JAHL, JAHM) and combination therapy study (JAIY) were randomized or assigned to this arm to receive placebo orally.
89420521|NCT03334435|Experimental|Bari 1 mg|Participants from previous Baricitinib monotherapy studies (JAHL, JAHM) were randomized or assigned to this arm to receive Baricitinib 1 mg orally.
89420522|NCT03334435|Experimental|Bari 2 mg|Participants from previous Baricitinib monotherapy studies (JAHL, JAHM) and combination therapy study (JAIY) were randomized or assigned to this arm to receive Baricitinib 2 mg orally.
89420523|NCT03334435|Experimental|Bari 4 mg|Participants from previous Baricitinib monotherapy studies (JAHL, JAHM) and combination therapy study (JAIY) were randomized or assigned to this arm to receive Baricitinib 4 mg orally.
89420524|NCT03334435|Experimental|Bari 2-mg Open-Label Addendum|Participants were directly enrolled to this open-label arm to receive Baricitinib 2-mg orally.
89420525|NCT03333395|Active Comparator|HS Group (study group)|
89420526|NCT03333395|Active Comparator|S Group (control group)|
89420527|NCT03328104|Experimental|Everolimus in combination with standard chemotherapy|A treatment course lasts 28 days, during which participants take everolimus by mouth every day and also get standard chemotherapy via IV on certain days.
89420528|NCT03327519|Experimental|SHUTi|Self-guided, automated, interactive, and tailored web-based program
89420529|NCT03327519|Experimental|Emmi|A program that is an animated online video that walks patients through important information about a health topic, condition or procedure.
89420530|NCT03300284||Thyroid cancer|This study does not involve any intervention, but rather data collection on patient and physician preferences and beliefs, communication, and patient psychological outcomes.
89420531|NCT03260400|Experimental|New Grafts|In this arm, participants will have an initial surgery to place partial muscle grafts on the amputated nerves. After a healing period, the participant will have a shorter surgical procedure to implant the electrodes onto the muscle grafts and in residual muscles. After another healing period, experiments with prosthetic control and sensory feedback will begin.
89420532|NCT03260400|Experimental|Existing Grafts|In this arm, participants have already had partial muscle grafts placed on the amputated nerves to control neuroma growth. The participant will have a short surgical procedure to implant the electrodes onto the muscle grafts and in residual muscles. After a healing period, experiments with prosthetic control and sensory feedback will begin.
88900215|NCT01507922|Experimental|Fenoverine|Fenoverine 100mg three times a day will be administered for 8 weeks.
89420533|NCT03239496|Experimental|Group A|3 doses IPV IM at 10, 14 & 36 weeks of age incl. blood sampling at 10, 14, 18 & 40 weeks.
88900216|NCT01507922|Active Comparator|Trimebutine|Trimebutine maleate 150mg three times a day will be administered for 8 weeks.
88900217|NCT01507935|Active Comparator|Intervention Group I|Healthy infants receiving regular non-hydrolysed cow's milk based infant formula with added prebiotic oligosaccharides mixture I
88900218|NCT01507935|Active Comparator|Intervention Group II|Healthy infants receiving regular non-hydrolysed cow's milk based infant formula with added prebiotic oligosaccharides mixture II
88900219|NCT01507935|Placebo Comparator|Control Group|Healthy infants receiving regular non-hydrolysed cow's milk based infant formula with the same composition as the Investigational Formulas but without supplementation of prebiotic oligosaccharides
88900220|NCT01507935|No Intervention|Reference group|Exclusively breast-fed infants
88900221|NCT01507948|Experimental|Immediate Prolonged Exposure Treatment|Intake procedures include clinician-administered diagnostic battery, cognitive testing, self-report measures of symptoms, and functional imaging scan. Participants in this arm will complete a concurrent TMS/fMRI scan before beginning Prolonged Exposure (PE). PE will be delivered in 9-12 90-minute sessions. Therapy will be delivered by PhD-level therapists at Stanford and Palo Alto VA.
88900222|NCT01507948|No Intervention|Wait list, immediately followed by Prolonged Exposure|Intake procedures include clinician-administered diagnostic battery, cognitive testing, self-report measures of symptoms, and functional imaging scan. NOTE: Participants in this arm receive treatment following a waitlist period of 12 weeks. After waitlist, will have a TMS/fMRI scan and then immediately begin Prolonged Exposure treatment. See above for description of Prolonged Exposure.
88900223|NCT01507974|No Intervention|control arm|The women in this arm will not receive preventive antibiotic treatment after delivery
88900224|NCT01507974|Active Comparator|preventive antibiotic treatment|The women in this arm will receive preventive antibiotic treatment after the delivery to 6 weeks
88900225|NCT01508000|Active Comparator|Arm A: modified FOLFOX6 and Surgery|"6 cycles before and 6 cycles after surgery consisting in:~Hour 0: Oxaliplatin 85 mg/m² IV 2-h infusion~Hour 0: Folinic Acid 400 mg/m² (DL form) or 200 mg/m2 (L form) IV 2-h infusion~Hour 2: 5-FU 400 mg/m² IV bolus over 2-4 minutes~Hour 2: 5-FU 2400 mg/m² given as a continuous infusion over 46h.~On day 1 of a 14 day cycle"
88900226|NCT01508000|Experimental|Arm B: modified FOLFOX6 + Bevacizumab and Surgery|"6 cycles before and 6 cycles after surgery consisting in:~Hour 0: Oxaliplatin 85 mg/m2 2-h infusion~Hour 0: Folinic Acid 400 mg/m2 (DL form) or 200 mg/m2 (L form) 2-h infusion~Hour 2 (before 5-FU bolus): Bevacizumab 5 mg/kg IV over 90 minutes infusion*.~Hour 3.5: 5-FU bolus 400 mg/m2 IV bolus over 2-4 minutes~Hour 3.5: 5-FU 2400 mg/m² given as a continuous infusion over 46h.~On day 1 of a 14 day cycle"
88900227|NCT01508000|Experimental|Arm C: modified FOLFOX6 + Panitumumab and Surgery|"Experimental: Arm B: modified FOLFOX6 + Bevacizumab and Surgery~6 cycles before and 6 cycles after surgery consisting in:~Hour - 1 (pre chemotherapy): Panitumumab 6 mg/kg IV over 60 minutes (≤ 1000 mg) or 90 minutes (> 1000 mg) +/- 15 min. infusion*.~Hour 0: Oxaliplatin 85 mg/m² IV 2-h infusion~Hour 0: Folinic Acid 400 mg/m² (DL form) or 200 mg/m2 (L form) IV 2-h infusion~Hour 2: 5-FU 400 mg/m² IV bolus over 2-4 minutes~Hour 2: 5-FU 2400 mg/m² given as a continuous infusion over 46h.~On day 1 of a 14 day cycle"
88900228|NCT01508039|Experimental|Treatment with chitin micro-particles|The study will involve 14-healthy subjects confirming to the inclusion criteria randomised to the treatments.
88900229|NCT01508065||controlled type one diabetes mellitus.|
88900230|NCT01508091|Experimental|Calorie restricted|25 % calorie restriction respect measured total energy expenditure, using a Mediterranean diet
88900231|NCT01508104|Experimental|BEZ235 and Everolimus|
88900232|NCT01507610|Experimental|Investigational|OPTINOSE SUMATRIPTAN, single dose of 20 mg intranasally (10 mg to each nostril).
88900233|NCT01507610|Active Comparator|IMITREX Nasal Spray|IMITREX® (sumatriptan) Nasal Spray, single dose of 20 mg intranasally (20 mg to one nostril).
88900234|NCT01507610|Active Comparator|IMITREX Oral Tablet|IMITREX® (sumatriptan) Oral Tablet, single dose of 100 mg, administered orally with 240 mL water.
88900235|NCT01507610|Active Comparator|IMITREX Subcutaneous Injection|IMITREX® (sumatriptan) Subcutaneous Injection, single dose of 6 mg injected subcutaneously in the abdomen.
88900236|NCT01508143|Experimental|400 microgram misoprostol|400 micrograms misoprostol each 6 hours for 8 dose
88900237|NCT01508143|Active Comparator|800 micrograms misoprostol|800 micrograms misoprostol each 12 hours for 4 dose
88900238|NCT01508156|Experimental|Group A: Healthy Participants|Healthy participants take IDX719 (5 mg - 100 mg) or matching placebo by mouth as either 1 single dose or as 7 daily doses.
88900239|NCT01508156|Experimental|Group B: HCV Participants|Treatment-naive participants infected with HCV genotype (GT) 1, GT2, or GT3 take IDX719 (1 mg - 100 mg) or matching placebo as either 1 single dose or as 7 daily doses.
89194431|NCT05741996|Experimental|Effetcs of Taping type and Orthosis on Pain,|The order of the elastic taping, rigid taping, and braces was randomized using a computer-generated random sequence created before the research (Random.org). Both knees of each participant were taped and braced. The participants were allowed to become accustomed to the applied elastic taping, rigid taping, and braces before the gait analysis and evaluations. All the taping techniques and braces were similar for all the participants. The participants performed four evaluation condition trials at baseline and with the elastic taping, rigid taping, and braces after 45 minutes.
88900240|NCT01508182|Experimental|Treatment Sequence AB|Treatment A (canaglifozin + metformin IR tablets) administered on Day 1 of Treatment Period 1 followed by Treatment B (canagliflozin/metformin IR FDC tablets) administered on Day 1 of Treatment Period 2 with a washout period of 10-15 days between Treatment Periods.
88900241|NCT01508182|Experimental|Treatment Sequence BA|Treatment B (canagliflozin/metformin IR FDC tablets) administered on Day 1 of Treatment Period 1 followed by Treatment A (canaglifozin + metformin IR tablets) administered on Day 1 of Treatment Period 2 with a washout period of 10-15 days between Treatment Periods.
89194432|NCT05741996|Experimental|Effetcs of Taping type and Orthosis on Gait and functionality|"The Western Ontario and McMaster Universities Turkish Version 3.1 (WOMAC) index is a self-administered questionnaire that assesses three aspects of a patient's health status -pain, stiffness, and physical function - in those with lower limb Osteoarthritis.~Gait analysis was conducted using a 3-dimensional VICON gait analysis system (Workstation Version 4.0, Oxford, UK). Each participant was assessed four times before and after the applications."
89194433|NCT00872794|Other|DePuy ASR Hip System|A metal-on-metal bearing surface replacement system for use in resurfacing hip arthroplasty.
89194434|NCT00878176|Experimental|1|(Crossover study)
89194435|NCT00711594|Experimental|BIBW 2992 MA2|Phase I step: Find maximum tolerated dose of the non-marketed substance:BIBW 2992 given orally. Escalating doses of BIBW 2992 starting at 20mg daily.
89194436|NCT00711594|Experimental|BIBW 2992 QD|Phase II step: Patients start continuous once daily oral treatment of BIBW 2992 at high dose, until progression or undue Adverse Events (AEs) develop. Patients can be dose-reduced up to two times if needed after temporary discontinuation of treatment due to drug-related AEs.
89194437|NCT02543866|Experimental|Fecal Microbiota Transplantation|Subjects will receive 50mL of prepared stool fecal via nasogastric tube
89194438|NCT00872872|Active Comparator|AZT/3TC 1 week after delivery|AZT/3TC 1week after delivery
89194439|NCT00872872|Experimental|AZT/3TC 2 weeks after delivery|AZT/3TC 2 weeks after delivery
89194440|NCT00864760|Experimental|A|Gabapentin 800 mg tablets, single dose (1 tablet)
89194441|NCT00864760|Active Comparator|B|NEURONTIN® 400 mg capsules, single dose (2 capsules)
89194442|NCT00878332||partially edentulous patients|"Adult (post growth period) patients who are interested in fixed dental rehabilitation (non- removable denture) by dental implants.~Partially edentulous patients with insufficient bone height for dental implant insertion."
89194443|NCT00710762|Experimental|BIBF1120|
89194444|NCT00710762|Placebo Comparator|Placebo|
88900242|NCT01508195|Experimental|Treatment Sequence AB|Treatment A (canaglifozin + metformin IR tablets) administered on Day 1 of Treatment Period 1 followed by Treatment B (canagliflozin/metformin IR FDC tablets) administered on Day 1 of Treatment Period 2 with a washout period of 10-15 days between treatment periods.
88900243|NCT01508195|Experimental|Treatment Sequence BA|Treatment B (canagliflozin/metformin IR FDC tablets) administered on Day 1 of Treatment Period 1 followed by Treatment A (canaglifozin + metformin IR tablets) administered on Day 1 of Treatment Period 2 with a washout period of 10-15 days between treatment periods.
88900244|NCT01508208|Other|Hypertensive disorder of pregnancy|Patients with an hypertensive disorder of pregnancy (28 weeks or more of gestation)will collect a random sample of urine for a spot test (protein/creatinine ratio) and urine for 24 hours. The level of proteinuria will be determined in this sample.
88900245|NCT01508247|Experimental|vaccine against EV71|Inactivated vaccine (Vero Cell) against EV71 of 320U /0.5ml in 5000 children aged 6-35 months on day0, 28
88900246|NCT01508247|Placebo Comparator|placebo|0/0.5ml placebo in 5000 children aged 6-35 months on day0, 28
88900247|NCT01508260|Experimental|Pilot Phase Aquapheresis|The first portion of this study is an open label pilot experience to evaluate the safety of aquapheresis in leukemia patients with severe fluid overload non-responsive to diuretics. A total of 10 patients will be treated.
89194445|NCT00736814|Active Comparator|Arm I|Patients receive standard chemotherapy of docetaxel and carboplatin.
89194446|NCT00736814|Experimental|Arm II, Genotype A1|Patients receive docetaxel and vinorelbine ditartrate.
89194447|NCT00736814|Experimental|Arm II, Genotype A2|Patients receive gemcitabine hydrochloride and vinorelbine ditartrate.
89194448|NCT00736814|Experimental|Arm II, Genotype B1|Patients receive docetaxel and carboplatin.
89194449|NCT00736814|Experimental|Arm II, Genotype B2|Patients receive gemcitabine hydrochloride and carboplatin.
89194450|NCT04063904|Experimental|Mifepristone and misoprostol|Mifepristone 200 mg orally, followed 24-48 hours later by misoprostol 400mcg sublingually every three hours until the abortion occurs. The experimental part of the regimen is that the first dose of misoprostol will be taken 1-2 hours before arriving at the clinic for continued dosing, monitoring and abortion completion.
89194451|NCT00573430|Experimental|1|Candesartan Cilexetil
89194452|NCT00573430|Experimental|2|Candesartan Cilexetil
89194453|NCT00573430|Experimental|3|Candesartan Cilexetil
89194454|NCT00711516|Experimental|1|Armodafinil treatment (200 mg/day) - Study drug was supplied as 50 mg tablets and the dose was titrated from a starting dose of 50 mg taken once daily in the morning (before 0800), increasing to 100 mg/day on Day 2, 150 mg/day on day 5, and then 200 mg/day beginning Day 8 and continuing through the end of the two week double-blind treatment period.
89194455|NCT00711516|Placebo Comparator|2|Placebo comparator - Placebo tablets matching the armodafinil 50 mg tablets drug were supplied and the dose was titrated from a starting dose of one tablet taken once daily in the morning (before 0800), increasing to two tablets/day on Day 2, three tablets/day on day 5, and then four tablets/day beginning Day 8 and continuing through the end of the two week double-blind treatment period.
89194456|NCT00864838|No Intervention|1|Patients submitted to 1,5 mg/0,06 ml intravitreal injection of bevacizumab and no treatment for intraocular pressure elevation
89420534|NCT03239496|Experimental|Group B|2 doses IPV IM at 14 & 36 weeks of age incl. blood sampling at 14, 18, 36 & 40 weeks.
89420535|NCT03239496|Experimental|Group C|3 doses f-IPV ID at 10, 14 & 36 weeks of age incl. blood sampling at 10, 14, 18 & 40 weeks.
89420536|NCT03239496|Experimental|Group D|2 doses f-IPV ID at 14 & 36 weeks of age incl. blood sampling at 14, 18, 36 & 40 weeks.
89420537|NCT03183037|Experimental|Acupuncture Treatment Group|Ten acupuncture treatments over the course of eight weeks, with twice weekly acupuncture treatments for the first two weeks, and then weekly treatment thereafter.
89420538|NCT03183037|Placebo Comparator|Sham Acupuncture Treatment Group|Ten sham acupuncture treatments over the course of eight weeks, with twice weekly sham acupuncture treatments for the first two weeks, and then weekly sham acupuncture treatment thereafter.
89420539|NCT03183037|Active Comparator|Usual Care Group|Twelve weeks of usual care.
89420540|NCT03170258|Experimental|Reward-related Brain Region Feedback|Participants in this group will receive neurofeedback from a reward-related brain area (e.g., VTA, PFC) using EEG and/or fMRI during the experiment.
89420541|NCT03170258|Sham Comparator|Noise Control|Participants in this group will receive sham neurofeedback. Participants will be debriefed at the end of the study.
89420542|NCT03151083|Active Comparator|Phase 1: Implementation As Usual (Implementation Through Rese|SHUTi digital CBTi Program was implemented in VACT primary care using implementation activities executed by the research team between June 2017 and January 2018 (8-months). Implementation activities included: Provider Education by the research team, Provider Reminders (information pamphlets in treatment rooms), Patient Advertising/Information (information pamphlets in treatment rooms), Single Referral Pathway Not Integrated Primary Care Workflow (Primary care provider contact research team for patient referral over email).
89420543|NCT03151083|Experimental|Phase 2: Primary Care Coached Digital CBTi Implementation (Im|SHUTi digital CBTi Program implemented in VACT primary care using implementation activities executed by primary care teams June 2018 and January 2019 (8-months). Implementation activities included: Provider Education by the research team, Provider Reminders (information pamphlets in treatment rooms), Patient Advertising/Information (information pamphlets in treatment rooms), patient education and motivational support supplied through a digital CBTi coach, the digital CBTi coach was a primary care nurse trained by the research team, technical support and oversight of the digital CBTi coach by the research team. Single Referral Pathway Not Integrated Primary Care Workflow.
89420544|NCT03151083|Experimental|Phase 3: Primary Care Mental Health Collaborative Care Implem|SHUTi digital CBTi Program implemented in VACT primary care using implementation activities executed by primary care teams April 2019 and November 2019 (8-months). Implementation activities included: Provider Education by the research team, Provider Reminders, Patient Advertising/Information, patient education and motivational support supplied through a digital CBTi coach, the digital CBTi coach was a peer support specialist working on the primary care mental health collaborative care team, the digital CBTi coach was trained by the research team, technical support and oversight of the digital CBTi coach by the research team. Additional members primary care mental health collaborative care team were educated to provide education about digital CBTi. Multiple referral pathways to digital CBTi: consults to the digital CBTi Coach, warm handoffs to primary care mental health collaborative care team. Digital CBTi coach consults integrated Primary Care Workflow.
89420545|NCT03058588||Analysis with molecular biology|"Any patient with acute leukemia or other myeloid malignancy AND~a first- or second-degree relative with acute leukemia or other myeloid malignancies~a first- or second-degree relative with lymphoproliferative neoplasms~or with clinical features that resemble one of the familial myeloid malignancies predisposition syndromes"
89420546|NCT02942979||MISSION Implementation as Usual|Passive implementation or, IU for MISSION-Vet is comprised of a two-hour webinar training, along with key information on how to access and use the MISSION-Vet Treatment Manual and Consumer Workbook. The manual is posted on the web and available inside the VA on the National Center for Homelessness Among Veterans website or at missionmode.org. This passive implementation strategy has been used in previous studies
89420547|NCT02942979||Facilitation Implementation of MISSION|Facilitation is a comprehensive approach in which implementation experts partner with local staff to support implementation planning and to tailor adoption strategies to the local context. Facilitation gives attention to addressing individual- and organizational-level factors that can influence successful implementation of an evidence based practice with good fidelity.
89420548|NCT02919449|Experimental|MV-NIS and Atezolizumab|MV-NIS will be administered intratumorally as a single dose on day 1. Atezolizumab will be given at day 15 and then every 3 weeks.
89420549|NCT02874573|Active Comparator|Treatment Group|Subjects in the tocilizumab group will receive a 4 mg/kg infusion at baseline, and weeks 4 and 8, as per the recommended starting dosing for rheumatoid arthritis
89420550|NCT02874573|Placebo Comparator|Control Group|Subjects in the placebo group will receive an infusion of normal saline (with the same packaging and volume as the tocilizumab group) at baseline, and weeks 4 and 8.
89420551|NCT02811094|Other|Adult patients with Systemic LupusErythematosus (SLE)|Adult patients with SLE, clinically quiescent and with no change in treatment in the past 3 months, will be included and followed-up for 12 months. Blood samples will be drawn every 3 months during 12 months in the absence of flare. Patients presenting a flare will be sampled at the time of the flare and 1 month later.
88900248|NCT01508260|Experimental|Aquapheresis|Participant connected to aquapheresis pump through an intravenous (IV) catheter placed in forearm. About 6 teaspoons of blood will flow through the blood circuit, and the excess fluid will slowly be collected in the collection bag. The exact length of time of aquapheresis treatment is determined by how much fluid needs to be removed and how fast it can be removed. The average treatment is about 24 hours but can extend up to 7 days. About 6 liters or 13 pounds will be removed.
88900249|NCT01508260|Active Comparator|Diuretics|Furosemide by vein over about 15 minutes every 8 hours or by vein as a continuous (non-stop) infusion.
89006734|NCT04617301||Group 2. external cervical resorption (ECR)|"Cementum is considered to protect the underlying root dentin from being resorbed. It is broadly accepted that damage to or deficiency of this protective cementum layer below the epithelial attachment exposes the root surface to osteoclasts, which then resorb the dentin.~Clinical sign; Located in cervical region of tooth Pink spot might be noted by patient/dentist Tooth usually responds positively to vitality tests unless there is pulpal involvement (in very advanced cases) Spontaneous and profuse bleeding on probing Sharp, thinned out edges around the resorptive cavity"
89420552|NCT02806570|Experimental|AccuCinch® Ventricular Restoration System|
89420553|NCT02796859|Active Comparator|Treatment Group|Subjects in the siltuximab group will receive an 11 mg/kg infusion at baseline, and weeks 3 and 6, as per the recommended dosing for multicentric Castleman's disease
89420554|NCT02796859|Placebo Comparator|Control Group|Subjects in the placebo group will receive an infusion of normal saline (with the same packaging and volume as the siltuximab group) at baseline, and weeks 3 and 6.
89420555|NCT02769832|Experimental|Nab-Paclitaxel with Gemcitabine|Nab-paclitaxel 100 mg/m2, day 1 and day 8 of a 21-day cycle Gemcitabine 1000 mg/m2, day 1 and day 8 of a 21-day cycle
89420556|NCT02735252|Experimental|Group A: Androgen Signaling Inhibition|"Tumor biopsies: required prior to treatment and optional at time of disease progression.~Blood draws: required prior to treatment, every 3 months during treatment, and at time of disease progression.~Molecular markers will be studied in patients receiving treatments that inhibit androgen signaling to identify predictors of benefit and/or response. Treatments are assigned per investigator discretion."
89420557|NCT02735252|Experimental|Group B: Immunotherapy|"Tumor biopsies: required prior to treatment and optional at time of disease progression.~Blood draws: required prior to treatment, every 3 months during treatment, and at time of disease progression.~Molecular markers will be studied in patients receiving immunotherapy to identify predictors of benefit and/or response. Treatments are assigned per investigator discretion."
89420558|NCT02735252|Experimental|Group C: Radiotherapy|"Tumor biopsies: required prior to treatment and optional at time of disease progression.~Blood draws: required prior to treatment, every 3 months during treatment, and at time of disease progression.~Molecular markers will be studied in patients receiving radiotherapy to identify predictors of benefit and/or response. Treatments are assigned per investigator discretion."
89420559|NCT02735252|Experimental|Group D: Targeted Therapy Not Otherwise Specified|"Tumor biopsies: required prior to treatment and optional at time of disease progression.~Blood draws: required prior to treatment, every 3 months during treatment, and at time of disease progression.~Molecular markers will be studied in patients receiving targeted therapy and investigational therapeutics to identify predictors of benefit and/or response. Treatments are assigned per investigator discretion."
89420560|NCT02735252|Experimental|Group E: DNA Damage Response|"Tumor biopsies: required prior to treatment and optional at time of disease progression.~Blood draws: required prior to treatment, every 3 months during treatment, and at time of disease progression.~Molecular markers will be studied in patients receiving therapies that target DNA damage response pathways to identify predictors of benefit and/or response. Treatments are assigned per investigator discretion."
89420561|NCT02735252|Experimental|Group F: Aggressive Variant Disease|"Tumor biopsies: required prior to treatment and optional at time of disease progression.~Blood draws: required prior to treatment, every 3 months during treatment, and at time of disease progression.~Molecular markers will be studied in patients with variants of disease that display aggressive behavior to identify predictors of benefit and/or response. Treatments are assigned per investigator discretion."
89420562|NCT02735252|Experimental|Group G1: Castration Sensitive, ADT naïve and ADT < 3 months|"Tumor biopsies: required prior to treatment and optional at time of disease progression.~Blood draws: required prior to treatment, every 3 months during treatment, and at time of disease progression.~Molecular markers will be studied in patients receiving therapies that target DNA damage response pathways to identify predictors of benefit and/or response. Treatments are assigned per investigator discretion."
89420563|NCT02735252|Experimental|Group G2:Castration Sensitive,Pre-treated w/ sub-optimal PSA|"Tumor biopsies: required prior to treatment and optional at time of disease progression.~Blood draws: required prior to treatment, every 3 months during treatment, and at time of disease progression.~Molecular markers will be studied in patients receiving therapies that target DNA damage response pathways to identify predictors of benefit and/or response. Treatments are assigned per investigator discretion."
89420564|NCT02735252|Experimental|Group R: Advanced Renal Cell Carcinoma|"Tumor biopsies: required prior to treatment and optional at time of disease progression.~Blood draws: required prior to treatment, every 3 months during treatment, and at time of disease progression.~Molecular markers will be studied in patients receiving therapies that target DNA damage response pathways to identify predictors of benefit and/or response. Treatments are assigned per investigator discretion."
89420565|NCT02735252|Experimental|Cohort U: Advanced Urothelial Carcinoma|"Tumor biopsies: required prior to treatment and optional at time of disease progression.~Blood draws: required prior to treatment, every 3 months during treatment, and at time of disease progression.~Molecular markers will be studied in patients receiving therapies that target DNA damage response pathways to identify predictors of benefit and/or response. Treatments are assigned per investigator discretion."
89420566|NCT02706704|Active Comparator|Intravitreal|Intravitreal injection of 1.5mg/0.03ml adalimumab given at zero, 2 weeks, and then every 4 weeks.
89420567|NCT02706704|Active Comparator|Systemic|Subcutaneous injection of 40 mg adalimumab (Humira) given every 2 weeks.
89420568|NCT02591472|Active Comparator|Usual Care (UsCare)|This group will receive UsCare for orthopedic trauma involves surgical intervention, acute care therapies, post-acute rehabilitation and follow-up clinic visits after discharge. Additionally, the following test will be performed: Lower Extremity Gain Scale (LEGS), dynamometer isometric handgrip strength, Active Range of Motion (AROM), Posttraumatic Stress Disorder (PTSD), Beck Depression Inventory-II, State-Trait Anxiety Inventory (STAI), Tampa Scale of Kinesiophobia-11 (TSK-11), and Patient-Reported Outcomes Measurement Information System (PROMIS).
89420569|NCT02591472|Experimental|Integrated Care (ICare)|This group will receive ICare for orthopedic trauma involves surgical intervention, acute care therapies, post-acute rehabilitation and follow-up clinic visits after discharge, plus simultaneous psychosocial support via the Transform-10 Program.. Additionally, the following test will be performed: Lower Extremity Gain Scale (LEGS), dynamometer isometric handgrip strength, Active Range of Motion (AROM), Posttraumatic Stress Disorder (PTSD), Beck Depression Inventory-II, State-Trait Anxiety Inventory (STAI), Tampa Scale of Kinesiophobia-11 (TSK-11), and Patient-Reported Outcomes Measurement Information System (PROMIS).
89420570|NCT02418156||Single Arm|Subjects undergoing femoral arterial reconstruction using CorMatrix ECM for vascular repair.
89420571|NCT02326311|Active Comparator|Fixed INTERIM TKI|"Intervention: fixed intermittent administration (one month ON/one month OFF) of TKIs (imatinib, nilotinib, dasatinib)"
89420572|NCT02326311|Experimental|Progressive INTERIM TKI|"Intervention: progressive intermittent administration (one month ON/one month OFF for the 1st year; one month ON/two months OFF for the 2nd year; one month ON/three months OFF for the 3rd year) (imatinib, nilotinib, dasatinib)"
88900250|NCT01508273|Experimental|Exercise Intervention Program Group|At baseline study visit, participant shown how to complete the physical exercises performed while on study. Pedometer received to track physical activity. Resistance training bands given to use as part of the home-based exercise program. At the baseline study visit, directions received on how to use the study website. Access given to website that will allow tracking of exercise behavior and help set goals. Access given to an internet-based curriculum that will help teach about goal-setting, overcoming barriers to physical activity, self-management strategies, and time-management skills. Participant asked to visit website every week. Participant records activity and the number of steps taken every day on the website. Survey completed monthly about attitudes and beliefs about physical activity.
88900251|NCT01508273|Other|Sedentary Behavior and Dietary Intervention Group|Access given to internet-based curriculum to help teach about goal-setting, overcoming barriers to physical activity, self-management strategies, and time-management skills. Participants read information about improving the quality of their diet and cutting back on sedentary behavior. Participants record on the website how much television watched and how many fruits and vegetables eaten every day. Survey completed monthly about attitudes and beliefs about sedentary behavior and dietary intake.
89420573|NCT02324543|Experimental|Dose level 1 - Phase 1|"Gemcitabine - 400 mg/m^2~Taxotere - 20 mg/m^2~Xeloda - 500 mg/twice daily (BID)~Cisplatin - 15 mg/m^2~Irinotecan - 20 mg/m^2"
89420574|NCT02324543|Experimental|Dose Level 2 - Phase 1|"Gemcitabine - 400 mg/m^2~Taxotere - 20 mg/m^2~Xeloda - 500 mg/BID~Cisplatin - 15 mg/m^2~Irinotecan - 40 mg/m^2"
89420575|NCT02324543|Experimental|Dose Level 3 - Phase 1|"Gemcitabine - 400 mg/m^2~Taxotere - 20 mg/m^2~Xeloda - 500 mg/BID~Cisplatin - 15 mg/m^2~Irinotecan - 60 mg/m^2"
89420576|NCT02324543|Experimental|Dose Level 1a - Phase 1|"Gemcitabine - 500 mg/m^2~Taxotere - 20 mg/m^2~Xeloda - 500 mg/BID~Cisplatin - 20 mg/m^2~Irinotecan - 20 mg/m^2"
89420577|NCT02324543|Experimental|Dose level 1b - Phase 1|"Gemcitabine - 500 mg/m^2~Taxotere - 20 mg/m^2~Xeloda - 500 mg/BID~Cisplatin - 20 mg/m^2~Irinotecan - 40 mg/m^2"
89420578|NCT02324543|Experimental|Phase 2|"Gemcitabine - 500 mg/m^2~Taxotere - 20 mg/m^2~Xeloda - 500 mg/BID~Cisplatin - 20 mg/m^2~Irinotecan - 20 mg/m^2"
89420579|NCT02279979|Experimental|Treatment Arm|All enrolled patients will be treated with the HeartMate PHP device
89420580|NCT02215265|No Intervention|A: No adjuvant treatment|Group A Patients with tumours which exhibit no adverse histological features. Patients in this group will not receive any adjuvant treatment as per standard of care.
89420581|NCT02215265|Active Comparator|B1: Postoperative radiotherapy 60 Gray|"Arm B1: postoperative radiotherapy (PORT) at a dose of 60 Gray (Gy) in 30 fractions over 6 weeks.~Group B: Patients with: T3 tumours (or T1-T2 tumours with additional risk factors), TNM 7th edition pN2a (metastasis in single ipsilateral node 31-60 mm diameter) or pN2b (metastasis in multiple ipsilateral nodes <61 mm diameter) disease, tumours with evidence of perineural and/or vascular invasion, and/or a histologically normal tissue margin around the primary tumour of 1-5mm and, in the case of TLM, marginal biopsies free of tumour."
89420582|NCT02215265|Experimental|B2: Postoperative radiotherapy 50 Gray|"Arm B2: Postoperative radiotherapy (PORT) at a dose 50 Gray in 25 fractions over 5 weeks.~Group B: Patients with: T3 tumours (or T1-T2 tumours with additional risk factors), TNM 7th edition pN2a (metastasis in single ipsilateral node 31-60 mm diameter) or pN2b (metastasis in multiple ipsilateral nodes <61 mm diameter) disease, tumours with evidence of perineural and/or vascular invasion, and/or a histologically normal tissue margin around the primary tumour of 1-5mm and, in the case of TLM, marginal biopsies free of tumour."
89420583|NCT02215265|Active Comparator|C1: Postoperative radiotherapy 60 Gray with Cisplatin|"Arm C1: postoperative radiotherapy at a dose of 60 Gray in 30 fractions over 6 weeks with concurrent Cisplatin chemotherapy (POCRT). Cisplatin may be given 3 weekly (100mg/m2 week 1 and week 4 of radiotherapy) or weekly (40mg/m2 weekly during radiotherapy), according to local practice.~Group C: Patients with tumours of any T or any N stage, which exhibit the following high risk pathological features will be included: A histologically normal tissue margin around the primary tumour of <1mm and, in the case of TLM, marginal biopsies free of tumour and /or extracapsular spread (ECS) of nodal disease"
88900252|NCT01508273|Experimental|Chair-based Study Group|Patients participate in chair-based exercise study. Participants receive chair-based exercise DVD. Chair-based exercise program participation for a total of 8 weeks. Participants receive self-report assessments about quality of life and asked to participate in physical assessments of their balance and coordination.
88900253|NCT01508299|Experimental|raw food skin test|skin test with the suspected raw food
88900254|NCT01508338|Placebo Comparator|Placebo|
88900255|NCT01508338|Experimental|HMB|
88900256|NCT01508338|Experimental|ATP and HMB|
88900257|NCT01508338|Experimental|ATP|
88900258|NCT01508351||Propofol Induction|All patients receiving propofol induction of anesthesia who are ASA 1-3
88900259|NCT01508364||Group 1|
88900260|NCT01508377|Experimental|Treatment of PTSD with cognitive restructuring|"In this arm the PTSD treatment can be divided into three phases.~First phase: self-confrontation (4 essays)~Second phase: cognitive restructuring (4 essays)~Third phase: parting (2 essays)"
89194457|NCT00864838|Experimental|2|Acetazolamide: 250 mg of oral acetazolamide 1 hour before intravitreal bevacizumab injection
89194458|NCT00864838|Experimental|3|topic brimonidine tartarate: one drop of brimonidine tartarate 1 hour before intravitreal bevacizumab injection
89420584|NCT02215265|Experimental|C2: Postoperative radiotherapy 60 Gray without chemotherapy|"Arm C2: Postoperative radiotherapy at a dose of 60 Gray in 30 fractions over 6 weeks without chemotherapy (Test Arm C2).~Group C: Patients with tumours of any T or any N stage, which exhibit the following high risk pathological features will be included: A histologically normal tissue margin around the primary tumour of <1mm and, in the case of TLM, marginal biopsies free of tumour and /or extracapsular spread (ECS) of nodal disease"
89420585|NCT02073331||CorMatrix ECM|Data collection for information on the use of CorMatrix ECM for pericardial reconstruction
89420586|NCT02055638|Experimental|SRX246|SRX246 capsules, 120mg bid for 4 weeks followed by 160mg bid for 4 weeks
89420587|NCT02055638|Placebo Comparator|Placebo|Placebo capsules to match the amount of SRX246 capsules for 8 weeks
89420588|NCT01887938|Experimental|Cohort 1|Participants will receive 10 milligram (mg) of HGT-1110 (Recombinant human arylsulfatase A) intrathecal (IT) injection every-other-week (EOW).
89420589|NCT01887938|Experimental|Cohort 2|Participants will receive 30 mg of HGT-1110 IT injection EOW.
88900261|NCT01508377|Experimental|Treatment of PTSD without cognitive restructuring|"In this arm the PTSD treatment can be divided into only two phases. Compared to the other arm the phase dealing with cognitive restructuring is excluded.~First phase: self-confrontation (4 essays)~Second phase: parting (2 essays)"
88900262|NCT01508403||Shuxuetong injection|a cohort using Shuxuetong injection
88900263|NCT01508416||Patients with Multiple Myeloma|Patients with newly diagnosed Multiple Myeloma required chemotherapy
88900264|NCT01508429|Active Comparator|misoprostol|800mcg misoprostol (four tablets of 200 mcg administered sublingually)
88900265|NCT01508429|Placebo Comparator|placebo|4 placebo tablets (resembling misoprostol) administered sublingually
88900266|NCT01508468|Active Comparator|active comparator|"Non Immunosuppressive Symptomatic Treatment (NIST). No specific treatment Converting Enzyme Inhibitor , Angiotensin II receptor antagonist, Anti-renin, Aldosterone antagonist diuretic, Beta blocker, Calcium inhibitor, statin."
88900267|NCT01508468|Experimental|experimental|NIST and Rituximab: 500 Mg and 100Mg in solution to be diluted for IV infusion (Mabthera®)
88900268|NCT01508481||Diabetes high risk group|
88900269|NCT01508494|Active Comparator|Galantamine|16mg galantamine progressively
88900270|NCT01508494|Placebo Comparator|placebo|placebo
88900271|NCT01508507||Cholera cases group|"Any diarrheal cases or suspected cholera cases from study area, whose stool specimen collected in study health center and examined in reference laboratory, reveals V. cholerae serotype O1/O139 is defined as cholera case"
88900272|NCT01508507||Control group|"A randomly selected age matched individual, who have been living in the study area and did not seek care for diarrheal illness in the study health center since vaccination is defined as control"
88900273|NCT01508533||Cohort 1|Cohort 1: Infants enrolled at ≤1 week and followed up weekly till one year of age.
88900274|NCT01508533||Cohort 2|Cohort 2: Infants enrolled at 12 months and followed up weekly till they are aged 24 months.
88900275|NCT01508546|Experimental|Arm 1: breast surgery with axillary lymphnodes removal|
88900276|NCT01508546|Experimental|Arm 2: breast surgery without axillary lymphnodes removal|
88900277|NCT01508559||HIV infected|HIV infected MSM 18-50 years old
88900278|NCT01508559||HIV uninfected|HIV uninfected MSM 18-50 years old
88900279|NCT01508572|Experimental|bevacizumab-IRDye800CW|In this two stage, non-randomized, non-blinded, prospective, multicenter feasibility study, bevacizumab-IRDye800CW will be administered to a total of 20 patients with proven breast cancer.
88900280|NCT01508585|Active Comparator|Pre-Op CBT|This group will receive CBT (Telephone Based Cognitive Behavioral Therapy) before bariatric surgery
88900281|NCT01508585|Active Comparator|Post-Op CBT|This group will receive CBT (Telephone Based Cognitive Behavioral Therapy) after bariatric surgery
89194459|NCT00864838|Experimental|4|anterior chamber paracentesis: anterior chamber paracentesis immediately after intravitreal bevacizumab
88900282|NCT01508611|Active Comparator|30% silver diammine fluoride|The 30% silver diamine fluoride (Cariestop, Biodinamica) will be applied in erupting molars with a disposable microbrush for 3m. Then the surface will be washed for 30s.
88900283|NCT01508611|Active Comparator|cross-toothbrushing|Children will be oriented to proceed cross-toothbrushing in erupting molars
88900284|NCT01508624|No Intervention|Control|participants will receive standard usual care
88900285|NCT01508624|Experimental|Interaction|Participants will interact with nurses during their procedure
88900286|NCT01508624|Experimental|Music|Participants will listen to music using head phones during their procedure.
88900287|NCT01508624|Experimental|Touch - stress balls|Participants will be provided with stress balls to use during their procedure
89420590|NCT01887938|Experimental|Cohort 3|Participants will receive 100 mg of HGT-1110 IT injection EOW.
89420591|NCT01887938|Experimental|Cohort 4|Participants will receive 100 mg of HGT-1110 IT injection once weekly for 12 weeks followed by 150 mg EOW.
89420592|NCT01850524|Placebo Comparator|Placebo + LenDex|Participants who were randomly assigned to receive placebo matching capsule single oral dose on Days 1, 8 and 15 along with standard regimen of LenDex (lenalidomide 25 mg capsules orally on Days 1-21 and dexamethasone 40 mg tablets orally on Days 1, 8, 15 and 22) for the first 18 cycles (each cycle was of 28 days). Following Cycle 18, participants received 3.0 mg ixazomib matching placebo capsule as single oral dose on Days 1, 8 and 15 along with lenalidomide 10 mg capsules orally on Days 1-21 in each 28-day cycle until progressive disease or unacceptable toxicity, whichever comes first up to end of study (up to approximately 109 months).
89420593|NCT01850524|Active Comparator|Active Comparator: Ixazomib + LenDex|Participants who were randomly assigned to receive Ixazomib 4.0 mg capsule single oral dose on Days 1, 8 and 15 along with standard regimen of LenDex (lenalidomide 25 mg capsules orally on Days 1-21 and dexamethasone 40 mg tablets orally on Days 1, 8, 15 and 22) for the first 18 cycles (each cycle was of 28 days). Following Cycle 18, participants received 3.0 mg ixazomib capsule as single oral dose on Days 1, 8 and 15 along with lenalidomide 10 mg capsules orally on Days 1-21 in each 28-day cycle until progressive disease or unacceptable toxicity, whichever comes first up to end of study (up to approximately 109 months).
89420594|NCT01816256|Other|Screening tests|This is a one arm study. All patients will receive two screening tests (Doppler ultrasound, upper gastrointestinal endoscopy).
89420595|NCT01700582||Patients with advanced lung cancer|Patients with advanced lung cancer
89420596|NCT01664910|Experimental|Treatment (transplant)|Patients receive inotuzumab ozogamicin IV over 1 hour on day -13, and fludarabine phosphate IV over 1 hour and bendamustine hydrochloride IV over 30 minutes to 1 hour on days -5 to -3. Patients with CD20-positive disease also receive rituximab IV over 4-6 hours on days -6, 1, and 8 and patients with MUD receive anti-thymocyte globulin IV over 3-4 hours on days -2 to -1. All patients also receive tacrolimus IV over 24 hours continuously or PO daily beginning on days -2 to 180 followed by taper in the absence of GVHD and methotrexate IV over 30 minutes on days 1, 3, and 6 (1, 3, 6, and 11 in patients with MUD). Patients undergo allogeneic BM or PBSC transplant on day 0.
89420597|NCT01654159|Placebo Comparator|Monofocal|"Monofocal IOL Implant~Manufacturers of IOLs used as monofocal comparator are Alcon, AMO, Bausch and Lomb, Lenstec, Oculentis, Ophthec, Physiol and Zeiss"
89420598|NCT01654159|Experimental|Multifocal|"Multifocal IOL~Manufacturers of multifocal IOLs under investigation are Alcon, AMO, Bausch and Lomb, Lenstec, Oculentis, Ophthec, Physiol and Zeiss"
89420599|NCT01654159|Experimental|Toric|"Toric IOL~Manufacturers of toric IOLs under investigation are Alcon, AMO, Bausch and Lomb, Lenstec, Oculentis, Ophthec, Physiol and Zeiss"
89420600|NCT01633489||LAL Deficiency patients|Patients are those with a diagnosis of LAL Deficiency (living and deceased), irrespective of treatment status or treatment choice.
89420601|NCT01609842|Experimental|Phone reminders and pharmacist|An alerted inpatient pharmacist or a designated study team member will bring the clopidogrel medication to the patient who has received a coronary stent. The patient will return home and receive IVR refill reminder calls.
89420602|NCT01609842|Other|Usual Care|The sites will have no interaction with the study personnel. The investigators will use database information to compare with the intervention sites
89420603|NCT01594580|Experimental|Antimicrobial impregnated scrubs|Those randomized to this arm of the study will wear scrubs impregnated with an antimicrobial.
89420604|NCT01594580|Placebo Comparator|Non-impregnated scrubs|Those randomized to this arm of the study will wear scrubs not impregnated with an antimicrobial.
89420605|NCT01569594||Carotid Endarterectomy Subjects|Subjects undergoing patch angioplasty of the carotid artery following carotid endarterectomy using the CorMatrix ECM for Carotid Repair
89420606|NCT01121107|Experimental|Left Atrial Pressure Monitoring System|Left Atrial Pressure (LAP) Monitoring System
89420607|NCT01121107|Active Comparator|Patient Advisor Module|Patient Advisory Module
88819911|NCT04556175|Experimental|Oral Health|Motivational interviewing sessions will involve in-person visits by Community Health Workers focused on the mitigation of behavioral risk factors for early childhood caries, with two sessions provided before childbirth and four more sessions at 6, 12, 18 and 24 months after childbirth. Children receive up to 4 fluoride varnish applications during the study. Early cohort of enrollees will be followed up in a 7th visit solely for oral health assessment.
88900288|NCT01508624|Experimental|DVD|Participants will watch a DVD during their procedure and will listen to the accompanying audio through head phones
88900289|NCT01508637|Experimental|Diesel Exhaust + Terazosin|
88900290|NCT01508637|Experimental|Diesel Exhaust + placebo|
88900291|NCT01508637|Sham Comparator|Filtered Air + terazosin|
88900292|NCT01508637|Sham Comparator|Filtered air + placebo|
88900293|NCT01508663|Experimental|PCI+OMT group|PCI (Everolimus Eluting Stent or Zotalolimus Eluting Stent) added to OMT after randomization and follow up for 12 months
88900294|NCT01508663|Active Comparator|OMT alone group|OMT alone after randomization and follow up for 12 months
89194460|NCT05740748|Experimental|Tezepelumab|tezepelumab 210 mg sc q4wks 20 weeks treatment
89530793|NCT02513693|Experimental|Deep Neuromuscular Blockade|"Drug: rocuronium + sugammadex~Administration of rocuronium 0,6 mg/kg iv, top-ups 5-10 mg iv to target value of Post-tetanic Count (PTC) = 1-2; PTC measurement every 4 min. Neuromuscular blockade reversal at the end of anesthesia: sugammadex 2 mg/kg iv (when PTC is 18-20 and TOF-count 0) or sugammadex 4 mg/kg iv (when PTC under 18).~Induction of anesthesia: midazolam 1-2 mg iv, sufentanil 10-30 mcg iv, propofol 1,5-2,5 mg/kg iv Anesthesia: sevoflurane in air to target 1.2-1.5 minimal alveolar concentration (MAC). Rescue medication: sevoflurane, propofol 20-40 mg iv.~Extubation when patient is conscious and attained recovery from neuromuscular blockade to a TOF-ratio of at least 0,9."
89420608|NCT00769782|Experimental|therapeutic conventional surgery|All patients undergo suegery to achieve macroscopic complete resection within 28 days after enrollment (including enrollment day). As long as tumor free margin is ensured, all resection margin distances and all surgical procedure are accepted. Surgical treatment in this study excludes the following, radiofrequency ablation (RFA) without resection of liver only or microwave coagulation therapy (MCT) only; for RFA or MCT is used as additional treatment under judgment of primary physician for new liver tumor which comfirmed during surgery in different parts of liver except portion scheduled for resection, RFA and MCT are included. After histological curative resection, patients are observed without treatment until comfirming recurrence. Patients with incomplete tumor removal are withdrawn from protcol treatment and receive imatinib treatment, 400 mg/day orally. For reccurrence is comfirmed, patients receive imatinib treatment, 400 mg/day orally.
89420609|NCT00764595|Experimental|imatinib mesylate|All patients start imatinib mesylate as oral dose of 400 mg/d once daily after meal within 28 days after enrollment, and continue the treatment until 3 years after enrollment of the last patient.
89420610|NCT00628745||Observational|
89420611|NCT00593840|Experimental|Intensity modulated radiation therapy (IMRT)|-This study provides guidelines for volume to be contoured during IMRT based on tumor site and stage of tumor site. The clinical tumor volume (CTV)1 will be treated to 66 Cy in 33 fractions or 60 Gy in 30 fractions. The CTV2 will be treated to 54 Gy in 33 fractions or 52 Gy in 30 fractions. The CTV3 will be modified based on tumor site and stage of tumor site in order to reduce volume.
89420612|NCT00576979|Experimental|Level 1: 1200cGy|150cGy BID x Days 1-4. Total dose 1200cGy.
89420613|NCT00576979|Experimental|Level 2: 1350cGy|150cGy BID Day 1-4 then 150 cGy QD Day 5. Total dose 1350cGy.
89420614|NCT00576979|Experimental|Level 3: 1500cGy limited dose to ribs, sternum, liver, brain 1200cGy|150cGy BID Day 1-5. Total dose 1500Gy.
89420615|NCT00576979|Experimental|Level 4: 1500cGy limited dose to liver, brain 1200cGy|150cGy BID Day 1-5. Total dose 1500Gy.
89420616|NCT00576979|Experimental|Level 5: 1600cGy limited dose to liver, porta-hepatic, brain 1200cGy|160cGy BID Day 1-5. Total dose 1600Gy.
89420617|NCT00576979|Experimental|Level 6: 1700cGy limited dose to liver, porta-hepatic, brain 1200cGy|170cGy BID Day 1-5. Total dose 1700Gy.
89420618|NCT00576979|Experimental|Level 7: 1800cGy limited dose to liver, porta-hepatic, brain 1200cGy|180cGy BID Day 1-5. Total dose 1800Gy.
89420619|NCT00576979|Experimental|Level 8: 1900cGy limited dose to liver, porta-hepatic, brain 1200cGy|190cGy BID Day 1-5. Total dose 1900Gy.
89420620|NCT00576979|Experimental|Level 9: 2000cGy limited dose to liver, porta-hepatic, brain 1200cGy|200cGy BID Day 1-5. Total dose 2000Gy.
89420621|NCT02228538||Total knee arthroplasty patients|ConforMIS iTotal (CR) knee implant system and off-the-shelf knee implant systems from various manufacturers
89420622|NCT03058042|Experimental|Home pelvic floor muscle training|Patients will perform strength training of the pelvic floor muscles daily at home. The training protocol consists of three sets of 30 slow contractions (type I muscle fibers), with maintenance contraction according to the initial evaluation, followed by three rapid contractions (type II muscle fibers) after each slow contraction. The protocol will account for 90 contractions of the pelvic floor muscles per day. At the end of one month, the patients will return for consultation, in which the MAP evaluation and training progression will be performed.
89420623|NCT03058042|Sham Comparator|Outpatient pelvic floor muscle training|The patients will perform 24 outpatient sessions of pelvic floor muscle strength training and home training. The training protocol consists of three sets of 30 slow contractions (type I muscle fibers), with maintenance contraction according to the initial evaluation, followed by three rapid contractions (type II muscle fibers) after each slow contraction. The protocol will account for 90 contractions of the pelvic floor muscles per day. At the end of one month, the patients will perform the evaluation of the MAP and progression of the training.
89420624|NCT03563391|Experimental|Evaluation of a new infant formula|To evaluate the effects of a new formula on the growth, safety and tolerance of infants with growth failure
89420625|NCT04003974|Experimental|Treatment|FSHD1 patients with genetic confirmation will receive Losmapimod 15 mg twice daily given as two 7.5 mg tablets per dose by mouth; for a total of 4 pills or 30 mg daily for 48 weeks.
89420626|NCT04003974|Placebo Comparator|Placebo|FSHD1 patients with genetic confirmation will receive a Placebo twice daily given as two 7.5 mg tablets per dose by mouth; for a total of 4 pills or 30 mg daily for 48 weeks.
89420627|NCT04949386|Experimental|Treatment with S-1226 (8%)|Subjects randomized to this treatment arm will receive S-1226(8%) twice daily for 7 consecutive days. S-1226 will be administered by inhalation for 3-4 minutes.
89420628|NCT04949386|Placebo Comparator|Placebo|Subjects randomized to receive placebo will be administered with medical grade air with 3ml saline (0.9% NaCl) using the Circulaire II hybrid system. Placebo will be administered by inhalation for 3-4 minutes.
89420629|NCT05133063|Experimental|Gratitude intervention|Participants will complete a gratitude letter where they spend eight minutes writing a letter of gratitude. The individual writes about his feelings of gratitude through a letter, based on a written instruction.
89194461|NCT05740748|Placebo Comparator|Placebo|placebo sc q4wks 20 weeks treatment
89194462|NCT00873028|Experimental|1|
89420630|NCT05133063|Active Comparator|Control intervention.|Participants spend eight minutes writing a note describing the lab in which the study is being run.
89420631|NCT04948684||Patients with dystonia secondary to atypical Parkinsonism or Parkinson's disease|Patients with dystonia secondary to idiopathic Parkinson's disease or atypical parkinsonism and treated with BoNT
89420632|NCT04948684||Patients with atypical Parkinsonism or Parkinson's disease and no dystonia|Patients with idiopathic Parkinson's disease or atypical parkinsonism and without reported dystonia
89420633|NCT03563235|Experimental|Xulin Jiangu granules|Xulin Jiangu granule 15g tablet by mouth every 6 hour for 6 months
89420634|NCT03563235|Active Comparator|Calcitriol capsules|Calcitriol capsules tablets 0.25 ug by mouth every 6 hour for 6 months
89420635|NCT01329900|Experimental|Ofatumumab + Stem Cell Collection|Ofatumumab 1000 mg by vein on Day 1 and 2000 mg by vein on Day 8. Ifosfamide 3.33 gm/m2 by vein on Days 2, 3, and 4 continuously. Etoposide 150 mg/m2 by vein over 2 hours every 12 hours for 6 doses. Mesna 2 gm/m2 by vein over 1 hour on Day 2 (given before Ifosfamide starts). Mesna 2.66 gm/m2/day by vein continuous infusion given over 24 hours daily for 3 days starting on Day 2 (together with Ifosfamide). After Ifosfamide/Mesna, 2 gm/m2 by vein given over 12 hours for one dose. G-CSF 6 mcg/kg subcutaneously twice a day on day 6 (rounded off to the nearest vial) until completion of apheresis. Blood stem cells will be collected when blood counts have returned to normal (about 10-16 days after chemotherapy). Stem cell collection takes about 4 hours each time.
89420636|NCT03677635|Experimental|Intervention|Guided autobiographical memory recall to enhance specificity and links to the future.
89420637|NCT03677635|No Intervention|Control|Recall without prompts or psychoeducation video.
89420638|NCT05127993|Experimental|Novel prosthesis|A unilateral transtibial amputee will conduct experiments with the novel prosthesis followed by experiments with the current prosthesis.
89420639|NCT05127993|Active Comparator|Current prosthesis|A unilateral transtibial amputee will conduct experiments with the current prosthesis followed by experiments with the novel prosthesis.
89420640|NCT03997812|Experimental|VVZ-149 Injections|
89420641|NCT03997812|Placebo Comparator|Placebo|
89420642|NCT02825043|Experimental|High Flow Nasal Cannula Participants|High Flow Nasal Cannula Participants will be their own control, they will be in study for 3 months prior to receiving equipment and then will be studied for 3 additional months on study.
89420643|NCT04948372|Experimental|The terlipressin group|Patients in the terlipressin group received a fixed dose of terlipressin added to usual care. Terlipressin was intravenously pumped at a fixed dose of 1.3μg/kg/hour for 24 hours.
89420644|NCT04948372|Placebo Comparator|The usual care group|Patients in the usual care group were treated with standard care.
89420645|NCT03960606|Experimental|10 mg PUR1900|Study drug (PUR1900) will be administered orally, using a Dry Powder Inhaler (DPI) specific to the study (RS01 Monodose inhaler)
89420646|NCT03960606|Experimental|20 mg PUR1900|Study drug (PUR1900) will be administered orally, using a Dry Powder Inhaler (DPI) specific to the study (RS01 Monodose inhaler)
89420647|NCT03960606|Experimental|35 mg PUR1900|Study drug (PUR1900) will be administered orally, using a Dry Powder Inhaler (DPI) specific to the study (RS01 Monodose inhaler)
89420648|NCT03960606|Placebo Comparator|Placebo|Placebo
89420649|NCT04947748|Active Comparator|24 hour intravenous antibacterial therapy|S.Augmentin 1,2g x 3 i/v
89420650|NCT04947748|Experimental|24 hour oral antibacterial therapy|T.Augmentin 1g x 3 p/o
88819912|NCT04556175|Active Comparator|Healthy Lifestyle|Didactic educational sessions delivered in-person by Community Health Workers cover nutrition and diet, physical activity, breastfeeding/formula feeding, substance use, mental/emotional health, personal and family goals, prenatal/postpartum health care access, labor and delivery, family support, infant/child care, oral health, and development milestones. Children receive up to 2 fluoride varnish applications during the study. Early cohort enrollees will be followed up in a 7th visit solely for oral health assessment.
89420651|NCT05184543|Active Comparator|Control Group|Participants in the control group will continue their routine warm-up programs.
88819913|NCT02973711|Experimental|Nilotinib + Ruxolitinib|"The first part of the trial will be Phase I and will enroll 25 participants. Participants will receive nilotinib BID and either 10, 15 or 20 mg of ruxolitinib BID. Maximum tolerated dose (MTD) of ruxolitinib will be determined.~The second part of the trial will be a Phase II and will enroll 25 subjects. Participants will receive nilotinib and the MTD of ruxolitinib."
88819914|NCT05456061|No Intervention|Group 1|No intervention
88819915|NCT05456061|Active Comparator|Group 2|3% diquafosol eye drops 6 times / day
89420652|NCT05184543|Experimental|Core Stability Group|A warm-up program including core stability exercises will be applied to the participants.
89420653|NCT05184543|Experimental|Neuromuscular Exercise Group|A warm-up program including dynamic neuromuscular exercises will be applied to the participants.
89420654|NCT04947826|Experimental|HAIC + HLX10 + HLX04|HAIC: FOLFOX, q3w, up to 8 times; HLX10: 4.5mg/kg, iv, q3w, up to 2 years; HLX04: 15.0mg/kg, iv, q3w, up to 2 years.
89420655|NCT04947826|Placebo Comparator|HAIC + Placebo|HAIC: FOLFOX, q3w, up to 8 times; Placebo1: saline, iv, q3w, up to 2 years; Placebo2: saline, iv, q3w, up to 2 years.
89420656|NCT02224716||Pre-intervention All patients admitted with a diagnosis of CAP|
89420657|NCT02224716||Post intervention All patient admitted with a diagnosis of CAP|
89420658|NCT04947982|No Intervention|Control|All laparoscopic surgical procedures were performed at 12 mmHg CO2 pressure throughout the surgery
88819916|NCT05456061|Active Comparator|Group 3|Punctal plug insertion, lower eyelid
88819917|NCT05456061|Active Comparator|Group 4|3% diquafosol eye drops 6 times / day + Punctal plug insertion, lower eyelid
88819918|NCT04300413|Experimental|High-Intensity Rehabilitation plus Mobility (HeRo)|The HeRo group will receive a behavior-change intervention based in the principals of behavioral economics to improve mobility. Physical and occupational therapists have been trained to deliver a high-intensity, functional intervention as the standard of care in this skilled nursing facility.
88819919|NCT02369874|Experimental|MEDI4736|MEDI4736 monotherapy
89420659|NCT04947982|Experimental|Study|All laparoscopic surgical procedures were performed at 8 mmHg CO2 pressure throughout the surgery
88819920|NCT02369874|Experimental|MEDI4736 + Tremelimumab|MEDI4736 + tremelimumab combination therapy
88819921|NCT02369874|Active Comparator|Standard of Care|Standard of Care
88819922|NCT04335045|Active Comparator|100mg Dose|1 x 100 mg PH100 capsule (n=6)
88819923|NCT04335045|Placebo Comparator|Control for 100mg Dose|1 placebo capsule (n=2)
88819924|NCT04335045|Active Comparator|200mg Dose|1 x 200 mg PH100 capsule (n=6)
88819925|NCT04335045|Placebo Comparator|Control for 200mg Dose|1 placebo capsule (n=2)
88819926|NCT04335045|Active Comparator|400mg Dose|2 x 200 mg PH100 capsules (n=6)
88819927|NCT04335045|Placebo Comparator|Control for 400mg Dose|2 placebo capsules (n=2)
89420660|NCT03563079|Experimental|trial group|The treatment will be performed using two pieces of Instrument Assisted Soft Tissue Mobilization (IASTM) stainless steel in the neck, bilaterally, which comprise the following muscles: Upper Trapezius, Splenius, scalenes and Sternocleidomastoid. An established time of 3 minutes will be used in each region, using an angle of 30 to 60º with the instrument. As it is observed, through the instrument, regions of greater adhesion, the researcher will use most of this time to release this condition.
89420661|NCT03563079|Active Comparator|group control|Treatment will be performed using manual Myofascial Release techniques. Release the upper Trapezius muscle bilaterally, sliding using roller with the dorsum of the fingers and ending with myofascial release. Sternocleidomastoid, sliding using roller with the dorsum of the fingers, ending with myofascial release. Afterwards the release of the scalenes muscles will be performed, with the fingers sliding and ending with the myofascial release. Soon afterwards techniques will be performed for the Splenius muscles, using finger slips and ending with posterior cervicothoracic release. The same time of 3 min will be used for the treatment bilaterally in each region.
89420662|NCT02228616|Experimental|Prucalopride plus Polyethylene glycol or lactulose|
89420663|NCT04759950|Experimental|Physical exercise & cognitive training group|The Physical exercise & cognitive training group receives a multicomponent physical exercise program combined with computer-based cognitive training.
89420664|NCT04759950|Experimental|Mindfulness & cognitive training group|The Mindfulness & cognitive training group receives mindfulness-based stress reduction therapy combined with computer-based cognitive training.
89420665|NCT04759950|Active Comparator|Cognitive training group|The Cognitive training group, as an active control group, receives only computer-based cognitive training.
89194463|NCT00873028|No Intervention|2|Those patients assigned to Control were followed by their own physicians, received routine nursing assistance, were visited daily by the one of the investigators (CPM), but were not exposed to any specific respiratory or motor physical intervention.
89194464|NCT03900338||PWV>10|Patients with PWV > 10 (SSphygmoCor) in two different measurements
88900295|NCT01508689|Other|Receive cereal bars first|This group will receive Kellogg's Nutri-Grain® cereal bars during the second three weeks of the study.
89194465|NCT03900338||PWV<10|Patients with PWV < 10 (SphygmoCor) in two different measurements
89420666|NCT05086965|No Intervention|Control Group|The nursing process course content prepared by the researchers in the classroom environment will be explained to the students in the control group by the researcher. After the theoretical course content is explained, the appendectomy case prepared by the researchers will be presented to the students and the case-specific nursing care plan will be explained to the students in the classroom environment by the researcher. After explaining the theoretical content and case-specific care plan preparation to the students, a test will be applied to the questions prepared according to the case sample specific to chronic obstructive pulmonary disease prepared by the researchers. Students will be asked to find the nursing diagnoses and goals specific to the presented COPD case and to prioritize the nursing diagnoses they find. Students will be graded in the order of given tests and nursing diagnoses.
89420667|NCT05086965|Experimental|Intervention Group|The nursing process course content prepared by the researchers will be explained to the students in the intervention group by the researcher in the classroom environment. After the theoretical course content is explained, a virtual game simulation specially developed for the appendectomy case will be played in the computer classroom of the school where the study will be conducted. At the end of the game, students will be able to see how many points they got, which questions they answered correctly and which questions they answered incorrectly. After the virtual training simulation game, students will play the virtual assessment simulation game developed for chronic obstructive pulmonary disease in the school's computer classroom. The scoring system in the game developed for COPD will be equal to the scoring system in the test that will be presented to the control group students.
89420668|NCT04947280|Experimental|Fractionated Stereotatic Radiation Therapy|
89420669|NCT04946890|Experimental|MRX2843 orally 80 mg/d|"Participants received 80 mg MRX2843 administered orally (PO), once daily (QD), in a fasted state on Days~1 to 21 of a 21-day cycle."
89420670|NCT04946890|Experimental|MRX2843 orally 120 mg/d|"Participants received 120 mg MRX2843 administered orally (PO), once daily (QD), in a fasted state on Days~1 to 21 of a 21-day cycle."
89420671|NCT04946890|Experimental|MRX2843 orally 180 mg/d|"Participants received 180 mg MRX2843 administered orally (PO), once daily (QD), in a fasted state on Days~1 to 21 of a 21-day cycle."
89420672|NCT04413604|Experimental|YCM Group (1- <3) Years old|2 servings / day of the investigational (test) young children's milk (YCM) for 16 weeks
89420673|NCT04413604|No Intervention|Observation Group (1-<3) Years old|Habitual diet, consume the same regular foods and drinks as the children would normally
89530794|NCT02510573||sTBI group|The patients with isolated head trauma and postresuscitation GCS score of 8 or less.
88819928|NCT04335045|Active Comparator|800mg Dose|4 x 200 mg PH100 capsules (n=6)
88819929|NCT04335045|Placebo Comparator|Control for 800mg Dose|4 placebo capsules (n=2)
88819930|NCT04335045|Active Comparator|1200mg Dose|6 x 200 mg PH100 capsules (n=6)
88819931|NCT04335045|Placebo Comparator|Control for 1200mg Dose|6 placebo capsules (n=2)
88819932|NCT04335045|Active Comparator|1600mg Dose|8 x 200 mg PH100 capsules (n=6)
88819933|NCT04335045|Placebo Comparator|Control for 1600mg Dose|8 placebo capsules (n=2)
88819934|NCT00372645|Experimental|Diet|200 µg folate per day from folate-rich foods
88819935|NCT00372645|Experimental|Folic acid supplement|200 µg folate per day from supplemental folic acid
88819936|NCT00372645|Experimental|Metfolin supplement|200 µg folate per day from supplemental Metafolin®
88819937|NCT00372645|Placebo Comparator|Placebo|Placebo
88819938|NCT04335435|Experimental|Oat Bran Consumption|Each subject consumed 120 g of oat bran (by dry weight) in a single dose, and samples (urine and fecal) were collected at different time points following the administration of oat bran.
88819939|NCT04279431||SIC Negative|Subjects will include males and females ranging from ages 18 to 85 who are admitted to the ED with a traumatic, closed head injury within 3 days of injury. Subject will undergo site standard clinical ED evaluation and a BrainScope evaluation. The SIC negative group are those patients who obtain a 'Negative' result on the BrainScope One Structural Injury Classifier (SIC) algorithm.
89420674|NCT02228772|Experimental|MLN 9708|"Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.~MLN 9708 will be given with standard multi-drug regimen for ALL . MLN 9708 will be administered on determined days during Induction therapy cycle and Consolidation cycle. If remission occurs and if eligible, the next stage with be either Stem Cell or Bone Marrow Transplant.~If not eligible to receive a transplant, the participant will continue on this study for the next 3 stages.~CNS Therapy~Consolidation 2~Continuation Therapy~No further MLN9708, the investigational drug, will be given after Consolidation 1 Standard chemotherapy -Vincristine, Cytarabine, Doxorubicin, Mercaptopurine, Cyclophosphamide, Methotrexate"
89420675|NCT03638466|Active Comparator|Single dose of SPN-810|Subjects will be treated with medium dose of SPN-810
89420676|NCT03638466|Placebo Comparator|Placebo|Subjects will be treated with a matching Placebo
89420677|NCT04786899||Hispanic/Latino patients undergoing cardiothoracic surgery|Observational study of patients scheduled for cardiothoracic surgery as part of standard of care. Patients will be followed up to 30 days prior to surgery and up to 7 days after surgery or hospital discharge, whichever is sooner. Patients preoperative sleep patterns and postoperative delirium will be followed.
89420678|NCT03630588|Placebo Comparator|Placebo|
89420679|NCT03630588|Experimental|Surimi intervention|
89420680|NCT02228850|Experimental|Alprostadil Cream (300mcg)|300 micrograms/.42% Alprostadil Cream with 2.5% Dodecyl-2-N,N-dimethylaminopropionate hydrochloride (DDAIP-HCl) and Placebo, one dispenser for each administration
89420681|NCT02228850|Experimental|Alprostadil Cream (1000mcg)|1000 micrograms/.42% Alprostadil Cream with 2.5% Dodecyl-2-N,N-dimethylaminopropionate hydrochloride (DDAIP-HCl) and Placebo, one dispenser for each administration
89420682|NCT02228850|Experimental|Alprostadil Cream (3000mcg)|3000 micrograms/.42% Alprostadil Cream with 2.5% Dodecyl-2-N,N-dimethylaminopropionate hydrochloride (DDAIP-HCl) and Placebo, two dispensers for each administration
89420683|NCT03826095||Multiple Sclerosis|Patients with a clinically definitive diagnosis of MS, 0-5.5 Extended Disability Status Scale range.
89420684|NCT03826095||Healthy individuals|Voluntary healthy individuals with similar age and gender
89420685|NCT02232828|Experimental|Selective removal|
89420686|NCT02232828|Active Comparator|Stepwise removal|
89420687|NCT03825393||Fibromyalgia|Non-anemic FMS patients who were diagnosed based on 2011 FMS diagnostic criteria of the American Rheumatology College
89420688|NCT03825393||Control|Non-anemic women without a FMS diagnosis
89420689|NCT02232906|Experimental|intravenous ferric carboxymaltose|
89194466|NCT04039516|Experimental|Lutathera Treatment Arm|• 4x cycles of 7.4 GBq (200mCi) of Lutathera therapy (177Lu-DOTA0-Tyr3-Octreotate) with concomitant amino acids for participants randomised onto the Lutathera therapy arm, every 8 weeks, plus long term somatostatin analogues (SSTA).
88900296|NCT01508689|Other|Receive cereal bars second|This group will receive Kellogg's Nutri-Grain® cereal bars during the last three weeks of the study.
89194467|NCT04039516|No Intervention|Best Supportive Care|Somatostatin analogue treatment according to current standard, routine care
89194468|NCT00736892||A|All patients meeting the American European Consensus definition of acute lung injury will be included, regardless of etiology of respiratory failure. Specifically, all patients with rapid onset of acute lung injury not of cardiac origin (no indication of heart failure or a pulmonary capillary wedge pressure of greater than 18 mmHg, with pulmonary infiltrates in all four quadrants and a PaO2/FIO2 of > 200 to <300 mmHg or ≤ 200 mmHg.
89420690|NCT03563001|Experimental|Chronic Obstructive Pulmonary Disease Group|Patients with diagnosis of chronic obstructive pulmonary disease according to Global Initiative for Chronic Obstructive Disease(GOLD 2018) are recruited.Small airways function of is assessed at baseline.And then budesonide(160ug) and formoterol(4.5ug) bid will be given to the subjects for 3 months.The subjects will have a follow-up visit with the same examinations after 3 months' treatment.
89420691|NCT03563001|Experimental|Asthma-Chronic Obstructive Pulmonary Disease Overlap Group|Patients with diagnosis of asthma-chronic obstructive pulmonary disease overlap according to Global Initiative for Chronic Obstructive Disease(GOLD 2018),Global Initiative for Asthma(GINA 2018) and Spanish COPD Guidelines(GesEPOC 2017) are recruited.Small airways function of is assessed at baseline.And then budesonide(160ug) and formoterol(4.5ug) bid will be given to the subjects for 3 months.The subjects will have a follow-up visit with the same examinations after 3 months' treatment.
89420692|NCT02228928|Experimental|CAPNP, 50 ug/cm2 capsaicin patch|50 ug/cm2 capsaicin patch, 49cm2, 1patch/4days
89420693|NCT02228928|Experimental|CAPNP, 100 ug/cm2 capsaicin patch|100ug/cm2 capsaicin patch, 49cm2, 1patch/4days
89420694|NCT02228928|Active Comparator|0.075% capsaicin cream|capsaicin cream qc/day
89420695|NCT02228928|Placebo Comparator|Placebo patch|
89420696|NCT03888378|Active Comparator|0.3% Topical Minocycline Ointment|Topical administration of 0.3% Topical Minocycline Ointment. Regimen: Apply BID (twice daily), morning and evening to eyelid margin
89420697|NCT03888378|Active Comparator|1% Topical Minocycline Ointment|Topical administration of 1% Topical Minocycline Ointment. Regimen: Apply BID (twice daily), morning and evening to eyelid margin
89420698|NCT03888378|Placebo Comparator|Topical Vehicle Ointment|Topical administration of Topical Vehicle Ointment. Regimen: Apply BID (twice daily), morning and evening to eyelid margin
89420699|NCT03603288|Experimental|idebenone 150 mg film-coated tablets|900 mg idebenone/day (2 tablets to be taken 3 times a day with meal)
89420700|NCT03597360|Experimental|CT scan subjects|Three participants with severe Alzheimer's dementia will be studied
89420701|NCT02229006||Aneurysm surveillance|Radiation: 18F-NaF PET-CT
88900297|NCT01508715|Active Comparator|Concentric exercise group|The participants in this group will perform the intervention exercises by actively completing the lifting portion of the resistive shoulder exercises. The physical therapist will then perform the lowering portion of the exercise for the participant.
89420702|NCT02229006||Control patients|Radiation: 18F-NaF PET-CT
89420703|NCT03576534|No Intervention|Control|Standard of care
89420704|NCT03576534|Active Comparator|Study|PBUF used prior to Cardiopulmonary bypass
89420705|NCT03556956|Experimental|Masitinib plus FOLFIRI|"Masitinib in combination with FOLFIRI (irinotecan, 5-fluorouracil and folinic acid).~Masitinib will be prescribed until disease progression (or treatment switch to next line of treatment), death, limiting toxicity or patient consent withdrawal."
89420706|NCT03556956|No Intervention|Best Supportive Care|Best Supportive Care (BSC) includes any concomitant medications or treatments: antibiotics, analgesics, radiation therapy for pain control (limited to bone metastases), corticosteroids, transfusions, psychotherapy, growth factors, palliative surgery, or any other symptomatic therapy necessary to provide BSC, except other investigational anti-tumor agents or anti-neoplastic chemo/hormonal/immuno-therapy.
89420707|NCT02229162||90 seconds DCC|the initial 15-20 subjects (15 enrolled subjects who complete study) will have cord clamped at 90 seconds. Then data will be analyzed and evaluated by DSMB
89420708|NCT02229162||Two minutes DCC|If Data Safety Monitoring Board (DSMB) concurs, DCC will then be practiced for 2 minutes for second group, which is the minimum amount of time recommended to be defined as DCC.
89420709|NCT02750592|Experimental|secukinumab 150mg|A screening (SCR) epoch running 4-10 weeks before baseline (BSL) was used to assess eligibility followed by 52 weeks of treatment. The treatment periods consist of Treatment period 1 (BSL to Week 24) and Treatment period 2 (Week 24 to Week 52). After Week 52 follows a post-treatment follow-up until Week 60. A follow-up visit was done at 12 weeks after last study treatment administration for all patients, regardless of whether they completed the entire study as planned (Week 60) or discontinue prematurely.
89420710|NCT03857646|Other|Intralipid|
89420711|NCT03857646|Other|SMOF lipid|
89420712|NCT03844074|Experimental|bevacizumab|ONS-5010
89420713|NCT03844074|Active Comparator|ranibizumab|
89420714|NCT02624986|Experimental|DLBCL Non-Bridging: Idasanutlin 100 mg + Obinutuzumab 1000 mg|Participants with diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 100 milligrams (mg) orally in combination with a fixed dose of obinutuzumab 1000 mg intravenously (IV) for 6 cycles (1 cycle = 28 days).
89420715|NCT02624986|Experimental|DLBCL Non-Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg|Participants with diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).
88900298|NCT01508715|Experimental|Eccentric exercise group|The participants in this group will actively perform the lowering portion of the resistive shoulder exercises in the intervention. The physical therapist will perform the lifting portion of the exercise for the participant.
88900299|NCT01508728|Experimental|Active vibration|
88900300|NCT01508728|Placebo Comparator|Placebo Vibration|
88900301|NCT01508741|Active Comparator|5-Aminolevulinic Acid (5-ALA)|Active component 50 mg. capsules of 5-Aminolevulinic Acid (5-ALA)
88900302|NCT01508741|Placebo Comparator|Placebo capsule|Non-active component capsules
88900303|NCT01508754|Active Comparator|CPAP|Treatment with Continuous Positive Airway Pressure
88900304|NCT01508754|No Intervention|Control|Usual anti-hypertensive treatment without CPAP treatment
88900305|NCT01508767|Experimental|Study group 1|Early removal of urethral catheter 48 hours post-operatively.
88900306|NCT01508767|Other|Study group 2|Removal of urethral catheter once epidural analgesia has been withdrawn.
88900307|NCT01508780|Experimental|Pulmonary Arterial Hypertension, bosentan|Subjects include patients being diagnosed with pulmonary arterial hypertension and starting treatment with bosentan.
88900308|NCT01508793|No Intervention|Control|
88900309|NCT01508793|Experimental|Optimize Sleep|
88900310|NCT01508806|Experimental|Normal renal function|
88900311|NCT01508806|Experimental|Mild renal impairment|
88900312|NCT01508806|Experimental|Moderate renal impairment|
88900313|NCT01508806|Experimental|Severe renal impairment|
88900314|NCT01508806|Experimental|End-stage renal disease|
88900315|NCT01508819||1|Guidelines for ICU admission of elderly patients arriving in Emergency Departments with a life threatening conditions
88900316|NCT01508819||2|no intervention
88900317|NCT01508845|Active Comparator|High MUFA/PUFA, 1600 IU vitamin D3|Subjects will receive 3 meals (1 day) with a high MUFA/PUFA ratio (20g/5g), along with 800 IU of vitamin D3 and 800 IU of deuterated vitamin D3
88900318|NCT01508845|Active Comparator|High MUFA/PUFA, 50,800 IU vitamin D3|Subjects will receive 3 meals (1 day) with a high MUFA/PUFA ratio (20g/5g), along with 50,000 IU of vitamin D3 and 800 IU of deuterated vitamin D3
88900319|NCT01508845|Active Comparator|Low MUFA/PUFA, 50,800 IU vitamin D3|Subjects will receive 3 meals (1 day) with a low MUFA/PUFA ratio (5g/20g), along with 50,000 IU of vitamin D3 and 800 IU of deuterated vitamin D3
89420716|NCT02624986|Experimental|DLBCL Non-Bridging: Idasanutlin 200 mg + Obinutuzumab 1000 mg|Participants with diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 200 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).
89420717|NCT02624986|Experimental|DLBCL Bridging: Idasanutlin 150 mg + Rituximab 375 mg/m^2|Participants with diffuse large B-cell lymphoma (DLBCL) in this bridging cohort received induction treatment with idasanutlin 150 mg orally in combination with rituximab 375 milligrams per square meter of body surface area (mg/m^2) IV for 6 cycles (1 cycle = 28 days).
89420718|NCT02624986|Experimental|DLBCL Bridging: Idasanutlin 200 mg + Rituximab 375 mg/m^2|Participants with diffuse large B-cell lymphoma (DLBCL) in this bridging cohort received induction treatment with idasanutlin 200 mg orally in combination with rituximab 375 mg/m^2 IV for 6 cycles (1 cycle = 28 days).
89530795|NCT03232723|Other|MEG Recording|Magnetic fields will be recorded using a 275-channel whole-head MEG system
89420719|NCT02624986|Experimental|FL Non-Bridging: Idasanutlin 100 mg + Obinutuzumab 1000 mg|Participants with follicular lymphoma (FL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 100 milligrams (mg) orally in combination with a fixed dose of obinutuzumab 1000 mg intravenously (IV) for 6 cycles (1 cycle = 28 days).
89420720|NCT02624986|Experimental|FL Non-Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg|Participants with follicular lymphoma (FL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).
89420721|NCT02624986|Experimental|FL Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg|Participants with follicular lymphoma (FL) in this bridging cohort received induction treatment with single-agent obinutuzumab 1000 mg IV for Cycle 1 and then idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for Cycles 2-6 (1 cycle = 28 days).
89420722|NCT04412200|Experimental|Hyperbaric oxygen chamber Arm|Patients will be randomized at a ratio of 2:1, to hyperbaric chamber (100% oxygen at 2 ATA)
89420723|NCT04412200|No Intervention|Control arm|control group will receive common practice management.
88900320|NCT01508845|Active Comparator|Fat free meal, 50,800 IU vitamin D3|Subjects will receive 3 fat-free meals (1 day) and 50,000 IU vitamin D3 and 800 IU of deuterated vitamin D3
88900321|NCT01508858|Experimental|Treatment period 1|
88900322|NCT01508858|Placebo Comparator|Treatment period 2|
88900323|NCT01508871||Cardiomyopathy|
88900324|NCT01508884|Active Comparator|IM vaccine and placebo cream|A single dose of intramuscular influenza vaccine (15ug non-adjuvanted 2011/2012 TIV) with pre-treatment of the injected skin with aqueous cream
88900325|NCT01508884|Active Comparator|ID vaccine and placebo cream|A single dose of intradermal influenza vaccine (15ug non-adjuvanted 2011/2012 TIV) with pre-treatment of the injected skin with aqueous cream
88900326|NCT01508884|Experimental|ID vaccine and imiquimod cream|A single dose intradermal influenza vaccine (15ug non-adjuvanted 2011/2012 TIV) with pre-treatment of the injected skin with imiquimod cream applied to the skin before vaccination
88900327|NCT01508923|Experimental|Treatment period 1|
88900328|NCT01508923|Placebo Comparator|Treatment period 2|
88900329|NCT01508975|Experimental|white rice|White rice
88900330|NCT01508975|Experimental|Brown rice|Brown Rice
88900331|NCT01508975|Experimental|Glucose|Glucose
88900332|NCT01508988|Experimental|Eye drops 0.3 µg/mL|
89194469|NCT05741684|Experimental|iCBT and ABM|A combined internet-delivered Cognitive Behavioral Therapy (iCBT) and Attention Bias Modification (ABM) intervention to reduce depressive symptoms in firefighters.
89420724|NCT03058198|Experimental|High Grade Glioma|"We plan to perform PET scanning on the patients with high grade gliomas after the injection of the second generation of EGFR tracer ,89Zr-ABT806（1-2mCi）, which can be specifically binded to EGFR vⅢ . After fusing the PET and MRI images, we precisely obtained the tissue from thehot-spot on the PET image through multimodal-neuronavigation-guided tumor biopsy. EGFRvⅢ status was detected by Sanger sequencing to analyze the correlation with the 89Zr-ABT806 PET image qualitatively and quantitatively. The final goal was to detect EGFR vⅢ by noninvasive molecular imaging procedure for the clinical outcome prediction and the selection of EGFR-targeted therapies."
88900333|NCT01508988|Experimental|Eye drops 1 µg/mL|
88900334|NCT01508988|Experimental|Eye drops 3 µg/mL|
88900335|NCT01508988|Experimental|Eye drops 10 µg/mL|
88900336|NCT01508988|Experimental|Eye drops 20 µg/mL|
88900337|NCT01508988|Experimental|Eye drops 30 µg/mL|
88900338|NCT01508988|Experimental|Eye drops placebo|
88900339|NCT01509001|Active Comparator|metformin|Participants will randomized into Metformin (750 to 2500 mg/day) or Glimepiride (1 to 8 mg/day) therapy. After 4 months, the patients will crossed-over with no washout period to the alternative treatment for an additional 4-month period on similar dosage schedule
88900340|NCT01509001|Active Comparator|glimepiride|Participants will randomized into Metformin (750 to 2500 mg/day) or Glimepiride (1 to 8 mg/day) therapy. After 4 months, the patients will crossed-over with no washout period to the alternative treatment for an additional 4-month period on similar dosage schedule
88900341|NCT01509014|Experimental|Pharmacy Intervention Arm|All patients receiving statins from pharmacies allocated to the pharmacist intervention arm of the study
88900342|NCT01509014|No Intervention|Usual Care|Pharmacies not allocated to the intervention arm will serve as the control. They received no training on the CPATCH intervention and provide usual care to patients at their pharmacy.
88900343|NCT01509027|Active Comparator|Education by DVD and dietician|Information on detrimental conseqences of hyperphosphatemia is presented on DVD and individual dietary counseling is given by dieticican
89194470|NCT05741684|No Intervention|Control|No intervention
89194471|NCT00615550|Placebo Comparator|Placebo|placebo vaginal gel
88900344|NCT01509027|Active Comparator|Education by unpersonalised DVD|Information on detrimental consequences of hyperphosphatemia is presented on DVD
88900345|NCT01509027|Placebo Comparator|Standard Care|standard care
88900346|NCT01509066|Experimental|Vegan diet|A vegan diet is one that does not contain any animal products (no meat, fish, poultry, eggs, or dairy) but emphasizes plant-based foods, such as fruits, vegetables, whole grains, and legumes/beans. We will also ask participants to keep foods low in fat and low in glycemic index.
88900347|NCT01509066|Active Comparator|Low-calorie|A low-calorie diet contains all food groups. However, participants will be provided with a calorie goal which should promote weight loss.
88900348|NCT01509092|No Intervention|obervation|patients in this arm received 6-months observation alone after injury
88900349|NCT01509092|Active Comparator|Surgical intervention|patients in this arm received vitrectomy surgery as soon as possible after injury
88900350|NCT01509131|Experimental|2L PEG-CS plus bisacodyl|Patients will be asked to take 2L PEG-CS plus bisacodyl (10-20 mg according to patient bowel habit)
88900351|NCT01509131|Active Comparator|2L PEG-ASC|Patients will be asked to take PEG-ASC according to labeling instructions
89420725|NCT04946500||Clindamycin and Rifampicin|Patients treated with Clindamycin and Rifampicin
89194472|NCT00615550|Active Comparator|Prochieve|Progesterone 8% Vaginal Gel
89194473|NCT04039594||ECMO|
89194474|NCT00864994||1|• 30 healthy subjects with 20 pack years smoking who have no signs of COPD (age 40-75 years)
89194475|NCT00864994||2|• 30 COPD patients with GOLD stage II (age 40-75 years)
89194476|NCT00873184|Other|1|A prospective, single-arm intervention study, potential participants will be identified and screened for eligibility via medical record review of patient scheduled for their post surgical primary adjuvant treatment consultation at DUMC.
89194477|NCT05127538|Active Comparator|Individuals diagnosed with neuropathic pain due to type 2 diabetes|"Individuals between the ages of 40-65~Individuals who take 4 points or more from the Douleur Neuropathique en 4 questions (DN4) questionnaire~Individuals who take 12 points or more from the Leeds Assessment of Neuropathic Signs and Symptoms (LANSS) scale"
89194478|NCT05127538|Active Comparator|Individuals with type 2 diabetes but no neuropathic pain|"Individuals between the ages of 40-65~Individuals who take 4 points from the Douleur Neuropathique en 4 questions (DN4) questionnaire~Individuals who take 12 points from the Leeds Assessment of Neuropathic Signs and Symptoms (LANSS) scale"
89194479|NCT05127538|Active Comparator|Healthy control group|"Individuals between the ages of 40-65~Individuals who have no pain (Taking 1 point or less according to the Visual Pain Scale)"
89194480|NCT00736164|Experimental|Arm I|Patients receive oral selenomethionine once daily for 8-9 weeks.
89194481|NCT00736164|Placebo Comparator|Arm II|Patients receive oral placebo once daily for 8-9 weeks.
89194482|NCT00739830|Experimental|1|40 mg once daily oral tablets for 5 days followed by 2 days without ridaforolimus
89194483|NCT00739830|Active Comparator|2|Investigator's choice of: oral medroxyprogesterone acetate tablets 200 mg daily or oral megestrol acetate tablets 40 mg 4 times per day (160 mg daily) OR Chemotherapy - carboplatin, paclitaxel, doxorubicin, pegylated liposomal doxorubicin or topotecan administered as a single agent or as a doublet, and will be administered at doses and schedules chosen by the investigator
89194484|NCT05111782|Experimental|Treatment Group|The treatment group will consist of persons with low back pain. This group will be further divided into groups for each decade.
89194485|NCT05111782|No Intervention|Healthy Control Group|The control group will consist of healthy controls. This group will be further divided into groups for each decade.
89194486|NCT00577382|Experimental|Sunitinib|"Cohort A participants received 50 mg sunitinib orally daily for 4 weeks followed by a two-week break from treatment. These 6-week cycles would be repeated until progression or unacceptable toxicity up to 1 year.~Cohort B participants received 37.5 mg sunitinib daily on a continuous basis until progression or unacceptable toxicity up to 1 year."
89194487|NCT00733434|Experimental|1|Patients receiving PGE 1 80mcg/500 ml saline continuous intravenous infusion per day after head and neck microsurgery for 5 days
88900352|NCT01509144|Active Comparator|nasal active low dose + IM active|Group 1 Nasal vaccine - Low-dose (20 µg in 40 µL) IM vaccine (200 µg in 400 µL)
88900353|NCT01509144|Active Comparator|nasal active mid dose + IM active|Group 2 Nasal vaccine - Mid-dose (100 µg in 200 µL) IM vaccine (200 µg in 400 µL)
89194488|NCT00733434|Placebo Comparator|2|Patients receiving 500 ml saline continuous intravenous infusion per day after head and neck microsurgery for 5 days
89194489|NCT04039282|Other|Patient Participant|Patients will be asked to complete an 3 days worth of an online dietary recall prior to their out patient appointment with the dietitian
89194490|NCT04039282|Other|Dietitian Participant|The Dietitian will be asked to review the patients completed dietary recalls prior to the patient attending their out patient appointment.
89194491|NCT00736320|Active Comparator|A|2 cycles ABVD followed by 20 Gy IF-RT irrespective of FDG-PET results after chemotherapy
89194492|NCT00736320|Experimental|B|2 cycles ABVD followed by 20 Gy IF-RT if FDG-PET is positive after chemotherapy; 2 cycles ABVD and treatment stop if FDG-PET is negative after chemotherapy
89194493|NCT00878566|Active Comparator|Usual Care|
89194494|NCT00878566|Experimental|Enhanced pharmacist care|
89194495|NCT04065282|Experimental|neoadjuvant therapy with Sintilimab plus Xelox|3 cycles of neoadjuvant therapy: Sintilimab iv d1 Q3W, Oxaliplatin 130mg/m2 iv d1 Q3W, and Capecitabine 1000mg/m2 po Bid d1-14 Q3W
89194496|NCT00873262|Active Comparator|Hormones|
89194497|NCT00873262|Placebo Comparator|Solvent|
88900354|NCT01509144|Active Comparator|nasal active full dose + IM active|Group 3 Nasal vaccine - Full-dose (200 µg in 400 µL) IM vaccine (200 µg in 400 µL)
88900355|NCT01509144|Active Comparator|nasal placebo + IM active|Group 4 Nasal Placebo - 400 µL IM vaccine (200 µg in 400 µL)
88900356|NCT01509144|Placebo Comparator|nasal placebo + IM placebo|Group 5 Nasal placebo - 40 µL in Cohort 1 / 200 µL in Cohort 2 IM placebo (400 µL)
89194498|NCT00736970|Experimental|1|10 mg oral tablets administered at 40 mg once daily for 5 consecutive days each week, followed by 2 days without ridaforolimus
89194499|NCT00879736|Active Comparator|THT PACE eLearning module|The PACE (prepare, ask, check, express) training methodology will be available to patients before their 2nd doctor visit
89194500|NCT00879736|Active Comparator|THT PACE eLearning module & nurse-led workshop training|THT PACE eLearning and then nurse-led workshop for training on PACE methodology
89194501|NCT00879736|Placebo Comparator|Usual care|Patients just go to their doctor as they normally would but get some disease specific information in the form of brochures as do intervention arms
89194502|NCT00873340||Group 1|
89194503|NCT00736398||Observation|Spinal fusion
89420726|NCT04946500||Clindamycin and Fluoroquinolone|Patients treated with Clindamycin and Fluoroquinolone
89420727|NCT04946578|Experimental|Prebiotic intervention group|Prebiotic supplementation
89420728|NCT04946578|Placebo Comparator|Placebo control group|Maltodextrin
89420729|NCT04946422||sports injury-related injuries|"Patients who are discharged from the hospital and diagnosed in accordance with sports injury-related injuries, and those whose service item names in the detailed database contain the keyword arthroscope. Any one of the above will be included in this topic."
88900357|NCT01509157|Experimental|MDRS system|Participants will be using the MDRS system combined with their regular treatment with Continuous Glucose Monitoring during nightime for 2 weeks. The MDRS will allow the supervising personal to get real time remote data of glucose level and to alarm the patients and intervene in cases such as pending hypoglycemia, long standing hyperglycemia or technical faults
89420730|NCT04945954|Experimental|Cyclophosphamide|
89420731|NCT04946188|Experimental|Opuz NICGM|Participants will be provided with one non-invasive, custom-built prototype device (study device), which they will use throughout their day-to-day life/activities over the study period.
89420732|NCT04945564|Experimental|Oxygen therapy and physical therapy|
89420733|NCT04945564|Active Comparator|Oxygen therapy|
89420734|NCT04945252|Experimental|Care Navigation group|The teachers will signpost dental caries based on ICCMS visual criteria and refer to the nearest service. Annual monitoring of caries
89420735|NCT04945252|No Intervention|No internvention|Caries experience (dmft) activity monitored annually
89420736|NCT04945096|Experimental|Acetylcysteine + decitabine|Acetylcysteine (1.2g twice a day, oral administration, from day -10 to day 365 after HSCT). Conditional regimen: decitabine (20mg/m2 intravenously from day -10 to day -8 of conditional regimen); semustine 250 mg/m2/day on day -9; cytarabine 2 g/m2 every 12 hours on day -8; busulfan 3.2mg/kg/day on day -7 to -5; cyclophosphamide 1.8g/m2/day on day -4 to -3; cyclosporin A: 3mg/kg/d from day -8. Anti-thymocyte globulin (2mg/kg/d on day -5 to day -2) and mycophenolate (500mg, oral, twice a day from day -8) were usually added for transplants with unrelated donor or HLA mismatched donor.
89420737|NCT04945096|Active Comparator|Standard Treatment|Conditional regimen: semustine 250 mg/m2/day on day -9; cytarabine 2 g/m2 every 12 hours on day -8; busulfan 3.2mg/kg/day on day -7 to -5; cyclophosphamide 1.8g/m2/day on day -4 to -3; cyclosporin A: 3mg/kg/d from day -8. Anti-thymocyte globulin (2mg/kg/d on day -5 to day -2) and mycophenolate (500mg, oral, twice a day from day -8) were usually added for transplants with unrelated donor or HLA mismatched donor.
89420738|NCT04944394||hospital professionals|all professionals working in hospitals in France
88900358|NCT01509157|Active Comparator|Continuous Glucose Monitoring|Participants will be using their regular Continuous Glucose Monitoring during nightime for 2 weeks, without using the MDRS remote control system
89420739|NCT04823806|Experimental|Healthy participants and participants with depressive disorder: dietary spermidine supplementation|Dietary Supplement: Polyamine 21 days of spermidine supplementation (3 sachets/day = 6mg spermidine/day)
88900359|NCT01509196|Experimental|HIP0901|Fenofibric acid
89420740|NCT04823806|Placebo Comparator|Healthy participants and participants with depressive disorder: dietary placebo supplementation|Dietary Supplement: Placebo 21 days of Placebo supplementation (3 sachets/day)
88900360|NCT01509196|Active Comparator|Lipidilsupra|Fenofibrate
88900361|NCT01509209|Placebo Comparator|Placebo|placebo
89420741|NCT04944238||Patients implanted with Ankoris IOL|To assess the IOL stability, slitlamp photos of the consecutive 30 patients with respect to time will then be analysed with a 5% confidence interval.
89420742|NCT04411108|Active Comparator|Exercise Instruction by PT and written handout|
89420743|NCT04411108|Experimental|Exercise Instruction by Motion Coach Technology|
89420744|NCT04944472||group I|"All participants will be divided into 4 groups (4 separate accounts), similar in gender, age and social status:~in group I, project participants will only be presented with video publications on each of the declared topics (8 in total)."
89420745|NCT04944472||group II|"All participants will be divided into 4 groups (4 separate accounts), similar in gender, age and social status:~in group II - only text publications (total 8)."
89420746|NCT04944472||group III|"All participants will be divided into 4 groups (4 separate accounts), similar in gender, age and social status:~in group III - first text publications, and then video publications (16 in total)."
89420747|NCT04944472||group IV|"All participants will be divided into 4 groups (4 separate accounts), similar in gender, age and social status:~in group IV - first video publications, and then text publications (16 in total)."
89420748|NCT04944082|No Intervention|Remdesivir only|(Dose 200 mg day one, 100 mg daily days 2-5), duration may extend to 10 days of remdesivir (200 mg day one, 100 mg daily days 2-10)
89420749|NCT04944082|Experimental|Combination remdesivir plus ivermectin group|(The same remdesivir dose as mentioned + ivermectin 4 tablet (6mg) once daily before meal for four days)
89420750|NCT04944004|Experimental|Experimental CBCT Group|Participants of CBCT group will attend individual computer-based cognitive training sessions. Researcher will give instruction in the use of the computerized training programs and assists participants during their training sessions.
89420751|NCT04944004|Active Comparator|Training As Usual (TAU) Group|Participants of TAU group will attend usual training sessions offered by the training centres with similar intensity and frequency as the CBCT training.
89420752|NCT04943692|Experimental|Group A: Metformin glycinate 1050 mg|Metformin glycinate 1050 mg Orally twice a day.
89420753|NCT04943692|Active Comparator|Group B: Metformin hydrochloride 850 mg|Metformin hydrochloride 850mg Orally twice a day.
88900362|NCT01509209|Experimental|Cossac L|Pseudoephedrine 120mg + Levocetirizine 2.5mg
88900363|NCT01509222|Other|Personalized nurition counseling|Personalized nutrition counseling based on dietary intake and motivation to change.
88900364|NCT01509222|No Intervention|Control|No intervention, control group.
89420754|NCT02587598|Experimental|Parts 1 and 2: INCB053914 100 mg QD|INCB053914 will be self-administered orally once a day in as a 100mg immediate release tablet as a monotherapy.
89420755|NCT02587598|Experimental|Parts 3 and 4: INCB053914 + Azacitidine|Azacitidine will be administered at a dose of 75 mg/m2 subcutaneously or via IV per day, as a combination therapy with INCB053914.
89420756|NCT02587598|Experimental|Parts 3 and 4: INCB053914 + I-DAC (Intermediate dose cytarabine)|I-DAC (intermediate dose cytarabine) will be administered at a dose of 1 g/m2 per day as an infusion as a combination therapy with INCB053914.
88900365|NCT01509235|Experimental|1. Exercise testing and self drainage session|
89420757|NCT02587598|Experimental|Parts 3 and 4: INCB053914 + Ruxolitinib|Ruxolitinib will be administered as an oral dose between 5 mg to 25 mg twice per day, as a combination therapy with INCB053914.
89420758|NCT02587598|Experimental|Parts 1 and 2: INCB053914 50 mg|INCB053914 will be self-administered orally twice day in as a 50mg immediate release tablet as a monotherapy.
88900366|NCT01509235|Active Comparator|2. Chest physiotherapy (CP) session|
88900367|NCT01509261|Experimental|Ilaprazole|Ilaprazole 20mg
88900368|NCT01509261|Active Comparator|lansoprazole|lansoprazole 30mg
89420759|NCT02587598|Experimental|Parts 1 and 2: INB053914 65 mg|INCB053914 will be self-administered orally twice day in as a 65mg immediate release tablet as a monotherapy.
88900369|NCT01509274|Experimental|Plasma|
88900370|NCT01509274|Sham Comparator|Saline|
88900371|NCT01509274|Active Comparator|Physiotherapy + heel cap|
88900372|NCT01509300|Experimental|HAPLO|
88900373|NCT01509313|Experimental|Uterine polypectomy using morcellator|A new instrument using a mechanical cutting edge has come to market for uterine polypectomy. In patients having a general anaesthesia the mechanical cutting instrument has been shown to be easier to learn, more effective at completely removing polyps and quicker than current techniques. However, the instrument is slightly larger, which could potentially cause more discomfort and prolong the procedure in the outpatient setting.
89194504|NCT00614926|Experimental|Modafinil|Eligible patients will be treated at baseline through Week 4. Those who choose to continue will have additional in-person visits at Weeks 8 and 12 visits (and Week 16 for those starting modafinil at Week 4).
89194505|NCT00614926|Placebo Comparator|Placebo|Sugar pill equivalent to the active comparator. Dosing schedule will be the same as the dosing schedule for Modafinil.
89194506|NCT00873418|Experimental|Coping Skills Training|16 week telephone intervention using coping skills training to teach heart failure patients self-management skills and how to cope more effectively with psychological distress associated with heart failure.
89194507|NCT00873418|Active Comparator|Educational Control|16 weekly telephone calls for extended (standardized) care on heart failure education.
89194508|NCT00873496||Sjögren|Pre and post treatment establishment of salivary flow rate, objective and subjective clinical oral complications' severity of the patients using hydroxychloroquine
89194509|NCT04849312||Training|A subset of patients that are used to train the machine learning algorithm.
89194510|NCT04849312||Validation|"A subset of patients that are held back and used to validate the algorithm's accuracy."
89420760|NCT02587598|Experimental|Parts 1 and 2: INB053914 80 mg|INCB053914 will be self-administered orally twice day in as a 80mg immediate release tablet as a monotherapy.
89420761|NCT02587598|Experimental|Parts 1 and 2: INB053914 100 mg BID|INCB053914 will be self-administered orally twice day in as a 100mg immediate release tablet as a monotherapy.
89420762|NCT02587598|Experimental|Parts 1 and 2: INB053914 115 mg|INCB053914 will be self-administered orally twice day in as a 115mg immediate release tablet as a monotherapy.
89420763|NCT04942990|Experimental|exercise training group|The duration of the study was targeted as 8 weeks. Our trainings consist of 3 sessions per week, with an average of 45 minutes of calisthenic exercises per session. Exercises initially started with an average of 30 minutes, 10 repetitions, gradually increased difficulty once every two weeks, time increased to 45 minutes movements were modified for those who were forced to perform the exercise program. The program was completed with 5 minutes of warm-up and 5 minutes of cooling exercises before exercise training. All exercises were conducted on a video chat platform supervised by an experienced physiotherapist.
89420764|NCT04942990|No Intervention|control group|no exercise was given
89420765|NCT04943146||control group|
89420766|NCT04943146||P+A group|aspirin: tablet 100mg qd 2-5weeks prednisone: tablet 10mg qd 2-5weeks
89420767|NCT04942912||French patients with juvenile Pompe disease|We aim to include all French patients with juvenile Pompe disease (maltase acid deficiency without cardiomyopathy)
89420768|NCT04942444|No Intervention|Control Group|Patients from the control group kept on taking the same medical treatment that they received before randomization
88900374|NCT01509313|Active Comparator|Electical Resection|At present the most commonly used device for removing the uterine polyps in the outpatient setting is by electrical resection. This will provide comparison for the morcellator device being tested
88900375|NCT01509326|Active Comparator|Chiropractic|spinal manipulation, mobilization, massage, advice, exercises
88900376|NCT01509326|Experimental|Chiropractic PLUS pillow|spinal manipulation, mobilization, massage, advice, exercises, pillow
88900377|NCT01509352|Active Comparator|with esophageal stitches|fundoplication with crural stitches
88900378|NCT01509352|Experimental|without esophageal stitches|fundoplication without crural stitches.
88900379|NCT01509365|No Intervention|sensible|Patients who show adequate response to loading dose of clopidogrel and receive standard 1x75 mg clopidogrel for at least 7 days.
89420769|NCT04942444|Experimental|Dry needling group|Besides maintaining their current medical treatment, patients from the experimental group received an additional weekly one-hour session of dry needling over the 18 tender points for a 6-week-period.
89420770|NCT02485574|Experimental|Left cage- auto bone|At the operated segment, left cage was filled with auto bone only. We evaluated bone bridging between inside and outside the cage in transforaminal lumbar interbody arthrodesis.
89420771|NCT02485574|Experimental|Right cage- auto local bone mixed with β-calcium phosphate + hydroxyapatite|At the operated segment, right cage was filled with auto local bone mixed with β-calcium phosphate + hydroxyapatite. We evaluated bone bridging between inside and outside the cage in transforaminal lumbar interbody arthrodesis.
89420772|NCT04942834|Active Comparator|Drug treatment group|receive class I or class III AAD to restore or maintain sinus rhythm.
89420773|NCT04942834|Experimental|cryoballoon ablation group|receive cryoballoon ablation to restore sinus rhythm.
89420774|NCT03484286|Other|Control group|Subject to standard care. No interventions above and beyond what is deemed standard care for heart failure patients in the region where the study takes place.
89420775|NCT03484286|Experimental|Intervention group|Device: OPTILOGG
89420776|NCT04942756|Experimental|Continuous Glucose Monitoring|"The FreeStyle Libre 2 Flash Glucose Monitoring System (FSL2) is a CGM device with real time alarms capability indicated for the management of diabetes in persons aged 4 and older. The Sensor holds eight (8) hours of data at a time. In order to have a daily diary of the Glucose level the patients or family or HCP must read the sensor (with reader or app) at least every height (8) hours. Every day at least three (3) scans of the sensor should be performed using the reader or the Smartphone App, generally at wake up in the morning, in the afternoon and at the time to go to sleep.~The alarm system will be activated, so that the Glucose level is over the cut off limit of 180 mmol/L or when it is lower than the cut-off limit of 80 mmol/L, the patient and/or the family members and/or the caregiver will check the Glucose level by scanning the reader/smartphone over the sensor."
89420777|NCT04942756|Active Comparator|Standard Care|"This arm will perform the usual standard routine for blood glucose monitoring in patients with insulin therapy, that is represented by at least three finger pricks/die according to the usual standards routine of each center.~Different frequency of finger pricks glucose measurements could be performed on the basis of health care professional patient assessment of each patient's needs."
89420778|NCT03484052|Other|Jugular ultrasound|
89420779|NCT04942132|Experimental|Treatment|A Smartphone self-administered cognitive-behavioral based intervention
89194511|NCT04040140|Experimental|APA Treatment|Oncology patients with a pain rating of four or greater will receive APA treatment for patients' cancer-related pain. The ear points will be determined by the corresponding body points related to the patient's specific pain. Pain data will be tracked by electronic surveys and Electronic Health Records.
89194512|NCT00879892|Active Comparator|Hypothermia and xenon|
89420780|NCT04941976|Experimental|0.3% benzydamine hydrochloride spray oromucosal solution|A single application of 0.3% benzydamine hydrochloride spray oromucosal solution, corresponding to 2.04 mg of benzydamine (4 nebulizations)
88900380|NCT01509365|Active Comparator|simple dose|Patients who show suboptimal response to loading dose of clopidogrel and receive 1x75 mg clopidogrel for 1 month followed by standard 75 mg clopidogrel for 3 months to one year.
88900381|NCT01509365|Experimental|double dose|Patients who show suboptimal response to loading dose of clopidogrel and receive 1x150 mg clopidogrel for 1 month followed by standard 75 mg clopidogrel for 3 months to one year.
88900382|NCT01509391|Experimental|Keyhole-limpet hemocyanine|
89194513|NCT00879892|Active Comparator|Hypothermia|
88900383|NCT01509417|Experimental|Ad lib feeding|ad lib feedings following pyloromyotomy
88900384|NCT01509417|Active Comparator|FLAP diet after pyloromyotomy|FLAP diet after pyloromyotomy
88900385|NCT01509430|Experimental|Early training patient|12 weeks of Progressive Resistance Training followed by 12 weeks of a self chosen level of physical activity
88900386|NCT01509430|Experimental|Late training patients|12 weeks of a self chosen level of physical activity followed by 12 weeks of progressive resistance training
89194514|NCT00873574||1|2 patients with MPD for each family. One case for each family will be randomised ; the cohort will be of 120 patients.
89194515|NCT00873574||2|1 control for each family
89420781|NCT04941976|Active Comparator|3 mg lozenge of benzydamine hydrochloride (mint flavour), corresponding to 2.68 mg of benzydamine|A single 3 mg lozenge of benzydamine hydrochloride (mint flavour), corresponding to 2.68 mg of benzydamine.
89420782|NCT04942288|Experimental|Acupressure + Massage Group|"Acupressure + Massage Group First menstrual cycle - On the first day, Personal Information Form, VAS, GMSSS and Quality of Life Scale Short Form SF- 12 will be applied. On the first day, intervention will be made and VAS will be applied after the intervention. On the second day, VAS will be applied before and after the intervention. On the third day, VAS before and after the intervention VAS, GMSSS will be applied.~Second menstrual cycle~- On the first day, VAS will be applied before the intervention, and VAS will be applied after (1 hour). On the second day, VAS will be applied before and after the intervention (1st hour). On the third day, VAS before and after the intervention (1st hour) VAS, GMSSS will be applied."
89530796|NCT03121547|Placebo Comparator|Placebo oral tablet|One inert calcium tablet is administered after a set of baseline measurements are performed. Subsequently outcomes are assessed every hour for 6 hours, yielding a total of 7 hourly measurements.
89194516|NCT00878956|Active Comparator|1|In all patients body weight adjusted dose of study medication will be achieved by infusion of sodium bicarbonate at a dose of 0.5 mmol/kg body weight (=bolus) diluted in 250 mL over 1 hour immediately after the induction of anesthesia, prior to the first surgical incision followed by continuous intravenous infusion of 0.2 mmol/kg/hr (=maintenance) diluted in 1000 mL 23 hours (total dose of 5 mmol/kg over 24 hours).
88900387|NCT01509443|Experimental|Interventional|Participants will receive standard asthmatic treatment and breathing/mild physical exercise
88900388|NCT01509443|No Intervention|Control Arm|The control arm will receive standard medical care for asthma
88900389|NCT01509456|Active Comparator|Potassium Bicarbonate|
88900390|NCT01509456|No Intervention|Control|
88900391|NCT01509469|Experimental|Low dose casein|Ileal infusion of low dose casein
88900392|NCT01509469|Experimental|High dose casein|Ileal infusion of high dose casein
89420783|NCT04942288|Experimental|Massage Group|"Massage Group First menstrual cycle - On the first day, Personal Information Form, VAS, GMSSS and Quality of Life Scale Short Form SF- 12 will be applied. On the first day, intervention will be made and VAS will be applied after the intervention (1st hour). On the second day, VAS will be applied before and after the intervention (1st hour). On the third day, VAS before and after the intervention (1st hour) VAS, GMSSS will be applied.~Second menstrual cycle~- On the first day, VAS will be applied before the intervention, and VAS will be applied after (1 hour). On the second day, VAS will be applied before and after the intervention (1st hour). On the third day, VAS before and after the intervention (1st hour) VAS, GMSSS will be applied."
89420784|NCT04942288|No Intervention|Control Group|"Control Group First menstrual cycle~- On the first day, Personal Information Form, VAS, GMSSS and Quality of Life Scale Short Form SF-36 will be applied. On the second day, VAS will be applied. On the third day, VAS, GMSSS will be applied.~Second menstrual cycle - On the first day, VAS, GMSSS will be applied. On the second day, VAS will be applied. On the third day, VAS, GMSSS will be applied.~Third menstrual cycle~- On the first day, VAS, GMSSS will be applied. On the second day, VAS will be applied. On the third day, VAS, GMSSS and Quality of Life Scale Short Form SF-12 will be applied."
89420785|NCT02624284|Sham Comparator|Sham dose|Participants in this arm will receive the sham transcranial direct current stimulation (tDCS) procedure. During sham tDCS, a 1.0 mA to 2.0 mA current will be delivered for approximately 30 seconds before being extinguished over a course of seconds. Again, the anodal electrode will be placed over the left F3 and the cathodal electrode over the right supraorbital area. Most participants cannot distinguish between real and sham tDCS.
89420786|NCT02624284|Experimental|1mA dose|Participants in this arm will receive the 1mA transcranial direct current stimulation (tDCS) procedure. A neuroConn DC-Stimulator Plus will apply a constant direct current (1.0 mA via 5x7 electrode) to the left dorsal lateral prefrontal cortex. Each participant will receive anodal stimulation for a period of 20 minutes. For anodal stimulation over the left DLPFC, the anodal electrode will be placed over the left F3 and the cathodal electrode over the right supraorbital area (international EEG 10/20 system).
89420787|NCT02624284|Experimental|2 mA dose|Participants in this arm will receive the 2 mA transcranial direct current stimulation (tDCS) procedure. A neuroConn DC-Stimulator Plus will apply a constant direct current (2.0 mA via 5x7 electrode) to the left dorsal lateral prefrontal cortex. Each participant will receive anodal stimulation for a period of 20 minutes. For anodal stimulation over the left DLPFC, the anodal electrode will be placed over the left F3 and the cathodal electrode over the right supraorbital area (international EEG 10/20 system).
89420788|NCT02738450|Active Comparator|ACI-24 low dose|Vaccine formulation will be administrated s.c. 7 times.
89420789|NCT02738450|Active Comparator|ACI-24 high dose|Vaccine formulation will be administrated s.c. 7 times.
89420790|NCT02738450|Placebo Comparator|Placebo|The placebo is ready-to-use solution for injection, administrated s.c. 7 times.
89420791|NCT04941820|Experimental|Clinical pharmacist intervention + usual care arm|Patients in the clinical pharmacist intervention + usual care arm received the clinical pharmacist intervention as well as usual care provided by the surgical team
89420792|NCT04941820|No Intervention|Usual care arm (Control arm)|Patients in the control arm received usual care by the surgical team without a coordinated contribution from the clinical pharmacist
89420793|NCT04941352|Experimental|Experimental: Study group|Study group intervention consists 6-session Interpersonal Relations Theory-Based Motivational Interviews and 3-month follow-up.
89420794|NCT04941352|No Intervention|No Intervention: Control group|Control group receives general care and the training booklet at the end of the study. Also includes 3-month follow-up.
89420795|NCT01291004|Experimental|28-day Desogestrel Oral Contraceptive|
89420796|NCT01291004|Active Comparator|28-day Drospirenone Oral Contraceptive|
89420797|NCT01291004|Active Comparator|28-day Levonorgestrel Oral Contraceptive|
89420798|NCT04941118|Sham Comparator|Control group|Only saline and local anesthetic (lidocaine)
89420799|NCT04941118|Active Comparator|Dextrose prolotherapy group|Dextrose, saline and local anesthetic (lidocaine)
89420800|NCT05136716|Active Comparator|Control|Children in this group received traditional physical therapy
89420801|NCT05136716|Experimental|Study|Children in this group received the same traditional physical therapy plus hyperbaric oxygen therapy
89420802|NCT04940806||120 patients with narcolepsy|
89420803|NCT03483974||neoplasm|neoplasm found in follow up
89420804|NCT03483974||non-neoplasm|non-neoplasm patients in follow up
89420805|NCT04940962|Experimental|Non-diabetic obese|
89420806|NCT04940962|Experimental|Diabetic obese|
89420807|NCT04940962|Active Comparator|Witnesses|
88900393|NCT01509469|Experimental|Low dose sucrose|Ileal infusion of low dose sucrose
88900394|NCT01509469|Experimental|High dose sucrose|Ileal infusion of high dose sucrose
88900395|NCT01509469|Placebo Comparator|Placebo|Ileal infusion saline
88900396|NCT01509469|Active Comparator|Safflower oil|Ileal infusion safflower oil
88900397|NCT01509482|Experimental|insulin resistance|unexplained oligospermia and azoospermia. Blood samples will be taken for hormonal and blood lipids analysis.
88900398|NCT01509482|Active Comparator|Fertile males|Healthy Men with proven fertility. Blood samples will be taken for hormonal and blood lipids analysis
89420808|NCT03480854|No Intervention|Baseline Analysis|To conduct studies of variation in performance across microsystems and to utilize benchmarking analyses to identify top performers.
89420809|NCT03480854|Experimental|The effect of continuous quality improvements (CQI)|To study the comparative improvement of selected primary process performance indicators (DMT and MRI process measures) over a 3 year period (Years 2-3) in microsystems receiving CQI interventions versus those not receiving CQI intervention, and between two different CQI intervention types (IHI Breakthrough Series and Patient Centered Medical Home).
89420810|NCT04940416||Cirrhosis|These will include patients with cirrhosis. They will perform the paper-based standard psychometric tests (number connection test A, number connection test B, line tracing test, and digital subtraction test, and serial dotting test, which take about 20 minutes). After completion of paper-based standard psychometric tests, participants will then perform the computer application test which takes about 5 minutes.
89420811|NCT04940416||Non-cirrhosis|These will include patients without cirrhosis seen in the general gastroenterology clinic. Participants will perform the paper-based standard psychometric tests (number connection test A, number connection test B, line tracing test, and digital subtraction test, and serial dotting test, which take about 20 minutes). After completion of paper-based standard psychometric tests, participants will then perform the computer application test which takes about 5 minutes.
89420812|NCT03483818|Active Comparator|Pharmacist-Led Pathway|Assessment & Treatment of HCV infection with oral antivirals in a community pharmacy pathway
89420813|NCT03483818|Active Comparator|Conventional Care Pathway|Assessment & Treatment of HCV infection with oral antivirals in a conventional care pathway
89420814|NCT04940728|Experimental|Creative Thinking Group|"Nursing students who took the Self-Knowledge and Communication Techniques course for the first time in March and agreed to participate in the study were divided into experimental (30) and control (30) groups using a simple randomization method.~Pre-tests (Descriptive Information Form, Communication Skills Scale, and Problem Solving Scale) were administered to the participants who volunteered to participate in the research using the Online Questionnaire System.~Considering the effect on the research data, after completing the routine courses of self-knowledge, communication skills, listening skills and problem solving skills; Intermediate tests (Communication Skills Scale, and Problem Solving Scale) were applied to the experimental and control groups.~An intervention program based on creative thinking techniques was applied to the experimental group and post-tests (Communication Skills Scale, and Problem Solving Scale) were applied."
89420815|NCT04940728|No Intervention|Standart Group|"Pre-tests (Descriptive Information Form, Communication Skills Scale, and Problem Solving Scale) were applied to the participants who volunteered to participate in the study by using the Online Questionnaire System.~Considering the effect on the research data, after completing the routine courses of self-knowledge, communication skills, listening skills and problem solving skills of the 4 main topics in the course; Intermediate tests (Communication Skills Scale, and Problem Solving Scale) were applied to the experimental and control groups by using the Online Questionnaire System.~After the interim tests were applied, no intervention was made to the control group until the end of the period. At the end of the semester, post-tests (Communication Skills Scale, and Problem Solving Scale) were applied."
89420816|NCT00374660|Experimental|1|
89420817|NCT04463108||Participants with MDD and Active Suicidal Ideation with Intent|Participants with Major Depressive Disorder (MDD) and active suicidal ideation with intent as defined/confirmed by Investigator will be enrolled and treated in accordance with routine clinical practice. The primary data source for this study will be the medical records of each participant.
89420818|NCT02624050|Active Comparator|Methohexital|Methohexital will be administered intravenously as a general anesthetic at a dosage of 1.5mg per kg of patient body weight.
89420819|NCT02624050|Active Comparator|Propofol|Propofol will be administered intravenously as a general anesthetic at a dosage of 2.5mg per kg of patient body weight.
89420820|NCT05152160|Experimental|Treatment group|Umbilical Cord Mesenchymal Stem Cell Therapy
89420821|NCT03483740|Experimental|Cognitive remediation group therapy|8 weekly 3-hour sessions of CRGT
89420822|NCT03483740|Active Comparator|Mutual aid support group|8 weekly 3-hour sessions of HIV group therapy
89420823|NCT04940104|Experimental|Botox|
89420824|NCT04940104|No Intervention|Control No Botox|
89420825|NCT03483428|Experimental|Parent Coaches|"Parent coaches will complete interventionist training and supervision in the Family Check-Up, an evidence-based behavioral parent training (BPT) program, including in the adaptations for families with DHH children. Each parent coach will deliver the intervention to 5 parent-child dyads."
89420826|NCT03483428|Experimental|Parent-Child Dyads|"Parents and children will receive the adapted Family Check-Up behavioral parent training (BPT) intervention delivered by parent coaches."
89420827|NCT03057886||Compare the Spot On with others consecrated thermometers|This study intends to compare the accuracy of the new device(SPOT ON thermometer) with the oral and esophageal in participants submitted to general and spinal anesthesia, in different types of population (pediatric and adult)
89420828|NCT03131882|Experimental|Hyaluronic acid|Hyaluronic acid
89420829|NCT03131882|Active Comparator|Triamcinolone acetonide|10mg/ml Triamcinolone acetonide
89420830|NCT04938934|Experimental|Aversive conditioning|
89420831|NCT04938934|Sham Comparator|Sham conditioning|
89420832|NCT04460534|Experimental|COHORT|Cohort
89420833|NCT04938700|Experimental|Probiotics intervention group|children with definitive diagnosis of allergic rhinitis, asthma，atopic dermatitis and chronic urticaria were enrolled, each with 25 cases. 2) collect manure application of 16s rDNA probe hybridization technique to analyze the fecal flora, and compared with clinical symptoms rating scale and serum sIgE, IgG4 correlation analysis (3) application of probiotic intervention and conventional drugs, again in 3 months, 6 months after collecting dung is used to detect the intestinal flora in children with its correlation with clinical symptoms change were observed.
88900399|NCT01509508|Experimental|Immediate ARV treatment initiation|Initiation of ARV treatment regardless of participants's immunological and clinical staging
88900400|NCT01509508|Other|South African recommendation guided ARV initiation|HIV-infected individuals will be assessed clinically and immunologically and when eligible for treatment as per South African guidelines will be offered ART
89530797|NCT03121547|Experimental|Tramadol Hydrochloride 100 mg Extended Release Oral Tablet|One tablet containing 100 milligrams (mg) Mandolgin Retard, Sandoz is administered after a set of baseline measurements are performed. Subsequently outcomes are assessed every hour for 6 hours, yielding a total of 7 hourly measurements.
88900401|NCT01509521|Active Comparator|Ephedrine|
88900402|NCT01509521|Active Comparator|Phenylephrine|
88900403|NCT01509560|Experimental|Everolimus|All patients will be given everolimus and the magnitude of the side effects will be measured
88900404|NCT01509573|Experimental|FSI-R (Intervention group)|The intervention group will participate in the mental health assessments and FSI-R, and will participate in post-intervention assessments and follow-up assessments.
88900405|NCT01509573|No Intervention|TAU (Treatment as Usual)|The TAU control group will not receive any intervention, but will participate in treatment as usual as provided by Partners In Health. They will complete assessments at all three time points.
89530798|NCT03121547|Experimental|Tapentadol 50 mg Oral Tablet|One tablet containing 50 milligrams (mg) Palexia Depot, Grünenthal is administered after a set of baseline measurements are performed. Subsequently outcomes are assessed every hour for 6 hours, yielding a total of 7 hourly measurements.
88900406|NCT01509599|Experimental|Cryotherapy|"Cryotherapy is delivered via a cooling gel wrap applied to the affected lower leg using a dosing regimen, starting with daily cooling in month one to PRN in the last 3 months over the 9 month study."
88900407|NCT01509599|Sham Comparator|Usual care|"The sham wrap, filled with cotton, is applied to the affected lower leg using a dosing regimen, starting with daily application in month one to PRN in the last 3 months over the 9 month study."
88900408|NCT01509651|Experimental|Sugammadex|
88900409|NCT01509703|Experimental|High flow therapy|
88900410|NCT01509729|Placebo Comparator|Sham operation|
88900411|NCT01509729|Active Comparator|Knee arthroscopic surgery|
88900412|NCT01509755|Placebo Comparator|Placebo|
88900413|NCT01509755|Experimental|0.045 mg|
88900414|NCT01509755|Experimental|0.225 mg|
88900415|NCT01509755|Experimental|0.45 mg|
88900416|NCT01509755|Experimental|0.60 mg|
88900417|NCT01509755|Experimental|0.75 mg|
88900418|NCT01509755|Active Comparator|Glim|
88900419|NCT01509768||No treatment|This is a longitudinal, prospective, observational, natural history study of patients with MPS IIIB to identify endpoints that may be used for future ERT trials via standardized clinical, biochemical, neurocognitive, developmental, behavioral and imaging measures
89006735|NCT04617301||Grup 3. external replacement resorption (ERR)|external replacement resorption also known as trauma-induced resorption - and this resorption may occur in teeth that also have external inflammatory resorption. This review will not discuss external replacement resorption in detail but it will be mentioned where relevant as both types of resorption may occur in some cases. This is because replacement resorption is a consequence of the same injuries that typically cause external inflammatory resorption - such as intrusion and avulsion where there is significant damage to the external root surface during the injury, as well as sometimes during the repositioning/ replantation of the tooth.
88900420|NCT01509781|Active Comparator|Suction drain|Patients in Arm A undergo simplex mastectomy or modified radical mastectomy. One plastic Redon drain (16 Ch) is placed after simplex mastectomy and two plastic Redon drains (16 Ch each) following modified radical mastectomy.
89006736|NCT04616989|Experimental|Psycho-education intervention arm|Participants will receive psycho-education materials
88900421|NCT01509781|Experimental|Adaptive suture|Following mastectomy, wound cavity is closed with adaptive skin sutures. No suction drain is inserted.
88900422|NCT01509794|Active Comparator|Low Valence|Participants in the low valence condition will participate in photo-based simulations. They will see a photo of the patient and hear affectively flattened audio. The script and clinical information remain the same as the high valence condition.
88900423|NCT01509794|Experimental|High Valence|Participants in the high valence condition will participate in video-based simulations. They will see a rich multimedia presentation of the clinical encounter, with affectively enhanced audio. The script and clinical information remain the same as the low valence condition.
88900424|NCT01509833|Experimental|rFSH|Administration of recombinant FSH for ovarian stimulation.
88900425|NCT01509833|Experimental|hCG(100IU)|Administration of late follicular low dose hCG(100U) for ovarian stimulation.
88900426|NCT01509833|Experimental|hCG(200IU)|Administration of late follicular low dose hCG(200IU) for ovarian stimulation.
88900427|NCT01509859|Active Comparator|PFNA|"these patients will be treated with synthes PFNA device"
88900428|NCT01509859|Active Comparator|INTERTAN|"these patients will be treated with Smith&Nephew INTERTAN device"
88900429|NCT01509885||Complete Spinal Cord Injured Subjects|Patients with no motor scores in their legs and suffering a complete spinal cord injury.
88900430|NCT01509885||Incomplete Spinal Cord Injured Subjects|Patient with some motor preservation below the injury and suffering an incomplete spinal cord injury.
88900431|NCT01509898|Experimental|water-Jet|use of water jet for 1 month
88900432|NCT01509911|Experimental|TL-118 with standard of care Gemcitabine|
88900433|NCT01509911|Active Comparator|Gemcitabine with out TL-118|
88900434|NCT01509924|Experimental|Physical activity on Prescription (PaP)|Intervention group receives a PaP for 12 month.
88900435|NCT01509924|No Intervention|Control Group|The control group has the same monitoring as the experimental group but receives no PaP.
88900436|NCT01509924|No Intervention|Cognitiv function in patients with TIA|"Before discharged from hospital cognitive function is assessed. At the first visit the patients fill in a self assessment questionnaire for mental fatigue.~If impaired at the previous assessment cognitive function will be assessed at 3, 6 and 12 month."
89530799|NCT03241381||Group A : Melasma|patients with facial pigmentation in the form of melasma
89530800|NCT03241381||Group B: Non Melasma|Patients without any facial pigmentation or melasma
88900437|NCT01509924|No Intervention|Controlgroup Cognitive function|In order to determine whether hospitalization in itself is associated with transient impaired cognition, a comparison group will be included. The comparison group will consist of patients with angina pectoris consecutively admitted to the Norrtälje Hospital. The patients with angina pectoris will be age and sex matched with the patients with TIA and assessed for cognitive function when their angina symptoms have subsided.
88900438|NCT01509937|Experimental|BCM Arm|BCM measured every 2 months
89420834|NCT04938700|Active Comparator|Contrast group|children with definitive diagnosis of allergic rhinitis, asthma，atopic dermatitis and chronic urticaria were enrolled, each with 25 cases. 2) collect manure application of 16s rDNA probe hybridization technique to analyze the fecal flora, and compared with clinical symptoms rating scale and serum sIgE, IgG4 correlation analysis (3) application of conventional drugs, again in 3 months, 6 months after collecting dung is used to detect the intestinal flora in children with its correlation with clinical symptoms change were observed.
88900439|NCT01509937|Sham Comparator|Control arm|patients care according to standard of care
88900440|NCT01509963||patients candidates for the SN procedure|The study will focus on patients candidates for the SN procedure as recommended by Saint-Paul de VENCE initially in 2005 but modified in 2009.
88900441|NCT01509976|Other|Red|This arm will either start with personal care products that contain triclosan and then and cross over to personal care products that do not contain triclosan or vice-versa. Since the investigators are blinded, it is not clear which arm is which.
88900442|NCT01509976|Other|Blue|This arm will either start with personal care products that contain triclosan and then and cross over to personal care products that do not contain triclosan or vice-versa. Since the investigators are blinded, it is not clear which arm is which.
88900443|NCT01510002|Active Comparator|TT|Extracapsular total thyroidectomy
88900444|NCT01510002|Experimental|TT+CND|Extracapsular total thyroidectomy puls prophylactic central neck dissection
88900445|NCT01510015|Active Comparator|Anti-psychotic medication|Participants are treated with psychological treatment both group and individually as well as medications according to their mental condition.
88900446|NCT01510015|Active Comparator|Counseling|Participants will receive individual and group therapy
88900447|NCT01510041|Experimental|Inspiratory muscle training group|
88900448|NCT01510041|Experimental|Respiratory exercise group|
88900449|NCT01510054||steroid support|Endometrial biopsies from subjects of with or without luteal phase steroid support will be compared for miRNA expression
88900450|NCT01510080|Experimental|Computer-assisted live supervision|"Supervisees assigned to this group will receive 8 sessions of computer-assisted live supervision and 4 sessions of delayed video-based supervision while treating 2 patients during 26 therapy sessions each. Computer-assisted live supervision is also known as bug-in-the-eye (BITE) supervision. The supervisor observes the therapy session with the help of a webcam and types messages on his computer. The instructions to the supervisee appear on a second monitor located in the therapy room where the supervisee can view it whenever he wants to."
88900451|NCT01510080|Experimental|Delayed video-based supervision|Supervisees assigned to this group will receive 12 sessions of delayed video-based supervision while treating 2 patients during 26 therapy sessions each. During delayed video-based supervision the supervisor and the supervisee spend 50 minutes reviewing selected parts of video recorded therapy sessions and discussing the case.
88900452|NCT01510093|Other|Insulin Aspart without glucose supply|Treatment with continuous subcutaneous Insulin Aspart 0.5-1.5 IE/time infusion overnight without intravenous glucose supply
89420835|NCT04837508|Experimental|MRG002|MRG002 will be administrated by an IV infusion of 2.6 mg/kg on Day 1 of every 3 weeks (21-day cycle).
88900453|NCT01510093|Other|Insulin Aspart with glucose supply|Treatment with continuous subcutaneous Insulin Aspart 0.5-1.5 IE/time infusion overnight combined with intravenous glucose supply
88900454|NCT01510132|Experimental|Travacom|Travoprost/timolol fixed combination self-administered at the rate of 1 drop per eye, one time a day, at approximately 8 a.m. each day for 8 weeks.
88900455|NCT01510171|Active Comparator|Prasugrel loading dose|
89420836|NCT04938622|Experimental|Sedentary Control|Participants did not exercise but consumed a diet that has an appropriate number of calories to maintain body weight throughout the intervention (3 menstrual cycles).
89420837|NCT04938622|Experimental|Exercising control|Participants exercised but were given extra calories to remain in energy balance throughout the intervention (3 menstrual cycles).
88900456|NCT01510171|Active Comparator|Ticagrelor Loading dose|
88900457|NCT01510223|Experimental|Dietary supplementation macademia oil|emia oil
88900458|NCT01510223|Experimental|Dietary supplementation olive oil|Olive oil
88900459|NCT01510223|Experimental|Dietary Supplementation fish oil|fish oil
88900460|NCT01510236|Experimental|Early self-help program|The early self-help program starts directly after randomization i.e. 4 weeks after diagnosis.
88900461|NCT01510236|Experimental|Later self-help program|The later self-help program starts sixty-two weeks after diagnosis.
88900462|NCT01510262|Experimental|Tailored Socio-Contextual Intervention|"Develop strengths based case management intervention using input from interviews with repeat STI patients, consultants, & piloting.~Recruit/enroll in the intervention 500 subjects (50% women; African American focus).~After subjects receive STI diagnosis, treatment,& partner notification services, randomly assign subjects to:~A. The STI strengths-based prevention case management, or B. Standard care.~Assess participants' risk behavior, determinants of behavior & quality of life. Investigators will assess the incidence of new STI & test the efficacy of the intervention relative to control.~Conduct a qualitative evaluation. Investigators will sample repeaters and non-repeaters from the experimental group.~Conduct cost effectiveness analyses of intervention compared to the standard."
89006737|NCT04616989|Active Comparator|Comparator arm|Participants will receive COVID-19 leaflets
89006738|NCT04617106|Active Comparator|Conventional Palpation group|In patients undergoing elective surgery who need arterial catheter placement, radial artery cannulation will be done using the conventional palpation method.
89420838|NCT04938622|Experimental|15 percent energy deficit (ED1)|Participants exercised for the equivalent of 15 percent of their daily caloric intake needs throughout the intervention cycles.
89420839|NCT04938622|Experimental|30 percent energy deficit (ED2)|Participants exercised for the equivalent of 30 percent of their daily caloric intake needs throughout the intervention cycles.
88900463|NCT01510262|Active Comparator|Standard of Care|Currently, the total time spent in an STI exam w/men is 30 minutes & 60 w/women. More time is devoted to patients with sexual assault hx. Reason for the visit, symptoms, STI hx, contraception, condom use, number/gender of partners & number/type of sexual activities are assessed. The nurse takes a health hx and asks about typical HIV risks behavior. Due to time the risk assessment is 5 minutes. A risk reduction kit including condoms is issued. Information includes symptoms/treatment of STI, location of sexual health clinics, location of free condoms & testing/treatment resources. Referral information is provided when needed & more involved w/sexual assault survivors. Partner notification is conducted w/syphilis and HIV. This didactic process follows the medical model.
88900464|NCT01510275|Experimental|Intervention|Combined use of RESPIVOL® and RESPILIFT® (with resistive load)
88900465|NCT01510275|Sham Comparator|Control|Combined use of RESPIVOL® and RESPILIFT® (without resistive load)
88900466|NCT01510288|Experimental|Ipilimumab and GVAX|
88900467|NCT01510301|Other|Self-report|
88900468|NCT01510340|No Intervention|Web sites|Patients assigned to this arm are given a list of Web sites where they can collect information related to their condition at their leisure.
88900469|NCT01510340|Experimental|VIH-TAVIE|Patients assigned to this arm must follow the four interactive computer sessions
88900470|NCT01510353|Experimental|Use of a radiation monitoring device|Use of a radiation monitoring device that provides real-time auditory feedback on radiation exposure during cardiac catheterization
88900471|NCT01510353|No Intervention|No use of radiation monitoring device|No use of a radiation monitoring device that provides real-time auditory feedback on radiation exposure during cardiac catheterization
88900472|NCT01510405||40 Participants|Participants undergoing or who have undergone thoracic surgery for presumed lung cancer with a wedge resection, lobectomy, bilobectomy, segmentectomy and/ or pneumonectomy thoracic surgical operation.
88900473|NCT01510418||Person with congenital bleeding disorder|Adult men with congenital hemophilia A or B
88900474|NCT01510418||Spouse/Significant Other|Spouse/significant other of person with congenital bleeding disorder participating in this study.
88900475|NCT01510483|Experimental|Obesity prevention|Orthodontist promotion of physical activity and healthy diet
88900476|NCT01510483|Active Comparator|Tobacco prevention|Orthodontist promotion of tobacco and second hand smoke avoidance
88900477|NCT01510496||Patients who had inguinal herniorraphy.|
88900478|NCT01510496||Patients who had hysterectomy.|
88900479|NCT01510496||Patients who had thoracotomy.|
88900480|NCT01510509|Experimental|Titanium bare metal stent|Titanium bare metal stent (Titan2®, Hexacath, Paris, France)
88900481|NCT01510509|Experimental|Everolimus Drug Eluting Stent|Xience-V®, Abbott Vascular, Santa Clara, California, USA
88900482|NCT01510522|Experimental|Glucophage sachets|Patients receive Glucophage sachets, the powder formulation for oral solution in sachets.
88900483|NCT01510522|Active Comparator|Glucophage tablets|Patients received Glucophage tablets.
88900484|NCT01510535|Experimental|Placebo and then LBSA0103|The experimental group receive once weekly for 2 weeks intraarticular injections of Placebo(saline). And then, they receive once intraarticular injections of LBSA0103 into the target knee.
88900485|NCT01510535|Active Comparator|Hyruan Plus|The control group received once weekly for 3 weeks intraarticular injections of Hyruan Plus Inj. into the target knee.
88900486|NCT01510548|Active Comparator|Adalimumab 20 mg per week|Patient will get at double blind situation adalimumab 20 mg every week (six injections) injections
88900487|NCT01510548|Active Comparator|Adalimumab 40 mg per week|Patient will get at double blind situation adalimumab 40 mg per week injections
88900488|NCT01510548|Placebo Comparator|placebo arm|Patient will get at double blind situation placebo (= NaCl liquid solution, absolutely same color as the active drug) injections one per week during six weeks - same as the adalimumab arms
88900489|NCT01510561|Experimental|90Y-hPAM4|90Y-hPAM4 is administered weekly for 3 weeks
88900490|NCT01510561|Experimental|90Y-hPAM4 + gemcitabine|90Y-hPAM4 is administered weekly for 3 weeks, while gemcitabine is administered weekly for 4 weeks.
88900491|NCT01510574|Active Comparator|misoprostol|3 tablets of 200mcg misoprostol self-administered following home birth, taken orally immediately after delivery of baby
88900492|NCT01510574|Placebo Comparator|placebo|3 tablets of placebo resembling misoprostol self-administered following home birth, taken orally immediately after delivery of baby
89420840|NCT04938622|Experimental|30 percent energy deficit 15/15 (ED2)|Participants exercised for the equivalent of 15 percent of their daily caloric intake needs throughout the intervention cycles, and their dietary intake was decreased by 15 percent to total a 30 percent energy deficit.
88900493|NCT01510587|Experimental|4-Health Educational curriculum|Parents participate in 10 face-to-face educational sessions delivered by Extension Agents at individual county locations over a 8-month period (fall to spring).
88900494|NCT01510587|Active Comparator|Healthy Living Information|Participants receive 10 mailed packets of written information derived from USDA's MyPlate website on approximately the same schedule as meetings of the experimental group.
89420841|NCT04938622|Experimental|60 percent energy deficit (ED3)|Participants exercised for the equivalent of 30 percent of their daily caloric intake needs throughout the intervention cycles, and their dietary intake was decreased by 30 percent to total a 60 percent energy deficit.
89420842|NCT04709822|Experimental|Trauma exposed women|"No Intervention: Baseline phase ('A'):~Measurements collected in a daily diary four times a day (morning, afternoon, evening and night) over one week (number of intrusive memories of trauma). Individual baseline phases will be used as control periods for the primary outcome.~Experimental: Intervention phase ('B'):~Measurements collected in a daily diary four times a day during the fifth week after the second intervention session for the primary outcome (number of intrusive memories of trauma)."
89420843|NCT04938310|Active Comparator|Control Group|Sleeve gastrectomy
89420844|NCT04938310|Experimental|Support garment group|Sleeve gastrectomy followed by a period of 12-month with a support garment
89420845|NCT03483350|Experimental|1- 1st group|1- 1st group will include 30 patients will receive intravenous granisetron 10 μg/kg after induction of anesthesia and before start of surgery
89420846|NCT03483350|Experimental|2- 2nd|2- 2nd group will include 30 patients will receive intravenous midazolam 50 μg/kg after induction of anesthesia and before start of surgery
89420847|NCT03483350|Experimental|3- 3rd group|3- 3rd group will include 30 patients will receive combination intravenous granisetron 5 μg/kg with midazolam 25 μg/kg after induction of anesthesia and before start of surgery
89420848|NCT03057730|Experimental|Group 1: Thin Biotype|"Gingival thickness < 0.8 mm~Acellular Dermal Matrix (ADM) will be used according to manufacturer's instructions during mucogingival surgery. Subjects will be anesthetized using local anesthesia. An envelope flap design will be involved with no releasing incisions. The ADM will be placed beneath the flap. The flap will then be advanced to the level of cemento-enamel junction (CEJ). The area will be sutured.~Mean root coverage, CPD, CAL, RH, RW, KTW, GT, and CRC will be measured and compared at 3 months, 6 months, 12 months, 24 months and 48 months post-surgery."
89420849|NCT03057730|Experimental|Group 2: Thick Biotype|"Gingival thickness ≥ 0.8 mm~Acellular Dermal Matrix (ADM) will be used according to manufacturer's instructions during mucogingival surgery. Subjects will be anesthetized using local anesthesia. An envelope flap design will be involved with no releasing incisions. The ADM will be placed beneath the flap. The flap will then be advanced to the level of cemento-enamel junction (CEJ). The area will be sutured.~Mean root coverage, CPD, CAL, RH, RW, KTW, GT, and CRC will be measured and compared at 3 months, 6 months, 12 months, 24 months and 48 months post-surgery."
89420850|NCT03480308|Active Comparator|Bupivacaine fentanyl group|Patients will receive bupivacaine (0.5%) 20 ml , fentanyl 1 μg/kg in paravertebral block
89420851|NCT03480308|Active Comparator|Bupivacaine dexamethasone group|Patients will receive bupivacaine (0.5%) 20 ml , dexamethasone 4 mg in paravertebral block
89420852|NCT03480308|Active Comparator|Bupivacaine fentanyl dexamethasone group|Patients will receive bupivacaine (0.5%) 20 ml , fentanyl 1 μg/kg , dexamethasone 4 mg in paravertebral block
89420853|NCT03057418|Experimental|Aurixim|"Dosage: 125 mg/m2, 250 mg/m2, 375 mg/m2 and 500 mg/m2. Formulation: concentrate for preparation of infusions 500 mg/50 ml and 100 mg/10 ml.~Mode of administration: intravenous."
89420854|NCT03480230|Experimental|Treatment arm|"Non-squamous histology:~Compound 121564 10 mg/Kg administered over 60 minutes given intravenously every 2 weeks for 4 doses.~Compound 565994 500 mg/m2 administered over 10 minutes, and~Compound 232673 AUC=5 mg/mL/min administered over 15-60 minutes or Compound 454893 at 75 mg/m2 over 1 hour.~Compound 565994 and platinum are to be given on day 1 of every 3-week cycle for 3 cycles.~Squamous histology:~Compound 121564 10 mg/Kg administered over 60 minutes every 2 weeks for 4 doses.~Compound 232673 AUC=5 mg/mL/min administered over 15-60 minutes or Compound 454893 at 75 mg/m2 over 1 hour on day 1 of every cycle.~Compound 343782 1,000 mg/m2 administered over 30 minutes on days 1 and 8 of each cycle.~Platinum and Compound 343782 will be given for 3 cycles."
89420855|NCT04938076|Experimental|tDCS group|"tDCS stimulation~affected side :~primary motor cortex (M1 cortex by using the C3 or C4 position of the 10-20 EEG system)~2mA anode (+) for 30 minutes total 10 times for 7 days (ex) twice a day for 5 days)~contralateral unaffected side~primary motor cortex (M1 cortex by using the C3 or C4 position of the 10-20 EEG system)~2mA cathode (-) for 30 minutes total 10 times for 7 days (ex) twice a day for 5 days)"
88900495|NCT01510613|Experimental|Pomalidomide and Dexamethasone|
88900496|NCT01510626|Experimental|One|
88900497|NCT01510639|Experimental|Cuff repair PRP|Cuff repair Platelet Rich Plasma: The application of autologous thrombocyte concentrate in the cuff repair group
88900498|NCT01510639|No Intervention|Cuff repair Control|No intervention
88900499|NCT01510639|Experimental|NEER PRP|Neer Platelet Rich Plasma: The application of autologous thrombocyte concentrate in the NEER surgery group
88900500|NCT01510639|No Intervention|NEER Control|No intervention
88900501|NCT01510665|Experimental|Magnesium Supplement|Magnesium citrate dietary supplement (300 mg elemental Magnesium daily dose) given week 13 to week 28 (two pills daily)
88900502|NCT01510665|Placebo Comparator|Placebo|Identical appearing pill with inactive ingredients given week 13 to week 28 (two pills daily)
88900503|NCT01510665|Active Comparator|Diet|Nutritionist counseling session and advice on following a magnesium rich diet from week 13 to week 28
88900504|NCT01510691||Epiretinal membrane|
88900505|NCT01510691||diabetic macular edema|
88900506|NCT01510691||vein occlusion|
88900507|NCT01510730|No Intervention|control group|no treatment for Helicobacter pylori infection
88900508|NCT01510730|Active Comparator|treatment group|treatment group receive eradication treatment for helicobacter pylori infection
88900509|NCT01510743|Active Comparator|Group SC|US guided subclavian vein catheterization
88900510|NCT01510743|Active Comparator|Group IJ|US-guided internal jugular vein catheterization
88900511|NCT01510782|Experimental|BI 655064 subcutaneous|Escalating single dose as solution for subcutaneous injection
89420856|NCT04938076|Sham Comparator|Sham group|". Sham stimulation~1) the current ramps up to 2mA and slowly decreased over 30 s to ensure the typical initial tingling sensation"
88900512|NCT01510782|Placebo Comparator|Placebo to BI 655064 subcutaneous|Escalation single dose as solution for subcutaneous injection (Placebo)
88900513|NCT01510782|Experimental|BI 655064 intravenous|Escalating single dose as solution for intravenous infusion
88900514|NCT01510782|Placebo Comparator|Placebo to BI 655064 intravenous|Escalating single dose as solution for intravenous infusion (Placebo)
88900515|NCT01510795|No Intervention|retrospective control|
88900516|NCT01510795|Active Comparator|spironolactone|
88900517|NCT01510808||aggressive Periodontitis|Aggressive Periodontitis during maintenance
88900518|NCT01510808||aggressive periodontitis|aggressive periodontitis patients during maintenance
88900519|NCT01510821|Experimental|Maquet Vasoshield Arm|Pressure limiting syringe
88900520|NCT01510821|Active Comparator|Non-regulated Arm|standard non-regulated syringe
88900521|NCT01510847|Other|Oral Testosterone Therapy|90 day oral testosterone therapy
88900522|NCT01510860|Active Comparator|Ursodeoxycholic acid (UDCA)250 mg|UDCA 250 mg capsule
88900523|NCT01510860|Experimental|Ursodeoxycholic acid (UDCA)500 mg|UDCA 500 mg tablet
89420857|NCT04937842|Experimental|MST|standard chemotherapy with microtransplantation
88900524|NCT01510873||Newly Diagnosed pITP|Patients within 3 months from diagnosis.
88900525|NCT01510873||Persistent pITP|Patients between 3 to 12 months from diagnosis; includes patients not reaching spontaneous remission or not maintaining complete response off therapy.
88900526|NCT01510873||Chronic pITP|Patients with ITP lasting for more than 12 months.
88900527|NCT01510886||1|
88900528|NCT01510899|Experimental|Healthy Subjects Arm|
88900529|NCT01510899|Experimental|Renal Impaired Subjects Arm|
88900530|NCT01510938|Placebo Comparator|Placebo|1 g of rice maltodextrin will be reconstituted in 25-50 ml of tepid water or juice and immediately fed once a day for 2-weeks trial period or to the end of acute respiratory infection depending on whatever is longer.
88900531|NCT01510938|Experimental|Probiotic|"powder of L. acidophilus DDS-1, B. lactis UABLA-12, 50 mg of fructooligosaccharide~1 g of probiotic will be reconstituted in 25-50 ml tepid water or juice and immediately fed once a day (5 billion CFU/daily) for 2-weeks trial period or to the end of acute respiratory infection depending on whatever is longer."
88900532|NCT01510951|Placebo Comparator|PLACEBO|
88900533|NCT01510951|Experimental|AMG 811|
88900534|NCT01510964|Experimental|prompt-sheet|"Patients and companions of intervention group receive a form on which to write their reply to the following request: Please indicate the arguments which you want to discuss today with your oncologist and the prompt sheet. An introduction explains the importance of asking questions during the consultations. The patient (companion) is invited to select among a written list of about 50 possible questions those, if any, s/he would like to ask today to the oncology."
88900535|NCT01510964|Other|control group|"Patients and companions of the control group receive a form on which to write their reply to the following request: Please indicate the arguments which you want to discuss today with your oncologist"
89420858|NCT04937842|No Intervention|CT|standard chemotherapy only, without microtransplantation
89420859|NCT05151614|Experimental|Colchicine group|Colchicine 0.5 mg tab 1x2 for 1 week then o.5mg tab. 1x1 for another week + the standard therapy
89420860|NCT05151614|No Intervention|Control group|"The patients in this group will receive only standard care which will include all or some of the following, according to the clinical condition of each patient:~Acetaminophen 500mg on need~Vitamin C 1000mg twice/ day~Zinc 75-125 mg/day~Vitamin D3 5000IU/day~Azithromycin 250mg/day for 5 days~Oxygen therapy/ C-Pap if needed~Dexamethasone 6 mg/day or methylprednisolone 40mg twice per day, if needed~Mechanical ventilation, if needed"
89420861|NCT04937764||Study population|Population who underwent a surgical arthrodesis procedure for arthritic or inflammatory involvement of the Lisfranc tarsometatarsal joint
89420862|NCT03483194|Active Comparator|Kalinox®|The included patients in this group will have, during the intervention, a local anesthesia by xylocaine® 10 mg / mL (1 bottle of 20 mL) in complement of a gas mixture composed of 50% Nitrous Oxide, 50% Oxygen (Kalinox®)
89420863|NCT03483194|Experimental|Virtual Reality|The included patients in this group will have, during the intervention, a local anesthesia by xylocaine® 10 mg / mL (1 bottle of 20 mL) in complement of a virtual reality (VR) session.
88900536|NCT01510977|Active Comparator|PEG|2L of polyethylene glycol addition immediately after first colonoscopy failure
88900537|NCT01510977|Experimental|PEG + bisacodyl|One week after initial colonoscopy failure, conventional amount (5L) of polyethylene glycol together with bisacodyl administration
88900538|NCT01510990|Experimental|Gefitinib|"After a baseline 18F FDG-PET, patients are treated with gefitinib 250mg/d as 1st line treatment for 7 days. And follow up 18F-FDG PET image is acquired after 1 week's treatment of gefitinib (with window period +/- 2 days).~If % decrease of peak SUV of main lesion is 20% or more, gefitinib treatment is continued till progression, unacceptable toxicities or patient's refusal. But if % decrease of peak SUV of main lesion less than 20% or peak SUV increase, gefitinib treatment is stopped, and changed to Pemetrexed/Cisplatin chemotherapy."
88900539|NCT01511003|Experimental|Tacrolimus group|oral
88900540|NCT01511029|Experimental|Dexpramipexole|
88900541|NCT01511029|Placebo Comparator|Dexpramipexole (placebo)|
88900542|NCT01511029|Active Comparator|Moxifloxacin|
88900543|NCT01511094|Experimental|Eye Surgery|Goniocurettage was used to treat open angle glaucoma patients
88900544|NCT01511120|Active Comparator|Tetraspan|
88900545|NCT01511133||HRV Group|Subjects received two or three doses of HRV in previous studies.
88900546|NCT01511133||Placebo Group|Subjects received two or three doses of placebo in previous studies.
88900547|NCT01511146|Experimental|Mitomycin+Gemcitabine|Intrahepatic treatment, where all standard treatments have been used
88900548|NCT01511159|Experimental|NNC 90-1170, initial dose|
88900549|NCT01511159|Experimental|NNC 90-1170|
88900550|NCT01511159|Active Comparator|Insulin|
88900551|NCT01511159|Experimental|NNC 90-1170, final dose|
89420864|NCT04937530|Experimental|RT001|RT001 960 mg capsule. 3 capsules TID for 4 weeks, followed by 3 capsules BID for the remaining 44 weeks.
89420865|NCT04937530|Placebo Comparator|Placebo|Inactive comparator capsule 960 mg (safflower oil). 3 capsules TID for 4 weeks, followed by 3 capsules BID for the remaining 44 weeks.
89420866|NCT04937608||COVID-19 group|men aged 18 to 45 who have been infected with SARS-CoV-2 in the past 6 months
89420867|NCT04937608||Control group|healthy men aged 18 to 45 with normal sperm parameters (WHO 2010 criteria) and who have never contracted COVID-19
89420868|NCT04937218|Experimental|Egg demand creation campaign|Egg demand creation campaign using Above-the-line and Below-the-line methods for 14 months. Above-the-line interventions include television, radio, celebrity ambassadors and out-of-home advertising (e.g., billboards). Below-the-line interventions include interpersonal communication activation, trade promotions, point-of-sale materials, food demonstrations and giveaways and door-to-door activation.
89420869|NCT04937218|No Intervention|Comparison|Comparison arm with no campaign
89420870|NCT04937140||rheumatoid arthritis patients|90 RA patients diagnosed according to the American college of rheumatology (ACR) -EULAR RA classification criteria 2010
89420871|NCT04937140||control group|50 age and sex matched healthy controls. All
89420872|NCT04409548|Active Comparator|Lumbar Disc Hernaition Group|The number of participants in this group is anticipated to be 153. The pain intensity of the patients was recorded by a Visual Analog Scale (VAS) immediately before performing the analysis. The patients were asked to continuously walk barefoot for ten times as straight as possible without any assistance on the Win-Track platform within the same day.
89420873|NCT04409548|Active Comparator|Healthy Control Group|The number of participants in this group is anticipated to be 54. The participants were asked to continuously walk barefoot for ten times as straight as possible without any assistance on the Win-Track platform within the same day.
88900552|NCT01511172|Experimental|NNC 90-1170 + Met|
88900553|NCT01511172|Experimental|NNC 90-1170 + Met placebo|
88900554|NCT01511172|Placebo Comparator|Met + NNC 90-1170 placebo|
88900555|NCT01511172|Active Comparator|Met + Glim|
88900556|NCT01511185|Experimental|NNC 90-1170|
88900557|NCT01511185|Placebo Comparator|Placebo|
88900558|NCT01511185|No Intervention|Healthy|
88900559|NCT01511198|Experimental|0.045 mg|
88900560|NCT01511198|Experimental|0.225 mg|
88900561|NCT01511198|Experimental|0.45 mg|
88900562|NCT01511198|Experimental|0.60 mg|
88900563|NCT01511198|Experimental|0.75 mg|
88900564|NCT01511198|Active Comparator|Met|
88900565|NCT01511211|Experimental|Ropivacaine + Dexamethasone Combination|
88900566|NCT01511211|Active Comparator|Ropivacaine-Only Block|
88900567|NCT01511224||Colistin monotherapy|
88900568|NCT01511224||Colistin based combination therapy|Colistin-Tigecycline, Colistin-Carbapenem, Colistin-Rifampin, Colistin-HD Unasyn
88900569|NCT01511224||Non-colistin containing regime|
88900570|NCT01511224||Glycopeptide with colistin combination|
88900571|NCT01511224||Colistin with loading dose|
88900572|NCT01511237|Experimental|Perinatal intensification|"Perinatal antiretroviral intensification (study treatment):~Mothers: One NVP 200 mg tablet at onset of labor with continuation of HAART for four weeks postpartum~Newborn: AZT+3TC+ NVP for 2 weeks, followed by AZT+3TC for 2 weeks~The standard of care in Thailand is defined as:~Maternal: ZDV 300 mg, 3TC 150mg and LPV/r 400/100 twice a day starting as soon possible after 14 weeks of pregnancy + ZDV 300 mg every 3 hours during labor~Newborn: ZDV 4 mg/kg every 12 hours for 4 weeks (ZDV dosing adjusted for premature infants)."
89420874|NCT04409548|Active Comparator|Preoperative and Postoperative Group|The number of participants in this group is anticipated to be 59. The patients were asked to continuously walk barefoot for ten times as straight as possible without any assistance on the Win-Track platform within the same day, before and 15 days after surgery.
88900573|NCT01511263|Active Comparator|Arm A|The patients will be divided into 4 strata according to cardiac dysfunction and to the quality of hematologic response. After stratification the patients will be randomized (1:1) within each stratum to receive Standard Therapy alone (Arm A) or Standard Therapy plus Investigational Drug (Arm B).
89420875|NCT04649840||COVID-19 moderate|moderate COVID-19 associated pneumonia
89420876|NCT04649840||COVID-19 severe|severe COVID-19 associated pneumonia
89420877|NCT03482960|Experimental|129Xe MRI|Participants will self-administer hyperpolarized xenon gas via inhalation prior to the investigators acquiring MRI images. MRI imaging will be taken during approximately 15-second breath-holds. After the MRI is complete, participant performs spirometry maneuvers in a room outside the magnet. Once a minimum of 15 minutes has elapsed since leaving the MRI scanner, the participant will return to the MRI scanner, where the second phase of the study will occur. PFP gas will be administered using a full-face mask during the MRI. Images are acquired during 12-second breath-hold after every 3rd breath.
89420878|NCT03482960|Experimental|19F MRI with PFP|PFP gas will be administered using a full-face mask during the MRI. Images are acquired during 12-second breath-hold after every 3rd breath. After the MRI is complete, participant performs spirometry maneuvers in a room outside the magnet. Once a minimum of 15 minutes has elapsed since leaving the MRI scanner, the participant returns to the MRI scanner, where he/she will self-administer hyperpolarized xenon gas prior to acquiring MRI images. MRI imaging will be taken during approximately 15-second breath-holds.
89420879|NCT05259644|Active Comparator|Conservative treatment group|Obese patients treated with conservative approach - diet.
89420880|NCT05259644|Active Comparator|Laparoscopic sleeve gastrectomy|Obese patients treated with laparoscopic sleeve gastrectomy.
89420881|NCT05259644|Active Comparator|endoscopic gastric plication|Obese patients treated with endoscopic gastric plication.
89420882|NCT05151224||Breast cancer patients eligible to neoadjuvant systemic therapy|Invasive breast cancer, age are 18 years or more, from stage IIB to stage IIIC, all subtypes are included, either HR (ER, PR) positive or negative, HER2 positive or negative, eligible to neoadjuvant systemic therapy.
89420883|NCT04936672|Experimental|Brisk walking group|"Type of exercise is brisk walking. The duration of each exercise is from 35 minutes to 60 minutes, with 5 minutes of training time added every two weeks.~The frequency of each exercise is 3 times a week. Total exercise time is 12 weeks. The intensity is 50%-70% of the individual's maximum heart rate, gradually increasing the intensity over time."
89420884|NCT04936672|Experimental|Tai Chi Chuan|"Type of exercise is Tai Chi Chuan. The duration of each exercise is from 35 minutes to 60 minutes, with 5 minutes of training time added every two weeks.~The frequency of each exercise is 3 times a week. Total exercise time is 12 weeks. The intensity is 50%-70% of the individual's maximum heart rate."
89420885|NCT04936672|Experimental|Brisk walking combined with Tai Chi Chuan|"Type of exercise is brisk walking combine with Tai Chi Chuan. The duration of each exercise is from 35 minutes to 60 minutes, with 5 minutes of training time added every two weeks.~The frequency of each exercise is 3 times a week. Total exercise time is 12 weeks. The intensity of brisk walking is 50%-70% of the individual's maximum heart rate, gradually increasing the intensity over time.~The intensity of Tai Chi Chuan is 50%-70% of the individual's maximum heart rate."
89420886|NCT04936672|No Intervention|Control Group|Keeping their daily life.
89420887|NCT05259488||patients receiving immunonutrition supply|Dietary Supplement: Immunonutrition nutridrinks 3 times a day 5 days prior surgery plus maltodextrins the day of surgery
89420888|NCT05259488||historical control group|standard dietary advice
89006739|NCT04617106|Active Comparator|DNTP group|In patients undergoing elective surgery who need arterial catheter placement, radial artery cannulation will be done using USG-guided dynamic needle tip positioning method.
89420889|NCT02523872||Acute respiratory failure|Patients with acute respiratory failure who might benefit from a strategy designed to limit fluid administration
89420890|NCT03479996|Experimental|Anesthetic|
89420891|NCT03479996|No Intervention|Control|
89420892|NCT05151068|Experimental|Group A,traditional|"The control group is given conventional nursing care: ①Preoperative education, informing patients of the importance of the tube and the adverse effects of unauthorised extubation after the operation on the recovery of the disease. ②Pipe care: The nose wing is fixed with modified human elastic tape, and the same side cheek bridge is fixed to keep the duct unobstructed and pour gastric juice in time. ③Oral care: routinely brush teeth and gargle with mouthwash daily. ④Skin care: Observe the condition of the nose, cheek skin and oral and nasal mucosa. Replace the tape as needed, and clean the skin before fixing. ⑤ Pain care: assess the degree of pain, follow the doctor's prescription for medication, and observe the efficacy of medication. ⑥Psychological care: pay attention to the emotional changes of patients and provide psychological support.This group is planned to enroll 100 patients."
89420893|NCT05151068|Experimental|Group B,Precise|On the basis of conventional nursing, the experimental group adopted a precision nursing program of acupoint application combined with ear acupoint embedding.This group is planned to enroll 100 patients.
89420894|NCT02524184|Experimental|Sildenafil|Eleven patients receive sildenafil 100mg/day (25 mg at 8 AM plus 25 mg at 4 PM plus 50 mg at 10 PM)for 7 days.
88900574|NCT01511263|Experimental|Arm B|The patients will be divided into 4 strata according to cardiac dysfunction and to the quality of hematologic response. After stratification the patients will be randomized (1:1) within each stratum to receive Standard Therapy alone (Arm A) or Standard Therapy plus Investigational Drug (Arm B)
88900575|NCT01511276|Experimental|Diet-induced weight loss|The diet-induced weight loss group will follow a calorie restricted diet. They are asked to keep their habitual sedentary lifestyle. The aim of this group is to loose 5-6 kg of body weight in 14 weeks time.
88900576|NCT01511276|Experimental|Mainly exercise induced weight loss|"Participants in the exercise- plus diet-induced weight loss group are enrolled in an exercise programme. Next to the exercise programme, they will follow a calorie restricted diet.~The aim of this group is to loose 5-6 kg of body weight in 14 weeks time."
88900577|NCT01511276|No Intervention|Control, stable weight|The control group is asked to follow a baseline isocaloric diet and to not change their habitual sedentary lifestyle.
88900578|NCT01511289|Active Comparator|Imatinib|Imatinib 400mg QD
88900579|NCT01511289|Experimental|Radotinib 600mg|Radotinib 300mg BID
88900580|NCT01511289|Experimental|Radotinib 800mg|Radotinib 400mg BID
88900581|NCT01511302|Experimental|RNS60-BD 0.25|RNS60 in combination with Budesonide 0.25mg/2ml concentration
88900582|NCT01511302|Experimental|RNS60-BD 0.5|RNS60 in combination with Budesonide 0.5mg/2ml concentration
88900583|NCT01511302|Placebo Comparator|NS-BD 0.5|Normal Saline control (NS) in combination with Budesonide 0.5mg/2ml concentration
88900584|NCT01511341|Experimental|Telenursing|
88900585|NCT01511341|No Intervention|Standard practice|Group receive the standard practice, without telephone nursing intervention.
88900586|NCT01511354||Standard clinical care|Standard nutritional therapy and treatment
88900587|NCT01511367|Active Comparator|Flutiform|
88900588|NCT01511367|Active Comparator|Seretide|
89194517|NCT00878956|Placebo Comparator|2|In all patients body weight adjusted dose of study medication will be achieved by infusion of sodium chloride at a dose of 0.5 mmol/kg body weight (=bolus) diluted in 250 mL over 1 hour immediately after the induction of anesthesia, prior to the first surgical incision followed by continuous intravenous infusion of 0.2 mmol/kg/hr (=maintenance) diluted in 1000 mL 23 hours (total dose of 5 mmol/kg over 24 hours).
88900589|NCT01511367|Active Comparator|Flixotide|
88900590|NCT01511380|Experimental|Risk Reduction Therapy for Adolescents|Youth randomly assigned to RRTA will complete a family focused treatment program that will work with the youth and his or her caregiver to help reduce youth substance use and risky sexual behavior using principals of behavior modification and contingency management.
88900591|NCT01511380|Active Comparator|Usual services|For youth randomly assigned to usual treatment services, the youth will receive the treatment services recommended by the drug court.
88900592|NCT01511406|Experimental|cognitive behavioral therapy|Cognitive behavioral therapy up to 26 sessions
88900593|NCT01511432|Experimental|Part A|Part A will be a 4-formulation, 4-sequence, 4-period crossover relative bioavailability study of 3 novel oral telaprevir formulations relative to the 375-mg Incivek tablet in the fed state.
88900594|NCT01511432|Experimental|Part B|Part B will be a 2-formulation, 6-sequence, 3-period cross-over relative bioavailability study of the novel oral telaprevir formulation selected from Part A in the fasted relative to the fed state and relative to the 375-mg Incivek tablet in the fasted state
88900595|NCT01511458||Case|Patient with a trisomy 21 pregnancy confirmed by genetic testing.
88900596|NCT01511458||Control|Patients without a trisomy 21 pregnancy confirmed by either genetic testing or a normal newborn phenotype.
88900597|NCT01511471|Experimental|Ticagrelor|Ticagrelor 90mg twice a day for 15 days
88900598|NCT01511484|Experimental|Information-only|"Selected pages from the British National Health Service (NHS) information booklets [5 A Day, Just Eat More (fruit & veg); pages i, ii, 12-15, 20 & 21] and [5 A Day, Just Eat More (fruit & veg): What's it all about?; pages i-ii)] were provided to all participants on completion of baseline questionnaires. The pages provided information on recommended portion sizes, meal planning, health benefits and answered frequently asked diet-related questions"
89006740|NCT04617145|Active Comparator|Aerobic exercise group|Included 30 patients who underwent aerobic training with 50 %-60% of maximum heart rate in the form of cycling by Bicycle ergometer for eight weeks, three sessions/week.
89194518|NCT00740142|Active Comparator|1|Interventional arm: oral L-ornithine-L-aspartate and oral lactulose
89194519|NCT00740142|Placebo Comparator|2|Oral lactulose
89420895|NCT02524184|Placebo Comparator|Placebo group|An identical placebo for 7 days in placebo group.
89420896|NCT03486236|Experimental|Cohort C1|
89420897|NCT03486236|Placebo Comparator|Cohort C1: Triple Placebo|
89420898|NCT03486236|Experimental|Cohort C2|
89420899|NCT03486236|Placebo Comparator|Cohort C2: Triple Placebo|
88900599|NCT01511484|Experimental|Generic-appearance intervention|"Participants in the generic appearance intervention group received images to illustrate the impact of fruit and vegetable consumption on skin appearance. Participants in this group were presented with gender congruent stimuli, constructed by averaging the facial shape and colour of four male/female faces.~Participants viewed the gender-congruent set of the resulting stimuli in two forms. Firstly, after completion of baseline questionnaires, images were displayed on a computer monitor. Participants were instructed to select what they perceived as the healthiest face colour, which was recorded by the computer program over two trials.~Participants in this group also received a take-home photo quality leaflet to further illustrate the effect of fruit and vegetable consumption on skin colour."
89420900|NCT04935892|Experimental|Slippers|Patients wear slippers any time they are out of bed with a goal of avoiding any contact between socks/feet and the floor
89420901|NCT04935892|No Intervention|Control|Patients receive standard care with no intervention
88900600|NCT01511484|Experimental|Personalised appearance intervention|Participants in this group received stimuli manipulated in identical ways to that received by the generic appearance-intervention group, except the illustrations were performed upon images of the participant's own face.
88900601|NCT01511497|Experimental|PF-04427429|
89420902|NCT03486158|Experimental|CalproSmart application|In addition to regular outpatient clinic visits and a routine CalproSmart test every 3 months, patients are instructed to obtain fecal samples if they experience symptoms suspect of recurrent IBD and to perform home analysis with CalproSmart™ system test kit
88900602|NCT01511497|Placebo Comparator|Placebo|Normal saline
88900603|NCT01511510|Experimental|PF-04958242|
88900604|NCT01511510|Placebo Comparator|Placebo|
88900605|NCT01511523|Active Comparator|RGMA001|Proprietary blend of Vitamin E, Silymarin, and Carnitine.
88900606|NCT01511523|Placebo Comparator|Sugar Pill|No treatment.
88900607|NCT01511549|Experimental|Dose 1|SAR113945 low dose
88900608|NCT01511549|Experimental|Dose 2|SAR113945 medium dose
88900609|NCT01511549|Experimental|Dose 3|SAR113945 high dose
88900610|NCT01511549|Placebo Comparator|Placebo|Placebo
88900611|NCT01511562|Other|Arm I|Patients undergo induction therapy for five cycles as defined in the protocol. Patients undergo stem cell transplant.
88900612|NCT01511562|Other|Arm II|Patients undergo induction therapy for five cycles as defined in the protocol. Patients undergo consolidation chemotherapy.
88900613|NCT01511627|Active Comparator|General Anesthesia|
88900614|NCT01511627|Experimental|General Anesthesia + Spinal Anesthesia|
88900615|NCT01511666|Experimental|Hyperinvasive arm|Hyperinvasive arm encompasses immediate institution of a mechanical chest compression device (LUCAS) and pre-hospital intraarrest cooling by Rhino-Chill device. Immediately after institution of these two devices the patients will be directly transferred to cardiac center cathlab under continuous CPR. The use of drugs and further defibrillations are on a discretion of the emergency physician. After admission to cathlab, overall status, ROSC presence and ECLS inclusion/exclusion criteria will be evaluated.
89420903|NCT03486158|No Intervention|Standard follow-up|In addition to regular outpatient clinic visits and a routine calprotectin test in the same week as the visit date, patients bring home an Fecal-calprotectin tube and envelope and are instructed to obtain fecal samples and send these to local lab if they experience symptoms suspect of recurrent IBD
89420904|NCT03479918|Active Comparator|R-DA-EPOCH-21|The protocol involves 4-6 cycles. Intrathecal administration of dexamethasone 4 mg, methotrexate 15 mg and cytarabine 30 mg is required once during chemotherapy. In case of CNS involvement intrathecal administration is repeated 3 times a week till the normal cell count in cerebrospinal liquid.
88900616|NCT01511666|Active Comparator|Standard arm|Patients in standard arm will be further managed as per recent ERC guidelines, ie. continued ACLS. The use of drugs and further defibrillations are on a discretion of the emergency physician. If ROSC is attained, patients will be transferred to the same hospital to one of intensive care units, coronary angiography/PCI will be performed only if indicated according to routine practice and mild therapeutic hypothermia will be instituted as soon as possible as per recent guidelines recommendation.
88900617|NCT01511679||Alcohol-naive adolescents|A general population longitudinal cohort of alcohol-naïve (or h/o minimal recent-onset drinking) adolescents in three specific age-groups: early (12-14 y/o), middle (15-17 y/o), and late (18-21 y/o).
88900618|NCT01511679||Treatment sample|A sample of adolescents who have a >1 year history of heavy drinking but have agreed to stop drinking as part of their treatment plan
88900619|NCT01511679||High risk sample|High-risk adolescents who have a family history of alcohol-use disorder and other risk factors (symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD), Conduct Disorder, or Mood Disorder)
88900620|NCT01511692|Experimental|Lira --> placebo|
88900621|NCT01511692|Placebo Comparator|Placebo --> glim|
88900622|NCT01511692|Active Comparator|Glim --> lira|
88900623|NCT01511705|Experimental|Ondansetron Hydrochloride Tablets 8 mg|Ondansetron Hydrochloride Tablets 8 mg of Dr. Reddy's Laboratories Limited
88900624|NCT01511705|Active Comparator|Zofran Tablets 8 mg|Zofran Tablets 8 mg of GlaxoSmithKline
88900625|NCT01511718|Experimental|Ondansetron Hydrochloride Tablets 8 mg|Ondansetron Hydrochloride Tablets 8 mg of Dr. Reddy's Laboratories Limited
88900626|NCT01511718|Active Comparator|Zofran Tablets 8 mg|Zofran Tablets 8 mg of GlaxoSmithKline
88900627|NCT01511731|Experimental|Famotidine|Famotidine tablets 40 mg of Dr. Reddy's
88900628|NCT01511731|Active Comparator|Pepcid|Pepcid 40 mg Tablets of Merck & Co.,
88900629|NCT01511744|Experimental|Inactivated influenza split vaccine|Biological: Experimental: influenza split vaccine of 15 μg HA, one dose regime
88900630|NCT01511744|No Intervention|Blank control|
89006741|NCT04617145|Active Comparator|Resistive exercise group|Included 30 patients who underwent a resistive training which were conducted in the form of a series of exercises using free weights, and dumbles to increase the strength of arms, pectoral muscles, abdominal, back muscles and gluteal region. Sessions were conducted three sessions/week for eight weeks.
89006742|NCT04616911|Active Comparator|Rerouting seton|Placement of seton with rerouting of the fistula tract around the internal anal sphincter
89006743|NCT04616911|Active Comparator|LIFT|Ligation of the intersphincteric fistula tract
89006744|NCT04616638|Experimental|RT-POWER Intervention|Six familiarization sessions and 20 RT-POWER sessions.
89420905|NCT03479918|Active Comparator|R-BL-M-04|"Course A:~Rituximab 375 mg/m2 IV 0 day, Dexamethasone 10 mg/m2/day IV 1 - 5 days, Methotrexate 1500 mg/m2 12 h IV 1 day, Ifosfamide 800 mg/m2/day 1 h IV 1 - 5 days, Etoposide 100 mg/m2/day IV 4, 5 days, Doxorubicin 50 mg/m2/day IV day 3, Vincristine 2 mg IV 1 day, Cytarabine 150 mg/m2/day IV 1 h 4, 5 days.~Course C:~Rituximab 375 mg/m2 IV 0 day, Dexamethasone 10 mg/m2/day IV 1 - 5 days, Methotrexate 1500 mg/m2 12 h IV 1 day, Vinblastine 5 mg/m2 IV day 1, Cytarabine 2000 mg/m2/day IV 3 h 2, 3 days, Etoposide 150 mg/m2/day IV 3-5 days.~Intrathecal administration of dexamethasone 4 mg, methotrexate 15 mg and cytarabine 30 mg is required once during chemotherapy. In case of CNS involvement intrathecal administration is repeated 3 times a week till the normal cell count in cerebrospinal liquid."
89420906|NCT03479918|Active Comparator|R-DA-EPOCH-21 + auto-SCT|"The protocol involves 4-6 cycles. Patients with complete remission after 4 cycles undergo auto-SCT.~Intrathecal administration of dexamethasone 4 mg, methotrexate 15 mg and cytarabine 30 mg is required once during chemotherapy. In case of CNS involvement intrathecal administration is repeated 3 times a week till the normal cell count in cerebrospinal liquid."
89420907|NCT03479918|Active Comparator|R-BL-M-04 + auto-SCT|"The protocol involves 4 cycles. Patients with complete remission after 4 cycles undergo auto-SCT.~Intrathecal administration of dexamethasone 4 mg, methotrexate 15 mg and cytarabine 30 mg is required once during chemotherapy. In case of CNS involvement intrathecal administration is repeated 3 times a week till the normal cell count in cerebrospinal liquid."
89006745|NCT04616638|Active Comparator|Control Intervention|Six control familiarization sessions and 20 traditional RT sessions.
89006746|NCT04616872|Experimental|Methotrexate-LDE|Methotrexate carried by a lipid nanoparticle (MTX-LDE)
89006747|NCT04616872|Placebo Comparator|Placebo-LDE|Lipid nanoparticle (LDE)
89006748|NCT04616755|Active Comparator|Bonded retainer 13-23|This group have bonded retainer behind six front teeth in the maxilla to keep front teeth stable.
89420908|NCT04935970||patients with peripherial vestibular disorder|Forty patients with BPPV, vestibular neuritis or another peripherial vestibular disorder
89006749|NCT04616755|Active Comparator|Bonded retainer 12-22|This group have bonded retainer behind four front teeth in the maxilla to keep front teeth stable.
89006750|NCT04616755|Active Comparator|Vacuum-formed retainer|This group have Vacuum-formed retainer covering all erupted teeth in maxilla to keep front teeth stable
89006751|NCT04616716|Experimental|1|"Drug:FMTN fasted in P1,low-fat diet in P2,high-fat diet in P3~FMTN administration in fasted condition in period 1,FMTN administration after low-fat diet in period 2,FMTN administration after high-fat diet in period 3"
89420909|NCT04935970||patients with central vestibular disorder|Forty patients vestibular disorder of central origin
88900631|NCT01511757|Experimental|Fluconazole|Fluconazole Tablets 200 mg of Dr. Reddy's Laboratories limited.
88900632|NCT01511757|Active Comparator|Diflucan|Diflucan 200 mg fluconazole tablets of Pfizer
88900633|NCT01511770|Experimental|Fluconazole|Fluconazole Tablets 200 mg of Dr. Reddy's Laboratories limited.
88900634|NCT01511770|Active Comparator|Diflucan|Diflucan 200 mg fluconazole tablets of Pfizer
89420910|NCT04935970||healthy controls|twenty healthy control without balance problems
89420911|NCT03479840||Patients undergoing PCI|all-comer population undergoing PCI
89420912|NCT03482726|Other|Cycling Cadence Modulation|3 initial visits to collect baseline information; 6-week HIIT indoor cycling program at the individual prescribed cadence; final study visit for post-intervention measures.
89420913|NCT04935502|Experimental|Home based exercises with postural and ergonomic training|Home based exercises which consist of stretching, strengthening exercises along with postural and ergonomic training will be given to participants for a period of one month by a physiotherapist for 60 minutes via distance education
89420914|NCT04935502|Experimental|Home based exercises|Home based exercises which consist of stretching and strengthening exercises will be given to participants for a period of one month by a physiotherapist for 60 minutes via distance education.
88900635|NCT01511783|Experimental|E2609|E2609 at ascending doses
89420915|NCT03482648|Experimental|Single Ascending Doses|
89420916|NCT03482648|Experimental|Multiple Ascending Doses|
89420917|NCT04935190||Group 1|Subjects that have a diagnosis of a cardiac, pulmonary, or cardio-pulmonary condition (e.g., Congestive Heart Failure, COPD, Asthma) will be assigned to Group 1.
88900636|NCT01511783|Placebo Comparator|Placebo|
88900637|NCT01511796|Experimental|upper limb rehabilitation for total of 6 months|upper limb rehabiliation
88900638|NCT01511822|Active Comparator|Drospirenone + Ethinyl estradiol|
88900639|NCT01511822|Experimental|Drospirenone + Ethinyl estradiol + Myo-inositol|
88900640|NCT01511822|Placebo Comparator|Placebo|
88900641|NCT01511835|Experimental|Myo-inositol powder|
88900642|NCT01511835|Experimental|Myo-inositol soft gel capsules|
88900643|NCT01511835|Placebo Comparator|Folic acid|
88900644|NCT01511848|Active Comparator|arm 1|30 Patients will be treated with combined DFP and deferasirox.
88900645|NCT01511848|Active Comparator|arm 2|Patients will be treated for 6 days with a combination of deferoxamine and DFP
88900646|NCT01511874|Experimental|ELIGRAD 22.5mg|a subcutaneous injection of ELIGARD 22.5mg at 0 and 12weeks
88900647|NCT01511887|Experimental|Oral Ibuprofen|10mg/kg oral ibuprofen followed by two 5mg/kg in 12 hours intervals. If there was no improvement after first cycle of treatment this treatment was repeated.
88900648|NCT01511887|No Intervention|No treatment|No treatment
88900649|NCT01511900|Experimental|Cohort 1: Dose level 1|Multiple dose orally: CAT-1004 Dose level 1 or placebo
88900650|NCT01511900|Experimental|Cohort 2: Dose level 2|Multiple dose orally: CAT-1004 Dose level 2 or placebo
88900651|NCT01511900|Experimental|Cohort 3: Dose level 3|Multiple dose orally: CAT-1004 Dose level 3 or placebo
88900652|NCT01511900|Experimental|Cohort 4: Dose level 4|Multiple dose orally: CAT-1004 Dose level 4 or placebo
88900653|NCT01511900|Experimental|Cohort 5: Dose level TBD|Multiple dose orally: CAT-1004 Dose level TBD or placebo
88900654|NCT01511926||1|Adult patients treated with Vimovo™ for diagnosed osteoarthritis (OA), rheumatoid arthritis (RA) or ankylosing spondylitis
88900655|NCT01511952|Active Comparator|Music intervention- SGA|Infants will be randomly assigned to receive one of three music interventions randomized for the AM or PM
88900656|NCT01511952|Active Comparator|Music Intervention- RDS|Infants will be randomly assigned to receive music-one of 3 randomized interventions in the AM or PM
88900657|NCT01511952|Active Comparator|Music Intervention- Sepsis|Infants randomly assigned to receive one of three interventions-randomized for the AM or PM
88900658|NCT01511965|Other|traitement A|Lesion 1= graft and lesion 2 = UltraViolet B
88900659|NCT01511965|Other|traitement B|Lesion 1 = UltraViolet B and lesion 2 = graft
89420918|NCT04935190||Group 2|Subjects who are not known to have a cardiac, pulmonary, or cardio-pulmonary condition will be assigned to Group 2.
89420919|NCT05150834||ChAdOx1 vaccinated group|From Febrary 25, 2021 to July 16, 2021, healthy healthcare workers were prospectively recruited at a tertiary hospital in Seoul, Republic of Korea, and they were assigned to get ChAdOx1 (Oxford/AstraZeneca) (n=26) vaccines. Participants were excluded if they had history of medication which would affect gut microbiota in the past 1 month, including antibiotics, laxatives, and motility drugs; previous history of positive SARS-CoV-2 test on nasopharyngeal PCR; or positive serum Spike IgG results.
89420920|NCT05150834||BNT162b2 vaccinated group|From Febrary 25, 2021 to July 16, 2021, 53 healthy healthcare workers were prospectively recruited at a tertiary hospital in Seoul, Republic of Korea, and they were assigned to get BNT162b2 (n=27) vaccines. Participants were excluded if they had history of medication which would affect gut microbiota in the past 1 month, including antibiotics, laxatives, and motility drugs; previous history of positive SARS-CoV-2 test on nasopharyngeal PCR; or positive serum Spike IgG results.
89420921|NCT04934644|Experimental|Hyperbaric oxygen treatment|30 HBO treatments and standard care. If surgery is needed an additional 10 HBO treatments postoperative.
88819940|NCT04279431||SIC Positive/Equivocal|Subjects will include males and females ranging from ages 18 to 85 who are admitted to the ED with a traumatic, closed head injury within 3 days of injury. Subject will undergo site standard clinical ED evaluation and a BrainScope evaluation. The SIC positive group are those patients who obtain a 'Positive' or 'Equivocal' result on the BrainScope One SIC algorithm.
89420922|NCT04934644|No Intervention|Control|Standard care. Surgery if needed.
89420923|NCT03486080|Active Comparator|Dutogliptin/filgrastim combination|Twice daily SC injections of 60 mg dutogliptin tartrate for 14 days in combination with 10 µg/kg filgrastim injectable product for 5 days
89420924|NCT03486080|Placebo Comparator|Placebo control|Twice daily dutogliptin SC placebos for 14 days in combination with matching filgrastim SC placebos for 5 days
89420925|NCT04934878||Referral information|first visit to our hospital/transfer from another hospital
89420926|NCT03479528||Dyspepsia|All patients who were satisfied with the inclusion criteria and exclusion criteria in the department of the second affiliated hospital of Xi'an jiaotong university,Xijing Hospital, Tangdu Hospital, Xi'an No.3 Hospital, and received investigation.
89420927|NCT03131258|Other|Donor Nephrectomy|Donor Nephrectomy
89420928|NCT03057262||Study group|Study group consisted of 56 subjects of both genders with unilateral or bilateral disc displacement(s) with reduction and pain in the area of temporomandibular joint. Patients were recruited from the Consulting Room of Temporomandibular Joint Dysfunction at the Jagiellonian University in Krakow during the years 2014-2016. In the study group was used the typical acrylic anterior repositioning splint fabricated in tete-a-tete (incisal) jaws position, covered the lower teeth arch to recapture a displaced disc(s) and decrease the intensity of pain. The anterior repositioning splint was recommended to 20 - hour use for a period of four months.
89194520|NCT02568774|Experimental|Traditional Acupuncture|Acupoints which are empirical for treating OAB in terms of Traditional Chinese medicine theory are used (in the sequence of scalp reproduction area and motor area of the unaffected side, RN3, bilateral BL32, BL33, BL28, BL39). And Ear point urinary bladder, and Ear point uterus will be treated after removal of needles. Needles will be left for 30 minutes and then removed. Subjects will be treated with acupuncture 2 times per week for the first 2 weeks and 1 per week for the 3rd and 4th week.
89420929|NCT03057262||Control group|Control group consisted of 56 subjects of both genders with unilateral or bilateral disc displacement(s) with reduction and pain in the area of temporomandibular joint. Patients were recruited from the Consulting Room of Temporomandibular Joint Dysfunction at the Jagiellonian University in Krakow during the years 2014-2016. In the control group the investigators used the biostymulation laser (Terapus 2, Accuro, Poland), wave length 808 nm, power 32 J in the form of 12 session (duration of a single session was 3 min 45 s), performed every second day, on the area of the both temporomandibular joints (distance to the skin was 1 cm) with opened mouth and systematic performing of muscles self-exercises with a dominant protrusive position of mandible.
88819941|NCT04275843|Active Comparator|Traditional Diet|Unprocessed/minimally processed whole foods.
88819942|NCT04275843|Active Comparator|Modern Diet|Multi-ingredient, ultra-processed formulations of the traditional diet.
88819943|NCT01462292|Experimental|GSK2402968 3 mg/kg/week|3 mg/kg/week of investigational product
88819944|NCT01462292|Experimental|GSK2402968 6 mg/kg/week|6 mg/kg/week of investigational Product
88819945|NCT01462292|Experimental|Placebo to match GSK2402968 3 mg/kg/week|Placebo
88819946|NCT01462292|Experimental|Placebo to match GSK2402968 6 mg/kg/week|Placebo
88819947|NCT05455749|Experimental|holoBLG|
88819948|NCT05455593|Active Comparator|Water aerobics|Aerobic exercises performed in a swimming pool.
88819949|NCT05455593|Active Comparator|Metacognitive Training (MCT)|Treatment program for psychosis based on Cognitive-behavioral therapy (CBT), cognitive remediation (CRT) and psychoeducation.
88819950|NCT05455593|Experimental|Combined intervention (water aerobics + MCT)|Combination of water aerobics and MCT sessions.
88819951|NCT02958735|No Intervention|Rest|Participants randomly assigned to this arm rest quietly for thirty minutes instead of participating in the exercise challenge.
88819952|NCT02958735|Experimental|Mild Exercise|Participants randomly assigned to this arm are made to maintain a heart rate equivalent to 60% of the heart rate observed when VO2 max was achieved in the maximal stress test from the first visit.
88819953|NCT02958735|Experimental|Hard Exercise|Participants randomly assigned to this arm are made to maintain a heart rate equivalent to 80% of the heart rate observed when VO2 max was achieved in the maximal stress test from the first visit.
88819954|NCT05455359|Experimental|Arm 1|Patients will be undergo 1 week observation period followed by 4 weeks of prucalopride followed by 1 weeks of a wash out followed by 4 weeks of famotidine
88819955|NCT05455359|Experimental|Arm 2|Patients will be undergo 1 week observation period followed by 4 weeks of famotidine followed by 1 weeks of a wash out followed by 4 weeks of prucalopride
88819956|NCT05441007|Experimental|Hypoxic|Participants inhale ambient air, the hypoxic gas mixture, and ambient air.
88819957|NCT05441007|Experimental|Hypercapnic|Participants inhale ambient air, the hypercapnic gas mixture, and ambient air.
89420930|NCT03477344|Active Comparator|Dexmédétomidine|Intravenous infusion with electric syringe of Dexmedetomidine 0,4ug/ml. Rate 0,1ug/kg/h to 1,4ug/kg/h. Nightly infusion from 20:00 to 08:00. The drug is titrated to achieve RASS between -1 and 1. Modification of infusion rate by 0,1ug/kg/h is recommended with stabilization phase of 1 hour before another rate adjustment.
89420931|NCT03477344|Placebo Comparator|Sodium Chloride 0,9%|Intravenous infusion with electric syringe of normal saline. Rate modifications follow the same rules as in experimental group.
89194521|NCT02568774|Other|Usual Care|Patients will receive conventional rehabilitation as usual, including standard physiotherapy, bladder training and general advise of fluid intake.
89194522|NCT04039048|Experimental|ctDCS during Balance training|
89194523|NCT04039048|Sham Comparator|ctDCS sham during Balance training|
89420932|NCT04933864|Experimental|Methylene Blue and Photodynamic Therapy|Methylene Blue 1 mg/kg water solution. Participants have orally received Methylene Blue solution of 1 mg/kg concentration one time in addition to the current therapy of the participant (e.g., azithromycin, hydroxychloroquine, aminodihydrophthalazinedione sodium, levofloxacin, etc.), if any. After 3 hours of Methylene Blue administration irradiation of chest using 650 nm laser source with 18 J/cm^2 energy dose was performed.
89420933|NCT04933864|No Intervention|Control group|COVID-19 positive participants treated with standard medical supportive therapy (e.g. azithromycin, hydroxychloroquine, aminodihydrophthalazinedione sodium, levofloxacin, etc.).
89420934|NCT03477266|Experimental|Mouth dissolving mosapride|Fluxopride 5mg of Macryrl egypt 2 tablets one day before and immediately after elective cesarean section every 8hour for maximum of 5 days
89420935|NCT03477266|Placebo Comparator|Placebo mouth dissolving tablets|Dummy identical tablets taken in the same way
89420936|NCT04933318|Active Comparator|Transcutaneous electrical nerve stimulation (TENS)|Transcutaneous electrical nerve stimulation (TENS)- analgesic current therapy
89420937|NCT04933318|Sham Comparator|shamTENS|shamTranscutaneous electrical nerve stimulation (TENS)- analgesic current therapy
89420938|NCT04933318|Active Comparator|Interferential current therapy (IFC)|Interferential current therapy (IFC)- analgesic current therapy
89420939|NCT04933318|Sham Comparator|shamIFC|shamInterferential current therapy (IFC)- analgesic current therapy
89194524|NCT00423319|Active Comparator|Apixaban, 2.5 mg BID plus placebo|Participants received apixaban, 2.5 mg twice daily (BID), as oral tablets, and matching enoxaparin-placebo injection once daily (QD)
89194525|NCT00423319|Experimental|Enoxaparin, 40 mg QD plus placebo|Participants received enoxaparin, 40 mg QD subcutaneously, and matching apixaban-placebo tablets BID
89194526|NCT05224492|Experimental|Sulforaphane Group|
89194527|NCT05224492|Placebo Comparator|Placebo Group|
89194528|NCT00879112|Experimental|1|MB07811 Cohort 1
88819958|NCT05441007|Experimental|Hypoxic and Hypercapnic|Participants inhale ambient air, the hypoxic and hypercapnic gas mixture, and ambient air.
89194529|NCT00879112|Experimental|2|MB07811 Cohort 2
88819960|NCT04694001|Other|Hemiplegia due to Cerebrovascular Accident (CVA)|
88819961|NCT00373503|Experimental|lofexidine, dronabinol, marijuana|lofexidine (.6 mg qid), dronabinol (20 mg tid)
88819962|NCT04333797|Other|Transitional age youth|Assessed group.
88819963|NCT02923323|Experimental|Group 1 T1DM aged 12-18 years.|T1DM patients. Receiving regularly insulin. Interventions: performance of continuous EEG , CGMS, MRI of brain with DTI , actigraph, neurocognitive testing
88819964|NCT02923323|Active Comparator|Group 2 Healthy aged 12-18 years.|Healthy Interventions: performance of continuous EEG , CGMS, MRI of brain with DTI , actigraph, neurocognitive testing
89194530|NCT00879112|Experimental|3|MB07811 Cohort 3
89194531|NCT00879112|Placebo Comparator|4|Cohort 4
89194532|NCT00736710|Experimental|1|
88819965|NCT02696265|Active Comparator|CFAE guided ablation|CFAE/spatiotemporal dispersion guided ablation: CFAE mapping and ablation during AF aimed at restoring sinus rhythm during ablation.
88819966|NCT02696265|Active Comparator|PVI guided ablation|PVI guided ablation: wide antral pulmonary vein isolation during mapping catheter control of pulmonary vein signals.
88819967|NCT04737525|Experimental|Test group|Immediate implant placement and temporization of tapered implants after tooth extraction with buccal augmentation using allogenic bone and porcine-derived membrane.
88819968|NCT04737525|Experimental|Control group|Immediate implant placement and temporization of tapered implants after tooth extraction with buccal augmentation using allogenic bone and connective tissue grafting (CTG).
89194533|NCT00736710|Sham Comparator|2|
89194534|NCT04039126|Experimental|PATIENTS WITH MALIGNANT PLEURAL EFFUSION|PARTICIPANTS WITH MALIGNANT PLEURAL EFFUSIONS REQUIRING PLEURODESIS, COMBINATION OD POVIDONE IODOONE-TETRCYCLINE TO BE USED.
89194535|NCT04039126|Active Comparator|PATEINT WITH MALIGANT PLEURAL EFFUSION REQUIRNG PLEURODESIS|TO USE POVIDONE IODINE ALONE IN THIS GROUP
89194536|NCT00880126|Experimental|CDT|Community Development Teams bring together counties who are implementing a new practice
88819969|NCT01515176|Experimental|Treatment (ofatumumab, dinaciclib)|Patients receive ofatumumab IV over 4-6 hours on days 1, 8, 15, and 22 of courses 1-2, and on day 1 of courses 4-7. Beginning on course 2, patients also receive dinaciclib IV over 2 hours on days 2, 8, and 15 of course 2, and on days 1, 8, and 15 of courses 3-7. Treatment repeats every 28 days for up to 7 courses in the absence of disease progression or unacceptable toxicity.
89420940|NCT03479372|Experimental|PAN-90806 Eye Drops, dose 1|PAN-90806 Ophthalmic Suspension taken once daily for 12 weeks
88900660|NCT01511991|Experimental|sevoflurane|10 min exposure to sevoflurane 1.0, 2.0 and 3.0 inspiratory vol% at sevoflurane dosage titration
88900661|NCT01512004|Active Comparator|Propiverine Hydrochloride Extended-Release Capsule|30 mg/capsule; oral; once per day
88900662|NCT01512004|Placebo Comparator|Tolterodine Extended-release Tablet|4mg/tablet; oral; once per day
88900663|NCT01512017|Active Comparator|Veloderm|
88900664|NCT01512017|Placebo Comparator|Vaseline|
88900665|NCT01512043|Experimental|1. Breathing control|Description ...
88900666|NCT01512043|Active Comparator|2. Listening to music|Listening to music without guiding on breathing on the same device as breathing control twice a day for four weeks. Using the device to measure breathing movements.
88900667|NCT01512043|Sham Comparator|3. Silence|Using the device to measure breathing movement twice a day for four weeks. No instruction on breathing control and no music.
88900668|NCT01512056|Experimental|the immunogenicity profiles of the AdimFlu-S|"Experimental group: to receive either only one dose of influenza vaccine at day 0 or one more booster vaccination 3 weeks later.~Negative control group: dialysis patients who refused to receive influenza vaccination."
88900669|NCT01512056|No Intervention|The safety outcome of the vaccine|Any adverse effect, including systemic or local site, will be recorded during the study period.
88900670|NCT01512069|Experimental|Web-based, Stage-matched Exercise and Diet Planning program|The experimental arm is a group that assigned to use web-based, stage-matched exercise and diet planning program.
88900671|NCT01512069|Active Comparator|Non-tailored booklet on exercise and diet|The control group is provided a booklet containing same information on exercise and diet as in the experimental group's web-based program, but the information on a booklet is not tailored to participants' stage of motivational readiness for exercise and diet based on the TTM.
88900672|NCT01512082|Experimental|Active pulsed electromagnetic field|
88900673|NCT01512082|Sham Comparator|Non-active pulsed electromagnetic field|
88900674|NCT01512121||functional MRI testing|"fMRI scanning with SCS on and off at different settings."
88900675|NCT01512134|Experimental|DBS Surgery|All patients enrolled will undergo DBS implantation in the targeted region to assess the safety of the procedure and the efficacy through weight loss.
88900676|NCT01512147|Other|Isoflurane, Propofol, Dexmedetomidine|Our trial will examine the changes in latency and amplitude of SSEP and changes in amplitude and morphology of MEP while using different anesthetic combinations including isoflurane, proposal and dexmedetomidine. Monitoring teams will document any changes throughout the surgery and communicate with the team about those changes. The design of the study will be a prospective AB design.
88900677|NCT01512173|Experimental|propranolol gel|
88900678|NCT01512173|Placebo Comparator|Placebo|
88900679|NCT01512199|Experimental|U3-1287 with trastuzumab + paclitaxel (Phase 1b)|The Phase 1b portion is an open label, dose de escalation, single arm study designed to assess the safety and tolerability of up to 3 dose levels of U3- 1287 in combination with trastuzumab plus paclitaxel and will determine the recommended Phase 2 dose (RP2D) of U3 1287. The first cohort will receive U3- 1287 18 mg/kg intravenously (IV) in combination with trastuzumab plus paclitaxel once every 3 weeks (q3w).
88900680|NCT01512199|Experimental|U3-1287 with trastuzumab+paclitaxel (Ph 2)|The Phase 2 portion is a randomized, 2 arm, placebo controlled, double blind study designed to evaluate the safety and the efficacy of U3-1287 at the recommended phase 2 in combination with trastuzumab plus paclitaxel (experimental arm) relative to the control arm (trastuzumab plus paclitaxel and placebo).
88900681|NCT01512199|Placebo Comparator|Placebo with trastuzumab+paclitaxel (Ph 2)|The Phase 2 portion is a randomized, 2 arm, placebo controlled, double blind study designed to evaluate the safety and the efficacy of U3-1287 at the recommended phase 2 dose in combination with trastuzumab plus paclitaxel (experimental arm) relative to the control arm (trastuzumab plus paclitaxel and placebo).
88900682|NCT01512212|No Intervention|single group|FNAB will be perform first with standart technique and after with new FNAB apparatus
88900683|NCT01512238||Pharmaceutical care|
88900684|NCT01512238||Control|
88900685|NCT01512277|Experimental|3 administrations of 100 µg of rSh28GST|Adult volunteers (n=8) receive 100μg of rSh28GST together with aluminium hydroxide (Alum) as adjuvant at D0, D28, and D150.
88900686|NCT01512277|Experimental|2 administrations of 300 µg of rSh28GST|Adult volunteers (n=8) receive 300μg of rSh28GST together with aluminium hydroxide (Alum) as adjuvant at D0 and D28.
89194537|NCT00880204|Experimental|Trained doctors|ESS-EMCH Training will be provided to doctors working in general emergency, pediatrics and obstetrics department in district hospitals.
89194538|NCT00880204|No Intervention|No Training|No training will be given to doctors (act as controls)
89420941|NCT03479372|Experimental|PAN-90806 Eye Drops, dose 2|PAN-90806 Ophthalmic Suspension taken once daily for 12 weeks
89194539|NCT04064190|Experimental|Vactosertib+Durvalumab|Vactosertib will be administered in combination with standard dose of durvalumab every four weeks.
89194540|NCT00873886|Experimental|Oseltamivir (Tamiflu)|
89194541|NCT00873886|Other|Esterase|
89194542|NCT00736788|Experimental|1|Four different oral dose levels of a suspension containing AZD1704
89420942|NCT03479372|Experimental|PAN-90806 Eye Drops, dose 3|PAN-90806 Ophthalmic Suspension taken once daily for 12 weeks
89420943|NCT03131336|Experimental|PeproStat|PeproStat 2.5mg/mL soaked into haemostatic gelatin sponge, applied to a target bleeding site
89420944|NCT03131336|Placebo Comparator|Saline|Saline soaked into haemostatic gelatin sponge, applied to a target bleeding site
89530801|NCT02510807|Experimental|Pedometer group|Patients will be instructed to walk a minimum of three times per week up to one half hour total walking time. If they started to get pain in their legs, they will be instructed to stop and rest, and then to start again when the pain has subsided. The pedometer group will be instructed to carry the pedometer in their pocket during these exercise periods.
88814013|NCT02248571|Experimental|Arm B|"Everolimus plus Exemestane (1st treatment phase) followed by Bevacizumab plus Capecitabine (2nd treatment phase)~Dosing (treatment cycle: 21days):~Everolimus: 10 mg/day orally applied tablet --- Exemestane: 25 mg/day orally applied tablet~Capecitabine: 1000 mg/m2 orally applied twice daily as combined 150 mg and 500 mg tablets on days 1 to 14 of each 21-day cycle, followed by a seven day rest period (i.e. off-treatment) --- Bevacizumab: 15 mg/kg intravenously applied once every three weeks (i.e. 5 mg/kg/wk dose equivalent)~Patient questionaires to assess patient reported outcome and patients' preference will be completed at four specific time points during study treatment (two timepoints in each treatment phase)"
88814014|NCT04376840|Experimental|adults with severe SARS-CoV2 pneumonia|adult with severe SARS-CoV2 pneumonia
88814015|NCT00019604|Experimental|Radiofrequency ablation in liver cancer|This trial is designed to gain experience with the use of ablation devices with liver tumors. Radiofrequency ablation is a procedure that heats tumors to several degrees above body temperature and may kill tumor cells.
88814016|NCT03002675|Experimental|exenatide|Participants will receive exenatide (Bydureon, 2mg s.c. 1x/wk, AstraZeneca) during 12 weeks
88814017|NCT03402074|Experimental|Group Hypnosis|5 sessions of group hypnosis, each 90 minutes; plus CDs/MP3 recordings to train at home
88814018|NCT03002441|Active Comparator|Same-day Dilators|Participants will have Dilapan-S cervical dilators placed 4-6 hours prior to D&E and will receive 400 mcg buccal misoprostol pills 3 hours prior to D&E.
88814019|NCT03002441|Active Comparator|Overnight dilators|Participants will have Dilapan-S cervical dilators placed the day prior to their D&E procedure and will receive buccal placebo pills (vitamin B12) 3 hours prior to D&E.
88814020|NCT03002363|Experimental|Video Modeling Intervention|The intervention group receives a video that is a behavior modeling video that walks through the entire audiological evaluation. It also includes tips for caregivers to practice with their child before the appointment.
88814021|NCT03002363|Placebo Comparator|Placebo Video|The other video is a placebo video that discusses hearing, listening and ears, that does not discuss tips for caregivers to practice with their child before the appointment. The placebo video is not related to the audiological evaluation.
88814022|NCT04374344||Medical professionals|Medical professionals including cardiologists and cardiology residents.
88814023|NCT03002285|Experimental|Cerebral Palsy group|Group with Cerebral Palsy that performed the Fitts law in a computer task
89420945|NCT03057340|Experimental|DRibble vaccine|Blood samples collection: collect of 10ml patients peripheral blood, separate PBMC;Day 1: DRibble group guided by ultrasound in patients with inguinal lymph nodes injected the DRibble vaccine;Day8: collecte 50 ml peripheral blood and separate monocytes and lymphocytes;Intensify immune cells amplification;Identification of immune cell;Detection of Immune cells microbial;20-22 days: immune cells back to patients;55 days: collecte 10 ml peripheral blood, after the separation of PBMC in vitro induced to DC, cocultivate with DRibble and subcutaneous injection at 60th day;Day 75: collecte 10 ml peripheral blood, separate PBMC and detecte T cell immune response ability.
88900687|NCT01512277|Placebo Comparator|Placebo|Adult volunteers (n=8) receive aluminium hydroxide (Alum) alone at D0 and D28.
88900688|NCT01512290|Active Comparator|Theta burst treatment|patients randomized to this arm will receive 10 TBS treatments distributed over 5 days
88900689|NCT01512290|Placebo Comparator|sham treatment|
88900690|NCT01512303|Experimental|Sudarshan Kriya Yoga: SKY|SKY incorporates yoga, discussion periods and several types of breathing exercises for relaxation. Initial breathing exercises are calming and focusing. Subsequent breathing exercises are more fully engaging energizing, allowing the practitioner to focus more fully in each moment. All are soothing and present-focused. Participants will be encouraged to learn all the breathing exercises, and to utilize the exercises the ones that seems most appropriate for their needs. 8-day intensive group class (2.5 hours/day) followed by 4 weekly sessions (3 hours/session).
88900691|NCT01512303|Experimental|Mindfulness-Based Stress Reduction: MBSR|MBSR incorporates yoga, discussion periods, and several types of meditation, all involving attention to the present moment and acceptance of any feelings, sensations or thoughts, allowing the practitioner to calm his or her mind and come back to the present moment. The typical MBSR format will be adapted to match the SKY intervention. This intervention will include an 8-day intensive group class (2.5 hours/day) followed by 4 weekly sessions (3hrs/session).
89006752|NCT04616716|Experimental|2|"Drug:FMTN high-fat diet in P1,fasted in P2,low-fat diet in P3~FMTN administration after high-fat diet in period 1,FMTN administration in fasted condition in period 2,FMTN administration after low-fat diet in period 3"
89194543|NCT00736788|Placebo Comparator|2|oral suspension
88900692|NCT01512303|No Intervention|Wait-List Control: WLC|Participants will undergo no intervention. These participants will have the option of receiving one of the two interventions at the conclusion of the study.
89420946|NCT02523950|Active Comparator|Staged group|Procedure/Surgery: Phacoemulsification + IOL implantation is performed in the first stage and DMEK is performed secondarily.
89420947|NCT02523950|Active Comparator|Combined group|Procedure/Surgery: Phacoemulsification + IOL implantation and DMEK are performed simultaneously.
88900693|NCT01512303|No Intervention|Non-PTSD control|Baseline measures only will be collected from a group of 50 combat-exposed veterans without PTSD to assess group differences on these measures prior to treatment.
88900694|NCT01512329|Experimental|pacing|The pacing self-management program (3 one-on-one sessions weekly for 3 consecutive weeks) focused on teaching the patient to estimate their current physical capabilities prior to commencing an activity. In order to appropriately pace activities (daily activities and exercise bouts), MS patients were learned to estimate their current physical capabilities prior to commencing an activity, keeping in mind the regular fluctuating nature of their symptoms. The activity duration used within the program was less than that reported by the patient so to account for typical overestimations made by the patient. Each activity block was interspersed with breaks, with the length of this break equating to the duration of the activity.
89006753|NCT04616716|Experimental|3|"Drug:FMTN low-fat diet in P1,high-fat diet P2,fasted in P3~FMTN administration after low-fat diet in period 1,FMTN administration after high-fat diet in period 2,FMTN administration in fasted condition in period 3"
89420948|NCT03477188|Experimental|Somatosensorial and Vestibular Exercises Group|This group of patients received patients with acute stroke. It will be applied somatosensorial and vestibular rehabilitation additional conventional therapy
89420949|NCT03477188|Active Comparator|Conventional Group|This Group patients received patient with acute stroke. It will be applied classical physiotherapy and conventional exercises.
89420950|NCT03482492|Active Comparator|Tramadol|Group Tramadol patients received tramadol 1 mg kg-1 iv
89420951|NCT03482492|Active Comparator|Tramadol-Paracetamol|Group Tramadol-Paracetamol patients received paracetamol 1 gr iv in addition to tramadol 1 mg kg-1 iv 30 minutes before the end of the operation and after the operation at 6 hour intervals for 24 hours
89420952|NCT03874286||Liver Transplant|Participants will obtain a liver biopsy at 4 months post transplant and 12 months post transplant.
89420953|NCT03482414|Active Comparator|traditional wooden checkerboard|upper limb training with traditional wooden checkerboard
89420954|NCT03482414|Experimental|gaming board with single-player games|upper limb training with a LED-based interactive gaming board equipped with single-player games
89420955|NCT03482414|Experimental|gaming board with two-player games|upper limb training with two LED-based interactive gaming boards equipped with two-player competitive games
89420956|NCT03479294||Exposure group|Exposure group patients are those who voluntarily choose to use Shenlingcao Oral Liquid recommended by the doctor in NSCLC patients receiving adjuvant chemotherapy. Jiangzhong Group will donate the first 30 bottles of medicine, and afterwards, patients may purchase if they still need to take it. The length of time and dose of Shenlingcao Oral Liquid are unlimited and other adjunctive treatments may be used at the same time.
89420957|NCT03479294||Control group|Control group patients are those who voluntarily choose not to use Shenlingcao Oral Liquid recommended by the doctor in NSCLC patients receiving adjuvant chemotherapy.
89420958|NCT03482336|Other|Uninstructed Group|"For the first block of participants recruited (39, one of which withdrew from boredom), no overt reference was made regarding the FOP labels that were present on the images that participants viewed during the course of the video game. Participants comprising this block were referred to as uninstructed."
89420959|NCT03482336|Other|Minimally trained|"Realizing that subjects might not use the FOP during decision making when not informed that it contained nutrition information, we conducted a second experiment (N= 41) which provided minimal information about the FOP. These subjects (the minimally instructed group) were provided with further instruction. At the beginning of the experiment, in addition to being shown the basic premise of the game and told that Munchy preferred to eat healthy options, the researcher pointed to one of the FOPs and told children this information might be helpful when you decide what's healthy."
89420960|NCT03482258|Experimental|Treatment Prebiotic|3 week daily dose of Vivinal-GOS (galacto-oligosaccharide)
89420961|NCT03482258|Placebo Comparator|Placebo|3 week daily dose of Maltodextrin
89420962|NCT05259098|Experimental|Sufentanil Sublingual Tablet System|Group treated with Sufentanil Sublingual Tablet System
89420963|NCT05259098|Experimental|Intravenous Patient-Controlled Analgesia with Morphine|Group treated with intravenous Patient-Controlled Analgesia with Morphine
88900695|NCT01512329|Active Comparator|relaxation|Relaxation therapy (3 one-on-one sessions weekly for 3 consecutive weeks) comprised of education about the role of stress in MS biology, and the opportunities stress management provides to handle this issue. Patients were then taught how to apply stress management techniques like Jacobson relaxation skills, Schultz relaxation skills, visualization, etc.
89006754|NCT04616716|Experimental|4|"Drug:FMTN fasted in P1,high-fat diet P2,low-fat diet in P3~FMTN administration in fasted condition in period 1,FMTN administration after high-fat diet in period 2,FMTN administration after low-fat diet in period 3"
89420964|NCT05259020|Experimental|ID140009|
89420965|NCT05259020|Active Comparator|ID1803+ID1805|
89420966|NCT03482180|Experimental|Investigational Group- KI1106|KI1106 tablet - daily administration
89420967|NCT03482180|Active Comparator|Control Group - Atorvastatin|Atorvastatin Calcium 20mg - daily administration
89420968|NCT04459442|Experimental|Early cord clamping|Cord clamping at 60 seconds after birth.
89420969|NCT04459442|Experimental|Delayed cord clamping|Cord clamping at 180 seconds after birth.
89420970|NCT04689932|Experimental|Pre- Dialyzer Infusion and Post- Dialyzer Infusion|On study day 1, day 3 and day 5, patients will receive 6.75 mg Fe/4.5 mL Triferic AVNU intravenously using the Freedom Pump-20 during hemodialysis into the pre-dialyzer blood line. On study day 2, day 4 and day 6, patients will receive the 6.75 mg Fe/4.5 mL Triferic AVNU intravenously using the Freedom Pump-20 during hemodialysis into the post dialysis blood line.
88900696|NCT01512342|Experimental|Pacing|The pacing self-management program focussed on teaching the patient to estimate their current physical capabilities prior to commencing an activity. In order to appropriately pace activities (daily activities and exercise bouts), CFS patients were learned to estimate their current physical capabilities prior to commencing an activity, keeping in mind the regular fluctuating nature of their symptoms. The activity duration used within the program was less than that reported by the patient so to account for typical overestimations made by the patient. Each activity block was interspersed with breaks, with the length of this break equating to the duration of the activity.
88900697|NCT01512342|Active Comparator|relaxation therapy|Relaxation therapy comprised of education about the role of stress in CFS biology, and the opportunities stress management provides to handle this issue. Patients were then taught how to apply stress management techniques like Jacobson relaxation skills, Schultz relaxation skills, visualization, etc.
88900698|NCT01512355|Experimental|dexmedetomidine|
88900699|NCT01512355|Placebo Comparator|placebo|
88900700|NCT01512381|Experimental|CRT|
88900701|NCT01512381|Active Comparator|pacemaker|
88900702|NCT01512394|Active Comparator|Standard bowel prep|Standard bowel prep
88900703|NCT01512394|Experimental|No bowel prep|No bowel prep
88900704|NCT01512420||Cohort|
88900705|NCT01512095|Experimental|Norditropin®|
88900706|NCT01512095|Active Comparator|Nutropin AQ®|
88900707|NCT01512433|Active Comparator|True acupuncture|True acupuncture was a real acupuncture which had been used in conventional Chinese medicine practice
88900708|NCT01512433|Sham Comparator|Sham acupuncture|Sham acupuncture was a procedure which mimicked the real acupuncture procedure.
88900709|NCT01512459|Experimental|Venlafaxine MR Capsules 150|Venlafaxine MR Capsules 150 of Dr.Reddy's Laboratories Limited
88900710|NCT01512459|Active Comparator|Effexor XR 150 mg Capsules|Effexor XR 150 mg Capsules of Wyeth Laboratories Philadelphia, PA, USA
88900711|NCT01512472|Active Comparator|10 month degarelix therapy|
88900712|NCT01512472|Active Comparator|4 month degarelix therapy arm|
88900713|NCT01512485|Experimental|Clopidogrel|Clopidogrel tablets 75 mg of Dr. Reddy's Laboratories Limited
88900714|NCT01512485|Active Comparator|Plavix|Clopidogrel Tablet 75 mg
88900715|NCT01512498||Patients who underwent allogeneic HSCT|Patients who underwent allogeneic HSCT before the age of 18, who are 18 years or older at the time of the study and who are alive.
88900716|NCT01512511|Experimental|nitrous oxide|use nitrous oxide for pneumoperitoneum creation
88900717|NCT01512511|Placebo Comparator|carbon dioxide|use carbon dioxide for pneumoperitoneum creation
88900718|NCT01512524|Other|Patients With Traumatic Brain Injury|Study of the association between quality of life and MRI scans and endocrinology analysis (quantification of Growth Hormone) 18 months post-trauma.
88900719|NCT01512537|Active Comparator|UVB|UVB exposed group
88900720|NCT01512537|Active Comparator|Oral vitamin D tablet|Vitamin D supplementation
88900721|NCT01512550|Active Comparator|instrumented hip guide technique|A mechanical device used to measure and decide how the hip prosthesis (ABG II modular) should be implanted
88900722|NCT01512550|No Intervention|conventional measuring technique|Standard way of implanting the prosthesis (ABG II standard) without special measuring device or computer navigation technique
88900723|NCT01512550|Active Comparator|computer assisted navigation|A method to use computer navigation when positioning and sizing the hip prosthesis (ABG II modular).
88900724|NCT01512563|Experimental|Paclitaxel ElutingCovered Metal Stent|
88900725|NCT01512563|Active Comparator|Covered Metal Stent|
88900726|NCT01512576|Experimental|acupuncture|All patients were treated at the basic points bilaterally situated in the local region (neck), distal region (low back, arms and legs) and ear. In addition, acupuncture treatment was performed according to the rules of traditional Chinese medicine and was semi-standardized. This means that the therapist was allowed to choose from a list of the following acupuncture points: GV14, Huatuojiaji C1-C7, GB20, SI11, GB21, TE15, SI14, BL17, MT10, SI3, BL64, TE5, GB41, Zero point, Jerome point, C0. The combination of acupuncture points were chosen individually, according to the patients' self-reported symptoms. In order to obtain the required information, patients had to fill out a Margolis pain diagram, and the acupuncturist questioned the patient and performed a tongue- and pulse diagnosis.
88900727|NCT01512576|Active Comparator|relaxation|For the relaxation treatment the method of guided imagery is applied. Guided imagery is a system of visualization. During guided imagery relaxation, the patient's state of consciousness is similar to one which occurs in meditative status. Patients are instructed to listen to a CD with relaxation music (Arcade TV-CD Ad Vissesr's Brainsessions, track 3). Patients will sit in an identical position like during the acupuncture treatment (i.e. on a relaxation chair) and listened to the audio CD by headphone.
88900728|NCT01512602|Active Comparator|Dialectical Behavior Therapy DBT|16 weeks DBT-treatment
88900729|NCT01512602|Active Comparator|CAMS|Collaborative Assessment and Management of Suicidality, CAMS-informed supportive psychotherapy
88900730|NCT01512615|Experimental|Intervention group|Complex Cardiac Rehabilitation
88900731|NCT01512615|Experimental|Control group|Usual care
88900732|NCT01512628|Active Comparator|PENTA group|Pentaspan is administered as a colloid.
88900733|NCT01512628|Active Comparator|voluVEN group|Voluven is administered as a colloid.
88900734|NCT01512628|Active Comparator|voluLYTE group|Volulyte is administered as a colloid.
88900735|NCT01512641|Experimental|Children with Dissociative Disorders|Children will take first the primary stage. If one child is positive, he will pass the secondary stage.
88900736|NCT01512654|Other|algorithm DIAdvisor activated|Glucose predictions and therapy advices will be displayed to the patient. Patients will be asked to follow the advices suggested by DIAdvisor system according to their own judgement. Patient will decide his need of insulin according to the results given by the HemoCue glucometer, CGM trends, glucose predictions as well as therapy advices. In case of any doubt with the predictions displayed or the advices suggested, the patients will be invited to ask study personal and/or the study physician for help.
89006755|NCT04616716|Experimental|5|"Drug:FMTN low-fat diet in P1,fasted P2,high-fat diet in P3~FMTN administration after low-fat diet in period 1,FMTN administration in fasted condition in period 2,FMTN administration after high-fat diet in period 3"
88900737|NCT01512654|Other|algorithm of DIAdvisor disactivated|Glucosepredictions and therapy advices will not be displayed. Patient will decide his need of insulin according to the results given by the HemoCue glucometer and CGM trends. He/She will inject insulin at mealtimes or program a bolus on his/her pump by him/herself and will adapt his/her basal insulin doses or pump delivery rates as usual. As needed or on request and more particularly if hypo or hyperglycaemia occurs, the subject will be advised and helped by nurses and physicians.
88900738|NCT01512680|Experimental|Type 1 diabetes patient|Type 1 diabetes patient are included in this study to have an education to Functional Insulin Therapy (intervention)
88900739|NCT01512719|Experimental|POEM procedure|Patients with achalasia that undergo POEM
88900740|NCT01512732||healthy control group|Young (20-49) and Older (50-70) healthy group (n=60)
88900741|NCT01512732||Parkinson's disease patients|(n=30).
88900742|NCT01512732||Major depressive disorder patients|(n=30).
88900743|NCT01512784|Experimental|HIV-infected adolescents and young adults|female and male HIV-infected subjects aged from 13-27 years old
88900744|NCT01512784|Active Comparator|healthy adolescents and young adults|female and male healthy adolescents and young adults aged 13-27 years
88900745|NCT01512823|Experimental|Interactive educational intervention|Two education sessions (four-hours and two-hours respectively), emailed notes and reminders
88900746|NCT01512823|Experimental|Didactic educational intervention|Education alone
88900747|NCT01512836|Experimental|Case Management|The patients who are randomized to the intervention group will be assigned to case management. The case manager is expected to integrate care from a health maintenance and promotion perspective, where the overall goal is the promote and support the patients self care (see intervention description).
88900748|NCT01512836|No Intervention|Usual Care|Patients randomized to the usual care group will receive conventional health and social services. Patients in this group will not receive support from a case manager.
88900749|NCT01512862|Experimental|Calcitriol|
88900750|NCT01512862|No Intervention|Placebo|
88900751|NCT01512875||biopsy proven H. pylori|Patient must have lived in the districts of Lima, Peru listed in the protocol.
88900752|NCT01512901|Experimental|1|
88900753|NCT01512901|Experimental|2|
88900754|NCT01512901|Sham Comparator|3|
88900755|NCT01512914|Placebo Comparator|CONTROL group|
88900756|NCT01512914|Experimental|PREOPERATIVE nebulization|
88900757|NCT01512914|Experimental|POSTOPERATIVE nebulization|
88900758|NCT01512914|Active Comparator|INSTILLATION group|
88900759|NCT01512927||ESRD with regular hemodialysis|
88900760|NCT01512953|No Intervention|no PPI|Patients, stratified according to the genetic stratum, will be randomized not to take any PPI on top of clopidogrel
88900761|NCT01512953|Experimental|PPI|Patients stratified to the genetic stratum will be randomized to take PPI on top of clopidogrel
88900762|NCT01512966|Experimental|VTE 2Q4 first, then VTE 2Q8|VEGF Trap-Eye [BAY86-5321; EYLEA (aflibercept) Injection] 2 mg Q4 (VTE 2Q4) administered every 4 weeks from Week 0 to Week 16, followed by every 8 weeks until Week 48 (2Q8)
88900763|NCT01512992|Experimental|Home telehealth|
88900764|NCT01512992|No Intervention|Usual care|
88900765|NCT01513005|Experimental|Laparoscopic Sleeve Gastrectomy|
89006756|NCT04616716|Experimental|6|"Drug:FMTN high-fat diet in P1,low-fat diet P2,fasted in P3~FMTN administration after high-fat diet in period 1,FMTN administration after low-fat diet in period 2,FMTN administration in fasted condition in period 3"
88814024|NCT03002285|Active Comparator|Control group|Group with typical development that performed the Fitts law in a computer task
88814025|NCT04374422||1|study group pre-pandemic time interval
88814026|NCT04374422||2|same population during pandemic
88814027|NCT03002051|Experimental|EUS guided drainage|Patients suffering from the conditions in focus would receive EUS guided drainage with the lumen apposing stent
88814028|NCT02247557|Experimental|Group A: Liposome encapsulated BoNT-A|Liposome encapsulated BoNT-A ( mixed BOTOX 200U/10ml in Liposome 80mg/40ml) in single intravesical instillation
88814029|NCT02247557|Experimental|Group B: BoNT-A 200 U in Normal saline|BOTOX 200U in normal saline (BoNT-A/NS) 50ml in single intravesical instillation
88814030|NCT02247557|Placebo Comparator|Group C: Normal saline|Normal saline (N/S) 50ml in single intravesical instillation
88814031|NCT03401996|Experimental|Real tDCS|
88814032|NCT03401996|Sham Comparator|Sham tDCS|
88814033|NCT04374110||Hospitalized patients with COVID-19|Hospitalized patients with COVID-19 will be included in the study in centers around Poland.
88814034|NCT04374110||Infected SARS-CoV-2 patients|patients with SARS-CoV-2 infection not requiring hospitalization
88814035|NCT04374110||Controls|structure-matched and co-existing disease matched control group from the general population.
88814036|NCT02996045|Experimental|Treatment|Clinical Decision Support (CDS)
88814037|NCT02996045|No Intervention|Control|Will not receive Clinical Decision Support (CDS)
88814038|NCT03401684|Experimental|Resilient Minds|Four comprehensive, skill-building learning modules in the areas of psychological trauma, mental health problems, resiliency and workplace stress.
88814039|NCT02240264|Active Comparator|Krill oil capsules|"Capsules containing krill oil rich in omega-3 fatty acid's.~Dietary supplements (krill oil) are provided by Aker BioMarine Antarctic AS equalling almost the daily recommended amount of 450 mg of EPA/DHA intake per day.~Addendum 25-4-2016: In the Original protocol a dose adjustment after 3 months according to Omega-3 Index was to be executed. As no participant achieved the target Omega-3 Index the dosage was adjusted to 800mg DHA + EPA per day for all participants. The also led to the decision to increase the starting dosage of cohort II to 800mg DHA+ EPA."
88814040|NCT02240264|Placebo Comparator|Placebo|Capsules containing a fatty acid mixture that reflects the fatty acid composition of the average European diet.
88814041|NCT04373798||Suspected COVID-19|Individuals with symptoms who are seen at covid19 check points for covid19 diagnosis.
88814042|NCT02226965|Experimental|PNT2258|"PNT2258 will be administered at 120 mg/m2 on days 1-5 of a 21-day cycle. Treatment may continue unless there is disease progression or the occurrence of unacceptable toxicity for a total of 8 induction cycles of therapy. Subjects with CR/CMR, PR/PMR or SD/NMR at the end-of-cycle 8 scan then receive ongoing PNT2258 therapy at a dose of 100 mg/m2 on days 1-4 of a 28 day cycle until progressive disease, the occurrence of unacceptable toxicity, non-compliance, voluntary withdrawal or if in the opinion of the investigator the subject is no longer benefiting from exposure to PNT2258."
88814043|NCT04374188|Active Comparator|ciprofloxacin|ciprofloxacin tablets
88814044|NCT04374188|Active Comparator|levofloxacin|levofloxacin tablets
88814045|NCT04374032|Experimental|ENKORTEN|
88814046|NCT04374032|Other|The standard of care treatment|The usual therapeutically established protocol for the treatment of patients with moderate to severe COVID-19 infection
88814047|NCT02227121|Experimental|VT/VF induction and defibrillation|Ventricular Tachycardia and Ventricular Fibrillation (VT/VF) induction and defibrillation will be carried out as the invention in all subjects undergoing study procedures.
88814048|NCT02492958|Experimental|SA4Ag|Staphylococcus aureus 4-antigen vaccine
88814049|NCT02492958|Placebo Comparator|Placebo|a lyophile match to the vaccine, consisting of excipients of SA4Ag formulation minus the active ingredients
88814050|NCT04373408||ACL rupture without indication for ALL surgery|Patients with an ACL rupture undergoing surgical repair of the ACL only
89420971|NCT03479060|Active Comparator|Continue WCT Application|From the 3rd month to the 12th month Wet cupping applied as an intervention MIDAS was applied at the end of the 6th and 12th months.
89420972|NCT03479060|No Intervention|Discontinue WCT Application|No intervention in this arm.Only MIDAS applied
89420973|NCT03478748|Active Comparator|one-to-one dental health education|Conventional oral health education programme that mainly focuses at child level, which has been the normal practice at the Ministry of Health, were provided to the control participants.
89420974|NCT03478748|Experimental|anticipatory guidance technique|Anticipatory guidance technique were applied where appropriate dental health education (according to the children's milestones) were provided to mothers and their children.
88900766|NCT01513018|Active Comparator|high (10 ml/kg) tidal volumes|Evaluate the influence of low (5 ml/kg) and high (10 ml/kg) tidal volumes on arterial oxygenation and Intrapulmonary shunt during one lung ventilation.
88900767|NCT01513018|Active Comparator|low tidal volume (5 ml/kg)|Evaluate the influence of low (5 ml/kg) and high (10 ml/kg) tidal volumes on arterial oxygenation and Intrapulmonary shunt during one lung ventilation.
88900768|NCT01513031|Experimental|Phone follow-up|All study participants will be receiving education and monthly telephone follow-up.
88900769|NCT01513044|Experimental|Mycophenolate Mofetil|Mycophenolate Mofetil 250 mg capsules of Dr. Reddy's Laboratories Limited
89194544|NCT00740454||A|Pregnant or post-partum women with a clinically suspected DVT and a negative distal and proximal leg veins compression ultrasonography
89194545|NCT00880282|Experimental|Treatment (cixutumumab, temsirolimus)|Patients receive cixutumumab IV over 60 minutes and temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 25 courses in the absence of disease progression or unacceptable toxicity.
89420975|NCT03481946|Experimental|BAY1093884 in subjects with Hemophilia|Single dose of BAY1093884 over 30 minutes administered in subjects with severe congenital Hemophilia A or B, with inhibitors or without inhibitors
89420976|NCT04334408|Active Comparator|Subjects with CADASIL treatment intervention|Subjects that have been diagnosed with both CADASIL and moderately to severely disabling migraine headaches will be treated with Fremanezumab injections.
89420977|NCT04334408|Placebo Comparator|Subjects with CADASIL placebo intervention|Subjects that have been diagnosed with both CADASIL and moderately to severely disabling migraine headaches will be treated with placebo injections.
89420978|NCT02523560|Experimental|telerehabilitation group|1 week hospital rehabilitation and 8 weeks home-based telerehabilitation and telemanagement (including HomeMonitoring)
89420979|NCT02523560|No Intervention|control group|Patients qualified to the control group will undergo a 9-week procedure appropriate to their clinical condition/status standardized for a particular center (usual care).
89420980|NCT03476564|Experimental|intervention group|intervention group will receive pentoxifylline (Trental S.R.) 400 mg/BD plus vit E (PHARCO) 400 mg/BD 2 cycles before starting ICSI cycle and the medication will be continued until the beta-hCG becomes positive or the cycle is cancelled.
89420981|NCT03476564|No Intervention|comparison group|. The comparison group will not receive the above drugs. The main outcome measure will be clinical pregnancy rate.
89420982|NCT05258552|Experimental|Enema group|
89420983|NCT05258552|No Intervention|Control group|
89420984|NCT05258474|Experimental|healthy subjects|healthy subjects (single-ascending and multiple-ascending doses)
89420985|NCT05258474|Experimental|IBD-patients|inflammatory bowel disease patients (multiple dose)
89420986|NCT05258396|Experimental|Patients with MS|Children with MS
89420987|NCT05258396|Experimental|Volunteers|matched in age and sex with patients. Volunteers will perform only one brain MRI, as requested by the neurologist
88900770|NCT01513044|Active Comparator|Cellcept|Cellcept 250 mg capsules of Roche Laboratories Inc.
88900771|NCT01513057|Experimental|Mycophenolate Mofetil|Mycophenolate Mofetil 250 mg capsules of Dr. Reddy's Laboratories Limited
88900772|NCT01513057|Active Comparator|Cellcept|Cellcept 250 mg capsules of Roche Laboratories Inc.
88900773|NCT01513070|Experimental|Quick-Acting Heart Reliever group|Drug: Quick-Acting Heart Reliever and Placebo of isosorbide dinitrate and Aspirin Enteric-coated Tablets
88900774|NCT01513070|Active Comparator|Isosorbide Dinitrate group|Isosorbide Dinitrate and Placebo of Quick-Acting Heart Reliever and Aspirin Enteric-coated Tablets
88900775|NCT01513083|Experimental|Mild hepatic dysfunction|
89194546|NCT00740532||Observation|Breast cancer patients treated with Herceptin-based therapy
89194547|NCT05741268|Experimental|Dialectical behavior therapy|Dialectical behavior therapy will be applied through psychoeducation, discussion, rehearsal, and homework assignments. Four modules were administered in Mindfulness, Emotion Regulation, Emotion Regulation, and Emotion Regulation.
89194548|NCT05741268|Active Comparator|Routine psychological care|they will receive psychological care such as stress management and social skills training.
89420988|NCT03478436|Other|fed group|14 once daily oral doses of doxycycline 40 mg, preceded by a standardized high-fat, high-calorie breakfast
89420989|NCT03478436|Other|fasting group|14 once daily oral doses of doxycycline 40 mg in fasting conditions (no food allowed 8 hours prior to dosing)
89420990|NCT03476486|Experimental|Treatment|The hand that was subject to thread carpal tunnel release surgery
89420991|NCT03476486|No Intervention|Control|The hand that was not treated
89420992|NCT01338987|Active Comparator|Arm1 First Transplt/males/leuprolide/+/-FLT Imaging|"Males randomized to leuprolide for first transplant.~[18F]fluorothymidine (FLT) imaging"
88900776|NCT01513083|Experimental|Moderate hepatic dysfunction|
88900777|NCT01513083|Experimental|Normal hepatic function|
88900778|NCT01513096|No Intervention|Split-dose PEG|Bowel preparation using split dose PEG without prokinetics
89194549|NCT00879346|Experimental|1|160mg oral dose of AZD8931
88900779|NCT01513096|Active Comparator|Split dose PEG with prokinetics|Bowel preparation using split-dose PEG with prokinetics
88900780|NCT01513109|Experimental|Treatment arm|Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic combined with Treg depletion
88900781|NCT01513135|Experimental|Group A, Tat|Recombinant biologically active Tat 30 mcg in Phosphate saline buffer, pH 7.4, 1% sucrose, 1% Human Serum Albumin; administered intradermally 3 times at weeks 0, 4 & 8
88900782|NCT01513135|Placebo Comparator|group B, Placebo|Phosphate saline buffer, pH 7.4, 1% sucrose, 1% Human Serum Albumin, administered intradermally 3 times at weeks 0, 4 & 8
88900783|NCT01513161|Active Comparator|TRK-820 5μg|Taking TRK-820 5μg(two 2.5μg capsules) by oral route once daily for 14 days
88900784|NCT01513161|Active Comparator|TRK-820 2.5μg|Taking TRK-820 2.5μg(one 2.5μg capsule & one placebo capsule)by oral route once daily for 14 days
88900785|NCT01513161|Placebo Comparator|Placebo|Taking Placebo(two placebo capsule) by oral route once daily for 14 days
88900786|NCT01513174|Active Comparator|Gefitinib|Gefitinib will be administered once daily, continuously, in 28-day cycles, as a fixed dose of 250 mg/day.
88900787|NCT01513174|Experimental|Gefitinib in combination with olaparib|Gefitinib 250 mg once a day, in combination with olaparib (at the recommended dose in the previous Phase I study) twice a day, continuously, in 28-day cycles.
88900788|NCT01513200|Placebo Comparator|UFH + Placebo|UFH (60U/kg bolus followed by 12U/kg/hr for approx.11 hours) with saline (placebo) administered as infusion for the last 4 hours of UFH
88900789|NCT01513200|Experimental|UFH + Bendavia|UFH (60U/kg bolus followed by 12U/kg/hr for approx.11 hours) with Bendavia (0.25mg/kg/hr) administered as infusion for the last 4 hours of UFH
88900790|NCT01513226|Experimental|Dim light|Day and nighttime dim light conditions
88900791|NCT01513252|Experimental|1|Gröber and Buschke test
89194550|NCT00874042|Experimental|ARQ 197 in combination with gemcitabine|
89194551|NCT00736866|Experimental|Acetylcysteine|
89194552|NCT00736866|Placebo Comparator|Control|
89194553|NCT00879424|Experimental|1|
88900792|NCT01513265|Active Comparator|RASP|
89194554|NCT00879424|Placebo Comparator|2|
89194555|NCT00710684|Experimental|DONEPEZIL + SB-742457 15 MG|SB-742457 - 15mg added to existing donepezil treatment
89194556|NCT00710684|Placebo Comparator|DONEPEZIL + PLACEBO|Placebo added to existing donepezil
89194557|NCT00710684|Experimental|DONEPEZIL + SB-742457 35 MG|SB-742457 - 35mg added to existing donepezil
89194558|NCT00740688|Experimental|Experimental Group|A Logan Basic Apex Contact, which is a contact that is placed on the anterior surface of the sacrotuberous ligament with a light force directed posterior with varying degrees of laterality.
89194559|NCT00740688|Sham Comparator|Sham Group|light force contact applied to the inferior surface of the sacrotuberous ligament, directed straight superiorly.
88900793|NCT01513265|No Intervention|Control group|Subjects enrolled in this arm will undergo usual medical and pharmaceutical care with registration of drug use at admission and discharge without interference of RASP or clinical pharmacist.
88900794|NCT01513278|Placebo Comparator|Control arm|All patients receive APN201 and placebo at the same time. The irradiated region is divided vertically into two symmetric areas (left and right). One area is treated with APN201, the other area is treated with placebo (empty liposomes formulated as a hydrophilic gel) in a double-blind fashion.
88900795|NCT01513278|Active Comparator|APN201|APN201 (recombinant human superoxide dismutase (rhSOD) encapsulated in liposomal vesicles formulated as a hydrophilic gel)
88900796|NCT01513304|Experimental|Chiropractic manual therapy|
88900797|NCT01513356|Experimental|CBKM120|BKM120 will be administered on a continuous once daily dosing schedule at a dose of 100 mg (p.o.)during 28 days
88900798|NCT01513369|Experimental|ferric carboxymaltose|Dose: according to SmPC; Duration: 12 weeks; Frequency: at week 1 and again at week 5 (if again indicated according to principal inclusion criteria); Application: intravenous
88900799|NCT01513369|Placebo Comparator|NaCl (0,9%)|Duration: 12 weeks; Frequency: at week 1 and again at week 5 (if again indicated according to principal inclusion criteria); Application: intravenous
88900800|NCT01513382|Experimental|Methylene Blue|The effect of methylene blue dye in detection and total excision of pilonidal sinus will be studied histopathologically.
88900801|NCT01513395|No Intervention|Immediate|"Participants randomized to the Immediate or control arm (voiding within five minutes of cervical assessment), will undergo any indicated trans-abdominal ultrasound imaging and preparations for vaginal ultrasound (including readying the probe and preparing the exam table for lithotomy position) prior to using the restroom. The participant will be instructed to proceed to the restroom to empty her bladder completely. A synchronized clock will be placed in the restroom, and the patient will be asked to note the time that she completes voiding. This will be confirmed by the research staff by noting the time the participant enters and exits the restroom. Vaginal ultrasound and cervical assessment will then be performed immediately upon return to the ultrasound room (within a maximum of 5 minutes from voiding time)."
88900802|NCT01513395|Experimental|Interval|"Participants randomized to the Interval or experimental arm (cervical assessment 15 minutes or more after voiding) will be notified of their allocation and asked to immediately use the rest room and attempt to void completely. A synchronized clock will be located in this restroom, and each participant will be asked to note the time that she completes voiding. This will be confirmed by the research staff by noting the time the participant enters and exits the restroom. The participant will return to the waiting room or ultrasound room. Any indicated trans-abdominal ultrasound imaging will be performed, and preparations will be made for the vaginal ultrasound. The participant will be asked not to void prior to the vaginal ultrasound. Cervical assessment will take place at a minimum of 15 minutes from voiding time"
88900803|NCT01513421||Active vacuum pressure drainage|
88900804|NCT01513421||Free drainage|
88900805|NCT01513434|Active Comparator|transtibial technique|In anterior cruciate ligament reconstruction, femoral tunnel was made via tibial tunnel.
88900806|NCT01513434|Active Comparator|Transportal technique|In anterior cruciate ligament reconstruction, femoral tunnel was made via anteromedial portal.
88900807|NCT01513486|Experimental|Immobilization with NMES|Immobilization with daily NMES
89194560|NCT00879502||1|Men with the fragile X premutation
89194561|NCT00879502||2|Healthy men
88900808|NCT01513486|Placebo Comparator|Immobilization without NMES|Immobilization without daily NMES
88900809|NCT01513499|Active Comparator|Oxytocin|Intranasal oxytocin
88900810|NCT01513499|Placebo Comparator|Placebo|Intranasal placebo
88900811|NCT01513525|Experimental|Abdomen|
88900812|NCT01513525|Experimental|Thigh|
88900813|NCT01513525|Experimental|Upper arm|
89194562|NCT00879502||3|Brothers of men with the fragile X premutation
89194563|NCT00879580||Non-ruptured aneurysms|Patients with intracranial aneurysm(s) requiring an endovascular treatment with a Codman ENTERPRISE stent who have one or more non-ruptured or late ruptured (>30days), intracranial aneurysm.
89194564|NCT00879580||Acute ruptured Aneurysms|Patients with intracranial aneurysm(s) requiring an endovascular treatment with a Codman ENTERPRISE stent who have a on or more acute ruptured (<30Days) aneurysms
89194565|NCT00710606|Experimental|1- Obese Women /Nuvaring|Obese subjects (BMI 30-39.9)received two contraceptive hormonal rings. During the second cycle of ring use, subjects returned to the study site for serial serum hormone measurements and transvaginal ultrasound twice weekly during four weeks of continuous use.
88814051|NCT04373408||ACL rupture with indication for ALL surgery|Patients with an ACL rupture undergoing surgical repair of the ACL and the ALL
88814052|NCT03401606|Active Comparator|Remifentanil|remifentanil and dexmedetomidine, 0.25 ng/mL, given intravenous, infusion, until surgery finished.
88814053|NCT03401606|Active Comparator|Dexmedetomidine|dexmedetomidine and remifentanil, 0.125 mcg/kg/hour, given intravenous, infusion, until surgery finished
88814054|NCT02240732||Total knee replacement patients|"Patients who are due to have a total knee replacement will be studied to look for the presence of Emboli.~Observational with imaging."
88814055|NCT04347668|Active Comparator|Usual Care|All residents are seen by a RN, with care by Registered Practical Nurse (RPN) and Personal Support Worker (PSW) staff 24/7. Residents supported by behavior support Ontario staff; include Behavior responsive team. Residents prior to admission have been assessed by the Geriatric program. Residents may receive psychotropic or cognitive enhancement medications. The residents are seen routinely seen once a week by the physician. Their Dementia is monitored weekly but the physician as well as daily by the registered staff. Quarterly or more frequently cognitive assessments are completed and referrals made to appropriate specialists. A day would include meals, engagement in scheduled and non-scheduled programs such as exercise, and activities, groups. Residents are supported in their activities of daily living, and social engagement. Specific interventions based on resident needs are supported in a Dementia capable environment.
88819970|NCT01515410|Experimental|DM-1992|DM-1992, a gastric-retentive extended-release tablet containing 72.5mg carbidopa (CD) and 230mg levodopa (LD)
88819971|NCT01515410|Active Comparator|Sinemet IR|An Immediate-release (IR) tablet containing 25mg carbidopa (CD) and 100mg levodopa (LD)
88819972|NCT01515488|Experimental|Self-triage kiosk|Audio-assisted self-triage kiosk for obtaining medical history and presenting problem(s)
88819973|NCT01515488|Experimental|Nurse-initiated triage|Nurse-initiated triage for obtaining medical history and presenting problem(s)
88819974|NCT01515566|Experimental|Fentanyl|Fentanyl subcutaneously (SQ) dose equivalent to 15-25% of the morphine equivalent daily dose (MEDD) 15 minutes before walk test, and 6 minute walk test (6MWT) at baseline and 15 minutes after Fentanyl. Two (2) Questionnaires completed at baseline taking about 10 minutes to complete, and one completed after study visit taking about 5 minutes to complete.
88819975|NCT01515566|Active Comparator|Placebo|Normal saline 0.9% preservative free SQ 15 minutes before walk test, and 6 minute walk test at baseline and 15 minutes after Placebo. Two (2) Questionnaires completed at baseline taking about 10 minutes to complete, and one completed after study visit taking about 5 minutes to complete.
89006757|NCT04616521|Experimental|Asymmetric DBS group|In this arm, a one-staged combined unilateral STN and contralateral GPi DBS will be implanted into PD patients. For postural instability and gait difficulty (PIGD)-dominant patients, the GPi in the side contralateral to the leg with longer step length will be targeted. For tremor-dominant (TD) patients, the STN in the side contralateral to the body side that mostly affected will be targeted. For PD patients of mixed type, the choice of target will depend on the judgement of a multidisciplinary team based on clinical features.
89006758|NCT00251043|Experimental|1|Participants will Psychotherapy weekly for 12 weeks
89006759|NCT00251043|Active Comparator|2|Parenting Education will include 45-minute weekly sessions for 12 week
89006760|NCT00563056|Experimental|Flutiform|2 puffs 50/5 or 125/5 mcg
89006761|NCT00563056|Active Comparator|Flixotide plus Foradil|Flixotide 2 puffs 50 or 125 mcg; Foradil 1 puff 12 mcg
89006762|NCT00563173|Other|1|Low dose
89006763|NCT00563173|Other|2|Medium dose
89006764|NCT00563173|Other|3|High dose
89006765|NCT00221468|Experimental|Quetiapine|Patients will begin 100mg of quetiapine on day 1 and titrated to a maximum dose of 400mg by day 4, with flexible dosing to 600mg by day 28. The total duration of treatment will be 84 days (12 weeks).
89006766|NCT00563212|Experimental|A1|
89006767|NCT03454516|No Intervention|Standard Care|This group is the usual standard treatment group
89006768|NCT03454516|Other|Telemonitoring group|This group will followed up with telemonitoring
89006769|NCT02961543|Experimental|Group 1.|"The participants randomly allocated to this arm will undergo a muscular rehabilitation program based on the isokinetic eccentric exercise for the extensor muscles of the operated knee.~The contralateral non-operated lower limb will be used as control, so it will not undergo any muscular rehabilitation program."
89006770|NCT02961543|Active Comparator|Group 2.|"The participants randomly allocated to this arm will undergo a muscular rehabilitation program based on the isotonic eccentric exercise for the extensor muscles of the operated knee.~The contralateral non-operated lower limb will be used as control, so it will not undergo any muscular rehabilitation program."
89006771|NCT00221507|No Intervention|Historical Cohort|This study will first examine risk factors in a defined population of inner city children, using a historical cohort.
89006772|NCT00221507|Active Comparator|Reminder Recall Outreach|"To determine how well Reminder Recall Outreach will increase immunization rates and well child care delivery in those children most at risk for falling through the cracks. These studies will be conducted in the Denver Health community health network, the largest integrated community health care system in the United States."
89006773|NCT00221507|Active Comparator|Case Management|"To determine how well Case Management will increase immunization rates and well child care delivery in those children most at risk for falling through the cracks. These studies will be conducted in the Denver Health community health network, the largest integrated community health care system in the United States."
89194566|NCT00710606|Active Comparator|2- Normal Weight / Nuvaring|Normal weight subjects (BMI 19-24.9) received two contraceptive hormonal rings. During the second cycle of ring use, subjects returned to the study site for serial serum hormone measurements and transvaginal ultrasound twice weekly during four weeks of continuous use.
89194567|NCT00713544|Active Comparator|1|
89194568|NCT00713544|Experimental|2|20mg
89194569|NCT00713544|Experimental|3|50mg
89194570|NCT00713544|Experimental|4|100mg
89420993|NCT01338987|Active Comparator|Arm2 First Transplt/males/No Leuprolide/+/- FLT Imaging|"Males not receiving leuprolide for first transplant~[18F]fluorothymidine (FLT) imaging"
89420994|NCT01338987|Experimental|Arm3 First Transplt/females/leuprolide+/- FLT Imaging|"Females receiving leuprolide for first transplant.~[18F]fluorothymidine (FLT) imaging"
89420995|NCT01338987|Experimental|Arm4-Second Transplt/leuprolide and FLT Imaging|Second transplant with leuprolide and [18F]fluorothymidine (FLT) imaging
89420996|NCT01338987|No Intervention|Healthy Volunteer - Arm 5|Healthy Volunteer
89420997|NCT04234100|Experimental|Orange juice rich in hesperidin and narirutin|The consumption of the orange juice will be made in a single dose of 500 ml. The juice is presented in a concentrated and frozen format, packed in opaque cans of 500 mL, for which it must be thawed and diluted with mineral water up to 1.5 L before its ingestion.
89194571|NCT00713544|Experimental|5|150mg
89420998|NCT03476408|Experimental|Single Group Correlation|Correlation between these topics.
89420999|NCT03131180|Experimental|RLHS dashboard|Patients randomized to RLHS website access are given instructions on how the RLHS dashboard works both by phone and by email and are given open access to the RLHS dashboard website immediately after enrollment and before meeting with the CCPR clinical team for their consultation. Each user has an access code, which allows them to track their access. They maintain access to the website throughout their care in the CCPR. Patients in the RLHS access group complete the System Usability Scale (SUS; a 10 item questionnaire to evaluate software, websites, and applications) after use of the RLHS at consultation. Those in the RLHS access group also complete a 7-item exit interview either via phone or on REDCap.
89421000|NCT03131180|No Intervention|Standard consultation alone|Those not randomized to RLHS access undergo standard consultation only.
89194572|NCT00713544|Placebo Comparator|6|
89194573|NCT00737126|Placebo Comparator|1|Administration of an oral placebo pill
89194574|NCT00737126|Experimental|2|Administration of oral folic acid
89194575|NCT04063436|Experimental|Experimental|Participants will be placed in the experimental arm for 14±5 days, during which they will be using the new nasal pillows mask for PAP therapy.
89194576|NCT00740766|Experimental|Monitored|
89194577|NCT00740766|No Intervention|Unmonitored|
89194578|NCT00415363|Experimental|A|
89194579|NCT00415363|Placebo Comparator|B|
89194580|NCT04063046|Active Comparator|General anesthesia|General anesthesia involving intubation or supraglottic airway device insertion
89194581|NCT04063046|Experimental|peripheral nerve block|popliteal sciatic nerve block
89194582|NCT00740844|No Intervention|1|No intermittent pneumatic compression of the lower limbs during patient hospitalisation in réanimation unit
89194583|NCT00740844|Experimental|2|Intermittent pneumatic compression of the lower limbs during hospitalisation in reanimation unit
89194584|NCT05529056|Experimental|Test Arm 1|LPTAT01
89194585|NCT05529056|Experimental|Test Arm 2|LPTAT02
89194586|NCT05529056|Experimental|Test Arm 3|LPTAT03
89194587|NCT05529056|Placebo Comparator|Reference Arm|LPTAT04
89194588|NCT00740922||1|
89194589|NCT00741000|Experimental|Experimental|Cervical low force mobilization procedure.
89194590|NCT05740436||Frail elderly subjects|Frail subjects of 60 years and older will get geriatric rehabilitation program based on CGA
89194591|NCT05740436||Pre-Frail elderly subjects|Pre-Frail subjects of 60 years and older will get geriatric rehabilitation program based on CGA
89194592|NCT05740436||Non-frail elderly Frail subjects|Non-frail Frail subjects of 60 years and older will get geriatric rehabilitation program based on CGA
89194593|NCT00741078|Experimental|atorvastatin, amlodipine|
89194594|NCT02568800|Experimental|Prolonged Cefepime Infusion|Cefepime infusions should last 4 hours at least
89194595|NCT02568800|Active Comparator|Usual Cefepime Infusion|Cefepime infusion should last no more than 30 minutes
89194596|NCT00415051|Experimental|Single Group Assignment|RVF MP-12
89194597|NCT00741234|Experimental|A|Advanced solid tumors
89421001|NCT03478280|Active Comparator|Brodalumab|Subjects will receive 210 mg of Kyntheum administered by subcutaneous injection at Weeks 0, 1 and 2 followed by 210 mg every other week (EOW) thereafter.
89421002|NCT03478280|Placebo Comparator|Placebo|Subjects will receive placebo doses administered by subcutaneous injection at Weeks 0, 1 and 2 followed by placebo EOW thereafter.
89421003|NCT04856007|Experimental|Dapagliflozin 5mg + Metformin 500mg XR|co-administration of a single oral dose of a 5mg dapagliflozin (Forxiga® 5mg) tablet and a 500mg metformin XR (Glucophage XR®) tablet
89421004|NCT04856007|Experimental|Dapagliflozin/metformin XR FDC 5/500 mg|single FDC tablet consisting of 5mg dapagliflozin and 500mg metformin XR subject
89421005|NCT04856007|Experimental|Dapagliflozin 10mg + Metformin 1000mg XR|co-administration of a single oral dose of a 10mg dapagliflozin (Forxiga® 10mg) tablet and two 500mg metformin XR (Glucophage XR®) tablets
89421006|NCT04856007|Experimental|Dapagliflozin/metformin XR FDC 10/1000 mg|ingle FDC tablet consisting of 10mg dapagliflozin and 1000mg metformin XR
89194598|NCT00741234|Experimental|B|Advanced hematologic malignancies
89194599|NCT00741234|Experimental|C|Myelodysplastic Syndrome
89194600|NCT00741312|Experimental|I|
89194601|NCT00741312|Active Comparator|II|
89194602|NCT02568228|Experimental|Krill group|Krill oil capsules. 4 g/day encapsulated krill oil (Rimfrost Sublime) corresponding to ~900 mg/day EPA + DHA + DPA for 8 weeks. The participants will be instructed to take the capsules with the breakfast and dinner meals.
89421007|NCT04936906|Experimental|Extra Care (EC) Treatment Group|Participants in this group will receive the EC intervention pre and post standard of care (SoC) scheduled Mohs Surgery.
89421008|NCT04936906|Active Comparator|Usual Care (UC) Group|Participants in this group will receive the usual care provided to patients undergoing standard of care (SoC) scheduled Mohs Surgery.
88900814|NCT01513564|Experimental|Conservative treatment program|"The control group were supervised isometric passive and active exercises by a physiotherapist. On the second day patients were allowed to sit in a chair being instructed to a low intensity exercise training program with regard to back pain and fear of activity. From the third or fourth day stair training, low intensity exercise, daily walks and instruction in home training were allowed.~The intervention group received the same training program but with a faster program plus a higher intensity exercise-training program."
88900815|NCT01513577|Experimental|Minimal invasive pedicular screw|
89194603|NCT02568228|Experimental|Fish group|Lean and fatty fish. Three weekly test-meals, containing two meals of fatty fish and one meal of lean fish for 8 weeks corresponding to ~900 mg/day EPA + DHA + DPA.
88900816|NCT01513577|Experimental|Standard open insertion|
89194604|NCT02568228|Placebo Comparator|Control group|Placebo capsules. 4 g/day encapsulated high oleic sunflower oil (HOSO) for 8 weeks. The participants will be instructed to take the capsules with the breakfast and dinner meals.
89421009|NCT02523794|Experimental|Electro-kinetically Modified Water|Subjects will drink 2 to 3 500 mL bottles of EMW daily for 3 months
89421010|NCT02523794|Placebo Comparator|Placebo|Subjects will drink 2 to 3 500 mL bottles of purified drinking water daily for 3 months
89421011|NCT03706430|Experimental|Pulse Co-Oximeter sensor|All subjects are enrolled into this arm and will receive an investigational pulse CO-Oximeter sensors.
88900817|NCT01513603|Experimental|CLAG-M|
88900818|NCT01513616|Experimental|Pulmonary rehabilitation|A supervised 8-wk outpatient pulmonary rehabilitation program consisting of multi-modality exercise training and COPD self-management education.
88900819|NCT01513616|Sham Comparator|Usual care control|An 8-wk control period consisting of usual medical care which included optimization of respiratory medications, instructions on how best to manage COPD, standard access to treatment in the event of an exacerbation, self-management education.
88900820|NCT01513642|Other|Incentive spirometry|
88900821|NCT01513642|No Intervention|Breath Stacking|
88900822|NCT01513655|Experimental|LTNIV group|"LTNIV group is discharged with the ventilator and the settings and pressures which reversed the respiratory failure and the hypercapnic acidosis. We know the patients are able to tolerate these settings. The ventilators are Philips A30. The patients must use the ventilator for a minimum of six hours a night.~Furthermore, the patients are discharged with usual care, i.e., the golden standard of COPD treatment as described in GOLD-guidelines.~Outpatient visits are given every three months."
88900823|NCT01513655|No Intervention|Control group|"Patients in the control group are discharged with usual care, i.e., the golden standard of COPD treatment as described in GOLD-guidelines.~Outpatient visits are given every three months."
88900824|NCT01513668|Experimental|Acetaminophen extended release Gel tabs|Acetaminophen extended release Gel tabs 650 mg of OHM Laboratories Inc. (A subsidiary of Ranbaxy Pharmaceuticals Inc., USA)
89194605|NCT02568306|Experimental|NNC0165-1562|
89194606|NCT02568306|Placebo Comparator|Placebo|
89421012|NCT03825003||Basketball Players|Outcome assessments were done.
89421013|NCT03825003||Sedentary Peers|Outcome assessments were done.
89421014|NCT03651050|Experimental|intervention FBOs receive the P-MHDT|
89421015|NCT03651050|Experimental|control FBOs receive no P-MHDT|
88900825|NCT01513668|Active Comparator|Tylenol® 650 mg|Tylenol® 650 mg of McNeil Consumer and Specialty Pharmaceuticals, Division of McNeil PPC, INC. Fort Washington, PA 19034 USA
88900826|NCT01513681|Experimental|Lamotrigine Tablets 200 mg|Lamotrigine Tablets 200 mg of Dr. Reddy's Laboratories Limited
88900827|NCT01513681|Active Comparator|Lamictal® 200 mg Tablets|Lamictal® 200 mg Tablets of GlaxoSmithKline Inc
88900828|NCT01513694|Experimental|MSC seeded onto a phosphate ceramic|Instrumented posterolateral fusion and autologous mesenchymal stem cells arranged in a phosphate ceramic.
88900829|NCT01513707||Hemodialysis group|Hemodialysis group
88900830|NCT01513707||peritoneal dialysis group|peritoneal dialysis group
88900831|NCT01513720|Experimental|Lamotrigine Tablets 200 mg|Lamotrigine Tablets 200 mg of Dr. Reddy's Laboratories Limited
89421016|NCT03562923|Experimental|Test Product|Test Product, 100/50 mcg, 2 x daily
89421017|NCT03562923|Active Comparator|Reference Product|Reference Product, 100/50 mcg, 2 x daily
89421018|NCT03562923|Placebo Comparator|Placebo|Placebo Product 2 x daily
89421019|NCT03476252|Experimental|patients|ST elevation myocardial infarction
89421020|NCT03593252|Experimental|Combination bowel prep|"Patients will received mechanical bowel preparation (age appropriate dose, starting 2 days before surgery) and prophylactic oral antibiotics (3 doses, 1 day before surgery).~Clear fluids (or breast milk if applicable) will be given starting day before surgery.~The standard care will also be delivered (NPO for anesthesia and intravenous antibiotics on induction) Patients/parents will be provided with stool diary to document the adequacy of preparation. This will include frequency and character of stool according to Bristol grade. The treating surgeon will rate the adequacy of the preparation intra-operatively."
89421021|NCT03593252|Active Comparator|Oral antibiotics|The patients will receive prophylactic oral antibiotics (3 doses, 1 day before surgery)as well as standard care (NPO for anesthesia and intravenous antibiotics on induction).
89421022|NCT03593252|Placebo Comparator|No prep|Patients will receive no pre-operative bowel prep. The will receive the standard care only.
89421023|NCT03476174|Experimental|Pembrolizumab and HD Interleukin 2|Pembrolizumab 200 mg IV over 30 minutes; Day 1 of each cycle 3 weeks (21 days) for 2 cycles. IL-2 600,000 IU/kg2 IV over 15 minutes every 8 hours for up to 14 doses over 5 days; Days 1-5 = Cycle 1; 9 days of rest in between; Days 15-19 = Cycle 2
89194607|NCT00713258|Active Comparator|PTH (1-84)|PTH (1-84) + placebo alendronate
89194608|NCT00713258|Active Comparator|Alendronate|PTH (1-84) placebo + alendronate
89194609|NCT00710034|Active Comparator|Nicotine Gum|Nicotine replacement therapy (4 mg nicotine gum) was provided to the participants for an 12 weeks. Participants were encouraged to completely substitute nicotine gum for cigarettes and asked to use at least 6-8 pieces a day or optimally every 1-2 h and more if necessary. They were advised to reduce consumption by half during weeks 7-9 and three-quarters during weeks 10-12.
89421024|NCT04725045|Active Comparator|Standard clinical pulse shape|Standard clinical pulse shape as used in clinical practice (cathodic stimulation).
88819976|NCT02445105|Active Comparator|Autism Navigator Enhanced Practice|A 6-hour training will be provided to community service providers with the Autism Navigator for Primary Care professional development course and use of a web-based platform that includes an automated communication and autism screening and monthly electronic monitoring.
88819977|NCT02445105|Experimental|Family Engagement plus Autism Navigator|A 6-hour training will be provided to community service providers on the use of Motivational Interviewing, an evidence-based counseling method to improve engagement of families who are ambivalent about screening or intervention for their toddler, in addition to Autism Navigator Enhanced Practice.
88819978|NCT00571389||Cancer Cohort|The first cohort of patients to be enrolled for this study will be adults (males and females) with histological proven solid tumors of any stage, seen for routine cancer care at participating community cancer clinic sites. Patients on clinical trials with experimental study drugs will be allowed to participate in this observational prospective study.
88819979|NCT00571389||Healthy Volunteer Cohort|Healthy volunteers make up the second, smaller study population for this observational biospecimen laboratory study. Healthy volunteers serve primarily to aid in the proficiency, quality control and/or optimization of study procedures, experimental design assay development, and for device/equipment validation.
88819980|NCT00571389||COVID-19 Disease Cohort|Due to the COVID-19 pandemic and the consequent amendment to aid in the research response, study subjects with COVID-19 disease may participate in all aspects of this protocol, but depending on their disease state, infection timeline, and age, participation may be limited to only one component, procedure, and/or type of biospecimen collection. Age is a very important criteria, as pediatric subjects (5-17 years old) will only be eligible to participate in minimally invasive biospecimen collection procedures.
88819981|NCT02777931|Experimental|NFC-1|Doses of NFC-1 will be administered as 100, 200, or 400 mg twice daily as capsules for oral administration.
88819982|NCT02777931|Placebo Comparator|Placebo|Matching placebo capsules.
88819983|NCT01515956|Experimental|BMN 110 Weekly|
88819984|NCT02779491|Experimental|Intervention for two weeks|Receipt of the mobile phone application for two weeks
88819985|NCT02779491|No Intervention|Control for two weeks|Usual habitual activity - no receipt of mobile phone application for two weeks
88819986|NCT02779491|Experimental|Intervention for four weeks|Receipt of the mobile phone application for four weeks
88819987|NCT02779491|No Intervention|Control for four weeks|Usual habitual activity - no receipt of mobile phone application for two weeks
88819988|NCT02207972|Active Comparator|Use of Ultrasound|Woman requests epidural for pain relief Ultrasound guided CSE placed Continuous epidural infusion started Infusion 12 ml/hr of 0.0625% Bupivacaine and Fentanyl 2mcg/ml
89421025|NCT04725045|Experimental|Complex pulse shape|Complex pulse shape (i.e. biphasic pulse shape anode first, biphasic pulse shape cathode first, hyperpolarizing pre-pulse or depolarizing pre-pulse)
89421026|NCT03478202|Experimental|Open Label RELEASE Supplement|
89421027|NCT02259933|Experimental|KUC 7483 CL|increasing repeated oral doses
89421028|NCT02259933|Placebo Comparator|Placebo|
89421029|NCT05258318|Active Comparator|DR crush technique|
89421030|NCT05258318|Experimental|DK crush technique|
88900832|NCT01513720|Active Comparator|Lamictal® 200 mg Tablets|Lamictal® 200 mg Tablets of GlaxoSmithKline Inc
88900833|NCT01513733|Experimental|Tasquinimod single dose|
88900834|NCT01513733|Experimental|tasquinimod 0.25 mg followed by 0.5 mg|tasquinimod 0.25 mg for 3 weeks followed by 0.5 mg continuously, if tolerated
89421031|NCT05258162|Experimental|Mobilization|"Mobilizations are performed with minimum 6 seconds distraction stretch followed by partial release then followed by slow intermittent stretch at 3-4 seconds intervals.~Oscillations for 2 minutes at 2-3 oscillations per second."
89421032|NCT05258162|Experimental|Muscle Energy Technique|Muscle Energy Technique is given in the form of post isometric relaxation with 5-7 sec hold for 8-10 repetitions followed by a gentle passive stretch. Only 20% resistance is offered to the isometric contraction.
89421033|NCT04459520|Experimental|Testing Unavailable Group|This arm will complete an online survey where they will be presented a vignette asking them to imagine they have symptoms consistent with COVID-19, a physician telling them they likely have COVID-19, but that COVID-19 testing is not available. All arms will then be asked to fill out the same questions regarding behavior intentions and demographic questions. All participants will have completed five construct questions based off of Theory of Planned Behavior/Reason Action Approch during the pre-test survey.
88819989|NCT02207972|Active Comparator|No ultrasound used|Palpation of anatomical landmarks Woman requests epidural for pain relief CSE placed using palpation of anatomical landmarks Continuous epidural infusion started Infusion 12 ml/hr of 0.0625% Bupivacaine and Fentanyl 2mcg/ml
88819990|NCT02780349|Experimental|WIRION EPS|Single arm study. All patients undergo procedure with the WIRION EPS
88819991|NCT01516268|Active Comparator|Sufentanyl group|IN case group we add 1cc sufentanyl to 20 cc bupivacain in TAP block
88819992|NCT01516268|Placebo Comparator|Control group|In control group we add 1cc salin to 20cc bupivacain in TAP block
89421034|NCT04459520|Active Comparator|Positive Test Result|This arm will complete an online survey where they will be presented a vignette asking them to imagine they have symptoms consistent with COVID-19, a physician telling them they likely have COVID-19, and a positive COVID-19 test result. All arms will then be asked to fill out the same questions regarding behavior intentions and demographic questions. All participants will have completed five construct questions based off of Theory of Planned Behavior/Reason Action Approch during the pre-test survey.
89421035|NCT04459520|Placebo Comparator|Negative Test Result|This arm will complete an online survey where they will be presented a vignette asking them to imagine they have symptoms consistent with COVID-19, a physician telling them they likely have COVID-19, and a negative COVID-19 test result. All arms will then be asked to fill out the same questions regarding behavior intentions and demographic questions. All participants will have completed five construct questions based off of Theory of Planned Behavior/Reason Action Approch during the pre-test survey.
88819993|NCT02780661|Experimental|Denture Cleanser Daily Use Period|Participants will be instructed to soak upper arch dentures in the evening in cup of very warm water (150 millilitre [ml]) with 1 denture cleansing tablet from Day 0 to Day 7 for 15 minutes (mins). Brush dentures for 30 seconds using the solution, rinse under running water for 10 seconds. Cleaning of upper arch dentures in the morning is not permitted. Lower arch dentures will be cleaned using the participant's normal oral hygiene procedures in the morning and evening. If the participants will have lower removable partial or complete dentures, the soaking of these dentures will be done in a separate cup from the cup provided for soaking the upper denture.
89421036|NCT02524028||Case Participant Cohort|Participants with atrial fibrillation
89421037|NCT02524028||Control Participant Cohort|Participants without atrial fibrillation or any other heart disease
89421038|NCT03476096||Control|healthy pregnant women
89421039|NCT03476096||Pre-eclampsia|high-risk pregnant women
89421040|NCT04459754|Experimental|Fuzheng Yiliu group|
89421041|NCT04459754|No Intervention|control group|
89421042|NCT03481868||Chronic Myeloid Leukemia|Patients newly diagnosed for Chronic Myeloid Leukemia, according to inclusion and exclusion criteria
88900835|NCT01513733|Experimental|tasquinimod 0.25 mg; 0.5 mg; 1.0 mg|tasquinimod 0.25 mg for 3 weeks followed by 0.5 mg for 3 weeks followed by 1.0 mg continuously, if tolerated
89194610|NCT00710034|Experimental|Snus|Oral tobacco (Camel Snus) was provided to the participants for an 12 weeks. Participants were encouraged to completely substitute snus for cigarettes and asked to use at least 6-8 pieces a day or optimally every 1-2 h and more if necessary. They were advised to reduce consumption by half during weeks 7-9 and three-quarters during weeks 10-12.
89194611|NCT02567942|Other|propofol group|The patient who anesthetized by using propofol.
89194612|NCT02567942|Other|sevoflurane group|The patient who anesthetized by using propofol.
88900836|NCT01513772|Placebo Comparator|Control|
88900837|NCT01513772|Active Comparator|Dexmedetomidine|
88900838|NCT01513785|Active Comparator|group R20A|All the patients were sent to a penicillin skin test before treatment except they were given penicillin before. The group R20A will receive 14 days of Amoxicillin 1g t.i.d and Rabeprazole 20 mg b.i.d. PPI was taken 30 minutes before meals while antibiotic was taken 30 minutes after meals.
88900839|NCT01513785|Active Comparator|group R10A|All the patients were sent to a penicillin skin test before treatment except they were given penicillin before. The group R10A will receive 14 days of Amoxicillin 1g t.i.d and Rabeprazole 10 mg b.i.d. PPI was taken 30 minutes before meals while antibiotic was taken 30 minutes after meals.
89421043|NCT02523638|Other|Pegylated- Proline-Interferon alpha-2b|Pegylated-Proline-Interferon alpha-2b in a Pre-filled Pen single arm
88900840|NCT01513798|Experimental|Exercise under observation|Modified paleolithic diet and exercise 3 sessions/week under observation
88900841|NCT01513798|Experimental|General advice on exercise|Modified paleolithic diet and general advice on exercise
88900842|NCT01513811|Active Comparator|group PEG|This group is set as a control group and received 2 packets of Polyethylene glycol electrolyte solutions on the morning of the examination day as us we usually done.
88900843|NCT01513811|Active Comparator|group PEG+Itp|Patients in group were assigned to itopride half hour before administration of lavage solution in the morning of examination day.
88900844|NCT01513811|Active Comparator|group PEG+4Itp|Patients in this group received itopride three times 24 hours before the examination day and another time 30 min before administration of lavage solution.
88900845|NCT01513824|Active Comparator|stress management, acupressure|bio feedback guided stress management by daily measurement of pressure pain sensitivity followed by acupressure´for 3 months
88900846|NCT01513824|No Intervention|bio feedback guided, stress management|control without treatment
89194613|NCT00414973|Experimental|A|
89421044|NCT03478124||PSP patients|Patients suffering from Progressive Supranuclear Palsy (PSP)
89421045|NCT03478124||PD Patients|Patients suffering from Parkinson's disease (PD)
89421046|NCT03478046|Experimental|Obese individuals|Apparently healthy, weight-stable, obese and physically inactive male volunteers will be recruited. Intervention is an 8 to 10% weight loss induced by chronic exercise training and dietary modification
89421047|NCT05257148|Active Comparator|Zofenopril arm|Single dose Phase (one month): patients will be treated with Zofenopril 30 mg. Combination Phase (two months) patients will be treated with the extemporaneous combination of Zofenopril 30 mg and Nebivolol 5mg
88900847|NCT01513850|Experimental|Hepabulin IV|
88900848|NCT01513863|Experimental|Metronidazole Topical Gel 1%|
88900849|NCT01513863|Active Comparator|Metronidazole Topical Gel 1% (Metrogel )|
88900850|NCT01513863|Placebo Comparator|Placebo|
88900851|NCT01513915|Active Comparator|A parent only group CBT|"There was a Group cognitive behavioral intervention -based on parent training component of FRIENDS program- for parents of children with anxiety disorders who were allocated to intervention group."
88900852|NCT01513915|No Intervention|Waiting list group|Parents of children with anxiety disorders who met the inclusion criteria and gave written informed consent and were allocated to wait list group.
88900853|NCT01513941|Experimental|Telaprevir plus Pegylated-Interferon-alfa-2a /ribavirin (RBV)|All patients who will receive 12 weeks of treatment with telaprevir 750 mg q8h except for patients on efavirenz will receive 1125 mg every 8 hours (q8h) in combination with Pegylated-Interferon-alfa-2a (Peg-IFN-alfa-2a) 180 μg/week and RBV 800 mg/day. At Week 12, telaprevir dosing will end and the patients will continue on Peg-IFN-alfa-2a and RBV.
88900854|NCT01513954||IVF population|Long Lupron IVF Population
89194614|NCT00414973|Active Comparator|B|
89194615|NCT00423085|Placebo Comparator|Placebo|Participants received daily matching placebo patch for the duration of the 24-week double-blind treatment phase of the study.
89421048|NCT05257148|Active Comparator|Nebivolol arm|Single dose Phase (one month): patients will be treated with Nebivolol 5 mg. Combination Phase (two months) patients will be treated with the extemporaneous combination of Zofenopril 30 mg and Nebivolol 5 mg
89421049|NCT03481790|Experimental|Lactoferrin|100mg of bovine lactoferrin (Pravotin sachets, Hygint, Egypt) twice a day.
89194616|NCT00423085|Experimental|rivastigmine 5 cm^2|During the 16-week titration period patients received daily rivastigmine 2.5 cm^2 patch for the first 4 weeks and thereafter daily rivastigmine 5 cm^2 patch. For patients who experienced intolerability, the dose was adjusted to rivastigmine 2.5 cm^2 daily. Patients then entered the 8-week maintenance period during which time they continued to receive the dose of rivastigmine they were taking at the end of the titration period.
89194617|NCT00423085|Experimental|Rivastigmine 10 cm^2|During the 16-week titration period patients received daily rivastigmine 2.5 cm^2 patch for the first 4 weeks, rivastigmine 5 cm^2 patch for the next 4 weeks, rivastigmine 7.5 cm^2 patch for the next 4 weeks and then rivastigmine 10 cm^2 patch for the final 4 weeks. For patients who experienced intolerability, the dose was adjusted downward. Patients then entered the 8-week maintenance period during which time they continued to receive the dose of rivastigmine they were taking at the end of the titration period.
89194618|NCT00414661||Study group|All enrolled subjects
89421050|NCT03481790|Experimental|ferrous sulphate + folic acid (vitamin B9)|150mg of dried ferrous sulphate + folic acid (vitamin B9) 0.50mg (Ferrofol, E.I.P.I.C.O, Egypt) three capsules per day.
89421051|NCT03475862|Experimental|PTI-821 Manipulated|oxycodone 40 mg capsule
89421052|NCT03475862|Active Comparator|Oxycodone|Oxycodone 40 mg IR tablet crushed
89421053|NCT03475862|Active Comparator|OxyContin|Oxycodone ER 40 mg tablet crushed
89421054|NCT03475862|Placebo Comparator|Placebo|Matching placebos for experimental and active comparator arms
89421055|NCT03475862|Experimental|PTI-821 Non-manipulated|Oxycodone 40 mg non-manipulated
89421056|NCT03477968||PE|"Patients presenting with PE suspicion. Diagnosis will be performed according to Standard of Care. Plasma samples will be collected if PTP score is Low or Moderate. If diagnosis is negative, patients will be followed for 3 months to evaluate potential VTE development.~Enrolment completed for this group : 13th February 2020"
89421057|NCT03477968||DVT|"Patients presenting with DVT suspicion. Diagnosis will be performed according to Standard of Care. Plasma samples will be collected if PTP score is Low or Moderate. If diagnosis is negative, patients will be followed for 3 months to evaluate potential VTE development.~Enrolment on going"
88900855|NCT01513954||IUI patients|Patients undergoing IUI
89421058|NCT03430934|Experimental|NAVI mapping with Indocyanine green|Participants will undergo their scheduled Mohs surgery with the addition of the NAVI mapping with ICG dye
88900856|NCT01513980|No Intervention|Control group|Treatment as usual
88900857|NCT01513980|Experimental|Self monitoring for patients with COPD|Procedure: self-monitoring for patients with severe COPD
88900858|NCT01513980|Experimental|Nurse monitoring for patients with COPD|Procedure: nurse-monitoring for patients with severe COPD
89421059|NCT03477812||Healthy children|Healthy children 7-14 years of age.
88900859|NCT01513993|No Intervention|Control group|Treatment as usual
88900860|NCT01513993|Experimental|Telemonitoring for patients with Congestive Heart Failure|
89421060|NCT03477812||Nocturnal enuresis with polyuria|Children with nocturnal enuresis and polyuria aged 7-14 years.
89421061|NCT03477812||Nocturnal enuresis without polyuria|Children without nocturnal enuresis and polyuria aged 7-14 years.
89421062|NCT03475784|Experimental|Restricted fluid therapy group|Restrictive fluid therapy: this group will not receive fluid pre-load, and will receive intraoperative crystalloids at rate of 10 mL/Kg/hour followed by postoperative crystalloids at rate of 2mL/Kg/hour.
89421063|NCT03475784|Active Comparator|Liberal fluid therapy group|Liberal fluid therapy: this group will receive fluid pre-load (5 mL/Kg), and will receive intraoperative crystalloids at rate of 10 mL/Kg/hour followed by postoperative crystalloids at rate of 6 mL/Kg/hour.
89421064|NCT03368066|Experimental|Hospitalized cirrhosis patients|Administration of cortisol stimulation test to assess for presence or absence of adrenal insufficiency
89421065|NCT02481986|Experimental|Community health worker|Participants in this arm will be offered 10 home visits in a 12-month period from community health workers (CHWs). Visits will cover a core asthma curriculum and provide social support.
89421066|NCT02481986|Active Comparator|Certified asthma educator|Participants in this arm will be offered 2 education sessions with a certified asthma educator in the clinic at start of the study and again at 6-months. These sessions will be followed by a telephone call from the certified asthma educator several weeks after the sessions.
89421067|NCT03475628|Experimental|Daratumumab|Daratumumab at a dose of 16 mg/kg administered as an IV infusion at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter.
89421068|NCT03477734|Experimental|CS1 & heart monitor - AF patients|Males and females diagnosed with atrial fibrillation will be fitted with the CardiacSense1 and Holter heart monitor for 24-48 hours while going about daily activities, results shall be compared and analysed
89421069|NCT03477734|Active Comparator|CS1 & heart monitor -Healthy volunteers|Males and females not diagnosed with atrial fibrillation will be fitted with the CardiacSense1 and Holter heart monitor for 24-48 hours while going about daily activities, results shall be compared and analysed
89421070|NCT05234294||Omicron cases|All confirmed COVID-19 cases during January 2022 in the Faroe Islands
89421071|NCT05234294||Controls|Participants in previous serological surveys during 2020 in the Faroe Islands.
89421072|NCT05231564|Experimental|Hybrid training|15 women for hybrid training.
89421073|NCT05231564|No Intervention|Healthy lifestyle counseling|15 women for healthy lifestyle counseling
89421074|NCT02738138|Experimental|ABT-493/ABT-530 for 8 weeks|HCV Genotype (GT)1-6/HIV-1 co-infected non-cirrhotic subjects treated with ABT-493/ABT-530 300 mg/120 mg once a day (QD) for 8 weeks
89421075|NCT02738138|Experimental|ABT-493/ABT-530 for 12 weeks|HCV GT1-6/HIV-1 co-infected subjects with compensated cirrhosis treated with ABT-493/ABT-530 300 mg/120 mg once a day (QD) for 12 weeks
88900861|NCT01514006||Study Cohort|Patients, aged 65 or above, undergoing elective primary unilateral hip arthroplasty in a fast-track setting.
88900862|NCT01514019|Experimental|Acebutolol|Acebutolol 200 mg capsule (Acetanol®)
88900863|NCT01514019|Placebo Comparator|Placebo|
88900864|NCT01514032|Active Comparator|Extracorporal shockwave lithotripsy|
88900865|NCT01514032|Active Comparator|Retrograde intrarenal surgery|
88900866|NCT01514058|Active Comparator|EUS-FNA First|Patients will undergo EUS-FNA first, followed by ERCP with biliary stenting (using a plastic stent).
88900867|NCT01514058|Active Comparator|ERCP with stent placement first|Patients will undergo ERCP with stent placement first, followed by EUS-FNA.
88900868|NCT01514071|Experimental|Pop-up picture|
89421076|NCT03018860|Experimental|"Moderate management"|Women are encouraged by physicians to push only 2 times per contractions, to respect contractions without pushing and there is no limit of pushing duration.
89421077|NCT03018860|Active Comparator|"Intensive management"|Usual obstetrical care in France
89421078|NCT05195450|Experimental|Tenofovir Alafenamide Fumarate|• TAF 25 mg OD vs no treatment x 5 years and beyond
89421079|NCT05195450|No Intervention|No Treatment Arm|No treatment
89421080|NCT03477656|Experimental|Large volume specific immunoadsorption|1 to 2 sessions of large volume specific immunoadsorption according to the initial isoagglutinin titer.
89421081|NCT03477656|Experimental|Double Filtration Plasmapheresis|1 to 5 sessions of double filtration plasmapheresis according to the initial isoagglutinin titer.
89421082|NCT03477578||FoG+|Parkinsonian patients with Freezing of Gait
89421083|NCT03477578||FoG-|Parkinsonian patients withou Freezing of Gait
88900869|NCT01514084||PEM group|Patients whose lacerations have been repaired by PEM trained physicians.
88900870|NCT01514084||GP group|Patients whose lacerations have been repaired by general pediatricians.
88900871|NCT01514084||PNP group|Patients whose lacerations have been repaired by PNPs.
88900872|NCT01514084||RN group|Patients whose lacerations have been repaired by suture RNs.
88900873|NCT01514097||Fractures reduced|
88900874|NCT01514097||Fractures splinted|
88900875|NCT01514110|Experimental|RAD001|
88900876|NCT01514123|Experimental|Arm A - VGX-100 alone|Dose escalation of VGX-100 monotherapy
88900877|NCT01514123|Experimental|Arm B - VGX-100 plus bevacizumab|Dose escalation of VGX-100 in combination with escalating doses of bevacizumab
88900878|NCT01514175|Experimental|ibuprofen versus ketoralac|IV ibuprofen (800 mg intravenous ibuprofen administered intravenously over 10 minutes) will be administered as a single dose prior to surgery at the initiation of anesthesia. A corresponding volume of NS will be administered to the group randomized to ketorolac, at the same time to maintain the study blind.
88900879|NCT01514188|Active Comparator|Doxorubicin|
88900880|NCT01514188|Experimental|INNO-206|
88900881|NCT01514214|Active Comparator|Winged perimeter stent|Patients who receive the Viaduct stent during ERCP
88900882|NCT01514214|Active Comparator|polyethylene stent arm|Patient who receive the traditional polyethylene stent during ERCP
88900883|NCT01514227|Experimental|Short-term DAPT (6 months) group|6 months DAPT (aspirin and thienopyridine) prescription following Nobori stent
88900884|NCT01514227|Experimental|Long-term DAPT (18 months) group|18 months DAPT (aspirin and thienopyridine) prescription following Nobori stent
88900885|NCT01514253|Experimental|glucose 25%|1 ml of glucose once
88900886|NCT01514253|Experimental|infant formula|Materna RTF stage 1
88900887|NCT01514253|Placebo Comparator|Water for Injection|1 ml Water for Injection (WFI), 2-3 minutes prior red-reflex examination
88900888|NCT01514266|Experimental|Curcumin+bioprine|The study involves active arm of Curcumin+Bioprine
88900889|NCT01514266|Placebo Comparator|Placebo|
89194619|NCT01608451|No Intervention|No additional treatment|No Injection Vit D3 or Injection Progesterone prior to chemotherapy cycle
89530802|NCT02510807|No Intervention|Control group|Patients will be instructed to walk a minimum of three times per week up to one half hour total walking time. If they started to get pain in their legs, they will be instructed to stop and rest, and then to start again when the pain has subsided.
88900890|NCT01514305||Type 1 Diabetes Mellitus (TIDM)Type 2 Diabetes Mellitus (T2DM)|Adults that have been diagnosed with insulin-requiring diabetes and are on multiple daily injections (MDI) or Continuous Subcutaneous Insulin Infusion (CSII) insulin therapy;
89421084|NCT03477422|Experimental|CSE-1034 (Ceftriaxone + Sulbactam + EDTA)|"CSE-1034 (Ceftriaxone + Sulbactam + EDTA) was an Experimental drug in this study and is a combination of Ceftriaxone 1000mg, Sulbactam 500mg and EDTA 37mg available as dry powder for reconstitution. It was administered twelve hourly through intravenous route as infusion over 30 minutes. The duration of the active treatment was for 5-14 days depending upon the severity of the disease, which was determined by the Principal Investigator (PI).~Interventions:~Drug: CSE-1034 (Ceftriaxone + Sulbactam + EDTA)~Drug: Matching Placebo"
89421085|NCT03477422|Active Comparator|Meropenem|"Meropenem was the active comparator in the study. It was also available as dry powder for reconstitution and contained active ingredient Meropenem 1000mg. It was administered eight hourly through intravenous route as infusion over 30 minutes.The duration of the active treatment was for 5-14 days depending upon the severity of the disease, which was determined by the PI.~Interventions:~Drug: Meropenem~Drug: Matching Placebo"
88900891|NCT01514331|Active Comparator|PSV+VG|Neonates who require mechanical ventilation and randomised to pressure support + volume guarantee (PSV+VG) mode
88900892|NCT01514331|Active Comparator|SIMV+VG|Neonates who require mechanical ventilation and randomised to synchronised intermittant mandatory ventilation + volume guarantee (SIMV+VG) mode
88900893|NCT01514409|Experimental|5-Hydroxytryptophan|
88900894|NCT01514409|Placebo Comparator|Placebo|
88900895|NCT01514435|Experimental|ECT verum group|Patients with treatment refractory depression treated with ECT
88900896|NCT01514487|Experimental|pH 7.7|
88900897|NCT01514487|Experimental|pH 7.9|
88900898|NCT01514487|Experimental|pH 8.15|
89421086|NCT03920384|Experimental|Experimental therapy arm|16 (minimum 4, maximum 20) sessions of therapy for psychosis including new therapeutic ingredients
88900899|NCT01514500|Experimental|Single dose (SD)|Single dose administered s.c. (subcutaneously, under the skin). Escalation to the next dose level will be based on safety evaluation
88900900|NCT01514500|Experimental|Multiple dose (MD)|Multiple doses administered s.c. (subcutaneously, under the skin). All subjects will be dosed four times with a dosing frequency of once weekly. Escalation to the next dose level will be based on safety evaluation
88900901|NCT01514526|Experimental|Dovitinib|Dovitinib (TKI-258) f 500 mg / day (5 x 100mg) once daily. The patient will continue on treatment until disease progression,unacceptable toxicity, death or premature withdrawal.
88900902|NCT01514539|Other|Four weeks Postpartum Lactating|women between 18 and 45 who delivered their first child 4 weeks prior and who were currently lactating and planning to lactate for one year postpartum.
88900903|NCT01514539|Other|Control Never Pregnant|women between 18 and 45 who have never been pregnant
88900904|NCT01514578|Experimental|TRV130A|
88900905|NCT01514578|Placebo Comparator|Dextrose in Water|
88900906|NCT01514591||Non-elective Cesarean Delivery|We will only enroll patients undergoing non-elective CS with an 'epidural top-up' for surgical anesthesia. By definition, our study will only apply to laboring women with working labor epidurals (which were provided for labor analgesia).
88900907|NCT01514604||Little or no experience.|All participants will be asked to declare their degree of experience in the technique being studied. Those declaring themselves as 'New to in-plane ultrasound guided needling. Little or no experience in technique' belong to this cohort and will form the study group.
89421087|NCT03920384|Active Comparator|Standard Psychological Therapy for Psychosis|16 (minimum 4 maximum 20) sessions of standard psychological therapy for psychosis.
89421088|NCT01355289|Placebo Comparator|Placebo (Core Study)|Placebo, will be administered orally, once daily for up to 21 days.
89421089|NCT01355289|Active Comparator|Avatrombopag 10 mg (Core Study)|Avatrombopag 10 mg, will be administered orally, once daily, preferably with food for up to 21 days.
89006774|NCT00221507|Active Comparator|Patient Navigation|"To determine how well Patient Navigation will increase immunization rates and well child care delivery in those children most at risk for falling through the cracks. These studies will be conducted in the Denver Health community health network, the largest integrated community health care system in the United States."
89421090|NCT01355289|Active Comparator|Avatrombopag 20 mg (Core Study)|Avatrombopag 20 mg, will be administered orally, once daily, preferably with food for up to 21 days.
89421091|NCT01355289|Active Comparator|Avatrombopag 30 mg (Core Study)|Avatrombopag 30 mg, will be administered orally, once daily, preferably with food for up to 21 days.
89421092|NCT01355289|Experimental|Avatrombopag (Open-Label Extension)|Avatrombopag will be initiated at a dose of 20 mg, once daily in the open-label extension (OLE) period. The avatrombopag dose will be titrated up or down in accordance with the participant's individual response, within the range of a minimum of 5 mg and a maximum of 50 mg for up to 48 weeks.
89421093|NCT04680741|Experimental|Addiction Pilot App|"Patients in this arm will be asked to use an application that works by allowing patients to check in to meetings and tracks patients' location for a period of 90 days.~Patients will be asked to download the application to their smart phone. At each of patients' usual meetings we will ask patients to check in and check out of the meeting via the App. At the conclusion of this study patients may be invited to participate in a focus group."
89421094|NCT03473288|Active Comparator|Moderate Intensity Treadmill Exercise|Moderate intensity treadmill exercise three times per week for 10-12 weeks
88900908|NCT01514604||Regular practitioner. Teaching|Participants declaring themselves as 'Regularly incorporate in-plane ultrasound guided needling in clinical practice. Teaching technique to others' fall within this cohort and form the 'control' group allowing application of a realistic acceptable failure rate to Cusum analysis of the study group.
88900909|NCT01514604||Some exposure. Infrequent clinical use.|Participants declaring themselves as belonging to this group will not form part of the analysis. They will be welcome to complete training and receive feedback on their performance according to the study protocol.
88900910|NCT01514695|Experimental|Fentanyl|Fentanyl arm
88900911|NCT01514695|Placebo Comparator|Placebo|Placebo of identical appearance
88900912|NCT01514708|Experimental|AdimFlu-S Influenza Vaccine, 0.5mL/dose, receive 1 dose|
88900913|NCT01514721|Experimental|DuoTrav|Travoprost/Timolol Maleate BAK-Free Fixed Combination, 1 drop self-administered in treated eye(s) once a day for 12 weeks
88900914|NCT01514747||ELBW infants|
88900915|NCT01514773||ICD placement|Those subjects who have an ICD.
88900916|NCT01514773||No ICD placement|Those subjects who have not had an ICD placed.
88900917|NCT01514799|Active Comparator|standard length bp limb, long alimentary limb|our normal way of doing a gastric bypass 60 cm BP limb
88900918|NCT01514799|Experimental|Long BP limb|200 cm BP limb
88900919|NCT01514812|Experimental|YM150-placebo sequence group|YM150+digoxin; Washout; Placebo+digoxin
88900920|NCT01514812|Experimental|placebo-YM150 sequence group|Placebo+digoxin; Washout; YM150+digoxin
88900921|NCT01514825|Experimental|YM150 low dose group|
88900922|NCT01514825|Experimental|YM150 middle dose group|
88900923|NCT01514825|Experimental|YM150 high dose group|
88900924|NCT01514825|Placebo Comparator|placebo group|
88900925|NCT01514838|Experimental|1941 group|Once daily over a 24-week treatment period
88900926|NCT01514838|Active Comparator|acarbose group|Once daily over a 24-week treatment period
88900927|NCT01514851|Experimental|Arm 1|750-2250mg/day, tid (three times a day), 8 weeks
88900928|NCT01514851|Active Comparator|Arm 2|1500-4500mg/day, tid, 8 weeks
88900929|NCT01514877|Experimental|Icotinib plus Whole Brain Radiotherapy|Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, have shown efficacy in advanced non-small cell lung cancer (NSCLC) patients with brain metastases (BM). Icotinib is a new first generation EGFR-TKI. We conducted a phase II study to evaluate the efficacy and safety of icotinib in combination with whole brain radiotherapy （WBRT） in Chinese NSCLC patients with BM and investigated the cerebrospinal fluid (CSF)/ plasma concentrations of icotinib.
88900930|NCT01514890||Telaprevir|
89421095|NCT03473288|Placebo Comparator|Sedentary Controls|Serve as a sedentary (little exercise) control for 10-12 weeks
88900931|NCT01514890||Boceprevir|
89421096|NCT03473210|Active Comparator|Amniopatch group|in which women were subjected to active treatment included prophylactic antibiotics and antenatal corticosteroids with an effort to seal the ruptured membranes using the amniopatch technique.
88900932|NCT01514929|Experimental|Supratherapeutic Dose|20mg/kg ACHN-490 Injection
88900933|NCT01514929|Experimental|Possible Therapeutic Dose|15mg/kg ACHN-490 Injection
88900934|NCT01514929|Active Comparator|Moxifloxacin|400mg moxifloxacin
88900935|NCT01514929|Placebo Comparator|Placebo|Placebo
88900936|NCT01514942|Other|Insulin resistant patients|
88900937|NCT01514942|Other|Non-insulin resistant patients|
88900938|NCT01514968|Experimental|DNV/r+cyclosporine|
88900939|NCT01514968|Active Comparator|cyclosporine|
88900940|NCT01514968|Active Comparator|danoprevir+ritonavir|
88900941|NCT01514981|Experimental|AMG 761|
88900942|NCT01514981|Placebo Comparator|Placebo|
88900943|NCT01514994|Experimental|AngioScore's Valvuloplasty Scoring Balloon|
88900944|NCT01515020|Active Comparator|vancomycin monotherapy|vancomycin monotherapy: standard therapy
88900945|NCT01515020|Experimental|daptomycin monotherapy|daptomycin monotherapy: experimental therapy
88900946|NCT01515033|Experimental|Continuous exercise training|The continuous exercise training was performed on a treadmill with a 50-minutes duration and intensity at ventilatory anaerobic threshold.
88900947|NCT01515033|Experimental|interval exercise training|The interval exercise training consisted of 7 sets of 3 minutes at respiratory compensation point and 7 sets of 3 minutes of exercise at moderate intensity corresponding to the ventilatory anaerobic threshold totaling 42 minutes
89421097|NCT03473210|Active Comparator|control group|in which women were subjected to conservative management with prophylactic antibiotics and antenatal corticosteroids
88900948|NCT01515059||Bariatric sugery patients|Obese patients who are awaiting either a gastric bypass or sleeve gastrectomy
88900949|NCT01515085||biopsy proven glioma, no prior treatment|
88900950|NCT01515111||Internal Medicine Staff|All interns, residents and attendings training (or working) at an Internal Medicine department of a Guatemalan teaching hospital.
89194620|NCT01608451|Active Comparator|Inj. Proluton|Injection Progesterone 500 mg deep IM before each cycle of NACT (for total 4 cycles) and one injection before surgery.
89194621|NCT01608451|Active Comparator|Inj. Arachitol|Injection Arachitol (Vitamin D3) 300,000 I.U/ml IM before each cycle of NACT (for total 4 cycles) and one injection before surgery.
89194622|NCT01608451|Active Comparator|Inj. Proluton and Inj. Arachitol|Injection Arachitol (Vitamin D3) 300,000 I.U/ml IM and Injection Progesterone 500 mg deep IM before each cycle of NACT (for total 4 cycles) and one injection before surgery.
89194623|NCT00708708||A|Patients with moderate to severe plaque psoriasis
89194624|NCT00404755|Experimental|escitalopram|escitalopram 10 mg/d for 1 week, then increasing by 10 mg/week if tolerated and not remitted to maximal dose of 40 mg/d
89194625|NCT00404755|Experimental|bupropion|bupropion extended release (XL) 150 mg/d for a week, then 300 mg/d for a week and then 450 mg/d; all dose increases if tolerated and not remitted
89194626|NCT00404755|Experimental|imipramine|imipramine 50 mg/d increasing twice weekly by 50 mg/increase to 200 mg/d, then by 50 mg/week to a maximum dose of 300 mg/d; all dose increases if tolerated and not remitted
89194627|NCT03742453|Experimental|Hepatic nodule group|This group meets eligibility criteria, and undergo contrast-enhanced ultrasound (CEUS) and scheduled gadoxetic acid MRI (gadoxetic acid-enhanced liver MRI; EOB-MRI; Gd-EOB-MRI)
89194628|NCT03904381|Active Comparator|stand-alone procedure of XEN implantation in phakic eyes|
89194629|NCT03904381|Active Comparator|stand-alone procedure of XEN implantation in pseudophakic eyes|
89194630|NCT03904381|Active Comparator|XEN implantation combined with cataract extraction|
89194631|NCT02568150|Other|Intervention|Onset time of improvement effect of glabellar lines at maximum frown of botulinum toxin treatment
89194632|NCT00737256|Experimental|1|
89194633|NCT00737256|Active Comparator|2|
89194634|NCT00614614|Experimental|Menhibrix 1 Group|Subjects received 3 doses of Menhibrix vaccine and 3 doses of Pediarix vaccine at 2, 4 and 6 months of age during the Primary Vaccination Phase. For the Booster Vaccination Phase, subjects were re-randomized and received either 1 dose of Nimenrix vaccine (at 12-15 months of age) and 1 dose of Infanrix vaccine (at 15-18 months of age) [Nimenrix 1 Group] or a fourth dose of Menhibrix vaccine (at 12-15 months of age) and 1 dose of Infanrix vaccine (at 15-18 months of age) [Menhibrix 2 Group], or 1 dose of Nimenrix vaccine co-administered with 1 dose of Infanrix vaccine (at 15-18 months of age) [Nimenrix 2 Group].
89194635|NCT00614614|Active Comparator|ActHIB- Infanrix Group|Subjects received 3 doses of ActHIB vaccine and 3 doses of Pediarix vaccine at 2, 4 and 6 months of age and 1 booster dose of Infanrix vaccine at 15-18 months of age.
88900951|NCT01515150||Out-patients in diverticulitis|All patient with acute uncomplicated diverticulitis how accept participation in the study will be enrolled in the study.
89194636|NCT00713310|Experimental|Low-Dose|1.2 - 2.4 g/day Asacol dependent on body weight
89194637|NCT00713310|Experimental|High-Dose|2.0 - 4.8 g/day Asacol dependent on body weight
89194638|NCT00737334|Active Comparator|1|All patients will have continuous EEGo, BIS and FORE-SIGHT monitoring, which will be correlated with arterial to jugular venous lactate differences.
89194639|NCT05740488|Experimental|apalutamide combined with 89Sr and ADT|Neoadjuvant therapy with apalutamide in combination with 89Sr and ADT
89194640|NCT00874354|Experimental|Autologous bone marrow stem cells|Patients within 3 to 14 days from percutaneous coronary intervention (PCI) and stent implantation for Acute Myocardial Infarction (AMI) will receive either 50 cc's or 100 cc's of autologous bone marrow mononuclear cells through an intracoronary tranplantation of stem cells into the infarct-related coronary artery.
89421098|NCT05177432|Experimental|QPOP-based drug screen assay using patient tumour-derived organoids|"Patients with Histological confirmed breast carcinoma of any subtype (any estrogen receptor, progesterone receptor and HER2 receptor status) with at least 1 tumour lesion (primary or metastatic) amendable to fresh biopsy and measurable based on RECIST 1.1 criteria will undergo biopsy to obtain a sample of cancer tissue that will be used to generate Patient Derived Organoids (PDOs).~Patients' cells will be subjected to testing with 10-12 anti-cancer drugs and a table for treatment sensitivity to each drug will be derived after 8 to 12 weeks of treatment in the laboratory. Results will be reviewed at an expert panel discussion to decide on the most suitable anti-cancer drug treatment"
88900952|NCT01515163|Experimental|Exercise|3-month exercise training program
88900953|NCT01515163|No Intervention|Control|Control group
88900954|NCT01515163|Experimental|Healthy control|
88900955|NCT01515202|Experimental|Panel 1: BMS-823778 or Placebo matching BMS-823778|Healthy Subjects
88900956|NCT01515202|Experimental|Panel 2: BMS-823778 or Placebo matching BMS-823778|Healthy Subjects
88900957|NCT01515202|Experimental|Panel 3: BMS-823778 or Placebo matching BMS-823778|Healthy Subjects
89194641|NCT05742126|Experimental|HSK36273|Multiple continuous IV infusion ascending doses in cohort 1-5
89194642|NCT05742126|Placebo Comparator|Placebo|5 cohorts with matching placebo to HSK36273
89194643|NCT05742126|Active Comparator|Heparin sodium injection|Cohort 1-2 with matching positive control to HSK36273
89194644|NCT00737412|Active Comparator|1|The probiotic Bio-K+ CL1285 RX®
89194645|NCT00737412|Placebo Comparator|2|Placebo
89194646|NCT00882856|Active Comparator|Bisoprolol-washout -placebo|Bisoprolol - wash out - placebo
89194647|NCT00882856|Active Comparator|Placebo - wash out - bisoprolol|Placebo - wash out - bisoprolol
89194648|NCT02568462|Experimental|Coronary Scaffold Implantation|AmM APTITUDE Bioresorbable Drug-Eluting Coronary Scaffold
89194649|NCT00882934|Experimental|A1|Arm 1 received an informative letter explaining that they were allocated to receive a substance for Erectile Dysfunction treatment.
89194650|NCT00882934|Placebo Comparator|A2|Arm 2 (A2) was written informed that they could or could not receive an active drug for ED treatment.
89194651|NCT00882934|Experimental|A3|Arm 3 (A3) was properly written informed to be using no effective drug for ED treatment.
89194652|NCT00874588|Experimental|Phase I study|
89421099|NCT05161520|Active Comparator|IOL plus CTR Patients will undergo phacoemulsification combined with IOL and CTR implantation.|
89421100|NCT05161520|Placebo Comparator|single IOL Patients will undergo phacoemulsification combined with IOL implantation.|
88900958|NCT01515202|Experimental|Panel 4: BMS-823778 or Placebo matching BMS-823778|Subjects with T2DM
88900959|NCT01515202|Experimental|Panel 5: BMS-823778 or Placebo matching BMS-823778|Subjects with T2DM
88900960|NCT01515215|Active Comparator|High-frequency Left rTMS|"Intensity: rTMS treatment intensity determined by using resting motor threshold (RMT). Treatment will be delivered at 120% of the RMT.~Site of Stimulation: left hemisphere of DLPFC.~Frequency: 10 Hz.~Duration: 42 Trains, 5 second duration, 25 second inter-train interval."
88900961|NCT01515215|Active Comparator|Bilateral rTMS|"Intensity: rTMS treatment intensity determined by the RMT. Treatment will be delivered at 120% of the RMT.~Sites of Stimulation: right and left hemispheres of the DLPFC.~Frequency: 1 Hz over the right DLPFC followed by 10 Hz over the left DLPFC.~Duration: right: 1 Train of 600 pulses; left: 30 Trains, 5 second duration, 25 second inter-train interval."
88900962|NCT01515215|Sham Comparator|Sham rTMS|Sham rTMS Treatment is applied as either Bilateral rTMS or HFL-rTMS (randomly assigned), but with the coil angled 90 degrees away from the skull in a single-wing tilt position. This method produces sound and some somatic sensation (e.g., contraction of scalp muscles) similar to those of active stimulation, but with minimal direct brain effects.
88900963|NCT01515228|Active Comparator|Xience Prime stent|everolimus eluting stent
88900964|NCT01515228|Experimental|Cilotax stent|paclitaxel with cilostazol dual drug eluting stent
88900965|NCT01515254|No Intervention|No intervention- control group|Visits to physicians, WIC offices, nutrition program etc will be tracked. The subjects will undergo the energy regulation tests at baseline and 3 months. They will complete surveys and have their weight taken. The control group subjects will have the opportunity to receive the intervention at the end of the study
88900966|NCT01515254|Experimental|lifestyle counseling, parental feeding|Intervention group subjects will undergo a Feeding Dynamic Intervention (FDI). The intervention will be delivered in a closed group setting and will consist of 6 intervention sessions lasting 90 minutes each. Visits to physicians, WIC offices, nutrition program etc will be tracked. The subjects will undergo the energy regulation tests at baseline and 3 months. They will complete surveys and have their weight taken.
88900967|NCT01515280||Chronic cough|Patients taking part in supplementary study must be randomised to main study which includes a placebo arm and treatment arm
88900968|NCT01515293|Experimental|Single Incision Laparoscopic Appendectomy|
89421101|NCT03473132|Experimental|Treatment|Based on starting international normalized ratio (INR) and target INR, the dose of four factor prothrombin complex concentrate will be calculated and infused. Coagulation factor levels will be assessed over 48-72 hours.
89421102|NCT02899754|Experimental|Intervention Group|Participants in this arm will use the lung cancer screening decision aid (LCSDecTool)
88900969|NCT01515293|Experimental|Conventional appendectomy|Conventional appendectomy
88900970|NCT01515358|Placebo Comparator|Placebo|Single dose of placebo administered orally in 1 out of 3 study periods separated by at least a 7-day wash-out period between each dose.
89421103|NCT02899754|Active Comparator|Control Group|Content that provides general information on disease prevention and health promotion unrelated to lung cancer. The information will be delivered on the same modality and take a similar amount of time to administer.
88900971|NCT01515358|Experimental|LY3000328|Single escalating dose of up to 300 mg/kg of LY3000328 administered orally in 2 out of 3 study periods separated by at least a 7 day wash-out period between each dose.
88900972|NCT01515371|Experimental|IncobotulinumtoxinA (Xeomin) 2.5 Units [U], 5U and 7.4U|"IncobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection."
89421104|NCT03475238||Cohort for nursing care|Patients in ICU under oxygen and/or mechanical ventilation and/or vasoactive drugs and/or non-invasive ventilation
88900973|NCT01515371|Placebo Comparator|Placebo Comparator|Placebo to incobotulinumtoxinA (Xeomin) powder for solution for injection.
88900974|NCT01515384|Experimental|Type 1 Diabetes|
88900975|NCT01515384|Experimental|Type 2 Diabetes|
88900976|NCT01515384|Experimental|Healthy Controls|
88900977|NCT01515397|Experimental|balanced gelatine solution|isotonic colloidal volume substitute
88900978|NCT01515397|Active Comparator|non-balanced gelatine solution|colloidal volume substitute
89421105|NCT02737592|Experimental|Healthy subject|"Healthy subject exposed to Trojan Simply Pleasures Personal Lubricant at least four times weekly for two weeks"
89530803|NCT02454049|Active Comparator|beetroot juice|beetroot juice containing 6mmol nitrate, ingested 3hours before the exercise test
89530804|NCT02454049|Active Comparator|sodium nitrate|6mmol sodium nitrate dissolved in plain water, ingested 3hours before the exercise test
88900979|NCT01515436|Active Comparator|Mozart alternating with Beethoven|Study participants will listen to Mozart's Sonata for Two Pianos in D Major, K. 448 alternating with Beethoven's Fur Elise.
89530805|NCT02454049|Placebo Comparator|water|85ml of plain water, ingested 3 hours before the exercise test
89421106|NCT02720432|Experimental|CIMT|"A soft splint or restraint will be posed to best functioning hand of the infant only during the therapy session. Parents will be educated to perform the therapy, which consists of stimulation of reaching and grasping with the hemiplegic arm.~The whole intervention period lasts 18 weeks, separated into 3 blocks of 4 weeks intervention and 2 blocks of 3 weeks of rest. During the intervention weeks parents will perform CIMTfor 30 minutes, 6 days a week."
89421107|NCT02720432|Experimental|HABIT|"No restraint will be implemented and instead of promoting unilateral grasping, bimanual grasping will be stimulated. Toys will be precisely selected to stimulate progressed bimanual grasping. The approach of the therapist and parents remain equal.~The whole intervention period lasts 18 weeks, separated into 3 blocks of 4 weeks intervention and 2 blocks of 3 weeks of rest. During the intervention weeks parents will perform HABIT for 30 minutes, 6 days a week."
89421108|NCT02720432|Sham Comparator|Baby-massage|3 sessions of baby-massage will be given by a qualified instructor
89421109|NCT03475160|Active Comparator|Sildenafil Citrate|Sildenafil Citrate vaginal suppositories: 25 mg every 6 hours. Uterine artery Doppler before treatment. Uterine artery Doppler after treatment.
89421110|NCT03475160|Placebo Comparator|Placebo|Placebo vaginal suppositories: every 6 hours. Uterine artery Doppler before treatment. Uterine artery Doppler after treatment.
89421111|NCT03475082|Placebo Comparator|Placebo TENS|30 minute TENS treatment where the stimulation ramps slowly to zero after 45 seconds. The lights/display on the unit are identical to the Active unit.
89421112|NCT03475082|Active Comparator|High Frequency TENS|30 minute TENS treatment at 100 Hertz (HZ). Intensity set at a strong but comfortable setting and subject asked to increase intensity as tolerated every 5 minutes. Final stimulation intensity at end of Day 1 treatment used for the remainder of the treatment sessions for all 5 days.
88900980|NCT01515436|Active Comparator|Beethoven alternating with Mozart|Study participants will listen to Beethoven's Fur Elise alternating with Mozart's Sonata for Two Pianos in D Major, K. 448.
88900981|NCT01515501|Other|Endoscopic mucosal resection|At time of rectal section biopsy all subjects will under go the additional intervention of an endoscopic muscosal resection.
88900982|NCT01515553|Experimental|Formulation 4|
89421113|NCT03475082|Active Comparator|Alternating frequency TENS|30 minute TENS treatment with a pre programed mode alternating from 4 Hz and 100 HZ. Intensity set at a strong but comfortable setting and subject asked to increase intensity as tolerated every 5 minutes. Final stimulation intensity at end of Day 1 treatment used for the remainder of the treatment sessions for all 5 days.
89530806|NCT03241303|Experimental|Acarbose|50 mg and 100 mg glucobay tablets. 2 weeks. Other name: Precose
88900983|NCT01515553|Experimental|Final formulation 4|
88900984|NCT01515579|Experimental|Formulation 3|
88900985|NCT01515579|Experimental|Formulation 4|
88900986|NCT01515592|Experimental|15 mcg/kg|
88900987|NCT01515592|Experimental|20 mcg/kg|
88900988|NCT01515592|Experimental|25 mcg/kg|
88900989|NCT01515631||Study|Patients with alagille syndrome
88900990|NCT01515644|Experimental|Intervention group I|Intervention group I: Powder based Infant formula with Inulin I
88900991|NCT01515644|Experimental|Intervention group II|Intervention group II: Powder based Infant formula with Inulin II
88900992|NCT01515644|Placebo Comparator|Intervention group III|Intervention group III: Powder based Infant formula without Inulin
89530807|NCT03241303|Placebo Comparator|Placebo Oral tablets|180 mg. 2 weeks.
89421114|NCT03475082|Active Comparator|Modulated frequency TENS|30 minute TENS treatment at a pre programmed mode that ramps between 4 and 125 HZ over 12 seconds. Intensity set at a strong but comfortable setting and subject asked to increase intensity as tolerated every 5 minutes. Final stimulation intensity at end of Day 1 treatment used for the remainder of the treatment sessions for all 5 days.
89421115|NCT03475082|Active Comparator|High frequency TENS - increasing intensity|30 minute TENS treatment at 100 HZ. Intensity set at initial strong but comfortable setting on day one as above, then subjects asked for possible increases in intensity every 5 minutes on all five days.
89421116|NCT02694068||Discovery for Aim One|2173 subjects will be involved in the discovery cohort.
89421117|NCT02694068||Replication for Aim One|1673 subjects will comprise the replication cohort.
89421118|NCT02694068||Discovery for Aim Two|824 subjects will be involved in the discovery cohort.
89421119|NCT02694068||Replication for Aim Two|538 subjects will comprise the replication cohort.
89421120|NCT04458896|Experimental|Stand When You Can|The intervention is grounded in Social Cognitive Theory and the Social Ecological Model (SEM). Multiple levels of the SEM will be targeted (individual, environmental, and organizational) over 6 weeks.
89421121|NCT03473054||Web-based Mindfulness Course|Participants will complete a 2 week baseline phase, followed by the four week web-based mindfulness course intervention phase, and a four week follow-up period.
89421122|NCT02541188||breast cancer in young women is in the Maghreb|breast cancer in young women (< 40years old) is in the Maghreb
89421123|NCT02541188||Breast cancer in young women in the western countries|Breast cancer in young women (< 40years old) in the western countries
89421124|NCT03474926|Experimental|Routine lymph node dissection (LND) during nephroureterectomy|"Template-based LND was carried out in all patients in this group. The anatomical extent of LND is described in previous study. Lymph node specimens were sampled en bloc with surrounding adipose tissue, and were sent to pathological examination as individual packets with the surrounding adipose tissue."
89421125|NCT03474926|Active Comparator|LND for lymph nodes enlargement found before or during surgery|LND was carried out only in patients who have lymph nodes enlargement in preoperative imaging (CTU or enhanced MRI) or who were found lymph nodes enlargement during surgery.
89421126|NCT03474848|Experimental|HABIT|Protocol of 90-hour of Hand-Arm Bimanual Intensive Training - 6 hours/day; 5 days/week, for 3 weeks
89421127|NCT03474848|Active Comparator|Conventional Occupational Therapy (OT)|Provision of 2 sessions/week (45 minutes), for 3 weeks
89421128|NCT00308516|Experimental|Cohort A - Preoperative|"Each patient enrolled in the preoperative cohort received 5-fluorouracil (5-FU) 225 mg/m2 as a continuous infusion (IVCI) on days 1-42 through a portable infusion pump and central venous catheter. Bevacizumab 5 mg/kg was administered intravenously (IV) on days 1 and 15. Additionally these patients received radiation therapy to 50.4 Gy (1.8 Gy/day or 28 fractions) Monday through Friday during weeks 1-6.~At least 8 weeks after surgery, patients in cohort A began 4 months of chemotherapy and bevacizumab. This adjuvant treatment consisted of 5-FU 400 mg/m2 IV bolus over 2-4 minutes followed by 2400 mg/m2 IVCI over 46 hours, leucovorin 350 mg as a 2-hour infusion, oxaliplatin 85 mg/m2 IV (modified FOLFOX6) and bevacizumab 5 mg/kg IV all on days 1 and 15 of each cycle."
89421129|NCT00308516|Experimental|Cohort B - Combined Modality|"All patients enrolled in cohort B received 5-fluorouracil (5-FU) 225 mg/m2 IVCI on days 1-42. Bevacizumab was administered at 5 mg/kg IV on day 1 every 2 weeks. These patients also received radiation to 50.4 Gy (1.8 Gy/day or 28 fractions)Monday through Friday during weeks 1-6.~Six weeks after the completion of adjuvant 5-FU/radiation, patients began treatment with 5-FU 400 mg/m2 IV bolus over 2-4 minutes followed by 2400 mg/m2 IVCI over 46 hours, leucovorin 350 mg as a 2-hour infusion, oxaliplatin 85 mg/m2 IV (modified FOLFOX6) and bevacizumab 5 mg/kg IV all on days 1 and 15 of each cycle."
89421130|NCT03471572||1|Ovarian Cancer
89421131|NCT03471494||Breast cancer|
89421132|NCT03471494||Gastric cancer|
89421133|NCT03471494||Colon cancer|
89421134|NCT02523404|Experimental|HepaSphere|lung cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
89421135|NCT02523404|Placebo Comparator|control|lung cancer patients received traditional therapy
89421136|NCT04331366|Experimental|Treatment with GO2 PEEP MOUTHPIECE|Participants receiving treatment with the GO2 PEEP MOUTHPIECE
89421137|NCT05155592|Experimental|Patients with inactive uveitis|Patients with non-infectious uveitis whose inflammation reached remission for at least six months after treatment with Adalimumab
89421138|NCT03471416||Children with ALL|Children undergoing ALL treatment at UNOP Guatemala who are under the age of 18 years.
89421139|NCT03474614|Experimental|treatment group|A Treatment group of ten (n=10) patients that will receive oral propranolol at a dose of 60mg per day (one 60mg ER capsule per day) for 7- to 10-days prior to surgery plus their usual medications.
89421140|NCT03474614|Other|Control Group|A control group of 10 (n=10) patients will receive only their routine medications (no propranolol) during the (-7 to -10 days) preoperative period. A control group (n=10) is required to allow for a semi-quantitative comparison with mRNA and miRNA levels in the treatment group.
89421141|NCT05155514||Group H|"Hypertension group (Group H):~Patients with a previous diagnosis of hypertension~Patients receiving antihypertensive therapy~Systolic blood pressure (SBP) ≥140mmHg and/or diastolic blood pressure (DBP) ≥90mmHg"
89421142|NCT05155514||Group N|Normotensive group (Group N): Other non-hypertensive patients
89421143|NCT05154812|Experimental|Yang Yin Fu Zheng Jie Du therapy|
89421144|NCT05154812|Placebo Comparator|Routine medical care|
89421145|NCT03474380|Experimental|Intervention|"Implementation of iHI-FIVES program~Intervention: Behavioral: iHI-FIVES"
89421146|NCT03474380|No Intervention|Usual Care|Pre-implementation before iHI-FIVES program
89421147|NCT03215342|Experimental|pGMT|Pediatric Goal Management Training
89421148|NCT03215342|Experimental|pBHW|Pediatric Brain Health Workshop
89421149|NCT03088202|Experimental|Intervention arm|Educational program Standardized care pathways Early palliative care
89421150|NCT03088202|No Intervention|Control arm|Usual care
89421151|NCT03063164|Active Comparator|Intralase IFS|Intralase IFS vs. Visumax
89421152|NCT03063164|Active Comparator|Visumax|Visumax vs. Intralase iFS
89421153|NCT05154422||Normal body fat cohort|Determining the general amount of lipolysis, circulating insulin and growth hormone, and muscle quality of a group of recreational female endurance athletes with normal body fat determined by air displacement plethysmograph.
89421154|NCT05154422||Excess body fat cohort|Determining the general amount of lipolysis, circulating insulin and growth hormone, and muscle quality of a group of recreational female endurance athletes with excess body fat determined by air displacement plethysmograph.
89421155|NCT02737358|Placebo Comparator|Placebo|Matched placebo will be given to half of the study participants.
89421156|NCT02737358|Active Comparator|N-Acetylcysteine (NAC)|NAC will be given to half of the study participants. The dose of NAC will be 2400 mg per day (1200 mg taken twice per day as two 600 mg capsules)
89421157|NCT03474302|Experimental|Physical Activity|The intervention will be a 12-week community-based physical activity promotion program
88900993|NCT01515670||Fast-track THA/TKA|Any patient receiving THA/TKA in the participating wards
88900994|NCT01515683|Experimental|An anaesthetic nurse|
89421158|NCT03474302|Active Comparator|Successful Aging|Those randomized to the successful aging group will receive health information pertinent to African Americans over the 12 weeks
89421159|NCT05052710|Experimental|Treatment Arm|Subjects will receive midazolam on Day 1 and AZD4831 once daily from Days 2 to 10, and AZD4831 plus midazolam on Day 11.
89421160|NCT02866838|Experimental|Tranexamic acid|Intravenous tranexamic acid: 1g loading dose given as 100 mls infusion over 10 minutes, followed by another 1g in 250 mls infused over 8 hours.
89421161|NCT02866838|Placebo Comparator|Placebo|Saline 0.9% given in identical dosage as experimental
89421162|NCT03474146|Experimental|Ocimum sanctum extract as mouthrinse|10ml mouthrinse was rinsed for 60sec twice a daily for 03 weeks.
89421163|NCT03474146|Active Comparator|Chlorhexidine Gluconate as mouthrinse|10ml mouthrinse was rinsed for 60sec twice a daily for 03 weeks.
89421164|NCT03474146|Placebo Comparator|Propylene Glycol as mouthrinse|10ml mouthrinse was rinsed for 60sec twice a daily for 03 weeks.
89421165|NCT04458350|Experimental|Digital Promotions Group|Eligible zip codes (n=96) will be randomized using stratified randomization at the state level. The intervention will last 13 weeks (Summer 2020 market season) and consist of receiving digital ads on the Fresh EBT app and Facebook for SNAP fruit and vegetable incentive programs at farmers' markets.
89421166|NCT04458350|No Intervention|Control Group|No intervention administered. Eligible zip codes (n=96) will be randomized using stratified randomization at the state level.
89194653|NCT04064658|Sham Comparator|Sham RIPC group|"Treatment:Patients in this group received standard medical therapy and sham remote ischemic preconditioning treatment.~Device:Sham RIPC consisted of five 5-min cycles of bilateral arm ischemia/reperfusion, which is induced by a sphygmomanometer placed on bilateral arm and inflated to 60 mmHg for 5-min followed by deflating the cuff for 5-min, each patient in Sham RIPC group do it twice a day for at least five days before encephaloduroarteriosynangiosis.~Procedure: Encephaloduroarteriosynangiosis"
89530808|NCT03241303|Experimental|Exendin (9-39)|Infusion of GLP-1 receptor antagonist as a study tool to block GLP-1 activity on experimental day.
89530809|NCT03241303|Placebo Comparator|Placbo Saline|9 mg/ml placebo saline infusion on experimental day.
88900995|NCT01515683|Active Comparator|Theatre nurse + An anaesthetic nurse|Support from theatre nurse and an anaesthetic nurse
89421167|NCT04458662||Eumenorrheic women|"The project consisted on two sections carrying out at the same time: Iron physiology (Study I) and Muscle damage (Study II).~For the study I, the exercise protocol consisted on an interval running test. 5 min warm-up at 60% of the vVO2peak followed by 8 bouts of 3 min at 85% of the vVO2peak with 90 secs recovery at 30% of the vVO2peak between bouts. Finally, a 5 min cool down was performed at 30% of the vVO2peak.~The study II protocol was based on an eccentric-based resistance exercise protocol consisted on 10 sets of 10 reps of plate-loaded parallel back squats at 60% of their previously calculated 1RM with 2 mins recoveries between sets.~In both studies, eumenorrheic participants were evaluated at three specific moments of the menstrual cycle: Early-follicular phase (EFP), late-follicular phase (LFP) and mid-luteal phase (MLP);"
89421168|NCT04458662||Oral contraceptive users|"The project consisted on two sections carrying out at the same time: Iron physiology (Study I) and Muscle damage (Study II).~For the study I, the exercise protocol consisted on an interval running test. 5 min warm-up at 60% of the vVO2peak followed by 8 bouts of 3 min at 85% of the vVO2peak with 90 secs recovery at 30% of the vVO2peak between bouts. Finally, a 5 min cool down was performed at 30% of the vVO2peak.~The study II protocol was based on an eccentric-based resistance exercise protocol consisted on 10 sets of 10 reps of plate-loaded parallel back squats at 60% of their previously calculated 1RM with 2 mins recoveries between sets.~Oral contraceptive users performed the trial at two moments: Withdrawal phase (WP) and active pill phase (APP)."
89421169|NCT04458662||Postmenopausal women|"he project consisted on two sections carrying out at the same time: Iron physiology (Study I) and Muscle damage (Study II).~For the study I, the exercise protocol consisted on an interval running test. 5 min warm-up at 60% of the vVO2peak followed by 8 bouts of 3 min at 85% of the vVO2peak with 90 secs recovery at 30% of the vVO2peak between bouts. Finally, a 5 min cool down was performed at 30% of the vVO2peak.~The study II protocol was based on an eccentric-based resistance exercise protocol consisted on 10 sets of 10 reps of plate-loaded parallel back squats at 60% of their previously calculated 1RM with 2 mins recoveries between sets.~Postmenopausal women were tested only once, since their hormonal status does not fluctuate."
89421170|NCT01090154|Experimental|Cimzia|Treatment with open label Cimzia (certolizumab pegol)
89421171|NCT05159024||Patients with leak after colorectal anastomosis|Patients who developed anastomotic leak, clinical or radiologic, after colorectal resection and anastomosis
89006775|NCT03454477|Experimental|conventional open surgery|Patients who met the inclusion criteria were selected for a conventional open surgery procedure for a conventional neck incision for thyroid surgery.
89421172|NCT05158868||Post covid infected group|normal pregnant women infected by covid during 3rd trimester
89421173|NCT05158868||Control group|normal pregnant women
89421174|NCT03473990|Active Comparator|Laboratory HIT|Supervised (Laboratory HIT) exercise in the lab up to 4 times per week for 4 weeks
89421175|NCT03473990|Active Comparator|Home HIT|Unsupervised (Home HIT) exercise at home up to 4 times per week for 4 weeks
89421176|NCT03473990|No Intervention|Control Group|No intervention
89421177|NCT05043038||General Anesthesia Night Float|The residents will be followed over a three week period - one week prior to night float (baseline), the week of night float, and one week after night float (recovery). Participants will be asked to fill out PROMIS surveys weekly.
88900996|NCT01515683|Experimental|A nurse from ward + an anaesthesic nurse|Support from a nurse from the ward and an anaesthetic nurse
88900997|NCT01515683|Experimental|Optional relative + an anaesthetic nurse|Support from an optional relative and an anaesthetic nurse
88900998|NCT01515709||Chronic Obstructive Pulmonary Disease|Patients with a diagnosis of COPD
88900999|NCT01515722|Experimental|Health education intervention (HEI)|
88901000|NCT01515722|No Intervention|No intervention|
88901001|NCT01515735||pseudoexfoliation|The study group composted of the patients with pseudoexfoliation syndrome
88901002|NCT01515761|Active Comparator|Postero-lateral|Left ventricular lateral wall lead position
88901003|NCT01515761|Active Comparator|Antero-lateral|Left ventricular lateral wall lead position
88901004|NCT01515774|Active Comparator|Group 1|Give QD dose first then BID dosing
88901005|NCT01515774|Active Comparator|Group 2|Give BID dosing and then QD dosing
88901006|NCT01515800|Experimental|Text message reminder|Patients undergo a text message education checklist involving confirmation of cellular telephone capability to receive text messages, how to retrieve and read messages, including a confirmation evaluation, at baseline and at any time a patient obtains a new cellular telephone. Patients then receive a text message twice a week at 8 o'clock in the morning (for each time zone) for up to 3 years. Additionally, patients receive standard follow-up care.
88901007|NCT01515800|No Intervention|No text message reminder|Patients receive standard follow-up care.
89530810|NCT02510963|Experimental|Tenofovir 24 week|Pregnant women with high HBV DNA load in serum and normal liver function were treated with Tenofovir Disoproxil Fumarate 300 mg/day from 24 weeks of gestation to 1 month postpartum
88901008|NCT01515813|Experimental|Arm A: Pravastatin sodium alone for 24 weeks|One 40 mg tablet of Pravastatin sodium taken orally once daily for 24 weeks starting at week 0 and ending at week 24.
88901009|NCT01515813|Experimental|Arm B: EFV/FTC/TDF plus Pravastatin sodium at week 13|EFV/FTC/TDF once daily for 24 weeks starting at week 0 and ending at week 24 plus pravastatin sodium (80 mg)once daily for 12 weeks starting at week 13 ending at week 24.
89006776|NCT03454477|Experimental|endoscopic thyroidectomy|Patients who met the inclusion criteria were selected to undergo thyroid surgery via endoscopic thyroidectomy
89421178|NCT05043038||Obstetric Anesthesia Rotation|The residents will be followed and asked to wear the fitbit over a four week period during their rotation. Participants will complete three PROMIS surveys over the four week rotation, and as well as a follow-up PROMIS survey one week after the study period has completed
89421179|NCT01354431|Experimental|Arm 1: nivolumab - 0.3 mg/kg|
89421180|NCT01354431|Experimental|Arm 2: nivolumab - 2.0 mg/kg|
89421181|NCT01354431|Experimental|Arm 3: nivolumab - 10.0 mg/kg|
89421182|NCT05019872|Active Comparator|Penne hard|20 g penne cooked for 7 minutes
89421183|NCT05019872|Active Comparator|Penne soft|20 g penne cooked for 20 minutes
89421184|NCT05019872|Active Comparator|Carrot hard|50 g diced carrot cooked for 2 minutes
89421185|NCT05019872|Active Comparator|Carrot soft|50 g diced carrot cooked for 20 minutes
88901010|NCT01515813|Experimental|Arm C: Pravastatin sodium + EFV/FTC/TDF for 24 weeks|Participants will be administered Pravastatin sodium once daily for 24 weeks starting at week 0 and ending at week 24 plus EFV/FTC/TDF once daily for 24 weeks starting week 0 and ending at week 24.
88901011|NCT01515826|Experimental|VIGADEXA Gel|VIGADEXA ophthalmic gel topically administered TID to the operative eye starting the day before surgery, continuing on the day of surgery, and for 15 days following surgery.
88901012|NCT01515826|Active Comparator|VIGADEXA Solution|VIGADEXA ophthalmic solution topically administered QID to the operative eye starting the day before surgery, continuing on the day of surgery, and for 15 days following surgery.
88901013|NCT01515839|Experimental|Supplement intervention|Dietary Supplement: Multivitamin, Omega 3 Supplement, Brain and Memory Formula
88901014|NCT01515852|Other|Stress level after general anesthesia|
88901015|NCT01515852|Other|Stress level after local anesthesia|
88901016|NCT01515878|Experimental|Dialysis with BVT|Dialysis using the BVT monitor biofeedback called Hemocontrol
88901017|NCT01515878|No Intervention|Conventional dialysis|Conventional dialysis without blood volume tracking or similar therapies
88901018|NCT01515917|Experimental|Citicoline and Omega-3|At visit 1 and again at visit 2, participants assigned to the experimental arm will receive a 14-day supply of citicoline and omega-3 fatty acid, of which they will be instructed to take 1000 mg and 2000 mg daily, respectively. This will be done in a double-blind, randomized fashion.
88901019|NCT01515917|Placebo Comparator|Placebo|At visit 1 and again at visit 2, participants assigned to the placebo group will be given 14-day supplies of placebo to be taken daily throughout the study period. This will be done in a double-blind, randomized fashion.
88901020|NCT01515930|Active Comparator|Active Caregiver and Active Child|Parent & Child Computer-Delivered Motivational Intervention will be delivered to participants. A brief computer delivered behavior change counseling intervention for parents of children with diabetes to improve monitoring of diabetes care and a brief computer delivered behavior change counseling intervention for children with diabetes to improve completion of daily diabetes care.
88901021|NCT01515930|Experimental|Active Caregiver and Child Education|Parent Computer-Delivered Motivational Intervention will be delivered to the parents only. A brief computer delivered behavior change counseling intervention for parents of children with diabetes to improve monitoring of diabetes care and a brief computer delivered informational session about diabetes related topics for their child with diabetes.
88901022|NCT01515930|Active Comparator|Education Caregiver/Education Child|Participants will receive computer-delivered information. A brief computer delivered information session about diabetes related topics for both the caregiver and the child with diabetes.
89006777|NCT03454477|Experimental|robotic thyroidectomy|Patients who met the inclusion criteria chose the Da Vinci robot for thyroid surgery.
88901023|NCT01515969|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive erlotinib hydrochloride PO QD. Starting on day 15, patients also receive dovitinib lactate PO QD on days 1-5 of each week. Treatment continues in the absence of disease progression or unacceptable toxicity.
88901024|NCT01515982|Experimental|Aerobic exercise|The training exercise intensity is established at 60% of VO2máx. Each aerobic session began with a 10-minute warm-up period (40%VO2máx), followed by 20 minutes of continuous treadmill walking at an intensity established by 60% of VO2máx. The exercise session will be concluded with a 5 minutes of cool down. Heart hate (Polar® Sport Tester, Finland) and perceived exertion (Borg Scale) will be monitored and recorded at each five minutes during each exercise session by physical education instructors.
88901025|NCT01515982|No Intervention|Control group|All participants were asked not to commence any new exercise regimen.
88901026|NCT01516021|Experimental|high fat yoghurt intake|500 ml of a high fat yoghurt
88901027|NCT01516021|Experimental|low fat yoghurt intake|
88901028|NCT01516047|Experimental|Cohort 1|Patients with severe hepatic impairment.
88901029|NCT01516047|Experimental|Cohort 2|Healthy individuals with normal hepatic function.
88901030|NCT01516060|Experimental|Reduced dose Efavirenz arm|Patient's on main study that was randomised to receive TDF (300mg qd)/FTC (200mg qd) + EFV (400mg qd; 2 x 200mg + 1 x 200mg placebo qd).
88901031|NCT01516060|Active Comparator|Normal Efavirenz dose arm|Patient's on main study randomised to receive tenofovir (TDF) (300mg qd)/emtricitabine (FTC) (200mg qd) + EFV (600mg qd; 3 x 200mg qd)
88901032|NCT01516099|Experimental|General Practitioners|The general practitioner can refer his patients to a physical activity counselor for an individual coaching. The investigators aim for a brief coaching period of 10 weeks with the objective that the people continue their active lifestyle afterwards.
88901033|NCT01516099|Experimental|Social-cultural organizations|In the social-cultural organization, members can sign in for group sessions led by the physical activity counselor. The investigators aim for a brief coaching period of 10 weeks with the objective that the people continue their active lifestyle afterwards.
88901034|NCT01516138|Active Comparator|GIK|glucose-insulin-potassium (GIK) consists of 20% glucose (200 g/L), 66.7 U/L regular insulin and 80 mmol/L potassium chloride (KCl).
88901035|NCT01516138|Placebo Comparator|Control|6.12 g/L sodium acetate, 5.85 g/L sodium chloride, 0.3 g/L potassium chloride and 0.33 g/L calcium chloride
88901036|NCT01516151|Active Comparator|Group A|0.5g total CaPre™ from baseline to week 4 and 1.0g total CaPre™ from week 4 to week 8
88901037|NCT01516151|Active Comparator|Group B|1.0g total CaPre™ from baseline to week 4 and 2.0g total CaPre™ from week 4 to week
88901038|NCT01516151|Active Comparator|Group C|2.0g total CaPre™ from baseline to week 4 and 4.0g total CaPre™ from week 4 to week 8
88901039|NCT01516151|Other|Group D|Standard of care
88901040|NCT01516151|Active Comparator|Group E|4.0g total CaPre™ from baseline to week 8
88901041|NCT01516164|Active Comparator|MacIntosh|
88901042|NCT01516164|Active Comparator|McGrath MAC direct|
88901043|NCT01516164|Active Comparator|McGrath MAC indirect|
88901044|NCT01516177||Renal Transplant Recipients|Subjects who received a kidney transplant within the past 1 to 5 years
88901045|NCT01516229||Somatropin|
88901046|NCT01516242||NovoPen® 4|
88901047|NCT01516255|Experimental|Double-blind / liraglutide|
88901048|NCT01516255|Placebo Comparator|Double-blind / placebo|
88901049|NCT01516255|Active Comparator|Open-label / moxifloxacin|
88901050|NCT01516255|Placebo Comparator|Open-label / placebo|
88901051|NCT01516281||mTBI|Historical cohort of subjects seen in the emergency rooms of NorthShore University HealthSystem with ICD-9 diagnoses of mild or moderate traumatic brain injury during the years 2006-2011 (7,122 subjects). 100 mTBI+ subjects are randomly selected for clinical assessment and DaTscan.
89006778|NCT03454399|No Intervention|TEE image before suction|Suction orogastric tube which is attached to TEE probe
89006779|NCT03454399|Experimental|TEE image after suction|Suction orogastric tube which is attached to TEE probe
89006780|NCT00251082|Experimental|A|
88901052|NCT01516281||mTBI-|Historical cohort of subjects seen in the emergency rooms of NorthShore University HealthSystem with ICD-9 diagnoses of disorders other than mild or moderate traumatic brain injury during the years 2006-2011 (7,122 subjects). 100 mTBI- subjects are randomly selected for clinical assessment and DaTscan.
88901053|NCT01516294|Experimental|Iray plus Lucentis|open label arm in which all subjects recieve a single 16 gy dose of radiation plus an injection of Lucentis.
88901054|NCT01514903|Active Comparator|viagra,anti-erectile dysfunction agent|
88901055|NCT01514903|Experimental|HIP0908|
88901056|NCT01516320|Experimental|Gastric Bypass (GBP) Subjects|Subjects enrolled in the study who are receiving Roux-en-Y Gastric Bypass surgical technique for treatment of their obesity.
88901057|NCT01516320|Active Comparator|Laparoscopic adjustable gastric banding (LAGB) Subjects|Subjects enrolled in the study who are receiving laparoscopic adjustable gastric banding surgical technique for treatment of their obesity.
88901058|NCT01516320|Active Comparator|Vertical Sleeve Gastrectomy (VSG) Subjects|Subjects enrolled in the study who are receiving vertical sleeve gastrectomy surgical technique for treatment of their obesity.
88901059|NCT01516333|Experimental|Diet 1|High GI; High Carb; High GL
88901060|NCT01516333|Experimental|Diet 2|High GI, Low Carb, Med GL
88901061|NCT01516333|Experimental|Diet 3|Low GI, High Carb, Med GL
88901062|NCT01516333|Experimental|Diet 4|Low GI, Low Carb, Low GL
88901063|NCT01516359||patients with cardiac surgery|
88901064|NCT01516372|Experimental|Treatment 1|Healthy Volunteers will receive Treatments ABDC
88901065|NCT01516372|Experimental|Treatment 2|Healthy Volunteers will receive Treatments BCAD
88901066|NCT01516372|Experimental|Treatment 3|Healthy Volunteers will receive Treatments CDBA
89421186|NCT05019872|Active Comparator|Penne hard + sauce|20 g penne cooked for 7 minutes + 10 g tomato sauce
88901067|NCT01516372|Experimental|Treatment 4|Healthy Volunteers will receive Treatments DACB
88901068|NCT01516385||spinal cord injury|
88901069|NCT01516385||other neurological conditions|
88901070|NCT01516398||Preterm infants|No interventions were performed. Group consisted of preterm infants enrolled in the study.
89006781|NCT00251082|Active Comparator|B|
89421187|NCT05019872|Active Comparator|Penne soft + sauce|20 g penne cooked for 20 minutes + 10 g tomato sauce
89421188|NCT05019872|Active Comparator|Carrot hard + sauce|50 g diced carrot cooked for 2 minutes + 10 g tomato sauce
89421189|NCT05019872|Active Comparator|Carrot soft + sauce|50 g diced carrot cooked for 20 minutes + 10 g tomato sauce
89421190|NCT05019872|Active Comparator|Penne hard + carrot hard + sauce|20 g penne cooked for 7 minutes + 50 g diced carrot cooked for 2 minutes + 20 g tomato sauce
89421191|NCT05019872|Active Comparator|Penne hard + carrot soft + sauce|20 g penne cooked for 7 minutes + 50 g diced carrot cooked for 20 minutes + 20 g tomato sauce
89421192|NCT05019872|Active Comparator|Penne soft + carrot hard + sauce|20 g penne cooked for 20 minutes + 50 g diced carrot cooked for 2 minutes + 20 g tomato sauce
89421193|NCT05019872|Active Comparator|Penne soft + carrot soft + sauce|20 g penne cooked for 20 minutes + 50 g diced carrot cooked for 20 minutes + 20 g tomato sauce
89421194|NCT03473912||RA patients|before or after medication
88901071|NCT01516398||Term control infants|No interventions were performed. Group consisted of term infants enrolled in the study to serve as controls for the preterm infant group.
89421195|NCT03473912||Systemic sclerosis patients|before or after medication
88901072|NCT01516411|Active Comparator|Cognitive app|Cognitive app promotes behavior change via goal setting, feedback, and problem solving
89421196|NCT03473912||IgG4 RD patients|before or after medication
88901073|NCT01516411|Active Comparator|Social app|Social app promotes behavior change via social relationships and feedback
88901074|NCT01516411|Active Comparator|Affect app|Affect app promotes behavior change via game-like elements including the use of a bird avatar as a visual representation of one's activities and operant conditioning
88901075|NCT01516411|Active Comparator|Nutrition app|Nutrition app promotes behavior change bvia tracking of food consumption
88901076|NCT01516450|Active Comparator|GSK1550188 200mg for SC|Single SC dose of belimumab 200mg
89421197|NCT03473912||Lupus patients|before or after medication
88901077|NCT01516450|Active Comparator|GSK1550188 200mg for IV|Single IV dose of belimumab 200 mg
88901078|NCT01516463|Active Comparator|Collagenase Santyl|
88901079|NCT01516463|Sham Comparator|Bacitracin|
88901080|NCT01516489|No Intervention|Stage 1 Control Group|In the FOBT kit, individuals will receive a card that asks them to complete and return their FOBT kit within 30 days.
88901081|NCT01516489|Experimental|$5 Incentive|In the FOBT kit, individuals will receive a card that states that if they complete and return their FOBT kit within 30 days, they will be mailed a voucher that can be exchanged for $5 at PVAMC.
88901082|NCT01516489|Experimental|$10 Incentive|In the FOBT kit, individuals will receive a card that states that if they complete and return their FOBT kit within 30 days, they will be mailed a voucher that can be exchanged for $10 at PVAMC.
88901083|NCT01516489|Experimental|$20 Incentive|In the FOBT kit, individuals will receive a card that states that if they complete and return their FOBT kit within 30 days, they will be mailed a voucher that can be exchanged for $20 at PVAMC.
88901084|NCT01516489|Experimental|$5 Voucher-Based Incentive|In the FOBT kit, individuals will receive a card that states that if they complete and return their FOBT kit within 30 days, they will be mailed a voucher that can be exchanged for $5 at PVAMC.
89006782|NCT00251082|Placebo Comparator|C|
89006783|NCT00221546|Active Comparator|DHA-rich supplement|
89421198|NCT05004272|Active Comparator|Massage|
89421199|NCT05004272|Active Comparator|Gymnastics|
89421200|NCT05004272|Placebo Comparator|Lecture|
89421201|NCT04940234|Experimental|Black Expert|Survey respondents are exposed to a Black person wearing expert attire.
89421202|NCT04940234|Experimental|Black Layperson|Survey respondents are exposed to a Black person wearing layperson's attire.
89421203|NCT04940234|Experimental|White Expert|Survey respondents are exposed to a white person wearing expert attire.
89421204|NCT04940234|Experimental|White Layperson|Survey respondents are exposed to a white person wearing layperson's attire.
89421205|NCT02736578|Experimental|Cetuximab IRDye800, 50 mg|On day 0, participants receive a 100 mg cetuximab loading dose by intravenous infusion (IV), followed 1 hour later by cetuximab-IRDye 800CW IV at 50 mg, followed by surgery with intraoperative imaging within 2 to 5 days.
88901085|NCT01516489|Experimental|$50 Lottery-Based Incentive|In the FOBT kit, individuals will receive a card that states that if they complete and return their FOBT kit within 30 days, they will have a 1 in 10 chance of being mailed a voucher that can be exchanged for $50 at PVAMC.
88901086|NCT01516489|Experimental|$500 Raffle-Based Incentive|In the FOBT kit, individuals will receive a card that states that if they complete and return their FOBT kit within 30 days, they will be entered into a raffle in which 1 randomly chosen patient (out of about 100 patients) will be mailed a check in the amount of $500.
89421206|NCT02736578|Experimental|Cetuximab IRDye800, 100 mg|On day 0, participants receive a 100 mg cetuximab loading dose by intravenous infusion (IV), followed 1 hour later by cetuximab-IRDye 800CW IV at 100 mg, followed by surgery with intraoperative imaging within 2 to 5 days.
89421207|NCT05158400|Experimental|Cases|
89421208|NCT04366856|Experimental|1: Prone positioning|the interventional group will be suggested to spend at least 6 hours a day in prone position
88901087|NCT01516489|No Intervention|Stage 2 Control Group|In the FOBT kit, individuals will receive a card that asks them to complete and return their FOBT kit within 30 days.
89421209|NCT04366856|Other|2: No instruction regarding positioning|the control group will get no instruction regarding positioning
89421210|NCT05157776|Active Comparator|Control group|Neoadjuvant therapy of Sintilimab and chemotherapy in 2 cycles before surgery and optional adjuvant therapy of Sintilimab and chemotherapy in 2 cycles after surgery
88901088|NCT01516502|Active Comparator|laser to acupoint|
88901089|NCT01516502|Sham Comparator|sham laser to acupoint|
88901090|NCT01516502|Active Comparator|laser to trigger point|
88901091|NCT01516502|Sham Comparator|sham laser to trigger point|
88901092|NCT01516515|Placebo Comparator|placebo, gel|placebo comparator
88901093|NCT01516515|Active Comparator|SR-T100 with 2.3% of SM, gel|2.3% of SM in Solanum undatum plant extract
88901094|NCT01516528||All|All subjects enrolled in the study
89421211|NCT05157776|Experimental|Experimental group|Neoadjuvant therapy of Sintilimab and chemotherapy in 4 cycles before surgery
88901095|NCT01516554|Experimental|Testosterone undecanoate|
88901096|NCT01516554|Placebo Comparator|Sugar pill|
89421212|NCT02479568|Active Comparator|Control|Control drink (placebo)
89421213|NCT02479568|Experimental|Natural Florida orange juice|100% Florida orange juice (OJ) (natural content of hesperidin)
89421214|NCT02479568|Experimental|Enriched Florida orange juice|100% Florida orange juice (OJ) (enriched hesperidin content)
88901097|NCT01516567|Experimental|DA-EPOCH-R|6 courses of Dose Adjusted-EPOCH-Rituximab
88901098|NCT01516580|Active Comparator|LMB chemo|"Prephase (COP) for all groups followed by:~in group B: 4 courses: 2 COPADM + 2 CYM, with MTX 3g/m²~in group C: 6 courses: 2 COPADM + 2 CYVE + 2 maintenance courses, with MTX 8g/m², in 4h in C1, in 24h in C3 (except the 1st course) and CNS positive patients receive additional IT before each CYVE courses and HDMTX between CYVE courses."
88901099|NCT01516580|Experimental|LMB chemo + Rituximab|LMB chemo as in the comparator arm Rituximab 375 mg/m² i.v.: 6 injections: two doses at 48h interval are given at D-2 and D1 of the 2 first courses (COPADM) and one dose at the beginning of the 2 following courses (CYM or CYVE).
88901100|NCT01516645|Experimental|KHK2898|
88901101|NCT01516658|Experimental|Hydrogel coil group|use Hydrogel Coil as much as be able to use
88901102|NCT01516658|Active Comparator|Bare platinum coil group|use only bare platinum coil
88901103|NCT01516697|Other|Control|The patients in Group A will serve as controls and will receive standard monitoring in addition to continuous measurement of SV and CO. The physicians will not know the CO and SV and will manage the patients in a standard fashion.
88901104|NCT01516697|Experimental|experimental|The patients in Group B will receive the same monitoring as those in Group A. But the physicians will know instantaneously the CO and SV in real time and will manage the patients accordingly.
88901105|NCT01516710|Active Comparator|Open liver resection|Patients will be operated with open liver resection
88901106|NCT01516710|Active Comparator|Laparoscopic liver resection|Patients will be operated with laparoscopic liver resection
88901107|NCT01516723|Experimental|Hybrid sirolimus-eluting stents|ORSIRO, Biotronik Inc.
88901108|NCT01516723|Active Comparator|Everolimus-eluting stents|XIENCE PRIME, Abbott
88901109|NCT01516775|Experimental|1 hour fluid fasting|allowed to drink until 1 hour before scheduled anaesthesia induction
88901110|NCT01516775|Active Comparator|2 hours fluid fasting|allowed to drink until 2 hour before scheduled anaesthesia induction
88901111|NCT01516788|Experimental|Phototesting|
88901112|NCT01516801|Experimental|PSA flyer|
88901113|NCT01516801|No Intervention|Control|
88901114|NCT01516814|Experimental|Arm 1|
88901115|NCT01516814|Active Comparator|Arm 2|
89421215|NCT02479100|Other|Undergo a CESM|Patients will undergo an experimental Contrast Enhanced Spectral Mammogram (CESM) in addition to standard diagnostic procedures
89421216|NCT02479100|No Intervention|Follow Standard care|Patient will follow standard care pathway.
89421217|NCT03473834|Experimental|Modified exercise programme|Modified exercise program is the intervention for the exercise group that they will be received this programm over 1 month.
89421218|NCT03473834|Active Comparator|Parkinson's disease Medication|Medication is the standard treatment for individuals with Parkinson's disease. Therefore, the control group will be received the medication only.
89421219|NCT03473678|Active Comparator|Nitrate-rich beetroot juice|2 x 70mL concentrated juice per day for 10 days
88901116|NCT01516814|Active Comparator|Arm 3|
89421220|NCT03473678|Placebo Comparator|Nitrate-depleted beetroot juice|2 x 70mL concentrated juice per day for 10 days
89421221|NCT05157542|Experimental|Arm|"Durvalumab 1500mg, IV, Q3W, 2 cycles Albumin paclitaxel 260 mg/m2 +~Carboplatin AUC5, IV, Q3W, 2 cycles Chemoradiotherapy(CRT):~Cohort 1: 2 Gy in 5 Fraction~Cohort 2: 2 Gy in 10 Fraction~Cohort 3: 2 Gy in 15 Fraction"
89421222|NCT03472976|Experimental|Group 1|0.1 ml of influenza A/H5N1 IIV vaccine (9 mcg HA) intradermally 15 minutes after the application of approximately 250 mg of Imiquimod (Aldara) cream topically (deltoid) on Day 1 and Day 22. N=25
89421223|NCT03472976|Experimental|Group 2|0.1 ml of influenza A/H5N1 IIV vaccine (9 mcg HA) intradermally 15 minutes after the application of approximately 250 mg of Aqueous Cream B.P. (Control Cream) topically (deltoid) on Day 1 and Day 22. N=25
88901117|NCT01516827|Experimental|TF-CBT|"12 Sessions Trauma-focused Cognitive Behavioral Therapy including the child/adolescents and a non-abusive caregiver according to the treatment manual:~Cohen JA, Mannarino AP, and Deblinger E (2006) Treating Trauma and Traumatic Grief in Children and Adolenscents. Guilford, N.Y."
88901118|NCT01516827|No Intervention|Wait-list|Patients in the control condition will be assigned to a wait-list (duration 4 months). During waiting time, clinical services will be provided as needed (excluding TF-CBT).
88901119|NCT01516840|Experimental|Arm 1|
89421224|NCT04457726|Experimental|Recipients with severe COVID-19|Recipients who are confirmed positive by SARS-CoV-2 testing and have severe COVID-19.
89421225|NCT04457726|Experimental|Recipients with mild to moderate COVID-19|Recipients who are confirmed positive by SARS-CoV-2 testing and have mild to moderate COVID-19.
88901120|NCT01516840|Experimental|Arm 2|
88901121|NCT01516840|Active Comparator|Arm 3|
88901122|NCT01516840|Active Comparator|Arm 4|
88901123|NCT01516853||Patient Group|Subjects with known or suspected iron overload will undergo serum iron measurements and a non-contrast MRI scan.
88901124|NCT01516853||Control Group|Subjects with no known history of iron overload or liver disease will undergo a serum iron measurement and a non-contrast MRI scan.
88901125|NCT01516866||Cohort A: Microtubule directed chemotherapy treatment|Subjects receiving antimicrotubule chemotherapy-based treatment will have NaF PET/CT scans at baseline and again after 8 weeks of starting treatment. A subset of subjects will have a second NaF PET/CT scan at baseline 1-8 days after the first baseline scan.
88901126|NCT01516866||Cohort B: AR-directed therapy|Subjects receiving AR-directed therapy will undergo a baseline NaF PET/CT scan at baseline and again after having been on treatment for 6 weeks and again at 12 weeks. A subset of subjects will also undergo a second baseline NaF PET/CT scan 1-8 days after the first baseline scan.
89006784|NCT00221546|Placebo Comparator|Placebo|
89421226|NCT04457570||exposed patients|"The exposed patients are patients with cancer that are hospitalized in one of the participating centers for a SARS-CoV-2 infection. A patient will be considered as an exposed patient if he/she had a surgical procedure or a medical treatment for cancer in the past 5 years preceding the SARS-CoV-2 infection."
89421227|NCT04457570||control patients|"The control patients  are all of the patients without cancer that are hospitalized in one of the participating centers for a SARS-CoV-2 infection"
89421228|NCT03471104|Experimental|PAID in clinical diabetes consultations|Participants randomised to the intervention arm. Participants complete the Problem Area in Diabetes scale (PAID) and evaluation PROMs. Participants with specified PAID scores will be offered an empowerment-based follow-up by diabetes specialist nurses.
89421229|NCT03471104|No Intervention|Control group|Participants randomised to the control group. Participants complete PROMs but the results/answers will not be available in the electronic patient records until the trial is finished. The participants will receive standard care.
89421230|NCT04608578|Experimental|Intervention group|The intervention group gain access to the game after filling in the baseline online questionnaire. The participants are asked to play at least two characters in the game. They have two weeks to play the game.
89421231|NCT04608578|No Intervention|Control group|Waitlist control group
89006785|NCT04616092|Experimental|FERINJECT Group|Patients with FERINJECT injection
89006786|NCT04616092|No Intervention|Observation Group|Patients without FERINJECT injection
89006787|NCT04616482||Digital therapeutic carbohydrate restriction (TCR) program|The intervention involves 12 weeks of online/app-based behaviour change coaching. Each week the participant focuses on a different aspect of healthy eating habits designed to cut sugar and refined carbohydrates while encouraging and providing resources for lower-carbohydrate food options. Education is done through short videos and information sheets. Participants set goals and complete worksheets/tasks based on their individual goals.
89006788|NCT04616404|Active Comparator|Intervention Group|
89006789|NCT04616404|Placebo Comparator|Control Group|
89006790|NCT04720482||Comatose survivors of cardiac arrest|Adult (>18 years) patients remaining comatose during intensive care 48 hours after cardiac arrest. All patients are submitted to both clinical routine measurements: pupillometry and somatosensory evoked potentials.
89006791|NCT04616053|Experimental|Intervention group|IMPACT intervention
89006792|NCT04616053|No Intervention|Control group|Usual care
89006793|NCT04615975|Experimental|Intervention|Patients will receive 21 days of a very low carbohydrate mediterranean ketogenic diet with phytoextracts and 7 days of a low carbohydrate diet
89006794|NCT04615897|Experimental|Experimental aging|The subjects received 16 sessions (Two per week) of exercise with new tecnology between two measurements of the variable.
89421232|NCT03473600|Experimental|study group|•The first group (20 patients) will be treated with cryotherapy using liquid nitrogen spray, two cycles each one 3-5 seconds, one session every two weeks, for three months.
89421233|NCT03473600|Active Comparator|control group|•The second group (20 patients) will be treated with intralesional injection of 4mg/ml/ session of triamcinolone-acetonide, it will be injected into deep dermis or upper subcutaneous tissue using a 0.5-inch long 30-gauge needle at multiple sites, 1 cm apart and 0.1 ml into each site, once every three weeks, for three months, using insulin syringes.
89006795|NCT04615897|No Intervention|Control Aging|The subjects doesn´t received 16 sessions (Two per week) of exercise with new tecnology between two measurements of the variable.
89006796|NCT04615741|Experimental|Trauma Informed Yoga|Participants will receive 8 x 60 min group-based yoga sessions, delivered synchronously over Zoom.
89006797|NCT04615741|Experimental|Trauma Informed Psychotherapy|Participants will receive 8 x 90 min group-based psychotherapy sessions, delivered synchronously over Zoom.
89006798|NCT04615741|No Intervention|Control|These participants will not receive an intervention.
89006799|NCT04615663||face-to-face patients|During this visit, the investigator will complete the SMI score.
89421234|NCT03473522|Experimental|anodal tDCS +Exercise Therapy|Anodal tDCS (2mA of intensity, for twenty minutes) over the motor cortex representation of trunk and lower limbs. Immediately after tDCS application all the patients will participate in an exercise therapy protocol involving balance control, strength,
89421235|NCT03473522|Sham Comparator|Sham tDCS+ Exercise Therapy|Anodal tDCS (2mA of intensity, for twenty minutes but thirdy seconds ON) over the motor cortex representation of trunk and lower limbs.
89421236|NCT02523326||Group A|Each patient was instructed how to prepare for saliva sampling. Patients were instructed to rinse their mouth vigorously with 10 ml of mouthwash during 30 s, then spit it into the tube and the extraction of DNA was performed at distinct times: group A at 10 days
88901127|NCT01516905||I124-NM404 brain metastases or GBM imaging|determining appropriate imaging timepoints. Image at 6 hour, 24 hour and 48 hour post injection of I-124NM404
88901128|NCT01516931|Experimental|active rTMS and venlafaxine|"rTMS：Intensity of 120% of individually determined motor threshold; frequency : 1 Hz; 360 impulsions; on period : 1 min; off period : 30 s.5 sessions per week for 4-6 weeks,than 2 sessions per week for 2 months, repeat that for 12 months.~venlafaxine：150-225mg/day"
88901129|NCT01516931|Placebo Comparator|sham rTMS and venlafaxine|Sham stimulation will be given at the same site and frequency, using a Magstim sham-coil system. During rTMS, participants will be instructed to keep their eyes open and relax.
89006800|NCT04615663||Email patients|this visit at M0 + 7d will correspond to the emailing of the Mc_QoL and Burden_MCD questionnaires completed by the patient.
89006801|NCT04615780|Experimental|mouthwash with green tea group|The intervention group rinsed the mouth with 100 ml green tea solution for 60 seconds at least twice daily.
89006802|NCT04615780|Placebo Comparator|mouthwash with tap water group|The control group rinsed the mouth with 100 ml tap water for 60 seconds at least twice daily.
89194654|NCT04064658|Experimental|RIPC group|"Treatment:Patients in this group received standard medical therapy and remote ischemic preconditioning (RIPC) treatment.~Device:RIPC consisted of five 5-min cycles of bilateral arm ischemia/reperfusion, which is induced by a sphygmomanometer placed on bilateral arm and inflated to 200 mmHg for 5-min followed by deflating the cuff for 5-min,each patient in the RIPC group do it twice a day for at least five days before encephaloduroarteriosynangiosis.~Procedure: Encephaloduroarteriosynangiosis"
88901130|NCT01516931|Placebo Comparator|venlafaxine alone|responders will be maintained on the same effective dose of venlafaxine for the entire duration of the RCT, unless they relapse and will have to exit the protocol and enter a naturalistic follow-up
88901131|NCT01516983|Experimental|Icotinib+WBRT|"Standard whole brain radiotherapy plus icotinib, which is designed to administered at 5 dose according to 3+3 until disease progression or intolerable toxicity."
88901132|NCT01516996|Active Comparator|Neoadjuvant and CCRT|
88901133|NCT01516996|Experimental|Neoadjuvant and CCRT and Nimotuzumab|
88901134|NCT01517022|No Intervention|Control arm|Control arm patients will receive pre designed pamphlets and structured conselling for smoking cessation by trained counsellors along with routine DOTS treatment
88901135|NCT01517022|Active Comparator|Intervention arm|Cessation arm patients will receive pre designed pamphlets and structured conselling for smoking cessation by trained counsellors along and nicotine replacement therapy(NRT) and routine DOTS treatment
88901136|NCT01517035|Experimental|1|Myeloablative conditioning (Flu/Cy/TBI) followed by CD3/19/34 selected stem cell graft.
88901137|NCT01517087||1|neurologically normal, healthy adults, age 35 or older.
88901138|NCT01517139||Feasibility Cohort|100 pairs of children and their mothers recruited from 2 provinces.
88901139|NCT01517165|Experimental|Group 1|
88901140|NCT01517165|Placebo Comparator|Group 2|
88901141|NCT01517191||Influenza Positive Case|Influenza cases are hospitalized adults who have tested positive for influenza.
88901142|NCT01517191||Influenza Negative Control|Control Controls are hospitalized adults who have tested negative for influenza.
88901143|NCT01517204|Experimental|Direct laryngoscope|Direct laryngoscope was used to facilitate the intubation of left-sided double lumen endobronchial tube.
88901144|NCT01517204|Experimental|Trachway(R) intubating stylet|Trachway(R) intubating stylet was used to facilitate left-sided double lumen endobronchial tube intubation.
88901145|NCT01517217|Other|No girdle postoperative|patients undergoing major abdominal surgery will get NO individualized girdle. Functional outcomes as pulmonary function and pain are measured daily. Participants will be followed for the duration of 5 days or the duration of hospital stay, if shorter than 5 days.
88901146|NCT01517217|Other|Girdle postoperative|patients undergoing major abdominal surgery will get an individualized girdle. Functional outcomes as pulmonary function and pain are measured daily. Participants will be followed for the duration of 5 days or the duration of hospital stay, if shorter than 5 days.
88901147|NCT01517230|Active Comparator|intervention|seven clusters where radio media campaign will be broadcast.
88901148|NCT01517230|No Intervention|control|Seven clusters where radio media campaign won't be broadcast.
88901149|NCT01517256|Experimental|Early Intervention Group|
88901150|NCT01517256|Placebo Comparator|Delayed Intervention Group|Initially wait-listed and served as control group. But later participants underwent the experimental intervention.
88901151|NCT01517269|Experimental|Education with simulator|Parent randomized to this group will be taught diabetes management with vignette and simulator
88901152|NCT01517269|Active Comparator|Control arm: standard diabetes education|Parents will receive standard diabetes education with a diabetes educator
88901153|NCT01517308|Active Comparator|Control Arm 24 weeks|PEG-IFN α2a 180 μg/week+ ribavirin 800 mg/die for 24 weeks
89194655|NCT00883012|Experimental|Influenza vaccine|Two doses of trivalent sub-unit influenza vaccine (2009) to be administered one month apart
89194656|NCT00883012|Placebo Comparator|Placebo|Two doses of saline administered one month apart
88901154|NCT01517308|Experimental|Active arm (48 weeks)|PEG-IFN α2a 180 μg/week + ribavirin 800 mg/die per 48 weeks
88901155|NCT01517321|Experimental|E|
88901156|NCT01517321|Placebo Comparator|P|
88901157|NCT01517334|Experimental|Treatment|Treatment (minocycline HCl microspheres, 1mg) administered at Baseline (following randomization) and Day 90 to qualifying implant sites, plus full-mouth mechanical debridement (deep cleaning) at Baseline and Day 180.
88901158|NCT01517334|No Intervention|Control|Full-mouth mechanical debridement (deep cleaning) at Baseline and Day 180; no treatment
88901159|NCT01517347|Experimental|Interleukin-2|Interleukin-2 post-transplantation to prevent relapse of standard risk leukemia
89194657|NCT00737490|Active Comparator|1|"Echocardiographically guided optimized device programming: specifically sequential BiV pacing. Sequential Arm"
89194658|NCT00737490|Active Comparator|2|"Simultaneous BiV pacing. Simultaneous Arm"
89194659|NCT00883324||1|fetal fibronectin specimens collected with a speculum
89194660|NCT00883324||2|fetal fibronectin specimens collected without a speculum
89194661|NCT00737646|Other|1|Usual care
89421237|NCT02523326||Group B|Each patient was instructed how to prepare for saliva sampling. Patients were instructed to rinse their mouth vigorously with 10 ml of mouthwash during 30 s, then spit it into the tube and the extraction of DNA was performed at distinct times: group B at 20 days
89421238|NCT02523326||Group C|Each patient was instructed how to prepare for saliva sampling. Patients were instructed to rinse their mouth vigorously with 10 ml of mouthwash during 30 s, then spit it into the tube and the extraction of DNA was performed at distinct times: group C at 30 days
89421239|NCT04457882|Experimental|Without Drainage Tube|No place the drainage tube after the intraperitoneal laparoscopic radical prostatectomy
89421240|NCT04457882|Active Comparator|With Drainage Tube|Place the drainage tube after the intraperitoneal laparoscopic radical prostatectomy
89421241|NCT04457804|Experimental|Online ACT workshop for Emotional Eating|All participants will be assigned to 2, 1.5 hour interventions using Acceptance and Commitment Therapy (ACT) techniques to help reduce emotional eating.
89421242|NCT04457648|Placebo Comparator|Conventional|
89421243|NCT04457648|Active Comparator|Manuka Honey|
89421244|NCT05004584|Experimental|Wheat home-based|
89421245|NCT05004584|Experimental|Rye home-based|
89421246|NCT05004584|Experimental|Rye clinic-based|
89421247|NCT05004584|Experimental|Wheat clinic-based|
89421248|NCT05004584|Experimental|Wheat/Rye clinic-based with blood sampling|
89421249|NCT04993976|Experimental|Prehabilitation group|Strength training along with warm-up and cool down for 8 weeks
89421250|NCT04993976|Active Comparator|Control group|Supervised Standard care plan for 8 weeks
89421251|NCT02622724|Experimental|FP-1201-lyo 10 μg|"FP-1201-lyo 10 μg (Interferon beta-1a) will be administered once daily as an intravenous bolus injection for 6 days.~Investigational product is lyophilisate for solution for injection which will be reconstituted in water for injection."
89421252|NCT02622724|Placebo Comparator|FP-1201-lyo Placebo|"FP-1201-lyo Placebo will be administered once daily as an intravenous bolus injection for 6 days.~Investigational placebo product is lyophilisate for solution for injection which will be reconstituted in water for injection."
89421253|NCT03471026||pCMS+|Children undergoing infratentorial craniotomy for brain tumour resection whom develop pCMS will undergo pre-, post-operative and delayed follow-up advanced MRI sequences
89421254|NCT03471026||pCMS-|Children undergoing infratentorial craniotomy for brain tumour resection whom do not develop pCMS will undergo pre-, post-operative and delayed follow-up advanced MRI sequences
89421255|NCT03471026||Controls|Healthy control children whom have never undergone intracranial surgery have had advanced MRI sequences acquired
89421256|NCT03710720|Experimental|TF-CBT plus TIPS app|
89421257|NCT03710720|Active Comparator|TF-CBT|
89421258|NCT03690596|Experimental|NRT + QuitBuddy|This smartphone app will identify high-risk situations through real-time EMA data collected before and during a quit attempt. One week of pre-quit smoking behaviors will be integrated with passively sensed GPS data to create hotspot maps. Hotspot maps will provide interactive visualizations of relapse risk. GPS triggered NRT/behavioral prompts will occur when participants come within 50m from the centroid of a hotspot.
89421259|NCT03690596|Experimental|NRT + QuitBuddy-Recall|This smartphone app will identify high-risk situations through retrospective recall of locations where the patient typically smoked. Hotspot maps will provide interactive visualizations of relapse risk. GPS triggered NRT/behavioral prompts will occur when participants come within 50m from the centroid of a hotspot.
89421260|NCT03690596|Active Comparator|NRT Control (treatment as usual)|Standard Care Control is intended to approximate the real-world experience where smokers obtain over-the-counter NRT and, after brief instructions at the outset (~1 lozenge per hour, during cravings, and <20 per day), determine usage for themselves.
89421261|NCT04932928|Experimental|FreeStyle Libre (CGM) Group|Device: FreeStyle Libre (ver 1.0) Education on lifestyle modification
89421262|NCT04932928|Active Comparator|Self Monitoring of Blood Glucose (SMBG) Group|Device: Blood glucose meter Education on lifestyle modification
89421263|NCT04932616||Face To Face (Clinic) Group Functional Gait Assessment|"Evaluations to be applied for the cultural adaptation and reliability study of the scale:~Functional Gait Assessment, Timed Up and Go Test, Four-Step Square Test, Timed 25-Foot Walk Test, 12-Item Multiple Sclerosis Walking Scale Berg Balance Scale"
88901160|NCT01517347|No Intervention|controlled group|controlled standard risk leukemia received regular transplantation without IL-2 intervention
88901161|NCT01517360|Active Comparator|Placebo+Social Cognitive Skills Training|The training utilizes skill building techniques that are commonly used in psychiatric rehabilitation. These include breaking down complex social cognitive processes into their components and automating these skills through repetition and practice. The training programs will include 12 sessions and will be administered in a small group format (6-8 participants per group) twice a week for 6 weeks. The treatment groups will include individuals who are assigned to placebo. Each training session will last for about 90 minutes (1 hour training and 30 minutes between placebo administration and start of training).
88901162|NCT01517360|Experimental|Oxytocin+Social Cognitive Skill Training|The training utilizes skill building techniques that are commonly used in psychiatric rehabilitation. These include breaking down complex social cognitive processes into their components and automating these skills through repetition and practice. The training programs will include 12 sessions and will be administered in a small group format (6-8 participants per group) twice a week for 6 weeks. The treatment groups will include individuals who are assigned to oxytocin. Each training session will last 90 minutes (1 hour training and 30 minutes between oxytocin administration and start of training).
88901163|NCT01517386||paravertebral anesthesia|patients scheduled for elective unilateral thoracic surgery under paravertebral block and general anesthesia
88901164|NCT01517399|Other|Test drug administration|All drugs except vitamin K will be administered as a single dose once by itself as a reference treatment and once with tivantinib
88901165|NCT01517425||Cases|Subjects previously enrolled in the Scripps Genebank Study
88901166|NCT01517425||Controls|Subjects previously enrolled in the Scripps Healthy Elderly Active Longevity (HEAL) Cohort
88901167|NCT01517464|Experimental|SGT-94|Dose escalation of experimental therapeutic SGT-94 to assess safety
88901168|NCT01517490||Type 1 Insulin Pump|Patients with type 1 diabetes starting insulin pump treatment
88901169|NCT01517490||Type 1 conventional therapy|Patients with type 1 diabetes continuing treatment with multiple daily insulin injections.
88901170|NCT01517490||Type 2 Bariatric surgery|Patients with type 2 diabetes who are enrolled in pre-operative weight loss protocol prior to bariatric surgery.
88901171|NCT01517490||Type 2 conventional|Severely obese patients with type 2 diabetes who are to continue with non-surgical treatments of diabetes and obesity and with no planned bariatric surgery.
88901172|NCT01517490||Type 1 insulin pumpe follow-up|Patients with type 1 diabetes previously followed in an observational study with electrophysiological and psychophysical measures of retinal function.
88901173|NCT01517490||Healthy|Healthy volunteers.
88901174|NCT01517503|Experimental|Cognitive Therapy (CT)|Cognitive Therapy (CT)
88901175|NCT01517503|Experimental|Acceptance and Commitment Therapy (ACT)|Acceptance and Commitment Therapy (ACT)
88901176|NCT01517516||Functional Pain Conditions and Inflammatory bowel disease|Cyclical Vomiting Syndrome, Irritable Bowel Syndrome, Inflammatory Bowel disease (Ulcerative colitis and Crohns)and Vulvodynia (vestibulodynia)
88901177|NCT01517516||Inflammatory Bowel Disease|Subjects diagnosed with Crohn's Disease or Ulcerative Colitis.
88901178|NCT01517542|Experimental|Nutritional counseling|It was composed by patients who received specific written orientation to follow the DASH diet recommendations. Calories were calculated with the goal of maintaining body weight and divided into 3 main meals and two to three snacks.
88901179|NCT01517542|No Intervention|Usual diet|It was composed by patients who were stimulated to follow the general orientations of the neurologist or keep their food intake habits
88901180|NCT01517555|Experimental|Liraglutide|
88901181|NCT01517555|Placebo Comparator|Placebo|
88901182|NCT01517568|Experimental|Liraglutide|
89194662|NCT00737646|Experimental|2|Clinic-focused intervention: The clinicians and clinical staff in each of the clinics will be scheduled for training sessions. The provider trainings will be designed for clinicians and clinical staff and will be conducted in at least two separate sessions of approximately 3 hours total duration. The sessions will be scheduled to accommodate the clinic schedule, but will be held with no more than 1 month between them. Participants in clinic training sessions will receive continuing education credit.
89194663|NCT00737646|Experimental|3|"Clinic-focused and patient focused intervention: The clinic focused-intervention as described in Arm 2 will be combined with a patient-focused intervention.~Patient focused intervention: CRC education packets, based upon previously developed CDC CRC patient education materials, have been adapted for each study site. These CRC educational packets will be mailed to average-risk patients aged 50-80 years who are due for CRC screening (based on electronic records) and who schedule a non-acute ambulatory care visit in clinics assigned to the patient-focused intervention. A cover letter signed by the patient's physician will be included with each packet. The packets will be mailed approximately 1 week before the medical appointment."
89194664|NCT00880672|Active Comparator|dutasteride|oral, 5mg, once per day, 2 weeks
89194665|NCT00880672|Placebo Comparator|placebo|oral, 5mg, once per day, 2 weeks
89194666|NCT04064034|Experimental|Subjects with pancreas cancer|Subjects will have blood collected and tested for Quiescin Sulfhydryl Oxidase 1 (QSOX1) protein with the lateral flow assay (LFA).
89194667|NCT04064034|Experimental|Subjects with non-cancerous disorders|Subjects will have blood collected and tested for Quiescin Sulfhydryl Oxidase 1 (QSOX1) protein with the lateral flow assay (LFA).
89194668|NCT04064034|Experimental|Subjects with pancreas cyst|Subjects already undergoing biopsy of a pancreas cyst will have cyst fluid collected and tested for Quiescin Sulfhydryl Oxidase 1 (QSOX1) protein with the lateral flow assay (LFA).
89194669|NCT00874666|Active Comparator|1|Positive control with 100% allicin bioavailability
89194670|NCT00874666|Experimental|2|garlic powder tablet
89194671|NCT00737724|Experimental|Group 1|Receives both, simultaneously antiretroviral therapy and antituberculosis therapy
89194672|NCT00737724|Experimental|Group 2|Receives only antituberculosis therapy, and 2 months afterwards antiretroviral therapy
89194673|NCT00880828|Experimental|A|FIR cervical collar plus Acetaminophen
89194674|NCT00880828|Active Comparator|B|Conservative cervical collar plus Acetaminophen
89194675|NCT00880828|Placebo Comparator|C|Acetaminophen only
89194676|NCT05741970|Active Comparator|IL-6 and CRP levels of the hypertensive and periodontitis group|All patients with periodontitis received phase I periodontal therapy including oral hygiene instruction (OHI) and scaling/root planning (SRP) without any antimicrobial therapy. GCF and saliva samples were obtained and clinical measurements were performed at baseline (before treatment (BT) and four weeks (4 weeks 3 days) after the phase I periodontal therapy (AT).
89194677|NCT05741970|No Intervention|IL-6 and CRP levels of the hypertensive and healthy group|GCF and saliva samples were obtained and clinical measurements were performed at baseline
89194678|NCT05741970|Active Comparator|IL-6 and CRP levels of the periodontitis and healthy group|All patients with periodontitis received phase I periodontal therapy including oral hygiene instruction (OHI) and scaling/root planning (SRP) without any antimicrobial therapy. GCF and saliva samples were obtained and clinical measurements were performed at baseline (before treatment (BT) and four weeks (4 weeks 3 days) after the phase I periodontal therapy (AT).
89421264|NCT04932616||Tele- Assessment Group Functional Gait Assessment|"The evaluation to be applied for the tele-evaluation reliability study of the scale:~Functional Gait Assessment"
89421265|NCT04932772|Experimental|Group A (kinesiotaping group)|include 24 women will receive kinesiotaping combined with abdominal exercise (2sessions /week for eight weeks).
88901183|NCT01517581||Malignant Disease with no visualized BAT|Children 18 years or younger who 1) had PET/CT scans with evidence of malignant disease but no metabolically active brown adipose tissue (BAT) at diagnosis and 2) were disease free within 1 year of diagnosis.
88901184|NCT01517607||Mesalazine|
88901185|NCT01517620|Experimental|Total Glucosides Paeony, Capsules|
88901186|NCT01517620|No Intervention|no intervention|
88901187|NCT01517633|Experimental|A device for identifying between amniotic fluid and urine|
88901188|NCT01517646|No Intervention|Fat Reduction|
88901189|NCT01517685|Experimental|Flax Oil and then Fish Oil|All people in the study will use the flax seed oil and then the fish oil.
88901190|NCT01517724|Experimental|Bortezomib consolidation|Bortezomib administered once a week 1.3mg/sq m; maximum of 8 cycles (each cycle is 4 weeks)
88901191|NCT01517789|Experimental|Patients|
88901192|NCT01517815|Experimental|No overweight patient|Patient with weight less than or equal to 120kg
88901193|NCT01517815|Experimental|Overweight patients|Patient with weight more than 120kg
88901194|NCT01517828|Experimental|Ketamine Arm|Phial of Ketamine (50mg/5ml) will be used and the dose administered will be 2 mg/kg.
88901195|NCT01517828|Active Comparator|Midazolam Arm|Phials of midazolam (5mg/5ml)will be used and the dose administered will be 0.2 ml/kg.
88901196|NCT01517841||Chronic kidney disease|Patients with chronic kidney disease (20% or less kidney function remaining. Patients with end stage renal disease who are currently receiving dialysis.
88901197|NCT01517854|Active Comparator|Revatio|
88901198|NCT01517854|Placebo Comparator|Placebo|
88901199|NCT01517906|Experimental|Cognitive behavioral counseling|
88901200|NCT01517906|Active Comparator|Supportive therapy|
88901201|NCT01517919|Experimental|Intervention: Peer Led Self-Management|Intervention: Peer Led Self-Management (PLSM) involves the DSME program followed by 12 months of peer-led ongoing self-management support
88901202|NCT01517919|No Intervention|Diabetes Self-Management Education|Control: Diabetes Self-Management Education (DSME) involves 12 sessions of self-management training including diabetes education, one-on-one sessions, bi-weekly phone contacts, and preparation for a clinic visit.
88901203|NCT01517932|Experimental|Group-DEX|Patients in this arm received dexmedetomidine 0.2 microgram per kg i.v. during 10 minutes 1 hour before the end of surgery
88901204|NCT01517932|Placebo Comparator|Group-PLB|Patients in this arm received saline placebo 0.05 ml per kilogram i.v. during 10 minutes 1 hour before the end of surgery
88901205|NCT01517958||Respiratory Distress Group|Neonates 28 weeks GA or greater with respiratory distress
88901206|NCT01517958||Control Group|Neonates 28 weeks GA or greater without respiratory distress.
88901207|NCT01517971||Ancillary-correlative (whole-genome expression)|RNA extracted from archived tumor tissue samples are analyzed for whole-genome expression profiling by Gene Profiling Array cGMP U133 P2 and RT-PCR.
88901208|NCT01517997|Experimental|Drug Coated Balloon (DCB) Arm|Patients included in this arm will undergo PTA with the use of a paclitaxel coated balloon.
88901209|NCT01517997|Active Comparator|Drug Eluting Stents (DES) Arm|Patients in this arm will undergo primary infrapopliteal stenting of the target lesion using a drug-eluting stent.
88901210|NCT01518010|Experimental|GamePlay|
88901211|NCT01518023||Cancer gastrectomy|Patients previously submitted to partial/total gastrectomy for gastric cancer
88901212|NCT01518023||Colorectal cancer operation|Patients previously submitted to right colectomy or rectosignoidectomy for cancer
88901213|NCT01518023||Bariatric patients|Morbidly obese participants who underwent antiobesity Roux-en-Y gastric bypass
88901214|NCT01518036|Experimental|Low dose|
88901215|NCT01518036|Experimental|High dose|
88901216|NCT01518062|Experimental|Low dose|
88901217|NCT01518062|Experimental|Medium dose|
88901218|NCT01518062|Experimental|High dose|
88901219|NCT01518075|Experimental|Non invasive mechanical ventilation|Evaluation of breathing swallowing interaction under non invasive mechanical ventilation
88901220|NCT01518075|Active Comparator|Spontaneous Breathing|Evaluation of breathing swallowing interaction without non invasive mechanical ventilation
88901221|NCT01518088|Experimental|Low dose dietary fiber|
88901222|NCT01518088|Experimental|High dose dietary fiber|
88901223|NCT01518088|Placebo Comparator|No added fiber|
88901224|NCT01518101|Experimental|Vildagliptin/Metformin followed by Liraglutide+Metformin|In period I, Patients receiving vildagliptin will receive a stable dose of 50mg vildagliptin bid (twice daily) + 1000mg metformin bid for 12 weeks. In period II, patients will receive 0.6mg liraglutide od (once daily) + 1000mg metformin bid for the first week (week 13 - week 14) and increase the dose after 7 days up to 1.2mg liraglutide od/1000mg metformin bid.
88901225|NCT01518101|Experimental|Liraglutide + Metformin followed by Vildagliptin/Metformin|In period I, patients will receive 0.6mg liraglutide od (once daily) + 1000mg metformin bid (twice daily) for the first week (week 0 - week 1) and increase the dose after 7 days up to 1.2mg liraglutide od/1000mg metformin bid (week 2 -12). In period II, patients will receive a stable dose of 50mg vildagliptin bid (twice daily) + 1000mg metformin bid for next 12 weeks.
89006803|NCT06178250|Other|placenta, fetal liver, sectional ductus venosus volumes between 24-29 weeks pregnant women|The placenta, fetal liver and ductus venosus volumes of 46 patients diagnosed with GDM and 93 patients without a GDM diagnosis between 24-29 weeks were evaluated with 3D ultrasound.
89006804|NCT06178237|No Intervention|Standard of care|Standard of care post-neck dissection
89421266|NCT04932772|Active Comparator|Group B (abdominal exercise group)|include 24 women will receive abdominal exercise only.
89421267|NCT04932304|Active Comparator|Active stimulation|Participants recieving active trancranial direct current stimulation (tDCS) Parameters: 20 minutes anodal tDCS 1mA. Two times a week, for three weeks. Anode placed at F3, cathode placed at right cerebellum.
89421268|NCT04932304|Placebo Comparator|Sham stimulation|Participants recieving passive / sham trancranial direct current stimulation (tDCS) Two times a week, for three weeks. Anode placed at F3, cathode placed at right cerebellum.
89421269|NCT01354353|Active Comparator|Aripiprazole|Part A: Continue current prescribed dosing regimen -- Study Day 1 to discharge (Study Day 21). Part B: Continue current prescribed dosing regimen (≤ 30 milligrams [mg]/day ) -- Study Day 1 to discharge (Study Day 23, 25 or 28 based on adaptive design)
89421270|NCT01354353|Experimental|Part A: 160 mg LY2140023|Administered orally, twice daily (BID) for 6 days (Study Days 10-15) and as a single morning dose on the 7th day (Study Day 16)
88901226|NCT01518114|Experimental|Exercise Training|"Exercise will be performed under continuous telemetry monitoring and medical supervision. Each session will include 5-10 worm-up, 30 min of aerobic activity on treadmill or bicycle ergometer followed by 10-15 min of stretch and relaxation exercise. Blood pressure will be obtained before the onset and at the end of each session. Participants will be requested to rest and observed 15-30 min before going home. The exercise intensity will be monitored and adjusted, per protocol, according to RPE using the Borg scale.~Exercise prescription will be based upon cardiopulmonary test done at baseline."
88901227|NCT01518114|Active Comparator|Best Medical Care|Advanced HCM patients who are eligible to participate in the study but cannot do so for technical reasons will be invited to participate in the project as a control group.These subjects will continue their regular follow up in the Cardiomyopathy Clinic and their usual voluntary physical activity at home.
88901228|NCT01516944|Active Comparator|postoperative chemotherapy,SOX|
88901229|NCT01516944|Experimental|Perioperative chemotherapy,SOX|
88901230|NCT01516944|Experimental|Perioperative chemotherapy,XELOX|
88901231|NCT01518127|Experimental|stem cell group|intravitreal injection of autologous bone marrow stem cells
88901232|NCT01518140|Experimental|VapoTherm|"Participants receive air through VapoTherm for 1 hour, and then on an as needed basis for up to 4 hours. Participants then receive air through bilevel positive airway pressure (BiPAP) for up to 30 minutes, followed by 30 minutes using non-rebreather mask."
88901233|NCT01518140|Experimental|BiPAP|"Participants receive air through bilevel positive airway pressure (BiPAP) for 1 hour, and then on an as needed basis for up to 4 hours. Participants then receive air through VapoTherm for up to 30 minutes, followed by 30 minutes using non-rebreather mask."
88901234|NCT01518140|Experimental|Non-Rebreather Mask|"Participants receive air through Non-Rebreather Mask for 1 hour, and then on an as needed basis for up to 4 hours. Participants then receive air through VapoTherm for up to 30 minutes, followed by 30 minutes using bilevel positive airway pressure (BiPAP)."
88901235|NCT01518166|Experimental|Trial period A|
88901236|NCT01518166|Experimental|Trial period B|
88901237|NCT01518179|Experimental|Made-to-Measure Compression Gloves|Made-to-Measure Compression Gloves in addition to routine follow up and treatment.
88901238|NCT01518179|Other|Control|Routine follow up and treatment
89006805|NCT06178237|Experimental|Standard of care plus Purabond|Standard of care post-neck dissection plus Purabond
89006806|NCT06178224||Participants (qualified)|This arm consists of participants who are able to collect all sample types No intervention is administered
89006807|NCT06178211|Experimental|adebrelimab and chemotherapy|
89194679|NCT05741970|No Intervention|IL-6 and CRP levels of the systemically and periodontally healthy group|GCF and saliva samples were obtained and clinical measurements were performed at baseline
89194680|NCT00883402|Active Comparator|CEA|Carotid endarterectomy
89194681|NCT00883402|Active Comparator|CAS|Carotid Artery Stenting
89194682|NCT00422461|Placebo Comparator|Placebo|
89194683|NCT00422461|Experimental|PF-00489791 20 mg titrated to 40 mg|
89194684|NCT00422461|Experimental|PF-00489791 4 mg|
89194685|NCT00422461|Experimental|PF-00489791 10 mg|
89194686|NCT04346134|Experimental|mini-PNL group|In which percutaneous nephrolithotomy will be performed using miniature nephroscope.
89194687|NCT04346134|Experimental|SWL group|In which extracorporeal shock wave lithotripsy will be performed using Dornier lithotripter SII
89194688|NCT00712920|Placebo Comparator|1|Placebo
89194689|NCT00712920|Experimental|2|0.15% azelastine hydrochloride 1644 mcg/2 sprays per nostril 2 times a day for 4 weeks
88901239|NCT01518205|Experimental|LDL-apheresis and TT|"The patient of the experimental Arm, in addition to Traditional Therapy (TT), will undergo a cycle of 10 LDL-apheresis session.~Apheretic treatment scheme: 10 apheretic session carried out as follow: first and second apheresis with a 3 days interval (i.e. 2 treatment in one week), then one session per week (every 7 days).~To perform the treatment, the forearm surface veins will be punctured by means of 17 Ga needles, as an alternative a two-ways CVC will be used."
88901240|NCT01518205|No Intervention|Traditional Treatment|"All patients will receive the traditional treatment for the ulcer healing Standardized medication.~All lesions taken into consideration will be treated in a standardized way, with a different approach according to the presence of a possible infection.~The evolution of lesions might be documented by means of mapping the same by drawing their profiles on an Opsite film.~antibiotics therapy (according to antibiogram). Anti-platelet therapy. Statin therapy."
88901241|NCT01518231|Experimental|cell transplantation|The study group will not only be implanted with autologous hematopoietic stem cells, but also receive drug therapy.
88901242|NCT01518231|No Intervention|Convention therapy|The control group just receive drug therapy.
88901243|NCT01518283|Experimental|Cabazitaxel|Drug: Cabazitaxel 10 mg/m2
88901244|NCT01518296|Experimental|Patients referred to urodynamic test|Patients that are referred to urogynecology and the pelvic reconstruction unit undergoes a physical gynecological examination and a urodynamic test, During which the degree of pelvic organs prolapse is evaluated with full and empty bladder.
88901245|NCT01518335|Experimental|Platelet Rich Plasma|Patients receive Platelet rich plasma injection + standard of care therapy(bandaging or boot and crutches) + non-NSAID pain medicine
88901246|NCT01518335|Placebo Comparator|Placebo/Standard of Care|Patient receives Placebo Comparator: Placebo/Standard of Care [saline injection + standard of care (bandaging or boot and crutches)] + non-NSAID pain medicine
88901247|NCT01518348|Experimental|Patch Test|
88901248|NCT01518387|Experimental|Arm 1|750-2250mg/day, tid, 8 weeks
88901249|NCT01518413|Experimental|Combination Therapy|Three to 6 patient will be enrolled at each dose level and dose escalations will proceed in the absence of dose-limiting toxicity attributed to therapy, first with dose escalation of sorafenib and then, if tolerated, escalation of irinotecan.
88901250|NCT01518426|Experimental|Extraction of P300 ERPs|Extract P300 ERPs with Emotiv EEG headset
88901251|NCT01518439|Experimental|neuromuscular patients|neuromuscular patients with cough inefficiency in a stable respiratory state upon inclusion
88901252|NCT01518452|Experimental|working memory training|Cogmed JM working memory training
88901253|NCT01518452|Experimental|delayed working memory training|Cogmed JM working memory training after 8 weeks waiting
88901254|NCT01518465|Experimental|Arm I (5000 IU dalteparin)|Patients receive a prophylactic dose of dalteparin SC on days 1-28; lenalidomide PO on days 1-21; and low-dose dexamethasone PO on days 1, 8, 15, and 22.
88901255|NCT01518465|Experimental|Arm II (200 IU/kg dalteparin)|Patients receive a therapeutic dose of dalteparin SC on days 1-21 and lenalidomide PO and low-dose dexamethasone PO as in Arm I.
88901256|NCT01518478|Other|20 Non-atopic|Non-atopic, healthy control.
88901257|NCT01518478|Other|20 ADEH- (mild to severe AD)|Atopic Dermatitis without previous or current Eczema Herpeticum.
88901258|NCT01518491|Experimental|NanoDOX Hydrogel plus VAC|NanoDOX™ Hydrogel in conjunction with serial wound debridement and irrigation on open traumatic orthopedic and soft tissue wounds in patients receiving negative pressure wound therapy/vacuum assisted closure (NPWT/VAC) with reticulated open cell foam (ROCF) dressings.
88901259|NCT01518491|Active Comparator|VAC Alone|Serial wound debridement and irrigation alone in patients receiving negative pressure wound therapy/vacuum assisted closure (NPWT/VAC) with reticulated open cell foam (ROCF) dressings.
88901260|NCT01518504|Experimental|Thoracic Mobilization|The subject will be in a prone position and the physical therapist will first identify the upper thoracic spine region. The physical therapist will then cross his or her hands and place them on opposite sides of the spinous processes using the pisiforms as the contact area. The subject will be asked to exhale and upon exhalation the physical therapist will apply a small amplitude, quick thrust at end of range.
88901261|NCT01518504|Sham Comparator|Sham|The subject will be in a prone position and the physical therapist will first identify the upper thoracic spine region. The physical therapist will then cross his or her hands and place them on opposite sides of the spinous processes using the pisiforms as the contact area. The subject will be asked to exhale and upon exhalation the physical therapist will not apply any other force than light hand contact.
88901262|NCT01518543||ASTUS|Patient candidate for an arthrodesis in the following joints:Ankle,1st MTP, Metatarso - Cuneiform (1st), Navicular - Cuneiform, Talo-Navicular, Calcaneum - Cuboid, and whose surgeon has recommended the implantation of an ASTUS Staple from Newdeal-INTEGRA.
88901263|NCT01518569|Placebo Comparator|placebo|normal saline, same amount, iv
88901264|NCT01518569|Active Comparator|ulinastatin|5000 unit/kg iv
88901265|NCT01518582||Radiculopathy Cervical|Radiculopathy, Cervical
88901266|NCT01518595|Placebo Comparator|placebo|Patients will receive placebo tablets twice daily for 3 months.
88901267|NCT01518595|Active Comparator|bosentan|pts. will receive bosentan for 3 months
88901268|NCT01518621|Active Comparator|Radiotherapy alone|Total brain irradiation, 3Gy x10
88901269|NCT01518621|Experimental|Radiation plus erlotinib|Total brain irradiation, 3Gy x10 plus erlotinib 150 mg q d from radiation day -1 through last day of irradiation
88901270|NCT01518634|Experimental|Imipramine treatment|
89421271|NCT01354353|Experimental|Part A: 240 mg LY2140023|Administered orally BID for 6 days (Study Days 10-15) and as a single morning dose on the 7th day (Study Day 16)
89421272|NCT01354353|Experimental|Part A: 320 mg LY2140023|Administered orally BID for 6 days (Study Days 10-15) and as a single morning dose on the 7th day (Study Day 16)
88901271|NCT01518634|Placebo Comparator|Placebo|
88901272|NCT01518647|Experimental|Group Therapy|ACT given as conventional group therapy in groups of 7-8 patients 3,5 hours each session, 9 sessions during 3 month
88901273|NCT01518647|Experimental|Workshop|ACT given as a one-day workshop with 15 patients with a following individual consultation
88901274|NCT01518647|Active Comparator|Standard treatment|Standard treatment is one single advisory consultation given 2 weeks after randomization
88901275|NCT01518660|Experimental|Training|
88901276|NCT01518660|No Intervention|Control|
88901277|NCT01518686|No Intervention|one arm|observational study, no cohort, single group of different ages
88901278|NCT01518712|Experimental|Treatment Sequence AB|
88901279|NCT01518712|Experimental|Treatment Sequence BA|
88901280|NCT01518725|Experimental|Vitamin D Supplementation|The vitamin D supplementation will consist of 100 mcg of vitamin D/d, to be taken throughout the day. Participants will achieve 100 mcg by taking 2 x 25 mcg capsules per day. One will be taken at each time point (i.e., morning and evening) throughout the day.
88901281|NCT01518725|Placebo Comparator|Gel-like Substance|Participants in the placebo group will receive a capsule containing the inactive ingredients that include cellulose and silica to create a gel-like substance
88901282|NCT01518738|Experimental|breath attention training|
88901283|NCT01518738|Active Comparator|working memory attention training|
88901284|NCT01518738|No Intervention|no training|
88901285|NCT01518764|Experimental|Red Wine Polyphenols|Red Wine Polyphenols 600mg/day (capsules)
88901286|NCT01518764|Placebo Comparator|placebo|placebo (capsules)
88901287|NCT01518777|Other|Half-dose isotope for NuclearStressTest|"Intervention is Nuclear stress test of the heart. Single-arm of this study Half-dose of isotope for Nuclear stress test is group of study subjects who will do Research Nuclear stress test with half-dose of isotope that normally used for routine Nuclear stress test. Isotope is the tracer CZT (cadmium zinc telluride) that used for Nuclear stress test routinely to see the function of arteries of the heart. Patients with suspected Coronary Artery Disease who meet entry criteria undergo a research nuclear stress test using a decreased dose of isotope, using a new camera."
88901288|NCT01518790|Experimental|Polyethylene glycol 3350|
89421273|NCT01354353|Experimental|Part A: 400 mg LY2140023|Administered orally BID for 6 days (Study Days 10-15) and as a single morning dose on the 7th day (Study Day 16)
89421274|NCT01354353|Experimental|Part A: 480 mg LY2140023|Administered orally BID for 6 days (Study Days 10-15) and as a single morning dose on the 7th day (Study Day 16)
88901289|NCT01518803|Active Comparator|Mediterranean-style breakfast|
88901290|NCT01518803|Active Comparator|Western-style breakfast|
88901291|NCT01518816||preterm labor cases|Group A: 35 pregnant women diagnosed with preterm labor(Preterm labor pain at least 3 contraction every 20 minutes ,cervical dilatation < 2cm and effacement< 50%) which will deliver within one week maximum after hospitalization.
88901292|NCT01518816||control group|Group B: 35 pregnant women( controls )with uncomplicated pregnancies at a similar gestational ages followed routinely in the antenatal care unit.
88901293|NCT01518842|Experimental|test group intravitreal stem cell|"Open-label study of Ischemic Retinopathy patients with best-corrected visual acuity (BCVA) worse than 20/200.~Intervention: Biological: intravitreal injection of autologous bone marrow stem cells"
88901294|NCT01518855|Experimental|Arm 1|Adalat CR 20-40mg od + Diovan 40-80mg od
88901295|NCT01518855|Active Comparator|Arm 2|Norvasc 2.5-5mg od + Diovan 40-80mg od
88901296|NCT01518881|Experimental|TKM-100201|
88901297|NCT01518881|Placebo Comparator|Placebo|
88901298|NCT01518894|Experimental|PF-04958242|
88901299|NCT01518894|Placebo Comparator|Placebo|
88901300|NCT01518907|Experimental|AA4500 0.0029 mg in 1 mL|
88901301|NCT01518907|Experimental|AA4500 0.0145 mg in 5 mL|
88901302|NCT01518907|Experimental|AA4500 0.0145 mg in 1 mL|
88901303|NCT01518907|Experimental|AA4500 0.0435 mg in 5 mL|
88901304|NCT01518907|Experimental|AA4500 0.0435 mg in 1 mL|
88901305|NCT01518907|Experimental|AA4500 0.116 mg in 5 mL|
88901306|NCT01518907|Experimental|AA4500 0.116 mg in 1 mL|
88901307|NCT01518907|Experimental|AA4500 0.232 mg in 5 mL|
88901308|NCT01518907|Experimental|AA4500 at 0.232 in 1 mL|
88901309|NCT01518907|Experimental|AA4500 0.464 mg in 5 mL|
88901310|NCT01518907|Experimental|AA4500 0.464 mg in 1 mL|
88901311|NCT01518920|Experimental|PF-04958242|
88901312|NCT01518920|Placebo Comparator|Placebo|
88901313|NCT01518933|Experimental|Silibilin (Legalon-SIL)|20 mg/kg Silibinin (Legalon SIL) ,as per randomization schedule, will be administered daily as a 2-h infusion for 14 days.
88901314|NCT01518933|Placebo Comparator|Saline|Placebo (saline), as per randomization schedule, will be administered daily as a 2-h infusion for 14 days.
88901315|NCT01518959|Placebo Comparator|Placebo|no treatment
88901316|NCT01518959|Active Comparator|Cholecalcipherol|Treatment with 180 000 IU cholecalcipherol monthly
88901317|NCT01518985|Placebo Comparator|Placebo|Intravenous infusion of saline (0.9%) for 4 hours with smoking of one unfiltered cigarette at 30 minutes post-study-drug administration start
89194690|NCT00712920|Experimental|3|0.1% azelastine hydrochloride 1096 mcg/2 sprays per nostril 2 times a day for 4 weeks
89421275|NCT01354353|Experimental|Part B: LY2140023|If doses up to or equal to 400 mg BID are not tolerated, Part B of the study may be started. The dose of LY2140023 will be titrated in the same participant from highest dose that was tolerated in Part A, with the intention to reach a dose of 480 mg LY2140023.
89421276|NCT04932538|No Intervention|Control Group|Every group received routine traditional physiotherapy twice a week over the period of 4 weeks. This routine traditional treatment consisted of stretching, weight bearing, functional reaching, walking, and electrotherapy.
89421277|NCT04932538|Experimental|Kinesio Taping|Every group received routine traditional physiotherapy twice a week over the period of 4 weeks. This routine traditional treatment consisted of stretching, weight bearing, functional reaching, walking, and electrotherapy. Sessions were 40 minutes. The children in the taping group were taped 6 days per week for 4 weeks. The children were checked for allergies before applying the tape. A 5-cm tape was applied and kept in position for 3 days, and the region was then left to rest for 24 hours.
89421278|NCT02622568|Active Comparator|Cryotherapy and Veregen|Cryotherapy will be performed on the day of first clinic visit according to current standard of care in Children's Medical Center pediatric outpatient dermatology clinic, which consists of two freeze/thaw cycles for maximum of 10 seconds each. Sinecathecins 15% ointment will be prescribed and initiated immediately following the day of first clinic visit. Sinecathecins 15% ointment will be applied to verrucous lesions twice daily. Follow-up clinical visits will be required at 0 weeks, 6 weeks, and 12 weeks. Clinical photos will be taken at each visit. Verrucae will be measured at each visit using a standard ruler. Outcome measures will be numerical reduction in diameter of verruca.
89421279|NCT02622568|Experimental|Veregen only|Veregen ™or sinecathecins 15% ointment will be prescribed and initiated immediately following the day of first clinic visit. Veregen ™ or sinecathecins 15% ointment will be applied to verrucous lesions twice daily per current Children's Medical Center protocol. Follow-up clinical visits will be required at 0 weeks, 6 weeks, and 12 weeks. Clinical photos will be taken at each visit. Verrucae will be measured at each visit using a standard ruler. Outcome measures will be numerical reduction in diameter of verruca.
89421280|NCT04932460|Experimental|CEUS+blue dye|The included patients will accept essential tests and CEUS before and after neoadjuvant chemotherapy to evaluate axillary lymph nodes status. When patients finish neoadjuvant therapy, SLNB with or without axillary lymph node dissection will be performed using CEUS lymphatic mapping to mark SLN on the skin combined with blue dye.
89421281|NCT04326309||Cohort 1|Individual Application Downloaders
89421282|NCT04326309||Cohort 2|Public Space and Vehicle Data Capture
89421283|NCT04326309||Cohort 3|Individuals dialing a voice-recording study phone number
89421284|NCT04326309||Cohort 4|Individuals utilizing study website's audio recording functionality
89421285|NCT04326309||Cohort 5|Individuals participating in Return-to-Work Project
89421286|NCT04932070|Experimental|Berberine|2 daily oral doses (one before lunch and one dinner) of 550 mg of berberine tablets
88901318|NCT01518985|Experimental|Bendavia|Intravenous infusion of Bendavia (0.25mg/kg/hr) for 4 hours with smoking of one unfiltered cigarette at 30 minutes post-study-drug administration start
88901319|NCT01518998|Placebo Comparator|Placebo|Take one double-blind capsule filled with a placebo tablet in the every morning
88901320|NCT01518998|Active Comparator|Fimasartan 60mg|Take one double-blind capsule filled with of Fimasartan 60mg in the every morning
88901321|NCT01518998|Active Comparator|Fimasartan 30mg|Take one double-blind capsule filled with Fimasartan 30mg in the every morning
88901322|NCT01518998|Active Comparator|Amlodipine 5mg|Take one double-blind capsule filled with Amlodipine 5mg in the every morning
88901323|NCT01518998|Active Comparator|Amlodipine 10mg|Take one double-blind capsule filled with Amlodipine 10mg in the every morning
88901324|NCT01518998|Experimental|Fimasartan 60mg/ Amlodipine 5mg|Take one double-blind capsule filled with Fimasartan 60mg and Amlodipine 5mg in the every morning
88901325|NCT01518998|Experimental|Fimasartan 60mg/Amlodipine 10mg|Take one double-blind capsule filled with Fimasartan 60mg and Amlodipine 10mg in the every morning
88901326|NCT01518998|Experimental|Fimasartan 30mg/Amlodipine 5mg|Take one double-blind capsule filled with Fimasartan 30mg and Amlodipine 5mg in the every morning
88901327|NCT01518998|Experimental|Fimasartan 30mg/Amlodipine 10mg|Take one double-blind capsule filled with Fimasartan 30mg and Amlodipine 10mg in the every morning
88901328|NCT01519011|Experimental|1: A, B, C|"Dose A: Single oral administration with three 100-mg tablets under fasted condition Dose B: Single oral administration with two 150-mg tablets under fasted condition.~Dose C: Single oral administration with two 150-mg tablets under fed condition."
88901329|NCT01519011|Experimental|2: B, C, A|"Dose A: Single oral administration with three 100-mg tablets under fasted condition Dose B: Single oral administration with two 150-mg tablets under fasted condition.~Dose C: Single oral administration with two 150-mg tablets under fed condition."
88901330|NCT01519011|Experimental|3: C, A, B|"Dose A: Single oral administration with three 100-mg tablets under fasted condition Dose B: Single oral administration with two 150-mg tablets under fasted condition.~Dose C: Single oral administration with two 150-mg tablets under fed condition."
88901331|NCT01519011|Experimental|4: B, A, C|"Dose A: Single oral administration with three 100-mg tablets under fasted condition Dose B: Single oral administration with two 150-mg tablets under fasted condition.~Dose C: Single oral administration with two 150-mg tablets under fed condition."
89421287|NCT03070899|Experimental|OBE2109 dose 1 (100mg) + Placebo Add-back|
89421288|NCT03070899|Experimental|OBE2109 dose 1 (100mg) + Add-back|
89421289|NCT03070899|Experimental|OBE2109 dose 2 (200mg) + Placebo Add-back / OBE2109 dose 2 (200 mg) + Add-back|
89421290|NCT03070899|Experimental|OBE2109 dose 2 (200mg) + Add-back|
89421291|NCT03070899|Placebo Comparator|Placebo + Placebo Add-back / OBE2109 dose 3 (200mg) + Add-back|At W24, half of the patients switched to active treatment, while half remained on Placebo; the switch was defined at randomization.
89421292|NCT04931680||Patients with treatment success|"Patients with diagnosis of confirmed or clinical scabies and treatment success"
89421293|NCT04931680||Patients with treatment failure|"Patients with diagnosis of confirmed or clinical scabies and treatment failure"
89421294|NCT04931992||Molecular relapse|Confirmed molecular relapse, without overt cytological relapse
89421295|NCT04931992||Cytological relapse|Overt cytological relapse, without prior molecular relapse
89421296|NCT04931992||Persistent responders|No molecular or cytological relapse during follow-up
89530811|NCT02510963|Experimental|Tenofovir 28 week|Pregnant women with high HBV DNA load in serum and normal liver function were treated with Tenofovir Disoproxil Fumarate 300 mg/day from 28 weeks of gestation to 1 month postpartum
89421297|NCT04931524|Experimental|carbon-14-[14C]-ANG-3777|Administered IV as a single dose over 30 minutes on the morning of Day 1 following an 8 hour overnight fast and remain in the clinical unit until up to 168 hours after dosing (to Day 8). If mass balance criteria have not been met on Day 8, the clinical unit residency may be extended up to an additional 96 hours (to Day 12).
89421298|NCT03820167||Fresh sample|"Morphologically good embryos will be cultured in a culture dish and the supernatants will be collected freshly from culture system at day 3 and stored at -20 ̊ c until being tested.~Quantification of mtDNA in fresh and frozen culture media using qPCR technique."
88901332|NCT01519011|Experimental|5: A, C, B|"Dose A: Single oral administration with three 100-mg tablets under fasted condition Dose B: Single oral administration with two 150-mg tablets under fasted condition.~Dose C: Single oral administration with two 150-mg tablets under fed condition."
88901333|NCT01519011|Experimental|6: C, B, A|"Dose A: Single oral administration with three 100-mg tablets under fasted condition Dose B: Single oral administration with two 150-mg tablets under fasted condition.~Dose C: Single oral administration with two 150-mg tablets under fed condition."
89421299|NCT03820167||Frozen embryos|Morphologically good embryos scheduled for freezing will be cryopreserved for less than one year and thawed, the supernatant will be collected and stored at -20 ̊ c until being tested. Quantification of mtDNA in fresh and frozen culture media using qPCR technique.
88901334|NCT01519011|Experimental|Extension|300-mg (three 100-mg tablets) once daily for 21 days of a 28-day cycle.
88901335|NCT01519024||Women with breast hypertrophy|Fourteen women with breast hypertrophy
88901336|NCT01519024||Women without breast hypertrophy.|Fourteen women without breast hypertrophy for de control group (CG).
88901337|NCT01518829||Patients with hepatocellular carcinoma|Patients with hepatocellular carcinoma who will undergo locoregional therapy
88901338|NCT01518829||patients with chronic liver disease|patients with chronic liver disease, as a control group
88901339|NCT01519037|Active Comparator|calcimimetic agent (cinacalcet)|3 days of a low-sodium diet (50 mmol of Na+ per day, equivalent to 3 grams of salt/day), followed by an investigation day at the hospital during which the subjects will be studied before and after exposure to the cinacalcet or the placebo. The 2 periods will be separated by a therapeutic wash-out lasting 14-28 days. The total length of the study per participant will be 1, max. 2 months
88901340|NCT01519037|Placebo Comparator|Placebo|3 days of a low-sodium diet (50 mmol of Na+ per day, equivalent to 3 grams of salt/day), followed by an investigation day at the hospital during which the subjects will be studied before and after exposure to the cinacalcet or placebo. The 2 periods will be separated by a therapeutic wash-out lasting 14-28 days. The total length of the study per participant will be 1, max. 2 months
88901341|NCT01519102|Active Comparator|CHO-independent partial insulin bolus with closed-loop|
88901342|NCT01519102|Active Comparator|CHO-dependent full insulin bolus combined with closed-loop|
88901343|NCT01519115|Active Comparator|Usual care|usual care of one physical therapy visit in hospital after ACF surgery
88901344|NCT01519115|Experimental|Early physical therapy intervention|early physical therapy program instructed and followed at home for 6 weeks
88901345|NCT01519128|Experimental|Treatment sequence AB|In Treatment A, digoxin 0.5 mg (single oral dose) will be administered on Day 1. In Treatment B, TMC278 at 25 mg, once daily will be administered for 16 days, with digoxin 0.5 mg (single oral dose) administered in the morning on Day 11.
89194691|NCT01037647||Type 2 diabetic men|Men with type 2 diabetes
89194692|NCT01037647||Healthy men|Healthy men
89194693|NCT00874744|Experimental|bevacizumab|
89194694|NCT00874744|Experimental|Triamcinolone|
89194695|NCT03993769|Experimental|A19010-F, B19010-F Use Group|Use of product A19010-F exclusively for 4 days prior to a PK assessment for plasma nicotine concentrations, followed by use of product B19010-F exclusively for 4 days prior to a PK assessment for plasma nicotine concentrations.
89194696|NCT03993769|Experimental|B19010-F, A19010-F Use Group|Use of product B19010-F exclusively for 4 days prior to a PK assessment for plasma nicotine concentrations, followed by use of product A19010-F exclusively for 4 days prior to a PK assessment for plasma nicotine concentrations.
89421300|NCT04431310||Serial seroconversion measurements in hospital employees|Serial seroconversion measurements in hospital employees during the COVID-19 pandemic
89421301|NCT04931446||Gastroenteropancreatic neuroendocrine neoplasms|
89421302|NCT04930510||Group 1 : Elderly 80 years or over patients referred for TAVI with CAD|Elderly 80 years or over patients referred for TAVI with CAD Group 1: Coronary lesion defined as significant (>50% narrowing) on the coronary angiography performed before TAVI, with or without PCI (decision of the heart team) Description of the coronary lesions included: proximal/non proximal, number of lesions, location of lesion
89421303|NCT04930510||Group 2 : No significant coronary disease group|No significant coronary disease group in the cohort of elderly 80 years or over referred for TAVI
89421304|NCT03562611|Active Comparator|flurbiprofen axetil|flurbiprofen axetil intraoperative administration 100mg
89421305|NCT03562611|Experimental|nalbuphine|nalbuphine intraoperative administration 0.1mg/kg
89421306|NCT03562611|Experimental|nalbuphine and flurbiprofen axetil|flurbiprofen axetil intraoperative administration 100mg and nalbuphine intraoperative administration 0.1mg/kg
88901346|NCT01519128|Experimental|Treatment sequence BA|In Treatment B, TMC278 at 25 mg, once daily will be administered for 16 days, with digoxin 0.5 mg (single oral dose) administered in the morning on Day 11. In Treatment A, digoxin 0.5 mg (single oral dose) will be administered on Day 1.
89421307|NCT04930120||Transferred group|The transferred group includes all severe COVID patients admitted in a French ICU ward and then transferred between the 03/13/2020 and 04/10/2020 to another ICU located outside the region of the initial ICU stay.
89421308|NCT04930120||Control group|The control group includes patients selected out of those whose entire ICU care has taken place in one of the hospitals which transferred patients. Up to 4 control patients will be selected for each transferred patient.
89421309|NCT04930276|Experimental|GDM group|After participants are enrolled, they would be given medical nutrient treatment. Besides, they need have a follow-up visit every two weeks. Blood glucose, body weight, lifestyle and clinical information are collected. Blood samples and stool samples are collected in 28 and 32 pregnant weeks, respectively.
89421310|NCT04930276|Other|non-GDM group|After participants enrollment, they also would be given medical nutrient treatment. And the other conditions are same as the group of GDM.
89421311|NCT04442763|Experimental|Densah burs|Osseodensification using Densah burs
89421312|NCT04442763|Active Comparator|Standard drills|conventional drilling using standard drills
89421313|NCT03057574|Experimental|Treatment|Follitropin Alfa (Gonapure)
89421314|NCT04929964||Breast cancer|
89421315|NCT03056950|No Intervention|non-oclusion training group|The control (non-occlusion training) group will follow the standard s/p distal radius fracture rehabilitation protocol. Treatment will include passive, active assistive,active range of motion (P/AA/AROM) to wrist, forearm and hand; desensitization as needed; edema control as needed; heat/cold modalities as needed; and strengthening exercises.
89421316|NCT03056950|Active Comparator|occlusion traingn with tourniquet|The occlusion training group will follow the same protocol as described above but will utilize occlusion training with the strengthening exercises. Investigators will use an established occlusion training protocol already being used. Intervention: Occlusion training with tourniquet (DELFI PTS ii portable tourniquet system)
89421317|NCT03057028|Experimental|anakinra|Patients will be treated with anakinra, injected SQ daily in a dose of 100mg for 14 days. Before and after this intervention, patients will undergo cardiopulmonary exercise testing (as well as echocardiography, EKG analysis, and serologic analysis). Subjects will be assessed for changes in exercise capacity, as determined by peak oxygen uptake and ventilatory efficiency to CO2 production slope.
89421318|NCT04406961|Active Comparator|Standard sphincterotomy.|"Standard retrograde sphincterotomy is performed on 750 patients using a standard sphincterotome. After deep bile duct cannulation, the standard sphincterotome, the Erlangen pull-type model, retrogradely cuts all layers of the wall of the duodenum and sphincter of Oddi. Precut papillotomy using a needle knife used in 20% to improve insert standard sphincterotome to bile duct. The number of patients with complications is calculated: bleeding, perforation, pancreatitis, cholangitis, acute cholecystitis, recurrent cholangiolithiasis, restenosis."
88901347|NCT01519154|Active Comparator|Propofol|Propofol 10 mg/h as maintenance infusion
88901348|NCT01519154|Experimental|Ketamine-Propofol|Additional Ketamine at induction, Propofol 5 mg/h as maintenance infusion
88901349|NCT01519180||Control group|Healthy volunteers
88901350|NCT01519180||Idiopathic gastroparesis|Idiopathic gastroparesis
88901351|NCT01519193|Experimental|Narrative Exposure Therapy|
88901352|NCT01519193|No Intervention|No treatment control|
89421319|NCT04406961|Active Comparator|Antegrade sphincterotomy. ASD.|750 patients underwent a new antegrade sphincterotomy using the new sphincterotome design developed by Dr. Dovbenko (ASD). After deep bile duct cannulation, the new design of sphincterotome, antegradely cuts only circular muscle layer of the sphincter of Oddi. Precut papillotomy using a needle knife used in 20% to improve cannulation new design sphincterotome to bile duct. The number of patients with complications is calculated: bleeding, perforation, pancreatitis, cholangitis, acute cholecystitis, recurrent cholangiolithiasis, restenosis.
89421320|NCT04929652|Experimental|Advanced CRC|Patients with Advanced CRC were given Surufatinib Combine With Immunotherapy and Chemotherapy.
88901353|NCT01519219||Hepatic Irradiation|
88901354|NCT01519232||Liver Irradiation|patients already scheduled to undergo liver irradiation
88901355|NCT01519258|Active Comparator|PSV|Patients will be ventilated with the a conventional mode of ventilation called Pressure Support Ventilation (PSV) for 15 minutes. Mechanical ventilator settings will be set to match the tidal volume applied by the ICU team, in accordance to current standard of care recommendations.
88901356|NCT01519258|Experimental|NAVA|Patients will be ventilated with NAVA for 15 minutes. Nava level will be titrated prior to randomization, to deliver the same peak of airway pressure obtained with the active comparator, PSV. The resulting tidal volume should match the tidal volume applied by the ICU team, in accordance to current standard of care recommendations.
88901357|NCT01519297|Other|Single arm intervention|Irbesartan 150 mg orally for one dose
89421321|NCT04929574||beta thalassemia patients|
89421322|NCT04394949|Active Comparator|Business as Usual Arm|Consumers will usual care
89421323|NCT04394949|Experimental|Experimental Arm|Center for Independent Living (CIL) consumers randomized to work with a group of CIL employees who received training in SOAR, Customized Employment, Supported Employments, and Benefits Planning (CWIC).
89421324|NCT04929418|Other|10 km continuous running|Participants will perform a test of 10 km coninuous running.
89421325|NCT04929418|Other|1.5 km swimming|Participants will perform a test of 1.5 km coninuous swimming.
89421326|NCT04929340|Experimental|experimental|5 drops each day before bedtime but after toothbrushing. L. reuteri DSM 17938, L. reuteri ATCC PTA 5289, with a minimum of 100 million live bacteria of each strain.
89421327|NCT04929340|Placebo Comparator|placebo|5 drops each day before bedtime but after toothbrushing. The placebo drops had identical composition color and taste but no probiotic bacteria.
89421328|NCT04929106|Experimental|MHealth intervention|Tailored physical activity program with motivational mobile health support on everyday levels of physical activity
88901358|NCT01519310|Active Comparator|Group 1|Group 1 (Antibiotics/probioitic):
88901359|NCT01519310|Active Comparator|Group 2|Group 2 (Antibiotics/no-probiotic):
88901360|NCT01519310|Active Comparator|Group 3|Group 3 (no-Antibiotics/probiotic):
88901361|NCT01519336|Active Comparator|A danoprevir|
89421329|NCT01353963||1|
89421330|NCT04928404|Other|obstructive sleep apnea patients|
89421331|NCT04928170||HALLOA|306 individuals with knee pain in the age between 30 and 65 years, without cruciate ligament injury
89421332|NCT04927936|Active Comparator|Janssen vaccine only|"HCW already vaccinated with Janssen vaccine once. 84 days after the first vaccination, blood samples will be drawn (day =0, baseline) This will be repeated at day 28 (primary endpoint), day 180 and day 365. This arm will have 87 +25% seropositive for SARS-CoV-2 IgG at baseline or loss to follow-up = 108 participants.~In this arm half of the participants will undergo a detailed immunological assessment (n=54 per arm)."
89421333|NCT04927936|Experimental|Janssen vaccine - Janssen vaccine|"HCW already vaccinated with Janssen vaccine once. 84 days after the first vaccination a boost will be given with Janssen vaccine and blood samples will be drawn (day =0, baseline) This will be repeated at day 28 (primary endpoint), day 180 and day 365. This arm will have 87 +25% seropositive for SARS-CoV-2 IgG at baseline or loss to follow-up = 108 participants.~In this arm half of the participants will undergo a detailed immunological assessment (n=54 per arm)."
89421334|NCT04927936|Experimental|Janssen vaccine - Moderna vaccine|"HCW already vaccinated with Janssen vaccine once. 84 days after the first vaccination a boost will be given with Moderna vaccine and blood samples will be drawn (day =0, baseline) This will be repeated at day 28 (primary endpoint), day 180 and day 365. This arm will have 87 +25% seropositive for SARS-CoV-2 IgG at baseline or loss to follow-up = 108 participants.~In this arm half of the participants will undergo a detailed immunological assessment (n=54 per arm)."
89530812|NCT02510963|Active Comparator|Tenofovir 32 week|Pregnant women with high HBV DNA load in serum and normal liver function were treated with Tenofovir Disoproxil Fumarate 300 mg/day from 32 weeks of gestation to 1 month postpartum
89530813|NCT03241147|Experimental|Subjects with severe renal impairment (Group A)|
89530814|NCT03241147|Experimental|Healthy subjects (Group B)|
89530815|NCT03241147|Experimental|Subjects with moderate renal impairment (Group C)|
89530816|NCT03241147|Experimental|Subjects with mild renal impairment (Group D)|
89530817|NCT02513381|Active Comparator|Vitamin D3, 3200IU|Each participant will receive either Vitamin D3, 3200IU or Placebo daily for three months.
89530818|NCT02513381|Placebo Comparator|Placebo|Each participant will receive either Vitamin D3, 3200IU or Placebo daily for three months.
89530819|NCT04499417|Experimental|Experimental-Condition|"8 weeks x weekly 20 minutes whole-body-workouts with simultaneous muscle stimulation (EMS).~Participants carry out easy whole-body-exercises while wearing a EMS-vest-belt-system with interwoven electrodes. During the workout the muscles are simultaneously stimulated by those external electrodes with medium level (5) of stimulation intensity."
89421335|NCT04927936|Experimental|Janssen vaccine - Pfizer vaccine|"HCW already vaccinated with Janssen vaccine once. 84 days after the first vaccination a boost will be given with Pfizer vaccine and blood samples will be drawn (day =0, baseline) This will be repeated at day 28 (primary endpoint), day 180 and day 365. This arm will have 87 +25% seropositive for SARS-CoV-2 IgG at baseline or loss to follow-up = 108 participants.~In this arm half of the participants will undergo a detailed immunological assessment (n=54 per arm)."
89421336|NCT04928248|Experimental|Diabetes Dashboard integrated with Disease Manager App|When patients are seen in clinics in this arm, the clinical providers will have access to the intervention (EHR-integrated Diabetes Dashboard that is integrated with the diabetes module of the Disease Manager App).
89421337|NCT04928638|Experimental|Virtual educational intervention|Educational intervention about the disease, the use of medication and the context of pandemic
89194697|NCT04038658|Experimental|Intervention Group (MoveIt)|10-minute Qigong exercise session (video demonstration via website) delivered twice a day at set break times during the working day for 12 consecutive weeks
89421338|NCT04928638|Experimental|Written educational intervention|Educacional intervention about the disease, the use of medication and the context of pandemic
89421339|NCT04928638|No Intervention|Control intervention|Control intervention
89421340|NCT04928560||disease free survival|disease free survival
89421341|NCT04928560||non-disease free survival|non-disease free survival
89421342|NCT03562533||pegylated liposomal doxorubicin + carboplatin|carboplatin area under the curve [AUC] 5 plus pegylated liposomal doxorubicin (PLD) 30 mg/m2 every 4 weeks
88901362|NCT01519336|Placebo Comparator|B darunavir|
88901363|NCT01519336|Experimental|C danoprevir/darunavir|
88901364|NCT01519375||1|Patients with Osteoarthritis, Rheumatoid Arthritis and Ankylosing Spondylitis, 18 years or older
88901365|NCT01519388|Experimental|neuromuscular patients|Neuromuscular non invasively ventilated patients in stable at the time of the study
88901366|NCT01519401|Active Comparator|3 mg drospirenone and 20 µg ethinyl-estradiol|
88901367|NCT01519401|Active Comparator|3 mg drospirenone and 30 µg ethinyl-estradiol|
88901368|NCT01519440||blunt|Blunt expansion of the primary incision was derived by placing the index fingers of the operating surgeon into the incision and pulling the fingers apart laterally and cephalad.
89421343|NCT03562533||paclitaxel + carboplatin|carboplatin AUC 5 plus paclitaxel 175 mg/m2 every 3 weeks
89421344|NCT04927858||Population 1|Patients ≥ 18 years old on 31st of December 2017 with Type 2 Diabetes Mellitus (T2DM) who were alive on 31st of December 2017 and had at least one registration in the Swedish National Diabetes Registry (NDR) between 1996 - 2017.
89421345|NCT04927858||Population 2|Population 2 is a sub-population of population 1. Patients with Type 2 Diabetes Mellitus (T2DM) who were initiated on Empagliflozin between 1st of January 2015 and 31st of December 2017, who had at least one registration in the Swedish National Diabetes Register (NDR).
89421346|NCT04927624|Active Comparator|transversus abdominis plane|In the group in which Transversus Abdominis Plan Block was applied, the patient was placed in the supine position. After skin antisepsis was achieved with 10% povidone iodine, the USG probe was placed transversely between the iliac crest and the anterolateral abdominal wall. After visualizing the external-internal obliq and transversus abdominis muscles, 0.5 ml/kg of 0.25% bupivacaine was injected after negative aspiration by advancing the needle into the fascia between the internal obliq muscle and the transversus abdominis muscle with the in-plane technique.
89421347|NCT04927624|Active Comparator|quoadratus lumborum block|In the Quadratus Lumborum Block (Lateral approach) group, the patient was placed in the lateral position with the side to be blocked on top. After skin antisepsis was achieved with 10% povidone iodine, the USG probe was placed transversely between the iliac crest and costa edge. After visualizing the extarnal-internal obliq and transversus abdominis muscles, the probe was advanced posteriorly. Quadratus lumborum muscle and thoracolumbar fascia were visualized. The needle was advanced to the anterolateral border of the quadratus lumborum muscle with the in-plane technique and 0.5 ml/kg of 0.25% bupivacaine was injected after negative aspiration.
89421348|NCT02820597|Experimental|Intervention|Cryoablation with the ClariFix device
89421349|NCT04927546|Experimental|IL-6 blockade|RA patients under pharmacological treatment with interleukin-6 blockade.
89421350|NCT04927546|Experimental|Anti-TNF-alpha|RA patients under pharmacological treatment with anti-TNF-alpha.
88901369|NCT01519440||sharp|Sharp expansion of the primary incision was developed by cutting laterally and cephalad using bandage scissors
89421351|NCT04927546|Experimental|Healthy controls|Healthy participants.
89421352|NCT04927468|Experimental|supramaximal rectus recession|supramaximal rectus recession to treat large-angle restricted strabismus in thyroid associated ophthalmopathy
88901370|NCT01519479|Experimental|Palliative Care Consultation|Participant will get one palliative care consultation while in the hospital. The participants desire for subsequent palliative care visits will be determined and mutually agreed upon at the initial consultation.
88901371|NCT01519479|Active Comparator|Control|Usual care for HF patient which may include a palliative care consult if ordered by treating physician.
88901372|NCT01519492|Experimental|AFN-12520000|100 mg tablet
88901373|NCT01519505|Experimental|Lifestyle counseling|"Complete lifestyle counseling including~Individual intervention, OR~Group intervention"
88901374|NCT01519505|No Intervention|Usual health care|Usual health care, including self-administered information by leaflets
88901375|NCT01519531|Experimental|VIA-3196|
88901376|NCT01519531|Placebo Comparator|Placebo|Multiple, ascending dosing groups (cohorts) will be evaluated.
88901377|NCT01519544|Active Comparator|Temazepam|50 subjects are instructed to take 7.5mg temazepam by mouth prior to going to sleep for one night only.
88901378|NCT01519544|Active Comparator|Acetazolamide|50 subjects are instructed to take 125mg of acetazolamide by mouth prior to going to sleep one night only.
89421353|NCT04927468|Active Comparator|normal rectus recession|normal rectus recession to treat large-angle restricted strabismus in thyroid associated ophthalmopathy
89421354|NCT02035761||MSA Case|The screening evaluation will take less than 1 to 2 hours, and is usually conducted over the telephone. The visit for testing will take approximately 3 days, consisting (usually) of a day for clinical examinations and questionnaires and one day each for PET and MRI brain imaging and the third day for PET imaging of the heart and autonomic testing. If some checklists and questionnaires could not be completed conveniently in the time available, they may be finished over the telephone on a later day. At the completion of the 3-day evaluation, subjects are asked to return home and keep a log of their MSA symptoms and medication responses for 2 days. This will complete the active participation of MSA subjects in all aspects of the entire research program. The average time the subjects will be followed could be up to 1 week during which time the subjects are undergoing research related procedures.
89421355|NCT03056716|Experimental|Silastic drain|Placement of 19FR silastic drain as basal drain
89421356|NCT03056716|Active Comparator|Conventional drain|Placement of 32FR conventional drain as basal drain
89421357|NCT03056560|Experimental|Video Bystander Program|TakeCARE video
88901379|NCT01519557|Experimental|DAR-100A|DAR-0100A is a dopamine D1 full agonist, the active component of the racemic mixture DAR-0100
88901380|NCT01519557|Placebo Comparator|Placebo|Intravenously over 30 minutes for 5 days, 9 days off then again for 5 more days
88901381|NCT01519596|Experimental|Arm I (physical activity)|Patients participate in an orientation session introducing the exercise program and protocol, reviewing fundamental principles, and demonstrating each activity. Patients also receive educational materials to facilitate orientation and adherence. Patients are offered 20-50 minute standard, intermediate, and/or low intensity physical activity sessions 5 days a week for 4 weeks. Patients also receive lifestyle-related counseling for 20-30 minutes once weekly.
88901382|NCT01519596|Active Comparator|Arm II (usual care)|Patients undergo usual care for 4 weeks.
88901383|NCT01519609|Active Comparator|Moviprep|Moviprep bowel preb
88901384|NCT01519609|Active Comparator|Phosphoral|Bowel prep
88901385|NCT01519622||Sick elderly in community|
89194698|NCT04038658|No Intervention|Wait-list control group|No intervention for 12 weeks. Then received the MoveIt Intervention for 12 weeks.
89421358|NCT03056560|No Intervention|Control Video|Study Skills Video
89421359|NCT04927000|No Intervention|control group|"All subjects used one or two the basic DMARDs: Methotrexate (10mg) combined with sulfasalazine (2G / day), Iguratimod (50 mg / day), leflunomide (20 mg / day)].~All subjects were treated with Glucocorticoid (10-15mg)/Days)."
89421360|NCT04927000|Experimental|Tofacitinib treatment group|"All subjects used one or two the basic DMARDs: Methotrexate (10mg) combined with sulfasalazine (2G / day), Iguratimod (50 mg / day), leflunomide (20 mg / day)].~All subjects were treated with Glucocorticoid (10-15mg)/Days). All subjects were treated with Tofacitinib 5mg/BID."
89530820|NCT04499417|Sham Comparator|Sham-Condition|"8 weeks x weekly 20 minutes whole-body-workouts without simultaneous muscle stimulation (EMS).~Participants carry out easy whole-body-exercises while wearing a EMS-vest-belt-system with interwoven electrodes. During the workout the muscles are not actually stimulated by EMS."
89421361|NCT02822235||Crohn's Disease|Participants with diagnosis of moderate to severe Crohn's disease (CD) for at least 6 months prior to Day 1 were observed to collect the retrospective data including previous inflammatory bowel disease (IBD) treatments (drug dose, treatment duration, drug changes), and use of other health resources related with the management of IBD for previous three years at Day 1. Participants with active IBD and CD at Day 1 were followed up for 12 months in prospective phase.
89194699|NCT05736744|Active Comparator|Rocuronium/MgSO4|"The patients will be pretreated with magnesium sulphate infusion (30 mg kg-1, total volume 100 ml, infusion rate 5 ml min-1) 20 min. before induction of anesthesia.~Rocuronium will be administered for intubation at a dose of 0.45-0.6 mg/kg IV and Maintenance at a dose of 0.1-0.2 mg/kg IV on fixed interval"
89421362|NCT02822235||Ulcerative Colitis|Participants diagnosed with diagnosis of moderate to severe ulcerative colitis (UC) for at least 6 months prior to Day 1 were observed to collect the retrospective data including previous inflammatory bowel disease (IBD) treatments (drug dose, treatment duration, drug changes), and use of other health resources related with the management of IBD for previous three years at Day 1. Participants with active IBD and UC at Day 1 were followed up for 12 months in prospective phase.
89194700|NCT05736744|Active Comparator|Cis-Atracurium/MgSO4|"The patients will be pretreated with magnesium sulphate infusion (30 mg kg-1, total volume 100 ml, infusion rate 5 ml min-1) 20 min. before induction of anesthesia.~Cis-Atracurium will be administered at 0.1-0.15 mg/kg IV bolus for intubation and maintenance at a dose of 0.03 mg/kg iv on fixed intervals."
89421363|NCT04927078||Participants with COVID 19 diagnosis|We will measure the breathing rate (BR) before and after the clinical diagnosis of COVID 19.
89421364|NCT04927078||Participants without COVID 19 diagnosis|Breathing rates will be measured for the same time duration as the cases.
89421365|NCT04926532|Experimental|Toripalimab + Sorafenib|Toripalimab was administered intravenously at a fixed dose of 240 mg, and the infusion time was 60 ± 5 min, once every 21 days. The cumulative longest medication period is 2 years. Sorafenib was taken orally after meals, twice a day.
89421366|NCT04925674|Experimental|HEC53856|HEC53856 Oral TIW There will be a total of 3 dose cohorts in the hemodialysis: 100mg，150mg，200mg； There will be only one dose cohort in the peritoneal dialysisp:100mg.
88820031|NCT01520558|Experimental|CNDO-109-AANK Cells Dose 2|In stage 1, patients will receive one of three doses of CNDO-109-AANK cells, and the middle dose of these three doses (dose 2) is 1×10^6 cells/kg recipient body weight. In stage 2, the MTD will have been determined and all patients will receive either Dose 1, Dose 2 or Dose 3.
88820032|NCT01520558|Experimental|CNDO-109-AANK Cells Dose 3|In stage 1, patients will receive one of three doses of CNDO-109-AANK cells, and the highest dose of these three doses (dose 3) is 3×10^6 cells/kg recipient body weight. In stage 2, the MTD will have been determined and all patients will receive either Dose 1, Dose 2 or Dose 3.
88820033|NCT01468532|Experimental|Treatment (chemotherapy, receptor agonist)|Patients receive pasireotide IM, 40 mg on day 1, docetaxel 75mg/m2 IV over 1 hour, and prednisone 5mg PO BID continuously. Courses with docetaxel repeat every 21 days and courses with pasireotide repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89421367|NCT04925596|Experimental|Intervention|general practitioners randomized to intervention group will be given access to ePrimaPrescribe online program
89421368|NCT04925596|Active Comparator|Control|general practitioners randomized to control group will be given access to an online program concerning doctor-patient communication
89421369|NCT02035995||Healthy volunteers|This group consisted of age matched non-pregnant healthy volunteers
88901386|NCT01519687|Experimental|Levotofisopam|All patients will receive a single dose of 50 mg on Day 1, 50 mg three times a day (TID) on Days 2 through 6, and a single dose of 50 mg on Day 7. Each dose of study drug will be administered by authorized site personnel throughout the 7-day inpatient treatment period.
88901387|NCT01519726|Experimental|Morbidly obese patients|
88901388|NCT01519739|Experimental|MediGuide Arm|
88901389|NCT01519752|Experimental|Oxiconazole Nitrate Cream 1%|
88901390|NCT01519752|Active Comparator|Oxiconazole Nitrate Cream 1% (Oxistat®)|
88901391|NCT01519752|Placebo Comparator|Placebo|
88901392|NCT01519830|Experimental|Verum|Iron Carboxymaltose (Ferinject)
88901393|NCT01519830|Placebo Comparator|Placebo|0.9% NaCl solution
88901394|NCT01519856||tablet|
88901395|NCT01519895|No Intervention|Existing care|routine existing care
88901396|NCT01519895|Experimental|Telephone intervention|in addition to provide telephone intervention support
88901397|NCT01519973|Other|Evaluation of technology in SPECT|Evaluation of the accuracy of SPECT with new technologies for attenuation correction (AC), scatter correction (SC) and resolution recovery (RR) for assessment of myocardial perfusion using Rb-82 PET as the gold standard.
88901398|NCT01519986|Experimental|Low fat Meal|50,000 UI vitamin D3 with low fat meal
88901399|NCT01519986|Experimental|Medium fat meal|50,000 UI vitamin D3 with medium fat meal
88901400|NCT01519986|Experimental|High fat meal|50,000 UI vitamin D3 with high fat meal
88901401|NCT01519999|Experimental|Shared Decision Making|
88901402|NCT01519999|No Intervention|Comparison (control)|
88901403|NCT01520012|Experimental|Sequence 1|
88901404|NCT01520012|Experimental|Sequence 2|
88901405|NCT01520012|Experimental|Sequence 3|
88901406|NCT01520012|Experimental|Sequence 4|
88901407|NCT01520012|Experimental|Sequence 5|
88901408|NCT01520025|Experimental|18F-FDG PET imaging|Positron Emission Tomography nuclear stress scan following either pharmacologic or treadmill stress test with radiopharmaceutical injection at peak stress or within 1 hour following peak stress.
88901409|NCT01520051|Experimental|Mepolizumab|
88901410|NCT01520051|Placebo Comparator|Saline|
88901411|NCT01520077|Other|Vytorin|"Subjects will receive Vytorin for 24 weeks. At 24 weeks if regrowth greater or equal than 20%, subjects will be randomized 1/1 to either stop or continue vytorin. Subjects will be follow for additional 24 weeks.~Subjects that at 24 weeks don't meet the 20% regrowth will be dropped out of the study."
89421370|NCT02035995||Healthy pregnant volunteers|This group consisted of age matched healthy pregnant volunteers
89194701|NCT04270084|Other|Treatment|Participants will be asked use a mobile health (m-health) app for 2 months. The app is designed to provide weekly education and motivation about healthful diet and physical activity behaviors in adolescents and their parent/adult caretaker. Both adolescent and parent/adult caretaker participants will use the app to enter weekly self-report data, set healthy eating and exercise goals, and receive educational and motivational content. Participants will conduct a weekly self-assessment of waist circumference, diet, and physical activity during the 2 month trial.
89194702|NCT00920868|Experimental|Dasatinib 50mg|Cohort 1
89194703|NCT05735106||Group A (predicted easy intubation)|Group A labelled as predicted easy intubation on the basis of NC/TM distance ratio <5
89194704|NCT05735106||Group B (predicted difficult intubation)|Group B labelled as predicted Difficult intubation on the basis of NC/TM distance ratio ≥ 5
89194705|NCT00874900|Experimental|Game|
89194706|NCT00874900|Experimental|Game + Activation|
89194707|NCT00874900|No Intervention|Booklet|
89194708|NCT00874900|Experimental|Booklet + Activation|
89194709|NCT00881062|Experimental|25 mg Proellex|25 mg (100 µCi) [14C]-Proellex
89194710|NCT05741814|Active Comparator|Propofol|Patients receive gynaecologist guided individualised propofol sedation
89194711|NCT05741814|Active Comparator|Anaesthetic guided anaesthesia|Patients receive anaesthetist guided full anaesthesia
89194712|NCT04064892|Experimental|Exercise Intervention|Participants will receive a 12-week, individually-tailored, video conference-based physical activity intervention
89194713|NCT00881140|Experimental|antiprogestin|Daily use of 10 mg administrated per vagina
89194714|NCT00737802||Normal Control|Normal control subjects are the participants with no history of GERD, no signs and symptoms of GERD
89194715|NCT00737802||GERD Patients|GERD patients are those with history of GERD, signs and symptoms of GERD and selected signs and symptoms of GERD in the questionnaire.
89194716|NCT00737802||Barrett's patients|Barrett's patients are those participants who in addition to all the qualities of GERD patients have long standing history of GERD and mucosal changes in the esophagus.
89194717|NCT05741736|Other|Group|A structured 5-day lifestyle modification program led by endocrinologists-diabetologists together with a nutritionist, a psychologist, and a kinesiologist is aiming to educate on lifestyle modification necessary to lose weight.
89194718|NCT00883636||Focal Segmental Glomerulosclerosis|
89194719|NCT00883636||Non-Focal Segmental Glomerulosclerosis|
89194720|NCT00883714|Experimental|Supervised exercise|
89194721|NCT00883714|Active Comparator|Control group|
89194722|NCT05733078|Placebo Comparator|Control / Crossover|"The patients in control group will have a oral rehydration effervescent tablet to take with their usual dose of Levothyroxine for 12 weeks, with thyroid function tests assessed at 6 and 12 weeks.~Crossover: After first 12 weeks, the control group will then be provided vitamin C (intervention) effervescent tablets to use 1 gram daily with their usual dose of Levothyroxine for 12 weeks, with thyroid function tests assessed at 6 and 12 weeks to see if there is any difference on biochemical testing or clinical scores."
89194723|NCT05733078|Experimental|Intervention|The patient in test group will be provided vitamin C effervescent tablets to use 1 gram daily with their usual dose of Levothyroxine for 12 weeks, with thyroid function tests assessed at 6 and 12 weeks. The patients who wish to continue at the end of 12 weeks will be provided another 12 weeks supply of vitamin C effervescent tablets to use 1 gram daily with their usual dose of Levothyroxine for with thyroid function tests and clinical score assessed at the end of week 24.
89421371|NCT04925518|Active Comparator|Conventional Ventilation Mode|Patients mechanically ventilated with a conventional mechanical ventilation mode until steady state is achieved for several hours.
89421372|NCT04925518|Experimental|Closed Loop Ventilation Mode|Once steady state on the conventional mechanical ventilation mode is achieved for several hours, switch to closed loop ventilation mode for the remainder of the study period.
89421373|NCT04925362|Other|Patients|Patients with histologically confirmed NAFLD
89421374|NCT03842709|Placebo Comparator|Standard Treatment + Placebo|Patients reporting sub-optimal results of pain therapy, assigned to placebo in addition to routine care.
89421375|NCT03842709|Experimental|Standard Treatment + Pramipexole|Patients reporting sub-optimal results of pain therapy, assigned to receive pramipexole in addition to routine care.
89421376|NCT05707533||Patients underwent TVM using the Vaginal Adventitia Reserved and Anatomical Implant Technique|Patients with pelvic organ prolapse who underwent TVM using the Vaginal Adventitia Reserved and Anatomical Implant Technique between June 2008 and December 2020
89421377|NCT03056482|Active Comparator|Ondansetron 8mg|8mg Ondansetron prepared in a 100mL normal saline mini-bag
89421378|NCT03056482|Experimental|Haloperidol 0.05mg/kg|0.05mg/kg of Haloperidol prepared in a 100mL normal saline mini-bag
88814123|NCT04347512|Experimental|Hydroxychloroquine and Azithromycin|"Hydroxychloroquine is given for 5 days, with a loading dose of 400 mg qd at D1, and 200 mg qd for the next 4 days (D2-D5).~Azithromycin is given for 5 days, with a loading dose of 500 mg at D1, and 250 mg for the next 4 days.~Standard of care is also prescribed (oxygen therapy, analgesics, antipyretics, anticoagulant drug, etc) In case of moderate renal failure (glomerular filtration rate between 30 and 60 mL/min/m²), hydroxychloroquine dosage are lowered by half."
88814124|NCT04366076||nonlaboring term singleton pregnancies|A total of 51 nonlaboring term singleton pregnancies were enrolled.
88814125|NCT02460978|Experimental|Dapagliflozin 5 mg|Dapagliflozin 5 mg tablet orally, once daily for 52 weeks
88901412|NCT01520103|Experimental|Vinorelbin and Everolimus|
89421379|NCT03056482|Experimental|Haloperidol 0.1mg/kg|0.1mg/kg of Haloperidol prepared in a 100mL normal saline mini-bag
89421380|NCT02817555|Active Comparator|Epoetin alfa|Patients who are enrolled and randomized to the Epoetin arm will remain on their current dose and frequency. After the first hemoglobin (Hb) measurement the study algorithm will be used to guide anemia management. The subjects in this arm will remain on epoetin for the required run-in phase followed by the 12 month active phase.
89421381|NCT02817555|Active Comparator|Darbepoetin alfa|"Patients who are enrolled and randomized to the Darbepoetin arm will have their epoetin discontinued at the end of the week preceding entry into the study and will switch to darbepoetin on the date that they would normally be receiving their next dose of epoetin.~Switching patients to darbepoetin will be done using the conversion ratio of 200 units of epoetin to 1 μg of darbepoetin as used per week, rounded up or down to the nearest available pre-filled syringe dose available from the manufacturer.~After the first Hb measurement the study algorithm will be used to guide anemia management. The subjects in this arm will remain on darbepoetin for the required run-in phase followed by the 12 month active phase."
89421382|NCT04924738||MOZART_SG|Women treated for hyperglycemia in pregnancy. Observational data are to be collected at follow-up visits during pregnancy, at delivery and postpartum.
89421383|NCT04924192|Experimental|TQB3616 capsules+Anlotinib hydrochloride capsules|TQB3616 capsules 120/150/180mg orally on an empty stomach, once a day for 21 consective days as a treatment cycle;Anlotinib hydrochloride capsules 12mg, once a day for 2 consecutive weeks and stop for 1 week.
89421384|NCT04924192|Experimental|TQB3616 capsules +Irinotecan Hydrochloride for Injection|TQB3616 capsules 120/150/180mg orally on an empty stomach, once a day for 28 consecutive days as a treatment cycle. Irinotecan Hydrochloride Injection 100 mg/m2 intravenous infusion on D1、D8 and D15, a total of 4-6 cycles.
88901413|NCT01520103|Other|standard therapy|Vinorelbin
89421385|NCT02036073|Experimental|EPO|In EPO group, the EPO was given by 500IU/kg every other day intravenously for 2 weeks. Recombinant human erythropoietin was configured by the hospital pharmacy intravenous Center Configuration, melted configured with saline to 1ml/kg solution. For severe patients, they were started to treat with EPO when their vital signs, blood pressure were stable.
88901414|NCT01520116|Experimental|Stage 1 - Arm 1 - Dose 1|
89421386|NCT03793803|Experimental|Home Palliative Care|Randomized to Intervention Arm
89421387|NCT03793803|No Intervention|Control Arm|Usual Care - Patients will be cared for by the physician who treats their primary illness(es).
89421388|NCT04924426||Patients with AMI|Patients with AMI
89421389|NCT04924426||Patients with no AMI|Patients with no AMI
89421390|NCT02036229|Experimental|0.5% ivermectin cream|Each participant will be treated with topical ivermectin cream 0.5% qd for one half of the face for 1 month. In the second month all patients will be treated with ivermectin cream for the entire skin involvement.
89421391|NCT02036229|Placebo Comparator|vehicle cream|Each participant will be treated with a vehicle cream qd for the other half of the face for 1 month. In the second month all patients will be treated with ivermectin cream for the entire skin involvement.
89421392|NCT03056404|Experimental|control subject|additional blood sample and 15 control subjects will be seen in consultations in the service of pneumology. The visit will include an auscultation, a respiratory functional exploration and a blood test (2 tubes of 7 ml of total blood). A questionnaire of exhibition will be realized to collect the species of birds and the times of exhibition.
89421393|NCT02817087|Active Comparator|repetitive Transcranial Magnetic Stimulation -On|Participants wear the repetitive transcranial magnetic stimulation (rTMS) cap delivering magnetic stimulation to part of the brain.
89421394|NCT02817087|Sham Comparator|repetitive Transcranial Magnetic Stimulation -Off|Participants wear the repetitive transcranial magnetic stimulation (rTMS) cap that does NOT delivery any magnetic stimulation to the brain.
88901415|NCT01520116|Experimental|Stage 1 - Arm 2 - Dose 2|
89421395|NCT02036307|Experimental|DHA-enriched|DHA-enriched supplement (DHA 3g + 600 mg EPA in 6 g of fish oil/day)
89421396|NCT02036307|Experimental|EPA-enriched|EPA-enriched supplement (EPA 2.4 g + DHA 600mg in 6 g of fish oil/day)
89421397|NCT03056326|Experimental|CHF6333 Active|
89421398|NCT03056326|Placebo Comparator|Placebo|
89421399|NCT03056170|Active Comparator|Active tDCS|The anode is placed over the left dorsolateral prefrontal cortex (DLPFC) and the cathode is placed over the left temporo-parietal cortex (TPJ) In active stimulation with a Transcranial Direct Current Stimulation, the device will deliver a charge of 1 mA for 30 minutes.
88901416|NCT01520116|Experimental|Stage 1 - Arm 3 - Dose 3|
88901417|NCT01520116|Experimental|Stage 1 - Arm 4 - Dose 4|
88901418|NCT01520116|Placebo Comparator|Stage 1 - Arm 5 - Vehicle|
88901419|NCT01520116|Experimental|Stage 2 - Arm 1 - Dose A - to be selected based on Stage 1|
88901420|NCT01520116|Experimental|Stage 2 - Arm 2 - Dose B - to be selected based on Stage 1|
88901421|NCT01520116|Active Comparator|Stage 2 - Arm 3 -Timoptic 0.5% BID|
88901422|NCT01520129|Other|Interpersonal and social rhythm therapy|IPSRT Subjects will receive weekly 45 minute sessions of IPSRT for 20 weeks. IPSRT sessions focus on reducing symptoms by teaching patients to: a) increase regularity of social rhythms and regulate sleep-wake cycles; b) resolve interpersonal problems that contribute to mood symptoms (role dispute, role transition, grief, or interpersonal deficits); and c) recognize and accept the symptoms of subthreshold BP disorder (psychoeducation). Although we train therapists in techniques that are specific to each component, in practice, these strategies are administered flexibly and fluidly, without distinct boundaries between modalities. During the course of a session, therapists move seamlessly among the techniques, according to patients' needs.
88901423|NCT01520142|Experimental|Treatment|
89421400|NCT03056170|Sham Comparator|Sham tDCS|In sham stimulation, with a Transcranial Direct Current Stimulation, no current will be delivered from one electrode to the other except one 30 s ramp up and down at the beginning and one at the end of the sham stimulation duration (30 min) Same electrode montage than in the active group.
89530821|NCT03235921|Other|nitroglycerin|nitroglycerin patch 5 mg applied to front of chest in each patient at time of admission once.
88901424|NCT01520142|Placebo Comparator|Placebo|
88901425|NCT01520155||Systemic lupus erythematosus with renal affection|30 patients will be investigated suffering from a known systemic lupus erythematosus with renal affection
88901426|NCT01520155||Systemic lupus erythematosus without renal affection|30 patients will be investigated suffering from a known systemic lupus erythematosus without renal affection
88901427|NCT01520155||Non-autoimmune kidney disease|Patients with non-systemic, non-autoimmune kidney disease
88901428|NCT01518218|Experimental|laying-on-of-hands|Patients of this arm received laying-on-of-hands twice a day (45 minutes each) every weekday for 1year, and received conventional medical treatment if necessary.
89530822|NCT03235921|Other|control group|no drug given to the patients in control group
89421401|NCT04923022|Experimental|Vegan diet|Participants with chronic neck pain who will be on a vegan diet will follow a diet program prepared by an expert dietitian under the supervision of an endocrinologist. In this diet program, a diet that includes grains, fruits, vegetables, legumes, as well as dairy products and eggs, known as lacto-ovo vegetarian, will be applied. Consumption of meat, poultry, fish, seafood and processed food and beverages will not be allowed. There will be no calorie restriction in the diet, and the diet will be arranged according to the amount of calories calculated by the expert dietitian according to BMI. The diet will last for eight weeks. Individuals who follow a diet will be constantly checked by the workers with the mobile device application (My Fitness Pal®).
89421402|NCT04923022|Experimental|Therapeutic exercise|"The participants in the therapeutic exercise group will perform the following therapeutic exercises for eight weeks, 3 days a week, accompanied by a specialist physiotherapist.~The patient, sitting in the cervical spine neutral position, performs flexion, extension and rotation of the cervical spine, unloaded and in the maximum possible range of motion.~While the patient is in the supine position, she performs passive lateral mobilization to the neck with the help of a physiotherapist.~In the supine position, the patient performs isometric neck flexion, lateral flexion and rotation movements against the manual resistance given by the physiotherapist~The patient lying on his back does isometric neck extension movement against gravity~The patient performs isometric neck flexion, lateral flexion and rotation movements against the elastic band in the sitting position"
89421403|NCT04923022|No Intervention|Control group|Participants in this group will not receive any intervention.
88901429|NCT01518218|No Intervention|control group|Patients of this arm did not receive any alternatives other than conventional treatment.
88901430|NCT01520194||psychosocial burden|122 women attending reproductive health clinics were interwied using HPV Impact Profile (HIP) and a socio-economic characteristics questionnaire.
88901431|NCT01520194||economic burden|Medical records of 102 patients diagnosed with genital warts were reviewed in the six BEMFAM's participating reproductive health clinics
88901432|NCT01520220|Experimental|Part A: LY2784544 Dosing Regimen A|LY2784544 will be taken by mouth per a specified schedule. Different participants will be treated at different doses until reaching the highest dose a participant can tolerate. Each cycle is 28 days.
88901433|NCT01520220|Experimental|Part A: LY2784544 Dosing Regimen B|LY2784544 will be taken by mouth per a specified schedule. Different participants will be treated at different doses until reaching the highest dose a participant can tolerate. Each cycle is 28 days.
88901434|NCT01520220|Experimental|Part B: LY2784544 Dosing Regimen A|LY2784544 will be taken by mouth per a specified schedule. Different participants will be treated at different doses from Part A that are determined to be safe and have potential clinical merit. Each cycle is 28 days.
88901435|NCT01520220|Experimental|Part B: LY2784544 Dosing Regimen B|LY2784544 will be taken by mouth per a specified schedule. Different participants will be treated at different doses from Part A that are determined to be safe and have potential clinical merit. Each cycle is 28 days.
88901436|NCT01520259||cases|Women from the cohort with gallbladder cancer
88901437|NCT01520259||cohort|Women from Chile screened for gallbladder cancer with and without gallstones
88901438|NCT01520259||controls|Women from the cohort with gallstones
88901439|NCT01520285|Active Comparator|Zanidip|tablets
88901440|NCT01520285|Placebo Comparator|Control Drug|Felodipine sustained-release tablet (5mg/tablet)
88901441|NCT01520298|Placebo Comparator|Placebo|For the control group, a total of 100 mLs of 0.9% sodium chloride will be transferred to a Hospira LifeCare container and infused over 15 minutes (6.7 mL/min). A beyond use expiration of 6 hours will be placed on the container.
88901442|NCT01520298|Active Comparator|Acetaminophen treatment|For the treatment group, a total of 100 milliliters (mLs) of acetaminophen (1000 mg) will be transferred to a Hospira LifeCare container and infused over 15 minutes (6.7 mLs/min). A beyond use expiration of 6 hours at room temperature will place on the container, as recommended by the manufacturer.
88901443|NCT01520311|Other|SVG + eSVS Mesh vs Control SVG|Either the Circumflex Coronary Artery or the Right Coronary Artery will receive the mesh supported vein graft and the native saphenous vein as second and control graft.
88814126|NCT02460978|Experimental|Dapagliflozin 10 mg|Dapagliflozin 10 mg tablet orally, once daily for 52 weeks
89421404|NCT02813577|Other|Lutonix® 035 Drug Coated Balloon PTA Catheter|This is a single-arm study. Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.
88814127|NCT02460978|Placebo Comparator|Placebo|Placebo tablet orally, once daily for 52 weeks
88814128|NCT04365842|Experimental|Digital exercise group|"After the 6-week digital intervention, 1) qualitative interviews have done with 6-15 patients from intervention group to assess the feasibility of digital intervention.~2) The primary outcomes are hand pain and function and exercise adherence will be evaluated for all participants"
88814129|NCT04365842|Active Comparator|Waiting list conrol|A hand rehabilitation home program will be given to the patients in the group through the telephone messages with brochures.
88814130|NCT04372316|Active Comparator|methylcobalamin injection|
88814131|NCT04372316|Active Comparator|methylcobalamin tablet|
88814132|NCT02221739|Experimental|Ipilimumab + radiotherapy|Patients receive ipilimumab (Ipi) 3mg/kg i.v. over 90 minutes, within 24 hours of starting radiotherapy (RT) to the biopsied lesion, 6 Gy x5, later changed to 9.5 Gy x3 (conformally or by intensity modulated RT (IMRT) with image guidance to maximally spare normal tissue). Ipilimumab is repeated on days 22, 43 (for patients who consent to the first biopsy), and 64. Repeat biopsy is performed between day 22-29, and patients are re-imaged between day 81-88 and evaluated for response (defined as an objective response by irRC of the measurable metastatic sites outside the radiation field).
88814133|NCT02241356|Active Comparator|single vision glasses|single vision glasses
88814134|NCT02241356|Experimental|bifocals|bifocal glasses
88814135|NCT02241434|Experimental|Stem Cell|bone marrow mononuclear cell transplantation
88814136|NCT04365686|Active Comparator|Group K|Ketofol group
88814137|NCT04365686|Active Comparator|Group P|propofol group
88814138|NCT02241590|Placebo Comparator|Entecavir + Placebo|Tablet with Entrcavir+ Tablet with starch
88814139|NCT02241590|Experimental|Entecavir + Fuzheng Huayu Tablet|Tablet with Entrcavir+ Tablet with Fuzheng Huayu
88814140|NCT04083755|Active Comparator|Line A|One dose of Ferric carboxymaltose (1000mg) intravenous. Duration of administration 15 minutes.
88814141|NCT04083755|Other|Line B|No treatment or treatment oral with iron supplementation if iron-deficiency anemia
88814142|NCT04372394|Experimental|Fed/Fasted|surufatinib with food on Day 1 and surufatinib without food on Day 8
88814143|NCT04372394|Experimental|Fasted/Fed|surufatinib without food on Day 1 and surufatinib with food on Day 8
88814144|NCT04365608|Active Comparator|Direct laryngoscopy|Intubation will be done using direct laryngoscopy. The standard intubation procedure is to use a styletted tube and no sedation. When standard laryngoscopy-assisted intubation is not possible, an alternate procedure will be used based on the guidelines on difficult airway management.
88814145|NCT04365608|Active Comparator|Vie Scope laryngoscopy|Intubation will be done using Vie Scope laryngoscopy
88814146|NCT05465603|Experimental|20-22 hours of daily TERT intervention|Patients that have suffered an injury to the finger causing flexion contracture of the Proximal interphalangeal joint will be treated using an elastic tension neoprene orthosis for a period of 3 weeks.
88814147|NCT05465603|Active Comparator|11-13 hours daily TERT intervention|Patients that have suffered an injury to the finger causing flexion contracture of the Proximal interphalangeal joint will be treated using an elastic tension neoprene orthosis for a period of 3 weeks.
88814148|NCT04372550|Active Comparator|Standard of Care|"Standard of care treatment:~- including passive / assisted / active movements, stretching, functional exercise, scar treatment~Duration: 6-12 weeks"
88814149|NCT04372550|Experimental|Exercise|"Standard of care + added exercises~Exercise type: resistance and aerobic exercise~Resistance Exercise: 3x / week (manual resistance, free weights, machines) Aerobic exercise: 2x / week (cycle ergometer, treadmill)~Duration: 6-12 weeks"
88814150|NCT04372160||Younger school age children|Equal ratio of boys and girls, age range 7-13 years (68 subjects)
88814151|NCT04372160||Older school age children|Equal ratio of boys and girls), age range 14-17 years (68 subjects)
88814152|NCT04372160||Adults|Equal ratio of adult men and women, age range 18-65 years (68 subjects).
88814153|NCT04040075|Other|Open label|Open label Biktarvy to establish suppression of HIV 1 with 184 V/I Resistance Mutation
88814154|NCT04372004|Active Comparator|Viral RNA test using nasopharyngeal swab|
88814155|NCT04372004|Active Comparator|Viral RNA test using sputum|
88814156|NCT04372004|Active Comparator|Serology test using blood|
88814157|NCT02247635|No Intervention|Conventional medical treatment|Based on the clinical guidelines of the Ministry of Health, medical treatment was provided and consisted in counseling for chronic diseases such as obesity, hyperglycemia, hypertension, dyslipidemia
88814158|NCT02247635|Active Comparator|Healthy lifestyle and adherence|1) Maintain a caloric restriction of 500kcal in overweight adults, 2) Have a total fat intake <30% (including cholesterol and trans fat), 3) A total intake of complex carbohydrates for 50%, 3) 30g fiber, 4) Perform at least 30 minutes of moderate physical activity at least 5 days a week; 5) Maintain education and behavioral therapy changes in your lifestyle.
88814159|NCT04372082|Placebo Comparator|standard of care (SOC)|
88814160|NCT04372082|Experimental|SOC + Hydroxychloroquine|
88814161|NCT04372082|Experimental|SOC + Diltiazem-Niclosamide|
89421405|NCT04922788|Experimental|25 mcg Dose|Intramuscular injection, two doses given 28 days apart
89421406|NCT04922788|Placebo Comparator|Placebo|Intramuscular injection, two doses given 28 days apart
88814162|NCT02993393||Teachers|Anesthesiologists who have involved in SBL and PBL with more than 3 years of experience in teaching
88814163|NCT02993393||Students|Students were nurse anesthetist students in the academic years of 2015
89421407|NCT02815293|Experimental|AGN-195263|
89421408|NCT02815293|Placebo Comparator|Vehicle|
89421409|NCT04922398|Active Comparator|Group A: PRP group|Preparation of PRP sample fro the patient own blood then the volume immediately above the erythrocyte layer was collected. Calcium gluconate in conc. 1:9 will be used as an activator. After activation, in a period less than 2 min, approximately 4 ml of the PRP will be injected into each ovary by TVUS.
89421410|NCT04922398|Placebo Comparator|Group B: saline group|consists of 30 patients, who will receive 4 ml of a normal saline inj. 0.9% Nacl. then injected into each ovary by TVUS.
89421411|NCT04922086|Experimental|Test group|Patients will be submitted to ACL planned using cone beam computed tomography (CBCT), digital planning and guided dual technique.
89421412|NCT04922086|Active Comparator|Control group|Patients will be submitted to the conventional ACL planned using clinical examination.
88814164|NCT02241668|Experimental|FLT PET Scan + 3'-Deoxy-3'-18f-Fluorothymidine|After a magnetic resonance imaging (MRI) scan of brain performed, an FLT PET scan using 3'-Deoxy-3'-18f-Fluorothymidine solution performed. After solution is injected into a vein, the PET scanner takes pictures of the radioactive solution as it moves through the body and collects at various sites in the body. The entire procedure should last about 60-70 minutes.
88814165|NCT02241746||malnutrition|
88814166|NCT04365296|Experimental|Aerobic group|This group will include 30 burned patients who will receive aerobic exercises 8 weeks (3times/week) in form of treadmill exercise in addition to their physical therapy program (splinting, stretching ex. and ROM ex.) and medical treatment (medications as cataflam, alphintern, zinetac and hemacaps and wound dressings).
88814167|NCT04365296|Experimental|Resistance group|This group will include 30 burned patients who will receive resistance exercises 8 weeks (3times/week) by using dumbbells and sand bags in addition to their physical therapy program (splinting, stretching ex. and ROM ex.) and medical treatment (medications as cataflam, alphintern, zinetac and hemacaps and wound dressings).
88814168|NCT04263077|Placebo Comparator|PLACEBO|IN THE PLACEBO GROUP, THE ENDS OF THE TAPES WILL BE APPLIED NO TENSION WITHOUT OVERLAPPING EACH OTHER.
88814169|NCT04263077|Other|50% TENSION GROUP|KINESIOTAPE WILL BE APPLIED WITH 50% TENSION.
88814170|NCT04263077|Other|75% TENSION GROUP|KINESIOTAPE WILL BE APPLIED WITH 75% TENSION.
88814171|NCT04263077|Other|100% TENSION GROUP|KINESIOTAPE WILL BE APPLIED WITH 100% TENSION.
88814172|NCT02241824|Active Comparator|Elastic abdominal binder|To evaluate the opioid consumption in chronic low back pain patients on a stable opioid regimen after an intervention of an elastic abdominal binder.
88814173|NCT02241824|No Intervention|No brace|To evaluate the opioid consumption in chronic low back pain patients on a stable opioid regimen with no brace (control).
88814174|NCT02241824|Experimental|In-elastic lumbar brace|To evaluate the opioid consumption in chronic low back pain patients on a stable opioid regimen after an intervention of an in-elastic lumbar brace.
88814175|NCT04224155|Experimental|enVista MX60EFH trifocal intraocular lens (IOL)|
88814176|NCT04224155|Active Comparator|enVista MX60E monofocal intraocular lens (IOL)|
88814177|NCT02241902||No pyuria|
88814178|NCT02241902||Persistent pyuria|
88814179|NCT02489448|Experimental|MEDI4736|"The investigational product is MEDI4736 which will be supplied in glass vials containing 500 mg of liquid solution at a concentration of 50 mg/mL for intravenous (IV) administration.~Routine, standard of care chemotherapy will be given together with the investigational product and will include weekly nab-paclitaxel x12 treatments followed by every two-week doxorubicin, cyclophosphamide (ddAC) x 4 treatments."
88814180|NCT03850847||Multi-Methods Study|"Step 1: Semi-structured Interviews~Step 2: National Telephone Survey"
88814181|NCT00926588|Experimental|Stepped Care|Patients received automated pain monitoring. A nurse care manager partnering with a physician pain specialist decide on treatment changes collaborating with primary care physicians. Structured algorithms for stepped care analgesic management and explicit decision rules for adjusting treatment are used.
88814182|NCT00926588|No Intervention|Usual Care|Patients receive usual care for pain from their primary care physician
88814183|NCT05323331|Experimental|Circuit Training|"This group preformed interval training alternating between aerobic and resistance training, varying between moderate to high intensity. Each set started with 3 minutes of aerobic training on cycle or treadmill followed by resistance training and a rest interval. Eight circuits were formed; horizontal rowing, chest press, leg press, shoulder press, leg extension, lateral pull down, leg flexion and partial squat. Weight was calculated through 1 RM calculation.~This training is to be carried out for 12 weeks, in three phases, the intensity progressing from light to moderate (30% of RM to 50%). Sessions will be carried out thrice a week."
88814184|NCT05323331|Active Comparator|Aerobic Training|The control group consists of aerobic exercise training, with 20 minutes on the cycle, 15 minutes of treadmill and 10 minutes of walking
88814185|NCT04371926|Active Comparator|HCQ arm|"COVID-19 positive cases will receive receive hydroxychloroquine sulfate 400 mg twice daily on the day of enrollment, then 200 mg twice daily for the next 4 days for a 5 day total course.~Staff randomized to this group will receive HCQ sulfate 400 mg/week for 4 weeks"
88814186|NCT04371926|No Intervention|No-HCQ arm|Will receive standard treatment as needed, but no HCQ
88814187|NCT02248883|Experimental|low TPV/RTV|
88814188|NCT02248883|Experimental|high TPV/RTV|
88814189|NCT02248883|Experimental|Placebo/RTV|
89194724|NCT00883792|Experimental|Colonoscopy screening|One-time colonoscopy is the screening tool used in this trial. All individuals in the screening group will be offered a full colonoscopy. At colonoscopy, all detected CRC precursor lesions will be removed, whenever possible.
89421413|NCT02813421|Experimental|CGM Informed|CGM data was available for use when determining starting insulin pump doses.
89421414|NCT02813421|No Intervention|Control|CGM data will remain secure and not used. Starting insulin pump doses will be made by standard of care.
89194725|NCT00883792|No Intervention|Control|"The control group will not be offered any screening or intervention within the trial, but follow usual care in the participating countries. Individuals assigned to the control group will not be informed about their status as controls in the trial. This approach facilitates a truly population-based study, which will be used to estimate the effect of the screening intervention in the general population, mimicking national CRC screening programs.~All ethics committees at the participating centres have approved the study protocol before recruiting individuals to the trial. In Sweden, the national ethics committee particularly reviewed the non-information of the control group and found it ethically acceptable."
89421415|NCT04922008|Experimental|IRIS-C|
89421416|NCT04922008|Experimental|IRIS-D|
89421417|NCT03056092|Other|AMD/RVO/DME|Patients presenting to St. Michael's Hospital retina clinic with neovascular age related macular degeneration, macular edema secondary to RVO and diabetic macular edema treated with intravitreal ranibizumab in a variable dosing regimen.
89421418|NCT04921852|Active Comparator|costoclavicular group|
89421419|NCT04921852|Active Comparator|lateral sagittal group|
88814190|NCT04365452|Experimental|Invia Motion Arm|
88814191|NCT04371692||High-risk|staff working in a unit specifically for patients infected or suspected of being infected with SARS-Cov2
88814192|NCT04371692||Medium- risk|staff working in a unit that can accommodate patients infected or suspected of being infected with SARS-Cov2, i.e., all care services that do not fall into the high-risk group.
88814193|NCT04371692||Low-risk|off-patient staff
89194726|NCT00874978|Experimental|lenalidomide|
89194727|NCT04063254|Experimental|High-Dose Stereotactic Radiotherapy|
89194728|NCT04063254|Active Comparator|Standard-Dose Stereotactic Radiotherapy|
89194729|NCT00737880|Active Comparator|1|In situ organ perfusion using HTK solution during pancreas procurement
89194730|NCT00737880|Active Comparator|2|In situ perfusion using UW solution during pancreas procurement
89194731|NCT05728632|Experimental|Nebivolol|nebivolol, capsule, 5 mg once daily, for 12 months
89421420|NCT04921540|Experimental|Dermatologic intervention|Surgery with chemical cauterisation TCA
89421421|NCT04921540|Active Comparator|Orthopedic intervention|Only surgery
89421422|NCT04921306|Experimental|Clenbuterol hydrochloride|"Subjects will ingest clenbuterol hydrochloride capsules (20 microgram/each) twice daily (40 microgram/day) for a maximum of 28 days.~Subjects that received the clenbuterol hydrochloride capsules (at random) in the first study period will receive the placebo capsules during the second study period."
89421423|NCT04921306|Placebo Comparator|Placebo|"Subjects will ingest placebo capsules matching the clenbuterol hydrochloride capsules one time per day for a maximum of 28 days.~Subjects that received the placebo capsules (at random) in the first study period will receive the clenbuterol hydrochloride capsules during the second study period."
89421424|NCT04921462|Active Comparator|Silastic group|included patients who underwent nasal septoplasty followed by insertion of silastic intranasal splint
89421425|NCT04921462|Active Comparator|Quilting group|included patients who underwent septoplasty followed by quilting suture (Septal through and through suture)
88814194|NCT04364906|Active Comparator|Quadratus Lumborum Block 2|Quadratus Lumborum Block 2 (QLB 2) will be performed the patients in Group A after the cesarean section surgery. Patient controlled analgesia device (PCA) is used for all the patients in the first 24 hours postoperatively
88814195|NCT04364906|Active Comparator|Quadratus Lumborum Block 3|Quadratus Lumborum Block 3 (QLB 3) will be performed the patients in Group B after the cesarean section surgery. Patient controlled analgesia device (PCA) is used for all the patients in the first 24 hours postoperatively
88814196|NCT02488980|Experimental|Tafenoquine|Tafenoquine 200 mg for three days followed by Tafenoquine 200 once a week for 24 weeks.
88814197|NCT02488980|Active Comparator|Mefloquine|Mefloquine 250 mg for three days followed by Mefloquine 250 once a week for 24 weeks.
88814198|NCT02488980|Placebo Comparator|Placebo|Placebo
88814199|NCT04371302||Intensive Care Unit nurses|Nurses working in the Intensive care Unit of an exclusive Covid-19 hospital in Malaysia, during the Covid-19 pandemic
88814200|NCT04130321|Experimental|Camu camu|
88814201|NCT04130321|Placebo Comparator|Placebo|
88814202|NCT02242058||High frequency pain group|39 pediatric or adult patients with high pain frequency (greater than or equal to 3 ER visits and/or hospitalizations for pain per year over the last two years)
88814203|NCT02242058||Low Pain Frequency group|39 pediatric or adult patients with low pain frequency (less than or equal to 1 severe pain episode for the last two years)
89421426|NCT04920760|No Intervention|Control|Participants receiving standard treatment alone.
89421427|NCT04920760|Experimental|Vitamin A|Participants receiving standard treatment with an additional vitamin A supplementation.
89421428|NCT03056248|Active Comparator|Lithium|Patients will be identified by chart review and be explained the purpose of the study and informed consent taken
89421429|NCT03056248|Placebo Comparator|Placebo|Patients will be identified by chart review and be explained the purpose of the study and informed consent taken
89421430|NCT04920604||Teleconsultation|
89421431|NCT04920604||Control group|
89421432|NCT04920526||QHPV Vaccine|all participants have received QHPV
89421433|NCT04920448|Experimental|N-Acetylcysteine 150 mg/kg|Single intravenous injection of N-Acetylcysteine (150 mg/kg in 15 minutes).
89530823|NCT02510339||Observational|The Lysholm Knee score and the SF-36 questionnairs will be given to patients presenting to Orlando Regional Medical Center with open or closed fractures of the tibial shaft during their follow up visits post operativily.
89530824|NCT03232021|Placebo Comparator|Group I|Administration of a placebo capsule 1 hour prior to the surgical operation
89530825|NCT03232021|Experimental|Group II|Administration of 75mg of pregabalin 1 hour prior to the surgical operation
88814204|NCT02242058||Healthy control group|39 pediatric or adult relatives of sickle cell disease patients, who do not have the sickle cell trait of SCD.
89194732|NCT05728632|Placebo Comparator|Placebo|placebo, capsule, once daily, for 12 months
89194733|NCT04180540|Experimental|Percutaneous Closure|Participants randomized to undergo percutaneous closure with PerClose after radiofrequency ablation or cryoablation for treatment of atrial fibrillation.
88814205|NCT02242058||Pain Crisis group|30 patients with sickle cell disease with severe phenotype (HbSS, HbSβ0 thalassemia, HbSOArab)
89194734|NCT04180540|Active Comparator|Manual Compression|Participants randomized to undergo manual compression after radiofrequency ablation or cryoablation for treatment of atrial fibrillation.
89194735|NCT05741580||peri-urethral bulk agent injection of Bulkamid® for urinary incontinence|patients who received a first injection of Bulkamid® in the context of urinary incontinence
88814206|NCT02242058||Pain Service group|10 patients without sickle cell disease admitted to the pain service.
88814207|NCT04952064|Experimental|200 mg group|Monosialoganglioside GM1, 200 mg/day, for 12-14 days
88814208|NCT04952064|Experimental|400 mg group|Monosialoganglioside GM1, 400 mg/day, for 12-14 days
88814209|NCT02242136|Experimental|FORNET|During FORNET, the client, with the assistance of the therapist, constructs a chronological narrative of his or her entire life with a focus on exposure to traumatic stress and committed violence. Empathic understanding, active listening, congruency and unconditional positive regard are key components of the therapist's behavior. The therapist asks in detail for the client's emotions, cognitions, physiological reactions, and sensory informations during traumatic and aggressive events to link them to an autobiographical context, namely time and place. In total the individuals receive 8 sessions of FORNET, every session lasting between 1,5 and 2 hrs depending on the needs of the participant.
88814210|NCT02242136|No Intervention|Waiting list|
88814211|NCT02227667|Experimental|Patients with Advanced Colorectal Cancer|This will be a Simon two-stage design, single arm, phase II study. All subjects will receive MEDI4736 via IV infusion. Subjects will continue treatment for 12 months, or until progression of disease, initiation of alternative cancer therapy, unacceptable toxicity, or other reasons to discontinue treatment occur. Following the 12-month treatment period, subjects without evidence for progressive disease or other reason to discontinue treatment will be monitored without further treatment. Upon evidence of PD (with or without confirmation according to RECIST 1.1) during the monitoring period, administration of MEDI4736 may resume at the Q2W schedule, for up to another 12 months. The same treatment guidelines followed during the initial 12-month treatment period will be followed during the retreatment period, including the same dose and frequency of treatments and the same schedule of assessments.
88814212|NCT04365062|Experimental|Intervention: Excimer laser and drug coated balloon|Intervention: Excimer laser and drug coated balloon group
88814213|NCT04365062|Active Comparator|Excimer laser and plain balloon|Excimer laser and plain balloon group
88814214|NCT04365062|Active Comparator|plain balloon and drug coated balloon|plain balloon and drug coated balloon group
88814215|NCT04926090|Experimental|Emotional Support Plan - Clinician Guided (ESP-C) + (Bi)Weekly Monitoring|This will involve brief assessment visits throughout the fall semester, without prompting to use the ESP-C. Visits will be weekly for the first 6 weeks and then biweekly for the remaining 9 weeks of the term.
88814216|NCT04926090|Experimental|Emotional Support Plan - Clinician Guided (ESP-C) + 4x Daily Monitoring|Participants in this arm will be prompted on their phones 4x/day, to report on activities, mood, suicidal ideation, distress level and ESP use since the last prompt. They will also participate in brief assessment visits conducted weekly for the first 6 weeks and then biweekly for the remaining 9 weeks of the term.
88814217|NCT04926090|Experimental|Emotional Support Plan - Self Guided (ESP-S) + 4x Daily Monitoring|Participants in this arm will be prompted on their phones 4x/day, to report on activities, mood, suicidal ideation, distress level and ESP use since the last prompt. They will be asked to complete questionnaires weekly for the first 6 weeks and then biweekly for the remaining 9 weeks of the term.
88814218|NCT02242214||Misoprostol 200 µg VDS|At the discretion of the investigator in accordance with their usual practice and consistent with the Dutch prescribing information.
88814219|NCT04371068||Patients suspected of low-grade PJIs|Adult patients suspected of low-grade PJIs, who have a scheduled prosthesis removal or change and who meet the inclusion criteria
88814220|NCT02245256|Placebo Comparator|Normal saline|same infusion rate as experimental group (dexmedetomidine)
88814221|NCT02245256|Experimental|dexmedetomidine|0.1mcg/kg/hr of dexmedetomidine infusion started after induction of anesthesia for liver transplantation and continued until 48 hours after surgery.
88814222|NCT02460822|Experimental|MyChemoCare|Participants will receive access to the the MyChemoCare iPad application, which allows them to track cancer and chemotherapy related symptoms daily, and suggests strategies that may help the participant deal with these symptoms. While using the application, high symptom severity scores will be reported to the participant's medical team, who may intervene to help relieve the symptom. Participants will also be contacted if they have not checked in for 48 hours to make sure they are coping well with their chemotherapy regimen.
89194736|NCT00737958||1|Patients with documented stable coronary artery disease, symptoms of stable angina pectoris, and a positive standard BRUCE exercise stress test at 3 - 13 minutes.
89536028|NCT03074955|Active Comparator|Control|"leg wrapping without tension & maintain supine position~Apply elastic bandages to both legs without tension.~Maintain supine position after injecting propofol.~After 3 minutes from propofol injection, remove elastic bandages~induction using propofol 2mg/kg~After bispectral index (BIS) goes below 60 & patient become unconsciousness, inject rocuronium 0.6mg/kg~intubate patient between 3 and 4 minutes after propofol injection~measure blood pressure ( systolic, diastolic, mean ) & heart rate at 1,2,3,4,5 minutes after propofol injection~phenylephrine injection if hypotension develops"
88814223|NCT05208983||70 years and Older|Persons aged 70 years and over receiving a first or second dose of an approved COVID-19 vaccine and is a resident of Ontario
88814224|NCT05208983||30 - 50 years of age|Persons aged 30 - 50 years receiving a first or second dose of an approved COVID-19 vaccine and a resident of Ontario
88814225|NCT02242292|Experimental|Hyoscine butylbromide|"5 tablets taken in a 24-hour period/each episode:~for up to 7 episodes, or~over a period of up to 6 weeks"
88814226|NCT02242292|Placebo Comparator|Placebo|
88814227|NCT02994329|Active Comparator|Oral HIV self test|In this arm, community health workers conducting door-to-door HIV testing will offer oral HIV self testing (OraQuick® HIV Self-Test (Orasure Technologies, Thailand)) as an alternative to standard of care finger-prick HIV testing for individuals who are present at the time of the visit. In addition they will provide demonstration to an adult who is present at the time of the visit and leave up to 2 oral HIV self test kits to allow testing with the partner
88814228|NCT02994329|No Intervention|Standard of Care|In this arm community health workers will conduct door-to-door HIV testing using the current Zambian national HIV testing algorithm of finger-prick rapid HIV tests
88820034|NCT01469234|Experimental|loratadine|Participants will receive one dose of loratadine following randomization at 120 minutes of exposure during visit 4.
88820035|NCT01469234|Experimental|fexofenadine|Participants will receive one dose of fexofenadine following randomization at 120 minutes of exposure during visit 4.
88901444|NCT01520337||patients undergoing outpatient colonoscopy|
88901445|NCT01520350|Experimental|Mood stabilizer + Aripiprazole|
89194737|NCT05577936|Experimental|Xperience no rinse antimicrobial solution group|XPERIENCE Advanced Surgical Irrigation will be utilized as the final wash after the TKA or THA procedure prior to closure
89194738|NCT05577936|Active Comparator|Normal saline solution group|Standard of care irrigation will be utilized as the final wash after the TKA or THA procedure prior to closure.
89194739|NCT00612586|Experimental|Enzastaurin + 5-FU/LV + Bev|5-fluorouracil/leucovorin (5-FU/LV) plus bevacizumab (Bev) in combination with enzastaurin
89194740|NCT00612586|Placebo Comparator|Placebo + 5-FU/LV + Bev|5-fluorouracil/leucovorin (5-FU/LV) plus bevacizumab (Bev) in combination with placebo
89194741|NCT00738036||Group P|Exposed to an acute painful phenomenon requiring an analgesic management
89194742|NCT00738036||Group C|Control, not exposed to acute pain
89194743|NCT05741424||Before innovative diagnostic technologies|
89194744|NCT05741424||After innovative diagnostic technologies|
89194745|NCT00883870|Experimental|mesenchymal stem cells|Intramuscular injection
89194746|NCT00883870|Experimental|Placebo|Intramuscular injection
89194747|NCT04038892|Active Comparator|Control Group|Patients in this group will receive conventional chest physiotherapy, two times a day, 7 days a week for 8 weeks. After the training given by the physiotherapist, all exercise sessions will be performed at home.
89421434|NCT04969900|Placebo Comparator|Placebo - Jojoba Oil (100% organic golden expeller-pressed Simmondsia chinensis)|Study randomization to lavender aromatherapy or placebo will occur just prior to the initiation of the abortion procedure. A permutated block stratified randomization scheme will be utilized so that equal numbers of participants receiving no sedation and PO sedation will be randomized to lavender aromatherapy or placebo. 1cc of dilute lavender aromatherapy and placebo will be pre-filled in a 5/8 dram mini amber glass bottle provided to the patient. Immediately prior to procedure start (defined as after receiving antibiotic and emptying bladder), participants will be instructed to self-administer the study product. They will bring down their personal cloth mask to chin level and rub the study product within the amber glass bottle on their upper lip and nose (left and right ala, alarfacial grooves, and columella). Participants will be instructed to take 4 deep breaths and then replace their mask over their nose. The patient will then proceed to the procedure.
89530826|NCT03232021|Experimental|Group III|Administration of 150mg of pregabalin 1 hour prior to the surgical operation
89530827|NCT04499183|Experimental|non-digestible carbohydrates|fructo- and galacto-oligosaccharides
88820036|NCT01469234|Placebo Comparator|placebo|Participants will receive one dose of placebo following randomization at 120 minutes of exposure during visit 4.
89530828|NCT04499183|Placebo Comparator|placebo|maltodextrin
88820037|NCT04349319|Other|Digital preoperative planning|To use digital preoperative planning software
88820038|NCT06196021|Active Comparator|Grup 1 quadriceps strengthening exercises|"The patients in group 1 received Quadriceps strengthening exercises with isokinetic dynamometer device. Strengthening exercises were applied to the Quadriceps muscle group by the physiotherapist for 4 weeks, 3 days a week, 30 minutes a day, for a total of 12 sessions.~All patients received patient education and intra-articular hyaluronic acid injection (once a week, 3 times in total) into the symptomatic knee.~Patient education: Just before the start of treatment, an education program consisting of general information about their disease, daily activity modifications and knee joint protection principles was applied by the physician to the patients within a period of approximately 10-15 minutes."
88820039|NCT06196021|Active Comparator|Grup 2 a home exercise program|"The patients in group 2 received a home exercise program. A home exercise program consisting of knee joint range of motion, quadriceps adjustment, and strengthening exercises for abductor and adductor muscle groups was demonstrated by the physiotherapist.They were asked to do the exercises 5 days a week, 2 times a day, with 10 repetitions. Patients were called every 15 days and asked to continue their home exercise program.~All patients received patient education and intra-articular hyaluronic acid injection (once a week, 3 times in total) into the symptomatic knee.~Patient education: Just before the start of treatment, an education program consisting of general information about their disease, daily activity modifications and knee joint protection principles was applied by the physician to the patients within a period of approximately 10-15 minutes."
88820040|NCT06196021|Placebo Comparator|Grup 3 did not receive exercise|"The patients in group 3 did not receive an exercise program.~All patients received patient education and intra-articular hyaluronic acid injection (once a week, 3 times in total) into the symptomatic knee.~Patient education: Just before the start of treatment, an education program consisting of general information about their disease, daily activity modifications and knee joint protection principles was applied by the physician to the patients within a period of approximately 10-15 minutes."
88820041|NCT06196008|Experimental|Arm I (Telephone-based coaching session)|Patients attend telephone-based coaching sessions over 20-50 minutes once 7-14 days before standard of care surgery, and then at days 7, 14, 21, and 51 post-discharge, for a total of 5 sessions. Patients also receive a personalized physical activity program and set fitness goals. FCGs also receive coaching and serve as a walking buddy for their patient. Patients and FCGs also wear an activity monitor throughout the trial.
88820042|NCT06196008|Active Comparator|Arm II (Written education)|Patients receive written educational materials on physical activity and cancer survivorship. Patients and FCGs also wear an activity monitor throughout the trial.
88901446|NCT01520350|Placebo Comparator|Mood stabilizer + placebo|
88901447|NCT01520376|Active Comparator|Counselling|People receiving a psychiatric evaluation after screening (HADS test > 12 points) and revised at 1 and 6 months
88901448|NCT01520376|No Intervention|Usual care|People after screening (HADS test > 12 points) and send to their primary care physician
88901449|NCT01520389|Experimental|MM-151 Dose Escalation|MM-151 Dose escalation frequency - once weekly, once every two weeks, once every three weeks
88901450|NCT01520389|Experimental|MM-151 Expansion in KRAS wild type colorectal cancer|MM-151 given weekly
88901451|NCT01520389|Experimental|MM-151 + irinotecan|MM-151 given weekly, irinotecan 180 mg/m2 given once every two weeks
88901452|NCT01520415|Active Comparator|bupivacaine|
88901453|NCT01520415|Placebo Comparator|saline|
88901454|NCT01520428|Active Comparator|Motivational Interviewing, CBT and E-mail support|
88901455|NCT01520428|Active Comparator|E-Mail-support|
88901456|NCT01520441|Experimental|BOTOX Injection|A total of 200 units of BoNT-A diluted in 4ml of preservative free saline will be injected into the right prostate lobe (i.e. transition and peripheral zones). A similar injection template with 1.0ml volume injections of saline will be injected into the left prostate lobe (2 injections in transition zone, 2 injections in peripheral zone for total volume of 4ml).
88901457|NCT01520467|Experimental|Anastrozole|stratification according to the rare disease. Oral administration of Anastrozole (1mg/day) for 18 months
88901458|NCT01520467|Placebo Comparator|Placebo|stratification according to the rare disease. Oral administration of 1 placebo tablet /day for 18 months
88901459|NCT01520480||Non-pathological fracture|Non pathological subtrochanteric femur fractures
88901460|NCT01520480||Pathological fracture|Pathological subtrochanteric fractures
88901461|NCT01520493|Experimental|Exercise|All patients are subject to this Arm.
88901462|NCT01520571|Active Comparator|Non-Computer Assistance TKA|Non-Computer Assistance TKA
88901463|NCT01520571|Experimental|Computer Assistance TKA|Computer Assistance TKA
88901464|NCT01520584|Active Comparator|vitamale|
88901465|NCT01520584|Placebo Comparator|sham pill|
88901466|NCT01520610||CTT|Patients with cardiopathy of tako TSUBO.
88901467|NCT01520610||SCA|Patients with acute coronary syndrome but without Tako-TSUBO cardiomyopathy.
88901468|NCT01520610||Surgical stress|patients with stressful event (emergency postoperative patients) but without Tako-TSUBO cardiomyopathy.
88901469|NCT01520623|Other|Allografted patients|Allografted patients with myeloablative conditioning for an haematological malignancy. Patients will be followed for at least 12 months after transplantation and blood samples drawn before conditioning and once a week for 12 weeks after transplantation to analyze the serum concentration of Complement factors (C3, C4, B factor), Complement regulatory proteins (C1-inhibitor, I and H Factors) and analysis of the surface expression of Complement regulatory molecules such as CD46, CD55 and CD59 and the serum inflammatory cytokine levels
88901470|NCT01520636|Placebo Comparator|group 1: standard physiotherapy|daily physiotherapy aiming at preventing complications, going with the patient progress capacities, passive mobilisation, sitting as soon as possible, walking when possible, respiratory physiotherapy. 15-20 minutes total per day.
88901471|NCT01520636|Experimental|group 2: experimental physiotherapy|physiotherapy as described above added to verticalisation as soon as possible; active, intense and repeated motor exercises for limbs and trunk with all the available techniques. 60 minutes total per day.
89421435|NCT04969900|Active Comparator|Investigational Product - A 10% dilute Lavandula angustifolia - jojoba oil essential oil blend|Study randomization to lavender aromatherapy or placebo will occur just prior to the initiation of the abortion procedure. A permutated block stratified randomization scheme will be utilized so that equal numbers of participants receiving no sedation and PO sedation will be randomized to lavender aromatherapy or placebo. 1cc of dilute lavender aromatherapy and placebo will be pre-filled in a 5/8 dram mini amber glass bottle provided to the patient. Immediately prior to procedure start (defined as after receiving antibiotic and emptying bladder), participants will be instructed to self-administer the study product. They will bring down their personal cloth mask to chin level and rub the study product within the amber glass bottle on their upper lip and nose (left and right ala, alarfacial grooves, and columella). Participants will be instructed to take 4 deep breaths and then replace their mask over their nose. The patient will then proceed to the procedure.
89421436|NCT04969666|Experimental|IPED2015_dose 1|Active treatment
89421437|NCT04969666|Experimental|IPED2015_dose 2|Active treatment
88901472|NCT01520649|Experimental|NSI-189 Phosphate|There will be 3 ascending cohorts. The first cohort will be administered 40 mg once daily (q.d). The second cohort will be administered 40 mg twice daily (b.i.d). The third cohort will be administered 40 mg three times daily (t.i.d).
88901473|NCT01520649|Placebo Comparator|microcrystalline cellulose capsules|The first cohort will be administered 40 mg once daily (q.d). The second cohort will be administered 40 mg twice daily (b.i.d). The third cohort will be administered 40 mg three times daily (t.i.d).
88901474|NCT01520662|Experimental|Wellness Portal Intervention|Wellness Portal Intervention: patients have access to the portal in the course of the study.
88901475|NCT01520662|No Intervention|Wellness Portal Control|Control patients don't have access to the Wellness Portal in the course of the study.
88901476|NCT01520675|Active Comparator|Surgery|Patients will be randomized to surgery
88901477|NCT01520675|Active Comparator|Endotherapy|Patients will be randomized to endoscopic therapy
88901478|NCT01520740|Active Comparator|Collateral Ventilation Positive (CV+)|
88901479|NCT01520740|Active Comparator|Collateral Ventilation Negative (CV-)|
88901480|NCT01520753|Experimental|BIAsp 70|
88901481|NCT01520753|Experimental|BIAsp 70 + BIAsp 50|
88901482|NCT01520766|Experimental|glass fiber|
88901483|NCT01520766|Experimental|titanium|
88901484|NCT01520779||Patients with recurrence|Hepatocellular carcinoma patients with intra-hepatic or distant recurrence of hepatocellular carcinoma within 1 year after radiofrequency ablation
88901485|NCT01520779||Patients with no recurrence|Hepatocellular carcinoma with no intra-hepatic or distant recurrence of hepatocellular carcinoma within 1 year after radiofrequency ablation
88901486|NCT01520792|Experimental|Paracetamol|
89421438|NCT04969666|Placebo Comparator|Placebo|Placebo treatment
89421439|NCT04969588||Children and adult|Participants aged 6-65 years old are recruited for the measurements of depth camera, bioelectrical impedance analysis and dual energy X-ray absorptiometry.
88901487|NCT01520805|Experimental|CPI-613|CPI-613 will be intravenously infused over 2 hours, given twice weekly for 3 weeks followed by a week of rest.
88901488|NCT01520818|Experimental|BIAsp 50 or 70|
88901489|NCT01520818|Active Comparator|BHI 30|
88901490|NCT01520831|Experimental|BIAsp 30|
88901491|NCT01520831|Experimental|BIAsp 50|
88901492|NCT01520831|Experimental|BIAsp 70|
88901493|NCT01520831|Active Comparator|Insulin aspart|
89421440|NCT04432168|Experimental|Fetoscopic Laser Surgery|fetoscopic laser coagulation of the vascular anastomoses at the placental surface
89421441|NCT04432168|Other|Standard Treatment|Expectant management, IUT (with or without PET), preterm delivery
88901494|NCT01520844|Other|Cohort study|Blood sampling
88901495|NCT01520857|Active Comparator|Spinal anesthesia|Transabdominal Preperitoneal repair of inguinal hernia. spinal anesthesia
88901496|NCT01520857|Active Comparator|General Anesthesia|Transabdominal Preperitoneal repair of inguinal hernia. general anesthesia
89194748|NCT04038892|Experimental|Nintendo Wii Fit Training Group|In addition to conventional chest physiotherapy programme, patients in this group will also receive Nintendo Wii Fit based exercise training for 40 minutes, 2 times in a week for 8 weeks. All exercise sessions will be supervised by physiotherapist in a clinic per week.
89194749|NCT04038892|Experimental|BreathingLabs Breathing Games Training Group|In addition to conventional chest physiotherapy programme, patients in this group will also receive BreathingLabs Breathing Games based exercise training for 40 minutes, 2 times in a week for 8 weeks. All exercise sessions will be supervised by physiotherapist in a clinic per week.
89194750|NCT00738114||1|group without hyperglycemia (fasting blood glucose below 126mg/dl) approximately 1000 patients
89194751|NCT00738114||2|group with hyperglycemia (fasting blood glucose above 125 mg/dl) or history of diabetes approximately 500 patients
89194752|NCT05525130|Experimental|Food supplement|Two doses (sachets) a day during 4 weeks before the ESWL. After the ESWL, one dose a day during 6 weeks.
89194753|NCT05525130|Placebo Comparator|Placebo|Two doses (sachets) a day during 4 weeks before the ESWL. After the ESWL, one dose a day during 6 weeks.
89194754|NCT05507190|Experimental|One arm|Self-management group. This pilot-study uses a one-group before-after design.
89194755|NCT02567994|Experimental|Teneligliptin|20mg qd
89194756|NCT02567994|Active Comparator|Sitagliptin|100mg qd
89194757|NCT00738192|Active Comparator|1|Fentanyl delivered for controlling awaking pain
89194758|NCT00738192|Active Comparator|2|Sufentanil delivered for controlling awaking pain
89194759|NCT00738192|Active Comparator|3|Butorphanol delivered for controlling awaking pain
89194760|NCT00875134|Experimental|Verbal prompt, cutaneous stimulation|Patient receives either or both a verbal stimulus or cutaneous stimulus
89194761|NCT05697978|Other|Monofocal lens|Eyes of patients with implanted monofocal aspheric lens Clareon (Alcon LLC)
88901497|NCT01520883||DEcisional conflict|
89194762|NCT04681534|Active Comparator|conventional DBS|
89194763|NCT04681534|Experimental|adaptive DBS|
89194764|NCT00883948|Experimental|1|Participants will receive initial minimal (trophic) enteral feeding.
88901498|NCT01520896|Experimental|Part 1 - A|Single dose NKTR-118 25 mg on Day 1 only
88901499|NCT01520896|Active Comparator|Part 1 - B|Ketoconazole 400 mg once daily on Days 4 to 8
89194765|NCT00883948|Experimental|2|Participants will receive initial full-calorie enteral feeding.
89194766|NCT05695326|Experimental|Effects of a 3D Printing Technology Learning Program|
89194767|NCT00738348|Active Comparator|2|250mL of 5% glucose plus 300mg of sivelstat was infected through the vein at 10mL per an hour
89194768|NCT00738348|Placebo Comparator|1|250mL of 5% glucose was injected though the vein at 10mL per an hour
89194769|NCT00884026|Active Comparator|1|Subjects that experience hypotension after spinal anesthesia.
89194770|NCT00884026|Active Comparator|2|Subjects that do not experience hypotension after spinal anesthesia.
89194771|NCT05678946||Integrated face-to-face rehabilitation and telerehabilitation|Participation in integrated face-to-face rehabilitation and telerehabilitation services for family caregivers organized by the Social Insurance Institution of Finland (Kela)
89194772|NCT05678946||Social Holidays|Participation in face-to-face Social Holidays for family caregivers organized by Maaseudun Terveys- ja Lomahuolto (MTLH), a non-profit organization
89194773|NCT05678946||Face-to-face rehabilitation|Participation in face-to-face rehabilitation services for family caregivers and the care recipients organized by Kela
89194774|NCT00875290|No Intervention|Control|Observational arm
89194775|NCT00875290|Experimental|Real-time glucose sensor|Subjects wear real-time glucose sensor
89194776|NCT00923416||Prostate Cancer|
89194777|NCT00884104|Experimental|1.tamsulosin + solifenacin|
89194778|NCT04140214|Experimental|Standard Care and HTS|Standard care and twice-daily nebulised HTS (MucoClear 6%, PARI Pharma). Participants will be instructed to administer a 1 x 4 mL ampoule twice daily for 52 weeks using the eFlow rapid nebuliser and eTrack controller (PARI Pharma).
89421442|NCT04969354|Experimental|CAR-T cell immunotherapy|The registered patients will received CAR-T cell immunotherapy for the new specific chimeric antigen receptor of CAIX antigen by infusion.
88901500|NCT01520896|Active Comparator|Part 1- C|Ketoconazole 400 mg plus NKTR-118 25 mg on Day 7
88901501|NCT01520935||Cohort Group|
88901502|NCT01520948|Experimental|Exercise-based behavioral therapy|Pelvic floor muscle exercise-based behavioral therapy
89421443|NCT04969432|Experimental|Telerehabilitation|
89421444|NCT04969432|Experimental|Face-to-face|
89421445|NCT04969042|Experimental|Stimulation|Participants will receive pre-implantation rehabilitation, implantation of the closed-loop spinal cord stimulator, and stimulation (according to the functional mapping) assisted rehabilitation post-implantation during the trial.
89421446|NCT04968730|Placebo Comparator|control group A|routine nursing after operation
89421447|NCT04968730|Experimental|intervention group B|Nursing care after operation with stage intervention
89421448|NCT04968262||Sepsis|Patients receive sepsis therapy.
89421449|NCT04968262||Sepsis-related acute kidney injury|Patients receive sepsis and sepsis-related acute kidney injury therapy.
88901503|NCT01520948|Placebo Comparator|Behavioral control|Mirrored Star Drawing
88901504|NCT01520961||Hueter Anterior Approach|
88901505|NCT01520961||posterolateral approach|
88901506|NCT01520974|Active Comparator|Probiotic tablet|
88901507|NCT01520974|Placebo Comparator|Placebo tablet|Comparison tablet without the probiotic bacteria
88901508|NCT01521000|No Intervention|Observation|Observation arm will continue to be followed with serial L-Dex and water volume displacement methods.
88901509|NCT01521000|Other|Intervention-garment sleeve|If the L-Dex is outside the normal range, or has increased 10 units from baseline, the patient will then be randomized to wear a compression sleeve (20 to 30 mm of Hg) daily for 4 weeks or observation (no sleeve). After 4 weeks, L-Dex measurements and water volume displacement will be reassessed in the treatment group.
88901510|NCT01521013|Active Comparator|Supported self-care|
88901511|NCT01521013|Active Comparator|Unsupported self-care|
88901512|NCT01521052|Experimental|elderly depressed patients|Twenty seven (27) patients aged 68 years or above, currently suffering from a major depressive episode, who did not respond to treatment with at least one antidepressant medications in the recommended dosage and duration, or could not tolerate at least two antidepressants.
88901513|NCT01521065|Experimental|16 Gy IRay|16 Gy IRay + PRN Lucentis®
88901514|NCT01521078|Experimental|Intervention|Provided access to the Check Your Drinking University version (CYDU).
88901515|NCT01521078|No Intervention|Control|No invention control group
88901516|NCT01521130|No Intervention|Healthy Control|Healthy Control
88901517|NCT01521130|No Intervention|BECTS, no medication|BECTS, no medication
89194779|NCT04140214|Experimental|Standard Care and Carbocisteine|Standard care and carbocisteine (750 mg three-times-per-day until visit 3, reducing to 750 mg two times per day) over 52 weeks.
88901518|NCT01521130|Experimental|Levetiracetam Higher dose|Levetiracetam Higher dose
88901519|NCT01521156|Active Comparator|1 = Control product|
88901520|NCT01521156|Experimental|2 = Tested product|
88901521|NCT01521169|Active Comparator|1 = Tested product dose 1|
88901522|NCT01521169|Active Comparator|2 = Tested product dose 2|
88901523|NCT01521169|Sham Comparator|3 = Control product|
88901524|NCT01521182|Active Comparator|1 = Tested product|
88901525|NCT01521182|Placebo Comparator|2 = Control product|
88901526|NCT01521195|Experimental|Patients on veno-arterial (VA) ECMO|
89421450|NCT03061006|Experimental|Dabigatran Etexilate|150 mg BID (CrCL > 30 mL/min) or 75 mg BID (CrCL 15-30 mL/min)
89421451|NCT03061006|Active Comparator|Warfarin|Dose-adjusted warfarin (INR: 2.0-3.0)
89421452|NCT03060928|Active Comparator|Control|Arthroscopic Rotator Cuff Repair with standard treatment
89421453|NCT03060928|Experimental|Experimental 1|Arthroscopic Rotator Cuff Repair with standard treatment + biological stimulation with micro-perforations
89421454|NCT03060928|Experimental|Experimental 2|Arthroscopic Rotator Cuff Repair with standard treatment + biological stimulation with the combination of micro-perforations and use of Artelon® Tissue Reinforcement
89421455|NCT03061240|Experimental|Postoperative patients|We recruit postoperative patients who undergo open surgery and are not receiving local anesthesia. We install a smart pain assessment tool on patient's skin to capture different type of data.
89421456|NCT03055702|Experimental|SMS group|receive a mobile phone text reminder for scheduled clinic appointment 24-72 hours before,
89421457|NCT03055702|No Intervention|Usual care group|Usual care, either telephone reminder or no reminder
89421458|NCT04980274||Group 1|Patients with SOFA score < 2 on admission
89421459|NCT04980274||Group 2|Patients with SOFA score equal to or > 2 on admission and who improved after 48 hours of treatment
89421460|NCT04980274||Group 3|Patients with SOFA score equal to or > 2 on admission and who did not improve after 48 hours of treatment
89421461|NCT04920214||Experimental group|"patients with hepatic focal lesions~patients with non-high risk factors for hepatocellular carcinoma"
89421462|NCT04919902||Electric cardioversion|Patients who underwent elective cardioversion for atrial arrhythmia
89421463|NCT04967794|Active Comparator|Group Whatsapp|Will receive standardized brushing Teleorientation consultation through the Whatsapp communication platform
89421464|NCT04967794|Active Comparator|Group Vídeo for Health|You will receive a standardized brushing Teleorientation consultation through the V4H Platform, created specifically for Teleconsultations
89421465|NCT04967794|Active Comparator|Group de Orientação presencial|You will receive a standardized face-to-face brushing orientation consultation.
88814229|NCT02488824|Experimental|Warm Temperature Exposure in Tetraplegia|Subjects are persons with higher-level spinal cord injury, levels C3 to T4, and ASIA Impairment Scale (AIS) level A and B, ages 18-68 years. Procedure is exposure to warm temperature (95 degrees Fahrenheit) for up to 2 hours in a temperature-controlled room in order to assess the body's temperature-regulating mechanisms and any associated change in cognitive performance
89421466|NCT04919746|Experimental|Group Acupuncture 1 - GA1|Healthy individuals aged between 18 and 38 years. The dielectric constant will be evaluated with a depth measurement of 0.5 mm, elasticity and infrared thermography in the region of the systemic acupuncture points.
89421467|NCT04919746|Experimental|Group Acupuncture 2 - GA2|Healthy individuals aged between 18 and 38 years. The dielectric constant will be evaluated with a depth measurement of 2.5 mm, elasticity and infrared thermography in the region of the systemic acupuncture points.
89421468|NCT04919746|Experimental|Group Acupuncture 3 - GA3|Healthy individuals aged between 18 and 38 years. The dielectric constant will be evaluated with a depth measurement of 5.0 mm, elasticity and infrared thermography in the region of the systemic acupuncture points.
89421469|NCT04919746|No Intervention|Group Control 1 - GC1|Healthy individuals aged between 18 and 38 years. The dielectric constant will be evaluated with a depth measurement of 0.5 mm, elasticity and infrared thermography in the region of the systemic acupuncture points.
89421470|NCT04919746|No Intervention|Group Control 2 - GC2|Healthy individuals aged between 18 and 38 years. The dielectric constant will be evaluated with a depth measurement of 2.5 mm, elasticity and infrared thermography in the region of the systemic acupuncture points.
89421471|NCT04919746|No Intervention|Group Control 3 - GC3|Healthy individuals aged between 18 and 38 years. The dielectric constant will be evaluated with a depth measurement of 5.0 mm, elasticity and infrared thermography in the region of the systemic acupuncture points.
89421472|NCT04980196||(1) URODYNAEMICS GROUP|30 patients allocated for group (1) had been thoroughly evaluated by history and examination. A standardized questionnaire was obtained to evaluate the symptoms of stress urinary incontinence, urge urinary incontinence and obstructive symptoms. Clinical staging of pelvic organ prolapse by POP Q Staging .Ultrasound examination had been also carried out to rule out any pelvic pathology. Patients had completed a 3-day bladder diary (frequency volume chart) to assist in arriving at an urodynamic diagnosis. Urinalysis was performed. And to urodynamic studies were performed before surgical intervention and then corrective procedures for POP had been done uroflowmetry and cystometry. All participants were followed-up with same questionnaire and clinical examination after 12 weeks post -operatively
89421473|NCT04980196||(2)NON URODYNAMICS GROUP|30 patients allocated for group (2) had been thoroughly evaluated by history and examination. A standardized questionnaire was obtained to evaluate the symptoms of stress urinary incontinence, urge urinary incontinence and obstructive symptoms. Clinical staging of pelvic organ prolapse by POP Q Staging .Ultrasound examination had been also carried out to rule out any pelvic pathology. Patients had completed a 3-day bladder diary (frequency volume chart) to assist in arriving at an urodynamic diagnosis. Urinalysis was performed and then corrective procedures for POP had been done.All participants were followed-up with same questionnaire and clinical examination after 12 weeks post-- operatively
89421474|NCT04980118|Placebo Comparator|Control group|Individual nutritional intervention.
89421475|NCT04980118|Experimental|Experimental group|Individual nutritional intervention with two groupal sessions and physical activity.
89421476|NCT03672188|Experimental|Part A: SAD VIR-2218 50 mg|Healthy subjects received a single dose of VIR-2218 of 50 mg administered SC
89421477|NCT03672188|Experimental|Part A: SAD VIR-2218 100 mg|Healthy subjects received a single dose of VIR-2218 of 100 mg administered SC
89421478|NCT03672188|Experimental|Part A: SAD VIR-2218 200 mg|Healthy subjects received a single dose of VIR-2218 of 200 mg administered SC
89421479|NCT03672188|Experimental|Part A: SAD VIR-2218 400 mg|Healthy subjects received a single dose of VIR-2218 of 400 mg administered SC
89421480|NCT03672188|Experimental|Part A: SAD VIR-2218 600 mg|Healthy subjects received a single dose of VIR-2218 of 600 mg administered SC
89421481|NCT03672188|Experimental|Part A: SAD VIR-2218 900 mg|Healthy subjects received a single dose of VIR-2218 of 900 mg administered SC
89421482|NCT03672188|Placebo Comparator|Part A: SAD Placebo|Healthy subjects received a single dose of placebo administered SC
89421483|NCT03672188|Experimental|Part B: MAD VIR-2218 20 mg|Chronic HBV, HBeAg negative, subjects received 2 SC doses of 20 mg VIR-2218 administered 4 weeks apart.
89421484|NCT03672188|Experimental|Part B: MAD VIR-2218 50 mg|Chronic HBV, HBeAg negative, subjects received 2 SC doses of 50 mg VIR-2218 administered 4 weeks apart.
89421485|NCT03672188|Experimental|Part B: MAD VIR-2218 100 mg|Chronic HBV, HBeAg negative, subjects received 2 SC doses of 100 mg VIR-2218 administered 4 weeks apart.
89421486|NCT03672188|Experimental|Part B: MAD VIR-2218 200 mg|Chronic HBV, HBeAg negative, subjects received 2 SC doses of 200 mg VIR-2218 administered 4 weeks apart.
89421487|NCT03672188|Experimental|Part C: MAD VIR-2218 50 mg|Chronic HBV, HBeAg positive, subjects received 2 SC doses of 50 mg VIR-2218 administered 4 weeks apart.
88814230|NCT02488824|Active Comparator|Warm Temperature Exposure in Able-Bodied|Subjects are able-bodied controls matched with participants with tetraplegia for age and gender. Procedure is exposure to warm temperature (95 degrees Fahrenheit) for up to 2 hours in a temperature-controlled room in order to assess the body's temperature-regulating mechanisms and any associated change in cognitive performance
88814231|NCT04346966|Experimental|Study Group|The group to which the exercise videos consisting of aerobic and strengthening exercises will be applied.
88814232|NCT04346966|No Intervention|Control Group|The control group where only the evaluations will be made and information about the benefits of exercise will be given.
88814233|NCT05204615||Prospective Long COVID cases|The target population will be 10 patients diagnosed during 2021 with long COVID, who will then be followed-up for one month.
88814234|NCT02242370|Experimental|Telmisartan low dose|
88814235|NCT02242370|Experimental|Telmisartan high dose|
88814236|NCT04371146|Experimental|Dopamine reuptake inhibitor|Participants in the dopamine reuptake inhibitor group will be asked to take one pill containing 35 mg methylphenidate 1.5 hours before performing the tasks.
88814237|NCT04371146|Experimental|Noradrenaline reuptake inhibitor|Participants in the noradrenaline reuptake inhibitor group will be asked to take one pill containing 8 mg reboxetine 1.5 hours before performing the tasks.
89421488|NCT03672188|Experimental|Part C: MAD VIR-2218 200 mg|Chronic HBV, HBeAg positive, subjects received 2 SC doses of 200 mg VIR-2218 administered 4 weeks apart.
89421489|NCT03672188|Placebo Comparator|Part B: MAD Placebo|Chronic HBV, HBeAg negative, subjects received 2 SC doses of placebo administered 4 weeks apart.
89421490|NCT03672188|Placebo Comparator|Part C: MAD Placebo|Chronic HBV, HBeAg positive, subjects received 2 SC doses of placebo administered 4 weeks apart.
89421491|NCT04919668|Sham Comparator|Low budget; no game|Participants will be asked to shop for 12 list items in the simulated grocery store without game elements (crowns and scoreboards) displayed. They will be given a low budget of $30.
88901527|NCT01521208|Active Comparator|LUCAS, Continuous chest compressions|Mechanical continuous chest compressions performed by LUCAS device (also during defibrillation)
89421492|NCT04919668|Active Comparator|High budget; no game|Participants will be asked to shop for 12 list items in the simulated grocery store without game elements (crowns and scoreboards) displayed. They will be given a high budget of $50.
88901528|NCT01521208|Active Comparator|Manual chest compressions|Manual chest compression is performed, chest compressions halted during defibrillation
88901529|NCT01521221|Experimental|Patients|Patients with autonomic failure.
89421493|NCT04919668|Active Comparator|Low budget; game|Participants will be asked to shop for 12 list items in the simulated grocery store with game elements (crowns and scoreboards) displayed. They will be given a low budget of $30.
89421494|NCT04919668|Active Comparator|High budget; game|Participants will be asked to shop for 12 list items in the simulated grocery store with game elements (crowns and scoreboards) displayed. They will be given a high budget of $50.
88901530|NCT01521221|Experimental|Healthy subjects|Control group
88901531|NCT01521234|Experimental|Feedback group|For participants assigned to the feedback group, physiotherapists will receive a summary of patients' walking activity for the previous week as a tool to guide goal planning. Physiotherapists will use the information as a 'homework checker' to determine if patients are complying with an assigned walking program. In the case of non-compliance, the physiotherapist will discuss a coping strategy for better integrating walking activity into the patients' day. In the event that the patient is meeting their specific sub-goals for walking activity, the physiotherapist will re-evaluate these sub-goals and suggest more challenging goals.
88901532|NCT01521234|No Intervention|No-feedback group|For participants assigned to the control group, physiotherapists will not receive accelerometer-based feedback of daily walking activity. However, physiotherapists will still discuss the achievement of walking goals with their patients. This is usual care around goal planning.
88901533|NCT01521247|No Intervention|Control group|Usual care.
88901534|NCT01521247|Other|Asthma Transition Program|Asthma Transition Program
88901535|NCT01521273|Experimental|high iron bean with native phytic acid concentration|
89194780|NCT04140214|Experimental|Standard Care and Combination of HTS and Carbocisteine|Standard care and combination of twice-daily nebulised HTS (MucoClear 6%, PARI Pharma) and carbocisteine. Participants will be instructed to administer a 1 x 4 mL ampoule twice daily for 52 weeks using the eFlow rapid nebuliser eFlow rapid nebuliser and eTrack controller (PARI Pharma). They will also be given carbocisteine (750 mg of three times per day until visit 3, reducing to 750 mg twice per day) over 52 weeks.
89194781|NCT04140214|No Intervention|Standard Care Only|Standard care over 52 weeks. Patients in the standard care group will use airway clearance techniques in the management of their BE.
89421495|NCT04919434|Other|Intervention|Women will be asked NOT to use their own personal care product during the intervention. They will only have to use the substitute one given by the research team
89421496|NCT03060694||Diabetes group|Patients in this group are recruited from both departments of endocrinology and gastroenterology. The diagnosis of diabetes is confirmed by medical history, using anti-diabetic medicines or laboratory tests.
89421497|NCT03060694||Non-diabetes group|Patients in this group are recruited from department of gastroenterology. The exclusion of diabetes is confirmed by medical history or laboratory tests.
89421498|NCT03239990|Experimental|Incredible Years, Parent support|Incredible Years, Parent group supported by home visiting includes the Incredible Years Parent Training Program, Preschool Basic version, with 18-20 group meetings. Four home visits are added to the program to support parents in practicing new skills and to provide individual practical consultation.
89421499|NCT03239990|No Intervention|Treatment as usual|The control group will receive treatment as usual
89421500|NCT03060850|Experimental|AC0010MA|This is dose escalation study. Patients will receive AC0010MA 200mg bid,300mg bid,400mg bid or 500mg bid by mouth (the dose escalation whether ended depends on DLT and occupancy) everyday until intolerable toxicity or disease progression
89421501|NCT04432558||Preoperative anxiety level|
89421502|NCT04432558||Postoperative pain and analgesic consumption|
89421503|NCT04770428|Experimental|Cohort 1: Japanese MEDI7352|Randomized Japanese participants will receive single doses of MEDI7352 subcutaneously.
89421504|NCT04770428|Placebo Comparator|Cohort 1: Japanese Placebo|Randomized Japanese participants will receive matching placebo subcutaneously.
89421505|NCT04770428|Experimental|Cohort 2: Caucasian MEDI7352|Randomized Caucasian participants will receive single doses of MEDI7352 subcutaneously.
89421506|NCT04770428|Placebo Comparator|Cohort 2: Caucasian Placebo|Randomized Caucasian participants will receive matching placebo subcutaneously.
89421507|NCT04919278|Experimental|Intervention group|Participants will be evaluated for any health contraindication. Once reviewed they will received full spine chiropractic treatment for 4 weeks, at the rate of one adjustment per week. After three visits they will complete the outcome measures
88901536|NCT01521273|Experimental|normal iron bean with native phytic acid concentration|
88901537|NCT01521273|Experimental|high iron bean partially dephytinized|
88901538|NCT01521273|Experimental|normal iron bean partially dephytinized|
88901539|NCT01521273|Experimental|high iron bean totally dephytinized|
88901540|NCT01521273|Experimental|normal iron bean totally dephytinized|
88901541|NCT01521286||Group A|Subjects presenting with HZ episode.
88901542|NCT01521312|Experimental|Saxagliptin|Saxagliptin 5 mg (tablet) at BREAKFEAST
88901543|NCT01521312|Placebo Comparator|placebo pill|at BREAKFEAST
88901544|NCT01521325|Experimental|Amatuximab infusion|Subjects will receive one infusion of radiolabeled amatuximab.
89421508|NCT04919278|No Intervention|Control group|Paticipants will be selected amongst thse attending predelivery sessions. They receive no chiropracti care. They will complete the outcomes at the same time as the Intervention group and then 4 weeks later.
89421509|NCT04979650|Active Comparator|The intervention group|The intervention group will receive 1 gram of methylprednisolone succinate within 500 ccs of normal saline within 5 hours.
89421510|NCT04979650|Placebo Comparator|The control group|The control group will receive 500 g of normal saline without methylprednisolone succinate.
89421511|NCT04919044|Experimental|Motor Imagery|The participants were instructed to imagine and visualize to straighten both knees with eyes closed. You have to see and feel only what you would see and feel if you had to perform the action to straighten both of your knees in sitting position. Imagine the movement using the most comfortable way for you, and make sure not to contract your muscles.
89421512|NCT04919044|No Intervention|Control|No intervention provided.
89421513|NCT04919200||modeling group|Of these 628 individuals, we set 407 patients enrolled from January 2018 to November 2019 as the modeling group
89421514|NCT04919200||verification cohort|221 patients enrolled from December 2019-December 2020 served as a prospective verification cohort
88901545|NCT01521351||carotid thermal heterogeneity|Patients that have carotid thermal heterogeneity detected by MR
89421515|NCT04967716||Peroneal muscular atrophy|Peroneal muscular atrophy (Charcot-Marie-Tooth, CMT) is a group of genetic diseases that invade the peripheral nervous system with very high genetic heterogeneity. It was proposed by Charcot, Marie of France and Tooth of the United Kingdom in 1886. The prevalence is about 1/2500-4000. It is the most common hereditary peripheral neuropathy. Inheritance includes all forms of Mendelian inheritance. The typical clinical manifestations are progressive, length-dependent limb weakness and atrophy, accompanied by hypoesthesia and weakened tendon reflexes.
89421516|NCT04703738|Active Comparator|Control|Soft tissue flap + Connective Tissue Graft
89421517|NCT04703738|Experimental|Test|Soft tissue flap + Geistlich Fibro-Gide®
89421518|NCT04967404|Experimental|Phosphatidylserine, 800 mg per day, 10 days|
89421519|NCT04967404|Placebo Comparator|Maltodextrin, 800 mg per day, 10 days|
89421520|NCT04650152||Fenofibrate|Adult patients with triglycerides > 2,3 mmol/l who are on statins and who are primary prescribed fenofibrate (or fenofibrate treatment break is at least 6 months) in accordance with ordinary physician practice in Russia.
89421521|NCT04967950|Experimental|Secukinumab 300mg|Randomized in a 1:1:1 ratio to secukinumab 300mg or secukinumab 150mg or MTX 15mg qw
89421522|NCT04967950|Experimental|Secukinumab 150mg|Randomized in a 1:1:1 ratio to secukinumab 300mg or secukinumab 150mg or MTX 15mg qw
89421523|NCT04967950|Active Comparator|methotrexate|methotrexate
89421524|NCT04967326|Experimental|Patients with epilepsy|The therapies of patients with epilepsy were optimized using pharmacists' interventions, including medication consultation, dosage adjustment, medication switching/discontinuation, or combination therapy.
89421525|NCT03145142|Active Comparator|Umbilical Cord Milking|Milking the umbilical cord 4 times towards the infant at a speed of 20cm over 2 seconds.
89421526|NCT03145142|Active Comparator|Delayed Cord Clamping|Delayed clamping of the umbilical cord for at least 60 seconds.
89421527|NCT03062176|Experimental|Active Treatment|Anakinra (Kineret)
89421528|NCT03472820|Experimental|Intervention Group|The intervention will be diet, lifestyle, exercise and stress management recommendations combined with taking two different supplements twice daily, in divided doses.
89421529|NCT03472820|No Intervention|Control Group|The control group will undergo the same testing measures as the intervention group, but will not have access to the education information or be instructed to change diet or lifestyle factors. They will have access to the information after the study is complete.
89421530|NCT04967014|Experimental|Sequence A|Period I : RLD2104 Period II : HIP2104
89421531|NCT04967014|Experimental|Sequence B|Period I : HIP2104 Period II : RLD2104
89421532|NCT03055286|Experimental|CWP232291 in combination with cytarabine (ara-C)|
89421533|NCT04918498|Placebo Comparator|routine treatment|Review the collection of patient-related clinical data, collation of clinical data and outcome indicators
89421534|NCT04918498|Experimental|Experimental group|Implement early physiotherapy programs. The early physiotherapy program for VV-ECMO patients mainly includes the establishment of multidisciplinary teams, safety assessment, early activity physiotherapy and respiratory physiotherapy.
89421535|NCT02915432|Experimental|3 mg/kg anti-PD-1 mAb JS001 Q2W|Subjects will be eligible for this study after they fulfill the inclusion criteria and exclusion criteria. Subjects diagnosed as the gastric adenocarcinoma, esophageal squamous cell carcinoma, nasopharyngeal carcinoma, or head and neck squamous cell carcinoma will receive treatment at the dose of 3 mg/kg.
89421536|NCT02915432|Experimental|360 mg anti-PD-1 mAb JS001 Q3W|Subjects will receive corresponding regimen of standard first-line chemotherapy combined with JS001 360 mg once every 3 weeks (Q3W). JS001 360 mg Q3W can be administrated after the end of chemotherapy until absence of further benefits judged by the investigator, disease progression, occurrence of intolerable toxicity, investigator's decision, and withdrawal of informed consent by the subject, or death.
89421537|NCT02915432|Experimental|240mg anti-PD-1 mAb JS001 Q3W|Subjects will receive corresponding regimen of standard first-line chemotherapy combined with JS001 240 mg once every 3 weeks (Q3W). JS001 240 mg Q3W can be administrated after the end of chemotherapy until absence of further benefits judged by the investigator, disease progression, occurrence of intolerable toxicity, investigator's decision, and withdrawal of informed consent by the subject, or death
88901546|NCT01521351||no carotid thermal heterogeneity|Patients that DONT have carotid thermal heterogeneity detected by MR
88901547|NCT01521351||carotid artery disease|Patients with detected carotid artery disease by ultrasound
88901548|NCT01521351||no carotid artery disease|Patients with no carotid artery disease detected by ultrasound
88901549|NCT01521377|Placebo Comparator|Placebo|Single inhalation from matching placebo dry powder inhaler once daily on days 1-10. Single dose placebo oral tablet moxifloxacin.
88901550|NCT01521377|Active Comparator|Moxifloxacin Positive|Single inhalation from matching placebo dry powder inhaler once daily on days 1-10. Single dose oral tablet moxifloxacin (400mg) on day 10.
88901551|NCT01521377|Experimental|GSK573719 Supra-therapeutic dose|Single inhalation from GSK573719 (500 microgram) dry powder inhaler once daily on days 1-10. Single dose placebo oral moxifloxacin.
88901552|NCT01521377|Experimental|GSK573719/Vilanterol Therapeutic dose|Single inhalation from GSK573719/Vilanterol (125/25 microgram) dry powder inhaler once daily on days 1-10. Single dose placebo oral tablet moxifloxacin on day 10.
88901553|NCT01521377|Experimental|GSK573719/Vilanterol Supra-therapeutic dose|Single inhalation from GSK573719/Vilanterol (500/100 microgram) dry powder inhaler once daily on days 1-10. Single dose placebo oral tablet moxifloxacin on day 10.
88901554|NCT01521390|Other|Treatment Arm|Subjects receive one inhalation from each intervention
88901555|NCT01521416||Cohort Group|
88901556|NCT01521429||MPS I|Mucopolysaccharidosis I (Hurler, Scheie, Hurler-Scheie)
88901557|NCT01521429||MPS II|Mucopolysaccharidosis II (Hunter)
88901558|NCT01521429||MPS VI|Mucopolysaccharidosis VI (Maroteaux-Lamy)
88901559|NCT01521442|Experimental|Arm 1|12 sessions of Mindful Yoga Therapy delivered two times per week for 75 minutes each.
88901560|NCT01521442|Other|Arm 2|12-week delay before beginning Mindful Yoga Therapy treatment which will consist of 12 sessions of Mindful Yoga Therapy delivered two times per week for 75 minutes each.
88901561|NCT01521455|Experimental|HCP0910|Fluticasone /salmeterol 250/50 combination capsule
88901562|NCT01521455|Active Comparator|Seretide Diskus|Seretide 250 Diskus
88901563|NCT01521481|Experimental|Triple inguinal nerve block|Ropivacaine 5 mg/ml
88901564|NCT01521481|Active Comparator|Unilateral subarachnoid anesthesia|Bupivacaine 10 mg/ml
88901565|NCT01521520||Clinical Type 1 Diabetes|This group will be subdivided into individuals with recent onset clinical type 1 diabetes (within 6 months of diagnosis), latent autoimmune diabetes of the adult, and longer standing type 1 diabetes.
88901566|NCT01521520||High Risk Pre-Type 1 Diabetes|High risk pre-type 1 diabetes is defined as first degree family relative with type 1 diabetes and at least one islet autoantibody marker (GAD, IAA, or IA-2).
88901567|NCT01521520||Low Risk Pre-Type 1 Diabetes|Low risk pre-type 1 diabetes is defined as first degree family relative with type 1 diabetes but no islet autoantibody markers (GAD, IAA, or IA-2).
88901568|NCT01521520||Normal Control|Normal control is based on history with no known history or family history of type 1 diabetes.
88901569|NCT01521533|Experimental|NOX-A12|
88901570|NCT01521572|Experimental|Salbutamol|Short-acting bronchodilator for use in humans released by the Ministry of Health, widely used worldwide for the treatment of chronic obstructive pulmonary disease.
88901571|NCT01521585|Experimental|SEN0014196 50 mg oral tablet|
88901572|NCT01521585|Experimental|SEN0014196 200 mg oral tablet|
89194782|NCT00612508|Active Comparator|Desogen|"Drug: ethinyl estradiol and desogestrel~1 tablet every day; each tablet contains 0.15mg desogestrel and 0.03mg ethinyl estradiol; secen inactive pills every 28 days.~Subjects receive baseline vaginal biopsy, followed by treatment with the OC for six cycles and repeat biopsy at 3 and after 6 cycles"
89194783|NCT00612508|Active Comparator|NuvaRing|"Intravaginal Contraception~ethinyl estradiol (0.15 mg/d) and etonogestrel (0.12 mg/d) Place the ring in the vagina for 3 weeks, remove for one week. Repeat with new Ring~Subjects had baseline vaginal biopsy followed by 6 cycles of ring use and repeat biopsy at 3 and after 6 cycles"
89421538|NCT03062098|Experimental|IVF patients|IVF patients before embryo transfer. Before performing embryo transfer in the routine manner, ten patients will be asked to participate in the study. After signing informed consent, participants will undergo the experimental procedure: Speculum will be placed to visualize the cervix. The thin ultrasound probe will be places posterior to the cervix. While viewing the image on the ultrasound screen, the probe will be moved manually to obtain the best imaging of the cervical canal. An empty embryo transfer catheter will be introduced to the cervical canal and will be advanced under ultrasound imaging up to the internal os. The catheter will be withdrawn, and routine embryo transfer will follow.
89421539|NCT02178332|Experimental|Yhteispeli, whole school programme|Yhteispeli-programme aims to support children's socio-emotional skills and well being at schools. Schools receive the Yhteispeli manual and teachers receive 3 and head masters 2 lecture days about use of Yhteispeli methods including group discussions and exercises. In addition every school is visited 4 times to support the use of Yhteispeli methods. (Lectures for the head masters March 2013 - November 2013, teachers August 2013 - January 2014)
89421540|NCT02178332|Active Comparator|Two theoretical lectures|Teachers receive two theoretical lectures on development of children's socio-emotional skills (3 hours in November 2013 and 3 hours in March 2014 ).
89421541|NCT02620384|Placebo Comparator|Experimental: Placebo|This group will receive all standard heart failure therapy and placebo pill.
89421542|NCT02620384|Active Comparator|Experimental: Metolazone|This group will receive all standard heart failure therapy with addition of metolazone.
89421543|NCT03470870||Patients discharged before 2 days after surgery|patients discharged before 2 days of hospitalization following surgery
89421544|NCT03470870||Patients discharged after 2 days after surgery|patients discharging after 2 days of hospitalization following surgery
89421545|NCT04918576|Experimental|Tranexamic Acid|3 grams of tranexamic acid (30mL of 100 mg/mL solution) diluted in 10 mL of normal saline
89421546|NCT04918576|Placebo Comparator|Normal Saline|40 mL topical of 0.9% normal saline
89421547|NCT04214756||Patients treated pre-MAPP|The registry will collect data on all AP patients since August 2011, and will continue until a sufficient number of cases are obtained to reach statistical significance
89421548|NCT04214756||Patients treated post-MAPP|The registry will collect data on all AP patients since August 2011, and will continue until a sufficient number of cases are obtained to reach statistical significance
89421549|NCT04403308|Experimental|ONO-7913 as a Single Agent|
89421550|NCT02523170|Experimental|EUS guided nCLE|For patients with indeterminate cystic lesions of the pancreas, in addition to routine diagnostic investigations, patients participating in the study will undergo needle based confocal laser endomicroscopy (using the AQ-flex 19 probe - Mauna Kea Technologies, Paris France) at the time of their endoscopic ultrasound.
89421551|NCT03472508|Sham Comparator|0 mg folic acid|Enalapril Maleate (10mg) with 0 mg folic acid
89421552|NCT03472508|Active Comparator|0.4mg Folic acid|Enalapril Maleate and Folic Acid Tablets (Yiye) (10mg:0.4mg)
89421553|NCT03472508|Active Comparator|0.6mg Folic acid|Enalapril Maleate and Folic Acid Tablets (Yiye) (10mg:0.4mg) with 0.2 mg folic acid
89421554|NCT03472508|Active Comparator|0.8mg Folic acid|Enalapril Maleate and Folic Acid Tablets (Yiye) (10mg:0.8mg)
88901573|NCT01521585|Placebo Comparator|Placebo tablet|
88901574|NCT01521611|Experimental|Targeted radiotherapy|Patients receive therapy with an yttrium-90 labelled anti-CD66 following favourable dosimetry with the same antibody radiolabelled with indium-111.
88901575|NCT01521624|Active Comparator|Case|Metformin 1000 mg Daily in two divided doses plus advice for lifestyle modification
88901576|NCT01521624|No Intervention|Control|Subjects provided only advice for lifestyle modification with no drug intervention
88901577|NCT01521637|Experimental|NMES|The 'NMES' arm will be treated with NMES.
88901578|NCT01521637|Sham Comparator|No NMES|The 'No NMES' arm of the experiment will be sham-treated with NMES. The device will be installed, but not used.
88901579|NCT01521650|Experimental|Probiotics|Patients will gurgle and swallow a mixture of probiotic bacteria
89194784|NCT00881218|Experimental|Regadenoson CMR|Images in the cardiac short axis will be obtained using a gradient recalled echo sequence, TR 2.3 msec/TE 1.1 msec, 80*256 matrix, slice thickness 10 mm. Images will be obtained during power injection of 0.075 mmol/Kg of a conventional gadolinium based MR contrast agent at a rate of 5 mL/sec followed by a 15 mL saline flush into an antecubital vein. Perfusion imaging will be performed at stress and rest. Stress: Regadenoson 400 mcg will be administered IV bolus via an antecubital cannula. Immediately after injection, MR scanning will begin and contrast will be given. Rest: After 10 minutes, rest imaging will be performed identically, but without regadenoson injection. To identify late enhancement of myocardial tissue inversion recovery prepared images will be obtained.
88901580|NCT01521650|No Intervention|Control|No intervention. What has been the standard procedure so far
88901581|NCT01521676|Experimental|breast cancer|blood and tumor sample
88901582|NCT01521689|Experimental|Rituximab|Consolidation treatment with sub cutaneaous low doses of Rituximab
88901583|NCT01521702|Experimental|Neoadjuvant chemotherapy|After initial staging laparoscopy, Neoadjuvant chemotherapy consists of four bi-weekly cycles of gemcitabine (intravenous infusion of 1000mg/m2 over 30 minutes) and oxaliplatin (intravenous infusion of 100mg/m2 over 2 hours, modified from the Louvet protocol11).
88901584|NCT01521702|Active Comparator|surgery|surgery
88901585|NCT01521715|Experimental|Pazopanib|800 mg (2x400mg) pazopanib per day
89421555|NCT03472508|Active Comparator|1.2mg Folic acid|Enalapril Maleate and Folic Acid Tablets (Yiye) (10mg:0.8mg) with 0.4 mg folic acid
89421556|NCT03472508|Active Comparator|1.6mg Folic acid|Enalapril Maleate and Folic Acid Tablets (Yiye) (10mg:0.8mg) with 0.8 mg folic acid
89421557|NCT03472508|Active Comparator|2.0mg Folic acid|Enalapril Maleate and Folic Acid Tablets (Yiye) (10mg:0.8mg) with 1.2 mg folic acid
89421558|NCT03472508|Active Comparator|2.4mg Folic acid|Enalapril Maleate and Folic Acid Tablets (Yiye) (10mg:0.8mg) with 1.6 mg folic acid
89421559|NCT03470792|Experimental|Microcirculation-assisted|ECMO blood flow will be adjusted by conventional clinical conditions, hemodynamic parameters and microcirculation parameters
88901586|NCT01521728|Active Comparator|Resistance Exercise|Resistance will be administered using a series of adjustable cuff weights for the upper limbs and hip flexion. Knee flexion and extension will be administered with a weight bench using a leg exercise attachment and free weights.
88901587|NCT01521728|Active Comparator|Endurance Exercise|Endurance will be administered using a minicycle. It can be used from a sitting position (chair or wheelchair) for lower limb exercise and then placed on a tabletop for upper limb use.
89194785|NCT00613834|Experimental|Lidocaine group|Participants receive transcervical instillation of 5 ml 4% lidocaine solution 3 minutes prior to transcervical tubal sterilization
89421560|NCT03470792|Active Comparator|Control|ECMO blood flow will be adjusted by clinical conditions and conventional hemodynamic parameters
89421561|NCT04966936||Unilateral traumatic transfemoral amputee patients using C-Leg prosthesis|The activity levels of the patients will be evaluated by the Amputee Mobility Predictor, the mobility of the patients by the Locomotor Capacity Index, the prosthesis satisfaction in general with the visual analog scale (VAS), the walking ability and capacity with the prosthesis will be evaluated by the 2 min walking test, and the gait analysis will be evaluated in the motion analysis laboratory.
89421562|NCT04966936||Unilateral traumatic transfemoral amputee patients using Genium prosthesis|The activity levels of the patients will be evaluated by the Amputee Mobility Predictor, the mobility of the patients by the Locomotor Capacity Index, the prosthesis satisfaction in general with the visual analog scale (VAS), the walking ability and capacity with the prosthesis will be evaluated by the 2 min walking test, and the gait analysis will be evaluated in the motion analysis laboratory.
89421563|NCT04966936||Unilateral traumatic transfemoral amputee patients using Genium-X3 prosthesis|The activity levels of the patients will be evaluated by the Amputee Mobility Predictor, the mobility of the patients by the Locomotor Capacity Index, the prosthesis satisfaction in general with the visual analog scale (VAS), the walking ability and capacity with the prosthesis will be evaluated by the 2 min walking test, and the gait analysis will be evaluated in the motion analysis laboratory.
89421564|NCT04966312|Other|study group|mothers receiving routine education plus digital video disk before surgery
88901588|NCT01521728|Active Comparator|Stretching/Range-of-Motion Exercise|"In ALS, stretching and range of motion are routinely recommended for the prevention of frozen shoulder syndrome and contractures resulting from weakness. The problem is compounded in ALS where upper motor neuron dysfunction may result in spasticity and incapacitating contractures with pain. Therefore, maintaining an aggressive program for stretching and range of motion exercise is widely accepted as a standard of care for ALS management."
88901589|NCT01521754||Perspective|Prospective cohort: new patients who are initially implanted with a Medtronic neurostimulation system on or after a site's activation date. The classification is static and will not change in the case of a re-implant.
89194786|NCT00613834|Placebo Comparator|Control group|Participants receive transcervical instillation of 5 ml saline 3 minutes prior to transcervical tubal sterilization
89421565|NCT04966312|Other|control group|mothers receiving routine education
89421566|NCT03472430|Active Comparator|Treatment group|Transcutaneous electrical nerve stimulation machine, start 5 minutes before start of oocyte retrieval and stop 5 minutes after removal of oocyte retrieval needle
88901590|NCT01521754||Retrospective|Retrospective cohort: existing patients comprised the sub-group of patients who were implanted with a Medtronic neurostimulation system prior to a site's activation date. This cohort contains a part of retrospective data and a part of prospective data according to the enrolment date. The classification is static and will not change even when an existing patient will be subsequently re-implanted after the site's activation date.
88901591|NCT01521767|Experimental|A|4 mg tolterodine extended release capsules, administered with water and under fasting condition.
88901592|NCT01521767|Experimental|B|4 mg microspheres in powder blend release rate 2 (MPB-RR2), administered without water and under fasting condition.
88901593|NCT01521767|Experimental|C|4 mg microspheres in powder blend release rate 1 (MPB-RR1), administered without water and under fasting condition.
88901594|NCT01521767|Experimental|D|4 mg MPB-RR1, administered without water and under fed condition.
88901595|NCT01521767|Experimental|E|4 mg MPB-RR1, administered with water and under fasting condition.
88901596|NCT01521806|Experimental|Low dose|15 g of fiber per day will be added to snack foods
88901597|NCT01521806|Experimental|High dose|30 g of fiber per day will be added to snack foods
88901598|NCT01521806|Placebo Comparator|No fiber|Snack foods without fiber will be given
88901599|NCT01521819|Experimental|Iray plus Lucentis|open label arm in which all subjects receive a single 16 gy dose of radiation plus an injection of Lucentis.
88901600|NCT01521832|Experimental|Dose Group A|
89421567|NCT03472430|Sham Comparator|Placebo group|TENS machine with electrodes not emitting any impulses, start 5 minutes before start of oocyte retrieval and stop 5 minutes after removal of oocyte retrieval needle
89421568|NCT04966234|Experimental|Posaconazole arm|"90 patients (out of the 135 total patients, therefore with a 2:1 randomization ratio) will receive posaconazole for 12 weeks. Patients in the posaconazole arm will be stratified for body weight and positive sputum cultures for Aspergillus species.~Patients will be followed-up for a total of 12 months post-randomization."
88901601|NCT01521832|Experimental|Dose Group B|
88901602|NCT01521832|Experimental|Dose Group C|
88901603|NCT01521832|Experimental|Dose Group D|
88901604|NCT01521832|Experimental|Dose Group E|
88901605|NCT01521832|Experimental|Dose Group F|
88901606|NCT01521832|Experimental|Dose Group H|
88901607|NCT01521832|Experimental|Dose Group I|
88901608|NCT01521832|Experimental|Dose Group J|
88901609|NCT01521832|Experimental|Dose Group K|
88901610|NCT01521832|Experimental|Dose Group L|
88901611|NCT01521910|Experimental|Low protein diet|
88901612|NCT01521910|Active Comparator|Normal protein diet|
88901613|NCT01521936|Experimental|Arm I (25(OH)-D3 levels 20-31.9 ng/mL [insufficient levels])|Patients receive a loading dose of cholecalciferol PO on day 1. Patients then receive lower-dose cholecalciferol PO beginning on day 8.
89194787|NCT00875368|Active Comparator|Maraviroc|
88901614|NCT01521936|Experimental|Arm II (25(OH)-D3 levels 20-31.9 ng/mL [insufficient levels])|Patients receive a loading dose of cholecalciferol PO on day 1. Patients then receive higher-dose cholecalciferol PO beginning on day 8.
88901615|NCT01521962|Experimental|SYR-322 (Alogliptin) QD|SYR-322 25 mg, orally.
88901616|NCT01521962|Placebo Comparator|Insulin|injection
89421569|NCT04966234|No Intervention|Control arm|"45 patients (out of the 135 total patients, therefore with a 2:1 randomization ratio) will not receive the active treatment.~Patients will be followed-up for a total of 12 months post-randomization. If participants in the control arm are deteriorating during the first 3 months after randomization, it is up to the treating physician to consider treatment for the initial asymptomatic Aspergillus infection"
89421570|NCT03472352|Experimental|Single Arm|The subjects will be given an anticancer medication (A01) and immune cells (IC01).
89421571|NCT04018820|Experimental|Training program|
89421572|NCT04979026|No Intervention|active ankle pumping without any reminders|In group 1, active ankle pumping exercise for the operative limb was performed without any reminder during hospitalization and at home after being discharged.
89421573|NCT04979026|Active Comparator|intermittent pneumatic compression|In group 2, intermittent pneumatic compression was applied to the operative low limb during hospitalization, while active ankle pumping exercise was adopted without any reminder after discharge.
89421574|NCT04979026|Experimental|active ankle pumping with a regular watch alarm|In group 3, in addition to the active ankle pumping exercise for the operative limb, the patients were reminded to exercise at specific time points with a vocal alarm and vibration through a wrist watch during the hospitalization period and at home after discharge. The watch was continuously used until the 14th day when the patients returned to the hospital for examination.
89421575|NCT03927794|Experimental|Self-Assembling Peptide P11-4|"Twenty two teeth affected with white spot lesions of ICDAS II score 1-2 will be assessed at baseline using ICDAS II Scoring and Light Induced Fluorescence by Soprolife System.~Then they will receive the intervention by the self-Assembling Peptide P11-4 at Day 0 and will be followed up at 3 months, 6 months and 1 year."
89421576|NCT03927794|Active Comparator|5% Fluoride Varnish|"Twenty two teeth affected with white spot lesions of ICDAS II score 1-2 will be assessed as baseline using ICDAS II Scoring and Light Induced Fluorescence by Soprolife System.~Then they will receive Topical Fluoride Varnish at Day 0 and will be followed up at 3 months, 6 months and 1 year."
88901617|NCT01521975|Experimental|HBeAg Negative Hepatitis|HBeAg Negative Hepatitis patients.
88901618|NCT01521988|Active Comparator|Atrial flutter ablation|RF atrial flutter ablation
89194788|NCT00875368|Placebo Comparator|Placebo|Placebo drug
89194789|NCT00884182|Experimental|Group 1|Participants on vaccination schedule 1 (Day 0 and Day 21)
89194790|NCT00884182|Experimental|Group 2|Participants on vaccination schedule 2 (Day 0 and Day 14)
89194791|NCT00884182|Experimental|Group 3|Participants on vaccination schedule 3 (Day 0 and Day 42)
88901619|NCT01521988|Experimental|Atrial flutter ablation and pulmonary vein isolation|RF Atrial flutter ablation and pulmonary vein isolation using cryoablation
88901620|NCT01522001|No Intervention|Hospital-based|"First visit at cardiac ambulatory approximately 14 days after discharge includes physician examination by cardiologist and counseling from nurse specialized in cardiac rehabilitation.~Dietary counseling with dietician~Exercise (1 hour, 2 timer pr week for 12 weeks)~Smoking cessation if smoker with educated smoking cessation instructor~Patient education and psychosocial support in 2 to 3 individual consultations with nurse specialized in cardiac rehabilitation~Examination by cardiologist 8-12 weeks after discharge."
89194792|NCT00875446|Experimental|Subjects receiving GSK1223249|"Eligible subjects will receive sequential dose of intravenous infusion of GSK1223249 with a starting dose of 0.01 milligram per kilogram followed by 0.1, 0.5,~1, 2.5, 5, 7.5, and 15 milligrams per kilograms."
89194793|NCT00875446|Placebo Comparator|Subjects receiving placebo|Eligible subjects will receive intravenous infusion of placebo.
88901621|NCT01522001|Active Comparator|Shared care Model|"First visit at cardiac ambulatory approximately 14 days after discharge includes examination by cardiologist and counseling from nurse specialized in cardiac rehabilitation.~Dietary counseling with dietician~Exercise (1 hour, 2 timer pr week for 12 weeks)~Smoking cessation if smoker with educated smoking cessation instructor~Patient education and psychosocial support in 2 individual consultations and 8 group based consultations with experienced nurse~Examination by the patient´s general practitioner 8-12 weeks after discharge."
89421577|NCT04966468|Experimental|VR Group|Patients will be given the VR headset with non-interactive and interactive contents at home for four days
89421578|NCT04966468|Active Comparator|CTR group|Patients will be given a tablet at home for four days with relaxing non-interactive 2D videos with natural and artistic scenarios
89421579|NCT03130946|Experimental|Cryo-assisted core needle biopsy|Eligible patients undergo lymph node biopsy with FNA and crpo-assisted stick freeze device sequentially.
89421580|NCT03130946|Active Comparator|Fine needle aspiration alone|Patients undergo lymph node biopsy with FNA alone.
88901622|NCT01522014|Active Comparator|Ceramic on Ceramic|Subjects received a ceramic on ceramic bearing total hip replacement.
88901623|NCT01522014|Active Comparator|Ceramic-on-Highly Crosslinked Polyethylene|
89421581|NCT04978714||Women with cystocele|All women with ≥ stage II cystocele who visited the urogynecological department of a medical center for cystocele repair
89421582|NCT03061942|Active Comparator|Conventional|Arthroscopic rotator cuff repair without synovectomy
89421583|NCT03061942|Experimental|Synovectomy|Arthroscopic rotator cuff repair with synovectomy
88901624|NCT01522027|Experimental|Nerve stimulator|Twenty ICU patients will receive percutaneous tracheostomy via insertion of a needle/catheter connected to a nerve stimulator.
88901625|NCT01522040|Active Comparator|Magnesium|Half the enrolled subjects will be randomized to receive active drug, a magnesium infusion.
88901626|NCT01522040|Placebo Comparator|Control|Half the subjects will be randomized to receive a drip that does not have active drug (magnesium sulfate).
88901627|NCT01522053|Experimental|Catheter-over-needle|Patients will receive a catheter placed by a catheter-over-needle method.
88901628|NCT01522053|Active Comparator|Catheter-through-needle|Patients will receive a catheter placed by the traditional catheter-though-needle method.
88901629|NCT01522066|Experimental|Perineural catheter|Local anesthetic will be delivered through an indwelling perineural catheter
88901630|NCT01522066|Active Comparator|Single-shot block|Local anesthetic will be delivered by the conventional, single-shot method.
88901631|NCT01522079|Experimental|Air stacking|Electrocardiogram signals were recorded for analyses of heart rate variability during air stacking in supine and sitting position.
88901632|NCT01522092|Experimental|escitalopram|escitalipram tablets 5mg, 10 mg and 20 mg, once a day for 12 months
88901633|NCT01522105|Experimental|1|i.v. daptomycin given 24 hours after first ceftriaxone dose at age appropriate dosage
88901634|NCT01522118|Experimental|HIFU|(high intensity focused ultrasound)
88901635|NCT01522144|Experimental|Asthma clinical decision support|decision support compared to no decision support in a cluster-randomized trial by practise
88901636|NCT01522157|Active Comparator|All test patients|All test patients are given low-fat, low-carbohydrate and mediterranean diet, in randomised order on different days.
88901637|NCT01522222|No Intervention|Control|half of the study subjects will receive standard of care during their open heart surgery.
88901638|NCT01522222|Experimental|Treatment|half of the study subjects will receive the prescribed ventilatory support during open heart surgery.
89421584|NCT03915860|Experimental|Trifarotene|Participants applied Trifarotene 50 μg/g topically once daily in the evening for 24 weeks.
88901639|NCT01522261|Active Comparator|Mechanical Bowel Prep|Patients randomized to complete a Mechanical Bowel Prep. (complete bowel cleansing) and fleet enemas prior to surgery.
88901640|NCT01522261|Active Comparator|No Mechanical Bowel Prep.|Patients randomized to complete two fleets enemas only prior to surgery.
88901641|NCT01522274|Active Comparator|Moderate intensity exercise|Brisk walk on treadmill for 56 minutes 3x per week.
88901642|NCT01522274|Active Comparator|Health education|Attend health education sessions 3x per week.
88901643|NCT01522287|Active Comparator|BT STEPS alone|"Subjects assigned to BT STEPS without coaching will receive computer assisted Cognitive Behavior Therapy. They will receive a welcome and orientation call from the project manager and up to three automated reminder e-mails if there is no activity in the BT Steps website for 5 days. E-mails will describe most recent step the participant used and what to expect in upcoming steps. The focus of reminder messages is on the patients progress through BT STEPS."
88901644|NCT01522287|Active Comparator|BT Steps with non-therapist coaching|Subjects randomized to BT STEPS with coaching will receive computer assisted Cognitive Behavior Therapy plus regularly scheduled weekly coaching, encouragement and support via phone. Calls will focus on user's progress in BT STEPS, troubleshoot problems the participant is having with the program, and set progress goals for the next coaching session. Coaches will be supervised by the CBT therapist, and may consult with the CBT clinician as needed.
88901645|NCT01522287|Active Comparator|BT STEPS with therapist coaching|Subjects randomized to BT STEPS with therapist coaching will receive computer-assisted Cognitive Behavior Therapy plus regularly scheduled weekly coaching and support from a CBT therapist via phone. Calls will focus on user's progress in BT STEPS, troubleshoot problems the participant is having with the program, and set progress goals for the next coaching session.
89421585|NCT04965922|Experimental|Multimodal intervention at inclusion|Multimodal intervention will be proposed to Multiple system atrophy patients and their caregivers.
89421586|NCT04965922|Other|Multimodal intervention at 6 month|Multimodal intervention will be proposed to Multiple system atrophy patients and their caregivers.
89421587|NCT03470714|Experimental|Kinesiotaping Group|The group in which kinesiotaping is applied to non-dominant biceps brachii muscle of participants before 24 hours the force irradiation experiment.
89421588|NCT03470714|Active Comparator|Control group|The group in which the participants only perform the the force irradiation experiment.
89421589|NCT04170998|Experimental|Evogliptin 5mg group|Evogliptin 5mg/d + Dapagliflozin 10mg/d + Metformin ≥ 1000mg/d
89421590|NCT04170998|Placebo Comparator|Evogliptin Placebo group|Evogliptin Placebo + Dapagliflozin 10mg/d + Metformin ≥ 1000mg/d
89421591|NCT04458740||Patient|Patients with a diagnosis of colorectal cancer after 65 years.
89421592|NCT04458740||The spouse and /or children and /or parents|The spouse and /or children and /or parents of a patient 's diagnosis of colorectal cancer before 65 years.
89421593|NCT03055780||CT-FFR. CTA. FFR|59 patients with suspected CAD that have been scheduled for an interventional FFR study
89421594|NCT04966078|Active Comparator|liposuction|group A will be treated with liposuction
89421595|NCT04966078|Active Comparator|periareolar surgical excision|Group B will be treated with periareolar surgical excision
89421596|NCT04965532|Experimental|chemotherapy patients using sevoflurane anesthesia|Following induction of anesthesia and laryngeal mask placement, anesthesia will be maintained by inhalation of sevoflurane (approximately 1.3 × minimum alveolar concentration) and IV fentanyl according to clinical need.
89421597|NCT04965532|Active Comparator|chemotherapy patients using total intravenous anesthesia|Following induction of anesthesia and laryngeal mask placement, maintenance of anesthesia will consist of target-controlled infusion of propofol at a plasma target concentration of 1.5-3.0µg/ml and IV fentanyl according to clinical need.
89421598|NCT04965532|Active Comparator|nonchemotherapy patients using sevoflurane anesthesia|Following induction of anesthesia and laryngeal mask placement, anesthesia will be maintained by inhalation of sevoflurane (approximately 1.3 × minimum alveolar concentration) and IV fentanyl according to clinical need.
89421599|NCT04965532|Active Comparator|nonchemotherapy patient using total intravenous anesthesia|Following induction of anesthesia and laryngeal mask placement, maintenance of anesthesia will consist of target-controlled infusion of propofol at a plasma target concentration of 1.5-3.0µg/ml and IV fentanyl according to clinical need.
89421600|NCT04965610|Experimental|Preoxygenation via THRIVE/High Flow Nasal Cannula|Patients receive preoxygenation for induction of general anaesthesia via High Flow Nasal Cannula for the duration of 5 minutes. After that the induction agents will be given. Now arterial blood gases will be drawn every 2 minutes and the SpO2 will be measured until the 6th apnoeic ABG or if the SpO2 decreases to 92%. After that normal intubation follows.
89421601|NCT04965610|Active Comparator|Preoxygenation via face mask (PROX)|Patients receive preoxygenation for induction of general anaesthesia via tight fitting face mask for the duration of 5 minutes. After that the induction agents will be given. Now arterial blood gases will be drawn every 2 minutes and the SpO2 will be measured until the 6th apnoeic ABG or if the SpO2 decreases to 92%. After that normal intubation follows.
88901646|NCT01522313||Patients|Data of patients anesthetized in the years 2006 to 2012 (Hospital stay: January 2006 - June 2012) will be analysed in the study.
89421602|NCT03055546|Experimental|Oxytocin|intranasal administration of oxytocin
88901647|NCT01522326|Experimental|Metoclopramide|150 subjects with acute mountain sickness will be randomly assigned to take metoclopramide.
89421603|NCT03055546|Placebo Comparator|Placebo|intranasal administration of placebo
89421604|NCT04918264||Uracil concentration <16 ng/mL|Patients were included in this arm if they have digestive cancer and an uracil dosage <16 ng/mL performed between February 2018 to January 2020, and if they received at least one cycle of fluoropyrimidine-based chemotherapy in one of the four oncology departments (Hopital Edouard Heriot [Lyon], Centre Hospitalier de Lyon Sud [Lyon], Hopital de la Croix Rousse [Lyon].
89421605|NCT04918264||Uracil concentration ≥16 ng/mL|Patients were included in this arm if they have digestive cancer and an uracil dosage <16 ng/mL performed between February 2018 to January 2020, and if they received at least one cycle of fluoropyrimidine-based chemotherapy in one of the four oncology departments (Hopital Edouard Heriot [Lyon], Centre Hospitalier de Lyon Sud [Lyon], Hopital de la Croix Rousse [Lyon].
89421606|NCT04917718|Experimental|Extended Release Tacrolimus|All participants who consent to the study will be in this group.
89421607|NCT04917952|Experimental|BFR group|The intervention group will receive resisted knee extension 30% of 1RM with blood flow restriction.
89194794|NCT03920098||Mother-infant dyads|Mother-infant dyads
89194795|NCT02543710|Experimental|phase 4 implementation study|The historical MoMaTEC1 outcome data, collected from 2001-2015 serve as control arm. These data have been rigorously collected and quality controlled with extensive clinical annotation and follow-up data, and reflect the outcome in (for a larger part) the same population as expected for MoMaTEC2 as there have not been major changes in surgical or medical treatment for endometrial cancer in this time period that could cause confounding. Internal validity, and to a degree also external validity, covering practice in multiple countries, should in this way be assured.
89194796|NCT02543710|Experimental|phase 2b biomarker study|For the current study, stathmin is used as an integrated marker and does not dictate treatment modality, therefore there is no requirement for a control arm.
89194797|NCT00884260|Experimental|Arm 1|
89194798|NCT04038814||VAP1 - historical group|Routine prevention of VAP
89194799|NCT04038814||VAP2 - study group|Modified prevention of VAP
89194800|NCT00881296|Experimental|1|"Gemcitabine 1000mg/m2 Day 1,15~Carboplatin AUC=3 Day 1, 15 every 4 weeks"
89194801|NCT00881296|Active Comparator|2|Gemcitabine 1000mg/m2 Day 1, 8, 15
89194802|NCT05201872||laparoscopic surgery|Different surgical methods for rectal cancer resection
89194803|NCT05201872||Transanal endoscopic surgery|Different surgical methods for rectal cancer resection
89194804|NCT02543788|Other|patients|patients with chronic optic neuropathy in multiple sclerosis
89194805|NCT02543788|Other|Controls|healthy volunteers
89194806|NCT02543632||Treated group|Subjects who meet the inclusion/exclusion criteria listed and also are approved via anatomical inclusion criteria for treatment with the Parachute Implant System.
88901648|NCT01522326|Active Comparator|Ibuprofen|150 subjects with acute mountain sickness will be randomly assigned to take ibuprofen.
89421608|NCT04917952|Placebo Comparator|Sham BFR group|The control group will receive resisted knee extension 30% of 1RM with sham blood flow restriction.
89194807|NCT02543632||Control group|Subjects who meet the inclusion/exclusion criteria listed and also are are excluded for treatment with the Parachute Implant System due to anatomical characteristics such as obstructing pseudochordae, calcification, or wall thickness.
89194808|NCT00884338|Experimental|Exercise|
89194809|NCT00884338|Active Comparator|Control group|
89194810|NCT00881374|Experimental|Dermacyd Infantile (Lactic Acid)|six weeks treatment
89194811|NCT00613366|Experimental|Misoprostol|Cervical preparation with misoprostol prior to intrauterine device insertion
89194812|NCT00613366|Placebo Comparator|Placebo|Cervical preparation with placebo prior to intrauterine device insertion
89194813|NCT00875602|No Intervention|control|before-after (retrospective) and concurrent controls as comparators with a prospective intervention group
89194814|NCT00875602|Active Comparator|Study unit|Hospitalized patients in the study group will be continously monitored / supervised by the contact-free device
89194815|NCT02543476||patients' group with tumor sample|SCCHN patients having available archived tumor sample(s).
89194816|NCT00875680|Experimental|autoPPC|
89194817|NCT00612352|Active Comparator|Family HIstory Positive|Subjects with a positive family history of alcoholism.
89194818|NCT00612352|Active Comparator|Family History Negative|Subjects with a negative family history of alcoholism.
89194819|NCT00884416|Experimental|Sorafenib dose titration|
89194820|NCT00875758|Active Comparator|Standard threshold|
89194821|NCT00875758|Experimental|Low-threshold|
89194822|NCT04018300|Experimental|Ferrous sulfate|Subjects will take a 65 mg Fe capsule of ferrous sulfate, once daily for 21 consecutive days. The first treatment capsule will be consumed with a semi-purified meal (egg albumin, sugar, vanilla, maltodextrose and corn oil) and will have blood drawn hours 0, 1, 2, 3, 4, 6 and 8 post consumption. Serum will be used to determine non-transerrin bound iron, serum iron and percent saturation. Throughout the treatment period, subjects are informed to consume the capsule with food and report symptoms in an online questionnaire. Following three weeks treatment, participants return for a blood draw and oxidative stress indicators are measured. A three week washout period with placebo treatment takes place between treatment crossover.
89194823|NCT04018300|Experimental|Aspiron|AspironTM which is an iron-enriched supplement will follow the same guidelines and protocol as ferrous sulfate arm. Equivalent 65 mg Fe per capsule will be administered to participants.
89194824|NCT04018300|Placebo Comparator|Placebo|Participants will follow the same description for the other two experimental treatment groups. Capsules will be given to subjects in opaque formation, therefore will be unable to differentiate the iron supplements.
88901649|NCT01522352|Experimental|pericardial aortic valves|Comparison of short and mid-term hemodynamic performance between three types of stented pericardial aortic valves: Trifecta aortic valve (St. Jude Medical), Mitroflow aortic valve (Sorin Group), Magna Ease (Edwards Lifesciences)
88901650|NCT01522378|Experimental|Biv-ICD|Subjects will be imaged with 123 iodine metaiodobenzylguanidine.
88901651|NCT01522430|Experimental|Renal angiography followed by renal sympathetic denervation|Catheter based therapy for renal denervation using the Simplicity (TM) catheter (Ardian/Medtronic)
88901652|NCT01522430|Sham Comparator|Renal angiography alone|Renal selective angiography using standardized method: Local anesthesia of the femoral site to allow the placement of a 4-Fr sheath in the femoral artery. Using JR-4 or similar diagnostic catheter, a selective renal angiography will be realized.
88901653|NCT01522482|Experimental|High saturated fat meal|
88901654|NCT01522482|Experimental|Saturated fatty acid and fish oils meal|Equivalent to two portions of oily fish
88901655|NCT01522482|Active Comparator|High unsaturated fat meal|Provided a fatty acid profile representative of a typical UK diet
88901656|NCT01522495|Experimental|SPY Imaging|SPY Imaging Prior to Amputation or Debridements (50 participants)
88901657|NCT01522495|No Intervention|No SPY Imaging|Amputation or Debridements as Standard of Care (50 participants)
88901658|NCT01522495|Experimental|Validation Against Angiogram|"Patients who are scheduled to undergo an angiogram will also receive ICG angiography (SPY). This will occur at specific time points: 1.) before the angiogram/intervention is performed 2.) immediately after the angiogram/intervention is performed 3.) 5-7 days after angiogram/intervention 4.) 21-30 days after angiogram/intervention.~(30 participants)"
88901659|NCT01522495|Experimental|Establishing Normal Values|To establish baseline lower extremity perfusion in non-PVD patients. Patients requiring an angiogram for other vascular processes unrelated to the lower extremity will be recruited into this study. ICG angiography (SPY) of the lower extremity will be performed at the time of the angiogram. (30 Participants)
88901660|NCT01522508||propofol/remifentanil|patients receive standardized propofol and changing remifentanil concentrations
88901661|NCT01522508||sevoflurane/remifentanil|patients receive standardized sevoflurane and changing remifentanil concentrations
88901662|NCT01522521|Experimental|1.|
88901663|NCT01522521|Placebo Comparator|2.|
88901664|NCT01522534|Experimental|Blind block with mepivacaine|Blind block with mepivacaine and intravenous morphine
88901665|NCT01522534|Active Comparator|Morphine|Intravenous Morphine and placebo blind block
89006808|NCT06178172|Experimental|Early discharge with remote home monitoring.|After at least 48 hours of hospital admission, patients are discharged early with the use of remote home monitoring. At home, patients receive guidance for the management of pain, nutrition and pancreatitis-related complaints by a daily phone call from a nurse from the Virtual Monitoring Centre (VMC). The pancreatitis-related complaints, intake of fluids and food, pain and the use of analgesics are assessed using short questionnaires in a smartphone app. Core temperature is monitored using an ear thermometer and a wearable sensor measures heart rate, respiratory rate, posture and movement every 5 minutes. Remote home monitoring will continue for at least 4 days.
89006809|NCT06178159|Experimental|Disitamab Vedotin + Pertuzumab|Disitamab Vedotin With Pertuzumab arm
89006810|NCT06178159|Experimental|Disitamab Vedotin + Toripalimab+ Pertuzumab|Disitamab Vedotin+ Toripalimab with Pertuzumab arm
89006811|NCT06178146|Experimental|Tα-1 group|Subcutaneous injection with 1.6mg Thymosin alpha 1 in combination with the conventional therapy
89006812|NCT06178146|Active Comparator|Control group|Conventional therapy includes corticosteroids and other immunosuppressants according to CSCO guidelines.
89006813|NCT06178133||FFR|In this single-center cross-sectional study, we included patients with non-acute myocardial infarction who were admitted to the Department of Cardiology at Peking University Third Hospital for FFR testing from January 2019 to December 2021.
89006814|NCT06178107|Experimental|Probiotic|Lactobacillus plantarum (LPLDL®) equivalent to 4 x10^9 CFU (0.1 g) with the addition of filling carrier (0.12 g; 30% w/v maltodextrin and 5% w/v sucrose) as a capsular format (vegetable) to be consumed once a day, after lunch with 250mL of water.
89006815|NCT06178107|Placebo Comparator|placebo|Maltodextrin (an oligosaccharide without prebiotic effect) (0.12 g; 30% w/v maltodextrin and 5% w/v sucrose) as a capsular format (vegetable) to be consumed once a day, after lunch with 250mL of water.
89006816|NCT06178081|Active Comparator|Clinical Healthy|Clinical measurements (Plaque index, probing depth, gingival recession, clinical attachment level, bleeding on probing) salivary sample and gingival crevicular fluid will be taken from all individuals at the beginning of the study. IL-39 and cotinine levels will be examined to evaluate the effects of smoking before and after treatment in periodontal health and periodontitis. A pre-treatment saliva sample and gingival crevicular fluid will be collected from the clinically healthy group.
89006817|NCT06178081|Experimental|Periodontitis|Non-surgical periodontal treatment will be applied to individuals with periodontitis, clinical measurements, saliva collection and gingival crevicular fluid will be repeated 12 weeks after the treatment. IL-39 analysis will be performed by ELISA in saliva and gingival crevicular fluid of individuals. IL-39 and cotinine levels will be examined to evaluate the effects of smoking before and after treatment in periodontal health and periodontitis. Clinical measurements (Plaque index, probing depth, gingival recession, clinical attachment level, bleeding on probing) and salivary sample will be taken from all individuals at the beginning of the study.
89006818|NCT06178068|Active Comparator|Group 1; jet nebulizer group|The Respirox® RNEB-18 device was used for the bronchodilator treatment given before the randomization of the patients and for the maintenance bronchodilator treatment given in Group 1 patients. After calibrating the device, it was determined that it performed nebulization with a flow of 6 lt/min.
89006819|NCT06178068|Active Comparator|Group 2; dry air nebulizer group|In Group 2 patients, a HAVELSAN® EHSİM brand nebulizer produced in our country, compatible with the central system of our hospital, was used as a dry air nebulizer.
89006820|NCT06178068|Active Comparator|Group 3; Classic nebülizer group|For classical nebulizer treatment in Group 3 patients, a nebulizer device compatible with our hospital's central oxygen system was used.
89006821|NCT06178042|Experimental|MI Paste Plus|Patients were instructed to use MI Paste Plus (GC Europe, Leuven, Belgium) according to manufacturers instructions.
89006822|NCT06178042|Experimental|Remin Pro|Patients were instructed to use (Remin Pro, VOCO GmbH, Cuxhaven, Germany) a pea-sized amount of the cream.
89006823|NCT06178042|Active Comparator|Control|Patients used a 1450 ppm fluoridated tooth paste (Colgate Sensitive Pro-Relief, Colgate-Palmolive, Swidnica, Poland) for conventional tooth brushing.
89006824|NCT06177990|Experimental|CAN-DO Immediate program group|Each participant will be engaged in a baseline interview. Subsequently, each will be asked to take part in follow-up interviews at points 2, 4, 6, and 8 months following the launch of their cohort.
89006825|NCT06177990|Active Comparator|Attention Control program group|"Participants will receive an online course about Healthy Living for the first 4 months after randomization.~After the Attention Control participants complete their 4-month interview, they will be invited to participate in the CAN-DO program."
89006826|NCT06177990|Active Comparator|Usual care group|Participants randomized to the Usual care group will not receive intervention from the study but after they complete their 4-month interview, they will be invited to participate in the CAN-DO program.
89006827|NCT06177938|Experimental|Lactose solution|Single ingestion of a lactose solution (25 g lactose dissolved in 150 mL water).
89006828|NCT06177938|Placebo Comparator|Glucose solution|Single ingestion of a glucose solution (13 g glucose dissolved in 150 mL water).
89006829|NCT06177925|Experimental|Treatment (Adebrelimab, chemotherapy, radiation therapy)|Participants will receive Adebrelimab intravenously in combination with carboplatin /Cisplatin and etoposide during the induction phase (2 Cycles ). Thereafter, participants will receive concurrent chemoradiotherapy(thoracic radiation therapy and SBRT for metastases,combination with carboplatin /Cisplatin and etoposide for 1-2 Cycles).Then participants will receive Adebrelimab combination with carboplatin /Cisplatin and etoposide for 1-2 Cycles,followed by Adebrelimab maintenance until persistent radiographic PD, intolerable toxicity or withdrawal of consent during the maintenance phase.
89194825|NCT00875914|Experimental|Manually guided|Treatment with manually guided RF-catheter
89194826|NCT00875914|Experimental|Magnetically navigated|Treatment with magnetically navigated RF-catheter.
89194827|NCT02543164|Other|REFERENCE: white bread|Participants will consume a meal standardised to contain 50 g of available carbohydrates. Sample Will be consumed together with 250 mL of water, within 10-15 minutes.
89421609|NCT03060538|Experimental|Multiple Ascending Dose BFKB8488A|Participants will be randomized to receive BFKB8488A. When adequate safety data are available, a review will be done for all participants to make a dose-escalation or dose and/or regimen modification decision. This will be repeated for each cohort.
89421610|NCT03060538|Placebo Comparator|Placebo|Participants will receive BFKB8488A-matching placebo.
89421611|NCT06016595||singel|
88901666|NCT01522547|Experimental|Cohort 1: 0.5 mg pomalidomide|0.5 mg pomalidomide orally daily for 84 days
88901667|NCT01522547|Experimental|Cohort 2: 1.0 mg pomalidomide|1.0 mg pomalidomide orally daily for 84 days
88901668|NCT01522547|Experimental|Cohort 3: 2.0 mg pomalidomide|2.0 mg pomalidomide orally daily for 84 days
88901669|NCT01522547|Experimental|Cohort 4: 3.0 mg pomalidomide|3.0 mg pomalidomide orally daily for 84 days
88901670|NCT01522547|Experimental|Cohort 5: 4.0 mg pomalidomide|4.0 mg pomalidomide orally daily for 84 days
88901671|NCT01522560|Placebo Comparator|Control Group|Residents will be randomly assigned to a feedback group or to the control group. Besides the standard evaluation at the end of the rotation, in both groups, residents will receive every week a MSF evaluation from the faculty, the patients' parent, and the coworker. Also, for every resident a baseline self assessment will be applied at the beginning and at the end of the rotation. Only the group assigned to feedback is going to have a 'coaching meeting' every month with the Chairman of Department of Pediatric Anesthesia to identify strengths and weaknesses and create strategies for improvement, based on the MSF.
88901672|NCT01522560|Active Comparator|Feedback group|Residents will be randomly assigned to a feedback group or to the control group. Besides the standard evaluation at the end of the rotation, in both groups, residents will receive every week a MSF evaluation from the faculty, the patients' parent, and the coworker. Also, for every resident a baseline self assessment will be applied at the beginning and at the end of the rotation. Only the group assigned to feedback is going to have a 'coaching meeting' every month with the Chairman of Department of Pediatric Anesthesia to identify strengths and weaknesses and create strategies for improvement, based on the MSF.
88901673|NCT01522573||EUS guided ERCP procedure group|Subjects who will undergo Endoscopic Ultrasound (EUS) guided Endoscopic retrograde cholangiopancreatography (ERCP) procedures for their pancreatico-biliary conditions.
88901674|NCT01522586|Experimental|DWP09031|DWP09031 50mg/100mg/400mg/200mg/800mg/1200mg/1600mg/2000mg single dosing
88901675|NCT01522586|Placebo Comparator|Placebo|placebo comparator 50mg/100mg/400mg/200mg/800mg/1200mg/1600mg/2000mg single dosing
88901676|NCT01522599|Active Comparator|ARDS-Net strategy (Control)|
88901677|NCT01522599|Experimental|ECCO2-R with 4 mL/Kg Vt (Treatment)|
88901678|NCT01522612|Experimental|5-fluorouracil/leucovorin plus cetuximab|
88901679|NCT01522612|Active Comparator|5-fluorouracil/leucovorin alone|
88901680|NCT01522625|Experimental|TDF|tenofovir disoproxil fumarate (TDF) 300mg
88901681|NCT01522625|Placebo Comparator|Placebo|
88901682|NCT01522638||ADOA|This group includes subjects diagnosed with autosomal dominant optic atrophy
88901683|NCT01522638||Healthy subjects|
88901684|NCT01522664|Experimental|Single group|
88901685|NCT01522677|Experimental|PDT|Participants receive neoadjuvant 5-ALA and PDT.
88901686|NCT01522716|Experimental|Mesenchymal stromal cell treatment|
88901687|NCT01522729|Experimental|Fentanyl|
88901688|NCT01522729|Experimental|Placebo|
88901689|NCT01522742||Healthy control subjects|Healthy control subjects matched to psoriasis patients on traditional cardiovascular risk factors will be studied at baseline.
88901690|NCT01522742||Psoriasis patients starting etanercept|Patients with moderate to severe psoriasis with or without arthritis who are about to be started on etanercept (enbrel) by their treating clinicians will be studied at baseline and 3 months after etanercept therapy.
88901691|NCT01522794|Experimental|NOX-H94|Single dose of NOX-H94
88901692|NCT01522794|Placebo Comparator|Placebo|Single dose of placebo control
88901693|NCT01522807|Experimental|100 mg PF-05190457|Three fasted treatments and fed with the short-duration osmotic capsule
88901694|NCT01522807|Experimental|100 mg PF - 05190457|Three fasted treatments and fed with the long-duration osmotic capsule
88901695|NCT01522820|Experimental|Cohort 1a (vaccine therapy)|Patients receive DEC-205/NY-ESO-1 fusion protein CDX-1401 protein vaccine intranodally on days 1, 29, 57, and 113.
88901696|NCT01522820|Experimental|Cohort 1b (vaccine therapy and immunotherapy)|Patients receive DEC-205/NY-ESO-1 fusion protein CDX-1401 as in Cohort 1a and sirolimus PO or PEG on days 1-14, 29-42, and 57-70.
88901697|NCT01522820|Experimental|Cohort 1c (vaccine therapy and immunotherapy)|Patients receive DEC-205/NY-ESO-1 fusion protein CDX-1401 vaccine as in Cohort 1a and sirolimus PO or PEG on days 15-28, 43-56, and 71-84.
88901698|NCT01522820|Experimental|Cohort 1d (vaccine therapy and immunotherapy)|Patients receive DEC-205/NY-ESO-1 fusion protein CDX-1401 as in Cohort 1a and sirolimus PO or PEG on days 1-84.
88901699|NCT01522820|Experimental|Cohort 2 (vaccine therapy with or without immunotherapy)|Patients receive DEC-205/NY-ESO-1 fusion protein CDX-1401 as in the Cohort (1a-1d) that is determined to be safe and produces optimal immunological effects and sirolimus PO on days 1-14 as in Cohort 1b dose.
88901700|NCT01522833||Cohort A|EGFR Wild Type patients
88901701|NCT01522833||Cohort B|EGFR mutation patients
88901702|NCT01522846||Heparin|
88901703|NCT01522859|No Intervention|standard care|A standardised home based programme of specialist respiratory assessment and monitoring provided by the local Community Respiratory Team (CRT) and General Practitioner (GP) for a period of six months.
88901704|NCT01522859|Experimental|Telehealth monitoring|Daily monitoring of patient's health status using a small telecommunications device.
88901705|NCT01522872|Experimental|Monotherapy TH-302 Dose Escalation|
88901706|NCT01522872|Experimental|TH-302 and Dexamethasone Dose Expansion|
89421612|NCT06016569|Experimental|LDCT and collection of breath condensate and blood sample|Each participant of the study will provide exhaled breath condensate sample and blood sample for further laboratory analyses. Each participant will have LDCT (low dose computer tomography) performed. A pulmonologist examines the patient for any concomitant diseases and performs spirometry. Vital signs will be measured.
89421613|NCT06016530|Experimental|Healthy participants|"The study will involve 20 to 30 healthy participants, with approximately 15 females and 15 males. Each participant will undergo three measurements: 1) Baseline assessment, 2) Sleep Deprivation, and 3) Dexamethasone Supplementation.~The baseline measurement will be the starting point taken before any interventions are applied. It will serve as a control and reference to evaluate the impact of interventions."
88814238|NCT04371146|Placebo Comparator|Placebo|Participants in the placebo group will be asked to take a placebo pill 1.5 hours before performing the tasks.
89421614|NCT06016491|Experimental|Acupressure group|Before the acupressure application, the woman to be applied was informed in a quiet room for ease of application, and then she was ensured to be in a comfortable position. Women were taught to practice on a total of two points, the kidney meridian (Yong Quan-KD1) and the spleen meridian (Sanyinjiao-SP6). Since the symmetry of the selected two different points on the other extremity will also be applied, a total of 8 minutes of compression was applied to each point, provided that it was two minutes. Depending on the preparation and compression time on each point, an average of 10 minutes was applied to each patient, and then the patients were asked to apply it to themselves. After making sure that the women learned, they were asked to apply acupressure on their own. They applied a total of 12 sessions, three times a week for a total of four weeks. To remind the session day, information was given by the researcher via short message.
89421615|NCT06016491|Sham Comparator|Sham acupressure group|"After all the preparations (suitability of sound and environment and information) before the application to the acupressure group were made in the sham group, the sham acupressure points determined parallel to the KD1 and SP6 points (approximately 1-1.5 cm away) were put on the bone area where the meridians do not pass has been applied.~Similar to the acupressure group, the sham acupresuure group was treated with symmetrical extremities and for similar durations."
89421616|NCT06016426|Active Comparator|mass closure|infants and children whose transverse laparotomy incisions will be closed in mass closure.
89421617|NCT06016426|Active Comparator|layer by layer closure|infants and children whose transverse laparotomy incisions will be closed layer by layer.
89421618|NCT06016413|Experimental|intervention group|All patients received nab-paclitaxel 260 mg/m2, carboplatin AUC=5 and adelbelimumab 1200 mg intravenously on day 1 of each 3-week cycle for 3 cycles. All patients were given conventional drugs to prevent vomiting in each cycle, and intravenous dexamethasone was given to prevent allergy before each dose
89421619|NCT06016400|Experimental|intervention group|Alfacalcidol Drops,1ug a day,40day
89421620|NCT06016400|Placebo Comparator|control group|Placebo
89421621|NCT06016374|Experimental|telerehabilitation for post stroke patient|During the study, the patient will be asked to use the TeleRé programme on the devices on a regular, daily basis, either in a hospital room or at home. They will also be asked to evaluate the programme via various questionnaires and assessments.
89421622|NCT06016361|Sham Comparator|Standard of Care|Standard of Care
89421623|NCT06016361|Active Comparator|Investigational Product|Investigational product
89421624|NCT06016309||Phase 1|"In Phase 1 of the study, we aim to include a minimum of 300 patients to identify how often which CEBA symptoms occur among pwMS and which symptoms cluster together, forming CEBA profiles. In addition, in Phase 1, an on age and education level matched group of 100 Healthy controls will be included to allow comparison of performance-based measures.~In Phase 2 of the study, we aim to include a minimum of 100 patients, after approximately two years, to investigate whether we can replicate the results of Phase 1, validating the different CEBA profiles."
89421625|NCT06016309||Retest Phase 1|After a year, a retest of around 50 patients will take place in order to determine whether CEBA symptoms are stable over time which is important information in deciding whether CEBA profiles can be used as a guide for further care.
89421626|NCT06016296|Experimental|Upper middle level experimental groups|The intervention will be implemented by early childhood educators, who will be previously trained in Combined Movement and Storytelling Intervention (CMSI). Each session will take place in the classroom where the preschoolers usually attend, which will depend on the admission policies of each educational community regarding to level classes (upper middle). The intervention will last 12 weeks (36 sessions), distributed in 3 weekly sessions (Monday, Wednesday and Friday) of 40 minutes per session. The CMSI is based on 2 previous studies, and a book related to CMSI. Twelve unpublished motor stories were elaborated, of which one per week will be executed distributed in 3 sessions per week with the corresponding progressions for each session carried out, placing the children in a sequence of stories that begin with the presentation of a motivating character that will accompany children's in the development of the whole story.
88814239|NCT01623479||Hypotrichosis of the Eyelashes|Subjects with hypotrichosis of the eyelashes using bimatoprost 0.03% (Latisse®) as prescribed by physician for at least 12 months
89006830|NCT06177899||Split-box group|"Before augmentation, according to the 3D topography of the alveolar ridge of the patients, the split-box technique was applied if there was more than 3 mm bone thickness at the top of the crest and the bone thickness did not increase towards the lower border.~All surgical procedures were performed under local anesthesia. A mid-crestal incision was made along the ridge crest and two vertical incisions were made at the termination of the crestal incision. All osteotomies were made using with piezoelectric surgery. Horizontal and vertical osteotomies were performed 1.5 mm away from adjacent teeth. Lower border osteotomy of the vestibular cortical bone was performed. A chisel osteoma was used to separate completely and mobilize the segmented bone. This separated, corticocancellous block was stabilized on the distance to the native alveolar crest with micro screws. The space between the block and the alveolar crest was filled with allograft. The flaps were closed using 3-0,4-0 vicryl."
88814240|NCT04347044|Experimental|Pulmonary Rehabilitation Group|Optimal medication and clinical follow-up plus Pulmonary rehabiltation
88814241|NCT04347044|Active Comparator|Non-Pulmonary Rehabilitation Group|Optimal medication and clinical follow-up
88901707|NCT01522872|Experimental|TH-302 Dose Escalation and Dexamethasone with Bortezomib|
88901708|NCT01522872|Experimental|TH-302 Dose Escalation and Dexamethasone with Pomalidomide|
88901709|NCT01522885|Active Comparator|KatGuide|Chest tube insertion is performed by using the KatGuide
88901710|NCT01522885|Active Comparator|Conventional group|Chest tubes are inserted by using conventional method (forceps) for large bore chest tube insertion.
88901711|NCT01522898|Active Comparator|Medical Rate Control|Medical Rate Control aimed at ventricular rate target of 90 beats per minute. Specific medical therapy to be determined for each patient by individual clinician.
88901712|NCT01522898|Experimental|AV nodal ablation|AV node ablation performed by percutaneous catheter ablation, with endpoint of complete heart block.
88901713|NCT01522911|Other|atrial and brain natriuretic peptide|Impact on atrial an brain natriuretic peptide secretion after percutaneous left atrial appendage closure
88901714|NCT01522989|Experimental|PD-0332991, 5-FU and oxaliplatin|PD-0332991 with 5-FU and oxaliplatin
88901715|NCT01523015|Experimental|Combined therapy|The combined modality therapy will be consisted of preoperative chemoradiotherapy (Docetaxel, Oxaliplatin, 5-Fluorouracil, 45Gy) for type I i II cancer or preoperative chemotherapy (Docetaxel, Oxaliplatin, 5-Fluorouracil) for type III cancer and followed by surgery.
88901716|NCT01523015|Active Comparator|Surgery|The extent of surgery will be associated with the topographic type of carcinoma of the esophagogastric junction: type I - subtotal esophagectomy with superior gastric resection, splenectomy and two-field mediastinal lymph node dissection; type II and III - total gastrectomy with distal esophagectomy, splenectomy and D2 with mediastinal inferior lymph node dissection.
88901717|NCT01523028|Experimental|Coffee, bread and honey|200 mL coffee + 2 bread rolls + honey
88901718|NCT01523028|Experimental|Coffee, bread and peanut butter|200 mL coffee + 1 bread roll + peanut butter
88901719|NCT01523028|Experimental|200 mL black coffee|
88901720|NCT01523041|Experimental|BIAsp 70 clinical trial formulation|
88901721|NCT01523041|Experimental|BIAsp 70 final formulation|
88901722|NCT01523041|Experimental|BIAsp 50 final formulation|
88901723|NCT01523054|Experimental|Metoprolol- Toprol XL|Metoprolol extended release (CR/XL) tablet 200 mg once daily
88901724|NCT01523054|Active Comparator|Metoprolol- Lopressor|Metoprolol immediate release (IR) tablet
88901725|NCT01523067|Active Comparator|Vasomera (PB1046)|
88901726|NCT01523067|Placebo Comparator|0.9% Sodium Chloride|
88901727|NCT01523080|Active Comparator|Tylenol® 650 mg|Tylenol® 650 mg of McNeil Consumer and Specialty Pharmaceuticals, Division of McNeil PPC, INC. Fort Washington, PA 19034 USA.
88901728|NCT01523080|Experimental|Acetaminophen extended release Gel tabs 650 mg|Acetaminophen extended release Gel tabs 650 mg of OHM Laboratories Inc. (A subsidiary of Ranbaxy Pharmaceuticals Inc., USA)
88901729|NCT01523093|Active Comparator|Zofran ODT|Zofran ODT (Ondansetron) orally disintegrating tablets 8mg Manufactured By Cardinal Health, Blagrove, Swindon, Wiltshire, UK SN58RU
88901730|NCT01523093|Experimental|Ondansetron Orally Disintegrating Tablets|Ondansetron 8 mg Orally Disintegrating Tablets Manufactured By OHM Laboratories Inc (A subsidiary of Ranbaxy Pharmaceuticals Inc, USA)
89421627|NCT06016296|No Intervention|Upper middle level control groups|The upper middle level control groups (n= 2 classes; n= 24 children) will participate in the assessments (initial and final) and will be asked to maintain their regular session of their educational establishments. At the end of the intervention period (according to the results obtained), the control groups children, parents and/or legal guardians, managers and coordinators of each community will be contacted and provided with the material so that they can replicate the experience. In addition, the educators of these establishments (teachers and classroom assistants) will be trained in the CMSI strategy.
89421628|NCT06016296|Experimental|Transition level 1 experimental groups|The intervention will be implemented by early childhood educators, who will be previously trained in Combined Movement and Storytelling Intervention (CMSI). Each session will take place in the classroom where the preschoolers usually attend, which will depend on the admission policies of each educational community regarding to level classes (transition level 1). The intervention will last 12 weeks (36 sessions), distributed in 3 weekly sessions (Monday, Wednesday and Friday) of 40 minutes per session. The CMSI is based on 2 previous studies, and a book related to CMSI. Twelve unpublished motor stories were elaborated, of which one per week will be executed distributed in 3 sessions per week with the corresponding progressions for each session carried out, placing the children in a sequence of stories that begin with the presentation of a motivating character that will accompany children's in the development of the whole story.
89421629|NCT06016296|No Intervention|Transition level 1 control groups|The transition level 1 control groups (n= 2 classes; n= 24 children) will participate in the assessments (initial and final) and will be asked to maintain their regular session of their educational establishments. At the end of the intervention period (according to the results obtained), the control groups children, parents and/or legal guardians, managers and coordinators of each community will be contacted and provided with the material so that they can replicate the experience. In addition, the educators of these establishments (teachers and classroom assistants) will be trained in the CMSI strategy.
89421630|NCT06016296|Experimental|Transition level 2 experimental groups|The intervention will be implemented by early childhood educators, who will be previously trained in Combined Movement and Storytelling Intervention (CMSI). Each session will take place in the classroom where the preschoolers usually attend, which will depend on the admission policies of each educational community regarding to level classes (transition level 2). The intervention will last 12 weeks (36 sessions), distributed in 3 weekly sessions (Monday, Wednesday and Friday) of 40 minutes per session. The CMSI is based on 2 previous studies, and a book related to CMSI. Twelve unpublished motor stories were elaborated, of which one per week will be executed distributed in 3 sessions per week with the corresponding progressions for each session carried out, placing the children in a sequence of stories that begin with the presentation of a motivating character that will accompany children's in the development of the whole story.
88901731|NCT01523106|Active Comparator|Carnitine|Patients will take 4grams of L-carnitine (2 grams twice daily) for 3 months
88901732|NCT01523106|Placebo Comparator|Placebo|Patients will take placebo for 3 months. Placebo is manufactured by the same company as the L-carnitine and will have a similar appearance.
88901733|NCT01523119|Active Comparator|Zofran ODT|Zofran ODT (Ondansetron) Orally Disintegrating Tablets 8mg Manufactured By Cardinal Health, Blagrove, Swindon, Wiltshire, UK SN58RU
88901734|NCT01523119|Experimental|Ondansetron Orally Disintegrating Tablets|Ondansetron Orally Disintegrating Tablets 8 mg Manufactured By Ohm Laboratories Inc (A subsidiary of Ranbaxy Pharmaceuticals, USA)
88901735|NCT01523132||Breast cancer patients|Female breast cancer patients without metastasis and locally advanced disease
88901736|NCT01523145|Experimental|Intervention|
88901737|NCT01523145|Experimental|Control gruop|
88901738|NCT01523158|Other|Immunotherapy|Open label study of changes to cellular responses following immunotherapy
88901739|NCT01523197|Other|ventilator|The comparison of the curative effect on OS between BiPAP and auto-trilevel ventilations
88901740|NCT01523210||upper limb spasticity|patients suffering from upper limb spasticity and are treated with botulinum toxin
88901741|NCT01523236|Experimental|Investigational Test Product|Mometasone furoate anhydrous 50 mcg/actuation Nasal Spray (Teva)
88901742|NCT01523236|Active Comparator|Reference Listed Drug|Nasonex® (mometasone furoate monohydrate) 50 mcg/actuation Nasal Spray (Schering)
88901743|NCT01523236|Placebo Comparator|Placebo|Saline Placebo Nasal Spray
88901744|NCT01523249||Scanned and palpated|Healthy, pregnant, term women delivering at BC Women's Hospital and expecting to have neuraxial anesthesia.
88901745|NCT01523262|Active Comparator|Preconditioning and normal treatment|
88901746|NCT01523262|Placebo Comparator|normal treatment|Standard treatment
88901747|NCT01523288||Prader-Willi patients|
88901748|NCT01523288||Control group|Control group for ultrasound scan
88901749|NCT01523314|Experimental|dexamethasone - Cyclodextrin|
88901750|NCT01523314|Active Comparator|Avastin/Laser|
88901751|NCT01523327||A|40 pregnant Women with hypertension who have uric acid level more than 6 mg per dL.
88901752|NCT01523327||B|40 pregnant women with hypertension who have uric acid level less than 6 mg per dl.
88901753|NCT01523340||Erlotinib treatment|
89006831|NCT06177899||Reverse split-box group|"Before augmentation, according to the 3D topography of the alveolar ridge of the patients, the reverse split-box technique was applied if there was more than 3 mm bone thickness at the top of the crest and the bone thickness increase towards the lower border.~This technique differs from the split-box technique as follows: If the bone thickness of the alveolar crest is thick enough to be split, in addition to the bone thickness increases toward the lower border at the alveolar bone, it involves reversing the separated corticocancellous bone block before fixation."
89421631|NCT06016296|No Intervention|Transition level 2 control groups|The transition level 2 control groups (n= 2; n= 24 children) will participate in the assessments (initial and final) and will be asked to maintain their regular session of their educational establishments. At the end of the intervention period (according to the results obtained), the control groups children, parents and/or legal guardians, managers and coordinators of each community will be contacted and provided with the material so that they can replicate the experience. In addition, the educators of these establishments (teachers and classroom assistants) will be trained in the CMSI strategy.
89421632|NCT06016283||MDMR|Male recipient receiving kidney graft from male donor
89421633|NCT06016283||FDMR|Male recipient receiving kidney graft from female donor
89421634|NCT06016283||MDFR|Female recipient receiving kidney graft from male donor
89421635|NCT06016283||FDFR|Female recipient receiving kidney graft from female donor
89421636|NCT06016231||LAL in at least one eye|
89421637|NCT06016166|Experimental|Eye mask users|The eyes of the patients will be defined as the intervention
89421638|NCT06016166|No Intervention|Non eye mask users|The eyes of the patients will be defined as the controls
89421639|NCT06016101||100 Patients|"Socio-demographic data (age, gender, lifestyle, medication management aids)~Medical data (number and type of medications)~Variables for calculating assessment criteria:~< Pill count: this is a simple way of estimating compliance with medication. The pharmacist will calculate the pill count. The remaining pills (not taken by the patient) are brought to the pharmacist, who then calculates them. The pill count is not used as part of routine care for Medipac beneficiaries.~< The Morisky adherence questionnaire is an 8-item hetero-questionnaire used to measure adherence to treatment. It will be carried out by the home care nurse as part of routine care. The scores can be interpreted as follows: ≥ 8: good adherence; 6 to 7: average adherence; < 6: poor adherence."
89421640|NCT06016101||Healthcare professionals (20 doctors, 20 pharmacists and 20 nurses)|"Socio-demographic data (age, gender, profession)~Evaluation of the user experience using the SUS (Sytem usability scale) questionnaire. This is an easy-to-use Likert-type scale consisting of 10 questions. The aim is to assess the point of view of the person using the Medissimo nurse application, after having had the opportunity to use it. The questions offer quick answers, ranging from strongly disagree to strongly agree.~Assessment of the monthly reports produced by the application for nurses, GPs and pharmacists. Using a Likert-type questionnaire, they will be asked to describe their satisfaction, and the beneficial or negative aspects of this application in relation to patient monitoring. The questionnaire consists of 12 questions, 10 of which offer the following 5 responses: Strongly agree; Agree; Neither disagree nor agree; Disagree; Strongly disagree, and 2 short-answer, open-ended questions."
89421641|NCT06016062|Experimental|RC148|Participants will be allocated to one of the following dose groups:1.0, 3.0, 10.0, 20.0, and 30.0mg/kg, and receive a treatment of RC148 followed by 28 days of dose limited toxicity (DLT) observation period.
89421642|NCT06016049|Active Comparator|EMLA®|adjuvant forearm anesthesia cream (EMLA®) and sensibility training in a program involving 15 sessions (8 weeks) of guided plasticity
89421643|NCT06016049|Placebo Comparator|Skin cream|skin cream and sensibility training in a program involving 15 sessions (8 weeks) of guided plasticity training
89194828|NCT02543164|Other|TEST: b-glucan enriched bread|Participants will consume a meal standardised to contain 50 g of available carbohydrates. Sample Will be consumed together with 250 mL of water, within 10-15 minutes.
89194829|NCT00884494|Experimental|Roux-en-Y gastric bypass|
89421644|NCT06016036|Experimental|SAL-0951|
89421645|NCT06016036|Placebo Comparator|Placebo|
89421646|NCT06015984|Experimental|Web-Based 8-week Asynchronous Renal Transplantation Nurse Training|"1. Week: application of pre-tests~1. Month: administration of post-tests 3. Month: administration of post-tests"
89421647|NCT06015984|No Intervention|non-trained nurse group|"1. Week: application of pre-tests~1. Month: administration of post-tests 3. Month: administration of post-tests"
89421648|NCT06015971|Active Comparator|standard hypercaloric, hyperproteic oral supplement|
89421649|NCT06015971|Experimental|omega-3 enriched oral supplement|
89421650|NCT06015958|Active Comparator|Active Comparator: Streptococcus salivarius M18 toothpaste dose 1|Streptococcus salivarius M18 toothpaste containing 1 million cfu/g
89421651|NCT06015958|Active Comparator|Active Comparator: Streptococcus salivarius M18 toothpaste dose 2|Streptococcus salivarius M18 toothpaste containing 10 million cfu/g
89421652|NCT06015932|Experimental|Group I (CBCSM)|Patients participate in five CBCSM group sessions on study. Patients complete questionnaires throughout the trial.
89421653|NCT06015932|Active Comparator|Group II (no CBCSM)|Patients complete questionnaires throughout the trial.
89421654|NCT06015919|Experimental|effect of dash diet and acupuncture on hypertention in post menopausal women|"Group (A): It will include 15 post-menopausal women who will be treated by DASH diet and anti-hypertensive drugs.~Group (B): It will include 15 post-menopausal women who will be treated by acupuncture and anti-hypertensive drugs.~Group (C): It will include 15 post-menopausal women who will be treated by DASH diet, acupuncture and anti-hypertensive drugs."
89421655|NCT06015854|Experimental|HPV16+ CIN3|Patients with histological proven HPV16-positive cervical intraepithelial neoplasia grade 3.
89421656|NCT06015828|Experimental|lactoferrin group|Neonates will receive a daily dose of 150 mg/kg body weight per day (up to a maximum of 300 mg/day) of bovine lactoferrin and will be prepared for administration by addition by syringe of sterile water (4 mL) orally or through gavage feeding, once the infant's enteral feed volume is more than 12 mL/kg per day until 36 weeks corrected gestation or for a minimum of 2 weeks, whichever is longer. (Asztalos.,et al 2020)
89194830|NCT00884494|Experimental|Lean|
89194831|NCT00875992|Experimental|ETN with ASLS|Angle stable locking of the Expert Tibial Nail using ASLS
89194832|NCT00875992|Active Comparator|ETN with conventional locking|Conventional locking of the Expert Tibial Nail using conventional locking bolts
88901754|NCT01523353|Active Comparator|Exercise Intervention|4 week personalised exercise program on a static bicycle.
88901755|NCT01523353|No Intervention|Control Arm|Patients having standard preoperative preparation and advice.
89421657|NCT06015828|No Intervention|control group|Neonates will receive their routine feds and will not receive lactoferrin.
89421658|NCT06015815||stage III non-small cell lung cancer|A total of 21 patients with stage III NSCLC who received definitive CRT were prospectively evaluated. The expression levels of miRNA-21 and miRNA-155 in serum at the beginning and end of the treatment
89421659|NCT06015802||Pituitary neuroendocrine tumors|Patients with pituitary neuroendocrine tumors: pituitary adenoma was diagnosed by clinical imaging, with or without pituitary hormone secretion function was confirmed by pituitary hormone detection.
88901756|NCT01523405||1|
89421660|NCT06015776||Men|Men who are undergoing cardiac surgery
89421661|NCT06015776||Women|Women who are undergoing cardiac surgery
89421662|NCT06015763|Other|Relation between gastritis and H.pylori|Endoscopic
89421663|NCT06015711|Experimental|Maxigesic group|Administration of Maxigesic before surgery start.
89421664|NCT06015711|No Intervention|Control group|Administration of normal saline before surgery start.
89421665|NCT06015698|Experimental|Tubal disconnection|"The tube is grasped in the isthmic portion of the tube at least 2cm from the cornua. Bipolar coagulation will provide a more localized area of tubal burn so requiring at least 3cm of the tube to be coagulated~The electrosurgical generator should set to deliver a power of 25W in nonmodulated mode to desiccate tissue sufficiently~The tube should be coagulated with 2 to 3 contiguous burns to provide an area of about 3cm of coagulation. Th endpoint of coagulation is cessation of the current flow~Then, the tube is severed in the middle of the burn area with laparoscopic scissors~Ensure adequate hemostasis"
89421666|NCT06015698|Active Comparator|Salpingectomy|"The tube will be removed from its anatomical attachements by progressive bipolar coagulation~Progressive coagulation and cutting of the mesosalpinx begins at the proximal isthmus of the tube and progresses to the fimbriated end using bipolar coagulation and laparoscopic scissors~Removal of the tube through one of the ancillary ports using artery forceps~Ensure adequate hemostasis"
89421667|NCT06015633||Exudative AMD|Subjects that have at least one eye with a history of, or active, exudative age related macular degeneration
88901757|NCT01523418||Group 1|
88901758|NCT01523431|Active Comparator|Standard FOLFIRI for wild/hetero UGT1A1|Irinotecan Injection [Camptosar] (CPT-11) 180 mg/m2, day 1; Leucovorin (LV) 400mg/m2, day 1; 5-fluorouracil (5-FU) 400mg/m2, day 1, 5-fluorouracil (5-FU) 2400mg/m2, day 1; Repeat every two weeks.
88901759|NCT01523431|Experimental|Reduced Dose of CPT-11 for homo UGT1A1|Irinotecan Injection [Camptosar] (CPT-11) 90 mg/m2, day 1; Leucovorin (LV) 400mg/m2, day 1; 5-fluorouracil (5-FU) 400mg/m2, day 1, 5-fluorouracil (5-FU) 2400mg/m2, day 1; Repeat every two weeks.
88901760|NCT01523431|Active Comparator|Standard FOLFIRI for homo UGT1A1|Irinotecan Injection [Camptosar] (CPT-11) 180 mg/m2, day 1; Leucovorin (LV) 400mg/m2, day 1; 5-fluorouracil (5-FU) 400mg/m2, day 1, 5-fluorouracil (5-FU) 2400mg/m2, day 1; Repeat every two weeks.
88901761|NCT01523470|Active Comparator|stepwise withdrawal of NIV|On the day of decision of withdrawal (day0), the duration of non-invasive ventilator (NIV) will be decreased to 16 hours. On the following day (day1), the duration of NIV will be further decreased to 12 hours. The duration will be further decreased to 8 hours at night on the following day (day 2), and it will be stopped on the day after (day 3). Vital signs and blood gases will be monitored for a total of 5 days after withdrawal is planned (day 0 to day 5).
89194833|NCT00881686|Experimental|adenosine|Adenosine will be administered intravenously before surgery
89421668|NCT06015633||Non-exudative AMD|Subjects that have at least one eye with late stage non-exudative age-related macular degeneration (presence of geographic atrophy)
89421669|NCT06015594|Experimental|Metformin group|Treated with metformin
89421670|NCT06015594|No Intervention|Control group|not treated
89421671|NCT06015568|Experimental|MCLA-129+ Befotertinib|Drug:MCLA-129 1500mg or 2000mg IV Q2W Other name:MCLA-129 Drug:Befotertinib (75 mg or 100 mg orally, once daily) Other name:D-0316
89421672|NCT06015555|Experimental|The TAMO therapy|For four months, TAMO therapy will last 30 minutes every day, twice a week. The therapist first applies light loading for a short period of time to his left hemiocciput directed toward the supporting surface.
89421673|NCT06015555|Experimental|Postural Control exercises|For four months, posture control exercises will be taught twice a week for 30 minutes each time. Under the age of 3 months, infants were required to shift their chin as far to the affected side and upward in the supine or dominant prone posture before they could regulate their neck. Instead of passively adjusting the newborns' heads, we waited for them to actively turn toward their midline.
89421674|NCT06015503|Experimental|PLB1004|PLB1004 given alone as monotherapy
88901762|NCT01523470|Experimental|immediate withdrawal of NIV|The patient will have immediate withdrawal of non-invasive ventilator (NIV). Vital signs and blood gases will be monitored for 2 more days after NIV is stopped (day 0-2).
88901763|NCT01523483|Experimental|Progesterone|Patients in this arm will receive two micronized progesterone capsules (Utrogestan® 200 mg, i.e. 400 mg of micronized progesterone in sunflower oil) placed into the posterior vaginal fornix once daily for up to 36+6 weeks of gestation.
88901764|NCT01523483|Placebo Comparator|placebo|Patients will receive two placebo capsules placed into the posterior vaginal fornix once daily for up to 36+6 weeks of gestation.
88901765|NCT01523509|Experimental|Contrast|All subjects will be in one group who will have a control radiograph of teeth before applying the Sodium Iodide contrast agent topically between the teeth (the intervention) when another radiograph will be taken to test for the presence of contrast in a cavity.
88901766|NCT01523522|Active Comparator|myoblast injection|autologous myoblast
88901767|NCT01523522|Placebo Comparator|saline solution injection|saline solution injection in anal sphincter
88901768|NCT01523535|Placebo Comparator|normal sleep|Subjects have 8 hours of sleep opportunity per night
89194834|NCT00885508|Experimental|Aracytidine, Daunaurubicine, Lenalidomide|
89421675|NCT06015464||prospective cohort|To retrospectively collect information on DLBCL patients treated with orelabrutinib in combination with standard first-line regimens, pooled analysis of the association between recent efficacy and patient characteristics (including biomarkers) in different types of patients to assess the predictive value of ctDNA for prognosis and subsequent therapeutic adjustments during treatment
89421676|NCT06015464||Prospective cohort|Prospective observation to collect information on the efficacy of orelabrutinib in combination with standard treatment regimens in specific types of populations (with a focus on genotyped patients such as MCD, BN2 and N1 subtypes) to validate the predictive value of ctDNA in diagnosis and treatment
89421677|NCT06015451|Active Comparator|Follow-up face-to face|"Home-based and in-house exercise, supervised both by telephone and face-to-face.~Every week the first three weeks participants will exercise one session at the hospital, and the BCTT/BCCT will be performed every 3rd week, at the hospital in order to be able to shape the intervention."
89421678|NCT06015451|Active Comparator|Follow-up over the phone|Home-based exercise only, supervised by telephone. The participants will exercise solely in the home setting and will be contacted by telephone, every week during the first three weeks, thereafter every third week. Based on the therapist's evaluation during these calls, the intervention is shaped.
89421679|NCT06015412||Grade 1 osteoarthritis|disease stages 1 according to the Kellgren-Lawrence radiographic classification system
89421680|NCT06015412||Grade 2 osteoarthritis|disease stages 2 according to the Kellgren-Lawrence radiographic classification system
89421681|NCT06015412||Grade 3 osteoarthritis|disease stages 3 according to the Kellgren-Lawrence radiographic classification system
89421682|NCT06015412||Grade 4 osteoarthritis|disease stages 4 according to the Kellgren-Lawrence radiographic classification system
89421683|NCT06015399|Experimental|Closed insufflation technique group|Closed insufflation technique is characterized by ligation in the proximal portion of targeted bronchus and gas injection in the distal portion. Closed insufflation technique group includes patients undergoing segmentectomy using closed insufflation technique.
88901769|NCT01523535|Experimental|cycles of sleep restriction|subjects are exposed to bouts of reduced sleep duration. The sleep loss is the intervention (experimental challenge).
88901770|NCT01523548|Experimental|Carbon Monoxide|Inhaled Carbon Monoxide therapy administered over 16 weeks
88901771|NCT01523561|No Intervention|usual care|The participants in the no intervention group were informed that they should continue living as usual
89421684|NCT06015399|Active Comparator|Dilatation and collapse technique|Dilatation and collapse technique is characterized by pure oxygen dilatation and subsequent collapse after the division of targeted bronchus. Dilatation and collapse technique group includes patients undergoing segmentectomy using Dilatation and collapse technique.
89421685|NCT06015386|Experimental|inclined plane|group treated with inclined plane
89421686|NCT06015386|Experimental|clear aligner|group treated with clear aligner
89421687|NCT06015373|Experimental|Patients with CSPH receiving carvedilol twice daily and supress the night dose of carvedilol|In this experimental study, 34 patients with CSPH receiving carvedilol twice daily were asked to supress the night dose of carvedilol, in order to have a dose interval of approximately 24 hours. Spleen stiffness measurement (SSM) by transient elastography (TE) was performed and compared with SSM prior or under treatment. Same procedure was applied to liver stiffness measurement (LSM).
89421688|NCT06015347||Assessment|Infants at risk rated with the Alberta Infant Motor Scale between 1-18 months
89421689|NCT06015334|Active Comparator|Bilateral implantation of trifocal intraocular lens|Patients will receive bilateral implantation of TECNIS Synergy intraocular lens
89421690|NCT06015334|Active Comparator|Bilateral monofocal intraocular lens implantation with monovision|Patients will receive bilateral implantation of TECNIS monofocal intraocular lens
89421691|NCT06015321|Experimental|Enzalutamide|First-Line Maintenance Enzalutamide Following Docetaxel plus Androgen-Deprivation Therapy in Patients with Previously-Untreated, Metastatic, Castration-Naïve Prostatic Adenocarcinoma
89421692|NCT06015295|Experimental|18F-Fluciclovine (Axumin)|Participants are expected to be in this research study for about 6-12 months. Participants will have up to 6 visits for screening tests, Axumin PET-CT scans, and information collection.
89421693|NCT06015269|Experimental|DC cells|Super DC Vaccine (DC)
89421694|NCT06015243|Experimental|Experimental: GR1802|GR1802 injection 300mg every two weeks for 16-week treatment
89421695|NCT06015230|Experimental|Treatment group 1-Ⅰb|6 subjects in GR1603 low dose，2 subjects in placebo
89421696|NCT06015230|Experimental|Treatment group 2-Ⅰb|6 subjects in GR1603 high dose，2 subjects in placebo
89421697|NCT06015230|Experimental|treatment group 3-Ⅱ|low dose GR1603 monthly
89421698|NCT06015230|Experimental|treatment group 4-Ⅱ|high dose GR1603 monthly
89421699|NCT06015230|Placebo Comparator|treatment group 5-Ⅱ|placebo
88901772|NCT01523561|Experimental|dance intervention|"The dance intervention took place twice weekly for a period of 1 year under the guidance of two dance class teachers. The duration of the class was 75 min. and the dance training was always carried out to popular music. The dance choreography was adjusted to the level of the participants' skills in order to make them feel successful in their exercise. During the intervention year, the theme of dance styles varied from hip hop, jazz and contemporary dance. African dance was used in the warm up section. The dance class always ended with a relaxation. The dance intervention had a focus on emphasizing the participants' resources and creates a feeling of affinity. Listening to signals from the body, reducing focus on the performance and become part of the movement was encouraged."
88901773|NCT01523574|Placebo Comparator|Control Group|Five days before chemotherapy:1 x daily Used until one week after third oxaliplatin infusion: 1 x daily
88901774|NCT01523574|Experimental|Vitamin e|Five days before chemotherapy:1 x daily Used until one week after third oxaliplatin infusion: 1 x daily
88901775|NCT01523600|Experimental|Whole body vibration training|
89421700|NCT06015217|Experimental|Treatment Group|"All subjects have mild to moderate diaper dermatitis and are given Cetaphil Healing Ointment to use with every diaper change."
89421701|NCT06015152|Experimental|GROUP A Tazarotene 0.045%|"Topical tazarotene 0.045% and halobetasol Propionate 0.01% . TAZ is the first receptor-selective retinoid used externally to treat plaque psoriasis . The major metabolite of tazarotene, tazarotenic acid, is quickly formed after application and binds to retinoic acid receptors (RARs) in the nucleus. Tazarotenic acid has a weak affinity for retinoid X receptors and prefers to bind to RARs b and g.~Halobetasol propionate is a medication used to treat scalp psoriasis. It is a form of topical corticosteroid, which means it works by suppressing the immune system and reducing inflammation."
89421702|NCT06015152|Experimental|GROUP B Halobetasol Propionate 0.01%|"Topical tazarotene 0.045% and halobetasol Propionate 0.01% . TAZ is the first receptor-selective retinoid used externally to treat plaque psoriasis . The major metabolite of tazarotene, tazarotenic acid, is quickly formed after application and binds to retinoic acid receptors (RARs) in the nucleus. Tazarotenic acid has a weak affinity for retinoid X receptors and prefers to bind to RARs b and g.~Halobetasol propionate is a medication used to treat scalp psoriasis. It is a form of topical corticosteroid, which means it works by suppressing the immune system and reducing inflammation.~."
88901776|NCT01523600|Active Comparator|Wellness group|
88901777|NCT01523626|Other|Conventional imaging|The control group will be evaluated with X-rays, ultrasonography and selective CT scanning.
88901778|NCT01523626|Other|Immediate total body CT|The intervention group will receive a 'total body' CT scan from head to pelvis. Conventional radiography and FAST will be completely omitted.
88901779|NCT01523639|Active Comparator|Metformin|FOLFIRI + cetuximab + metformin every 2 weeks for 12 cycles
88901780|NCT01523639|Placebo Comparator|Placebo|FOLFIRI + cetuximab + placebo every 2 weeks for 12 cycles
88901781|NCT01523652||Nadroparin/control (phase 1)|patients affected by benign pelvic gynaecologic diseases were enrolled and treated with nadroparin for prophylactic anticoagulation; patients untreated with nadroparin were as control group.
88901782|NCT01523652||Nadroparin (phase 2)|patients were enrolled among women planning gynaecological pelvic surgery and treated for 4 weeks with nadroparin for prophylactic anticoagulation. All these patients underwent laparotomy;
88901783|NCT01523678|Experimental|Filgrastim|
88901784|NCT01523691|Experimental|repeated sleep restriction and recovery|
88901785|NCT01523691|Experimental|control sleep|
88901786|NCT01523730|Active Comparator|Repetitive Transcranial Magnetic Stimulation (rTMS)|
88901787|NCT01523730|Placebo Comparator|Sham rTMS|
88901788|NCT01523769|No Intervention|Control|Control group, the cord was not milked
88901789|NCT01523769|Experimental|Umbilical Cord Milking|Approximately 10 cm of umbilical cord was milked toward the baby immediately following delivery
89421703|NCT06015139|Active Comparator|viscoelastic polymer pads|while the control group used a Relton-Hall prone frame with a viscoelastic polymer pads
89421704|NCT06015139|Experimental|cotton roll-coated viscoelastic polymer pads|The experimental group used a Relton-Hall prone frame with cotton roll-coated 3 cm viscoelastic polymer pads
89421705|NCT06015126|Experimental|Label 1|metronomic oral vinorelbine plus anlotinib
89421706|NCT06015113|Experimental|Label 1|tale Disitamab Vedotin with pyrotinib or neratinib
89421707|NCT06015100|Experimental|Label 1|Inetetamab plus pyrotiniband and capecitabine
89421708|NCT06015074|Active Comparator|Propofol group|patients in Propofol group receive sufentanil+ propofol
88901790|NCT01523795|Experimental|Motion-controlled video gaming|Participants played motion-controlled video games that involved at least throwing, hitting, or dancing motions using a Wii or Xbox 360 console for one hour
89421709|NCT06015074|Experimental|Ciprofol group|patients in Ciprofol group receive sufentanil+ ciprofol
89421710|NCT06015061||Pheochromocytoma or Paraganglioma Patients with Anlotinib Treatment|to evaluate the efficiency of contrast enhanced ultrasound in assessing effectiveness of anlotinib in patients with locally advanced, metastatic, or unresectable pheochromocytoma or paraganglioma(PPGL).
89421711|NCT06015035|Experimental|anlotinib for anti-angiogenesis and sintilimab and chemotherapy|Neoadjuvant treatment involved administering anlotinib (10 mg orally, once a day, 2 weeks on and 1 week off) for anti-angiogenesis and sintilimab (200 mg) and chemotherapyfor three cycles.
89421712|NCT06014177|Other|Control|"After enrollment but before the start of their clinical visit, participants assigned to a provider in the control arm will scan a QR code. They will receive a prompt stating, If you would like to be tested for a sexually transmitted infection today, please tell your medical doctor.~At the end of the visit, the participant will complete the Patient Control Exit Survey while the provider will complete the Provider Control Exit Survey.~These participants will not receive STIckER training."
89421713|NCT06014177|Experimental|STIckER|"After enrollment but before the start of their clinical visit, participants assigned to a provider in the intervention arm will scan a QR code using their personal mobile phone at the start of their ED visit. If they do not have a mobile phone present, a secure password-protected tablet will be provided by the research staff. This will lead them to go through the STIckER decision aid modules. After completing the modules, participants will show the final outcome to their ED provider which may facilitate an SDM conversation about STI testing.~At the end of the visit, the participant will complete the Patient Intervention Exit Survey while the provider will complete the Provider Intervention Exit Survey."
89421714|NCT06014060|Experimental|24 Months DAPT|Dual antiplatelet therapy consisting of aspirin and clopidogrel will be continued for 12 months after randomisation.
89421715|NCT06014060|Active Comparator|12 Months DAPT|Dual antiplatelet therapy will be discontinued and patients will receive aspirin monotherapy for 12 months after randomisation.
89421716|NCT06013280|Experimental|Relaxing Exercise Group|Relaxing exercise group participants applied 40 minutes of progressive muscle relaxation and breathing exercises, 3 times a week for 4 weeks
89421717|NCT06013280|No Intervention|Control Group|This group received no intervention, continued their daily life as usual.
89421718|NCT06013267|Experimental|experimental group|"The experimental group will receive a four-week CTAR exercise protocol  and routine dysphagia care."
89421719|NCT06013267|No Intervention|control group|The control group will only receive routine dysphagia care.
89421720|NCT06013202|Experimental|Group 1 (TEST GROUP) Nigella Sativa oil mouth rinse|Ten patients will receive Nigella Sativa oil mouth rinse. Patients will be asked to use the NS oil mouth rinse (10 ml each 6 hrs.) four times daily . Subjects will be provided with 72 hours supply of the study product. Patients will be instructed to use it for 72 hours with a minimum frequency of four times per day, swished for one minute at each use, in which the first dose was used upon awakening and the last dose just before evening sleep. Patients will be instructed not to use over the counter (OTC) or pharmacy formulated oral rinses or gels during the active treatment phase.
88901791|NCT01523795|Active Comparator|Traditional video gaming|Participants played traditional (handheld gamepad controller-based) video games using a Playstation 3 console for one hour
88901792|NCT01523795|Active Comparator|Television watching|Participants watched television via Netflix instant streaming for one hour
88901793|NCT01523847|Experimental|MBVD (Myocet+BVD)|"2 MBVD courses, after early restaging with PET scan (PET-2)~The subsequent treatment will be planned as follows:~-Stage I and IIA patients will go on with 1 more course of MBVD (total of 3 courses) followed by involved field radiotherapy (30 Gy-36 Gy).~-Advanced stage (IIB-IV) patients will go on with 4 more courses of MBVD (total of 6 courses). Radiotherapy limited to bulky or non complete responder areas (30 Gy) is optional."
89421721|NCT06013202|Active Comparator|Group 2 (CONTROL GROUP)|Ten patients will receive the placebo isotonic (normal saline) with concentration 0.90% of sodium chloride (NaCl). Patients will be asked to use it as mouth rinse (10 ml each 6 hrs.) four times daily . Subjects will be provided with 72 hours supply of the study product. Patients will be instructed to use it for 72 hours with a minimum frequency of four times per day, swished for one minute at each use, in which the first dose was used upon awakening and the last dose just before evening sleep. Patients will be instructed not to use over the counter (OTC) or pharmacy formulated oral rinses or gels during the active treatment phase.
89421722|NCT06010550||Dizziness/vertigo|Patients aged 20 or above, presenting to the emergency department with dizziness or vertigo.
89421723|NCT06005766|Experimental|Intervention group|Patients with a psychosis spectrum disorder participating in the group-based metacognitive skills training and receiving treatment as usual
88901794|NCT01523860|Experimental|1|Rituximab will be supplied as 375 mg/sqm for i.v.administration.Mitoxantrone will be supplied as 8 mg/sqm for i.v.administration.Bendamustine will be supplied as 90 mg/sqm for i.v.administration.
88901795|NCT01523912|Experimental|gastric RFA|Ablation of gastric dysplastic mucosa
88901796|NCT01523925|Experimental|Combined dCIT with FET|Combined distributed constraint induced therapy with functional electrical therapy
88901797|NCT01523925|Experimental|Combined BAT with FET|Combined bilateral arm treatment with functional electrical therapy
88901798|NCT01523925|Active Comparator|Control intervention group|Control intervention
88901799|NCT01523925|Experimental|dCIT|distributed constraint induced therapy
88901800|NCT01523925|Experimental|BAT|bilateral arm treatment
88901801|NCT01523938|Experimental|Hypnotherapy|
88901802|NCT01523938|No Intervention|No Hypnotherapy|
88901803|NCT01523951||Healthy volunteers|
88901804|NCT01523990|Experimental|Panel I (TG-2349)|Sequential single oral dose taken by healthy East and Caucasian volunteers from 50 mg (fasted) to 50 mg (fed) of TG-2349 with 1 week follow-up after each dosage. A washout period of at least 10 days between the 1st and the 2nd dose is required.
88901805|NCT01523990|Placebo Comparator|Panel I (placebo)|Sequential single oral dose taken by healthy East and Caucasian volunteers from 50 mg (fasted) to 50 mg (fed) of placebo with 1 week follow-up after each dosage. A washout period of at least 10 days between the 1st and the 2nd dose is required.
89421724|NCT06005766|Active Comparator|Patient controls|Patients with a psychosis spectrum disorder receiving standard long-term care in the hospital
89421725|NCT06005766|No Intervention|Non-patient controls|Control group consisting of test subjects without a diagnosis of psychosis spectrum disorder
89536029|NCT03074955|Experimental|Trendelenburg only|"leg wrapping without tension & apply Trendelenburg position~Apply elastic bandages to both legs without tension.~After injecting propofol, apply Trendelenburg position ( 10 degree )~After 3 minutes from propofol injection, remove elastic bandage and revert to supine position.~induction using propofol 2mg/kg~After bispectral index (BIS) goes below 60 & patient become unconsciousness, inject rocuronium 0.6mg/kg~intubate patient between 3 and 4 minutes after propofol injection~measure blood pressure ( systolic, diastolic, mean ) & heart rate at 1,2,3,4,5 minutes after propofol injection~phenylephrine injection if hypotension develops"
88814242|NCT02242526|Active Comparator|Parietex™ Composite Hiatal Mesh, North Haven, CT|Synthetic prosthetic mesh Parietex™ Composite Hiatal (PCO 2H) Mesh (Covidien, North Haven, CT) designed for hiatal hernia repair.
88814243|NCT02242526|Active Comparator|Biodesign™ Surgisis® Graft, Cook Medical, Bloomington|Biologic mesh Biodesign™ Surgisis® Graft Reinforcement in Hiatal, Cook Medical, Bloomington, IN which will be placed for repair of hiatal hernia
88814244|NCT02242604||Not treatment|Patients with the age of 70 years or above, that have a serum sodium of below 130 mmol/L on admission. All patients will be routinely evaluated at admission with a standardized multidimensional geriatric assessment (MGA) consisting of a battery of validated assays.
88814245|NCT02242682|No Intervention|Control|This group of subjects will not be exposed to a video during their time in the ED waiting room
88814246|NCT02242682|Experimental|Child passenger safety video|This group of subjects will be exposed to a video during their time in the ED waiting room
88814247|NCT01623869|Experimental|Treatment (trebananib)|Patients receive 30 mg/kg trebananib IV over 30-60 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88814248|NCT04364594|Experimental|affected individual|Patients affected by Coronavirus 19 admitted to the hospital setting
88814249|NCT04370600|Active Comparator|Group A|These patients will receive ketone supplementation between visits 1 and 2 and will receive placebo drink between visits 2 and 3 (after the washout period).
88814250|NCT04370600|Active Comparator|Group B|These patients will receive ketone supplementation between visits 2 and 3 (after the washout period) and will receive placebo drink between visits 1 and 2
88814251|NCT04364204|Experimental|Kangaroo mother care with bracelet|
88814252|NCT04364204|Active Comparator|Kangaroo mother care|
88814253|NCT01625507|Experimental|PANDA intervention|12 week nutritional intervention, including 6 classroom/community sessions, plus two sample collection visits.
88814254|NCT02242838||Hypertensive patients|
88814255|NCT03207347|Experimental|Cohort A|This cohort will enroll patients with mesothelioma, uveal melanoma, renal cell carcinoma (clear cell type), and cholangiocarcinoma.
88814256|NCT03207347|Experimental|Cohort B|This cohort will enroll patients whose tumors have a known DNA damage response mutation in any of the following genes: ARID1A, ATM, ATR, BACH1 (BRIP1), BAP1, BARD1, BLM, CHEK1, CHEK2, CDK2, CDK4, ERCC, FAM175A, FEN1, IDH1, IDH2, MRE11A, NBN (NBS1), PALB2, POLD1, PRKDC (DNA-PK) PTEN, RAD50, RAD51, RAD52, RAD54, RPA1, SLX4, WRN, or XRCC. This cohort is open to patients with any type of malignancy (except prostate).
88814257|NCT04364438|No Intervention|Control Group|Patients will be treated with conventional medical treatment for overactive bladder including anticholinergic drugs and pelvic floor muscle exercises
88814258|NCT04364438|Experimental|EMS Group|Patients will be treated with conventional medical treatment for overactive bladder including anticholinergic drugs and pelvic floor muscle exercises along with Electric Muscle Stimulation (EMS)
88814259|NCT04364438|Experimental|TENS Group|Patients will be treated with conventional medical treatment for overactive bladder including anticholinergic drugs and pelvic floor muscle exercises along with Transcutaneous Electric Nerve Stimulation (TENS)
88814260|NCT02242916||Patients with recurrent HN tumors|Patients with recurrent Head and Neck tumors
88814261|NCT02243072|Experimental|Fit Familes plus Standard Medical Care|Participants will receive the intervention Fit Families plus Standard Medical Care which is an adaptation of Multisystemic Therapy for Type 1 Diabetes delivered by Community Health Workers (CHWs) in addition to standard medical care.
88814262|NCT02243072|No Intervention|Standard Medical Care|Standard medical care is provided at Children's Hospital of Michigan consistent with the standards for the care of children with T1D outlined by the American Diabetes Association.
88814263|NCT04370210||Child without follow-up in child psychiatry|Child enrolled, and their parents, must complete online questionnaires
89421726|NCT06004102|Experimental|reminder text message|"At the baseline of the study, the Sociodemographic and Descriptive Characteristics Form and IMAS were administered to patients in the intervention groups as a pretest. Short text messages to remind the use of immunosuppressive medication and educational text messages were sent to patients in the intervention group four times a day, every day for three months. The intervention group also received educational text messages three days a week, in addition to such text message reminders.~The text message contents prepared for the intervention group were sent automatically to patients at specified times via the purchased program. At the end of the study, intervention groups of participants completing the 9-month follow-up were administered the IMAS questionnaire as a posttest."
89421727|NCT06004102|No Intervention|no intervention|At the baseline of the study, the Sociodemographic and Descriptive Characteristics Form and IMAS were administered to patients in the control groups as a pretest. The control group did not receive any such intervention. At the end of the study, control groups of participants completing the 9-month follow-up were administered the IMAS questionnaire as a posttest.
89421728|NCT05999773||SGLT-2i Group|Patients diagnosed with Child-Turcotte-Pugh A6-B9 class Hepatic Cirrhosis (moderately impaired liver function) and type 2 Diabetes Mellitus assigned to start SGLT-2 inhibitors intake, according diabetology indications, in addition to standard medical therapy for 6 months.
89421729|NCT05999773||Standard Therapy Group|Patients diagnosed with Child-Turcotte-Pugh A6-B9 class Hepatic Cirrhosis (moderately impaired liver function) and type 2 Diabetes Mellitus assigned to continue standard medical therapy, according diabetology indications, for 6 months.
89421730|NCT05994989||Group 1|"Patients who have undergone coronary artery bypass surgery and received intravenous tranexamic acid either as a bolus or infusion during the intraoperative period will be included in the study. The cases collected over a period of 6 months will be divided into two groups and compared.~The first group will consist of patients who receive a 10 mg/kg i.v. bolus of tranexamic acid after anesthesia induction, followed by an 8-hour i.v. tranexamic acid infusion at a dose of 2 mg/kg/hour."
88814264|NCT04370210||Child with follow-up in child psychiatry|Child enrolled, and their parents, must complete online questionnaires
88814265|NCT02249039|Experimental|intermittent IV CLON|Mechanically ventilated infants and children receive intravenous intermittentClonidine
88814266|NCT04363892|Experimental|Receiving optical and infrared imaging|This is the only arm of the study. All patients will have optical and infrared images acquired of skin on the treated and contralateral sides.
88814267|NCT04370288|No Intervention|Control group|Covid-19 patients treated with standard medical therapy (supportive therapy).
88814268|NCT04370288|Experimental|Intervention group|Covid-19 patients treated with mixture of MCN (Methylene blue, vitamin C, N-acetyl cysteine).
88814269|NCT02993705|Experimental|Trabectedin|Trabectedin will be infused at the dose of 1.3 mg/m2 as a 3- hour iv infusion every 3 weeks via a central venous catheter.
88814270|NCT02245178||Obervational - CARDIA participants|CARDIA study participants will undergo lung function testing and have existing thoracic CT scans analyzed for lung structure.
88814271|NCT02243150|Experimental|Cohort 1|6mg/m2 of G1T28-1 or placebo will be administered in 50mL of 5% dextrose by IV infusion
88814272|NCT02243150|Experimental|Cohort 2|Dose of G1T28-1 or placebo will be determined based on the safety and PK data from Cohort 1; G1T28-1 or placebo will be administered in 50mL of 5% dextrose by IV infusion.
88814273|NCT02243150|Experimental|Cohort 3|Dose of G1T28-1 or placebo will be determined based on the safety and PK data from Cohort 2; G1T28-1 or placebo will be administered in 50mL of 5% dextrose by IV infusion.
88814274|NCT02243150|Experimental|Cohort 4|Dose of G1T28-1 or placebo will be determined based on the safety and PK data from Cohort 3; G1T28-1 or placebo will be administered in 50mL of 5% dextrose by IV infusion.
88814275|NCT02243150|Experimental|Cohort 5|Dose of G1T28-1 or placebo will be determined based on the safety and PK data from Cohort 4; G1T28-1 or placebo will be administered in 50mL of 5% dextrose by IV infusion. Subjects from this cohort may be selected to participate in the Whole Blood Ex-Vivo Stimulation group.
88814276|NCT02243150|Experimental|Cohort 6|Dose of G1T28-1 or placebo will be determined based on the safety and PK data from Cohort 5; G1T28-1 or placebo will be administered in 50mL of 5% dextrose by IV infusion. Subjects from this cohort may be selected to participate in the Whole Blood Ex-Vivo Stimulation group.
88901806|NCT01523990|Experimental|Panel II (TG-2349)|Sequential single oral dose taken by healthy East and Caucasian volunteers from 100 mg (fasted) to 100 mg (fed) of TG-2349 with 1 week follow-up after each dosage. A washout period of at least 10 days between the 1st and the 2nd dose is required.
89421731|NCT05994989||Group 2|Group 2 will consist of patients who receive three doses of tranexamic acid, 10 mg/kg i.v. bolus after anesthesia induction, in the pump, and after protamine sulfate administration.
89421732|NCT05994339|Experimental|Radiotherapy Combined with Almonertinib|Radiotherapy was administered using Intensity-Modulated Radiation Therapy (IMRT) technique, with a prescribed dose of 60 Gy in 30 fractions. Almonertinib was orally administered at 110 mg per day, starting from the first day of radiotherapy and continued for 42 days until the completion of radiotherapy, followed by continuous medication until disease progression.
89421733|NCT05994339|Active Comparator|Radiotherapy Combined with Chemotherapy|Radiotherapy was administered using Intensity-Modulated Radiation Therapy (IMRT) technique, with a prescribed dose of 60 Gy in 30 fractions. Chemotherapy with paclitaxel at 135 mg/m2 and cisplatin at 70 mg/m2 was intravenously infused for two cycles during the 1st and 4th weeks. After the completion of radiotherapy, there was a rest period of 4 weeks, followed by continuation of the TP regimen for consolidation chemotherapy for 4 cycles.
89421734|NCT05993338|Experimental|assess pulmonary hemodynamics in COVID-19 survivors|COVID-19 survivors from a moderate/severe COVID-19 pulmonary infection according to WHO COVID-19 clinical severity classification, ≥ 18 years, with residual symptoms and signs suggestive of pulmonary hypertension and not explained by other condition
89421735|NCT05965869|Experimental|Diabetes program and education|Receive diabetes program and education
88901807|NCT01523990|Placebo Comparator|Panel II (placebo)|Sequential single oral dose taken by healthy East and Caucasian volunteers from 100 mg (fasted) to 100 mg (fed) of placebo with 1 week follow-up after each dosage. A washout period of at least 10 days between the 1st and the 2nd dose is required.
88901808|NCT01523990|Experimental|Panel III (TG-2349)|Sequential single oral dose taken by healthy East and Caucasian volunteers from 200 mg (fasted or fed) to 400 mg (fasted or fed) of TG-2349 with 1 week follow-up after each dosage. A washout period of at least 10 days between the 1st and the 2nd dose is required.
88901809|NCT01523990|Placebo Comparator|Panel III (placebo)|Sequential single oral dose taken by healthy East and Caucasian volunteers from 200 mg (fasted or fed) to 400 mg (fasted or fed) of placebo with 1 week follow-up after each dosage. A washout period of at least 10 days between the 1st and the 2nd dose is required.
88901810|NCT01523990|Experimental|Panel IV (TG-2349)|Sequential single oral dose taken by healthy East and Caucasian volunteers from 600 mg (fasted or fed) to 800 mg (fasted or fed) of TG-2349 with 1 week follow-up after each dosage. A washout period of at least 10 days between the 1st and the 2nd dose is required.
88901811|NCT01523990|Placebo Comparator|Panel IV (placebo)|Sequential single oral dose taken by healthy East and Caucasian volunteers from 600 mg (fasted or fed) to 800 mg (fasted or fed) of placebo with 1 week follow-up after each dosage. A washout period of at least 10 days between the 1st and the 2nd dose is required.
88901812|NCT01523990|Experimental|Panel V (TG-2349)|Oral dose taken once daily for 5 consecutive days at dose level of 100 mg taken by healthy East and Caucasian volunteers .
89421736|NCT05963932|Experimental|Treatment A: BMS-986419 DR Capsule - Fasted|
89421737|NCT05963932|Experimental|Treatment B: BMS-986419 IR Tablet - Fasted|
89421738|NCT05963932|Experimental|Treatment C: BMS-986419 IR Tablet - Fed|
89421739|NCT05963932|Experimental|Treatment D: BMS-986419 Crushed IR Tablet - Fed|
89421740|NCT05949437|Experimental|Group (I)|consists of 30 patients with iron deficiency anemia and will receive medical treatment of anemia, Dietary advices and 50 minutes yoga therapy 6 days a week for 12 weeks
89421741|NCT05949437|Other|Group (II)|consists of 30 patients with iron deficiency anemia and will receive medical treatment for anemia, Diet advices and 30 minutes of aerobic exercises in form of treadmill according to the target exercise heart rate for 12 weeks.
89421742|NCT05924360|Other|Control Group|The individuals in this group will undergo a conventional exercise program.
89421743|NCT05924360|Experimental|Mulligan Group|In addition to the conventional treatment program, individuals in this group will receive the mobilization with movement technique in the directions of flexion, abduction, and external rotation, twice a week.
88901813|NCT01523990|Placebo Comparator|Panel V (placebo)|Oral dose taken once daily for 5 consecutive days at dose level of 100 mg taken by healthy East and Caucasian volunteers .
88901814|NCT01523990|Experimental|Panel VI (TG-2349)|Oral dose taken once daily for 5 consecutive days at dose level of 200 mg taken by healthy East and Caucasian volunteers .
88901815|NCT01523990|Placebo Comparator|Panel VI (placebo)|Oral dose taken once daily for 5 consecutive days at dose level of 200 mg taken by healthy East and Caucasian volunteers .
88901816|NCT01523990|Experimental|Panel VII (TG-2349)|Oral dose taken once daily for 5 consecutive days at dose level of 400 mg taken by healthy East and Caucasian volunteers .
88901817|NCT01523990|Placebo Comparator|Panel VII (placebo)|Oral dose taken once daily for 5 consecutive days at dose level of 400 mg taken by healthy East and Caucasian volunteers .
88901818|NCT01523990|Experimental|Panel VIII (TG-2349)|Oral dose taken once daily for 5 consecutive days at dose level of 600 mg taken by healthy East and Caucasian volunteers .
88901819|NCT01523990|Placebo Comparator|Panel VIII (placebo)|Oral dose taken once daily for 5 consecutive days at dose level of 600 mg taken by healthy East and Caucasian volunteers .
88901820|NCT01523990|Experimental|Panel IX (TG-2349)|Oral dose taken once daily for 3 consecutive days at dose level of 200 mg (fed) taken by HCV genotype 1 (including subtypes 1a or 1b or mixed 1a/1b) infected patients.
88901821|NCT01523990|Placebo Comparator|Panel IX (placebo)|Oral dose taken once daily for 3 consecutive days at dose level of 200 mg (fed) taken by HCV genotype 1 (including subtypes 1a or 1b or mixed 1a/1b) infected patients.
88901822|NCT01523990|Experimental|Panel X (TG-2349)|Oral dose taken once daily for 3 consecutive days at dose level of 400 mg (fed) taken by HCV genotype 1 (including subtypes 1a or 1b or mixed 1a/1b) infected patients.
88901823|NCT01523990|Placebo Comparator|Panel X (placebo)|Oral dose taken once daily for 3 consecutive days at dose level of 400 mg (fed) taken by HCV genotype 1 (including subtypes 1a or 1b or mixed 1a/1b) infected patients.
88901824|NCT01523990|Experimental|Panel XI (TG-2349)|Oral dose taken once daily for 3 consecutive days at dose level of 600 mg (fed) taken by HCV genotype 1 (including subtypes 1a or 1b or mixed 1a/1b) infected patients.
88901825|NCT01523990|Placebo Comparator|Panel XI (placebo)|Oral dose taken once daily for 3 consecutive days at dose level of 600 mg (fed) taken by HCV genotype 1 (including subtypes 1a or 1b or mixed 1a/1b) infected patients.
88901826|NCT01523990|Experimental|Panel XII (TG-2349)|Oral dose taken once daily for 3 consecutive days at dose level of 600 mg (fed) taken by HCV genotype 2 infected, treatment-naive patients.
88901827|NCT01523990|Experimental|Panel XIII (TG-2349)|Oral dose taken once daily for 3 consecutive days at dose level of 600 mg (fed) taken by HCV genotype 3 infected, treatment-naive patients.
88901828|NCT01523990|Experimental|Panel XIV (TG-2349)|Oral dose taken once daily for 3 consecutive days at dose level of 600 mg (fed) taken by HCV genotype 4 infected, treatment-naive patients.
88901829|NCT01523990|Experimental|Panel XV (TG-2349)|Oral dose taken once daily for 3 consecutive days at dose level of 600 mg (fed) taken by HCV genotype 5 infected, treatment-naive patients.
88901830|NCT01523990|Experimental|Panel XVI (TG-2349)|Oral dose taken once daily for 3 consecutive days at dose level of 600 mg (fed) taken by HCV genotype 6 infected, treatment-naive patients.
88901831|NCT01524003|Experimental|Cryotherapy after VIA triage|Women who test HPV positive will be randomized to the experimental arm or the standard of care arm. In the Experimental arm VIA will be done to determine acceptability for cryotherapy [R/O high-grade CIN too large for cryotherapy (usually 3-4 quadrant disease) or cancer]. All acceptable patients will have an ECC done and then immediate cryotherapy.
88901832|NCT01524003|Active Comparator|Colposcopy and biopsy|Standard of care. Women testing positive for HPV will be randomized to the experimental arm (immediate cryotherapy) or the Standard of care arm, for colposcopy, biopsy, and leep based on the pathology results.
88901833|NCT01524016|Experimental|68Ga-DOTATATE, PET/CT scan|We will perform 68Ga-DOTATATE PET/CT scanning on subjects
88901834|NCT01524029||Breast Cancer Screening Patients|Group 1 consists of Women referred to Breast Cancer Screening examinations at a participating Austrian Breast Imaging Site
88901835|NCT01524029||Diagnostic Patients|Patients referred to a participating Breast Imaging Center for a clinically or radiologically detected breast lesion
88901836|NCT01524042|Experimental|group 2|study group:double pants group
88901837|NCT01524055|Other|Air|Air as insufflation gas during single-balloon enteroscopy.
88901838|NCT01524055|Other|CO2|CO2 as insufflation gas during single-balloon enteroscopy.
88901839|NCT01524068|Experimental|Arm A - Standard Steroid Treatment|
88901840|NCT01524068|Experimental|Arm B - Experimental Treatment|
88901841|NCT01524081|Experimental|APPE - antibiotic prophylaxis|Patients indicated for emergent appendectomy with antibiotic prophylaxis
88901842|NCT01524081|Experimental|GERD - antibiotic prophylaxis|Patients indicated for emergent surgery due to gastroduodenal perforation with antibiotic prophylaxis.
88901843|NCT01524081|Experimental|ILEUS - antibiotic prophylaxis|Patients indicated for emergent due to small bowel obstruction with antibiotic prophylaxis
88901844|NCT01524081|Placebo Comparator|APPE - placebo|Patients indicated for emergent appendectomy without antibiotic prophylaxis. Placebo (saline) was administrated.
88901845|NCT01524081|Placebo Comparator|GERD - placebo|Patients indicated for emergent surgery due to gastroduodenal perforation without antibiotic prophylaxis. Placebo (saline) was administrated.
88901846|NCT01524081|Placebo Comparator|ILEUS - placebo|Patients indicated for emergent due to small bowel obstruction without antibiotic prophylaxis. Placebo (saline) was administrated.
88901847|NCT01524094|Experimental|Arm A: CRS plus postop intraperitoneal chemotherapy.|Cytoreductive surgery and postoperative intraperitoneal chemotherapy.
88901848|NCT01524094|Active Comparator|Arm B: Systemic chemotherapy alone|Systemic chemotherapy alone
88901849|NCT01524107||Urgent Caesarian Section|
88901850|NCT01524107||Elective Caesarian Section|
88901851|NCT01524120||Crohn's disease (CD)|Patients with CD and mucosal healing on endoscopy.
88901852|NCT01524120||Crohn's disease|Patients with CD and mucosal healing on endomicroscopy.
88901853|NCT01524120||Ulcerative colitis (UC)|Patients with UC and mucosal healing on endoscopy.
88901854|NCT01524120||Ulcerative colitis|Patients with UC and mucosal healing on endomicroscopy.
88901855|NCT01524146||Photodynamic therapy|Subjects who will receive photodynamic therapy for palliation of unresectable Cholangiocarcinoma.
88901856|NCT01524159|Placebo Comparator|placebo group|This group will receive placebo capsule (wheat starch) for 12 weeks period. The 1050 mg dosage of wheat starch was divided into three capsules and to be taken two (2 x 350 mg) after breakfast and another one (350 mg) after dinner. The capsules should be taken two hours after the meals.
88901857|NCT01524159|Active Comparator|bromelain group|Bromelain Group This group will receive bromelain capsule for 12 weeks period. The 1050 mg dosage of bromelain was divided into three capsules and to be taken two (2 x 350 mg) after breakfast and another one (350 mg) after dinner. The capsules should be taken two hours after the meals.
88901858|NCT01524172|Active Comparator|Standard Mental Health Treatment|Trauma-informed evidence supported mental health treatment
88901859|NCT01524172|Experimental|Yoga Based Psychotherapy Group|Yoga Based Psychotherapy will be used as an adjunct mental health interventions
88901860|NCT01524185|Experimental|FamilyLive|Multi-therapist group intervention for families with a history of intergenerational neglect and trauma exposure
88901861|NCT01524185|Active Comparator|Standard Mental Health Treatment|Standard trauma-informed mental health treatment
88901862|NCT01524237|Experimental|10 mg LY2140023 + ketamine|Single oral dose of 10 mg LY2140023 followed by intravenous (IV) ketamine during one of the crossover periods
88901863|NCT01524237|Experimental|20 mg LY2979165 + ketamine|Single oral dose of 20 mg LY2979165 followed by IV ketamine during one of the crossover periods
88901864|NCT01524237|Experimental|40 mg LY2140023 + ketamine|Single oral dose of 40 mg LY2140023 followed by IV ketamine during one of the crossover periods
88901865|NCT01524237|Experimental|60 mg LY2979165 + ketamine|Single oral dose of 60 mg LY2979165 followed by IV ketamine during one of the crossover periods
88901866|NCT01524237|Experimental|160 mg LY2140023 + ketamine|Single oral dose of 160 mg of LY2140023 followed by IV ketamine during one of the crossover periods
88901867|NCT01524237|Placebo Comparator|Placebo capsules + ketamine|Single oral dose of placebo capsules followed by IV ketamine during one of the crossover periods
88901868|NCT01524237|Placebo Comparator|Placebo tablets + ketamine|Single oral dose of placebo tablets followed by IV ketamine during one of the crossover periods
88901869|NCT01524250|Experimental|oral prednisone|1250mg oral prednisone daily for 3 days
88901870|NCT01524250|Active Comparator|IV methylprednisolone|1000mg IV methylprednisolone daily for 3 days
88901871|NCT01524315|Experimental|Supplementation|6 ml Vitamin-B1-ratiopharm in 100 ml normal saline, intravenous, preoperative
88901872|NCT01524315|Placebo Comparator|Placebo|100 ml normal saline, intravenous, preoperative
88901873|NCT01524341|Experimental|Cohort 1|10 subjects with Plasmodium vivax malaria will receive 30 mg KAE609 once a day for three days
88901874|NCT01524341|Experimental|Cohort 2|10 subjects with Plasmodium falciparum malaria will receive 30 mg KAE609 once a day for three days
88901875|NCT01524354|Active Comparator|Control|Patients received maintenance of anesthesia with continuous infusion of propofol according to recommendations of the manufacturer.
88901876|NCT01524354|Active Comparator|cerebral state index|Patients received continuous infusion of propofol with rate maintaining cerebral state index (CSI) between 40 and 60 points.
88901877|NCT01524367|Placebo Comparator|saline group|We administrate the saline single bolus (0.01ml/kg,intravenously) at time of oral cavity sealing.
88901878|NCT01524367|Experimental|dexmedetomidine group|We administrate the dexmedetomidine single bolus (1ug/kg, intravenously) at time of oral cavity sealing.
88901879|NCT01524380|Active Comparator|Ginkgo biloba extract, antioxidant|Active treatment with Ginkgo biloba extract
88901880|NCT01524380|Placebo Comparator|Placebo|Treatment with placebo
88901881|NCT01524393||IVF pregnancy|
88901882|NCT01524406|Experimental|HPP593|
88901883|NCT01524406|Placebo Comparator|Placebo|
88901884|NCT01524419||women after vaginal birth|
88901885|NCT01524432|Experimental|Drug loaded microcapsules socks|Study medication
88901886|NCT01524432|Placebo Comparator|No drug loaded microcapsules socks|Placebo medication
89421744|NCT05924360|Experimental|Maitland Group|In addition to the conventional treatment program, The Maitland application will be administered in the anterior-posterior, posterior-anterior, and caudal directions. The Maitland application will be delivered at grades 2-3. Patients in this group will receive the application in five sets of 30 seconds, twice a week.
89421745|NCT05920226||A: 150 patients with indications for pacemakers implantation;|"men or women over 60 years of age~with signed informed consent form~in presence of cardiac pathology and arrhythmia requiring pacemakers implantation.~without active cancer or remission period less than 5 years;~without decompensated somatic pathology;~without active viral hepatitis, HIV or syphilis.~Patients will be under observation for 2 years (inclusion in the study, visit 1, 12, 24 months after inclusion in the study)."
89421746|NCT05920226||B: 150 patients without pacemakers implantation;|"men or women over 60 years of age~with signed informed consent form~in presence of cardiac pathology and arrhythmia not requiring pacemaker implantation.~without active cancer or remission period less than 5 years;~without decompensated somatic pathology;~without active viral hepatitis, HIV or syphilis."
89421747|NCT05918406|Experimental|Nasal Guide|Use of Nasal Guide with administration of Tyrvaya (varenicline solution 0.03 mg) BID
89421748|NCT05911802||symptomatic WM|WM patients with symptom(s) : cytopenia, bulky disease or when the physicochemical or immunological properties of IgM explain the occurrence of amyloidosis, cryoglobulin, neurological manifestations, or hyperviscosity syndrome (due to the presence of a large amount of IgM)
89421749|NCT05911802||asymptomatic WM|WM patients without any symptom
89421750|NCT05903820|Active Comparator|Continuous estradiol 50 mcg/day|The continuous standard-dose 17-β-estradiol group will receive the standard therapy for prevention of osteoporosis. A transdermal patch that releases 50ug/24 hrs of 17-β-estradiol will be administered continuously during the 16 weeks of treatment.
89421751|NCT05903820|Active Comparator|Continuous estradiol 25 mcg/day|The continuous low-dose 17-β-estradiol group will receive a transdermal patch that releases 25ug/24 hrs of 17-β-estradiol administered continuously during the 16 weeks of treatment.
89421752|NCT05903820|Experimental|Rhythmic estradiol 25-50 mcg/day|The rhythmic 17-β-estradiol group will receive a transdermal patch for two weeks that releases 25ug/24hrs of 17-β-estradiol, and a patch of 50ug/24hrs for 2 weeks in each 4-week cycle.
89421753|NCT05901675|Experimental|DIET|Focus-15 is a 15-week lifestyle change program developed and delivered by the Weight Management Center at the Medical University of South Carolina.
88901887|NCT01524445||bortezomib retreatment|bortezomib retreatment due to relapse Patients who received bortezomib-containing chemotherapy as first-line treatment for MM experienced partial response or better and were re-treated (second-line) with bortezomib (for at least 3 cycles) due to a relapse of the disease after a treatment free interruption of at least 6 months
89530829|NCT02510495|No Intervention|"0 group"|After a small sphincterotomy was performed, a controlled radial expansion (CRE) balloon (diameter 8, 9, 10, 11, 12, 13.5, 15; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast in 15 seconds. When the waist disappeared, the balloon was deflated immediately. The stones were then retrieved by a basket or retrieval balloon. Mechanical lithotripsy was used if necessary.
88901888|NCT01524458|Experimental|POEM|To perform myotomy using endoscopy through a long submucosal tunnel
88901889|NCT01524471|Experimental|POEM|Endoscopic Myotomy
88901890|NCT01524484||Anesthesia staff Interviewees|Staff entering quality data into the electronic anesthesia record are interviewed regarding working conditions and record layout
88901891|NCT01524484||Anesthesia records|Anesthesia records (all types of procedures) are checked for correct reporting of defined events
88901892|NCT01524497|Active Comparator|Trazodone|
88901893|NCT01524497|Placebo Comparator|Placebo|
88901894|NCT01524510|Experimental|MRA|All OSAS patients will be asked to sleep two nights without MRA and, +/- 1 week later, two nights with MRA
88901895|NCT01524562||Rakai Community Cohort|HIV Patients
88901896|NCT01524562||Rakai HIV Care Program|HIV Patients
88901897|NCT01524575|No Intervention|ERCC1 high expression|Patients with ERCC1 high expression tumors will be treated at discretion of investigator
88901898|NCT01524575|Experimental|ERCC1 low expression|Patients with ERCC1 low expression will be treated with gemcitabine and oxaliplatin
88901899|NCT01524601|Experimental|Rosuvastatin|Rosuvastatin treatment for 4 weeks
88901900|NCT01524614|Experimental|Nasal mask with no PEEP|Nasal mask with PEEP 0, then add PEEP 5, and 10
89421754|NCT05901675|Experimental|DIET+Exercise|As above with, the addition of supervised exercise. The investigators developed an innovative rehabilitation approach, Post-stroke Optimization of Walking using Explosive Resistance (POWER) training; a high-velocity, high-intensity lower extremity resistance training intervention that improves post-stroke muscular and locomotor function. POWER training will take place over a 12-week period (3 sessions/week) with exercises including leg press, calf raises, and jump training, all performed at high concentric velocity, as well as trials of fast walking and functional movements.
89421755|NCT05901675|No Intervention|Wait-list Control|Participants will undergo pre-, post- and follow-up testing but will not partake in any intervention during the same timeframe as those listed in the other arms. Participants will have the opportunity to be enrolled in one of the other arms once they have completed the WLC group timeframe.
89421756|NCT05892874||Parents|
89421757|NCT05888402|Experimental|Induction Toripalimab and chemotherapy followed by concurrent chemoradiotherapy|Participants will receive 2 cycles of induction therapy of platinum-based chemotherapy combined with Toripalimab, followed by platinum-based concurrent chemoradiation. Then participants will receive Toripalimab consolidation therapy after chemoradiotherapy with maximum 1 years or until disease progression or intolerable toxicity.
89421758|NCT05888402|Active Comparator|Induction chemotherapy followed by concurrent chemoradiotherapy|Participants will receive 2 cycles of induction platinum-based chemotherapy, followed by platinum-based concurrent chemoradiation. Then participants will receive Toripalimab consolidation therapy after chemoradiotherapy with maximum 1 years or until disease progression or intolerable toxicity.
89421759|NCT05888207|Experimental|Savolitinib/Savolitinib+Fluvoxamine|In period 1, subjects will receive a single oral dose of savolitinib on Day 1 after overnight fasting. Following minimum 10 days of washout after the last dose of savolitinib, in period 2 subjects will take oral doses of fluvoxamine alone, twice daily from Days 1 to 4. On Day 5 subject will receive a single oral dose of savolitinib and a twice daily oral dose of fluvoxamine. On Day 6, subjects will receive a twice daily oral dose of fluvoxamine alone.
88901901|NCT01524614|Experimental|Nasal mask with PEEP|Nasal mask with PEEP 5, then add PEEP 10
88901902|NCT01524614|Experimental|Face mask with no PEEP|Face mask with PEEP 0 then add PEEP 5, 10
88901903|NCT01524614|Experimental|Face mask with PEEP|Face mask with PEEP 5, then add PEEP 10
88901904|NCT01524640|Experimental|Killed oral cholera vaccine|"Killed Bivalent (O1 and O139) Whole cell oral cholera vaccine (Shanchol TM) Vaccine strain Reformulated version~V. cholerae O1 Inaba El Tor strain Phil 6973 formalin killed 600 Elisa units (EU) of lipopolysaccharide (LPS) V. cholerae O1 Ogawa classical strain Cairo 50 heat killed 300 EU LPS V. cholerae O1 Ogawa classical strain Cairo 50 formalin killed 300 EU LPS V. cholerae O1 Inaba classical strain Cairo 48 heat killed 300 EU LPS V. cholerae O139 strain 4260B formalin killed 600 EU LPS"
88901905|NCT01524640|Placebo Comparator|Placebo|"Non biologic placebo~Ingredients Per 1.5 ml dose~Starch 60mg~Red color[1mg/ml] 10 µl~Yellow color [1mg/ml] 5 µl~Xanthum Gum (1% solution) 300 µl~Water for Injection Upto 1.5 ml~All the above ingredients are of pharmaceutical grade.~Non-biological placebo of above composition has been used in 2010 for Randomized, double-blind, placebo controlled trial to evaluate the safety and immunogenicity of orally administered, killed, bivalent whole-cell , cholera vaccine, Shanchol in Bangladeshi Adults and Children. This study involving 330 subjects was carried out at International Center for Diarrheal Disease Research Bangladesh (ICDDR,B) located in Dhaka, Bangladesh with Dr. Firdausi Qadri as Principal Investigator (NCT01042951). There were no safety concerns associated with this placebo in this study and the report of this study has been submitted to the National Regulators in Bangladesh and the World Health Organization."
88901906|NCT01524653|Experimental|Rosuvastatin First, Placebo Last|This arm will receive rosuvastatin during the first treatment period followed by placebo in the second treatment period after washout.
88901907|NCT01524653|Experimental|Placebo First, Rosuvastatin Last|This arm will receive placebo during the first treatment period followed by rosuvastatin in the second treatment period after washout.
89421760|NCT05887843|Experimental|Mometasone + Azelastine, then Mometasone Furoate, then Azelastine Hydrochloride|
89421761|NCT05887843|Experimental|Mometasone Furoate, then Azelastine Hydrochloride, then Mometasone + Azelastine|
89421762|NCT05887843|Experimental|Azelastine Hydrochloride, then Mometasone + Azelastine, then Mometasone Furoate|
89421763|NCT05883163|Experimental|Stimulation Group|The intervention group will receive non-invasive stimulation of the phrenic nerve for activation of the diaphragm.
89421764|NCT05883163|No Intervention|Control Group|The control group will not received intervention and will be treated with standard of care.
89421765|NCT05880784|Placebo Comparator|Usual Practice|Eight primary healthcare centers in the Bhaktapur district of Nepal will be selected as a control group. The centers will be assessed for the baseline PEN service evaluation and at the end of one year, evaluation will be performed again in the centers for any change in the PEN services.
89421766|NCT05880784|Active Comparator|Peer coaching and clinical audit|Nine primary healthcare centers in the Bhaktapur district of Nepal will be selected as an intervention group. The centers will be assessed for the baseline PEN service evaluation and then will be provided the peer coaching and clinical audit sensitization within 6 months of the intervention period. At the end of one year, an evaluation will be performed again in the centers for any change in the PEN services.
89421767|NCT05866367|Experimental|Low dose Intranasal Insulin|One dose of 40 international units of regular insulin administered intranasally using the SipNose SP1N1C1 device.
89421768|NCT05866367|Experimental|High dose Intranasal Insulin|One dose of 80 international units of regular insulin administered intranasally using the SipNose SP1N1C1 device.
88901908|NCT01524718|Experimental|Imaging with two X-ray image intensifiers|There is no change in the procedure except for the imaging technique, while in the first group the X- ray image intensifier serves in the two planes, and being moved from one plane to the other, and in the second group the two devices are static in the same position, one in the AP plane and the other as the axial plane.
88901909|NCT01524718|No Intervention|Imaging with one X-ray image intensifier.|The X- ray image intensifier serves in the two planes, and being moved from one plane to the other
88901910|NCT01524731|Placebo Comparator|Placebo|Placebo group
88901911|NCT01524731|Active Comparator|4 mg dexamethasone|4 mg dexamethasone group
88901912|NCT01524731|Active Comparator|Dexamethasone 8 mg|Dexamethasone 8 mg group
89421769|NCT05859347|Active Comparator|High-Frequency (HF)|10 Hz rTMS
89421770|NCT05859347|Active Comparator|Low-Frequency (LF)|1 Hz rTMS
89421771|NCT05859191||LUPUS PATIENTS|Three extra tubes of blood will be taken at each consultation or inpatient visit when routine blood samples are taken as part of lupus monitoring.
89421772|NCT05852613|Experimental|Group (A)|this group will receive high power laser therapy (HPLT) for 15 minutes in addition to selected physical therapy program for 8 session two times weekly for 4 weeks.
89421773|NCT05852613|Active Comparator|Group (B)|"this group will receive the same selected physical therapy program only for 8 session.~All patients will attended the physical therapy clinic two times weekly for 4 weeks ."
89421774|NCT05852314|Experimental|Culturally Adapted Manual Assisted Therapy (CMAP-SI)|Participants in this arm will be offered the CMAP-SI intervention. The intervention will be delivered by trained researchers.
88901913|NCT01524744|Active Comparator|Pimecrolimus ointment 0.1 %|This group used drugs 3 times a day for 2 months and then didn't eat or drink for 20 minutes after use
88901914|NCT01524744|Active Comparator|Adcortyle|Control group used adcortyle (triamcinolone acetonide 0.1% in orabase, Bristol-Myers Squibbb, Anagn, Italy)
88901915|NCT01524757|Experimental|pantoprazol|
88901916|NCT01524757|Placebo Comparator|placebo|
88901917|NCT01524809|Experimental|Treatment period 1|
88901918|NCT01524809|Experimental|Treatment period 2|
88901919|NCT01524835||Live lung donors|Live lung donors who participated in donation from 1993 through 2006
88901920|NCT01524848|Other|Open label|Single arm pazopanib
88901921|NCT01524861|Placebo Comparator|Placebo|30 subjects receive placebo (placebo group)
88901922|NCT01524861|Experimental|alpha-lipoic acid|30 subjects receive alpha-lipoic acid, 400 mg/day per os bis in die (800 mg/day)(ALA group)
88901923|NCT01524861|Experimental|L-acetil-carnitine|30 subjects receive L-acetyl carnitine, 500 mg per os bis in die (1000 mg/day) (LAC group)
88901924|NCT01524874|Active Comparator|Powder D3 Capsule - 2,000 IU per Cap|Vital Nutrients
88901925|NCT01524874|Active Comparator|Chewable D3 Tablet - 2,000 IU per Tab|Integrative Therapeutics Inc.
88901926|NCT01524874|Active Comparator|Liquid D3 Drop - 2,000 IU per Drop|Biotics Research
88901927|NCT01524939|Experimental|Investigational product|
88901928|NCT01524952|Experimental|Active|cTEMS
88901929|NCT01524965|Experimental|Immediate mobilisation|
88901930|NCT01524965|Active Comparator|Standard mobilisation|
88901931|NCT01525004|Active Comparator|Standard dose trivalent inactivated influenza vaccine|
88901932|NCT01525004|Experimental|High-Dose trivalent inactivated influenza vaccine|
88901933|NCT06053606|Experimental|expandable cryoballoon|POLARxFIT
88901934|NCT06053606|Experimental|standard cryoballoon|POLARx
89421775|NCT05852314|No Intervention|Treatment as Usual (TAU)|Local medical, psychiatric, and primary care services provide standard routine care in Pakistan. Participants will receive an initial assessment along with TAU as ascertained by their treating primary care physician (General Practitioner, GP). As part of the safety protocol, we will obtain the contact details of the participants GP. We will also obtain the details of any treatment received by each participant. Research psychologists delivering the interventions will not be involved with the participants allocated to the TAU.
88901935|NCT06053541||Tiotropium treatment - MAT1 Period|In the MAT1 (total arithmetic mean 1) period, August 2017 to July 2018, patients received Tiotropium bromide (SPIRIVA® RESPIMAT®) as part of the treatment plan for Chronic Obstructive Pulmonary Disease (COPD) defined by the Health State Secretariat of Federal District in Brazil.
88901936|NCT06053541||Glycopyrronium treatment - MAT2 Period|In the MAT2 (total arithmetic mean 2) period, August 2018 to July 2019, patients received Glycopyrronium bromide (Seebri® Breezhaler®) as part of the treatment plan for Chronic Obstructive Pulmonary Disease (COPD) defined by the Health State Secretariat of Federal District in Brazil.
88901937|NCT06053346|Experimental|Pay For Performance (PFP)|Participants receive a tailored mix of assertive case management, crisis intervention, substance use counseling, mental health treatment, peer support, skill-building and care coordination, among other services delivered by a provider agency contracted by Santa Clara County. Individual and organizational performance incentives relative to traditional contracted service arrangements were also included. Specifically, the agreement between the contracted provider and the County included an agreed schedule of financial rewards and penalties for the contracted provider based on whether its enrollees utilized more or less care than had a historical cohort of patients enrolled before the program began.
88901938|NCT06053346|Active Comparator|Usual Care (UC)|Participants receive the usual array of mental health and psychosocial services offered by Santa Clara County.
88901939|NCT06053333||Observational|Patients complete a questionaire, undergo blood sample collection and have their medical records reviewed on study.
88901940|NCT06053320|Active Comparator|Young Able-Bodied individuals|18-30 years old able-bodied individuals (healthy without any physical disability or neurological disorder).
88901941|NCT06053320|Active Comparator|Old Able-Bodied individuals|45-90 years old able-bodied individuals (healthy without any physical disability or neurological disorder).
88901942|NCT06053320|Experimental|Stroke with Spatial Neglect (SN) individuals|40-90 years individuals with more than 3 months following right hemisphere stroke.
88901943|NCT06053203||University of Abuja Teaching Hospital|Pregnant women with Hypertensive Disorder of Pregnancy who seek care in the Federal Capital Territory, attending antenatal clinics on the 2nd or subsequent visit and pregnant women presenting to the labor and delivery room.
89421776|NCT05847647|Experimental|1. group: Retrograde Filling Group / RG Group|Surgical curettage of the periapical lesion and root tip resection will be performed, MTA will be applied retrogradely and no material will be applied to the bone defect
89421777|NCT05847647|Experimental|2. Group: Retrograde Filling+L-PRF Group / RG+L-PRF Group|Surgical curettage of the periapical lesion and root tip resection will be performed, MTA will be applied retrogradely and L-PRF will be applied to the bone defect.
89421778|NCT05847647|Experimental|3. Group: Orthograde Filling Group / OG Group|Surgical curettage of the periapical lesion will be performed, MTA will be applied orthogradely without root tip resection and no material will be applied to the bone defect.
88901944|NCT06053203||Amino Kano Teaching Hospital|Pregnant women with Hypertensive Disorder of Pregnancy who seek care in Kano State in Nigeria, attending antenatal clinics on the 2nd or subsequent visit and pregnant women presenting to the labor and delivery room.
88901945|NCT06053203||National Hospital, Abuja|Pregnant women with Hypertensive Disorder of Pregnancy who seek care in the Federal Capital Territory, attending antenatal clinics on the 2nd or subsequent visit and pregnant women presenting to the labor and delivery room.
88901946|NCT06053203||Murtala Muhammad Specialist Hospital|Pregnant women with Hypertensive Disorder of Pregnancy who seek care in Kano State in Nigeria, attending antenatal clinics on the 2nd or subsequent visit and pregnant women presenting to the labor and delivery room.
88901947|NCT06053190|Experimental|Speech Study|"The study is a within-subjects 2 x 3 factorial design. All participants are exposed to all experimental conditions or interventions"
88901948|NCT06053177||Type 2 Diabetes|Participants with type 2 diabetes
88901949|NCT06053177||Pre Diabetes|Participants who's most recent HbA1c is in the prediabetes range.
88901950|NCT06053151|Experimental|experiemental group|The experimental group will receive the cloud platform integration model for exercise consultation intervention for two phases continue 24 weeks to promote exercise behavior during pregnancy.
88901951|NCT06053151|No Intervention|control group|The control group will receive standard antenatal treatments without intervention.
88901952|NCT06053138|Experimental|Ketosis|Ketosis (the condition being investigated) is obtained by ingestion of a ketone monoester
88901953|NCT06053138|Placebo Comparator|Control|The control arm is a drink matched in taste, volume, appearence, and viscosity to that of the active/experimental arm
88901954|NCT06053112|Experimental|Test group|New infant formula with 6 HMOs blend
88901955|NCT06053112|Active Comparator|Control group|Standard infant formula without 6 HMOs blend
88901956|NCT06053112|No Intervention|Reference group|Breastfeeding
88901957|NCT06053086|Experimental|Cohort A : Experimental group|In cohort A, for patients with high and undetermined risk of fibrosis (bf+), an adaptive BC RT (ETHOS) will be delivered.
88901958|NCT06053086|Active Comparator|Cohort B : Control group|In cohort B, for patients with low risk of fibrosis (bf-), an IMRT will be delivered.
88901959|NCT06053073|Experimental|At home patients group|After insertion of the Cervical Rippening Balloon and checking fetal and maternal well-being, the patient will go home between 6 and 8 hours to complete the cervical rippening process. The patient will remove autonomously the balloon and will go to the hospital one hour later, where the induction will continue.
88901960|NCT06053073|Active Comparator|Hospitalized patients group|After the insertion of the Cervical Rippening Balloon and verifications of the fetal and materna well-being, the patient will undergo the cervical rippening process for between 6 and 8 hours in the hospital and will remain hospitalized until the time of the delivery.
88901961|NCT06053060|Other|Standard Dynacup|Hip arthroplasty with a standard Dynacup cup
88901962|NCT06053060|Other|Dynacup One C|Hip arthroplasty with a cup Dynacup One C
88901963|NCT06053034|Sham Comparator|Sham device|a round device equipped with a strap for hand holding, it is to be used while connected to a socket. The device is used by an assistant (usually a family member) on the participant's back for 20 minutes while moving it around in circles on the lower back.
88901964|NCT06053034|Active Comparator|Solio Alpha Plus|The SOLIO Alfa Cure Plus Device for patients with LBP- is a round device equipped with a strap for hand holding, it is to be used while connected to a socket. The device is used by an assistant (usually a family member) on the participant's back for 20 minutes while moving it around in circles on the lower back. It should be mentioned this is the first trial in Home-RF using an external
88901965|NCT06053008|Other|Geriatric individuals|The relationship among pain perception, temporomandibular joint disorder severity and spine health
88901966|NCT06052982|Other|Drain|At the end of the knee arthroplasty, a drain is placed at the surgical site
88901967|NCT06052982|Other|Without drain|At the end of the knee arthroplasty, a drain is not placed at the surgical site
88901968|NCT06052930|Experimental|VR group|12 consecutive weeks of physiotherapy + training with the IVR
88901969|NCT06052930|Active Comparator|Active control group|6 consecutive weeks of physiotherapy only, followed by 6 consecutive weeks of physiotherapy + training with the IVR
88901970|NCT06052917|Experimental|DECIdE|General practitionners and pharmacists will propose to their patients, complaining of a common symptom for which a drug is usually prescribed or dispensed, to discuss this drug and the symptom in order to reach a shared decision, using DECIdE as a support, on whether to take it or choose another alternative.
88901971|NCT06052917|No Intervention|routine without decision aid|General practitionners and pharmacists will prescribe or dispense to their patients, complaining of a common symptom, the drug they usually use and advise them or discuss the benefits and risks as they are used to doing.
88901972|NCT06052865|Experimental|Exposed: High neurological risk|25 very preterm infants with advanced neurological injury
88901973|NCT06052865|Experimental|Exposed: Low neurological risk|25 very preterm infants with low/no neurological injury
89194835|NCT02543086|Experimental|Multiple Sequential Cohort|"This study is divided in 2 parts (Part A and part B). Each participant in each of the cohorts will be inoculated with viable parasites of Plasmodium falciparum-infected human erythrocytes administered intravenously. For Part A & Part B, commencement of treatment will be determined by Quantitative-Polymerase Chain Reaction results.~The First cohort of Part A (A1) will be dosed with a single dose of KAE609. During Part A, an additional second single-dose of KAE609 may be tested (~15 days after first dose of KAE609 but may vary) if sexual parasitemia is identified. Subsequent cohorts of part A (An) will be dosed based on the results of first cohort (A1).~Subjects enrolled in Cohort B will receive a pre-treatment with Piperaquine followed by KAE609 (~15 days)."
88901974|NCT06052865|Other|Reference/ Standard of care|25 very preterm infants with no study exposure/ standard of care
88901975|NCT06052826|Experimental|Arm I (PT, cognitive education, nutrition education)|Patients undergo GA before lymphodepleting chemotherapy and recommendations based on assessment results communicated to treating physicians. Patients receive PT and delirium prevention education prior to lymphodepletion, at least once before CAR-T therapy, at least 2 times a week while inpatient, and at least once every other week outpatient up to day 30. Additionally, patients receive personalized nutritional guidance from a registered dietician prior to lymphodepletion, prior to CAR-T therapy and at least once a week up to day 30.
88901976|NCT06052826|Active Comparator|Arm II (standard of care)|Patients undergo GA and receive standard of care throughout study.
89194836|NCT00885586|Sham Comparator|Sham-laser acupuncture|Sham laser acupuncture (c) is applied at equivalent points as needle acupuncture. Laser irradiation is faked.
89194837|NCT00885586|Active Comparator|gabapentine|standard analgesic treatment
89194838|NCT00885586|Active Comparator|Acupuncture|Acupuncture treatment is semi-standardized, i.e. beside a scheme of basic points, individual points can be chosen according to the TCM diagnostic pattern.
89194839|NCT02543242|Experimental|Intervention|Participants will undergo the InTone TM (InControl Medical, LLC) medical device treatment for Urinary Incontinence. The frequency of treatment is once/day (12 minutes), 5-6 days/week. The route of administration is vaginal.
89194840|NCT02543008|Experimental|Physical activity plus thoracic mobilization|Subjects randomly allocated to this arm will be submitted to a 10 minutes anaerobic exercise (2 minutes warming up, 5 minutes of 75% to 85% maximal heat rate, 3 minutes slowdown), followed by 5 minutes of passive intervertebral thoracic mobilization (3 sets of 1 minute, grade III, and 1 minute rest between each set).
89194841|NCT02543008|Active Comparator|Physical activity|Subjects allocated to this arm will be submitted to the same anaerobic exercise protocol, without the thoracic mobilization.
89194842|NCT02543008|Placebo Comparator|Placebo|Subjects in this group will be conducted to a placebo thoracic mobilization, without anaerobic exercise protocol. The investigator will apply only a manual contact, to mimic the genuine thoracic mobilization. The same 5 minutes period will be respected, and the same position of therapist and subject.
88901977|NCT06052748|Experimental|Test group|AD-223A+AD-223B+AD-223C Placebo
88901978|NCT06052748|Active Comparator|Control group 1|AD-223A+AD-223B Placebo+AD-223C Placebo
88901979|NCT06052748|Active Comparator|Control group 2|AD-223A Placebo+AD-223B+AD-223C Placebo
88901980|NCT06052748|Active Comparator|Control group 3|AD-223A Placebo+AD-223B Placebo+AD-223C
89194843|NCT02542930|Experimental|Radiotherapy and Thymalfasin arm|Patients with metastatic lesions of Non-small cell lung cancer receiving 3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin;
89194844|NCT00704730|Experimental|1|
89194845|NCT00704730|Placebo Comparator|2|
89194846|NCT00881764||Exposed Cohort|Children who had inguinal hernia surgery and general anesthesia before 36 months of age (n=500). These children should be ages 8 yr, 0 mo to 15 yr, 0 mo at the time of the study period.
89421779|NCT05847647|Experimental|4. Group: Orthograde Filling+L-PRF Group / OG+L-PRF Group|Surgical curettage of the periapical lesion will be performed, MTA will be applied orthogradely without root tip resection and L-PRF will be applied to the bone defect.
89421780|NCT05838482|Experimental|Subject's Scanned with Investigational Device|
89421781|NCT05836272|Active Comparator|Early NE|The early NE arm will receive low-dose NE as soon as hypotension secondary to sepsis is observed in addition to a classic therapeutic regimen that complies with the guidelines of the 2021 Surviving Sepsis Compaign. Sepsis is defined according to the sepsis 3 consensus by a sepsis related organ failure assessment (SrOFA) score greater than 2 following an infection (documented or suspected)
88901981|NCT06052735|Other|Correlation arm|
88901982|NCT06052722|Other|Individuals with premenstrual syndrome|Level of relationship between premenstrual syndrome and temporomandibular disorders
88901983|NCT06052722|Other|Individuals with primary dysmenorrhea|Level of relationship between primary dysmenorrhea and temporomandibular disorders
88901984|NCT06052709|Active Comparator|Individuals with bruxism|After the sociodemographic information of individuals is questioned, the presence and severity of temporomandibular joint disorders with the Fonseca Anamnestic Index, self-reported occupational balance with the Activity-Role Balance Questionnaire, and the individuals' stress levels with the Perceived Stress Scale will be evaluated.
89421782|NCT05836272|Placebo Comparator|Placebo|The placebo arm will receive only the classic therapeutic regimen that complies with the guidelines of the 2021 Surviving Sepsis Compaign.
89421783|NCT05835024||Participants|Patients enrolled for a right heart catheterization procedure as part of their standard of care.
88901985|NCT06052709|Placebo Comparator|Individuals without bruxism|After the sociodemographic information of individuals is questioned, the presence and severity of temporomandibular joint disorders with the Fonseca Anamnestic Index, self-reported occupational balance with the Activity-Role Balance Questionnaire, and the individuals' stress levels with the Perceived Stress Scale will be evaluated.
88901986|NCT06052696|Experimental|Gardasil 9|see intervention
88901987|NCT06052696|Placebo Comparator|placebo|see intervention
88901988|NCT06052683|Active Comparator|Low-Dose Rate Brachytherapy to the prostate using Iodine-125 seed implant|Low-Dose Rate Brachytherapy to the prostate using Iodine-125 seed implant to a total dose of 144 Gy.
88901989|NCT06052683|Experimental|Stereotactic Body Radiation Therapy to the prostate|Stereotactic Body Radiation Therapy to the prostate using 36.25 Gy in 5 fractions.
88901990|NCT06052605|Experimental|HAP-E Epilepsy Participants|
88901991|NCT06052332|Experimental|SCRT arm|"SCRT (5 fractions of 5 Gy)~Surgery (according to the principle of TME) or watch & wait~Optional adjuvant chemotherapy"
89194847|NCT00881764||Unexposed Cohort|Children who are siblings of the exposed children (inguinal hernia surgery and general anesthesia) and differ in age from the exposed children by less than 36 months and have no history of surgery or exposure to volatile and intravenous anesthetics or sedatives including barbiturates, benzodiazepines and chloral hydrate less than 36 months of age. These children should also be ages 8 yr, 0 mo to 15 yr, 0 mo at the time of the study period.
89421784|NCT05821387|Experimental|Lucid-21-302|Single-ascending dose cohorts
89421785|NCT05821387|Placebo Comparator|Placebo|Single-ascending dose cohorts
89421786|NCT05816044||preeclamptic pregnant woman|
89421787|NCT05816044||healty preagnant woman|
89421788|NCT05814198||FGR|In the group with FGR, we will calculate the HALP score with the complete blood count and albumin values.
89421789|NCT05814198||SGA|In the group with SGA, we will calculate the HALP score with the complete blood count and albumin values.
89421790|NCT05795504|Experimental|resistive exercises|Premenopausal women in group A will perform resistive exercise for upper and lower limbs, three times per week in addition to calcium and vitamin d supplementations.
89421791|NCT05795504|Experimental|high intensity interval training|Premenopausal women in group B will receive high intensity interval training for three times per week in addition to calcium and vitamin D supplementations
89421792|NCT05795504|Active Comparator|conventional therapy|Premenopausal women in group C will receive calcium and vitamin D supplementations only.
89421793|NCT05780008|Experimental|Eat My ABCs|"The experimental arm will receive the 14-week program including three main components: (1) Eat My ABCs child curriculum, (2) child fruit/vegetable letters to parents, and (3) program cookbook."
89421794|NCT05748184||Radiologists|
89421795|NCT05747846|Active Comparator|wide-awake local anesthesia no tourniquet|Patients will be operated under local anesthesia without a tourniquet (WALANT technique)
89421796|NCT05747846|Active Comparator|Tourniquet|Patients will be operated under local anesthesia with the use of a tourniquet
89421797|NCT05738811|Experimental|TENS treatment group|Group A was given exercise protocol along with TENS treatment protocol.
88901992|NCT06052332|Active Comparator|TNT arm|"Rapido regimen:~SCRT (5 fractions of 5 Gy)~Up to 18 weeks of oxaliplatin based chemotherapy (mFOLFOX6 or CAPOX)~Surgery (according to the principle of TME) or watch & wait~Or~Rapido light regimen:~SCRT~Up to 12 weeks of oxaliplatin based chemotherapy~Surgery or watch & wait~Or~OPRA with induction chemotherapy (INCT-CRT) regimen:~Up to 16 weeks of oxaliplatin-based chemotherapy~CRT (25-28 fractions of 1.8-2.0 Gy each +/- a boost to the primary tumour and involved lymph nodes, for a total of 50-56 Gy of radiation combined with either continuous infusion ﬂuorouracil or capecitabine)~Surgery or watch & wait~Or~OPRA with consolidation chemotherapy (CRT-CNCT) regimen:~CRT~Up to 16 weeks of oxaliplatin-based chemotherapy~Surgery or watch & wait"
88901993|NCT06052280|Experimental|Telerehabilitation Exercise group (TrE arm)|
88901994|NCT06052280|Active Comparator|Home Self-Exercise group (HSE arm)|
88901995|NCT06052254|Active Comparator|12 cm2 - 2 Active DMTS Patches|2 Active DMTS patches will be applied to the upper back and worn for 4 days (96 hours)
88901996|NCT06052254|Active Comparator|6 cm2 - 1 Active and 1 Placebo DMTS Patches|1 Active and 1 Placebo DMTS patches will be applied to the upper back and worn for 4 days (96 hours)
88901997|NCT06052254|Placebo Comparator|Placebo - 2 Placebo DMTS Patches|2 Placebo DMTS patches will be applied to the upper back and worn for 4 days (96 hours)
88901998|NCT06052241|Active Comparator|Post-treatment|After treatment using shampoo and scalp serum personalized according to their Scalp Photographic Index Artificial Intelligence (SPI-AI)-defined scalp types
88901999|NCT06052241|No Intervention|Pre-treatment|
88902000|NCT06052215|Experimental|Solomon-1|
88902001|NCT06052215|Experimental|Solomon-2|No pretest measurement
88902002|NCT06052215|No Intervention|Solomon-3|
88902003|NCT06052215|No Intervention|Solomon-4|No pretest measurement
88902004|NCT06052189||Easy laryngoscopy|Laryngeal view grading according to the modified Cormack and Lehane grading scale where grades 1 and 2a are considered easy laryngoscopy and grades 2b, 3, and 4 are considered difficult laryngoscopy.
88902005|NCT06052189||Difficult laryngoscopy|Laryngeal view grading according to the modified Cormack and Lehane grading scale where grades 1 and 2a are considered easy laryngoscopy and grades 2b, 3, and 4 are considered difficult laryngoscopy.
88902006|NCT06052163|Active Comparator|Bumetanide low dose|"15 participants will take bumetanide low dose orally for 6 months and will be evaluated on cognitive and functional tests.~Participants blood samples will be tested for levels of proteins involved in Alzheimer's disease."
88902007|NCT06052163|Active Comparator|Bumetanide high dose|"15 participants will take bumetanide high dose orally for 6 months and will be evaluated on cognitive and functional tests.~Participants blood samples will be tested for levels of proteins involved in Alzheimer's disease."
88902008|NCT06052163|Placebo Comparator|Placebo|"10 participants will take placebo orally for 6 months and will be evaluated on cognitive and functional tests.~Participants blood samples will be tested for levels of proteins involved in Alzheimer's disease."
88902009|NCT06052124|Experimental|Pilot Usability (Part 1)|Five patients will be enrolled to test whether the AR device functions appropriately, but no clinical decisions or changes to care will be determine by the AR device at this point.
88902010|NCT06052124|Experimental|AR Guided SEPS Placement (Part 2)|AR guidance is used to place SEPS drain
88902011|NCT06052124|No Intervention|Anatomical Guided SEPS Placement (Part 2)|Standard of care, non AR guided SEPS drain placement
88902012|NCT06052111|Experimental|Group F (fentanyl group)|Fentanyl (1 μg/kg) was given intravenously slowly over 60 seconds before induction of anesthesia as a loading dose followed by continuous infusion at a rate of (1μg/kg/hr) after intubation. It was stopped 10 minutes before the end of surgery.
89194848|NCT04038034|Placebo Comparator|group A|35 patients treated with pressure lowering drugs and placebo
89194849|NCT04038034|Experimental|group B|35 patients with pressure lowering drugs and COQUN oral formulation 100 mg BID.
88902013|NCT06052111|Experimental|Group D (dexmedetomidine group)|The patients were received a loading dose of dexmedetomidine (1 μg/kg) intravenously over 15 minutes before induction of anesthesia, followed by continuous infusion at a rate of (0.6 μg/ kg/ hr) after intubation and was stopped 10 minutes before the end of surgery.
88902014|NCT06052085|Active Comparator|Pain Neuroscience Education|"Pain Neuroscience Education; Four sessions of education will be applied. The neurophysiology of pain and the ability of the nervous system to modulate the experience of pain will be explained to the patient.~Standard Physiotherapy Program; Soft tissue mobilization will be applied to the upper extremity twice a week for 6 weeks.~Upper extremity exercises including breathing, warming, stretching and strengthening will be performed twice a week for 6 weeks."
88902015|NCT06052085|Active Comparator|Biomedical Pain Education|"Biomedical Pain Education; 4 sessions of education will be applied in 6 weeks. Pain will be explained to the patient from a biological point of view.~Standard Physiotherapy Program; Soft tissue mobilization will be applied to the upper extremity twice a week for 6 weeks.~Upper extremity exercises including breathing, warming, stretching and strengthening will be performed twice a week for 6 weeks."
88902016|NCT06052007|Experimental|LC-Based Debriefing|LC-based debriefing session in one intervention group.
88902017|NCT06052007|Experimental|3D Model-Based Debriefing|One facilitator conducted a 3D model-based debriefing session in the other intervention group.
88902018|NCT06052007|No Intervention|Standard Debriefing|One facilitator conducted a non-model-based unstructured debriefing session in the control group
88902019|NCT06051981|Experimental|Fluoride Varnish (control)|The study involves 22 patients with WSLs at Riyadh Elm University's dental clinics, who will undergo dental examinations and receive ICDAS codes. In group I, FV EnamelastTM will be applied to all teeth using compressed air and cotton rolls, leaving them to dry for one minute. Patients will be advised to avoid eating, drinking, or brushing for 3-4 hours after application.
88902020|NCT06051981|Experimental|Intensive Fluoride Varnish|The study involves 22 patients with WSLs at Riyadh Elm University's dental clinics, who will undergo dental examinations and receive ICDAS codes. Patients in group II Intensive FV will be applied three times a week for a week (every two days).
88902021|NCT06051981|Experimental|Casein Phosphopeptide-Amorphous Calcium Phosphate|The study involves 22 patients with WSLs at Riyadh Elm University's dental clinics, who will undergo dental examinations and receive ICDAS codes. Group III (CPP-ACP) uses Tooth Mousse® for 12 weeks, will be applied after daily brushing with traditional toothpaste, left intact for 180 seconds, and rinsed with distilled water.
88902022|NCT06051981|Experimental|Resin Infiltration|The study involves 22 patients with WSLs at Riyadh Elm University's dental clinics, who will undergo dental examinations and receive ICDAS codes. Group IV uses ICON® resin infiltration, applying a 15% hydrochloric acid solution, rinsing with water, drying, and applying ICON-Dry. Excess resin is removed, and a light curing process is performed. The roughened enamel surface is polished using composite resin polish discs and cups.
88902023|NCT06051955|Other|oral sodium sulfate|OSS is a colon cleansing agent administered in a split dose fashion, inducing diarrhea by drawing water into the intestine.
89536030|NCT03074955|Experimental|Trendelenburg & leg wrapping|"leg wrapping with tension & apply Trendelenburg position~Apply elastic bandages to both legs with tension.~After injecting propofol, apply Trendelenburg position ( 10 degree )~After 3 minutes from propofol injection, remove elastic bandage and revert to supine position.~induction using propofol 2mg/kg~After bispectral index (BIS) goes below 60 & patient become unconsciousness, inject rocuronium 0.6mg/kg~intubate patient between 3 and 4 minutes after propofol injection~measure blood pressure ( systolic, diastolic, mean ) & heart rate at 1,2,3,4,5 minutes after propofol injection~phenylephrine injection if hypotension develops"
89194850|NCT04037878|Experimental|TAP block group|Patients in this arm will be given Transversus Abdominal Plane(TAP) block after the induction of anesthesia. They will also be given post operative patient controlled intravenous analgesia(PCIA) using tramadol.
88902024|NCT06051929|Experimental|MIED group|provide standard audio instructions for mindfulness exercises, introduce the nature and law of anxiety, depression and other emotions, the source of anxiety, depression and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems
88902025|NCT06051929|No Intervention|Waitlist control group|no intervention.
88902026|NCT06051916|Active Comparator|group B|Group B is the intervention group with minimalistic voiding trial. The patients in this group need to have one spontaneous voiding before discharge with the sensation of normal voiding, meaning there is no measurement of the voiding volume or residual volume.
88902027|NCT06051916|No Intervention|Group A|Group A is the control group and presents the current procedures with strict voiding trial. The bladder is scanned before voiding to determine the bladder volume, and the voiding volume is measured. If the voiding volume is >150 ml and the residual volume is <200 ml, the patient can be discharged. If no acceptable residual volume is reached, the patient will be instructed in intermittent catheterization
88902028|NCT06051877||suspPD|People referred to clinic with suspected PD
88902029|NCT06051877||confPD|People with confirmed PD
88902030|NCT06051877||HC|Healthy controls
88902031|NCT06051851|Experimental|Trial group|penpulimab in combination with anlotinib and AG regimen in the first-line treatment of advanced metastatic pancreatic cancer
88902032|NCT06051851|Active Comparator|Control group|AG regimen in the first-line treatment of advanced metastatic pancreatic cancer
88902033|NCT06051838||TD cohort|Tumor deposits (TD) positive group, which was determinded by the pathologists at department of pathology. Any tumor mass, either circumscribed or with irregular contours, devoid of lymph node architecture was identified as a tumor deposit.
88902034|NCT06051838||Non-TD cohort|Tumor deposits (TD) negative group, which was determinded by the pathologists at department of pathology. No visiblet umor mass, either circumscribed or with irregular contours, devoid of lymph node architecture in the sections of specimens from these patients.
88902035|NCT06051825||Patients with acute appendicitis|Patients with acute appendicitis, after surgery and with pathohistological confirmation
89194851|NCT04037878|Experimental|Local infiltration|Patients in this arm will be given local and intraperitoneal infiltration of local anesthetic before closure.They will also be given post operative patient controlled intravenous analgesia(PCIA) using tramadol.
88902036|NCT06051825||Patients without acute appendicitis|Patients without acute appendicitis, after laboratory, clinical and/or radiological exclusion of acute admittance
88902037|NCT06051799|Experimental|TREATMENT GROUP|The Pressure Release Technique will be applied. One session per week will be carried out for four weeks. It will be performed on as many trigger points as we find in each muscle associated with the study, leaving a record of them. Also adding postural hygiene and home exercise guidelines. A progression of exercises involving contraction of the deep neck flexor muscles Subjects will be taught to perform slow and controlled craniocervical flexion. It should be performed a minimum of once daily during the treatment regimen. A follow-up of the patients will be carried out with respect to home therapeutic exercise and postural hygiene guidelines.
89421798|NCT05738811|Experimental|EMS treatment group|Group B received exercise protocol along with EMS treatment protocol.
89421799|NCT05738135|Experimental|Aminophylline group|Patients will receive 4 mg/kg aminophylline diluted in 50 ml normal saline over 30 minutes.
89421800|NCT05738135|Placebo Comparator|Control group|Patients will receive 50 ml normal saline over 30 minutes.
88902038|NCT06051799|Active Comparator|CONTROL|Postural hygiene guidelines will be given, as well as home therapeutic exercise (identical to the treatment group). About therapeutic exercise, a progression of exercises involving contraction of the deep neck flexor muscles shall be included in the first session. Subjects will be taught to perform slow and controlled craniocervical flexion. Subjects will then be trained to be able to progressively maintain craniocervical flexion through feedback from an air device (Stabilizer™, Chattanooga Group Inc., Chattanooga, TN) placed behind the neck. This sensor monitors the slight flattening of the cervical curve that occurs with contraction of the craniocervical deep flexor musculature. It should be performed a minimum of once daily during the treatment regimen. To this end, patients will be monitored and their understanding and correct follow-up of the treatment will be assessed in each face-to-face session per week, for four weeks, the same as in experimental group.
88902039|NCT06051786|Experimental|azelastine hydrochloride and fluticasone propionate, 137/50 mcg|The test product, azelastine hydrochloride and fluticasone propionate, 137/50 mcg is manufactured by the sponsor, administered as one spray in each nostril twice daily for 28 days.
88902040|NCT06051786|Active Comparator|Dymista™|The active control product, Dymista™, is manufactured by Meda Pharmaceuticals, administered as one spray in each nostril twice daily for 28 days.
88902041|NCT06051773||SSc patients|
88902042|NCT06051760|Experimental|NV-001|The patients will be treated with vaccines generated based on their tumor tissues.Various doses will be tested according to the protocol.
88902043|NCT06051747|Experimental|Treated|Three-dimensional patient-specific bioprinting trachea implantation
88902044|NCT06051682|Experimental|Patient with emergency physician and AI for diagnosis|Patient benefiting from imaging submitted to radiological reading by the emergency physician and the AI for diagnosis and treatment decision
88902045|NCT06051682|Placebo Comparator|Patient with emergency physician only for diagnosis|
88902046|NCT06051630|Experimental|Lidocaine group|The group will receive 1.5 mg/kg lidocaine 2% bolus, followed by a continuous electric syringe dose of 1.5 mg/kg/hour intraoperatively, then 1.5 mg/kg/hour during the first 24 hours postoperatively
88902047|NCT06051630|Placebo Comparator|Saline group|The control group will receive an equivalent volume of saline: the volume of saline to be administered will be obtained by considering the dose of lidocaine 2% that the patient would have received if he/she had been in the interventional group.
89421801|NCT05734261|Other|Single Arm|
88902048|NCT06051526||Critically ill in-patients|All adult inpatients in hospitals across Africa that are critically ill.
88902049|NCT06051461|Active Comparator|Metabolic Syndrome patients|
88902050|NCT06051461|Experimental|Healthy patients|
88902051|NCT06051370|Experimental|Glenohumeral injection|Ultrasound-guided posterior approach of glenohumeral space injection for impingement syndrome with mild stiffness of the shoulder. The injection mixture was: 1 mL triamcinolone, 4 mL lidocaine, 7 mL normal saline.
88902052|NCT06051370|Active Comparator|Subacromial injection|Ultrasound-guided anterolateral approach of subacromial space injection for impingement syndrome with mild stiffness of the shoulder. The injection mixture was: 1 mL triamcinolone, 4 mL lidocaine, 7 mL normal saline.
88902053|NCT06048289||Immunotherapy combined with chemotherapy|
89194852|NCT04037878|Other|Control group|These patients will be given post operative analgesia in the form of patient controlled intravenous analgesia(PCIA) using tramadol. Neither local infiltration nor TAP block will be administered
89194853|NCT00881842|Experimental|1|
89421802|NCT05732259|Active Comparator|Percussion therapy group|"Group A was given Conventional treatment along with percussion therapy with Theragun PRO (1750-2400 rpm).~•Participants lying in prone position on the couch received percussion therapy with Theragun PRO using standard ball head at speed of 1750 rpm, for total of 90 seconds, split into 3 sets of 30 seconds with 10 seconds rest"
89421803|NCT05732259|Active Comparator|Manual Myofascial Release technique group|Group B was given Conventional treatment along with manual myofascial release technique for 90 sec continuous.
89421804|NCT05732246|No Intervention|Conventional treatment group|"Hot pack and TENS at neck for 10minutes. Therapeutic ultrasound for 5 minutes Soft tissue techniques (gliding and kneading) was applied at a slow speed for 5 minutes over the neck muscles.~Gentle stretching and strengthening exercises"
89421805|NCT05732246|Experimental|First rib mobilization with balloon breathing exercises group|Patient was in supine position, placing the soles of his feet against the wall so that the ankle, knee, and thigh joints are at a 90-degree angle. The subject placed a 3-4-inch ball between his/her knees, which he/she has to maintain through the pressure of the internal thigh muscles during the whole training period and puts his/her back on the bed. Holds the right hand above the head and the left hand with the balloon. Meanwhile examiner palpated 1st rib with head in left side flexion. Patient was then asked to inhale through the nose in three-four seconds and then exhales slowly into the balloon. Then, holding the first rib in place, the patient was asked to inhale and exhale deeply again. The examiner continued applying pressure to hold the first rib in a position of relative depression during inhalation, and further depress the first rib as able during exhalation.
89421806|NCT05730595|Experimental|D2 lymph node dissection|The D2 lymph node region are dissected. And 1-3 lymph nodes of the D2 region will be selected for intraoperative frozen section. If no lymph node metastasis is found in freezing, the D3 region lymph nodes in the root of the submesenteric artery were preserved.
89421807|NCT05730595|Active Comparator|D3 lymph node dissection|Thorough dissection of lymph nodes in the D3 region.
89421808|NCT05724797|Experimental|NRS-033: Cohorts 1-3|Cohorts 1-3: 6 participants in each cohort will receive active drug (NRS-033)
89421809|NCT05724797|Placebo Comparator|Placebo: Cohorts 1-3|Cohorts 1-3: 2 participants in each cohort will receive the matching placebo dose
89421810|NCT05716815|Active Comparator|2D Reconstruction|Before minimally invasive lung segmentectomy, preoperative chest CT scans are processed and evaluated with multi-plane (2D) reconstructions, according to the usual center protocol.
89421811|NCT05716815|Experimental|2D plus 3D Reconstruction|Before minimally invasive lung segmentectomy, preoperative chest CT scans are processed and evaluated with volume rendering (3D) reconstructions.
89421812|NCT05708625|Active Comparator|Intralesional Sodium stibogluconate|Patients will receive intralesional infiltration of (SSG) at a dose of 50 mg/0.5 ml (0.2-0.4ml) maximum dose per session 1-3 ml. Sessions will be held once weekly for a maximum of 6 weeks.
88902054|NCT06047743|Experimental|Alternating unilateral Isometric Handgrip Exercise Group|Participants (n=19) will be performing alternating unilateral Isometric Handgrip exercises using a dynamometer for 3-5 days a week for a total duration of 8 weeks. The participant will be seated with their elbow resting on the armrest and wrists off the supporting surface. A single session will consist of 4 sets of 30%MVC (calculated by dynamometer) of handgrip exercise with a maximum 2 minutes contraction time/ hold time followed by a rest period/ recovery period of 1 minute during each set.
88902055|NCT06047743|Experimental|Dominant knee extension Isometric Exercise Group|Participants enrolled in this group will be performing dominant leg isometric knee extension. The knee will be 35° flexed from a fully extended position when performing isometric knee extension using a hand-held dynamometer retrained by a belt. The intervention duration will be 8 weeks. A single session will consist of performing 4 sets of 30% MVC (calculated using a dynamometer) of unilateral knee extension isometrics with a maximum 2 minutes contraction time/ hold time followed by a rest/ recovery period of 1 minute during each set.
88902056|NCT06046261|Experimental|General routine care and ACP board game for life|
88902057|NCT06046261|No Intervention|General routine care|"General routine care means that when a CKD stage 4-5 patient is in critical condition or at the end of life, the renal medical team will explain the content of DNR to the patient's family (without cardiopulmonary resuscitation: including endotracheal tube intubation, extracorporeal cardiac compression, Emergency treatment items such as cardiac electric shock, emergency drug injection, and artificial cardiac pacemaker adjustment), the concept of palliative care (supportive care for end-of-life patients to relieve physical discomfort symptoms to reduce physical, mental and spiritual pain) or ACP."
88902058|NCT06046248|Experimental|Belumosudil Plus Rituximab|Belumosudil plus Rituximab
88902059|NCT06045702||Group control|Adult patients with no genetic pathology other than male infertility of any type leading to an inability to procreate without medical assistance, and requiring surgery to recover spermatozoa for possible in vitro fertilization.
88902060|NCT06045702||CFTR-associated pathology|Major patients with cystic fibrosis or male infertility due to agenesis of the vas deferens. These patients will be included in the study because they have the prospect of procreation by in vitro fertilisation requiring surgery to recover spermatozoa.
89421813|NCT05708625|Experimental|intralesional Cryotherapy|Patients will be treated with intralesional Cryotherapy. Sessions will be held every two weeks till complete cure or a maximum of 6 sessions
89421814|NCT05708625|Experimental|Intralesional Voriconazole|Patients will be treated with intralesional Voriconazole weekly till complete cure or a maximum of 6 sessions
89421815|NCT05708625|Experimental|Oral doxycycline|Patients will be treated with oral doxycycline, 200 mg daily, until complete cure or a maximum of 6 weeks
89421816|NCT05698602|Experimental|NivolisMonitor and NivolisAnton Arm|"For each patient enrolled in the study, a NivolisMonitor device is added to the usual ventilatory device for 3 days. NivolisMonitor is connected to the patient circuit, between the ventilatory device and the patient interface, ideally at the patient end of the circuit or possibly at the end of the breathing support device of the circuit (NIV or HDN).~NivolisMonitor continuously measures pressure (P in cm H20) and flow (F in L.min-1) as well as temperature (T in degree Celsisus), relative humidity (RH in percent RH) and, optionally, the Fi02 (in percent).~In addition, an overnight transcutaneous capnia recording will be performed using a Sentec SDM monitor to which a NivolisAnton device will be connected and will be able to collect data and transmit it via remote monitoring."
89421817|NCT05697276|Active Comparator|Lidocaine|Patients will receive lidocaine
89421818|NCT05697276|Experimental|Bupivacaine|Patients will receive bupivacaine
89421819|NCT05674500|Experimental|Training Group|"Faculty participants will participate in educational training designed to teach them standardized coaching language for endoscopy instruction and strategies to promote effective communication during an endoscopy teaching. It will be comprised of:~A 15-minute-long training video demonstrating the use of recommended coaching language for endoscopy instruction (e.g., recommended 14 standard terms, need to refer to the screen when directing a trainee as opposed to their hands, use of a clockface analogy) and communication best practices (e.g., checking to ensure understanding, avoidance of cognitive overload, task deconstruction)~The faculty will be given a small (10x10 cm) flash card with the recommended 14 standard terms which they can access during the second simulated encounter. To control for any potential effect of the presence of the card on the trainee during teaching, each faculty be given an identical card with 14 random words on it to hold during the first encounter"
89421820|NCT05674500|Active Comparator|Control Group|"Faculty participants will take part in 'dummy' educational training comprised of:~A 15-minute-long 'dummy' colonoscopy training video which outlines how to set goals ahead of an endoscopy training session. The video will not discuss standardized coaching language and/or communication best practices~This group will also be provided a small (10x10cm) flash card but with random words on it (identical to the first simulated colonoscopy teaching encounter)."
89421821|NCT05672784|Active Comparator|C group|the patients will take standard analgesia (paracetamol 1 gm thrice daily and meloxicam (15 mg) every 24). ,with no nerve block
88902061|NCT06045637|Experimental|Group included in a psychoeducational program based on cognitive behavioral approach (experiment)|"Emerging adults between the ages of 18-29 who experienced the Kahramanmaraş 2023 earthquake in Turkey constitute the experimental group.~The cognitive behavioral approach-based psychoeducation program will be implemented in 9 sessions, two days a week and 90 minutes a day.In the psychoeducation program, based on the cognitive behavioral approach, trauma and trauma symptoms, emotion-thought-behavior analysis, cognitive errors, automatic thoughts, alternative thought generation, mentality and distorted thoughts that reveal feelings of depression, anxiety, stress, anger, guilt, inadequacy, helplessness, The cognitive aspect of hopelessness and methods of coping with negative emotions will be discussed.The training program includes verbal expression, visual material (projection), question and answer, homework, sample stories, entertaining activities, warm-up games, etc. It will be continued and feedback will be shared."
88902062|NCT06045637|No Intervention|Group not included in the psychoeducation program based on cognitive behavioral approach (Control)|No intervention will be made to this group.
88902063|NCT06045481|Experimental|Single Dose of 200mg doxycycline|Treatment of a single dose of 200mg doxycycline
88902064|NCT06045481|No Intervention|Standard treatment of 5 days doxycycline (200mg at 1st day followed by 4 days of 100mg)|Treatment of 5 days doxycycline (200mg at 1st day followed by 4 days of 100mg)
88902065|NCT06045143||Apical pacing|Study LV strain with speckle Echo when lead of pacemaker on apical site
88902066|NCT06045143||Septal pacing|Study LV strain with speckle Echo when lead of pacemaker on septal site
88902067|NCT06044727|Experimental|Test group|After phase 1 therapy, management of RT1 cases will be done with Minimally invasive non surgical periodontal therapy.
89421822|NCT05672784|Active Comparator|G group|the patients will take standard analgesia plus genicular nerves block
88902068|NCT06044727|Active Comparator|Control Group|After phase 1 therapy, management of RT1 cases will be done with Conventional subgingival instrumentation.
88902069|NCT06044220|Experimental|Intervention|The intervention group is given a 3-month reminder after the TSE training.
88902070|NCT06044220|Other|control|No training or reminders are given to the control group
88902071|NCT06043388|Experimental|Group 1|Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cell)
88902072|NCT06043388|Placebo Comparator|Group 2|physiological saline
88902073|NCT06040801|Experimental|Frail group|All patients receive a frailty assessment within 7 days before initiating the first cycle of palliative chemotherapy, followed by geriatric intervention. Patients exhibiting impairments in at least two dimensions are considered frail. The frail group will receive management and recommendations based on the specific impairment domain.
88902074|NCT06040801|No Intervention|Non-frail group|All patients receive a frailty assessment within 7 days before initiating the first cycle of palliative chemotherapy, followed by geriatric intervention. Patients exhibiting impairments in at least two dimensions are considered frail. The non-frail group will not receive additional interventions, but the clinical physicians will still provide appropriate treatment based on the patient's condition.
88902075|NCT06030388|Active Comparator|Strength training|"Standardised programme with the following exercises: chest press, leg press, row, leg curl, latissimus dorsi pull down and leg extension in seated resistance machines. Training will be preceded by 7-10 minutes of warm-up and followed by two body-weight exercises for the abdominal and back muscles for two sets as many repetitions as possible, and thereafter cool down and stretches. The set-up of each machine will be recorded in the training diary.~Weeks 1-3 will include two sets of training with 15-20 repetition-maximum (RM) and weeks 4-15 two sets with 8-12 RM. Throughout the intervention, loads will be adjusted to achieve muscle fatigue and approach training to failure during each set with the intent to maximize beta-endorphin release."
88902076|NCT06030388|Active Comparator|High-intensity aerobic training|Participants will be recommended to attend spinning classes three times per week. During their first visit to the training venue, they will meet a sports physiotherapist or personal trainer to be introduced to the spinning bike intervention. The intended intensity is ≥ 14 on the Borg rating of perceived exertion scale, equivalent to high intensity training (>70% of VO2max) with the aim of attaining sufficient stimulus for beta-endorphin release. During weeks 1-3 participants will attend spinning classes for beginners with lower intensity and predominantly seated cycling. They will progress to higher intensity classes with greater variation between seated and standing cycling during week 4-15.
89421823|NCT05672784|Active Comparator|GI group|the patients will take standard analgesia plus genicular nerves block plusinfiltration Between Popliteal Artery and Capsule of Posterior Knee
89421824|NCT05661253|No Intervention|Control group|will take general anesthesia without nerve block
89530830|NCT02510495|Experimental|"30 group"|After a small sphincterotomy was performed, a controlled radial expansion (CRE) balloon (diameter 8, 9, 10, 11, 12, 13.5, 15; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast in 15 seconds. When the waist disappeared, the balloon was inflated till 30 seconds prior deflated. The stones were then retrieved by a basket or retrieval balloon. Mechanical lithotripsy was used if necessary.
89421825|NCT05661253|Active Comparator|SAP block group|After sterilization of the skin and draping, the high frequency linear probe of Sonosite M Turbo ultrasonography (FUJIFIM sonosite, Inc., Bothell, WA, USA) will be placed at the level of the midclavicular line in a sagittal plane. The second rib will be recognized at the axillary artery. The probe will be moved downward to count the ribs until the level of the ﬁfth rib in the mid-axillary line. At this time, the latissimus dorsi muscle (lying superficial) and the serratus anterior muscle (lying deep) will be clearly visualized under ultrasound . Next, A 22-gauge, 80 mm needle (Stimuplex D, B-Braun, Germany) will be inserted in plane relative to the ultrasound probe between the latissimus dorsi and the serratus anterior muscle. After confirming negative aspiration of blood, 1 ml normal saline will be injected for hydro-dissection sign to verify the needle tip, then a volume of 25 ml 0.25% bupivacaine will be injected superficially to serratus anterior muscle. .
89421826|NCT05661253|Active Comparator|modified SAP block group|The patient will be placed in the lateral decubitus position according to the selected site of surgical intervention. After sterilization of the skin and draping, the high frequency linear probe of Sonosite M Turbo ultrasonography ( FUJIFIM sonosite, Inc., Bothell, WA, USA) will be placed horizontally midway between tip of the scapula and posterior axillary line to identify the view of latissimus dorsi(lying superficial) and serratus anterior muscle(lying deep) over either the sixth or seventh rib. A 22-gauge, 80 mm needle (Stimuplex D, B-Braun, Germany) will be inserted in plane relative to the ultrasound probe from posteromedial to anterolateral direction toward posterior axillary line till reaching the interfacial plane between latissimus dorsi and serratus anterior muscle . After confirming negative aspiration of blood, 1 ml normal saline will be injected for hydro-dissection sign to verify the needle tip, then a volume of 25 ml 0.25% bupivacaine will be injected .
88902077|NCT06030388|No Intervention|Control group|The control group will be recommended to carry on physical activity as usual and not to change their training or dietary habits during the 15-week study period. The control group will be contacted every fourth weeks by a research nurse to follow up on their general well-being and any questions they might have about menopause. After the study period they will be offered individual advise about training from a physiotherapist or personal trainer.
88902078|NCT06024785|Active Comparator|Indication for decompression, randomization for decompression|microsurgical lumbar laminotomy with partial removal of the medial facet joint by preserving the midline structures; approach: bilateral or ipsilateral with cross-over to the contralateral side
88902079|NCT06024785|Experimental|Indication for decompression, randomization for vertebropexy|decompression (see above) and additional stabilization of the spine with a biological ligament (for instance semitendinosus donor allograft), which will be pulled through a drilled hole in the spinous process of two adjacent vertebra in a looping technique and tendon ends fixed by an anchor knot after baseball stitches in a standardized fashion. Situation-related application of laminar bands or analogous suture material (for instance FiberTape, Arthrex, Naples or Nile Band, K2M, Virginia). Passive stability in clinically important directions of motion such as flexion-extension and shear movements will be provided, yet without stiffening other directions of motion.
88902080|NCT06024785|Active Comparator|Indication for fusion, randomization for fusoin|decompression and posterolateral instrumented fusion (arthrodesis) with implantation of pedicle screws, titanium alloy rods across the level of listhesis, an intervertebral fusion device and local autograft as well as DBX (demineralized bone matrix) to improve bony fusion
89421827|NCT05656001|Experimental|real-time functional magnetic resonance imaging neurofeedback and real-time biofeedback|Three sessions of real-time functional magnetic resonance imaging neurofeedback (rt-fMRI-NF) or real-time biofeedback training where participants will receive direct visual feedback from the blood oxygenation level dependent (BOLD) imaging signaling from the salience network in rt-fMRI-NF or visual feeback from a physiological signal in the real-time biofeedback (active condition)
89421828|NCT05656001|Sham Comparator|Sham feedback|Three session where participants will be given a yoked sham feedback as control condition.
88902081|NCT06024785|Experimental|Indication for fusion, randomization for vertebropexy|decompression (see above) and additional stabilization of the spine with a biological ligament (for instance semitendinosus donor allograft), which will be pulled through a drilled hole in the spinous process of two adjacent vertebra in a looping technique and tendon ends fixed by an anchor knot after baseball stitches in a standardized fashion. Situation-related application of laminar bands or analogous suture material (for instance FiberTape, Arthrex, Naples or Nile Band, K2M, Virginia). Passive stability in clinically important directions of motion such as flexion-extension and shear movements will be provided, yet without stiffening other directions of motion.
88902082|NCT06018961||Adult patients with digestive surgery|Patients who have planned abdominal surgery
88902083|NCT06015490|Experimental|Conditioned Stimulus: Sucrose (aim 1)|Participants will undergo exposure sessions with flavored beverage solutions containing sucrose.
88902084|NCT06015490|Experimental|Conditioned Stimulus: Glucose (aim 1)|Participants will undergo exposure sessions with flavored beverage solutions containing glucose.
89421829|NCT05639192|Experimental|Standard of Care + Asunercept 100 mg|
89421830|NCT05639192|Placebo Comparator|Standard of Care + Placebo|
88902085|NCT06015490|Experimental|Conditioned Stimulus: Fructose (aim 1)|Participants will undergo exposure sessions with flavored beverage solutions containing fructose.
88902086|NCT06015490|Experimental|Conditioned Stimulus: Sucrose (aim 2)|Participants will undergo exposure sessions with flavored beverage solutions containing sucrose.
88902087|NCT06015490|Experimental|Conditioned Stimulus: High Fructose Corn Syrup (aim 2)|Participants will undergo exposure sessions with flavored beverage solutions containing high fructose corn syrup.
88902088|NCT06015490|Experimental|Conditioned Stimulus: Sucrose + Non-nutritive Sweetener (aim 2)|Participants will undergo exposure sessions with flavored beverage solutions containing sucrose and a non-nutritive sweetener.
88902089|NCT06000254|Experimental|physiotherapy and high-PEMF|The patient receives physiotherapy and high-PEMF therapy twice weekly, over a period of three weeks.
88902090|NCT06000254|Sham Comparator|physiotherapy and sham high-PEMF|The patient receives physiotherapy and sham high-PEMF therapy twice weekly, over a period of three weeks.
88902091|NCT05999214|Experimental|Experimental group|99mTc-H7ND SPECT/CT imaging was performed
88902092|NCT05999214|No Intervention|Control group|99mTc-H7ND SPECT/CT imaging was not performed
88902093|NCT05990751|Experimental|GD2 CAR T cells|Treatment with GD2 CAR T cells
89421831|NCT05620576|Experimental|LY3857210|Participants will be given LY3857210 orally.
89421832|NCT05620576|Placebo Comparator|Placebo|Participants will be given placebo orally.
89421833|NCT05619081|Experimental|NAP GROUP|30min of Powernap before second performance measure
89421834|NCT05619081|No Intervention|NO NAP GROUP|30min of free quiet occupation before second performance measure
89421835|NCT05617885|Experimental|Phase 1 Lead In in CRPC|Standard 3+3 dose escalation scheme with 3 dose levels of abemaciclib and a constant dose of darolutamide, per protocol, for 6, 28-day cycles
89421836|NCT05617885|Experimental|Phase 2 - Neoadjuvant Darolutamide and ADT prior to Radical Prostatectomy|per protocol, for 6, 28-day cycles
89421837|NCT05617885|Experimental|Phase 2 - Neoadjuvant Darolutamide, Ademaciclib, and ADT prior to Radical Prostatectomy|per protocol, for 6, 28-day cycles
89421838|NCT05616338|Experimental|Eligible patients|
89421839|NCT05614570||Baseline|This cohort contains individuals tested at baseline, usually in the pre-season of their sporting season
88902094|NCT05990075|Experimental|Self-monitoring|This research study will evaluate a self-monitoring intervention to increase awareness, provide support, and promote motivation to initiate treatment after referral to mental health. The proposed intervention is a user-driven program delivered online and by mobile text. This will be initially piloted for acceptability among Veterans referred to mental health service for depression treatment.
89421840|NCT05614570||Concussed|This cohort contains individuals who have had a concussion, diagnosed by a doctor.
89421841|NCT05601271|Placebo Comparator|Placebo|pills exactly as the drug will be delivered to participants. Instructions will be made to take the pill once a day.
89421842|NCT05601271|Active Comparator|Allopurinol|pills exactly as the placebo will be delivered to participants. Instructions will be made to take the pill once a day.
88902095|NCT05968638|Placebo Comparator|Regular Diet|
88902096|NCT05968638|Active Comparator|Ketogenic Diet|
88902097|NCT05954949||Ileoanal pouch adenomas detection assessment|Every patient who needs follow up lower digestive examination for familial adenomatous polyposis after colectomy can join this study with ileal pouch adenomas detection by experienced endoscopist.
88902098|NCT05935618|Experimental|Combined skill- and strength-based swallowing exercise|The intervention is delivered as face-to-face therapy 2 times per week in 8 weeks
89421843|NCT05593198|Active Comparator|Guided bone regeneration|Patients will be treated with guided bone regeneration.
89421844|NCT05593198|Experimental|Bone block|Patients will be treated with bone blocks using the Khoury technique.
89421845|NCT05565495|Experimental|Hydromorphone|Hydromorphone was administered intravenously at a rate of 0.03 mg/kg/h for 72 h for analgesia. Blood samples were collected before administration and at different time points after administration, and the content of hydromorphone and hydromorphone-3-glucuronide (the main metabolite) was detected by quantitative liquid chromatography tandem mass spectrometry. And then a population pharmacokinetic model of hydromorphone in patients under ECMO was established.
88820043|NCT06195969|Experimental|Intervention group|Participants in intervention group will receive the EMI for 4 weeks. Based on the steps of mobile message development recommended by Abroms, et al. , we will develop a message content library and protocol for EMI delivery.
88820044|NCT06195969|No Intervention|Control group|The control group will receive instant messages about general stroke management including hypertension management from the Hospital Authority of HK SAR Government website, which is open to the public (https://www21.ha.org.hk/smartpatient/SPW/en-US/Disease-Information/Disease/?guid=29ac1219-3d68-4378-a2bd-09e111da3650), with reminder text messages of importance follow-up surveys.
88820045|NCT06195917|Experimental|Experimental group|Robotic-assisted Interventional Percutaneous transhepatic puncture
88820046|NCT06195865|Active Comparator|Randomised DIEP flap|
88820047|NCT06195865|Active Comparator|Randomised implant-based|
88820048|NCT06195865|Active Comparator|Preference DIEP-flap|
88820049|NCT06195865|Active Comparator|Preference implant-based|
88820050|NCT06195852|Active Comparator|In-Person Safe Touches|Delivered in-person in a classroom
88820051|NCT06195852|Experimental|Virtual Safe Touches|Delivered by facilitators via interactive video conferencing software to students in the classroom
88820052|NCT06195839|Experimental|Immediate Financial Incentives for BP monitoring|"instructions for participating in a 2-month remote patient monitoring program~home blood pressure monitor and associated smartphone app, which includes a module for logging medication-taking~wrist-worn sensor and associated smartphone app~weekly adherence feedback to home blood pressure monitoring~immediate financial incentives for home blood pressure monitoring distributed weekly"
88820053|NCT06195839|Active Comparator|Delayed Financial Incentives for BP monitoring|"instructions for participating in a 2-month remote patient monitoring program~home blood pressure monitor and associated smartphone app, which includes a module for logging medication-taking~wrist-worn sensor and associated smartphone app~weekly adherence feedback to home blood pressure monitoring~delayed financial incentives for home blood pressure monitoring distributed at the end of the study"
88820054|NCT06195826||gravity infusion|women who received hysteroscopic myomectomy with gravity infusion method
88820055|NCT06195826||pump infusion|women who received hysteroscopic myomectomy with pump infusion method
88820056|NCT06195800||Patients treated with aHSCT|Patients with aggressive disease treated with autologous haematopoetic stem cell transplantation.
88820057|NCT06195800||Patients treated with disease modifying treatment|Patients with aggressive disease treated with high efficacy disease modifying treatment
88820058|NCT06195774||Observational cohort|Measure regional electric impedance of the lung for before and after insertion of an epidural analgesia catheter
88820059|NCT06195722|No Intervention|control|control
88820060|NCT06195722|Experimental|experimental|experimental
88820061|NCT06195683|Experimental|anti-PDL-1 Immunotherapy followed by Surgical Resection|Participants will receive four preoperative doses of PDL-1 inhibitor Serplulimab in adults with untreated, surgically resectable early (stage IB, II, or IIIA) NSCLC. Serplulimab (at a dose of 4.5mg per kilogram of body weight) was administered intravenously every 3 weeks, with surgery planned approximately 4 weeks after the last dose.
88820062|NCT06195670|Experimental|SCRT + fruquintinib + sintilimab|
88820063|NCT06195670|Active Comparator|Bevacizumab + Capecitabine|
88820064|NCT06195644|Experimental|GVS group|Galvanic Vestibular Stimulation in addition to the Conventional Physical Therapy program of moderate intensity aerobic training on cyclic ergometer for upper limb and task oriented training for hand dexterity.
88820065|NCT06195644|Active Comparator|CPT group|Conventional Physical Therapy program of moderate intensity aerobic training on cyclic ergometer for upper limb and task oriented training for hand dexterity.
88820066|NCT06195631|Experimental|Standardized Checklist for Optimizing Procedural Ergonomics in Endoscopy (SCOPE- E) Bundle|Endoscopists in each unit that is randomized to the intervention will be asked to use an ergonomic check list to conduct a verbal time-out before commencing each colonoscopy procedure.
88820067|NCT06195631|No Intervention|Standard of practice|Usual practice does not involve any of the core components of the SCOPE-E bundle. Endoscopy units in the control arm will not undergo any targeted intervention(s) to enhance ergonomic behaviors throughout the study period.
88820068|NCT06195618|Experimental|Vaccine|Triple-negative breast cancer patients with specific tumor mutation, with six doses of peptide-pulsed autologous dendritic cells after surgery
88820069|NCT06195605|Experimental|Photodamaged skin|
88820070|NCT06195579|Experimental|Intervention arm|Participants receiving the intervention whilst on a waiting list for treatment as usual
88820071|NCT06195553|Experimental|STEPPS for patients plus Family Connections for their families|Intervention group that receives STEPPS program for patients to carry out the intervention about BPD symptoms and in parallel another group that receives Family Connectios program for their families to carry out the intervention about associated symptoms.
88820072|NCT06195553|Active Comparator|STEPPS for patients only|Intervention group that receives STEPPS program for patients only to carry out the intervention about BPD symptoms.
88820073|NCT06195501||Acute ischemic stroke|Patients with acute ischemic stroke and an indication for a transesophageal ecocardiography
88820074|NCT06195488||Group D|Group Diabetic
88820075|NCT06195488||Group Control|Non-diabetic patients
89536031|NCT03200431|Experimental|Test of a new adhesive strip|This is a sub-study testing the effect of real output applied under two adhesive strips on the skin after 24 hours. The adhesive strip is not yet part of a marketed ostomy device.
88902099|NCT05930587|Experimental|Cold water immersion|"The experimental group will be informed about the lower extremity cold immersion bath during the outpatient clinic controls and will be given a liquid meter digital thermometer that will allow them to check the cold water temperature at home. Patients will then be asked to do the lower extremity cold water immersion bath every day in their own home, for a total of four weeks, lasting 20 minutes in the evening before going to sleep.~It is recommended that the cold dip bath last for 20 minutes and the temperature of the water should be 15 0C for it to be effective on the symptoms.~At the end of four weeks, patients will be informed that they should come to the outpatient clinic again. When the patients come to the outpatient clinic, information about the application will be repeated and data collection forms will be applied by face-to-face interview method."
88902100|NCT05930587|No Intervention|Control|No intervention will be made to the control group, only the data will be collected at the same time as the study group.
88902101|NCT05905094|Experimental|Postural correction exercises|cervical retraction, shoulder shrugging, neck isometrics,
88902102|NCT05891262|Experimental|BMS-986196 and Loestrin|
88902103|NCT05878587|Experimental|Group A|thermotherapy+ TENS+ low intensity high repetition exercises and Buerger Allen.
88902104|NCT05878587|Active Comparator|Group B control group|Thermotherapy+ TENS+ low intensity high repetition exercises.
88902105|NCT05877469|Active Comparator|mat pilates training group|Mat pilates training involve leg lifts, toe taps, Single leg stretch, one leg circle, side bend preparation, side kicks, side leg lifts, swan dive, hovers, roll down, crisscross and planks. Treatments will be provided in 30 mins, three sessions per week for 8 consecutive weeks.
88902106|NCT05877469|Experimental|Functional training group|Functional training involve glute bridge, squats, pushups, lateral lunge, step up to shoulder press, goblet squats and woodchop. Treatments will be provided in 30 mins, three sessions per week for 8 consecutive weeks.
88902107|NCT05877183|Experimental|Wearable device group|Participants will be instructed to wear the wristwatch for a minimum of 3 hours per day, 5 days per week and engage in telerehabilitation, 1 hour per day 5 times per week over 4 weeks. Weekly, there will be a 45-minute therapy consultation.
88902108|NCT05877183|Sham Comparator|Sham group|The participants will be instructed to wear the sham device for a minimum of 3 hours per day, 5 days per week. In addition, they will be instructed to engage in upper limb training with the prescribed exercises presented in the form of a pictorial handout rather than an in-app video, 1 hour per day 5 times per week over 4 weeks. Weekly, there will be a 45-minute therapy consultation.
88902109|NCT05874570|Active Comparator|Tetracycline Bismuth Quadruple Therapy|Esomeprazole 20mg bid, Bismuth Potassium Citrate 110mg qid, Tetracycline 500mg qid, Metronidazole 400mg qid
88902110|NCT05874570|Experimental|Doxycycline Bismuth Quadruple Therapy|Esomeprazole 20mg bid, Bismuth Potassium Citrate 110mg qid, Doxycycline 100mg bid, Metronidazole 400mg qid
88902111|NCT05874531||Responders to fluid challenge|Responders to fluid loading after an increase in sub-aortic VTI of more than 10% following a volume expansion.
88902112|NCT05874531||Non responders to fluid challenge|Non responders to fluid loading after an increase in sub-aortic VTI of more than 10% following a volume expansion.
88902113|NCT05854316|Experimental|Frail elders|Frail elders; Age: 65-80 years; Body Mass Index: 18.5-30 kg/m²; Frailty diagnosed according to Fried's criteria (i.e., at least three of the following items: unintended loss of weight, weakness, self-reported exhaustion, slow walking speed, low level of physical activity).
88902114|NCT05853081||FEV1 < 30%|open groups with forced expiratory flow in the first second (FEV1) < 30%. It will be followed for at least two years.The fat-free mass index (FFMI) will be measured instead of the body mass index (BMI) with bioelectrical impedance analysis.
88902115|NCT05853081||FEV1 30-50%|open groups with forced expiratory flow in the first second (FEV1) < 30%. It will be followed for at least two years.The fat-free mass index (FFMI) will be measured instead of the body mass index (BMI) with bioelectrical impedance analysis.
88902116|NCT05853081||FEV1 > 50%|open groups with forced expiratory flow in the first second (FEV1) < 30%. It will be followed for at least two years.The fat-free mass index (FFMI) will be measured instead of the body mass index (BMI) with bioelectrical impedance analysis.
88902117|NCT05848076|Experimental|TNE with core stability|Group A (TNE WITH CORE STABILITY) on low back this McGill exercise focuses on the ability of the spine to stabilize in different positions 3 sets of 3 repletion with of each of muscle and briefly explain the patient about their pain.The study participants will receive the total 18 session over 6 weeks period consider 3 treatment session per week
88902118|NCT05848076|Active Comparator|Core stability|McGill exercises for the low back. involved 3 sets of 3 repetitions for each muscle with a 30-second hold and 30-second rest interval for each repetition. The researcher will reassess the patient. Post treatment patient will complete Numeric Pain Rating Scale (NPRs), range of motion (Goniometer and Oswestry disability index (ODI). All study participant will receive a total of 18 treatment sessions over a six-week period, which consisted of 03 treatment sessions per week.
88902119|NCT05840276|Experimental|CRYO|Receives cryoneurolysis treatment on the anterior femoral cutanous nerve and the infrapatellar branch of the saphenous nerve.
88902120|NCT05840276|Sham Comparator|SHAM|Receives similar procedures as in CRYO but with no freezing temperatures.
88902121|NCT05834114|Experimental|McKenzie protocol|In this group, 20 participants will be included. the interventions will be given for 15 mint. The exercises then repeated five or six times in a Session. the session will be of 45 mins, 3 session per week.
88902122|NCT05834114|Active Comparator|Rhythmic stabilization technique|In this group, 20 participants will be included. Rhythmic Stabilization with traditional physical therapy will be given for 3 sessions of 45 minutes a week, over a period of 10 weeks.
89536032|NCT02450149|Experimental|Sorafenib|Sorafenib 400 mg will be administered orally twice a day for 28 days.
89536033|NCT02479217||Adjuvant therapy|Patients prescribed Xeloda per registered indicatilons were observed until disease progression or 8 cycles for adjuvant colon cancer
89536034|NCT02479217||Combination Therapy|Patients prescribed Xeloda with docetaxel for metastatic breast cancer after failure to anthacyclines were observed until disease progression
89536035|NCT02479217||Monotherapy|Patients prescribed Xeloda per registered indicatilons were observed until disease progression or 8 cycles for adjuvant colon cancer
89421846|NCT05557825||Radiodermatitis Case Group|03 patients with grade 2 to 4 radiodermatitis after radiotherapy for the treatment of head and neck cancer submitted to a PBM/PDT therapy protocol
88902123|NCT05824650||Frail Congenital Heart Disease Group|Frailty Fried et al. will be evaluated according to the five-parameter criteria set in the Cardiovascular Health Study by Having 3 or more parameters positive is defined as fragility. Individuals who meet this criterion will be included in this group.
88902124|NCT05824650||Non-frail Congenital Heart Disease Group|Frailty Fried et al. will be evaluated according to the five-parameter criteria set in the Cardiovascular Health Study by Having 3 or more parameters positive is defined as fragility. Individuals who do not meet this criterion will be included in this group.
88902125|NCT05811260|Active Comparator|Myofascial Release|Group A (Myofascial release technique) on low back 3 repetitions (30 second rest between reps), lasting for 30 s for each myofascial track for 1 set to targeted muscles (plantar fascia, gastrocnemius, hamstrings, and erector spinae). The position will be held for 10-15 seconds when a pain point is found lacrosse ball excellent for this type of massage because their surface area is much less than that of foam rollers.
88902126|NCT05811260|Active Comparator|Post facilitation stretch|Group B (Post facilitation stretch) static stretching exercises for the low back (plantar fascia, gastrocnemius, hamstrings, and erector spinae). Static stretching involved 3 sets of 3 repetitions for each muscle with a 30-second hold and 30-second rest interval for each repetition.
88902127|NCT05808608|Experimental|Combination treatment group|Subjects in this group will receive AK104 (RP2D, administered intravenously) plus Axitinib 5 mg bid, administered orally.
88902128|NCT05803200||HyQvia|Pregnant female participants who have insurance coverage with full prescriptions benefits exposed to HyQvia during the period from 90 days before the last menstrual period (LMP) through 30 days after delivery will be observed retrospectively from 1 January 2014 to 31 December 2020 (up to 7 years).
88902129|NCT05790031|Experimental|Intelligent Nighttime Brace|The design of intelligent nighttime brace will incorporate different mechanism, such as a) compression and pulling forces through a customisable rigid brace, b) lumbar flexion by using a supporting air-belt, c) three-point pressure system is used to exert corrective forces by the intelligent paddings in the transverse direction, d) adjust the pressure of the brace padding through a pressure monitoring system in accordance with the sleeping posture of the users
88902130|NCT05782309|Experimental|Flavanol|500 mg of flavanols twice daily
88902131|NCT05782309|Placebo Comparator|Placebo|nutrient matched control capsule
88902132|NCT05781243|Experimental|Lactated Ringer solution (LR)|LR: Lactated Ringer solution. Patients in the LR treatment arm will receive fluid therapy based on lactated Ringer's solution for a minimum of 48 hours.
88902133|NCT05781243|Active Comparator|Normal saline (NS)|NS: Normal Saline. Patients in the NS treatment arm will receive fluid therapy based on normal saline for a minimum of 48 hours.
89421847|NCT05547503|Placebo Comparator|Placebo Control|Double blind placebo control
89421848|NCT05547503|Experimental|AFA-281|"Part 1: AFA-281 administered as an oral capsule at 5 dose levels for one day.~Part 2: AFA-281 administered as an oral capsule at 3 dose levels twice daily for 14 consecutive days. Doses will be determined after completion of Part 1."
89421849|NCT05542394|Experimental|Curcumin H2O SAP|Water soluble version of turmeric extract standardized to 10% curcuminoids will be administered orally (1 dose)
89421850|NCT05542394|Active Comparator|Tumeric with piperine SAP|Turmeric extract standardized to 95% curcuminoids in combination with 5 mg of piperine per capsule will be administered orally (1 dose)
89421851|NCT05542394|Placebo Comparator|Tumeric without piperine|Turmeric extract standardized to 95% curcuminoids without piperine will be administered orally (1 dose)
89194854|NCT00651261|Experimental|Induction and consolidation chemotherapy plus midostaurin|Patients will receive a standard combination of chemotherapy drugs during remission induction therapy that includes cytarabine, daunorubicin, and the experimental drug midostaurin. Depending on the outcome of remission induction treatment, there may be a decision to discontinue the study treatment or a second remission induction cycle may be given. If remission induction therapy is successfully completed, patients will receive four courses of high-dose cytarabine consolidation chemotherapy plus dexamethasone together with the experimental drug midostaurin. All patients will undergo a bone marrow aspiration (and perhaps a biopsy) after the final course of remission consolidation chemotherapy. If the patient continues to respond to the treatment, the patient will receive continuation therapy with midostaurin for twelve (12) months.
89421852|NCT05539742|Active Comparator|Coconut oil|The coconut oil will be given to each participant in the amount of 40 g, which will be incorporated into biscuits. Each participant will have ten minutes to consume biscuits with 250 ml of water. No other food will be consumed during the study period (6 hours). After that, participants will be allowed an ad libitum intake of standard meals. Each meal will be weighed before and after it is consumed, with the amount of food ingested being calculated. Then the participants will take the other treatment after a 1-week washout interval.
89421853|NCT05539742|Active Comparator|Palm oil|The palm oil will be given to each participant in the amount of 40 g, which will be incorporated into biscuits. Each participant will have ten minutes to consume biscuits with 250 ml of water. No other food will be consumed during the study period (6 hours). After that, participants will be allowed an ad libitum intake of standard meals. Each meal will be weighed before and after it is consumed, with the amount of food ingested being calculated. Then the participants will take the other treatment after a 1-week washout interval.
89421854|NCT05531734|Experimental|volunteers|Health volunteers
89194855|NCT00651261|Active Comparator|Induction and consolidation chemotherapy plus placebo|Patients will receive a standard combination of chemotherapy drugs during remission induction therapy that includes cytarabine, daunorubicin, and placebo. Depending on the outcome of remission induction treatment, there may be a decision to discontinue the study treatment or a second remission induction cycle may be given. If remission induction therapy is successfully completed, patients will receive four courses of high-dose cytarabine consolidation chemotherapy plus dexamethasone together with placebo. All patients will undergo a bone marrow aspiration (and perhaps a biopsy) after the final course of remission consolidation chemotherapy. If the patient continues to respond to the treatment, the patient will receive continuation therapy with placebo for twelve (12) months.
89194856|NCT00885820|Experimental|1|Protocol biopsies at 1, 2 and 3 months
89194857|NCT00885820|Active Comparator|2|No protocol biopsies
89421855|NCT05522023|Experimental|Experimental group (group treated with aromatic solution)|"Informed consent form will be signed by the patients selected by randomization and a personal information form will be filled.~Hour 0: The patients will be completely awakened from the anesthesia resting unit, their vital signs will be stable, they will be transferred to the clinic where they lie normally with a 15 glaskow scale, the bed head will be elevated 45 degrees and the risk of aspiration will be ruled out. After controlling the vital signs of the patient, sore throat and thirst with VAS and nausea and vomiting with the verbal descriptive scale VDS will be evaluated. After the data are collected, the aromatic solution will be shaken and applied to the oral cavity and throat as a spray 4 times. After the aromatic solution application is finished, the patients' sore throat, thirst and nausea and vomiting will be re-evaluated with the same forms.~2., 4., 6. The same procedures will be repeated in the 8th and 8th hours."
88902134|NCT05774509|Experimental|Treated group|"A maximum of 12 patients will be included in the study following a dose-escalating design:~Cohort 1 (4 patients) will receive 20x10E9 particles/kg for each infusion, with a total of 3 infusions, for a cumulative dose of 60x10E9 particles/kg;~Cohort 2: in the absence of safety issues in Cohort 1, 8 patients will receive 40x10E9 particles/kg for each infusion, with a total of 3 infusions, for a cumulative dose of 120x10E9 particles/kg."
88902135|NCT05768035|Experimental|Patients with acute leukemia or myelodysplastic syndrome and eligible for an haplo PT-Cy HSCT|"Segment 1: 3 dose-level SMART101 cells/infusion~1.5 x 106 CD7+ cells per kg of body weight~4.5 x 106 CD7+ cells per kg of body weight~9.0 x 106 CD7+ cells per kg of body weight~Segment 2:~2 cohorts of patients will be included in the study based on the type of conditioning regimen:~The cohort A will include up to 17 patients receiving a myeloablative conditioning (MAC).~The cohort B will include up to 17 patients receiving a reduced intensity conditioning (RIC).~Enrollment of patients in each cohort will be done in parallel."
88902136|NCT05739890||Age >18yrs|The study will compare embryos from >50 couples and their embryo samples flagged not suitable for transfer from deidentified couples with date of birth required.
88902137|NCT05735847||Total Knee Arhroplasty (TKA)|Study participants will be adults (i.e. at least 18 years old) who have diagnosis of KOA with an indication for primary Total Knee Arthroplasty (TKA).
89194858|NCT02542618|Experimental|Inquiry Based stress Reduction (IBSR)|"IBSR intervention is the clinical implementation of a mindful-process, named The Work developed by Byron Katie. It teaches the individual to identify and question the thoughts that causes stress and suffering through four questions and turnarounds."
89536036|NCT03200119|Experimental|Mobile application user group|In the active group, participants were educated to modify their lifestyle to lose weight by using a smart phone-based lifestyle app which was designed to collect daily activity and dietary information. The app was composed of two main modules: a diet module, and a physical activity module.
88902138|NCT05735847||Unicompartmental Knee Arthroplasty (UKA)|Study participants will be adults (i.e. at least 18 years old) who have diagnosis of KOA with an indication for primary medial Unicompartmental Knee Arthroplasty (UKA).
88902139|NCT05729984|Experimental|Paula|The patients will perform Paula exercises after cesarean delivery.
89536037|NCT03200119|No Intervention|Control group|Conventional lifestyle modification
89194859|NCT02542618|Active Comparator|Cognitive Behavioral Therapy (CBT)|CBT is a psychological treatment method, focusing on a structured way to identify and modify unhelpful thinking patterns, underlying assumptions and idiosyncratic cognitive schemes about the self, the world (including other people) and the future.
88902140|NCT05729984|Active Comparator|Gum chewing|The patients will chew gum after the cesarean delivery.
88902141|NCT05700396|Experimental|Breast Cancer Survivor Education Program|"Participants will complete study procedures as outlined:~- 6 weekly sessions of a modified version of the PAVING the Path to Wellness education program."
88902142|NCT05695131|Experimental|Virtual Reality Delivered Therapy + Standard Clinical Care|The GlenXRose virtual reality therapies will be delivered to participants using a head-mounted device to allow vocal therapy and practice. Participants will also receive routine clinical care provided by speech-language pathologists.
88902143|NCT05695131|No Intervention|Standard Clinical Care|Participants will receive routine clinical care provided by speech-language pathologists.
88902144|NCT05694741|Experimental|Cohort 1 (healthy volunteers)|The planned number of cohorts is up to 6 cohorts; additional cohorts may be included if it is considered necessary to repeat a dose level or if additional dose steps are required for safety purposes. Six subjects will receive AZD0186, and two subjects will receive placebo.
88902145|NCT05694741|Experimental|Cohort 2 (healthy Japanese volunteers)|The planned number of Japanese cohorts is 1, but more than 1 cohort may be included if the SRC considers it necessary to repeat a dose level or if additional dose steps are required. No sentinel dosing will be performed for the Japanese cohort.
88902146|NCT05694741|Experimental|Cohort 3 (healthy Chinese volunteers)|The planned number of Chinese cohorts is 1, but more than 1 cohort may be included if it is considered necessary to repeat a dose level or if additional dose steps are required. No sentinel dosing will be performed for the Chinese cohort.
88902147|NCT05694741|Experimental|Cohort 4 (healthy volunteers - food effect)|One of the Part 1 cohorts (planned for Cohort 6, can be updated pending emerging data) will continue into the food-effect part after a washout period. This part will be initiated after SRC review of all available data from preceding cohorts in this study.
89194860|NCT02567838|Experimental|Lidocaine gel|Instillagel (2% lidocaine) was administered rectally prior to probe insertion.
89194861|NCT02567838|Placebo Comparator|Placebo|Placebo (Aquagel) was administered rectally prior to probe insertion.
88902148|NCT05675709|No Intervention|Comparison group|PCPs at the two clinics who are in pods that are not assigned to receive the intervention will serve as study comparators. Comparison group has no exposure to the group or online training sessions.
88902149|NCT05675709|Experimental|Other, Pragmatic|PCP participants complete group training and online training sessions. All training participants will also be offered series of short booster teaching points delivered virtually. Participants who complete the training also take part in pre-post knowledge assessments. PCP participants may also participate in a qualitative interview.
89194862|NCT00885898|Active Comparator|1|"Non-invasive ventilation"
89194863|NCT00885898|Active Comparator|2|"Conventional"
89194864|NCT03897816||"PERINATAL"|Pregnant women consecutively referred and admitted to the Perinatal Psychiatric Outpatient Department
89194865|NCT03897816||"OUTPTS"|Pregnant women belonging to the Outpatients Psychiatric Department who did not have psychiatric issues linked to their pregnancy or in the relationship with their children
88902150|NCT05672121|Experimental|KH631 Dose 1|dose1:Administered by Subretinal injection. Dosage form: injection solution. Dose: 200uL. Frequency of administration: one time injection.
88902151|NCT05672121|Experimental|KH631 Dose 2|dose2:Administered by Subretinal injection. Dosage form: injection solution. Dose: 200uL. Frequency of administration: one time injection.
88902152|NCT05672121|Experimental|KH631 Dose 3|dose3:Administered by Subretinal injection. Dosage form: injection solution. Dose: 200uL. Frequency of administration: one time injection.
88902153|NCT05672121|Experimental|KH631 Dose 4|dose4:Administered by Subretinal injection. Dosage form: injection solution. Dose: 200uL. Frequency of administration: one time injection.
88902154|NCT05672121|Experimental|KH631 Dose 5|dose5:Administered by Subretinal injection. Dosage form: injection solution. Dose: 200uL. Frequency of administration: one time injection.
88902155|NCT05671887||Cohort A: Primary lung cancers|- Examples include invasive mucinous/non-mucinous non-small cell lung cancers and multifocal carcinomas
88902156|NCT05671887||Cohort B: Metastatic cancers to the lung only|- Examples include germ cell tumors, head & neck tumors, colorectal tumors, renal cell tumors
88902157|NCT05671887||Cohort C: Respiratory failure with a history of cancer in the last 5 years|- Examples include, but not limited to interstitial lung disease (ILD), pulmonary fibrosis (idiopathic or secondary), advanced chronic obstructive pulmonary disease (COPD), bronchiectasis, emphysema, cystic fibrosis (CF), emphysema due to alpha-1 antitrypsin deficiency, and pulmonary arterial hypertension (PAH)
88902158|NCT05663112|Active Comparator|Arm with massage|"5 ml of isosulfan blue will be injected into the subareolar region. 5-minutes massage will be applied.~Drug: Isosulfan Blue 5 ml"
88902159|NCT05663112|Experimental|Arm without massage|"5 ml of isosulfan blue will be injected into the subareolar region. No massage will be applied.~Drug: Isosulfan Blue 5 ml"
88902160|NCT05661344|Experimental|Group 1: participants with mild hepatic impairment (Child-Pugh A)|
88902161|NCT05661344|Experimental|Group 2: participants with moderate hepatic impairment (Child-Pugh B)|
88902162|NCT05661344|Experimental|Group 3: participants with normal hepatic function individually matched to participants of Group 1|"One participant with normal hepatic function may match one participant in one or both groups of participants with hepatic impairment.~The matching criteria of the participants with normal hepatic function to the participants with hepatic impairment:~Age (± 10 years)~Gender~Weight (± 15%)"
88902163|NCT05661344|Experimental|Group 4: participants with normal hepatic function individually matched to participants of Group 2|"One participant with normal hepatic function may match one participant in one or both groups of participants with hepatic impairment.~The matching criteria of the participants with normal hepatic function to the participants with hepatic impairment:~Age (± 10 years)~Gender~Weight (± 15%)"
88902164|NCT05643183|Experimental|Patients receiving Astmakompas|30 patients from two hospital sites (AMC and MST)
88902165|NCT05629520||Participants with Major Depressive Disorder including TRD|Treatment resistant depression (TRD) participants are defined as participants with Major Depressive Disorder (MDD) who fail to respond to at least two lines of antidepressant medication treatment interventions.
88902166|NCT05616949|Active Comparator|Arm 1 Title: Treatment as Usual (TAU)|Arm 1: Treatment as Usual (TAU): The treatment and/or other services received as part of usual care while living in a recovery residence. This arm serves as the active comparator group for the study.
88902167|NCT05616949|Experimental|Arm 2 Title: Peer Recovery Support Services (PRSS) + TAU|Arm 2: Peer Recovery Support Services (PRSS) Intervention: The experimental group for this study that involves the implementation of the PRSS intervention. This study will test the preliminary efficacy of the PRSS intervention on Medications for Opioid Use Disorder (MOUD) retention by evenly randomizing N=50 individuals on MOUD living in recovery residences (RRs) to either a 24-week course of the experimental PRSS intervention layered on top of treatment as usual services (TAU+PRSS) vs. an active comparator composed of treatment as usual services without the PRSS intervention (i.e., TAU-alone). Follow ups will be conducted at weeks 2, 4, 8, 12, 16, 20, 24 (end of intervention), 36, and 52 to collect data on the primary outcome of MOUD retention and other outcomes.
88902168|NCT05603702|Experimental|Dose Escalation Level|In the first 3-patient cohort, the dose of lacosamide given is 50mg/d BID. Enrollment to the next higher dose cohort will be initiated only if none of the 3 participants exhibits a DLT in the 21 ±3 days following completion of the 7 day drug therapy. Dose escalation will proceed according to the Bayesian optimal interval (BOIN) design at incremental increase of 100mg/day in two divided doses. The maximum daily dose of lacosamide will be 400mg/day.
88902169|NCT05575206||Patients with rare genetic variant in ELAPOR1 or ELAPOR2|Patients undergo several examinations. Beside anthropometric measurements, bioelectrical impedance analysis, an 2h-oral glucose tolerance test (OGTT) and a hyperglycemic clamp is performed.
89006832|NCT06177899||Sliding split-box group|"Before augmentation, according to the 3D topography of the alveolar ridge of the patients, the sliding split-box technique was applied if there was less than 3 mm bone thickness at the top of the crest and the bone thickness increase towards the lower border.~This technique differs from the split-box technique as follows: If the bone thickness of the alveolar crest is not thick enough to split at the alveolar crest (<3 mm), but the bone thickness increases toward the lower border of the alveolar bone, horizontal osteotomy is performed at the level where the bone thickness reaches at least 3 mm. Separated corticocancellous bone block is slid toward the coronal of alveolar crest and fixed in line with the native alveolar bone."
89194866|NCT03897816||Healthy controls|Pregnant women the general population, with no history of mental health issues
89194867|NCT00810225||1|GWI: veterans of the 1990-1991 Persian Gulf War who have autonomic, neurological and other symptoms
89194868|NCT00810225||2|HC: healthy veterans of the 1990-1991 Persian Gulf War
89194869|NCT00810381|Active Comparator|1|"Nitroglycerin: (Perlinganit, Nycomet Heilmittelwerke, Vienna, Austria):~0, 0.25, 0.5, 1, 1.5 and 2 µg/kg/min, each infusion step for 20 minutes"
89536038|NCT05459909|Experimental|Synbiotic supplementation|Synbiotic supplementation
88902170|NCT05558865|Experimental|somnovia|somnovia is a digital health application for people with Insomnia Disorder. Content is continuously adapted to patients' concerns and needs. somnovia is a comprehensive program, which is conceptually and substantially based on the Cognitive Behavioral Therapy for Insomnia (CBT-I) used in patients with Insomnia Disorder. It contains interactive dialogues that can be accessed via computer or smartphone, illustrations, audio recordings and motivating text messages. Techniques to cope with insomnia symptoms (e.g., psychoeducation about causes and basic emotional needs in addition to relevant strategies to improve sleep quality) are conveyed in interactive sequences that are accompanied by audio recordings, illustrations, and worksheets. Patients are also prompted to regularly complete brief symptom severity self-monitoring questionnaires. Optional daily text messages with motivational content accompany the program. The program can be accessed for 365 days after registration.
88902171|NCT05558865|No Intervention|Care as Usual|Care as Usual: In the CAU control group, participants are free to continue to engage with any treatment they require. However, they will be offered access to somnovia after 6 months post-baseline.
88902172|NCT05548036|Active Comparator|OPEP|Oscillatory Positive Expiratory Pressure OPEP is a technique aimed at loosening and mobilising secretions it can be achieved by using a device (AerobikaTM). The device provides pulses of resistance as you exhale acting to open airways and shake secretions, enabling expectoration using a huff and cough technique. Key factors to consider when completing a treatment session are body position, users should be seated, with good posture, in a comfortable position.
88902173|NCT05548036|Active Comparator|ACBT|Active Cycle of Breathing Technique ACBT is a method of breathing performed in a cycle, used to help loosen and clear secretions from within the lungs (Panaligan et al., 2012). It consists of three different phases.
88902174|NCT05546606|No Intervention|Single standard of care|COPD patients who require respiratory support for severe acute exacerbation (AE), either with NIV or with IMV.
88902175|NCT05546606|Other|Strengthen standard of care reinforced with ECCO2R|COPD patients who require respiratory support for severe acute exacerbations (AE), either with NIV or with IMV reinforced with ECCO2R
88902176|NCT05526313|Experimental|1.2mg/m2|
88902177|NCT05526313|Experimental|2.4mg/m2|
88902178|NCT05526313|Experimental|4.0mg/m2|
88902179|NCT05526313|Experimental|6.0mg/m2|
88902180|NCT05526313|Experimental|8.4mg/m2|
88902181|NCT05526313|Experimental|11.2mg/m2|
88902182|NCT05526313|Experimental|15mg/m2|
89194870|NCT00810381|Active Comparator|2|"Isosorbide-Dinitrate: (Isoket 0,1 %, Gebro Broschek, Fieberbrunn, Austria):~0, 0.5, 1, 2, 4 and 6 µg/kg/min , each infusion step for 20 minutes"
89194871|NCT00810381|Active Comparator|3|"Sodium-Nitroprusside: (Nipruss, Sanol-Schwarz, Monheim, Germany):~0, 0.25, 0.5, 1, 2 and 4 µg/kg/min, each infusion step for 20 minutes"
89194872|NCT00810381|Placebo Comparator|4|Physiologic saline solution
89194873|NCT02553057|Active Comparator|Group 1|mechanical ventilation with Tidal volume 4 ml/kg and PEEP 8-10 cm H2o
89194874|NCT02553057|Active Comparator|Group2|mechanical ventilation with Tidal volume 6 ml/kg and PEEP 8-10 cm H2o
88902183|NCT05515159||ECT group|patients undergoing electroconvulsive therapy for depression
88902184|NCT05515159||control group|healthy controls; patients undergoing electroconversion for atrial fibrillation
88902185|NCT05513716||All patients|Colorectal cancer patients
88902186|NCT05509101|Active Comparator|Clinically Available Control Algorithm (MyoPro)|Binary control of the orthosis is based on a clinically available control algorithm. This condition serves as a control. Participants will use a commercially available device, the MyoPro.
88902187|NCT05509101|Experimental|High-Density EMG Control Algorithm|Control of the orthosis is based on residual muscle activity mapped to intended movement using advanced predicted algorithms. This condition is a novel algorithm and serves as the experimental condition.
89194875|NCT02553057|Active Comparator|Group 3|mechanical ventilation with Tidal volume 8 ml/kg and PEEP 8-10 cm H2o
89194876|NCT00800319|Experimental|RDC-0313, 5mg|5 mg of RDC-0313; single dose
89194877|NCT00800319|Experimental|RDC-0313, 15 mg|15 mg RDC-0313; single dose
89194878|NCT00800319|Experimental|RDC-0313, 25mg|25 mg RDC-0313; single dose
89194879|NCT00800319|Experimental|RDC-0313, 50 mg|50 mg RDC-0313; single dose
89194880|NCT00800319|Experimental|RDC-0313, 75 mg|75 mg RDC-0313; single dose
89194881|NCT00800319|Placebo Comparator|Placebo|volume-match placebo; single dose
89194882|NCT00699972|Experimental|1|
89194883|NCT00699972|Experimental|2|
89194884|NCT00699972|Placebo Comparator|3|
89194885|NCT00800475|Active Comparator|Test Drug|
89194886|NCT00800475|Active Comparator|Reference Drug|
89536039|NCT05459909|Experimental|Dietary intervention|Dietary intervention
88902188|NCT05508854|Experimental|Experimental (counselling) group|Experimental (counseling) group Prenatal genetic counseling is a consultancy service that covers the evaluation of the risk status of the baby in the mother's womb for diseases, the tests that can be done for the diagnosis of the disease, test results and presentation.A data collection form will be applied to all pregnant women between the ages of 18-49 who applied to the medical genetics polyclinic between September and November 2022 and wished to participate in the study. Prenatal genetic counseling will then be given. When it comes to obtaining genetic results, an individual interview will be made with the pregnant woman and the data collection form will be applied again. In the study, routine clinical information will be given to the pregnant women in the control group by the physician. Before the clinical information and when they come to get genetic results, the data collection form will be applied again by making an individual interview with the pregnant woman.
89530831|NCT02510495|Experimental|"60 group"|After a small sphincterotomy was performed, a controlled radial expansion (CRE) balloon (diameter 8, 9, 10, 11, 12, 13.5, 15; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast in 15 seconds. When the waist disappeared, the balloon was inflated till 60 seconds prior deflated. The stones were then retrieved by a basket or retrieval balloon. Mechanical lithotripsy was used if necessary.
88902189|NCT05508854|No Intervention|Control group|In the study, routine clinical information will be given to the pregnant women in the control group by the physician. Before the clinical information and when they come to get genetic results, the data collection form will be applied again by making an individual interview with the pregnant woman.
88902190|NCT05498883|Other|patient requiring NIV|Clinical examination, completion of the ALS-FRS score, completion of the SRI score.
88902191|NCT05494593|Experimental|ITR + ELAPRASE|"Participants will receive prophylactic ITR which consist of rituximab, methotrexate and IVIG in a 5-week cycle. Following the completion of 1 cycle and at the Month 6, 12, and 18 study visits, an assessment will be made regarding the need for administering another 5-week cycle of the ITR depending on the trend of the participants anti-idursulfase antibody titers and lymphocyte quantitation and CD19 percent (%) recovery.~Elaprase treatment (IV, weekly) will start 1 day after the initiation of the first cycle of ITR and continue for 104 weeks.~The dose of ELAPRASE will be calculated based on the participant's weight at each visit."
89536040|NCT05459909|Experimental|Synbiotic supplementation & dietary intervention|Synbiotic supplementation & dietary intervention
89536041|NCT03199807|Experimental|NRT + radiotherapy|HCC received NRT and radiotherapy
89536042|NCT03074877|Experimental|Family Check-Up (FCU)|"Families recruited in Year 1 who are randomized to the FCU group will be provided with the Family Check-Up (FCU) after the initial in-home assessment and after 1 year follow-up assessment. The FCU is a brief (i.e., typically 3-5 sessions per year) family-centered intervention. The FCU intervention process consists of 3, and in some cases, 4 components: a) family assessment, b) a Get to Know You session, c) feedback, and d) follow-up treatment sessions."
88902194|NCT05481151|Experimental|P1101 250-350-500mcg|Pre-filled Syringe, Q2W starting at 250-350-500, SC injection
88902195|NCT05481151|Active Comparator|Ropeginterferon alfa-2b-njft|Pre-filled Syringe, Q2W starting at 100 up to 500 (50mcg increases), SC injection
88902196|NCT05473013|Active Comparator|Base BT (Skills Monitoring Off + No Micro-Interventions)|16 weekly sessions of standard behavioral therapy for eating disorders aimed at changing behaviors that maintain binge eating (e.g. rigid dietary restriction outside of binge episodes, irregular or chaotic eating patterns). This will include traditional self-monitoring of participants' eating patterns, binging, and (if applicable) compensatory behaviors via a smartphone application.
89006833|NCT06177873|Experimental|intervention group|Hot water foot bath will applied to intervention group.
89006834|NCT06177873|No Intervention|control group|Patients in the control group will not have a hot water foot bath and the scales will be applied at the same hours as the patients in the experimental group.
89194887|NCT00810849|Placebo Comparator|Prednisolone|Six-week tapering course of prednisolone and those assigned to the prednisolone control arm will receive the same number of identically-coated placebo tablets.
88902197|NCT05473013|Experimental|Base BT + Skills Monitoring On + No Micro-Interventions|16 weekly sessions of standard behavioral therapy for eating disorders aimed at changing behaviors that maintain binge eating (e.g. rigid dietary restriction outside of binge episodes, irregular or chaotic eating patterns). This will include a more complex self-monitoring than the self-monitoring protocol with traditional behavioral treatment. Via a smartphone application, participants will be asked to self-monitor skill usage of the skills provided during treatment sessions on top of monitoring their eating patterns, binging, and (if applicable) compensatory behaviors.
88902198|NCT05473013|Experimental|Base BT + Skills Monitoring On + Automated Reminder Messages|16 weekly sessions of standard behavioral therapy for eating disorders aimed at changing behaviors that maintain binge eating (e.g. rigid dietary restriction outside of binge episodes, irregular or chaotic eating patterns).This will include a more complex self-monitoring than the self-monitoring protocol with traditional behavioral treatment. Via a smartphone application, participants will be asked to self-monitor skill usage of the skills provided during treatment sessions on top of monitoring their eating patterns, binging, and (if applicable) compensatory behaviors. It will also include participants receiving two randomly time automated push notifications from the application each week to remind them about skills they have learned in session to encourage skill use.
88902199|NCT05473013|Experimental|Base BT + Skills Monitoring On + JITAIs|16 weekly sessions of standard behavioral therapy for eating disorders aimed at changing behaviors that maintain binge eating (e.g. rigid dietary restriction outside of binge episodes, irregular or chaotic eating patterns). This will include a more complex self-monitoring than the self-monitoring protocol with traditional behavioral treatment. Via a smartphone application, participants will be asked to self-monitor skill usage of the skills provided during treatment sessions on top of monitoring their eating patterns, binging, and (if applicable) compensatory behaviors. It will also include participants receiving push notifications each week to remind them about skills they have learned in session to encourage skill use during app-identified moments of need (i.e., JITAIs, just-in-time adaptive interventions).
88902200|NCT05473013|Experimental|Base BT + Skills Monitoring Off + Automated Reminder Messages|16 weekly sessions of standard behavioral therapy for eating disorders aimed at changing behaviors that maintain binge eating (e.g. rigid dietary restriction outside of binge episodes, irregular or chaotic eating patterns). This will include traditional self-monitoring of participants' eating patterns, binging, and (if applicable) compensatory behaviors via a smartphone application. It will also include participants receiving two randomly time automated push notifications from the application each week to remind them about skills they have learned in session to encourage skill use.
88902201|NCT05473013|Experimental|Base BT + Skills Monitoring Off + JITAIs|16 weekly sessions of standard behavioral therapy for eating disorders aimed at changing behaviors that maintain binge eating (e.g. rigid dietary restriction outside of binge episodes, irregular or chaotic eating patterns). This will include traditional self-monitoring of participants' eating patterns, binging, and (if applicable) compensatory behaviors via a smartphone application. It will also include participants receiving push notifications each week to remind them about skills they have learned in session to encourage skill use during app-identified moments of need (i.e., JITAIs, just-in-time adaptive interventions).
88902202|NCT05470400|Experimental|Dose Escalation - Group 1|Dose Escalation will evaluate the safety, tolerability, and immunogenicity of single adjuvanted doses of the FP conjugate, Trimer 4571 or Trimer 6931 vaccines, in a dose-escalation design. Each product must be assessed as safe prior to use in Prime Boost Regimen.
88902203|NCT05470400|Experimental|Dose Escalation - Group 2|Dose Escalation will evaluate the safety, tolerability, and immunogenicity of single adjuvanted doses of the FP conjugate, Trimer 4571 or Trimer 6931 vaccines, in a dose-escalation design. Each product must be assessed as safe prior to use in Prime Boost Regimen.
88902204|NCT05470400|Experimental|Dose Escalation - Group 3|Dose Escalation will evaluate the safety, tolerability, and immunogenicity of single adjuvanted doses of the FP conjugate, Trimer 4571 or Trimer 6931 vaccines, in a dose-escalation design. Each product must be assessed as safe prior to use in Prime Boost Regimen.
88902205|NCT05470400|Experimental|Dose Escalation - Group 4|Dose Escalation will evaluate the safety, tolerability, and immunogenicity of single adjuvanted doses of the FP conjugate, Trimer 4571 or Trimer 6931 vaccines, in a dose-escalation design. Each product must be assessed as safe prior to use in Prime Boost Regimen.
89194888|NCT00810849|Placebo Comparator|Mycobacterium w|Patients enrolled in the Mycobacterium w experimental arm will receive 5 doses of 0.1 ml of the vaccine intradermally (on enrolment, at 2 weeks, 4 weeks, 6 weeks, and 3 months).
89194889|NCT00922311|Experimental|Aliskiren|
89194890|NCT00810927|Active Comparator|1|Phenylephrine (Neosynephrine®, Abbott Laboratories, North Chicago, IL, USA) dose: 1µg/(kg.min), infusion period 20 minutes
89194891|NCT00810927|Active Comparator|2|NG-monomethyl-L-arginine (L-NMMA, Clinalfa, Läufelfingen, Switzerland) dose: bolus 6mg/kg over 5 minutes followed by a continuous infusion of 60µg/(kg.min) over 15 minutes
89194892|NCT00810927|Placebo Comparator|3|Physiologic saline solution
89194893|NCT00813657|Experimental|Lifestyle counseling|
89194894|NCT00811005|Active Comparator|Acitretin-PUVA combination|"Acitretin-PUVA combination:~Acitretin monotherapy: Patients randomized to the acitretin group will receive acitretin in a dose of 1mg /kg daily two weeks prior to additional PUVA treatment.~PUVA treatment (see below) will be applied thrice weekly in addition to acitretin until (near) complete clearance or over a maximum period of 12 weeks. (Near) complete clearance is defined by improvement of the clinical baseline score (see below) by ≥90%.~PUVA treatment:~Intake of 8-methoxypsoralen in a dose of 0.6 mg/kg 1 hour before UVA irradiation or, in case of 8-methoxypsoralen intolerance, 5-methoxypsoralen in a dose of 1.2 mg/kg 2 hours before UVA irradiation."
89530832|NCT02510495|Experimental|"180 group"|After a small sphincterotomy was performed, a controlled radial expansion (CRE) balloon (diameter 8, 9, 10, 11, 12, 13.5, 15; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast in 15 seconds. When the waist disappeared, the balloon was inflated till 180 seconds prior deflated. The stones were then retrieved by a basket or retrieval balloon. Mechanical lithotripsy was used if necessary.
89006835|NCT06177847|Experimental|BIS Guided|In the group with BIS where the anesthesia protocol is opened, namely the use of anesthetic gas, the anesthetic drug will be adjusted to the BIS value range of 40-60 or BIS-guided
89006836|NCT06177847|No Intervention|BIS Blinded|The anesthesia protocol used in closed BIS is carried out like general anesthesia without using BIS.
89006837|NCT06177821|Experimental|Group A, 5 seconds|Patients with benign prostatic hyperplasia featuring a small median lobe enlargement will be allocated to the 5-second Rezum therapy group.
89006838|NCT06177821|Experimental|Group B, 9 seconds|Patients with benign prostatic hyperplasia featuring a big prominent median lobe enlargement will be allocated to the 9-second Rezum therapy group.
89006839|NCT06177808|Experimental|Wolverine cutting balloon group|Patients who received PCI with Wolverine cutting balloon to modify calcified coronary lesion
89006840|NCT06177808|Active Comparator|NC(Non-compliant) balloon group|Patients who received PCI with Non-compliant balloon to modify calcified coronary lesion
89006841|NCT06177782|Active Comparator|Tooth Modified Scan Bodies|The intraoral scanner (IOS) impression will be recorded using modified scan bodies. The IOS device will be calibrated right before the impression. The scan strategy will be consistent for all the procedures following the manufacturer guidelines.
89006842|NCT06177782|Placebo Comparator|Conventional Scan Bodies|The intraoral scanner (IOS) impression will be recorded using conventional implant scan bodies secured at the multiunit abutment level.
89006843|NCT06177769||Group I|Airway is secured with LMA classic
89006844|NCT06177769||Group II|Airway is secured with LMA proseal
89006845|NCT06177769||Group III|Airway is secured with I-gel
89006846|NCT06177756|Experimental|Intervention Arm|
89006847|NCT06177756|No Intervention|Comparator Arm|
89006848|NCT06177743||Coroflex ISAR NEO|Patients receiving percutaneous coronary intervention with Coroflex ISAR NEO stents
89006849|NCT06177730|Active Comparator|Pre-hospital ECPR Strategy|All patients will have high performance CPR at the scene throughout the resuscitation. If the patient is randomised to the Pre-hospital ECPR Strategy, this will be continued until the PACER team arrives. If return of spontaneous circulation (ROSC) has not been achieved at this point, ECPR will be implemented. The patient will be transported to The Alfred Hospital to receive ongoing care.
89530833|NCT02510495|Experimental|"300 group"|After a small sphincterotomy was performed, a controlled radial expansion (CRE) balloon (diameter 8, 9, 10, 11, 12, 13.5, 15; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast in 15 seconds. When the waist disappeared, the balloon was inflated till 300 seconds prior deflated. The stones were then retrieved by a basket or retrieval balloon. Mechanical lithotripsy was used if necessary.
89006850|NCT06177730|No Intervention|Conventional Cardiac Arrest Strategy|All patients will have high performance CPR at the scene throughout the resuscitation. If the patient has been randomised to the Conventional Cardiac Arrest Strategy and ROSC has not occurred after >20 minutes, ongoing resuscitation will occur and the patient may be transported via AV to the nearest emergency cardiac catheterisation capable hospital where conventional resuscitation care will continue and Hospital based ECPR may be implemented if the patient meets local eligibility criteria. This is in line with current practice.
89006851|NCT06177691||Cohort A|Participants with body weight ≥30 kg (Cohort A) were randomly assigned in a factorial design during the RCT to (1) HCL plus intensive diabetes management or usual care with no HCL and (2) verapamil or placebo. No interventions were administered during the observational extension.
89006852|NCT06177691||Cohort B|Participants with body weight <30 kg (Cohort B) were randomly assigned during the RCT 2:1 in a parallel group design to HCL plus intensive diabetes management or to usual care with no HCL. No interventions were administered during the observational extension.
89006853|NCT06177678|Experimental|TFC-003|Dorzolamide 20mg/Timolol 5mg/Brimonidine 2mg combination drug. Participants will be administered 1 drop of TFC-003 ophthalmic solution twice a day for 4 weeks.
89536043|NCT03074877|Experimental|Waitlist Group|Families recruited in Year 1 who are randomized to the wait-list group, and all families recruited in Year 2 will be assigned to the wait-list group. This group will receive the materials provided to all families, noted above, and the initial in-home assessment within 2 weeks of the screening to be conducted by a trained research assistant. At 1 year post-screening, the families in the wait-list group will be administered the follow-up assessment and will begin the Family Check-Up (FCU) intervention.
88902206|NCT05470400|Experimental|Dose Escalation - Group 5|Dose Escalation will evaluate the safety, tolerability, and immunogenicity of single adjuvanted doses of the FP conjugate, Trimer 4571 or Trimer 6931 vaccines, in a dose-escalation design. Each product must be assessed as safe prior to use in Prime Boost Regimen.
88902207|NCT05470400|Experimental|Prime Boost Regimen - Group 6|Prime Boost Regimen will evaluate the safety, tolerability, and immunogenicity of adjuvanted vaccines: FP conjugate prime, Trimer 4571 prime, or an FP plus Trimer 4571 prime, all followed by subsequent doses of Trimer 4571, Trimer 6931 and both Trimers combined.
88902208|NCT05470400|Experimental|Prime Boost Regimen - Group 7|Prime Boost Regimen will evaluate the safety, tolerability, and immunogenicity of adjuvanted vaccines: FP conjugate prime, Trimer 4571 prime, or an FP plus Trimer 4571 prime, all followed by subsequent doses of Trimer 4571, Trimer 6931 and both Trimers combined.
88902209|NCT05470400|Experimental|Prime Boost Regimen - Group 8|Prime Boost Regimen will evaluate the safety, tolerability, and immunogenicity of adjuvanted vaccines: FP conjugate prime, Trimer 4571 prime, or an FP plus Trimer 4571 prime, all followed by subsequent doses of Trimer 4571, Trimer 6931 and both Trimers combined.
88902210|NCT05451862|Other|166Ho-TARE treatment|Patients with unresectable HCC with a single nodule ≤ 8 cm or up to three nodules with a diameter of ≤ 5 cm (each). Those patients who fulfil the initial selection criteria will undergo a work-up procedure for further screening of 166Ho-TARE eligibility. If a patient is deemed eligible for 166Ho-TARE, the patient will be included in the study.
88902211|NCT05438836||Online adaptive radiotherapy|Daily online adaptive radiotherapy
88902212|NCT05433948||Liver cirrhosis with normal cognition|Liver cirrhosis and performs normally in all psychometric tests. n=100
88902213|NCT05433948||Liver cirrhosis with minimal hepatic encephalopathy|Liver cirrhosis and performs abnormally en 2 or more psychometric test. n=100
88820076|NCT06195475||exposure to tidal volumes greater than 8 ml/kg of predicted body weight|exposure to tidal volumes greater than 8 ml/kg of predicted body weight during the initial 48 hours of pressure support mode mechanical ventilation
88820077|NCT06195475||tidal volume equal to or less than 8 ml/kg of predicted body weight|individuals who maintain a tidal volume equal to or less than 8 ml/kg of predicted body weight
88820078|NCT06195462|Sham Comparator|Laying on of hands with healing intent (LHHI)|The non-healers volunteers will move their hands in a longitudinal direction, starting at the top of the patient's head, slowly lowering their hands along the body, 5 times and asked to send thoughts of health and healing to the participant. Then, they will place their hands on the patient's head, distance about 10 to 15 cm, during 5 minutes. Weekly sessions.
88902214|NCT05433948||Liver cirrhosis and overt hepatic encephalopathy|West Haven grade 2 or more. n=50
88902215|NCT05433948||Healthy control persons|Completely healthy persons, age, and gender-matched to cirrhosis patients. n=100
88902216|NCT05433948||Sick control persons|Persons with other chronic diseases than liver disease. n=100
88902217|NCT05433948||Pre-cirrhotic liver disease|Not yet cirrhosis. Will primarily be NAFLD patients. n=100
88902218|NCT05427578||Remitted depression|Patients in full remission of a major depressive disorder (rMDD)
88902219|NCT05427578||Healthy participants at risk|Healthy participants with increased MDD risk (having a 1st-degree relative with MDD)
88902220|NCT05427578||Healthy participants low risk|Healthy participants with low MDD risk (having no 1st-degree relatives with MDD)
88902221|NCT05423184|Active Comparator|Exercise Therapy For Lower Extremities|Participants will treated exercises with focused on lower extremities especilly knee joint and muscles. Exercise program continue for 18 sessions with 3 times a week and 6 week duration. Exercises are; straight leg raise, assisted squat, lunge. All sessions supervised by a physiotherapist with synchron tele-rehabilitation.
88902222|NCT05423184|Experimental|Exercise Therapy For Myofascial Chains|"Participants will treated exercises with focused on whole body especilly myofascial chains.~Exercise program continue for 18 sessions with 3 times a week and 6 week duration. Exercises are; straight leg raise, assisted squat, lunge with upper extremities and whole body participation. All sessions supervised by a physiotherapist with synchron tele-rehabilitation."
88902223|NCT05423184|No Intervention|Control Group|Participants will do any exercises. They will join only assessment sessions.
88902224|NCT05415397|Experimental|Celecoxib|Celecoxib 400 mg/day, 2 capsules (200 mg) daily, 12 weeks
88902225|NCT05415397|Placebo Comparator|Placebo|Placebo, 2 capsules daily, 12 weeks
88902226|NCT05414201|Experimental|Adalimumab|Participants will receive a loading dose of Adalimumab 80mg SC at Baseline followed a week later by a dose of Adalimumab 40mg SC every other week.
88902227|NCT05413733|Experimental|Digital care pathway|Intervention group goes through a web-based neuropsychological intervention program. The program includes eight structured sessions regarding general neuropsychological symptoms after ABI - problems with fatigue, attention, executive functions and memory. A new session opens after the previous one is completed, and after a minimum of 3 days between the sessions. The intervention takes approximately 2 months depending on the progression pace of a patient. The eight sessions consist of psychoeducation, self-assessments, cognitive strategy training and feedback (automatic or given by a monitoring neuropsychologist). A neuropsychologist from HUS monitors patients' progression and provides personal feedback when needed. Participants can also be in contact with a monitoring neuropsychologist via message feature of the program.
88902228|NCT05413733|Active Comparator|Care as usual|Control group attends the standard care of patients with ABI in HUS including all necessary outpatient rehabilitation visits. When available, neuropsychological rehabilitation typically takes 1-2 months among the study target group.
88902229|NCT05410288|Experimental|Acu-TENS+SHP|Participants in the Acu-TENS group will receive Acu-TENS coupled with a sleep hygiene program (SHP). 4 weeks and comprise thrice-weekly 30-min sessions.
88902230|NCT05410288|Experimental|acupressure+SHP|The acupressure group will receive acupressure and SHP. 4 weeks and comprise thrice-weekly 30-min sessions.
88902231|NCT05410288|Placebo Comparator|placebo stimulation+SHP|The placebo group will receive a placebo stimulation and SHP. 4 weeks and comprise thrice-weekly 30-min sessions.
88902232|NCT05397665|Active Comparator|AT-007|AT-007 is an Aldose reductase inhibitor
88902233|NCT05397665|Sham Comparator|Placebo|Is an non-active control
88902234|NCT05386810|Experimental|Safety group in adults|24 adults will receive one dose of 5-person sIPV vaccine to evaluate the safety of msIPV vaccine.
88902235|NCT05386810|Experimental|Safety group in children|24 children will receive one dose of 5-person sIPV vaccine to evaluate the safety of msIPV vaccine.
88902236|NCT05386810|Experimental|Safety group in infants|24 infants will receive 4 doses of vaccine according to the primary immunization schedule of 0,1,2 months and booster immunization schedule of 18 months to evaluate the safety of msIPV vaccine .
88902237|NCT05386810|Experimental|Experimental Vaccine-lot 1|300 infants will receive 4 doses of 5-person sIPV vaccine of commercial scale lot 1 according to the primary immunization schedule of 0,1,2 months and booster immunization schedule of 18 months.
88902238|NCT05386810|Experimental|Experimental Vaccine-lot 2|300 infants will receive 4 doses of 5-person sIPV vaccine of commercial scale lot 2 according to the primary immunization schedule of 0,1,2 months and booster immunization schedule of 18 months.
88902239|NCT05386810|Experimental|Experimental Vaccine-lot 3|300 infants will receive 4 doses of 5-person sIPV vaccine of commercial scale lot 3 according to the primary immunization schedule of 0,1,2 months and booster immunization schedule of 18 months.
88902240|NCT05386810|Active Comparator|IPV control group|300 infants will receive 4 doses of IPV vaccine produced by Pasteur according to the primary immunization schedule of 0,1,2 months and booster immunization schedule of 18 months.
88902241|NCT05386810|Active Comparator|single-person sIPV control group|300 infants will receive 4 doses of single-dose sIPV vaccine produced by Pasteur according to the primary immunization schedule of 0,1,2 months and booster immunization schedule of 18 months.
88902242|NCT05376345|Experimental|LCAR-BCDR cells product|Each subject will receive LCAR-BCDR cells
88902243|NCT05368090|Experimental|EUS-RFA of left adrenal gland treatment group|PA patients with AVS-confirmed lateralisation to the left adrenal and consent for EUS-RFA, will have a first EUS performed. If EUS identifies an adrenal nodule in the left adrenal, an EUS-guided fine needle tissue sampling will be performed of the adenoma/nodule and of adjacent non-adenoma adrenal tissue. If the tissue sampling confirms benign aldosterone-producing cells in the adenoma, a subsequent EUS-RFA treatment procedure will be performed.
89006854|NCT06177678|Active Comparator|COSOPT ophthalmic solution|Dorzolamide 20mg/Timolol 5mg combination drug. Participants will be administered 1 drop of TFC-003 ophthalmic solution twice a day for 4 weeks.
89530834|NCT03235843|Active Comparator|Rate Adaptive Pacing ON|AAIR pacing using a MV sensor
89530835|NCT03235843|Placebo Comparator|Rate Adaptive Pacing OFF|DDI-pacing
89530836|NCT04486183|Experimental|Intervention|The data were collected by the researcher at the waiting room of the blood collection unit at a close distance to the lavatory. The capillary first and second blood drop values taken from the patients after fasting and at two hours following OGTT and capillary and venous blood glucose values were compared.
89421856|NCT05522023|Placebo Comparator|Placebo group (group treated with drinking water)|"Patients included in this group as a result of randomization will have to sign an informed consent form and fill out a personal information form.~Hour 0: The patients will be completely awakened from the anesthesia resting unit, their vital signs will be stable, they will be transferred to the clinic where they sleep normally with a 15 glaskow scale, the bed head will be elevated 45 degrees and the risk of aspiration will be ruled out. Nausea and vomiting will be evaluated with a verbal descriptive scale. After the data are collected, drinking water will be applied to the oral cavity and throat in the form of a spray 4 times. After the drinking water application is finished, the patients' sore throat, thirst and nausea and vomiting will be re-evaluated with the same forms.~2., 4., 6. The same procedures will be repeated in the 8th and 8th hours."
89421857|NCT05522023|No Intervention|Control Group|"Patients in the control group were planned to be followed according to their clinical procedures. Since there were no procedures or interventions in the clinical procedures, it was decided to follow up only the patient, and the control group patients to be followed up at the same times with the same forms.~Patients included in this group as a result of randomization will have to sign an informed consent form and fill out a personal information form. Hour 0: Patients will be transferred from the recovery unit to the clinic. After controlling the vital signs of the patient, sore throat and thirst with VAS and nausea and vomiting with a verbal descriptive scale will be evaluated. 2., 4., 6. The same procedures will be repeated in the 8th and 8th hours."
89421858|NCT05519579|Experimental|Intrathecal chemotherapy before blinatumomab|
89421859|NCT05491967||Continuous Positive Airway Pressure (CPAP)|Obstructive Sleep Apnea/Hypopnea Syndrome treated with Continuous Positive Airway Pressure (CPAP
89421860|NCT05491967||Mandibular Advancement Orthosis|Obstructive Sleep Apnea/Hypopnea Syndrome treated with Mandibular Advancement Orthosis
89421861|NCT05485142|Experimental|overactive bladder|Overactive bladder
89421862|NCT05485142|Experimental|Underactive bladder|Underactive bladder
89421863|NCT05470608|Experimental|SL-1002|SL-1002 injectable solution, single dose
89421864|NCT05470608|Placebo Comparator|Matching placebo|Matching placebo injectable solution
89421865|NCT05470517|Active Comparator|Standard of Care (Arm A)|Intra-operative aspiration of intra-peritoneal fluid after successful appendectomy.
88902244|NCT05368090|Active Comparator|Adrenalectomy control group|Patients with AVS lateralisation to the left adrenal gland with EUS performed but no visible tumour found by EUS or EUS-guided tissue sampling not showing benign aldosterone-producing cells, therefore not suitable for RFA treatment, will be treated with conventional unilateral left adrenalectomy and will be included in an adrenalectomy control group. Patients with AVS lateralisation to the left adrenal but not consenting to EUS, and patients with AVS lateralisation to the right adrenal, will all likewise be treated with conventional unilateral adrenalectomy, and included in the adrenalectomy control group
89421866|NCT05470517|Experimental|Standard of Care and Antibiotic instillation (Arm B)|Intra-operative aspiration of intra-peritoneal fluid after successful appendectomy and subsequent instillation of 10ml of intra-peritoneal ceftriaxone (2g)
88902245|NCT05364788||All participants|Appendiceal Cancer Patients
88902246|NCT05345951|Experimental|e-PBI+|The e-PBI+ is an electronic handbook developed by the PI to guide parents in discussing drinking, behaviors, and consequences with their teens, with additional content on cannabis use.
89194895|NCT00811005|Experimental|Fumaric acid ester -PUVA combination|"FAE monotherapy:~Patients randomized to this group will receive FAE in weekly incremental doses (initial daily dose: 30 mg dimethylfumarate (DMF), highest daily dose: 720 mg DMF) starting two weeks prior to additional PUVA treatment.~FAE-PUVA combination:~PUVA treatment will be applied thrice weekly in addition to FAE until (near) complete clearance or over a maximum period of 12 weeks. (Near) complete clearance is defined by improvement of the clinical baseline score (see below) by ≥90%.~PUVA treatment:~Intake of 8-methoxypsoralen in a dose of 0.6 mg/kg 1 hour before UVA irradiation or, in case of 8-methoxypsoralen intolerance, 5-methoxypsoralen in a dose of 1.2 mg/kg 2 hours before UVA irradiation."
88902247|NCT05345951|Experimental|e-PBI|the e-PBI is an electronic handbook developed by the PI to guide parents in discussing drinking, behaviors, and consequences with their teens.
88902248|NCT05345951|No Intervention|e-AC|The e-AC is the attention matched control. They will receive general university-related materials to read, sections on parent and family resources (e.g., message from administrators, getting involved, academic calendar), advising, money matters, financial aid, campus life (arts, entertainment, housing, etc.), health and safety (health, counseling services, alcohol and drug laws). It is equivalent to the e-PBI+ and e-PBI on length of content and time to read. This group will not receive an intervention.
88902249|NCT05328440|Experimental|Arm A|HR-positive/HER2-positive MBC
88902250|NCT05328440|Experimental|Arm B|HR-negative/HER2-positive MBC
89194896|NCT00813735|Experimental|Eszopiclone|Drug: Eszopiclone 2mg, Drug: Escitalopram 10mg or 20mg
89421867|NCT05465122||Carotid Stenting Group (CAS)|Subjects assigned to the intensive medical management with carotid stenting group in the CREST-2 study (NCT02089217)
89421868|NCT05465122||Carotid Endarterectomy Group (CEA)|Subjects assigned to the intensive medical management with carotid endarterectomy group in the CREST-2 study (NCT02089217)
89421869|NCT05465122||Intensive Medical Management Group - no CAS|Subjects assigned to the intensive medical management alone with no carotid stenting (CAS) group in the CREST-2 study (NCT02089217)
89421870|NCT05465122||Intensive Medical Management Group - no CEA|Subjects assigned to the intensive medical management alone with no carotid endarterectomy (CEA) group in the CREST-2 study (NCT02089217)
89421871|NCT05460494|No Intervention|Usual Care|Usual care for AD/ADRD care partners consists of a screen for stress and burden, an evaluation of needs for resources to support the patients, and a referral to AD/ADRD support agencies.
89530837|NCT02510183|Active Comparator|Acupressure Wrist Band|Patient receive preoperative education a day before surgery, education for acupressure application on the day of surgery, an acupressure wrist band is applied on P6 acupoint in both wrist an hour before surgery
89530838|NCT02510183|Placebo Comparator|Placebo Wrist Band|Patient receive preoperative education a day before surgery, an placebo acupressure wrist band is applied in both wrist an hour before surgery
89530839|NCT02510183|No Intervention|Control Grup Without Band|Patient receive preoperative education a day before surgery, and patient are only visited an hour before surgery
89421872|NCT05460494|Experimental|Intervention Arm 1|MCP videos alone. Care partners randomized to intervention arm 1 during Step 2 randomization will receive usual care + RELOAD-C, consisting of: 1) 6 brief (~5 minute) videos of Dr. Allison Applebaum introducing concepts from MCP for care partners of persons with AD/ADRD; and 2) written content associated with the videos, such as directions for homework assignments. The tab with links to the virtual group meetings will be removed. Participants in this arm use RELOAD-C on their own and do not have interaction with other care partners while using the platform. One video will become available for viewing each week for the first 6 weeks after step 2 randomization, and each care partner will have a unique user ID/login.
89421873|NCT05460494|Experimental|Intervention Arm 2|"MCP videos + MCP-focused virtual groups. In addition to the components that the intervention arm 1 participants receive (usual care content, 6 MCP videos, written text), the RELOAD-C platform for the intervention arm 2 participants will include links to the virtual group meetings (7 in total). The first 6 group meetings will occur weekly, during the first 6 weeks after participants are randomized in step 2. Each of the first 6 group meetings will facilitate discussion of the MCP concepts introduced in that week's video, as participants receive access to each video ~3 days prior to the group meeting. The 7th virtual meeting will be used as a booster in week 9 after step 2 randomization, and will focus on sharing how participants are using the MCP concepts in their daily lives. All meetings will be facilitated by our social worker, Katherine Henthorne, LCSW."
89421874|NCT05449119||Non small eaters|Elderly subjects who are not malnourished
89421875|NCT05449119||Small eaters|Elderly subjects with loss of appetite
89421876|NCT05448144||Alcohol-associated liver disease|drinking, had fatty liver, hepatitis, or hepatic cirrhosis
89421877|NCT05448144||Purely drinking|drinking, but had no fatty liver and hepatitis.
89194897|NCT00813735|Placebo Comparator|Placebo|Drug: Placebo, Drug: Escitalopram 10mg or 20mg
89421878|NCT05448144||Healthy control|no drinking and no liver diseases.
89421879|NCT05428566|Experimental|Pulse-based diet|"The pulse diet will include two pulse-based meals; each pulse meal will be consisted of about one cup of non-oil seed pulses, different varieties of pulses (dried beans, peas, lentils, lupine, and chickpeas) will be used. Varieties of pulses will be included and the participants will be provided with recipes and preparation ideas, which would enhance the palatability of pulses, give different taste choices, and ease the follow of the prescribed diet and encourage the participants to consume it for the target duration.~The diet is isocaloric and balanced with a fixed macronutrient composition of 28% fat, 55% carbohydrate, and 17% protein."
89421880|NCT05428566|Placebo Comparator|TLC diet|"TLC group will be provided with instructions to follow the TLC guidelines and a sample diet plan will be individualized for each participant. The healthy TLC diet will be tailored for each participant according to their energy levels in order to achieve the following amount of nutrients: less than 7% of total calories of saturated fatty acids, up to 10% of total calories of polyunsaturated fat, up to 20% of total calories of monounsaturated fat, less than 200 mg a day of cholesterol, at least 5 to 10 grams a day of soluble fiber.~The diet is isocaloric and balanced with a fixed macronutrient composition of 28% fat, 55% carbohydrate, and 17% protein."
89530840|NCT03235609|Active Comparator|Fentanyl|Group I (FP): will receive 0.5 µg/ kg fentanyl + 2 mg/ kg propofol IV.
89530841|NCT03235609|Active Comparator|Ketamine|Group II (KP): will receive 0.5 mg/kg ketamine + 2 mg/kg propofol IV.
89530842|NCT02509871|Other|Body composition measurement|DXA, impedance
89530843|NCT02510105|Experimental|ARDS patients|
88902251|NCT05304858||TME Analysis|Participants who have been diagnosed with metastatic castration-resistant prostate cancer (mCRPC) will volunteer for a biopsy of a site in the body that contains prostate cancer, such as a bone, a lymph node or an organ such as the liver OR are planned to undergo standard of care surgical procedures such as orthopedic surgery or neurosurgery based on a subjects clinical needs.
88902252|NCT05296577|Experimental|anlotinib and vinorelbine|anlotinib combined with vinorelbine
88902253|NCT05296577|Placebo Comparator|vinorelbine|placebo and vinorelbine
88902254|NCT05296564|Experimental|HBI 0201-ESO TCRT (Anti-NY-ESO-1 TCR-transduced peripheral blood lymphocytes)|"This is a two-part, non-randomized, open label, single-site Phase I/II study. The first Part A is a dose ranging maximum tolerated dose (MTD) study and Part B is an extension phase to evaluate safety at the selected safe dose. A Data Safety Monitoring Board (DSMB) will determine the safe dose for testing in the expansion phase (Part B).~Part A will be according to a 3+3 dose escalation design. A total of up to 20 patients will participate in this Part.~Part B will be an expansion phase. The objective will be to determine if the treatment regimen is associated with a clinical response rate that can rule out 5% (p0=0.05) in favor of a modest 20% Partial Response (PR) + Complete Response (CR) rate (p1=0.20).~A total of up to 43 patients may be enrolled in Part B (41 +2, allowing for up to 2 non-evaluable patients)."
88902255|NCT05290025|Experimental|Intervention|Patients will be offered brief weekly behavioural interventions for smoking cessation and prescription-free nicotine replacement products in addidition standard opioid replacement therapy.
89194898|NCT00811083|Active Comparator|DMSA- 1 round|Subjects receive 1 round of DMSA (10 mg/kg-dose, 9 doses over 3 days), followed by 3 months of placebo
89194899|NCT00811083|Active Comparator|DMSA-7 rounds|Participants receive 7 rounds of DMSA over 4 months; each round consists of 3 days of DMSA (10 mg/kg-dose, 9 doses over 3 days), followed by 11 days off (no treatment), and then repeating.
89194900|NCT00642759|Experimental|Chemotherapy|Carboplatin, nab-paclitaxel, and bevacizumab
89194901|NCT00813891|Active Comparator|Pre-PDT|Participants in this group will receive an intraocular Ranibizumab injection one week prior to the first PDT with verteporfin.
89194902|NCT00813891|Active Comparator|Post-PDT|Participants in this group will receive an intraocular Ranibizumab injection one week post the first PDT with verteporfin.
89194903|NCT00813891|Active Comparator|No PDT|Participants in this group will receive an intraocular Ranibizumab injection with no accompanying PDT with verteporfin.
89194904|NCT00817557|Active Comparator|Loteprednol|Loteprednol BID
89194905|NCT00817557|Placebo Comparator|Rewetter|Rewetter BID
89194906|NCT00811161|Experimental|needle free injector of HA|
89194907|NCT00611026|Active Comparator|1|
89194908|NCT00611026|Placebo Comparator|2|
89194909|NCT00611026|Experimental|3|
89194910|NCT00813969|Experimental|Autologous MSC transplantation|
89194911|NCT02552589|Experimental|Test group|Amine fluoride toothpaste
89194912|NCT02552589|Placebo Comparator|Control group|Placebo Sodium monofluorophosphate toothpaste
89194913|NCT00811239|Other|control group|As the antivenom was not yet clinically available until 2006, all patients included during the first two years (2004-2005) received supportive therapy only.
89194914|NCT00811239|Active Comparator|antivenom group|The patients included during the third year (2006) were treated with antivenom therapy and supportive care.
89194915|NCT00646113|Experimental|OsseoSpeed™ TX 3.0S (Dental implant)|OsseoSpeed™ TX 3.0S, Dental implants, 3.0 mm diameter, in lengths of 11, 13 and 15 mm
89194916|NCT00814125|Active Comparator|1|Arimidex 1mg + Nolvadex placebo
89194917|NCT00814125|Active Comparator|2|Arimidex placebo + Nolvadex 20mg
89194918|NCT00814125|Active Comparator|3|Arimidex 1mg + Nolvadex 20mg
89194919|NCT04016883|Sham Comparator|Conventional web platform|Participants asked to review the web platform for 4 weeks.
89194920|NCT04016883|Experimental|Problem Solving Therapy offered through a web platform|4 sessions with cognitive behavioral therapy, offered through a web platform. Each session will be offered per week.
89194921|NCT00817713|Active Comparator|anthelminthic treatment|Albendazol plus fix-dose Praziquantel plus Ivermectin
89194922|NCT00817713|No Intervention|HIV care, no anthelminthic treatment|HIV care as per Tanzanian National AIDS Control Program (NACP) guidelines
89194923|NCT00814203||Chronic obstructive lung disease|those with a condition
89194924|NCT00422383|Experimental|1|
89194925|NCT00422383|Experimental|2|
89194926|NCT00422383|Experimental|3|
89194927|NCT00814281|Placebo Comparator|1|Subject will exercise in high levels of ultrafine and fine particulate air pollution 1 hour after ingesting a placebo.
89194928|NCT00814281|Placebo Comparator|2|Subject will exercise in low levels of ultrafine and fine particulate air pollution 1 hour after ingesting a placebo.
89194929|NCT00814281|Experimental|3|Subject will exercise in high levels of ultrafine and fine particulate air pollution 1 hour after ingesting Montelukast 10 mg orally.
88902256|NCT05290025|Other|Intitial screening only|Participants will receive standard opioid replacement therapy. At the start of the intervention number of cigarettes smoked during the past week will be recorded. Smokers will be adviced to make a cessation or reduction attempt. Advice that nicotine replacement products ( patches, lozenges or gum) may be bought over the counter in grocery-stores and pharmacies and information about goverment home-pages giving cessation advice.
89536044|NCT03074877|No Intervention|Control Group|These families will be recruited in Year 3 of the study. These families will be provided the materials noted above and will receive the in-home assessments conducted by a trained research assistant. The initial in-home assessments will be conducted within 2 weeks of the screening, and follow-up assessments conducted 1 year post-screening.
88902257|NCT05274321|Active Comparator|Pediatric Participant's Eyes Using Standard Pupilary Dilation|Consenting pediatric participants will undergo standard pupillary dilation in one eye.
89536045|NCT02479529|Experimental|administration of norepinephrine by dynamic elastance|The norepinephrine weaning strategy is based on an index that reflects the vasomotor tone: dynamic arterial elastance
88902258|NCT05274321|Experimental|Pediatric Participant's Eyes using Nanodropper attachment|Consenting pediatric participants will undergo pupillary dilation in the second eye using the Nanodropper attachment.
88902259|NCT05259475|Other|Lifestyle advice alone|"The participants in Lifestyle advice alone arm (study control) will receive 1 session of diet advice from the study dietitian at the start of the study only. The dietitian will provide dietary advice on the eating plans and instructions for completion of diet checklist. The lifestyle advice on maintaining a healthy diet and regular exercise (~180 mins/ week) will be compatible with recommendations by the Health Promotion Board (Singapore)."
88902260|NCT05259475|Experimental|Diet Intervention|Participants will be supplied with 2 main meals per day as part of their daily diet, for 6 days a week. This diet is prescribed as a moderate energy restriction (500-1000 kcal/day) to facilitate weight loss. Additional food products are supplied for breakfast and snacks. Participants will receive individual diet consultations with the study dietitian during the study. Participants are told to consume only low-fat dairy products (milk, yoghurt), and avoid ruminant meat (beef, lamb), cheese, butter, butter-containing food products, and sugar-sweetened beverages.
88902261|NCT05259475|Experimental|OCFA Meal-Based Diet-Intervention|"Participants in the OCFA meal-based diet-intervention arm will be provided with OCFA-containing food product, in addition to the lunch and dinner meals (6 days a week) given in the Diet Intervention arm. Participants will receive individual diet consultations with the study dietitian during the study. Participants are told to consume only low-fat dairy products (milk, yoghurt), and avoid ruminant meat (beef, lamb), cheese, butter, butter-containing food products, and sugar-sweetened beverages."
88902262|NCT05255835|Active Comparator|Semiconductor knee-sleeves|Knee-sleeves containing semiconductor elements within the fabric constitute the intervention arm.
88902263|NCT05255835|Placebo Comparator|Placebo knee-sleeves|Cotton knee-sleeves constitute the placebo arm.
89194930|NCT00814281|Experimental|4|Subject will exercise in low levels of ultrafine and fine particulate air pollution 1 hour after ingesting Montelukast 10 mg orally.
89194931|NCT00817791|Experimental|HBO|
89194932|NCT02542540|Experimental|OI Children training with Nintendo Wii console|Training for 3 months using the Nintendo Wii console on physical capacity in a group of children with Osteogenesis Imperfecta
89194933|NCT02542540|No Intervention|Children with OI without training|No training
89194934|NCT00811629||control group|
89194935|NCT00814359|Experimental|Magic Mouthwash Plus Sucralfate|
89194936|NCT00814359|Active Comparator|Benzydamine HCl|
89194937|NCT00814437||Donors|Oocyte donor
89194938|NCT00811707||1: volunteers|non-pregnant female
88902264|NCT05252429|Experimental|Docetaxel plus pembrolizumab|Docetaxel 75mg/m2 plus pembrolizumab 200mg will be administered every 3 weeks intravenously for 6 cycles. Thereafter pembrolizumab 200mg every 3 weeks will be given as maintenance therapy until progression or up to 35 cycles.
88902265|NCT05249309||Treatment|The administration will be done subcutaneously, in the abdominal wall, using ketamine without dilution. The ketamine dose will be 0.5mg/kg, recommended for the first infusion. If there is no adequate response, according to psychiatric scales and clinical evaluation, the second infusion must be performed at least two days after the first, using 0.75mg/kg and the subsequent 1mg/kg. If the patient adequately responds to a dose (0.5 or 0.75mg/kg), it should be repeated after over twice weekly over a period of 4 weeks.
88902266|NCT05249309||Control|Will be checked weight, height and waist circumference and collected about 15 mL of peripheral blood.
88902267|NCT05224271||Observational (surveys, medical records & Fitbit collection)|Patients complete surveys via the Hugo Platform at baseline (before treatment), after treatment, and at 3 and 6 months after treatment. Patients' medical records and Fitbit information are also collected into the Hugo Platform.
88902268|NCT05220202|No Intervention|Waitlist Control Group|The waitlist control group will continue with usual care management of musculoskeletal pain and depression. All participants, regardless of what group they have been assigned to will undergo several outcome assessments (pre-screening, baseline, midpoint, final assessments) conducted by a blinded research assistant. Subjects randomized to the waitlist control group will be offered the intervention once they have completed the end outcomes assessment.
88902269|NCT05220202|Experimental|Behavior Intervention Group (MOTIVATE)|For participants assigned to the intervention arm, trained health coaches will deliver the 8 session intervention via telephone. MOTIVATE users motivational interviewing techniques, values elicitation and physical activity based goal setting. All participants, regardless of what group they have been assigned to will undergo several outcome assessments (pre-screening, baseline, midpoint, final assessments) conducted by a blinded research assistant.
88902270|NCT05217381||Cohort 1|Patients with an initial diagnostic of early breast cancer or locally advanced breast cancer or de novo metastatic breast cancer
88902271|NCT05199480|Experimental|E-cigarette liquid type 1|Participants will be instructed to use at least one study product daily in place of their own e-cigarettes during the intervention period.
88902272|NCT05199480|Active Comparator|E-cigarettes liquid type 2|Participants will be instructed to use at least one study product daily in place of their own e-cigarettes during the intervention period.
88902273|NCT05199480|No Intervention|No e-cigarettes|No e-cigarette use
88902274|NCT05198336|Experimental|Experimental Group of children aged 3-5 years old|200 subjects aged 3-5 years old who have received two doses of inactivated COVID-19 vaccine(CoronaVac) manufactured by Sinovac Research & Development Co., Ltd and is currently 28-42 days after the second dose
88902275|NCT05198336|Experimental|Experimental Group of children aged 6-11 years old|200 subjects aged 6-11 years old who have received two doses of inactivated COVID-19 vaccine(CoronaVac) manufactured by Sinovac Research & Development Co., Ltd and is currently 28-42 days after the second dose
88902276|NCT05193019||Patients undergoing PCI|
88902277|NCT05186337|Experimental|Experimental|Functional Remediation for Older-Age Patients With Bipolar Disorder (FROA-BD)
88902278|NCT05186337|No Intervention|Control|The control group (42 patients) will not receive any type of add-on psychotherapy.
88902279|NCT05176964||HFRT with concurrent chemotherapy and immunotherapy|CAPOX chemotherapy plus tislelizumab treatment plus split-course HFRT
88902280|NCT05174702||Percutaneous surgery|Patient will have a percutaneous hallus valgus surgery
88902281|NCT05174702||conventional surgery|Patient will have a conventional hallus valgus surgery
88902282|NCT05150028|Experimental|Intervention - Pediatric parent/caregiver|Questionnaires along with educational videos
88902283|NCT05150028|Experimental|Clinicians|Will complete pre and post survey about medication education practices
88902284|NCT05149040||very elderly outpatients|outpatients (eyes, ear-nose-and throat, orthopaedic outpatient clinics at Haukeland University Hospital, Bergen, Norway) aged 80 years and older
88902285|NCT05149040||proxy|next of kin who likely would act as a proxy in a medical emergency, identified by the very elderly respondent
88902286|NCT05116644||Included patients|Included patients: 165
88902287|NCT05090111|Experimental|ALG-055009|Oral dose(s) of ALG-055009 in Healthy Volunteer or subjects with mild hyperlipidemia once daily up to 14 days
88902288|NCT05090111|Placebo Comparator|Placebo|Oral dose(s) of placebo in Healthy Volunteer or subjects with mild hyperlipidemia once daily up to 14 days
88902289|NCT05077098|Experimental|ADXS-504 Monotherapy Dose Escalation|Subjects with Biochemically Recurrent Prostate Cancer will receive ADXS-504 with dose escalation schema.
88902290|NCT05063916|Experimental|AK104|cadonilimab) can help to control neuroendocrine cervical cancer that is recurrent (has come back after treatment) or metastatic (has spread).
88902291|NCT05034458|Experimental|Diet|Patients will do biologic treatment according to international guidelines and will do Crohns Disease Exclusion Diet( modulen- phase one ant two CDED) for 12 weeks.They will be monitored periodically by interview and physical examination by physician and nutritionist, laboratory, fecal calprotectin.
88902292|NCT05034458|No Intervention|Control|Patients with normal treatment( biologic treatment indicated for CD)
88902293|NCT05017025|Experimental|Treatment (osimertinib, aurora A kinase inhibitor LY3295668)|Patients receive osimertinib PO QD and aurora A kinase inhibitor LY3295668 PO BID on days 1-28. Treatment repeats every 28 days for 24 cycles (2 years) in the absence of disease progression or unacceptable toxicity.
88902294|NCT05003739|Experimental|Logica Mirror|Since the trial is not comparative, the only arm implies the use of the investigational device (Logica Mirror femoral stem)
88902295|NCT04992208|Experimental|Experimental Group|All of the participants(N=33000) will receive two doses inactivated SARS-CoV-2 vaccine . Vaccine will given by intramuscular injection on day 0 and day 28.
88902296|NCT04987320|Experimental|Olpasiran Dose A|Participants will be administered Olpasiran dose A as a subcutaneous injection.
88902297|NCT04987320|Experimental|Olpasiran Dose B|Participants will be administered Olpasiran dose B as a subcutaneous injection.
88902298|NCT04979728||Oral Antivirals|Arm 1: People continuing oral (PO) antivirals for HIV treatment or prevention
88902299|NCT04979728||Q8W CAB±RPV Continuation|Arm 2: People continuing Q8W injections of CAB±RPV for HIV treatment or prevention
89006855|NCT06177626|Active Comparator|Balance Training|A physical therapist will tailor a home balance training program for each participant based on pre- training capabilities. Participants will be asked to perform exercises five times a week for thirty-minute sessions. Both dynamic and static exercises will be performed in sitting and standing positions. Exercises will start with stabilizing in a challenging static position and progress to dynamic arm and leg movements in the same or modified position. Participants will be contacted weekly by e-mail or phone to answer any questions about the exercise protocol and will be required to log their exercise effort in terms of frequency and level of balance challenge.
89006856|NCT06177626|Experimental|Aerobic Training|Participants will be given a stationary exercise bike for home use. They will be instructed to use the exercise bike five times a week for thirty-minute sessions. The exercise intensity prescription will be based on the subject's VO2max determined on pre-test day. The exercise program will start at 60% of intensity per session, and then will be increased by steps of 5% intensity every 2 sessions until participants reach 30 minutes of training at 80% intensity. Participants will be contacted weekly by e-mail or phone to answer any questions about the exercise protocol and will be instructed to log each training session. Participants will record duration of exercise, perceived exertion, average heart rate, maximum heart rate, and distance.
89006857|NCT06177587||Assesment of platelet biomarkers in acute coronary syndromes - low level of parameters|Blood is collected within the first 24 hours from hospital admission and after 72 hours following hospital admission. The level of selected biomarkers is measured.
89006858|NCT06177587||Assesment of platelet biomarkers in acute coronary syndromes - high level of parameters|Blood is collected within the first 24 hours from hospital admission and after 72 hours following hospital admission. The level of selected biomarkers is measured.
89006859|NCT06177574|Experimental|study group|HIV-1 infected adults, ART-naive subjects, who start BIC/FTC/TAF using test and treat strategy recruited at infectious diseases units from various Spanish public healthcare centers.
89006860|NCT06177561|Experimental|LPE group|"Serum DSA positive: MFI ≥ 2000；Between the ages of 18 and 65, male and female are not limited；Planned to undergo allo-HSCT , with an estimated survival time of>3 months and an ECOG physical fitness score of 0-2；Normal renal function (BUN, Cr ≤ 1.5 times the upper limit of normal value, Ccr>80ml/min)~Normal liver function (defined as ALT and AST ≤ 1.5 times the upper limit of normal~TBiL ≤ 1.5 times the upper limit of normal)~ECG did not indicate any AMI, arrhythmia, or IAVB~No CI (defined as LVEF ≥ 50%, normal MYO and BNP)~Non active RHD~Chest X-ray or physical examination did not indicate cardiac dilatation~Normal lung function (defined as FEV1, FVC, DLCO ≥ 60% predicted value)."
89006861|NCT06177548||Minimally invasive Group|Patients who underwent minimally invasive Bentall procedure will be included. The minimally invasive Bentall procedure is performed through a small incision in the right intercostal space.
89006862|NCT06177548||Control Group|Patient who underwent Bentall procedure through median sternotomy will be included.
89006863|NCT06177522|Experimental|Adbelizumab combined with chemotherapy administration group|Adbelimumab is a humanized anti-PD-L1 monoclonal antibody independently developed by Hengrui Pharmaceutical. It can block the PD-1/PD-L1 pathway leading to tumor immune tolerance through specific binding of PD-L1 molecules, and reactivate the anti-tumor activity of the immune system, so as to achieve the purpose of tumor treatment.
89006864|NCT06177509|Experimental|Intervention group - Graded Aerobic Exercise|Participants will follow a sub-symptom aerobic exercise program (approx. 30 min) 3 - 5 times pr week for twelve weeks. Sub-symptom threshold aerobic exercise means to exercise at 80-90% of the maximum threshold heart rate achieved during the BCTT. To ensure proper exercise dose and progression, participants will be retested every three weeks. During the first three weeks, the participants will be offered one weekly guided exercise session. The other 2 - 4 weekly sessions the participants will carry out on their own, choosing activities based on experience, preferences and possibilities (e.g. walking, jogging, stationary bike, swimming). The intensity of the sub-symptom threshold aerobic exercise will be monitored using a heart rate monitor and the BORG scale. Compliance with the sub-symptom threshold aerobic exercise program will be recorded by the patients in an exercise diary, which is followed up by a weekly reminder over the phone/sms by a physiotherapist in the project.
89006865|NCT06177509|No Intervention|Control group - Outpatient multidisciplinary follow-up (Treatment as usual - TAU)|TAU includes assessment and treatment provided by a multidisciplinary outpatient rehabilitation team. Patients will undergo a medical examination and assessment of physical, cognitive, and mental health and functioning, followed by individually adapted rehabilitation program. The interdisciplinary team consists of a specialist in physical medicine and rehabilitation, (neuro)psychologist, occupational therapist, physiotherapist, and social worker. The main focus is on improving the level of function in everyday life and gradual return to work and education.
89006866|NCT06177496||Group A|HCC patients underwent local ablation
89006867|NCT06177496||Group B|HCC patients underwent TACE
89006868|NCT06177496||Group C|HCC patients received sorafenib
89006869|NCT06177470|Active Comparator|active accelerated deep TMS|Accelerated dTMS on anterior cingulate cortex and medial prefrontal cortex.
89006870|NCT06177470|Sham Comparator|sham TMS|Sham TMS on anterior cingulate cortex and medial prefrontal cortex
89006871|NCT06177444||Postoperative prophylactics|Patients receiving postoperative prophylactic antibiotic treatment
89006872|NCT06177444||non-postoperative prophylactics|Patients NOT receiving postoperative prophylactic antibiotic treatment
89006873|NCT06177366||Adults with MPN who need a bone marrow biopsy during the management of the disease|
89006874|NCT06177314||Active contact dermatitis|patient suffering from contact dermatitis and presenting active cllinical lesions. Allergic or non allergic form of contact dermatitis was diagnose based on patch-test results and exposure assessment
89194939|NCT00811707||2: parturients|parturients was scheduled to receive lumbar epidurals for elective cesaeran delivery labor analgesia
89194940|NCT00817869|Experimental|New Flooring|Will receive 8.3mm thick floor covering (Omnisports EXCEL) to replace previous floor covering.
89194941|NCT00817869|No Intervention|Standard Flooring|Ward will remain with standard floor covering. The overlay will have a comparable slip resistance rating to the new flooring. The sub-floor will also be comparable.
89194942|NCT03864861||Elective Bariatric Surgery|Patients older than 18 undergoing elective bariatric surgery
89194943|NCT00612040|Experimental|SIBA (D)|
89194944|NCT00612040|Experimental|SIBA (E)|
89194945|NCT00612040|Experimental|IGlar|
89421881|NCT05427799|Experimental|Honey|"Treatment with honey will extend for four months and the actual treatment phases will be preceded by a 2-week run-in period, in which the participants will be asked to refrain from honey consumption.~During the six months intervention, a daily dose of 0.5 g/kg body weight of honey will be consumed by each participant. Participants will be provided with Mixed flora honey that will be obtained from local producers. The daily dose of treatments will be divided into two doses to simulate a natural pattern of consumption.~All participants will be required to limit the consumption of caffeinated beverages to two beverages a day during the study periods.~A nutritionist will calculate the energy requirement and provide dietary instructions and a nutritionally adequate, hypocaloric, balanced sample diet plan with a fixed macronutrient composition of 28% fat, 55% carbohydrate, and 17% protein will be individualized for each participant monthly."
89530844|NCT02509949|Experimental|Dexmedetomidine|Dexmedetomidine ivpump 0.2ug/kg/h during living donor renal transplantation.
88902300|NCT04979728||Q8W CAB±RPV Initiation|Arm 3: People initiating Q8W injections of CAB±RPV for HIV treatment or prevention
88902301|NCT04979728||Q4W CAB±RPV Continuation/Initiation|Arm 4: People continuing or initiating Q4W injections of CAB±RPV for HIV treatment or prevention
88902302|NCT04979728||Q26W LEN Continuation/Initiation|Arm 5: People continuing or initiating Q26W injections of LEN for HIV treatment or prevention
88902303|NCT04968288||Cohort 1|Subjects with KSHV-associated MCD
88902304|NCT04966000|Experimental|Prism Adaptation Therapy|10 sessions (60 trials each) 1x/day of Prism Adaptation Therapy
88902305|NCT04941664|Other|Levobupivacaine|Superior trunk nerve block will be done under ultrasound guidance to patients scheduled for shoulder surgeries. Local anesthetic agent (0.5% levobupivacaine) 8ml will be injected at the superior trunk of the brachial plexus in order to produce surgical anesthesia or analgesia for shoulder surgeries.
88902306|NCT04918420|Experimental|Flow Diverter (Tonbridge)|Treatment with Flow Diverter (Tonbridge)
88902307|NCT04911790|Experimental|Experimental Group|Participant will receive two doses inactivated SARS-CoV-2 vaccine . Vaccine will given by intramuscular injection on day 0 and day 28.
88902308|NCT04899908|Experimental|Stereotactic Radiation plus AGuIX gadolinium-based nanoparticles|"Randomly assigned participants will receive:~AGuIX gadolinium-based nanoparticles 3-5 days before radiation is initiated~AGuIX gadolinium-based up to 2x during radiation, depending on standard of care radiation treatment.~If standard of care radiation treatment involves only one day of radiation, participant will receive AGuIX gadolinium-based nanoparticles on the day of radiation.~If standard of care radiation treatment involves 5 or 6 days of radiation, participant will receive AGuIX gadolinium-based nanoparticles two-times (2x) in total, on the first and third day of radiation."
88902309|NCT04899908|Experimental|Stereotactic Radiation plus placebo|"Randomly assigned participants will receive:~Placebo 3-5 days before radiation is initiated~Placebo up to 2x during radiation, depending on standard of care radiation treatment.~If standard of care radiation treatment involves only one day of radiation participant will receive Placebo on the day of radiation.~If standard of care radiation treatment involves 5 or 6 days of radiation participant will receive Placebo two-times (2x) in total, on the first and third day of radiation."
89530845|NCT02509949|Placebo Comparator|Saline|Saline ivpump 0.2ug/kg/h during living donor renal transplantation.
88902310|NCT04890002|Experimental|Far-infrared emitting pyjamas (FIR pyjamas) group|Subjects in this group will be provided the Far-infrared emitting pyjamas. The FIR pyjamas was fabricated by using two textile materials, pure cotton fibres and the proposed man-made FIR fibres with the far-infrared emitting function.
88902311|NCT04890002|Sham Comparator|Sham-pyjamas Group|To control the placebo effect in the FIR pyjamas group, participants in this group will receive pyjamas with identical physical appearance which are produced using the same fabrication process as the pyjamas received in FIR pyjamas group. The sham-pyjamas are made of pure cotton fibres and man-made fibres without the far-infrared emitting function. The participants will be asked to wear the sham-pyjamas daily at night for 6 consecutive weeks.
89006875|NCT06177288|Experimental|DEBIRI|After dissolving 100 mg of irinotecan in water for injection or 4 ml of 5% glucose water, use 2 mL of 70 μm uniform particle size microspheres for loading and adsorption for 5 minutes. Then mixed with non-plasma contrast agent to embolize the tumor feeding artery.
89194946|NCT00422227|Active Comparator|1|Etanercept + Methotrexate
89194947|NCT00422227|Active Comparator|2|DMARD therapy Methotrexate + Sulfasalazine/Hydroxychloroquine/Leflunomide
89194948|NCT02551497|Experimental|Other drug|Other drug BID
88902312|NCT04888858|Experimental|Epidural Analgesia|All subjects will be given epidural analgesia to treat their labor pain. As part of standard protocol for all patients who receive a labor epidural, the epidural will then be tested using 3ml of 1.5% lidocaine and 1:200,000 epinephrine test solution, and the epidural catheter will then be loaded with 10ml of 0.125% bupivacaine solution. The epidural catheter will then be connected to a programmed intermittent epidural bolus pump which will administer 5ml of a 0.125% bupivacaine/2mcg fentanyl solution every 30minutes. The first dose will be given following 30minutes after the loading dose. 30 minutes after loading the loading dose and after the first pump dose has been given, we will assess the VAS pain scores and the level of the analgesic based on decreased sensation to ice.
88902313|NCT04873687|Experimental|Intervention|The intervention arm will comprise study participants who receive intervention therapy (i.e eligible stable angina pectoris patients in intervention arm who agree to participate)
88902314|NCT04873687|No Intervention|Control|Eligible stable angina pectoris patients in the control arm will receive no intervention therapy
88902315|NCT04859842|Active Comparator|Pulse Electromagnetic Field Group|Pulse Electromagnetic Field Therapy (PEMF) will be applied to patients' low back region. Also, patients will receive a conventional therapy program consisting of hotpack, ultrasound, and transcutaneous electrical stimulation in addition to PEMF therapy.
88902316|NCT04859842|Active Comparator|Interferential Current Group|Interferential current will be applied to patients' low back pain region. Also, patients will receive a conventional therapy program consisting of hotpack, ultrasound, and transcutaneous electrical stimulation in addition to Interferential current.
88902317|NCT04859842|Sham Comparator|Sham Group|Sham electrodes will be placed on the low back region. Also, patients will receive a conventional therapy program consisting of hotpack, ultrasound, and transcutaneous electrical stimulation in addition to sham therapy.
88902318|NCT04854291|Experimental|Donor FMT|FMT from a healthy donor
88902319|NCT04854291|Placebo Comparator|Placebo|NaCl + glycerol mixture (carrier solution of FMT arm)
88902320|NCT04799964|Experimental|Flow Diverter (Tonbridge)|Treatment with Flow Diverter (Tonbridge)
88902321|NCT04799964|Active Comparator|Tubridge (MicroPort)|Treatment with Tubridge (MicroPort)
89194949|NCT02551497|Experimental|placebo|Placebo to match BID
88902322|NCT04784247|Experimental|Leiomyosarcoma|Patients enrolled in the study will be treated initially with a 2 week run-in of lenvatinib 20 mg orally daily. Subsequently, they will start pembrolizumab 200 mg intravenously every 3 weeks (21-day cycles). Treatment will continue until progression or other indications for study withdrawal Otherwise, treatment will be discontinued after a maximum of 35 cycles of pembrolizumab (approximately 2 years) or after achieving CR. RECIST v1.1 tumor assessments will be made at baseline (CT or MRI) and approximately every 3 cycles (or every 9 weeks +/- 1 week) for the first 9 cycles (27 weeks), then every 4 cycles (or every 12 weeks +/- 1week). Patients who progress after having discontinued therapy after completing 2 years of treatment or after achieving confirmed CR may be eligible to reinitiate therapy for an additional 1 year (approximately 17 cycles).
88902323|NCT04784247|Experimental|High grade undifferentiated pleomorphic sarcoma|Patients enrolled in the study will be treated initially with a 2 week run-in of lenvatinib 20 mg orally daily. Subsequently, they will start pembrolizumab 200 mg intravenously every 3 weeks (21-day cycles). Treatment will continue until progression or other indications for study withdrawal . Otherwise, treatment will be discontinued after a maximum of 35 cycles of pembrolizumab (approximately 2 years) or after achieving CR. RECIST v1.1 tumor assessments will be made at baseline (CT or MRI) and approximately every 3 cycles (or every 9 weeks +/- 1 week) for the first 9 cycles (27 weeks), then every 4 cycles (or every 12 weeks +/- 1week). Patients who progress after having discontinued therapy after completing 2 years of treatment or after achieving confirmed CR may be eligible to reinitiate therapy for an additional 1 year (approximately 17 cycles).
88902324|NCT04784247|Experimental|Vascular sarcomas (including angiosarcoma and epithelioid hemangioendothelioma)|Patients enrolled in the study will be treated initially with a 2 week run-in of lenvatinib 20 mg orally daily. Subsequently, they will start pembrolizumab 200 mg intravenously every 3 weeks (21-day cycles). Treatment will continue until progression or other indications for study withdrawal. Otherwise, treatment will be discontinued after a maximum of 35 cycles of pembrolizumab (approximately 2 years) or after achieving CR. RECIST v1.1 tumor assessments will be made at baseline (CT or MRI) and approximately every 3 cycles (or every 9 weeks +/- 1 week) for the first 9 cycles (27 weeks), then every 4 cycles (or every 12 weeks +/- 1week). Patients who progress after having discontinued therapy after completing 2 years of treatment or after achieving confirmed CR may be eligible to reinitiate therapy for an additional 1 year (approximately 17 cycles).
88902325|NCT04784247|Experimental|Other soft tissue sarcomas (including synovial sarcoma and malignant peripheral nerve sheath tumor|Patients enrolled in the study will be treated initially with a 2 week run-in of lenvatinib 20 mg orally daily. Subsequently, they will start pembrolizumab 200 mg intravenously every 3 weeks (21-day cycles). Treatment will continue until progression or other indications for study withdrawal. Otherwise, treatment will be discontinued after a maximum of 35 cycles of pembrolizumab (approximately 2 years) or after achieving CR. RECIST v1.1 tumor assessments will be made at baseline (CT or MRI) and approximately every 3 cycles (or every 9 weeks +/- 1 week) for the first 9 cycles (27 weeks), then every 4 cycles (or every 12 weeks +/- 1week). Patients who progress after having discontinued therapy after completing 2 years of treatment or after achieving confirmed CR may be eligible to reinitiate therapy for an additional 1 year (approximately 17 cycles).
89006876|NCT06177275|Experimental|Thin vertical soft tissue biotype, Placement of BLX implants 2 mm sub-crestal|In Thin vertical soft tissue biotype, Placement of BLX implants 2 mm sub-crestal in single missing anterior or premolar teeth in the esthetic zone with immediate provisionalization via a straight emergence profile temporary crown on a temporary abutment.
89006877|NCT06177275|Active Comparator|Thin vertical soft tissue biotype, Placement of BLX implants equicrestal|In Thin vertical soft tissue biotype, Placement of BLX implants equicrestal in single missing anterior or premolar teeth in the esthetic zone with immediate provisionalization via a straight emergence profile temporary crown on a temporary abutment.
89194950|NCT00814515|Active Comparator|1|Ciclosporin 0.1%
89194951|NCT00814515|Placebo Comparator|2|Vehicle
89536046|NCT02479529|Other|control administration of norepinephrine|The usual procedure of withdrawal norepinephrine is based on hemodynamic parameters (blood pressure), clinical (cutaneous perfusion, mottling, hourly diuresis) and biological (SVO2, arterial lactate).
88902326|NCT04784247|Experimental|Bone sarcomas (including osteosarcoma and chondrosarcoma)|Patients enrolled in the study will be treated initially with a 2 week run-in of lenvatinib 20 mg orally daily. Subsequently, they will start pembrolizumab 200 mg intravenously every 3 weeks (21-day cycles). Treatment will continue until progression or other indications for study withdrawal. Otherwise, treatment will be discontinued after a maximum of 35 cycles of pembrolizumab (approximately 2 years) or after achieving CR. RECIST v1.1 tumor assessments will be made at baseline (CT or MRI) and approximately every 3 cycles (or every 9 weeks +/- 1 week) for the first 9 cycles (27 weeks), then every 4 cycles (or every 12 weeks +/- 1week). Patients who progress after having discontinued therapy after completing 2 years of treatment or after achieving confirmed CR may be eligible to reinitiate therapy for an additional 1 year (approximately 17 cycles).
88902327|NCT04771650|Experimental|CAMI/CAMI booster|Culturally Adapted Motivational Interview. Participants will receive a single session, 75 minute addiction counseling discussion that focuses on the causes of addictive behavior. They will receive a CAMI booster session at 2 months and standard care in a primary care setting.
88902328|NCT04771650|No Intervention|Control|Assessment plus standard care. Participants will complete an assessment, including measures on drinking and drug use. They will also receive standard care in a primary care setting.
88902329|NCT04766073|Experimental|New Closure Technique|This group will have the uterus closed after delivery of the fetus during cesarean section with a new technique.
88902330|NCT04766073|No Intervention|Regular closure technique|The usual method of closing the surgical incision is to suture the entire wall of the uterus with a stratafix suture without locking the suture.
88902331|NCT04730570|Experimental|Essential Coaching for Every Mother Intervention|Women in the intervention arm will receive the Essential Coaching for Every Mother messages up to six-weeks postpartum. No changes in standard care.
88902332|NCT04730570|No Intervention|Standard care|Women in the control group will receive no content messages. No changes in standard care.
88902333|NCT04681287|Experimental|inetetamab and PD-1 inhibitor combined with chemotherapy.|
88902334|NCT04681131|Experimental|CAB-AXL-ADC (BA3011)|CAB-AXL-ADC (BA3011) alone
88902335|NCT04681131|Experimental|CAB-AXL-ADC (BA3011)+PD-1 inhibitor|CAB-AXL-ADC (BA3011) with PD-1 inhibitor
88902336|NCT04641741||Control|Healthy adults
88902337|NCT04641741||Severe eosinophilic asthma|Severe uncontrolled asthma according to ERS/ATS criteria and persistent eosinophilia in blood (>300 cells/μL)
88902338|NCT04626141|Experimental|Abaloparatide group|Patients in the experimental group will receive abaloparatide after their surgery.
88902339|NCT04626141|Placebo Comparator|Control group|Patients in the control group will receive a placebo after their surgery.
88902340|NCT04625959|Active Comparator|Base BT|16 weekly sessions of behavioral therapy.
88902341|NCT04625959|Experimental|Base BT + Distress Tolerance|16 weekly sessions of behavioral therapy with distress tolerance components of MABTs.
88902342|NCT04625959|Experimental|Base BT + Emotion Regulation|16 weekly sessions of behavioral therapy with emotion regulation components of MABTs.
88902343|NCT04625959|Experimental|Base BT + Mindful Awareness|16 weekly sessions of behavioral therapy with mindful awareness components of MABTs.
88902344|NCT04625959|Experimental|Base BT + Values|16 weekly sessions of behavioral therapy with values components of MABTs.
88902345|NCT04625959|Experimental|Base BT + Distress Tolerance and Emotion Modulation|16 weekly sessions of behavioral therapy with emotion regulation and distress tolerance components of MABTs.
88902346|NCT04625959|Experimental|Base BT + Distress Tolerance and Mindful Awareness|16 weekly sessions of behavioral therapy with distress tolerance and mindful awareness components of MABTs.
88902347|NCT04625959|Experimental|Base BT + Distress Tolerance and Values|16 weekly sessions of behavioral therapy with distress tolerance and values components of MABTs.
88902348|NCT04625959|Experimental|Base BT + Emotion Modulation and Mindful Awareness|16 weekly sessions of behavioral therapy with emotion regulation and mindful awareness components of MABTs.
88902349|NCT04625959|Experimental|Base BT + Mindful Awareness and Values|16 weekly sessions of behavioral therapy with values and mindful awareness components of MABTs.
88902350|NCT04625959|Experimental|Base BT + Emotion Modulation and Values|16 weekly sessions of behavioral therapy with emotion regulation and values components of MABTs.
88902351|NCT04625959|Experimental|Base BT + EM, DT, MA|16 weekly sessions of behavioral therapy with emotion regulation, mindful awareness, and distress tolerance components of MABTs.
88902352|NCT04625959|Experimental|Base BT + DT, ER, and V|16 weekly sessions of behavioral therapy with emotion regulation, distress tolerance, and values components of MABTs.
88902353|NCT04625959|Experimental|Base BT + DT, MA, and V|16 weekly sessions of behavioral therapy with distress tolerance, mindful awareness, and values components of MABTs.
88902354|NCT04625959|Experimental|Base BT + ER, MA, and V|16 weekly sessions of behavioral therapy with emotion regulation, mindful awareness, and values components of MABTs.
88902355|NCT04625959|Experimental|Base BT + ER, MA, V, DT|16 weekly sessions of behavioral therapy with emotion regulation, mindful awareness, distress tolerance, and values components of MABTs.
88902356|NCT04613440|Other|Standard of care - Proband-mediated cascade testing|Probands randomized to the standard of care group will be instructed to share a family letter (providing information on the familial mutation) with their FDRs and encourage FDRs to complete genetic testing.
88902357|NCT04613440|Other|Intervention - Facilitated cascade testing|In the intervention group, a patient navigator will provide facilitated support, including an initial genetic counseling call, an email with a link to an educational video, and, for individuals who are interested in completing testing - a link to create an account for a free saliva kit and a follow-up call to discuss the results and ensure participants are connected with their primary care provider or other clinician, as appropriate.
88902358|NCT04613440|Experimental|Exploratory Arm|Probands of Jewish heritage at WCM only who do not meet eligibility criteria for randomization to the intervention and control arms will be offered enrollment in a third arm, in which they will receive the intervention in addition to referral to a culturally sensitive support organization for additional guidance.
88902359|NCT04609852|Experimental|Cohort 1: E8001 or Placebo|Participants will receive specified dose of E8001 or placebo (isotonic sodium chloride solution), infusion, intravenously, once on Day 1.
89194952|NCT00884728||Indigenous children aged <15 years|Indigenous children aged <15 years within participating communities of the Northern Territory
88902360|NCT04609852|Experimental|Cohort 2: E8001 or Placebo|Participants will receive specified dose of E8001 or placebo (isotonic sodium chloride solution), infusion, intravenously, once on Day 1.
89421882|NCT05427799|Placebo Comparator|Other carbohydrate alternatives|"Treatment with simple sugar alternatives (other carbohydrates, such as jell-o) will extend for four months and the actual treatment phases will be preceded by a 2-week run-in period, in which the participants will be asked to refrain from honey consumption, and during the study periods.~A daily dose of 0.5 g/kg body weight of jell-O will be consumed by each participant and will be divided into two doses to simulate a natural pattern of consumption. Jell-O was selected as a source of sucrose with negligible phenolic capacity, which will serve as a control.~All participants will be required to limit the consumption of caffeinated beverages to two beverages a day during the study periods.~A nutritionist will calculate the energy requirement and provide dietary instructions and a nutritionally adequate, hypocaloric, balanced sample diet plan with a fixed macronutrient composition of 28% fat, 55% carbohydrate, and 17% protein will be individualized for each participant monthly."
88902361|NCT04609852|Experimental|Cohort 3: E8001 or Placebo|Participants will receive specified dose of E8001 or placebo (isotonic sodium chloride solution), infusion, intravenously, once on Day 1.
88902362|NCT04609852|Experimental|Cohort 4: E8001 or Placebo|Participants will receive specified dose of E8001 or placebo (isotonic sodium chloride solution), infusion, intravenously, once on Day 1.
88902363|NCT04597619|No Intervention|Pre-Implementation Cohort|Cohort undergoing PCNL prior to implementation of the novel nonopioid pathway
88902364|NCT04597619|Experimental|Implementation Cohort|Cohort undergoing PCNL with implementation of the novel nonopioid pathway
88902365|NCT04595760||EPS Study Participants|Women who participated in the 1982-1986 North Carolina Early Pregnancy Study (EPS)
88902366|NCT04593940|Active Comparator|Standard of Care + infliximab or matching placebo|infliximab (single dose IV 5mg/kg given on day 1) or matching placebo
88902367|NCT04593940|Active Comparator|Standard of Care + abatacept or matching placebo|abatacept (single dose IV 10 mg/kg up to 1,000 mg given on day 1) or matching placebo
88902368|NCT04593940|Active Comparator|Standard of Care + cenicriviroc or matching placebo (closed to enrollment as of 3-Sep-2021)|cenicriviroc [tablet, Day 1/Loading Dose: 450 mg (300mg morning and 150mg evening) Day 2 - 29/Maintenance Dose: 300 mg (150 mg BID) through Day 29]. or matching placebo
88902369|NCT04566900|Experimental|Active Treatment|Subjects will be given a choice of videos consisting of still images set to music. Whether the video progresses and music continues to play will depend on the subject's ability to maintain frontal gamma oscillatory activity within a prespecified range. Over successive weeks, the parameters for positive feedback (music and video progression) will become incrementally more difficult.
88902370|NCT04566900|Sham Comparator|Placebo|Video and music progression will be random and will not depend on brain activity. Any progression will be by random chance alone.
88902371|NCT04562831|Experimental|Newly diagnosed ALS patients|"High dose EH301 (1500mg Nicotinamide riboside / 300mg Pterostilbene)~Single dose EH301 (1000mg Nicotinamide riboside / 200mg Pterostilbene)~Placebo"
88902372|NCT04562831|Experimental|Earlier diagnosed ALS patients|"High dose EH301 (1500mg Nicotinamide riboside / 300mg Pterostilbene)~Placebo"
88902373|NCT04548648|Other|Open-label, single-arm|A multicenter open-label, single-arm, phase 2 study designed to investigate the antitumor effects of acalabrutinib in subjects with relapsed primary central nervous system lymphoma (PCNSL), and relapsed secondary CNS lymphoma (SCNSL) with no evidence of current systemic disease. Subjects will receive acalabrutinib at the dose of 100 mg every 12 hours. Prophylactic administration of broad spectrum triazole antifungal agent isavuconazole will be performed while subjects receive acalabrutinib.
88902374|NCT04544111|Experimental|Cohort A-BRAF WT tumors|Cohort A (BRAF WT tumors): trametinib (T) 2mg by mouth daily plus PDR001 400mg IV every 4 weeks
88902375|NCT04544111|Experimental|Cohort B-BRAF Mutant|Cohort B (BRAF Mutant, resistant to previous BRAF inhibitors): dabrafenib (D) 150 mg twice daily (OR at dose the patient previously tolerated) plus PDR001 400mg IV every 4 weeks.
88902376|NCT04539483|Experimental|HDIT101|Topical application of HDIT101 solution to orolabial herpes lesion (4 times over 2 days). Blinded study drug will be applied to 2 lesions in the study
88902377|NCT04539483|Placebo Comparator|Placebo to HDIT101|Topical application of placebo solution to orolabial herpes lesion (4 times over 2 days). Blinded study drug will be applied to 2 lesions in the study
88902378|NCT04531969|Active Comparator|Inpatient group|Spa therapy,HP application, deep heater application, and TENS.
88902379|NCT04531969|Active Comparator|Outpatient group|Spa therapy,HP application, deep heater application, and TENS.
88902380|NCT04522739|Experimental|Spironolactone|Participants with mild cognitive impairment or early Alzheimer's Disease who are randomized to receive spironolactone for 12 months.
88902381|NCT04522739|Placebo Comparator|Placebo|Participants with mild cognitive impairment or early Alzheimer's Disease who are randomized to receive a placebo to match spironolactone for 12 months.
88902382|NCT04517487|Active Comparator|VMT recipients|"In order to prevent transfer of pathogens, sperm, or antibiotic-resistant commensals we will establish a vaginal fluid bank in which samples from suitable donors will be kept for future use:~Donors will be screened using a questionnaire addressing risk factors for potentially transmissible infections, undergo screening for cervico-vaginal infections, cervical cytology screening, and serology analysis for transmittable infections {see detailed screening in Lev-Sagie et al. Nat Med. 2019;25(10):1500-1504. doi: 10.1038/s41591-019-0600-6.}~The collected samples for VMT will be examined for bacteria,viruses and sperm.~Before transplantation, patients will be treated with intravaginal antibiotics. A frozen specimen will be thawed at room temperature and will be placed in the patient's vagina.~Following VMT, patients will be evaluated every 14 days for the first 2 months, then every month for additional 10 months."
88902383|NCT04517487|Placebo Comparator|Placebo|"Vaginal fluid of all recipients will be collected before initiation of the study using the same protocol, will be clearly labeled and will be kept frozen in similar conditions. These samples will be used in the placebo arm for autologous vaginal fluid transplantation.~Before transplantation, patients will be treated with intravaginal antibiotic.~Following Placebo, patients will be evaluated every 14 days for the first 2 months, then every month for additional 2-4 months.~After 4-6 months, patients who initially received placebo will be offered a VMT in case they are still symptomatic and fulfill inclusion criteria, in an open-label phase."
88902384|NCT04487041|Active Comparator|Young HIV negative group|HIV uninfected participants that are 18-35 years of age will receive the standard dose flu vaccine. Participants who did not respond to the standard dose flu vaccination, as defined by less than a four-fold increase in flu antibody titer from baseline, will then receive the high dose flu vaccination 1 year after initial standard dose flu vaccination. Participants who respond to the standard dose flu vaccination will not receive the high dose flu vaccination.
88902385|NCT04487041|Experimental|Young HIV positive group|HIV infected viral suppressed participants, who are on anti-retroviral therapy (ART) aged 18-35 years of age, will receive the standard dose flu vaccine first followed by the high dose flu vaccine 1 year after initial standard dose.
88902386|NCT04487041|Experimental|Old HIV negative group|HIV uninfected participants that are 65 years and older will receive the standard dose flu vaccine first followed by the high dose flu vaccine 1 year after initial standard dose.
88902387|NCT04487041|Experimental|Old HIV positive group|HIV infected viral suppressed participants, who are on anti-retroviral therapy (ART) aged 65 years and older, will receive the standard dose flu vaccine first followed by the high dose flu vaccine 1 year after initial standard dose.
88902388|NCT04478708|Experimental|Part A: AMG 133|Up to 7 single ascending dose cohorts (cohorts 1 to 6 and cohort 11).
88902389|NCT04478708|Placebo Comparator|Part A: Placebo|Up to 7 single ascending dose cohorts (cohorts 1 to 6 and cohort 11).
88902390|NCT04478708|Experimental|Part B: AMG 133|Up to 4 multiple ascending dose cohorts (cohorts 7 to 10).
88902391|NCT04478708|Placebo Comparator|Part B: Placebo|Up to 4 multiple ascending dose cohorts (cohorts 7 to 10).
89421883|NCT05419635|Experimental|Arm A: Child-Pugh A|Participants with mildly impaired hepatic function (Child-Pugh A)
89421884|NCT05419635|Experimental|Arm B: Child-Pugh B|Participants with moderately impaired hepatic function (Child-Pugh B)
88902392|NCT04478708|Experimental|Part C: AMG 133|Up to 2 open-label, multiple ascending dose cohorts (cohorts 12 to 13) treated with doses previously studied in Part A and Part B.
88902393|NCT04478006||Childhood Leukemia|Peripheral blood and bone marrow samples are collected for genetic analysis, invitro drug sensitivity test and animal experiment.
88902394|NCT04461899|Other|sclerotherapy|a sclerotherapy will be done in patients
88902395|NCT04455048|Experimental|Intervention Group|A single-session manipulation with a high-speed low-amplitude thrust technique in the cervicothoracic transition region will be applied each week for two weeks.
88902396|NCT04455048|Sham Comparator|Control Group|A sham manipulation without a high-speed low-amplitude thrust technique in the cervicothoracic transition region will be applied.
88902397|NCT04442828||Primary mitral regurgitation|Patients with mitral regurgitation due to mitral valve disease
88902398|NCT04442828||Secondary mitral regurgitation|Patients with mitral regurgitation due to ventricular or atrial disease
88902399|NCT04419818||Left brain damaged patients|"A group of 20 left brain damaged (LBD) patients will perform:~a computerized test battery to measure time abilities (Mental Time Travel, Time Estimation and Time Reproduction);~a neuropsychological screening (Mini Mental State Examination and Token Test) to assess inclusion/exclusion criteria;~questionnaires to evaluate the time needed to execute actions and the ability to locate daily activities in time."
89421885|NCT05419635|Experimental|Arm C: Normal hepatic (Matched A and B)|Participants with normal hepatic function matched to Arm A and B
89421886|NCT05402384|Experimental|Main study arm - AVTX-801|subjects will wash out from food grade D-galactose then be put on medical grade D-galactose
89421887|NCT05402384|Placebo Comparator|Placebo|placebo crossover
88902400|NCT04419818||Right brain damaged patients|"A group of 20 right brain damaged (RBD) patients will perform:~a computerized test battery to measure time abilities (Mental Time Travel, Time Estimation and Time Reproduction);~a neuropsychological screening (Mini Mental State Examination and Token Test) to assess inclusion/exclusion criteria;~questionnaires to evaluate the time needed to execute actions and the ability to locate daily activities in time."
88902401|NCT04419818||Healthy controls|"A group of 40 (20 young and 20 elderly) healthy controls (HC) will perform:~a computerized test battery to measure time abilities (Mental Time Travel, Time Estimation and Time Reproduction);~a neuropsychological screening (Mini Mental State Examination) to assess inclusion/exclusion criteria;~questionnaires to evaluate the time needed to execute actions and the ability to locate daily activities in time."
88902402|NCT04402346|Experimental|Radiofrequency-assisted|
88902403|NCT04402346|Active Comparator|Stapler|
88902404|NCT04397484|Active Comparator|Levobupivacaine|0.5% levobupivacaine (0.5% Chirocaine) 30ml (150mg) will be injected once for regional anaesthesia before surgery
88902405|NCT04397484|Active Comparator|Xylocaine + adrenaline|2% Xylocaine with adrenaline 1:200,000 30ml (450mg) will be injected once for regional anaesthesia before surgery
88902406|NCT04396600||Healthcare Workers Already Starting Peer Support Program|
88902407|NCT04396600||Healthcare Workers Starting Peer Support Program Later|
88902408|NCT04372641|Experimental|Treatment (p97 inhibitor CB-5339 tosylate)|Patients receive p97 inhibitor CB-5339 tosylate PO QD 4 days on and 3 days off. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89194953|NCT00811863||1|Subjects with moderate renal insufficiency defined as an eGFR 30-60 mL/min/1.73 m2
89421888|NCT05394506|Other|Collection of biological material|"Patients carrying LMNA mutation with no contrindication for skin and/or muscle biopsy:~from large families with striking intrafamilial phenotypic variability (3 families identified).~patients carrying p.Arg453Trp or p.Glu358Lys LMNA gene mutations"
89421889|NCT05393219|Experimental|Cardiac Biofeedback|Relaxing breathing exercise coupled with cardiac biofeedback
88902409|NCT04352296|Experimental|Experimental group|Individualized BP management during mechanical thrombectomy with the administration of diluted norepinephrine (5-10 µg/ml) or nicardipine (1 mg/ml) or urpidil (5 mg/ml) to maintain the MAP within 10% of the first MAP measured in the angiography suit.
88902410|NCT04352296|Active Comparator|Control group|Standard BP management based on international guidelines: Treatment of hypotension defined by a systolic blood pressure <140 mm Hg, and treatment of hypertension defined by a systolic blood pressure > 180 mm Hg or diastolic blood pressure >105 mm Hg) with usual treatments (norepinephrine, ephedrine or phenylephrine for hypotension; intravenous nicardipine or uradipil for hypertension).
88902411|NCT04304911|Experimental|UP in blended format|Clinicians will follow the UP therapist manual, 2nd edition, recently translated by Osma and Crespo (13,14). The same contents through a digital material (video and audio) will be integrated in the UP-APP. The program can be developed in a range of 12 to 16 sessions. The UP includes 8 modules
88902412|NCT04304911|Active Comparator|Treatment as usual (TAU)|Cognitive Behavioral Therapy in individual format is the treatment of choice (TAU) by psychologists and psychiatrists at the collaborating Public Mental Health Centers and Primary Care Centers, together with pharmacological treatment (i.e., antidepressants and / or anxiolytics).
89421890|NCT05393219|Experimental|Mindfulness|Mindfulness guided through a video tape
89421891|NCT05393219|Experimental|Inner resource mobilization|Resources and inner strength mobilization guided through a video tape
89421892|NCT05393219|Sham Comparator|Control|Standardized video tape
89421893|NCT05390515|Experimental|Tildrakizumab treatment|Biological/vaccine: tildrakizumab
89421894|NCT05387980||Patients receiving CIBINQO|Patients receiving CIBINQO tablets by mouth for the treatment of Atopic Dermatitis.
89421895|NCT05381675|Experimental|Intervention|Participants will receive a supervised tele-rehabilitation program 2 days a week for 6 weeks.
89421896|NCT05381675|Other|Control|Participants will receive the same rehabilitation program as prescribed.
88814277|NCT02243150|Experimental|Cohort 7 - Bone Marrow Cohort|All subjects in this cohort will receive active drug, G1T28-1. Dose of G1T28-1 will be determined based on the safety and PK data from previous cohorts. G1T28-1 will be administered in 50mL of 5% dextrose by IV infusion. Subjects in this cohort will be selected for the Ex-Vivo Stimulation group and will have a one time bone marrow aspirate at one of the following time points: pre dose, 12 or 24 hours post dose.
88814278|NCT02243228|Experimental|GM-CSF, nebulizer|After the patients were randomly divided into two groups, they will be treated by GM-CSF (using nebulizer, 150ug bid) every other week for 6 months.
89421897|NCT05378243|Experimental|Robotic Gait Training|8 weeks of therapy with the robotic gait training device 4-5 times a week for 1 hour each session
89421898|NCT05378243|Experimental|Functional Clinical Therapy|8 weeks of therapy with a custom designed therapy program for the participant's needs 4-5 times a week for 1 hour each session
89421899|NCT05377593|Active Comparator|eminoplasty with patient specific Titanium onlay implant|
89421900|NCT05377593|Active Comparator|eminoplasty with patient specific zirconium dioxide onlay implant|
89421901|NCT05372588|Experimental|Group A (NVX-CoV2515 )|1 intramuscular (IM) injection of NVX-CoV2515 of 0.5 mL injection volume on Day 0.
89421902|NCT05372588|Experimental|Group B (NVX-CoV2373 )|1 intramuscular (IM) injection of NVX-CoV2373 of 0.5 mL injection volume on Day 0.
89421903|NCT05372588|Experimental|Group C (NVX-CoV2515 )|1 intramuscular (IM) injection of NVX-CoV2515 of 0.5 mL injection volume on Day 0.
89421904|NCT05372588|Experimental|Group D (NVX-CoV2373)|1 intramuscular (IM) injection of NVX-CoV2373 of 0.5 mL injection volume on Day 0.
89421905|NCT05372588|Experimental|Group E (BA.1 Bivalent Vaccine)|1 intramuscular (IM) injection of Bivalent Vaccine (NVX-CoV2373 + NVX-CoV2515) of 0.5 mL injection volume on Day 0.
89421906|NCT05372588|Experimental|Group F (NVX-CoV2540)|2 intramuscular (IM) injections of NVX-CoV2373 of 0.5 mL injection volume on Day 0 and on Day 90.
89421907|NCT05372588|Experimental|Group G (NVX-CoV2373)|2 intramuscular (IM) injections of NVX-CoV2373 of 0.5 mL injection volume on Day 0 and on Day 90.
89421908|NCT05372588|Experimental|Group H (NVX-CoV2373 + NVX-CoV2540)|2 intramuscular (IM) injections of NVX-CoV2373 of 0.5 mL injection volume on Day 0 and on Day 90.
88814279|NCT01628159|Experimental|Lutonix Drug Coated Balloon|Formerly called the Moxy Drug Coated Balloon, the Lutonix Drug Coated Balloon (Lutonix DCB) is a paclitaxel coated balloon catheter
88814280|NCT04363970||group A- early catheter removal)|in group A, we will remove the catheter after 24 h.
88814281|NCT04363970||Group B- delayed catheter removal|In group B, we will remove the catheter after 48 h.
88814282|NCT02243462|Other|No pre-op warming|No pre-warming in bay before surgery.
88814283|NCT02243462|Active Comparator|Pre-op forced air warming|A forced air warmer device (WarmTouch Convective Warming System) will be used to pre-warm patients in holding bay before surgery
88814284|NCT02243618|Active Comparator|Rebamipide group|
88814285|NCT02243618|Active Comparator|Polaprezinc group|
88814286|NCT03481751||Patients with Crohn Disease|Patients with Crohn's disease scheduled for ileocolonoscopy
88814287|NCT02243774|No Intervention|No letter|Individuals randomized to the control group who will not receive any of the four letters
88814288|NCT02243774|Experimental|Core letter signed by Surgeon General|Individuals randomized to receive only a core letter signed by the Surgeon General
88814289|NCT02243774|Experimental|Core letter signed by Director of the National Vaccine Program|Individuals randomized to receive only a core letter signed by the Director of the National Vaccine Program
88814290|NCT02243774|Experimental|Core letter signed by Surgeon General + implementation prompt|Individuals randomized to receive a core letter signed by the Surgeon General with an implementation intention prompt added in an appended P.S. tag region below the signature line
88814291|NCT02243774|Experimental|Core letter signed by SG + enhanced implementation prompt|Individuals randomized to receive a core letter signed by the Surgeon General (SG) with an enhanced implementation intention prompt added in an appended P.S. tag region below the signature line
88814292|NCT02243852||Growth Hormone Deficiency (n=16)|16 asymptomatic GHD patients (who have confirmed GHD but who remain without GH replacement) will be compared with 16 healthy controls. Participants will be asked to undertake a single fasting blood sample and an MRI scan (whole body MRI and proton- and phosphorus-MR spectroscopy) to determine VAT, SAT and liver fat and muscle mitochondrial function. FGF21, body composition and mitochondrial function will be assessed in each of cohort to determine the correlation of FGF21 levels with VAT, SAT and liver fat.
88814293|NCT02243852||Healthy Controls (n=16)|16 healthy controls will be compared with 16 asymptomatic GHD patients (who have confirmed GHD but who remain without GH replacement). Participants will be asked to undertake a single fasting blood sample and an MRI scan (whole body MRI and proton- and phosphorus-MR spectroscopy) to determine VAT, SAT and liver fat and muscle mitochondrial function. FGF21, body composition and mitochondrial function will be measured in all cohorts to determine the correlation of FGF21 levels with VAT, SAT and liver fat.
88814826|NCT03030950|Experimental|Dexmedetomidine group|Adductor canal block will be performed before induction of general anesthesia. Patients will be positioned in the supine position with knee slightly flexed and leg externally rotated followed by ultrasound scanning of the middle of thigh using 13-6 MHz linear array probe. The ultrasound probe will be placed over the anterior aspect of the patient's thigh, mid-point between the inguinal crease and medial femoral condyle. The scan will be focused on the femoral artery pulsations aiming to try to visualize the nerves in the adductor canal on both sides (lateral and medial) of the pulsating femoral artery. 20 ml bupivacaine 0.25% combined with 75 mcg dexmedetomidine will be injected. The study solution will be injected underneath the fascia of sartorius muscle.
89194954|NCT00811863||2|Subjects with severe renal insufficiency defined as an eGFR <30 mL/min/1.73 m2 and ESRD defined as requiring dialysis
89421909|NCT05363267|Experimental|Curcumin with high phenolic extra virgin olive oil (HP-EVOO)|Identical for all participants with the exception of the curcumin dose level, which is assigned at study enrollment.
89421910|NCT05352776|Experimental|AtaCor EV-ICD Lead System|Subjects implanted with the AtaCor EV-ICD Lead Model AC-7001
89421911|NCT05342363||cardiopulmonary resuscitation during treatment with extracorporeal membrane oxygenation|Patients treated with venovenous extracorporeal membrane oxygenation (vv-ECMO) for acute respiratory distress syndrome (ARDS) during the retrospective observation period who required mechanical cardiovascular resuscitation (CPR) during their treatment.
89421912|NCT05342363||Treatment with extracorporeal membrane oxygenation without resuscitation|Patients treated with venovenous extracorporeal membrane oxygenation (vv-ECMO) for acute respiratory distress syndrome (ARDS) without the need for cardiovascular resuscitation during the retrospective observation period.
89421913|NCT05338593||prolonged veno-venous extracorporeal membrane oxygenation|Critically affected patients treated with veno-venous extracorporeal membrane oxygenation (VV-ECMO). Based on severe acute respiratory distress syndrome (ARDS) and prolonged therapy for more than 2 weeks.
89421914|NCT05336539||Positive group|subjects received colorectal cancer polygene methylation test at baseline, and all positive results were included in the positive group. They will undergo further FIT testing, blood carcinoembryonic antigen testing and colonoscopy within three months of colorectal cancer polymethylation testing.
89421915|NCT05335798|Experimental|Adults with Cerebral Palsy|Adults with Cerebral Palsy who are able to be self-ambulatory for minimum 100 feet
89421916|NCT05330312|Experimental|Digital cognitive behavioral therapy|Part 1: 4 weeks digital cognitive behavioral therapy. Part 2: 9 weeks digital cognitive behavioral therapy.
89421917|NCT05330312|No Intervention|Control group|Note: Access to dCBT-PF for the control group will be provided under an Exclusive Release of the product, following completion of the Week 12 visit in the investigation.
89421918|NCT05326633|No Intervention|UC only|LTACH control group receiving usual care (UC) only.
89421919|NCT05326633|Active Comparator|MRP+HPRO+NMES+UC|LTACH group receiving mobility based rehabilitation (MRP) + neuromuscular electric stimulation (NMES) + high protein supplementation (HPRO) + usual care (UC)
89421920|NCT05297747|Experimental|Apical periodontitis|Radiography of the patients in the apical periodontitis group was evaluated and blood samples were collected from those patients
89421921|NCT05297747|Experimental|Chronic periodontitis|Radiography of the patients in the chronic periodontitis group was evaluated and blood samples were collected from those patients
89421922|NCT05297747|No Intervention|Control|Radiography of the participants in the healthy, control group was evaluated and blood samples were collected from those participants
89421923|NCT05282797|Experimental|Part A - ANEB-001|Subjects receive THC and varying amounts of ANEB-001
88902413|NCT04288635||Septic shock admitted in Angers' ICU|Patients aged more than 18, admitted in University Hospital of Angers, who meet the full criteria of septic shock
88902414|NCT04215679|Experimental|Three-dimensional immersive virtual reality application|25 stroke patients between the ages of 18-80, stroke duration of less than 2 months and not more than 2 years whose mini Mental State Examination (MMSE) scores equal or above the 25 will be included in this study. Oculus Rift and Leap motion will be used to create an immersive interactive environment. Modified Ashworth Scale (MAS), Functional independence scale, self-care questionnaire,Action Research Arm Test, Fugl meyer upper extremity motor evaluations will be applied just before the rehabilitation program, after the application and at the end of 6 weeks.
88902415|NCT04215679|Active Comparator|Motor imagery|25 stroke patients between the ages of 18-80, stroke duration of less than 2 months and not more than 2 years whose MMSE scores equal or above the 25 will be included in this study. Oculus Rift and Leap motion will be used to create an immersive interactive environment. Modified Ashworth Scale (MAS), Functional independence scale, self-care questionnaire,Action Research Arm Test, Fugl meyer upper extremity motor evaluations will be applied just before the rehabilitation program, after the application and at the end of 6 weeks.
88902416|NCT04215679|Active Comparator|Conventional physiotherapy|25 stroke patients between the ages of 18-80, stroke duration of less than 2 months and not more than 2 years whose MMSE scores equal or above the 25 will be included in this study. Oculus Rift and Leap motion will be used to create an immersive interactive environment. Modified Ashworth Scale (MAS), Functional independence scale, self-care questionnaire,Action Research Arm Test, Fugl meyer upper extremity motor evaluations will be applied just before the rehabilitation program, after the application and at the end of 6 weeks.
88902417|NCT04185935||Ancillary-correlative (biospecimen collection)|Participants may provide a sample of blood, a saliva sample, a sample of eyebrow plucks, a sample of urine, and/or stored tumor or healthy tissue.
88902418|NCT04150497|Experimental|Dose Escalation|"Several tested doses of UCART22 until the Maximum Tolerated Dose (MTD) is identified and establish Recommended Phase 2 Dose (RP2D)~Dose Expansion: UCART22 administered at the RP2D"
89194955|NCT00886054||Neurocritical patients|Neurocritical patients including those sustaining head injury, cerebrovascular events (such as intracerebral hemorrhage, subarachnoid hemorrhage, etc.), brain tumor, or hydrocephalus.
89421924|NCT05282797|Placebo Comparator|Part A - Placebo|Subjects receive THC and placebo
89421925|NCT05282797|Experimental|Part B - Cohort 1 - ANEB-001|Subjects receive 21 mg of THC and 30 mg of ANEB-001
89421926|NCT05282797|Placebo Comparator|Part B - Cohort 1 - Placebo|Subjects receive 21 mg of THC and placebo
89421927|NCT05282797|Experimental|Part B - Cohort 2 - ANEB-001|Subjects receive 21 mg of THC and 10 mg of ANEB-001
89421928|NCT05282797|Placebo Comparator|Part B - Cohort 2 - Placebo|Subjects receive 21 mg of THC and placebo
89421929|NCT05282797|Experimental|Part B - Cohort 3 - ANEB-001|Subjects receive 21 mg of THC and 1 hour later, 30 mg ANEB-001
89421930|NCT05282797|Placebo Comparator|Part B - Cohort 3 - Placebo|Subjects receive 21 mg THC and 1 hour later, placebo
89421931|NCT05282797|Experimental|Part B - Cohort 4 - ANEB-001|Subjects receive 40 mg of THC and 1 hour later, 10 mg of ANEB-001
89421932|NCT05282797|Placebo Comparator|Part B - Cohort 4 - Placebo|Subjects receive 40 mg of THC and 1 hour later, placebo
89421933|NCT05282797|Experimental|Part B - Cohort 5 - ANEB-001|Subjects receive 30 mg of THC and 1 hour later, 10 mg of ANEB-001
89421934|NCT05282797|Placebo Comparator|Part B - Cohort 5 - Placebo|Subjects receive 30 mg of THC and 1 hour later, 10 mg of ANEB-001
89421935|NCT05282797|Experimental|Part B - Cohort 6 - ANEB-001|Subjects will consume a high fat meal prior to receiving 30 mg of THC and 1 hour later, 10 mg of ANEB-001
89421936|NCT05282797|Placebo Comparator|Part B - Cohort 6 - Placebo|Subjects will consume a high fat meal prior to receiving 30 mg of THC and 1 hour later, placebo
89421937|NCT05282797|Experimental|Part C - Cohort 7 - ANEB-001|Subjects receive a 40 mg dose of THC and a 10 mg dose of ANEB-001
89421938|NCT05282797|Experimental|Part C - Cohort 8 - ANEB-001|Subjects receive a 60 mg dose of THC and a 20 mg dose of ANEB-001
89421939|NCT05281952|Experimental|endoscopic ligation|
89421940|NCT05281952|Active Comparator|Supra-selective embolization|
89421941|NCT05276492|Experimental|Group 1: Dose Regimen 1|"You will be enrolled in the study based on the study group that is open at that particular time. If you are enrolled in this group, you will receive:~- Abiraterone 500 mg and prednisone 5mg with a low-fat meal every other day.~You will take 2 pills (500 mg total) of abiraterone acetate, first thing in the morning with breakfast. The tablets should be swallowed whole and not crushed, chewed, or dissolved in water. This breakfast should be a low-fat meal (avoid high calorie foods with a high percentage of fat, such as bacon or sausage). You will be asked to document the details of the meal/taking abiraterone in a daily log.~You will also take prednisone 5 mg daily in the form of tablets taken by mouth with approximately 8 ounces of water with food. You do not have to take prednisone and abiraterone at the same time of day. If you inadvertently miss a dose of the study drug, you should take the dose the next day and record this on your Drug Diary."
88902419|NCT04116723|Experimental|Flexible brace|The design of the flexible brace incorporates different mechanisms, such as 1) compression and pulling forces through a close fit of the intimate apparel, 2) artificial hinge bone for the strategical application and fixation of corrective panel, 3) lumbar flexion by using supporting belt, 3) transverse forces applied by inserting pads inside the pocket lining by using the principle of the 3-point pressure system.
88902420|NCT04116164|Experimental|Dosimetry and targeting|"Three sub-cohorts in cohort 1 will receive one slow bolus IV injection of 2 mg 111In-DOTA-h11B6 with 0, 8 and 18 mg unlabeled h11B6 respectively.~In cohort 2, up to 6 patients will receive a slow bolus IV injection of 2 mg 111In-DOTA_h11B6 with any unlabeled h11B6 as determined from cohort 1, and will be imaged at one time-point"
89421942|NCT05276492|Experimental|Group 2: Dose Regimen 2|"You will be enrolled in the study based on the study group that is open at that particular time. If you are enrolled in this group, you will receive:~- Abiraterone 500 mg and prednisone 5mg with a low-fat meal on day 1, day 3, day 5 of every week~You will take 2 pills (500 mg total) of abiraterone acetate, first thing in the morning with breakfast. The tablets should be swallowed whole and not crushed, chewed, or dissolved in water. This breakfast should be a low-fat meal (avoid high calorie foods with a high percentage of fat, such as bacon or sausage). You will be asked to document the details of the meal/taking abiraterone in a daily log.~You will also take prednisone 5 mg daily in the form of tablets taken by mouth with approximately 8 ounces of water with food. You do not have to take prednisone and abiraterone at the same time of day. If you inadvertently miss a dose of the study drug, you should take the dose the next day and record this on your Drug Diary."
89421943|NCT05276492|Experimental|Group 3: Dose Regimen 3|"You will be enrolled in the study based on the study group that is open at that particular time. If you are enrolled in this group, you will receive:~- Abiraterone 500 mg and prednisone 5mg with a low-fat meal on day 1 and day 4 of every week~You will take 2 pills (500 mg total) of abiraterone acetate, first thing in the morning with breakfast. The tablets should be swallowed whole and not crushed, chewed, or dissolved in water. This breakfast should be a low-fat meal (avoid high calorie foods with a high percentage of fat, such as bacon or sausage). You will be asked to document the details of the meal/taking abiraterone in a daily log.~You will also take prednisone 5 mg daily in the form of tablets taken by mouth with approximately 8 ounces of water with food. You do not have to take prednisone and abiraterone at the same time of day. If you inadvertently miss a dose of the study drug, you should take the dose the next day and record this on your Drug Diary."
89421944|NCT05276492|Experimental|Group 4: Dose Regimen 4|"You will be enrolled in the study based on the study group that is open at that particular time. If you are enrolled in this group, you will receive:~- Abiraterone 500 mg and prednisone 5mg with a low-fat meal on day 1 of every week~You will take 2 pills (500 mg total) of abiraterone acetate, first thing in the morning with breakfast. The tablets should be swallowed whole and not crushed, chewed, or dissolved in water. This breakfast should be a low-fat meal (avoid high calorie foods with a high percentage of fat, such as bacon or sausage). You will be asked to document the details of the meal/taking abiraterone in a daily log.~You will also take prednisone 5 mg daily in the form of tablets taken by mouth with approximately 8 ounces of water with food. You do not have to take prednisone and abiraterone at the same time of day. If you inadvertently miss a dose of the study drug, you should take the dose the next day and record this on your Drug Diary."
89421945|NCT05269732|Experimental|Treatment (9-week online CBT group)|Participants assigned to the treatment group will continue to receive any healthcare they might already be receiving (e.g. family doctor, midwife, Obstetrician/Gynecologist, etc.) and participate in a 9-week group Cognitive Behavioral Therapy (CBT) intervention for Postpartum Depression (PPD) delivered via Zoom by two trained psychologists, social workers, nurses, and/or psychiatrists.
89421946|NCT05269732|No Intervention|Control (treatment as usual)|The control group will receive standard postnatal care from their obstetrician, midwife, and/or family physician
88902421|NCT04112173|Experimental|Perturbation-Based Balance Training|perturbation-based balance training
88902422|NCT04074824||Necrotizing enterocolitis|Neonates diagnosed with NEC based on the Modified Bell criteria for NEC including clinical, radiological and Laboratory findings.
88902423|NCT04074824||Non-NEC|Neonates diagnosed with other conditions including low birthweight, prematurity, infection, metabolic, cardiovascular, CNS, respiratory or gastrointestinal problems.
89194956|NCT00814593|Experimental|Arm I|Patients undergo intracranial placement of polifeprosan 20 with carmustine implant (Gliadel® wafer) at the time of therapeutic craniotomy.
88902424|NCT04074746|Experimental|Treatment (AFM13-NK, AFM13)|Patients receive standard of care fludarabine IV over 1 hour and standard of care cyclophosphamide IV over 30-60 minutes on days -5 to -3, AFM13-NK IV over 4 hours on day 0, and then AFM13 IV over 4 hours on days 7, 14, and 21.
88902425|NCT04053075|Active Comparator|Routine cluster detection|Hospitals will use routine practices for cluster detection with a structured cluster response protocol when a cluster is detected.
88902426|NCT04053075|Active Comparator|Enhanced cluster detection|Hospitals will use an automated statistical cluster detection tool in addition to routine practices for cluster detection with a structured cluster response protocol when a cluster is detected.
88902427|NCT04038619|Experimental|Treatment (loperamide, colonoscopy, FMT)|Patients receive loperamide PO. After 4 hours, patients undergo FMT via colonoscopy over 15-30 minutes.
88902428|NCT04033497|Experimental|TRAMs I|"Magnetic resonance imaging (MRI)-based treatment response assessment maps (TRAMs)~Patients with an enlarging lesion in the site of a brain metastasis treated with stereotactic radiation for which neurosurgical resection is planned will undergo preoperative TRAMs"
88902429|NCT04030507|Experimental|Inflammatory Breast Cancer Managed with Curative Intent|"Patients will receive an initial screening magnetic resonance imaging (MRI) of the brain~If no evidence of intracranial involvement is identified, additional screening MRIs of the brain every six months for two years and at initial systemic progression."
88902430|NCT04030507|Experimental|HR+ or HER2+ Metastatic Breast Cancer - Screening Arm|"An initial MRI screening will be conducted~If negative, patients will receive a second MRI of the brain at first systemic progression after study entry"
88902431|NCT04030507|No Intervention|HR+ or HER2+ Metastatic Breast Cancer - No Screening Arm|No initial MRI screening will be conducted
88902432|NCT04030507|Experimental|Triple Negative Breast Cancer|"An initial MRI screening will be conducted~If negative, patients will receive a second MRI of the brain at first systemic progression after study entry"
88902433|NCT03987386|Active Comparator|Arm I (conventional radiation therapy)|Patients undergo conventional radiation therapy daily over 7 weeks after standard of care surgery.
88902434|NCT03987386|Experimental|Arm II (hypofractionated radiation therapy)|Patients undergo hypofractionated radiation therapy over 4.5 weeks after standard of care surgery.
88902435|NCT03983577|Experimental|Point of service delivery model|After the informed consent is signed, the participant will watch a standardized video on the principles of genetic testing. At the end of the video, the provider will return to answer any remaining questions. The participant will receive pre- and post- surveys for evaluation of the delivery model.
88902436|NCT03967834|Other|Patient with Soft Tissue Sarcoma (Prospective cohort)|
89194957|NCT00814593|Experimental|Arm II|Patients undergo leukapheresis to obtain autologous lymphokine-activated killer (LAK) cells, followed 3-7 days later by therapeutic craniotomy. The autologous LAK cells are then instilled into the tumor bed cavity at the time of therapeutic craniotomy.
89194958|NCT02542306|Experimental|fibrinogen concentrate-treated group|The initial fibrinogen concentrate dose was 25 - 50 mg/kg, but additional fibrinogen concentrate was administered repeatedly if the first infusion of fibrinogen concentrate did not increase the fibrinogen level over 2.0 g/L.
89194959|NCT02542306|No Intervention|non-fibrinogen concentrate-treated group|The participants who did not received fibrinogen concentrate treatment were enrolled as the non-fibrinogen concentrate-treated group
89194960|NCT00817947|Active Comparator|Usual airway clearance technique|Airway clearance using the active cycle of breathing techniques, autogenic drainage, positive expiratory pressure or oscillating positive expiratory pressure
89194961|NCT00817947|Other|HFCWO|High frequency chest wall oscillation
89194962|NCT00421993|Experimental|1|Adapalene/Benzoyl Peroxide Topical Gel
89194963|NCT00421993|Active Comparator|2|Adapalene Topical Gel
89194964|NCT00421993|Active Comparator|3|Benzoyl Peroxide Topical Gel
89194965|NCT00421993|Placebo Comparator|4|Topical Gel Vehicle
89194966|NCT00884884|Placebo Comparator|Double Placebo|Placebo, Placebo
89194967|NCT00884884|Experimental|Aripiprazole 15, Placebo|15 mg Aripiprazole, Placebo
88902437|NCT03951831|Experimental|ADT Followed by Chemoimmunotherapy|"REGN2810 followed by chemoimmunotherapy:~Initiate degarelix 240mg SC once, followed by leuprolide acetate 22.5mg SC every 3 months.~Week 4 start cemiplimab (REGN 2810) 350mg IV every 3 weeks (flat dose) for up to 55 weeks or intolerable side effect or progression of disease.~Week 10 start docetaxel 75 mg/m2 every 21 days for up to 6 cycles."
89194968|NCT00884884|Experimental|Aripiprazole 7.5, Placebo|Aripiprazole 7.5 mg daily plus Placebo daily
89194969|NCT00884884|Experimental|Topiramate 100mg, Placebo|Topiramate 100 mg daily plus Placebo daily
89194970|NCT00884884|Experimental|Topiramate 200, Placebo|Topiramate 200 mg daily plus Placebo daily
89194971|NCT00884884|Experimental|Topiramate 100, Aripiprazole 5|Topiramate 100 daily plus, Aripiprazole 5mg daily
89194972|NCT00884884|Experimental|Topiramate 200, Aripiprazole 15|Topiramate 200 mg daily plus Aripiprazole 15mg daily
89194973|NCT00884884|Experimental|Topiramate 100, Aripiprazole 7.5|Topiramate 100 mg daily, Aripiprazole 7.5 mg daily
89194974|NCT00884884|Experimental|Topiramate 200, Aripiprazole 7.5mg|Topiramate 200 mg daily plus Aripiprazole 7.5mg daily
89194975|NCT00884962|Experimental|PLVR|
89194976|NCT00814749|Active Comparator|surgical therapy|
89194977|NCT00814749|Active Comparator|individual management|
89194978|NCT01037725|Experimental|AZD5847 oral suspension|Active
89194979|NCT01037725|Placebo Comparator|Placebo to AZD5847|Placebo
89194980|NCT02551029|Experimental|Duodenal capsaicin infusion|Through a naso-duodenal tube, a capsaicin solution will be infused into the duodenum.
89194981|NCT02551029|Placebo Comparator|Placebo (saline)|Through a naso-duodenal tube, a saline solution will be infused into the duodenum.
89194982|NCT00812019|Experimental|3.75_0%MF59|Subjects received two 0.5mL vaccinations of cell culture derived H5N1 3.75µg subunit influenza vaccine containing 0% of MF59 three weeks apart.
89194983|NCT00812019|Experimental|3.75_25%MF59|Subjects received two 0.5mL vaccinations of cell culture derived H5N1 3.75µg subunit influenza vaccine containing 25% of MF59 three weeks apart.
89194984|NCT00812019|Experimental|3.75_50%MF59|Subjects received two 0.5mL vaccinations of cell culture derived H5N1 3.75µg subunit influenza vaccine containing 50% of MF59 three weeks apart.
88902438|NCT03911687|No Intervention|Control Group|"Control data will be collected in the CONCERN CDS system that will be live in the EHR, but in silent release mode (e.g., not providing notification to clinicians)."
88902439|NCT03911687|Experimental|Intervention Group|"Experimental data will be collected in the CONCERN CDS system that will be live in the EHR in active release mode (e.g., providing CONCERN CDS system notification to clinicians)."
89421947|NCT05268731||Extrahepatic bile duct obstruction and failed ERCP|"Patients with extrahepatic bile duct obstruction and obstructive jaundice have received a percutaneous transhepatic biliary drainage.~The choice between an insertion of an external or an external/internal drainage has been made during the procedure depending on whether the guide wire could be accessed to the jejunum/duodenum or not.~The choice between internal/external drainage or a primary metal stent has been made by the investigators preference or was made on the basis of an existing malign bile duct obstruction or not."
89421948|NCT05255887|Experimental|Informing patients group|24-48 hours before the surgery, the patients will be shown an informative video about the intensive care environment in a separate room through a one-on-one interview. In the study, the day of discharge from the intensive care unit will be counted as the first day, and on the second day, the 'Intensive Care Experience Scale' will be applied to the patients in the experimental group by face-to-face interview method.
89421949|NCT05255887|No Intervention|Control Group|patients who were no intervation
89421950|NCT05238415|No Intervention|Control group receiving no Post-/Long-COVID assessment|"Questionnaires at timepoints t1 (screening), t2 (one week later), t3 (before the intervention), t4 (after the intervention), t5 (6 weeks after intervention), t6 (6 months after the intervention)~Patients from Bavaria Germany: Contact to personal pilots and digital health interventions."
89421951|NCT05238415|Experimental|Intervention group receiving a Post-/Long-COVID assessment|"Questionnaires at timepoints t1 (screening), t2 (one week later), t3 (before the intervention), t4 (after the intervention), t5 (6 weeks after intervention), t6 (6 months after the intervention)~Patients from Bavaria Germany: Assessment in clinics for post-/long-COVID, contact to personal pilots and digital health interventions."
89421952|NCT05238415|No Intervention|Comparison group receiving no Post-/Long-COVID assessment|"Questionnaires at timepoints t1 (screening), t2 (comparable to t2 in the other groups), t3 (comparable with t4 in the other groups), t3 (comparable to t5 in the other groups)~Patients from Germany: No intervention at all"
89421953|NCT05190315|Experimental|Chlorpromazine with standard of care chemoradiation|"Each patient will undergo 3 phases of treatment.~Concurrent Phase: includes concurrent radiation Monday - Friday (60 Gy total radiation dose in 2 Gy fractions), oral temozolomide (75 mg/m2/day) daily for a maximum 49 days starting Day 1 of radiation, and oral chlorpromazine (25 mg for first 3 patients, then escalate to 50 mg if no DLT) daily starting 7 days prior to radiation start.~Interim Phase: Continue oral chlorpromazine daily dose post-radiation and prior to beginning adjuvant temozolomide.~Adjuvant Phase: 28 days after radiation fini (+/- 5 business days), Start oral temozolomide (starting dose 150 mg/m2/day and escalated to 200 mg/m2/day if no treatment related adverse events noted) once daily for 5 consecutive days of a 28 day cycle, and continue oral daily chlorpromazine seven days a week per cycle. The adjuvant phase treatment will continue for up to 6 cycles. Cycle length is 28 days."
89421954|NCT05160961|Active Comparator|Serratus Anterior Plane Block|Following the visualization of the anatomical structures, the nerve block needle will be advanced via the in-plane technique beneath the serratus anterior muscles until the interfascial space was reached. After hydrodissection with 2 ml normal saline, 20 ml 0.25% bupivacaine will be injected into the area.
89421955|NCT05160961|Active Comparator|Erector spinae plane block|After the linear ultrasound (US) probe will be placed 2-3 cm lateral to the T5 spinous process, 20 ml of 0.25% bupivacaine hydrochloride will be injected into the interfacial space below the erector spinae muscle, above the transverse process.
89421956|NCT05157789|Experimental|Sms group|Relatives of patients who were sent SMS
89421957|NCT05157789|No Intervention|Control Group|Relatives of patients who were no intervation
89421958|NCT05134974|Active Comparator|Phentolamine Ophthalmic Solution 0.75%|2 drops in study eye and 1 drop in non-study eye, 1 hour post pharmacologically-induced mydriasis
89421959|NCT05134974|Placebo Comparator|Phentolamine Ophthalmic Solution Vehicle|2 drops in study eye and 1 drop in non-study eye, 1 hour post pharmacologically-induced mydriasis
89421960|NCT05113043||Ischemic stroke|Young patients who suffered from acute ischemic stroke within 12 hours for the first time before entry into the study.
89421961|NCT05113043||Hemorrhagic stroke|Young patients who suffered from acute hemorrhagic stroke within 12 hours for the first time before entry into the study.
89421962|NCT05113043||Healthy Controls|Healthy young people
89421963|NCT05109442|Experimental|Escalation Phase|The Escalation phase will determine the MTD/RP2D of AFM24 in combination with atezolizumab. A traditional 3+3 design will be used to determine the RP2D.
89421964|NCT05109442|Experimental|Expansion Phase|The expansion phase will collect preliminary evidence of efficacy and further confirm the safety of AFM24 in combination with atezolizumab.
89421965|NCT05108870|Experimental|Phase 1: Dose-Finding Group 1 - Drug Combination 1|"All participants in this group will receive HB-201 combined with chemotherapy using carboplatin and paclitaxel.~- HB-201 will be administered on cycle 1 day 15, cycle 2 day 15, and cycle 3 day 15 with three 21-day cycles of carboplatin on day 1 and paclitaxel 100mg/m2 on days 1, 8, and 15"
88902440|NCT03897270|Experimental|Diagnostic (photoacoustic imaging of the breast)|Participants undergo photoacoustic imaging of the breast over 30 minutes. At subject's discretion, imaging may repeat for a total of 10 studies, each in a separate day.
88902441|NCT03884972|Experimental|Cohort I (BTK-refractory)|Patients receive venetoclax PO QD beginning on day 1 for 5 weeks (cycle 1). Beginning in cycle 2, patients receive venetoclax PO QD and trabectedin IV over 3 hours on day 1. Cycles 2+ repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
88902442|NCT03884972|Experimental|Cohort II (BTK-intolerant)|Patients receive trabectedin IV over 3 hours on day 1 of a 3-week cycle (cycle 1), then receive venetoclax PO QD beginning on day 1 of a 5-week cycle (cycle 2). Beginning in cycle 3, patients receive trabectedin IV over 3 hours on day 1 and venetoclax PO QD every 3 weeks in the absence of disease progression or unacceptable toxicity.
89194985|NCT00812019|Experimental|3.75_100%MF59|Subjects received two 0.5mL vaccinations of cell culture derived H5N1 3.75µg subunit influenza vaccine containing 100% of MF59 three weeks apart.
88902443|NCT03872453|Experimental|Zavegepant 5 mg|Participants administered a single intranasal dose of zavegepant 5 mg on occurrence of migraine that reached moderate or severe intensity within 45 days after randomization. The dose was administered using Aptar Unidose System (UDS) liquid spray device.
88902444|NCT03872453|Experimental|Zavegepant 10 mg|Participants administered a single intranasal dose of zavegepant 10 mg on occurrence of migraine that reached moderate or severe intensity within 45 days after randomization. The dose was administered using Aptar UDS liquid spray device.
88902445|NCT03872453|Experimental|Zavegepant 20 mg|Participants administered a single intranasal dose of zavegepant 20 mg on occurrence of migraine that reached moderate or severe intensity within 45 days after randomization. The dose was administered using Aptar UDS liquid spray device.
88902446|NCT03872453|Placebo Comparator|Placebo|Participants administered a single intranasal dose of zavegepant-matching placebo on occurrence of migraine that reached moderate or severe intensity within 45 days after randomization. The dose was administered using Aptar UDS liquid spray device.
88902447|NCT03869463|Experimental|EF/PS CCT|This group will complete EF/PS (executive functioning/processing speed) computerized cognitive training (CCT) which includes games specifically focused on executive function & processing speed.
88902448|NCT03869463|Active Comparator|Verbal CCT|This group will complete verbal-focused computerized cognitive training.
88902449|NCT03869463|Placebo Comparator|Waitlist Control|This group will not receive cognitive training during study participation.
88902450|NCT03819517|Active Comparator|Resveratrol|500 mg of time released micronized trans-Resveratrol
88902451|NCT03819517|Placebo Comparator|Placebo|Placebo will be used in the form of an empty white colored soft vegetarian capsule as resveratrol is presented
88902452|NCT03803761|Experimental|Treatment (copanlisib, fulvestrant)|Patients receive copanlisib IV over 1 hour on days 1, 8, and 15 and fulvestrant IM over 1-2 minutes on days 1 and 15 of cycle 1 and on day 1 beginning cycle 2. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89530846|NCT02510027||Women aged 30-64 years old|Women aged 30 to 64 years who attend the Cervical Cancer Screening Program in 100 health centers in the state of Tlaxcala, Mexico
89530847|NCT02509715|No Intervention|Standard Conventional group|Standard conventional thyroid surgery
89006878|NCT06177275|Experimental|Thick vertical soft tissue biotype, Placement of BLX implants 2 mm sub-crestal|In Thick vertical soft tissue biotype, Placement of BLX implants 2 mm sub-crestal in single missing anterior or premolar teeth in the esthetic zone with immediate provisionalization via a straight emergence profile temporary crown on a temporary abutment.
89006879|NCT06177275|Active Comparator|Thick vertical soft tissue biotype, Placement of BLX implants equicrestal|In Thick vertical soft tissue biotype, Placement of BLX implants equicrestal in single missing anterior or premolar teeth in the esthetic zone with immediate provisionalization via a straight emergence profile temporary crown on a temporary abutment.
89006880|NCT06177249|Active Comparator|Experimental vaccines and vaccine|A total of 1956 subjects were randomly divided into three groups at a ratio of 1:1:1, 652 subjects in each group were vaccinated with the test vaccine or the control vaccine on a schedule of 0, 3, 7, 14, 28 days (a total of 5 doses). Blood samples were collected from the subjects for antibody detection on 0, 7/14, 35/42 days, respectively.
89006881|NCT06177249|Active Comparator|experimental vaccines|An additional group of 652 people received the trial vaccine in a 0 -, 7 -, and 21-day schedule (two first doses for a total of four doses). Blood samples were collected at 0, 7/14 and 35/42 days for antibody detection, and all subjects were systematically observed for safety.
89006882|NCT06177236|Experimental|randomıze|Assuming that a t-test between two independent groups with 80% power, d=0.5 effect size, and t-test between two independent groups will be used in the study, it was found that there should be at least 102 women in total, including 51 self-sampling and 51 clinician sampling groups. Considering the losses that may occur during the study, it was planned to include 110 women in the sample for this phase. These women will be randomly assigned to Self-Sampling (n=55) or Clinician Sampling (n=55) groups in a 1:1 ratio using https://randomizer.org/. The self-sampling group will be trained on the subject and will be provided with a self-sampling HPV DNA test kit, while the HPV DNA test
89006883|NCT06177223|Experimental|Treatment Group|Cognitive Behavioral Therapy based sessions would be conducted with women victims of domestic violence in shelter homes
89006884|NCT06177223|No Intervention|Waitlist Control Group|no intervention would be given to the participants
89006885|NCT06177197|Experimental|Physiomer|"It is a sterile, isotonic seawater-based solution, with a concentration equivalent to 9 g/L sodium chloride. This solution is packaged in 5 mL single-dose units.~It is a Class IIa medical device manufactured by Laboratoire de la mer, and is CE marked.~Electrodialyzed seawater solution is administered via the nasal passage, in line with current recommendations. Dosage varies according to age, and the pressure exerted on the unit dose enables the product to be administered into the nostril."
89006886|NCT06177197|Active Comparator|Saline solution|"It is a sterile, isotonic seawater-based solution, with a concentration egal to 0,9 g/L sodium chloride. This solution is packaged in 5 mL single-dose units.~It is a Class IIa medical device manufactured by GiLBERT, and is CE marked. The saline solution is administered via the nasal passage, in line with current recommendations. Dosage varies according to age, and the pressure exerted on the unit dose enables the product to be administered into the nostril."
89006887|NCT06177171|Experimental|Phase 1: Olaparib, ASTX727 (D1,D3)-Starting Dose|Participants enrolled in the starting dose cohort will receive 300 mg Olaparib orally, twice a day (BID) on day 1 and day 14 for each 28-day cycle. Participants will also receive 35/100mg ASTX727 on days 1, and 3 of the 28-day cycle. Participants may continue study treatment indefinitely until disease progression unacceptable toxicity, withdrawal, or study closure; whichever comes first. If no DLTs are reported for the first 3 participants, an additional dose escalation cohort may open at the next dose level.
89006888|NCT06177171|Experimental|Phase 1: Olaparib + ASTX727 (D1,D3,D5)|If no DLTs are reported in the previous dose level, participants enrolled in this cohort will receive 300 mg olaparib orally, twice a day (BID) on day 1 and day 14 for each 28-day cycle. Participants will also receive 35/100mg ASTX727 on days 1, 3 and 5 of the 28-day cycle. Participants may continue study treatment indefinitely until disease progression unacceptable toxicity, withdrawal, or study closure; whichever comes first.
89006889|NCT06177171|Experimental|Phase 1b: RP2D (Olaparib, ASTX727) - Dose Expansion|Participants enrolled in this cohort will receive the RP2D based on the safety and efficacy profile determined in the Phase 1 cohorts. Participants will receive the RP2D dose of olaparib orally, twice a day (BID) on day 1 and day 14 for each 28-day cycle. Participants will also receive 35/100mg ASTX727 at the RP2D for the 28-day cycle. Participants may continue study treatment indefinitely until disease progression unacceptable toxicity, withdrawal, or study closure; whichever comes first.
89006890|NCT06177158|Active Comparator|cigarette smoker with gingivitis.|oral hygiene instructions
89006891|NCT06177158|Active Comparator|electronic cigarette smoker with gingivitis.|oral hygiene instructions
89006892|NCT06177158|Active Comparator|non-smoker with gingivitis.|oral hygiene instructions
89006893|NCT06177145|Experimental|experimental|This study was carried out with the immigrant women living in Akdağmadeni district of Yozgat province. Trainings and measurement tools in the HASCV-R programme was implemented in the training centres in the neighbourhoods where immigrant women lived with the support of Akdağmadeni Lausanne Immigrants Association.
89006894|NCT06177145|No Intervention|control|
89006895|NCT06177119|Experimental|Test 1|Scaling and root planing + Metronidazole (400 mg/thrice a day,TID) and Amoxicillin (500 mg/ TID) for 14 days, starting with the first SRP session
89006896|NCT06177119|Experimental|Test 2|Scaling and root planing (SRP) + Metronidazole (400 mg/thrice a day,TID) and Amoxicillin (500 mg/ TID) immediately after the end of the SRP in the following 14 days.
89006897|NCT06177093|Experimental|Interventional|All radiotherapy will be delivered on the MR-linac
89006898|NCT06177080|Other|Definitions of active phase angle of progression, head symphysis distance and examination findings|Definitions of active phase AOP and HSD and examination findings measured in each period according to the type of birth
89006900|NCT06177028|Experimental|Lenalidomide|Lenalidomide 10 mg/day taken daily orally for 26 weeks of treatment followed by 4 weeks of washout. The trial will last up to 30 weeks in duration.
89006901|NCT06177028|Placebo Comparator|Placebo|Placebo taken daily orally for 26 weeks of treatment followed by 4 weeks of washout. The trial will last up to 30 weeks in duration.
89530848|NCT02509715|Active Comparator|IONM group|Intraoperative nerve monitoring used thyroid surgery
89530849|NCT03344783||mother-children pairs|
89194986|NCT00812019|Experimental|7.5_0%MF59|Subjects received two 0.5mL vaccinations of cell culture derived H5N1 7.5µg subunit influenza vaccine containing 0% of MF59 three weeks apart.
89421966|NCT05108870|Experimental|Phase 1: Dose-Finding Group 2 - Drug Combination 2|"All participants in this group will receive alternating doses of HB-201 and HB-202 combined with chemotherapy using carboplatin and paclitaxel.~Participants will be given 3 doses of HB-201 & HB-202 alternating two vector therapy. Patients will receive 2 doses of HB-202 and 1 dose of HB-201. HB-202 will be administered on cycle 1 day 15 and cycle 3 day 15, and HB-201 will be administered on cycle 2 day 15 with three 21-day cycles of chemotherapy with carboplatin on day 1 and paclitaxel 100mg/m2 on days 1, 8, and 15."
89194987|NCT00812019|Experimental|7.5_25%MF59|Subjects received two 0.5mL vaccinations of cell culture derived H5N1 7.5µg subunit influenza vaccine containing 25% of MF59 three weeks apart.
89421967|NCT05108870|Experimental|Phase 2: Efficacy Arm 1 - HB-201 + Chemotherapy|"Participants in this group will receive HB-201 combined with chemotherapy using carboplatin and paclitaxel at the dose established in the first phase of the study.~After completing treatment at the established phase 2 dose, subjects will receive surgery, radiotherapy alone, or chemotherapy with radiotherapy together based on how their tumor responds to the medications."
89536047|NCT03202147|Active Comparator|ALZT-OP1a|ALZT-OP1a: cromolyn (17.1 mg, capsule) for oral inhalation via dry powder inhaler, taken twice per day (morning and evening), 8-12 hours apart.
89421968|NCT05108870|Experimental|Phase 2: Efficacy Arm 2 - HB-201 and HB-202 + Chemotherapy|"Participants in this group will receive alternating doses of HB-201 and HB-202 combined with chemotherapy using carboplatin and paclitaxel at the dose established in the first phase of the study.~After completing treatment at the established phase 2 dose, subjects will receive surgery, radiotherapy alone, or chemotherapy with radiotherapy together based on how their tumor responds to the medications."
89421969|NCT05107401|Experimental|Crowdsourced Intervention|The digital crowdsourced intervention will be presented to participants in the intervention arm.
89421970|NCT05107401|No Intervention|Standard of Care|Standard HIV informational materials currently used by the Kazakhstan Ministry of Health will be presented to participants in the control arm.
89421971|NCT05095948||Supportive Care (questionnaire, clinic conversation)|Patients complete questionnaires over 15-20 minutes and undergo audio recording of clinic conversations between the oncology team or the specialist palliative care team. Patients' medical records are also reviewed.
89421972|NCT05093855|Experimental|Treatment group|
89421973|NCT05080439|Experimental|Diacutaneous Fibrolysis|Diacutaneous Fibrolysis in the teres major muscle
89421974|NCT05080439|Experimental|Dry needling|Dry needling based on fast-in fast-out technique in the teres major muscle
89421975|NCT05070650|Experimental|Acetylcysteine/Paracetamol/Phenylephrine 200 mg/500 mg/10 mg granules for oral solution|Acetylcysteine/Paracetamol/Phenylephrine 200 mg/500 mg/10 mg granules for oral solution: one sachet three times per day
89421976|NCT05070650|Active Comparator|Paracetamol/Phenylephrine 500 mg/10 mg granules for oral solution|Paracetamol/Phenylephrine 500 mg/10 mg granules for oral solution: one sachet three times per day
89421977|NCT05056766||single group assignement|
88902453|NCT03772834|Experimental|Group I (methylphenidate, resistance training, walking)|Patients receive methylphenidate PO BID and undergo exercise program consisting of resistance training BIW and walking 15- 40 minutes a day 4 days a week for 12 weeks.
89006902|NCT06177002||Male COVID-19 patients|Male patients with an age > 18 affected by COVID-19 with biological samples positive for SARS-CoV-2 but with negative test
89421978|NCT05056324|Experimental|Intervention group|
89421979|NCT05056324|Active Comparator|Control group|
89421980|NCT05047211|Active Comparator|Oral Iron group|"Ferrous sulfate 325 mg (65 mg elemental iron) by mouth for a total of 6 weeks three times daily.~Intravenous placebo in sodium chloride 0.9% 500mL IV infusion will be given before discharge home over 1 hour preceded by placebo test dose IV infusion of 100mL 0.9% sodium chloride."
89421981|NCT05047211|Experimental|IV Iron group|"Low molecular weight iron dextran (infed) 1000mg in sodium chloride 0.9% 500mL IV infusion over 1 hour preceded by test dose 25 mg IV low molecular weight iron dextran infusion in 100mL 0.9% sodium chloride.~Oral placebo will be given by mouth for a total of 6 weeks TID."
89421982|NCT05040893|Experimental|Outpatient Physiotherapy Intervention|POETIC will test a patient-oriented, outpatient physiotherapy intervention tailored to each patient based on their symptoms, functional limitations, and goals. The intervention consists of eight one-on-one, supervised sessions delivered over 8 to 10 weeks, approximately one week apart. Each session will be approximately one hour long.
89421983|NCT04958642|Experimental|Adrabetadex|All participants receive their prescribed dose of adrabetadex. Dose is allowed to be adjusted down to a minimum of 400 milligrams (mg) or up to a maximum of 900 mg, at the investigator's discretion.
89421984|NCT04956432|Experimental|Treatment group A|SHR4640+Allopurinol Placebo；once a day, orally, for 52 weeks
89421985|NCT04956432|Active Comparator|Treatment group B|Allopurinol+ SHR4640 Placebo；once a day, orally, for 52 weeks.
89421986|NCT04950010|Experimental|High-Intensity Interval Training (HIIT)|Breast cancer survivors randomized to HIIT will participate in a high-intensity interval training program for 8 weeks.
89421987|NCT04950010|Active Comparator|Moderate-Intensity Exercise (MOD)|Breast cancer survivors randomized to MOD will participate in a moderate-intensity aerobic exercise program for 8 weeks.
88902454|NCT03772834|Active Comparator|Group II (placebo, resistance training, stretching)|Patients receive a placebo PO BID and undergo exercise program consisting of resistance training BIW and walking 15-40 minutes a day for 4 days a week for 12 weeks.
88902455|NCT03772834|Active Comparator|Group III (methylphenidate, stretching)|Patients receive methylphenidate PO BID and undergo stretching for 4 days a week for 12 weeks.
88902456|NCT03772834|Active Comparator|Group IV (placebo, stretching)|Patients receive a placebo PO BID and undergo stretching for 4 days a week for 12 weeks.
88902457|NCT03739073|Experimental|Patient with coronary arterial indication|A fundus oculi and an OCTA (angiography by tomography in optical coherence) examination will be performed for patients with intermediate stenosis of the left anterior descending artery (LDA).
88902458|NCT03735095|Experimental|Treatment (porfimer sodium, EBUS, and photodynamic therapy)|Patients receive porfimer sodium IV over 20 minutes 2-4 hours prior to the delivery of I-PDT. Patients then undergo EBUS-TBN guided I-PDT over 30-45 minutes.
89421988|NCT04950010|No Intervention|Usual Care (UC)|Individuals randomized to UC will be instructed to continue standard cancer care and engage in habitual lifestyle behaviors.
89421989|NCT04935762|Experimental|CST-103/CST-107 to Placebo|Subjects will receive daily doses of CST-103 co-administered with CST-107 for 14 days, followed by a washout period of no drug for 14 days, followed by matching placebo for CST-103 and matching placebo for CST-107 for 14 days.
89421990|NCT04935762|Experimental|Placebo to CST-103/CST-107|Subjects will receive daily doses of matching placebo for CST-103 and matching placebo for CST-107 for 14 days, followed by a washout period of no drug for 14 days, followed by daily doses of CST-103 co-administered with CST-107 for 14 days.
89421991|NCT04920084|Experimental|Plant-based meals|Patients who will be administered a whole-foods plant-based diet for 12 weeks with nutrition counselling for 24 weeks.Participants will be asked to complete a survey via MSK Engage and a notification will be sent via email notification.
89421992|NCT04914832|Experimental|All individuals who register on the National Vaccination Registry|This will be open-label, single-arm implementation study in Eswatini. All individuals who register on the National Vaccination Registry will be eligible for enrolment. Participants will receive appointments for vaccination using the registry.
89421993|NCT04912492|Active Comparator|RealConsent 1.0 with Alcohol|Men assigned to complete a web-based multi-media sexual violence and bystander intervention prevention program. Men assigned to alcohol intoxication arm (target breath alcohol concentration (BrAC=.08).
89421994|NCT04912492|Active Comparator|RealConsent 1.0 with Placebo|Men assigned to complete a web-based multi-media sexual violence and bystander intervention prevention program. Men assigned to a no-alcohol placebo control arm.
89421995|NCT04912492|Experimental|RealConsent2.0 with Alcohol|Men assigned to complete a revised web-based multi-media sexual violence and bystander intervention prevention program. Men assigned to alcohol intoxication arm (target BrAC=.08).
89006903|NCT06177002||male healthy individuals|Healthy donors with an age> 18 accessing the IRCCS OSR Blood Donor Center
89006904|NCT06176976|No Intervention|Thyroidectomy without lugols solution preparation|euthyroid patients undergoing total thyroidectomy for toxic thyroid disease, no preoperative preparation with 5% lugols solution
89006905|NCT06176976|Experimental|Thyroidectomy with lugols solution preparation|euthyroid patients undergoing total thyroidectomy for toxic thyroid disease, preoperative preparation with 5% lugols solution for 10 days
89421996|NCT04912492|Experimental|RealConsent2.0 with Placebo|Men assigned to complete a revised web-based multi-media sexual violence and bystander intervention prevention program. Men assigned to a no-alcohol placebo control arm.
89421997|NCT04912492|Active Comparator|Stress Management with Alcohol|Men assigned to complete a web-based stress management program. Men assigned to alcohol intoxication arm (target BrAC=.08).
89421998|NCT04912492|Active Comparator|Stress Management with Placebo|Men assigned to complete a web-based stress management program. Men assigned to a no-alcohol placebo control arm.
89421999|NCT04906278|Other|Amniotomy group|Amniotomy will be performed by toothed forceps. The handle of the device will be held with one hand outside the vagina while 2 fingers of the opposite hand will be placed in the vagina to guide the tip.
89422000|NCT04906278|Other|No-amniotomy group|No-amniotomy will be done
89422001|NCT04895475||Lactating Mothers|Lactating mothers who plan to receive or have received the SARS-CoV-2 vaccine within 60 days.
89422002|NCT04895202||Siponimod|Patients administered Siponimod as per Swiss label
89006906|NCT06176937|Active Comparator|hyaluronic acid gel|Hyaluronic acid considers as a high molecular weight glycosaminoglycan (GAG) consists of multiple disaccharide non-sulfated units of D-glucuronic acid and N-acetylglucosamine
89006907|NCT06176937|Other|empty socket|extraction socket without application any drug
89422003|NCT04895124||Healthy volunteers|
89422004|NCT04895124||Healthy smokers|
89422005|NCT04895124||COPD GOLD I|
89422006|NCT04895124||COPD GOLD II|
89422007|NCT04895124||COPD GOLD III/IV|
89422008|NCT04878458|Experimental|PEI+GSL+GT|Sixty-two patients with advanced primary angle-closure glaucoma will receive phacoemulsification with intraocular lens implantation combined with goniosynechialysis and goniotomy.
89422009|NCT04878458|Experimental|PEI+Trab|Sixty-two patients with advanced primary angle-closure glaucoma will receive phacoemulsification with intraocular lens implantation combined with trabeculectomy.
89422010|NCT04864587||Restorative colectomy with ileoanal pouch|Patients with restorative colectomy with ileoanal pouch who receive pouchoscopy for detection of pouchitis or neoplasm
89422011|NCT04845399|Experimental|Arm 1|Participants will receive prophylaxis treatment with Recombinant Human Coagulation Factor VIII-Fc fusion for 6 months.
89422012|NCT04841317|Experimental|Single-arm: Blood pressure intervention|Participants will use a mobile technology system comprising of a remote home blood pressure monitoring cuff and a mobile application integrated with a clinician-facing component to view and manage remote blood pressures. Participants will use this for 12 weeks, with assessment of blood pressure outcomes and anonymous surveys regarding the technology at 12 weeks.
89422013|NCT04826614|Experimental|optimized treatment|early adjust dose or change drug
89422014|NCT04826614|Active Comparator|routine treatment|slowly adjust dose or change drug
89422015|NCT04826523||Participants treated with Venetoclax|Participants who were prescribed venetoclax for the treatment of Acute Myeloid Leukemia (AML) will be enrolled for this study.
89422016|NCT04807374|Experimental|Single arm- HCL Therapy|Single arm study with all participants being treated with HCL for 6 months given the non-randomized interrupted time series study design.
89422017|NCT04766853|Active Comparator|Dexamethasone+Saline|
89422018|NCT04766853|Experimental|Dexamethasone+Hyaluronic Acid|
89422019|NCT04765605|Experimental|WeFlow-Tbranch Stent Graft System|Participants will be treated with WeFlow-Tbranch Stent Graft System
89422020|NCT04755218|Experimental|Vaginal Misoprostol|Patients will receive vaginal misoprostol 25 micrograms given every 3 hours for a maximum of 5 doses
89422021|NCT04755218|Active Comparator|Oral Misoprostol|Patients will receive oral misoprostol 100 micrograms given every 4 hours for a maximum of 2 doses.
89422022|NCT04732845|Experimental|Group A - NHL/CLL|"Upon enrollment, peripheral blood mononuclear cells will be collected, and T-cell selection and manufacture of CAR-T cells will be done.~Participants will receive 60 mg/Kg/IV Cyclophosphamide on day -6 and 25 mg/m^2 Fludarabine from day -5 to day -3.~Participants with CD19+ lymphomas and chronic lymphocytic leukemia will be enrolled on this arm sequentially in a 3 + 3 design starting with infusion of CAR-T cells at dose level 1 (DL1) on day 0.~The maximum tolerated dose (MTD) will be determined and then 6 additional participants will be enrolled at the MTD."
89422023|NCT04732845|Experimental|Group B - ALL|"Upon enrollment, peripheral blood mononuclear cells will be collected, and T-cell selection and manufacture of CAR-T cells will be done.~Participants will receive 60 mg/Kg/IV Cyclophosphamide on day -6 and 25 mg/m^2 Fludarabine from day -5 to day -3.~Participants with Acute Lymphoblastic Leukemia (and lymphoblastic lymphoma as a solid tumor equivalent) will be enrolled on this arm sequentially in a 3 + 3 design starting with infusion of CAR-T cells at DL1 on day 0 and 7.~The maximum tolerated dose (MTD) will be determined and then 6 additional participants will be enrolled at the MTD."
89422024|NCT04693585|Experimental|Arm 1: live support|Real-time live voice call plus standard of postnatal care.
89422025|NCT04693585|Experimental|Arm 2: asynchronous support|Text-based, asynchronous, on-demand social support plus standard of postnatal care
89006908|NCT06176924|Experimental|Active tDCS and Relaxation technique|Subjects within an experimental group had received 9 sessions of tDCS (2mA, 20 min anode placed on DLFPC of left side and cathode on supraorbital cortex of right side) along with relaxation technique.
89422026|NCT04693585|Experimental|Arm 3: both live and asynchronous support|Real-time live voice call plus standard of postnatal care; text-based, asynchronous, on-demand social support plus standard of postnatal care
89422027|NCT04693585|No Intervention|Arm 4: control|Standard of postnatal care.
89422028|NCT04670536||PASS LP implants|Patient suffering from a spinal degenerative disease and who is operated with PASS LP
89422029|NCT04670536||PASS Degen implants|Patient suffering from a spinal degenerative disease and who is operated with PASS DEGEN
89422030|NCT04670536||PASS Tulip PRIME implants|Patient suffering from a spinal degenerative disease and who is operated with PASS TULIP PRIME
89422031|NCT04634435|Experimental|Newly diagnosed multiple myeloma patients|Newly diagnosed MM patients who have minimal residual disease (MRD+) in first remission prior to autologous stem cell transplant (ASCT)
89422032|NCT04614610|Active Comparator|Lidocaine|Lidocaine 1.5mg/kg (Max: 200mg) in dextrose 5% 100mL over 10 minutes along with either morphine 0.1-0.15mg/kg IV OR hydromorphone 0.01-0.02mg/kg IV.
89422033|NCT04614610|Placebo Comparator|Placebo|Dextrose 5% 100mL (placebo) over 10 minutes along with either morphine 0.1-0.15mg/kg IV OR hydromorphone 0.01-0.02mg/kg IV.
89422034|NCT04613453|Experimental|Ketamine Infusion|Participants will receive four Ketamine infusions over two weeks, each 0.5mg/kg over 40 minutes.
89422035|NCT04613453|Active Comparator|Midazolam Infusion|Participants will receive four Midazolam infusions over two weeks, each 0.045mg/kg over 40 minutes.
89422036|NCT04562740|Experimental|ABLUMINUS DES|"ABLUMINUS DES drug eluting stent will be deployed after successful conventional balloon angioplasty.~Sirolimus drug dosage on the ABLUMINUS DES drug eluting stent system is determined by Concept Medical to deliver the optimal dose of sirolimus to the abluminal surface of the BTK lesions."
89422037|NCT04535219|Experimental|Group A|Participants will have vascular function assessed following total sleep deprivation
89422038|NCT04535219|No Intervention|Group B|Participants will have vascular function assessed following a full night of sleep
89422039|NCT04535219|Experimental|Group C|Participants will have vascular function assessed following total sleep deprivation preceded by exercise
89422040|NCT04535219|No Intervention|Group D|Participants will have vascular function assessed following a full night of sleep
89422041|NCT04499924|Experimental|Phase 2 Arm|Tucatinib + trastuzumab + ramucirumab + paclitaxel
89422042|NCT04499924|Experimental|Arm 3A|Tucatinib + trastuzumab + ramucirumab + paclitaxel
89194988|NCT00812019|Experimental|7.5_50%MF59|Subjects received two 0.5mL vaccinations of cell culture derived H5N1 7.5µg subunit influenza vaccine containing 50% of MF59 three weeks apart.
89422043|NCT04499924|Active Comparator|Arm 3B|Ramucirumab + paclitaxel + tucatinib placebo + trastuzumab placebo
89422044|NCT04499924|Experimental|Arm 3C|Tucatinib + ramucirumab + paclitaxel + trastuzumab placebo
89422045|NCT04481555|No Intervention|"Eosinophil_Control/Azithro_Control"|"Azithromycin: patients are given placebo~ICS: The patients are given the usual LAMA/LABA/ICS product in the usual dose."
89422046|NCT04481555|Experimental|"Eosinophil_Active/Azithro_Control:"|"a. Azithromycin: placebo b. ICS: All patients will receive LABA/LAMA medication. The ICS medication will be switched on/off according to the most recent blood eosinophil count (at inclusion + every 3 months): i. If blood eosinophil ≥ 300 cells/μL, ICS in usual dose next 3 months. Blood eosinophils are measured every 3 months.~ii. If blood eosinophil <300 cells/μL, ICS is discontinued."
89422047|NCT04481555|Experimental|"Eosinophil_Control/Azithro_Active group"|Azithromycin: 250 mg azithromycin three times weekly. b. ICS: The patients are given the usual LAMA/LABA/ICS product in the usual dose, where the medical treatment for severe COPD is unchanged throughout the entire project period
89422048|NCT04481555|Experimental|"Eosinophil_Active/Azithro_Active:"|"Azithromycin: 250 mg azithromycin three times weekly.~ICS: All patients will receive LABA/LAMA medication. The ICS medication will be switched on/off according to the most recent blood eosinophil count (at inclusion + every 3 months):"
89422049|NCT04453020|Experimental|LHA DBS|Subjects will receive bilateral DBS of the LHA
89422050|NCT04434768|Experimental|UMSC01|UMSC01 cells mixed with normal saline will be administered to patients after the onset of stroke.
89422051|NCT04370587|Experimental|Phase 1|T3011 single agent dose escalation in participants with solid tumors
89422052|NCT04370587|Experimental|Phase 2a Part 1 Arm A|RP2D T3011 single agent in participants with melanoma
89422053|NCT04370587|Experimental|Phase 2a Part 1 Arm B|RP2D T3011 single agent in participants with other solid tumors
89422054|NCT04370587|Experimental|Phase 2a Part 2 Arm C|RP2D T3011 + pembrolizumab in participants with NSCLC
89422055|NCT04370587|Experimental|Rollover Arm|RP2D T3011 + pembrolizumab in participants who have progressed on T3011 single agent
89422056|NCT04357353|Sham Comparator|Placebo|All arms will have phlebotomy (blood drawn). This group will receive saline injection only.
89422057|NCT04357353|Experimental|Platelet rich plasma|All arms will have phlebotomy (blood drawn). This group will receive PRP injection only.
88902459|NCT03726879|Experimental|Atezolizumab +ddAC-PacHP|Participants will receive atezolizumab (atezo) 840 mg IV Q2W for 4 cycles during neoadjuvant phase with ddAC (doxorubicin 60 mg/m2 & cyclophosphamide 600 mg/m2 IV), followed by atezo 1200 mg IV Q3W for 4 cycles with paclitaxel 80 mg/m2 IV weekly for 12 continuous weeks, trastuzumab 6 mg/kg IV (with initial 8mg/kg IV loading dose) Q3W for 4 cycles, & pertuzumab 420 mg IV (with initial 840-mg IV loading dose) Q3W for 4 cycles. During adjuvant phase, participants will continue to receive following study treatments Q3W to complete up to 1 year HER2-target therapy inclusive of therapy given both in neoadjuvant and adjuvant setting: atezo 1200 mg IV Q3W, trastuzumab 6 mg/kg IV (with initial 8-mg/kg IV loading dose) Q3W, & pertuzumab 420 mg IV (with initial 840-mg IV loading dose) Q3W. Participants who do not achieve pCR have option of receiving blinded atezo+trastuzumab emtansine post surgery for 14 cycles. In response to USM DIL dated 3 Feb 2021 treatment with atezo must be discontinued.
88902460|NCT03726879|Placebo Comparator|Placebo + ddAC-PacHP|Participants will receive placebo 840 mg IV Q2W for 4 cycles during neoadjuvant phase with ddAC (doxorubicin 60 mg/m2 & cyclophosphamide 600 mg/m2 IV), followed by placebo 1200 mg IV Q3W for 4 cycles with paclitaxel 80 mg/m2 IV weekly for 12 continuous weeks, trastuzumab 6 mg/kg IV (with initial 8-mg/kg IV loading dose) Q3W for 4 cycles & pertuzumab 420 mg IV (with initial 840-mg IV loading dose) Q3W for 4 cycles. During adjuvant phase, participants will continue to receive following study treatments Q3W to complete up to 1 year HER2-target therapy inclusive of therapy given both in neoadjuvant & adjuvant setting: placebo 1200 mg IV Q3W, trastuzumab 6 mg/kg IV (with initial 8-mg/kg IV loading dose) Q3W, & pertuzumab 420 mg IV (with initial 840-mg IV loading dose) Q3W. Participants who do not achieve pCR have option of receiving blinded atezolizumab + trastuzumab emtansine post surgery for 14 cycles. In response to USM DIL, dated 3 Feb 2021 treatment with placebo must be discontinued.
88902461|NCT03723187|Experimental|experimental group|use Normal saline
88902462|NCT03723187|Active Comparator|comparator group|use Heparin
89536048|NCT03202147|Placebo Comparator|Placebo|ALZT-OP1a: placebo capsule for oral inhalation via dry powder inhaler, taken twice per day (morning and evening), 8-12 hours apart.
88902463|NCT03721835|Other|Control femoral neck fracture system|This is a single arm study of subjects who are to be implanted with the CONQUEST FN™Femoral Neck Fracture System for treatment of a trauma related femoral neck fracture
88902464|NCT03716843||Pressure monitoring system for AIS|"Adolescent idiopathic scoliosis (AIS) patients~(1) all target subjects are aged 10 to 15 years old with immature skeletons (Risser grade 0-2); (2) they are diagnosed with AIS with a Cobb angle between 25-45° and high risk for curve progression; (3) the types of scoliosis are classified by the Lenke classification system; and (4) the subjects have received rigid brace treatment."
88902465|NCT03712462|Experimental|ABBT Weight Loss Therapy for BED|Acceptance-Based Behavioral Weight Loss Therapy for BED
88902466|NCT03712462|Active Comparator|Standard Behavior Therapy|Standard Behavioral Weight Loss Therapy
88902467|NCT03697096|Active Comparator|Routine Care|Continued routine antibiotic stewardship strategies.
88902468|NCT03697096|Active Comparator|INSPIRE CPOE Smart Prompt|Use of a computerized physician order entry (CPOE) smart prompt alert to guide empiric choice of antibiotics for UTI in non-ICU patients in the first 3 days of hospitalization.
88902469|NCT03697070|Active Comparator|Routine Care|Continued routine antibiotic stewardship strategies.
88902470|NCT03697070|Active Comparator|INSPIRE CPOE Smart Prompt|Use of a computerized physician order entry (CPOE) smart prompt alert to guide empiric choice of antibiotics for PNA in non-ICU patients in the first 3 days of hospitalization.
88902471|NCT03691051|Experimental|Pyrotinib Plus Capecitabine|Pyrotinib + Capecitabine
88902472|NCT03653598||AF patients|Patients with Atrial Fibrillation
88902473|NCT03630042|Experimental|Pembrolizumab and Rituximab|
88902474|NCT03565991|Experimental|Combination of avelumab and talazoparib|Single arm open label
88902475|NCT03535142|Experimental|Intervention|The intervention is bariatric surgery (Roux en Y gastric bypass or gastric sleeve operation).
88902476|NCT03535142|No Intervention|Control|Age, BMI and co-morbidity matched group who do not undergo surgery.
88902477|NCT03504488|Experimental|Monotherapy - CAB-ROR2-ADC (BA3021) alone|BA3021 alone Q2W dosing regimen
88902478|NCT03504488|Experimental|Combination Therapy|CAB-ROR2-ADC (BA3021) with PD-1 inhibitor
88902479|NCT03465813|Experimental|CaringGuidance Intervention|Three months of web-based CaringGuidance psychoeducational program use, independently on home computer in addition to usual care.
88902480|NCT03465813|No Intervention|Usual Care|Three months of care as usual from subjects' clinics and community as the subject chooses.
88902481|NCT03461276|Experimental|ABvac40|Six administrations of ABvac40; the first five administered once every 4 weeks and the sixth at week 42. Each administration consists of 1mL subcutaneous injection of ABvac40.
88902482|NCT03461276|Placebo Comparator|Placebo|Six administrations of Placebo; the first five administered once every 4 weeks and the sixth at week 42. Each administration consists of 1mL subcutaneous injection of the vaccine's vehicle buffer without the active component.
89006909|NCT06176924|Other|Relaxation technique|Subjects in the control group are going to receive 9 sessions of relaxation technique
89194989|NCT00812019|Experimental|7.5_100%MF59|Subjects received two 0.5mL vaccinations of cell culture derived H5N1 7.5µg subunit influenza vaccine containing 100% of MF59 three weeks apart.
89536049|NCT04492085||Primary hospital or clinics|
89536050|NCT04492085||Secondary hospital|
89536051|NCT04492085||Tertiary hospital|
89536052|NCT03213769|Active Comparator|topical coenzyme Q10 gel|Q10 gel will give 2 times /day after breakfast and evening meal for 7 days.
89422058|NCT04347447|Experimental|normal protein diet|The normal protein diet (Control) will contain the RDA for protein of (0.8 g/kg/d), with the protein provided from a variety of animal and plant-based sources, including lean beef (one 3-oz portion per week), chicken, eggs, dairy, beans, grains, nuts, seeds.
89422059|NCT04347447|Experimental|a beef protein-rich diet|High protein diet predominantly provided from lean beef (one 3-oz portion per day; total beef intake 24 oz/week). The energy content of the additional protein foods will be isocalorically offset by substitution for low-protein foods.
88902483|NCT03391362|Experimental|Stereotactic Radiation|"Stereotactic radiation will begin within 14 days of the MRI used for radiation planning~Lesions <2 cm in maximum diameter will be treated with stereotactic radiosurgery, generally 20 Gy in 1 fraction~Lesions between 2.0 and 3.0 cm in maximum diameter will generally be treated to 18 Gy in 1 fraction~Lesions >3 cm will be generally be treated with stereotactic radiotherapy to 30 Gy in 5 fractions"
88902484|NCT03364868|Experimental|oral insulin capsule (dose escalation using 3 dose strengths)|Dose 1 is 7.5 mg rH-insulin crystals; dose 2 is 22.5 mg rH-insulin crystals; dose 3 is 67.5 mg rH-insulin crystals. The insulin crystals are formulated together with filling substance (microcrystalline cellulose to a total weight of 200 mg) and contained in hard gelatine capsules. The study treatment will be given orally.
88902485|NCT03364868|Placebo Comparator|Placebo capsule|Daily treatment with placebo capsules containing filling substance (microcrystalline cellulose).
89194990|NCT00812019|Experimental|15_0%MF59|Subjects received two 0.5mL vaccinations of cell culture derived H5N1 15µg subunit influenza vaccine containing 0% of MF59 three weeks apart.
89422060|NCT04347447|Experimental|a protein-rich diet non-red meat|High-protein group from a variety of animal and plant-based sources (excluding additional red meats).
88902486|NCT03354897|Other|Treatment|16 weeks treatment 5mg/day
89422061|NCT04321343|Experimental|Group 1|PXL065 Dose 1
89422062|NCT04321343|Experimental|Group 2|PXL065 Dose 2
89422063|NCT04321343|Experimental|Group 3|PXL065 Dose 3
89422064|NCT04321343|Placebo Comparator|Group 4|Placebo oral tablet
89422065|NCT04318938|Active Comparator|Standard Arm with any available ALK TKI|"st line: Any approved 2nd-generation TKI according to investigator's choice~nd line: Any available ALK TKI according to investigator's choice (patients from the standard Arm A can be offered brigatinib in the 2nd line)"
89422066|NCT04318938|Experimental|Experimental Arm with Brigatinib|"st line: 90 mg brigatinib once daily p.o. for the first 7 days (lead-in) followed by 180 mg brigatinib once daily p.o. afterwards, starting with day 8~nd line: Any available ALK TKI according to investigator's choice"
88902487|NCT03332251|Experimental|Posture Correction Girdle|The design of posture correction girdle will incorporate different mechanisms, such as a) compression and pulling forces through a close fit of the intimate apparel, b) lumbar flexion by using a supporting belt, c) transverse forces applied by inserting pads inside the pocket lining by using the principle of the 3-point pressure system, d) axial rotation or coupled motion by using a system with uneven straps, and e) an active mechanism that aims to shift the trunk away from areas of pressure
89422067|NCT04298255|Experimental|ROSI only|Option 1: injecting extracted round spermatids (less mature form of haploid germ cells than elongated spermatid or spermatozoon) from male partner into the harvested egg of a female partner
89422068|NCT04298255|Experimental|Half ROSI-half Sperm Donor Fertilization|Option 2: Harvested eggs from the female partner will be separated in two groups, with one group being fertilized with round spermatids and the other group fertilized with donor sperm
89422069|NCT04292717|Active Comparator|Deficit-oriented training group|
89422070|NCT04292717|Active Comparator|Non-specific, standardised walking training group|
89422071|NCT04274153|Experimental|Gardasil9|Two doses of the 9-valent HPV vaccine to be administered to participants at 0 and 6 months. Additional HPV vaccine dose will be offered after final blood draw at 12 months.
89422072|NCT04238754|Experimental|Epidiolex (CBD) Then Placebo|Participants first receive 8 mL of Epidiolex (800 mg of cannabidiol) + 16 mL of inactive cherry syrup delivered every 12 hours for 48 hours total (4 doses) during which prescribed methadone is withheld. After 1 week, they receive 20 mL of inactive cherry syrup delivered every 12 hours for 48hours total (4 doses) during which prescribed methadone is withheld.
89536053|NCT03213769|Placebo Comparator|carbapol gel|placebo carbapol gel will give 2 times /day after breakfast and evening meal for 7 days.
88902488|NCT03332251|No Intervention|Control|No treatment will be provided for control participants.
88902489|NCT03186638|Experimental|Arm I (ibuprofen)|Patients receive ibuprofen PO BID for 6 weeks.
88902490|NCT03186638|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID for 6 weeks.
88902491|NCT03165292|Experimental|Arm A: High administered activity 131I-mIBG radiolabelled with iodine-131 and Topotecan|"The trial will evaluate two randomised arms. Each arm includes~three cycles of Temozolomide-Irinotecan, similar in both arms,~a specific consolidation course detailed hereinafter,~a BuMel sequence, followed by an ASCT, similar in both arms,~external radiotherapy as appropriate, and/or local surgery of the tumour residues as appropriate."
88902492|NCT03165292|Experimental|Arm B: High dose Thiotepa|"The trial will evaluate two randomised arms. Each arm includes~three cycles of Temozolomide-Irinotecan, similar in both arms,~a specific consolidation course detailed hereinafter,~a BuMel sequence, followed by an ASCT, similar in both arms,~external radiotherapy as appropriate, and/or local surgery of the tumour residues as appropriate."
88902493|NCT03075072|Active Comparator|Whole Brain Radiation|"MRI will be performed prior to radiation is administered~A hippocampal sparing approach will be used when possible~Dose will be 30 Gy in 10 fractions"
88902494|NCT03075072|Experimental|Stereotactic Radiation (SRS)|"MRI will be performed prior to radiation is administered~Radiation will be given in 1-5 fractions (dose depends on the size of the tumor that will be treated)"
88902495|NCT03010657|Experimental|Intervention|Subjects will add certain foods to what they normally eat.
88902496|NCT03010657|No Intervention|Non-experimental intervention|Subjects will continue eating normally.
88902497|NCT02998385|Active Comparator|Radiotherapy|"Arm A~Radiation therapy: 66 to 70 Gy in fractions of 2 Gy, 1 fraction/day, 5 fractions per week.~Radiation therapy will be conducted by conformational intensity modulation radiotherapy (IMRT) or protontherapy. Irradiation by 3D conformational radiotherapy can be discussed on a case by case with the Intergroup Coordinator GORTEC."
88902498|NCT02998385|Experimental|Radiotherapy + concomitant cisplatin|"Arm B Concomitant systemic treatment with cisplatin + radiotherapy~According to standard protocol of concomitant cisplatin 100 mg/m2 IV on day 1 - J22 - 43 (3 maximum cycles).~Radiation therapy: 66 to 70 Gy in fractions of 2 Gy, 1 fraction/day, 5 fractions per week.~Radiation therapy will be conducted by conformational intensity modulation radiotherapy (IMRT) or protontherapy. Irradiation by 3D conformational radiotherapy can be discussed on a case by case with the Intergroup Coordinator GORTEC"
88902499|NCT02958007|Experimental|Peer Education on Exercise for Recovery|A 24-week group-based peer coaching intervention delivered by a VA Peer Specialist, to promote participation in a supervised fitness training program and general physical activity
88902500|NCT02958007|Active Comparator|Enhanced supervised fitness training|A 24-week intervention to promote participation in a supervised fitness training program and general physical activity, which includes individual support from non-peer staff
88902501|NCT02876302|Experimental|Paclitaxel (12weeks)|"Paclitaxel is administered weekly followed by standard Doxorubicin and Dyclophosphamide (AC) given every 2 weeks for 4 cycles preoperatively~16 patients will be randomized from the Run-In 7 days of Ruxolitinib~The drug will be administered at a pre-determine dosage"
88902502|NCT02876302|Experimental|Ruxolitinib with Paclitaxel (12weeks)|"Paclitaxel is administered with daily Ruxolitinib, followed by standard Doxorubicin and Cyclophosphamide (AC) given every 2 weeks for 4 cycles preoperatively~16 patients will be randomized from the Run-In 7 days of Ruxolitinib~The drug will be administered at a pre-determine dosage"
89006910|NCT06176911|Experimental|Teriflunomide plus danazol|Oral teriflunomide was given at a starting dose of 7 mg once daily and danazol was given at a dose of 200mg twice daily for 24 weeks. Treatment was discontinued if very severe or life-threatening adverse events developed or at the patient's request.
89422073|NCT04238754|Placebo Comparator|Placebo Then Epidiolex|Participants first receive 20 mL of inactive cherry syrup delivered every 12 hours for 48hours total (4 doses) during which prescribed methadone is withheld. After 1 week washout, they receive 8 mL of Epidiolex (800 mg of cannabidiol) + 16 mL of inactive cherry syrup delivered every 12 hours for 48 hours total (4 doses) during which prescribed methadone is withheld.
89422074|NCT04232358|Experimental|Corticosteroid injections + resistance training|Corticosteroid injections every 4 weeks until symptoms resolve with a maximum of 3 injections + resistance training at home instructed via a smart phone training app and avoidance of pain aggravating activities for 3 months
89422075|NCT04232358|Placebo Comparator|Local anesthesia injections + resistance training|Local anesthesia injections every 4 weeks until symptoms resolve with a maximum of 3 injections + resistance training at home instructed via a smart phone training app and avoidance of pain aggravating activities for 3 months
89422076|NCT04225234|Active Comparator|Weight loss incentive|Participants will receive incentive rewards based on WEIGHT LOSS outcomes.
89422077|NCT04225234|Experimental|Weigh-in incentive|Participants will receive incentive rewards based on WEIGH-INs frequency
88902503|NCT02876302|Experimental|Ruxolitinib and Paclitaxel (12weeks)|"Paclitaxel is administered with daily Ruxolitinib, followed by standard Doxorubicin and Cyclophosphamide (AC) given every 2 weeks for 4 cycles preoperatively~32 patients will be randomized from the Run-In 7 days of Ruxolitinib + Paclitaxel~The drug will be administered at a pre-determine dosage"
88902504|NCT02846623|Experimental|Cohort I (obinutuzumab, atezolizumab, venetoclax)|Patients receive obinutuzumab IV over 4-6 hours on days 1, 2, 8, and 15 of cycle 1 and on day 1 of cycles 2-9 and atezolizumab IV over 30-60 minutes on days 3-4 of cycle 1 and on days 1-2 of cycles 2-9. Treatment repeats every 28 days for 9 cycles in the absence of disease progression or unacceptable toxicity. Beginning cycle 3, patients also receive venetoclax PO on days 1-28. Treatment repeats every 28 days for 14 cycles in the absence of disease progression or unacceptable toxicity.
88902505|NCT02846623|Experimental|Cohort II (obinutuzumab, atezolizumab, venetoclax)|Patients receive obinutuzumab intravenously IV over 4-6 hours on days 1, 2, 8, and 15 of cycle 1 and on day 1 of cycles 2-9 and atezolizumab IV over 30-60 minutes on days 3-4 of cycle 1 and on days 1-2 of cycles 2-9. Treatment repeats every 28 days for 9 cycles in the absence of disease progression or unacceptable toxicity. Beginning cycle 2, patients receive venetoclax PO on days 1-28. Treatment repeats every 28 days for 25 cycles in the absence of disease progression or unacceptable toxicity.
88902506|NCT02691663|Active Comparator|Oral bicarbonate supplementation group|0.3 meq/kg/day NaHCO3 capsules
89422078|NCT04225234|Experimental|Combination incentive|Participants will receive half of the incentive from WEIGHT LOSS and WEIGH-INs
89422079|NCT04225234|Experimental|Choice option incentive|Participants will choose one out of the three incentive programs (Weight-loss, Weigh-ins, and Combination).
88902507|NCT02691663|Placebo Comparator|Placebo group|Methylcellulose capsules
89422080|NCT04220190|Experimental|Phase 2/3 Expansion Cohort, Single-agent RAPA-501 T cells|80 x 10^6 cells per infusion (no host conditioning)
89422081|NCT04220190|Experimental|Phase 1/2 Only, Single-agent RAPA-501 T cells (dose level Arm 1)|Dose level 1 is 20 x 10^6 cells/infusion
89422082|NCT04220190|Experimental|: Phase 1/2 Only, Single-agent RAPA-501 T cells (dose level Arm 2)|Dose level 2 is 80 x 10^6 cells/infusion
89422083|NCT04220190|Experimental|Phase 1/2 Only, RAPA-501 + PC Regimen (Arm 3A)|RAPA-501 T cell therapy preceded by the 3-day pentostatin-cyclophosphamide (PC) regimen
89422084|NCT04213820|Active Comparator|Treatment as usual|Participants will receive treatment as usual at the eating disorder unit at the Child and adolescent psychiatric clinic and at the Psychiatric clinic during 4 weeks.
89422085|NCT04213820|Experimental|TMS and body image intervention|Participants will receive TMS and a body image intervention daily 5 times/week during 4 weeks
88902508|NCT02649868|Experimental|1|Treatment of hepatic tumors using bead embolization.
88902509|NCT02649868|Experimental|2|Treatment of hepatic tumors using bead embolization
88902510|NCT02639065|Experimental|Investigational Treatment|Durvalumab 1500 mg IV every 4 weeks (1 cycle) for a maximum 13 doses (12 months), or until unacceptable toxicities or disease recurrence.
89006911|NCT06176911|Active Comparator|Danazol|Danazol was given at a dose of 200 mg twice a day for 24 weeks. Treatment was discontinued if very severe or life-threatening adverse events developed or at the patient's request.
88902511|NCT02620072|Experimental|oral insulin capsule (dose escalation using 2 dose strengths)|Dose 1 is 7.5 mg rH-insulin crystals; dose 2 is 67.5 mg rH-insulin crystals. Insulin crystals are formulated together with filling substance (microcrystalline cellulose to a total weight of 200 mg) contained in hard gelatine capsules given orally.
88902512|NCT02620072|Placebo Comparator|Placebo capsule|Daily administration of placebo capsules containing filling substance (microcrystalline cellulose).
88902513|NCT02589106|Experimental|Anisotropic Textile Braces|The design of the anisotropic textile braces will provide different mechanisms with rigid, semi-rigid and flexible materials: a) axial elongation through a close fit of the brace supported with textile composites on the lateral sides of the trunk, b) 3-point pressure with push and counter-pushes through semi-rigid pads inserted inside the pocket lining, c) pulling or compression to correct kyphosis or lordosis in the sagittal plane with elastic bands, d) derotation between the pelvis and shoulders with uneven straps, and e) an active mechanism with sensors added to the brace to maintain correct posture.
89422086|NCT04213820|Sham Comparator|sham TMS and body image intervention|Participants will receive sham TMS and a body image intervention Daily 5 times/week during 4 weeks
89422087|NCT04212143||children with kidney disease|Kidney transplant recipients age 3 to 21 years
88902514|NCT02566785|Experimental|Intervention Group|Those allocated to the intervention group will participate in a supervised group session exercise one time per week and be asked to exercise two more times per week at home.
88902515|NCT02566785|Other|Wait List Control Group|The wait list control group will not participate in the intervention and will be asked to continue their usual activity level during the first 12 weeks and will receive the multi-component balance intervention during weeks 12-24.
88902516|NCT02532257|Experimental|Treatment (lenalidomide, rituximab, ibrutinib)|Patients receive lenalidomide PO on days 1-21, rituximab IV over 4-6 hours on days 1, 8, 15, and 22 of cycle 1 and day 1 of all subsequent cycles, and ibrutinib PO QD on days 1-28. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
88902517|NCT02441101|Experimental|RV DDD(R)-60 with AV optimization|RBBB pacing
88902518|NCT02441101|Placebo Comparator|RV DDD(R)-60|Standard demand pacing
88902519|NCT02344537|Experimental|Meditation Group Therapy|Kundalini Yoga incorporates mindfulness practice with a triad of stretching, breathing, and meditation. The three components of treatment consist of muscular relaxation/stretching exercises, a meditation period characterized by a directed breathing exercise, and then a guided meditation.
89422088|NCT04212143||healthy control|Healthy children age 3 to 21 years
89422089|NCT04208958|Experimental|VE800 combination treatment with nivolumab|Subjects received 5 days of oral vancomycin, followed by daily VE800 in combination with nivolumab every 4 weeks.
89422090|NCT04205955|Experimental|Arm I (diet modification coaching, motivational messages)|Patients receive diet modification coaching via telephone for 10 sessions over 30-60 minutes over 17 weeks. Patients also receive 3 motivational messages per week via email and/or text message beginning after session 6.
89422091|NCT04205955|Active Comparator|Arm II (standard of care, motivational messages)|Patients receive general healthy living education via telephone for 10 sessions over 30-60 minutes over 17 weeks. Patients also receive 3 motivational messages per week via email and/or text message beginning after session 6.
89422092|NCT04183179|Experimental|Program|"The 14-week healthy eating program activities including four components:~A 14-week parent Facebook-based program focusing on stress management and healthy eating to reduce emotional eating and increase parents' capacity to initiate healthy eating practices at home~Three parent face-to-face or virtual meetings at Head Start centers to connect parents with each other in person, offer healthy cooking tools/classes, and discuss behavioral change strategies and challenges~14-week child Eat My ABCs program at Head Start centers to provide an age-appropriate, healthy eating program to children~Weekly child letter to parents to connect child learning at the Head Start center with parental practices at home"
88902520|NCT02344537|No Intervention|Wait-List Controls|The wait-list group will not take part in study treatment (daily meditation or stretching) during the study wait of 8 weeks in order for us to compare change related to the study intervention to change associated with no active treatment ( treatment-as-usual). (After completing 8 weeks of no study treatment as part of the wait-list group, these patients will be offered the opportunity to receive 8 weeks of treatment.)
88902521|NCT02236429|Experimental|recurrent bacterial vaginitis|
88902522|NCT02113657|Experimental|Ipilimumab|Ipilimumab administered by vein at a dose of 3 mg/kg once every 3 weeks for a total of 4 doses.
88902523|NCT02004704|Experimental|GZ402665|GZ402665 administered intravenously once every 2 weeks at the dose each patient was receiving at the end of their previous olipudase alfa study, for 9 years or until olipudase alfa becomes commercially accessible, whichever comes first, unless the patient decides to enter another olipudase alfa clinical trial within the 9-year period prior to when olipudase alfa is commercially accessible.
88902524|NCT01971125||No treatment|"Patients with:~diabetes mellitus type 2~absence of heart disease previously reported~age >45 years~Informed Consent~Patients without:~presence of heart disease previously reported~diabetes type 1~serious systemic disease, with an expected lifetime lower than 2 years~no willingness to participate to the screening~inadequate compliance to study procedure~participation to other study"
88902525|NCT01415882|Experimental|Arm A (ixazomib citrate and dexamethasone, closed to accrual)|Patients receive ixazomib citrate PO on days 1, 8, and 15. Patients with lack of minor response by the end of the second cycle or lack of partial response by the end of the fourth cycle also receive dexamethasone PO on days 1, 2, 8, 9, 15, and 16. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88902526|NCT01415882|Experimental|Arm B (ixazomib citrate and dexamethasone)|Patients receive ixazomib citrate PO on days 1, 8, and 15 and dexamethasone PO on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89006912|NCT06176898|Experimental|Neurostimulating device.|
89422093|NCT04175444||Normal Subjects|This is a study of normal subjects to establish a normative database.
89536054|NCT05002101|Active Comparator|zinc group|The children were randomized to receive daily zinc sulphate. The elemental zinc dose was 3 mg/ day to children whose weight is less than 10 kg and 7 mg/ day to children whose weight is 10 kg or more.
89536055|NCT05002101|Placebo Comparator|placebo group|The placebo was non-nutritious and vitamin-free, designed to be identical to the zinc syrup in colour, odour, consistency and taste. Zinc and placebo syrups were packaged in similar bottles.
89194991|NCT00812019|Experimental|15_25%MF59|Subjects received two 0.5mL vaccinations of cell culture derived H5N1 15µg subunit influenza vaccine containing 25% of MF59 three weeks apart.
89006913|NCT06176872||Cardiac Computed Tomography Angiography|Patients with acute ischemic stroke who receive cardiac computed tomography angiography as part of the routine diagnostic work-up of acute ischemic stroke.
89194992|NCT00812019|Experimental|15_50%MF59|Subjects received two 0.5mL vaccinations of cell culture derived H5N1 15µg subunit influenza vaccine containing 50% of MF59 three weeks apart.
89194993|NCT00812019|Experimental|15_100%MF59|Subjects received two 0.5mL vaccinations of cell culture derived H5N1 15µg subunit influenza vaccine containing 100% of MF59 three weeks apart.
89422094|NCT04150068|Experimental|Cohort 1A: Lenacapavir|"Participants with human-immunodeficiency virus-1 ribonucleic acid (HIV-1 RNA) ≥ 400 copies/mL and with a <0.5 log10 HIV-1 RNA decline at Cohort Selection visit compared with screening visit will receive oral lenacapavir 600 mg tablet on Days 1 and 2 and 300 mg tablet on Day 8, while continuing their failing regimen in blinded Functional Monotherapy Period (Baseline to Day 14); followed by unblinded Maintenance Period where participants will receive subcutaneous (SC) lenacapavir 927 mg and will initiate an OBR at Day 1 SC Visit (14 days after the first dose of oral lenacapavir). Participants will receive their subsequent SC lenacapavir injection at Week 26 Visit (relative to Day 1 SC).~At Week 52 (relative to Day 1 SC), participants will be given an option to receive SC lenacapavir injections every 6 months (26 weeks), while continuing their OBR, until product becomes accessible to participants through an access program or until Gilead elects to discontinue the study in the country."
89422095|NCT04150068|Placebo Comparator|Cohort 1B: Placebo to Lenacapavir|"Participants with HIV-1 RNA ≥ 400 copies/mL and with a <0.5 log10 HIV-1 RNA decline at the Cohort Selection visit compared with screening visit will receive oral lenacapavir placebo on Days 1, 2, and 8 while continuing their failing regimen in blinded Functional Monotherapy Period (Baseline to Day 14); followed by unblinded Maintenance Period where participants will receive oral lenacapavir 600 mg on Days 15 and 16 and 300 mg on Day 22, and will initiate an OBR on Day 15. At Day 1 SC (14 days after the first dose of oral lenacapavir), participants will receive SC lenacapavir 927 mg while continuing OBR. Participants will receive their next SC injection at the Week 26 Visit (relative to Day 1 SC).~At Week 52 (relative to Day 1 SC), participants will be given an option to receive SC lenacapavir every 6 months (26 weeks), while continuing their OBR, until the product becomes accessible to participants through an access program or until Gilead elects to discontinue study in the country."
89006914|NCT06176872||Retrospective matched cohort|A retrospective matched cohort of patients with acute ischemic stroke who did not receive cardiac computed tomography angiography.
89006915|NCT06176859|Experimental|Home-based PrEP|In the home-based PrEP arm, participants will complete the HIV self-test at home with support received through telemedicine or over the phone. Confirmation of HIV test result will be shared with the provider through a photograph of the test. PrEP refills will be delivered to participants at home by courier.
89006916|NCT06176859|Active Comparator|Community-based PrEP|In the community-based PrEP arm, participants will be tested using rapid diagnostic tests (RDT) in person (at a community venue) or through telemedicine (at a community venue) where they will be linked by counsellor telephonically to nurse or clinician. PrEP refills will be collected by participants at a community venue.
89006917|NCT06176846|Experimental|Immersive Virtual Reality Exergaming Group|Patients in this group will be included in an exergaming program using Oculus Quest 3 glasses.
89006918|NCT06176846|Experimental|Home-Based Exercise Group|Patients in this group will be included in a home-based exercise program.
89006919|NCT06176833|Active Comparator|Early Intervention|Additional training will begin no more than 60 days following spinal cord injury
89006920|NCT06176833|Active Comparator|Sub-acute Intervention|Additional training will occur 3 months following spinal cord injury
89006921|NCT06176833|Active Comparator|Chronic Intervention|Additional training will occur 6-12 months following SCI
89006922|NCT06176833|No Intervention|Standard of Care|This group only receives standard of care treatment but is assessed at the same time points as the other groups
89006923|NCT06176781|Experimental|Sequential group|Edaravone Dexborneol concentrated solution for injections 37.5 mg BID administered intravenously for 5 - 10 days, and then followed by Edaravone Dexborneol Sublingual Tablets 30 mg BID administered sublingually for the last days, the total duration of treatment was 14 days
89006924|NCT06176781|Placebo Comparator|Placebo group|Injection Simulants(Edaravone Dexborneol concentrated solution for injections) administered intravenously for 5 - 10 days, and then followed by Sublingual Tablet Simulants(Edaravone Dexborneol Sublingual Tablets) BID administered sublingually for the last days, the total duration of treatment was 14 days
89422096|NCT04150068|Experimental|Cohort 2: Lenacapavir|"Participants with a ≥ 0.5 log10 copies/mL HIV-1 RNA decline at the Cohort Selection Visit compared with the screening visit or with HIV-1 RNA < 400 copies/mL or if Cohort 1 is fully enrolled will receive oral lenacapavir 600 mg tablet on Days 1 and 2 and 300 mg tablet on Day 8, and will initiate an OBR on Day 1 in Oral Lead-in Period (Baseline to Day 14); followed by Maintenance Period where participants will receive SC lenacapavir 927 mg at Day 1 SC Visit (14 days after the first dose of oral lenacapavir) while continuing their OBR. Participants will receive their subsequent SC lenacapavir injection at the Week 26 Visit (relative to Day 1 SC).~At Week 52 (relative to Day 1 SC), participants will be given the option to receive SC lenacapavir injections every 6 months (26 weeks), while continuing their OBR, until the product becomes accessible to participants through an access program or until Gilead elects to discontinue the study in the country."
89422097|NCT04144153|Experimental|Opioid Free Anesthesia Group|
89422098|NCT04144153|Active Comparator|Opioid Anesthesia Group|
89422099|NCT04128995|Active Comparator|Medical Therapy and Bariatric Surgery in Youth with Type 2 Diabetes|Youth with type 2 diabetes undergoing bariatric surgery, n=45
89422100|NCT04128995|Active Comparator|Medical Therapy in Youth with Type 2 Diabetesin Youth with Type 2 Diabetes|Youth with type 2 diabetes receiving medical management, n=45
89422101|NCT04128995|Active Comparator|Bariatric Surgery in Youth with Obesity|Youth with no obesity undergoing bariatric surgery, n=10
88902527|NCT01415882|Experimental|Arm C (higher-dose ixazomib citrate and dexamethasone)|Patients receive higher doses of ixazomib citrate PO on days 1, 8, and 15 and dexamethasone PO on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89422102|NCT04126577||Patients with suspected peritonitis|Secondary peritonitis, sepsis and endotoxemia
89422103|NCT04114175|Active Comparator|Control Group|People with unilateral transtibial amputation. Participants will be provided from the sample group according to the randomization.
89422104|NCT04114175|Experimental|Spinal Stabilization Group|People with unilateral transtibial amputation. Participants will be provided from the sample group according to the randomization.
89422105|NCT04106154|Experimental|Intervention|The kinesiology intervention will involve physical activity education appropriate to the MC&D delivered in a group format through twelve 2.5-hour weekly sessions49 (30 hours of kinesiology support). The sessions will combine participation in physical activities appropriate to the MC&D with education and goal-setting discussions. Each week, children will be guided to develop an individualized SMART (Specific, Measurable, Agreed upon, Realistic, Time-based) plan for changing their activity behaviour. Their weekly SMART plan, which will require an additional 2 hours per week, will specify the home/community activities they will do prior to the next session.
89422106|NCT04106154|No Intervention|Control|Patients in the control group will continue with clinical care as usual. To encourage their cooperation, children in the control group will be offered the intervention after all of their study visits have been completed.
89422107|NCT04056247||Newly diagnosed NSCLC stage IV|Patients with newly diagnosed stage IV NSCLC treated with Immunotherapy or Immunotherapy + Chemotherapy.
89422108|NCT04056247||NSCLC stage IV 2nd line and further of immunotherapy|Patients with NSCLC stage IV treated with Immunotherapy at 2nd line or consecutive lines.
89422109|NCT04056247||Malignant melanoma stage IV|Patients with stage IV malignant melanoma treated with Immunotherapy with or without targeted therapy.
89422110|NCT04056247||Malignant melanoma stage IIIb-d|Patients with stage IIIb-d malignant melanoma treated with Immunotherapy as adjuvant therapy.
89422111|NCT04056247||SCLC stage IV|Patients with stage IV SCLC treated with Immunotherapy or Immunotherapy + Chemotherapy.
88902528|NCT01415882|Experimental|Arm D (ixazomib citrate, dexamethasone, and cyclophosphamide)|Patients receive ixazomib citrate PO on days 1, 8, and 15 and cyclophosphamide PO (cycles 1-18 only) and dexamethasone PO on days 1, 8, 15, and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88902529|NCT01415882|Experimental|Arm E (ixazomib citrate, cyclophosphamide, daratumumab)|Patients receive ixazomib citrate PO on days 1, 8, and 15, cyclophosphamide PO (cycles 1-12 only) on days 1, 8, 15, 22, and daratumumab IV on days 1, 8, 15, 22 (cycles 1-2), days 1 and 15 (cycles 3-6), and day 1 in all subsequent cycles. Patients also receive dexamethasone IV or PO on days 1, 8, 15, and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89422112|NCT04045184||B-FED|Clients of the Birmingham AIDS Outreach Food and Education Delivery (B-FED) program who are also patients at the 1917 Clinic.
89422113|NCT04045184||non B-FED|Patients at the 1917 Clinic who have chosen not to participate in B-FED at this time.
88902530|NCT01254942|Active Comparator|Usual Care|Usual care following hip fracture
89422114|NCT04028531||Sample Collection|"Blood tests required for assessment~Specimens and data will also be collected from outside sites~Clinical data from patients with Chronic Lymphocytic Leukemia will be gathered into a database at Dana Farber Cancer Institute"
88902531|NCT01254942|Experimental|Intervention|Follow-up Fracture Clinic
88902532|NCT01113112||Biobehavioral factors|Those with biobehavioral factors that contribute to a permissive local environment for macrophage-tumor interactions that enhance tumor growth in ovarian cancer
88902533|NCT01092702|Other|Varenicline|Everyone on study will receive Varenicline daily for 12 weeks
88902534|NCT01057134|Experimental|Site treated with UHAIR|The arm, calf, and thigh will be treated
89194994|NCT00413959|Experimental|Velcade, Rituximab,Cyclophosphamide & Decadron|Velcade 375 mg/m^2 given intravenously on days 1, 8, 15 and 22 during the first cycle then on day 1 of each subsequent cycle.
89194995|NCT00814905|Placebo Comparator|vaginal delivery 1|no further antibiotics after delivery (the patient will receive a saline infusion instead of antibiotics)
89422115|NCT04003896|Experimental|Abemaciclib|Abemaciclib will be given as a single oral agent A sample size of 10 subjects is determined to be minimally sufficient for these pilot study objectives. The starting dose will be 200 mg twice daily. Dosing will continue daily for 28 days, this being one cycle. There will be no protocol scheduled hiatus and daily dosing will be continuous unless there is unacceptable toxicity, disease progression, or death.
89422116|NCT03996005|Experimental|MRI Guided Transurethral Ultrasound|Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Tissue
88902535|NCT00926848|Experimental|PaTH intervention group|"The PaTH intervention group for patients and partners consisted of participation in a structured and formal cardiac rehabilitation program:~18-36 exercise sessions~18 educational sessions. The intervention consisted of patients and partners participating together in a formal cardiac rehabilitation program when typically just patients participate. In addition, partners were asked to make the same healthy eating and exercise changes that patients did to meet guidelines for health."
88902536|NCT00926848|Active Comparator|Usual care group|"The usual care group intervention for patients only consisted of participation in a structured and formal cardiac rehabilitation program:~18-36 exercise sessions and 18 educational sessions~Partners participated in the 18 educational sessions only."
89422117|NCT03952156|Experimental|Cohort 1|Dose Level 1 of HMI-102 delivered intravenously one time
89422118|NCT03952156|Experimental|Cohort 2|Dose Level 2 of HMI-102 delivered intravenously one time
88902537|NCT00919217||Relapsing-remitting multiple sclerosis|Females with relapsing-remitting multiple sclerosis
88902538|NCT00861848||12-50 with heart disease|12-50 with heart disease
88902539|NCT00861848||12-50 normal controls|12-50 normal controls
88902540|NCT00658879||Somavert (Pegvisomant)|Patients taking Somavert (Pegvisomant).
88902541|NCT00600717||Pediatric Patients and Healthy Children|Healthy children without dental works. Pediatric patients with epilepsy and migraine (headache).
89422119|NCT03952156|Experimental|Cohort 3|Dose Level 3 of HMI-102 delivered intravenously one time
89422120|NCT03952156|Experimental|Delayed Treatment Control|Delayed Treatment Control Arm
89422121|NCT03952156|Experimental|Expansion Phase First Dose level|Expansion Phase First Dose Level of HMI-102 delivered intravenously one time
89422122|NCT03952156|Experimental|Expansion Phase Second Dose level|Expansion Phase Second Dose Level of HMI-102 delivered intravenously one time
88902542|NCT00591851|Experimental|1|single arm study
89194996|NCT00814905|Active Comparator|vaginal delivery antibotics2|one additional dose of antibiotics (ampicillin 2 grams IV, gentamicin 1.5 mg/kg IV) following vaginal delivery
89422123|NCT03925675|Experimental|Axumin (fluciclovine-F18) PET/CT scan|Axumin (fluciclovine-F18) PET/CT scan to evaluate possible glioma recurrence to help differentiate scar (fake recurrence) from true tumor recurrence
89422124|NCT03920293|Experimental|Ravulizumab|Participants will receive ravulizumab for the duration of the study.
89422125|NCT03920293|Placebo Comparator|Placebo|Participants will receive placebo during the 26-week randomized-controlled period of the study, after which they will enter the open-label extension period of the study and receive ravulizumab.
89422126|NCT03912376||Healthy Volunteer|Healthy status is defined by absence of evidence of any active or chronic disease following a detailed medical and surgical history.
89422127|NCT03910387|Experimental|Group 1 (gemcitabine/nab-paclitaxel and telotristat ethyl)|Patients receive gemcitabine/nab-paclitaxel combination chemotherapy on days 1, 8 and 15, and telotristat ethyl PO QD, BID, or TID on days 1 and 8. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89422128|NCT03910387|Active Comparator|Group 2 (gemcitabine/nab-paclitaxel)|Patients receive gemcitabine/nab-paclitaxel chemotherapy (at the discretion of the investigator) on days 1, 8 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88902543|NCT00336024|Active Comparator|Arm I (induction+consolidation chemotherapy, autologous PBSC)|"Patients receive vincristine IV over 1 minute on days 1, 8, and 15; etoposide IV over 1 hour on days 1-3; cyclophosphamide IV over 1 hour on days 1 and 2; cisplatin IV over 6 hours on day 3. Treatment repeats every 3 weeks for 3 courses.~Within 6 weeks after completion of induction therapy, patients receive consolidation therapy comprising carboplatin IV over 2 hours and thiotepa IV over 2 hours on days 1 and 2 and G-CSF IV or SC beginning on day 5 and continuing until blood counts recover. Patients also receive autologous PBSC IV on day 4. Treatment repeats every 4 weeks for 3 courses in the absence of disease progression or unacceptable toxicity."
88902544|NCT00336024|Experimental|Arm II (induction+consolidation chemotherapy, autologous PBSC)|"Patients receive vincristine IV over 1 minute on days 1, 8, and 15; high-dose methotrexate IV over 4 hours on day 1; and leucovorin calcium IV or PO every 6 hours beginning on day 2 and continuing until methotrexate levels are in a safe range. Patients then receive etoposide IV over 1 hour on approximately days 4, 5, and 6, cyclophosphamide IV over 1 hour on approximately days 4 and 5, and cisplatin IV over 6 hours on approximately day 6. Treatment repeats every 3 weeks for 3 courses.~Within 6 weeks after completion of induction therapy, patients receive consolidation therapy comprising carboplatin IV over 2 hours and thiotepa IV over 2 hours on days 1 and 2 and G-CSF IV or SC beginning on day 5 and continuing until blood counts recover. Patients also receive autologous PBSC IV on day 4. Treatment repeats every 4 weeks for 3 courses in the absence of disease progression or unacceptable toxicity."
89422129|NCT03871712|Experimental|Motivational Interview (MI)|In the MI arm, a NAV case worker will meet the participants after the baseline assessment (electronic questionnaires) and randomisation and conduct the MI. The NAV case-worker will either meet (or call) again after a few weeks (anticipated 2-4 weeks) and conduct another MI.
89422130|NCT03871712|Active Comparator|Stratified vocational advice intervention (SVAI)|A trained physiotherapist will call the participants after the baseline assessment and randomisation. The SVAI intervention will be stratified due to the participants risk of long term sick leave estimated by the Orebro Screening Questionnaire and The Keele STarT MSK Tool. The low/moderate risk group will receive 1-2 phone calls, and the high risk group will be followed up 2-4 times. The follow-up can include face to face Meetings bewteen the Physical therapist and the participant, and also the employer and general practitioner when needed. The intervention will include an assessment of the participants obstacles for returning to work and help to develop and implement an action plan to overcome obstacles. The physical therapists' will cooperate with other health care providers and employer when needed.
88902545|NCT00133705|Experimental|Mifepristone|Mifepristone 5 MG capsule taken once daily by mouth
88902546|NCT00133705|Placebo Comparator|Inert capsule|Placebo (for Mifepristone) capsule of nearly identical color, size, and weight taken once daily by mouth
88902547|NCT01525017|Experimental|Combig-DC Cancer Vaccine|Two vaccinations of Combig-DC (allogeneic dendritic cells) Cancer Vaccine given before nephrectomy.
88902548|NCT01525043|Active Comparator|Naproxen|
88902549|NCT01525043|Experimental|Synera single patch applied for 12 hrs/day|
88902550|NCT01525043|Experimental|Synera sinlgle patch applied for 4hrs twice daily|
88902551|NCT01525056|Other|imaging with ct, mri and pet scans|ct,mri and pet scans pre and post radiation
88902552|NCT01525095||Candida Positive Patients|Symptomatic adult patients, confirmed via concordant diagnostic blood culture and species identification and subsequent second blood culture results and species identification that are Candida positive
88902553|NCT01525095||Candida Negative Patients|Hospitalized adult patients, confirmed via concordant diagnostic blood culture with subsequent species identification and subsequent second blood culture with subsequent species identification that are Candida negative
88902554|NCT01525108|Experimental|Home-based blood pressure monitoring|
88902555|NCT01525108|Active Comparator|Usual care|
88902556|NCT01525121|Experimental|Expiratory Rib Cage Compression|This a crossover study, so all subjects performed both, control and experimental interventions. The patients were kept in supine at 30 degree head-up position. Ventilatory mode was changed to volume-controlled, with a tidal volume of 8mL/kg, inspiratory flow of 60 Lpm and positive end expiratory pressure (PEEP) of 5 cmH2O. A first tracheal suctioning was done, and the mucus was discarded. Then, a series of two minutes of bilateral expiratory rib-cage compressions ensued. Aiming to minimize inter-therapist variability, the maneuver was applied by the same registered and trained physiotherapist. Control intervention followed the same sequence, but instead of the compressive maneuver they were kept on normal ventilation with the parameters described above.
89006925|NCT06176742|Experimental|Bubble Positive Expiratory Pressure Device|Diaphragmatic breathing technique will be the baseline treatment. B group will be treated with bubble positive expiratory pressure device. Patients will be encouraged to blow down the tubing into the water, and make bubbles. This creates positive pressure back up the tubing and into patient's airways and lungs. As the pressure holds open your patient's airways, it helps more air to move in and out of their lungs. All study participant will receive a total of 18 treatment sessions over a six-week period, which consisted of 03 treatment sessions per week.
89422131|NCT03871712|No Intervention|Usual follow-up|This arm will be the control group receiving usual NAV follow-up. The other two groups will also receive usual NAV follow-up additionally to the interventions.
89006926|NCT06176742|Active Comparator|Active Cycle Breathing Technique|"Diaphragmatic breathing technique will be the baseline treatment.A group will be treated with active cycle breathing technique. The technique consists of inspiratory hold technique, deep breathing and forced expiration. These are repeated in a cycle until your chest feels clear. You can carry out ACBT when either sitting or lying down.~Physiotherapist will discuss this with you during your physiotherapy assessment. All study participant will receive a total of 18 treatment sessions over a six-week period, which consisted of 03 treatment sessions per week."
89422132|NCT03851445|Other|Lung-MAP Screening|This is a screening study and does not have an intervention. LUNGMAP is an overarching umbrella study to which patients are screened and then assigned to a treatment sub-study. The treatment sub-studies are standalone trials and have their own NCT numbers. The Lung-MAP Study is considered a single study under one IND, consisting of the Screening Protocol and multiple sub-studies. Each sub-study protocol operates independently and has its own version date.
89422133|NCT03844815|Experimental|Treatment|"Cycle 1 of Treatment will be Decitabine days 1-10 plus Venetoclax ramp up on days 1-3 followed by Venetoclax target dose on days 4-21~Cycle 2 of Treatment will be Decitabine days 1-10 plus Venetcolax target dose days 1-21~During maintenance Decitabine on days 1-5 plus Venetoclax days 1-21"
89006927|NCT06176729|Experimental|Experimental arm|Pola-R2 regimen Drug: Polatuzumab Vedotin, Rituximab, Lenalidomide polatuzumab vedotin 1.8 mg/kg ivgtt D1, rituximab375 mg/m2 ivgtt D1, lenalidomide 25mg po D1-14, one cycle every 21 days
89006928|NCT06176716|Experimental|participants with mild hepatic impairment (Child-Pugh A)|
89006929|NCT06176716|Experimental|participants with moderate hepatic impairment (Child-Pugh B)|
89006930|NCT06176716|Experimental|Normal hepatic function|
89422134|NCT03841669|Experimental|Aerobic Exercise Group|This is the experimental group. Exercise is prescribed for 150 min/week. Due to COVID-19 restrictions the exercise supervision was allowed to be either remotely or in the context of a laboratory setting.
89422135|NCT03841669|Active Comparator|Physical Activity & Health Information Group|This is the control group. Participants will engage in daily life monitoring every 6 weeks.
89422136|NCT03838445|Experimental|Therapy: V-Wave Shunt|Treatment arm patients will undergo a diagnostic right heart catheterization and invasive echocardiography to determine study eligibility followed by transseptal catheterization and V-Wave Shunt implantation.
88902557|NCT01525121|No Intervention|Control|This a crossover study, so all subjects performed both, control and experimental interventions. The patients were kept in supine at 30 degree head-up position. Ventilatory mode was changed to volume-controlled, with a tidal volume of 8mL/kg, inspiratory flow of 60 Lpm and positive end expiratory pressure (PEEP) of 5 cmH2O. A first tracheal suctioning was done, and the mucus was discarded. Then, a series of two minutes of bilateral expiratory rib-cage compressions ensued. Aiming to minimize inter-therapist variability, the maneuver was applied by the same registered and trained physiotherapist. Control intervention followed the same sequence, but instead of the compressive maneuver they were kept on normal ventilation with the parameters described above.
88902558|NCT01525147|Experimental|YHB1411-2: Level 2|The ratio of Test Drug(YHB1411-2) to Placebo is 4 :1.
88902559|NCT01525147|Experimental|YHB1411-2: Level 3|The ratio of Test Drug(YHB1411-2) to Placebo is 13 :2.
88902560|NCT01525147|Experimental|YHB1411-2: Level 4|The ratio of Test Drug(YHB1411-2) to Placebo is 4 :1.
88902561|NCT01525147|Experimental|YHB1411-2: Level 5|The ratio of Test Drug(YHB1411-2) to Placebo is 4 :1.
88902562|NCT01525147|Experimental|YHB1411-2: Level 1|All investigational products are YHB1411-2(This level is pilot study).
88902563|NCT01525199||Case|
88902564|NCT01525199||Control|
88902565|NCT01525212|Experimental|Arm 1: BMS-929075 (≤ 25 mg) OR Placebo matching BMS-929075|
88902566|NCT01525212|Experimental|Arm 2: BMS-929075 (≤ 100 mg) OR Placebo matching BMS-929075|
88902567|NCT01525212|Experimental|Arm 3: BMS-929075 (≤ 400 mg) OR Placebo matching BMS-929075|
88902568|NCT01525212|Experimental|Arm 4: BMS-929075 (≤ 800 mg) OR Placebo matching BMS-929075|
88902569|NCT01525264|Experimental|Culturally Relavent Education|Education about improving diet using a DVD with Korean role models and native Korean language.
88902570|NCT01525264|Active Comparator|Healthy Wife Intervention|Intervention group of couples who received education about importance of a Healthy Diet. It was an attention control group
88902571|NCT01525277||left subclavian vein|CVC implanted in the left subclavian vein
88902572|NCT01525277||right subclavian vein|CVC implanted in the right subclavian vein
88902573|NCT01525290|Experimental|intravenous tissue plasminogen activator|Intervention drug: intravenous tissue plasminogen activator (tPA), alteplase
88902574|NCT01525290|Placebo Comparator|Placebo|Intervention drug: placebo
88902575|NCT01525303|Experimental|Exercise-Start (ES)|The ES group will receive standard behavioral treatment in the Self-Management Training Program for Chronic Headaches. In addition to this material, participants in this group will receive an exercise prescription for 20 minutes of moderate-intensity aerobic activity at the beginning of Week 1. The exercise prescription will increase to 25 minutes in Week 2, and 30 minutes in Week 3. They are asked to maintain 30 minutes per day of exercise through Week 8. Participants choose the type of exercise, and have the option to break it up into 10-minute increments throughout the day.
88902576|NCT01525303|Experimental|Exercise-Middle (EM)|The EM group will receive standard behavioral treatment in the Self-Management Training Program for Chronic Headaches.In addition to this material, participants in this group will receive an exercise prescription for 20 minutes of moderate-intensity aerobic activity at the beginning of Week 5. The exercise prescription will increase to 25 minutes in Week 6, and 30 minutes in Week 7. They are asked to maintain 30 minutes per day of exercise through Week 8. Participants choose the type of exercise, and have the option to break it up into 10-minute increments throughout the day.
88902577|NCT01525355||EUS prior to ERCP|
88902578|NCT01525368||cognitive intervention group|
89422137|NCT03791619|Active Comparator|Higher Cylinder Toric IOL|Consented subjects that are eligible will have both eyes implanted with a TECNIS Symfony IOL. Each eye may have a different TECNIS Symfony IOL implanted, as determined by the surgeon and the TECNIS Symfony Toric IOL calculator; however, at least one eye must be implanted with either a Symfony Toric IOL Model ZXT150 (lower-cylinder group) or a Model ZXT300 or ZXT375 (higher-cylinder group) and the fellow eye must have the same or a lower toric power. The eye with the highest toric power IOL will determine the model group.
88902579|NCT01525368||active control group|
88902580|NCT01525433|No Intervention|Control|
88902581|NCT01525433|Active Comparator|Low Intensity Information (DVD)|A low-intensity information program, consisting of a video approach educating women on the importance of cervical cancer screening;
88902582|NCT01525433|Active Comparator|High Intensity Information (Promotora)|A higher intensity information program consisting of the video plus a 'promotora' or lay-community health educator led-intervention at the participant's home to encourage cervical cancer screening.
88902583|NCT01525446|Experimental|SBRT with proton beam radiation|4 consecutive days for the delivery of 48 Gy (tumors 3 cm or less) or 5 consecutive days for the delivery of 60 Gy (tumors of > 3 cm)
88902584|NCT01525459||Glioma patients|
88902585|NCT01525485||Electrical Stimulation|Participants will have a dedicated visit with a pelvic floor physical therapist during which instructions on usage and technique for the Minnova unit will be given. The electrical parameters selected will be: 10 Hertz frequency, 5-second on/10=second off cycle, and a pulse width of 0.4 milliseconds. The bipolar square will be delivered over a range that varies from 0 to 100 milliamps, depending on the maximum current intensity comfortably tolerated by the patient. The participant will perform each treatment session for 20 minutes twice daily for 8 weeks. Participants will be asked to keep a log recording the dates, times, and duration of each treatment session.
88902586|NCT01525485||Interstim device|Participants assigned to the sacral neuromodulation group will undergo InterStim device placement by one of the three Urogynecologists at OUHSC using a staged implant technique according to manufacturer's specifications.
88902587|NCT01525498||1 day catheter removal|Participants randomized to group 1 will have their catheter removed 1 day after surgery.
88902588|NCT01525498||2 day catheter removal|Participants randomized to group 2 will have their catheter removed 2 days after surgery.
88902589|NCT01525511|Experimental|Group A|Primaquine only followed by Dihydroartemisinin-piperaquine and followed by Primaquine together with Dihydroartemisinin-piperaquine.
88902590|NCT01525511|Active Comparator|Group B|Primaquine only followed by Primaquine together Dihydroartemisinin-piperaquine and followed by Dihydroartemisinin-piperaquine only.
88902591|NCT01525524|Sham Comparator|Sham Stimulation|In active stimulation, the anode is placed over the left dorsolateral prefrontal cortex and the cathode is placed over the right prefrontal cortex with the Transcranial Direct Current Stimulation. They are located five centimeters ventrally of the primary motor area, which are located five centimeters laterally of the central point of the scalp. The device will deliver a charge of 2mA for 1 minute, after that the device will be automatically turned off for 29 minutes.
88902592|NCT01525524|Active Comparator|Active Stimulation|In active stimulation, the anode is placed over the left dorsolateral prefrontal cortex and the cathode is placed over the right prefrontal cortex with the transcranial Direct Current Stimulation device. They are located five centimeters ventrally of the primary motor area, which are located five centimeters laterally of the central point of the scalp. The device will deliver a charge of 2mA for 30 minutes.
88902593|NCT01525537|Experimental|SPI guided arm|sufentanil was adjusted to SPI level
88902594|NCT01525537|Active Comparator|Standard practise|Sufentanil was given at standard practise
88902595|NCT01525576|No Intervention|Control group|No offer of booster program.
88902596|NCT01525576|Experimental|Booster|3 week booster program + 2 additional weeks two months later for follow-up.
88902597|NCT01525654|Active Comparator|Partners|Patients who are matched with support partners and have a billing diagnosis of RA (714.0) or seronegative inflammatory arthritis who are enrolled in the Brigham and Women's Rheumatoid Arthritis Sequential Study (BRASS) or the Patient-Centered Outcomes Initiative (PACO)
88902598|NCT01525654|No Intervention|Controls|Controls will be BRASS patients who continue to receive regular care without being matched with a peer support partner.
88902599|NCT01525680|Active Comparator|Prolonged Exposure therapy with Hydrocortisone|
88902600|NCT01525680|Placebo Comparator|Prolonged Exposure therapy with placebo|
88902601|NCT01525693||Diagnosed within 6 months|No (test) intervention to be adminisitered
88902602|NCT01525706|Experimental|Ethanol and Paclitaxel Injection|All patients will receive at least one treatment with alcohol and paclitaxel.
88902603|NCT01525719|Experimental|RAD001|
88902604|NCT01525732|Other|POEM|Per Oral Endoscopic Myotomy
88902605|NCT01525758|Experimental|SI000413 400mg|tablet, SI000413 200mg bid
88902606|NCT01525758|Experimental|SI000413 600mg|tablet, SI000413 200mg tid
88902607|NCT01525758|Experimental|SI000413 800mg|SI000413 200mg, 2T bid
88902608|NCT01525758|Placebo Comparator|placebo|placebo 2T tid for 8 weeks
88902609|NCT01525771|No Intervention|No intervention|Single-center, open-label, prospective, single-arm, phase I-II study
88902610|NCT01525784||Rt-CGMS|Using Rt-CGMS, approved by ministry of health as part f clinical care
88902611|NCT01525784||Control|Not approved or suggested for RtCGMS. Other acceptabl means of therapy
88902612|NCT01525797||Control|
88902613|NCT01525797||Rejection|
88902614|NCT01525810||Subjects treated with Peginterferon Lambda-1a (BMS-914143)|Subjects who participated in a clinical trial in which Peginterferon Lambda-1a (BMS-914143) was administered for the treatment of chronic hepatitis C
88902615|NCT01525823|Experimental|BMS-754807 + Metformin|
88902616|NCT01525836|Experimental|combination treatment group|120 enrolled patients are randomly picked up to take Rituximab in combination with Rh-TPO at the indicated dose.
88902617|NCT01525836|Active Comparator|single treatment group|120 enrolled patients are randomly picked up to take Rituximab at the indicated dose.
89194997|NCT00814905|Other|cesarean delivery one dose3|one dose of ampicillin 2 grams IV, gentamicin 1.5 mg/kg IV, clindamycin 900 mg IV and then saline infusions instead of antibiotics until they are afebrile for 24 hours ( they will receive saline infusions instead of antibiotics)
88902618|NCT01525888|No Intervention|control|continue with treatment with angiotensin converting enzyme inhibitor or angiotensin blocker during all study period
88902619|NCT01525888|Experimental|drug stop|temporary stop of angiotensin converting enzyme inhibitor and angiotensin blocker treatment at least 72 hours before coronary angiography and renew of treatment 72 hours after angiography
89194998|NCT00814905|Other|cesarean multiple antibiotics 4|ampicillin 2 g IV every 6 hours, gentamicin 1.5mg/kg every 8 hours, and clindamycin 900 mg IV every 8 hours until the patient has been afebrile for 24 hours
88902620|NCT01525914||dutasteride, active surveillance|men with favorable risk prostate cancer on surveillance treated with dutasteride
88902621|NCT01525940|Other|Colon capsule and CT-colonography|PillCam Colon Capsule Endoscopy (Given® Diagnostic System) ingestion first and CT-colonography about 10-12 hours post-ingestion
88902622|NCT01525979|Experimental|Task-Related UAT|Therapist conducted unilateral arm training Task-related unilateral arm training
88902623|NCT01525979|Experimental|Task-Related BAT|Therapist conducted bilateral arm Training Task-related bilateral arm training
88902624|NCT01525979|Experimental|Task-Related UAT coupling BAT|Therapist conducted task-related unilateral training for 45 minutes, followed by task-related bilateral arm training for another 45 minutes during each training session
88902625|NCT01525979|Experimental|Robot-assisted UAT|Robot-assisted unilateral arm training
88902626|NCT01525979|Experimental|Robot-assisted BAT|Robot-assisted bilateral arm training
88902627|NCT01525992|Experimental|Community Pharmacy-based Program|
88902628|NCT01525992|Active Comparator|Usual care|
88902629|NCT01526005||Active agent (nicotine patch)|
88902630|NCT01526005||Placebo patch|
88902631|NCT01526018||Novel bottle|
88902632|NCT01526031|Experimental|BV1|1:10,000 bee venom (BV) acupuncture plus physiotherapy
88902633|NCT01526031|Experimental|BV2|1:30,000 bee venom (BV) acupuncture plus physiotherapy
88902634|NCT01526031|Placebo Comparator|NS|Normal saline injection plus physiotherapy
88902635|NCT01526044|Experimental|Freestyle group|Glucose levels are being monitored with the Freestyle Navigator up to 5 days, or until discharge from the ICU
88902636|NCT01526044|Active Comparator|AccuChek group|Glucose levels are being measured by the AccuChek. Patients also get a Freestyle Navigator, which will be blinded. The device will stay on the patient up to 5 days, or until discharge from the ICU.
88902637|NCT01526070||Patients with Exudative Age-Related Macular Degeneration|Patients with eAMD who received intravitreal thearpy
88902638|NCT01526083|Other|Single dose of Warfarin on day 3|Single dose of Warfarin on day 3 of a 7 day course of Lacosamide 200 mg BID
89194999|NCT00645567||Unassisted manual transfer|this group will use no additional aid in transfer.
89422138|NCT03791619|Active Comparator|Lower Cylinder Toric IOL|Consented subjects that are eligible will have both eyes implanted with a TECNIS Symfony IOL. Each eye may have a different TECNIS Symfony IOL implanted, as determined by the surgeon and the TECNIS Symfony Toric IOL calculator; however, at least one eye must be implanted with either a Symfony Toric IOL Model ZXT150 (lower-cylinder group) or a Model ZXT300 or ZXT375 (higher-cylinder group) and the fellow eye must have the same or a lower toric power. The eye with the highest toric power IOL will determine the model group.
89422139|NCT03770572|Experimental|Cohort 1: AT-GTX-502 Low-Dose|No more than 5 mL of 6 x 1013 vg AT-GTX-502 administered via intrathecal injection
89422140|NCT03770572|Experimental|Cohort 2: AT-GTX-502 High-Dose|No more than 10 mL of 1.2 x 1014 vg of AT-GTX-502 administered via intrathecal injection
88902639|NCT01526083|Other|Single dose of Warfarin|
88902640|NCT01526109|Experimental|strength training group|Participants will undergo a training program set for the three functional groups, which lasted ten minutes, followed by thirty minutes of strength training twice a week consists of six exercises for major muscle groups: leg press, bench press, lat pull down, knee extension, knee flexion and Abdominal (3 sets of 10-12 repetitions at 60-80% of 1 RM with 3 min interval between sets and between workouts).
88902641|NCT01526109|Placebo Comparator|Control group|Participants will undergo a training program set for the three functional groups of ten minutes duration, followed by thirty minutes of functional exercises twice a week (2-3 sets of 30 sec. At intervals of 60 s between stimuli) carry out a range of six functional exercises combining squats and isometric or dynamic exercises for the upper limbs and trunk without intensity
88902642|NCT01526109|Experimental|whole-body vibration training group|Participants will undergo a training program set for the three functional groups, which lasted ten minutes, followed by thirty minutes of exercise stimuli to whole-body vibration twice a week (2-3 sets of 30 sec. with frequency of stimulation at 30 Hz with 60 s intervals between stimuli), the platform will hold a range of six functional exercises combining squats and isometric or dynamic exercises for the upper limbs and trunk.
88902643|NCT01526122|Experimental|G0041(75/100mg)|
89422141|NCT03737760||Older Adults|Community-dwelling men and women age 70+ years
89422142|NCT03737760||Younger Adults|Healthy young adults, age 20-40 years for baseline assessments only
88902644|NCT01526122|Active Comparator|Clopidogrel & Aspirin|
88902645|NCT01526161|Experimental|Inhaled Fluticasone propionate and salmeterol|inhaled fluticasone propionate 100 micrograms and salmeterol 50 m
88902646|NCT01526161|Active Comparator|Inhaled Fluticasone propionate and placebo|inhaled fluticasone propionate 100micrograms twice daily + placebo
88902647|NCT01526161|Active Comparator|Inhaled Fluticasone propionate and Montelukast|inhaled fluticasone propionate 100micrograms twice daily + Montelukast
88902648|NCT01526174|Experimental|First Arm|Determine safety of intratympanic injection
88902649|NCT01526174|Experimental|Second Arm|Efficacy evaluation of 4 intratympanic injections
88902650|NCT01526187||Sub-Saharan Africa|
88902651|NCT01526187||Asia|
88902652|NCT01526187||Latin America|
89195000|NCT00645567||Standard sliding board transfer|The standard transfer board is a flat surface board designed to bridge the gap that exists with transfers from wheelchair to vehicle and/or other horizontally displaced seating surfaces.
89422143|NCT03696433|Experimental|Low- then high-salt diet|10 subjects will be enrolled and each will undergo study procedures at 4 separate visits. Subjects will be randomly assigned to this study arm, differing in the order of low and high salt diets. After a baseline visit to include a noninvasive MRI scan, the subject will begin this study diet: low-salt diet, then washout consisting of the subject's typical diet, then high-salt diet. Each dietary or washout period lasts for 7 days, and study visits will occur after each period.
89422144|NCT03696433|Experimental|High- then low-salt diet|10 subjects will be enrolled and each will undergo study procedures at 4 separate visits. Subjects will be randomly assigned to this study arm, differing in the order of low and high salt diets. After a baseline visit to include a noninvasive MRI scan, the subject will begin this study diet: high-salt diet, then washout consisting of the subject's typical diet, then low-salt diet. Each dietary or washout period lasts for 7 days, and study visits will occur after each period.
89422145|NCT03672331|Other|Standard arm|Participants will be screened for breast cancer according to current national/regional guidelines and procedures: with a mammogram and/or tomosynthesis (TS) every 1-3 years starting at age 40-50 years, up to age 69-74 years, with or without ultrasound and MRI depending on breast mammographic density and current recommendations. The national/regional guidelines in use in the including center may be subjected to changes during the study. Guidelines and procedures in the standard arm will be updated accordingly.
89422146|NCT03672331|Experimental|Risk-based arm|Participants will be screened according to a personalised timetable based on their estimated 5-year risk of developing breast cancer: with a mammography and/or tomosynthesis every 1-4 years with or without ultrasound depending on breast density. Risk estimation will be performed using the following variables: age, family history, previous history of benign breast biopsy, personal hormone and reproductive history, breast mammographic density and genotyping (polygenic risk score). Risk assessment will be conducted using Mammorisk™ for women with at most one first-degree relative with breast or ovarian cancer and using Tyrer-Cuzick™ risk score for those women with more than one first-line first degree relative with breast or ovarian cancer.
89422147|NCT03659565|Experimental|Enhanced Pre-Visit Consultation|Patients and caregivers will participate in an enhanced pre-visit consultation using Zoom for remote video and audio conferencing with screen sharing capabilities.
89422148|NCT03659565|Active Comparator|Usual Care Control|Patients continue to receive usual care from their cardiologist.
89422149|NCT03546049|Active Comparator|US-guided percutaneous biliary drainage|The initial percutaneous transhepatic puncture of the bile duct is performed by ultrasound guidance with a Chiba-needle (0.7 mm). After injection of a radiopaque contrast media into the bile duct system, the malignant extrahepatic bile duct stenosis can be visualized by fluoroscopic guidance (digital remote-controlled fluoroscopy device). Then a 0.018 inch guide wire is introduced and proceeded beyond the tumor stenosis into the duodenum. Next, the Chiba needle is exchanged by a 5 F catheter and the 0.018 inch guide wire is exchanged by a 0.035 inch guide wire. After dilatation of the hepatic access route with bougies up to 12 F, a self-expandable metal stent is introduced. The placement of the metal stent is controlled by endoscopic luminal guidance (gastroscope or duodenoscope).
89422150|NCT03546049|Experimental|EUS-guided biliary drainage|The initial transluminal puncture of the bile duct is performed by endoscopic ultrasound guidance (longitudinal echoendoscope) with an 19 G access needle. After injection of a radiopaque contrast media into the bile duct system, the malignant extrahepatic bile duct stenosis can be visualized by fluoroscopic guidance. Then, a 0.035 inch guide wire is introduced into the bile duct. After dilatation of the transluminal access route with a balloon catheter, a self-expandable metal stent is introduced as an antegrade biliary drainage, a transhepatic biliary drainage or a choledochal biliary drainage. The placement of the metal stent is controlled by fluoroscopic and endoscopic luminal guidance.
89422151|NCT03530189||Normoglycemic group|"The infant will enter this group if a single blood glucose concentration is between 2.1 and 2.5 mmol/l (38-45 mg/dL), or a single blood glucose concentration is between 8.6 - 10 mmol/l (155-180 mg/dL) with all other measures between 2.6 and 8.5 mmol/l (47-153 mg/dL).~To all premature infants intravenous 10% dextrose at 60-90 mL/kg/day will be started as soon as possible after birth."
89422152|NCT03530189||Group with impaired glucose|"The infant can be hypoglycemic, hyperglycemic or unstable. The infant will be hypoglycemic if blood glucose concentration is ≤2,5 mmol/l (45 mg/dL) on ≥2 measures >1 hour apart, or any blood glucose concentration is≤2,0 mmol/l (36 mg/dL). Hypoglycemia will be treated with intravenous bolus of 10% dextrose.~The infant will be hyperglycemic if blood glucose concentration is ≥8,6 mmol/l (155 mg/dL) on ≥2 measures >1 hour apart, or any blood glucose concentration ≥10,1 mmol/l (182 mg/dL). Hyperglycemia will be managed by reducing the glucose infusion rate or initiation of an insulin infusion.~The infant will be unstable if at least 1 blood glucose concentration is ≤2,5 mmol/l (45 mg/dL) and ≥1 blood glucose concentration is ≥8,6 mmol/l (155 mg/dL)."
88902653|NCT01526200||CEIOUS|One hundred and twenty-seven consecutive patients -77 males and 50 females, mean age of patients was 61 years (median 65 years; range 29-85 years)- underwent liver resection using intraoperative ultrasound and contrast-enhanced intraoperative ultrasound.
88902654|NCT01526226|Experimental|HFNC|High flow nasal cannula
88902655|NCT01526226|Active Comparator|nCPAP|Nasal CPAP
88902656|NCT01526239|Experimental|Intervention group|Intervention consisted of a pamphlet about the benefit of CRC-S, given to patients prior to their PCP visit and a reminder note about CRC screening to be given to their physician during the encounter.
88902657|NCT01526239|No Intervention|Control group|Control group will not receive the pamphlet regarding colorectal cancers.
88902658|NCT01526265|Active Comparator|Usual Care|Participants will be offered free smoking cessation programs, and be provided web-based education regarding the health and economic benefits of smoking cessation. Participants will also have the opportunity to submit weekly reports on their smoking habits. They will be informed that they will receive reimbursements for completing the surveys that are part of the Way To Quit program and for submitting saliva or urine samples at 14 days, 30 days, 6 months, and 12 months (among those eligible).
88902659|NCT01526265|Experimental|Individual Rewards|Same as USUAL CARE arm, plus financial incentive as follows: if participants quit smoking by their target quit date, and that is confirmed by cotinine or anabasine tests, they will receive a monetary award from the study investigators.
89195001|NCT00645567||Glide n' Go Lift|The Glide n' Go lift is a flip down power list seat that enables the person to enter and exit the vehicle by lifting them from their wheelchair up tot eh vehicle seat that they can make an easy transfer into the vehicle. Trunk stability may be required to successfully use the device.
88902660|NCT01526265|Experimental|Fixed Deposits|Same as USUAL CARE arm, plus financial incentive as follows: participants will have to deposit a certain monetary amount of their own money as an incentive to quit smoking. If they quit smoking by their target quit date, and that is confirmed by cotinine or anabasine tests, participants will receive their deposit back. If participants do not quit, their money will be used to support future research studies designed to help people stop smoking. As a motivation to quit smoking, the participant's deposit will be matched by the study investigators in a rate of 3:1.
88902661|NCT01526265|Experimental|Competitive Deposits (Pari-Mutuel)|"Same as USUAL CARE, plus financial incentive as follows: groups (or cohorts) of 6 smokers each will be formed on a rolling basis, linking individuals with target quit dates (day 0's) near each other. Participants will deposit a certain monetary amount (Y) in an account, which will be matched on a rate of 3:1 by the study investigators (M), and the payout for quitting on this arm will be (Y+M) x 6/Q , where Q is the number of quits in the cohort. Again, success will be confirmed by cotinine or anabasine tests, and if participants do not quit, their money will be used to support future research studies designed to help people stop smoking."
88902662|NCT01526265|Experimental|Collaborative Rewards|"Same as USUAL CARE arm, plus financial incentive as follows: groups (or cohorts) of 6 smokers each will be formed on a rolling basis, linking individuals with target quit dates (day 0's) near each other. If participants quit smoking by their target quit date, and that is confirmed by cotinine or anabasine tests, they will receive a monetary award from the study investigators. On top of that, participants will receive an additional monetary amount for each member of their group who also quits smoking. These participants will interact through a chat room, which will help motivate them to quit smoking."
88902663|NCT01526278|Other|Maxmarvil®|single-arm study
89422153|NCT03485391|Experimental|PE+Exposure Workout Buddy|Prolonged Exposure with assistance of Veteran who has successfully completed treatment to meet patients at exposure sites in the community to offer support during exposure.
89422154|NCT03485391|Active Comparator|PE+Peer General Support|Prolonged Exposure with assistance of Veteran who has successfully completed treatment to call and talk to patients once per week, informally meet at patient appointments, encourage session attendance and check in about progress.
88902664|NCT01526317|Experimental|1|This arm is consist of 6 subject. Crestor 10mg and Glucodown 750mg for 5 day during period 1. Crestor 10mg alone for 5 day during period 2. Glucodown 750mg alone for 5 day during period 3.
88902665|NCT01526317|Experimental|2|This arm is consist of 6 subject. Glucodown 750mg alone for 5 day during period 1. Crestor 10mg and Glucodown 750mg for 5 day during period 2. Crestor 10mg alone for 5 day during period 3.
89422155|NCT03438747|Experimental|P-15L Bone Graft|The investigational group will be treated with P-15L Bone Graft in an instrumented TLIF
89422156|NCT03438747|Active Comparator|Local autologous bone|The active control group will be treated with local autologous bone in an instrumented TLIF
88902666|NCT01526317|Experimental|3|This arm is consist of 6 subject. Crestor 10mg alone for 5 day during period 1. Glucodown 750mg alone for 5 day during period 2. Crestor 10mg and Glucodown 750mg for 5 day during period 3.
89422157|NCT03434769|Experimental|Cyclophosphamide + Fludarabine + Infusion of CAR-T Cells|Lymphodepletive regimen, consisting of Cyclophosphamide 60mg/kg IV on day -6 and Fludarabine 25mg/m2 IV on days -5 to -3. Followed by infusion of Chimeric antigen receptor T-cells (CAR-T) on day 0
89422158|NCT03425500|Experimental|Bridging Rotator Cuff Group|Bridging Rotator Cuff Reconstruction of massive rotator cuff tear using GRAFTJACKET™ allograft.
89422159|NCT03425500|Active Comparator|Superior Capsular Group|Superior Capsular Reconstruction of massive rotator cuff tear
89422160|NCT03404492|Other|Patients with pulmonary hypertension|
89422161|NCT03398070||Motor Functional Neurological Disorder.|"The cohort will consist of patients with clinically established motor functional neurological disorder, which includes individuals with functional movement disorders, psychogenic nonepileptic seizures and functional limb weakness.~Patients will be receiving the standard of care within the Massachusetts General Hospital (MGH) Functional Neurological Disorders Clinic.~The updated standard of care that patient's receive in the MGH Functional Neurological Disorders Clinic includes the following:~Delivery of a positive rule-in diagnosis of functional neurological disorder~Individuals are provided with educational materials on functional neurological disorders~Referred to physical therapy and/or occupational therapy as clinically indicated~FND related cognitive behavioral therapy (CBT) referral when appropriate~Psychotropic medication management based on standard psychiatric care"
89422162|NCT03331198|Experimental|Phase 1 JCAR017 monotherapy|Subjects will be assigned to receive JCAR017 (lisocabtagene maraleucel)
89422163|NCT03331198|Experimental|Phase 1 JCAR017 + ibrutinib|Subjects receiving ibrutinib at baseline will be assigned to receive JCAR017 (lisocabtagene maraleucel) at the recommended dose from the Phase 1 monotherapy arm + ibrutinib
89422164|NCT03331198|Experimental|Phase 2 JCAR017 monotherapy|Subjects will receive JCAR017 (lisocabtagene maraleucel) at the recommended dose from the Phase 1 monotherapy arm
89422165|NCT03331198|Experimental|Phase 1 JCAR017 + venetoclax|Subjects will receive venetoclax as bridging anticancer therapy until lymphodepletion chemotherapy/ JCAR017 (lisocabtagene maraleucel) at the recommended dose from the Phase 1 monotherapy arm. After JCAR017 infusion subjects will receive venetoclax until Day 90.
89422166|NCT03326310|Experimental|Azacitidine and selumetinib|Subjects will receive azacitidine subcutaneously on days 1-7. Selumetinib will be administered on days 8-21. Subjects will continue on this schedule in cycles of 28 days duration in the absence of disease progression.
89422167|NCT03317496|Experimental|Group A Cohort A1|Non-squamous non-small cell lung cancer (NSCLC) patients treated with 800 mg avelumab plus pemetrexed/carboplatin
89422168|NCT03317496|Experimental|Group A Cohort A2|Cisplatin-eligible urothelial cancer (UC)patients treated with 800 mg avelumab plus gemcitabine/cisplatin
89422169|NCT03317496|Experimental|Group A Cohort A3|Non-squamous non-small cell lung cancer (NSCLC) patients treated with 1200 mg avelumab plus pemetrexed/carboplatin
89422170|NCT03317496|Experimental|Group A Cohort A4|Cisplatin-eligible urothelial cancer (UC) patients treated with 1200 mg avelumab plus gemcitabine/cisplatin
89422171|NCT03242174||Traditional Obstetrical Prenatal Care|Pregnant women receiving traditional obstetrical prenatal care and delivering in a hospital will be offered the Health Behavior questionnaire packet at third trimester prenatal appointment
89422172|NCT03242174||Prenatal Care from Midwife|Pregnant women receiving prenatal care from a midwife and delivering at the birth center will be offered the Health Behavior questionnaire packet at third trimester prenatal appointment
89422173|NCT03236441|Active Comparator|RIPC Group|3 cycles of blood pressure cuff inflations to occlusive pressure of 200 mmHg for 5 minutes and deflation for 5 minutes
89422174|NCT03236441|Sham Comparator|Sham-RIPC Group|3 cycles of blood pressure cuff inflations to non-occlusive pressure of 10 mmHg for 5 minutes and deflation for 5 minutes (Control)
89422175|NCT03228667|Other|Cohort 1|"Patients with any of the cancers listed below who have progressed on or after single-agent checkpoint inhibitor therapy after experiencing an initial complete response (CR) or partial response (PR) while taking a checkpoint inhibitor.~1a - Non-small cell lung cancer~1b - Small cell lung cancer~1c - Urothelial carcinoma~1d - Head and neck squamous cell carcinoma~1e - Merkel cell carcinoma~1f - Melanoma~1g - Renal cell carcinoma~1h - Gastric cancer~1i - Cervical cancer~1j - Hepatocellular carcinoma~1k - Microsatellite instability-high or mismatch repair deficient solid tumor cancer or colorectal cancer"
89422176|NCT03228667|Other|Cohort 2|Patients with NSCLC whose tumors have high PD-L1 expression (TPS ≥ 50%) and who relapsed on a PD-1 checkpoint inhibitor after experiencing an initial CR or PR when they received checkpoint inhibitor as a single-agent for first-line treatment.
88902667|NCT01526317|Experimental|4|This arm is consist of 6 subject. Glucodown 750mg alone for 5 day during period 1. Crestor 10mg alone for 5 day during period 2. Crestor 10mg and Glucodown 750mg for 5 day during period 3.
88902668|NCT01526317|Experimental|5|This arm is consist of 6 subject. Crestor 10mg alone for 5 day during period 1. Crestor 10mg and Glucodown 750mg for 5 day during period 2. Glucodown 750mg alone for 5 day during period 3.
88902669|NCT01526317|Experimental|6|This arm is consist of 6 subject. Crestor 10mg and Glucodown 750mg for 5 day during period 1. Glucodown 750mg alone for 5 day during period 2. Crestor 10mg alone for 5 day during period 3.
88902670|NCT01526330|Experimental|Group A|
88902671|NCT01526330|Experimental|Group B|
88902672|NCT01526330|Experimental|Group C|
88902673|NCT01526330|Placebo Comparator|Group D|
88902674|NCT01526369|Active Comparator|Paclitaxel and Trastuzumab|Weekly paclitaxel (80mg/m², for 3 weeks of a 4 week cycle) + trastuzumab (8mg/kg loading dose on cycle 1 day 1 and 4mg/kg every 2 weeks) until disease progression, unacceptable toxicity or consent withdrawal.
88902675|NCT01526369|Experimental|Paclitaxel, Trastuzumab and Lapatinib|"Weekly paclitaxel (80 mg/m², for 3 weeks of a 4 week cycle) + trastuzumab (8 mg/kg loading dose on cycle 1 day 1 and 4 mg/kg every 2 weeks)~+ lapatinib (1,000 mg daily), until disease progression, unacceptable toxicity or consent withdrawal."
88902676|NCT01526382|Active Comparator|intervention arm|patients allocated to intervention arm receive PiCCO monitoring for hemodynamics and pulmonary conditions
88902677|NCT01526382|Placebo Comparator|control arm|Patients in this arm do not receive PiCCO monitoring device to guide fluid management, but central venous catheter can be inserted at the discretion of treating physician.
88902678|NCT01526395|No Intervention|Unmodified ECT|Data will be collected on patients receiving ECT in its unmodified form prior to the introduction of low dose propofol sedation.
88902679|NCT01526395|Active Comparator|Low Dose Propofol|Subjects will be given low dose propofol prior to ECT.
88902680|NCT01526421|Experimental|monetary reinforcer|
88902681|NCT01526421|No Intervention|no reinforcer|
88902682|NCT01526434||Certolizumab Pegol treatment|Patients with RA who begin therapy with Certolizumab Pegol (CZP) will be consecutively included in accordance with the selection criteria. The choice of medical treatment is made independently by the physician before evaluating the possible participation of the patient in the protocol.
88902683|NCT01526447|Experimental|Craniosacral Therapy (CST)|Each participant of the experimental group receives 8 Craniosacral Therapy units once a week of 45 minutes.
88902684|NCT01526447|Sham Comparator|Sham Craniosacral Therapy (SHAM)|Each participant of the sham group receives 8 sham therapy units once a week of 45 minutes.
88902685|NCT01526460|Active Comparator|Atorvastatin|Atorvastatin 80 mg
88902686|NCT01526460|Active Comparator|Rosuvastatin|Rosuvastatin 40 mg
88902687|NCT01526460|Placebo Comparator|No statin loading dose|No statin loading dose
88902688|NCT01526473|Experimental|AVX901|AVX901 at 4 x 108 IU intramuscularly, given every 2 weeks for a total of three doses.
88902689|NCT01526486|Experimental|Videoscopic (Minimally invasive)|Patients in this arm will have the procedure done through the three port minimally invasive approach.
88902690|NCT01526486|Active Comparator|Open (traditional approach)|Patients in this arm will have the traditional, open approach in conjunction with a sartorius muscle transposition.
88902691|NCT01526499|Experimental|TC|Docetaxel plus Cyclophosphamide
88902692|NCT01526499|Active Comparator|T|Docetaxel
88902693|NCT01526512|Experimental|metroCX|metroCX Cyclophosphamide 50mg PO d1-28; Capecitabine 1500mg PO d1-28; every 28days
88902694|NCT01526525|Placebo Comparator|TK|In TK group when the closure of the abdominal walls started, a certified acupuncturist expert put needles, Ener-Qi 0.26Χ25mms, in LI4 point in both hands, the needles were not inserted in the skin but they were put atop the skin and were secured by adhesive tape. For 30min in the E/A stimulator ITO ES-160 the indicator light was on but no electrical current was applied. Thereafter the E/A device deactivated and after the awakening of the patients, it was connected in ST36 and LI4 points for 30min with the same technique. The electrodes were connected to each other in every point, as the right with the left point of LI4 and the right with the left point of ST36. The patients were told that they may or may not feel electrical current because of its very high frequency.
88902695|NCT01526525|Active Comparator|TKE|In TKE group when the closure of the abdominal walls started, a certified acupuncturist expert put needles, Ener-Qi 0.26Χ25mms, in LI4 point at 2cm depth in both hands and E/A was applied for 30min with the E/A stimulator ITO ES-160 in constant pulse program with 300μs duration and 100Hz frequency. After the needles were connected to the E/A stimulator, they were secured by adhesive tape. The response which certified the right needle placement was the adjacent muscular twitch. Thereafter the E/A device was deactivated and after the awakening of the patients, E/A was administered in ST36 and LI4 points for 30min with 4Hz frequency. The electrodes were connected to each other in every point, as the right with the left point of LI4 and the right with the left point of ST36.
88902696|NCT01526564|Active Comparator|ALC|ALC
88902697|NCT01526564|Placebo Comparator|Placebo|
88902698|NCT01526590|Experimental|Definity|Patients enrolled in the study will undergo contrast enhanced endoscopic ultrasound of the pancreas with Definity contrast after they have undergone their standard of care endoscopic ultrasound of the pancreas.
88902699|NCT01526616|Active Comparator|Metformin|850 mg/day twice a day
88902700|NCT01526616|Active Comparator|Metformin plus spironolactone|Metformin 850 mg twice a day for six months plus Spironolactone 25 mg day
88902701|NCT01526642|No Intervention|Long Term Oxygen Therapy|
88902702|NCT01526642|Active Comparator|Non Invasive Ventilation|
88902703|NCT01526655|Active Comparator|Abdominal total hysterectomy|Standard extrafascial abdominal total hysterectomy through a low transverse abdominal wall incision
89195002|NCT00645567||Easy Reach lift|The Easy Reach lift seat allows the vehicles original seat to swivel out of the vehicle and lower to wheelchair height. the chair extends far from the vehicle to provide access for a safe, easy transfer.
88902704|NCT01526655|Active Comparator|Robot assisted laparoscopic hysterectomy|Robot assisted laparoscopic total hysterectomy
88902705|NCT01526694|Experimental|treatment with BDT|Bendamustine + Dexamethasone + Thalidomide in patients with multiple myeloma (MM) patients after treatment with lenalidomide and bortezomib or which are ineligible to one of these drugs.
88902706|NCT01526707|Experimental|inhaled steroid|inhaled steroid treatment for 7 days
88902707|NCT01526720||Group A: Diabetic|Newly diagnosed type 2 diabetic patients (i.e. diagnosis made no more than 6 months before recruitment)
88902708|NCT01526720||Group B: Relatives|Relatives of patients with potentially monogenic newly diagnosed type 2 diabetes
88902709|NCT01526746|Experimental|End Stage Renal Disease, dialysis|eGFR <15 ml/min/1.73m^2
88902710|NCT01526746|Experimental|Severe renal impairment|eGFR < 29 ml/min/1.73m^2
88902711|NCT01526746|Experimental|Healthy controls|eGFR > 80 mL/min/1.73m^2 Matched to renally impaired subjects by age, gender, BMI, and smoking status
88902712|NCT01526759|Experimental|pectin|10 gram high gelling-high viscous fiber, added to a drink
88902713|NCT01526759|Placebo Comparator|control|10g gelatin, added to a drink
88902714|NCT01526772||Patients who have undergone RYGB|Patients who have undergone RYGB and have been referred for an EGD
88902715|NCT01526798|Experimental|Therlite hemodialysis|
88902716|NCT01526798|Active Comparator|Control group hfHDF|Control group hfHDF
88902717|NCT01526811||AAA patients|Subjects presenting with a non-ruptured infra-renal abdominal aortic aneurysm (AAA) and requiring endovascular treatment with Endurant™ Stent Graft, and who meet the inclusion/exclusion criteria are intended to participate in this non-interventional study
89422177|NCT03228667|Other|Cohort 3|Patients with NSCLC who had an initial CR or PR but subsequently relapsed on maintenance PD-1 checkpoint inhibitor therapy when they initially received checkpoint inhibitor therapy in combination with chemotherapy as first-line treatment.
88902718|NCT01526824|No Intervention|Control arm, clopidogrel without Lovaza|These patients will be receiving standard of care therapy with either standard dose (75mg daily) or high dose (150mg daily) clopidogrel +/- aspirin based on physician discretion.
88902719|NCT01526824|Experimental|Clopidogrel plus Lovaza|This is the study arm of the trial, in which patients will be receiving either a standard dose (75mg daily) or high dose (150mg daily) clopidogrel with or without aspirin as well as therapy with daily Lovaza.
88902720|NCT01526837|Experimental|bevacizumab (Avastin)|Open-label, dose-escalating study conducted in cohorts of 1-3 patients treated at increasing doses of bevacizumab in the dose range of 1-25mg/Ml. A maximum of 24 subjects will be treated in this study (up to 8 cohorts of 3 subjects).
88902721|NCT01526850|Experimental|allogenic mesenchymal stem cells (MSCs)|patients who have developed an extensive chronic graft versus host disease (with skin and/or liver damage) after HSCs transplantation and do not respond to standard first-line regimen including cyclophosphamide and prednisolone.
88902722|NCT01526850|Active Comparator|Control group|patients who have developed an extensive chronic graft versus host disease (with skin and/or liver damage) after HSCs transplantation and do not respond to standard first-line regimen including cyclophosphamide and prednisolone.
88902723|NCT01526863|Placebo Comparator|Placebo|
88902724|NCT01526863|Active Comparator|HA egg|
88902725|NCT01526876|Experimental|Single Arm drug study|The effect of systemic blood pressure reduction using Clevidipine on intracranial pressure (ICP) and cerebral perfusion pressure (CCP)
88902726|NCT01526915|Experimental|Bone curettage + PRF|Bone curettage and PRF insertion
88902727|NCT01526915|Other|Bone curettage alone|Bone curettage without PRF insertion
88902728|NCT01526941|Experimental|Treatment period 1|
88902729|NCT01526941|Experimental|Treatment period 2|
88902730|NCT01526954|Experimental|TissuGlu Surgical Adhesive|Experimental Arm: standard of care plus TissuGlu Surgical Adhesive and no drains
88902731|NCT01526954|No Intervention|Control- Standard of Care|Control Arm: standard of care plus drains and no TissuGlu Surgical Adhesive
88902732|NCT01526967||New moldable user|Subjects presenting with peristomal lesions with a traditional barrier and for whom a ConvaTec Moldable Technology™ Skin Barrier is used as a replacement.
88902733|NCT01526967||New osomate|Subjects for whom a ConvaTec Moldable Technology™ Skin Barrier is used as the first long-term (within 7 days of ostomy surgery) system following surgery and have intact peristomal skin.
88902734|NCT01526980|Experimental|Treatment period 1|
88902735|NCT01526980|Active Comparator|Treatment period 2|
88902736|NCT01527019|Experimental|Cephalosporin oral suspension|130 research subjects on cephalosporin oral suspension (test) 400 mg once daily
88902737|NCT01527019|Experimental|Cephalosporin capsules|130 research subjects on cephalosporin capsules (test) 400 mg once daily
88902738|NCT01527019|Active Comparator|Norfloxacin|130 research subjects on norfloxacin (test) 400 mg twice daily
88902739|NCT01527058|Experimental|68Ga-BNOTA-PRGD2 PET/CT scanning|Determine if 68Ga-BNOTA-PRGD2 PET/CT is safe and effective method for imaging of lung cancer
88902740|NCT01527084|Other|Group A|undergo surgery between days 10 - 15 after PCD
88902741|NCT01527084|Other|Group B|"continued with PCD beyond 15 days and indications for surgery in them will be,~Persistent sepsis or symptoms~Worsening of clinical condition~Failure to thrive~Complications of SAP or PCD"
88902742|NCT01527097|Experimental|Atorvastatin|
88902743|NCT01527097|Placebo Comparator|Placebo|
88902744|NCT01527123|Experimental|GSK2585823|External Preparation
88902745|NCT01527175|Active Comparator|supraclavicular|supraclavicular: supraclavicular approach for subclavian venous catheterization
88902746|NCT01527175|Placebo Comparator|infraclavicular|infraclavicular: infraclavicular approach for subclavian venous catheterization
88902747|NCT01527188|Experimental|100IR|
88902748|NCT01527188|Experimental|300IR|
89422178|NCT03228667|Experimental|Cohort 4|Patients who are currently receiving PD-1/PD-L1 checkpoint inhibitor therapy and have disease progression after experiencing stable disease (SD) for at least 6 months during their previous treatment with PD-1/PD-L1 checkpoint inhibitor therapy.
88902749|NCT01527188|Experimental|500IR|
88902750|NCT01527188|Placebo Comparator|Placebo|
88902751|NCT01527201|Experimental|Treatment Group|Worn out cartilage will be surgically treated.
88902752|NCT01527201|No Intervention|Control Group|Worn out cartilage will be observed, but will not be treated surgically.
88902753|NCT01527214|Experimental|CT scan and education|All general practices referring to the Department of Pulmonary Medicine, Aarhus University Hospital.Randomized 1:1. In the intervention group, GPs continue to refer to the lung cancer fast track when indicated. In addition, they are allowed to refer directly to a rapid chest CT scan in cases where they find reasons to examine the patient for lung diseases without having sufficient suspicion of lung cancer to refer the patient to the lung cancer fast track. The GPs will be offered special training related to the diagnosis of lung cancer in general practice before the new referral option is introduced. This will be done by offering training sessions and written material.
88902754|NCT01527214|No Intervention|Control|Cluster eligibility: all practices referring to the Department of Pulmonary Medicine, Aarhus University Hospital. Randomized 1:1. Control arm continues with the usual referral pattern
88902755|NCT01527227||children of mentally ill|This research will include 130 children between the ages of 10-18 who live with at least one parent who struggles with serious mental illness in a comparison to 130 children of the same socio-demographic characteristics raised by parents from a non-clinical population
88902756|NCT01527240|Experimental|Ciclosporin A|Injection of 50 mg / ml IV infusion. 5 ml ampoules (250 mg of ciclosporin)
88902757|NCT01527240|Placebo Comparator|Placebo|Injectable Saline Solution.
88902758|NCT01527253|Experimental|Active Diet|Subjects eat a diet designed according to the Nordic Dietary Recommendations containing important amounts of specific legume and cereal ingredients that provide substrates for the intestinal microflora (prebiotics)
88902759|NCT01527253|Experimental|Control diet|Subjects eat a diet designed according to the Nordic Dietary Recommendations but lacks the specific legume and cereal ingredients that provide substrates for the intestinal microflora (prebiotics).
88902760|NCT01527266|Experimental|carbohydrate mouth rinse fasted|sucrose mouth rinse in the fasted state
88902761|NCT01527266|Experimental|carbohydrate mouth rinse fed|sucrose mouth rinse fed state
88902762|NCT01527266|Placebo Comparator|Placebo mouth rinse fed|placebo (non-caloric sweetened drink) in the fed state
88902763|NCT01527266|Placebo Comparator|Placebo mouth rinse fasted|placebo (non-caloric sweetened drink) in the fasted condition
88902764|NCT01527279|Placebo Comparator|Placebo|Any patient fulfilling the inclusion criteria will be prepared to pharmacological cardioversion in a standard way comprising of standard baseline 12-lead ECG, continuous ECG monitoring, periodic noninvasive blood pressure monitoring (BP) and iv line. After drug administration the patient will be observed for 1.5 hour after the last dose with exit ECG and BP measure taken at the end of observation. Further treatment of the patient depends on clinical state and follows appropriate clinical guidelines.
88902765|NCT01527279|Experimental|Antazoline|Any patient fulfilling the inclusion criteria will be prepared to pharmacological cardioversion in a standard way comprising of standard baseline 12-lead ECG, continuous ECG monitoring, periodic noninvasive blood pressure monitoring (BP) and iv line. After drug administration the patient will be observed for 1.5 hour after the last dose with exit ECG and BP measure taken at the end of observation. Further treatment of the patient depends on clinical state and follows appropriate clinical guidelines.
88902766|NCT01527305|Experimental|Paliperidone palmitate|
88902767|NCT01527318|Experimental|Fibrate Treatment|Patients will be treated during 28 weeks with a fibrate to assess the effects of PPAR activation on the NLSDM disease.
88902768|NCT01527331|No Intervention|control group|usual care
88902769|NCT01527331|Experimental|Video decision aid arm|
88902770|NCT01527409|Experimental|Experimetal Arm|"Providing tailored health care program, which provides various information related to exercise, diet, and posttraumatic growth.~Tailored health partnership program consists of three strategic areas (exercise, diet, and posttraumatic growth). Those areas are based on the transtheoretical model (TTM), social cognitive theory, PRECEDE-PROCEED model, and Health behavior model.~Patients who participate in the tailored health partnership program will be received tailored manual and workbook for tele-coaching that help them to lead their healthy life.~Also, patients will be provided a workshop for leadership that is dealt with controlling their healthy life."
88902771|NCT01527409|No Intervention|Control Arm|"Providing usual care. Also, patients will be provided a workshop for health education that is dealt with ten areas (smoke and drinking, diet, exercise, posttraumatic growth, distress, pain, comorbidity, sleep disturbance, pain, and energy conservation).~Twelve month later, patients will be provided the tailored health partnership program which is especially dealing with exercise, diet, and posttraumatic growth."
88902772|NCT01527448|Experimental|Atypical antipsychotic treatment|Quetiapine XR is given to postpartum women diagnosed with bipolar disorder II. Starting dose is 50mg, maximum dose is 300mg/day.
88902773|NCT01527461||Lung Cancer Patients|diagnosed lung cancer patients .
88902774|NCT01527461||COPD Patients|COPD patients, not diagnosed with lung cancer.
88902775|NCT01527539|Experimental|BIAsp 30|
88902776|NCT01527552|Experimental|Formulation A|
88902777|NCT01527552|Experimental|Formulation B|
89422179|NCT03228667|Experimental|Cohort 5|Patients that have experienced disease progression by Investigator-assessment per irRECIST while receiving treatment in Cohorts 1-4.
89422180|NCT03212404|Experimental|CK-301 (cosibelimab)|Part 1 - Dose Escalation; Part 2 - Dose Expansion
89422181|NCT03206736|Experimental|Loop DS Patients|Patients who receive a Loop DS procedure
88902778|NCT01527565|Experimental|Formulation A|
88902779|NCT01527565|Experimental|Formulation B|
88902780|NCT01527604|Active Comparator|Avenanthramide-enriched oat muffin|
88902781|NCT01527604|Placebo Comparator|Refined flour muffin|
88902782|NCT01527617|Active Comparator|Cranberry beverage|
88902783|NCT01527617|Placebo Comparator|Non-cranberry beverage|
88902784|NCT01527630|Experimental|Formulation A|
88902785|NCT01527630|Experimental|Formulation B|
88902786|NCT01527643|Experimental|Formulation A|
88902787|NCT01527643|Experimental|Formulation B|
88902788|NCT01527656|Experimental|Formulation A|
88902789|NCT01527656|Experimental|Formulation B|
88902790|NCT01527669|Experimental|LipoCol Forte capsules|The pharmacokinetic study of red yeast rice capsule compared to lovastatin tablet in healthy subjects.
88902791|NCT01527669|Experimental|Lovastatin Tablet|The pharmacokinetic study of red yeast rice capsule compared to lovastatin tablet in healthy subjects.
88902792|NCT01527695|Experimental|AZD3241|AZD3241 tablets 25 mg or 100 mg, titration first 5 days (50 mg bd on Day 1, 100 mg bd on Day 2, 200 mg bd on Day 3, 300 mg bd on Day 4, 400 mg bd on Day 5) Maintenance treatment from Day 6, 600 mg bd until Day 56±3 days
88902793|NCT01527695|Experimental|Placebo|AZD3241 placebo bid for 8 weeks
88902794|NCT01527708||Keratoconus Group (KCG)|Keratoconus group (KCG) included patients with progressive keratoconus.
88902795|NCT01527708||Collagen-Cross-linking group (CXLG)|Collagen-Cross-linking group (CXLG) included keratoconus patients that had been treated with uneventful corneal collagen cross-linking (CXL) at least on year prior to their enrolment in the study.
89195003|NCT00645567||Ryno lift|The Ryno lift is an under-vehicle list (UVL) system. Using this lift, the wheelchair user is raised into the vehicle cab using independent controls and can then maneuver into a convenient position in the cab. The wheelchair is locked down and the lift stored beneath the vehicle chassis. This technology eliminated the need to store and retrieve a wheelchair during transit.
89422182|NCT03181048|Experimental|Periacetabular osteotomy|Standard periacetabular osteotomy on the day of surgery.
89422183|NCT03181048|Active Comparator|Periacetabular osteotomy with hip arthroscopy|Hip arthroscopy on the day of surgery, followed by a standard periacetabular osteotomy.
89422184|NCT03127215|Experimental|Arm E: Olaparib / Trabectedin|Olaparib / Trabectedin
89422185|NCT03127215|Other|Arm C: Physician's choice|Physician's choice
89422186|NCT03125811|Active Comparator|Inhaled Isopropyl Alcohol (IPA)|Inhaled Isopropyl Alcohol (alcohol prep pad)
89422187|NCT03125811|Other|Oral Dissolvable Tablet Zofran (OZ)|4 mg Oral Dissolvable Tablet Zofran (ondansetron)
89422188|NCT03081195|Experimental|MFG-delivered by trained family peers|"MFG delivered by trained parent peers drawn from local school planning councils:~10 schools; 60 parent peers (6 per school x 10); 1,000 children and adult caregivers; children screened to evidence serious emerging and clinically significant DBDs"
89422189|NCT03081195|Experimental|MFG-delivered by CHWs|"MFG delivered by community health workers (CHW) drawn from local primary care clinics:~10 schools; 60 community health workers (6 assigned to children per school x 10); 1,000 children and adult caregivers; children screened to evidence serious emerging and clinically significant DBDs"
89422190|NCT03081195|No Intervention|Bolstered care|"Comparison (Bolstered care): Mental health wellness materials and educational supports (e.g. books, uniforms)~10 schools; 1,000 children and adult caregivers; children screened to evidence serious emerging and clinically significant DBDs"
89422191|NCT02962401|Experimental|Idelalisib and Obinutuzumab|"6 cycles of Idelalisib and Obinutuzumab~Cycle 1 :~Idelalisib 150 mg x 2 p.o. day 1 to 28 Obinutuzumab 1000mg I.V. (2 parts) 100mg day 1 and 900mg day 2 day 1, 8 and 15~Cycle 2 - 6 :~Idelalisib 150 mg x 2 p.o. day 1 to 28 Obinutuzumab 1000mg I.V. day 1~Consolidation Idelalisib alone 150 mg twice a day until day 672 = 2 years after the beginning of the treatment"
89422192|NCT02920996|Experimental|NSCLC (Met Exon 14 Mutation)|Merestinib at the recommended phase II dose of 120 mg by mouth daily.
89422193|NCT02920996|Experimental|Solid Tumor (NTRK1,2,3 Rearrangement)|Merestinib at the recommended phase II dose of 120 mg by mouth daily.
88902796|NCT01527708||Normal Group (NG)|Normal group (NG) was formed by refractive surgery candidates who visited EIT's refractive surgery service for their preoperative examination. Eligibility for participation in the NG was confirmed by consecutive topographies, while all NG participants had to present uneventful ophthalmologic history, no indications of corneal pathology in slit-lamp biomicroscopy and Placido disk-based videokeratography.
89422194|NCT02898181|Experimental|Tragus Stimulation|In this group patients will receive neuromodulation for 2 hours daily
88902797|NCT01527721|Experimental|CxL group|Volunteers of this group received CxL treatment.
88902798|NCT01527721|Experimental|tCxL group|Volunteers of this group received CxL combined with t-PRK treatment
88902799|NCT01527734|Placebo Comparator|Placebo|
88902800|NCT01527734|Experimental|Tetrodotoxin, TTX|
88902801|NCT01527773||COPD cohort|Cohort of patients with proven COPD
89422195|NCT02898181|No Intervention|Control group|Sham neuromodulation will be done
89422196|NCT02880319|Experimental|Oligometastatic Disease|"Stereotactic Body Radiation Therapy (SBRT)to up to 3 sites of disease occurring in the bone or spine~Treatments will be delivered on a dedicated stereotactic linear accelerator that includes onboard conebeamCT imaging and orthogonal 2D/3D matching with robotic couch top.~Dosage will be determined by physician"
89422197|NCT02880319|Experimental|Re-irradiation to Metastatic Disease|"Stereotactic Body Radiation Therapy (SBRT) to site(s) of disease occurring in the bone or spine~Treatments will be delivered on a dedicated stereotactic linear accelerator that includes onboard conebeamCT imaging and orthogonal 2D/3D matching with robotic couch top.~Dosage will be determined by physician"
89422198|NCT02836249|Experimental|TAF|TAF + TDF placebo for up to 144 weeks
88902802|NCT01527786|Experimental|SNRI treatment|Participants are undergoing pharmacotherapy treatment with Desvenlafaxine (SNRI).
88902803|NCT01527799||Subjects with Sickle Cell Anemia|Subjects with Sickle Cell Anemia, 10-21 years of age
89422199|NCT02836249|Active Comparator|TDF|TDF + TAF placebo for up to 144 weeks
89422200|NCT02836249|Experimental|Open-label TAF|All participants who complete the double-blind period will be eligible to receive open-label TAF until Week 384 of the study.
89422201|NCT02827344||Stage IV non-small cell lung cancer|"Intervention to be done are :~- Blood sample collection for CTC and MDSC analysis"
89422202|NCT02769416||Spinal Cord and Traumatic Brain Injury Subjects|Patients with a history of spinal cord and/or traumatic brain injury will provide data and samples so that they may be queried for interventional studies.
89422203|NCT02769416||Family Members and Healthy Volunteers|Healthy volunteer controls or family members may be enrolled for identification of genetic mutations.
89422204|NCT02688985|Experimental|RMS Cohort Arm 1: Ocrelizumab + LP|Participants with RMS will receive ocrelizumab as two 300-mg IV infusion on Days 1 and 15 then as single infusion of 600 mg on Weeks 24 and 48. Participants will receive a LP before the start of dosing (Week 1, treatment baseline) with ocrelizumab and a second LP at Week 12. Participants will be asked to have an additional optional LP at Week 52. Participants that complete the study and continue to receive ocrelizumab will receive single infusions every 24 weeks starting from Week 72.
88902804|NCT01527799||Healthy controls|Healthy controls, 10 to 21 years of age
88902805|NCT01527812|Experimental|Above the femoral nerve|In Group I we will inject the local anaesthetic below the fascia iliaca and above the femoral nerve.
88902806|NCT01527812|Experimental|Below the femoral nerve|In Group II we will inject the local anaesthetic below the femoral nerve and above the fascia of the iliopsoas muscle.
88902807|NCT01527812|Experimental|Circumferential|In Group III a circumferential spread will be achieved with multiple injections.
88902808|NCT01527825|Active Comparator|Single dose|Trivalent Influenza Vaccine (seasonal)
88902809|NCT01527825|Experimental|Double dose TIV|Trivalent Influenza vaccine (seasonal) Two doses will be administered at enrolment
88902810|NCT01527825|Experimental|Two dose TIV|Trivalent Influenza vaccine (seasonal) Participants will receive two doses of TIV, one month apart
88902811|NCT01527838|Experimental|Single FT1050 treated UCB Unit|Ex-vivo CXCR4 upregulated hematopoietic progenitor cells, cord blood
88902812|NCT01527864|Experimental|pegylated endostatin|
88902813|NCT01527864|Placebo Comparator|Control|
88902814|NCT01527877|Experimental|BKM120|
88902815|NCT01527903|Active Comparator|Propofol|
88902816|NCT01527903|Active Comparator|Midazolam|
89195004|NCT00611884|Experimental|SIBA (D)|
89422205|NCT02688985|Experimental|RMS Cohort Arm 2: Ocrelizumab + LP|Participants with RMS will receive ocrelizumab as two 300-mg IV infusion on Days 1 and 15 then as single infusion of 600 mg on Weeks 24 and 48. Participants will receive a LP before the start of dosing (Week 1, treatment baseline) with ocrelizumab and a second LP at Week 24. Participants will be asked to have an additional optional LP at Week 52. Participants that complete the study and continue to receive ocrelizumab will receive single infusions every 24 weeks starting from Week 72.
88902817|NCT01527929|Experimental|Cohort A|Normal renal function - Cabazitaxel administered once every 3 weeks
88902818|NCT01527929|Experimental|Cohort B|Moderate renal dysfunction - Cabazitaxel administered once every 3 weeks
88902819|NCT01527929|Experimental|Cohort C|Severe renal dysfunction - Cabazitaxel administered once every 3 weeks
88902820|NCT01527968|Active Comparator|Tranexamic Acid|TXA as 10mg/kg x 1 dose in 100mL normal saline over 15 minutes prior to the procedure then an infusion of 1mg/kg/hr during the procedure + placebo (normal saline as the dummy for eACA.)
89195005|NCT00611884|Experimental|SIBA (E)|
89195006|NCT00611884|Experimental|SIBA (D) M, W, F|
89195007|NCT00611884|Active Comparator|IGlar|
89195008|NCT00420745|Experimental|Rotarix Group|All subjects received 2 oral doses of Rotarix vaccine, 1 dose at Day 0 and 1 dose at Month 1 or 2 depending on the country.
89195009|NCT00420745|Placebo Comparator|Placebo Group|All subjects received 2 oral doses of placebo, 1 dose at Day 0 and 1 dose at Month 1 or 2 depending on the country.
89195010|NCT00611806|Active Comparator|Folate with B12|Participants will take folic acid plus B12 for 18 weeks.
89195011|NCT00611806|Placebo Comparator|Placebo|Participants will take placebo for 18 weeks.
89195012|NCT00413413|Experimental|Valsartan/amlodipine 80/5 mg|
89195013|NCT00413413|Active Comparator|Valsartan 80 mg|
89195014|NCT00413413|Active Comparator|Valsartan 160 mg|
89195015|NCT00886132|Experimental|Sunitinib|Patients with progressive, recurrent and/or metastatic ACC treated with sunitinib 37.5 mg daily in this single-arm, two-stage phase II trial.
89195016|NCT01040455|Experimental|lansoprazole|lansoprazole 15mg (Takepron®, Takeda Pharmaceutical Company, Osaka, Japan) once daily for eight weeks
89195017|NCT01040455|Placebo Comparator|placebo|placebo once daily for eight weeks
89195018|NCT01040533||Failed / complicated jejunoileal bypass|
89195019|NCT01040611|Experimental|Music therapy|This study examined the effectiveness of music therapy on anxiety, depression and physiological responses for patients with tuberculosis.
89195020|NCT01040611|No Intervention|Placebo|No music therapy apply to this arm
89195021|NCT01040767|Active Comparator|Class|
89195022|NCT01040767|Active Comparator|Web|
89195023|NCT01040767|No Intervention|Control|
88902821|NCT01527968|Active Comparator|Epsilon Aminocaproic Acid|eACA as 150mg/kg in 250mL of IV normal saline over 15 minutes prior to the procedure then an infusion of 15mg/kg/hr during the procedure + placebo (normal saline as the dummy for TXA).
88902822|NCT01527968|Placebo Comparator|Placebo|Control Normal Saline x 2 infusions as the double dummy for TXA and eACA.
88902823|NCT01527981|Experimental|CBT-AD|Participants received weekly one-hour CBT-AD sessions focusing on diabetes self-care and depression for approximately 10 sessions. Participants also had meetings with a registered dietitian and a nurse educator, focusing on nutritional management of diabetes and diabetes self-care education, respectively.
88902824|NCT01527994|Experimental|Aprepitant 125 mg|Day Number Dose Procedure Day 0 Aprepitant 125mg Admitting Medication Treatment Day 1 Aprepitant 125mg Saline-Saline Day 2 Aprepitant 125mg Morphine-Morphine Day 3 Aprepitant 125mg Saline-Morphine Day 4 Aprepitant 125mg Naloxone-Morphine and Discharge
88902825|NCT01527994|Placebo Comparator|Placebo|Day Number Dose Procedure Day 0 placebo Admitting Medication Treatment Day 1 placebo Saline-Saline Day 2 placebo Morphine-Morphine Day 3 placebo Saline-Morphine Day 4 placebo Naloxone-Morphine and Discharge
88902826|NCT01528007|Placebo Comparator|Placebo pill.|
88902827|NCT01528007|Active Comparator|50mg Naltrexone when needed|
89195024|NCT01040923||Cardiac CT|All patients in the study will be those presenting themselves for cardiac CT angiography who meet the proper inclusion / exclusion criteria
89195025|NCT01041001|Experimental|Cartistem|A single dose of 500㎕/㎠ of cartilage defect
89195026|NCT01041001|Active Comparator|Microfracture treatment|
89195027|NCT01041079||Chronic marginal ulcer after RYGB|Patients with intractable or chronic marginal ulcer disease after gastric bypass complaining of abdominal pain, GI bleeding, obstruction, perforation and penetration. Sometimes with other associated diagnosis such as narcotic and tobacco dependence, protein-calorie malnutrition, excessive weight loss, poor pouch emptying syndrome, weight regain, inadequate initial weight loss, severe dumping syndrome among others.
89195028|NCT01041157|Experimental|1|resistance training
89195029|NCT01041235|Experimental|ATI-1123|
89195030|NCT01041313|Active Comparator|Opiate Naive|Subjects who have not taken opiate medication in previous 6 weeks before surgery
89195031|NCT01041313|Active Comparator|Opiate tolerant|Subjects who have taken opiate medications for the 6 weeks before surgery
89195032|NCT01041391||Surgical treatment for Lumbar disc herniation|Patients who had or will have surgery for Lumbar disc herniation
89195033|NCT01041391||Non-surgical treatment for Lumbar disc herniation|Patients that have chosen conservative treatment for lumbar disc herniation
89195034|NCT01041469||with abnormalities|Down syndrome patients presenting with at least one sign of auto immune abnormality
89195035|NCT01041469||without abnormality|Down syndrome patients without any sign of recognized auto immune condition
89195036|NCT01041547||Healthy adults|healthy adults with BMI below 32, between ages 19-60 yrs, both males and females
89195037|NCT03760939|Experimental|Ambulatory care|Colorectal surgery in ambulatory care
89195038|NCT03760939|Other|Standard hospitalization|Colorectal surgery with standard hospitalization for retrospective patients who benefit from the ERAS program, selected by statistical matching.
89195039|NCT00610714|Active Comparator|Active Comparator|carboplatin plus paclitaxel
89195040|NCT00610714|Experimental|2|AZD0530 in combination with carboplatin plus paclitaxel
89195041|NCT04038112|Other|Method of Levels (MOL)|all participants will be offered intervention
89195042|NCT00886210|Active Comparator|1LC with drain|Under general anesthesia, and same antibiotics (3rd generation cephalosporin). Surgery was performed using conventional four ports umbilical port, port below xiphoid and two ports below right costal margin. Pneumoperitonum at pressure 12 mmHg. In group A nelton catheter (no 20) inserted at the end of operation.
89195043|NCT00886210|Active Comparator|2LC without drain|Under general anesthesia, and same antibiotics (3rd generation cephalosporin). Surgery was performed using conventional four ports umbilical port, port below xiphoid and two ports below right costal margin. Pneumoperitonum at pressure 12 mmHg. no drain at the end of operation.
89195044|NCT00645411|Experimental|Cohorts 1 + Cohort 2 (9-17 Yrs) cTIV|All subjects received one 0.5 mL IM injection, of cell culture-derived trivalent influenza vaccine containing 15μg of HA for each strain (A/Solomon Islands/3/2006 [H1N1]-like, A/Wisconsin/67/2005 [H3N2]-like, and B/Malaysia/ 2506/2004-like), recommended for the 2007-2008 influenza season in the Northern Hemisphere
89195045|NCT00645411|Active Comparator|Cohorts 1 + Cohort 2 (9-17 Yrs) eTIV|All subjects received one 0.5 mL injection, of egg -derived trivalent influenza vaccine containing 15μg of HA for each strain (A/Solomon Islands/3/2006 [H1N1]-like, A/Wisconsin/67/2005 [H3N2]-like and B/Malaysia/ 2506/2004-like), recommended for the 2007-2008 influenza season in the Northern Hemisphere.
89422206|NCT02688985|Experimental|RMS Cohort Arm 3: Ocrelizumab + LP|Participants with RMS will receive ocrelizumab as two 300-mg IV infusion on Days 1 and 15 then as single infusion of 600 mg on Weeks 24 and 48. Participants will receive a LP before the start of dosing (Week 1, treatment baseline) with ocrelizumab and a second LP at Week 52. Participants that complete the study and continue to receive ocrelizumab will receive single infusions every 24 weeks starting from Week 72.
89422207|NCT02688985|Experimental|RMS Cohort Arm 4: Ocrelizumab + LP|Ocrelizumab treatment will be delayed for 12 weeks from pre-treatment baseline. Participants with RMS will receive ocrelizumab as two 300-mg IV infusion on Days 1 and 15 then as single infusion of 600 mg on Weeks 24 and 48. Participants will receive a LP at Week -12 (pre-treatment baseline) and a second LP before the start of dosing (Week 1, treatment baseline). Participants will be asked to have an additional optional LP at Week 52. Participants that complete the study and continue to receive ocrelizumab will receive single infusions every 24 weeks starting from Week 72.
89422208|NCT02688985|Experimental|PPMS Cohort: Ocrelizumab + LP|For the PPMS cohort, ocrelizumab will be administered as two 300-mg IV infusions separated by 14 days at a scheduled interval of every 24 weeks during the treatment period and then as a single 600-mg dose every 24 weeks starting week 72 during the Long-Term Extension period.
89422209|NCT02672826|Experimental|adipose tissue surgery|The adipose tissue surgery (gluteo-femoral and abdominal) will be obtained from women programmed for surgery in which the estrogenic status as well as adipose tissue mass profile will be evaluated.
89422210|NCT02669186|Experimental|'Bupivacaine + Fentanyl' (Opioid Group)|Group 1 (opioid group) will receive general endotracheal anesthesia augmented with an epidural. The epidural solution intraoperatively and post-operatively will contain fentanyl + bupivacaine titrated to appropriate surgical conditions and post-operative pain control.
89422211|NCT02669186|Active Comparator|Bupivacaine (Local Anesthetic Group)|Group 2 (local anesthetic group) will receive general endotracheal anesthesia augmented with an epidural. The epidural solution intraoperatively and post-operatively will contain bupivacaine titrated to appropriate surgical conditions and post-operative pain control.
88902828|NCT01528020|Experimental|Dialectical Behavior Therapy|
88902829|NCT01528020|Active Comparator|Inidividual and Group Supportive Therapy|
88902830|NCT01528059|Active Comparator|Billroth II|After stomach resection, the remnant stomach is connected to the jejunum.
88902831|NCT01528059|Active Comparator|Roux en Y|After stomach resection, the remnant stomach is connected to the distal jejunum while duodenum and the proximal jejunum is reconnected to jejunum.
88902832|NCT01528098||PEG plus bisacodyl|Those who taken PEG 4L + bisacodyl 10mg
88902833|NCT01528098||PEG 4L|Those who taken PEG 4L alone
88902834|NCT01528137|Experimental|Treatment (immunomodulator)|Patients receive talactoferrin PO BID for 12 weeks. Courses repeat every 14 weeks in the absence of disease progression or unacceptable toxicity.
88902835|NCT01528163|Experimental|Cabazitaxel|Cabazitaxel (XRP6258) is a new taxoid, which promotes tubulin assembly in vitro and stabilizes microtubules against cold-induced depolymerization as efficiently as docetaxel
88902836|NCT01528163|Active Comparator|Methotrexate|"Methotrexate is the historical control and has been widely used in SCCHN for palliation.~This medication is an antimetabolite and antifolate drug. It acts by inhibiting the metabolism of folic acid."
88902837|NCT01528176|Other|(CKD) stages III-V and non -CKD patients|We recruited patients with wide range of eGFR
88902838|NCT01528202|No Intervention|Baseline placebo|measures taken before administration of placebo
88902839|NCT01528202|Placebo Comparator|Placebo|Placebo intervention given after 'baseline placebo' arm
88902840|NCT01528202|No Intervention|baseline cherry juice|measures taken before the cherry juice intervention
88902841|NCT01528202|Experimental|cherry juice|trial where cherry juice is taken following the 'baseline cherry juice' arm
88902842|NCT01528241|Experimental|ABP688|Elderly MDD patients and demography matched healthy volunteer
88902843|NCT01528267|Active Comparator|Autologous blood|Patients will have 50mls of autologous blood injected into each of 3 bronchopulmonary segments during bronchoscopy under conscious sedation.
88902844|NCT01528267|Sham Comparator|Saline|Patients will have 50mls of normal saline injected into each of 3 bronchopulmonary segments during bronchoscopy under conscious sedation.
88902845|NCT01528280|Experimental|Shiftwork|The comparison will consider nightworkers versus dayworkers.
88902846|NCT01528306|Experimental|HP802-247|
88902847|NCT01528306|Placebo Comparator|Placebo (Vehicle)|
88902848|NCT01528358||Early Sepsis Critically Ill Patients|Patients who are admitted to ICU with a diagnosis of early sepsis.
89422212|NCT02602145||Peripheral artery disease patients|Patients with peripheral artery disease who were treated with a stent as part of their standard of care. Patients who meet the inclusion criteria (i.e. already have a stent in their femoropopliteal artery) will be consented after their endovascular repair, and those who choose to participate in the study will be followed for 6-12 months. During the follow-up, a post-operative contrast-enhanced CTA of the lower extremities will be obtained to assess for restenosis.
88902849|NCT01528358||Non-septic Critically ill patients|Patients who are critically ill and admitted to ICU without diagnosis of sepsis.
89195046|NCT00645411|Experimental|Cohort 3 (3-8 Yrs) cTIV|All subjects received two 0.5 mL injections, administered four weeks apart, of cell culture-derived trivalent influenza vaccine containing 15μg of HA for each strain (A/Solomon Islands/3/2006 [H1N1]-like, A/Wisconsin/67/2005 [H3N2]-like and B/Malaysia/ 2506/2004-like), recommended for the 2007-2008 influenza season in the Northern Hemisphere
89422213|NCT02568566|Experimental|Prevention (Gardasil 9)|Patients receive recombinant human papillomavirus nonavalent vaccine IM at baseline (priming injection) and at 24 and 30 months (booster injections).
88902850|NCT01528371|Active Comparator|Midazolam|Intravenous administration of midazolam at dose of 0.02mg/kg
88902851|NCT01528371|Placebo Comparator|NSS|Intravenous administration of saline solution at dose of 0.004ml/kg as a placebo drug
88902852|NCT01528410|Experimental|ALFApump removal of ascites|Removal of ascites
88902853|NCT01528410|Active Comparator|Large volume paracentesis for removal of ascites|Removal of ascites
88902854|NCT01528423||Men 16 - 18yrs|
88902855|NCT01528423||Men 30 - 32 yrs|
88902856|NCT01528423||Men 70 yrs +|
88902857|NCT01528423||Women 16 - 18 yrs|
88902858|NCT01528423||Women 30 - 32 yrs|
88902859|NCT01528423||Women 70 yrs +|
88902860|NCT01528449|Experimental|retrospective|archived specimens from blood donors whose units have already been released and transfused into recipients will be tested. Attempts will be made to contact and obtain follow up specimens from both the donor and recipient of units initially testing positive for B.microti. the interventions are investigational diagnostic tests for B.microti (PCR and IFA).
88902861|NCT01528449|Experimental|prospective, real time|specimens from current blood donors will be tested and those testing positive for B.microti will not be released and the units will be disgarded, and the donors notified and deferred from future blood donation. the interventions are investigational diagnostic tests for B.microti (PCR and IFA).
88902862|NCT01528475|Active Comparator|Pre-hospital cooling|Patients in this arm will receive pre-hospital cooling by paramedics. This treatment includes placement of surface ice-pacs, initiation of an intravenous infusion of cold saline, and wrist and ankle bands with text to remind in-hospital clinicians to continue therapeutic hypothermia.
88902863|NCT01528475|No Intervention|Usual pre-hospital care|Patients in this arm will receive usual post-resuscitation care by paramedics. Usual post-resuscitation care does not include initiation of cooling in the pre-hospital setting.
88902864|NCT01528488|Experimental|EVOZAC|EVOZAC should be sprayed to the skin of the total face three times per day.
88902865|NCT01528488|Placebo Comparator|Physiological saline|Physiological saline should be sprayed to the total face three times per day.
88902866|NCT01528501|Experimental|I|
88902867|NCT01528514|Active Comparator|Curcuminoids|
88902868|NCT01528514|Placebo Comparator|Placebo|
88902869|NCT01528540|Placebo Comparator|Placebo|This group will contain a placebo for antioxidant cocktail and pregabalin
88902870|NCT01528540|Experimental|Antioxidant plus pregabalin|This group will contain antioxidant cocktail and pregabalin
88902871|NCT01528553|Active Comparator|Staples|Old implant type
88902872|NCT01528553|Active Comparator|8plate|New implant type
88902873|NCT01528566|Experimental|Tai Chi|
88902874|NCT01528566|Placebo Comparator|Attentation control|
88902875|NCT01528579|Active Comparator|Neck Specific exercises|Neck Specific exercises from a structured frame of exercises
88902876|NCT01528579|Active Comparator|Behavioral approach|Behavioral physiotherapeutic approach in combination with neck specific exercises from a structured well defined frame of exercises and how to treat the patient. 2 times a week for 3 months.
88902877|NCT01528579|Active Comparator|Prescribed physical activity|Prescribed physical activity from a physiotherapist without neck specific exercises
88902878|NCT01528618|Experimental|gemcitabine and cisplatin|gemcitabine 1,000 mg/m2 over 30 to 60 minutes on days 1, 8, and plus cisplatin 80 mg/m2 on day 1, every 3 weeks.
88902879|NCT01528618|Active Comparator|5-Fluorouracil and cisplatin|5-Fluorouracil 4,000 mg/m2 CIV over 96 hours and plus cisplatin 80 mg/m2 on day 1, every 3 weeks.
88902880|NCT01528631|Placebo Comparator|Control Product|200 ml water with 50g of sucrose
88902881|NCT01528631|Active Comparator|Product 1|200 ml water with 50g of sucrose and supplemented with 30 mg of D-Fagomine
88902882|NCT01528644|Experimental|Iron in beads|All experimental days will be exactly the same with the exception of the test meal administered to the volunteer. Volunteers will undergo a 10 hour overnight fast from 10:00pm, then they will be asked to attend the CRTU at approximately 8:00 am the following morning. A nurse will take and record the volunteer's blood pressure and if within the range an intravenous (i.v.) cannula will be inserted into a vein in one of the volunteer's arms. The cannula will remain in situ for six hours. After the first blood sample (t=0) will be taken, volunteers will consume one out of 4 test meals. After consumption further blood samples will be collected at: 20, 40, 60, 80, 100, 120, 150, 180, 240, 300 and 360 min. Blood samples will subsequently be analysed for serum iron concentrations.
88902883|NCT01528644|Experimental|Iron in capsule|All experimental days will be exactly the same with the exception of the test meal administered to the volunteer. Volunteers will undergo a 10 hour overnight fast from 10:00pm, then they will be asked to attend the CRTU at approximately 8:00 am the following morning. A nurse will take and record the volunteer's blood pressure and if within the range an intravenous (i.v.) cannula will be inserted into a vein in one of the volunteer's arms. The cannula will remain in situ for six hours. After the first blood sample (t=0) will be taken, volunteers will consume one out of 4 test meals. After consumption further blood samples will be collected at: 20, 40, 60, 80, 100, 120, 150, 180, 240, 300 and 360 min. Blood samples will subsequently be analysed for serum iron concentrations.
88902884|NCT01528644|Experimental|Iron in beads in presence of calcium|All experimental days will be exactly the same with the exception of the test meal administered to the volunteer. Volunteers will undergo a 10 hour overnight fast from 10:00pm, then they will be asked to attend the CRTU at approximately 8:00 am the following morning. A nurse will take and record the volunteer's blood pressure and if within the range an intravenous (i.v.) cannula will be inserted into a vein in one of the volunteer's arms. The cannula will remain in situ for six hours. After the first blood sample (t=0) will be taken, volunteers will consume one out of 4 test meals. After consumption further blood samples will be collected at: 20, 40, 60, 80, 100, 120, 150, 180, 240, 300 and 360 min. Blood samples will subsequently be analysed for serum iron concentrations.
89195047|NCT00645411|Active Comparator|Cohort 3 (3-8 Yrs) eTIV|All subjects received two 0.5 mL injections, administered four weeks apart of egg -derived trivalent influenza vaccine containing 15μg of HA for each strain (A/Solomon Islands/3/2006 [H1N1]-like, A/Wisconsin/67/2005 [H3N2]-like and B/Malaysia/ 2506/2004-like), recommended for the 2007-2008 influenza season in the Northern Hemisphere
89195048|NCT04037644|Experimental|Albumin|fluid loading with 200 mL of 4% albumin over a 10' interval
89195049|NCT04037644|Active Comparator|Ringer Lactate|fluid loading with 5 mL/kg actual body weight of Ringer Lactate over a 10' interval
89195050|NCT00403273|Experimental|A|Single Intra-articular Injection of 100 units of Botulinum toxin A in 5 cc of normal saline in the Painful TKA at screening visit
89195051|NCT00403273|Placebo Comparator|B|Single Intra-articular Injection of 5 cc of normal saline in the Painful TKA at screening visit
89195052|NCT03835546||Early treated patients|Patients with confirmed HIV-1 infection attended in the HIV Unit of the Hospital Universitari Germans Trias i Pujol who initiated therapy presenting recent HIV-1 infection. Recent HIV-1 infection was defined as having a positive plasma viral load and/or p24 antigen with a negative ELISA or having a positive ELISA and undetermined Western-Blot, or having a positive ELISA and absence of p31 antigen in a positive Western-Blot, or seroconversion ELISA in less than 3 months.
89195053|NCT03835546||Regularly treated patients|Patients with confirmed HIV-1 infection attended in the HIV Unit of the Hospital Universitari Germans Trias i Pujol who initiated therapy, did not fulfil the criteria for recent HIV-1 infection, and had an estimated time >6 months reported by the patient and/or by the responsible physician since HIV transmission.
89195054|NCT03835546||Seronegative volunteers|HIV-uninfected volunteers, matched to age, sex, and educational level with groups A and B.
89195055|NCT00885274|Experimental|Split Dose|Doses of Pico-Salax split: one dose administered the night prior to colonoscopy and the other dose administered the day of the procedure.
89195056|NCT00885274|Active Comparator|Traditional Dose|Both doses of Pico-Salax taken the evening prior to colonoscopy.
89195057|NCT00885430|Experimental|Pico-Salax|
89195058|NCT00886366|Experimental|1|AZD6714 in 8 increasing oral single doses a-h given to 8 groups (3 on active and 1 on placebo in each group)
89195059|NCT00886366|Experimental|2|2 oral single doses d and g suspensions of AZD6714 given to 2 groups (3+1) together with food
89195060|NCT00886366|Experimental|3|Two increasing oral doses of AZD6714 and one placebo given to 2 groups with 3 type 2 diabetic patients.
89195061|NCT00886444|Experimental|Ferucarbotran|
89195062|NCT00888550|Experimental|1. Splinting|
89195063|NCT00888550|Active Comparator|2. No Splinting|
89195064|NCT00888706|Active Comparator|1|
89195065|NCT00888706|Active Comparator|2|
89422214|NCT02548104|Active Comparator|Adductor canal block (ACB)|Group I Adductor canal block (ACB): 0.25% bupivacaine with 1:200,000 epinephrine 30 ml and ultrasound-guided genicular (IPACK) with normal saline 15 ml
89195066|NCT00888706|Active Comparator|3|
89195067|NCT00888706|Experimental|4|
89195068|NCT00402727|Experimental|Moxifloxacin|Moxifloxacin (Avelox, BAY 12-8039) 400 mg intravenous (IV) once daily followed by Moxifloxacin 400 mg oral tablets once daily for a minimum of 7 days and a maximum of 21 days. Oral phase was not always mandatory.
89195069|NCT00402727|Active Comparator|PIP/TAZ-AMC|Piperacillin/Tacobactam 4.0/0.5 g (PIP/TAZ) administered intravenous three times daily followed by Amoxicillin/Clavulanic acid (AMC) oral tablets 875/125 mg twice daily for a minimum of 7 days and a maximum of 21 days. Oral phase not always mandatory.
89195070|NCT04037722|Experimental|Healthy + Whey|Healthy conditions (overnight fast)
89195071|NCT04037722|Experimental|Catabolic + Whey|Catabolic conditions (36-hour fast, bed rest and inflammation (LPS))
89195072|NCT04037722|Experimental|Catabolic + 3-OHB / Whey|Catabolic conditions (36-hour fast, bed rest and inflammation (LPS))
89195073|NCT02541916|Experimental|Controlled weaning of immunosuppression|Participants who are found to have the tolerance gene expression profile during phase 1 of the study will undergo closely monitored immunosuppression weaning during phase 2.
89195074|NCT00923494|Active Comparator|Group R20|Patient will receive 20 ml of ropivacaine 0.5% for their ultrasound guided supraclavicular block.
89195075|NCT00923494|Active Comparator|Group R30|Patient will receive 30 ml of ropivacaine 0.5% for their ultrasound guided supraclavicular block.
89195076|NCT00923494|Active Comparator|Group R40|Patient will receive 40 ml of ropivacaine 0.5% for their ultrasound guided supraclavicular block.
89195077|NCT00886522|Experimental|Intrabone cord blood infusion|All adults patients with hematological malignancies, lacking a HLA matched donor but with a HLA compatible CB unit, fulfilling the inclusion criteria, will undergo to intrabone HSC infusion of CB.
89195078|NCT00402649|Experimental|1|All subjects will receive at least 2 and up to 3 doses of the vaccine approximately 28 days apart.
89195079|NCT00888784|Active Comparator|1. Endoscopic Cyanoacrylate injection|Endoscopic Cyanoacrylate injection in the gastric varix
89195080|NCT00888784|Placebo Comparator|2. Beta-blocker|Propranolol was started at a dose of 20 mg twice daily. The principle of incremental dosing was used to achieve the target heart rate for propranolol. The dose was increased every alternate day to achieve a target heart rate of 55/min or to the maximal dose to 360 mg/day if the medication was well tolerated and the systolic blood pressure was >90 mm Hg. On the occurrence of intolerable adverse effects, systolic blood pressure <90 mm Hg or pulse rate <55/min, the dose of the medication was decreased step-wise, and eventually stopped if these adverse events persisted. Reintroduction of the medication was attempted if cessation of the medication did not result in improvement of the reported side-effect.
89195081|NCT00886678|Experimental|1|patients receiving pemetrexed, carboplatin and radiation therapy.
89195082|NCT00886756|Experimental|1|
89195083|NCT00886756|Placebo Comparator|2|
89195084|NCT00402337|Active Comparator|72 ug linaclotide acetate|
89195085|NCT00402337|Active Comparator|145 ug linaclotide acetate|
89195086|NCT00402337|Active Comparator|290 ug linaclotide acetate|
89195087|NCT00402337|Active Comparator|579 ug linaclotide acetate|
89195088|NCT00402337|Placebo Comparator|Matching Placebo|
89195089|NCT00888862|Experimental|A|Use of desvenlafaxine succinate, flexible dose (50-100mg/day)
89195090|NCT00886912|Active Comparator|Hypoxia|training in simulated altitude
89195091|NCT00886912|Placebo Comparator|Normoxia|training under normoxic conditions
89195092|NCT04037332||Pre-RAS roll-out . Group I|I. Children presenting directly to a referral health facility without prior administration of RAS (pre-RAS): provides a baseline assessment of artemisinin resistance marker prevalence before the introduction of RAS
89195093|NCT04037332||Post-RAS roll-out - Group II|II. Children presenting directly to a referral health facility without prior administration of RAS (post-RAS): group not receiving pre-referral RAS and hence having baseline pressure for K13 resistance markers.
89195094|NCT04037332||Post-RAS roll-out - Group III|III. Children receiving pre-referral RAS from community-based provider and successfully referred to a referral health facility: group receiving pre-referral RAS (monotherapy).
89195095|NCT04037332||Post-RAS roll-out - Group IV|IV. Children receiving pre-referral RAS from community-based provider but not completing referral to a referral health facility, followed-up at their home on day 28: children malaria-positive on Day 28 may have an increased chance of harboring a resistant infection.
89195096|NCT00886990||1|Receiving a single PI boosted by low dose ritonavir
89195097|NCT00886990||2|Receiving two PIs boosted by low dose ritonavir or one PI plus full dose ritonavir
89195098|NCT00650091|Active Comparator|1|Participants will receive N-acetylcysteine (NAC) for 60 weeks.
89195099|NCT00650091|Placebo Comparator|2|Participants will receive placebo for 60 weeks.
89195100|NCT00889018|Active Comparator|group 1|chemotherapy using carboplatin 560mg/m2
89195101|NCT00889018|Experimental|group 2|chemotherapy using 750mg/m2 carboplatin
89195102|NCT00889096|Active Comparator|study day 1 propanolol|Oral administration of 80 mg propranolol (1 capsule containing two Obsidan® tablets: 2 x 40 mg propranolol) according to randomization list with 240 ml. Determination of blood pressure, heart rate over 4 hours and until return to the initial baseline values.
89195103|NCT00889096|Placebo Comparator|study day 1 placebo|Oral administration of placebo (1 capsule containing two placebo tablets) according to randomization list with 240 ml. Determination of blood pressure, heart rate over 4 hours and until return to the initial baseline values.
89006931|NCT06176690|Experimental|Treatment Phase|"Four dose levels will be evaluated based on safety data from our current study of CD30 CAR T cells.~Cohorts of three patients will be enrolled at each dose level The dose is based on the number of CD.30 CAR-EBVT-expressing cells administered.~The total number of dose levels evaluated will depend upon toxicities experienced. Dose level cohorts will be numbered sequentially.~Dose Level 1: 4 × 10^7 C7R.CD30.CAR-EBVST cells~Dose Level 2: 1 × 10^8 C7R.CD30.CAR-EBVST cells~Dose Level 3: 4 × 10^8 C7R.CD30.CAR-EBVST cells~Dose Level 4: 8 × 10^8 C7R.CD30.CAR-EBVST cells"
89006932|NCT06176664|No Intervention|Standard of Care|Participants will receive pneumonia care per World Health Organization guidelines. If their oxygen saturation falls below 90% after enrollment, they will be treated with low-flow oxygen.
89006933|NCT06176664|Experimental|Low-flow Oxygen|Participants will be treated with low-flow oxygen to achieve a goal oxygen saturation above 94%
89006934|NCT06176664|Experimental|High-flow Nasal Cannula Oxygen|Participants will be treated with high-flow nasal cannula oxygen to achieve a goal oxygen saturation above 94%.
89006935|NCT06176638|Experimental|RRF4H Combination Intervention Group|This is a combination intervention that builds on the Usual Care and will consist of (1) a MFG-based FS model, which targets issues such as communication, relationship, and social support network development to assist with parenting and stress management, and stigma reduction96 and (2) a peer-mentoring program called TeenAge Health Consultants (Virtual TAHC) adapted for delivery in virtual environment.
89006936|NCT06176638|No Intervention|Usual Care Group|Youth in RRF4H study will receive the usual mental health counseling provided through their school counselors. There is no structured curriculum for the group counseling programs but are available to all students as needed. The Lincoln Public School District also provides additional resources on specific topics such as trauma, depression and anxiety in children and adolescents, and alcohol substance use in families and provide appropriate referrals for those in need. Additionally, through organizations such as the International Council for Refugees and Immigrants (ICRI), refugee youth 7 to 18 years of age can receive educational and social support programs, after-school STEM clubs and one-on-one peer mentoring. Through the New Life Family Alliance, in addition to after-school program, boys and girls basketball program, youth are connected to youth-serving agencies that can help them effectively and successfully develop and take advantage of opportunities available to them.
89006937|NCT06173284|Experimental|611|Induction treatment period : subcutaneous injection, 611 600mg (loading dose, week 0) + 300mg Q2W (from Week 2 to Week 14, 7 cycles) Maintenance treatment period : subcutaneous injection, 611 300mg Q2W or Q4W
89006938|NCT06173284|Placebo Comparator|Placebo|Induction treatment period : subcutaneous injection, placebo Q2W (from Week 0 to Week 14, 7 cycles) Maintenance treatment period : subcutaneous injection, 611 600mg (loading dose, week 16) + 300mg Q2W or Q4W
89006939|NCT06171802|Active Comparator|Empagliflozin|Empagliflozin 1 capsule of 10 mg, once daily for six months.
89006940|NCT06171802|Placebo Comparator|Placebo|1 capsule of placebo, once daily for six months
89006941|NCT06171763|Experimental|Telehome care|"For patients/caregivers assigned to the tele-homecare group, before discharge, instruction on the use of the TytoCareTM system was provided by healthcare personnel trained in the use of the system. Subsequently, each patient give the device they used until the scheduled post-discharge clinical assessment. A parent/caregiver was invited to participate for each pediatric patient.~Every 24 hours, the patient was assessed remotely in synchronous teleconsultation by medical staff; during tele-visit, the physician performed the complete routine procedure, including medical history and physical examination with user friendly medical device and completed the data collection sheet.~At 72 hours after discharge, an in-person clinical assessment was scheduled for outcome evaluation. In particular, during the visit, the complete resolution of the disease state was assessed through the post-discharge objective examination."
89006942|NCT06171763|No Intervention|Standard care|"Patients remained hospitalized for the continuation of the treatment. Every 24 hours, the patient was assessed in person by medical staff; the traditional physical examination involved assessment of the clinical parameters using standard equipment such as a digital thermometer, conventional stethoscope, and otoscope and completed the same data collection sheet.~After 72 hours of hospital observation, an in-person clinical examination was conducted to evaluate the outcome. In particular, during the visit, the complete resolution of the disease state was assessed through the post-discharge objective examination."
89006943|NCT06171698|Experimental|Research Prototype Monitor|
89006944|NCT06171503|Experimental|intervention group|participants on intervention group will receive letter of invitation to invite her partner to attend antenatal care clinic on subsequent visit 2 to 8 weeks
89006945|NCT06171503|No Intervention|comparison group|participant on comparison group do not receive a letter but will receive routine care to attend antenatal care along with her partner on subsequent visit 2 to 8 weeks
89006946|NCT06171269|Experimental|Radiation therapy|Participants will receive MRI scan before starting Radiation treatment. The results of this scan will be used to identify areas of the prostate to receive low doses of radiation (areas that show no cancer cells seen by the MRI scan).
89006947|NCT06170697|Experimental|Camrelizumab+（Cisplatin or Carboplatin or Lobaplatin or Nedaplatin）+radiotherapy|patients with short-term postoperative progression receive camrelizumab and platin-based chemotherapy concurrent with radiotherapy.
89006948|NCT06170476|Experimental|HSK21542-60μg|
89006949|NCT06170476|Experimental|HSK21542-120μg|
89006950|NCT06170476|Experimental|HSK21542-180μg|
89006951|NCT06170476|Placebo Comparator|Placebo|
89422215|NCT02548104|Experimental|Adductor canal ACB + genicular (IPACK)|Group II Adductor canal block (ACB): 0.25% bupivacaine with 1:200,000 epinephrine 30 ml and ultrasound-guided genicular (IPACK) with 0.25% Bupivicaine with 1:200,000 epinephrine 15 ml
89006952|NCT06170463|Active Comparator|Met Group|
89006953|NCT06170463|Active Comparator|MI Group|
89006954|NCT06170463|Active Comparator|MM Group|
89006955|NCT06170398|Other|Interventional|Electrophysiological tests
89195104|NCT00818103|Experimental|Atorvastatin, β-interferon, EPO|
89422216|NCT02536365|Experimental|Sensory Integration Therapy|Children receive manualized SIT intervention that follows principles of sensory integration. SIT directly addresses the specific sensory factors hypothesized to underlie the child's functional skills difficulties and follows the Data Driven Decision Making Process, to tailor the intervention to the child's specific sensory issues.
89422217|NCT02536365|Active Comparator|Applied Behavioral Analysis|This involves examination of environmental variables that influence behavior and altering those variables to improve the child's skills. Intervention is individualized based on identified needs of the child, assessment of environmental variables impacting their performance of specific functional skills, and their abilities.
89422218|NCT02536365|No Intervention|No Treatment|Treatment as usual will occur through the treatment period. As with the other treatment conditions, the participant agrees to refrain from beginning new treatments during participation in this study.
89422219|NCT02536183|Experimental|Part A|LTLD will be administered intravenously in combination with MR-HIFU ablation on day 1 of every 21 day cycle. There will be two potential dose escalation of LTLD with highest dose not to exceed the adult recommended MTD. Patients may receive up to a total of 6 cycles.
89422220|NCT02536183|Experimental|Part B|LTLD at dose determined from Part A will be administered intravenously on day 1 of every 21 day cycle. MR-HIFU induced MHT will follow immediately post LTLD infusion for one hour to target area with target temperatures of 40-45°C. Patients may receive up to a total of 6 cycles
89422221|NCT02317874|Experimental|Schedule A (7-day talazoparib, paclitaxel, carboplatin)|"Patients receive talazoparib PO QD on days 1-7, paclitaxel IV over 1 hour on days 1, 8, and 15, and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 4-6 cycles in the absence of disease progression or unacceptable toxicity.~At any time after 4-6 cycles of treatment, patients may continue combination study therapy with talazoparib, carboplatin, and paclitaxel, talazoparib and carboplatin, talazoparib alone (continuous dosing), or observation without therapy at the discretion of the treating physician."
88902885|NCT01528644|Experimental|Iron in capsule in presence of calcium|All experimental days will be exactly the same with the exception of the test meal administered to the volunteer. Volunteers will undergo a 10 hour overnight fast from 10:00pm, then they will be asked to attend the CRTU at approximately 8:00 am the following morning. A nurse will take and record the volunteer's blood pressure and if within the range an intravenous (i.v.) cannula will be inserted into a vein in one of the volunteer's arms. The cannula will remain in situ for six hours. After the first blood sample (t=0) will be taken, volunteers will consume one out of 4 test meals. After consumption further blood samples will be collected at: 20, 40, 60, 80, 100, 120, 150, 180, 240, 300 and 360 min. Blood samples will subsequently be analysed for serum iron concentrations.
88902886|NCT01528657|Experimental|Ventricular Pace Suppression (VpS)|The function Ventricular Pace Suppression (VpS) is activated
88902887|NCT01528657|Experimental|Intrinsic Rhythm Support (IRSplus)|The function Intrinsic Rhythm Support (IRSplus) is activated
88902888|NCT01528670||Skull Base|
88902889|NCT01528670||Lower GI|
88902890|NCT01528670||Prostate|
88902891|NCT01528670||Pelvic Region|
88902892|NCT01528670||Head-and-Neck|
88902893|NCT01528670||Upper GI|
88902894|NCT01528670||Brain|
88902895|NCT01528670||Other|
88902896|NCT01528683|Experimental|Carbon Ion Radiotherapy|
88902897|NCT01528722|Sham Comparator|Saline sham injection|Sham wash and injection with normal saline (09%)
88902898|NCT01528722|Active Comparator|Bupivacaine|Bupivacaine injection/wash treatment arm
88902899|NCT01528748||Chronically Depressed, Alcohol Dependent|Participants who have been formally diagnosed with a clinical diagnosis of Chronic Depression and Alcohol Dependence.
89006956|NCT06169748|Experimental|Real UHCDS a-TDCS + Therapeutic Exercise|Real unihemispheric concurrent dual-site anodal transcranial direct current stimulation combined with therapeutic exercise.
88902900|NCT01528761|Experimental|Prosocial Behavior Physical Activity|The PBPA condition involves a cognitive-behavioral intervention to teach participants the behavioral skills to engage in independent physical activity. Participants will engage in supervised physical activity delivered two times a week during months 1 to 3 at the William G. White, Jr. Family YMCA in Winston-Salem, NC. During months 4 to 6, supervised sessions will be held once per week, and sessions will be held once per month in months 7 to 9. Participants will engage in completely independent physical activity in months 10 to 12. PBPA participants will also be able to earn boxes of food for donation to the Second Harvest Food Bank (SHFB) of Northwest North Carolina based upon their weekly physical activity. Lowe's Foods, a regional grocery chain, will donate the food. Participants in the PBPA intervention also will receive a 12-month membership to the William G. White, Jr. Family YMCA at no cost.
88902901|NCT01528761|Active Comparator|Healthy Aging (HA)|Behavioral: Healthy Aging (HA) The HA group will receive a health education intervention based on topics from several sources, including the National Institute on Aging's Age Pages, University of Pittsburgh's 10 Keys to Healthy Aging; and Stanford University's Successful Aging program, among other topics . The HA intervention will receive ongoing staff contact, and will provide participants with excellent information on health-related topics. Biweekly 45-minute lectures will be given during months 1 to 6, and once per month during months 7 to 9. After each session, participants will engage in a 15-minute stretching routine. During months 10 to 12, no lectures will be given. After completion of the 12-month assessments, participants will receive a 12-month membership to the YMCA at no cost.
88902902|NCT01528774||Melanoma|Patients with histologically confirmed melanoma
88902903|NCT01528774||Prostate|Patients with histologically confirmed prostate cancer
88902904|NCT01528774||Solid tumors - other|Patients with histologically confirmed solid tumor cancers other than melanoma and prostate
88902905|NCT01528774||Benign Hematologic Conditions|Patients diagnosed with non-cancerous hematologic conditions
88902906|NCT01528774||Healthy Volunteers|Family members of patients undergoing treatment at Comprehensive Cancer Centers of Nevada, or other healthy volunteers
88902907|NCT01528800|Placebo Comparator|Placebo|Microcrystalline Methylcellulose
88902908|NCT01528800|Active Comparator|Vitamin K1|Vitamin K1
88902909|NCT01528813|Active Comparator|Er:YAG + amorolfine lacquer|30 ungual units affected by onychomycosis due to dermatophytes
88902910|NCT01528813|Placebo Comparator|Amorolfine lacquer|30 ungual units affected by onychomycosis due to dermatophytes
89422222|NCT02317874|Experimental|Schedule B (3-day talazoparib, paclitaxel, carboplatin)|"Patients receive talazoparib PO QD on days 1-3, paclitaxel IV over 1 hour on days 1, 8, and 15, and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 4-6 cycles in the absence of disease progression or unacceptable toxicity.~At any time after 4-6 cycles of treatment, patients may continue combination study therapy with talazoparib, carboplatin, and paclitaxel, talazoparib and carboplatin, talazoparib alone (continuous dosing), or observation without therapy at the discretion of the treating physician."
88902911|NCT01528826|Experimental|NVBOX regimen|Vinorelbine plus oxaliplatin
88902912|NCT01528839|Placebo Comparator|Pill|
88902913|NCT01528839|Experimental|L-Thyroxine as addon|
88902914|NCT01528865|Experimental|Study Drugs|The medications to be used in this study are Lamivudine (EPIVIR®) and Tenofovir disoproxil fumarate (VIREAD®), medications already used in people with certain other types of viruses [but not HERV-K(HML2)] in their body. Treatment will last 16 weeks. This is an experiment combining these two drugs and has been issue an Investigational New Drug (IND) Exemption by the FDA.
88902915|NCT01528904||Hyperthyroid pregnant women|hyperthyroidism diagnosed and treated by an endocrinologist, based on clinical and laboratory tests and ultrasound thyroid examination.
88902916|NCT01528904||Hypothyroid pregnant women|hypothyroidism diagnosed and treated by an endocrinologist, based on clinical and laboratory tests and ultrasound thyroid examination
88902917|NCT01528904||Healthy pregnant women|uncomplicated pregnancies in healthy women, older then 35 years, directed for cordocentesis due to age, because of missed karyotyping in previous period of pregnancy
88902918|NCT01528930|Experimental|Amikacin for inhalation|"Drug: Amikacin~Amikacin is provided for inhalation via nebulization.~500 mg of amikacin is administered once daily using the Pari-Boy N/Long Life Nebulizer.~Administration time is approximately 20 minutes.~Amikacin will be administered for 2 years."
88902919|NCT01528943|Experimental|Prostacyclin|Treatment with prostacyclin
88902920|NCT01528943|Placebo Comparator|Isotonic saline|Treatment with isotonic saline
88902921|NCT01528995|Active Comparator|sacral nerve modulation|Implantation of Interstim II-3058 impulse generator after positive PNE test. Randomized controlled trial.
88902922|NCT01528995|Active Comparator|anal bulking agents|anal injection with Permacol after positive PNE test. Randomized controlled trial.
89422223|NCT02255383|Other|PERSONA TKA|Primary total knee arthroplasty subjects that receive the Zimmer Persona Total Knee System
89422224|NCT02253251||Family Registry|For individuals identified with the KRAS-variant. Patients will be prospectively followed to determine the impact of lifestyle on disease risk.
88902923|NCT01528995|Active Comparator|Anal bulking agents|Anal injection with Permacol after negative PNE test. cohort study.
88902924|NCT01529021||humanoid robot distration|The robot NAO, academic edition (Aldebaran Robotics) was used in this study. Some of its features include an on-board fully programmable computer CPU: x86 AMD Geode with 500 MHz, 256 MB SDRAM and 1 GB flash memory, WiFi (802.11g) and Ethernet, two cameras with up to 30 frames per second, two hands with self adaptive gripping abilities, force sensitive sensors on its arms and feet to perceive contact with objects, Light Emission Diodes in its eyes and body, four microphones to identify the source of sounds, and two loud speakers for communication where tone and voice pitch can be modified in real-time. It runs on a native Linux Operating system platform and can be programmed using a proprietary SDK called NaoQi, or in C, C++, Ruby and Urbi, which makes it compatible with other robot simulators such as Microsoft Robotics Developer Studio.
89422225|NCT02253251||KRAS-variant BRCA negative Breast Cancer|Women with breast cancer who are BRCA negative will be tested for the KRAS-variant, to determine the associations as well as the prevalence.
88902925|NCT01529021||control|standard care procedures were used during the vaccination
88902926|NCT01529073|Experimental|Nitazoxanide|
88902927|NCT01529086||Group 1|"Subjects on Dutasteride that meet the following criteria:~. A rise in PSA from nadir at any time post-nadir~. PSA change from baselin >0.2 mg/ml at any time post-baseline~. Abnormal DRE at any time post-baseline~. Free-PSA <12% at any time post-baseline~. At least one of the above 4 criteria~Subjects on Dutasteride that do not meet the above criteria"
88902928|NCT01529086||Group 2|"Subjects on placebo treatment that meet the following criteria:~Change from baseline PSA between 0.0 and 0.35 (ie, 0.0 ≤ change from baseline PSA < 0.35) at any time post-baseline. Note that in REDUCE PSA was recorded to the nearest 0.1.~Abnormal DRE at any time post-baseline~Change from baseline PSA ≥ 0.35 at any time post-baseline~Change from baseline PSA ≥ 0.75 at any time post-baseline~PSA ≥ 2.5 at any time post-baseline~PSA ≥ 4.0 at any time post-baseline~Percent Free PSA < 12% at any time post-baseline~At least one of the above 7 criteria.~Subjects on placebo that do not meet the above criteria"
88902929|NCT01529099|Experimental|Sigma HP Partial Knee|Partial knee replacement
88902930|NCT01528436|Experimental|Umbilical Cord Blood and Rehabilitation|Allogeneic Umbilical Cord Blood infusion and Active Rehabilitation
88902931|NCT01528436|Active Comparator|Placebo Umbilical Cord Blood and Rehabilitation|Placebo Umbilical Cord Blood infusion and Active Rehabilitation
88902932|NCT01529125||Kwashiorkor|HIV-positive children aged 6-59 months with kwashiorkor receiving nutritional rehabilitation and who are started on HAART.
88902933|NCT01529125||Marasmus|HIV-positive children aged 6-59 months with marasmus receiving nutritional rehabilitation and who are started on HAART.
88902934|NCT01529125||Control|HIV-positive children aged 6-59 months who are not severely malnourished and who are started on HAART for a non-nutritional reason.
88902935|NCT01529138|Experimental|Temsirolimus|An ester of the macrocyclic immunosuppressive agent sirolimus.
88902936|NCT01529138|Experimental|Axitinib|An oral, selective inhibitor of vascular endothelial growth factor (VEGF) receptors 1, 2, 3.
88902937|NCT01529151|Active Comparator|OMT Group|Participants will receive Osteopathic Manipulative Treatment (OMT) with the objective of treating diagnosed somatic dysfunction and this will entail the use of specific indirect and direct techniques, including soft tissue, inhibitory, myofascial release, articulatory and high-velocity / low-amplitude (HVLA) techniques.
88902938|NCT01529151|Active Comparator|VRT Group|Participants will receive Vestibular Rehabilitation Therapy (VRT), which includes balance exercises in sitting and standing positions that include gaze stabilization, kinesthetic and proprioceptive retraining.
88902939|NCT01529151|Active Comparator|OMT - VRT Group|Participants will receive both Osteopathic Manipulative Treatment (OMT) and Vestibular Rehabilitation Therapy (VRT).
88902940|NCT01529151|No Intervention|Control Group|
88902941|NCT01529164|Experimental|treatment|
89006957|NCT06169748|Sham Comparator|Sham UHCDS a-TDCS + Therapeutic Exercise|Sham unihemispheric concurrent dual-site anodal transcranial direct current stimulation combined with therapeutic exercise.
88902942|NCT01529177|Experimental|Metformin / clomid / hCG|"Metformin 1000 mg orally to be given daily for one week then twice daily for 2 weeks then 3 times daily for 6 months.~After 3 months from starting metformin the participant will receive 2 more medications in addition to metformin:~Clomid 50 mg orally per day and 5000 IU human chorionic gonadotrophin (hCG ) IM once per week for three months."
88902943|NCT01529177|Experimental|Clomid / hCG|Clomid 50 mg per day will be administered orally and human chorionic gonadotrophin ( choriomon ) 5000 IU will be administered IM once per week. Both medications will be given for 6 month.
88902944|NCT01529190|Active Comparator|pregabalin 300mg|Group 1 patients will receive a single dose of 300 mg pregabalin, 1 hour before the surgical incision; group 2 patients will receive a placebo dose. Pain intensity will be assessed with the numeric rating scale. The consumption of tramadol in 24 hours after surgery and the time for the first complementation dose will be registered. Blood samples will be collected by 6 hours and 24 hours after surgical incision, for IL-6 dosage, and maintained at -70 celsus degree
88902945|NCT01529190|Placebo Comparator|sugar pill|group 2 will receive a placebo dose, 1 hour before tue surgical icnision
88902946|NCT01529216|Experimental|Electrical signal ON|Subjects randomized to this group (Group A) will receive electrical stimulation delivered to the fundus for 24 months.
88902947|NCT01529216|Sham Comparator|Sham|"Subjects randomized to this group (Group B) will have their device in turned off mode for the first 12 months (48 weeks) after implant. Then the device will be turned ON and these subjects will receive therapy for the remaining 12 months of the study."
88902948|NCT01529229|Experimental|Desloratadine + Prednisolone|Desloratadine(0.5 mg/ml) Associated With Prednisolone (4 mg/ml) Oral Solution once a day - bottle 1 + placebo 2 times a day - bottles 2 and 3.
88902949|NCT01529229|Active Comparator|Dexchlorpheniramine + Betamethasone|Dexchlorpheniramine (0.4 mg/ml) + Betamethasone (0.05 mg/ml) three times a day - bottles 1, 2 and 3.
88902950|NCT01529242|Experimental|Desloratadine + Prednisolone|desloratadine 0,5 mg/ml + prednisolone 4 mg/ml - oral solution
88902951|NCT01529242|Active Comparator|Dexchlorpheniramine + Betamethasone|dexchlorpheniramine maleate 0,4 mg/ml + Betamethasone 0,05 mg/ml - oral solution
88902952|NCT01529255|Experimental|ROADMAP|
88902953|NCT01529255|Active Comparator|SOC (Standard of Care)|
88902954|NCT01529281|Experimental|BCAA|Branched chain amino acid
88902955|NCT01529281|Placebo Comparator|Asparmate|Placebo control containing no protein or carbohydrate
88902956|NCT01529294|Experimental|Iloperidone|Eligible subjects receive a single oral dose of 2 mg iloperidone as a tablet
88902957|NCT01529307|Experimental|TAS266|
88902958|NCT01529320|Experimental|Adventan® (metilprednisolona aceponato 0,1%)|
88902959|NCT01529359|Placebo Comparator|Placebo|Probiotics Excipients
88902960|NCT01529359|Experimental|Lactibiane Tolerance|Probiotics combination
88902961|NCT01529372|Experimental|Percutaneous renal denervation|
88902962|NCT01529398|Active Comparator|sensorimotor training (SMT)|
88902963|NCT01529398|Active Comparator|Resistance training (RT)|
88902964|NCT01529398|Sham Comparator|Control group (CG)|
89195105|NCT00642369|Experimental|quetiapine fumarate|quetiapine fumarate was administered 25mg on the 1st day,738±41mg/day on the 14th day, and 738±48mg/day on the 28th day.
89422226|NCT02253251||Double primary breast cancer|Women with multiple primary breast cancer will be tested for the KRAS-variant and compared between those with this mutation and those without.
89422227|NCT02253251||Autoimmunity|We have shown that the KRAS-variant and other members of this genetic class of mutations associate with altered immunity, leading to immunosuppression as well as autoimmunity.
88902965|NCT01529411|Experimental|Vinflunine|"Vinflunine 320 mg/m2 IV infusion in 20 minutes every 21 days (280mg/m2 if PS=1, age ≥ 75 years, previous pelvic radiotherapy or creatinine clearance < 60ml/min)~+ best suportive care, with regards clinical practice."
88902966|NCT01529411|Other|Best suportive care|Best suportive care
88902967|NCT01529437|Active Comparator|Sublingual immunotherapy|Subjects will take sublingual immunotherapy who have dust mite and timothy grass allergies
88902968|NCT01529437|Placebo Comparator|placebo arm|The placebo arm will be double blinded and is an important control in SLIT therapies
88902969|NCT01529463||Disease Management|
88902970|NCT01529476|Experimental|Nemonoxacin 500 mg|
88902971|NCT01529476|Active Comparator|Levofloxacin 500 mg|
88902972|NCT01529489|Active Comparator|Interval physical training Control group|
88902973|NCT01529489|Experimental|Resisted/Aerobic physical training group|
88902974|NCT01529489|Active Comparator|Aerobic/resisted physical training group|
88902975|NCT01529489|Experimental|Interval physical training group|COPD, interval physical training, elliptical equipament, oxygen uptake kinetic, heart rate kinetic
88902976|NCT01529528|Placebo Comparator|Placebo of CWP-0403 100mg|Placebo of CWP-0403 100mg
88902977|NCT01529528|Experimental|CWP-0403 200mg|CWP-0403 200mg
89195106|NCT00642369|Active Comparator|haloperidol|haloperidol was administered 2mg on the 1st day,16±7mg/day on the 14th day, and 18±6mg/day on the 28th day.
89195107|NCT02551575|Active Comparator|Treatment of MTX and HCQ|Patients were treated with methotrexate (MTX), hydroxychloroquine (HCQ), oral Qingre Huoxue granule placebo and Qingre Huoxue external preparation placebo.
89195108|NCT02551575|Experimental|Treatment of TCM|Patients were treated with oral Qingre Huoxue granule, Qingre Huoxue external preparation, methotrexate placebo and hydroxychloroquine placebo.
88902978|NCT01529528|Experimental|CWP-0403 100mg|CWP-0403 100mg
88902979|NCT01529541|Active Comparator|Sitagliptin|Sitagliptin 100mg
88902980|NCT01529541|Experimental|CWP-0403|CWP-0403 100mg
88902981|NCT01529554|Active Comparator|Everolimus|Everolimus p.o. for 5 days (d0=7.5 mg, d1=7.5 mg, d2=7.5 mg, d3=5 mg, d4=5mg)
88902982|NCT01529554|Placebo Comparator|Placebo|Placebo comparator with identical composition of tablets except everolimus
88902983|NCT01529567|Active Comparator|CBT without exposure|
88902984|NCT01529567|Experimental|CBT with exposure|
88902985|NCT01529580|Experimental|1 Week Basline Prior to Intervention|If eligible, you will be randomly assigned- as if by flipping a coin- to one of three baseline durations, during which your child will engage in daily interactions with their interventionist to determine if skills targeted by this intervention are improving naturally as your child matures, without active treatment from the study's interventionist. In this case, the duration is 1 week before your child begins active treatment with their interventionist.
88902986|NCT01529580|Experimental|2 Week Basline Prior to Intervention|If eligible, you will be randomly assigned- as if by flipping a coin- to one of three baseline durations, during which your child will engage in daily interactions with their interventionist to determine if skills targeted by this intervention are improving naturally as your child matures, without active treatment from the study's interventionist. In this case, the duration is 2 weeks before your child begins active treatment with their interventionist.
88902987|NCT01529580|Experimental|3 Week Basline Prior to Intervention|If eligible, you will be randomly assigned- as if by flipping a coin- to one of three baseline durations, during which your child will engage in daily interactions with their interventionist to determine if skills targeted by this intervention are improving naturally as your child matures, without active treatment from the study's interventionist. In this case, the duration is 3 weeks before your child begins active treatment with their interventionist.
88902988|NCT01529619|Experimental|Rivastigmine 18 mg|During the 16-week titration period patients received daily rivastigmine 4.5mg patch for the first 4 weeks, rivastigmine 9mg patch for the next 4 weeks, rivastigmine 13.5mg patch for the next 4 weeks and then rivastigmine 18mg patch for the final 4 weeks. For patients who experienced intolerability, the dose was adjusted downward. Patients then entered the 8-week maintenance period during which time they continued to receive the dose of rivastigmine they were taking at the end of the titration period.
88902989|NCT01529658|No Intervention|No hypothermia|After clamping of the renal vessels, no ice slush will be used.
88902990|NCT01529658|Experimental|Hypothermia|saline ice slush around kidney for 10 minutes.
88902991|NCT01529671|Experimental|Cohort 1: Experimental intervention: PF-05089771 or placebo|Subjects will receive multiple doses of PF-05089771 or placebo twice daily to investigate the safety/tolerability and Pharmacokinetics (PK) of PF-05089771.
88902992|NCT01529671|Experimental|Cohort 2: Experimental intervention: PF-05089771 or placebo|Subjects will receive multiple doses of PF-05089771 or placebo twice daily to investigate the safety/tolerability and PK of PF-05089771.
88902993|NCT01529671|Experimental|Cohort 3: Experimental intervention: PF-05089771 or placebo|Subjects with osteoarthritis of the knee will receive multiple doses of PF-05089771 or placebo twice daily to investigate the safety/tolerability and Pharmacokinetic (PK) of PF-05089771.
88902994|NCT01529671|Experimental|Cohort 4: Experimental intervention: PF-05089771 or placebo|Elderly Subjects will receive multiple doses of PF-05089771 or placebo twice daily to investigate the safety/tolerability and Pharmacokinetic (PK) of PF-05089771.
88902995|NCT01529671|Experimental|Cohort 5: Experimental intervention: PF-05089771 or placebo|Subjects will receive multiple doses of PF-05089771 or placebo twice daily to investigate the safety/tolerability and PK of PF-05089771.
88902996|NCT01529684|Experimental|OSI-906|"Two Parts:~Part A: 14C-labeled OSI-906~Part B: (Optional) OSI-906 (non-labeled)"
88902997|NCT01529697|Active Comparator|Active Feedback|In this arm patients will receive monthly review and education on inhaler technique and use based on a computer download of their last month of inhaler use
88902998|NCT01529697|Placebo Comparator|Control|In this arm patients will be reviewed monthly, however will not have information from INCA device to tailor inhaler education.
88902999|NCT01529710|Experimental|Mirazid|Mirazid is an antischistosomal drug available in the local Egyptian market since 2001 (Mirazid®). It originates from Myrrh a medicinal herb that has been used for thousands of years. Myrrh (Arabian or Somali Myrrh) is an oleo-gum resin, obtained from the stem of various species of Commiphora (Burseraceae) growing in northeast Africa and Arabia.
88903000|NCT01529710|Active Comparator|Praziquantel|Tablets
88903001|NCT01529788|Active Comparator|Lateral orbital injection of Botox Cosmetic or Dysport|Lateral orbital injection of either Botox Cosmetic, 10 units or Dysport, 30 units as a single dose in a randomized (right or left sides) double blind fashion in 90 consecutive subjects
88903002|NCT01529840|Experimental|Low dose 33 mcg/kg/day|
88903003|NCT01529840|Experimental|High dose 66 mcg/kg/day|
88903004|NCT01529892|Experimental|methamphetamine EM|Extensive metabolizer will be give a single oral 5 mg of duterium labeled methamphetamine
88903005|NCT01529892|Experimental|methamphetamine PM|Poor Metabolizers will be give a single oral 5 mg of duterium labeled methamphetamine
88903006|NCT01529918|Experimental|web-intervention group|Participants will receive access to the CAN-RISK (Canadian Diabetes Risk Assessment) questionnaire either via personal patient electronic health record or an online version
88903007|NCT01529918|No Intervention|paper-based group|Participants allocated to paper-based will receive the CAN-RISK questionnaire for diabetes risk-assessment via paper-based
88903008|NCT01529931|Experimental|Maintenance|This arm receives Hair2Go treatments once a month for 6 months
88903009|NCT01529957|Active Comparator|Nemonoxacin Malate Sodium Chloride 25 mg|Nemonoxacin Malate Sodium Chloride 25 mg
88903010|NCT01529957|Active Comparator|Nemonoxacin Malate Sodium Chloride 50 mg|Nemonoxacin Malate Sodium Chloride 50 mg
88903011|NCT01529957|Active Comparator|Nemonoxacin Malate Sodium Chloride 125 mg|Nemonoxacin Malate Sodium Chloride 125 mg
88903012|NCT01529957|Placebo Comparator|placebol|placebol
88903013|NCT01529957|Active Comparator|Nemonoxacin Malate Sodium Chloride 250 mg|Nemonoxacin Malate Sodium Chloride 250 mg
88903014|NCT01529957|Active Comparator|Nemonoxacin Malate Sodium Chloride 500 mg|Nemonoxacin Malate Sodium Chloride 500 mg
88903015|NCT01529957|Active Comparator|Nemonoxacin Malate Sodium Chloride 650 mg|Nemonoxacin Malate Sodium Chloride 650 mg
88903016|NCT01529957|Active Comparator|Nemonoxacin Malate Sodium Chloride 750 mg|Nemonoxacin Malate Sodium Chloride 750 mg
88903017|NCT01529957|Active Comparator|Nemonoxacin Malate Sodium Chloride 1000 mg|Nemonoxacin Malate Sodium Chloride 1000 mg
88903018|NCT01529957|Active Comparator|Nemonoxacin Malate Sodium Chloride 1250 mg|Nemonoxacin Malate Sodium Chloride 1250 mg
88903019|NCT01529970||parkinson's disease, young onset|
88903020|NCT01529970||Normal|
88903021|NCT01530022|Other|LCM 300 mg/CBZ-IR 600 mg|Crossover sequence of experimental treatment and active comparator
88903022|NCT01530022|Other|CBZ-IR 600 mg/LCM 300 mg|Crossover sequence of active comparator and experimental treatment
88903023|NCT01530035|Active Comparator|soccer training intervention|
88903024|NCT01530035|Other|strength training intervention|
88903025|NCT01530035|No Intervention|control group|elderly men with no change in daily activities
88903026|NCT01530035|No Intervention|active soccer control group|veteran soccer players with a 40 year history of continues soccer playing
88903027|NCT01530048|Experimental|U200|
88903028|NCT01530048|Active Comparator|U100|
88903029|NCT01530074|Experimental|Study Group|
88903030|NCT01530126|Active Comparator|B-TCP +buffer|Administration of synthetic beta-tricalcium phosphate (B-TCP) mixed in sodium acetate buffer only.
88903031|NCT01530126|Experimental|B-TCP + 0.3 mg/ml rhPDGF-BB in buffer|Administration of synthetic beta-tricalcium phosphate (B-TCP) mixed with purified 0.3 mg/ml recombinant human platelet-derived growth factor (rhPDGF-BB) in sodium acetate buffer.
88903032|NCT01530126|Experimental|B-TCP + 1.0 mg/ml rhPDGF-BB in buffer|Administration of synthetic beta-tricalcium phosphate (B-TCP) mixed with purified 1.0 mg/ml recombinant human platelet-derived growth factor (rhPDGF-BB) in sodium acetate buffer.
89006958|NCT06169748|Active Comparator|Therapeutic Exercise|Therapeutic Exercise.
88903033|NCT01530139|Placebo Comparator|Level 0|Level 0: Control group - participants will receive non-personalized dietary advice for improved food choice based on standard population healthy eating guidelines.
88903034|NCT01530139|Experimental|Level 1|Level or Group 1: participants will receive personalised dietary advice based on their dietary intake data alone.
88903035|NCT01530139|Experimental|Level 2|Level or Group 2: participants will receive personalised dietary advice taking their dietary intake and phenotypic data ( obesity-related phenotypes and clinical biomarkers) into account.
88903036|NCT01530139|Experimental|Level 3|Level or Group 3 : participants will receive personalised dietary advice taking their dietary intake, phenotypic (obesity-related markers) and genotypic data into account.
88903037|NCT01530165|Other|Standard|Pre diabetics randomized to control arm will receive standard life style advice which is given to all pre diabetics seeking medical advice.
88903038|NCT01530165|Experimental|life style intervention arm|This arm would be given aggressive life style intervention in comparison to standard (control) arm. The intervention would consist of nutritional and physical activity advice.
88903039|NCT01530191||Abdominal|- Participants undergoing surgeries with an abdominal approach will be given a Morphine PCA at a dose of 2mg every 10 minutes with a 12mg/hour lockout. They will also be given IV Toradol at 30mg every 6 hours as needed for a maximum of four doses.
88903040|NCT01530191||Vaginal|- Participants undergoing surgeries with a vaginal approach will be given hydrocodone/acetaminophen at a dose of 5/325 (1-2 tablets every four hours as needed), and provided with Ibuprofen 800mg every 8 hours as needed.
88903041|NCT01530204|Active Comparator|Physical Therapy|8-12 sessions of knee-focused physical therapy and a home-based conditioning program.
88903042|NCT01530204|Active Comparator|Cognitive Behavioral Therapy for Pain|8-12 session pain-focused Cognitive Behavioral Therapy
88903043|NCT01530204|Active Comparator|Enhanced Treatment as Usual|Information about state-of-the-art pharmacotherapy for osteoarthritis is communicated to the primary care physicians of participants.
88903044|NCT01530230|Other|Oxytocin 5 units|
88903045|NCT01530230|Other|Oxytocin 10 units|
88903046|NCT01530269|Experimental|PET/CT imaging with C11-Sodium Acetate|
88903047|NCT01530282|Experimental|measurement of respiratory mechanics|Invasive method: two catheters will be inserted to measure reference respiratory mechanics Non_invasive method: airway pressure measured during a 150-200 ms occlusion at the beginning of inspiration.
88903048|NCT01530295|No Intervention|contol|control group
88903049|NCT01530295|Other|chemotherapy|neoadjuvant chemotherapy
88903050|NCT01530308|Active Comparator|Investigational medicinal product|Haloperidol 1 mg twice daily at 12am and 20pm
88903051|NCT01530308|Placebo Comparator|Placebo group|Placebo 1 mg twice daily at 12am and 20pm
88903052|NCT01530321|Experimental|High dose spinal manipulation|18 visits for spinal manipulation
88903053|NCT01530321|Experimental|Moderate dose spinal manipulation|12 visits for spinal manipulation and 6 visits for light massage
88903054|NCT01530321|Experimental|Low dose spinal manipulation|6 visits for spinal manipulation and 12 visits for light massage
88903055|NCT01530321|Other|High dose massage|18 visits for light massage
88903056|NCT01530347|Experimental|Easy Check versus reference glucometer and blood ketone meter|Collection of paired measurements of capillary blood glucose using reference method (approved glucometer)and blood beta Hydroxybutyrate (approved ketone meter) and data generated by the non invasive study device
88903057|NCT01530360|Experimental|cerebral oximetry + treatment guideline|Cerebral oximetry applied as soon as possible after birth and continued until 72 hours of life Clinical staff administer the routine medical management according to local practice as well as respond to out-of-range values with the help of the treatment guideline
88903058|NCT01530386|Experimental|Lacosamide|300 mg/day
88903059|NCT01530412|No Intervention|Control Group|Patients are randomized to the control group and are assessed pre rehabilitation and post rehabilitation after which they proceed to the intervention group.
88903060|NCT01530412|Experimental|Pulmonary Rehabilitation|Patients undergo an active seven week pulmonary rehabilitation programme. Assessments occur pre rehabilitation, post rehabilitation, at three months and at one year.
88903061|NCT01530425||Phase 1 assessments|Regency Wheelchairs and APDK 12-inch wide wheelchairs
88903062|NCT01530425||Phase 2 assessments|Hope Haven and APDK 14-16 inch wide wheelchairs
88903063|NCT01530425||Phase 3 assessments|Motivation and Whirlwind wheelchairs
88903064|NCT01530438|Other|ALS patients without cognitive disorders|Amyotrophic lateral sclerosis without cognitive disorders
88903065|NCT01530438|Other|ALS patients with cognitive disorders|Amyotrophic lateral sclerosis with cognitive disorders
88903066|NCT01530438|Other|ALS patients + frontal-temporal dementia|Amyotrophic lateral sclerosis plus frontal-temporal dementia
88903067|NCT01530451|Experimental|A: Drug/ Placebo|Initial phase on Desmopressin and then cross over to placebo on the second phase
88903068|NCT01530451|Experimental|B: Placebo/ Drug|Initial phase on Placebo and then cross over to Desmopressin on the second phase
88903069|NCT01530490|No Intervention|Hemoes|
88903070|NCT01530490|Experimental|Cabergoline|cabergoline
88903071|NCT01530503|Experimental|capecitabine|oral capecitabine 2000 mg/m2 day 1-14 in two divided doses taken with food
88903072|NCT01530503|Experimental|capecitabine plus mitomycin|oral capecitabine 2000 mg/m2 day 1-14 in two divided doses taken with food plus bolus IV infusion Mitomycin 6 mg/m2 day 1
88903073|NCT01530516|Active Comparator|Full brackets plus Forsus springs|Standard of care - Class II springs used after le el and alignment.
88903074|NCT01530516|Experimental|Xbow plus full brackets|Alternative treatment - First use the Xbow appliance and then full brackets after Class II occlusion has been corrected.
88903075|NCT01530529|Experimental|PF-05180999 Immediate-Release|
88903076|NCT01530529|Experimental|PF-05180999 Modified-Release 1|
88903077|NCT01530529|Experimental|PF-05180999 Modified-Release 2|
88903078|NCT01530529|Experimental|PF-05180999 Modified-Release 1 With Food|
88903079|NCT01530542|Experimental|Treatment A|
88903080|NCT01530542|Experimental|Treatment B|
88903081|NCT01530542|Experimental|Treatment C|
88903082|NCT01530542|Experimental|Treatment D|
89422228|NCT02221999|Active Comparator|Chemotherapy only|Paclitaxel injection 80mg/m2,given on days1,8,15 and 22 of a 28-day cycle；Cisplatin 25mg/m2, given on days 1,8,and 15 of a 28-day cycle； for 4 cycles
89422229|NCT02221999|Experimental|GnRHa|Paclitaxel 80mg/m2,given on days1,8,15 and 22 of a 28-day cycle; Cisplatin 25mg/m2, given on days 1,8,and 15 of a 28-day cycle; for 4 cycles Gonadotropin-releasing hormone agonist （GnRHa）11.25 mg every 3 months or 3.6mg every month subcutaneously
88903083|NCT01530542|Experimental|Treatment E|
88903084|NCT01530555|Experimental|Treatment arm|"Rabbit ATG, Thymoglobuline (Genzyme) 1.5 vials/10kg (3.75mg/kg) daily for 5 days given as an intravenous infusion over 12-18 hours.~Ciclosporin (CSA) 5mg/kg/day orally from day +1 for a minimum of 6 months, with later tailing according to individual patient response. Aim to maintain trough whole blood CSA levels between 150 and 250 ng/ml."
88903085|NCT01530568|Active Comparator|Smear|Routine microbiology based diagnostics for TB
88903086|NCT01530568|Experimental|GeneXpert|Arm that will receive the Xpert test
88903087|NCT01530581|Experimental|G-BM Transplant|
88903088|NCT01530581|Other|G-PB Transplant|G-PB Transplant
88903089|NCT01530594|Active Comparator|Lenalidomide|Lenalidomide/Low dose Dex (LLD)
88903090|NCT01530594|Experimental|Bortezomib/Lenalidomide|Bortezomib/Lenalidomide/ Low dose Dex (BLLD)
88903091|NCT01530607|Active Comparator|cyclophosphamide|Standard cyclophosphamide containing adjuvant or neoadjuvant chemotherapy
88903092|NCT01530607|Experimental|Goserelin (Zoladex)|Goserelin (Zoladex) plus Standard cyclophosphamide containing adjuvant or neoadjuvant chemotherapy
88903093|NCT01530620|Experimental|Propiverine hydrochloride ER|45 mg
88903094|NCT01530620|Active Comparator|Propiverine hydrochloride IR|15 mg
88903095|NCT01530646|Placebo Comparator|Control|Carbohydrate & 750 kcal dietary restriction while they receive a daily supplement (2 x 25 g) of maltodextrin (no protein) for 14 days. Weight loss.
88903096|NCT01530646|Experimental|Whey|Whey protein & 750 kcal dietary restriction while they receive a daily supplement (2 x 25 g) of WPI for 14 days. Weight loss.
88903097|NCT01530646|Experimental|Soy|Soy protein & 750 kcal dietary restriction while they receive a daily supplement (2 x 25 g) of SPC for 14 days. Weight loss.
88903098|NCT01530672|Experimental|ANC clients|
88903099|NCT01530685|Experimental|Glycabiane, gelule|
88903100|NCT01530685|Placebo Comparator|Placebo|
88903101|NCT01530698|Experimental|single step DC treatment|vaccination with autologous dendritic cells treated with mRNA electroporation for single-step antigen loading and TLR activation (TriMix-DC)
88903102|NCT01530698|Active Comparator|two step DC treatment|vaccination with autologous dendritic cells treated with mRNA electroporation for antigen loading and separately for TLR activation
88903103|NCT01530711|Experimental|terlipressin|
88903104|NCT01530724|Experimental|low fat diet|Weight-loss diet strategy
88903105|NCT01530724|Experimental|low carb diet|Weight-loss diet strategy
88903106|NCT01530737|Placebo Comparator|Control Group|
88903107|NCT01530737|Experimental|Active Antithrombin Group|
88903108|NCT01530750||Post cardiac surgery|
88903109|NCT01530763|Experimental|Ceftaroline fosamil|
88903110|NCT01530763|Active Comparator|Ceftriaxone|
88903111|NCT01530776|Experimental|Healthy Lifestyle Group|Participants randomized to this condition will receive information and strategies to help them eat healthier and be more active during and after pregnancy. They will get this information about eating and activity through handouts, text messages, Facebook updates, and in-person visits and phone calls from a health coach.
88903112|NCT01530776|No Intervention|Usual Care|This condition is meant to represent standard clinical care provided to pregnant and postpartum mothers at Temple University.
88903113|NCT01530802|Experimental|Uterine artery clipped|Both uterine arteries are temporarily clipped by Yasargil clips during laparoscopic myomectomy.
88903114|NCT01530802|No Intervention|Control group|Conventional laparoscopic myomectomy is performed. (No intervention to temporarily occlude uterine arteries is made)
88903115|NCT01530815|Experimental|Bupivicaine Infusion|We will infuse bupivicaine between the abdominal wall and mesh to try and reduce postoperative pain
88903116|NCT01530828||Premature infants|Weight less than 1000 grams, age 1 - 16 days.
88903117|NCT01530841|Experimental|AVAPS|Arm assigned to AVAPS mode for nocturnal ventilation with the same setting than bilevel pressure support but with AVAPS mode activated
88903118|NCT01530841|Active Comparator|Bilevel pressure|Arm treated only with bilevel pressure support for nocturnal ventilation without activation of AVAPS mode
88903119|NCT01530854||Septic|
88903120|NCT01530854||Healthy|
89422230|NCT02221999|Experimental|letrozole|Paclitaxel 80mg/m2,given on days1,8,15 and 22 of a 28-day cycle; Cisplatin 25mg/m2, given on days 1,8,and 15 of a 28-day cycle; for 4 cycles Letrozole 2.5mg/day
89422231|NCT02038140|Other|Zimmer TM Total Ankle System|Primary or revision total ankle arthroplasty subjects that receive the Zimmer Trabecular Metal Total Ankle System
89422232|NCT01849562|Active Comparator|Sovaprevir 200 milligrams (mg), ACH-3102 150/50 mg, RBV 1000-1200 mg|Sovaprevir 200 mg once daily (qd) + ACH-3102 150 mg loading dose on Day 1, followed by 50 mg qd + RBV weight-based 1000-1200 mg qd for 12 weeks.
89422233|NCT01849562|Active Comparator|Sovaprevir 400 mg, ACH-3102 150/50 mg, RBV 1000 -1200 mg|Sovaprevir 400 mg qd + ACH-3102 150 mg loading dose on Day 1, followed by 50 mg qd + RBV weight-based 1000-1200 mg qd for 12 weeks.
89422234|NCT01849562|Placebo Comparator|Placebo|Placebo for sovaprevir capsule qd + placebo for ACH-3102 150 mg loading dose on Day 1, followed by placebo for 50 mg qd + placebo for weight-based RBV qd for 12 weeks.
89422235|NCT01778894||Healthy Control|Healthy controls with no history of heart disease or heart failure. Subjects will undergo a medical history review and 1 echocardiograph procedure.
89422236|NCT01778894||>Grade 2 Diastolic Dysfunction|Diastolic Heart Failure, > Grade II (NYHA functional class) and/or > Grade II Diastolic Dysfunction as evaluated by echocardiography
89422237|NCT01700179|Experimental|ACH-0143102 plus ribavirin daily|ACH-0143102 loading dose (225 milligrams [mg]) on Day 1, followed by maintenance doses (75 mg) on Days 2-84, plus weight-based ribavirin as per label on Days 1-84.
89422238|NCT01474200|Experimental|Aquapheresis (AQ) - isolated veno-venous ultrafiltration|Excess fluid from the patient is removed by isolated veno-venous ultrafiltration treatment using the Aquadex Flex Flow System
89422239|NCT01474200|Active Comparator|IV Loop Diuretics (LD)|Excess fluid from the patient is removed by IV (Intravenous) loop diuretic treatment
89422240|NCT01416714||Gastric Cancer|
89422241|NCT01416714||Gastrointestinal Stromal Tumors (GIST)|
89422242|NCT01416714||Esophageal Cancer|
89422243|NCT01416714||Pancreas Cancer|
88903121|NCT01530893|Experimental|Intervention group A: flavanones|All experimental days will be exactly the same. All volunteers will attend the clinical research and trial unit in a fasted state. Prior to test administration, baseline vascular function will be assessed and biological samples taken by a trained and qualified research nurse. Subsequently, assessments will be repeated at times corresponding to anticipated peak plasma concentration of the flavonoid of interest.
89422244|NCT01416714||Hepatocellular Cancer|
89422245|NCT01416714||Biliary Cancer|
89422246|NCT01416714||Neuroendocrine Cancer|
89422247|NCT01416714||Peritoneal Mesothelioma|
88903122|NCT01530893|Experimental|Intervention group B: isoflavones|All experimental days will be exactly the same. All volunteers will attend the clinical research and trial unit in a fasted state. Prior to test administration, baseline vascular function will be assessed and biological samples taken by a trained and qualified research nurse. Subsequently, assessments will be repeated at times corresponding to anticipated peak plasma concentration of the flavonoid of interest.
89006959|NCT06169254|Active Comparator|High-frequency Transcranial Random Noise Stimulation (Hf-tRNS)|The stimulation parameters of hf-tACS include: 20 minutes at 101-640 Hz, 2 milliamps.
89422248|NCT01416714||Anal Cancer|
89422249|NCT01416714||Colorectal Cancer|
89422250|NCT01171131||Chronic TBI Patients - Non-penetrating|"Chronic TBI patients should have a history of head trauma manifesting in one or more of the following:~Loss of consciousness~Post-traumatic amnesia~Focal neurologic deficits, seizure~Persistent symptoms of increased arousal (e.g. difficulty falling or staying asleep, anger and hypervigilance)~Impairment in social, occupational, or other important areas of functioning (e.g. problems with work and relationships.) Patients will be excluded from the study if we are unable to obtain informed consent and if they are non-communicative (i.e. in a vegetative state)."
89422251|NCT01171131||Chronic TBI Patients - Blast|"Chronic TBI Blast injury patients should have a history of head trauma manifesting in one or more of the following:~Loss of consciousness~Post-traumatic amnesia~Focal neurologic deficits, seizure~Persistent symptoms of increased arousal (e.g. difficulty falling or staying asleep, anger and hypervigilance)~Impairment in social, occupational, or other important areas of functioning (e.g. problems with work and relationships.) Patients will be excluded from the study if we are unable to obtain informed consent and if they are non-communicative (i.e. in a vegetative state)."
89422252|NCT01171131||Healthy Volunteers|"Healthy volunteers include gender, age and race matched volunteers able to provide informed consent who have,~No significant medical history~Take no medications (other than birth control pills)~Fever free~No history of head trauma or recent injury/infection~No history of neurological or psychiatric disorders or alcohol or drug dependency."
89422253|NCT00913471||Acute-Longitudinal SCI|
89422254|NCT00913471||Chronic SCI|
89422255|NCT00913471||Healthy volunteers|
89422256|NCT00698854||Vanguard™ Complete Knee System|Vanguard Total Knee System, Cruciate-Retaining (CR) or Posterior-Stabilized (PS)
89422257|NCT00698854||Vanguard™ Patient-Specific Femur|Vanguard Total Knee System used in combination with Signature technique to provide a patient-specific femur
89422258|NCT00665223|Placebo Comparator|Placebo|Participants will receive a placebo capsule matching to ACR16 once daily for the first 4 weeks. After 4 weeks (Weeks 5 to 26), placebo capsule will be taken twice daily as 2 separate doses.
89422259|NCT00665223|Experimental|ACR16 45 mg|Participants will receive ACR16 45 milligrams (mg) capsule orally once daily for the first 4 weeks. After 4 weeks (Weeks 5 to 26), one ACR16 45 mg capsule and one placebo capsule will be taken as 2 separate doses.
89422260|NCT00665223|Experimental|ACR16 90 mg|Participants will receive ACR16 45 mg capsule once daily for the first 4 weeks. After 4 weeks (Weeks 5 to 26), ACR16 45 mg capsule will be taken twice daily as 2 separate doses (total dose: 90 mg)
89422261|NCT00178659||1 healthy volunteers|Healthy volunteers to act as controls - Recruitment is complete for this cohort
89422262|NCT00178659||2 head trauma|Head trauma patients meeting enrollment criteria - Recruitment is complete for this cohort
89422263|NCT00178659||3 orthopedic injury|"The orthopedic injury cohort will include patients admitted to the ED able to provide informed consent with the following:~Fracture confirmed radiographically~No head trauma~No other known inflammatory process or infection~No history of neurological or psychiatric disorders or alcohol or drug dependency"
88903123|NCT01530893|Experimental|Intervention group C: Flavan-3-ols|All experimental days will be exactly the same. All volunteers will attend the clinical research and trial unit in a fasted state. Prior to test administration, baseline vascular function will be assessed and biological samples taken by a trained and qualified research nurse. Subsequently, assessments will be repeated at times corresponding to anticipated peak plasma concentration of the flavonoid of interest.
88903124|NCT01530893|Experimental|Intervention group D: Anthocyanins|All experimental days will be exactly the same. All volunteers will attend the clinical research and trial unit in a fasted state. Prior to test administration, baseline vascular function will be assessed and biological samples taken by a trained and qualified research nurse. Subsequently, assessments will be repeated at times corresponding to anticipated peak plasma concentration of the flavonoid of interest.
88903125|NCT01530906|Experimental|rTMS|"patients included in this arm will receive 10 sessions of transcranial magnetic stimulation (10 TMS sessions of 20 trains of 5s with 55s interval cross train, at a frequency of 10 Hz and 110% of motor threshold intensity of the left DLPFC).~Fifty percent of patients will be included in this arm. During the first and last session a food challenge task will be administered before and after rTMS. Salivary cortisol level will be assessed throughout the protocol Intervention: Repetitive transcranial Magnetic Stimulation (rTMS)"
88903126|NCT01530906|Placebo Comparator|rTMS SHAM|Transcranial magnetic stimulation SHAM Intervention: Repetitive transcranial Magnetic Stimulation SHAM Fifty percent of patients will be included in this arm. During the first and last session a food challenge task will be administered before and after rTMS. Salivary cortisol level will be assessed throughout the protocol
88903127|NCT01530919||Parathyroid surgery|Database of patients who have undergone minimally invasive radioguided parathyroidectomy
88903128|NCT01530958|Experimental|ATSM + Health Coach and CKD Registry|
88903129|NCT01530958|Active Comparator|CKD Registry|
88903130|NCT01530958|Active Comparator|ATSM + Health Coach|
88903131|NCT01530958|Placebo Comparator|Usual Care (no interventions)|
88903132|NCT01530971|No Intervention|room air|no supplemental oxygen in intraoperative period
88903133|NCT01530971|Experimental|Oxygen|Supplemental 3LPM oxygen via canula
88903134|NCT01530984|Experimental|Ipilimumab alone|Ipilimumab 3 mg/kg (IV) will be given every 28 days for six cycles (induction) followed by administration once every three months for patients who are not progressing (maintenance).
88903135|NCT01530984|Experimental|Ipilimumab with GM-CSF|Ipilimumab 3 mg/kg (IV) will be given every 28 days for six cycles (induction) followed by administration once every three months for patients who are not progressing (maintenance). GM-CSF 250 mcg/m2 SQ will be administered on days 1-14 in Cycles 1-6 and then every 3 months for 14 days beginning on the day of ipilimumab administration during the maintenance therapy phase
89422264|NCT00178659||4 Mild TBI|"The mild TBI patients will be defined as those admitted to the ED experiencing, - Recruitment is complete for this cohort~Non-penetrating head trauma manifesting one or more of the following:~Loss of consciousness~Post-traumatic amnesia~Altered mental status~Focal neurologic deficits, seizure~GCS> 12~No abnormalities on CT other than contusion~No operative Lesions~Length of hospital stay < 48 hrs~No other known inflammatory process or infection~No history of neurological or psychiatric disorders or alcohol or drug dependency"
89422265|NCT00131014||Next of Kin of deceased subj by lymphoma|Next of Kin of deceased subject by lymphoma
88903136|NCT01531010|Active Comparator|Pressure-limited ventilation|
88903137|NCT01531010|Active Comparator|Volume-targeted ventilation|
88903138|NCT01531023||ESBL producing E. coli bacteria|Group of patients with identified ESBL producing E.coli in a urine sample taken in a primary care setting.
88903139|NCT01531023||Non-ESBL E.coli urinary tract infection|E.coli bacteria found in the setting of a urinary tract infection in a primary care setting where ESBL producing bacteria are not found.
88903140|NCT01531036|Experimental|shear wave imaging|Single arm study evaluating breast 3D elastography by means of shear wave propagation into breast tissue.
88903141|NCT01531049|Experimental|Varenicline|A varenicline treatment group (with motivational interview technique combined with varenicline and placebo transdermal patch). Intervention with Nicorette 15mg /16 h patch
88903142|NCT01531049|Experimental|Nicotine cutaneous patch 15mg|Intervention with Varenicline for 12 weeks. Nicotine cutaneous patch 15mg/16h
88903143|NCT01531049|Experimental|Nicotine cutaneous patch 10mg|Intervention with Placebo transdermal patch for 8 weeks. Nicotine cutaneous patch 10mg/16h
88903144|NCT01531049|Placebo Comparator|Placebo cutaneous patch|No active medication.One transdermal patch/16 h.Total duration was 8 weeks.
88903145|NCT01531062|Experimental|Nigella sativa|Nigella sativa extracts, 300 mg twice daily
88903146|NCT01531062|Placebo Comparator|Placebo|
88903147|NCT01531075|Experimental|ENGERIX-B|
88903148|NCT01531075|Experimental|Sci-B-Vac|
88903149|NCT01531088|No Intervention|Usual care|Recommendations made by consultant pharmacists as part of their federally-mandated medication regimen review process
88903150|NCT01531088|Experimental|Active medication monitoring|Active medication monitoring system providing consultant pharmacists with alerts representing potential adverse drug events
88903151|NCT01531101|Experimental|Individual PDT with TW|Individual Psychodynamic psychotherapy with transference work (TW).
88903152|NCT01531101|Active Comparator|Individual PDT without (TW)|Individual Psychodynamic psychotherapy without focus on transference work (TW).
88903153|NCT01531114|Active Comparator|Prasugrel loading dose|Patients will be randomized to this arm to receive loading dose of prasugrel
88903154|NCT01531114|No Intervention|ticagrelor loading dose|Patients will be randomized to this arm to receive loading dose of ticagrelor
88903155|NCT01531127||Combined Therapy|ADHD Medication and Learning Strategies Treatment
88903156|NCT01531127||ADHD Medication Treatment|Control group
88903157|NCT01531140|Active Comparator|Polyethylene glycol|Polyethylene glycol p.o.(Fortrans):60 ml/kg for 2 days
88903158|NCT01531140|Experimental|PEG + Bisacodyl|Polyethylene glycol p.o.(Fortrans): 30 ml/kg for 2 days + Bisacodyl p.o.: 10-15 mg/day
88903159|NCT01531140|Experimental|Sennosides|Sennosides: 1tbl/8kg/day for 2 days (1 tbl=8,6 mg sennosides B)
88903160|NCT01531166||Chronic hepatitis B|
88903161|NCT01531179|Experimental|Lactobacillus reuteri|Lactobacillus reuteri 100 million CFU/day for 3 months
88903162|NCT01531179|Placebo Comparator|Control|Placebo for 3 months
89422266|NCT00131014||Subject unaffected by lymphoma|Subject unaffected by lymphoma
89422267|NCT00131014||Subject affected by lymphoma|Subject affected by lymphoma
89422268|NCT03060226|Other|Control group|
89422269|NCT03060226|Other|radiosensibility group|
89422270|NCT03786380|Experimental|Relamorelin 10 μg|Relamorelin 10 micrograms (μg) injected subcutaneously twice daily for up to approximately 22 months.
89422271|NCT03055234|Experimental|Oral Treprostinil|Extended-release oral tablet for three times daily (TID) administration
89422272|NCT03055234|Placebo Comparator|Placebo|Placebo (sugar pill) for TID administration
89422273|NCT03055312|Active Comparator|TPC chemotherapy|"Conventional chemotherapy(choose a):~TX (Taxotere and Xeloda),GT (Gemcitabine and Paclitaxel),GC (Gemcitabine and Carboplatin)"
89422274|NCT03055312|Experimental|Bicalutamide|Bicalutamide 150mg/day every 28 days
89422275|NCT03055468|Experimental|Peer Support|Participants in this group will receive peer support as well as antidepressant medications comprised of either Fluoxetine 20mg O.D or Imipramine 75mg nocte.
89422276|NCT03055468|Active Comparator|No Peer support|Participants will only receive antidepressant medications comprised of either Fluoxetine 20mg O.D or Imipramine 75mg nocte.
89422277|NCT04977544|Active Comparator|drug only|Sertraline was given as a single drug, with an initial dose of 50 mg/d, and gradually increased to the maximum dose of 200 mg/d after 2 weeks. The treating physician will determine the specific dose adjustment according to the patient's condition.
89422278|NCT04977544|Experimental|vert combine with drug|On the basis of sertraline drug treatment, phobia patients were given 2d/times from the 5th week, each 35-45min VR exposure treatment, 15 times as a course of treatment.
89422279|NCT04917640||SBRT|Patients treated with Stereotactic Body Radiation Therapy (SBRT)
89422280|NCT04917640||IMRT|Patients treated with Intensity Modulated Radiation Therapy (IMRT)
89422281|NCT03470636|Experimental|HeartLight X3|Pulmonary vein isolation using HeartLight X3
89422282|NCT05157074|Experimental|Parkinson's Disease (PD) Group|Participants with PD and their caregivers receive group drum classes twice a week for 12 weeks (24 lessons).
89422283|NCT05157074|Experimental|Huntington's Disease (HD) Group|Participants with HD and their caregivers receive group drum classes twice a week for 12 weeks (24 lessons).
89422284|NCT02626000|Experimental|Talimogene Laherparepvec + Pembrolizumab|Talimogene laherparepvec is administered by intralesional injection into injectable cutaneous, subcutaneous, and nodal lesions at an initial dose of 10⁶ plaque-forming units (PFU) per mL on day 1 followed by a dose of 10⁸ PFU/mL 3 weeks after the initial dose and every 3 weeks (Q3W) thereafter. Pembrolizumab is administered by intravenous infusion at a dose of 200 mg Q3W after the initial dose. Participants are treated until complete response, no injectable lesions, confirmed disease progression, intolerance of study treatment, 24 months from the date of the first dose of talimogene laherparepvec, or end of study, whichever occurred first.
89422285|NCT03769376|Active Comparator|Bio-Oss®|Bio-Oss® xenograft bone material will be placed into the socket following tooth extraction. Half of participants will be randomly assigned to this treatment group (1:1).
89422286|NCT03769376|Active Comparator|Salvin-Oss®|Salvin-Oss® xenograft bone material will be placed into the socket following tooth extraction. Half of participants will be randomly assigned to this treatment group (1:1).
89422287|NCT03060460|Experimental|Ultrasound arm - Randomized group|Ultrasound guided sheath insertion
89422288|NCT03060460|No Intervention|Conventional arm - Randomized group|Conventional arm during randomized phase
89422289|NCT03060460|No Intervention|Historical control group|Conventional arm, non-randomization phase
89422290|NCT03744494|Experimental|Bilateral simple orchidectomy (BSO)|The patients would have the testis, epididymis and distal cord structures excised
89422291|NCT03744494|Experimental|Subcapsular orchidectomy (BSCO)|The tunica albuginea was incised longitudinally and the testicular parenchyma scraped off it. The hilar region was secured with a haemostat and the parenchyma excised off it. A haemostatic suture was applied at the hilum. A running interlocking water-tight capsular suture was inserted
89422292|NCT03744494|Experimental|Epididymal-sparing orchidectomy (BESO)|The epididymal sinus was developed. The epididymal vessels were sequentially clamped and divided, removing the testicle from the epididymis. The caput was looped to meet the head and the adjoining surfaces of the body sutured together (epididymoplasty) Vasectomy done to reduce future risk of epididymitis
89422293|NCT03060382|Experimental|balanced buttress absorbable spacer|For the patients of study group, a balanced buttress absorbable spacer was placed into tibia.
89422294|NCT03060382|Placebo Comparator|total knee arthroplasty|For the patients of control group, total knee arthroplasty was conducted.
89422295|NCT05156450|Experimental|Dose Extension|"At the recommended phase II dose of TQB3616 combined with abiraterone acetate (1000 mg, q.d.) plus prednisone (5 mg, b.i.d.), 20-40 patients are planned to be enrolled to evaluate the efficacy and safety of the combination therapy.~Metastatic and genomic tests based on tissue biopsy samples (primary or metastatic) and blood samples will be performed before treatment and after disease progression."
89536056|NCT02483117||Eating disorder patients by type of compensating behavior.|Data collection started in 2010; one year follow-ups were conducted through 2011-2012. Psychiatrists collaborating in the study informed personally their patients about the objectives of the study, and recorded the sociodemographic information, including age, gender, marital status, level of education, employment status, and people with whom the patient lived. Those who agreed to take part were also sent the questionnaires and informed consent form by mail. They were asked to return these by mail using an enclosed, pre-stamped envelope. Two reminders also were sent at intervals of 15 days to those who did not respond to the first mailing.
89536057|NCT03201913|Experimental|Accelerated dose escalation study|"Dose escalation of TTC-352 administered as an oral capsule, twice a day for 28 days (one cycle).~Patients will receive sequential 28-day cycles of treatment until disease progression, unacceptable toxicity, patient refusal to continue treatment, any other reason to discontinue treatment (e.g., further participation is not in the patient's best interest) or study completion/termination."
89422296|NCT03060304|Experimental|study group|Patients in study group will receive tamoxifen at a daily dose of 40 mg from day 3 to day 8. Follicle diameters are monitored by transvaginal ultrasound and serum levels of E2, P are tested on day 9. If there is a dominant follicle (almost 12 × 12 mm in diameter), endometrial thickness and endometrial pattern, as well as follicular diameters, were monitored daily or every other day till embryo transfer. Serum levels of E2, P are tested on the day before ovulation. If there isn't dominant follicle and intramuscular human menopausal gonadotropin at a dose of 75-150 IU was administered each day after day 12 if there follicle development was poor. The embryo transfer day is decided according embryo development.
89422297|NCT03060304|Active Comparator|control group|Patients in control group will receive estradiol valerate at a dose of 3 mg twice per day from day 3. Follicle diameters are monitored by transvaginal ultrasound and serum levels of E2, P are tested on day 9. If endometrial thickness <7mm and E2<100pg/ml, the dose of estradiol valerate can increase or combine other estradiol. Endometrial thickness and endometrial pattern, as well as follicular diameters, were monitored daily or every other day till embryo transfer. Serum levels of E2, P are tested on the day before endometrium transformation. The embryo transfer day is decided according embryo development. Serum levels of E2, P are tested on the day before embryo transfer.
89422298|NCT03665636|Experimental|Triheptanoin|Open Label Study
88903163|NCT01531192|Experimental|Lactobacillus reuteri|Lactobacillus reuteri 100 million CFU/day for 3 months
89422299|NCT04432402|Experimental|Lenalidomide in Combination With R-GemOx|Lenalidomide 10mg、15mg、20mg、25mg qd PO d1-7 Rituximab 375mg/m2 ivd d0 Gemcitabine 1g/m2 ivd d1 Oxaliplatin 100mg/m2 ivd d1 every14 days as a cycle
89422300|NCT03663764|Experimental|Expeiment|"HRT using the IMRT technique was administered. For patients with limited pulmonary or pleural metastases (≤3 lesions), stereotactic body radiation therapy (SBRT) could be used.~All patients received weekly docetaxel(25mg/㎡) and nedaplatin or cisplatin (25mg/㎡), each of 1 day's duration, concurrently with hypofractionated radiotherapy .~Meanwhile they received weekly thymosin a1(1.6mg) during and within 2 months after the end of chemoradiotherapy."
88903164|NCT01531192|Active Comparator|Nystatin|50000 unit/3 times a day
88903165|NCT01531218|Active Comparator|azithromycin|azithromycin 500mg
89422301|NCT03060148|Active Comparator|Spinal cord stimulation|Medtronic neurostimulation system for spinal cord stimulation
89422302|NCT03060148|No Intervention|Control|No implantation of Medtronic neurostimulation system
88903166|NCT01531218|Placebo Comparator|placebo|placebo 500mg
88903167|NCT01531231||YOUNGER HEALTHY NO CORONARY ARTERY DISEASE (CAD)|- Whether an association between typical daily experiences and recovery time varies with age; this group will be compared to the older comparison group and to previous data collected from those subjects who participated in the Long QT Syndrome study (LQTS).
88903168|NCT01531231||OLDER HEALTHY SUBJECTS NO CORONARY ARTERY DISEASE (CAD)|- Determine whether daily emotion influences ischemia and repolarization differentially as a function of the severity of CAD and presence of CAD when comparing CAD patients with healthy patients
88903169|NCT01531231||HIGH RISK CORONARY ARTERY DISEASE (CAD)|- Determine whether emotion assessed randomly throughout the day is associated with myocardial ischemia
88903170|NCT01531231||LOW RISK CORONARY ARTERY DISEASE (CAD)|- Determine whether typical daily emotion influences ischemia and repolarization differentially as a function of the severity of CAD and presence of CAD
88903171|NCT01531244|Experimental|Treatment (targeted gene therapy and ILI)|Patients receive melphalan and dactinomycin via ILI. Patients then receive CRAd 3/5-delta via ILI.
88903172|NCT01531257||Kidney Transplant Recipients|The intention of our biomarker panel is to be broadly applicable to all patients with a kidney transplant with the assumption that there are common underlying molecular mechanisms of AR and CAN/IFTA that can be detected hopefully at early stages of disease. We therefore want to validate and test our biomarker panel in a broad collection of patient types. We chose not to include patients with dual organ transplants so that we could isolate the molecular signal we are studying.
88903173|NCT01531283|Experimental|decaylated ghrelin|UAG (4.0 µg/kg/hr)
88903174|NCT01531283|Experimental|acyl ghrelin|AG (1.0 µg/kg/hr)
88903175|NCT01531283|Experimental|combined acyl and desacyl ghrelin|the combination of AG (1 µg/kg/hr) and UAG (4 µg/kg/hr)
88903176|NCT01531283|Placebo Comparator|saline|saline
89422303|NCT04432324|Experimental|Intravenous Immune Globulin + Standard Medical Treatment|Participants will receive the first intravenous (IV) infusion of IVIG on Day 1 up to a net dose of 2 gram per kilogram (g/kg), based upon participant's (body weight) administered in divided doses as infusions of 500 milligram per kilogram (mg/kg), based upon participant's body weight, over 4 days or 400 mg/kg, based upon participant's body weight, over 5 days. Participants will also receive all standard of care interventions while hospitalized, from Day 1 to Day 29.
89422304|NCT04432324|Active Comparator|Standard Medical Treatment|Participants will receive all standard of care interventions required throughout the participant's hospitalization, from Day 1 to Day 29
89422305|NCT02736890|Active Comparator|Botulinum Toxin A|Each vial of botulin toxin (100U, BOTOX, Allergan) will be reconstituted with 4ml non-preserved saline solution (0.9%) as recommended by the manufacturer (concentration of 5 units Botulinum Toxin A/0.2ml). Each injection will be 0.2mL (BOTOX, 5 units), administered through a 25 gauge needle. The marked area will have subcutaneous injections, each separated by a radius of 1 cm, from the other injections into the marked area,(maximum of 80 injections, 400 Units).
89422306|NCT02736890|Placebo Comparator|Placebo|Placebo consists of 0.9% normal saline. Each injection will be 0.2mL, administered with a 25 gauge needle subcutaneously into the affected area. The marked area will have subcutaneous injections (maximum of 80) each separated from the surrounding ones by a radius of 1 cm.
89422307|NCT04977388|Active Comparator|Northera™ (Droxidopa) (Treatment A)|Northera (Droxidopa) (Treatment A) will be provided to adult subjects as a capsule with 100mg, 200mg, or 300mg of Northera (Droxidopa) contained within gelatin color capsules (sky blue and white, size 0) based on findings from the dose titration visit. These capsules are physically indistinguishable from the Treatment B (placebo) capsules. Frequency of administration (by mouth) will be twice daily for six weeks.
89422308|NCT04977388|Placebo Comparator|Placebo (Treatment B)|Empty gelatin color capsules (sky blue and white, size 0) filled with cellulose microcrystalline and physically indistinguishable from Treatment A capsules. Frequency of administration (by mouth) will be twice daily for six weeks
89422309|NCT04965376|Active Comparator|Glenohumeral joint injection|Ultrasound guided steroid injection into the glenohumeral joint (10mls of 1% lidocaine with 40mg depo-medrone)
89422310|NCT04965376|Active Comparator|Suprascapular nerve block|Ultrasound guided steroid injection as a suprascapular nerve block at the spinoglenoid notch adjacent to the nerve as it traverses under the spinoglenoid ligament (10mls of 1% lidocaine with 40mg depo-medrone)
89422311|NCT03472196|Experimental|EndoZip System|"The Nitinotes EndoZip system is designed to allow for the creation of multiple internal gastric segmentation (4-8) in the stomach by using an endoscopic approach. The system allows the forming of wall-to-wall longitudinal attachments of the anterior and posterior stomach walls, creating multiple strictures within.~Creation of this segmentation may significantly reduce gastric volume, may affect gastric motility and consequently, reduce weight."
89422312|NCT03470480|Experimental|Treatment rTMS + meth pictures|Participants in this group will receive real repetitive transcranial magnetic stimulation treatments. Before each rTMS session they will be exposed to a series of methamphetamine-related pictures to evaluate response to methamphetamine visual cues while receiving real rTMS treatments. This group will be referred to as real METH (RM).
89422313|NCT03470480|Active Comparator|Treatment rTMS + neutral pictures|Participants in this group will receive real repetitive transcranial magnetic stimulation treatments. Before each rTMS session they will be exposed to a series of neutral pictures to evaluate response to neutral visual cues while receiving real rTMS treatments. This group will be referred to as real neutral (RN).
89422314|NCT03470480|Sham Comparator|Sham rTMS + meth pictures|Participants in this group will receive sham repetitive transcranial magnetic stimulation treatments. Before each rTMS session they will be exposed to a series of methamphetamine-related pictures to evaluate response to methamphetamine visual cues while receiving sham rTMS treatments. This group will be referred to as sham METH (SM).
88903177|NCT01531309|Experimental|Mild Hepatic Impaired Participants|Mild hepatic impaired participants will receive a single sublingual dose of AGO178, 1 milligram (mg) on Day 1.
88903178|NCT01531309|Experimental|Moderate Hepatic Impaired Participants|Moderate hepatic impaired participants will receive a single sublingual dose of AGO178, 1 mg on Day 1.
89422315|NCT03470480|Sham Comparator|Sham rTMS + neutral pictures|Participants in this group will receive sham repetitive transcranial magnetic stimulation treatments. Before each rTMS session they will be exposed to a series of neutral pictures to evaluate response to neutral visual cues while receiving sham rTMS treatments. This group will be referred to as sham neutral (SN).
89422316|NCT04958018|Experimental|Almond|57 g almonds each day in split doses (half in the morning, half in the afternoon)
89422317|NCT04958018|Active Comparator|Snack Bar|snack bar group will ingest a matched calorie, common snack bar in split doses (324 calories/day, Nutri-Grain cereal bars, 120 kcal each)
89422318|NCT04976998||patients|those with symptoms of CTS
89422319|NCT04976998||control group|normal people those with no symptoms of CTS
89422320|NCT05156294|Experimental|Test|Mucoperiosteal flaps will be raised and the conventional drilling sequence for implants will be implemented (Camlog Conelog Screw-Line Promote Plus implants). Implants will be placed 1 mm below the bone crest. The diameter of the implant will be in the range of 3.8 and 4.3 mm. Consecutively, 4 to 6 mm height healing abutments and the allogenic membrane (NovoMatrix®, BioHorizon) folded in two on top of the implant (secured with the healing abutment), will be placed. Finally, flaps will be sutured with 6/0 polypropylene monofilament. Patients will be instructed to rinse with 15 ml of 0.12% chlorhexidine (Perio-Aid tratamiento, Dentaid SL, Barcelona, Spain) 60 seconds twice per day until suture removal, that will take place 14 days later. Anti-inflammatory drugs will also be prescribed (Ibuprofen 600 mg every 8 hours upon patient´s needs).
88903179|NCT01531309|Experimental|Healthy Participants Matched by Aged, Gender and Body Mass Index (BMI)|Healthy participants matched by aged, gender and BMI will receive a single sublingual dose of AGO178, 1 mg on Day 1.
88903180|NCT01531322|Experimental|Group 1|Adults aged 18 through 55 years (before the fifty sixth birthday)
88903181|NCT01531322|Experimental|Group 2|Children aged 3 through 5 years (before the sixth birthday)
88903182|NCT01531322|Experimental|Group 3|Infants aged approximately 2 months (42 to 98 days)
88903183|NCT01531348|Experimental|BM-MSC|Bone marrow-derived mesenchymal stem cells 1 million cells in balanced salt solution 100 microlitres will be injected into the vitreous cavity.
89195109|NCT02551575|Experimental|Integrative Medicine|The patients were treated with methotrexate, hydroxychloroquine, oral Qingre Huoxue granule and Qingre Huoxue external preparation.
89195110|NCT02541448|Active Comparator|AIS at 9±1mmHg|Use of the SurgiQuest AIRSEAL® Insufflation System (AIS) at 9±1mmHg
89195111|NCT02541448|Active Comparator|AIS at 15±1mmHg|Use of the SurgiQuest AIRSEAL® Insufflation System (AIS) at 15±1mmHg.
89195112|NCT02552043|Experimental|Nintendo Wii exercise program group|The EG will perform a domiciliary Pulmonary Rehabilitation program of 30-60 min exercise, 5 days/week during 6 weeks using a Nintendo Wii platform with the game EA SPORTS ACTIVE 2. The exercise activities were loaded into each participant´s console during the clinical interview and adjusting the exercises according to their age in 2 groups (>12 years and <13 years). The program consisted of 6 different workouts (1st and 2nd weeks: legs exercises; 3rd week: upper limb exercises; 4th week: thorax exercises; 5th and 6th weeks: cardio exercises), so the patients had a gradual increase reaching the maximum load at the end of training.
89195113|NCT02552043|No Intervention|Control group|The CG carried out their routine patient management
89195114|NCT00889408|Experimental|Treatment|DT2219ARL at assigned dose IV over 4 hours in the outpatient setting on day 1, 3, 5, and 8
89195115|NCT00887614|Experimental|MBSR|Participation will involve online completion of a questionnaire survey before and after the Mindfulness-Based Stress Reduction (MBSR) intervention. Specifically, research study participants will complete validated self-report measures to assess mindfulness, cognitive-emotional processes, sleep quality, symptoms of stress, sense of spirituality, and quality of life before and after the MBSR intervention.
89195116|NCT01154335|Experimental|Dose Level 1|"combination of OSI-906 and everolimus~OSI-906: 50 mg Twice a Day, cycle-28 days~Everolimus: 5mg Daily, cycle-28 days"
89195117|NCT01154335|Experimental|Dose Level 2|"combination of OSI-906 and everolimus~OSI-906: 100 mg Twice a Day, cycle-28 days~Everolimus: 10mg Daily, cycle-28 days"
89195118|NCT01154335|Experimental|Dose Level 2a|"combination of OSI-906 and everolimus~OSI-906: 100 mg Twice a Day, cycle-28 days~Everolimus: 5mg Daily, cycle-28 days"
89195119|NCT00889642|Active Comparator|Active|Contains Lidocaine and Epinephrine
89195120|NCT00889642|Placebo Comparator|Placebo|Contains Epinephrine
89195121|NCT01126333||Long term Sirolimus or Tacrolimus|"Ths study cohort will consist of participants who successfully completed two years of the original Spare the Nephron (STN) study, a two year prospective multi-center study where participants were assigned to receive either center-specific CNI regimen (assigned at the time of transplantation) or were switched to replace the CNI with Sirolimus therapy.~In this current long-term follow-up study, we will approach patients who previously enrolled in the STN study and offer them the opportunity to enroll to be followed-up for another 3 years. There will be no change in immunosuppression unless clinically indicated. The majority of effort is standard care with every 6 month follow-up appointments.Participants will be required to consent to participate in the three year extension study."
89422321|NCT05156294|Other|Control|Mucoperiosteal flaps will be raised and the conventional drilling sequence for implants will be implemented (Camlog Conelog Screw-Line Promote Plus implants). Implants will be placed 1 mm below the bone crest. The diameter of the implant will be in the range of 3.8 and 4.3 mm. Finally, flaps will be sutured with 6/0 polypropylene monofilament. Patients will be instructed to rinse with 15 ml of 0.12% chlorhexidine (Perio-Aid tratamiento, Dentaid SL, Barcelona, Spain) 60 seconds twice per day until suture removal, that will take place 14 days later. Anti-inflammatory drugs will also be prescribed (Ibuprofen 600 mg every 8 hours upon patient´s needs).
89195122|NCT02541526|Experimental|mirtazapine|30 mg mirtazepine will be given to patients on day 6 of their treatment for a period pf 3 days to observe for tolerability followed by 60 mg from day 9 of treatment until the end of the study (16 weeks).
89422322|NCT03469856|Other|single arm|The ASET Pilot study is a multicenter, single arm, open-label trial of single antiplatelet therapy with prasugrel for patients undergoing successful and optimal PCI for chronic stable angina with normal cardiac biomarkers values. angiographic and/or findings from intracoronary imaging, only then patients will be enrolled in the study and loaded with prasugrel 60 mg and continued with prasugrel only (10 mg once a day) for three months. Aspirin and clopidogrel will be discontinued. At the 3-months follow-up visit, prasugrel (only) will be replaced by aspirin (only) or dual-antiplatelet therapy according to local standard of care.
89422323|NCT04153786|Experimental|Cohort|Pacemakers will be programmed to BiV pacing, left ventricular (LV) pacing, right ventricular (RV) pacing and no pacing for five minutes each. LVAD flow will be recorded every thirty seconds for five minutes with each setting. Once the interventions have been completed, all pacemakers will be returned to their original setting.
89422324|NCT04912232||Trauma Patients|"Patients suffering blunt and/or penetrating trauma but without physiologic criteria suggestive of ongoing hemorrhage:~Awake and alert GCS >14~Admission systolic blood pressure greater than 90 and heart rate less than 120~Without signs of clinically significant ongoing external hemorrhage with no active bleeding documented on radiology/ultrasound and stable vital signs (no signs of hemodynamic deterioration) during initial evaluation (approximately 15 minutes post admission)"
89422325|NCT04917016||Study group|Women undergoing hysteroscopy for removal of RPOC
89422326|NCT04917250|Experimental|treatment arm|Treated with gemcitabine, pegaspargase, etoposide and dexamethasone
89422327|NCT05156138||study group|patients with pseudoexfoliation fulfilling the inclusion criteria
89422328|NCT05156138||control group|patients without pseudoexfoliation fulfilling the inclusion criteria
89422329|NCT04913038||case group|children over 2 years of age and prepubescent ventilated and sedated in pediatric intensive care.
89422330|NCT05155748|Experimental|Intervention|"Nursing staff, physicians and pharmacists will be invited to a continuous education - knowledge exchange session to inform them on the study rationale and the means of medication optimization.~Pharmacists will be asked to perform medication reviews, guided by the information and tools provided, for the participating residents.~Pharmacists' recommendations will be discussed during meetings with physician and nurses."
89422331|NCT05155748|No Intervention|Control|Care as usual.
89422332|NCT04977076|Active Comparator|Interrupted NOAC use (group 1)|Patients in group 1 will receive standard care. Therefore, DOAC use will be interrupted at least 24 hours in advance of ICA or PCI. Based on the renal clearance, last DOAC intake may be extended to 48 hours prior to the procedure [Table 2]. After the procedure, patients will continue using their DOAC as usual.
89422333|NCT04977076|Experimental|Uninterrupted NOAC use (group 2)|In group 2, all patients will continue to use their specific DOAC as usual. This means that no adjustments of DOAC use will be made before and after ICA or PCI. After the procedure patients will continue to use DOAC from the next planned dose.
89422334|NCT03469778|Experimental|Robotic Therapy|After consent, 10 participants will be included in a training program, as described below: 1º session will be robotic calibration and assessment; the following 18 sessions will be conducted the robotic therapy for upper limbs, three times a week. Each session will have a total duration of 55 minutes, including initial patient positioning and adjusting and after a sequence of game tasks.
89422335|NCT04976764||liver cirrhosis with cirrhotic cardiomyopathy|
89422336|NCT04976764||liver cirrhosis without cirrhotic cardiomyopathy|
88814362|NCT03060083|Experimental|Switch to VLNC cigarettes|Participants will be instructed to use nicotine patches and gradually switch to very low nicotine content (VLNC) cigarettes throughout the study period. They will receive regular nicotine cigarettes (16.5 mg/g) during week 1, 11.26 mg/g cigarettes during week 2, 5.54 mg/g cigarettes during week 3, 2.54 mg/g cigarettes during week 4, and 0.44 mg/g cigarettes during week 5.
88903184|NCT01531361|Experimental|Arm I (vemurafenib and sorafenib tosylate)|Patients receive vemurafenib PO BID and sorafenib tosylate PO BID on days 1-28.
89422337|NCT04859582|Experimental|Pembrolizumab + FP or CAPOX|Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (approximately 2 years) + physicians' choice of either cisplatin 80 mg/m^2 IV on Day 1 Q3W and 5-fluorouracil (5FU) 800 mg/m^2/day via continuous IV infusion on Days 1 to 5 Q3W OR oxaliplatin 130 mg/m^2 IV on Day 1 Q3W + capecitabine 1000 mg/m^2 orally twice a day (BID) on Days 1 to 14 Q3W. Participants who complete 35 administrations or achieve a complete response (CR) but progress after discontinuation can initiate a second course of pembrolizumab for up to 17 cycles (approximately 1 additional year).
89006960|NCT06169254|Active Comparator|Transcranial alternating current stimulation (tACS)|The stimulation parameters of HD-tACS include: 20 minutes at 40 Hz, 2 milliamps.
89006961|NCT06169254|Sham Comparator|Sham transcranial current stimulation (tCS)|In sham condition, the stimulation only last for 30 seconds with the electrodes left in place for a further 20 minutes.
89006962|NCT06169020|Experimental|Experimental group|All subjects will participate in this arm. They will conduct a series of fitness tests in order to assess energy expenditure, from rest to maximal, body composition and health related fitness. They will also use the wearable during free living condition to estimate free living energy expenditure.
89006963|NCT06168565|Experimental|Sequence 1|Measures of end-diastolic peak velocity, systolic peak velocity, heart rate, and arterial diameter will be collected for two minutes, two minutes before, at the 8th minute after the start of the IPC administration, and two minutes after the conclusion of each IPC protocol. End-diastolic peak velocity and systolic peak velocity will be measured across different phases of the IPC cycle (all cuffs inflated, half of the cuffs inflated, and all cuffs deflated). Both the athletes and assessors will be unaware of which protocol is being carried out. All protocols will be performed with participants lying down in a supine position, on a stretcher. The moderate pressure protocol applies a pressure of 80mmHg and the high pressure protocol applies a pressure of 200mmHg.
89006964|NCT06168565|Experimental|Sequence 2|Measures of end-diastolic peak velocity, systolic peak velocity, heart rate, and arterial diameter will be collected for two minutes, two minutes before, at the 8th minute after the start of the IPC administration, and two minutes after the conclusion of each IPC protocol. End-diastolic peak velocity and systolic peak velocity will be measured across different phases of the IPC cycle (all cuffs inflated, half of the cuffs inflated, and all cuffs deflated). Both the athletes and assessors will be unaware of which protocol is being carried out. All protocols will be performed with participants lying down in a supine position, on a stretcher. The moderate pressure protocol applies a pressure of 80mmHg and the high pressure protocol applies a pressure of 200mmHg.
89006965|NCT06168045||Term neonates|Neonates with gestational age 37+0 - 42+0 weeks
89006966|NCT06168045||Preterm neonates|Neonates with gestational age < 37+0 weeks
89006967|NCT06167525|Other|Neck posture monitoring device without feedback option|Real-time feedback through the device. For surgeons who consent, bio-feedback signals will be given once deviated from a neutral posture for >1 minute.
89006968|NCT06167395|Experimental|Beta Alanine high dose|Consumption for 30 days.
89006969|NCT06167395|Experimental|Beta Alanine low dose|Consumption for 30 days.
89006970|NCT06167395|Placebo Comparator|Control group|Consumption for 30 days.
89006971|NCT06167057|Experimental|A|Single post-operative MMC 40mg or gemcitabine 2gr in Saline 0.9% 50cc bladder instillation
89006972|NCT06167057|Placebo Comparator|B|Single post-operative 50cc Saline 0.9% bladder instillation
89006973|NCT06166394||Mepivacaine|Day surgery patients(30 patients); For these patients- Administration of a spinal hypobaric mepivacaine injection
89006974|NCT06166394||Bupivacaine|In-patients(30 patients): For these patients- Administration of a spinal hypobaric bupivacaine injection
89006975|NCT06166368|Experimental|diurnal variations|Venous blood samples were obtained under standardized conditions from 24 healthy young men every third hour through 24 hours
89006976|NCT06166316|Active Comparator|lateral incisor group|patients having mandibular two implants in lateral incisor positions.
89006977|NCT06166316|Active Comparator|canine group|patients having mandibular two implants in the canine positions.
89006978|NCT06166316|Active Comparator|premolar group|patients having mandibular two implants in the premolar positions.
89422338|NCT04859582|Active Comparator|Placebo + FP or CAPOX|Participants receive placebo for pembrolizumab IV on Day 1 Q3W for up to 35 cycles (approximately 2 years) + physicians' choice of either cisplatin 80 mg/m^2 IV on Day 1 Q3W and 5FU 800 mg/m^2/day via continuous IV infusion on Days 1 to 5 Q3W OR oxaliplatin 130 mg/m^2 IV on Day 1 Q3W + capecitabine 1000 mg/m^2 orally BID on Days 1 to 14 Q3W.
89422339|NCT04976608||Group 1|The BCVA of eyes is greater than 0.6
89422340|NCT04976608||Group 2|The BCVA of eyes is from 0.1 to 0.6
89422341|NCT04976608||Group 3|The BCVA of eyes is less than 0.6
89422342|NCT03469700|Experimental|GA+PVB|Patients will receive general anesthesia with paravertebral block
89422343|NCT03469700|Active Comparator|GA+placebo PVB|Patients will receive general anesthesia with placebo block
89006979|NCT06164470|Other|Support Group|Non-randomized pre-post trial, in which each participant will serve as their own control. Participants will be recruited from a bronchiectasis specialty clinic.
89006980|NCT06164457|No Intervention|Control Group|Patients in this group will attend their cardiology appointment as normal. No intervention present.
89006981|NCT06164457|Experimental|Intervention Group|Patients in this group will complete the ePROM patient survey in advance of their care visit.
89006982|NCT06161987|Active Comparator|Rehabilitation Intervention Group|Comprehensive rehabilitation plan containing 18 sessions of a structured exercise and inspiratory muscle training program over 6 weeks (3 times per week).
89006983|NCT06161987|No Intervention|Attention Control|Conventional care with bi-weekly contact from study personnel.
89195123|NCT02541526|Placebo Comparator|Placebo|matched placebo mirtazapine capsules will be given to patients in this group
89195124|NCT01037959|Active Comparator|Norfloxacin|Patients with severe cirrhosis treated with norfloxacin
89195125|NCT01037959|Placebo Comparator|Placebo|Patients with severe cirrhosis treated with placebo
89422344|NCT03062020|Experimental|Intervention group: QUIPP tool arm|In this group, QUIPP tool will be used to select and manage patients attending our PBPC: high-risk patients will be followed-up in our PBPC and low-risk patients will be discharged from PBPC and managed in a low-risk unit.
89422345|NCT03062020|No Intervention|Control group: no QUIPP tool arm|Women will be managed according to current clinical practice.
89422346|NCT03469622|Active Comparator|EndoRings|Colonoscopy is performed with the EndoRings attached
89422347|NCT03469622|Active Comparator|Standard Colonoscopy|Standard colonoscopy without any additional devices
89422348|NCT04912726|Experimental|Intervention|The intervention group will receive intravenous sildenafil loading dose of 0.4 mg / kg in 3 hours and continue in continuous infusion at 1.6 mg / kg / day (0.067 mg / kg / h).
89422349|NCT04912726|No Intervention|Placebo|The control group will receive placebo at the same loading dose and infusion with 0.9% saline solution plus standard management under the unit protocol immediately after the echocardiographic diagnosis.
89422350|NCT03130712|Experimental|GPC3-CART cells|
89422351|NCT04912882||Training Group|Training group including about 500 patients that be using to building the prognosis model
89422352|NCT04912882||Validation Group|Validation group including about another 500 patients that be using to validating the prognosis model
89422353|NCT03472118|Experimental|High Flow Apneic Oxygenation|Apneic oxygenation using Transnasal Humidified Rapid-Insufflation Ventilatory Exchange (THRIVE)
89422354|NCT04976842|Active Comparator|Opioid-free anesthesia|Opioid free anesthesia protocol for urological procedurs
89422355|NCT04976842|Active Comparator|Opioid-based anesthesia|Opioid based anesthesia protocol for urological procedures
89422356|NCT02779556|Other|Enhanced Usual Care|ADA Living Well with Diabetes Workbook, 15 minute in-person counseling, follow-up every 3 months
89422357|NCT02779556|Other|Intervention|ACP Living with Diabetes Guide, 15 minute in-person counseling , 15 minute follow-up counseling (3, 6, and 9 months), monthly phone calls after 3 months
88814363|NCT03060083|Experimental|Reduce CPD|Participants will be instructed to use nicotine patches and gradually reduce the number of regular nicotine content cigarettes that they smoke throughout the study period. They will receive regular nicotine content cigarettes (16.5 mg/g) throughout the study study period. After establishing a baseline CPD during week 1, participants will receive 70% of their baseline CPD during week 2, 35% during week 3, 15% during week 4, and 3% during week 5. Participants will receive a minimum of 1 CPD during week 5.
88814364|NCT02244710|Experimental|Ticagrelor|180mg initial dose next day 90mg BID
88814365|NCT02244710|Active Comparator|Clopidogrel|600mg po initial dose and 75mg qd starting next day
88903185|NCT01531361|Experimental|Arm II (vemurafenib and crizotinib)|Patients receive vemurafenib as in Arm I and crizotinib PO QD or BID on days 1-28.
88903186|NCT01531400|Experimental|music|Investigators played self-selected background music in the music group
89422358|NCT05133206|Experimental|Non-Fasting|Oral fluids and food up to the time of the procedure.
89422359|NCT05133206|No Intervention|Fasting|Clear fluids up to the time of the procedure and no food for at least 2 hours before the procedure - current practice.
89422360|NCT03470402|Experimental|Intervention group|"Women who screen as eligible for BRCA genetic counseling will receive the education and decision support tool, RealRisks, along with standard educational material and a high-risk message. The high-risk status of the women will also be flagged in the online tool used by the hospital to visualize electronic health record data (iNYP).~The enrolled health care providers of these women will be given access to BNAV, which summarizes their enrolled patients' breast cancer risk profiles and provides educational resources on genetic testing and prevention options. Before their clinical encounter with an enrolled patient, these providers will also be sent the personalized breast cancer risk summary that is created by data the patient entered into RealRisks."
88814366|NCT04362332|Active Comparator|chloroquine|1. Supportive care + chloroquine base arm: loading dose 600mg, followed by 300mg 12 hours later, followed by 300mg bid for 4 days; total treatment duration of 5 days
88814367|NCT04362332|Active Comparator|hydroxychloroquine|2. Supportive care + hydroxychloroquine arm: loading dose 400mg bid, followed by 200mg bid for 4 days; total treatment duration of 5 days.
88814368|NCT04362332|No Intervention|Supportive care only|3. Supportive care only.
88814369|NCT02308241|Experimental|Ribavirin|Study subjects will self-administer ribavirin 1400 mg PO BID (total dose, 2800 mg/day). All patients will complete pill diaries to document administration of study drug. Cycle length is 28 days with continuous dosing. Clinic visits for safety assessments and routine laboratory studies will occur weekly in Cycle 1, in weeks 1 and 3 of Cycle 2, and on Week 1 of subsequent cycles. Cross sectional imaging (CT or MRI) is obtained at baseline and q2 cycles and at End-of Treatment (EOT). Response assessments will follow RECIST 1.1 criteria.
88814370|NCT01632683|Active Comparator|C-MAC|Providers will utilize the C-MAC video laryngoscope equipped with a D-blade to facilitate intubation
88814371|NCT01632683|Active Comparator|Glidescope|Providers will utilize the Glidescope video laryngoscope equipped with the #4 blade to facilitate intubation
88814372|NCT00932282|Active Comparator|12 month maintenance of PnOIT|"Randomized subjects who will stay on the maintenance dose of oral peanut immunotherapy (PnOIT) for 12 months.~The study has 4 phases: anti-IgE therapy before immunotherapy (Omalizumab), an initial desensitization day(s), a buildup period, and a daily home maintenance phase with a final dose of 8000mg peanut flour (~50% peanut protein). Then all subjects will be randomized to an additional 1 or 2 years (12 or 24 months) of maintenance OIT. An OFC will be performed at the end of the long-term maintenance in all groups."
88903187|NCT01531400|No Intervention|no music (control)|Investigators played no music in the music group
88903188|NCT01531413|Experimental|Oxygen Insufflation|At the end of the laparoscopic appendectomy we will desufflate the abdomen of CO2 then reinsufflate with oxygen to washout the CO2 leaving an oxygen rich environment
88903189|NCT01531426||NIRS continuous monitoring|
89536058|NCT02483039|Experimental|AKI Follow-up Clinic|Participants randomized to this arm will be referred to the AKI Follow-up Clinic where they will see a nephrologist who will coordinate follow-up care. The target appointment date is within 30 days of hospital discharge. Routine laboratory investigations will be performed at minimum every three months. Additional in-person visits with a nephrologist at the AKI Follow-up Clinic will be determined at the local sites based upon the participant's clinical status. If in-person visits at 12, 24, and/or 36 weeks are not necessary given the patient's clinical status, they may be replaced with a telephone visit
88903190|NCT01531452|Experimental|treatment|oxaliplatin+s1
88903191|NCT01531465|Other|HFNC to NCPAP|Infants who are currently on HFNC.
88903192|NCT01531465|Other|NCPAP to HFNC|Infants who are currently on NCPAP.
88903193|NCT01531478||Young adult survivors of childhood cancer|Young adult survivors of childhood cancer diagnosed between 1987 and 1992 in the Rhône-Alpes and Auvergne regions of France.
88903194|NCT01531491|Experimental|Hypercapnia group|Respiratory rate will be 10/min and the rebreathing tube will be connected between the y-piece of corrugated tube and the tracheal tube to maintain the partial pressure of the end-tidal carbon dioxide at around 50 mmHg during emergence after propofol anesthesia.
88903195|NCT01531491|Experimental|Hypocapnia group|No rebreathing tube (Nothing) will be connected. Respiratory rate will be 10/min and the tidal volume will be modulated to maintain the partial pressure of the end-tidal carbon dioxide at around 30 mmHg during emergence after propofol anesthesia.
88903196|NCT01531504|Other|Hysterectomy|candidate for a conventional laparoscopic-assisted
88903197|NCT01531517|Experimental|Pedyphar|Ointment
88903198|NCT01531517|Active Comparator|Panthenol|Ointment
88903199|NCT01531530|Experimental|Vaccine-recipients|
88903200|NCT01531530|Placebo Comparator|Placebo|
88903201|NCT01531543|Experimental|VAC-laparostomy|Primary use of Vacuum Assisted Closure (VAC) laparostomy after surgical revision because of severe peritonitis
88903202|NCT01531543|No Intervention|Primary abdominal closure|The abdominal wall is primary closed after the surgical revision because of severe peritonitis
88903203|NCT01531569|Experimental|BeneFlax|BeneFlax given as a single oral dose to assess pharmacokinetics
88903204|NCT01531595|Experimental|Chemotherapy plus bevazicumab|
88903205|NCT01531621||mCRC treatments|All used treatments for metastatic colorectal cancer
88903206|NCT01531634|Active Comparator|Dynamic Cognitive Intervention Group|Twelve Meetings of Dynamic Cognitive Intervention.
88903207|NCT01531634|No Intervention|No Additional Intervention|
88903208|NCT01531647|Active Comparator|Period 1 Control|
88903209|NCT01531647|Experimental|Period 2 danoprevir/ritonavir|
88903210|NCT01531660|Experimental|training|step up jogging program
88903211|NCT01531712|Experimental|QT + QRT|"Chemotherapy (6 cycles x 14 days): Gemcitabine 1000 mg/m2 (day 1) + Oxaliplatin 100 mg/m2 (day 2) + Tarceva 100 mg/day.~Chemoradiotherapy (5,5 weeks): Gemcitabine 40 mg/m2 (2 days/week) + Tarceva 100 mg/day + Radiotherapy (1,8 Gy/day x 28 doses, total dose: 50,4 Gy)."
88903212|NCT01531751|Experimental|High Cut-off Hemodialysis|
88903213|NCT01531777|Experimental|Apatinib 500mg|500mg,p.o.,qd
88903214|NCT01531777|Experimental|Apatinib 750mg|750mg,p.o.,qd
88903215|NCT01531790|Experimental|Endostar plus pemetrexed/carboplatin|21 days as one cycle, for a total of 4-6 cycles
88903216|NCT01531816|Experimental|Single Arm: Study Intervention|Cycle ergometry and/or Interactive video-game
88903217|NCT01531829|Experimental|Low dose (50mg/2h) rt-PA plus LMWH|Low dose (50mg/2h) recombinant tissue plasminogen activator (rt-PA) plus low molecular weight heparin(LMWH)regimen
88903218|NCT01531829|Active Comparator|LMWH|Low molecular weight heparin
88903219|NCT01531842|Experimental|Topical antibiotic|Patients will be randomized in a 1:1 fashion to receive a drop of topical antibiotic before and after the intravitreal injection in the +ABX arm (in addition to the typical prep with betadine).
88903220|NCT01531842|Other|No Antibiotic Arm|No topical antibiotics in the -ABX arm (only the typical prep with betadine)
89195126|NCT01038115|Active Comparator|Cryoballoon|
89422361|NCT03470402|Active Comparator|Control group|Women who screen as eligible for BRCA genetic counseling will receive standard educational material and a high-risk message. The high-risk status of the women will also be flagged in the online tool used by the hospital to visualize electronic health record data (iNYP).
89422362|NCT02603900|Experimental|Adductor Canal Catheter|This group will receive ropivacaine 0.5% 15 ml for the adductor canal block under ultrasound guided nerve block. A multi-orifice catheter will be placed in the adductor canal and an infusion of ropivacaine 0.2% at 10 ml/hr will be continued for 72 hours.
89422363|NCT02603900|Experimental|Local Infiltration of Analgesia|Local infiltration using 20 ml of free bupivacaine solution (Marcaine 0.25% with epinephrine 1:200000, ) diluted with 40 ml of normal saline following implantation of the knee prosthesis, the solution will be injected into the vastus medialis (5 ml), medial retinaculum (5 ml), origin of MCL (5 ml) and LCL (5 ml), lateral portion of quadriceps tendon (5 ml), vastus lateralis (5 ml), and subcutaneous tissues especially along saphenous nerve distribution (30 ml). Postoperatively, a sham adductor canal catheter will be placed as in the ACC arm following stabilization in the PACU to infuse only normal saline with an initial bolus of 15 ml saline and infusion of saline at 10ml/hr for 72 hours.
89422364|NCT01669798|Experimental|BIBF 1120|BIBF 1120 will be administered at a daily oral dose of 200 mg BID until disease progression or adverse effects prohibit further therapy.
89422365|NCT03055078|Experimental|mesenchymal stem cells|According to the inclusion and exclusion criteria, selected patients were divided into a cell therapy group and a control group. Umbilical cord derived mesenchymal stem cells at a dose of 100-300 million by intravenous infusion.
89422366|NCT02334722|Experimental|1 Week Levetiracetam|Levetiracetam taken by mouth at a daily dose of 1000 mg for one week.
89422367|NCT02334722|Active Comparator|6 Week Levetiracetam|Levetiracetam taken by mouth at a daily dose of 1000 mg for six weeks.
89422368|NCT04916626|Experimental|OPUS YOUNG|OPUS YOUNG is a two years out-patients specialized early intervention services for children and adolescents with a first episode psychosis. OPUS YOUNG is characterized by a multidisciplinary team, assertive outreach, tailored cognitive behavioral case management, and low caseload and insensitive psychoeducational family involvement
89422369|NCT04916626|Active Comparator|Treatment as Usual, TAU|Treatment as Usual will be carried out by outpatient clinic in Child and Adolescent Mental Health Services (CAMHS). Patients will be offered treatment following national Danish guidelines and local guidelines, provided by a multidisciplinary team, case-management (no defined upper-case load), family support. In general, office visits take place in outpatient clinics.
89422370|NCT05035784|Active Comparator|Fecal supernatant|Fecal supernatant is used for treatment of childhood Constipation
89422371|NCT05035784|Placebo Comparator|non-Fecal supernatant|Placebo is used for treatment of childhood Constipation
89422372|NCT04534400||Patients with SARS-CoV-2 infection|
89422373|NCT04534400||Patients with Postoperative hypoxemic respiratory failure|
89422374|NCT03469544||Group 1 (30)|"Patient with cancer thyroid proved by cytological analysis Interventions;complete blood picture ,serum urea and creatinine,liver function test,T3,T4,thyroid stimulating hormone,thyroglobuline and thyroglobuline anti body .~specific test is quantitation of long non coding RNA HOTAIR by Real time polymerase chain reaction in peripheral blood ,Enzyme linked Immunosorbent Assay for serum midkine level"
89422375|NCT03469544||Group 2 (30)|"Patient with benign thyroid nodule Interventions;complete blood picture ,serum urea and creatinine,liver function test ,T3,T4,thyroid stimulating hormone,thyroglobuline and thyroglobuline anti body .~specific test is quantitation of long non coding RNA HOTAIR by Real time polymerase chain reaction in peripheral blood,Enzyme linked Immunosorbent Assay for serum midkine level"
89422376|NCT03469544||Group 3 (30)|"Normal healthy subjects as control group Interventions;complete blood picture ,serum urea and creatinine,liver function test,T3,T4,thyroid stimulating hormone,thyroglobuline and thyroglobuline anti body .~specific test is quantitation of long non coding RNA HOTAIR by Real time polymerase chain reaction in peripheral blood,Enzyme linked Immunosorbent Assay for serum midkine level"
89422377|NCT02204462|Experimental|Newly diagnosed breast cancer|Patients with newly-diagnosed invasive and/or intraductal breast cancer detected by core needle or vacuum-assisted biopsy (i.e. index cancer). Patients will undergo FBnTP PET imaging for detection of malignant breast cancer.
89422378|NCT03062254|Experimental|Radium-223|
89422379|NCT02125136|Experimental|Gem/nab-Pac|2 further cycles Gem/nab-Pac (duration of each cycle 28 days)
89422380|NCT02125136|Experimental|FOLFIFINOX|4 cycles combination therapy with 5-fluorouracil/folinic acid, irinotecan, oxaliplatin (FOLFIFINOX) - duration of each cycle 14 days
88903221|NCT01531855|Other|Insulin dose|Reducing rapid-acting insulin dose (insulin aspart or lispro) after exercise.
89422381|NCT04912258|Experimental|Arm A|DEB-TACE before liver surgery
89422382|NCT04912258|No Intervention|Arm B|direct liver surgery
89422383|NCT01952288|Experimental|simvastatin|simvastatin 40 mg/day
89422384|NCT01952288|Placebo Comparator|placebo|placebo
89422385|NCT04912414|Experimental|Brief Family Therapy (BFT) for the treatment of psychosomatic symptoms in Rwanda|The participants from the control group were assigned to the Brief Family Therapy for reducing the medically unexplained symptoms. But the control group was not assigned to the intervention (BFT).
89422386|NCT03054532|Experimental|Durvalumab and lenalidomide|"Open-label use of 2 drugs:~Durvalumab 1500 mg intravenously on day 1 of a 28-day cycle until progressive disease or intolerance.~Lenalidomide orally on days 1 through 21 of each 28-day cycle for 6 cycles."
88903222|NCT01531868|Other|Auditory qualitative|
88903223|NCT01531868|Other|Auditory absolute risk|
88903224|NCT01531868|Other|Auditory relative risk|
88903225|NCT01531868|Other|Visual qualitative|
88903226|NCT01531868|Other|Visual relative risk|
88903227|NCT01531868|Other|Visual absolute risk|
89422387|NCT04975360|Experimental|Caffeine|Administration of a time-controlled, pulsatile-release caffeine formulation (160 mg caffeine) at 22:30. Participants are kept awake until 03:00 and then given a 4-hour sleep opportunity.
89422388|NCT04975360|Placebo Comparator|Placebo|Administration of a placebo formulation at 22:30. Participants are kept awake until 03:00 and then given a 4-hour sleep opportunity.
89422389|NCT00812708|Experimental|Morcher iris diaphragm implantation|This is a non-randomized, non-comparative interventional surgical series. Patients will undergo Morcher iris diaphragm implantation in their affected eye(s). After surgery, patients will complete 5 postoperative examinations. At each examination, they will be evaluated for changes in light and glare sensitivity and visual acuity. They will also be monitored for adverse reactions.
89422390|NCT03054454|Active Comparator|intervention|This group will receive Podiatry treatment and care from the MDT which is the intervention group.
89422391|NCT03054454|No Intervention|comparator|This group will receive usual care
89422392|NCT00563576|Experimental|Depo-Provera/Femring|Subjects will receive an estrogen vaginal ring (100 mcg) during the first 90 days of Depo-Provera use.
89422393|NCT00563576|Other|Depo-Provera Injection Alone|Subjects will receive Depo-Provera intramuscular injection.
89422394|NCT04911946||R1|Resident of the first year of orthopedics and traumatology at IOT-HC-FMUSP.
89422395|NCT04911946||R2|Resident of the second year of orthopedics and traumatology at IOT-HC-FMUSP.
89422396|NCT04911946||R3|Resident of the third year of orthopedics and traumatology at IOT-HC-FMUSP.
89422397|NCT04912102|Active Comparator|Group H|Oxygen will be delvered via HFNO canula at 20 L/min, Fio2 0.4 and temperature of 37o c using Vapotherm Precision Flow.
89422398|NCT04912102|Active Comparator|Group M|Mask group will be provided with nasal CPAP (10cmH2O) at an oxygen flow rate of 15 L/min.
89422399|NCT04912102|Active Comparator|Group C|In the Control group, oxygen via a nasal cannula at a flow rate of 5 L/min will be delivered
89422400|NCT04390178|Experimental|Convalescent plasma treatment|All participants will receive a bag of convalescent plasma. The bag volume will be 180-200 ml. The first 10 patients will receive 1, 5, 10, 50 and 134 ml of plasma at 30 minute intervals while being closely monitored for adverse events, especially allergic reactions. The remaining twenty patients will receive the convalescent plasma as a slow infusion according to normal routines.
89422401|NCT04911218|Experimental|GlideSheath Slender 5Fr arterial sheath|Placement of GlideSheath Slender 5Fr arterial sheath for diagnostic angiography through the distal radial artery (anatomical snuffbox).
88903228|NCT01531907||Obese|Premenopausal women, 25 - 40 years with BMI of ≥30kg/m2
88903229|NCT01531907||Lean|Premenopausal women, 25 - 40 years with BMI of 18.5-24.9 kg/m2
88903230|NCT01531920|Other|alcohol + placebo|Part A alcohol + placebo
88903231|NCT01531920|Other|alcohol + perampanel|Part A : alcohol + perampanel
88903232|NCT01531920|Other|perampanel + alcohol|Part B: perampanel + alcohol
88903233|NCT01531920|Other|placebo + alcohol|Part B: placebo + alcohol
88903234|NCT01531933|Experimental|DLBS3233|
88903235|NCT01531933|Placebo Comparator|Placebo of DLBS3233|
88903236|NCT01531972|Experimental|SEP-228432 (Cohort 1)|Subjects will receive 40 mg of SEP-228432 (titration) orally once per day for 3 days; followed by (steady state) at a dose of 200 mg orally once per day for 5 days.
89422402|NCT04911218|Active Comparator|Conventional 5Fr arterial sheath|Placement of Conventional 5Fr arterial sheath arterial sheath for diagnostic angiography through the distal radial artery (anatomical snuffbox).
89422403|NCT04904744|Placebo Comparator|No message|No message sent
89422404|NCT04904744|Active Comparator|Low tailored message|2 text or phone reminders that child is overdue for well child check visit
89422405|NCT04904744|Active Comparator|Low tailored message plus COVID-19 vaccine message|2 text or phone reminders that child is overdue for well child check visit AND COVID-19 vaccine is available
89422406|NCT04975282||Bottle Feeding|The bottle feeding method was being used in the NICU (1 January -31 December 2018).
88903237|NCT01531972|Experimental|SEP-228432 (Cohort 2)|Subjects will receive 40 mg of SEP-228432 (titration) orally once per day for 3 days followed by a dose (TBD) of SEP 228432 ≤ 300mg, orally once per day for 5 days.
88903238|NCT01531972|Experimental|SEP-228432 (Cohort 3)|Subjects will receive 40 mg of SEP-228432 (titration) 40 mg of SEP 228432 orally once per day for 3 days followed by a dose (TBD) of SEP 228432 ≤ 300mg, orally once per day for 5 days.
88903239|NCT01532011|Experimental|Erlotinib + Pralatrexate|"Dose escalation group starting dose: Erlotinib 75 mg by mouth daily for a 28 day cycle. Starting dose of Pralatrexate 15 mg/m2 by vein on days 1, 8, and 15 of a 28 day cycle.~Dose expansion group starting dose: Maximum tolerated dose (MTD) from dose escalation group."
88903240|NCT01532024|Experimental|Healthy Volunteers|Delivery of intrapulmonary NAP Dose escalation from 5 mcgs to 80mcgs
88903241|NCT01532024|Experimental|Pulmonary Infiltrate in ICU|Delivery of NAP (80mcgs) to ventilated patients with pulmonary infiltrates
88903242|NCT01532024|Experimental|Patients with Bronchiectasis|Delivery of NAP (80mcgs) to patients with bronchiectasis
88903243|NCT01532037|Experimental|Guided Self Help|Participant receives usual care and 4, 45 minute sessions with a therapist to support them to complete the cognitive behavioural therapy based workbook for fatigue in Multiple Sclerosis.
88903244|NCT01532037|Experimental|Pure Self Help|Participant receives usual care and cognitive behavioural therapy based self help work book for fatigue in multiple sclerosis to complete alone
88903245|NCT01532037|Placebo Comparator|Treatment as Usual|Participants receive usual care from healthcare professionals
88903246|NCT01532050|Other|Mandibular Advancement Device (MAD)|Mandibular Advancement Device (MAD)
88903247|NCT01532063|Other|INTUBATION|Subjects intubed in Intensive Care Unit
89195127|NCT01038115|Active Comparator|Radiofrequency|
89195128|NCT01038115|Active Comparator|Cryoballoon + Radiofrequency together|
89195129|NCT00645099|Experimental|001|paliperidone ER 6-mg or 9-mg tablet once daily flexible dosing for 6 months
89422407|NCT04975282||Cup Feeding|The cup feeding method was being used in the NICU (1 January -31 December 2019).
89422408|NCT03109574|Other|Standard of Care Device|Current standard of care polyurethane catheter used at the hospital
89422409|NCT03109574|Other|Study Device|BioFlo DuraMax Chronic Hemodialysis Catheter
89195130|NCT00645099|Active Comparator|002|olanzapine 10-15 mg (using 5-mg or 10-mg tablets) once daily flexible dosing for 6 months
89195131|NCT04401982||Glaucoma Suspect|Individuals with a diagnosis of glaucoma suspect
89422410|NCT04911712|Active Comparator|Randomly selected malnourished patients for normal protein liquid diet supplementation|Randomly selected malnourished patients for normal protein liquid diet supplementation
88903248|NCT01532076|Experimental|cellularized composite graft augmentation|lipoaspiration by experienced plastic surgeon, isolation of SVF cells using a Cellution/CR800® cell isolation device and single use kits (Cytori Therapeutics Inc., San Diego) during open reduction and internal fixation, augmentation of bone with cell-seeded bone graft substitute;
88903249|NCT01532076|Active Comparator|Control acellular composite graft augmentation|open reduction internal fixation (ORIF) of the fracture, augmentation with acellular bone graft substitute.
88903250|NCT01532102|Experimental|AP611074 5% gel|Twice daily application of 100 mg dose of AP611074 5% gel for 41 days followed by a single morning application on Day 42
88903251|NCT01532102|Placebo Comparator|Placebo gel|Twice daily application of 100 mg dose of placebo gel for 41 days followed by a single morning application on Day 42
88903252|NCT01532115|Experimental|BIA 9-1067|
88903253|NCT01532115|Placebo Comparator|Placebo|
88903254|NCT01532115|Active Comparator|moxifloxacin|
88903255|NCT01532180|Experimental|THN Therapy|
88903256|NCT01532193|Experimental|Hipoxia|The low oxygen tension group
88903257|NCT01532193|No Intervention|Control group|Conventional culture conditions
89422411|NCT04911712|Experimental|Randomly selected Malnourished patients with high protein liquid diet supplementation|Malnourished patients with high protein liquid diet supplementation
89422412|NCT03469466||untrained|Volunteers untrained in bedside ultrasound technique
89422413|NCT03469466||trained|Volunteers previously trained and experienced in bedside ultrasound technique
89422414|NCT03469466||healthy volunteer|Standardized patient who will undergo ultrasound study
88903258|NCT01532206|Experimental|Remote ischemic preconditioning|Remote ischemic preconditioning performed with Blood pressure cuff insufflation
88903259|NCT01532206|No Intervention|Standard of care|Standard of care
88903260|NCT01532219|Experimental|Internet-delivered Psychodynamic Treatment|Participants in the experimental condition will receive 8 text-modules delivered as guided self-help, via the Internet. The intervention lasts for 10 weeks and includes weekly contacts with a therapist via a secure online environment similar to e-mail. The treatment is a short-term psychodynamic treatment psychodynamic treatment.
88903261|NCT01532219|Active Comparator|Internet-delivered structured support|Participants in the active control condition will receive a structured support treatment via the Internet. The intervention lasts for 10 weeks and includes weekly contacts with a therapist via a secure online environment similar to e-mail.
89422415|NCT04975126|Experimental|CatInfo tool + Face-to-face discussion with physician|audio-visual presentation (CatInfo tool) before face-to-face informed-consent discussion with the physician
89422416|NCT04975126|No Intervention|Face-to-face discussion with physician only|face-to-face informed-consent discussion with the physician only
89422417|NCT04316156|Experimental|Exercise using Uincare Homeplus|Uincare Homeplus
89422418|NCT04316156|Active Comparator|Exercise using brochure|brochure
88903262|NCT01532232||placebo|This is a randomized, double-blind, placebo-controlled trial comparing the effectiveness and tolerability of varenicline with placebo for smoking cessation in 30 tobacco dependent breast cancer patients.
88903263|NCT01532232||varenicline|This is a randomized, double-blind, placebo-controlled trial comparing the effectiveness and tolerability of varenicline with placebo for smoking cessation in 30 tobacco dependent breast cancer patients.
88903264|NCT01532245|Active Comparator|two-lung ventilation (TLV)|During two-lung ventilation (TLV) and OLV 8 ml•kg-1 tidal volume was used.
89422419|NCT03061864|No Intervention|Standard Counseling|Patients at risk of delivery between 20 and 25+6 weeks gestation will receive the normal counseling from Ob/gyn and Neonatology.
89422420|NCT03061864|Experimental|Periviable Birth Plan|Patients at risk of delivery between 20 and 25+6 weeks gestation will receive the normal counseling from Ob/gyn and Neonatology with completion of the written periviable birth plan.
89422421|NCT05160818|Active Comparator|Arm A: HSFRT|Hypofractionated stereotactic radiotherapy to the resection cavity, dose prescription: 6-7 x 5 Gy
89422422|NCT05160818|Active Comparator|Arm B: SRS|Single fraction stereotactic radiotherapy to the resection cavity, dose prescription: 1 x 12-20 Gy
89422423|NCT04915222|Experimental|Natural apophyseal glides|This group receives natural apophyseal glides along with conventional physical therapy and manual techniques as treatment for 3 sessions per week on alternate days for 3 weeks
89422424|NCT04915222|Active Comparator|Cervical manual traction|This group receives cervical manual traction along with conventional physical therapy and manual techniques as treatment for 3 sessions per week on alternate days for 3 weeks
89422425|NCT04911556|Placebo Comparator|the placebo group|A placebo made of starch
88903265|NCT01532245|Active Comparator|one lung ventillation (OLV) without PEEP|During OLV, ventilation periods of ten minutes, with and without 5 cmH2O positive end-expiratory pressure (PEEP) were alternated.
89422426|NCT04911556|Experimental|Bifidobacterium longum group 1|Bifidobacterium longum 274
89422427|NCT04911556|Experimental|Bifidobacterium longum group 2|Bifidobacterium longum 4-1
89422428|NCT04911556|Experimental|Bifidobacterium longum group 3|Bifidobacterium longum gs
89422429|NCT03470324|Active Comparator|[standard STN] + swallowing therapy|standard stimulation on subthalamic (STN) contacts plus swallowing therapy
89422430|NCT03470324|Experimental|[STN+SNr] + swallowing therapy|Combined stimulation of the subthalamic nucleus (STN) and the substantia nigra pars reticulata (SNr) plus swallowing therapy
89422431|NCT03470246|No Intervention|CABG control group|The group of coronary artery disease patients receiving the standard postoperative rehabilitation of Kuopio and Turku university hospitals after coronary artery bypass grafting. The post-operative rehabilitation includes written and oral physical activity guidance from a physiotherapist.
89422432|NCT03470246|Experimental|PACO intervention for CABG patients|The group of coronary artery disease patients receiving the PACO intervention for CABG patients besides the standard postoperative rehabilitation of Kuopio and Turku university hospitals after coronary artery bypass grafting. The PACO intervention includes activity guidance (i.e. goals to improve daily steps and physical activity levels, and reduce prolonged sitting) provided to the patients with the novel combination of ExSed application, MoveSense accelerometer and cloud system. In addition, exercise guidance (short video files) and regular mobile phone contacts from physiotherapist will be included to the intervention.
88903266|NCT01532245|Active Comparator|one lung ventilation (OLV) with PEEP|During OLV, ventilation periods of ten minutes, with and without 5 cmH2Opositive end-expiratory pressure (PEEP) were alternated
89422433|NCT03470246|No Intervention|AVR control group|The group of aortic valve stenosis patients receiving the standard postoperative rehabilitation of Kuopio and Turku university hospitals after aortic valve replacement. The post-operative rehabilitation includes written and oral physical activity guidance from a physiotherapist.
89422434|NCT03470246|Experimental|PACO intervention for AVR patients|The group of aortic valve stenosis patients receiving the PACO intervention for AVR patients besides the standard postoperative rehabilitation of Kuopio and Turku university hospitals after aortic valve replacement. The PACO intervention includes activity guidance (i.e. goals to improve daily steps and physical activity levels, and reduce prolonged sitting) provided to the patients with the novel combination of ExSed application, MoveSense accelerometer and cloud system. In addition, exercise guidance (short video files) and regular mobile phone contacts from physiotherapist will be included to the intervention.
89422435|NCT03470246|No Intervention|MVR control group|The group of mitral valve insufficiency patients receiving the standard postoperative rehabilitation of Kuopio and Turku university hospitals after mitral valve repair. The post-operative rehabilitation includes written and oral physical activity guidance from a physiotherapist.
88903267|NCT01532271||Concussed|Patients with recent concussion
88903268|NCT01532271||Matched controls|Athletes with no recent concussion
88903269|NCT01532284|Experimental|Polar Body Biopsy|PB biopsy (PBB) will be performed between 9 and 12 hours after ICSI using laser or the mechanical procedure. PB1 and PB2 will be removed simultaneously (both at the same time) and transferred to different tubes for the chromosomal analysis.
88903270|NCT01532284|No Intervention|No Polar Body Biopsy|
88903271|NCT01532297|Active Comparator|HD treated with standard dialysate|
88903272|NCT01532297|Active Comparator|post-dilution oHDF with standard dialysate|
88903273|NCT01532297|Experimental|pre-dilution oHDF with citrate dialysate|
88903274|NCT01532297|Experimental|HD treated with citrate dialysate|
88903275|NCT01532297|Experimental|post-dilution oHDF with citrate dialysate|
88903276|NCT01532297|Active Comparator|pre-dilution oHDF with standard dialysate|
88903277|NCT01532323|Experimental|Oral disorder children|Oral disorder children aged 2 to 15 years
88903278|NCT01532323|Active Comparator|Control group|No oral disorder children aged 2 to 15 years
88903279|NCT01532336|Experimental|NVC-422 Solution, 0.3%|Dosed for 10 days
88903280|NCT01532336|Placebo Comparator|NVC-422 Vehicle Solution|Dosed for 10 days
88903281|NCT01532375|Experimental|Kochujang(32g)|
88903282|NCT01532375|Placebo Comparator|placebo(32g)|
88903283|NCT01532401|Experimental|chlorure de sodium|
88903284|NCT01532401|Placebo Comparator|Methylcellulose|
88903285|NCT01532466|Experimental|Rocuronium, fentanyl-induced cough, normal saline|All patients were given oxygen via a face mask. The patients were then administered with the following medications intravenously: the rocuronium group received rocuronium 0.06 mg kg-1 30 s before the injection of an IV fentanyl bolus (1.5 mcg kg-1, within 2 s).
88903286|NCT01532466|No Intervention|Normal saline|All patients were given oxygen via a face mask. The patients were then administered with the following medications intravenously: the control group received the same volume of normal saline 30 s before the injection of an IV fentanyl bolus (1.5 mcg kg-1, within 2 s).
88903287|NCT01532479||Treatment Group|Subjects with ORN treated with Hyperbaric Oxygen Therapy
88903288|NCT01532479||Postive Control Group|Subjects treated with Hyperbaric Oxygen Therapy that have not had head or neck radiation therapy
88903289|NCT01532479||Negative Control Group|Subjects who have had head and neck radiation that have not had Hyperbaric Oxygen Therapy
88903290|NCT01532492||Rotator cuff repair group|Patients undergoing an arthroscopic rotator cuff repair
88903291|NCT01532492||DRC without rupture|Disorders of the rotator cuff without rupture
88903292|NCT01532492||Shoulder instability|Shoulder instability
88903293|NCT01532531|Experimental|Collateral Meridian Therapy|"The CMT group patients received, according to the CMT protocol described previously, CMT at the selected points with the CMT Electrotherapy Stimulator (GEMORE Multi-Function Electrotherapy Stimulator; GM390TE, GEMORE Co Ltd, Taiwan) to treat the affected OA knee. The 6-minute treatment (electrotherapy was set at 40 Hz biphasic and 30 mA) comprises reduction and enhancement procedures on the specific points. Each patient received CMT twice per week for three weeks during the study."
88903294|NCT01532531|No Intervention|Control (CT) group|Patients in the CT group received electronic lead-patches applied on the treatment points, which was identical to what the CMT patients received, also for 6 minutes, though no electric stimulation was applied.
88903295|NCT01532544|Experimental|Integrilin and Ilomedin given as continous infusion|
88903296|NCT01532544|Placebo Comparator|Standard treatment daily doses of low molecular weight heparin|Standard treatment daily doses of low molecular weight heparin.
88903297|NCT01532583||Patients operated on with the TOT|
88903298|NCT01532596|Experimental|Mindfulness-Based Stress Reduction|A standardized 8-week mindfulness meditation training program
88903299|NCT01532596|No Intervention|Wait-List|
88903300|NCT01532622|Active Comparator|Blueberry Powder|Patients will take 30 grams of blueberry powder daily for up to 30 days.
88903301|NCT01532622|Placebo Comparator|Placebo Powder|Patients will take 30 grams of placebo powder daily for up to 30 days.
88903302|NCT01532661||observational study|haemorrhagic trauma received rFVIIa
88903303|NCT01532674|Experimental|Antimicrobial photodynamic therapy|Antimicrobial photodynamic therapy and scaling and root planing
88903304|NCT01532674|Active Comparator|scaling and root planing|Only scaling and root planing
88903305|NCT01532713|Experimental|non-block side|
88903306|NCT01532726||Eslicarbazepine Acetate (ESL)|ESL and concomitant medication should be managed by the neurologist according to the respective SPC.Summary of Product Characteristics
88903307|NCT01532739|Experimental|Cognitive training|
89195132|NCT01038271|Active Comparator|Standard Palliative Care Group|
89195133|NCT01038271|Active Comparator|Integrated Palliative Care Group|
89195134|NCT00889954|Experimental|TGFBeta resistant HER2/EBV-CTLs|"The following dose levels will be evaluated:~Dose Level 1: 1 x 10^4 cells/m^2~Dose Level 2: 3 x 10^4 cells/m^2~Dose Level 5: 1 x 10^6 cells/m^2~Dose Level 6: 3 x 10^6 cells/m^2~Dose Level 7: 1 x 10^7 cells/m^2~Dose Level 8: 3 x 10^7 cells/m^2~Dose Level 9:1 x 10^8 cells/m^2"
89195135|NCT00887770|Experimental|A|600mg AZD5672 + Moxifloxacin placebo
88903308|NCT01532739|No Intervention|No cognitive training|
88903309|NCT01532765|Active Comparator|Epiretinal Membrane Surgery without ILM peel|
88903310|NCT01532765|Active Comparator|Epiretinal Membrane Surgery with ILM peel (ICG assisted)|
88903311|NCT01532765|Active Comparator|Combined CE & IOL and ERM surgery without ILM peel|
88903312|NCT01532765|Active Comparator|Combined CE & IOL and ERM surgery with ILM peel (ICG assisted)|
89195136|NCT00887770|Experimental|B|100mg AZD5672 + Moxifloxacin placebo
88903313|NCT01532804|Experimental|Arm A|FOLFOX6 + bevacizumab (D1=D15, 12 cycles)
88903314|NCT01532804|Experimental|Arm B|Raltitrexed + Oxaliplatin + Bevacizumab (D1=D21, 8 cycles)
88903315|NCT01532843|Active Comparator|PegIFN alfa-2b + nucleos(t)ide analogue|Peginterferon alfa-2b 1.5 μg/kg per week s.c. for 48 weeks in addition to standard nucleos(t)ide analogue treatment
88903316|NCT01532843|No Intervention|Nucleos(t)ide analogue|Continuation of Nucleos(t)ide analogue mono-therapy
88903317|NCT01532856|Active Comparator|Group A induction therapy|Thalidomide + Cyclophosphamide + Dexamethasone
88903318|NCT01532856|Active Comparator|Group B induction therapy|thalidomide + dexamethasone
88903319|NCT01532856|Active Comparator|Group C induction therapy|thalidomide + melphalan + prednisone
88903320|NCT01532882|Experimental|Diosmin|
88903321|NCT01532882|Placebo Comparator|Placebo|
88903322|NCT01532895||Hydromorphone HCI OROS|
88903323|NCT01532947|Experimental|post restoration|
88903324|NCT01532947|No Intervention|no post restoration|no post placement
88903325|NCT01532960|Experimental|9 Peptides from Her-2/neu, CEA, & CTA, peptide-tet, poly-ICLC|9 class I MHC-restricted synthetic peptides (100 mcg each peptide) derived from breast cancer associated proteins, a class II MHC-restricted tetanus derived peptide (200 mcg), plus polyICLC (1 mg).
89195137|NCT00887770|Active Comparator|C|AZD5672 placebo + Moxifloxacin 400mg
89195138|NCT00887770|Placebo Comparator|D|AZD5672 placebo + Moxifloxacin placebo
89195139|NCT01038505|Active Comparator|Tacrolimus and Myfortic|Immunosuppressive
89195140|NCT01038505|Active Comparator|Tacrolimus and Sirolimus|Immunosuppressive
89195141|NCT00890032|Experimental|BTSC mRNA-loaded DCs|BTSC mRNA-loaded DCs administered intradermally weekly for first 3 vaccines, then monthly until progression or withdrawal.
89195142|NCT01038583||Aspirin|100 mg enteric-coated aspirin
89195143|NCT01038583||Placebo|Placebo
89195144|NCT02551107|Experimental|Congenital heart disease|"Inclusion criteria: All participants, less than one year of age, with CHD will be eligible for this study with the exception of those patients with only patent foramen ovale (PFO) and patent ductus arteriosus (PDA). The diagnosis of CHD will be confirmed by echocardiography.~Exclusion criteria: Participants with only PDA or PFO, without written informed consent, patients older than one year of age or any subject on oxygen at the time of nNO assessment."
89195145|NCT02551107|Active Comparator|Controls|The control group will consist of age matched infants, less than one year of age, without CHD or acute respiratory illness. The participants will also require written informed consent and will have to be breathing room air at the time of the nNO test.
88903326|NCT01533012|Experimental|Pressure difference|Peak inspiratory pressures difference between two lungs
88903327|NCT01533012|No Intervention|FOB evaluation|FOB evaluation for the optimal position of tubes
88903328|NCT01533025|Active Comparator|bone-tendon Achilles allograft group|the group which underwent anterior cruciate ligament reconstruction using bone-tendon Achilles allograft
88903329|NCT01533025|Active Comparator|free tendon Achilles allogarft group|the group which underwent anterior cruciate ligament reconstruction using free tendon Achilles allograft
88903330|NCT01533051||Chronic hepatitis B|
88903331|NCT01533064||Psychiatric Outpatients|
88903332|NCT01533090|Active Comparator|polyethylene glycol (PEG)|
88903333|NCT01533090|Experimental|PEG low volume with bisacodyl|
88903334|NCT01533129|Active Comparator|Daily testosterone transdermal gel|
88903335|NCT01533129|Active Comparator|Injectable Testosterone esters|Testosteron 250mg injection per 3-4 weeks for 6 months
88903336|NCT01533142||surgical methods|Different methods are used among hospitals in Helse-Vest, and this allows us to compare different clinical and biological effects following bariatric surgery different methods) among a homogeneous population in the western part of Norway (Vestlandet
88903337|NCT01533142||Morbid obesity|
88903338|NCT01533155|Active Comparator|NKTR-118/ Quinidine|One 25-mg NKTR-118 tablet will be administered once with 3 Quinidine 200mg tablets in the morning of period 1 or period 2 (part 1)
88903339|NCT01533155|Placebo Comparator|NKTR-118/ Placebo|One 25-mg NKTR-118 tablet will be administered once with 3 Placebo tablets in the morning of period 1 or period 2 (part 1)
88903340|NCT01533155|Active Comparator|NKTR-118/ Quinidine/ Morphine|One 25-mg NKTR-118 tablet will be administered with 3 Quinidine 200mg tablets with Morphine inj 5mg/70kg once in the morning on period 3 or period 4 (Part 2)
88903341|NCT01533155|Placebo Comparator|NKTR-118/ Placebo/ Morphine|One 25-mg NKTR-118 tablet will be administered with 3 placebo tables with Morphine inj 5mg/70kg once in the morning of period 3 or period 4 (part 2)
88903342|NCT01533194|Experimental|Treatment (wild-type reovirus)|Patients receive wild-type reovirus IV over 60 minutes on days 1-5. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
88903343|NCT01533220|Experimental|Test group|"Naphazoline Hydrocloride (1.0mg) + Pheniramine Maleate (0.2mg) + Panthenol(5.0mg).~02 drops in each nostril every 12 hours for 3 days"
88903344|NCT01533220|Active Comparator|Comparator group|"Naphazoline Hydrocloride (0.5mg)~02 drops in each nostril every 12 hours for 3 days"
88903345|NCT01533233|Experimental|nonintubated anesthesia|Thoracoscopic lobectomy using nonintubated anesthesia
88903346|NCT01533233|Active Comparator|intubated general anesthesia|Thoracoscopic lobectomy using intubated general anesthesia
88903347|NCT01533272|Experimental|Tenofovir, emtricitabine, Maraviroc|New postexposure prophylaxis (it is a combination drug)
88903348|NCT01533272|Active Comparator|Tenofovir, emtricitabine, lopinavir/r|Standard prophylaxis (it is a combination drug)
88903349|NCT01533285|Other|Group 1|Treatment AB: Treatment A (Placebo vaccination) administered [Period 1], after the washout period (7-14 days) Treatment B (typhoid vaccination) administered [Period 2]
88903350|NCT01533285|Other|Group 2|Treatment BA: Treatment B (typhoid vaccination) administered [Period 1], after the washout period (7-14 days) Treatment A (Placebo vaccination) administered [Period 2]
88903351|NCT01533285|Other|Group 3|Treatment AC: Treatment A (Placebo vaccination) administered [Period 1], after the washout period (7-14 days) Treatment C (TSST+Placebo vaccination) administered [Period 2]
88903352|NCT01533285|Other|Group 4|Treatment CA: Treatment C (TSST+Placebo vaccination) administered [Period 1], after the washout period (7-14 days) Treatment A (Placebo vaccination) administered [Period 2]
88903353|NCT01533285|Other|Group 5|Treatment AD:Treatment A (Placebo vaccination) administered [Period 1], after the washout period (7-14 days) Treatment D (TSST+typhoid vaccination) administered [Period 2]
88903354|NCT01533285|Other|Group 6|Treatment DA:Treatment D (TSST+typhoid vaccination) administered [Period 1], after the washout period (7-14 days) Treatment A (Placebo vaccination) administered [Period 2]
88903355|NCT01533298|Experimental|CombiflexOmega peri|
88903356|NCT01533298|Active Comparator|SmofKabiven peripheral|
88903357|NCT01533324|Experimental|S-1 combined with LV|S-1 combined with LV
88903358|NCT01533350||group1|women with a ultrasonographic homogeneous echo endometrium in the late follicle phase
88903359|NCT01533350||group2|"women with a ultrasonographic  triple-line endometrium in the late follicle phase"
88903360|NCT01533363|Active Comparator|Stapled hemorrhoidopexy|surgical procedure to treat hemorrhoids
88903361|NCT01533363|Active Comparator|Milligan Morgan|surgical procedure to treat hemorrhoids
88903362|NCT01533376|Experimental|Timolol|Participants in this group will receive topical timolol
88903363|NCT01533376|Placebo Comparator|Placebo|Participants in this group will receive Preservative free artificial tear gel.
88903364|NCT01533389|Experimental|Silodosin|8mg QD
88903365|NCT01533389|Placebo Comparator|Placebo|8mg QD
88903366|NCT01533402|Placebo Comparator|Attention control|Weekly support from therapist without CBT-interventions
88903367|NCT01533402|Experimental|Internet CBT|Internet-delivered cognitive behavioural therapy with therapy support
88903368|NCT01533415|Active Comparator|Active CES treatment|Out of the total population of 150 participants,75 of them will be assigned to the active treatment group. Because this is a double-blind study it is unknown which members will belong to this group until completion of the study.
88903369|NCT01533415|Sham Comparator|Sham CES treatment|Of the 150 participants in this study, half of them will be assigned to the sham treatment group. Because this is a double-blind study, it is unknown which members will be assigned to this group until the completion of the study.
88903370|NCT01533441|Placebo Comparator|placebo low VKA|
88903371|NCT01533441|Placebo Comparator|Placebo high VKA|Microcrystalline cellulose
88903372|NCT01533441|Active Comparator|Vitamin K2 Low VKA|
88903373|NCT01533441|Active Comparator|Vitamin K2 high VKA|
88903374|NCT01533454|No Intervention|Control|Control participants will attend a 4-month structured weight-loss program and attend subsequent follow-ups at 4-month intervals upon completion of the program.
89422436|NCT03470246|Experimental|PACO intervention for MVR patients|The group of mitral valve insufficiency patients receiving the PACO intervention for MVR patients besides the standard postoperative rehabilitation of Kuopio and Turku university hospitals after mitral valve repair. The PACO intervention includes activity guidance (i.e. goals to improve daily steps and physical activity levels, and reduce prolonged sitting) provided to the patients with the novel combination of ExSed application, MoveSense accelerometer and cloud system. In addition, exercise guidance (short video files) and regular mobile phone contacts from physiotherapist will be included to the intervention.
89422437|NCT04911010|Experimental|Experimental: Prolonged Exposure + Treatment as usual|"Participants in this arm will receive 16 weekly sessions with Prolonged Exposure Therapy (RT) over 4 months in addition to their treatment as usual.~Interventions:~Behavioral: Prolonged Exposure Therapy Other: Treatment as usual"
89422438|NCT04911010|No Intervention|Waiting-Controll-Group|"Treatment as usual Treatment as usual will include medication management, supportive brief counselling sessions and various types of psychosocial (e.g. social work guided support, peer support) and monitoring provided by Mental Health Services, with individual and family psychological therapies offered occasionally.~Intervention: Other: Treatment as usual"
89422439|NCT03998540||Patients with myopathy suspected of titinopathy|Patients with myopathy in which one or more potentially pathogenic TTN variants have been previously identified (index cases and related cases affected). Muscle biopsy performed previously
89422440|NCT03782636|Experimental|Aldesleukin|Ultra-low dose aldesleukin injected subcutaneously, at a dose of 0.2 x 106 IU/m2 twice-weekly , three days apart, for 6 months.
89422441|NCT03782636|Placebo Comparator|Placebo|Placebo sc, at a similar dose (expressed in ml) to the active drug
89422442|NCT04911244|Experimental|VAP group|patients confirmed diagnosis of VAP with bronchoalveolar lavage
89422443|NCT04911244|Experimental|Non VAP group|patients confirmed not VAP with bronchoalveolar lavage
89422444|NCT04910620|Placebo Comparator|Placebo|Placebo without TCI378 and TCI507
89422445|NCT04910620|Experimental|TCI378|probiotics TCI378 (Lactobacillus plantarum TCI378)
89422446|NCT04910620|Experimental|TCI507|TCI507 (Lactobacillus plantarum TCI507)
89422447|NCT03761810|Experimental|S6G5T-3|Participants will topically apply S6G5T-3 cream, once daily to face for 12 weeks
89422448|NCT03761810|Placebo Comparator|S6G5T-8 Vehicle Cream|Participants will topically apply S6G5T-8 vehicle cream, once daily to face for 12 weeks.
89422449|NCT04915456|Experimental|Systemic steroid (Prednisolone)|Prednisolone 50mg (tapered down until postoperative day (POD) 14, then 5mg for 14 days), tablets
89422450|NCT04915456|Placebo Comparator|Placebo|Lactose monohydrate, tablets
89422451|NCT04575740|Experimental|Positive Airway Pressure Device|All participants will receive PAP therapy
89422452|NCT04853836|Placebo Comparator|Rehabilitation therapy only (control group)|Olfactory training / stimulation through Sniffin' Sticks, administered twice every day (10 minutes session)
89422453|NCT04853836|Active Comparator|Rehabilitation and treatment with PEA-LUT|Olfactory training / stimulation through Sniffin' Sticks, plus daily treatment with PEA/Luteolin oral supplement
89422454|NCT04853836|Active Comparator|Treatment with PEA-LUT one sachet daily|Patients in this group only used a single dose of PEA-LUT
89422455|NCT04853836|Active Comparator|Treatment with PEA-LUT two sachet daily|Patients in this group only used two doses of PEA-LUT
89195146|NCT02541682|Other|Control|Participants who have PUQE ( Pregnancy Unique Quantification of Emesis scoring index) score equal to 3 and showing no symptom of nausea and/or vomiting during the three control visits. Control visits are performed a month apart.
89422456|NCT04498130|Experimental|12-Week Home Exercise Group|The 12-week theory-based physical activity intervention will involve mailing participants an exercise manual with health and exercise information (i.e. information about exercising safely, modules related to the social cognitive theory, weekly goal setting worksheets, exercise-tracking logs, etc.), a resistance band, and a standard Omron pedometer. Participants will receive a weekly 30-minute Zoom--based group meetings to discuss different strategies to begin and maintain a consistent exercise routine and access to a social media page to facilitate social support and interaction among the group participants. Participants will be able to join the group if they would like, but it will not be required. Participants will be encouraged to connect with each other to promote social support and social modeling. Lastly participants will receive a weekly exercise video to follow along with on their own time and tailored weekly step goals.
88903375|NCT01533454|Experimental|Incentives|Incentive arm participants will be offered an additional program (in addition to the COMM program) where they can earn incentives for meeting specified weight loss targets or step goals. They will be offered a choice between traditional (payments with certainty) and behavioral(payments paid via lottery) incentives.
88903376|NCT01533467|Other|Perineal device used|Use of the perineal device during delivery
88903377|NCT01533467|No Intervention|No intervention|Controls, delivered as normal
88903378|NCT01533480|Active Comparator|Zirgan, Adenovirus conjunctivitis,|Zirgan
88903379|NCT01533480|Placebo Comparator|genteal gel|0.3% Hypromellose gel (genteal gel)
88903380|NCT01533519|Experimental|NPY/placebo|This arm gets NPY first then placebo (saline). The placebo is 0.9% USP-grade saline without NPY.
88903381|NCT01533519|Experimental|placebo/NPY|This arm gets placebo (saline) first then NPY.
88903382|NCT01533532|Experimental|KLH-2109, low dose|
88903383|NCT01533532|Experimental|KLH-2109, medium dose|
88903384|NCT01533532|Experimental|KLH-2109, high dose|
88903385|NCT01533532|Placebo Comparator|placebo|
88903386|NCT01533545|Active Comparator|Plain mepivacaine|
88903387|NCT01533545|Active Comparator|Mepivacaine with epinephrine|
88903388|NCT01533558||caspofungin|caspofungin dosing
88903389|NCT01533571|Active Comparator|Immediate implant + xenogenic graft|Treatment with immediate implant and GBR using xenogenic bone graft material
88903390|NCT01533571|Active Comparator|Immediate implant + allogenic graft|Treatment with immediate implant and GBR using allogenic bone graft material.
88903391|NCT01533623|Other|mandibular advancement device treatment|Patients diagnosed with sleep-disordered breathing that receive treatment with a titratable, duobloc mandibular advancement devices
88903392|NCT01533649|Experimental|A/R intervention|The A/R intervention will accommodate 10 study subjects who will participate in an epilepsy-specific counseling intervention.
88903393|NCT01533649|Experimental|Relaxation|The relaxation group will accommodate 10 study subjects who will participate in a condition unspecific supportive relaxation intervention.
88903394|NCT01533649|No Intervention|Usual care|10 Potential study subjects who are not interested in participating in either intervention will be asked to provide data as a usual care control group.
88903395|NCT01533662|Experimental|phenylephrine|patients more than 60 years receiving 100micrograms of phenylephrine infusion (2 groups 60-75 years and more than 75 years)
88903396|NCT01533662|Placebo Comparator|placebo|patients more than 60 years receiving saline infusion (2 groups 60-75 years and more than 75)
88903397|NCT01533675|Experimental|Hydrogen peroxide|
88903398|NCT01533675|Active Comparator|Saline|
88903399|NCT01533727|Experimental|Group A|Autologous CIK Transfusion plus Chemotherapy
88903400|NCT01533727|Active Comparator|Group B|chemotherapy alone
88903401|NCT01533766|Experimental|CombiflexOmega|
88903402|NCT01533766|Active Comparator|SmofKabiven|
88903403|NCT01533792|Experimental|Supra/subgingival therapy|The experimental group received supra and subgingival scaling associated with oral hygiene orientation (OHO)
88903404|NCT01533792|Active Comparator|Control group|Control group received only supragingival scaling with OHO too.
88903405|NCT01533805|Experimental|Pilates with stabilization|This group will do pilates exercises with a focus on control of segmental stabilization of the lumbar spine neutral.
88903406|NCT01533805|Active Comparator|Classic Pilates|This group will make Pilates exercises its focus is on mobilization exercises of the lumbar spine.
88903407|NCT01533818|Active Comparator|Amoxicillin|This is an active intervention
88903408|NCT01533818|Placebo Comparator|Sugar Syrup|
88903409|NCT01533844||Neonates|Neonates with CDAD
88903410|NCT01533857|Experimental|Black tea|black tea
88903411|NCT01533857|Placebo Comparator|placebo|
88903412|NCT01533870|Experimental|NKTR-118|Single dose NKTR-118 25 mg on Day 1 only
88903413|NCT01533870|Active Comparator|Rifampin|Rifampin 600 mg once daily on Days 4 to 12
88903414|NCT01533870|Active Comparator|Rifampin/ NKTR-118|Rifampin 600 mg plus NKTR-118 25 mg on Day 13
88903415|NCT01533896|No Intervention|Control|Parents and children in the control group received routine primary care during the well child visit.
88903416|NCT01533896|Experimental|Grow Nicely|Grow Nicely multimedia program.
88903417|NCT01533909||Cancer patients|As this is not an intervention study there is only one cohort. Patients that will be included and excluded are described in the eligibility section.
88903418|NCT01533961|Experimental|SCYX-7158|In each dose group (8 subjects) , 6 Healthy Volunteers receive SCYX-7158
88903419|NCT01533961|Placebo Comparator|Placebo of SCYX-7158|In each dose group (8 subjects) , 2 Healthy Volunteers receive placebo of SCYX-7158
88903420|NCT01533987|Experimental|Juice Plus|Juice Plus is the combination of Juice Plus+® Garden Blend, Juice Plus+® Orchard Blend and Juice Plus+® Vineyard Blend.
88903421|NCT01533987|Placebo Comparator|Placebo|The placebo consists of microcrystalline cellulose,dicalcium phosphate, magnesium stearate, and FD & C yellow #6.
88903422|NCT01534000|Active Comparator|CT guided group|For Patients with chest pain randomised to this arm, clinical decision will be based on the results of a Cardiac computed tomographic angiography (CCTA)
88903423|NCT01534000|No Intervention|Control group|Patients with chest pain randomised to the control group will be evaluated using the standard functional-based strategy with either a treadmill stress-test or SPECT (single-photon emission computed tomography). A Cardiac CT will will be performed, but will be blinded for initial clinical evaluation.
88903424|NCT01534026|Active Comparator|Aspirin|Current dose of aspirin for 12 weeks
88903425|NCT01534026|Experimental|Withdrawal arm|Withdrawal of aspirin for 12 weeks
88903426|NCT01534039|Active Comparator|Sur-Fit Natura/FormaFlex|Subject will be on Surfit Moldable for 2 weeks then crossover to Formaflex
88903427|NCT01534039|Active Comparator|FormaFlex/Sur-Fit Natura|Subject will be on Formaflex for 2 weeks then crossover to Surfit Moldable
88903428|NCT01534091|Active Comparator|Pedometer with supervision|Participants will get pedometers to evaluate their daily PA. The sport center stuff will review the child weekly reports, guide the child, encourage him and supervise that the recommended PA level is achieved.
88903429|NCT01534091|Active Comparator|Pedometer without supervision|Participants will get pedometers to evaluate their daily PA. The sport center stuff won't give any recommendation or supervision for PA level.
88903430|NCT01534091|No Intervention|Control group|Overweight & obese children not participating in an intervention.
88903431|NCT01534117|Active Comparator|Platelets/DDAVP|Fall on ASA/Plavix that sustained head trauma requiring administration of platelets and/or DDAVP
88903432|NCT01534117|No Intervention|No Platelets|Those that sustain head trauma NOT requiring platelet transfusion. The investigators are evaluating platelet function in those not requiring platelet transfusion
88903433|NCT01534130|Experimental|acupuncture|
88903434|NCT01534130|Sham Comparator|sham acupuncture|
88903435|NCT01534169|Experimental|Isotonic Na chloride|The treatment strategy is the same with intervention, only the drug (dexamethasone) will be changed to isotonic Na chloride.
88903436|NCT01534221|Active Comparator|Study group two|Endeavor resolute drug eluting stent
88903437|NCT01534221|Active Comparator|Study group three|The precise selection of brand name depends on negotiations with suppliers and may change during the study period
88903438|NCT01534221|Active Comparator|Study group four|The precise selection of brand name depends on negotiations with suppliers and may change during the study period
88903439|NCT01534221|Active Comparator|Study group five|The precise selection of brand name depends on negotiations with suppliers and may change during the study period
88903440|NCT01534221|Active Comparator|Study group one|The precise selection of brand name depends on negotiations with suppliers and may change during the study period
88903441|NCT01534234|Experimental|SonR group|SonR CRT Optimization
88903442|NCT01534234|Active Comparator|ECHO group|Echocardiographic Optimization
88903443|NCT01534247|Experimental|CAZAVI|CAZ-AVI (2000 mg ceftazidime/500 mg avibactam)
88903444|NCT01534247|Active Comparator|Metronidazole|Metronidazole (500 mg)
88903445|NCT01534247|Active Comparator|CAZAVI+metronidazole|CAZ-AVI (2000mg ceftazidime/500 mg avibactam) + metronidazole (500 mg)
88903446|NCT01534286|Active Comparator|Theramine|Theramine 2 capsules three times per day in addition to post surgical analgesic medication.
88903447|NCT01534286|Placebo Comparator|Theramine-like Placebo|Theramine-like placebo 2 capsules three times per day in addition to post surgical analgesic medication.
88903448|NCT01534312|Experimental|CGMP protein|Casein glycomacropeptide 30 gram/day, unchanged prophylactic 5ASA dose
88903449|NCT01534312|Active Comparator|Standard oral 5ASA maximal dose|Increase from prophylactic dose 5ASA (mesalazine) to maximal oral dose, i.e. 4800 grams of mesalazine (Asacol/Mezavant)
88903450|NCT01534325|Experimental|Study arm|The Arm who uses the real study device Daily use of SD device
88903451|NCT01534325|Sham Comparator|Control Arm|Daily use of Sham comperator
89422457|NCT04498130|Active Comparator|Educational Comparison Group|The education group participants will receive the same exercise manual, fitness items, exercise videos, and same weekly tailored step goal as the 12-week intervention group. This group will not have weekly zoom discussions, or be a part of the same social media page as the 12-week intervention group. Instead, the education group will be contacted by research staff once a week via telephone to discuss their manuals and activity for the week, and to ensure they have been safely engaging in exercise. A separate social media page will be created for this group, where pre-existing materials related to physical activity recommendations, benefits, other resources, and more will be shared.
89422458|NCT03469388|Experimental|elective EVAR patients|Elective EVAR patients will be included in one arm only
88903452|NCT01534325|Experimental|Staudy2 arm|Uses the under study device in a different time frames Daily use of SD device in a different time frames than of Study Arm
88903453|NCT01534338|Experimental|Mindfulness Meditation|The MAPs program is based on experiential training in mindfulness meditation offered at the UCLA Mindful Awareness Research Center (MARC). A certified UCLA instructor will provide didactic training in mindfulness meditation in a group-based setting. Participants will be guided through in-class meditation practices and will be assigned daily meditation homework. Active program components include sitting and walking somatosensory-focused meditation, audio-guided body scan meditation, and loving kindness meditation. Participants will attend weekly 2-hour classes for a total of 6 weeks and participants will monitor their sleep with a daily sleep diary. In addition to the MAPs training, sleep hygiene material will also be presented to match the sleep hygiene material in the sleep education condition.
89195147|NCT02541682|Other|Mild nausea and vomiting of pregnancy|Participants who have maximum PUQE ( Pregnancy Unique Quantification of Emesis scoring index) score equal to 4-6 during the three control visits. Control visits are performed a month apart.
89195148|NCT02541682|Other|Moderate nausea and vomiting of pregnancy|Participants who have maximum PUQE ( Pregnancy Unique Quantification of Emesis scoring index) score equal to 7-12 during the three control visits. Control visits are performed a month apart.
89422459|NCT04492904||COVID-19 Positive (Case)|Participants who were present for COVID-19 screening and their test results will later indicate positive of infection. Participants will complete a one-time assessment of the various online questionnaires (Singapore Smell and Test Questionnaire, Sino-nasal Outcome Test-22, and Global Consortium for Chemosensory Research Questionnaire - Optional) in the hospital/clinic. Taste and smell acuity, as well as experienced symptoms, changes in appetite and food-related quality of life will be assessed using the Home-use Tests and Follow-up questionnaire over a period of 28 days.
89422460|NCT04492904||COVID-19 Negative/Other respiratory diseases (Control)|Participants who were present for COVID-19 screening and their test results will later indicate negative of infection. Participants will complete a one-time assessment of the various online questionnaires (Singapore Smell and Test Questionnaire, Sino-nasal Outcome Test-22, and Global Consortium for Chemosensory Research Questionnaire - Optional) in the hospital/clinic. Taste and smell acuity, as well as experienced symptoms, changes in appetite and food-related quality of life will be assessed using the Home-use Tests and Follow-up questionnaire over a period of 28 days
88814893|NCT02982278|Experimental|CINGS Intervention|CINGS is a 12-week nurse coordinated, Community Health Worker (CHW) intervention structure. Registered Nurse (RN) developed After hospital care plan with home visits sessions will be conducted by the CHW and intermittent televideo RN interactions. After baseline assessment, participants randomized to the intervention group will have home visits, once a week for the first month, and biweekly during months two and three. follow up assessments at 3, 6, and 12-month intervals.
88814894|NCT02982278|Experimental|Control|Control group will receive usual care. Base line visit and follow up at 3, 6, and 12 months post stroke enrollment.
88814895|NCT03030248|Active Comparator|Vancomycin treated group|This group will be given vancomycin oral capsules, 125 mg, every 6 hours, for 14 days.
88814896|NCT03030248|Placebo Comparator|Placebo group|This group will be given placebo oral capsules every 6 hours for 14 days.
88814897|NCT03030014|Experimental|educational programm|"Oral health education will be done for children and their care givers about various diseases affecting the oral cavity, the effects of bad oral hygiene and tooth decay, importance of tooth brushing, and correct methods of tooth brushing.~Three follow up examination is assessed after one week, three weeks and six weeks using questionnaire for evaluation of participant satisfaction about oral health and using OHIS index for evaluating the effect of the dental educational program on the oral health status of deaf children."
89422461|NCT03469310|Experimental|Acetaminophen|Tylenol (also known as acetaminophen) 1000mg every 6 hours for 3 days and tramadol 50 mg every 6 hours as needed for moderate to severe pain
89422462|NCT03469310|Active Comparator|Codeine Acetaminophen|Tylenol #3 (codeine-acetaminophen) 1 tab every 4 hours or 2 tabs every 6 hours as needed for pain
89422463|NCT03469232|Experimental|Huanglian-Jiedu Decoction in acute pericoronitis|All eligible patients entering this group will receive Huanglian-Jiedu Decoction(prepared as granule). 1 bag per time and twice a day for 5 days.
89422464|NCT03469232|Experimental|Huanglian-Jiedu Decoction in recurrent aphthous stomatitis|All eligible patients entering this group will receive Huanglian-Jiedu Decoction(prepared as granule). 1 bag per time and twice a day for 5 days.
89422465|NCT03469232|Experimental|Huanglian-Jiedu Decoction in recurrent herpes simplex labialis|All eligible patients entering this group will receive Huanglian-Jiedu Decoction(prepared as granule). 1 bag per time and twice a day for 5 days.
89422466|NCT04904224|Active Comparator|PICE|Participants receive a panintestinal video capsule endoscopy (PICE)
89422467|NCT04904224|Active Comparator|Colonoscopy|Participants receive an (Ileo-)Colonoscopy
89422468|NCT03527186|Experimental|Risperidone ISM® 100 mg|A single intramuscular (IM) dose of 100 mg risperidone ISM® will be administered deeply into the gluteal muscle. A total of 4 IM doses will be given; each dose will be separated by 4 weeks
89422469|NCT05159882|Experimental|THR-1442 20mg|Each subject will receive THR-1442 20 mg and Dapagliflozin placebo, once daily for the duration of the study.
89422470|NCT05159882|Active Comparator|Dapagliflozin10mg|Each subject will receive Dapagliflozin 10 mg and THR-1442 placebo, once daily for the duration of the study.
89422471|NCT04910698||Short course treatment|Patients who received antibiotic for 7 or less days, except for nonfermenting bacteria and Staphylococcus aureus or lugdunensis for which the threshold was 10 days and 14 days, respectively.
89422472|NCT04910698||Long course treatment|Patients who received antibiotic for more than 7 days, except for nonfermenting bacteria and Staphylococcus aureus or lugdunensis for which the threshold was 10 days and 14 days, respectively.
89422473|NCT04461236|Experimental|Isoleucine|Type 2 Diabetics randomized to isoleucine group
89422474|NCT04461236|Placebo Comparator|Placebo|Type 2 Diabetics randomized to placebo group
89422475|NCT04461236|No Intervention|Healthy|gender-, age-, BMI-matched controls for baseline measurements only. No supplementation provided.
89422476|NCT04904146||Patients with Mycosis fungoides and Sézary syndrome|
89422477|NCT04904146||Healthy volontaires|
89422478|NCT04455464|Experimental|Midodrine|Midodrine will be given 10 mg for one time only. HVPG will be done at baseline and after 3 hours
89422479|NCT04914598|Active Comparator|ENDOSTAR combined with cisplatin|
89422480|NCT04914598|Placebo Comparator|Placebo combined with cisplatin|
89422481|NCT04312256|Experimental|Dominant Hand and great toe|Subject scheduled to undergo an elective surgical procedure will have TetraGraph device lead placement on the dominant hand and great toe.
89422482|NCT04903990||Patients|"women 18-50 years~with previous history of a male birth~scheduled for malignant breast tumor surgery"
89195149|NCT02541682|Other|Severe nausea and vomiting of pregnancy|Participants who have maximum PUQE ( Pregnancy Unique Quantification of Emesis scoring index) score equal to 13-15 during the three control visits. Control visits are performed a month apart.
89195150|NCT00815139||ZES group|Groups who were treated with zotarolimus eluting stent
89422483|NCT04903990||Controls|"women 18-50 years~with previous history of a male birth~scheduled for benign breast tumor surgery~or cancer free"
89422484|NCT03470168|Experimental|Hyperbaric Oxygen Therapy|Received the Hyperbaric Oxygen therapy treatment at 2.4 ATA for 90 minutes each day.
89422485|NCT03470168|Placebo Comparator|Placebo group|were also taken inside the Hyperbaric Chamber, but received only normobaric oxygen therapy for the same period of time at 1 ATA
89422486|NCT04904380|Experimental|Intervention|HMS, HBS and peer learning in combination with AIR and PRISMS
89422487|NCT04904380|Active Comparator|Comparison arm|HMS, HBS and peer learning in combination with PRISMS but no AIR
89422488|NCT04913974||Uni-condylar knee arthroplasty|A cohort of patients who will undergo uni-condylar knee replacement surgery with the Univation X system and have biomechanical anaylsis
89422489|NCT03099746|Experimental|INVOLVE|"The first study condition, called Interactive Virtual Decision Support for End-of-Life and Palliative Care (INVOLVE) will consist of exposures to an avatar-based decision support technology that will be administered via tablet computer and allow SDMs opportunities to practice their communication and decision making skills through interactions with avatars that portray a decision coach and various healthcare providers."
89422490|NCT03099746|Experimental|Informational Support|The second condition, called Informational Support (IS), will also be administered via tablet computers and expose SDMs to educational resources of INVOLVE without the experiential components.
89422491|NCT03099746|Experimental|Usual Care|The third condition, usual care (UC), will expose SDMs to the routine communication and decisional support practices provided by the healthcare team.
89422492|NCT03054220|Experimental|CYP2D6 gene score 1|carriers of 1 fully functional and 1non functional CYP2D6 alleles
89422493|NCT03054220|Experimental|CYP2D6 gene score 2|carriers of 2 fully functional CYP2D6 alleles
89422494|NCT05388188||Sickle Cell Disease Vaso-Occlusive (SCD VOC) crisis|Adult patients with known sickle cell disease present in the ED with a SCD VOC and ED provider has ordered as part of the patient's standard of care, sublingual opioid called sufentanil [Dsuvia] (a strong pain medicine that dissolves under your tongue) for the patient.
89422495|NCT05388188||Historical Sample|collection of retrospective data of SCD VOC patients.
89422496|NCT04903834||COVID-19 - no hyperinflammation|Confirmed Sars-CoV-2 infection Hospitalised case
89422497|NCT04903834||COVID-19 - hyperinflammation|Sars-CoV-2 infection Hospitalised case
89422498|NCT03470090|Experimental|Neuromuscular Exercises Group|This group of patients received patient with knee osteoarthritis. It will be applied classical physiotherapy and neuromuscular exercises training
89422499|NCT03470090|Active Comparator|Conventional Group|This group of patients received patient with knee osteoarthritis. It will be applied classical physiotherapy and conventional exercises.
89422500|NCT03053908|Experimental|Elderly Patients|
89195151|NCT00818181|Experimental|Solution of birch pollen allergen extract|In total up to 4 drops (dose for maintainace therapy)are administered under the tongue.
89195152|NCT00887848|Experimental|Lokomat training|Lokomat training
89422501|NCT04203836|Experimental|Fed|Single oral dose given after a full breakfast
89195153|NCT00887848|Other|Waiting list|Lokomat training after waiting phase of 5 weeks
89422502|NCT04203836|Experimental|Fasting|Single oral dose given in fasting state
89422503|NCT04118036|Experimental|Surgery Arm|"In the surgical arm participants who require reoperation and have evidence of CDKN2A/B or C loss and intact RB from a prior tumor sample will receive~Pembrolizumab-prior to surgery, at predetermined dose and time point~Abemaciclib: every 12 hours from the day of pembrolizumab infusion to the morning of surgery~Post surgery Participants with receive~Abemaciclib, twice daily oral at specified dose for 21 day cycle~Pembrolizumab intravenous once in 21 day cycle (3 weeks)"
89422504|NCT04118036|Experimental|Non Surgery Arm|"The treatment arm will be comprised of participants not requiring surgery.~- Participants will receive treatment with~Abemaciclib, twice daily oral at specified dose for 21 day cycle~Pembrolizumab intravenous once in 21 day cycle (3 weeks)"
89422505|NCT05159336|Experimental|schizophrenia patients with auditory hallucinations|For schizophrenia patients with auditory hallucinations, tACS for implementation intervention
88814898|NCT03030014|Placebo Comparator|no educational programm|without educational program Three follow up examination is assessed after one week, three weeks and six weeks using questionnaire for evaluation of participant satisfaction about oral health and using OHIS index for evaluating the effect of the dental educational program on the oral health status of deaf children.
89195154|NCT01038661|Experimental|First line treatment: docetaxel 75 mg/m² + cisplatin 75 mg/m²|Docetaxel 75 mg/m² + cisplatin 75 mg/m² on day 1, repeated every 3 weeks, up to 4 cycles
89195155|NCT01038661|Experimental|First line treatment:: docetaxel 60 mg/m² + cisplatin 75 mg/m²|Docetaxel 60 mg/m² + cisplatin 75 mg/m² on day 1, repeated every 3 weeks, up to 4 cycles
89195156|NCT01038661|Experimental|Maintenance treatment: docetaxel (60 mg/m2)|Docetaxel 60 mg/m² on day 1, repeated every 3 weeks until progressive disease or up to 6 cycles
89195157|NCT01038661|Active Comparator|Maintenance treatment: best supportive care (BSC)|BSC until progressive disease
89422506|NCT04914130||Older HIV-positive cohort (n=500)|"documented HIV infection~age >50 years at study entry~Korean ethnicity~likely route of HIV acquisition via sexual exposure by male to male exposure~able to comprehend study patient information leaflet.~Virologically suppressed subjects Subjects with primary HIV infection are eligible and investigators are encouraged to recruit such subjects. Our target population (those infected with HIV via sexual routes of men who have sex with men) has been chosen as this group represent the vast majority of older HIV-positive individuals attending for care in Korea; analyses of other groups (e.g. injection drug users, those infected through blood/blood products and transgender individuals), who may have very different needs and outcomes, would likely be under-powered."
89422507|NCT04914130||Younger HIV-positive cohort (n=250)|"documented HIV infection~age <50 at study entry*~Korean ethnicity~likely route of HIV acquisition via sexual exposure by male to male exposure~able to comprehend study patient information leaflet * this group will comprise of at least 70 subjects in each of the following age groups: 20-29, 30-39, 40-49 years. Recruitment will be monitored by the Study Monitoring Team"
89195158|NCT02355613|Active Comparator|Radiosurgery with Gamma Knife Perfexion|A single dose of 24 Gy at 50% isodose will be prescribed at metastases with diameter ≤ 20 mm, while a dose of 20 Gy at 50% isodose will be prescribed for metastases with diameter 21-30 mm
89195159|NCT02355613|Active Comparator|Linac-based Radiosurgery with EDGE|A single dose of 24 Gy will be prescribed at mean dose to PTV at metastases with diameter ≤ 20 mm, while a dose of 20 Gy will be prescribed for metastases with diameter 21-30 mm
89195160|NCT01038817|Active Comparator|fluoride varnish|"Duraphat:~Application of fluoride varnish on one side of the mandibles (left or right, randomly selected)"
89195161|NCT01038817|No Intervention|control|no application on the other side
89195162|NCT01324219|Active Comparator|Staff|
89195163|NCT01324219|Experimental|Resident|
89195164|NCT00420511|Experimental|Sitagliptin|Sitagliptin 100mg once a day (od) by mouth (po)
89195165|NCT00420511|Placebo Comparator|Placebo arm|Placebo once a day (od) by mouth (po)
89195166|NCT01038895|Active Comparator|Ramipril|10 mg/daily
89195167|NCT01038895|Experimental|Aliskiren|300 mg/ daily
89195168|NCT00420199|Active Comparator|Abatacept + Methotrexate (Double-blind period)|
89195169|NCT00420199|Placebo Comparator|Placebo + Methotrexate (Double-blind period)|
89195170|NCT01039051|Experimental|Diet and Lifestyle counseling|increasing consumption of vegetables and fruits; maintaining energy balance through reducing excessive energy from meat, eggs and brown sugar and increasing energy expenditure from appropriate physical activity, such as doing maternal keep-fit exercises.
89195171|NCT00649389|Experimental|OM40/AML10|olmesartan medoxomil 40mg and amlodipine 10mg
89195172|NCT00649389|Active Comparator|OM40/HCTZ25|olmesartan medoxomil 40mg and hydrochlorothiazide 25mg
89195173|NCT00649389|Active Comparator|AML10/HCTZ25|amlodipine 10mg and hydrochlorothiazide 25mg
89195174|NCT00649389|Active Comparator|OM40/AML10/HCTZ25|olmesartan medoxomil 40mg, amlodipine 10mg, and hydrochlorothiazide 25mg
89195175|NCT00402103|Experimental|Aliskiren/Amlodipine|
89195176|NCT00402103|Experimental|Aliskiren/Amlodipine/HCTZ|
89195177|NCT00815217|Experimental|1 lipoaspirate|wounds which have received the lipoaspirate
89422508|NCT04914130||HIV-negative cohort (n=250)|"documented negative HIV test at screening~age >50 years at study entry~Korean ethnicity~self reported sexual preferences of men who have sex with men~To enroll matched control, we will try to match age, sexual orientation, and participating clinic."
89422509|NCT04903600|Experimental|Probiotics|32g probiotics fruit vegetable fiber powder product contained 1.12*10(11) CFU of probiotics for 12 weeks
89422510|NCT04903600|Placebo Comparator|Placebo|32g placebo contained only maltodextrin (100%) for 12 weeks
89422511|NCT03471884|Experimental|Nonintubated thoracoscopic lobectomy|Lung cancer patients undergoing thoracoscopic lobectomy without tracheal intubation
89422512|NCT03471884|Active Comparator|Intubated thoracoscopic lobectomy|Lung cancer patients undergoing thoracoscopic lobectomy with tracheal intubation and one-lung ventilation
89422513|NCT04909918|Experimental|(Group D )Dexamethasone|Intravenous dexamethasone 8 mg/day given for 7 days
89422514|NCT04909918|Experimental|(Group M) methylprednisolone|Intravenous methylprednisolone 1 mg/kg/day in 2 divided doses per day given for 7 days
89195178|NCT00815217|Placebo Comparator|2 control|For the control wound, only the sterile injectable tumescence solution (1 liter of LR, 30 cc of 1% lidocaine, 1 ampule of 1:1,000,000 epinepherine) will be used. The solution will be injected in a similar fashion with single tunnels radially around the control wound spaced at 5-10 mm apart and approximately 3 - 5 cm in length.
89195179|NCT00812175||Group 1|
89195180|NCT00815373|Active Comparator|1|Cosopt* b. i. d. (dosed morning and bedtime) will be administered topically
89422515|NCT04903444|Experimental|with AI navigation system|The endoscopists in the experimental group will be assisted by AI system, which can instruct the direction of guide wire and the position of stent placement in real time. The system is an non-invasive AI system.All patients underwent MRCP in the prone position prior to ERCP. A round box with a diameter of 2mm filled with water was pasted next to the patient's spine at the level of angulus inferior scapulae during MRCP, and a sheet metal with a diameter of 2mm was pasted at the same area during ERCP.
89195181|NCT00815373|Active Comparator|2|Xalacom* q.d.(dosed bedtime) and placebo vehicle q.d. (dosed morning) topically in the other group
89195182|NCT00641667|Experimental|Fentanyl|
89422516|NCT04903444|No Intervention|without AI navigation system|The endoscopists in the contrpl group performs ERCP routinely without special prompts.All patients underwent MRCP in the prone position prior to ERCP. A round box with a diameter of 2mm filled with water was pasted next to the patient's spine at the level of angulus inferior scapulae during MRCP, and a sheet metal with a diameter of 2mm was pasted at the same area during ERCP.
89422517|NCT03054688|Experimental|Somnotouch NIBP|Blood pressure measurement with Somnotouch-NIBP device in addition to standard cuff based device
89422518|NCT04903678|Experimental|intrathecal chemotherapy in patients with central metastases|Systemic chemotherapy and intrathecal chemotherapy are performed every 3 weeks. After three treatment cycles, the treatment response is comprehensively evaluated including cerebrospinal fluid, intracranial and orbital tumors. If necessary, local radiotherapy and arterial interventional chemotherapy are performed for local solid tumors. Cerebrospinal fluid is detected in each treatment cycle. If RB tumor cells still exist in cerebrospinal fluid, chemotherapy and intrathecal chemotherapy are continued until the end event. If cerebrospinal fluid was negative, intrathecal chemotherapy is supplemented for another 2 cycles with a total of 6 cycles of systemic chemotherapy. The patients are followed up after treatment.
89422519|NCT04903366||Chronic wound|Any chronic wound, for greater than 30 days with minimal improvement
89422520|NCT04903366||Glaucoma|Any diagnosis of glaucoma and active prescription of timolol drops
89422521|NCT03054610|Active Comparator|Control|5 ml of local anesthetic (ropivacaine 7.5%)
89422522|NCT03054610|Active Comparator|Steroid|1ml of steroid Betamethason Sodium Phosphate (Celestone®) and local anesthetic (ropivacaine 7.5%)
89422523|NCT03054610|Experimental|BTX-A|200U Botulinum Toxins, Type A
89422524|NCT03053752|Experimental|Transcutaneous Electric Stimulation|Eight sessions were held, once a week, lasting twenty minutes. For this purpose, the electrodes of the acoustic surface Taichong (LR-3), Hé gǔ (Ll-4), Yanglingquan (GB-34) and Neiguan (PC-6) connected to the TENS equipment (EL 608, brand NKL). The current of choice for a BURST type, with intermittent pulses, isolated at a frequency of 2 Hz, ranging from 1 to 10 mA.
89422525|NCT04909762|Other|Early rehabilitation and mobilisation|Early rehabilitation/mobilisation (ERM) encompasses patient-tailored interventions, delivered individually or in a bundled package, provided by health care professionals from multiple disciplines and parents/carers within intensive care settings to promote recovery, both physical (e.g. movement, functional activities, ambulation) and non-physical (e.g. speech, play, psychological, cognitive). In adult intensive care, ERM has been shown in clinical trials to improve long term physical functioning and return to independence. It can also shorten the length of ventilation and stay in intensive care and hospital with significant economic benefit.
89422526|NCT04902742|Active Comparator|Ganglion impar block group|Fluoroscopy-guided ganglion impar block is applied to patients in this group.
89422527|NCT04902742|Active Comparator|Caudal epidural steroid injection group|Fluoroscopy-guided caudal epidural steroid injection is applied to patients in this group.
89422528|NCT03053830|Experimental|Intervention Group|Veterans with Major Depressive Disorder getting up to 6 infusions of 0.5mg/kg ketamine in normal saline; one infusion per week, 40 minutes per infusion with time points lasting up to 5 hours.
89422529|NCT04913740|No Intervention|Control group|health care workers who did not use any preventive measures on the basis of tertiary protection
89422530|NCT04913740|Experimental|Experimental group|"On the basis of three-level protection, skin correlation prevention is carried out:~pay attention to the protection of exposed skin, so that it is local dry.~Do a good job of facial moisturizing work before workuse moisturizing ointment, more durable and non-irritating cream or emulsion, such as vitamin E cream, petroleum jelly, to do a good job of moisturizing work.~Use appropriate dressing to avoid direct contact between the mask and the skin, and select the appropriate type of protective device; Reduce friction by applying foam patches, hydrocolloidal dressings, and empleters to the hair area. However, it should be noted that it must be confirmed that airtightness is good and that the protective effect is still the primary purpose of the medical staff.~After work, avoid using irritantsto clean the face, and massage local skin with skin moisturizer; (5) If severe skin damage occurs, treat it as prescribed by the doctor"
89422531|NCT04913896||Single Group Assignment|Patients with AGC who underwent neoadjuvant immunotherapy and/or chemotherapy would recieve MRI and CT examination before and after 3 cycles treatment.
89195183|NCT00704184|Placebo Comparator|Placebo + Peg-IFN/Ribavirin|Participants took double-blind Placebo + Peg-IFN/Ribavirin from Week 1 to Week 4, followed by open-label Peg-IFN/Ribavirin from Week 5 to Week 48.
89195184|NCT00704184|Experimental|Vaniprevir 300 mg b.i.d. + Peg-IFN/Ribavirin|Participants took double-blind Vaniprevir 300 mg twice daily (b.i.d.) + Peg-IFN/Ribavirin from Week 1 to Week 4, followed by open-label Peg-IFN/Ribavirin from Week 5 to Week 48.
89195185|NCT00704184|Experimental|Vaniprevir 600 mg b.i.d. + Peg-IFN/Ribavirin|Participants took double-blind Vaniprevir 600 mg b.i.d. + Peg-IFN/Ribavirin from Week 1 to Week 4, followed by open-label Peg-IFN/Ribavirin from Week 5 to Week 48.
88813057|NCT03217838|Experimental|Group 2 Arm A (AZD2811 Dose 4 + Azacitidine 75 mg/m^2)|Participants with AML will receive Azacitidine 75 mg/m^2 of BSA by SC injection or IV infusion prior to the start of AZD2811 infusion on Days 1 through 7 or for 5 consecutive weekdays (Days 1 through 5) with treatment holidays on the 2 weekend days (Days 6 and 7), and the remaining azacitidine dosing will be administered on the first 2 weekdays of the 2nd week (Days 8 and 9) of each 28-day cycle. Participants will receive IV infusion of AZD2811 Dose 4 on Days 1 and 4 of each 28-day cycle. Participants will receive the treatment until disease progression, unacceptable toxicity, or the decision to discontinue treatment by the participant or the study physician, whichever occurs first.
89422532|NCT04913662|Experimental|PIPAC Paclitaxel with FOLFOX|PIPAC (Paclitaxel) + Systemic mFOLFOX6(5-FU, Oxaliplatin, Leucovorin)
89422533|NCT04913506|Active Comparator|Group Mirror|Along with conventional rehabilitation techniques, patients will be given ROM exercises in all directions, in front of the real mirror, by the practitioner on the healthy upper extremity for 30 minutes.
89422534|NCT04913506|Active Comparator|Group NMES|Along with conventional rehabilitation techniques, NMES will be applied to the hemiplegic arm for 30 minutes by the practitioner while the patients are sitting in a chair.
89422535|NCT04913506|Active Comparator|Group Mirror+NMES|In addition to conventional rehabilitation techniques, patients will be given ROM exercises for 30 minutes in all directions in front of the real mirror to the healthy extremity, which the practitioner will synchronize with visual or auditory stimuli, and NMES treatment for 30 minutes to the paretic upper extremity.
89422536|NCT04913428|Experimental|Interdigital exercise group|"Interdigital exercises:~12 repetitions in 3 sets of 4 repetitions~Conventional Physical Therapy:~Incentive spirometer 3 - 4 times a day, Percussion twice a day, Mobilization of the patient Total session given was for 20 -30 minutes"
89422537|NCT04913428|Active Comparator|Blow-Bottle technique group|"Blow-Bottle technique:~12 repetitions in 3 sets of 4 repetitions~Conventional Physical Therapy:~Incentive spirometer 3 - 4 times a day, Percussion twice a day, Mobilization of the patient Total session given was for 20 -30 minutes"
89422538|NCT04902586|Experimental|E group|All patients received chemoradiotherapy (CRT) ( PTV-GTV: 60Gy at 2.0Gy per fraction, 5 fractions per week for 6 weeks; PTV-CTV: 54Gy at 1.8Gy per fraction, 5 fractions per week for 6 weeks) with a Temozolomide (TMZ) regimen（75mg/m2 per day during RT）and TTFields therapy during RT. The TTFields therapy started on the day the radiotherapy started.
89422539|NCT04902586|No Intervention|C group|All patients received chemoradiotherapy (CRT) ( PTV-GTV: 60Gy at 2.0Gy per fraction, 5 fractions per week for 6 weeks; PTV-CTV: 54Gy at 1.8Gy per fraction, 5 fractions per week for 6 weeks) with a Temozolomide (TMZ) regimen（75mg/m2 per day during RT）
89422540|NCT03053674|Experimental|Explanation|Explanation to parents on importance of post-partum influenza vaccination on health of their newborn infant with a follow-up questionnaire to determine rate of vaccination
89422541|NCT03053674|Active Comparator|No explanation|No explanation will be given to parents but they will be followed-up with a questionnaire to determine rate of vaccination
89422542|NCT03053284|Placebo Comparator|Placebo|Normal saline s.c. injection once
89422543|NCT03053284|Experimental|Pasireotide|Pasireotide 0.6mg s.c. once
89422544|NCT04894318|Other|Low-fat, low-cholesterol diet|Patients diagnosed with dyslipidemia by the endocrinologist were followed up for 12 weeks with a low-fat, low-cholesterol diet on a monthly basis, provided that they were suitable for each.
89422545|NCT03053128|Experimental|CSWT group|Patients in CSWT group will receive cardiac shock wave therapy for three moths, every first week of the month.
89422546|NCT03053128|Sham Comparator|Sham CSWT group|Patients in sham CSWT group will receive sham cardiac shock wave, which segregated by an air-cushion.
89422547|NCT03053206|Experimental|ADE arm|"ADE arm~Cytarabine (100mg/m2 d1-d10 BD), Daunorubicin (50mg/m2 d1-d3) and Etoposide (100 mg/m2 d1-5) over a period of 10 days"
89422548|NCT04908982|Experimental|Aspirin|Participants in this arm will be instructed to take 1 81mg aspirin daily beginning between weeks 12 and 16 of pregnancy and continuing until delivery.
89422549|NCT04908982|No Intervention|No Aspirin|Participants in this arm will receive no aspirin.
89422550|NCT04893850|Experimental|BRIDGE-KIDTHINK Condition|Caregivers in this group will participate in 16 sessions of online therapy delivered through a combination of asynchronous material and virtual support groups. These sessions will include Dialectical Behaviour Therapy (DBT) and parenting training. This group will be asked to evaluate the program with surveys completed pre-program, immediately post-program, and three months post-program. This group will also be invited to complete weekly surveys expected to take 5 minutes.
89422551|NCT04893850|Experimental|Services as Usual Condition|Caregivers in this group will not participate in Dialectical Behaviour Therapy (DBT) and parenting training. Rather, this group will be asked to refer to a list of community mental health and family support services as part of the BRIDGE therapy program. This group will be asked to complete weekly surveys expected to take 5 minutes.
89422552|NCT02811159|Experimental|Telapristone Acetate 12 mg|Telapristone acetate 12 milligrams (mg), orally, once daily for two 18-weeks courses (Treatment Courses 1 and 2) separated by an off-drug interval (ODI).
89195186|NCT00704184|Experimental|Vaniprevir 600 mg q.d. + Peg-IFN/Ribavirin|Participants took double-blind Vaniprevir 600 mg q.d. + Peg-IFN/Ribavirin from Week 1 to Week 4, followed by open-label Peg-IFN/Ribavirin from Week 5 to Week 48.
89422553|NCT04901338||Veno-arterial ECMO patients|Patients with severe SIRS post extracorporeal cardiopulmonary resuscitation (ECPR) or accompanying cardiogenic shock who were treated with hemoadsorption.
89422554|NCT04901338||Veno-venous ECMO patients|Patients with refractory septic shock on VV ECMO who were treated with hemoadsorption.
89422555|NCT04901650||Inpatient population|A survey will be administered to find out the prevalence of pain in hospitalized patients for any cause and its intensity. The medical history will be reviewed to assess the presence of pain medications and their impact on the pain perception and patients' satisfaction.
89195187|NCT00704184|Experimental|Vaniprevir 800 mg q.d. + Peg-IFN/Ribavirin|Participants took double-blind Vaniprevir 800 mg q.d. + Peg-IFN/Ribavirin from Week 1 to Week 4, followed by open-label Peg-IFN/Ribavirin from Week 5 to Week 48.
89530850|NCT02509637|Active Comparator|Flutter Intervention|After initial evaluation, the subjects will perform breathing exercises with quiet inspiration and prolonged expiration on the device for thirty minutes, with breaks of one minute every four minutes. Immediately after the exercise will be performed new assessment against Impulse Oscillometry. Then patients will be kept for 30 minutes at rest and at the end will be applied the acceptability and tolerance scale and a third evaluation with Impulse Oscillometry. The secretions expectorated during the protocol will be evaluated for weight, adhesiveness and purulence.
89195188|NCT00641043|Experimental|BI 1356 (5 mg)|BI 1356 5mg in initial combination therapy with pioglitazone 30 mg
89195189|NCT00641043|Placebo Comparator|Placebo matching BI 1356 5 mg|Placebo in initial combination therapy with pioglitazone 30 mg
89422556|NCT03052192||FAM group (n=98)|"≥65 years. Acutely admitted medical patients.~Included consecutively at admission to the Acute Medical Department at Amager and Hvidovre Hospital and Rigshospitalet - Glostrup.~Follow-up at 4 weeks and 56 weeks after discharge and at any readmissions in the study period.~Participants are interviewed on physical, mental and nutritional status, tested for functional and cognitive status, and have anthropometry, biochemistry, blood pressure, and immune activity measured. Participants are followed in national registries for information on diagnoses, hospital admissions, health care services used, and mortality.~If a patient uses ≥5 prescribed drugs before hospitalization, a medication review will be performed by a clinical pharmacist and a geriatrician.~Sample size calculations were performed for each primary outcome, and the final sample size was based on the calculation for the eating validation scheme which resulted in the largest sample size."
89195190|NCT04062318|Experimental|Tactile detection task with online TMS-EEG|Participants receive perceptual threshold-level tactile stimuli to the third digit of the right hand and report detection or non-detection. EEG is recorded and TMS is applied over somatosensory cortex during the tactile detection task.
89422557|NCT03052192||Control group 1 (n=54)|"≥65 years. No hospital admissions within the past two years.~Matched individually with patients in the FAM group by age, sex, and municipality.~Examined at inclusion and 52 weeks after inclusion.~Participants are interviewed on physical, mental and nutritional status, tested for functional and cognitive status, and have anthropometry, biochemistry, blood pressure, and immune activity measured. Participants are followed in national registries for information on diagnoses, hospital admissions, health care services used, and mortality."
89422558|NCT03052192||Control group 2 (n=60)|"20-35 years No admissions due to chronic or critical illness within the past 5 years (except admissions related to child birth, abortion, appendicitis, poisoning, traumas, concussion etc.)~Examined at inclusion and 4 weeks after inclusion. The examination includes a questionnaire about life style, a physical examination, and blood samples."
89195191|NCT04062318|Active Comparator|Tactile detection task with online control TMS-EEG|Participants receive perceptual threshold-level tactile stimuli to the third digit of the right hand and report detection or non-detection. EEG is recorded and TMS is applied over a control brain region during the tactile detection task. This control condition is intended to mimic the peripheral (e.g. cranial/facial muscle and/or nerve activation, auditory evoked response), but not biological effects of TMS specifically related to somatosensory perception.
89195192|NCT02551965|Experimental|Caregiver of cancer patient followed in geriatric oncology|caregiver of cancer patient with 70 years old or more, for which a treatment is planned, along with their long term evolution
89422559|NCT04412356|Experimental|Early tracheotomy|Tracheotomy within 7 days after intubation.
89422560|NCT04412356|Active Comparator|Late tracheotomy|Tracheotomy after at least 10 days after intubation.
89422561|NCT04893304|Other|1 group of 20 patients doing both types of lasers on 2 sites|comparing both types of laser
88814899|NCT03029546||Glucose load|"50 subjects undergoing routine gestational diabetes screen with 50g glucose load.~5 subjects undergoing follow-up gestational diabetes screen with 100g glucose load."
88814900|NCT03029546||Control|50 subjects undergoing water ingestion with the same study measurements as the glucose load group at the same time intervals.
88814901|NCT03028532|Experimental|Clomid|All participants will be receiving Clomid and will follow the same study procedures.
88814902|NCT02245724|Experimental|Stem Cell|Bone marrow mononuclear cell transplantation
88814903|NCT03027206|Experimental|Vibration technique|Rhythmic and rapid movements of isometric contraction of the forearm, applied manually over the anterior region of the thorax
88814904|NCT03027206|Experimental|Acceleration of expiratory flow|Soft compression of the thorax applied with one hand on the lower ribs and the other using the ulnar border on the supramammary line
88814905|NCT04815590||Sublocade|The only group consists of participants with moderate to severe OUD who will be starting treatment with extended-release injectable buprenorphine as part of standard of care. While individual treatment regimens may vary, these will often consist of 2 once-monthly 300 mg subcutaneous injections followed by 4 once-monthly 100 mg subcutaneous injections. However, participants may receive once-monthly 300 mg subcutaneous injections in place of 100 mg subcutaneous injections for as many months as is deemed necessary by their prescribing physician.
88903454|NCT01534338|Active Comparator|Sleep Education|The sleep education condition is founded on knowledge acquisition. In the sleep seminar condition, a trained health educator will provide didactic presentations on sleep, sleep hygiene, sleep problems, and potential solutions to sleep problems in a group-based setting. Active components of sleep education include increasing knowledge of sleep biology, identifying characteristics of healthy and unhealthy sleep, sleep problems, and self-monitoring of sleep behavior. Participants attend weekly 2-hour classes for a total of 6 weeks and participants will monitor their sleep with a daily sleep diary. The health education condition is comparable to MAPs in terms of time, attention, group support, and participant expectancy of a benefit in sleep parameters.
88903455|NCT01534364|No Intervention|control|Ad libitum alimentation
88903456|NCT01534364|Other|calorie restriction|Calorie Restriction to 60% of the calculated daily energy rate from day -7 until day -1 (included) pre-surgery day 0 corresponds to day of surgery)
88903457|NCT01534377|Experimental|Interpersonal Psychotherapy|Adolescents will receive Interpersonal Psychotherapy for the treatment and prevention of depression.
88903458|NCT01534377|Experimental|Enhanced Care|Adolescents will receive the Enhanced care model or care that they would typically receive in community setting to treat and prevent depression.
88903459|NCT01534390|Experimental|Use of in-line microfilters|
88903460|NCT01534390|No Intervention|Standard therapy without the use of in-line microfilters|
88903461|NCT01534429||chronic post-herniorraphy pain|patients with severe chronic post-herniorraphy pain
88903462|NCT01534442|Active Comparator|Atropin|Atropin
88903463|NCT01534442|Placebo Comparator|Placebo|Saline
88903464|NCT01534455|Experimental|Lapatinib + 1,23 mg Eribulin|
88903465|NCT01534455|Experimental|Lapatinib + 1,76 mg Eribulin|
88903466|NCT01534468|Experimental|Group 1: Previous H7N7 ca LAIV recipients|Participants in Group 1 will have previously received an H7N7 ca LAIV. In this study, they will receive one intramuscular (IM) injection of the H7N7 vaccine at study entry.
88903467|NCT01534468|Experimental|Group 2: Previous H7N3 ca LAIV recipients|Participants in Group 2 will have previously received an H7N3 ca LAIV. In this study, they will receive one IM injection of the H7N7 vaccine at study entry.
88903468|NCT01534468|Experimental|Group 3: Previous H2N3 ca LAIV recipients|Participants in Group 3 will have previously received an H2N3 ca LAIV. In this study, they will receive one IM injection of the H7N7 vaccine at study entry.
88903469|NCT01534468|Experimental|Group 4: Vaccine-naive participants|Participants in Group 4 will have not previously received a LAIV. In this study, they will receive one IM injection of the H7N7 vaccine at study entry.
89422562|NCT04901026|Active Comparator|An in-house manikin|Participants use an in-house manikin
89422563|NCT04901026|Sham Comparator|A manikin in market|Participants use a manikin from market
89422564|NCT04892992|Experimental|Intervention group I|6 sessions of intervention DFG starting at once (baseline). After DFG treatment as usual at Helsinki University hospital. The change between before the intervention (baseline) and after the intervention (3 months later) is being assessed.
88903470|NCT01534507||Healthy Volunteer 1 (Group 1)|For study 1 : Up to 5 healthy volunteers for the initial pilot study and further 21 healthy volunteers for the main study 1
88903471|NCT01534507||Group 2 for study 2|Patients with diarrhoea due to irritable bowel syndrome
88903472|NCT01534507||Group 3 for study 2|Patients with constipation due to irritable bowel syndrome
89422565|NCT04892992|Experimental|Intervention group II|6 sessions of intervention DFG starting 3 months after baseline (3 months on waiting list). Between baseline and 3 months waiting list families were getting treatment as usual at Helsinki University hospital. The change between baseline - after 3 months waiting list (3 months from baseline)/ before the intervention - and after intervention (6 months from baseline) is being assessed. Also the difference between Intervention group I and II is assessed.
89422566|NCT04430998|Experimental|Zinc L-Carnosine mouth rinse|Using undiluted 10 ml of Zinc L-Carnosine mouth rinse, retain for 60 seconds, 3 times daily
88903473|NCT01534507||Group 4 for study 2|Patients with mixed bowel habit due to irritable bowel syndrome
89422567|NCT04430998|Active Comparator|Chlorhexidine|Using undiluted 10 ml of Chlorhexidine mouth rinse, retain for 60 seconds, 3 times daily
89422568|NCT04430998|Placebo Comparator|Water|Mouth rinsing with 10 ml of water, retain for 60 seconds, 3 times daily
89422569|NCT03052894|Experimental|Hydraulic Monitoring Device|Monitoring device to be compared to electromyographic (EMG) device in the same patient; measures depth of neuromuscular blockade during general anesthesia based on the pressure exerted by the muscles of the thumb.
89422570|NCT03052894|Active Comparator|Standard EMG Monitoring Device|Currently used standard monitoring device; measures depth of neuromuscular blockade during general anesthesia based on the action potential of the muscles of the thumb.
89422571|NCT03051958|Experimental|Internet mindfulness&exposure treatment|A 12-week treatment where the main treatment components are mindfulness, exposure and response prevention, a form of cognitive behavior therapy. The treatment entails methods to increase acceptance and non-reactivity to aversive thoughts and emotions associated with AD. The treatment is delivered via the Internet and comprises 10 modules, each with a specific theme. Throughout treatment, the patient is given structured exercises to work with on a daily basis.
89422572|NCT03051958|Active Comparator|Treatment as usual|"Participants receive information about moisturizer and anti-inflammatory lotion treatment which is treatment as usual.~After 12 weeks, patients in this arm are crossed over to treatment."
89422573|NCT04908124|Experimental|Lubricant A - Tolerance|"A 3-Day wash-out period followed by 2 visits. Visit 1 will include baseline assessments and application of allocated IP. Visit 2 will consist of clinical assessment.~This is conducted on a sub-set of the population enrolled into the arm using the same IP for the treatment phase."
89422574|NCT04908124|Experimental|Lubricant B - Tolerance|"A 3-Day wash-out period followed by 2 visits. Visit 1 will include baseline assessments and application of allocated IP. Visit 2 will consist of clinical assessment.~This is conducted on a sub-set of the population enrolled into the arm using the same IP for the treatment phase."
89422575|NCT04908124|Experimental|Lubricant C - Tolerance|"A 3-Day wash-out period followed by 2 visits. Visit 1 will include baseline assessments and application of allocated IP. Visit 2 will consist of clinical assessment.~This is conducted on a sub-set of the population enrolled into the arm using the same IP for the treatment phase."
89536059|NCT02483039|No Intervention|Usual Care|Participants randomized to this arm will have a letter outlining their AKI diagnosis mailed to their family physician. Participants may still be referred to a nephrologist by their inpatient or outpatient healthcare provider, but these participants will not have access to the AKI Follow-up Clinic. Rather, they will proceed through the standard local nephrology referral pathway. In addition, all usual care participants will be contacted via telephone by study staff every three months to assess their clinical condition and ensure study engagement. All usual care participants will be offered a nephrologist assessment and/or bloodwork one year after randomization to determine if ongoing nephrology care is indicated based upon the same criteria applied to AKI Follow-up Clinic participants.
89536060|NCT02482883|Active Comparator|active Transcutaneous Electrical Nerve Stimulation|Arm A, treated by active stimulation of the trigeminovascular system after placement of the TENS device.
89536061|NCT02482883|Sham Comparator|sham Transcutaneous Electrical Nerve Stimulation|Arm B, treated by non-active (sham) stimulation after placement of the TENS device. This absence of stimulation corresponds to the standard of care currently received by patients hospitalized for SAH due to ruptured aneurysm.
88903474|NCT01534507||Group 5 for study 2: Healthy volunteer 2|Healthy participants to act as control
88903475|NCT01534546|Active Comparator|arm A postoperative Oxaliplatin/capecitabine（XELOX）|"postoperative Oxaliplatin/capecitabine（XELOX） patients in arm A will receive standard gastrectomy with D2 Lymphadenectomy first, and 8 cycles of adjuvant XELOX later.~capecitabine：1000 mg/m2 ，bid, d1~14 q3W oxaliplatin：130mg/m2，iv drip for 2h，d1,q3W 8 cycles (6 months)"
88903476|NCT01534546|Experimental|arm B: postoperative Oxaliplatin/S-1（SOX）|"postoperative Oxaliplatin/S-1（SOX） patients in arm B will receive standard gastrectomy with D2 Lymphadenectomy first, and 8 cycles of adjuvant SOX later.~S-1：40~60mg bid，d1~14 q3W oxaliplatin：130mg/m2，iv drip for 2h，d1,q3W 8 cycles (6 months)"
88903477|NCT01534546|Experimental|Arm C：postoperative Oxaliplatin /S-1（SOX）|"Postoperative Oxaliplatin /S-1（SOX） patients in arm C will receive 3 cycles of neoadjuvant SOX first, and then standard gastrectomy with D2 lymphadenectomy, and 5 cycles of adjuvant SOX followed by 3 cycles of S-1 monotherapy.~Dose of s-1 and oxaliplatin are same to arm B Dose of S-1 monotherapy is same to combination therapy (SOX 3 cycles before surgery, 5 cycles of SOX and 3 cycles of S-1 monotherapy, 6 months after surgery)"
88903478|NCT01534559|Experimental|Outpatient Medicine Management Clinic|Consented patients will attend two outpatient clinic appointments to receive help with any (potential) medicine-related problems
88903479|NCT01534559|No Intervention|Control|Patients will receive the normal care provided by the hospital
88903480|NCT01534572|Experimental|Probiotics_Lactobacillus|Intervention (2 weeks) with a strain of Lactobacillus
88903481|NCT01534572|Experimental|Probiotics_Bifidobacterium|Intervention (2 weeks) of daily supplementation of a probiotic strain of Bifidobacterium.
88903482|NCT01534702|Experimental|Treatment|
88903483|NCT01534715|Experimental|IMGN529|Dose escalation study, dosing done every 3 weeks.
88903484|NCT01534741|Active Comparator|Dialyser|FX CorDiax 60 dialyzer
88903485|NCT01534741|Active Comparator|FXDialyser|FX 60 dialyzer
88903486|NCT01534754|Active Comparator|Mesalazine|Active mesalazine 800 mg, 2 tablets/day for 10 days/month plus Lactobacillus casei placebo, 1 sachet/day for 10 days/month.
88903487|NCT01534754|Active Comparator|Lactobacillus casei|Active Lactobacillus casei, 1 sachet/day for 10 days/month plus mesalazine 800 mg placebo, 2 tablets/day for 10 days/month.
89422576|NCT04908124|Experimental|Lubricant D - Tolerance|"A 3-Day wash-out period followed by 2 visits. Visit 1 will include baseline assessments and application of allocated IP. Visit 2 will consist of clinical assessment.~This is conducted on a sub-set of the population enrolled into the arm using the same IP for the treatment phase."
89422577|NCT04908124|Experimental|Lubricant E - Tolerance|"A 3-Day wash-out period followed by 2 visits. Visit 1 will include baseline assessments and application of allocated IP. Visit 2 will consist of clinical assessment.~This is conducted on a sub-set of the population enrolled into the arm using the same IP for the treatment phase."
89422578|NCT04908124|Experimental|Lubricant A - Treatment|"A 4-week run-in period followed by 2 visits. Visit 1 will include baseline assessments and provision of allocated IP. Visit 2 will consist of clinical assessment.~This includes a sub-set population who were also enrolled into the arm using the same IP for the tolerability phase."
89422579|NCT04908124|Experimental|Lubricant B - Treatment|"A 4-week run-in period followed by 2 visits. Visit 1 will include baseline assessments and provision of allocated IP. Visit 2 will consist of clinical assessment.~This includes a sub-set population who were also enrolled into the arm using the same IP for the tolerability phase."
89422580|NCT04908124|Experimental|Lubricant C - Treatment|"A 4-week run-in period followed by 2 visits. Visit 1 will include baseline assessments and provision of allocated IP. Visit 2 will consist of clinical assessment.~This includes a sub-set population who were also enrolled into the arm using the same IP for the tolerability phase."
89422581|NCT04908124|Experimental|Lubricant D - Treatment|"A 4-week run-in period followed by 2 visits. Visit 1 will include baseline assessments and provision of allocated IP. Visit 2 will consist of clinical assessment.~This includes a sub-set population who were also enrolled into the arm using the same IP for the tolerability phase."
89422582|NCT04908124|Experimental|Lubricant E - Treatment|"A 4-week run-in period followed by 2 visits. Visit 1 will include baseline assessments and provision of allocated IP. Visit 2 will consist of clinical assessment.~This includes a sub-set population who were also enrolled into the arm using the same IP for the tolerability phase."
89422583|NCT04430764|Experimental|smoker|
89422584|NCT04430764|Active Comparator|non-smoker|
89422585|NCT04892836|Experimental|High Intensity Training (HIT)|They have trained at 80-90% of 1RM for 12 weeks, twice per week
89422586|NCT04892836|Experimental|Moderate Intensity Training|They have trained at 65-75% of 1RM for 12 weeks, twice per week
88814906|NCT03017768|Active Comparator|Acute tryptophan depletion|Administration of an amino acid mixture consisting of 15 amino acids, (4.1g L-alanine, 2.4g glycine, 2.4g L-histidine, 6.0g L-isoleucine, 10.1g L-leucine, 6.7g L-lysine, 4.3g L-phenylalanine, 9.2g L-proline, 5.2g L-serine, 4.3g L-threonine, 5.2g L-tyrosine, 6.7g L-valine, 3.7g L-argine, 2.0g L-cysteine, 3.0g L-methionine) lacking tryptophan to investigate the effect of tryptophan depletion on esophageal sensitivity
88903488|NCT01534754|Active Comparator|Mesalazine plus Lactobacillus casei|Active mesalazine 800 mg, 2 tablets/day plus active Lactobacillus casi, 1 sachet/day for 10 days/month.
88903489|NCT01534754|Placebo Comparator|Placebo|Mesalazine 800 mg placebo, 2 tablets/day and Lactobacillus casei placebo, 1 sachet/day for 10 days/month.
88903490|NCT01534780|Experimental|fixation with Protack|
89422587|NCT04892836|Experimental|Low Intensity Training|They have trained at 50-60% of 1RM for 12 weeks, twice per week
89422588|NCT04892836|No Intervention|Control Group|This groups subjects did not participate in any training
89422589|NCT04901182|Active Comparator|White sesame soy milk smoothie (WS)|a formula developed from natural ingredients such as soybean and white sesame
88903491|NCT01534780|Experimental|fixation with Securestrap|
88903492|NCT01534780|Experimental|fixation with Glubran|surgery
88903493|NCT01534793||HoLEP|Holmium Laser Enucleation of the Prostate
88903494|NCT01534806|Experimental|ketorolac|
88903495|NCT01534806|Placebo Comparator|Placebo|Placebo IV push
88903496|NCT01534832|Experimental|Smoke clearance|Smoke clearance device active
88903497|NCT01534845|No Intervention|only Radiotherapy|fractionated focal irradiation in daily fractions of 2 Gy given 5 days per week for 6 weeks, for a total of 60 Gy
89422590|NCT04901182|Active Comparator|Chicken shitake smoothie (CS)|a formula developed from natural ingredients such as chicken and shitake mushroom
89422591|NCT04901182|Placebo Comparator|Ensure|a conventional well-known commercial formula
89422592|NCT04900948|Experimental|Experimental group №1|proactive therapy with local calcineurin inhibitors + emollients
89422593|NCT04900948|Active Comparator|Experimental group №2|proactive therapy with local glucocorticosteroids + emollients
89422594|NCT04892368|Active Comparator|Home supervised exercise program|This group receives standard preoperative physiotherapy education as well a home-exercise instructions. They will also receive 3-4 home visits by physiotherapists between recruitment and surgery, to conduct exercises in their homes.
89422595|NCT04892368|No Intervention|Home unsupervised exercise program|This group receives standard preoperative physiotherapy education as well a home-exercise instructions.
89422596|NCT04901104||thymosin α1 group|The patient was treated with thymosin α1 in sepsis
89422597|NCT04901104||placebo group|The patient was treated without thymosin α1 in sepsis
89422598|NCT04900324|Experimental|MRI guidance|Injections of botulinum toxin performed using MRI guidance
89422599|NCT04900324|Experimental|Ultrasound guidance|Injections of botulinum toxin performed using ultrasound guidance
89422600|NCT04892680|Experimental|Online Diabetes Self-Management Education and Support (DSMES) Program|Participants will receive access to a 6-month online DSMES program that includes several components that are standard to DSMES. Participants receive online curriculum, access to a live Certified Diabetes Care and Education Specialist (CDCES), interactive group message forums, and connected devices for monitoring food intake, weight, physical activity and glucose levels.
89422601|NCT04892680|No Intervention|Matched Control|A de-identified dataset of control subjects matched on baseline demographics and clinical characteristics will be cultivated for comparison to the active intervention arm.
88903498|NCT01534845|Active Comparator|CCRT with Temozolomide|RT with daily temozolomide (75 mg/m2/day, 7 days/week) from the first to the last day of radiotherapy) and adjuvant TMZ chemotherapy (150-200 mg/m2 po qd for 5 days q 28 days for 6 cycles).
88903499|NCT01534858|Experimental|Partial and full thickness burns with split thickness grafts|
88903500|NCT01534884|Active Comparator|MabThera|rituximab
88903501|NCT01534884|Active Comparator|CT-P10|rituximab
88903502|NCT01534923||Pts having colorectal cancer screening|The target sample of this study will be approximately 200 primary care physician-patient consultations who discuss CRC screening during the course of a clinical visit. Physician and patient participants will come from primary care practices associated with the New York City Research and Improvement Networking Group (NYC RING).
88903503|NCT01534936||Schizophrenic outpatients with affective symptoms.|
88903504|NCT01534949|Experimental|CT-P10|rituximab
88903505|NCT01535027|Active Comparator|Teriparatide|18 months of daily 20 ug sc. teriparatide monotherapy (TPTD)
88903506|NCT01535027|Active Comparator|Teriparatide and Raloxifene|9 months teriparatide 20 ug/day sc. monotherapy (TPTD) continued by combination therapy of raloxifene 60 mg/day orally(RAL)and TPTD for another 9 months
88903507|NCT01535027|Active Comparator|Teriparatide and Alendronate|9 months teriparatide monotherapy 20 ug/day sc.(TPTD) continued by combination therapy of alendronate 70 mg/week orally(ALN)and TPTD for another 9 months
89422602|NCT04907812|Experimental|Tranexamic Acid (TXA)|Patients in the TXA arm will receive 1 gram dose of intravenous (IV) tranexamic acid mixed with 50cc 0.9% sodium chloride before their surgery and 1 gram dose of intravenous (IV) tranexamic acid mixed with 50cc 0.9% sodium chloride 3-6 hours after the first dose on the day of their surgery
89536062|NCT04997421|Active Comparator|CVVHDF with Oxiris®-AN69 membrane|Control arm
88903508|NCT01535079|Placebo Comparator|Placebo|
88903509|NCT01535079|Experimental|V0498TA01A 15 mg|
88903510|NCT01535079|Experimental|V0498TA01A 25 mg|
88903511|NCT01535079|Experimental|V0498TA01A 35 mg|
88903512|NCT01535079|Other|Strefen|Positive control
88903513|NCT01535092|Experimental|silibinin|Silibinin 20mg/Kg/day (Legalon SIL) by intravenous infusion for 14-21 days before OLT and for 7 days after OLT
88903514|NCT01535092|Placebo Comparator|Placebo|Placebo (NaCl 0.9% - saline) administered daily by intravenous infusion for 14-21 days before OLT and 7 days after OLT
88903515|NCT01535105||Obese Adolescents|
88903516|NCT01535144|Experimental|degradable metallic device|
88903517|NCT01535144|Active Comparator|non-degradable metallic device|
88903518|NCT01535157|Experimental|Fenretinide/LXS + Ketoconozale|One course is defined as 7 days of Fenretinide/LXS + Ketoconazole followed by 14 days of rest. A course is repeated every 21 days if no evidence of disease progression for six courses.
89422603|NCT04907812|Placebo Comparator|Standard of Care (SOC)|Patients in the (SOC) arm will receive 50cc of IV Placebo (standard intravenous normal saline fluid - 0.9% sodium chloride) before their surgery and 50cc of IV Placebo (standard intravenous normal saline fluid - 0.9% sodium chloride) 3-6 hours after the first dose on the day of their surgery
89422604|NCT04892290||Group C|Postdural puncture headache patients treated with Conservative treatment
89422605|NCT04892290||Group SGB|Postdural puncture headache patients treated with Sphenopalatine Ganglion Block and conservative treatment
89422606|NCT01889186|Experimental|Main Cohort|Participants received ABT-199 tablets once daily (QD) orally for up to 79 months. The starting dose was 20 mg daily, increasing over a period of 5 weeks up to the daily dose of 400 mg.
89422607|NCT01889186|Experimental|Safety Expansion Cohort|Participants received ABT-199 tablets once daily (QD) orally for up to 68 months. The starting dose was 20 mg daily, increasing over a period of 5 weeks up to the daily dose of 400 mg.
89422608|NCT04900558||Radical Cystectomy|Patients who underwent radical cystectomy for bladder cancer in our centre
88903519|NCT01535170|Experimental|bovine Lactoferrin|"Lactoferrin and placebo will be masked as drug A and B in the factory. Randomization will be stratified by center and patients will be randomized into A or B groups by a random-number table sequence after informed consents are obtained. No patients, research nurses, investigators, or other medical staffs in RCC will be aware of the assignment during the study period.~Patients will receive either bLF (10 mg/Kg/day) (Westland Co-operative Dairy Company, New Zealand) or placebo (starch) as control. The dosage of bLF is based on the mean hLF intake that very low body weight neonates ingest with mother's fresh milk in the first 2 weeks of life (30-150 mg/d) [16] and bLF 200 mg bid is found to be effective to suppress Helicobacter pylori [17]. Drug administration will begin within 24 hours after RCC admission and will last for 6 weeks or until discharge. Medication and nutritional support will be prescribed as the medical routine."
88903520|NCT01535170|Placebo Comparator|Placebo|Patients will receive either bLF (10 mg/Kg/day) (Westland Co-operative Dairy Company, New Zealand) or placebo (starch) as control.
89422609|NCT04892212|Experimental|Sirolimus group|"The initial dose of sirolimus is 1mg/day. And the serum trough level of sirolimus is monitored at Week 2, Week 4, Week 8, and Week 12，respectively. The target serum trough level of sirolimus is 5-8 ng/mL. The dose of sirolimus is titrated according to therapeutic drug level monitoring.~The previous immunosuppressive medication is not allowed to be changed during the 3-month follow-up, unless premature discontinuation from study."
89422610|NCT04892056|Experimental|Anterior Segment Retraction using Friction mechanics by elastomeric power chains|"Elastomeric power chains extending from 8mm crimpable hooks, distal to the lateral incisors, on 0.017x0.025 Stainless Steel WIres, to the mini-screws. The power chains delivered 160g of force per side."
89422611|NCT04892056|Experimental|Anterior Segment Retraction using Frictionless mechanics by T-loops|"T shaped closing loops were fabricated on 0.017x0.025 Titanium- Molybdenum wires (TMA) were used to deliver 160g of force per side by 4mm distal activations."
89422612|NCT04907578||postpartum full term neonates|immediate postpartum full term neonates with no intrauterine growth restricted
89422613|NCT04907578||intrauterine growth restricted neonates|preterm or full-term intrauterine growth restricted neonates
89422614|NCT03052582|Active Comparator|Team 1: skimmed/whole|Milktype: 3 weeks with skimmed milk followed by 3 weeks with whole milk
89422615|NCT03052582|Active Comparator|Team 2: whole/skimmed|Milktype: 3 weeks with whole milk followed by 3 weeks with skimmed milk
89422616|NCT01510184|Experimental|Zevalin|Participants received rituximab 250 milligram per meter square (mg/m^2) by intravenous infusion on Day 1. If required by the governing regulatory agency, rituximab was to be followed 4 hours later by In-111-Zevalin 5.0 millicurie (mCi) on Day 1. And on Days 7-9: participants received rituximab 250 mg/m^2 by intravenous infusion, followed 4 hours later by Y-90-Zevalin 0.4 millicurie/kilogram (mCi/kg) 10-minute intravenous push (0.3 mCi/kg in participants with a platelet count in 100,000/ microliter [μL] to 149,000/μL).
89422617|NCT01510184|No Intervention|Observation|Participants who were randomized in this arm group did not receive any anti-lymphoma therapy unless they had a relapse of their disease.
89422618|NCT04907422||CXPA group|carcinoma ex pleomorphic adenoma of major and minor salivary glands.
89422619|NCT04907422||PA group|Benign pleomorphic adenoma of major and minor salivary glands.
89195193|NCT02567058|Experimental|3 groups of subjects|"3 groups:~group I : healthy volunters~group II : patient with an immobilisation (between 1 and 2 months)~group III : patient with an antecedent of Achilles tendon breakage during the 10 past years~Each group have the same interventions : ultrasound exam, IPAQ questionnaire"
88903521|NCT01535183|Experimental|Irinotecan|
88903522|NCT01535196|Experimental|25-OH-D3 vitamin|180 000 IU 25-OH-D3 vitamin oil per os, per month in the 0, 1, 2, 3, and 6 month at the visit. The patient take the drug under medical control
88903523|NCT01535196|Placebo Comparator|MCT oil|9 ml MCT oil as placebo in the 0,1,2,3,6 month at the visit, under medical contol
89195194|NCT00815451|Placebo Comparator|placebo dark chocolate|polyphenol-poor dark chocolate
89195195|NCT00815451|Experimental|polyphenol-rich dark chocolate|
89422620|NCT04907422||Control group|normal controls obtained from border of excision biopsy of mucocele in the lip mucosa of healthy individuals.
89422621|NCT04906954|Other|Neuromuscular electrical stimulation (NMES)|"30 NMES sessions will be performed by patients for 30 min, for a period of 8 weeks, according to a standardized protocol.~The number of sessions per week will be gradually increased to reach 5 sessions/week at week 4."
89422622|NCT04907344|Experimental|Part 1: Camrelizumab + Chemotherapy|
89422623|NCT04907344|Experimental|Part 2: Camrelizumab + Chemotherapy|
89422624|NCT04907344|Active Comparator|Part 2: Chemotherapy|
89422625|NCT04906876|Experimental|Stratum A: Soft Tissue Sarcoma|Patients with advanced soft tissue sarcoma previously treated with 0-3 prior lines of systemic therapy will receive 15 mg/kg 9-ING-41 twice weekly with 900 mg/m2 gemcitabine on days 1 and 8 and 75 mg/m2 docetaxel on day 8 of a 21-day cycle until disease progression or unacceptable toxicity.
89422626|NCT04906876|Experimental|Stratum B: Bone Sarcoma|Patients with relapsed or refractory bone sarcoma previously treated with at least one line of systemic therapy will receive 15 mg/kg 9-ING-41 twice weekly with 900 mg/m2 gemcitabine on days 1 and 8 and 75 mg/m2 docetaxel on day 8 of a 21-day cycle until disease progression or unacceptable toxicity.
89422627|NCT00858728|Experimental|1|5 portions fruit and vegetables/day
89422628|NCT00858728|Other|2|2 portions fruit and vegetables/day
89536063|NCT04997421|Active Comparator|CVVHDF with Oxiris®-AN69 membrane + Hemoadsorption using HA380|Intervention arm
88903524|NCT01535209|Experimental|SBRT to resection cavity|18Gy in 1 fraction for resection cavity <2cm in maximum diameter, 15Gy in 1 fraction for resection cavity 2.1-3cm in maximum diameter, 15Gy in 1 fraction or 25 Gy in 5 fractions over 5 days for resection cavity 3.1-4cm in maximum diameter, 25 Gy in 5 fractions over 5 days for resection cavity >4cm in maximum diameter
88903525|NCT01535209|Active Comparator|WBRT|30Gy in 10 fractions over 12 days to whole brain
88903526|NCT01535300||Elective pediatric surgery|
88903527|NCT01535313|Active Comparator|Manual (Hospital Systems TRAP Needle)|Bone marrow biopsy with a standard manual system
89195196|NCT02566980||Pre-partum|130 pregnant women will be enrolled in first trimester. Healthy women or those with any degree of depressive symptoms are eligible. Blood samples and psychiatric assessments will take place once every trimester and once in the post-partum. At delivery placenta will be collected. Enrollment takes place at Spectrum Health Ob/gyn out-patient clinics in Grand Rapids, Michigan.
89422629|NCT04906798|Experimental|Sequence1|"Period 1: Reference drug(D744)~Period 2: Test drug(CKD-385)"
88903528|NCT01535313|Experimental|Powered|
89422630|NCT04906798|Experimental|Sequence2|"Period 1: Test drug(CKD-385)~Period 2: Reference drug(D744)"
89422631|NCT05039138|Experimental|Group I (control)|: it includes 17 patients who will receive traditional strength training program.
89422632|NCT05039138|Experimental|Group II (experimental):|it includes 17 patients who will receive upper extremity neuromuscular training exercises
89422633|NCT03785912|Experimental|Internet-based self-help|The self-help program consists of eight text- and video-based modules. All participants in this group receive immediate access to the self-help program. The program's self-management approach does not provide for regular support from a specialist. However, participants can contact the study team if they need or want additional help.
89422634|NCT03785912|No Intervention|Waiting control group|Access to internet-based intervention after 12 weeks.
89422635|NCT04891744|Experimental|Selinexor in combination with thalidomide and Dexamethasone|Selinexor in combination with thalidomide and Dexamethasone. Thalidomide will be given at 100mg/d d1-28,and Dexamethasone 20 mg/d will be given on day 1, 2,8,9,15,16,22,23. Treatment will be administered in 28-day cycles,include a total of 12 cycles. Selinexor dose escalation: 60, 80, 100mg respectively on day 1,8,15,22 for 4-week cycles. Then Selinexor will be given at the recommended dose level on phase II.
89422636|NCT04891900|Experimental|TQB2450 combined with anlotinib, oxaliplatin and capecitabine in the treatment of GC or AEG|In this study, all subjects were treated with TQB2450 (PD-L1 inhibitor) plus anlotinib combined with oxaliplatin and capecitabine, once every 3 weeks, six cycles of chemotherapy with oxaliplatin and capecitabine. Subsequently, TQB2450 (PD-L1 inhibitor) combined with anlotinib was maintained until disease progression, intolerable toxicity, withdrawal of informed consent, loss of follow-up or death, or other circumstances that the researcher judged should stop treatment, whichever occurred first.
89422637|NCT03687320|Experimental|Standard and B-Cure Pro|Subjects from the Standard and B-Cure Pro group will receive standard care and in addition will self-treat at home daily with the B-Cure device.
89422638|NCT03687320|Sham Comparator|Standard and Sham|Subjects from the Standard and sham group will receive standard care and in addition will self-treat at home daily with the sham B-Cure device.
89422639|NCT04891588|Experimental|Switching the preserved to preservative free prostaglandin analog-timolol FC|To switch preserved prostaglandin analog- timolol FC (Fixapost 50 micrograms/ml + 5 mg/ml eye drops, solution in single-dose container) in the period of three months in patients with ocular hypertension and open angle glaucoma who exhibit ocular surface disease (OSD) signs and symptoms to an equally effective and safe preservative - free (PF) latanoprost - timolol FC in order to investigate whether that can result in alleviation or elimination of OSD and improvement of local tolerability.
89422640|NCT04900012||Distal pancreatectomy|All cases operated on performing distal pancreatectomy in involved Units
89422641|NCT03050866|Other|Treatment|Treatment intervention with Cabazitaxel with premedication as necessary (antihistamine, corticosteroid, H2 antagonist, antiemetic prophylaxis)
88903529|NCT01535339||Phase I - Normative|Athletes who does not participate in contact sport with no recent concussion
89195197|NCT02566980||Post-partum|50-100 women experiencing perinatal depression with and without suicidality will be enrolled from a partial hospitalization program, the Mother and Baby unit as well as outpatient clinics at Pine Rest Christian Mental Health Services, Grand Rapids, Michigan.
89422642|NCT03471806|Experimental|Bulimia Nervosa patients|Bulimia Nervosa patient group: Assessment of dopamine release to food reward at baseline (before treatment) and to food reward after treatment.
88903530|NCT01535339||Phase IIa - Concussed|Athletes with recent concussion
88903531|NCT01535339||Phase IIa - Control|Athletes with no recent concussion
88903532|NCT01535339||Phase IIb - Athletes|Athletes with no recent concussion
89195198|NCT00812409|Experimental|1|Control group: non-protein supplement with resistance and aerobic exercise.
89195199|NCT00812409|Experimental|2|Low protein supplement with resistance and aerobic exercise.
89195200|NCT00812409|Experimental|3|Moderate protein supplement with resistance and aerobic exercise.
89195201|NCT00812409|Experimental|4|High protein supplement with resistance and aerobic exercise.
89422643|NCT03471806|Experimental|Healthy controls|Healthy control group: Assessment of dopamine release to food reward at baseline, for comparison with Bulimia Nervosa patients.
89422644|NCT04455308|Experimental|Subjects with chilblains|
89422645|NCT04455308|Active Comparator|Subjects without chilblains|
89422646|NCT03051880|Experimental|Repair Control EGF®|EGF cream was applied. One half side of face and one hand were treated with emollient containing EGF.
89422647|NCT03051880|Placebo Comparator|Cream without rhEGF|Placebo cream without EGF was applied. The other half side of face and the other hand were treated with only emollient which was not containing EGF.
89422648|NCT05390996|Active Comparator|condensation drilling technique|condensation of bone (osseodensefecation technique)
89006984|NCT06161636||Patients with Parkinson Disease (PD)|"Participants will then have to perform three blocks of tests: the first focused on the scripted motor signature, a second on the voice signature, and a complementary block aimed at capturing the motor signature using gestures of greater amplitude.~All the tests were designed to allow the characterization of the motor signature according to different aspects of motor control, but also to reproduce the same concepts in the three fields (scripted signature, voice signature and large amplitude motor signature), while allowing an acquisition of an approximate total duration of 30 minutes.~For retinal photos, the subject's pupils will be dilated using eye drops (1% tropicamide and 2.5% phenylephrine) 15-20 minutes before taking the measurement. These drugs are considered the standard used by optometrists and ophthalmologists during pupil dilation."
89195202|NCT02567604||Focus groups|AMD patients' caregivers defined as people actively taking part in providing support for AMD patients (e.g. family members, unpaid friends, volunteers)
89195203|NCT02551419|Experimental|ketogenic drink|MCT ketogenic drink: ketogenic drink providing 30 g/d of MCT oil in 250 ml of lactose-free skim milk for 6 months supplementation
89195204|NCT02551419|Placebo Comparator|Placebo|Lactose-free skim milk-based placebo drink containing high-oleic sunflower oil of equivalent energy value to the active arm for a 6 months supplementation
89195205|NCT04063644|Experimental|Vis Glyc Neo|"Vis glyc eye drops is administered.~Eye drops based on N-Acetylcoarnosine, Vaccinium myrtillus and Chondroitin sulfate"
89195206|NCT04063644|Active Comparator|physiological saline solution|Physiological saline solution ALVITA is administered.
89422649|NCT05390996|Sham Comparator|conventional drilling technique|control group
89422650|NCT04906486||Observational: Patients with restless legs syndrome|A total of 70 patients who diagnosed with primary restless legs syndrome according to the five essential criteria as established by the International Restless Legs Syndrome Study Group.
89422651|NCT04906486||Observational: Healthy controls|The control group consisted of 85 age- and gender-matched healthy volunteers.
89422652|NCT05163236||CRC in excluded population|CRC diagnosed in the population excluded from screening
89422653|NCT05163236||Screen-detected colorectal cancers (SD-CRCs)|CRC diagnosed after a positive fecal immunochemical test (FIT)
89422654|NCT05163236||Colorectal cancers (CRCs) with delayed diagnosis|CRCs diagnosed after a positive fecal immunochemical (FIT) test, but without colonoscopy or > 2 years after a positive fecal immunochemical test
89422655|NCT05163236||Fecal immunochemical test interval colorectal cancers (FIT IC)|CRCs diagnosed 2 years after a negative FIT
89422656|NCT05163236||colorectal cancers (CRCs) in non-responders|CRCs diagnosed in the FIT non-responders population
89422657|NCT05163236||Post-colonoscopy interval cancers|CRCs diagnosed within 5 years after a colonoscopy performed following a positive test that did not find colorectal cancer
89422658|NCT04899466|Experimental|ActiGraft|Whole blood clot (WBC) gel
89422659|NCT03052660|Experimental|Midazolam|Midazolam, 3.75 mg , oral, once, 30-45 minutes before surgery
88903533|NCT01535352|Experimental|Internet-facilitated CBT|Participants in the randomized trial will be 300 mothers of 3-5 year old children recruited through Head Start (HS) classrooms and screened for the presence of major or minor depression. Subsequent to the pre-intervention assessment, participants will be randomized, with an allocation ratio of 1:1, to either the Mom-Net (MN) intervention or facilitated usual care (FUC) condition. Participants in the MN condition will receive the Mom-Net intervention. The Mom-Net program is an internet-facilitated cognitive-behavioral intervention for depression, adapted from the CWDC, and tailored to mothers of young children. Participants in both conditions will receive Booster calls during the follow-up period.
89422660|NCT03052660|Placebo Comparator|Placebo|Placebo, oral, once, 30-45 minutes before surgery
88903534|NCT01535352|Active Comparator|Coach-facilitated Treatment as Usual|Participants in the FUC condition will receive assistance in accessing mental health interventions through community providers that serve low-income individuals. In order to control for the supportive attention provided to mothers in the MN condition by the weekly coach calls, mothers in the FUC condition will receive weekly check-in calls from research staff during the intervention period. Participants in both conditions will receive Booster calls during the follow-up period.
88903535|NCT01535404|Active Comparator|Right ventricular apex pacing|
88903536|NCT01535404|Experimental|Left ventricular apex pacing|
88903537|NCT01535417|Experimental|GCSB|
88903538|NCT01535417|Active Comparator|Celebrex|
88903539|NCT01535456|Experimental|F-FLT PET scan, 5-azacitidine treatment|F-FLT Pet scan followed by 5-azacitidine treatment followed by FLT-PET scan. Three additional cycles of 5-azacytidine and follow up FLT-PET scan.
88903540|NCT01535469|Experimental|CrAg Screening and Fluconazole|Cryptococcal Antigen (CrAg) Screening with preemptive antifungal treatment per World Health Organization (WHO) guidelines. Randomized Stepped Wedge design of phased implementation.
88903541|NCT01535482|Experimental|Cognitive Therapy|A cognitive therapy protocol specifically designed to target suicidal ideation in older adults.
88903542|NCT01535482|Active Comparator|Enhanced Usual Care|Enhanced usual care consists of the usual care that individuals receive for suicide prevention, plus assessment and referral services provided by project staff, and weekly phone calls provided by study therapists.
89422661|NCT05159180||patients with atrial arrhythmias undergoing catheter ablation of these|Patients will be submitted to mapping of both voltage and tissue impedance. The accuracy of the two maps identifying the extent and transmurality of the infarction will be assesssed by gadolinium imaging.
89422662|NCT04891120|Experimental|With, then without a mask|Participants will first perform a treadmill test with a mask and 48 hours or more later will perform another similar treadmill test without a mask.
89422663|NCT04891120|Experimental|Without, then with a mask|Participants will first perform a treadmill test without a mask and 48 hours or more later will perform another similar treadmill test with a mask.
89422664|NCT05006456||Cohort 1|Cohort 1 consists of 2000 subjects undergoing catheter ablation with STSF catheter, in which AI is used to guide the ablation lesion creation.
89422665|NCT05006456||Cohort 2|Cohort 2 consists of 2000 subjects who undergoing catheter ablation using QDOT or HELIOSTAR catheter.
89422666|NCT04891042||Latent Phase of Labour|
89422667|NCT04891042||Active Phase of Labour|
89422668|NCT04958174||Users|Users of the web-application
88903543|NCT01535495|Experimental|Complete laser|Patients who have had complete panretinal photocoagulation laser treatment and active retinal neovascularization
88903544|NCT01535495|Experimental|Laser naive|"Patients who have not had panretinal photocoagulation laser treatment and active retinal neovascularization without so called high-risk characteristics"
88903545|NCT01535521|Other|SPT in patients with MAD|
88903546|NCT01535547|Experimental|isavuconazole and tacrolimus|
89422669|NCT04753814|Other|Identyfication of prognostic factors in HFrEF|Selected prognostic factors will be analyzed in patients with LVEF ≤40%
89422670|NCT04753814|Other|Identyfication of prognostic factors in HFmrEF|Selected prognostic factors will be analyzed in patients with LVEF 41-49%
89422671|NCT04753814|Other|Identyfication of prognostic factors in HFpEF|Selected prognostic factors will be analyzed in patients with LVEF ≥50%
89422672|NCT04412278||Turkish society|Individuals speak Turkish and lives in Turkey, ages between 15 - 65, literate and with internet access
89422673|NCT05162534||Patients needing IoC|"Patients needing IoC can be recognized by the acronym IoCp"
89422674|NCT05162534||30-day deceased patients|"Patient died after a period of observation of 30 days are presented with the acronyms 30-ddp (30-day deceased patients)"
89422675|NCT05162534||did not undergo IoC|"Patients did not undergo IoC, we chose the acronym nIoCp."
89422676|NCT05162534||30-day survived patients|"Patient survived after a period of observation of 30 days are presented with the acronyms 30-dsp (30-day survived patients)"
89422677|NCT04890808|Experimental|Over-the-Counter Dietary Supplement Inosine|capsules containing 500 mg of inosine Two capsules Twice Daily Other Name: hypoxanthine 9-β-D-ribofuranoside 9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-hydroxymethyl) oxolan-2-yl]-1H-purin-6-one
89422678|NCT04890808|Experimental|Over-the-Counter Dietary Supplement IP6|"capsules containing 500mg of IP6 Two capsules Twice Daily Other Name: Inositol hexaphosphate~(1R,2S,3r,4R,5S,6s)-cyclohexane-1,2,3,4,5,6-hexayl hexakis[dihydrogen (phosphate)]"
89422679|NCT05162456||participants willing to receive a 3-dose vaccination schedule|participants willing to receive a 3-dose vaccination schedule
88903547|NCT01535586|Active Comparator|CPAP|participants will be treated with continuous positive airway pressure (CPAP) for 12 weeks
88903548|NCT01535586|Active Comparator|MAD|Participants will be treated with a mandibular advancing device for 12 weeks
88903549|NCT01535612|Experimental|PaQ™ insulin infusion device|PaQ™ insulin infusion device which delivers rapid acting insulin.
88903550|NCT01535625|Other|Momo stent|Patients with PCI
88903551|NCT01535651|Experimental|TOP Program plus Text messaging|Boys and Girls Club members who participate in TOP over 9 months will receive regular text messages in addition to TOP
88903552|NCT01535651|No Intervention|TOP Program alone|Boys and Girls Club participants will participate in TOP for 9 months
88903553|NCT01535677|Experimental|1|5 mg dapagliflozin and 850 mg Glucophage in fasted state
89195207|NCT04045275|Experimental|Calm|"The intervention will occur across 8 weeks. During Week 1, it is suggested to intervention participants that they complete 7 days of Calm meditation series (7 meditations, each approximately 10 minutes long, created to help users learn the basics of mindfulness meditations. For the remaining weeks (Week 2- Week 8) intervention participants will be asked to meditate for 10 minutes per day using any of the meditation sessions/features. Throughout the intervention, participants not completing 30 minutes of meditation per week will be sent reminders texts/emails."
89195208|NCT04045275|No Intervention|Control|This group is a wait-list control group who will receive the intervention following the 8-week waiting period. Participants in this condition are instructed not to start meditating before the waiting period. After the 8-week waiting period, waitlist participants will receive the same intervention as described in the Calm Arm.
89195209|NCT05325138||Parents|Parents of girls aged 9-14 years old
89195210|NCT02567916|Experimental|FRESOFOL MCT|To compare the incidence and intensity of pain on injection that is caused by propofol (LCT propofol) versus fresofol (MCT/LCT propofol) .
89195211|NCT02567916|Active Comparator|Propofol|The purpose of this study is to compare the incidence and intensity of possible pain on injection as well as patient satisfaction caused by propofol (LCT propofol) versus fresofol (MCT/LCT propofol).
89195212|NCT04045509|Other|Group 'young age'|Group 'young age': 18 - 30 years of age; healthy eyes
89195213|NCT04045509|Other|Group 'advanced age'|Group 'advanced age': 50 - 70 years of age; healthy eyes
89195214|NCT02567526|No Intervention|Usual Care Control Group|Eligible, consented residents continued to receive usual care from nursing home staff and were monitored by trained research staff.
89195215|NCT02567526|Experimental|Between-meal Intervention Group|Non-nursing staff trained as Feeding Assistants were utilized to deliver supplements and snacks twice per day, between meals for 24 study weeks.
89195216|NCT00402025|Experimental|Talimogene Laherparepvec|Participants received 3 doses of talimogene laherparepvec administered by direct injection 3 weeks apart. At the discretion of the investigator, treatment with talimogene laherparepvec could continue beyond the third dose until week 15 in a regimen of at least 3 weeks between doses.
89195217|NCT00812721|Placebo Comparator|1|Preservative Free Saline
89195218|NCT00812721|Active Comparator|2|Optive (TM)
89195219|NCT00812721|Active Comparator|3|Refresh Moderate/Severe (TM)
89195220|NCT00812721|Active Comparator|4|Systane (TM)
89195221|NCT00812721|Active Comparator|5|Systane Ultra (TM)
89195222|NCT03896100||Element 2|Four clinical samples will be taken from each eligible subject and used to assess two clinical removal methods and two in vitro removal methods.
89195223|NCT03896100||Element 3|Four clinical samples will be taken from each eligible subject and used to assess three different storage methods.
89195224|NCT03896100||Element 4|Four clinical samples will be taken from each eligible subject and used to assess different ocular regions.
89195225|NCT00812799|Active Comparator|Grass pollen extract|Subjects will receive 19.000 BU grass pollen extract daily sublingually
89422680|NCT05162456||participants unwilling to receive a 3rd dose of vaccination|participants who received a 2-dose vaccination schedule, unwilling to receive a 3rd dose
89422681|NCT04890964|Active Comparator|Transcranial Direct Current Stimulation (tDCS), Active Stimulation - DLPFC|Participants received Active stimulation 20 minutes daily for 20 days, and 4 times after continuous stimulation, every 15 days.
88903554|NCT01535677|Experimental|2|dapagliflozin/metformin (5 mg/850 mg) immediate release (IR) FDC in fasted
88903555|NCT01535677|Experimental|3|5 mg dapagliflozin and 850 mg Glucophage in fed state
88903556|NCT01535677|Experimental|4|dapagliflozin/metformin (5 mg/850 mg) IR FDC in fed state
89195226|NCT00812799|Placebo Comparator|Placebo control|Subjects will receive matching placebo control daily sublingually
89195227|NCT00815763|Experimental|ginsenoside-Rd 20mg|infusion of ginsenoside-Rd 20mg once a day and continued for 14 days
89195228|NCT00815763|Placebo Comparator|placebo|infusion placebo (group B)once a day and continued for 14 days
89195229|NCT00609622|Experimental|A|Treatment arm A - sunitinib plus mFOLFOX6
89195230|NCT00609622|Active Comparator|B|Treatment arm B - bevacizumab plus mFOLFOX6
89195231|NCT04045119|Experimental|Before-and-after|54 Healthy adults 18 years of age or older at the visit or will receive the first application and will be evaluated according to the objectives defined in the study (short-term data) and to evaluate the longterm effects, two other visits will be made at intervals of 2 weeks to evaluate the impact of topical skin application according to the parameters defined in the study
89195232|NCT00818415|Experimental|Arm 1|
89195233|NCT00818415|Active Comparator|Arm 2|
89195234|NCT04045197|Experimental|Intervention group|In the intervention group; informed consent forms, Relaxation Focused Nursing Care and routine nursing care in the hospital were performed. Then data collection tools were applied.
89195235|NCT04045197|No Intervention|Control group|Women in the control group received routine nursing care in the hospital and data collection tools were applied at the same hours as the intervention group.
88903557|NCT01535690|Experimental|laser and methilene blue|After random allocation, all patients received full-mouth ultrasonic debridement using an ultrasonic scaler (Profi III Bios, Dabi Atlante, Ribeirão Preto, São Paulo, Brazil) for 1 hour. Specific tips were used (Perio sub, Dabi Atlante, Ribeirão Preto, São Paulo, Brazi). PDT was performed on only one side of the mouth and the initial step was subgingival irrigation with 0.005% methylene blue dye. To avoid contamination of the control sites with the dye, the methylene blue was applied only inside the periodontal pockets and a high-powered suction device controlled the flow. Two minutes after applying the photosensitizer, the low power laser - AsGaAl (Photon Laser III - PL7336, DMC, São Carlos -São Paulo, Brazil) was applied (660 nm, 100 mW, 9 J, 90 seconds per site, 320 J/cm2).
88903558|NCT01535716|Experimental|ECOM group|50 Patients scheduled for elective coronary surgery with cardiopulmonary bypass
88903559|NCT01535716|Active Comparator|standard management group|50 Patients scheduled for elective coronary surgery with cardiopulmonary bypass
88903560|NCT01535742|Experimental|Ambu Aura-i size 1.5|patients will receive either the Ambu Aura-i size 1.5 or air-Q ILA 1.5 based on manufacturer recommendations of body weight
88903561|NCT01535742|Experimental|air-Q size 1.5|patients will receive either the Ambu Aura-i size 1.5 or air-Q ILA 1.5 based on manufacturer recommendations of body weight
88903562|NCT01535742|Experimental|Ambu Aura-i size 2|patients will receive either the Ambu Aura-i size 2 or air-Q ILA 2 based on manufacturer recommendations of body weight
88903563|NCT01535742|Experimental|air-Q size 2|patients will receive either the Ambu Aura-i size 2 or air-Q ILA 2 based on manufacturer recommendations of body weight
88903564|NCT01535755|Active Comparator|protocol group|This group patients are weaned as the protocol which the investigators described.
88903565|NCT01535755|Other|clinicians' order group|This group patients are weaned as the clinicians' order.
88903566|NCT01535768|Experimental|Intervention Group|Patients randomized to the intervention group will receive aqueous suppressant eyedrops in a stepwise fashion in order to maintain their intraocular pressure between 7-10mmHg.
88903567|NCT01535768|No Intervention|Control Group|"Patients randomized to the control group will receive standard of care treatment. They will not be aqueous suppressed within the first three postoperative months unless the bleb hyperencapsulates.~(If they experience the hyperencapsulation phase, they will continue to receive standard of care treatment, which would then be aqueous suppressant eye drops added in a stepwise fashion)"
88903568|NCT01535781|Placebo Comparator|Placebo|Patients are given saline instead of tranexamic acid in the placebo group
88903569|NCT01535781|Active Comparator|Tranexamic Acid|Tranexamic acid; 1 gram as a bolus prior to surgery. 3 grams of Tranexamic acid in 1 liter of saline as a 24 hour infusion.
88903570|NCT01535794||18-26 year old men who have sex with men|
88903571|NCT01535820|Experimental|Treatment sequence AB|
88903572|NCT01535820|Experimental|Treatment sequence BA|
88903573|NCT01535833|Other|Robotic sacral colpopexy|To assess subjects with stage 2 pelvic organ prolapse undergoing robotic sacral colpopex
88903574|NCT01535846|Experimental|Conscious food tasting intervention|Instead of focusing on dieting rules to restrict food intake, paying attention to sensory stimulation allow the recognition of internal cues of hunger and satiety which can be helpful to facilitate a more internalized regulation of food intake among restrained eaters. In the experimental group, the conscious food tasting intervention will be conducted by a registered dietitian into small groups of ten to twelve women during six weekly 2-hour workshops. Workshops will be taking place in a well-ventilated room to insure that there are no extraneous odours or noises that may hamper the activities involving senses.
88903575|NCT01535846|No Intervention|Control|
88903576|NCT01535859|Experimental|Cabergoline|
88903577|NCT01535859|Placebo Comparator|Placebo|
88903578|NCT01535872|Experimental|DHEA treatment|
88903579|NCT01535872|No Intervention|No treatment|
88903580|NCT01535885|Experimental|Multi-Virus CTLs|The treatment plan delivers a single dose of Multi-Virus CTL to all patients enrolled on study.
88903581|NCT01535898||Pts having an MRI|This is a technology assessment protocol. The study is designed to assess the utility of the technology using a limited number of participants.
88903582|NCT01535989|Experimental|intravenous|dose escalation
88903583|NCT01536002|Experimental|Pharmacokinetics|Propofol pharmacokinetics
88903584|NCT01536028|Active Comparator|BIAsp 30|
88903585|NCT01536028|Experimental|BIAsp 50|
88903586|NCT01536028|Experimental|BIAsp 70|
88903587|NCT01536028|Active Comparator|IAsp|
88903588|NCT01536054|Experimental|Treatment (vaccine, sirolimus, GM-CSF)|Patients receive ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine SC on day 1 and GM-CSF SC on days 1-4. Patients also receive sirolimus PO QD on days 1-14 OR 15-28 OR 1-28. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients then receive an additional course of ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine only followed by ALVAC(2)-NY-ESO-I (M)/TRICOM vaccine SC 8 weeks after completion of course 4.
88903589|NCT01536080||Reflux esophagitis (RE)|
88903590|NCT01536080||Non-erosive reflux disease (NERD)|
88903591|NCT01536080||Functional heartburn (FH)|
88903592|NCT01536106|Experimental|Treatment|Implantation of bone marrow derived mononuclear cells
89422682|NCT04890964|Sham Comparator|Transcranial Direct Current Stimulation (tDCS), Sham Stimulation - DLPFC|Participants received Sham stimulation 20 minutes daily for 20 days, and 4 times after continuous stimulation, every 15 days.
89422683|NCT04890964|Active Comparator|Transcranial Direct Current Stimulation (tDCS), Active Stimulation - M1|Participants received Active stimulation 20 minutes daily for 20 days, and 4 times after continuous stimulation, every 15 days.
89422684|NCT04890964|Placebo Comparator|Transcranial Direct Current Stimulation (tDCS), Sham Stimulation - M1|Participants received Sham stimulation 20 minutes daily for 20 days, and 4 times after continuous stimulation, every 15 days.
89422685|NCT04890886||Pre-existing Type 1 Diabetes and Type 2 Diabetes|Women with type 1 diabetes and type 2 diabetes diagnosed prior to pregnancy
89422686|NCT04890886||Gestational Diabetes|Women with gestational diabetes diagnosed in pregnancy by the oral glucose tolerance test
89422687|NCT04890886||Intrahepatic cholestasis of pregnancy|Women with intrahepatic cholestasis of pregnancy
89422688|NCT04890886||Control|Women without metabolic disease in pregnancy
89422689|NCT03469154|Experimental|Dyad training|The participants in this arm will train in teams of two. Participants will be instructed in paediatric basic life support by instructional videos in a computer programme and train on children resuscitation manikins. Training involves recognition of cardiac arrest, cardio-pulmonary resuscitation and foreign body airway obstruction management. The training involves series of short video clips and following exercises. Each participant performs the exercise and the other gives feedback. Afterwards roles are changed. The procedure is done for all exercises after a video clip. The duration of the training is maximum 50 minutes
89422690|NCT03469154|Active Comparator|Instructor led training|"Participants train in courses of up to 6 participants with an instructor. Training content is identical to dyad training content involving: recognition of cardiac arrest, cardio-pulmonary resuscitation and foreign body airway obstruction management.~Skills are instructed by an instructor using af 4 step approach (1. show skills, 2. show with explanation, 3. participants instruct instructor, 4. participants performs the skills on resuscitation manikins). Training is maximum two hours but course duration is adjusted to number of participants two allow for similar hands-on time per participant as in the experimental arm."
89422691|NCT04906252||Ventricular Fibrillation|Patients presenting to the Emergency Department after out of hospital cardiac arrest demonstrating Ventricular Fibrillation (Vfib) Cardiac Arrest or Patients demonstrating Vfib during cardiac arrest.
89422692|NCT04906252||PEA|Patients presenting to the Emergency Department after out of hospital cardiac arrest demonstrating Pulseless Electrical Activity (PEA) Cardiac Arrest. Patients demonstrating PEA during cardiac arrest
89422693|NCT04906252||Asystole Cardiac Arrest|Patients presenting to the Emergency Department after out of hospital cardiac arrest demonstrating Asystolic Cardiac Arrest. Patients demonstrating Asystole during cardiac arrest
89422694|NCT05137886|Experimental|PD-1 inhibitor combined with decitabine followed by ASCT|Patients will receive salvage treatment of PD-1 inhibitor Tislelizumab combined with decitabine for four cycles, If PR or CR was obtained after salvage treatment, patients will receive GBM (gemcitabine, bulsufan and melphalan) conditioning regimen followed by ASCT. High-risk patients will receive PD-1 inhibitor for 1 year after ASCT as maintenance therapy.
89422695|NCT04905394|Experimental|Treatment with subchondroplasty for bone edema in the knee|Patients treated with subchondroplasty for bone edema of the knee
89422696|NCT05135624|Experimental|Cohort dose 1 of SP16|Patients in cohort 1 (low dose SP16) will receive a single dose of SP16 (0.1 mg/kg or 6 mg) by subcutaneous injection
89422697|NCT05135624|Experimental|Cohort dose 2 of SP16|Patients in cohort 2 (high dose SP16) will receive a single dose of SP16 (0.2 mg/kg or 12 mg) by subcutaneous injection
89422698|NCT05135624|Placebo Comparator|Placebo|Patients in placebo arm will receive sterile water by subcutaneous injection.
89422699|NCT03469076|Experimental|ACN Cream|Patients with mild to moderate acne using ACN Cream
89422700|NCT04905472|Experimental|Vestibular & Cochlear Implant Patients|"scheduled for CI surgery because of deafness~a minimum of five year history of documented absence of auditory and vestibular function, based on review of their audiograms and vestibular tests.~Specific vestibular criteria are: peak ice water caloric response of less than 3 deg/s for each ear; yaw VOR time constant < 3.0 sec and gain < 0.25; and reduced head impulse gain (<0.25) for all canal planes.~Specific audiographic criteria: 80dB or greater sensorineural hearing loss in both ears"
89422701|NCT04905550|Experimental|Craniocerebral radiotherapy combined with Almonertinib 110mg p.o qd|"Almonertinib mesylate tablet, 110mg, qd; until the disease progresses or unacceptable toxicity.~The craniocerebral radiotherapy was acceptable from 1 week before to 6 weeks after treatment with Almonertinib.~Dose adjustment and delay of Almonertinib are allowed. Delay of Almonertinib is allowed for up to 9 weeks, calculated from the time of last administration, otherwise, treatment is terminated."
89422702|NCT04890496||inpatients of ZOC|Patients have retrospective hopitalization record of ZOC from 1998 to 2020.
89422703|NCT04667000|Experimental|lower extremities|the women's lower extremities will be heated with Forced Air Warming
88903593|NCT01536106|Placebo Comparator|Placebo Control|Infusion of autologous peripheral blood
88903594|NCT01536132|Active Comparator|Levosimendan|levosimendan at a dose of 0.2 micrograms/kg/min for 6 hours intravenous infusion
88903595|NCT01536132|Placebo Comparator|Placebo|placebo (same appereance than levosimendan in colour) at a dose of 0.2 micrograms/kg/min for 6 hours intravenous infusion
88903596|NCT01536158|Active Comparator|Oral paracetamol|Patients will receive oral paracetamol 15 mg/kg per dose every 6 hours.
88903597|NCT01536158|Active Comparator|Oral ibuprofen|Patients will receive oral ibuprofen at an initial dose of 10 mg/kg, followed by 5 mg/kg at 24 and 48 h.
88903598|NCT01536210|Experimental|YY-162|"YY-162(Ginkgo Extract 30mg + Ginseng Extract 50mg)~1T/Three times a day(Tid) for 8 weeks, PO medication"
88903599|NCT01536210|Placebo Comparator|Placebo|Placebo 1T /Three times a day(Tid) for 8 weeks, PO medication
88903600|NCT01536223|Active Comparator|PF group|the group of participants who undergoing cisplatin and 5-fluorouracil(PF)neoadjuvant chemotherapy
88903601|NCT01536223|Experimental|TPF group|TPF(docetaxel , cisplatin and 5-fluorouracil)neoadjuvant chemotherapy
88903602|NCT01536236|Active Comparator|Subthreshold programming|During one of the first 2 weeks of the trial the subject will be randomized to a subthreshold stimulation arm. They will be blinded and receiving therapy, but will it will be delivered at a level (subthreshold) that they will not feel the stimulation.
88903603|NCT01536236|Placebo Comparator|Placebo or Stimulation off arm|During one of the first two weeks of the study, the patient will be randomized to a no stimulation arm. They will be blinded and will not be receiving therapy.
88903604|NCT01536236|Active Comparator|Optimal stimulation programming|During the third week of the trial period, all subjects will receive optimal stimulation.
88903605|NCT01536249|Experimental|Dexpramipexole single dose & 12 Doses Cimetidine|300 mg Dexpramipexole Oral Dose (to be taken in conjunction with multiple doses of Cimetidine at 400 mg per dose)
88903606|NCT01536249|Experimental|Dexpramipexole single Dose|300 mg Dexpramipexole Oral Dose
89195236|NCT04044963|Experimental|Exercise Group|All participants who are allocated to the exercise group will be asked to complete 4-5 days per week of mixed modality exercise incorporating aerobic, resistance, and flexibility training. The exercise intervention is prescribed based on the FITT principle: frequency, intensity, time and type. The 10-point Rating of Perceived Exertion (RPE) scale, which has been well correlated to target HR levels, will be used to monitor exercise intensity levels throughout the intervention, with participants instructed to maintain their intensity level at 3-5 during exercise sessions. Participant progression will be individualized and based on their subjective perceived intensity level using the RPE scale. In person instruction, from a member of the research team with standard first aid and CPR-C training, and an instructional handout and exercise log will be provided, as well as exercise resistance bands to perform resistance exercises.
89422704|NCT04667000|Experimental|upper extremities|the women's upper extremities will be heated with Forced Air Warming
89422705|NCT04667000|Experimental|whole body|the women's whole body will be heated with Forced Air Warming
89422706|NCT04667000|No Intervention|control group|there is no intervention for this group
89422707|NCT04890418|Active Comparator|Study drug|0.3 mg/kg intravenous ketamine diluted into 10mL saline after the realization of peripheral nerve block (PNB), before tourniquet set up and beginning of surgery
89195237|NCT04044963|No Intervention|Control Group|This will consist of regular care, which is standard procedure.
89195238|NCT02567760|Active Comparator|MP1 group|Subjects receive the MP1 product at the dose of 400 mg/day for 8 weeks.
89195239|NCT02567760|Placebo Comparator|Placebo group|Subject receive the Placebo product for 8 weeks.
89195240|NCT00813033|Other|patient decision aid|
89195241|NCT00813189|Experimental|1 : early start (GH treatment) group|in the early start group, patients were treated with growth hormone for one year immediately after randomisation
89195242|NCT00813189|No Intervention|2 :delayed start (GH treatment) group|in the delayed start group patients took GH treatment for 1 year , 6 months after randomisation
89195243|NCT02551263||Observational group|All patients will receive adequate treatment for breast cancer which selected by the primary physician after enrollment using the Japanese Breast Cancer Society Clinical Practice Guideline of Breast Cancer and the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Investigators at the investigational sites will enter patient data into an electronic data capture (EDC) system up to the third chemotherapy in the study.
89195244|NCT02567214|Experimental|Ultibro® versus sham Spiriva®|"Indacaterol 110 µg/Glycopyrronium 50 µg Inhaled~1 time per day 21 days"
89195245|NCT02567214|Experimental|Sham Ultibro® versus Spiriva®|"Tiotropium 18 µg Inhaled~1 time per day 21 days"
89195246|NCT04044885|Experimental|Nap|After each night with a 6.5-hour sleep opportunity, participants have a daytime nap opportunity of 1.5 hours.
89195247|NCT04044885|No Intervention|No nap|After each night with a 8-hour sleep opportunity, participants do not have a daytime nap opportunity, but instead have free time.
89195248|NCT00888004|Experimental|Active|
89195249|NCT00888004|Placebo Comparator|Placebo|
89195250|NCT05537922||Retrospective Cohort|This cohort includes the analysis of a multicentric retrospective cohort of more than 2,000 patients. This cohort will be used to perform a preliminary knowledge extraction phase and to build a retrospective predictive model for IO (R-Model). All available clinical data will be collected. Also, CT and PET scans will be collected and a first radiomic signature.
89195251|NCT05537922||Prospective Cohort|The prospective part of the project includes the collection and the analysis of multi-OMICs data from a multicentric prospective cohort of about 200 patients.
89195252|NCT00813267|Experimental|stem cell|mesenchymal stem cell infusion and bone marrow mononuclear cell infusion
89195253|NCT00890110|Experimental|Autologus vaccination with suntinib|Combination of autologous dnp irradiated modified cells with sunitinib treatments
89195254|NCT02566824|Experimental|Cognitive Behavioural & Skills Training|Participants can choose to be on medication or not. If they decide to take medication, they will be titrated to an optimal dose of stimulant medication. Then they undergo the 12 weeks of group cognitive behavioral and skills training therapy.
89195255|NCT02566824|Active Comparator|Supportive Group Therapy|Participants can choose to be on medication or not. If they decide to take medication, they will be titrated to an optimal dose of stimulant medication. Then they undergo the 12 weeks of supportive group therapy.
89195256|NCT02566824|Active Comparator|Treatment as Usual - community resources|Participants can choose to be on medication or not. If they decide to take medication, they will be titrated to an optimal dose of stimulant medication. Then they are referred to their treating physicians and are free to use any resources that are available to them in their communities.
89195257|NCT00813345|Experimental|A - Light therapy|Light therapy (1500 lux)
89195258|NCT00813345|Placebo Comparator|B - identical control lamp|identical control lamp
88903607|NCT01536288|Active Comparator|Rhodiola crenulata-placebo sequence|Rhodiola crenulata for the first treatment period and placebo for the second treatment period, with a washout period of 4 months. Overall study population were 120 subjects, who were randomised and allocated into 2 sequences.
88903608|NCT01536288|Active Comparator|Placebo-Rhodiola crenulata sequence|Placebo for the first treatment period and Rhodiola crenulata for the second treatment period, with a washout period of 4 months. Overall study population were 120 subjects, who were randomised and allocated into 2 sequences.
88903609|NCT01536301|Active Comparator|Morphine|The patients in this arm will have post-operative analgesia including morphine (patient controlled analgesia).
88903610|NCT01536301|Experimental|Oxycodone|The patients in this arm will have post operative analgesia including oxycodone (patient controlled analgesia).
89195259|NCT00890188|Experimental|THALIDOMIDE and UFUR|
88903611|NCT01536327||Observation|Patients with Metachromatic Leukodystrophy disease or profound suspicion for Metachromatic Leukodystrophy disease
88903612|NCT01536353|Experimental|AGSAV301|
88903613|NCT01536353|Active Comparator|Exforge 10/160|
89195260|NCT05388942|Experimental|Virtual reality hypnosis (VRH)|
89195261|NCT05388942|Active Comparator|Nitrous oxide (NO)|
89195262|NCT04037566|Experimental|XYF19 CAR-T cell|"One arm study consisting of 3 + 3 dose escalation study design followed by dose expansion phase at determined MTD."
89195263|NCT00699660|Experimental|CAPS/WHODAS|PTSD assessed using Clinical Assessment of PTSD Symptoms (CAPS) and WHODAS functional impairment structured evidence-based interview
89195264|NCT00699660|Active Comparator|Nonstructured Interview|Usual clinical interview to assess PTSD, without CAPS or WHODAS
89195265|NCT00888082|No Intervention|A|Patients receiving only adjuvant chemotherapy
89195266|NCT00888082|Experimental|B|Patient receiving goserelin acetate along with adjuvant chemotherapy
88903614|NCT01536431|Experimental|Pro insulin peptide|Patients will receive 10 micro gr of the peptide every 2 weeks (12 doses).
88903615|NCT01536431|Active Comparator|Pro insulin peptide & saline|Patients will receive 10 micro gr of the peptide monthly (ever 4 weeks, 6 doses) and saline injections monthly alternating with the peptide (2 weeks interval between the drug and saline).
88903616|NCT01536431|Placebo Comparator|Saline|Patients will receive 0 micro gr of peptide, but have saline injections every 2 weeks (controls)
88903617|NCT01536444|Experimental|Micrografting|
88903618|NCT01536470|Experimental|Noradrenaline|Continuous infusion of noradrenaline to maintain arterial blood pressure management in high-risk surgical patients
88903619|NCT01536470|Experimental|Ephedrine chorhydrate|Conventional treatment of hypotension (defined as a blood pressure of below 80 mmHg or a decrease of more than 40% from baseline)using intravenous bolus of Ephedrine chorhydrate
88903620|NCT01536483|Experimental|Butyrate|"New born with a birth weight <1000g: Seven enemas of butyrate will be performed every 2 days from PND5~New born with a birth weight >1000g: Seven enemas of butyrate will be performed every day from PND5"
88903621|NCT01536483|No Intervention|Therapeutic Abstention|The protocol will pretend enema: instillation in the diaper the product under consideration, to make the two indistinguishable processes (time, odor, wicking diaper ...)
89195267|NCT00627705|Active Comparator|N-Acetyl Cysteine|active compound N-Acetyl Cysteine
89195268|NCT00627705|Placebo Comparator|Sugar pill|Placebo or sugar pill
89195269|NCT04062162|Active Comparator|Interventional group|Walking football training
89195270|NCT04062162|No Intervention|Control group|Usual care
89195271|NCT04037488||Cohort: ADT patients|"All enrolled patient data entered in single group cohort. All patient who started androgen deprivation therapy for prostate cancer can included this cohort by following inclusion and exclusion criteria. We do not planned any intervention on this cohort. We measuring changes of body composition by Inbody 320 in the planned follow-up period.~We planned sub-group analysis for timing of intervention (Intervention 1) , ADT type(Intervention 2), LHRH agonist type(Intervention 3), patients age(Intervention 4), initial PSA level (Intervention 5) and Gleason Grade Group (Intervention 6)."
89195272|NCT00890422|Experimental|1FSME vaccination|2 vaccination on day 0
89195273|NCT00890422|Experimental|2 FSME vaccination|1 vaccination on day 0 and one vaccination on day 4
89195274|NCT00890422|Experimental|3 FSME vaccination|2 vaccinations on day 0 and 1 vaccination on day 4
89195275|NCT00816075|Experimental|1, Distilled water|the group of patients with superficial bladder cancer in the intermediate risk group who had their first recurrence after 6 months from the initial TUR. We plan to administer 200 ml of distilled water as immediate instillation for 2 hours
89195276|NCT02541370|Experimental|anti-CD133 CAR T cells|"Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.~Patients receive anti-CD133-CAR retroviral vector-transduced autologous-derived T cells on days 0, 1, 2 in the absence of disease progression or unacceptable toxicity."
89195277|NCT05045820|Active Comparator|Treatment|
89195278|NCT05045820|Sham Comparator|Sham|
89195279|NCT00610168|Experimental|BOOSTRIX I GROUP|Subjects, who had received Boostrix™ vaccine in the primary study (263855/004), received one additional booster dose of Boostrix™ vaccine in this study, administered as an intramuscular injection into the deltoid region of the non-dominant arm.
89195280|NCT00610168|Experimental|BOOSTRIX II GROUP|Subjects, who had received Wyeth's (formerly Lederle) combined adult diphtheria and tetanus vaccine and GSK Biologicals' acellular pertussis vaccine in the primary study (263855/004), received one booster dose of Boostrix™ vaccine in this study, administered as an intramuscular injection into the deltoid region of the non-dominant arm.
89195281|NCT00921102|Placebo Comparator|Control|Patients in this group will receive both an intrathecal and intravenous injection of saline solution, as a placebo comparator.
89422708|NCT04890418|Placebo Comparator|Placebo|10 mL 0.9% saline after the realization of PNB, before tourniquet set up and beginning of surgery
88903622|NCT01536509|Experimental|Telehealth Behavioral Treatment|
88903623|NCT01536509|Active Comparator|Education Only|
88903624|NCT01536548|Experimental|Skin drawing|
88903625|NCT01536548|Active Comparator|No skin drawing|
88903626|NCT01536600||BIAsp 30 users|
89195282|NCT00921102|Experimental|Intrathecal Atropine|Patients in this group will receive intrathecal atropine as a prophylactic antiemetic agent. They will also receive intravenous saline solution to maintain blinding.
89195283|NCT00921102|Active Comparator|IV Atropine|Patients in this group will receive a small dose of atropine via the intravenous route to examine its possible antiemetic activity. They will also receive intravenous saline solution to maintain blinding.
89195284|NCT00890500|Active Comparator|Group 1|2 umbilical cord units: Second cord blood unit modulated with ProHema
89195285|NCT00890500|Active Comparator|Group 2|2 umbilical cord units: First cord blood unit modulated with ProHema
89195286|NCT00890578||1-abdominal|half abdominal surgeries (20 patients out of 40)
89195287|NCT00890578||2-breast|half breast surgeries (20 out of 40)
89195288|NCT00890734|Experimental|1|
89195289|NCT00890734|Placebo Comparator|2|
89195290|NCT00890812||Factors VIII, IX and XI levels measured|Case group
89195291|NCT00890812||Non Stroke patients|This is the control group. This group represents patients who were initially evaluated for stroke.
89195292|NCT04061772|Experimental|BCHEP|Bortezomib：1.3mg/m2, intravenous drip, d1,d8, every 3 weeks； Etoposide：100mg/m2,intravenous drip, d1-3, every 3 weeks； Cyclophosphamide：750mg/m2,intravenous drip, d1, every 3 weeks； Pharmorubicin：75mg/m2,intravenous drip, d1,every 3 weeks； Prednisone：100mg,tablet by mouth, d1-5, every 3 weeks.
89195293|NCT04061928|Experimental|Combination of toripalimab with preoperative chemoradiotherapy|"This is a one arm study, enrolled locally advanced EGJ patients will receive toripalimab and combined with preoperative chemoradiotherapy and operation.~generic name：PD-1 dosage form：Injection dosage：240mg (6ml) frequency：every 3 weeks duration：4 times before operation and 4 times after operation"
89195294|NCT00644787|Experimental|Fentanyl 1-day transdermal patch (Titration Phase)|Fentanyl 1-day application transdermal patch releasing the drug at the rate of 12.5 microgram per hour (mcg/hr) applied once daily, and maintained for 2 days. Dose escalation or reduction is done as per Investigator's discretion (maximum applied dose is 100 mcg/hr) up to Day 11 and then dose is fixed up to end of treatment period, that is Day 14. Participants who met the predefined criteria at the end of Titration Phase enter the Double Blind Phase.
89195295|NCT00644787|Experimental|Fentanyl 1-day transdermal patch (Double Blind Phase)|Participants who meet the predefined criteria at the end of Titration Phase and enter the Double Blind Phase receive fentanyl 1-day application transdermal patch and placebo matched to fentanyl 3-day application (JNS005) transdermal patch applied once daily releasing the drug at the same dose as maintained at the end of Titration Phase with maximum applied dose of 100 mcg/hr for 10 days.
89195296|NCT00644787|Active Comparator|Fentanyl 3-day transdermal patch (Double Blind Phase)|Participants who meet the predefined criteria at the end of Titration Phase and enter the Double Blind Phase receive fentanyl 3-day application transdermal patch and placebo matched to fentanyl 1-day application transdermal patch applied once daily releasing the drug at the same dose as maintained at the end of Titration Phase with maximum applied dose of 100 mcg/hr for 10 days.
89195297|NCT00699582|Experimental|1|
89195298|NCT00699582|Experimental|2|
88903627|NCT01536613||BIAsp 30 users|
88903628|NCT01536626||BIAsp 30 users|
88903629|NCT01536639||BIAsp 30 users|
88903630|NCT01536652||BIAsp 30 users|
88903631|NCT01536665|Experimental|Low|
88903632|NCT01536665|Experimental|Medium|
88903633|NCT01536665|Experimental|High|
88903634|NCT01536678|Active Comparator|Test formulation of levothyroxine|Single dose of 600 mcg of levothyroxine administered in dosing period 1 or 2..
88903635|NCT01536678|Active Comparator|Reference formulation of levothyroxine|Single dose of 600 mcg of levothyroxine administered in dosing period 1 or 2.
88903636|NCT01536691|Experimental|ramosetron, aprepitant, dexamethasone|ramosetron 0.3 mg iv D1 aprepitant 125 mg po D1, 80 mg po D2, 80 mg po D3 dexamethasone 12 mg po D1, 8 mg po D2-4
88903637|NCT01536691|Active Comparator|ondansetron, aprepitant, dexamethasone|ondansetron 16 mg iv D1 aprepitant 125 mg po D1, 80 mg po D2, 80 mg po D3 dexamethasone 12 mg po D1, 8 mg po D2-4
89195299|NCT00699582|Placebo Comparator|3|
89195300|NCT04062084|Experimental|Multifunctional Cataract-assisted Retractor|Patients undergoing cataract with lens subluxation surgery with Multifunctional cataract-assisted retractor
89195301|NCT04062084|Experimental|Capsule Retractor|Patients undergoing cataract with lens subluxation surgery with traditional capsule retractor
89195302|NCT00640341|Experimental|PureVision|PureVision Contact Lens
89195303|NCT00640341|Active Comparator|Acuvue Oasys|Acuvue Oasys Contact Lens
89195304|NCT00640341|Active Comparator|O2Optix|O2Optix Contact Lens
89195305|NCT00816153|Experimental|PVI|PVI guided fluid management
89195306|NCT00816153|No Intervention|Control|
89195307|NCT00699348|Experimental|C.E.R.A.|
89195308|NCT05327634||Deprescribing|Prospective study on patients aged 75 and over, hospitalised in geriatric short stay or geriatric rehabilitation units
89195309|NCT00643851|Experimental|Arm 1|Dapagliflozin (5 mg) + Metformin XR (up to 2000 mg)
89195310|NCT00643851|Experimental|Arm 2|Dapagliflozin (5 mg)
89195311|NCT00643851|Active Comparator|Arm 3|Metformin XR (500 mg up to 2000 mg)
89195312|NCT00816231|Experimental|Alcohol and Nicotine Group|Alcohol and Nicotine Drug/Cue Interactions
89195313|NCT00816231|Active Comparator|Alcohol Only Group|Alcohol Only Drug/Cue Interactions
89195314|NCT00816231|Active Comparator|Nicotine Only Group|Nicotine Only Drug/Cue Interactions
89195315|NCT00816231|Placebo Comparator|Placebo and Placebo Group|Placebo Only Drug/Cue Interactions
89195316|NCT00821457|Active Comparator|Group 1|250ng Juvista vs placebo
89195317|NCT00821457|Active Comparator|Group 2|500 ng Juvista vs placebo
89422709|NCT04890184|Active Comparator|grape juice|100 g of grape juice daily
89422710|NCT04890184|Placebo Comparator|control|no dietary intervention
89422711|NCT04905238|Active Comparator|Continuous positive airway pressure|Diet and general life style recommendations plus continuous positive airway pressure (CPAP).
89422712|NCT04905238|No Intervention|Conservative treatment|Diet and general life style recommendations.
89422713|NCT04349150|Experimental|Virtual reality|Participants on this arm will have their colonoscopy initiated under virtual reality instead of standard sedatives and narcotics
89422714|NCT03051724|Experimental|Intervention group|"These OSA patient's are not familiarized with the use of internet and mobile technologies and with CPAP prescription. They follow the intervetion follow up that consists in an adaptation session where the tecnitian delivers them an automatic CPAP machine. Patient's are titrated with this automatic device in 5-7 days and are treated with the automatic device during 3 months.~The other part of the follow up consists on a voicemail where the patient can contact us 24h a day and on an , with an internet-connected tablet with a special app where the patient's answer a questionnaire once two weeks."
89422715|NCT03051724|No Intervention|Control group|These patient's are patient's that follow the process that all patient's take during CPAP treatment. During the three months of study, the follow up will be the usual.
89422716|NCT04456010||Infertile couple|Infertile couple who had a fertility treatment prescribed during the past 9 months which was not completed yet.
89422717|NCT04905004|Experimental|2-week reactivation interval|Replacement of elastomeric chain every 2 weeks and reestablishing a 150 g force
89422718|NCT04905004|Active Comparator|4-week reactivation interval|Replacement of elastomeric chain every 4 weeks and reestablishing a 150 g force
89422719|NCT04905004|Experimental|6-week reactivation interval|Replacement of elastomeric chain every 6 weeks and reestablishing a 150 g force
89422720|NCT04905004|Experimental|8-week reactivation interval|Replacement of elastomeric chain every 8 weeks and reestablishing a 150 g force
89422721|NCT04455932|Experimental|HCC surveillance with US and aNC-MRI|
89422722|NCT04899154|Experimental|Patients with spondyloarthritis (Spa)|
88903638|NCT01536717|Active Comparator|Bupivacaine hydrochloride 0.5%|Bupivacaine hydrochloride is related chemically and pharmacologically to the aminoacyl local anesthetics. Bupivacaine hydrochloride is indicated for the production of local or regional anesthesia or analgesia for surgery, for oral surgery procedures, for diagnostic and therapeutic procedures, and for obstetrical procedures.
89422723|NCT04899154|Experimental|Healthy subjects|
89422724|NCT04890548|Experimental|Patients with HFpEF or HFrEF|Patients will be enrolled in 2 cohorts in parallel: 1 cohort of patients with HFpEF and 1 cohort of patients with HFrEF. Patients will receive a sequence of 5 IA infusions into the brachial artery, consisting of a baseline saline infusion of approximately 20 minutes, followed by 3 sequential infusions of AZD3427 at ascending doses of approximately 10 minutes (each) and a washout saline infusion of approximately 15 minutes.
89422725|NCT03050944||Cases|Lifestyle behaviour and dietary habits assessment in couples achieving pregnancy after in vitro fertilization process.
89422726|NCT03050944||Controls|Lifestyle behaviour and dietary habits assessment in couples failed to achieve pregnancy after in vitro fertilization process.
88903639|NCT01536717|Placebo Comparator|Sodium chloride 0,9%|
88903640|NCT01536730|Experimental|Homework Intervention Strategy|
89422727|NCT05053958|No Intervention|Implant planning without using superimposition of intraoral scan and CBCT.|Patients will receive a pre-operative CBCT examination. Implants will be inserted using freehand drilling protocol. The implants will be placed using flapless technique with the reference of neighboring teeth and 3D radiographic information.
89422728|NCT05053958|Active Comparator|Implant planning using superimposition of intraoral scan and CBCT.|Patients will receive a pre-operative CBCT examination and optical scan of the oral tissues by intra-oral scanner. Digital Imaging and Communications in Medicine (DICOM) file from the CBCT examination and the Standard Tessellation Language (STL) file from the optical scan will be imported and merged in implant planning software. The virtual implant planning will be performed. The surgical guide and prosthesis are designed according to the virtual plan.
88903641|NCT01536730|No Intervention|Control|
88903642|NCT01536743|Experimental|PD0332991|"30 patients with recurrent ovarian epithelial carcinoma demonstrating Rb-proficiency and absent or low expression of p16 will be registered to receive PD0332991 once a day by mouth in the morning on an empty stomach.~PD0332991 will be administered daily for 3 weeks followed by 1 week off treatment (28 day cycle)."
88903643|NCT01536756|Experimental|Exercise Intervention -- Physical Rehabilitation Program|
88903644|NCT01536756|Other|Wait List Control Group|
88903645|NCT01536769||Parkinson patients|Parkinson patients, symptom onset > 50 years of age, non-smoker, no relevant gastrointestinal or ENT diseases
89422729|NCT04898998|Experimental|TENS to alleviate the effect of thirsty after surgery|Transcutaneous electrical nerve stimulation (TENS) on experimental group 20 mins to treatment postoperative thirsty.
89422730|NCT04898998|Placebo Comparator|Routine care to alleviate the effect of xerostomia (dry mouth) after surgery|routine care
89422731|NCT03051022|Active Comparator|Dexamethasone 8 mg|Bupivacaine 0,125% 12,5 mg combined with dexamethasone 8 mg plus NaCl 0,9% until the volume was 10 cc, prepared in a 10 cc syringe.
89422732|NCT03051022|Active Comparator|Morphine 2 mg|Bupivacaine 0,125% 12,5 mg combined with morphine 2 mg plus NaCl 0,9% until the volume was 10 cc, prepared in a 10 cc syringe.
89422733|NCT03052504||Cx prospective|Cystectomy patients followed with prospective registration of complications
88903646|NCT01536769||Control subjects|No parkinsonism, age and gender matched to PD subjects, non-smoker, no relevant gastrointestinal or ENT diseases
88903647|NCT01536782|Active Comparator|Bolus|Upon tube feeding initiation determined by the HNC multidisciplinary team, the patients will be randomized into three different groups, each consisting of 20 patients each: Bolus (Group 1), Gravity (Group 2), and Pump (Group 3). The randomization process within these three groups will based on 1) age and 2) estimated caloric need. For example, if we have three 60-year-old patients whose estimated kcals needs are ≤ 1900kcals/day, then each patient will be randomized to either Bolus, Gravity or Pump group. Another example is that if we have two 45-year-old patients whose estimated needs are 2400kcals/day, then one patient will randomly be assigned to the Bolus group, and the other one will be randomly assigned to the Gravity group. The third patient that will fit that category will be assigned to the Pump group.
89422734|NCT03052504||Cx retrospective|Cystectomy patients followed with retrospective registration of complications
89422735|NCT03052504||Nx prospective|Nephrectomy patients followed with prospective registration of complications
89422736|NCT03052504||Nx retrospective|Nephrectomy patients followed with retrospective registration of complications
89422737|NCT04648826|Experimental|1/ Phase I Dose Escalation|Azacytidine (aerosolized) at escalating doses (given on 3 consecutive days in the first week of every 3-week cycle) with a flat dose of Bintrafusp alfa 2400 mg (given on day 13 [+/- 3 days] of every 3-week cycle starting with Cycle 2)
89422738|NCT04648826|Experimental|2/ Phase II Dose Expansion|Azacytidine (aerosolized) at the RP2D established in Phase I (given on 3 consecutive days in the first week of every 3-week cycle) with a flat dose of Bintrafusp alfa 2400 mg (given on day 13 [+/- 3 days] of every 3-week cycle)
89422739|NCT03052270|Experimental|Vaginal progesterone and Pessary|"Short cervical length equal or less than 20 mm~Singleton pregnant women between 18 -24 weeks with no prior history of preterm deliveries.~18 years or older at the time of enrollment.~Consent to participate in the study~Vaginal progesterone as standard of care plus Arabin pessary"
89422740|NCT03052270|Active Comparator|Vaginal progesterone only|"Short cervical length equal or less than 20 mm~Singleton pregnant women between 18 -24 weeks with no prior history of preterm deliveries.~18 years or older at the time of enrollment.~Consent to participate in the study~Vaginal progesterone as standard of care"
88903648|NCT01536782|Active Comparator|Gravity|Upon tube feeding initiation determined by the HNC multidisciplinary team, the patients will be randomized into three different groups, each consisting of 20 patients each: Bolus (Group 1), Gravity (Group 2), and Pump (Group 3). The randomization process within these three groups will based on 1) age and 2) estimated caloric need. For example, if we have three 60-year-old patients whose estimated kcals needs are ≤ 1900kcals/day, then each patient will be randomized to either Bolus, Gravity or Pump group. Another example is that if we have two 45-year-old patients whose estimated needs are 2400kcals/day, then one patient will randomly be assigned to the Bolus group, and the other one will be randomly assigned to the Gravity group. The third patient that will fit that category will be assigned to the Pump group.
89422741|NCT04898842|Experimental|4 stage bowel obstruction diet|"All eligible participants will be assessed by a specialist dietitian and a diet history and symptoms will be recorded. Depending on the degree of sub-acute bowel obstruction, symptoms and type of diet being followed, patients will be given detailed instructions on which stage of the 4 stage diet to use. They will be followed up by telephone or face to face weekly for a 4 week period and shown how to alter their diet by moving up and down the stage of the diet if symptoms resolve or worsen. This is current standard of care.~Additional assessments will be carried out at the start and end of the study when participants will complete the Memorial Symptom Assessment Scale (MSAS) and EORTC QLQ-30 quality of life questionnaire. They will be asked to complete a daily diet diary, and an 'ease of use' questionnaire at the end of the 4 week period."
89422742|NCT05390762|Active Comparator|Conventional care in a day hospital|"A common face to face day hospital, combining physical therapies with psychotherapeutic support such as Cognitive Behavioral Therapy to combat kinesiophobia.~A Second phase of 5 weeks of care face to face day hospital of the reconditioning type of 15 sessions."
89422743|NCT05390762|Experimental|Telecare rehabilitation|"A common face to face day hospital, combining physical therapies with psychotherapeutic support such as Cognitive Behavioral Therapy to combat kinesiophobia.~A Second phase of 5 weeks of Telecare rehabilitation of the reconditioning type of 15 sessions."
89422744|NCT03052348|Active Comparator|Group R|Polyethylene glycol hexadecyl ether & betamethasone valerate cream 0.1% . ( 4 applications per day for 14 days treatment to taper fortnightly)
89422745|NCT03052348|Experimental|Group A|Fusidic acid & Polyethylene glycol hexadecyl ether,& betamethasone valerate cream 0.1%). ( 4 applications per day for 14 days treatment to taper fortnightly)
89422746|NCT04172480||acute HIV1 infection|Patient infected by HIV1, prior treatment initiation
89422747|NCT04172480||chronic HIV1 infection|Patient infected by HIV1, untreated or without treatment since at least 3 months
89422748|NCT04172480||HIV2 infection|Patient infected by HIV2, untreated or without treatment since at least 3 months
89422749|NCT04890340||Women in age 35 to 65 with suspected breast cancer|Women in age 35 to 65 with suspected breast cancer, previously untreated. Additionally, eligible patients should have appropriate mammography results, either breast ultrasound or breast MRI.
89422750|NCT04890340||Healthy Volunteers|Healthy woman in age 35 to 65.
89195318|NCT03667690|Experimental|Group 1: Rezafungin for Injection|"Subjects in Rezafungin treatment group will receive a 400 mg loading dose in Week 1, followed by 200 mg once weekly, for a total of 2 to 4 doses.~Daily intravenous placebo infusions, when not administered Rezafungin and a daily placebo for oral step-down therapy (first eligibility on Day 4 or later as advised by a site's national/regional/local guidelines) administered every day."
89422751|NCT05018234|Experimental|Treatment|
89422752|NCT05015114||Primary Sjogren's Syndrome|Participants with Primary Sjogren's Syndrome
89422753|NCT05015114||Control group|Healthy controls
89422754|NCT03963518||Control|chemotherapy
89422755|NCT03963518||Experimental|immune-checkpoint inhibitor
89422756|NCT04885114|Experimental|Cohort 1 Unilateral low dose|3.0 x 10^9 (vg/mL) rAAV1-miHHT
88903649|NCT01536782|Active Comparator|Pump|Upon tube feeding initiation determined by the HNC multidisciplinary team, the patients will be randomized into three different groups, each consisting of 20 patients each: Bolus (Group 1), Gravity (Group 2), and Pump (Group 3). The randomization process within these three groups will based on 1) age and 2) estimated caloric need. For example, if we have three 60-year-old patients whose estimated kcals needs are ≤ 1900kcals/day, then each patient will be randomized to either Bolus, Gravity or Pump group. Another example is that if we have two 45-year-old patients whose estimated needs are 2400kcals/day, then one patient will randomly be assigned to the Bolus group, and the other one will be randomly assigned to the Gravity group. The third patient that will fit that category will be assigned to the Pump group.
89422757|NCT04885114|Experimental|Cohort 2 Bilateral low dose|3.0 x 10^9 (vg/mL) rAAV1-miHHT
89422758|NCT04885114|Experimental|Cohort 3 Bilateral mid dose|1.7 x 10^10 (vg/mL) rAAV1-miHHT
89422759|NCT04885114|Experimental|Cohort 4 Bilateral high dose|9.9 x 10^10 (vg/mL) rAAV1-miHHT
89422760|NCT04889170||Biofeedback therapy + Voice training|The intervention has two parts. One part of the intervention is the biofeedback therapy. The biofeedback therapy means that the patient and a speech and language therapist watch the video of the FEES together and discuss the findings. The other part of the intervention is a voice training. The frequency of therapy is minimum 3 times a week, the duration of one therapy is minimum 25 minutes.
89422761|NCT04889170||Biofeedback therapy + Swallow training|The intervention has two parts. One part of the intervention is the biofeedback therapy. The biofeedback therapy means that the patient and a speech and language therapist watch the video of the FEES together and discuss the findings. The other part of the intervention is a swallow training. The frequency of therapy is minimum 3 times a week, the duration of one therapy is minimum 25 minutes.
89422762|NCT04526912|Experimental|VIB7734 Dose|Participants will receive a single subcutaneous dose of VIB7734.
89422763|NCT04526912|Placebo Comparator|Placebo|Participants will receive a single subcutaneous dose of placebo (saline) matched to single dose of VIB7734.
89422764|NCT04884646|Experimental|Virtual Reality with Routine Physical Therapy|The duration of the VR will be from 10 to 15 minutes during each session and Routine Physical Therapy for 40 minutes which consists of warming-up, stretching, strengthening and active exercises for relaxation, coordination exercises for limbs, trunk, neck, and gait training)
89422765|NCT04884646|Experimental|Motor imagery technique with Routine Physical Therapy|Motor Imagery techniques will be given for 5 to 10 minutes along with routine physical therapy for 40 minutes which consists of warming-up, stretching, strengthening and active exercises for relaxation, coordination exercises for limbs, trunk, neck, and gait training)
89422766|NCT04884646|Experimental|Routine Physical Therapy|Only routine physical therapy will be given (including warming-up, stretching, strengthening and active exercises for relaxation, coordination exercises for limbs, trunk, neck, and gait training)
89422767|NCT04406896|Experimental|Participants with mild hepatic impairment (Group 1)|Participant with Child-Pugh Grade A Score of 5-6.
89422768|NCT04406896|Experimental|Participants with moderate hepatic impairment (Group 2)|Participant with moderate hepatic impairment with a Child-Pugh Grade B Score of 7-9.
89422769|NCT04406896|Experimental|Healthy participants (Group 3)|
89422770|NCT04454996|Experimental|Non-erosive reflux disease test group|
89422771|NCT04454996|Placebo Comparator|Non-erosive reflux disease control group|
89422772|NCT04454996|Experimental|Diarrhea-type irritable bowel syndrome test group|
88903650|NCT01536808|Experimental|Type 2 Diabetes Mellitus|
88903651|NCT01536834|Experimental|Medical Device|The Investigational device is a liquid in a delivery system for the treatment of verrucas
88903652|NCT01536847|Placebo Comparator|Control Test Drink|Control drink
89422773|NCT04454996|Placebo Comparator|Control group with diarrheal irritable bowel syndrome|
89422774|NCT04454996|No Intervention|Healthy control group|
89422775|NCT04297124|Experimental|[14C]-CC-90009|A single IV dose of 0.6 mg [14C]-CC-90009 containing approximately 2 µCi of radioactivity will be administered on Day 1 under fasted conditions.
89422776|NCT04888780|Experimental|Experiment adolescent group|The web-based Watson's Human Care Theory oriented training and support program are applied to the intervention group.
89422777|NCT04888780|No Intervention|Control adolescent group|No intervention is applied to the control group.
89422778|NCT04101890|Experimental|Diaper care with Theraworx|Participants will be given a 4 week supply of Theraworx Spray Foam, an FDA-registered OTC drug (NDC 61594-000), to apply a thin layer to their infant's entire diaper area with every diaper change (2-4 foam pumps or 4-6 sprays depending on the infant's size) for 4 weeks.
89422779|NCT04101890|No Intervention|Routine diaper care|Participants continue their typical diaper care.
89422780|NCT04898218|Active Comparator|Group A (Aerobic Exercise Group)|Warm-up exercises were performed by the participants on a cycle ergometer for a duration of 5-10 minutes. Group A was advised to start walking at a comfortable speed on a treadmill for the duration of 30-60 minutes; the intensity of the exercises was 55-75% of MHR, calculated by using a Karvonen method. Initially with the minimum intensity that was gradually raised up to the intensity of Targeted Heart Rate (THR). Once the THR is achieved the intensity was gradually decelerated and patient proceeded for the cool-down phase for 5-10 min.
89422781|NCT04898218|Active Comparator|Group B (Resistance Exercise Group)|Group B was instructed for strengthening exercises of ten major muscle groups that include Biceps, Triceps, Pectoralis Major, Deltoid, Latissimus Dorsi, Abdominals, Back Extensors, Hamstrings, Quadriceps and Calf. The intensity of the weight-bearing exercises was calculated using 1 Repetition Maximum (RM) method.
89422782|NCT04898218|Experimental|Group C (Osteoanabolic Exercise Group)|"Group C was performed Osteoanabolic exercise divided into two different phases:~Aerobic Conditioning Phase Participants were instructed to walk on treadmill for 30-60 min. The intensity of the exercises was 55-75% MHR, calculated by Karvonen method. Intensity gradually raised up to the Targeted Heart Rate (THR). Once the THR is achieved the intensity was gradually decelerated and patient proceeded for the cool-down phase. The participants performed 3 days per week for 12 weeks on alternative days.~Anaerobic (Resistance) Conditioning Phase Resistance training was started on every alternative day of the aerobic conditioning (3 days per week) for 45 min. The intensity of the weight-bearing exercises was calculated using 1 RM method. Resistance training muscle and protocol was the same as for Group B. The participants performed warm-up and cool down similar to that of group A and group B."
89422783|NCT04456712|Experimental|ciprofloxacin for diabetic patients|50 diabetic patients received intravenous ciprofloxacin 400mg/12 hours.
89422784|NCT04456712|Experimental|levofloxacin for diabetic patients|50 diabetic patients received intravenous levofloxacin 750mg/24 hours.
89422785|NCT04456712|Experimental|ciprofloxacin for non-diabetic patients|50 non-diabetic patients received intravenous ciprofloxacin 400mg/12 hours.
89422786|NCT04456712|Experimental|levofloxacin for non-diabetic patients|50 non-diabetic patients received intravenous levofloxacin 750mg/24 hours.
89422787|NCT04889014|Active Comparator|Personal genomic educational testing (PGET)|PGET group participants received their own pharmacogenomic testing results prior to the course modules covering material tested in the knowledge assessment
89422788|NCT04889014|Placebo Comparator|No personal genomic educational testing (NPGET)|No PGET (NPGET) group participants did not receive their own pharmacogenomic testing results until after study completion.
89422789|NCT04456868|Active Comparator|Healthy volunteers|Healthy volunteers at least 18 years old and without a history of psychiatric or neurological disorders
89422790|NCT04456868|Experimental|Anhedonic drug-resistant bipolar depression patient|Adult patients at least 18 years old with drug-resistant bipolar depression of the anhedonic type
89422791|NCT04456868|Active Comparator|Non-anhedonic drug-resistant bipolar depression Pat|Adult patients at least 18 years old with drug-resistant bipolar depression of the non-anhedonic type
89422792|NCT04456868|Active Comparator|Mild to moderate Parkinson's disease patient|Adult patients at least 18 years of age with mild to moderate Parkinson's disease
89422793|NCT04884490|Experimental|Intervention|"Eligible patients will be receiving either to oral co-trimoxazole + standard therapy.~Tab. Co-trimoxazole 960 mg (trimethoprim 160mg + sulphamethoxazole 800mg) thrice (8 hourly) daily for 7 days orally.~The following treatments are recommended as standard therapy:~Antibiotics for secondary bacterial infection as per institutional guidelines~Supplemental oxygen (to keep saturations between 92% to 96%)~Intravenous hydration (to maintain euvolumia)~Thrombo-prophylaxis as per local guidelines~Paracetamol (oral or I/V 1gram QDS as required or regular)~To consider steroids in appropriate cases.~Nasopharyngeal and throat swab to be sent for RT PCR to detect SARS-CoV-2 (if not already done) and blood culture Tab. Co-trimoxazole 960 mg (trimethoprim 160mg + sulphamethoxazole 800mg) thrice (8 hourly) daily for 7 days orally."
88903653|NCT01536847|Experimental|Experimental Test Drink 1|Control drink containing ingredient 1
88903654|NCT01536847|Experimental|Experimental Test Drink 2|Control drink containing ingredient 2
88903655|NCT01536977|Experimental|Supportive care (BBT-I)|"Patients complete the BBT-I, comprising the following modules: 1) What to expect in terms of fatigue and insomnia as it occurs with cancer and cancer treatment; 2) A review of the Spielman Model of insomnia; 3) A discussion (based on the Spielman Model) regarding how insomnia and fatigue may co-occur and interact in the context of cancer and cancer treatment; 4) An introduction to the concept and practice of Stimulus Control Therapy; 5) An introduction to Sleep Scheduling Specifically modified for cancer patients; 6) Sleep Compression; and 7) Concomitant Medications and Substance Use."
88903656|NCT01537003|Experimental|Promogran and Low EPA|Patients with low EPA will be treated with PROMOGRAN and standard of care for vlu compression
88903657|NCT01537003|Active Comparator|Low EPA and compression|Patients with Low EPA will only get standard of care for VLU which is compression.
88903658|NCT01537003|Active Comparator|High EPA and compression|Patients with high EPA will get standard of care for VLU which is compression.
88903659|NCT01537003|Experimental|Promogran High EPA|patients with HIGH EPA will then be treated with PROMOGRAN and standard of care for VLU compression
88903660|NCT01537016|Experimental|Promogran and High EPA|Wound with high EPA will be treated with promogran and covered with a secondary dressing that is standard of care
88903661|NCT01537016|Experimental|Promogran and Low EPA|Wounds with low EPA will be treated with Promogran and covered with a secondary which is standard of care
88903662|NCT01537016|Active Comparator|High EPA and standrad of care|Wounds with high EPA will get standard of care as in line with current practice as they is no other test currently available for EPA
88903663|NCT01537016|Active Comparator|Low EPA and standard of care|Low EPA wounds will be treated with the standard of care for diabetic foot ulcers.
88903664|NCT01537055|Experimental|levofloxacin-based sequential therapy|levofloxacin-based sequential therapy
88903665|NCT01537055|Active Comparator|levofloxacin-based triple therapy|levofloxacin-based triple therapy for 10 days
88903666|NCT01537094|Active Comparator|Vitamin C low dose|vitamin C 250 mg oral once daily
88903667|NCT01537094|Active Comparator|Vitamin C high dose|vitamin C 1,000 mg oral once daily
88903668|NCT01537094|Placebo Comparator|Placebo|Placebo oral once daily
88903669|NCT01537107|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive sirolimus PO QD and vismodegib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88903670|NCT01537146|Active Comparator|Femoral Block|
88903671|NCT01537146|Active Comparator|Local Infiltration Anagesia|
88903672|NCT01537159||Acute Myelogenous Leukemia (AML)|Patients who have been diagnosed with AML
88903673|NCT01537172|Experimental|ONO-4053|E Experimental Intervention Drug: ONO-4053
88903674|NCT01537172|Placebo Comparator|Placebo|
88903675|NCT01537224|Other|neurostimulation|
89422794|NCT04884490|Placebo Comparator|Standard|"Standard therapy along with placebo.~Placebo thrice (8 hourly) for 7 days.~The following treatments are recommended as standard therapy:~Antibiotics for secondary bacterial infection as per institutional guidelines~Supplemental oxygen (to keep saturations between 92% to 96%)~Intravenous hydration (to maintain euvolumia)~Thrombo-prophylaxis as per local guidelines~Paracetamol (oral or I/V 1gram QDS as required or regular)~To consider steroids in appropriate cases.~Nasopharyngeal and throat swab to be sent for RT PCR to detect SARS-CoV-2 (if not already done) and blood culture"
89422795|NCT04883866|Experimental|Intervention Group|"Sending breastfeeding guidelines for premature babies to phones after the discharge procedure is completed.and implementing a Telephone Breastfeeding Support Program."
89422796|NCT04883866|Experimental|Control Group|Sending breastfeeding guidelines for premature babies to phones after the discharge procedure is completed.
88903676|NCT01537237||intra-procedure 3DATG|Patients who will undergo intra-procedure 3DATG rotational angiography to guide their ablation procedure
88903677|NCT01537237||pre-procedure CT|Patients who will undergo pre-procedure CT scan to guide their ablation procedure
88903678|NCT01537250|Active Comparator|Nemonoxacin 750 mg|Nemonoxacin 750 mg 2 tablets.
88903679|NCT01537250|Active Comparator|Nemonoxacin 500 mg|Nemonoxacin 500 mg 3 tablets
89195319|NCT03667690|Active Comparator|Group 2: Caspofungin|"Subjects in caspofungin arm will receive a total treatment of ≥14 days beginning with a single caspofungin 70 mg IV loading dose on Day 1 followed by 50 mg IV once daily up to 28 days. After ≥3 days of caspofungin treatment(or the minimum duration of IV therapy advised by the site's national/regional/local guidelines, whichever is greater), subjects may be switched to oral fluconazole if specific parameters are met.~If the subject qualifies, then oral step-down therapy of fluconazole (6 mg/kg to the nearest 200 mg) is administered. After switch to oral step down before Day 8, subjects in the caspofungin group will receive IV placebo on Day 8 to preserve the study blind."
89195320|NCT00821535|Other|Active group|maraviroc dosing group
88903680|NCT01537250|Active Comparator|Levofloxacin 500 mg|Levofloxacin 500 mg
88903681|NCT01537263||Ultrasound Perfusion Imaging|Patient with subarachnoid hemorrhage.
88903682|NCT01537276|Experimental|real-time fluoroscopy|evaluating the tubal patency and pathology under fluoroscopy real-timely
88903683|NCT01537276|No Intervention|respective image|evaluating the tubal patency and pathology by Two supine and two oblique static images.
89195321|NCT04062006|Experimental|Interleukin-2|low dose interleukin-2 injected subcutaneously, at a dose of 1 x 10~6 IU/m2 five days per week for 4 weeks (day1-5, 8-12, 15-19, 22-26) and then once a week for 8 weeks (day33, 40, 47, 54, 61, 68, 75, 82).
89195322|NCT04872582|Experimental|PD-1 immune checkpoint inhibitor combined with bevacizumab|
89195323|NCT04061538|Experimental|Zinc sulfate|Zinc sulfate 20 mg by mouth, once a day for 10 days
89195324|NCT04061538|Placebo Comparator|Placebo|Placebo tablet, once a day for 10 days
88903684|NCT01537289|Experimental|Pigtail catheter|
88903685|NCT01537289|Active Comparator|Traditional chest tube|28-French chest tube
88903686|NCT01537328|Experimental|Progressive Treatment|Progressive intervention will involve the early initiation of intensive rehabilitation using progressive exercise and faster progression to functional strengthening exercises.
88903687|NCT01537328|Active Comparator|Traditional treatment|Traditional intervention represents the synthesis of previously published total knee arthroplasty rehabilitation programs.
88903688|NCT01537341|Active Comparator|Traditional Treadmill|Participants will follow the same guidelines as the split belt component but will complete the intervention on a traditional, single belt/speed treadmill.
88903689|NCT01537341|Experimental|Split-belt|Participants will walk on a custom-built split-belt treadmill comprised of two separate belts, each with its own motor, that permitted the speed of each belt (i.e. each leg) to be controlled independently.
88903690|NCT01537354|Active Comparator|Survanta®|Survanta® (Beractant, Abbot Laboratories, Columbus, OH) Surfactant will be administered by respiratory therapist not involved in patient's care.
88903691|NCT01537354|Active Comparator|Curosurf®|Curosurf® (Cornerstone Therapeutics, Inc., Cary, NC Surfactant will be administered by respiratory therapist not involved in patient's care.
88903692|NCT01537380|Experimental|Cefazoline|
88903693|NCT01537445||Patients with pancreastransplantation|All patients undergoing pancreas transplantation.
89422797|NCT03681392|Experimental|Once daily then twice daily|One 6.5 cc scoop of S4S once a day for 7 days, then one 6.5 cc scoop of S4S twice a day for 7 days
89422798|NCT03681392|Experimental|Twice daily then once daily|One 6.5 cc scoop of S4S twice a day for 7 days, then one 6.5 cc scoop of S4S once a day for 7 days
89422799|NCT04888546|Other|Anlotinib hydrochloride capsules combined with TQB2450 injection|Anlotinib hydrochloride capsules (10mg po qd, Two weeks off for one week) combined with TQB2450 injection (1200mg ivgtt, q3W)
89422800|NCT05390294||Patients free of the disease|Patients treated due to SGC without local recurrence or metastases
89422801|NCT05390294||Patients with the disease|Patient with relapse of SGC, metastases or died due to SGC
89422802|NCT04888234|Experimental|Treatment group|The treatment group receive topical treatment of Ru-Yi-Jin-Huang Powder.
89422803|NCT04888234|No Intervention|Control group|The control group receive regular management for radiation-induced dermatitis.
89422804|NCT04454762|Experimental|Cabozantinib|40 mg cabozantinib oral daily. When dose reduction is necessary, it is recommended to reduce to 20 mg daily.
89422805|NCT03050788|Experimental|Smartphone confocal microscopy imaging|Subject's skin lesion will be imaged with the smartphone confocal microscopy.
89422806|NCT04897984|Experimental|Liver-enriched antimicrobial peptide 2|IV infusion of LEAP2, 2 hours
89422807|NCT04456088|Experimental|Phase 1- Nitric oxide treatment- 80ppm|
89422808|NCT04456088|Experimental|Phase 2- Group 1- Nitric oxide treatment- 150ppm|
89422809|NCT04456088|No Intervention|Phase 2- Group 2- control|Standard of Care
89422810|NCT04897828||Covered Stent Group|Patients with a dysfunctional hemodialysis vascular access undergoing treatment procedure using a covered stent (stent graft).
89422811|NCT04454840|Experimental|Biological+Riluzole|Plasma from healthy young people treatment + Riluzole
89422812|NCT04454840|Active Comparator|Riluzole|Riluzole
89422813|NCT03050710|Other|Princess® VOLUME Lidocaine|
89422814|NCT03051568|Experimental|PTCL patients with 18F-FDG PET/CT|18F-FDG PET/CT scans is to be evaluated using liver SUVmax-based criteria, Deauville 5-point criteria and reduction of SUVmax criteria
89195325|NCT00888316||Without Iron Overload|Patients entering study without pre-HSCT iron-overload. Iron overload will be defined as liver ion concentration (LIC above normal (>1.8 mg/g) on R2 magnetic resonance imaging (MRI) of the liver.
89422815|NCT04981964|Experimental|Conventional physical therapy plus forward walking|25 minutes of the forward walking training program It is based on methods as described by Grecco et al. (2013) The children were instructed to walk at a comfortable, self-selected speed during the first and final five minutes of the session and encouraged to increase the speed during the other 15 minutes.
89422816|NCT04981964|Experimental|Conventional physical therapy plus backward walking|25minutes of the backward walking training It is based on methods as described by Davis (1992) Firstly, the subject is asked to take a step backwards within the parallel bar and can support him or herself with the unaffected hand as required. The therapist provides help to move the subject's leg in the correct pattern, preventing subject from moving the leg back in full extension, when the subject can move the leg back with the correct pattern, the therapist gradually reduces the amount of assistance. Secondly, as the movement components have been practiced and the subjects has taken over actively with only slight help, the therapist facilitates walking backward within the parallel bars. Thirdly, the subject walks backwards actively away from the parallel bars. Finally, the distance and speed of walking backwards is progressively increased.
89195326|NCT00888316||With Iron-Overload|Patients entering study with pre-HSCT iron-overload. Iron overload will be defined as liver ion concentration (LIC above normal (>1.8 mg/g) on R2 magnetic resonance imaging (MRI) of the liver.
89195327|NCT04351620|Experimental|Hydroxychloroquine|"Hydroxychloroquine 1200 mg daily administered as 600 mg BID for five days or until fevers abate (maximum ten days of treatment allowed).~If patients report gastrointestinal discomfort, the dose will be administered as 400 mg TID."
89195328|NCT00888394|Experimental|1|
89195329|NCT00888394|Experimental|2|
89195330|NCT00888394|Experimental|3|
89195331|NCT00888394|Experimental|4|
89422817|NCT04888390|Experimental|Intervention group|The intervention group will receive multi-model exercise intervention 2-3 times per week for 3 months.
89422818|NCT04888390|Active Comparator|Usual care group|The Usual care group will receive heart failure disease and exercise-related education.
89422819|NCT03993314|Active Comparator|Bupivacaine|1 ml 0.5% isobaric bupivacaine (5 mg) + 15 mcg fentanyl intrathecal plus epidural volume extension (EVE)
89422820|NCT03993314|Experimental|Chloroprocaine|5 ml 1% spinal chloroprocaine (50 mg) intrathecal plus epidural volume extension (EVE)
89422821|NCT04887532|Experimental|HR19042 capsule|
89422822|NCT03889340||Phase 1 cohort|Subjects resuscitated from cardiac arrest will undergo cooling per standard of care with the IQool device.
89422823|NCT03050632|Experimental|Working Memory Intervention (N-back)|Participants will complete the working memory priming task either for the first 3 days of the intervention or the last 3 days of the intervention, with order counterbalanced across participants. The working memory prime is the N-back test, a measure of working memory in which individuals need to make a response to targets which are repeated letters either in a row (i.e., one-back) or in every-other-letter format (i.e., two-back) (Jaeggi et al., 2010).
89422824|NCT03050632|Placebo Comparator|"White Bear Task"|Participants will complete this non-working-memory control task either for the first 3 days of the intervention or the last 3 days of the intervention, depending on counterbalanced order. The task consists of a procedure developed by Wegner and colleagues (1987) in a study of thought suppression, which instructs participants to inhibit thoughts of a white bear, and to indicate with a pencil mark every time the thought of the white bear occurs to them.
89422825|NCT04920890|Active Comparator|Patients receiving radiofrequency treatment with manual therapy.|Patients without previous pathology of any kind who have passed the Covid19 and have respiratory, neurological or musculoskeletal sequelae; who will receive radiofrequency treatment with manual therapy.
89422826|NCT04920890|Placebo Comparator|Patients receiving placebo.|Patients without previous pathology of any kind who have passed the Covid19 and have respiratory, neurological or musculoskeletal sequelae; to those who will be administered placebo (device off, without emitting).
89422827|NCT04920890|Sham Comparator|Patients receiving only manual therapy.|Patients without previous pathology of any kind who have passed the Covid19 and have respiratory, neurological or musculoskeletal sequelae; who will receive treatment of manual therapy.
89422828|NCT04883164||Healthy non-immunocompromized subjects|"Healthy individuals are those with no pre-existing conditions that cause immune deficiency, and who are not receiving drugs to suppress the immune system.~•"
89422829|NCT04883164||Immunocompromized|Immunocompromised subjects are those receiving immunosuppressive or immunomodulatory drugs such as those given for autoimmune disease, inflammatory bowel disease, malignancies and transplantation. Bone marrow transplant recipients and subjects with known immune deficiency diseases are also considered immunocompromised.
89422830|NCT02809833||Tocilizumab for RA in Routine Practice|Participants from routine clinical practice in Germany who are receiving tocilizumab for RA according to SmPC are eligible.
89422831|NCT03788642|Active Comparator|Control LED Shoe arm|Patients with DFU will wear LED shoe 30 minutes per day
88903694|NCT01537471|Other|Placebo|A counterbalanced design will be used with each male subject receiving placebo and each of the anti-histamine low (12.5 mg) and high (25 mg) doses in a counterbalanced order to keep order of administration from being confounded with dose level. On one of three visits, a subject will receive placebo. The subject, study coordinator, co-investigator and outcomes assessor will remain blinded to what they received until data analysis is completed.
88903695|NCT01537471|Experimental|Meclizine|A counterbalanced design will be used with each male subject receiving placebo and each of the anti-histamine low (12.5 mg) and high (25 mg) doses in a counterbalanced order to keep order of administration from being confounded with dose level. By the time they finish, they will have all received placebo, 12.5mg meclizine and 25mg meclizine. The subject, study coordinator, co-investigator and outcomes assessor will remain blinded to what they received until data analysis is completed.
88903696|NCT01537484|Experimental|Swedish Massage|Swedish massage for one hour, once per week, for eight weeks. At week 10, 50% of patients will be randomized to a maintenance dose (one hour of Swedish massage every two weeks), and 50% will be randomized to Usual Care.
88903697|NCT01537484|Active Comparator|Light Touch Bodywork|Light-touch bodywork for one hour, once per week, for eight weeks. At week 10, 50% of the patients will be randomized to a maintenance dose (one hour of light-touch massage every two weeks, and 50% will be randomized to Usual Care.
88903698|NCT01537484|Other|Usual Care|Those initially randomized to the usual care control will be rolled into the Swedish massage intervention (one hour of Swedish massage, once/week for eight weeks) at week 25. At week 34, 50% of patients will be randomized to a maintenance dose (one hour of Swedish massage every two weeks), while 50% will be randomized back to Usual Care.
88903699|NCT01537497|Experimental|100 mg PF-05175157|The chance of receiving 100 mg, 250 mg, 600 mg or placebo will be randomized.
88903700|NCT01537497|Experimental|250 mg PF-05175157|The chance of receiving 100 mg, 250 mg, 600 mg or placebo will be randomized.
88903701|NCT01537497|Experimental|600 mg PF-05175157|The chance of receiving 100 mg, 250 mg, 600 mg or placebo will be randomized.
88903702|NCT01537497|Placebo Comparator|Placebo|The chance of receiving 100 mg, 250 mg, 600 mg or placebo will be randomized.
88903703|NCT01537510|Active Comparator|Usual Care|
89195332|NCT00891124||1|Type II DM and Hypertension and/or Hyperlipidemia
89195333|NCT02541760|Experimental|Montelukast|4 ml monteleukast daily for one month
89422832|NCT03788642|Active Comparator|Laser Shoe arm|Patients with DFU will wear Laser shoe 30 minutes per day
89530851|NCT02509637|Active Comparator|Chest Compression Intervention|After initial evaluation, the subjects will be instructed to perform deep breaths between three quiet inspiration brought, and expiration will be accompanied by bilateral compression with the therapist's hands on the lower ribs during thirty minutes with one minute intervals of rest every four minutes. Immediately after the exercise will be performed new assessment against Impulse Oscillometry. Then patients will be kept for 30 minutes at rest and at the end will be applied the acceptability and tolerance scale and a third evaluation with Impulse Oscillometry. The secretions expectorated during the protocol will be evaluated for weight, adhesiveness and purulence.
88903704|NCT01537510|Experimental|Clinician intervention only|This arm will entail the development and deployment of alerts and access to a SmartSet at the time of a well child visit with a child between the ages of 6-12 years with a BMI ≥ 95th percentile.
88903705|NCT01537510|Experimental|Clinician intervention plus Direct-to-parent communication|Parents of children enrolled in this intervention arm will receive mailings, text messages and a series of 4 calls with a health coach to encourage behavior change in addition to the intervention received by the clinicians.
88903706|NCT01537523|Experimental|community-care program|receive intervention for 12 weeks
88903707|NCT01537523|No Intervention|control|
89195334|NCT02541760|Active Comparator|Mometasone|Inhaled mometasone 1 puff in each side of nose for one month
89195335|NCT02541760|No Intervention|Control|No intervention
89195336|NCT00888472|Experimental|1|
89422833|NCT03161054|Experimental|One arm for all patient|"Induction phase:~Eligible Pts will receive 6 cycles (every 28 days) of the DEVEC combination: DE: Prednisone, V: Vinorelbine, E: Etoposide, C: Cyclophosphamide and R:Rituximab ; R will be administered only in patients suitable for infusion treatment and relapsed after >6 months from last R-chemotherapy. Refractory patients who received at least 5 doses of R will not repeat it during the metronomic therapy.~Super-frail patients will not receive etoposide during cycles 1 and 2.~Maintenance Phase:~Pts in CR, CRu and PR at the end of the induction phase, will continue treatment with maintenance therapy including Vinorelbine, Cyclophosphamide, and Prednisone oral combination to be repeated every 28 days for up to 6 cycles.~Post Maintenance Phase:~Pts in CR/CRu at the EOT may, at discretion of the local investigator, continue maintenance with only Vinorelbine and Prednisone for up to further 12 months, progression or inacceptable toxicity at the same doses of maintenance"
89422834|NCT03050554|Experimental|SBRT+Avelumab|"SBRT: 12Gy x 4 fractions or 10Gy x 5 fractions (4-5 radiation doses given over 10-12 days every other day.)~Avelumab 10mg/kg IV infusion every 2 weeks for 6 cycles"
89422835|NCT04909112|Other|group 1: patients with Sjogren's syndrome|Patients with Sjogren's syndrome
88903708|NCT01537536|Experimental|EndoTAG-1|Weekly treatment with EndoTAG-1 (22 mg/m2) plus paclitaxel (70 mg/m2) for 12 weeks (ET+P) followed by subsequent treatment with the standard FEC regimen (Fluorouracil 500 mg/m2, Epirubicin 100 mg/m2, Cyclophosphamide 500 mg/m2) once every 3 weeks for 3 cycles of therapy followed by surgery.
88903709|NCT01537562|Active Comparator|Delayed IUC insertion|Patients randomised to delayed, routine, insertion had their IUC inserted at 3-4 weeks (day 21-35 after mifepristone treatment
88903710|NCT01537562|Active Comparator|Early IUC insertion|Patients randomised to early insertion had their IUC inserted on day 5-9 after mifepristone treatment.
88903711|NCT01537575|Placebo Comparator|saline solution|
88903712|NCT01537575|Experimental|intravenous immunoglobulins|
89422836|NCT04909112|Other|group 2: patients without sicca syndrome|Patients without sicca syndrome
89422837|NCT03050164|Experimental|Gefitinib Tablet 250mg of Hunan Kelun|During the study session, healthy subjects were orally administered a single dose of Gefitinib Tablet 250mg of Hunan Kelun under fasting conditions.
89422838|NCT03050164|Active Comparator|Iressa® Tablet 250mg of AZN|During the study session, healthy subjects were orally administered a single dose of Iressa® Tablet 250mg of AZN under fasting conditions.
89422839|NCT02037087|Experimental|Good household prenatal practice (GHPP)|The GHPP arm receives SMS messages regarding knowledge on nutrition, labor, non-medical pain management, breastfeeding, and depression. This arm also receives messages delivered to the control group.
89422840|NCT02037087|Experimental|Care seeking (CS)|The CS arm receives SMS messages which include danger-sign recognition and reminders for government-subsidized projects. This arm also receives messages delivered to the control group.
89422841|NCT02037087|Experimental|Full bank of SMS|This arm receives the SMS messages delivered to the GHPP, CS and control group.
88903713|NCT01537588|Active Comparator|Standard|ACL reconstruction with autograft harvest of STG from ACL-deficient leg
88903714|NCT01537588|Experimental|Autograft harvest of STG from ACL-deficient leg|Autograft harvest of STG from leg contralateral to ACL-deficient leg
88903715|NCT01537588|No Intervention|Normal matched|
88903716|NCT01537614|Experimental|COLIMYCINE injectable|
88903717|NCT01537614|Experimental|COLIMYCINE inhalation|
88903718|NCT01537627|Active Comparator|Low-intensity training (LT)|
89422842|NCT02037087|No Intervention|Control|"Control group receives SMS messages regarding:~Reminders of prenatal visits and certified skilled attendance of labor (status quo);~Fetal development in different gestational stages.~The three experimental groups receive the control messages as well."
88903719|NCT01537627|Active Comparator|High-intensity training (HT)|
88903720|NCT01537640|Experimental|SAR231893 (REGN668) Drug Product (DP) 1|SAR231893 (REGN668) Drug Product 1 in a single subcutaneous injection
88903721|NCT01537640|Experimental|SAR231893 (REGN668) Drug Product (DP) 2|SAR231893 (REGN668) Drug Product 2 in a single subcutaneous injection
88903722|NCT01537653|Experimental|SAR231893 (REGN668), Dose Level 4|Dose Level 4
88903723|NCT01537653|Placebo Comparator|Placebo|Placebo
88903724|NCT01537653|Experimental|SAR231893 (REGN668), Dose Level 1|Dose Level 1
88903725|NCT01537653|Experimental|SAR231893 (REGN668), Dose Level 2|Dose Level 2
88903726|NCT01537653|Experimental|SAR231893 (REGN668), Dose Level 3|Dose Level 3
88903727|NCT01537679|Other|Meditation Intervention|
88903728|NCT01537679|Other|Relaxation Intervention|
88903729|NCT01537692|Experimental|BDP HFA Nasal Aerosol 80 mcg/d|single dose, intranasal aerosol
88903730|NCT01537692|Experimental|BDP HFA Nasal Aerosol 320 mcg/d|single dose, intranasal aerosol
88903731|NCT01537692|Active Comparator|BDP HFA Inhalation Aerosol 320 mcg/d|single dose, orally inhaled aerosol
88903732|NCT01537705|Experimental|Neuron012703|Amino acid formulation for the dietary management of symptoms related to periphal neuropathy.
88903733|NCT01537718|Experimental|REPLY 200 implanted patients|REPLY 200 implanted patients
88903734|NCT01537731||hysterectomy|Patient who previously underwent vaginal or laparoscopic hysterectomy
89422843|NCT02797262|Experimental|Intervention|"Building on the available Proteus devices, the investigators will design and create a Proteus digital health feedback (PDHF) system to transmit the adherence data using mobile technology to allow treatment monitoring that is, direct confirmation of the type, dose, date and time of oral pharmaceutical ingestion using wirelessly observed therapy (WOT).~The investigators will test overall utility (including feasibility, acceptability and sustainability) of the PDHF system, its accuracy for measuring adherence and its impact on enhancing patients' level of adherence and the effect on virologic and clinical outcomes (exploratory), the retention of its impact on keeping up with adherence and improvement of plasma HIV RNA and CD4 cell count after the 16-week usage of the PDHF system."
89422844|NCT02797262|No Intervention|Control|UC is chosen as the control condition because it meets ethical and moral requirements to attempt treatment. Eligible patients will be randomized to one of the two conditions using a stratified urn randomization procedure to increase the likelihood of balanced allocation of prognostic variables at baseline.
89422845|NCT03049930|Experimental|Ketamine|Participants randomized to this arm will receive ketamine (1 mg/ml solution) infused at 0.2 mg/kg/hour (0.2 ml/kg/h) for a maximum of 20 ml/hour.
89422846|NCT03049930|Placebo Comparator|Placebo|Participants randomized to this arm will receive 0.9 mg/ml sodium chloride, infused at a rate of 0.2 ml/kg/hour
89422847|NCT02036463|Active Comparator|Immediate Release Prednisone|During the entire 18 months of the protocol, these subjects will receive immediate release prednisone as a morning dose. All observations and measurements are performed the same as the other study groups.
88903735|NCT01537744|Experimental|oral 5-azacitidine + romidepsin|oral 5-azacitidine in combination with romidepsin
88903736|NCT01537757|Experimental|Part 1, Panel A - Severe Renal Impairment Group|
88903737|NCT01537757|Experimental|Part 1, Panel B - Healthy Control Group to Match Panel A|
88903738|NCT01537757|Experimental|Part 2, Panel C - Moderate Renal Impairment Group|
88903739|NCT01537757|Experimental|Part 2, Panel D - Healthy Control Group to Match Panel C|
88903740|NCT01537757|Experimental|Part 2, Panel E - Mild Renal Impairment Group|
88903741|NCT01537757|Experimental|Part 2, Panel F - Healthy Control Group to Match Panel E|
88903742|NCT01537770|Active Comparator|Vertebroplasty|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine). 11-gauge or 13-gauge needles are passed into the central aspect of the target vertebra or vertebrae. Bone cement is prepared on the bench and injected under constant fluoroscopy into the vertebral body. Injection is stopped when the cement reaches to the posterior aspect of the vertebral body or leaks into an extraosseous space, such as the intervertebral disk or an epidural or paravertebral vein.
88903743|NCT01537770|Sham Comparator|lidocaine injection|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine). 11-gauge or 13-gauge needles are passed into the central aspect of the target vertebra or vertebrae. 2 ml of 1% Lidocaine is injected in each needle. Bone cement is prepared on the bench simulating the vertebroplasty-procedure.
88903744|NCT01537796|Experimental|In-Person weight loss|Participants will attend weekly group intervention meetings. These sessions will address barriers associated with altering physical activity participation and dietary intake. Group discussions will be facilitated by the interventionist and interactive participation will be encouraged. Participants will be provided with written materials at each meeting to supplement group discussions. Paper diaries will be provided each week to assist participants with self-monitoring of calorie and fat consumption, and physical activity minutes and intensity. Participants will return the diary to the intervention staff each week for review and constructive feedback.
88903745|NCT01537796|Experimental|FIT weight loss|Intervention materials will be provided and mailed weekly to participants. Participants will be provided with the BodyMedia® FIT System that includes a wearable device to monitor physical activity and energy expenditure, a display device to provide feedback on achievement of energy expenditure and physical activity goals, and web-based software to assist with self-monitoring of dietary intake and to provide feedback on goal achievement. Participants will attend one introductory session in which a tutorial of the components of the enhanced FIT System will be provided. Participants will receive a one-hour lesson on basic guidelines of the weight loss intervention. Once per month participants will receive a scheduled 10 minute intervention telephone call with the intervention staff.
88903746|NCT01537796|Experimental|FIT-BT weight loss|Participants will be provided with intervention materials that are mailed weekly to them. Participants will be provided with the enhanced BodyMedia® FIT System that includes a wearable device with Bluetooth® technology to allow participants to receive real-time feedback on calories expended and physical activity on their smart phone. This also supports self-monitoring of dietary behaviors and body weight. Participants will attend one introductory session in which a tutorial of the components of the enhanced FIT System will be provided. Participants will also receive a one-hour lesson on basic guidelines of the weight loss intervention. Once per month participants will receive a scheduled 10 minute intervention telephone call with the intervention staff.
88903747|NCT01537809|Active Comparator|D3 600 IU/ daily|Subjects randomized to 600 IU/day of vitamin D3 taken orally for six months.
88903748|NCT01537809|Active Comparator|D3 1000 IU/ daily|Subjects randomized to 1000 IU/day of vitamin D3 taken orally for six months.
88903749|NCT01537809|Active Comparator|D3: 2000 IU/daily|Subjects randomized to 2000 IU/day of vitamin D3 taken orally for six months.
89195337|NCT00627393|Experimental|1|Participants will receive granulocyte transfusions in addition to standard antimicrobial therapy
89195338|NCT00627393|Active Comparator|2|Participants will receive standard antimicrobial therapy alone
89195339|NCT00627393|Other|3|Participants will donate granulocytes after receiving a combination of two drugs, G-CSF and dexamethasone
89195340|NCT04534959|No Intervention|Pre-Implementation|The control (pre-implementation) group will be trauma patients admitted to the surgical/trauma ICU during the site's control period of the stepped-wedge implementation process (up to 22 months).
89195341|NCT04534959|Experimental|Post-Implementation Targeting Normoxemia in Trauma ICU|The intervention (post-implementation) group will be patients admitted to the surgical/trauma ICU during the targeted normoxemia intervention period of the stepped-wedge implementation process (up to 25 months).
89422848|NCT02036463|Experimental|Delayed Release Prednisone|During the entire 18 months of the protocol, these subjects will receive delayed release prednisone as an evening dose. All observations and measurements are performed the same as the other study groups.
89422849|NCT02036463|Placebo Comparator|Placebo-Delayed Release Prednisone|During the first 6 months of the protocol, these subjects will receive placebo. After 6 months, this half of the placebo group was re-randomized to receive the delayed release prednisone medication. All observations and measurements are performed the same as the other study groups.
89195342|NCT00816309|Experimental|Acapella Physiotherapy|Physiotherapy with acapella versus no physiotherapy
89422850|NCT02036463|Placebo Comparator|Placebo-Immediate Release Prednisone|During the first 6 months of the protocol, these subjects will receive placebo. After 6 months, this half of the placebo group was re-randomized to receive the immediate release corticosteroid medication. All observations and measurements are performed the same as the other study groups.
89422851|NCT04887844|Active Comparator|Group I|34 patients who were diagnosed with concomitant knee osteoarthritis and pes anserine bursitis and met inclusion criteria were included in the study. Inclusion criteria were as follows: having stage II-IV knee osteoarthritis along with pes anserine bursitis, duration of symptoms for more than three months, and age between 20 and 70 years. Primary knee osteoarthritis was diagnosed as per American College of Rheumatology (ACR) criteria and graded via Kellgren-Lawrence radiological classification included in this study.
89422852|NCT04887844|Active Comparator|Group II|34 patients who were diagnosed with concomitant knee osteoarthritis and pes anserine bursitis and met inclusion criteria were included in the study. Inclusion criteria were as follows: having stage II-IV knee osteoarthritis along with pes anserine bursitis, duration of symptoms for more than three months, and age between 20 and 70 years. Primary knee osteoarthritis was diagnosed as per (ACR) criteria and graded via Kellgren-Lawrence radiological classification included in this study.
89422853|NCT04887844|Other|Group III|34 patients who were diagnosed with concomitant knee osteoarthritis and pes anserine bursitis and met inclusion criteria were included in the study. Inclusion criteria were as follows: having stage II-IV knee osteoarthritis along with pes anserine bursitis, duration of symptoms for more than three months, and age between 20 and 70 years. Primary knee osteoarthritis was diagnosed as per (ACR) criteria and graded via Kellgren-Lawrence radiological classification included in this study.
89422854|NCT05390138|Experimental|Smart Sleep Apnea Self-management Support Programme (4S)|Patients will receive Smart Sleep Apnea Self-management Support Programme (4S) in addition to usual care
89422855|NCT05390138|Placebo Comparator|General Hygiene Information (GH)|Patients will receive general hygiene information (GH) in addition to usual care
89422856|NCT04897204|Experimental|Left Atrial Appendage Electrical Isolation with One-stop treatment of atrial fibrillation|The patients received routine catheter ablation of atrial fibrillation with left atrial appendage occlusion and additional left atrial appendage electrical isolation operation.
89422857|NCT04897204|Other|One-stop treatment of atrial fibrillation|The patients received routine catheter ablation of atrial fibrillation with left atrial appendage occlusion.
88903750|NCT01537822|Experimental|hysteroscopic morcellator|Women, randomized into getting a treatment with the hysteroscopic morcellator.
88903751|NCT01537822|Active Comparator|Resectoscope|Women, randomized into getting a treatment with the resectoscope.
88903752|NCT01537848||post-operative collection|patients suffering from a post-operative abdominal collection
88903753|NCT01537861|Experimental|Arm 1|"Filgrastim 5 ug/kg from Day -3 to Day 10 of a single cycle.~Bortezomib will be given at the patient's current dose on Days 1, 4, 8, and 11 OR Carfilzomib will be given at the patient's current dose on Days 1, 2, 8, 9, 15, and 16 OR IMID will be given at the patient's current dose once daily on Days 1-21. Patients receiving an IMID (thalidomide, lenalidomide, or pomalidomide) as part of a bortezomib or carfilzomb regimen should continue the same scheduled as the current regimen.~Dexamethasone should be continued at the same dose and schedule as the patient's current regimen.~PO cyclophosphamide should be continued at the same dose and schedule as the patient's current regimen."
88903754|NCT01537874|Experimental|Motivational Interview Intervention|Motivational interviewing session (1 hour in home) plus 2 follow-up phone calls
88903755|NCT01537874|Other|Usual Best Practices|Standard care delivered using informational materials
88903756|NCT01537939|Other|Walking|Quasi-experimental design with one-group, post-test only
88903757|NCT01537978|Experimental|Video game play|Changes in upper limb; strength, active range of motion, electromyographic activity as well as heart rate response.
88903758|NCT01537991|Experimental|Group 1A|Group 1A is where less than or equal to 6.5cm length of oesophagus is lying with the Planning Target Volume. Dose will be between 58 and 65Gy determined by current trial cohort in Phase I.
88903759|NCT01537991|Experimental|Group 1B|Group 1A is where more than 6.5cm length of oesophagus is lying with the Planning Target Volume. Dose will be between 58 and 65Gy determined by current trial cohort in Phase I.
89195343|NCT00816309|No Intervention|No physiotherapy|Physiotherapy with acapella versus no physiotherapy
89195344|NCT00821691|Other|1|"Amantadin - Placebo: 5 amantadin caps - 4 days wash out - 5 placebo caps~5 amantadin caps (100mg); 2 caps a day during 3 days; after wash out period (4 days): 5 placebo caps (2 caps a day during 3 days)"
89195345|NCT00821691|Other|2|"Placebo - Amantadin: 5 placebo caps - 4 days wash out - 5 amantadin caps~5 placebo caps: 2 caps a day during 3 days after wash out period (4 days): 5 amantadin caps(100mg) (2 caps a day during 3 days)"
89195346|NCT00821847||1:experimental|male, caucasian, HIV infected patients with glomerular filtration rate between 60 and 30 ml/min (estimated with cockcroft and Gault formulae)
89195347|NCT00816387|Active Comparator|IUI|Intrauterine insemination using standard catheter
88903760|NCT01537991|Experimental|Phase II|All patients will receive radiotherapy to a maximum dose of 65Gy in 20 fractions. The dose to the individual patient will be determined by their individual dose constraints for organs at risk.
89195348|NCT00816387|Experimental|FSP|Fallopian tube sperm perfusion using a commercial device for hysterosalpingography and tubal hydropertubation
89195349|NCT00816465|Experimental|1|Patients receiving Hoodia
89195350|NCT00816465|Placebo Comparator|2|Patients receiving placebo
89195351|NCT00822003|Active Comparator|1|Human GLP-1
89195352|NCT00822003|Placebo Comparator|2|Placebo tablet
89195353|NCT00822081|Active Comparator|1|brimonidine/timolol. Fixed-combination monotherapy.
89195354|NCT00822081|Active Comparator|2|dorzolamide/timolol. Fixed-combination monotherapy.
89195355|NCT00822081|Active Comparator|3|prostaglandin analogue+ brimonidine/timolol fixed combination.
89195356|NCT00822081|Active Comparator|4|prostaglandin analogue+dorzolamide/timolol fixed combination.
89195357|NCT00696774|Experimental|Duloxetine|Patients who met criteria in Study Period I (screening) were treated with duloxetine 60 milligrams (mg) once daily (QD) in an open-label manner for 4 weeks (Study Period II). Study Period II was considered the acute therapy period. Study Period III was a 4-week interval where patients who did not respond during Study Period II had their duloxetine doses optimized to 120 mg.
89195358|NCT00608842|Experimental|Deoxycholic Acid 1%|Participants received 1.0% deoxycholic acid administered at a volume dependent on the size of the lipoma, up to a maximum of 4.8 mL per treatment session, at 28-day intervals for up to a maximum of 4 treatments.
89195359|NCT00608842|Experimental|Deoxycholic Acid 2%|Participants received 2.0% deoxycholic acid administered at a volume dependent on the size of the lipoma, up to a maximum of 4.8 mL per treatment session, at 28-day intervals for up to a maximum of 4 treatments.
89195360|NCT00608842|Experimental|Deoxycholic Acid 4%|Participants received 4.0% deoxycholic acid administered at a volume dependent on the size of the lipoma, up to a maximum of 4.8 mL per treatment session, at 28-day intervals for up to a maximum of 4 treatments.
89195361|NCT00608842|Placebo Comparator|Placebo|Participants received matching vehicle placebo administered at a volume dependent on the size of the lipoma, up to a maximum of 4.8 mL per treatment session, at 28-day intervals for up to a maximum of 4 treatments.
89195362|NCT00626925|Active Comparator|Total Topiramate Group|topiramate capsules beginning at 25 mg/day with gradual increase to a maximum of 200 mg orally)
89195363|NCT00626925|Placebo Comparator|Total Placebo Group|inactive placebo matched in appearance with topiramate capsules
89195364|NCT02566746|Experimental|Chait Trapdoor caecostomie catheter|Patients randomized in this arm will undergo percutaneous endoscopic caecostomy with Chait Trapdoor caecostomie catheter
89195365|NCT02566746|Active Comparator|Continuation of optimal medical therapy|"Patients randomized in this arm will continue this medical treatment of constipation with laxative and / or suppositories and / or enemas retrograde during 12 months.~At 12 months : patients will undergo percutaneous endoscopic caecostomy with Chait Trapdoor caecostomie catheter during 12 months."
89195366|NCT00816543|Experimental|1|3 cycles of neoadjuvant chemotherapy of Docetaxel, Oxaliplatin and S-1. Surgery 5 to 6 weeks after completion of the chemotherapy.
89195367|NCT00819117|Active Comparator|Transvenous Lead (TVN CRT)|Control group: resynchronization via a transvenous left ventricular lead (TVN CRT)
89195368|NCT00819117|Experimental|Epicardial Lead (EPI CRT)|Treatment group: resynchronization via an epicardial left ventricular lead (EPI CRT)
89195369|NCT00816621|Experimental|ABC for Children Adopted Internationally|ABC for Children Adopted Internationally: 10 session in home intervention that targets parent nurturance, synchrony, pseudo-autistic behaviors, and indiscriminate sociability
89195370|NCT00816621|Active Comparator|DEF for Children Adopted Internationally|DEF for Children Adopted Internationally: 10 session in home intervention that targets cognitive and motor delays
89195371|NCT00698646|Active Comparator|Valsartan|(patients initiated on valsartan)
89195372|NCT00698646|Active Comparator|HCTZ|(patients initiated on HCTZ)
89195373|NCT00698646|Experimental|Valsartan + HCTZ|(patients initiated on Valsartan+HCTZ)
89195374|NCT00891358|Experimental|Focus Group|Participants in focus groups will meet and discuss their intervention needs.
89195375|NCT02541292||Patient group|Patients over 18 years old with confirmed FSHD (facioscapulohumeral muscular dystrophy).
89195376|NCT02565888|Active Comparator|Treatment A|Daclatasvir 30 mg QD film-coated tablet + atazanavir 300mg QD hard capsule + ritonavir 100mg QD from film-coated tablet for 10 days.
89195377|NCT02565888|Experimental|Treatment B|Daclatasvir 30 mg QD film-coated tablet + atazanavir 300mg QD hard capsule + cobicistat 150mg QD from film-coated tablet for 10 days.
89195378|NCT04061616|Experimental|Participants|All the participants volunteer to participate to the study that were included.
89195379|NCT00609466|Experimental|1|CG5503 IR 75mg 4 to 6 hourly for 72 hours
89195380|NCT00609466|Active Comparator|2|Morphine IR 30 mg 4 to 6 hourly for 72 hours
89195381|NCT00609466|Placebo Comparator|3|Matching placebo 4 to 6 hourly for 72 hours
89195382|NCT00822315|Active Comparator|1|efavirenz
89195383|NCT00822315|Experimental|2|raltegravir 400 mg
89195384|NCT00822315|Experimental|3|raltegravir 800 mg
89195385|NCT00608530|Experimental|Cognitive Behavioral Therapy-Psychologist-Delivered|10 hours of Cognitive Behavioral Training delivered by a psychologist over 8 weeks by telephone and face-to-face contact
89195386|NCT00608530|Active Comparator|Supportive Psychotherapy-Psychologist-Delivered|10 hours of Rogerian Psychotherapy delivered by a psychologist over 8 weeks by telephone and face-to-face contact
89195387|NCT00608530|Experimental|Cognitive Behavioral Therapy-Nurse-Delivered|10 hours of Cognitive Behavioral Training delivered by a primary care medical nurse over 8 weeks by telephone and face-to-face contact
89195388|NCT00608530|Active Comparator|Supportive Psychotherapy-Nurse-Delivered|10 hours of Rogerian Psychotherapy delivered by a primary care medical nurse over 8 weeks by telephone and face-to-face contact
89195389|NCT00642993|Experimental|SCH 497079|SCH 497079, administered orally, once daily
89195390|NCT00642993|Placebo Comparator|Placebo|Placebo capsules, administered orally, once daily
89422858|NCT03686228|Active Comparator|PB-MNC therapy|The patientsin PB-MNC therapy group will be injected with G-CSF mobilized PB-MNC into calf or thigh muscle of ischemic limb and Aspirin 81 mg/day and supportive treatment including wound care and pain killer drug.
89422859|NCT03686228|Active Comparator|No PB-MNC therapy|In patients in No PB-MNC therapy, they will receive aspirin 81 mg/day and supportive treatment including wound care and pain killer drug.
89422860|NCT03049696|No Intervention|Control Group (Standard of Care)|All patients will receive the Centre for Metabolic and Bariatric Surgery (CMBS) standard of care including two to four multidisciplinary visits over six months, exercise counseling (kinesiologist), completion of a the CMBS behavior modification program (Craving ChangeTM), and achievement of lifestyle and dietary modification goals in order to be scheduled for surgery. The standard of care will be used as the control group (n=24). Matched historical controls (1:1) will be selected (based on age, gender, and body mass index) from the existing CMBS database.
89422861|NCT03049696|Experimental|Intervention Group-ENCOURAGEING START|Intervention group participants (n=24) will receive the standard of care and complete a 16-week supervised physical activity/behaviour modification program at no cost. The first eight weeks of the program involves structured exercise (two per week) and education classes that patients must attend. Progression to a moderate/high-intensity interval program based the patient's capabilities will occur. Participants will also attend education sessions on risk factor reduction, healthy eating, exercise, stress management and promotion of self-managed care. During the second eight week period, participants will be given access to attend drop-in exercise classes or can opt to complete at home exercise. Participants will have an opportunity to meet with the kinesiologist on at least 4 occasions (60 minutes/meeting) for additional physical activity counseling and assistance with overcoming barriers preventing physical activity.
89422862|NCT04430608|Other|Fingerprick glucose|Standard care with fingerprick glucose + blinded CGM stratification on COVID-19 status
89422863|NCT04430608|Experimental|Open continous glucose monitoring (CGM)|Standard care with fingerprick glucose + un-blinded CGM stratification on COVID-19 status
89422864|NCT02595320|Experimental|Group A|capecitabine, 1500 mg, twice a day for 7 days on then 7 days off
89422865|NCT02595320|Active Comparator|Group B|capecitabine, 1250 mg/m2 OR 1000 mg/m2, twice a day for 14 days on then 7 days off
89195391|NCT02541136|Experimental|Exercise|Participants in this arm took part in the aerobic exercise component of the study and attended St. James's Hospital in Dublin twice a week for 16 weeks. Furthermore, exercising participants were asked to engage in recorded aerobic activity outside of the class, which followed a standardised progression from 1-3 additional sessions, at the same intensity as the week's class.
89422866|NCT04887376|Active Comparator|Mirror Therapy|Participants were asked to sit with their knee joints in full extension and both ankle joints in a neutral position. Five sessions of neuromuscular electrical stimulation (NMES) were applied to the non-affected side ankle dorsiflexors. In addition to this application, mirror therapy was applied simultaneously with NMES.
89195392|NCT02541136|No Intervention|Control|Participants in the control group didn't change their sedentary habits.
89195393|NCT00696696|Experimental|Combination GES|Combination of Gemcitabine, Erlotinib, and Sorafenib
89195394|NCT00822393|Active Comparator|1|Busulfan
89195395|NCT00822393|Experimental|2|Treosulfan
89195396|NCT00892840|Experimental|Panels 1 to 7 (BMS-820836 or Placebo)|
89195397|NCT02541058||Confirmed 22q.11.2 deletion/duplication|
89195398|NCT02541058||Suspected 22q.11.2 deletion/duplication|
89422867|NCT04887376|Placebo Comparator|Control|Participants were asked to sit with their knee joints in full extension and both ankle joints in a neutral position. Five sessions of neuromuscular electrical stimulation (NMES) were applied to the non-affected side ankle dorsiflexors.
88903761|NCT01538004||BpTRU readings in private office area|Consenting patients will be randomly allocated using a random number table to BpTRU in an exam room. The first reading will be done with the research assistant present to ensure proper placement and recording and will then be left alone for the subsequent five measurements at one minute intervals. This will be immediately followed by a second set of readings in the alternate location. During both sets of readings the patient will be seated comfortably in a chair with arms and will be instructed not to talk or cross their legs. The same arm will be used for both sets of measurements with the blood pressure cuff at heart level. The average of the last five out of six blood pressure readings for each office location will be recorded. The decibel levels in each location will be recorded during BP readings using a Reed Sound Level Meter C-322. The patient's weight in kg, height in cm, gender and self reported history of hypertension will also be recorded.
88903762|NCT01538004||BpTRU readings in open office area|Consenting patients will be randomly allocated using a random number table to BpTRU in an open office area The first reading will be done with the research assistant present to ensure proper placement and recording and will then be left alone for the subsequent five measurements at one minute intervals. This will be immediately followed by a second set of readings in the alternate location. During both sets of readings the patient will be seated comfortably in a chair with arms and will be instructed not to talk or cross their legs. The same arm will be used for both sets of measurements with the blood pressure cuff at heart level. The average of the last five out of six blood pressure readings for each office location will be recorded. The decibel levels in each location will be recorded during BP readings using a Reed Sound Level Meter C-322. The patient's weight in kg, height in cm, gender and self reported history of hypertension will also be recorded.
88903763|NCT01538017|Active Comparator|Collagenase injection|Injection of collagenase obtained from Clostridium Histolyticum in contracture string
88903764|NCT01538017|Active Comparator|Percutaneous needle fasciotomy|PNF ad modum Lermusiaux and Debeyre
88903765|NCT01538030||Amniotic Fluid Volume > 5|Pregnant patients with gestations between 24-34 weeks with premature rupture of membranes that, when the decision was made to interrupt the pregnancy, had amniotic fluid volume index above 5.1
88903766|NCT01538030||Amniotic Fluid Volume < 5|Pregnant patients with gestations between 24-34 weeks with premature rupture of membranes that, when the decision was made to interrupt the pregnancy, had amniotic fluid volume index of 5 or less.
88903767|NCT01538043|Active Comparator|local mud packs and thermal-mineral bath|50 patients with primary knee OA will be treated with daily local mud packs and thermal-mineral bath at Chianciano Terme Spa Center (Siena, Italy) for a total of 12 applications carried out over a period of two weeks
89422868|NCT04666766|Active Comparator|Traumatic intracranial hemorrhage|Patients with traumatic intracranial hemorrhage diagnosed by Computerized Tomography of the head
89422869|NCT04666766|Active Comparator|Trauma without traumatic intracranial hemorrhage|Patients with trauma to the head but traumatic intracranial hemorrhage ruled out by Computerized tomography of the head
89422870|NCT04666766|Active Comparator|Healthy age-matched volunteers|Healthy age-matched volunteers with no previous trauma to the head within the past two weeks.
89422871|NCT02809053|Experimental|SAIT101|
89422872|NCT02809053|Active Comparator|MabThera®|
89422873|NCT04396756|Experimental|Placebo|Placebo
89422874|NCT04396756|Experimental|PLN-74809 Dose Level 1 (Part A)|PLN-74809 Dose Level 1 (Part A) - 4 weeks
89422875|NCT04396756|Experimental|PLN-74809 Dose Level 2 (Part A)|PLN-74809 Dose Level 2 (Part A) - 4 weeks
89422876|NCT04396756|Experimental|PLN-74809 Dose Level 2 (Part B)|PLN-74809 Dose Level 2 (Part B) - 12 weeks
89422877|NCT04396756|Experimental|PLN-74809 - Dose Level 3 (Part C)|PLN-74809 Dose Level 3 (Part C) - 12 weeks
89422878|NCT04396756|Experimental|PLN-74809 - Dose Level 4 (Part C)|PLN-74809 Dose Level 4 (Part C) - 12 weeks
89422879|NCT04396756|Experimental|PLN-74809 - Dose Level 5 (Part D)|PLN-74809 Dose Level 5 (Part D) - ≥ 24 weeks
89422880|NCT05390060|Experimental|Neuromonitoring arm|Neuromonitoring placed after cardiac arrest
89422881|NCT04887142||The discharged subjects|The COVID-19 inpatients treated with standard care who survived the disease and discharged from hospital.
89422882|NCT04887142||The deceased subjects|The COVID-19 inpatients treated with standard care who died from the disease.
89422883|NCT04666688|Experimental|Part 1 single agent dose escalation|LYT-200 in metastatic solid tumors
89422884|NCT04666688|Experimental|Part 1 combination agents dose expansion|LYT-200 in combination with chemotherapy or Tislelizumab in select metastatic solid tumors
88903768|NCT01538043|No Intervention|regular routine ambulatory care|50 patients, the control group, will continue regular routine ambulatory care
88903769|NCT01538069|No Intervention|Control group|
88903770|NCT01538069|Experimental|Exercise group|
88903771|NCT01538069|Experimental|CPAP group|
88903772|NCT01538069|Experimental|Exercise and CPAP group|
88903773|NCT01538082||Patients without stress|Patients without any of the next items: Zung's questionnaire score over 19 points; SF-12 questionnaire score over 5 points; Stressful vital events score over 150 points.
88903774|NCT01538082||Patients with stress|Patients with stress, including: Zung's questionnaire punctuation over 19 points; SF-12 questionnaire score over 5 points; stressful vital events score over 150 points. All combinations are considered positive in stress.
88903775|NCT01538095|Experimental|Treatment (trebananib)|Patients receive trebananib IV over 30-60 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
88903776|NCT01538108|Experimental|NMB's PTA Balloon catheter with paclitaxel|
88903777|NCT01538108|Active Comparator|Standard Angioplasty Balloon|
88903778|NCT01538121||Cases-Early Severe Preeclampsia|Patients with severe preeclampsia before 34 weeks of gestation
88903779|NCT01538121||Controls|Patients with normal pregnancies at term.
88903780|NCT01538134||Cases|Patients with ultrasonographic diagnosis of fetal growth restriction.
88903781|NCT01538134||Control|Patients with normal pregnancies at term.
88903782|NCT01538147||Cases|Patients with Severe preeclampsia
88903783|NCT01538147||Control|Patients with normal pregnancies at term
88903784|NCT01538173|Experimental|HES group|Application of twice a day 250ml HES 6% for three days postoperatively.
88903785|NCT01538173|Active Comparator|NaCl group|Application twice a day 500ml 9% NaCl for three days postoperatively.
89006985|NCT06161636||Patients with atypical Parkinsonian Syndromes (PS)|"Participants will then have to perform three blocks of tests: the first focused on the scripted motor signature, a second on the voice signature, and a complementary block aimed at capturing the motor signature using gestures of greater amplitude.~All the tests were designed to allow the characterization of the motor signature according to different aspects of motor control, but also to reproduce the same concepts in the three fields (scripted signature, voice signature and large amplitude motor signature), while allowing an acquisition of an approximate total duration of 30 minutes.~For retinal photos, the subject's pupils will be dilated using eye drops (1% tropicamide and 2.5% phenylephrine) 15-20 minutes before taking the measurement. These drugs are considered the standard used by optometrists and ophthalmologists during pupil dilation."
89006986|NCT06161636||Healthy volunteers|"Participants will then have to perform three blocks of tests: the first focused on the scripted motor signature, a second on the voice signature, and a complementary block aimed at capturing the motor signature using gestures of greater amplitude.~All the tests were designed to allow the characterization of the motor signature according to different aspects of motor control, but also to reproduce the same concepts in the three fields (scripted signature, voice signature and large amplitude motor signature), while allowing an acquisition of an approximate total duration of 30 minutes.~For retinal photos, the subject's pupils will be dilated using eye drops (1% tropicamide and 2.5% phenylephrine) 15-20 minutes before taking the measurement. These drugs are considered the standard used by optometrists and ophthalmologists during pupil dilation."
89006987|NCT06160713|Active Comparator|Standard care|Standard care of bronchiectasis
89006988|NCT06160713|Experimental|Itraconazole arm|Supra-bioavailable- Itraconazole capsule 65 mg
89006989|NCT06160687|Active Comparator|PSV arm|Delivery of NIV using PSV mode
89006990|NCT06160687|Experimental|ASV intellisync arm|Delivery of NIV using Intelllisync ASV
88903786|NCT01538186||PCI without treating the side branch|
88903787|NCT01538186||PCI with treating the side branch|
88903788|NCT01538225|Experimental|first sativex, second placebo|2 weeks first titration period (as per approved SmPC), a 2-week first treatment period (Sativex), a 2-week washout, a cross-over followed by another 2 weeks titration period (as per SmPC), followed by a second 2-week period treatment (placebo)
88903789|NCT01538225|Experimental|first placebo, second sativex|2 weeks first titration period (as per approved SmPC), a 2-week first treatment period (placebo), a 2-week washout, a cross-over followed by another 2 weeks titration period (as per SmPC), followed by a second 2-week period treatment (Sativex)
88903790|NCT01538238|Experimental|pazopanib|pazopanib 800mg qd
88903791|NCT01538251|Experimental|Propionyl-L-carnitine|modified release tablets 500 mg
88903792|NCT01538251|Placebo Comparator|Placebo|Modified release tablet 500 mg
88903793|NCT01538277|Experimental|Contact Force arm|the real-time contact force will be known to the operator
88903794|NCT01538277|Active Comparator|Standard|Standard ablation arm
88903795|NCT01538316|Active Comparator|Quercetin supplement|
88903796|NCT01538316|Active Comparator|Genistein supplement|
88903797|NCT01538316|Placebo Comparator|Placebo|
88903798|NCT01538329|Experimental|Amantadine|Patients with amantadine
88903799|NCT01538329|Placebo Comparator|Placebo|Patients with amantadine placebo
88903800|NCT01538355|Experimental|Prolonged fasting|Patients undergo an initial 7-day fasting episode.
88903801|NCT01538355|Experimental|Ketogenic low glycemic load treatment|Patients receive a ketogenic low glycemic load treatment from the outset of the study.
88903802|NCT01538355|Experimental|Control diet|Patients stay on their regular diet.
88903803|NCT01538381|Experimental|Afatinib|Afatinib given orally for 2 weeks after randomization till day -1 prior to surgery (day 0) at a dose of 40 mg/day
88903804|NCT01538381|Other|Observation|No treatment only observation
88903805|NCT01538394|Experimental|Varenicline & nicotine patches|"Combined therapy by using Varenicline plus nicotine patches.The intervention-phase will comprise two fasses:~Pre-NRT: Patients take 1 week VRN impregnation (0.5mg/day during the first 3 days + 0.5mg twice daily for the next for days)~Treatment: starting at day 8 and during the next 11 weeks patients continue taking VRN 1mg twice daily plus placebo transdermal patches of 30cm2/24 hours per 8 weeks and then 20cm2/24 hours per 3 weeks."
89422885|NCT04666688|Experimental|Part 2|LYT-200 combination dose expansion in select metastatic solid tumors based on outcomes of Part 1
89422886|NCT04548986|Other|single arm|single arm study
89422887|NCT05701839|Experimental|face mask airway management without oxygen reserve index monitoring|Participants inhale oxygen through face mask at a flow rate of 5 L/min and will be monitored with oxygen saturation.
89422888|NCT05701839|Experimental|face mask airway management with oxygen reserve index monitoring|Participants inhale oxygen through face mask at a flow rate of 5 L/min and will be monitored with oxygen reserve index.
89422889|NCT05701839|Experimental|nasopharyngeal tube airway management without oxygen reserve index monitoring|Participants inhale oxygen through face mask before induction and through nasopharyngeal tube after consciousness disappear at a flow rate of 5 L/min and will be monitored with oxygen saturation.
89422890|NCT05701839|Experimental|nasopharyngeal tube airway management with oxygen reserve index monitoring|Participants inhale oxygen through face mask before induction and through nasopharyngeal tube after consciousness disappear at a flow rate of 5 L/min and will be monitored with oxygen reserve index.
89422891|NCT04882618|Experimental|ICG group|ICG injection before LRRP via cystoscopy
89422892|NCT03462290|Experimental|Botulinum toxin|
89422893|NCT03462290|Placebo Comparator|placebo|
89422894|NCT02036619||pregnant women without known diabetes|
89422895|NCT04879394|Experimental|Hypnosis|4 weekly hypnosis sessions, aiming at pain control and distress management. The 90 min. sessions will be conducted in group format by a doctorate-level psychologist trained in hypnosis. Contents will be detailed on hypnosis protocols to ensure standardization.
89422896|NCT04879394|No Intervention|Control|Receives standard care as usual. Assessments will be made in the same time points as experimental group, but without undergoing intervention.
89422897|NCT03108638||R3 Supervisor Strategy Region 1|First cohort to be trained and monitored with remote coaching in the R3 model
89422898|NCT03108638||R3 Supervisor Strategy Region 2|Second cohort to be trained and monitored with remote coaching in the R3 model
89422899|NCT03108638||R3 Supervisor Strategy Region 3|Third cohort to be trained and monitored with remote coaching in the R3 model
89422900|NCT03108638||R3 Supervisor Strategy Region 4|Fourth cohort to be trained and monitored with remote coaching in the R3 model
88814907|NCT03017768|Placebo Comparator|Placebo|Administration of an amino acid mixture consisting of 15 amino acids, (4.1g L-alanine, 2.4g glycine, 2.4g L-histidine, 6.0g L-isoleucine, 10.1g L-leucine, 6.7g L-lysine, 4.3g L-phenylalanine, 9.2g L-proline, 5.2g L-serine, 4.3g L-threonine, 5.2g L-tyrosine, 6.7g L-valine, 3.7g L-argine, 2.0g L-cysteine, 3.0g L-methionine and 3.0g L-trypyophan). Since this amino-acid mixture contains tryptophan it is used as the placebo arm of this cross-over study
88814908|NCT03017690||lanreotide group (Somatuline Depot®)|
88814909|NCT03017690||octreotide LAR group (Sandostatin LAR®)|
88814910|NCT02981732|Experimental|Shen (Kidney) yin deficiency|Shen (Kidney) yin deficiency
88814911|NCT02981732|No Intervention|the control group|the control group,there is no intervention
88814912|NCT03017534|Experimental|Gender Match, Labcoat, Explanation|Subjects will receive Spinal Manual Therapy (sham thoracic spine manipulation) by a gender matched therapist, wearing a labcoat and receive a detailed anatomic explanation of the technique.
88814913|NCT03017534|Experimental|Gender Match, Labcoat, No Explanation|Subjects will receive Spinal Manual Therapy (sham thoracic spine manipulation) by a gender matched therapist, wearing a labcoat, and receive a colloquial discussion of the technique.
88814914|NCT03017534|Experimental|Gender Match, No Labcoat, Explanation|Subjects will receive Spinal Manual Therapy (sham thoracic spine manipulation) by a gender matched therapist, not wearing a labcoat, and receive a detailed anatomic explanation of the technique.
88814915|NCT03017534|Experimental|Gender Match, No Labcoat, No Explanation|Subjects will receive Spinal Manual Therapy (sham thoracic spine manipulation) by a gender matched therapist, not wearing a labcoat, and receive a colloquial discussion of the technique.
88814916|NCT03017534|Experimental|Gender Mis-match, Labcoat, Explanation|Subjects will receive Spinal Manual Therapy (sham thoracic spine manipulation) by a gender mis-matched therapist, wearing a labcoat and receive a detailed anatomic explanation of the technique.
88814917|NCT03017534|Experimental|Gender Mis-match, Labcoat, No Explan.|Subjects will receive Spinal Manual Therapy (sham thoracic spine manipulation) by a gender mis-matched therapist, wearing a labcoat, and receive a colloquial discussion of the technique.
88814918|NCT03017534|Experimental|Gender Mis-match, No Labcoat, Explan.|Subjects will receive Spinal Manual Therapy (sham thoracic spine manipulation) by a gender mis-matched therapist, not wearing a labcoat, and receive a detailed anatomic explanation of the technique.
88814919|NCT03017534|Experimental|Gender Mis-match, No Labcoat, No Explan.|Subjects will receive Spinal Manual Therapy (sham thoracic spine manipulation) by a gender matched therapist, not wearing a labcoat, and receive a colloquial discussion of the technique.
88814920|NCT03026660|Experimental|Moringa treatment|Moringa Oleifera was distributed in two 500mg capsules of dried and powdered Moringa Oleifera leaves. Two capsules were taken daily.
88814921|NCT03026660|Placebo Comparator|Placebo|The placebo consisted of dried and powdered cabbage in two 500mg capsules. Two capsules were taken daily.
88814922|NCT02981576|Active Comparator|Recipient of AT-MSC|Patients who will receive Autologous Mesenchymal Stem Cells from AdiposeTissue by Intrathecal injection of stem cells that will be performed 3 times.
88814923|NCT02981576|Active Comparator|Recipient of BM-MSC|Patients who will receive Autologous Mesenchymal Stem Cells from Bone marrow by Intrathecal injection of stem cells that will be performed 3 times.
88814924|NCT01006538|Experimental|Arm A (treatment)|Arm A: A single surgical procedure with epimacular brachytherapy using the VIDION® System, with Lucentis® (0.5 mg) administered on a monthly basis as required.
88814925|NCT01006538|Active Comparator|Arm B (control):|Arm B: Lucentis® (0.5 mg) administered on a monthly basis as required, using the re-treatment criteria below.
88814926|NCT03017222|Active Comparator|Ondansetron group|
89422901|NCT04896424|Other|Cryoballoon-based pulmonary veins isolation cohort|Patients treated with a 28-mm second-generation cryoballoon (Arctic Front Advance, Medtronic) for paroxysmal atrial fibrillation and screened over a 2-year post-ablation period.
88903806|NCT01538394|Placebo Comparator|Varenicline & placebo patches|"Monotherapy by using Varenicline plus placebo patches.The intervention-phase will comprise two fasses:~Pre-NRT: Patients take 1 week VRN impregnation (0.5mg/day during the first 3 days + 0.5mg twice daily for the next for days)~Treatment: starting at day 8 and during the next 11 weeks patients continue taking VRN 1mg twice daily plus nicotine transdermal patches of 30cm2/24 hours per 8 weeks and then 20cm2/24 hours per 3 weeks."
88903807|NCT01538407|No Intervention|Control group|No intervention group
88903808|NCT01538407|Active Comparator|Strength training group|The knee extension strength training intervention period is 12 weeks with training sessions three times per week.
88903809|NCT01538420|Experimental|GLPG0492 oral solution|Multiple ascending doses once daily for 7 days (part 1) or 14 days (part 2), starting at 0.5 mg/day
88903810|NCT01538420|Placebo Comparator|Placebo|Placebo oral solution, once daily for 7 days (part 1) or 14 days (part 2).
88903811|NCT01538433||biopsy-proven IgA nephropathy|
88903812|NCT01538446|Experimental|1: Monitoring Arm|Monitoring Arm: dose adjustment of prasugrel with down-adjustment of the dose of prasugrel in high responders and up-adjustment of the dose of prasugrel in low responders
88903813|NCT01538446|Active Comparator|2: Conventional Arm|Conventional Arm: fixed dose of prasugrel 5 mg
88903814|NCT01538459|Active Comparator|Bupivacaine|50 randomized participants in group receive 20cc 0.25% bupivacaine injected perineurally for interscalene nerve block.
88903815|NCT01538459|Experimental|Dexamethasone and Bupivacaine|50 randomized participants in group will 8 mg(2cc of 4mg/cc solution) Dexamethasone added to 20 cc 0.25% bupivacaine in one syringe resulting in 364 µgm/cc for injection. Injected perineurally for interscalene nerve block pre-operatively.
88903816|NCT01538485|Experimental|Cholecalciferol|
88903817|NCT01538511|Experimental|BIAsp 70|
88903818|NCT01538511|Experimental|BIAsp 30|
89195399|NCT00819195||RRMS|Relapsing-remitting multiple sclerosis patients who have not yet received glatiramer acetate (Copaxone) therapy recommended as part of clinical care
89195400|NCT00819195||HC|Healthy control volunteers
89195401|NCT00891514|Experimental|Aerobic Exercise|Treadmill training
89195402|NCT00891514|Active Comparator|Stretch Control|Stretching exercises
89195403|NCT00819273||1|patients who have records of clinic visit with circulatory and endocrine internal medicines of nationwide tertiary hospitals within the last one year.
89422902|NCT03732339|Experimental|GILUPI CellCollector®|
88903819|NCT01538550|Experimental|Flexible sigmoidoscopy|70,000 men and women at age 50-74 years are randomised from the population registry to be invited to have a screening examination using flexible sigmoidoscopy once-only
88903820|NCT01538550|Experimental|iFOBT|70,000 men and women at age 50-74 years randomised from the population registry to be invited to have a screening examination biennially using an immunochemical test for fecal occult blood testing (iFOBT).
88903821|NCT01538576||Insulin aspart users|
88903822|NCT01538589||Insulin aspart users|
88903823|NCT01538602||PCOS patients|
88903824|NCT01538602||Healthy volunteers|
88903825|NCT01538641|Experimental|1|
88903826|NCT01538654||'enteral protein tube feeding in obese|protein sparing modified fast with a defined enteral formula by tube
88903827|NCT01538667|Experimental|Arm 1|
89006991|NCT06159699||Non-structured population|The respondent will represent the non-structured population of the Russian Federation invited to participate in the study using the SMS-Target tool provided by OOO T2 Mobile Company.
89195404|NCT02567682|Experimental|Fixed sequence, 2-periods|An open-label, fixed sequence, 2-period drug interaction study Period 1 Treatment A: Single dose of drug cocktail on Day 1 Period 2 Treatment B: GBT440 on Days 1 through 3 and Treatment C: Single dose of drug cocktail on Day 4 and GBT440 on Days 4 through 7
88903828|NCT01538667|Experimental|Arm 2|
88903829|NCT01538667|Experimental|Arm 3|
88903830|NCT01538667|Experimental|Arm 4|
88903831|NCT01538693|Active Comparator|escitalopram oxalate|Exercise testing with escitalopram oxalate dose
88903832|NCT01538693|Active Comparator|cyproheptadine|exercise testing with cyproheptadine dose
88903833|NCT01538693|Placebo Comparator|placebo|exercise testing with placebo dose
89195405|NCT00892918|Active Comparator|Moxifloxacin|About 20 patients treated by Moxifloxacin ophthalmic solution 0.5% (Vigamox) 4 times a day (one drop each time) after pterygium excision with Mitomycin C application.
89195406|NCT00892918|Active Comparator|Gatifloxacin|About 20 patients treated by Gatifloxacin ophthalmic solution 0.3% (Zymar) 4 times a day (one drop each time) after pterygium excision with Mitomycin C application.
89195407|NCT04739280||Single center registry for WACE|We propose a single center registry for patients requiring diagnostic, screening, or surveillance for potential or existing cardiac illness. All eligible patients will undergo an MCG with periodic follow-ups. No treatment decisions will be based on the MCG findings, until CardioFlux has appropriate FDA labelling for clinical use.
89195408|NCT02551185|Experimental|ACY-241 in combination with Paclitaxel|
89195409|NCT00892996|No Intervention|1|Metoclopramide 10 mg intravenous
89195410|NCT00892996|No Intervention|2|Ondansetron 8 mg intravenous
89195411|NCT00892996|Active Comparator|3|dexamethasone 5 mg and metoclopramide 10 mg
89195412|NCT00892996|Active Comparator|4|dexamethasone 5 mg and ondansetron 8 mg IV
89195413|NCT02567448|Active Comparator|COPD Group|Patients who were previously diagnosed of moderate to severe COPD as determined by spirometry. All patients will have sleep and pulmonary physiologic measurements.
89195414|NCT02567448|Active Comparator|Normal Control Group|Patients who are healthy, without major medical or sleep problems, and have normal spirometry. All patients will have sleep and pulmonary physiologic measurements.
89195415|NCT02551341|No Intervention|control|normal ventilation
89195416|NCT02551341|Experimental|intervention|higher PEEP ventilation
89195417|NCT00891592|Experimental|Dose Escalation Arm|Subjects with cord blood stored in more than one fraction will be enrolled into Dose Escalation Arm. Subjects will receive Cord Blood Stem Cell Transplant followed by expanded Cord Blood T cells on Day 0.
89195418|NCT00891592|Active Comparator|Observation Arm|Subjects with cord blood stored in one fraction will be enrolled into the Observation Arm. Subjects will receive Cord Blood Stem Cell Transplant on Day 0.
89422903|NCT03468842|Placebo Comparator|Placebo|Composition: excipients without probiotic: 2%w/v Guam guar and 6% w/v hydroxyethilcellulose Application in mouth of a bucoadhesive gel. Applied by the profesional at days 0, 15 and 30 and by the participants the rest of the days Frequency: each 48 h by the participants Duration: during 30 days
89422904|NCT03468842|Active Comparator|Probiotic|Composition: Streptococcus dentisani: 2,5E+09CFUs, 2% (p/v) Guam Guar and 6% (p/v) Hidroxietilcelulosa. Dose of 2.5E+09 cfu/vial considering one administration every 48 hours, it will be equivalent to a dose of 1.0E+10 cfu/week Application in mouth of a bucoadhesive gel. Applied by the profesional at days 0, 15 and 30 and by the participants the rest of the days Frequency: each 48 h by the participants Duration: during 30 days
89422905|NCT02047539|Experimental|1000 mg/day aspirin|1000 mg/day aspirin
89422906|NCT02047539|Placebo Comparator|sugar pill|sugar pill
89422907|NCT05389748|Placebo Comparator|Placebo|Placebo which appears the same as the treatment to investigators, clinicians and subjects.
89422908|NCT05389748|Active Comparator|NanO2|A milky white intravenous injectable emulsion
88814927|NCT03017222|Experimental|Ramosetron group|
88903834|NCT01538706|Experimental|Hospital-based home care|Patients were included if below the age of 18, had been diagnosed with any type of cancer at least one month prior to inclusion, on intravenous anticancer therapy with a curative intent, and the parent was fluent in speaking and reading Danish. Patients living within a radius of 50 kilometres from the hospital were assigned to the home care program. Moreover, patients were assigned to one of three groups according to the geographical distance from the hospital and timing of the inclusion period: (1) home care group if participating in the program, (2) historical standard care group for an eight-month period before the program started regardless of their residence distance from the hospital, and (3) concurrent standard care group if living more than 50 km from the university hospital.
88903835|NCT01538758|Active Comparator|Us guided needling|"Us guided needling is a therapeutical technique treating calcifying tendinitis of the shoulder. Calcifications in the rotator cuff tendon are visualised with ultrasound. Under ultrasound guidance a 20 gauge needle is inserted in the calcification. Lidocaine 1% in a 1cc syringe is injected in the calcification and aspirated. The calcification is flushed until the fluid is clear. Sometimes it is not possible to flush the calcification. In this case the calcification will be fragmented.~After flushing or fragmentation of the calcification, 20 mg triamcinolone with 1cc lidocaine 1% will be injected in de subacromial bursa under us guidance."
88903836|NCT01538758|Active Comparator|corticosteroid injection|Us guided subacromial bursa injection with 20 mg triamcinolone with 1cc lidocaine 1%.
88903837|NCT01538771|Placebo Comparator|Control group|Received same volume of saline
88903838|NCT01538771|Active Comparator|Darbepoetin group|Darbepoetin alfa 300ug intracoronary bolus infusion via over-the-wire balloon before the 1st ballooning & conventional treatment
88903839|NCT01538823||Group 1|Enrollment of surgical patients at Barnes Jewish Hospital (BJH) with a presumptive diagnosis of RCC and planned nephrectomy or partial nephrectomy.
88903840|NCT01538823||Group 2|Surgical patients at BJH with non urological cancers
88903841|NCT01538823||Group 3|Surgical patients at BJH with a presumptive diagnosis of RCC and planned nephrectomy or partial nephrectomy
88903842|NCT01538823||Group 4|Surgical patients at BJH with non urological cancers
88903843|NCT01538823||Group 5|Healthy volunteers with no history of cancer or renal disease
88903844|NCT01538823||Group 6|Patients at BJH/Washington University School of Medicine under post procedure surveillance for RCC recurrence and patients under treatment for metastatic disease.
88903845|NCT01538823||Group 7|Patients with a presumptive diagnosis of bladder cancer or prostate cancer
88903846|NCT01538836|No Intervention|Weight maintenance|Weight maintenance with normal protein intake
88903847|NCT01538836|Active Comparator|Weight loss with normal protein intake|
88903848|NCT01538836|Experimental|Weight loss with protein supplementation|
88903849|NCT01538849|Experimental|YH4808 A mg (Twice daily)|YH4808 A mg (Twice daily, Oral administration)
88903850|NCT01538849|Experimental|YH4808 B mg (Once daily)|YH4808 B mg (Once daily, Oral administration)
88903851|NCT01538849|Experimental|YH4808 B mg (Twice daily)|YH4808 B mg (Twice daily, Oral administration)
88903852|NCT01538849|Experimental|YH4808 C mg (Once daily)|YH4808 C mg (Once daily, Oral administration)
88903853|NCT01538849|Active Comparator|Esomeprazole 40mg (Once daily)|Esomeprazole 40mg (Once daily, Oral administration)
88903854|NCT01538875|Experimental|Hydralazine|Patients with an hypertensive crisis during pregnancy will receive 5mg IV every 15 minutes (Maximum number of doses: 3).
88903855|NCT01538875|Active Comparator|Labetalol|Patients with an hypertensive crisis during pregnancy will receive 20 mg of Labetalol IV. After 15 minutes if the crisis continue, 40 mg IV. After 15 minutes if the crisis continue, 80 mg IV. Then, if the crisis continue, 80 mg IV every 15 minutes (maximum dose: 300 mg IV in total).
88903856|NCT01538888|Experimental|WHOLE BODY VIBRATION|SEARCH THE CARDIOPULMONARY EFFECTS IN WHOLE BODY VIBRATION IN HEALTH ELDERLY
88903857|NCT01538901|Experimental|photodynamic therapy|Methyl-aminolaevulinate 16% cream (Metvix 160mg/g cream) will be applied 1 mm thick on the treated area, which has a maximal diameter of 8 cm2, and will be covered with a semipermeable dressing (Suprasorb F, Lohmann & Rauscher, Vienna, Austria)for 3 hours. Afterwards the cream leftovers will be removed by 0.9% NaCl solution. Following the treated area will be irradiated with heat-free visible red light at a peak wavelength of 630 nm with a single dose of 37 J/cm2 (Actilite model: CL128, PhotoCure, Norway). This treatment will be repeated in two weeks.
89195419|NCT00822471|Other|Diabetes Self-Management Education|Education intervention with historic self-controls.
88903858|NCT01538901|Active Comparator|imiquimod 5% cream|250 mg imiquimod 5% cream (Aldara 5% cream) will be applied over night, for a total of 3 nights in a week, for duration of 4 weeks.
88903859|NCT01538914|Experimental|PVB|Postoperative pain is controlled with local analgesics delivered via PVB.
88903860|NCT01538914|Active Comparator|PCA|Postoperatve pain is controlled with intravenous PCA.
88903861|NCT01538927|Experimental|Fibrin Sealant|One quadrant surgically elevated will be closed with fibrin sealant
88903862|NCT01538927|Placebo Comparator|Suture|The surgically elevated flap is closed with non resorbable sutures.
88903863|NCT01538940|Active Comparator|HIV+, CD4<200, ID vaccine|
88903864|NCT01538940|Active Comparator|HIV+, CD4<200, IM vaccine|
88903865|NCT01538940|Active Comparator|HIV+, CD4>=200, ID vaccine|
89195420|NCT00893230|Experimental|Lactobacillus sakei KCTC 10755BP|
89195421|NCT00893230|Placebo Comparator|microcrystalline cellulose|
89195422|NCT00891670|Active Comparator|triple group|received cilostazol 100 mg twice daily in addition to aspirin 100mg and clopidogrel 75mg once daily
89195423|NCT00891670|Active Comparator|high maintenance dose group|received clopidogrel 150 mg/day with aspirin 100mg once daily
89195424|NCT00699192|Experimental|Amlodipine/Valsartan 5/80 mg|1 capsule amlodipine 5 mg, 1 capsule valsartan 80 mg once daily
89195425|NCT00699192|Active Comparator|Amlodipine/Valsartan 5/40 mg|1 capsule amlodipine 5 mg, 1 capsule valsartan 40 mg once daily
89195426|NCT00699192|Active Comparator|Amlodipine 5 mg|1 capsule amlodipine 5 mg, 1 capsule placebo to match valsartan once daily
89195427|NCT00891748|Experimental|AdCD40L|Adenovirus vector serotype 5, E1/E3 deletion with human CD40L gene driven by RSV promoter.
89195428|NCT00921180|Experimental|Entecavir and peginterferon|Entecavir 0.5 mg/day at week 1-4, followed by peginterferon alfa-2a 180 ug/week at week 5-52
89195429|NCT00921180|Active Comparator|Placebo and peginterferon|Placebo 0.5 mg/day at week 1-4, followed by peginterferon alfa-2a 180 ug/week at week 5-52
89195430|NCT00891826|Placebo Comparator|Corn oil|
89195431|NCT00891826|Experimental|Omega-3 fatty acids|
88903866|NCT01538940|Active Comparator|HIV+, CD4 >=200, IM vaccine|
88903867|NCT01538940|Other|HIV-, ID vaccine|
88903868|NCT01538940|Other|HIV-, IM vaccine|
88903869|NCT01538953|Experimental|Handwashing|participants received weekly, in-home handwashing promotion and soap as needed
88903870|NCT01538953|Experimental|handwashing and water treatment|
88903871|NCT01538953|Experimental|Water treatment with sodium hypochlorite|
88903872|NCT01538953|Experimental|Water treatment with flocculent-disinfectant|participants received a supply of flocculent-disinfectant product and instruction to use it to treat drinking water
88903873|NCT01538953|No Intervention|Control|
88903874|NCT01538979|Experimental|BM32 low dose|7 subcutaneous injections of 20 micrograms over two grass pollen seasons
88903875|NCT01538979|Experimental|BM32 high dose|7 subcutaneous injections of 40 micrograms over two grass pollen seasons
88903876|NCT01538979|Placebo Comparator|Placebo|7 subcutaneous injections over a time span of two pollen seasons
88903877|NCT01538992|Experimental|renal denervation|in this group percutaneous renal denervation with Standard steerable Mariner Radiofreqency ablation Catheter (5F or 7F)
88903878|NCT01538992|No Intervention|medical thrapy|medical treatment
88903879|NCT01539018|Active Comparator|Sorafenib alone.|Sorafenib 400 mg p.o. twice daily until progression or intolerable toxicity alone.
88903880|NCT01539018|Experimental|sorafenib plus tegafur-uracil|Sorafenib 400 mg p.o. twice daily continuously and UFT 125mg/m2 PO BID For 4 weeks and to be repeated on day 36 till progression or intolerance
89195432|NCT04060992|Experimental|Early Follicular Phase|Women enrolled will be anywhere from cycle day 1 through 5 of their menstrual cycle and take elagolix 200mg oral tablet BID for 3 days total.
89195433|NCT04060992|Active Comparator|Late Follicular Phase|Women enrolled will be anywhere from cycle day 8 through 13 of their menstrual cycle and take elagolix 200mg oral tablet BID for 3 days total.
89195434|NCT04060992|Active Comparator|Luteal Phase|Women enrolled will be anywhere from cycle day 21 through cycle day 26 of their menstrual cycle and take elagolix 200mg oral tablet BID for 3 days total.
89195435|NCT04061304|Experimental|Active rTMS (Anorexia Nervosa)|"Patients in this arm will receive 40 sessions of active rTMS. Every day, the first session of rTMS for both groups will be applied to the left DLPFC using intermittent Theta Burst Stimulation (iTBS).~For the second session each day the patients in the anorexia group will receive low-frequency treatment (1 Hz, 60 second cycles, 30 second inter-train interval, 20 trains, 1200 total pulses) at 120% of the resting motor threshold to the orbitofrontal cortex"
89195436|NCT04061304|Experimental|Active rTMS (Bulimia Nervosa)|"Patients in this arm will receive 40 sessions of active rTMS. Every day, the first session of rTMS for both groups will be applied to the left DLPFC using intermittent Theta Burst Stimulation (iTBS).~For the second session each day the patients in the bulimia group will receive high-frequency (10 Hz, 5 second cycles, 50 pulses, 25 second inter-train interval, 60 trains, 3000 total) at 120% of the resting motor threshold treatment to the left dorsomedial prefrontal cortex"
89422909|NCT02047617|Active Comparator|the standard physiotherapy group|Physiotherapy rehabilitation techniques used in the management of this group include passive range of motion, active range of motion/bed exercises, sitting at edge of bed, sitting in armchair, active transfer from the bed to chair. Mobilization and rehabilitation program is progressively introduced after clinical stabilization with a goal of progressing to ambulation and pulmonary rehabilitation.
89422910|NCT02047617|Experimental|standing table group|The same program as standard physiotherapy group is applied, with daily sessions of standing table in supplement. Standing table was performed on a motorized tilt table (ref: table de verticalisation, Franco&fils). The protocol involved a stepwise process to gradually raise the subject into a standing position on the standing table platform, at 10° intervals from 30° to 80°.
89422911|NCT04896190|Experimental|Experimental group|Before the evaluation of EMG amplitude on dynamic balance position, the Q angle was measured in supine and standing positions. The EMG signals collected by measuring the muscle activation of the Vastus Medialis and Vastus Lateralis during dynamic balance position on the ProKin device were recorded. Q angle evaluations, static and dynamic balance and functional status of all participants were evaluated.
89422912|NCT02522858|Placebo Comparator|Placebo|After fixation of the block level of spinal anesthesia, and just before starting dexmedetomidine, normal saline 0.5mL would be injected intravenously.
88903881|NCT01539044|Active Comparator|IB-neostigmine|subject will be given intermittent bolus of rocuronium during the surgery and reversal of neostigmine at the end of surgery at TOF 2
88903882|NCT01539044|Experimental|CI-Sugammadex|subject will be given continuous infusion of rocuronium and reversal of sugammadex at the end of surgery at PTC 1-2
88903883|NCT01539057|Experimental|Intravenous Fibrinogen|Fibrinogen will be administered until an expected plasmatic value of 2.9 g / L is achieved.
88903884|NCT01539057|Placebo Comparator|Saline Serum|the same dose in volume of saline dilution will be administered. The potential dose of fibrinogen required to obtain a final plasmatic reading of 2.9 g / L. will be computed. A serum will contain the corresponding ml of saline dilution
88903885|NCT01539096|Sham Comparator|Sham tDCS plus CIMT|Subjects in this group will be trained on Constraint induced movement therapy (CIMT) for the hand while concurrently receiving placebo noninvasive brain stimulation (tDCS). They will be receiving Sham tDCS: placebo noninvasive brain stimulation. They will be provided treatment for 3 days a week for 5 weeks for 1 hr each day at the Cleveland Clinic. They would be asked to use affected hand in daily activities for 5 hrs everyday at home while wearing a mitt on their unaffected hand.
88903886|NCT01539096|Experimental|tDCS plus CIMT|Patients with stroke affecting the hand will receive Constraint-induced movement therapy (CIMT) concurrent with tDCS: noninvasive brain stimulation. TDCS will be applied to areas of the brain responsible for movement of the affected hand. This combination of tDCS and CIMT will be delivered for 1 hr each day for 3 days a week for 5 weeks. Patients will also be asked to use their affected hand in daily activities at home for 5 hrs a day while wearing a mitt on the unaffected hand.
88903887|NCT01539109|Experimental|Rehab and tDCS|Patients in this group will receive Noninvasive brain stimulation: tDCS, during rehabilitation exercises of the weak upper limbs for 2 hours per day, 5 times a week, for 2 weeks. tDCS is Transcranial Direct Current Stimulation. Prior to this 2-week intervention phase, all patients will be monitored over a 2-week control phase.
88903888|NCT01539109|Sham Comparator|Rehab and sham tDCS|Patients in this group will receive Sham tDCS: placebo noninvasive brain stimulation, during rehabilitation exercises of the weak upper limbs for 2 hours per day, 5 times a week, for 2 weeks. tDCS is Transcranial Direct Current Stimulation. Prior to this 2-week intervention phase, all patients will be monitored over a 2-week control phase
88903889|NCT01539161|Experimental|Reveal XT plus SOC|Standard of care treatment plus the Reveal XT Implantable Cardiac Monitor. Treatment will follow the same schedule of the standard of care arm regarding exam, ECG and Holter every 6 months, and an Echo, Chest X-Ray and Stress test every 12 months. The addition will be device interrogation at every 6 month exam. Participation will last 36 months.
88903890|NCT01539161|Active Comparator|Standard of Care|Standard of care arm as described by exam, ECG and Holter every 6 months, and an Echo, Chest X-Ray and Stress test every 12 months. Participation will last 36 months.
88903891|NCT01539174|Experimental|Treatment (monoclonal antibody, combination chemotherapy)|Patients receive rituximab IV on days 0, 1, 4, 8, and 15 of course 1; days 1, 8, and 15 of course 2; and day 1 of all subsequent courses. Patients also receive CHOP chemotherapy comprising cyclophosphamide IV, doxorubicin hydrochloride IV, and vincristine sulfate IV on day 1, and prednisone PO on days 1-5. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
88903892|NCT01539187|Experimental|VizAblate intervention|VizAblate System with subject serving as her own control
88903893|NCT01539200|Placebo Comparator|Control|
88903894|NCT01539200|Active Comparator|Oral Nutritional Supplement (ONS) and JDR|
88903895|NCT01539213|Experimental|AIN457|secukinumab (AIN457)
88903896|NCT01539252|Active Comparator|Single dialyzer|Single dialyzer
88903897|NCT01539252|Experimental|Double dialyzer|Two dialyzers in parallel
88903898|NCT01539265|Experimental|silodosin, arm 1|
88903899|NCT01539265|Experimental|silodosin, arm 2|
89422913|NCT02522858|Experimental|Atropine|After fixation of the block level of spinal anesthesia, and just before starting dexmedetomidine, ,atropine 0.03mg/kg would be injected intravenously.
89422914|NCT04455542||LMND-ALS|The main clinical manifestations were muscle weakness with atrophy and bundle fibrillation, the pyramidal tract sign was relatively mild, and extensive neurogenic damage with CMAP amplitude decreased could be seen in patients with electromyography.
88903900|NCT01539265|Placebo Comparator|placebo|
88903901|NCT01539278|Active Comparator|Observation, no surgery (control)|Patients have been diagnosed with mild OSA, no intervention is done; enrolled patients may be randomly or nonrandomly placed in this group
88903902|NCT01539278|Experimental|Surgery (adenotonsillectomy)|Patients who have been diagnosed with mild OSA. Patient may be randomly assigned or non-randomly choose to be in this group; all undergo adenotonsillectomy
88903903|NCT01539304|Experimental|CITUS Dry Syrup|Pranlukast dry syrup 10%
88903904|NCT01539304|Placebo Comparator|Placebo|Placebo
89422915|NCT04455542||UMND-ALS|The main clinical manifestations were limb stiffness and spasm, obvious pyramidal tract signs, relatively mild muscle atrophy and fasciculation, and no significant decrease in amplitude of electromyography CMAP.
89422916|NCT04455542||FAS and FLS|The clinical symptoms were confined to upper limbs (FAS) or lower limbs (FLS) for more than 12 months, and the main manifestations were lower motor neuron involvement signs such as muscle weakness and atrophy
89422917|NCT02036697|Experimental|Low Dose Spinal|"Hyperbaric bupivacaine 4.5mg with fentanyl 15mcg and preservative free morphine 150mcg.~The patient will be positioned right side down and head down 20-30 degrees for the dural puncture and then positioned supine in the left lateral tilt position after the anesthetic solution has been given. The OR table will be kept in 20-30 degrees head down for the cesarean section."
88903905|NCT01539343|Experimental|Antimicrobial Lock Solution|Participants receive the HEAL antimicrobial solution for 2 hours once daily for a minimum of 5 consecutive days. Participants also receive the lock therapy once weekly for two additional weeks. Principle ingredients include minocycline, calcium disodium ethylenediaminetetraacetate (CaEDTA) and ethanol.
88903906|NCT01539356||preterm infants|"preterm infants receiving blood transfusion~preterm infants with neonatal sepsis."
88903907|NCT01539369|Experimental|High fibre diet|
88903908|NCT01539369|Active Comparator|Healthy eating diet|
88903909|NCT01539382|Experimental|Cerebral oxygenation intervention|Cerebral oxygenation levels for people in this group will be monitored and maintained above 60%. If levels decrease to below 60%, a protocol is followed to guide possible interventions to increase cerebral oxygenation levels above 60%
88903910|NCT01539382|No Intervention|Cerebral oxygenation control|Cerebral oxygenation levels for people in this group will be masked and thus doctors and care staff will not use the cerebral oxygenation levels to make any interventions. If the cerebral oxygenation levels drop to below 40%, the cerebral oxygenation levels will be unmasked so that doctors can follow the protocol to increase levels to above 60%.
88903911|NCT01539395||Inactive Disease|Inactive disease; RRMS patients who have been treated with monthly infusions of Tysabri for 12 months and have had stable disease for the last 6 months or more and show stable or improving neurological deficits over 3 months on Tysabri.
88903912|NCT01539395||Active Disease|Active disease; RRMS patients in acute clinical relapse or with active MRI. Blood sample obtained within 30 days of event AND before steroid treatment (or) patients in early disease on or off first line agents with relapse in prior 3 months AND not treated with steroids for at least 2 months.
89422918|NCT02036697|Active Comparator|Control Spinal Group|"Hyperbaric bupivacaine 1.2cc (9mg) with fentanyl 15mcg and preservative free morphine 150mcg.~The patient will be in the sitting position for the dural puncture and then positioned supine, in the left lateral tilt position after the anesthetic solution has been given. Once block height has been established the patient will be placed in 20-30 degrees trendelenberg for the cesarean section."
88903913|NCT01539395||Active Disease - Steroid Therapy|Patient with a diagnosis of relapsing remitting multiple sclerosis (RRMS) who is about to begin steroid therapy for a relapse in clinical symptoms (either diagnosed clinically or via gadolinium MRI).
89422919|NCT04882462|Experimental|single arm|
89422920|NCT03106688|Active Comparator|Low-risk group|Individuals in the low-risk group are not in a risk of developing obesity according to traditional risk criteria.
88903914|NCT01539408|Active Comparator|Misoprostol|400 mcg of sublingual misoprostol in one dose
89422921|NCT03106688|Active Comparator|High-risk group|Individuals in the high-risk group are in a risk of developing obesity according to traditional risk criteria.
89422922|NCT04882228|Experimental|Entelon Tab.150mg|
89422923|NCT04882228|Active Comparator|Venitol tab.|
89422924|NCT02037009|No Intervention|Usual surveillance|surveillance performed by a qualified nurse, present in the operating room during the whole anesthesia.
88903915|NCT01539408|Active Comparator|Manual vacuum aspiration (MVA)|Standard surgical treatment (MVA)
88903916|NCT01539421|Experimental|Exercise Intervention|Use of Wii computer for enhanced exercise in COPD patients.
88903917|NCT01539434|Experimental|Behavioural intervention|Patients in the behavioural intervention group will get a personal meeting with the physiotherapist and get advice about the value of physical activity and also get recommendations on how to be physically active. The behavioural intervention to support physical activity behaviour includes weekly motivational interviewing telephone calls for the first month, two telephone calls for the following two months and thereafter monthly telephone calls.
88903918|NCT01539434|Active Comparator|Usual care group|Patients in the usual care group will get a personal meeting with the physiotherapist and get advice about the value of physical activity and also get recommendations on how to be physically active.
88903919|NCT01539460|Experimental|minimally invasive surgery|There is only one arm to this study. All patients will receive treatment with the minimally invasive surgery for their axillary bromidrosis
88903920|NCT01539473|Experimental|TR-701 FA with Tyramine|TR-701 FA 200 oral with Tyramine
88903921|NCT01539473|Placebo Comparator|Placebo-controlled with Tyramine|Placebo-controlled with Tyramine
88903922|NCT01539551||1|sepsis and septic shock patients
88903923|NCT01539564|Experimental|Treatment|Treatment (minocycline HCl microspheres, 1mg) administered at Baseline (following randomization) and Day 90 to qualifying implant sites, plus full-mouth mechanical debridement (deep cleaning) at Baseline and Day 180.
88903924|NCT01539564|No Intervention|Control|Full-mouth mechanical debridement (deep cleaning) at Baseline and Day 180; no treatment
88903925|NCT01539577||OZURDEX®|OZURDEX® (dexamethasone 700 μg intravitreal implant) administered according to general clinical practice.
88903926|NCT01539603|Experimental|DEB-BMS|Drug eluting balloon + Bare metal stent
88903927|NCT01539603|Active Comparator|Drug eluting stent|conventional PCI with drug eluting stent drug eluting stent (Zotarolimus-eluting stent)
88903928|NCT01539616|Experimental|ZYH7 4mg|ZYH7 4mg
88903929|NCT01539616|Experimental|ZYH7 8mg|ZYH7 8mg
88903930|NCT01539616|Experimental|ZYH7 16mg|ZYH7 16mg
88903931|NCT01539616|Active Comparator|Fenofibrate 160mg|Fenofibrate 160mg
89422925|NCT02037009|Experimental|centralised monitoring surveillance|1 anesthetic nurse is posted at a centralised monitoring station outside of the 3 operating rooms, while another one can intervene inside the 3 operating rooms whenever needed. Interphones allow communication between the monitoring station and the operating rooms.
88903932|NCT01539629||Pulse Width|One group reflecting two different pulse widths.
88903933|NCT01539655|Experimental|vandetanib then vandetanib + omeprazole|Vandetanib alone in period 1 followed by vandetanib in combination with omeprazole in period 2
88903934|NCT01539655|Experimental|vandetanib + omeprazole then vandetanib|Vandetanib in combination with omeprazole in period 1 followed by vandetanib alone in period 2
88903935|NCT01539655|Experimental|vandetanib then vandetanib + ranitidine|Vandetanib alone in period 1 followed by vandetanib in combination with ranitidine in period 2
88903936|NCT01539655|Experimental|vandetanib + ranitidine then vandetanib|Vandetanib in combination with ranitidine in period 1 followed by vandetanib alone in period 2
88903937|NCT01539668||Pap sampling|Women who have undergone Pap sampling and HPV and cytology analysis. The samples will be collected in Mobile Units and Non-Mobile Units.
88903938|NCT01539681||Group 1|
89422926|NCT04882306|Other|Main study group|
89422927|NCT02047383||respiratory infection|Hospitalized patients with a respiratory infection
89422928|NCT04886674||Remuverol|The neonates will receive the colostrum in a dose of 2 g/dose for the 1000-1500 g stratum and 1.2 g/dose for < 1000 g stratum, four times a day until discharge or death or day 21 of life, whichever is earlier.
88903939|NCT01539707|Experimental|AD-PED 5 mg|Male and female adolescents aged 12 to less than 18 years old who receive pediatric equivalent dose (PED) of 5 mg of solifenacin succinate.
88903940|NCT01539707|Experimental|CH-PED 5 mg|Male and female children aged 5 to less than 12 years old who receive PED of 5 mg of solifenacin succinate.
88903941|NCT01539733|Experimental|Olanzapine|
88903942|NCT01539733|Active Comparator|Haloperidol|
88903943|NCT01539772||Becker|"BMD participants over 4 years of age with in-frame deletions in the dystrophin gene.~."
88903944|NCT01539785|Active Comparator|Secondary cytoreduction|The eligible patients, after anesthesia preparation will be submitted to a surgical complete cytoreduction.
88903945|NCT01539785|Experimental|Hyperthermic intra-peritoneal chemotherapy (HIPEC)|If the patient is randomized to make chemo-hyperthermia, surgery will be followed by HIPEC with the closed technique.
88903946|NCT01539798|Experimental|Oral Saline|Ingestion of 0.9% saline solution
89422929|NCT02047695||Migraine with aura|Participants with migraine with aura (cases), their co-twins, and unrelated migraine-free twins (controls)
89422930|NCT02260011|Experimental|Ipratropium bromide HFA-134a low|
89422931|NCT02260011|Experimental|Ipratropium bromide HFA-134a high|
89422932|NCT02260011|Active Comparator|Atrovent® CFC low|
89422933|NCT02260011|Active Comparator|Atrovent® CFC high|
89422934|NCT02260011|Placebo Comparator|Placebo|
89422935|NCT02047773|Placebo Comparator|14 days Duration|14 days of antibiotics regardless of bacterial load.
89422936|NCT02047773|Active Comparator|Bacterial load guided duration|Antibiotics stopped early on day 8 or day 11 if the bacterial load when checked on day 7 and day 10 is less than 10^6cfu/ml.
88903947|NCT01539798|Active Comparator|Intravenous Saline|Intravenous infusion of 0.9% saline solution
88903948|NCT01539824|Experimental|IMM-101 plus SBRT|The treatment regimen with IMM-101 (Mycobacterium obuense) will be every 2 weeks for the first three doses with the last of these doses being on the same day as the radiotherapy by CyberKnife treatment on a liver lesion targeted by the Principal Investigator. Following a rest of 4 weeks, patients will again receive IMM-101 every 2 weeks for the next 3 doses followed by a further 4 weeks rest. Thereafter, IMM-101 will be given at 4 week intervals for up to 12 months or until patient withdrawal for any reason
88903949|NCT01539876|Other|Fine Needle aspiration will be done X5:|Fine Needle aspiration will be done X5: 1 hr pre-treatment, 1hr post treatment,24 hrs post treatment, 48 hrs post treatment, and following last chemotherapy cycle
88903950|NCT01539889|Experimental|DFH-12 PulmoBind|DFH-12 PulmoBind - 3 doses of; 5mCi for 5 subjects, 10mCifor 5 subjects and 15mCi for 10 subject
88903951|NCT01539902|Experimental|Human Umbilical Cord derived MSCs|
88903952|NCT01539902|Placebo Comparator|Cyclophosphamide|
88903953|NCT01539915|Experimental|BCT194|
88903954|NCT01539928||lung cancer or high suspicion of lung cancer|After initial work-up (chest x-ray, CT of thorax and upper abdomen, spirometry) found to have surgically resectable lung cancer
88903955|NCT01539941|Experimental|Medication Integration Protocol|
88903956|NCT01539954||Youth 9-18 years of age|
88903957|NCT01539993||1|
88903958|NCT01540019|Experimental|Paullinea cupana|50mg of Paullinia cupana as capsule, twice daily
88903959|NCT01540032|No Intervention|Control|
88903960|NCT01540032|Experimental|Diet|
88903961|NCT01540058|Experimental|test-guided strategy|"Treatment considered as the standard at the time of patient inclusion based on the primary cancer suspected by the BioTheranostics Cancer Type ID test molecular analysis"
88903962|NCT01540058|Active Comparator|Empiric strategy|Gemcitabine/Cisplatin
89422937|NCT03562299|Experimental|Experimental|Reconstruction of the Anterior Cruciate Ligament (ACL) using OrthoPure™ XT in patients with a partial or complete tear of the Anterior Cruciate Ligament (ACL)
89422938|NCT04886830||Appendectomy performed with single endoloop to appendiceal stump|Appendectomy performed with single endoloop for closure of appendiceal stump
89422939|NCT04886830||Appendectomy performed with two endoloops to appendiceal stump|Appendectomy performed with two endoloops for closure of appendiceal stump
89422940|NCT04886830||Appendectomy performed with a clip to appendiceal stump|Appendectomy performed with a clip for closure of appendiceal stump
88903963|NCT01540084|Active Comparator|conventional group|For induction, 25 mg of meperidine and 2.5 mg of midazolam were administered. To maintain conscious level of patient at moderate or deep level, 25 mg of meperidine and/or 2.5 mg of midazolam were administered as necessary.
89422941|NCT04886752|Sham Comparator|vitamin C without liposome|vitamin C without liposome
89422942|NCT04886752|Placebo Comparator|liposomal process A vitamin C|liposomal process A vitamin C
89422943|NCT04886752|Experimental|liposomal process B vitamin C (Double Nutri™)|liposomal process B vitamin C (Double Nutri™)
89422944|NCT02047851|Active Comparator|Acupuncture in active points|Patients in this group will receive real acupuncture
89422945|NCT02047851|Sham Comparator|Acupuncture in non-active points|Patients in this group will receive acupuncture, but in non-active points
89422946|NCT02047851|No Intervention|No treatment, just observation|Patients in this group will receive no treatment and will only be observed.
88903964|NCT01540084|Experimental|cocktail group|For induction, 25 mg of meperidine and 2.5 mg of midazolam were administered. To maintain conscious level of patient at moderate or deep level, 1% propofol at the rate of 1 mg/kg/hr was administered. An additional 0.5 mg/kg bolus was administered as needed to achieve the designed conscious level.
88903965|NCT01540110|Experimental|Docetaxel + cyclophosphamide|
88903966|NCT01540123|Placebo Comparator|Control|Sugar matched control containing no phytochemicals
88903967|NCT01540123|Experimental|Berry drink standardised to contain 500mg of polyphenols|Cold pressed berry drink standardised to contain 500mg of berry polyphenols
88903968|NCT01540136|Experimental|Nedaplatin|Nedplatin combine with IMRT
89422947|NCT03051490|Experimental|Liprotamase|Individually-optimized dose to be administered orally
89422948|NCT03051490|Active Comparator|porcine PERT|Individually-optimized dose to be administered orally
89422949|NCT03816657||Cohort1|Cohort1 (PD-L1+/low NLR)
88903969|NCT01540136|Active Comparator|Cisplatin|Cisplatin combine with IMRT
88903970|NCT01540149||ICD implant|
88903971|NCT01540175||Participants|Participants enrolled on the study will have blood samples obtained.
88903972|NCT01540188|No Intervention|Starndard care arm|Participants of the standard care arm are control groups of IDUs and family members. They do not attend intervention sessions.
88903973|NCT01540188|Experimental|Intervention arm|"Intervention for IDUs: there are 4 sessions of the intervention with the following titles: My family, my health, my actions, my community.~Intervention for family members: there are 4 intervention sessions for family members covering the following topics: my family, my responsibility, my support and my community"
88903974|NCT01540201|Active Comparator|1:2 group|conventional I:E ratio group, inspiratory time : expiratory time = 1:1
88903975|NCT01540201|Experimental|1:1 group|inspiratory time : expiratory time = 1:1
88903976|NCT01540214||POP surgery|All women who present with POP at the outpatient clinic of our centre and who will undergo prolapse repair surgery will be asked informed consent for participation in this study
88903977|NCT01540227||Syphilis Patients|Individuals presenting for treatment of primary, secondary or early latent syphilis at the Ottawa Hospital Immunodeficiency Clinic, the Ottawa Sexual Health Clinic or its satellite GayZone, the Montreal Chest Institute Immunodeficiency Clinic, or the Toronto General Immunodeficiency Clinic will be invited by their attending health care worker to participate in this study. Only patients presenting for and requiring treatment of infectious syphilis will be asked to participate.
88903978|NCT01540240|Active Comparator|standard dosage zidovudine|Standard AZT arm: AZT 300 mg/3TC 150 mg(Combivir 1 cap) twice a day. Nevirapine 200 mg 1 cap twice a day.
88903979|NCT01540240|Active Comparator|low dosage zidovudine|
88903980|NCT01540279||Cohort one with abdominal wall closure with Monocryl|
89422950|NCT03816657||Cohort2|Cohort 2 (PD-L1-/High NLR)
89422951|NCT04895800|Experimental|Herbal Supplement|(Phytovive™); comprised of Bacopa monnieri bacosides, Kaempferia parviflora methoxy flavones, pomegranate peel polyphenols, and Moringa oleifera leaf saponins)
89422952|NCT04895800|Active Comparator|Caffeine|Green tea caffeine extract (170 mg; to deliver 34 mg caffeine [20% natural caffeine]),
89422953|NCT04895800|Placebo Comparator|Placebo|Flavored placebo
89422954|NCT02037243|Experimental|Water Treatment|Chlorine dispenser promotion and provision
89422955|NCT02037243|Experimental|Hand washing|Hand washing with soapy water promotion
88903981|NCT01540279||Cohort two with abdominal wall closure with Monocryl plus|
88903982|NCT01540292|Experimental|MSC|Patients with Crohn's disease (refractory or intolerant to conventional therapies) treated with 2 successive injections of 1.5-2.0 x 10E6 allogenic MSC/kg BW at baseline and 4 weeks later.
89422956|NCT02037243|Experimental|Standard public health intervention|Health promotion using information about germs and disease
89422957|NCT02037243|Experimental|Disgust and shame intervention|Health promotion using disgust shame
89422958|NCT04886362|Experimental|Intervention Group|Ivermectin 600 mcg/kg every 12 hours for 5 days.
89422959|NCT04886362|Placebo Comparator|Control Group|Same volume like ivermectin
89422960|NCT02050035|Experimental|CKD Aerobic Exercise Training|Chronic Kidney Disease participants randomly allocated to the CKD Exercise arm will receive 12 weeks of Aerobic Exercise Training three times per week.
88903983|NCT01540305|Active Comparator|Transcranial Magnetic Stimulation|Actual transcranial magnetic stimulation of supplementary motor areas bilaterally.
88903984|NCT01540305|Sham Comparator|Sham Transcranial Magnetic Stimulation|Sham transcranial magnetic stimulation over the supplementary motor areas.
88903985|NCT01540318|Experimental|Abdominal Ultrasound|"Patients in the experimental arm will receive a Focused Assessment with Sonography for Trauma (FAST) which includes the use of abdominal ultrasound."
88903986|NCT01540318|No Intervention|No Abdominal Ultrasound|
88903987|NCT01540331|Experimental|PNT treatment|all subjects enrolled in the study, that underwent PNT treatment
88903988|NCT01540344|Experimental|Treatment Arm|"FOLFOX/FOLFIRI + cetuximab (6 cycles)~CRS and HIPEC~FOLFOX/FOLFIRI + cetuximab (6 cycles)"
88903989|NCT01540357|Active Comparator|Mindfulness-based therapy|Treatment was performed as group therapy at two training weekends which were separated by an interval of 7 weeks (eleven hours/weekend) and in four further two-hour sessions (week 2, 9, 18 and 22).
88903990|NCT01540357|Active Comparator|Treatment after waiting time|Treatment was performed after completion of the active arm.
88903991|NCT01540383|Experimental|Intensive aphasia therapy group|Group starts intensive integrative aphasia therapy within 3 workdays (or as soon as possible) after baseline exam
88903992|NCT01540383|Other|Waiting list control group|Group starts intensive integrative aphasia therapy after a waiting period of at least three weeks
88903993|NCT01540396|Active Comparator|75 Gram OGTT|The 2011 ADA criteria will be used to diagnose gestational diabetes in this study arm.
88903994|NCT01540396|Active Comparator|100 gram OGTT|A 2 step approach to the diagnosis of gestational diabetes will be used in this arm. Patients who have a 50 gram, 1 hour glucose challenge test result greater than 135 mg/dL will be diagnosed with gestational diabetes if their 3 hour, 100 gram OGTT results exceed the diagnostic threshold recommended by Carpenter and Coustan.
88903995|NCT01540422||CABG w/saphenous vein grafts harvested using endoscopy|Those who have CABG surgery with saphenous vein grafts harvested using endoscopic techniques
88903996|NCT01540435|No Intervention|Postoperative Arm (Arm A)|"FOLFOX:~Oxaliplatin at a dose of 85 mg/m2 iv over two hours (day 1) I-LV at a dose of 200 mg/m2 iv over two hours (day 1) 5-FU at a dose of 3200 mg/m2 iv over 48 hours (day 1-3)~Duration of treatment:~Treatment will be administered for 12 cycles (6 months) postoperatively starting 6 weeks after surgery."
88903997|NCT01540435|Experimental|Perioperative Arm (Arm B)|"Therapy will be administered in a biweekly schedule. First preoperative cycle will be administered with 75% of dosage for FOLFOXIRI, if no diarrhea ≥ grade 3 occurs, following cycles should be administered in full dosage.~FOLFOXIRI + bevacizumab:~bevacizumab at a dose of 5 mg/kg iv over 30 to 90 min (day 1) irinotecan at a dose of 165 mg/m2 iv over two hours (day 1) oxaliplatin at a dose of 85 mg/m2 iv over two hours (day 1) I-LV at a dose of 200 mg/m2 iv over two hours (day 1) 5-FU at a dose of 3200 mg/m2 iv over 48 hours (day 1-3)~Duration of treatment:~Treatment will be administered for 6 cycles (3 months) preoperatively (last cycle without bevacizumab), after 6 weeks followed by liver surgery, after further 6 weeks followed by 6 cycles (3 months) postoperatively."
88903998|NCT01540448|Active Comparator|No-3DCT|All patients were subjected to a CT scan with 3D mesenteric angiography but the surgeon was able to view the 3D reconstruction only after surgery.
88903999|NCT01540448|Experimental|3DCT|All patients were subjected to a CT scan with 3D mesenteric angiography and the surgeon was able to view 3D reconstruction before and during laparoscopic colorectal resection.
88904000|NCT01540461|Experimental|Arm: Brivanib|
88904001|NCT01540500|Experimental|Steady State PK Group|
88904002|NCT01540526|Experimental|Safety cohort|6 evaluable patients with RECIST measurable solid malignancies will be enrolled to establish the safety and toxicity of axitinib at 7 mg PO BID days 1-14 in 21 day cycles.
88904003|NCT01540526|Experimental|Pharmacodynamic cohort|PD cohort A: Up to 6 patients with metastatic castrate-resistant prostate cancer (evidence of soft-tissue metastases amendable to FLT-PET/CT imaging), and PD cohort B: Up to 12 patients with other solid malignancies (evidence of radiographic metastases amendable to FLT-PET/CT imaging) will be enrolled with scans obtained at baseline, peak exposure, and peak withdrawal of axitinib, in cycle#1, with repeat imaging in select patients in PD cohorts A and B at a later cycle of therapy.
88904004|NCT01540539|Experimental|Dosing cohort 1|
88904005|NCT01540539|Experimental|Dosing cohort 2|
88904006|NCT01540539|Experimental|Dosing cohort 3|
88904007|NCT01540539|Experimental|Dosing cohort 4|
88904008|NCT01540539|Experimental|Dosing cohort 5|
89195437|NCT04061304|Sham Comparator|Sham rTMS (Anorexia Nervosa)|Patients in this arm will receive 40 sessions of sham rTMS. They will be set up the same as the active Anorexia Nervosa group however their will be no actual brain stimulation.
88904009|NCT01540539|Experimental|Dosing cohort 6|
88904010|NCT01540539|Experimental|Dosing cohort 7|
88904011|NCT01540539|Experimental|Dosing cohort 8|
89195438|NCT04061304|Sham Comparator|Sham rTMS (Bulimia Nervosa)|Patients in this arm will receive 40 sessions of sham rTMS. They will be set up the same as the active Bulimia Nervosa group however their will be no actual brain stimulation.
89195439|NCT00921336|Experimental|KW-2450|
89195440|NCT04036786|Experimental|study gorup|The study was a prospective randomized trial with a control group (standard care group) and an intervention group, using a repeated measures design. Sixty six pregnant participants with preeclampsia risk were included in the control group and 66 pregnant participants with preeclampsia risk were included in the intervention (exercise) group.
89195441|NCT04036786|Other|control group|The study was a prospective randomized trial with a control group (standard care group) and an intervention group, using a repeated measures design. Sixty six pregnant participants with preeclampsia risk were included in the control group and 66 pregnant participants with preeclampsia risk were included in the intervention (exercise) group.
89195442|NCT05195112|Experimental|MT921|"Injection volume/interval: 0.2mL/1.0cm~Number of Injection: Maximum 50 times~Concentration per unit area: 3mg/cm2"
89195443|NCT05195112|Placebo Comparator|Placebo|"Injection volume/interval: 0.2mL/1.0cm~Number of Injection: Maximum 50 times~Concentration per unit area: 0mg/cm2"
88904012|NCT01540552||Budesonide Arm|Retrospective Medical Chart Review of low dose CT scans for participants who received Budesonide.
88904013|NCT01540552||Placebo Arm|Retrospective Medical Chart Review of low dose CT scans for participants who received Placebo.
88904014|NCT01540578||Observational|Archived cell samples are analyzed for replication timing by flow cytometry, microarray, and single-cell fluorescence in situ hybridization (FISH) assays. Replication-timing results among cases and controls are also analyzed.
88904015|NCT01540591|Placebo Comparator|control|Saline 0.9% IV infusion between day 4 and 9 of ovarian stimulation & another dose when got pregnant within the 1st week of positive pregnancy test
88904016|NCT01540591|Experimental|intralipid|IV infusion of intralipid 20% between day4 and 9 of ovarian stimulation & another dose when got pregnant within the 1st week of positive pregnancy test
88904017|NCT01540604|Experimental|CRD007 10 mg tablet|
88904018|NCT01540617||Persons with low back pain|
88904019|NCT01540617||Healthy persons|
88904020|NCT01540643||Abdominal aortic aneurysm|
88904021|NCT01540656|Active Comparator|Group 1|This group will receive immediate TMNS treatment beginning at baseline and ending at the 6 week point of the study.
88904022|NCT01540656|Active Comparator|Group 2|This group will receive delayed TMNS treatment beginning at the 6 week point of the study and ending at 12 weeks.
88904023|NCT01540669|Active Comparator|Polydextrose, low dose|Polydextrose, low dose
88904024|NCT01540669|Active Comparator|Polydextrose, medium dose|Polydextrose, medium dose
88904025|NCT01540669|Active Comparator|Polydextrose, high dose|Polydextrose, high dose
88904026|NCT01540669|Placebo Comparator|Placebo powder|Placebo powder
88904027|NCT01540708|Experimental|SERETIDE Rotacaps|Fluticasone propionate/Salmeterol combination administered at 2 doses (250/50 mcg and 100/50 mcg) and delivered in a capsule-based inhaler (Rotahaler). Devices with varying airflow resistance, low, intermediate and high, will be used.
88904028|NCT01540708|Active Comparator|SERETIDE Diskus|Fluticasone propionate/Salmeterol combination administered at 2 doses (250/50 mcg and 100/50 mcg) and delivered in a multi-dose dry powder inhaler
88904029|NCT01540721|Experimental|Experimental paracetamol formulation|Experimental formulation
88904030|NCT01540721|Active Comparator|Marketed paracetamol|Marketed formulation
88904031|NCT01540734|Active Comparator|Marketed paracetamol|marketed formulation
88904032|NCT01540734|Experimental|Experimental paracetamol formulation|Experimental formulation
88904033|NCT01540747|Experimental|Inofolic plus|178 patients
88904034|NCT01540747|Active Comparator|Inofolic|180 patients
88904035|NCT01540760|Experimental|MCAF5352A|
88904036|NCT01540760|Placebo Comparator|Placebo|
88904037|NCT01540786|Experimental|Part 1: OAB subjects|
88904038|NCT01540786|Experimental|Part 2: Healthy subjects|
88904039|NCT01540786|Experimental|Part 2: OAB subjects|
88904040|NCT01540799|Experimental|Treatment|
88904041|NCT01540799|Other|Other|Stimulation not able to be felt
88904042|NCT01540812||V + Dauno+ Pred+ Metot+ Cyta+ Hc + Ida + Flud|Vincristine in induction:5 mg/m2 i.v. days 1, 8, 15 and 22 in induction phase Daunorubicin in induction 45 mg/m2 i.v. days 1, 8, 15 and 22 Prednisone in induction: 60 mg/m2/ day, i.v. o p.o., days 1 to 14; 30 mg/m2/day, i.v. o p.o., days 15 to 21; 15 mg/m2/day i.v. o p.o., days 21 to 28 Metotrexato 12 mg days 1 and 22 (intrathecal) Cytarabine (ARA-C): 30 mg days 1 and 22 (intrathecal) Hydrocortisone: 20 mg days 1 and 22 (intrathecal) Idarubicin-induction 2 12 mg/m2, i.v., days 1, 3 and 5 Fludarabine in induction-2: Fludarabine 30 mg/m2, i.v., days, 1 to 5
88904043|NCT01540877|Experimental|Capsaicin application|application of 0.6%
88904044|NCT01540877|Experimental|Local anesthetics application|application of EMLA
88904045|NCT01540877|Experimental|Combined application of 1. capsaicin 2. local anesthetics|application of 1. capsaicin 0.6% and 2. EMLA
88904046|NCT01540877|Experimental|Combined application of 1. local anesthetics and 2. capsaicin|application of 1. EMLA and 2. capsaicin 0.6%
89195444|NCT05190978|Experimental|Acellular Dermal Matrix|Patients will receive ADM during their initial tissue expander placement.
89195445|NCT05190978|Active Comparator|Control|Patients will not receive ADM during their initial tissue expander placement.
89195446|NCT00893386||Non-4195 Lead, 181 days|Patients with a Medtronic LV Lead, other than Model 4195, implanted at least 181 days
89195447|NCT00893386||4195 Lead, 181 days|Patients with a Medtronic Model 4195 LV Lead implanted at least 181 days
89422961|NCT02050035|No Intervention|CKD Control|Chronic Kidney Disease participants allocated to the the CKD Control arm will receive their standard routine care over a 12 week period.
89422962|NCT02050035|No Intervention|Healthy Control|Healthy participants will act as comparators, they will undergo baseline testing only and will not receive an intervention.
89422963|NCT02048007|Active Comparator|Biannual mass oral azithromycin|"Comparison of childhood infectious and nutritional morbidity in communities randomized to azithromycin versus communities randomized to placebo.~Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral azithromycin suspension every 6 months for 2 years~Morbidity monitoring:~Collect swabs (nasopharyngeal, nasal, conjunctival), blood samples, (thick/thin blood smears, hemoglobin, dried blood spots), and stool samples from 40 randomly selected children aged 1 month to 60 months per community; collect swabs (nasopharyngeal) from 40 randomly selected children aged 7-12 years per community.~Anthropometry for all children aged 1 to 60 months per community.~Collect nasopharyngeal swabs from all children aged 1-60 months who are seen at a local health clinic and have a respiratory complaint."
89422964|NCT02048007|Placebo Comparator|Biannual mass oral placebo|"Comparison of childhood infectious and nutritional morbidity in communities randomized to azithromycin versus communities randomized to placebo.~Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral placebo every 6 months for 2 years~Collect swabs (nasopharyngeal, nasal, conjunctival), blood samples, (thick/thin blood smears, hemoglobin, dried blood spots), and stool samples from 40 randomly selected children aged 1 month to 60 months per community; collect swabs (nasopharyngeal) from 40 randomly selected children aged 7-12 years per community~Anthropometry for all children aged 1 to 60 months per community~Collect nasopharyngeal swabs from all children aged 1-60 months who are seen at a local health clinic and have a respiratory complaint"
89422965|NCT04881994|Experimental|Mild hepatic impairment (Child Pugh A)|Participants with mild hepatic impairment (Child Pugh A) received single oral dose of finerenone.
89422966|NCT04881994|Experimental|Moderate hepatic impairment (Child Pugh B)|Participants with moderate hepatic impairment (Child Pugh B) received single oral dose of finerenone.
89422967|NCT04881994|Experimental|Healthy participants|Healthy age-, weight-, and gender- matched participants received single oral dose of finerenone.
88904047|NCT01540890||withdrawal|patients who undergo an opioid withdrawal
88904048|NCT01540890||opioids|patients on opioid medication without withdrawal
88814928|NCT03026426|Experimental|CONEMO|"Participants in the intervention arm will receive a smartphone with CONEMO, an application with 18 sessions that are delivered 3 times a week for 6 weeks.~Additionally, all study participants, including those in the intervention arm, who present a high risk of suicide and/or have a PHQ-9 score ≥20 are referred to the system for follow up. Participants with lower levels of depressive symptoms receive the recommendation of going to a mental health professional."
88814929|NCT03026426|No Intervention|Control Group|Participants in the control group will receive enhanced usual care. Participants who present a high risk of suicide and/or have a PHQ-9 score ≥20 are referred to the system for follow up. Participants with lower levels of depressive symptoms receive the recommendation of going to a mental health professional.
88814930|NCT03025724|No Intervention|Control|After the surgical excision, subjects will be asked to fill out a satisfaction survey. They will not receive any PDT treatment.
88814931|NCT03025724|Experimental|Intervention Group|Subjects will undergo a surgical excision of the tumor. Then a clear transparency film will be used to trace the clinical margins of the lesion, as well as any other distinctive skin markings such as nevi or birthmarks. Subjects will then undergo the study procedure where the area to be treated will be swabbed with an alcohol wipe and allowed to dry. Next, the investigator will apply topical 20% 5-ALA (Levulan Kerastick; DUSA Pharmaceuticals) to the SCCis. Then, the area will be occluded with Tegaderm film for 3 hours. At the end of the incubation period, the Tegaderm will be removed and the patient will be exposed to a blue light source (BLU-U; DUSA Pharmaceuticals). Lastly, they will be asked to fill out a satisfaction survey.
88814932|NCT03017378|Active Comparator|TB/FLU-01L (intranasal application)|Vaccine safety analysis of TB/FLU-01L at double intranasal application in healthy volunteers aged 18 to 50 years.
88814933|NCT03017378|Active Comparator|TB/FLU-01L (sublingual application)|Vaccine safety analysis of TB/FLU-01L at double sublingual application in healthy volunteers aged 18 to 50 years.
88820079|NCT06195462|Experimental|"Laying on of hands by spiritist passe"|The healers will prepare before the start with prayer for connection with Good Spirits. Volunteers will move their hands in a longitudinal direction, starting at the top of the patient's head, slowly lowering their hands along the body, 5 times and asked to send thoughts of health and healing to the participant. Then, they will place their hands on the patient's head, distance about 10 to 15 cm, during 5 minutes. Weekly sessions.
88820080|NCT06195462|Other|Without laying on of hands|The participants will not receive the laying on of hands. A volunteer will stand next to the patient with hands behind them and will mentally repeat the alphabet or do math for 5 minutes. Weekly sessions.
88820081|NCT06195449|Experimental|Alkasite restorative material in primary molar|ARM 1 : ALKASITE RESTORATIVE MATERIAL( INTERVENTION)
88820082|NCT06195449|Active Comparator|Glass Ionomer Cement in primary molar|ARM2: Glass Ionomer Cement(CONTROL)
88904049|NCT01540890||opioid-free|patients with chronic pain without opioid medication
89006992|NCT06154174|Experimental|C-RUTF (Ready-to-Use Therapeutic Food with added choline)|A daily dose of 500mg choline will be added to RUTF. 2 sachets (daily dose) of RUTF will provide approximately 1000 Kcal, 14g of protein, 28g of fat, and 1 RDA of 14 micronutrients.
89006993|NCT06154174|Active Comparator|S-RUTF (Ready-to-Use Therapeutic Food without added choline)|A daily dose of 5mg choline will be added to RUTF for masking. 2 sachets (daily dose) of RUTF will provide approximately 1000 Kcal, 14g of protein, 28g of fat, and 1 RDA or 14 micronutrients.
89422968|NCT02048085|Experimental|Ticagrelor|Ticagrelor Arm will be dosed with a loading dose of 180 mg followed by maintenance dose of 90 mg BID until discharge or up to 8 days.
89422969|NCT02048085|Active Comparator|Clopidogrel|Clopidogrel arm will be dose with a loading dose of 300 mg followed by maintenance dose of 75 mg everyday until discharge or up to 8 days.
89422970|NCT03051412||Current Patellofemoral Pain|This group has current patellofemoral pain
89422971|NCT03051412||Recovered|This group has a previous history of patellofemoral pain, but currently self reports as recovered.
89422972|NCT03051412||Control|This is a control group with no history of knee pain.
89422973|NCT03051334||BiAV|Bicuspid aortic valve
89422974|NCT03051334||TAV|Tricuspid aortic valve
89422975|NCT02808975|Placebo Comparator|Placebo|"Period A: Day 1- 4 subcutaneous (SC) injections; Week 2- 2 SC injections; Weeks 4-12- 1 SC injection each week~Period B: Weeks 13-14- 1 SC injection each week~Period C: Weeks 15-23- 1 SC injection each week"
89422976|NCT02808975|Active Comparator|Adalimumab|"Period A: Day 1- 4 subcutaneous (SC) 40 mg injections; Week 2- 2 SC 40 mg injections; Weeks 4-12- 1 SC 40 mg injection each week~Period B: Weeks 13-14- 1 SC 40 mg injection each week~Period C: Weeks 15-23- 1 SC 40 mg injection each week"
89422977|NCT04881136|Experimental|Reveal LINQ|The Reveal LINQ™, which is a small implantable loop recorder that is used to monitor cardiac parameters at present is implanted to the participants who are have experienced non accidental falls. The Investigational Falls Prediction RAMware is software that will be downloaded on to the Reveal LINQ™ that will enable it to collect additional sensor information including accelerometer and posture count data.
89422978|NCT04885738||Chronic Cough|cough as a sole presenting lasted more than 8 weeks; with an age of 18-70years; with a normal chest X-ray; without steroids treatment in the last 4 weeks.
89422979|NCT04885738||Asthma|classic asthma
89422980|NCT04885738||COPD|patients with COPD in stable stage or acute exacerbation
89422981|NCT02050191|No Intervention|program feasibility|
89422982|NCT02976038|Experimental|elamipretide|Open-label once daily subcutaneous injection of 40mg elamipretide
89422983|NCT02669511|Other|PQR309|A single arm study with PQR309, a phosphoinositide-3-kinases (PI3K) and inhibitor of the mammalian target of rapamycin (mTOR), 60mg/80mg given once a day, orally.
89422984|NCT02048163||Short infusion meropenem|Meropenem 20 mg/ml IV will be administered at a dose of 40 mg/kg (maximum 2,000 mg) every eight hours for 12 doses and will be infused over a 30 minute period. An equal volume of normal saline will be infused at the same time over four hours.
88820083|NCT06195436|Active Comparator|Acceptance and Commitment Therapy for people with depression|Acceptance and Commitment Therapy for people with depression
89422985|NCT02048163||Prolonged infusion meropenem|Meropenem 20 mg/ml IV will be administered at a dose of 40 mg/kg (maximum 2,000 mg) every eight hours for 12 doses and will be infused over a four hour period. An equal volume of normal saline will be infused at the same time over 30 minutes.
88820084|NCT06195436|Active Comparator|Acceptance and Commitment Therapy for people without depression.|
88820085|NCT06195397|Experimental|Experimental: Intervention Group|A total of 12 hours of Evidence-Based Education intervention was applied to students in the intervention group, spread over 7 sessions.
88820086|NCT06195397|No Intervention|No Intervention: Control Group|No training was given.
88820087|NCT06195345||Pediatric Patients|Children scheduled for clinical MR imaging.
88820088|NCT06195306|Experimental|Group 1 (tamoxifen)|Participants receive tamoxifen PO QD for 180 days in the absence of unacceptable toxicity. Participants may continue to receive tamoxifen PO QD for up to 60 additional days in the case of scheduling delays. Participants also undergo mammography at screening and undergo RPFNA and collection of blood samples at screening and on study.
88820089|NCT06195306|Experimental|Group 2 (tamoxifen, omega-3 fatty acids)|Participants receive tamoxifen PO QD and omega-3 fatty acids PO BID for 180 days in the absence of unacceptable toxicity. Participants may continue to receive tamoxifen PO QD and omega-3 fatty acids PO BID for up to 60 additional days in the case of scheduling delays. Participants also undergo mammography at screening and undergo RPFNA and collection of blood samples at screening and on study.
88820090|NCT06195280|Experimental|superficial endometriosis|Endometriosis is a chronic, estrogen-dependent inflammatory disease secondary to tissue growth outside the uterine cavity, affecting approximately 10% of women of childbearing age.
88820091|NCT06195267|Experimental|Sivelestat|
88820092|NCT06195267|No Intervention|Blank control|The control group did not receive any intervention.
88820093|NCT06195254||SBRT+PD-1 blockers|pembrolizumab (200 mg every 3 weeks), carelizumab (200 mg every 3 weeks), tislelizumab (200 mg every 3 weeks), sintilimab (200 mg every 3 weeks), zimberelimab (240 mg every 3 weeks) until the tumor progressed or the side effects became intolerable.
88820094|NCT06195163|Experimental|Study group|Daily 10 mg transdermal testosterone for 21 days prior to the start of ovarian stimulation.
88820095|NCT06195163|Active Comparator|Control group|No pre-treatment prior to ovarian stimulation.
88820096|NCT06195150||VHL patients|Patients with hereditary Von Hippel-Lindau (VHL) with genetic diagnosis of VHL disease who have at least three tumors larger than 3cm that have to be surgically removed. The procedure involves standard surgery with the additional collection of 15ml of blood.
88820097|NCT06195137|Experimental|Caffeine group|Burning mouth syndrome (BMS) patients in Caffeine group were provided with BMS disease explanation and psychological counseling. Then they were told to drink instant coffee containing 120-150 mg of the active ingredient caffeine (2 bags of Nescafe Black Coffee, 1.8g each) at a certain point in time from 8:00 to 12:00 every day, for 2 consecutive weeks.
89195448|NCT00893386||4195 Lead, 90-180 days|Patients with Medtronic Model 4195 LV Lead implanted for 90-180 days
89195449|NCT04062474|Experimental|Epidural Intervention with Steroids|Epidural Intervention with Steroids
89195450|NCT02541214|Experimental|Trial Nasal Mask|The participant will use the Saturn nasal mask for 2 weeks in home
89195451|NCT00892138|Experimental|Mindfulness training|Mindfulness training
89195452|NCT00892138|No Intervention|Control|Study program as usual
89195453|NCT02567370|Placebo Comparator|Placebo|
89195454|NCT02567370|Active Comparator|AMG 581|
89195455|NCT00892216|Experimental|Acupressure Band|A band with bead attachment will be used to produce Acupressure and applied to the P6 (three fingers breath from the wrist crease on th ventral surface of the upper limb). The application will be done 20 minutes prior to anesthesia and explanation as to usage after surgery will be given. The patient of caregiver will apply pressure on the bead for three minutes and repeat this four times a day for the next five days. None of the protocol for prevention of PONV in this group of patients will be changed. The postoperative therapy for nausea and vomiting will be on a PRN (as required) basis. Nausea and vomiting scores and VAS scores for pain estimation will be carried out according to hospital protocol in the PACU amd twice a day thereafter for their period of stay in the hospital. The amount of analgesics and antiemetics used and the number of days spent in the hospital will be registered.
89195456|NCT00892216|Sham Comparator|Sham Acupressure|The same band will be placed and turned so the beads face the corresponding point on the dorsal surface of the upper limb area.
89195457|NCT00401245|Active Comparator|A|
89195458|NCT00401245|Active Comparator|B|
89195459|NCT00401245|Active Comparator|C|
89195460|NCT00401245|Active Comparator|D|
89195461|NCT00401245|Active Comparator|E|
89195462|NCT00401245|Active Comparator|F|
89195463|NCT00401245|Active Comparator|G|
89195464|NCT00401245|Placebo Comparator|H|
89195465|NCT05278702||hemodialysis|
89195466|NCT05278702||peritoneal dialysis|
89195467|NCT04036474|Experimental|Smoking Prevention Education Program|In addition to the lecture on the hazards of smoking, students received the SPEP intervention. The SPEP consisted of three lessons and each lesson took one to two hours to be implemented. The SPEP intervention was delivered to participants in their usual classroom setting, during school hours combined with relevant school subjects such as physical education class. The duration of SPEP intervention took approximately one month.
89195468|NCT04036474|No Intervention|Control|Immediately after the collection of baseline data, students received a one-time lecture on the hazards of smoking by the research assistant.
89195469|NCT04036240|Experimental|Finger feeder|HMF supplementation will be given by finger feeder
89195470|NCT04036240|No Intervention|Control|HMF supplementation will be given by mother preference such as cup, bottle.
89195471|NCT00696384|Experimental|Azilsartan Medoxomil QD-Open Label Phase (Baseline - Week 26)|
89536064|NCT03199729|Experimental|Slip-only training|Overground, slip specific perturbation training only delivered in a fixed sequence. After the baseline walking trials, subjects will walk for 30-35 trials, after which training will begin consisting of a first block of 8 repeated slips (S1-S8), a block of 3 regular (non-perturbed) walking trials (W1-W3), another block of 8 slips (S9-16), a second block of 3 regular walking trials (W4-W6), and a final block of 8 slips (S17-S24) mixed with 10 regular walking trials.
89195472|NCT00696384|Experimental|Azilsartan Medoxomil QD - Double-Blind Phase (Week 26-32)|
89195473|NCT00696384|Placebo Comparator|Placebo QD - Double-Blind Phase (Week 26- 32)|
89195474|NCT00892372||1 (type 2 diabetes, body weight, HbA1c)|The investigators analyzed the recorded data (body weight and glycohemoglobin) of 70 type 2 diabetic patients treated with the diet therapy. Recorded values at 0, 2 and 4 months for body weight (BW) and glycohemoglobin (HbA1c) were used. And changes from baseline (0 month) in BW (ΔBW) were plotted against those of HbA1c (ΔHbA1c).
89195475|NCT00892372||2 (type 2 diabetes, pioglitazone, HbA1c)|The investigators analyzed the recorded data (body weight and glycohemoglobin) of 23 type 2 diabetic patients treated with pioglitazone. Recorded values at 0, 2 and 4 months for body weight (BW)and glycohemoglobin (HbA1c) were used. And changes from baseline (0 month) in BW (ΔBW) were plotted against those of HbA1c (ΔHbA1c).
89195476|NCT04036162|Experimental|Young group|Young Right-handed healthy volunteers
89195477|NCT04036162|Experimental|Aged group|Aged Right-handed healthy volunteers
89195478|NCT01041625|Experimental|Apremilast|Apremilast 20 mg PO administered BID over 12 weeks
89195479|NCT02566356|Experimental|Oxytocin|40 IU Oxytocin
89195480|NCT02566356|Placebo Comparator|Saline Nasal Spray|Placebo Comparator
89195481|NCT00893620|Other|1|Treatment
89195482|NCT01039129|Experimental|Endoscopic Cholecystectomy|20 patients in this arm will undergo cholecystectomy, or removal of the gallbladder, through this experimental approach. This arm will compose of patients with symptomatic gallstones (cholelithiasis).
89195483|NCT01039129|Experimental|Endoscopic Appendectomy|Participants will with chronic appendicitis will undergo appendectomy through this experimental approach.
89195484|NCT01039129|Experimental|Endoscopic Peritoneoscopy|20 patients in this arm will undergo diagnostic peritoneoscopy with or without biopsy for any indication.
89195485|NCT00892450|Experimental|Arm 1|crossover design
89195486|NCT00657787||PTSD|Combat-exposed men and women with PTSD deployed to OIF/OEF.
89195487|NCT00657787||High Utilizers|A comparison group of combat veterans who are high utilizers of VA medical care, but who have not received a diagnosis of PTSD
89195488|NCT00657787||Not OIF/OEF|A second comparison group will consist of veterans with similar service record and demographic backgrounds, who were not deployed to the OIF/OEF war zones
89195489|NCT01566565|Active Comparator|Theophylline|
89195490|NCT01566565|Active Comparator|Bambuterol|
89195491|NCT01039363|Experimental|Vorinostat|Vorinostat combined with salvage reinduction chemotherapy including Gemtuzumab ozogamicin, Idarubicin and Cytarabine and Vorinostat maintenance
89195492|NCT01039441|Placebo Comparator|instillation of normal saline 50ml under the diaphragm|
89195493|NCT01039441|Experimental|the instillation of 0.5% bupivacaine under the diaphragm|
89195494|NCT01039441|Experimental|CO2 removal by means of a pulmonary recruitment maneuver|
89195495|NCT01039441|Experimental|the instillation of bupivacaine + CO2 removal by maneuver|
88904050|NCT01540903|Experimental|Group 1 10,000 PfSPZ|12 volunteers, ID PfSPZ Challenge total dose 10,000 PfSPZ administered by 2 injections of 50µL each.
88904051|NCT01540903|Experimental|Group 2 25,000 PfSPZ|12 volunteers, ID PfSPZ Challenge total dose 25,000 PfSPZ administered in 4 injections of 10µL each.
88904052|NCT01540903|Placebo Comparator|Controls - saline|4 Volunteers, ID saline administered in 2 injections of 50µL each and 2 volunteers, ID saline administered in 4 injections of 10µL each.
88904053|NCT01540916|Experimental|Hyperventilation|Minute ventilation will be increased of about 30% of baseline value, through an increase in respiratory rate
88904054|NCT01540916|Experimental|Hypoventilation|Minute ventilation will be decreased of about 30% of baseline value, through a decrease in respiratory rate
88904055|NCT01540942|Active Comparator|Nutrition treat|perioperative nutrition support until the patients get the normal nutrition or disease remission
88904056|NCT01540942|Active Comparator|bowel resection|bowel resection until the patients get the normal nutrition or disease remission after bowel resection
88904057|NCT01540955|Experimental|Group Intervention program|
88904058|NCT01540955|No Intervention|Wait-list control group|The wait-list-control group will also be able to participate in the group intervention, but not until after all the study visits have been completed.
88904059|NCT01540968|Experimental|Nutrition & physical exercise|
88904060|NCT01540968|No Intervention|Control|
88904061|NCT01540994|Experimental|SBRT|Stereotactic Body Radiation Therapy
88904062|NCT01541007|Active Comparator|Standard Cabazitaxel Schedule|Cabazitaxel 25 mg/m2 every three weeks
88904063|NCT01541007|Experimental|Weekly cabazitaxel schedule|cabazitaxel 10 mg/m2 given weekly for 5 consecutive weeks of a six week cycle
88904064|NCT01541020||Healthy individuals|
88904065|NCT01541020||Individuals with low back pain|
88904066|NCT01541033||Autism with FAH|Children diagnosed with autism with first degree relatives that have autoimmune disorders.
88904067|NCT01541033||Autism without FAH|Children diagnosed with autism without first degree relatives that have autoimmune disorders.
88904068|NCT01541033||Control|Typically developing children
88904069|NCT01541046|Experimental|Biogaia L. reuteri DSM 17938|Biogaia L. reuteri DSM 17938, probiotic infant drops (5 drops=10^8 cfu),5 drops, once per day for 21 days.
88904070|NCT01541046|Placebo Comparator|Probiotic Placebo|Placebo drops (sunflower oil, medium chain triglyceride oil, silicon chloride), 5 drops, once a day for 21 days.
88904071|NCT01541059|Placebo Comparator|Placebo|Patients in this arm will have standard anesthesia with the injection of placebo solution into the vestibular of each tooth to be extracted
88904072|NCT01541059|Experimental|Ropivacaine|Patients in this arm will have general anesthesia with injection of ropivacaine into the vestibular next to each tooth to be extracted.
89536065|NCT03199729|Experimental|Trip-only training|Trip specific training delivered in an identical sequence (mixed with non-trip trials) as the Group with slip only training.
89536066|NCT03199729|No Intervention|Control|Walk for about 70-75 trials at the preferred walking pace to match the total trials the other groups receive before the test perturbations.
88904073|NCT01541072|Experimental|Pegfilgrastim|
88904074|NCT01541072|Active Comparator|Filgrastim|
88904075|NCT01541098|Active Comparator|Licensed Plasma|
88904076|NCT01541098|Experimental|Lyophilized Plasma|
88904077|NCT01541111|Other|Magnesiun, pain relief, sugar pills|Magnesiun 75mg po each 12h pain relief Sugar pills po each 12h
88904078|NCT01541124|Experimental|Morphine, Pain intensity|For cancer pain treatment, World Health Organization recomends tritation of opioids associated with non steroidal antiinflamatory drugs. This study compares the analgesic effect with diferents dosages in 63 patients with cancer pain.
88904079|NCT01541137|Active Comparator|diclofenac + IV-PCA|oral diclofenac 75 mg, a 44-hour iv-infusion of diclofenac 150 mg/24h, intercostal nerve block with 20 ml of 0.5% bupivacaine, IV-PCA programmed with morphine boluses, from the 2nd postoperative morning the patients were given oral diclofenac 75 mg x 2, IV-PCA-morphine was discontinued after removal of pleural drains, and the patients were given oral oxycodone
88904080|NCT01541137|Active Comparator|parecoxib/ valdecoxib + IV-PCA|oral valdecoxib 40 mg, a 44-hour iv-infusion parecoxib 80 mg/24h, intercostal nerve block with 20 ml of 0.5% bupivacaine, IV-PCA programmed with morphine, From the 2nd postoperative morning valdecoxib 40 mg x 2, IV-PCA-morphine was discontinued after removal of pleural drains, and the patients were given oral oxycodone
88904081|NCT01541137|Active Comparator|patient controlled epidural analgesia|At the induction of anesthesia the PCEA-patients were given IV paracetamol 1g and an epidural loading dose of 1 ml/10 kg of 0.15% bupivacaine with fentanyl 6 µg/ml. Thereafter a continuous infusion was started at 1 ml/10 kg/h. In the PACU PCEA-patients could take incremental doses, IV paracetamol 1g x 4 for the first 24 hours and thereafter 1g x 3 orally, PCEA was discontinued and paracetamol was replaced with ibuprofen 600 mg x 3 and oral oxycodone
88904082|NCT01541150|Active Comparator|patient suffering pedophilia|This group is the active comparator because patients suffering pedophilia with neuropsychological questionnaires
88904083|NCT01541150|Placebo Comparator|control group|This group is the placebo comparator
88904084|NCT01541163||Acute Ischemic Stroke|Patients with acute ischemic stroke admitted within 12 hours after onset.
88904085|NCT01541176|Experimental|Absence of corticotherapy post-transplantation|All patients included in this arm will receive the usual treatment strategy (including Advagraf, Cellcept ou Myfortic and Simulect) without corticotherapy post-transplantation.
88904086|NCT01541176|Active Comparator|Corticotherapy post-transplantation|All patients included in this arm will receive the usual treatment strategy (including Advagraf, Cellcept ou Myfortic and Simulect) with corticotherapy post-transplantation : prednisone or prednisolone orally for at least one year post-transplantation.
88904087|NCT01541189|Experimental|valsartan|After 1-week screening period, all of the eligible patients receive valsartan 80mg/day for 2 weeks, then the dosage will be titrated to 160mg/day for further 8 weeks therapy for all of the subjects.
88904088|NCT01541202|Placebo Comparator|Placebo|placebo in addition to standard therapy
89536067|NCT03199729|Experimental|Combined slip+trip training|Training consisting of repeated exposure to both slips and trips.
89536068|NCT02726945|Experimental|Low Dose SVF|This group of subjects will receive a low dose of SVF for treatment of knee OA.
89422986|NCT04885660|Experimental|Compound lisinopril tablets|a single oral of Compound lisinopril tablets test formulation( Lisinopril 10mg/Levamlodipine besylate 5mg)
89422987|NCT04885660|Active Comparator|Compound lisinopril tablets(Lisonorm®)|a single oral of Compound lisinopril tablets reference formulation( Lisinopril 10mg/Levamlodipine besylate 5mg)
89422988|NCT02050269|Experimental|Iohexol|injection of 5 ml of iohexol
89422989|NCT02037633|Active Comparator|Fascia iliaca compartment block|
89422990|NCT02037633|Active Comparator|Fentanyl|
89422991|NCT03050008|Other|FLACS USFREE|Cataract Surgery with Femtosecond Laser Without Ultrasound
89422992|NCT03050008|Other|Traditional Surgery|Traditional phacoemulsification cataract surgery using ultrasound
89422993|NCT05106218|Experimental|SurroundScope|For laparoscopic camera system, the SurroundScope, 270-degree angle videoscope (270Surgical, Israel) is used
89422994|NCT05106218|Active Comparator|Standard laparoscope|For laparoscopic camera system, the Standard laparoscope that is in a standard use at the medical center is used
89422995|NCT05684211|Active Comparator|Ametumumab (QW) + anti-PD-1 monoclonal antibody+ FOLFIRI|Ametumumab 450 mg/m2 (QW) + anti-PD-1 monoclonal antibody (in the case of toripalimab 3 mg/kg, Q2W) + FOLFIRI;
89422996|NCT05684211|Active Comparator|Ametumumab(Q2W) + anti-PD-1 monoclonal antibody + FOLFIRI;|Ametumumab 450 mg/m2 (Q2W) + anti-PD-1 monoclonal antibody (in the case of toripalimab 3 mg/kg, Q2W) + FOLFIRI;
89422997|NCT05684211|Active Comparator|Ametumumab (Q2W) + FOLFIRI;|Ametumumab 450 mg/m2 (Q2W) + FOLFIRI
89422998|NCT05684211|Active Comparator|Cetuximab + FOLFIRI;|Cetuximab 500 mg/m2 (Q2W) + FOLFIRI
89422999|NCT03130634|Experimental|prescription of silymarin|During six cycles of FOLFIRI chemotherapy, the patients will take silymarin (150mg) three times daily from day 1 to day 7 during one cycle of treatment.
89423000|NCT03130634|No Intervention|control|During six cycles of FOLFIRI chemotherapy, the patients will not take silymarin during chemotherapy
89423001|NCT02050425|Active Comparator|Therapeutic CPAP|Patients continue therapeutic continuous positive airway pressure (CPAP).
89423002|NCT02050425|Placebo Comparator|Subtherapeutic CPAP|Placebo-CPAP device delivering subtherapeutic pressure for two weeks.
89423003|NCT02050503||intranasal transmucosal fentanyl pectin|intranasal transmucosal fentanyl in pectin (100, 200, 400 or 800 microg) intranasal route titration phase 7 days treatment phase until completing treatment of 12 consecutive episodes of breakthrough pain
89423004|NCT04885582||Patients with biliary complications|patients with postoperative biliary fistula, biliary stenosis
89423005|NCT04885582||Patients without biliary complications|patients without postoperative biliary fistula and biliary stenosis
89423006|NCT02124824|Experimental|Arm 1: Control|Control
89423007|NCT02124824|Experimental|Arm 2: Heart Failure|Heart Failure
89536069|NCT02726945|Experimental|High Dose|This group of subjects will receive a high dose of SVF for treatment of knee OA.
88820098|NCT06195137|Active Comparator|Alpha Lipoic Acid (ALA) group|Burning mouth syndrome (BMS) patients in the ALA group were provided with BMS disease explanation and psychological counseling. Then they took α-lipoic acid (ALA) 3 times a day, after meals, 200 mg each time, for 2 consecutive weeks.
89195496|NCT01034917|Experimental|Etravirine group|To switch from the PI to Etravirine 400 mg dissolved in water every 24 hours
89423008|NCT04895020|Experimental|9-valent HPV vaccine|9-valent HPV recombinant vaccine (Hansenula Polymorpha) All subjects aged 9 to 45 years received 3 doses of 9v HPV vaccine at 0,2,6 month scehdule
88904089|NCT01541202|Experimental|rhNRG-1|rhNRG-1 in addition to standard therapy
89423009|NCT04880746|Active Comparator|BEAC|Patients in this arm will receive BEAC (Semustine, Etoposide, Cytarabine, Cyclophosphamide) as pretreatment regimen of ASCT
88904090|NCT01541228|Active Comparator|Group I|Patients with actinic keratosis (AK) on the left and right sides of face/scalp region treated with photodynamic therapy using 20% 5-aminolevulinic acid.
88904091|NCT01541228|Active Comparator|Group II|Patients with actinic keratosis (AK) on the left and right sides of the face/scalp region treated with photodynamic therapy using 20% 5-aminolevulinic acid.
88904092|NCT01541241||copper IUD used|"Group I: includes 50 cases using CIUD and complaining of menorrhagia or menometrorrhagia.~Group II: includes 50 cases using CIUD and not complaining of abnormal uterine bleeding."
89423010|NCT04880746|Experimental|Cladribine combined with BEAC|Patients in this arm will receive Cladribine combined with BEAC (Semustine, Etoposide, Cytarabine, Cyclophosphamide) as pretreatment regimen of ASCT
89423011|NCT03050086|Experimental|BPX-04 1% Minocycline Topical Gel|once daily topical administration of 1% minocycline gel to the face
89423012|NCT03050086|Experimental|BPX-04 2% Minocycline Topical Gel|once daily topical administration of 2% minocycline gel to the face
88904093|NCT01541267|Active Comparator|C - A - B|(A) telmisartan 80 mg + aliskiren 300 mg - (B) telmisartan 80 mg + eplerenon 50 mg - (C) telmisartan 160 mg
88904094|NCT01541267|Active Comparator|B - A - C|(A) telmisartan 80 mg + aliskiren 300 mg - (B) telmisartan 80 mg + eplerenon 50 mg - (C) telmisartan 160 mg
88904095|NCT01541267|Active Comparator|A - B - C|(A) telmisartan 80 mg + aliskiren 300 mg - (B) telmisartan 80 mg + eplerenon 50 mg - (C) telmisartan 160 mg
88904096|NCT01541293|Experimental|Intrauterine Lidocaine|The experimental arm will receive 100mg lidocaine (5mL of 2% concentration) instilled into the uterine cavity via a flexible trans-cervical catheter immediately prior to laminaria insertion.
89195497|NCT01034917|Active Comparator|Control group|Continue with the same antiretroviral regimen
89195498|NCT01039597|Experimental|Active study drug|ORE1001 300 mg oral capsules
89195499|NCT01039597|Placebo Comparator|Placebo control|300 mg oral capsules containing placebo material
89423013|NCT03050086|Placebo Comparator|BPX-01 Vehicle Topical Gel|once daily topical administration of vehicle gel to the face
89423014|NCT04885348|Experimental|Dental Home Visits and Dental Home Education Leaflets|Two trained dental home visitors made 6-monthly Dental Home Visits (DHVs) to families in the Intervention Group. Dental Home Education Leaflets (DHELs) and oral health messages were delivered through a personalized approach that avoids direct persuasion.
89423015|NCT04885348|Active Comparator|Dental Home Education Leaflets|Only Dental Home Education Leaflets were provided every six months for 2 years.
89423016|NCT03050242|Experimental|Glycopyrrolate|Glycopyrrolate 0.005mg/kg is administered intramuscularly, one hour before the surgery.
89423017|NCT03050242|No Intervention|Control|No injection is conducted in this group.
89423018|NCT04894630|Other|infective keratitis|150 patients with mean age 30 (range 12 to 85 years), 90 patients (60 %) were males and 60 (40%) were females, clinically diagnosed as infective corneal ulcer, attending the Ophthalmology Department - Faculty of Medicine. Minia University, Minia, Egypt. From 2018 to 2020.
89423019|NCT04880902|Experimental|sleeve gastrectomy followed by volumetric assessment|
89423020|NCT04894552|Experimental|One arm clinical trial|Convenience sampling method in which the first twenty cases of endometrial carcinoma patients who will undergo laparoscopic hysterectomy will be included. All cases will undergo laparoscopic hysterectomy. Sentinel lymph node biopsy will be detected, dissected and isolated. Then standard lymphadenectomy will be done
89006994|NCT06146530|Experimental|Treatment|"Participants in the treatment arm will have access to Cerina for 6 weeks.~The intervention (Cerina) consists of 7 sessions of Cognitive Behavioural Threapy (CBT) for the treatment of GAD. Each session contains a range of information and tasks/exercises to help the user understand the condition of GAD, the treatment approach, and how it will apply to them."
89006995|NCT06146530|Active Comparator|Wait-list|Participants in the waiting-list control condition will have access to the campus-based well-being services offered by the Student Wellbeing team.
89006996|NCT06144671|Experimental|GT201 treatment group|GT201 5E9（5×10^9）;GT201 1E10（1×10^10）;GT201 5E10（5×10^10）.
89006997|NCT06140186|Active Comparator|Timolol combination treatment|Patients will received topical timolol 0.5% eye drops (liquid form) twice daily with occlusion (i.e. covered with adhesive badge) and betamethasone valerate 0.1% cream twice daily with occlsuion for 1 month
89006998|NCT06140186|Active Comparator|Routine arm|Patients in routine arm would receive the management according to routine clinical practice, including prescription of betamethasone valerate 0.1% cream twice daily for 1 month with occlusion.
89006999|NCT06138002|Experimental|Test Intervention arm|"The LumbaCure® is a robotic system which provide active, specific and controlled mobilization of the low back. The device is to be used by the Physiotherapist at the rehabilitation centre. The duration of a session for the patient is 15 minutes.~Patients follow a serie of 12 consecutive LumbaCure® sessions at a frequency of 3 sessions / week for 4 weeks."
89007000|NCT06138002|Active Comparator|Control Intervention arm|"A set of core stability exercises/active qualitative mobilization has been defined with principal investigator according to the standard of care at Investigator site. At each session, 5 exercises will be selected by the investigator depending on the evolution and pathology of the patient. Five minutes of warm-up will be performed before starting the exercises session.~The program will last 15 to 30 min depending on the time required for the patient to complete the prescribed exercises.~Patients follow a serie of 12 consecutive physical exercises sessions at a frequency of 3 sessions / week for 4 weeks."
89007001|NCT06137066|Placebo Comparator|Placebo|Placebo supplement consisting of microcrystalline cellulose with 5mg magnesium stearate and 5mg silicon dioxide.
89007002|NCT06137066|Experimental|200mg GCE +200mg ALA|200mg green coffee extract +200mg alpha-lipoic acid
89007003|NCT06137066|Experimental|200mg GCE +400mg ALA|200mg green coffee extract +200mg alpha-lipoic acid
89007004|NCT06137066|Experimental|200mg GCE +200mg DHB|200mg green coffee extract + 200mg dihydroberberine
89007005|NCT06136000|Active Comparator|SACRAL EREKTÖR SPİNAE PLANE BLOK|
89007006|NCT06136000|Active Comparator|RİNG BLOCK|
89007007|NCT06134323|Experimental|medication-combined transcutaneous vagus nerve stimulation|Participants will receive anti-anxiety medication and transcutaneous vagus nerve stimulation
89007008|NCT06134323|Placebo Comparator|medication-combined sham stimulation group|Participants will receive anti-anxiety medication and sham stimulation
89007009|NCT06123598|Experimental|Action observation plus exercise|Therapeutic exercise plus action observation training
89007010|NCT06123598|Sham Comparator|Sham observation plus exercise|Therapeutic exercise plus sham action observation training
89007011|NCT06119048|Experimental|Genetic Carriers and Non-Carriers of PKU|
89007012|NCT06112613|Experimental|ARM A (Enhanced usual care)|Patients use the WiseBag medication dispenser and receive access to educational materials every 4 weeks over 12 months.
89007013|NCT06112613|Experimental|ARM B (CONCURxP program)|Patients use the WiseBag medication dispenser and receive personalized text message reminders, medication tracking and healthcare provider follow ups as part of the CONCURxP platform over 12 months. Patients may complete an interview over 20-30 minutes within 6 months of study completion.
89423021|NCT04880356||Retrospective study|collection of retrospective data from adult patients with ultra-rare inherited neurological diseases
89007014|NCT06112613|Experimental|ARM C (Non-patient interview)|Participants complete an interview over 20-30 minutes 15-39 months post-first patient enrollment.
89007015|NCT06105801|Active Comparator|EBUS-TBNA Group|The same needle gauge will be used for these participant to acquire the initial diagnosis on ROSE (either 21 or 22G). Using standard sampling techniques, the mass or LN will be penetrated with the needle as confirmed by ultrasound, and the needle will be passed back from the proximal to the distal ends of the node to obtain the samples for an adequate cell block. The minimum number of cell passes to obtain a cell block will be set at three.
89195500|NCT01041937|Active Comparator|Cemented Tibia|Assessing the clinical outcomes of the different type of fixation
89195501|NCT01041937|Active Comparator|Cementless Tibia|Assessing the clinical outcomes of the different type of fixation
89007016|NCT06105801|Experimental|Transbronchial Mediastinal Cryobiopsy Group|The operator will switch to a flexible, single-use, 1.1 mm cryoprobe (Erbe 20402-401, Erbe, Tübingen, Germany) for these participants to obtain cryobiopsies. The operator will introduce the probe into the working channel of the EBUS bronchoscope. The cryoprobe will then be advanced toward the puncture site and inserted gently through the previous puncture site created by the initial EBUS-TBNA needle. The operator will confirm the placement of the probe via the EBUS image, and photo capture will be done. The cryo-probe will be activated and cooled for 3 seconds before retracting with the bronchoscope with the frozen biopsy tissue attached to the tip. The minimum number of freeze attempts to obtain a cell block will be set at three.
89007017|NCT06100146|Placebo Comparator|Control group|Teenage girls randomly assigned to the control group will receive a standard bag of unfortified cereal flours every week for six months.
89423022|NCT04880356||Prospective study|prospective data will be collected starting from March 2021 (date of protocol approval) and spanning the next ten years
89423023|NCT04880512|Experimental|SYHX 1901 tablets for SAD|Two subjects will be enrolled in a single dose group which is recommended as the initial dose. 8 out of 10 healthy subjects will be randomized to receive a single dose of SYHX 1901 tablets in fasted state.
89423024|NCT04880512|Placebo Comparator|Placebo for SAD|2 out of 10 healthy subjects will be randomized to receive a single dose of placebo in fasted state
89423025|NCT04880512|Experimental|SYHX 1901 tablets for MAD|8 out of 10 healthy subjects will be randomized to receive multiple doses of SYHX 1901 tablets in fasted state
89195502|NCT00816699|Placebo Comparator|1|Routine anesthetic risk information
89195503|NCT00816699|Active Comparator|2|Preprint preoperative risk information
89195504|NCT00822549||1|all the patients included in the study received intravenous morphine in PACU and in the wards
89195505|NCT00822627|Experimental|Vaccination group|Vaccination group
89007018|NCT06100146|Experimental|folic acid & vit B12 fortified flour|Teenage girls randomly assigned to the control group will receive a standard bag of cereal flours fortified with folic acid and Vit B12 every week for six months.
89423026|NCT04880512|Placebo Comparator|Placebo for MAD|2 out of 10 healthy subjects will be randomized to receive multiple doses of placebo in fasted state
89423027|NCT04885270|Experimental|Arm i.p|paclitaxel i.v. and cisplatin i.p.
89423028|NCT03048994|Placebo Comparator|Placebo|Placebo
89423029|NCT03048994|Active Comparator|Glutamine|Glutamine
89423030|NCT04885426|Experimental|low-dose metformin group|low-dose metformin, 250mg/day
89423031|NCT04885426|Experimental|high-dose metformin group|high-dose metformin, 500mg/day
89423032|NCT04885426|Placebo Comparator|control group|placebo
89423033|NCT04879888|Experimental|Vacuna|Triple-negative breast cancer patients with specific tumor mutation, with six doses of peptide-pulsed autologous dendritic cells after surgery.
89423034|NCT03048682|Experimental|Early Voiding Trial|"All subjects that are discharged home with a Foley catheter will need an in-office repeat voiding trial.~Subjects in this group will have their repeat voiding trial on post-op day #2, 3, or 4"
89423035|NCT03048682|Active Comparator|Late Voiding Trial|"All subjects that are discharged home with a Foley catheter will need an in-office repeat voiding trial.~Subjects in this group will have their repeat voiding trial on post-op day #7 or after. This is our current practice."
89423036|NCT04880122|Experimental|Nursing home residents/staff members|Matched venous blood/dried blood spots collection in a single arm.
89423037|NCT04879576|Experimental|Treatment Group|
89423038|NCT04879576|No Intervention|Control Group|
89423039|NCT02808819|Other|Benralizumab Arm A|Benralizumab administered subcutaneously every 4 weeks
89423040|NCT02808819|Other|Benralizumab Arm B|Benralizumab administered subcutaneously every 8 weeks
89530852|NCT02509637|Active Comparator|Crontrol Intervention|After initial evaluation, patients will be remain seated quiet breathing without any guidance for thirty minutes. Immediately after this time will be held reassessment with Impulse Oscillometry. Then patients will be kept for 30 minutes at rest and at the end will be applied to acceptance and tolerance scale and a third evaluation with Impulse Oscillometry. The secretions expectorated during the protocol will be evaluated for wight, adhesiveness and purulence.
89536070|NCT02726945|Placebo Comparator|Placebo|This group of subjects will receive a placebo with no SVF Cells for treatment of knee OA.
88820099|NCT06195137|No Intervention|Control gruop|Without intervention treatment, we provided BMS patients in Control group with disease explanation and psychological counseling for patients.
89195506|NCT00822627|Experimental|Education/referral|Education/referral
89195507|NCT00819351|Experimental|PEG-asparaginase 6 weeks intervals|"PEG-asparaginase (1.000 IU/m2/dose) given at six weeks intervals (from week 13 after diagnosis to week 33).~All additional therapy (High Dose Methotrexate, Vincristin, Dexamethasone, 6-Mercaptopurine, doxorubicin, intrathecal chemotherapy) is the same in both arms."
89423041|NCT04879108|Experimental|Physiotherapy rehabilitation and Transcutaneous Electrical Nerve Stimulation (TENS) group|"Physiotherapy rehabilitation and Transcutaneous Electrical Nerve Stimulation (TENS) group received TENS therapy in addition to physiotherapy rehabilitation approaches after thoracic surgery.~Physiotherapy and rehabilitation program was started after surgery and it was performed for 30 min, twice a day, 5 day a week. The program was included respiratory and posture exercises, coughing, enhancing mobility.~TENS therapy was performed with the a 2-channel portable TENS device and using disposable electrodes. TENS applied on both sides of the incision line. After surgery, TENS was performed before the Physiotherapy rehabilitation for 30 min, twice a day, 5 day a week.~Patients were evaluated before the surgery and the end of postoperative 5th day."
88904097|NCT01541293|Placebo Comparator|Intrauterine Saline|Placebo arm will receive 5mL of normal saline instilled into the uterine cavity via a flexible trans-cervical catheter immediately prior to laminaria insertion.
88904098|NCT01541306||achondroplasia or hypochondroplasia|Children or adults with achondroplasia or hypochondroplasia
88904099|NCT01541319||Randomized to <= 10day RBCs & transfused|Subjects in the RECESS study who were randomized to receive red blood cell (RBC) units stored no more than 10 days, and who received at least one RBC transfusion between randomization and 96 hours after the cardiac surgery ends
89423042|NCT04879108|Active Comparator|Physiotherapy rehabilitation Group|"This group was enrolled only physiotherapy and rehabilitation program after thoracic surgery.~Physiotherapy and rehabilitation program was started after surgery and it was performed for 30 min, twice a day, 5 day a week. The program was included respiratory and posture exercises, coughing, enhancing mobility.~Patients were evaluated before the surgery and the end of postoperative 5th day."
89423043|NCT04884880|Experimental|Luo-Fu-Shan Plaster 10g|10g，once daily，4 weeks
89423044|NCT04884880|Placebo Comparator|Placebo|10g，once daily，4 weeks
89423045|NCT04884958||Index patient|Adults with confirmed clinical infection caused by Staphylococcus aureus, including skin and soft tissue infection or infection of a normally sterile site. These cases will be identified following admission to Anuradhapura General Hospital.
89423046|NCT04884958||Household contacts|This cohort are resident in the same household as the index patient (maximum of four).
89423047|NCT04872244|Experimental|patients with isthmosele that mirena ( levonorgestrel releasing intrauterine device) was applied|outcome measures of patients suffering from postmenstruel spotting due to ısthmosele whom mirena ( levonorgestrel releasing intrauterine device) was applied
89423048|NCT04872322|Active Comparator|Standard Popliteal Nerve Block|Participants undergoing foot or ankle surgery will receive an initial injection of 0.5% ropivacaine as the initial anesthetic followed by continuous injection of 0.25% ropivacaine.
89423049|NCT04872322|Active Comparator|Partial Popliteal Nerve Block|Participants undergoing foot or ankle surgery will receive 0.25% ropivacaine initially followed by the usual continuous injection of 0.25% ropivacaine during surgery
89423050|NCT04879264|Experimental|Patients irradiated for breast cancer|Participants with breast cancer who receive adjuvant radiotherapy following breast-conserving surgery or mastectomy.
88904100|NCT01541319||Randomized to >= 21day RBCs & transfused|Subjects in the RECESS study who were randomized to receive red blood cell (RBC) units stored at least 21 days, and who received at least one RBC transfusion between randomization and 96 hours after the cardiac surgery ends
88904101|NCT01541319||Randomized but not transfused|Subjects randomized in the RECESS study who did not receive any red blood cell units between randomization and 96 hours after the end of surgery
88904102|NCT01541319||Healthy volunteers|
88904103|NCT01541332|Experimental|Pomalidomide + PLD + Dexamethasone|Pomalidomide + Pegylated Liposomal Doxorubicin + Dexamethasone in an open label, dose escalation study
88904104|NCT01541436|Active Comparator|Capsaicin, UV-B, RIPC|
88904105|NCT01541436|Sham Comparator|Capsaicin, UV-B|
88904106|NCT01541449||RA patients treated with plaquenil|
88904107|NCT01541449||Patients who do not use plaquenil|
89536071|NCT02449993||MammaTyper™|MammaTyper™ will be used to assess tumor material of patients treated with neo-adjuvant therapy.
88904108|NCT01541462|Active Comparator|Pressure support|Patients randomized to the pressure support arm will wean using pressure support ventilation. The level of pressure support will be decreased by 2 cm H2O every 6 hours. The maximum decrement in pressure support permitted in one day will be 6 cm H2O.
88904109|NCT01541462|Active Comparator|Spontaneous Breathing|Patients randomized to spontaneous breathing arm will be disconnected from the ventilator and allowed to breathe spontaneously through the tracheostomy. Duration of the trial will be increased sequentially as tolerated.
88904110|NCT01541475|Experimental|Escitalopram + Bupropion|
88904111|NCT01541475|Active Comparator|Escitalopram|
88904112|NCT01541488|Experimental|BI 1021958|Single rising dose (SRD) part
88904113|NCT01541488|Experimental|BI 1021958 (Food effect)|Food effect part (FE)
88904114|NCT01541488|Placebo Comparator|Placebo to BI 1021958|Matching placebo as drinking solution and tablets
88904115|NCT01541501||Pachymetry|All recruited volunteers in present study, that underwent pachymetry measurement with four different instruments
88904116|NCT01541527||severe, moderate and mild HA patients|one Arm: biological collection of 300 severe, moderate and mild HA patients
88904117|NCT01541540|Experimental|e-Counseling plus Usual Care|
88904118|NCT01541540|Active Comparator|e-Info Control plus Usual Care|
88904119|NCT01541566||Home blood pressure telemonitoring|Patients regularly monitoring their blood pressure at home with an electronic validated upper arm device, transmitting blood pressure values at monthly intervals to the doctors office through the Internet.
88904120|NCT01541566||Conventional blood pressure measurement|Blood pressure measured only in the doctor's office during quarterly visits, without regular home blood pressure monitoring.
88904121|NCT01541579|Experimental|Treatment Arm|Cx601 is a cell suspension in aseptic buffered solution containing human expanded adipose-derived stem cells (eASCs) of allogeneic origin in disposable vials with no preservative agents. The cells will be given at a dose of 120 million cells (5 million cells / mL) for intralesional injection.
88904122|NCT01541579|Placebo Comparator|Placebo-control group|Placebo (saline solution) will be given also for intralesional injection at the same quantity (volume, 24 mL) and following the same schedule.
88904123|NCT01541592|Active Comparator|Saturated fat|Palm oil (rich in the saturated fat palmitate)
89423051|NCT04871932||Recently unvaccinated group (Female)|This study intends to collect peripheral blood from healthy adults aged 18 to 50 years. Gender and vaccination may be independent potential factors that affect the changes in peripheral blood immune cells. This study collects basic clinical information from volunteers, and classifies the population based on gender and whether they have been vaccinated recently (including influenza vaccine, human papillomavirus [HPV] vaccine, and severe acute respiratory syndrome [SARS]-CoV-2 vaccines and others), aiming at systematically classify the peripheral blood mononuclear cells of healthy adults under different conditions and search for molecular markers related to different cell types. This group is Recently unvaccinated group (Female)．
89423052|NCT04871932||Recently unvaccinated group (Male)|This study intends to collect peripheral blood from healthy adults aged 18 to 50 years. Gender and vaccination may be independent potential factors that affect the changes in peripheral blood immune cells. This study collects basic clinical information from volunteers, and classifies the population based on gender and whether they have been vaccinated recently (including influenza vaccine, HPV vaccine, and SARS-CoV-2 vaccines and others), aiming at systematically classify the peripheral blood mononuclear cells of healthy adults under different conditions and search for molecular markers related to different cell types. This group is Recently unvaccinated group (Male)．
89530853|NCT03344705|Experimental|IM19 CART|All patients will be treated with fludarabine and cyclophosphamide for 3 days,then,CAR-T cells expressing CD19 CAR will be infused 24-96 hours later.
89530854|NCT02501525|Active Comparator|UAS (+)|RIRS with ureteral access sheath: A ureteral access sheath (UAS) will be positioned into the ureter of the patient prior to the insertion of the flexible ureterorenoscope (RIRS).
88904124|NCT01541592|Active Comparator|Monounsaturated fat|Olive oil (rich in the monounsaturated fat oleate)
88904125|NCT01541592|Active Comparator|Polyunsaturated fat|Safflower oil (rich in the polyunsaturated fat linoleate)
88904126|NCT01541605|Active Comparator|methylphenidate|
88904127|NCT01541605|Placebo Comparator|placebo|
88904128|NCT01541618||Tysabri Group|Patients with a diagnosis of relapsing remitting multiple sclerosis (RRMS) who is about to begin Natalizumab (Tysabri) therapy for a relapse in clinical symptoms (either diagnosed clinically or via gadolinium MRI).
88904129|NCT01541631|Experimental|HIV-1 co-infected with schistosoma mansoni|HIV-1 patients co-infected with Schistosoma mansoni
88904130|NCT01541631|No Intervention|HIV-1 positive individuals with negative S. mansoni|HIV-1 positive individuals with negative Schistosoma mansoni
88904131|NCT01541631|Experimental|Schistosoma mansoni positive but HIV-1 negative|Schistosoma mansoni positive individuals but HIV-1 negative to be compared with HIV-1 co-infected with Schistosoma mansoni individuals
88904132|NCT01541631|No Intervention|HIV-1 and Schistosoma mansoni negative|Individuals with no HIV-1 and S. mansoni infections
89007019|NCT06097273|Experimental|Cohort A1: mRNA-1083 and Placebo|Participants of age 65 years and older will receive mRNA-1083 and placebo administered as 2 intramuscular (IM) injections of on Day 1.
89007020|NCT06097273|Active Comparator|Cohort A2: Influenza Vaccine and COVID-19 Vaccine|Participants of age 65 years and older will receive age recommended quadrivalent influenza vaccine and COVID-19 vaccine administered as 2 IM injections on Day 1.
88904133|NCT01541657|No Intervention|Control Group|This group will only take part in the data collection sessions. After the first testing session (Pre-Intervention) the participants will be asked to rest comfortably for 5 minutes. After the rest period, they will be reassessed. Upon completion of the second testing, they will be asked to maintain the same lifestyle over the course of 2 weeks. They will then be asked to return to the lab after the 2 week interval to be tested again. Upon completion of the third testing session, they will be contacted after 1 month to complete the self-reported function questionnaires.
88904134|NCT01541657|Experimental|Ankle Joint Mobilization|The posterior ankle mobilization treatment is a manual therapy technique that consists of gently gliding your ankle in the backward direction through a pain free range of motion. This is a common therapy technique used by athletic trainers for the treatment of ankle sprains. The objective of this therapy technique is to glide the ankle into the area which restricts range of motion and gently stretch the restricted area. To begin this treatment, a certified athletic trainer with experience in applying this therapy technique will provide mild traction to the ankle joint to lightly distract the bones of the ankle joint. The athletic trainer will then apply two sets of joint mobilizations which will each last 2 minutes. Each repetition will consist of gently gliding the ankle joint in the backward direction until an area of restriction is reached. The athletic trainer will push into the restriction and then glide the ankle back to the starting position.
89007021|NCT06097273|Experimental|Cohort B1: mRNA-1083 and Placebo|Participants of age 50 to <65 years will receive mRNA-1083 and placebo administered as 2 IM injections of on Day 1.
89007022|NCT06097273|Active Comparator|Cohort B2: Influenza Vaccine and COVID-19 Vaccine|Participants of age 50 to <65 years will receive age recommended quadrivalent influenza vaccine and COVID-19 vaccine administered as 2 IM injections on Day 1.
89007023|NCT06095661|Experimental|Virtual Reality|Each enrolled participant in a single arm will be offered a virtual reality headset with a menu of virtual reality environments and experiences such as nature scenes, mindful meditation, travel, and various games. Enrolled participants be offered the virtual reality as early as the first day after their inpatient surgery in their hospital room. Each virtual reality session will last 5-30 minutes, depending on the participant's selection of the virtual reality environment/experience. Participants will have the option to use the virtual reality as often as twice daily up through the third day after their surgery during their hospitalization, for a total of six sessions.
89423053|NCT04871932||Recently vaccinated group (Female)|This study intends to collect peripheral blood from healthy adults aged 18 to 50 years. Gender and vaccination may be independent potential factors that affect the changes in peripheral blood immune cells. This study collects basic clinical information from volunteers, and classifies the population based on gender and whether they have been vaccinated recently (including influenza vaccine, HPV vaccine, and SARS-CoV-2 vaccines and others), aiming at systematically classify the peripheral blood mononuclear cells of healthy adults under different conditions and search for molecular markers related to different cell types. This group is Recently vaccinated group (Female)．
89423054|NCT04871932||Recently vaccinated group (Male)|This study intends to collect peripheral blood from healthy adults aged 18 to 50 years. Gender and vaccination may be independent potential factors that affect the changes in peripheral blood immune cells. This study collects basic clinical information from volunteers, and classifies the population based on gender and whether they have been vaccinated recently (including influenza vaccine, HPV vaccine, and SARS-CoV-2 vaccines and others), aiming at systematically classify the peripheral blood mononuclear cells of healthy adults under different conditions and search for molecular markers related to different cell types. This group is Recently vaccinated group (Male)．
89423055|NCT03048526|Experimental|NovaTears®|
89423056|NCT03048526|Active Comparator|Hydrabak®|Unpreserved sodium chloride (0.9%) eye drops in ABAK® system
88904135|NCT01541657|Experimental|Foot Massage|The foot massage treatment is a manual therapy technique that consists of gently rubbing the bottom of your feet with both hands like kneading dough. To begin the treatment, you will be asked to lie comfortably on a treatment table you're your feet hanging slightly off the edge. The athletic trainer with experience in applying this therapy will place his hands on the bottom of your foot and begin to massage your feet from your toes down to your heel. The athletic trainer will perform 2 sets of 2 minutes of massage with 1 minute rest in between sets.
88904136|NCT01541657|Experimental|Calf Stretching|The calf stretching treatment is a technique that is commonly used in sports and rehabilitation. You will be asked to place your foot on a slant board located next to a wall with your heel positioned below your toes on the slant board. You will be asked to lean towards the wall until you feel tension in your calf muscles that feels like a good stretch. You will perform 2 sets of 3 stretches that are held for 30 seconds each. Between each stretch, you will rest for 10 seconds. Between each set, you will rest for 1 minute.
88904137|NCT01541670|Experimental|Open-label Dose-Escalation Arm|Conducted in an ascending dose manner, subjects will be assigned to single- or multiple-dose administration of the investigational product
88904138|NCT01541683|Experimental|Halls|every patient will drink 4 Liters of PEG solution (FORTRANS®) split into 2 days with sugar-free mentholyptus drops (2 L at 7-9 pm on the day prior to the colonoscopy with Halls®, and 2 L on the day of the colonoscopy to be completed a minimum of 1.5 hours before the procedure with Halls®).
88904139|NCT01541683|Other|no Halls|Every patient will drink 4 liters of PEG solution (FORTRANS®) split into 2 days (2 L at 7-9 pm on the day prior to the colonoscopy, and 2 L on the day of the colonoscopy to be completed a minimum of 1.5 hours before the procedure)
88904140|NCT01541696||Group B|subjects in this group will receive Micronutrient Supplements only.
88904141|NCT01541696||Group C|Subjects in this Group will receive Micronutrient Supplements plus Zinc.
88904142|NCT01541774|Experimental|Phoenix Atherectomy System|
88904143|NCT01541800||Patients|All children who are in treatment for leukemia, lymphoblastic lymphoma and central nervous system tumors between 3 years and 21 years of age
88904144|NCT01541813||iron overloads except C282Y homozygosity|Patients with an iron overloads except C282Y homozygosity
88904145|NCT01541852|Active Comparator|Losmapimod|7.5mg tablet twice daily
88904146|NCT01541852|Placebo Comparator|Placebo|One tablet twice daily
88904147|NCT01541904|Experimental|Arm A. PRO-118/Placebo 0.015%,0.020%|
88904148|NCT01541904|Experimental|Arm B. PRO-118/Placebo 0.015%,0.020%|
88904149|NCT01541904|Experimental|Arm C. PRO-118/Placebo 0.015%,0.020%|
88904150|NCT01541904|Experimental|Arm D. PRO-118/Placebo 0.015%,0.020%|
88904151|NCT01541904|Placebo Comparator|Arm E PRO-118/Placebo 0.015%,0.020%|
88904152|NCT01541085||Darunavir/Ritonavir (DRV/r)|
88904153|NCT01541085||Efavirenz (EFV)|
88904154|NCT01541943|Experimental|HL-040XC|Once daily, administered orally, 8 week
88904155|NCT01541943|Active Comparator|Atorvastatin|Once daily, administered orally, 8 week
88904156|NCT01541943|Active Comparator|Losartan|Once daily, administered orally, 8 week
89423057|NCT04871620||Hemodynamic optimization|Patients scheduled for intermediate and high-risk abdominal surgery were eligible to participate
89423058|NCT04879186||Patients undergoing peripheral endovascular angioplasty|Patients undergoing peripheral endovascular angioplasty. No intervention other than what was already completed as part of routine clinical care, as this is a retrospective cohort.
89423059|NCT04879030|Active Comparator|beta-lactam monotherapy|only beta-lactam antibiotics
89423060|NCT04879030|Experimental|beta-lactam and fluoroquinolone combination therapy|one beta-lactam antibiotic and one fluoroquinolone
89423061|NCT04871386|Experimental|Acceptance and commitment therapy (ACT)|"14 consecutive days of exercises (prompted via email every morning) derived from acceptance and commitment therapy (ACT); the instructions were text-based, contained a brief introduction to the general goal and the exercise of the day; the exercises were designed to be completable individually in 20 minutes. Additionally: completion of a daily review questionnaire (online diary) including two open questions (Relevant events during the day? Helpful things for coping positively with the current situation?)"
89423062|NCT04871386|Experimental|Positive psychology intervention (PP)|"14 consecutive days of exercises (prompted via email every morning) derived from positive psychology (PP) interventions; the instructions were text-based, contained a brief introduction to the general goal and the exercise of the day; the exercises were designed to be completable individually in 20 minutes. Additionally: completion of a daily review questionnaire (online diary) including two open questions (Relevant events during the day? Helpful things for coping positively with the current situation?)"
89423063|NCT04871386|No Intervention|Control group|"completion of a daily review questionnaire (online diary) including two open questions (Relevant events during the day? Helpful things for coping positively with the current situation?); no additional intervention"
89423064|NCT04870996|Experimental|Active transcranial Direct Current Stimulation (tDCS) + Cognitive training (CT)|Twenty-three participants received five treatment sessions of concurrent active tDCS and CT on five consecutive days. The participants received a ramp-up of 30 seconds, followed by active stimulation with a steady current of two milliamps for 20 minutes, then a ramp-down of 30 seconds.
89423065|NCT04870996|Sham Comparator|Sham transcranial Direct Current Stimulation (tDCS) + Cognitive training (CT)|Twenty-three participants received five treatment sessions of concurrent sham tDCS and CT on five consecutive days. The current was only delivered in the 30-second ramp-up and 30-second ramp-down periods.
89423066|NCT04871230||Pregnant women suspected TB|This group enrolled as cases
89423067|NCT04871230||Pregnant women without signs suspected TB|This group enrolled as controls
89423068|NCT04582318|Experimental|Part 1 Dose Level 1 - Active|
89423069|NCT04582318|Placebo Comparator|Part 1 Dose Level 1 - Placebo|
88904157|NCT01541943|Placebo Comparator|Placebo|Once daily, administered orally, 8 week
88904158|NCT01541956|Active Comparator|metformin up titration|metformin 500 mg bid will be up titrated (total daily dose up to 2000 mg)
88904159|NCT01541956|Experimental|vildagliptin add on to metformin|Vildagliptin 50 mg twice daily + Metformin 500mg twice daily
88904160|NCT01541982||virtual and classic autopsy|"Goldstandard: A group of patients in which virtual and classic autopsy is performed."
88904161|NCT01541982||virtual autopsy only|"Intervention: A group of patients in which for various reasons virtual autopsy only is performed."
88904162|NCT01541995||virtual and classic autopsy|Patients where contrast medium enhanced post mortem CT and classic autopsy will be performed.
89423070|NCT04582318|Experimental|Part 1 Dose Level 2 - Active|
89423071|NCT04582318|Placebo Comparator|Part 1 Dose Level 2 - Placebo|
89423072|NCT04582318|Active Comparator|Part 2 Multi-Dose Level 1 - Active|
89423073|NCT04582318|Placebo Comparator|Part 2 Multi-Dose Level 1 - Placebo|
89423074|NCT04582318|Active Comparator|Part 2 Multi-Dose Level 2 - Active|
89423075|NCT04582318|Placebo Comparator|Part 2 Multi-Dose Level 2 - Placebo|
89423076|NCT03048916|Other|general swallowing therapy|"including:~oral exercises~tactile stimulation~compensatory techniques~swallowing maneuvers"
89423077|NCT03048916|Experimental|the NMES therapy with VitalStim therapeutic device|The placement of 2-channel electrodes is depended on the dysphagic types and the findings on VFS
89423078|NCT03048916|Active Comparator|: the combined NMES and general swallowing therapies|
89423079|NCT04878250|Experimental|Bintrafusp alfa|
89423080|NCT04877938|Experimental|Echological Intervention|A starting point for this 'Ecological-Exercise-Intervention'(EEI), would be to limit sitting time to no more than 2 hours/day, and to stand up and move after 30 minutes of continuous sitting. In accordance with several epidemiologic evidences light-intensity activities would be encouraged to substitute sedentary time (e.g., standing up while talking on the telephone, ironing while watching TV). Taking into consideration the guidance provided by ecologic models of health behavior evidences about specific constructs to guide EEI may be derived from behavioral research on physical activity.
89423081|NCT04877938|Active Comparator|Standard Physical Activity Intervention|People included in this group will be assigned to a standard physical activity program that will follow the guidelines of the American College of Sport and Medicine. The program will include moderate intensity aerobic and strength training, three times a week for a total amunt of 200 min of physical activity/week.
89423082|NCT04877938|No Intervention|Control group|Individuals included in this group will be asked to keep their life style,without taking part in any physical activity program.
88904163|NCT01541995||virtual autopsy only|Patients where only contrast medium enhanced post mortem CT will be performed.
88904164|NCT01542008|Experimental|Customized Adherence Enhancement (CAE)|This arm will receive the CAE intervention.
88904165|NCT01542008|Active Comparator|broad non-individualized education (EDU)|This arm will receive the EDU intervention.
88904166|NCT01542047|Experimental|Carboplatin AUC5 + escalating pazopanib|Carboplatin AUC5 IV Day 1 Pazopanib in escalating dosages, 200 mg to 800 mg starting on days 2 or 3 and ending on days 19 or 21
88904167|NCT01542060||BIAsp 30 users|
88904168|NCT01542073|Experimental|68Ga-BNOTA-PRGD2 cardiac PET/CT scanning|We will perform 68Ga-BNOTA-PRGD2 cardiac PET/CT scanning on myocardial infarction patients to determine its value.
88904169|NCT01542086|Active Comparator|Myocardial SPECT|
88904170|NCT01542086|Experimental|64-channel coronary CT angiography (CCTA)|
89423083|NCT04877548|Experimental|Fermented orange flour|Volunteers will have to consume a standardized breakfast including fermented orange flour and presenting 50g of available carbohydrates
89423084|NCT04877548|Experimental|Fermented grape flour|Volunteers will have to consume a standardized breakfast including fermented grape flour and presenting 50g of available carbohydrates
89423085|NCT04877548|Placebo Comparator|Control|Volunteers will have to consume a standardized breakfast without fermented flour but also presenting 50g of available carbohydrates
89423086|NCT04871152||Patients with chronic migraine|In the same group of patients, the response to triptans will be analyzed at 3 different times with respect to the start of treatment with onabotulinumtoxinA: before treatment, after 4 months and after 7 months of treatment.
89423087|NCT02808429|Experimental|Placebo|
88904171|NCT01542099|Active Comparator|Single lumen tube|Single lumen tube intubation during remifentanil infusion
88904172|NCT01542099|Active Comparator|Double lumen tube|Double lumen tube intubation during remifentanil infusion
88904173|NCT01542112|Experimental|PSactive model|"The model is designed to address the main issues that lie at the core of initiatives to manage patient expectations and improve patient satisfaction. It is a structured interventional set of activities, which gives the clinician an opportunity to meet patient expectations and improve patient satisfaction.~The interventional model is comprised of teachable-learnable interpersonal communicative steps occurring between the clinician and the patient which are: Gather information on the patient's expectations and perception of the hospitalization, respond, provide relevant information and document the intervention."
88904174|NCT01542112|Experimental|No treament|Usual routine in the department
88904175|NCT01542138|Active Comparator|Niacinamide|4% niacinamide cream that will be randomly applied on axillar hyperpigmentation once-a-day for 9 weeks.
88904176|NCT01542138|Active Comparator|Desonide|Once-a-day application of 0.05% desonide cream on axillar hyperpigmentation
88904177|NCT01542138|Placebo Comparator|Placebo|Humectant placebo cream
88904178|NCT01542151|Active Comparator|Morning|Women randomized to a labor induction in the morning between 0600 and 1000.
88904179|NCT01542151|Experimental|Evening|Women randomized to a labor induction begun in the evening between 1700-2100
89423088|NCT02808429|Experimental|Atacicept 25 mg|
89423089|NCT02808429|Experimental|Atacicept 75 mg|
88904180|NCT01542190|Active Comparator|ketorolac tromethamine|
88904181|NCT01542190|Placebo Comparator|Dextrano 70 / Hypromellose|
89423090|NCT04870372|Experimental|Selegiline|Subjects who meet all of the inclusion and none of the exclusion criteria will be received Selegiline.The study medication dosage will be escalated from 5mg/daily to the target dose(5~10mg/daily) in 2 weeks and then maintained for the remaining 6 weeks.
89423091|NCT02048319|Experimental|Experimental: Pasireotide LAR 60 mg|The subjects will be randomized (1:1) into two groups. Both groups will undergo aspiration sclerotherapy following the standard procedure. The intervention group will additionally receive two injections of 60 mg pasireotide long-acting release (LAR) intramuscularly: the first injection 14 days before and the second injection 14 days after the intervention.
88904182|NCT01542203||Breast Cancer, Various BMIs|18 female breast cancer patients who are normal weight (body mass index [BMI] < 25 kg/m2, overweight or class I obese(BMI 25-34.9 kg/m2), or class II-III obese (BMI > 35 kg/m2).
88904183|NCT01542216|Placebo Comparator|Yoga and Stretching Group|Patients undergo yoga and stretching exercises
89423092|NCT02048319|Placebo Comparator|Placebo|Patients in the placebo arm will receive two injections of saline solution corresponding to the scheme of the intervention group.
89423093|NCT01594762|Placebo Comparator|Topical placebo control|Drug: Topical placebo cream
88904184|NCT01542216|Active Comparator|Nutrition and Exercise Group|Patients are provided with nutrition, cardiovascular exercise and strength exercise consultations
88904185|NCT01542242|Experimental|Liraglutide|Treatment of Diabetes Mellitus Type 2 with Liraglutide in the setting of Prader Willi Syndrome
88904186|NCT01542268|Active Comparator|pentoxifylline|
88904187|NCT01542268|Placebo Comparator|pentoxifylline placebo|
88904188|NCT01542281|Experimental|Nutritional supplementation and prehab|The first group (pre-hab) will receive both nutritional supplementation and a prehabilitation program.
88904189|NCT01542281|Active Comparator|Prehab exercise|
88904190|NCT01542294|Experimental|treatment|s1+oxaliplatin
88904191|NCT01542320|Experimental|Probiotic|Lactobacillus reuteri DSM 17938
88904192|NCT01542320|Placebo Comparator|Placebo|Solution without the active probiotic Lactobacillus reuteri
88904193|NCT01542346|Experimental|wound closure with subcutaneous adaption|
88904194|NCT01542359|Experimental|Yoga|"The integrated yoga program was designed to: 1) include the three primary elements of yoga as most commonly practiced in western cultures (physical postures, breath control and meditation); and 2) be appropriate for those without any prior yoga experience and with pre- and Stage I hypertension. The yoga program was designed by Eddie Stern, Founder and Director of Ashtanga Yoga New York (AYNY) in consultation with Drs. Hagins and Rundle, and are in large part congruent with the yoga program we studied previously (see Preliminary Studies). The yoga class includes: instruction on yogic principles regarding moral precepts (yamas and niyamas); active postures requiring mild-moderate physical exertion; conscious control of the breath in synchrony with active postures; and meditation. We expect approximately 10-15 minutes of the integrated yoga program to consist of isolated practice of meditation (occurring independently of the moving postures, typically in seated or lying positions)."
88904195|NCT01542359|Active Comparator|Conventional Exercise|Conventional exercise such as standing toe touch with arm swings, curl ups, push ups, leg lifts, etc. All done at a relatively slow rate which will be non-aerobic and at an average rate across the session of 3 METs
88904196|NCT01542385|Active Comparator|Immediate stenting|the stent selection (bare metal vs drug eluting) and implantation will be performed as recommended by current practice guidelines.
88904197|NCT01542385|Experimental|Delayed stenting|participants randomised to delayed stenting will be treated with GPIIb-IIIa inhibitors for 12-18 hours after reperfusion followed by anticoagulation for until the control angiogram, expected no sooner than 18-24 hours after the index reperfusion.
88904198|NCT01542411||recurrent pregnancy loss|
88904199|NCT01542411||thrombophilia, aspirin|
88904200|NCT01542411||heparin|
88904201|NCT01542424||BIAsp 30 users|
88904202|NCT01542424||IDet users|
88904203|NCT01542450|Experimental|Treatment period 1|
88904204|NCT01542450|Active Comparator|Treatment period 2|
88904205|NCT01542463||IDet users|
88904206|NCT01542476||IDet users|
88904207|NCT01542489||IDet + IAsp users|
89423094|NCT01594762|Experimental|Topical pexiganan cream 0.8%|Drug: Topical pexiganan cream 0.8%
89423095|NCT03812367||Group 1|The denosumab naïve group
88904208|NCT01542489||IDet + HI users|
88904209|NCT01542515||Osteoarthritis of the carpometacarpal joint of the thumb|The group of patients enrolled in this study all have the diagnosis of carpometacarpal arthritis of the thumb. The patients did not respond favorably to non-operative management including oral anti-inflammatory medications, corticosteroid injections, and thumb splinting. Operative management was therefore recommended using the technique of meniscal allograft arthroplasty.
88904210|NCT01542554|Experimental|Low glycaemic index diet|
88904211|NCT01542554|Active Comparator|Usual diabetic diet|
88904212|NCT01542567|Active Comparator|diclofenac|suppositories to prevent BCG side effects
88904213|NCT01542567|Placebo Comparator|placebo suppositories|
88904214|NCT01542593|Experimental|Ureteral catheterization|"During a planned procedure involving ureteroscopy or ureteral stenting, ureteral catheterization will be performed for the purpose of measuring exact ureteral length.~Measurement results will be compared to measurements performed on CT scan (obtained before surgery)."
88904215|NCT01542606|Experimental|color status|The NORMA-SENSE gen 3 polymer matrix is stained by blue or green color on a pale yellow background when the pH level of the fluid in contact with it is greater than the cutoff value, and the user can consider any stain of color, which is different from the original background, as a positive result of the test.
88904216|NCT01542619|Experimental|rVIIa-FP|
88904217|NCT01542619|Placebo Comparator|Placebo (0.9% normal saline)|
88904218|NCT01542658||uterine myoma|
88904219|NCT01542671|Experimental|Intervention|Lifestyle counseling at baseline, six, twelve months; Food and exercise log recording and feedback, motivational phone calls monthly for 12 months, 4 tailored mailings on lifestyle change, and weekly mailings on weight loss, exercise, and healthy eating for first 12 months. Maintenance mailings biweekly for six months and then monthly during the second year.
89423096|NCT03812367||Group 2|The zoledronic acid naïve group
89423097|NCT03812367||Group 3|The chronic denosumab (> 1 year with at least 3 biannual injections)
89423098|NCT03812367||Group 4|The chronic zoledronic acid (≥2 years with at least 2 annual injections)
89530855|NCT02501525|Experimental|UAS (-)|RIRS without ureteral access sheath: A ureteral access sheath (UAS) will not be positioned into the ureter of the patient prior to the insertion of the flexible ureterorenoscope (RIRS).
89530856|NCT02501603|Experimental|afatinib plus paclitaxel|afatinib plus paclitaxel
89530857|NCT03344627|Active Comparator|Meropenem standard dose|Meropenem 1 g every 8 hours
89530858|NCT03344627|Active Comparator|Meropenem high dose|Meropenem 2 g every 8 hours
89007024|NCT06095531|Experimental|Cranial flap replacement following a craniotomy using Tetranite for Cranial Flap Fixation (TN-CFF)|All patients enrolled in study will receive the use of Tetranite (TN-CFF) for their cranial flap fixation following a craniotomy. The flap fixation will be assessed at various time points.
89007025|NCT06095323|Experimental|Prophylactic compression sleeves group|The intervention group will wear compression sleeves for upper limbs with a pressure level of 1 (15-20mmHg) during the day for 12 months.
89007026|NCT06095323|No Intervention|routine care group|The routine care group will proceed as an observation and receive standard lymphedema education during the clinical trial.
89007027|NCT06091215|Active Comparator|Single Treatment Arm|Subjects will receive a single treatment of BBL/MOXI/HALO
89007028|NCT06091215|Active Comparator|Double Treatment Arm|Subjects will receive double treatment of BBL/MOXI/HALO 4-6 weeks apart.
89007029|NCT06088277|Experimental|HIV text messages (TM HIV)|Eligible participants randomized into this arm will receive text messages to reduce the risk for HIV and promote HIV testing.
89007030|NCT06088277|Active Comparator|TM HL|Eligible participants randomized into this arm will receive text messages to promote healthy living, but not specific to HIV risk or testing..
89007031|NCT06087354|Experimental|Low Oxygen Concentration CAPA-IVM culture|Half of COCs were cultured in the CAPA step and IVM step in a low oxygen concentration (5%) and 6% carbon dioxide at 37 degree
89007032|NCT06087354|Experimental|Air Oxygen Concentration CAPA-IVM culture|Half of COCs were cultured in the CAPA step and IVM step in a air oxygen concentration (20%) and 6% carbon dioxide at 37 degree
89007033|NCT06086951|Experimental|Pai.ACT Group|Parents allocated to this experimental group will gain complete access to the Pai.ACT mobile app.
89007034|NCT06086951|Active Comparator|Control Group|Parents allocated to this comparator group will receive conventional familial support offered by the hospital's Children with Complexity Community Support Programme (CCCSP) and allied Non-Governmental Organizations (NGOs). This support encompasses disseminating educational content focused on the management of children's affective and behavioral manifestations.
89423099|NCT03561987||Obese patients and bariatric surgery|"The investigators include men and women, over 18 years old, with morbid obesity and candidates for bariatric surgery, under the routine of the treating service, with signature of acceptance of your participation, by informed consent.~The investigators exclude patients with medication with potential effect on adipose tissue or cardiovascular risk in the last month, also with severe infections in the last month or clinically unstable conditions.~Patients are eliminated in the study if they dont have the desire to continue in the study, and if the samples or the information are insufficient for an adequate analysis."
89007035|NCT06084013||Observational|Patients receive indocyanine green IV during surgery, undergo imaging and have their medical records reviewed on study.
89007036|NCT06083948|Experimental|Noradrenaline|Noradrenaline
89007037|NCT06083948|Active Comparator|Phenylephrine|Phenylephrine
89007038|NCT06083870|Experimental|Oba01|
89007039|NCT06082492|Experimental|Intervention group|"The intervention group (n = 345) consists of usual care until 3 years of follow-up (see comparator) with additional whole-body 18F FDG PET/CT scans (from the skull to, at least, the midfemoral region) during follow-up visits at 6 months, 12 months, 18 months, 24 months, and 36 months of follow-up. After the 36-month follow-up period, patients will receive follow-up usual care (i.e. CT-scans).~The scanning protocol of Boellaard et al (2015) is the basis of all center-specific protocols and therefore will be followed approximately (PET low dose CT 60 minutes post injection with scan trajectory from skull to (at least the) thighs followed by a CT scan)."
89423100|NCT03561987||No obese patients and abdominal surgery|"The investigators include men and women, over 18 years old, without obesity and candidates for abdominal surgery (hernioplasty, cholecystectomy, fundoplication), under the routine of the treating service, with signature of acceptance of your participation, by informed consent.~The investigators exclude patients with medication with potential effect on adipose tissue or cardiovascular risk in the last month, also with severe infections in the last month or clinically unstable conditions.~Patients are eliminated in the study if they dont have the desire to continue in the study, and if the samples or the information are insufficient for an adequate analysis."
89423101|NCT02048397|Other|Pulmonary Rehabilitation (PRP)|Pulmonary Rehabilitation (PRP)
89423102|NCT02048397|Other|Pulmonary Rehabilitation plus oral nutritional supplement|Hyperproteic oral nutritional supplement enriched with beta-hydroxy-beta-methylbutyrate (HMB)
89007040|NCT06082492|Active Comparator|Control group (care as usual)|"The control group (n = 345) consists of regular follow-up visits with physical check-ups and CT-scans at least every 6 months for the first 2 years and then at least yearly CT-scans until 3 years of follow-up. In case of suspected recurrence/metastasis or inconclusive results of a CT-scan (eg, after radiotherapy), 18F FDG PET/CT should be considered.~The standard protocol for a diagnostic CT of the thoracic region during IV contrast administration according to the lung tumor protocol will be followed"
89423103|NCT04870450||Healthcare professionals|No intervention. Gathering data on their experiences of using video diaries.
89007041|NCT06081998|Experimental|Sleep deprivation|This subproject will be conducted in two sessions separated by three nights of sleep deprivation. Each session will last approximately 2 hours. At the beginning of the first visit and after the last visit, 9 ml of blood will be drawn, and plasma will be isolated. After plasma isolation, the CRP concentration will be analyzed. In each forearm of the participant, a 4x4 cm area will be selected as Area of Interest (AOI). In these selected areas, itch will be induced in both sessions using histamine and cowhage and several tests will be conducted.
89007042|NCT06078540|Experimental|USeeBP|Participants will be asked to use the USeeBP mHealth app alongside participating in UCM-RPM program as part of their routine care.
89007043|NCT06077591|Experimental|Patient-Derived Tumor Organoids (PDO) Guided Therapy|Intervention in this study is to perform tissue sampling to patient's tumor which are then subjected to DNA extraction for whole exome sequencing, organoid culture, and drug screen. An MDT board will review the drug screen results and excluded drug choice of poor response. Then the referring oncologist has the final discretion on the choice of chemo- or targeted agent as usual.
89007044|NCT06077578||Healthcare professionals|Healthcare professionals, including nurses, physicians, physiotherapists, occupational therapists, and radiotherapists, have at least one year experience in caring for hospitalized children will be recruited.
89007045|NCT06077578||Previously hospitalized children|Previously hospitalized children who had received a hospital play service provided by hospital play specialists.
89423104|NCT04870450||Family members of ICU patients|No intervention. Gathering data on their experiences of using video diaries.
89423105|NCT03935308|Experimental|MR-guided SBRT With SIB to the DILs to Prostate Cancer|Dose escalation to the DIL(s) will be performed in the traditional Phase I 3+3 design. Patients will be treated in four cohorts (three patients per dose level) starting with a dose of 9 Gy to the DIL(s). If no dose limiting toxicity (DLT), defined below, is observed after 90 days, then an additional three patients will be entered at the next dose level. Dose to the DIL(s) will be escalated at 1 Gy increments until DLT is observed or if maximum dose level (60 Gy in 5 fractions of 12 Gy) is reached with no observed DLT. If one of the three patients experience a DLT at a particular dose level an additional three patients will be enrolled at that level. If two or more patients experience a DLT a lower dose level will be explored to define the maximum tolerated dose (MTD). The three patients within any cohort can be enrolled simultaneously or sequentially without any waiting period among them.
89423106|NCT02048475|No Intervention|desflurane|inhalation concentration
89423107|NCT02048553|Experimental|Tablet-guided|Guide-assisted ventriculostomy.
89007046|NCT06077578||parents|Parents of previously hospitalized children who had received a hospital play service provided by hospital play specialists.
89007047|NCT06064474|Experimental|High ventilation breathwork with retention (HVBR)|Guided audio of HVBR pre-recorded by a trained breathwork facilitator for ~20min/day over 21 days (three weeks). Delivered remotely through audio link, comprising evocative music and four rounds of hyperventilation with four separate retentions (breath holds), progressively increasing in length (from ~45seconds up to ~90 seconds).
89007048|NCT06064474|Placebo Comparator|Placebo HVBR|Guided audio of placebo HVBR pre-recorded by a trained breathwork facilitator for ~20min/day over 21 days (three weeks). Delivered remotely through audio link, comprising music and four rounds of paced breathing at 15b/min (equal inhale:exhale) with four separate brief retentions, progressively increasing in length (from ~10secs to ~25secs).
89007049|NCT06063031|Experimental|Active nutritional supplement plus telerehabilitation|Active nutritional supplement plus telerehabilitation
89007050|NCT06063031|Placebo Comparator|Placebo nutritional supplement plus telerehabilitation|Placebo nutritional supplement plus telerehabilitation
89007051|NCT06062810|Experimental|Crizotinib - Usual|"XALKORI - Crizotinib~Chemotherapy~XALKORI - crizotinib capsule~XALKORI 250 mg taken orally twice daily~Usual Approach Group (high dose)"
89423108|NCT02048553|Experimental|Freehand|standard ventriculostomy.
89423109|NCT03046888|Experimental|PCNL|Percutant nephrolithotomy is a standard procedure for stones treatment over 2 cm.The puncture will be performed with an 18-G nephrostomy needle. The access thus gained guaranteed the transpapillary route of the percutaneous tract, a basic condition for the prevention of bleeding. Subsequently, following withdrawal of the puncture needle and urine drainage, a flexible guidewire will be inserted and advanced to the upper calyx or ureter.
89536072|NCT03072225|Experimental|Herbal Medicine C-117|Herbal Medicine C-117 Prescription (6g/bag，one bag each time, twice a day.) for 6 months
89007052|NCT06062810|Experimental|Crizotinib - Study|"XALKORI - Crizotinib~Chemotherapy~XALKORI - crizotinib capsule~XALKORI 200 mg taken orally twice daily~Usual Approach Group (low dose)"
89007053|NCT06057922|Experimental|Phase 1 dose expansion stage|Patients will be treated with YL201 intravenous (IV) infusion once every 3 weeks (Q3W) as a cycle.
89007054|NCT06057922|Experimental|Phase 2 stage with expanded sample size|Patients will be treated with YL201 intravenous (IV) infusion at PR2D once every 3 weeks (Q3W) as a cycle.
89007055|NCT06056050|Experimental|Experimental vaccine group 1A,≥18 years old|1 dose of Tdcp vaccine
89007056|NCT06056050|Active Comparator|Control vaccine group 1B,≥18 years old|1 dose of PPV23 vaccine
89007057|NCT06056050|Experimental|Experimental vaccine group 2A,12~17 years old|1 dose of Tdcp vaccine
89007058|NCT06056050|Active Comparator|Control vaccine group 2B,12~17 years old|1 dose of PPV23 vaccine
89007059|NCT06056050|Experimental|Experimental vaccine group 3A,6~11 years old|1 dose of Tdcp vaccine
89007060|NCT06056050|Active Comparator|Control vaccine group 3B,6~11 years old|1 dose of DT vaccine
89007061|NCT06054425|Experimental|Arm 1|Participants will receive risankizumab manufactured with using the current process (CMC2).
89007062|NCT06054425|Active Comparator|Arm 2|Participants will receive risankizumab manufactured with using the new process (CMC3).
89007063|NCT06052800||Cohort 1|Patients with Galactosidase Alpha gene (GLA) IVS4 who have already received agalsidase beta treatment
89007064|NCT06052800||Cohort 2|Patients with GLA IVS4 who will initiate agalsidase beta treatment
89007065|NCT06052800||Cohort 3|Enzyme replacement therapy (ERT)-naive Fabry disease patients with GLA IVS4
89007066|NCT06050187|Active Comparator|Group I conventional stone cast|Mandibular stone cast with 4 parallel implants analogues in canines and second premolar regions will be fabricated conventionally.
89007067|NCT06050187|Active Comparator|Group II 3D printed implant cast|3D printed implant mandibular cast with 4 parallel digital implants analogues in canines and second premolar regions will be fabricated digitally.
89007068|NCT06046495|Experimental|PLB1004|PLB1004 given as a mono-therapy in dose escalation and dose expansion phase.
89007069|NCT06040723||Experimental: Intervention arm|All patients within the study are included in the intervention arm: The Hill classification is determined by the physician and the AI method.
89007070|NCT06036225|Experimental|Receiving the prehabilitation intervention|All participants will receive the prehabilitation intervention.
89007071|NCT06035744|Experimental|CLN-617 Dose Escalation (Part A)|Patients with Advanced Solid Tumors enrolled in dose escalation cohorts treated with CLN-617 alone and in combination with pembrolizumab
89007072|NCT06035744|Experimental|CLN-617 Dose Optimization (Part B)|Patients with Advanced Solid Tumors enrolled in dose optimization receiving selected doses of CLN-617 in combination with pembrolizumab
89007073|NCT06035744|Experimental|CLN-617 Dose Expansion (Part C)|Patients with Advanced Melanoma or Head and Neck Squamous Cell Carcinoma (HNSCC) enrolled in dose expansion treated with CLN-617 in combination with pembrolizumab
89007074|NCT06035536|Experimental|Symphony™ treatment|Arm receives an application of Symphony™ treatment and appropriate Off-loading.
89007075|NCT06035536|Active Comparator|Standard of Care (SOC) treatment|Arm receives an application of SOC comprising of calcium alginate Fibracol dressing and appropriate Off-loading.
89423110|NCT03046888|Experimental|Robot assisted pyelolithotomy|Robot assisted pyelolithotomy, is a new technique to remove stones of more than 2 cm. A 12-mm camera port is placed at the level of the umbilicus and lateral. Two 8-mm robotic trocars are placed under direct vision and a 12-mm assistant port is placed in the midline a 5-8 cm above the umbilicus. After reflecting the colon medially, the renal pelvis will be dissected and identified, a flexible cystoscope will be inserted via an assisted trocar and introduced into the renal pelvis through a minor incision. The kidney stones will then be extracted with a basket and either removed via the port or placed in a specimen retrieval bag.
89423111|NCT03046498|Experimental|Program participants|Patients enrolled in the DSMP and DPP who provide consent.
89423112|NCT03049384|Active Comparator|Traditional Exercise|A classical exercise intervention based on current guidelines for cancer survivors.
89423113|NCT03049384|Experimental|Tailored Exercise|A tailored and individualized exercise intervention based on the results of pre-intervention testing.
89423114|NCT03561909|Other|Platelet transfusion|HLA-A2 and/or HLA A9 negative healthy study subjects will be transfused with a small dose of platelets from an HLA-A2 and/or HLA-A9 positive donor.
89423115|NCT03562143|Experimental|Alternate-day iron supplementation|Patients taking iron supplementation given as 2 tabs of 325 mg ferrous sulfate (equivalent to 130 mg of elemental iron) for 6 weeks.
88904220|NCT01542671|Placebo Comparator|Control|Lifestyle counseling at baseline, six and twelve months similar to intervention group, and infrequent non-tailored pamphlets.
88904221|NCT01542697|Active Comparator|Magnesium sulphate|intraperitoneal nebulisation of 1.5 gm of magnesium sulphate with 2 ml of normal saline at the end of surgery before closure
88904222|NCT01542697|Placebo Comparator|normal saline|intraperitoneal nebulisation of 5 ml of normal saline after end of surgery before closure
88904223|NCT01542710|Experimental|Glaucoma fixed Combination Medications|
88904224|NCT01542723|Experimental|LMWH|750 patients with an arthroscopy or the knee will be randomized to receive treatment with a LMWH
88904225|NCT01542723|No Intervention|No intervention|750 patients with an arthroscopy of the knee will be randomized to receive no treatment.
88904226|NCT01542762|Experimental|LMWH|750 patients with lower leg cast immobilization will be randomized tot receive treatment with a LMWH.
88904227|NCT01542762|No Intervention|No intervention|750 patients with lower leg cast immobilization will be randomized tot receive no treatment with LMWH.
88904228|NCT01542775|Placebo Comparator|Control|
88904229|NCT01542775|Active Comparator|Exercise|
88904230|NCT01542801|Active Comparator|Norfloxacin|norfloxacin 400 mg once daily administration
88904231|NCT01542801|Experimental|Ciprofloxacin|Ciprofloxacin 750 mg per week
88904232|NCT01542814||Fujifilm 3Dimensional Mammography|Group of subjects being given Fujifilm 3D Mammography Imaging
88904233|NCT01542814||2D FFDM|Group of Subjects receiving FujiFilm or other FDA Approved 2D Mammography Imaging
89423116|NCT03562143|Active Comparator|Daily iron supplementation|Patients taking iron supplementation given as 1 tab of 325 mg ferrous sulfate (equivalent to 65 mg of elemental iron) for 6 weeks.
89423117|NCT03049228||Type 2 Diabetic Patients|"Obese (BMI > 27 kg/m2 < 35 kg/m2)~Non-insulin dependent; they must be on sulphonylurea(SU)- derivate or metformin therapy for at least six months with a constant dose for at least two months, or on dietary treatment for at least six months~They should have a (moderately) well-controlled diabetes (defined by a HbA1c<8%)"
89423118|NCT03049228||Obese Subjects|"A similar BMI as T2DM patients (BMI > 27 kg/m2< 35)~Normo-glycemic with fasting plasma glucose levels lower than 6,1 mmol/L."
89423119|NCT03049228||Lean subjects|"BMI between 20-25 kg/m2~Normo-glycemic with fasting plasma glucose levels lower than 6,1 mmol/L."
89423120|NCT03812133||Surgical patients|Patients who were electively scheduled for surgery.
89423121|NCT02615470|Experimental|Enhanced immunization delivery model|Pharmacist-technician pairs employed by community pharmacies that are assigned to this arm will receive a) immunization update training, b) training by immunization experts to enhance immunization delivery model and foster practice change at the beginning of 6-month and c) regular feedback and clinical support for the period of 6 months.
89423122|NCT02615470|Active Comparator|Immunization update|Pharmacist-technician pairs employed by community pharmacies that are assigned to the control arm will receive an immunization update training. They will not receive a training by immunization experts nor regular feedback and clinical support.
89423123|NCT02048631||Oral Cancer Patients underwent Free Flap Reconstruction|
88904234|NCT01542827|Placebo Comparator|Placebo|Topical gel containing a menthol scent, but no active menthol
88904235|NCT01542827|Experimental|Biofreeze|Biofreeze topical gel containing 3.5% menthol
88904236|NCT01542866|Experimental|Home Monitoring Test|Health management tool (HMT) for measuring vision impairment
88904237|NCT01542892|Experimental|Supplement|
88904238|NCT01542892|Sham Comparator|Placebo|
88904239|NCT01542892|Experimental|Exercise|
88904240|NCT01542905|Experimental|Korean Red Ginseng|
88904241|NCT01542905|Placebo Comparator|Placebo|
88904242|NCT01542918|Experimental|Study intervention|Lenalidomide Plus Rituximab
88904243|NCT01542931|No Intervention|Surgery and radiotherapy|Surgery and post-operative radiotherapy.
88904244|NCT01542931|Experimental|TPF induction chemotherapy|Induction chemotherapy before surgery: docetaxel, cisplatin, and 5-fluorouracil.
88904245|NCT01542944|Experimental|TevaGastrim|treatment with TevaGastrim for allogeneic stem cell collection
88904246|NCT01542970|Placebo Comparator|Placebo|Placebo for both L. reuteri and omega-3 fatty acids.
88904247|NCT01542970|Experimental|L. reuteri and placebo|Active Lactobacillus reuteri and placebo for omega-3 fatty acids
88904248|NCT01542970|Experimental|Omega-3 fatty acids and placebo|Placebo for L. reuteri and active for omega-3 fatty acids
88904249|NCT01542970|Experimental|L. reuteri and omega-3 fatty acids|Active L. reuteri and active omega-3 fatty acids
88904250|NCT01542983|Active Comparator|Treatment-as-usual|Treatment as usual for fatigue and insomnia
88904251|NCT01542983|Active Comparator|Behavioral treatment|Brief behavioral treatment for insomnia and bright light Light and BBTI combined treatment for insomnia and fatigue
88904252|NCT01543009|No Intervention|Emla + no additional intervention|Children in this arm will receive standard preparation of the venipuncture site (local analgesia with Emla) without warming
88904253|NCT01543009|Experimental|Emla + Local Warming|Children in this arm will receive standard preparation of the venipuncture site (local analgesia with Emla) plus warming with a heating pad at 40°C for 5 minutes
89423124|NCT05674227||Robotic surgery|Patients who have undergone pulmonary robotic surgery
89423125|NCT05674227||VAT surgery|Patients who have undergone pulmonary video-assisted thoracoscopy surgery (VATS)
89423126|NCT05674227||Open surgery|Patients who have undergone pulmonary open surgery
89423127|NCT03046654|Experimental|Cervical cerclage|Women with a poor obstetric history that require cervical cerclage in order to avoid late abortion/early delivery.
89423128|NCT03806517||Tremor dominant type group|Tremor dominant type (TDT) group will consist of the patients with tremor premotor symptoms.
88904254|NCT01543022|Experimental|Symphony system|
88904255|NCT01543035|Experimental|Etravirine switch|Patients in need of lipid-lowering drug switched from boosted PI or EFV to Etravirine
88904256|NCT01543048||Women with CIN3 treated by conization|
88904257|NCT01543061|Active Comparator|New study eye drop|One month of contact lens wear with use of the Test study eye drops
88904258|NCT01543061|Placebo Comparator|No Eyedrop|One month of contact lens wear with no eye drop use
88904259|NCT01543061|Active Comparator|BLINK Contacts Lubricating eye drop|One month of contact lens wear with use of the Control study eye drops
88904260|NCT01543100|Experimental|monoclonal gamopathy|"Patients with monoclonal gammopathy either MGUS or myeloma at diagnosis or more than 3 months after a first myeloma treatment with chemotherapy and/or antiangiogenic drugs.~Patient's age ≥18 yo,~Patients having signed the specific consent of the study."
88904261|NCT01543126||pleural effusion|patients with pleural effusion
88904262|NCT01543139|Experimental|Valproate+Cytidine-+Creatine-|The subjects with bipolar depression, treated with cytidine- and creatine-containing drug and dietary supplement in addition to valproate
88904263|NCT01543139|Active Comparator|Valproate+Cytidine-|The subjects with bipolar depression, treated with cytidine-containing drug and dietary supplement in addition to valproate
88904264|NCT01543139|Active Comparator|Valproate|The subjects with bipolar depression, treated with valproate
88904265|NCT01543165|Experimental|Group 1|Sequential intravenous administration of ketorolac and nefopam
88904266|NCT01543165|Active Comparator|Group 2|Sequential intravenous administration of ketorolac and morphine
88904267|NCT01543165|Placebo Comparator|Group 3|Intravenous administration of ketorolac
88904268|NCT01543191|Experimental|PUR118|
88904269|NCT01543191|Placebo Comparator|Placebo|
89423129|NCT03806517||PIGD dominant type group|Postural instability and gait difficulty dominant type (PIGDT) group will consist of the patients with axial premotor symptoms.
89423130|NCT03806517||Healthy control group|Healthy control group will consist of the subjects with same age and sex matched individuals in PD group.
89423131|NCT02048709|Experimental|GDC-0919 Dose Escalation|GDC-0919 to be given on an outpatient basis as a single agent. Starting dose of GDC-0919 will be 50 mg by mouth every 12 hour. Patients will receive the study drug daily for 21 days followed by 7 days off for a cycle length of 28 days; or on 28 consecutive days of a 28-day cycle
89423132|NCT03048448|Experimental|Fevipiprant 450mg|450mg Film Coated Tablet
89423133|NCT02050815|Experimental|MEK162|A minimum of 24 subjects (6 subjects per group) will be enrolled. Enrollment into Group 1 (control group with normal hepatic function) should be similar to the enrollment into Group 2, 3 and 4 with respect to age, gender, and body weight. Enrollment into Group 1 will remain open until the enrollment into the mild, moderate, and severe impairment groups are complete with matching controls for comparison. Serum level of total bilirubin and AST will be used to determine which group the hepatic impaired patient will be allocated l. Dosing of the different treatment groups will be staggered. Initially, 6 subjects in Group 1 (normal hepatic function) and 6 subjects in Group 2 will receive a single oral dose of MEK162 on Day 1.
89423134|NCT02048787|Experimental|Moderate renal impairment group|Subjects with moderate renal impairment defined as eGFR of 30-59 mL/min/1.73m2 at screening can be enrolled in this group
89423135|NCT02048787|Experimental|Severe renal impairment group|Subjects with severe renal impairment defined as eGFR of 15-29 mL/min/1.73m2 at screening can be enrolled in this group
88904270|NCT01543217|Active Comparator|Control|Ususal care.
88904271|NCT01543217|Active Comparator|Intervention|Patients assigned to the RT management arm will receive a 1-hour educational in-service conducted by a respiratory therapist case manager. The patient education session will include general information about COPD, direct observation of inhaler techniques, a review and adjustment of outpatient COPD medications, smoking cessation counseling, recommendations concerning influenza and pneumococcal vaccinations, encouragement of regular exercise, and instruction in hand hygiene.
88904272|NCT01543230|Experimental|CoMplete™ Acetabular Hip System (CoM)|Total hip arthroplasty (THA) using CoMplete™ Acetabular Hip System
88904273|NCT01543243|Experimental|Group 1|"Group 1: immediate effects: T0, Stochastic resonance whole-body vibration A intervention, immediate T1 (one minute after Stochastic resonance whole-body vibration B intervention), 7 days wash-out period; T2, Stochastic resonance whole-body vibration intervention, immediate T3 (one minute after Stochastic resonance whole-body vibration intervention)~long term effect: T4, Stochastic resonance whole-body vibration A intervention over four weeks, three time a week;T5, 16 days wash-out period; T6, Stochastic resonance whole-body vibration B intervention over four weeks, three times week, T7"
89007076|NCT06032286|Experimental|Microneedling|4 microneedling sessions at baseline and days 30, 60 and 90.
89536073|NCT03072225|Placebo Comparator|The Placebo of Herbal Medicine C-117|Placebo of Herbal Medicine C-117 (6g/bag，one bag each time, twice a day.) for 6 months
88904274|NCT01543243|Experimental|Group 2|"Group 2: immediate effect: T0, Stochastic resonance whole-body vibration B intervention, immediate T1 (one minute after intervention), 7 days wash-out period; T2, Stochastic resonance whole-body vibration A intervention, immediate T3 (one minute after intervention)~Long term effect: T4, Stochastic resonance whole-body vibration B intervention over four weeks, three time a week;T5, 16 days wash-out period;T6, Stochastic resonance whole-body vibration A intervention over four weeks, three times week, T7"
88904275|NCT01543269|Active Comparator|ZYT1 tablets|ZYT1 tablets: Route of administration: Oral Dosage: 0.5mg, 1mg, 2 mg, 4mg, 8 mg, 16mg, 32mg and 64mg
88904276|NCT01543269|Placebo Comparator|Placebo|Placebo tablets: Route of administration: Oral Dosage: 0.5mg, 1mg, 2 mg, 4mg, 8 mg, 16mg, 32mg and 64mg
88904277|NCT01543282|Active Comparator|EUS 22 gauge needle|EUS 22 g needle is the most common needle used in clinical practice. EUS-FNA passes will be performed without stylet until sample adequacy or until a maximum of 5 FNA passes in pancreatic lesions or 3 FNA passes in other lesions. In case of inadequate sample after 3 passes, or needle failure, cross over to the other type of needle is allowed.
88904278|NCT01543282|Experimental|EUS 25 gauge needle|25 gauge needle is usually used less frequently but nowadays is increasingly used and is as well a valid option. EUS-FNA passes will be performed without stylet until sample adequacy or until a maximum of 5 FNA passes in pancreatic lesions or 3 FNA passes in other lesions. In case of inadequate sample after 3 passes, or needle failure, cross over to the other type of needle is allowed.
88904279|NCT01543295||Known Positive Syphilis Infection|Individuals known to have a clinical diagnosis of Syphilis
88904280|NCT01543295||High Risk for Syphilis Infection|Individuals with previous and confirmed STD infection, MSM, persons with high risk sexual behavior or clinical examination with classic manifestations of syphilis.
88904281|NCT01543295||Pregnant Women (High Risk and Low Risk)|"1st or 3rd trimester from either High Risk (see description above) or Low Risk population.~Low Risk are individuals not known to belong to any of the defined high-risk groups - i.e. healthy patients presenting for routine physicals or other unrelated non-life threatening illnesses, or individuals from a general low risk population such as students, employees of academic or other institutions, etc…"
88904282|NCT01543308||coronary heart disease|
88904283|NCT01543308||healthy control group|
88904284|NCT01543321|Experimental|Tetrabenazine group|Tetrabenazine is a drug that is administered orally. This is 25 mg tablets, divisible into 2.
88904285|NCT01543321|Placebo Comparator|Plagebo group|Patients will receive a buccal tablet identical to the experimental product
88904286|NCT01543334||Patients|Patients with a vein or artery catheter and who are being administered antibiotics. The latter can be of the following: Amoxicillin-clavulanic acid, ampicillin, piperacillin-tazobactam, penicillin G, flucloxacillin, dicloxacillin, cloxacillin, cefazolin, ceftazidime, ceftriaxone, cefepime, meropenem, imipenem, doripenem, ertapenem; Vancomycin, teicoplanin. (see inclusion/exclusion criteria).
88904287|NCT01543347|Experimental|Temocillin|Treatment group
88904288|NCT01543360|Active Comparator|Axillary strategy|The first two attempts at central venous catheterization will be performed via the distal approach (axillary vein). The third and fourth attempts at central venous catheterization will be performed by the medial approach (subclavian vein).
88904289|NCT01543360|Active Comparator|Subclavian strategy|The first two attempts at central venous catheterization will be performed by the medial approach (subclavian vein). The third and fourth attempts at central venous catheterization will be performed by the distal approach (axillary vein).
88904290|NCT01543373|Experimental|CRE8 arm|
88904291|NCT01543373|Active Comparator|Vision/Multilik8 arm|
88904292|NCT01543386|Other|curcumin|The aim of this study is to determine if an oral loading-dose of curcumin can improve vascular endothelium reactivity in patients with moderate cardiovascular risk
88904293|NCT01543399|Experimental|Tibolone use|climacteric women will use Tibolone for 30 days
88904294|NCT01543399|Placebo Comparator|Placebo use|climacteric women will use placebo for 30 days
88904295|NCT01543412|Experimental|FOLFIRI|Folfiri consist of Irinotecan 180 mg/m2 iv on day 1, Leucovorin(l-form) 200 mg/m2 iv on day 1and 2, 5-FU 400 mg/m2 iv bolus on day 1and 2, 5-FU 600 mg/m2 iv by ci for 22 hours on day 1 and 2, repeated every 2 wks The use of antiemetic prophylaxis was decided locally.
88904296|NCT01543438|No Intervention|Control|current standard of care
88904297|NCT01543438|Experimental|Intervention Group|receives video prescription
88904298|NCT01543464|Experimental|Vaccine+adjuvants+temozolomide treatment|Experimental arm
88904299|NCT01543477||Single group|
88904300|NCT01543516||Patients with Asthma|"Affected patients~-20 Patients suffering from asthma with an eNO over 30 bbp"
88904301|NCT01543516||Healthy Subjects|"Non-affected patients~-20 matched controls not suffering from asthma"
88904302|NCT01543529|Active Comparator|RO4917838 + non-alcoholic drink|
88904303|NCT01543529|Experimental|RO4917838 + alcohol|
88904304|NCT01543529|Placebo Comparator|RO4917838 placebo + alcohol|
88904305|NCT01543529|Placebo Comparator|RO4917838 placebo + non-alcoholic drink|
88904306|NCT01543542|Other|Radiation Therapy Treatment|Whole Brain XRT 30Gy/10 fractions with Simultaneous Infield Boost of Brain Lesions to 60Gy
88904307|NCT01543555|Experimental|Atorvastatin active|Atorvastatin 80mg anytime within 18 hours before surgery. A postoperative 40mg atorvastatin dose administered at least 12 hours after the 80mg loading dose. Subsequently, 40mg atorvastatin daily for the next seven days.
89423136|NCT02048787|Experimental|Matching healthy control group|Subjects with normal renal function defined as eGFR ≥ 90 mL/min/1.73m2 at screening and matching to the renal impaired subject based on gender, race, age, and weight can be enrolled in this group.
89423137|NCT04374448|Other|Sinus Tumor Resection|Those who are undergoing endoscopic sinonasal surgery for benign and malignant tumor removal.
89423138|NCT04374448|Other|Skull Base Surgery|Those who are receiving Endoscopic Skull Base Surgery (ESBS) for minimally-invasive access for removal of skull base tumors, most commonly for ones of pituitary origin.
89423139|NCT04374448|Other|Endoscopic Sinus Surgery|Individuals with chronic rhinosinusitis (CRS) with or without polyposis that are to have endoscopic sinus surgery, a minimally invasive procedure to open the sinuses.
88904308|NCT01543555|Placebo Comparator|Placebo|Matching placebo 80mg anytime within 18 hours before surgery. A postoperative 40mg placebo dose administered at least 12 hours after the 80mg loading dose. Subsequently, 40mg placebo daily for the next seven days.
88904309|NCT01543620||Patients with cystic fibrosis treated with aminoglycosides|
88904310|NCT01543620||Patients with cystic fibrosis not treated with aminoglycosides|
88904311|NCT01543646||Liver Biopsy patients|All patients due to have a liver biopsy for the assessment of parenchymal liver disease.
88904312|NCT01543672|Experimental|SBRT group A|escalate MLD in medically inoperable patients with tumors larger than 5 cm in diameter (primary or solitary metastases)
88904313|NCT01543672|Experimental|SBRT group B|Escalate the MLD in patients with ≥ 2 lung metastases
88904314|NCT01543711||Breast cancer survivors|Women treated for breast cancer, without signs of recurrence or metastasis
88904315|NCT01543724|Experimental|Lithium|
88904316|NCT01543737|Active Comparator|Single injection hyaluronic acid|3ml hyaluronic acid (DUROLANE)
88904317|NCT01543737|Active Comparator|Three injection hyaluronic acid|2ml hyaluronic acid (HYALGAN)
88904318|NCT01543750|Experimental|Study Medication|4-aminopyridine 10mg twice daily for 8 weeks
88904319|NCT01543750|Experimental|Placebo|placebo twice daily for 8 weeks
89423140|NCT04374448|Other|Epistaxis Management|Those who have severe nose bleeds and requires going into the operating room for management.
89423141|NCT02048865|Active Comparator|Apixaban|2.5 mg BID for 6 months
89423142|NCT02048865|Placebo Comparator|Placebo drug|2.5 mg BID for 6 months
89423143|NCT03663946||Patients taking combination therapy with Yervoy and Opdivo|Medical records will be reviewed for safety and treatments for specific ADR
88904320|NCT01543802|Experimental|Pazopanib|
88904321|NCT01543815|Experimental|WBT-WEB|Well-Being Therapy based on Web Mobile technology
89423144|NCT02048943|Experimental|Treatment (dovitinib, gemcitabine, nab-paclitaxel)|Patients receive dovitinib lactate PO QD 5 days per week, paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89423145|NCT02049021|Experimental|Electroconvulsive Therapy|Patients in use of clozapine randomized to receive ECT treatment
89423146|NCT02049021|Sham Comparator|SHAM ECT|Patients receiving clozapine randomized to sham ECT (placebo)
89423147|NCT04430296|Active Comparator|High Intensity Focused Ultrasound Cyclophotocoagulation (HIFU)|
89423148|NCT04430296|Active Comparator|MicroPulse cyclophotocoagulation (MP-CPC)|
89423149|NCT04430296|Active Comparator|Continuous Wave cyclophotocoagulation (CW-CPC)|
89423150|NCT02050893|Experimental|Midazolam|Midazolam infused at a 0.03mg/kg loading dose ,and 0.02-0.1mg/kg.h maintenance dose to achieve Ramsay score of 4
88904322|NCT01543815|Active Comparator|CBT|Cognitive Behavior Therapy
88904323|NCT01543815|No Intervention|CM|Standardized Care Management
88904324|NCT01543841||Advanced Cancer|Patients with histologically confirmed metastatic or unresectable solid tumors will have one tube of whole blood (~6mL) collected at the time of venipuncture for routine sample collection. The sample will undergo in vitro stimulation of TEMs with ANG 1 and 3 in the presence or absence of pharmalogic inhibitors, and flow cytometry analysis.
88904325|NCT01543841||Healthy Volunteers|Eligible volunteers will have one tube of whole blood (~6mL) collected. The sample will undergo in vitro stimulation of TEMs with ANG 1 and 3 in the presence or absence of pharmalogic inhibitors, and flow cytometry analysis.
89195508|NCT00819351|Active Comparator|PEG-Asparaginase 2 weeks intervals|"PEG-asparaginase (1.000 IU/m2/dose) given at two weeks intervals (from week 13 after diagnosis to week 33).~All additional therapy (High Dose Methotrexate, Vincristin, Dexamethasone, 6-Mercaptopurine, doxorubicin, intrathecal chemotherapy) is the same in both arms."
89195509|NCT00636675|Experimental|Fall QI|Falls QI includes quality improvement training about falls to be implement by indigenous nursing home staff with support of study personnel.
89195510|NCT00636675|Experimental|Connect & Falls QI|Connect is delivered, followed by Falls. Behavioral intervention to improve staff interaction for better care planning and execution. Connect will be delivered, followed by the Falls quality improvement intervention.
89195511|NCT00699998|Experimental|Prasugrel|Prasugrel and Low-dose Commercially-available Aspirin
89195512|NCT00699998|Active Comparator|Clopidogrel|Clopidogrel and Low-Dose Commercially-available Aspirin
89195513|NCT00696072|Active Comparator|A1|
89195514|NCT00696072|Active Comparator|A2|
89195515|NCT00816855|Other|1|All patients will receive docetaxel 75 mg/m2 on day 1; cisplatin 75 mg/m2 on day 1; and a continuous fluorouracil infusion at 500 mg/m2/d on days 1 through 5. Cycles are repeated every 21 days for a total of three cycles. Patients then will receive definitive radiotherapy with 3D-CRT or IMRT, and cisplatin (40mg/m2) weekly during external radiotherapy.
89536074|NCT03212677|Active Comparator|Iron-deficient children|Previously iron-deficient children aged 6-24 months on iron therapy. Ferrous sulfate administered at 4 mg Fe/kg/d per standard of care.
89536075|NCT03212677|No Intervention|Non-iron-deficient children|Non-iron-deficient children aged 6-24 months used as a reference.
89536076|NCT03212677|Placebo Comparator|Adult Placebo|Iron-replete postmenopausal women, and men, receiving placebo daily for 4 weeks.
88820100|NCT06195111||Trifluridine/Tipiracil|Patients with metastatic colorectal cancer plan to recieve Trifluridine/Tipiracil-containing treatment will be enrolled in this study. The prescription all determined by doctor based on patient's situation.
88820101|NCT06195098|Other|Nosy Mitsio Population|Women of childbearing age from 14 to 49 years, pregnant or not and lactating or not, and their children and adolescent form 2 to 18 years old.
88820102|NCT06195085||CT-guided radioactive iodine-125 seed implantation|The patients, diagnosed with recurrent desmoid tumor, undergoing CT-guided radioactive iodine-125 seed implantation in 3 different centers including Peking University Third Hospital, First Affiliated Hospital of the Army Medical University, and Shengli Oilfield Central Hospital from July 2013 to July 2021.
88820103|NCT06195072|Experimental|Amlitelimab|
88820104|NCT06195072|Placebo Comparator|Amlitelimab matching placebo|
88820105|NCT06195072|Experimental|BI 1015550|
88820106|NCT06195072|Placebo Comparator|BI 1015550 matching placebo|
88820107|NCT06195046|Sham Comparator|control (BAT off)|Baroreflex activation therapy turned off for three months
88820108|NCT06195046|Experimental|treatment (BAT on)|Baroreflex activation therapy turned on for three months
88820109|NCT06195033|Experimental|AI-guided surgical protocol group|
88820110|NCT06195033|No Intervention|traditional surgical protocol group|
88820111|NCT06195020|Experimental|Experimental Group|This group will be informed by sharing and using educational videos prepared in the Metaverse universe on mobile.
88820112|NCT06195020|Active Comparator|Control Group|This group will be informed through routine outpatient clinic service.
88820113|NCT06195007|Experimental|Motivational Interview|Patients included in the study who are being treated by a resident in the MI intervention group will have a motivational interview during their initial hospitalization.
88820114|NCT06195007|No Intervention|Control|Patients included in the study who are being treated by a resident in the Control group will not have a motivational interview during their hospitalization.
88820115|NCT06194994|Experimental|Parent Training|Behavioral parent training intervention. Individual sessions.
88820116|NCT06194994|Experimental|Child directed treatment|Child directed cognitive behavioral therapy. Individual sessions.
88820117|NCT06194968||Experimental: Urokinase|
88820118|NCT06194968||Active Comparator: Alteplase|
88820119|NCT06194955|Active Comparator|GIPR variant carriers|Inidividuals with GIPR variants: Determination of the incretin effect, and the insulinotropic actions of GIP and GLP-1 infusions during hyperglycemic clamp.
88820120|NCT06194955|Placebo Comparator|GIPR variant carrier controls|Healthy matched individuals: Determination of incretin effect, and the insulinotropic actions of GIP and GLP-1 infusions during hyperglycemic clamp.
88820121|NCT06194955|Active Comparator|GLP-1R variant carrier|Individuals with GLP-1R variants: Determination of incretin effect, and the insulinotropic actions of GIP and GLP-1 infusions during hyperglycemic clamp
88820122|NCT06194955|Placebo Comparator|GLP-1R variant carrier controls|Healthy matched individuals: Determination of incretin effect, and the insulinotropic actions of to GIP and GLP-1 infusions during hyperglycemic clamp.
88820123|NCT06194955|Active Comparator|GLP-2R variant carrier|Individuals with GLP-2R variants: Determination of bone resorption marker levels (CTX) and response to GLP-2 infusions during fasting blood glucose levels
88820124|NCT06194955|Placebo Comparator|GLP-2R variant carrier control|Healthy matched individuals: Determination of bone resorption marker levels (CTX) and response to GLP-2 infusions during fasting blood glucose levels
88820125|NCT06194942|Experimental|Treatment Group|
88820126|NCT06194942|Sham Comparator|Control Group|
89423151|NCT02050893|Experimental|Propofol|Propofol infuse at a loading dose of 0.5mg/kg，and 0.5-2.0mg/kg.h maintenance dose to achieve Ramsay score of 4
89423152|NCT02050971|Active Comparator|Autologous cord blood transfusion|Treatment Group 1 Interventions: collected autologous whole cord blood at birth will be transfused for the preterm neonate
88904326|NCT01543854|Experimental|RLX030|RLX030 as intravenous infusion for 20 hours
89423153|NCT02050971|Sham Comparator|Standard treatment for neonatal anemia|Treatment Group 2 Interventions: transfusion of allogeneic whole peripheral blood or any of its components at a time of anemia of prematurity development
89423154|NCT03551782|Experimental|Cohort 1|Biomarker-negative or biomarker-unknown participants with adenocarcinoma (and not treatment-emergent small-cell neuroendocrine prostate cancer [t-SCNC]) who progressed on abiraterone acetate plus prednisone/prednisolone (AA-P) will be enrolled in this cohort. Participants will receive cetrelimab 480 milligram (mg) plus apalutamide 240 mg daily starting Cycle 1 (each cycle of 28 days).
89423155|NCT03551782|Experimental|Cohort 2|Biomarker-negative or biomarker-unknown participants with adenocarcinoma (and not t-SCNC) who progressed on apalutamide, darolutamide, or enzalutamide will be enrolled in this cohort. Participants will receive cetrelimab 480 mg plus apalutamide 240 mg daily starting Cycle 1.
89423156|NCT03551782|Experimental|Cohort 3|Biomarker-positive participants who progressed on AA-P will be enrolled in this cohort. Participants will receive cetrelimab 480 mg plus apalutamide 240 mg daily starting Cycle 1 (each cycle of 28 days).
89423157|NCT03551782|Experimental|Cohort 4|Biomarker-positive participants who progressed on apalutamide, darolutamide, or enzalutamide will be enrolled in this cohort. Participants will receive cetrelimab 480 mg plus apalutamide 240 mg daily starting Cycle 1 (each cycle of 28 days).
88904327|NCT01543854|Placebo Comparator|Placebo|Matching placebo as intravenous infusion for 20 hours.
88904328|NCT01543867||Users of somatropin|
88904329|NCT01543880||Users of somatropin|
88904330|NCT01543893|Experimental|Video instruction|"Participants will receive an elastic resistance tubing, an internet link and a poster with instructions to perform four different elastic resistance exercises Participants are encouraged to perform the exercises daily on weekdays during the next two weeks~Link to exercises: http://www.jobogkrop.dk/Ondt-i-muskler-og-led/Ondt-i-nakke-skulder-og-arm/Elastikoevelser-for-nakke-skulder-og-arm"
88904331|NCT01543893|Active Comparator|Personal instruction|"Participants will receive an elastic resistance tubing, an internet link and a poster with instructions to perform four different elastic resistance exercises Participants are encouraged to perform the exercises daily on weekdays during the next two weeks In addition to the video group, this group will also receive personal instruction during the two weeks.~Link to exercises: http://www.jobogkrop.dk/Ondt-i-muskler-og-led/Ondt-i-nakke-skulder-og-arm/Elastikoevelser-for-nakke-skulder-og-arm"
88904332|NCT01543906|Experimental|QLT091001|oral QLT091001 administered once daily for 7 days
88904333|NCT01543932|Experimental|Prasugrel standard dose|Patient will be randomized to this intervention will receive in the first time prasugrel and after 15 days and 30 days we will control the responsivness of the study drug.
88904334|NCT01543932|Experimental|high clopidogrel dose|Patient will be randomized to this intervention will receive in the first time the high clopidogrel dose and after 15 days and 30 days we will control the responsivness of the study drug.
88904335|NCT01543932|Experimental|Ticagrelor standard dose|Patient will be randomized to this intervention will receive in the first time ticagrelor and after 15 days and 30 days we will control the responsivness of the study drug.
88904336|NCT01543945|Experimental|Multimodal antiemetic management group|Multimodal antiemetic group : Low risk :no PONV prophylaxis moderate risk : ondansetron 4 mg iv high risk : dexamethasone 4 mg + ondansetron 4 mg Extremely high risk : dexamethasone 4 mg + ondansetron 4 mg + dimenhydrinate 1 mg
88904337|NCT01543945|Active Comparator|Control group|Control group: Low and moderate risk : no PONV prophylaxis High risk : Ondansetron 4 mg. iv Extremely high risk : Ondansetron 4 mg .iv
88904338|NCT01543971|Active Comparator|TXA127|(Group A) TXA127 at 300 mcg/kg once a day for 5 days
88904339|NCT01543971|Active Comparator|Neupogen|(Group B) Neupogen 10 mcg/kg once a day for 5 days
89423158|NCT03551782|Experimental|Cohort 5|Biomarker-negative participants with t-SCNC who progressed on treatment with AA-P, apalutamide, darolutamide, or enzalutamide will be enrolled in this cohort. Participants will receive cetrelimab 480 mg plus apalutamide 240 mg daily starting Cycle 1 (each cycle of 28 days).
89423159|NCT02806947|Experimental|Sirolimus|Sirolimus, a steroid-free therapy, will be administered after a diagnosis of standard-risk aGVHD is clinically established.
89423160|NCT02806947|Active Comparator|Prednisone|Prednisone, standard of care therapy for GVHD, will be administered after a diagnosis of standard-risk aGVHD is clinically established.
89423161|NCT03046732|Experimental|Explore Transplant Ontario|"Intervention 'Implementing Explore Transplant Education'"
89423162|NCT03046732|No Intervention|Control|The control arm (Usual Treatment) is at the Toronto General Hospital dialysis center.
88904340|NCT01543971|Active Comparator|TXA127 and Neupogen|(Group C) both TXA127 (300mcg/kg) and Neupogen (10mcg/kg) together once a day for 5 days
88904341|NCT01543984|Experimental|Tailored Physical Activity|"Health guidance (1,5h) and Tailored Physical Activity (3*50 min/week in 10 weeks)"
88904342|NCT01543984|Other|Reference group|Health Counselling (1,5h)
88904343|NCT01543997|Experimental|Mind-Body Bridging Program|The Mind-Body Bridging Program (MBBP) is an awareness training program (ATP)to help individuals improve their health condition and attain a state of well-being. Bridging is the primary technique that facilitates the healing process, by bringing one back to the present moment to experience thoughts, emotions and physical sensations. Bridging aims to reduce the impact of negative thought patterns that contribute to stress in the body.
88904344|NCT01543997|Active Comparator|Supportive Education|Supportive Education program will provide educational lectures on disability, sleep hygiene, and current research on depression and non-directive, supportive discussions about these topics.
88904345|NCT01544010|No Intervention|assessment only control group|Assessment at baseline, 12, and 24 months
88904346|NCT01544010|Active Comparator|Minimal Stage Tailoring|This group will receive a Stage-Tailored Manual at baseline. It will also get Stage Tailored Feedback Reports based on assessments at Baseline, 6, and 12 months. Outcomes will be assessed at 24 months.
88904347|NCT01544010|Active Comparator|Moderate TTM Tailoring|This group will receive a Stage-Tailored Manual at baseline. It will also get Moderate TTM-Tailored Feedback Reports, that is, integrated tailored feedback reports based on assessments of stage of change, decisional balance and temptations at Baseline, 6, and 12 months. Outcomes will be assessed at 24 months.
88904348|NCT01544010|Active Comparator|Full TTM tailoring|This group will receive a Stage-Tailored Manual at baseline. It will also get Full TTM-Tailored Feedback Reports, that is, integrated tailored feedback reports based on assessments of stage of change, decisional balance (pros + cons), temptations and (ten) processes of change at Baseline, 6, and 12 months. Outcomes will be assessed at 24 months.
88904349|NCT01544010|Active Comparator|Enhanced TTM+Addiction Tailoring|This group will receive a Stage-Tailored Manual at baseline. It will also get Enhanced TTM+Addiction Tailored Feedback Reports, that is, integrated tailored feedback reports based on assessments of addiction levels (# cigarettes/day) stage of change, decisional balance (pros + cons), temptations and (ten) processes of change at Baseline, 6, and 12 months. Outcomes will be assessed at 24 months.
88904350|NCT01544036|Experimental|Contrast Enhanced Ultrasound|Renal blood flow before and after exposure to iodinated contrast agent (perflutren) also known as Definity will be measured using contrast enhanced ultrasound (CEUS).
88904351|NCT01544049||Fallopian tube removal|Women who have had one or both fallopian tube(s) removed as method of ovarian cancer prevention.
88904352|NCT01544075|Experimental|PNE+PI|The interventional group who will receive the experimental PNE+PI treatment.
88904353|NCT01544075|Active Comparator|NS|The control group who will receive the neck school treatment.
88904354|NCT01544101|Experimental|Vegan Diet|
88904355|NCT01544101|Placebo Comparator|Supplement|
88904356|NCT01544140|Experimental|midazolam then midazolam + vandetanib|Midazolam alone followed by midazolam in combination with vandetanib
88904357|NCT01544192|Active Comparator|retinal nerve fiber thickness|
88904358|NCT01544192|Active Comparator|Mean Deviation|
88904359|NCT01544192|Active Comparator|Pattern Standard Deviation|
88904360|NCT01544192|Active Comparator|ganglion cell count|
88904361|NCT01544192|Active Comparator|c/d ratios|
88904362|NCT01544205|Experimental|Emotion network up-regulation|Participants use fMRI-based neurofeedback to train the upregulation of brain areas that respond to positive affective pictures (as identified during a functional localiser scan).
88904363|NCT01544205|Active Comparator|Place processing network up-regulation|Participants use fMRI-based neurofeedback to train the upregulation of brain areas that respond to place and house pictures (as identified during a functional localiser scan).
88904364|NCT01544218||YCMC|Youth ages 9-18 with one of four chronic medical conditions - asthma, diabetes, rheumatic or gastroenterologic conditions
88904365|NCT01544231||Patients|Adult patients with suspected rhabdomyolysis admitted to the participating University Hospital emergency rooms (see inclusion/exclusion criteria).
88904366|NCT01544244|Experimental|GSC physcial therapy|Patients included in this arm of the study will follow the Global Shoulder Concept physical therapy sequence.
88904367|NCT01544244|Active Comparator|Standard|Patients in this arm of the study will follow the standard physical therapy sequence.
88904368|NCT01544257|Experimental|OMT|patients under standard medical care plus OMT.
88904369|NCT01544257|No Intervention|Control|patients under standard medical care plus only osteopathic evaluation
88904370|NCT01544270|Active Comparator|Study product containing milk proteins|Yoghurt-like milk-based product
88904371|NCT01544270|Active Comparator|Study product containing probiotics|Yoghurt-like milk-based product
88904372|NCT01544270|Placebo Comparator|Control product|Yoghurt-like milk-based product without supplemented nutrients
88904373|NCT01544283|Experimental|Patch|Patch will be applied directly to the lateral tip of the affected shoulder, at the site of maximal tenderness. Subjects will apply a single patch at home approximately every 12 hours (e.g., morning and evening patch applications) for 14 days. Subjects will remove each patch after 4 hours. Subjects will have the option of applying the Synera patch as needed for an additional 2 week period (weeks 2-4) if they feel their shoulder impingement pain is severe enough to warrant treatment. Patches will be applied every 12 hours for up to 4 hours as needed during this period.
88904374|NCT01544283|Active Comparator|Subacromial Injection|A single injection will be administered into the subacromial space utilizing triamcinolone acetonide at the baseline visit.
88904375|NCT01544296|Experimental|KHK6188, high dose|
88904376|NCT01544296|Experimental|KHK6188, low dose|
88904377|NCT01544296|Placebo Comparator|Placebo|
88904378|NCT01544374|Experimental|Tracking & Feedback|Systems based intervention tracking oncology consultations and feeding back information to surgeons
88904379|NCT01544374|No Intervention|Control- no intervention|Usual Care
88904380|NCT01544387|Other|Bed Rest|Subjects will have limited activity. Bed Rest
89195516|NCT00822705|Active Comparator|ORAL GLP-1, TABLET|
88904381|NCT01544387|Other|Activity|Activity
89195517|NCT00822705|Active Comparator|Oral PYY3-36|
89195518|NCT00822705|Active Comparator|Oral GLP-1 plus oral PYY3-36|
89195519|NCT00822705|Placebo Comparator|4|
89195520|NCT00822783|Active Comparator|Omalizumab|
89195521|NCT00822783|Placebo Comparator|Placebo|
89195522|NCT00816933|Experimental|one port|Patients undergo one port appectomy. Skin incision about 2cm size is made upon umbilicus and dissection is performed to make opening. Then, wound retractcor(Alexis) is iserted on opening site and wound is extended. Rubber glove built-in three 5mm trocars is applied over wound retractor. Pneumoperitoneum is achieved via trocar and appendectomy is performed. After appendectomy, wound is repaired.
89195523|NCT00816933|Active Comparator|Three ports|"Paitents will undergo three port appendectomy. 10 mm trocar is inserted on umbilicus, and two 5mm trocas is inserted low abdomen, left flank respectively.~Appendectomy is performed vis these trocas. After operation, wounds are repaired."
88820127|NCT06194916|Experimental|education group|A 4-week web-based self-management training will be administered to epilepsy patients in the experimental group.
89423163|NCT03442114|Experimental|Hydroxyurea SDM Toolkit (H-SDM)|During the H-SDM toolkit condition, sites will develop methods for identifying Eligible Patients & Monitoring Progress, have the opportunity to use Implementation Tools, and will use the Visit Decision Aids. The H-SDM toolkit has four visit decision aids to support parents in their decision about hydroxyurea: pre-visit brochure, in-visit issue card, after-visit booklet and video narratives {videos of parents telling their story about how they made a decision about hydroxyurea).
89423164|NCT03442114|Active Comparator|Clinician Pocket Guide|In this condition, sites will provide current guidelines for offering hydroxyurea and use the American Society of Hematology (ASH) pocket guide as a reference. ASH developed 'The Hydroxyurea and Transfusion Therapy for the Treatment of Sickle Cell Disease' clinician pocket guide based on the National Heart, Lung, and Blood Institute's Evidence Based Management of Sickle Cell Disease: Expert Panel Report, 2014.'
89423165|NCT03562065|Experimental|mesenchymal stem cells|"Phase I-II, Allogeneic Umbilical Cord derived-MSCs injected by slow intravenous infusion according to the weight of the recipient and patient groups in the study, at doses of:~1.10^6 CSM / kg~2.10^6 CSM / kg~4.10^6 CSM / kg 1 injection during 30min to 1h by Intravenous infusion"
89423166|NCT04870684||sucess of revascularization|group of patients for whom after thrombolysis neurological improvement will be observed and recanalization on imaging will be seen.
89423167|NCT02037399|Experimental|intravenous dexamethasone|To receive intravenous dexamethasone (0.15 mg/kg) immediately after ESD
89423168|NCT02037399|Placebo Comparator|intravenous normal saline|To receive normal saline as placebo intravenous immediately after ESD
89423169|NCT03561753|Active Comparator|Group A (the standard 2HRZE/4HR regimen)|Group A, Standard Regimen (2EHRZ/4HR): Control group, use the standard six-month regimen with eight weeks of daily treatment with isoniazid, rifampin, ethambutol, and pyrazinamide followed by sixteen weeks of isoniazid and rifampin.
89195524|NCT00634647|Experimental|Satraplatin|satraplatin - 80 mg/m^2 days 1-5 of every 35 day cycle prednisone - 5 mg twice daily every 35 days
89423170|NCT03561753|Experimental|Group B (New short course PRS regimen, 4EZ(high dose)PtoCfz)|Group B, PRS Regimen (4EZ [high dose] Cfz Pto): Experience group，use the PRS regimen is 4 months of daily Cfz, Emb, Pto, and high dose pyrazinamide, dosed by weight.
89423171|NCT02260089|Experimental|Low dose of telmisartan|4 week placebo run-in phase followed by 6 weeks of treatment with low dose of telmisartan
89195525|NCT00576732|Experimental|001|Risperidone low dose Risperidone oral solution 0.125 mg (if <45 kg) or 0.175 mg (if >=45 kg) qd or bid for 6 weeks
89423172|NCT02260089|Experimental|High dose of telmisartan|After 6 weeks of treatment with low dose of telmisartan, titration to high dose of telmisartan if blood pressure level is higher than 140/90 mm Hg
89423173|NCT02049177||Head and Neck Cancer Cases|Cases of Head and Neck Cancer identified in North West England in 2002/2003. Observational study - no intervention other than usual care.
89423174|NCT02049255|Placebo Comparator|Marcaine|Rachianesthesia with marcaine or chloroprocaine
89423175|NCT02049255|Active Comparator|Chloroprocaine|Rachianesthesia with marcaine or chloroprocaine
89423176|NCT02049333|Active Comparator|Phacoemulsification|Cataract extraction alone
88820128|NCT06194916|Active Comparator|Control Group|routine interventions
88820129|NCT06194890|No Intervention|Control group|"When the patients are admitted, their written consent will be obtained and personal information forms and the Visual Comparison Scale (VAS) pain scale will be applied to all participants. VAS pain scale will be applied to both groups during the active phase of labor with 6-8 cm dilatation and 8-10 cm dilatation phases. At the end of the labor, the Birth Satisfaction Scale Short Form will be applied to both groups."
88820130|NCT06194890|Experimental|Intervention group|"When the patients are admitted, their written consent will be obtained and personal information forms and the Visual Comparison Scale (VAS) pain scale will be applied to all participants.~Women in the experimental group will watch a 15-20 minute video with comedy content during the active phase of the action (4-6 cm dilation), and no intervention will be made to women in the control group.~VAS pain scale will be applied to both groups during the active phase of labor with 6-8 cm dilatation and 8-10 cm dilatation phases. At the end of the labor, the Birth Satisfaction Scale Short Form will be applied to both groups."
88820131|NCT06194851|Experimental|Brief Cognitive Behavioral Conjoint Therapy for PTSD plus Intranasal Oxytocin|Couples will receive Brief Cognitive-Behavioral Conjoint Therapy (bCBCT) weekly. Prior to each session, the veteran participant will self-administer intranasal oxytocin.
88820132|NCT06194851|Placebo Comparator|Brief Cognitive Behavioral Conjoint Therapy for PTSD plus Intranasal Placebo|Couples will receive Brief Cognitive-Behavioral Conjoint Therapy (bCBCT) weekly. Prior to each session, the veteran participant will self-administer intranasal placebo solution.
88820135|NCT06194812|Other|İNTERVENTİON|The surveys in the study will be applied to the patients in this group and initial and final measurements will be taken.
88820136|NCT06194799|Experimental|ACP-204|ACP-204 30mg or 60mg
88820137|NCT06194773|Experimental|Totalfil|
88820138|NCT06194773|Experimental|NeoSealer|
88820139|NCT06194773|Active Comparator|AH-Plus|
88820140|NCT06194760|Other|myopic eyes with macular hole and only posterior retinal detachment|
88820141|NCT06194747|No Intervention|Baseline phase|During this arm, sites will provide routine care.
88820142|NCT06194747|Experimental|Adoption phase|Following the dissemination visit, sites will actively work to implement the bundle of interventions.
88820143|NCT06194747|Experimental|Sustain phase|During this arm, sites will actively work to sustain the implemented interventions and will be allowed to develop site-specific plan-do-study-act cycles in order to address site-specific key drivers with central data and methodological support.
88820144|NCT06194747|Experimental|Independent phase|During this arm, sites will continue to sustain the implemented interventions and develop site-specific plan-do-study-act cycles in order to address site-specific key drivers without central data and methodological support.
88820145|NCT06194734|Experimental|KC1036|KC1036 will be administrated.
88820146|NCT06194734|Active Comparator|Investigator's choice of chemotherapy|Irinotecan, Docetaxel or S-1 will be administrated.
88820147|NCT06194721|Experimental|Cryotherapy|
89423177|NCT02049333|Experimental|Phacoemulsification with Endoscopic Cycloplasty (ECPL)|Cataract extraction combined with endoscopic cycloplasty
89423178|NCT02806713|Placebo Comparator|no phenazopyridine|Patients not receiving phenazopyridine (standard of care)
89423179|NCT02806713|Experimental|phenazopyridine|Patients receiving phenazopyridine
89423180|NCT02051517||Vitrectomy|Subjects expected to have normal vitreous, undergoing vitrectomy surgery for medically indicated reasons.
89423181|NCT02037711|Active Comparator|Chirocaine group (levobupivacaine )|
89423182|NCT02037711|Sham Comparator|Control group|
89423183|NCT03561675|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
89423184|NCT03561675|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m.
89195526|NCT00576732|Experimental|002|Risperidone high dose Risperidone oral solution 1.25 mg (if <45 kg) or 1.75 mg (if >=45 kg) qd or bid for 6 weeks
89423185|NCT02051049||Inborn errors of liver metabolism|
89423186|NCT02049411|Experimental|Ketamine group|Ketamine: (dose 0.3 mcg/kg) included in physiological solution at 0.9% (250 ml) during 2 hours, intravenously.
89423187|NCT02049411|Sham Comparator|physiological solution|Control group: only physiological solution at 0.9% (250 ml) during 2 hours, intravenously.
89423188|NCT02807493|Experimental|Occlusal Support Device|Support device for women in labor
89423189|NCT02807493|Placebo Comparator|Control|No device given for women in labor
89423190|NCT02051127|Experimental|Exercise|Physical training Duration: 45-60 minutes Frequency: 3 times per week Intensity: mean heart rate > 75% of maximum heart rate determined by exercise test before start of the intervention
89423191|NCT02051127|No Intervention|Control|Instructed to continue with their sedentary behavior for another 6 months.
89423192|NCT02049489|Experimental|ICT-121 DC vaccine|Autologous dendritic cells pulsed with peptide antigens
89423193|NCT02051751|Experimental|BYL719 and paclitaxel|All patients enrolled in the study will receive BYL719 once daily plus weekly paclitaxel
89423194|NCT02049567|Experimental|FluidVision|FluidVision AIOL implanted in the capsular bag of the eye during cataract surgery
89423195|NCT02051829||All patients|Comparison of the four screening score
89423196|NCT02051907|Experimental|KAM1403 Gel|A group treated with KAM1403 for the study period.
89423197|NCT02051907|Sham Comparator|Aloevera Gel|A group treated with Aloevera Gel for the study period
88820148|NCT06194721|Active Comparator|Room temperature|
88820149|NCT06194708||Mid-low rectal cancer patients with temporary stoma after radical surgery|
88820150|NCT06194656|Experimental|Experimental group|Experimental group in part one. It will be 10mg/kg or 15mg/kg of SIBP-03. It will determine whether a 15mg/kg dose study is necessary based on actual research results.
88820151|NCT06194656|Experimental|Group A|Experimental group in part two. Its dose will be determined by results of study part one, and the tentative dose is 10mg/kg.
88820152|NCT06194656|Placebo Comparator|Group B|Placebo of SIBP-03 (SIBP-03 solvent without HER3 antibody), and the dose will be the same with group A.
88820153|NCT06194643||Pregnant people at high risk of preeclampsia (case group)|Investigators will collect a sample of blood (up to 50ml) at the time of a previously scheduled visit as part of routine prenatal care. Platelet phenotyping, measuring platelet activity, and the platelet transcriptome will be performed on samples. Plasma, serum, whole blood RNA and DNA will be collected.
88820154|NCT06194643||Pregnant people at low risk of preeclampsia (control group)|Investigators will collect a sample of blood (up to 50ml) at the time of a previously scheduled visit as part of routine prenatal care. Platelet phenotyping, measuring platelet activity, and the platelet transcriptome will be performed on samples. Plasma, serum, whole blood RNA and DNA will be collected.
88820155|NCT06194630|Experimental|68Ga-A3|Within 1 week, each participant underwent PET/CT scan after intravenous administration of 68Ga-A3
88820156|NCT06194617||Patients with pulmonary embolism and using direct oral anticoagulants|Patients with pulmonary embolism and using direct oral anticoagulants
88820157|NCT06194578|Experimental|Subcutaneous Infusion of Sterile Saline|Participants will receive sterile saline subcutaneous infusion administered into abdomen and/or anterior thigh through various sizes of needles at various volume and rate of delivery at Visit 1.
88820158|NCT06194565|Experimental|99mTc-ABH2 SPECT/CT|The patients will be injected with 5.55 to 7.4 MBq per kilogram body weight of 99mTc-ABH2 in one dose intravenously and undergo SPECT/CT scan 1h to 2h later.
88820159|NCT06194552|Experimental|NTRX-07 Low Dose Normal Volunteers|NTRX-07 administered orally once per day for 7 days
88820160|NCT06194552|Experimental|NTRX-07 Mid Dose Normal Volunteers|NTRX-07 administered orally once per day for 7 days
89423198|NCT02049723||Patients with GERD|The knowledge level on GERD among Korean patients with gastroesophageal disease was evaluated by the method of multicenter survey
89423199|NCT02049801|Experimental|Treatment (MEK inhibitor, MEK162, idarubicin, cytarabine)|"INDUCTION THERAPY: Patients receive MEK inhibitor MEK162 PO BID on days -4 to -1 and days 5-18, cytarabine IV continuously over 24 hours on days 1-4, and idarubicin IV over 1 hour on days 1-3. Patients may receive a second course of induction at the discretion of the principal investigator.~POST-REMISSION THERAPY: Patients receive cytarabine IV continuously over 24 hours on days 1-3, idarubicin IV over 1 hour on days 1 and 2, and MEK inhibitor MEK 162 PO BID on days 4-17. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity."
89423200|NCT02049879|Experimental|Injection|Corticosteroids injection
89423201|NCT02051283||patients with HCC eligible for RFA|patients with HCC eligible for RFA
89423202|NCT02051361||Clopidogrel treated patients|Patients pre and post operatively following stent implantation treated with clopidogrel and aspirin
89423203|NCT02053311|Active Comparator|Arm A: Orteronel|300mg orteronel twice daily and best supportive care until disease progression
89423204|NCT02053311|Active Comparator|Arm B: Placebo|Placebo twice daily and best supportive care until disease progression
88904382|NCT01544413|Experimental|Laparoscopic sentinel lymph node biopsy|This is a single armed study. After endoscopic marking using Tc99m HSA and indocyanine green fluid, Laparoscopic sentinel lymph node biopsy was performed and evalute at backtable.
89536077|NCT03212677|Experimental|Adult Ferrous sulfate daily|Iron-replete postmenopausal women, and men, receiving ferrous sulfate daily (containing 60 mg Fe per day) for 4 weeks. In Phase II, iron-replete postmenopausal women, and men, receiving ferrous sulfate daily (containing 120 mg Fe per day) for 4 weeks.
88904383|NCT01544439|Experimental|Oral stabilization appliance,counselling|The reversible occlusal therapy by stabilizing appliance used by patients in Study Group shall be made by the same dental technician and will be adjusted by the same dentist, therapist represented by the researcher. Will be played simultaneous occlusal contacts in centric relation position and malocclusion by canine and protrusive guides. Patients receive oral and written instructions about self-care (counseling), including, in addition to instructions on their condition of TMD and an explanation of the possible factors that contribute to the etiology of the same.
88904384|NCT01544439|Placebo Comparator|Non-occluding splint, counselling|The non-occlusive splint (placebo) will also be made by the same dental technician. They differ by the plates did not interfere with the occlusal tooth gear, ie, do not alter the position of closing jaws. As not lead acrylic on the occlusal surfaces of teeth, adequate retention is given by an arch wire in orthodontic buccal surface of teeth. All patients will submitted a counseling approach / self-care. Patients receive oral and written instructions about self-care, including, in addition to instructions on their condition of TMD and an explanation of the possible factors that contribute to the etiology of the same.
88904385|NCT01544452|Other|Total preoperative MR evaluation|Total diagnostic evaluation with MRI of the liver, abdomen, colonography and rectum in one session combined with CT thorax
88904386|NCT01544452|Other|Standard diagnostic evaluation|Standard preoperative diagnostic evaluation for patients with rectal cancer, incl. CT thorax, abdomen and MRI of the rectum and colonoscopy
88904387|NCT01544465|Experimental|Structured physical activity|Rehabilitation evaluation followed by physical therapy for approximately 8 weeks
88904388|NCT01544465|Active Comparator|Sleep hygiene education|Sleep hygiene education consists of educational materials on insomnia published by the American Academy of Sleep Medicine.
88904389|NCT01544504|Experimental|Norepinephrine|Topical norepinephrine
88904390|NCT01544517|Experimental|5d-QCT|5-day eradication regimen consisting in the concomitant administration of esomeprazole 40mg bid + amoxicillin 1g bid + levofloxacin 500mg bid + tinidazole 500mg bid
88904391|NCT01544517|Active Comparator|10-day sequential regimen|5 days of esomeprazole 40mg bid + amoxicillin 40mg bid followed by 5 more days of esomeprazole 40mg bid + levofloxacin 500mg bid + tinidazole 500 mg bid
88904392|NCT01544530|Experimental|Hypothermia (32-33 degree C)|Following randomization, hypothermia will be induced by a combination of cold isotonic fluid and sustained until organ procurement by a central venous catheter
88904393|NCT01544530|No Intervention|Normothermia (36.5 - 37.5 degree C)|Normothermia will be maintained until organ procurement as per current standard of care
88904394|NCT01544543||COPD Exacerbation Cohort|Patients hospitalized for a COPD exacerbation
88904395|NCT01544556||Prineo|An open, prospective, controlled, randomized clinical Study
88904396|NCT01544556||Steristrips|An open, prospective, controlled, randomized clinical Study
88904397|NCT01544608||Subjects who are hospitalized due to acute psychotic episode.|All subjects who are hospitalized due to acute psychotic episode. The subjects should be managed according to normal clinical practice until discharge time.
88904398|NCT01544621||Successful quitters Sustained smokers|Successful quitters
88904399|NCT01544634|Experimental|Propranolol + Low dose Qvar|
88904400|NCT01544634|Active Comparator|Placebo + high dose Qvar|
88904401|NCT01544647|Active Comparator|Usual spa protocol|4 treatments (massages, showers, mud and pool sessions) are provided 6 days a week during 3 weeks.
88904402|NCT01544647|Active Comparator|Active spa protocol|4 treatments (massages, showers, mud and pool sessions) are provided 3 days a week during 3 weeks then patients will follow an exercise program 3 days a week during 3 week.
88904403|NCT01544660||Scanning|no treatment
88904404|NCT01544660||scanning|no treatment
88904405|NCT01544673|Active Comparator|Arm A|
88904406|NCT01544673|Placebo Comparator|Arm B|
88904407|NCT01544686|Active Comparator|3M™ Tegaderm CHG IV|Patients receive the 3M Tegaderm CHG IV securement dressing after placement of a central venous catheter.
88904408|NCT01544686|Placebo Comparator|3M™ Tegaderm™ Advanced IV'|Patients receive the 3M Tegaderm Advanced IV securement dressing after placement of a central venous catheter.
88904409|NCT01544712|Active Comparator|Control|Core decompression
88904410|NCT01544712|Experimental|Bone marrow|core decompression plus autologous concentrated bone marrow
88904411|NCT01544725|Experimental|Ketamine-propofol|
88904412|NCT01544725|Active Comparator|Ketamine alone|
88904413|NCT01544738|Experimental|Aponeurotic stimulation group|The stimulation consisted of manipulating, with a hook (the diacutaneous fibrolysis method), the aponeurotic tissues enrobing the heads of the trunk and upper limb muscles.
88904414|NCT01544738|Active Comparator|Placebo stimulation group|Placebo stimulation (PS) consisted of manipulating the skin along the same paths over the trunk, shoulder and arm muscles that were the targets for treatment in the Aponeurotic stimulation group.
88904415|NCT01544751|Active Comparator|Low dose Metformin|500 mg twice a day for one year
88904416|NCT01544751|Active Comparator|Metformin|1000 mg twice a day for one year
88904417|NCT01544751|Active Comparator|Atorvastatin|20 mg day
88904418|NCT01544764|No Intervention|Control|This arm includes 30 health centers in North Carolina with at least 200 adolescent (age 11-18) patients. Practices in this arm were randomly assigned to receive no AFIX visit.
88904419|NCT01544764|Experimental|AFIX In-Person Visit|"This arm includes 30 health centers in North Carolina with at least 200 adolescent (age 11-18) patients. These practices received an in-person AFIX visit from a North Carolina Immunization Branch employee.~Intervention:~Other: Assessment , Feedback, Incentives, and eXchange Program"
89195527|NCT00576732|Placebo Comparator|003|Placebo Oral solution qd or bid for 6 weeks
89195528|NCT02550639|Active Comparator|A1-prophylaxis group,positive elispot test|POSITIVE ELISPOT TEST, PROPHYLAXIS GROUP (CMV PROPHYLAXIS)
89423205|NCT02051439|Other|Valsava|The patients were randomized to 2 groups. The first group performed conventional Valsava before balloon assisted Valsava. The second group performed balloon assisted Valsava before conventional Valsava for venous reflux examination by duplex scan.
89423206|NCT02807259|Experimental|Multi-level intervention|This is a cluster-randomised controlled trial design. The unit of randomisation is village.
88904420|NCT01544764|Experimental|AFIX Webinar Visit|"This arm includes 31 health centers in North Carolina with at least 200 adolescent (age 11-18) patients. These practices received a webinar during which a North Carolina Immunization Branch employee completed the components of an AFIX visit.~Intervention:~Other: Assessment , Feedback, Incentives, and eXchange Program"
89423207|NCT02807259|Other|Control|The intervention will rolled out to all participating villages after 24 months.
89423208|NCT02053389|Experimental|DVD Decision Aid|"Eligible participants receive the written decision aid (Making the Choice: Deciding What to Do About Early Stage Prostate Cancer) AND the DVD decision aid (Discussing the Choice: Talking with your Doctor about Early Stage Prostate Cancer), which provides instruction and recommendations on how to participate in shared decision making with one's physician."
89423209|NCT02053389|Active Comparator|Written Decision Aid|"Eligible participants receive the written decision aid (Making the Choice: Deciding What to Do About Early Stage Prostate Cancer) alone."
89423210|NCT02053467|Experimental|eConsult|Physicians randomized to the intervention will have access to the Champlain BASE eConsult service right away (pending completion of an orientation session)
89195529|NCT02550639|Experimental|A2- preemptive group,positive elispot test|POSITIVE ELISPOT TEST, PREEMPTIVE GROUP (NO CMV PROPHYLAXIS)
89195530|NCT02550639|Active Comparator|B1- prophylaxis group,negative elispot test|NEGATIVE ELISPOT TEST, PROPHYLAXIS GROUP (CMV PROPHYLAXIS)
89423211|NCT02053467|No Intervention|Control|Physicians randomized to the control group will use their standard referral practices for one year after randomization and only then will be given the option to use eConsult.
89423212|NCT02053545|Experimental|Conditioning Regimen & GVHD Prophylaxis|"Stratum 1 (Refractory disease, relapse after previous transplant): Clofarabine, Melphalan,Thiotepa, Cyclophosphamide, Mesna, Tacrolimus and mycophenolate mofetil (MMF)~Stratum 2 (Myeloid in remission): Busulfan, Fludarabine, Thiotepa, Cyclophosphamide, Mesna, Tacrolimus, MMF~Stratum 3 (Lymphoid in remission): Fractionated total body irradiation (fTBI), Fludarabine, Thiotepa, Cyclophosphamide, Mesna, Tacrolimus, MMF"
89423213|NCT02051985|Experimental|Aerobic exercise training|
89423214|NCT02051985|Active Comparator|Standard physical therapy|
89423215|NCT02802345|Experimental|Nintedanib + placebo matching sildenafil|
88904421|NCT01544777|Experimental|Both Eyes|Model 751 IOL implanted in both eyes.
88904422|NCT01544777|Experimental|Single eye|Model 751 IOL in one eye
88904423|NCT01544777|Active Comparator|Control|Aphakia treatment by negatively aspheric IOL implant, Hoya iSert model 251 or equivalent
88904424|NCT01544790|Experimental|Robot-assisted esophagectomy|Robot-assisted thoraco-laparoscopic esophagectomy with gastric conduit formation.
88904425|NCT01544790|Active Comparator|Open transthoracic esophagectomy|traditional open transthoracic esophagectomy with gastric conduit formation.
88904426|NCT01544803|No Intervention|Control group|
89423216|NCT02802345|Active Comparator|Nintedanib + Sildenafil|
89423217|NCT02052063|Experimental|Surgery|Patient who undergone stapled transanal rectal resection for rectocele. Anal compliance will be evaluated before and starting the surgery using endoflip system
89423218|NCT02053779|Experimental|GnRH-agonist|Experimental Arm: Triptorelin 0.1 mg
89423219|NCT02053779|No Intervention|Control Arm|Control Arm: No intervention
88904427|NCT01544803|Experimental|Web based self-monitoring|
88904428|NCT01544803|Active Comparator|Web based self-help|
88904429|NCT01544816|Placebo Comparator|Control Food Product|Control food product
88904430|NCT01544816|Experimental|Experimental Food Product 1|Experimental food product 1
88904431|NCT01544816|Experimental|Experimental Food Product 2|Experimental food product 2
88904432|NCT01544829|Active Comparator|Active Comparator: Single serving of theobromine|
88904433|NCT01544829|Active Comparator|Multiple servings of theobromine|
88904434|NCT01544829|Placebo Comparator|Placebo capsules|
89195531|NCT02550639|Experimental|B2- preemptive group,negative elispot test|NEGATIVE ELISPOT TEST, PREEMPTIVE GROUP (NO CMV PROPHYLAXIS)
89195532|NCT00822861|Experimental|Dose level No.1|TPI ASM8 1 mg BID
89195533|NCT00822861|Experimental|Dose level No.2|TPI ASM8 2 mg BID
89195534|NCT00822861|Experimental|Dose level No.3|TPI ASM8 4mg BID
89195535|NCT00822861|Experimental|Dose level No.4|TPI ASM8 8 mg Die
89195536|NCT05180370||Outpatient or inpatient diagnosed with Heart Failure at least 6 months ago|ADAPTATION HF is a prospective, observational, cross-sectional, multicenter, survey-based study. Patients who applied to the cardiology outpatient clinic with a preliminary diagnosis of HF or were hospitalized for HF and had a diagnosis of HF for at least 6 months will be included in the study.
89195537|NCT00817011|Experimental|SSRI treated group|SSRI treated group are depressive patients treated with fluoxetine, paroxetine, citalopram or sertraline
89195538|NCT00817011|Active Comparator|non-SSRI treated group|non-SSRI treated group are depressive patients treated with venlafaxine, nortriptyline, bupropion, duloxetine, trazodone or mirtazapine
89195539|NCT04061460|Other|non smokers|patient who never smoked
89195540|NCT04061460|Other|former smoker|patient who smoked in the past
89195541|NCT04061460|Other|smoker|patient who still smoke
89423220|NCT02801877|Experimental|IntelliCare Hub recommender, coach|Participant is randomly assigned to receive the IntelliCare Hub App with the recommender system, and receive coaching for the 8 week IntelliCare program.
89423221|NCT02801877|Experimental|IntelliCare Hub recommender, no coach|Participant is randomly assigned to receive the IntelliCare Hub App with the recommender system, and independently use the IntelliCare program for 8 weeks.
89423222|NCT02801877|Experimental|IntelliCare Hub no recommender, coach|Participant is randomly assigned to receive the IntelliCare Hub App without the recommender system, and receive coaching for the 8 week IntelliCare program.
89423223|NCT02801877|Experimental|IntelliCare Hub no recommender, no coach|Participant is randomly assigned to receive the IntelliCare Hub App without the recommender system, and independently use the IntelliCare program for 8 weeks.
88904435|NCT01544842|Active Comparator|Tacrolimus|Tacrolimus ointment 0.1%, three times a day for 6-9 weeks.
89536078|NCT03212677|Experimental|Adult ferrous sulfate weekly|Iron-replete postmenopausal women, and men, receiving ferrous sulfate weekly (containing 60 mg Fe per day) for 4 weeks.
88904436|NCT01544842|Active Comparator|Triamcinolone|Triamcinolone paste 0.1%, three times a day for 3-6 weeks.
88904437|NCT01544842|Placebo Comparator|Placebo|Orabase paste, three times a day for 3-6 weeks.
89195542|NCT00823017|Experimental|1|Patient-preferred music
88820161|NCT06194552|Experimental|NTRX-07 High Dose Normal Volunteers|NTRX-07 administered orally once per day for 7 days
89195543|NCT00823017|Experimental|2|Relaxation Music
89536079|NCT03212677|Experimental|Adult ferrous sulfate + micronutrient|Iron-replete postmenopausal women, and men, receiving ferrous sulfate + micronutrient supplement (containing 60 mg Fe per day) for 4 weeks.
89536080|NCT03212677|Experimental|Adult IHAT|Iron-replete postmenopausal women, and men, receiving IHAT (containing 60 mg Fe per day) for 4 weeks. In Phase II, iron-replete postmenopausal women, and men, receiving IHAT (containing 120 mg Fe per day) for 4 weeks
88820162|NCT06194552|Experimental|NTRX-07 High Dose Alzheimer's Participants|NTRX-07 administered orally once per day for 7 days
88820163|NCT06194552|Placebo Comparator|Placebo Control|Placebo administered orally once per day for 7 days
88820164|NCT06194552|Experimental|Mid Dose Fed|NTRX-07 administered orally once with high fat meal
88820165|NCT06194513|Experimental|Intervention 1: Twice a day for 1 week PIOMI|Mothers of preterm babies in this group who have oral feeding difficulties will be taught Oral Motor Intervention (PIOMI) and asked to apply it. During the applications, visual monitoring of the application will be provided via video call, and objective monitoring of the application will be provided with the PIOMI Reliability Assessment Tool.
88820166|NCT06194513|Experimental|Intervention 2: Once a day for 2 weeks PIOMI|Mothers of preterm babies in this group who have oral feeding difficulties will be taught Oral Motor Intervention (PIOMI) and asked to apply it. During the applications, visual monitoring of the application will be provided via video call, and objective monitoring of the application will be provided with the PIOMI Reliability Assessment Tool.
88820167|NCT06194513|No Intervention|Control|In the control group, no extra intervention will be given to preterm babies who have difficulty in oral feeding, and oral activation will be provided only with a pacifier.
88820170|NCT06194474||Delirium Group|
88820171|NCT06194474||No Delirium Group|
88820172|NCT06194435|Experimental|Telemedicine Group: Remote Assessments and Asynchronous Exercise Guidance|For the Telemedicine Group, the study initiates with a video call from the physician on day one via FaceTime or WhatsApp. During these calls, patients will receive guidance and complete Quick-DASH questionnaire and numeric-VAS scale. On the same day, they will also receive an exercise video and an exercise diary via WhatsApp. Follow-up video calls on the 7th day will serve as reminders and allow patients to ask questions. The final video call, scheduled for the 15th day, will involve completing the same questionnaire and scale. After this last remote interaction, patients will send photos of their completed exercise logs to the physician via WhatsApp for adherence tracking.
88820173|NCT06194435|Active Comparator|Control Group: In-Person Assessments in Clinic and Exercise Brochure|For the Control Group, the study begins with an in-person visit to the physician on day one. During this visit, patients will receive guidance, complete Quick-DASH questionnaire and numeric-VAS scale, and be provided with an exercise brochure. Additionally, patients will receive an exercise diary on the same day to record their exercise sessions. Follow-up visits to the physician's office at the hospital on the 7th day will serve as reminders and opportunities for patients to ask questions. On the 15th day, patients will revisit the hospital to complete the same questionnaire and scale. We will also assess the time spent and economic burden associated with hospital visits. Furthermore, exercise diaries will be collected for adherence tracking and progress evaluation.
88820174|NCT06194370|Experimental|BOPPPS Teaching Model Group|BOPPPS: Bridge-in,Objective,Pre-assessment,Participatory learning,Post-assessment,Summary
88820175|NCT06194370|Placebo Comparator|Regular Teaching Group|
88820176|NCT06194357|Experimental|Intervention group|Intervention group will receive training on Qigong exercise and mindfulness.
88820177|NCT06194357|No Intervention|Control group|Control group will not receive intervention.
88820178|NCT06194240|Experimental|Slow ACT|This group will follow an intervention online based on Acceptance and Commitment Therapy (ACT).
88820179|NCT06194240|Experimental|Slow Diabète|This group will follow an online Slow Diabète (Slow Diabetes) program created by the French Federation of Diabetics.
88820180|NCT06194240|No Intervention|No program|This group will not follow an online program, in order to do the comparaison.
88820181|NCT06194214|Experimental|Pirtobrutinib|Pirtobrutinib in multiple oral doses will be administered on Days 8 through Day 16.
88820182|NCT06194214|Experimental|Digoxin|Digoxin will be administered from Day 1 to Day 16.
88820183|NCT06194201|Experimental|HRS9432|
88820184|NCT06194201|Active Comparator|Caspofungin Acetate for Injection|
88904438|NCT01544855|Experimental|APOE4 carriers|The results obtained for APOE4 carriers will be compared to the one obtained from APOE4 non-carriers. Carriers are defined as being at least carrier of one APOE4 allele.
89195544|NCT00823017|Placebo Comparator|3|Standard of Care
88904439|NCT01544868|Other|Energy expenditure measurement|Descriptive measurements
88904440|NCT01544881|Experimental|TI Inhalation Powder|Technosphere Insulin Inhalation Powder using the Gen2C inhaler
89195545|NCT00823173|Experimental|Topical ESBA105|ESBA105 applied as eye drops
89423224|NCT02056041||Hepatectomy for HCC|Patients submitted to surgery for HCC
89423225|NCT02053857|Active Comparator|RUTF|Standard RUTF at a dose of 175 kcal/kg/d
89423226|NCT02053857|Experimental|RUTF-P|RUTF fortified with polyunsaturated fatty acids (PUFA) at a dose of 175 kcal/kg/d
89423227|NCT02053935|Other|Dopamine|All patients will receive the same intervention.
89423228|NCT02037867||Patients|"Patients identified with one of the below chronic liver disease risk factors and undergoing community liver disease stratification using fibrosis biomarkers:~Hazardous alcohol use (>14 units per week in females, >21 units per week in males, alcohol AUDIT score >=8 or read code relevant to alcohol abuse on GP system)~Type 2 Diabetes~Obesity~Persistently raised serum ALT level, negative liver serology, and absence of above 2 risk factors"
88904441|NCT01544881|Active Comparator|RAA|Rapid Acting Analog
88904442|NCT01544894|Active Comparator|raloxifene|60 mg/d for one year.
88904443|NCT01544894|Active Comparator|strontium ranelate|2 g/d for one year.
88904444|NCT01544907|Active Comparator|Conventional PTA only|"Treatment Arm 1- Conventional PTA only~The conventional balloon is used and the diameter of the balloon should be the same or oversized by 1mm the diameter of the reference vessel.~An inflation device with a pressure gauge is used to inflate up to manufacturers' stated burst pressure. The duration of balloon inflation will be 2 minutes.~At the end of the first angioplasty, an AVFistulogram/AVGraftogram will be obtained to document results. If there is residual stenosis of >30%, a repeat angioplasty using the same balloon or another appropriately oversized balloon by 1mm will be used for an additional 2 minutes. A final angiogram will be obtained for documentation."
88904445|NCT01544907|Experimental|Drug Eluting Balloon (DEB)|"Treatment arm 2 - Conventional Balloon with DEB~A Conventional balloon is used to pre-dilate the target lesion. The DEB of a similar diameter to the conventional balloon used is then inflated across the stenosis. An inflation device with a pressure gauge is used to inflate up to manufacturers' stated burst pressure. The duration of balloon inflation will be 1 minute. A final angiogram will be obtained for documentation. The drug coated on the DEB is Paclitaxel."
88904446|NCT01544933||burst fractures in vertebrae with true ribs|between T1 and T10
88904447|NCT01544933||burst fractures in vertebrae with floating ribs|between T11 and T12
88904448|NCT01544946|Experimental|sucrose po|
88904449|NCT01544946|Placebo Comparator|placebo po|
88904450|NCT01544959|Active Comparator|fentanyl|
88904451|NCT01544959|Experimental|beta-blocker|Instead of narcotics (fentanyl), esmolol and lopressor are being used for hemodynamic control
88904452|NCT01544972|Active Comparator|Oral paracetamol|Patients will receive oral paracetamol 15 mg/kg per dose every 6 hours for 3 days
88904453|NCT01544972|Active Comparator|Oral ibuprofen|Patients will receive oral ibuprofen at an initial dose of 10 mg/kg, followed by 5 mg/kg at 24 and 48 h.
88904454|NCT01544985|Experimental|sucrose po|88% sucrose solution (Syrup B.P.)
88904455|NCT01544985|Placebo Comparator|placebo po|sterile water
88904456|NCT01545011|No Intervention|standard|conventional respiratory rehabilitation
88904457|NCT01545011|Experimental|IMT|Inspiratory muscle training and conventional respiratory rehabilitation
88904458|NCT01545024||DPP-IV inhibitor|
88904459|NCT01545037|Active Comparator|Probiotic capsules|L. acidophilus CL1285® + L. casei LBC80R® + L. rhamnosus CLR2®. Dosage of 2 capsules per day , corresponding to 100 billions bacterias for a period of 12 weeks.
89195546|NCT00819429|Experimental|1|"Omega-3 + Standard treatment~Children in this group will be given 400 mg of DHA and 600 mg of EPA. Caregivers will be instructed to give two 500mg Omega-3 capsules twice a day, at breakfast and at the evening meal for 6 months. Parents will be seen by the attending on a monthly basis for standard treatment procedure."
89195547|NCT00819429|Experimental|2|"Social skills + Omega-3 placebo + Standard treatment~Children in this group will be given two placebo capsules twice daily; at breakfast and at the evening meal for a total period of 6 months. They will also undergo a manualised group social problem solving skills training protocol of 12 weekly 1-hour sessions (Ang & Ooi, 2003a, 2003b). There will be booster sessions scheduled at 3-week intervals after the initial treatment period of 12 weeks, for a total of 4 booster sessions."
89195548|NCT00819429|Experimental|3|"Omega-3 + Social skills + Standard treatment~Children in this group will receive omega-3 supplement and social skills training on top of standard treatment. Procedures for administration of Omega-3 supplement are similar to those stated in (1) and (2)."
89423229|NCT02054091|No Intervention|Control group|Infants are fed according to the standard feeding practices at each hospital. At FWCH & SBMCH babies are fed infant formula supplemented to mother's own milk (if avaible), and at RH, babies are fed donor milk supplemented to Mother'w own milk (if avaible).
89423230|NCT02054091|Experimental|Colostrum group|Infants are fed bovine colostrum supplemented to mother's own milk (if avaible) for max. 10 days at RH and 14 days at FWCH & SBMCH.
89423231|NCT02056197|Placebo Comparator|Placebo|Shortwave 30 minutes.
89423232|NCT02056197|Active Comparator|Stable|Stable surface exercises
89423233|NCT02056197|Experimental|Unstable|Unstable surface exercises
89423234|NCT02056275|Experimental|ONS + dietary counseling|ONS/day + dietary counseling
89423235|NCT02056275|Active Comparator|Dietary counseling|Dietary counseling
89423236|NCT02054169||pre-test group|All patients aged 65 or older presenting to the ED during the pre-test period
89423237|NCT02054169||post-test period|All patients aged 65 or older presenting to the ED in the post-test period
89423238|NCT02038101|Experimental|Education and Feedback Intervention|"This intervention includes the following components:~Formal Rounds on AUC for TTE:~Appropriate Use for TTE Application for Smartphone~Individualized Feedback Reports provided by email"
89423239|NCT02038101|No Intervention|Control|Usual echocardiography ordering pratice.
89423240|NCT02056353|Active Comparator|Nurse-directed|Blood glucose control guided by paper protocol
88904460|NCT01545037|Placebo Comparator|Placebo capsules|The placebo capsules are identical in shape, taste, and smell yet are devoid of live bacteria. Dosage of 2 capsules per day , corresponding to 100 billions bacterias for a period of 12 weeks
88904461|NCT01545050|Experimental|Induction Cohort: Placebo matching with BMS-945429 (Clazakizumab)|
89423241|NCT02056353|Experimental|LOGIC-Insulin|Blood glucose control guided by the LOGIC-Insulin algorithm
89423242|NCT03636633|Active Comparator|Control Group|"Standard respiratory physiotherapy~Patients in this group will receive standard respiratory physiotherapy two times a day, 7 days a week for 4 weeks. During hospitalization, sessions will be performed by a respiratory physiotherapist. After discharge, other sessions will be performed at home by themselves."
88904462|NCT01545050|Experimental|Induction Cohort: BMS-945429 (Clazakizumab)(600 IV/200 SC mg)|
89195549|NCT00819429|Placebo Comparator|4|"Omega-3 placebo + Standard treatment.~Children in this group will receive placebo as well as a course of the standard treatment. Procedure for administering the placebo capsules is similar to that outlined in (2)."
89423243|NCT03636633|Experimental|Training Group|"Standard respiratory physiotherapy and inspiratory muscle train~In addition to the standard respiratory physiotherapy program, patients in this group will receive 3 sets of inspiratory muscle training with 10 repetitions twice a day for 4 weeks. During hospitalization, sessions will be performed by a respiratory physiotherapist. After discharge, other sessions will be performed at home by themselves."
88904463|NCT01545050|Experimental|Induction Cohort: BMS-945429 (Clazakizumab)(300 IV/100 SC mg)|
88904464|NCT01545050|Experimental|Induction Cohort: BMS-945429 (Clazakizumab)(150 IV/100 SC mg)|
88904465|NCT01545050|Experimental|Induction Cohort: BMS-945429 (Clazakizumab)(400 SC/200 SC mg)|
88904466|NCT01545050|Experimental|Maintenance Cohort: Placebo matching with BMS-945429 (Clazakizumab)|
88904467|NCT01545050|Experimental|Maintenance Cohort: BMS-945429 (Clazakizumab)(100 SC mg)|
88904468|NCT01545050|Experimental|Maintenance Cohort: BMS-945429 (Clazakizumab)(200 SC mg)|
88904469|NCT01545050|Experimental|Open Label Cohort: BMS-945429 (Clazakizumab)(200 SC mg)|
88904470|NCT01545089|Experimental|Mattress protector days 1,2|A mattress protector is placed in the bed for the first two days and then removed for days 3 and 4.
88904471|NCT01545089|Experimental|Mattress protector days 3,4|A mattress protector is not placed in the bed for the first two days and then added to the bed for days 3 and 4.
88904472|NCT01545154||Prostate Cancer|
89195550|NCT00697788|Experimental|Ascending dose study|Ascending doses of dexmedetomidine (as per protocol)
88904473|NCT01545167||African Americans with pancreatitis|pancreatitis
89195551|NCT02568878|Experimental|Creatine monohydrate|5 grams of daily creatine monohydrate by mouth for 8 weeks
89195552|NCT00817167|Experimental|inReach (A)|Bronchoscopy procedure is planned using inReach planning software
89423244|NCT03603951|Experimental|SHR2554 treated group|Part I：treated with escalated doses of EZH2 inhibitor SHR2554 respectively； Part II：treated with fixed dose (RP2D) SHR2554 respectively
89423245|NCT02052219|Experimental|Blisibimod|
89423246|NCT02052219|Placebo Comparator|Placebo|
88904474|NCT01545167||African Americans without Pancreatitis controls|people without pancreatitis
88904475|NCT01545206||acute STEMI, Primpary PCI|
88904476|NCT01545219|Experimental|Prebiotic|
88904477|NCT01545219|Experimental|Probiotic|
88904478|NCT01545219|Experimental|Synbiotic|
88904479|NCT01545219|Placebo Comparator|Placebo|
89423247|NCT02054403||angle closure|
89423248|NCT03561519|Active Comparator|FMT|IBS patients randomized to receive FMT from a healthy donor.
89423249|NCT03561519|Placebo Comparator|Placebo|IBS patients randomized to receive autologous FMT (fecal suspension made of their own feces) as a placebo.
89423250|NCT02056509||Out of hospital cardiac arrest|Out of hospital cardiac arrest of non-traumatic cause
88904480|NCT01545245||Treated|Palivizumab treated
88904481|NCT01545245||Untreated|Palivizumab untreated
88904482|NCT01545258|Experimental|Exercise|Exercise training supervised by trained physiotherapists lasting 60 minutes performed 3 times/week.
88904483|NCT01545258|No Intervention|Control|
88904484|NCT01545284|Experimental|Acitretin|Patients will receive acitretin once daily for a maximum of 24 weeks. Patients who reach a Physician Global Assessment (PGA) of clear or almost clear at week 12 will end the study. Patients who do not reach a PGA of clear or almost clear at week 12 will continue treatment up to week 24. The starting dose will be 10mg/day and, if well tolerated, it will be increased in the first 4 weeks to a maximum of 30 mg/day.
88904485|NCT01545297|Active Comparator|Propofol-Remifentanil|Group I. (propofol/remifentanil): Infusions begin at remifentanil (0.01-0.1 mcg/kg/min) and propofol (25-250 mcg/kg/min) for 15 min, and then titrated to effect.
88904486|NCT01545297|Experimental|Dexmedetomidine|Group II. (dexmedetomidine): The infusion begins at 0.3-0.4 mcg/kg/hr for 15 min, and then titrated down to 0.1-0.2 mcg/kg/hr.
88904487|NCT01545310|Experimental|Group 1 (healthy), Group 2 (schizophrenia)|
88904488|NCT01545323|Experimental|One 20cm2/10cm2 autologous skin sheet graft|Adults will receive a graft of approximately 20cm2. Children under 16 years of age will receive a graft around half this size, around 10cm2 .The graft is derived from SPINK5 transduced cells
88904489|NCT01545349|Experimental|LGG|Lactobacillus rhamnosus GG (LGG) containing 1x10^10 LGG per capsule will be given to subjects with verbal and written instructions at the baseline visit. Capsules are to be taken orally twice a day on an outpatient basis.
88904490|NCT01545349|Placebo Comparator|Placebo|Placebo capsules composed of microcrystalline cellulose are to be taken orally twice a day on an outpatient basis.
88904491|NCT01545362||Staged bilateral total knee arthroplasty|Patients that have bilateral total knee arthroplasty staged within one week
88904492|NCT01545401|Experimental|EMPOWER-PAR Intervention|"The intervention arm receives the EMPOWER-PAR intervention package consisting of:~Chronic Disease Management (CDM) Training Workshops for the staff in the respective clinics~The Global CV Risks Self-Management Booklet (patient self-management tool) to empower patients to self-manage their CV risk factors~Facilitation and support of the staff in these clinics so that they may implement the interventions"
88904493|NCT01545401|No Intervention|Control|"The control arm continues with usual care.~The EMPOWER-PAR intervention package will be made available after the trial ends."
88904494|NCT01545414|Experimental|ICBT|Internet-based Cognitive Behavioral Therapy with a focus on behavioral activation
88904495|NCT01545414|Active Comparator|ICONTROL|Internet-based treatment with a focus on relaxation training
88904496|NCT01545414|No Intervention|SMT|Standard Medical Treatment while being on the waitlist for randomization to any of the active treatments
88904497|NCT01545427|Experimental|Gleevec|Gleevec 200 mg bid for 6 months.
88904498|NCT01545427|Placebo Comparator|Placebo|Placebo coated to appear identical to Gleevec.
88904499|NCT01545440|Experimental|lebrikizumab - highest dose|
88904500|NCT01545440|Experimental|lebrikizumab - lowest dose|
88904501|NCT01545440|Experimental|lebrikizumab - middle dose|
88904502|NCT01545440|Placebo Comparator|placebo|
88904503|NCT01545466|Experimental|Mindfulness Based Stress Reduction|Participants will complete an 8 week course in Mindfulness Based Stress Reduction (MBSR), meeting once/week for 8 weeks and having a 4-6 hour retreat after the 6th class
88904504|NCT01545466|No Intervention|Wait-List Control Group|These participants will continue in usual care during the trial and will be offered the intervention of MBSR after the trial is over.
88904505|NCT01545479|Other|Captopril 25mg|To study the renal blood oxygenation, the subjects took captopril (25mg).
88904506|NCT01545492||Tight|"Children born to women in the CHIPS RCT randomized to Tight blood pressure control [target diastolic BP 85mmHg]"
88904507|NCT01545492||Less Tight|"Children born to women in the CHIPS RCT randomized to Less Tight [target diastolic BP 100mmHg]."
88904508|NCT01544426|Experimental|Office hysteroscopy and endometrial snip|Office hysteroscopy and endometrial snip
88904509|NCT01544426|Active Comparator|Office hyteroscopy|Office hysteroscopy
88904510|NCT01545505|Other|In remission phase of PTSD|Patients having suffered from PTSD in the past and in remission od PTSD and their parents
88904511|NCT01545505|Other|Activ PTSD|patients suffering from PTSD (Post-traumatic Stress Disorder) and their parents
88904512|NCT01545531||Iohexol GFR|
88904513|NCT01545570|Active Comparator|GSK2376497|single dose escalation or multiple-dose titration
88904514|NCT01545570|Placebo Comparator|0.9% sodium chloride|placebo injection
88904515|NCT01545596|Experimental|Notification Group|Anesthesia team receives notification when a double low condition exists. The anesthesia team makes a decision to intervene or not.
88904516|NCT01545596|No Intervention|No Notification|No additional notification given to anesthesia team apart from the information on their monitors.
88904517|NCT01545609|Experimental|Text messaging|Text messaging
88904518|NCT01545609|No Intervention|No intervention|No intervention
88904519|NCT01545635|Active Comparator|Coagulation factor concentrates|
88904520|NCT01545635|Active Comparator|Fresh Frozen Plasma|
88904521|NCT01545661|Experimental|Sputum induction|Enrolled patients receive sputum induction (using ultrasonic nebulisation with hypertonic saline)
88904522|NCT01545661|Active Comparator|No sputum induction|Enrolled patients randomised to this study arm will receive an observed expectorated sputum collection attempt. Research nurses train study patients on the method of producing sputum spontaneously.
88904523|NCT01545687|Experimental|Arm I|Patients dissolve in mouth 1 lozenge of Lactobacillus bevis CD2 every 2-3 hours (total of 6 per day) daily during CRT (comprising cisplatin and radiotherapy [RT]) and for 4 weeks after, including weekends.
88904524|NCT01545687|Placebo Comparator|Arm II|Patients dissolve in mouth 1 lozenge of placebo every 2-3 hours (total of 6 per day) daily during CRT and for 4 weeks after, including weekends.
88904525|NCT01545713||Renal Transplant Recipients|Patients undergoing living-donor kidney transplant at NMH who have a positive XM-One AbSorber® positive test result.
88904526|NCT01545726|Experimental|QAW039|Eligible patients will receive QAW039 po 450 mg daily dose.
88904527|NCT01545726|Placebo Comparator|Placebo|Placebo to QAW039 (oral capsules) will be administered to match QAW039 schedule.
88904528|NCT01545739||CRT pacemaker implantation|
88904529|NCT01545752|No Intervention|coventional group|Teaching just by book
88904530|NCT01545752|Experimental|non-interactive CD|Teaching book with non-interactive CD
88904531|NCT01545752|Experimental|interactive CD|Teaching book with interactive CD
88904532|NCT01545778||Tapentadol IR|
88904533|NCT01545778||Oxycodone IR|
88904534|NCT01545791||Insulin detemir users|
88904535|NCT01545804|Experimental|Lenalidomide|
88904536|NCT01545830|Active Comparator|Regular Dose|Intervention: 600 IUs of cholecalciferol taken by mouth daily.
88904537|NCT01545830|Experimental|High Dose D|Intervention: 6,000 IUs of cholecalciferol taken by mouth daily.
88904538|NCT01545856||New levodopa users|Individuals with one or more prescriptions of levodopa between 1st July 2004 and 30th June 2010 but no previous levodopa prescriptions prior to study period
88904539|NCT01545869|Experimental|Fractional carbon dioxide laser|
88904540|NCT01545882|Experimental|Degarelix|Degarelix treatment will consist of a starting dose of 240mg injected subcutaneously (s.c) and monthly s.c. maintenance doses of 80mg for a total duration of 6 months.
88904541|NCT01545908|Placebo Comparator|placebo enema|Participants in this arm undergo 6 retention enemas, week 1, week 2, week 3, week 4, week 5, week 6
88904542|NCT01545908|Active Comparator|Fecal transplant from an unrelated donor|Participants in this arm undergo 6 retention enemas,week 1, week 2, week 3, week 4, week 5, week 6,using stool specimen prepared from a healthy, screened donor.
88904543|NCT01545921|Experimental|Arm A|"Patients will complete QoL questionnaires in the following order :~MVQOLI, then QLQ-C15-PAL, then QUAL-E, evaluation every month until death"
88904544|NCT01545921|Experimental|Arm B|"Patients will complete QoL questionnaires in the following order :~QLQ-C15-PAL, then MVQOLI, then QUAL-E, evaluation every month until death"
88904545|NCT01545921|Experimental|Arm C|"Patients will complete QoL questionnaires in the following order :~MVQOLI, then QLQ-C15-PAL, then QUAL-E, evaluation every month and spontaneous QoL completion, until death"
88904546|NCT01545921|Experimental|Arm D|"Patients will complete QoL questionnaires in the following order :~QLQ-C15-PAL, then MVQOLI, then QUAL-E, evaluation every month and spontaneous QoL completion, until death."
88904547|NCT01545947|Experimental|CC-223/erlotinib concurrent|Cohorts will receive escalating continuous daily doses (15 mg and 30 mg) of CC-223 in capsules concurrently with at least two different daily dose levels of erlotinib tablets (100 mg and 150 mg) in 28-day cycles.
89195553|NCT00817167|Active Comparator|Control (B)|Bronchoscopy procedure is planned using standard CT viewer software
89195554|NCT00400153|Experimental|COMBIVENT Respimat 20/100 mcg|
89423251|NCT02056509||Unexpected in-hospital cardiac arrest|Unexpected cardiac arrest during emergency department stay
89423252|NCT02056587|Experimental|Everolimus|All patients with metastatic renal cell carcinoma progressing on prior treatment with bevacizumab ± interferon enrolled into this study will receive everolimus in the dose of 10 mg daily until the disease progression or unacceptable toxicity.
89423253|NCT02038335||DMPA|Depot medroxyprogesterone acetate
89423254|NCT02038335||NET-EN|Norethisterone enantate
89423255|NCT02038335||MPA/E2|Medroxyprogesterone acetate and estradiol cypionate
89423256|NCT02038335||LNG-I|Levonorgestrel subdermal implant
89423257|NCT02038335||ENG-I|Etonogestrel subdermal implant
89423258|NCT02038335||Cu-IUD|Copper IUD
89423259|NCT02056665|Experimental|MINOCYCLINE 8 weeks|"Duration of treatment: 8 weeks~Patients <35 kg. 100 mg / day. Administered at a dose of one capsule of 50 mg breakfast and dinner.~Patients 35 - 50 kg. 150 mg / day. Administered at a dose of 2 capsules of 50 mg breakfast and 1 capsule of 50mg dinner.~Patients > 50 kg. 200 mg / day. Administered at a dose of two capsules of 50 mg of breakfast and dinner."
88904548|NCT01545947|Experimental|CC-223/oral azacitidine concurrent|Cohorts will receive escalating continuous daily doses of CC-223 (15 mg and 30 mg) with one or more dose levels of oral azacitidine (200 mg or 300 mg, as two or three 100 mg tablets) administered on Day 1 to 21 of each 28-day cycle.
88904549|NCT01545947|Experimental|CC-223/oral azacitidine sequential|Cohorts will receive escalating continuous daily dose levels of CC-223 (15 mg and 30 mg) administered on Days 8 through 28 sequentially with one or more dose levels of of oral azacitidine (200 mg or 300 mg, as two or three 100 mg tablets) administered on Days 1 to 7 of each 28-day cycle
88904550|NCT01545960||Healthy Volunteers|
88904551|NCT01545973||Healthy Volunteers|Human subjects without chronic medical conditions, defined as conditions requiring chronic medication use.
88904552|NCT01545986|Experimental|High Velocity Exercise|The high velocity exercise group performed the concentric contraction phase of resisted exercise in one second or less. This group performed sit to stand exercise, walking, curbs, and stairs as fast as was comfortable without an increased limp. Other exercises were performed at the participant preferred rate.
88904553|NCT01545986|Active Comparator|Low Velocity exercise|The low velocity exercise group performed the concentric contraction phase of resisted exercise in two seconds. This group performed sit to stand exercise, walking, curbs, stairs, and other exercises at the participant preferred rate.
88904554|NCT01546012|Experimental|HYABAK®|Hyaluronic Acid eye drops CE marked, packaged in multidose ABAK® container (preservative free)
88904555|NCT01546012|Active Comparator|HYLO-COMOD®:|Hyaluronic Acid eye drops CE marked, packaged in multidose COMOD® container (preservative free)
89195555|NCT00400153|Experimental|COMBIVENT CFC-MDI 36/206 mcg|
89195556|NCT00400153|Experimental|Ipratropium Respimat 20 mcg|
89195557|NCT04062890|Active Comparator|Vigabatrin|Vigabatrin - Pill, 500 mg twice daily for 7 days (days 1-7), 1000 mg twice daily for 7 days (days 8-14), 1500 mg twice daily for 10 days (days 15-24), 1000 mg twice daily for 7 days (days 25-31), 500 mg twice daily for 7 days (days 32-38).
89195558|NCT04062890|Placebo Comparator|Placebo|Placebo - Pill, 1 pill twice daily for 7 days (days 1-7), 2 pills twice daily for 7 days (days 8-14), 3 pills twice daily for 10 days (days 15-24), 2 pills twice daily for 7 days (days 25-31), 1 pill twice daily for 7 days (days 32-38).
89195559|NCT02566512|Other|Tracheostomy cuff inflated|The tracheostomy cuff will be inflated.
89195560|NCT02566512|Other|Tracheostomy cuff deflated|The tracheostomy cuff will be deflated.
89423260|NCT02056665|Placebo Comparator|PLACEBO 8 weeks|Pill manufactured to mimic Minocycline 50 mg capsule
89423261|NCT02056665|Experimental|MINOCYCLINE 16 weeks|"Duration of treatment: 16 weeks~Patients <35 kg. 100 mg / day. Administered at a dose of one capsule of 50 mg breakfast and dinner.~Patients 35 - 50 kg. 150 mg / day. Administered at a dose of 2 capsules of 50 mg breakfast and 1 capsule of 50mg dinner.~Patients > 50 kg. 200 mg / day. Administered at a dose of two capsules of 50 mg of breakfast and dinner."
89423262|NCT02056743|Experimental|Fermented-red ginseng|"At period 1, the fermented-red ginseng group administered CYP cocktail (Caffeine 200mg + Losartan 50mg + Omeprazole 20mg + Dextromethorphan 30mg + Midazolam 7.5mg) under fasting conditions on the first day. At second day, they administered Fexofenadine 30mg under fasting conditions.~During 4~17th days they administered fermented-red ginseng. At period 2, the fermented-red ginseng group administered CYP cocktail (Caffeine 200mg + Losartan 50mg + Omeprazole 20mg + Dextromethorphan 30mg + Midazolam 7.5mg) under fasting conditions on the 15th day. At 16th day, they administered Fexofenadine 30mg under fasting conditions."
89195561|NCT00823251|Experimental|IlluminOss device|IlluminOss bone-pin device
89536081|NCT03212677|Experimental|Adult Aspiron|Iron-replete postmenopausal women, and men, receiving Aspiron (containing 60 mg Fe per day) for 4 weeks. In Phase II, iron-replete postmenopausal women, and men, receiving Aspiron (containing 120 mg Fe per day) for 4 weeks.
89536082|NCT04991259|Experimental|Preemptive CRRT|In patients randomized to early CRRT, CRRT would be initiated within 12 hours of randomization.
88904556|NCT01546025|Placebo Comparator|Relaxation training|
88904557|NCT01546025|Active Comparator|Brief Motivational Counseling|
88904558|NCT01546051|Experimental|BCI-838 Food Effect Dosing Arm 1|Eight subjects will be enrolled, 6 will receive BCI-838 and 2 will receive matching placebo.
88904559|NCT01546051|Experimental|BCI-838 Fasted Dosing (100 & 300 mg)|Eight subjects will be enrolled, 6 will receive BCI-838 and 2 will receive matching placebo.
88904560|NCT01546051|Experimental|BCI-1038, BCI-1206 & BCI-1283|Six subjects will be enrolled, all 6 will receive single doses of BCI-1038, BCI-1206 and BCI-1283.
88904561|NCT01546051|Experimental|BCI-838 Fasted Dosing (900 mg)|Eight subjects will be enrolled, 6 will receive BCI-838 and 2 will receive matching placebo.
88904562|NCT01546064|Active Comparator|Bile duct anastomosis with T-tube|
89195562|NCT00817245|Active Comparator|1|Oral Amoxicillin Capsule Metronidazole Tablet Omeprazole Capsule
89195563|NCT00817245|No Intervention|2|No medical treatment
89195564|NCT02566278|Experimental|Obstructive Sleep Apnea|Upper airway collapsibility (passive Pcrit) will be measured using both clinically available equipment and research equipment in patients with obstructive sleep apnea (OSA) and stable on treatment of continuous positive airway pressure (CPAP) > 3 months to verify the Pcrit measurement obtained by the clinical equipment.
88904563|NCT01546064|Active Comparator|Bile duct anastomosis without T-tube|
88904564|NCT01546077|Active Comparator|Hydrolocalization technique group|Technique of placement of popliteal perineural catheter using the hydrolocalization technique with ultrasound
88904565|NCT01546077|Active Comparator|Stimulating Catheter technique group|A technique for placement of popliteal catheter with the aid of a neurostimulator
88904566|NCT01546090|Experimental|alprazolam|Alprazolam is a short-acting anxiolytic of the benzodiazepine class of psychoactive drugs
88904567|NCT01546090|Placebo Comparator|placebo|placebo capsules were filled with starch
88904568|NCT01546103|Active Comparator|Vitamin D3 supplementation of 1000 IU|
88904569|NCT01546103|Active Comparator|Vitamin D3 supplementation of 5000 IU|
88904570|NCT01546116|Experimental|Adefovir and lamivudine combination|
88904571|NCT01546129|Experimental|Dianatal Obstetric Gel|Standard of care according to the established Guidelines of the Department plus use of Dianatal applied with a vaginal applicator in stage I and stage II of labor
88904572|NCT01546129|No Intervention|Control|Standard of care according to the established Guidelines of the Department.
88904573|NCT01546220|No Intervention|Air colonoscopy|Colonoscopy will be performed without medications and with judicious air insufflation during colonoscope insertion.
89536083|NCT04991259|Active Comparator|Standard Medical Treatment|"In patients randomized to SMT group, CRRT would be initiated as per the existing standard protocol.~in patients with worsening hyperammonemia despite two sessions of plasma-exchange~patients meeting renal indications (hyperkalemia, volume overload, oliguria or metabolic acidosis etc)."
88904574|NCT01546220|Other|Water colonoscopy|Colonoscopy will be performed without medications and aided by water infusion in-lieu of air insufflation during insertion of the colonoscope.
89536084|NCT03315065|Other|Patients diagnosed with Lung cancer|patients diagnosed with Lung cancer and Thoracic radiotherapy
88904575|NCT01546233||multidisiplinary self care program|Patient with Lung cancer will be participated in group education with multidisiplinary self care program
88904576|NCT01546233||Conventional education|Lung cancer patient will be received standard education
88904577|NCT01546246|No Intervention|Air colonoscopy|Colonoscopy will be performed without medications and with judicious air insufflation during colonoscope insertion.
88904578|NCT01546246|Other|Water colonoscopy|Colonoscopy will be performed without medications and aided by water infusion in-lieu of air insufflation during insertion of the colonoscope.
88904579|NCT01546259|No Intervention|Air colonoscopy|Colonoscopy will be performed without medications and with judicious air insufflation during colonoscope insertion.
88904580|NCT01546259|Other|Water colonoscopy|Colonoscopy will be performed without medications and aided by water infusion in-lieu of air insufflation during insertion of the colonoscope.
88904581|NCT01546272|Experimental|Resorbable staples|Suture using Insorb Resorbable staples
88904582|NCT01546272|Active Comparator|Resorbable wires|Suture using Monocryl resorbable wire
88904583|NCT01546311||lower limb amputees|
88904584|NCT01546324||Pregnant women|Women pregnant following the use of Natera's PGS/PGD testing
88904585|NCT01546350|No Intervention|Control - regular ART treatment|patients will have up to two embryos replaced on day 5 based on morphological and developmental characteristics, and the other embryos reaching blastocyst stage will be vitrified. If patients in the control group do not have a pregnancy to term from that fresh cycle, they will be offered free PGD either for the frozen embryos of that cycle or for the next cycle (up to the center and patient). Data from that PGD is not part of the study.
88904586|NCT01546350|Experimental|Test - PGD|patients will have grade A,B or C blastocysts hatched on day 5, biopsied on day 5, analyzed by array CGH, and a single euploid embryo transferred on day 6. Any morulas developing to grade A,B or C blastocyst on day-6 will be also analyzed but vitrified for use in a future cycle.
88904587|NCT01546363||Validation|
88904588|NCT01546363||Testing|
88904589|NCT01546376||HIV-cancer patients who recived RT|
88904590|NCT01546389|Experimental|Cohort 3, Group E|Cohort 3 (High Dose, Low Aliquot), Group e: 50,000 PfSPZ in 2 divided doses (e.g., 25,000 PfSPZ per 10 mcL dose); 5 subjects
88904591|NCT01546389|Experimental|Cohort 1, Group A|Cohort 1 (Medium Dose, Medium Aliquot), Group a: 10,000 PfSPZ in 2 divided doses (e.g., 5000 PfSPZ per 50 microliter (mcL) dose); 5 subjects.
88904592|NCT01546389|Experimental|Cohort 1, Group B|Cohort 1 (Medium Dose, Medium Aliquot), Group b: 10,000 PfSPZ in 8 divided doses (e.g., 1250 PfSPZ per 50 mcL dose); 5 subjects
88904593|NCT01546389|Experimental|Cohort 3, Group F|Cohort 3 (High Dose, Low Aliquot), Group f: 50,000 PfSPZ in 8 divided doses (e.g., 6,250 PfSPZ per 10 mcL dose); 5 subjects
88904594|NCT01546389|Experimental|Cohort 2, Group D|Cohort 2 (Medium Dose, Low Aliquot), Group d: 10,000 PfSPZ in 8 divided doses (e.g., 1250 PfSPZ per 10 mcL dose); 5 subjects
88904595|NCT01546389|Experimental|Cohort 2, Group C|Cohort 2 (Medium Dose, Low Aliquot), Group c: 10,000 PfSPZ in 2 divided doses (e.g., 5000 PfSPZ per 10 mcL dose); 5 subjects
88904596|NCT01546415|Experimental|Desferasirox|
88904597|NCT01546428|Experimental|INC280|
88904598|NCT01546441|Experimental|interprofessional assessment|patients receive an interprofessional assessment in a team environment
88904599|NCT01546441|Active Comparator|usual care|Usual care in family practice
88904600|NCT01546467|Experimental|Cognitive remediation|30 hour computer based cognitive remediation integrated in participants current rehabilitation program (school, work, day program)
88904601|NCT01546467|No Intervention|Wait list control group|Participant continues in treatment/rehabilitation program as usual until 9 month assessment when participant receives the same cognitive remediation program as the experimental group.
88904602|NCT01546480||Pain patients|Patients with unexplained chronic abdominal pain 12 months after elective cholecystectomy
88904603|NCT01546480||Operated painfree Patients|Painfree patients 12 months after elective cholecystectomy
88904604|NCT01546480||Nonoperated painfree patients|Painfree patients with no previous abdominal operation
88904605|NCT01546506|Experimental|Midodrine|Midodrine 2.5 mg orally 3 times daily, 5 day-treatment.
88904606|NCT01546506|No Intervention|No treatment|
88904607|NCT01546558|Experimental|Metformin, Ranolazine|"Single cohort, 2-period study:~Period 1, metformin 1000 mg bid on Days 1-5~Period 2, metformin 1000 mg bid + ranolazine 500 mg bid on Days 6-10"
88904608|NCT01546597|Experimental|Metformin, Ranolazine|"Single cohort, 4-period study:~Period 1, metformin 500 mg bid on Days 1-5~Period 2, metformin 850 mg bid on Days 6-10~Period 3, metformin 500 mg bid + ranolazine 1000 mg bid on Days 11-15~Period 4, metformin 850 mg bid + ranolazine 1000 mg bid on Days 16-20"
88904609|NCT01546610|Experimental|intervention foot orthoses|Ethyl vinyl acetate (EVA) insole with medial arch support and bar retrocapital
88904610|NCT01546610|Placebo Comparator|placebo insole|Foot orthose with support retrocapital and support of medial arch insole intervention
88904611|NCT01546662|Experimental|E-RH-06 - Low Dose|1 Capsule twice daily
88904612|NCT01546662|Experimental|E-RH-06 - High Dose|2 capsules twice daily
88904613|NCT01546662|Placebo Comparator|Placebo ;|Placebo Comparator
88904614|NCT01546701|Experimental|Buprenorphine|Renal Colic Patients treated by 2 mg sublingual Buprenorphine.
88904615|NCT01546701|Active Comparator|Morphine|Renal Colic Patients treated by 0.1 mg/kg intravenous morphine.
88904616|NCT01546714||AAWSW/AAWSWM|African American Women Who Have Sex with Women/African American Women Who Have Sex with Women and Men
88904617|NCT01546727|Experimental|Family Behavioral Treatment|This intervention will provide nutritional counseling for a health diet, parent training in effective child behavioral management strategies, and stimulus control of the home environment delivered via group based clinic visits and individual home visits on alternate weeks
88904618|NCT01546727|Active Comparator|Motivational Interviewing|This intervention will shared information with parents about their child's weight and use motivational interviewing to elicit changes parents would like to make to their child diet and activity patterns.
88904619|NCT01546727|No Intervention|Standard of Care|Participants in this arm will be followed over time and be assessed on the primary and secondary outcomes at the same time points as the two treatment arms
88904620|NCT01546740||Glaucoma patients|all the ,medical records of patients who were diagnosed with primary open angle glaucoma, closed angle , pseudoexfoliative and neovascular glaucoma.
88904621|NCT01546779|Experimental|lung function|
88904622|NCT01546792|No Intervention|Usual care control|Leaflet on exercise and diet
88904623|NCT01546792|Experimental|Lifestyle intervention|Exercise training (mixture of supervised and non-supervised) Dietary advice Behaviour change counselling (physical activity, diet)
88904624|NCT01546805|Placebo Comparator|Placebo|
88904625|NCT01546805|Experimental|Zinc Group|
88904626|NCT01546844|Experimental|Care4Life|Text message and online interactive component to help patients with self-management.
88904627|NCT01546844|No Intervention|Standard of Care|Patients enrolled in this arm will receive their normal standard of care from their physician for treatment of type II Diabetes Mellitus.
88904628|NCT01546870||pediatric heart transplant recipients|
88904629|NCT01546896|Experimental|buspirone+alprazolam|
88904630|NCT01546896|Active Comparator|alprazolam|
88904631|NCT01546896|No Intervention|healthy controls|
88904632|NCT01546909|Experimental|TETRAVAC-ACELLULAIRE|
88904633|NCT01546935|Experimental|Oseltamivir|The dose of Oseltamivir will be 3 mg/kg 12 hourly for 5 days (seasonal influenza and 2009 H1N1) or 10 days (avian influenza) for children whose renal function is ≥ 30 mls/min/1.73m2.
88904634|NCT01546961|Experimental|Chloroquine|"Chloroquine phosphate GPO® (Government Pharmaceutical Organization, Thailand) 250 mg (equivalent to chloroquine base 150 mg).~Dosing will be at 0, 24, 48 hrs with 10 mg/kg on day 0 and day 1, and 5 mg/kg on day 2."
88904635|NCT01546974|Experimental|HME filter|
88904636|NCT01546974|Experimental|Heated humidificator MR 730 Fisher & Paykel|
88904637|NCT01547013||COHORT 1|"Critical Controls: Twenty five (25) critically injured subjects with NO severe traumatic lower extremity traumatic injuries to provide control data for critically injured physiological status, a state which may induce systemic, vs. regional hypoperfusion. (Critical CONTROLS)"
88904638|NCT01547013||COHORT 2|"Ninety five (95) total (35 Cohort 2A; 35 Cohort 2B; 25 Cohort 2C) subjects with severe leg injuries presenting to a participating level 1 trauma center within 12 hours of their injury, to provide data on the acute post-injury phase. (STUDY COHORT)"
88904639|NCT01547013||COHORT 2A|"Subjects meeting COHORT 2 inclusion criteria, who have UNILATERAL severe leg injuries. Unilateral injuries include patients who meet the inclusion criteria for a severe lower extremity injury for ONE lower extremity, with no more than a simple soft tissue injury (eg, simple laceration) on the contralateral leg."
88904640|NCT01547013||COHORT 2B:|"Subjects meeting COHORT 2 inclusion criteria, who have BILATERAL lower extremity injuries, with at least one being a severe leg injury. Bilateral injury patients include patients with at least one lower extremity injury classified as severe based on Cohort 2 inclusion criteria, with a contralateral injury greater than a simple soft tissue injury, including femur, foot, and crush injuries. Note that it is not necessary for both lower extremity injuries to meet the inclusion criteria to be enrolled in this cohort."
88904641|NCT01547013||COHORT 2C|Subjects meeting COHORT 2 inclusion criteria, clinically diagnosed by the treating provider using that treating provider's standards of diagnosing ACS, and in addition to being diagnosed with ACS, the subject undergoes four-compartment leg fasciotomy. data collection to start BEFORE fasciotomy and continue AFTER fasciotomy.
88904642|NCT01547026|Active Comparator|Psycho-education|Patients receive a 10 min. psycho-education on positive health effects of sports
88904643|NCT01547039||Carotid endarterectomy (CEA)|Patients undergoing carotid endarterectomy
88904644|NCT01547052|Experimental|DBT for children|Dialectical Behavior Therapy adapted for children
88904645|NCT01547052|Active Comparator|Enhanced Supportive-Educational Therapy|Enhanced Treatment-As-Usual, including supportive-educational model, cognitive-behavioral skills and parent management training
88904646|NCT01547078|Active Comparator|Licensed Plasma|
88904647|NCT01547078|Experimental|Lyophilized Plasma|
88904648|NCT01547091|Experimental|UC-MSCs Treatment|Patients in UC-MSCs treatment will be infused umbilical cord-derived mesenchymal stem cells intravenously only.
88904649|NCT01547091|Active Comparator|DMARDS|Patients will be treated by Rheumatoid Arthritis With Disease-Modifying Drugs (DMARDs).
88904650|NCT01547091|Active Comparator|UC-MSC+DMARDS|Patients will be treated in combination with UC-MSC and DMARDS.
88904651|NCT01547104|Active Comparator|Glimepiride-ratiopharm|Glimepiride (1-4mg) as add on therapy
88904652|NCT01547104|Experimental|Trajenta|Linagliptin 5 mg as add on therapy
88904653|NCT01547143|Experimental|IST and/or alloHCT|Patients who are newly diagnosed as HLH by HLH-2004 criteria, excluding those with HLH owing to malignancy or rheumatic disorder.
88904654|NCT01547156|No Intervention|Control group|Control group received usual care
88904655|NCT01547156|Experimental|Telemonitoring group|Intervention patients were given a remote patient monitoring toolbox that included a mobile telephone, software application, and assessment devices for measuring and remote reporting of hypertension and diabetes -related health parameters at home. The monitored parameters were body weight, steps, blood pressure and blood glucose. Based on their self-monitored data, patients received feedback that was automatically generated, theory-based, health promotion rich information that aimed at strengthening their self-care practices.
88904656|NCT01547169|Placebo Comparator|Saline|
88904657|NCT01547169|Experimental|Low Dose Insulin Detemir (10IU bid)|
88904658|NCT01547169|Experimental|High Dose Insulin Detemir (20IU bid)|
88904659|NCT01547182|Active Comparator|Weight Loss|Caloric restriction
88904660|NCT01547182|Experimental|Weight Loss and Aerobic Training|Caloric restriction and walking
88904661|NCT01547182|Experimental|Weight Loss and Resistance Training|Caloric restriction and lifting weights
88904662|NCT01547195|Experimental|Group-swimming|
88904663|NCT01547195|Active Comparator|Control-walk|
88904664|NCT01547208|Experimental|Group A|Patients will be randomized to a VT ablation procedure immediately after an appropriate ICD shock
88904665|NCT01547208|Active Comparator|Group B|Patients will wait until an arrhythmic storm to undergo a VT ablation procedure
88904666|NCT01547221|Active Comparator|3% boric acid|control
88904667|NCT01547221|Experimental|1% clotrimazole ear drop|3% boric acid is set as control while 1% clotrimazole ear drop is set as intervention.
88904668|NCT01547273|Experimental|bone graft inside socket only|bone graft inside socket only
88904669|NCT01547273|Experimental|bone graft inside and outside socket|bone graft inside and outside socket
88904670|NCT01547273|Experimental|no bone graft|no bone graft
88904671|NCT01547312|Experimental|Main Pt. 2: 800 mg Grazoprevir + Peg-IFN/RBV|800 mg Grazoprevir combined with Peg-Interferon/Ribavirin treatment.
88904672|NCT01547312|Experimental|Main Pt. 2: 100 mg Grazoprevir + Peg-IFN/RBV|100 mg Grazoprevir combined with Peg-Interferon/Ribavirin treatment.
88904673|NCT01547312|Experimental|Main Pt.1: 800 mg Grazoprevir|800 mg Grazoprevir.
88904674|NCT01547312|Experimental|Procedural Pilot|Optimization of FNA procedure.
88904675|NCT01547325|Experimental|NanoDOX Hydrogel|
88904676|NCT01547325|Placebo Comparator|Placebo Hydrogel|
88904677|NCT01547338||Breast reconstruction patient|Unilateral breast reconstruction patients
88904678|NCT01547351||ARMS Questionnaire Group|Patients with confirmed multiple sclerosis relapse who are willing to participate in the ARMS questionnaire. These patients could not have been treated with any therapies other than oral or intravenous corticosteroids for their previous relapse.
88904679|NCT01547364|Placebo Comparator|Caudal Saline|
88904680|NCT01547364|Active Comparator|Caudal Dextrose|
88904681|NCT01547377|Experimental|zinc and selenium supplementation|Patients received 10 mg rosuvastatin, concomitantly with zinc (30mg/d) and selenium (150μg/d) supplementation during 4 months
88904682|NCT01547377|Placebo Comparator|rosuvastatin + placebo|Patients received 10 mg rosuvastatin concomitantly placebo pills similar zinc and selenium supplementation
88904683|NCT01547416|Experimental|combined general/epidural anesthesia|epidural catheter was inserted in group GE at T8/9, T9/10, or T10/11 interspinous space with a 17-gauge Tuohy needle in lateral decubitus position and advanced 5 cm cephalad. Epidural analgesia was maintained using the patient-controlled analgesia technique.
88904684|NCT01547416|Active Comparator|General anesthesia|Patients allocated to general anesthesia group did not receive epidural anesthesia.
88904685|NCT01547455|Experimental|Atorvastatin|participants take 80mg Atorvastatin orally 12h before surgery with another 40mg 2h before surgery
88904686|NCT01547455|Placebo Comparator|Control|Participants randomized to Control arm take 80mg placebo 12h before surgery with another 40mg 2h before surgery
88904687|NCT01547481||Parkinson's Disease Cohort|Individuals Diagnosed with Parkinson's Disease
89423263|NCT02056743|Experimental|Red ginseng|"At period 1, the red ginseng group administered CYP cocktail (Caffeine 200mg + Losartan 50mg + Omeprazole 20mg + Dextromethorphan 30mg + Midazolam 7.5mg) under fasting conditions on the first day. At second day, they administered Fexofenadine 30mg under fasting conditions.~During 4~17th days they administered red ginseng. At period 2, the red ginseng group administered CYP cocktail (Caffeine 200mg + Losartan 50mg + Omeprazole 20mg + Dextromethorphan 30mg + Midazolam 7.5mg) under fasting conditions on the 15th day. At 16th day, they administered Fexofenadine 30mg under fasting conditions."
89423264|NCT02805309|Experimental|Exercise & Cognitive Behavioral Int.|A physical therapist will make home visits, beginning within 1 week of discharge, to deliver an individualized exercise program and cognitive behavioral interventions.
88904688|NCT01547481||Essential Tremor cohort|Individuals Diagnosed with Essential Tremor
88904689|NCT01547481||Rapid Eye Movement Disorder Cohort|Individuals Diagnosed with Rapid-Eye Movement Behavior Disorder (RBD). Eligible individuals will have been diagnosed with RBD based on a sleep study prior to entering the study. This study does not pay for or support a sleep study.
88904690|NCT01547481||Healthy Control group|Individuals are healthy, without a known neurologic disease.
88904691|NCT01547481||Progressive Supranuclear Palsy Cohort|Individuals diagnosed with Progressive Supranuclear Palsy (PSP).
88904692|NCT01547481||Parkinsonism - Undifferentiated|Individuals with any form of Parkinsonism, not meeting any of the above cohorts.
88904693|NCT01547494|Placebo Comparator|Dietary Supplement|
88904694|NCT01547494|Experimental|Vegan Diet|
88904695|NCT01547507|Active Comparator|KimVent Turbo-Cleaning Closed Suction System Kimberly clark|
88904696|NCT01547507|Active Comparator|Airway Medix Closed Suction System|
88904697|NCT01547520|Experimental|meperidine|25 mg of meperidine is injected intramuscularly before EGD
88904698|NCT01547520|Placebo Comparator|placebo|placebo was given intramuscularly before EGD
89423265|NCT02805309|Experimental|Exercise Alone|A physical therapist will make home visits, beginning within 1 week of discharge, to deliver an individualized exercise program, without cognitive behavioral interventions.
88904699|NCT01547533||Lactating Women with Chagas disease|Women with Chagas disease who fulfill clinical criteria for treatment with benznidazole, and who are also lactating
88904700|NCT01547546|Experimental|Single Arm|
89423266|NCT02805309|Active Comparator|Attention Control Education Program|Participants will receive telephone-based education sessions from a study health professional.
89423267|NCT02804763|Placebo Comparator|Placebo|Placebo in a specified sequence for a total of 24 weeks
88904701|NCT01547559|No Intervention|part1:blank control|NO maintain drugs with Hp negative patients.
88904702|NCT01547559|Experimental|part1:teprenone 1|maintain treatment with Teprenone for Hp negative patients
88904703|NCT01547559|Experimental|part1:EAC-T|eradication of Hp with triple treatment
88904704|NCT01547559|Experimental|part1：EA-EMC-T|eradication of Hp with sequential therapy
88904705|NCT01547559|Active Comparator|part1：T-T|Teprenone as maintain drugs for Hp positive patients
88904706|NCT01547559|Experimental|part2:GGA group|Geranylgeranylacetone plus diclofenac sodium for patients with rheumatic diseases
88904707|NCT01547559|No Intervention|part2:control group|diclofenac sodium only for patients with rheumatic diseases
88904708|NCT01547572|Experimental|Study group|The study group will get a video and leaflet on enhanced recovery.
88904709|NCT01547572|No Intervention|Control group|The control group will receive a leaflet only.
88904710|NCT01547585|Placebo Comparator|Control|- Isocaloric control muffins
88904711|NCT01547585|Experimental|Low Dose Soy|- Isocaloric muffins containing low dose of soy
88904712|NCT01547585|Experimental|High Dose Soy|- Isocaloric muffins containing high dose soy
88904713|NCT01547611|Active Comparator|Customary treatment|Group A (physiotherapy as usual), customary treatment. The staff at the Neurosurgical clinic will give the patient ordinary pre- and postoperative information. The physiotherapist at the Neurosurgical clinic informs the patients what to avoid the first weeks after surgery and the importance of a good posture and ergonomic thinking in daily life. The patient is also instructed how to do exercises for the shoulder range of motion. Patients have ordinary post-surgery visit to the surgeon and to the physiotherapist about 6 weeks after the surgery, where physiotherapist instructs the patient in exercises for active neck range of motion.
88904714|NCT01547611|Experimental|structured behavioural medicine program|Group B (extended physiotherapy treatment), customary treatment (please see above) plus a standardised and structured behavioural medicine program. The behavioural medicine program includes functional behavioural analysis of the problem, medical exercise therapy, strategies to increase self-efficacy in activities and problem-solving strategies for coping with disability.
88904715|NCT01547624|Experimental|Neck Specific exercises|3 months of neck specific exercises for 30 patients.
88904716|NCT01547624|No Intervention|Waiting list|Thirty patients on the waiting list for 3 month before they have their intervention
88904717|NCT01547624|No Intervention|Healthy controls|Forty healthy controls. Comparisons between forty included WAD patients and 40 healthy controls matched for age and gender will be investigated at baseline.
88904718|NCT01547637|Experimental|Ultrasound Guided|Ultrasound guided obturator nerve block will be performed after induction of general anesthesia. The anterior and posterior divisions of the obturator nerve will be identified with ultrasound. A stimulating needle will be inserted under direct ultrasound visualization. The anterior division will be blocked first. When adductor twitches are present at less than or equal to 0.5 mA, 10 ml of 2% lidocaine will be injected. Next, the needle will be re-directed under direct ultrasound visualization towards the posterior branch of the obturator nerve. After twitches < 0.5 mA are achieved then 10 mL of 2% lidocaine will be injected when the needle tip is visualized in proximity of the posterior branch.
88904719|NCT01547637|Experimental|Anatomic landmark|Obturator nerve block will be performed after induction of general anesthesia. The adductor magnus tendon approach will be used. A 4 cm insulated stimulating needle will be used to verify location of the obturator nerve by contraction of the thigh adductor group. The needle will be advanced until nerve stimulation is still present at less than or equal to 0.5 mA. When the appropriate nerve stimulation is achieved 10 ml of 2% lidocaine will be injected in divided doses with frequent aspiration. Nerve conduction studies will be repeated once a minute for the first 10 minutes after block completion.
88904720|NCT01547650||SIADH, CSWS, CDI, PP, DIH, HF|CSWS (cerebral salt wasting syndrome), SIADH (syndrome of inappropriate ADH) , CDI (central diabetes insipidus), PP (primary polydipsia), DIH (drug-induced hyponatremia), HF (heart failure with hyponatremia)
88904721|NCT01547676|Experimental|Arm A (unclamped partial nephrectomy)|Patients undergo unclamped partial nephrectomy. Some patients may undergo unclamped partial nephrectomy with controlled hypotension.
88904722|NCT01547676|Active Comparator|Arm B (clamped partial nephrectomy)|Patients undergo clamped partial nephrectomy.
88904723|NCT01547689|Experimental|Human Umbilical Cord Derived MSC|
88904724|NCT01547702|Experimental|Treatment|This group will have access to the Teacher Help for ADHD intervention program during the randomized controlled trial.
88904725|NCT01547702|No Intervention|Waitlist Control|This group will not receive the intervention until all data collection is complete for their study cohort.
88904726|NCT01547884||1|Latent TB positive with helminth positive
88904727|NCT01547884||2|Latent TB positive with helminth negative
88904728|NCT01547897|Active Comparator|NOX-E36|
88904729|NCT01547897|Placebo Comparator|Placebo|
88904730|NCT01547910|Experimental|Fish oil|Children will receive fish oil capsules according to age as described in the protocol
88904731|NCT01547910|Placebo Comparator|Placebo|Sunflower oil in the same capsules (the same shape and colour) given in the same regime as 'fish oil' capsules
88904732|NCT01547923|Experimental|A : pre-therapeutic screening for DPD deficiency|Prior to treatment by fluoropyrimidines,a DPD deficiency is identified by a joint phenotypic-pharmacogenetic approach.
89195565|NCT05457686|Experimental|kinesiology group|In the group receiving kinesiology treatment, kinesiotaping is applied to the sub-knee region in accordance with the lymphatic correction technique from the first postoperative day to reduce edema and pain. Accordingly, the proximal part of the tape is placed close to the lymph node. In our study, as stated in the literature, the proximal part of the tape will be adhered to the fibular head area next to the lymph nodes without applying any stretching. Then 5-10% stretching is applied and the distal part is adhered. 2 separate bands are applied so that the strips cross each other (from the medial and lateral of the knee). On the first postoperative day, on the third day, the patients will be taped with kinesio tape and discharged on the fourth day. After discharge, they will be asked to remove the tapes after 3 days as they were taught.
89195566|NCT05457686|Sham Comparator|sham taping group|Sham application will be taped with a plaster from the same area on the same days as the kinesio application. No tension will be applied while taping. The difference of the plaster from the kinesiotape is that it does not contain tension and does not allow stretching.
89423268|NCT02804763|Experimental|DZP dose 1|Dapirolizumab pegol (DZP) dose 1 in a specified sequence for a total of 24 weeks
89423269|NCT02804763|Experimental|DZP dose 2|Dapirolizumab pegol (DZP) dose 2 in a specified sequence for a total of 24 weeks
88904733|NCT01547923|Other|B : no pretherapeutic research of DPD deficiency|For patients included in this arm, a blood sample will be taken prior to treatment by fluoropyrimidines but not analysed. If grade 3 or 4 toxicity levels are encountered during treatment, DPD deficiency will be detected.
88904734|NCT01547949|Experimental|tart cherry juice|
88904735|NCT01547949|Placebo Comparator|cherry flavored fruit drink|
88904736|NCT01547962|Experimental|Split-mouth design: Treatment|
88904737|NCT01547962|Active Comparator|Split-mouth design: Control|
88904738|NCT01547988|Experimental|Balance Training Intervention|The Balance Training Intervention group received 24 training sessions over three months that included perturbation as well as dual-task exercises.
88904739|NCT01547988|No Intervention|Reference Group|
88904740|NCT01548001|Experimental|Iguratimod monotherapy|
88904741|NCT01548001|Experimental|Iguratimod and MTX combination|
88904742|NCT01548001|Active Comparator|MTX monotherapy|
88904743|NCT01548027|Experimental|No intervention|no injection of local anesthetic agents
89423270|NCT02804763|Experimental|DZP dose 3|Dapirolizumab pegol (DZP) dose 3 in a specified sequence for a total of 24 weeks
89423271|NCT02052297|Other|Part A|In Part A, up to 6 healthy subjects will be enrolled in order to determine the human radiodosimetry following administration of the PET radioligand.
89423272|NCT02052297|Other|Part B|In Part B, up to 8 healthy subjects will be recruited to provide sufficient PET data to quantify the uptake and distribution of GSK2634673F in healthy subjects.
89423273|NCT02052297|Other|Part C|In Part C, up to 20 IPF subjects will be recruited to provide sufficient PET data to quantify the uptake and distribution of GSK2634673F in IPF subjects and, if appropriate, potentially quantify the test/re-test variability.
89423274|NCT02052375|Experimental|ASP2408 low dosing frequency|
89423275|NCT02052375|Experimental|ASP2408 high dosing frequency|
89423276|NCT02052375|Experimental|Placebo low dosing frequency|
89423277|NCT02052375|Experimental|Placebo high dosing frequency|
89007077|NCT06028334|Experimental|Immediate Treatment|"The 10-week GetUp&Go intervention will be delivered entirely remotely, with 2 weekly sessions with a therapist delivered over videoconference (Zoom for Healthcare) followed by 3 sessions in weeks 3, 5, and 8, over Zoom or phone according to participant preference.~The overall goal of the intervention is to develop and support a personalized plan to increase physical activity and decrease sedentary behavior, in concert with the unique capabilities, opportunities, and motivational factors of each participant. In session 2 and thereafter, RehaBot will be supplied to participants to deliver therapeutic ingredients to supplement those provided by the therapist."
89007078|NCT06028334|Placebo Comparator|Waitlist|A 10-week waitlist with baseline and outcome assessment, followed by receipt of the full GetUp&Go program.
88814373|NCT00932282|Active Comparator|24 month maintenance of PnOIT|"All subjects will be on the same intervention until Randomization. Randomized subjects who will stay on the maintenance dose of peanut oral immunotherapy (PnOIT) for 24 months.~The study has 4 phases: anti-IgE therapy before immunotherapy (Omalizumab), an initial desensitization day(s), a buildup period, and a daily home maintenance phase with a final dose of 8000mg peanut flour (~50% peanut protein). Then all subjects will be randomized to an additional 1 or 2 years (12 or 24 months) of maintenance OIT. An OFC will be performed at the end of the long-term maintenance in all groups."
88814374|NCT04367558|Experimental|Interventional|Patient suffering from OSA, and found to suffer from obstruction of one or more of the following areas - Lower turbines, Soft Palate, Tonsils, Base-of-tongue.
88814375|NCT04346810||Recovery room caregivers|Caregivers working at a recovery room shifted into an intensive care unit for the management of patients suffering from coronavirus infection and needing a resuscitation
88814376|NCT04346810||Intensive care unit caregivers|Caregivers working at a conventional intensive care unit for the management of patients suffering from coronavirus infection and needing a resuscitation
88814377|NCT01632995|Experimental|Emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)|All study participants will be assigned to this arm and will receive one FTC/TDF tablet orally once a day.
88814378|NCT04362098|Experimental|Nurse home visits|Nurse home visits biweekly.
88814379|NCT04362098|No Intervention|Usual care|Usual care.
88814380|NCT02245022|Experimental|Dolutegravir 50mg od|30 patients who will receive dolutegravir 50mg once daily plus the same NRTI backbone as the active comparator group (lamivudine and tenofovir)
88814381|NCT02245022|Active Comparator|Standard of Care|Patients randomised to receive antiretroviral therapy as per Uganda national guidelines (Efavirenz 600mg od based plus Tenofovir 300mg od and Lamivudine 300mg od)
88814382|NCT02224313|No Intervention|1.Premenopausal women|No treatment
88814383|NCT02224313|Experimental|2.Postmenopausal women with hormones|"Oral hormone therapy will be given to women in this group. Daily dose of oral estradiol 1 mg will be given the first 14 days after enrollment. Then a daily dose of oral estradiol 1 mg and progesterone 100 mg for 14 days will be given during the following 14 days."
88814384|NCT04362410|Experimental|Tezepelumab: Low dose|Tezepelumab: Tezepelumab single dose subcutaneously injection.
88814385|NCT04362410|Experimental|Tezepelumab: Medium dose|Tezepelumab: Tezepelumab single dose subcutaneously injection.
88814386|NCT04362410|Experimental|Tezepelumab: High dose|Tezepelumab: Tezepelumab single dose subcutaneously injection.
88814387|NCT04362410|Placebo Comparator|Placebo|Placebo single dose subcutaneously injection.
88814388|NCT02460198|Experimental|Cohort A - Pembrolizumab 200 mg|Participants were previously treated with standard therapies, which must include fluoropyrimidine, oxaliplatin, and irinotecan. Cohort A participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of every 3-week cycle (Q3W) for up to approximately 52 cycles (up to approximately 3 years).
88814389|NCT02460198|Experimental|Cohort B - Pembrolizumab 200 mg|Participants were previously treated with at least one line of systemic standard of care therapy: fluoropyrimidine + oxaliplatin or fluoropyrimidine + irinotecan +/ - anti vascular endothelial growth factor (VEGF)/ epidermal growth factor regulator (EGFR) monoclonal antibody. Cohort B participants receive pembrolizumab 200 mg IV on Day 1 Q3W for up to approximately 52 cycles (up to approximately 3 years).
88814390|NCT01633853|Experimental|Vitamin D2 Treatment|Patients will be treated by vitamin D2. Oral Vit D2 1.25mg(50,000 unit) once weekly as a start and maintain 1.25mg(50,000 unit) once monthly according to the blood 25(OH)vitamin D level.
88814391|NCT01633853|Active Comparator|1,25(OH)2 Vitamin D3|Patients will be treated by 1,25(OH)2 Vitamin D3. Oral 1,25(OH)2 Vitamin D3(Rocaltrol) by 0.25 microgram once daily at start and regulate the dose according to the changes of blood levels of 25(OH)Vit D, calcium, phosphorus, and intact parathyroid hormone.
88814392|NCT04367402||Symptomatic Patients|Patients who had symptoms related to COVID-19 infection
88814393|NCT04367402||Health people|Healthy people who never had syntomps related to COVID-19 infection
88814394|NCT04367402||Asyntomatic Individuals|Asyntomatic people to recruit after the restriction have ended
88814395|NCT04361552|Experimental|Arm I (tocilizumab, standard of care)|Patients receive tocilizumab IV every 12 hours for up to 3 doses in the absence of disease progression or unacceptable toxicity. Patients also receive standard of care.
88814396|NCT04361552|Active Comparator|Arm II (standard of care)|Patients receive standard of care.
88814397|NCT02487810|Experimental|Intuitive|Patients in each arm will be asked all of the same questions. The only difference between the arms will be the instructions regarding how and when to answer the series of hypothetical questions regarding medical interventions. The instructions will be designed to influence patients to think either intuitively or deliberatively about the questions regarding life-sustaining interventions.
88814398|NCT02487810|Experimental|Deliberative|Patients in each arm will be asked all of the same questions. The only difference between the arms will be the instructions regarding how and when to answer the series of hypothetical questions regarding medical interventions. The instructions will be designed to influence patients to think either intuitively or deliberatively about the questions regarding life-sustaining interventions.
88814399|NCT04367324||Low level laser therapy|Applied the low-level laser irradiation
88814400|NCT04367324||Control|No low-level laser application
89423278|NCT03561363|Experimental|Saturated high-fat diet|"In this intervention group, subjects ingest a saturated eucaloric high-fat diet (64 E%) with total fat content being similar to the polyunsaturated high-fat diet.~The diet is enriched in saturated fat (36 E%). The main saturated fatty acids in the diet are primarily palmitic acid (C16:0) and stearic acid (C18:0). The main food sources are milk products, high-fat meat and vegetables.~Carbohydrate comprise 20 E% and protein 15 E%."
89423279|NCT03561363|Experimental|polyunsaturated high-fat diet|In this intervention group, subjects ingest a polyunsaturated eucaloric high-fat diet (64 E%), with total fat content being similar to the saturated high-fat diet. The diet is enriched in polyunsaturated fat (32 E%). The main polyunsaturated fatty acids in the diet are primarily linoleic acid (C18:2 n-6) and alpha-linoleic acid (C18:3 n-3). The main food sources are vegetable oils, nuts and high-fat fish (e.g. salmon). Carbohydrate comprise 20 E% and protein 15 E%.
89423280|NCT02054559|Active Comparator|Total 6 cycles of R-CHOP|
89423281|NCT02054559|Experimental|Total 3 cycles of R-CHOP + RT|Total 3 cycles of R-CHOP followed by radiotherapy (involved field or involved site radiotherapy, 30-50 Gy/ 15-25 fractions)
89423282|NCT02054637|Experimental|Lanreotide|Lanreotide autogel 120mg injection every 4 weeks (every patient will receive 3 injections)
89423283|NCT02056977|Experimental|Titration|Individualized PEEP titration by EIT
89423284|NCT02056977|Active Comparator|Control|PEEP stablished according to the routines at the institution (PEEP table according to the P/F ratio)
89423285|NCT02038413||NSCLC stage I|Consecutive patients were identified from October 2009 onwards in MAASTRO clinic, Maastricht. All patients received respiratory gated CT (4DCT) scans. All were patients referred for primary radiotherapy or chemo radiation.
89423286|NCT02057055|Experimental|Soap 300000027003|Subjects will apply this soap to one of their arms daily in the shower for 3 weeks
89423287|NCT02057055|Experimental|Soap 300000029240|Subjects will apply this soap to one of their arms daily in the shower for 3 weeks
89423288|NCT02057211|Placebo Comparator|sham transplantation of mesenchymal stem cells|control arm with sham transplantation
89423289|NCT02057211|Active Comparator|autologous mesenchymal stem cell transplantation|Active arm with transplantation of cells
89423290|NCT02052531|Experimental|PAC-14028 cream 0.3%|PAC-14028 cream 0.3%, twice daily for 28 days
89423291|NCT02052531|Experimental|PAC-14028 cream 1.0%|PAC-14028 cream 1.0%, twice daily for 28days
89423292|NCT02052531|Placebo Comparator|Vehicle|Vehicle, twice daily for 28days
89423293|NCT02052687|Experimental|Part 1: LFX453/placebo|once daily: LFX453 cream 1 high dose / LFX453 cream 1 low dose /Placebo 1 / LFX453 cream 2 high dose / LFX453 cream 2 low dose / Placebo 2
89423294|NCT02052687|Experimental|Part 2 groupA: LFX453/placebo|once daily: LFX453 cream 1 / Placebo 1
89423295|NCT02052687|Experimental|Part 2 groupB: LFX453/placebo|once daily: LFX453 cream 2 / Placebo 2
88814401|NCT04361630|Experimental|Main treatment group|Collagen membranes incorporating 10ng/ml human recombinant basic fibroblast growth factor (FGF-2/bFGF) will be placed in the sites.
88814402|NCT04376216|No Intervention|Control|No treatment
88814403|NCT04376216|Active Comparator|Prednisone|Oral prednisone. Starting dose of 60 mg with tapering for 2 months
88814404|NCT02452320|Placebo Comparator|Control|Subjects randomized into the control group will not receive study medication, they will receive a placebo administered at the same schedule as the active drug in the other arm.
88814405|NCT02452320|Active Comparator|Randomized|Subjects randomized into the active treatment group will receive intravenous acetaminophen
88814406|NCT02459964|Experimental|Fentanyl Nasal Spray|"Fentanyl nasal spray 100 mcg delivered at time 0 (defined as the time when intranasal Fentanyl spray is administered) with a rescue dose allowed at time 0.5 hour (h).~Study nurse to call patient 24 hours after participation to ask about side effects since taking part in the study."
88814407|NCT02459964|Active Comparator|Hydromorphone Hydrochloride|"Hydromorphone hydrochloride 1.5 mg pushed intravenously (IV) at time 0 (defined as the time of completion of opioid IV push) with a rescue dose allowed at time 0.5 hour (h).~Study nurse to call patient 24 hours after participation to ask about side effects since taking part in the study."
88814408|NCT01635101|Experimental|Low Dose Acetaminophen|Participants receive a low dose of acetaminophen intravenously (IV) for 24 hours
88814409|NCT01635101|Experimental|High Dose Acetaminophen|Participants receive a low dose of acetaminophen (IV) for 24 hours
88814410|NCT01635101|Placebo Comparator|Placebo|Participants receive matching placebo (IV) for 24 hours
89423296|NCT02052687|Experimental|Part 2 groupC: LFX453/LFX453|once daily: LFX453 cream 1 / LFX453 cream 2
89423297|NCT02052687|Other|Part 2 groupD: Imiquimod|once daily: imiquimod cream
89423298|NCT02052687|Experimental|Part 3: LFX453/placebo|twice daily: LFX453 cream 1 high dose / LFX453 cream 1 low dose /Placebo 1 / LFX453 cream 2 high dose / LFX453 cream 2 low dose / Placebo 2
88814412|NCT02087111|Experimental|Treatment|All patients who are fulfil the entry criteria are treated for 24 weeks with 40 Kd Pegylated interferon alfa 2a, Ribavirin and 12 weeks with telaprevir.
88814413|NCT02993939|Active Comparator|Interscalene block|Ultrasound guided Brachial plexus block injecting 20 ml of levobupivacaine 0,25% plus epinephrine 5 micrograms per ml, in the Interscalene groove.
89423299|NCT02052765|Experimental|ajmaline test|All patients underwent ajmaline test for ST shift recording
89423300|NCT02057289|Experimental|Micafungin|"Subjects will be administered 5 mg/kg of micafungin intravenously as a ONE TIME dose.~For patients undergoing Hematopoietic Stem Cell Transplant (HSCT), Micafungin will be given on during rest days (i.e. days when no chemotherapy is administered) and blood for pharmacokinetic measurements will be drawn over next 96 hours.~Following this, further anti-fungal coverage will be at the discretion of the patient's attending physician. (I.e. other antifungal agent(s) or Micafungin at a standard clinical dose; repeat doses of 5mg/kg will NOT be administered.)"
89423301|NCT02057367|Experimental|Scalp block with 0.5% plain marcaine|Anterior scalp block with 0.5% plain Marcaine 20 ml.
89423302|NCT02057367|Placebo Comparator|Scalp block with 0.9% normal saline|Anterior scalp block with 0.9% normal saline 20 ml.
88904744|NCT01548027|Experimental|Local infiltration group|patients would have 0.5 ml/kg of 0.25% bupivacaine if age < 6 months or 1 ml/kg if age > 6 months around the wound by surgeon. The needle will be injected in subcutaneous tissue parallel to the wound.
88904745|NCT01548027|Experimental|TAP block group|Surgical TAP block (sTAP: Patients would have 0.5 ml/kg of 0.25% bupivacaine if age < 6 months or 1 ml/kg if age > 6 months
88904746|NCT01548066|Experimental|Sodium valproate|spray 7.2% of sodium valproate on scalp twice a day (morning and evening) for 24 weeks
88904747|NCT01548066|Placebo Comparator|Control|spray vehicle without sodium valproate on scalp twice a day (morning and evening) for 24 weeks
88904748|NCT01548079|No Intervention|Control|Untreated controls
88904749|NCT01548079|Active Comparator|Ursodeoxycholic acid|Oral ursodeoxycholic acid 20 mg/kg/day in three weeks
88904750|NCT01548092|Experimental|Autologous SVF|Intralesional application
88904751|NCT01548105||Prolapse and Smoker|Patients in this arm have been determined to have more than stage 2 pelvic organ prolapse and have been smoking more than one pack per day Blood draw for the study participants will be done. These will include: Procollagen 1-N propeptide levels (PINP), Matrix metalloproteinase (MMP9) and Plasma Vitamin C levels
88904752|NCT01548105||Prolapse and non smoker|Patients in this arm have been determined to have more than stage 2 pelvic organ prolapse and non smoker for more than 7 years Blood draw for the study participants will be done. These will include: Procollagen 1-N propeptide levels (PINP), Matrix metalloproteinase (MMP9) and Plasma Vitamin C levels
88904753|NCT01548105||No prolapse and smoker|Patients in this arm, have been determined not to have prolapse and smokes more than 1 pack per day Blood draw for the study participants will be done. These will include: Procollagen 1-N propeptide levels (PINP), Matrix metalloproteinase (MMP9) and Plasma Vitamin C levels
88904754|NCT01548105||No prolapse and non smoker|Patients in this arm have been determined not to have prolapse and non smoker for more than 7 years Blood draw for the study participants will be done. These will include: Procollagen 1-N propeptide levels (PINP), Matrix metalloproteinase (MMP9) and Plasma Vitamin C levels
88904755|NCT01548118|Experimental|Adult Group 1, HPV vaccine 0.5ml|20 women between 18-45 yeas of age, receiving 0,2,6 month-schedule of 0.5ml experimental HPV vaccines.
88904756|NCT01548118|Placebo Comparator|Adult Group 1, Placebo 0.5ml|20 women between 18-45 yeas of age, receiving 0,2,6 month-schedule of 0.5ml aluminum phosphate.
88904757|NCT01548118|Experimental|Adult Group 2, HPV vaccine 1.0ml|20 women between 18-45 yeas of age, receiving 0,2,6 month-schedule of 1.0ml experimental HPV vaccines.
88904758|NCT01548118|Placebo Comparator|Adult Group 2, Placebo 1.0ml|20 women between 18-45 yeas of age, receiving 0,2,6 month-schedule of 1.0ml aluminum phosphate.
88904759|NCT01548118|Experimental|Children Group 1, HPV vaccine 0.5ml|20 girls between 9-17 yeas of age, receiving 0,2,6 month-schedule of 0.5ml experimental HPV vaccines.
88904760|NCT01548118|Placebo Comparator|Children Group 1, Placebo 0.5ml|20 girls between 9-17 yeas of age, receiving 0,2,6 month-schedule of 0.5ml aluminum phosphate.
88904761|NCT01548118|Experimental|Children Group 2, HPV vaccine 1.0ml|20 girls between 9-17 yeas of age, receiving 0,2,6 month-schedule of 1.0ml experimental HPV vaccines.
88904762|NCT01548118|Placebo Comparator|Children Group 2, Placebo 1.0ml|20 girls between 9-17 yeas of age, receiving 0,2,6 month-schedule of 1.0ml aluminum phosphate.
89423303|NCT02057445|Experimental|Recipient|EBV+ patients will receive 3rd party LMP-CTLs for treatment of EBV infection and/or disease
89423304|NCT02057445|Other|Donor|Healthy donors who are EBV+ will be asked to donate 60-120 ml of peripheral blood for development of cell lines to be stored for cell line bank.
88904763|NCT01548131|Experimental|Psychoeducative group therapy|Psychoeducative group therapy
88904764|NCT01548131|No Intervention|Control|Women screened for fear of childbirth were taken cared by primary health care nurses and if needed referred to specialized care in hospital
88904765|NCT01548144|Experimental|Crizotinib + Pazopanib - Group A|"Starting dose for Crizotinib: 250 mg by mouth every other day, 1 or 2 times a day on Day 1 of a 21 day cycle. Participant told how often to take this drug.~Dose Expansion Group: MTD from Phase 1.~Starting Dose for Pazopanib: 200 mg by mouth daily in a 21 day cycle.~Dose Expansion Group: MTD from Phase 1."
88904766|NCT01548144|Experimental|Crizotinib + Pemetrexed - Group B|"Starting dose for Crizotinib: 250 mg by mouth every other day, 1 or 2 times a day on Day 1 of a 21 day cycle. Participant told how often to take this drug.~Dose Expansion Group: MTD from Phase 1.~Starting dose for Pemetrexed: 200 mg/m2 by vein every 3 weeks on Day 1 of a 21 day cycle.~Dose Expansion Group: MTD from Phase 1."
88904767|NCT01548144|Experimental|Pazopanib + Pemetrexed - Group C|"Starting dose for Pazopanib: 200 mg by mouth daily in a 21 day cycle.~Expansion group starting dose: MTD from Phase 1.~Starting dose for Pemetrexed: 200 mg/m2 by vein on Day 1 of a 21 day cycle.~Expansion group starting dose: MTD from Phase 1."
88904768|NCT01548144|Experimental|Crizotinib + Pazopanib + Pemetrexed - Group D|"Starting dose for Crizotinib: 250 mg by mouth every other day, 1 or 2 times a day on Day 1 of a 21 day cycle. Participant told how often to take this drug.~Dose Expansion Group: MTD from Phase 1.~Starting Dose for Pazopanib: 200 mg by mouth daily in a 21 day cycle.~Dose Expansion Group: MTD from Phase 1.~Starting dose for Pemetrexed: 400 mg/m2 by vein every 3 weeks on Day 1 of a 21 day cycle.~Dose Expansion Group: MTD from Phase 1."
88904769|NCT01548157|Experimental|HCP1007|HCP1007
88904770|NCT01548157|Active Comparator|omarco and crestor|Rosuvastatin plus Omega-3
88904771|NCT01548170|Active Comparator|Sunitinib 50mg|Sunitinib 50 mg administered as a single dose.
88904772|NCT01548170|Experimental|Sunitinib 37.5mg + Ketoconazol 200mg|"The drugs will be administered as follows:~Sunitinib 37.5mg oral single dose.~Ketoconazole 200 mg orally, once daily for 6 days. (Combination with sunitinib will be performed on day 4)"
88904773|NCT01548170|Experimental|Sunitinib 37.5 mg + Ketoconazol 400 mg|"The drugs will be administered as follows:~Sunitinib 37.5mg oral single dose.~Ketoconazole 400 mg orally, once daily for 6 days. (Combination with sunitinib will be performed on day 4)"
88904774|NCT01548170|Experimental|Sunitinib 25mg + Ketoconazol 200mg|"The drugs will be administered as follows:~Sunitinib 25mg oral single dose.~Ketoconazole 200 mg orally, once daily for 6 days. (Combination with sunitinib will be performed on day 4)"
89423305|NCT02054871|Experimental|EGFR 30-60|"Experimental: RIPC Remote preconditioning Calculated EGFR based on MDRD. Patients receive intravenous fluids preprocedure as additional renal protection.~Preconditioning will be performed in the same manner as several previous trials. Immediately prior to angiography a CE-approved blood pressure cuff will be placed around one arm of the patient. It will then be inflated to a pressure of 200mmHg for 5 minutes. For patients with a systolic blood pressure >185mmHg, the cuff will be inflated to at least 15mmHg above the patient's systolic blood pressure. The cuff will then be deflated and the arm allowed reperfuse for 5 minutes. This will be repeated so that each patient receives a total of 4 ischaemia-reperfusion cycles."
89423306|NCT02054871|Experimental|EGFR 60-90|Experimental: RIPC Remote preconditioning. EGFR calculated using MDRD equation. Oral hydration pre-procedural as reno-protective measure. Preconditioning will be performed in the same manner as several previous trials. Immediately prior to angiography a CE-approved blood pressure cuff will be placed around one arm of the patient. It will then be inflated to a pressure of 200mmHg for 5 minutes. For patients with a systolic blood pressure >185mmHg, the cuff will be inflated to at least 15mmHg above the patient's systolic blood pressure. The cuff will then be deflated and the arm allowed reperfuse for 5 minutes. This will be repeated so that each patient receives a total of 4 ischaemia-reperfusion cycles.
89423307|NCT02054871|No Intervention|EGRF 30-60|"No Intervention: Remote preconditioning control Calculated EGFR based on MDRD. Patients receive intravenous fluids preprocedure as additional renal protection.~Patients randomised to this group will receive routine care."
89423308|NCT02054871|No Intervention|EGRF 60-90|No Intervention: Remote preconditioning control EGFR calculated using MDRD equation. Oral hydration pre-procedural as reno-protective measure. Patients randomised to this group will receive routine care.
89423309|NCT02054949|Experimental|N-Acetyl Cysteine (NAC)|NAC will be started at 500 mg by mouth twice daily for the first 2 weeks, then increased to 500 mg in the am and 1000 mg in the pm for week 3, and then increased to 1000 mg am and pm for weeks 4 through 8. Subjects will be maintained at the highest tolerated dose.
88904775|NCT01548170|Experimental|Sunitinib 25mg + Ketoconazol 400mg|"The drugs will be administered as follows:~Sunitinib 25mg oral single dose.~Ketoconazole 400 mg orally, once daily for 6 days. (Combination with sunitinib will be performed on day 4)"
89423310|NCT02748057|Experimental|Ezetimibe 10 mg + Rosuvastatin 2.5 mg|1 Ezetimibe 10 mg tablet and 1 Rosuvastatin 2.5 mg capsule/tablet orally, once daily for 52 weeks. If participant does not achieve low-density lipoprotein- cholesterol (LDL-C) goal after Week 12, dosage of Rosuvastatin may be increased to 5.0 mg
89423311|NCT02748057|Experimental|Ezetimibe 10 mg + Rosuvastatin 5.0 mg|1 Ezetimibe 10 mg tablet and 2 Rosuvastatin 2.5 mg capsules/tablets orally, once daily for 52 weeks.
89423312|NCT02057601|Experimental|Infiltration group|The patients in this group will receive spinal anaesthesia with intrathecal bupivacaine 0.5% 2.0ml and will receive peri-surgical site infiltration before wound closure with a solution of levobupivacaine 0.5% 2mg/kg body weight with epinephrine made up to a volume of 1.5ml/kg with saline.
89423313|NCT02057601|No Intervention|Non infiltration group|The patients in this group will receive spinal anaesthesia with intrathecal bupivacaine 0.5% 2.0 ml.
89423314|NCT02052843|Experimental|Steps to Success|Steps to Success enhanced home visits-including instruction for both young mothers and fathers on contraception, comprehensive sex education, and the importance of adequate birth spacing, and accompanied by group sessions on adulthood preparation topics.
89423315|NCT02052843|Active Comparator|Traditional Healthy Families|Traditional Healthy Families home visits which cover topics of parenting and child development
89423316|NCT02055027||Adherent Patients|Comparison between groups
89423317|NCT02055027||Non-adherent patients|Comparison between groups
89423318|NCT02057679|Active Comparator|Group A (Amoxicillin Clavulanic)|Intake of active drug (Amoxicillin Clavulanic). 3 g per day divided into 3 oral intakes of 1 g each (2 pill of Amoxicillin Clavulanic every 8 hrs). This treatment will begin on postoperative day 1 for 5 days.
89423319|NCT02057679|Placebo Comparator|Placebo|Intake of placebo (Lactose). 1 pill of the same characteristics as Amoxicillin clavulanic every 8 hs. This will begin on postoperative day 1 for 5 days.
89423320|NCT02055105|Other|miRNA|
88904776|NCT01548183|Experimental|Lifestyle counseling|Weekly SMS assessing risky sexual encounters and providing feedback including concern, goal-setting and tools to reduce risk
88904777|NCT01548183|No Intervention|Usual care|Usual care includes ED provider counseling as per normal clinical care
89423321|NCT02038491||regional anesthesia|patients undergoing regional anesthesia procedures
89423322|NCT02055261|Other|OFF PPN DBS-ON PPN DBS|Patients randomly allocated to the order OFF Low frequency DBS of the pedunculopontine nucleus then ON Low frequency DBS of the pedunculopontine nucleus
89423323|NCT02055261|Other|ON PPN DBS - OFF PPN DBS|Patients randomly allocated to the order ON Low frequency DBS of the pedunculopontine nucleus then OFF Low frequency DBS of the pedunculopontine nucleus
89423324|NCT02055339|Experimental|Fisher & Paykel heated humidified high flow nasal cannula|For neonates randomized to HHHFNC, they will be placed on a flow rate equivalent to the pressures of nCPAP they were originally receiving based on a published chart, or stay on the same flow rate prior to randomization. When it is time for oral feeds, the Registered Nurse (RN) will turn the dial of the high flow circuit down to 2 lpm. The baby will then proceed to feed for up to one hour, and afterwards, will be turned back up to the flow rate they were on prior to feeds.
88904778|NCT01548196|Other|standard percutaneous nephrostomy|Standard PCN
88904779|NCT01548196|Other|double-J ureteral stent,|double-J ureteral stent,
89423325|NCT02055339|Active Comparator|InfantFlow/RAM nasal continuous positive airway pressure|Neonates randomized to the nCPAP arm will remain on the nCPAP pressures they were on before recruitment into the study or match the flow rate they were receiving on high flow based on a published chart. The nCPAP circuit will only be removed when it is time for oral feeds. The respiratory therapist (RT) will exchange the circuit for a low flow nasal cannula which will be set at the flow that is optimal for the baby's gestational age saturations. The baby will then proceed to feed for up to one hour, and afterwards, will be changed back to the nCPAP circuit.
89423326|NCT02052921|Active Comparator|Rectal resection|Surgical rectal resection
88904780|NCT01548196|Other|open-ended ureteral catheter|open-ended ureteral catheter
88904781|NCT01548196|No Intervention|no nephrostomy or ureteral stent/catheter.|no nephrostomy or ureteral stent/catheter.
89423327|NCT02052921|Experimental|Observation|Conservative approach
89423328|NCT02055417|Experimental|Personal Approaches to Treatment Choices for HIV|PATCH is a brief intervention designed to support participants' decision-making processes and enhance intrinsic motivation to initiate ART.
89423329|NCT02055417|Active Comparator|Stress Reduction Skills Program|SRSP includes training in stress reduction skills such as relaxation, problem solving, and expressing negative feelings.
89423330|NCT02052999|Experimental|PAC-14028 cream 1%|PAC-14028 cream 1%, twice daily for 8 weeks
89423331|NCT02052999|Active Comparator|Rozex gel 0.75%|Rozex gel 0.75%, twice daily for 8 weeks
88904782|NCT01548209|Experimental|Group D|A single dose dexmedetomidine 0.5 mcg/kg iv. 30 min before end of the surgery
88904783|NCT01548209|Placebo Comparator|Group P|Placebo 0.5 mcg/kg iv. 30 min before end of the surgery
88904784|NCT01548235||BIAsp 30 users|
88904785|NCT01548248||Levemir® users|
88904786|NCT01548261||Health people.|
88904787|NCT01548300||Enrolled participants|Subjects will be recruited from clinics affiliated with the Fuwai Hospital, PUMC. The participants will be nonsmokers with cardiometabolic disease, that are not taking anti-hypertensive, glucose-lowering, or lipid-lowering medications or drugs that alter baseline insulin sensitivity, blood pressure, or endothelial function, daily use of NSAIDS is not allowed.
88904788|NCT01548313||Pregnant women from Ljubljana region|Women at 3rd trimester of pregnancy living in the Ljubljana region.
89423332|NCT02052999|Placebo Comparator|Vehicle|Vehicle, twice daily for 8 weeks
89423333|NCT02055573|Experimental|Ready To Learn|1) The Ready to Learn (RTL) arm will receive a DVD in both Spanish and English and a bilingual booklet (both produced by Parents' action for Children) addressing the benefits of reading, talking and playing with young children, as well as a new children's board book.
89423334|NCT02055573|Experimental|All Babies Cry|2) The All Babies Cry (ABC) arm will receive a DVD in both, Spanish and English and a bilingual booklet (both produced by VIDA Health Communications, INC) explaining crying as part of normal infant behavior, highlighting signs of parental distress and providing strategies to sooth parents and their children
89423335|NCT03561285||Stroke with antiphospholipid|
89423336|NCT03561285||stroke without antiphospholipid|
89423337|NCT02055651||Bayer Sao Paulo employees|Workers from Bayer in site Socorro who participate in the trial
88904789|NCT01548313||Pregnant women from Izola region|Women at 3rd trimester of pregnancy living in the Izola region.
89423338|NCT02057913|Experimental|Vinflunine|All patients will receive on Day 1 of a 21 day cycle, vinflunine 320mg/m2 via intravenous infusion in either 100ml sodium chloride 0.9% or glucose 5% over 20 minutes; four cycles to be given in total prior to formal re-staging.
89423339|NCT02055729||The study population|"The proposed study is a prospective, single-center pilot study lasting 28 days. Our goal is to study the temporal evolution of the bacterial communities present in the skin and digestive flora (stool) of spinal cord injured persons having one or more sacral bedsores. The study timespan can include treatment initiation, notably of antibiotics. Urinalysis for studying urinary flora will simultaneously occur.~For a description of the study population, see the inclusion/exclusion criteria.~Intervention: Superficial bedsore sample Intervention: 3mm tissue punch biopsy Intervention: Stool sample Intervention: Urine sample"
88904790|NCT01548313||Pregnant women from Murska Sobota region|Women at 3rd trimester of pregnancy living in the Murska Sobota region.
88904791|NCT01548326|Active Comparator|Atorvastatin|will receive one 40 mg Atorvastatin tablet orally per day for 10 days and in 5th day 1 dose of recombinant yeast-derived Hepatitis B vaccine intramuscular in left Deltoid muscle
88904792|NCT01548326|Placebo Comparator|Placebo|will receive one Placebo tablet orally per day for 10 days and in 5th day 1 dose of recombinant yeast-derived Hepatitis B vaccine intramuscular in left Deltoid muscle
88904793|NCT01548365|No Intervention|Control Group|routine care for the selection, placement and maintenance of venous access devices (VAD).
88904794|NCT01548365|Experimental|Infusion Therapy Nursing Expert|Patients in this group will receive the infusion therapy nursing expert (ITNE) service.
88904795|NCT01548378|Experimental|High Dose|Patients in this treatment group will receive 8mg NL003 respective in D0、14、28
88904796|NCT01548378|Experimental|Middle Dose|Patients in this treatment group will receive 6mg NL003 respective in D0、14、28
88904797|NCT01548378|Experimental|Low Dose|Patients in this treatment group will receive 4mg NL003 in D0、14、28
88904798|NCT01548378|Placebo Comparator|Placebo|Patients in this group will receive normal saline respective in D0、14、18
88904799|NCT01548391|Experimental|HX-1171 20 mg (20mg 1T)|
88904800|NCT01548391|Experimental|HX-1171 40 mg (20mg 2T)|
88904801|NCT01548391|Experimental|HX-1171 80 mg (20mg 4T)|
88904802|NCT01548391|Experimental|HX-1171 160 mg (20mg 8T)|
88904803|NCT01548391|Experimental|HX-1171 300 mg (200mg 1T, 20mg 5T)|
88904804|NCT01548391|Experimental|HX-1171 600 mg (200mg 3T)|
88904805|NCT01548391|Experimental|HX-1171 1200 mg (500mg 2T, 200mg 1T)|
88904806|NCT01548391|Experimental|HX-1171 1500 mg (500mg 3T)|
88904807|NCT01548391|Experimental|HX-1171 2000 mg (500mg 4T)|
88904808|NCT01548430|Experimental|TTP4000 1.0 mg/kg|Administered subcutaneously
88904809|NCT01548430|Experimental|TTP4000 3.0 mg/kg|Administered subcutaneously
88904810|NCT01548430|Placebo Comparator|Placebo|Administered subcutaneously
88904811|NCT01548443|Experimental|Medifoam H|"A group which treated with medifoam H on the wound."
88904812|NCT01548443|Active Comparator|Duoderm THIN|"A group which treated with  Duoderm THIN  on the wound"
88904813|NCT01548456||Intramedullary nailing|Subjects with a femur fracture who undergo operative fixation with an intramedullary nail
88904814|NCT01548456||Open Reduction Internal Fixation|Subjects with a femur fracture who undergo open reduction internal fixation with a dynamic compression plate
88904815|NCT01548469|Active Comparator|Perio Total Care toothpaste|A Group which use Perio Total Care toothpaste during participation.
88904816|NCT01548469|Experimental|Bio Mineral toothpaste|A Group which use Bio Mineral toothpaste during participation.
88904817|NCT01548482|Experimental|Treatment (trebananib, temsirolimus)|Patients receive trebananib IV over 60 minutes and temsirolimus IV over 30-60 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88904818|NCT01548495||Responded to rHuEPO treatment|response to EPO was defined as a rise in untransfused hemoglobin concentration of at least 2 g/dl or a 50% decrease in transfusion requirements over the treatment period
88904819|NCT01548495||IR to rHuEPO treatment|No rise in hemoglobine consentration at normal and high dose rHuEPO treatment
88904820|NCT01548495||Responded to high level rHuEPO|Responded to more than 80,000UI of rHuEPO treatment
88904821|NCT01548495||No rHuEPO treatment|
88904822|NCT01548508|Experimental|Functionnal ElectroStimulation (FES)|
88904823|NCT01548508|Sham Comparator|SHAM|
88904824|NCT01548521|Experimental|Oxytocin|
88904825|NCT01548534|Placebo Comparator|DHA-free arm|Dietary supplementation with vegetable oil.
88904826|NCT01548534|Experimental|DHA arm|Dietary supplementation with fish oil.
88904827|NCT01548547|Experimental|LP mastery learning group|
88904828|NCT01548547|Active Comparator|IV mastery learning group|
88904829|NCT01548560|Experimental|Dapivirine Vaginal Gel|Dosage form: vaginal gel Dosage: 0.5%, 2.5g Frequency: 7 daily doses
88904830|NCT01548560|Placebo Comparator|Placebo Gel|Dosage form: vaginal gel Dosage: N/A Frequency: 7 daily doses
88904831|NCT01548560|Experimental|Dapvirine Vaginal Film|Dosage form: vaginal film Dosage: 1.25mg Frequency: 7 daily doses
89423340|NCT02057991|No Intervention|Group I (standard of care)|Patients and caregivers receive standard of care.
89423341|NCT02057991|Experimental|Group II (educational video)|Patients and caregivers receive a 20-minute self-playing interactive educational video brochure.
88904832|NCT01548560|Placebo Comparator|Vaginal Film|Dosage form: vaginal film Dosage: N/A Frequency: 7 daily doses
88904833|NCT01548586|Active Comparator|Anodal tDCS|
88904834|NCT01548586|Active Comparator|Cathodal tDCS|
88904835|NCT01548586|Placebo Comparator|Placebo type tDCS|
88904836|NCT01548612|Experimental|Sodium nitroprusside|
88904837|NCT01548612|Placebo Comparator|Placebo|Glucose solution 5%
88904838|NCT01548625||Healthy middle-aged human volunteers|
88904839|NCT01548664|Experimental|Nintendo Wii FitTM|Fifteen minutes of gaming activity on the Wii Fit™ following each regularly scheduled 60 minute physiotherapy session, in a separate treatment area.
88904840|NCT01548664|Active Comparator|Lower extremity exercise|Fifteen minutes of lower extremity exercises that addressed balance, posture, weight shifting and strengthening were provided bilaterally, following each regularly scheduled 60 minute physiotherapy session, in a separate treatment area
88904841|NCT01548677|No Intervention|observation|18 weeks
88904842|NCT01548677|Experimental|Herceptin (trastuzumab)|18 weeks
88904843|NCT01548703|Experimental|BCI-838 Dosing Arm 1|Ten subjects will be enrolled, 8 will receive BCI-838 and 2 will receive matching placebo.
89423342|NCT02057991|Experimental|Group III (educational video, mindfulness exercise video)|Patients and caregivers receive a 20-minute self-playing interactive educational video brochure and watch a 20-minute interactive mindfulness exercise video.
89423343|NCT02053155|Experimental|computer based patient education|The patients will complete a pre module and post module set of questions to determine whether their knowledge about peri operative smoking cessation increase smoking has changed. According to their willingness and eligibility, pharmacotherapy will be given.
89423344|NCT02055807|Experimental|PEEP and recruitment maneuvers|A PEEP of 7 cm H2O will be applied starting after intubation until the end of surgery. Recruitment maneuvers (continuous positive pressure of 30 cm H20 for 30 seconds) will be initiated following intubation and repeated every 30 minutes during surgery and immediately prior to extubation. Lung ultrasound examinations will be performed at different time-points immediately before surgery, during surgery under general anesthesia and after surgery in the recovery room to detect and monitor atelectasis.
89423345|NCT02055807|Active Comparator|ZEEP (Zero end-expiratory pressure)|No PEEP nor recruitment maneuvers will be used during surgery. Lung ultrasound examinations will be performed at different time-points immediately before surgery, during surgery under general anesthesia and after surgery in the recovery room to detect and monitor atelectasis.
88904844|NCT01548703|Experimental|BCI-838 Dosing Arm 2|Ten subjects will be enrolled, 8 will receive BCI-838 and 2 will receive matching placebo.
88904845|NCT01548703|Experimental|BCI-838 Dosing Arm 3|Ten subjects will be enrolled, 8 will receive BCI-838 and 2 will receive matching placebo.
89423346|NCT02055885||Positive responders|Positive responders (R+): patients exhibiting an increase in the 6WT distance ≥ 10% and/or a decrease in dyspnea ≥ 10% (i.e., ≥ 1 point on the visual analogue scale).
88904846|NCT01548729|Experimental|Patient with cystic fibrosis|Patients with end-stage cystic fibrosis
88904847|NCT01548781|Experimental|Viscous Resistance & Abduction Loading|The intervention for the experimental group entails practicing reaching utilizing the robotic device, ACT3D, with the experimental element of horizontal viscosity in combination with abduction loading.
89423347|NCT02055885||negative responders|Negative responders(R-): patients exhibiting a decrease in the distance ≥ 10% and/or an increase in dyspnea ≥ 10%.
89423348|NCT02260167|Experimental|Treatment with MIND|
89423349|NCT02748213|Experimental|Herceptin + Taxotere|Participants will receive dual therapy with Herceptin and Taxotere until disease progression, unmanageable toxicity, or withdrawal.
89423350|NCT02748213|Experimental|Herceptin + Taxotere + Xeloda|Participants will receive triple therapy with Herceptin, Taxotere, and Xeloda until disease progression, unmanageable toxicity, or withdrawal.
88904848|NCT01548781|Active Comparator|Abduction Loading|The intervention for the active comparison group entails practicing reaching utilizing the robotic device, ACT3D, with only abduction loading.
88904849|NCT01548794|Active Comparator|Bupivacaine(Group B)|spinal anesthesia
88904850|NCT01548794|Experimental|Bupivacaine+Lidocaine (Group BL)|spinal anesthesia
88904851|NCT01548794|Active Comparator|Local Infitration Anesthesia(Group LI)|local infiltration anesthesia
88904852|NCT01548820||Chronic HBV Egyptian patients|chronic HBV patients receiving Lamivudine therapy in hepatology clinic in the National Hepatology & Tropical Medicine Research Institute in Egypt.
89423351|NCT05257096|Experimental|Medical clown EEG|50 Children performing the EEG at the days that the medical clown is available will be included in the study group.
89423352|NCT05257096|No Intervention|Regular EEG|50 Children performing the EEG at the days that the medical clown is unavailable will be included in the control group. The EEG will be performed in the traditional way without medical clowns.
89423353|NCT03048604|Experimental|Genio(TM) system therapy|
89423354|NCT02058225||Infant Group 1|This group consist of healthy, full-term babies whose mothers have no known medical conditions or complications during pregnancy.
89423355|NCT02058303|Experimental|Exparel forearm block|Under ultrasound guidance, 3-5 mL Exparel will be injected around the 3 nerves of the forearm prior to surgery. 20-30 mL Mepivacaine will be used for the supraclavicular block following the forearm block.
89423356|NCT02058303|Active Comparator|Bupivacaine supraclavicular block|Under ultrasound guidance, 20-30 mL 0.5% Bupivacaine will be used for the supraclavicular block.
89423357|NCT02058381|Experimental|Group 1 (alpelisib)|Alpelisib plus Tamoxifen and Goserelin (Group 1)
89423358|NCT02058381|Experimental|Group 2 (buparlisib)|Buparlisib plus Tamoxifen and Goserelin (Group 2)
89423359|NCT02053233|Experimental|Walkbot group|The Walkbot group received conventional physical therapy (session I for 40 min/day) companied with Walkbot training (session II for 30 min/day) 5 days a week for 4 weeks, 40 session in all. After 4-week intervention all subjects received conventional physical therapy only, 40 min/day, 5 days/week for 4 weeks.
88904853|NCT01548859|Active Comparator|Midazolam|Used for maintenance anaesthesia (0.2 mg/kg/saat continuous infusion)
88904854|NCT01548859|Active Comparator|Sevoflurane|Used for the maintenance for anaesthesia (% 0.5-8 end tidal concentration)
88904855|NCT01548872|Active Comparator|crystalloid cardioplegia solution|After aortic cross clamp 30ml/kg will be administered
88904856|NCT01548872|Active Comparator|HTK solution|After aortic cross clamp 50ml/kg will be administered
88904857|NCT01548911|Experimental|Treatment (monoclonal antibody therapy)|Patients receive gemtuzumab ozogamicin IV over 2 hours on days 1 and 15. Treatment continues for 28 days in the absence of disease progression or unacceptable toxicity.
89423360|NCT02053233|Placebo Comparator|control group|The control group received conventional functional rehabilitation for 40 min/session, 2 sessions/day, 5 days/week for 4 weeks, 40 sessions in all. After 4-week intervention all subjects received conventional physical therapy only, 40 min/day, 5 days/week for 4 weeks. During the test period, general rehabilitation and drug treatment can be done at the same time.
88904858|NCT01548924|Experimental|Priming Phase|The study treatment begins with the period of seven days of priming Phase, which is administered in monoterapi dovitinib
88904859|NCT01548924|Experimental|Treatment Phase|The phase of treatment with two drugs (paclitaxel dovitinib more fixed dose of 80 mg/m2 per week) will begin after a washout period of seven days after the priming phase.
88904860|NCT01548937|Experimental|I-123 ADAM|I-123 ADAM Serotonin transporter imaging
88904861|NCT01548950|Other|Single-arm study|Preoperatively, sildenafil until development of pulmonary congestion (1-4 weeks). On treatment pulmonary congestion (dyspnea and need for increasing diuretics) occurs when there is a substantial decrease in pulmonary vascular resistance, which may be confirmed noninvasively by Doppler-echocardiography. At that moment, patient will be assigned to surgery. If pulmonary congestion is not observed, bosentan will be added on top of sildenafil, and the patient will be kept on treatment for 10-12 months. In this case, a new cardiac catheterization will be performed before surgery. In both cases (short-term and medium-term treatment) patients will be kept on treatment for six months following surgery, and then re-catheterized.
88904862|NCT01548963|Experimental|Perioperative glycemia control|Group of perioperative intensive glycemia control: blood glucose level will be maintained by continuous insulin infusion (Actrapid, Novo Nordisk A/S, Bagsvaerd, Danemark - 50 IU/50 ml FR) according to actual glycemia to keep it within normoglycemia limits (4.4 - 6.1 mmol/l) since patient's admission to operating room. Samplings will be taken in 1 to 4 hours intervals in accordance with glycemia stability and MPC algorithm suggestions.
88904863|NCT01548963|Active Comparator|Postoperative glycemia control|Group of standard glycemia control: blood glucose level will be maintained by continuous insulin infusion (see above) within normoglycemia limits (4.4 - 6.1 mmol/l) after patient's admission to ICU after cardiac surgery. During surgery hyperglycemia will not be interfered before it will reach level of 10 mmol/l.
88904864|NCT01548976||The study population|Patients suffering from pelvic organ prolapse and/or urinary incontinence and/or fecal incontinence. See inclusion/exclusion criteria.
88904865|NCT01548989||The study population|Patients suffering from pelvic organ prolapse and/or urinary incontinence and/or fecal incontinence. See inclusion/exclusion criteria.
88904866|NCT01549028|Experimental|Mobile-based PR program.|Home based mobile PR program for 3 months.
88904867|NCT01549054|Experimental|10-mg dose of E5501 2G tablet|
88904868|NCT01549054|Experimental|10-mg dose of E5501 cyclodextrin oral solution|
88904869|NCT01549054|Experimental|10-mg dose of E5501-P21% powder|
88904870|NCT01549054|Experimental|10-mg dose of E5501 lipid-based oral|
88904871|NCT01549080||research|biological research on the effects of yisuishengxuegranule
88904872|NCT01549080||clinical research|clinical research on thalassemia
88904873|NCT01549093|Experimental|Endostar -Continued Pumping into+GC|Endostar that is Continued Pumping into vein Combining With Gemcitabine -Carboplatin
88904874|NCT01549093|Active Comparator|Endostar -injecting into +GC|Endostar that is injecting into vein with Gemcitabine -Carboplatin
88904875|NCT01549093|Active Comparator|GC|Gemcitabine -Carboplatin
88904876|NCT01549106|Experimental|IPI-145|
88904877|NCT01549106|Placebo Comparator|Placebo|
88904878|NCT01549119|Experimental|Low dose VAC-3S|
88904879|NCT01549119|Experimental|Medium dose VAC-3S|
88904880|NCT01549119|Experimental|High dose VAC-3S|
88904881|NCT01549119|Placebo Comparator|Placebo|
88904882|NCT01549119|Experimental|Double-dose VAC-3S|
88904883|NCT01549145|Experimental|NIMBUS multifunctional stimulator|A Multifunctional Stimulator (Nimbus by Newmedic, Hemodia) for clinical use. The stimulator is also dedicated for Electrical Promontory Stimulation (EPS)
88904884|NCT01549158|Experimental|Torasemide PR 10 mg|
88904885|NCT01549158|Active Comparator|Furosemide-IR 40 mg|
88904886|NCT01549158|Active Comparator|Torasemide-IR 10 mg|
88904887|NCT01549171||Iloprost|This is the study group with 1 uM Iloprost.
88904888|NCT01549171||Control|This is the control group with vehicle (normal saline) only.
88904889|NCT01549197||ICU staff and relatives|
89195567|NCT05457686|Other|only physical therapy group(control group)|"Conservative will be explained on the second day after the operation. Go for a visit with a local cold application 20 times once a day. Ankle pumping exercises, deep breathing exercises, isometric and hip exercises will be planned with a load that can be applied to students who are being applied for bed training.~Increased the number and allowance of exercises; isotonic knee and exercises that make you feel It will be added. You will be discharged on the 4th day after the surgery on the 2nd or 3rd day. You will do home exercises after discharge. On the 10th day, you will be called for control."
89195568|NCT05132634|Experimental|Arms|"Experimental Group:~Braden Risk Assessment Scale was completed on the first day of admission to the Intensive Care Unit and every morning in the morning.~Since the care hours were between 08:00_10:00 in the morning and 20:00-22:00 at night, classical hand massage was applied to the patient by the researcher between the time zones specified daily.~It was followed up with the Pressure Wound Staging Form.~Control Group:~The Braden Risk Assessment Scale was completed on the first day of admission to the Intensive Care Unit and every morning in the morning.~It was followed up with the Pressure Wound Staging Form."
88904890|NCT01549249|No Intervention|vitrectomy|
88904891|NCT01549262|Active Comparator|Standard Incubator|
88904892|NCT01549262|Experimental|ESD Time-lapse Monitoring system|
88904893|NCT01549288|Experimental|modified Atkins diet|
89423361|NCT04147156|Active Comparator|Epley's Maneuver|Treatment of posterior canal BPPV with Epley's maneuver in the ROTUNDUM-chair.
89423362|NCT04147156|Experimental|Semont Maneuver|Treatment of posterior canal BPPV with the Semont maneuver in the ROTUNDUM-chair.
88904894|NCT01549288|Other|control arm|the control arm continues the anti-epileptic drugs without any added dietetic input
88904895|NCT01549301|Experimental|Group D 10 i.v.|Two periods, crossover, single dose, i.v., 10 mcg, Comparator (n=16) x Test (n=16) in the first period and Test (n=16) x Comparator (n=16) in the second period, in a crossover basis.
89423363|NCT04147156|Active Comparator|360 degree vertical rotation|Treatment of posterior canal BPPV with a 360 degree vertical rotation in the ROTUNDUM-chair.
88904896|NCT01549301|Experimental|Group C 5 i.v.|Two periods, crossover, single dose, i.v., 5 mcg, Comparator (n=16) x Test (n=16) in the first period and Test (n=16) x Comparator (n=16) in the second period, in a crossover basis.
88904897|NCT01549301|Experimental|Group B 10 s.c.|Two periods, crossover, single dose, s.c., 10 mcg/kg, Comparator (n=16) x Test (n=16) in the first period and Test (n=16) x Comparator (n=16) in the second period, in a crossover basis.
88904898|NCT01549301|Experimental|Group A 5 s.c.|Two periods, crossover, single dose, s.c., 5 mcg, Comparator (n=16) x Test (n=16) in the first period and Test (n=16) x Comparator (n=16) in the second period, in a crossover basis.
88904899|NCT01549327|Active Comparator|Routine Care|Participants who are randomized to the active comparator arm will receive routine care, which is the care routinely provided to the participant's patient population at the study centre.
88904900|NCT01549327|Experimental|Routine Care plus OIN|OIN (Oncology Interactive Navigator) is the intervention. Participants who are randomized to routine care plus OIN will receive routine care and have unlimited access to the website for the study duration.
88904901|NCT01549353|Experimental|chewing gum|
89195569|NCT02565654||Rifaximin group|Patients are treated with rifaximin (Alfa Wassermann Pharmaceutical Co., Ltd. Italy) for 14 days at a daily dosage of 1200 mg (400 mg, three times daily)
89195570|NCT02550483|Active Comparator|Beta-Carotene Tomato Juice|Participants will receive high beta-carotene tomato juice daily as part of controlled diet (base diet + high beta-carotene tomato juice).
89423364|NCT02058771||Ischaemic cardiomyopathy|Patients with ischaemic cardiomyopathy attending for ICD implantation
88904902|NCT01549366|Experimental|Aspen Spinous Process Fixation Device|Subjects randomized to the Aspen study arm will have the Aspen device implanted as supplemental posterior fixation only and according to the manufacturer's recommendations.
88904903|NCT01549366|Active Comparator|Pedicle Screws|Subjects randomized to the pedicle screw group will have polyaxial top loading pedicle screws implanted according to the standard procedures and practices at that institution. The procedure may be performed according to surgeon preference, including a traditional open, minimally invasive or percutaneous approach. Only pedicle screws cleared by FDA for this indication will be used in this study.
89195571|NCT02550483|Active Comparator|Lycopene Tomato Juice|Participants will receive high lycopene tomato juice daily as part of controlled diet (base diet + high lycopene tomato juice).
88904904|NCT01549379|Active Comparator|Surgical patients|This group will consist of 15 patients with locally advanced HNSCC of the oral cavity, larynx or hypopharynx presenting with adenopathy ≥ 1 cm where the recommended treatment is surgical resection of the primary malignancy with bilateral neck dissection. These patients will receive a DCE-CT scan of the head and neck prior to surgery.
88904905|NCT01549379|Active Comparator|Chemoradiation Patients|This group will consist of 15 patients with locally advanced HNSCC with lymph nodes ≥3 cm in which chemoradiotherapy is the primary treatment as per standard of care. This group will be composed of patients with a primary malignancy originating in the nasopharynx, oropharynx, hypopharynx or larynx. Pre-treatment DCE-CT of neck will be obtained. The standard therapy, radiation and chemotherapy, will be administered and the patients will have standard follow up. A post-treatment DCE-CT of neck will be obtained 8-10 weeks after treatment along with standard CT neck.
88904906|NCT01549418|Active Comparator|Aspirin|Patients with at least one large polyps taking aspirin in dose 75 mg daily for 21 days (7 days before and 14 days after polypectomy)
88904907|NCT01549418|Placebo Comparator|Placebo|Patients with at least one large polyps taking placebo daily for 21 days (7 days before and 14 days after polypectomy)
88904908|NCT01549431|Experimental|Combo of Panobinostat and Carfilzomib|A cycle of therapy is 4 weeks (28 days in duration). Carfilzomib (with dexamethasone during cycle 1) will be administered intravenously infusion on days 1, 2 and 8, 9 and 15, 16 of every 28 day cycle. Panobinostat is administered orally three times per week.
88904909|NCT01549444||Group 1|Babies of mothers that have diabetes and/or hypertension and babies that are small for dates
88904910|NCT01549444||Group 2|Babies born to mothers without diabetes and/or hypertension and babies that are correct size for gestational age
88904911|NCT01549457|No Intervention|Non-intervention|Participants will only receive standard of care
88904912|NCT01549457|Experimental|Cell phone intervention arm|Upon consent, participants will be randomly assigned to receive either 1) standard of care (9 months of INH or 4 months of RIF) and weekly SMS text messages via mobile phone or 2) standard of care (9 months of INH or months of RIF) without weekly SMS text messages via mobile phone.
88904913|NCT01549470|Experimental|Study vaccine|Participants in this arm will receive a total of three doses of study vaccine: the first dose at Day 0, the second dose at Day 28 (plus or minus 7 days), and the third dose at Day 56 (plus or minus 7 days). Each dose will consist of a 1-mL injection (dose strength 4 mg/mL) and will be administered by IM injection in the deltoid muscle.
89195572|NCT02550483|Placebo Comparator|Placebo Beverage|Participants will receive placebo beverage daily as part of controlled diet (base diet + placebo beverage).
89423365|NCT04869904||Patients with Alzheimer's disease|
89423366|NCT04869904||patients without Alzheimer's disease|
88904914|NCT01549470|Placebo Comparator|Placebo vaccine|Participants in this arm will receive a total of three doses of a placebo vaccine: the first dose at Day 0, the second dose at Day 28 (plus or minus 7 days), and the third dose at Day 56 (plus or minus 7 days). Each dose will consist of a 1-mL injection and will be administered by IM injection in the deltoid muscle.
89195573|NCT04646382|Placebo Comparator|Control|Microcrystalline cellulose (9892- Capsules®) up to 400 mg.
89195574|NCT04646382|Experimental|Intervention|Garlic concentrated extract. Onion concentrated extract. Microcrystalline cellulose (9892- Capsules®) up to 400 mg.
89195575|NCT00817323|Experimental|Quetiapine fumurate (Seroquel)|See Detailed description
89195576|NCT05739188|Experimental|Anti-GPRC5D CAR-T|Subjects who meet the enrollment conditions will receive intravenous infusion of anti--GPRC5D CAR-T Cells after lymphodepleting therapy.
89423367|NCT04870060|No Intervention|Control|Patients in this arm received only standard supportive care
89423368|NCT04870060|Experimental|Curcumin|Patients in this arm received curcumin lozenges (4 lozenges BD) along with standard supportive care
89423369|NCT04870294|Active Comparator|Teeth treated with composite resin, control group|The teeth grouped in group R were treated with composite resin restoration without liner material, considered a control group.
89423370|NCT04870294|Experimental|Teeth treated with lining, pulp wall with PBS DTA® cement and composite resin restoration|The teeth grouped in group D received PBS CIMMO DTA® as indirect capping material of the cavity, followed by restoration of composite resin.
89423371|NCT02613910|Experimental|Ofatumumab|t the Baseline (Bln) and wk 4 visits, Subjects will receive 40mg ofatumumab sc (Oft) (as two 20mg sc inj) and as 1 Oft 20mg sc inj every 4 wks from wk 8 through wk 56. Subjects will return to clinic 4 wks after the last dose for a follow-up (f/u) visit (wk 60). Antihistamine 10 mg and Acetaminophen/paracetamol (A/P) 1 grams(g) will be given 1-2 hours(h) before and 4 h after each dose of Oft. A/P 1 g will be supplied for self administration if needed. Prednisone/Prednisolone dose will continue to be tapered during core study period (CSP) by 1 dose level every 2 wks to <= 10 mg/day from Bln through wk 60. Upon completion of the CSP, subjects will enter Individualized f/u Period, where subjects will monitored every 12 wks for a minimum of 1 yr and for up to 2 yr, until CD19+ B-LC or IgG recover to lower limit of normal (LLN) or to the subject's Bln value from Study OPV116910 (if <LLN) or if study withdrawal criteria are met or for a maximum of 2 yr after the last dose of Oft.
89423372|NCT02802735|Experimental|Part 1: Apremilast 20 mg|A single oral dose of 20 mg apremilast.
89423373|NCT02802735|Experimental|Part 1: Apremilast 30 mg|A single oral dose of 30 mg apremilast.
89423374|NCT02802735|Experimental|Part 1: Apremilast 40 mg|A single oral dose of 40 mg apremilast.
89423375|NCT02802735|Experimental|Part 2: Apremilast 30 mg BID|30 mg apremilast orally twice a day (BID) for 14 days.
89423376|NCT02802735|Placebo Comparator|Part 2: Placebo|Matching placebo orally twice a day for 14 days.
89423377|NCT04869748|Experimental|experimental group|After recruitment, signed inform consent and allocation, researcher collected demographic data of each participant. First outcome assessment was done before session. Participants received a 15-minute session of Perfetti method on affected elbow flexor.Immediate after session, last outcome assessment was collected.
88904915|NCT01549483||Asthma|asthmatic subjects
88904916|NCT01549483||Asymptomatic AHR|Asymptomatic subjects with airway hyperresponsiveness
88904917|NCT01549483||Control|Healthy controls, without airway hyperresponsiveness
88904918|NCT01549496|Experimental|boceprevir|boceprevir 800 mg tid
88904919|NCT01549509|Experimental|VRC-HIVADV014-00-VP Vaccine|All participants will receive one injection of the study vaccine (VRC-HIVADV014-00-VP) in their upper arm at study entry.
88904920|NCT01549535|Active Comparator|Group A (study group)|Subjects in Group A (study group) will undergo a Standard view colonoscopy followed immediately by a PeerScope System™ extended view colonoscopy.
88904921|NCT01549535|Active Comparator|Group B (control group)|Group B (control group) will undergo a PeerScope System™ extended view colonoscopy followed immediately by a Standard view colonoscopy.
89423378|NCT04869748|Active Comparator|control group|After recruitment, signed inform consent and allocation, researcher collected demographic data of each participant. First outcome assessment was done before session. Participants received a 15-minute session of Passive stretching on affected elbow flexor.Immediate after session, last outcome assessment was collected.
88904922|NCT01549561|No Intervention|Services As Usual|Foster care services as usual
88904923|NCT01549561|Experimental|Parent and Youth Training|16 Weeks of Parent Training in group context with 5 to 10 relative and non-relative foster caregivers; Youth training with skills coaches
88904924|NCT01549561|Experimental|Parent Training|16 weeks of parent training with 5 to 10 relative and non-relative foster caregivers
88904925|NCT01549574|Experimental|crizotinib/crizotinib+esomeprazole crossover|Each subject in this study will receive two treatments (A and B) separated by at least 14 days of washout period. Treatment A is a 250 mg single oral dose of crizotinib administered in a fasted state as 1x 250 mg Formulated Capsule. Treatment B consists of 40 mg daily esomeprazole dose from Day 1 to Day 5 and a 250 mg single oral dose of crizotinib administered in a fasted state as 1x 250 mg Formulated Capsule on Day 5.
88904926|NCT01549600|Experimental|psyllium|5.1 g psyllium husk in at least 8 ounces of water
88904927|NCT01549600|Active Comparator|Microcrsytalline Cellulose|1.18 g Microcrystalline Cellulose in at least 8 ounces of water, taken twice a day
88904928|NCT01549626|Active Comparator|defatted flaxseed flour|30 grams per day of defatted flaxseed flour
88904929|NCT01549626|Active Comparator|golden flaxseed flour|30 grams per day of golden flaxseed flour
88904930|NCT01549626|Active Comparator|whole brown flaxseed flour|30 grams per day of whole brown flaxseed flour
88904931|NCT01549639||General Anaesthesia|Patients undergoing general anaesthesia using Marsh model target controlled infusion in effect site mode.
88904932|NCT01549678|Experimental|Intervention foot orthoses|Ethyl Vinil Acetate EVA insole shaped in the cast of the patient's foot.
88904933|NCT01549678|Placebo Comparator|Placebo insole|EVA flat insole.
88904934|NCT01549691|Experimental|zopiclone|zopiclone given before sleep, the day before surgery (placebo given at awakening the day of surgery)
88904935|NCT01549691|Experimental|alprazolam|given at awakening, the day of surgery (placebo given before sleep, the day before surgery)
88904936|NCT01549691|Placebo Comparator|placebo|Placebo given night before operation and the morning of operation
88904937|NCT01549704|Other|Arm RP|first blockade: ropivacaine 7,5mg/ml 30 ml second blockade: placebo: saline 30 ml
88904938|NCT01549704|Other|Arm PR|first blockade: placebo: saline 30 ml second blockade: ropivacaine 7,5mg/ml 30 ml
88904939|NCT01549717|Experimental|Elective cardiac surgery patients|Patients undergoing elective cardiac surgery
88904940|NCT01549743|Experimental|Celecoxib|
88904941|NCT01549743|Experimental|Rebamipide|
88904942|NCT01549743|Experimental|Celecoxib plus Rebamipide|
88904943|NCT01549756||Qualitative Research|Experiential/opinion based research
89195577|NCT02566434|Experimental|Methionine|All participants will consume free methionine at 10 mg/kg body weight/day (=requirement), 25 mg/kg body weight/day, 50 mg/kg body weight/day and 100 mg/kg body weight/day for the duration of a 4-week intervention period. Participants will cease intake when signs of toxicity are measured in blood work.
89195578|NCT00737750|Experimental|KH|Kneehab is a garment integrated NMES device with multipath technology.
89195579|NCT00737750|Active Comparator|PS|Poli-Stim, a standard NMES device, used for 3 times per day, five days per week for 12 weeks.
88904944|NCT01549782|Active Comparator|Fiber supplement|6 gr daily of fibre (50% inulin and 50% FOS). Patients underwent a 1-week run-in period before starting RT and continued taking the same products throughout the treatment course, until three weeks after RT was finished.
88904945|NCT01549782|Placebo Comparator|Maltodextrine|6 gr daily of maltodextrine. Patients underwent a 1-week run-in period before starting RT and continued taking the same products throughout the treatment course, until three weeks after RT was finished.
88904946|NCT01549808|Experimental|group 2|"Participants:~100 patients will be included in the observation phase of this project, and another 100 in the intervention phase, according to the following criteria: Patients hospitalized in Unit 4141, at Rigshospitalet or ICU at Slagelse, who have been intubated for more than 48 hours, age ≥18, and after positive confirmation from relatives that the patient before the hospitalization was able to read and understand instructions.~The research is divided in 3 phases:~An 8 month observation phase.Current practice relatede to mobilize is measured.~An 2 month implementation phase and third: an 8 month intervention phase. The effect is measured as the difference in the functional level between the observation phase and the intervention phase related to primary and secondary outcome.~The effect of the intervention is described by using following test:~walking distance,ADL function, capability to sit and stand"
88904947|NCT01549847|Experimental|L-carnitine and piracetam|
88904948|NCT01549847|Placebo Comparator|Placebo|
88904949|NCT01549899|Active Comparator|In-person CBT of Insomnia|CBTi consisted of 6 weekly 60-minute sessions and included identical informational material. The treatments contained the following efficacious and commonly used modules of cognitive behavioral treatments for insomnia: Stimulus Control, Sleep Restriction, Sleep Hygiene, Relaxation Training, Cognitive Restructuring.
89195580|NCT00737750|Active Comparator|CO|Control group performed voluntary muscle contractions for 20 minutes 3 times per day, 5 days per week for 12 weeks.
89195581|NCT05733806||Gynecologic rare tumors|The study will include patients with rare gynecologic malignancies
89423379|NCT03048214|Sham Comparator|General Anaesthesia|Patients would receive routine general anaesthesia for their distal radial fracture surgery
88904950|NCT01549899|Active Comparator|Internet CBT of Insomnia|The I-CBTi protocol was developed by the National Center for Telehealth and Technology with the first author (DJT) serving as the subject matter expert, and administered on the afterdeployment.org website. The information and instructions for I-CBTi were identical to in-person CBTi; however, their mode of delivery in I-CBTi is considerably different due to the constraints of its automated, online format. The lessons were presented as audio recordings accompanied by visual graphics and animations and several lessons, had interactive components such as games, quizzes, and prompts for participants to schedule healthy sleep habits.
89007079|NCT06017817|Experimental|Non-surgical treatment, Study group (NST-1)|Lumoral Treatment; Standard, non-surgical anti-infective treatment by scaling and root planing (SRP); and Standard oral hygiene instructions for electric toothbrushing, interdental brush, and dental floss use.
89007080|NCT06017817|Active Comparator|Non-surgical treatment, Control group (NST-2)|Standard, non-surgical anti-infective treatment by scaling and root planing (SRP); and Standard oral hygiene instructions for electric toothbrushing, interdental brush, and dental floss use.
89195582|NCT04063358|Experimental|Lucentis injected Pre-operatively|Lucentis injected 2 weeks before cataract surgery
89195583|NCT04063358|Active Comparator|Lucentis injected intra-operatively|Lucentis injected during the course of the surgery by cataract surgeon.
89195584|NCT04063358|Experimental|Lucentis injected post-operatively|Lucentis injected 2 weeks after cataract surgery
89195585|NCT00921258||control group|Patient with latent prostate cancer who agree to be controled instead of to be treated
89423380|NCT03048214|Experimental|Regional Anaesthesia|Patients would receive routine infraclavicular nerve block for their distal radial fracture surgery
89423381|NCT02058615|Experimental|Male Spouse Transition Toolkit|All participants in this group will be given access to the Male Spouse Transition Toolkit (MaTT). MaTT is a website based application that is designed to help male spouses of women with breast cancer to increase their awareness of the transitions and experiences they have as a husband and caregiver as well as to stay organized and seek help and resources as needed. To do so it consists of six sections: about me; common changes to expect; frequently asked questions; resources; calendar; and, important health information. These sections contain activities and exercises, as well as fillable templates (i.e., resources, calendar) that users can download at their convenience, from their home computer, tablet, or smart phone. They will be asked to use the MaTT for one month.
89423382|NCT02058615|No Intervention|Usual Care|Participants in this group will not receive access to the Male Spouse Transition Toolkit, and thus will not receive an intervention. Data collection for outcome variables will be the same as the participants in the experimental arm.
89195586|NCT00631917|Experimental|Aliskiren|For the first 2 weeks of the study, participants received aliskiren 150 mg once a day and were then forced titrated to aliskiren 300 mg once a day for 52 weeks. Participants also received a placebo capsule to match ramipril once a day for the study duration.
89423383|NCT02058927||HIV-1 infected children|HIV-1-infected children initiating ART
89423384|NCT02058927||HIV-1 uninfected children|control group of HIV-1 uninfected children matched by age
89423385|NCT02058927||HIV-1 infected children revaccinated|nested study of revaccination against measles virus of HIV-1-infected children receiving ART who lack protective antibody titers
89423386|NCT02059083|Active Comparator|Cognitive behavioral therapy (CBT) alone|
89423387|NCT02059083|Experimental|Cognitive behavioral therapy plus HRV biofeedback|
89007081|NCT06017817|Experimental|Surgical treatment, Study group (ST-1)|Lumoral Treatment; Surgical anti-infective peri-implantitis treatment; and Standard oral hygiene instructions for electric toothbrushing, interdental brush, and dental floss use.
89423388|NCT02060955|Experimental|Alecsat|"The experimental product is an autologous product based on the individual patients blood. Blood donation are performed in study weeks 0, 6, 11, 23 and 43.~The patient receives treatment as bolus injection at study weeks 4, 9, 14, 26 and 46."
89007082|NCT06017817|Active Comparator|Surgical treatment, Control group (ST-2)|Surgical anti-infective peri-implantitis treatment; and Standard oral hygiene instructions for electric toothbrushing, interdental brush, and dental floss use.
89007083|NCT06015750|Experimental|Pediatric participants with HPP|Pediatric participants who have been receiving asfotase alfa treatment for their HPP, and who demonstrate immune-mediated LoE.
89195587|NCT00631917|Active Comparator|Ramipril|For the first 2 weeks of the study participants received 5 mg ramipril orally once a day and were then forced titrated to ramipril 10 mg once a day for 52 weeks. Participants also received placebo to aliskiren for the duration of the study.
89423389|NCT02060955|Active Comparator|bevacizumab/irinotecan|Patients allocated to the comparator arm will be treated in accordance with standard practice in Denmark for relapsed glioblastoma multiforme, up to 16 treatment cycles with 4 weeks duration
89195588|NCT00823407|Other|MDA|
89423390|NCT02059317||Group 1|"Six groups are created in order to randomized the order of interventions. In group 1, the order of interventions is as follows:~Flexion-extension in the sagittal plane~Rotation in a transverse plane~Complex movement in three dimensions~2 minutes of rest and walking occurs between interventions. The above-mentioned exercises (1, 2 & 3) are performed on day 0, day 7 and week 6 for patients, and only on day 0 for healthy volunteers."
89423391|NCT02059317||Group 2|"Six groups are created in order to randomized the order of interventions. In group 2, the order of interventions is as follows:~Flexion-extension in the sagittal plane~Complex movement in three dimensions~Rotation in a transverse plane~2 minutes of rest and walking occurs between interventions. The above-mentioned exercises (1, 2 & 3) are performed on day 0, day 7 and week 6 for patients, and only on day 0 for healthy volunteers."
88904951|NCT01549899|No Intervention|Minimal Contact|Those assigned to the MC control group will be asked to not work with another therapist or seek additional treatment for insomnia-related difficulties during the 6-week MC period. They will be called every other week to monitor their status and to provide support as needed. The calls will be limited to 10-15 minutes. MC participants will also be given contact information to use in case of worsening of symptoms or increasing distress. At the end of six weeks, they will complete the baseline assessments again, which will serve as the post-treatment assessment for the MC period. They will then be randomly assigned to either the CBTi or ICBTi groups.
88904952|NCT01549912||Rotator cuff tear|
88904953|NCT01549938|Active Comparator|Treatment|20,000 IU cholecalciferol capsule
88904954|NCT01549938|Placebo Comparator|Placebo|Microcellulose capsule
88904955|NCT01549990||Sevoflurane group|donors who went through donor nephrectomy under general anesthesia with sevoflurane
88904956|NCT01549990||desflurane group|donors who went through donor nephrectomy under general anesthesia with desflurane
88904957|NCT01550016||Febrile Patients|Observation of patients with possible dengue fever in the early phase of disease
88904958|NCT01550029|Experimental|Counseling/Mood Management|"A trained counselor will meet with subjects for approximately 60 minutes each week during the 12-week treatment period to provide support for quitting and to help you develop knowledge and skills that can help you quit. Also, subjects will receive the National Cancer Institute's Clearing the Air guide to smoking cessation. Some specific areas of focus for this intervention are managing negative moods without smoking and overcoming other obstacles to quitting."
88904959|NCT01550029|Active Comparator|Counseling/Healthy Lifestyle|"A trained counselor will meet with subjects for approximately 60 minutes each week during the 12-week treatment period to provide support for quitting smoking and to help develop knowledge and skills for quitting. Also, subjects will receive the National Cancer Institute's Clearing the Air guide to smoking cessation. Some specific areas of focus for this intervention are developing a better understanding of reasons for smoking and the consequences of tobacco use and identifying ways to establish a healthier lifestyle."
88904960|NCT01550042||Intensive observation cohort|Patients > 18 years of age diagnosed with a recent episode of cryptogenic stroke with long term rhythm observation using an implantable loop recorder for detecting atrial fibrillation.
88904961|NCT01550055|Experimental|CMAB009 plus Irinotecan|
88904962|NCT01550055|Active Comparator|Irinotecan-only and sequential-CMAB009|
88904963|NCT01550068|Experimental|Experimental Arm|Echocardiographic screening
88904964|NCT01550068|No Intervention|Control Arm|No echocardiographic screening
88904965|NCT01550081|Active Comparator|Rate of perceived exertion|Exercise intensity controlled by Borg
88904966|NCT01550081|Active Comparator|Heart rate monitor|Exercise intensity controlled by heart rate monitors
88904967|NCT01550107|Active Comparator|Allopurinol|Allopurinol 600mg tablets
88904968|NCT01550107|Placebo Comparator|Lactose tablets|Placebo Lactose tablets
88904969|NCT01550146|Experimental|Dexamethasone, 0.1 mg/kg|The patients in the Dexamethasone group get iv 0.1 mg/kg dexamethasone preoperative.
88904970|NCT01550146|Placebo Comparator|Placebo|In the Placebo group the patients get 0.1 ml/kg normal saline.
88904971|NCT01550172|Experimental|Sleep Behavioral Therapy A and NHMS|Participants in this arm receive behavioral therapy A for insomnia and the night home monitoring system.
88904972|NCT01550172|Active Comparator|Sleep Behavioral Therapy B and NHMS|Participants in this arm receive sleep behavioral therapy B and the night home monitoring system.
88904973|NCT01550211||Students|Healthy students from Bar-Ilan University
88904974|NCT01550211||Schizophrenic patients' relatives|Healthy family members (parents or siblings) of the schizophrenic participants (chronic and naive)
88904975|NCT01550211||Naive schizophrenic patients|Naive patients with a diagnosis of schizophrenia, a history of only one psychotic episode and un-medicated
88904976|NCT01550211||Chronic schizophrenia patients|Chronic patients with a diagnosis of schizophrenia and a history of more than one psychotic episode
89195589|NCT04514523|Experimental|Implementation Arm|
89195590|NCT00419341|Experimental|IgPro20|Human Normal Immunoglobulin for Subcutaneous Administration (IgPro20) is a liquid formulation of normal human IgG at a concentration of 20% administered as a SC infusion at weekly intervals. The initial weekly dose was determined based on subjects' previous treatment. Dose adjustments could be performed during the wash-in/wash-out period at the discretion of the investigator.
89195591|NCT00694122|Active Comparator|Glargine (Lantus) insulin|"Long acting insulin, glargine, that subject currently used as an outpatient. SC injections. Dose given at 22:00 is based on past week blood glucose data during evening overnight hours and AM glucose. 20.2 +/- 11.7 units glargine (mean +/- SD).~Glargine (Lantus): Sanolfi Aventis~Hourly blood glucose from 22:00 to 08:00 while receiving glargine (Lantus) insulin will be compared with the NPH insulin arm."
89195592|NCT00694122|Active Comparator|NPH insulin|"Long acting insulin, NPH, that participant was currently while an outpatient. SC injections. Dose (units) given at 22:00 is based on past week blood glucose during evening overnight period and AM glucose. 20.7 +/- 10.0 units NPH (mean +/- SD).~NPH: Eli Lilly~Hourly blood glucose from 22:00 to 08:00 while receiving glargine (Lantus) insulin will be compared with the glargine (Lantus) insulin arm."
89195593|NCT02550951|Experimental|pre-operation Lymphedema|before magnetic resonance imaging(MRI), GADOVIST PFS [Bayer Korea] 7.5mL and local anesthetics 0.5m L mixed. and then 24 gauge needle using about 1 mL by the first , and second , the third the space between the toes intradermal injection , and then about 1-2 minutes , and massage the injection site, and Acquiring an image(coronal T1-weighted three-dimensional gradient-echo sequence) of the foot from a range including up to the pelvis from the comparison with lymphoscintigraphy
89195594|NCT02550951|Experimental|post-operation Lymphedema|before magnetic resonance imaging(MRI), GADOVIST PFS [Bayer Korea] 7.5mL and local anesthetics 0.5m L mixed. and then 24 gauge needle using about 1 mL by the first , and second , the third the space between the toes intradermal injection , and then about 1-2 minutes , and massage the injection site, and Acquiring an image(coronal T1-weighted three-dimensional gradient-echo sequence) of the foot from a range including up to the pelvis from the comparison with lymphoscintigraphy
89195595|NCT05417048||Breat cancer|Histologically confirmed breast cancer patients(Stage I-III)
89195596|NCT05417048||Benign breast disease|Histologically confirmed breast fibroma, intraductal papilloma,mammary hyperplasia, breast cyst etc
89423392|NCT02059317||Group 3|"Six groups are created in order to randomized the order of interventions. In group 3, the order of interventions is as follows:~Rotation in a transverse plane~Flexion-extension in the sagittal plane~Complex movement in three dimensions~2 minutes of rest and walking occurs between interventions. The above-mentioned exercises (1, 2 & 3) are performed on day 0, day 7 and week 6 for patients, and only on day 0 for healthy volunteers."
89423393|NCT02059317||Group 4|"Six groups are created in order to randomized the order of interventions. In group 4, the order of interventions is as follows:~Rotation in a transverse plane~Complex movement in three dimensions~Flexion-extension in the sagittal plane~2 minutes of rest and walking occurs between interventions. The above-mentioned exercises (1, 2 & 3) are performed on day 0, day 7 and week 6 for patients, and only on day 0 for healthy volunteers."
89423394|NCT02059317||Group 5|"Six groups are created in order to randomized the order of interventions. In group 5, the order of interventions is as follows:~Complex movement in three dimensions~Flexion-extension in the sagittal plane~Rotation in a transverse plane~2 minutes of rest and walking occurs between interventions. The above-mentioned exercises (1, 2 & 3) are performed on day 0, day 7 and week 6 for patients, and only on day 0 for healthy volunteers."
89423395|NCT02059317||Group 6|"Six groups are created in order to randomized the order of interventions. In group 6, the order of interventions is as follows:~Complex movement in three dimensions~Rotation in a transverse plane~Flexion-extension in the sagittal plane~2 minutes of rest and walking occurs between interventions. The above-mentioned exercises (1, 2 & 3) are performed on day 0, day 7 and week 6 for patients, and only on day 0 for healthy volunteers."
89423396|NCT04429906||test group|"Wear the pulse-oxygen monitoring finger set of the medical monitor while wearing the Huami Smart Wearable device on the ipsilateral wrist according to the instructions for use. The medical monitor displays a steady pulse oximetry level for at least 30 seconds, starts the first measurement, slides the main dial page of the wearable device to the Oxygen Saturation measurement interface, clicks the measurement button to start the single measurement of blood oxygen saturation. Record the pulse oximetry and pulse rate values measured at the same time by the medical monitor and the Huami Smart Wearable Pulse Oximetry Device, respectively. After an interval of 30 seconds, repeat the above steps to start the second measurement and record the measured value. After an interval of 30 seconds, repeat the above steps to start the third measurement and record the measured value. The average of three measurements was taken as data for the test group."
89423397|NCT04429906||control group A|Pulse oximetry monitor/desktop ECG monitor with a medical device registration certificate was selected as reference device A. The mean value of qualified pulse oximetry measured by pulse oximetry monitor/desktop ECG monitor within 2 minutes of each successive measurement of the Huami Smart Wearable Device was used as control group A measurement.
89423398|NCT04429906||control group B|A carbon monoxide blood gas analyzer (CO-oximeter) was selected as reference device B. Arterial blood was sampled and arterial oxygen saturation (SaO2) was obtained from the blood gas analyzer as a control group B measurement.
89423399|NCT02060175|Experimental|1 CILOTAX arm|Cilotax drug-eluting stents implantation
89423400|NCT02060175|Active Comparator|2 DESyne arm|DESyne drug-eluting stents implantation
89423401|NCT03048760|Experimental|MRI scan|All participants will undergo 2 MRI scans - 1 at the time of their radiotherapy planning scan & 1 after approx. 2 weeks of radiotherapy treatment.
89423402|NCT03560817||breast cancer|No intervention is added with the study. Patients follow their standard treatment and respond to an online questionnaire about their health preferences.
89423403|NCT03560817||colorectal cancer|No intervention is added with the study. Patients follow their standard treatment and respond to an online questionnaire about their health preferences.
89423404|NCT01027858|Experimental|1|AT (aerobic-based exercise training)
89423405|NCT01027858|Active Comparator|2|CON (control; usual care)
89423406|NCT02059473|Experimental|Physiotherapy & Surgery|Mini-open rotator cuff repair
89423407|NCT02059473|Active Comparator|Physiotherapy|Structured physiotherapy
89423408|NCT03048838|Experimental|Risk reduction behavioral intervention|"Couples randomized to the risk reduction behavioral intervention (Conectando Latinos en Pareja) will participate in four weekly sessions with a facilitator. Each session will last 2 hours. Participants will receive information and complete activities, participate in games and discussions to improve their relationship and improve health."
89423409|NCT03048838|Active Comparator|Wellness Promotion Intervention|Couples randomized to the wellness promotion control group will receive the same number of hours of attention as the active experimental group but will not receive the risk reduction intervention. Information presented will consist of topics related to general health.
88904977|NCT01550250|Experimental|Immediate Night-time Compression|Women randomized to the immediate night-time compression system group will be measured for a custom-made night-time compression system. Women in this group will be instructed to wear their night-time compression system garment for a minimum of 5 nights per week over the 12-week intervention period. A gradual increase in nights worn and wear-time of the garment will occur over the first two weeks. From weeks 3 to 12 of the study, the participants will be asked to wear the garment for 8 hours per night, for a minimum of five nights per week.
88904978|NCT01550250|Active Comparator|Delayed Group: Standard Care|Women randomized to the delayed night-time compression system group will receive standard care for lymphedema maintenance. Each participant will be instructed to wear their day-time compression sleeve with or without a glove/ gauntlet, providing a minimum of 30 mm Hg of pressure, for twelve hours per day, each day of the week. Following the twelve-week delay period, women in this arm of the trial will be fitted for their respective night-time compression system garment and will follow the protocol outlined in the experimental arm of the trial.
88904979|NCT01550276|Experimental|Suboccipital soft tissue inhibition|The SI treatment aims to release the suboccipital muscle spasm that maintains the occiput-atlas-axis joint dysfunction.
89423410|NCT03046810|Experimental|Wellness toileting system|This group will use the wellness toileting system for their perineal hygiene and treatment of dermatitis
89423411|NCT02059629||Group A: Eluna pacemaker family|Patients with standard indication for pacemaker therapy or Cardiac Resynchronization Therapy (CRT), who will be implanted with a pacemaker or CRT device of the Eluna pacemaker family. Single-, Dual- and Tripple-chamber pacemakers are applicable.
89423412|NCT02059629||Group B: Sentus BP lead|Heart failure patients with indication for Cardiac Resynchronization Therapy (CRT) therapy, who will be implanted with the left ventricular Sentus BP lead. Patients can receive either CRT pacemaker or CRT-D (CRT with defibrillator function).
89423413|NCT04877626|Active Comparator|AQ+AS|Group 1 received the combination AQ+AS (COARSUCAM®) which was administered orally at an initial dose of 2 tablets (200 mg AQ/540 mg AS) followed by 2 additional doses of 2 tablets at 24 and 48 hours (6 tablets in 48 hours).
89423414|NCT04877626|Active Comparator|AM+L|Group 2 received the combination Artemeter+lumefantrina (COARTEM®) administered orally at an initial dose of 4 tablets (80 mg artemeter/480 mg lumefantrina) followed by 5 additional doses of 4 tablets at 8, 24, 36, 48, and 60 hours (24 tablets in 60 hours)
89423415|NCT03801993||All Subjects|Subjects with a diagnosis of Cystic Fibrosis (CF) who meet all the inclusion and none of the exclusion criteria will be eligible for participation in this study.
89423416|NCT03046030|Experimental|Healthy Volunteers|In this experiment, we will apply a crossover design in healthy subjects. Each subject will receive four treatments in four separate sessions: 1) VGAIT, 2) VGAIT control condition, 3) real acupuncture, and 4) sham acupuncture. Each session will be separated by at least 7 days. Subjects will participate in five experimental sessions: a training and familiarity behavioral session and four fMRI sessions during which the subject will receive one of the four treatments.
89423417|NCT02059707|Experimental|LAA exclusion procedure|LAA exclusion with the LARIAT RS Suture Delivery Device
89423418|NCT05255848|Experimental|Intervention|Heparin sodium will be administered as a nebulised aerosol dose of 5000 IU heparin three times a day (TDS) via an ai compressor nebuliser plus standard of care treatment
88904980|NCT01550276|Experimental|Occiput-atlas-axis global manipulation|The OAA manipulation was bilaterally administered and it attempts to restore the motion dysfunction of this complex
89423419|NCT05255848|No Intervention|No Intervention|Participants assigned to 'standard care' will receive the standard care required as determined by the treating team and will not be treated with nebulised heparin
88904981|NCT01550276|Experimental|The combination of both treatments|
89423420|NCT04877704|Experimental|Symprove|Symprove probiotic
89423421|NCT04877704|Placebo Comparator|Placebo|Matched placebo provided by Symprove. Identical in appearance to Symprove probiotic.
89423422|NCT04430062||Covid-19 patients operated (February 21st -April 10th)|
89423423|NCT02799381|Active Comparator|Optimized Medical Treatment (OMT)|Participants randomized to OMT continued their current anti Parkinson's disease (anti-PD) medication regimen for the duration of the study. All anti-PD medications and medications to treat dyskinesia must have remained stable for the duration of the study unless adjustments were medically indicated. The Investigator provided the prescription for continued OMT.
89423424|NCT02799381|Experimental|Levodopa-Carbidopa Intestinal Gel (LCIG)|The total daily dose of infusion LCIG was composed of three components: (i) the morning dose, (ii) continuous maintenance infusion dose and (iii) extra doses. A temporary nasojejunal (NJ) tube may have been used initially with the infusion pump to determine a participant's response to this method of treatment and to optimize the dose of LCIG before treatment with a permanent percutaneous endoscopic gastrostomy - with jejunal extension (PEG-J) tube was started. Following optional NJ and/or PEG-J placement and, at the investigator's discretion, the participant may have begun initiation and titration of LCIG infusion on Day 1 once tube placement was confirmed. The dose of LCIG was adjusted to obtain the optimal clinical response. The rate of LCIG infusion is typically within the range of 1 to 10 mL/hour (20 to 200 mg of levodopa/hour) in most instances and runs over a period of 16 consecutive hours each day.
89423425|NCT04877158|Experimental|Self-Blame and Perspective-Taking Intervention|These participants are enrolled with intent to participate in the group therapy intervention.
89423426|NCT04387942|Experimental|Recombinant Human Interleukin-2|patients were treated with IL-2.
88904982|NCT01550276|Placebo Comparator|control group|
88904983|NCT01550302|No Intervention|Controls|Subjects enrolled in this group will only have a line drawn on the side of their neck for superficial cervical plexus block, but we will not perform the injection. The subjects will not be aware whether they received an intra-operative block or not. In addition, neither the Post-Anesthesia Care Unit nurse nor the providers involved in the post-operative care will be aware of subjects group assignment.
88904984|NCT01550302|Active Comparator|Superficial Cervical Plexus Block|Subjects enrolled in this group will have a line drawn and will receive a superficial cervical plexus block at the end of the surgery just prior to emergence from anesthesia.
88904985|NCT01550354|Active Comparator|Propofol group|Intravenous administration of propofol 2 mg/kg before intubation
88904986|NCT01550354|Active Comparator|Alfentanil group|Intravenous administration of alfentanil 14 μg/kg before intubation
88904987|NCT01550354|Active Comparator|Rocuronium group|Intravenous administration of rocuronium 0.3 mg/kg before intubation
88904988|NCT01550380|Experimental|All participants|
88904989|NCT01550406|Active Comparator|Tachocomb|Tachocomb will be applicated on the cut surface of distal pancreatectomy
88904990|NCT01550406|Active Comparator|PGA|PGA will be applicated on the cut surface of distal pancreatectomy
89423427|NCT04387942|No Intervention|Traditional therapy|patients were treated with dipyridamole and/or glucocorticoid，immunosuppressor.
88904991|NCT01550406|No Intervention|Control|No mesh will be applicated on the cut surface of distal pancreatectomy
88904992|NCT01550419|Experimental|Atorvastatin(50 characters)|
88904993|NCT01550419|Placebo Comparator|Placebo(50 characters)|
88904994|NCT01550445|No Intervention|steroid withdrawal|The clinical outcome after kidney transplantation, under the immunosuppression of steroid withdrawal starting at 3 months post-transplantation using tacrolimus, mycophenolate mofetil, and basilixumab should be analyzed.
88904995|NCT01550497|Experimental|Home Exercise Group|Perform home exercises of unsupervised spinal stabilization exercises for 8 weeks
88904996|NCT01550497|Experimental|Weeky Physical Therapy Group|weekly physical therapy of supervised spinal stabilization exercises for 8 weeks
88904997|NCT01550523|Experimental|18-mer oligodeoxynucleotide|
88904998|NCT01550588|Placebo Comparator|Medication|Anticoagulation, Antiplatelet agent
89423428|NCT04877002|Experimental|SARS_CoV_2 Antigen Rapid Test|"The same group of patients participated in two arms of the study:~One arm was for obtaining performance data of the Sona Saliva C-19 Rapid test and the comparator arm was to obtain data from the primary care route using approved RT-PCR testing."
88904999|NCT01550588|Active Comparator|Device closure|Amplatzer PFO occluder device
88905000|NCT01550601|Other|bariatric surgery 1|Longitudinal gastrectomy (sleeve gastrectomy) is a technique of bariatric surgery. In this arm, patients have a bariatric surgery with conservation of gastric antrum.
88905001|NCT01550601|Experimental|bariatric surgery 2|Longitudinal gastrectomy (sleeve gastrectomy) is a technique of bariatric surgery. In this arm, patients have a bariatric surgery with ablation of gastric antrum.
88905002|NCT01550614|Experimental|Arm A: Ad5FGF-4|Adenovirus serotype-5 mediated human fibroblast growth factor-4 gene transfer and standard of care angina medication
88905003|NCT01550614|No Intervention|Arm B|Standard of care angina medication
88905004|NCT01550627|Active Comparator|extra-fluid|The study group received an extra intravenous fluid intake of 20% of the total fluid demand per 24 hours of NaCl 0,9% during each two hour period of phototherapy (12h total per day).
89423429|NCT01333059|Experimental|Experimental Group|"In this arm Fentanyl and Midazolam was replaced with placebo (normal saline) during cycling.~At cycling time for midazolam, the continuous infusion of midazolam was stopped by the bedside nurse. The nurse started a pump containing a syringe labeled Study Drug M which contained the placebo drug (normal saline). The switch to Study Drug M occurred twice daily at 0800 and 2000 for a period of 3 hours each. At cycling time for fentanyl, the continuous infusion of fentanyl was stopped by the bedside nurse. The pump containing a syringe labeled Study Drug F, which contained the placebo drug (normal saline), was started. The switch Study Drug F occurred twice daily at 1400 and 0200 for a period of 3 hours each.~Dosing was done per standard of care and not prescribed per protocol"
89423430|NCT01333059|Active Comparator|Control Group|"In this arm, midazolam and fentanyl were administered during cycling.~At cycling time for midazolam, the continuous infusion of midazolam was stopped by the bedside nurse. The nurse started a pump containing a syringe labeled Study Drug M which contained the control drug (midazolam). The switch to Study Drug M occurred twice daily at 0800 and 2000 for a period of 3 hours each. At cycling time for fentanyl, the continuous infusion of fentanyl was stopped by the bedside nurse. The pump containing a syringe labeled Study Drug F, which contained the control drug (fentanyl), was started. The switch to Study Drug F occurred twice daily at 1400 and 0200 for a period of 3 hours each.~Dosing was done per standard of care and not prescribed per protocol."
88905005|NCT01550627|Placebo Comparator|non extra fluid (control group)|The control group received the previous fluid regime, as intravenous fluid was given constantly, without a specific guideline according to extra fluid intake.
88905006|NCT01550640|Experimental|remifentanil|bolus of remifentanil 1 µg/kg will be given 30 sec before induction to general anesthesia
88905007|NCT01550640|No Intervention|standard|control standard group
88905008|NCT01550653|Experimental|Liraglutide|"See Intervention"
88905009|NCT01550653|Placebo Comparator|Placebo|"See Intervention"
88905010|NCT01550666|Experimental|MOVE|MOVE Program group: MOVE consists of medication follow-up at the CHCS or ATCMHMR and meeting once a week for 9 months with a MOVE trainer in your home. You and your trainer will work on interviews for the first three visits that will talk about negative symptoms, thoughts, attitudes, and social skills that will help each of you develop goals together. Activities will be developed around improving initiation, enjoyment, success and outcome. These activities will be customized to you and will change based on your needs weekly throughout the 9 months
89423431|NCT03046186||Gastric sleeve operated subjects|12 patients who have undergone gastric sleeve operation >12 month prior to inclution.
89423432|NCT03046186||Control Subjects|12 Healthy un-operated control subjects matched to the gastric sleeve group in a one to one manner with respect to BMI, sex and age
89423433|NCT03046186||Gastric bypass operated subjects|12 patients, who have undergone Roux-en-Y gastric bypass >12 month prior to inclution, matched to the gastric sleeve group in a one to one manner with respect to pre-operative BMI, post-operative BMI, sex and age.
89423434|NCT02060253|Experimental|ganetespib, paclitaxel, and trastuzumab with pertuzumab|Patients receive trastuzumab intravenously (IV) over 30 minutes on days 1, 8, 15, and 22, pertuzumab IV over 30 minutes every 3 weeks (only in Part II of the study, starting day 1), paclitaxel IV over 1 hour on days 1, 8, 15, and 22, and ganetespib IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. The MTD for ganetespib in combination with paclitaxel and trastuzumab is 150 mg/m2.
89423435|NCT03560973|Experimental|Gemcitabine + Ramucirumab|Gemcitabine 1000 mg/m2 iv D1, D8 plus Ramucirumab 10 mg/kg iv (21 days cycles)
89423436|NCT03560973|Placebo Comparator|Gemcitabine + Placebo|Gemcitabine 1000 mg/m2 iv D1, D8 plus placebo (21 days cycles)
88905011|NCT01550666|No Intervention|Treatment As Usual|Participants of this group will continue to receive medication follow up at the Center for Health Care Services. They will not be required to do anything additional except to complete assessment visits.
88905012|NCT01550679||Smokers or ex-smokers|Smokers or ex-smokers 40-65 years of age with a smoking history of at least 20 pack-years with no diagnosis of COPD or asthma
88905013|NCT01550718|Active Comparator|ESML-Exercise (Physical Activity Program)|ESML-Exercise consists of four weekly 90-minute classes. Each class includes exercises and a brief discussion of a specific health topic. Classes are carried out in small groups of five to six participant/care partner dyads (10-12 people total), to ensure everyone in the class gets individual attention and that all exercises are done safely using proper form.
88905014|NCT01550718|Active Comparator|ESML-SOCIAL (Social Activity Program)|"ESML-SOCIAL consists of four weekly 90-minute seminars. Each seminar includes discussion of a specific topic, open time for socializing, and a homework assignment to be completed prior to the next session. Seminars are carried out in small groups of five to six participant/care partner dyads (10-12 people total), to ensure everyone in the seminar gets individual attention and that everyone has a chance to bring up any concerns."
88905015|NCT01550718|No Intervention|No Intervention|This arm will receive no intervention during the active treatment period. After the 4 month assessment participants can choose to attend a support group.
88905016|NCT01550770|Experimental|proprofol|
89423437|NCT03046264||coronary angiography|patients undergoing routine coronary angiography, invasive and non-invasive determination of central blood pressure
89423438|NCT02059785|Experimental|Pinocembrin for Injection|40mg /60mg in 100ml of a solution of 0.9 percent saline,iv.drip bid,14day
89423439|NCT02059785|Placebo Comparator|placebo|60mg in 100ml of a solution of 0.9 percent saline,iv.drip bid,14day
89423440|NCT04383574|Experimental|Experimental Vaccine-medium dosage|24 participants in medium-dosage group in phase Ⅰ will receive two doses of primary immunization according to the immunization schedule of day 0, 28 and will receive 1 dose of booster immunization 1 year after primary immunization; 100 participants in medium-dosage group in phase Ⅱ will receive two doses of primary immunization according to the immunization schedule of day 0,28 ,1 dose of booster immunization 6 months after primary immunization(the third dose ) and the second booster dose (the fourth dose) 1 year after the second dose.
89423441|NCT04383574|Experimental|Experimental Vaccine-high dosage|24 participants in high-dosage group in phase Ⅰ will receive two doses of primary immunization according to the immunization schedule of day 0, 28 and will receive 1 dose of booster immunization 1 year after primary immunization; 100 participants in high-dosage group in phase Ⅱ will receive two doses of primary immunization according to the immunization schedule of day 0,28 ,1 dose of booster immunization 6 months after primary immunization(the third dose) and the second booster dose (fourth dose) 1 year after the second dose .
89423442|NCT04383574|Placebo Comparator|Placebo|24 participants including 12 at medium dosage stage and 12 at high dosage in phase Ⅰ will receive two doses of placebo according to the immunization schedule of day 0, 28 and will receive 1 dose of booster immunization 1 year after primary immunization; 50 participants in phase Ⅱ will receive two doses of primary immunization according to the immunization schedule of day 0,28 and will receive 1 dose of booster immunization 6 months after primary immunization.
89423443|NCT04383574|Experimental|Experimental Vaccine-low dosage|100 participants at low dosage stage in phase Ⅱ will receive two doses of primary immunization according to the immunization schedule of day 0,28 and will receive 1 dose of booster immunization 6 months after primary immunization.
89423444|NCT02060331||Pelvic Organ Prolapse with Nocturia|Pelvic Organ Prolapse with Nocturia
89423445|NCT04876768|Experimental|Use of 80% oxygen(high oxygen fraction) during ERCP|Anesthetist will open the envelope of randomly assigned groups which will assign patients to 80% FIO2(supplemental perioperative high oxygen fraction). 80% FIO2 will be maintained during the ERCP procedure. Maintaining oxygen saturation of > 92% through administration of oxygen via nasal cannula, mask or ventilator will be per anesthetist discretion. Additional supplemental oxygen will be given to patients at any time, as necessary, to maintain oxygen saturation as measured by pulse oximeter > 92%.
89423446|NCT04876768|Active Comparator|Use of 30% oxygen(normal oxygen fraction) during ERCP|Anesthetist will open the envelope of randomly assigned groups which will assign patients to 30% FIO2 (normal oxygen fraction). 30% FIO2 will be maintained during the ERCP procedure. Maintaining oxygen saturation of > 92% through administration of oxygen via nasal cannula, mask or ventilator will be per anesthetist discretion. Additional supplemental oxygen will be given to patients at any time, as necessary, to maintain oxygen saturation as measured by pulse oximeter > 92%.
89423447|NCT03046108|Active Comparator|blind injection of Morton neuroma|"Percoutaneous blind injection in Morton neuroma by subcutaneous needle group 1 are going to be injected by an experimented orthopaedic surgeon based on anatomic landmark. There is no internal control of the needle placement.~Mixture of 1 cc of 2% mepivacaine (Mepivacaina Normon 2%® )+ 40 mg of triamcinolone (Trigon Depot®) in each of the web spaces affected with Morton neuroma is injected.~Up to 4 injections are allow in the first three months of follow-up"
89423448|NCT03046108|Active Comparator|blind injection of Mepivacaine|"1 cc of 2% mepivacaine (Mepivacaina Normon 2%® )+ 40 mg of triamcinolone (Trigon Depot®) in each of the web spaces affected with Morton neuroma is injected.~Up to 4 injections are allow in the first three months of follow-up"
89423449|NCT03046108|Active Comparator|blind injection of Triamcinolone|40 mg of triamcinolone (Trigon Depot®) in each of the web spaces affected with Morton neuroma is injected. Up to 4 injections are allow in the first three months of follow-up
89007084|NCT06015659|Experimental|ZN-c3 + Gemcitabine|"Study procedures will be conducted as follows:~Cycle 1 - End of Treatment~Days 1 - 5 of 21-day cycle: Predetermined dose of ZN-c3 1x daily.~Days 8 - 12 of 21-day cycle: Predetermined dose of ZN-c3 1x daily.~Days 15 - 19 of 21-day cycle: Predetermined dose of ZN-c3 1x daily.~Day 1 and 8 of 21-day cycle: Predetermined dose of Gemcitabine 1x daily.~On-treatment tumor biopsy will be collected on either Cycle 1 Day 9 - 10 or Cycle 2 Day 9 - 10.~Tumor assessment by Computerized Tomography (CT) or Magnetic Resonance Imaging scan every 8 weeks while on treatment.~End of treatment visit with tumor assessment by CT or MRI and optional tumor biopsy.~Follow up visit every 2 months after treatment has ended."
89423450|NCT03046108|Experimental|ultrasound guided injection|US guided injection in Morton neuroma by subcutaneous needle. group 2 are going to be injected by an experimented musculoskeletal radiologist under ultrasound guidance. There is internal control of needle placement by ultrasound.
89423451|NCT03046108|Experimental|guided injection of mepivacaine|"2% mepivacaine (Mepivacaina Normon 2%® ) in each of the web spaces affected with Morton neuroma is injected.~Up to 4 injections are allow in the first three months of follow-up"
89423452|NCT03046108|Experimental|guided injection of Triamcinolone|40 mg of triamcinolone (Trigon Depot®) in each of the web spaces affected with Morton neuroma is injected. Up to 4 injections are allow in the first three months of follow-up
89423453|NCT01370733|Experimental|Active sTMS|Treatment with the NEST-1 Device
89007085|NCT06012981|Experimental|Acceptance & Commitment Therapy (ACT)|Psyhotherapy based on principles of functional analysis, behavioral activation, and experiential avoidance.
89007086|NCT06008704|Other|PD patients with central chronic pain|Patients from both groups will receive the same interventions, the difference between groups is the eligibility criteria. In this arm only patients presenting central chronic pain will be included
89007087|NCT06008704|Other|PD patients without pain|Patients from both groups will receive the same interventions, the difference between groups is the eligibility criteria. In this arm only patients without central chronic pain will be included
89007088|NCT06007352|Experimental|Gentamicin-Based Irrigation|This group will receive 120 mg of Gentamicin in 3 L NaCl as irrigation fluid during ureteroscopy
89007089|NCT06007352|Placebo Comparator|3 L NaCl Irrigation|This group will receive the typical NaCl irrigation used during ureteroscopy
89007090|NCT06004479||Pregnant|Adult females between 18-40 years old who have a confirmed pregnancy.
89423454|NCT01370733|Sham Comparator|Sham|Treatment with a sham (inactive) device, identical in sound and appearance to the NEST-1 Device
89423455|NCT03048292||Mobilized Neurointervention Team|Patients undergoing endovascular stroke interventions.
89423456|NCT03048292||Mobilized Patient|
89423457|NCT03048292||Core Comprehensive Stroke Center Treatment|
88905017|NCT01550783|Experimental|Group I (home-based HPV screening)|Participants collect 2 vaginal specimens using polyester swabs that are then placed in a specimen tube. Specimens are then submitted to the Harborview Medical Center clinical pathology lab. Participants with a positive HPV test result will have a Pap test. Participants with an abnormal Pap test will undergo standard of care as in Group II.
88905018|NCT01550783|Experimental|Group II (clinic-based standard of care screening)|Participants undergo standard of care cervical cancer screening and follow-up. That is, participants undergo Pap testing. Participants with an abnormal Pap test undergo HPV testing, colposcopy, cervical biopsy and/or ECC. Participants with cervical biopsies showing precancerous changes are offered to undergo LEEP or are referred to appropriate care.
88905019|NCT01550796|Active Comparator|d-cycloserine|d-cycloserine 250 mg two days per week one hour prior to(cognitive training)
88905020|NCT01550796|Placebo Comparator|Placebo|Placebo pill two days per week 1 hour prior to cognitive training
88905021|NCT01550822|Active Comparator|HEALS|Intervention group which will receive group clinics addressing smoking cessation, healthy eating, physical activity, and the risk factors of stroke.
88905022|NCT01550822|No Intervention|Usual Care|This group will receive usual care for stroke survivors
88905023|NCT01550835|Experimental|Distal Embolic Protection Only|Carotid stenting with distal embolic protection only
88905024|NCT01550835|Active Comparator|Distal embolic protection and aspiration thrombectomy|Aspiration thrombectomy following stent deployment and prior to removal of distal embolic protection
88905025|NCT01550848|Experimental|Abraxane and Gemcitabine|Abraxane and Gemcitabine
88905026|NCT01550874|No Intervention|Control Group|Wear the pedometer provided by study everyday with weekly charging and syncing of data.
88905027|NCT01550874|Experimental|Experimental Group|Wear the pedometer provided by the study everyday and also participate in phone-based physical activity behavior-change counselling for 6 months and then check sustainability without further motivational support for another 6 months.
88905028|NCT01550887|No Intervention|Impulsivity evaluation|
88905029|NCT01550900|Experimental|Metformin ER|Participants receive two tablets of Metformin ER 500 mg once daily for no more than twelve to eighteen months allowing time for at least one follow up colonoscopy. Dose will be reached in a gradual escalation scheme to improve gastrointestinal tolerance. If participants experience side effects during dose escalation regimen, they will be reduced to one tablet of 500 mg daily, and may continue taking 500 mg daily for the duration of the study.
88905030|NCT01550900|Active Comparator|Placebo|Control group given matched Placebo once daily for no more than twelve to eighteen months allowing time for at least one follow up colonoscopy.
88905031|NCT01550913|Experimental|Sober Network IPT|Participants are assigned to Sober Network Interpersonal Psychotherapy (IPT)
88905032|NCT01550913|Other|Treatment as Usual|Participants are assigned to have Treatment as Usual
88905033|NCT01550926|Active Comparator|Arm 1|60 mg orlistat
88905034|NCT01550926|Active Comparator|Arm 2|120 mg orlistat (2 X 60 mg capsules)
88905035|NCT01550926|Experimental|Arm 3|orlistat experimental formulation
88905036|NCT01550939|No Intervention|Time Comparison between the Lenstar and IOLMaster|
88905037|NCT01550978|Experimental|Study Group|Patients intubated with AnapnoGuard EndoTracheal Tube and connected to the AnapnoGuard 100 Control System
88905038|NCT01550978|No Intervention|Control Group|Patients intubated with the Standard of Care EndoTracheal Tube and Connected to a Suction Regulator
88905039|NCT01551004|Experimental|Cohort A|8 subjects (6 active, 2 placebo) receive a single oral dose of 100 mg CRS3123 or placebo
88905040|NCT01551004|Experimental|Cohort B|8 subjects (6 active, 2 placebo) receive a single oral dose of 200 mg CRS3123 or placebo
88905041|NCT01551004|Experimental|Cohort C|8 subjects (6 active, 2 placebo) receive a single oral dose of 400 mg CRS3123 or placebo
88905042|NCT01551004|Experimental|Cohort D|8 subjects (6 active, 2 placebo) receive a single oral dose of 800 mg CRS3123 or placebo
88905043|NCT01551004|Experimental|Cohort E|8 subjects (6 active, 2 placebo) receive a single oral dose of 1200 mg CRS3123 or placebo
88905044|NCT01551017||c-treatment|test group
88905045|NCT01551017||standard cooling|comparison group
88905046|NCT01551043|Experimental|Arm 1|
88905047|NCT01551069|Active Comparator|HCQ|HCQ 200~400mg, once daily, oral administration
88905048|NCT01551069|Other|Placebo|HCQ-placebo, once daily, oral administration
88905049|NCT01550458|Experimental|Mibefradil|
88905050|NCT01550458|Placebo Comparator|Placebo|
88905051|NCT01551108|Active Comparator|Mobile phone intervention: minimal|Intervention: limited behavioral strategies
88905052|NCT01551108|Experimental|Mobile phone intervention: intensive|Intervention: advanced behavioral strategies
88905053|NCT01551121||intervention group|"Patient in the intervention group will have camera installed in their room. These cameras can either work in visible or infrared range. They are physically linked to a server that will store and analyze images in real-time. The server works 24h/24 and 7d/7 and will send an alert to the care personnel via their computers and personal pagers if it detects an anomaly. Anomaly could be falls, high risk behavior (patient standing up on its bed), abnormal length of stay in the bathroom, prolonged inertia. It will then allow them to intervene at the right time and the right place. Geriatrician can also review images in order to determine the cause of the incident and then act on each patient prevention and care strategy"
88905054|NCT01551121||non-equipped group|"Patient in the non-equipped group will have usual care"
88905055|NCT01551134|Active Comparator|Open fundoplication|Fundoplication performed with open surgery
88905056|NCT01551134|Experimental|Lap fundoplication|Primary fundoplication performed by laparoscopic surgery
88905057|NCT01551147|Experimental|Experimental 200 mg dose|
88905058|NCT01551147|Active Comparator|Active Comparator|
88905059|NCT01551147|Placebo Comparator|Placebo Comparator|
88905060|NCT01551160|Experimental|Medical Emergency Team|A communication and team-working initiative
88905061|NCT01551225|Active Comparator|Escitalopram|17 or 18 Patients with IBS and panic disorder treated with Escitalopram.
88905062|NCT01551225|Placebo Comparator|Placebo tablets to Escitalopram|17 or 18 Patients with IBS and panic disorder treated with placebo.
88905063|NCT01551238|Experimental|Protein intake of 5 energy percent|
88905064|NCT01551238|Experimental|Protein intake of 30 energy percent|
88905065|NCT01551251||Advanced NSCLC with high TAM|All patients with advanced non-small cell lung cancer who had been treated at the Linkou Branch of Chang Gung Memorial Hospital were included. Tumor specimens with high TAM were included as one cohort group.
88905066|NCT01551251||Advanced NSCLC with low TAM|All patients with advanced non-small cell lung cancer who had been treated at the Linkou Branch of Chang Gung Memorial Hospital were included. Tumor specimens with low TAM were included as one cohort group.
88905067|NCT01551277|Placebo Comparator|Control Group|
88905068|NCT01551277|Experimental|BREATH STACKING|
88905069|NCT01551290|Placebo Comparator|Group I: Placebo|Participants in Group I receive placebo
88905070|NCT01551290|Experimental|Group II: Infliximab|Participants in Group II receive 5 mg/kg infliximab
88905071|NCT01551316|Experimental|MN-221|If the participants qualify, they will be randomized into one of two arms for 4 days. The arms are either Placebo (no medication) or MN-221 intravenously infused.
88905072|NCT01551316|Experimental|PLACEBO|If the participants qualify, they will be randomized into one of two arms for 4 days. The arms are either Placebo (no medication) or MN-221 intravenously infused.
88905073|NCT01551329|Experimental|Drug: Ketamine|
88905074|NCT01551342||Cystoscopic surveillance, TURT or Cystectomy|The following subjects will be enrolled: Subjects previously diagnosed with bladder cancer undergoing routine cystoscopic surveillance, TURT or Cystectomy.
88905075|NCT01551368|Experimental|Nimodipine|Nimodipine 30 mg tablets will be self-administered by the subjects every 6 hours starting on the day that the ultrasound criterion for hCG triggering is met. The tablets will be taken for two days or until an LH surge is detected, whichever comes first. If no LH surge by 2 days, the hCG trigger (250 micrograms recombinant hCG) will be given followed by intrauterine insemination (IUI)in 40 hours. If the LH surge is detected, hCG will be given immediately and two IUIs will be performed 24 hours apart.
88905076|NCT01551368|Placebo Comparator|Placebo|Same as for nimodipine but an identical placebo will be self-administered.
88905077|NCT01551381|Experimental|EV-077|Oral administration
88905078|NCT01551381|Placebo Comparator|Placebo|Oral administration
88905079|NCT01551394|Experimental|Meropenem|"Infants will received the Meropenem 20 mg/kg every 8 hours (every 12 hours in the youngest age group: < 32 weeks GA and < 2 weeks postnatal age). The dose will be given as an infusion over 30 minutes.~Treatment duration is 11 ± 3 days."
88905080|NCT01551394|Active Comparator|Standard of care|"The two accepted therapeutic options are:~ampicillin + gentamicin (SOC regimen 1) and~cefotaxime + gentamicin (SOC regimen 2)."
88905081|NCT01551433||Pts scheduled for Ivor Lewis esophagectomy|During the operation, once the gastric conduit has been mobilized and positioned, and once the anastomotic site has been identified by the surgeon, the assigned RSA will provide the Wipox instrument to the fellow (the primary surgeon will be blinded to the result) who will then obtain one measurement from the anastomotic site.
88905082|NCT01551459|Active Comparator|Arm 1: Dacarbazine|Patients will receive 1000mg/m2 every 21 days by IV until progression or unacceptable toxicity.
88905083|NCT01551459|Experimental|Arm 2: Sunitinib|Sunitinib: Patients will take 50mg orally once a day, for 28 days followed by a 14 day break, until progression or unacceptable toxicity.
88905084|NCT01551485|Experimental|Zolpidem|
88905085|NCT01551485|Placebo Comparator|Placebo|
88905086|NCT01551498|Placebo Comparator|Placebo|subject takes one oral placebo lozenge, three times per day
88905087|NCT01551498|Active Comparator|Anatabloc Supplement|subject takes one oral Supplement lozenge, three time per day
88905088|NCT01551511|Experimental|delta-9-tetrahydrocannabinol (namisol)|
88905089|NCT01551511|Placebo Comparator|Placebo|
88905090|NCT01551524|Experimental|Intravenous Erwinia|
88905091|NCT01551537||Cohort Group|Healthy females aged 10 years and above will receive 1, 2 or 3 doses of Cervarix as per the Prescribing Information (PI) in Sri Lanka.
88905092|NCT01551576||photoacoustic imaging (PAI)|Men seen in the urology clinic for elevated PSA and/or abnormal digital rectal exam (DRE) will be offered PAI at the time of transrectal ultrasound guided biopsy, which is standard of care. In addition, patients with a biopsy proven prostate cancer may also be approached for this PAI scan
88905093|NCT01551589|Experimental|Involved Field Irradiation(IFI)|Involved Field Irradiation(IFI):The clinical target volume of regional lymph node (CTVn) of IFI included the nodal region(s) in which the involved lymph node(s) was/were located.chemothrapy:docetaxel and cisplatin.
88905094|NCT01551589|Active Comparator|Elective Nodal Irradiation (ENI)|Elective Nodal Irradiation (ENI):The CTVn of ENI included the involved lymph node regions and clinically uninvolved lymph nodal stations according to the location of primary tumor. Lymph node station numbers 1/2/4/5/7, 2/4/5/7 and 4/5/7/16/17 were included for upper, middle and lower thoracic ESCC in the ENI arm respectively.chemothrapy:docetaxel and cisplatin.
88905095|NCT01551602|Experimental|AK159 SD 1|Single administration of AK159 dose level 1
88905096|NCT01551602|Experimental|AK159 SD 2|Single administration of AK159 dose level 2
88905097|NCT01551602|Experimental|AK159 SD 3|Single administration of AK159 dose level 3
88905098|NCT01551602|Experimental|AK159 SD 4|Single administration of AK159 dose level 4
88905099|NCT01551602|Active Comparator|MN-10-T SD|Single administration of MN-10-T
88905100|NCT01551602|Experimental|AK159 MD 1|Multiple administration of AK159 dose level 1
88905101|NCT01551602|Experimental|AK159 MD 2|Multiple administration of AK159 dose level 2
88905102|NCT01551602|Experimental|AK159 MD 3|Multiple administration of AK159 dose level 3
88905103|NCT01551602|Experimental|AK159 MD 4|Multiple administration of AK159 dose level 4
88905104|NCT01551602|Active Comparator|MN-10-T MD|Multiple administration of MN-10-T
88905105|NCT01551602|Placebo Comparator|Placebo MD|Multiple administration of placebo AK159
88905106|NCT01551615|Experimental|Metformin then metformin + vandetanib|Metformin alone followed by metformin in combination with vandetanib
88905107|NCT01551628|Experimental|Recombinant Human Arginase 1 Peg5000|
88905108|NCT01551641|Experimental|VEGF decressed|patients will receive concurrent chemoradiotherapy only
88905109|NCT01551641|Experimental|thalidomide|patients will be given thalidomide concurrent chemoradiotherapy
88905110|NCT01551641|Experimental|without thalidomide|patients will receive concurrent chemoradiotherapy only
88905111|NCT01551654|Placebo Comparator|Placebo Acu-TENS|No Electrical output was coming out from the TENS unit
88905112|NCT01551654|Experimental|TENS over acupuncture points|A constant mode of electrical stimulation at 2 pulses per second and pulse width at 200µs for 45 minutes. Intensity was set to just initiate muscle contraction.
88905113|NCT01551667||Cases / bacteraemia|Patients consulting at the departments of Diabetology, Dermatology or Infectious Diseases of the participating hospitals and who have (1) inaugural or recurrent diabetic foot/ankle ulcers of Grade 2-4, or (2) who have an infected leg ulcer (arterial, venous, or mixed. This infection must involve S. aureus in a mono-or polymicrobial setting. This group of patients has bacteraemia.
88905114|NCT01551667||Controls|Patients consulting at the departments of Diabetology, Dermatology or Infectious Diseases of the participating hospitals and who have (1) inaugural or recurrent diabetic foot/ankle ulcers of Grade 2-4, or (2) who have an infected leg ulcer (arterial, venous, or mixed. This infection must involve S. aureus in a mono-or polymicrobial setting. This group of patients does not have bacteraemia.
88905115|NCT01551680|Experimental|Concurrent whole brain radiotherapy and iniparib|
88905116|NCT01551706|Active Comparator|ENI Patented Whole Grape Extract|ENI Patented Whole Grape Extract (350 mg) per day
88905117|NCT01551706|Placebo Comparator|Exicipient pill|
88905118|NCT01551719|No Intervention|Standard Procedure (phase I)|Antibiotic prescription following in vitro sensitivity test according to each surgeon's will.
88905119|NCT01551719|Experimental|Implemented procedure|Prescription following in vitro sensitivity test implemented with MIC/Breakpoint ratio and penetration of antibiotic in the site of infection, according to each surgeon's will.
88905120|NCT01551732|Active Comparator|Anger Control Therapy|10 session manualized cognitive behavioral anger control therapy
88905121|NCT01551732|Experimental|ACT with RAGE-Control|10 session manualized cognitive behavioral anger control therapy augmented with an interactive biofeedback videogame.
88905122|NCT01551771|Experimental|GW824575|Investigational treatment - Swedish Orange Coloured, opaque hard gelatin capsule
88905123|NCT01551771|Placebo Comparator|GW824575 matched-placebo|Placebo
88905124|NCT01551784||1|
88905125|NCT01551797|Experimental|Test Sustained Release (SR) Paracetamol (2000 mg)|A single 2000 mg oral dose of SR paracetamol formulation (2 x 1000 mg) administered with 150 mL of water.
88905126|NCT01551797|Experimental|Test SR Paracetamol (1500 mg)|A single 1500 mg oral dose of SR paracetamol formulation (2 x 750 mg) administered with 150 mL of water.
88905127|NCT01551797|Active Comparator|Reference Paracetamol (2000 mg)|Two single 1000 mg doses of paracetamol (2 x 500 mg/dose) administered orally 6 hours apart, administered with 150 mL of water.
88905128|NCT01551836|Other|Paracetamol formulation 1|Higher dose level of marketed paracetamol (compared to the other dosage arm)
88905129|NCT01551836|Other|Paracetamol formulation 2|Lower paracetamol concentrations
88905130|NCT01551849||VA-ECMO patients|Patients placed on VA-ECMO support for primary cardiac dysfunction.
88905131|NCT01551875||subjects who are meeting the inclusion criteria|
88905132|NCT01551901|Experimental|Luna Interbody System|
88905133|NCT01551914|Experimental|ultrasonic scissors|
88905134|NCT01551914|Active Comparator|conventional techniques of haemostasis|clips, ligatures, and bipolar coagulation
88905135|NCT01551940|Experimental|Botox|Botox injection : 100 UI of botulinum toxin type A (Botox®) diluted in 2.2 ml of NaCl 0.9 %
88905136|NCT01551940|Placebo Comparator|Placebo|Placebo injection : NaCl 0.9 %
88905137|NCT01551953|Experimental|tai chi exercise|
88905138|NCT01551953|Experimental|mind-body breathing|
88905139|NCT01551953|Active Comparator|education|
88905140|NCT01551966|Experimental|video capsule endoscopy|
88905141|NCT01551992|Active Comparator|Interrupted suture|interrupted technique using 0 non-barbed delayed absorbable suture (PDS II™, Ethicon, Somerville, NJ, USA)
88905142|NCT01551992|Active Comparator|Quill suture|self-anchoring 1 barbed delayed absorbable suture (Quill™ SRS, Angiotech Pharmaceuticals, Inc. Vancouver, Canada)
88905143|NCT01552005||Population of patients treated with Saxagliptin|
88905144|NCT01552018|Active Comparator|Saxagliptin|Saxagliptin 5 mg/day
88905145|NCT01552018|Placebo Comparator|Placebo|Placebo
88905146|NCT01552031||Observational group|
88905147|NCT01552044|Experimental|spironolactone|Spironolactone 25mg/day
88905148|NCT01552044|Placebo Comparator|Placebo|placebo tablets
88905149|NCT01552070|Experimental|With recruitment maneuver group|Recruitment maneuver will be performed immediately (within 2 minutes) after intubation, consisting of a continuous positive airway pressure of 40 cmH2O over 30 seconds. Blood gases were sampled and blood samples taken for culture before, within 2 minutes, 5 minutes, and 30 minutes after intubation. Haemodynamic and respiratory parameters were continuously recorded throughout the study.
88905150|NCT01552070|Active Comparator|Without recuritment maneuver|After oral intubation, each patient will be mechanically ventilated, with a tidal volume of 6mL/kg, a respiratory rate of 20 to 25 breaths/minute, a positive end-expiratory pressure (PEEP) of 5 cmH2O, and an FiO2 of 100%. PEEP titration according to FiO2 and ARDSnet.
88905151|NCT01552122|Experimental|Odanacatib|
88905152|NCT01552122|Active Comparator|Alendronate|
88905153|NCT01552135||Healthy|Healthy men above 50 years old
88905154|NCT01552148|Active Comparator|Group TAP (US guided)|23 patients receiving bilateral US guided transversus abdominis plane block with 20ml of 0.375% levobupivacaine on each side, under general anaesthesia (TIVA), after induction and before surgical start
88905155|NCT01552148|Other|Group Control|
88905156|NCT01552161||Patients with negative coronarography.|Subjects who underwent coronary angiography and were classified as having no critical lesions in coronary arteries (a lesion of up to 50% of artery lumen is accepted as non-critical).
88905157|NCT01552161||Patients with positive coronarography|Subjects who underwent coronary angiography and were classified as having critical lesions in coronary arteries (over 50% narrowing of artery lumen).
88905158|NCT01552174||Outpatients attending general ophthalmologic consultation|"Outpatients of either sex, aged at least 18 years, seen in general ophthalmological consultation~Patients informed of the objectives of the survey and agreeing to participate.~Patient attending to the ophthalmological consultation for any reasons: regular check-up of chronic disease, acute symptoms, or for surgery preparation or follow up."
88905159|NCT01552187|Placebo Comparator|Placebo|Placebo
88905160|NCT01552187|Active Comparator|Colchicine|Colchicine
89423458|NCT02061189|Experimental|Swimming pool training group|"10 patients will be selected to perform a 6 months training in a swimming pool, from M12 to M18 or M18 to M24 or M24 to M36, in defined and reproducible conditions.~M0, M6, M12 and M18 or M0, M6, M12, M18 and M24 or M0, M6, M12, M18, M24 and M30 assessments: Medical examination + MFM + Hammersmith scale + Non-invasive motor capacity analysis.~M12 to M18 or M18 to M24 or M24 to M30: Physical exercise in a swimming pool (3 times per week).~M24 or M30 or M36: Medical examination + MFM + Hammersmith scale + Non-invasive motor capacity analysis."
89423459|NCT02061189|No Intervention|Control group|"20 patients with same assessments at M0, M6, M12 and M18, but:~without swimming pool training.~without M24 assessment."
89423460|NCT02613364|Experimental|Arm I (behavioral intervention-yoga)|Patients undergo the YOCAS intervention comprising 18 specific physical postures and mindfulness exercises focused on breathing and meditation and meet with the yoga instructor over 75 minutes 2 times a week for 4 weeks.
89423461|NCT02613364|Experimental|Arm II (cognitive intervention-CBT-I)|Patients undergo CBT-I intervention comprising sleep education, sleep hygiene, sleep restriction, stimulus control, cognitive therapy, and relapse prevention delivered by a health professional over 90 minutes once a week for 8 weeks.
89423462|NCT02613364|Active Comparator|Arm III (educational intervention)|"Patients attend survivorship health education sessions over 75 minutes 2 times a week for 4 weeks based on the American Society of Clinical Oncology cancer survivorship educational recommendations delivered by a community health educator. Patients also receive a booklet entitled, Cancer Survivorship Next Steps for Patients and Their Families."
89423463|NCT02061267|Experimental|Niacin Control|The subjects will receive a vitamin B3 supplement (2 g)
89423464|NCT02061267|Experimental|Niacin + SAT|The subjects will receive a vitamin B3 supplement (2 g) and a test meal with high-fat (containing 72% saturated fat, 22% carbohydrate, and 6% protein)
89423465|NCT02061267|Experimental|Niacin + ROO|The subjects will receive a vitamin B3 supplement (2 g) and a test meal with high-fat (containing 72% monounsaturated fat, 22% carbohydrate, and 6% protein)
89423466|NCT02061267|Experimental|Niacin + O3|The subjects will receive a vitamin B3 supplement (2 g) and a test meal with high-fat (containing 72% polyunsaturated omega-3 fat, 22% carbohydrate, and 6% protein)
89423467|NCT02060409||spliceosome|patient who have available data for spliceosome mutation status
89423468|NCT01370655|Experimental|MK-7145 6 mg (Treatment A)|MK-7145 3 mg (three x 1-mg MK-7145 capsules administered orally) and placebo to HCTZ (two 12.5-mg capsules) then three x 1-mg MK-7145 capsules 4 hours later, daily for 4 weeks.
89423469|NCT01370655|Experimental|MK-7145 3 mg (Treatment B)|MK-7145 3 mg (one 2mg MK-7145 and one MK-7145 placebo capsule) then one 1-mg MK-7145 capsule and two MK-7145 placebo capsules 4 hours later and placebo to HCTZ (2 capsules once daily) daily for 4 weeks.
89423470|NCT01370655|Active Comparator|Hydrochlorothiazide 25 mg (Treatment C)|HCTZ 25 mg (two 12.5-mg capsules) and placebo to MK-7145 (one 3-mg capsule) then placebo for MK-7145 (one 3-mg capsule) 4 hours later daily for 4 weeks.
89423471|NCT01370655|Placebo Comparator|Placebo (Treatment D)|Placebo to MK-7145 (2 x 3-mg capsules) and placebo to HCTZ 25 mg (2 capsules) then placebo to MK-7145 (2 x 3-mg capsules) 4 hours later daily for 4 weeks
89423472|NCT02059863|Experimental|SPRING intervention clusters|"SPRING package: Home visits by community based agents carried out from pregnancy to 2 years of age to encourage key behaviours to promote child growth, survival and development together with regular supervision~PLUS access to routine maternal and child health services"
89423473|NCT02059863|No Intervention|Control clusters|access to routine maternal and child health services
89423474|NCT02612194|Experimental|Cohort 1|c-MET high (> 50%), RON null (0-9%)
89423475|NCT02612194|Experimental|Cohort 2|c-MET + (10-100%), RON + (10-100%)
89423476|NCT02612194|Experimental|Cohort 3|c-MET null (0-9%), RON + (10-100%)
89423477|NCT03044860|Experimental|Type 2 diabetes|Adult patients with type 2 diabetes undergoing double-balloon enteroscopy (DBE) with biopsy retrieval using a DBE-device.
89423478|NCT03044860|Experimental|Healthy|Adult subjects without type 2 diabetes undergoing double-balloon enteroscopy (DBE) with biopsy retrieval using a DBE-device.
88905161|NCT01552200|Experimental|A-Standard Colonoscopy, G-Eye procedure|Standard Colonoscopy,G-Eye procedure
88905162|NCT01552200|Active Comparator|B- G-Eye procedure, Standard Colonoscopy|G-Eye procedure,Standard Colonoscopy
88905163|NCT01552226|Active Comparator|Continuous Preperitoneal Analgesia|Continuous Preperitoneal Analgesia for pain management
89423479|NCT03044626|Experimental|study group A|"Patients with metastatic non-squamous NSCLC with the necessity of radiotherapy of a metastatic site (e.g. bone) in 2nd-line or 3rd-line treatment:~Nivolumab 240 mg fixed dose (q2w). First dose followed by radiotherapy. Radiotherapy has to start at the latest 72 hours after nivolumab administration.~Radiotherapy: A metastatic site will be treated with a radiation dose of 4 Gy for a total of 5 courses during a two week time interval (total dose 20 Gy)"
88905164|NCT01552226|Active Comparator|Continuous Epidural Analgesia|Continuous Epidural Analgesia for pain management
88905165|NCT01552239|Experimental|1 Arm|"Stratum A:~R0, primary wound closure~Stratum B:~R0, secondary wound closure~Stratum C:~R1, tertiary wound closure"
88905166|NCT01552252|Placebo Comparator|0% POs-Ca|
88905167|NCT01552252|Active Comparator|0.5% POs-Ca|
88905168|NCT01552252|Active Comparator|1% POs-Ca|
88905169|NCT01552252|Active Comparator|1.5% POs-Ca|
88905170|NCT01552252|Active Comparator|2% POs-Ca|
88905171|NCT01552265||single-group MCI patients|
88905172|NCT01552291|Active Comparator|Glutamin|
89423480|NCT03044626|Other|study group B|"Patients with metastatic non-squamous NSCLC without the necessity of radiotherapy in 2nd-line or 3rd-line treatment:~Nivolumab 240 mg fixed dose (q2w)."
89423481|NCT04875832|Experimental|Intervetion Group|EMDR intervention group
89423482|NCT04865692|Experimental|Interventional group|The interventional group received resisted knee extension 20% of 1RM with blood flow restriction along with routine physical therapy.
89423483|NCT04865692|Other|Control Group|The Control group received routine physical therapy alone including knee isometrics and resisted knee extension
88905173|NCT01552291|Placebo Comparator|Placebo|
88905174|NCT01552304|Experimental|Oxygen treatment group|Besides routine care, patients in this group will receive postoperative oxygen therapy with nasal prolong at 3 liters/min during the first 3 nights after surgery.
88905175|NCT01552304|Other|Control group|Patients will be managed by the anesthesiologists and surgeons as per routine practice.
88905176|NCT01552317|Experimental|lifestyle counselling|A package of advice and interventions to help participants reduce their salt intake.
88905177|NCT01552317|No Intervention|Normal care|This group will receive the normal care that they would get anyway.
88905178|NCT01552330|Experimental|Group A|Primaquine only followed by Pyronaridine-Artesunate and followed by Primaquine together with Pyronaridine-Artesunate.
88905179|NCT01552330|Active Comparator|Group B|Primaquine only followed by Primaquine together Pyronaridine-Artesunate and followed by Pyronaridine-Artesunate only.
88905180|NCT01552382||cardiac surgical patients|patients undergoing a cardiac surgical procedure
88905181|NCT01552421|Active Comparator|TV NOTES cholecystectomy|Participants randomized to TV NOTES cholecystectomy
88905182|NCT01552421|No Intervention|Laparoscopic cholecystectomy|Participants randomized to laparoscopic cholecystectomy
88905183|NCT01552447|Other|1 application of EpiFix|1 x dehydrated human amnion/chorion membrane
88905184|NCT01552447|Other|2 applications of EpiFix|2 x dehydrated human amnion/chorion membrane
88905185|NCT01552447|Other|Standard of care|Compression bandaging
88905186|NCT01552473|Active Comparator|Brain Training Program 1|Training Program focusing on providing educational information of cognitive issues related to TBI
88905187|NCT01552473|Experimental|Brain Training Program 2|Program focuses on strategies to address cognitive issues following TBI
88905188|NCT01552486|Experimental|Chiropractic Spinal Manipulative Therapy|
88905189|NCT01552486|Other|Usual Care|
88905190|NCT01552499|Other|Control|
88905191|NCT01552499|Experimental|Treatment|
88905192|NCT01552512|No Intervention|MSPP Integrated Package|Participants in this arm only receive the standard care offered by the Ministry of Health (MSPP)called the Integrated Package. During the trial, they do not receive Nutributter.
88905193|NCT01552512|Experimental|Nutributter 3 Months, Integrated Package|Participants receive a one-month supply for the first 3 months of the 6-month trial in addition to the Integrated Package.
88905194|NCT01552512|Experimental|Nutributter 6 Months, Integrated Package|Participants receive a one-month supply for each month of the 6-month trial in addition to the Integrated Package.
88905195|NCT01552525||acute kidney injury|Patients with acute kidney injury according to the definition of AKIN (Acute Kidney Injury Network)
88905196|NCT01552538|Experimental|Cyberonics VNS System|Continued stimulation w/Cyberonics VNS
88905197|NCT01552551|Active Comparator|Healthy Steps|Healthy Steps program as currently implemented by the PA Department of Aging
88905198|NCT01552551|Experimental|Healthy Steps with Falls Case Management|Healthy Steps program augmented with research interventionist guidance on seeking physician care and home safety assessment
88905199|NCT01552551|Experimental|Healthy Steps in Motion|Healthy Steps program augmented with Healthy Steps in Motion, a 4-week, twice a week program of group exercise.
88905200|NCT01552564||STEMI patients|Consecutive patients presenting through the PPCI service
89423484|NCT03045952|Experimental|microwave ablation|Antenna in the microwave ablation device was percutaneously inserted into the tumor and placed at designated place under US guidance. For tumors less than 1.5 cm, one antenna was inserted and for tumors measuring 1.5 cm or greater, two antennae were inserted in parallel with an inter-antenna distance of 1.0-2.5 cm, which were used simultaneously during MWA to obtain larger ablation zone. A 20G thermocouple was inserted about 0.5-1 cm away from the tumor for real-time temperature monitoring during MWA. MW emission didn't stop until the heat-generated hyperechoic water vapor completely encompassed the entire tumor and the measured temperature reached 60°C or remained above 54°C for at least three minutes.
89423485|NCT03045874||30 parent-child dyads|Stratified purposive sampling will assure representation proportional to the minority representation in the community and will include equal subsamples (15 families each) of families with children 6-18 months of age and children aged 19-36 months.
89423486|NCT03045874||30 primary care providers|"Investigators will purposively recruit 30 primary care providers to assure proportional representation of physicians and NPs with a snowball method. The sample sizes should be sufficient to achieve saturation of the data for qualitative analyses, but we will recruit more participants if saturation is not obtained with the planned sample."
89423487|NCT03045874||focus groups|The investigators will hold separate focus groups for parents of the two age groups and clinicians. We anticipate conducting approximately 6 focus groups with 8-10 participants in each to review and refine the sleep program.
89423488|NCT03045874||22 parent-child dyads|The investigators will conduct feasibility testing of a 3 week sleep health promotion intervention. The intervention will be delivered to parents of children ages 12-36 months enrolled in one childcare center.
89423489|NCT03045874||5 childcare teachers|Teachers will be trained to deliver a brief sleep health intervention
89423490|NCT03045796||Maintenance Hemodialysis Patients|Following the initial recruitment, all individuals who are willing to participate and sign the informed consent document will be provided with a medical history form to complete. In addition, we will ask them to sign a HIPAA authorization form in order to look into their medical records for monthly blood work (blood chemistry), anthropometric data (height and weight), interdialytic weight gain (weight gain since last treatment) history, and current medications.
89423491|NCT04876144|No Intervention|Usual care group - clinical|Usual prenatal and postpartum psychiatric care involves regular visits with a psychiatrist from the perinatal psychiatric outpatient clinic of the National Institute of Mental Health, Czechia.
89423492|NCT04876144|No Intervention|Usual care group - general|Usual prenatal and postpartum care involves regular visits with one's health care provider while pregnant and after the baby is born.
89423493|NCT04876144|Experimental|Kogito - clinical|Usual prenatal and postpartum psychiatric care in perinatal psychiatric outpatient clinic of the National Institute of the National Institute of Mental Health, Czechia plus use of the Kogito app.
89423494|NCT04876144|Experimental|Kogito - general|Usual prenatal/postpartum care plus use of the Kogito app.
89423495|NCT04875598|Active Comparator|Group 1|30 patients will be injected with local anesthetic into the fascia between the transversus abdominis and internal oblique muscles with the help of ultrasound from the designated area (Before the operation starts, TAPBwith 20 ml 0.25 % bupivacaine will be applied to the surgical side under ultrasonography)
89423496|NCT04875598|Active Comparator|Group 2|30 patients, local anesthetic injection will be made to the same area under laparoscopic direct vision. 50 mg Bupivacaine (0.25 % 20 ml bupivacaine solution) has been determined as the application dose and this amount will be applied in both groups.
89423497|NCT04865380|No Intervention|No Tranexamic Acid|The anesthesiologist will not administer Tranexamic Acid at any point.
89423498|NCT04865380|Experimental|Intravenous Tranexamic Acid|1g of Tranexamic Acid will be administered intravenously prior to the start of the operation.
89423499|NCT04865068|Experimental|African migrant's population located in la region New Aquitaine.|Echocardiography norms will be harvested data on SSA participants located in la region New Aquitaine, France
89423500|NCT04869046|Experimental|Levobupivacaine group|Instillation of 0,1 ml/kg (0,5 mg/kg) levobupivacaine 0,5% in surgical wound before fascia closure
89423501|NCT04869046|Placebo Comparator|Control Group|Instillation of 0,1 ml/kg 0,9% Sodium Chloride in surgical wound before fascia closure
89423502|NCT04430530|Experimental|4SCAR-CD22/CD123/CD38/CD10/CD20 infusion|Patients who have relapsed after anti-CD19 immunotherapy or have CD19 negative B cell malignancies
89423503|NCT04875910|Experimental|Stroke survivors participants|"Subjects who have been diagnosed with stroke 6 months or more.~1)Either right and left hemiparesis. 2) Subjects able to walk with or without assistive device. 3) age between 40-80. 4) Subjects can understand and follow commands.~Exclusion criteria is: 1) subjects with uncontrolled Blood pressure, heart rate or breathing problems. 2) Having an orthopedic problem or"
89423504|NCT04385680|Experimental|Chlorhexidine vaginal prep.arm|"Women in labor who will receive vaginal cleaning immediately before cesarean section using 50 ml of chlorhexidine gluconate 0.05% solution and standard abdominal scrub with chlorhexidine gluconate 4%. This concentration is indicated within the British National Formulary for swabbing in obstetrics. A swab soaked in the antiseptic will be used to clean the vagina for 30 seconds prior to CS at the time of urinary catheter insertion by long forceps.~After the CS procedure, the vagina is always cleaned of excess blood as with a dry swab."
89423505|NCT04385680|No Intervention|No vaginal antiseptic arm|Women in labor who will receive abdominal scrub with chlorhexidine gluconate 4% only. Vaginal preparation is not including antiseptic or using normal saline only.
89423506|NCT04864756|Experimental|Before/After|Grade performance before and after introduction of simulation based learning
89423507|NCT04868422|Experimental|Telemonitoring|After CPAP titration, patients will be followed with telemonitoring device attached to the fixed pressure CPAP device
89423508|NCT04868422|No Intervention|Usual care|Patients with fixed pressure CPAP will be followed according to routine protocol without telemonitoring
89423509|NCT02798211|Active Comparator|Group 1|secukinumab 300mg s.c. injection
89423510|NCT02798211|Active Comparator|Group 2|secukinumab 150 mg s.c. injection
89423511|NCT02798211|Placebo Comparator|Group 3|Placebo s.c. injection
89423512|NCT04874896|Active Comparator|Control|Patients of this branch will not have autotransplantation of gut microbiota in capsules and will follow their usual post-transplant treatment
89423513|NCT04874896|Active Comparator|Microbiota autotransplantation|Patients in this branch will receive autotransplantation of intestinal microbiota in capsules for 6 months post-transplantation
89423514|NCT04868344|Experimental|MRG003|Phase Ia: MRG003 will be administrated by an IV infusion of escalating doses (0.1, 0.3, 0.6, 1.0, 2.0, 2.5, 3.0 mg/kg) on Day 1 of every 3 weeks (Q3W); Phase Ib: MRG003 will be administrated by an IV infusion of MTD/RP2D.
89423515|NCT03045640|Experimental|FSI ECD|"Vulnerable Households (ubudehe 1 or 2) in the Government of Rwanda's poverty classification system, when categories ranged from 1 to 6; the system has since been restructured to have four categories only. Often a way to identify households for public works opportunities or other government assistance programs. For this arm, families had to be Ubudehe 1 or 2 and have a child aged 0-3 years. Households meeting these criteria in the catchment area(s) received the FSI ECD home-based parenting intervention from bachelor-level interventionists/coaches."
89423516|NCT04868266|Experimental|end tidal carbon dioxide monitoring|
89423517|NCT04868266|No Intervention|Oxygen saturation monitoring|
89423518|NCT03045718|Experimental|Horticultural Therapy|Horticultural Therapy will consists of 1 hour sessions, weekly for 9 months, to engage subjects in gardening-based activities.
89007091|NCT06004479||Non-pregnant|Adult females between 18-40 years old who do not have a confirmed pregnancy.
89007092|NCT05979584|Experimental|Platelet Fibrin Plasma|Participants of intervention group will receive Platelet Fibrin Plasma in addition with clinical optimal treatment plan after the wound bed preparation for closure.
89423519|NCT03045718|Other|Waitlist Control|The control group will be placed on a waiting list and only be contacted for assessments. They will receive the same Horticultural Therapy intervention after the active treatment group at a later date.
89423520|NCT02060019|Experimental|exforge 10/160mg(amlodipine 10mg, valsartan160mg)|1 tablet daily for 10days
89423521|NCT02060019|Experimental|crestor 20mg(rosuvastatin 20mg)|1 tablet daily for 7days
89423522|NCT04864600|Active Comparator|Standard Stearin Candle|Several candles will be lit. We will be using realistic burning cycles i.e. burning candles which extinguish and new ones being lit.
89423523|NCT04864600|Experimental|Modified low emission candle|Several candles will be lit. We will be using realistic burning cycles i.e. burning candles which extinguish and new ones being lit.
89423524|NCT04864600|No Intervention|Clean Air|No candles in the chamber.
89423525|NCT02061501|Active Comparator|Speech therapy|Speech therapy (30 min per week) alone for the 6 first months. Then speech therapy (30 min per week) and optometric therapy (30 min per week) for the 6 last months.
89423526|NCT02061501|Experimental|Speech therapy and optometric therapy|Speech therapy (30 min per week) and optometric therapy (30 min per week) for 12 months.
89423527|NCT05654415|Experimental|Deprivation group|Sleep deprivation of 50% of physiological sleep
89007093|NCT05979584|Placebo Comparator|Platelet Rich Plasma|Participants of intervention group will receive Platelet Rich Plasma in addition with clinical optimal treatment plan after the wound bed preparation for closure.
89007094|NCT05975047|Experimental|LIV001|"Drug: LIV001~Dosage level:~Part A will receive single dose of either one or 10 capsules of 280 mg capsule of IP or placebo on Day 1; Part B participants will receive multiple doses of 280 mg capsule of IP or placebo from Day 1 to Day 14 after overnight fast ;~Dosage form- capsule~Route of administration- Oral"
89007095|NCT05975047|Placebo Comparator|Placebo|Placebo comparator taken by participants randomized to the placebo arm across Part A, B and C of the study.
89423528|NCT05654415|Experimental|Melatonin group|Melatonin oral solution 5 mg 30 minutes before EEG performing
89423529|NCT03044548|Experimental|Experimental|Supportive supervision
89423530|NCT03044548|No Intervention|Control|No intervention
89423531|NCT03044938|Experimental|Salbutamol|Salbutamol is a bronchodilator that relaxes the muscles of the airways and increases the flow of air to the lungs. With the aid of a spacer, 400mcg of the drug will be administered once during the protocol.
88814414|NCT02993939|Experimental|Diaphragm-sparing block|Ultrasound guided combinated infraclavicular-Suprascapular block of the braquial plexus, injecting 20 ml of levobupivacaine 0,25% plus epinephrine 5 micrograms per ml dorsal to the axillary artery in the infraclavicular fossa plus an Ultrasound guided injection of 10 ml of levobupivacaine 0,25% plus epinephrine 5 micrograms per ml in the suprascapular fossa.
89007096|NCT05966766|Active Comparator|Mozart|Subjects in this arm will listen to music from a list of pre-selected pieces by Mozart that have been previously shown to have beneficial effects on anxiety.
89007097|NCT05966766|Active Comparator|Patient preference|Subjects in this arm will listen to music from a list of pre-selected pieces of their own choosing.
89007098|NCT05955482||NuvoAir Clinical service|Patients with COPD receiving usual care plus NuvoAir clinical services.
89423532|NCT03044938|Placebo Comparator|Placebo|Inoculant treatment through a substance that does not have an inherent power to produce an effect that is desired or expected. Four placebo puffs will be offered through a device similar to the salbutamol intervention device.
89423533|NCT03045484|Experimental|The moderate group|Patient who was suffering from moderate pain in the mouth, pharynx, or larynx during the treatment of chemoradiotherapy consented to take controlled-release oxycodone, oxycodone was begun at the level of mild pain. We called this the moderate group. Controlled-release oxycodone was used to relieve oral mucositis pain induced by chemoradiotherapy in this group.
89536085|NCT04997343|Experimental|MS patients|All MS patients will undergo clinical and neurophysiological evaluation at baseline (T0). The baseline will consider the radiological data of disease activity obtained from the most recently performed MRI according to clinical practice. These evaluations will be repeated according to clinical practice in patients taking DMT or every 6 months, in a stable condition or according to the indication of the treating neurologist in case of disease reactivation. A one-year neurophysiological, clinical and radiological observation is foreseen. Healthy subjects will undergo only the neurophysiological evaluation at baseline.
89536086|NCT04997343|Other|Healthy controls|Healthy subjects will undergo only the neurophysiological evaluation at baseline.
89536087|NCT03199339|Active Comparator|SAD Part 1 Cohort 1 First Dose - Active|N = 2, 100 mg TBA-7371 or matching placebo
89536088|NCT03199339|Placebo Comparator|SAD Part 1 Cohort 1 First Dose - Placebo|N = 1, 100 mg TBA-7371 or matching placebo
89536089|NCT03199339|Active Comparator|SAD Part 1 Cohort 1 Second Dose - Active|N = 4, 100 mg TBA-7371 or matching placebo
89536090|NCT03199339|Placebo Comparator|SAD Part 1 Cohort 1 Second Dose -Placebo|N = 1, 100 mg TBA-7371 or matching placebo
89536091|NCT03199339|Active Comparator|SAD Part 1 Cohort 2 - Active|N= 6, 250 mg TBA-7371 or matching placebo
89536092|NCT03199339|Placebo Comparator|SAD Part 1 Cohort 2 - Placebo|N = 2, 250 mg TBA-7371 or matching placebo
89536093|NCT03199339|Active Comparator|SAD Part 1 Cohort 3 - Active|N = 6, 500 mg TBA-7371 or matching placebo
88905201|NCT01552577||TBI Group|Adults (civilian or military) with a history of one or more brain injuries / concussions.
88905202|NCT01552577||Control Group|Healthy adults (civilian or military) with no history of brain injury.
88905203|NCT01552616|Experimental|Activation Treatment|
88905204|NCT01552616|No Intervention|Usual Care|This arm will not receive any study-motivated intervention. Subjects will receive usual care, but will participate in outcomes assessments.
88905205|NCT01552629|Experimental|Group 1 QGE031|QGE031 will be administered as a subcutaneous dose q2 weeks
88905206|NCT01552629|Placebo Comparator|Group 2 Placebo|A QGE031 matched placebo will be administered as a subcutaneous dose q2 weeks
88905207|NCT01552629|Experimental|Group 3 Cyclosporine A|Cyclosporine A will be administered (as per label) for atopic dermatitis.
89195597|NCT05417048||Healthy control|No breast lesions detected by clinical examination/mammography/ultrasound/breast magnetic resonance imaging (MRI)
89536094|NCT03199339|Placebo Comparator|SAD Part 1 Cohort 3 - Placebo|N = 2, 500 mg TBA-7371 or matching placebo
89536095|NCT03199339|Active Comparator|SAD Part 1 Cohort 4 - Active|N = 6, 1000 mg TBA-7371 or matching placebo
89536096|NCT03199339|Placebo Comparator|SAD Part 1 Cohort 4 - Placebo|N = 2, 1000 mg TBA-7371 or matching placebo
89536097|NCT03199339|Active Comparator|SAD Part 1 Cohort 5 - Active|N = 6, 1500 mg TBA-7371 or matching placebo
88905208|NCT01552642|Active Comparator|Intervention Group|Intervention Group
88905209|NCT01552642|No Intervention|Control Group|Control Group
88905210|NCT01552655|Other|Dual-time PET/CT|
88905211|NCT01552668|Experimental|Fidaxomicin|Receive 200 mg of fidaxomicin twice daily
88905212|NCT01552668|Placebo Comparator|Placebo|
88905213|NCT01552707|Experimental|XCEL-MT-OSTEO-ALPHA|"ex-vivo expanded autologous mesenchymal stem cells fixed in allogenic bone tissue for spinal fusion"
88905214|NCT01552707|Sham Comparator|Standard treatment|Instrumented spinal fusion together with patient's bone iliac crest.
88905215|NCT01552733|Experimental|Robotic Therapy|Robotic Therapy using 'Inmotion' device plus standard care. Participants randomised to robotic therapy will receive up to 12 sessions (approximately 1 hour each) performing tasks (including circle drawing, reaching targets and holding/moving against moderate resistance.
88905216|NCT01552733|Placebo Comparator|Standard Care|Rehabilitation therapy according to local guidelines.
88905217|NCT01552759|Experimental|Obese subjects with BED|"Subjects who meet the BMI requirement for obesity (>30 kg/m^2) and the DSM requirements for binge eating disorder based on responses to validated questionnaires.~Subjects will undergo the postprandial responses, cold pressor test and ad libitum test meal."
89007099|NCT05955482||Standard Care|Propensity matched controls with COPD who receive usual care.
89007100|NCT05955352|Experimental|Procedural intervention and Control group with standard care|There will be two groups. Interventional group will receive perineal warm compression and control group will receive standard care
89007101|NCT05953870|Experimental|MUSIC AND COMFORT THERAPY|"The intervention group will be exposed pre- and postoperatively to relaxing music, which is defined as a slower tempo music that can quiet mind and make patients feel soothed."
89195598|NCT03922620|Experimental|Liposomal Bupivacaine Group|No peripheral nerve block will be given. Local infiltration of 20cc of Liposomal Bupivacaine infiltrated to the surgical area.
89423534|NCT03045484|Experimental|The severe group|Patients who did not ask for controlled-release oxycodone until the pain reached a moderate level during the treatment of chemoradiotherapywere called the severe group. Controlled-release oxycodone was also used to relieve oral mucositis pain induced by chemoradiotherapy in this group..
88905218|NCT01552759|Experimental|Obese without BED|"Subjects who meet the BMI requirement for obesity (>30 kg/m^2) but who do not meet the DSM requirements for binge eating disorder based on responses to validated questionnaires.~Subjects will undergo the postprandial responses, cold pressor test and ad libitum test meal."
88905219|NCT01552759|Experimental|Normal-weight without BED|"Subjects with BMI 20-25 kg/m^2 who do not meet the DSM requirements for binge eating disorder based on responses to validated questionnaires.~Subjects will undergo the postprandial responses, cold pressor test and ad libitum test meal."
88905220|NCT01552785||Healthy adults|
89423535|NCT04874506|Experimental|Cohort 1|"Cohort 1 will receive standard of care concomitantly with1000 mg/day of MBM-02.~Patients will receive standard of care treatment for newly diagnosed Glioblastoma multiforme consisting of four sequential periods:~1 week run-in with MBM-02 prior to radiotherapy;~6 weeks of radiotherapy and concomitant temozolomide;~4 weeks of rest post-radiotherapy and concomitant temozolomide; and~Adjuvant temozolomide treatment post 4-week rest period. Patients will be administered daily MBM-02 during all four sequential periods."
89536098|NCT03199339|Placebo Comparator|SAD Part 1 Cohort 5 - Placebo|N = 2, 1500 mg TBA-7371 or matching placebo
89536099|NCT03199339|Active Comparator|MAD Part 2 Cohort 1 - Active|N = 9, 100 mg TBA-7371 or matching placebo
88905221|NCT01552798|Experimental|Arm 1|
88905222|NCT01552798|Active Comparator|Arm 2|
88905223|NCT01552798|Placebo Comparator|Arm 3|
89423536|NCT04874506|Experimental|Cohort 2|"Cohort 2 will receive standard of care concomitantly with1200 mg/day of MBM-02.~Patients will receive standard of care treatment for newly diagnosed Glioblastoma multiforme consisting of four sequential periods:~1 week run-in with MBM-02 prior to radiotherapy;~6 weeks of radiotherapy and concomitant temozolomide;~4 weeks of rest post-radiotherapy and concomitant temozolomide; and~Adjuvant temozolomide treatment post 4-week rest period. Patients will be administered daily MBM-02 during all four sequential periods."
89423537|NCT04874506|Experimental|Cohort 3|"Cohort 2 will receive standard of care concomitantly with1400 mg/day of MBM-02.~Patients will receive standard of care treatment for newly diagnosed Glioblastoma multiforme consisting of four sequential periods:~1 week run-in with MBM-02 prior to radiotherapy;~6 weeks of radiotherapy and concomitant temozolomide;~4 weeks of rest post-radiotherapy and concomitant temozolomide; and~Adjuvant temozolomide treatment post 4-week rest period. Patients will be administered daily MBM-02 during all four sequential periods."
89423538|NCT04874506|Experimental|Cohort 4|"Cohort 2 will receive standard of care concomitantly with1400 mg/day of MBM-02.~Patients will receive standard of care treatment for newly diagnosed Glioblastoma multiforme consisting of four sequential periods:~1 week run-in with MBM-02 prior to radiotherapy;~6 weeks of radiotherapy and concomitant temozolomide;~4 weeks of rest post-radiotherapy and concomitant temozolomide; and~Adjuvant temozolomide treatment post 4-week rest period. Patients will be administered daily MBM-02 during all four sequential periods."
88905224|NCT01552096|Placebo Comparator|Placebo|The placebo group (n=30) will receive a submucosal infiltration with 3 mL of normal saline (1.5 ml around each tonsil), 3 minutes before surgical incision.
89423539|NCT04867876|Experimental|Intervention Cohort|Physical Therapy
89423540|NCT04429672|Experimental|Experimental Group (EG)|"The participants of the Experimental Group receive as treatment the intervention called The Right to your Sexual Health, which is socio-educational and is composed of five thematic axes; Sexual Rights, Sexuality, Reproductive Health, Sexual Conduct and Life Project divided into ten sessions (two weekly) of 30 minutes each, each session has a structure of the opening, development and closing phase established in a manual for the facilitator, it should be noted that the intervention is applied by a multidisciplinary team in which the areas of medicine, nursing and psychology participate. In addition, Information and Communication Technologies (ICTs) are used through a Moodle platform that has available to participants digital support material as digital presentations on each of the thematic axes, as well as audiovisual material through the Podcast format of conversations concerning each of the axes."
88905225|NCT01552096|Active Comparator|lidocaine|will receive a total of 2 mg.kg-1 of 2% lidocaine HCl (Xylocaine, Astra-Zeneca,) in 3 mL of normal saline (1.5 ml around each tonsil), 5 minutes before surgical incision.
88905226|NCT01552096|Experimental|Tramadol|(n=30) will receive a submucosal infiltration with 2 mg kg-1 tramadol in 3 mL of normal saline (1.5 ml around each tonsil), 3 minutes before surgical incision.
88905227|NCT01552811||Type 1 diabetes|
88905228|NCT01552811||healthy controls|
88905229|NCT01552824|Experimental|Vesico-amniotic shunt|In this arm, patients will be randomly selected to undergo vesico-amniotic shunting.
88905230|NCT01552824|Experimental|CYSTO|In this arm, all patients will be randomly selected for fetal cystoscopy.
88905231|NCT01552837|No Intervention|Healthy volunteers|MRI compatible, no present or past DSM-IV diagnosis
88905232|NCT01552837|Active Comparator|patients with Bipolar Disorder|MRI compatible, presence of DSM-IV diagnosis for Bipolar Disorder
89423541|NCT04429672|Active Comparator|Control Group (CG)|The participants of the Control Group receive the usual sexual health intervention applied by Secretary of Health consisting of six sessions (one a week) lasting 50 minutes each using illustrative material through rotating official secretary of health folios on reproductive health, sexually transmitted diseases and sexual violence.
88905233|NCT01552850|Experimental|Oxycodone Formulation A Capsule|single dose of 40 mg PF-00345439 capsule under 50 mg naltrexone block
88905234|NCT01552850|Experimental|Oxycodone Formulation B Capsule|single dose of 40 mg PF-00345439 capsule under 50 mg naltrexone block
88905235|NCT01552850|Experimental|Oxycodone Formulation C Capsule|single dose of 40 mg PF-00345439 capsule under 50 mg naltrexone block
88905236|NCT01552850|Experimental|Oxycodone Formulation D Capsule|single dose of 40 mg PF-00345439 capsule under 50 mg naltrexone block
88905237|NCT01552850|Experimental|Oxycodone Oral Solution|40 mg oxycodone oral solution (5 mg/5 ml) under 50 mg naltrexone block
88905238|NCT01552863|Experimental|Treatment A|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
88905239|NCT01552863|Experimental|Treatment B|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
88905240|NCT01552863|Experimental|Treatment C|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
88905241|NCT01552863|Experimental|Treatment D|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
88905242|NCT01552863|Experimental|Treatment E|Single dose of 5 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
88905243|NCT01552863|Experimental|Treatment F|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
88905244|NCT01552941|Experimental|Vagal Nerve Stimulation|
88905245|NCT01552993|Experimental|paracetamol|Paracetamol mixture 20 mg/kg + pacifier and sucrose
88905246|NCT01552993|Placebo Comparator|placebo|pacifier and sucrose only
88905247|NCT01553006|Active Comparator|cefditoren pivoxil|cefditoren 10 mg/kg/day for 14 days
88905248|NCT01553006|Active Comparator|cefditoren pivoxil high dose|cefditoren 20 MKD were used to compare efficacy of treatment.
88905249|NCT01553019|Experimental|1- R(0) negative|50.40 cobalt gray equivalent (CGE) Proton Radiation and concomitant chemotherapy with weekly gemcitabine
89423542|NCT04874428|Experimental|Rivaroxaban|Pharmacokinetics and pharmacodynamics of rivaroxaban
89423543|NCT04874428|Experimental|Apixaban|Pharmacokinetics and pharmacodynamics of apixaban
89423544|NCT04863976|Experimental|Dynamic stretching|
89423545|NCT04863976|Active Comparator|Passive stretching|
89423546|NCT04863976|Active Comparator|Self-stretching|
89423547|NCT04864288||1|male patients (age ≥ 21) with erectile dysfunction (ED) and non-responders to intracorporal injection
89423548|NCT04864288||2|age matched thirty men with normal erectile function
88905250|NCT01553019|Experimental|2- R(1) micro-positive|54.00 cobalt gray equivalent(CGE) Proton Radiation and concomitant chemotherapy with weekly gemcitabine
88905251|NCT01553019|Experimental|3- R(2) gross positive|59.40 cobalt gray equivalent (CGE) Proton Radiation and concomitant chemotherapy with weekly gemcitabine
88905252|NCT01553045||atrial fibrillation, catheter ablation|Patients referred for ablation of atrial fibrillation
89195599|NCT03922620|Active Comparator|Peripheral Nerve Block Group|Peripheral Nerve Block performed by anesthesia team (blocks will be given by same anesthesia provider utilizing same technique every time in order to reduce variations in delivery of peripheral nerve block). No local analgesic agent infiltration
89195600|NCT00419263|Experimental|Peramivir 150 mg|
89195601|NCT00419263|Experimental|Peramivir 300 mg|
89195602|NCT00419263|Placebo Comparator|Placebo|
89423549|NCT04867720|Experimental|CertiroBell Tablet|Use in combination with Tacrolimus at least 6 months after liver transplantation.
89423550|NCT02799069|Active Comparator|BF-200 ALA|Topical application of BF-200 ALA gel containing 78 mg/g 5-aminolevulinic acid (ALA). Application of a 1 mm thick layer covering each lesion and a 0.5 cm to 1 cm surrounding margin.
89423551|NCT02799069|Active Comparator|MAL Cream|Topical application of MAL cream (Metvix) containing 160 mg/g methyl-aminolevulinate (MAL). Application of a 1 mm thick layer covering each lesion and a 0.5 cm to 1 cm surrounding margin.
88905253|NCT01553097||women with stage I or II BC with adjuvant chemotherapy|"women with Stage I or II BC who~have undergone surgical treatment (biopsy, lumpectomy or mastectomy) and;~will be receiving adjuvant chemotherapy"
88905254|NCT01553097||women with Stage I or II BC without adjuvant therapy|"Women with stage I or II BC who~Have undergone surgical treatment (biopsy, lumpectomy or mastectomy) \~will not be receiving adjuvant chemotherapy"
89423552|NCT02799069|Placebo Comparator|Vehicle|Topical application of matched Placebo to BF-200 ALA gel (without containing active ingredient) ). Application of a 1 mm thick layer covering each lesion and a 0.5 cm to 1 cm surrounding margin.
89423553|NCT02060643||Cross-sectional hemi-neck RT|
89423554|NCT01669174|Experimental|BYM338|
88905255|NCT01553097||Healthy control|healthy education-age-matched women without cancer
88905256|NCT01553110||Cold Population|Male and female subjects 12 years of age and older with acute nasal discharge fewer then 7 days. Patients must be symptomatic at screening.
88905257|NCT01553110||Allergic Rhinitis|Male and female subjects of 12 years of age and older with a history suggesting nasal allergic symptoms for at least 1 year. Patients must be symptomatic at screening.
88905258|NCT01553123|Experimental|Ulipristal with iron|
88905259|NCT01553123|Placebo Comparator|Placebo|Placebo with iron
89423555|NCT01669174|Placebo Comparator|Placebo|
89423556|NCT02060097|Active Comparator|Cocoa flavanol beverage|flavanol 320mg/day
89423557|NCT02060097|Placebo Comparator|Placebo beverage|no flavanol
89423558|NCT03800043||Children with own caries experience|Children with own caries experience (visible on a photo; teeth clearly visible), sufficient compliance
89423559|NCT03800043||Children without own caries experience|Children without own caries experience (visible on a photo; teeth clearly visible), sufficient compliance
89423560|NCT03045562|Placebo Comparator|Control group|Patients will be assigned to receive 100ml of normal saline
88905260|NCT01553227|Experimental|ventilator|The overall purpose of this study is to determine the effects of auto-Trilevel ventilation on patients with OSAHS and OHS by comparison with BiPAP ventilation. The following parameters are compared such as apnea hypopnea index, lowest SPO2, arousal index, sleep efficiency, PaCO2, daytime sleepiness and so on.
88905261|NCT01553266||MDET intervention|
89195603|NCT01034995|Experimental|SSR125543 20 mg|1 capsule of SSR125543 20 mg + 1 capsule of placebo
89195604|NCT01034995|Experimental|SSR125543 50 mg|1 capsule of SSR125543 50 mg + 1 capsule of placebo
89195605|NCT01034995|Experimental|SSR125543 100 mg|2 capsules of SSR125543 50 mg
89195606|NCT01034995|Active Comparator|escitalopram 10 mg|1 capsule of escitalopram 10 mg + 1 capsule of placebo
89195607|NCT01034995|Placebo Comparator|placebo|2 capsules of placebo
89195608|NCT00921414|Active Comparator|1|observation : 3 years maintenance period with assesments and surveillance every 2 months
89195609|NCT00921414|Experimental|2|maintenance period infusions of Rituximab 375 mg/m2/2 months and assessement and surveillance
89195610|NCT04060914|Experimental|Ticagrelor(90mg)|
89195611|NCT04060914|Experimental|Ticagrelor(90/60mg)|
89423561|NCT03045562|Experimental|Experimental group|Patients will be assigned to receive Salvianolate injection dissolved in 100ml of normal saline
89423562|NCT02062047|Experimental|FMSRP+CLX|Full-mouth scaling and root planing in a maximum of 24 hours, application and irrigation of chlorhexidine 2% gel, rinsing chlorhexidine 0.12% solution during 60 days
89423563|NCT02062047|Placebo Comparator|FMSRP + placebo group|Full-mouth scaling and root planing in a maximum of 24 hours, application and irrigation of placebo, rinsing placebo solution during 60 days
89423564|NCT02062047|Active Comparator|PMSRP group|Partial-mouth scaling and root planing in 4-6 sessions in a maximum of 2 weeks
89423565|NCT03047902|Active Comparator|Parent Present|"The adolescents in group 1 (Parent Present) will be aware that their parents will be able to share the information on the questionnaire, but they will be assured of the confidentiality of the CO test. This will also be explained to the parent.~Intervention: Parents will be present for the questionnaire but not for the CO test."
89423566|NCT03047902|Active Comparator|Parent Absent|"The adolescents in group 2 (parents not present) will be assured of the confidentiality of the questionnaire and CO test. The confidentiality of the test will also be explained to the parent.~Intervention: Parents will not be present for the questionnaire or the CO test"
88905262|NCT01553266||Control group|Patients who have not received the MDET intervention.
88905263|NCT01553305|Experimental|Supervised exercise programme|Six-weeks supervised high-intensity exercise programme with training sessions twice a week followed by 6-weeks unsupervised exercise programme.
88905264|NCT01553305|No Intervention|Unsupervised exercise programme|
88905265|NCT01553331|Active Comparator|conventional diathermy hook|Laparoscopic cholecystectomy made with diathermy hook starting from Calot´s triangle
88905266|NCT01553331|Active Comparator|ultrasonic dissection|Laparoscopic cholecystectomy made with ultrasonic dissection starting from gallbladder fundus
88905267|NCT01553370|Active Comparator|Alternate Intake-time|
88905268|NCT01553370|Experimental|Immediately post-exercise|
88905269|NCT01553383|Active Comparator|Dental device|"Provent nasal peep valve vs dental device"
88905270|NCT01553383|Active Comparator|CPAP|"continuous positive airway pressure CPAP vs nasap peep valve Provent"
89195612|NCT04060914|Active Comparator|Clopidogrel(75mg)|
89195613|NCT00399763|Placebo Comparator|1|placebo plus individual cognitive behavioral therapy
89195614|NCT00399763|Experimental|2|atomoxetine plus individual cognitive behavioral therapy
88905271|NCT01553422|Active Comparator|before fluid Therapy|
88905272|NCT01553422|Active Comparator|after fluid Therapy|
88905273|NCT01553435|Placebo Comparator|Dextromethorphan, opioid analgisia, efficacy|
88905274|NCT01553435|Placebo Comparator|Placebo,opioid analgesia, efficacy|
88905275|NCT01553487|Experimental|Excercise|The forearm vibration training
88905276|NCT01553487|No Intervention|Control|Patients will be treated by routine fracture treatment methods (fixation and rest).
88905277|NCT01553500|Experimental|glucomannan|
88905278|NCT01553500|Placebo Comparator|placebo|
88905279|NCT01553513||Group 1 - STEMI|Patients with acute cardiovascular event and typical aberrations in the ECG(STEMI) and positive serum markers
89195615|NCT05324904|Active Comparator|group 1|this group will be intralesionaly injected with vitamin D3
89195616|NCT05324904|Active Comparator|group 2|this group will be intralesionally injected with acyclovir
89195617|NCT02085265|Experimental|Telmisartan|Telmisartan 40 mg or 80 mg/day (depending on age and tolerability)
89195618|NCT02085265|Active Comparator|Perindopril|Perindopril 2 mg, 4 mg or 8 mg/day (depending on kidney function and tolerability)
89536100|NCT03199339|Placebo Comparator|MAD Part 2 Cohort 1 - Placebo|N = 3, 100 mg TBA-7371 or matching placebo for 14 days
89423567|NCT03045406|Experimental|Apixaban|orally administered, at the dose of 10 mg bid for 7 days, followed by 5 mg bid (total period of treatment: six months)
89423568|NCT03045406|Active Comparator|Dalteparin|subcutaneously administered, at a dose of 200 IU/kg SC o.i.d for 1 month. Thereafter, dalteparin will be administered at a dose of 150 IU/kg o.i.d. for 5 months
88905280|NCT01553513||Group 2 - NSTEMI|Patients with acute coronary syndrome without typical aberrations in the ECG (NSTEMI) or without positive serum markers
88905281|NCT01553513||Group 3 - symptomatic CAD|Symptomatic patients with stable CAD, who are eligible for ICA
89423569|NCT02798835|Active Comparator|Adductor Canal block|Postoperatively in the PACU, this group will receive 20ml 0.5% ropivacaine for their ACB.
88905282|NCT01553513||Group 4 - STEMI|Patients eligible for ICA 6 months after STEMI and revascularization
88905283|NCT01553526||Orsiro DES|
88905284|NCT01553552||Infected by Schistosoma haematobium|
88905285|NCT01553552||Not infected by Schistosoma haematobium|
88905286|NCT01553565|Active Comparator|Conventional polypectomy|All colorectal polyps up to 10 mm found except for tiny hyperplastic polyps in the rectum and distal sigmoid colon are removed with electrocautery. Submucosal injection of some solution before the removal are not performed.
88905287|NCT01553565|Experimental|Cold polypectomy|
88905288|NCT01553578|Experimental|Arm A (healing touch therapy)|Patients receive 30 minutes of healing touch therapy consisting of magnetic clearing, pain drains, hands in motion/hands still and mind clearing.
88905289|NCT01553578|Experimental|Arm B (guided imagery)|Patients listen to guided imagery audiotapes for 30 minutes.
88905290|NCT01553578|Active Comparator|Arm C (standard care)|Patients receive standard of care.
88905291|NCT01553604|Experimental|Postoperative day 6|Dressing is removed on the sixth postoperative day
88905292|NCT01553604|Experimental|Postoperative day 1|Dressing is removed on the first postoperative day
88905293|NCT01553617|Experimental|Volulyte|6 % hydroxyethyl starch 130/0.4 in an isotonic electrolyte solution (VolulyteTM)
88905294|NCT01553617|Active Comparator|Human serum albumin|Human serum albumin (HSA 50g/L)
88905295|NCT01553630|Active Comparator|RIA bone graft|Surgery: open reduction and internal fixation (ORIF) of high energy metaphyseal fractures with Reamed Irrigator Aspirator (RIA) bone graft at the time of fixation.
88905296|NCT01553630|Active Comparator|Surgery without bone graft|Surgery:open reduction and internal fixation (ORIF) of high energy metaphyseal fractures without Reamed Irrigator Aspirator (RIA) bone graft at the time of fixation.
88905297|NCT01553643|Experimental|Chinese Herb Huang-Chi-Wu-Wu-Tang|
88905298|NCT01553643|Placebo Comparator|Placebo|
88905299|NCT01553656|Experimental|Cabozantinib capsules and tablets|Subjects will be enrolled in cohorts at different dose levels in order to determine the maximum tolerated dose of cabozantinib. Initially, subjects enrolled will receive the capsule formulation; other subjects will receive the tablet formulation.
88905300|NCT01553669|Experimental|reminiscence therapy|Reminiscence therapy is a method of using the memory to protect mental health and improve the quality of life.
89423570|NCT02798835|Active Comparator|Adductor canal block with dexamethasone|Postoperatively in the PACU, this group will receive 20ml 0.5% ropivacaine for their ACB along with 8mg IV dexamethasone.
89423571|NCT02798835|Active Comparator|Adductor canal catheter|Postoperatively in the PACU, this group will receive 20ml 0.5% ropivacaine for their adductor canal block and have a catheter placed in the adductor canal at the mid-thigh. 0.2% ropivacaine at 5ml/hr will be run for 48 hours.
89423572|NCT03044236|Experimental|Novel Stretching Technique|Participants will perform the novel stretch in a supine position. Participants will place a small ball between their knees and squeeze the ball. Participants will be then bridge as high as possible . Participants will then flex their shoulder and elbow to 90°, and actively rotate to the end of ROM. Participants will use the other hand to push to the point of mild discomfort and simultaneously maintain contraction while progressing the stretch.
88905301|NCT01553669|No Intervention|Control group|The participants assigned to the waiting-list as the control group will be treated as before. After the intervention period, we will conduct reminiscence therapy on them if they ask for.
88905302|NCT01553682|No Intervention|Enhanced Standard-Of-Care|Participants will watch a video about how to prevent STIs and HIV, then do question and answer session. This group will be last 1 hour. It will be led by one African American health educator, and have about 4-8 other young women participants. Participants will be asked to rate the workshop anonymously.
88905303|NCT01553682|Active Comparator|Horizons+General Health Promotion (GHP)|Participants will attend the Horizons HIV Prevention Program with an extra workshop on nutrition health promotion. Participants will attend a total of two (2) 5-hour workshops over 2 consecutive Saturdays. They will be led by African American health educators, and have about 8-12 other young women participants. The workshops will discuss gender and ethnic pride, self-esteem, good role models, and how to reduce risky sexual behavior. The nutrition health promotion workshop will give ideas on healthy nutrition and exercise. Participants will be asked to rate the workshop anonymously.
88905304|NCT01553682|Experimental|Horizons+Motivational Enhancement Therapy (GMET)|Participants will attend the Horizons Plus HIV Prevention Program. Participants will attend a total of two (2) 5-hour workshops over 2 consecutive Saturdays. They will be led by African American health educators, and have about 8-12 other young women participants. The workshops will discuss gender and ethnic pride, self-esteem, good role models, and how to reduce risky sexual behavior. Participants will be asked to rate the workshop anonymously.
88905305|NCT01553695|Active Comparator|general population|
88905306|NCT01553695|Experimental|ADHD Patient|
89423573|NCT03044236|Active Comparator|Traditional Stretching Technique|Participants will perform the modified sleeper stretch in a side-lying position on the side of the throwing shoulder with the throwing shoulder and elbow flexed to 90° . The participants will be instructed to allow the throwing shoulder to naturally fall into internal rotation to the end ROM where resistance will be felt . The participants will be then instructed to use the non-throwing hand to push the throwing shoulder into further internal rotation to the point of mild discomfort by applying pressure at the area of the wrist joint.
88905307|NCT01553721|Experimental|udenafil|"Phase IIa Experimental : Udenafil Dose 1, Dose 2~Phase IIb Experimental : Udenafil"
88905308|NCT01553721|Placebo Comparator|placebo|"Phase IIa Placebo Comparator : Placebo~Phase IIb Placebo Comparator : Placebo"
89423574|NCT02061579|Experimental|Once-Weekly Structured Contact|Participants in the Once Weekly Structured Contact group will take part in an 6-month exercise intervention and attend one structured group exercise session per week. They will engage in aerobic and resistance training for approximately 80 minutes per exercise session. Additionally, they will attend three exercise evaluations and six study visits.
89423575|NCT02061579|Experimental|Thrice-Weekly Structured Contact|Participants in the Thrice-Weekly Structured Contact group will take part in an 6-month exercise intervention and attend three structured group exercise sessions per week. In total, they will engage in aerobic and resistance training sessions for approximately 200 minutes per week. Additionally, they will attend three exercise evaluations and six study visits.
89423576|NCT02061579|No Intervention|Usual Care|Participants in the Usual Care group will not take part in an 6-month exercise intervention. They will continue to seek regular care from their primary care providers and attend six study visits.
89423577|NCT03044470|Experimental|Cold saline|Saline stored at 4 degrees centigrade
88905309|NCT01553760|Experimental|Tri-MICS|
88905310|NCT01553760|Active Comparator|Conventional Phaco|
88905311|NCT01553773|Experimental|Isoflavone|a gel with isoflavones (genistein 4%)
88905312|NCT01553773|Experimental|Estradiol|gel with 17-β estradiol 0.01%
88905313|NCT01553786|Experimental|lenalidomide|lenalidomide + CHOP
89423578|NCT03044470|Experimental|Normal Saline|Saline stored at room temperature
88905314|NCT01553799||US check tube|
88905315|NCT01553799||US check tube, Endobronchial|
88905316|NCT01553825||Pathologically diagnosed carcinoma|
88905317|NCT01553838|Experimental|Sequentially MRI guided and TRUS guided biopsy|Targeted MRI guided biopsy according to findings in a multiparametric MRI followed by transrectal guided biopsy
88905318|NCT01553877|Active Comparator|Pushti Packet|
88905319|NCT01553877|Experimental|Rice based Ready to Use Complementary Food Supplements|
88905320|NCT01553877|Active Comparator|Chick-pea based Ready to Use Complementary Food Supplements|
88905321|NCT01553890|Other|Patients diagnosed with scleroderma|patients diagnosed with scleroderma, clinical and lab support
88905322|NCT01553890|Other|No disease|Blood sample, venous blood, about 10 ml will be drawn from participants
88905323|NCT01553903|Experimental|Tamoxifen,|Current hormonotherapy treatment in hormone dependent breast cancer
88905324|NCT01553903|Experimental|Exemestane|Current hormonotherapy treatment in hormone dependent breast cancer
88905325|NCT01553903|Experimental|Anastrozole|Current hormonotherapy treatment in hormone dependent breast cancer
89007102|NCT05953870|No Intervention|CONTROL GROUP|These patients will follow the standard surgical pathways as per daily routine.
89423579|NCT02061657|Experimental|Myomectomy, rectal Misoprostol|25 patients undergoing myomectomy operation will receive two tablets of misoprostol (400 mcg) rectally two hours before the operation.
89007103|NCT05950841|Experimental|Low dose IHAT|IHAT in capsule form and carob flour in capsule form - taken as 1 x 100mg IHAT capsule (equiv 30mg iron) in the morning with water and 1 x placebo capsule in the evening with water
89423580|NCT02061657|Active Comparator|Myomectomy, Placebo|Include 25 patients undergoing myomectomy operation will not receive misoprostol before the operation.
89423581|NCT03048136|Experimental|Flat-Dose|Nivolumab flat dose + Ipilimumab
89423582|NCT03048136|Experimental|Weight-Based Dose|Nivolumab weight-based dose + Ipilimumab
89423583|NCT02062203|Experimental|AKB-6548 (therapeutic dose)|
88905326|NCT01553903|Experimental|Letrozole|Current hormonotherapy treatment in hormone dependent breast cancer
88905327|NCT01553929|Experimental|Physical and cognitive activity group|
88905328|NCT01553929|Active Comparator|Physical activity group|
88905329|NCT01553929|Placebo Comparator|control group|
88905330|NCT01553942|Experimental|Afatinib|Afatinib
88905331|NCT01553968|Other|Endurance Trained Subjects|
88905332|NCT01553968|Other|Untrained Subjects|
88905333|NCT01553981|Active Comparator|Tadalafil|Tablet Tadalafil 20 mg every alternate day
88905334|NCT01553981|Placebo Comparator|Placebo|Tablet Placebo every alternate day
88905335|NCT01553994||HPV vaccinated, non-vaccinated|Individuals born between 1989 and 1996. HPV-vaccinated will be compared to non-vaccinated in regards to condyloma status post vaccination.
88905336|NCT01554007||Crohn's disease|Korean patients diagnosed with Crohn's disease
88905337|NCT01554020|Active Comparator|Multiherb product|Herbal product
88905338|NCT01554020|Placebo Comparator|Placebo|Maltodextrin control
88905339|NCT01554033||Huntington's disease patients|Huntington's disease patients and his(/her) family
88905340|NCT01554033||age-sex matched control|age-sex matched control about huntington patients
88905341|NCT01554072|Placebo Comparator|Placebo|Patients will receive a booklet of exercises, besides containing an explanation of his illness and the importance of exercise in their quality of life, an exercise routine physical to be held three times a week for two consecutive months. Patients will be instructed individually on each exercise, performing with supervisor that there be no doubt about execution, thereby minimizing any possible mistake in practice at home. For each day of the year ended data should be recorded in a daily monitoring. At the end of two months of the PR program semi-home patients will be subject to review so that all tests should be applied again.
89007104|NCT05950841|Experimental|High dose IHAT|IHAT in capsule form - taken as 2 x 100mg (equiv 60mg iron) daily with water (1 in the morning and 1 in the evening)
89007105|NCT05950841|Placebo Comparator|Carob flour|Carob flour in capsule form - taken as 2 x capsules daily with water (1 in the morning and 1 in the evening)
89423584|NCT02062203|Experimental|AKB-6548 (supratherapeutic dose)|
89423585|NCT02062203|Placebo Comparator|Placebo|
89423586|NCT02062203|Active Comparator|Moxifloxacin|
89423587|NCT03560661||Amyotrophic lateral sclerosis (ALS) patients|
89423588|NCT03560661||Primitive Lateral Sclerosis (PLS) patients|
89423589|NCT03560661||Kennedy's disease (KD) patients|
89423590|NCT04863742|Experimental|Dextenza Arm|
89423591|NCT04863742|Active Comparator|Prednisolone Acetate 1%|
88905342|NCT01554072|Active Comparator|exercise|Patients will receive a booklet of exercises, besides containing an explanation of his illness and the importance of exercise in their quality of life, an exercise routine physical to be held three times a week for two consecutive months. For each day of the year ended data should be recorded in a daily monitoring. Is also scheduled a visit to the laboratory biweekly in which patients demonstrate their exercise routine program RP semi-home settings for any load, postural corrections and execution of physical exercise, should be refocused. At the end of two months of the PR program semi-home patients will be subject to review so that all tests should be applied again.
88905343|NCT01554085|Experimental|ALS-002158|
88905344|NCT01554085|Placebo Comparator|Placebo|
88905345|NCT01554098|Active Comparator|Strategy : supine first|"This study will be performed as a cross over study, comparing withdrawal in the supine position versus withdrawal with dynamic position change.~Withdrawal in supine position followed by withdrawal with dynamic position change"
88905346|NCT01554098|Active Comparator|Strategy : dynamic first|This study will be performed as a cross over study, comparing withdrawal in the supine position versus withdrawal with dynamic position change.
88905347|NCT01554111|Active Comparator|Picosalax with rectal enema|This arm will receive one satchet of Picosalx and a rectal enema before the sigmoidoscopy for their bowel preparation regimen.
88905348|NCT01554111|Active Comparator|rectal enema|This group of patients will receive only a rectal enema for bowel preparation before their flexible sigmoidoscopy.
88905349|NCT01554111|Active Comparator|Pico-Salax|patient will take one sachet of pico-salax
88905350|NCT01554124|Experimental|Meropenem|"Infants will received Meropenem 40 mg/kg every 8 hours (every 12 hours in the youngest age group: < 32 weeks GA and < 2 weeks postnatal age).~Treatment duration = 21 ± 7 days"
88905351|NCT01554137|Experimental|With isokinetic strength training|60 minutes isokinetic strength training on concentric mode
88905352|NCT01554137|Placebo Comparator|without isokinetic strength training|passive motion 60 minutes
88905353|NCT01554150|Experimental|Method of Levels Cognitive Therapy (MOL)|Participants in this arm will be able to receive therapy over a 3 month period. They will be able to schedule sessions with a therapist as and when they need them.
88905354|NCT01554150|No Intervention|Contact Service|The Contact Service arm is effectively a waiting list control. Participants assigned this arm will remain on the service's waiting list during the 3 months of the therapy phase. These participants will have access to a 'Contact Service' provided by the study therapist, where they are able to contact him if they want further information about the study or their treatment options.
88905355|NCT01554189|Experimental|Panel A (GT1 10 mg)|
88905356|NCT01554189|Experimental|Panel B (GT1 50 mg)|
88905357|NCT01554189|Experimental|Panel C (GT1 100 mg)|
88905358|NCT01554189|Experimental|Panel D (GT1 200 mg)|
88905359|NCT01554189|Experimental|Panel E (GT3 10 mg)|
88905360|NCT01554189|Experimental|Panel F (GT3 50 mg)|
88905361|NCT01554189|Experimental|Panel G (GT3 100 mg)|
88905362|NCT01554189|Experimental|Panel H (GT3 200 mg)|
88905363|NCT01554189|Experimental|Panel I (GT1a 10 mg)|
88905364|NCT01554189|Experimental|Panel J (GT1a 50 mg)|
88905365|NCT01554189|Placebo Comparator|Placebo Panel|
88905366|NCT01554202|Experimental|Young controls|Assessment of memory, circulating tPA dosage, ApoE4, brain imaging examination MRI and PET examinations.
88905367|NCT01554202|Experimental|Middle age controls|Assessment of memory, circulating tPA dosage, ApoE4, brain imaging examination MRI and PET examinations.
88905368|NCT01554202|Experimental|Elderly controls|Assessment of memory, circulating tPA dosage, ApoE4, brain imaging examination MRI and PET examinations.
88905369|NCT01554202|Experimental|Autosomal dominant forms of early-onset Alzheimer disease|Assessment of memory, circulating tPA dosage, ApoE4, brain imaging examination MRI and PET examinations.
89423592|NCT03799497||Patients suffering from Anorexia Nervosa|Subjects with a diagnostic of anorexia nervosa disorder
88905370|NCT01554202|Experimental|Subjectif Cognitive Impariment patients|Assessment of memory, circulating tPA dosage, ApoE4, brain imaging examination MRI and PET examinations.
88905371|NCT01554202|Experimental|Mild Cognitive Impairment patients|Assessment of memory, circulating tPA dosage, ApoE4, brain imaging examination MRI and PET examinations.
88905372|NCT01554202|Experimental|Alzheimer Disease patients|Assessment of memory, circulating tPA dosage, ApoE4, brain imaging examination MRI and PET examinations.
88905373|NCT01554202|Experimental|Non degenerative amnsesic syndrome|Assessment of memory, circulating tPA dosage, ApoE4, brain imaging examination MRI and PET examinations.
88905374|NCT01554202|Experimental|Frontotemporal lobe dementia|Assessment of memory, circulating tPA dosage, ApoE4, brain imaging examination MRI and PET examinations.
89007106|NCT05949294|Experimental|ARO-SOD1|ARO-SOD1 Injection
88905375|NCT01554215|Experimental|Mom Power Intervention Group|Participants that are randomly assigned to be in the intervention group will be invited to learn about parenting and self-care skills information at a community location, facilitated by two trained and experienced clinicians in a group setting. They will benefit from the en-vivo experience of being supported as a parent and will receive feedback and support about their challenges and strengths in parenting.
88905376|NCT01554215|Active Comparator|Mom Power Attentional Control Group|Participants randomly assigned to this group will receive parenting and self-care skills information through the mail weekly.
88905377|NCT01554228||Bariatric Surgery|
88905378|NCT01554254|Experimental|300mcg/kg/day for 28 days|
88905379|NCT01554267|Experimental|Mastectomy Skin Flap SPY Excision|Single arm study where areas of necrosis predicted by Laser-Assisted Indocyanine Green Dye Angiography (SPY system) will be excised intraoperatively during breast reconstruction surgery.
88905380|NCT01554280|Experimental|Oesophageal Stents|Patients enrolled will receive a fully coated, removable, self-expanding oesophageal stent.
88905381|NCT01554293|Experimental|PBL 1427 capsules|
88905382|NCT01554293|Placebo Comparator|Matching placebo|
88905383|NCT01554306||parkinson's disease, nocturnal hypokinesia, rotigotine|
89423593|NCT03799497||Control group|Healthy subjects with no psychiatric disorder
89536101|NCT03199339|Active Comparator|MAD Part 2 Cohort 2 - Active|N = 9, 200 mg TBA-7371 or matching placebo for 14 days
88905384|NCT01554332|Active Comparator|Active stimulation|
88905385|NCT01554332|Sham Comparator|Sham stimulation|
88905386|NCT01554358|Other|Lifestyle counseling|The women in the intervention group will be given detailed advice about how to achieve the six evidence-based goals of the intervention,7-9 including: 1) reduction in 5-10% of initial body weight in women with body mass index (BMI) ≥24 kg/m2 through the reduction of at least 10% of total calories of their normal meals, 2) total fat intake <30% of energy consumed, 3) carbohydrate intake 55-65% of energy consumed, 4) fiber intake 20-30g per day, and 5) moderate or vigorous exercise for at least 30 min daily, seven days each week.
88905387|NCT01554358|No Intervention|Control|"the subjects in the control group had been educated regarding general principles of healthy lifestyle that benefits T2D and obesity prevention, and also informed about the current evidence showing that the lifestyle intervention is effective in women at high risk for T2D during the run-in period."
88905388|NCT01554384|Experimental|Xpert MTB/RIF|Patients in this arm will receive 1 sputum Xpert MTB/RIF test (point-of-treatment) and 1 sputum sample for MGIT liquid TB culture (regional lab)
88905389|NCT01554384|Active Comparator|Sputum smear microscopy|Patients in this study arm will receive 2 sputum samples for same-day smear microscopy and 1 of the sputum samples will have a MGIT Liquid culture (regional lab).
88905390|NCT01554397|Experimental|Phase II|All patients receive IMRT with concurrent cisplatin 40 mg/m2
88905391|NCT01554397|Active Comparator|Phase III - A|Patients in Phase III, Arm A receive 4-field box RT with concurrent cisplatin 40 mg/m2
89423594|NCT02611882|Experimental|High-risk prostate cancer pre-prostatectomy (preRP) population|"Patients with high-risk prostate cancer pre-prostatectomy.~Patients receive Ga-68-HBED-CC-PSMA and then undergo PET/CT or PET/MRI approximately 55-70 minutes later."
88905392|NCT01554397|Experimental|Phase III - B|Patients in Phase III, Arm B receive IMRT with concurrent cisplatin 40 mg/m2
88905393|NCT01554423|Active Comparator|Testing and Counseling|One of the four RCT arms will be comprised of couples randomly assigned to testing and counseling on HIV and associated STI co-infections based on revised procedures developed by the CDC. Couples will receive information on the transmission and prevention of HIV and STIs, the meaning of test results, and health consequences. Randomized trial studies of behavioral interventions have incorporated testing and counseling as a comparison condition and studies in the US and SSA countries have shown that testing and counseling on its own can help to reduce HIV/STI risk behaviors.
88905394|NCT01554423|Experimental|Brief Motivational Interview (BMI)|The brief motivational interview (BMI) to be tested in the RCT in Pretoria is a one-session, 45 minute intervention that will coordinate three, 15-minute modules with one module each to (1) reduce hazardous drinking; (2) reduce illicit drug use; and (3) promote condom use. Each module is delivered by the clinician using a two-sided laminated card that includes scripted questions and visual aids. Consistent with brief intervention models, the BMI intervention is delivered during one 45 minute session with advice giving as a primary characteristic. Motivational interviewing is also incorporated within the BMI intervention by using a client-centered method of communication to foster behavior change through five techniques of expressing empathy, developing discrepancy, avoiding argumentation, supporting self-efficacy, and motivational rules.
88905395|NCT01554423|Experimental|Integrated Family and Cognitive Behavioral Therapy|The IFCBT model is 6 sessions in length and coordinates the delivery of 4 cognitive-behavioral group couples' sessions with 2 individual couples' sessions to prevent HIV and STI co-infections among adult drug users. IFCBT targets HIV risk and protective factors that operate across multiple ecological systems. The four group couples' sessions coordinate Rational Emotive Therapy and Problem Solving Therapy strategies to reduce HIV risk behavior and promote protective behaviors. The two individual couples' sessions utilize structural and strategic approaches to promote adaptive communication and shared responsibility for condom use and gender equality and to directly address and reduce any form of abuse between partners when present. The six IFCBT sessions are delivered during a 2-week period with two group couples' sessions and one individual couples' session each week.
89423595|NCT02611882|Experimental|Biochemical Recurrence (BCR)|"Patients with prostate cancer with biochemical recurrence~Patients receive Ga-68-HBED-CC-PSMA and then undergo PET/CT or PET/MRI approximately 55-70 minutes later."
89423596|NCT02611882|Experimental|Castrate Resistant Prostate cancer (CRCP) population|"Patients with castrate resistant prostate cancer.~Patients receive Ga-68-HBED-CC-PSMA and then undergo PET/CT or PET/MRI approximately 55-70 minutes later."
89423597|NCT02060877||patients suspected of having lung cancer|observational study, there is no study intervention, only patient questionnaires
89423598|NCT02062281|Active Comparator|23-valent Pneumococcal Polysaccharide vaccine|"0.5ml 23-valent pneumococcal Polysaccharide vaccine made by Chengdu Institute of Biological Products Co.,Ltd.~lot number: 20130106-1, duration:JAN,17,2015."
89423599|NCT02062281|Active Comparator|Trivalent Influenza Vaccine|"0.5ml trivalent influenza vaccine made by Shanghai Institute of Biological Products Co.,Ltd.~lot number:20130713, duration:Jul,1,2014."
88905396|NCT01554423|Experimental|BMI + IFCBT|Participants assigned to this experimental arm will receive Brief Motivational Interviewing combined with Integrated Family and Cognitive Behavioral Therapy.
88905397|NCT01554436|Experimental|patients in smoking cessation|patients in smoking cessation
88905398|NCT01554449|Experimental|Serious game|In this group, patients will have a session of conventional retraining with a serious game retraining.
88905399|NCT01554449|Active Comparator|control patients|In this group, patients will have the conventional retraining with an other conventional retrainning session. The difference between both groups of patients is the serious game session for one group and conventional session for the other group
88905400|NCT01554449|Placebo Comparator|controls|For the neurologic assessments, patients are compared to healthy patient (without stroke)
88905401|NCT01554462|Active Comparator|ADHD active|4 month intervention with EPA/DHA in ADHD group
88905402|NCT01554462|Placebo Comparator|ADHD Placebo|4 month dietary intervention with placebo in ADHD group
88905403|NCT01554462|Active Comparator|Active Healthy control|4 month dietary intervention with DHA/EPA in healthy control group
88905404|NCT01554462|Placebo Comparator|Healthy placebo|4 month dietary intervention with placebo in healthy control group
88905405|NCT01554501||Community sample|
88905406|NCT01554319|Experimental|SB010|"The drug will be administered in phosphate-buffered saline solution, inhaled over 5 - 10 min, using a hand-held inhalation device.~Initial single dose on Day 1 (single-dose PK profile); after 48 h washout, twice-daily with a dosing interval of 12 h for 9 consecutive days (Days 3 to 11); last inhalation on Day 12."
88905407|NCT01554319|Placebo Comparator|Placebo|"The placebo (phosphate-buffered saline) is administered as a solution, inhaled over 5 - 10 min, using a hand-held inhalation device.~Initial single dose on Day 1 (single-dose PK profile); after 48 h washout, twice-daily with a dosing interval of 12 h for 9 consecutive days (Days 3 to 11); last inhalation on Day 12."
88905408|NCT01554540|Experimental|Cutaneous iontophoresis of Treprostenil|
88905409|NCT01554540|Placebo Comparator|Cutaneous iontophoresis of placebo|
88905410|NCT01554553|Experimental|Posterior crural repair|
89423600|NCT02062281|Experimental|23vPPV+TIV|
89423601|NCT03047824|Other|Continuous monitoring-guided therapy|Healthcare providers were allowed to use the blood glucose values displayed on the intravascular continuous monitoring to adapt insulin therapy
88905411|NCT01554553|No Intervention|No posteriorcrural repair|
88905412|NCT01554566|Experimental|honey, no honey|
88905413|NCT01554592|Experimental|Statin withdrawal|Participants will received a placebo for 12 weeks.
88905414|NCT01554592|Active Comparator|Stable statin therapy|Participants need to have been receiving statin therapy for at least 3 months and be on a stable dose.
88905415|NCT01554631|Experimental|Arm 1|Day 0: oral sucrose load (75 g sucrose dissolved in 225 mL water) without Glucobay ODT 100 mg; Day 1: oral sucrose load plus Glucobay ODT 100 mg taken without water
88905416|NCT01554631|Experimental|Arm 2|Day 0: oral sucrose load (75 g sucrose dissolved in 225 mL water) without Glucobay ODT 100 mg; Day 1: oral sucrose load plus Glucobay ODT 100 mg taken with water
88905417|NCT01554631|Active Comparator|Arm 3|Day 0: oral sucrose load (75 g sucrose dissolved in 225 mL water) without Glucobay standard tablet 100 mg; Day 1: oral sucrose load plus Glucobay standard tablet 100 mg taken with water
88905418|NCT01554644|Active Comparator|Prontosan Solution and Gel|ProntosanTM Wound Irrigation Solution (PHMB 0.1%, Betaine 0.1%) and ProntosanTM Wound Gel (PHMB 0.1%, Betaine 0.1%)
88905419|NCT01554644|Placebo Comparator|Saline Solution and Inert Gel|
88905420|NCT01554657|Experimental|5 Days|
88905421|NCT01554657|Placebo Comparator|7 days|
88905422|NCT01554670|No Intervention|arthroscopic subacromial decompression|A thorough subacromial decompression was performed as described by Neer (which include coracoacromial ligament resection, excision of the anterio-lateral tip of the acromion and thorough debridement of the bursa).
88905423|NCT01554670|Active Comparator|decompression+RF micro-tenotomy|A thorough subacromial decompression was performed as described by Neer (which include coracoacromial ligament resection, excision of the anterio-lateral tip of the acromion and thorough debridement of the bursa).an additional bipolar RF-based device (TOPAZ, Arthrocare, Austin, TX) connected to a System2000 generator (Arthrocare, Austin, TX) was used to perform the micro-tenotomy. The device functions using a controlled plasma-mediated RF-based process (Co-ablation).The device was placed on the tendon perpendicular to its surface, for 500 milliseconds, and micro-debridement was performed at 5-mm intervals by a 2-row fashion, which covered most of the foot-print region of the supraspinatous tendon and at a depth of 3 to 5 mm
88905424|NCT01554709|Experimental|CardioGard Cannula|
88905425|NCT01554709|Active Comparator|Reference Cannula|
88905426|NCT01554722|Experimental|in plane needle placement|
88905427|NCT01554722|Experimental|out of plane needle placement|
89423602|NCT03047824|Other|Standard of care|Healthcare providers used the usual intermittent method to adapt insulin therapy; the blood glucose values measured by the intravascular continuous monitoring were not displayed but recorded. Usual care involves the adjustment of insulin infusion based on BG values measured with a blood gas analyser 4-6 times per day.
88905428|NCT01554735|Experimental|lifestyle counselling|exercise and diet counselling for weight loss
88905429|NCT01554748|Other|Patient cohort|TMC total joint arthroplasty
89423603|NCT05654571||significant weight loss+ breast cancer|The group that lost significant weight after laparoscopic sleeve gastrectomy and was diagnosed with breast cancer
89423604|NCT05654571||regain+breast cancer|The group who lost significant weight after laparoscopic sleeve gastrectomy and regained it afterwards, or who could not lose weight and were diagnosed with breast cancer
88905430|NCT01554774||GOLD II|Will be included in this group the patients with COPD stage II
89423605|NCT04863508||Low-risk hypertensive patients|Patients without diabetes, chronic kidney disease, hypertension-mediated organ damage, or established cardiovascular diseases
89423606|NCT04863508||With-risk hypertensive patients|Patients with diabetes, chronic kidney disease, hypertension-mediated organ damage, but without established cardiovascular diseases
88905431|NCT01554774||GOLD III|Will be included in this group the patients with COPD stage III
88905432|NCT01554774||GOLD IV|Will be included in this group the patients with COPD stage VI.
88905433|NCT01554787|Experimental|Chinese Herb Astragalus membranaceus|
88905434|NCT01554787|Placebo Comparator|Placebo|
88905435|NCT01554800|Experimental|ACP-501|
88905436|NCT01554813|Experimental|Influenza split vaccine of 15μg HA|15μg HA/strain/0.5ml/vial
88905437|NCT01554813|Experimental|Influenza split vaccine of 15 μg HA|15μg HA/strain/0.5ml/syringe
88905438|NCT01554813|Active Comparator|Influenza split vaccine|15μg HA/strain/0.5ml/syringe
88905439|NCT01554826|Experimental|Influenza Split Vaccine|7.5μg HA/strain/0.25ml/syringe
88905440|NCT01554826|Active Comparator|Inactivated Influenza Vaccine|7.5μg HA/strain/0.25ml/syringe
88905441|NCT01554839|Experimental|Treatment Group|Treatment group participates in 1 hour online educational tool in addition to baseline and follow up surveys
89423607|NCT04863508||Hypertensive patients with cardiovascular diseases|Patients with established cardiovascular diseases
89423608|NCT04873804|Active Comparator|LEFT DLPFC|The anode electrode of tDCS was applied to the left DLPFC and the cathode electrode was connected to the contralateral shoulder.
89423609|NCT04873804|Active Comparator|RİGHT PPC|The anode electrode of tDCS was applied to the right PPC and the cathode electrode was connected to the contralateral shoulder.
89423610|NCT04873804|Sham Comparator|Sham|Placebo was applied by placing the electrodes in the right PPC and left DLPFC without applying current.
89423611|NCT04863586||Tested positive for SARS-CoV-2|Eligible participants who have had a positive SARS-CoV-2 test will be included in the case group of the study.
89423612|NCT04863586||Not tested for SARS-CoV-2|A random sample of age, sex, and DMT matched people with MS who have not been tested for SARS-CoV-2 will be included in the control group of the study.
89423613|NCT03045172|Active Comparator|Group 1|20 subjects with Platelet Rich Plasma injections
89423614|NCT03045172|Placebo Comparator|Group 2|10 subjects with placebo injections
89423615|NCT02061735||oral propranolol|Dosage of 1 mg/kg per day divided 2 times daily. Blood pressure, heart rate and oxygen saturation are monitored after propranolol initiation. Treatment is continued with a gradual increase to 2 mg/kg per day divided 2 times daily. Treatment is continued until the hemangioma no longer changes in the characteristics judged by the physicians, including, color, size, temperature and deformability.
89423616|NCT02061735||timolol maleate 0.5% gel|One drop of of timolol maleate 0.5% gel is topically applied and massaged into the hemangioma twice per day . This dosage provides an estimated 0.5 mg of timolol per day. The treatment is continued until it is considered to be no longer effective as judged by the physicians.
89423617|NCT02061735||No treatment, observation only|No oral or topical treatment will be given as recommended by the treating physicians and elected by the parents. Patients will be evaluated periodically to determine what changes in treatment are warranted. If this occurs, the patients will be included in the appropriate study group.
89423618|NCT03560583|Experimental|Metoclopramide 10 mg BID|
89423619|NCT03560583|Placebo Comparator|Placebo 10 mg BID|
89423620|NCT03560427|Experimental|duloxetine+morphine|
89423621|NCT03560427|Placebo Comparator|placebo+morphine|
88905442|NCT01554839|Placebo Comparator|Non Treatment Group|Non Treatment group participates in baseline and follow up surveys
89423622|NCT04873648|Experimental|food addiction and binge eating follow caloric reduced -intermitted fasting diet|Obese women diagnosed with binge eating disorder and food addiction follow caloric reduced -intermitted fasting diet
89423623|NCT04873648|Active Comparator|food addiction and binge eating follow caloric restriction diet|Obese women diagnosed with binge eating disorder and food addiction follow caloric restriction diet
89423624|NCT04873648|Experimental|binge eating disorder follow follow caloric reduced -intermitted fasting diet|Obese women diagnosed with binge eating disorder follow caloric reduced -intermitted fasting diet
89423625|NCT04873648|Active Comparator|binge eating disorder follow caloric restriction diet|Obese women diagnosed with binge eating disorder follow a caloric restriction diet
89423626|NCT04873648|Placebo Comparator|obese women without food addiction and binge eating follow caloric restriction diet|Obese women without eating disorder follow a caloric restriction diet
89423627|NCT02796963|Experimental|Immediate Intervention|Men will be exposed immediately to a comprehensive intervention promoting HIV testing.
89423628|NCT02796963|Experimental|Delayed Intervention|Men will be exposed to a comprehensive intervention promoting HIV testing after a delay period.
89423629|NCT04429828|Experimental|e-package: psychological wellbeing for healthcare workers|A COVID-19 educational package on psychological wellbeing for healthcare workers, accessible to all healthcare students.
89423630|NCT04867330|Experimental|conventional treatment arm|Two cycles Toripalimab+docetaxel+cisplatin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy with standard radiation dose (70Gy/35Fx) when responses to induction chemotherapy are less than 50% Partial Response(PR)
88905443|NCT01554852|Active Comparator|Intensive pathway|"The intensive pathway is aimed at younger and fitter patients who will receive the standard dose of chemotherapy. The initial treatments will be followed by high-dose chemotherapy with a stem cell transplant which is generally standard practice.~Participants receive one treatment from each following stage in intensive pathway, depending on what they are randomised to (Protocol v6.0):~Induction treatment:~CRD regimen - cyclophosphamide, lenalidomide, dexamethasone~CTD regimen - cyclophosphamide, thalidomide, dexamethasone~CCRD regimen - carfilzomib, cyclophosphamide, lenalidomide, dexamethasone~Consolidation treatment (depending on response to induction treatment):~VCD regimen - bortezomib, cyclosphosphamide, dexamethasone~No consolidation treatment~High-dose therapy and stem cell transplant~Maintenance treatment:~Lenalidomide maintenance~No maintenance~Lenalidomide plus vorinostat maintenance (Protocol v5.0 only)"
89423631|NCT03560505||Common fibular compression neuropathy|"Patients referred for electrophysiological assessment of common fibular compression neuropathy with subsequent confirmation of referral diagnosis.~Intervention: Ultrasound protocol."
88905444|NCT01554852|Active Comparator|Non-intensive pathway|"The non-intensive pathway is aimed at participants who are not deemed suitable for the stem cell transplant, and will receive lower doses of some of the drugs.~Interventions in each stage of non-intensive pathway (depending on what the participant has been randomised to) - from Protocol v6.0:~Induction treatment~CRDa regimen - cyclophosphamide, lenalidomide, dexamethasone attenuated~CTDa regimen - cyclophosphamide, thalidomide, dexamethasone attenuated~Consolidation treatment (depending on participant's response to induction treatment):~VCD regimen - bortezomib, cyclosphosphamide, dexamethasone~No consolidation treatment~Maintenance treatment~Lenalidomide maintenance~No maintenance~Lenalidomide plus vorinostat maintenance (*for participants recruited under Protocol v5.0 only*)"
88905445|NCT01554865|Active Comparator|conventional diet counselling|counselling given by dietician on diet modification and caloric restriction
88905446|NCT01554865|Active Comparator|partial meal replacement diet|calorie-restricted diet using 1-2 meal replacements
88905447|NCT01554878||knee surgery|
88905448|NCT01554917|Experimental|Iguratimod|
88905449|NCT01554930|Active Comparator|Western therapy|
88905450|NCT01554930|Experimental|Xiyanping injection plus western therapy|
88905451|NCT01554943|Active Comparator|CMF|adjuvant standard CMF given from 1988 to 1996
88905452|NCT01554943|Experimental|EC|Adjuvant EC chemotherapy given from 1988 to 1996
88905453|NCT01554943|Experimental|HEC|High dose epirubicin (HEC) given from 1988 to 1996
88905454|NCT01554969|Experimental|capecitabine + ganetespib .|Capecitabine oral medication. Ganetespib IV medication
88905455|NCT01554995|Experimental|LCB01-0371|active
88905456|NCT01554995|Experimental|Linezolid|comparator
88905457|NCT01555008|Experimental|Treatment A|
88905458|NCT01555008|Placebo Comparator|LX4211 Placebo|
89007107|NCT05931861|Experimental|T2769|One drop in each eye, from 3 to 6 times daily, at any time but only when patients are wearing their contact lenses.
89423632|NCT03560505||Type 2 diabetes polyneuropathy|"Patients with type 2 diabetes referred for polyneuropathy involving the common fibular nerve with subsequent confirmation of referral diagnosis.~Intervention: Ultrasound protocol."
89423633|NCT04867564||NSCLC patients treated with curative radiotherapy|Consecutive NSCLC patients treated with standard RT with curative intent with or without platinum-based CHT
89423634|NCT03793335||Gastric cancer prevention|This prospective study consists of 40,000 participants; after randomization, each arm has 20,000 participants. Arm 1: participants receive H. pylori stool antigen test; Arm 2: participants receive the combination of H. pylori stool antigen test and serum pepsinogen test.
89007108|NCT05930067|Other|Pinnacle Gription|Pinnacle Gription Acetabular Cup
89007109|NCT05930067|Other|Pinnacle Dual Mobility|Pinnacle Dual Mobility System
89423635|NCT03793335||Colorectal cancer prevention|This prospective study consists of 40,000 participants; after randomization; each arm has 20,000 participants. Arm 1: participants with positive fecal immunochemical test (FIT) receive routine referral confirmatory diagnosis approach; Arm 2: participants with positive FIT receive routine referral confirmatory diagnosis approach and participants with high FIT results receive additional aggressive referral confirmatory diagnosis approach.
88905459|NCT01555021||Treatment as Usual (TAU)|"This group will provide blood samples to be analyzed at a later date for genotyping to determine the activity of CYP-450 enzymes that are important in metabolizing antidepressant medications.Treatment will be initiated based on the attending clinicians decision making absent genotyping results.~All subjects in the group will receive the following assessment instruments for diagnosis: SCID-I/P and the Mini International Neuropsychiatric Interview (MINI)~All subjects in the group will have the severity of their depression measured by the HAM D-17 (physician rating scale), the QIDS-SR-16 (patient rating). Clinical status will be measured by the CGI-S scale (1-7 with 7 being high functioning). Side effects ratings will be measured by the UKU. ATRQ will be used to assess the degree of treatment resistance by measuring the number of prior antidepressant trials.~Patients in the TAU group will provide saliva samples for future GWAS analysis."
88905460|NCT01555021||Assay Guided Treatment (AGT)|"This group will provide blood samples for genotyping test to determine the activity of CYP-450 enzymes that are important in metabolizing antidepressant medications . This test result will be available within 3-5 days available to guide clinicians in their choice and dosing of antidepressant medications.~All subjects in the group will have the severity of their depression measured by the Hamilton Depression Rating Scale-17 (physician rating scale), the QIDS-SR-16 (patient rating scale). Clinical status will be measured by the CGI-S scale (1-7 with 7 being high functioning). Side effects ratings will be measured by the Udvalg for Kliniske Undersogelser (UKU). ATRQ will be used to assess the degree of treatment resistance by measuring the number of prior antidepressant trials.~Patients in the AGT group will provide saliva samples for future GWAS analysis."
88905461|NCT01555034|Active Comparator|intervention plus therapy|
88905462|NCT01555034|Active Comparator|intervention no therapy|exercise and nutrition
88905463|NCT01555047|Active Comparator|males who were not infected by mycoplasma|100 male patients whose spouse was going to conduct IUI, was not infected by mycoplasma.
88905464|NCT01555047|Experimental|infected by mycoplasma males|100 male patients whose spouse was going to conduct IUI, was infected by mycoplasma.
88905465|NCT01555047|No Intervention|fertile males|50 fertile males were chose as control samples
88905466|NCT01555060|Experimental|Iron supplements|Subjects who are randomized to receive daily iron supplements after donating blood
88905467|NCT01555060|No Intervention|Control|Subjects who are randomized not to receive daily iron supplements after donating blood
88905468|NCT01555086|Experimental|Limited pelvic Lymphadenectomy|
88905469|NCT01555086|Experimental|Extended pelvic Lymphadenectomy|
88905470|NCT01555099|Experimental|AZD5423|New study drug
88905471|NCT01555099|Active Comparator|Budesonide|Comparator to which the new study drug will be compared
88905472|NCT01555099|Placebo Comparator|Placebo|No drug to which both other arms will be compared
88905473|NCT01555112|Experimental|Topical AS101|15% AS101 ointment applied twice a day for treatment of external genital warts.
88905474|NCT01555177||Peri-operative NSTEMI patients|Patients with POMI undergoing cardiac catheterization within 72 hours of first troponin elevation and within 2 weeks of their non-cardiac surgery.
88905475|NCT01555177||Non-surgery related NSTEMI patients|Patients with NSTEMI undergoing cardiac catheterization within 72 hours of symptom onset.
88905476|NCT01555190|Active Comparator|myo-inositol 1500 gr|6 months treatment with myo-inositol 1500 gr
88905477|NCT01555190|Active Comparator|myo-inositol 2000gr + folic acid 200 mcg|
88905478|NCT01555203|Experimental|liveWell: A healthy foundation for life|
88905479|NCT01555216|Active Comparator|Posterior tibial nerve catheter|5 ml bolus of 0.5% ropivacaine. The catheter will then be connected to a portable pump delivering 3 ml/h of 0.2% ropivacaine with a 2ml bolus every two hours.
88905480|NCT01555216|Active Comparator|Single injection PTNB|Single injection posterior tibial nerve block (PTNB) of 0.5% ropivacaine
88905481|NCT01555229|Experimental|Intermittent drainage|Intermittent subglottic secretion drainage at -100 mmHg during 8 sec every 15 seconds.
88905482|NCT01555229|Active Comparator|Continuous drainage.|Continuous subglottic secretion drainage at -20 mmHg.
89423636|NCT04867252|Active Comparator|Combination Therapy Group|ARM 1: Resveratrol (1000mg Twice a day) Myoinositol (1000mg Twice a day)
89423637|NCT04867252|Other|Standard Therapy Group|ARM 2:Metformin 500mg (Twice a day) Pioglitazone (15mg Twice a day)
89423638|NCT03560271|Experimental|Dose A|Cyclo-Z containing 23 mg zinc plus 6 mg CHP
88905483|NCT01555242|Experimental|Aneustat (OMN54)|
89423639|NCT03560271|Experimental|Dose B|Cyclo-Z containing 23 mg zinc plus 15 mg CHP
89423640|NCT03560271|Placebo Comparator|Dose C|Placebo
89423641|NCT04863274||Expanded consultation group|In an expanded consultation group is being conducted in the study group on the importance of primary prevention of cardiovascular diseases and on the reduction of cardiovascular risk by taking statins. Patients are given brochures and information materials on the risk factors for cardiovascular diseases and the possibility of their correction. Also, the patients of the study group are regularly reminded (2 times a month) with the help of SMS mailings and calls of health workers about the need to follow the doctor's recommendations for taking atorvastatin and returning to the medical institution.
89423642|NCT02062515|Experimental|Icotinib|Icotinib is administered orally 125 mg three times per day continuously for four weeks
89423643|NCT04873414|Experimental|Treatment group|Subjects in the Treatment Group are given 200 ml of Plasma collected from Convalescent Patients recovered from COVID-19 at two-day intervals in addition to standard supportive treatment
88905484|NCT01555294||community-based cohort|"The present study is a substudy in the Nijmegen Biomedical Study (NBS). The NBS is a prospective population survey aimed at investigating the frequency of genetic variations in the general population. The study population is recruited as a sex- and age-stratified random sample of all inhabitants of Nijmegen 20 to 90 years old (n=10.000). Recruitment has started in october 2001.~In the current study 1517 participants aged 50-70 years were included from 2005 to 2008, from whom baseline characteristics were obtained. All visited our hospital and during the visit venous blood was drawn, height and weight were measured, a questionnaire about medical history, life style habits, and family history was completed and non-invasive measurements of atherosclerosis were performed."
89007110|NCT05926765|Experimental|AAV2-hAQP1 Group 1|Eligible participants will receive up to 3 mL of concentration 1 of AAV2-hAQP1 via Stensen's duct to each parotid gland
89423644|NCT04873414|No Intervention|Control group|Subjects in the Control Group are given standard supportive treatment
89423645|NCT02063373|Experimental|biomechanis knee OA and HA injection|Weekly intra- articular Hyaluronic acid injection (20 MG/ 2 ML) into both knees for five weeks
89423646|NCT02063451|Other|Obese, Weight Loss, Very Low Calorie Diet|Obese individuals will a Very Low Calorie Diet (VLCD) using the HMR meal replacement (Health Management Resources, Boston, MA) for 3-6 months until individually targeted weight loss determined by a clinician is reached. Typically, individuals consume 850-1000 kilocalories per day.
89423647|NCT02063451|No Intervention|Lean, baseline measure|MOR binding will be observed in lean individuals at one timepoint. Lean individuals will not receive any intervention.
89423648|NCT02062671|Experimental|immediate renal denervation|immediate renal denervation
88905485|NCT01555294||Familial Combined Hyperlipidemia|FCH is the most common inherited dyslipidemia in man. Affected individuals are characterized by elevated cholesterol and/or triglyceride levels and an increased risk of CVD. Our data base contains a unique population of 40 well-characterized FCH families, including 687 patients, relatives and spouses. These families were recruited in 1994 and extensively studied, including information on an extensive panel of biochemical and genetic parameters. In total 343 participants were included in the NIMA study; 103 FCH patients and 240 unaffected relatives from whom baseline characteristics were obtained.
88905486|NCT01555307|Experimental|Balance group|Typical plus balance exercises
88905487|NCT01555307|Other|Typical group|Typical exercises
88905488|NCT01555320|Placebo Comparator|Qishen Yiqi dripping pills dummy|
88905489|NCT01555320|Experimental|Qishen Yiqi Dripping Pills|
88905490|NCT01555333|Experimental|Arbaclofen|Open Label Study
88905491|NCT01555346||High risk pregnant subjects undergoing an invasive procedure|Women with one or more high risk factors for fetal chromosome 21 aneuploidy scheduled to undergo an invasive procedure for fetal karyotype determination.
89195619|NCT00699842|Experimental|Lenalidomide|Lenalidomide will be given orally on day 1-21, followed by a 7day rest (28 day cycle). Cycles will be repeated every 28 days.
89195620|NCT01589107|No Intervention|control group|usual care
88905492|NCT01555346||High risk subjects electing not to undergo invasive procedure|Women with one or more high risk factors for fetal chromosome 21 aneuploidy who elect not to undergo an invasive procedure for fetal karyotype determination.
88905493|NCT01555359||Patients undergoing stem cell collection|
88905494|NCT01555372|Active Comparator|Hook Plate|20 participants will be enrolled in this group.
88905495|NCT01555372|Experimental|Locking Plates|20 paticipants will be enrolled in this group
88905496|NCT01555385|Active Comparator|Dietary supplement: high-protein breakfast|high-protein juice
88905497|NCT01555385|Active Comparator|Dietary supplement: high-carbohydrate breakfast|high-carbohydrate juice
88905498|NCT01555385|Placebo Comparator|Dietary supplement: low energy breakfast|low-calorie juice
88905499|NCT01555398|Experimental|Fasting conditions|Investigational product administrated under fasting condition.
88905500|NCT01555398|Active Comparator|Fed conditions|Investigational product administrated 30min after starting a high-fat breakfast.
88905501|NCT01555424|Active Comparator|High dose|
88905502|NCT01555424|Active Comparator|Reference dose|
88905503|NCT01555450|Experimental|With Patient Navigator|People in this arm receive the Intervention of a Patient Navigator
88905504|NCT01555450|No Intervention|Control - Without Patient Navigator|People in this arm receive just the usual care of colorectal cancer screening
89195621|NCT01589107|Experimental|Video Arm|
89423649|NCT02062671|Active Comparator|delayed renal denervation|delayed renal denervation
89536102|NCT03199339|Placebo Comparator|MAD Part 2 Cohort 2 - Placebo|N = 3, 200 mg TBA-7371 or matching placebo for 14 days
89536103|NCT03199339|Active Comparator|MAD Part 2 Cohort 3 - Active|N = 9, 400 mg TBA-7371 or matching placebo for 14 days
89536104|NCT03199339|Placebo Comparator|MAD Part 2 Cohort 3 - Placebo|N = 3, 400 mg TBA-7371 or matching placebo for 14 days
89423650|NCT04863196|Experimental|Laser therapy Treatment Group|"Treatment evaluation and follow-up will be done for 15 days. The application of the laser at first will be done three times a week.~The application will be by points with continuous or selective technique, which will depend on each patient. The device is a pen type that will be by contact or without contact with the lesion, irradiation and the dose will be according to the calculation for each patient, using power in milliwatt and fluency, where the dose will vary according to area and patient, and may vary from 0.1 to 1J / cm² as calculated.~The laser tip will be disinfected before each use with 70% alcohol and later coated with plastic film. Patients, companion and operator will wear specific eye protection glasses and all biosafety rules will be followed during therapy."
89423651|NCT04863196|Active Comparator|Barrier Dust Treatment Group|"The evaluation and follow-up of the treatment will be done for 15 days. The principle application will be made three times a week using the protective barrier powder over the entire affected area, forming a protective barrier when adhering to the skin.~For all patients, the injured area will be previously cleaned with 0.9% saline solution."
89007111|NCT05926765|Experimental|AAV2-hAQP1 Group 2|Eligible participants will receive up to 3 mL of concentration 1 of AAV2-hAQP1 via Stensen's duct to each parotid gland
89007112|NCT05926765|Placebo Comparator|Placebo group|Eligible participants will receive up to 3 mL of diluent via Stensen's duct to each parotid gland
89007113|NCT05922943|Experimental|Harmony & Health program|Participants will take part in the Harmony & Health program or participants will attend in-person group health education sessions 2 times a week for 8 weeks.
89007114|NCT05911958|Experimental|SHR-A1811|SHR-A1811 group
89007115|NCT05907135|Experimental|Beet|Powdered beets with green tea extract, Camu Camu, Quinoa sprouts, 3 mushroom blend.
89007116|NCT05907135|Placebo Comparator|Placebo|Similar colored powder with no active ingredients.
89423652|NCT04429594|Other|volonteers|
89423653|NCT02062749|Experimental|Hyperthermic Intraperitoneal Chemotherapy|After cytoreductive surgery and lysis of adhesions, two large bore catheters are placed in the peritoneal cavity through the incision. Thirty minutes before HIPEC is begun, body temperature is cooled to 35°C. ). The catheters are connected to a perfusion circuit. Heated Oxaliplatin is added to the perfusate administered over 90 minutes. The starting dose of Oxaliplatin is 175 mg/m2.
89423654|NCT04866940|Experimental|Sequence validation|This research aims to provide a generic framework to test the feasibility of MRI sequences requested as part of protocols, but also to optimize MRI acquisition sequences already in place, to improve image quality and reduce artifacts that can degrade the quality of images obtained.
89423655|NCT04872946|Experimental|InnerCalm+skin care|An oral supplement and topical agent will be assigned.
89423656|NCT04872946|Experimental|InnerCalm only|An oral supplement will be assigned.
89423657|NCT04872946|Experimental|Skincare Only|A topical agent only will be assigned.
89423658|NCT04863040|No Intervention|Usual classroom teaching methodology|Students in the CG will receive mandatory lessons on Spain (one 45-minute session of Psychomotor/Physical Education), and the usual classroom teaching methodology. Teachers in the CG schools will be asked not to make any changes to their methodology during the time of the study, with the promise by the research team to share and explain the MOVI-HIIT materials once the interventions are completed.
89423659|NCT04863040|Experimental|Usual classroom teaching methodology + MOVI-HIIT intervention|The design of the MOVI-HIIT intervention is framed within the socio-ecological model of behavior modification, in such a way that it will be designed to intervene in the individual, family and school environment. It will have a duration of one school year and will consist of two 5-minute daily physical activity breaks based on intervallic training, five days a week.
89423660|NCT02796651|Experimental|Formoterol 6 μg|Participants received formoterol fumarate 6 μg administered via Pressair twice daily (BID).
89007117|NCT05887609|Experimental|Safety Lead In|
89007118|NCT05887609|Experimental|Treatment|"All patients will receive MIRV at 5mg/kg AIBW administered through IV infusion on Day 1 of every 3-week cycle (Q3W).~All patients will receive Olaparib at 300mg taken orally twice daily with or without food. Dosage and administration will follow current single-agent Olaparib package insert dosage and administration guidelines.~Patients will continue to receive MIRV and Olaparib until PD, unacceptable toxicity, withdrawal of consent, or death, whichever comes first. If toxicity deems the patient to discontinue one drug, the patient may continue the other drug until PD, unacceptable toxicity, withdrawal of consent, or death, whichever comes first."
89007119|NCT05869799|Experimental|Vigiis 101 Lactobacillus Capsules|Vigiis 101 Lactic Acid Bacteria Capsules is a commercially available product for Lactobacillus paracasei subspecies paracasei NTU 101 (NTU 101) is a strain of Lactobacillus isolated from the intestinal tract of newborns in Taiwan. 10 billion CFU/cap of NTU 101 freeze-dried powder (production research and development: Chenhui Biotechnology Co., Ltd. Biotechnology Co., Ltd., Taipei, Taiwan), corn starch, crystalline cellulose and excipients in vegetable capsules were prepared.
89007120|NCT05869799|Placebo Comparator|Placebo Capsules|Maltodextrin was used as a placebo.
89007121|NCT05856266|Other|Efmoroctocog alfa or eftrenonacog alfa|Efmoroctocog alfa or eftrenonacog alfa is prescribed and used according to usual clinical practice.
89007122|NCT05842434|Experimental|Felix|
89007123|NCT05837845|Experimental|MDMA-assisted therapy (MDMA-AT)|This arm consists of three, 90-minute, non-drug Preparatory Sessions and a ~12-week Treatment Period comprised of three Experimental Sessions with MDMA (~ 8 hours), each followed by three 90-minute, non-drug Integration Sessions. Participants will receive 60mg MDMA HCl for first Experimental Session and 60mg or 120mg MDMA HCl for following Experimental Sessions. During each Experimental Session, participants will have the option of receiving a supplemental dose of 40mg or 60mg MDMA HCl 1.5-2 hours after the initial dose. Participants will have the option to crossover to the CPT arm 6 months after all study visits are completed.
89423661|NCT02796651|Experimental|Formoterol 12 μg|Participants received formoterol fumarate 12 μg administered via Pressair BID.
89423662|NCT02796651|Experimental|Formoterol 24 μg|Participants received formoterol fumarate 24 μg administered via Pressair BID.
89423663|NCT02796651|Placebo Comparator|Placebo|Participants received placebo to formoterol fumarate administered via Pressair BID.
89423664|NCT02796651|Experimental|Formoterol 20 μg|Participants received Perforomist inhalation solution and were instructed to take one puff from each of the two Pressair inhalers or to inhale one vial from the Perforomist 20 μg inhalation solution BID for 7 ± 1 consecutive days.
89423665|NCT02796651|Experimental|Formoterol 40 μg|Participants received Perforomist 40 μg (2 vials of Performist 20 μg) as a single dose of administration.
89423666|NCT03044080|Active Comparator|IncobotulinumtoxinA|Injection of 200-300 units of IncobotulinumtoxinA (Xeomin ®)
89423667|NCT03044080|Active Comparator|OnabotulinumtoxinA|Injection of 200-300 units of onabotulinumtoxiA (Botox®)
89423668|NCT03047668|Active Comparator|low-carb with PUFA|49 weeks of hypo- to isocaloric low-carb diet (< 40 EI% carbs), amplified with walnuts and walnut-sunflower muffins
89423669|NCT03047668|Active Comparator|low-carb without PUFA|49 weeks of hypo- to isocaloric low-carb diet (< 40 EI% carbs), without walnuts / walnut-sunflower muffins
89423670|NCT03047668|Active Comparator|low-fat with PUFA|49 weeks of hypo- to isocaloric low-fat diet (< 30 EI% fat), amplified with walnuts and walnut-sunflower muffins
89423671|NCT03047668|Active Comparator|low-fat without PUFA|49 weeks of hypo- to isocaloric low-fat diet (< 30 EI% fat), without walnuts / walnut-sunflower muffins
89423672|NCT04429282|Experimental|ibuprofen( 400mg group)|Patients were randomly divided into the group received respectively IV ibuprofen 400 mg .
89423673|NCT04429282|Experimental|ibuprofen( 800mg group)|Patients were randomly divided into the group received respectively IV ibuprofen 800 mg.
89423674|NCT04429282|Placebo Comparator|placebo group|Patients were randomly divided into the group received respectively IV placebo,.
89423675|NCT03796611||multiple sclerosis patient|MS is defined according to McDonald criteria 2017. MS patients included have a disease duration of less than 1 year
89423676|NCT03796611||other neurological inflammatory disease|autoimmune encephalitis, myasthenia gravis, chronic inflammatory demyelinating polyradiculitis
89423677|NCT03796611||neurological non inflammatory disease|benign intracranial hypertension, degenerative disorder
89423678|NCT03796611||healthy controls|transfusion volunteers from transfusion center
89423679|NCT02063529|Experimental|A (FOLFOXIRI + Cetuximab)|FOLFOXIRI + Cetuximab
89423680|NCT02063529|Active Comparator|B (FOLFOXIRI)|FOLFOXIRI
89423681|NCT02063607|Active Comparator|Peginterferon alfa 2a|Peginterferon alfa 2a 180 mcg
89423682|NCT02063607|Experimental|Peginterferon Lambda|Peginterferon Lambda 60,120,180 and 240 mcg
89423683|NCT02062983||Herceptin|The study will be carried in prospective manner enrolling all patients diagnosed with breast cancer and over expressed human epidermal growth factor receptor 2 (HER2) and they are requiring Trastuzumab Neu adjuvant/ adjuvant /metastatic therapy as per standard care.
89423684|NCT02613208||Participants With Metastatic Breast Cancer|Participants with metastatic breast cancer receiving bevacizumab in combination with paclitaxel, will be observed for treatment responses for up to 18 months from the start of treatment.
89423685|NCT02063841|Active Comparator|sterile identical sham drape|Sham drape and conventional protection (wearing a lead apron and thyroid shield as well as suspension of a standard lead skirt over the X-ray source).
89423686|NCT02063841|Experimental|lead-free protective drape containing bismuth and antimony|lead-free protective drape containing bismuth and antimony (RADPAD®) hung around the fluoroscopy image intensifier to prevent scatter radiation, and conventional protection (wearing a lead apron and thyroid shield as well as suspension of a standard lead skirt over the X-ray source).
89423687|NCT02063919||endomicroscopy|
89423688|NCT03045250|Active Comparator|Type 1 Diabetes|Subjects with known Type 1 diabetes
89423689|NCT03045250|Placebo Comparator|Healthy Controls|Healthy controls
89423690|NCT02064075|Active Comparator|Hydroxyethyl starch|15 ml/kg Lactated-Ringer's and 15-50 ml/kg hydroxyethyl starch solution was given intravenously every day.
89423691|NCT02064075|Active Comparator|Lactated Ringer's solution|15-50 ml/kg Lactated-Ringer's solution was given intravenously every day.
89423692|NCT02064153|Active Comparator|Cool dialysate|Recruited study subject undergoes cool dialysate (35.5ºC) session.
89423693|NCT02064153|Active Comparator|Warm dialysate|Recruited study subject undergoes warm dialysate (37ºC) session.
89423694|NCT04866628|Experimental|Helichrysum italicum|1 g of milled plant material (Helichrysum italicum) immersed in hot water (200 mL, 100 °C) for 10minutes
89423695|NCT04866628|Active Comparator|Helichrysum arenarium|1 g of milled plant material (Helichrysum arenarium) immersed in hot water (200 mL, 100 °C) for 10minutes
89423696|NCT04866394|Experimental|Hypofractionated Pelvic Radiation|
89423697|NCT04862884|Experimental|HRS4800 tablets|
89423698|NCT04862884|Placebo Comparator|placebo|
88814415|NCT00932438|Experimental|LC Beads loaded with Irinotecan and FOLFOX6|"Device: LC Beads loaded with 100mg Irinotecan~Drug: Systemic Chemotherapy (FOLFOX6) Oxaliplatin 85 mg/sqm, IV infusion every two weeks Leucovorin 200mg/sqm, IV infusion every two weeks 5-Fluorouracil 2400mg/sqm, IV infusion every two weeks Bevacizumab 5mg/kg given at the discretion of treating physician"
89423699|NCT02063061|Sham Comparator|Sham treatment|Subject will answer standardized questionnaires. Sham treatment arm will receive initially 5 sham series and after they answer standardized questionnaires they will receive 5 series of active treatment. Afterwards patients will answer standardized questionnaires again.
89423700|NCT02063061|Active Comparator|ESWT treatment|Subject will answer standardized questionnaires. Subjects will receive 10 treatments with ESWT. Afterwards patients will answer standardized questionnaires again.
89423701|NCT03044002||4French Intervention|Patient with infrainguinal Peripheral Artery Disease (PAD), requiring endovascular treatment
89423702|NCT03044002||6French Intervention|Patient with infrainguinal Peripheral Artery Disease (PAD), requiring endovascular treatment
89423703|NCT03043846||Tight control and Treat to Target arm|For this group, the treating rheumatologist will agree to monitor very closely (at least every 4 weeks) and also to treat their patients in accordance with a pre-defined strategy.
89423704|NCT03043846||Usual care arm|For this arm, the treating rheumatologists will continue to manage the enrolled patients in accordance to their usual care.
89423705|NCT04862806|Experimental|Israel CLL study group|BNT162b2 mRNA vaccine
89423706|NCT04862494||diaphragmatic eventation with medical surveillance|Patients with a diagnosis of diaphragmatic eventration without respiratory or digestive consequences, thus not requiring surgical repair.
89423707|NCT04862494||diaphragmatic eventration treated with plication|Patients with a diagnosis of diaphragmatic eventration with respiratory or digestive repercussion, requiring surgical repair.
89423708|NCT04872634|Experimental|SNK01 (4ⅹ10^9 cells) + GC|Administration of SNK01 4ⅹ10^9 cells/dose 8 times at an interval of 1 week + Administration of Cytotoxic Chemotherapy (GC) up to 4 cycles at an interval of 3 weeks
89423709|NCT04872634|Experimental|SNK01 (4ⅹ10^9 cells) + GC + Cetuximab|Administration of SNK01 4ⅹ10^9 cells/dose 8 times at an interval of 1 week + Administration of Cytotoxic Chemotherapy (GC) up to 4 cycles at an interval of 3 weeks + Weekly administration of Cetuximab until the disease progresses or unacceptable toxicity develops
89423710|NCT04872634|Experimental|SNK01 (6ⅹ10^9 cells) + GC|Administration of SNK01 6ⅹ10^9 cells/dose 8 times at an interval of 1 week + Administration of Cytotoxic Chemotherapy (GC) up to 4 cycles at an interval of 3 weeks
89423711|NCT04872634|Experimental|SNK01 (6ⅹ10^9 cells) + GC + Cetuximab|Administration of SNK01 6ⅹ10^9 cells/dose 8 times at an interval of 1 week + Administration of Cytotoxic Chemotherapy (GC) up to 4 cycles at an interval of 3 weeks + Weekly administration of Cetuximab until the disease progresses or unacceptable toxicity develops
89423712|NCT04862104|Experimental|Intervention group (Discharge Training)|In addition to the general care provided by health professionals, the study group received discharge training created according to the Nursing Interventions Classification.
89423713|NCT04862104|No Intervention|Control group (Usual Care)|The control group continued to receive the routine care
89423714|NCT03047356|Experimental|"First-person if-then plan"|"Participants are asked to form if-then plans and the instructions are presented in the first person (if I...then I...). Ifs are critical situations, thens are appropriate responses."
88905505|NCT01555476|Experimental|A-IBU|A single 5 mL dose of 200 mg ibuprofen/5 mL experimental suspension, administered orally, with a 48-hour washout between visits.
89423715|NCT03047356|Experimental|"Second-person if-then plan"|"Participants are asked to form if-then plans and the instructions are presented in the second person (if you...then you...). Ifs are critical situations, thens are appropriate responses."
89423716|NCT03047356|Placebo Comparator|Control|"Participants are presented with ifs (critical situations) and thens but are not asked to form if-then plans."
89423717|NCT03047590|Experimental|Choice-No Affect|These participants self-select (i.e., choose) their exercise intensity with the goal of walking 30-60 minutes on most days of the week. For safety reasons, they are instructed not to exceed 59% of their heart rate reserve. This is choice-based exercise intensity with no focus on positive affect.
88905506|NCT01555476|Active Comparator|B-IBU|A single 5 mL dose of 200 mg ibuprofen/5 mL reference suspension, administered orally, with a 48-hour washout between visits
88905507|NCT01555502||low complications|Patients who had VATS lung resection for NSCLC, and have no or low grade (grade 1 and 2) post operative complications based on the Clavien classification system.
88905508|NCT01555502||High complications|Patients who had VATS lung resection for NSCLC, and have no or high grade (grade 3 and 4) post operative complications based on the Clavien classification system.
89423718|NCT03047590|Experimental|Choice-Affect|These participants self-select their exercise intensity with the goal of walking 30-60 minutes on most days of the week. They're instructed to choose the intensity that makes them feel the best. For safety reasons, they are instructed not to exceed 59% of their heart rate reserve. This is choice-based exercise intensity with a focus on positive affect.
88905509|NCT01555515|Experimental|EPODURE Low dose|EPODURE pump secreting hEPO 18-25 IU/kg/day
88905510|NCT01555580|Experimental|GM-CSF|
88905511|NCT01555593|Experimental|COPD FEV1<70%pred feNO Cardioline Exp'air|COPD subjects with FEV1<70% of predicted value and Forced Expiratory Volume Forced to Forced Vital Capacity ratio (FEV1/FVC) less than 88% (males)or less than 89% (females) of Low Levels of Normality (LLN) entering the respiratory rehabilitation unit will undergo multiflow feNo measure with Cardioline Exp'air by Medi-soft - Sorinnes (B)
88905512|NCT01555606||Moderate to severe plaque psoriasis patients|The group includes adult patients (either male or female) diagnosed with plaque psoriasis for at least 6 months prior to screening with PGA value of greater than or equal to 3. The patients in the group needed are currently receiving treatment with conventional systemic agents, topical therapy and/or phototherapy or biologic therapy
88905513|NCT01555619||CRT-D System|St. Jude Medical (SJM) Promote® Q/Promote® Quadra/Unify Quadra™ CRT-D system.
88905514|NCT01555645|Experimental|Stress management Individual format|The methods and techniques will be the same as those used in the group intervention. The first session will be used for a detailed assessment of the individual's psychosocial problems, as used in earlier studies. The sessions will last 45 - 60 minutes. The number of sessions will depend on the individual patient's problems and the joint assessment made by the patient and nurse together. The total number of sessions will be at least 4, with a maximum of 8. The contents of the sessions are Session 1: Assessment, Session 2: Analysis of diary (self-registration) and suggestions for problem management, Session 3: Evaluation of problem management skills Session 4: Follow-up and conclusion of the intervention. When necessary Sessions 5 -8 will address specific obstacles and continued practice.
89423719|NCT03047590|Experimental|No Choice-Affect|"These participants regulate their exercise intensity using their heart rate, with the goal of walking 30-60 minutes on most days of the week. The intensity is moderate according to the American College of Sports Medicine (40-59% of their heart rate reserve). Meanwhile, these participants are instructed to focus on the good feelings that come with exercise. this is heart rate-based exercise intensity with a focus on positive affect."
89423720|NCT03047590|Active Comparator|No Choice-No Affect|"These participants regulate their exercise intensity using their heart rate, with the goal of walking 30-60 minutes on most days of the week. The intensity is moderate according to the American College of Sports Medicine (40-59% of their heart rate reserve). This is heart rate-based exercise intensity with no focus on positive affect."
89423721|NCT01668784|Experimental|Arm 1: Nivolumab|Nivolumab 3 mg/kg solution intravenously every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
89423722|NCT01668784|Active Comparator|Arm 2: Everolimus|Everolimus 10 mg tablets by mouth daily until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
89423723|NCT04866238|Active Comparator|Vestibular fixed appliances|Adult patients in this group will be treated using fixed appliances.
89423724|NCT04866238|Experimental|Clear aligners|Adult patients in this group will be treated using clear aligners.
89423725|NCT02750514|Active Comparator|Nivolumab|Nivolumab Monotherapy - Arm associated with this intervention is closed. Nivolumab is no longer given as an active comparator
89423726|NCT02750514|Experimental|Nivolumab & Dasatinib|Nivolumab in combination with Dasatinib
89423727|NCT02750514|Experimental|Nivolumab & Relatlimab|Nivolumab in combination with Relatlimab
89423728|NCT02750514|Experimental|Nivolumab & Ipilimumab|Nivolumab in combination with Ipilimumab
89423729|NCT02750514|Experimental|Nivolumab & BMS-986205|Nivolumab in combination with BMS- 986205
89423730|NCT02229240|Experimental|Albiglutide|Subjects will receive once-weekly subcutaneous injections of albiglutide 30 mg (with forced uptitration to albiglutide 50 mg at Week 4) in addition to intensification of background basal-bolus insulin therapy (with or without metformin) according to predefined titration algorithms.
89423731|NCT02229240|Placebo Comparator|Matching albiglutide placebo|Subjects will receive once-weekly subcutaneous injections of matching albiglutide placebo in addition to intensification of background basal-bolus insulin therapy (with or without metformin) according to predefined titration algorithms
89423732|NCT04611750|Experimental|Active Medication (AD036)|Participants will take AD036 QHS for 14 days.
89423733|NCT04611750|Placebo Comparator|Placebo Medication|Participants will take placebo QHS for 14 days.
89423734|NCT02820714|Experimental|BLI801 Laxative|BLI801 oral laxative
89423735|NCT02259426|Active Comparator|Dihydroartemisínin-piperaquine (Artekin)|Dihydroartemisínin-piperaquine combination alone
89423736|NCT02259426|Experimental|Dihydroartemisinin-piperaquine, Primaquine|Dihydroartemisinin-piperaquine with single-dose 0.25mg/kg Primaquine
88905515|NCT01555645|Experimental|Stress management Group format|Participants will meet for 2 hours every week for a total of 20 hours. In the intervals between the group meetings patients will be asked to do homework. Homework entails practicing problem-solving techniques, keeping a diary, practicing relaxation or physical activities. Each group meeting has a specific subject, i.e. What is stress and stress behaviors, Stress related symptoms, How to manage anger and negative thoughts, Self-registrations and behavioral changes, Future perspectives, Cancer, stress and relations, Expectations and demands, Body, pleasure and sexuality.
88905516|NCT01555658|Experimental|Bivalirudin|Enrolled patients will be randomized 1:1 in the catheterization laboratory, after the decision to perform PCI by means of planned implantation of stents>33 mm in length in the same coronary vessel, to Bivalirudin
89423737|NCT02229630|Experimental|Pregnant women|Foetuses with intra-uterine growth restriction, between 28 and 32 weeks of gestation, with an estimated foetal weight < 5th percentile (Hadlock calculator)
89423738|NCT03742518|Experimental|Topical SM04554 0.15% solution|Topical SM04554 0.15% solution, once daily for up to 48 weeks
88905517|NCT01555658|Experimental|Unfractioned Heparin|Enrolled patients will be randomized in the catheterization laboratory, after the decision to perform PCI by means of planned implantation of stents>33 mm in length in the same coronary vessel, to Unfractioned Heparin.
88905518|NCT01555684|Experimental|venoplasty proceedures|Half of the participants receive treatment and the other half do not
88905519|NCT01555684|Placebo Comparator|Control - no treatment|
89423739|NCT03742518|Experimental|Topical SM04554 0.25% solution|Topical SM04554 0.25% solution, once daily for up to 48 weeks
89423740|NCT03742518|Placebo Comparator|Vehicle|Topical vehicle solution, once daily for up to 48 weeks
89423741|NCT03412890|Experimental|Relugolix plus E2/NETA|Relugolix co-administered with E2/NETA for 28 weeks.
89423742|NCT02229708|No Intervention|Usual Care|The Usual Obstetric Care group will receive usual advice about nutrition and activity during pregnancy from their obstetrician along with some additional information about pregnancy and childbirth through readings from The American College of Obstetricians and Gynecologists. In addition, participants will receive weekly text messages to maintain contact and ensure follow-up.
89423743|NCT02229708|Experimental|Healthy Lifestlye Group|The Healthy Lifestyle Group will take part in an individual, technology-based behavioral intervention program which will include specific information about nutrition and physical activity, and strategies for helping them make changes to their diet, physical activity, and weight-related behaviors during pregnancy. Participants will receive information through print materials, text messages, a private Facebook group, and in-person visits and phone calls from a health coach who is part of our research team.
89423744|NCT03371082|Experimental|Gan & Lee Insulin Glargine Injection|Gan & Lee Insulin Glargine Injection for subcutaneous injection, 100 U/mL, in the integrated, disposable 3.0-mL pre-filled Gan & Lee injector pen. Subjects randomized to the Gan & Lee Insulin Glargine Injection group will participate in the study for 26 weeks.
89423745|NCT03371082|Active Comparator|Lantus®|Lantus® (insulin glargine injection) solution for subcutaneous injection, 100 U/mL, in the SoloStar® 3.0 mL pre-filled insulin pen. Subjects randomized to the Lantus® group will participate for 26 weeks.
89423746|NCT02258880|Experimental|SUN13837|Drug: SUN13837 daily for 28 days.
89423747|NCT02258880|Placebo Comparator|Placebo|Placebo: Matching Placebo daily for 28 days
89423748|NCT03340974|Experimental|GC4419 90mg +50 Gy SBRT|Avasopasem manganese (GC4419) +SBRT
89423749|NCT03340974|Experimental|GC4419 90 mg + 55 Gy SBRT|Avasopasem manganese (GC4419) +SBRT
89423750|NCT03340974|Placebo Comparator|Placebo + 50 Gy SBRT|Placebo +SBRT
89423751|NCT03340974|Placebo Comparator|Placebo + 55 Gy SBRT|Placebo + SBRT
88905520|NCT01555710|Experimental|Palifosfamide-tris plus Carboplatin and Etoposide|Drug: palifosfamide-tris in combination with carboplatin and etoposide palifosfamide-tris: 130 mg/m2/day 3 days every 21 days for a max of 6 cycles. carboplatin: AUC 4 mg/mL/min 1 day every 21 days for a max of 6 cycles. etoposide: 100 mg/m2/day 3 days every 21 days for a max of 6 cycles.
88905521|NCT01555710|Active Comparator|Carboplatin plus Etoposide|Drug: carboplatin in combination with etoposide carboplatin: AUC 5mg/mL/min 1 day every 21 days for a maximum of 6 cycles. etoposide: 100 mg/m2/day 3 days every 21 days for a maximum of 6 cycles.
88905522|NCT01555736|Active Comparator|preseasonal immunotherapy scheme|
88905523|NCT01555736|Active Comparator|perennial immunotherapy scheme|
88905524|NCT01555749|Experimental|NNC172-2021 low dose / Placebo|
88905525|NCT01555749|Experimental|NNC172-2021 high dose / Placebo|
88905526|NCT01555775|Experimental|P-CHO supplement|This group will drink the P-CHO supplement in the first trial and the fruit milk shake in the second.
88905527|NCT01555775|Experimental|Fruit Milk Sake|This group will drink the fruit milk shake in the first trial and the P-CHO supplement in the second.
88905528|NCT01555788|Experimental|Type 1 diabetic population|The only one arm (type 1 diabetic patients treated by basal-bolus insulin and external pumps) of this study will test an artificial pancreas system that uses the intraperitoneal route to deliver insulin (through DiaPort).
89423752|NCT03731052|Experimental|Drug: 188-0551 Spray|188-0551 Spray applied topically twice daily to psoriatic lesions within the assigned treatment area for up to four (4) weeks
89423753|NCT03731052|Placebo Comparator|Vehicle Spray|Vehicle Spray applied topically twice daily to psoriatic lesions within the assigned treatment area for up to four (4) weeks
89423754|NCT02229786|Experimental|Buscopan® plus|
89423755|NCT02229786|Active Comparator|Buscopan®|
89423756|NCT02229786|Active Comparator|Paracetamol|
89423757|NCT02229786|Placebo Comparator|Placebo|
88905529|NCT01555801|Experimental|Submucosal injection combining with EUS|The enrolled patients will be accepted submucosal injection of saline,then ultrasonography will performed(EUS+SIS group).So,stages of EUS in these early esophageal cancer will be recorded and compared with the pathological stages afer endoscopic mucosal resection(EMR) or endoscopic submucosal dissection(ESD) or esophagectomy.
88905530|NCT01555801|Placebo Comparator|ordinary endosonography(EUS)|The enrolled patients will accept ordinary ultrasonography .So,stages of EUS in these early esophageal cancer will be recorded and compared with the pathological stages afer endoscopic mucosal resection(EMR) , endoscopic submucosal dissection(ESD) or esophagectomy.
88905531|NCT01555814|Experimental|Amisulpride|For 4 weeks, all patients will be treated with amisulpride open label.
89423758|NCT02612428|Experimental|ELAD System|This group will receive treatment with ELAD plus standard of care therapy.
89423759|NCT02612428|Other|Standard of Care (Control)|This group will receive standard of care therapy as defined in the protocol.
88905532|NCT01555827|Experimental|Alzheimer Disease|
88905533|NCT01555827|Active Comparator|Control|
88905534|NCT01555840|Other|patients requiring upper GI endoscopy|patients with upper abdominal complaints requiring upper GI endoscopy
88905535|NCT01555853|Experimental|Phase I-Dose Level 0|Abraxane 100 mg/m2 IV on Days 1, 8, and 15 of each 28 day cycle for a maximum of 6 cycles.
89007124|NCT05837845|Experimental|Cognitive processing therapy|This arm consists of one, 60-minute, introductory meeting with the therapist followed by a ~12-week Treatment Period comprised of 12 1-hour CPT sessions with three optional additional sessions, each approximately one week apart. Participants will have the option to crossover to the MDMA-AT arm 6 months after all study visits are completed.
89007125|NCT05835544|Active Comparator|HIIT Control|High intensity interval cycling
89423760|NCT03287232|Placebo Comparator|Placebo|
88905536|NCT01555853|Experimental|Phase I-Dose Level 1|Abraxane 125 mg/m2 IV on Days 1, 8, and 15 of each 28 day cycle for a maximum of 6 cycles.
88905537|NCT01555853|Experimental|Phase I-Dose Level 2|Abraxane 150 mg/m2 IV on Days 1, 8, and 15 of each 28 day cycle for a maximum of 6 cycles.
88905538|NCT01555853|Experimental|Phase II|Abraxane (dose to be determined in Phase I) IV on Days 1, 8, and 15 of each 28 day cycle for a maximum of 6 cycles.
88905539|NCT01555866|Experimental|Part 1 Subjects with End Stage Renal Disease (ESRD)|
88905540|NCT01555866|Experimental|Part 1 Healthy Subjects|
88905541|NCT01555866|Experimental|Part 2 Subjects with Mild Renal Impairment|
89423761|NCT03287232|Experimental|Prasterone|
89423762|NCT03281382|Experimental|Investigational Arm|Patients will receive a single intratumoral injection of the oncolytic Ad5-yCD/mutTKSR39rep-hIL12 adenovirus at one of three dose levels. Two days later, subjects will be administered (orally) 7 days of 5-fluorocytosine (5-FC) prodrug therapy. Fourteen days after completion of the 5-FC prodrug therapy course, subjects will be administered chemotherapy at the discretion of the treating physician. On an optional basis, subjects will be administered [18F]-FHBG, a HSV-1 TK substrate, and will undergo PET imaging to quantify the intensity, persistence, and biodistribution of HSV-1 TK gene expression in the pancreas.
89423763|NCT02229942|Experimental|Rituximab|Rituximab induction (two infusions two weeks apart) and maintenance (infusions at 3, 6, 9 and 12 months)
88905542|NCT01555866|Experimental|Part 2 Subjects with Moderate Renal Impairment|
88905543|NCT01555866|Experimental|Part 2 Subjects with Severe Renal Impairment|
88905544|NCT01555866|Experimental|Part 2 Subjects with no Renal Impairment|
88905545|NCT01555879||All patients|All patients in T3 who have used Abatacept for at least 3 months between 2009-03-17 and 2011-11-30.
88905546|NCT01555918|Experimental|Isavuconazole single oral dose - Part 1|
88905547|NCT01555918|Experimental|Isavuconazole single intravenous (IV) dose - Part 1|
88905548|NCT01555918|Experimental|Isavuconazole multiple oral doses - Part 2|
88905549|NCT01555918|Experimental|Isavuconazole multiple intravenous (IV) doses -Part 2|
89007126|NCT05835544|Experimental|HIIT + BFR between cycling sets|High intensity interval cycling with blood flow restriction applied between sets of cycling
89423764|NCT02229942|Placebo Comparator|Placebo|Saline (with added albumin), two infusions two weeks apart, followed by infusions at 3, 6, 9 and 12 months.
89536105|NCT03199339|Active Comparator|DDI Part 3 Cohort 1|14 subjects to receive midazolam and bupropion before and after orally giving 200mg of TBA-7371, 1 per day for 14 days
89536106|NCT02478905||surveillance cohort|Flocked mid-turbinate nasal swabs for influenza PCR will be collected from study participants daily
89423765|NCT03047512|Experimental|Internet-based program|The internet based program includes the following modules: (1) information and psychoeducational material, (2) symptom monitoring with personalized automatic feedback, (3) forum (peer support moderated by mental health professionals) and (4) chat (individualized support by mental health professionals). It also considers (5) the referral to face-to-face treatment of cases with symptoms that require it. (6) In addition to the web page in the institutions, there will be a monthly health promotion booth during breaks.
89423766|NCT03047512|No Intervention|Control Group|The control group will receive two psychoeducational workshops / conferences. In addition, the adolescents in the control group can participate in the monthly health promotion booths offered by the program.
89423767|NCT03047278|Active Comparator|Control Group|Adult patients (18 - 59 years old) with neuropathic pain of score ≥ 4 that do not use gabapentin were recruited. All patients received oral single dose of gabapentin (300 mg) as capsules after 12 hour-fasting (phase I). To investigate GBP pharmacokinetics, blood samples were collected in heparinized tubes up to 36 hours after GBP administration. The urine of the patients was collected up to 36 hours after GBP administration. The intensity of pain was evaluated in each time of blood sampling through the visual analog scale (0-10). In phase II, after 15 days (wash-out) from phase I, cetirizine hydrochloride (10 mg) was administered orally, twice a day, as pills, for five days. On the last day of cetirizine treatment, an oral single dose of gabapentin (300 mg), as capsule, was administered. Serial blood and urine samples were collected up to 36 hours after GBP administration. The intensity of pain was evaluated in each time of blood sampling.
89423768|NCT03047278|Experimental|Controlled Diabetes Group|Adult patients (18 - 59 years old) with controlled type 2 diabetes (glycated hemoglobin ≤ 8.0%) and diabetic neuropathy of score ≥ 4 that do not use gabapentin were recruited. All patients received oral single dose of gabapentin (300 mg) as capsules after 12 hour-fasting. To investigate GBP pharmacokinetics, blood samples were collected in heparinized tubes up to 36 hours after GBP administration. The urine of the patients was collected up to 36 hours after GBP administration. The intensity of pain was evaluated in each time of blood sampling through the visual analog scale (0-10).
88813058|NCT03217838|Experimental|Group 2 Arm B (AZD2811 Dose 2 + Azacitidine 75 mg/m^2)|Participants with AML will receive Azacitidine 75 mg/m^2 of BSA by SC injection or IV infusion prior to the start of AZD2811 infusion on Days 1 through 7 or for 5 consecutive weekdays (Days 1 through 5) with treatment holidays on the 2 weekend days (Days 6 and 7), and the remaining azacitidine dosing will be administered on the first 2 weekdays of the 2nd week (Days 8 and 9) of each 28-day cycle. Participants will receive IV infusion of AZD2811 Dose 2 on Days 1, 4, 15, and 18 of each 28-day cycle. Participants will receive the treatment until disease progression, unacceptable toxicity, or the decision to discontinue treatment by the participant or the study physician, whichever occurs first.
88905550|NCT01555970|Experimental|NAC|Patients allocated in this group will receive N-acetylcysteine 1200 mg (one 600 mg capsule twice a day) during the first week of the study. On day 8 this will increase to 4 capsules per day (2400 mg NAC; 2 capsules twice a day). Finally, on day 15 (after 1 week at 2400 mg) the dose will be increased to the target dose of 5 capsules per day (3000 mg; 2 capsules in the morning and 3 in the evening), at which dose it will be continued for the remainder of the study.
89423769|NCT03047278|Experimental|Uncontrolled Diabetes Group|Adult patients (18 - 59 years old) with uncontrolled type 2 diabetes (glycated hemoglobin ≥ 8.0%) and diabetic neuropathy of score ≥ 4 that do not use gabapentin were recruited. All patients received oral single dose of gabapentin (300 mg) as capsules after 12 hour-fasting. To investigate GBP pharmacokinetics, blood samples were collected in heparinized tubes up to 36 hours after GBP administration. The urine of the patients was collected up to 36 hours after GBP administration. The intensity of pain was evaluated in each time of blood sampling through the visual analog scale (0-10).
89423770|NCT03047044|Active Comparator|Conventional PCA mode|(Mode setting; total volume: 140 ml, flow rate: 2 ml, bolus volume: 0.5 ml, and LOT: 15 minutes)
89423771|NCT03047044|Experimental|Optimizing B.I (New) PCA mode|(Mode setting; total volume: 140 ml, flow rate: changable by patients' requirement, bolus volume: 0.5 ml, and LOT: 15 minutes)
89423772|NCT03045016|Experimental|Prazosin, ALPRESS® LP 2,5 et 5 mg|Patients included in this study will be adults with acute stress as a result of a direct experience traumatic event. They will be treated with Prazosin, ALPRESS® LP 2,5 et 5 mg during 28 days.
89423773|NCT04849858|Active Comparator|Bupivacaine TAP Block|The first 15 patients enrolled will receive perioperative plain bupivacaine TAP blocks.
89423774|NCT04849858|Active Comparator|Liposomal Bupivacaine TAP Block|After enrolling all 15 participants in the first arm, the next 15 patients enrolled will receive perioperative single-dose Liposomal Bupivacaine TAP blocks.
89423775|NCT04849858|Active Comparator|Liposomal Bupivacaine TAP Block with Re-dosing|After enrolling all 30 patients in the first two arms, the final 15 patients enrolled will receive perioperative Liposomal Bupivacaine TAP blocks followed by redosing of the TAP blocks in 48-60 hours.
89423776|NCT04861402||Non-intubated COVID-19 group|Men and women (not pregnant) Older than 18 years old Diagnosis of COVID-19 confirmed by Reverse Transcription Polymerase Chain Reaction (RT-PCR) Subjects intubated Time between admission and study inclusion ≤ 72h Non-intubated during the monitoring carried out in the study Time between onset symptoms and study inclusion ≤ 14 days No neurological acute disease No cutaneous injury in the head to impossibility the ICP monitoring No cutaneous injury in the head to impossibility the monitoring with the transcranial doppler helmet Patients who have not been submitted to decompressive craniectomy previously.
89423777|NCT04861402||Intubated COVID-19 group|Men and women (not pregnant) Older than 18 years old Diagnosis of COVID-19 confirmed by Reverse Transcription Polymerase Chain Reaction (RT-PCR) Subjects intubated Time between admission and study inclusion ≤ 72h For intubated group time between IUC admission and study inclusion ≤ 72h Time between onset symptoms and study inclusion ≤ 14 days No neurological acute disease No cutaneous injury in the head to impossibility the ICP monitoring No cutaneous injury in the head to impossibility the monitoring with the transcranial doppler helmet Patients who have not been submitted to decompressive craniectomy previously.
88905551|NCT01555970|Placebo Comparator|Placebo|Patients allocated in this group will receive one capsule of placebo twice a day during the first week of the study. On day 8 this will increase to 4 capsules per day (2 capsules twice a day). Finally, on day 15 the dose will be increased to the target dose of 5 capsules per day (2 capsules in the morning and 3 in the evening), at which dose it will be continued for the remainder of the study.
88814416|NCT00932438|Active Comparator|FOLFOX6 and Bevacizumab|Drug: Systemic Chemotherapy (FOLFOX6) Oxaliplatin 85 mg/sqm, IV infusion every two weeks Leucovorin 200mg/sqm, IV infusion every two weeks 5-Fluorouracil 2400mg/sqm, IV infusion every two weeks Bevacizumab 5mg/kg given at the discretion of treating physician
88814417|NCT01635881|Experimental|Emerge|Single arm with investigational Emerge™ 1.20 mm PTCA Dilatation Catheter
89423778|NCT04861402||Health control group|"Men and women (not pregnant) Older than 18 years old No cutaneous injury in the head to impossibility the ICP monitoring No symptoms of COVID-19 on the last 15 days~• For healthy group: No previous neurological disease No chronic disease as Diabetes Mellitus Type 2, Chronic Obstructive Pulmonary Disease (COPD), Heart Failure, hypertension or Chronic Kidney Disease (CKD) No cutaneous injury in the head to impossibility the monitoring with the transcranial doppler helmet Patients who have not been submitted to decompressive craniectomy previously."
88814418|NCT02100683||PDA Coil|Patients age 6 months to 21 years weighing > 5kg with an angiographically confirmed PDA with a minimum diameter of < 4 mm.
88814419|NCT01869413|Experimental|Tranexamic Acid|Tranexamic acid will be administered as an intravenous infusion of 10 mg/kg over 10 minutes (loading dose) prior to surgical incision, followed by 5 mg/kg/hour continuous maintenance infusion for the length of surgery (typically 4 to 8 hours). For example, an 80 kg patient would receive 800 mg prior to incision and a 400 mg/hr infusion for the duration of surgery. For a 6 hour procedure, the total dose administered would be 3200 mg.
88814420|NCT01869413|Placebo Comparator|Placebo control|As there is no standard of care concerning administration of anti-fibrinolytic agents in cystectomy procedures, controls will follow the same dosing and schedule as above (loading dose followed by maintenance infusion), but with 0.9% sodium chloride.
88814421|NCT01636661|Experimental|Transcranial Direct Current Stimulation|Receiving active tDCS
88814422|NCT01636661|Sham Comparator|Sham tDCS|tDCS equipment set to placebo setting.
88814423|NCT01637207|Experimental|palpation|
88814424|NCT01637207|Experimental|ultrasound|
88814425|NCT02982512|No Intervention|Control recording|Recording of local field potentials without drugs from the deep brain stimulator
88814426|NCT02982512|Experimental|Dexmedetomodine recording|Recording of local field potentials at different dexmedetomidine concentrations from the deep brain stimulator
88814427|NCT01555697|Active Comparator|Memantine/high|memantine 20 mg
88814428|NCT01555697|Placebo Comparator|Placebo/high|placebo comparator for memantine 20 mg
88814429|NCT01555697|Active Comparator|Memantine/low|memantine 10 mg
88814430|NCT01555697|Placebo Comparator|Placebo/low|placebo comparator for memantine 10 mg
88814431|NCT02982434|Experimental|Group 1|All patients underwent conventional CABG surgery. After the main stage of the surgery new pharmaceutical composition containing botulinum toxin (50 U/1 mL) was injected into the entire four visible area of the major epicardial fat pads. First epicardial left atrial fat pad is located anterior to the right superior pulmonary vein and corresponding to the anterior right ganglionated plexi (GP); second epicardial fat pad is located inferoposterior to the right inferior pulmonary vein and corresponding to the inferior right GP; third fat pad is located anterior to the left superior pulmonary vein (PV) and left inferior PV (between the PVs and left atrial appendage (LAA), corresponding to the Marshall tract GP and superior left GP; forth fat pad located inferiorly to the left inferior PV and extends posteriorly and corresponding to the inferior left GP
88814432|NCT02982434|Active Comparator|Group 2|All patients underwent conventional cardiac surgery. After the main stage of the surgery 0.9% normal saline (1 mL at each fat pad) was injected into the entire four visible area of the major epicardial fat pads. First epicardial left atrial fat pad is located anterior to the right superior pulmonary vein and corresponding to the anterior right GP; second epicardial fat pad is located inferoposterior to the right inferior pulmonary vein and corresponding to the inferior right GP; third fat pad is located anterior to the left superior PV and left inferior PV (between the PVs and LAA), corresponding to the Marshall tract GP and superior left GP; forth fat pad located inferiorly to the left inferior PV and extends posteriorly and corresponding to the inferior left GP
88819378|NCT04505085|Experimental|Active Dads Healthy Families: Outdoor Education|The intervention will include outdoor education and physical activity opportunities at various outdoor parks. The program will be held one day a week for eight consecutive weeks. Parks and Recreation will facilitate and run the program. Each session will last 60 minutes and include a brief educational discussion and opportunities for various games and activities. Each session will have a special theme relevant to the outdoors. Families will also receive a home toolbox to facilitate activity and learning outside of the program. Feedback on physical activity will be provided at the beginning and the end of the program.
89423779|NCT04861402||Non-COVID-19 and non-neurological disease intubated group|"Men and women (not pregnant) Older than 18 years old No cutaneous injury in the head to impossibility the ICP monitoring~• For intubated group: ICF signed by the participant or his/her legal representative* Intubated patients for others causes than COVID-19 or neurological diseases IUC admission and study inclusion ≤ 72h No symptoms of COVID-19 on the last 15 days No cutaneous injury in the head to impossibility the monitoring with the transcranial doppler helmet Patients who have not been submitted to decompressive craniectomy previously."
89423780|NCT03043690||Ammonium succinate|Patients in main pooled study group received 2 capsules of ammonium succinate-based dietary supplement (one white, 200 mg, and one orange, 200 mg), once a day, in the morning with a meal, for 90 days.
89423781|NCT03043690||Placebo|Patients in placebo study group received 2 capsules of ammonium succinate-based dietary supplement (one white, 200 mg, and one orange, 200 mg), once a day, in the morning with a meal, for 90 days.
89423782|NCT04858984|Experimental|Virtual reality group|"All participants experienced an immersive guided meditation virtual reality (VR1) and an interactive game virtual reality (VR2) experience during labour. Both VR interventions were offered for 10 minutes. Before and immediately after an intervention, the patient was asked to fill out a Numeric Rating Scale (NRS) score for pain.~During the 30-minute intermission after the VR intervention the patient completed the post-intervention questionnaire.~VR1 consisted of a video of an exotic location guided by the sound of the waves and a calm English-speaking voice. VR2 required women to use the controller to throw snowballs in order to catch presents and reach the next level. Patients were allowed to stop using the VR at any moment during the intervention.~Five days post-partum all participants who completed both VR interventions were contacted by telephone for an interview."
89423783|NCT04429204|Experimental|Basic science (cryoablation, tissue collection)|At the time of standard of care pleural biopsy, patients undergo cryoablation over 30 minutes, then a sample of tissue from the ablated region and a non-ablated (tumor negative control) region are collected.
89423784|NCT03679884|Experimental|Daridorexant 10 mg|Film-coated tablets administered orally, once daily in the evening
89423785|NCT03679884|Experimental|Daridorexant 25 mg|Film-coated tablets administered orally, once daily in the evening
89423786|NCT03679884|Experimental|Daridorexant 50 mg|Film-coated tablets administered orally, once daily in the evening
89423787|NCT03679884|Placebo Comparator|Placebo|Film-coated tablets administered orally, once daily in the evening
89423788|NCT03679884|Experimental|Ex-Placebo Daridorexant 25 mg|Film-coated tablets administered orally, once daily in the evening
89423789|NCT04861480|Experimental|C-4-29 cells|Infusion of C-4-29 cells by dose-escalating
89423790|NCT04849702||Postoperative complication after colorectal resection|Documentation of all postoperative complications after colorectal resections
89423791|NCT02230020||Nasal High Flow|All subjects are in this group
89423792|NCT03043612|Experimental|Ureteral Study Stent|Commercially available Cook Sof-Flex® Double Pigtail Ureteral Stent that is coextruded with an alpha-blocker medication
89423793|NCT03043612|Active Comparator|Ureteral Control Stent|Commercially available Cook Sof-Flex® Double Pigtail Ureteral Stent
89423794|NCT04861168|Experimental|Driving pressure guided ventilation|Patients will be mechanically ventilated with driving pressure guided ventilation with VT 6-8 ml /kg of predicted body weight, and after recruitment we will return to the baseline PEEP 5 cmH2O that will be increased by 2 cmH2O until reaching the lowest possible driving pressure for every patient. Each PEEP level will be applied for 10 respiratory cycles and DP will be calculated at the last cycle.
89423795|NCT04861168|Active Comparator|Conventional protective lung strategy|Patients will be mechanically ventilated with conventional protective lung strategy with VT 6-8 ml /kg of predicted body weight, after recruitment, we will return to the baseline PEEP 5 cmH2O and will be maintained until the end of surgery.
89423796|NCT02233062|Experimental|Semen quality|
89423797|NCT02230098|Experimental|Remote Ischemic Conditioning|By use of short-term obstruction of the blood supply to the arm
89423798|NCT02230098|No Intervention|Before Remote Ischemic Conditioning|
89423799|NCT02230176|Experimental|177Lu-DOTA0-Tyr3-Octreotate or OCLU|7.4 GBq per injection (max: 4 injections)
89423800|NCT02230176|Active Comparator|Sunitinib|37.5 mg/day
89423801|NCT03042208|Experimental|Intervention|Access to Weight Watchers in-person meetings and online tools.
89423802|NCT03042208|Other|Self-Guided Control Group|Received handout with basic weight management advice.
89423803|NCT02232516|Experimental|Treatment (romidepsin, lenalidomide)|Patients receive romidepsin IV over 4 hours on days 1, 8, and 15 and lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
89423804|NCT03042130|Experimental|Iron Carboxymaltose|"standard of care + double dose of IV iron ferinject~the medicine will be given twice within one week."
89423805|NCT03042130|Other|control|standard of care
89423806|NCT04849468|Active Comparator|Diclofenac (D) group|Diclofenac (D) group which will receive 75 mg (3ml) intramuscular Diclofenac in a 5ml syringe in the holding area 30 minutes before spinal block
89423807|NCT04849468|Active Comparator|Saline (S) group|Saline (S) group which will receive 3ml intramuscular saline in a similar 5ml syringe in the holding area 30 minutes before spinal block
89423808|NCT02232594||chronic obstructive respiratory tract disease patients|
89423809|NCT04848922|Experimental|Intervention Group|Took a hot shower intervention and usual care.
89423810|NCT04848922|No Intervention|Control Group|No intervention other than usual care.
89423811|NCT04858906|Active Comparator|from neutral to sniffing position|The patients in this group will be assessed firstly in the neutral position then subsequently in the sniffing position.
88905552|NCT01556022|Experimental|ADRCs processed by the Celution System|400,000 adipose-derived regenerative cells (ADRCs) per kilogram (kg) of body weight not to exceed 40,000,000 cells.
88905553|NCT01556022|Placebo Comparator|Lactated Ringers and Subject's blood|Sterile Lactated Ringers Solution (3mL) mixed with ≤ 0.10 ml of the study Subject's own freshly drawn blood.
88905554|NCT01556035|Experimental|Lenalidomide treatment|
88905555|NCT01556048|Experimental|IMMEDIATE START GROUP|Randomized to participate in Behavioral Activation for pathological grief starting at Week 1 of entry into the study
88905556|NCT01556048|Placebo Comparator|DELAY START GROUP|Randomized to participate in Behavioral Activation for pathological grief starting at Week 12 of entry into the study
88905557|NCT01556074|Experimental|Yoga treatment|
89423812|NCT04858906|Active Comparator|from sniffing position to neutral position|The patients in this group will be assessed firstly in the sniffing position then subsequently in the neutral position.
89423813|NCT04858438|Active Comparator|Standard Insufflation Group|Patients will receive standard insufflation during surgery (15 mm Hg).
88905558|NCT01556087|Experimental|Distress Tolerance|7 sessions aimed at increasing distress tolerance skills
88905559|NCT01556087|Placebo Comparator|Health Education|7 didactic health education sessions
89423814|NCT04858438|Experimental|Low Insufflation Group|Patients will receive a lower level of insufflation during surgery (12 mm Hg or lower).
89423815|NCT03175068|Active Comparator|CBT|The clinical psychologist will use a manualized CBT approach tailored to MDD or gSAD. Over a 12-week period sessions will include core CBT strategies -- psychoeducation, cognitive intervention (e.g., cognitive restructuring), behavioral changes (i.e., fear exposure, behavioral activation strategies) and relapse prevention.
89423816|NCT03175068|Placebo Comparator|ST|The clinical psychologist will use an ST approach that resembles client-centered therapy of Carl Rogers (1951) which has been used as a control psychotherapy. The manual is based on supportive psychotherapy principles. Over a 12-week period sessions will emphasize reflective listening and elicitation of affect. In contrast to CBT, therapists allow patients to determine the focus of each session, pulling for emotion, validating emotions when possible, and offering empathetic comments. Therapists will refrain from delineating any CBT theoretical framework and avoided cognitive and behavioral techniques that might overlap with CBT.
89423817|NCT04858516|Experimental|Neoadjuvant treatment with palbociclib and exemestane plus trastuzumab and pyrotinib|
89423818|NCT03148860|Active Comparator|Methotrexate naive - Ustekinumab and Methotrexate|Methotrexate naive subjects will be randomised to receive Methotrexate or Placebo, Ustekinumab will be given open-label
89423819|NCT03148860|Placebo Comparator|Methotrexate naive - Ustekinumab and Placebo to Methotrexate|Methotrexate naive subjects will be randomised to receive Methotrexate or Placebo, Ustekinumab will be given open-label
88905560|NCT01556113|Active Comparator|omega diet carrying CC/CG genotype|Subjects homozygous for the major allele of the rs73049 SNP or heterozygous (CC and CG)
88905561|NCT01556113|Active Comparator|omega diet carrying GG genotype|Subjects homozygous for the minor allele of the rs73049 SNP (GG)
88905562|NCT01556126|Experimental|Amphilimus eluting stent (Cre8)|Sirolimus formulated coronary eluting stent
88905563|NCT01556152|Active Comparator|Treatment Arm 1|
88905564|NCT01556152|Active Comparator|Traetment Arm 2|
88905565|NCT01556152|Placebo Comparator|Treatment Arm 3|
88905566|NCT01556178||Children without central nervous system tumors|Children without central nervous system tumors between the ages of 1 year and 21 years who are undergoing a neurosurgical procedure to address hydrocephalus
88905567|NCT01556191|Experimental|Gefinitib + Fulvestrant (patient with EGFR mutations)|
88905568|NCT01556191|Active Comparator|Erlotinib (wild type patients)|
88905569|NCT01556191|Experimental|Erlotinib + Fulvestrant (wild type patients)|
88905570|NCT01556191|Active Comparator|Gefinib (patient with EGFR mutations)|
88905571|NCT01556217|Experimental|JNJ-39393406|
88905572|NCT01556217|Placebo Comparator|Placebo|
88905573|NCT01556282|Experimental|Therasphere|
89423820|NCT03148860|Active Comparator|Methotrexate pre-treated subjects-Ustekinumab and Methotrexate|subjects pretreated with Methotrexate will be randomised to receive Methotrexate or Placebo, Ustekinumab will be given open-label
89423821|NCT03148860|Placebo Comparator|Methotrexate pre-treated subjects-Ustekinumab and PLC|subjects pretreated with Methotrexate will be randomised to receive Methotrexate or Placebo, Ustekinumab will be given open-label
88905574|NCT01556295||Experimental|
88905575|NCT01556295||Control|
88905576|NCT01556308|Experimental|DM-EBS|
88905577|NCT01556321|Experimental|Green tea, normal weight|Subjects with a BMI 18.5-25 kg/m2 will receive green tea capsules, which they have to consume daily for a period of twelve weeks
88905578|NCT01556321|Placebo Comparator|Placebo, normal weight|Subjects with a BMI 18.5-25 kg/m2 will receive placebo capsules, which they have to consume daily for a period of twelve weeks
88905579|NCT01556321|Experimental|Green tea, overweight|Subjects with a BMI >30 kg/m2 will receive green tea capsules, which they have to consume daily for a period of twelve weeks
88905580|NCT01556321|Placebo Comparator|Placebo capsules, obese|Subjects with a BMI >30 kg/m2 will receive placebo capsules, which they have to consume daily for a period of twelve weeks
88905581|NCT01556334|Experimental|Azithromycin|Azithromycin 1g po
88905582|NCT01556334|Active Comparator|Erythromycin|Erythromycin IV followed by po for a total of 5 days.
88905583|NCT01555528||Growth Disorders|
88905584|NCT01556373||severe sepsis|patients with severe sepsis
88905585|NCT01556373||Controls|Controls matched to patients on age, sex and cardiovascular risk factors
88905586|NCT01555996|Experimental|Early and intensive OT|
88905587|NCT01555996|Active Comparator|Standard non-pharmacological prevention|
88905588|NCT01556386||Pharmacogenetic analysis, ALL|
89007127|NCT05835544|Experimental|HIIT + BFR moderate occlusion during cycling|High intensity interval cycling with moderate blood flow restriction applied during cycling
89423822|NCT03043300||US Travelers to South or Southeast Asia|"Adult individuals who are planning a short term trip to South or Southeast Asia and meet all eligibility criteria will complete the questionnaires and/or provide stool specimens at the following time points:~No greater than 4 weeks prior to travel departure: Screening Criteria Review~One week prior to travel departure: Pre-Travel Questionnaire and Pre-Travel Stool Specimen Collection~Two weeks after return from travel: Short-Term Post-Travel Questionnaire and Short-Term Post-Travel Stool Specimen Collection~14 weeks after return from travel: Long-Term Post-Travel Questionnaire and Long-Term Post-Travel Stool Specimen Collection"
89423823|NCT02230488|Active Comparator|Intensive Diabetes Case Management|Intensive Case Diabetes Management : A diabetes team , led by an endocrinologist and CDE, will manage the patients diabetes while in the hospital and will assist with the patient's discharge Diabetes endocrine consult team will manage the patient's diabetes daily while in the hospital Discharge diabetes medication reconciliation per research team Research team will provide 30 day supply of diabetes medication/supplies at discharge Research Team will provide 30 day supply of glucose test strips at discharge Discharge telecommunication from endocrinologist to primary care provider Patient-centered discharge diabetes education per research CDE Post-discharge 48-72 hours continuity check per phone by a diabetes research team member/CDE
89423824|NCT02230488|No Intervention|Control :Standard/ usual care|
89423825|NCT04860622||Pregnant women|500 pregnant women with a singleton pregnancy, free of pre-existing thyroid disease, that do not use thyroid interfering medication, that did not undergo IVF treatment, and are TPOAb negative. Serum thyroid function tests will be obtained on the first visit.
89423826|NCT03131154|Experimental|ADX-102 Ophthalmic Solution (0.5%)|
89423827|NCT03131154|Placebo Comparator|Vehicle of ADX-102 Ophthalmic Solution|
89423828|NCT03120702|Experimental|Neonatal Test Subjects|All test subjects in this group are neonatal patients who will receive a investigational Rainbow SpHb sensor.
89423829|NCT03040648|Experimental|cervical TFEB under DSA|cervical TFEB was performed under DSA
88905589|NCT01556412||Chronic hepatopathy suspicious of PSC|"All patients with chronic hepatopathy of unknown origin and a high risk of primary sclerosing cholangitis as the underlying disease for chronic hepatopathy.~This group includes all patients with cholestatic hepatopathy (predominantly elevated gamma-glutamyltransferase and alkalic phosphatase) and positive ANCAs (Anti-neutrophil cytoplasmic antibodies) and/or inflammatory bowel disease in medical history.~Other explanations of cholestatic hepatopathy (like pancreatic tumor or cholelithiasis) must not be apparent in patients eligible for this study.~Furthermore, infection oder extrahepatic cholestasis already proven by laboratory results or percutaneous ultrasound, which make endoscopic retrograde cholangiography necessary, are exclusion criteria in this study."
88905590|NCT01556464|Experimental|ACPAP|Patients in the intervention group will be introduced to the auto-adjusting CPAP (ACPAP) (ResMed S9) during the day and placed on it at night with a nocturnal oximetry and ACPAP download to assess its effectiveness and pressure requirements. The intervention is the application of the ACPAP. The patients will be discharged on ACPAP pressure determined by the ACPAP download (95th percentile pressure in absence of significant air leak) and will be scheduled for an outpatient repeat diagnostic PSG and, if indicated, a full night titration study.
89423830|NCT03040648|Active Comparator|TFEB under RTF|cervical TFEB was performed under RTF
89423831|NCT02232672|Experimental|MeAIB PET/CT|Choline PET/CT and MeAIB PET/CT
89423832|NCT04858282|Experimental|shared decision-making group (SDMG)|Receiving mobile application( BC-SDM)
88905591|NCT01556464|No Intervention|Control|The control group will receive nocturnal oxygen or no therapy while in the hospital and after discharge at the discretion of the attending physician. They will be scheduled for outpatient repeat diagnostic PSG and then, if indicated, a full night titration study.
88905592|NCT01556477|Active Comparator|azacitidine|
88905593|NCT01556477|Experimental|azacitidine + lenalidomide|
89423833|NCT04858282|No Intervention|usual care group (UCG)|Receiving material health education
89423834|NCT05072262|Active Comparator|Control (dexamethasone only)|Topical dexamethasone 1 mg/ml (Spersadex) started the day after surgery
89423835|NCT05072262|Experimental|Study group (NSAIDs and dexamethasone)|Topical nepafenac (Nevanac) 3 mg/ml and dexamethasone 1 mg/ml (Spersadex) started the day after surgery.
89423836|NCT04857970||Electronic HRQoL questionnaires with feedback to physicians|40 patients allocated in this arm will answer HRQOL questionnaires using an electronic form in CHES Software. The HRQoL scores, presented as graphics, will be transmitted to physicians.
89423837|NCT04857970||Paper-pencil HRQoL questionnaires w.o. feedback to physician|"40 patients allocated in this arm will answer HRQOL questionnaires using pencil-paper, without transmission of the HRQoL scores to physicians."
88905594|NCT01556503||Pigmented Lesion|Patients identified as having a concerning pigmented lesion and the physician believes it is appropriate to biopsy to rule out melanoma.
88905595|NCT01556516||Women with Pompe Disease|
88905596|NCT01556529|Experimental|risk profile information|patient gets information on quantitative individual complication risk profile and patient gets standard T2DM DMP care
88905597|NCT01556529|Active Comparator|Control|Control group: patient gets standard T2DM DMP care
88905598|NCT01556542|Active Comparator|standard PTA|nitinol stent implantation
89423838|NCT02230644|Experimental|Audio enhanced|Enhanced Clinical Environment: participants wait for their operation in the enhanced audio-visual booth.
88905599|NCT01556542|Experimental|DEB|paclitaxel-eluting balloon angioplasty followed by nitinol stent implantation
89423839|NCT02230644|Active Comparator|Other distraction method|Participants wait for their operation in a booth with another distraction such as the news on television
89423840|NCT02230644|No Intervention|Ordinary|Participants wait for their operation in an ordinary, unenhanced booth
89423841|NCT04858048||Group with general anesthesia performed during the forefoot surgery|
89423842|NCT04858048||Group with WALANT anesthesia performed during the forefoot surgery|
89423843|NCT02233140|Experimental|Shockwave with manual manipulation|A shockwave (EPAT) therapy with two supervised manual manipulation per week
89423844|NCT02233140|Active Comparator|Manual manipulation|A Placebo (no) shockwave with two supervised manual manipulations per week
89423845|NCT04857736||Trial group: 62 healthy female college students during menstruation|"The pulse sound waves of three parts and five layers of each of the two hands of 62 healthy female college students during menstruation will be collected by thePulse Detection System of Sound Waves."
88905600|NCT01556555||Primary sclerosing cholangitis|Patients with a definite diagnosis of sclerosing cholangitis and a clinical indication for ERCP.
89423846|NCT04857736||Control group :62 healthy female college students during non-menstrual period|"The pulse sound waves of three parts and five layers of each of the two hands of 62 healthy female college students during non-menstrual period will be collected by the Pulse Detection System of Sound Waves."
89423847|NCT05629650|Experimental|Tai Chi for memory|TCM is a standardized type of Tai Chi for health developed by Dr. Lam specifically for those who experience or want to prevent cognitive problems. TCM, consisting of 12 Sun-style and Yang-style Tai Chi movements, can be provided while sitting and while standing with five blocked movement sets so that cognitively impaired individuals (MCI vs. dementia) are able to follow them.
88905601|NCT05847660|Active Comparator|Progesterone primed ovarian stimulation protocol.|Group (A): Women in progesterone primed (PPOS) will be prescribed a 30 mg oral dose of dydrogesterone (Duphaston, Abbott, Egypt) from the 2nd day of the cycle and continued until the triggering day. Vaginal sonography will be done for all patients since 6th day of the cycle.
88905602|NCT05847660|Active Comparator|conventional antagonist protocol.|Group (B): Women in the antagonist group will be monitored by transvaginal ultrasonography till the size of dominant follicles reached to 12-13 mm, 0.25 mg of Cetrotide (Merck-Serono, Germany) will be injected subcutaneously daily and continued until triggering day, follow up for all patients in both groups by transvaginal ultrasound every other day.
88905603|NCT05847595|Sham Comparator|Control group A|will be treated by selected physical therapy program only for 60 minutes.
88905604|NCT05847595|Experimental|Study group B|will be treated by implicit motor training program for 30 minutes, in addition to the conventional physical therapy program for the lower extremity for 30 minutes ,total duration 60 minutes.
88905605|NCT05847595|Experimental|Study group C|will be treated by explicit motor training program for 30 minutes, in addition to the conventional physical therapy program for the lower extremity for 30 minutes, total duration 60 minutes.
88905606|NCT05847491||Healthcare workers|"Clinical evaluation, chest x-ray and Interferon-γ release assay (IGRA). Immunocompromised patients will be submitted to a tuberculin skin test.~The patients will be evaluated in two or more separate appointments. In the first appointment, patients will be submitted to clinical evaluation and exam request. In the second appointment the results will be evaluated."
88905607|NCT05847413|Experimental|Targeting Beta cell Dysfunction with Verapamil in Longstanding T1D|Participants will receive verapamil for 12 weeks
88905608|NCT05847400||CKD patients with T2DM on regular HD|CKD patients with T2DM attending Assuit university diabetic outpatients clinic and ESRD on regular HD at dialysis unit of Assuit University Hospital
88905609|NCT05847400||CKD patients with T2DM not on regular HD|CKD patients with T2DM attending Assuit university diabetic outpatients clinic and ESRD not on regular HD at dialysis unit of Assuit University Hospital
88905610|NCT05847335||University students' forms|A socio-demographic data form will be given to the participants and the childhood trauma scale, Bar-On emotional intelligence scale and Personality Beliefs scale will be administered.
88905611|NCT05847257|Sham Comparator|Group A|group A (29) patients received letrozole 2.5mg twice weekly for 3 months
89423848|NCT04857268|Experimental|ATP-C120 application|ATP-C120 will be applied to the high patients for new-onset atrial fibrillation
89423849|NCT02230722|Active Comparator|Attention Control|The neutral 10-15 minute visit with the Care Manager will consist of a brief review of ATHENA-OT safety education and the patient's Pain Care Plan. The CM will answer patient questions, but will avoid using Motivational Interviewing communication. The Care Manager will review upcoming telephone check-in and assessment sessions.
89423850|NCT02230722|Experimental|Collaborative Care|Collaborative Care intervention in which one of two Care Managers delivering both interventions will assist primary care providers (PCPs) by using Motivational Interviewing to communicate computer-based ATHENA-OT (opioid therapy) decision support guidelines to veterans with chronic pain.
88905612|NCT05847257|Experimental|Group B|Group B (38) patients receive letrozole 2.5mg twice a week plus Co Q10 400 mg per day for 3 months
89423851|NCT03043456|Active Comparator|Thermoplastic Resin group|Thermoplastic complete denture placement is done (Thermoplastic Comfort Systems, inc.)
89423852|NCT03043456|Placebo Comparator|conventional acrylic resin group|Conventional acrylic resin complete denture placement is done. (Acrostone, inc.)
89423853|NCT05628402||exhibitionist patients|
89423854|NCT03043222|Experimental|PAE-Prostate Arterial Embolization|PAE-Prostate Arterial Embolization
89423855|NCT03043222|Active Comparator|PUL- Prostatic urethral lift|PUL- Prostatic urethral lift
89423856|NCT03043144||End stage renal disease|Observational study, no intervention
88905613|NCT05847218|Experimental|Cohort A1 (750mg RHN-001 or Placebo) in fasting state|Eligible 16 subjects will be randomized in Cohort A1 (n=16; 12 active: 4 Placebo) and fast for at least 10 hours on check-in day after dinner till 4 hours after they receive the investigational product (RHN-001 750mg caplet) or placebo at the study site on the morning of Day 2 of the study.
88905614|NCT05847218|Experimental|Cohort A2 (750mg RHN-001 or Placebo) in fed state|Eligible 16 subjects will be randomized in Cohort A2 (n=16; 12 active: 4 Placebo) and will receive the investigational product (RHN-001) or placebo on Day 2 (dosing day) within 30 minutes after a standard breakfast. All subjects will undergo a 24-hour PK study during their stay at the clinical trial site.
88905615|NCT05847218|Experimental|Cohort B1 (1500mg RHN-001 or Placebo) in fasting state|Eligible 16 subjects will be randomized in Cohort B1 (n=16; 12 active: 4 Placebo) and fast for at least 10 hours on check-in day after dinner till 4 hours after they receive the investigational product (RHN-001 1500mg caplet) or placebo at the study site on the morning of Day 2 of the study.
88905616|NCT05847218|Experimental|Cohort B2 (1500mg RHN-001 or Placebo) in fed state|Eligible 16 subjects will be randomized in Cohort B2 (n=16; 12 active: 4 Placebo) and will receive the investigational product (RHN-001) or placebo on Day 2 (dosing day) within 30 minutes after a standard breakfast. All subjects will undergo a 24-hour PK study during their stay at the clinical trial site.
88905617|NCT05847205|Experimental|r-Hirudin|Patients will be treated with r-Hirudin (Thrombexx) for a total of 15 days beginning with 15 mg BID s.c starting 6 hours after surgery or upon adequate hemostasis and continued until end of study.
89007128|NCT05835544|Experimental|HIIT + BFR high occlusion during cycling|High intensity interval cycling with high blood flow restriction applied during cycling
88905618|NCT05847192||Alzheimer's disease|"Age 65-85 years old.~Diagnosis of probable AD dementia according to NIA-AA criteria.~Mini-Mental State Examination (MMSE) score ≥ 10 and ≤ 26 at the screening visit.~Clinical Dementia Rating (CDR) score ≥ 0.5.~Logical Memory delay score of ≤8 for 16+ years of education, ≤4 for 8-15 years of education, and ≤2 for 0-7 years of education~Participants will undergo neuropsychological examination, blood collection, sensorimotor gating/ERP testing, MRI and [18F]-PI2620 PET scan."
89423857|NCT02234466|Active Comparator|Oral Dexamethasone|"Oral dexamethasone- two 4mg tabs and one 2mg tab contained within a gelatin capsule Administered a single time, 2 hours pre-induction~Ondansetron 6mg IV will be administered at skin closure"
89423858|NCT02234466|Placebo Comparator|Gelatin pill|"Gelatin capsule contained within second gelatin capsule. Administered a single time, 2 hours pre-induction~Ondansetron 6mg IV will be administered at skin closure"
89423859|NCT03042832|Experimental|LOCI|Leadership development with coaching and organizational change support
89423860|NCT03042832|Active Comparator|Internet Based Training|Internet based Webinar leadership training
89423861|NCT02230800|Experimental|Tocovid SupraBio plus pentoxifylline (PTX)|Tocovid SupraBio* 200mg po bd plus pentoxifylline (PTX) 400mg po bd for 12 months.
89423862|NCT02230800|Placebo Comparator|Matching placebos|Matching placebos bd for 12 months.
89423863|NCT02234544|Placebo Comparator|Placebo + Cholecalciferol|The groups will be randomized to ezetimibe or placebo. All participants will receive orally a cholecalciferol capsule.
89423864|NCT02234544|Active Comparator|Ezetimibe + Cholecalciferol|The groups will be randomized to ezetimibe or placebo. All participants will receive orally a cholecalciferol capsule.
88905619|NCT05847192||Alzheimer's disease with psychosis|"- All the criteria for AD are met.~Presence of one (or more) of the following symptoms:~Visual or auditory hallucinations (e.g., seeing silent individuals standing in the room, seeing children in the yard, or seeing animals in the house).~Delusions (fixed false beliefs that the patient believes to be true, e.g., that the spouse is unfaithful, that possessions are being stolen, or that one is not who one claims to be).~Participants will undergo neuropsychological examination, blood collection, sensorimotor gating/ERP testing, MRI and [18F]-PI2620 PET scan."
88905620|NCT05847192||Cognitively Unimpaired Healthy|"Age 65-85 years old.~No known genetic risk factors for dementia.~No cognitive complaint~Mini-Mental State Examination (MMSE) score ≥ 26 at the screening visit.~Logical Memory delay score of ≥9 for 16+ years of education, ≥5 for 8-15 years of education, and ≥3 for 0-7 years of education~Participants will undergo neuropsychological examination, blood collection, sensorimotor gating/ERP testing, MRI and [18F]-PI2620 PET scan."
88905621|NCT05847179|Experimental|Treatment Group|all subjects will receive Progerinin 2400mg (1200mg twice daily) after morning and evening meals for a year
88905622|NCT05847075|Experimental|Sedentary Diabetic people|Sedentary people with Type 2 Diabetes.
88905623|NCT05847075|Experimental|Heat Therapy|Diabetic people allocated in Heat Therapy for 12 weeks.
88905624|NCT05847075|Experimental|StrengthTraining|Diabetic people allocated in Strength training for 12 weeks.
88905625|NCT05847062|Active Comparator|patients operated on by means of an inverted shoulder prosthesis with medialized component|patients meeting the inclusion criteria who underwent surgery for a rotator cuff tear using an inverted shoulder prosthesis with a medially rotated center of rotation.
88905626|NCT05847062|Active Comparator|patients operated by means of inverted shoulder prosthesis with lateralized component|patients meeting the inclusion criteria who underwent surgery for a rotator cuff tear using an inverted shoulder prosthesis with a lateralized center of rotation.
89007129|NCT05833828||on-pump coronary artery bypass graft surgery|"Due to the observational design of the study, no study-specific interventions are performed. Except for the above mentioned laboratory analyses, the treatment of the patients is completely guided by the responsible ICU physicians.~Study participation does not influence the determination of surgical procedure (on- vs off-pump)."
89423865|NCT02259036|Other|SmartCAT Enhanced Treatment|Cognitive Behavioral Therapy enhanced with an ecological momentary treatment enhancement smartphone app called SmartCAT.
89423866|NCT04860388|Active Comparator|unilateral labially impacted maxillary canines|Distalization of the maxillary molars and/or protrusion of the maxillary and mandibular incisors made for creating sufficient space for impacted maxillary canines. After sufficient space for impacted maxillary permanent canine was obtained combine surgical-orthodontic treatment was performed via closed eruption technique. When the crown of the maxillary impacted canine was fully visible in the mouth, its bracket was inserted, and aligned within the dental arch. Posttreatment plaque index, gingival index, gingival bleeding index, probing depth, keratinized and attached gingival width and gingival thickness measurements of the impacted canines and controls were performed. The periodontal health of labially impacted maxillary canines compared with the contralateral canines that served as control teeth.
89423867|NCT04860388|Active Comparator|unilateral palatally impacted maxillary canines|Distalization of the maxillary molars and/or protrusion of the maxillary and mandibular incisors made for creating sufficient space for impacted maxillary canines. After sufficient space for impacted maxillary permanent canine was obtained combine surgical-orthodontic treatment was performed via closed eruption technique. When the crown of the maxillary impacted canine was fully visible in the mouth, its bracket was inserted, and aligned within the dental arch. Posttreatment plaque index, gingival index, gingival bleeding index, probing depth, keratinized and attached gingival width and gingival thickness measurements of the impacted canines and controls were performed. The periodontal health of palatally impacted maxillary canines compared with the contralateral canines that served as control teeth.
89423868|NCT03043066|Placebo Comparator|Group A -control group|15 subjects underwent scaling and root planing
89423869|NCT03043066|Active Comparator|Group B-Interventional group|15 subjects underwent scaling and root planing along with antibiotic intervention of amoxicillin of 500 mg and metronidazole of 400 mg thrice daily for 7 days
89423870|NCT04860310||21 years old group|
88905627|NCT05847023|Experimental|Immediate LUNA intervention|LUNA intervention between T1 and T2. No treatment between T2 and T3. LUNA intervention comprises 20hrs of face-to-face treatment, 2 sessions per week of 60 minutes each, for 10 weeks. One session is delivered by a qualified speech and language therapist; the other session is delivered by an assistant (student or volunteer) following guidance and under distance supervision. Both therapist and assistant will receive LUNA training. The treatment is specified in the TIDIER checklist. In brief, it aims to improve spoken discourse production, using personal narratives as assessment and treatment stimulate, and by integrating word, sentence and discourse level tasks. Treatment is manualised and has been codesigned with key stakeholders (providers and users).
88905628|NCT05847023|Experimental|Delayed LUNA intervention|Wait between T1 and T2. LUNA between T2 and T3. LUNA intervention as above
88905629|NCT05846971|No Intervention|Control Group|The control group will receive standard-of-care clinical data for their virtual patient cases. No educational material on the methylation assay will be provided.
88905630|NCT05846971|Experimental|Intervention Group|The intervention group will receive standard-of-care clinical data for their virtual cases along with educational materials about the methylation assay. This group will then be provided with methylation assay data to be used in addition to clinical data.
88905631|NCT05846958|Experimental|laser acupuncture|Each patient in this group will receive laser acupuncture based on the recommended LLLT treatment doses for CTS of the World Association of Laser Therapy.
88905632|NCT05846958|Active Comparator|control group|Each patient in this group will wear night splint every night for 4 weeks
88905633|NCT05846945|Active Comparator|IMT group|Training by inspiratory muscle device plus chest physiotherapy
88905634|NCT05846945|Active Comparator|TS group|Adjusting trigger sensitivity of the mechanical ventilator to the lowest pressure tolerated plus chest physiotherapy
89423871|NCT04860310||28 years old group|
89423872|NCT04860310||35 years old group|
89423873|NCT04860310||42 years old group|
89423874|NCT04860310||49 years old group|
89423875|NCT04848532|Experimental|Adolescent-specific behavioral weight loss treatment|
88905635|NCT05846945|Sham Comparator|PT group|Routine chest physiotherapy
89195622|NCT00399529|Experimental|Allo GM-CSF-secreting vaccine, Trastuzumab, Cyclophosphamide|"Allogeneic GM-CSF-secreting breast cancer vaccine : the vaccine containing a mixture of two GM-CSF-secreting allogeneic breast cancer cell lines (two parts 2T47D-V and one part 3SKBR3-7 mixed in a fixed dose of 5 X 10^8 cells for each patient and each vaccination cycle) given intradermally every 4-6 weeks for 3 cycles and then a 4th dose given 6-8 months after beginning the study.~Trastuzumab : An initial loading dose of 4 mg/kg for participants beginning treatment with Trastuzumab, otherwise 2 mg/kg given every week intravenously~Cyclophosphamide : 300 mg/m^2 given intravenously every 4-6 weeks for 3 cycles and then once 6-8 months after beginning the study"
89195623|NCT00921050|Experimental|Levothyroxine|Half of participants randomly assigned, take a pill daily, bimonthly thyroid test
89423876|NCT04857346|Experimental|Controlled Type 2 diabetes mellitus|
89423877|NCT04857346|Experimental|Uncontrolled Type 2 diabetes melltius|
89423878|NCT04857346|Active Comparator|Non-diabetic patients|
89423879|NCT03040570|Experimental|Conservative oxygenation target|Children in the conservative oxygenation target group receive treatment targeting oxygen saturation values of 88-92%.
89423880|NCT03040570|Active Comparator|Liberal oxygenation target|Children in the liberal oxygenation target group receive treatment targeting oxygen saturation values of >94%.
89423881|NCT03041974||Transfused critical care patients|Patients included in the Age of BLood Evaluation (ABLE) trial in either arms and included in a French center.
89423882|NCT03042520||IFN-based therapy historical controls|Patients who had ever participated the parent studies, GS-US-334-0115 or GS-US-337-0131, will be invited to participate the current study in outpatient clinic. For the patients who have participated study will be invited to participate the current study as matched historical control n our outpatient clinic,
89423883|NCT03042520||Sofosbuvir-based therapy observational group|"Patients ≥ 20 of years who had ever participated in parent studies, GS-US-337-0131 (NCT02021656) or GS-US-334-0115 (NCT02021643)~Patients who had received at least one dose of sofosbuvir-based therapy in the parent studies.~Who IFN-based therapy historical controls, matched with sex, age, level of liver fibrosis and virological response:~Patients ≥ 20 of years who had received peginterferon plus ribavirin therapy with match of sex, age, level of liver fibrosis and virological response~Patients who have ever participated study will be collected as historical control."
89423884|NCT03042442||Patients with pancreatic cancer|Patients with pancreatic ductal adenocarcinoma, based on the results of an endoscopic ultrasonography (EUS) biopsy or surgery were enrolled at the diagnosis, before any therapeutic intervention.
89423885|NCT03042442||health patients (controls)|Health patients
89423886|NCT03042676||ATLG group|ATLG treatment for GVHD prophylaxis.
89423887|NCT03042676||no ATLG group|No ATLG treatment.
89423888|NCT04848766||De-escalation treatment group|Patients diagnosed as acute coronary syndrome, and who receive de-escalation antiplatelet therapy after percutaneous coronary intervention
89423889|NCT04848766||Conventional treatment group|Patients diagnosed as acute coronary syndrome, and who receive conventional (non-de-escalation) antiplatelet therapy after percutaneous coronary intervention
89423890|NCT04856878|Experimental|Intervention|Standard of care (SOC) + single-dose intravenous vancomycin 15mg/kg
89423891|NCT04856878|No Intervention|Control|Standard of care (SOC)
89423892|NCT04848376||Spine surgery|"Use these system:~(1) SmartLoc (2) SmartLoc Evo(3) Winloc (4) Vigor PEEK Cervical Disc Spacer (5) Combo C (6) Polymer Lumbar Disc Spacer (7) X'Plo (8) Rainboo (9) Combo L"
89423893|NCT04847830|Experimental|Laser|One side of the mouth will undergo root surface debridement using hand instruments and ultrasonic scaler, with the addition of the Er:YAG laser
89423894|NCT04847830|Placebo Comparator|Control|The other side of the mouth undergo root surface debridement using hand instruments and ultrasonic scaler alone
89423895|NCT04856644|Experimental|4-month regimen (2HZPM/2HPM)|"Eight weeks of daily treatment with isoniazid (H), pyrazinamide (Z), rifapentine (P), and moxifloxacin (M), followed by~Nine weeks of daily treatment with isoniazid, rifapentine and moxifloxacin"
89423896|NCT04856644|No Intervention|Standard 6-month regimen (2HERZ/4HR) historical control|"a standard, six-month regimen, with~Eight weeks of daily treatment with isoniazid (H), rifampin (R), pyrazinamide (Z) and ethambutol (E) followed by~Eighteen weeks of daily treatment with isoniazid and rifampin, with or without ethambutol"
89423897|NCT01329978|Experimental|SOF+PEG+RBV 12 weeks|Participants were randomized to receive sofosbuvir+PEG+RBV for 12 weeks.
89423898|NCT01329978|Experimental|SOF+PEG+RBV 24 weeks|Participants were randomized to receive sofosbuvir+PEG+RBV for 24 weeks.
89423899|NCT01329978|Experimental|SOF+PEG+RBV 12 week/Rerandomization Group|Participants were randomized to receive sofosbuvir+PEG+RBV for 12 weeks, then were rerandomized to receive sofosbuvir only or sofosbuvir+RBV for 12 additional weeks.
89423900|NCT03041818|Experimental|hippotherapy|16 sessions of horseback riding therapy
89423901|NCT04859686|Experimental|Treatment|Participants underwent intervention.
89423902|NCT04859686|No Intervention|Waitlist|Participants received no intervention.
89007130|NCT05833828||off-pump coronary artery bypass graft surgery|"Due to the observational design of the study, no study-specific interventions are performed. Except for the above mentioned laboratory analyses, the treatment of the patients is completely guided by the responsible ICU physicians.~Study participation does not influence the determination of surgical procedure (on- vs off-pump)."
89423903|NCT04847518|Experimental|Kan Jang|70 patients take Kan Jang, two capsules three times a day for the two weeks in the treatment period. Daily dose - 90-120 mg of andrographolides.
89423904|NCT04847518|Placebo Comparator|Placebo|70 patients take Placebo, two capsules three times a day for the two weeks in the treatment period
89423905|NCT04859998|No Intervention|Control group|Participants in this group will simply continue with their daily living and therapies. They will be assessed before and after the 10 week program but will not take part in it.
89423906|NCT04859998|Experimental|Experimental group|Participants in this group will take part in the 20 session dog-assisted therapy. This therapy will be added to their usual daily living and therapies. They will be assessed before and after the 10 week program.
89423907|NCT04978740|Experimental|Participants affected by cutaneous and systemic mastocytosis|Participants affected by cutaneous and systemic mastocytosis with or without eye disabilities
89423908|NCT03042364|No Intervention|No intervention|Standard treatment
89423909|NCT03042364|Experimental|Intervention|Endometrial scratching before standard treatment
89423910|NCT02233218|Experimental|telmisartan, Amlodipine, Rosuvastatin|This arm is consist of 40 subjects. Telmisartan80mg + Amlodipine 10mg 9 days, Telmisartan80mg + Amlodipine 10mg , Rosuvastatin 20mg 5days Total 14days administration of investigational products to healthy male volunteers
89423911|NCT02233218|Experimental|Telmisartan, Amlodipine, Rosuvastatin|This arm is consist of 20 subjects. Rosuvastatin 20mg 5 days, Rosuvastatin 20mg , Telmisartan80mg + Amlodipine 10mg 9days, Total 14days administration of investigational products to healthy male volunteers
89423912|NCT03042598|Experimental|Biphasic Cuirass Ventilation|Patients requiring emergent intubation in the Emergency Department will be provided ventilation during the apnic phase of intubation via the use of BCV.
89423913|NCT04429438|Experimental|4SCAR19 and 4SCAR20/22/70/PSMA/13/79b/GD2|Patients who have relapsed and refractory B cell lymphoma (BCL) after chemotherapy will be treated with a combination of 4SCAR gene-engineered T cells.
89423914|NCT02262546|Experimental|Pramipexole|
89423915|NCT02262546|Active Comparator|Moxifloxacin|
89423916|NCT02262546|Placebo Comparator|Pramipexole Placebo|
89423917|NCT02262546|Placebo Comparator|Moxifloxacin Placebo|
89423918|NCT05626608|Experimental|Directional|Directional stimulation of the subthalamic nucleus in the treatment of Parkinson's disease using Boston Cartesia(TM) electrodes
89423919|NCT05626608|Active Comparator|Conventional ring (Monopolar and Bipolar)|Unilateral or bilateral subthalamic nucleus stimulation in the treatment of Parkinson's disease using Boston Cartesia(TM) electrodes
89423920|NCT05623878|Experimental|68Ga-Anti-PSMA mAbs|
89423921|NCT04859374|Other|Treatment as usual (TAU)|Any pharmacological therapy used for managing chronic pain or chronic migraine
89423922|NCT04859374|Other|TAU plus behavioral approach|Any pharmacological therapy used for managing chronic pain or chronic migraine added with behavioral approach (mindfulness) delivered on line and smart phone for 6 weekly sessions
89195624|NCT00921050|Placebo Comparator|Placebo|Half of participants randomly assigned, take a pill daily, bimonthly thyroid test
89195625|NCT01035307||Genomic and Proteomic Profiling|
89195626|NCT02565966|Experimental|Modified Atkins Diet (MAD)|
89423923|NCT03042052||Patients suffering from NDO managed with Botox|"Doses used were 300 units Botox® from January 2001 to January 2011 and 200 units after 2011~Frequency depended on patient's symptoms~Duration was an outcome of the study"
89423924|NCT04804618||Healthy control group|aged ≥55 years old, no dementia, MCI or no family history of AD.
89423925|NCT04804618||Alzheimer's disease high-risk group|aged ≥55 years old, immediate family members of AD patients
89195627|NCT02565966|No Intervention|Normal Diet|Those patients in the normal diet (no intervention) group will also meet with the epilepsy center nutritionist to review the food diary and completion of this document, similar to those in the intervention (MAD) group. No dietary restrictions will be made in this group.
89195628|NCT01035385|Experimental|FOFLOX4,resectable liver metastasis from CRC|
89423926|NCT04804618||Alzheimer's disease group|aged ≥55 years old, diagnosed as AD patients
89423927|NCT04804618||Mild cognitive impairment group|patients ≥55 years of age, diagnosed with MCI
89423928|NCT01338012|Experimental|sipuleucel-T|Men with metastatic castrate resistant prostate cancer previously treated with sipuleucel-T in the androgen dependent setting in the Dendreon P-11 study. Subjects received one infusion of sipuleucel-T every two weeks for for a total of three infusions.
89423929|NCT04856098|Experimental|Part 1 Ultibro Breezhaler 2 capsules, Batch A|
89423930|NCT04856098|Experimental|Part 1 Ultibro Breezhaler 2 capsules with charcoal, Batch A|
89423931|NCT04856098|Experimental|Part 1 Ultibro Breezhaler 1 capsule, Batch A|
89423932|NCT04856098|Experimental|Part 2 Ultibro Breezhaler 2 capsules, Batch A|
89423933|NCT04856098|Experimental|Part 2 Ultibro Breezhaler 2 capsules, Batch B|
89423934|NCT05611554|Experimental|Treatment|Psychological intervention will consist in an 3-session group ACT-based treatment.
89423935|NCT05611554|No Intervention|Waiting List|Participants assigned to Waiting List arm waited for 5 months before receiving treatment (i.e., after completing the measures they continued in the study and received Psychological intervention five months later)
89195629|NCT00712712|Experimental|Patient who has undergone radiofrequency ablation of bone metastases|Patient who has undergone radiofrequency ablation of bone metastases, localized, causing pain refractory to radiotherapy or not accessible to new irradiation, biphosphonates and well-conducted morphine analgesic treatment.
89195630|NCT00607048|Other|Schedule A|Schedule A (CP-870,893 administration schedule)
89423936|NCT03041584|Experimental|Materialise Universal®/ mucosa (Mat Mu)|
89423937|NCT03041584|Experimental|Materialise Universal®/ bone (Mat Bo)|
89423938|NCT03041584|Experimental|FacilitateTM/ mucosa (Fac Mu)|
89423939|NCT03041584|Experimental|FacilitateTM/ bone (Fac Bo)|
89423940|NCT03041584|Active Comparator|mental navigation (Mental)|
89423941|NCT03041584|Active Comparator|pilot-drill template (Templ)|
89423942|NCT04905498|Placebo Comparator|Control|Children were exposed to food commercials without narratives.
89423943|NCT04905498|Experimental|Intervention|Children were exposed to narrative statements that were shown and read aloud in between commercials played.
89423944|NCT04859452|Experimental|The DDI of DBPR108 tablets and Metformin hydrochloride tablets|Subjects will receive a single dose of metformin hydrochloride on Day 1, then take once-daily DBPR108 100 mg on Day 4 through Day 8 and a single dose of metformin hydrochloride on Day 8.
89423945|NCT04859452|Experimental|The DDI of DBPR108 tablets and Glibenclamide tablets|Subjects will receive a single dose of Glibenclamide on Day 1, then take once-daily DBPR108 100 mg on Day 4 through Day 8 and a single dose of Glibenclamide on Day 8.
89423946|NCT04859452|Experimental|The DDI of DBPR108 tablets and Valsartan Capsules|Subjects will receive a single dose of Valsartan on Day 1, then take once-daily DBPR108 100 mg on Day 4 through Day 8 and a single dose of Valsartan on Day 8.
89423947|NCT04859452|Experimental|The DDI of DBPR108 tablets and Simvastatin tablets|Subjects will receive a single dose of Simvastatin on Day 1, then take once-daily DBPR108 100 mg on Day 4 through Day 8 and a single dose of Simvastatin on Day 8.
89195631|NCT00607048|Other|Schedule B|Schedule B (CP-870,893 administration schedule)
89195632|NCT00895492||Sotero del Rio|Emergency Room and Hospital based surveillance
89195633|NCT00895492||Van Buren|Emergency Room and Hospital based surveillance
89195634|NCT00699608|Experimental|Crossover|All subjects received all three treatments in a randomised order
89195635|NCT00893776|Active Comparator|1 Unilateral Group|This group will wear the SaeboFlex orthosis on their affected extremity and do exercises with that extremity only. SaeboFlex exercises include moving the ball in high repetition of grasp and release while wearing the SaeboFlex orthosis to various positions individualized to each participant based on movement deficits, as well as Task Training (using the affected arm during specific functional activities to use newly acquired movement patterns)
89423948|NCT04859140|Experimental|Foam rolling|The foam rolling routine consisted in unilateral exercises alternatively performed on both legs and bilateral exercises on lower and back muscles. All participants started with the feet in a standing up position with a lacrosse ball. Then, participants performed on the ground the foam rolling exercises with the foam roller targeting leg and back muscles.
89423949|NCT04859140|Experimental|Manual massage|Participants in the manual massage group received manual massage by a professional physiotherapist who was blinded to the purpose of the experiment (20 years of registered practice). Participants were lying in the prone position on a massage table. To facilitate the physiotherapist's maneuvers, massage oil was used. The manual massage protocol reproduced several features of the foam rolling intervention, i.e., order of the areas massaged, massage time per muscles and total duration of the session.
89423950|NCT04859140|Active Comparator|Autogenic relaxation|Participants in the relaxation group listened to a 16 min relaxation audio tape, based on the autogenic training method. Participants were lying on the massage table in supine position, wearing headphones. During this desensitization-relaxation technique, they were guided to visualize bodily perceptions of heaviness and warmth in their arms, thorax and legs. To facilitate concentration, participants were left alone in a dark room.
89423951|NCT04881162|Experimental|NOVIS Transcarotid Neuroprotection System (NPS)|Patients that have failed transfemoral endovascular therapy in the case of anterior circulation strokes due to large vessel embolic occlusions will enrolled in the study and treated using the NOVIS Transcarotid NPS.
89423952|NCT02262624|Experimental|Telmisartan/HCTZ fixed combination|
89423953|NCT02262624|Active Comparator|Telmisartan and HCTZ monocomponents|
89423954|NCT02605044|Experimental|Masitinib + FOLFIRI|masitinib + FOLFIRI
89423955|NCT02605044|Placebo Comparator|Placebo + FOLFIRI|Placebo + FOLFIRI
89423956|NCT04856410|Experimental|2-Month Arm|Astronauts on 2-month International Space Station missions will be exposed to spaceflight for a duration of 2 months. Biometric and cognitive data will routinely be collected.
89423957|NCT04856410|Experimental|6-Month Arm|Astronauts on 6-month International Space Station missions will be exposed to spaceflight for a duration of 6 months. Biometric and cognitive data will routinely be collected.
89423958|NCT04856410|Experimental|12-Month Arm|Astronauts on 12-month International Space Station missions will be exposed to spaceflight for a duration of 12 months. Biometric and cognitive data will routinely be collected.
89423959|NCT04856410|Experimental|No Intervention|Subjects matched to 12-month astronauts that stay on Earth and are investigated at similar time points.
89423960|NCT04428892|Experimental|Clinical Simulation|The group denominated SP received a teaching strategy based on a class session with simulated practice for decision-making in clinical skills when caring for a person with LBP. Each session lasted approximately 120 minutes, and the clinical case used for the SP sessions was subjected to face validity with experts in the area of study.
89423961|NCT04428892|Active Comparator|Conventional Pedagogical strategy|"received a class session based on a role playing simulation strategy, structured for the same purpose established in the SP group. This session lasted approximately 120 minutes, and the learning environment was the classroom in which students assumed different roles to act out; some of them acted as people with LBP and others as physiotherapists"
89423962|NCT04712526||AEON Endostapler|Stapling performed with AEON Endostapler
89423963|NCT02607280|Experimental|DS-5565 group|DS-5565 15 mg (for moderate renal impairment) or 7.5 mg (for severe renal impairment), oral administration, Treatment period; 2-weeks titration and 12-weeks fixed dose
89423964|NCT02233374|Experimental|Assessing response with MRI + PET.|"Pre-operative chemo/RT as per standard treatment. Intensity Modulated Radiotherapy (IMRT) / Volumetric Arc Therapy (VMAT) 45Gray/25 fractions with simultaneous integrated Boost of 50Gray/25 fractions + concurrent capecitabine chemotherapy.~Intervention 1 'Early MRI and PET/CT - 2 weeks after commencing chemo/RT' involves additional Multiparametric MRI + PET/CT 2 weeks into chemo/RT Intervention 2 :\'Late MRI and PET/CT 6 weeks post chemo/RT' involves additional Multiparametric MRI + PET/CT 6 weeks post chemo/RT"
89423965|NCT02233452|Active Comparator|Methadone|Group treated with methadone solution.
89423966|NCT02233452|Active Comparator|Ketamine|Group treated with ketamine solution
89423967|NCT02233452|Active Comparator|Methadone plus ketamine|Group treated with methadone plus ketamine solution
89423968|NCT04846660|Experimental|Production pressured environment|Participants in this group were exposed to 4 audio recordings applying standardized pressure. Unlimited time.
88905636|NCT05846867|Experimental|AK119 20mg/kg+ AK112 20mg/kg|Subjects will receive AK119 plus AK112 via intravenously (IV) Q2W, up to 2 years
89195636|NCT00893776|Experimental|2 Bilateral training|Members of this group will wear the SaeboFlex orthosis on the affected extremity and do exercises with the affected extremity and the non-affected extremity at the same time. SaeboFlex exercises include moving the ball in high repetition of grasp and release while wearing the SaeboFlex orthosis to various positions individualized to each participant based on movement deficits, as well as Task Training (using the affected arm during specific functional activities to use newly acquired movement patterns)
89423969|NCT04846660|No Intervention|Regular environment|The control group was asked to complete the same task also with unlimited time. They were not exposed to the audio recordings.
89423970|NCT02262702||Extended Release Paracetamol|Participants prescribed with extended release paracetamol tablet containing 665 mg paracetamol.
89423971|NCT02262702||Standard Paracetamol|Participants prescribed with standard paracetamol tablet containing 500 mg paracetamol.
89423972|NCT05596578||Group A|Patients who underwent an anatomical resection for NSCLC <3 cm (lobectomy, bilobectomy, segmentectomy) with samples from the intrapulmonary stations 12, 13, and 14 lymph nodes and resection of lymph nodes station 10 and 11 during hilar separation.
89423973|NCT04846894|Experimental|Biochemical Recurrence|Prostate cancer patient with biochemical recurrence
89423974|NCT05571696|Active Comparator|Intervention Group|Assigned to Immune Strength program
89423975|NCT05571696|Active Comparator|Control Group|Assigned to 12 week waitlist, receiving usual care. Study participants assigned to the wait list will receive access to Immune Strength 12 weeks after study commencement.
89423976|NCT04846192||Patients|
89423977|NCT04477044|No Intervention|No GoPro|No GoPro Hero4 to be mounted on the participant's head while he/she performs intubation on a manikin.
88905637|NCT05846867|Experimental|AK119 40mg/kg+ AK112 20mg/kg|Subjects will receive AK119 plus AK112 via intravenously (IV) Q2W, up to 2 years
88905638|NCT05846867|Experimental|AK119 + AK112 20mg/kg +mFOLFOX6|Subjects will receive AK119 and AK112 plus mFOLFOX6 via intravenously (IV)Q2W, up to 12 cycles. Afterward, AK119 and AK112 will continue to be treated up to 2 years.
88905639|NCT05846867|Experimental|AK119 + AK112 20mg/kg +FOLFIRI|Subjects will receive AK119 and AK112 plus FOLFIRI via intravenously (IV)Q2W, up to 12 cycles. Afterward, AK119 and AK112 will continue to be treated up to 2 years.
88905640|NCT05846854|Experimental|Alagille syndrome|Patients with complex cardiac conditions requiring cardiothoracic surgery who also have a history of Alagille syndrome.
89423978|NCT04477044|Experimental|GoPro|GoPro Hero4 to be mounted on the participant's head while he/she performs intubation on a manikin.
89423979|NCT04840576|Placebo Comparator|Conventional Dressing|waterproof sterile dressing OPSITE Post-Op Visible, Smith & Nephew, UK
89423980|NCT04840576|Experimental|Prophylactic negative wound pressure dressing|PICO-7, Smith & Nephew, UK
89423981|NCT04476498|No Intervention|Standard pull-PEG|"Standard pull-PEG~In this group the participants receive a conventional pull-PEG as firstly described by Ponsky and Gauderer."
88905641|NCT05846854|Experimental|No history of Alagille syndrome|Patients with complex cardiac conditions requiring cardiothoracic surgery who do not have a diagnosis of Alagille syndrome.
88905642|NCT05846737|Experimental|BCMA CAR-T in high-risk MM with detectable MRD after first-line ASCT|Autologous BCMA-directed CAR-T cells, infusion intravenously at a target dose of 2-4 x 10^6 anti-BCMA CAR+T cells/kg.
88905643|NCT05845736||control group|absence of neurocognitive disorder (ND), Mini-Mental State Examination (MMSE) from 27 to 30 inclusive
88905644|NCT05845736||mild neurocognitive disorder|MMSE from 21 to 26 inclusive
88905645|NCT05845736||moderate neurocognitive disorder|MMSE from 11 to 20 inclusive
88905646|NCT05845736||severe neurocognitive disorder|MMSE less than or equal to 10
88905647|NCT05843942||Non-pregnant women of reproductive age|In the first stage, a three-day food consumption record will be taken from 50 non-pregnant (menstruating) women of reproductive age in order to determine the foods to be included in the food consumption frequency section, and the questionnaire sections and questions (nutrition habits and food consumption frequency questionnaire) will be designed. In the second stage of the study, the questionnaire developed in the first stage will be applied to 350 non-pregnant (menstruating) volunteer women of reproductive age through face-to-face interviews. A 24-hour recall food consumption record will be taken. In this stage, the blood parameters of at least 100 individuals whose blood counts have already been taken for routine tests and treatments and who meet the inclusion criteria. In the third stage, the questionnaire will be applied again to 75 individuals who have completed the second stage at least 2 weeks later in order to evaluate the reliability of the questionnaire results.
89007131|NCT05820893|Experimental|Prebiotic arm|Subjects will consume the RS prebiotic daily for 4 weeks. A dose escalation will be used with subjects taking 4g of the prebiotic for the first 4 days, 7g the next 3 days and the full dose of 10g on day 8.
89007132|NCT05820893|No Intervention|Standard diet|Subjects randomized to this arm will be asked to maintain their usual diet.
89423982|NCT04476498|Active Comparator|Pull-PEG with gastropexy|"Pull-PEG with gastropexy~In this group the participants firstly receive a gastropexy with the Funada style gastropexy device. Afterwards a conventional pull-PEG will be inserted."
89423983|NCT04840420|Active Comparator|Intervention|"Inpatient~The WBCs conducts approximately daily visits to:~collect demographics and baseline data;~co-develop personalised social prescription plan with the participant based on Social Determinants of Health (SDoH) using SBAR4;~referring and accompanying the participant to attend inpatient activities that suit the participant's interests and preferences; and~informing and seeking the participant's agreement with community assets identified for the participant together with CNS.~About 1-week post-discharge, the WBCs will call to check his/her transition back to community and readiness to start attending community activities or receiving services. For community activities, the WBCs and CNS will visit the participant, accompanying him/her to the activity premise on the first day of the activity session and send the participant home after the session."
89423984|NCT04840420|Other|Control|"Usual Care~Inpatient phase For the control group, the interviewer will conduct approximately 2 visits to collect demographics and baseline data. The duration of each visit will range from 15 to 30 minutes.~Community phase For the control group, no intervention will be administered."
89423985|NCT04845880|Other|SARS Cov_2 Incidence of Healthy Health Workers|
89423986|NCT04600752|Experimental|Participants receiving Augmentin (ES)-600|Eligible participants will receive Augmentin (ES)-600 at 90/6.4 mg/kg/day administered in two divided doses, every 12 hours with food for 10 days.
89423987|NCT04840810|Active Comparator|Out of plane/ short axis central venous cannulation|"In a short-axis view, the image plane is perpendicular to the course of the vessel and to the needle (needle is out of plane). The vessel appears as an anechoic circle on the screen of ultrasound with the needle visualized as a hyperechoic point in cross-section. The central venous cannulation was done in out of plane axis."
88905648|NCT05842148||Patients undergoing oncoplastic surgery with type 1 (unilateral) techniques.|"All patients with clinical-instrumental diagnosis of breast cancer, candidates for conservative oncoplastic surgery who give informed consent to the study, will be included in the study.~Type 1 procedures generally involve a unilateral approach, able to guarantee good resective quality, without a significant alteration of the volume with respect to the contralateral breast.~Post-surgical histopathological data and any associated postsurgical complications will be collected through the compilation of a database.~Aesthetic and functional post-surgical results related to the quality of life, as data perceived by the surgeon and by the patient, will be collected through the administration of a questionnaire."
88905649|NCT05842148||Patients undergoing oncoplastic surgery with type 2 (bilateral) techniques.|"All patients with clinical-instrumental diagnosis of breast cancer, candidates for conservative oncoplastic surgery who give informed consent to the study, will be included in the study.~Type 2 procedures (therapeutic mammoplasty), offer a greater resective potential, but generally require the use of contralateral surgery to obtain symmetry, simultaneous or delayed.~Post-surgical histopathological data and any associated postsurgical complications will be collected through the compilation of a database.~Aesthetic and functional post-surgical results related to the quality of life, as data perceived by the surgeon and by the patient, will be collected through the administration of a questionnaire."
88905650|NCT05841173|Experimental|The Product Group|The Product group is prescribed with the investigated product - exogeneous ketone bodies.
89423988|NCT04840810|Active Comparator|In-plane/long axis central venous cannulation|"In a long-axis view, the image plane is parallel to the course of the vessel (needle is in-plane). The image shows the course of the vessel across the screen and the shaft and point of the needle as it is advanced. The central venous cannulation was done in in-plane axis."
89423989|NCT05565066||FNB group|FNB needles adpted to acquire lesion tissues according patients' advice and patients' willings.
89423990|NCT05565066||FNA group|FNA needles adpted to acquire lesion tissues according patients' advice and patients' willings.
89423991|NCT04840186|Active Comparator|2nd line chhemotherapy|Patients in this arm will be receiving the standard care which is 2nd line chemotherapy. Type of chemotherapy determined by treating oncologist.
89423992|NCT04840186|Active Comparator|2nd line chemotherapy + resection|Patients in this arm will be treated with liver resection and/or ablation at Oslo University Hospital followed by adjuvant 2nd line chemotherapy. Type of chemotherapy is determined by treating oncologist.
89423993|NCT04476810|Experimental|combined (phaco-kdb)|Prospective, non-comparative, uncontrolled, non-randomized interventional case series. Consecutive patients with medically-treated glaucoma and visually-significant cataract underwent combined surgery. Subgroup analysis of glaucoma subtypes was performed.
88905651|NCT05841173|Active Comparator|The Combined Intervention Group|The Combined Intervention Group is prescribed with the investigated product -in combination with regular physical trainings.
88905652|NCT05841173|Placebo Comparator|The Placebo Group|The Placebo Group is prescribed with the Placebo.
88905653|NCT05841173|Active Comparator|The Diet Group|The Diet Group is prescribed with the Diet designed with 500 kcal reduction from daily energy expenditure.
88905654|NCT05841173|No Intervention|The Control Group|The Control Group is prescribed with standard recommendations for weight loss.
89423994|NCT03041506|Active Comparator|Sedation|"Analgesia and sedation through IV medication for pain relief will be administered to the patient.~Midazolam: up to a maximum dosage of 0.1 mg/kg (bolus of 1 mg by titration every 30-60 second).~Ketamine: up to maximum dosage of 100 mg IV (bolus of 25 mg by titration every 30-60 seconds)."
89423995|NCT03041506|Experimental|US guided ISCB|"Infiltration of local anesthetic agents around target nerves (C5, C6 nerve roots), US guidance, for shoulder pain relief and muscle relaxation.~Lidocaine 2%: 15-20 ml."
89423996|NCT02586792|Experimental|Group 2|N up to 10 in prior receipt of a placebo in DMID Protocol 07-0023 will receive 45 mcg of HA/0.75 ml of Monovalent inactivated influenza A/H7N9 virus vaccine
89423997|NCT02586792|Experimental|Group 1|N up to 40 in prior receipt of a monovalent inactivated influenza A/H7N7 virus vaccine in DMID Protocol 07-0023 will receive 45 mcg of HA/0.75 ml of Monovalent inactivated influenza A/H7N9 virus vaccine
89423998|NCT04428970||TBI patients with ICP monitoring|Patients with severe TBI (GCS<9 on arrival) receiving invasive ICP monitoring
89423999|NCT05544006||Active study group|Active study group with self monitoring reminders in 3,7,14,28th days after discharge
89424000|NCT05544006||Usual care group|Usual care group with self monitoring recommendations at discharge
88905655|NCT05841082||CAD|The investigators recruited all consecutive end-stage renal disease patients requiring dialysis who had significant coronary artery disease, defined as 50% or greater stenosis in any of three main coronary arteries or left main coronary artery on visual assessment of the coronary angiogram
89424001|NCT04590144|Experimental|INVICTA lead|All patients eligible for enrolment in whom the INVICTA lead is attempted (Implant of the INVICTA lead
88905656|NCT05840757|Other|Hemodynamic Monitoring|Simultaneous measurement of hemodynamic parameters such as Cardiac output, cardiac index and blood pressure with invasive right heart catheterization and non-invasive application of the Clearsight Finger Cuff.
88905657|NCT05840705|Experimental|Total knee arthroplasty|
88905658|NCT05840692|Active Comparator|Cipralex|Escitalopram 20 mg x 1 for 12 weeks
88905659|NCT05840692|Placebo Comparator|Placebo|Placebo 20 mg x 1 for 12 weeks
89424002|NCT04845724|Active Comparator|Standard Diet|The standard diet was based on the current dialysis diet sheet. The standard diet main meal contained a higher proportion of foods with a higher phosphorus to protein ratio (salmon and dairy), and foods with higher phosphorus bioavailability (cake). The diet was tailored for each participant to provide 1.1g protein/kg ideal body weight. The major differences between the diets were at the main meal.
89424003|NCT04845724|Experimental|Modified Diet|The modified diet, representative of the proposed modified phosphorus diet used food of lower phosphorus to protein ratio such as beef and less dairy. Approximately 30% dietary phosphorus in the modified diet came from foods with significant phytate content such as pulses, nuts and whole grains. The modified diet was tailored for each participant to provide 1.1g protein/kg ideal body weight.
88905660|NCT05840679|Experimental|3% NaOCl concentration group|Participants in this group will receive endodontic irrigation with lower conc 3% sodium hypochlorite
88905661|NCT05840679|Experimental|6% NaOCl concentration group|Participants in this group will receive endodontic irrigation with higher conc 6% sodium hypochlorite
89195637|NCT00895570|Experimental|Modafinil|During each day of the 7-day sleep restriction phase of the study modafinil was administered (200 mg tablet at 0600, and a second dose of 100 mg tablet at 1300).
89195638|NCT00895570|Placebo Comparator|Placebo|During each day of the 7-day sleep restriction phase of the study a sugar pill was administered.
89195639|NCT00895648|Experimental|Alimta plus Cisplatin|
89195640|NCT05361512||Patients having an epidural placed for labour analgesia or anesthesia for cesarean delivery|Patients with BMI>=50 who are having an epidural placed may take part in this study.
89424004|NCT04839796||Participants residing in urban areas|Urban residents enjoy convenient transportation, have access to abundant medical resources, have more job opportunities, and are on average younger but are also exposed to more air pollution.
89424005|NCT04839796||Participants residing in rural areas|Rural residents have less access to transportation, medical resources, and job prospects comparatively and are comparatively older. However, Rural residents are exposed to less pollution in general.
89424006|NCT02580708|Experimental|Rociletinib and Trametinib|
89424007|NCT03041272||Nurses and nursing personnel|All registered nurses and assistive nursing personnel, including patient care associates (PCAs) , patient care technicians (PCTs), clinical technicians (CTs), primary employment on the study unit, minimum of 24 hours per week of employment on study unit.
89424008|NCT03041428|Experimental|Recruited patients|Ultraprotective ventilation
89424009|NCT04845802|Experimental|Training Group|Dancers in this group will perform inspiratory muscle training for 30 breaths, twice daily [morning: between 7:00 and 13:00 and evening: between 16:00 and 22:00], 7 days per week for 8 weeks, with a breathing frequency of 15 breaths per minute and a duty cycle of 0.5. One exercise session will be supervised in a clinic per week, other sessions will be performed at home in every week during the training.
89424010|NCT04845802|Sham Comparator|Sham Group|Dancers in this group will perform inspiratory muscle training for 30 breaths, twice daily [morning: between 7:00 and 13:00 and evening: between 16:00 and 22:00], 7 days per week for 8 weeks, with a breathing frequency of 15 breaths per minute and a duty cycle of 0.5. One exercise session will be supervised in a clinic per week, other sessions will be performed at home in every week during the training.
89424011|NCT03041350|Experimental|Smartphone video-assisted ALS & Conventional CPR|"In study period, using this video medical control, high-quality CPR, cardiac arrest rhythm confirmation, defibrillation, proper drug administration instructions, advanced airway insertion, etc. are performed. The medical director then decides on patient transfer if the asystole and pulseless electrical activity findings are persistent even after more than 20-minutes of ALS.~The conventional CPR is Basic life support only in the automatic external defibrillator (AED) mode 5-10 minutes at the scene, are not allowed to stop resuscitation at the scene unless there is a return of spontaneous circulation (ROSC) or pre-hospital cardiac arrest patient has already been transported to a hospital."
89424012|NCT04845646|Experimental|ASC41 + Itraconazole group|"ASC41 5 mg po, One 5 mg ASC41 tablet on day 1 and 11.~Itraconazole oral capsule 200 mg po qd (2 capsules given 1x/day or 200 mg/day) on days 6-16."
88905662|NCT05840653|Experimental|experimental 1: Intervention group|Experiment 1 group will first be given a pre-test, then a 5-week hope placement program will be applied. The final test will be administered after the program is completed.
89424013|NCT04845646|Experimental|ASC41 + Phenytoin group|"ASC41 5 mg po, One 5 mg ASC41 tablet on day 1 and 19.~Phenytoin oral capsule 300 mg (100 mg 3 x/day) on days 6-19."
89424014|NCT04845646|Experimental|ASC41 group|(1) ASC41 5 mg po. One 5 mg ASC41 tablet on day 1.
89424015|NCT02234778|Experimental|Study Treatment|Each subject will receive up to 30 cc of the TGI SVF material via intramuscular injection (injections at multiple locations on the lower leg - up to 20 total injections) through a 23 gauge needle over a 2- to 4- minute period. TGI SVF material injection will be completed within 4 hours of cell separation.
89424016|NCT03038776|Experimental|1|Two i.m. administrations 4 weeks apart of recombinant influenza hemagglutinin corresponding to avian H7N9 virus strain (rH7 antigen)
89424017|NCT03038776|Experimental|2|Two i.m. administrations 4 weeks apart of recombinant influenza hemagglutinin corresponding to avian H7N9 virus strain (rH7 antigen) + Advax-1 adjuvant
89424018|NCT03038776|Experimental|3|Two i.m. administrations 4 weeks apart of recombinant influenza hemagglutinin corresponding to avian H7N9 virus strain (rH7 antigen) + Advax-2 adjuvant
89424019|NCT03038776|Experimental|4|Two i.m. administrations 4 weeks apart of T cell epitope modified recombinant influenza hemagglutinin corresponding to avian H7N9 virus strain (rH7m antigen) antigen
89424020|NCT03038776|Experimental|5|Two i.m. administrations 4 weeks apart of T cell epitope modified recombinant influenza hemagglutinin corresponding to avian H7N9 virus strain (rH7m antigen) + Advax-1 adjuvant
88905663|NCT05840653|Experimental|experimental 2 group; Intervention group|A 5-week hope placement program will be applied to the experimental 2 group without the pre-test application. After the program is completed, the final test will be administered.
88905664|NCT05840653|No Intervention|control 1 group; not Intervention group|only the pre-test will be applied, other than that, no intervention will be applied in the 5-week period. Then the final test will be applied.
88905665|NCT05840653|No Intervention|control 2 group; not Intervention group|No intervention will be applied during the pre-test application and the 5-week period. then the final test will be administered.
88905666|NCT05840640|Active Comparator|Standard Medical therapy|Standard medical therapy involves primary treatment with normal hospital nutrition (1800 to 2000 kcal per day). Diuretics, sodium restriction and albumin for treatment of ascites or fresh frozen plasma for coagulopathy or antibiotics for any focus of infection as spontaneous bacterial peritonitis (SBP), pneumonia, cellulitis, and urinary tract infection as indicated.
88905667|NCT05840640|Experimental|G-CSF|Standard Medical Therapy plus G-CSF- 5μg/Kg s.c every 12 hours for 5 consecutive days
89195641|NCT00893854|Experimental|Diclophenac|
89424021|NCT03038776|Experimental|6|Two i.m. administrations 4 weeks apart of T cell epitope modified recombinant influenza hemagglutinin corresponding to avian H7N9 virus strain (rH7m antigen) + Advax-2 adjuvant
89424022|NCT02570490|Experimental|CEM-102 (Sodium fusidate)|1500 mg by mouth every 12 hours for 2 doses, then 600 mg by mouth every 12 hours thereafter, until end of therapy (10 days total)
89424023|NCT02570490|Active Comparator|Linezolid|600 mg by mouth every 12 hours for 10 days
89424024|NCT04839640|Active Comparator|reinforced acrylic resin denture teeth|Shufo acrylic denture teeth
89424025|NCT04839640|Experimental|Composite resin denture teeth|Bredent denture teeth
89424026|NCT04845334|Experimental|Clinical RR intervention|Clinical RR intervention
89424027|NCT04845334|No Intervention|Standard care|Standard care
89424028|NCT02565732|Experimental|Dose A|Botulinum toxin type A
89424029|NCT02565732|Experimental|Dose B|Botulinum toxin type A
89195642|NCT00893854|Experimental|Triamcinolone|
89195643|NCT00893932||SIRS|
89195644|NCT00895726|Experimental|APD209|
89195645|NCT00895804|Other|Pindolol, Placebo|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but two (actually 4) treatment conditions in the same subject.
89424030|NCT02565732|Placebo Comparator|Dose C|Placebo comparator
89195646|NCT00895804|Other|MDMA, Placebo|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but two (actually 4) treatment conditions in the same subject.
89424031|NCT04845412||Children of GDM parents|Children of mothers who have gestational diabetes mellitus
89424032|NCT04845412||Children of non-diabetic parents|Children of mothers without diabetes
89195647|NCT00895882|Experimental|1|vaniprevir 300 mg b.i.d. + peg-IFN + RBV for 12 weeks, followed by placebo to vaniprevir + peg-IFN + RBV for 12 weeks
89424033|NCT02234856|No Intervention|conventional residency training|no intervention
89424034|NCT02234856|Experimental|Laparoscopic Hysterectomy trainer|Intervention: An educational video and web-based e-module will be created. The final product will be reviewed by the expert contributors. Once approved, these tools will be showcased to a voluntary focus group of Obstetrics and Gynecology residents at the University of Toronto. A quantitative assessment of effectiveness of this tool will be performed through the use of pre- and post-tests of knowledge. A qualitative needs assessment will also be performed using post-viewing surveys. If found to be effective, this educational tool will be incorporated in the University of Toronto Obstetrics and Gynecology residency curriculum.
89424035|NCT04855084|Experimental|Complete Digital Fixed Dental Prosthesis|"Following the Digital Impression using 3 Shape Trios Intraoral scanner, digital design, and manufacturing of the Monolithic Zirconia FDPs.~Monolithic FDPs: before adjustment~Using Intraoral Scanner, occlusal relationship assessment of the Monolithic FDPs before the occlusal adjustment.~Monolithic FDPs: after adjustment~Using Intraoral Scanner, occlusal relationship assessment of the Monolithic FDPs after the occlusal adjustment."
89424036|NCT04855084|Active Comparator|Analog Fixed Dental Prosthesis|"Following the Conventional Impression, transfer to the articulator with Face bow. Manufacturing of the FDPs with lost wax technique and veneering.~Metal fused porcelain FDPs: before adjustment~Using Intraoral Scanner, occlusal relationship assessment of the metal fused to porcelain FDPs before the occlusal adjustment.~Metal fused porcelain FDPs: after adjustment~Using Intraoral Scanner, occlusal relationship assessment of the metal fused to porcelain FDPs after the occlusal adjustment."
89424037|NCT02561442|Active Comparator|IV ceftriaxone (0.5hr) 1 gm|ceftriaxone for injection, (total dose = 1.0 g) administered IV over 30 minutes via infusion pump (Open Label)
89424038|NCT02561442|Experimental|subcutaneous ceftriaxone, (2hr), 1 gm|ceftriaxone for injection, (total dose = 1.0 g) administered subcutaneous over 2 hours (Blinded).
89424039|NCT02561442|Experimental|subcutaneous ceftriaxone, (2 hr), 2 gm|ceftriaxone for injection, (total dose = 2.0 g) administered subcutaneous over 2 hours (Blinded).
89424040|NCT02262858|Experimental|Telmisartan and HCTZ (fix dose combination)|
89424041|NCT02262858|Active Comparator|Telmisartan and HCTZ (monocomponent)|
89424042|NCT04845100|Experimental|Intervention|"The Effect Of Animal Assisted Activities On The Stress And Social Anxiety Levels Of Disabled Children~Animal Assisted Activity Program (HayDAP)"
89424043|NCT04845100|Other|Control group|No intervention
89424044|NCT04476732|Experimental|Paraben-free then Paraben-containing|Paraben free facial lotion is applied twice a day for 1 week and measurements are taken. Then, paraben-containing facial lotion is applied twice a day for 1 week and measurements are taken.
89424045|NCT02235012|Experimental|Ketamine then placebo|Infusion of low dose Ketamine then infusion of a saline solution
89424046|NCT02235012|Experimental|Placebo then ketamin|Infusion of a saline solution then infusion of low dose Ketamine
89424047|NCT02235090|Sham Comparator|Zero-strength of direct current stimulation|Sham transdermal direct current stimulation of cervical spinal cord
89424048|NCT02235090|Experimental|100 microamperes direct current stimulation|Transdermal direct current stimulation of cervical spinal cord
89424049|NCT02235090|Experimental|1 milliampere direct current stimulation|Transdermal direct current stimulation of cervical spinal cord
89424050|NCT04854928|Experimental|LTX-109 treatment|Single Dose by Nasal application of LTX-109 gel 3%, 250 microliters in each nostril.
89424051|NCT04854928|Placebo Comparator|Placebo|Single Dose by Nasal application of placebo gel, 250 microliters in each nostril.
89195648|NCT00895882|Experimental|2|vaniprevir 300 mg b.i.d. + peg-IFN + RBV for 24 weeks
89195649|NCT00895882|Experimental|3|vaniprevir 600 mg b.i.d. + peg-IFN + RBV for 12 weeks, followed by placebo to vaniprevir + peg-IFN + RBV for 12 weeks
89195650|NCT00895882|Experimental|4|vaniprevir 600 mg b.i.d. + peg-IFN + RBV for 24 weeks
89195651|NCT00895882|Experimental|5|vaniprevir 600 mg q.d. + peg-IFN + RBV for 24 weeks
89424052|NCT05412966|Experimental|PEAR-002B / reSET-O|Digital Therapeutic
89424053|NCT02262936|Active Comparator|Desmopressin|Patients randomized to receive Desmopressin will be given 0.1mg daily by mouth at bedtime. After 4 weeks, patients will have the option to increase their dose to 0.2mg daily by mouth at bedtime. Total time of drug administration will be 12 weeks.
89424054|NCT02262936|Active Comparator|Fesoterodine|Patients randomized to receive Fesoterodine will be given 4mg daily by mouth at bedtime. After 4 weeks, patients will have the option to increase their dose to 8mg daily by mouth at bedtime. Total time of drug administration will be 12 weeks.
89424055|NCT04838704|Experimental|RUX group|
89424056|NCT04838704|Active Comparator|Control group|
89424057|NCT04844710|Experimental|Treatment|Manual acupuncture and standard care
89424058|NCT04844710|Other|Control|Standard care only
89424059|NCT02235168|Experimental|With rollator|Six minutes walking test with rollator
89424060|NCT02235168|Active Comparator|Without rolator|Six minutes walking test without rollator
89424061|NCT04844398|Experimental|Clown visits (four times)|Children and adolescents in psychiatric care participate in clown visits in a group setting on a weekly basis over four consecutive weeks.
89007133|NCT05814835|Experimental|68Ga/64Cu-FAPI-XT117 PET/CT|Each patient will receive 2-4 mCi, 4-6 mCi or 6-8 mCi 68Ga/64Cu-FAPI-XT117 intravenously (IV), and then PET/CT scanning within the specified time. On another day, patients receive 18F-FDG and then undergo PET/ CT.
89424062|NCT02259660|Active Comparator|Active Group|Subjects in this arm will train their respiratory muscles at home. The training protocol will use progressively higher pressure threshold training valves to provide respiratory muscle strength training at a pressure threshold greater than 70% maximum inspiratory (MIP) and expiratory (MEP) pressures. The total daily training time should be 20 to 30 minutes in duration.
89424063|NCT02259660|Placebo Comparator|Sham Training|The intervention in the sham training arm will be identical in every way to that of the active arm with the exception of the trainer that is provided. Subjects in the sham training arm will have inspiratory and expiratory muscle strength trainers which have had the pressure threshold spring removed and are therefore unable to provide a load to the muscles being trained.
89424064|NCT04844320|Active Comparator|> 50 %EWL|Postoperative weight loss in first year > 50 % EWL
89424065|NCT04844320|Active Comparator|50 - 25 % EWL|Postoperative weight loss in first year 25 - 50 % EWL
89424066|NCT04844320|Active Comparator|< 25 % EWL|Postoperative weight loss in first year < 25 % EWL
89424067|NCT02263092|Experimental|15 minutes of physical exercise|the subjects will do physical exercise on a treadmill with 64 to 74% of maxHR
89424068|NCT02263092|Experimental|10 minutes of physical exercise|- the subjects will do physical exercise on a treadmill with 77 to 95% of maxHR.
89007134|NCT05814588|Experimental|Group A|
89007135|NCT05814588|Sham Comparator|Group B|
89007136|NCT05796505|No Intervention|Treatment as usual|Participants receive standard interventions currently in use (treatment as usual).
89424069|NCT02263092|Experimental|30 minutes of physical exercise|- the subjects will do physical exercise on a treadmill with 57 to 63% of maxHR.
89424070|NCT02263092|Experimental|Rest/control|the subjects will be on 15 or 30 minutes seat without move the legs.
89424071|NCT02263092|Experimental|Anodal tDCS + physical exercise 1|the subjects will be undergo to anodal tDCS + physical exercise 1
89195652|NCT00895882|Placebo Comparator|6|Placebo to vaniprevir + peg-IFN + RBV for 24 weeks, followed by peg-IFN + RBV for 24 weeks
89195653|NCT03823404|Experimental|COR388 80 mg twice daily (BID)|COR388 hydrochloric acid (HCl), 80 mg orally administered capsule, BID (twice daily) with water approximately 12 hours apart and no less than 6 hours apart
89424072|NCT02263092|Experimental|Anodal tDCS + physical exercise 2|the subjects will be undergo to anodal tDCS + physical exercise 2
89424073|NCT02263092|Experimental|Cathodal tDCS + physical exercise 1|the subjects will be undergo to cathodal tDCS + physical exercise 1
89424074|NCT02263092|Experimental|Cathodal tDCS + physical exercise 2|- the subjects will be undergo to cathodal tDCS + physical exercise 2
89424075|NCT02263092|Experimental|Sham tDCS + physical exercise 1|the subjects will be undergo to sham tDCS + physical exercise 1
89424076|NCT02263092|Experimental|Sham tDCS + physical exercise 2|the subjects will be undergo to sham tDCS + physical exercise 2
89424077|NCT03038542|Experimental|Treatment Text Arm|
89424078|NCT03038542|Active Comparator|Standard Text Arm|
89424079|NCT02259738|Experimental|Human urinary kallidinogenase and Shuxuening injection|Human urinary kallidinogenase 0.15PNA and Shuxuening injection 20mg, every day for 7 days.
89424080|NCT04854460|Experimental|T test|Test drug (Revemact) 1 tablet contains 6 mg Ivermectin
89424081|NCT04854460|Active Comparator|B reference (first dose)|Reference drug (Stromectol) 2 tablets contain 3 mg each Ivermectin
89424082|NCT04854460|Active Comparator|B reference (second dose)|Reference drug (Stromectol) 2 tablets contain 3 mg each Ivermectin
89424083|NCT04854538|Experimental|T test|Test drug (Ekmasonid) 1 tablet contains 9 mg Budesonide
89424084|NCT04854538|Experimental|B reference (first dose)|Reference drug (Uceris) 1 tablet contains 9 mg Budesonide
89424085|NCT04854538|Experimental|B reference (second dose)|Reference drug (Uceris) 1 tablet contains 9 mg Budesonide
88905668|NCT05840640|Experimental|G-CSF and NAC|Standard Medical Therapy plus G-CSF with intravenous NAC (day 1: NAC at 150, 50, and 100 mg/kg in 250, 500, and 1000 ml of 5% glucose solution over 30 minutes, 4 hours, and 16 hours, respectively; days 2 through 5: 100 mg/kg/day in 1000 ml of 5% glucose solution followed by oral NAC from days 6 to 28)
89424086|NCT05331690|Active Comparator|Group 1 NSAIDs pre|Topical nepafenac (Nevanac) 3 mg/ml started 1 day before surgery
89424087|NCT05331690|Active Comparator|Group 2 NSAIDs post|Topical nepafenac (Nevanac) 3 mg/ml started the day after surgery
89424088|NCT05331690|Active Comparator|Group 3 NSAIDs and steroids|Topical nepafenac (Nevanac) 3 mg/ml + topical dexamethasone (Spersadex) started the day after surgery
89424089|NCT04373668|No Intervention|Control, optimised usual care|Treatment delivered as usual in the care home
88905669|NCT05840627|Experimental|Fruit juice|
88905670|NCT05840614|Experimental|The remote family support program plus TAU|Behavioral: The remote family support program Remote family support programs consist of interpersonal psychotherapy (IPT) and family psychoeducation.
89424090|NCT04373668|Experimental|Hypnotic Drug Review, Structured Sleep Hygiene and NightCAP|Care homes to receive all three interventions: Hypnotic Drug Review, Structured Sleep Hygiene and NightCAP interventions
89424091|NCT02556372|Experimental|JKB-122|AIH-positive subjects (n=20) who are intolerant, refractory, ineligible or unwilling to take current therapies, and have liver enzymes that are 2 to 10 times the upper limit of normal
89424092|NCT04854226|Experimental|Macronutrient_CARB|High carbs, low fat composition.
89424093|NCT04854226|Active Comparator|Macronutrient_FAT|Low carbs, high fat composition.
89424094|NCT02202434|Experimental|Lotus Valve System - Randomized|Transcatheter aortic valve replacement (TAVR) with Lotus Valve System
89424095|NCT02202434|Active Comparator|CoreValve TAVR System - Randomized|Transcatheter aortic valve replacement (TAVR) with CoreValve/Evolut R Transcatheter Aortic Valve Replacement System
89424096|NCT02202434|Experimental|Lotus Valve Sytem - Single-arm 21mm Cohort|Transcatheter aortic valve replacement (TAVR) with 21mm Lotus Valve System
89424097|NCT02202434|Experimental|Lotus Valve System - Single-arm Continued Access Cohort|Transcatheter aortic valve replacement (TAVR) with Lotus Valve System
89424098|NCT02202434|Experimental|Lotus Valve System - Single-arm Roll-in Cohort|Transcatheter aortic valve replacement (TAVR) with Lotus Valve System
89424099|NCT02202434|Experimental|LOTUS Edge Valve System - Single-arm Edge Nested Registry|Transcatheter aortic valve replacement (TAVR) with 23mm, 25mm and 27mm LOTUS Edge Valve System.
89424100|NCT03038386|Other|Dual Energy CT|In this study all patients undergo DECT scan to assess the value of DECT scan in diagnosing acute arthritis caused by gout. If the DECT scan demonstrates MSU depositions and the diagnosis of gout was not ascertained prior to DECT scanning by MSU crystals in the synovial fluid, then additional ultrasound guided aspiration will take place, with knowledge of DECT results, followed by repeat microscopy
89424101|NCT04373200|Experimental|COVID-19 patients with associated ARDS|
88905671|NCT05840614|No Intervention|Treatment as Usual|Treatment as usual administrated by physician.
89195654|NCT03823404|Experimental|COR388 40 mg BID|COR388 HCl, 40 mg orally administered capsule, BID with water approximately 12 hours apart and no less than 6 hours apart
89424102|NCT04373200|Active Comparator|COVID-19 patients without associated ARDS|
89424103|NCT04373200|Active Comparator|Patients with ARDS from other causes|
89424104|NCT02263170||All study participants|Healthy (m/f), normal weighted
89424105|NCT03040258|Experimental|Intervention group- Health-E-PALS-Pilot|Group of students receiving the school-based intervention: Health-E-PALS (pilot), it consists of in class activities and lessons.
89424106|NCT03040258|No Intervention|Control group|Group of students not receiving any intervention
88905672|NCT05840601|Experimental|Pointdexter|The investigational device being tested is Pointdexter, a novel prosthetic finger with a built-in split gripper. The device is an index finger which can drop in place of existing fingers on a prosthetic hand. The investigational device is controlled with the same signals used to control the hand. Participants will use a commercially available prosthetic hand compatible with the Pointdexter device for this study.
89424107|NCT03038152|Experimental|Diagnostic (Magseed marker)|Patients receive the Magseed marker via ultrasound guided injection into the previously clipped lymph node or within perinodal tissue =< 3mm from the clipped node. Patients then undergo axillary lymph node localization and targeted dissection within 30 days.
89424108|NCT05284890|Experimental|CC-99677|
89424109|NCT03038230|Experimental|MCLA-117 bispecific antibody|"Dose escalation cohorts, with escalating doses of MCLA-117 until MTD or RP2D is reached. The dose is given weekly after initial ramp-up dosing steps. Each Cycle is 28 days. Single agent treatment.~Part 2-Expansion Cohort: The RP2D of MCLA-117 is given weekly after initial ramp-up dosing steps. Each Cycle is 28 days. Single agent treatment."
88905673|NCT05840601|Active Comparator|Comparator|The comparator device is the same commercially available hand that is being used for the Pointdexter arm, except that it will be unmodified (i.e., it will have its usual index finger attached instead of the Pointdexter finger).
88905674|NCT05840588|Experimental|Probiotic Bifidobacterium breve PRL2020|Patients in this arm will receive Probiotic Bifidobacterium breve PRL2020 (20 billion CFU) 2 sticks/day for 10 days in addition to the antibiotic Amoxicillin or Amoxicillin/Clavulanic acid.
89424110|NCT02784288|Experimental|Neck Dissection|Patients undergo up-front neck dissection of the cervical lymph nodes to determine stratification into one of three standard-of-care treatment groups: transoral surgery of the primary site, radiation or chemoradiation.
89424111|NCT03040180|Experimental|Electrochemotherapy with bleomycin|"Systemic injection of bleomycin followed by electroporation of the primary tumor. Bleomycin administration: 15.000 IU/m2 BSA.~BSA by Du Bois formula."
89424112|NCT03040180|No Intervention|Standard care|Standard care
89424113|NCT04454606|Experimental|Fit test|All the subjects will be tested for fit test
89424114|NCT02235246|Experimental|normal saline|
89424115|NCT02235246|Active Comparator|magnesium sulfate|
89195655|NCT03823404|Placebo Comparator|Placebo BID|Placebo orally administered capsule, BID with water approximately 12 hours apart and no less than 6 hours apart
89195656|NCT00706706|Experimental|sunitinib|single agent sunitinib, single arm
89424116|NCT02135276|Experimental|End stage renal disease (ESRD) subjects|A single dose of intravenous eravacycline (1.5 mg/kg) administered over 60 minutes
89424117|NCT02135276|Experimental|Normal healthy subjects|A single dose of intravenous eravacycline (1.5 mg/kg) administered over 60 minutes
89424118|NCT02235324|Experimental|Treatment (ziv-aflibercept, leucovorin calcium, fluorouracil)|"PHASE I:~Patients receive ziv-aflibercept IV over 1 hour on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity. At the time of progression, patients proceed to Phase II.~PHASE II:~Patients receive ziv-aflibercept IV over 1 hour, leucovorin calcium IV over 1 minute, and fluorouracil IV over 46 hours on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity."
89424119|NCT04843696|Experimental|NPV group|"The hospital-based maintenance NPV program includes NPV support, breathing training, and an educational program (relaxation techniques and a home pacing walking exercise) in daily clinical practice. The patients in the NPV group undergo the hospital-based NPV once per week in the maintenance program at least three times per month.~The patients received NPV with breathing training via a cuirass ventilator (cuirass diameter 21 cm or 34 cm, Dima Italia Srl.,Bologna, Italy) for 60 min, once per week.~Breathing training consisted of breathing techniques (pursued-lipped, controlled, and diaphragmatic breathing)."
89424120|NCT04843696|Active Comparator|Control group|"Control group receives breathing training, and an educational program (relaxation techniques and a home pacing walking exercise) in daily clinical practice.~Breathing training consisted of breathing techniques (pursued-lipped, controlled, and diaphragmatic breathing)."
88814487|NCT04356872|Experimental|treatment|The patients with metastatic and unresectable soft tissue sarcoma including undifferentiated pleomorphic sarcoma, synovial sarcoma, de-differentiated liposarcoma and myxoid liposarcoma will be enrolled and given sintilimab (PD-1) , doxorubicin and doxorubicin every three weeks for 6 cycles followed by sintilimab mono therapy till disease progression. The first enrolled six patients is safety run-in step for observing drug-limiting toxicity (DLTs). If the combinatory treatment is intolerable, the doses of chemo regimens will be reduced according to drug instruction.
88814488|NCT02487108|Placebo Comparator|Placebo|Participants will receive placebo matching to TV46763 (hydrocodone bitartrate/acetaminophen) immediate release (IR) tablets for 48 hours (every 4 to 6 hours) on Days 1, 2, and 3 during the inpatient treatment period. Participants will continue to take the same treatment daily, every 4 to 6 hours after discharge on Day 3, over a 10-day (±1 day) outpatient treatment period.
88814489|NCT02487108|Experimental|TV-46763 5.0 mg/325 mg|Participants will receive TV46763 (hydrocodone bitartrate/acetaminophen) 5.0 mg/325 mg IR tablets for 48 hours (every 4 to 6 hours) on Days 1, 2, and 3 during the inpatient treatment period. Participants will continue to take the same treatment daily, every 4 to 6 hours after discharge on Day 3, over a 10-day (±1 day) outpatient treatment period.
88814490|NCT02487108|Experimental|TV-46763 7.5 mg/325 mg|Participants will receive TV46763 (hydrocodone bitartrate/acetaminophen) 7.5 mg/325 mg IR tablets for 48 hours (every 4 to 6 hours) on Days 1, 2, and 3 during the inpatient treatment period. Participants will continue to take the same treatment daily, every 4 to 6 hours after discharge on Day 3, over a 10-day (±1 day) outpatient treatment period.
88814491|NCT02487108|Experimental|TV-46763 10.0 mg/325 mg|Participants will receive TV46763 (hydrocodone bitartrate/acetaminophen) 10.0 mg/325 mg IR tablets for 48 hours (every 4 to 6 hours) on Days 1, 2, and 3 during the inpatient treatment period. Participants will continue to take the same treatment daily, every 4 to 6 hours after discharge on Day 3, over a 10-day (±1 day) outpatient treatment period.
88814492|NCT02982356|Other|Fetal Selective Reduction Technology|Potassium chloride fetal heart injection in the dichorial twins with abnormal chromosome and structure
88814493|NCT02982356|No Intervention|control group|normal dichorial twins without any intervention
88814494|NCT04360382||Enhanced recovery|"Part I: Preoperative evaluation and preparation:~Part II: Postoperative daily intervention:~Part III: Expected daily outcome :~Phase three: Implementing enhanced recovery program:~The established pathway will implement on the study group by researcher from admission till discharge as conventional care group assessment in phase one.~Phase four: Evaluating enhanced recovery program outcomes:~The efficacy of enhanced recovery program will be determined by comparing outcomes for patients of both control and study groups"
88814495|NCT04360382||Regular care|usual care for all cases of cesarean section at our hospital.
88814496|NCT02487030|Experimental|LDV/SOF 8 wk TN (Cohort 1, Group 1)|LDV/SOF for 8 weeks (treatment-naive (TN))
88814497|NCT02487030|Experimental|LDV/SOF+RBV 8 wk TN (Cohort 1, Group 2)|LDV/SOF+RBV for 8 weeks (treatment-naive)
88814498|NCT02487030|Experimental|LDV/SOF 12 wk TN (Cohort 1, Group 3)|LDV/SOF for 12 weeks (treatment-naive)
89424121|NCT01230242|Experimental|Mirena IUD Placement Immediately Post-delivery|Participants enrolling in this study agree to have the IUD placed immediately post-delivery versus waiting the standard 6 weeks.
89424122|NCT02263248|Experimental|venlafaxine XR plus buprenorphine|Drug Intervention: venlafaxine XR plus buprenorphine Dosage varies. Subject remains on antidepressant throughout the 32 week study. Will be randomized to buprenorphine or placebo for up to 16 weeks.
89424123|NCT02263248|Placebo Comparator|venlafaxine XR plus placebo|Drug Intervention: venlafaxine XR plus placebo Dosage varies . Subject remains on antidepressant throughout the 32 weeks study. Will be randomized to buprenorphine or placebo for up to 16 weeks
89424124|NCT04838860|Active Comparator|Parallel Arm of iMCD Patients|Enrolling in Stage 1a of this study in parallel will be up to 6 patients each with siltuximab-relapsed or refractory IL-6-driven iMCD patients, respectively, who will undergo intrapatient dose escalation of siltuximab beginning with 22 mg/kg q3w, then possibly dose escalating to 33 mg/kg q3w then 44 mg/kg q3w if clinically indicated in the absence of DLT. The justifications for escalating siltuximab doses up to 44 mg/kg q3w will be based on intrapatient dose escalation and DLT assessments as described below.
88905675|NCT05840588|Active Comparator|Control|Patients in this arm will receive only antibiotic Amoxicillin or Amoxicillin/Clavulanic acid.
88905676|NCT05840575||Solid tumor patients|Patients diagnosed with solid tumor cancers
89195657|NCT00895960|Experimental|Dasatinib Plus RT + TMZ|Dasatinib (Sprycel) with Radiotherapy (RT) and 6 weeks of concomitant Temozolomide (TMZ)
88905677|NCT05840575||Haematological patients|Patients diagnosed with haematological cancers
89195658|NCT00737828|Active Comparator|A|Control - Standard Perioperative Pathway, clinician decides post-operative care environment (usual care)
89195659|NCT00737828|Experimental|B|Intervention - Perioperative care pathway guided by CPX Results i.e.anaerobic threshold & ventilatory equivalents
89195660|NCT00896194|Active Comparator|1: Standard Behavioral Treatment (SBT)|This group receives standard behavioral treatment for weight loss as described below.
89195661|NCT00896194|Experimental|2: Modified SBT + Self-Efficacy|This group receives modified SBT with an additional self-efficacy component as described below.
89195662|NCT04035460|Active Comparator|Helmet oxygenation group|Patients randomized to helmet NIPPV will receive noninvasive oxygenation and ventilation via a latex free helmet
89424125|NCT04838860|Active Comparator|Parallel Arm of TAFRO-iMCD Patients|Enrolling in Stage 1b of this study in parallel will be up to 6 patients each with siltuximab-relapsed or refractory IL-6-driven TAFRO-iMCD patients, respectively, who will undergo intrapatient dose escalation of siltuximab beginning with 22 mg/kg q3w, then possibly dose escalating to 33 mg/kg q3w then 44 mg/kg q3w if clinically indicated in the absence of DLT. The justifications for escalating siltuximab doses up to 44 mg/kg q3w will be based on intrapatient dose escalation and DLT assessments as described below.
89424126|NCT04839016|Experimental|Treatment group A|
89424127|NCT04839016|Placebo Comparator|Treatment group B|
89424128|NCT05166278|Experimental|EXPER|Deescalation training.
88905678|NCT05840536|Experimental|Combination Diuretic Therapy|Patients will receive lasix infusion starting at 5mg/hr along with a bolus dose of chlorothiazide 250mg at the initiation of the protocol. The lasix infusion can be titrated to 10mg after 12hrs based on volume of diuresis. This arm will also receive 250mg bolus doses of chlorothiazide every 12hrs for the duration of the study.
88905679|NCT05840536|Active Comparator|Monotherapy Diuretic|Patients will receive furosemide infusion at 5mg/hr along with an initial bolus dose of furosemide equal to twice their home oral dose. The furosemide infusion can be increased to 10mg/hr after 12hrs based on urine output. This arm will receive bolus doses of furosemide every 12hrs equal to twice their home oral dose until completion of the protocol.
88905680|NCT05840523|Experimental|Proprioceptive Neuromuscular Facilitation (PNF) Exercise Group|The PNF group performed flexion-abduction-internal rotation and extension-abduction-internal rotation patterns as 15 repetitions, 2 sets. The metronome was used to fix the construction speed of the exercises (50bpm). PNF exercises were performed with EB at a metronome speed of 50bpm at a ratio of 1:2 sec. In other words, while transition from the antagonist to agonist pattern in 3 clicks, there was return from agonist to antagonist in 6 clicks.
88905681|NCT05840523|Experimental|Range Of Motion (ROM) Exercise Group|The ROM group performed hip flexion abduction, neutral abduction and extension abduction exercises with an EB at 50bpm metronome speed in 3 sets of 10 repetitions. In both groups, 30 seconds of rest was given between exercises.
88905682|NCT05840523|No Intervention|Control Group|No exercise practice was done
88905683|NCT05840497|Experimental|Resistance exercise|
88905684|NCT05840497|No Intervention|Control Group|Standard control and usual recommendations.
89424129|NCT05166278|No Intervention|CONTR|Management of aggressive behaviour as usual.
89424130|NCT03037918|Experimental|Treatment Group|"Participants will receive 2 x 65mL doses of Yakult light per day, for 28 days.~Participants will consume a high-fat (65% of kilocalories) high-calorie (150% of requirements) diet from day 21 to day 28."
89424131|NCT03037918|No Intervention|Control Group|Participants will consume a high-fat (65% of kilocalories) high-calorie (150% of requirements) diet from day 21 to day 28.
89424132|NCT04324554||MRI of the right knee|An MRI of the right knee will be done to define the role of imaging in the diagnosis of early femoro-patellar osteoarthritis.
89424133|NCT04838392|Experimental|CGM System|Blood draw and glucose challenge will be performed to evaluate performance of CGM system compared to reference measurement during in in-clinic visits.
89424134|NCT04454294|Experimental|Control|The first method; There is no application in maintaining the drain opening, but if there are necessary medical indications such as clot formation, blood accumulation in the drainage connections, lack of drainage, this group is intervened by milking method. In our study, this group will be taken as a control group, there will be a situation that requires intervention in the first 6 hours, and if the milking method is used, it will be excluded from the sample.
89424135|NCT04454294|Experimental|Experimental Group (Absorption Group)|The second method used to maintain the drain opening is the suction method. In this study, this group will be taken as the first experimental group. The suction method is a continuous use until the patient's drainage requirement and the physician's request is terminated by ensuring that the pressure is between 5 and 15 kPa (kilopascals) or 10-20 cm H20 after the appropriate negative pressure tracking system of the patient, who is accepted with intensive care under water drainage system, is established. system.
89424136|NCT04454294|Experimental|Experimental Group (Milking Group)|The third method is milking. In our study, this group will be taken as the 2nd experimental group. In the milking method, the process starts from the area close to the drain entry point. The latex tube is folded into 12 cm long pieces and gripped with two hands. The nurse repeats the process 3 times by compressing the parts gripped by the hand. This process is then used at intervals every hour to repeat the distal part.
89424137|NCT02782806|Experimental|Test group|All subjects are enrolled into the test group and receive Masimo Rad-67 Pulse Oximeter for measurement of hemoglobin.
89424138|NCT05389358|Experimental|Intervention|"The Asiphephe (meaning Let us stay safe) intervention is a problem-solving therapy manual delivered in a one-on-one setting by lay health workers during routine antenatal care. Lay health workers are already employed by the Department of Health and are trained in-service (30 hours) and receive monthly supervision (total of approximately 6 one-on-one hours; 15 group hours). Asiphephe includes illustrated job aids, participant workbook, intervention checklist, and an intervention manual. The model is informed by problem-solving therapy (Lund, 2018), trauma-informed coping (Sikkema, 2018) and safety planning (Garcia-Moreno, forthcoming) and was piloted with 12 health workers with input from 3 global mental health experts."
89424139|NCT05389358|Active Comparator|Enhanced standard of care|The enhanced standard of care condition will entail a clinic-wide training (5 hours) on IPV, mental health, and HIV care in order to sensitize staff to the nature of the research. The clinic will receive access to established referral network to which participants can gain additional help with violence exposure or mental ill health. Participants in this arm will also be observed for adverse events and social harms, with referrals made appropriately by study staff.
89424140|NCT04853680|Experimental|Treatment|Use of Anti-adhesion barrier on the thyroidectomy space. After the thyroidectomy, anti-adhesion barrier will be applied on the thyroidectomy space, around the trachea, cricothyroid muscle and platysma muscle before the closure of surgical wound.
88814499|NCT02487030|Experimental|LDV/SOF+RBV 12 wk TN (Cohort 1, Group 4)|LDV/SOF+RBV for 12 weeks (treatment-naive)
88814500|NCT02487030|Experimental|LDV/SOF+RBV 12 wk TE (Cohort 2)|Treatment-experienced (TE) participants who completed treatment in Gilead sponsored study GS-US-334-0138 or in Cohort 1 of this study and did not achieve SVR12 will receive LDV/SOF+RBV for 12 weeks.
88814501|NCT02487030|Experimental|LDV/SOF 12 wk TE (Cohort 3, Group 1)|LDV/SOF for 12 weeks (treatment-experienced)
88814502|NCT02487030|Experimental|LDV/SOF+RBV 12 wk TE (Cohort 3, Group 2)|LDV/SOF+RBV for 12 weeks (treatment-experienced)
88814503|NCT04360148|Experimental|Very-low-calorie-ketogenic-diet|Very-low-calorie-ketogenic-diet (VLCKD) for 12 weeks; hypocaloric-balanced-diet (HBD)
88814504|NCT04360148|Active Comparator|Hypocaloric-balanced-diet|Hypocaloric-balanced-diet (HBD)
88814505|NCT02486952||Diffuse Large B-Cell Lymphoma (DLBCL)|Participants, who were not treated previously for DLBCL, will receive rituximab (MabThera) in combination with Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone (CHOP) or CHOP-like chemotherapy at the treating physician's discretion and according to package labeling, within approved indication and local approval status of respective drugs. Participants will be followed up for safety and efficacy in accordance with routine practice until progression of disease, unacceptable toxicity, withdrawal of consent or death from any reason.
88814506|NCT02486796|Active Comparator|Immediate and Continuous Dosing|Subjects will be dosed with Reishi mushroom extract, Coenzyme Q10 and Melatonin beginning with Cycle 1 Day 1 of their prescribed neoadjuvant chemotherapy.
88814507|NCT02486796|Active Comparator|Delayed Dosing|Subjects will be dosed with Reishi mushroom extract, Coenzyme Q10 and Melatonin beginning with Cycle 3 Day 1 of their prescribed neoadjuvant chemotherapy.
88814508|NCT02459262|Active Comparator|GBS-NN Vaccine|GBS-NN vaccine administered either adsorbed to Alhydrogel® or alone.
88814509|NCT02459262|Placebo Comparator|Sterile dilution buffer with Alhydrogel|The placebo will contain either Alhydrogel® or buffer alone.
88814510|NCT01598831|Active Comparator|ART-123|
88814511|NCT01598831|Placebo Comparator|Placebo|
88814512|NCT00841685|Experimental|1|Goldlock
88814513|NCT00841685|Active Comparator|2|Visicoil smallest size
88814514|NCT00841685|Active Comparator|3|Visicoil larger size
88814515|NCT00841685|Active Comparator|4|Bard goldmarker smallest size
88814516|NCT00841685|Active Comparator|5|Bard goldmarker larger size
88814517|NCT00620477|Experimental|1|injection in the knee joint with 20 ml of chirocaine 0.125%
88814518|NCT00620477|Placebo Comparator|2|injection in the knee joint with 20 ml of physiological fluid
88814519|NCT01640327|Experimental|TIVf|
88814520|NCT01641653|Placebo Comparator|placebo|half of the patients will receive placebo (normal saline 2cc/) prior to entering the OR
88814521|NCT01641653|Active Comparator|Midazolam|half of the patients will receive Midazolam 1-2.5mg prior to entering the OR
89424141|NCT04853680|No Intervention|Control|No use of anti-adhesion barrier. After the thyroidectomy, don't use the anti-adhesion barrier before the wound closure.
88905685|NCT05840458||PENG Block|Patients will be submitted to PENG block intervention guiding by ultrasound.
88905686|NCT05840445|Placebo Comparator|Onabotulinum Group|This group received an intramuscular application of onabotulinum toxin-A in the upper facial third.
88905687|NCT05840445|Active Comparator|Prabotulinum Group|This group received an intramuscular application of prabotulinum toxin-A in the upper facial third.
88905688|NCT05840419||Airseal group (A)|Patients operated with Airseal
88905689|NCT05840419||Standard group (S)|Patients operated with standard insufflation
89424142|NCT04853524|Experimental|Bictegravir (BIC) plus Emtricitabine (FTC) plus Tenofovir Alafenamide (TAF) plus JNJ-56136379|Participants will receive a single oral dose of the combination of BIC plus FTC plus TAF tablet on Day 1. Multiple oral doses of JNJ-56136379 once daily on Day 6 to Day 24. A single oral dose of the combination of BIC plus FTC plus TAF tablet on Day 20.
89424143|NCT04853134|Placebo Comparator|Standard Care|Standard of care as determined by the PI
89424144|NCT04853134|Active Comparator|Proxalutamide + Standard Care|Proxalutamide + standard of care as determined by the PI
88905690|NCT05840406|Active Comparator|Group SA|No TAP block applied.
88905691|NCT05840406|Experimental|Group L|Ultrasound-guided bilateral TAP block (in-plane technique) will be performed in this group. Levobupivacaine 0.25 % 20 ml will be administered in the block on each side.
88905692|NCT05840406|Experimental|Group D|Ultrasound-guided bilateral TAP block (in-plane technique) will be performed in this group. Levobupivacaine 0.25 % 20 ml + dexmedetomidine 0,5 μg/kg will be administered in the block on each side.
88905693|NCT05840393|Experimental|Intervention Group: Discharge training based on the Roy adaptation model|Oncologic palliative care patients and caregivers in this group will receive discharge training based on the Roy adaptation model.
88905694|NCT05840393|No Intervention|Control Group: Standard discharge training|Oncologic palliative care patients and caregivers in this group will not receive any training other than the discharge training routinely applied in the clinic.
88905695|NCT05840341|Experimental|Experimental group|QingyiHuaji optimized formula combined with standard treatment
88905696|NCT05840341|Placebo Comparator|Placebo group|placebo combined with standard treatment
88905697|NCT05840328|Placebo Comparator|plan group|bupivacaine will be administered epidurally as a loading dose then epidural continuous infusion with 0.125 % bupivacaine at rate 10 ml will be a maintainance for analgesia .IV placebo (normal saline) infusion will be connected to each patient at a rate of 10 ml \hr.
89424145|NCT05389202|Experimental|Patients benefitting from a perfusion CT scan before embolization|Prostatic perfusion parameters seem to be correlated with the effectiveness of embolization. Studying these prostatic perfusion parameters in perfusion CT and evaluating the prostatic Iodine load in dual energy CT will make it possible to better select responder patients.
88905698|NCT05840328|Active Comparator|epidural group|10 ml of 0.125 % buoivacaine with 0.5 µg\ml dexmetomidine as a loading dose then continuous epidural infusion of 0.125% bupivacaine with 0.5µ/ml dexmetomidine at a rate of 10 ml\hr will be used as maintainance . IV placebo (normal saline) infusion will be connected to each patient at a rate of 10 ml\hr
88905699|NCT05840328|Active Comparator|intravenous group|continuous intravenous dexmetomidine infusion at rate of 0.5 µg / kg / hour in addition to same epidural infusion of 0.125% bupivacaine
89424146|NCT04852900|Experimental|Decompression with 30%|Decompression with 30% and mobilization
89424147|NCT04852900|Experimental|Decompression with 40%|Decompression with 40% and mobilization
89424148|NCT04852900|Experimental|Decompression with 50%|Decompression with 50% and mobilization
89424149|NCT05164328||Athletes|"Males and females aged 14-23 years old~Athletes competing in endurance sports at national or international level for at least 2 years. Sports include:~Triathlon~Cycling~Distance running (≥ 1500 meters)~Rowing~Swimming"
89424150|NCT05164328||Non-athletes|"Males and females aged 14-23 years old~Non athletes engaged in < 3 hours per week of physical activity"
89424151|NCT04852744|Other|Borderline girls with PTSD|"female~Age between 13 and 17 years inclusive~Diagnosis of borderline personality disorder according to the criteria of the Diagnostic and Statistical Manual for mental disorders, fifth edition (DSM-5; American Psychiatric Association, 2013; SIDP-IV)~Post-traumatic stress disorder according to DSM-5 criteria (American Psychiatric Association, 2013; K-SADS-PL)~Level of general psychopathology compatible with participation in the study (score> 20 on the CGA-S)~Oral and written comprehension of the French language~Affiliation to the social security scheme~Informed consent signed by the legal representatives holding the exercise of parental authority and the adolescent herself"
89424152|NCT04852744|Other|Borderline girls without PTSD|"female~Age between 13 and 17 years inclusive~Diagnosis of borderline personality disorder according to the criteria of the Diagnostic and Statistical Manual for mental disorders, fifth edition (DSM-5; American Psychiatric Association, 2013; SIDP-IV)~Level of general psychopathology compatible with participation in the study (score> 20 on the CGA-S)~Oral and written comprehension of the French language~Affiliation to the social security scheme~Informed consent signed by the legal representatives holding the exercise of parental authority and the adolescent herself"
89424153|NCT04852744|Other|Healthy controls|"female~Age between 13 and 17 years inclusive~Absence of mental disorder according to DSM-5 (American Psychiatric Association, 2013 ; K-SADS-PL et SIDP-IV)~Oral and written comprehension of the French language~Affiliation to the social security scheme~Informed consent signed by the legal representatives holding the exercise of parental authority and the adolescent herself"
89424154|NCT03040882|Experimental|cotton sock|
89424155|NCT03040882|Active Comparator|Elastic Compression Wraps|
89424156|NCT04843540|Experimental|CTP-543|On Day 1, participants will receive a single oral dose of CTP-543. Following a washout period on Days 2 and 3, participants will receive a single oral dose of rifampin on Day 4 through Day 15, with a single oral dose of CTP-543 being co-administered on Day 14.
89424157|NCT05380622||Without ICA or deferral of PCI after ICA group|Patients didn't undergo invasive coronary angiography (ICA) or with a vessel determined to defer revascularization.
89424158|NCT05380622||PCI group|Patients with a vessel that undergo percutaneous coronary intervention (PCI)
89424159|NCT04838548|Experimental|MRG003|On the first day of every 3 weeks, MRG003 will be administered via intravenous infusion at 2.0 mg/kg calculated based on the actual body weight
89424160|NCT05379062|Experimental|Active Singing Group|Active singing in a group
89424161|NCT05379062|Experimental|Receptive Music Group|Receptive music/auditive group
89424162|NCT05379062|No Intervention|Control Group|Treatment as usual
89424163|NCT04838158|Active Comparator|Intervention group|Those cases who underwent operative treatment and isokinetics evaluation.
89424164|NCT04838158|Other|Control group|Those who were control group of healthy subjects to compare to normative data
89424165|NCT05216198||TIA patients|Diagnostic of TIA by the exams performed in the emergencies of CHUGA.
89424166|NCT04852510|Active Comparator|Group A|Metformin 500 mg three times daily (5) with meals for 6 months (Metfor® 500 mg, Metformin hydrochloride tablets. TABUK Pharmaceutical. KSA).
89424167|NCT04852510|Active Comparator|Group B|A combination of Metformin 500 mg three times daily with meals (Metfor® 500 mg, Metformin hydrochloride tablets. TABUK Pharmaceutical. KSA) and Thymoquinone (TQ) in the form of Black Cumin oil (Cumin Mar® Black cumin oil 500 mg soft gel capsules, MARNYS. Spain) three times daily before meals for 6 months.
89424168|NCT05204810|Experimental|Night_1dosis|"anticoagulation at dialysis start~blood sampling 5min after start dosis, and at 1h, 4h and 8h after dialysis start~microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
89424169|NCT05204810|Experimental|Night_2doses|"anticoagulation split over dialysis start and halfway dialysis (after 4h)~blood sampling 5min after start dosis, and at 1h, 4h (1 sample before and 1 sample after the extra anticoagulant dosis) and 8h after dialysis start~microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
88905700|NCT05840315|Experimental|Phase 1|"First subtrial (participants 1-10):~Sit-to-stand-to-sit training"
88905701|NCT05840315|Experimental|Phase 2|"Second subtrial (participants 11-20):~Sit-to-stand and leg press training."
89424170|NCT04843384|Experimental|Reiki|"One of these methods, reiki, has roots which go back thousands of years. Modern reiki was rediscovered and introduced by Mikao Usui in Japan at the end of the 19th century. Reiki means universal life energy . The aim in reiki, in which healing energy is purposefully directed, is to provide restoration of unbalanced energy layers which might be the source of physical, emotional or psychological pain."
89424171|NCT04843384|Sham Comparator|Sham reiki|With the Sham Reiki patients, a nurse without reiki training performed Sham Reiki randomly for approximately, following a protocol which did not include the body's energy centers or chakras.
89424172|NCT04843384|No Intervention|Control|The control group received no intervention beyond routine care.
89424173|NCT04842916||Gastric cancer patients|gastric cancer patients with histologically confirmed, potentially resectable adenocarcinoma of the stomach or the gastroesophageal junction receiving the standard of medical care in Europe
89424174|NCT05163704|Other|MRI Dexmedetomidine sedation|"Drug used: Dexmedetomidine. Given in increments of 0.2 ml at the time with atomizer (MAD Nasal™, Wayne Pennsylvania). Administered by radiology staff.~Dose 1 of nasal dexmedetomidine: 4 mcg/kg max 200 mcg Dose 2 of nasal dexmedetomidine: 2 mcg/kg max 100 mcg"
88905702|NCT05840315|Experimental|Phase 3|"Third subtrial (participants 21-30):~Sit-to-stand, leg press training and hip abduction training."
89424175|NCT03037840||cancer patients|Low intensity amplitude-modulated RF EMFs
89424176|NCT03037840||healthy participators|Low intensity amplitude-modulated RF EMFs
89424177|NCT04838002|Active Comparator|Focus ESWT|
89424178|NCT04838002|Active Comparator|Radial ESWT|
89424179|NCT04838002|Sham Comparator|Sham ESWT|
89424180|NCT03130556|Experimental|Glasdegib BE and Food|Subjects receive 100 mg single dose of ICH glasdegib under fasted condition with washout and then 100 mg single dose of Phase 2 tablet under fasted condition with washout in a randomized fashion. Finally subjects receive a 100 mg single dose ICH tablet after a high fat, high calorie meal.
89424181|NCT03130556|Experimental|Glasdegib BE and PPI Effect|Subjects receive 100 mg single dose of ICH glasdegib under fasted condition with washout and then 100 mg single dose of Phase 2 tablet under fasted condition with washout in a randomized fashion. Finally subjects receive a 100 mg single dose ICH tablet in the fasted state after repeated daily dosing with rabeprazole.
88905703|NCT05840172|Experimental|Test condom A (NRL condom with 5% benzocaine paste)|Following randomization, each subject will be given one set of 8 condoms as per randomisation schedule. After reporting at least 4 duration records (from vaginal entry to ejaculation), subjects will return to the clinical site for collection of their next set of condoms.
89424182|NCT04838080|Experimental|Low dose vaccine|Inactivated COVID-19 Vaccine 4 µg/0.5 ml
89424183|NCT04838080|Experimental|High Dose Vaccine|Inactivated COVID-19 Vaccine 6 µg/0.5 ml
89424184|NCT04838080|Placebo Comparator|Placebo|0.9 % NaCl
89424185|NCT04842838|Experimental|DCB strategy|
89424186|NCT04842838|Active Comparator|DES strategy|
89424187|NCT03877016|Active Comparator|TENS Eco2|TENS Eco2 is the classical device in patients with chronic neuropathic pain
89424188|NCT03877016|Experimental|actiTENS|ActiTENS is a new TENS device, that seems less cotraining.
89424189|NCT03037606|Experimental|Rabelis DDR 50 mg Capsules and 1 placebo tablet|Placebo as comparator group is not used. Since study is double-blind, one placebo capsule and tablet is added to treatment groups in order to remove the discrepancy between investigational products.
89424190|NCT03037606|Active Comparator|Pariet 20 mg Enteric Coated Tablets and 1 placebo capsule|Placebo as comparator group is not used. Since study is double-blind, one placebo capsule and tablet is added to treatment groups in order to remove the discrepancy between investigational products.
89424191|NCT05391152|Experimental|robotic-arm assisted modified kinematic alignment total knee replacement|The patients in this group receive robotic-arm assisted total knee replacement. And these patients achieve modified kinematic alignment.
89424192|NCT05391152|Active Comparator|traditional manual total knee replacement|The patients in this group receive traditional manual total knee replacement. And these patients achieve traditional alignment.
89424193|NCT03821090||cases|"Eighty rheumatoid arthritis patients fulfilling American College of Rheumatology (ACR) 2010 classification criteria, all of them will be subjected to~History including disease duration , course and associated diseases~Clinical examination with specific joint examination~RA disease activity will be evaluated by a 28- joint DAS (DAS28). 4-12-lead ECG~5-Echocardiography 6-Carotid intima media thickness using carotid doppler 7-Venous blood will be withdrawn to do the following laboratory tests~Complete Blood Count(CBC)~Erythrocyte Sedimentation Rate (ESR) &C Reactive Protein(CRP)~Rheumatoid Factor (RF)& anti cyclic citrullinated peptide (Anti-CCP)~Urine analysis , Urea and creatinine ,~Uric acid level~Lipogram~HA1C~TNF α~hs-cTnI"
88814522|NCT01600703|Experimental|Sitagliptin|sitagliptin, 100mg, oral, single dose
88814523|NCT01600703|Placebo Comparator|Placebo|Placebo, oral, single dose
88814524|NCT01643213|Experimental|BSC approved SCS Trial Therapy w/ OMG|Precision Plus SCS Trial Therapy w/ OMG. Spinal cord stimulation (SCS) trial therapy activated using FDA-approved BSC SCS trial systems with the Observational Mechanical Gateway(OMG) to connect to non-BSC lead(s)
88814525|NCT01643213|Active Comparator|Non Boston Scientific SCS Trial Therapy|Non Boston Scientific SCS Trial Therapy. Spinal cord stimulation (SCS) trial therapy activated using FDA-approved non BSC SCS system that the subject was implanted with, and received SCS therapy from, prior to study enrollment
88814526|NCT01644695||Candidate for BARS procedure.|The subjects selected for this trial were over 18 years of age with an appropriate complex, incisional hernia. These patients were consented and treated with the BARS(bony anchoring reinforcement system)procedure.
88814527|NCT01602731|Experimental|Automated Medication Dispensing Device|Subjects with <88% medication adherence, determined by 30-day pillcount, and with cognitive impairment (determined by Saint Louis University Mental Status score) proceeded to AMDD portion of study.
88814528|NCT02450526|Experimental|AbobotulinumtoxinA|Dysport, 50 Units, divided into five injections into the glabellar area. Administered in double blind fashion at cycle 1 followed by up to 4 cycles Dysport, 50 Units administered with an interval period depending on response, no less than 12 weeks between each treatment cycle.
88814529|NCT02450526|Active Comparator|OnabotulinumtoxinA|Botox will be administered in treatment cycle 1 only. On Day 1, 20 Units, divided into five injections into the glabellar area.
88814530|NCT02450526|Placebo Comparator|AbobotulinumtoxinA Placebo|Dysport placebo will be administered in treatment cycle 1 only. On Day 1, 50 Units, divided into five injections into the glabellar area.
88814531|NCT02450526|Placebo Comparator|OnabotulinumtoxinA Placebo|Botox placebo will be administered in treatment cycle 1 only. On Day 1, 20 Units, divided into five injections into the glabellar area.
88814532|NCT01604291||Cohort|
88905704|NCT05840172|Experimental|Test condom B (NRL condom with 3% benzocaine paste)|Following randomization, each subject will be given one set of 8 condoms as per randomisation schedule. After reporting at least 4 duration records (from vaginal entry to ejaculation), subjects will return to the clinical site for collection of their next set of condoms.
88905705|NCT05840172|Placebo Comparator|Control NRL condom|Following randomization, each subject will be given one set of 8 condoms as per randomisation schedule. After reporting at least 4 duration records (from vaginal entry to ejaculation), subjects will return to the clinical site for collection of their next set of condoms.
89424194|NCT03821090||control|"Eighty healthy subjects age and sex matched will be included , all of them will be subjected to~History~Clinical examination . 3-12-lead ECG~4-Echocardiography 5-Carotid intima media thickness using carotid doppler 6-Venous blood will be withdrawn to do the following laboratory tests~Complete Blood Count (CBC)~ESR & CRP~RF& Anti-CCP~Urine analysis , Urea and creatinine~Uric acid level~Lipogram~HA1C~TNF α~hs-cTnI"
88905706|NCT05840146|Experimental|Kinesiotaping group|Kinesiotape was applied to the lateral side of the affected hip for gluteus medius muscle. Each patient was positioned lying down with the affected side up, and two I-strips were used.
88905707|NCT05840146|Sham Comparator|Sham taping group|Sham tape was applied with a single I-strip without tension in tape or muscle stretch. After paper backing was completely removed, tape was essentially placed on the skin across the lateral side of the affected hip.
88905708|NCT05840133||HBV-associated HCC group|The age and gender of patients are not limited. The patient was finally diagnosed as HBV-associated HCC by imaging examination and pathology.
89424195|NCT04851574||Group I with dose of Sugammadex of 0.5 Mg/kg|After general anesthesia children received one dose of 0.5 Mg/kg of Sugammadex to reverse neuromuscular blockade.
89424196|NCT04851574||Group II with dose of Sugammadex of 1.0 Mg/kg|After general anesthesia children received one dose of 1.0 Mg/kg of Sugammadex to reverse neuromuscular blockade.
88905709|NCT05840133||negative control group|The age and sex of this group were matched with that of HBV-associated HCC patient group. The patient did not have any tumor but had HBV infection. The functions of the renal and heart were normal.
88905710|NCT05840133||Healthy control group|The age and sex of the healthy control group were matched with that of HBV-associated HCC patient group. There was no tumor in the liver or other parts of the body, and no tumor in the blood system. The healthy control group did not have any liver benign diseases. There are no inflammatory diseases in other parts of the body. The functions of the liver, kidney, and heart were normal.
88905711|NCT05840094|Experimental|PET/CT+MR+EBUS|Subjects will receive 18F-FDG PET/CT and MR STIR sequence combined with EBUS-TBNA, to diagnose the N-stage of NSCLC
88905712|NCT05840094|Experimental|PET/CT+EBUS|Subjects will receive 18F-FDG PET/CT and EBUS-TBNA, to diagnose the N-stage of NSCLC
88905713|NCT05840094|Experimental|MR+EBUS|Subjects will receive 18F-FDG PET/CT and EBUS-TBNA, to diagnose the N-stage of NSCLC
88905714|NCT05840081|Experimental|Full-fat milk beverage|Beverage made with full-fat milk
89424197|NCT04851574||Group III with dose of Sugammadex of 2.0 Mg/kg|After general anesthesia children received one dose of 2.0 Mg/kg of Sugammadex to reverse neuromuscular blockade.
89424198|NCT04842994|Experimental|IONM arm|Intra operative nerve monitoring (IONM) is a technique of monitoring the RLN during surgery, to help identification and safe guarding of the nerve during total thyroidectomy as well as central compartment clearance (CCC). This is a well established technique with many centers in the world routinely using monitoring during surgery.
89424199|NCT04842994|No Intervention|Visual Identification arm|Patients randomized to this arm will undergo total thyroidectomy as per standard procedures with visual identification of the RLNs
89424200|NCT05165420||RV4941A arm|RV4941A study product is applied twice a day (morning and evening) on the face, neck and eye contour during the whole study.
89424201|NCT04842370|Experimental|Dose escalation and expansion of PHI-101|
89424202|NCT03037450|Other|Miniinvasive corneal neurotization|
89424203|NCT03037372|Experimental|ART-Atorvastatin adjunct therapy|ART, atorvastatin
89424204|NCT03037372|Experimental|ART-Rosuvastatin adjunct therapy|ART, rosuvastatin
88905715|NCT05840081|Experimental|Fat-free milk beverage|Beverage made with fat-free milk
88905716|NCT05840081|Experimental|Full-fat yogurt beverage|Beverage made with full-fat yogurt
89424205|NCT03037372|Experimental|ART-without statin adjunct therapy|ART, no statin
88905717|NCT05840081|Experimental|Fat-free yogurt beverage|Beverage made with fat-free yogurt
88905718|NCT05840029||Group A: Patients who will get neoadjuvant chemotherapy based on VATS finding.|Patients will be considered to receive neoadjuvant chemotherapy if there is residual intrathoracic disease
88905719|NCT05840029||Group B: Patients who will proceed into debulking surgery based on VATS finding.|Patients will be considered to be eligible for complete debulking, if VATS showed no intrathoracic tumor or if VATS achieves complete removal of tumor nodules through intraoperative frozen section histopathological examination.
88905720|NCT05840003|Experimental|Patients undergoing Ultra-Low-Dose scan plus conventional standard dose thoraco-abdominopelvic scan|All adult patients (except pregnant women) presenting to the imaging department of the Institut de Cancérologie du Gard for a thoraco-abdominopelvic scan as part of an oncology follow-up will under a standard-dose can as well as an ultra-low-dose scan.
89424206|NCT03037372|Experimental|Healthy-HIV-negative|Age-matched HIV-negative, healthy volunteers from the same community
89424207|NCT03037138|Other|Washed-out scale after using BFR profiling|Blood flow profiling will be used as intervention for washed-out dialysis patients
89530859|NCT02501369|Experimental|Self-directed Teen Triple P|"Self-directed Teen Triple P is a behaviourally based parenting intervention that parents follow at home using a workbook. It is based upon social learning theory principles and is used to help parents build upon their existing skills and information to practice positive parenting. Key skills promoted include: Increasing positive parent-teenager interactions, increase desirable behaviour, teach new behaviours and skills, and manage problem behaviour.~As this is a case series design participants will act as their own controls and so there are no other arms to the study."
88905721|NCT05839977|Experimental|Individual telerehabilitation group|20 patients with multiple sclerosis
88905722|NCT05839977|Active Comparator|Video based exercise group|20 patients with multiple sclerosis
88905723|NCT05839977|No Intervention|Control group|20 patients with multiple sclerosis
88905724|NCT05839964|Active Comparator|CHI-560: Total daily dose: 20 mg CBN|2 units (i.e., 2 gummies). Each gummy: 10 mg CBN
88905725|NCT05839964|Active Comparator|CHI-563: Total daily dose: 20 mg CBN + 10 mg CBD|2 units (i.e., 2 gummies). Each gummy: 10 mg CBN + 5 mg CBD
88905726|NCT05839964|Active Comparator|CHI-564: Total daily dose: 20 mg CBN + 20 mg CBD|2 units (i.e., 2 gummies). Each gummy: 10 mg CBN + 10 mg CBD
88905727|NCT05839964|Active Comparator|CHI-565: Total daily dose: 20 mg CBN + 100 mg CBD|2 units (i.e., 2 gummies). Each gummy: 10 mg CBN + 50 mg CBD
88905728|NCT05839964|Placebo Comparator|CHI-660: Placebo|2 units (i.e., 2 gummies). Each gummy: Placebo
88905729|NCT05839834||Cancer|Patients with new diagnosis of cancers
89424208|NCT04851418||Possible NSTE-ACS|All patients with a suspicion of non-ST-elevation acute coronary syndrome (NSTE-ACS) in the pre-hospital phase are eligible for inclusion. In all included patients, the POC cTn will be performed and the HEART-score will be calculated in the pre-hospital phase. Simultaneously, a venous blood sample will be drawn from the venous access site for later hs-cTn testing. Outcomes of both the POC cTn or the pre-hospital HEART-score will be blinded for the physicians at the emergency department (ED) and will not affect current treatment strategy. All patients with suspected NSTE-ACS will undergo hs-cTn testing and the HEART-score will also be calculated at the ED (T1, standard of care). Here, an additional venous blood sample will be drawn next to routine blood testing testing (T1).
89424209|NCT04851730|Experimental|Orthopedic Intervention|All subjects are receiving an orthopedic intervention that is specific to their presentation but made up of all intervention categories: Manual therapy, dry needling, deep breathing, stretching, strengthening, and progressive overload.
89424210|NCT03708068|Experimental|Early Exclusive Enteral Nutrition|"Feeds will start at least at 80% of reference daily fluid intake from day one of life.~Feeds will be advanced by 20-30 ml/kg per day on second day onwards until infant reaches full enteral feed."
89424211|NCT03708068|No Intervention|Conventional Enteral Nutrition|"Infants will be fed as per current Neonatal Intensive Care Unit feeding tables:~Infants with birth weight 1000-1500 g will be fed on 15-20 ml/kg human milk in day one. Feeds will be advanced by 15-20 ml/kg per day on second day onwards until infant reaches full enteral feeds.~Infants with birth weight >1500 g will be started on 20-30 ml/kg per day on day one. Feeds will be advanced by 20-30 ml/kg per day on second day onwards until infant reaches full enteral feeds."
89424212|NCT04842136||Myofascial Temporomandibular Disorder (TMD) with Sleep Bruxism (SB)|Patients with Myofascial TMD and with sleep bruxism with the diagnosis of regular or frequent teeth grinding sounds during the sleep, and one or more following clinical signs, such as jaw muscle pain or fatigue on waking up in the morning, temporal headache, hypertrophy of the masseter muscle, abnormal tooth wear, and/or jaw locking were included in the group.
88905730|NCT05839834||Non-cancer|Healthy participants
88905731|NCT05839821||PD patients|Patients with Parkinson's disease
88905732|NCT05839821||Healthy controls|Healthy older adults
88905733|NCT05839782||Re-PLM|Patient in which a new mitral valve repair is performed to treat failed mitral valve repair
88905734|NCT05839782||Re-SVM|Patient in which a mitral valve replacement is performed to treat failed mitral valve repair
88905735|NCT05839704|Experimental|Bilateral Erector Spinae Plane Block|Patients in this arm will receive standard anaesthesia as per our bariatric anaesthesia protocol. They will also receive preoperative ultrasound guided bilateral single shot erector spinae plane blocks at the level of the 8th transverse process.
88905736|NCT05839704|Active Comparator|Abdominal Wall Blocks|Patients in this arm will receive standard anaesthesia as per our bariatric anaesthesia protocol. They will also receive bilateral subcostal transversus abdominus plane blocks and a left sided serrratus plane block, postoperatively, while under general anaesthetic.
88905737|NCT05839613|Experimental|PG/TDM group|experimental group with PG/TDM analysis results avalaible
88905738|NCT05839613|Experimental|blinded group|experimental group with PG/TDM analysis results blinded
88905739|NCT05839587|Experimental|Robotic TAPP|Repair of primary unilateral and bilateral hernias with robotic technology
88905740|NCT05839587|Active Comparator|Laparoscopic TAPP|Repair of primary unilateral and bilateral hernias with laparoscopic repair
88905741|NCT05839548|Active Comparator|2% Mepivacaine with epinephrine 1:100,000.|Brand Name: 2% Medicaine with epinephrine 1:100,000.
88905742|NCT05839548|Experimental|4% Articaine with epinephrine 1:100,000|Brand Name: 4% Septanest with epinephrine 1:100,000.
88905743|NCT05839535|Active Comparator|BDJ + real tDCS|
88905744|NCT05839535|Active Comparator|Exercise + real tDCS|
88905745|NCT05839535|Active Comparator|BDJ + sham tDCS|
88905746|NCT05839535|Active Comparator|Exercise + sham tDCS|
88905747|NCT05839522||Persons in custody in Australia|Representative sample of 2400 people in prison from 25 representative prisons in Australia will participate in a biobehavioural survey involving point-of-care testing for HCV antibodies and RNA (if antibody positive), HBV surface antigens and antibodies, and HIV antibodies, and an interview-style survey.
88905748|NCT05839509|Experimental|GH001 Individualized Dosing Regimen|GH001 (Mebufotenin, 5-Methoxy-N,N-Dimethyltryptamine) is administered via inhalation, as an IDR consisting of up to 3 increasing doses of GH001 (6 mg, 12 mg, and 18 mg), on a single day. The second and third doses are only administered if the patient did not achieve intense psychoactive effects (a peak experience [PE]) at the previously administered dose.
88905749|NCT05839288||PyroHC|Patients used pyrotinib (Pyro) plus trastuzumab (H) and chemotherapy (C) as treatment for metastatic breast cancer.
88905750|NCT05839275|Experimental|Treatment Arm|"There will be 52 patients with high-risk localized extremity and truncal soft tissue sarcoma recruited.~In safety lead-in phase (phase Ib): using 3+3 design, patients will receive 6 cycles of Surufatinib in three different dosages and Sintilimab. And radiotherapy will begin in week 4.~In extended phase (phase II): Surufatinib in RP2D, Sintilimab and radiotherapy will be applied as before."
89007137|NCT05796505|Experimental|ADVANCE Steering Committee chosen interventions|Interventions will be selected by the ADVANCE Steering Committee and will be rapidly deployed without additional effort on the part of front-line staff at four distinct levels: patient, provider, practice and prison level. Interventions will be tested one at a time in an iterative process. A participatory, assets-based framework will be used to identify acceptable and feasible strategies to improve vaccine acceptance. Each round of testing will include 1 month of preparation by the steering committee,12-week intervention period, and 2 months for analysis and rapid dissemination.
88905751|NCT05839236|Experimental|LDL-C Detox|"The participant is continued from the trial NCT05711810. The follow-up study is separately registered for the etiological evidence from vaccine poisoning.~With the prior study's angiotensin-converting enzyme receptor inhibition therapy reaching desired power level and outcome, the participant's blood pressure. has dropped to normal range in a steady state without signs of sudden death risks.~The separate study defines the treatment medicines in NCT05711810 as rescue medicines for discretions, and experiments with Atorvastatin Calcium Tablets with 20 mg per day, and Chinese herb compounded Anti-Viral Granules 12 g (total) in 3 times per day.~The main ingredients for Anti-Viral Granules are the roots of Isatis indigotica L., Forsythia suspensa, Gypsum, Common Anemarrhena, Reed Rhizome, Rehmannia glutinosa, Patchouli, Tatarinow Sweerflag Rhizome, and Curcuma aromatica. They're mixed with dextrin, Sodium cyclamate, patchouli oil, peppermint oil, and angelica dahurica tincture."
88905752|NCT05839223|Experimental|Intervention|received the educational process (recommendations) about isotretinoin by a clinical pharmacist in addition to the routine education about isotretinoin provided by the physician
88905753|NCT05839223|No Intervention|Control|received only the routine education about isotretinoin provided by the physician
88905754|NCT05839197|Experimental|HAIC Combined With Apatinib and Camrelizumab|"All patients were treated with standard HAIC on the first day (D1). Immediately after the first HAIC, the liver function was reexamined. If the liver function was grade Child-Pugh A, Camrelizumab was given intravenously once every 3 weeks (D1) on the same day, 200mg/, once every 3 weeks (D1).~Apatinib capsule was given orally to 250mg within half an hour after breakfast on the second day (D2) after the first HAIC. The drug was given continuously once a day and stopped on the same day of each HAIC.~The combination of drugs for 3 weeks is a cycle.The treatment continued until the patient developed the disease or met the other criteria for terminating the study."
88905755|NCT05839171|Experimental|Person's Chosen Music + Mandala coloring|Every day for at least 20 minutes/7-10 days
88905756|NCT05839171|Experimental|Meditation Music + Mandala coloring|Every day for at least 20 minutes/7-10 days
88905757|NCT05839171|No Intervention|Standard care|Every day
88905758|NCT05839132|Experimental|acupuncture treatment group|"Disposable acupuncture needles will be inserted into acupoints for a depth of 20-30 mm in a direction oblique or parallel to the surface. To ensure allocation concealment, all needles will be affixed with plastic O-rings and adhesive tapes.~Acupuncture points: Baihui(DU20), Sishencong(EM1), Hegu(LI4), Taichong(LR3)"
88905759|NCT05839132|Placebo Comparator|sham acupuncture treatment group|"Streitberger's non-invasive placebo acupuncture needles will be used in the control group; blunt-tipped needles will touch the skin quickly without being inserted. To ensure allocation concealment, all needles will be affixed with plastic O-rings and adhesive tapes.~Acupuncture points: Baihui(DU20), Sishencong(EM1), Hegu(LI4), Taichong(LR3)"
88905760|NCT05839080|Experimental|Intervention schools|Pupils are exposed to the schoolgarden intervention eight times during two school years
88905761|NCT05839080|Experimental|Control Schools|Pupils are not exposed to the interventions and will complete questionaries
89424213|NCT04842136||Myofascial Temporomandibular Disorder (TMD) without Sleep Bruxism (SB)|Patients with Myofascial TMD without sleep bruxism were included in the group.
89424214|NCT04646330|Experimental|AK104 10mg/kg Q2W plus anlotinib|Subjects receive AK104 10mg/kg every 2-week cycle(Q2W) intravenously (IV) plus anlotinib 1-14days of every 3-week cycle (Q3W) until no more benefits from treatment.
88905762|NCT05839067|Experimental|CARE-HF|The problem-solving intervention will be led by a registered nurse. Participants will receive a program manual containing examples of common HF-related problems experienced by heart failure patients and suggested management strategies, with some strategies tailored to the rural sociocultural context. The nurse will lead participants in a card sorting task intended to help participants prioritize current HF-related problems and will guide participants in developing management strategies for the highest priority problem(s). Participants will utilize these strategies until the next session at which time the nurse will guide participants in evaluating the effectiveness of chosen strategies. The iterative process then begins again. Participants will receive 7 follow-up telephone sessions with the nurse. In the intervention, the nurse will focus on problems related to self-care, disease management, mental health, and quality of life, including those specific to the rural population.
88905763|NCT05839002||Training cohort|Training cohort will be used to find the best calculation and cut-off values for PTBS in ESCC after nCRT.
88905764|NCT05839002||Validation cohort|The study's conclusion will be verified in Zhongshan Hospital Xiamen branch.
89007138|NCT05793827|Experimental|Adapted Hatha Yoga|
89195663|NCT04035460|Active Comparator|High Flow Nasal Oxygen|Oxygen will be passed through a heated humidifier and applied continuously through large-bore nasal prongs
89424215|NCT04646330|Experimental|AK104 15mg/kg Q3W plus anlotinib|Subjects receive AK104 15mg/kg intravenously (IV) plus anlotinib 1-14days of every 3-week cycle (Q3W) until no more benefits from treatment.
89424216|NCT04646330|Experimental|AK104 10mg/kg Q3W plus anlotinib|Subjects receive AK104 10mg/kg Q3W plus anlotinib 1-14days of every 3-week cycle until no more benefits from treatment.
89424217|NCT05165342|Experimental|Treatment|This treatment is delivered by contact electrodes built in a mask, which is worn by the patient over closed eyes. The device setup is really easy and intuitive.
89424218|NCT05165342|Sham Comparator|Sham-intervention|The same device as treatment but the power of device will be set to ZERO power.
88905765|NCT05838989|Experimental|Group A: Stretching and Prefabricated Orthoses|Participants in this arm will receive supervised general and lumbrical muscle stretching exercises for 10 minutes, three times per week, for 8 weeks, as well as prefabricated wrist orthoses.
88905766|NCT05838989|Experimental|Group B: Orthoses Alone|Participants in this arm will receive prefabricated wrist orthoses only.
88905767|NCT05838989|Placebo Comparator|Group C: Placebo Treatment|Participants in this arm will receive placebo treatment consisting of gentle wrist and hand movements.
88905768|NCT05838976||Study Participants|This group will consist of at least 50 patients with carpal tunnel syndrome who are undergoing nonsurgical management. Participants will complete the shorter version of the CTQ-SSS and other functional measures, such as the Disabilities of the Arm, Shoulder, and Hand (DASH) questionnaire and the Patient-Rated Wrist Evaluation (PRWE). The validity and reliability of the CTQ-SSS will be assessed in this group using test-retest reliability and internal consistency analyses, as well as construct validity analyses comparing CTQ-SSS scores with other functional measures.
88905769|NCT05838950|Experimental|5s HIIT|5s HIIT group will perform one bout of sprint running for 5-seconds followed by 25-second, resting of total 40 repetition.
88905770|NCT05838950|Experimental|10s HIIT|10s HIIT group will perform one bout of sprint running for 10-seconds followed by 50-second, resting of total 20 repetition.
88905771|NCT05838950|Experimental|20s HIIT|20s HIIT group will perform one bout of sprint running for 20-seconds followed by 100-second, resting of total 10 repetition.
88905772|NCT05838950|Experimental|Control|Control group
89424219|NCT04842526|Experimental|Anlotinib and irinotecan combined with temozolomide|
89424220|NCT04851106||Patient with a solid pancreatic lesion of an undetermined nature|Patient with a solid pancreatic lesion of an undetermined nature
89424221|NCT05326958|Experimental|Normal Eyes of Subjects without DM|Study Part 1 conducted at only site 1 . Single measurement made on 3 separate visits at site 1 (total 3 images acquired) with HRT RCM and HRT RCM-E functional module (investigational).
89424222|NCT05326958|Experimental|Eyes of DM Type 2 subjects without coexisting DPN|"Study part 2 conducted at site 2.~1 image acquired with HRT RCM-E functional module (investigational)."
89424223|NCT05326958|Experimental|Eyes of DM Type 2 subjects with coexisting early to moderate DPN|"Study part 2 conducted at site 2.~1 image acquired with HRT RCM-E functional module (investigational)."
88905773|NCT05838924|Experimental|Physical Activity + Virtual Reality|"A program of 8 VR exercises will be applied, of a therapeutic nature, based on the applied exercises of the Back School, aimed at gaining strength, stability, mobility and flexibility of the abdomino-lumbo-pelvic region and the lower extremities. For each exercise, the VR goggles will manipulate the visual proprioceptive information by modifying the perceived degree of lumbar flexion and extension, i.e., in the VR goggles they will perceive that your movements are different from what you are actually doing."
88905774|NCT05838924|Active Comparator|Physical Activity|The same therapeutic exercise program will be applied as the experimental group, but without VR. The training methodology and progression of loads, evaluations and supervision by the physiotherapist will also be the same.
88905775|NCT05838872|Experimental|Minuteful - Kidney Urine Analysis Test System|
88905776|NCT05838846|Experimental|Group A (iMil)|"Patients will receive 2 doses of inhaled milrinone at the following time points (after sternotomy and after aortic cross clamp off) at dosage of 50 mcg/kg by nebulization, inhaled milrinone will be administered through Aerogen solo with Pro-X controller - continuous mode- attached to ventilator circuit distal to viral/ bacterial heat and moisture exchange filter.~Then pulmonary vascular resistance and systemic vascular resistance will be calculated after first dose ended by 2 minutes and after second dose ended by 15 minutes till stabilization of post CPB other variables like temperature and acid-base status, both measurements will be done while using inspired oxygen of 0.80."
88905777|NCT05838846|Active Comparator|Group B (IvMil)|Patients will receive intravenous milrinone - started after induction of anesthesia - infusion at dosage of 0.5 mcg/kg/min without loading dose (24), Pulmonary vascular resistance and systemic vascular resistance will be calculated at the same corresponding time points to group A.
88905778|NCT05838833|Experimental|Low dose|low dose ointment
88905779|NCT05838833|Experimental|High dose|high dose ointment
88905780|NCT05838833|Placebo Comparator|Placebo|same ingredient with active drug except API
89424224|NCT04837690||UEMR|
89424225|NCT03445754|Experimental|Interventional Arm|Active TVS will be performed by use of a Tragus stimulator device with electrodes attached to the tragus of the ear. Stimulator will be applied continuously for 1 hour.
88905781|NCT05838820||Carpal Tunnel Syndrome (CTS) Group|This group will consist of individuals diagnosed with carpal tunnel syndrome (CTS) who are 18 years of age or older and who are able to provide informed consent to participate in the study. The group will be recruited from a single center and will be asked to complete the Jebsen-Taylor Hand Function Test and the Nine-Hole Peg Test twice, with a 1-week interval between the two assessments. The aim is to establish the test-retest reliability of these tests in individuals with CTS. The group will include at least 50 participants and will be diverse in terms of age, gender, and race/ethnicity to ensure that the study findings are generalizable to a broader population.
88905782|NCT05838040|Active Comparator|General Exercises|This exercise activates paravertebral and abdominal muscles. Because this exercise impose extra loading on the spinal tissues, the general exercise was selected on the basis of maximizing the contraction benefit/spinal loading ratio.
88905783|NCT05838040|Experimental|General exercises with TA contraction|This exercise activates paravertebral and abdominal muscles. Because this exercise impose extra loading on the spinal tissues, the general exercise was selected on the basis of maximizing the contraction benefit/spinal loading ratio. The patients will be asked to contract TA will doing these exercises.
88905784|NCT05837702|Experimental|Erector Spinae Plane Block (ESPB)|The spinous processes of the vertebrae were marked up to T8 level. After providing antisepsis of the skin with 10% povidone iodine, the ultrasound probe was placed at T8 level parallel to the vertebral spine at T8. The transverse process (TP) and hyperechoic pleura were observed 2.5cm right lateral of the spinous process. Using the in-plane approach, the needle was placed in the caudal direction. After confirming displacement of the pleura with 0.5-1ml local anaesthetic (LA), 20ml 0.25% bupivacaine was administered for the block .
88905785|NCT05837702|Active Comparator|Paravertebral Block (PVB)|After sterilisation of the skin with povidone iodine, the probe covered with a sterile sheath was placed 3cm lateral of the T8 spinous process. The trapezius, rhomboid major, and erector spinae muscles, and the TP of the vertebrae were visualised. The needle was placed craniocaudally within the fascial plane of the deep surface of the erector spina muscle above the bone shadow of the TP. The fluid dissemination was confirmed by raising the placement of the needle tip towards the erector spina muscle. 20ml 0.25% bupivacaine was applied to this region and the spread of local anaesthetic was observed
88905786|NCT05837702|Active Comparator|Control|No block has been done
88905787|NCT05837650|Experimental|Emotional Awareness and Expression Therapy (EAET)|In this experimental arm, participants are required to attend 8 online sessions and fill out questionnaires before treatment, and immediately after treatment.
88905788|NCT05837650|No Intervention|Wait list control|In this control arm, participants are required to wait 8 weeks until the treatment arm is completed and fill out questionnaires before and after the treatment date.
88905789|NCT05837403|Active Comparator|Nitroglycerin only|application of local Nitroglycerin ointment 2% (Recto-Relief Nitroglycerin Ointment, 30 g) applied twice daily.
88905790|NCT05837403|Experimental|platelet rich plasma injection|injection of platelet rich plasma under fissure base and edges
88905791|NCT05837208||Treated Group|all subjects will apply the study product RV4369A
88905792|NCT05836935|Experimental|Participants|
88905793|NCT05836610|Active Comparator|Standard dose hydrocortisone|The standard dose of hydrocortisone therapy in neonates for hypotension is 0.5 mg/kg every 6 hours.
88905794|NCT05836610|Active Comparator|Modified dose hydrocortisone|The modified dose of hydrocortisone therapy will be determined based on the pharmacokinetic results.
88905795|NCT05835804|Experimental|Intratumoral chemotherapy|
88905796|NCT05832944|Experimental|Group HMD (30 patients)|"where the size of LMA will be according to measured hyomental distance by ultrasound as follows:~If Less than 2 cm: LMA size 2 will be used.~If 2-3 cm: LMA size 2.5 will be used.~If more than 3 cm: LMA size 3 will be used."
88905797|NCT05832944|No Intervention|Group CONTROL (30 patients)|where size selection will be based on the weight guide
88905798|NCT05832866|Experimental|"Clinical Based Isometric contraction strengthening Exercises using Thera band CBG"|Participants underwent strengthening exercises to the quadriceps and harmstring using thera band at the hospital. The band was attached around the ankle for strengthening of the quadriceps and hamstring muscles using isometric muscle contraction using a standard protocol. The patient performed four sets of eight repetitions for each of the exercises.
88905799|NCT05832866|Experimental|"Telemonitored Home based Isometric Contraction strengthening exercises using Thera band THB"|Participants underwent strengthening exercises to the quadriceps and harmstrings with thera band but doing the intervention at home but monitored with telephone call. The band was attached around the ankle for strengthening of the quadriceps and hamstring muscles using isometric muscle contraction using a standard protocol. The patient performed four sets of eight repetitions for each of the exercises.
88905800|NCT05830630|Experimental|Bupivacaine methylene blue group|"Patients in this group will receive the following regimen through the perineural catheter:~Bolus dose of 1 ml methylene blue 1% (10 mg) plus 19 ml bupivacaine 0.25% will be given intraoperatively before wound closure, and perineural infusion of methylene blue plus bupivacaine 0.25% (1 ml of methylene blue added to each 49 ml of bupivacaine 0.25%) will be started in the recovery room at a rate of 2-5 ml/hour for 72 hours postoperatively"
88905801|NCT05830630|Active Comparator|Bupivacaine saline group|"Patients in this group will receive the following regimen through the perineural catheter:~Bolus dose of 1 ml normal saline plus 19 ml bupivacaine 0.25% will be given intraoperatively before wound closure, and perineural infusion of bupivacaine 0.25% will be started in the recovery room at a rate of 2-5 ml/hour for 72 hours postoperatively"
88905802|NCT05838859||Female service users of childbearing age|Contraception Advice Experiences Survey - using a self-report questionnaire of female service users.
88905803|NCT05838859||Mental health care professionals|Contraception in Mental Health Survey - self-report questionnaire of professionals' current practices, attitude and knowledge
88905804|NCT05827367|Experimental|high power pain thershold ultrasound|"Patients will reseiv high power pain ultrasound~,intrinsic muscle strength and plantar fascia streatching"
88905805|NCT05827367|Experimental|myofascial release|Plantar fascia myofascial release,gastrocnmias Myofascial release ,soluse myofascial release,foot interstice muscle strength and plantar fascia streatching
89007139|NCT05793827|Active Comparator|Low-Impact Exercise|
89007140|NCT05769582|Experimental|Anti-BK polyomavirus (AntiBKV)|1,000mg Anti-BK polyomavirus (AntiBKV) intravenous infusion every 4 weeks (4 doses)
89195664|NCT05508776|Experimental|LEO 152020 Dose A|A single oral dose of LEO 152020 Dose A according to the randomization schedule.
88905806|NCT05827367|Placebo Comparator|control arm|Plantar fascia stretching and foot interstice muscle strength
88905807|NCT05826132|Experimental|Adjusted Content Intervention Video|Participants will watch a 2-3-minute video in which an empowered essential worker protagonist shares her COVID-19 related mental health problems and describes how she was able to confront her mental health problems and pursuit of mental health care, using language that speaks to the specific experience of being a young Latina woman.
89195665|NCT05508776|Experimental|LEO 152020 Dose B|A single dose of LEO 152020 Dose B according to the randomization schedule.
89195666|NCT05508776|Active Comparator|Moxifloxacin|A single oral dose of moxifloxacin 400 mg according to the randomization schedule.
89195667|NCT05508776|Placebo Comparator|Placebo|A single dose of placebo according to the randomization schedule.
89195668|NCT02565342|Experimental|Interscalene brachial plexus block|
89195669|NCT00896350|Experimental|BOLD MRI|Determine the amount of oxygen supply to tumors.
89007141|NCT05769582|Placebo Comparator|Placebo|Placebo intravenous infusion every 4 weeks (4 doses)
89195670|NCT02565264|Experimental|plasma-derived exosomes|plasma-derived exosomes
89195671|NCT00896428|Experimental|1|16 patients with a diagnosis of severe asthma under gallopamil treatment
89195672|NCT00896428|Placebo Comparator|2|16 patients with a diagnosis of severe asthma under placebo treatment
89195673|NCT02962050||ALS|Participants enrolled will complete the following tests: Videofluoroscopic Swallowing Study, Voluntary Peak Cough Flow Testing, lingual strength and endurance trials using the Iowa Oral Performance Instrument, reflexive cough testing, Pulmonary Function Testing; Eating Assessment Tool-10 (EAT-10), Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R), and the The Center for Neurologic Study Bulbar Function Scale (CNS-BFS).
89195674|NCT00410605|Experimental|Arm I|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15, oral lenalidomide on days 1-21, and oral dexamethasone on days 1, 8, 15, and 22. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
88905808|NCT05826132|Experimental|Non-Adjusted Intervention Video|Participants will watch a 2-3-minute video in which an empowered essential worker protagonist shares her COVID-19 related mental health problems and describes how she was able to confront her mental health problems and pursuit of mental health care, without any language alluding to her particular identity characteristics.
88905809|NCT05826132|No Intervention|Control Arm|Participants will watch a control video discussing daily activities.
88905810|NCT05823753|Active Comparator|Cannabidiol 900 mg/d|Participants will receive CBD (900 mg/d). Evenly split doses of 450 mg will be taken at morning and evening meals for 3 days, and a 450 mg dose will be taken in the morning of day 4 (before the post-test).
88905811|NCT05823753|Active Comparator|Cannabidiol 300 mg/d|Participants will receive CBD (300 mg/d). Evenly split doses of 150 mg will be taken at morning and evening meals for 3 days, and a 150 mg dose will be taken in the morning of day 4 (before the post-test).
88905812|NCT05823753|Placebo Comparator|Placebo|Participants will receive a CBD matching placebo. Evenly split doses will be taken at morning and evening meals for 3 days, and a dose will be taken in the morning of day 4 (before the post-test).
89195675|NCT00742638|Experimental|The arm 1|Quetiapine fumarate tablet:25mg and 200mg
89195676|NCT00742638|Active Comparator|The arm 2|Sodium valproate tablet 200mg
89195677|NCT00418717|Experimental|1|Arm 1: Period A-25mg BW; Arm 1: Period B-50mg QW
89195678|NCT01042249|Experimental|Treatment|Treated with Pelvic Floor Muscle Training in 12 weeks
89195679|NCT01042249|No Intervention|Control|Receives standard rehabilitation after stroke
89424226|NCT03445754|Sham Comparator|Control|Sham TVS will be performed by use of a Tragus stimulator device with electrodes attached to the ear lobule. Stimulator will be applied continuously for 1 hour.
89424227|NCT04837612||Subjects with dilated cardiomyopathy|Subjects diagnosed with dilated cardiomyopathy by medical history, physical examination and echocardiography.
89424228|NCT03352232|Experimental|Subacute Ischemic Stroke|Subacute stroke patients post stroke within 3 months of enrollment, have persistent neurological deficits despite conventional rehabilitation
89424229|NCT03352232|Experimental|Chronic Ischemic Stroke|Chronic stroke patients more than 6 months from stroke with persistent neurological deficits despite conventional rehabilitation
89424230|NCT04837456|Experimental|Calorie restricted diet and excecise intervention|a balanced diet that provided an energy deficit of 800 kcal/day from their daily energy requirement [36]. Macronutrient content of low caloric diet, expressed as percentage of ingested energy with carbohydrates 45-65%; fat 20-35%; and protein 10- 35%[36].Each session was approximately 150 minutes one week for six months and consisted of aerobic exercises, resistance training, and exercises to improve flexibility and balance.
89424231|NCT04837456|Experimental|libitum diet and waiting list control group|participants then underwent a calorie of 2000 calorie above based on libitum free diets recommended to adults and normal physical activity without exercise during the program.
89424232|NCT04837456|Experimental|Early APM group|Early APM group participants received APM with syndrome within 3 to 6 months
89195680|NCT00572572|Experimental|Arm A: Aprepitant, Then Placebo|Participants first received Aprepitant 125mg PO day 3 then 80mg on days 4 and 7 during study cycle 1, then received matched placebo PO daily on days 3 through 7 during study cycle 2
89195681|NCT00572572|Experimental|Arm B: Placebo, Then Aprepitant|Participants first received matched placebo PO daily on days 3 through 7 during study cycle 1, then received Aprepitant 125mg PO day 3 then 80mg on days 4 and 7 during study cycle 2
89195682|NCT00896974|Experimental|Arm I|Participants receive a single dose of oral 9cUAB30 on day 1.
89424233|NCT04837456|Experimental|delayed APM group recruit participants with symptoms lasting for more than 6 months|delayed APM group recruit participants with symptoms lasting for more than 6 months
89424234|NCT04850950|Experimental|Arm 1|Tenofovir alafenamide fumarate discontinued at delivery date.
89424235|NCT04850950|Experimental|Arm 2|Tenofovir alafenamide fumarate discontinued at postpartum month 1.
89424236|NCT03140852|Active Comparator|Treatment|Completes the Mind Over Matter; Healthy Bowels, Healthy Bladder workshop in the spring 2017.
89424237|NCT03140852|Other|Control|Completes the Mind Over Matter; Healthy Bowels, Healthy Bladder workshop in the fall 2017.
89424238|NCT02608450|Experimental|CB-03-01 cream|CB-03-01 cream, 1% applied twice daily for 12 weeks
89424239|NCT02608450|Placebo Comparator|Vehicle cream|Vehicle cream applied twice daily for 12 weeks
89424240|NCT05165030|Experimental|Blood Sample|Blood Sample
89424241|NCT05309486|Experimental|Online pilates group|Online pilates, which lasts for eight weeks, three days a week for 1 hour, will be carried out by Australian Pilates and Physiotherapy Institute certified and experienced Ph.D. Physiotherapist Halil Ibrahim Bulguroglu. Microsoft Teams program will be used to implement the online practice method. The individuals in both pilates exercise groups will be divided into six small groups of 3 or 4 people to make the exercises more effective. In this study, the program will be 15 minutes of warm-up, 30 minutes of pilates, and 15 minutes of cool-down and stretching exercises. The exercises will be performed in ten repetitions. The same exercises will be applied in online pilates and face-to-face pilates trainings.
89424242|NCT05309486|Active Comparator|Face-to-face pilates group|Face-to-face pilates training, which lasts for a total of 8 weeks, 3 days a week for 1 hour, will be carried out by Australian Pilates and Physiotherapy Institute certified and experienced Ph.D. Physiotherapist Halil Ibrahim Bulguroglu. Face-to-face pilates training will be held at Ankara Medipol University. To make the exercises more effective, the individuals in both pilates exercise groups will be divided into six small groups of 3 or 4 people. In this study, the program will be 15 minutes of warm-up, 30 minutes of pilates exercises, 15 minutes of cool-down and stretching exercises, and the exercises will be performed as 10 repetitions. The same exercises will be applied in online pilates and face-to-face pilates trainings.
89424243|NCT02629016|Experimental|Mindfulness|Education and experiential exercises for mindfulness including movement, thoughts and meditation
89424244|NCT02629016|Active Comparator|Wellness|Education and experiential exercises for general wellness including sleep hygiene, goal setting and power poses.
89424245|NCT02629016|No Intervention|Waitlist|Students receive regular health class instruction without intervention.
89424246|NCT04837300|Experimental|Experimental-1|Resisted Sprint Training
89424247|NCT04837300|Experimental|Experimental-2|Plyometric Training
89424248|NCT04837300|No Intervention|Control|No Training
89424249|NCT04837144|Experimental|Intervention Group|The Intervention Group will receive 9 physical rehabilitation sessions using the MAK device. Each session will consist of approximately 90 minutes.
89424250|NCT05164952|Experimental|Delayed use of zoledronic acid arm|delayed-ZOL patients will receive ZOL only if their T-score fall below -2.0, after a nontraumatic clinical fracture, or if an asymptomatic fracture will be detected by spinal X-ray at the 3- monthly assessment.
89424251|NCT05164952|Experimental|Immediate use of zoledronic acid arm|Immediate-ZOL patients will receive ZOL immediately after randomization
89424252|NCT04841824||Critically ill patients with sepsis|
88905813|NCT05823402|Experimental|SPECT/CT|"All patients enrolled will undergo 5 additional (6 total) SPECT/CT scans per treatment cycle. Current FDA approved PSMA radioligand therapy is administered over 6 cycles, so there will be a total of 30 additional SPECT/CT scans during this study.~During each treatment cycle, patients will have a SPECT/CT scan at the following time points after administration of PRLT:~4 Hours~24 Hours (+/- 8 Hours)~48 Hours (+/- 8 Hours)~96 Hours (+/- 8 Hours)~168 Hours (+/- 24 Hours)~336 Hours (+/- 24 Hours)"
88905814|NCT05822388||Parkinson's Disease undergoing DBS|This study will recruit patients with Parkinson disease (PD) participants who will undergo DBS surgery and and are scheduled for a pre-DBS neuropsychological evaluation at MUSC.
88905815|NCT05820464||Control group|"Standard care:~Doppler velocimetry: UA & MCA PI, DV PIV, CPR;~Indirect cardiotocography (CTG)~Biophysical profile (BPP)"
88905816|NCT05820464||DDA Doppler group|Standard care plus DDA Doppler monitoring
88905817|NCT05813158|Active Comparator|Group 1|Patients will preoperatively receive low concentration-high volume U/S ESP block, and then the patient will be transferred to the operating room one syringe of 30ml bupivacaine 0.25% {15 ml bupivacaine 0.5% and 15ml normal saline}, for each patient.
88905818|NCT05813158|Active Comparator|Group 2|Patients will preoperatively receive high concentration-low volume U/S ESP block block, and then the patient will be transferred to the operating room one syringe of 15 ml bupivacaine 0.5% {15 ml bupivacaine 0.5% }, for each patien).
89195683|NCT00418561|Experimental|Cohort 1|Metazym (Recombinant human arylsulfatase A (rhASA)): 25 U/kg as a single dose - hereafter 50 U/kg
89424253|NCT04841824||Critically ill patients without sepsis|
89424254|NCT03037216|Experimental|Experimental Exercise-Training Intervention|Subjects will undergo a 10-week aerobic exercise protocol.
89424255|NCT05164874|Experimental|Intervention|"Women will receive a proposition for an appointment at the MMU in complement to the current screening invitation, keeping the choice of their place of screening.~Women will also receive the timetable of prevention actions with the invitation to participate in screening."
89424256|NCT05164874|No Intervention|Control|No change from the usual breast cancer screening organization
89424257|NCT04850482|Experimental|Intervention Arm|Participants get immediate access to the intervention on completion of baseline assessment.
88905819|NCT05805683|Experimental|Calcitonin group|patients in this group will receive 100 IU (1 ml) of calcitonin subcutaneously per day for 2 weeks starting within 48 hours after injury.
88905820|NCT05805683|Placebo Comparator|Placebo group|patients in this group will receive 1 ml of saline placebo solution subcutaneously per day for 2 weeks starting within 48 hours after injury.
88905821|NCT05803057|Experimental|TMS treatment|Using nrTMS coli to stimulate the thumb related motor cortex with high-frequency.
89424258|NCT04850482|No Intervention|Wait list control Arm|Participants get access to the intervention in 10 weeks after completion of the baseline and follow up assessment.
89424259|NCT05294042|Experimental|Paraprofessional Navigation Condition|Paraprofessional Navigators will implement a model of navigation with caregivers focused on reducing logistical and attitudinal barriers to care.
89424260|NCT05294042|Active Comparator|Case Manager Navigation Condition|Case Manager Navigators will implement a model of navigation with caregivers focused on reducing logistical and attitudinal barriers to care.
89424261|NCT05294042|No Intervention|Wait-List as Usual|Participants will be assigned as wait-list as usual at each agency.
89424262|NCT04850560|Experimental|CD19 PD-1/CD28 CAR-T Plus Low Dose Decitabine|
89424263|NCT02522702||Routine colonoscopy Cohort|
89424264|NCT04850404|Experimental|the group of abdominal nerve block combined with moderate NMB|The patients of group N-M received the rectus abdominis block combined with transverse plane block.
89424265|NCT04850404|No Intervention|moderate NMB group|The patients of group M received moderate NMB through the surgery.
89424266|NCT04842058||Orthostatic tolerant patients (OT)|Patients that experience symptoms of orthostatic intolerance (dizziness, nausea, vomiting, blurry vision or syncope) or orthostatic hypotension (fall in systolic pressure > 20 mmHg and/or diastolic pressure > 10 mmHg) during mobilisation
89424267|NCT04842058||Orthostatic intolerant patients (OI)|Patients that do not experience symptoms of orthostatic intolerance (dizziness, nausea, vomiting, blurry vision or syncope) or orthostatic hypotension (fall in systolic pressure > 20 mmHg and/or diastolic pressure > 10 mmHg) during mobilisation
89424268|NCT05400044|Experimental|bone marrow aspirate mixed with xenograft|
89424269|NCT05400044|Active Comparator|xenograft mixed with autografts only:|
89424270|NCT04778722|Experimental|Probiotic group|pilot study with one interventional group
89424271|NCT05399810|Experimental|Computer Application (ICOGNI) Training|Apart from routine physical therapy, participants in this group will be randomized to active training after baseline assessment. Participants will be given App-based training which will include multiple games with multiple levels along with routine physiotherapy. The active group will start training immediately and will have 8 weeks to perform the 40 training sessions.
89424272|NCT05399810|No Intervention|Conventional group|Participants in are already being given routine physiotherapy which includes range of motion exercises, stretching and strengthening exercises of upper extremity, fine motor activities, functional activities, and cognitive activities (art and crafts, placing objects in specific positions, organizing objects, color sorting games, teamwork, and moving and tracing objects).
89424273|NCT04850326|Experimental|AP green tea extract|
89424274|NCT04850326|No Intervention|No intervention control|
89424275|NCT03039946|Experimental|Closed-loop GDFT|This group consists of patients undergoing laparoscopic and/or robotic abdominal surgery where fluid maintenance with Plasmalyte is carried out using a closed-loop system guided by the Clearsight non-invasive hemodynamic flow monitor.
89424276|NCT03039946|Active Comparator|Restrictive fluid therapy|This group consists of patients undergoing laparoscopic and/or robotic abdominal surgery where fluid management is based on a restrictive (4ml/kg/h) Plasmalyte infusion.
89424277|NCT04850014||Poisoned patients|All subjects with paracetamolemia in the context of paracetamol poisoning
89424278|NCT04850014||Control group|Acetaminophen-poisoned patient being non-obese
89424279|NCT03039868||Normal Pap smears|This is the control group.
89424280|NCT03039868||Abnormal Pap smears|This is the case group.
89424281|NCT04841746|Experimental|Cycling rehabilitation with functional electrical stimulation|
89424282|NCT04841746|Active Comparator|Cycling rehabilitation|
89424283|NCT04836676|Experimental|C-REX group|After resection of the disease in colon, the intestinal ends will be anastomosed by the investigational device, i.e. C-REX LapAid Cath or C-REX RectoAid Cath.
89424284|NCT04836598|Active Comparator|Multiport laparoscopic cholecystectomy|controlled group
89424285|NCT04836598|Active Comparator|Bikini line laparoscopic cholecystectomy|bikini line 2 ports
89424286|NCT06059573|Experimental|Robot-guided|Implant placement by robot-guided based on a digital plan
89424287|NCT06059573|Active Comparator|Freehand surgery|Implant placement by freehand based on a digital plan
89424288|NCT06059560|Experimental|interventian group|Intensive nutritional interventions based on real-world treatments
89424289|NCT06059560|Experimental|control group|Nutritional guidance and education based on real world treatments
89424290|NCT06059547|Active Comparator|Combination with Placebo|Placebo + Checkpoint Inhibitor nivolumab
89424291|NCT06059547|Experimental|Combination with Visugromab/Verum|visugromab (CTL-002) + Checkpoint Inhibitor nivolumab
89424292|NCT06059521|Experimental|Software Refraction|Refraction is done by software with subjective refraction through a mobilerone.
89424293|NCT06059521|Active Comparator|Refraction by retinoscopy|Refraction is done objectively by retinoscopy.
89424294|NCT06059469|Experimental|Patients with progressive metastatic TNBC and presenting measurable disease on 18F-FDG PET/CT|Patients with progressive metastatic TNBC and presenting measurable disease on 18F-FDG PET/CT
89424295|NCT06059430||patient already on treatment|Patients already on biologic or synthetic TRT will be followed for 10 years
89424296|NCT06059430||Naive patients|Patients who are naive to biological or synthetic treatments
89424297|NCT06059417|Other|Foam-tape/Control|"One of the participants upper extremity (arm) was used for intervention and the same participants other arm was used as the control in this study.~There was only 1 research arm in this study and all study participants were in it."
89424298|NCT06059365|Active Comparator|hospitalization group|Patients in the hospitalization group, once the surgical intervention was finished, were transferred to the postoperative recovery unit and later they were discharged to the usual hospital ward. Patients received adequate intravenous fluid resuscitation based on their individual hemodynamic parameter and fluid balance, and they received analgesia according to personal requirement. In the hospital ward, the usual patient management protocols were followed until a complete recovery and consequently discharged according to the usual criteria
89424299|NCT06059365|Experimental|outpatient group|Patients in the outpatient group , once operated, were transferred to the surgery unit without admission and were later discharged home if they met the ALDRETE criteria in less than 23 hours after the intervention (following the surgery criteria without admission stages). If the patient was operated during the night shift, following the advice of major outpatient surgery where overnight stays are allowed, the patient was admitted to the post-anesthetic recovery unit and discharged the next day, always in less than 23 hours. In case of being discharged after 23 hours or not meeting ALDRETE criteria, it was considered a failure of the outpatient treatment.
89424300|NCT06059326|Experimental|HSK7653 10 mg|
89424301|NCT06059326|Experimental|HSK7653 25 mg|
89424302|NCT06059326|Experimental|HSK7653 50 mg|
89424303|NCT06059326|Placebo Comparator|Placebo|
89530860|NCT03344549|Experimental|Teleconsultation|In the patients of the experimental group, the nutritional intervention is carried out through teleconsultation with the free technological tool chosen (the patients from home and the nutritionist from the remote clinic).
89424304|NCT06059300|Experimental|Intervention group|18200 participants who will be screened with tomosynthesis instead of digital mammography. All participants will be asked to participate in the study for 2 screening rounds. The number of participants for the second round will be less, due to drop-outs.
89424305|NCT06059287|Experimental|Henagliflozin|Henagliflozin 10mg qd po
89424306|NCT06059287|Active Comparator|Metformin|Metformin 1000mg bid po
89424307|NCT06059261|Experimental|Envafolimab and recombinant human endostatin combined with chemoradiotherapy|Intervention Description: Induction envafolimab combined with recombinant endostatin and gemcitabine and cisplatin therapy for three cycle (every 3 weeks) followed by definitive radiotherapy with or without concurrent cisplatin chemotherapy. After 4weeks of the completion of radiotherapy, adjuvant envafolimab therapy will begin every 3 weeks for 5 cycles or continue until progression or unacceptable toxicity.
89424308|NCT06059235|Experimental|intervention|"Package of clinical pharmacy activities including :~Medication history (during assessment consultation)~Medication review and consultation with the geriatrician~Therapeutic education (during results consultation)~Shared decision (at results consultation)~One-week follow-up call + usual care"
88905822|NCT05803057|Sham Comparator|TMS Sham-treatment|Using nrTMS sham-coli to stimulate the thumb related motor cortex with high-frequency.
88905823|NCT05797051||diabetic nephropathy|Urine samples were collected from patients with IgA nephropathy, idiopathic membranous nephropathy, diabetic nephropathy and minimal change nephropathy. The samples were centrifuged and frozen in a refrigerator at -80 degrees Celsius. The images were divided into a training set and a test set at a fixed ratio. The digital images were input into classification models such as one-dimensional convolutional neural network to learn and test. The training set was used for the training and parameter iteration of the artificial intelligence non-invasive fluid diagnosis model, and the test set was used for the recognition and interpretation of the model. The confusion matrix, accuracy and ROC curve were calculated through the interpretation results to evaluate the performance of the model.
88905824|NCT05797051||minimal change nephropathy|Urine samples were collected from patients with IgA nephropathy, idiopathic membranous nephropathy, diabetic nephropathy and minimal change nephropathy. The samples were centrifuged and frozen in a refrigerator at -80 degrees Celsius. The images were divided into a training set and a test set at a fixed ratio. The digital images were input into classification models such as one-dimensional convolutional neural network to learn and test. The training set was used for the training and parameter iteration of the artificial intelligence non-invasive fluid diagnosis model, and the test set was used for the recognition and interpretation of the model. The confusion matrix, accuracy and ROC curve were calculated through the interpretation results to evaluate the performance of the model.
88905825|NCT05797051||IgA nephropathy|Urine samples were collected from patients with IgA nephropathy, idiopathic membranous nephropathy, diabetic nephropathy and minimal change nephropathy. The samples were centrifuged and frozen in a refrigerator at -80 degrees Celsius. The images were divided into a training set and a test set at a fixed ratio. The digital images were input into classification models such as one-dimensional convolutional neural network to learn and test. The training set was used for the training and parameter iteration of the artificial intelligence non-invasive fluid diagnosis model, and the test set was used for the recognition and interpretation of the model. The confusion matrix, accuracy and ROC curve were calculated through the interpretation results to evaluate the performance of the model.
89007142|NCT05758701|Experimental|Cohort 1|A cohort will be given a 1/3rd reduced dose of iodinated contrast agent (33 ml).
89424309|NCT06059235|No Intervention|controle|Medication history (during assessment consultation) + usual care
89007143|NCT05758701|Experimental|Cohort 2|If imaging with 1/3 dose is satisfactory, a second cohort with 1/4th the standard dosage (25 ml) will be assessed. If images are not satisfactory, contrast dose will be increased to 50 ml.
89007144|NCT05747196|Experimental|Open Label Treatment Arm|Hospitalized patients with acute decompensated heart failure that meet eligibility criteria will have an eLym System temporarily placed via left internal jugular access. The eLym System will be in place for up to 72 hours.
89007145|NCT05745636|Experimental|Broccoli, mustard, vitamin C|770 mg Broccoli Seed Extract (BSE) with 290 mg mustard seed powder (MSP) and 200 mg vitamin C
89424310|NCT06059209|No Intervention|Breast Milk|
89424311|NCT06059209|Other|Enfamil Infant|
89424312|NCT06059209|Active Comparator|Enfamil NeuroPro|
89424313|NCT06059170|Other|QOL, risk factor and therapeutic options|questionnaires
89424314|NCT06059144|Experimental|Induced hypertension using norepinephrine|"Standard care and peripheral intravenous norepinephrine. Norepinephrine (dilution: 10µg/ml, initial dose: 0.04µg/kg/min) will be titrated until MAP is between 110 and 120mmHG (with a maximal systolic blood pressure of 210mmHG) Gradually decrease of norepinephrine will start after 24h of NIHSS stabilization.~Standard care includes antithrombotic treatments according to the physician's choice and ESO recommendations"
89424315|NCT06059144|No Intervention|Standard care|Standard care includes antithrombotic treatments according to the physician's choice and ESO recommendations
89424316|NCT06059131|Experimental|KeenMind|
89424317|NCT06059131|Placebo Comparator|Placebo|
89424318|NCT06059105|Experimental|Test Group|Inverted Co-Axis 12º Southern Implants (15 patients): The implant is placed in the center of the socket due to that has an angled neck of 12º, which allows the implant to be placed in the center of the alveolus, optimizing the alveolar bone and improving the prosthetic emergence. This is due to the access of the screw being located palatally, simplifying the restoration of the crown, avoiding cemented crowns, lowering the laboratory cost and of prosthetic accessories.
89424319|NCT06059105|Active Comparator|Control Group|Internal Conical (Deep Tapered Conical) South Implants (15 patients): conventional conical implant with internal connection. The implant is placed palatally in order to have a good emergence profile.
89424320|NCT06059092|Experimental|Adapt Module|Module targeting reactive adaptation processes
89424321|NCT06059092|Experimental|Engage Module|Module targeting proactive adaptation processes
89424322|NCT06059092|Experimental|Interact Module|Module targeting interpersonal adaptation processes
89007146|NCT05745636|Placebo Comparator|Placebo|inactive excipients including microcrystalline cellulose, rice hull, maltodextrin, ascorbyl palmitate and silicon dioxide
89007147|NCT05744466||Cohort 1|Participants that have initiated deucravacitinib
89007148|NCT05744466||Cohort 2|Participants that have initiated apremilast
89007149|NCT05742971|Experimental|VR group|The intervention group can choose for an immersive guided relaxation VR experience or an interactive VR experience during the external version Immediately after the external version, a pain measurement is taken with regard to the pain during the ECV by means of the NRS score. After the ECV procedure, participants of the VR-group receive a structured questionnaire in which tolerability, feasibility and satisfaction of VR use is evaluated.
89007150|NCT05742971|No Intervention|Standard care group|The participants randomised to the standard care group receive the usual standard care given during external version.Immediately after the external version, a pain measurement is taken with regard to the pain during the ECV by means of the NRS score.
89007151|NCT05739292|Experimental|EuNmCV-5|Healthy adults received 0.5mL single intramuscular dose on Day 0.
89007152|NCT05739292|Active Comparator|Menveo|Healthy adults received 0.5mL single intramuscular dose on Day 0.
89007153|NCT05737225||Popliteal sciatic nerve block group|regional anesthesia applied patients who will undergo percutaneous transluminal angioplasty (PTA) procedure
89007154|NCT05737225||Control group|patients who will undergo percutaneous transluminal angioplasty (PTA) procedure
89007155|NCT05695560||Phase 1: Adult Participants|Adult participants with severe VWD (self-bleeding assessment tool [BAT] score ≥10) and their caregivers will be enrolled as per protocol specifications. Data will be collected from participants via questionnaire, semi-structured interviews, and focus groups using a virtual platform.
89007156|NCT05695560||Phase 2: Pediatric Participants|Pediatric participants with severe VWD (self-pediatric bleeding questionnaire [PBQ] score of ≥3 for at least one symptom and caregivers will be enrolled as per protocol specifications. Data will be collected from participants via questionnaire, semi-structured interviews, and focus groups using a virtual platform. The decision to proceed with Phase 2 will be determined following completion of Phase 1.
89007157|NCT05692401|No Intervention|Standard of Care|CAM boot prescribed as standard of care. No nutritional guidelines or upper body exercises instructions provided. Height and weight recorded at enrollment and final visit.
89424323|NCT06059092|Placebo Comparator|Control group|Sessions targeting cognitive functions
89424324|NCT06059079||Elevated hs-cTnT group|
89424325|NCT06059040|Active Comparator|intervention groups|Patients in the intervention group will not be monitored for GRV (no GRV monitoring) and will be evaluated for the presence of feeding intolerance indicators such as vomiting, regurgitation, and abdominal distention.
89424326|NCT06059040|No Intervention|control group|Patients in the control group will be subjected to GRV monitoring (with GRV monitoring).
89424327|NCT06059001|Experimental|Nab-Paclitaxel+Gemcitabine+OMO-103|SoC Gemcitabine/Nab-Paclitaxel plus experimental OMO-103
89424328|NCT06058988|Experimental|Cohort A|Participants with Her2-expressing or solid tumors with activating ERBB2 mutations with 1 or more CNS metastases requiring neurosurgical resection/biopsy with no prior T-DXd
89424329|NCT06058988|Experimental|Cohort B|Participants with Her2-expressing or solid tumors with activating ERBB2 mutations with 1 or more CNS metastases requiring neurosurgical resection/biopsy with no prior T-DXd and prior T-DXd exposure and with documented radiological CNS progression while on T-DXd, requiring neurosurgical resection/biopsy of 1 or more recurrent metastases, with continuation of T-DXd until prior to surgery
89007158|NCT05692401|Active Comparator|Nutrition and Exercise Instruction|CAM prescribed as standard of care. Nutritional guidelines provided and upper body exercise instructions provided. Height and weight recorded at enrollment and final visit. Subjects in this group will undergo a follow up interview that will ultimately be used to examine and assess the helpfulness of the intervention in preventing weight for CAM boot wearing patients.
89424330|NCT06058988|Experimental|Cohort C|Participants with recurrent glioblastoma requiring neurosurgical resection/biopsy
89007159|NCT05688657|Experimental|Lens A|All participants wore Lens A for 15 minutes (Period 1)
89007160|NCT05688657|Experimental|Lens B|All participants wore Lens B for 15 minutes (Period 2)
89007161|NCT05677282|Experimental|Rifaximin with loperamide|
89007162|NCT05677282|Active Comparator|Azithromycin mg with loperamide|
89007163|NCT05672303|No Intervention|Control|Routine procedure will be applied
89007164|NCT05672303|Experimental|Experimental|Palmar grasp reflex will be stimulated with routine procedure.
89007165|NCT05665335|Experimental|Renuvion APR System|Subjects treated with the Renuvion APR system in both breasts.
89007166|NCT05657119|Experimental|FSN Lethal Means Reduction|"* Participants will be screened into the lethal-means reduction-focused FSN program if they answer yes to one or more of the following questions:~In the past two months, has anyone in your household been going through a rough time?~In the past two months, has someone in your home seemed down, sad, or depressed?~Are you worried that someone in your home is at risk of suicide?~Participants are then assigned to either the MI FSN intervention or the Scripted FSN intervention"
89195684|NCT00418561|Experimental|Cohort 2|100 U/kg Metazym (Recombinant human arylsulfatase A (rhASA))
88905826|NCT05797051||idiopathic membranous nephropathy|Urine samples were collected from patients with IgA nephropathy, idiopathic membranous nephropathy, diabetic nephropathy and minimal change nephropathy. The samples were centrifuged and frozen in a refrigerator at -80 degrees Celsius. The images were divided into a training set and a test set at a fixed ratio. The digital images were input into classification models such as one-dimensional convolutional neural network to learn and test. The training set was used for the training and parameter iteration of the artificial intelligence non-invasive fluid diagnosis model, and the test set was used for the recognition and interpretation of the model. The confusion matrix, accuracy and ROC curve were calculated through the interpretation results to evaluate the performance of the model.
89424331|NCT06058806|Experimental|Multimodal Physical Therapy|Patients in this group will receive Multimodal Physical Therapy program consisting of electrophysical agents, manual therapy interventions, and core stability exercises.
89424332|NCT06058780|Active Comparator|Implantable Collamer Lens (ICL)|
88905827|NCT05793996|Active Comparator|Experimental: 1|Drug: Ferinject ® (Ferric carboxymaltose)
89424333|NCT06058780|Active Comparator|Implantable Intraocular Lens (IPCL)|
89424334|NCT06058754|Experimental|ADAPT Program|The ADAPT Program is a structured and individualized group-based program
89424335|NCT06058754|Active Comparator|Usual Occupational Therapy (UOT)|UOT is delivered by one occupational therapist in the clients homes or local environments. .
89424336|NCT06058715|Experimental|TAP block|"Bilateral TAP block is administered intraoperatively at laparoscopy, directly after insufflation and insertion of the first trocar and camera. The ultrasound probe is placed longitudinally on the midaxillary line near umbilicus, and the transversus abdominis and internal oblique muscles are scanned and observed. The needle (22-gauge 90 mm disposable spinal needle) is inserted in plane. After placing the needle-tip into the fascia between transversus abdominis and internal oblique muscles, Ropivacaine 0.25% (Naropin) is injected bilaterally at the dose of 0.5 mg/kg. It is all done by one Anesthetist which is expert in that area and is not in charge of collecting the data.~No additional regional anesthesia, including epidural or spinal anesthesia, is given.~The patients are mobilized in the recovery room 2 h after surgery."
88905828|NCT05793996|Other|Comparison Group: 2|Diet therapy, without drug therapy
88905829|NCT05793996|No Intervention|Control Group: 3|Without therapy
88905830|NCT05793762||Healthy participants|30 right handed healthy participants aged between 18 and 60.
88905831|NCT05779826|Experimental|Play Dough Group|Play dough was played while receiving nebulizer therapy for the children in play dough group.
88905832|NCT05779826|No Intervention|Routine Treatment Group|Play dough was not used for the children in the routine treatment group. Routine nebulizer treatment was applied to this group.
88905833|NCT05757856|Experimental|Regimen 5|NDX-3315 or NDX-3324 delivered via oral syringe at ~ 3 mL per minute .
88905834|NCT05757856|Experimental|Regimen 10|NDX-3315 or NDX-3324 delivered via oral syringe at ~ 1.5 mL per minute.
88905835|NCT05757856|Experimental|Regimen 1|NDX-3315 or NDX-3324 delivered via oral syringe single ~15 mL dose.
88905836|NCT05757856|Experimental|Regimen 10 (Reclined)|NDX-3315 or NDX-3324 delivered via oral syringe at ~ 1.5 mL per minute while sitting reclined.
88905837|NCT05748496|Experimental|Intervention|
88905838|NCT05748496|No Intervention|Controle|
88905839|NCT05746845||Healthy individuals|"Group 1: Healthy individuals, so-called control donors whose blood samples will be collected from the EFS (French Blood Establishment)"
88905840|NCT05746845||Stable MS patients treated with high efficacy treatment|Group 2: Stable MS patients without inflammatory activity of the disease treated with high efficacy treatment (Natalizumab or Ocrelizumab)
88905841|NCT05746845||Stable MS patients treated with moderately effective treatment|Group 3: Stable MS patients without inflammatory disease activity treated with moderately effective treatment (Teriflunomide or Fumarate)
88905842|NCT05743491|Experimental|Standard Care|Cancer survivors assigned to this condition continued with the standard follow-up care provided by their treating oncologists as appropriate for individual diagnoses. Participants in the control condition were offered the 4-week YOCAS©® program gratis after completing all study requirements.
88905843|NCT05743491|Experimental|YOCAS©®|YOCAS©® is a standardized yoga program designed specifically for use by cancer patients and survivors. The YOCAS©® program is a low to moderate intensity mode of exercise that draws from two basic types of yoga: gentle Hatha and Restorative yoga. The program includes 18 specific physical postures (asanas) and mindfulness exercises focused on breathing (pranayama) and meditation (dhyana). The program is designed to be delivered by certified yoga instructors in community settings, two times a week for 75 minutes over four weeks.
88905844|NCT05731791|Active Comparator|ARM 1 - CT-based breast radiation treatment|Patients randomized to ARM 1 will receive 3000 cGy in 5 fractions partial breast radiotherapy with CT-based breast radiation treatment.
89195685|NCT00418561|Experimental|Cohort 3|200 U/kg Metazym (Recombinant human arylsulfatase A (rhASA))
89424337|NCT06058715|Active Comparator|Conventional analgesia|"No additional regional anesthesia, including epidural or spinal anesthesia, is given.~For postoperative analgesia, all patients receive paracetamol intravenously at the dose of 1 g three times up to 24 hours, starting immediately after surgery. Complementary opioids are given on request when pain numerical rating scale (pain NRS) : NRS > 3 at rest or for pain NRS > 5 on exercise. Oxycodone is given intravenously at the dose of 0.05 mg/kg only in the recovery room up to two hours after the surgery. It is administrated intramuscularly at the dose of 0.1 mg/kg up to 24 hours after surgery. Then, it is given orally at the dose of 0.2 mg/kg from 24 to 48 hours after surgery."
89424338|NCT06058702|Active Comparator|Delta-9-THC|Active delta-9-THC (0.036 mg/kg) administered intravenously over 20 minutes.
89424339|NCT06058702|Placebo Comparator|Placebo|Control: small amount of alcohol administered intravenously (quarter teaspoon), with no delta-9-THC, over 20 minutes.
89424340|NCT06058689|Experimental|Pomalidomide Test|Pomalidomide 4 MG Oral Capsule per os,1 capsule per period
89424341|NCT06058689|Experimental|Pomalidomide Reference|Pomalidomide 4 MG Oral Capsule (Pomalyst) per os,1 capsule per period
89424342|NCT06058676||Patients with reduced cerebrovascular reserve|"Interventions:~Procedure: carotid artery stenting"
89424343|NCT06058676||Patients with sufficient cerebrovascular reserve|"Interventions:~Procedure: carotid artery stenting"
89424344|NCT06058637|No Intervention|Care as usual|
89424345|NCT06058637|Experimental|Eye screening on top of care|
89424346|NCT06058624|Experimental|Veteran ACT for Chronic Pain (VACT-CP)|Participants will complete seven modules (each approximately 15 minutes) over seven weeks. The purpose of VACT-CP is to assist with at home therapeutic and behavioral self-management of chronic pain, based on the principles of acceptance and commitment therapy. Following the end of treatment (7 weeks), participants will complete post-treatment surveys at Week 7, Month 3, and Month 6 to provide feedback and information regarding 1) the intervention and 2) the potential impact of the intervention on functioning, quality of life, and other mental and physical health factors.
88905845|NCT05731791|Active Comparator|ARM 2 - MRI-based breast radiation treatment|Patients randomized to ARM 2 will receive 3000 cGy in 5 fractions partial breast radiotherapy with MRI-based breast radiation treatment.
88905846|NCT05730933|Experimental|Intervention|
89530861|NCT03344549|Other|Face-to-face consultation|In the patients of the other group, the nutritional intervention is offered through face-to-face consultations carried out by the nutritionist of the nutrition service of the institution.
89195686|NCT00897130|Experimental|Azacytidine|Azacitidine will be given at a dose of 75mg/sqm subcutaneous daily for 5 consecutive days every 28 days (every month) for a total of 8 courses. 5-Aza dosages will be adjusted.
89530862|NCT02501213|No Intervention|A : observation|Clinical monitoring and best supportive care.
88905847|NCT05730933|No Intervention|Control|
88905848|NCT05725239|Experimental|Vagus Nerve Stimulation (VNS) only|
88905849|NCT05725239|Experimental|Transcranial Magnetic Stimulation (TMS) only|
88905850|NCT05725239|Experimental|Synchronized VNS and TMS|
88905851|NCT05720689|Experimental|MEOPA dental care with music|diffusion of relaxing music during dental care under MEOPA
88905852|NCT05720689|Active Comparator|MEOPA dental care without music|dental care under MEOPA as usual
89530863|NCT02501213|Active Comparator|B : diuretics|Diuretics (spironolactone +/- Furosemide) are administered the day after the paracentesis and until the next episode requiring paracentesis.
89530864|NCT02509403|Experimental|Intervention|Essential oils infused Perineal Hygiene wipe
89424347|NCT06058624|Active Comparator|Online Pain School|Participants will complete seven modules (each approximately 15 minutes) over seven weeks. Online Pain School is designed to balance for time participating in the intervention, and is also an active online attention control. The goal of this program will be to provide Veterans with more tools and options for pain management, and the online format will allow us to monitor website use/dose. Following the end of treatment (7 weeks), participants will complete post-treatment surveys at Week 7, Month 3, and Month 6 to provide feedback and information regarding 1) the intervention and 2) the potential impact of the intervention on functioning, quality of life, and other mental and physical health factors.
89424348|NCT06058585|Experimental|Mineralocorticoid receptor antagonist|Mineralocorticoid receptor antagonist
89424349|NCT06058585|Placebo Comparator|Placebo|Placebo
89424350|NCT06058507||Patients with carotid web detected|Patients in whom carotid web was detected by examining carotid CTA images
89424351|NCT06058494||Single-Bundle|Single-bundle ACL reconstruction
89424352|NCT06058494||Single-Bundle+Lateral Plasty|Single-bundle ACL reconstruction with lateral plasty
89424353|NCT06058494||Double-Bundle|Double-bundle ACL reconstruction
89424354|NCT06058481|Experimental|Group A|The investigator inserted the BlockBuster (supraglottic airway device) in Group A patients after induction of anaesthesia.
88905853|NCT05701085|Experimental|PRE-ACT Adaptation|"At the scheduled oncologic visit: consent obtained and all participants will complete the Demographics/Clinical Characteristics survey and Pre-Intervention Survey~Within 3 months of consent: tailored educational intervention and patient navigation program will take place and the scored Pre-Intervention survey will be used to generate a list of barrier for each patient. The patient will be asked to view educational videos on an iPad that correspond with each identified barrier. Afterwards, the patient navigator will lead a discussion based on the topics discussed.~Within 4 weeks of the educational video: the participant will be contacted via phone to complete a Post-Intervention Survey that assesses knowledge, attitudes, and preparation related to participation in clinical trials~Two years after intervention: chart review will be performed to assess if the patient participated in a clinical trial."
88905854|NCT05700799|Experimental|Intervention|This is a single arm pilot intervention.
88905855|NCT05693792||Follow-up Group|Participants randomized to {WB001+TAU} and {ED001+TAU} in the parent study (WB001-001) will be assessed for 6 months following treatment completion.
88905856|NCT05686005|No Intervention|Control|No intervention
88905857|NCT05686005|Active Comparator|Oral tranexamic|The participants will receive 4 tablets of tranexamic acid 500mg (equal 2gm) 2 hours before surgery in the ward.
88905858|NCT05686005|Active Comparator|Intravenous tranexamic|The participants will receive 15 mg/kg in a 20ml syringe slowly tranexamic acid during induction.
88905859|NCT05682950|Experimental|Online Adaptive Radiotherapy|Patients receive online adaptive radiotherapy. The CTV contours of the following areas: vaginal cuff, obturator nodal chain, internal iliac nodal chain, external iliac nodal chain, presacral nodal chain and common iliac nodal chain. The upper border of CTV is at the level of aortic bifurcation. A dose of 45-50.4Gy is delivered to CTV with online adaptive radiotherapy.
88905860|NCT05681923||High-Risk Cohort|"High family risk cohort for recurrence of autism and other developmental disorders in siblings (have at least one child with a confirmed diagnosis of autism)~Specific to the High Risk cohort:~Clinical observations of the unborn child will be performed at 3 months, 6 months, 12 months, between 24 and 30 months, 36 months, between 60 and 66 months, and 72 months by psychologists or child psychiatrists in the participating hospitals. They will allow to evaluate the child's behaviors in the areas of communication and social interaction.~A video recording of the baby at 3 months of age will allow the analysis of the General Movements Assessment.~If genetic consultation is provided to the family as part of the routine care, the results will be collected and additional blood samples may be taken"
88905861|NCT05681923||Low Risk Cohort|Low family risk cohort for recurrence of autism and occurrence of other developmental disorders in siblings. The risk is comparable to the risk observed in the general population (do not have a child with autism, nor with other developmental disorders).
88905862|NCT05658757|Experimental|Regular sweetened commercial foods (processed and high added sugar)|"This is the usual habits period. Participants consume the chosen, sweetened commercial products of their choice in the breakfast cereal/cereal-granola bar category (at least 1 daily serving) and sweetened baked goods/candy/desserts (at least 1 daily serving).~If they eat peanuts or nuts, and willingly consume chocolate covered peanuts or nuts, they will eat regular sweetened chocolate covered nuts/peanuts at least 3 days a week (1 serving/day), or as frequently as their usual habits if more often.~If they consume sweetened beverages (artificial or regular) or sweetened coffee or tea, they will consume these regular sweetened beverages as they usually do."
88905863|NCT05658757|Experimental|Allulose sweetened commercial foods (processed and low added sugar)|"This period emphasizes minimizing added sugar, aligning intake levels with recommendations from the AHA and Dietary guidelines by consuming allulose sweetened products.~Participants will eat at least 1 daily serving of the chosen, provided allulose sweetened breakfast/cereal-granola bar, and at least 1 daily serving of allulose sweetened baked goods/candy/desserts in place of the usual sweetened products from these food categories.~If they eat peanuts or nuts, and willingly consume chocolate covered peanuts or nuts, eat allulose sweetened chocolate covered nuts/peanuts at least 3 days a week (1 serving/day), or as frequently as usual habits if more often.~If they consume sweetened beverages (artificial or regular) or sweetened coffee or tea, consume allulose sweetened beverages in place of their artificial or regular sweetened beverages (provided commercial and/or syrups), and sweeten coffee or tea with the provided allulose sweetener. Do this according to usual habits."
88922202|NCT05655325|Experimental|Home-based walking exercise|A 6-month partially supervised walking exercise training using a tapered approach. Participants begin with exercising (walking) in person, on-site one time per week and 3 times per week at home for a minimum exercise dosage of 30 minutes of accumulated exercise per session during month 1. During month 2, participants will exercise on-site once every other week and 3-4 times per week at home a minimum exercise dosage of 30 minutes of accumulated exercise per session. During months 2-6, participants will exercise at home 4 times per week for a minimum exercise dosage of 30 minutes of accumulated exercise per session and they will receive a phone call every two weeks to help coach and address any problems. Participants will receive a Fitbit fitness tracker that will be used to deliver their personalized exercise program, exercise monitoring, feedback, and motivational messages.
89424355|NCT06058481|Active Comparator|Group B|The investigator inserted the Proseal-LMA (supraglottic airway device) in Group B patients after induction of anaesthesia.
89424356|NCT06058390|Experimental|Group 1|Participants will receive Bepirovirsen vial administered by Healthcare Professionals (HCP).
89424357|NCT06058390|Experimental|Group 2|Participants will receive Bepirovirsen PFS SSD administered by HCP.
89424358|NCT06058390|Experimental|Group 3|Participants will receive Bepirovirsen PFS SSD self- administered with training by HCP.
89424359|NCT06058390|Experimental|Group 4|Participants will receive Bepirovirsen PFS SSD self- administered with no training by HCP.
89424360|NCT06058364|Experimental|Intervention 1|Participants receiving triglyceride supplement
89424361|NCT06058364|Placebo Comparator|Intervention 2|Participants receiving placebo
89424362|NCT06058351|Experimental|ABI-motion group|Patients following outpatient rehabilitation after implementation of the ABI-motion program
89424363|NCT06058351|No Intervention|Control group|Patients following outpatient rehabilitation before implementation of the ABI-motion program
89424364|NCT06058325|No Intervention|Control group|Students will bring their own lunch box in the control period.
89424365|NCT06058325|Experimental|Intervention group|Students will get a healthy lunch at school in the intervention period.
89424366|NCT06058312|Experimental|Experimental Arms|
89424367|NCT06058286|Experimental|Continuous quality improvement of antenatal HIV, syphilis and hepatitis B testing|Intervention facilities will receive targeted and enhanced support in line with the continuous quality improvement (CQI) approach, over a period of approximately 12 months, to promote implementation of the national guidelines and sustained provision of routine testing for HIV, syphilis and hepatitis B at least once during pregnancy. District-level CQI coaches will provide training in CQI methods to two facility representatives from each of the 20 intervention arm facilities. The CQI coaches will then work with these facility-level 'CQI advocates' to implement a process of quality improvement to identify and address barriers to antenatal testing.
89424368|NCT06058286|No Intervention|Routine antenatal care and testing|"In the control clusters, pregnant women will receive the existing standard of antenatal care, including antenatal testing for HIV, syphilis and hepatitis B (usual care).~Current Indonesian guidelines recommend antenatal screening and treatment for HIV/syphilis/hepatitis B according to clinical protocols (for syphilis this is a single rapid test with no further confirmation of positive tests before commencing treatment using one injection of penicillin at an ANC clinic; for HIV there are three sequential rapid tests with confirmed cases initiating HIV antiretroviral therapy from the closest Care Support and Treatment clinic within the pregnancy period, and for hepatitis B, pregnant women with a reactive hepatitis B serum antigen test will be referred to a hospital for management based on clinical features)"
89424369|NCT06058273|Experimental|OPHL patients|
89424370|NCT06058247|Experimental|Active nutritional supplementation|The participants in active nutritional supplementation arm received nutritional support targeting specific protein (over 1.5 g/kg/day) and calorie intake (over 20 kcal/kg/day), with consultation from the nutritional support team and the initiation of nutritional supplementation on the same day as intensive care unit admission.
89424371|NCT06058247|Experimental|Conventional nutritional supplementation|The participants in conventional nutritional supplementation arm underwent conventional nutrition management without specific protein or caloric targets.
89530865|NCT02501291|Experimental|Thalidomide|Thalidomide was administered at a daily dose of 50 mg to the patients. Dosage adjustment of thalidomide from 25mg daily to 100mg daily was tailored individually according to patients' tolerance to thalidomide. To minimize the sedative effect of thalidomide, the investigators recommended patients take a single dose of the study drug in the evening before bedtime.
89195687|NCT00894400|Experimental|Targeting of most fractionated electrograms first|During catheter ablation of AF patients will have fractionated electrograms targeted. In the experimental group the fractionated electrograms believed to be most critical will be targeted first.
89424372|NCT06058208|Experimental|Baby Smell Group|"Firstly the baby beret worn by the researcher on the baby will be removed at the end of the 12th hour (at the 12th hour and 24th hour of the hospitalization in the clinic) and taken to the Obstetrics and Gynecology Service on the same floor as the NICU without waiting;Odor stimulation will be applied in the form of 30 sec odor-30 sec standby-30 sec odor-30 sec standby-30 sec odor. A total of 4 rSO2 values, including the initial value and the average of the values during three 30 sec stimulation, will be recorded in the Cortical and Breast Oxygenation Follow-up Form. The amount of the first amount of milk, the total amount of milk until the 12th hour, the amount of oral fluid intake, the amount of milk until the 24th hour (12th hour -24th hour) and the amount of oral fluid intake will be recorded in the Milk Amount Follow-up Form."
89424373|NCT06058208|Experimental|Baby Smell and Visual Stimulus Group|Firstly the baby video (visual stimulus) and beret worn by the researcher on the baby will be removed at the end of the 12th hour (at the 12th hour and 24th hour of the hospitalization in the clinic) taken by researcher and taken to the clinic on the same floor as the NICU without waiting; Once the initial rSO2 value has been recorded, the mother will be instructed to sniff the beret uninterruptedly until further warning by the researcher and to watch the image of her baby unfolding on the tablet fixed to the floor during the entire measurement process. Odor stimulation to the mother will be applied in the form of 30 sec odor-30 sec waiting-30 sec odor-30 sec waiting-30 sec odor respectively, and visual stimulation will be applied as uninterrupted 2.5 min. At the end of 24 hours, the Mother-Baby Interaction Form and the MIBS tool will be re-applied as the final test.
89424374|NCT06058208|No Intervention|Control Group|The intervention and data collection process in the control group is the same as the intervention in the odor group; As a placebo instead of odor stimulation, the odorless beret will be offered in the same conditions.
89424375|NCT06058143|Experimental|Group 1|Patients who received CLIF-LP treatment
89424376|NCT06058143|Active Comparator|Group 2|Patients who received TLIF treatment
89424377|NCT06058117||children with invasive group A streptococcal disease|children with invasive group A streptococcal disease or other invasive or emergent infectious disease
89424378|NCT06058104|Experimental|Charades-based mobile digital therapeutic|The mobile app is a charades style game and app that engages parent and child in fluid social interaction where the parent must guess what the child is acting out based on the prompt shown on the phone screen. Participants will use their own personal phone to download the study app. Parents are asked to play with their child for 15 minutes 3-4 times per week for 8 weeks.
89424379|NCT06058104|No Intervention|Treatment as Usual|Participants in control group will continue their Applied Behavior Analysis therapy as usual for 8 weeks, and then will be able to cross-over to the treatment condition at week 8.
89424380|NCT06058000|Experimental|QLM3003 Low Dose|2% cream applied once daily (QD)
88905864|NCT05658757|Experimental|Whole and minimally processed and sweetened foods (low processed and low added sugar)|"This period emphasizes incorporating minimally processed (e.g., intact whole grains) foods with minimal to no added sugar, aligning added sugar intake levels with recommendations from the American Heart Association and Dietary guidelines.~Consume at least 1 daily serving of the chosen, minimal to no sweetened breakfast food in place of usual sweetened breakfast cereal/cereal-granola bar and consume a whole piece of fruit (or serving of fruit) in place of a sweetened baked goods/candy/desserts (at least 1 daily serving).~If they eat peanuts or nuts, consume plain or dry-roasted (no to low sodium) nuts/peanuts at least 3 days a week (1 serving), or as frequently as usual habits if more often~If consume sweetened beverages (artificial or regular) or sweetened coffee or tea, consume unsweetened coffee or tea and consume plain water in place of the sweetened beverages at the same frequency/amount that usually do"
89424381|NCT06058000|Experimental|QLM3003 Middle Dose|1.5% cream applied twice daily (BID)
89424382|NCT06058000|Experimental|QLM3003 High Dose|2% cream applied twice daily (BID)
89424383|NCT06058000|Placebo Comparator|Placebo Comparator: Vehicle|Vehicle cream applied twice daily (BID)
89424384|NCT06058000|Placebo Comparator|High Placebo Comparator: Vehicle|Vehicle cream applied twice daily (BID)
89424385|NCT06057961|Experimental|Experimental|"Personal Information Form, Difficulties in Emotion Regulation Scale-Brief Form (DERS-16), Coopersmith Self-Esteem Scale, Beck Hopelessness Scale will be applied to the intervention group as part of the pre-test application. In the research, art therapy will be applied face to face to the participants in the intervention group, in groups of 4-12 people, in the group guide room, on a common day and time determined by the group members and the researchers.The art therapy to be applied to the participants in the intervention group in the study consists of eight sessions.Each session is planned to last approximately 60-90 minutes."
88905865|NCT05654519|Active Comparator|Group QL Block|A convex transducer will be placed in the transverse plane on the flank cranial to the iliac crest to visualise the transverse process of the 4th lumbar vertebra, erector spina, quadratus lumborum and psoas muscles as a 'Shamrock sign'. The needle will inserted in to the fascial plane between the quadratus lumborum and psoas muscles and 30 ml bupivacaine 0.25% will be administered.
88905866|NCT05654519|Active Comparator|Group PENG+LFCN Block|"A linear probe will be placed on the anterior inferior iliac crest in the transverse plane while the patient is in the supine position. After rotating 45 degrees, the pubic ramus, femoral artery and psoas muscle will be visualized. Puncture will be performed in a lateromedial direction until the needle tip reached the plane between the iliopsoas tendon and the iliopubic eminence After a negative aspiration test, 25 ml bupivacaine 0.25% will be injected.~Then, the lateral femoral cutaneous nerve (LFCN) block was performed using linear US probe (10-18 MHz).The LFCN will be localized, infero-medially to the antero-superior iliac spine, laterally to the sartorius muscle and 5 ml of bupivacaine 0.25% will be carefully injected."
89195688|NCT00894400|Active Comparator|Targeting least fractionated electrograms first|During catheter ablation of AF fractionated electrograms are targeted. In this arm the least fractionated electrograms will be targeted first.
89530866|NCT02509559|Active Comparator|Propanolol|Memory performance for pictures, electrocortical activity, pharmacokinetics, skin-conductance, pulse waves, burdening heart frequency, pulmonary function, α-amylase in saliva, heart rate and blood pressure after administration of one Propranolol-CT 80 mg film-coated tablet.
89424386|NCT06057961|No Intervention|Control|"Individuals who meet the inclusion criteria and agree to participate in the research will be informed about the research and their verbal and written consent will be obtained. Interviews will be held to implement the pre-tests (Personal Information Form, Emotion Regulation Difficulties Scale-Short Form (DERS-16), Coopersmith Self-Esteem Scale, Beck Hopelessness Scale). A session will be held to implement the post-tests and to implement the Awareness of Emotions themed session with the intervention group to the control group."
89424387|NCT06057948|Experimental|Group 1|Participants will receive oral β-glucan (40 mg/kg/day) for 14 days on, and 14 days off, beginning with vaccination #1 and continuing until vaccination #5 (~20 weeks), then only one 14-day cycle with each of vaccinations #6-#10.
89424388|NCT06057948|Experimental|Group 2|Participants will receive oral β-glucan (40 mg/kg/day) for 14 days on, and 14 days off, beginning with vaccination #1 and continuing until vaccination #7 (~52 weeks), then only one 14-day cycle with each of vaccinations #8-#10.
89424389|NCT06057935|Experimental|IVC arm|Pemetrexed and cisplatin will be administered intravenously for a total of 4 to 6 cycles. Participants will receive 4 cycles, but can receive up to 6 cycles based on clinician discretion. Substitution with carboplatin allowed for pre-existing impairment of hearing, renal function, or neuropathy.
89424390|NCT06057935|Active Comparator|NIPC arm|After completion of hyperthermic intraperitoneal chemotherapy/HIPEC, an intraperitoneal catheter with a subcutaneous reservoir will be inserted through the abdominal wall. When the participant's condition is considered stable by the physicians, the NIPC will be started. Pemetrexed and either cisplatin or carboplatin will be administered through the intraperitoneal port.
89424391|NCT06057857||Employees in Ahram Canadian university|
89424392|NCT06057792|Experimental|NEGATIVE PULSED PRESSURE INTERVENTION GROUP|The number of treatment sessions will consist of a total of 6 sessions, so there will be two sessions over 3 weeks. The evaluations of the participants will be carried out before and after the first session, after the last session of the treatment program received, 15 days and one month after finishing the treatment.
89424393|NCT06057740|Experimental|ACT Bibliotherapy|Participants will read 10 chapters (140 pages) of The Anxious Perfectionist by Clarissa Ong and Michael Twohig over the course of 10 weeks.
89424394|NCT06057740|Experimental|CBT Bibliotherapy|Participants will read 8 chapters (149 pages) of When Perfect Isn't Good Enough by Martin Antony over the course of 10 weeks.
89424395|NCT06057740|No Intervention|Waitlist Control|Waitlist condition; assessment only
89424396|NCT06057051|Experimental|iStent Infinite|iStent Infinite Trabecular Micro-Bypass System
89424397|NCT06056349|Experimental|Orodispersable clonazepam|50 patients will receive oral orodispersable clonazepam.
89424398|NCT06056349|Experimental|Buccal midazolam|50 patients will receive buccal midazolam.
89424399|NCT06056349|Active Comparator|Conventional treatment|"50 patients will receive usual/ conventional treatment of seizure clusters"
89424400|NCT06056128|Experimental|Robotic assisted bronchoscopy|Robotic assisted bronchoscopy procedures performed using the Galaxy System.
89424401|NCT06054763|Experimental|Buyang Huanwu Decoction group|Oral administration of Buyang Huanwu Decoction (3 grams), two times in a day after breakfast and dinner, for 12 consecutive weeks
89007167|NCT05657119|Active Comparator|General Firearm Safety Comparison|"General Firearm Safety~* Participants will be screened into the general firearm safety arm of the program if they do not answer yes to any of the following questions:~In the past two months, has anyone in your household been going through a rough time?~In the past two months, has someone in your home seemed down, sad, or depressed?~Are you worried that someone in your home is at risk of suicide?~Participants are then assigned to either the General Firearm Safety Intervention or General Firearm Comparison"
89424402|NCT06054763|Placebo Comparator|Placebo group|the same method as the treatment group, but taking Buyang Huanwu Decoction placebo (90% starch and 10% Buyang Huanwu Decoction)
89424403|NCT06054438|Other|Group A- having treatment at second stage|"110 long-COVID patients will be divided into 2 groups (55 individuals per group).~⚫ Group A: 55 long-COVID patients (NO. 1- NO.55) Group B: 55 long-COVID patients (NO. 56- NO.110)~Group distribution and treatment in a two-stage waitlist design: ⚫ First-stage clinical trial for 12 weeks:~Group A (patients NO.1-55 will have no treatment on the waiting list) Group B (patients NO.56-110 will have Cs4 treatment)~⚫ Second-stage clinical trial for 12 weeks (After finishing the first-stage study): Group A (patients NO.1-55 will have Cs4 treatment) Group B (patients NO.56-110 will have no treatment)"
89424404|NCT06054438|Other|Group B- having treatment at first stage|"110 long-COVID patients will be divided into 2 groups (55 individuals per group).~⚫ Group A: 55 long-COVID patients (NO. 1- NO.55) Group B: 55 long-COVID patients (NO. 56- NO.110)~Group distribution and treatment in a two-stage waitlist design: ⚫ First-stage clinical trial for 12 weeks:~Group A (patients NO.1-55 will have no treatment on the waiting list) Group B (patients NO.56-110 will have Cs4 treatment)~⚫ Second-stage clinical trial for 12 weeks (After finishing the first-stage study): Group A (patients NO.1-55 will have Cs4 treatment) Group B (patients NO.56-110 will have no treatment)"
89424405|NCT06053632|No Intervention|Control group|Control group will be asked to maintain their usual lifestyle.
89424406|NCT06053632|Experimental|Experimental group|The research group performed additional low-load and high-velocity - lying prone - eccentric hamstring exercise 3 times per week for 4 weeks. 12 sessions in total.
89424407|NCT06052358||Patients with a history of AF and GI bleeding who will undergo LAAC|This is group of patients who will undergo LAAC with Watchman FLX device and have a history of AF and GI bleed.
88820185|NCT06194175||Patients undergoing bariatric surgery|"350 adults (1) suffering from obesity, with a body mass index (BMI) greater than or equal to 40, or a BMI greater than or equal to 35 with at least one obesity-related comorbidity; (2) and whose candidacy for bariatric surgery has been accepted (i.e. who have obtained an operation date).~Participants are recruited from four hospitals practicing bariatric surgery in Belgium."
89195689|NCT00398047|Experimental|Azacitadine and Hematopoietic Growth Factors|Combination of Azacitadine andHematopoietic Growth Factors
89195690|NCT04016584|Experimental|Latino adults with type 2 diabetes|"Participants of the Diabetes Pueblo Education Program will include adults with T2D from the Santa Barbara Latino community whose diabetes is poorly controlled, defined as -~hemoglobin A1c > 8% at or prior to enrollment, or~hemoglobin A1c < 8% (within the last 3 months), AND with at least one of the following (also within the last 3 months):~Fasting plasma glucose > 130 mg/dL~2-hour post-prandial or random blood glucose > 180 mg/dL~> 1 hypoglycemic event (blood glucose < 70 mg/dL) , or~adults with T2D from the community who are new to insulin or being considered for insulin therapy by their healthcare provider."
89195691|NCT00631371|Experimental|1|Bevacizumab 10 mg/kg intravenous (IV) q8wks + Temsirolimus 25 mg IV weekly
89195692|NCT00631371|Active Comparator|2|Bevacizumab 10 mg/kg intravenous (IV) q8wks + Interferon-Alfa 9MU SC TIW
89195693|NCT00409747|Experimental|Minocycline|
89195694|NCT04016740|Experimental|Multimodal General Anesthesia|"Intraoperative~The anesthesiologists involved in this study will be trained to infer differences in anti-nociception, unconsciousness movement and changes during other perioperative events by monitoring EEG. They will also be trained in titrating hypnotic and nociceptic medications based on changes in EEG.~Routine anesthetic induction~Bilateral Pectoro-interfascial block (PIFB) with 20 mL of 0.25% ropivacaine on either side of the sternum after anesthetic induction but before surgical incision~Ketamine (0.06 to 0.12 mg.kg/hr)~Remifentanil (0.05-0.2 mcg/kg/min)~Dexmedetomidine (0.2-1.0 mcg/kg/hr)~Rocuronium intermittent bolus (TOF)~Propofol infusion ± Sevoflurane titrated based on EEG monitoring~Postoperative~Standard pain management protocol~Dexmedetomidine infusion 0.2-1.4 mcg/kg/hr (EEG guided)~Infusion continued till extubation~Propofol infusion may be added/used for sedation based on the treating physician's discretion"
89195695|NCT04016740|Other|Standard Practice with EEG monitoring|The initial 2 patients will receive standard anesthesia practice and perioperative EEG monitoring will be recorded to learn the patterns associated with our standard practice.
89195696|NCT01035541||P group|Fluid Management according to measurements with PiCCO®
89195697|NCT01035541||C group|Conventional fluid management
89195698|NCT01039831||Patients with Parkinson's Disease|Consecutive patient sampling
89195699|NCT02540512|Placebo Comparator|Standard Drug Group|"Participants randomized into this group will be receiving the standard medical care and placebo acupuncture. For the placebo acupuncture procedure, the ASP® needles will be double taped onto the ear in the same anatomical position as the acupuncture groups. The needles will be taped so that the needles will never puncture the skin. The patients will then be given hydrocodone / acetaminophen 5mg/325mg (generic) with a prescription to take home and use as needed."
89195700|NCT02540512|Experimental|Standard Drug Plus Acupuncture Group|"The participants in this group will receive auricular acupuncture following the Battlefield Acupuncture Protocol. The patients will then be given hydrocodone / acetaminophen 5mg/325mg (generic) with a prescription to take home and use as needed (in the acupuncture groups, the physician administering the treatment will not know if the patient is receiving the standard drug or the placebo pill). The physician can administer up to 10 needles (5 in each ear) until the patient has a significant drop in pain (pain level 0 or 1)."
89195701|NCT02540512|Experimental|Acupuncture Group|"The participants in this group will receive auricular acupuncture following the Battlefield Acupuncture Protocol. The physician can administer up to 10 needles (5 in each ear) until the patient has a significant drop in pain (pain level 0 or 1). The patient will then be given a placebo pill."
89195702|NCT01039909|Placebo Comparator|Placebo|"The Placebo treatment group will be administered 8 placebo capsules per day. Placebo will be administered orally once daily for twenty-eight consecutive days.~During the clinic visits, the subjects will receive placebo approximately 15 minutes following the start of consumption of a standardized meal. During non-clinic days, the subject will self-administer the test material approximately 15 minutes following the start of consumption of a standardized meal. Test material should be administered with approximately 400 mL of water at approximately the same time every dosing day. Subjects must wait at least 2 hours before consuming additional calories."
89195703|NCT01039909|Active Comparator|2.0g SRT2104|"The 2.0g SRT2104 treatment group will be administered 8 SRT2104 0.25g capsules per day. 2.0g SRT2104 will be administered orally once daily for twenty-eight consecutive days.~During the clinic visits, the subjects will receive SRT2104 approximately 15 minutes following the start of consumption of a standardized meal. During non-clinic days, the subject will self-administer the test material approximately 15 minutes following the start of consumption of a standardized meal. Test material should be administered with approximately 400 mL of water at approximately the same time every dosing day. Subjects must wait at least 2 hours before consuming additional calories."
89195704|NCT00825903|Experimental|1|Aquatic based exercise
89195705|NCT03742375|Experimental|HPV genotyping|
89195706|NCT00894478||1|12 children with MRI-negative partial epilepsy who are being worked-up for epilepsy surgery
89195707|NCT00894478||2|12 children with MRI-visible FCD who are being worked-up for epilepsy surgery
89195708|NCT00894478||3|Control Group- Healthy Volunteers
89195709|NCT00897442||Ancillary-Correlative (biomarker sampling and analysis)|Snap frozen tumor tissue, OCT molds of tumor tissue, formalin-preserved tumor tissue, buffy coat-prepared tumor tissue, and blood samples are collected and stored in the repository. Patient information is kept confidential, and patients are not informed of any research/test results from use of their tissues.
89195710|NCT04017676|No Intervention|Control group|The first group will be under the usual treatment conditions (TAU)
89195711|NCT04017676|Experimental|Experimental group|The second group will be exposed to a multidisciplinary therapeutic program that has a monitoring component and after two months an intervening component will be.
89424408|NCT06052358||Patients with a history of AF and GI bleeding without LAAC|This is a historical cohort of patients with AF and recurrent GI bleeding without LAAC.
89424409|NCT06051903|Experimental|Talar mobilization with movement|(group A) postmenopausal women who receive the talar mobilization with movement technique for knee joint , their age raged from 50-60 years (n= 20)
89424410|NCT06051903|Experimental|Acupuncture for knee joint|(group B) postmenopausal women who receive acupuncture for knee joint (n= 20), their age ranged from 50-60 years
89424411|NCT06051279||Cases with TNH|Newborns with raised TSH level and normal FT4 (the confirmed raised TSH cases after thyroid hormone screening) that return normal without intervention within one month after birth.
89424412|NCT06051279||Cases with permanent congenital hypothyroidism|Newborns with raised TSH level and low FT4 (confirmed cases after thyroid hormone screening)
89424413|NCT06051279||Control group|Control group with matched age and gender with normal TSH at birth according to the neonatal TSH screening. Matched normal neonates will be selected to be compared with transient neonatal hyperthrotropinemia cases and permanent congenital hypothyroidism cases for studying of the predictors of transient neonatal hyperthyrotopinemia.
89424414|NCT06047392|No Intervention|Usual Care|
89424415|NCT06047392|Active Comparator|CT coronary angiography + usual care|
89424416|NCT06047262|Experimental|Intervention Group|1000 mg dapansutrile (2 × 500mg tablets) administered twice a day from day 1 through the week 26 visit, inclusive. All tablets will be self-administered by mouth with water, with or without food.
89424417|NCT06047262|Placebo Comparator|Control Group|Matching placebo (2 tablets) administered twice a day from day 1 through the Week 26 visit, inclusive. All tablets will be self-administered by mouth with water, with or without food.
89424418|NCT06045988|Experimental|Long-Term Care Facility Residents with Alzheimer's Disease or other Related Dementias|
89424419|NCT06045663|Active Comparator|laminectomy group|"patient will divided into two group the first group will undergo cervical laminectomy while the second group will undergo cervical laminectomy with lateral mass fixation .all surgical related events and comorbidities will be recorded.~the patient will examine after 3 months of operation and patient's myelopathy grade and functional status was evaluated after 6 months using modified Japanese orthopedic association (mJAO) score. Radiological Follow-up by using plain X-rays, 6 months follow up assessment of cervical spine sagittal alignment using (C2-C7) Cobb's angle and MRI scan if needed follow up will be at our department follow up clinic ."
89424420|NCT06045663|Active Comparator|laminectomy with lateral mass fixation|"patient will divided into two group the first group will undergo cervical laminectomy while the second group will undergo cervical laminectomy with lateral mass fixation .all surgical related events and comorbidities will be recorded.~the patient will examine after 3 months of operation and patient's myelopathy grade and functional status was evaluated after 6 months using modified Japanese orthopedic association (mJAO) score. Radiological Follow-up by using plain X-rays, 6 months follow up assessment of cervical spine sagittal alignment using (C2-C7) Cobb's angle and MRI scan if needed follow up will be at our department follow up clinic ."
89424421|NCT06044909||Patients undergoing minimally invasive hepatectomy by conventional or robot-assisted laparoscopy|Patients undergoing minimally invasive hepatectomy by conventional or robot-assisted laparoscopy will be included.
89424422|NCT06042465|Experimental|TCM group|As decided and performed by the registered Chinese Medicine Practitioners (CMP) on standardized treatment method
89424423|NCT06042465|Experimental|PT group|As decided and performed by physiotherapist of HKBH on standardized treatment method
89424424|NCT06042465|No Intervention|Educational Group|Included patients in this group are provided with educational talk on knee health protection. Patients are advised with daily-life protection on their PFPS. Questionnaire assessments are performed to assess the healthy situation of their PFPS.
89195712|NCT04035772|Experimental|Wiki101 and WikiTrauma|"Wiki101, a theory-based continuing professional development (CPD) program, will train participants at the selected trauma centers to use WikiTrauma effectively and safely to create and share different types of Knowledge Transfer (KT) tools (e.g., care protocols, order sets, patient decision aids). Participants will receive Wiki101 training and then gain access to WikiTrauma with editing rights to the knowledge implementation tools (e.g. care protocols, order sets, care pathways) found in the wiki.~WikiTrauma is the wiki we created to promote best practices in trauma care and will be implemented in four trauma centers in Quebec during 12 months. During this period, we will continue to measure the impact on the quality of care."
89424425|NCT06039072||Subjects in the withdrawal group|Subjects received a combination of ACEI/ARB analogues, beta-blockers, MRA analogues, and diuretics during the standardized treatment phase, and after their cardiac function was restored, in order to avoid adverse effects on patients' cardiac function due to sudden withdrawal of drugs, the drugs were withdrawn according to a program to gradually stop the drug
89424426|NCT06039072||Subjects in the continuing medication group|Subjects received a combination of ACEI/ARB analogues, beta-blockers, MRA analogues, and diuretics during the standardized treatment phase, and were continued on the original regimen after their cardiac function recovered
89424427|NCT06033534|Experimental|STIMULAN DEVICE USED|Patients allocated to this arm will receive an extended-release antibiotic device, STIMULAN, as a prophylactic measure against bacterial infection post-fracture repair surgery. The device is designed to release antibiotics in a controlled manner over a specified period of time.
89424428|NCT06033534|No Intervention|STIMULAN DEVICE NOT USED|Patients in this arm will undergo the surgical repair of their open fracture but will not receive any antibiotic device for prophylaxis against bacterial infections.
89424429|NCT06032780|Experimental|Eccentric Resistive Training + Aerobic training Group|
89424430|NCT06032780|Active Comparator|Resistance Training + Aerobic training Group|
89424431|NCT06032780|Active Comparator|Aerobic training Group|
89195713|NCT00894634|Experimental|Brompheniramine maleate|Brompheniramine maleate oral solution 1 mg/5 mL, single dose
89195714|NCT02540278|Experimental|Treatment|Received the 11 lesson Positive Prevention Curriculum
89195715|NCT02540278|No Intervention|Control|Did not receive any sex-related instruction
89195716|NCT00630747|Experimental|Idursulfase|
89195717|NCT02540902|Experimental|All-poly|Knee arthroplasty with all-polyethylene tibia
89195718|NCT00819663||Crohns patients|Established Crohn's disease patients who underwent CTE imaging before and after initiating infliximab therapy
89195719|NCT05278078|Other|psychological support|Psychological support will be given to the experimental group.
89424432|NCT06021860|Experimental|Part 1: multiple doses spironolactone oral suspension (Group 1)|Patients aged ≥12 to ≤17 years of age in Part 1 of the study, administered spironolactone oral suspension QD for 10 days
89424433|NCT06021860|Experimental|Part 1: multiple doses spironolactone oral suspension (Group 2)|Patients aged ≥6 to <12 years of age in Part 1 of the study, administered spironolactone oral suspension QD for 10 days
89424434|NCT06021860|Experimental|Part 1: multiple doses spironolactone oral suspension (Group 3)|Patients aged ≥2 to <6 years of age in Part 1 of the study, administered spironolactone oral suspension QD for 10 days
89424435|NCT06021860|Experimental|Part 1: single and multiple doses spironolactone oral suspension (Group 4)|Patients aged from birth to <2 years of age in Part 1 of the study, administered spironolactone oral suspension as a single dose, and then QD for 10 days
89424436|NCT06021860|Experimental|Part 2: multiple doses spironolactone oral suspension (Group 1)|Patients aged ≥12 to ≤17 years of age in Part 2 of the study, administered low or high dose spironolactone oral suspension QD for 10 days
89424437|NCT06021860|Experimental|Part 2: multiple doses spironolactone oral suspension (Group 2)|Patients aged ≥6 to ≤12 years of age in Part 2 of the study, administered low of high dose spironolactone oral suspension QD for 10 days
89424438|NCT06021860|Experimental|Part 2: multiple doses spironolactone oral suspension (Group 3)|Patients aged ≥2 to ≤6 years of age in Part 2 of the study, administered low or high dose spironolactone oral suspension QD for 10 days
89424439|NCT06021860|Experimental|Part 2: single and multiple doses spironolactone oral suspension (Group 4)|Patients aged from birth to <2 years of age in Part 2 of the study, administered low or high dose spironolactone oral suspension as a single dose, and then QD for 10 days
89424440|NCT06019832|Active Comparator|Group A: Stemmed Tibial Implant|This study group will receive a stemmed tibial implant as part of their TKA.
89424441|NCT06019832|Active Comparator|Group B: Non-Stemmed Tibial implant|This study group will receive a non-stemmed tibial implant as part of their TKA.
89424442|NCT06019026|Experimental|Tri-Lock|Total hip arthroplasty performed through posterolateral access using the uncemented Tri-Lock short stem.
89424443|NCT06019026|Active Comparator|Summit|Total hip arthroplasty performed through posterolateral access using the uncemented Summit standard stem.
89424444|NCT06007742|Experimental|Intervention group: parent-administered pediatric tuina (n=20)|
89424445|NCT06007742|Active Comparator|Active control group: parent-child interactive exercise (n=20)|
89424446|NCT06007742|No Intervention|Control group: usual care (n=20)|
89424447|NCT06004713||Cohort A|Patients will initially receive monotherapy PD1/PDL1 monoclonal antibody therapy.
89195720|NCT05278078|Other|nutritional education|Nutrition education will be given to the experimental group.
89424448|NCT06004713||Cohort B|Patients will initially receive dual blockade of both PD1/PDL1 and CTLA4
89424449|NCT06004713||Cohort C|Patients will initially receive PD1/PDL1 monoclonal antibody combined with chemotherapy or targeted therapy.
89424450|NCT06004713||Cohort D|Patients will receive other standard treatments for this tumor other than ICIs.
89424451|NCT06002750||Dermatomyositis patients|
89195721|NCT05278078|Other|psychological support and nutritional education|psychological support and nutritional education will be given to the experimental group.
89195722|NCT05278078|Other|no intervation|No intervention will be applied to the control group
89424452|NCT06002750||The control group was comprised of age- and gender-matched healthy volunteers|
89195723|NCT00823485|Active Comparator|2|drainage of hemorraghia
89195724|NCT00823485|Experimental|1|Actylise
89195725|NCT00897832||pancreatic cancer|Patients with pancreatic cancer
89195726|NCT02550405|Experimental|Craving behavioral intervention|The craving behavioral intervention (CBI) was developed based on the framework of craving, combining with behavior intervention (Dong and Potenza, 2014), and conducted among individuals with IGD.
89195727|NCT02550405|No Intervention|Control|The control group were individuals with Internet gaming disorder who did not receive any intervention but were scanned twice with the similar interval period as experimental group.
89195728|NCT00823641|Experimental|Infliximab|Infliximab 3mg/kg infused intravenously at weeks 0, 2 and 8 and then every 8 weeks until and including week 40 of the study
89195729|NCT00397891|Experimental|1|bapineuzumab 0.15 mg/kg or placebo
89195730|NCT00397891|Experimental|2|bapineuzumab 0.5 mg/kg or placebo
89195731|NCT00397891|Experimental|3|bapineuzumab 1.0 mg/kg or placebo
89195732|NCT03859557||4-Quadrant Random Forceps Biopsy|Random sampling within a quadrant of esophageal tissue using forceps.
89195733|NCT03859557||WATS biopsies|Wide area transepithelial sampling with computer aided pathologic interpretation of tissue.
89195734|NCT00823875|Experimental|1|
89195735|NCT00823875|Experimental|2|
89195736|NCT00823875|Experimental|3|
89424453|NCT06001528||Discovering cohort|Discovering cohort was used for the discovery and screening of metabolic differences. Two groups were included-SLN+ group and SLN- group, meaning the breast cancer patients with/without sentinel lymph node metastasis respectively. Abundance and distribution of serum and tissue metabolites in this cohort of patients would be observed.
89424454|NCT06001528||Modeling cohort|Modeling cohort refer to the cohort of patients included for targeted metabolites detection. Two groups were included-SLN+ group and SLN- group. Abundance and distribution of targeted metabolites in this cohort of patients would be detected, and a predictive model would be established using the data of this cohort.
89424455|NCT06001528||Validation cohort|Validation cohort means a cohort of patients included to validate the prediction model established in the modeling stage. Patients of validation cohort will be enrolled from several different hospitals. Also, it included SLN+ group and SLN- group. Abundance and distribution of targeted metabolites in this cohort of patients would be detected, and the accuracy and stability of prediction model will be verified in this cohort.
89424456|NCT06001346|Experimental|ActiveCBT|Participants will complete a standardized 30-minute exercise session on a stationary bike prior to therapy. Participants will view one of 8 standardized 30-minute nature documentary videos while exercising.
89424457|NCT06001346|Active Comparator|CalmCBT|Participants will view one of 8 standardized 30-minute nature documentary videos while resting quietly prior to therapy.
89424458|NCT05995132||Intensive care unit|This group will be composed of patients admitted to the intensive care unit who did not receive invasive mechanical ventilation.
89007168|NCT05654662|Experimental|Corsodyl Original Dentifrice|Participants will be instructed to brush their teeth using test product for at least a minute twice a day (morning and evening) for 12 weeks. Participants will dose the toothbrush provided with a ribbon of paste to cover the brush head (a full brush head) on each brushing occasion.
89007169|NCT05654662|Active Comparator|Colgate Cavity Protection Dentifrice|Participants will be instructed to brush their teeth using reference product for at least a minute twice a day (morning and evening) for 12 weeks. Participants will dose the toothbrush provided with a ribbon of paste to cover the brush head (a full brush head) on each brushing occasion.
89424459|NCT05995132||Intensive care unit and invasive mechanical ventilation|This group will be composed of patients admitted to the intensive care unit who did receive invasive mechanical ventilation.
89424460|NCT05989165|Experimental|Minoxidil 5% solution|Patients will receive minoxidil 5%, twice a day, for a total duration of 12 weeks.
89424461|NCT05989165|Experimental|Combination therapy of microneedling and minoxidil 5% solution|Patients will receive a combination therapy of microneedling and minoxidil 5%. Minoxidil 5%, will be given twice a day for a total duration of 12 weeks. The microneedling treatment will be given every 4 weeks (week 0, week 4, week 8)for a total duration of 12 weeks.
89007170|NCT05650567|Experimental|Double-blind Placebo Controlled (DBPC) Period: M5049 high dose|
89007171|NCT05650567|Placebo Comparator|DBPC Period: Placebo|
89007172|NCT05650567|Experimental|Open Label Extension (OLE) Period: M5049 high dose|
89007173|NCT05633459|Experimental|QRL-201 - Arm 1|Placebo Comparator: Placebo consists of the same components as the formulation buffer for QRL-201
89007174|NCT05633459|Experimental|QRL-201 - Arm 2|Placebo Comparator: Placebo consists of the same components as the formulation buffer for QRL-201
89007175|NCT05633459|Experimental|QRL-201 - Arm 3|Placebo Comparator: Placebo consists of the same components as the formulation buffer for QRL-201
89007176|NCT05633459|Experimental|QRL-201 - Arm 4|Placebo Comparator: Placebo consists of the same components as the formulation buffer for QRL-201
89007177|NCT05633459|Experimental|QRL-201 - Arm 5|Placebo Comparator: Placebo consists of the same components as the formulation buffer for QRL-201
89007178|NCT05633459|Experimental|QRL-201 - Arm 6|Placebo Comparator: Placebo consists of the same components as the formulation buffer for QRL-201
89007179|NCT05633459|Experimental|QRL-201 - Arm 7|Placebo Comparator: Placebo consists of the same components as the formulation buffer for QRL-201
89007180|NCT05633459|Experimental|QRL-201 - Arm 8|Placebo Comparator: Placebo consists of the same components as the formulation buffer for QRL-201
89007181|NCT05626634|Experimental|LP352|Subjects will be titrated up to highest tolerated dose of LP352 during a 15-day period, followed by a 48-week maintenance period and a 15-day taper/down titration period.
89007182|NCT05601284|Experimental|Acceptance and commitment therapy|ACT teaches skills to develop acceptance, mindfulness, and defusion from difficult internal experiences while increasing connections with personal values and encouraging meaningful behavioral changes. ACT for misophonia combines core ACT processes with a traditional audiological behavioral intervention for a integrated, multi-disciplinary approach for the assessment and treatment of misophonia. Treatment begins with a brief focus on the behavioral intervention, followed by the teaching of ACT skills to support the use of the behavioral methods. The intervention consists of 12 total individual sessions of ACT+behavioral management.
89007183|NCT05601284|Active Comparator|Progressive relaxation training|PRT for misophonia consists of basic psychoeducation for misophonia followed by PRT. PRT involves learning to tense and relax muscles. Early sessions focus on tensing and relaxing smaller muscle groups, while later sessions focus on larger muscle groups. Final sessions focus on relaxation as produced by recalling previous relaxation and a review of skills learned. PRT consists of 12 individual total sessions.
89007184|NCT05599048|Experimental|Part A / Phase 1: Feasibility Run-In|Participants will undergo MR imaging at a single time point. Imaging will take one day. and no follow up is planned.
89007185|NCT05599048|Experimental|Part B/ Phase II: Biomarker Cohort|Participants will undergo paired hyperpolarized pyruvate/metabolic MR imaging at baseline and again after approximately 21 days of the participants SOC or investigational therapy outside of this protocol.
89007186|NCT05598333|Experimental|AB-1002|"Randomized in 1:1:1 into one of three groups.~Group 1: 3.25E13vg (n=30-50)"
88905867|NCT05649150||Healthy group|For healthy group A.K.As adults without LBP are: (1) aged from 20 to 65 years old, (2) no specific low back pain in the past 6 months.
88905868|NCT05649150||LBP group|The inclusion criteria for adults with LBP are: (1) aged from 20 to 65 years old, (2) persistent LBP for more than 3 months.
89007187|NCT05598333|Experimental|Treatment Group 2 AB-1002|"Randomized in 1:1:1 into one of three groups.~Group 2: 6.5E13vg (n=30-50)"
89007188|NCT05598333|Placebo Comparator|Treatment Group 3|"Randomized in 1:1:1 into one of three groups.~Group 3: Placebo (n=30-50)"
89195737|NCT00823875|Other|4|Control Group
89424462|NCT05988489|Experimental|Dynamic Deconstructive Psychotherapy (DDP)|53 participants will meet with an assigned DDP therapist in-person or through televideo for 50 to 60 minutes on a weekly basis for 12 months. Participants will also meet with a psychiatric provider for a 60-minute psychiatric consultation with at least monthly 30-minute follow-up visits. In addition, participants in this arm will have the option of attending family and group therapy if interested and indicated. At baseline, 3, 6, 9, and 12 months, participants will meet with a research coordinator for 60-minute visits to complete outcome measures.
89530867|NCT02509559|Placebo Comparator|Placebo|Memory performance for pictures, electrocortical activity, pharmacokinetics, skin-conductance, pulse waves, burdening heart frequency, pulmonary function, α-amylase in saliva, heart rate and blood pressure after administration of one placebo capsule.
89530868|NCT00707993|Experimental|Alogliptin 25 mg QD|
89530869|NCT00707993|Active Comparator|Glipizide 5 mg QD|
88905869|NCT05643196|Experimental|Pulsed Low-Intensity Focused Ultrasound (PLIFUS), then Sham|Participants will receive PLIFUS sonication on the first intervention visit, then sham sonication on the second intervention visit. Visits will be separated by 1 week. Sonication at both visits will be preceded and followed by fMRI and an exit medical examination. Sonication will be delivered in a pulse pattern over 10 minutes.
89424463|NCT05988489|Active Comparator|Brief Intervention and Contact (BIC)|53 participants will meet with an assigned BIC therapist in-person or through televideo for an initial 60-minute visit with eight 30-minute follow-up contacts at 1, 2, 4 weeks and 2, 3, 4, 6 and 12 months after study entry. Participants will also meet with a psychiatric provider for a 60-minute psychiatric consultation with at least monthly 30 minute follow-up visits. In addition, participants in this arm will be encouraged to receive services in the community, such as weekly individual psychotherapy, family and group therapy. At baseline, 3, 6, 9, and 12 months, participants will meet with a research coordinator for 60-minute visits to complete outcome measures.
89424464|NCT05974176|Experimental|Trauma Focused CBT (TF-CBT)|Patients and families randomized to engage in TF-CBT.
89424465|NCT05974176|Experimental|Trauma Systems therapy (TST)|Patients and families randomized to engage in TST.
89424466|NCT05963906||SCFI|SCFI participants will complete a survey once per week for three consecutive weeks. They will participate in training for the FoodImage app and deploy it the last two weeks of their study period. During these last two weeks, these participants will also have waste collected on designated days by a waste pickup contractor.
89424467|NCT05963815||Degenerative spine disorder|Patients who are eligible for surgical treatment of the spine, including a lumbar herniated disk or lumbar spinal canal stenosis, discopathy and spondylolisthesis.
89424468|NCT05958368|Experimental|Avocado|Participants will consume 1 Hass avocado a day.
89424469|NCT05958368|Active Comparator|Other Fruit(s)|Participants in the other fruit arm will receive other fruits.
89424470|NCT05948371|Experimental|High Intensity interval Training|
89424471|NCT05948371|Active Comparator|Continuous Aerobic training|
89424472|NCT05948306|Experimental|Patient-centered skin care group|A patient-centered skin care protocol developed according to the Stetler Model will be applied to the experimental group.
89424473|NCT05948306|No Intervention|Routine skin care group|The routine skin care of the ICU will be applied to the control group during the study.
89424474|NCT05947032|Experimental|Supervised endurance exercise training + Patient Education|
89007189|NCT05571410|Experimental|Intervention|Patients assigned to intervention arm will a text message notifying them of enrollment, be mailed a BP cuff and receive a recruitment phone call if nonresponsive to text. If the patient does not opt out, the research coordinator will mail a blood pressure cuff and proper measurement instructions and start their remote monitoring program in the Way to Health platform. Intervention arm participants will also receive usual care. Usual care for hypertension is as needed determined by the clinical expertise of the primary care provider and can include regular follow-up visits (in person or virtual), home blood pressure readings, titration of medications during visits or via telephone, referral to specialty care (e.g., Nephrology or Cardiology), blood tests or imaging studies.
89007190|NCT05571410|No Intervention|Control|Patients in the usual care arm will not be contacted by study staff at the start of the pilot, they will not receive a blood pressure cuff, and they will not receive any text messaging or any component of the program. They will eventually be contacted by study staff to schedule the 6 month BP check. Usual care for hypertension is as needed determined by the clinical expertise of the primary care provider and can include regular follow-up visits (in person or virtual), home blood pressure readings, titration of medications during visits or via telephone, referral to specialty care (e.g., Nephrology or Cardiology), blood tests or imaging studies.
89007191|NCT05564273|No Intervention|Placebo|Participants may be provided with any combination of nutritional recommendations and they receive placebo supplements. Placebo capsules will contain inert and inactive materials. The participants are asked to take the supplements on a daily basis.
89007192|NCT05564273|Active Comparator|Viome's Precision Nutrition Program|Participants may be provided with any combination of nutritional recommendations and supplements. The participants are asked to take the supplements on a daily basis.
89424475|NCT05947032|Active Comparator|Home exercises + Patient Education|
89424476|NCT05946226|Experimental|IMC002 dose 1-3|IMC002 single infusion
89424477|NCT05913921|Experimental|Sequence TR|16 healthy subjects assigned to the sequence TR were administrated intravenously for 120 mins with the test product of amphotericin B liposome for injection in period 1 and the reference product of AmBisome® in period 2
89424478|NCT05913921|Experimental|Sequence RT|16 healthy subjects assigned to the sequence RT were administrated intravenously for 120 mins with the reference product of AmBisome® in period 1 and the test product of amphotericin B liposome for injection in period 2
89424479|NCT05908409|Experimental|Dose Escalation: IDP-121 0.015 Up to 0.70 mg/kg|"IDP-121 will be administered as a 4-hours i.v. infusion twice a week (3 weeks on, 1 week off) on days 1, 4, 8, 11, 15 and 18 in 28-day treatment (a Cycle) (Table 4). A minimum interval of 3 days and no more than 5 days between dosing is allowed.~Patients can receive IDP-121 until disease progression, unacceptable toxicity or any other discontinuation criteria are met, or for a maximum treatment period of 1 year, whichever occurs first. Patients at the RP2D may enter the expansion phase."
89424480|NCT05908409|Experimental|Expansion Phase: IDP-121 at RP2D|Additional 17 patients will be enrolled for treatment at the RP2D level to further study safety and evaluate efficacy. DP-121 will be administered as a 4-hours i.v. infusion twice a week (3 weeks on, 1 week off) on days 1, 4, 8, 11, 15 and 18 in 28-day treatment Patients can receive IDP-121 until disease progression, unacceptable toxicity or any other discontinuation criteria are met, or for a maximum treatment period of 1 year, whichever occurs first.
89424481|NCT05906641|Experimental|High-protein diet|Participants will receive an isocaloric diet with a distribution of 50% carbohydrates, 30% fat and 20% protein for the two-week intervention. Additionally, they will receive a dietary supplement for the second week that will contribute another 10% of protein, obtaining 30% of protein consumption in the second week.
89424482|NCT05868954|Active Comparator|American College of Obstetricians and Gynecologists (ACOG)-based Dietary Program|Routine dietary counseling program
89424483|NCT05868954|Experimental|Mediterranean Diet (MedDiet) Program|Well-known healthy diet that consists of a large amount of plant-based foods such as fruits, vegetables, beans, and nuts with extra virgin olive oil (EVOO) as the principal source of fat. Dairy, fish, and poultry are consumed in moderation and red meat only eaten occasionally.
89424484|NCT05864742|Experimental|Standard-Risk Cohort|Patients without the high-risk mutations (no 9p21.1-24.3 loss, no SMARCA2 or SMARCA4 mut/del) will be treated with ibrutinib, rituximab and venetoclax.
89424485|NCT05864742|Experimental|High-Risk Cohort|Patients with the high-risk mutations (9p21.1-24.3 loss, SMARCA2 and/or SMARCA4 mut/del) will be treated with ibrutinib, rituximab, venetoclax and navitoclax.
89424486|NCT05859490|Experimental|Vaccination arm|Participants will receive a standard dose of of the yellow fever vaccine 17D (YFVax(r)), 0.5mL suspension in normal saline administered subcutaneously once.
89424487|NCT05845996|Experimental|SAR441344|Single or multiple Ascending dose of SAR441344 Dose 1 administered intravenously and/or subcutaneously
89424488|NCT05845996|Placebo Comparator|placebo|matching placebo
89424489|NCT05843253|Experimental|Stratum A (n=40)|Patients with localized, intracranial, non-pontine, and non-thalamic HGG (who do not meet criteria for strata B, C, or D).
89424490|NCT05843253|Experimental|Stratum B (n=40)|Patients with DIPG, defined as a tumor with pontine epicenter and diffuse involvement of at least 2/3 of the pons, with histopathology consistent with diffuse WHO grade 2-4 glioma (e.g., diffuse astrocytoma, anaplastic astrocytoma, glioblastoma, H3K27-altered diffuse midline glioma).
89424491|NCT05843253|Experimental|Stratum C (n=6-12)|Patients with primary thalamic, spinal cord, and/or secondary (radiation-related) HGG.
89424492|NCT05843253|Experimental|Stratum D (n=6-12)|Patients with metastatic/disseminated HGG, multifocal HGG, and/or gliomatosis cerebri who received craniospinal irradiation.
89424493|NCT05836766|Active Comparator|Y-6 sublingual tablets|Y-6 sublingual tablets (each tablet contains 25 mg cilostazol and 6 mg dexborneol) Manufacturer: Nanjing Neurodawn Pharmaceutical Co., Ltd.
89424494|NCT05836766|Placebo Comparator|Placebo tablets of Y-6 sublingual tablet|Y-6 strength: Placebo tablets of Y-6 sublingual tablet (each tablet contains 0 mg cilostazol and 0.06 mg dexborneol) Manufacturer: Nanjing Neurodawn Pharmaceutical Co., Ltd.
89424495|NCT05825235|Experimental|Pramipexole|Pramipexole prolonged-release tablet with doses ranging from 0.26 mg base to 3.15 mg base / day, study duration 6 months
89424496|NCT05822375|Experimental|Intervention|Will be offered the BT coaching intervention over 4-months (Sept 1st 2023- Dec 31st 2023).
89424497|NCT05822375|No Intervention|Waitlist control|Will be offered the coaching intervention following 4-month waitlist control (Feb 1st 2024 - May 31st 2024).
89424498|NCT05812924|Experimental|Platelet-rich plasma (PRP) Group|Participants will undergo two sessions of platelet-rich plasma (PRP) injections to the vulva/vagina one month apart.
89424499|NCT05808803||HIV without leukemia|
89424500|NCT05808803||HIV leukemia|
89424501|NCT05806190||Study group|Participants who live with insulin- treated diabetes and adrenal insufficiency.
89424502|NCT05806190||Control group|Participants who live with adrenal insufficiency and NOT with insulin-treated diabetes.
89424503|NCT05796648|Experimental|Food is Medicine approach|Groups of 10 will attend a 12 week intervention that includes cooking classes, grocery delivery and nutrition education.
89424504|NCT05791877|Experimental|cerebral palsy group|Respiratory sensor will measure breathing in patients with Cerebral palsy
89424505|NCT05787418|Experimental|HH-120 group|HH-120 Nasal Spray
89424506|NCT05787418|Placebo Comparator|Control group|Placebo
89424507|NCT05785442|Placebo Comparator|Placebo|Treatment Arm 1: patients receiving placebo (N/S 0.9% w/v) subcutaneously once daily for 10 days plus Standard of Care
89424508|NCT05785442|Active Comparator|Anakinra|Treatment Arm 2: patients receiving anakinra subcutaneously 100 mg once daily for 10 days plus Standard of Care
89424509|NCT05774132|Active Comparator|ultrasound guided Subgluteal sciatic nerve block group|using 0.25% bupivacaine ( 0.3ml/Kg )
89424510|NCT05774132|Active Comparator|ultrasound guided Caudal block group|using 0.25% bupivacaine ( 1ml/Kg)
89424511|NCT05766735|Active Comparator|Routine Care (RC)|Participants will be actively working with their primary care provider during the study and will attend appointments with their provider as needed. The study team will monitor their progress at the scheduled Assessment Visits. The participants should discuss any concerns they have, including side effects or cost, in order to adjust the medication regime with their primary care team. Their physician/clinician may recommend additional things, like weight loss, exercise programs and/or diabetes education programs.
89424512|NCT05766735|Experimental|Routine Care + Glucose Excursion Minimization (RC+GEM)|Participants will actively work with their primary care provider and receive personalized routine care (RC). In addition, participants will receive GEM, an individualized, person-centered, empowerment program, not a behavior modification program. GEM provides individuals with personally relevant information to make choices that will help them achieve their diabetes goals. It focuses on techniques - eating low glycemic load foods, increasing moderate and vigorous exercise, and monitoring blood glucose (BG) to educate individuals about the impact of high glycemic load nutrients and vigorous exercise. The emphasis is on minimizing glucose excursions by any practical means, e.g., nutrient selection, timing and combinations of nutrient intake, time restricted eating, eating carbohydrates after protein and fat, post prandial physical activity, whatever is personally affirmed by BG feedback.
88905870|NCT05643196|Experimental|Sham, then Pulsed Low-Intensity Focused Ultrasound (PLIFUS)|Participants will receive sham sonication on the first intervention visit, then PLIFUS sonication on the second intervention visit. Visits will be separated by 1 week. Sonication at both visits will be preceded and followed by fMRI and an exit medical examination. Sonication will be delivered in a pulse pattern over 10 minutes.
88905871|NCT05624294|Experimental|2mg CS0159|One tablet daily for seven days.
89424513|NCT05763862|Experimental|Genetic testing|"Patients randomised to testing will have blood drawn for testing of CYP2C19 LOF mutations. Physicians of patients who test positive for an LOF mutation (intermediate and poor metabolizers) will be notified of the mutation with recommendations of possible alternative antiplatelet regimens suggested. Aspirin will be the recommended monotherapy, and aspirin in combination with ticagrelor or dipyridamole will be the recommended dual antiplatelet regimen. Decision of alternative medications used in patients with LOF mutations will be left to the discretion of the primary physician. Patients in the genotype guided antiplatelet therapy group who do not have LOF mutations will be left to continue the original intended antiplatelet regimen (this may be clopidogrel monotherapy, or in combination with aspirin).~No randomisation for patients with known CYP2C19 status prior to recruitment as these patients will be recruited as a comparison arm for outcomes measurements."
89424514|NCT05763862|No Intervention|Standard medical therapy|Patients on this arm will be placed on clopidogrel monotherapy, or in combination with aspirin, which is the original intended antiplatelet regimen.
89424515|NCT05754515||target controlled infusion (TCI) group|Propofol and remifentanil will be used in TCI anesthesia, and while the patient is under adequate sedation (BIS40-60), muscle relaxation will be provided with 0.6 mg/kg rocurium bromide. While applying TCI anesthesia, the device will use the Minto model for Remifentanil infusion and the Schnider model for Propofol infusion.
89424516|NCT05754515||inhalation anesthesia (IA) groups|During anesthesia induction of patients receiving inhalation anesthesia, 60 mg 2% lidocaine, 2 mg/kg propofol, 0.6 mg/kg rocuronium bromide and 1 mcg/kg fentanyl will be used. Desflurane will be used with a minimum alveolar concentration of 1 and for additional intraoperative sedation. remifentanil will be given between 0.05 and 0.2mcg/kg/min according to the patient's needs.
89530870|NCT02509247|Experimental|Telemonitoring group|Patients allocated to the telemonitoring group started with wireless telemonitoring after the titration period, i.e. in the beginning of habituation phase of CPAP treatment.
88905872|NCT05624294|Experimental|4mg CS0159|Two tablet daily for seven days.
88905873|NCT05624294|Experimental|6mg CS0159|Three tablet daily for seven days.
88905874|NCT05590273|Experimental|Proof-of-concept trial|Inform CALM adaptations for caregivers of patients with brain cancer.
89424517|NCT05753059|Placebo Comparator|Placebo/ Placebo|This study will employ a randomized placebo-controlled, double-blind, double-dummy, crossover design testing combinations placebo/placebo, bendroflumethiazide/placebo, amiloride/placebo, and bendroflumethiazide/amiloride added to bumetanide on Days 0, 7, 14 and 21
89007193|NCT05564273|Active Comparator|Viome's condition-based supplements|Participants may be provided with any combination of nutritional recommendations and they receive condition based supplements. The participants are asked to take the supplements on a daily basis.
89007194|NCT05563857|No Intervention|Placebo|Participants who have mental health issues are randomized into this arm. They may be provided with any combination of nutritional recommendations and supplements. Placebo capsules will contain inert and inactive materials. Participants may need to use a mobile app in order to participate in the trial.
89007195|NCT05563857|Active Comparator|Viome's Precision Nutrition Program (VPNP)|Participants who have mental health issues are randomized into this arm. They may be provided with any combination of nutritional recommendations and supplements. Participants may need to use a mobile app in order to participate in the trial.
89007196|NCT05563857|Active Comparator|Viome's condition-based supplements|Participants who have mental health issues are randomized into this arm. They may be provided with any combination of nutritional recommendations and supplements. Participants may need to use a mobile app in order to participate in the trial.
89007197|NCT05562011|Experimental|Caretaker Device|participants will undergo active CareTaker monitoring for 24-48 hours
89007198|NCT05554640|Experimental|Test/Control|Eligible subjects that are habitual contact lens wearers will be randomized into the sequence, Test/Control.
89007199|NCT05554640|Experimental|Control/Test|Eligible subjects that are habitual contact lens wearers will be randomized into the sequence, Test/Control.
89007200|NCT05550727|Experimental|PorchLight|
89007201|NCT05550727|No Intervention|Control|
89007202|NCT05548712|Experimental|Treatment group|
89007203|NCT05548712|Sham Comparator|Sham group|
89007204|NCT05540327|Experimental|M5049 low dose + Placebo|Participants with CLE (active SCLE and/or DLE) or SLE who received low dose of M5049 in WILLOW study will continue to receive M5049 low dose and matching placebo.
89007205|NCT05540327|Experimental|M5049 medium dose+ Placebo|Participants with CLE (active SCLE and/or DLE) or SLE who received medium dose of M5049 in WILLOW study will continue to receive M5049 medium dose and matching placebo.
89007206|NCT05540327|Experimental|M5049 high dose + Placebo|Participants with CLE (active SCLE and/or DLE) or SLE who received M5049 matched placebo or high dose of M5049 in WILLOW study will receive M5049 high dose .
89424518|NCT05753059|Active Comparator|Placebo/ Amiloride|This study will employ a randomized placebo-controlled, double-blind, double-dummy, crossover design testing combinations placebo/placebo, bendroflumethiazide/placebo, amiloride/placebo, and bendroflumethiazide/amiloride added to bumetanide on Days 0, 7, 14 and 21
89424519|NCT05753059|Active Comparator|Placebo/ Bendroflumethiazide|This study will employ a randomized placebo-controlled, double-blind, double-dummy, crossover design testing combinations placebo/placebo, bendroflumethiazide/placebo, amiloride/placebo, and bendroflumethiazide/amiloride added to bumetanide on Days 0, 7, 14 and 21
89424520|NCT05753059|Active Comparator|Bendroflumethiazide/ Amiloride|This study will employ a randomized placebo-controlled, double-blind, double-dummy, crossover design testing combinations placebo/placebo, bendroflumethiazide/placebo, amiloride/placebo, and bendroflumethiazide/amiloride added to bumetanide on Days 0, 7, 14 and 21
89424521|NCT05752903|Active Comparator|Dexmedetomidine-propofol|Dexmedetomidine-propofol bolus will be administered then Dexmedetomidine-propofol infusion continued during the procedure
89424522|NCT05752903|Active Comparator|ketamine-propofol|ketamine-propofol bolus will be administered then Dexmedetomidine-propofol infusion continued during the procedure
89424523|NCT05751694|Experimental|Visceral manual treatment|The objective of this technique is to reduce the tension of the tissues of the epigastric area.
89424524|NCT05751694|Active Comparator|Respiratory listening|It is a maneuver to evaluate the mobility of the ribs during respiration.
89424525|NCT05744778|Experimental|Physical therapy and rehabilitation|The patient group who underwent physical therapy and rehabilitation.
89424526|NCT05744778|Experimental|Dry needling|The patient group who underwent dry needling for trigger points in the upper trapezius muscle along with physical therapy and rehabilitation.
89424527|NCT05743803||Before|This group will undergo their preoperative fasting period as standard care.
89424528|NCT05743803||After|This group will undergo their preoperative fasting period after the sensitization campaign about preoperative fasting rules.
89424529|NCT05735353|Experimental|High-Speed Circuit Resistance Training Group|Participants in this group will receive high-speed circuit resistance training for 12 consecutive weeks.
89007207|NCT05540327|Experimental|M5049 very high dose + Placebo|Participants with CLE (active SCLE and/or DLE) or SLE who received M5049 matched placebo or very high dose of M5049 in WILLOW study will receive M5049 very high dose.
89007208|NCT05534464|Experimental|Skimmed milk powder|One rumen-fistulated Holstein-Friesian dairy cow in high lactation status will be given 0.6 L deuteriated water 3 times per day for 3 days long. Milk collection will take place twice a day on the fourth and fifth day. Milk will be processed into skimmed milk powder.
89424530|NCT05735353|Experimental|High-Speed Multidirectional Yoga Group|Participants in this group will receive high-speed multidirectional yoga for 12 consecutive weeks.
89424531|NCT05734638|Experimental|MIM-DASH|A trained MIM provider (layperson) and a registered dietitian will deliver the MIM DASH group intervention in eight 1-hour (30 minutes MIM and 30 minutes DASH) sessions via telehealth (video and telephone access).
89424532|NCT05734638|Experimental|MIM Only|"The MIM-only intervention group will receive the MIM education only in eight weekly sessions of 30 minutes each. To maintain equipoise among the intervention groups, this group will also have 30 minutes of social time to interact with the trainer and peers."
89424533|NCT05734638|Experimental|DASH Only|"The DASH-only group will receive the DASH education only in eight weekly sessions of 30 minutes each. This group will also have 30 minutes of social time to interact with the trainer and peers, will receive their education from a different interventionist (also a registered dietician) and receive two coaching calls per month for 3 months, in this case focused on healthy eating DASH principles."
89424534|NCT05733780|Experimental|Arm 1|ProLectin M 1,400 mg Tab. Number of Doses -04 Dosing Frequency-once every 2 hours Total Dose/Day-5600 mg
89424535|NCT05733780|Experimental|Arm 2|ProLectin M 1,400 mg Tab. Number of Doses -08 Dosing Frequency-Hourly Total Dose/Day-11200mg
89424536|NCT05733780|Experimental|Arm 3|ProLectin M 1,400 mg Tab. Number of Doses -12 Dosing Frequency-Hourly Total Dose/Day-16800
89424537|NCT05733780|No Intervention|Arm 4|Matching Placebo. Number of Doses -08 Dosing Frequency-Hourly Total Dose/Day-0 mg
89424538|NCT05728619|Experimental|Phase 1b|Escalating doses of HTMC0435 and Temozolomide
88814575|NCT04931394|Experimental|Organoid-Guided Adjuvant Chemotherapy|The pancreatic cancer specimens are obtained from surgery to be cultured for organoids. Then drug sensitivity is tested using organoid to obtain the sensitivity to the first-line drugs for pancreatic cancer (Gemcitabine, 5-fluorouracil, Paclitaxel, Oxaliplatin, Irinotecan). Patients will receive relatively sensitive chemotherapy regimen based on the test results. Adjuvant chemotherapy should start within 2 months after surgery, and last at least 6 months.
88820186|NCT06194136|Experimental|PBM Intervention|Application of commercially-available PBM over the skin of first the right breast and chest tissue and then the left breast and chest tissue, each for 30 seconds in single application. This intervention is to applied once per day, for a total of three times per week, with a minimum of 24 hours between each application.
89424539|NCT05728619|Experimental|Phase 2|Recommended phase 2 dose (RP2D) of HTMC0435 and Temozolomide
89424540|NCT05726032|Active Comparator|Empagliflozin|Empagliflozin vs placebo for 14 days, followed by 14 day washout period, before crossing over to the alternate drug.
89424541|NCT05726032|Placebo Comparator|Placebo|Empagliflozin vs placebo for 14 days, followed by 14 day washout period, before crossing over to the alternate drug.
89530871|NCT02509247|No Intervention|Usual care group|Patients were followed-up during the habituation phase according to hospital's standard procedure.
89424542|NCT05723159||Clínica Universidad Navarra site|Research subjects will be enrolled at Clínica Universidad Navarra. Research subjects will be instructed to wear the HCMS and a second watch serving as an audio recorder. These devices will be kept on the wrist or within 3 feet (~91 cm) of the mouth, a behavior abetted by keeping the charging station for both watches on the bedside table. Participants will be asked to go about their day as usual while wearing these devices.
89424543|NCT05723159||OHSU site|Research subjects will be enrolled at OHSU. Research subjects will be instructed to wear the HCMS and a second watch serving as an audio recorder. These devices will be kept on the wrist or within 3 feet (~91 cm) of the mouth, a behavior abetted by keeping the charging station for both watches on the bedside table. Participants will be asked to go about their day as usual while wearing these devices.
89424544|NCT05723159||Decentralized - US-based|"Research subjects will be enrolled in a decentralized manner ou of the Hyfe North American Clinical Office.~Research subjects will be instructed to wear the HCMS and a second watch serving as an audio recorder. These devices will be kept on the wrist or within 3 feet (~91 cm) of the mouth, a behavior abetted by keeping the charging station for both watches on the bedside table. Participants will be asked to go about their day as usual while wearing these devices."
89424545|NCT05720143|Experimental|Osseodensification group:|Ridge splitting by piezosurgery and osseodensification bur
89424546|NCT05720143|Experimental|Magnetic mallet group:|Ridge splitting by piezosurgery and chisels by magnetic mallet
89424547|NCT05720143|Experimental|Piezo-surgery group|Ridge splitting by inserts of piezosurgery and bone expander
89424548|NCT05686902|Experimental|PH 5.5 BABY SHAMPOO GROUP|Distilled water+Ph 5.5 baby shampoo for stoma care of patients in the first group
89424549|NCT05686902|Active Comparator|SERUM PHYSIOLOGIC GROUP|0.9% saline solution for stoma care of patients in the second group
88820187|NCT06194110||Endurance Trained Athletes|
88820188|NCT06194097|Experimental|Adenoidectomy|
88820189|NCT06194097|Experimental|Endoscopic Sinus surgery and Adenoidectomy|
88820190|NCT06194084|Experimental|Intervention - durian pulp.|Two-sequence of doses (100 g and 200 g) of durian pulp.
88820191|NCT06194071||Patients with Traumatic Brain Injury|Patients with all types of TBI will be recruited (mild, moderate and severe). They mus accept participation in the prolonged follow-up (up to 18 months after the accident). Relatives will also accept to participate. Patients will undergo routine care regarding TBI in our institution. Only the prolonged follow-up and monitoring is proposed which combines remote questionnaire completion, and on-site visits at 3 time-points (6, 12 and 18 months). No on-site visit is proposed for relatives who will fill out questionnaires. However, they may accompany patients during on-sites visits.
88820192|NCT06194006|Other|Long term follow-up|"Formalized and standardized follow-up~Retrospective data collection~Biological collections~Biological collections's centralisation"
88820193|NCT06193993|Experimental|Abiraterone Acetate|500 mg dose of Abiraterone Acetate plus prednisolone
89424550|NCT05678790|Experimental|Balance and Coordination|Since it is a case study, there will be only one group in the study.
89424551|NCT05672654|Active Comparator|Control group|
89424552|NCT05672654|Active Comparator|HIV positive CD4<350 cells/mm^3|
89424553|NCT05672654|Active Comparator|Immune-compromised patients- department rheumatology|
89424554|NCT05672654|Active Comparator|Immune-compromised patients- department nephrology|
89424555|NCT05672654|Active Comparator|Immune-compromised patients- department neurology|
89424556|NCT05672654|Active Comparator|Primary immune deficiency en common variable immunodeficiency|
88905875|NCT05585112|Active Comparator|A (Lidocaine 2%)|26 children will be injected with 1 ml of lidocaine 2% with epinephrine
88905876|NCT05585112|Experimental|B (Articaine 4%)|26 children will be injected with 1 ml of Articaine 4% with epinephrine.
89424557|NCT05672602||LONG COVID patients|Measurement of ncRNAs and cytokines in patients with new diseases or intermittent or permanent symptoms after COVID-19 at the moment of the recruitment
89424558|NCT05672602||Controls|Measurement of ncRNAs and cytokines in Individuals who have never suffered from COVID-19 at the moment of the recruitment
89424559|NCT05672602||Asymptomatic LONG COVID patients|Measurement of ncRNAs and cytokines in patients who have never suffered from LONG COVID symptoms or with only resolved symptoms at the moment of the recruitment
89424560|NCT05655962|Experimental|STARS center|Centers in the southeast region of Sweden working according to STARS.
89424561|NCT05655962|No Intervention|Control center|Centers in the southeast region of Sweden not working according to STARS.
89424562|NCT05653739|Experimental|Mindfulness Based Intervention Group|Mindfulness Based Stress Reduction Intervention , The training consists of eight weekly group sessions with the duration of approximately 2-2.5 hours with a trained instructor. Further participants were given daily audio-guided home practice (approximately 45 min/day), and a day-long mindfulness retreat (occurring during week sixth of the 8-week program)
89424563|NCT05653739|No Intervention|Control Group|Participants in the control group were not given any intervention in order to compare with the experimental group. At the end of the study participants in this group were also offered relaxation trainings in order to deal with the psychological distress, quality of life and distress tolerance.
89424564|NCT05647759|Experimental|HEART Camp Connect|Participants will have access to a virtual exercise platform or membership to a medical exercise facility. Participants will meet with a virtual exercise coach via zoom on a weekly basis.
89424565|NCT05628649|Experimental|Intervention|Participants in the intervention group will gather together in a 2-hour group setting once a week for the first 16 week intensive, then change to a once a month 2-hour gathering for the remaining 8 months of boosters of the intervention. Follow-up will occur 6 months after the final intervention class to assess long-term changes. The total time span of the study will be 18 months.
89424566|NCT05628649|No Intervention|Control|The control group follows clinical care in the usual standard (i.e. continuing to receive usual care from one's primary care physician)
89424567|NCT05600374|Experimental|Personalized stimulation|Each 100 Hz triplet is triggered when a real-time analyzed EEG-defined state of high corticospinal excitability is detected (i.e., the negative peak of the ongoing sensorimotor ~10 Hz μ-oscillation).
89424568|NCT05600374|No Intervention|Non-personalized stimulation|The identical rTMS protocol as in Arm 1, but 100 Hz triplets are not synchronized to the ongoing sensorimotor μ-oscillation.
89424569|NCT05600374|No Intervention|Sham stimulation|The same protocol as in arm 1 synchronized to the EEG-defined high excitability state, but with ineffective rTMS, using the sham side of an active/placebo TMS coil designed for double-blind clinical trials. Conditions/arm 2 and 3 are control conditions. Arm 2 controls for the specific effect of Condition/arm 1 to synchronize stimulation to the ongoing μ-oscillation. Arm 3 tests if auditory or somatosensory inputs (which are identical in the real and sham stimulation conditions) synchronized with the ongoing μ-oscillation are relevant for the effects of Arm 1.
88905877|NCT05568576||patients with HCC underwent resection|patients with HCC underwent resection
88905878|NCT05562544||Heading Group only|Subjects will perform a ball-passing task using their head
88905879|NCT05562544||Kicking Group then Heading Group|Subjects will perform a ball-passing task with their foot first, then will perform a ball-passing task using their head
89424570|NCT05597774|Experimental|Exercise training + Inspiratory and expiratory muscle training group|Participants will perform a cardiovascular exercise program 2 days per week during 8 weeks in the hospital, combined with an inspiratory and expiratory muscle training by a threshold device at home, twice a day, 3 days per week, for 8 weeks supervised by a physiotherapist through a virtual platform.
89424571|NCT05597774|Sham Comparator|Exercise training + Inspiratory and expiratory muscle training sham group|Participants will perform a cardiovascular exercise program 2 days per week during 8 weeks in the hospital, combined with an inspiratory and expiratory muscle training by a sham threshold device at home, twice a day, 3 days per week, for 8 weeks supervised by a physiotherapist through a virtual platform.
88905880|NCT05560477|Experimental|Treated with repair and AM3101|Syringe containing AM3101 for injection.
88905881|NCT05560477|Placebo Comparator|Treated with repair and 0.9% sodium chloride (saline)|Syringe containing commercially available 0.9% sodium chloride for injection.
88905882|NCT05559515|Active Comparator|National Diabetes Prevention Program|The Diabetes Prevention Program was a successful clinical trial demonstrating that intensive lifestyle support for weight loss reduced diabetes incidence by 58%. The intervention was translated into the National Diabetes Prevention Program (NDPP) and disseminated by the Centers for Disease Control and Prevention as a yearlong group-based program since 2012.
89007209|NCT05534464|Experimental|Sorghum whole grain|Sorghum plants are grown in the greenhouse. Those receive deuteriated water for five days with one day in between. On the first day the water has a 25% dilution and the other four days the water has a 5% dilution.
89424572|NCT05593341|No Intervention|Control Group|Patients are referred to the Hospital's standard 1-hour virtual patient education webinar prior to surgery.
89424573|NCT05593341|Experimental|In-person and PDF|Patients will receive two in-person education sessions (1st session before surgery and 2nd session after surgery). Patients will also receive pdf handouts about opioids and pain management.
89424574|NCT05593341|Experimental|Video and PDF|Patients will receive two video education sessions (1st session before surgery and 2nd session after surgery). Patients will also receive pdf handouts about opioids and pain management.
89424575|NCT05590806|Experimental|Arm 1|Restoration
89424576|NCT05590806|Experimental|Arm 2|Evaluate
89424577|NCT05590364|Experimental|Profhilo® Body treatment group|"1.5 ml per hand injected by a blunt tip microcannula (25G or 22G, preferably 22G), with fanning technique through a single entry point performing 5 passages and injecting 0,3 ml per passage.~Day 0: Information and consent form provided. Clinical photography, Clinical assessment, Instrumental assessment, First treatment of Profhilo® (refer to study protocol).~Day 30 (1 month after day 0): Clinical photography, Clinical assessment, Instrumental assessment, Second treatment of Profhilo® (refer to study protocol), Self-evaluation questionnaire.~Day 120 (4 months after day 0): Clinical photography, Clinical assessment, Instrumental assessment, NO treatment, Self-evaluation questionnaire."
89424578|NCT05590312||Low Flow Group - Group D|Vitamin D, Albumin, CRP, TAS and TOS values will be checked before and during the operation in 36 patients who will receive general anesthesia. Flow of 1 L/min will be given during the operation. The processed EEG values of all patients will be monitored and they will be ensured to be at the same anesthesia depth. Albumin, CRP, TAS and TOS values will be checked again from the blood taken postoperatively in the patients who were taken to the service after the operation and these values will be compared with the previous ones.
89424579|NCT05590312||High Flow Group - Group Y|Vitamin D, Albumin, CRP, TAS and TOS values will be checked before and during the operation in 36 patients who will receive general anesthesia. Flow of 4 L/min will be given during the operation. The processed EEG values of all patients will be monitored and they will be ensured to be at the same anesthesia depth. Albumin, CRP, TAS and TOS values will be checked again from the blood taken postoperatively in the patients who were taken to the service after the operation and these values will be compared with the previous ones.
89424580|NCT05561959|Experimental|Phonophoresis Group|Phonophoresis with topical glyceryl trinitrate traditional therapy three times a week for four week
89424581|NCT05561959|Active Comparator|Eccentric exercises Group|eccentric exercises three times a week for four weeks
89424582|NCT05558228||Patients achieving return of spontaneous circulation|All patients in cardiac arrest with an arterial line in place in the emergency department will be a potential subject. The FloPatch FP120 device will be placed on patients and the carotid artery peak systolic velocity associated with a systolic blood pressure ≥60 mmHg on a femoral arterial line during a pulse check will be determined.
89424583|NCT05558228||Patients not achieving return of spontaneous circulation|All patients in cardiac arrest with an arterial line in place in the emergency department will be a potential subject. The FloPatch FP120 device will be placed on patients and the carotid artery peak systolic velocity associated with a systolic blood pressure ≥60 mmHg on a femoral arterial line during a pulse check will be determined.
89424584|NCT05545813|Experimental|Probiotic|Participants will be randomized to receive the probiotic formulation for 8 weeks.
89424585|NCT05545813|Placebo Comparator|Placebo|Participants will be randomized to receive the placebo formulation for 8 weeks.
89424586|NCT05544994|Experimental|Aerobic Exercise Training Group|"Aerobic training will be performed 3 days a week for 12 weeks at 60% -%75 of their maximum hearth rate with 30 minutes total duration consisting of 5 min warm up and 5 min cool down period in treatment group.~Home exercise program will be given. This home program will include stretching, breathing, normal joint movement for 3 to 5 days a week"
89424587|NCT05544994|Active Comparator|Control Group|Home exercise program will be given. This home program will include stretching, breathing, normal joint movement, for 3 or 5 days a week.
89424588|NCT05542303|Experimental|ZB001 for injection|Treated different dose cohorts with single intravenous injection of ZB001
89424589|NCT05537961|Experimental|Mindfulness|Weekly mindfulness instruction embedded in classroom setting
89424590|NCT05537961|No Intervention|No Intervention|Classroom setting completed as usual
89424591|NCT05536206||Observed patients|Adult patients (≥18 years) admitted with an acute medical disease and who are scheduled for discharge to their own homes within five days from inclusion.
89424592|NCT05531799|Other|Group 1 DARE/CYTOLOGY/HPV/HRA|Participant request physician assessment for Digital anal rectal exam, Anal cytology, Anal HPV test and High resolution anoscopy for every 6 months within 12 months period
89424593|NCT05531799|Other|Group 2 DARE/CYTOLOGY/HPV|Participant request physician assessment for Digital anal rectal exam, Anal cytology, Anal HPV test for every 6 months within 12 months period
89424594|NCT05531799|Other|Group 3 DARE/CYTOLOGY/HRA|Participant request physician assessment for Digital anal rectal exam, Anal cytology and High resolution anoscopy for every 6 months within 12 months period
89424595|NCT05531799|Other|Group 4 DARE/CYTOLOGY|Participant request physician assessment for Digital anal rectal exam, Anal cytology for every 6 months within 12 months period
89424596|NCT05531799|Other|Group 5 DARE/HPV/HRA|Participant request physician assessment for Digital anal rectal exam, Anal HPV test and High resolution anoscopy for every 6 months within 12 months period
89424597|NCT05531799|Other|Group 6 DARE/HPV|Participant request physician assessment for Digital anal rectal exam and Anal HPV test for every 6 months within 12 months period
89424598|NCT05531799|Other|Group 7 DARE/HRA|Participant request physician assessment for Digital anal rectal exam and High resolution anoscopy for every 6 months within 12 months period
89424599|NCT05531799|Other|Group 8 DARE|Participant request physician assessment for Digital anal rectal exam for every 6 months within 12 months period
89007210|NCT05534464|Experimental|Black beans|Black bean plants are grown in the greenhouse. Those receive deuteriated water for five days with one day in between. On the first day the water has a 25% dilution and the other four days the water has a 5% dilution.
89007211|NCT05534126|Active Comparator|Stellate Ganglion Block|
89007212|NCT05534126|Placebo Comparator|Placebo|
89007213|NCT05518721|Active Comparator|Synthetic Cartilage Implant|
89424600|NCT05531799|Other|Self-collection CYTOLOGY/HPV|Participant request Self-sampling collection for Anal cytology and Anal HPV test for every 6 months within 12 months period
89424601|NCT05531799|Other|Self-collection CYTOLOGY|Participant request Self-sampling collection for Anal cytology for every 6 months within 12 months period
89424602|NCT05531799|Other|Self-collection HPV|Participant request Self-sampling collection for Anal HPV test for every 6 months within 12 months period
89424603|NCT05531799|Other|Self-collection control group CYTOLOGY/HPV|Participant request Self-sampling collection for Anal cytology and Anal HPV only at month 12
89424604|NCT05528874|Experimental|Group 1: randomized to receive recipe 4 after the 5 days single arm study, and then recipe 5|Healthy volunteers that signed informed consent. Will consume all recipes in crescent order.
88905883|NCT05559515|Experimental|NDPP-Flex|"NDPP-Flex. The primary difference between NDPP-Flex and the standard NDPP is the approach to goal setting. In NDPP-Flex, coaches use the latest CDC-published curriculum, but adapted such that participants are encouraged to 1) set attainable, individually-tailored goals for risk-reduction, 2) adjust goals over time as needed, and 3) avoid all-or-nothing assessments of goal attainment. At each session, coaches provide a goal setting worksheet (see excerpt) with a simple, fillable format to better accommodate low literacy (e.g., I will limit my soda and sugary drinks to __ per day)."
88905884|NCT05555004|Experimental|TEST1|
88905885|NCT05555004|Experimental|TEST2|
88905886|NCT05552443|Experimental|Intrathecal Hydromorphone 2.5 mcg/kg|Subjects undergoing posterior spinal surgery will receive 2.5 mcg/kg hydromorphone in the intrathecal space at the low lumbar level
88905887|NCT05552443|Experimental|Intrathecal Hydromorphone 2.75 mcg/kg|Subjects undergoing posterior spinal surgery will receive 2.75 mcg/kg hydromorphone in the intrathecal space at the low lumbar level
89424605|NCT05528874|Experimental|Group 2: randomized to receive recipe 5 after the 5 days single arm study, and then recipe 4|Same as before but randomized to receive recipe 5 before recipe 4.
89424606|NCT05518162|Experimental|women receiving InBloom app|
89424607|NCT05518162|Active Comparator|women receiving ROSE as usual|
89424608|NCT05518162|No Intervention|historical controls- no treatment|We will capitalize on data from a large ROSE trial which consists of a demographically similar sample by comparing depression diagnosis outcomes for Inbloom and ROSE to the 96 participants in the care as usual group (an educational pamphlet on PPD).
89424609|NCT05518162|No Intervention|electronic health record utilization data|We will leverage EHR utilization data by retrospectively identifying 152 people from the same clinics who did not receive ROSE or InBloom and matched for eligibility criteria, demographics and PPD risk factors using propensity scores, and comparing their utilization to those in the ROSE and InBloom groups.
89424610|NCT05515744|Experimental|Intervention Arm 1|Intervention Arm 1 Experimental Initiation of Delivery by induction or planned cesarean at 37 weeks 0-2 days.
89424611|NCT05515744|Experimental|Intervention Arm 2|Intervention Arm 2 Experimental Initiation of Delivery by induction or planned cesarean at 37 weeks 3-5 days.
89424612|NCT05515744|Experimental|Intervention Arm 3|Initiation of Delivery by induction or planned cesarean at 37 weeks 6 days to 38 weeks and 1 day.
89424613|NCT05515744|Experimental|Intervention Arm 4|Intervention Arm 4 Experimental Initiation of Delivery by induction or planned cesarean at 38 weeks 2-4 days.
89424614|NCT05515744|Experimental|Intervention Arm 5|Initiation of Delivery by induction or planned cesarean at 38 weeks 5 days to 39 weeks and 0 days.
89424615|NCT05515744|Experimental|Intervention Arm 6|Intervention Arm 6 Experimental Initiation of Delivery by induction or planned cesarean at 39 weeks 1-3 days.
89424616|NCT05515744|Experimental|Intervention Arm 7|Intervention Arm 7 Experimental Initiation of Delivery by induction or planned cesarean at 39 weeks 4-6 days.
89424617|NCT05504850|Other|All participants will receive the intervention|
89424618|NCT05495932|Experimental|Eligible patients|
88905888|NCT05552443|Experimental|Intrathecal Hydromorphone 3 mcg/kg|Subjects undergoing posterior spinal surgery will receive 3 mcg/kg hydromorphone in the intrathecal space at the low lumbar level
88905889|NCT05552443|Experimental|Intrathecal Hydromorphone 3.25 mcg/kg|Subjects undergoing posterior spinal surgery will receive 3.25 mcg/kg hydromorphone in the intrathecal space at the low lumbar level
89424619|NCT05488691|Experimental|Eye Movement Desensitization and Reprocessing therapy|8 to 10 individual 60-minutes sessions over 2 months.
89424620|NCT05488691|Active Comparator|Treatment as usual|Same periodicity as the experimental group and at the same time range.
88905890|NCT05552443|Experimental|Intrathecal Hydromorphone 3.5 mcg/kg|Subjects undergoing posterior spinal surgery will receive 3.5 mcg/kg hydromorphone in the intrathecal space at the low lumbar level
88905891|NCT05552443|Experimental|Intrathecal Hydromorphone 4 mcg/kg|Subjects undergoing posterior spinal surgery will receive 4 mcg/kg hydromorphone in the intrathecal space at the low lumbar level
88905892|NCT05552443|Experimental|Intrathecal Hydromorphone 4.5 mcg/kg|Subjects undergoing posterior spinal surgery will receive 4.5 mcg/kg hydromorphone in the intrathecal space at the low lumbar level
88905893|NCT05552443|Experimental|Intrathecal Hydromorphone 5 mcg/kg|Subjects undergoing posterior spinal surgery will receive 5 mcg/kg hydromorphone in the intrathecal space at the low lumbar level
88905894|NCT05551195|Other|WB001 with adjunctive Treatment as Usual|Participants randomized to the WB001 + TAU group will be asked to download and use the study application.
88905895|NCT05551195|Other|Educational Control (ED001) with adjunctive Treatment as Usual|Participants randomized to the ED001 + TAU group will be asked to download and use the study application.
89424621|NCT05488093|Experimental|total knee replacement surgery group|"The study will be conducted in 4 visits:~a pre-inclusion visit during a routine care consultation where the patient will be informed about the study~a V1 inclusion visit (pre-surgery of the knee) during which informed consent, clinical examination, VAS, self-questionnaires, DXA, X-SENS sensor, MRI, isokinetism will be collected~a V2 visit during the operation, during which biological samples will be taken (muscle biopsy, collection of osteoarticular parts, and serum collection)~a V3 visit at 12 months with a clinical examination, EVA, self-questionnaires, DXA, isokinetics, X-SENS sensor, serum collection, and collection of adverse events."
89424622|NCT05487755|No Intervention|control group|: (n=30) control group will receive traditional therapy blood glucose lowering agent +RAAS blockade ACEI or ARBs for six months.
89424623|NCT05487755|Experimental|Tadalafil group|:( n=30) will receive traditional therapy +tadalafil PO 20 mg every other day for six months
89424624|NCT05487755|Experimental|pentoxifylline group|:( n=30) will receive traditional therapy+ pentoxifylline PO 400 mg twice daily for six months.
89424625|NCT05482633|Experimental|Intervention Group|Experimental group is going to perform inspiratory muscle training exercises everyday for 8 weeks.
89424626|NCT05482633|No Intervention|Control Group|No new interventions will be given to control group.
89424627|NCT05480553|Experimental|NPC-06|
89424628|NCT05480553|Placebo Comparator|Placebo|
89424629|NCT05479760|Experimental|Implementation for anti-HCV reactive client|All clients who test anti-HCV positive at the study CBOs will be assessed for the inclusion criteria. Eligible clients will be informed and offered to participate in the study.
89424630|NCT05477225|Experimental|NovoSorb® BTM|
89424631|NCT05477225|Active Comparator|Human Cadaver Allograft|
89424632|NCT05477212|Experimental|intervention arm with VLCKD|all patients will receive a very low calorie Ketogenic diet (VLCKD) and will be followed for all the time of the study, monitoring gut permeability, liver steatosis and microbiome composition
89424633|NCT05476952||Group 1|"Patients with a normal weight between 18.5 and 24.9 BMI Groups will be divided into 2 groups by their own luck. According to DDA, rocuronium will be evaluated as DDA, and group numbers given according to TBW will be evaluated as K."
89424634|NCT05476952||Group 2|"overweight patients with a BMI between 25-29.9 Groups will be divided into 2 groups by their own luck. According to DDA, rocuronium will be evaluated as DDA, and group numbers given according to TBW will be evaluated as K."
89424635|NCT05476952||Group 3|"patients with a BMI of 30-34.9 in obesity class 1 Groups will be divided into 2 groups by their own luck. According to DDA, rocuronium will be evaluated as DDA, and group numbers given according to TBW will be evaluated as K."
89424636|NCT05473624|Experimental|HRS-1167|
89424637|NCT05468307|Experimental|Membrane Bound Cytokine Modified TIL|2x10^8-1x10^10 in vitro expanded autologous TIL engineered with membrane-binding cytokine (GC203 TIL) will be infused i.v. to patients with advanced gynecologic tumors after NMA lymphodepletion treatment with cyclophosphamide.
89424638|NCT05462483|Experimental|Rice sock and instructions to heat quadriceps|Receives heating device and instructions to heat the quadriceps musculature.
89424639|NCT05462483|No Intervention|No heating device or instructions to heat quadriceps|WIll not receive heating device or instructions to heat quadriceps musculature.
89424640|NCT05433142|Experimental|Dose Escalation and Expansion|"Dose Escalation (Part A): Part A will establish the dosing schedule for XmAb819 administered IV and the dosing schedule of XmAb819 administered SC in subjects with ccRCC. The dosing schedule includes the priming dose, step-up priming dose(s), the minimum safe and biologically active dose.~Dose Expansion (Part B): Part B-1 may administer XmAb819 IV, and Part B-2 may administer XmAb819 SC."
89424641|NCT05415202||Remimazolam Sedation|"Patients receiving a nerve block prior to surgery or a re-block the day after surgery will receive remimazolam sedation for their nerve block.~The nerve block will then be performed under standard conditions with standard monitors. Remimazolam will be used for sedation following the guidelines on the label.~Dosing will be as follows:~Induction of Procedural Sedation For adult patients: Administer 5 mg intravenously over a 1-minute time period. For ASA* III and IV patients: Administer 2.5 mg to 5 mg intravenously over 1 minute based on the general condition of the patient.~Maintenance of Procedural Sedation (as needed) For adult patients: Administer 2.5 mg intravenously over 15 seconds. At least 2 minutes must elapse prior to administration of any supplemental dose.~For ASA III and IV patients: Administer 1.25 mg to 2.5 mg intravenously over 15 seconds.~At least 2 minutes must elapse prior to administration of any supplemental dose."
88905896|NCT05531253||Main cohort|Patients undergoing cardiac surgery who will have a pulmonary artery catheter in-situ at the time of admission to cardiac intensive care postoperatively.
89424642|NCT05414838|Experimental|Curcumin, Omega-3 and Vitamin-D (COD)|
89424643|NCT05406232||Observational (RT, biopsy)|Patients undergo RT on day 1. Patients also undergo tumor punch biopsies and blood sample collection prior to the first fraction and on days 1, 3, and 7.
89424644|NCT05393024||Belantamab Mafoditin|MMRR patients included in Named Patient Program and Expanded Access Program
89424645|NCT05384860|Active Comparator|Active Acupuncture Group|For the patients randomized to the acupuncture group, once sedation has been deemed adequate by the anesthesiologist, a certified medical acupuncturist will perform ipsilateral Auricular Trauma Protocol (ATP) acupuncture at eight ear points (Hypothalamus, Amygdala, Hippocampus, Prefrontal Cortex, Point Zero, Shen Men, Insula, Vagus) with 30Hz electrostimulation at two of those points (Shen Men and Hypothalamus). Acupuncture needles will be left in place and stimulated for 60 min and then removed.
89424646|NCT05384860|Placebo Comparator|Placebo No Acupuncture Group|These patients will not receive acupuncture treatment during surgery, their surgery will continue as normal.
89424647|NCT05381792||Known colorectal advanced neoplasia group|Subjects with known colorectal advanced neoplasia and requiring endoscopic resection
88905897|NCT05529641|Experimental|Combined diaphragmatic resistance training and cervical stabilization exercise group|Participants in this group will receive supervised cervical stabilization exercise and diaphragmatic resistance training as home grogram.
88905898|NCT05529641|Active Comparator|Cervical stabilization exercise group|Participants in this group will only receive supervised cervical stabilization exercise.
88905899|NCT05527483||[F-18]NaF|Patients will receive 8-12 mCi of [F-18]NaF delivered as an intravenous (IV) bolus injection, followed by digital PET/CT imaging.
89424648|NCT05381129|Other|Chronic migraine|Patients diagnosed with chronic migraine according to the International Headache Society Classification (ICHD-3).
88905900|NCT05527483||[Ga-68]PSMA|Patients will receive up to 6 mCi of [Ga-68]PSMA delivered as an intravenous (IV) bolus injection, followed by digital PET/CT imaging
88905901|NCT05527470|Active Comparator|Induction CT+IMRT Combined Concurrent CT|Induction Chemotherapy(CT) Followed by Intensity-modulated Radiation Therapy (IMRT ) Combined Concurrent Chemotherapy
88905902|NCT05527470|Experimental|Induction CT+IMRT alone|Induction Chemotherapy(CT) Followed by Intensity-modulated Radiation Therapy (IMRT )alone
89424649|NCT05381129|Other|Temporomandibular dysfunction|Patients diagnosed with chronic migraine according to the International Headache Society Classification (ICHD-3), and patients with temporomandibular dysfunction.
89424650|NCT05381012|Other|Chronic migraine|Patients diagnosed with chronic migraine according to the International Headache Society Classification (ICHD-3).
89424651|NCT05381012|Other|Fibromyalgia syndrome|Patients diagnosed with chronic migraine according to the International Headache Society Classification (ICHD-3), and patients with fibromyalgia syndrome .
89424652|NCT05380765|Experimental|Native PATHS Condition|A strengths-based, behavioral economic approach to increasing engagement and reinforcement for engaging in alternative activities.
89424653|NCT05380765|No Intervention|Wait-List Control|Participants will receive the Native PATHS program once 6-month follow up surveys have been completed.
89424654|NCT05374811||Multiple sclerosis.|Those diagnosed with Multiple Sclerosis according to the 2017 Revised McDonald criteria
89424655|NCT05369195|Experimental|LAAC with neuroprotection|Arm in which is used a transcatheter system to protect the cerebral circulation during the left atrial appendage closure procedures.
89424656|NCT05369195|Placebo Comparator|LAAC without neuroprotection|Arm in which the left atrial appendage closure procedures are performed without transcatheter cerebral protection.
88905903|NCT05519631||subacute stroke|Participants were evaluated for clinical outcome before the electroencephalogram examination. They were evaluated with the National Institute of Health Stroke Scale (NIHSS) to quantify the severity and magnitude of neurological deficit after stroke and by the Montreal Cognitive Assessment (MoCA) to assess cognitive function.
89424657|NCT05368012|Other|Active MIDCAB|USG with a 25G needle, Bupivacaine 0.5% 30ml with 4mg preservative free dexamethasone divided as follows into the following 5 nerves: Posterior Tibial nerve (10ml), Saphenous nerve (5ml), Deep peroneal Nerve (5ml), Superficial peroneal nerve (5 ml), and Sural Nerve (5ml).
89424658|NCT05366153||Survivor Screening/Management Plan|"In cancer survivors;~A novel clinical and CT imaging-based screening algorithm to select those most likely to develop coronary artery disease,~A clinical review to ensure optimal risk factor control and cardiac protection."
89424659|NCT05366153||Non-cancer Screening/Management Plan|"In matched non-cancer patients (from EDCAD trial);~A novel clinical and CT imaging-based screening algorithm to select those most likely to develop coronary artery disease,~A clinical review to ensure optimal risk factor control and cardiac protection."
89424660|NCT05352646|Experimental|NewishT|This study is divided into two dose groups and two phases. Phase Ia climbed from low-dose group to high-dose group in turn according to the 3+3 dose escalation principle. Phase Ib extended 10 subjects each group.
89424661|NCT05347147|Experimental|Presendin|2.0 mg
89007214|NCT05518721|Active Comparator|Dermal Interposition Arthroplasty|
89424662|NCT05347147|Placebo Comparator|Placebo|
89424663|NCT05344755|Experimental|Plantar Sensorial Training|In addition to hallux valgus mobilization, active thumb abduction, strengthening of the muscles around the feet, hallux valgus taping and hallux valgus night splint, sensory training (using deep plantar massage, brushing, dipping techniques) will be performed.
89424664|NCT05344755|Active Comparator|Control Group|Routine hallux valgus physiotherapy approaches such as: hallux valgus mobilization, active thumb abduction, strengthening of the muscles around the feet, hallux valgus taping and hallux valgus night splint.
89007215|NCT05517785||Medicated|Assessment of motor function will be performed 1 hour after taking the usual stimulant ADHD medication.
89424665|NCT05343702||standard|standard rapid sequence intubation group (paralysis following induction)
89424666|NCT05343702||priming|group primed with rocuronium before induction
89424667|NCT05321498|Experimental|1.0 mg/kg XPro1595|1.0 mg/kg XPro1595 will be administered via subcutaneous injection once a week for 12 weeks.
89424668|NCT05321498|Placebo Comparator|1.0 mg/kg Placebo|1.0 mg/kg of Placebo will be administered via subcutaneous injection once a week for 12 weeks.
89424669|NCT05303649|Experimental|Intermittent TBS (iTBS) of the left hemisphere plus behavioral aphasia therapy|15 sessions of 200-second of iTBS over the pars triangularis of Broca's area in the left hemisphere (BA 45), preceding 45-minutes of behavioral aphasia therapy.
89424670|NCT05303649|Experimental|Continuous TBS (cTBS) of the right hemisphere plus behavioral aphasia therapy|15 sessions of 40 seconds of cTBS over the pars triangularis of the right inferior frontal gyrus (BA 45 homologue), preceding 45-minutes of behavioral aphasia therapy.
89424671|NCT05303649|Sham Comparator|Sham TBS (sTBS) of the left hemisphere plus behavioral aphasia therapy|15 sessions of sham TBS over the pars triangularis of Broca's area in the left hemisphere (BA 45), preceding 45-minutes of behavioral aphasia therapy.
89424672|NCT05289297|Active Comparator|Karydakis Flap Procedure|Vertical eccentric elliptical incision down to the post-sacral fascia, complete removal of unhealthy tissue, and normal tissue around the cyst and sinus tracts. Mobilization of the medial wound edge and advancement of the skin. Flap along the midline to the post-sacral fascia and suturing its margin to the lateral wound margin.
89424673|NCT05289297|Active Comparator|Burow's Triangle Advancement Flap Procedure|The flap is incised along the base of the wedge-shaped defect, and a small Burow's triangle is excised on the opposite side. The skin is mobilized and shifted in the direction of the arrow to close the defect. Excising the small Burow's triangle eliminates a dog ear at the base of the flap.
89424674|NCT05281016|Experimental|Delayed Intervention Control Group|Participants randomised to the Control Group will be offered standard care and will be introduced to 6 month delayed intervention which consists of the online community LITE programme.
89424675|NCT05281016|Experimental|Intervention Group|Participants randomised to the Intervention Group will receive standard care plus invitation to participate in the online community LITE programme for 4-5 months.
89424676|NCT05275608|Experimental|VLCKD|"20 Patients recruited from our endocrinology department that will keep the same medical visits frequency and drugs and accept to be randomized to one of the two groups.~Inclusion criteria:~Age 25-65~BMI 30-40 mg/m2~NAFLD~DM2 drug-treated (metformin, SGLT2 inhibitors, GLP-1 analogues, DPPIV inhibitors, insulin) and HbA1c > 7 and < 10 %."
89424677|NCT05275608|Active Comparator|Hypocaloric Mediterranean Diet|"20 Patients recruited from our endocrinology department that will keep the same medical visits frequency and drugs and accept to be randomized to one of the two groups.~Inclusion criteria:~Age 25-65~BMI 30-40 mg/m2~NAFLD~DM2 drug-treated (metformin, SGLT2 inhibitors, GLP-1 analogues, DPPIV inhibitors, insulin) and HbA1c > 7 and < 10 %."
89424678|NCT05270798|Experimental|Patients with low triiodothyronine levels who received triiodothyronine|
89424679|NCT05270798|Placebo Comparator|Patients with low triiodothyronine levels who received placebo|
89424680|NCT05270798|Experimental|Patients with low triiodothyronine and low tetraiodothyronine levels who received triiodothyronine|
89424681|NCT05270798|Placebo Comparator|Patients with low triiodothyronine and low tetraiodothyronine levels who received placebo|
89424682|NCT05268653|Experimental|Motivational İnterviewing Group|For the Motivational Interviewing (MI) treatment group, a clinical public health nursing doctoral student trained in Motivational Interviewing administered six motivational interviewing therapy sessions, each 30 minutes long. A 3-month follow-up will then be applied.
89424683|NCT05268653|No Intervention|Control Group|No attempt will be made
89424684|NCT05255328|Experimental|MELAS|Patients with MELAS syndrome will receive 12-18g/day of glutamine
89424685|NCT05241366|Experimental|Transcranial Magnetic Stimulation + usual treatment with SSRIs|"Transcranial Magnetic Stimulation + SSRIs The TMS group will be comprised of 10 patients, each subject will receive 12 sessions of low frequency (1 Hz) rTMS over right dorsolateral prefrontal cortex with a total of 1500 each session.~All patients will continue with the usual treatment established by their treating physician. Those who do not have a previous pharmacological treatment will start a protocol with sertraline, which should be started at a 50 mg/day dosage."
89424686|NCT05241366|Sham Comparator|Sham TMS coil + usual treatment with SSRIs|"The sham TMS coil group will be comprised of 10 patients, sham TMS stimulation will be performed with the B-65 coil, which has similar sound and scalp contact to those experienced during active stimulation. The duration of treatment will be the same as in the experimental arm.~All patients will continue with the usual treatment established by their treating physician. Those who do not have a previous pharmacological treatment will start a protocol with sertraline, which should be started at a 50 mg/day dosage."
89424687|NCT05238025|Experimental|Group 1: Single dose MVA-BN-RSV|Single dose (Week 0): MVA-BN-RSV virus with a titer of at least 3x10E8 Inf.U/0.5mL (intramuscular vaccination)
89424688|NCT05238025|Experimental|Group 2: Single dose Placebo|Single dose of TBS (intramuscular injection; 0.5mL)
89424689|NCT05233137|Experimental|PA coaching and exercise training|Patients in this group will receive physical activity telecoaching as well as an exercise training program provided by a physiotherapist in primary care
89424690|NCT05233137|Active Comparator|PA coaching|Patients in this group will receive physical activity telecoaching
89424691|NCT05219006|Experimental|ketogenic dieting + conventional treatment|Nutrition team will help patients implement an Atkins-type ketogenic diet. The diet should be continued for at least 6 weeks. They will be able to continue with the pharmacological-based treatment but without any changes having been made in the last 6 weeks or during the time they are in the study. To ensure adherence to the diet, urine ketones will be determined twice a week.
89424692|NCT05219006|Active Comparator|Healthy dieting + conventional treatment|In addition to their basic (pharmacological) treatment, the nutrition team will help them implement a low-calorie, non-ketogenic diet. The presence of ketones will also be determined in urine to avoid bias
89424693|NCT05203419|Experimental|Part A: Cohort 1 - MHS552 low dose|Participants will receive MHS552 low dose once weekly subcutaneously for 4 weeks
89424694|NCT05203419|Placebo Comparator|Part A: Cohort 1, 2, 3 - Placebo|Participants will receive placebo once weekly subcutaneously for 4 weeks
89424695|NCT05203419|Experimental|Part A: Cohort 2 - MHS552 medium dose|Participants will receive MHS552 medium dose once weekly subcutaneously for 4 weeks
89424696|NCT05203419|Experimental|Part A: Cohort 3 - MHS552 high dose|Participants will receive MHS552 high dose once weekly subcutaneously for 4 weeks
89424697|NCT05203419|Experimental|Part B: MHS552|Participants will receive MHS552 (dose to be determined) once weekly subcutaneously for 12 weeks
89424698|NCT05203419|Placebo Comparator|Part B: Placebo|Participants will receive placebo once weekly subcutaneously for 12 weeks
89424699|NCT05182164|Experimental|Stratum 1: advanced undifferentiated pleomorphic sarcoma|Patients with advanced undifferentiated pleomorphic sarcoma will be treated by the combination of pembrolizumab + cabozantinib
89007216|NCT05517785||Unmedicated|Participants will remain unmedicated for the duration of the assessment, and will delay taking their usual stimulant ADHD medication until all the motor function assessments are completed.
89424700|NCT05182164|Experimental|Stratum 2: advanced osteosarcoma|Patients with advanced osteosarcoma will be treated by the combination of pembrolizumab + cabozantinib
89007217|NCT05510674|Experimental|OWL-EVO1|OWL-EVO1 probe will be administered to those who are fully eligible, including those diagnosed with lung cancer and healthy volunteers
89007218|NCT05503992|Experimental|Intervention arm|CHWs affiliated with intervention facilities randomized to the intervention arm will be given the intervention package.
89007219|NCT05503992|No Intervention|Control arm|CHWs affiliated with control sites randomized to the control arm will continue to implement the current standard of care which includes using paper records for inventory management and dispensing.
89007220|NCT05497453|Experimental|OTX-2002|Monotherapy: OTX-2002 (Cycle length = 4 weeks) OTX-2002 will be administered as an IV infusion over 80-120 minutes every 2 weeks
89007221|NCT05497453|Experimental|OTX-2002 + Tyrosine Kinase Inhibitor One|"OTX-2002 + Tyrosine Kinase Inhibitor One: (Cycle length = 4 weeks) OTX-2002 will be administered as an IV infusion over 80-120 minutes every 2 weeks.~Tyrosine Kinase Inhibitor One will be standard per the respective fixed local approved dose"
89007222|NCT05497453|Experimental|OTX-2002 + Tyrosine Kinase Inhibitor Two|"OTX-2002 + Tyrosine Kinase Inhibitor Two : (Cycle length = 4 weeks) OTX-2002 will be administered as an IV infusion over 80-120 minutes every 2 weeks.~Tyrosine Kinase Inhibitor Two will be standard per the respective fixed local approved dose"
89007223|NCT05497453|Experimental|OTX-2002 + Checkpoint Inhibitor|"OTX-2002 + Immune Checkpoint Blockade: (Cycle length = 6 weeks) OTX-2002 will be administered as an IV infusion over 80-120 minutes every 2 weeks.~Checkpoint Inhibitor will be standard per the respective fixed local approved dose"
89007224|NCT05481190|Experimental|Tele-exercise program to Child with Cystic Fibrosis|"Inclusion criteria were Voluntary to participate in the study, Getting consent from parents, Being a child with cystic fibrosis between the ages of 10-18, Having no psychological health problems, No physical problems that would prevent the child from exercising and Computer/ owning a smart phone and being able to use these devices, Having an internet connection at home.~The exclusion criteria were Not volunteering to participate in the study, Not being able to get consent from their parents, Being under the age of 10 or over the age of 18 with a diagnosis of Cystic Fibrosis, Having a psychological health problem, Having a physical problem that prevents the child from exercising and Not having a computer/smart phone and not being able to use these devices and Not having an internet connection at home.~Exclusion criteria are Not participating in the exercise regularly (at least 2 times), Not wanting to continue working out."
89007225|NCT05481190|Experimental|Without exercise Child with Cystic Fibrosis|"Inclusion criteria were Voluntary to participate in the study, Getting consent from parents, Being a child with cystic fibrosis between the ages of 10-18, Having no psychological health problems, No physical problems that would prevent the child from exercising and Computer/ owning a smart phone and being able to use these devices, Having an internet connection at home.~The exclusion criteria were Not volunteering to participate in the study, Not being able to get consent from their parents, Being under the age of 10 or over the age of 18 with a diagnosis of Cystic Fibrosis, Having a psychological health problem, Having a physical problem that prevents the child from exercising and Not having a computer/smart phone and not being able to use these devices and Not having an internet connection at home.~Exclusion criteria are Not participating in the exercise regularly (at least 2 times), Not wanting to continue working out."
89007226|NCT05472168|Other|Obese|Age 18-55 years Obesity (BMI ≥30 kg/m2) Written informed consent Normosmia (defined by sniffing Sticks test)
89007227|NCT05472168|Other|Lean|Age 18-55 years Lean (BMI 18-25 kg/m2) Written informed consent Normosmia (defined by sniffing Sticks test)
89007228|NCT05465629|No Intervention|Placebo|Participants who have gastrointestinal issues are randomized into this arm. They may be provided with any combination of nutritional recommendations and supplements. Placebo capsules will contain inert and inactive materials. Participants may need to use a mobile app in order to participate in the trial.
89007229|NCT05465629|Active Comparator|Viome's Precision Nutrition Program|Participants who have gastrointestinal issues are randomized into this arm. They may be provided with any combination of nutritional recommendations and supplements. Participants may need to use a mobile app in order to participate in the trial.
89007230|NCT05465629|Active Comparator|Viome's condition-based supplements|Participants who have gastrointestinal issues are randomized into this arm. They may be provided with any combination of nutritional recommendations and supplements. Participants may need to use a mobile app in order to participate in the trial.
89007231|NCT05465616|No Intervention|Placebo|Participants with HbA1c levels between 5.7-8.9% (inclusive) are randomized into this arm. They may be provided with any combination of nutritional recommendations and supplements. Placebo capsules will contain inert and inactive materials. Participants may need to use a mobile app in order to participate in the trial.
89424701|NCT05182164|Experimental|Stratum 3: advanced Ewing sarcoma|Patients with advanced Ewing sarcoma will be treated by the combination of pembrolizumab + cabozantinib
89424702|NCT05180955|Other|Digital drainage system group|chest tube removal will be determined by air flow criteria as indicated by the digital drainage system data.
89424703|NCT05180955|Other|Digital drainage system + clamping trial group|In the control group removal will be determined by the same criteria of the digital drainage system but before removal, a chest tube clamping test will be performed.
89424704|NCT05179993||Study Group|Proof of principle Study group: detection of microplastics in human granulosa cells and in the follicular fluid of women undergoing intracytoplasmic sperm injection (ICSI) treatment
89424705|NCT05172921||Exposed|High exposure to environmental pollutants
89424706|NCT05172921||Non-exposed|Low exposure to environmental pollutants
89424707|NCT05169658|Experimental|Treatment (mosunetuzumab, obinutuzumab, polatuzumab vedotin)|"PART A: Patients receive mosunetuzumab SC over 30 seconds-2 minutes on days 1, 8, and 15 of cycle 1 and day 1 of subsequent cycles. Treatment repeats every 21 days for 8 cycles in the absence of disease progression or unacceptable toxicity.~PART B: Beginning cycle 9, patients who do not achieve a CR receive obinutuzumab IV on day 1 of cycle 9 and day 1 of subsequent cycles and polatuzumab vedotin IV on day 1. Treatment repeats every 21 day for 6 cycles in the absence of disease progression or unacceptable toxicity."
89424708|NCT05164055|Experimental|Avalglucosidase alfa|Administered intravenously every other week
89424709|NCT05144152||History of colorectal adenomas group|Subjects with known colorectal adenomas at the index colonoscopy
89424710|NCT05143554|Active Comparator|Active percutaneous neurostimulation|Subject randomized to maximum of 5 days of active vs sham neurostimulation therapy with moderate to severe emetogenic chemotherapy admission . With the next scheduled identical chemotherapy cycle, each subject will cross over to the other one (active vs sham)
89424711|NCT05143554|Sham Comparator|Sham percutaneous neurostimulation|Subject randomized to maximum of 5 days of active vs sham neurostimulation therapy with moderate to severe emetogenic chemotherapy admission . With the next scheduled identical chemotherapy cycle, each subject will cross over to the other one (active vs sham)
89424712|NCT05134571|Experimental|Aldurazyme (laronidase)|Aldurazyme (laronidase) treatment at approved dose and regimen, administered every week as an IV infusion
89424713|NCT05128032|Experimental|Sequence A: Standard microcatheter for Mapping #1 and PEDD device for Mapping #2.|Participants with either hepatocellular carcinoma (HCC) or colorectal liver metastases tumors receiving standard of care radioembolization treatment will be randomly assigned to undergo a routine mapping procedure first using a standard microcatheter 2-21 days before their radioembolization treatment day. Then on day of radioembolization treatment, an extra mapping procedure using the PEDD device catheter will be done just prior to the treatment.
89424714|NCT05128032|Experimental|Sequence B: PEDD device for Mapping #1 and standard microcatheter for Mapping #2.|Participants with either hepatocellular carcinoma (HCC) or colorectal liver metastases tumors receiving standard of care radioembolization treatment will be randomly assigned to undergo a routine mapping procedure first using the PEDD device catheter 2-21 days before their radioembolization treatment day. Then on day of radioembolization treatment, an extra mapping procedure using a standard microcatheter will be done just prior to the treatment.
89424715|NCT05123755|Active Comparator|AV-001 Injection with standard of care (SOC).|A total of 120 eligible patients (20 patients in each of cohort 1, 2 and 3 and 60 patients in cohort 4) will be randomized in a 1:1 ratio to receive either AV-001 Injection or AV-001 placebo Injection, together with standard of care (SOC). Doses of AV-001 Injection will start with 12.5 μg/kg/day in cohort 1 and are anticipated to increase to 25 μg/kg/day in cohort 2, 56 μg/kg/day in cohort 3 and to be determined (TBD) in cohort 4. The dose for cohort 4 will be determined by the Data Safety Monitoring Board (DSMB) based on emerging data from cohorts 1, 2 and 3.
89424716|NCT05123755|Placebo Comparator|AV-001 Placebo Injection with standard of care (SOC).|A total of 120 eligible patients (20 patients in each of cohort 1, 2 and 3 and 60 patients in cohort 4) will be randomized in a 1:1 ratio to receive either AV-001 Injection or AV-001 placebo Injection, together with standard of care (SOC).
89424717|NCT05123729|Experimental|Crowdsourced campaign package|The intervention will be developed through a crowdsourcing process, including an open call for submissions.
89424718|NCT05123729|Active Comparator|Standard information|The control will be the provision of standard information (e.g., view standard informational videos promoting the adoption of health-protective behaviors and COVID-19 testing).
89424719|NCT05106036|Experimental|Intervention Arm|Home BP data will be averaged each month via OmronConnect app on the patients' smartphone, which is programmed to send home BP readings to MyChart via Apple or Google Health.Participants whose home blood pressure reading average is systolic ≥ 130 and diastolic ≥ 80 will trigger the CDS (Clinical Decision Support) tool to assist their physicians with their blood pressure management. Study Team will not be involved in treatment decision making, it will be determined by subject's treating physician. .
89424720|NCT05106036|No Intervention|Usual Care Arm|Physicians will continue to make decisions about the participant's blood hypertension management as usual without the CDS tool.
88820194|NCT06193291|No Intervention|Thermoneutral|Participant sits at room temperature during an oral glucose tolerance test
88820195|NCT06193291|Experimental|Feet heating|Participant sits with feet placed in hot water during an oral glucose tolerance test
89424721|NCT05095740|Active Comparator|repetitive transcranial magnetic stimulation (rTMS)|5 consecutive days of rTMS to the individualized, targeted, left laryngeal motor cortex associated with laryngeal function to down-regulate cortical motor signal to intrinsic laryngeal muscles and improve vocal function of individuals with LD.
88905904|NCT05519631||chronic stroke|Participants were evaluated for clinical outcome before the electroencephalogram examination. They were evaluated with the National Institute of Health Stroke Scale (NIHSS) to quantify the severity and magnitude of neurological deficit after stroke and by the Montreal Cognitive Assessment (MoCA) to assess cognitive function.
88905905|NCT05519631||healthy|Only the EEG will be collected
88905906|NCT05492435|Experimental|m1 stimulation + dual task training|participants will receive real current over the primary motor area (M1)
88905907|NCT05492435|Experimental|stimulation in M1 and DLPF + dual task training|participants will receive real current over the M1 and over the dorsolateral prefrontal area (DLPFC)
88905908|NCT05492435|Sham Comparator|sham stimulation + dual task training|Participants will receive simulated stimulation
88905909|NCT05475730|Experimental|Bone regeneration|Minimally invasive horizontal bone augmentation using hyaluronic acid, deproteinized bovine bone and dermal matrix.
88905910|NCT05473988||Admission to General Ward Positive|Admission to General Ward Positive
88905911|NCT05473988||30 Day Mortality Positive|30 Day Mortality Positive
88905912|NCT05473988||Admission to Intensive Care Unit Positive|Admission to Intensive Care Unit Positive
88905913|NCT05473988||Admission to General Ward Negative|Admission to General Ward Negative
88905914|NCT05473988||30 Day Mortality Negative|30 Day Mortality Negative
88905915|NCT05473988||Admission to Intensive Care Unit Negative|Admission to Intensive Care Unit Negative
88905916|NCT05472545|Experimental|Neurofeedback Group|Mothers of adolescent participants will view real-time fMRI neurofeedback representing activity in their daughter's anterior insula during an emotion discussion task. Activity will be presented as a colored bar of moving height, and mothers will be instructed to attempt to downregulate the activity through what they say to their daughter.
88905917|NCT05472545|No Intervention|Control Group|The paradigm for the control condition will be identical to that of the experimental condition except that no neurofeedback will be presented. Participants in the control group will be told that we would like to see if the mother can regulate her daughter's brain activity through supportive statements.
88905918|NCT05471921|Experimental|SBIRT|Experimental condition: Participants residing in the study community (displaced and host population) will receive Screening, Brief Intervention, and Referral to Treatment (SBIRT). The treatment will consist of brief intervention (CETA-BI) and full Common Elements Treatment Approach (CETA) depending on the severity of the participant's substance use.
88905919|NCT05471921|Active Comparator|Treatment as usual|Comparison condition: Participants residing in the study community (displaced and host population) will receive the current standard of treatment.
88905920|NCT05467111|Experimental|Exercise|Patients will perform an acute bout of exercise (different types of exercise for each cycle of anthracyclines) 24-48 hours prior to each cycle of anthracyclines.
88905921|NCT05467111|No Intervention|Control|Patients will receive standard treatment for each type of tumor proposed by the hospital. This group of patients will be provided with the international recommendations on physical exercise for cancer patients.
88905922|NCT05466188||Outcome CPC Positive|Outcome CPC Positive
88905923|NCT05466188||Outcome CPC Negative|Outcome CPC Negative
88905924|NCT05465070|Experimental|Heat therapy|Patients will be provided with water-circulating trousers, a water heater, and a water tank coupled to a water pump. The heater will be adjusted to warm up the water to 42ºC. Participants will be asked to apply the therapy daily for 90 min while seated or in the supine position.
88905925|NCT05465070|Active Comparator|Sham Control|Patients will be provided with water-circulating trousers, a water heater, and a water tank coupled to a water pump. The heater will be adjusted to warm up the water to 33ºC. Participants will be asked to apply the therapy daily for 90 min while seated or in the supine position.
88905926|NCT05462340|Experimental|Healthy Volunteers|Visit 3: (ASEM/AZAN) Blood draw for DNA, PET scan/art line Visit 3: (ASEM only) Blood draw for DNA, PET scan/art line Visit 4: (ASEM only) PET scan/art line
88905927|NCT05462340|Experimental|Schizophrenia (ari, brex, risp)|Visit 3: (ASEM/AZAN) Blood draw for DNA, PET scan/art line Visit 3: (ASEM only) Blood draw for DNA, PET scan/art line Visit 4: (ASEM only) PET scan/art line
88905928|NCT05462340|Experimental|Schizophrenia (olanz)|Visit 3: (ASEM/AZAN) Blood draw for DNA, PET scan/art line Visit 3: (ASEM only) Blood draw for DNA, PET scan/art line Visit 4: (ASEM only) PET scan/art line 2-wk Titration, 3-wk steady state
88905929|NCT05462340|Experimental|Schizophrenia (no med)|Visit 3: (ASEM/AZAN) Blood draw for DNA, PET scan/art line Visit 3: (ASEM only) Blood draw for DNA, PET scan/art line Visit 4: (ASEM only) PET scan/art line 2-wk Titration, 3-wk steady state
88905930|NCT05452278|Experimental|Product sequence ABCD|Subjects use Product A on Day 1, Product B on Day 2, Product C on Day 3 and Product D on Day 4
88905931|NCT05452278|Experimental|Product sequence BCDA|Subjects use Product B on Day 1, Product C on Day 2, Product D on Day 3 and Product A on Day 4
88905932|NCT05452278|Experimental|Product sequence CDAB|Subjects use Product C on Day 1, Product D on Day 2, Product A on Day 3 and Product B on Day 4
88905933|NCT05452278|Experimental|Product sequence DABC|Subjects use Product D on Day 1, Product A on Day 2, Product B on Day 3 and Product C on Day 4
88905934|NCT05451485||Young volunteers|Volunteers with age between 20-30 years
88905935|NCT05451485||Old volunteers|Volunteers with age between 65-75 years
88905936|NCT05439356|Experimental|Colchicine Group|Patients in this arm will receive colchicine for 90 days in addition to standard medical care
89424722|NCT05095740|Sham Comparator|Sham rTMS|5 consecutive days of sham rTMS to the individualized, targeted, left laryngeal motor cortex associated with laryngeal function to down-regulate cortical motor signal to intrinsic laryngeal muscles and improve vocal function of individuals with LD.
89424723|NCT05093621|Active Comparator|Furosemide|"Furosemide, oral, dosage and frequency determined by treating physician or provider.~1 mg torsemide to 2-4 mg oral furosemide"
89424724|NCT05093621|Active Comparator|Torsemide|"Torsemide, oral, dosage and frequency determined by treating physician or provider.~1 mg torsemide to 2-4 mg oral furosemide"
89424725|NCT05054387|Experimental|Agalsidase beta|Agalsidase beta treatment at approved dose and regimen, administered once every 2 weeks as an IV infusion
89424726|NCT05045157|Experimental|percutaneous A1 pulley release with corticosteroid injection|
89424727|NCT05045157|Active Comparator|corticosteroid injection alone|
89424728|NCT05022667|Experimental|PTeye|The surgeon will use the PTeye as an intraoperative tool to identify if a suspect tissue is a parathyroid or not, during the total thyroidectomy procedure.
89424729|NCT05022667|No Intervention|Standard of Care|The surgeon will not use the PTeye and will proceed with the total thyroidectomy as usual, while relying solely on her/his surgical experience in identifying the parathyroid glands during the operations.
89424730|NCT05022641|Experimental|PTeye|The surgeon will use the PTeye as an intraoperative tool to identify if a suspect tissue is a parathyroid or not, during the parathyroid surgery.
88905937|NCT05439356|Placebo Comparator|Placebo Colchicine Group|Patients in this arm will receive placebo colchicine for 90 days in addition to standard medical care
88905938|NCT05425004|Experimental|Cabozantinib|Participants will self-administer cabozantinib 60 mg at the same time daily by mouth on a continuous 28-day schedule. Participants will continue to take this medication as long as they are deriving benefit from it without significant treatment-related toxicities.
88905939|NCT05421351||Experimental|All patients with overt HE in ACLF of any etiology.
89424731|NCT05022641|No Intervention|Standard of Care|The surgeon will rely solely on her/his surgical experience in identifying the parathyroid glands during the operations.
88905940|NCT05421351||Disease Control Group|"Diseased Control patients with Acute-on-Chronic Liver Failure with no Hepatic Encephalopathy~Diseased Control patients with Decompensated Cirrhosis with no Hepatic Encephalopathy"
89424732|NCT05001087||Patients registry|"Non-interventional, multicentre, retrospective and prospective registry. In order to increase the sample size and the validity of the Registry, patients who were diagnosed with myeloma since 1st January 2019 will also be included retrospectively, once their informed consent has been obtained by the enrolling centre. Being a registry, patients will be enrolled consecutively according to their appointments at the centre, at the discretion of their doctor and only once the patient has signed the informed consent form.~Also patients participating in interventional or other observational studies can be enrolled. In case of patients enrolled in interventional trials, only baseline and survival data can be collected for the period in with the patient is in interventional trial.~The data will be collected using an electronic data capture (EDC) platform. Hospital visits are planned every 6 months."
89424733|NCT04998188|Experimental|Collagen Injection|This group of patients will be treated with single intra-articular injection of collagen.
88905941|NCT05421351||Control Group 2|Healthy Control without any liver disease
88905942|NCT05413421|Experimental|Dose Escalation|ORIC-944 dosed orally on a continuous daily dosing regimen in 28-day cycles
88905943|NCT05413252|No Intervention|Current Practice|Practices will deliver care as usual and patients at these sites receive standard HTN care delivered.
88905944|NCT05413252|Active Comparator|Practice Facilitation|Practices review coaching and support from a trained practice facilitator. This includes 24 site visits in which facilitators meet with staff to work on implementing system changes to improve hypertension management.
88905945|NCT05412979|Experimental|ST-1891|
88905946|NCT05412979|Active Comparator|Levothyroxine|
88905947|NCT05396846|Active Comparator|Eating Plan 1|This group will receive a pamphlet from the American Institute for Cancer Research (AICR) on dietary prevention and the results of their own breath test, Veggie Meter score and anthropometric measures.
88905948|NCT05396846|Experimental|Eating Plan 2|This group will receive the MyBestGI App and User Manual that encourages limiting four food groups: three or less foods each day made with refined flour, no more than 8% of calories from added sugars, no processed meats and less than 18 oz./week red meat. They will also receive the results of their own breath test, Veggie Meter score and anthropometric measures.
88905949|NCT05396846|Experimental|Eating Plan 3|This group will receive a version of the MyBestGI App and User Manual that encourages meeting 11 food group goals: four food groups to limit and seven food groups to encourage. The 7 groups to encourage are: 3-4 cups/day fruits and vegetables, at least one dark orange or dark green vegetable daily, daily allium and culinary herbs, 3-6 oz./day whole grains, 6-8 oz./week foods high in omega-3 fatty acids, 8-10 tsp./day olive oil or the equivalent from other foods high in monounsaturated fats and at least ½ cup/day of legumes or 1 TB/day nut butter. Some of the goals are personalized based on calculated energy needs. They will also receive the results of their own breath test, Veggie Meter score and anthropometric measures.
88905950|NCT05385458|Experimental|ACT Intervention|Participants will attend 6-8 individual psychotherapy sessions via telephone, text or videoconference. Sessions will last approximately 1 hour and occur every 3-4 weeks. Participants will be enrolled in the Intervention Group for 18-36 weeks. All sessions will be audio recorded. Participants will also be able to attend all available usual care services such as: support groups, First Link, education classes at the Alzheimer Society. Any services utilized will be documented by Alzheimer Society staff.
89424734|NCT04998188|Placebo Comparator|Placebo (saline solution)|This group of patients will be treated with single intra-articular injection of saline solution (placebo). At the 6-month follow-up visit, patients will be informed about the treatment received. Patients of this group can cross-over to the treatment arm after 6 months.
89424735|NCT04982744||Patients affected by Li Fraumeni and Li Fraumeni Like syndromes|The group comprises all patients affected by Li Fraumeni and Li Fraumeni Like syndromes
89195738|NCT01042327|Experimental|dialyzer comparison|"Stable chronic kidney dialysis patients, currently dialyzing on the main Royal Free hospital dialysis unit will be asked to participate in the study. It is aimed to recruit 15 patients currently dialysing using the Fresenius FX100 dialyzer, who have used Fresenius polysulphone membranes for > 3 months.~During a mid week dialysis session, dialysis adequacy will be assessed by on line clearance, and samples of both blood and dialysate taken to assess, both clearances and bio-compatibility.~Thereafter patients would be switched to dialyse using the ELISIOTM-H dialyzer, but continue with the same dialysis prescription, and after 3 months, measurements repeated"
89195739|NCT04035928|Experimental|3D digital scanning for maxillofacial prosthetics|
88820196|NCT06193291|Experimental|Calf heating|Participant sits with legs, up to calves, placed in hot water during an oral glucose tolerance test
89195740|NCT00823953|Placebo Comparator|Placebo|placebo powder (wheat flour) The placebo arm will be administered capsules containing a total of 500 mg of starch powder, at dose level 1; 1000 mg at dose level 2; 1500 mg at dose level 3.
89195741|NCT00823953|Active Comparator|Momordica charantia|"Thirty patients will be assigned to each arm in a double blind manner. The active arm will be administered capsules containing a total of 500 mg of Momordica charantia freeze dried powder, at dose level 1; 1000 mg at dose level 2; 1500 mg at dose level 3.~The placebo arm will be administered capsules containing a total of 500 mg of starch powder, at dose level 1; 1000 mg at dose level 2; 1500 mg at dose level 3."
89195742|NCT04036084||Patients|Patients with CADASIL disease : Diagnosis confirmed by the detection of a pathogenic mutation in the NOTCH3 gene characteristic of CADASIL
89195743|NCT04036084||Control|
89195744|NCT00397189|Experimental|Circadin|
89195745|NCT00397189|Placebo Comparator|placebo|
89195746|NCT00824109|Other|Single Arm Study|Consecutive patients meeting the selection criteria
89195747|NCT00898300||Patients with confirmed or suspected head and neck cancer|
89195748|NCT01035619|Experimental|Moxidectin|
89195749|NCT00819819|Active Comparator|1 Gluten containing diet|Gluten added to diet at 6 months per American Academy of Pediatrics recommendations
89195750|NCT00819819|Active Comparator|2 Gluten free diet|Non gluten containing food starch added to diet from 6-12 months
89195751|NCT04044651|Experimental|Lenvatinib plus nivolumab|nivolumab 480 mg IV infusions for 30 minutes q4w+ lenvatinib 12 mg (or 8 mg) by mouth (Po) once daily
89195752|NCT04044651|Active Comparator|Lenvatinib|Lenvatinib 12 mg (or 8 mg) Po once daily
89195753|NCT00606034|Experimental|All subjects active|All subjects will receive the experimental treatment (U-500 insulin via Omnipod) since they have already failed all other previous insulin treatment regimens.
89195754|NCT00898378||Colorectal Cancer Patients|Patients with stages I/II, III and IV colorectal cancer
89195755|NCT00898378||Colorectal Polyps Patients|Patients with adenomatous polyp(s) after colonoscopy.
89195756|NCT00898378||Healthy Controls|No abnormalities after colonoscopy.
89195757|NCT00819975|Active Comparator|Casein|
89195758|NCT00819975|Active Comparator|Whey Isolate|
89195759|NCT00819975|Active Comparator|Whey Hydrolysate|
89195760|NCT00819975|Active Comparator|Alphalact-Albumin|
88820197|NCT06192966|Experimental|Experimental|Probiotic formulation comprising Lactobacillus plantarum CECT8675 and CECT8677 in combination with cranberry, and vitamine C in a capsule format. Probiotic strains have Qualified Presumption of Safety (QPS) sttus by European Food Safety Authority.
88820198|NCT06192966|Placebo Comparator|Placebo|Placebo composed of maltodextrin
88820199|NCT06192251||Cohort 1|Weekly classes of pillars of lifestyle medicine, monthly sessions with dietician, Lifestyle Medicine physician,kinesiologist and health coach
88820200|NCT06191718|Experimental|Tria Mitral Valve|Patients receiving the Foldax Mitral Valve
88820201|NCT06191705||Individuals with Arm, Shoulder or Hand pain /symptoms.|
88820202|NCT06191653|Experimental|Treatment group|The adapted form of the MSC, composed for 12 sessions, will be delivered on a weekly basis in group. This intervention program intends to cultivate a compassionate-self as well as increase the awareness of personal patterns of functioning and learning to respond to them in a kind, courageous, and fierce way. All the sessions will be delivered in a space on each YDC.
88820203|NCT06191653|No Intervention|Control Group|This group, wich will be a waiting list control goup, will not receive any mind training or group intervention during the study. Participants of this group will be assessed at 4 different time points (pre- and post-treatment and at a 3- and 6-month follow-up). After all assessment moments are completed, the intervention program will be delivered with the caregivers of this group. These caregivers will receive the intervention after the end of all assessment moments and at a time to be agreed with the Portuguese Juvenile Ministry of Justice. Adolescents cared both by wokers in the TG and CG will not receive any intervention during the study.
88820204|NCT06191640||HEMT Group|Children with CF planning to start ivacaftor or elexacaftor/tezacaftor/ivacaftor CFTR modulator therapy. Participants from the non-HEMT group of this study may enroll into the HEMT cohort if they become eligible for these CFTR modulator therapies and plan to start them.
88820205|NCT06191640||Non-HEMT/Control Group|Children with CF not on ivacaftor or elexacaftor/tezacaftor/ivacaftor CFTR modulator therapy.
88820206|NCT06191627|Active Comparator|Patch testing on the legs|Patches to be applied on the legs
88820207|NCT06191627|Active Comparator|Patch testing on the back|Patches to be applied on the back
88820208|NCT06191575||Observational (7T MRI, cognitive assessment, blood collection)|Patients undergo 7T MRI over 1-2 hours at baseline and at 12 months after baseline. Patients also undergo a proctored cognitive assessment over approximately 1 hour prior to each MRI. Additionally, patients undergo blood sample collection at screening and at 12 months after baseline MRI.
88820209|NCT06191549|Experimental|To explore the effect of brain stimulation on locomotor skill acquisition in stroke survivors|To explore the trends of locomotor skill acquisition in stroke survivors after anodal tDCS (a-tDCS, real brain stimulation), stroke survivors after sham tDCS (s-tDCS), and stroke with no brain stimulation (control; CON).
89424736|NCT04977180|Experimental|Treatment arm (beta blocker and ACE inhibitor)|Participants will receive a beta blocker (either metoprolol or carvedilol) and an ACE inhibitor (lisinopril) at standard doses based on tolerance starting from when they start induction therapy for AML through 90 days after the first day of the last cycle of therapy that includes an anthracycline (whether that is in the induction, re-induction, or consolidation phase of treatment). They will also undergo regular assessments via ECG/EKG and echocardiogram, and to measure troponin levels
89424737|NCT04977180|No Intervention|Standard Clinical Care|Participants will receive standard clinical care, but will also undergo regular assessments via ECG/EKG and echocardiogram, and to measure troponin levels
89424738|NCT04967833|Experimental|Tumor Infiltrating Lymphocytes|1x10^9-5x10^10 in vitro expanded autologous TILs will be infused i.v. to patients with advanced solid tumors after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.
89424739|NCT04962711|Experimental|Heart failure intervention ( Cardio-Oncology Disease Management Plan (CO-DMP)|"Optimization of pharmacotherapy: Cardioprotection with angiotensin-converting enzyme inhibitor (ACEi, Ramipril) and beta blocker (Metoprolol).Participants will be initially treated with ramipril at a dose of 1.25 or 2.5mg (according to baseline systemic arterial pressure), once or twice a day, and gradually up-titrated to 10mg/day, or to the maximal-tolerated dose. In patients receiving at least 2.5mg/day of ramipril, metoprolol will be started at an initial dose of 50 (25mg twice a day) and progressively up-titrated to the maximal dose of 100mg/day. Patients will be reviewed every 2 weeks during the up titration phase.~Exercise intervention: Individualized training program provided by an exercise physiologist."
89424740|NCT04962711|Active Comparator|Usual care|Provided by participants' usual healthcare professional(s), guided by a brochure regarding optimal risk factor management addressing hypertension, lipids, alcohol intake and tobacco use.
89424741|NCT04960930|Experimental|FMX101|FMX101 4% minocycline foam
89424742|NCT04960930|Placebo Comparator|Vehicle Foam|Vehicle Foam
89424743|NCT04960072|Experimental|Tumor Infiltrating Lymphocytes|1x10^9-5x10^10 in vitro expanded autologous TILs will be infused i.v. to patients with relapsed/refractory malignant gastrointestinal tumors after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.
89424744|NCT04943913|Experimental|Tumor Infiltrating Lymphocytes|1x10^9-5x10^10 in vitro expanded autologous TILs will be infused i.v. to patients with brain glioma after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.
89424745|NCT04918784|Experimental|Treatment with Synthetic Hybrid-Scale Fiber Matrix|Diabetic foot ulcers will be treated by application of the Synthetic Hybrid-Scale Fiber Matrix. The synthetic matrix will be applied weekly or as needed based on the clinician discretion and ongoing wound assessment.
89424746|NCT04918784|Active Comparator|Treatment with Standard of Care|Diabetic foot ulcers will be treated by application of an appropriate dressing (foam or alginate dressing) to maintain wound moisture balance in the wound and changed daily.
89424747|NCT04896632|Experimental|INE963|Part A is a single ascending dose (SAD) study with 7 planned cohorts Part B is a multiple dose (MD) study with 2 planned cohort q24h x 3 day of either INE963 or placebo
89424748|NCT04896632|Placebo Comparator|Placebo group|Part A is a single ascending dose (SAD) study with 7 planned cohorts Part B is a multiple dose (MD) study with 2 planned cohort q24h x 3 day of either INE963 or placebo
89424749|NCT04896047|Experimental|CKD patients|Patients with CKD, non-diabetic, without a history of renal transplantation, without digestive pathology, aged 18 to 70 and an estimate of the glomerular filtration rate (eGFR) <60 ml / min / 1.73m2 according to the formula of CKD-EPI.
88905951|NCT05385458|Active Comparator|Usual Care|Participants will be enrolled as an Alzheimer Society client. Participants will receive 1 First Link 'check-in' telephone call from a staff member at the time of enrolment. Participants will receive a 2nd 'check-in' First Link telephone call from a staff member 3-4 months following enrolment. Participants will be enrolled in the Usual Care Group 12-16 weeks. Participants will also be able to attend all available usual care services such as: support groups, etc. Any services utilized will be documented by Alzheimer Society staff.
88905952|NCT05373836||brain tumor surgery|adult patients undergoing brain tumor surgery
89424750|NCT04896047|Active Comparator|Haemodialysis patients|Patients on hemodialysis, for more than 3 months, with no history of kidney transplantation, without digestive pathology, aged 18 to 70 with a BMI between 18 and 30 kg / m2
89424751|NCT04896047|Active Comparator|Healthy volunteers|Healthy volunteers (controls) recruited from the population of living kidney donors
89424752|NCT04883892|Experimental|BMAC injection|Single injection of Bone Marrow Aspirate Concentrate (BMAC) into the ankle joint
89007232|NCT05465616|Experimental|Viome's Precision Nutrition Program (VPNP)|Participants with HbA1c levels between 5.7-8.9% (inclusive) are randomized into this arm. They may be provided with any combination of nutritional recommendations and supplements. Participants may need to use a mobile app in order to participate in the trial.
89424753|NCT04883892|Active Comparator|HA injections|"two injections of Hyaluronic Acid (HA) into the ankle joint - one injection every 15 days.~After 12 months patients are allowed to cross-over in the BMAC arm."
89424754|NCT04874311|Experimental|Experimental Arm A: treatment by bintrafusp alfa combined with doxorubicin|Soft-tissue sarcoma patients with an inflammed tumor will be treated with bintrafusp alfa combined with doxorubicin for 6 cycles, followed by bintrafusp alfa maintenance
89424755|NCT04874311|Other|Standard Arm B: treatment by doxorubicin|Soft-tissue sarcoma patients with an inflammed tumor will be treated with doxorubicin for 6 cycles
88905953|NCT05373511||bronchial asthma|"Inclusion criteria:~Participants over the age of 18 who have had mild to moderate bronchial asthma since childhood and have been referred by a pulmonologist or physician~Exclusion criteria:~Participants with other health issues such as cardiorespiratory issues, neurological deficits or diseases such as nerve compressions, any chronic diseases or suffering from respiratory tract infections, participants with a history of previous serious injuries to the musculoskeletal system, which may result in body posture disturbances Any disease that impairs one's sense of balance"
88905954|NCT05373511||non-asthmatic control group:|"Inclusion and Exclusion criteria for non-asthmatic control group:~Inclusion criteria:~For the healthy subjects referred by a consultant pulmonologist/physician, age- and gender-matched volunteers were recruited from the community~Exclusion criteria:~Other health issues, such as cardiorespiratory issues, neurological deficits, musculoskeletal problems, and peripheral vascular diseases& pregnancy may affect test performance."
89424756|NCT04874311|Experimental|Experimental Arm C: treatment by bintrafusp alfa combined with doxorubicin|Soft-tissue sarcoma patients with a cold tumor will be treated with bintrafusp alfa combined with doxorubicin for 6 cycles, followed by bintrafusp alfa maintenance
89424757|NCT04874311|Other|Standard Arm D: treatment by doxorubicin|Soft-tissue sarcoma patients with a cold tumor will be treated with doxorubicin for 6 cycles
89424758|NCT04869696||Subjects with tape samples|each subject had 8 types of tape samples applied on their arms
89424759|NCT04867434|Active Comparator|RZL-012 50mg/ml|Subjects treated with RZL-012 will undergo a single treatment session with 32±4 injections. The maximal number of injections will be 36 with maximal doses 270 mg for the high doses. Each injection point will be dosed with 7.5 mg for the high dose in a volume of 0.15 mL/injection site.
89424760|NCT04867434|Active Comparator|RZL-012 34mg/ml|Subjects treated with RZL-012 will undergo a single treatment session with 32±4 injections. The maximal number of injections will be 36 with maximal doses of 183.6 mg for the low dose. Each injection point will be dosed with 5.1 mg RZL-012 for the low dose in a volume of 0.15 mL/injection site.
89424761|NCT04867434|Placebo Comparator|Placebo|Placebo (vehicle) subjects will be injected with a 0.15 mL vehicle per each injection site. The maximal injection volume for all groups will be up to 5.4 mL.
88905955|NCT05348538|Experimental|Medication review with follow up or MaJ? for the acronym in french|All the pharmacists accepting to participate in the study will perform the intervention.
89195761|NCT00825981||coronary artery bypass graft|patients undergoing elective coronary artery bypass graft with or without cardiopulmonary bypass
88905956|NCT05344872|Active Comparator|Group A|Weaning trial will be done for 17 patients using PSV 0 cmH2O with 100% automatic tube compensation (ATC).
88905957|NCT05344872|Active Comparator|Group B|Weaning trial will be done for 17 patients using PSV 8 cmH2O without ATC.
89007233|NCT05463770|Experimental|SEP-363856|
89195762|NCT04044417|Placebo Comparator|open flap debridement only|surgical treatment of periodontal defects
89195763|NCT04044417|Active Comparator|curcumin and simvastatin|open flap debridement followed by application of curcumin-simvastatin paste (2% curcumin and 1.2% simvastatin).
89195764|NCT04044417|Active Comparator|EDTA, curcumin and simvastatin|open flap debridement followed by 24% EDTA root surface etching and application of curcumin-simvastatin paste (2% curcumin and 1.2% simvastatin).
89195765|NCT00397033|Experimental|002|Paliperidone ER 12mg/day paliperidone er for 6 weeks
89195766|NCT00397033|Experimental|001|Paliperidone ER 6mg/day paliperidone er for 6 weeks
89195767|NCT00397033|Placebo Comparator|003|Placebo Placebo for 6 weeks
89195768|NCT00820053|No Intervention|no adjuvant TACE|controll group with patients who don't receive any adjuvant therapy after liver resection, to compare with the treatment group with patients who receive adjuvant TACE after liver resection
89424762|NCT04859868|Experimental|Galvanic Vestibular Stimulation During the Entire Session|Subjects given Galvanic Vestibular Stimulation (GVS) to mitigate motion sickness in the rotating chair turning stimulation ON from beginning.
88905958|NCT05344274|Experimental|Isocapnic Oxygen|Investigators will evaluate retinal blood flow in response to oxygen supplementation.
88905959|NCT05340179|Active Comparator|Interlaminar cervical epidural steroid injection|
88905960|NCT05340179|Experimental|Cervical selective nerve root block|
89007234|NCT05457608|Experimental|Lens A|All participants wore lens A for 15 minutes (Period 1)
89195769|NCT00820053|Experimental|adjuvant TACE|patients who adjuvant TACE after liver resection
89195770|NCT00572728|Experimental|Diagnostic (18F-FLT)|Patients undergo 18F-FLT PET /CT at baseline (prior to chemotherapy, FLT-1), early therapy (5-10 days after the initiation of the first course of chemotherapy, FLT-2), and post therapy (within 3 weeks prior to surgery, FLT-3). Patients undergo standard surgical resection of residual tumor following completion of neoadjuvant chemotherapy.
89195771|NCT00820131|Experimental|1|
89195772|NCT00820131|Active Comparator|2|
89195773|NCT00699374|Experimental|Arm A|sunitinib arm
89195774|NCT00699374|Active Comparator|Arm B|sorafenib arm
89195775|NCT00898534|Experimental|Immediate Feedback|Subjects receive point-of-care hemoglobin A1c testing prior to their diabetes clinic visit, with results made available to the provider during the visit.
89007235|NCT05457608|Experimental|Lens B|All participants wore lens B for 15 minutes (Period 2)
89007236|NCT05452447|Experimental|Spatial Repellent|Transfluthrin
89424763|NCT04859868|No Intervention|No Galvanic Vestibular Stimulation|Subjects were not given Galvanic Vestibular Stimulation (GVS) to mitigate motion sickness in the rotating chair turning stimulation entire session.
89424764|NCT04859868|Experimental|Galvanic Vestibular Stimulation Starting From Mid-session|Subjects given Galvanic Vestibular Stimulation (GVS) to mitigate motion sickness in the rotating chair turning stimulation ON from the middle of the session.
89424765|NCT04843410|Experimental|Experimental: Exercise group|"In this prospective study, patients who applied to Zonguldak Atatürk State Hospital Oncology Outpatient Clinic received at least three cures of taxane and platinum-based treatment (monotherapy or combined) and developed grade 2 and higher peripheral neuropathy (lung cancer, breast cancer) as a result of motor and sensory neuropathy evaluation. , gynecological cancers, colorectal cancers), patients with stable vital signs who can tolerate the exercise, patients without bone metastases, patients older than 18 years of age, and patients who agree to participate in the study.~The experimental group will be taught an exercise program to apply regularly twice a day. The researcher will give the patient the barbed ball and barbed roller required for the exercise. In addition, visual training material will be given for the exercise program so that the patient can repeat the training whenever he wants to ensure the permanence of the patient education."
89195776|NCT00898534|No Intervention|Conventional Feedback|Subjects receive laboratory hemoglobin A1c testing at the clinic visit, with results made available to the provider several days later.
89007237|NCT05452447|Placebo Comparator|Placebo|Inert ingredients
89424766|NCT04843410|Sham Comparator|The routine care: Control Group|In this prospective study, patients who applied to Zonguldak Atatürk State Hospital Oncology Outpatient Clinic received at least 3 cures of taxane and platinum-based treatment (monotherapy or combined) and developed grade 2 and higher peripheral neuropathy (lung cancer, breast cancer) as a result of motor and sensory neuropathy evaluation. , gynecological cancers, colorectal cancers), patients with stable vital signs, patients without bone metastases, patients older than 18 years of age, and patients who agree to participate in the study. The routine care of the clinic will be applied to the control group.
89424767|NCT04837547|Experimental|Arm 1: Subjects with Diffuse Intrinsic Pontine Glioma (DIPG).|"This Phase I study is will utilize a standard 3+3 dose escalation design to establish the MTD and will evaluate the following three pre-specified dose levels of xALT:~Dose Level 1: 3 x10^7 cells/kg Dose Level +1: 3 x10^8 cells/kg Dose Level -1: 3 x10^6 cells/kg~The dose escalation scheme will be evaluated for Arm 1 and Arm 2 separately. For each Study Arm, a minimum of 4 DLT evaluable subjects and a maximum of 12 DLT evaluable subjects will be enrolled (a total of 8 to 24 DLT evaluable subjects)."
89195777|NCT00824187|Experimental|Arm 1|
89195778|NCT00824187|Placebo Comparator|Arm 2|
89195779|NCT00826137|Experimental|A|Treated with prebiotics.
89195780|NCT00826137|Placebo Comparator|B|Placebo treated.
89424768|NCT04837547|Experimental|Arm 2: Relapsed/Refractory Neuroblastoma (NB)|"This Phase I study is will utilize a standard 3+3 dose escalation design to establish the MTD and will evaluate the following three pre-specified dose levels of xALT:~Dose Level 1: 3 x10^7 cells/kg Dose Level +1: 3 x10^8 cells/kg Dose Level -1: 3 x10^6 cells/kg~The dose escalation scheme will be evaluated for Arm 1 and Arm 2 separately. For each Study Arm, a minimum of 4 DLT evaluable subjects and a maximum of 12 DLT evaluable subjects will be enrolled (a total of 8 to 24 DLT evaluable subjects)."
89007238|NCT05447884|Experimental|Group A - Participants without neurological disorders|Individuals without any neurological disorders will be recruited (Group A). Usually, participants from this group are able to walk normally on different terrains and at multiple typical walking speeds.
89195781|NCT00606892|Experimental|Placebo First, varenicline, + IV Nic|Subjects received a Placebo tablet once per day for 4 days and then received a laboratory session where they were given ascending doses of Nicotine (0.1, 0.4, and 0.7 mg per 70 kg).After a minimum of a 5 day washout subjects then received varenicline tablet (1mg). once per day for 4 days and then received a laboratory session where they were given ascending doses of Nicotine (0.1,0.4,0.7 mg per 70kg).
89424769|NCT04829643|Experimental|PET/MRI|Patients with early breast cancer up to 3 cm without overt nodal involvement who are candidates to upfront surgery
89424770|NCT04826211|Experimental|Node positive BC patients undergoing PST|Patients with breast cancer of any size with positive axillary nodes and candidates to PST will undergo PET/MRI both prior to PST and after PST before surgery
89424771|NCT04821492||Hyperhomocysteinemia|
89424772|NCT04821492||Normal Hcy levels|
89424773|NCT04810858|Other|HIV+ marijuana user|Participants with HIV who report marijuana use
89424774|NCT04810858|Other|HIV+ non-drug user|Participants with HIV who report no drug use
89424775|NCT04810858|Other|HIV- marijuana user|Participants without HIV who report marijuana use
89424776|NCT04810858|Other|HIV- non-drug user|Participants without HIV who report no drug use
89007239|NCT05447884|Experimental|Group B - Participants with paretic stroke|Individuals with paretic stroke will be recruited (Group S). Usually, participants from this group have limited hip joint motion of range, weakened hip joint flexion or extension, or both flexion and extension functionalities, but they can also walk independently.
89424777|NCT04807816|Experimental|Experimental Arm A: treatment by berzosertib combined with gemcitabine|Patients with advanced leiomyosarcomas will be treated with berzosertib combined with gemcitabine
89424778|NCT04807816|Other|Standard Arm B: treatment by gemcitabine alone|Patients with advanced leiomyosarcomas will be treated with with gemcitabine alone (control arm)
89424779|NCT04789655|Experimental|CC-96191|CC-96191 will be administered intravenously on a 28-day Cycle
89424780|NCT04786444|Active Comparator|VLA1553 Lot 1|
89424781|NCT04786444|Active Comparator|VLA1553 Lot 2|
89424782|NCT04786444|Active Comparator|VLA1553 Lot 3|
89424783|NCT04785092|Experimental|Treatment - All Autologous Cartilage Regeneration|
89424784|NCT04783363|Experimental|Arm A|"Visit 1: with Snoezelen session before invasive care~Visit 2: standard care (=without Snoezelen session) before invasive care"
89424785|NCT04783363|Experimental|Arm B|"Visit 1: standard care (=without Snoezelen session) before invasive care~Visit 2: with Snoezelen session before invasive care"
89424786|NCT04771962|Experimental|DESFLURANE|desflurane group- this group of patients will be induced with sevoflurane and maintained with desflurane during spontaneous general anaesthesia
89424787|NCT04771962|Active Comparator|SEVOFLURANE|the controlled group.patients will be induced and maintained with sevoflurane through out spontaneous general anaesthesia.
89424788|NCT04771026|No Intervention|Control|Receiving routine conduct of general anaesthesia for supraglottic airway device
89424789|NCT04771026|Experimental|Dexamethasone|Receiving pre-operatively single dose nebulised dexamethasone 8mg prior to induction of general anaesthesia
89424790|NCT04768309|Experimental|CKD group|CKD adult patients stage 4-5 Without diabetes BMI between 18 and 30 kg/m2
89424791|NCT04768309|Other|Healthy volunteers group|Adult without chronic treatment, without renal dysfunction
89424792|NCT04768010|Experimental|Misoprostol|Participants will receive 100-200 micrograms of oral misoprostol twice daily.
89424793|NCT04767997|Experimental|Experimental group|Participants in this group will be randomized to receive probiotic formulation for the following 12 weeks.
89424794|NCT04767997|Placebo Comparator|Control group|Participants in this group will be randomized to receive placebo for the following 12 weeks.
89424795|NCT04765800|Active Comparator|Unified Psychodynamic Protocol for Emotional Disorders (UPP-EMO)|manualized treatment with a focus on core psychodynamic treatment principles; no use of imagery-based interventions.
89424796|NCT04765800|Experimental|Guided Imagery Psychotherapy for Emotional Disorders (GIP-EMO)|manualized treatment with regular applications (every 4-5 sessions) of guided affective imagery; the therapeutic work is explicitly focused on the patient's guided imagery.
89424797|NCT04749108|Experimental|Experimental: Arm A: immediate rectal surgery|"Very good responder patients will be randomly assigned to proctectomy performed within 4 to 6 weeks from randomization."
89424798|NCT04749108|Active Comparator|RCT Cap 50 and then rectal surgery|"Very good responder patients will be randomly assigned to receive chemoradiotherapy combining the administration of oral capecitabine (1600 mg/m2/day, BID) and radiotherapy at a total dose of 50 grays (2Gy/day, 5 days a week, 5 weeks, boost 6 Gy) followed after 7 weeks by a proctectomy."
89424799|NCT04746573||Natrox Topical Oxygen Therapy managed by telehealth|Pilot study using topical oxygen managed by telehealth in the home setting.
89424800|NCT04744155|Experimental|Multi-Level Intervention|All adolescents receive the Motivational Interviewing (MI) enhanced counseling and clinic referral.Those randomized to MLI will be offered immediate, ED-based contraception (i.e., oral pill, transdermal patch, vaginal ring, injection, subdermal implant) in addition to receive a warm referral (provider helping to schedule follow-up appointment) to follow-up on selected method (or to initiate in clinic, if preferred)
89424801|NCT04744155|Active Comparator|Enhanced Standard of Care|All adolescents receive the Motivational Interviewing (MI) enhanced counseling and clinic referral. eSOC participants may obtain contraception only at the referral.
89424802|NCT04730544|Experimental|Experimental Arm A|"Treatment for 108 weeks (one cycle = 12 weeks; 9 cycles):~Nivolumab 480 mg every 4 weeks (27 infusions) and ipilimumab 1 mg/kg every 6 weeks (18 infusions) for a total of 24 months of treatment (or less in case of RECIST progression (PD) or limiting toxicity, whichever occurs first)."
89424803|NCT04730544|Active Comparator|Control Arm B|"Induction of 12 weeks (one cycle = 3 weeks; 4 cycles):~Nivolumab 240 mg and ipilimumab 1 mg/kg every 3 weeks for 4 dosing cycles (4 infusions of nivolumab and ipilimumab), Maintenance of 96 weeks (one cycle = 4 weeks; 24 cycles): Nivolumab 480 mg every 4 weeks for 24 dosing cycles (24 infusions) for a total of 24 months of treatment (or less in case of RECIST progression (PD) or limiting toxicity, whichever occurs first)."
89424804|NCT04715178||Patients with suspected or confirmed pediatric solid tumors|Patients with suspected or confirmed pediatric solid tumors
89424805|NCT04697368|Experimental|Experimental Group (EG)|The experimental group (EG), in addition to the standard treatment, will perform one session per day, each lasting 40 minutes, with the Armeo Power robotic system for upper limb rehabilitation. Each subject will perform a total of 25 ± 3 treatment sessions with a frequency of 5 times a week for 5 weeks.
89424806|NCT04697368|Active Comparator|Control Group (CG)|The control group (CG), in addition to the standard routine rehabilitation treatment, will follow 40 minutes of conventional upper limb rehabilitation. Each subject will perform a total of 25 ± 3 conventional upper limb treatment sessions with a frequency of 5 times a week for 5 weeks.
89424807|NCT04692155|Experimental|phase 1b and phase 2|"for phase 1 B portion, Ublitixumab will be given IV at dosage 900mg from Cycle 1 Day1 till cycle 6. If investigator decides to continue the treatment as maintenance, Ublitixumab will be given IV every 8 weeks for 24 months Umbralisib (800mg) will be given orally once a day within 30 minutes of a meal from Cycle 1 Day1 till cycle 6.If investigator decides to continue the treatment as maintenance,• Umbralisib will be given at orally daily for 24 months.~Chemotherapy combination of CHOP-cyclophosphamide IV 750mg/m2 for Age <70 years, 500 mg/m2 for Age>70 years doxorubicin IV 50mg/m2for Age <70 years, 25 mg/m2 for Age>70 years , and vincristine IV 1mg/m2 (max 2mg)) are administered on Cycle 1 day 1 till Cycle 6. Prednisone 50-100mg will be given orally on days 1 through 5 of every cycle.~For Phase II portion- Once Umbralisib dose is defined in phase Ib, the study will expand to phase II portion after SMC/DSMB (Safety monitoring committee/Data Safety Monitoring Committee) agrees."
89195782|NCT00606892|Experimental|Varenicline first, placebo, + IV Nic|Subjects received Varenicline tablet (1 mg) per day for 4 days and then received a laboratory session where they were given ascending doses of Nicotine (0.1, 0.4, and 0.7 mg per 70 kg). After a washout of a minimum of 5 days subjects then received placebo tablet for per day for 4 days and then received a laboratory session where they were given ascending doses of Nicotine (0.1,0.4,, and 0.7mg per 70 kg).
89195783|NCT00826215|Experimental|1|Electroacupuncture treatment
89195784|NCT00826215|Sham Comparator|2|Sham laser acupuncture
89195785|NCT00826293|Active Comparator|True Stabilization Group|Patients will be randomized to one of the two treatment groups (true stabilization vs. sham stabilization). Patients will be exercising with a belt that is expected to reduce impingement of the rotator cuff tendons.
89195786|NCT00826293|Sham Comparator|Sham Stabilization|Patients receive sham stabilization. The sham procedure imitates the treatment without any true effect.
89424808|NCT04687358||Active RP|Patients who are currently under the care of a physician for treatment of RP, currently on treatment for RP, and have had an episode (recurrence of typical pericarditis pain associated with supportive objective evidence of pericarditis) in the last 3 years prior to enrollment. Once included in the registry, these patients will have both retrospective and prospective follow-up and data collection (hybrid design).
89424809|NCT04687358||Inactive RP|Patients who have had a diagnosis of RP, have not had an episode for 3 years and have not been prescribed any treatment for RP in the last 3 years, prior to enrolling in the registry. Once included in the registry, data collected from these patients will be retrospective only.
89424810|NCT04663321|Experimental|MK-1942 Daily Dose Group|Participants receive a total daily dose titrated from 5 mg to 20 mg of MK-1942 twice daily (BID), orally, over 4 weeks of treatment duration: 5 mg in Week 1, 10 mg in Week 2, and 20 mg in Weeks 3 and 4. Participants receive MK-1942 and matching placebo packaged in blister cards with an equal number of capsules administered in the morning and evening regardless of treatment assignment.
89424811|NCT04663321|Experimental|MK-1942 Intermittent Dose Group|Participants receive a total daily dose of 10 mg of MK-1942 twice weekly (BIW), orally, for Weeks 1-4. Participants receive MK-1942 and matching placebo packaged in blister cards with an equal number of capsules administered in the morning and evening regardless of treatment assignment.
89195787|NCT04035538|Experimental|A group|
89195788|NCT04035538|Experimental|B group|
89195789|NCT00894946|Experimental|Recurrent IVF implantation failure|
89195790|NCT00894946|Experimental|Endometriosis|
89195791|NCT00737906|Experimental|I|Surgical turbinate reduction procedure
89195792|NCT05312996|Experimental|Hypertension|Hypertension test group.
89424812|NCT04663321|Placebo Comparator|Placebo|Participants receive a dose-matched placebo BID, orally, for 4 weeks. Participants receive matching placebo packaged in blister cards with an equal number of capsules administered in the morning and evening regardless of treatment assignment.
89424813|NCT04663178|Experimental|Warm Salt Water Foot Bath Group|"In the first interview Patient Identification Form, Fatigue Severity and Piper Fatigue Scale (PFS) were applied to the patients. A training booklet about chemotherapy-induced fatigue containing the definition, causes, ad development process of chemotherapy-induced fatigue and effective coping approaches were delivered to patients.~Each patient received iodine salt and a liquid thermometer to measure the temperature of the water. The patients were asked 1 day after the treatment to apply warm salt water bath of 41-42ºC once a day for 20 minutes for 7 days.~Subsequently, the fatigue level of the patients was evaluated 30 minutes after having a warm saltwater foot bath and recorded by questioning via calling them with phone every day and using the Visual Fatigue Scale for 7 days. In the last interview PFS was used to evaluate the effect level of fatigue on the quality of life and the assessment process was completed."
89424814|NCT04663178|No Intervention|Control Group|"A training booklet about chemotherapy-induced fatigue~In the first interview Patient Identification Form, Fatigue Severity and Piper Fatigue Scale were applied to the patients.~A training booklet about chemotherapy-induced fatigue containing the definition, causes, ad development process of chemotherapy-induced fatigue and effective coping approaches were delivered to experimental group.~Subsequently, the fatigue level of the patients was evaluated and recorded by questioning via calling them with phone every day and using the Visual Fatigue Scale for 7 days. The patients were evaluated in the evening. In the last interview conducted with the patient on the 7th day, Piper's Fatigue Scale was used to evaluate the effect level of fatigue on the quality of life and the assessment process was completed."
89424815|NCT04654546|Experimental|Abdominal scans|Participants who performed an abdominal CT exam up to one month prior to the experimental ultrasound exam.
89424816|NCT04652908|Experimental|Treatment with PMSC-ECM|One-time administration of PMSC-ECM during the course of in utero fetal myelomeningocele surgery will be administered
89424817|NCT04652908|Other|non-PMSC untreated contemporaneous cohort|Contemporaneous cohort of patients undergoing routine fetal or postnatal MMC repair without PMSC-ECM (non-PMSC untreated contemporaneous cohort).
89424818|NCT04649749||Patients - bionic hand acquired|3 adult patients who acquired a bionic hand at the Medical University of Vienna after a traumatic brachial plexus lesion.
89424819|NCT04649749||Patients - bionic hand not yet acquired|3 patients eligible for the bionic hand prior to a possible amputation.
89424820|NCT04649749||Control subjects|Ten control subjects will be included for comparison.
89195793|NCT05312996|Other|Active Comparator|Non Hypertension compare group.
89424821|NCT04648787|Experimental|Intervention group: traditional nursing with family-integrated care|traditional nursing with family-integrated care
89424822|NCT04648787|Experimental|Control group: traditional nursing|traditional nursing
89424823|NCT04639869|Experimental|Phenyramydol then Cabral|Participants first receive Phenyramydol HCl 400 mg Film Tablet manufactured by Pharmactive Ilac San ve Tİc A.S. in fed state. After a wash out period of 7 days, they then received Cabral 400 mg Film Tablet manufactured by Recordati Ilac San ve Tİc A.S. in fed state
89424824|NCT04639869|Active Comparator|Cabral then Phenyramydol|Participants first receive Cabral 400 mg Film Tablet manufactured by Recordati Ilac San ve Tİc A.S. in fed state. After a wash out period of 7 days, they then received Phenyramydol HCl 400 mg Film Tablet manufactured by Pharmactive Ilac San ve Tİc A.S.in fed state
89424825|NCT04639869|Experimental|Phenyramydol then Cabral Replicate|Participants first receive Phenyramydol HCl 400 mg Film Tablet manufactured by Pharmactive Ilac San ve Tİc A.S. in fed state. After a wash out period of 7 days, they then received Cabral 400 mg Film Tablet manufactured by Recordati Ilac San ve Tİc A.S. in fed state
89195794|NCT01035775|Experimental|Insertion|Inspection on colonoscope insertion in addition to inspection during withdrawal from the cecum.
89424826|NCT04639869|Active Comparator|Cabral then Phenyramydol Replicate|Participants first receive Cabral 400 mg Film Tablet manufactured by Recordati Ilac San ve Tİc A.S. in fed state. After a wash out period of 7 days, they then received Phenyramydol HCl 400 mg Film Tablet manufactured by Pharmactive Ilac San ve Tİc A.S.in fed state
89424827|NCT04639128|No Intervention|No-Device|No placement of an adductor canal catheter
89424828|NCT04639128|Experimental|Device|Placement of an adductor canal catheter
89424829|NCT04631185|Active Comparator|SPD (Arm A)|Single pre-operative dose of intravenous antibiotics with intraoperative redosing (SPD): Intravenous cefazolin, a cephalosporin antibiotic, will be prescribed to all patients before surgery. All patients will receive one dose of antibiotic within 60 minutes prior to incision, and any intraoperative doses of antibiotics according to current recommendations based on the antibiotic's dosing and on operative time.
89424830|NCT04631185|Experimental|WPO (Arm B)|The patients assigned to this arm will receive same pre-op and intraoperative antibiotics similar to SPD (Arm A). In addition, patients in this group will receive one week of post-operative antibiotics (WPO). The post-operative antibiotic will be a first generation Cephalosporin of their surgeon's choice.
89424831|NCT04626284|Experimental|Donors After Circulatory Determined death|Recipients receiving an organ from donors after circulatory determined death
89424832|NCT04617587|Experimental|Early Intervention|All the enrolled preterm infants are assigned to receive the early neurodevelopmental intervention during the NICU stay.
89424833|NCT04611282|Experimental|Microsurgery group|All defects were treated with a CPF plus an SCTG by the same investigator using microsurgery technique.
89424834|NCT04611282|Active Comparator|Macrosurgery group|All defects were treated with a CPF plus an SCTG by the same investigator using macrosurgery technique.
89424835|NCT04604353|Experimental|PRS score group|Risk information provided on the basis of Polygenic Risk Score combined with the Pooled Cohort Equation
89424836|NCT04604353|Active Comparator|CCS score group|Risk information provided on the basis of Coronary Calcium Score combined with the Pooled Cohort Equation
89424837|NCT04577807|Experimental|Arm 1: Lerapolturev Only|Lerapolturev (up to 1.6x10^9 TCID50) administered via direct injection of up to 6 lesions given weekly for 7 weeks, followed by every 3 weeks thereafter.
89424838|NCT04577807|Experimental|Arm 2: Lerapolturev and anti-PD-1|Lerapolturev (up to 1.6x10^9 TCID50) administered via direct injection of up to 6 lesions given weekly for 7 weeks, followed by every 3 or 4 weeks thereafter. Anti-PD-1 therapy given as per the anti-PD-1 approved package insert.
89424839|NCT04562987|Active Comparator|Core Component (tele-coaching, emails, smartphone app & Fitbit)|All participants will receive the Core component, which includes access to weekly tele-coaching, weekly emails from the interventionist, a smartphone app, and a Fitbit monitor. Tele-coaching will include discussion of general cancer-related and wellness topics, and the smartphone app will have basic activity monitoring features.
89424840|NCT04562987|Experimental|Move (tele-coaching calls, smartphone app & Move goals & badges)|Tele-coaching calls for Move participants will be based in social cognitive theory to encourage behavior adoption and goal setting focused on reducing prolonged sitting. Smartphone app features include activity monitoring that visualizes progress toward Move-based goals and goal achievement badges specific to Move.
89424841|NCT04562987|Experimental|Exercise (tele-coaching calls & smartphone app)|Tele-coaching calls for Exercise participants will be based in social cognitive theory to encourage behavior adoption and goal setting focused on engaging in 30 minutes of moderate-intensity physical activity per day (in 10+ minute bouts). Smartphone app features include activity monitoring that visualizes progress toward Exercise-based goals and goal achievement badges specific to Exercise.
89424842|NCT04562987|Experimental|Combo (Move+Exercise)|Includes tele-coaching that encourages behavior adoption and goal setting focused on reducing prolonged sitting and engaging in 30+ minutes of physical activity per day. Participants are able to visualize progress toward Move and Exercise goals and are eligible to receive achievement badges for Move and Exercise.
89424843|NCT04546295|Experimental|Brushlink|This group will use Brushlink and interdental cleaner. The Brushlink app downloaded to participant's cell phone. A small Brushlink device is attached to participant's toothbrush. When participant's brush their teeth, the device on the toothbrush will send information to the app on your phone about how long teeth are brushed and at what angle the toothbrush is being held against the tooth.
89424844|NCT04546295|Active Comparator|Water-flosser|This group will brush their teeth using a waterflosser that sprays the tooth with a small jet of water.
89424845|NCT04546295|Placebo Comparator|Interproximal Brush|This group will brush their teeth with only a toothbrush.
89424846|NCT04525950|Experimental|Navio|Using the new technology during surgery
89424847|NCT04525950|Active Comparator|Conventional|Using the conventional surgical instruments
89424848|NCT04508244|Active Comparator|TBI with positive troponin|Patients will receive IV propranolol for 6 days
89424849|NCT04508244|Placebo Comparator|TBI with negative troponin (a)|Patients will receive IV placebol for 6 days
89424850|NCT04508244|Experimental|TBI with negative troponin (b)|Patients will receive IV propranolol for 6 days
88905961|NCT05325996|Experimental|Moderate Glaucoma|"Subjects between ages 20-80 years with a diagnosis of mild and moderate Open Angle Glaucoma in at least one eye with 20/50 vision or better will be included in this study. All subjects will have the Olleyes Perimeter measure their own visual acuity and field once a week during a 2 year period and iCare home to measure their eye pressure 3 times a day for 7 days every 3 months during a 2 year period.~All patient will have their routine glaucoma assessment with the standard 24-2 Automatic Perimetry Humphrey Field Analyzer at baseline and every 6 months during a 2 year period; and Spectralis Optical Coherence Tomography thickness of peripapillary RNFL and macular ganglion cell at baseline and yearly during a 2 year period."
89424851|NCT04507100|Experimental|Lifestyle and environment intervention|Schools will receive the components of Salud Escolar
89424852|NCT04507100|No Intervention|Wait-list control|Wait-list control of schools without intervention.
89424853|NCT04502719||Screened|Patients with liver cirrhosis screened for malnutrition.
89424854|NCT04499963|Experimental|Open Label Arm|The intervention is twice daily dosage of Theracurmin 90 mg capsules. This same dose was used in a successful trial of patients with mild cognitive impairment. Theracurmin HP capsules containing 90 mg curcumin each that will be taken as one capsule twice daily for 6 months. Each capsule contains 300 mg Theracurmin enhanced bioavailable water-dispersible turmeric rhizome complex providing 30% curcumin (90 mg). The content of Theracurmin HP has been independently certified by NSF International under NSF/ANSI 173.
89424855|NCT04499963|No Intervention|Healthy Control Arm|We will seek to enroll 50 healthy control participants. We will attempt to enroll one control subject from each enrolled primary participant's home, preferably a spouse or partner of similar age if possible. We plan to use this data to compare the microbiome of control participants to that of the ALS participants at baseline, week 4 and month 6. We will not conduct further follow-up or collect additional samples with the control subjects.
89424856|NCT04479241|Experimental|Lerapolturev|
89424857|NCT04461210||Vulvodynia|Women with localized, provoked vulvodynia
89424858|NCT04461210||Health Controls|Women without vulvar pain or other vulvar disorders.
89424859|NCT04460287|Placebo Comparator|Milk Drink Unfortified (Negative Control)|Children will get the product (packed for its individual portion) that must be consumed once a day for 30 days.
89424860|NCT04460287|Active Comparator|Milk Drink Unfortified Plus Fish Oil (Positive Control)|Children will get the product (packed for its individual portion) that must be consumed once a day for 30 days
88905962|NCT05323487|Active Comparator|Bumetanide 10 mg|Randomized to doses 10 mg, 5 mg, 2.5 mg, 1.25 mg
88905963|NCT05323487|Active Comparator|Bumetanide 5 mg|5 mg Randomized to doses 10 mg, 5 mg, 2.5 mg, 1.25 mg
88905964|NCT05323487|Active Comparator|Bumetanide 2.5 mg|2.5 mg Randomized to doses 10 mg, 5 mg, 2.5 mg, 1.25 mg
88905965|NCT05323487|Active Comparator|Bumetanide 1.25 mg|1.25 mg Randomized to doses 10 mg, 5 mg, 2.5 mg, 1.25 mg
89424861|NCT04460287|Experimental|Milk Drink Fortified with DHA Used Wet Mixing Method|Children will get the product (packed for its individual portion) that must be consumed once a day for 30 days
89424862|NCT04460287|Experimental|Milk Drink Fortified with DHA Used Dry Blending Method|Children will get the product (packed for its individual portion) that must be consumed once a day for 30 days
89424863|NCT04451954|Experimental|Group 1: Quadrivalent RIV with H3 strain 1, without adjuvant|1 injection of quadrivalent RIV containing H3 strain 1, without adjuvant, in participants ≥ 50 years old
89424864|NCT04451954|Experimental|Group 2: Quadrivalent RIV with H3 strain 1, with adjuvant|1 injection of quadrivalent RIV containing H3 strain 1, with adjuvant, in participants ≥ 50 years old
89424865|NCT04451954|Experimental|Group 3: Quadrivalent RIV with H3 strain 2, without adjuvant|1 injection of quadrivalent RIV containing H3 strain 2, without adjuvant, in participants ≥ 50 years old
89424866|NCT04451954|Experimental|Group 4: Quadrivalent RIV with H3 strain 2, with adjuvant|1 injection of quadrivalent RIV containing H3 strain 2, with adjuvant, in participants ≥ 50 years old
89424867|NCT04451954|Active Comparator|Group 5: Quadrivalent RIV Control, without adjuvant|1 injection of quadrivalent RIV containing 2018-19 Northern Hemisphere (NH) recommended H3 strain, without adjuvant, in participants ≥ 50 years old
89424868|NCT04451954|Active Comparator|Group 6: Quadrivalent RIV Control, with adjuvant|1 injection of quadrivalent RIV containing 2018-19 NH recommended H3 strain, with adjuvant, in participants ≥ 50 years old
89424869|NCT04451954|Active Comparator|Group 7: Quadrivalent RIV Control, without adjuvant|1 injection of quadrivalent RIV containing 2018-19 NH recommended H3 strain, without adjuvant, in participants 18-30 years old
89424870|NCT04418804|Experimental|Healthy|Participants without an active diagnosis of pleural disease.
89424871|NCT04418804|Experimental|Pneumothorax|Participants diagnosed with pneumothorax during the past 24 hours.
89424872|NCT04418804|Experimental|Pleural effusion|Participants diagnosed with current pleural effusion during the past 48 hours.
89424873|NCT04366050|Experimental|Ramipril 2.5mg orally daily|"Total 2.5 mg Ramipril per day once a day orally for 14 days~Intervention: Ramipril"
89424874|NCT04366050|Placebo Comparator|Placebo|Placebo in the form of a capsule, taken orally for 14 days
89424875|NCT04330482|Other|Internet Links|A tablet pre-loaded with a list of internet links relating to dementia caregiving that participants will be instructed to use at least 4 times weekly for 3 months.
89424876|NCT04330482|Experimental|CARE-Well App|A tablet pre-loaded with the CARE-Well app that participants will be instructed to use at least 4 times weekly for 3 months.
89424877|NCT04325503|Experimental|Treatment|carbidopa and carbidopa-levodopa treatment for parkinsonian signs in older persons using standard dosing, frequency for a duration for 1-2 weeks
89424878|NCT04301843|Experimental|Eflornithine (DFMO)|"In this study subjects will receive six 21-day cycles of Etoposide and DFMO followed by an additional 630 days of DFMO alone.~Etoposide will be given at 50 mg/m2/dose PO daily for the first 14 days of each 21 days until 6 cycles of etoposide are completed.~DFMO (difluoromethylornithine) will be given at a dose of 1000 mg/m2 BID on each day of study."
89424879|NCT04282031|Experimental|phase 1 (dose escalation study, dose expansion study and PK trail)|Participants will first receive single dose BPI-1178 orally at dose levels of 25mg, 75mg, 150mg, 250mg, 400mg and 500mg followed by a 7-day washout period , and then start receiving the 28 days/cycle continuous treatment until disease progression or unacceptable toxicity. After the 500 mg dose escalation trial is completed, the PK study will be conducted for the 400 mg dose group, the 300 mg dose group and the 200 mg dose group.
89424880|NCT04282031|Experimental|phase 2a cohort A|Participants will receive BPI-1178 at dose levels of MTD, MTD-1 or MTD-2 in combination with fulvestrant for 3 consecutive weeks, followed by 1 week drug withdrawal or continuous dosing for 28 days, in each 28-day treatment cycle, until disease progression or unacceptable toxicity.
89424881|NCT04282031|Experimental|phase 2a cohort B|Participants will receive BPI-1178 at dose levels of MTD, MTD-1 or MTD-2 in combination with letrozole for 3 consecutive weeks, followed by 1 week drug withdrawal or continuous dosing for 28 days, in each 28-day treatment cycle, until disease progression or unacceptable toxicity.
89424882|NCT04263038|Active Comparator|Anticoagulation|Patients in the anticoagulation group will receive rivaroxaban 15 mg twice daily for the first 21 days, followed by 20 mg once daily for an overall treatment duration of 90 days.
89424883|NCT04263038|Placebo Comparator|No anticoagulation|Patients in the group without anticoagulation will receive placebo twice daily for the first 21 days, followed by one tablet daily for an overall treatment duration of 90 days.
89195795|NCT01035775|Active Comparator|Withdrawal|Inspection during withdrawal (usual care) without deliberate inspection during insertion.
89424884|NCT04241172|Experimental|Immersive Virtual Reality (HIVR)|"The HIVR exercises will be performed using Nirvana system, a medical device based on virtual reality specifically designed to support motor rehabilitation, by projecting aquatic scenarios on the floor that simulates the movement and the noise of the water due to the motor exercise execution by the patient. In particular, the following virtual reality scenarios will be used:~Swimming pool: the environment represents a swimming pool (water and edge). The patient must perform exercises by moving the lower limbs while sitting on a chair. The virtual environment gives the sensation of having the lower limbs immersed in water above the knees;~Water metal: the environment gives the feeling of being immersed in water up to the waist. The subject interacts with the virtual water performing walking exercises and receiving visual and auditory biofeedback."
89424885|NCT04241172|Active Comparator|Traditional Hydrotherapy (TH)|"The TH group exercises will be performed in a swimming pool suitable for hydrotherapy treatments. In particular, patients will perform:~exercises with patients sitting on the swimming pool edge with lower limb immersed in the water;~flexion-extension of the knee;~leg and hip circling;~flexion-extension of the ankle;~triple flexion;~water walking exercises."
89424886|NCT04241172|Active Comparator|Traditional Rehabilitation (TR)|"The TR group exercises will be performed in the gym with a physiotherapist. In particular, patients will perform:~exercises with a patient sitting on a chair (3 minutes per exercise):~flexion-extension of the knee;~leg and hip circling;~flexion-extension of the ankle;~triple flexion;~walking (with and without aids)."
89424887|NCT04236557|Experimental|Intervention|
89424888|NCT04236557|Placebo Comparator|Wait-list Control|
89424889|NCT04235816|Active Comparator|Group 1|AZi at DTP-1 visit at 6 weeks of age, AZi (plus IPTi) at measles visit at 9 months of age and AZi (plus IPTi) at measles booster visit at 15 months of age.
89424890|NCT04235816|Placebo Comparator|Group 2|Placebo at DTP-1 visit at 6 weeks of age, placebo (plus IPTi) at measles visit at 9 months of age and placebo (plus IPTi) at measles booster visit at 15 months of age.
89195796|NCT00737984|No Intervention|1|Group 1 patients will receive standard superovulation-IUI treatment without endometrial sampling
89424891|NCT04220385|Active Comparator|Wii fit Plus|"This study group will perform the following Wii fit plus exercises~Single-Leg Extension~Arm and Leg Lift~Balance Bridge~Single-Leg Twist~Single-Leg Reach~Sideways Leg Lift~Single Arm Stand~Torso Twists~Plank"
89424892|NCT04220385|Active Comparator|Core Stability|"This study group will perform the following exercises.~Curl-up~Side Bridge~Bird Dog"
89424893|NCT04218123|Experimental|Venlafaxine Arm|
89424894|NCT04218123|Placebo Comparator|Placebo|
89424895|NCT04205240|Experimental|Treatment (conditioning regimen, stem cell transplant)|Patients receive fludarabine IV on days -5 to -2 and melphalan IV on days -3 to -2, then undergo stem cell transplantation on day 0. Patients receive cyclophosphamide on days 3 and 4, tacrolimus PO BID or IV starting on day 5, and mycophenolate mofetil IV or PO TID on days 5 to 35. Patients also receive daratumumab IV starting between days 90-150 for up to 1 year. Treatment continues in the absence of disease progression or unacceptable toxicity.
89424896|NCT04176666|Experimental|Intervention group receiving NettOpp|The effectiveness study will be conducted as a randomized controlled trial with an intervention group and a waiting-list control group. Data will be collected at baseline (T1, pre intervention) and after about 2 weeks of intervention (T2, post intervention). A follow-up evaluation (T3) will be conducted after about 3 months to examine if the effects were stable over time.
89424897|NCT04176666|No Intervention|Control group|The control group will receive the intervention after study completion.
89424898|NCT04174079|Experimental|Experimental group|patients with R0 resected T≥3 or N≥1 thoracic esophageal squamous cell carcinoma began to receive chemotherapy of docetaxel combined with nedaplatin within 8 weeks after total two-field lymph node dissection. Docetaxel 75mg/m2 day 1, nedaplatin 75mg/m2 day 1, every 21 days for 4 cycles
89424899|NCT04174079|No Intervention|control group|patients with R0 resected T≥3 or N≥1 thoracic esophageal squamous cell carcinoma were reviewed regularly after surgery.
89424900|NCT04153383||TMAD|Tissue motion annular displacement (TMAD) of tricuspid valve annulus transesophageal echocardiography
89195797|NCT00737984|Active Comparator|2|Group 2 patients will receive standard superovulation-IUI treatment with endometrial sampling performed in the preceding cycle. It will be done in the follicular phase not later than day 10 of the cycle
89195798|NCT04035616|Placebo Comparator|Placebo|placebo were manufactured and supplied by B-Crobes Laboratory Sdn. Bhd. as powder in identical sachets with active comparator and labelled as A
89424901|NCT04134572||Ollier Disease and Maffucci Syndrome patients|The group comprises all patients affected by Ollier Disease and Maffucci Syndrome.
89424902|NCT04127994|Experimental|3 meals|"Patients with type 2 diabetes will be submitted to a 3 meal regimen for 3 months.~We will compare their basal complete blood chemistry, somatometric measurements versus the same variables after 3 months."
89424903|NCT04127994|Experimental|6 meals|"Patients with type 2 diabetes will be submitted to a 6 meal regimen for 3 months.~We will compare their basal complete blood chemistry, somatometric measurements versus the same variables after 3 months."
89424904|NCT04109222|Experimental|Group 1: Fluzone Quadrivalent Influenza vaccine: 6 to < 36 Months|Participants aged 6 to <36 months received a 0.5-milliliters (mL) dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0. Participants for whom 2 doses of influenza vaccine were recommended per ACIP, a second dose was administered at Day 28.
89424905|NCT04109222|Experimental|Group 2: Fluzone Quadrivalent Influenza Vaccine: 3 to < 9 years|Participants aged 3 to 9 years received a 0.5-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0. Participants for whom 2 doses of influenza vaccine were recommended per ACIP, a second dose was administered at Day 28.
89424906|NCT04109222|Experimental|Group 3: Fluzone High-Dose Influenza Vaccine: >= 65 years|Participants aged >=65 years received a of 0.5-mL dose of Fluzone high-dose vaccine, intramuscularly, at Day 0.
88905966|NCT05307523|Experimental|Enriched Environment Play With Harness Support|Enriched environment play, movement, and exploration for children with Down Syndrome while using a portable partial body weight support harness to facilitate movement and exploration.
88905967|NCT05307523|Active Comparator|Enriched Environment Play Without Harness Support|Enriched environment play, movement, and exploration without additional partial body weight support provided.
88905968|NCT05307302||Adolescent basketball players|Adolescent basketball players between the ages of 13-18 playing in basketball teams
89424907|NCT04105920|Experimental|hyaluronic acid arm|Patients included in this arm, will have, before insertion of brachytherapy seeds in the prostate, an injection of hyaluronic acid between the prostate, rectum, and pudendal arteries
88905969|NCT05300685|Active Comparator|Group 1: Standard of care|"Prior to graft harvest - infiltration of 1% lidocaine with 1:100,000 epinephrine up to a maximum of 10 mL~Routine, standard graft site hemostasis with monopolar cautery~No suture closure of graft site~No further infiltration of local anesthetic in mouth"
88905970|NCT05300685|Experimental|Group 2: Standard of care + Long acting local|"Prior to graft harvest - infiltration of 1% lidocaine with 1:100,000 epinephrine up to a maximum of 10 mL~Routine, standard graft site hemostasis with monopolar cautery~No suture closure of graft site~Up to a maximum of 10mL of 0.5% bupivacaine infiltration in the buccal graft site"
88905971|NCT05300685|Experimental|Group 3: Standard of care + Buccal block|"Prior to graft harvest - infiltration of 1% lidocaine with 1:100,000 epinephrine up to a maximum of 10 mL~Routine, standard graft site hemostasis with monopolar cautery~No suture closure of graft site~Up to a maximum of 10mL of 0.5% bupivacaine infiltration as a buccal block"
88905972|NCT05276817|Sham Comparator|Perio maint. then sham laser|
88905973|NCT05276817|Experimental|Perio maint. then medicament|
88905974|NCT05276817|Experimental|Perio maint. then diode laser 1|
88905975|NCT05276817|Experimental|Perio maint. then diode laser 2|
88905976|NCT05266807|Experimental|SoC + oral Fecal Microbiota Transplantation|Antibiotic (vancomycin 125 mg 4 times daily or fidaxomicin 200 mg 2 times daily, as initially prescribed per SoC) for 10 days, followed 12h to 4 days later by one oral FMT (20 capsules administered at D1 and 20 capsules at D2), and a second oral FMT if CDI is severe.
88905977|NCT05266807|Active Comparator|SoC|Antibiotic (vancomycin 125 mg 4 times daily or fidaxomicin 200 mg 2 times daily, as initially prescribed per SoC) for 10 days.
89424908|NCT04105920|Active Comparator|Conventional brachytherapy|Patients included in this arm will have the conventional brachytherapy.
89424909|NCT04080544|Experimental|Follow up DLBS participants|Eight to ten year follow-up DLBS participants who were cognitively normal at the time of enrollment from 2008 to 2014.
89424910|NCT04074798|Active Comparator|Patients with low back pain|
89424911|NCT04074798|Sham Comparator|Healthy controls|
89424912|NCT04066348|Experimental|Etanercept Injection Group|Subjects will receive 2 X 25mg/ 1ml etanercept injection (experimental) weekly for 12 weeks.
88905978|NCT05254418|Experimental|dulagutide arm|Patient will receive 1.5 mg injections per week for 12 weeks.
88905979|NCT05250375||Nucleotide-binding protein-like (NUBPL)-Primary Mitochondrial Disease adult and child subjects|Any patient with NUBPL-Primary Mitochondrial Disease is eligible to be enrolled
88905980|NCT05233072|Other|Fracture|Patients with a fracture of the upper neck of the femur
88905981|NCT05233072|Other|Control|Patients with no fracture of the upper neck of the femur
88905982|NCT05227079|Active Comparator|Group A (double bite forceps)|Participants in group A will proceed to have their biopsies during endoscopy taken with the conventional double bite forceps. Meaning, they will have two biopsies taken each time the forcep is passed through the endoscope. To obtain a total of six biopsies, the forceps will be passed through the endoscope a total of three times.
88905983|NCT05227079|Experimental|Group B (multiple bite forceps)|Participants in group B will have their biopsies during endoscopy retrieved with the multiple bite forceps. Meaning, they will have six consecutive biopsies taken with each pass through the endoscope.
88905984|NCT05222477|Active Comparator|Pelvic floor group|pelvic floor exercises (intervention) will be applied for patients with nocturia and type 2 DM for 6 weeks, 3 times/week
88905985|NCT05222477|Active Comparator|Abdominal group|Abdominal exercises (intervention) will be applied for patients with nocturia and type 2 DM for 6 weeks, 3 times/week
88905986|NCT05213520|Experimental|Alternate Day Intermittent Energy Restriction|Participants assigned to this diet will be asked to alternate between full calorie (no restriction) eating days with eating 40% of their daily caloric requirement on the other day. For example, if their requirement is 2000 calories they would eat 800 calories one day and as much as you want on the other day and repeat every two days. There will be occasional exceptions allowed with maximum of two 40% days in a row (followed by two full days) based on personal schedule with prior approval. They will follow this for 4 weeks.
88820210|NCT06191549|Experimental|To explore improvements in learning capacity between healthy adults and stroke participants.|Compare stimulation-induced improvements in learning capacity between three groups: stroke group, healthy young group, and healthy older group.
88820211|NCT06191549|Experimental|To explore the trends of functional improvements after single a-tDCS session in stroke survivors.|To explore functional improvements (gait performance, brain neural activation) between a-tDCS, s-tDCS, and control groups.
88820212|NCT06191549|Experimental|To explore the accumulated effects of brain stimulation on gait improvements in stroke survivors|To explore the accumulated, longitudinal trends of a four-week visuomotor stepping training in conjunction with brain stimulation on treadmill walking training and gait improvements for persons with chronic stroke.
88820213|NCT06191536|Experimental|Pilates Group (PG)|"Pilates exercises will be performed under the supervision of a certified pilates instructor.~Pilates exercises will be performed for 50 minutes, 2 days a week for 8 weeks."
88820214|NCT06191536|Active Comparator|Pelvic Floor Exercise Group (PFEG)|"It consists of voluntary pelvic floor muscle contractions applied in addition to pilates exercises.~Pelvic floor muscle contractions involve maximum contraction of the pelvic floor muscles alternately for five repetitions during exhalation.~Pelvic floor exercises will be applied under the supervision of a pelvic floor certified physiotherapist.~In addition to pilates exercises, pelvic floor exercises will be applied 2 days a week, 50 minutes, for 8 weeks."
89424913|NCT04066348|Placebo Comparator|Placebo Injection Group|Subjects will receive 2 X 1ml saline injection (placebo) weekly for 12 weeks.
89424914|NCT04055948|No Intervention|Control - Standard of Care|- All participants will be screened for health literacy using a 4-item Brief Health Literacy Screening Tool (BRIEF)
89424915|NCT04055948|Experimental|Intervention|"All participants will be screened for health literacy using a 4-item Brief Health Literacy Screening Tool (BRIEF)~Three in-person, one-on-one teaching sessions with the caregiver during radiation treatments, followed by a telephone booster contact 2 weeks post-treatment."
89424916|NCT04044521|Experimental|Academic detailing only|Clinicians will attend an educational meeting and receive audit and feedback reports for 18 months.
89424917|NCT04044521|Experimental|Academic detailing+practice facilitation|"Clinicians of this group will attend an educational meeting and receive a monthly audit and feedback report for 18 months.~At month 3, clinics will be randomized to receive practice facilitation. Clinics will be asked to follow-up with the facilitators via phone or video chat monthly for months 4-6, then quarterly for months 7-18."
89424918|NCT04044521|Experimental|Academic detailing+practice facilitation+physician peer consul|Clinicians will receive academic detailing at month 0 and practice facilitation at month 3. At month 6, clinics will be randomized to receive physician peer consulting. Clinicians of the clinics will meet up to 4 times, quarterly, with the physician peer consultant.
88905987|NCT05213520|Active Comparator|Reduced Calorie Diet|Participants assigned to this diet will be asked to restrict calorie intake by 500-1000 calories below their daily energy requirement every day. They will follow this for 4 weeks.
89424919|NCT04044521|Experimental|Academic detailing+physician peer consulting|"Clinicians of this group will attend an educational meeting and will receive a monthly audit and feedback report for 18 months.~At month 6, clinicians of the clinics will meet up to 4 times, quarterly, with the physician peer consultant."
89424920|NCT04037098|Experimental|Magnesium|Magnesium lactate, 2 tablets orally every 12 hours (equivalent to 360 mg of elemental magnesium) for 3 months plus baseline dietary magnesium requirement.
89424921|NCT04037098|Placebo Comparator|Control|2 tablets orally every 12 hours of on inert placebo for three months plus baseline dietary magnesium requirement.
89424922|NCT04034316|Experimental|MSC|"During the first part of the study, 11 SDNS pediatric patients will receive 3 intravenous infusions of CB-MSCs at the dosage of 1.5 x 10^6/kg at a time interval of 1 to 2 weeks. The ongoing immunosuppressive treatment will be gradually tapered off after the first CB-MSC administration, as follows:~25% reduction of the ongoing immunosuppressive treatment following the first administration;~50% reduction of the ongoing immunosuppressive treatment following the second administration;~interruption of the ongoing immunosuppressive treatment following the third administration.~In the case that the hypothesis that P ≥ 0.600 is rejected and therefore the second part of the study will be required, 11 additional pediatric patients with SDNS will be treated with 3 intravenous infusions of CB-MSCs at the dosage of 2x10^6/kg at a time interval of 1 to 2 weeks."
89424923|NCT03999957|Other|Interventional Arm|Telehealth conferencing
89424924|NCT03992235|Experimental|Study Group|Chest physiotherapy + educational material
89424925|NCT03992235|Other|Control group|Chest physiotherapy
89424926|NCT03940521||HIV-A infected patients|
88905988|NCT05202418|Experimental|Biofeedback Enhanced Treatment|Participants in this group will participate in biofeedback enhanced cognitive behaviorally based coping skills treatment. Treatment will consist of a 6-visit group intervention conducted online, via Emory zoom. Groups will include 5-8 patients each. Sessions will include brief, daily homework to facilitate mastery that is developmentally tailored to youth (e.g., practice skills with support from phone or tablet apps). Groups will meet approximately every week for 6 weeks. Advanced Ph.D. students in clinical psychology and Principal Investigator will deliver the treatment protocol. They will complete questionnaires before and after each session to measure autonomic reactivity in response to stress induction and coping strategies.
89424927|NCT03915678|Experimental|Population 1: Pancreatic cancer|Participants with pancreatic cancer will be treated with Atezolizumab combined with BDB001 and radiotherapy.
89424928|NCT03915678|Experimental|Population 2: Virus-associated tumors|Participants with virus-associated tumors will be treated with Atezolizumab combined with BDB001 and radiotherapy.
89424929|NCT03915678|Experimental|Population 3: anti-PD-1/L1 refractory non-small lung cancer|Participants with anti-PD-1/L1 refractory non-small lung cancer will be treated with Atezolizumab combined with BDB001 and radiotherapy.
88905989|NCT05202418|No Intervention|Wait-list control|Participants randomized to the wait-list control group will complete the same measures of lifetime stress, autonomic reactivity, depression, anxiety. The identical treatment will be offered to control participants after the 6-week time point.
88905990|NCT05182359|Other|CVD-T2D Informed Medical Management (Informed)|The SomaSignal Metabolic Factors test results will be provided in the Open Label Extension; results will not be provided to provider and participant until study conclusion.
89424930|NCT03915678|Experimental|Population 4: Soft-tissue sarcoma|Participants with soft-tissue sarcoma will be treated with Atezolizumab combined with BDB001 and radiotherapy.
89424931|NCT03915678|Experimental|Population 5: anti-PD-1/L1 refractory bladder cancer|Participants with anti-PD-1/L1 refractory bladder cancer will be treated with Atezolizumab combined with BDB001 and radiotherapy.
89424932|NCT03915678|Experimental|Population 6: Triple negative breast cancer|Participants with triple negative breast cancer will be treated with Atezolizumab combined with BDB001 and radiotherapy.
89424933|NCT03897478||Ischemic Stroke|"Ischemic stroke subjects presenting within 30 hours from symptom onset will have al PAX Gene Blood RNA tubes drawn upon arrival to the Emergency Department (if available) or hospital.~Biomarker blood draw"
89195799|NCT04035616|Active Comparator|Hexbio® MCP|The treatment sample is labelled as B.This is an orange-flavoured, granulated microbial cell preparation containing 30 billion colony forming units (cfu) of Lactobacilli and Bifidobacteria strains: Lactobacillus acidophilus BCMC® 12130, Lactobacillus casei BCMC® 12313, Lactobacillus lactis BCMC® 12451, Bifidobacterium bifidum BCMC® 02290, Bifidobacterium infantis BCMC®02129, Bifidobacterium longum BCMC® 02120. The placebo sample was similar in appearance and taste, but contained no microbial cells.
88905991|NCT05182359|Other|Standard of Care (Uninformed)|The SomaSignal Cardiovascular Risk in Type 2 Diabetes (CVD-T2D) and Metabolic Factors test results will be provided in the Open Label Extension; results will not be provided to provider and participant until study conclusion.
88905992|NCT05156996||Treatment Group|
88905993|NCT05156996||Control Group|
88905994|NCT05154786|Experimental|Early Mobilization and endurance training|Early Mobilization and endurance training for prolonged mechanical ventilator
88905995|NCT05154786|Active Comparator|Usual care|Weaning protocols, bed exercise, and early mobilization.
88905996|NCT05141162|Experimental|case group|In the first stage, an information form including socio-demographic characteristics prepared within the framework of the literature and State-Trait Anxiety Inventory will be applied to mothers before surgery. Later, the experimental group will be knitted by the researcher during the surgical operation. The necessary materials (knitting needle and thread) for the knitting attempt will be given to the participants in the experimental group by the researcher. A neutral color, white, will be used as the knitting yarn color. Knitting will start 15 minutes after the child enters the operation and will be knitted for 30-40 minutes on average. At the end of the surgery, the State-Trait Anxiety Inventory scale will be applied again to evaluate the anxiety levels of the participants in the experimental and control groups. The vital signs of the mothers will be measured at the beginning of the operation and close to the end of the operation.
88905997|NCT05141162|No Intervention|control group|An information form including socio-demographic characteristics prepared within the framework of the preoperative literature and State-Trait Anxiety Inventory will be applied to mothers. No attempt will be made to this group. At the end of the surgery, the State Trait Anxiety Inventory scale will be applied again to evaluate the anxiety levels of the participants in the experimental and control groups. The vital signs of the mothers will be measured at the beginning of the operation and near the end of the operation.
88905998|NCT05123989|Experimental|Personalized move goals|Participants will be sent daily messages in the Welltory mobile app with personalized move goals that are based on each participant's historical physical activity data and their daily wellbeing
88905999|NCT05123989|Active Comparator|Constant move goals|Participants will be sent daily messages in the Welltory mobile app with a static move goal of 10,000 steps per day
88906000|NCT05123989|No Intervention|No intervention|Participants will not be sent any messages with move goals in the Welltory mobile app
88906001|NCT05117866|Experimental|Prasugrel Monotherapy|The patients will be loaded with standard dual antiplatelet therapy according to local practice (usually aspirin 81 to 330 mg and clopidogrel 300 mg or prasugrel 20 mg or ticagrelor 180 mg, unless patient is on long-term therapy) prior to the PCI procedure. After PCI, if the results are considered to be satisfactory by the operator based on clinical (e.g. clinical status, ECG, etc.), angiographic and/or findings from intracoronary imaging, only then patients will be enrolled in the study and loaded with prasugrel 20 mg if the patients have not loaded prasugrel prior to PCI or have not taken a maintenance dose of prasugrel before the index PCI. Patients continued with prasugrel only (3.75 mg once a day) for three months in CCS patients and for 12 months in NSTE-ACS patients. Aspirin, clopidogrel, and ticagrelor will be discontinued just after the index procedure.
88906002|NCT05117177|Experimental|Part 1a|Part 1A will evaluate the safety as well as to determine the maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D) of inupadenant in participants with advanced solid tumors.
88906003|NCT05117177|Experimental|Part 1b|The effect of food on the exposure to inupadenant will be investigated.
88906004|NCT05114031|Experimental|FB101|Active intervention with microbial product FB101
88906005|NCT05114031|Placebo Comparator|Placebo|Non-microbial placebo intervention
88906006|NCT05107284|Placebo Comparator|Intervention-only Control|Participants navigate through e-checkup to go, the well-established alcohol intervention. Any follow-up emails sent to them later contain only a reminder to participate in follow-up surveys.
88906007|NCT05107284|Experimental|Intervention plus delayed feedback booster|Participants navigate through e-checkup to go, the well-established alcohol intervention, then receive a series of feedback booster emails. It contains a reminder to participate in follow-up surveys, plus personalized feedback based on participant-reported perceived alcohol norms, actual alcohol norms, their own use, and harm reduction strategies.
88906008|NCT05106686|Experimental|Aureobasidium pullulans produced β-glucan group|This group takes Aureobasidium pullulans produced β-glucan for 12 weeks.
88906009|NCT05106686|Placebo Comparator|Placebo group|This group takes placebo for 12 weeks.
88906010|NCT05102136|Experimental|Intravenous Cohorts|Randomized 6:2 to REGN9933 or placebo
88906011|NCT05102136|Experimental|Subcutaneous Cohorts|Randomized 6:2 to REGN9933 or placebo
88906012|NCT05095259|Experimental|Participants with Type 1 Diabetes Mellitus|Participants with Type 1 Diabetes Mellitus
88906013|NCT05095259|Active Comparator|Healthy Controls|Healthy Controls
89195800|NCT05289362|Experimental|Treating pancreatic duct stones by using baskets|ERCP will be performed under conscious sedation with intramuscular administration of diazepam 2.5-5.0 mg and pethidine 25-50 mg. If necessary, Endoscopic Sphincterotomy or Endoscopic Papillary Balloon Dilatation will be performed. A dilating bougie or balloon will be used to dilate the stenosis after sphincterotomy. After that, the basket will be used to remove the stones first, and the balloon will replace the basket after 15 minutes to remove any remaining stones. Finally, the effect of the basket will be evaluated.
88906014|NCT05073185||Children with healthy weight status|100 child-parent dyads (200 total) will be followed for 1 year to determine the behavioral and neural impact of food and toy advertising exposure. Children will be 7-9 years old, with body mass index < 85th % for age and sex, and either with a mother who has BMI of 30 kg/m-sq or over or a BMI of 25 kg/m-sq or less.
89195801|NCT05289362|Active Comparator|Treating pancreatic duct stones by using balloons|ERCP will be performed under conscious sedation with intramuscular administration of diazepam 2.5-5.0 mg and pethidine 25-50 mg. If necessary, Endoscopic Sphincterotomy or Endoscopic Papillary Balloon Dilatation will be performed. A dilating bougie or balloon will be used to dilate the stenosis after sphincterotomy. After that, the balloon will be used to remove the stones first, and the basket will replace the balloon after 15 minutes to remove any remaining stones. Finally, the effect of the balloon will be evaluated.
88906015|NCT05068284|Experimental|Induction Phase: ABBV-154 Randomized Dose A|Varying doses of ABBV-154 as described in the protocol.
88906016|NCT05068284|Experimental|Induction Phase: ABBV-154 Randomized Dose B|Varying doses of ABBV-154 as described in the protocol.
88906017|NCT05068284|Experimental|Induction Phase: ABBV-154 Randomized Dose C|Varying doses of ABBV-154 as described in the protocol.
88906018|NCT05068284|Experimental|Induction Phase: ABBV-154 Randomized Dose D|Varying doses of ABBV-154 as described in the protocol.
88906019|NCT05068284|Placebo Comparator|Induction Phase: Randomized Placebo|Fixed dose placebo as described in the protocol.
88906020|NCT05068284|Experimental|Re-Induction Phase: ABBV-154 Randomized Dose A|Varying doses of ABBV-154 as described in the protocol.
88906021|NCT05068284|Experimental|Re-Induction Phase: ABBV-154 Randomized Dose B|Varying doses of ABBV-154 as described in the protocol.
88906022|NCT05068284|Experimental|Maintenance Phase: ABBV-154 Randomized Dose A|Fixed dose ABBV-154 every other week.
88906023|NCT05068284|Experimental|Maintenance Phase: ABBV-154 Randomized Dose B|Fixed dose ABBV-154 every other week.
88906024|NCT05068284|Placebo Comparator|Maintenance Phase: Randomized Placebo|Fixed dose placebo every other week.
88906025|NCT05049278|Active Comparator|Norepinephrine|Norepinephrine Bitartrate Hydrate : 4 mg/4 mL
88906026|NCT05049278|Active Comparator|Phenylephrine|Phenylephrine hydrochloride : 10 mg/1 mL
88906027|NCT05032963|Active Comparator|Undisturbed Sleep|8 hours sleep - Subjects randomized to the undisturbed sleep will be instructed to go to sleep at 11pm, and awoken at 7am.
88906028|NCT05032963|Experimental|Restricted Sleep|4 hours sleep - Subjects randomized to the restricted sleep will be instructed to go to sleep at 3am and awoken at 7am.
88906029|NCT04995237|Experimental|Prescription Produce Plan (PPP)|PPP provides access to fresh produce along with individual goal setting and education
88906030|NCT04994054|Experimental|silkworms (Bombyx mori L.) pupae extracts group|This group takes silkworms (Bombyx mori L.) pupae extracts for 12 weeks.
88906031|NCT04994054|Placebo Comparator|Placebo group|This group takes placebo for 12 weeks.
88906032|NCT04993729|Experimental|T89 low-dose group|Subjects in this group will take three T89 capsules and one Placebo capsule each time by oral administration three times daily for 5 days.
88906033|NCT04993729|Experimental|T89 high-dose group|Subjects in this group will take four T89 capsules each time by oral administration three times daily for 5 days.
88906034|NCT04993729|Placebo Comparator|Placebo group|Placebo capsule does not contain any amount of active substance. Subjects in this group will take four placebo capsules each time by oral administration three times daily for 5 days.
88906035|NCT04982354|Experimental|Investigational Treatment|Daunorubicin-cytarabine liposome (CPX-351) Plus FLT3-inhibitor (Midostaurin) Induction Therapy followed by Busulfan/Melphalan/Fludarabine Conditioning therapy and CD34+-selected allografts.
88906036|NCT04981834|Experimental|Arm I (radical prostatectomy, vesicopexy)|Patients undergo standard RARP with anterior approach plus vesicopexy. Urethral catheters are removed 7-14 days following surgery at provider discretion.
88906037|NCT04981834|Active Comparator|Arm II (radical prostatectomy)|Patients undergo standard RARP with anterior approach without vesicopexy. Urethral catheters are removed 7-14 days following surgery at provider discretion.
88906038|NCT04975633|Experimental|BodyPort Cardiac Scale|Patient will receive the Bodyport scale with access to Bodyport care services, such as remote monitoring, educational materials, different biomarkers detected by the scale, and online access to their data
88906039|NCT04975633|No Intervention|Control|Patients will receive usual care and a Bodyport scale that only displays weight and weight change. No other access to care services, features, or materials will be provided during this 90 day period
88906040|NCT04959461|Experimental|webCHAT|Single session 20-40minute self-guided web program that discusses promotes healthy decision making around driving and discusses the risks of alcohol and cannabis-influenced driving.
89195802|NCT01042639|Active Comparator|physical activity once a day|
89195803|NCT01042639|Experimental|physical activity twice a day|
89195804|NCT01042639|No Intervention|control|
89424934|NCT03897478||Control|"Control group subjects will have PAX Gene Blood RNA tubes drawn. Control group matched with ischemic stroke subjects for age, race, gender, smoking history with at least one of the following vascular risk factors: diabetes, hypertension, atrial fibrillation, hyperlipidemia.~Biomarker blood draw"
88906041|NCT04959461|Active Comparator|Usual Care|Existing driving school education
89424935|NCT03896646|Experimental|Treatment (personalized radioembolization, SPECT/CT HIDA)|Patients undergo yttrium-90 microsphere radioembolization with yttrium Y 90 glass microspheres using personalized dose measurements. Patients also undergo SPECT/CT HIDA scan before radioembolization and 2-4 months after radioembolization.
89424936|NCT03884712|Experimental|CalmiGo Recipients|This arm will receive a CalmiGo handheld device during their participation in the study. Participants will first complete validated surveys assessing their anxiety and panic attack symptoms. Investigators will then demonstrate how to use the CalmiGo handheld device. Participants will use the device with the investigator and then participants will use the device on their own for at least 2 times. After using CalmiGo, participants will complete validated surveys reassessing their anxiety and panic attack symptoms, asking about their past medical history, and inquiring about their experience using CalmiGo.
89424937|NCT03854110|Experimental|GP-2250 Monotherapy|GP-2250 in doses of 250 mg up to 30 grams intravenously on Days -7, 1, 8, 15 (Cycle 1) and Cycle 2 and all subsequent cycles on Days 7, 8, 15 of a 28-day cycle with gemcitabine 1000 mg/m2 on Days 1, 8, 15 days of the cycle.
89424938|NCT03846050|Experimental|BAC Feedback, immediate onset|"Participants will receive aBAC Feedback/Warning intervention based on their assessed BAC. Participants in this arm will have a warning presented on their smartphone when they provide a breath sample that indicated their BAC has reached a set limit. The cutpoint for this warning is not disclosed but is well below the legal limit for driving. Warning will notify them that their results indicate it is not safe for them to drive.~In this condition, participants will start their 6 week AA portion of their participation immediately after their laboratory session, and will be followed for 6 weeks afterwards.~Comparisons between the two experimental conditions will allow for inferences about the onset and offset of any effects of the BAC Feedback/Warning intervention."
88906042|NCT04935606|Experimental|Usual Care|Usual Care participants will receive their standard medical care as usual (no provider advice or telephone coaching sessions) and all screening and study assessments. To reduce biases, Usual Care arm patients will be given a cancer screening booklet and will be shown a cancer screening Video Doctor. They will also receive 2 re-contact telephone sessions at weeks 2 and 6 corresponding to the timing of the coaching sessions for the QUIT and QUIT-Mobile arms. All participants will also receive re-contact calls monthly from 7-weeks to 12-months. The re-contact calls (5 min) provide attention control for the Usual Care arm, motivate continued trial participation by reminding them of the next research assessment, but do not provide an active intervention. At study end, the Usual Care arm will receive the QUIT video doctor and drug use reduction booklet brochure materials including overdose prevention materials and a list of clinic/community resources to help them reduce substance use.
89424939|NCT03846050|Experimental|BAC Feedback, delayed onset|"Participants will receive the BAC Feedback/Warning intervention based on their assessed BAC during drinking events.The cutpoint for this warning is not disclosed but is well below the legal limit for driving. Warning will notify them that their results indicate it is not safe for them to drive.~In this condition, participants will be followed for 6 weeks after their laboratory session prior to starting their 6 week AA portion of their participation.~Comparisons between the two experimental conditions will allow for inferences about the onset and offset of any effects of the BAC Feedback/Warning intervention."
89424940|NCT03846050|Placebo Comparator|Minimal Assessment Control|"Participants will receive the No BAC Feedback/Warning intervention. Participants in this condition will complete the laboratory and interview portions of the project. However the AA portion of the project will not contain warning about their BAC (No BAC Feedback/Warning) and will ask fewer questions regarding their AID decisions.~The role of this condition is to provide a baseline comparison of AID behavior for the two active assessment conditions."
88906043|NCT04935606|Experimental|QUIT|The QUIT brief intervention protocol will consist of 5 steps corresponding to the 5A's approach for assisting behavior change in the clinic setting (Ask, Advise, Assess, Assist, and Arrange) that will focus on patients' HSD (highest scoring drug on the baseline ASSIST) use in the past 30 days.
88906044|NCT04935606|Experimental|QUIT-Mobile|"QUIT-Mobile will include a mobile platform with self-monitoring surveys and feedback message and robust data transfer protocols across three mobile technology platforms to meet diverse patient's preferences and needs regardless of literacy and phone type: a mobile-optimized web-app (using any smart phone's web-browser, not native apps), SMS (text-messaging), and IVR (automated voice calls for low literacy patients). Data collected during this study on patient platform preferences and exploratory analyses on intervention efficacy across platform types will inform the development of future effectiveness trials that can evaluate effectiveness of different mobile platforms."
88906045|NCT04932382|Other|Misoprostol group|400 µg misoprostol vaginally ; these tablets will be introduced by the principal investigator, digitally without using speculum, 3 hours before IUD insertion into the posterior vaginal fornix of the woman while lying in the lithotomy position
88906046|NCT04932382|Other|No misoprostol group|will not receive any pre-insertion medications.
88906047|NCT04921475||Renal regional oxygen saturation|Renal regional oxygen saturation is measured by using near infrared spectroscopy during transcatheter aortic valve implantation
88906048|NCT04910256|Experimental|HuaTuo ZaiZao group|"In this arm, patients take 8g of HuatuoZaizao pill three times a day. Besides，participants will receive basic treatment in accordance with the Guidelines for diagnosis and treatment of ischemic stroke in China,and the drug and dosage will be formulated by the researchers according to the clinical situation.Treatment lasts for 12 weeks"
88906049|NCT04910256|Active Comparator|Control group|"participants will receive basic treatment in accordance with the Guidelines for diagnosis and treatment of ischemic stroke in China,and the drug and dosage will be formulated by the researchers according to the clinical situation.Treatment lasts for 12 weeks"
88906050|NCT04901715|Active Comparator|Genotypes associated mild phenotype|Subjects with 2 confirmed mutations in RSPH1, Radial Spoke Head Component 9 (RSPH9), Radial Spoke Head Component 4A (RSPH4a), or Dynein Axonemal Heavy Chain 11 (DNAH11). This group may also include subjects with mutations in newly identified genes that are associated with a milder clinical phenotype.
89424941|NCT03845205|Experimental|Integrated AUD Treatment (IAT)|IAT will include computer-delivered CBI in the hospital, nurse-delivered clinical monitoring and treatment adherence counseling, and at-home participation in web-based, 7-session computerized cognitive-behavioral therapy (CBT4CBT), supplemented by tailored text messages. Alcohol pharmacotherapy will be added to behavioral treatments as needed.
89424942|NCT03845205|No Intervention|Treatment As Usual|All LT patients receive physician instructions to not drink alcohol. Consistent with current discharge procedures, AH patients are encouraged to engage in alcohol treatment services. Patients receive regular blood draws for monitoring of liver function, and regular phone calls for post-operative monitoring.
89424943|NCT03829462|Experimental|Irinotecan + regorafenib (REGIRI)|irinotecan (180 mg/m2) at day1 of each cycle + regorafenib (160 mg/day) from day 2 to day 8
89424944|NCT03829462|Active Comparator|regorafenib|Regorafenib (160 mg/day) for 3 weeks followed by 1 week off
89424945|NCT03825796|Experimental|Treatment (CPX-351, enasidenib mesylate)|See detailed description
89424946|NCT03818061|Experimental|HPV +|Patient with Human papillomavirus (HPV +) treated by Atezolizumab combined with Bevacizumab.
89424947|NCT03818061|Experimental|HPV -|Patient without Human papillomavirus (HPV - ) treated by Atezolizumab combined with Bevacizumab.
89424948|NCT03799354|Experimental|Treatment Group|Maximal strenght training (MST) plus endurance training (ET)
89424949|NCT03799354|Active Comparator|Control group|Endurance training (ET)
89424950|NCT03783351|No Intervention|Conventional Therapy|Patients randomized to the Conventional Therapy arm will receive either clopidogrel or ticagrelor, according to the clinical and procedural characteristics of patients. CYP2C19 genotyping will be performed at the end of study.
89424951|NCT03783351|Active Comparator|CYP2C19 Genotyping|CYP2C19 genotyping will be performed within 48 hours after randomization. CYP2C19 *2 or *3 reduced function allele patients will receive ticagrelor 90 mg bid, whereas non-*2 or -*3 CYP2C19 patients will receive clopidogrel 75 mg once daily.
89424952|NCT03761186|Active Comparator|traditional diabetes diet|Participants in this arm will follow a diet with carbohydrate intake 50-60% of total energy intake
89424953|NCT03761186|Experimental|moderately low carbohydrate diet|Participants in this arm will follow a diet with carbohydrate intake 30-40% of total energy intake
88906051|NCT04901715|Active Comparator|Genotypes associated with severe phenotype|Subjects with 2 confirmed mutations in DNAH5, Dynein Axonemal Intermediate Chain 1 (DNAI1), Coiled-Coil Domain Containing 39 (CCDC39), or Coiled-Coil Domain Containing 40 (CCDC40). This group may also include subjects with mutations in newly identified genes that are associated with a more severe clinical phenotype.
89424954|NCT03761186|Experimental|strictly low carbohydrate diet|Participants in this arm will follow a diet with carbohydrate intake 15-20% of total energy intake
89424955|NCT03729869|Experimental|Progesterone Males|35 men will take 400 mg of progesterone a day for 7 days and will complete a stress and marijuana cue reactivity task following the final dose.
89424956|NCT03729869|Placebo Comparator|Placebo Males|35 men will take placebo twice a day for 7 days and will complete a stress and marijuana cue reactivity task following the final dose.
89424957|NCT03729869|Experimental|Progesterone Female|35 women will take 200 mg of progesterone twice a day for 7 days and will complete a stress and marijuana cue reactivity task following the final dose.
89424958|NCT03729869|Placebo Comparator|Placebo Females|35 women will take placebo twice a day for 7 days and will complete a stress and marijuana cue reactivity task following the final dose.
88906052|NCT04901715|Active Comparator|Healthy Control|Healthy subjects with no pre-existing lung disease.
89424959|NCT03713437||Cystic Fibrosis|Serum sample will be drawn once
89424960|NCT03713437||Healthy, age-matched controls|Serum sample will be drawn once
89424961|NCT03703960|Experimental|"Group 1 Hypnosis"|
89424962|NCT03703960|Active Comparator|"Group 2 music"|
89424963|NCT03703960|No Intervention|Control group|
89424964|NCT03690557|Experimental|IncentaHealth|All patients who decide to join the weight loss program will be enrolled in the commercially-available IncentaHealth program - a comprehensive, evidence-based, behavioral weight management program designed to help patients initiate and maintain weight loss. The program is delivered completely online, via website, emails, mobile app, and (if requested by the participant) text messaging over 12 months. Each participant will be given a digital scale that wirelessly syncs with a smartphone app. Participants' weights are automatically uploaded to the Incentahealth online portal. In the informed consent process, participants will need to agree to release their weight data to researchers at the University of Nebraska Medical Center in order to participate in this program.
89424965|NCT03687671|Experimental|Animal-assisted therapy|The intervention is animal-assisted occupational therapy, animal-assisted physiotherapy or animal assisted speech therapy with different animals. All animals are trained for the specific service with vulnerable patients. There are guinea pigs, rabbits, miniature pigs, sheeps, goats, chicken, dogs, cats and horses.
89424966|NCT03687671|Active Comparator|Treatment as usual (activation program)|As control intervention patients receive treatment as usual (TAU) in speech therapy, occupational therapy or physiotherapy. The control intervention is named activation program.
89424967|NCT03687658|Experimental|Binge Eating Group|All participants in the study will be invited to use Laddr, described in the intervention section.
89424968|NCT03687658|Experimental|Smoking Group|All participants in the study will be invited to use Laddr, described in the intervention section.
89424969|NCT03682588|Experimental|Functional exercise group|Functional exercise program with 14 exercises, two times/week, during 14 weeks. Two sets of 10 repetitions each, with 30 seconds interval.
89424970|NCT03682588|Active Comparator|Stretching exercise group|Stretching exercise program with 17 exercises, two times/week, during 14 weeks and each movement was repeated by three times and held for 20 seconds each
88906053|NCT04895592|Experimental|Arm A (SRS, low dose dexamethasone, surgery)|Patients undergo SRS to the brain metastasis for 1-3 fractions over 1-5 days. Patients also receive low dose dexamethasone PO or IV for 2-21 days until the day of surgical resection. Patients then undergo surgical resection.
89424971|NCT03662737||Group 1 -Chronic cannabis use|Individuals between 18 and 50 years old who have been using at least 2 joints per day for at least 3 years. They should have used cannabis during the last 24h but not during the 3h prior to participation to the study and they should test positive for cannabis in their urine. Individuals with another substance use or severe mental disorder will be excluded (except tobacco use)
89424972|NCT03662737||Group 2 - Alcohol dependence|Individuals between 18 and 50 years old diagnosed with alcohol use disorder according to DSM-V criteria and have been consuming alcohol for at least 3 years. Individuals who are diagnosed with another substance use or severe mental disorder will be excluded (except tobacco use).
89424973|NCT03662737||Control Group|Individuals matched in gender and age with the experimental groups and with no diagnosis of substance use or severe mental disorder (except tobacco use)
89424974|NCT03580668||B/F/TAF|Bictegravir/Emtricitabine/Tenofovir alafenamide (B/F/TAF) therapy in HIV-1 infected adults who initiate B/F/TAF therapy
89424975|NCT03573297|Experimental|Double-Blind Cariprazine 3.0 mg/day|Participants randomized to receive cariprazine 3.0 mg once daily (QD) for up to 39 weeks.
89424976|NCT03573297|Experimental|Double-Blind Cariprazine 1.5 mg/day|Participants randomized to receive cariprazine 1.5 mg QD for up to 39 weeks.
89424977|NCT03573297|Placebo Comparator|Double-Blind Placebo|Participants randomized to receive placebo QD for up to 39 weeks.
89424978|NCT03573297|Experimental|Open Label Treatment|Participants started on cariprazine 1.5 mg QD, with a target dose of 3.0 mg QD, for up to 16 weeks.
89424979|NCT03536884|Experimental|Bimekizumab dosage regimen 1|"Subjects randomized to this arm will receive bimekizumab dosage regimen 1 (BKZ 1).~At Week 16 subjects will be re-randomized and continue to receive BKZ 1 or to switch to bimekizumab regimen 2 (BKZ 2).~Placebo will be administered at pre-specified time-points to maintain the blinding over the double-blind Treatment Period.~Subjects allowed to enroll in the open-label extension (OLE) Period will receive BKZ 1 or BKZ 2. Subjects will switch from BKZ 1 to BKZ 2 at Week 64 or at the next scheduled Visit.~Eligible subjects who completed OLE, have entered Safety Follow Up (SFU) or completed SFU would start OLE2 on BKZ 1 before switching to BKZ 2 after 16 weeks or start OLE2 on BKZ 2."
89424980|NCT03536884|Experimental|Bimekizumab dosage regimen 2|"Subjects randomized to this arm will receive bimekizumab dosage regimen 2 (BKZ 2) starting at Week 16 after initial treatment on bimekizumab regimen 1 (BKZ 1) for 16 weeks.~Placebo will be administered at pre-specified time-points to maintain the blinding over the double-blind Treatment Period.~Subjects allowed to enroll in the open-label extension (OLE) Period will receive BKZ 1 or BKZ 2. Subjects will switch from BKZ 1 to BKZ 2 at Week 64 or at the next scheduled Visit.~Eligible subjects who completed OLE, have entered SFU or completed SFU would start OLE2 on BKZ 1 before switching to BKZ 2 after 16 weeks or start OLE2 on BKZ 2."
88906054|NCT04895592|Experimental|Arm B (SRS, high dose dexamethasone, surgery)|Patients undergo SRS to the brain metastasis for 1-3 fractions over 1-5 days. Patients also receive high dose dexamethasone PO or IV for 2-21 days until the day of surgical resection. Patients then undergo surgical resection.
88906055|NCT04879927|Experimental|RESOURCE Matching|Participants randomized into the intervention arm will receive customized resource matching
88906056|NCT04879927|Active Comparator|Usual Care|Participants randomized into the control group will receive a pre-existing pamphlet detailing DFCI resources
89424981|NCT03536884|Active Comparator|Secukinumab|"Subjects will receive secukinumab. Subjects allowed to enroll in the open-label extension (OLE) Period will be re-randomized to receive bimekizumab dosage regimen 1 (BKZ 1) or bimekizumab dosage regimen 2 (BKZ 2).~Eligible subjects who completed OLE, have entered SFU or completed SFU would start OLE2 on BKZ 1 before switching to BKZ 2 after 16 weeks or start OLE2 on BKZ 2."
88906057|NCT04861103|Experimental|Factor Xa levels in pregnant women with therapeutic Lovenox divided into three times a day dosing|Therapeutic Lovenox dosing split into three times a day dosing for 5 day. Xa levels a measured.
88906058|NCT04855123|Other|patient|
88906059|NCT04843761|Experimental|Aviptadil + Remdesivir + SOC|
88906060|NCT04843761|Placebo Comparator|Aviptadil + Remdesivir Placebo + SOC|
88906061|NCT04843761|Experimental|Aviptadil Placebo + Remdesivir + SOC|
88906062|NCT04843761|Experimental|Aviptadil Placebo + Remdesivir Placebo + SOC|
88906063|NCT04797572|Other|Treated group|Patients in whom the free margin cusp sizer will be used to measure the free margin of the three leaflets of the aortic valve during aortic valve repair.
88906064|NCT04795635|Experimental|CMM + Axon Therapy|"Participants will return to the clinic for assessment at Day 30 (± 14 days), Day 90 (± 14 days), Day 180 (± 30 days) and Day 365 (± 30 days). Participants randomized to the CMM plus Axon Therapy group will return to the clinic for Axon Therapy treatments as follows:~Month 1: 6 treatments~WEEK 1: 3 treatments (consecutive treatments are best)~WEEK 2-4: Weekly treatments~Month 2: Bi-monthly treatment~Months 3-12: Treatments every 2-4 weeks~In addition to in-clinic assessments and treatments, all participants will a receive weekly phone follow-up to assess pain intensity and occurrence of adverse events after treatment starts. Weekly phone follow-ups will only occur during weeks when the participant is not in clinic for treatment."
88906065|NCT04795635|No Intervention|CMM Only|Participants will return to the clinic for assessment at Day 30 (± 14 days), Day 90 (± 14 days), Day 180 (± 30 days) and Day 365 (± 30 days)
88906066|NCT04766190|Other|Group 1: Usual Care|"The patient will be asked to arrive 30 minutes early to their next scheduled appointment with their oncologist so they can complete a survey.~The patient will be video recorded at their appointment. The oncologist has agreed to be video recorded. Immediately after this appointment, the patient will be asked to complete another brief survey that takes about 20 minutes. The questions will ask about how the meeting went. The patient's meeting with the oncologist will not be delayed or changed in any way because of this study."
88906067|NCT04766190|Other|Group 2: The DISCO App|"The patient will be asked to arrive 30 minutes early to their next scheduled appointment with their oncologist so they can complete a survey.~The patient will be shown an iPad with an app while waiting to see their oncologist. The app includes a short video and asks questions about the patient's financial concerns. The app will give the patient a list of questions the patient may want to ask their oncologist during their appointment. The patient will then meet with their oncologist. The meeting with the patient's oncologist will be video recorded. The oncologist has agreed to be video recorded. Immediately after meeting the oncologist, the patient will complete another brief survey. The questions will ask about how the meeting went and what the patient thought of the app. The meeting with the oncologist will not be delayed or changed in any way because of this study."
88906068|NCT04766190|Other|Group 3: The DISCO App + Booster|"The patient will be asked to arrive 30 minutes early to their next scheduled appointment with their oncologist so they can complete a survey.~The patient will be shown an iPad with an app while waiting to see your oncologist. The app includes a short video and asks questions about your financial concerns. The app will give the patient a list of questions they may want to ask their oncologist during their appointment. The patient will then meet with their oncologist. The meeting with their oncologist will be video recorded. The oncologist has agreed to be video recorded. Immediately after meeting their oncologist, they will complete another brief survey. The questions will ask about how the meeting went and what they thought of the app. The patient's meeting with the oncologist will not be delayed or changed in any way because of this study. Two months after that appointment, the patient will be sent a reminder of the information that was presented on the app."
88906069|NCT04742881|Experimental|Low pressure + microsurgical instruments|Low pressure pneumoperitoneum (5-7mmHg) and use of microsurgical instruments (3mm and 5mm instruments)
88906070|NCT04742881|Active Comparator|Low pressure + standard instruments|Low pressure pneumoperitoneum (5-7mmHg) and use of standard instruments (5mm and 10mm instruments)
88906071|NCT04721925|No Intervention|Control group|Link to an educational website about alcohol; link to resources.
88906072|NCT04721925|Experimental|Social media messaging|Health coaching via social media for 8 weeks
88906073|NCT04720313|Experimental|CART BCMA|The dose escalation phase (Part A) will include the following doses of CAR-positive (CAR+) T cells: 150×10^6, 450×10^6, 800×10^6 or 1200 ×10^6 The expansion phase (Part B) will include a dose between 450×10^6 to 800×10^6 CAR-positive (CAR+) T cells
88906074|NCT04699604|Active Comparator|Levocetirizine (LTZ)|Participants will take Levocetirizine dihydrochloride/ Xyzal® (UCB, Inc.) immediate release oral solution 2.5mg/5ml (2.5mg in children 6-11 years of age; 5mg in children >11 years per recommended doses) in addition to their current asthma regimen.
88906075|NCT04699604|Placebo Comparator|Placebo|Participants will take a placebo solution previously developed by the Children's Mercy Investigational Pharmacy to match the color, flavor, and consistency of the active drug in addition to their current asthma regimen.
88906076|NCT04677660|Experimental|TAK-919|TAK-919 0.5 mL, intramuscular injection in the upper arm
88906077|NCT04677660|Placebo Comparator|Placebo|TAK-919 Matching Placebo, intramuscular injection in the upper arm
88906078|NCT04664842|Experimental|Manual Therapy Group|
88906079|NCT04664842|Sham Comparator|Manual Control Group|
88906080|NCT04664842|Experimental|Breathing Training Group|
88906081|NCT04664842|Sham Comparator|General Exercise Control Group|
88906082|NCT04664842|Experimental|Manual Therapy Combined Breathing Training Group|
88906083|NCT04648215|Experimental|lavender oil|lavender oil as aromatherapy two drops dispensed on a 2x2 gauze and pinned to subject's gown
88906084|NCT04648215|Placebo Comparator|grapeseed oil|grapeseed oil as aromatherapy two drops dispensed on a 2x2 gauze and pinned to subject's gown
88906085|NCT04648215|No Intervention|Standard of Care|Routine nursing care at bedtime (HS)
88906086|NCT04644419||Control group of the LCCC1848|Patients in the control arm will receive standard of care.
88906087|NCT04633928|Experimental|N-TEC|N-TEC is based on autologous nasal chondrocytes expanded and further cultured on type I/III collagen membranes for about 2 weeks to allow cells to produce extracellular matrix containing cartilage specific proteins. The tissue engineered graft is then implanted in the nasal septum in an interposition graft with a temporoparietal fascia flap.
88906088|NCT04605445|Experimental|1 visit endodontics|Root canal treatment is performed in one visit.
89424982|NCT03535116|Experimental|Patients receiving ketorolac|Patient receives 30mg IV ketorolac(single dose) towards the end of the operation.
89424983|NCT03535116|Placebo Comparator|Control|Patients receive saline intravenously towards the end of the operation.
89424984|NCT03515213|Active Comparator|Active|
89424985|NCT03515213|Placebo Comparator|Placebo|
89424986|NCT03507790|Active Comparator|Active Treatment- CT1812 100 mg|CT1812 at a dose of 100 n=48 group
89424987|NCT03507790|Active Comparator|Active Treatment- CT1812 300 mg|CT1812 at a dose of 300mg, n=48 group
89424988|NCT03507790|Placebo Comparator|Placebo Comparator - Placebo|Placebo, n=48 group
89424989|NCT03477942|Experimental|Osteoarthritis|The OA subgroup will be patients aged 18-60 years who have chronic knee pain due to early OA that have not responded to conservative, non-invasive measures such as physical therapy, medications, and activity modification.
89424990|NCT03477942|Experimental|Cartilage|The focal chondral defect subgroup will be patients aged 18-60 years who participate in recreational or professional sports and are symptomatic from a focal chondral defect shown on MRI.
89424991|NCT03470155||functional mitral insufficiency op|Patients with functional mitral insufficiency with restricted leaflet movement during systole (type IIIb Carpentier) undergoing operative reconstruction (mitral valve repair)
89424992|NCT03446040|Experimental|Part A Dose Escalation: BMS-986258|
89424993|NCT03446040|Experimental|Part A1: BMS-986258 + Recombinant human hyaluronidase PH20 (rHuPH20)|
89424994|NCT03446040|Experimental|Part B Dose Escalation: BMS-986258 + nivolumab|
89424995|NCT03446040|Experimental|Part C Cohort Expansion: BMS-986258 + nivolumab|
89424996|NCT03406273|Experimental|≥ 5 years of age|Cerebral Spinal (CS) radiation
89424997|NCT03406273|Experimental|< 5 yo and ≥ 3 yo and CSF +|Cerebral Spinal (CS) radiation
89424998|NCT03406273|Experimental|All < 3 yo & < 5 yo/≥ 3 yo CSF neg|Focal radiotherapy (SRS)
89424999|NCT03383289|Experimental|R-REM training|3 module training for frontline staff in assisted living facilities related to recognizing and management of resident-to-resident elder mistreatment
89425000|NCT03383289|No Intervention|Control condition|Usual care
89425001|NCT03308058|Experimental|Breastfeeding Computer education|Breastfeeding Computer education
89425002|NCT03308058|No Intervention|Printed Educational material|Printed educational material
89425003|NCT03299348|Experimental|Active Treatment Group|This group will get the AgingPLUS intervention program which addresses negative views on aging, low internal control beliefs, and deficient goal planning skills.
89425004|NCT03299348|Placebo Comparator|Active Control Group|"This group will get a generic health education program, called the 10 Keys to Healthy Aging. The control program will control for the effect of social contact and will not address the intervention targets of the active treatment group. The health education program will only provide information related to some of the most important health conditions, such as cardiovascular disease, cancer, type 2 diabetes, and clinical depression, and how these conditions can be managed."
89425005|NCT03268135||Non end-stage heart failure|Measurement of RNAs in non end-stage heart failure patients undergoing to left ventricle reconstruction
89425006|NCT03268135||End-stage heart failure|Measurement of RNAs in end-stage heart failure patients undergoing to left ventricular assisted device (LVAD)
89425007|NCT03268135||Aortic Stenosis|Measurement of RNAs in patients affected by cardiac hypertrophy leading to aortic stenosis and requiring cardiac myectomy
89425008|NCT03268135||Controls|Measurement of RNAs in individuals not affected by cardiovascular diseases
88820215|NCT06191523|Placebo Comparator|Control Group|The control group will receive standard therapy and placebo.
88820216|NCT06191523|Experimental|Treatment Group|The participants in the treatment group will receive standard therapy and a single dose of oral melatonin 20 mg
88906089|NCT04605445|Active Comparator|2 visits endodontics|Root canal treatment is performed in two visits.
88906090|NCT04587167|Experimental|HPV ECHO|Clinics randomly assigned to this arm will receive the intervention via real-time, interactive videoconferencing using Zoom at no cost to participants. The intervention has a curriculum of 10 sessions focused on the evidence-based Announcement Approach. Sessions will be 60 minutes in duration and held every other weekly for 4 months at regularly scheduled times.
88906091|NCT04587167|Experimental|HPV ECHO+|Clinics randomly assigned to this arm will receive the HPV ECHO intervention plus a systems communication strategy to deliver recall notices to parents who initially decline HPV vaccination. This arm includes 12 primary care clinics in Pennsylvania.
89425009|NCT03225287|Experimental|Zilucoplan (RA101495)|Subjects will continue to receive the final maintenance dose they were receiving in the qualifying study
89425010|NCT03189641|Experimental|Cilostazol eluting stent system (CES-1)|
89425011|NCT03158389|Experimental|Subtrial A: APG101|"weekly application of 800 mg i.v. for 6 months or until progression~in conjunction with radiotherapy (at 60 Gy in 2 Gy fractions) for the first 6 weeks"
89425012|NCT03158389|Experimental|Subtrial B: Alectinib|"600 mg orally twice daily (bid) for 6 months or until progression~in conjunction with radiotherapy (at 60 Gy in 2 Gy fractions) for the first 6 weeks"
89425013|NCT03158389|Experimental|Subtrial C: Idasanutlin|"at escalating doses from 100 mg until maximum tolerated dose daily administered (orally) on five consecutive days of a 28-day cycle for 6 months or until progression~in conjunction with radiotherapy (at 60 Gy in 2 Gy fractions) for the first 6 weeks"
89425014|NCT03158389|Experimental|Subtrial D: Atezolizumab|"application of 1200 mg i.v. every three weeks for 6 months or until progression~in conjunction with radiotherapy (at 60 Gy in 2 Gy fractions) for the first 6 weeks"
89425015|NCT03158389|Experimental|Subtrial E: Vismodegib|"daily application of 150 mg orally for 6 months or until progression~in conjunction with radiotherapy (at 60 Gy in 2 Gy fractions) for the first 6 weeks"
89425016|NCT03158389|Experimental|Subtrial F: Palbociclib|"75/100/125 mg orally once daily on 21/28 days~in conjunction with radiotherapy (at 60 Gy in 2 Gy fractions) for the first 6 weeks~followed by a 4 weeks break (after last dose of 2nd cycle)~and with maintenance therapy with palbociclib at 125 mg daily for 6 months or until progression"
89425017|NCT03158389|Experimental|Subtrial G: Temsirolimus|"weekly application of 25 mg i.v. for 6 months or until progression~in conjunction with radiotherapy (at 60 Gy in 2 Gy fractions) for the first 6 weeks"
89425018|NCT03140670|Experimental|Single Arm|
89425019|NCT03037346|Experimental|Supportive Care (questionnaires, educational video)|Participants (patients and family caregiver/MPOA) complete questionnaires about knowledge, attitudes, and beliefs of MPOAD. Participants without a MPOAD watch a 4-minute educational video about the importance of the role of MPOA.
89425020|NCT02999646|Experimental|MVX-ONCO-1|MVX-ONCO-1 vaccine treatment once weekly starting on week 1 for 4 weeks followed by two additional treatments 2 weeks apart (total 6 treatments over 8 weeks). Each treatment consists of two macrocapsules containing the MVX-1 cell line and lethally irradiated autologous tumor cells.
89425021|NCT02986178|Experimental|Polio/Rhinovirus Recombinant (PVSRIPO)|Polio/Rhinovirus Recombinant (PVSRIPO)
89425022|NCT02945280|Experimental|patients with acute UEDVT|Patients will receive 10 mg PO apixaban for 7 days and then 5 mg PO for 11 weeks, for a total of 12 weeks of treatment.
89425023|NCT02900079||travelers|persons intending to travel for 3 weeks or longer to South-East Asia, Sub-Saharan Africa or South-/ Central America; they will be trained to use a rapid diagnostic test for malaria antigen when febrile. Upon a positive test result they are recommended to use standby emergency treatment (SBET)
88906092|NCT04587167|No Intervention|Control|Clinics randomly assigned to this arm will receive no ECHO interventions. This arm includes 12 primary care clinics in Pennsylvania.
89425024|NCT02889172|Experimental|Problem Solving Therapy|Will be apply a Brief Intervention (PST) for patients with Type II Diabetes Mellitus and Obesity who receive treatment in primary care centers from Mexico City. The aim is evaluate if PST improvement the depressive and anxiety symptoms and help to adhere to treatment and stabilize their metabolic variables
89425025|NCT02889172|No Intervention|Control|This group will receive the usual treatment , without intervention with Brief Intervention ( PST )
89425026|NCT02848001|Experimental|CC-90009 - Part A|Will be administered intravenously per dosing schedule in a 28-day cycle.
89425027|NCT02848001|Experimental|CC-90009 - Part B - AML and MDS patients|Relapsed or refractory AML and MDS subjects. IP will be administered intravenously per dosing schedule determined in Part A
88906093|NCT04581616|Active Comparator|ICNB group|After patient was turned to lateral decubitus position, local anesthetics is injected around incision site and ICNB is performed once after surgeon geys into chest cavity.
88906094|NCT04581616|Experimental|ESPB group|After patient was turned to lateral decubitus position, ESPB is performed via ultrasound guided technique before sound incision.
89425028|NCT02682927|Experimental|ZX008 - 0.8 mg/kg/day|ZX008 (fenfluramine HCl) is supplied as an oral solution in concentrations of 1.25, 2.5, and 5 mg/mL. ZX008 will be administered twice a day (BID) in equally divided doses with food.
89425029|NCT02682927|Experimental|ZX008 - 0.2 mg/kg/day|ZX008 (fenfluramine HCl) is supplied as an oral solution in concentrations of 1.25, 2.5, and 5 mg/mL. ZX008 will be administered twice a day (BID) in equally divided doses with food.
88906095|NCT04573582|Experimental|Enasidenib (CC-90007) tablet|Participants will receive one 100 mg enasidenib (CC-90007) tablet the morning of Day 1 which will be administered in the fasted state.
89425030|NCT02682927|Placebo Comparator|Matching Placebo|Placebo will be administered twice a day (BID) in equally divided doses with food.
89425031|NCT02677493|Experimental|IL-YANG Quadrivalent Influenza Vaccine|The QIV is included both B strain (Yamagata, Victoria).
89425032|NCT02677493|Active Comparator|IL-YANG Flu Vaccine Prefilled Syringe|This TIV is included the B/Yamagata strain, and it was approved for commercial sale by MFDS.
89425033|NCT02677493|Active Comparator|IL-YANG Trivalent Influenza Vaccine|This TIV is included the B/Victoria strain.
89425034|NCT02670161|Active Comparator|Treatment A (see interventions description)|The investigators will conduct 11 pragmatic trials using the EMR: brain tumors (prevent seizures), epilepsy (prevent other seizure types), mild cognitive impairment (improve memory), migraine (prevention), migraine (abortive), mild traumatic brain injury (prevent post concussion syndrome), multiple sclerosis (attenuate relapses), neuropathy (pain management), Parkinson's (treat motor symptoms), restless legs syndrome (treat sensory symptoms), stroke (secondary prevention). For each trial they will compare up to three medications or treatments either FDA approved for the indication, or commonly employed. The pragmatic trials will be small and primarily to demonstrate the feasibility of subgroup based adaptive assignment of treatments, electronic consenting, and data capture at the point of care using the EMR. The focus is on the development of the study design and methodology and not on the treatments per se.
88906096|NCT04571164|Experimental|LY03003|
88906097|NCT04571164|Placebo Comparator|Placebo|
88906098|NCT04559880|Experimental|Tranexamic Acid|"Intra-procedural tranexamic acid (TXA) - 1 gram, IV~Post-procedural tranexamic acid (TXA) - 1 gram, oral, three times per day for 5 days"
89195805|NCT04035304|Experimental|Mindfulness Coach Mobile App|Participants in this condition will complete 3 assessments: initial, end of month two and end of month four. Each participant, following initial assessment will be provided with a link to download the Mindfulness Coach mobile app as well as with brief recommendations for how to use the app over the subsequent 16 weeks of the study. Mindfulness Coach is a mobile app for iPhone and Android, developed by the VA National Center for PTSD in collaboration with National Center for Telehealth and Technology (T2).
89425035|NCT02670161|Active Comparator|Treatment B (see interventions description)|The investigators will conduct 11 pragmatic trials using the EMR: brain tumors (prevent seizures), epilepsy (prevent other seizure types), mild cognitive impairment (improve memory), migraine (prevention), migraine (abortive), mild traumatic brain injury (prevent post concussion syndrome), multiple sclerosis (attenuate relapses), neuropathy (pain management), Parkinson's (treat motor symptoms), restless legs syndrome (treat sensory symptoms), stroke (secondary prevention). For each trial they will compare up to three medications or treatments either FDA approved for the indication, or commonly employed. The pragmatic trials will be small and primarily to demonstrate the feasibility of subgroup based adaptive assignment of treatments, electronic consenting, and data capture at the point of care using the EMR. The focus is on the development of the study design and methodology and not on the treatments per se.
89425036|NCT02670161|Active Comparator|Treatment C (see interventions description)|The investigators will conduct 11 pragmatic trials using the EMR: brain tumors (prevent seizures), epilepsy (prevent other seizure types), mild cognitive impairment (improve memory), migraine (prevention), migraine (abortive), mild traumatic brain injury (prevent post concussion syndrome), multiple sclerosis (attenuate relapses), neuropathy (pain management), Parkinson's (treat motor symptoms), restless legs syndrome (treat sensory symptoms), stroke (secondary prevention). For each trial they will compare up to three medications or treatments either FDA approved for the indication, or commonly employed. The pragmatic trials will be small and primarily to demonstrate the feasibility of subgroup based adaptive assignment of treatments, electronic consenting, and data capture at the point of care using the EMR. The focus is on the development of the study design and methodology and not on the treatments per se.
89425037|NCT02633059|Experimental|Treatment (ixazomib citrate, idasanutlin, dexamethasone)|Patients receive ixazomib citrate PO on days 1, 8, and 15 and idasanutlin PO QD on days 1-5 every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive dexamethasone PO on days 1, 8, 15, and 22 every 28 days for 12 courses at the discretion of the treating physician.
89425038|NCT02630043|Experimental|Tolcapone and Oxaliplatin|"Subjects will receive oral tolcapone at their assigned dose level on each day of this 21-day cycle.~Oxaliplatin will be given at 100 mg/m2 IV on Day 1 of Cycle 2 through 5 and any subsequent 21-day cycle."
88820217|NCT06191497|Active Comparator|Non-smokers|15 non-smoking subjects with diagnosed periodontitis. All of them underwent NSPT
88820218|NCT06191497|Experimental|Non-smokers+ CHX|15 non-smoking subjects with diagnosed periodontitis. All of them underwent NSPT and used 0.12% chlorhexidine mouthwash for 15 days after therapy
88820219|NCT06191497|Active Comparator|Smokers|15 cigarette smoking subjects with diagnosed periodontitis. All of them underwent NSPT
88820220|NCT06191497|Experimental|Smokers + CHX|15 cigarette smoking subjects with diagnosed periodontitis. All of them underwent NSPT and used 0.12% chlorhexidine mouthwash for 15 days after therapy
88820221|NCT06191432|Experimental|NCWS Packets A-B|NCWS patients will undergo a Double-Blind Wheat Challenge DBWC with an ancient diploid wheat (TM) or a modern hexaploid wheat (TA). This DBWC will be performed with flour packets coded A or B, each containing respectively one of the wheat varieties. Packets A or B will be given for 1 week and then, after 1 week of washout (or until patients report complete well-being), the patients will receive the other packets for another 1 week (cross-over design).
88820222|NCT06191432|Experimental|NCWS Packets B-A|NCWS patients will undergo a Double-Blind Wheat Challenge DBWC with an ancient diploid wheat (TM) or a modern hexaploid wheat (TA). This DBWC will be performed with flour packets coded A or B, each containing respectively one of the wheat varieties. Packets A or B will be given for 1 week and then, after 1 week of washout (or until patients report complete well-being), the patients will receive the other packets for another 1 week (cross-over design).
88820223|NCT06191419|Experimental|Participants that Smoke|Each smoker is asked to smell up to 20 samples per session. Samples include controls (clean air, irrelevant odor), blocking odors, cigarette smoke, and cigarette smoke mixed with blocking odors or irrelevant odors.
88820224|NCT06191393|Experimental|OTC Study|This OTC study will take place in simulated home environments which will be set up within or near clinical settings (e.g., urgent care facilities). The study will enroll symptomatic subjects only. Candidate samples will be self-collected by participants (or collected by a guardian for participants under the age of 14 years) and comparator samples will be collected by a healthcare practitioner with informed consent and Institutional Review Board (IRB) approval. Each sample will be coded for confidentiality.
88820225|NCT06191367|Experimental|Group I (experimental) Aerobic Exercises and Traditional Chest Physiotherapy.|It was consisted of fifteen patients with positive covid-19 test from at least a month before trial. They received aerobic exercise techniques which consist of 3 levels of activity exercises and traditional program of chest physiotherapy. (Five times per week for two months).
88820226|NCT06191367|Experimental|Group II (experimental)Incentive Spirometer Device and Traditional Chest Physiotherapy.|It was consisted of fifteen patients with positive covid-19 test from at least a month before trial. They received incentive spirometer training techniques and traditional program of chest physiotherapy. (Five times per week for two months).
88906099|NCT04559867|Active Comparator|Needle Knife Fistulotomy|The study doctor will gain access to the bile ducts using the cutting technique called a needle knife fistulotomy. When using this technique, the study doctor makes a cut directly into the bile duct.
88906100|NCT04559867|Active Comparator|Sphincterotomy|The study doctor will gain access to the bile ducts using the cutting technique called a sphincterotomy. Using this method, a heated metal wire cuts the opening to the bile duct after a wire has been passed into it.
89425039|NCT02614534|Experimental|Proactive cytoreductive surgery + HIPEC|Tumoral cytoreductive surgery + apendicectomy + total omentectomy + round hepatic ligament + oophorectomy (postmenopausian women) plus HIPEC (Mytomicin C - 60 minutes).
89425040|NCT02614534|Active Comparator|Proactive cytoreductive surgery|Tumoral cytoreductive surgery + apendicectomy + total omentectomy + round hepatic ligament + oophorectomy (postmenopausian women).
89425041|NCT02566850|Experimental|Ekso Users|SCI subjects using Ekso
89425042|NCT02477176||Small annular defect group|Patients with lumbar defect less than 6mm wide after lumbar discectomy
89425043|NCT02477176||Large annular defect group|Patients with lumbar defect greater than 6mm wide after lumbar discectomy
88906101|NCT04548193|Experimental|Arm A (educational materials, phone call, phone messages)|HEALTHY EATING PROGRAM A: Patients receive mailed educational materials about the importance of consuming cruciferae, setting healthier eating goals, and the importance of keeping track of what they eat. Patients also receive one phone call from study staff to make sure they understood the educational materials received and 11 IVR phone messages over 6 months.
88906102|NCT04548193|Active Comparator|Arm B (educational materials, phone call, phone messages)|HEALTHY EATING PROGRAM B: Patients receive mailed educational materials about general fruit and vegetable intake, setting healthier eating goals, and the importance of keeping track of what they eat. Patients also receive one phone call from study staff to make sure they understood the educational materials received and 11 IVR phone messages over 6 months.
89425044|NCT02460692|Placebo Comparator|Placebos|The present study is designed to evaluate whether or not a medium dose of cannabis (3.7% delta-9-THC/5.6% CBD) can maintain an analgesic response over an eight week period compared to placebo.
89425045|NCT02460692|Active Comparator|Dronabinol|A direct comparison of cannabis and dronabinol has not been performed in a clinical population. The present study will fill this void by performing a randomized, controlled 8 week trial comparing the effectiveness of oral versus vaporized cannabis in patients with neuropathic low back pain.
89425046|NCT02460692|Experimental|Vaporized Cannabis 3.7% THC/5.6% CBD|The eight week outpatient study will compare the efficacy and side effect profile of cannabis (3.7%THC/5.6%CBD) and dronabinol. We will also perform a human laboratory experiment evaluating driving using the same study medications that subjects received during their 8 week outpatient treatment.
88906103|NCT04542369|Experimental|LS-SCLC|"Induction therapy: Tislelizumab 200mg, i.v., q3w, 4 cycles; cisplatin 75mg/m2, d1-3 or carboplatin AUC5, d1+ etoposide 100mg/m2, q3w, 4 cycles.~Regional therapy: Candidates for complete resection will receive surgery otherwise they will receive radiotherapy.~Adjuvant therapy: Patients received surgery will receive adjuvant Tislelizumab plus platinum-etoposide therapy for four cycles."
88906104|NCT04533334||Pediatric|FOB measurement of the distance between carina and right upper lobe bronchus and carina and labium oris in pediatric population
89195806|NCT04035304|No Intervention|No Treatment Control Group|Participants in this condition will initially be provided with links to resources for Veterans with PTSD (http://ptsd.va.gov) and will be told that they will be contacted again in 8 weeks (60 days) to complete a second assessment. Each participant will then be provided with a link to download the Mindfulness Coach mobile app and with brief recommendations for how to use the app over the subsequent 8 weeks of the study (see description above). Participants will participate in a final follow up survey 8 weeks after receiving the app.
89425047|NCT02408120|Active Comparator|Insulin Aspart for BG > 140 mg/dL|Subjects will consist of hospitalized patients with type 2 diabetes and be randomized to receive insulin glargine once daily and insulin aspart divided in three equal doses before meals. Supplemental insulin aspart will be given before meals and at bedtime to subjects with blood glucose (BG) levels >140 mg/dL.
89425048|NCT02408120|Active Comparator|Insulin Aspart for BG > 260 mg/dL|Subjects will consist of hospitalized patients with type 2 diabetes and be randomized to receive insulin glargine once daily and insulin aspart divided in three equal doses before meals. Supplemental insulin aspart will be given before meals and at bedtime to subjects with blood glucose (BG) levels >260 mg/dL.
89195807|NCT05274542|Experimental|high intensity with blood flow restriction group|
89425049|NCT02393183|Experimental|ASTED|"Antioxidant Supplements for TED (ASTED):~to evaluate the effect of selected antioxidant vitamins and minerals supplement (Twice daily)~β- Carotene (30 mg)~Vit C (100 mg)~Vit E (Alpha-Tocopherol Acetate): 60-200 IU~Calcium phosphate dihydrate (40 mg)~Zinc oxide (4 mg, elemental)~Copper gluconate (3.5 mg)~Sodium selenite 23 mg= Selenium 100 µg~Nicotinamide (a form of vit.B3) (10 mg)"
88906105|NCT04518995|Experimental|Placebo|Participants received CTP-543 matched placebo tablets, orally, twice daily (BID) for up to 24 weeks.
88906106|NCT04518995|Experimental|CTP-543 8 mg BID|Participants received CTP-543 8 mg tablets, orally, BID for up to 24 weeks.
89195808|NCT05274542|Active Comparator|high intensity without blood flow restriction group|
89425050|NCT02393183|Active Comparator|Selenium|Selenium (100mic) Twice daily
89425051|NCT02393183|Placebo Comparator|Placebo|Placebo Twice daily
89195809|NCT01036243|Experimental|Test formula 1|Hydrolyzed formula with probiotics
89195810|NCT01036243|Active Comparator|test formula 2|acidified hydrolyzed formula.
89195811|NCT01036243|Active Comparator|Test formula 3|hydrolyzed formula without probiotics
89195812|NCT01036243|Active Comparator|reference product|standard infant formula
89195813|NCT00895024||Caregivers|
89425052|NCT02391545|Experimental|Duvelisib and Rituximab|"Duvelisib is administered orally and supplied as 5 mg and 25 mg formulated capsules. Duvelisib will be administered orally, twice daily, in 28-day cycles.~Rituximab 375 mg/m2 will be administered intravenously (IV) beginning on Cycle 1 (28 day cycles); days 1, 8, 15 and 22. Thereafter, infusions will occur on Day 1 of the even cycles treatment; Cycles 4-26."
88906107|NCT04518995|Placebo Comparator|CTP-543 12 mg BID|Participants received CTP-543 12 mg tablets, orally, BID for up to 24 weeks.
88906108|NCT04496596|Experimental|Suramin|
88906109|NCT04496596|Placebo Comparator|Placebo|
89195814|NCT01042717|Experimental|Plerixafor|Plerixafor 16 hours
89195815|NCT00898768|Other|capsule endoscopy|capsule endoscopie at baseline and after 2 years
89195816|NCT03506932|Experimental|Untreated|Bread containing 20% yellow pea flour.
89195817|NCT03506932|Experimental|Heat treated with 0% moisture|Bread containing 20% yellow pea flour.
89195818|NCT03506932|Experimental|Heat treated with 10% moisture|Bread containing 20% yellow pea flour.
89195819|NCT03506932|Active Comparator|Wheat|Bread made with 100% wheat flour
89195820|NCT00738140|Experimental|A|Intensive lifestyle intervention based on the Diabetes Prevention Program
89425053|NCT02391545|Experimental|Duvelisib and Obinutuzumab|"Duvelisib is administered orally and supplied as 5 mg and 25 mg formulated capsules. Duvelisib will be administered orally, twice daily, in 28-day cycles.~Obinutuzumab 1000 mg will be administered intravenously (IV) beginning at Cycle 1 (28 day cycles); days 1, 8, 15 and 22. Thereafter, infusions will occur on Day 1 of the even cycles treatment; Cycles 4-26."
89425054|NCT02295475|Experimental|Apixaban|Subjects will receive apixaban 5 mg tablets taken twice daily for the duration of the study.
89425055|NCT02295475|Active Comparator|Warfarin|Subjects will receive warfarin for the duration of the study, with the dose and frequency adjusted per clinician discretion to achieve an INR (International Normalized Ratio) between 2 and 4.
89425056|NCT02254863|Experimental|Intrathecal administration of DUOC-01|Administration of DUOC-01, given intrathecally, between day 26 and 28 post unrelated cord blood transplant
89425057|NCT02193503|Experimental|treatment|MVX-1-loaded capsules and injection of irradiated autologous tumor cells
88906110|NCT04485286|Experimental|Lung Cancer or Pancreatic Cancer Subjects Undergoing Radiation Therapy|Lung cancer or pancreatic cancer patients will receive [68Ga]CBP8 and undergo PET imaging 1) prior to radiation therapy and 2) 3-6 months after radiation therapy
88906111|NCT04474691|Experimental|Visual-acoustic biofeedback|
88906112|NCT04474691|Active Comparator|Traditional articulation treatment|
88906113|NCT04453462|Active Comparator|Local direct median nerve block|The local anesthetic technique is proposed by Wood SH and Logan AM in 1999 by using the plastic catheter to inject the anesthetic 4 cm proximally to the incision site direct over the median and ulna nerve
88906114|NCT04453462|Active Comparator|Brachial plexus block|The brachial plexus block technique is axillary block performed under ultrasound-guided by the well-trained anesthesiologist.
89425058|NCT02162732|Experimental|Guided Therapy|A total of 200 neuroblastoma, brain tumor, and rare tumor patients will be treated. Guided therapy will allow the use of any therapeutic combination (up to 4 agents) provided it includes medications contained in the study report. All patients will be followed for survival, disease response, progression and safety. All patients will be treated according to the discretion of the treating oncologist and study committee (minimum 3 oncologists and one pharmacist). Extent of disease will be measured and assessed for changes throughout the course of the study and at 6-8 week intervals (every 2 cycles).
88906115|NCT04453007|Placebo Comparator|Intervention-only Control|Participants navigate through e-checkup to go, the well-established alcohol intervention. Any follow-up emails sent to them later contain only a reminder to participate in follow-up surveys.
88906116|NCT04453007|Active Comparator|Intervention plus 2-week feedback booster|Participants navigate through e-checkup to go, the well-established alcohol intervention, then receive the feedback booster email 2 weeks later. It contains a reminder to participate in follow-up surveys, plus personalized feedback based on participant-reported perceived alcohol norms, actual alcohol norms, their own use, and harm reduction strategies.
88906117|NCT04453007|Active Comparator|Intervention plus 6-week feedback booster|Participants navigate through e-checkup to go, the well-established alcohol intervention, then receive the feedback booster email 6 weeks later. It contains a reminder to participate in follow-up surveys, plus personalized feedback based on participant-reported perceived alcohol norms, actual alcohol norms, their own use, and harm reduction strategies.
88906118|NCT04453007|Active Comparator|Intervention plus 10-week feedback booster|Participants navigate through e-checkup to go, the well-established alcohol intervention, then receive the feedback booster email 10 weeks later. It contains a reminder to participate in follow-up surveys, plus personalized feedback based on participant-reported perceived alcohol norms, actual alcohol norms, their own use, and harm reduction strategies.
88906119|NCT04453007|Active Comparator|Intervention plus 14-week feedback booster|Participants navigate through e-checkup to go, the well-established alcohol intervention, then receive the feedback booster email 14 weeks later. It contains a reminder to participate in follow-up surveys, plus personalized feedback based on participant-reported perceived alcohol norms, actual alcohol norms, their own use, and harm reduction strategies.
88906120|NCT04453007|Active Comparator|Intervention plus repeated feedback boosters|Participants navigate through e-checkup to go, the well-established alcohol intervention, then receive the multiple feedback booster emails, 2, 6, 10, and 14 weeks later. Each time, the email contains a reminder to participate in follow-up surveys, plus personalized feedback based on participant-reported perceived alcohol norms, actual alcohol norms, their own use, and harm reduction strategies.
88906121|NCT04451057|Experimental|high flow nasal nasal cannula|Patients allocated for this arm are received high flow nasal cannula therapy after extubation.
88906122|NCT04451057|Active Comparator|low flow nasal cannula|Patients allocated for this arm are received conventional oxygen therapy after extubation.
88906123|NCT04445402||Heme/Non-Sickle Cell Disease|Subjects with a diagnosis of hemoglobinapathy except Sickle Cell Disease
88906124|NCT04445402||Heme/Sickle Cell Disease|Subjects with a diagnosis of Sickle Cell Disease
88906125|NCT04445402||Neuro-Oncological Disease|Oncology diagnosis with involvement of the neurological system
88906126|NCT04445402||Oncology/Non-Neuro-Oncological|Subjects with any oncology diagnosis except those that involve the neurological system.
88906127|NCT04445402||Transplant patients|Subjects who have received or are intending to have a stem cell transplant for treatment of disease.
89425059|NCT02156739|Experimental|Diagnostic (contrast-enhanced MRI)|Patient receives each of these over one minute. For the gadoxetate disodium, dynamic imaging is performed immediately and imaging is performed at 20 minutes. For the gadobutrol, dynamic imaging is performed immediately.
89425060|NCT01994252|Active Comparator|Optimal Medical therapy plus ICD|Patients randomized to the (ICD) Implantable-Defibrillator-Cardioverter only group will receive an ICD + optimal medical therapy
88906128|NCT04441619|Active Comparator|Repeated exposure|Participants will complete four exercise sessions designed to induce delayed onset muscle soreness in the biceps
88906129|NCT04441619|Active Comparator|Single exposure|Participants will complete one exercise session designed to induce delayed onset muscle soreness
88906130|NCT04441619|No Intervention|Natural history|Participants will complete all sensory testing and imaging but not perform any exercise sessions.
88906131|NCT04391374||Conservative treatment|Subjects with atherosclerotic peripheral artery disease (PAD) who undergo standard of care conservative treatment according to the current PAD guidelines.
88906132|NCT04391374||Peripheral artery bypass grafting|Subjects with atherosclerotic peripheral artery disease who undergo an open bypass grafting with synthetic prosthesis in aorto-iliac or femoro-popliteal position
88906133|NCT04391374||Peripheral artery balloon angioplasty and stenting|Subjects with atherosclerotic peripheral artery disease who undergo endovascular balloon angioplasty and stenting with bare-metal stents in aorto-iliac or femoro-popliteal position
88906134|NCT04352452||RALS|Surgeons perform robot-assisted laparoscopic surgery
88906135|NCT04352452||CLS|Surgeons perform conventional laparoscopic surgery
88906136|NCT04343521|Experimental|Targeted Indoor Residual Spraying (TIRS)|All households in Targeted Indoor Residual Spraying (TIRS) clusters will be offered the intervention, epidemiological and entomological evaluation will occur in the center of each cluster
89425061|NCT01994252|Active Comparator|Optimal Medical therapy plus CRT/ICD|Patients randomized to the (ICD) Implantable-Defibrillator-Cardioverter plus cardiac resynchronisation therapy (CRT) group will receive an ICD + CRT and optimal medical therapy
89425062|NCT01985568|Active Comparator|Standard Behavioral Therapy (Standard BT)|Standard BT: This group will follow a traditional model of initiating exercise concurrently with a dietary intervention for weight loss within an 18 month behavioral weight loss program.
89425063|NCT01985568|Experimental|Sequential Behavioral Therapy (Sequential BT)|Sequential BT: This group will receive diet and exercise interventions delivered sequentially within an 18 month behavioral weight loss program.
89536107|NCT03071523|Experimental|coronally advanced lingual flap|Full-thickness crestal incision will be made over the edentulous ridge followed by one full-thickness vertical incision on the buccal side. On the buccal side, full thickness mucoperiosteal flap will be raised with horizontal incision 1-3 mm in depth performed in the buccal flap. On the lingual side, a full-thickness mucoperiosteal flap will be elevated until reaching the mylohyoid line. A band of mylohyoid muscle is inserted into the inner part of the lingual flap approximately 5 mm from the crest in an apical direction. A blunt instrument will be inserted below that connective band, and, with gentle traction in the coronal direction, this muscular insertion should be detached freeing the lingual flap from the mylohyoid.
88906137|NCT04343521|No Intervention|Control|Routine Aedes-borne virus (ABV) prevention and control, no Targeted Indoor Residual Spraying (TIRS)
88906138|NCT04332783|Experimental|Healthy Typical Adults|Observers including radiologists and non-radiologists will be asked to participate in computer based tasks in which they visually search for, detect, localize, and categorize tumors in x-ray images.
88906139|NCT04315883||Standard Treatment|"Evaluation of change of HRQOL survey responses will be performed:~at baseline (time of treatment) and~1 month post treatment~6 months post treatment~12 months post treatment~5 years post-treatment~The HRQOL will be done by phone, mail or email. Responses will be captured and entered into a REDCAP database"
88906140|NCT04312958||Trauma patients|Trauma patients experiencing traumatic injuries requiring a full trauma team response.
88906141|NCT04312958||Liver transplant patients|Patients undergoing liver transplant surgery.
88906142|NCT04312503||COHORT A: Lurasidone|Patients treated with Lurasidone
88906143|NCT04312503||COHORT B: aripiprazole, olanzapine, quetiapine or risperidone)|Patients treated with other atipical antypsicothic as aripiprazole, olanzapine, quetiapine or risperidone)
89195821|NCT00738140|No Intervention|B|Will follow the guidelines for healthy living established by the Food Guide Pyramid and the National Cholesterol Education Program
89425064|NCT01920932|Experimental|Treatment|Participants receive AEPA regimen (brentuximab vedotin, etoposide, prednisone, doxorubicin), and CAPDac regimen (cyclophosphamide, brentuximab vedotin, prednisone, dacarbazine(R)). Filgrastim may be given as clinically indicated. For those with lymph nodes that do not go into remission after 2 courses of AEPA chemotherapy, radiation therapy will be given. Some participants may volunteer to complete the quality of life assessment.
88906144|NCT04305444|Experimental|Disease-specific cohorts|Participants will be administered the oral triple-combination therapy, DTRM-555 (comprised of 200mg of DTRMWXHS-12, 5mg of everolimus and 2mg of pomalidomide), once-daily for 21 consecutive days every 28 days
89425065|NCT01873560||FFRpost|High FFRpost group and low FFRpost group were defined according to the optimal cut-off value for predicting clinical outcome.
89425066|NCT01799915||REM sleep behavior disorder, RBD|Patients that have rapid eye movement sleep behavior disorder.
88906145|NCT04290975|Experimental|Task-shifted arm|In the task-shifted arm, all children will be prescribed anti-epileptic medication and receive follow-up care from a CHW, with a physician consult available to the CHW as needed.
89195822|NCT00625443|Experimental|Placebo (double-blind)|
89425067|NCT01799915||multiple system atrophy|is a neurodegenerative disorder charaterized by abnormal alpha-synuclein deposition in the cytoplasm of oligodendroglial cells in the CNS, and typically sparing peripheral autonomic nerves.
89425068|NCT01799915||Pure Autonomic failure|A neurodegenerative disorder characterized by loss of peripheral noradrenergic fibers, with low levels of plasma norepinephine.
89425069|NCT01799915||Parkinson disease|A degenerative disorder of the central nervous system that leads to termors, difficulty walking, movement and coordination.
89425070|NCT01799915||Dementia with Lewy bodies|A neurodegenerative disorder similar to PAF and PD with the accumulation of Alpha-synuclein in the CNS however DLB patients develop dementia.
89425071|NCT01774253|Experimental|Vismodegib|Vismodegib will be dosed at 150mg-300mg orally (max dose: 300mg) once a day on days 1 to 28 of a 28-day cycle. In the absence of unacceptable toxicity or disease progression, treatment may continue for as long as tolerated.
88906146|NCT04290975|Active Comparator|Enhanced usual care arm|In the enhanced usual care arm, all children will be prescribed anti-epileptic medication and receive follow-up care from a physician, with a CHW collecting standardized data to mirror that of the intervention arm.
88906147|NCT04282343|Other|Arm I- Usual care|Patients receive usual care consisting of general cancer treatment information on a sheet of paper before attending video-recorded meetings with their oncologist to discuss treatment plans.
88906148|NCT04282343|Other|Arm II - DISCO app|Patients use the DISCO education and communication app before attending video-recorded meetings with their oncologist to discuss treatment plans.
88906149|NCT04278131|Experimental|Cohort 1|BSO1 Cohort 1 dose
88906150|NCT04278131|Experimental|Cohort 2|BS01 Cohort 2 dose
88906151|NCT04278131|Experimental|Cohort 3|BS01 Cohort 3 dose
88906152|NCT04278131|Experimental|Cohort 4|BS01 Cohort4 dose
89425072|NCT01505608|Active Comparator|Arm A- Temozolomide and Irinotecan|"Oral (PO) Temozolomide at a dose of 100mg/m2 on days 1-5 of each 28 day cycle.~Intravenous (IV) Irinotecan at a dose of 10mg/m2 on days 1-5 and 8-12 of each 28 day cycle.~Patients who show progression on the I+TMZ arm may crossover to the I+TMZ+TPI 287 arm at anytime during cycles 1 to 6. If there is evidence of progression after completion of the I+TMZ arm (after completion of cycle 6) then the patient will have been considered to have completed therapy and is not eligible for the crossover."
89425073|NCT01505608|Experimental|Arm B- Temozolomide/Irinotecan + TPI 287|"Cycle 1 to 6: Irinotecan and Temozolomide in combination with TPI 287~Intravenous (IV) TPI 287 at a dose of 125 mg/m2 on Days 1, 8 and 15 of a 28-day cycle.~Oral (PO) Temozolomide at a dose of 100mg/m2 on days 1-5 of each 28 day cycle.~Intravenous (IV) Irinotecan at a dose of 10mg/m2 on days 1-5 and 8-12 of each 28 day cycle."
89425074|NCT01491893|Experimental|Dose Level 1 (dose escalation)|Participants received a single intratumoral infusion of 1.0 x 10^8 TCID50 Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO), via convection-enhanced delivery to the brain tumor, with 4 weeks of monitoring for toxicities after infusion.
88906153|NCT04273841|Active Comparator|Caffeine Group|This group will receive caffeine gum.
88906154|NCT04273841|Placebo Comparator|Placebo|This group will receive gum without caffeine.
89195823|NCT00625443|Experimental|Avatrombopag tablets (open-label)|
89195824|NCT00625443|Experimental|Avatrombopag tablets (double-blind)|
88906155|NCT04267029||Cases: CRTR (cardiorespiratory transfusion reaction)|Respiratory/cardiovascular disturbances after transfusion (>/=2 of respiratory distress, pulmonary edema, cardiovascular system changes, fluid shifts, cardiac strain indicators), with or without accompanying (or pre-existing) fever
88906156|NCT04267029||Controls: HRFTR (high risk febrile transfusion reactions)|Post-transfusion fevers requiring laboratory investigation (Tmax>/=39C, or lesser deflections if accompanied by chills/rigors), without respiratory features (hypoxia or dyspnea)
88906157|NCT04256889|Experimental|nfant(R) feeding system|Addition of nfant(R) technology, along with visual assessments and cue-based feeding practices, to facilitate an infant's progression to full oral feeding and potentially improve developmentally supportive feeding practices.
88906158|NCT04249063|Experimental|Treatment Group|NovaSure EA with an injection of local anaesthetic into the fundus. Paracervical block and procedural sedation as per usual.
89425075|NCT01491893|Experimental|Dose Level 2 (dose escalation)|Participants received a single intratumoral infusion of 3.3 x 10^8 TCID50 Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO), via convention-enhanced delivery to the brain tumor, with 4 weeks of monitoring for toxicities after infusion.
89425076|NCT01491893|Experimental|Dose Level 3 (dose escalation)|Participants received a single intratumoral infusion of 1.0 x 10^9 TCID50 Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO), via convection-enhanced delivery to the brain tumor, with 4 weeks of monitoring for toxicities after infusion.
89425077|NCT01491893|Experimental|Dose Level 4 (dose escalation)|Participants received a single intratumoral infusion of 3.3 x 10^9 TCID50 Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO), via convection-enhanced delivery to the brain tumor, with 4 weeks of monitoring for toxicities after infusion.
89195825|NCT00898846||UFT adjuvant therapy group|UFT is given at a dose of 500-600 mg/day as tegafur in 2 divided doses after meals for 5 days, followed by a 2-day rest. This one-week cycle is repeated for one year. During protocol treatment, clinical findings and laboratory values are evaluated every month. After the completion of protocol treatment, patients are followed-up, according to the schedule defined in the study protocol, for 5 years until recurrence, other malignancy or death is confirmed.
89195826|NCT00898846||Observation group|Patients are followed-up without adjuvant treatment, according to the schedule defined in the study protocol, for 5 years until recurrence, other malignancy or death is confirmed.
89195827|NCT00920894|Experimental|yoghurt type minidrink containing plant stanol ester|
89195828|NCT00920894|Placebo Comparator|yoghurt type minidrink without plant stanol ester|
89195829|NCT00824343|Experimental|Single P276-00 arm|This is a single experimental arm study
89195830|NCT00895102|Active Comparator|1. ABT-333 Capsule vs ABT-333 Tablet|400mg ABT-333 Tablet, QD, single dose vs eight 50mg ABT-333 Capsules, QD, single dose
89195831|NCT00895102|Active Comparator|2. ABT-333 Tablet|ABT-333 400mg Tablet, QD, single ascending doses (1200mg, 1600mg, 2400mg)
89195832|NCT00895102|Placebo Comparator|3. Placebo|Placebo tablets, QD, single ascending doses
89195833|NCT00826371|Experimental|1|
89195834|NCT00824499|Experimental|DPA|Regional complex intervention based on the Chronic Care Model
89195835|NCT00824499|No Intervention|VR|
89195836|NCT02540824|Experimental|Apatinib single agent arm|Apatinib, single agent, 750mg once daily p.o until disease progression
89195837|NCT00824577||250~300 patients|heart rate variability, heart function and Kt/V
89195838|NCT02540122|Active Comparator|Subject A (Neophytes)|Subjects will wear the Marketed Contact Lens 1, Marketed Contact Lens 2, Marketed Contact Lens 3, and Marketed Contact Lens 4 for a 6-hour period in a bilateral and random fashion, with a washout period of one week between lenses. Each subject will randomly be assigned to one of four unique sequences of a 4 x 4 crossover design. A block size of two sequences will be used.
89195839|NCT02540122|Active Comparator|Subject B (Habitual Lens Wearers)|Subjects will wear the Marketed Contact Lens 1, Marketed Contact Lens 2, Marketed Contact Lens 3, and Marketed Contact Lens 4 for a 6-hour period in a bilateral and random fashion, with a washout period of one week between lenses. Each subject will randomly be assigned to one of four unique sequences of a 4 x 4 crossover design. A block size of two sequences will be used.
89195840|NCT02549703||Relapsing Remitting Multiple Sclerosis|Patients with Relapsing Remitting Multiple Sclerosis/Clinically Isolated Syndrome
89195841|NCT02549703||Secondary Progressive Multiple Sclerosis|
89195842|NCT02549703||Primary Progressive Multiple Sclerosis|
89195843|NCT02540590||Mucograft|Laser speckle contrast imaging of the oral mucosa and wound fluid measurement before and after root coverage surgery. In this group the roots are covered by a combination of modified coronally advanced flap and xenograft collagen matrix (Mucograft).
89195844|NCT02540590||CTG|Laser speckle contrast imaging of the oral mucosa and wound fluid measurement before and after root coverage surgery. In this group the roots are covered by a combination of modified coronally advanced flap and subepithelial connective tissue graft (CTG), which was harvested from the patient's palate.
89425078|NCT01491893|Experimental|Dose Level 5 (dose escalation)|Participants received a single intratumoral infusion of 1.0 x 10^10 TCID50 Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO), via convection-enhanced delivery to the brain tumor, with 4 weeks of monitoring for toxicities after infusion.
89425079|NCT01491893|Experimental|Dose Level 4 (dose de-escalation)|Participants received a single intratumoral infusion of 3.3 x 10^9 TCID50 Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO), via convection-enhanced delivery to the brain tumor, with 4 weeks of monitoring for toxicities after infusion.
89425080|NCT01491893|Experimental|Dose Level 2 (dose expansion)|Participants received a single intratumoral infusion of 3.3 x 10^8 TCID50 of PVSRIPO, via convection-enhanced delivery to the brain tumor, with 4 weeks of monitoring for toxicities after infusion.
89425081|NCT01491893|Experimental|Dose Level -1 (dose expansion)|Participants received a single intratumoral infusion of 5.0 x 10^7 TCID50 Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO), via convection-enhanced delivery to the brain tumor, with 4 weeks of monitoring for toxicities after infusion.
89425082|NCT01491893|Experimental|Dose Level -2 (dose expansion)|Participants received a single intratumoral infusion of 1.0 x 10^7 TCID50 Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO), via convection-enhanced delivery to the brain tumor, with 4 weeks of monitoring for toxicities after infusion.
89425083|NCT01491893|Experimental|Dose Level -1 (selected dose expansion)|Participants received a single intratumoral infusion of 5.0 x 10^7 TCID50 Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO), via convection-enhanced delivery to the brain tumor, with 4 weeks of monitoring for toxicities after infusion.
88906159|NCT04249063|Placebo Comparator|Control Group|NovaSure EA with an injection of normal saline into the fundus. Paracervical block and procedural sedation as per usual.
88906160|NCT04239040|Experimental|Relapsed or Refractory High Risk Neuroblastoma|"Tissue Collection of Cancerous cells during primary or clinically indicated surgical resection.~Manufacture and cryopreservation of vaccine. Treatment with vaccine, nivolumab and ipilimumab.~Vaccine injected weekly over initial 21 day cycle, biweekly for cycles 2-4 of 21 day cycle duration and cycles 5 and subsequent of 28 day cycle duration until vaccine supply is exhausted.~Intravenous infusion of nivolumab every 3 weeks, for cycles 1-4. Cycles 1-4 are 21 days~Intravenous infusion of ipilimumab every 3 weeks, for cycles 1-4. Cycles 1-4 are 21 days~Intravenous infusion of nivolumab biweekly for cycle 5 and subsequent of 28 day cycle duration. Subsequent 28 day cycles will last up to 2 years."
88906161|NCT04237753|Active Comparator|MyHealthebladder|Daily mobile health education with information on bladder anatomy and function, pelvic floor muscle exercises with behavioral strategies, and self-monitoring tools for urine leakage
88906162|NCT04237753|Active Comparator|VA Video Connect|Remote telehealth visits with continence care provider who will provide education on bladder anatomy and function, pelvic floor muscle exercises with behavioral strategies, and self-monitoring tools for urine leakage
89425084|NCT01483820|Experimental|TPI 287|Subjects will receive six cycles of intravenous (IV) TPI 287 at a dose of 125 mg/m2 on Days 1, 8 and 15 of a 21-day cycle.
89425085|NCT01143766|Active Comparator|Standard sedation|Patients will receive combination opiate and benzodiazepine for sedation, the current standard of care.
89425086|NCT01143766|Active Comparator|Gapabentin|Patients will receive gabapentin 900mg PO x 1 dose, one hour prior to the procedure. At the time of ERCP, patients will be sedated in a standard fashion.
89425087|NCT01109238||Process Feasibility|
88906163|NCT04229017|Active Comparator|Anterior Cervical Discectomy and Fusion (ACDF)|ACDF is a a standard of care procedure that is performed using standard instruments and completed with an allograft interbody implant and anterior plate. The plate is intended to stabilize the treated levels until fusion occurs.
88906164|NCT04229017|Experimental|Circumferential Cervical Fusion (CCF)|Circumferential Cervical Fusion (CCF) is a combination of ACDF and Posterior Cervical Fusion (PCF) procedures. The PCF is completed with Posterior Cervical Stabilization System (PCSS).
88906165|NCT04209127|Experimental|Microwave treatment|Percutaneous or vaginal application of microwave antenna with microwave treatment for adenomyosis
88906166|NCT04209127|Active Comparator|Control|Uterine artery embolization; percutaneous application of a catheter into the femoral artery or branches thereof
88906167|NCT04204252|Active Comparator|Inhaled AAT|"Daily inhalation of 80 mg/day Kamada-AAT for Inhalation for 104 weeks"
88906168|NCT04204252|Placebo Comparator|Placebo|Daily inhalation of a solution of NaCl in phosphate buffer solution with 0.01% TWEEN-80
88906169|NCT04203433|Experimental|DLX105-DMP Multi-Dose Twice Weekly|4 Weeks of 1mg DLX105-DMP applied to a target lesion twice weekly
88906170|NCT04203433|Experimental|DLX105-DMP Multi-Dose Once Weekly|4 Weeks of 1mg DLX105-DMP applied to a target lesion once weekly
88906171|NCT04192955|Active Comparator|Active|Acetylsalicylic acid (ASA) will be given orally at a dose of 324 mg to be taken daily starting 3 days prior to the planned coiling procedure day, on the procedure day, and for one-day post-procedure.
89425088|NCT01108120|Experimental|continuous intra-femoral thrombolysis group|Continuous intra-femoral injection urokinase was taken by a mini-pump in 100 diabetic foot ulcers (Wegnar 2 ~ 4 stage) for 7 - 9 days.Then they receive conventional therapy. The healing rate of foot ulcers is observed during hospitalization period. At 1, 4 and 8 year during follow up, the recurrence rate of diabetic foot ulcers are observed.
89425089|NCT01108120|Active Comparator|conventional therapy group|Conventional therapy group receives an intravenous injection of prostaglandin E1 20 ug per day. The follow up was taken for 8 years.
89425090|NCT01106898|Experimental|Treatment (chemotherapy with or without maintenance therapy)|"SYSTEMIC CHEMOTHERAPY: Patients receive cyclophosphamide IV over 1 hour and paclitaxel IV over 3 hours on day 1. Treatment repeats every 14 days for 6 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY (Her-2 neu positive patients): Patients receive trastuzumab IV over 30 minutes on day 1. Treatment repeats every 14 days for 5 courses and then every 21 days for 14 courses in the absence of disease progression or unacceptable toxicity."
89425091|NCT01059071|Experimental|DFMO and Etoposide|
89425092|NCT01034969||Participants with hereditary angioedema (HAE)|All participants with hereditary angioedema (HAE) who are administered Cinryze (C1 inhibitor [human]) or Firazyr (Icatibant) for the treatment or prevention of angioedema attacks in routine clinical practice will be included into the study.
88820227|NCT06191367|Active Comparator|Group III (control) will receive Traditional Chest Physiotherapy only.|"As a control group it was consisted of fifteen patients with positive covid-19 test from at least a month before trial. They received traditional program of chest physiotherapy only. (Five times per week for two months).~for example: - Breathing Exercises. - Postural Drainage. - Percussion. - Coughing - Vibration."
89195845|NCT00898924||Group 1|Tissue samples were collected from patients on Day 1, Cycle 1. Whole blood and serum samples were collected on Day 1 (Cycle 1), Day 1 (Cycle 3), post-radiotherapy ZD1839 and at progression.
89195846|NCT02550717||Acetylsalicylic Acid|New users of low-dose Acetylsalicylic Acid (ASA)
89195847|NCT02550717||Other medications|Users of other medications such as clopidogrel, oral anticoagulants, non-steroidal anti-inflammatory drugs (NSAIDs) and selective serotonin reuptake inhibitors (SSRIs)
89425093|NCT01001637|Active Comparator|curcumin|
89425094|NCT01001637|Placebo Comparator|placebo|
89425095|NCT00923702|Active Comparator|3-dose|The participants received three doses of the Prophylactic quadrivalent HPV vaccine Merck (Gardasil®) at days 1, 60 and 180+.
89425096|NCT00923702|Experimental|2-dose|The participants received two doses of the Prophylactic quadrivalent HPV vaccine Merck (Gardasil®) at days 1 and 180+.
89425097|NCT00923702|Experimental|2 doses by default|The participants received two doses of the Prophylactic quadrivalent HPV vaccine Merck (Gardasil®) at days 1 and 60 by default (incomplete doses)
89425098|NCT00923702|Experimental|Single-dose|The participants received one dose of the Prophylactic quadrivalent HPV vaccine Merck (Gardasil®) by default (incomplete doses)
89425099|NCT00923702|No Intervention|Unvaccinated|A cohort of unvaccinated women
88820228|NCT06191354|Experimental|Dose-escalation|SKG0201 one-time deliver
88820229|NCT06191328|Experimental|Intervention group|
88820230|NCT06191302||SARS-CoV-2 positive patients|a cohort of former patients hospitalized with COVID-19
88820231|NCT06191302||SARS-CoV-2 negative patients|a control group of former patients hospitalized with other respiratory diseases
88820232|NCT06191289|Experimental|Transdermal Estradiol|.1mg per 24 hours transdermal estradiol applied to the skin weekly, for 14 days.
88820233|NCT06191289|Placebo Comparator|Placebo|Clear patch manufactured to mimic the E2 patch applied to the skin weekly, for 14 days.
89195848|NCT00895258|Experimental|IPS-CT|Participants will receive individual placement and support (IPS) plus cognitive training (CT).
88906172|NCT04192955|Placebo Comparator|Control|Lactose100-mg tablets to be taken daily starting 3 days prior to the planned coiling procedure day, on the procedure day, and for one-day post-procedure.
88906173|NCT04184869|Other|Wild Type UGT1A1|"Cohort A: Wild Type, UGT1A1, Belinostat IV Dose: 1000 mg/m2 Frequency: 30-minute infusion once daily from Day 1 to Day 5 of a 21-day cycle.~Duration: Up to five 21-day cycles (15 weeks) Treatment Period: Up to a total of six 21-day cycles (18 weeks) of treatment total from both the original study protocol and this extension protocol."
88906174|NCT04184869|Other|Heterozygous UGT1A1*28|"Cohort B: Heterozygous, UGT1A1, Belinostat IV Dose: 1000 mg/m2 Frequency: 30-minute infusion once daily from Day 1 to Day 5 of a 21-day cycle.~Duration: Up to five 21-day cycles (15 weeks) Treatment Period: Up to a total of six 21-day cycles (18 weeks) of treatment total from both the original study protocol and this extension protocol."
88906175|NCT04184869|Other|Homozygous UGT1A1*28|"Cohort C: Homozygous, UGT1A1, Belinostat IV Dose: 750 mg/m2 Frequency: 30-minute infusion once daily from Day 1 to Day 5 of a 21-day cycle.~Duration: Up to five 21-day cycles (15 weeks) Treatment Period: Up to a total of six 21-day cycles (18 weeks) of treatment total from both the original study protocol and this extension protocol."
88906176|NCT04184869|Other|Belinostat & Atazanavir|"Arm: Homozygous UGT1A1*28 genotype subjects with Belinostat IV & Atazanavir~Dose: 750mg/ m2 (Belinostat IV), 400mg (Atazanavir)~Frequency: two cycles of 21 days (Belinostat administered through Cycle 2, Day 5) Atazanavir 400mg administered Cycle 1 Day 15 to Day 21, and Cycle 2 Day 1 to Day 5~Duration: Up to five 21-day cycles (15 weeks) Treatment Period: Up to a total of six 21-day cycles (18 weeks) of treatment total from both the original study protocol and this extension protocol."
88906177|NCT04175262||Patients with mRCC|Patients diagnosed with metastatic RCC receiving first line (1L) combination of IOs therapies followed by Sunitinib as a second line (2L) treatment
88906178|NCT04156997||Patients with extreme lipid phenotypes|Adult patients (age 18 years or older) diagnosed with any lipid or metabolic disorder including hyperlipidemia, dyslipidemia, hyperlipoproteinemia, low HDL levels and deranged lipoprotein metabolism
88906179|NCT04156997||Healthy volunteers|Healthy adult volunteers with normal lipid metabolism will be recruited for the purpose of comparison
88906180|NCT04149899|Experimental|Part 1 (Period 1): WB007 0.05%|WB007 0.05%, single dose to study eye on Day 1
88906181|NCT04149899|Experimental|Part 1 (Period 2): WB007 0.15%|WB007 0.15%, single dose to study eye on Day 1
88906182|NCT04149899|Experimental|Part 1 (Period 3): WB007 0.4%|WB007 0.4%, single dose to study eye on Day 1
88906183|NCT04149899|Experimental|Part 2: WB007 0.15%|WB007 0.15%, dosed twice daily for 14 days
88906184|NCT04149899|Experimental|Part 2: WB007 0.4%|WB007 0.4%, dosed twice daily for 14 days
88906185|NCT04149899|Active Comparator|Part 2: Timolol 0.5%|Timolol 0.5%, dosed twice daily for 14 days.
88906186|NCT04137536|Experimental|Pancreatic Adenocarcinoma|Participants have metastatic pancreatic cancer who have received at least first line chemotherapy and have disease progression during or within 6 months of treatment.
88906187|NCT04119115||Interstitial Lung Disease (ILD)|CT-V and metabolite analysis of breath and serum at baseline
88906188|NCT04119115||COPD/Emphysema: Age-matched control|CT-V and metabolite analysis of breath and serum at baseline
88906189|NCT04119115||Healthy Volunteers: Age-matched + /- 10 yrs controls|Metabolite analysis of breath and serum at baseline
88906190|NCT04111029||Unresectable HCC undergoing locoregional therapy|Patients with unresectable HCC who have no curative option like tumour ablation, resection or transplantation and are being taken for locoregional therapy will be recruited
89195849|NCT00895258|Active Comparator|IPS-ES|Participants will receive individual placement and support (IPS) plus enhanced support (ES).
89425100|NCT00867568|Experimental|TPI 287|
89425101|NCT00737698|Experimental|Exercise|Exercise
89425102|NCT00737698|Experimental|Repetitive magnetic stimulation|Repetitive magnetic stimulation of femoral nerve
89425103|NCT00737698|No Intervention|Control|No active treatment
89425104|NCT00626366|Experimental|Nasal spray|This arm of the study will contain subjects who will spray 2-4 sprays of a nasal contrast solution in their nares. Following administration of the spray, the subjects will then have a Xoran mini-CAT scan of their sinuses.
89425105|NCT00626366|Experimental|Nasal drop|This arm will contain subjects who will place two drops of a nasal contrast solution in each nose. Following administration of the nasal contrast, the subjects will then have a Xoran miniCAT scan of their sinuses.
89425106|NCT00601003|Experimental|Nifurtimox|
89425107|NCT00575718|Active Comparator|1|Hospital Counseling + Nicotine Replacement Therapy (HC+NRT)
89425108|NCT00575718|Experimental|2|Hospital Counseling + Nicotine Replacement Therapy + Pre-surgical Schedule Reduced Smoking (HC+NRT+PS/SRS)
89425109|NCT00571493|Experimental|Bortezomib Dose Escalation|"The phase I section of the study will follow a standard 3 + 3 design to determine the maximum tolerated dose (MTD) of bortezomib when added to a standard BEAM (BCNU (carmustine), etoposide, cytarabine, melphalan) conditioning regimen followed by autologous hematopoietic stem cell transplantation (ASCT).~After the MTD is defined, additional patients will enroll in Phase II to obtain preliminary estimates of survival using the Phase I regimen."
89425110|NCT00552461|Experimental|1|
89425111|NCT00507572||Observational (medical chart review)|Patients' medical records are reviewed prospectively and retrospectively.
89425112|NCT00479128|Experimental|Bortezomib + Gemcitabine + Doxorubicin|Starting dose of Bortezomib 0.8 mg/m^2 IV Over 3-5 Seconds. Starting dose of Gemcitabine 225 mg/m^2 IV Up to 90 Minutes. Starting dose of Doxorubicin 12.5 mg/m^2 IV Over 15-30 minutes.
89425113|NCT04833478|Experimental|Application|Measuring anxiety level of the patients using Facial Image Scale and Pulse Oximeter
89425114|NCT04833478|Experimental|Dental Song|Measuring anxiety level of the patients using Facial Image Scale and Pulse Oximeter
89425115|NCT04833478|Experimental|Tell Show Do|Measuring anxiety level of the patients using Facial Image Scale and Pulse Oximeter
89425116|NCT04833868|Experimental|hippotherapy combined with Schroth Exercise|received hippotherapy combined with Schroth Exercise hippotherapy session for 30 minutes of walking and sitting trot training, 15 sessions split into 2 phases over ten weeks in addition to 60-minute session Schroth's intervention, 3 times/ week for 10 weeks
89425117|NCT04833868|Active Comparator|Schroth Exercise|received Schroth's intervention for a 60-minute session, 3 times/ week for 10 weeks
89425118|NCT04833712|Experimental|Stereotactic Radioablation|"Noninvasive Stereotactic Radioablation will be delivered in a single fraction to electrical isolate the pulmonary veins under CT-guidance.~Pulmonary vein isolation will be assessed by using Cardioinsight non-invasive mapping system"
89425119|NCT04841200|Experimental|Chinese medicine compound combined with symptomatic treatments|Patients in this arm will receive Chinese medicine compound based on TCM syndrome differentiation in addition to symptomatic treatments.
89425120|NCT04841200|Placebo Comparator|Chinese medicine compound placebod combined with symptomatic treatments|Patients in this arm will receive Chinese medicine compound placebo based on TCM syndrome differentiation in addition to symptomatic treatments.
89425121|NCT03036592|Experimental|MTNR1B CC|Test glucose tolerance in homozygous non-carriers (CC) for MTNR1B rs10830963 in Early OGTT and Late OGTT
89425122|NCT03036592|Experimental|MTNR1B GG|Test glucose tolerance in homozygous (GG) risk allele carriers for MTNR1B rs10830963 in Early OGTT and Late OGTT
89425123|NCT03036592|Experimental|MTNR1B CG|Test glucose tolerance in heterozygous (CG) risk allele carriers for MTNR1B rs10830963 in Early OGTT and Late OGTT
89425124|NCT04836130|Active Comparator|(ZMC) Fractures reduction Using Patient Specific Guide (PSG)|
89425125|NCT04836130|Active Comparator|(ZMC) Fractures reduction Using Conventional Technique|
89425126|NCT04428814|Experimental|CT-P43 (Part 1)|45mg single dose administration
89425127|NCT04428814|Active Comparator|EU-approved Stelara (Part 1)|45mg single dose administration
89425128|NCT04428814|Experimental|CT-P43 (Part 2)|45mg single dose administration
89425129|NCT04428814|Active Comparator|EU-approved Stelara (Part 2)|45mg single dose administration
89425130|NCT04428814|Active Comparator|US-licensed Stelara (Part 2)|45mg single dose administration
89195850|NCT00826605||Urobilinogen increase|Increase in urobilinogen increase on routine dipstick test at prenatal appointment after 37 weeks gestation
89195851|NCT00826605||Weight Loss at Term|Weight loss since previous prenatal appointment after 37 weeks gestation
89195852|NCT02550249|Experimental|Nivolumab|Nivolumab 3 mg every 2 weeks
89425131|NCT03036514|Experimental|Case|Sublingual sufentanil tablet system (SSTS) for postoperative pain relief after laminectomy or spinal fusion in the first 72 hour period. Orange-coloured tablets containing 15mcg sufentanil, the patient-controlled device is designed to deliver a single tablet with a minimum lockout interval of 20 minutes.
89425132|NCT03036514|Active Comparator|Control|Patient-controlled intravenous analgesia (PCIA) for postoperative pain relief after laminectomy or spinal fusion in the first 72 hour period. This classic patient-controlled IV-pump contains 1mg/ml morphine and 50mcg/ml dehydrobenzperidol. Pump characteristics include 1ml each asked bolus, lockout interval of 8 minutes.
88906191|NCT04100122||Wheat-allergic|"The diagnosis of IgE-mediated wheat allergy was made if they have one of the following criteria~a convincing clinical history of the reactions within 4 hours after wheat ingestion during the past 12 months combined with positive skin prick test (SPT) and/or the level of specific IgE (sIgE) to wheat or~a positive oral food challenge (OFC) result to wheat during the past 12 months"
88906192|NCT04100122||Wheat tolerant|Patients with wheat tolerant confirmed by negative oral food challenge (OFC) result to wheat during the past 12 months
88906193|NCT04100122||Wheat oral immunotherapy|Patients with IgE-mediated wheat allergy and underwent wheat oral immunotherapy for at least 6 months or at the maintenance phase of the treatment
88906194|NCT04087421|Experimental|Transanal irrigation|Participants receiving TAI will irrigate once/day with stepwise volumes; 1. month 150 ml, 2. month 300 ml, and 3. month 500 ml.
89425133|NCT04836052|Experimental|omega-3-oil arm|patients admitted to ICU in HMC on any kind of oxygen support will get omega-3-oil 2 gm PO/NGT/OGT twice daily for 28 days or till ICU discharge or till death .
89425134|NCT04836052|No Intervention|standard of care arm ( no omega -3-oil )|patients admitted to ICU in HMC on any kind of oxygen support will get ( standard of care= No Omega-3-oil ) but their labs will be monitored
89425135|NCT03036436|Experimental|Intervention|Participants in this group will receive the intervention. They will receive a Fitbit activity tracker, and will also receive support and goal setting with a view to improving their daily physical activity.
89425136|NCT04841278|Experimental|EUS/ERCP|Patients with liver graft dysfunction enrolled sequentially for proposed protocol: EUS with possible interventions and possible ERCP
88906195|NCT04087421|Active Comparator|Glycerol suppositories|Participants treated with glycerol suppositories will administer one glycerol suppository once/day.
88906196|NCT04077073|Experimental|ReIn-hand and robot|"The participant will practice reach, grasp, retrieve, and release (GR3) a plastic jar for 40 trials per session, with the assistance of ReIn-hand to open their paretic hand and of robot to reduce the shoulder load."
88906197|NCT04077073|Active Comparator|ReIn-Hand|"The participant will practice reach, grasp, retrieve, and release (GR3) a plastic jar for 40 trials per session, with the assistance of ReIn-hand to open their paretic hand."
88906198|NCT04073485|Other|Microwave ablation|The uterine fibroid will be identified and located with ultrasonography. A microwave electrode appropriate for the size of target lesion is placed into the target lesion under ultrasound guidance. Appropriate microwave power and application time are selected to provide sufficient ablation coverage to the target lesion.
88906199|NCT04038684|Experimental|Mindfulness-Based Weight Control|All participants will be randomly assigned to a 12-session group-based Mindfulness-Based Weight Control (MBWC) intervention or a Standard Behavioral Weight Control (SBWC) intervention. Participants assigned to the MBWC intervention will receive mindfulness curriculum informed by Mindfulness-Based Stress Reduction plus the standard behavioral weight control components. Group sessions will be approximately 60 minutes each week. Outside of group sessions, participants will be asked to engage in dietary self-monitoring (MBWC and SBWC groups) and practice mindfulness skills (MBWC only).
88906200|NCT04038684|Active Comparator|Standard Behavioral Weight Control|All participants will be randomly assigned to a 12-week group-based Mindfulness-Based Behavioral Weight Control (MBWC) intervention or a Standard Behavioral Weight Control (SBWC) intervention. Participants assigned to the SBWC intervention will receive the SBWC without mindfulness components. Each of the 12 group sessions will be approximately 60 minutes. Outside of group sessions, participants will be asked to practice dietary self-monitoring at home during the week.
89195853|NCT00824811|Experimental|Group 1: Cyclosporine eye drops|Cyclosporine Eye Drops (Restasis) 1 drop twice/day for 84 days to both eyes + Fluorometholone Eye Drops (FML Forte) on declining dose schedule.
88906201|NCT04014075|Experimental|All participants|Participants who have centrally confirmed HER2-positive gastric or gastro-esophageal junction cancer will be treated with trastuzumab deruxtecan by intravenous (IV) infusion every 3 weeks, until progression of disease or withdrawal from treatment for other reasons.
88906202|NCT03983993|Experimental|Treatment (niraparib, panitumumab)|Patients receive 200 or 300 mg niraparib orally once daily on days 1-28 and 6 mg/kg panitumumab intravenously over 60-90 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89425137|NCT03036358|Other|Teledermatology consult|To determine the benefit of teledermatology to differentiate cellulitis from pseudocellulitis in emergency departments through the analysis of time spent in the emergency department (ED), admission to the inpatient hospital, antibiotic use, time to improvement, and 30-day remission rate. This arm will undergo imaging, a dermatologic assessment will be performed, AND this assessment will be entered into the patients chart.
89425138|NCT03036358|Other|Routine Care|To determine the benefit of teledermatology to differentiate cellulitis from pseudocellulitis in emergency departments through the analysis of time spent in the emergency department (ED), admission to the inpatient hospital, antibiotic use, time to improvement, and 30-day remission rate. This arm will undergo imaging, a dermatologic assessment will be performed, AND this assessment WILL NOT be entered into the patients chart
89425139|NCT04833244|Active Comparator|Interventional|Patients are taught to draw their shoulders away from their heads and necks, activating the subscapularis and pectoralis muscles. When asked immediately afterwards to abduct and flex their shoulders, these muscles perform the action that generally engages the injured supraspinatus muscle, causing significant pain. However, when these muscles are substituted for the injured supraspinatus, abduction and flexion subsequently occur painlessly.
89425140|NCT04833244|Placebo Comparator|Control|Patients are taught a sham maneuver that does little or nothing to alleviate the pain of abduction and flexion of the shoulders. Therefore their pain levels before and after learning the maneuver are likely to be similar.
89425141|NCT04835740|Active Comparator|Conventional Rehabilitation|Based on the functional capacity of each participant, customized Aerobic exercise plan was designed by the on-site physiotherapist.
89425142|NCT04835740|Experimental|Combined Training (conventional rehabilitation plus high-intensity interval training):|The patients received 40 minutes of High intensity interval treadmill training in addition to their normal conventional rehabilitation.
89536108|NCT03071523|Active Comparator|periosteal releasing incision technique|Full-thickness crestal incision will be made over the edentulous ridge followed by one full-thickness vertical incision on the buccal side and a full thickness flap will be raised. Xenograft and Ti-mesh will be used to augment the defective site then incremental incisions of 1-3 mm into the periosteum and submucosa will be used to advance the muco-periosteal flap. The flap will then be sutured with interrupted sutures.
88906203|NCT03950661|Experimental|Forest|"Each subject is exposed to a 50 minute walk in a green location at some point during the crossover experiment. The psychological and physiological measurements taken during these walk location weeks are compared to the measurements from the other location. In addition a 'control' day is assigned for each location (ADL)."
88906204|NCT03950661|Experimental|Urban|"Each subject is exposed to a 50 minute walk in a gray location at some point during the crossover experiment. The psychological and physiological measurements taken during these walk location weeks are compared to the measurements from the other location. In addition a 'control' day is assigned for each location (ADL)."
88906205|NCT03944616|Active Comparator|Diet Beverage|Participants will receive and consume three daily servings (24 ounces) of a non-caloric commercial diet beverage of their choice sweetened with FDA approved artificial sweeteners.
88906206|NCT03944616|Experimental|Water|Participants will receive and consume three daily servings (24 ounces) of plain bottled/canned water in place of their usual commercial diet beverage. The water will be unflavored, unsweetened, non-caloric, and may be plain or sparkling. Participants randomized to consume water will be instructed to avoid intake of diet beverages.
88906207|NCT03909152|Experimental|PR+ Granulosa cell tumor (This Arm is CLOSED)|Enrolled patients will initiate treatment with onapristone ER 50 mg by mouth twice daily, about 12 hours apart, beginning Day 1 of Cycle 1. A Cycle is 28 days. This Arm is CLOSED.
88906208|NCT03909152|Experimental|PR+ Low grade serous ovarian cancer|Enrolled patients will initiate treatment with onapristone ER 50 mg by mouth twice daily, about 12 hours apart, beginning Day 1 of Cycle 1. A Cycle is 28 days
89195854|NCT00824811|Experimental|Group 2: Lubricant Eye Drops|Lubricant Eye Drops (Refresh Endura) 1 drop twice/day for 84 days to both eyes + Fluorometholone Eye Drops (FML Forte) on declining dose schedule.
89425143|NCT03039400|Experimental|Web-based physio group|Those in the web-based physio group will have an individual exercise program set up by a treating physiotherapist on webbasedphysio.com after an initial face-to-face assessment. They will be encouraged to undertake their exercise program at least twice per week and diarize their work. Participants will receive a weekly phone call from their treating physiotherapist for the first two weeks. The treating physiotherapist will review the exercise diary of each participant every two weeks, and remotely alter the participant's exercise program as appropriate, by changing exercises, level of difficulty or number of repetitions.
89425144|NCT03039400|Active Comparator|Standard care group|Those in the standard care group will have their exercise program explained to them at an initial face-to-face assessment with a treating physiotherapist as per usual care. They will receive a written, home-based exercise program. Participants in the usual care group will also be encouraged to undertake their exercise program at least twice per week, and will be asked to keep an exercise diary, in paper format. Participants in the usual care group will also receive a weekly phone call from the physiotherapist for the first two weeks to check on progress.
88820234|NCT06191276|Experimental|STEP@Home Intervention|This arm involves participants undergoing the 20-week STEP@Home multi-component exercise training program. The program is designed to recondition the functional status of older adults in the post-discharge period and develop long-term exercise engagement.
89195855|NCT00625365|Other|DEFINITY® (Perflutren Lipid Microsphere)|Patients who had undergone unenhanced echocardiography yielding suboptimal images and who were determined by the Principal Investigator to require DEFINITY-enhanced echocardiography
89195856|NCT00824889|Other|1|Healthy volunteer
89195857|NCT00824889|Other|2|atopic dermatitis patient
89195858|NCT00824889|Other|3|contact dermatitis patient
89425145|NCT04835896|Experimental|Study treatment|
89195859|NCT00824889|Other|4|psoriasis patient
89425146|NCT04835662|Other|Complementary feeding promotion|Intervention
89425147|NCT04833322|Experimental|Single arm group|Galactose supplementation
88820235|NCT06191276|Active Comparator|Usual care|Participants in this group receive the usual post-discharge care provided in the hospital setting, including general education on medication, disease-related self-care, and regular medical follow-ups.
88820236|NCT06191250|Experimental|Neoadjuvant NORT-durvalumab|administration of non-ablative oligofractionated radiation therapy using 12 Gy in 3 fractions in combination with one dose of durvalumab (750 mg IV) prior to surgery.
89195860|NCT00824889|Other|5|lichen planus patient
89195861|NCT00824889|Other|6|GVH patient
89195862|NCT00824889|Other|7|melanoma patient
89425148|NCT01668004|Experimental|GLM 50 mg|GLM given subcutaneously at a dose of 50 mg once monthly for up to 12 months
89425149|NCT03039556|Experimental|Change in physical activity for older adults|Older adult participants undergo alterations in daily ambulation by completing Normal Daily Steps for one week, followed by a two-week Step-Reduction and a subsequent Return to Normal Daily Steps for two weeks
89425150|NCT04835350|No Intervention|Hybrid closed loop group|Patients using AID system Pancreas4ALL in mode hybrid closed loop.
89425151|NCT04835350|Experimental|Closed loop meal announcment|Patients using AID system Pancreas4ALL in mode meal announcment. They only announce what amout of carbs going to eat. They calculate no bolus
89195863|NCT00824967|No Intervention|1- The reference group|one will take care of the patient in a habitual way: no consultation additional, step of exam on top of that...
89195864|NCT00824967|Other|2- The intervention group|Training and valuation of the treating personnel
89195865|NCT00820521|Experimental|active|
89195866|NCT00820521|Placebo Comparator|placebo|
89425152|NCT04835350|Experimental|Full closed loop|Patients using AID system Pancreas4ALL in mode full closed loop. They eating with no permission and they do not calculate and sending bolus anymore.
89195867|NCT00606580|Experimental|WR 279,396 Topical Treament|WR 279,396 topical cream (15% paromomycin + 0.5% gentamicin topical cream)
89425153|NCT04840966||HOS: hospitalized COVID19 patients|Patients positive to COVID19 hospitalized
89425154|NCT04840966||HI: Home-isolated COVID19 patients|Home-isolated patients positive to COVID19
89425155|NCT04840966||CTRL: Healthy controls|Healthy COVID19 negative subjects
89425156|NCT01667926|Experimental|Ketamine|Subject will receive 6 infusions of ketamine over three weeks.
89425157|NCT01667926|Placebo Comparator|Placebo|Subjects will receive 6 infusions of normal saline over 3 weeks.
89425158|NCT03039322||HCC|
89425159|NCT03039322||liver cirrhosis No HCC|
89425160|NCT04841044|Experimental|Intervention ( Cetoleic acid)|"6x mackerel oil (cetoleic acid: 16A%, estimated: 135 mg/g (FFA)) capsules every morning for 4 weeks~(A%= area percent)"
89425161|NCT04841044|Placebo Comparator|Control oil|"6x capsules control oil (Control oil= mix of anchovy oil, olive oil, high-oleic sunflower oil, rapeseed oil (cetoleic acid: 0,7 A% estimated: 6 mg/g (FFA)) every morning for 4 weeks~(A%= area percent)"
89425162|NCT04835974|Experimental|diabetic patients with reflow phenomenon|All Assiut University heart Hospital patients ,and who meet the listed inclusion and exclusion criteria will be eligible for the study. Patients' charts will be retrieved based on their intervention procedures. The charts will be reviewed and eligible patients will be filtered. The needed variables will be entered into our data base for later data analysis.
89195868|NCT00606580|Experimental|Paromomycin Alone Topical treatment|Paromomycin Alone topical cream (15% paromomycin topical cream)
89195869|NCT00606580|Placebo Comparator|Vehicle Placebo Cream|The cream base without the addition of paromomycin or gentamicin
89425163|NCT04832464|Active Comparator|Balance Training Home plan|"The Control group is undergoing balance training only, 3 days a week, and will be for 8 weeks. Balance training includes 10minutes of warm-up and 30 minutes of balance exercises. A force plate will be used to measure the postural sways. Measurements will be taken at a base-line, after the first session, at mid-level (4th week) and at the end (8th week).~These exercises include Static Balance exercises(1-2weeks): Romberg with eyes open & close, Tandem standing with eyes open & close with alternate feet, Single leg stance.~Static/ Dynamic/ Anticipatory Postural Control (3-4weeks): Sit to Stand, FRT( forward reach test) that is forward, sideways, cross reach, and timed up and go test.~Static/ Dynamic/ Anticipatory? Reactive Postural Control (5-6weeks): Perturbations:~Controlled by the therapist in sitting & standing, Throwing a ball, kicking a ball.~(7-8weeks): Combination of All"
89425164|NCT04832464|Experimental|BRACE Protocol: Balance training along with resistance, aerobic and cognitive excercises|"BRACE protocol for balance training 3 days a week for 8 consecutive weeks on alternate days.~These exercises include Static Balance exercises(1-2weeks) plus Chair rise 30 sec without using hands, 6-minute walk, count reverse from 50, push the wall, and reverse count from 20.~Static, dynamic, anticipatory postural control (3-4weeks) plus Stair climbing without using rails, marching in space, remember 5 words, name 5 animals, repeat 5 words, spell the word like APPLE, spell backward again.~Static, dynamic, anticipatory postural control (5-6weeks) plus Squatting, cycling, count even numbers from 1-50.~calculation: Addition, subtraction, multiplication, division. (7-8weeks): Combination of all."
89425165|NCT04840732|Experimental|Experimental: Intervention|The experimental group uses the VR program to training chemotherapy skill. Use VR software to make a training education program.
88906209|NCT03909152|Experimental|PR+ Endometrioid endometrial cancer|Enrolled patients will initiate treatment with onapristone ER 50 mg by mouth twice daily, about 12 hours apart, beginning Day 1 of Cycle 1. A Cycle is 28 days
88906210|NCT03909152|Experimental|PR+ Granulosa cell ovarian cancer|Enrolled patients will initiate treatment with onapristone ER 50 mg by mouth twice daily, about 12 hours apart and anastrozole 1mg po QD in AM beginning Day 1 of Cycle 1. A Cycle is 28 days.
89425166|NCT04840732|Placebo Comparator|No Intervention: usual care|Chemotherapy training as usual care (for training chemotherapy skill).
89195870|NCT00826683|Other|Control group of healthy subjects|Control group of healthy subjects : simple blood analysis of EPCs
89195871|NCT00826683|Active Comparator|COPD|COPD: one initial blood sample and simple clinical follow-up
89195872|NCT00826683|Active Comparator|NSCLC|NSCLC: one initial blood sample and usual clinical follow-up
89195873|NCT02550327|Experimental|All Patients|"All patients will receive Nab-paclitaxel, Gemcitabine, Cisplatin, and Anakinra given on Day 1 and 8 of a 21 day cycle (two weeks on with one week rest). Anakinra will be self-administered subcutaneously corresponding with chemotherapy.~The patient will complete a total of 6 cycles of chemotherapy."
89195874|NCT00881998|Active Comparator|1|Minimally invasive total hip arthroplasty
89195875|NCT00881998|Active Comparator|2|
89195876|NCT00825045|Experimental|Treatment with risperidone|Gradual titration of risperidone according to clinical response
89425167|NCT03039478|Active Comparator|Xylitol 7g in 300mL tap water|12 volunteers receive 7g xylitol in 300mL tap water via a nasogastric tube
88906211|NCT03874169||High-Risk of GI Bleed|Patients that have a high risk of having a gastrointestinal bleed upon admission into the ICU based on their medical history and symptoms. These patients will have a biosensor watch, the E4 wristband, placed on them to monitor their vital signs.
88906212|NCT03840174|Experimental|V160|Participants will receive V160 vaccination by IM injection on Day 1, Month 2, and Month 6.
88906213|NCT03840174|Placebo Comparator|Placebo|Participants will receive placebo by IM injection on Day 1, Month 2, and Month 6.
89195877|NCT02550015|Experimental|Training|Supervised high intensity interval training (uphill treadmill walking 4 x 4 min at 90-95% of peak heart rate) 3 times weekly for 8 weeks
89425168|NCT03039478|Active Comparator|Xylitol 17g in 300mL tap water|12 volunteers receive 17g xylitol in 300mL tap water via a nasogastric tube
89425169|NCT03039478|Active Comparator|Xylitol 35g in 300mL tap water|12 volunteers receive 35g xylitol in 300mL tap water via a nasogastric tube
88906214|NCT03811873|Other|Vertebral fracture assessment|Study participants undergoing evaluation for liver transplant and deemed to early for transplant will receive standard of care bone mineral density and vertebral fracture assessment..
88906215|NCT03810898|Experimental|Phase 1 (a & b)|"Radioligand [¹¹C]CHDI-00485180-R and/or Radioligand [¹¹C]CHDI-00485626/ 6 Stage II HDGECs and 6 young (< 35) HCs/ Imaging- MRI and PET/~Both radioligands administered- 1x each/ Optional CSF collection for HDGECs"
89195878|NCT02550015|Other|standard care|Standard clinical follow-up care, including general information about importance of physical activity as part of a healthy lifestyle
89195879|NCT00826761|Active Comparator|1|High dose Lb. casei
89195880|NCT00826761|Active Comparator|2|Low dose Lb. Casei
89425170|NCT03039478|Active Comparator|Erythritol 10g in 300mL tap water|12 volunteers receive 10g erythritol in 300mL tap water via a nasogastric tube
89425171|NCT03039478|Active Comparator|Erythritol 25g in 300mL tap water|12 volunteers receive 25g erythritol in 300mL tap water via a nasogastric tube
89425172|NCT03039478|Active Comparator|Erythritol 50g in 300mL tap water|12 volunteers receive 50g erythritol in 300mL tap water via a nasogastric tube
89425173|NCT03039244|Experimental|Test Group|After Scaling and root planing, periodontal pockets will receive the antimicrobial (aPDT) photodynamic therapy. Shortly phenothiazine hydrochloride photosensitizing is applied at a concentration of 10mg/mL from the pocket bottom to the gingival margin. After 1 minute, irrigation is performed from periodontal pockets with distilled water to remove excess dye. The stained area is then irradiated with a diode laser with 660 nm of wavelength and maximum power of 60 mW/cm², through a fiber-optic probe of 0.6 mm diameter. Exposure to radiation will occur at six sites per tooth under treatment, making the total time of 1 minute per element, or the equivalent of 10 seconds per site. The aPDT applications will be repeated in the same way until the second week in the days 2, 7 and 14.
89425174|NCT03039244|Sham Comparator|Control Group|A sham procedure will be held simultaneously in pairs of contralateral teeth selected that will not receive the aPDT (control group).
89425175|NCT04832776|Experimental|FOLFOXIRI+C225|
88906216|NCT03810898|Experimental|Phase 2a|"Per Radioligand- Radioligand [¹¹C]CHDI-00485180-R or Radioligand [¹¹C]CHDI-00485626/ 6 Stage II HDGECs and 6 age matched HCs/ Imaging- MRI and PET/~1 Radioligand administered 2x (test re-test)- HDGECs/ Optional CSF collection for HDGECs~1 Radioligand administered 1x- HCs/"
89195881|NCT00826761|Placebo Comparator|3|
89425176|NCT04832776|Active Comparator|FOLFOXIRI+BEV|
89425177|NCT03039166|Experimental|parkinson|
89425178|NCT03039166|Experimental|partial epilepsy|
89425179|NCT03039166|Experimental|alzheimer disease|
88906217|NCT03810898|Experimental|Phase 2b|"Per Radioligand- Radioligand [¹¹C]CHDI-00485180-R or Radioligand [¹¹C]CHDI-00485626/ 6 Stage I HDGECs and 6 age matched HCs/ Imaging- MRI and PET/~1 Radioligand 1 or 2x administered (test re-test optional)- HDGECs/ Optional CSF collection for HDGECs~1 Radioligand administered 1x -HCs/"
89425180|NCT03039166|Experimental|multiple sclerosis|
89425181|NCT03039166|Experimental|amyotrophic lateral sclerosis|
88906218|NCT03810898|Experimental|Phase 2c|"Per Radioligand- Radioligand [¹¹C]CHDI-00485180-R or Radioligand [¹¹C]CHDI-00485626/ 6 Pre-manifest HDGECs and 6 age matched HCs/ Imaging- MRI and PET/~1 Radioligand administered 1 or 2x (test re-test optional)- HDGECs/ Optional CSF collection for HDGECs~1 Radioligand administered 1x- HCs/"
88906219|NCT03808766|Other|Tumor <=3cm|Embolization with particulate or liquid embolic agent
89425182|NCT03039166|Active Comparator|healthy control patients|
88906220|NCT03808766|Other|Tumor >3cm to 7cm|Embolization with particulate or liquid embolic agent
88906221|NCT03808766|Other|Tumor > 7cm|Embolization with particulate or liquid embolic agent
88906222|NCT03789721||Adrenoleukodystrophy|All patients living in the United States diagnosed with adrenoleukodystrophy, either by newborn screen, based on family history or otherwise, are eligible to participate in this study.
88906223|NCT03786718|Experimental|Intervention|Patients have access to a patient web portal with the Patient-facing Diabetes Dashboard activated.
88906224|NCT03776864|Experimental|Treatment (pembrolizumab, umbralisib)|Patients receive pembrolizumab IV on day 1. Treatment repeats every 21 for up to 16 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive umbralisib PO daily on days 1-21 days. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
88906225|NCT03773575|Experimental|Prevena|PREVENA™ PEEL & PLACE™ Dressing Kit
88906226|NCT03773575|No Intervention|Standard Care|sterile gauze dressing supplemented with an Ace wrap
89425183|NCT03038932||Discovery Cohort|"A minimum of 50 recurrent Atopic Dermatitis with a history of Eczema Herpeticum(ADEH+), 500 Atopic Dermatitis without a history of Eczema Herpeticum (ADEH-), and 237 Non-Atopic (NA) European American participants from the Atopic Dermatitis Research Network (ADRN) DNA Repository.~The study will learn from this cohort:~All Single Nucleotide Variants (SNVs) in ADEH+~ADEH+ specific deleterious SNVs~The study will determine the function of:~4. ADEH+ risk variants"
89425184|NCT03038932||Independent populations of participants|"Two independent populations of participants:~Children, aged 3-17 years and~Adults 18-64 years of age.~A minimum of 12 recurrent Atopic Dermatitis with a history of Eczema Herpeticum (ADEH+) with ≥3 Eczema Herpeticum (EH) episodes, 12 Atopic Dermatitis without a history of Eczema Herpeticum (ADEH-) and 12 Non-Atopic (NA) participants will be enrolled in each of the two populations."
89425185|NCT04835116|Other|Local Anesthesia|Group A patients received peri tract local anaesthesia infiltration with 0.25% Bupivacaine.
89425186|NCT04835116|Other|Intravenous Analgesics|Group B patients received postoperative intravenous analgesia.
89425187|NCT04824976|Active Comparator|Blueberry|Freeze-dried pure blueberry powder
89425188|NCT04824976|Placebo Comparator|Placebo|Maltodextrin powder.
89007240|NCT05445583|Experimental|Motivational Enhancement System (MES) and Physical Activity Tracking (PAT)|MES is a web-based, mobile asthma management intervention delivered to participants' personal mobile devices. There are 4 sessions, completed over 10 weeks, with each session taking approximately 15-20 minutes. During Session 1, participants will identify asthma-related problems they may encounter and will receive asthma information and motivation. Between Session 1 and Session 2, participants will be asked to complete an electronic daily diary for 7 days. Session 2 allows participants to select up to 2 goals to address. Session 3 occurs over the course of 4 weeks and provides tailored messages based on problem and goal selection. The final session (Session 4), asks participants for feedback on how well they feel they accomplished their goal. Additionally, participants will be asked to track their daily and weekly step totals as well their total minutes of moderate to vigorous physical activity using a wearable activity tracker provided by the study.
89425189|NCT03036826||Piperacillin/Tazobactam|Group of patients receiving Piperacillin/Tazobactam as antiinfective therapy
89425190|NCT03036826||Meropenem|Group of patients receiving Meropenem as antiinfective therapy
89425191|NCT03036982||Use of Mobile ACT|Will answer ACT (or cACT) and other asthma questions using mobile app
89425192|NCT04832308|Experimental|SVS SET Program|Participants enroll in SVS Program which includes 1) educational information on PAD, exercise and nutrition, 2) weekly health coaching, and 3) walking therapy prescription.
89007241|NCT05445583|Experimental|Supportive Accountability (SA) and PAT|SA is an asthma management intervention delivered by asthma nurses trained in targeted MI skills (e.g., open-ended questions around change talk, affirmations) via participants' personal mobile devices (e.g., Skype, FaceTime, voice calls, and SMS). Sessions with the nurse will be approximately 15-20 minutes in length and will focus on ways to improve asthma care. There are 4 sessions with the nurse, over the course of 10 weeks. Additionally, participants will be asked to track their daily and weekly step totals as well their total minutes of moderate to vigorous physical activity using a wearable activity tracker provided by the study.
89007242|NCT05445583|Experimental|Text Messaging (SMS) and PAT|SMS will target asthma knowledge. One-way SMS messages will be sent to participants' personal mobile devices with facts about asthma management, links to educational web content, and videos providing information about living with asthma. Text messages will be sent twice a week for the first 5 weeks and once a week for the last 5 weeks. Additionally, participants will be asked to track their daily and weekly step totals as well their total minutes of moderate to vigorous physical activity using a wearable activity tracker provided by the study.
89007243|NCT05445583|Experimental|MES_SMS_PAT|Participants will receive a combination of the MES and SMS interventions. Additionally, participants will be asked to track their daily and weekly step totals as well their total minutes of moderate to vigorous physical activity using a wearable activity tracker provided by the study.
89007244|NCT05445583|Experimental|SA_SMS_PAT|Participants will receive a combination of the SA and SMS interventions. Additionally, participants will be asked to track their daily and weekly step totals as well their total minutes of moderate to vigorous physical activity using a wearable activity tracker provided by the study.
89007245|NCT05445583|No Intervention|Usual Care_PAT|Participants will continue to receive standard clinical asthma care. Additionally, participants will be asked to track their daily and weekly step totals as well their total minutes of moderate to vigorous physical activity using a wearable activity tracker provided by the study.
89007246|NCT05439772|No Intervention|Control|Pediatric patients between the ages of 2-20 who have a clinical indication for colonoscopy, who will undergo standard colonoscopy preparation of polyethylene glycol and bisacodyl
89195882|NCT00820677|Experimental|DVD/Video|Parents of newborns in the experimental group attending their first baby visit will be shown a video about newborn care.
89425193|NCT04832308|No Intervention|Usual Care|This usual care arm will allow sites to direct patients as they usually do. This could include an in-person exercise therapy program or simply exercise instruction during an office visit.
89425194|NCT02604160|Experimental|LY3113593|Escalating doses of LY3113593 administered by intravenous (IV) infusion once every 4 weeks (Q4W) on (Day 1 and 29) in part A.
89425195|NCT02604160|Placebo Comparator|Placebo|0.9% saline, administered by intravenous (IV) infusion once Q4W (Day 1 and 29) in part A.
89425196|NCT03036046|Experimental|F901318 with fluconazole low dose|safety assessment
89425197|NCT03036046|Experimental|F901318 with fluconazole high dose|safety assessment
89425198|NCT03036046|Experimental|F901318 with posaconazole|safety assessment
89425199|NCT04831528||No secondary changes of drug resistance|
89425200|NCT04831528||Secondary mutations of RAS|
89425201|NCT04831528||Secondary mutation of BRAF|
89425202|NCT04831528||HER2 amplification|
89425203|NCT04831528||Other secondary mutations|
89425204|NCT04834804|Experimental|Suspension training group|
89425205|NCT04834804|Experimental|Free weight training group|
89425206|NCT04834804|No Intervention|Control group|
89425207|NCT04824586|Experimental|Insulin infusion regimen|"Adult type II diabetic patients, who were admitted to hospital for cardiac surgery. These group received their dose of insulin; Insulin infusion regimen.~Fast-acting human insulin (Actrapid®) was used in this group."
89425208|NCT04824586|Experimental|Insulin bolus regimen|"Adult type II diabetic patients, who were admitted to hospital for cardiac surgery. These group received their dose of insulin; Insulin bolus regimen.~Fast-acting human insulin (Actrapid®) was used in this group."
89425209|NCT04834570||Breast Cancer Survivors|Women who have survived breast cancer for at least 1 year (12 months) and 2 years (24 months) after the end of primary treatment
89425210|NCT04825054|Experimental|A 60-min trial ventilated with NAVA|Patients underwent surgical repair of right ventricular hypertrophic congenital heart disease. Each patient will undergo three 60-min trials with 30-min wash out during the study period in randomized order. The cardiac output and volume status will be evaluated by a transpulmonary thermodilution device through a pulse contour cardiac output (PiCCO) catheter at the last 10min of each trial. At the mean while an arterial blood gas and echocardiography will perform.
89425211|NCT04825054|Experimental|A 60-min trial ventilated with PCV|Patients underwent surgical repair of right ventricular hypertrophic congenital heart disease. Each patient will undergo three 60-min trials with 30-min wash out during the study period in randomized order. The cardiac output and volume status will be evaluated by a transpulmonary thermodilution device through a pulse contour cardiac output (PiCCO) catheter at the last 10min of each trial. At the mean while an arterial blood gas and echocardiography will perform.
89425212|NCT04825054|Experimental|A 60-min trial ventilated with PSV|Patients underwent surgical repair of right ventricular hypertrophic congenital heart disease. Each patient will undergo three 60-min trials with 30-min wash out during the study period in randomized order. The cardiac output and volume status will be evaluated by a transpulmonary thermodilution device through a pulse contour cardiac output (PiCCO) catheter at the last 10min of each trial. At the mean while an arterial blood gas and echocardiography will perform.
89425213|NCT04824742|Experimental|neoadjuvant PDT + radical surgery|Photodynamic therapy for neoadjuvant treatment of cholangiocarcinoma
89425214|NCT04824742|Active Comparator|radical surgery|Patients with cholangiocarcinoma undergo radical surgical resection
89425215|NCT04824898|Experimental|simvastatin 1.2%gel|simvastatin 1.2%gel applied after open flap debridment in group I
89425216|NCT04824898|Experimental|I-prf|Injectable plasma rich fibrin will be collected from each patient in group II and the applied after open flap debridment
89425217|NCT04824352|Experimental|apatinib+IE|Apatinib: 500 mg QD po (BSA ≥ 1.0) or 250 mg QD po (BSA < 1.0); IE: ifosfamide 1.8 g/m2/d d1-3; etoposide 100 mg/m2/d d1-3 Q2w
89425218|NCT04325620|Experimental|HIP1601 Amg|The participants will receive tretment of HIP1601 Amg, orally, once daily for 4weeks.
88906227|NCT03762759|Experimental|Arm I (fluciclovine F18, PET/CT)|Patients receive fluciclovine F18 IV and undergo positron emission tomography (PET)/computed tomography (CT) over 30 minutes.
89425219|NCT04325620|Placebo Comparator|HGP1805|The participants will receive tretment of HGP1805(Placebo of HIP1601), orally, once daily for 4weeks.
88906228|NCT03762759|Active Comparator|Arm II (68Ga-PSMA, PET/CT)|Patients receive gallium Ga68-labeled PSMA-11 IV, wait 60 minutes, then undergo positron emission tomography (PET)/computed tomography (CT) over 30 minutes.
88906229|NCT03675412|Active Comparator|Glaucoma Patients|Eligible participants include patients with mild, moderate or advanced primary open angle glaucoma (POAG) or primary angle closure glaucoma (PACG). Each participant will complete baseline study tasks. Each participant will then receive one 200 mg caffeine tablet to ingest. Study tasks will be performed 1 hour and 2 hours after caffeine ingestion.
88906230|NCT03675412|Active Comparator|Healthy controls|Eligible participants include healthy subjects with no eye diseases. Each participant will complete baseline study tasks. Each participant will then receive one 200 mg caffeine tablet to ingest. Study tasks will be performed 1 hour and 2 hours after caffeine ingestion.
89425220|NCT04824196|Experimental|vestibular visual cues therapy|Pelvic rolling to right and left with head movement and stop first on right side for 3 minutes. Do this exercise in front of the mirror.Anterior, posterior, left, and right rectilinear stimulation activities on a therapeutic ball. Anterior, posterior, left and right rectilinear movements were performed for five minutes
89425221|NCT04824196|Active Comparator|propriocetion therapy|"Alternate knee flexion-extension with extended trunk posture using both hands for support.~Hip and knee flexion-extension with swiss ball between the back and wall.~Hip aises lying with their back on the floor with both legs on the swiss ball. Upper limbs leaning on the floor to help with the exercises.~then perform all exercise on gym ball"
89425222|NCT04319614|Experimental|Tranexamic acid|
89425223|NCT04319614|Placebo Comparator|Saline|
89425224|NCT04314856|Experimental|Fragile X Syndrome|"Adult males aged 18-30 years diagnosed with FXS will undergo a PET/MRI scan using 18F-FTC-146 to determine sigma-1 receptor density.~These participants will only be administered once with 18F-FTC-146."
88906231|NCT03672877|Experimental|Immediate training group|Children will participate in intensive exercise intervention for 3 months and will be followed for 9 months following the intervention
88906232|NCT03672877|No Intervention|Delay training group|Children will be assessed for 6 months with no intervention. After the 6 month period children will be given the same intervention as the immediate group and followed for 3 months after the intervention.
88906233|NCT03664180|Experimental|anticoagulation|
88906234|NCT03664180|Placebo Comparator|No anticoagulation|
88906235|NCT03662841|Other|ACE for HCC of size >10cm|Ablative chemoembolization (ACE) using Lipiodol-ethanol and anhydrous cisplatin
88906236|NCT03652870|Active Comparator|Nortriptyline|25mg tablet to be escalated from one tablet per day to a maximum of 4 tablets per day
88906237|NCT03652870|Active Comparator|Escitalopram|5mg tablet to be escalated from one tablet per day to a maximum of 4 tablets per day
89425225|NCT04314856|Experimental|Healthy Volunteers (Control)|"Adults aged 18-65 years undergo a PET/MRI scan using 18F-FTC-146 to determine sigma-1 receptor density.~Test-retest studies will be performed where these individuals will each be injected twice with 18F-FTC-146."
89425226|NCT03037060|Experimental|Experimental|"5 experimental sessions per participant:~(1) [11C]-(+)-PHNO PET scan, (2), Alcohol Self-Administration, (3) Craving Task, (4) MRI scan and (5) Neuropsychological Assessment."
89425227|NCT04823728||Autoimmune encephalitis and paraneoplastic neurological syndromes|Patients with well-characterized antibodies against onconeural antigens, synaptic or cell-surface antigens
89425228|NCT04834180|Sham Comparator|Vaccaria seeds plus diet therapy|Vaccaria seeds at the exterior side of the ear area, standard points were selected according to clinical experience in traditional Chinese medicine: Shenmen (TF4), Stomach (CO4), Hunger, Mouth (CO1), Point Zero HX1) and Sanjiao (CO17). Mustard seeds (Vaccaria ear seeds, Beijing Zhongyan Taihe Medicine, Beijing, China) were used, plus diet therapy prescribed by a licensed nutritionist.
89425229|NCT04834180|Active Comparator|ASP needles plus diet therapy|ASP needles on the outside of the ear standard points were selected according to clinical experience in traditional Chinese medicine: ASP gold needles, strengthening the centre with point 0 (the umbilicus) in the dominant ear, Porta Fortunae in the non-dominant ear, Barbiturate in the non-dominant ear, Psychosomatique key point in the dominant ear and the point Aggression, plus diet therapy prescribed by a licensed nutritionist.
89425230|NCT04834180|No Intervention|only diet therapy|only diet therapy prescribed by a licensed nutritionist.
89425231|NCT01359904|Active Comparator|high dialysate bath|additive is put in the dialysate to increase the concentration of glucose to 10mmol/l
89425232|NCT01359904|No Intervention|Standard dialysate glucose concentration|Standard 5.5 mmol/L dialysate glucose concentration.
88906238|NCT03652870|Placebo Comparator|Placebo|The placebo tablet consists of lactose and magnesium stearate. One tablet to be escalated from one tablet per day to a maximum of 4 tablets per day
89425233|NCT04834258|Experimental|Walking and respiratory muscle training group|"Walking and respiratory muscle training group (W+ RMT) received walking training in addition to respiratory muscle training for a period of 8 weeks.~Walking training was performed at least 5 days a week, twice a day, for 15 min. Walking distance was calculated according to patients' 6 minute walking distance.~Respiratory muscle training was performed using the threshold loading method as inspiratory and expiratory muscle training. This training was applied at least 5 days per week, twice a day, 15 minutes each session. (15 minutes inspiratory muscle training + 15 minutes expiratory muscle training). A Threshold Inspiratory Muscle Trainer (IMT) and threshold positive expiratory pressure (Threshold PEP) were used for the training.~Patients were called for the hospital once a week to asses mouth pressure and 6 minute walking test (6 MWT) and their training intensity was arranged."
88906241|NCT03635060|Active Comparator|Dorsal Bridge Plating|The intervention is surgery with dorsal distraction plating with or without any additional fragment specific fixation.
88906242|NCT03635060|Active Comparator|Volar Locking Plating|The intervention is surgery with open reduction and internal fixation with non-spanning fixation.
88906243|NCT03634852|Active Comparator|Topical|Moxifloxacin hydrochloride 0.5% eye drops and dexamethasone 0.1% eye drops were prescribed four times a day for 1 month postoperatively.
88906244|NCT03634852|Active Comparator|Intracameral - Subconjunctival|Intracameral Moxifloxacin 0.1% with Subconjunctival Triamcinolone acetonide 4 mg /0.4 ml had been administered at the conclusion of the surgery
88906245|NCT03612193||Study A: Chronic >1 year|
88906246|NCT03612193||Study A: Acute <1 year|
89007247|NCT05439772|Experimental|Ondansetron|Pediatric patients between the ages of 2-20 who have a clinical indication for colonoscopy, who will undergo standard colonoscopy preparation of polyethylene glycol and bisacodyl with the addition of one dose of ondansetron prior to initiating bowel preparation.
88906247|NCT03612193||Study A: Household Control|
88906248|NCT03612193||Study B: Newly Diagnosed <6 months|
88906249|NCT03612193||Study B: Household Controls|
88906250|NCT03593811|Active Comparator|Healthy Controls|Healthy Volunteers with no known gastrointestinal complications will be given questionnaires and testing by electrogastrogram (EGG) and/or magnetogastrogram (MGG) after an overnight fast to determine nausea parameters. They will also have a electrocardiogram (EKG) and do some testing after being fed a protein bar.
89007248|NCT05432271|Active Comparator|Control|Calorie labels shown on front of product packaging
89425234|NCT04834258|Active Comparator|Respiratory muscle training group|In the Respiratory muscle training group (RMT), Respiratory muscle training was performed using the threshold loading method as inspiratory and expiratory muscle training. This training was applied at least 5 days per week, twice a day, 15 minutes each session. (15 minutes inspiratory muscle training + 15 minutes expiratory muscle training). A Threshold Inspiratory Muscle Trainer (IMT) and threshold positive expiratory pressure (Threshold PEP) were used for the training. Patients were called for the hospital once a week to asses mouth pressure and their training intensity was arranged
89425235|NCT04823572|Active Comparator|A-PRF Advanced Platelet-Rich Fibrin|Comparing healing effect of an autologous product with open flap debridement.
89007249|NCT05432271|Experimental|Green labels|"Green label added to front of product packaging for healthy products; no additional labels shown for less healthy products"
89007250|NCT05432271|Experimental|Traffic light labels|Red/yellow/green labels added to front of product packaging for less healthy/moderately healthy/healthy products, respectively
89425236|NCT04823572|Active Comparator|OFD Open Flap Debridement|Comparing healing effect of an autologous product with open flap debridement.
89425237|NCT04823416|Active Comparator|Stoma|
89425238|NCT04823416|Active Comparator|Resection and stoma|
89536109|NCT03201991|Other|Exercise Program|Participants will be asked to take part in an exercise program that is focused on quadriceps strengthening.
89007251|NCT05432271|Experimental|Physical activity calorie equivalent labels|Labels added to front of product packaging that display products' calorie content in terms of physical activity required to burn those calories
88820308|NCT06190418|Active Comparator|Loaded sit to stand strengthening exercise group|This group will be provided with loaded sit to stand strengthening exercises in spastic diplegic children.1 repetition maximum of the load will be provided. Exercise will be conducted 3 times a week for 6 weeks, pre and post session functional strength of lower limb will be measured by performing functional strength tests and physiological cost index will be measured to calculate energy expenditure.
89425239|NCT04816318||Social and public health measures against COVID-19|Public Health and Social measures against COVID-19. This group refers to the population exposed to public health and social measures against COVID-19
88906251|NCT03593811|Active Comparator|Non-nauseated|Functional nausea patients with a score of 0-2 on the BARF (BAxter Retching Faces) scale will be given questionnaires and testing by EGG and/or MGG after an overnight fast to determine nausea parameters. They will also have a EKG and do some testing after being fed a protein bar.
88906252|NCT03593811|Active Comparator|Mildly nauseated|Functional nausea patients with a score of 3-4 on the BARF (BAxter Retching Faces) scale will be given questionnaires and testing by EGG and/or MGG after an overnight fast to determine nausea parameters. They will also have a EKG and do some testing after being fed a protein bar.
88906253|NCT03593811|Active Comparator|Moderately nauseated|Functional nausea patients with a score of 5-6 on the BARF (BAxter Retching Faces) scale will be given questionnaires and testing by EGG and/or MGG after an overnight fast to determine nausea parameters. They will also have a EKG and do some testing after being fed a protein bar.
88906254|NCT03593811|Active Comparator|Severely nauseated|Functional nausea patients with a score of 7-9 on the BARF (BAxter Retching Faces) scale will be given questionnaires and testing by EGG and/or MGG after an overnight fast to determine nausea parameters. They will also have a EKG and do some testing after being fed a protein bar. Some patients will also be tested after receiving a one time dose of a 4mg or 8mg dependent upon age disintegrating tablet of ondansetron followed by a 2 day washout period prior to testing again after a 5 day maintenance dose of oral cyproheptadine 4mg twice a day.
88906255|NCT03560453|No Intervention|Control|Attend assigned high school for 9 months
88906256|NCT03560453|Experimental|Project SEARCH plus ASD Supports|Attend Project SEARCH plus ASD Supports for 9 months
88906257|NCT03552575|Experimental|Sacubitril/valsartan|24mg/26mg (dose level 1), 49mg/51mg (dose level 2) and 97mg/103mg (dose level 3) twice daily
88906258|NCT03552575|Experimental|Valsartan|40mg (dose level 1), 80mg (dose level 2) and 160mg (dose level 3) twice daily.
88906259|NCT03535623|Experimental|RIPC|Remote ischemic preconditioning (RIPC) consisted of 4 cycles of 5-min ischemia using pneumatic cuff pressure of 200 mmHg and 5-min reperfusion is applied to the upper arm of the patients in the RIPC group.
88906260|NCT03535623|Sham Comparator|Sham-RIPC|Sham-RIPC consisted of 4 cycles of 5-min ischemia using pneumatic cuff pressure of < 10 mmHg and 5-min reperfusion is applied to the upper arm of the patients in the Sham-RIPC group.
88906261|NCT03528902|Experimental|Tamoxifen|20 mg po TID for 24 weeks
89425240|NCT04816318||Control|The comparator is the pre-intervention period
89425241|NCT04823182||Cases|Cases - Recent COVID-19 infection ≥ 6 weeks and ≤ 12 months before enrolment, as evidenced by positive reverse-transcriptase polymerase chain reaction (RT-PCR) SARS-CoV-2 swab
89425242|NCT04823260|Active Comparator|Arm A = 300 mg NMN supplement (n = 20)|Subjects who are assigned to 300 mg arm (NMN) will be instructed to take 2 capsules after breakfast once a day with ambient temperature water for 60 days.
89425243|NCT04823260|Placebo Comparator|Arm B = Placebo 300 mg (n=07)|Subjects who are assigned to 300 mg arm (placebo) will be instructed to take 2 capsules after breakfast once a day with ambient temperature water for 60 days.
89425244|NCT04823260|Active Comparator|Arm C = NMN Supplement 600 mg (n= 20)|Subjects who are assigned to 600 mg arm (NMN) will be instructed to take 4 capsules after breakfast once a day with ambient temperature water for 60 days.
89425245|NCT04823260|Placebo Comparator|Arm D = Placebo 600 mg (n=07)|Subjects who are assigned to 600 mg arm (Placebo) will be instructed to take 4 capsules after breakfast once a day with ambient temperature water for 60 days.
89536110|NCT03071679|Experimental|Omiganan|
88906262|NCT03528902|Placebo Comparator|Placebo|Placebo arm
88906263|NCT03522714|Active Comparator|Fluid Immersion Simulation System (FIS)|Pressure ulcer patients are assigned to Fluid Immersion Simulation System (Dolphin) after operative debridement and closure.
88906264|NCT03522714|Active Comparator|Air Fluidized Bed System (AFB)|Pressure ulcer patients are assigned to Air Fluidized Bed (Clinitron) after operative debridement and closure
88906265|NCT03511339|No Intervention|Control|Brain rest
88906266|NCT03511339|Experimental|TecTraum Device|Treatment with study device
88906267|NCT03463408|Experimental|Immunotherapy arm|"Cohort A will comprise adult soft tissue sarcoma patents who consent to and receive ipilimumab + nivolumab concurrently with standard of care radiation. Ipilimumab will be given at a dose of 1 mg/kg every 6 weeks (total two doses) and nivolumab given as a flat dose of 240 mg every 2 weeks (total four doses).~Standard surgical resection will be done 2 to 4 weeks after completion of radiotherapy. Accrual is expected to occur over 2 years. Follow up data will be collected for up to 3 years post-treatment."
88906268|NCT03463408|No Intervention|no immunotherapy arm|"Cohort B will comprise patients eligible for the trial who do not wish to receive immunotherapy but consent to the same blood draws, surveys, and specimen analysis as Cohort A. Cohort B will serve as a non-randomized but pragmatic and clinically relevant control group.~Standard surgical resection will be done 2 to 4 weeks after completion of radiotherapy. Accrual is expected to occur over 2 years. Follow up data will be collected for up to 3 years post-treatment."
89425246|NCT04823260|Active Comparator|Arm E = NMN Supplement 900 mg (n=10)|Subjects who are assigned to 900 mg arm (NMN) will be instructed to take 6 capsules after breakfast once a day with ambient temperature water for 60 days.
89425247|NCT04823260|Placebo Comparator|Arm F = Placebo 900 mg (n=06)|Subjects who are assigned to 900 mg arm (Placebo) will be instructed to take 6 capsules after breakfast once a day with ambient temperature water for 60 days.
89425248|NCT04823338|Experimental|Conectar Jugando Online Program|The program consisted of 12 one-hour intervention sessions. The sessions were biweekly with a total duration of 6 weeks. The modern board and card games used in the program were Bee Alert (Knizia, 2012), Monster Match (Gruhl & Weir, 2018), Sherlock Express (Kermarrec, 2019), Streams (Itsubaki, 2011) and Blurble (Bernard, 2013). The play sessions were carried out in groups of between 2 and 4 boys and girls of similar ages (same school stage) formed according to the availability of the participants. In the sessions, the physical games were projected on the videoconference tool by the researcher and the participating boys and girls carried out their actions using their voice and the platform tools. The program was gamified though a narrative about a space travel to different planets in discovering new games and get different mission badges and super team badges in their logbook.
89425249|NCT04823338|No Intervention|Wait-list group|Wait-list
89425250|NCT04816240|Experimental|Midodrine + Albumin +Standard Medical Treatment|SMT + Albumin + Midodrine (5mg thrice daily and will be increased every 3 days upto 15 mg thrice daily with target MAP (>75 mm and <90).
89425251|NCT04816240|Active Comparator|Albumin + Standard Medical Treatment+ Placebo|80grams/week for 2 weeks followed by 40gram/week + Placebo
89425252|NCT03986944|Experimental|Linzagolix 75 mg|
89425253|NCT03986944|Experimental|Linzagolix 200 mg + Add-back (E2 1 mg / NETA 0.5 mg)|
89425254|NCT03986944|Placebo Comparator|Placebo|
89425255|NCT04822792||Cancer Arm|Participants with new diagnosis of cancer, from whom blood samples will be collected
89425256|NCT04822792||Benign Diseases Arm|Participants with benign diseases corresponding to the tumor types in the Cancer Arm, from whom blood samples will be collected
89425257|NCT04822792||Healthy Arm|Participants without known presence of malignancies or benign disease, from whom blood samples will be collected
89425258|NCT04816084|Experimental|Population|Voluntary people over 18 from the staff of the University of Reims Champagne Ardenne
88906269|NCT03462238|Other|Kidney transplant patients|Group of renal transplant patients for 24 months
88906270|NCT03462238|Other|Dialysis patients|Group of dialysis patients for 24 months
88906271|NCT03420144|Active Comparator|Standard Medical Therapy|Standard medical therapy: diuretics, lactulose, rifaximin, diuretics, albumin infusion, nutritional support (as required)
88906272|NCT03420144|Active Comparator|Growth hormone|Growth Hormone: GH therapy is initiated at a low dose of 1U/day and titrated slowly upward to a maximum dose of 3U/day (based on IGF-1 levels) subcutaneously for 1 year.
88906273|NCT03415425|Active Comparator|Usual Care|The current version of the alert will fire for this arm of the study.
89425259|NCT04822558|Other|Ankle and hindfoot reconstruction surgery|Patients who underwent an ankle- or hindfoot reconstruction surgery
88906274|NCT03415425|Active Comparator|Alert Iteration|A modified version of the alert will fire for this arm of the study.
88906275|NCT03409744|Experimental|evinacumab|
88906276|NCT03408314|Experimental|PediQUEST Response|"Weekly PediQUEST surveys are automatically assigned to parents and children (if 5 years old or older) and sent 48 hours prior to participant's usual clinic day~Once a PediQUEST survey is assigned, automated email reminders/app notifications are sent daily for two days~After 48 hours, unanswered or incomplete surveys are auto-submitted~PQ-feedback report generated automatically after a PQ Survey is answered~A pdf of the report is automatically emailed/available on mobile App to designated recipients~Will also receive oncology-PC integrated care through the Response team~Duration of follow-up: 18 weeks (2-week run-in period, followed by a 16-week post-randomization follow-up)"
88906277|NCT03408314|Other|Usual Cancer Care|"Will receive the usual cancer care provided at the participating sites~Will complete weekly PQ-Surveys (no feedback reports will be generated)~Can receive regular palliative care consultations following the site's usual referral procedures~Same follow-up (18 weeks)"
88906278|NCT03400943|Experimental|Vilaprisan (A1)|Vilaprisan (2 mg) in treatment period 1 for 12 weeks and in treatment period 2 for 12 weeks, separated by 1 bleeding episode.
88906279|NCT03400943|Experimental|Vilaprisan (A2)|Vilaprisan (2 mg) in treatment period 1 for 12 weeks and in treatment period 2 for 12 weeks without a break.
88906280|NCT03400943|Experimental|Placebo+Vilaprisan (B1)|Placebo in treatment period 1 for 12 weeks, and vilaprisan (2 mg) in treatment period 2 for 12 weeks, separated by 1 bleeding episode.
88906281|NCT03400943|Experimental|Vilaprisan+Placebo (B2)|Vilaprisan (2 mg) in treatment period 1 for 12 weeks and placebo in treatment period 2 for 12 weeks, separated by 1 bleeding episode.
89425260|NCT04815460|Experimental|High intensity-interval training (HIIT)|Subjects performed HIIT (3-min intervals at 40% and 80%VO2peak) on a bicycle ergometer for 30 min/day, 5 days/week for 6 weeks.
89425261|NCT04815460|Experimental|Ｍoderate intensity-continuous (MCT)|Subjects performed MICT (sustained 60%VO 2max) on a bicycle ergometer for 30 min/day, 5 days/week for 6 weeks.
89425262|NCT04815460|No Intervention|Control group|Without any exercise training
88906282|NCT03384784|Experimental|Galantamine|"This study follows the FDA-recommended dosing regimen for galantamine extended release (GAL ER): 4 weeks at 8 mg (once a day), 4 weeks at 16 mg (once a day), and 4 weeks at 24 mg (once a day).~The University of Pennsylvania Investigational Drug Service (IDS) will oversee the randomization of all study medication, purchase study medication, manufacture matched placebo, encapsulate and package them in blister packs to maintain double-blind procedures."
89425263|NCT04815538||industrial workers|Active workers more than 1 year in petrochemical plant, fertilizer factory , electrical station and food industry
89425264|NCT04815538||control group|office work unexposed
89536111|NCT03071679|Experimental|Imiquimod|
89536112|NCT03071679|Experimental|Omiganan 1% and Imiquimod|
89007252|NCT05432271|Experimental|"High in nutrient warning labels"|Labels added to front of product packaging that signal when the product exceeds thresholds for sugar, sodium, saturated fat, or calorie content
89007253|NCT05423691|Experimental|Arm 1|CK0804 will be administered intravenously (IV) 100 million Treg Cells every 28 days up to 6 infusions.
89007254|NCT05418673|Experimental|BIIB122 225 mg|Participants will receive 225 mg of BIIB122 tablets, orally, once daily (QD) for up to 180 weeks.
89007255|NCT05418673|Placebo Comparator|BIIB122-Matching Placebo|Participants will receive BIIB122-matching placebo tablets, orally, QD for up to 180 weeks.
89007256|NCT05417763||Pressure Microcatheter-First|Per the result of prior randomization, physiological assessment to the enrolled patient will be performed by the TruePhysio pressure microcatheter system ahead of the Pressure Wire system.
89007257|NCT05417763||Pressure Wire-First|Per the result of prior randomization, physiological assessment to the enrolled patient will be performed by the Pressure Wire system ahead of the TruePhysio pressure microcatheter system, per the result of prior randomization.
89007258|NCT05417022||Diamondback 360TM orbital atherectomy system|
89007259|NCT05414175|Experimental|Mavacamten|
89007260|NCT05407064|Placebo Comparator|Arm 1- Placebo|A substance that is designed to have no therapeutic value.
89007261|NCT05407064|Experimental|Arm 2- 25 μg MM-120 (LSD D-Tartrate)|A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A).
89007262|NCT05407064|Experimental|Arm 3- 50 μg MM-120 (LSD D-Tartrate)|A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A).
89007263|NCT05407064|Experimental|Arm 4- 100 μg MM-120 (LSD D-Tartrate)|A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A).
89007264|NCT05407064|Experimental|Arm 5- 200 μg MM-120 (LSD D-Tartrate)|A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A).
89007265|NCT05402111|Experimental|SEP-363856|
89007266|NCT05402111|Active Comparator|Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole)|
89007267|NCT05378620|Other|Project Dulce + Dulce Digital|Patients will participate in a peer-led group diabetes self-management education and support program and receive ongoing support via text messages designed to improve knowledge, health beliefs, self-management behaviors and clinical outcomes.
89007268|NCT05376891||Advanced Non-small Cell Lung Cancer with METex14 skipping alterations|Participants diagnosed with advanced NSCLC and who receive available therapies in routine clinical practice setting will be part of this registry. Data will be collected routinely from the point of enrollment of a participants into the registry until death, loss to follow-up (drop-out), subsequent enrollment into a clinical trial, or end of data collection period for the registry.
89007269|NCT05362292|Active Comparator|Anticholinergic bladder medication plus behavioral self-management education|Tolterodine tartrate is a muscarinic receptor antagonist designed to treat urgency incontinence, urgency, and frequency associated with overactive bladder. Behavioral self-management education includes written education about timed urination, lifestyle changes, pelvic floor muscle exercises, and urge suppression.
89007270|NCT05362292|Active Comparator|Beta-3-adrenergic agonist medication plus behavioral self-management education|Mirabegron, currently sold under the brand name Mybetriq by Astellas Pharma, is a selective beta-3-adrenergic receptor agonist approved for treatment of urgency urinary incontinence, urgency, and frequency associated with overactive bladder. Behavioral self-management education includes written education about timed urination, lifestyle changes, pelvic floor muscle exercises, and urge suppression.
89007271|NCT05362292|Placebo Comparator|Placebo medication plus behavioral self-management education|Microcrystalline cellulose placebo encapsulated to appear identical to tolterodine and mirabegron medication will be prepared by a compounding pharmacy. Behavioral self-management education includes written education about timed urination, lifestyle changes, pelvic floor muscle exercises, and urge suppression.
89007272|NCT05360238|Experimental|Phase 1: Patients with aggressive B-cell NHL including, but not limited to, DLBCL and MCL.|MB-106, single intravenous infusion up to 3.3 x 10e7 chimeric antigen receptor t-cells (CAR-T cells)/kg
89007273|NCT05360238|Experimental|Phase 1: Patients with indolent NHL including, but not limited to, FL.|MB-106, single intravenous infusion up to 3.3 x 10e7 CAR-T cells/kg
89007274|NCT05360238|Experimental|Phase 1: Patients with CLL/small lymphocytic lymphoma (SLL).|MB-106, single intravenous infusion up to 3.3 x 10e7 CAR-T cells/kg
89007275|NCT05360238|Experimental|Phase 2: Patients with relapsed or refractory DLBCL|MB-106, single intravenous infusion. Dose based upon outcome Phase 1.
89007276|NCT05360238|Experimental|Phase 2: Relapsed or refractory FL|MB-106, single intravenous infusion. Dose based upon outcome Phase 1.
89007277|NCT05360238|Experimental|Phase 2: Basket - Relapsed or refractory B-cell NHL subtypes|MB-106, single intravenous infusion. Dose based upon outcome Phase 1.
89007278|NCT05360238|Experimental|Phase 2: Relapsed or refractory CLL/SLL|MB-106, single intravenous infusion. Dose based upon outcome Phase 1.
89195883|NCT00629265|Active Comparator|Active NMES + Swallowing Exercise|Active Neurotech NT2000 Neuromuscular Electrical Stimulation (NMES) therapy will be paired concomitantly with repeated effortful sallowing exercises, for 60 swallows, 2 times per day, 6 days per week, for 12 weeks.
89536113|NCT03071679|Experimental|Omiganan 2.5% and Imiquimod|
89425265|NCT04815694|Experimental|LARC patients treated by MRgRT with Early Regression Index (ERI) at 10th fraction >13.1|All patients will be treated on MRgRT, at the second week , patients with an ERI > 13.1 will underwent RT dose intensification on GTV + 3 mm to 60.1 Gy with a Simultaneous Integrated Boost (SIB).
89007279|NCT05351268|Experimental|3DPCT and CT guided RISI|All patients were treated with clinical routine treatment: 3DPCT combined with CT guided radioactive seed implantation. Collect patient information and treatment information for analysis.
89007280|NCT05348005|No Intervention|No TENS unit use|All subjects will start with 3 months of no TENS use and diary tracking
89007281|NCT05348005|Active Comparator|TENS unit use|All subjects will then have 3 months of TENS use during episodes of endometriosis pain flare and diary tracking.
89425266|NCT04815694|No Intervention|LARC patients treated by MRgRT with Early Regression Index (ERI) at 10th fraction < 13.1|All patients will be treated on MRgRT, at the second week , patients with an ERI < 13.1 will underwent standard RT dose of 55Gy on tumor and corresponding mesorectum
89536114|NCT03071679|Placebo Comparator|Placebo|Vehicle
89007282|NCT05347407||Control|Healthy Patients
89007283|NCT05347407||Parkinson's Disease|Patients diagnosed with Parkinson's disease
89536115|NCT03199261|Experimental|rE-4 Injection|10µg, rE-4 Injection, 30 minutes prior to the start time of a standard breakfast.
89536116|NCT03199261|Active Comparator|rE-4 Freeze-dried Powder|10µg, rE-4 Freeze-dried Powder, 30 minutes prior to the start time of a standard breakfast.
89007284|NCT05347407||At risk for PD|Defined as REM sleep behavior disorder, known genetic risk factor, and/or first degree relatives with PD
89007285|NCT05347407||Dementia with Lewy Bodies|Patients diagnosed with Dementia with Lewy Body Disease
89007286|NCT05347407||Multiple System Atrophy|Patients diagnosed with Multiple System Atrophy
89007287|NCT05345444|Experimental|Irreversible Electroporation and Radiotherapy|
89007288|NCT05343000|Experimental|Severe Comorbid OSA|Newly-diagnosed severe comorbid obstructive sleep apnea subjects will use technology to facilitate remote health coaching through a home-based pulmonary rehabilitation (PR) system
89007289|NCT05337982|Experimental|SCI Go|Participants with SCI randomized to the experimental group that have biomarkers that indicate low levels of inflammation will start immediately.
89007290|NCT05337982|Experimental|SCI No Go|Participants with SCI randomized to the experimental group that have biomarkers that indicate high levels of inflammation will have a delayed start of 3 months.
89007291|NCT05337982|No Intervention|SCI SOC|Participants with SCI randomized to the standard of care (SOC) group will continue with regular therapy.
89007292|NCT05337982|No Intervention|Healthy Control|Healthy controls will provide biomarker and/or myelin (MRI) data
89007293|NCT05331625|Experimental|Intervention|Participants in this group will consent to participate in a study about quality of life for patients with cancer seeking outpatient palliative care. They will be seen in a palliative care oncology clinic at which time they will be offered additional resources to promote symptom management. They will be asked to complete a series of surveys every two weeks for 16 weeks which will assess their quality of life, symptoms, and medication use.
89007294|NCT05331625|No Intervention|Usual Care|Participants in this group will consent to participate in a study about quality of life for patients with cancer seeking outpatient palliative care. They will be seen in a palliative care oncology clinic where they will receive symptom management and supportive care. They will be asked to complete a series of surveys every two weeks for 16 weeks which will assess their quality of life, symptoms, and medication use.
89007295|NCT05322044|No Intervention|Control (no financial incentive)|No incentive. Usual care (plus EMD with reminders) for 12-weeks.
89007296|NCT05322044|Experimental|Intervention (financial incentive)|Financial incentive dependent upon daily medication adherence (plus EMD with reminders) for 12-weeks.
89007297|NCT05317546|Experimental|Cannabidiol, Then Placebo|
89007298|NCT05317546|Experimental|Placebo, Then Cannabidiol|
89007299|NCT05313243|Experimental|Brentuximab vedotin (brentuximab) and pembrolizumab|"All subjects are scheduled to receive up to 16 cycles of combinatorial treatment with brentuximab + pembrolizumab, followed by up to 19 additional cycles of pembrolizumab monotherapy.~After receiving 35 total doses of pembrolizumab (i.e. scheduled for 16 doses in the combinatorial setting and 8 doses as monotherapy), a subject's pembrolizumab treatment will be complete."
89007300|NCT05311670||Single-arm|Participants will be assigned to the single-arm involving monitoring of their symptoms.
89007301|NCT05310565|Experimental|Chiropractic|Cervical chiropractic care
89007302|NCT05292365|Experimental|RE-PACT Intervention|Intervention participants receive respiratory illness action plans and weekly mobile health (mHealth) confidence surveillance. At times of low confidence or hospitalization, just-in-time action planning and coaching activities are conducted.
89007303|NCT05292365|No Intervention|Active Control (AC)|AC subjects will receive usual comprehensive medical care and coordination.
89007304|NCT05289661|Experimental|UT-DSAEK plus topical ripasudil|This arm will receive UT-DSAEK plus topical ripasudil 0.4%
89007305|NCT05289661|Placebo Comparator|UT-DSAEK plus topical placebo|This arm will receive UT-DSAEK plus topical placebo
89007306|NCT05289661|Experimental|DMEK plus topical ripasudil|This arm will receive DMEK plus topical ripasudil 0.4%
89007307|NCT05289661|Placebo Comparator|DMEK plus topical placebo|This arm will receive DMEK plus topical placebo
89007308|NCT05286853|Sham Comparator|Cohort 1|Participants randomized to Cohort 1 will receive 2 sham injections of REACT. Second injection to occur 3 months (+30 days) after the first REACT injection. Sham procedures simulate real procedure. No tissue is taken during biopsy and nothing is injected into kidney for injection.
89007309|NCT05286853|Experimental|Cohort 2|Participants randomized to Cohort 2 will receive 2 injections of REACT. The second injection to occur 3 months (+30 days) after the first REACT injection.
89425267|NCT04822714|Experimental|Mobile Career Competencies Intervention|The intervention protocol has five main components and is designed in English language. The first component consists of an educational session. The second component focuses on one's reflection on motivation and qualities. The third component assists users in working out strategies with others. The fourth component prompts users to reflect on and narrate their emerging career stories through goal-setting identification activities. The fifth component includes the government's human resource practices, training programs offered, and policies. The fourth and fifth component require users to reflect on their work exploration and career control career competencies.
89425268|NCT04822714|No Intervention|Waitlist control|Waitlist control group attended work and basic training from the organization as usual. They only receive the mobile intervention after the intervention group completing of the intervention.
88906283|NCT03384784|Placebo Comparator|Placebo|"12-week placebo-controlled medication period~Placebo ingredients will be purchased, encapsulated, and packaged into blister packs by the IDS at the University of Pennsylvania. Both active medication and placebo will look identical.~The study medication assignments for each participant in this project is randomized and counterbalanced. This means that approximately 50% of participants will take galantamine during the first medication period, followed by the placebo in the second medication period. Alternatively, approximately 50% of participants will take the placebo during the first medication period, followed by galantamine during the second medication period."
88906284|NCT03383094|Active Comparator|Control-radiotherapy/cisplatin|Intensity-modulated radiation therapy to 70 Gy in 33-35 fractions over 6.5 weeks plus concurrent cisplatin 100 mg/m2 every 3 weeks for 3 cycles (7 weeks)
88906285|NCT03383094|Experimental|Experimental-Radiotherapy/pembrolizumab|Intensity-modulated radiation therapy to 70 Gy in 33-35 fractions over 6.5 weeks plus concurrent and adjuvant pembrolizumab 200 mg IV infusion every 3 weeks x 20 cycles
89425269|NCT04822870|Experimental|quadratus lumborum block|Parturients receive ultrasound-guided quadratus lumborum block as post-operative analgesia.
89425270|NCT04822870|Experimental|iliohypogastric/ilioinguinal nerve block|Parturients receive ultrasound-guided iliohypogastric/ilioinguinal nerve block as post-operative analgesia.
89425271|NCT04822870|Active Comparator|epidural analgesia|Parturients receive epidural morphine via epidural catheter placed during anesthesia as post-operative analgesia.
89195884|NCT00629265|Sham Comparator|Sham NMES + Swallowing Exercise|Sham (inactive) Neurotech NT2000 Neuromuscular Electrical Stimulation (NMES) therapy will be paired concomitantly with repeated effortful sallowing exercises, for 60 swallows, 2 times per day, 6 days per week, for 12 weeks.
89195885|NCT00606502|Experimental|Pralatrexate|Intravenous (IV) push administration over 3-5 minutes into a patent IV line containing normal saline (0.9% sodium chloride).
89195886|NCT00606502|Active Comparator|Erlotinib|"150 mg orally in tablet form~Administered daily 1 hour before or 2 hours after ingestion of food until criteria for discontinuation per the protocol are met."
89195887|NCT02549625|Experimental|Single-arm|Intracoronary delivery of autologous bone marrow-derived mononuclear cells using catheterization procedure
89195888|NCT00825123|Experimental|Ivabradine|
89195889|NCT00825123|Active Comparator|Metoprolol|
89195890|NCT00825123|Placebo Comparator|Placebo|
89007310|NCT05286541|Experimental|Lateralized buccal cortex group with xenograft|the buccal cortical bone was osteotomized and separated to be fixed in a lateralized position at the desired distance and the gap filled with Xenograft
89195891|NCT02540746|Experimental|ERG Skills Training|ERG Skills Training for 12 weeks
89195892|NCT02540746|Experimental|ERG Skills Training + ME|ERG Skills Training for 12 weeks preceded by Motivational Enhancement for 4 weeks
89195893|NCT02540746|Experimental|ERG Skills Training + FAM|ERG Skills Training with concurrent 12-week Family Skills Training
88820309|NCT06190418|Active Comparator|Unloaded sit to stand strengthening exercise group|This Group will be provided with unloaded sit to stand exercises in diplegic spastic CP, 3 times a week for 6 weeks. Pre and post session functional strength of lower limb muscles will be measured by performing functional strength tests and physiological cost index will be measured to determine energy expenditure.
88820310|NCT06190405|Experimental|Universal hemoglobin A1c|Patients at <16 weeks will have a hemoglobin A1c obtained
89195894|NCT02540746|Experimental|ERG Skills Training + ME + FAM|ERG Skills Training with concurrent 12-week Family Skills Training preceded by Motivational Enhancement for 4 weeks
89195895|NCT00826839|Experimental|OCP/MDL|Oral contraceptive pills/microdose lupron
89195896|NCT00826839|Experimental|E2/antagonist|Estradiol patch/gonadotropin-releasing hormone antagonist
89425272|NCT04822324|Experimental|Spencer Muscle energy technique with conventional Physiotherapy|"shoulder extension with elbow flexion.~shoulder flexion with elbow extension.~circumduction with compression~circumduction with distraction~shoulder abduction and internal rotation with elbow flexion.~shoulder adduction and external rotation with elbow flexion~stretching tissue and pumping fluids with the arm extended: therapist interlocks his fingertips over the deltoid muscle, patient's hand was placed over the therapist shoulder, and the therapist slowly moved the arm away from the shoulder and released.~During all the movements patient is asked to use their muscle energy against the slight resistance offered by the therapist for 6-8 sec.~conventional therapy Joint mobilization~Exercise therapy:~Self stretching and strengthening exercises"
89425273|NCT04822324|Active Comparator|Strain counter strain along with conventional Physiotherapy and Spencer Muscle energy technique|"Palpate surrounding and opposing tissues to locate tender point for both shoulder abduction and external rotation.~Use one or two finger pads to monitor fasciculation and TP. Fine-tune position with rotation. Hold the POC (position of comfort) until fasciculation decreases significantly or ceases.~Average positions hold time while pressure is 90 s to 3 min. Transient periods of brief tingling, numbness, and temperature changes might occur. Release tissue or joint slowly and reassess."
89425274|NCT04822246|Other|Control: Hand instrumentation for caries excavation|Hand instrumentation for caries excavation
89425275|NCT04822246|Experimental|Intervention 1: EMS Airflow device for caries excavation|Powder/water jet prophylaxis device (EMS Airflow) for caries excavation
89425276|NCT04822246|Experimental|Intervention 2: Hand excavation + EMS Airflow device for caries excavation|Hand excavation and Powder/ jet prophylaxis device (EMS Airflow) for caries excavation
89425277|NCT04815148|Experimental|Phase Ia: MH004 (0.1%) in healthy volunteers|SAD and MAD
89425278|NCT04815148|Experimental|Phase Ia: MH004 (0.3%) in healthy volunteers|SAD and MAD
89425279|NCT04815148|Experimental|Phase Ia: MH004 (1%) in healthy volunteers|SAD and MAD
89425280|NCT04815148|Experimental|Phase Ia: MH004 (3%) in healthy volunteers|SAD and MAD
89425281|NCT04815148|Experimental|Phase Ib-1: MH004 (0.1%) in Atopic Dermatitis|28-Day Repeated Dosing in Participants with Mild to Moderate Atopic Dermatitis
89425282|NCT04815148|Experimental|Phase Ib-1: MH004 (0.3%) in Atopic Dermatitis|28-Day Repeated Dosing in Participants with Mild to Moderate Atopic Dermatitis
89425283|NCT04815148|Experimental|Phase Ib-1: MH004 (1%) in Atopic Dermatitis|28-Day Repeated Dosing in Participants with Mild to Moderate Atopic Dermatitis
89425284|NCT04815148|Experimental|Phase Ib-2: MH004 (0.3%) in Rheumatoid Arthritis|28-Day Repeated Dosing in Participants with Mild to Moderate Rheumatoid Arthritis
89425285|NCT04815148|Experimental|Phase Ib-2: MH004 (1%) in Rheumatoid Arthritis|28-Day Repeated Dosing in Participants with Mild to Moderate Rheumatoid Arthritis
88906286|NCT03374475|Placebo Comparator|Lead-in period: Placebo|Participants who successfully complete the baseline examination visit at the clinical site/unit, will be treated with placebo (2 capsules taken orally) for the duration of the lead-in period which will last up to 3 weeks. Investigators and participants will be blinded to exact duration of each participant-specific lead-in period throughout the study.
88906287|NCT03374475|Experimental|Treatment period: JNJ-42847922 or Placebo|Placebo lead-in period responders and non-responders will be randomized to receive either placebo or 20 milligram (mg) JNJ-42847922 or 40 mg JNJ-42847922 for 5 Weeks. Participants will swallow JNJ-42847922 20 mg (2*10-mg capsules) or JNJ-42847922 40 mg (2*20-mg capsules) or 2 matching placebo capsules once daily for 5 Weeks.
88906288|NCT03374475|Placebo Comparator|Withdrawal period: Placebo|Participants who will complete the treatment period prior to the end of Week 8 will enter the withdrawal period where they will be treated with placebo (2 capsules taken orally) for the remaining time of the double-blind phase of the study. Investigators and participants will be blinded to exact duration of each participant-specific withdrawal period.
88906289|NCT03373032|Experimental|Stiper - A|Stiper, breast cancer patients during chemotherapy cycles, once a week, during 10 weeks
88906290|NCT03373032|Experimental|Acupuncture - B|Acupuncture with needles, breast cancer patients during chemotherapy cycles, once a week, during 10 weeks
89425286|NCT04815148|Experimental|Phase Ib-2: MH004 (3%) in Rheumatoid Arthritis|28-Day Repeated Dosing in Participants with Mild to Moderate Rheumatoid Arthritis
89425287|NCT04822012||Female|Female patients going through an egg retrival procedure and were identified as post COVID-19 vaccine/ post COVIS-19 infection or not post vaccine/post disease and screened negative for COVID-19 in the week prior to the procedure.
89425288|NCT04822012||Male|male patients going through an in vitro fertilization cycle and were identified as post COVID-19 vaccine/ post COVIS-19 infection or not post vaccine/post disease and screened negative for COVID-19 in the week prior to the procedure.
89425289|NCT04814914||KB109 + Self Supportive Care (SSC)|
88906291|NCT03373032|Experimental|Exercise - C|Exercise, breast cancer patients during chemotherapy cycles, once a week, during 10 weeks
88906292|NCT03373032|Experimental|Follow Up - D|Selected patients from the 3 groups Stiper / Acupuncture / Exercise. One session with a Peridell Massager
88906293|NCT03373032|Other|Observation - S|Group patients who were unable to participate in the intervention group A / B and C. In this group, only the evaluation will be performed.
88906294|NCT03344419|Experimental|CI-581a+MET+MBRP|Administration of CI-581a at 0.71 mg/kg during weeks 1 and 5 combined with a 12-week course in MET and MBRP
88906295|NCT03344419|Active Comparator|CI-581b+MET+MBRP|Administration of CI-581b at 0.025 mg/kg during weeks 1 and 5 combined with a 12-week course in MET and MBRP
89007311|NCT05286541|Active Comparator|lateralized buccal cortex with autogenous particulate|the buccal cortex was lateralized same as in the interventional group but the gap filled with autogenous particulate
89007312|NCT05275972|Placebo Comparator|DMEK plus topical placebo|
89007313|NCT05275972|Experimental|DSO plus topical ripasudil 0.4%|
89425290|NCT04814914||Self Supportive Care (SSC) Alone|
89425291|NCT05399732|Experimental|efficiency and safety in luspatercept plus ciclosporin|luspatercept is at a dose of 1.0 mg per kilogram of body weight, administered subcutaneously every 3 weeks，and ciclosporin is at a dose of 3~5mg/kg /day for at least 6 months.
89425292|NCT05399732|Active Comparator|controll group in ciclosporin alone|ciclosporin is at a dose of 3~5mg/kg /day for at least 6 months.
89425293|NCT05399576|Experimental|Nicorandil and verapamil|intracoronary of 2mg Nicorandil and 500ug verapamil
89425294|NCT05399576|Placebo Comparator|saline|intracoronary of 4ml saline
89425295|NCT04789382|Other|Sequence 1|LID018869+RepleniSH in the right eye and Biofinity+RepleniSH in the left eye (first wear period), followed by PV+Biotrue in the right eye and LID018869+Biotrue in the left eye (second wear period). Each wear period will be 2 hours.
89007314|NCT05264207|Experimental|Intervention group|Participants allocated to the 'intervention group' arm will receive the usual care offered by the Public Andalusian Healthcare Service in conjunction with a 12-week nursing students' home-visit programme.
89425296|NCT04789382|Other|Sequence 2|Biofinity+RepleniSH in the right eye and LID018869+RepleniSH in the left eye (first wear period), followed by LID018869+Biotrue in the right eye and PV+Biotrue in the left eye (second wear period). Each wear period will be 2 hours.
89425297|NCT04789382|Other|Sequence 3|LID018869+Biotrue in the right eye and PV+Biotrue in the left eye (first wear period), followed by Biofinity+RepleniSH in the right eye and LID018869+RepleniSH in the left eye (second wear period). Each wear period will be 2 hours.
89007315|NCT05264207|Active Comparator|Control group|Participants allocated to the 'control group' arm will only receive the usual care offered by the Public Andalusian Healthcare Service for 12 weeks.
89425298|NCT04789382|Other|Sequence 4|PV+Biotrue in the right eye and LID018869+Biotrue in the left eye (first wear period), followed by LID018869+RepleniSH in the right eye and Biofinity+RepleniSH the left eye (second wear period). Each wear period will be 2 hours.
89425299|NCT05068076|Experimental|Patients undergoing ablation for HCC|Pre-procedure CEUS will be performed on patients undergoing ablation followed by targeting of lesions for precise needle placement in the Kupffer phase. 2 hours post procedure USG with contrast will also be done for response assessment
89425300|NCT05399420||functional kidney failure patients|Patients admitted to the nephrology department with suspicion of functional acute renal failures
89425301|NCT05399420||Organic kidney injury patients|Patients admitted to the nephrology department with suspicion of organic acute renal failure (kidney injury)
89425302|NCT05399264|Experimental|Auditory-working memory training group|"The auditory-working memory training (AT-WMT) program is home-delivered, non-clinician-administered, and computer-based. That is, training will be self-paced and administered by the participants themselves at home using a computer. A software program has been created to facilitate the administration. Participants will spend one hour per day and five days per week for 4 weeks on training.~During the training, the following two adaptive tasks will be administered simultaneously: repeating the sentences masked by noise (i.e., AT component) and recalling the first or the final two words of all sentences in a given sentence set (i.e., WMT component)."
89425303|NCT05399264|Active Comparator|Adaptive Auditory training group|The sentences used in the AT program are the same as those in the AT-WMT program. However, only the AT component (i.e., adaptive sentence perception in noise) of the AT-WMT program is required in the AT program. Participants do not need to recall the first or the final two words of the sentences. The same software in the experimental group will be used. Participants will spend one hour per day and five days per week for 4 weeks on training.
89425304|NCT05399264|Placebo Comparator|Mindfulness training group|Participants in this group will participate in a mindfulness training program using newlife.330 (Psychiatric Rehabilitation Association, 2018) which is a Cantonese online platform for self-guided mindfulness training. The time and computer use of the active-control group will match to those of the above two groups.
89425305|NCT04637984|Experimental|Implementation Group|Predictions will be provided to the rehabilitation team and discussed with the patient and their family. Patients will receive a multidisciplinary rehabilitation according to their individual needs.
89425306|NCT04637984|No Intervention|Control Group|This group will not received any information on the PREP2
89425307|NCT04956068|Experimental|Unresectable PM group|Patients who have progressed on conventional systemic therapy and PIPAC is used as a palliative strategy.
89425308|NCT04956068|Experimental|Extensive PM group|Patients who have significant volume of peritoneal disease are treated with the intent for potential conversion to curative surgery. Role of PIPAC is as an adjunct to systemic chemotherapy to downstage peritoneal metastases.
89425309|NCT04453904|Experimental|"sequential radiochemotherapy in a sanwich mode"|Two courses of TC regimen chemotherapy (paclitaxel 135-175mg / m2; carboplatin AUC = 5; once every 21 days) will be given first, followed by external pelvic radiation (± vaginal brachytherapy), and then four courses of the same regime consolidation chemotherapy.
89425310|NCT04453904|Active Comparator|concurrent chemoradiotherapy followed by chemotherapy|External pelvic radiation (± vaginal brachytherapy) will be given after operation. On the first day and the 29th day of radiotherapy, concurrent intravenous cisplatin (50mg/m2) will be given. After the concurrent radiochemotherapy, four courses of TC regimen (paclitaxel 135-175mg / m2; carboplatin AUC = 5; once every 21 days) chemotherapy will be given.
88922203|NCT05655325|Placebo Comparator|Health education|The health education group will receive the same amount of contact hours as the intervention group. The attention control group will receive health education and stretching exercises. Participants will be in person, on-site one time per week during month 1 for about 30 minutes. During month 2, participants will attend the health education on-site once every other week for about 30 minutes. During months 2-6 participants will receive a phone call every two weeks to help remind about the health education. Participants will receive a Fitbit fitness tracker that will be used for exercise monitoring.
89425311|NCT05697224|Active Comparator|chronicurinary schistosomiasis|
89425312|NCT05697224|Active Comparator|bladder cancer diseased patients|
89425313|NCT05283590||All patients|The IVC will be measured by the automated mode and manual measures will be recorded. All patients will have PPv by LiDCO
89425314|NCT05650112|Experimental|FB-001 Healthy Volunteer|Healthy volunteer participants in Part 1 receive FB-001 (1 x 10^12 viable cells) orally on Day 1 and Day 2 and FB-001 (1 x 10^11 viable cells) orally on Days 3 to 10.
88819379|NCT04505085|Experimental|Active Dads Healthy Families: Fitness|The intervention will include physical activity opportunities at a community center. The program will be held one day a week for eight consecutive weeks. Parks and Recreation will facilitate and run the program. Each session will last 60 minutes and include a brief educational discussion and opportunities for various games and activities. Families will also receive a home toolbox to facilitate activity outside of the program. Feedback on physical activity will be provided at the beginning and the end of the program.
88819380|NCT01500746|Experimental|Lavage arm|This group will serve as the experimental arm. They will undergo twice daily pulse lavage of their wounds for 4 days. In between the lavage treatments, their wounds will be dressed with moist gauze.
88819381|NCT01500746|Active Comparator|Moist dressings|This group will serve as the control group. They will undergo twice daily dressing changes with moist gauze dressings for a total of 4 days (8 dressing changes). Bacterial counts and gene expression analysis will be performed prior to the first dressing change and after the last dressing change.
88819382|NCT04707729|No Intervention|Standard of care|Patients will be intubated according to both the standard of care
88819383|NCT04707729|Experimental|Standard of care + ROX algorithm|In the intervention arm, patients will be intubated according to both the standard of care and the ROX index, whichever are met first. If the patient has a ROX index below different thresholds after different time-point within the first 12 hours since randomization, the NHF support will be increased to the maximum tolerated flow (up to 60L/min) and FIO2 of 1 and subsequently titrated with the target SpO2. Then, the ROX index will be recalculated in 30 minutes. If the patient is already treated with to 60L/min) and FIO2 of 1 and no further increase could be done, the ROX index will be recalculated after 30 minutes of full NHF support. Then: 1) if the ΔROX is <0 the patient will be intubated; 2) if the ΔROX is 0-0.5, the ΔROX will be reassessed in 30 minutes; and 3) if the ΔROX is >0.5 the patient will not be intubated, NHF will be managed as protocolized and respiratory condition will be reassessed every two hours or at any new clinical deterioration.
88819384|NCT04487613|Active Comparator|Moringa oleifera leaf|Participants received Moringa oleifera leaf 450 mg capsule orally twice daily for 3 days.
88819385|NCT04487613|Placebo Comparator|Placebo|Participants received placebo capsule orally twice daily for 3 days.
88819386|NCT02421588|Experimental|Arm A|lurbinectedin (PM01183)
88819387|NCT02421588|Active Comparator|Arm B|"pegylated liposomal doxorubicin~OR~topotecan"
88819388|NCT04479969|Other|Intervention|This is a small study to assess the usability of video conferencing. A total of 10 patients will be enrolled, 5 of which will be Spanish speakers. All patients will test the video conferencing.
88819389|NCT02768727|Experimental|Xenon|Xenon anesthesia to determine if neural inertia is present in humans as visualized by CT imaging.
88819390|NCT02748291|Experimental|Walking|Randomised participants will be instructed to walk 6,000 steps per day and throughout the day for 12 weeks. Step counts will be monitored by an issued pedometer. A 12 week paper diary will be provided for daily recording of step counts.
88819391|NCT02748291|Active Comparator|Control|Department of Health (United Kingdom) Physical Activity Guidelines flyer (current standard of care).
88819392|NCT02694393|Experimental|sodium nitrite|Inhalation of 46 or 80 mg of sodium nitrite twice daily for four weeks
88819393|NCT02688309||Clinic Patients|"Patients from the clinic will be considered for enrollment if they are receiving an intraocular injection of a steroid as part of standard care for macular edema or progressive fibrosis.~Clinic patients who are receiving an intraocular injection of steroid (Ozurdex) as part of standard care who agree to participate will have an anterior chamber (AC) tap just prior to the intraocular injection of steroid and a second AC tap at a follow up visit 6 ± 2 weeks after the steroid injection."
88819394|NCT02688309||OR Patients|Patients undergoing surgery for one of the following conditions: (1) Proliferative Diabetic Retinopathy, (2) rhegmatogenous retinal detachment with PVR, (3) rhegmatogenous retinal detachment without PVR, (4) macular pucker, (5) macular hole. Surgical patients who agree to participate will have an anterior chamber (AC) tap at the beginning of surgery.
88819395|NCT00370851|Experimental|1|Intravitreal injection of Avastin
89425315|NCT05650112|Placebo Comparator|Placebo|Healthy volunteer participants receive placebo once a day, orally, for 10 days in Part 1.
89425316|NCT05650112|Experimental|FB-001 Enteric Hyperoxaluria|Enteric hyperoxaluria participants in Part 2 receive FB-001 (1 x 10^12 viable cells) orally on Day 1 and Day 2 and FB-001 (1 x 10^11 viable cells) orally on Days 3 to 10.
89425317|NCT05640284||Adequate KMT|Keratinized mucosal thicknesses (KMT) on their buccal surfaces are 2 mm and above.
89425318|NCT05640284||inadequate KMT|Keratinized mucosal thicknesses (KMT) on their buccal surfaces are less than 2 mm.
89425319|NCT05640284||adequate KGW|keratinized gingival width (KGW) on their buccal surfaces are 2 mm and above.
89425320|NCT05640284||inadequate KGW|keratinized gingival width (KGW) on their buccal surfaces are less than 2 mm.
89425321|NCT05640284||Peri-implant health|"The absence of signs of inflammation (redness, swelling, bleeding on probing) in the peri-implant soft tissue, probing depth (PD) ≤5 mm with mild force (approximately 0.25 N), and no further bone loss following initial healing are defined as peri-implant health."
89425322|NCT05640284||peri-implant mucositis|"Peri-implant mucositis is defined as clinically observable signs of inflammation (swelling, redness and soft consistency of tissue), bleeding on probing (lines or drops) and/or signs of suppuration in the absence of bone loss greater than 2 mm, the threshold for initial bone remodulation."
89425323|NCT05398718||Sotrovimab Arm|
89425324|NCT05398718||Control|
89425325|NCT05398562|Experimental|RTA / 0.1 μg / 0.1 mL|at stage I - 5 healthy volunteers; at stage II - 20 healthy volunteers. frequency and route of administration: once, intradermally
89425326|NCT05398562|Experimental|RTA / 0.2 μg / 0.1 mL|at stage I - 5 healthy volunteers; at stage II - 20 healthy volunteers. frequency and route of administration: once, intradermally
89425327|NCT05398562|Placebo Comparator|Placebo / 0.1 mL|at stage I - 5 healthy volunteers; at stage II - 20 healthy volunteers. frequency and route of administration: once, intradermally
89425328|NCT05398406|Experimental|Subcostal TAP Block|In the supine position, the US probe was placed on the imaginary line connecting the anterior superior iliac spine (SIAS) and the umbilicus. The ilioinguinal and iliohypogastric nerves in the fascia of the internal obliq and transverse abdominis muscles were visualized by US. A total of 40 ml (20+20 ml) of local anesthetic was infiltrated around the nerve bilaterally with a 100 mm 21G peripheral nerve block needle (SonoPlex Stim Cannula, PAJUNK®,USA).
89425329|NCT05398406|Experimental|ESP Block|In the lateral decubitus position, a 100 mm 21G peripheral nerve block needle (SonoPlex Stim Cannula, PAJUNK®,USA) was inserted between the erector spinae muscle and the transverse process structures in an in-plane section guided by US from the T7-8 level. A total of 40 ml of the prepared solutions were injected bilaterally as 20+20 ml.
89425330|NCT05398406|Experimental|Paravertebral block|In the lateral decubitus position, the cranial to caudal transverse processes and the superior costotransverse ligament and the pleura were visualized from the T7-8 level in the in-plane section under US guidance. A 100 mm 21G peripheral nerve block needle (SonoPlex Stim Cannula, PAJUNK®, USA) was advanced until it passed through the superior costotransverse ligament. A total of 40 ml of injections were made bilaterally in the form of 20+20 ml.
89425331|NCT04454060||Extracapsular method group|consecutive 43 patients who received extracapsular method treatment for refractory tennis elbow
89425332|NCT05554016||Group 1|Pediatric patients with obesity
89425333|NCT05554016||Group 2|Pediatric patients with obesity complicated by Metabolic Syndrome
88819396|NCT00370851|Sham Comparator|2|
88819397|NCT05124171|Experimental|Comirnaty® (Pfizer-BioNTech)|Length of use : 1 day
88819398|NCT05124171|Experimental|CoV2 preS dTM adjuvanted vaccine (D614), Sanofi/GSK|Length of use : 1 day
88819399|NCT05124171|Experimental|CoV2 preS dTM adjuvanted vaccine (B.1.351), Sanofi/GSK|Length of use : 1 day
88819400|NCT00370305|Experimental|Rosiglitazone treatment|Rosiglitazone will be given to the subjects. All subjects will be analyzed before and after treatment
88819401|NCT05124093|Placebo Comparator|Apnoea without apnoeic oxygenation|High-flow nasal oxygen administration ceases at the onset of apnoea.
88819402|NCT05124093|Active Comparator|Apnoeic oxygenation with high-flow nasal oxygen at 70 L/min (HFNO)|100% oxygen is administered via high-flow nasal cannulae at 70L/min from the onset of apnoea until four minutes of apnoea has completed.
88819403|NCT05124093|Active Comparator|Apnoeic oxygenation with high-flow nasal oxygen at 120 L/min (uHFNO)|100% oxygen is administered via high-flow nasal cannulae at 120L/min from the onset of apnoea until four minutes of apnoea has completed.
88819404|NCT05119803||Parkinson's patients|"The cognitive status of the participants will be evaluated using the 'Standardized Mini Mental Test'.~The 'Unified Parkinson's Disease Assessment Scale Part 3' will be used to evaluate the motor function of Parkinson's patients.~Spinal posture will be assessed using the IDIAG M360 (IDIAG, Fehraltorf, Switzerland) Spinal Mouse. This device is an electronic computer aided measuring device that measures the range of motion of the spine and evaluates the angle and shape of the spine in the sagittal and frontal planes.~The upper extremity functions of Parkinson's patients will be evaluated with the '9-Hole Peg Test'.~A short version of PDQ-39, called the 8-item Parkinson's Disease Questionnaire (PDQ-8), will be applied to determine the quality of life of Parkinson's patients. The PDQ-8 consists of eight items that belong to each of the eight dimensions in the original PDQ-39."
89425334|NCT05554016||Group 3|Age- and sex-matched healthy controls
89425335|NCT03130400||Normal|This group is control group. Participants in this group do not have knee diseases or any other bad injuries in lower limbs.
89425336|NCT03130400||KOA|Participants in this group have knee osteoarthritis and have no other bad injuries in lower limbs.
89425337|NCT03130400||ACLD|Participants in this group have anterior cruciate ligament deficiency with or without meniscus deficiency and have no other bad injuries in lower limbs.
89425338|NCT03130400||MD|Participants in this group have meniscus deficiency and have no other bad injuries in lower limbs.
89425339|NCT03130400||Plica|Participants in this group have plica syndrome and have no other bad injuries in lower limbs.
89425340|NCT05398016|Experimental|Low-intensity behavioral intervention|Brief behavioral intervention for mild-to-moderate symptoms of anxiety. Delivered by a trained lay counselor.
89425341|NCT04615286|Experimental|Short course|Antibiotic course of 2-3 weeks overall duration for treating pleural infection
89425342|NCT04615286|Active Comparator|Long course|Antibiotic course of 4-6 weeks overall duration for treating pleural infection
89425343|NCT05397938|Experimental|JMT103 60 mg group|Patients will be administrated with JMT103 60 mg subcutaneously every 6 months (Q6W) and alendronate sodium tablet placebo once every week (QW).
88906296|NCT03321526|Experimental|JNJ-42847922|Participants will receive 20 mg of JNJ-42847922 as a starting dose and matching placebo (1 capsule of 20 mg JNJ-42847922 and 1 capsule of matching placebo) once daily for 14 days. After Day 14, if needed, JNJ-42847922 dose can be increased to 40 mg (2*20 mg capsules) and flexible dose of JNJ-42847922 (20 or 40 mg) will be taken once daily until Day 167. Dose of JNJ-42847922 (20 or 40 mg) will be adjusted by investigator based on the participant's clinical response and tolerability. Participants will continue to take their baseline selective serotonin reuptake inhibitor (SSRI)/serotonin-norepinephrine reuptake inhibitor (SNRI) antidepressant as a part of background therapy (at the same dose, without change, every day and at approximately the same time as prior to entering the study) throughout the screening, double-blind, and follow-up phases.
88906297|NCT03321526|Active Comparator|Quetiapine Extended-Release (XR)|Participants will receive 1 capsule of quetiapine XR 50 mg along with 1 capsule of matching placebo once daily for 2 days, followed by 1 capsule of quetiapine XR 150 mg along with 1 capsule of matching placebo once daily from Day 3 to Day 14. After Day 14, if needed, quetiapine XR dose can be increased to 300 mg (2*150 mg capsules) and flexible dose of quetiapine (150 or 300 mg) will be taken once daily until Day 167. Dose of quetiapine XR (150 or 300 mg) will be adjusted by investigator based on the participant's clinical response and tolerability. Participants will continue to take their baseline SSRI/SNRI antidepressant as a part of background therapy (at the same dose, without change, every day and at approximately the same time as prior to entering the study) throughout the screening, double-blind, and follow-up phases.
89425344|NCT05397938|Experimental|JMT103 90 mg group|Patients will be administrated with JMT103 90 mg subcutaneously every 6 months (Q6W) and alendronate sodium tablet placebo once every week (QW).
89425345|NCT05397938|Active Comparator|Alendronate sodium group|Patients will be administrated with alendronate sodium tablet orally 70 mg weekly (QW) and JMT103 placebo subcutaneously every 6 months (Q6W).
89425346|NCT05133674|Experimental|0|Blood concentrations of tamoxifen, 4-hydroxytamoxifen and Z-endoxifen will be measured.
89425347|NCT04593134|Experimental|exercise group|A 12-week regimen of home-based walking exercises, comprising walking at a moderate intensity for 40 min, three times a Week.
89425348|NCT04593134|No Intervention|usual-care group|These participants follows the standard post-surgery follow-up consisting of counseling by dietitians, nurses and doctors.
89425349|NCT02522936|Experimental|Biotene|Participants will be given Biotene oral spray to use as needed when taking oxybutynin.
88906298|NCT03297593|Experimental|nivolumab and ipilimumab|"Patients start treatment with nivolumab (240 mg every 2 weeks during the first 20 weeks, 480 mg every 4 weeks thereafter).~After 2 weeks, ipilimumab (1mg/kg every 6 weeks) will be introduced. As soon as a radiographic complete response (CR) or partial response (PR) is observed, ipilimumab has to be stopped and only the single-agent treatment with nivolumab is continued. Once ipilumimab has been stopped because of a response, it will not be re-started later on."
89425350|NCT02522936|No Intervention|Routine care|Participants will be given routine care.
89425351|NCT04674566|Experimental|Cohort 1|COR-101 low dose
89425352|NCT04674566|Experimental|Cohort 2|COR-101 mid dose 1
89425353|NCT04674566|Experimental|Cohort 3|COR-101 mid dose 2
89425354|NCT04674566|Experimental|Cohort 4|COR-101 high dose
89425355|NCT04405466||Group 1|Workers working within a production area
88906299|NCT03240653||Patients Type III|Stratified response to EnzymeTherapy Substrate Reduction Therapy (expected) Splenectomy (and interactions)
88906300|NCT03240653||Patients Type I|Stratified response to Enzyme Therapy and Substrate Reduction Therapy- Splenectomy (and interactions)
88906301|NCT03217669|Experimental|Sirolimus/Epacadostat Dose Escalation|"Traditional 3 + 3 dose escalation design.~Starting doses: sirolimus 3milligrams (mg) loading/1mg maintenance and epacadostat 300mg twice daily (BID). If 0 in 3 subjects develops dose limiting toxicity (DLT), next 3 subjects will be treated at dose level 2 (DL2): sirolimus 6mg loading/2mg maintenance and epacadostat 300mg BID. If 1 subject in dose level 1 (DL1) develops DLT, 3 additional subjects will be enrolled in DL1. If 2 or more subjects in a total of 6 subjects, or 2 or more subjects in the initial 3 subjects develop DLT, the next 3 subjects will be treated at dose level -1 (DL-1): 3mg loading/1mg sirolimus + epacadostat 100mg BID. If only 1 subject in a total of 6 develops DLT, dose escalation to DL2 will be made for the next 3 subjects. Same algorithm will apply to DL2 except no further dose escalation/de-escalation will be made.~Sirolimus lead-in phase: loading dose on day -7 and maintenance dose starting day -6. On Cycle 1 Day 1, epacadostat 300mg BID will be added."
89007316|NCT05263245|No Intervention|Standard regimen|Patients will continue to use cabozantinib in fasted state, as part of standard of care, in the recommended dose as prior to enrollment in the study.
89425356|NCT04405466||Group 2|Workers working within a laboratory area
89425357|NCT04405466||Group 3|Workers working within other areas
89425358|NCT04373954|Experimental|Forgiveness Therapy|6-month Forgiveness Therapy; Participants meet once per week, in group setting.
89425359|NCT04373954|Active Comparator|Carey Guides|6-month Carey Guides; Participants meet once per week, in group setting.
89425360|NCT04525898|Active Comparator|Methadone Group|The methadone group will receive a dose of methadone at induction of anesthesia (0.15 mg/kg ideal body weight (IBW)
89425361|NCT04525898|Placebo Comparator|Control Group|The control group will be administered an equal volume of saline in an identical appearing syringe.
89425362|NCT03130166|Experimental|Intracorporeal anastomosis|Patients undergo robotic right colectomy with intracorporeal anastomosis.
89425363|NCT03130166|Active Comparator|Extracorporeal anastomosis|Patients undergo robotic right colectomy with extracorporeal anastomosis.
89425364|NCT04452656|Active Comparator|bilateral erector spinae plane block|The patient WILL receive bilateral erector spinae plane block.
89425365|NCT04452656|No Intervention|NO BLOCK|The patient will not receive Erector spinae plane block
89425366|NCT04362800|Experimental|Interventional|10 days of intensive and structured motor therapy, 5 hours a day = 50h
89425367|NCT04362800|Placebo Comparator|Control|10 days of care and classic activities
89425368|NCT04282070|Experimental|SHR-1701 (Arm A)|SHR-1701 for R/M NPC failure after platinum-based chemotherapy
89425369|NCT04282070|Experimental|SHR-1701 (Arm B)|SHR-1701 for R/M NPC failure after anti PD-1/PD-L1 antibody therapy
89425370|NCT04282070|Experimental|SHR-1701 plus Gemcitabine and Cisplatin (Arm C)|SHR-1701+Gemcitabine+Cisplatin for first line treatment of R/M NPC
89425371|NCT04282070|Experimental|SHR-1701 plus Albumin Paclitaxel (Arm D)|SHR-1701+Albumin Paclitaxel for R/M NPC failure after first line anti PD-1/PD-L1 antibody therapy
89425372|NCT05397626|Active Comparator|Heart Rhythm Biofeedback|Heart rhythm biofeedback is a non-invasive physiological treatment that is administered via an app downloaded to personal smart phones. It involves participants attaching a wireless sensor to the ear that monitors heart rate that is displayed on the phone screen app. The participant is actively involved in modifying the heart biofeedback to achieve optimal levels of heart rate variability, an established indicator of health and well-being and a potential factor in chronic fatigue syndrome. The treatment lasts 8 weeks.
88906302|NCT03217669|Experimental|Sirolimus/Epacadostat Dose Expansion|"Once recommended phase 2 dose (RP2D) is defined, a total of 10 non-small cell lung cancer (NSCLC) patients who meet eligibility will be enrolled in the dose expansion cohort. Treatment will be sirolimus RP2D once daily and epacadostat RP2D twice daily (BID).~Sirolimus lead-in phase: loading dose on day -7 and maintenance dose starting day -6. On Cycle 1 Day 1, epacadostat 300mg BID will be added."
89425373|NCT05397626|Active Comparator|Hydrogen Water|Hydrogen pills are mixed in a water glass that is ingested up to 3 times a day for 8 weeks. The hydrogen supplement is intended to reduce oxidative stress and inflammation both of which are implicated in the pathophysiology of chronic fatigue syndrome. This is an 8 week treatment.
89425374|NCT05397626|Active Comparator|Combined treatment: Heart rhythm biofeedback plus hydrogen water|This condition combines heart rhythm biofeedback and hydrogen water, as described above, which is intended to assess any additive or synergistic effects of the two treatments. This is an 8 week treatment.
89425375|NCT04347122|Active Comparator|Bony tumor treated with Tranexamic acid (TXA)|This group of participants will undergo a bony tumor resection of the femur or proximal tibia and endoprosthetic reconstruction with TXA.
88906303|NCT03196427|Experimental|Vedolizumab High Dose Group|Participants with UC or CD having baseline weight of greater than or equal to (>=) 30 kilogram (kg) will receive vedolizumab 300 mg and participants with UC or CD having baseline weight of less than (<) 30 kg will receive vedolizumab 200 mg, IV infusion, every 8 weeks until vedolizumab IV is commercially available for pediatric indication(s) in the participant's country or until other drug access programs become available (whichever comes first), the participant turns 18 years of age and can be transitioned to commercial drug (up to approximately 8 years).
88906304|NCT03196427|Experimental|Vedolizumab Low Dose Group|Participants with UC or CD having baseline weight of >= 30 kg will receive vedolizumab 150 mg and participants with UC or CD having baseline weight of < 30 kg will receive vedolizumab 100 mg IV infusion, every 8 weeks until vedolizumab IV is commercially available for pediatric indication(s) in the participant's country or until other drug access programs become available (whichever comes first), the participant turns 18 years of age and can be transitioned to commercial drug (up to approximately 8 years).
88906305|NCT03185819|Placebo Comparator|Oral Midazolam + Intranasal Placebo|Participants will receive midazolam solution 0.125 milligram per kilogram (mg/kg) orally 2 times per week for 4 weeks and 3 intranasal doses of matched placebo to esketamine.
88906306|NCT03185819|Experimental|Oral Placebo + Esketamine 84 mg|Participants will receive intranasal esketamine 84 mg as 3 intranasal doses of esketamine in each nostril (each dose contains 14 mg of esketamine) along with oral placebo 2 times per week for 4 weeks.
88906307|NCT03185819|Experimental|Oral Placebo + Esketamine 56 mg|Participants will receive intranasal esketamine 56 mg as 2 intranasal doses of esketamine in each nostril (each dose contains 14 mg of esketamine) along with oral placebo 2 times per week for 4 weeks.
88906308|NCT03185819|Experimental|Oral Placebo + Esketamine 28 mg|Participants will receive intranasal esketamine 28 mg as 1 intranasal doses of esketamine in each nostril (each dose contains 14 mg of esketamine) along with oral placebo 2 times per week for 4 weeks.
88906309|NCT03153111|Active Comparator|Macitentan|Subjects randomized to the macitentan arm receives one tablet of macitentan 10 mg every day for at least 24 to maximum 52 weeks.
88906310|NCT03153111|Placebo Comparator|Placebo|Subjects randomized to the placebo arm received one tablet of placebo every day for at least 24 to maximum 52 weeks.
89425376|NCT04347122|No Intervention|Bony tumor treated without TXA|This group of participants will undergo a bony tumor resection of the femur of proximal tibia and endoprosthetic reconstruction.
88906311|NCT03151629||Castrate Resistant Prostate Cancer|
89425377|NCT04347122|Active Comparator|Soft tissue sarcoma treated with Tranexamic Acid (TXA)|This group of participants will undergo soft tissue sarcoma resection of the lower extremity with TXA
88906312|NCT03151629||Hormone Sensitive Prostate Cancer|
88906313|NCT03144921|Experimental|EPIC A|Group A will start the EPIC intervention immediately after assessment 1. The EPIC program consists of a 7-session, psychoeducational skills training intervention, held via Zoom, designed to provide education and skills on how to prepare for the future and reduce stress regarding memory changes and loss for both the person with early-stage dementia and their care partner. Following the 7 EPIC sessions, participants will attend monthly booster sessions, held via Zoom, to reinforce the skills/lessons. Participants may voluntarily choose to continue attending booster sessions through 2024.
88906314|NCT03144921|Active Comparator|EPIC B (WLC)|Group B - the wait list comparison (WLC) group - will have a 75-minute group education session (comparator intervention), held via Zoom, about 3 weeks after baseline assessment. The WLC session is an overview of memory loss/dementia and its related impact for EPs and CPs and an overview of aging network services in the community. They will receive a brief telephone check-in call approximately 3 weeks before the T2 assessment. The WLC group will start the complete EPIC psychoeducational skills training intervention, held via Zoom, immediately after Assessment 2. Following completion of the 7 EPIC sessions, participants will attend monthly booster sessions, held via Zoom, to reinforce the skills/lessons. Participants may voluntarily choose to continue attending booster sessions through 2024.
89425378|NCT04347122|No Intervention|Soft tissue sarcoma treated without TXA|This group of participants will undergo soft tissue sarcoma resection of the lower extremity.
89425379|NCT04453826|Experimental|Camrelizumab plus chemo-radiotherapy arm|3 cycles of gemcitabin and cisplatin induction chemotherapy plus concurrent chemo-radiotherapy with concurrent and adjuvant camrelizumab therapy.
89425380|NCT04453826|Active Comparator|Chemo-radiotherapy arm|3 cycles of gemcitabin and cisplatin induction chemotherapy plus concurrent chemo-radiotherapy.
89425381|NCT05439746|Experimental|Matrix Comparison|Qualified subjects are randomly assigned Microlyte Matrix in an open label fashion to half of a randomized similar depth donor site areas within a subject and determining percent healing at Day 14.
89425382|NCT03467438|Experimental|A|Zinc-l-carnosine, liquid oral formulation, 75mg twice daily (20mL, using the measuring cup, twice daily), to be swallowed on an empty stomach (waiting at least one hour from the last meal).
89425383|NCT03467438|Placebo Comparator|B|Placebo, liquid oral formulation, 75mg twice daily (20mL, using the measuring cup, twice daily), to be swallowed on an empty stomach (waiting at least one hour from the last meal).
89425384|NCT05397314|Experimental|Punalpin|
89425385|NCT05397314|Placebo Comparator|Placebo|
89425386|NCT05397236|Active Comparator|Bupivacaine Magnesium sulphate group|Patients received QL block with 20 ml of 0.25% bupivacaine (2, 4)plus 5 ml of 10% MgSO4.
89425387|NCT05397236|Active Comparator|Bupivacaine Dexamethasone group|Patients received QL block with 20 ml of 0.25% bupivacaine (2,4)plus 2 ml of 8 mg dexamethasone plus 3 ml of 0.9% NS.
89425388|NCT05397236|Active Comparator|bupivacaine saline group|Patients received QL block with 20 ml of 0.25% bupivacaine (2,4)plus 5 ml of 0.9% NS.
88906315|NCT03126435|Experimental|EndoTAG-1 and Gemcitabine|EndoTAG-1 22 mg/m² twice weekly plus Gemcitabine 1000mg/m² once weekly for 1 cycle (8 weeks) consisting of 3 weeks of treatment and 1 week rest followed by 3 weeks of treatment and 1 week rest until any one of the following occurs: progressive disease or unacceptable toxicity or withdrawal of consent.
89425389|NCT04306562|Experimental|Intervention group|Patients in an intervention group will be ask about a history of food consumption in the past seven days to analyze a nutritive value of food consumption with a program (INMUCAL-Nutrients V.4.0, Institute of Nutrition, Mahidol University) and estimate an enteral nutrition supplement to reach a target of total dietary protein intake of 1.5 g/kg/day with nutritional counseling by researchers. Special enteral formula will be selected if patients have specific conditions including renal failure, hyperglycemia/diabetes and liver failure, acute and chronic pulmonary disease and immunocompromised states. Otherwise, standard formula will be provided. Duration of enteral protein supplementation is at least 14 days from a preanesthetic clinic visit to a day of surgery.
89425390|NCT04306562|No Intervention|Control group|Patients in a control group will be sent to assess and improve nutritional status by primary doctor as a conventional care pathway.
88814576|NCT04931394|No Intervention|Physician-decided Adjuvant Chemotherapy|The pancreatic cancer specimens are obtained from surgery to be cultured for organoids. Then drug sensitivity is tested using organoid to obtain the sensitivity to the first-line drugs for pancreatic cancer (Gemcitabine, 5-fluorouracil, Paclitaxel, Oxaliplatin, Irinotecan). Physician will decide the the adjuvant chemotherapy regimen, according to National Comprehensive Cancer Network (NCCN) guideline for pancreatic ductal adenocarcinoma. And they don't know the drug sensitivity test results. Adjuvant chemotherapy should start within 2 months after surgery, and last at least 6 months.
88906316|NCT03126435|Active Comparator|Gemcitabine Monotherapy|Gemcitabine 1000mg/m² once weekly, for 1 cycle (8 weeks) consisting of 3 weeks of treatment and 1 week rest followed by 3 weeks of treatment and 1 week rest until any one of the following occurs: progressive disease or unacceptable toxicity or withdrawal of consent.
88906317|NCT03123809|Active Comparator|Gastric Electrical Stimulation (GES) ON|"Gastric Electrical Stimulation (GES) system involves surgical implantation of a pulse generator in the abdominal wall and 2 electrodes into the muscularis propria of the stomach.~After surgery this group of GP patients will have their GES programed and system will be turned ON for 3 months during a double-blind phase of the study. This step will be followed with additional 3 months of active stimulation (GES System will be turned ON) as it is described in the protocol.Therefore all subjects in this arm will receive overall 6 months of intervention, which will be provided by the active stimulation of GES System (GES turned ON for 6 months)."
89007317|NCT05263245|Experimental|Experimental regimen|Patients will take the prior recommended dose cabozantinib with a light breakfast.
89007318|NCT05263037|Experimental|56-day skills-based VR program|participants in the EaseVRx-8w arm will participate in an 8-week interventional program and continue to be followed for 24 months following completion of tx
89425391|NCT03467282|Experimental|Probiotic|1g probiotic mix (twice day): Lactobacillus acidophilus 1x109 CFU + Bifidobacterium lactis 1x109 CFU + Lactobacillus rhamnosus 1x109 CFU + Lactobacillus paracasei 1x109 CFU
88906318|NCT03123809|Placebo Comparator|Gastric Electrical Stimulation (GES) OFF|"Gastric Electrical Stimulation (GES) system involves surgical implantation of a pulse generator in the abdominal wall and 2 electrodes into the muscularis propria of the stomach.~After surgery this group of GP patients will have their GES programed and system will be turned OFF for 3 months.This step will be followed with additional 3 months of active stimulation (GES System will be turned ON) as it is described in the protocol. Therefore all subjects in this arm will receive first 3 months of non GES intervention (GES System OFF), and 3 following months of active intervention which will be provided by the stimulation of GES System (GES turned ON for 3 months)."
89007319|NCT05263037|Experimental|56-day skills-based VR program followed by an extended 56-day on-demand period|participants in the EaseVRx-8w plus extended on-demand arm will enroll in an 8-week interventional program and be offered an extended 8-week ondemand period, and continue to be followed for 24 months after the completion of treatment
89425392|NCT03467282|Placebo Comparator|Placebo|1g polydextrose/maltodextrin - twice day
89425393|NCT05397002|Other|Patient with class III malocclusion|
89425394|NCT05439278|Experimental|Hypofractionated radiochemotherapy|Radiotherapy: 40.05 Gy in 15 fractions (daily treatment, 5 per week) Temozolomide: concurrent (75 mg/m2/day qd) and adjuvant (6 cycles)
89425395|NCT05439278|Experimental|Conventional radiochemotherapy|Radiotherapy: 60 Gy in 30 fractions (daily treatment, 5 per week) Temozolomide: concurrent (75 mg/m2/day qd) and adjuvant (6 cycles)
89425396|NCT03130010|Placebo Comparator|The control group|One hour before the end of the operation, the control group was received 20 ml of saline.
89425397|NCT03130010|Active Comparator|The Nefopam group|One hour before the end of the operation, the Nefopam group was received 20 mg of nefopam.
89425398|NCT03466970||IgG4 patient|20 samples of IgG4 patients
89425399|NCT03466970||healthy donors|20 healthy donors
89425400|NCT05396144|Sham Comparator|5% inhaled nitrous oxide|Patients will received 5% nitrous oxide by face mask in addition to standard intravenous sedatives given at the discretion of the care provider.
88906319|NCT03084939|Experimental|Trastuzumab Emtansine|Participants with HER2-positive, unresectable LABC or MBC who have experienced disease progression after treatment with trastuzumab and a taxane will be treated with trastuzumab emtansine. Participants may continue to receive study treatment until disease progression (as assessed by the investigator), unmanageable toxicity, or study termination by the Sponsor.
89425401|NCT05396144|Active Comparator|50% inhaled nitrous oxide|Patients will received 50% nitrous oxide by face mask in addition to standard intravenous sedatives given at the discretion of the care provider.
89425402|NCT04453670||COVID-19 non-survivors|ICU adults who died from severe COVID-19 and in whom autopsy could be performed
88906320|NCT03084939|Active Comparator|Control (lapatinib + capecitabine)|Participants with HER2-positive, unresectable LABC or MBC who have experienced disease progression after treatment with trastuzumab and a taxane will be treated with lapatinib plus capecitabine. Participants may continue to receive study treatment until disease progression (as assessed by the investigator), unmanageable toxicity, or study termination by the Sponsor.
89195897|NCT04017988|Experimental|Ethanol Extracts of Porphyra Tenera(PTE10) group|2 times a day, 2 capsules for 1 time, after breakfast/dinner meal (2.512 g/day, Ethanol Extracts of Porphyra Tenera(PTE10) 2.5 g/day)
89195898|NCT04017988|Placebo Comparator|Placebo group|2 times a day, 2 capsules for 1 time, after breakfast/dinner meal (2.512 g/day, Ethanol Extracts of Porphyra Tenera(PTE10) 0 g/day)
89425403|NCT06150898|Experimental|No pre-operative treatment|"Control group: Standard of care~Number of subjects: 28 (14 lean patients, defined as Body mass index <25 kg/m², and 14 overweight/obese patients, defined as BMI ≥25 kg/m² )"
89425404|NCT06150898|Experimental|Pre-operative ketorolac|"Investigational Medicinal Product (IMP): Ketorolac~Number of subjects: 28 (14 lean patients, defined as Body mass index <25 kg/m², and 14 overweight/obese patients, defined as BMI ≥25 kg/m² )"
89425405|NCT06150898|Experimental|Pre-operative pregabalin|"Investigational Medicinal Product (IMP): Pregabalin~Number of subjects: 28 (14 lean patients, defined as Body mass index <25 kg/m², and 14 overweight/obese patients, defined as BMI ≥25 kg/m² )"
89195899|NCT00826917||Objective 1: XI VOCALTM in 3D fetal volumetry measurement|group 1: multiplanar; group 2: VOCALTM; group 3: XI VOCALTM
89195900|NCT00826917||Objective 2: XI VOCALTM in 3D placental volumetry measurement|group 1: multiplanar; group 2: VOCALTM; group 3: XI VOCALTM
89195901|NCT00826917||Objective 3: Comparison between 2 ultrasound machine|"intramachine reliability for (i)fetal, (ii)gestational sac and (iii)placenta volumetry measurement for (a)multiplanar and (b)VOCALTM:- group 1:Accuvix; group 2:Voluson 730~intermachine reliability for fetal, gestational sac and placenta volumetry measurement for (a)multiplanar and (b)VOCALTM for Accuvix and Voluson 730"
88906321|NCT03011684|Experimental|ER Positive - Letrozole|
88906322|NCT03011684|Experimental|ER Positive - Tamoxifen|
89425406|NCT06150898|Experimental|Pre-operative ketorolac and pregabalin|"Investigational Medicinal Products (IMPs): Ketorolac and pregabalin~Number of subjects: 28 (14 lean patients, defined as Body mass index <25 kg/m², and 14 overweight/obese patients, defined as BMI ≥25 kg/m² )"
88906323|NCT03011684|No Intervention|ER Negative|
89425407|NCT06150885|Experimental|CAR001|CAR001 cells mixed with normal saline will be administered to patients.
89425408|NCT06150833|Experimental|Boya IVIG|Patients with primary immunodeficiency will switch to Boya IVIG and optimize the posology in a run-in period of 2 to 6 administrations. In the one-year test period, the patients will receive the test IVIG at 21- or 28-day intervals and be followed. The minimum IgG concentration will be measured in all participants at all visits. The other pharmacokinetic parameters will be measured between visits 4 and 5 in 20 adult participants by taking additional blood samples. An independent Safety Data Monitoring Committee (SDMC) will periodically monitor adverse events.
88906324|NCT03003299|Experimental|TAVR - Failing surgical or transcatheter valve|Patients with a failing surgical or transcatheter bioprosthetic valve will undergo transcatheter aortic valve replacement (TAVR).
88906325|NCT02993120||Cohort 1|For the cohort of approximately 500 subjects taking a PCSK9i at baseline: proof consisting of a current prescription for an approved PCSK9i and subject confirmation that they have taken a PCSK9i within 30 days prior to enrollment is necessary.
89195902|NCT00826917||Objective 4:3D volumetry in fetuses at risk of Hb Bart's|Measurement of fetal, gestational sac and placenta volume per CRL quotient using multiplanar technique:- group 1: affected; group 2: unaffected
89195903|NCT00825201|Experimental|Treatment (paclitaxel albumin-stabilized nanoparticle)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation given IP on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89195904|NCT00901030||Patients with PCI on blood thinners|Patients have a coronary stent and are taking anti-clotting (anti-platelet) drug and are having non-cardiac surgery.
89195905|NCT00825279|Active Comparator|1-BMS|Bare Metal Stent (Euca STS Flex)
89425409|NCT06150781||Erenumab-aooe-exposed|Pregnant women with confirmed migraine who received erenumab-aooe before or during pregnancy will qualify to be included in the cohort. Dosing and treatment duration of erenumab-aooe as part of this observational study is at the discretion of the healthcare provider (HCP) in accordance with local clinical practice and local labeling.
89425410|NCT06150781||Erenumab-aooe-unexposed (Internal Comparator)|Pregnant women with clinically confirmed migraine who were not exposed to erenumab-aooe before or during pregnancy will be included in the internal comparator cohort.
89425411|NCT06150781||Women Without Migraine (External Comparator)|Pregnant woman without migraine will be included in this cohort as external comparator. The Metropolitan Atlanta Congenital Defects Program (MACDP) birth defects classification system will be used to characterize major and minor congenital malformations for this study.
89195906|NCT00825279|Experimental|2-DES|Drug Eluting Stent (Euca STS Flex DE), Paclitaxel Eluting stent with biodegradable polymer
89425412|NCT06150729||OnabotulinumtoxinA|Participants will receive OnabotulinumtoxinA as prescribed by their physician.
89425413|NCT06150703|Active Comparator|Ovulation triggering with hCG + Luteal phase support with vaginal progesterone|hCG 250µg subcutaneously between 36h and 38h before oocyte retrieval + Progesterone 600mg/d (200mg tid) vaginally from the evening of the oocyte retrieval until the first pregnancy test
89425414|NCT06150703|Experimental|Ovulation triggering with Triptorelin + Luteal phase support with Nafarelin|Triptorelin 0.2 mg subcutaneously between 36h and 38h before oocyte retrieval as a single dose Nafarelin 400µg /day (200µg in the morning 200µg in the evening) nasally from the evening of the oocyte retrieval until the first pregnancy test
89425415|NCT06150690||Type 2 diabetes|Patients with type 2 diabetes undergoing (partial) pancreatectomy
89425416|NCT06150690||Type 3 diabetes|Patients with type 3 diabetes undergoing (partial) pancreatectomy
88906326|NCT02993120||Cohort 2|• For the cohort of approximately 2000 subjects with LDL-C ≥ 100 mg/dL: confirmation of LDL-C ≥100 mg/dL with no change in LLT for 4 weeks.
88906327|NCT02993120||Cohort 3|For the cohort of approximately 2500 subjects with LDL-C 70-99 mg/dL: confirmation of LDL-C 70-99 mg/dL with no change in LLT for 4 weeks
88906328|NCT02968108|Experimental|Group1: Ustekinumab Dose Regimen 1|Subjects will receive a single intravenous (IV) induction dose of 3 milligram per kilogram (mg/kg) for subjects less than < 40 kilogram (kg) or 130 milligram (mg) for subjects greater than or equal to >= 40 kg at Week 0 followed by subcutaneous (SC) maintenance dose of 2 mg/kg for subjects < 40 kg or 90 mg for subjects >= 40 kg at week 8.
88906329|NCT02968108|Experimental|Group2: Ustekinumab Dose Regimen 2|Subjects will receive a single Intravenous (IV) dose of 9 mg/kg for subjects <40 kg or 390 mg for subjects >= 40 kg at Week 0 followed by SC maintenance dose of 2 mg/kg for subjects <40 kg or 90 mg for subjects >= 40 kg at week 8.
88906330|NCT02957149|Experimental|Platelet Rich Plasma (PRP) Treatment|Platelets that are collected from the subject during the radical prostatectomy, for prostate cancer. The Autologous Platelet-Rich Plasma is concentrated in a device (Angel Concentrated Platelet Rich Plasma System) to 1,000,000 platelets/mL and applied topically once to the neurovascular bundle during the surgery.
88906331|NCT02947347|Experimental|(Arm A) ibrutinib + rituximab|Participants will receive 560mg of ibrutinib and rituximab 375mg/m^2 weekly x4 with maintenance.
89195907|NCT00820833|Placebo Comparator|1|Standard infant formula
89195908|NCT00820833|Experimental|2|Test formula
89425417|NCT06150690||Non-diabetic controls|Patients with normal glucose metabolism undergoing (partial) pancreatectomy
89195909|NCT00820833|No Intervention|3|Breastfeeding reference group
88906332|NCT02947347|Placebo Comparator|(Arm B) placebo + rituximab|Participants will receive placebo and rituximab 375mg/m^2 weekly x4 with maintenance.
88906333|NCT02870907|Experimental|Low risk group|
89195910|NCT00820911|Active Comparator|cyclosporine (reduced exposure) / everolimus|
89195911|NCT00820911|Experimental|AEB071 300 mg b.i.d. / everolimus|
89195912|NCT00820911|Experimental|AEB071 200 mg b.i.d. / everolimus|
89195913|NCT00605722|Experimental|bevacizumab + erlotinib|Participants received bevacizumab (Avastin) 5 mg/kg intravenous (iv) on day 1 of each 2 week cycle plus erlotinib (Tarceva) 150 mg orally once a day until disease progression or unmanageable toxicity.
89007320|NCT05263037|Sham Comparator|56-day control (Sham VR)|participants in the first control arm will receive 2D Sham VR virtual reality content during the 8-week interventional program and continue to be followed for 24 months after the completion of treatment. participants in the Sham VR group will receive the same Pico G2 4K headset as participants in the immersive VR groups, but rather than view 360-degree, 3D, interactive content specially selected for efficacy, they will only have access to 2D nature footage with neutral music layered on top that is selected to be neither overly relaxing nor distracting. The experience of Sham VR is similar to watching a large-screen TV, but it is not interactive. The advantage of Sham VR is that it controls for the novelty and immersion of the hardware and isolates the effect of VR skill-based training
89195914|NCT00826995|Experimental|Video-based education arm:|Subjects receiving the video-based educational material
89195915|NCT00826995|Active Comparator|Written education arm:|Subjects receiving the written educational material
89195916|NCT00820989|Experimental|A|Time points after IV Endotoxin administration compared to baseline (immediately before Endotoxin administration).
89195917|NCT00882076|Experimental|Treatment Cohort 1|Etoposide (Days 1-5) 100 mg/m2; Mitoxantrone (Days 1-3) 8 mg/m2 (3 doses); Clofarabine (Days 2-6) 20 mg/m2
89425418|NCT06150625|Active Comparator|Orthopedic Manual Therapy|"Participants randomized to this arm will receive clinician-selected orthopedic manual therapy targeting the joints of the low back. Selected techniques can involve joint mobilizations or spinal manipulation. The dosage parameters will be determined by the clinician.~Patient Education Patients will receive education regarding their low back pain, advice to stay active, proper performance of their home exercise program.~Home exercise program The program will consist of 10 exercises which the clinician will select 5 they feel would be most beneficial to the patient. These can include aerobic, general strengthening, directional preference, or neural self-mobilizations."
89425419|NCT06150625|Active Comparator|Dry Needling|"Participants randomized to this arm will receive dry needling to the low back and lower extremity while being applied based on clinician-selected areas of symptomatic soft tissue. The dosage parameters will be determined by the clinician.~Patient Education Patients will receive education regarding their low back pain, advice to stay active, proper performance of their home exercise program.~Home exercise program The program will consist of 10 exercises which the clinician will select 5 they feel would be most beneficial to the patient. These can include aerobic, general strengthening, directional preference, or neural self-mobilizations."
89425420|NCT06150625|Experimental|Orthopedic Manual Therapy and Dry needling|"Participants randomized to this arm will receive dry needling to the lumbar spine and lower extremity based on clinician-selected areas of symptomatic soft-tissue and or orthopedic manual therapy targeting the joints of the low back.~Patient Education Patients will receive education regarding their low back pain, advice to stay active, proper performance of their home exercise program.~Home exercise program The program will consist of 10 exercises which the clinician will select 5 they feel would be most beneficial to the patient. These can include aerobic, general strengthening, directional preference, or neural self-mobilizations."
89425421|NCT06150599|Experimental|SNM for the treatment of CPP|Patients will be enrolled based on study eligibility criteria. Eligible patients will be scheduled for a Interstim X implant in the operating room. The procedure is completed under anesthesia, either conscious sedation with intubation or breathing assistance. Under fluoroscopic guidance a standard lead will be introduced. Each electrode on the lead will be tested by confirming motor response on at least 3 of 4 leads. Next the implantable pulse generator will be placed in a subcutaneous pocket and secured. Impedance will be tested, 4 standard programs will be set, and then the device will be shut off. The device settings will be adjusted per protocol and the device will be turned on and off during visits 2-7.
88906334|NCT02870907|Experimental|Intermediate risk sub group 1|2 cycles (4 courses): 2 courses of etoposide and Carboplatin from D1 to D5 and Vincristin at D22 and D26- Cyclophosphamide from D22 to D26.
89425422|NCT06150586||Preterm infants with minimal gestational age of 27 weeks requiring LISA|LISA will be preformed according to our local standard protocol while measuring skin conductance via a specific monitor. At the same time a video is recorded for later unblinded and blinded N-PASS assessment.
89425423|NCT06150547||Central Nervous System Malignant Tumor|Subjects may receive up to two CEST MRI's tests and/or up to two F-DOPA PET. The physician will determine which test is appropriate based on your tumor type, past treatment history and research question. Tests will be completed at initial baseline visit and at least one other MRI/PET after the initial baseline, up to a maximum of four scans.
89425424|NCT06150508|No Intervention|Comparative group|Comparators will not be provided with the O2O service, but will be treated as usual (TAU) through the 1st tier health care clinics/centers in Pyeongchang-gun county.
89425425|NCT06150508|Experimental|Intervention group|"Intervention group will use the service app Value Health for life-log recording. They regularly record life-log data such as blood pressure, blood glucose, medication, diet, exercise, and weight. (As mentioned, glucose level and blood pressure measurements will be automatically shared with the app using Bluetooth function of the provided checkers.) Interventions through application include automated message and alarm service through the app, as well as personalized intervention messages, record management, and other interventions from the Smart Healthcare Center and the primary healthcare provider."
89425426|NCT06150495||Healthy control|The controls included patients without DM who presented for regular ophthalmic examination.
89425427|NCT06150495||intensive control (IC) group|The mean HbA1c level was calculated during the 12 months prior to the OCT and OCTA. Based on the mean HbA1c level, T2DM patients were divided into intensive control (IC; mean HbA1c ≤ 7.0%) and moderate control (MC; mean HbA1c > 7.0%) groups
89425428|NCT06150495||moderate control (MC) group|The mean HbA1c level was calculated during the 12 months prior to the OCT and OCTA. Based on the mean HbA1c level, T2DM patients were divided into intensive control (IC; mean HbA1c ≤ 7.0%) and moderate control (MC; mean HbA1c > 7.0%) groups
88906335|NCT02870907|Experimental|Intermediate risk sub group 2|2 courses of Vincristin and Carboplatin
88906336|NCT02870907|Experimental|High risk group|"Orbital irradiation~3 cycles of two different types of alternating chemotherapy courses (id 6 courses) :~Etoposide (100 mg/m²/d) and Carboplatin (160 mg/m²/d) with intrathecal Thiotepa injection.~Vincristin (1,5 mg/m²/d) - Cyclophosphamide (1000 mg/m²/d)~Cytapheresis for peripheral blood stem cells collection after the primary or the secondary courses of Vincristine- Cyclophosphamide.~High dose chemotherapy :~Carboplatin (AUC : 7/d) - etoposide (250 mg/m²/d) - Thiotepa (300 mg/m²/d)~Peripheral bood stem cell transplantation."
88906337|NCT02823574|Experimental|Nivolumab and Ipilimumab|Specified dose on specified days
88906338|NCT02823574|Active Comparator|Nivolumab and Ipilimumab-placebo|Specified dose on specified days
88906339|NCT02746809|Experimental|CoreValve Evolut 34R TAVR system|Treatment of Aortic Stenosis with Medtronic CoreValve Evolut R 34R TAVR System.
88906340|NCT02641028|Experimental|CERC-501|Administered orally once daily, 15mg daily, 8 days.
88906341|NCT02641028|Placebo Comparator|Placebo|Administered orally daily, 8 days.
88906342|NCT02525796|Placebo Comparator|Placebo + Cinacalcet|Patients with primary hyperparathyroidism will receive placebo for 4 weeks followed by the addition of cinacalcet for 2 weeks
88906343|NCT02525796|Active Comparator|Amiloride + Cinacalcet|Patients with primary hyperparathyroidism will receive amiloride for 4 weeks followed by the addition of cinacalcet for 2 weeks
88906344|NCT02525796|Experimental|Eplerenone + Cinacalcet|Patients with primary hyperparathyroidism will receive eplerenone for 4 weeks followed by the addition of cinacalcet for 2 weeks
88906345|NCT02360280|Experimental|Six ketamine infusions|Six infusions of 0.5 mg/Kg of ketamine hydrochloride solution over 2 weeks.
89425429|NCT06150469|Active Comparator|Blend of ginger and lemon essential oils|"The experimental group will benefit from conventional management of NVCI (antiemetic prophylaxis in accordance with ESMO international recommendations) plus an aromastick of ginger and lemon essential oils renewed with each course of chemotherapy.~Patients were included for 3 cycles of chemotherapy (C1, C2, C3)."
89425430|NCT06150469|Placebo Comparator|Neutral oil|The control group will receive conventional management (antiemetic prophylaxis according to international recommendations, ESMO) of NVCI plus a placebo of aromastick containing a neutral, odourless oil, renewed with each course of chemotherapy.
89425431|NCT06150417|Active Comparator|SST + RT|"Participants will receive the standard of care. Standard systemic therapy (SST) and definitive local therapy (radiotherapy [RT] or radical prostatectomy [RP]) are the standard of care for de novo oligometastatic prostate cancer. This arm will be used to compare to the experimental arm.~SST will begin 6 weeks of randomization and occur for 12 months. The definitive local therapy will be RT, with a small portion undergoing RP. Local therapy should be completed by the end of Week 20."
89195918|NCT00882076|Experimental|Treatment Cohort 2|Etoposide (Days 1-5) 100 mg/m2; Mitoxantrone (Days 1-3) 8 mg/m2; Clofarabine (Days 2-6) 25 mg/m2
89195919|NCT00882076|Experimental|Treatment Cohort 3|Etoposide (Days 1-5) 100 mg/m2; Mitoxantrone (Days 1-3) 8 mg/m2; Clofarabine (Days 2-6) 30 mg/m2
89195920|NCT00882076|Experimental|Treatment Cohort 4|Etoposide (Days 1-5) 100 mg/m2; Mitoxantrone (Days 1-5) 8 mg/m2; Clofarabine (Days 2-6) 30 mg/m2
89195921|NCT00882076|Experimental|Treatment Cohort 0|Etoposide (Days 1-5) 100 mg/m2; Mitoxantrone (Days 1-3) 8 mg/m2; Clofarabine (Days 2-6) 10 mg/m2 (In the event of a DLT in Treatment Cohort 1)
89195922|NCT00825435|Experimental|1|Coronary CT angiogram plus Standard of care (CTA+SOC)
89195923|NCT00825435|No Intervention|2|Standard of Care (SOC)
89425432|NCT06150417|Experimental|SST + RT + MDRT|"Participants will receive the standard of care. Standard systemic therapy (SST) and definitive local therapy (radiotherapy [RT] or radical prostatectomy [RP]) are the standard of care for de novo oligometastatic prostate cancer. This arm will be used to compare to the experimental arm.~SST will begin 6 weeks of randomization and occur for 12 months. The definitive local therapy will be RT, with a small portion undergoing RP. Local therapy should be completed by the end of Week 20.~MDRT should be completed by the end of Week 24. Depending on the participant, there are different approaches to MDRT dosing and fraction size."
89425433|NCT06150391|Experimental|Group GA-E. Patients without previous occlusion o penalization treatment - Experimental|"GA-E volunteers (experimental) will be prescribed home therapy using computer-based exercises (Visionary) for 12 weeks, five days week, ½ half hour per day. Visionary target frequencies will be adjusted, considering BCVA, each three weeks. Contrast of Gabor patch frequencies will be adjusted to match patient contrast sensitivity thresholds.~In case BCVA does not improve at least 2 lines in two consecutive visits (6 weeks), patients will change to GA-C."
88906346|NCT02360280|Active Comparator|Single ketamine infusion preceded by 5 midazolam infusions|Single infusion of 0.5 mg/Kg of ketamine hydrochloride solution preceded by midazolam 0.045 mg/kg over 2 weeks.
88906347|NCT02201251|Experimental|Topiramate|Topiramate weight based dosing for participants 2 to less than (<) 10 years of age not to exceed 350 mg/day (milligram per day), as tolerated; not to exceed 400 mg/day in participants 10-15 years of age, as tolerated.
88906348|NCT02201251|Active Comparator|Levetiracetam|Levetiracetam weight based dosing for all participants 2-15 years of age, not to exceed 60 milligram per kilogram per day (mg/kg/day), as tolerated. The maximum recommended daily dosage is 3,000 milligram (mg).
88906349|NCT02174575|Active Comparator|Sevoflurane|Patients are randomized into 2 groups (Desflurane group and Sevoflurane group) depending on the anesthetic agents administered during anesthesia.
88906350|NCT02174575|Active Comparator|Desflurane|Patients are randomized into 2 groups (Desflurane group and Sevoflurane group) depending on the anesthetic agents administered during anesthesia.
88906351|NCT02153814|Sham Comparator|Control|Will undergo sham procedure twice
88906352|NCT02153814|Experimental|One Endometrial Scratch Procedure|Will undergo one sham procedure and one endometrial scratch procedure
88906353|NCT02153814|Experimental|Two Endometrial Scratch Procedures|Will undergo endometrial scratch procedure twice
89195924|NCT00901108|Active Comparator|Trabectome-IOL|Combined Trabectome and cataract extraction with intraocular lens insertion
89195925|NCT00901108|Active Comparator|Trab-IOL|Combined Trabeculetomy with Mitomycin C and cataract extraction with intraocular lens insertion
89425434|NCT06150391|Active Comparator|Group GA-C. Patients without previous occlusion o penalization treatment - Control|"GA-C patients (control) will be prescribed occlusion following Pediatric Eye Disease Investigation Group (PEDIG) criteria: 2 hours for mild and moderate amblyopia or 6 hours for severe amblyopia. Patients will receive a calendar to track patching accomplishment.~In case BCVA does not improve at least 2 lines in two consecutive visits (6 weeks), patients will change to GA-E."
89425435|NCT06150391|Experimental|Group GB-E. Patients with previous occlusion o penalization treatment - Experimental|"GB-E volunteers will receive occlusion following PEDIG criteria and will be prescribed home therapy using Visionary. Patients will receive a calendar to track patching accomplishment.~Visionary target frequencies will be adjusted, considering BCVA, each three weeks."
89425436|NCT06150391|Active Comparator|Group GB-C. Patients with previous occlusion o penalization treatment - Control|"GB-C volunteers will receive occlusion following PEDIG criteria and will be prescribed home therapy using Visionary. Patients will receive a calendar to track patching accomplishment.~Visionary target frequencies will always be low, no matter patient VA.~In case BCVA does not improve at least 2 lines in two consecutive visits (6 weeks), patients will be move to GB-E."
89425437|NCT06150378|Active Comparator|Corticoid|Patients that recieve corticosterone injection instead of plathet rich plasma.
88906354|NCT02027545|Experimental|Decision Aid|Patients of primary care providers randomly assigned to the Decision Aid intervention (DA) that includes an individualized decision aid, provider education, and modified performance measure/reminder.
88906355|NCT02027545|Other|No Decision Aid|Patients of primary care providers will be randomly assigned to the pragmatic control (PC) that includes provider education and modified performance measure/reminder, but no decision aid.
88906356|NCT01937039||Breast cancer patients|Participants have a known diagnosis of breast cancer and are receiving a breast cancer evaluation and/or treatment, who agree to sample collection, access, and follow-up as part of the repository.
88906357|NCT01937039||Benign breast disease|Participants have benign breast disease and are receiving a diagnostic procedure and/or evaluation, who agree to sample collection, access, and follow-up as part of the repository.
89195926|NCT00827151|Active Comparator|Estrogen and lifestyle|
89195927|NCT00827151|No Intervention|Lifestyle|
89195928|NCT00882154|Experimental|1|Cefdinir 300 mg Capsule (Sandoz, Austria)
89425438|NCT06150378|Experimental|Plathet rich plasma|Patients that recieve plathet rich plasma instead of corticoesterone
89425439|NCT06150365|Experimental|TCR-T cells|KSX01-TCRT cell therapy
89195929|NCT00882154|Active Comparator|2|Omnicef Cefdinir 300 mg Capsule (Abbott Laboratories, USA)
89195930|NCT00825591|Active Comparator|1|Individuals with abnormal rhythmicity will be treated with melatonin to assess if sleep patterns are improved.
89425440|NCT06150352||Subjective or mild cognitive impairment patients|Subjective or mild cognitive impairment patients with or without CPAP treatment
89425441|NCT06150339|Experimental|Intervention|"Intervention Dose: Up to 45 minutes per session, 5 sessions per week, for 6 weeks. Approximately up to 30 minutes will be spent walking; up to 15 minutes will be spent performing sit-to-stands.~Intervention Components:~Component 1: Patient-Centered Communication Care Plan. A patient-centered communication care plan will be created, to promote enjoyment and engagement during the sessions. The care plan will be informed by interviews with the participant and their care partner.~Component 2: Sit to Stand Activity. A target number of sit to stands per session will be determined based on a baseline assessment and according to an algorithm; the target will be progressed halfway into the intervention.~Component 3: Walking Program. Based on the findings from the patient-centered assessment interviews as well as the performance of the participants on a walk test at baseline (Time 1), an individualized walking program will be carried out with participants."
89425442|NCT06150326|Experimental|medical honey|the patients randomised to this arm will have honey (Activon® Advancis Medical.)
89425443|NCT06150326|Active Comparator|standard of care|the patients randomised to this arm will have standard of care recommanded by HAS (french organisation)
89425444|NCT06150313|Experimental|Mediational Intervention for Sensitizing Caregivers, Teachers' version (MISC-T)|MISC-T is an adaptation of MISC for trainers. The trainer is the figure who trains a caregiver to enable him/her to interact with higher quality (i.e., with more MISC components). MISC for trainers is commonly administered to groups of 6-20 trainees, either face to face or using videoconference, and consists of 8 hours of theory about MISC principles and 12 hours of practice using video feedback. Video feedback is the core component of MISC training, which aims to transfer more competency than knowledge, using ecological practice. This means using video recordings of daily interactions with a significant child and watching them together (supervisor and trainee) to enable the trainee to realize the consequences of MISC components. MISC for trainers was adapted to be administered to groups of 6-12 teachers using 4 x 2-hours theoretical sessions (8h) and 11 x 1.5-hours of practice using video-feedback.
89425445|NCT06150313|Experimental|Mediational Intervention for Sensitizing Caregivers, Self-Administered version (MISC-SA)|This MISC version (MISC-SA) aims to transference the MISC training to wider communities by diminishing the cost of the teaching and learning. By implementing the MISC lessons in an online platform, thus allowing self-learning, the new Self-Administered version of MISC allows to obtain MISC training in 25 weekly sessions distributed across 7 months (approximately, a scholar course). In contrast to MISC-T, this version allows the simultaneous self-training of a high number of participants with very low intervention of a supervisor, which diminishes the cost. As MISC-T, MISC-SA keeps the core component of MISC trainings (video-feedback) by fostering participants to record interactions and then visualize them using guided reflection.
89425446|NCT06150313|Active Comparator|Mediational Intervention for Sensitizing Caregivers - Readings version (MISC-R)|Teachers usually do not get training to improve the quality of the interactions. However, to avoid using a Waiting-List or a Placebo control group, a last version of MISC training was designed but, this time, without the core MISC component: video-feedback. MISC-Readings provides the theoretical knowledge of MISC but lacks practice and reflection of MISC components by watching once own video recorded interactions with a significant child. MISC-Readings substitutes all the practice time of the other versions (video-feedback) by readings, that is, theoretical knowledge. This assimilates this version to the 'intellectual' or more theoretical format of teachers' common training, even when it is referred to social-emotional learning.
89425447|NCT06150300|Active Comparator|Physical activity intervention|8 week virtual pulmonary rehab program including breathing exercises and educational messages.
89425448|NCT06150300|Placebo Comparator|Placebo|Breathing exercises and educational messages
89195931|NCT00825591|Placebo Comparator|2|
89007321|NCT05263037|Sham Comparator|• 56-day control (Sham VR plus 8w extended on-demand)|participants in the second control arm will receive 2D Sham VR virtual reality content during the 8-week interventional program and be offered an extended 8-week on-demand period, after which they will continue to be followed for 24 months after the completion of treatment.Participants in the Sham VR group will receive the same Pico G2 4K headset as participants in the immersive VR groups, but rather than view 360-degree, 3D, interactive content specially selected for efficacy, they will only have access to 2D nature footage with neutral music layered on top that is selected to be neither overly relaxing nor distracting.
89007322|NCT05250856|Experimental|CNP-201 1 mg|intravenous infusion on Day 1 and Day 8: 1 mg CNP-201
88906358|NCT01937039||Healthy volunteer|Participants have no known diagnosis of breast disease or abnormality and are undergoing routine screening or diagnostic breast imaging procedures and/or other clinical evaluation, who agree to sample collection, access, and follow-up as part of the repository.
89425449|NCT06150274|Active Comparator|standard Inoue balloon technique|Those randomized to the standard care will undergo the procedure using the contemporary Inoue balloon system (Toray Industries, Japan), which is available in 4 sizes: 24, 26, 28 and 30 mm.
89425450|NCT06150274|Active Comparator|wire assisted crossing|The procedure is performed on a similar fashion until atrial septal entry. Once the atrial wall is traversed, and the Mullins sheath is within the left atrium, the mitral valve is crossed with a flexible 0.032- or 0.035 in- 145 cm J-tipped wire. This step could be assisted by a steerable sheath. Once the mitral valve is crossed, the initial wire will be exchanged with a looped stiff wire (Safari or similar) to the left ventricle by use of a 5/6 f pigtail catheter. A commercially available balloon is used to perform the valvulotomy/commissurotomy procedure. Choice of balloon size is made following the formula: Balloon size = patient height (cm)/10 + 10. Fine tuning of the balloon size will be performed peri-operative based on transesophageal echo findings. Use of a separate stiff wire placed in the left atrium/pulmonary vein to ease passage through the atrial septum is left to the discretion of the operator based on the anatomical challenges faced during the procedure.
89425451|NCT06150261|Experimental|AvailOm|Availom capsules will be administered orally in a dose of 5 capsules/day per individum for a total of 6 months.
88906359|NCT01889810|Active Comparator|Vitamin D3 supplementation|Patients will take 3000IU (75 µg) Vitamin D3 supplementation per day for a period of 26 weeks.
88906360|NCT01889810|Placebo Comparator|Placebo|Placebo group
88906361|NCT01888198||renal mass ablation candidates|Standard of care interventions for the treatment of renal masses using energy ablation will be studied. Data collection can be divided into five basic categories: 1) Patient demographics and relevant history, 2) Renal mass characteristics, 3) Ablation procedure details, 4) Imaging studies, and 5) Patient-reported quality of life.
88906362|NCT01867242|Experimental|Usual Brand Cigarette|Smoking usual brand cigarette controls, who after 8-weeks will be offered Camel Snus and instructed for partial or complete substitution of cigarettes (subject's choice);
88906363|NCT01867242|Experimental|Complete Substitution|Use snus in place of cigarettes
88906364|NCT01867242|Experimental|Partial Substitution (Snus and Cigarettes)|Use snus and cigarettes how ever you like
88906365|NCT01860560|Experimental|CPAP First / HFT Second|Subjects to receive both therapies, order-randomized to receive Continuous Positive Airway Pressure (CPAP) therapy study first, followed by a washout period, and a follow-on High-Flow Therapy (HFT) therapy study
88906366|NCT01860560|Experimental|HFT First / CPAP Second|Subjects to receive both therapies, order-randomized to receive High-Flow Therapy (HFT) therapy study first, followed by a washout period, and a follow-on Continuous Positive Airway Pressure (CPAP) therapy study.
88906367|NCT01858688|Experimental|Accuracy of multi-parametric MRI relative to prostate biopsy|Determine the sensitivity and specificity of MP-erMRI relative to repeat 12 core TRUS biopsy for classifying upgrading of disease extent or Gleason grade in men considering AS.
88906368|NCT01840592|Experimental|Sorafenib plus Doxorubicin|Doxorubicin 60 mg/m2 IV on Day 1 of each 3 weeks cycle until unacceptable toxicity Sorafenib 400 mg PO BID or last dose patient from previous sorafenib based therapy, until unacceptable toxicity or disease progression, after which sorafenib can be continued as a single agent.
88906369|NCT01831895|Experimental|MobiusHD™|MobiusHD™
88906370|NCT01734694|Active Comparator|Vancomycin|
88906371|NCT01734694|Active Comparator|Comparator|
88906372|NCT01639053||Gel Participants|
88906373|NCT01639053||Control Participants|
89425452|NCT06150261|Placebo Comparator|Placebo|Placebo capsules matching AvailOm will be administered orally in a dose of 5 capsules/day per individum for a total of 6 months.
89425453|NCT06150235||Chronic hemodialysis patients|patients with chronic hemodialysis
89425454|NCT06150209|Other|Treatment with Vendaje|application of Vendaje
89425455|NCT06150196|Experimental|Mindfulness-based Stress Reduction class|Mindfulness-based Stress Reduction (MBSR) is a 9-week class that meets 2.5 hours/week and involves training in mindfulness (being present in the moment), meditation, and yoga. The MBSR course is taught by a certified MBSR instructor.
88906374|NCT01599234|Experimental|Sativex|Active treatment
88906375|NCT01599234|Placebo Comparator|Placebo|Control
88906376|NCT01393301|Experimental|Behavioral Intervention Arm|Standard smoking cessation treatment and nicotine replacement therapy (NRT) plus a cognitive-behavioral therapy for anxiety, depression, or other symptoms of distress.
88906377|NCT01393301|Other|Control Arm|Enhanced Treatment as Usual (ETAU); enhanced standard smoking cessation treatment and nicotine replacement therapy (NRT).
88906378|NCT01357668||Patients with JIA who are treated with Abatacept|Patients with JIA who are treated with Abatacept according to physicians'/families' decisions
88906379|NCT01339546||Study population|All ambulatory visits for otitis media, myringotomy tube insertion, skin rash or trauma among children age 5 or under during the periods of study
88906380|NCT00716625||sunitinib malate|Patients taking sunitinib malate
88906381|NCT00713817|Experimental|Sativex|
88906382|NCT00713817|Placebo Comparator|Placebo|
88906383|NCT00713323|Experimental|Sativex|Active treatment
88906384|NCT00713193|Experimental|Cyclosporine and Plasma Exchange Arm|"Patients in this arm will receive cyclosporine (Neoral) at a dose of 2-3 mg/kg orally as an adjunct to plasma exchange.~All patients initiated daily PEX (one plasma volume), using plasma as the replacement fluid. Patients randomized to the CSA arm received CSA at a dose of 2-3 mg/kg (rounded to the nearest 50 mg increment) divided into a twice daily dosing (Figure 1a). Patients randomized to CSA did not receive steroids, but were permitted to receive hydrocortisone as required for any hypersensitivity reactions to the infused plasma. Daily PEX was continued until a clinical response was achieved, then patients received PEX every other day for 2 additional procedures, with the first day that the platelet count and LDH were normal counting as the first of the 2 procedures."
89007323|NCT05250856|Experimental|CNP-201 2 mg|intravenous infusion on Day 1 and Day 8: 2 mg CNP-201
89007324|NCT05250856|Experimental|CNP-201 4 mg|intravenous infusion on Day 1 and Day 8: 4 mg CNP-201
89425456|NCT06150196|Active Comparator|Brain Health Education Class|the Brain Health Education Class is a 9-week class that meets 2.5 hours/week and involves lectures/discussion about how the brain works, how the brain ages, neuroplasticity, and other topics on the brain.
89425457|NCT06150131|Experimental|Treatment group|Supervised exercise one session per week, un-supervised exercise two sessions per week, for tree months, followed by three months without organized exercise.
89425458|NCT06150131|Other|Control group|Three months without organized exercise, followed by the same exercise as the Treatment group for three months.
89007325|NCT05250856|Experimental|CNP-201 8 mg|intravenous infusion on Day 1 and Day 8: 8 mg CNP-201
89425459|NCT06150079|No Intervention|PEEP Group|After endotracheal intubation, an esophageal balloon is placed and calibrated for accurate positioning and inflation pressure. Continuous monitoring of end-expiratory esophageal pressure (Pes_ee) is conducted. Fixed PEEP of 3 cmH2O is applied throughout the procedure without lung recruitment maneuvers.
89425460|NCT06150079|Experimental|Pes-Guided PEEP Group (PEEPPtp)|After endotracheal intubation, an esophageal balloon is placed and calibrated for accurate positioning and inflation pressure. Continuous monitoring of end-expiratory esophageal pressure (Pes_ee) is conducted. Lung recruitment is performed at each time point. After lung recruitment, ventilation is adjusted based on the target PEEP. PEEP is chosen to maintain a positive transpulmonary pressure at end-expiration (Ptp_ee = PEEP - Pes_ee). PEEP titration following lung recruitment should be performed within 1 hour after endotracheal intubation or any procedure that may cause lung collapse, such as pneumoperitoneum, deflation or inflation of the endotracheal tube cuff, changes in position, or endotracheal suctioning.
88906385|NCT00713193|Active Comparator|Prednisone and Plasma Exchange Arm|"Patients in this arm will receive prednisone at a dose of 1 mg/kg as an adjunct to plasma exchange.~All patients initiated daily PEX (one plasma volume), using plasma as the replacement fluid. Patients randomized to the corticosteroid arm received prednisone at a dose of 1 mg/kg/d rounded to the nearest 20 mg increment. Daily PEX was continued until a clinical response was achieved, then patients received PEX every other day for 2 additional procedures, with the first day that the platelet count and LDH were normal counting as the first of the 2 procedures."
89425461|NCT06150066||Smokers with peri-implantitis|24 patients with smokers with peri-implantitis were included in this group.
88906386|NCT00710554|Experimental|Sativex|
88906387|NCT00710554|Placebo Comparator|Placebo|
88906388|NCT00710424|Experimental|Sativex|
88906389|NCT00710424|Placebo Comparator|Placebo|
88906390|NCT00674609|Placebo Comparator|Placebo|Placebo control
88906391|NCT00674609|Experimental|Sativex|Active treatment
88906392|NCT00674609|Experimental|THC Alone|Active treatment
88906393|NCT00562549|Experimental|1|SLx-2101
89425462|NCT06150066||Non-smoker individuals with peri-implantitis|24 patients with non-smokers with peri-implantitis were included in this group.
89425463|NCT06150066||Smokers with healthy peri-implant tissues|24 patients with smokers with healthy peri-implant tissues were included in this group.
88906394|NCT00562549|Placebo Comparator|2|Matching Placebo Dose
88906395|NCT00289107|Active Comparator|1|P.F.C.® Sigma™ Rotating Platform Cruciate Substituting Knee System
88906396|NCT00289107|Active Comparator|2|P.F.C.® Sigma™ Fixed Cruciate Substituting Knee System
88906397|NCT00118846|Active Comparator|Isoflavone Soy Protein (ISP) Supplementation|25 gm soy protein supplementation administered twice daily in equivalent dosages (12.5 gm)
88906398|NCT00118846|Placebo Comparator|Placebo|Milk protein matching placebo administered twice daily in equivalent dosages
88906399|NCT01556568|Experimental|MEK162|Patients will be treated with MEK162 only and will be uptitrated or down titrated based on safety and tolerability observed.
88906400|NCT01556607|Active Comparator|Experimental: MDT-637|
88906401|NCT01556607|Placebo Comparator|Placebo|
89425464|NCT06150066||Non-smoker individuals with healthy peri-implant tissues|24 patients with non-smokers with healthy peri-implant tissues were included in this group.
89425465|NCT06150053||R-CHOP-14|
89425466|NCT06150053||R-mini-CHOP|
89425467|NCT06150027|No Intervention|Standard|Conventional strategy: patients will be managed regardless of their PALLIA-10 score. The need for additional care, including palliative care, will be assessed by the team in charge of the patient, as per routine practice.
88906402|NCT01556646|Experimental|Tolvaptan|Open label study of tolvaptan. First 3 days as an inpatient then outpatient for the remainder of the study
88906403|NCT01556659|Active Comparator|Triple antithrombotic therapy|Treatment with aspirin, P2Y12 inhibitors and vitamin K antagonist.
89195932|NCT00899704||Group 1|Patient tissue samples are screened using polymerase chain reaction (PCR) for human papilloma virus-specific primers. Samples are analyzed to identify a nodal-metastasis signature for oral squamous cell carcinoma. Samples also undergo microarray analysis to quantify expression levels for targeted genes. Initial data analysis is performed using Affymetrix® Microarray Suite 5.0 to quantify expression levels for targeted genes.
89195933|NCT00825669|Active Comparator|survival rate (TACE)|to compare the effects of TACE and TACE plus laser ablation for treating patients with PVTT
89195934|NCT00825669|Active Comparator|survival rate (TACE plus laser ablation)|to compare the effects of TACE and TACE plus laser ablation for treating patients with PVTT
89195935|NCT00821067|Active Comparator|1|A 6 gm/day (3 gm/bid) dose of D-ribose
89425468|NCT06150027|Experimental|Experimental|Experimental strategy: patients will be systematically referred to a palliative care team.
89425469|NCT06150001|Placebo Comparator|dilute with normal saline|Researchers will dilute rocuronium at a dose of 0.8mg/kg with 2mL of normal saline. The rocuronium mixture will be injected into participants intravenous catheter.
89425470|NCT06150001|Active Comparator|dilute with 2%lidocaine|Researchers will dilute rocuronium at a dose of 0.8mg/kg with 2mL of 2%lidocaine. The rocuronium mixture will be injected into participants intravenous catheter.
89425471|NCT06150001|Experimental|dilute with investigator's blood|Researchers will dilute rocuronium at a dose of 0.8mg/kg with 2mL of blood. The rocuronium mixture will be injected into participants intravenous catheter.
89425472|NCT06149988|Experimental|Single dose of THC/CBD S.E powder|On visit 1: Subjects will receive a single dose of THC/CBD S.E powder- 500 mg, given orally.
89425473|NCT06149988|Active Comparator|a single dose of THC/CBD oil|On visit 2 (30 days later): Subjects will receive a single dose of THC/CBD oil- 8 mg, given orally (equivalent dose to the powder).
89425474|NCT06149962|Active Comparator|WALANT|Flexor Tendon Repair under Wide-Awake Local Anesthesia No Tourniquet
88906404|NCT01556659|No Intervention|Triple anti-thrombotic therapy|Treatment with aspirin, P2Y12 inhibitors and vitamin K antagonist.
88906405|NCT01556672|Experimental|adalimumab|All patients will receive adalimumab 80 mg followed by 40 mg at week 1 and 40 mg every other week (EOW) thereafter.
88906406|NCT01556685|Active Comparator|Group 1 Avonex|Approximately 90 subjects treated with IFN beta 1a IM 30μg
88906407|NCT01556685|Active Comparator|Group 2 Jumtab|Approximately 90 subjects treated with IFN beta 1a IM biosimilar
88906408|NCT01556698|Experimental|NVN1000 Gel|NVN1000 Gel topically applied one daily at bedtime for 8 weeks
88906409|NCT01556698|Placebo Comparator|Vehicle Gel|Vehicle Gel topically applied once daily at bedtime for 8 weeks
88906410|NCT01556711||Head Injury|Males and females ages 18 to 80 (the entire age range), who are admitted to the ED, who are suspected of a traumatically induced structural brain
89007326|NCT05250856|Placebo Comparator|Placebo|200 ml intravenous infusion on Day 1 and Day 8: CNP-201 Placebo
88906411|NCT01556711||Control|"A 'normal' control group will be recruited for comparison and will consist of ED patients (ED normal control group) who have sustained an injury but do not exhibit any trauma above the clavicle and no history of MVA requiring an ED visit or TBI within the past one (1) year, and no primary complaint of syncope"
88906412|NCT01556737|Experimental|Supplement|
88906413|NCT01556737|Placebo Comparator|Placebo|
88906414|NCT01556789|Experimental|ONT-10 Vaccine|ONT-10 investigational agent
88906415|NCT01556802|Experimental|Minocicline|minocicline 100mg oral twice a day for 5 days
88906416|NCT01556802|Placebo Comparator|Placebo|Pills filled with vegetal fiber with similar presentation of the drug. Given one pill oral twice a day for five days
88906417|NCT01556815|Active Comparator|Group TACE|Patients who undergo TACE
88906418|NCT01556815|Experimental|Group Combination|Patients who are treated with sorafenib combined with TACE
88906419|NCT01556841|Experimental|TroVax®|TroVax® consists of a highly attenuated VV (Modified Vaccinia Ankara, MVA) containing the human TAA 5T4 under regulatory control of a modified VV promoter, mH5.
88906420|NCT01556841|Placebo Comparator|Placebo|
88906421|NCT01556867|Active Comparator|dry cord care|
88906422|NCT01556867|Active Comparator|antiseptic care|
88906423|NCT01556880|Experimental|Short Message Service (SMS)|A computer-based text message database was created. Messages prompted subjects to get rid of smoking and eating out, to persevere with the quit smoking attempt with the emphasis on the peer pressure on the smoking cessation by the smoking ban in restaurants. They encouraged them to overcome the barriers of healthy eating diet and physical activity with a block of text messages.
88906424|NCT01556880|No Intervention|Standard usual care|
88906425|NCT01556893|Other|LASIK Flap Arm|This is a single arm study.
88906426|NCT01556919||Mucosal Impedance Probe|
88906427|NCT01556945|Experimental|Group A : FMP1/AS02 + RTS,S/AS02|FMP1 malaria vaccine given with the GlaxoSmithKline (GSK) adjuvant system, number 2 (AS02) and a second experimental malaria vaccine RTS,S also given with AS02 adjuvant concomitantly as separate sites of injection on days 0, 28 and 84. Malaria challenge phase began 14-30 days after the last vaccine.
88906428|NCT01556945|Experimental|Group B : FMP1/AS02 + RTS,S/AS02|FMP1 malaria vaccine given with the adjuvant AS02 and a second experimental malaria vaccine RTS,S also given with AS02 adjuvant at one injection site and saline at the opposite site on days 0, 28 and 84. Malaria challenge phase began 14-30 days after the last vaccine.
88906429|NCT01556945|Experimental|Group C: FMP1/AS02 + AS02|FMP1 malaria vaccine given with the adjuvant AS02 and a second experimental malaria vaccine RTS,S also given with adjuvant AS02 adjuvant alone at one injection site and saline at the opposite site on days 0, 28 and 84. Malaria challenge phase began 14-30 days after the last vaccine.
88906430|NCT01556945|Experimental|Group D : RTS,S/AS02 + AS02|RTS,S malaria vaccine given with the adjuvant AS02 and an adjuvant AS02 alone concomitantly at separate sites of injection on days 0, 28 and 84. Malaria challenge phase began 14-30 days after the last vaccine.
88906431|NCT01556945|Placebo Comparator|Control cohort|Infectivity controls (unvaccinated). Non-randomized infectivity controls were recruited specifically for the malaria challenge phase of the trial.
88906432|NCT01556958||Active Wheezing - age 5-12|
88906433|NCT01556958||Active Wheezing - under age 5|
89195936|NCT00821067|Placebo Comparator|2|A 6 gm/day (3 gm/bid) dose of dextrose.
88906434|NCT01556958||No Wheezing|
88906435|NCT01556971|Active Comparator|Botox|The study will be divided randomly into two groups of equal number; one arm will receive a Botox injection; the other will receive saline solution injection
88906436|NCT01556971|Placebo Comparator|Saline Solution|A saline solution will be injected in to the procerus and corrugator supercilii frown muscles of randomly chosen study participants.
88906437|NCT01556984||DSA group|
88906438|NCT01556984||control group|
88906439|NCT01557010|Experimental|Treatment A|
88906440|NCT01557010|Experimental|Treatment B|
88906441|NCT01557010|Experimental|Treatment C|
88906442|NCT01557010|Placebo Comparator|Treatment D|
88906443|NCT01557023|Experimental|dienogest 2 mg/ethynilestradiol 30 mcg;|
88906444|NCT01557023|Active Comparator|Yasmin®|
89195937|NCT00899860||patients with renal cell cancer|
89425475|NCT06149962|Active Comparator|BRACHIAL BLOCK|Flexor Tendon Repair under Brachial Plexus Block
89425476|NCT06149923||cases|Patients that histopathologically confirmed gastric and/or colorectal cancer, males and females.
89195938|NCT00821145|Active Comparator|1|50 patients operated using a conventional open surgery to exclude an abdominal aortic aneurysm
88814631|NCT01614509|Experimental|Combined group|The combined group receive intravitreal injection of 1.25 mg/0.05 ml bevacizumab and posterior subtenon injection of 40 mg/1.0 ml triamcinolone acetonide. The injections are performed using 0.5% proparacaine drops for topical anesthesia under sterile conditions. The Bevacizumab is injected through the pars plana using a 30-gauge needle and triamcinolone acetonide is injected through the posterior subtenon area (near macula) by using a 27-gauge needle at the same time.
88814632|NCT01614743|Experimental|IncobotulinumtoxinA|
88814633|NCT01614743|Placebo Comparator|Placebo|
88814634|NCT01701011|Experimental|PRCI-monitoring|Coping intervention, Daily Record Keeping, Questionnaires
88814635|NCT01701011|No Intervention|Routine care control|Questionnaires
88814636|NCT01701011|No Intervention|Monitoring control|DRK and Questionnaires
88814637|NCT01653587|Active Comparator|Transradial approach|Transradial approach percutaneous coronary intervention using the TR Band device to obtain hemostasis
88814638|NCT01653587|Active Comparator|Transfemoral approach|Transfemoral approach percutaneous coronary intervention using the AngioSeal vascular closure device STS Plus Platform to obtain hemostasis
88814639|NCT00943202|Experimental|Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV|150 subjects to receive-Day 0: 15 mcg H1N1 vaccine; Day 21: 15 mcg H1N1 vaccine; Day 42: TIV.
88814640|NCT00943202|Experimental|Group 2: Day 0-H1N1+TIV; Day 21-H1N1|150 subjects to receive-Day 0: 15 mcg H1N1 vaccine + TIV; Day 21: 15 mcg H1N1 vaccine.
88814641|NCT00943202|Experimental|Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1|150 subjects to receive-Day 0: TIV; Day 21: 15 mcg H1N1 vaccine; Day 42: 15 mcg H1N1 vaccine.
88814642|NCT00943202|Experimental|Group 3: Day 0-H1N1; Day 21-H1N1+TIV|150 subjects to receive-Day 0: 15 mcg H1N1 vaccine; Day 21: 15 mcg H1N1 vaccine + TIV.
88814643|NCT00943436|Active Comparator|Active males|Males who participate in at least 30 minutes of physical activity on 5 or more days per week for the last month.
88814644|NCT00943436|Active Comparator|Inactive males|Males who participate in less than 1 hour of physical activity per week for the last month.
88814645|NCT01614821|Experimental|Treatment Arm|PCI-32765; ibrutinib
88814646|NCT01654445|Experimental|TNK-tPA Tenecteplase|This is an open-label trial, all patients will receive tenecteplase.
89195939|NCT00821145|Experimental|2|50 patients operated using a total laparoscopic aortic aneurysm resection
88814647|NCT01615367|Experimental|NEW Tx|25 people will be randomized to NEW Tx, a weekly individualized psychotherapy. Therapy is 20 weeks long.
89195940|NCT00821145|Active Comparator|3|25 patients using a laparoscopic approach for AAA resection with a stapled proximal anastomosis
89195941|NCT00882232|Experimental|1|Cross-linked hyaluronan gel and radiotherapy. Cross-linked hyaluronan gel is injected under anesthesia between the prostate and rectum prior to the start of radiotherapy. The gel pushes the prostate away from the rectum over several months, thereby reducing the dose of radiation delivered to the rectum. Hyaluronic acid is a naturally-occurring substance that is gradually absorbed by the body.
89195942|NCT04038424|Experimental|Study group|The intervention group (n = 30) will receive Routine Hospital Management (RHM), conventional rehabilitation activity and AT (painting, coloring, listening to music and Hand Therapy Ball Exercises). Overall 9 sessions over a period of three weeks will be performed and each session will take around 30 min.
89195943|NCT04038424|No Intervention|Control group|The control group (n = 30) will receive only the Routine Hospital Management (RHM) and the department conventional rehabilitation activity.
89195944|NCT00901264||1|Patients with pathological diagnoses of cancer or leukemia
89195945|NCT00901264||2|3.1.3 Patients for whom chemotherapy is planned.
88814648|NCT01615367|Active Comparator|Treatment as usual (TAU)|25 people will be randomized to TAU and will meet with their psychiatrist as often as clinically needed over the 20 week study duration.
88814649|NCT01702259|Experimental|Erchonia Scanner device (GLS)|The Erchonia® GLS device is made up of six independent diodes, each emitting 17 milliwatts (mW), 532 nanometer (nm) of green laser light.
88814650|NCT01702259|Sham Comparator|Placebo device|Inactive Erchonia GLS device
88814651|NCT01703039|Experimental|sertraline + riluzole|sertraline 100 mg po daily and riluzole 50 mg po bid
88814652|NCT01703039|Active Comparator|sertraline + placebo|sertraline 100 mg po daily and placebo
88814653|NCT01656629|Active Comparator|teriparatide|teriparatide 20 mcg sq for 3 months
88814654|NCT01656629|Active Comparator|Alendronate|70 mg po weekly for 3 months
88814655|NCT01656629|Active Comparator|calcium and vitamin D|calcium 630 mg vitamin D 500 units daily for 3 months
88814656|NCT02158520|Experimental|Arm A (bevacizumab and nab-paclitaxel)|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15 and nab-paclitaxel IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients experiencing progressive disease may cross-over to Arm B within 2-4 weeks.
88814657|NCT02158520|Experimental|Arm B (ipilimumab)|Patients receive ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients experiencing progressive disease may cross-over to Arm A within 2-4 weeks.
88814658|NCT01703663|Experimental|EPAP|Provent Sleep Apnea Therapy.
88814659|NCT01703663|No Intervention|control|
88814660|NCT01704521|Active Comparator|Lead-In|Kinetic assessment of response guided treatment per standard of care with PegInterferon + Ribavirin for 4 weeks followed by 12 weeks of PegInterferon + Ribavirin + Telaprevir followed by variable duration of PegInterferon + Ribavirin
88814661|NCT01704521|Active Comparator|No Lead-in|Kinetic assessment of response guided treatment per standard of care with PegInterferon + Ribavirin + Telaprevir for 12 weeks followed by variable duration of PegIntereron + Ribavirin
88814662|NCT04154072|Active Comparator|NLY01 (2.5 mg)|NLY01 2.5 mg injection
88814663|NCT04154072|Active Comparator|NLY01 (5.0 mg)|NLY01 5.0 mg injection
88814664|NCT04154072|Placebo Comparator|Vehicle|inactive drug, injection
88814665|NCT01617083|Active Comparator|Azithromycin|Antibiotic used to treat infections.
88814666|NCT01617083|Placebo Comparator|Placebo|Compound thickening agent with sugar and flavor additives.
88814667|NCT04136132|Experimental|Biological collection|"Biological collection~For all the patients include in the study :~blood and tissue samples collected before and during treatment. In parallel to this biological collection, standardized clinical data will be entered into a database"
88814668|NCT04359524|Active Comparator|Intervention|Received vitamin D3 capsules (1200 IU/30µg).
88814669|NCT04359524|Placebo Comparator|Control|Received placebo (oil capsules).
88814670|NCT00943904|Experimental|Interstim stimulation|Patients who receive the interstim implant in order to evaluate effectiveness of treatment
88814671|NCT01658657|Experimental|PRA-guided therapy|Participants randomized to the PRA-guided therapy treatment arm will be prescribed anti-hypertensive medications based on renin activity level as defined at baseline.
88814672|NCT01658657|Active Comparator|Fixed-dose combination treatment-guided therapy|Participants randomized to the fixed-dose combination treatment-guided arm will be prescribed standard anti-hypertensive medications without regard to renin activity level.
88814673|NCT04359212||Medical|subject with a confirmed infection for COVID-19 and needing admission to a medical division for a non-severe clinical disease
88814674|NCT04359212||Intensive|subject with a confirmed infection for COVID-19 and needing admission to an Intensive Cure Unit for a severe to critical disease
88814675|NCT04359290|Experimental|Ruxolitinib treatment|Ruxolitinib will be administered p.o. or by gavage feeding for max 28 days
88814676|NCT01618955|Active Comparator|VIBEX MTX|VIBEX MTX dose based on the subject's current therapeutic regimen of MTX and rheumatoid arthritis disease status
88814677|NCT04359368||patients with hypersensitivity reactions to NDIPs|Patients with previous hypersensitivity reaction grades I-IV to intravenous ferric carboxymaltose (Ferinject) or to iron sucrose (Venofer)
88814678|NCT01620047|Experimental|Femoral Nerve Fentanyl|Fentanyl 3 µg/ml delivered continuously through a femoral nerve sheath catheter for 24 hours post-total knee replacement. All study drugs were continuously infused for a 24 hour period at a basal rate of 10ml/hour starting from the time the patient entered the post anesthesia care unit (PACU).
88814679|NCT01620047|Active Comparator|Femoral Nerve Ropivacaine|Ropivacaine 0.1% continuously delivered through a femoral nerve sheath catheter for 24 hours post-total knee replacement. All study drugs were continuously infused for a 24 hour period at a basal rate of 10ml/hour starting from the time the patient entered the post anesthesia care unit (PACU).
88906445|NCT01557036||Aneurysms treated with Pipleline|Aneurysms treated with Pipleline. All patients independently treated according to the labeled indications for use with the Pipeline Embolization Device
88906446|NCT01557049|Experimental|Postural Reeducation Group|The participants, after obtaining a written informed consent, were randomized for one of the two groups: In the Global Postural Reeducation group (GPR), they were submitted 1 time per week, during 12 weeks, at GPR sessions. The duration of sessions was 60 minutes each, with the same physical Therapist of the study. After the intervention, subjects returned to assessment 3 months after, with the blinded assessor. All the 6 postures from GPR were used during the study. All outcomes measurements, in both groups, were validated for Portuguese language and applicable at baseline, 3 months and 6 months after baseline.
88906447|NCT01557049|No Intervention|Control Group|In the control group, no physical intervention was given during the study. After the study, 6 months after, all participants from control group received the same treatment given in GPR group, according to the Unifesp Ethics Committee orientations. All participants, of both groups, have a doctor from the study, if necessary.
88906448|NCT01557062|Other|Polysomnography|
88906449|NCT01557062|Other|Temperature measure|
88906450|NCT01557062|Other|Fibromyalgia Impact questionary|
88906451|NCT01557075|Active Comparator|Atorvastatin group|Atorvastatin 40 mg daily for 12 months after randomization
88906452|NCT01557075|Active Comparator|Pravastatin group|Pravastatin 20mg daily for 12 months after randomization
88906453|NCT01557101|Other|COLON CAPSULE ENDOSCOPY|
88906454|NCT01557101|Other|OPTICAL COLONOSCOPY|
88906455|NCT01557114|Experimental|radiation therapy with Ipilimumab|
88906456|NCT01557127||Group 1|
88906457|NCT01557140|Placebo Comparator|RASi plus placebo|RAS inhibition was optimized and after patients were randomly assigned to receive placebo
88906458|NCT01557140|Experimental|RASi plus carvedilol|RAS inhibition was optimized and after patients were randomly assigned to receive carvedilol
89195946|NCT04549324||Sleep Apnea (AHI ≥ 15 per hour)|Patients with moderate/severe sleep apnea (Apnea/hypopnea-index ≥ 15 per hour).
89195947|NCT04549324||Non-Sleep Apnea (AHI < 5 per hour)|Patients without sleep apnea (Apnea/hypopnea-index < 5 per hour).
89195948|NCT00605566|Experimental|I|Patients will receive sorafenib and cyclophosphamide.
89425477|NCT06149910||Platform|Patients in this cohort are participating in the All4Cure platform and there has been an established intention to treat according to the clinical pathway. Additionally, the patient's primary physician will also be a participant in the All4Cure platform.
88906459|NCT01557153|Experimental|Amlodipine|
88906460|NCT01557153|Placebo Comparator|Placebo|
89425478|NCT06149910||Documentation|Patients in this cohort are not participating in the All4Cure platform but there has been an established intention to treat according to the clinical pathway.
88906461|NCT01557179|Experimental|Hyaluronic acid vaginal gel (Hyalofemme)|The treatment in both groups was applied every 3 days for a total of 10 applications. Hyaluronic acid vaginal gel was supplied in a 30g aluminum tube with a vaginal applicator which provides a dose of around 5g
88906462|NCT01557179|Active Comparator|Estriol cream (Ovestin)|The treatment in both groups was applied every 3 days for a total of 10 applications;Estriol cream was supplied in a 15g vial with a prefilled applicator providing a dose of around 0.5 g
88906463|NCT01557192|Active Comparator|Active LFMS treatment|20 minute exposure to the LFMS electromagnetic field treatment
88906464|NCT01557192|Placebo Comparator|Sham LFMS treatment|20 minute exposure to either the sham (inactive) electromagnetic field treatment
88906465|NCT01557218|Experimental|Cucumber|
88906466|NCT01557218|Experimental|Pepper|
88906467|NCT01557218|Experimental|Tomato|
88906468|NCT01557218|Experimental|Vegetable variety|
88906469|NCT01557218|Experimental|Apple|
88906470|NCT01557218|Experimental|Peach|
88906471|NCT01557218|Experimental|Pineapple|
88906472|NCT01557218|Experimental|Fruit variety|
88906473|NCT01557231||No treatment|OA
88906474|NCT01557257|Experimental|40 mg ALO-02 capsule|Single- and multiple-dose of 40 mg ALO-02 capsule under 50 mg naltrexone block
89425479|NCT06149910||Off-pathway|Patients in this cohort are not participating in the All4Cure platform and there has not been in intention to treat according to the clinical pathway that has been established by a landmark time period.
89425480|NCT06149897|Sham Comparator|Control group|"Therapeutic education about post-stroke fatigue~Sham stimulation with tDCS: Anode placed in F3 and cathode in O2, 20 minutes.~Aerobic exercise measured with Borg scale (moderate intensity)"
89425481|NCT06149897|Active Comparator|Experimental group|"Therapeutic education about post-stroke fatigue~Stimulation with tDCS: Anode placed in F3 and cathode in O2, intensity 2mA during 20 minutes.~Aerobic exercise measured with Borg scale (moderate intensity)"
89425482|NCT06149871|Experimental|Intervention|The Experimental groups or physical activity groups were assigned to three groups based on their muscle mass: normal, probable sarcopenia, and sarcopenia groups. The volunteers were provided with instructions on individual physical activities to be practiced at home for 30 weeks, 2-5 days per week and 50 minutes per session. These physical activities consisted of flexibility exercise for 10 minutes, aerobic exercise for 20 minutes, and resistance exercise for 20 minutes, as outlined in supplement 1. The volunteers were instructed on exercise techniques and physical activities by either sports scientists or registered nurses, and caregivers such as relatives or staff from the social club for older adults were allowed to be present during practice.
88906475|NCT01557257|Experimental|80 mg ALO-02 capsule|Single- and multiple-dose of 80 mg ALO-02 capsule under 50 mg naltrexone block
88906476|NCT01557257|Experimental|40 mg OxyContin tablet|Single- and multiple-dose of 40 mg OxyContin tablet under 50 mg naltrexone block
88906477|NCT01557270|Experimental|ropivacaine + dexmedetomidine|This group represents the standard of care drug (ropivacaine) plus the new additive to be studied (dexmedetomidine)
88906478|NCT01557270|Active Comparator|ropivacaine + saline|This group represents the current standard of care in peripheral nerve blockade
88906479|NCT01557296|Placebo Comparator|Diabetic diet|Control group. Subjects with Insulin Treated Diabetes Mellitus and Gastroparesis. Diet: Food of large particle size during 20 weeks.
88906480|NCT01557296|Active Comparator|Diet food in small particle size|Intervention group: Subjects with Insulin Treated Diabetes and Gastroparesis. Intervention Diet: Food of small particle size during 20 weeks.
89425483|NCT06149871|No Intervention|Control|The control group did not receive any intervention apart from general suggestions and continued with their usual daily activities.
88906481|NCT01557335|Experimental|Clopidogrel (Plavix®) and PA32540|PA32540 and Clopidogrel (Plavix®) tablet, 10 hours post PA32540
88906482|NCT01557335|Active Comparator|EC aspirin, EC omeprazole, Clopidogrel|
89425484|NCT06149858|Experimental|sublay|patients with ventral hernia operated as sublay mesh repair positioning of mesh under sheath
89425485|NCT06149858|Experimental|laparoscopic|patients with ventral hernia operated as laparoscopic repair positioning TAPP mesh
89425486|NCT06149832|Experimental|MSCs treatment group|
89425487|NCT06149806||efficacy and tolerability of Sacubitril/Valsartan|efficacy and tolerability of Sacubitril/Valsartan in the treatment of chronic heart failure on complex congenital cardiopathy
89425488|NCT06149780|Experimental|Fractional laser patients treated with laser|Laser with topical steroid and laser with vehicle.
89425489|NCT06149767|Experimental|Adebrelimab Combined With Paclitaxel for Injection,cisplatin and radiotherapy|Adebrelimab : 20 mg/kg, D1, intravenously, 30-60 min, Q3w. Paclitaxel for Injection: 150 mg/m2, D1 Cisplatin: 50 mg/m2, IV, D1, Q3w. Radiotherapy: pelvic dose: 6MV-X, 180cGy/ times 27 times; Brachydose: 192Ir, 700cGy/ time 4 times.
89425490|NCT06149754||Acute ischemic stroke with large vessel occlusion|Patients between 18 and 85 years old who have and acute cerebral stroke due to a demonstrated occlusion in the anterior circulation (M1 or M2 segment of middle cerebral artery with or without ipsilateral internal carotid artery (ICA), that undergo endovascular acute therapy fulfilling all inclusion criteria and with non exclusion criteria for that treatment. We also exclude patient with well-documented history of neuromuscular disorders, stroke or central nervous system tumors that could interfere in the SEPs assessment.
89425491|NCT06149702|Other|Intervention|"Participants will attend a KOKU training session lasting for 60 minutes. A carer may also accompany if the participant feels that their support would be beneficial. An iPad will be provided to participants for the duration of the project and the app instruction booklet will also be provided for reference purposes. For participants who do not wish to attend the group training, ad hoc one-to-one training will be offered.~* Participants will be advised to use the modified KOKU programme for 30 minutes, 3 times per week, for 6 weeks"
88906483|NCT01557361|Active Comparator|Standard RRT initiation|RRT is initiated >12 hours after eligibility determination. Once a decision is made to start RRT, a dialysis catheter will be placed and RRT initiated as soon as possible.
88906484|NCT01557361|Experimental|Accelerated RRT initiation|A dialysis catheter will be placed and RRT initiated as soon as possible and within 12 hours of eligibility.
89425492|NCT06149702|Other|Control arm|Usual care
88906485|NCT01557374|Active Comparator|Maintenance Tocilizumab, Abatacept|No modification in biotherapy dose and administration frequency
88906486|NCT01557374|Experimental|Decrease Tocilizumab, Abatacept|Progressive decrease by predetermined pattern. Progressive injection interval increase (by stage)
88906487|NCT01557387||Patients with pseudopolyps.|No treatment involved in this study.
88906488|NCT01557413|Experimental|Intramedullary nail|Intramedullary nail
88906489|NCT01557413|Experimental|Locked plate|Locked plate
88906490|NCT01557426|Other|Ultrasound|Single interventional group - patients agree to an ultrasound of their skin or soft tissue infection and an ultrasound to an uninfected portion of skin.
88906491|NCT01557439|Experimental|Levocetirizine Dihydrochloride tablets 5 mg|Levocetirizine dihydrochloride Tablets, 5 mg of M/s Ipca Laboratories Limited, India
88906492|NCT01557439|Active Comparator|Xyzal|XYZAL (levocetirizine dihydrochloride) 5 mg Tablets of M/s UCB Inc.,USA
88906493|NCT01557478|Placebo Comparator|Matched placebo|Matched placebo (identical formulation and delivery, without active ingredient)
88906494|NCT01557478|Active Comparator|Melatonin 20mg|20 mg melatonin gelatin capsule
88906495|NCT01557491|Active Comparator|Straight Incision|incision made perpendicular to scalp surface
88906496|NCT01557491|Active Comparator|Bevelled Incision|Incision made at 45 degrees to scalp surface
88906497|NCT01557608|Experimental|Photon stimulation|
88906498|NCT01557608|Placebo Comparator|Placebo treatment|
88906499|NCT01557621|Experimental|Collaborative Population-Based Recall-Phone/Mail Group|Collaborative Pop-Based R/R: Phone/Mail Group Private providers, local public health departments, and the state immunization registry (CIIS) collaborate to send notices to families whose children appear in need of an immunization.
88906500|NCT01557621|Experimental|Collaborative Population-Based Recall-Mail Only Group|Collaborative Pop-Based R/R: Mail-Only Group Private providers, local public health departments, and the state immunization registry (CIIS) collaborate to send notices to families whose children appear in need of an immunization.
88906501|NCT01557621|Active Comparator|Practice-based Recall|Practice-based Recall
88906502|NCT01557634|Experimental|Closed-loop with diluted insulin|Insulin pump therapy using diluted insulin (20 IU/ml) will be driven by computer-based algorithm from 1700 on Day 1 until 0800 on Day 2
88906503|NCT01557634|Active Comparator|Closed-loop with non-diluted insulin|Insulin pump therapy using standard non-diluted insulin (100 IU/ml) will be driven by computer-based algorithm from 1700 on Day 1 until 0800 on Day 2
89425493|NCT06149676|Experimental|Probiotic with or without antibiotic|All patients will receive probiotics for this, only those with a UTI will get ciprofloxacin.
89425494|NCT06149676|No Intervention|Control|Patients will get standard of care treatment.
89425495|NCT06149637|Active Comparator|Traditional neck dissection approach|Traditional neck dissection approach
89425496|NCT06149637|Experimental|Anterior neck dissection approach|Anterior neck dissection
89425497|NCT06149611|Experimental|[14C] TQB3616|100 µCi [14C] TQB3616, 180mg, once in total.
88906504|NCT01557647|Experimental|inhaled treprostinil|
88906505|NCT01557647|Placebo Comparator|placebo|
88906506|NCT01557660|Experimental|inhaled treprostinil|
88906507|NCT01557673|Active Comparator|NG bolus feeding over 5 min|Tube bolus (TB): feed administered via syringe through NG tube over 5 min.
88906508|NCT01557673|Placebo Comparator|Continuous NG feeding over 4 h|Continuous tube drip feeding (TD): feed pump delivered via the NG tube over 4 h.
89425498|NCT06149585||Intra-Lock Fusion Implants|These patients will receive Intra-Lock Fusion Implants during implant placement
89425499|NCT06149585||Tapered Pro Implants|These patients will receive Tapered Pro Implants during implant placement
89007327|NCT05244278|Experimental|Operating room equipped with the CADe (Medtronic-GI genius for real-time detection)|The Medtronic-GI genius (CADe) system can be used to detect polyps of all sizes. Use of CADe is left to the discretion of the treating physician performing the colonoscopy. If used CADe will provide real-time feedback throughout each colonoscopy procedure and will alert the endoscopists of the presence of a polyp in the endoscopy field by displaying a bounding box on the same screen.
89425500|NCT06149572|Experimental|Lateral (L) Position group|Parturients will be put for spinal punctures at the lateral position
89425501|NCT06149572|Active Comparator|Sitting (S)position group|Parturients will get spinal punctures at the Sitting position as comparison
89425502|NCT06149546|Experimental|Control|"High protein, high energy diet~Fish oil supplement (ProSure®)~Pancreatic Enzymes (Creon®)~A daily individualised step target (10% above your own baseline)~Four scheduled appointments with a dietitian"
89425503|NCT06149546|Experimental|Intervention|"High protein, high energy diet~Fish oil supplement (ProSure®)~Pancreatic Enzymes (Creon®)~A daily individualised step target (10% above your own baseline)~Seven scheduled appointments with a dietitian~Six scheduled appointments with a physiotherapist"
89425504|NCT06149533|Experimental|The cohort 1|The cohort 1 is treated with edoxaban to prevent catheter-related thrombosis.
88906509|NCT01557712|Experimental|Ketamine+venlafaxine|one injection of 0.5 mg/kg of kentamine the first day plus venlafaxine (150-375 mg day) during 6 weeks
88906510|NCT01557712|Active Comparator|venlafaxine|venlafaxine (150-375 mg day) during 6 weeks
88906511|NCT01557725||THR/TKR patients|Any patients receiving fast-track THR or TKR in departments participating in the Lundbeck Foundation Centre for fast-track THR and TKR
88906512|NCT01557738|Experimental|Acute effects of flavanol consumption|The outcome measurements will be made on all study participants before and 2 hours after consumption of the high flavanol beverage.
88906513|NCT01557738|Placebo Comparator|Low Flavanol Trial; acute effects|Once again, the outcome measurements will be made on all study participants before and 2 hours after consumption of the low flavanol beverage.
88906514|NCT01557738|Experimental|Long-term effects of flavanol consumption|Only those study participants over 60 years of age will continue with this arm of the trial. The same outcome measures will be performed following 4 weeks of daily consumption of a high flavanol beverage.
89425505|NCT06149533|No Intervention|The cohort 2|The cohort 2 won't be treated with edoxaban.
89425506|NCT06149468||ASD group|child/adolescent (under 18 years of age) applying to an autism reference center or being followed up in an autism reference center
89425507|NCT06149455|Experimental|Short duration of preoperative antibiotics (2 days)|
89425508|NCT06149455|Active Comparator|Long duration of preoperative antibiotics (7 days)|
89425509|NCT06149429|Experimental|Single-Arm Open Pilot|"Pre- Post-intervention design. The intervention that participants will be experiencing is personalized virtual reality experiences. The content of this experience will be determined at the initial visit during which the participant will complete a preference questionnaire which identifies the location they want to go to. These experiences will be filmed on the insta360 One R camera by the research coordinator. Each experience will be approximately 20 minutes. To view the videos participants will wear the Oculus Quest 2 virtual reality headset."
88906515|NCT01557738|Placebo Comparator|Low Flavanol Trial; long-term effects|Only those study participants over 60 years of age will continue with this arm of the trial. The same outcome measures will be performed following 4 weeks of daily consumption of a low flavanol beverage.
88906516|NCT01557764|Experimental|Treatment (enzyme inhibitor and monoclonal antibody)|Patients receive lapatinib PO QD on days 1-21 and trastuzumab IV over 90 minutes on day 1 of a 21-day cycle. Treatment continues in the absence of disease progression or unacceptable toxicity.
88906517|NCT01557803||Starting ART|Adult patients starting anti retroviral therapy for the first time
88906518|NCT01557816|Active Comparator|Naproxen|
89425510|NCT06149416|Experimental|Experimental Arms|Experimental: Healthy adult participants All participants are enrolled in the test group and receive the noninvasive adhesive reprocessed pulse oximeter sensors
89425511|NCT06149390||Consoliation with ASCT|consolidation therapy with first-line ASCT in PTCL patients who achieved CR after first-line treatment.
89425512|NCT06149390||non-ASCT|consolidation therapy without first-line ASCT in PTCL patients who achieved CR after first-line treatment.
89425513|NCT06149364|Experimental|Control|Control - usual practice; participants in this arm will be informed that the project is aimed at an economic evaluation of costs associated with usual patterns of office-based routines among desk-based workers. The measurements for both CG and IG will be taken at four times (baseline, 3 months, 6 months, and 12 months).
89425514|NCT06149351|Other|Sub-group S-P|20 professional athletes whose weekly sport practice is more than 8 hours of contact sport.
89425515|NCT06149351|Other|Sub-group S-L|20 amateur athletes, having moderate physical activity whose weekly sport practice is between 4 and 8 hours of contact sport.
89425516|NCT06149351|Other|Sub-group S-O|20 control subjects who are occasional sport practitioners, having a low intensity physical activity with weekly practicing time is below 4h, excluding contacted sports.
89425517|NCT06149325|Experimental|Repetitive somatosensory stimulation (RSS), then SHAM|Adult patients suffering from post-stroke sensory deficits at the hand. Each participant will participate to the study on two different days, at least a week apart from each other. The length of the experimental session on these two days will be the same: 2 hours in the morning, to perform Pre-evaluation of the tactile acuity, absolute detection, overall hand functionality and manual dexterity, and 3 hours in the afternoon, including 45 minutes of stimulation (RSS or Sham) and 2 hours of Post-evaluation of the tactile acuity, absolute detection, overall hand functionality and manual dexterity. In total, the length of the participation of each patient will be of 10 hours, spread on two days.
88906519|NCT01557816|Sham Comparator|Placebo|
88906520|NCT01557829|Active Comparator|PEEK interbody cage|Posterior fusion with an interbody spacer (cage) made from polyetheretherketone (PEEK) plastic. The open space in the center of the cage is filled with local bone or bone harvested from the iliac crest.
88906521|NCT01557829|Experimental|Valeo OL ceramic cage|Posterior fusion with the Valeo OL cage, a silicon nitride ceramic interbody spacer. The center area of the cage is filled with autograft local bone or bone harvested from the iliac crest.
88906522|NCT01557907|Experimental|Intradermal - BD Research Catheter Set|Intradermal delivery of insulin (basal and bolus delivery) using the BD Research Catheter Set with 34G x 1.5 mm side-ported needle and the Animas Vibe insulin pump over a three day period.
88906523|NCT01557907|Active Comparator|Subcutaneous - Medtronic Quick-Set|Subcutaneous delivery of insulin (basal and bolus delivery) using the Medtronic Quick Set with 6 mm Teflon catheter and the Animas Vibe insulin pump over a three day period.
88906524|NCT01557933||ECT|All study subjects have consented to receive ECT.
88906525|NCT01557972||1. Morning HP and NT|Subjects based on HBP were divided into MH and MN patients
88906526|NCT01557972||2. Clinic HP and NT|Subjects based on CBP were divided into CH and CN patients
88906527|NCT01557985|Experimental|Transversus abdominis plane (TAP) Block|All participants in the study will receive a Transverses abdominis plane (TAP) Block in conjunction with their surgery.
88906528|NCT01557998|Other|Control - No intervention|PWID in the control arm will receive the behavioral survey, follow-up interviews, health education and training sessions on how to recruit peers, the rapid HIV and HCV test, and the point of care CD4 test but will not be assigned a peer case manager. Confirmed HCV viremic will receive HCV treatment.
88906529|NCT01557998|Experimental|POC CD4 and Peer Case Management|HIV-positives will receive prevention with positives (PwP) counseling and point of care CD4 counts. Those with CD4 <500/μL will be assigned a peer case manager to link the person to ART at study-participating HIV clinics, support ART and PwP adherence and care retention. Confirmed HCV viremic will receive HCV treatment.
88906530|NCT01557998|Other|HCV+PWID|Control and Experimental Confirmed HCV viremic study subject will receive HCV treatment
88906531|NCT01558011|Experimental|chemotherapy|"Chemotherapy:~Drug: Capecitabine, Oxaliplatin, Docetaxel Dosing Regimena: total of 6 cycles of modified XELOX regimen repeats every 2 weeks, and followed by 4 cycles of TX repeats every 3 weeks. After 10 cycles of treatment, patients may continue to treat with either of the regimen, preferably the one having the best efficacy."
88906532|NCT01558024||C1S patients|"18 Patients with venous insufficiency: C1S patients according to the CEAP (Clinical-Etiology-Anatomy-Pathophysiology)classification."
89425518|NCT06149325|Experimental|Sham Repetitive somatosensory stimulation (RSS), then RSS|Adult patients suffering from post-stroke sensory deficits at the hand. Each participant will participate to the study on two different days, at least a week apart from each other. The length of the experimental session on these two days will be the same: 2 hours in the morning, to perform Pre-evaluation of the tactile acuity, absolute detection, overall hand functionality and manual dexterity, and 3 hours in the afternoon, including 45 minutes of stimulation (RSS or Sham) and 2 hours of Post-evaluation of the tactile acuity, absolute detection, overall hand functionality and manual dexterity. In total, the length of the participation of each patient will be of 10 hours, spread on two days.
89425519|NCT06148688|Experimental|Intervention Group|In addition to the standard training, digital story videos were watched in the intervention group. Digital story videos created in line with four main topics related to diabetes self-management were sent to women via online platforms. During the follow-up period, reminder videos were sent once a week regarding the topics. Pre-test and post-test were administered face to face.
89425520|NCT06148688|No Intervention|Control Group|The control group received only standard training.
89425521|NCT06147310|Experimental|Study Group|Alveolar ridge preservation with Alb-PRF + A-PRF after extraction
88906533|NCT01558024||C3 patients|"18 Patients with venous insufficiency: C3 patients according to the CEAP (Clinical-Etiology-Anatomy-Pathophysiology)classification."
88906534|NCT01558024||C5 patients|"18 Patients with venous insufficiency: C5 patients according to the CEAP (Clinical-Etiology-Anatomy-Pathophysiology)classification."
89425522|NCT06147310|Placebo Comparator|Control Group|Spontaneous healing after extraction
89425523|NCT06147128||Active Comparator: Traditional Trained|Trainees in the Traditional trained group will have an e-learning didactic component (specifically on the steps of the procedure, clinical aspects of the procedure, published evidence etc) which they must complete before training by a procedure expert. On completion of the e-learning module the trainees will complete a summative assessment of their knowledge. The trainees will then be shown how and then trained to perform an emergency scenario where open conversion is necessary due to vessel injury during robotic surgery task. The scenario will be demonstrated initially by an expert and who will then proctor the trainees in the same technique.
89425524|NCT06147128||Experimental: PBP for Technical emergency undocking skills|Participants in the PBP trained group will follow the exact same e-learning didactic course as the Traditional trained group but the PBP group will be required to pass a test of procedure knowledge on TS before continuing to the robotic surgical training element. The trainees knowledge will be assessed in a formative and summative fashion. After the trainees initial assessment, procedure-specific and validated procedure metrics will be used to teach them the steps of the emergency undocking procedure, as well as the correct (and incorrect) way to perform it. The metrics will be used to give to the trainees performance feedback with specific advice on how they might improve their performance, in the regards of technical skills.
88906535|NCT01558024||Sedentary volunteers|18 healthy volunteers with a sedentary lifestyle (< 2h of physical activity per week)
88906536|NCT01558024||Active volunteers|18 healthy volunteers with an active lifestyle (between 2 and 6 hours of physical activity per week)
89425525|NCT06147128||Experimental: PBP for Non-Technical emergency undocking skills|Participants in the PBP trained group will follow the exact same e-learning didactic course as the Traditional trained group but the PBP group will be required to pass a test of procedure knowledge on NTS before continuing to the robotic surgical training element. The trainees knowledge will be assessed in a formative and summative fashion. After the trainees initial assessment, procedure-specific and validated procedure metrics will be used to teach them the steps of the emergency undocking procedure, as well as the correct (and incorrect) way to perform it. The metrics will be used to give to the trainees performance feedback with specific advice on how they might improve their performance, in the regards of non-technical skills.
89425526|NCT06147128||Experimental: PBP for Technical and Non-Technical emergency undocking skills|Participants in the PBP trained group will follow the exact same e-learning didactic course as the Traditional trained group but the PBP group will be required to pass a test of procedure knowledge on both TS and NTS before continuing to the robotic surgical training element. The trainees knowledge will be assessed in a formative and summative fashion. After the trainees initial assessment, procedure-specific and validated procedure metrics will be used to teach them the steps of the emergency undocking procedure, as well as the correct (and incorrect) way to perform it. The metrics will be used to give to the trainees performance feedback with specific advice on how they might improve their performance, in the regards of technical and non-technical skills.
89425527|NCT06147102||Endovascular treatment|Patients with unruptured intracranial aneurysms treated endovascularly
89425528|NCT06147102||Surgical treatment|Patients with unruptured intracranial aneurysms treated surgically
89425529|NCT06146868||Staff|A cross-sectional survey will be conducted.
88906537|NCT01558024||Athletic volunteers|18 healthy volunteers with an athletic lifestyle (over 6 hours of physical activity per week for at least one year)
89425530|NCT06146868||User|A cross-sectional survey will be conducted.
89425531|NCT06146868||Caregiver|A cross-sectional survey will be conducted.
89425532|NCT06146868||Supplier|A cross-sectional survey will be conducted.
89425533|NCT06146777|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg on Day 1 of each 3-week cycle for up to 17 cycles.
89425534|NCT06146777|Placebo Comparator|Placebo|Participants receive intravenous placebo on Day 1 of each 3-week cycle for up to 17 cycles.
89425535|NCT06146439||Successful|Patients who do not need advanced respiratory support treatments (invasive and noninvasive mechanical ventilation)
88906538|NCT01558037||Main study|Main study patients are enrolled before or at time of solid organ transplant. Qualifying subjects either have tested positive for Cytomegalovirus or have a donor who has tested positive for Cytomegalovirus.
89425536|NCT06146439||Failure|Patients who need advanced respiratory support treatments (invasive and noninvasive mechanical ventilation)
89425537|NCT06146413|Experimental|Double trigger|GnRH agonist ( Triptorelin ) ( 0.2 mg / S.C ) and hCG ( 10000 IU) are administered 40 and 34 h before oocyte retrieval
89425538|NCT06146413|Active Comparator|HCG trigger|HCG ( 100000 IU/ I.M ) is administered 36 h before oocyte retrieval
88906539|NCT01558037||Sub study|Subjects are enrolled to this arm who have begun replicating Cytomegalovirus post transplant. These subjects may or may not have been on the main study arm.
88906540|NCT01558050|Experimental|red rice|commercially available red rice nutritionial supplement
88906541|NCT01558050|Placebo Comparator|placebo|placebo capsules
88906542|NCT01558076||Subjects with sickle cell anemia|60 subjects with sickle cell anemia will be enrolled on the study.
88906543|NCT01558076||30 healthy controls|30 controls without sickle cell anemia or sickle cell trait will be enrolled on the study.
88906544|NCT01558141|Active Comparator|Follicular flushing|Flushing follicles with embryo culture media prior to aspiration.
89425539|NCT06146153||Class I|(medium U-vault)
88906545|NCT01558154|Experimental|Chinese herb|Chinese herbs special for depression
89425540|NCT06146153||Class II|(deep-vault)
89425541|NCT06146153||Class III|flat vault
88906546|NCT01558154|Experimental|acupuncture|
88906547|NCT01558154|Experimental|Psychotherapy|
88906548|NCT01558154|Experimental|physiotherapy|
89007328|NCT05244278|No Intervention|Colonoscopy performed in room without CADe system|In the control group (standard colonoscopy), the participating endoscopists will detect and classify colorectal lesions without using any AI modules.
89007329|NCT05226689|Other|POROUS TIBIA BASEPLATE W/ JRNY LOCK|Fixed-bearing POROUS TIBIA BASEPLATE W/ JRNY LOCK and a Legion cruciate-retaining High-Flex or Deep-dish XLPE tibial insert.
89425542|NCT06145815||MIC RCR patients|Patients who improved their SANE score beyond the minimal important change one year after arthroscopic rotator cuff repair
89425543|NCT06145815||No-MIC RCR patients|Patients who did not improve their SANE score beyond the minimal important change one year after arthroscopic rotator cuff repair
89425544|NCT06145386|Experimental|COVID-19 positive|
88906549|NCT01558167|Experimental|Bendamustine, Rituximab,Lenalidomide|Dose modification treatment plan of lenalidomide
88906550|NCT01558180|Experimental|Telephone Care Management|calls from a registered nurse to educate caregivers about behavioral sleep strategies
88906551|NCT01558180|Placebo Comparator|Usual Care|It's a placebo comparator because individuals in this group will receive an educational handout on behavioral sleep strategies. This handout approximates standard of care.
88906552|NCT01558193|Placebo Comparator|Placebo|Two placebos consumed
88906553|NCT01558193|Active Comparator|Multi-vitamin/mineral|Subjects took multi-vitamin/mineral and placebo fatty acid capsule
88906554|NCT01558193|Active Comparator|Docosahexaenoic acid|Subjects took docosahexaenoic acid capsule and placebo vitamins/minerals
88906555|NCT01558193|Active Comparator|DHA plus vitamins/minerals|Subjects took both fatty acid and vitamin/mineral supplements
88906556|NCT01558206||Patients with impression of PTE|Those with signs and symptoms in favor of pulmonary thromboembolism.
88906557|NCT01558219|Experimental|acitive anticancer drug|single cytostatic agent, cabazitaxel every second week in the treatment of castration resistant metastatic prostate cancer after docetaxel
88906558|NCT01558232|Experimental|Tibion Arm|Arm of the study in which enrolled subacute post-stroke subjects undergo lower extremity physical therapy using the Tibion Bionic Leg.
89425545|NCT06145386|Experimental|COVID-19 negative|
89425546|NCT06144567||Adult patients with PsA according to CASPAR classification criteria|"Adult patients (aged ≥ 18 years old and ≤ 65 years old) with PsA according to CASPAR classification criteria, who have been prescribed upadacitinib over the course of routine practice, in accordance with the applicable approved label and local regulatory and reimbursement policies (In patients with psoriatic arthritis, upadacitinib would be a therapeutic alternative after failure, inadequate response or intolerance to csDMARDs and anti-TNF) and have at least one ultrasound-determined peripheral enthesitis."
89425547|NCT06144320|Experimental|Treatment group|Practicing acupuncture on specific acupoints. The retention time of the needle is 30 minutes every time and the frequency of treatment is 3 times per week for 8 weeks.
88906559|NCT01558245|Experimental|Tissue kallikrein group|Patients in this group will be prescribed with intravenous infusion of TK (0.15 PNAU/d, dissolved in 100ml saline) for 7 days after stenting and then oral administration of pancreatic kallikrein enteric-coated tablet (240U, 3/d) to the end of study. As the foundation treatment, all the enrolled patients will receive aspirin (100 mg/d), clopidogrel (75 mg/d), and atorvastatin (20 mg/d) for the first 6 months and continue with the combination of aspirin and atorvastatin at the previous dosage.
88906560|NCT01558245|No Intervention|Control group|Patients in control group will receive foundation treatment, including aspirin (100 mg/d), clopidogrel (75 mg/d), and atorvastatin (20 mg/d) for the first 6 months and continue with the combination of aspirin and atorvastatin at the previous dosage.
88906561|NCT01558258|Experimental|Mindfullness Meditation-based Intervention|Mindfulness meditation-based intervention, is a 6-week program adapted from an existing program at Mindfulness Awareness Research Center(MARC),UCLA.
88906562|NCT01558258|No Intervention|Wait-list control group|The wait-list control condition will control for naturally occurring changes in stress and other outcomes over the six-week intervention period. After the post-treatment assessments have been completed, those assigned to the wait-list control group will be able to participate in the MAP classes.
88906563|NCT01558310|Active Comparator|Group A|Subjects will be randomized into one of two groups. Group A will receive ustekinumab at week 0, 4, 16, 28, and week 40 and placebo at week 12 and 52.The subjects when assigned to ustekinumab, depending on body weight, will receive either 45mg or 90mg ustekinumab doses
88906564|NCT01558310|Placebo Comparator|Group B|Group B will receive placebo at Week 0 and 4, and ustekinumab at weeks 12, 16, 28, 40 and 52. The subjects when assigned to ustekinumab, depending on body weight, will receive either 45mg or 90mg ustekinumab doses
88906565|NCT01558323|Experimental|LCQ908 (mild renal impairment plus healthy volunteers)|Healthy subjects will be matched pair-wise by, sex, race, age (±15 years) and weight (±20%) to subjects with mild renal impairment and will receive a single 40 mg dose of LCQ908.
88906566|NCT01558323|Experimental|LCQ908 (moderate renal impairment plus healthy volunteers)|Healthy subjects will be matched pair-wise by, sex, race, age (±15 years) and weight (±20%) to subjects with moderate renal impairment and will receive a single 40 mg dose of LCQ908.
88906567|NCT01558323|Experimental|LCQ908 (severe renal impairment plus healthy volunteers)|Healthy subjects will be matched pair-wise by, sex, race, age (±15 years) and weight (±20%) to subjects with severe renal impairment and will receive a single 40 mg dose of LCQ908.
88906568|NCT01558336|Experimental|Praziguantel|tablet single dose
88906569|NCT01558349||Hospitalized controls|Patients that have been hospitalized at the Nîmes University Hospital and who do not have dermatological cancer.
88906570|NCT01558349||Metastatic melanoma|This cohort includes patients with metastatic melanoma.
88906571|NCT01558362|Experimental|123I-CMICE-013|Administration and analysis of alternative MPI radiotracer
88906572|NCT01558375|Placebo Comparator|Water for injection|Placebo syringes will contain 0.67ml of sterile water for injection. This will be injected daily for 12 weeks.
89425548|NCT06144320|Sham Comparator|Placebo group|"Practicing sham acupuncture on specific acupoints is the same as the treatment group, and also the same retention and frequency.~This study used the specifically made needle with a blunt tip, the Streitberger device, as the sham acupuncture. The needle does not penetrate the skin and retracts in the handle while the acupuncturist needles into the skin."
89425549|NCT06143592|Experimental|Low-Intensity Inspiratory Muscle Training Group (LI-IMT)|"Before the training, the MIP value is recorded in cmH2O. The inspiratory muscle training intensity in the first four weeks is determined by taking 30% of the MIP value and the resistance of the device is adjusted to this level. The pressure measurements of the participants are repeated in the 4th week and the new MIP value is determined. Then, 30% of the new MIP value is taken to determine the training intensity in the 4th to 8th week and the resistance of the device is adjusted to this new level. This situation is repeated in the same way in the 8th week and the new training intensity in the 8th to 12th week is determined by taking 30% of the new MIP value. According to the MIP values obtained during the entire training period, participants are asked to work at home for 12 weeks, three to five days a week, 2 times a day, 15-minutes each, 30 minutes total."
89425550|NCT06143592|Experimental|Modarate-Intensity Inspiratory Muscle Training Group (MI-IMT)|"Before the training, the MIP value is recorded in cmH2O. The inspiratory muscle training intensity in the first four weeks is determined by taking 50% of the MIP value and the resistance of the device is adjusted to this level. The pressure measurements of the participants are repeated in the 4th week and the new MIP value is determined. Then, 50% of the new MIP value is taken to determine the training intensity in the 4th to 8th week and the resistance of the device is adjusted to this new level. This situation is repeated in the same way in the 8th week and the new training intensity in the 8th to 12th week is determined by taking 50% of the new MIP value. According to the MIP values obtained during the entire training period, participants are asked to work at home for 12 weeks, three to five days a week, 2 times a day, 15-minutes each, 30 minutes total."
88906573|NCT01558375|Experimental|Anakinra|Anakinra will be supplied in single use pre-filed glass syringes with 27-gauge needles. Anakinra syringe will contain 100mg of anakinra at a volume of 0.67 ml. This will be injected subcutaneously daily for 12 weeks.
88906574|NCT01558388|Experimental|Vaginal lactobacilli|
88906575|NCT01558388|Placebo Comparator|Placebo|
88906576|NCT01558401|Experimental|Physical activity program Group|The physical activity program consists of 123 sessions over 52 weeks. The initial assessment is followed by 12 weeks of physical activity. After this ten-week period, a second assessment is performed, followed by 3 weeks of rest. This is followed by a further 17 weeks of activities, 4 weeks of activities followed by 4 weeks of rest. Finally, there were 12 more weeks of activities.
89199187|NCT05953987|Experimental|aerobic combined with diaphragmatic breathing exercise (EXDB)|The participant underwent diaphragmatic breathing exercises which were performed in a supine position, gradually in-creasing the weight by 2.5 kg in weeks 1-4 and further increasing to 5 kg in weeks 5-8. After completing the prescribed breathing exercises and taking a 60-second rest, participants proceeded to perform aerobic exercises, either by running on a treadmill or on a regular floor surface. Each training session began with a 5-minute warm-up comprising stretching exercises. In weeks 1-4, moderate intensity was maintained, targeting 40-50% of the heart rate reserve (HRR) for a duration of 60 minutes. From weeks 5-8, the intensity increased to the range of 51-60% of the heart rate reserve, and a 5-minute cool down was added.
88906577|NCT01558414|Experimental|SILS|Cholecystectomy performed by Single Incision Laparoscopic Surgery with the SILS TM device
88906578|NCT01558414|Experimental|FSIS|Cholecystectomy performed by Flexible Single Incision Surgery with the flexible endoscope through a single incision at the umbilicus
88906579|NCT01558414|Active Comparator|Conventional laparoscopy|Cholecystectomy performed by a conventional laparoscopic approach
88906580|NCT01558440|Active Comparator|Infant Formula|A diet that is being fed to the young infants
88906581|NCT01558440|Experimental|F-100|• F-100: The estimated PRSL for F-100 is 360 mOsm/L or 53 mOsm/100kcal and in a young infant growing normally this could exceed the excretory capacity of the kidney with the risk of hypernatremic dehydration. In the rehabilitation phase, however, severely malnourished children grow extremely rapidly and the potential solutes (e.g. protein, potassium) are deposited in lean tissue and do not present to the kidney for excretion. Thus, although the potential RSL is high, this has been assumed to be a theoretical risk for rapidly growing infants
88906582|NCT01558440|Experimental|Diluted F-100|300 ml of water is added to 1000 ml of F-100
88906583|NCT01558453|Experimental|Eloxatin|Oxaliplatin
88906584|NCT01558466|Placebo Comparator|Group A - Placebo|iNO combined with placebo will be administered
88906585|NCT01558466|Active Comparator|Group B- Sildenafil|iNO combined with Sildenafil
88906586|NCT01558479||Case|Has a diagnosis of Parkinson's disease
88906587|NCT01558479||Control|No diagnosis of Parkinson's disease
88906588|NCT01558479||Family Member|Has a family history of Parkinson's disease. Can be affected or unaffected with Parkinson's disease
88906589|NCT01558505|Active Comparator|standard PTA|conventional balloon angioplasty
88906590|NCT01558505|Experimental|Drug-eluting balloon angioplasty|paclitaxel-eluting balloon angioplasty
88906591|NCT01558531||DEB|paclitaxel-eluting balloon angioplasty
88906592|NCT01558531||conventional PTA|historical conventional balloon angioplasty control group (patients referred to our institution between 2008 and 2009)
88906593|NCT01558557|Experimental|Gluten Free Diet|
88906594|NCT01558570||Schizophrenia|
88906595|NCT01558583|Other|Rating and Ranking Group|A group of individuals from the United States and Australia who complete a rating and ranking task.
88906596|NCT01558583|Other|Discrete Choice Group|A group of individuals from the United States and Australia who complete a discrete choice experiment task.
88906597|NCT01558583|Other|Balance Sheet Group|Individuals from the United States and Australia who will complete an implicit values clarification task
88906598|NCT01558622|Placebo Comparator|dexketoprofen trometamol|Dexketoprofen trometamol is a water-soluble salt of the dextrorotatory enantiomer of the nonsteroidal anti-inflammatory drug (NSAID) ketoprofen.
88906599|NCT01558622|Placebo Comparator|tramadol hydrochloride|Tramadol Hydrochloride is a well-known centrally acting opioid pain killer.
88906600|NCT01558622|Placebo Comparator|pethidine hydrochloride|Pethidine is a synthetic opioid analgesic which produces a pattern of effects similar to morphine the standard against which opioid analgesics are compared.
88906601|NCT01558622|Placebo Comparator|dexketoprofen trometamol + tramadol hydrochloride|
88906602|NCT01558622|Placebo Comparator|dexketoprofen trometamol + pethidine hydrochloride|
88906603|NCT01558622|Placebo Comparator|vitamin c|
89195949|NCT00900250||Ancillary-correlative (specimen collection and baking)|"Patients enrolled on HL therapeutic clinical trials undergo collection of tumor tissue samples at baseline and at relapse or disease progression. Serum and anticoagulated peripheral blood samples are collected at baseline, at week 1, on day 1 of course 2, after completion of chemotherapy, after completion of radiotherapy, at 1 year after diagnosis, and at relapse or disease progression.~Patients with relapsed or progressive disease who plan to enroll on HL relapse/retrieval clinical trials undergo collection of tumor tissue, serum, and anticoagulated peripheral blood samples at relapse or disease progression.~Patients enrolled more than 1 year after completion of treatment undergo collection of tumor specimens, serum, and anticoagulated peripheral blood samples at time of clinical evaluation."
89425551|NCT06143592|Experimental|Control Group (Sham Group)|Participants in the control group are given a POWERbreathe® device with the resistance set to the lowest level (0 cmH2O) at the end of the session where the initial assessments are made. As in the training group, participants are asked to work at home for 12 weeks, three to five days a week, 2 times a day, 15-minutes each, 30 minutes total. In order to eliminate the learning effect on the participants, pressure measurements are made in the 4th and 8th weeks, but the training intensity is kept constant at the lowest level during the 12 weeks.
89425552|NCT06143410|Active Comparator|Linisol|Patients will receive 1.5 mg/kg of intravenous linisol before propofol sedatation and gastroscope introduction
89007330|NCT05221645|Active Comparator|Control Arm A|"Patients will receive three cycles of R-ICE. Each cycle is 21 days +/- 3 days Rituximab 375mg/m2 Ifosfamide 5,000mg/m2 Carboplatin AUC = 5 (max dose 800mg) Etoposide 100mg/m2~All patients who are deemed to be in CR or PR on the post treatment PET-CT scan will undergo autologous stem cell transplant (ASCT) within 4 weeks of completing R-ICE treatment. BEAM (carmustine, etoposide, cytarabine and melphalan) conditioning will be employed according to institutional protocol."
89007331|NCT05221645|Experimental|Experimental Arm B|"Pembrolizumab 200mg Rituximab 375mg/m2 Ifosfamide 5,000mg/m2 Carboplatin AUC = 5 (max dose 800mg) Etoposide 100mg/m2 Patients will receive up to 3 cycles of: P+R-ICE, where each cycle is 21 days long +/-_3 days.~All patients who are deemed to be in CR or PR on the post treatment PET-CT scan will undergo autologous stem cell transplant (ASCT) within 4 weeks of completing P+R-ICE treatment. BEAM (carmustine, etoposide, cytarabine and melphalan) conditioning will be employed according to institutional protocol.~These patients will then be offered maintenance pembrolizumab every 3 weeks for one year."
89007332|NCT05217693|Experimental|dose escalation|Drug: BB-1705 BB-1705 will be administered as an intravenous infusion by Q3W for 8cycles
89007333|NCT05217693|Experimental|cohort expansion|BB-1705 will be administered as an intravenous infusion by Q3W for 8cycles
89425553|NCT06143410|Placebo Comparator|Control|Patients will receive intravenous placebo (saline solution),before propofol sedation and gastroscope introduction
89425554|NCT06142656|Active Comparator|Metformin|
89425555|NCT06142656|Active Comparator|Vildagliptin|
89425556|NCT06142305|Experimental|DDH surgery|DDH surgery open reduction and casting
89425557|NCT06141876|Experimental|Active|APEX-002-A02
88906604|NCT01558648||Pts having Minimally Invasive esophagectomy|This is a prospective non-randomized study comprising two surgical cohorts of esophageal cancer patients. Patients will be assigned to each of the two intervention groups, MIE versus OE, based on a combination of patient referral patterns, patient preference, and surgeon preference/expertise.
88906605|NCT01558648||Pts having open esophagectomy|This is a prospective non-randomized study comprising two surgical cohorts of esophageal cancer patients. Patients will be assigned to each of the two intervention groups, MIE versus OE, based on a combination of patient referral patterns, patient preference, and surgeon preference/expertise.
88906606|NCT01558687|Experimental|Group A = Cilengitide Group|Cilengitide + SoC (Temolozomide + Radiotherapy)
88906607|NCT01558687|Active Comparator|Group B = Control Group|SoC (Temolozomide + Radiotherapy)
88906608|NCT01558713|Active Comparator|Group BFS|Group B: BUPIVACAINE 0,5% 2ml + 10μg FENTANYL(0,2ml) INTRATHECALLY, FOLLOWED BY EPIDURAL ADMINISTRATION OF 10 ml N/S 0,9%
88906609|NCT01558713|Active Comparator|Group RFS|Group R : ROPIVACAINE 0,75% 2ml + 10μg FENTANYL ( 0,2ml) INTRATHECALLY, FOLLOWED BY EPIDURAL ADMINISTRATION OF 10 ml N/S 0,9%
88906610|NCT01558713|Active Comparator|Group LFS|Group L: LEVO-BUPIVACAINE 0,5% 2ml + 10μg FENTANYL(0,2ml) INTRATHECALLY, FOLLOWED BY EPIDURAL ADMINISTRATION OF 10 ml N/S 0,9%
88906611|NCT01558713|Active Comparator|BupivacaineF|Group BupivacaineF: BUPIVACAINE 0,5% 2ml + 10μg FENTANYL(0,2ml) INTRATHECALLY
88906612|NCT01558713|Active Comparator|RopivacaineF|Group RopivacaineF : ROPIVACAINE 0,75% 2ml + 10μg FENTANYL ( 0,2ml) INTRATHECALLY.
88906613|NCT01558713|Active Comparator|LevobupivacaineF|Group LevobupivacaineF: LEVO-BUPIVACAINE 0,5% (2ml) + 10μg FENTANYL(0,2ml) INTRATHECALLY.
88906614|NCT01558726|Experimental|Case management|
88906615|NCT01558726|Active Comparator|Usual treatment|Usual treatment of the CAPSad
88906616|NCT01558765|Experimental|Intervention group|Patients receive integrated rehabilitation
88906617|NCT01558765|No Intervention|Control group|Patients receive usual follow-up care without physical exercise
89425558|NCT06141876|Placebo Comparator|Placebo|matched placebo
89425559|NCT06140693|Experimental|Experimental group|All participants will perform all 5 exercise protocols (reduced-exertion high-intensity exercise, sprint interval exercise, below ventilatory threshold continuous exercise, at ventilatory threshold continuous exercise, and above ventilatory threshold continuous exercise) to determine the effect of intensity and duration of exercise on affective valence and felt-arousal, which will be measured using the feeling scale and felt-arousal scale respectively. Remembered enjoyment will be recorded using the physical activity enjoyment scale (PACES) 10 min post exercise.
89425560|NCT06139133|Placebo Comparator|Placebo supplementation Group|Pregnant women with 07-11 weeks of gestation having normal response to 75g OGTT but with low levels of Vitamin D3 (<30ng/ml) will be included. The study subjects will be randomly assigned to receive placebo until delivery.
89425561|NCT06139133|Experimental|Vitamin D supplementation group|pregnant women with 07-11 weeks of gestation having normal response to 75g OGTT but with low levels of Vitamin D3 (<30ng/ml) will be included for Vitamin D3 supplementation (2 00,000 IU/Week) for 04 -06 week. The study subjects will be randomly assigned to receive vitamin D3 supplementation (2 00,000 IU/Week) for 04 -06 weeks.
89425562|NCT06137391|Experimental|MIH and irreversible pulpitis|Group I (n=48) diagnosed with MIH and irreversible pulpitis. Group I will be randomly equally allocated into Group I A (n=24): partial pulpotomy (PP) and Group I B (n=24): full pulpotomy (FP). If pulpal bleeding cannot be controlled within 6 minutes using cotton pellets soaked in 3% sodium hypochlorite, the allocated procedure will be abandoned. The pulpotomy agent to be used will be mineral trioxide aggregate (MTA) and teeth will be restored using a resin modified glass ionomer restoration (RMGIC).
89425563|NCT06137391|Active Comparator|No MIH with irreversible pulpitis|Group II (n=48) diagnosed with irreversible pulpitis but not affected with MIH. Group II will be randomly equally allocated into Group II A (n=24): partial pulpotomy (PP) and Group II B (n=24): full pulpotomy (FP). If pulpal bleeding cannot be controlled within 6 minutes using cotton pellets soaked in 3% sodium hypochlorite, the allocated procedure will be abandoned. The pulpotomy agent to be used will be mineral trioxide aggregate (MTA) and teeth will be restored using a resin modified glass ionomer restoration (RMGIC).
89425564|NCT06136494|Experimental|Intervention group|The intervention group will receive an 8-week guided iCBT-program including goal setting, psychoeducation, physical activity, exposure, mindfulness, and acceptance.
89425565|NCT06136494|Active Comparator|Control group|The control group will receive general support via weekly email contact to check how they are feeling and how they are dealing with their situation. The control group will be offered iCBT after 3 months.
89425566|NCT06136403|Experimental|deucravacitinib treatment|challenge-dechallenge -rechallenge design
89425567|NCT06136351|Experimental|ZBR|
89425568|NCT06133816|Experimental|Arm 1 (Introductory Message A + Tobacco Use Message A + Incentive)|Participants will receive two framed messages (AA) plus an incentive
89425569|NCT06133816|Experimental|Arm 2 (Introductory Message A + Tobacco Use Message A)|Participants will receive two framed messages (AA)
89425570|NCT06133816|Experimental|Arm 3 (Introductory Message A + Tobacco Use Message B + Incentive)|Participants will receive two framed messages (AB) plus an incentive
88906618|NCT01558778|Experimental|Supportive care (whole body vibration)|Patients undergo mechanical stimulation over 20 minutes QD beginning on date of hospital admission and continuing through day 100 post-HCT, except for day 0 (date of transplant).
88906619|NCT01558817|Active Comparator|Informational brochure|Patients receive an informational brochure
89425571|NCT06133816|Experimental|Arm 4 (Introductory Message A + Tobacco Use Message B)|Participants will receive two framed messages (AB)
88906620|NCT01558817|Experimental|Intervention|Patients receive physician-directed informed assent intervention regarding CPR and informational brochure.
88906621|NCT01558830|Placebo Comparator|sugar pill|one pill twice daily, uptitrated to two pills twice daily to mirror ranolazine prescription strategy
89425572|NCT06133816|Experimental|Arm 5 (Introductory Message B + Tobacco Use Message A + Incentive)|Participants will receive two framed messages (BA) plus an incentive
88906622|NCT01558830|Active Comparator|Ranolazine|500 mg twice daily, titrated to 1000 mg twice daily if needed for relief of anginal symptoms
88906623|NCT01558843||traumatic brain injury|
88906624|NCT01558843||aneurysmal subarachnoid hemorrhage|
89425573|NCT06133816|Experimental|Arm 6 (Introductory Message B + Tobacco Use Message A)|Participants will receive two framed messages (BA)
89425574|NCT06133816|Experimental|Arm 7 (Introductory Message B + Tobacco Use Message B + Incentive)|Participants will receive two framed messages (BB) plus an incentive
89425575|NCT06133816|Experimental|Arm 8 (Introductory Message B + Tobacco Use Message B)|Participants will receive two framed messages (BB)
89425576|NCT06133816|Experimental|Arm 9 (Introductory Message C + Tobacco Use Message A + Incentive)|Participants will receive two framed messages (CA) plus an incentive
89425577|NCT06133816|Experimental|Arm 10 (Introductory Message C + Tobacco Use Message A)|Participants will receive two framed message (CA)
89425578|NCT06133816|Experimental|Arm 11 (Introductory Message C + Tobacco Use Message B + Incentive)|Participants will receive two framed messages (CB) plus an incentive
89425579|NCT06133816|Experimental|Arm 12 (Introductory Message C + Tobacco Use Message B)|Participants will receive two framed messages (CB)
89425580|NCT06130774|Experimental|Retro walking and conventional|Patient will start retro walking with first he/she will raise his/her one foot with toe off first then heel will be off from ground. swing phase of same leg would be done in backward direction with flexion on knee and extension will be performed on hip. Then patient will place the same foot on ground behind the other foot, with toe touch first on ground, and so this way patient would continue for 20 minutes continue his retro-walk for 20 minutes.
89425581|NCT06130774|Active Comparator|conventional therapy|Hot pack in supine lying (10min) TENS (10min ) Tibiofemoral mobilization (grade 1,2 ,3) (10rep) Static quadriceps exercise in supine (10rep x 3sec x2set) hip abduction in side lying(10repx 2set) knee bending exercise in prone lying ( 10rep x 2set) Hamstring stretch in supine ( 10 rep x 2 set)
89425582|NCT06128512|Experimental|AA|Auricular acupuncture (AA) 24 hours before the examination.
89425583|NCT06128512|Sham Comparator|Sham-AA|Sham Auricular acupuncture (Sham-AA) 24 hours before the examination.
89195950|NCT00900328||Ancillary-Correlative (biomarkers in resected AC specimens)|Previously collected tissue samples from patients enrolled in CALGB 140202 are assessed for mutation analysis of c-Met, EGFR, Kras, p53, and c-CBL via standard PCR and sequencing; gene amplification of c-Met via real time quantitative PCR; LOH analysis of c-CBL; expression levels of met/HGF protein in serum via ELISA; and expression levels of c-Met, EGFR, p53, c-CBL, DUB3, ALK, and EMT via IHC.
89195951|NCT00882388|Active Comparator|ASA|aspirin only
89195952|NCT00882388|Active Comparator|Cele|
89195953|NCT00882388|Experimental|ASA + Cele|
89425584|NCT06123390|No Intervention|Usual Care|"The 17 health centres randomized to Usual Care will provide care as per OptiMA program."
89425585|NCT06123390|Experimental|Intervention Arm|The 17 health centres randomized to the intervention arm will provide care as per OptiMA program with the addition of the RISQ System decision support.
89425586|NCT06122272|Experimental|Test products:|New formula for healthy term infants
89425587|NCT06122272|Active Comparator|Control products|Standard, commercially available infant formula for healthy term infants
89425588|NCT06119295|Experimental|Control Condition|Participants will be served a lunch - this will be of a fixed portion - this portion size will be the same amount of food as was consumed in the ad libitum lunch meal in the baseline session (participants will be told that the amount of food served is the same as the amount they consumed in the baseline session).
89425589|NCT06119295|Experimental|Reduce aware condition|Participants will be served a lunch - this will be of a fixed portion - this portion size will be 15% less than the amount of food consumed in the ad libitum lunch meal in the baseline session (participants will be told that the amount of food served has been reduced from the amount they consumed in the baseline session).
89425590|NCT06119295|Experimental|Reduced unaware condition|Participants will be served a lunch - this will be of a fixed portion - this portion size will be 15% less than the amount of food consumed in the ad libitum lunch meal in the baseline session (participants will be told that the amount of food served is the same as the amount they consumed in the baseline session).
89425591|NCT06115902|Experimental|TQB2102 for injection|Dose: 6.0 mg/kg or 7.5 mg/kg of TQB2102 for injection. Administration: Intravenous infusion, administered every 3 weeks, 21 days as a treatment cycle.
89425592|NCT06113302|Experimental|Cohort 1|Participants with lower risk MDS patients who have symptomatic anemia that are transfusion independent (TI). Participants will be asked to come to the study clinic weekly for the first 3 weeks and then 1 time every 3 weeks after that to have tests and procedures (such as physical exams and blood draws). Luspatercept will be administered once every 3 weeks.
89425593|NCT06113302|Experimental|Cohort 2|Participants with lower risk MDS that are transfusion dependent (TD). Participants will be asked to come to the study clinic weekly for the first 3 weeks and then 1 time every 3 weeks after that to have tests and procedures (such as physical exams and blood draws). Luspatercept will be administered once every 3 weeks.
89425594|NCT06110624||Arm 1|A targeted sample of healthcare providers (HCPs) who are not specialized in palliative care (GHCPs) constitutes the study population.
89425595|NCT06108180|Experimental|Dry Needling group|
89425596|NCT06108180|No Intervention|Control group|
89425597|NCT06107946|Other|symptom assessment|Patients will have assessed symptom burden using the Dutch validated ESAS (called USD), build in the MuSt-PC tool. Thereafter, they will record symptom burden in a diary during 2 weeks.
89425598|NCT06103955|Experimental|Digital Breathing Biofeedback system|Patients will receive 4 physiotherapist-guided breathing retraining sessions with the digital breathing biofeedback system.
88906625|NCT01558843||intracerebral hematoma|
88906626|NCT01558843||brain tumor|
89425599|NCT06097325||Residents in Anaesthesiology|"The residents in Anaesthesiology (French-speaking part of Switzerland) will be enrolled to both:~Fill a cross-sectional online survey~Enter a qualitative study from the beginning of their residency at Geneva's university hospital"
89425600|NCT06097325||Chief-Residents in Anaesthesiology|Chief-Residents (Board-certified anaesthesiologists after post-graduate training) in French-speaking part of Switzerland will be enrolled to fill a cross-sectional online survey
89425601|NCT06093269|Experimental|Cefazolin|20mg/kg to be administered in the hemodialysis circuit at the end of the 4-hour dialysis period, with no dosage adjustment planned afterwards.
89425602|NCT06088160||Direct Anterior|This group will consist of people undergoing elective unilateral THA for OA using the Direct Anterior surgical approach
89425603|NCT06088160||Direct Lateral|This group will consist of people undergoing elective unilateral THA for OA using the Direct Lateral surgical approach
88906627|NCT01558856|Active Comparator|Unilateral testing|"Following standard procedures, patients in this group will have unilateral testing for neuromodulation of the sacral nerves.~Intervention: Unilateral electrode placement and testing"
88906628|NCT01558856|Experimental|Bilateral testing|"Patients in this group will have bilateral testing for neuromodulation of the sacral nerves.~Intervention: Bilateral electrode placement and testing"
88906629|NCT01558869|Experimental|Arm 1|
88906630|NCT01558882||10 patients|The patients included desire tubal sterilization via the ESSURE technique.
89195954|NCT00882388|Active Comparator|ASA + Clo|
89425604|NCT06087978|Experimental|14C RPT193 400 mg|Radiolabelled RPT193
89425605|NCT06085911|Experimental|individual follow-ups|tailored individual follow-up rehabilitation program with home-based exercises
89425606|NCT06085911|Active Comparator|a one-day course.|a one-day course.
89425607|NCT06083818|Placebo Comparator|Placebo|Participants in this group will undergo a conventional physical preparation programme.
89425608|NCT06083818|Experimental|ACL injury prevention protocol|Participants in this group will undergo a specific 12-week prevention protocol.
89425609|NCT06082856|Experimental|Dexmedetomidine|
89425610|NCT06082856|Active Comparator|Sufentanil|
89425611|NCT06082141|Active Comparator|Ultrasound guided serratus anterior plane block|SAP block will be made with 10 ml 0.5% bupivacaine + 10 ml NaCl TTP block will be made with 10 ml NaCl
89425612|NCT06082141|Active Comparator|Combination of ultrasound-guided serratus anterior plane block and transversus thoracis plane block|SAP block will be made with 10 ml 0.5% bupivacaine + 10 ml NaCl TTP block will be made with 5 ml 0.5% bupivacaine + 5 ml NaCl
89425613|NCT06081283|Experimental|Seizure network Positive subjects|"Participants in this group encompass all SzNET-Positive subjects, including those who are EEG-Positive and EEG-Negative. Within six days of their initial rs-fMRI study, they will receive both loading and maintenance doses of two of the intervention drug regimens from the study's list. Maintenance doses should be administered every 12 hours, commencing 12 hours after the loading dose, with a maximum of 19 maintenance doses allowed. A second rs-fMRI and EEG will be conducted after participants have received at least five maintenance doses.~Following these follow-up rs-fMRI and EEG assessments, the use of the intervention drugs as part of the research intervention will be discontinued. However, if medically necessary, these drugs can continue as part of regular therapy. It's important to note that repeat EEG and rs-fMRI assessments cannot be conducted if more than 72 hours have passed since the last dose of the intervention drug regimen."
89425614|NCT06081283|No Intervention|Seizure network Negative subjects|Participants in this group encompass all SzNET-Negative subjects, including those who are EEG-Positive and EEG-Negative. These participants will not receive interventions after the initial study indicated rs-fMRI. They will neither receive repeat rs-fMRI or repeat EEG.
89425615|NCT06079268|Experimental|0 ml/kg of water|The child does not drink water, and then the gastric ultrasound is performed 3 minutes later blindly to the ingested volume.
89425616|NCT06079268|Experimental|0.6 ml/kg of water|The child drinks 0.6 ml/kg water, and then the gastric ultrasound is performed 3 minutes later blindly to the ingested volume.
88906631|NCT01558895|Experimental|Conventional Treatment and Infrared ray heat treatment group|conventional treatment consist of antiviral drugs, lowering aminotransferase and jaundice medicine.
89425617|NCT06079268|Experimental|1 ml/kg of water|The child drinks 1 ml/kg water, and then the gastric ultrasound is performed 3 minutes later blindly to the ingested volume.
89425618|NCT06079268|Experimental|1.25 ml/kg of water|The child drinks 1.25 ml/kg water, and then the gastric ultrasound is performed 3 minutes later blindly to the ingested volume
89425619|NCT06079268|Experimental|1.5 ml/kg of water|The child drinks 1.5 ml/kg water, and then the gastric ultrasound is performed 3 minutes later blindly to the ingested volume.
89425620|NCT06079268|Experimental|2 ml/kg of water|The child drinks 2 ml/kg water, and then the gastric ultrasound is performed 3 minutes later blindly to the ingested volume.
89425621|NCT06075810|Experimental|MBQ-167 oral capsule|A dose ranging from 10mg to 400mg BID following a standard 3+3 cohort design
89425622|NCT06068504|Experimental|Arm-cranking exercise|Patients will be perform arm-cranking exercise. The exercise will be performed in 15 sets of 2 min of exercise at a moderate intensity (13-15 in Borg scale)
89425623|NCT06068504|Active Comparator|Heating|Patients will perform 15 sets of 2 min of immersion of their foot in a warm water (42 degrees)
89425624|NCT06068504|No Intervention|Control|Patients will remain seated for 60 min
88906632|NCT01558895|Active Comparator|conventional treatment group|conventional treatment consist of antiviral drugs, lowering aminotransferase and jaundice medicine.
88906633|NCT01558908|Experimental|Intramuscular injection of ERC|
88906634|NCT01558934|Experimental|Lofexidine Titration in Methadone Maintained Subjects|Methadone maintained subjects will be titrated on lofexidine up to the target therapeutic dose of 0.8 mg QID or to the highest level tolerated. Following this initial titration attempt, all subjects will have their methadone dose reduced by 50% and lofexidine titration efforts will resume. If the therapeutic dose is not reached under 50% methadone reduction conditions, the methadone dose will be further reduced to 0 mg for 2 days followed by reintroduction of 25% of the starting dose on the 3rd day, and on such 3rd day lofexidine titration will resume again.
88906635|NCT01558947|Experimental|chemotherapy with ECX|chemotherapy with ECX
89425625|NCT06065462|Experimental|Dostarlimab + LB-100|Dostarlimab will be given by vein over about 30 minutes on Day 1 of each cycle. LB-100 will be given by vein on Days 1-3 of each cycle. The first doses will be given over about 2 hours. After that, doses may be given over as little as 30 minutes.
89425626|NCT06063642|Experimental|Experimental neurofeedback intervention|In an approximately 30-minute training session, participants receive activity feedback from a midbrain region involved in reward processing and gaming addiction. Feedback will be presented in the form of a thermometer/bar in the middle of the screen and updated every two seconds. They will be trained to down-regulate the activity in this region with the help of this feedback using cognitive strategies. This down-regulation training is believed to be beneficial to addictive behaviors by the investigators.
89425627|NCT06063642|Sham Comparator|Sham feedback intervention|In an approximately 30-minute training session, participants receive activity feedback from a brain region irrelevant to reward processing or gaming addictive behavior. The feedback presentation form and task instructions will be the same as for the experimental group. Based on the functional role of the feedback region, the investigators do not believe this feedback training will change the addictive behaviors of the participants who receive this intervention.
89425628|NCT06061848|Active Comparator|SLIT|Sublingual immunotherapy timothy pollen 75000 SQ-T 1 daily for 3 years
89425629|NCT06061848|Active Comparator|ILIT + Vitamin D|Intramuscular injection of kolecalciferol 100000 IU followed by intralymphatic immunotherapy with 3 monthly injections of grass pollen allergen 1000 SQ-U.
88906636|NCT01558947|Experimental|chemotherapy with XP|chemotherapy with XP
88906637|NCT01558960|Experimental|IVit Treatment group|Intravitreal injections of Melphalan
88906638|NCT01558973||Cocaine dependent|
88906639|NCT01558973||Opioid dependent|
88906640|NCT01558973||Alcohol dependent|
88906641|NCT01558973||Healthy controls|
88906642|NCT01558973||Adolescents|
88906643|NCT01558973||Pathological gamblers|
88906644|NCT01558986|Active Comparator|Treatment Arm|Patients to receive intravenous cefazolin 1 gram within 30 minutes prior to skin incision
88906645|NCT01558986|Placebo Comparator|Placebo Arm|Patients to receive sterile water only within 30 minutes prior to skin incision
89195955|NCT00882388|Experimental|ASA + Clo + Cele|
89195956|NCT00901420||Prostatectomy|
89195957|NCT00901420||Prostatectomy After Radiation Therapy|
89195958|NCT00900406||Recipients of stem cells with graft versus host disease|
89195959|NCT00900406||Recipients of stem cells at risk of graft versus host disease|
89195960|NCT00900406||Donator of stem cells|
89195961|NCT00396877|Placebo Comparator|Placebo|
89195962|NCT00396877|Experimental|Clopidogrel 0.2 mg/kg/day|
88906646|NCT01559025|No Intervention|Insulin therapy|Patients will receive the conventional treatment with insulin
88906647|NCT01559025|Active Comparator|Vildagliptin|Patients will receive vildagliptin besides the conventional treatment with insulin
88906648|NCT01559038||adalimumab|Responding to treatment with non-biologic DMARDs (disease-modifying antirheumatic drugs) and initiated on treatment with adalimumab as monotherapy or in combination with other medications
88906649|NCT01559038||DMARD (disease-modifying antirheumatic drugs)|Initiated on non-biologic DMARD(disease-modifying antirheumatic drugs) or requiring switching to another non biologic DMARD (disease-modifying antirheumatic drugs) as monotherapy, or in combination with other medications
88906650|NCT01559051|Experimental|Intravenous Injection and Inhalation infusion of AD-SVF|AD-SVF harvested from Autologous Adipose Tissue will be deliver after processing via IV and Inhalation
88906651|NCT01559077|Active Comparator|ALN-TTR02|
89425630|NCT06061848|Active Comparator|ILIT + placebo|Intramuscular injection of saline solution followed by intralymphatic immunotherapy with 3 monthly injections of grass pollen allergen 1000 SQ-U.
89425631|NCT06060639|Experimental|transfused patients|patients receiving red blood cell transfusion
89425632|NCT06060041||IC-8 Apthera intraocular lens (IOL) Group|Patients previously implanted with the IC-8 Apthera intraocular lens (IOL) and who have developed posterior capsular opacification (PCO) which requires treatment with Nd:YAG laser capsulotomy.
89195963|NCT02540044|Experimental|ANSWER-2 decision aid|The Intervention Group will receive simple instructions to access ANSWER-2 and complete the program on their own computers within two days. At the end of the session, ANSWER-2 will produce a one-page summary summarizing the participant's questions, concerns, and preferred medication option.
89425633|NCT06054009|Experimental|Treatment|In Study 1: x4 CBT sessions addressing cognitive appraisals of dissociation. In Study 2: x4 CBT sessions addressing rumination/worry. In Study 3: x4 CBT sessions addressing affect intolerance.
88906652|NCT01559077|Placebo Comparator|Sterile Normal Saline (0.9% NaCl)|
88906653|NCT01559103|Experimental|MEDI5117|Intravenous infusion administered over 60 minutes
89425634|NCT06053775|Active Comparator|Online Cognitive Training|15 sessions of 20 minutes each one.Training will focus on the stimulation of several cognitive functions (attention, memory and learning, language, executive functions,processing speed, etc) through different exercises. The sessions will be adjusted to the individual performance level. The participant will perform these exercises from their computer or tablet, through the NeuronUp2GO platform, and the researcher will have access to all the session data.
88906654|NCT01559103|Placebo Comparator|MEDI5117 Placebo|Intravenous infusion administered over 60 minutes
88906655|NCT01559142|Active Comparator|IFX TG|
88906656|NCT01559142|Active Comparator|IFX alone|
89195964|NCT02540044|Active Comparator|Control Group (TAS Consumer Guide)|The Control Group will receive the online Arthritis Medications: A Consumer's Guide, published by The Arthritis Society. It contains standard information about biologics, including an introduction of the different biologic options, dosages and side effects.
89007334|NCT05191823|Experimental|Docosahexaenoic Acid + Arachidonic Acid|Docosahexaenoic Acid + Arachidonic Acid (DHA+AA)
89007335|NCT05191823|Placebo Comparator|Placebo|Corn oil supplement
89007336|NCT05183477|Experimental|fast track|patients arriving at Emergency Department with suspected wrist or scaphoid fracture, randomly allocated to the fast track pathway (xray requested at triage by nurse)
89425635|NCT06053775|Experimental|Transcranial Direct Current Stimulation|"tDCS: 15 daily sessions targeting left DLPFC (anode: F3, cathode: Fp2) Current intensity will be set at 2mA and will be applied for 20 minutes, with 15-second ramps up and down at the beginning and end of the stimulation period.~During the session, the participant will be performing the OCT."
89007337|NCT05183477|Active Comparator|normal pathway|patients arriving at Emergency Department with suspected wrist or scaphoid fracture, randomly allocated to waiting room and than medical examination before asking for xrays
89007338|NCT05183230|Experimental|Proof-of-Concept WellPATH-PREVENT (R61)|
89007339|NCT05183230|Experimental|Optimized WellPATH-PREVENT (R33)|
89007340|NCT05183230|No Intervention|Attention Control Usual Care (R33)|The AC-UC group will parallel the delivery of the WellPATH-PREVENT intervention and will also include: a) meetings during hospitalization: a non-clinical member of the team will present the control tablet and explain its use; b) scheduled or requested meetings through zoom: to parallel the delivery of WellPATH-PREVENT. The tablet will still have a link to schedule a meeting with a non-clinician member of the team. The meetings will focus on issues that the patient may have in using the tablet. There will not be any therapeutic or psychological interaction between participants in the control group and the team. The experimental and the control group will also be under usual outpatient care, which is arranged during the hospitalization by the inpatient treatment team.
89007341|NCT05166837|Experimental|Cohort 1:2mg/kg|All participants (fasted) received either 2 mg/kg of STSA-1002 as a single dose or dose-matched placebo.
89425636|NCT06053775|Experimental|Transcranial Alternating Current Stimulation|"tACS: 15 daily sessions targeting left DLPFC (anodes: F3, F4; frequency: 4Hz -theta-tACS-). Current intensity will be set at 2mA and will be applied for 20 minutes, with 15-second ramps up and down at the beginning and end of the stimulation period.~Participant will be performing the OCT during stimulation."
89425637|NCT06053775|Sham Comparator|tES sham|"15 sessions of sham stimulation for 20 minutes, acting as a placebo control group. The electrode montage will be the same as that used in the active neuromodulation conditions: tDCS for half of the participants and tACS for the other half. In this sham stimulation condition, the current will only be delivered for a 15 seconds, at the ramp-up and ramp-down times at the beginning and end of the session.~The OCT will also be the same as those performed by participants in the other groups"
89425638|NCT06047899|Experimental|Intervention|In the intervention phase we will administer 500 mg luteolin (2x250 mg capsules, e.g. every morning and evening) per day formulated for oral administration for 14.5 days.
89425639|NCT06047899|Placebo Comparator|Placebo|Placebo control intervention consists of identical looking placebo capsules containing mannitol formulated for oral administration to be taken twice daily (e.g. every morning and evening) for 14.5 days.
89425640|NCT06047613|Experimental|Suicide attempters|Currently depressed patients with a suicide attempt within the 8 last days (with a maximal lifetime number of 3 previous suicide attempt including the most recent );
89425641|NCT06047613|Active Comparator|Affective controls|Currently depressed patients without any lifetime history of suicide attempt
89425642|NCT06047613|Active Comparator|Healthy controls|Participants with no lifetime history of psychiatric disorders
89425643|NCT06047132||Periodontal health status|Categorized according to 2018 classification of periodontal diseases (Papapanou et al. 2018), including healthy, gingivitis, treated periodontitis (stable/unstable), periodontitis Stages I & II, and periodontitis Stages III and IV.
89007342|NCT05166837|Experimental|Cohort 2:5mg/kg|All participants (fasted) received either 5 mg/kg of STSA-1002 as a single dose or dose-matched placebo.
89007343|NCT05166837|Experimental|Cohort 3:10mg/kg|All participants (fasted) received either 10 mg/kg of STSA-1002 as a single dose or dose-matched placebo.
89007344|NCT05166837|Experimental|Cohort 4:20mg/kg|All participants (fasted) received either 20 mg/kg of STSA-1002 as a single dose or dose-matched placebo.
89007345|NCT05166837|Experimental|Cohort 5:30mg/kg|All participants (fasted) received either 30 mg/kg of STSA-1002 as a single dose or dose-matched placebo.
89007346|NCT05146765|Experimental|Intervention|The intervention group will receive treatment as usual along with the speech therapy app.
89007347|NCT05146765|No Intervention|Control|The control group will receive treatment as usual only.
89007348|NCT05144763|Experimental|ePOCT+|Health facilities allocated to the ePOCT+ intervention arm will receive an electronic clinical decision support algorithm (ePOCT+) on a tablet that will guide them through pediatric consultations. Point-of-care tests proposed by ePOCT+ that are not part of routine care will be provided as part of the study (pulse oximeter, CRP rapid test, additional hemoglobin cuvettes, and salbutamol inhalers and spacers). Training on the use of ePOCT+ and associated clinical skills will be provided before the implementation of the study, along with mentorship visits to assist with issues related to the implementation of ePOCT+.
89195965|NCT00882466|No Intervention|PCI only|primary PCI only
89195966|NCT00882466|Experimental|EPO|
89195967|NCT00901498|Experimental|Treatment A (Reference)|
89195968|NCT00901498|Active Comparator|Treatment B|
89195969|NCT00901498|Active Comparator|Treatment C|
89195970|NCT00901498|Active Comparator|Treatment D|
89195971|NCT00901498|Active Comparator|Treatment E|
89425644|NCT06043739|Active Comparator|Treatment A:|filgotinib administered under fasting conditions
89425645|NCT06043739|Experimental|Treatment B:|filgotinib administered under fasting conditions
89425646|NCT06043739|Experimental|Treatment C:|filgotinib administered under high-fat fed conditions
89425647|NCT06042231|Experimental|Exercise Intervention|
89425648|NCT06042231|No Intervention|Standard Care|
89425649|NCT06034496|Active Comparator|Active CES|Active Cranial Electrotherapy Stimulation (CES)
89195972|NCT00628251|Experimental|1|AZD2281 Oral 200 mg BID
89195973|NCT00628251|Active Comparator|2|Liposomal Doxorubicin
89195974|NCT00628251|Experimental|3|AZD2281 Oral 400 mg BID
89425650|NCT06034496|Sham Comparator|Sham CES|Sham Cranial Electrotherapy Stimulation (CES)
89007349|NCT05144763|No Intervention|Routine care|In health facilities allocated to the control arm, pediatric consultations will be conducted in a routine manner; however, tests/test results, diagnoses, management and treatments will be recorded in an electronic case report form on a tablet. Equivalent clinical training will be provided before the start of the study.
89007350|NCT05140252|Experimental|Breast cancer decision aid|Participants receive a breast cancer decision aid.
89425651|NCT06034366|Experimental|study group|Participants in the study group will use 0.01% atropine (3 ml unit-concentration, preservative-free) once nightly in both eyes for 48 weeks,
89425652|NCT06034366|Other|placebo eye drops|participants in the control group will utilize placebo eye drops (0.9% sodium chloride, 3 ml unit-concentration, preservative-free) once nightly in both eyes for 48 weeks.
89425653|NCT06030908||Study Population|Patients who underwent surgical reconstruction of the Achilles tendon insertion using a knotless, double-row anchor system.
89425654|NCT06029959|Experimental|SCOUTS3 Optimization Arm|In a single-arm study, participants from acute ischemic stroke or intraparenchymal hemorrhage within the past 30 days will be tested for OSA with a single-night portable OSA test during inpatient rehabilitation (IPR). Eligible participants will then be started on continuous positive airway pressure (CPAP) therapy and exposed to a multicomponent CPAP adherence intervention, beginning during IPR and extending for 3 months. Participants' CPAP use will be monitored, and input regarding the intervention will be sought from the participants, CPAP partners, and the research team implementing the intervention. Data from an initial group of study participants will be reviewed in meetings with the study team and a patient advisory board, and adaptations will be devised and then implemented within the next batch of study participants. Through this iterative process that includes input from important stakeholders, the behavioral intervention will be adapted for use among stroke patients.
89425655|NCT06029114||Healthy Control Group|Subjects will have a magnetic resonance elastography (MRE) performed.
89425656|NCT06029114||Alzheimer's Disease Group|Subjects will have a magnetic resonance elastography (MRE) performed.
89007351|NCT05136846|Experimental|Treatment (papaverine, RT, paclitaxel, carboplatin)|Patients receive PPV IV or SC and undergo 5 fractions of RT per week. Patients also receive paclitaxel IV over 1 hour and carboplatin IV QW over 1-6 weeks or pemetrexed IV over 10 minutes followed by carboplatin IV every 3 weeks in the absence of disease progression or unacceptable toxicity. Beginning 1 month of completing CRT, patients with PD-L1 positive disease receive durvalumab IV Q2W for 12 months.
89425657|NCT06029114||Mild Cognitive Impairment Group|Subjects will have a magnetic resonance elastography (MRE) performed.
89425658|NCT06027801|Experimental|Iron fortification group|Participants assigned to this group will receive iron-fortified cookies daily for the whole study duration
89425659|NCT06027801|Placebo Comparator|Control group|Participants assigned to this group will receive the same cookies containing no iron daily for the whole study duration
89425660|NCT06027437|Experimental|Treatment A|
89007352|NCT05130463||Patients diagnosed with type 2 diabetes mellitus|
89007353|NCT05129358|Experimental|Hydration sensor|The subjects use the wearable hydration sensor for ten days and undergo a dehydration/rehydration intervention on day 2 or 3.
89195975|NCT01036399|Experimental|Revlimid|"Oral Revlimid is initiated on day 1 of cycle 1at the dose of 25 mg daily for 21 days with 7 days rest (28 day cycle) for a total of 4 cycles.~After this induction phase, the CR, PR and SD will continue Revlimid with the same schedule for other 8 months."
89425661|NCT06027437|Experimental|Treatment B|
89425662|NCT06027437|Experimental|Treatment C|
89425663|NCT06024434|Experimental|Experimental interventional group A|Exercises for core, gluts, upper body and lower body
89425664|NCT06024434|Active Comparator|Control group B|Walking for 30 min 5 days a week
89425665|NCT06024291|Experimental|HIIT group|The exercise intervention will consist of a supervised HIIT (two walking- and one indoor cycling-based session weekly), starting with a habituation week at an intensity of 75% of the maximal heart rate (HRmax). In the following seven weeks, the participants will perform a HIIT based on the following protocol and for a total duration of 45 min per session: warm-up for 10 min at 60%-70% HRmax followed by a high-intensity interval consisting of 4×4 min at 80%-95% HRmax with 3 min of active recovery at 60%-70% HRmax and a 10 min cool-down at 60%-70% HRmax. Heart rate will be monitored during training by Garmin HRM-Dual heart rate sensors combined with Garmin Forerunner 45S watches. Exercise scientists motivate the participants during the intervals and will control each participant's heart rate during and after every training session.
88906657|NCT01559155||Bullous pemphigoid|Patients in this cohort are newly diagnosed (or have not started treatment) with bullous pemphigoid
88906658|NCT01559155||Other bullous-like auto-immune|Patients in this cohort are newly diagnosed (or have not started treatment) with pemphigus (15 patients) or cutaneous lupus (15 patients)
88906659|NCT01559155||Control group|Patients in this cohort are hospitalized at the Nîmes University Hospital, and have no history of autoimmune, inflammatory or neoplastic disease. Patients are matched for age and sex with patients in the bullous pemphigoid cohort.
89536117|NCT02478827|Experimental|Working Memory group|The neurocognitive training program will be provided by an online platform called BrainGymmer (https://www.braingymmer.com/en/brain-games/). Users will receive an account where they will only have access to the training games they have been assigned to and where their activity will be logged. One experimental group will complete the working memory training, which involves three games: N-back, Multi-Memory, and Moving Memory. These games are designed to engage processes involving updating and manipulation of information. All of the training games are adaptive. Participants randomized to this cognitive training arm will complete the training games for 30 minutes per day, 5 days a week, for a total of 10 weeks.
89007356|NCT05108831|Experimental|ePOCT+|Health facilities allocated to the ePOCT+ intervention arm will receive an electronic clinical decision support algorithm (ePOCT+) on a tablet that will guide them through pediatric consultations. Point-of-care tests proposed by ePOCT+ that are not part of routine care will be provided as part of the study (pulse oximeter, CRP rapid test, additional hemoglobin cuvettes, and salbutamol inhalers and spacers). Training on the use of ePOCT+ and associated clinical skills will be provided before the implementation of the study, along with mentorship visits to assist with issues related to the implementation of ePOCT+.
89007357|NCT05108831|No Intervention|Routine care|In health facilities allocated to the control arm, pediatric consultations will be conducted in a routine manner; however, tests/test results, diagnoses, management and treatments will be recorded in an electronic case report form on a tablet. Equivalent clinical training will be provided before the start of the study.
89007358|NCT05106894|Experimental|smartphone application to promote nurturing care|a caregiver-directed smartphone application will directly engage first-time caregivers in providing nurturing care
89007359|NCT05106894|Active Comparator|printed caregiving materials|caregivers will receive print materials on early childhood stimulation
89425666|NCT06024291|Active Comparator|Physical activity recommendation group|Asking physically inactive participants to maintain their inactive habits may not reflect realistic conditions and is no longer considered the best option in a randomised controlled exercise intervention. Indeed, most participants will be aware of the positive effects of PA - or will become aware of them during an exercise intervention study. Further, denying an exercise intervention to participants who would have benefited from it (for instance, participants at risk of cardiometabolic diseases) might be ethically questionable. In accordance with current practices, control group participants will be informed about the World Health Organization physical activity guidelines at the beginning of the study.
89007360|NCT05101759|Other|Geriatric Follow-up (Comprehensive Geriatric Assessment)|A systematic reassessment of geriatric parameters
89007361|NCT05096169|Experimental|Clomiphene citrate 25 mg daily for 12 weeks|
89007362|NCT05096169|Experimental|Clomiphene citrate 50 mg every other day for 12 weeks|
89007363|NCT05089708|Experimental|Trifarotene (CD5789) 50 mcg/g Cream|
89007364|NCT05089708|Placebo Comparator|Trifarotene Vehicle Cream|
89007365|NCT05088980|Experimental|VOLBELLA with Lidocaine|Participants will receive VOLBELLA with Lidocaine on Day 1 and followed for 12 months.
89195976|NCT01040221|Experimental|Trichuris Suis Ova (TSO)|the eggs of intestinal helminthes (trichuris suis ova) administered as 2500 ova doses every two weeks.
89195977|NCT01040221|Placebo Comparator|Placebo|placebo dosage received every two weeks.
89195978|NCT00901654|Experimental|ACE527|
89195979|NCT00901654|Placebo Comparator|Placebo comparator|
89007366|NCT05088980|Placebo Comparator|Control Group|Participants will be followed for 3 months. Participants can opt to receive VOLBELLA with Lidocaine after 3 months and followed for 9 months.
89007367|NCT05088460|Experimental|Study Arm 1|Randomized to placebo for 12 weeks and then crossover to REGN4461 for 12 weeks
89425667|NCT06023472|Experimental|The microfluidic chip group|The Sperm Separation Device - ZyMōt Multi 850µL or 3 mL device (ZyMōt Fertility, Inc) will be used according to the volume of the raw semen samples. The microfluidics chamber will be used based on the manufacturer's instructions. 850 μL (850 μL device) or 3 mL (3mL device) of the semen sample will be added to the inlet port of the device and 750 μL (850 μL device) or 2.4 mL (3 mL device) of fertilization media will be added to the outlet port. The device will then be incubated in 6% CO2 at 37°C. After 30 minutes, 500 μL (850 μL device) or 1 mL (3mL device) of the prepared sample at the outlet port will be removed and pipetted into a labelled test tube.
89425668|NCT06023472|Active Comparator|The density gradient centrifugation group|After liquefaction, sperm preparation will be completed by a discontinuous density gradient centrifugation method, using Pureception (CooperSurgical, Denmark) sperm density gradient media. The resulting sperm pellet after centrifugation will be washed once with the sperm washing medium (G-IVF Plus, Vitrolife, Sweden) The washed spermatozoa will be resuspended with the same medium, adjusting the final volume to 0.5 mL.
89425669|NCT06022887|Experimental|TRE alone|Participants will be instructed to eat ad libitum from noon - 8:00pm daily and fast from 8:00pm - noon (16-h fast) for 8 weeks. During the 8-h eating window, there will be no restrictions on types or quantities of foods consumed. Participants will meet with a registered dietitian (RD) for 30 minutes at the start of the intervention to review instructions and goals and weekly thereafter. Adherence to the TRE intervention will be assessed as the number of adherent days per week.
89425670|NCT06022887|Experimental|MBSR alone|Participants in this study will be granted access to a remote mindfulness-based stress reductions (MBSR) protocol. Participants will have access to the MBSR course, consisting of 30 audio lessons, each ranging from 9 to 14 minutes long. During the study, participants will be asked to complete four lessons per week during weeks 1-7 and two lessons during week 8.
89425671|NCT06022887|Experimental|TRE + MBSR|This group will follow a combined protocol of the TRE and MBSR interventions as described above.
89007368|NCT05088460|Experimental|Study Arm 2|Randomized to receive REGN4461 for 24 weeks
89195980|NCT00821223|Active Comparator|manual small incision cataract surgery|surgical intervention by small incision cataract surgery
89195981|NCT00821223|Other|phacoemulsification|surgical intervention by phacoemulsification
89425672|NCT06022887|No Intervention|Control|The control group will not receive any of the interventions previously described. To maintain a relationship with each participant in the control group, we will contact them once a week via text message to engage them to finalize the intervention period. At the end of the intervention period and after all data is collected, the RD will meet with the participant for 30 minutes and will educate them regarding the TRE protocol and provide access to the MBSR web-based program.
89425673|NCT06021977|Experimental|Zanubrutinib|Each recruited subject will accept Zanubrutinib treatment.
89425674|NCT06020261|Experimental|Parent Management Training|12 sessions of manualized Parent Management Training.
89425675|NCT06017960|Experimental|Dry needling group|Dry needling + usual care. Subjects will receive a total of 4 sessions of ultrasound-guided dry needling over 4 weeks, one per week.
89195982|NCT00900640||ERCP group|All patients who have been scheduled for an ERCP due to medical necessity will be considered for this study.
89007369|NCT05071768|Experimental|ACT|Focused ACT Group Treatment
89195983|NCT00625131|Active Comparator|Active Nicotine Patch Group|Transdermal nicotine patch
89195984|NCT00625131|Placebo Comparator|Placebo Patch Group|Transdermal placebo patch
89195985|NCT01036633||Control Group no mucositis|Control patients with multiple myeloma who are not currently receiving chemotherapy and who do not suffer from oral mucositis
89195986|NCT01036633||Non-control Group Mucositis|Patients with multiple myeloma suffering from WHO Grade 3/4 Oral Mucositis
89195987|NCT00900718|Experimental|Straumann Bone Ceramic|Bone augmentation, after tooth extraction, with Straumann Bone Ceramic (synthetic bone graft material) in combination with resorbable collagen membrane Bio-Gide.
89007370|NCT05071014|Experimental|pembrolizumab followed by cryoablation|The treatment will consist of 1 cycle of pembrolizumab (200mg/flat dose) intravenously followed by cryoablation of an ablation index lesion 1-7 days prior to the start of cycle 2. Pembrolizumab will be continued for up to 24 months, until disease progression, or intolerable toxicity. Treatment beyond progression at discretion of the treating physician and Study PI. There will be a research biopsy within 1 week of cycle 5 start and an optional biopsy at end of treatment and/or progression of disease.
89007371|NCT05058898||Risk factors transmission cases|Human cases of monkeypox confirmed by PCR
89007372|NCT05058898||Risk factors transmission contacts and co-exposures|Human contact of confirmed monkeypox cases
89007373|NCT05058898||Serological follow up cases|Human cases of monkeypox confirmed by PCR from Lobaye region
89007374|NCT05058898||Serological follow up contacts and co-exposures|Human contact of confirmed monkeypox cases from Lobaye region adjusted for age, month of the year and village of origin
89007375|NCT05053646|Experimental|Marrow venting arm|Meniscal suture associated with marrow venting procedure
89007376|NCT05053646|Active Comparator|Control arm|Meniscal suture alone, without marrow venting procedure
89007377|NCT05029284|Experimental|teleABLE|Participants will complete 12 teleABLE sessions via videoconferencing, guided by an intervention therapist and participant workbook.
89007378|NCT05028374|Other|"A single booster dose of the Moderna mRNA COVID-19 vaccine administered intramuscularly"|The dose of Moderna mRNA vaccine to be administered is the same for all patients in all enrollment cohorts: 0.5 mL administered intramuscularly as a single dose, according to the manufacturer's package insert.
89007379|NCT05023369|Experimental|Dexamethasone group|Patient in this group will receive administration of 9 mg dexamethasone injected in the peri-articular tissues after the bone cut for hip endoprosthesis
89007380|NCT05023369|No Intervention|Routine care|In this group only routinely performed anaesthesia protocol will be provided
89007381|NCT05022251||Lumbar radiculopathy|Lumbar radiculopathy patients (n=122), classified as ASA I to II without any symptoms of spinal cord compression (i.e. bilateral leg pain), who are scheduled for a first-time, single-level, unilateral lumbar discectomy.
89007382|NCT05022251||Healthy controls|Sex, age, and BMI-matched healthy, pain-free control subjects (n=122) will be recruited for study participation.
89007383|NCT05020990|Experimental|Lens A, then Lens B|Participants wore Lens A for one week, then crossed over to wear Lens B for one week.
89007384|NCT05020990|Experimental|Lens B, then Lens A|Participants wore Lens B for one week, then crossed over to wear Lens A for one week.
89007385|NCT05001776|Active Comparator|Endovenous laser ablation without anticoagulants|Endovenous laser ablation without using of any anticoagulant
89007386|NCT05001776|Active Comparator|Endovenous laser ablation with short-term anticoagulant|Endovenous laser ablation and subsequent 7 days of subcutaneous fondaparinux sodium
89007387|NCT05001776|Active Comparator|Medical treatment|45 days of subcutaneous fondaparinux sodium
89007388|NCT04981678|Other|Buprenorphine Dose Reduction|Patients instructed to reduce buprenorphine to 8mg prior to surgery
89007389|NCT04981678|Other|Buprenorphine Full Dose Continuation|Patients instructed to continue taking the full prescribed dose of buprenorphine.
89007390|NCT04970901|Experimental|Part 1 (Dose Escalation): Loncastuximab Tesirine + Polatuzumab Vedotin (Arm C)|"Participants will receive escalating doses (90 µg/kg to 150 µg/kg) of loncastuximab tesirine on Day (D) 1 of each cycle (where each cycle is 21 days).~Participants will also receive polatuzumab vedotin at a dose of 1.8 mg/kg on D1 of each cycle, infusion will be started one hour after end of loncastuximab tesirine infusion."
89007391|NCT04970901|Experimental|Part 1 (Dose Escalation): Loncastuximab Tesirine + Glofitamab (Arm E)|"Participants will receive escalating doses (90 µg/kg to 150 µg/kg) of loncastuximab tesirine on D2 of Cycle (C) 1 and then D1 of all other cycles (where each cycle is 21 days).~Participants will also receive glofitamab 2.5 mg on C1 D8, 10 mg on C1 D15 and 30 mg for cycles 2-12 D1.~In addition participants will receive obinutuzumab pre-treatment 1000 mg on C1 D1."
89195988|NCT00900718|Active Comparator|Bio-Oss|Bone augmentation, after tooth extraction, with Bio-Oss (bovine-derived xenograft)in combination with resorbable collagen membrane Bio-Gide.
89425676|NCT06017960|Sham Comparator|Control group|Sham or simulated dry needling. + usual care. Subjects will receive a total of 4 sessions of sham ultrasound-guided dry needling over 4 weeks, one per week.
89425677|NCT06013800||Same Volume Status (Clinical and Point-of-Care Ultrasound)|The patient has the same volume status clinically and by point-of-care ultrasound
89425678|NCT06013800||Different Volume Status (Clinical or Point-of-Care Ultrasound)|The patient has a different volume status clinically or by point-of-care ultrasound
89425679|NCT06011655||General intensive care and emergency servise nurses|"The research was planned as a descriptive study to be carried out in the general intensive care and emergency departments of the Sanatorium Hospital. After obtaining permission from the institution where the study will be conducted, the Personal Information Form, Attitude Towards Suicide Attempts and Stigma towards Suicide scale will be sent to the nurses working in the general intensive care and emergency services of the hospital by the researcher online via Google Forms. Nurses, 5-10 min to answer. They will fill in the scales, which will continue, on their duty leave or on holidays."
89425680|NCT06009276||Heart Failure|Patients diagnosed with Heart Failure (HFrEF and HFpEF). Oral microbiome will be analyzed through tongue swabs, saliva samples, and a saliva rinse. Patients will undergo a maximal exercise test, blood draws, and vascular testing. Patients will have the option to participate in a supplementation assessment with concentrated beetroot juice.
89425681|NCT06009276||Peripheral Artery Disease|Patients diagnosed with Peripheral Artery Disease (PAD). Oral microbiome will be analyzed through tongue swabs, saliva samples, and a saliva rinse. Patients will undergo a maximal exercise test, blood draws, and vascular testing. Patients will have the option to participate in a supplementation assessment with concentrated beetroot juice.
89425682|NCT06009276||Healthy Controls|Individuals that are not diagnosed with cardiovascular disease. Oral microbiome will be analyzed through tongue swabs, saliva samples, and a saliva rinse. Patients will undergo a maximal exercise test, blood draws, and vascular testing. Patients will have the option to participate in a supplementation assessment with concentrated beetroot juice.
89425683|NCT06007794|Experimental|JUMP group|This study concerns adults with cancer treated with chemotherapy, radiotherapy, hormonal therapy or immunotherapy, in remission or cured. Patients took part in the dedicated post-cancer assessment day. In addition, an ultrasound of the thigh is performed to measure the size of the quadriceps on 5 different measurements.
89195989|NCT02549547|Experimental|Lifestyle Intervention|Physical Activity focused, interdisciplinary, Group Medical Visits (GMVs)
89195990|NCT00923338|Experimental|Vesico-vaginal fistula plug|Vesico-vaginal fistula plug
89425684|NCT06007443|Experimental|patients with neck pain|conditioned pain modulation, temporal summation and two-point discrimination will be evaluated in all included participants. Average pain intensity will be asked
89425685|NCT06005532|Experimental|Adalimumab (manufactured by Mabscale, LLC)|In the main period, patients will begin Visit 1 receiving Adalimumab therapy at an initial dose (80 /0, 16 ml) on Visit 1, from Visit 2 Adalimumab therapy at a maintenance dose (40 /0, 8 ml) for up to Visit 9 of therapy. Each visit is conducted every two weeks ± 2 days. In additional period (from Visit 11 until Visit 28), eligible patients will continue to receive treatment after additional randomization (Adalimumab or Humira® (40 /0, 8 ml)) every 2 weeks until the end of a trial.
89425686|NCT06005532|Active Comparator|Humira®|"In the main period, patients will begin Visit 1 receiving Humira® therapy at an initial dose (80 /0, 8 ml) on Visit 1, from Visit 2 Humira® therapy at a maintenance dose (40 /0, 4 ml) for up to Visit 9 of therapy. Each visit is conducted every two weeks ± 2 days.~In additional period (from Visit 11 until Visit 28), eligible patients will continue to receive treatment after additional randomization (Adalimumab or Humira® (40 /0, 4 ml)) every 2 weeks until the end of a trial."
89425687|NCT06005415|Active Comparator|Test cookie|Wire-cut cookie portion (85 g) containing wheat flour, coarse wheat semolina, sucrose, vegetable shortening, water, sodium chloride, sodium bicarbonate and sodium octanoate.
89425688|NCT06005415|Active Comparator|Control cookie|Wire-cut cookie portion (85 g) containing wheat flour, wheat bran, sucrose, vegetable shortening, water, sodium chloride, sodium bicarbonate and sodium octanoate.
89425689|NCT06005311|Experimental|microfluidic chip method|"Microfluidic chip method has been used for sperm sorting in order to select the most motile and morphologically normal sperm for use in assisted reproductive technologies (ART) such as in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI).~In the microfluidic chip method for sperm sorting, a small amount of semen sample is loaded onto the chip, which contains channels and chambers that allow for the separation of sperm based on their motility and morphology. The chip is designed to mimic the natural environment of the female reproductive tract, where sperm undergo a series of selection processes before reaching the egg."
89425690|NCT06005311|Active Comparator|density-gradient centrifugation method|Density-gradient centrifugation is a commonly used method for sperm separation and purification. It is a technique that involves layering a semen sample on top of a gradient of different densities of a solution, typically a mixture of colloidal silica and sucrose, and then centrifuging the sample. The centrifugal force causes the sperm to migrate through the gradient, where they become separated based on their density.
89007392|NCT04970901|Experimental|Part 1 (Dose Escalation): Loncastuximab Tesirine + Mosunetuzumab (Arm F)|"Participants will receive escalating doses (90 µg/kg to 150 µg/kg) of loncastuximab tesirine on Day (D) 1 of each cycle (where each cycle is 21 days).~Participants will also receive mosunetuzumab 5 mg on C1 D1, 45 mg for C1 D8, C1 D15 and cycles 2-8 D1."
89425691|NCT06005194|Placebo Comparator|Wait List Control (WLC) Condition|The WLC control condition entails following usual care and includes the ability to participate in the intervention at the 12 week-end point for the intervention group. The WLC condition is based on equity considerations; the investigators want all participants to have access to treatment. Equity is especially important given our plans to over-enroll African American persons given statistically increased barriers to access care.
89425692|NCT06005194|Active Comparator|InMotion Intervention Condition|"The intervention consists of a manualized physical activity counseling program and includes motivational interviewing over a HIPAA-compliant telehealth delivery model. There will be 8 counseling sessions over 12 weeks. Sessions will be 30-90 minutes long and scheduled during weeks 1-4, 6, 8, 10, and 12. The Fitbit Charge 5 will be set up to sync with the participants' internet-connected device to share activity data with the physical activity coach /interventionist to monitor progress and tailor treatment goals.~Given the InMotion intervention was designed to treat Major Depressive Disorder (MDD) in Traumatic Brain Injury (TBI), the intervention will be delivered by a mental health provider (licensed masters level social worker/MSW) with training and supervision in behavioral aspects of exercise promotion and supervised by a psychologist (who is also the study Principal Investigator) and a physical therapist."
89425693|NCT06005064|Experimental|Intervention|Krill oil 4g/day for 24 weeks
89425694|NCT06005064|Placebo Comparator|Placebo|Vegetable oil 4g/day for 24 weeks
89425695|NCT06003647|No Intervention|Control|Receive normal care
89425696|NCT06003647|Experimental|Intervention|Educational intervention
89425697|NCT06003439|Experimental|Virtual Reality Program|Students in classrooms randomized to this group will receive the Virtual Reality vaping cessation and prevention program.
89425698|NCT06003439|No Intervention|Assessment Only|Students in classrooms randomized to this group will not receive the VR intervention but will complete questionnaire assessment only.
89425699|NCT05999409|Experimental|d1|NBSAF's first rating on a full-reality birth simulator. During the first normal delivery practice of the student in the hospital environment, the second evaluation of NBSAF and the second application of SSSCSL and ESSBL were made.
89425700|NCT05999409|Experimental|d2|An initial evaluation of NBSAF was performed on a medium reality labor stimulator. During the first normal delivery practice of the student in the hospital environment, the second evaluation of NBSAF and the second application of SSSCSL and ESSBL were made.
89007393|NCT04970901|Experimental|Part 2 (Dose Expansion): Loncastuximab Tesirine + Polatuzumab Vedotin (Arm C)|Participants with B-NHL will receive loncastuximab tesirine in combination with polatuzumab vedotin at the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) if favorable results of Part 1 are received.
89425701|NCT05999409|No Intervention|d3 (control)|Without any simulation application, the second evaluation of NBSAF and the second application of SSSCSL and ESSBL were performed during the first normal delivery practice of the student in the hospital environment.
89425702|NCT05998915||Colorectal Cancer(CRC)|People who is diagnosed with CRC by colonoscopy and pathological biopsy
89425703|NCT05998915||Inflammatory Bowel Disease|People who is diagnosed with IBD by colonoscopy and pathological biopsy
89425704|NCT05998915||Colorectal adenoma(CRA)/adenomatous polyposis|People who is diagnosed with CRA by colonoscopy and pathological biopsy
89425705|NCT05998915||Non-adenomatous polyps|People who is diagnosed with non-adenomatous polyps by colonoscopy and pathological biopsy
89425706|NCT05998915||Irritable bowel syndrome|People who is diagnosed with IBS by colonoscopy and pathological biopsy
89425707|NCT05998915||normal|People who has no obvious abnormality in the whole colon
89425708|NCT05997849|Active Comparator|Monitoring and psychoeducation module|The participants in this group will have access only to the monitoring and psychoeducation module for 30 days. The monitoring module consists of a set of self-report measures, and the psychoeducation is delivered through videos.
89425709|NCT05997849|Experimental|Mindfulness strategies module|Participants in this group will have access to the monitoring, psychoeducation and mindfulness strategies modules for 30 days. The mindfulness strategies module includes a set of mindfulness-based self-guided techniques for depression and anxiety symptoms. These techniques are delivered in three steps: Learning, Understanding and Practicing.
89007394|NCT04970901|Experimental|Part 2 (Dose Expansion): Loncastuximab Tesirine + Glofitamab (Arm E)|Participants with B-NHL will receive loncastuximab tesirine in combination with glofitamab at the MTD and/or RDE if favorable results of Part 1 are received. In addition participants will receive obinutuzumab pre-treatment 1000 mg on C1 D1.
89007395|NCT04970901|Experimental|Part 2 (Dose Expansion): Loncastuximab Tesirine + Mosunetuzumab (Arm F)|Participants with B-NHL will receive loncastuximab tesirine in combination with mosunetuzumab at the MTD and/or RDE if favorable results of Part 1 are received.
89007396|NCT04959526|Experimental|Respiratory Function Testing|All subjects will receive standard respiratory function testing and ultrasound-based elastography measurements across various behaviors and conditions
89425710|NCT05997849|Experimental|Behavioral activation strategies module|Participants in this group will have access to the monitoring, psychoeducation and mindfulness strategies modules for 30 days. The behavioral activation strategies module includes a set of behavioral activation self-guided techniques for depression and anxiety symptoms. These techniques are delivered in three steps: Learning, Understanding and Practicing.
89425711|NCT05997849|Experimental|Cognitive strategies module|Participants in this group will have access to the monitoring, psychoeducation and mindfulness strategies modules for 30 days. The mindfulness strategies module includes a set of cognitive-based self-guided techniques for depression and anxiety symptoms, derived from CBT guidelines. These techniques are delivered in three steps: Learning, Understanding and Practicing.
89425712|NCT05997758||Patients|"Patients who suffer from potentially surgically remediable drug-resistant focal epilepsy and who require evaluation with intracranial stereo-EEG electrodes and have them implanted in the anterior insula.~N = 10"
89425713|NCT05997758||Subclinical|"Healthy individuals who match the clinical population in age and level of education.~N = 40"
89425714|NCT05996250|Other|Immersive virtual reality task|"The immersive virtual reality task, specifically designed for this research, is an adaptation to humans of Morris Pool. The virtual environment is composed of a circular arena 22 virtual meters in diameter, delimited by a low wall. It features two visual landmarks and an invisible object to find. The activity includes a control training sequence, an evaluation sequence and a delayed recall performed approximately 20 minutes after the end of the evaluation sequence.~The immersive reality task is performed once by the participants (the study consists on one visit)."
89007397|NCT04947397|No Intervention|Group 1|Traditional deep extubation at 1.5 minimum alveolar concentration (MAC)
89007398|NCT04947397|Experimental|Group 2|Deep extubation guided by pupillometry -- at < 0.5 MAC of vapor + propofol and fentanyl
89425715|NCT05996120|Active Comparator|Hypothermic Cardiopulmonary Bypass|Patients allocated to this arm will undergo standard care for coronary artery bypass grafting and/or valve surgery with mild hypothermia during CPB.
89425716|NCT05996120|Active Comparator|Normothermic Cardiopulmonary Bypass|Patients allocated to this arm will undergo intervention care for coronary artery bypass grafting and/or valve surgery with normothermia hypothermia during CPB.
89425717|NCT05986747|Experimental|Experimental Group|In the experimental group Video based CBT guided self help intervention will be provided
89425718|NCT05986747|No Intervention|Control Group|In the control group, the patients screened for depression or anxiety received treatment as usual (TAU). TAU consisted of standard care under the responsible family physician. TAU in Pakistan largely consists of pharmacological treatment with anti-depressant medication and follow-up in an outpatient clinic.
89425719|NCT05986643|Active Comparator|Exergame & Neurofeedback|Six 5 minutes sets of participants standing on a balance board within virtual environment playing the exergame and receiving real neurofeedback with 1 minute rest between each set.
89007399|NCT04940013|Other|Study participants|Study participants will be persons who have late period of up to 14 days
89007400|NCT04929249|Experimental|Inclisiran First|Inclisiran + usual care
89007401|NCT04929249|No Intervention|Usual Care|Usual care
89007402|NCT04924270|Experimental|cFMT|
89007403|NCT04924270|Placebo Comparator|Placebo|
89007404|NCT04916197|Experimental|Intervention group|Dexmedetomidine 0.1~1.0 μg/kg/h for 24h after patients finished endovascular thrombectomy and returned to ICU. Maintain Ramsay score 2-3.
89007405|NCT04916197|Placebo Comparator|Control group|An equal dose of saline 24h after patients finished endovascular thrombectomy and returned to ICU. If the Ramsay sedation score is 1, propofol will be administrated to maintain the Ramsay sedation score at 2 to 3.
89425720|NCT05986643|Sham Comparator|Exergame & SHAM Feedback|Six 5 minutes sets of participants standing on a balance board within virtual environment playing the exergame and receiving SHAM neurofeedback with 1 minute rest between each set.
89425721|NCT05985486|Experimental|Weight Loss|"Follow a reduced calorie diet daily for 12 months.~Attend monthly behavioral counseling/education"
89007406|NCT04910269|Experimental|Treatment Group|Participants in this group will receive the investigational treatment in addition to standard of care.
89007407|NCT04910269|Placebo Comparator|Placebo Group|Participants in this group will receive a placebo in addition to standard of care.
89425722|NCT05985486|Active Comparator|General Health Education Control|- Attend monthly health education sessions about general health.
89425723|NCT05980520|Experimental|Taurine treatment group|Taurine combined with behavioral rehabilitation therapy
89425724|NCT05980520|Placebo Comparator|Placebo group|Placebo combined with behavioral rehabilitation therapy
89425725|NCT05980481|Experimental|RC48-ADC+Toripalimab+CAPOX|Participants with HER2 positive(IHC2+FISH+ or IHC3+) will receive of RC48-ADC every 2 weeks (Q2W), Toripalimab 2 weeks (Q2W) and CAPOX every 3 weeks (Q3W) , as one treatment period until investigator assessed loss of clinical benefit, unacceptable toxicity, investigator or participant decision to withdraw from therapy, or death (whichever occurs first).
89007408|NCT04883008||Intervention|CorPath GRX with technIQ automated movements enabled (technIQ ON)
89425726|NCT05980481|Experimental|RC48-ADC+Toripalimab+Herceptin|Participants with HER2 positive(IHC2+FISH+ or IHC3+) will receive of RC48-ADC every 2 weeks (Q2W), Toripalimab 2 weeks (Q2W) and Herceptin every 3 weeks (Q3W) , as one treatment period until investigator assessed loss of clinical benefit, unacceptable toxicity, investigator or participant decision to withdraw from therapy, or death (whichever occurs first).
89425727|NCT05980481|Experimental|RC48-ADC+Toripalimab+CAPOX(HER2-low)|Participants with HER2-low (IHC1+) will receive of RC48-ADC every 2 weeks (Q2W), Toripalimab 2 weeks (Q2W) and CAPOX every 3 weeks (Q3W) , as one treatment period until investigator assessed loss of clinical benefit, unacceptable toxicity, investigator or participant decision to withdraw from therapy, or death (whichever occurs first).
89425728|NCT05977699|Active Comparator|salbutamol delivered via pressurized metered dose inhaler|200mcg of salbutamol will be delivered using a pressurized metered dose inhaler plus spacer
89425729|NCT05977699|Placebo Comparator|placebo|normal saline will be administered with a vibrating mesh nebulizer and 200mcg of placebo will be administered using a pressurized metered dose inhaler plus spacer
89007409|NCT04883008||Control|CorPath GRX with technIQ automated movements disabled (technIQ OFF).
89007410|NCT04879732|Other|ACTIS hip stem|All participants will receive the ACTIS hip stem.
89007411|NCT04854278||Pilot study|Pilot study with 22 cases, no intervention
89007412|NCT04854278||Baseline measurement|Baseline measurement of +/- 100 cases, no intervention
89007413|NCT04854278||Post measurement|Post measurement of +/- 100 cases after implementation of a Massive Open Online Course
89007414|NCT04822571|Other|Adolescent volunteers|Adolescent males aged 12-16 years old
89007415|NCT04822571|Other|Adult volunteers|Adult males aged 25-35 years old
89007416|NCT04822298|Experimental|Part 1: Dose Exploration|The dose exploration part of the study will estimate the MTD and/or the RP2D.
89425730|NCT05977699|Experimental|salbutamol delivered with vibrating mesh nebulizer|200microliters of salbutamol will be administered using a vibrating mesh nebulizer
89425731|NCT05976451|Experimental|collagen matrix|melatonin in collagen matrix with Modified Coronally Advanced Tunneling Technique (MCAT)
89425732|NCT05976451|Active Comparator|connective tissue graft (CTG)|connective tissue graft with Modified Coronally Advanced Tunneling Technique (MCAT)
89425733|NCT05974579|Experimental|Healthy participants|Will receive 40MBq of 89Zr-DFO-AP-101, once, at Day 0.
88906660|NCT01559168|Experimental|Prolapse patients recieving UpHold LITE|Non-pregnant female patients >= 50 years who are not considering future pregnancies, who are diagnosed with uterine or vault prolapse with ICS POP-Q score of stage 2 or greater, who are receiving the UpholdTM LITE mesh kit and who agree to be in the study.
88906661|NCT01559194|Active Comparator|Low Fat Diet + Exercise|Subjects were educated about a low fat diet plus exercise and then followed for weight loss. They were also asked to monitor their physical activity by wearing a pedometer and recording the total steps walked every day.
88906662|NCT01559194|Active Comparator|Low Carbohydrate Diet + Exercise|Subjects were educated about a low carbohydrate diet plus exercise and then followed for weight loss. They were also asked to monitor their physical activity by wearing a pedometer and recording the total steps walked every day.
88906663|NCT01559207||Patients with VTE|"Group P is composed of all patients with a history of VTE. Group Px is a subgroup of 15 patients from group P. Members of Px are randomly selected from P."
88906664|NCT01559207||Healthy volunteers|"Group T: 15 healthy volunteers with no history of VTE will be included in this group."
88906665|NCT01559220|Experimental|Open Label|DBS Implant and stimulation
88906666|NCT01559233|Experimental|FPlus|
88906667|NCT01559246||Cardiac Arrhythmia|Subjects 18 years of age or greater that have indications for traditional cardiac(Holter) monitoring.
88906668|NCT01559272|Experimental|Panel A|Panel A consists of 2 treatment groups
88906669|NCT01559272|Experimental|Panel B|Panel B consists of 5 treatment groups
88906670|NCT01559272|Experimental|Panel C|Panel C consists of 1 treatment group
88906671|NCT01559272|Experimental|Panel D|Panel D consists of 4 treatment groups
88906672|NCT01559285|Active Comparator|0.375% ropivacaine|0.375% ropivacaine 8ml was injected epidurally after induction of general anesthesia
88906673|NCT01559285|Active Comparator|0.75% ropivacaine|0.75% ropivacaine 8ml was injected epidurally after induction of general anesthesia
88906674|NCT01559285|Active Comparator|0.2% ropivacaine|0.2% ropivacaine 8ml was injected epidurally after induction of general anesthesia
89425734|NCT05974579|Experimental|Patients with ALS|Will receive 40MBq of 89Zr-DFO-AP-101, once, at Day 0.
89425735|NCT05974462|Placebo Comparator|Standard therapy|IV saline solution 250 mL daily for 3 days on top of standard therapy.
89425736|NCT05974462|Experimental|Pulsed corticosteroid therapy|IV methylprednisolone 125 mg daily for 3 days diluted in saline solution 250 ml on top of standard therapy.
89425737|NCT05971433||"Injury severity scored as severe"|"This group will include participants whose injury was scored as severe based on the recorded Injury Severity Score (ISS). Both cohorts will complete the same course of testing in this study."
89425738|NCT05971433||"Injury severity scored as minimal"|"This group will include participants whose injury was scored as minimal based on the recorded Injury Severity Score (ISS). Both cohorts will complete the same course of testing in this study."
89425739|NCT05968157|Other|Breast MRI Screening for High Risk Patients|Breast MRI will be recommended for patients who are deemed high risk by either the traditional model (Tyrer Cusick) or the Mirai model.
89425740|NCT05966623|Experimental|Experimental VRI sign language interpretation|Participants will be provided with a Tablet of 14' inches with interrupted VRI in Colombian Sign Language. Professionally accredited Sign language interpreter. At the end of the hospital visit, they will complete a scale measuring Doctor-Patient-Communication
89425741|NCT05966623|No Intervention|Experimental: primo control|Participants get welcome at the entry point of the hospital, they are not provided with VRI. At the end of the hospital visit, they will complete a scale measuring Doctor-Patient-communication
89007417|NCT04822298|Experimental|Part 2: Dose Expansion - Cohort 1 Non-squamous NSCLC|Participants with non-squamous non-small cell lung cancer (NSCLC) will be administered the RP2D identified from the dose exploration part of the study.
89425742|NCT05966506|Experimental|Health coaching|
89425743|NCT05965479|Experimental|Trastuzumab deruxtecan|"Participants in the study will be treated with trastuzumab deruxtecan at a dose of 6.4 mg/kg intravenously every 21 days for 8 cycles. If required, patients may dose reduce to level -1 or level -2:~Dose level 0 is 6.4 mg/kg intravenously every 21 days~Dose level -1 is 5.4 mg/kg intravenously every 21 days~Dose level -2 is 4.4 mg/kg intravenously every 21 days~T-DXd will be administered using an IV bag containing 5% (w/v) Dextrose Injection infusion solution and delivered through an IV administration set with a 0.2 or 0.22 μm filter. The standard infusion time for T-DXd is approximately 90 minutes +/- 10 minutes for the first infusion. If the first infusion is well tolerated and the participant does not experience an infusion-related reaction, then the minimum infusion time for subsequent cycles is 30 minutes. However, if there are interruptions during the infusion, the total time must not exceed 3 hours at room temperature."
89425744|NCT05965440|Other|impact of Dapagliflozin on Intestinal Microbiota on chronic renal failure patients|"Addition of 3 blood tubes of 5mL during the collection for the treatment~Collection of fresh urine (7 mL)~Collection of stools by the participant at his home~Collection of fresh stools for patients participating in the ancillary study~Constitution of a biocollection (blood, urine and stool)~Food collection for 3 days with no impact on patient follow-up~Stool appearance sheet to be completed by the patient at each collection"
89425745|NCT05964686|Active Comparator|Conventional group A|
89425746|NCT05964686|Experimental|Dual laser group B|
89425747|NCT05964686|Experimental|Combined group C|
89425748|NCT05963529|Other|Humidity-ramp protocol|Healthy male and female volunteers. Participants will complete all exposures. The humidity-ramp protocol will necessarily be performed first. The order of the fixed-condition exposures will be randomized.
89007418|NCT04822298|Experimental|Part 2: Dose Expansion - Cohort 2 Squamous NSCLC|Participants with squamous NSCLC will be administered the RP2D identified from the dose exploration part of the study.
89007419|NCT04786184|Experimental|CALM Breathing|
89007420|NCT04786184|Active Comparator|Wait-List Control|
89007421|NCT04773158|Experimental|Intervention Arm|The intervention clinic sites will be provided access to both the Functional gastrointestinal disorders (FGIDs) Screening Module and the Treatment Module
89425749|NCT05963529|Experimental|Above-inflection fixed-condition exposure|Healthy male and female volunteers. Participants will complete all exposures. The humidity-ramp protocol will necessarily be performed first. The order of the fixed-condition exposures will be randomized.
89195991|NCT01040299|Experimental|GangTrainer and tDCS|The experimental group patients receive a total of 10 treatments of repetitive locomotor training with electromechanical gait device (duration 30 min) + tDCS (duration first 7 min) with the anodal electrode is place over the presumed lower limb area of the lesioned hemisphere, and the cathodal electrode is place above the controlateral orbital.
89195992|NCT01040299|Sham Comparator|control group1|The control group 1 receive a total of 10 treatments with only GT (duration 30 min) with sham-stimulation.
88906675|NCT01559298|Active Comparator|Aspirin + clopidogrel|Patients will be randomized within the month prior to the TAVI procedure to receive aspirin (80 mg/d) + clopidogrel (75 mg/d) following the TAVI procedure.
88906676|NCT01559298|Active Comparator|Aspirin|Patients will be randomized within the month prior to the TAVI procedure to receive aspirin (80 mg/d)
88906677|NCT01559324|Experimental|Bifrontal ECT (BF)|Formula-based low dose BF ECT
88906678|NCT01559324|Experimental|Right unilateral ECT (RU)|Formula-based high-dose RU ECT
88906679|NCT01559337|Other|Nerve repair|the dorsal branch of the proper digital nerve was used as a pedicle nerve for reconstructing PDN defects
88906680|NCT01559350||RGEA group|A right gastroepiploic artery in situ grafting in the right coronary artery system during OPCAB
88906681|NCT01559350||SVG group|A saphenous vein grafting in the right coronary artery system during OPCAB
89195993|NCT01040299|Active Comparator|control group2|The control group 2 receive a total of 10 treatments with convectional physiotherapy.
89195994|NCT00882544||Diagnosed Pediatric Hydronephrosis|Children diagnosed with hydronephrosis who are to receive robotic pyeloplasty surgery
89195995|NCT00837291|Experimental|CF101 1 mg BID|
89195996|NCT00837291|Placebo Comparator|Placebo|Placebo tablets BID
88906682|NCT01559376||Endoscopic radial artery harvest|
88906683|NCT01559376||Conventional open radial artery harvest|
88906684|NCT01559402|Experimental|Start O2 100% and CPAP 10, end O2 100%.|This arm describes some aspects of ventilation during anesthesia for laparoscopic gastric bypass. Pre-oxygenation is with an inspiratory oxygen fraction(FIO2) of 1.0, supplied by a continuous positive airway pressure of 10 centimeters of water(cmH2O), during anesthesia a positive end-expiratory pressure of 10 cmH2O is used and during emergence from anesthesia a FIO2 of 1.0 is used. The intervention associated with this arm is labeled CPAP and 100% oxygen.
88906685|NCT01559402|Experimental|Start O2 100% and CPAP 10, end O2 31%.|This arm describes some aspects of ventilation during anesthesia for laparoscopic gastric bypass. Pre-oxygenation is with a FIO2 of 1.0, supplied by a continuous positive airway pressure of 10 cmH2O, during anesthesia a positive end-expiratory pressure of 10 cmH2O is used and during emergence from anesthesia a FIO2 of 0.3 is used. The intervention associated with this arm is labeled CPAP and 31% oxygen.
88906686|NCT01559402|Experimental|Start O2 100% and CPAP 0, end O2 100%.|This arm describes some aspects of ventilation during anesthesia for laparoscopic gastric bypass. Pre-oxygenation is with a FIO2 of 1.0, without a continuous positive airway pressure, during anesthesia a positive end-expiratory pressure of 10 cmH2O is used and during emergence from anesthesia a FIO2 of 1.0 is used. The intervention associated with this arm is labeled No CPAP and 100% oxygen.
89195997|NCT00882622|Active Comparator|RIPC|
89195998|NCT00882622|Sham Comparator|CONTROL|
88906687|NCT01559415|Experimental|Very Low Calorie Diet|
88906688|NCT01559415|Active Comparator|Low Calorie Diet|1250 kcal diet in which Modifast is given in combination with a normal diet
88906689|NCT01559428|Experimental|Plant sterol-enriched margarine|
88906690|NCT01559428|Experimental|Plant stanol-enriched margarine|
88906691|NCT01559428|Placebo Comparator|Control margarine|
88906692|NCT01559441|Experimental|Beetroot juice|
89195999|NCT02547909|Experimental|Study group|a probe-based Confocal Laser Endomicroscopy examination will be done using a standard recto-sigmoidoscopy, in women suffering from endometriosis who are referred for a TRUS examination as part of a suspected deep endometriosis diagnostic workup. pCLE images will be compared to normal bowel mucosa.
88906693|NCT01559441|Placebo Comparator|Carbohydrate control drink|
88906694|NCT01559467|Other|Routine clinical care plus early CMR|
88906695|NCT01559467|No Intervention|Routine clinical care|
88906696|NCT01559467|Other|Routine clinical care plus early CTA|
88906697|NCT01559480|Active Comparator|Desogestrel|
88906698|NCT01559480|Placebo Comparator|Placebo|
88906699|NCT01559493||FFR; iFR|Interventional Cardiology, Pressure wire, fractional flow reserve, coronary flow measurement
88906700|NCT01559519|Active Comparator|albumin|cirrhotic patients who underwent tips placement
88906701|NCT01559532||ATK patients|Patients from our institution that underwent cemented TKA for degenerative knee disorders.
88906702|NCT01559545|Active Comparator|Metronidazole|Immediate release metronidazole
88906703|NCT01559545|Experimental|Metronidazole-DRF1|Modified release metronidazole (DRF1)
88906704|NCT01559545|Experimental|Metronidazole-DRF2|Modified release metronidazole (DRF2)
89196000|NCT00882700|Experimental|1|Cefdinir 300 mg Capsule (Sandoz, Austria)
89196001|NCT00882700|Active Comparator|2|Omnicef Cefdinir 300 mg Capsule (Abbott Laboratories, USA)
88906705|NCT01559558||cystocele|
88906706|NCT01559584|Experimental|Phototherapeutic|"0.5% solution of 8-methoxypsoralen (MOP) will be applied 20 minutes before UVA exposure (315-400nm).~UVA sessions will be carried out twice weekly aiming to achieve a phototoxic reaction, in the form of erythema and vesiculation. Once a phototoxic reaction will be achieved, the patient will be asked to rest until the reaction subsides and then resume the phototherapy sessions."
88906707|NCT01559584|Active Comparator|Conventional therapy|One monthly injections of intralesional potent corticosteroids
88906708|NCT01559597|Active Comparator|Cold chain|Group vaccinated with tetanus toxoid vaccine kept in cold chain
88906709|NCT01559597|Experimental|CTC|Group vaccinated with tetanus toxoid vaccine kept in controlled temperature chain
88906710|NCT01559610|No Intervention|Control Group|Received preoperative guidance by a member of healthcare team with the aid of checklist
88906711|NCT01559610|Other|Group intervention|preoperative guideline by a nurse
88906712|NCT01559636|Active Comparator|Diarrhea|Infants with diarrhea will have blood and stool sample taken and receive zinc and ORS. They will then receive bivalent oral polio vaccine as the intervention. Four weeks later another blood sample will be drawn to measure seroconversion.
88906713|NCT01559636|Active Comparator|Non-diarrhea|Infants without diarrhea will have blood and stool sample taken and receive multivitamins. They will then receive bivalent oral polio vaccine as the intervention. Four weeks later another blood sample will be drawn to measure seroconversion.
88906714|NCT01559662|Experimental|Sugared Chewing Gum|Patient asked to chew sugared chewing gum postoperative day 1 to 7, 3 times a day, 45 minutes at a time
88906715|NCT01559662|No Intervention|No Gum|No gum given, routine postoperative care provided
88906716|NCT01559688|Experimental|ART therapy group|Participants in this arm will receive 2-5 sessions of ART therapy, depending on individual progress. Each session will last 60-90 minutes over a 2-week period.
88906717|NCT01559688|Active Comparator|Waitlist|Participants in this group will receive 2 fitness assessment or career counseling sessions. Each session will last 60-90 minutes over a 2-week period. Upon completion of this arm, participants will be offered the choice to start ART therapy.
88906718|NCT01559714||Clinical HCM patients|Patients with an echocardiographically proven hypertrophic cardiomyopathy according to the ESC and ACCF/AHA guidelines
88906719|NCT01559714||Pre-clinical HCM patients|Individuals with a HCM associated mutation without the clinical characteristics of hypertrophic cardiomyopathy
88906720|NCT01559727|No Intervention|Control|The patients with symptomatic heart failure were treated with standard treatment.
88906721|NCT01559727|Experimental|15 mg prednisone group|The patients with symptomatic heart failure are treated with prednisone at dose of 15 mg/day.
88906722|NCT01559727|Experimental|30 mg prednisone group|The patients with symptomatic heart failure are treated with prednisone at dose of 30 mg/day.
88906723|NCT01559727|Experimental|60 mg prednisone group|The patients with symptomatic heart failure are treated with prednisone at dose of 60 mg/day.
88906724|NCT01559740|Experimental|0.25% Bupivacaine|All children will receive a single dose of 1 mcg/kg of Fentanyl intravenously prior to incision. Group TAP 1 receiving a TAP block with 0.25% bupivacaine with 1:200,000 epinephrine at a dose of 1 mL/kg.
89196002|NCT00408499|Experimental|Erlotinib + Cetuximab|Daily erlotinib combined with weekly cetuximab
89007422|NCT04773158|No Intervention|Control Arm|The control clinics will have the Functional gastrointestinal disorders (FGIDs) Screening Module. However, control clinics will not have access to the FGIDs Treatment Module. These clinic sites will be given access to the pre-screener form section of the module, so that providers are made aware of a positive screen for a FGID.
89007423|NCT04707248|Experimental|Dose Escalation|Participants with ovarian cancer (OVC) or renal cell carcinoma (RCC) will receive an intravenous infusion of R-DXd (starting dose 1.6 mg/kg).
89007424|NCT04707248|Experimental|Dose Expansion: Cohort B-1|Participants with RCC will receive an intravenous infusion of R-DXd at the RDE.
89007425|NCT04707248|Experimental|Dose Expansion: Cohort B-2|Participants with OVC will receive an intravenous infusion of R-DXd at the RDE.
89007426|NCT04703595||50 non-smoking patients with chronic cough|50 non-smoking patients aged between 30 and 99 years with chronic and / or refractory cough as the only manifestation or associated with gastroesophageal reflux
89007427|NCT04690010|Active Comparator|Ambulatory tubeless PCNL|Patients will be discharged home on the same day as surgery. No nephrostomy tube will be placed (tubeless).
89007428|NCT04690010|Active Comparator|Inpatient PCNL with nephrostomy tube|Patients will be admitted to hospital for 1-3 days with a nephrostomy tube placed at the time of surgery that will then be removed prior to discharge.
89007429|NCT04681105|Experimental|Treatment (flotetuzumab)|"INDUCTION THERAPY: Patients receive flotetuzumab via continuous IV infusion on days 1-28. Patients who achieve SD/PR (Cohort A) or PR/CI (Cohort B), receive an additional induction cycle. Patients who achieve PR (Cohort A) or PR/CI/MMR (Cohort B) after cycle 2 re-induction, may continue induction therapy for up to 4 more cycles.~CONSOLIDATION THERAPY: Patients who achieve CR/CRi/CRh/MLFS (Cohort A) or CR/MR (Cohort B) after cycle 1 or cycle 2 of induction therapy, receive flotetuzumab via continuous IV infusion on days 1-28 for up to 5 and 6 cycles, respectively, in the absence of disease progression or unacceptable toxicity. Patients with PR (Cohort A) or PR/CI/MMR (Cohort B) who have received up to 6 cycles of induction therapy may receive up to 2 cycles of consolidation therapy in the absence of disease progression or unacceptable toxicity."
89007430|NCT04668924|Experimental|Epi-on PiXL in high oxygen|Photorefractive intrastromal corneal crosslinking without epithelium debridement during humidified high oxygen flow.
89196003|NCT00837369|Experimental|1|RTPE studies (resting and following Regadenoson 400 ug IV bolus injection) will be performed during a continuous infusion of lipid encapsulated microbubbles (Definity, Lantheus Medical Imaging) to qualitatively and quantitatively examine wall motion and myocardial contrast enhancement.
89196004|NCT00900874|Active Comparator|1|Salbutamol + steroid
89196005|NCT00900874|Active Comparator|2|Formoterol + steroid
88906725|NCT01559740|Experimental|0.125% Bupivacaine|All children will receive a single dose of 1 mcg/kg of Fentanyl intravenously prior to incision. Group TAP 2 will receive a TAP block with a total dose of 1 mL/kg given at a concentration of 0.125% bupivacaine with 1:200,000 epinephrine.
88906726|NCT01559753|Experimental|8 days of antibiotic treatment|Patients will receive a combination antibiotic during 5 days and then 3 days of a single Beta Lactam antibiotic
88906727|NCT01559753|Active Comparator|15 days antibiotic treatment|All patients included in the study will be treated by a combination of antibiotics during the first 5 days, then by monotherapy for 10 days according to the group. The beta-lactam antibiotics will be administered in high doses during the first 3 days of treatment. Aminoglycosides will be administered in a single daily dose, with a loading dose the first day of treatment.
88906728|NCT01559181||Exposure to intrauterine hyperglycemia|The study group includes the offspring of women with type 1 diabetes from the national diabetes birth registry (1993-99, n=900) with information of HbA1c prior to conception and/or 1st trimester HbA1c.
88906729|NCT01559181||Control group|The control group including offspring of women without diabetes who delivered during the same period matched with respect to gender and age of offspring and the family's postcode as an indirect marker of the socioeconomic background.
88906730|NCT01559766||4-6 years old group|
88906731|NCT01559766||7-9 years old group|
88906732|NCT01559779||Normal glucose tolerance|Morbidly obese subjects with normal glucose tolerance undergoing gastric bypass surgery
88906733|NCT01559831|Other|IXIARO|IXIARO, applied according to licensed dose, intramuscular
88906734|NCT01559870||patients with elective cardiac surgery|adult patients who had undergone elective cardiac surgery with CPB
88906735|NCT01559883||all eligible patients|there is only 1 Cohort in which all patients participating in this NIS are included
89007431|NCT04666467|Experimental|Single-arm study of PLAR Implant and Delivery System|All enrolled patients will receive the study device
89196006|NCT00901810|Active Comparator|Apex Locator|Working length for cleaning and shaping of the canal is measured by Electronic Apex Locator in this group.
89196007|NCT00901810|Active Comparator|Radiography|Working length for cleaning and shaping of the canal is measured by Radiography in this group.
89196008|NCT00830661|Active Comparator|LIFT|those subjects receiving the Ligation of Intersphincteric Fistula Track procedure
89196009|NCT00830661|Active Comparator|Plug|those subjects randomized to the receive the placement of the porcine anal fistula plug
89196010|NCT02539810|Experimental|Renal artery stenting|"Renal artery angioplasty plus stenting and standardized and optimized medication regimen.~Patients are treated with renal artery stenting plus a standardized optimal medical treatment, including the antihypertensive treatment which is adapted every month starting two month after randomization on the basis of home BP monitoring results at follow-up visits."
89196011|NCT02539810|Active Comparator|standardized and optimized medication regimen|Patients are treated with a standardized optimal medical treatment including the antihypertensive treatment which is adapted every month starting two month after randomization on the basis of home BP monitoring results at follow-up visits.
89196012|NCT04044183|Experimental|Active Brains|Active Brains uses a multimodal approach to introduce and reinforce new skills, including didactics, in-session activities, discussions, and weekly practice assignments (homework). The Active Brains sessions reflect a purposeful integration of the three treatment approaches (relaxation methods, stress appraisal & coping, and growth enhancement). The format is an 8-week program with weekly meetings and a focus on relaxation response strategies, cognitive behavioral training, positive psychology and mind-body interactions. Active Brains 1 uses a digital monitoring device (i.e., Fitbit) for recording of physical activity.
89196013|NCT04044183|Placebo Comparator|Active Brains 2|"This active comparison condition controls for the effect of time spent, group member support/feedback, and interventionist support/feedback. The original HEP was adapted to provide population-specific information on chronic pain and MCI/MRP symptoms. Participants also receive lifestyle education consistent from public health recommendations and standards for health promotion (e.g., Sleep, Nutrition, Healthy Weight, and Medical appointments). The HEP program consists on 8 group sessions (each session is 90 minutes) that occur concurrently with the active intervention condition. The HEP is conducted in the same format as Active Brains-Fitbit but are not taught the mind-body, walking, or cognitive-behavioral skills. HEP participants are encouraged to set lifestyle goals instead of quota-based walking goals aided by the Fitbit as in the Active Brains-Fitbit condition."
89196014|NCT00900952||1|Infected elderly patients
89196015|NCT00901888|Experimental|Angiotensin II infusion|Using forearm venous occlusion plethysmography angiotensin II will be infused to cause reduction in forearm blood flow. Infusion of apelin and sodium nitroprusside will given and vasodilatation will be assessed. Blood samples for the infused arm and contra-lateral arm will be taken at regular time points to assess local and systemic changes in relevant hormones.
89196016|NCT00901888|Active Comparator|Noradrenaline|Using forearm venous occlusion plethysmography noradrenaline will be infused to cause reduction in forearm blood flow. Infusion of apelin and sodium nitroprusside will given and vasodilatation will be assessed. Blood samples for the infused arm and contra-lateral arm will be taken at regular time points to assess local and systemic changes in relevant hormones.
89196017|NCT04416711|Active Comparator|Services As Usual|Participants assigned to the SAU condition will receive services as usual at their university, which include required programming related to heavy episodic drinking and sexually aggressive behavior either online or through new-student orientation.
89196018|NCT04416711|Experimental|Personalized Feedback and Cognitive Training|The prevention program will target heavy episodic drinking, sexually aggressive behavior, and risky sexual behavior through 2 sessions that integrate personalized feedback and cognitive training components.
89196019|NCT00908362|Active Comparator|A|Inhalation of Fluticasone (via discus) twice daily for 28 days
89196020|NCT00908362|Active Comparator|B|Inhalation of Fluticasone and Salmeterol (via discus) twice daily for 28 days
89196021|NCT00908362|Placebo Comparator|C|Inhalation of Placebo (via discus) twice daily for 28 days.
89196022|NCT02549469|Experimental|Naproxen sodium extended release 660 mg, 20% HPMC|Bioequivalence in healthy adult subjects in a fasted state relative to the established commercial Aleve (Naproxen sodium) 220 mg tablet
89196023|NCT02549469|Experimental|Naproxen sodium extended release 660 mg, 30% HPMC|Bioequivalence in healthy adult subjects in a fasted state relative to the established commercial Aleve 220 mg tablet
89196024|NCT02549469|Experimental|Naproxen sodium extended release 660 mg, 40% HPMC|Bioequivalence in healthy adult subjects in a fasted state relative to the established commercial Aleve 220 mg tablet
89196025|NCT02549469|Active Comparator|Naproxen sodium 220 mg|Bioequivalence in healthy adult subjects in a fasted state
89196026|NCT00905866||Quality of life|All participants undergoing parathyroidectomy
89196027|NCT02539576|Experimental|ABC/DTG/3TC FDC|Each subject will receive treatment with a single oral dose of ABC 600 mg/DTG 50 mg/3TC 300 mg FDC tablet administered under the fasted state
89196028|NCT00837603|Active Comparator|Training|Ergometer Training
89196029|NCT00837603|No Intervention|2|Counseling
89196030|NCT00905944|No Intervention|Control|
89196031|NCT00905944|Experimental|Intervention|The patients carry out an exercise program (walking on a treadmill) three times weekly for 12 weeks at a speed corresponding with an intensity of 70% of VO2max.
89196032|NCT00923793|Active Comparator|Titanium|Titanium implant for cranioplasty. Titanium implants are used since 10 years in Germany because of their high biocompatibility and accuracy of fit.
89196033|NCT00923793|Experimental|Hydroxylapatite|Hydroxylapatite (CustomBone) implant Hydroxylapatite implants are used since about 3 years in Germany. As this material is very similar to human bone structure an improved osteointegration has been observed.
89196034|NCT02548533|Active Comparator|Region 1|Standard topical anesthesia using eutectic mixture of lidocaine 25 mg/g and prilocaine 25 mg/g cream (EMLA cream) applied two hours before treatment.
89425750|NCT05963529|Experimental|Below-inflection fixed-condition exposure|Healthy male and female volunteers. Participants will complete all exposures. The humidity-ramp protocol will necessarily be performed first. The order of the fixed-condition exposures will be randomized.
89425751|NCT05963529|Active Comparator|Control fixed-condition exposure|Healthy male and female volunteers. Participants will complete all exposures. The humidity-ramp protocol will necessarily be performed first. The order of the fixed-condition exposures will be randomized.
89425752|NCT05962463||Canal adductor blockade|After surgical cleaning of the anteromedial thigh, all participants in this group received single shot ultrasound guided canal adductor blockade with 14 ml 0,25% levobupivacaine and 100 mcg clonidine mixed in the same syringe. Investigators previously scanned the adductor canal and chose the middle of the canal as the entry point of the 10 cm echogenic ultrasound needle. After the blockade, all participants were monitored in our ambulance for the next hour.
89425753|NCT05962463||Pulsed radiofrequency therapy|After surgical cleaning of the anteromedial thigh, all participants in this group received ultrasound-guided pulsed radiofrequency therapy. Investigators previously scanned the adductor canal and chose the middle of the canal as the entry point of the RF 10 cm needle with a 1 cm free tip. After sensory and motor checking all patients have gotten 6 minutes of therapy divided into 3 sequences of 2 minutes of 50 V current and 42. Before starting the PRF therapy all participants have gotten 2 ml 0,25% levobupivacaine through the needle for preventing discomfort during the procedure. After the treatment, all participants were monitored in our ambulance for the next hour.
89425754|NCT05959252|Active Comparator|Bivalirudin|Bivalirudin protocol with target activated thromboplastin time (aPTT) of 50-70 seconds
89425755|NCT05959252|Active Comparator|Unfractionated Heparin|Unfractionated heparin protocol with target anti-Xa of 0.3-0.5 IU/mL
89425756|NCT05956119|Experimental|dry needling|The intervention group will have a single session of dry nedling application in the medial gastrocnemius + usual care (physiotherapy)
89425757|NCT05956119|Sham Comparator|placebo|The control group will have a single session of sham dry nedling in the medial gastrocnemius + usual care (physiotherapy)
89425758|NCT05955755|Experimental|experimental group|A butterfly vacuum blood collection set will be used in the blood collection process from the children in the experimental group.
89425759|NCT05955755|No Intervention|control group|A standard vacutanier needle will be used for blood collection from the children in the control group. Vacutanier needle is used routinely in the blood collection unit where the study will be performed.
88906736|NCT01559896|Experimental|intervention and placebo|Once in the study, 20 subjects will be randomly assigned to a group taking capsules containing 5 gr egg protein hydrolysate per day, and 20 to a group taking placebo capsules. The subjects consume the capsules during three consecutive days (period 1). Following a wash-out period of minimally four weeks, the treatments are crossed-over.
88906737|NCT01559909|Experimental|Socket wall height|
89425760|NCT05949944|Experimental|Linperlisib in combination with CHOP|Patients will receive six cycles of induction therapy of linperlisib in combination with CHOP regimen. All patients with CR and PR after induction therapy receive linperlisib maintenance therapy every 28 days until disease progression or other reasons lead to discontinuation, and the duration of linperlisib maintenance does not exceed 24 months.
89425761|NCT05949606|Experimental|Study treatment|Participants will receive treatment during the first cycle. Participants with clinical benefits received more cycles of additional therapy. Administration will be discontinued due to disease progression or occurrence of intolerable toxicity or other reasons.
88906738|NCT01559961|Experimental|TTI-1612|Single intravesical 30-minute treatments with escalating doses of TTI-1612.
89425762|NCT05949424|Active Comparator|Control group|Standard SmPC dosing with dose adjustments for toxicity as per SmPC
88906739|NCT01559974|Active Comparator|Vitamin D|
88906740|NCT01559974|Placebo Comparator|Placebo|
88906741|NCT01559987|Other|Control|ADA (American Dental Association) Reference Manual Toothbrush (MTB)
88906742|NCT01559987|Other|Test|MTB + Floss
88906743|NCT01559987|Experimental|MTB + Waterpik Ultra Water Flosser High|MTB + Waterpik Ultra Water Flosser High
88906744|NCT01560533|Other|Treated by HIPEC|Patients treated by HIPEC for peritoneal cancer
88906745|NCT01560533|Other|Standard chemiotherapy|Patients treated by standard chemiotherapy for peritoneal cancer
88906746|NCT01560832||Laboratory (PCR)-confirmed C.difficile infection|patient who has experienced the passage of 3 or more unformed or loose stools [diarrhea] conforming to the shape of a container within a 24-hour period and has a positive laboratory test result confirmed by PCR.
88906747|NCT01560845|Experimental|ABMSCi plus surgery group|Autologous bone marrow stem cells infusion through hepatic artery in open abdominal portal hypertension surgery
88906748|NCT01560845|No Intervention|portal hypertension surgery group|only portal hypertension surgery for this group patients
88906749|NCT05570669|Experimental|full dose|"Group A delayed full-dose regimen (study arm): intake of two large A sachets and 2 small B sachets from 20:30 to 22:00 the evening before the exam. Taking the remaining 2 envelopes A large e 2 small B envelopes from 10.30 pm to midnight the evening before the exam."
88906750|NCT05570669|Other|split dose|"Group B split-dose regimen (control arm): intake of two large A sachets and two small B sachets from 20.30 to 22:00 the evening before the exam. The remaining two large A envelopes and two small B envelopes will be taken 5 hours earlier than the time when the exam is scheduled on the same day as the exam."
88906751|NCT05570643|Experimental|LPS group|Healthy male volunteers that will receive an intravenous administration of LPS (2ng/kg) twice.
89007432|NCT04648709||asymptomatic patients|asymptomatic patients with PCR-positive PCR
89425763|NCT05949424|Experimental|Intervention group|Lower starting dose with dose-escalation inversely following the dosing steps from the SmPC every 2 weeks in case of good tolerability
89425764|NCT05944718|Experimental|Arm 1|Arm 1 is those participants randomized to use of CGM in a continuous fashion; CGM use for the duration of 9 months.
89425765|NCT05944718|Experimental|Arm 2|Arm 2 is those participants randomized to intermittent use of CGM; CGM use for 4 time points consisting of 2 weeks of CGM use each, for the duration of 9 months.
89425766|NCT05944718|No Intervention|Arm 3|Arm 3 is those participants randomized to standard of care; regular use of self-monitoring of blood glucose (SMBG) for the duration of 9 months.
89425767|NCT05941663|Experimental|SLAactive|Implants provided were Bone Level Tapered (Bone Level Tapered) Roxolid® implants with a SLActive® surface
89425768|NCT05941663|Active Comparator|SLA|Implants provided were Bone Level Tapered (Bone Level Tapered) Roxolid® implants with a SLA® surface
89425769|NCT05939310|Experimental|Fluorescence guided surgery|10 mg bevacizumab-IRDye800CW, to intraoperatively assess possible tumour-positive margins.
88906752|NCT05570643|Placebo Comparator|Placebo group|Healthy male volunteers that will receive an intravenous administration of placebo (NaCl 0.9%).
88906753|NCT05570474|Experimental|Protein|Daily protein shake during 6 months after surgery
88906754|NCT05570474|Placebo Comparator|Control|Daily placebo shake during 6 months after surgery
88906755|NCT05570461|Experimental|Experimental Group|Experimental group will receive Modified Constraint-Induced Movement Therapy and traditional physical therapy to the impaired upper limb based on the repetitive training of functional activities and behavioral shaping and a task-oriented approach, while the unaffected arm of subjects in the Modified Constraint-Induced Movement Therapy group will be constrained by wearing a mitten during the treatment session
88906756|NCT05570461|Active Comparator|Control Group|Control group therapy will consist of increasing upper limb function with the use of both hands. The session include active or active assistive range of motion exercises, unilateral and bimanual activities, balance and strength training or coordination exercises depending on the severity of motor impairment. Similar to group A, daily therapy will be conducted for 40 min/day, 6 days/ week for upto 2 weeks.
88906757|NCT05570448|Active Comparator|Anti-reflux mucosal ablation (ARAT)|ablation in the gastric cardia using hybrid argon plasma coagulation
88906758|NCT05570448|Sham Comparator|No treatment|no ablation
88906759|NCT05570383|Placebo Comparator|In the control group|Half of the subjects（30 subjects）will be assigned to the control group，they will be using the Mometasone furoate nasal spray (Nasonex).
88906760|NCT05570383|Experimental|The experimental group|Half of the subjects (30) will be assigned to the experimental group. Received sublingual dust mite drops (trade name: Changdi, Zhejiang Wuwu Biotechnology Co., LTD.) for sublingual immunotherapy.
89425770|NCT05928624|Sham Comparator|Standard of Care|This arm will receive a home blood pressure monitor and scale; however, these data will not be shared with their treating provider in real-time.
89425771|NCT05928624|Experimental|Home Blood Pressure and Scale Monitoring to Inform Clinical Decisions|This arm will receive a home blood pressure monitor and scale. These data will be reviewed weekly and these data will be shared with the treating provider to inform clinical decisions.
89425772|NCT05928013|Experimental|Person With Diabetes|A health care professional will conduct the vibration perception threshold testing using both the Neurothesiometer and NERVE diagnostic testing on the person with diabetes. The person with diabetes will conduct the vibration perception threshold testing using the NERVE device. There is an option for a carer/buddy to conduct the vibration perception threshold testing with the NERVE device on the person with diabetes.
89425773|NCT05926258|Experimental|Chloroprocaine 3% gel|The assigned investigational product (2 drops) will be instilled in both eyes of each subject. Administrations will be performed at the clinical centre by the Investigator or his/her deputy on study day 1. For each administration, the 2 drops will be instilled one at the time, at a 1 min interval.
89425774|NCT05926258|Active Comparator|Oxybuprocaine 0,4% solution|The assigned active comparator (2 drops) will be instilled in both eyes of each subject. Administrations will be performed at the clinical centre by the Investigator or his/her deputy on study day 1. For each administration, the 2 drops will be instilled one at the time, at a 1 min interval.
89425775|NCT05923008|Experimental|IBI130|IBI130
89425776|NCT05920122|Experimental|2% Chlorhexidine gluconate with 70% alcohol (ChloraPrep)|Including cases undergoing elective &non elective caesarean section. Patients will be prepared similarly using the appropriate number of 26mL Chloraprep sticks for their body surface area. The lever will be pinched to activate the ampoule and release the antiseptic. The solution will be given time to partially load in the sponge. The sponge will be pressed against the skin area where the incision is intended moving back and forth for 30 sec , then working up towards the upper edge of the surgical field and then working from below the incision sight to the upper thighs. The antiseptic will be given time to dry (3 min)
88906761|NCT05570370||ADAD family members, mutation carriers|asymptomatic and presymptomatic individuals
88906762|NCT05570370||ADAD family members, non-mutation carriers|age-matched family members (non-mutation carriers) relative to the asymptomatic/presymptomatic group
88906763|NCT05570357|Active Comparator|Intervention|
88906764|NCT05570357|Placebo Comparator|Placebo|
88906765|NCT05570318|Active Comparator|Polyethylene glycols|"This group consists of children who have already been treated with oral laxatives (PEG) for at least 2 months, but still experience symptoms of constipation and fecal incontinence.~Their PEG dosage will be adjusted to the ideal dose for the individual child (this will be evaluated by a health care professional), with the minimum dosage being the maintenance dose of 0,5mg/kg/day, and the maximum dosage being the disimpaction dose of 1,5mg/kg/day"
89007433|NCT04648709||mild symptoms patients|patients with mild symptoms and PCR positive
89007434|NCT04648709||seriously symptomatic patients|seriously symptomatic patients with PCR positive
89007435|NCT04648709||patients in resuscitation|patients in resuscitation with positive PCR
88906766|NCT05570318|Experimental|Polyethylene glycols and low volume trans anal irrigation|This group consists of children who have already been treated with oral laxatives (PEG) for at least 2 months, but still experience symptoms of constipation and fecal incontinence. PEG dose will be adjusted in the same manner as in group a, but this group will also receive daily treatment with low volume trans anal irrigation.
88906767|NCT05570240||OA group|Knee osteoarthritis patients who were scheduled to receive elective total knee replacement surgery which need spinal anesthesia.
88906768|NCT05570240||Control group|Control group patients were scheduled to receive elective general surgery or urological surgery with spinal anesthesia.
88906769|NCT05570201|Experimental|Experimental Group|By visiting the women who met the research criteria, the purpose of the study was explained and their written informed consent was obtained. This study was conducted in two sessions using pre- and post-tests. The Personal Information Form, the SFQ, and the HADS were filled out using the face-to-face interview method by the researcher for the women included in the music and training on the day of their hospitalization, which lasted for 30-45 minutes.
89196035|NCT02548533|Experimental|Region 2|Anesthesia using articaine hydrochloride 40 mg/ml and epinephrine 10 µg/ml solution (AHES) applied on ablative fractional laser (AFXL) pretreated skin 15 minutes prior to the treatment.
89196036|NCT00908518||Total Intravenous Anesthesia|Propofol based anesthesia
89196037|NCT00908518||Inhaled anesthesia|Isoflurane based anesthesia
89196038|NCT00901966||Agricultural workers and spouses|Melanoma risk factors among Ag workers and spouses who use pesticides.
89196039|NCT02549391|Experimental|KHK7580|
89196040|NCT02549391|Active Comparator|KRN1493|
89196041|NCT00902122|Experimental|1|Five times of p53 gene intratumoral injection are given before surgery,then radical surgery will be conducted.
89196042|NCT00902122|Active Comparator|2|surgery
89196043|NCT00902122|Experimental|3|p53 gene therapy
89196044|NCT00902122|Active Comparator|4|p53 gene therapy plus radioactive iodine
89196045|NCT00837681||lung disease|hematopoietic stem cell transplantation (HSCT)
89196046|NCT02538172|Experimental|Intervention|T-Track® CMV assay Quantiferon-CMV® assays Valganciclovir
89196047|NCT02538172|Other|Control|T-Track® CMV assay Quantiferon-CMV® assays Valganciclovir
89196048|NCT00837837|Experimental|Chlorpheniramine|Chlorpheniramine dose by body weight.
89196049|NCT00908674||Group 1|
89196050|NCT00906022|Experimental|Astron Pulsar Stent|Device: Astron Pulsar Stent
89196051|NCT00906022|Active Comparator|PTA alone|Device: Balloon angioplasty alone
89196052|NCT00902356|Active Comparator|B|Six female subjects in each of cohorts 1 to 5 will receive AMG 167; six male subjects in each of cohorts 6 and 8; three female subjects in each of cohorts 7 and 9.
89196053|NCT00902356|Placebo Comparator|A|Two female subjects in each of cohorts 1 to 5 will receive placebo; two male subjects in each of cohorts 6 and 8; and 1 female subject in each of cohorts 7 and 9.
89196054|NCT00621777|Active Comparator|Randomized Phase: Varenicline|Varenicline is a partial agonist at alpha4beta2 nicotinic acetylcholine receptors (nAChRs) and a full agonist at alpha 7 nAChRs that has been shown to be effective for smoking cessation compared with placebo and bupropion, with effects on abstinence rates for up to one year. Varenicline has demonstrated safety when dosed at 1 mg twice per day for up to one year. Because varenicline, at a dose of 1 mg twice per day, may be a more effective treatment for sustained abstinence than bupropion, it was chosen as the medication intervention for this study.
89196055|NCT00621777|Placebo Comparator|Randomized Phase: Placebo|
89196056|NCT02538718|Active Comparator|YTP(ritodrine) arm|who randomly assigned to have Yutopar(ritodrine) as tocolytics
89196057|NCT02538718|Experimental|MgSO4 arm|who were randomised to have MgSO4 as tocolytics
89196058|NCT00827229|Other|LaborPro, active Labor, Vaginal Examination|
89196059|NCT02539420|No Intervention|Control|"Patients assigned to the control group will receive any treatment for status asthmaticus that does not entail use of positive pressure ventilation."
89196060|NCT02539420|Experimental|Late BiPAP treatment|"Patients assigned to the late treatment group will be started on BiPAP greater than 6 hours after randomization."
89196061|NCT02539420|Experimental|Early BiPAP treatment|"Patients assigned to the early treatment group will be started on BiPAP as soon as possible after randomization."
89196062|NCT04018599|Experimental|40 mg MSB11022 via Auto-injector|Participants will receive a single dose of 40 mg/0.8 mL of MSB11022 via an auto-injector on Day 1.
89196063|NCT04018599|Experimental|40 mg MSB11022 via Pre-filled Syringe|Participants will receive a single dose of 40 mg/0.8 mL of MSB11022 via a pre-filled syringe on Day 1.
89196064|NCT00902512|Active Comparator|Treatment A|Viagra® 100 mg tablet, administered with water
89196065|NCT00902512|Active Comparator|Treatment B|Sildenafil 100 mg CT administered with water
89196066|NCT00902512|Active Comparator|Treatment C|Sildenafil 100 mg CT administered without water
89425777|NCT05920122|Experimental|4% chlorhexidine gluconate (Hibiclens)|Including cases undergoing elective & nonelective caesarean section. Patients will be scrubbed preoperative with an applicator that contain 4% chlorohexidine aqueous solution (3 consecutive applications) liberally over 2 minutes followed by drying with sterile towel. The area scrubbed will be the same as the chloraprep group.
88906770|NCT05570175|Experimental|intervention group|The intervention group received a mobile application RA joint protection and activity self-management program based on self-efficacy theory for 6 weeks.
88906771|NCT05570175|No Intervention|control group|The control group received general information on rheumatoid arthritis care and follow-up.
89425778|NCT05917613|Experimental|Intervention|Psychotherapy
88906772|NCT05570110|Experimental|enoxolone|100 mg enoxolone in a capsule
88906773|NCT05570110|Placebo Comparator|placebo|Placebo in a capsule
88906774|NCT05570084|Active Comparator|Tamsulosin|0.4mg daily for 4 weeks
88906775|NCT05570084|Experimental|Silodosin|8mg daily for 4 weeks
88906776|NCT05569993|Active Comparator|Glutamine group|30 patients will recieve .3 mg/kg of glutamine for first 7 days in ICU
88906777|NCT05569993|Placebo Comparator|Placcebo group|30 patients will recieve placcebo for first 7 days in ICU
88906778|NCT05569967|Experimental|Group 1|Individuals in this group will receive spinal stabilization training through telerehabilitation.
88906779|NCT05569967|Active Comparator|Group 2|Individuals in this group will receive spinal stabilization training face-to-face.
88906780|NCT05569863||Hypospadias group|Patients with hypospadias diagnosis
88906781|NCT05569863||Control group|Patients without hypospadias
88906782|NCT05569850|Experimental|Recently introduced toothpaste|Brushing twice a day with a recently introduced toothpaste.
88906783|NCT05569850|Active Comparator|Commercial toothpaste|Brushing twice a day with a commercially available toothpaste.
88906784|NCT05569824||Prospective Study Pathway|Child or young person undergoing a Broncho-alveolar Lavage (BAL) for suspected pulmonary Invasive Fungal Disease (IFD) and consent obtained.
88906785|NCT05569785|Active Comparator|Group 1 Resistance Exercise Therapy Feasibility|One group who have been randomised to receive 4 weeks of Resistance Exercise Therapy to explore the feasibility of introducing such a programme in the bariatric population.
88906786|NCT05569785|No Intervention|Group 2 Standard Care|This group have been randomised to receive standard care post surgery.
88906787|NCT05569720|Experimental|ApTOLL treatment|Volunteers will receive a dose of ApTOLL of 0.1mg/kg administered intravenously as slow infusion one day and as a single bolus intravenous injection the second day. In a third and last admission day, volunteers will receive a dose of ApTOLL of 0.2mg/kg administered as a single bolus intravenous injection.
88906788|NCT05569707|Other|MelaDiff|Patients with melanoma of the extremities included in the protocol. Preoperative, patients will receive two MRI-scans and a magnetic tracer injection at the primary tumor site. During surgery, SLNs will be detected using two types of magnetometers (SentiMag® & DiffMag) in combination with Magtrace®, in addition to the standard procedure.
88906789|NCT05569668||Neoadjuvant chemotherapy group|Standard NAC comprised 2 cycles. Platinum plus paclitaxel or docetaxel was repeated once every 3 weeks. Cis-platinum was administered at a total dose of 75 mg/m2 by continuous infusion on d1 or equal divided on Days 2-4 or Days 1-3. Paclitaxel, 175 mg/m2, d1, or paclitaxel, 87.5 mg/m2, d1, d8. If the docetaxel was adopted, it was given as 75 mg/m2 on Day 1. Then surgery----esophagectomy and two-field extensive mediastinal lymphadenectomy. After surgery, there might be a adjuvant chemotherayp for pathologically positive lymph nodes patients.
88906790|NCT05569668||Primary surgery group|The patients would receive primary surgery----esophagectomy and two-field extensive mediastinal lymphadenectomy. After surgery, there might be a adjuvant chemotherayp for pathologically positive lymph nodes patients. .
88906791|NCT05569655|Experimental|Subjects in group A|For subjects in group A, tolvaptan (15 mg/d) is added to standard therapy (furosemide: 20mg-40mg/d).
88906792|NCT05569655|Active Comparator|Subjects in group B|Subjects in group B receive standard therapy (including furosemide: 20mg-40mg/d).
88906793|NCT05569616|Experimental|Hand massage group|Based on the hand massage procedure, hand massage with baby oil will be applied for 20 minutes, three times a week (12 times in total) for 4 weeks.
88906794|NCT05569616|Experimental|Play activity group|It will be played in groups of two for one hour once a week. The application will take 4 weeks.
88906795|NCT05569616|No Intervention|Control group|These elderly people in the control group will benefit from the standard care practices offered in the institution, and no intervention will be given to these elderly people by the researcher.
88906796|NCT05569603|Experimental|Chronobiology-guided lifestyle interventions group|A multimodal program that includes (1) timed bright light therapy, (2)guidance on meal timing, and (3) sleep hygiene education.
88906797|NCT05569603|No Intervention|wait-list control group|The participants in the wait-list group will be told that they are on a waiting list during the first 2 weeks to serve as the no-treatment control. Chronobiology-guided lifestyle interventions will be conducted after the posttest is completed.
89007436|NCT04648709||heathly volunteer|heathly volunteer as control
89007437|NCT04647890|Experimental|FT011 200mg|200mg once daily for 12 weeks
89007438|NCT04647890|Experimental|FT011 400mg|400mg once daily for 12 weeks
89425779|NCT05915884||Type 2 diabetic patients using SGLT-2 inhibitors|The data of all patients who applied to Samsun Training and Research Hospital Internal Medicine outpatient clinic for 12 months in 2022 and were started on SGLT-2 inhibitor will be examined. According to the inclusion and exclusion criteria, the patients will be evaluated and the data of the patients admitted to the study will be analyzed. The triglyceride glucose index of the patients before starting the SGLT-2 treatment and the triglyceride glucose index at the end of 3 months of treatment will be calculated by the researchers using the data in the system. No additional blood tests or laboratory analyses will be performed on the patients.
89425780|NCT05909969|Experimental|Pelvi-Fit Group|The experiment group will receive the treatment protocol for urinary incontinence based on evidence-based protocol through the Pelvi-Fit app.
89425781|NCT05909969|Other|Control|This group will receive the same treatment protocol in a descriptive form (non-app-based treatment) for urinary incontinence.
89425782|NCT05908760|Experimental|CO2 Rebreathing|Participants will breathe with the rebreather in the supine position until CO2 levels increase between 5-10mmHg. Once CO2 levels are increased, participants will be tilted upright, and will continue to breathe with the rebreather during a 5-min HUT test
89425783|NCT05908760|No Intervention|Room Air|Participants will breathe room air in the supine position and during a 5-min HUT test
89425784|NCT05901246|Experimental|PS-containing dietary supplement|Sachet containing a powdered ingredient source of microencapsulated free plant sterols (2,25 g ingredient/day)
89425785|NCT05901246|Placebo Comparator|Placebo|Sachet containing the excipients of the ingredient (2,25 g placebo/day)
89425786|NCT05898113|Experimental|EXTRA VIRGIN (intervention / control)|After a 3-day run in period avoiding EVOO consumption, participants will consume a daily amount of 0.7 g EVOO / kg body weight in addition to their usual diet for 1 months. They will then have 4 weeks with their usual diet and another 3-day run in period before starting the control intervention, which consists of following their usual diet plus 0.7 g olive oil low of polyphenol (OOLP)/ kg body weight daily for one month.
89425787|NCT05898113|Experimental|LOW POLYPHENOL (control/intervention)|After a 3-day run-in period avoiding EVOO consumption, participants will consume a daily amount of 0.7 g of OOLP/ kg body weight in addition to their usual diet for 1 month. Then, they will have 4 weeks with their usual diet and another run in period of 3 days before starting the intervention which consists of following their usual diet plus 0.7 g of EVOO / kg body weight daily for one month.
89007439|NCT04647890|Placebo Comparator|Placebo|Placebo once daily for 12 weeks
89007440|NCT04642638|Experimental|Phase 2: INO-4800 Dose Group 1|Participants received one ID injection of 1.0 milligram (mg) of INO-4800 followed by EP using the CELLECTRA® 2000 device on Day 0 and Day 28.
89007441|NCT04642638|Experimental|Phase 2: INO-4800 Dose Group 2|Participants received two ID injections of 1.0 mg (total 2.0 mg per dosing visit) of INO-4800 followed by EP using the CELLECTRA® 2000 device on Day 0 and Day 28.
89425788|NCT05893771|Placebo Comparator|Placebo control|With ultrasound guidance, 20 ml plain normal saline will be injected to spread lateral to the femoral artery and deep to the sartorius muscle, or more distal, below the knee after arrival to the theatre.
89425789|NCT05893771|Experimental|Depomedrol group|With ultrasound guidance, a mixture of 5 ml Bupivacaine 0.5%, 1 ml (20 mg) depomedrol, and 14 ml normal saline is injected to spread lateral to the femoral artery and deep to the sartorius muscle, or more distal, below the knee after arrival at the theatre.
89425790|NCT05893771|Active Comparator|Bupivacaine group|A mixture of 5 ml Bupivacaine 0.5%- and 14-ml normal saline is injected to spread lateral to the femoral artery and deep to the sartorius muscle, or more distal, below the knee, after arrival at the theatre.
89425791|NCT05893238||In Vitro Fertilisation (IVF)-Patients without hormonal stimulation (Natural cycle IVF)|Natural cycle IVF
89425792|NCT05893238||In Vitro Fertilisation (IVF)-Patients with hormonal stimulation (conventional IVF)|conventional IVF
89425793|NCT05891899||Antithrombin deficient patients|patients with proven, inherited antithrombin deficiency
89425794|NCT05889559|No Intervention|Control Pressure Monitoring Group|Participants in this group will have pressure monitoring of the anterior compartment of their leg using an indwelling IMP catheter (MY01, MY01 Inc., Montreal, CA). The participants will be treated according to the standard-of-care regarding management of their underlying injury and diagnosis of ACS as practiced by their treating surgeon. Participants will be followed for six months post-injury.
89425795|NCT05889559|Experimental|Tissue Ultrafiltration Intervention Group (TUF)|Participants in this group will have pressure monitoring of the anterior compartment of their leg using an indwelling IMP catheter (MY01, MY01 Inc., Montreal, CA). The participants will be treated according to the standard-of-care regarding management of their underlying injury and diagnosis of ACS as practiced by their treating surgeon. In addition, participants in this group will will undergo three TUF of the anterior compartment of the injured limb. Participants will be followed for six months post-injury.
89425796|NCT05888610|Experimental|Digital Outpost|
89425797|NCT05887570|Experimental|Intervention|"Specific intervention:~Modules for each of the above comprising:~didactic lecture on indications and contraindications of procedure, surgical anatomy, patient positioning in the OR, anesthesia type, suture materials and suturing techniques;~practical component with hands-on surgical skill training in basic and advanced techniques relevant to each procedure~immediate feedback from dedicated educator on technical aspects~post-test"
89425798|NCT05887570|Placebo Comparator|Control -|This group receives regular instruction.
89425799|NCT05886868|Experimental|BL0020|"Dose Escalation Stage: BL0020 will be administered via intravenous infusion on days 1 of a 21-days treatment cycle.~Dose Expansion Stage: Maximum tolerated dose or the recommended Phase 2 dose (RP2D) from dose escalation Stage."
88906798|NCT05569590|Active Comparator|Control|One visit three application of bleaching agent (hydrogen peroxide 35%) will be performed and desensitizing agent (fluoride varnish) will be applied for 10 minutes after bleaching.
88906799|NCT05569590|Experimental|Propolis|One sitting vital tooth bleaching procedure will be performed. Three application each of 15 minutes of bleaching agent (hydrogen peroxide 35%) will be applied and desensitizing agent propolis in paste form will be applied for 10 minutes.
88906800|NCT05569590|Experimental|Propolis mixed with bleaching agent|One visit vital tooth bleaching procedure will be performed. three application each of 15 minutes of Propolis mixed with bleaching agent (hydrogen peroxide 35%) will be applied.
89425800|NCT05879978|Experimental|BI 764532 + ezabenlimab treatment group|Successive cohorts of patients will receive increasing doses of BI 764532 in combination with ezabenlimab until the maximum tolerated dose (MTD) is reached, or upon decision of Dose Escalation Committee (DEC).
88906801|NCT05569577|Experimental|Additional hCG injection|An additional hCG injection of 2000-5000IU would be performed 48 hours following routine hCG trigger on the basis of supplementation of estrogen and dydrogesterone in IHH patients.
88906802|NCT05569577|Placebo Comparator|No additional hCG injection|Only estrogen and dydrogesterone would be given for luteal phase support in IHH patients.
88906803|NCT05569564|Experimental|Osseodensification with ridge splitting|Ridge splitting followed by osseodensification using osseodensifying burs .
88906804|NCT05569564|Active Comparator|Osseodensification|osseodensification will be performed using osseodensifying burs.
88906805|NCT05569473|Experimental|Test group|Intrabony defect filled with VCMX after along with open flap debridement [OFD+VCMX])
88906806|NCT05569473|Experimental|control group|OFD will be done and After this, flaps would be approximated and sutured at the original position with a monofilament suture material using interrupted sutures.
88906807|NCT05569460||Numeric Rating Scale (NRS) score after surgery <4|
88906808|NCT05569460||Numeric Rating Scale (NRS) score after surgery ≥ 4|
88906809|NCT05569434|Experimental|68Ga-P16-093 and MRI scan|Within 1 week, each patient underwent MRI scan and PET/CT scan after intravenous administration of 68Ga-P16-093, respectively.
89425801|NCT05876221||aTTP-Patients|Patients with immune Thrombotic Thrombocytopenic Purpura, who have been treated with caplacizumab (Cablivi®)
89425802|NCT05874154|Experimental|Tibial nerve selective neurotomy|
89425803|NCT05874154|Active Comparator|Botulinum toxin injection|
89425804|NCT05871580|Active Comparator|Laser Group (GL)|The patients will be submitted to eight sessions of low power laser. The radiation emission will be performed according to the protocol.
89425805|NCT05871580|Placebo Comparator|Control Group (CG)|In these patients the investigators will use the same protocol applied in the experimental group (time and application values) but the laser device will be turn off.
89425806|NCT05870345|Other|Ultrasound Exam|Every participant will undergo a pocket-sized ultrasound exam. The comparison to these images will either be a X-ray if fracture is suspected or bedside nursemaid reduction if subluxation is suspected (participants will act as their own comparison based not their routine ED clinical management)
89425807|NCT05865756|Other|Cough and voice analysis in HNC patients|Patients will undergo acoustic cough features analysis.
89425808|NCT05864794|Experimental|Screening population|Patients with newly diagnosed stage IV non-oncogene addicted NSCLC, who are fit for systemic treatment and don't have any symptoms of brain disease.
89425809|NCT05860842|Experimental|exercise training|6-month supervised exercise training program
89425810|NCT05859269|Experimental|Experimental Group: Medrol Dose|The perioperative Medrol dose treatment will consist of a course that lasts six days, with 24 milligrams administered on the first day, 20 milligrams on the second day, 60 milligrams on the third day, 12 milligrams on the fourth day, 8 milligrams on the fifth day, and 4 milligrams on the sixth day. Patients will then be followed up at the clinic for six weeks following their procedure to allow for clinical evaluation and to measure outcome variables.
89425811|NCT05859269|Active Comparator|Control Group: Standard of Care|Patients in this group will receive a single intraoperative dose of 10 mg intravenous dexamethasone (control group, IV dexamethasone is standard of care).
89425812|NCT05859022|Experimental|Roux-en-Y gastric By-pass (RYGB)|RYGB procedure requires 1-2 hours of operating time and two to three days length of hospital stay. Use the Kit-RYGB by J& company.
89425813|NCT05859022|Experimental|Bariatric Arterial Embolization (BAE)|Embosphere Microspheres (EM) are designed to offer controlled, target embolization. BAE procedure requires 1hour of operating time and one day length of hospital stay. Use the Kit by Merit MedicalCompany.
89425814|NCT05855382||COVID-19|Adults with at least one positive SARS-CoV-2 RT-qPCR test
89425815|NCT05854524|Active Comparator|Parkinson Disease|Participants diagnosed with Parkinson disease (PD) will the main arm of the study and will be compared to the control group.
89425816|NCT05854524|Active Comparator|Control|Older, adults who are age- and sex-matched to the PD participants.
89425817|NCT05853835|Experimental|Cohort-1|First dose of SAD cohort (6 treatment + 2 placebo)
89425818|NCT05853835|Experimental|Cohort-2|Second dose of SAD cohort (6 treatment + 2 placebo)
89425819|NCT05853835|Experimental|Cohort-3|Third dose of SAD cohort (6 treatment + 2 placebo)
89425820|NCT05853835|Experimental|Cohort-4|Fourth dose of SAD cohort (6 treatment + 2 placebo)
89425821|NCT05853835|Experimental|Cohort-5|Fifth dose of SAD cohort (6 treatment + 2 placebo)
89425822|NCT05853835|Experimental|Cohort-6|Sixth dose of SAD cohort (6 treatment + 2 placebo)
89425823|NCT05853497|No Intervention|Standard Care Control|Standard care
89425824|NCT05853497|Experimental|Intervention|Multi-component weight loss intervention
89425825|NCT05853484|Experimental|Home based prehabilitation|Participants will be subjected to two training periods of six weeks (or until transplantation) of a semi-supervised home-based bimodal lifestyle program. The bimodal lifestyle program consists of an exercise program combined with nutritional support. The exercise program comprises high intensity interval training and endurance training, combined with peripheral resistance training and breathing exercises
89425826|NCT05851781|Experimental|lacosamide and Acetaminophen arm|The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. All patients will receive Lacosamide 50 mg twice daily and Acetaminophen 500-1000 mg only in acute migraine attacks for 3 months. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of lacosamide was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
89425827|NCT05851781|Experimental|Propranolol and Acetaminophen group|The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. All patients will receive propranolol 160 mg once daily and Acetaminophen 500-1000 mg only in acute migraine attacks for 3 months. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of lacosamide was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
89425828|NCT05849610|Experimental|Induction VRD-Dara + Intensification Tec-Dara + Maintenance Tec-Dara + ERI Tal-Dara|"Induction (4 cycles) D-VRD. After Induction, all patients recieve 1st INTENSIFICATION treatment (6 cycles of Tec-Dara). Cycles will be of 28 days (4-week cycles) in duration for daratumumab and for Teclistamab. At the end of 1st Intensification timepoint treatments depends on MRD status:~MRD negative patients in CR at the end of Intensification will receive MAINTENANCE therapy with Tec-Dara continuously for 2 years. Crossover: patients who convert MRD positive or relapse from CR any time during Teclistamab maintenance will receive the same treatment as MRD positive individuals (early rescue intervention, ERI).~MRD positive patients or patients who didn't achieve CR despite MRD negativity, will have ERI (Tal-Dara 6 cycles). MRD and response will be evaluated again after 6 cycles treatment with Tal-Dara. MRD negative patients in CR will receive continuous treatment with Tal-Dara for 2 years."
89425829|NCT05848765|Experimental|Round 1: Epcoritamab and lenalidomide|Epcoritamab (weekly for cycles 1 and 2 and on day 1 of cycles 3-12 for up to 12 cycles) and lenalidomide (daily for days 1-21 of each cycle for up for 12 cycles), cycles will be 28 day cycles.
89425830|NCT05848765|Experimental|Round 2|Investigation agent 2
89425831|NCT05848765|Experimental|Round 3|Investigation agent 3
89425832|NCT05848765|Active Comparator|All rounds: Investigator Choice Therapy|Choice of therapy to be selected by the Investigator for each patient prior to randomisation. The Investigator will choose between; RCHOP, RCVP, rituximab and bendamustine, rituximab and lenalidomide or bendamustine and obinutuzumab.
89425833|NCT05847933|Experimental|cTBS experiment|Active brain stimulation on the inferior occipital gyrus using the cTBS protocol.
88906810|NCT05569369|Experimental|angioplasty with stenting|
89425834|NCT05847933|Sham Comparator|cTBS sham|Sham brain stimulation on the inferior occipital gyrus using the cTBS protocol
89425835|NCT05847933|Active Comparator|cTBS active control|Active brain stimulation on the right superior frontal cortex using the cTBS protocol
89425836|NCT05847933|Experimental|High frequency|Active brain stimulation on the inferior occipital gyrus using the 5Hz protocol
89425837|NCT05847933|Experimental|Low frequency|Active brain stimulation on the inferior occipital gyrus using the 1Hz protocol
89425838|NCT05845047|Experimental|PICTURE IT Intervention-CoDeLT Intervention|Participants will receive PICTURE IT Intervention for 15 sessions followed by Computer Delivered Lexical Treatment (CoDeLT)Intervention for 15 sessions
89425839|NCT05845047|Active Comparator|CoDeLT Intervention-PICTURE IT Intervention|Participants will receive Computer Delivered Lexical Treatment (CoDeLT) Intervention for 15 sessions followed by PICTURE IT Intervention for 15 sessions
89425840|NCT05840185|Experimental|Experimental: Test myopia control lenses (DAL)|A pair of myopia control spectacle lenses (test lenses) will be given to subjects to wear for 12 months
89425841|NCT05838352|Experimental|Telerehabilitation Group (TRG)|The group given physical activity and nutrition counseling for 2 months through telerehabilitation.
89425842|NCT05838352|Active Comparator|Conventional Rehabilitation Group (CRG)|The group who received conventional treatment and had no intervention, only pretest measurements
89425843|NCT05828693|Experimental|Experimental group|Use of the SysLife© application, with 2-, 4-, 6- and 8-month follow-up.
89425844|NCT05828693|Other|Waiting group with subsequent intervention|Use of the SysLife© application after 4-month waiting period, with 2- and 4-month follow-up.
89425845|NCT05825937||Elective Cardiac Surgery Patients|Patients having elective cardiac surgery, who have given written consent, will have the ClearSight device, along with the standard radial arterial line.
89425846|NCT05825937||Elective Neurointerventional Surgery Patients|Patients having elective neurointerventional surgery, who have given written consent, will have the ClearSight device, along with the standard radial arterial line.
88906811|NCT05569356||Arrhythmogenic Right Ventricular Cardiomyopathy (Prospective)|
89425847|NCT05824780|Experimental|Weigthlifting|It consists of a 4-week strength training program based on weightlifting. Participants received previously education-training program on how to correctly perform the technique.
89425848|NCT05824780|Active Comparator|Plyometric training|It consists of a 4-week strength training program based on plyometric exercises.
89425849|NCT05822596|Experimental|Tablet-based interactive games experimental group|The experimental group will take part in a 12-week cognitive training program using tablet-based interactive games.
89425850|NCT05822596|No Intervention|Control group|The control group will receive treatment as usual during the 12-week trial.
89425851|NCT05822414|Experimental|Erector Spinae Plane Block group|
89425852|NCT05822414|Active Comparator|Superior Trunk Block group|
89425853|NCT05818501|Experimental|The dysphagia cups|The participants will use the one of the two models of dysphagia cups for 5 days during trial period.
89425854|NCT05818488|Experimental|Experimental mind-body intervention|subjects will be randomized into intervention (one session of mindbody exercise), where they will be asked to sit in a comfortable armchair and remain in a comfortable posture with eyes closed. Cognitive evaluation will be done before and after the intervention.
88906812|NCT05569356||Arrhythmogenic Right Ventricular Cardiomyopathy (Retrospective)|
89425855|NCT05818488|No Intervention|Control group|This group will be submitted to the same evaluation. However, they will wiat for 15 minutes with no intervention.
89425856|NCT05816733|Experimental|Dapagliflozin group|Patients who will be randomized to receive dapagliflozin following the Cox-Maze IV Procedure.
89425857|NCT05816733|Placebo Comparator|Placebo group|Patients who will be randomized to receive placebo following the Cox-Maze IV Procedure.
89425858|NCT05813223|Experimental|Gefapixant treatment|Participants will asked to take an oral tablet containing 45mg Gefapixant twice daily (BID).
88906813|NCT05569343||Textbook outcome group|Achieving textbook outcome after laparoscopic duodenum-preserving total pancreatic head resection
88906814|NCT05569343||Non-Textbook outcome group|Not achieving textbook outcome after laparoscopic duodenum-preserving total pancreatic head resection
89425859|NCT05804552|Experimental|Dorsal genital nerve stimulation|
88906815|NCT05569330|Other|Arm 1|Two of the four participating day care units are allocated in arm 1
88906816|NCT05569330|Other|Arm 2|Two of the four participating day care units are allocated in arm 2
88906817|NCT05569304|Experimental|Endoscopic Sleeve Gastroplasty Arm|Prospective cohort of patients with classes 1 and 2 obesity that had consented to undergo endoscopic sleeve gastroplasty.
88906818|NCT05569304|No Intervention|Retrospective cohort|Retrospective cohort of patients with classes 1 and 2 obesity who did not undergo endoscopic sleeve gastroplasty and had been put on GLP-1 analogues
88906819|NCT05569239|Experimental|OVX836 480µg|Adjuvant-free recombinant influenza candidate vaccine based on Nucleoprotein in the influenza virus. One single administration intramuscularly of 480µg dose on Day1.
88906820|NCT05569239|Placebo Comparator|Placebo|Saline solution (B. Braun Ecoflac Plus) Saline solution (Nacl 0.9%), B. Braun Ecoflac Plus 50mL. One single administration intramuscularly of a 0.8mL dose on Day1.
88906821|NCT05569213||DBS latency/MEP latency|Each patient will serve as control and test. Control will be latency of hand MEP generated by DBS stimulation of the corticospinal tract. The test condition will be the latency of hand MEP generated by conventional MEP acquisition.
88906822|NCT05569200|Experimental|Haifu Focused Ultrasound tumor therapeutic System|
89425860|NCT05794425|Experimental|Cyclosporine A|
89425861|NCT05794425|Experimental|UCB+UC-MSCs|
89425862|NCT05793736|Experimental|biofeedback + treatment as usual|The selected sample (n 10) will undergo 10 total Biofeedback Training sessions, twice a week. Each session will last 45 minutes. The total duration of the treatment will be 5 weeks, plus standard therapies (treatment as usual)
89425863|NCT05793736|Active Comparator|treatment as usual|The control sample (n 10) will be treated only with standard therapies (treatment as usual) without the use of biofeedback training
89425864|NCT05792007|Active Comparator|Patients with acute leukemias|Children with acute lymphoid leukemia B, acute lymphoid leukemia -T or acute myeloid leukemia
89425865|NCT05792007|Other|Control group|Children without blood diseases
89425866|NCT05791565|Experimental|Salbutamol HFA-152a MDI followed by Salbutamol HFA-134a MDI|Participants will receive Salbutamol HFA-152a MDI in treatment period 1 followed by Salbutamol HFA-134a MDI in treatment period 2. There will be a minimum washout period of 72 hours between each treatment period.
89425867|NCT05791565|Experimental|Salbutamol HFA-134a MDI followed by Salbutamol HFA-152a MDI|Participants will receive Salbutamol HFA-134a MDI in treatment period 1 followed by Salbutamol HFA-152a MDI in treatment period 2. There will be a minimum washout period of 72 hours between each treatment period.
89425868|NCT05791474|Experimental|ATI-2231 monotherapy dose escalation|"Patients will receive single agent ATI-2231 at assigned dose levels (n=3-6 per dose level). Starting dose of 20 mg by mouth twice per day.~Each cycle is 21 days"
89425869|NCT05789979|Experimental|The resident-handling device|This group will use the resident-handling device during the 4-week trial.
89425870|NCT05787652|Experimental|ARTEMIS mobile app|Intervention participants will be asked to download the ARTEMIS app in the Apple or Google Play app stores. The app will comprise of daily self-weighing, daily weight-recording, daily action-planning, and weekly reports and reflection. Daily weight loss action plans will predominantly relate to diet, physical activity and sleep, and comprise of eight categories, to be chosen by participants and rotated on a weekly basis, each with 5-10 actions, to be chosen by participants and rotated on a daily basis. Participants can explore and engage in all of these actions for as long as they wish within the 52-weeks of the intervention but will be recommended to continue within the 'active exploratory phase' of the intervention for at least four weeks, before moving to a 'maintenance phase', where participants continue with the actions which worked best for them in the 'active exploratory phase'.
89425871|NCT05787652|No Intervention|Control|Control group participants will receive no intervention. They will be thanked for taking part in the study, advised that they may want to lose weight on their own and reminded of the next assessment at 12 weeks. The investigators will explain the value of control groups in randomised trials and the impact that remaining in follow-up has for the impact of the trial. They will also be reminded that they will receive equal financial reimbursement.
89425872|NCT05786118||SIJ Group|Individuals with sacroiliac joint dysfunction: Participants will be grouped as positive sacroiliac joint dysfunction according to Laslett's algorithm using provocation tests to detect sacroiliac joint dysfunction.
89425873|NCT05786118||Control Group|Individuals with no sacroiliac joint dysfunction: Individuals with sacroiliac joint dysfunction: Participants will be grouped as negative sacroiliac joint dysfunction according to Laslett's algorithm using provocation tests to detect sacroiliac joint dysfunction.
89425874|NCT05785897|Experimental|Potent P2Y12 receptor inhibitor-based single antiplatelet therapy (SAPT)|"P2Y12 receptor inhibitor-based SAPT with ticagrelor (90 mg bd) or prasugrel (10 mg od, or 5 mg in patients ≥75 years or with a body weight <60 kg), at the discretion of the investigator, during 12 months after the index procedure.~Clopidogrel-based SAPT will not be allowed.~Aspirin will be discontinued after primary PCI, or at latest at hospital discharge."
89425875|NCT05785897|Active Comparator|Conventional dual antiplatelet therapy (DAPT)|"DAPT combining aspirin (≥75 mg od) and a potent P2Y12 receptor inhibitor, either ticagrelor (90 mg bd) or prasugrel (10 mg od, or 5 mg in patients ≥75 years or with a body weight <60 kg), at the discretion of the investigator, during 6 or 12 months after the index procedure, followed by aspirin-based SAPT.~Clopidogrel (75 mg od orally) will be allowed if ticagrelor or prasugrel are contra-indicated or not available."
89425876|NCT05785702|Experimental|The anti-wandering system|The experimental group will use the anti-wandering system 4-6-week of pre-test and 12-week of test trial.
89425877|NCT05784103|Other|Multi-Modal Measurement of Oxygen Saturation|During a single study visit, participants will have oxygen saturation measured with a number of oximetry devices including Spatial Frequency Domain Imaging (SFDI), Transcutaneous oxygen monitoring (TCOM), an Apple Watch Oxygen Sensor, and a Pulse Oximeter. Each device will be used to measure oxygen saturation of the thumb and index fingers at rest, during occlusion of blood flow to the arm (using an inflated blood pressure cuff applied to the arm), and during the hyperemic post-occlusion period. Completion of all planned interventions may take up to 2 hours on the study visit day.
89425878|NCT05781464|Placebo Comparator|Traditional chest physiotherapy|This group receives traditional chest physiotherapy that include postural drainage, percussion and vibration ( manually or by a vibrator) in each session which is twice daily from admission to neonatal intensive care unit till discharge
89425879|NCT05781464|Active Comparator|Prolonged slow expiration technique and traditional chest physiotherapy|This group receives traditional chest physiotherapy that include postural drainage, percussion and vibration ( manually or by a vibrator) plus prolonged slow expiration technique in each session which is twice daily from admission in neonatal intensive care unit till discharge.
89425880|NCT05776459|Experimental|AC102|AC102 gel and placebo tablets
89425881|NCT05776459|Active Comparator|Prednisolone|Placebo gel and prednisolone tablets
88906823|NCT05569135||Debridement only|Debridement of the pilonidal cyst through pits was performed in this group. After the removal of hair and necrotic tissues through pits, the surgical site was covered with a simple gauze dressing for 1 day. Patients were allowed to return to work and sit freely on the day of surgery.
88906824|NCT05569135||Debridiment with laser ablation|This group underwent the same procedure as the debridement group. After the removal of hair and necrotic tissues through pits, a diode laser at 1470 wavelength was inserted and the pilonidal cavity was ablated in a continuous fashion. The surgical site was covered with a simple gauze dressing for 1 day. Patients were allowed to return to work and sit freely on the day of surgery.
88906825|NCT05569109||av fistula patency loss with hperphosphatemia|hemodialysis patients with av fistula patency loss by doppler ultrasound and hyperphosphatemia
88906826|NCT05569109||av fistula patency loss with normal phosphate level|hemodialysis patients with av fistula patency loss by doppler ultrasound and normal phosphate level
88906827|NCT05569031|Active Comparator|venlafaxidine|venlafaxine 75-225 mg per day.
88906828|NCT05569031|Active Comparator|Lofixidine|Lofixidine 1.6 to 2.4 per day.
89425882|NCT05773768|Experimental|New care program|The health care provider will use the EHRA-PATHS' newly developed care pathways to assess whether there is an indication for presence of risk factors and comorbidities. If this is the case, the care pathways will show possible next steps for confirming the presence of these risk factors and comorbidities. If confirmed, treatment according to the current guidelines should be initiated. Since this leads to an individualized management plan, procedures can differ between patients and will also depend on local processes.
88906829|NCT05568875|Experimental|e-self-management intervention|12-week e-self-management intervention consisting of exercise videos and videos with information about recommended treatment
88906830|NCT05568875|Active Comparator|Treatment as usual|Treatment as usual
88906831|NCT05568823|Other|"Patients responding to treatment after 8 weeks of treatment"|"Patients responding to treatment after 8 weeks of treatment: i.e. whose clinical evolution is beneficial."
88906832|NCT05568823|Other|"Patients non-responding to treatment after 8 weeks of treatment"|"Patients non-responding to treatment after 8 weeks of treatment: i.e. whose clinical evolution is not satisfactory."
88906833|NCT05568771|Experimental|Core exercise group|In the study, the exercise group was set as Istanbul University Club Basketball Team, and the control group was set as Galatasaray Basketball Club. While the 1st group, which is the exercise group, applied the additional warm-up program to the core training program to be included in the routine training of the team, for 8 weeks,
88906834|NCT05568771|No Intervention|Control group|the 2nd group, the control group, continued their routine training programs.
89425883|NCT05773768|No Intervention|Routine clinical care|The health care provider follows current clinical practice with regards to history taking, physical examination etc.
88906835|NCT05568732|Experimental|Test group|Scaling and root planing will be performed and after resolution of gingival inflammation, root coverage procedure will be done with VCMX using minimally invasive access technique.
89425884|NCT05772949|Experimental|Experimental group|The experimental group will use the smart hearing aid for 6 weeks.
89425885|NCT05772949|Experimental|Wait-list control group|The wait-list control group will follow existing practice (i.e. using no hearing aids or using hearing aids other than the smart hearing aids) for 6 weeks and then use the smart hearing aids for 6 weeks.
88906836|NCT05568732|Active Comparator|Control group|Scaling and root planing will be performed and after resolution of periodontal inflammation, root coverage procedure will be done with CTG using minimally invasive access technique.
88906837|NCT05568693|Experimental|mRNA-enhanced immunoem|1 dose of 0.3 ml of mRNA vaccine
88906838|NCT05568628||lacating femals|screening of breast lesions in lactating female
88906839|NCT05568628||pregnant|screening of breast lesions in pregnant female
88906840|NCT05568251|Active Comparator|Active tDCS combined with Cognitive Training|
89007442|NCT04642638|Placebo Comparator|Phase 2: Placebo Dose Group 1|Participants received one ID injection of placebo followed by EP using the CELLECTRA® 2000 device on Day 0 and Day 28.
89007443|NCT04642638|Placebo Comparator|Phase 2: Placebo Dose Group 2|Participants received 2 ID injections of placebo followed by EP using the CELLECTRA® 2000 device on Day 0 and Day 28.
89007444|NCT04642638|Experimental|Phase 3: INO-4800 Dose Group (2.0mg per dosing visit)|Participants received two 1.0 mg ID injections of INO-4800, each followed by EP using the CELLECTRA® 2000 device on Day 0 and Day 28.
89007445|NCT04642638|Placebo Comparator|Phase 3: Placebo Dose Group|Participants received 2 ID injections of placebo per dosing visit, each followed by EP using the CELLECTRA® 2000 device on Day 0 and Day 28.
89007446|NCT04634825|Experimental|Retifanlimab Cohort|Enoblituzumab 15 mg/kg every 3 weeks plus retifanlimab 375 mg every 3 weeks for up to 35 cycles
89007447|NCT04634825|Experimental|Tebotelimab Cohort|Enoblituzumab 15 mg/kg every 3 weeks plus tebotelimab 600 mg every 3 weeks for up to 35 cycles
89007448|NCT04614974|Experimental|Speech Language Therapy Alone|Patients in this group will receive a routine swallowing evaluation by a speech language pathologist. Patient caregivers will fill out the Infant Gastroesophageal Reflux Questionnaire (I-GERQ-R) and the Pittsburgh Airway Symptom Score (PASS) the day of the appointment and at the 3-month follow up appointment.
89196067|NCT00830973||Active Study Group|The active study group consists of 50 year or older postmenopausal women taking tamoxifen for the prevention of reoccurrence of breast cancer, do not meet exclusion criteria, meet all inclusion criteria, and are enrolled members for Medco clients agreeing to participate.
89196068|NCT04034914|Experimental|Yoga Therapy|
89425886|NCT05768815|Experimental|Breaking the Cycle Intervention group|
89425887|NCT05768815|Active Comparator|Maxxine Wright Intervention group|
89425888|NCT05767307||MRI-first|"Biopsy naïve men referred to MRI-first due to suspicion of PC (elevated PSA and/or suspect DRE) at one of the following three major urology/uroradiology centers in Denmark: Aarhus University Hospital (AUH), Herlev & Gentofte Hospital (HH), and Odense University Hospital (OUH), where MRI and targeted biopsy is already implemented in clinical use."
89425889|NCT05757934||Group A|vapers, who are ex-smokers.
89007449|NCT04614974|Active Comparator|Speech Language Therapy and Acid Suppression Therapy|Patients in this group will receive a routine swallowing evaluation by a speech language pathologist and famotidine (acid suppression therapy). Patient caregivers will fill out the Infant Gastroesophageal Reflux Questionnaire (I-GERQ-R) and the Pittsburgh Airway Symptom Score (PASS) the day of the appointment and at the 3-month follow up appointment.
89007450|NCT04609020|Experimental|HArmonyCA, Juvederm, BOTOX|All treatments will be administered according to the respective label and according to an agreed upon treatment plan between the subject and Health Care Provider. If required: HarmonyCA Lidocaine will be administered at Visit 1, Juvéderm filler injections (JUVÉDERM VOLBELLA with Lidocaine, and/or JUVÉDERM VOLIFT with Lidocaine, and/or JUVÉDERM VOLUMA with Lidocaine, and/or JUVÉDERM VOLITE with Lidocaine and/or JUVÉDERM VOLUX with Lidocaine) will be administered at Visit 3, BOTOX will be administered at Visit 5. Touch-ups may be performed as required by subject's treatment plan after each study visit.
89007451|NCT04603482|Experimental|Self-Management|
89007452|NCT04603482|Active Comparator|Attention Control Condition|
89007453|NCT04590001|Experimental|MobiusHD|Each subject enrolled in the study will undergo implantation of the MobiusHD device.
89007454|NCT04585425|Other|Control|Treatment as usual including sleep hygiene advice
89007455|NCT04585425|Experimental|Intervention|Treatment as usual (sleep hygiene advice) and bedtime music listening
89007456|NCT04583514|Experimental|Control|The control group will be expected to maintain their weight within 1 kg of baseline weight throughout the duration of the study.
89007457|NCT04583514|Experimental|Overfeeding|The overfeeding group will be subjected to a similar relative change in energy intake, in which their dietary intake will be 30% more kcal/d than needed for weight maintenance.
89007458|NCT04540432|Experimental|Profile AB|Patients on non-steroidal anti-inflammatory drugs followed by biotherapy.
89007459|NCT04540432|Experimental|Profile AM|Patients on non-steroidal anti-inflammatory drugs followed by treatment with methotrexate.
89425890|NCT05757934||Group B|vapers with no previous smoking experience.
89425891|NCT05757934||Group C|vapers, who are dual users (i.e., those who vape and smoke).
89425892|NCT05757934||Group D|ex-smokers who don't vape.
89425893|NCT05756387||COPD patients with Chronic Respiratory Failure|
89425894|NCT05754385|Active Comparator|Ambulatory liver fat monitoring|A novel portable, home-based device called the Gense-EIT liver scan will be given to each participant to practice ambulatory liver fat monitoring
89425895|NCT05754385|Placebo Comparator|Standard of care|Subjects will have follow-up every 6 months by hepatologists for routine care
89425896|NCT05744817|No Intervention|Control|30 breaths/day (5 sets of 6 breaths, one minute of rest between sets), 5 days/week, for 6 weeks, then no exercise for 12 weeks
89425897|NCT05744817|Experimental|IMST 1 day/week|30 breaths/day (5 sets of 6 breaths, one minute of rest between sets), 5 days/week, for 6 weeks, then 30 breaths/day (5 sets of 6 breaths, one minute of rest between sets), 1 day/week, for 12 weeks.
89425898|NCT05744817|Experimental|IMST 3 days/week|30 breaths/day (5 sets of 6 breaths, one minute of rest between sets), 5 days/week, for 6 weeks, then 30 breaths/day (5 sets of 6 breaths, one minute of rest between sets), 3 days/week, for 12 weeks.
89425899|NCT05741593||Patients having had a stroke|elderly patients previously treated with an antithrombotic and admitted to hospital for an ischemic stroke
89425900|NCT05738057|Experimental|Combined Therapy Using D-TACE, Gemcitabine and Cisplatin, and Camrelizumab|"D-TACE with cisplatin-eluting beads. More TACE can be done if clinically necessary.~Camrelizumab (200 mg, Intravenous drips (ivd), D1/3W) plus Gem (1000 mg/m2, ivd, D1&8/3W) and Cis (25 mg/m2, ivd, D1&8/3W). Three weeks are one cycle of treatment. Chemotherapy lasted for no more than 12 cycles."
89425901|NCT05732948|Experimental|autologous T cells & cyclophosphamide|This is a phase I dose escalation study to assess the safety and tolerability using increasing doses of engineered autologous T cells PD-1 silent targeted to PSMA/PSMA administered one day after pretreatment with cyclophosphamide.
89425902|NCT05732584|Experimental|structured family voice stimulation|Patients in this group were provided with structured family voice stimulation
89425903|NCT05732584|Experimental|unstructured family voice stimulation|Patients in this group were provided with unstructured family voice stimulation
89425904|NCT05732584|No Intervention|Control group|Patients in this group will receive no specific voice stimulation
89425905|NCT05723068||Patients with chronic hepatitis D|
88906841|NCT05568251|Sham Comparator|Sham tDCS combined with Cognitive Training|
88906842|NCT05568108||nerve transfer|masseteric nerve to central branch facial nerve. (Early fibrillation on EMG)
88906843|NCT05568108||nerve and free functioning muscle transfer|Masseteric nerve to free functioning muscle transfer. (Late no fibrillation on EMG)
88906844|NCT05566249||ArtiSential group|Patients undergoing laparoscopic surgery using ArtiSential
88906845|NCT05566249||Robot group|Patients undergoing robotic surgery
88906846|NCT05564975||Hospital-acquired pressure injury group|According to the hospital adverse event management system, patients diagnosed with pressure injury in the hospital were included in the HAPI group, and patients who reported high risk of pressure injury during the same period were selected and included in the non-HAPI group.
88906847|NCT05564975||No-hospital-acquired pressure injury group|According to the hospital adverse event management system, patients diagnosed with pressure injury in the hospital were included in the HAPI group, and patients who reported high risk of pressure injury during the same period were selected and included in the non-HAPI group.
88906848|NCT05564741|Active Comparator|15 s injection time|Patients in group A will be given the spinal anesthesia with an injection time of 15 s
88906849|NCT05564741|Active Comparator|90 s injection time|Patients in group B will be given the spinal anesthesia with an injection time of 90 s
88906850|NCT05560880|Experimental|High Intensity Interval gait training|subjects will receive 3x/week high intensity interval training for 20 minutes over a 4 week period
88906851|NCT05560880|Active Comparator|Moderate intensity continuous gait training|subjects will receive 3x/week moderate intensity continuous gait training for 20 minutes over a 4 week period
88906852|NCT05531084|Experimental|Thoracoabdominal aortic aneurysm extent I-III|Thoracoabdominal aortic aneurysm extent I-III (proximal seal can be from the left carotid artery to directly after the left subclavian artery):
88906853|NCT05531084|Experimental|Failed EVAR|Failed EVAR (defined as type IA endoleak or increase in aneurysm sac size in the setting of proximal seal loss)/juxtarenal/Pararenal/paravisceral/thoracoabdominal aortic aneurysm extent IV-V:
89425906|NCT05722236|Experimental|IBD Strong Peer2Peer intervention|
89425907|NCT05722236|Other|Waitlist -controls|
89425908|NCT05721742|Active Comparator|pre-existing online group education program for IBS|This arm will be enrolled in the online course run by Happy Bellies Nutrition https://www.happybelliesnutrition.com/ibs-gentle-group-program. The Happy Bellies nutrition course has 5.5 hours of total video content and optional biweekly group calls via Zoom (45-minutes per session). This course is designed to take 12 weeks to complete. The participants would have access to the content for one year.
89425909|NCT05721742|Experimental|virtual dietitian consults for IBS patients|This arm will receive consults with a virtual dietitian (60 minutes initial + 4 x30-minute follow-up appointment) by a dietitian who has had additional training in the dietary management of IBS.
89425910|NCT05719675|Experimental|Intervention|A healthcare model for people with Type 2 Diabetes Mellitus, based on Contingency Behavioral Analysis (CBA). The CCA model was constructed in a Mexican population by Ribes et al. (1986), and later operationalized in manuals by Rodriguez (2002). It has proven to be a suitable alternative for working with people with T2DM (Ocampo et al., 2017; Rodriguez et al., 2015; Rodriguez et al., 2016; Rivera et al., 2008; Rodriguez et al., 2013; Rosales et al., 2021). For this intervention, an application manual aimed at the intervention facilitator was developed and evaluated by a panel of experts in the field of nursing, endocrinology, diabetology and social work with experience in the care of people with T2DM. In general, they were asked to evaluate the congruence and adequacy of the activities proposed in the sessions to improve adherence to treatment in people with T2DM. Additionally, they evaluated whether the number of sessions was adequate for the objectives of the research project.
89425911|NCT05719519|Other|Smokers|
89425912|NCT05719519|Experimental|Non smokers|
89425913|NCT05715073|Experimental|TeaCrine and caffeine|150mg of Teacrine and 150mg of caffeine
89425914|NCT05715073|Active Comparator|Caffeine|300mg of caffeine
89425915|NCT05715073|Placebo Comparator|Placebo|300mg of cellulose
89425916|NCT05711862|Experimental|1 week Placebo then 1 week SUVO|After 1 week of placebo treatment there will be 1 week of wash out period before start of study medication
89425917|NCT05711862|Experimental|1 week SUVO then 1 week Placebo|After 1 week of SUVO treatment there will be 1 week of wash out period before start of placebo
89425918|NCT05710666|Experimental|T-DXd|
89425919|NCT05710536|Experimental|Formulation X|Participants will use the formulation once every 72 hour for 5 weeks
89425920|NCT05710185|Experimental|Subjects with Palmoplantar pustulosis|All participants will receive deucravacitinib 6 mg daily for 24 weeks, with study visits every 4 weeks.
89425921|NCT05707208|Experimental|ST-01 70 mg/mL|
89425922|NCT05707208|Experimental|ST-01 140 mg/mL|
89425923|NCT05707208|Active Comparator|1% Lidocaine HCL|
89425924|NCT05693948|Experimental|Serum X|Participants will used serum X twice daily for 12 weeks
89425925|NCT05692622|Experimental|Early start group|Participants in this group will receive a baseline monitoring period of 1 week, an active remotely supervised and monitored intervention period of 8 weeks and then an unsupervised but monitored follow up period of 4 months. They will be assessed at baseline (T0) and after one week (T1) to determine the sensitivity of the measures. They will then begin their intervention (T2) for a period of 8 weeks. At the end of the intervention phase (T3), assessment will be repeated that will also mark the beginning of a 16 weeks follow up period (T4), during this time they will have the choice to continue the exercises or stop them. At the end of the follow up period, assessment will be carried out again to measure any carry over effects.
89425926|NCT05692622|Experimental|Delayed start group|Participants in this group will receive a baseline monitoring period of 1 week, a control period of 8 weeks, an active remotely supervised and monitored intervention period of 8 weeks and then an unsupervised but monitored follow up period of 2 months. They will be assessed at baseline (T0) and after one week (T1) to determine the sensitivity of the measures. While the early start group receives their 8-week intervention, this group will not receive any intervention during this control period. At the end of 8 weeks, an assessment will be carried out for this group as well (T2). The participants will then begin their intervention (T3) for a period of 8 weeks. At the end of the intervention phase (T4), assessment will be repeated that will mark the beginning of an 8 weeks follow up period (T5), during this time they will have the choice to continue the exercises or stop them. At the end of the follow up period (T6), assessment will be carried out again to measure any carry over effects.
89425927|NCT05691413|Experimental|Product X facial cleanser|Participants will used Product X facial cleanser twice daily for 5 weeks
89425928|NCT05690516|Experimental|Face masks|Participants in the experimental arm are asked to wear face masks when close to others outside their home, e.g., in public spaces like shopping centres, and streets and on public transport.
89425929|NCT05690516|No Intervention|Not face masks|Participants in the no intervention arm arm are asked not to wear face masks when close to others outside their home, e.g., in public spaces like shopping centres, and streets and on public transport.
89425930|NCT05680857|Placebo Comparator|Placebo|The placebo group will receive a product in sachet form that doesn't have marine collagen peptide and Coenzyme Q10.
89425931|NCT05680857|Experimental|Product containing marine collagen peptide and Coenzyme Q10.|This group will receive the product containing marine collagen peptide from the fish origin and Coenzyme Q10 in sachet form.
89425932|NCT05680545|Experimental|Sevoflurane vaporized in ECMO machines|Patients' sedation will be managed with sevoflurane-based anesthesia directly vaporized into the ECMO machine.
89425933|NCT05679349|Experimental|Group A (Providers): (survey, online educational activity)|Participants complete survey on study. Participants undergo online educational activity on study. Participants undergo distance learning on study.
89425934|NCT05679349|Active Comparator|Group B (Providers): (survey)|Participants complete survey at baseline and end of study survey.
89425935|NCT05679349|Experimental|Group A (Patients): (EHR, educational activity, counseling))|Patients undergo EHR review on study. Patients undergo educational activity on study. Patients also undergo SDM counseling once on study.
89425936|NCT05679349|Active Comparator|Group B (Patients): (survey)|Patients undergo EHR review on study and complete telephone survey throughout the trial.
89425937|NCT05677997|No Intervention|Control|Receiving monthly resources only
89425938|NCT05677997|Experimental|Intervention Group|Receiving sessions with a resource navigator 2x a month, and monthly resources.
89007460|NCT04540432|Experimental|Profile AMB|Patients on non-steroidal anti-inflammatory drugs followed by treatment with methotrexate and then biotherapy if there is no improvement with methotrexate.
89007461|NCT04540432|Experimental|Profile A|Patients on non-steroidal anti-inflammatory drugs.
89425939|NCT05676619|Other|Single cohort of healthy volunteers|Single cohort of healthy volunteers
89007462|NCT04540432|Experimental|Profile M|methotrexate alone
89425940|NCT05676554|Experimental|Intervention|This arm will watch the growth mindset session
88906854|NCT05522582|Experimental|methotrexate+anti-PD-1 antibody+radiotherapy|Tablets with 5mg methotrexate are taken orally twice a week during radiotherapy. With anti-PD-1 monoclonal antibody, 200mg, Q3W.
88906855|NCT05491304|Experimental|Non-severe DXM group|Dexamethasone (DXM): week1-2: 10 mg/m2.d, week 3-4: 5 mg/m2.d, week5-6: 2.5 mg/m2.d, week7: 1.25 mg/m2.d, week8: tapering.
89196069|NCT00827307|Experimental|Combination|In the combination arm, patients receive ZOLADEX 3.6 mg by subcutaneous injection every 4 weeks along with once-daily oral dose of tamoxifen 20 mg.
89425941|NCT05676554|No Intervention|Waitlist|This arm will receive the intervention once they have completed the follow up at 4 weeks.
88906856|NCT05491304|Experimental|Non-severe Ruxo group|Ruxolitinib(Ruxo): body weight (BW)<10kg: 2.5mg Bid; 10-20kg: 5mg Bid; >20kg: 10mg Bid; Orally for 4 weeks.
88906857|NCT05491304|Experimental|Severe HLH-94 group|"DXM: week1-2: 10 mg/m2.d, week 3-4: 5 mg/m2.d, week5-6: 2.5 mg/m2.d, week7: 1.25 mg/m2.d, week8: tapering.~Etoposide (VP16): 100-150mg/m2 twice in the first two weeks, and once every week to week 8."
88906858|NCT05491304|Experimental|Severe HLH-94 plus ruxolitinib group|"DXM: week1-2: 10 mg/m2.d, week 3-4: 5 mg/m2.d, week5-6: 2.5 mg/m2.d, week7: 1.25 mg/m2.d, week8: tapering.~Etoposide (VP16): 100-150mg/m2 twice in the first two weeks, and once every week to week 8.~Ruxolitinib(Ruxo): body weight (BW)<10kg: 2.5mg Bid; 10-20kg: 5mg Bid; >20kg: 10mg Bid; Orally for 4 weeks."
88906859|NCT05453643|Experimental|Sleep deprivation|healthy volunteers
88906860|NCT05435417|Experimental|Manual segmentation technique of CBCT images of the condyles.|Using the manual edition built in tool, first a brush of small size will be used to demarcate the outline of the condyle in the sagittal cuts. Then shading the demarcated condylar area with a brush of larger size in each slice. The outline of the condyle will be refined on all cuts. The software built in tool 'create surface' will be used to create the segmented 3D volume
89007463|NCT04540432|Experimental|Profile B|biotherapy alone
89007464|NCT04522271|Active Comparator|Resistant Starch|Once daily oral consumption of 7.5 g/m2 of an individually optimized resistant starch for approximately 5 months
89196070|NCT00827307|Active Comparator|Conctrol|In the monotherapy arm, patients receive once-daily oral dose of tamoxifen 20 mg.
89425942|NCT05674383|Experimental|Intervention group|The intervention group will receive an axillary plexus nerve block as pain reduction before the fracture repositioning.
89425943|NCT05674383|Active Comparator|Control group|The control group will receive a fracture hematoma block as pain reduction before the fracture repositioning.
89425944|NCT05672628|Experimental|Oculus VR|
89425945|NCT05670340|Experimental|Swithed-platform|In this group the implants will be rehabilitated with a narrower emergence profile for the prosthetic rehabilitation.
89196071|NCT04034602|Experimental|vibration group|plantar vibration group is supine position, plantar vibration will be applied to both foot of each patient with a vibration device with a frequency of 15-100 Hz over 5 minutes.
89196072|NCT04034602|Active Comparator|placebo group|the placebo group, both sides will be held in the supine position under the soles of the foot for 5 minutes each so that the device is in contact with the foot without vibration.
89196073|NCT00837915|Experimental|1|Loratadine 10mg /Pseudoephedrine Sulfate 240 mg Extended-Release Tablets of Ranbaxy
89196074|NCT00837915|Active Comparator|2|(Claritin-D® 24 hour) Loratadine 10mg /Pseudoephedrine Sulfate 240 mg Extended-Release Tablets
89196075|NCT00908986|Experimental|Rituximab|Subjects receive rituximab in an open label manner
89196076|NCT00827385||hypertensive|
89196077|NCT00827385||normotensive|
89196078|NCT00827463|Experimental|NFS and iron in the first quater|first arm: dosage NFS and iron during the beginning of the pregnancy then in the sixth month of pregnancy then in th delivery.
89196079|NCT00827463|Experimental|No NFS and iron in the first quater|second arm: dosage NFS and iron during the sixth month of pregnancy then in th delivery. No dosage of NFS and iron during the beginning of the pregnancy
89196080|NCT00909142||Group1|
89425946|NCT05670340|Active Comparator|Matched-platform|This the conventional approach in wich the prosthetic rehabilitation is matched with the implant-platform dimensions
89425947|NCT05668026|Experimental|Immediate start|Study participants will receive venetoclax daily for 14 days followed by 14 days off defined as one cycle. This dosing will then be repeated for two additional cycles.
89425948|NCT05668026|Active Comparator|14-days lead-in|Study participants will receive placebo for 28 days, and then start venetoclax daily for 14 days followed by 14 days off defined as one cycle. This dosing will then be repeated for two additional cycles.
89425949|NCT05663268|Experimental|Patients of Hidradenitis suppurativa resistant to conventional therapy|injection Infliximab-dyyb biosimilar (according to weight, single injection of 120mg if weight <80kg, 2 injections if weight > 80kg) will be injected subcutaneously at week 0,1, 2,3,4, and then fortnightly till 24 weeks.
89425950|NCT05657379|Experimental|Product X moisturizer|Participants will used Product X moisturizer twice daily for 8 weeks
89425951|NCT05654454|Experimental|Bevacizumab with Paclitaxel and Carboplatin|"Patients will begin Period 1 receiving bevacizumab combination therapy (Bevacizumab 15 mg/kg IV + Paclitaxel 175 mg/m2 + IV Carboplatin AUC 6 IV) on Day 0 of Cycle 1 for up to 6 cycles of therapy. Each cycle will consist of 3 weeks (21 days ± 3 days) and a cycle will start with the administration of bevacizumab (produced by Mabscale, LLC).~In Period 2, eligible patients will continue to receive bevacizumab (produced by Mabscale, LLC) every 3 weeks as monotherapy."
89425952|NCT05654454|Active Comparator|Avastin® with Paclitaxel and Carboplatin|"Patients will begin Period 1 receiving bevacizumab combination therapy ( Avastin® 15 mg/kg IV + Paclitaxel 175 mg/m2 IV + Carboplatin AUC 6 IV) on Day 0 of Cycle 1 for up to 6 cycles of therapy. Each cycle will consist of 3 weeks (21 days ± 3 days) and a cycle will start with the administration of bevacizumab (as Avastin®).~In Period 2, eligible patients will continue to receive bevacizumab (Avastin®) every 3 weeks as monotherapy."
89425953|NCT05653713|Experimental|CSL324|Intravenous (IV) dose of CSL324
88906861|NCT05435417|Experimental|Semiautomatic segmentation technique of CBCT images of the condyles.|Using the water shed built in tool, first a brush of small size will be used to demarcate the outline of the condyle by the 'background' option in all planes. Then using the 'foreground' option, a brush of larger size will be used to shade the condylar area. The software built in tool 'expand water shed' will be used to include the whole condyle. At last, 'create surface' option will be used to create the segmented 3D volume.
89425954|NCT05653713|Placebo Comparator|Placebo|IV dose of 0.9% saline
89425955|NCT05653024|Experimental|Inhaled salbutamol|8 puffs of 100 mcg of inhaled salbutamol once
89425956|NCT05653024|Placebo Comparator|Placebo|8 puffs of inhaled placebo once
89425957|NCT05648006|Experimental|OH2+Capecitabine|OH2: 10^7 CCID50/mL intratumoral injection, once every 2 weeks; Capecitabine: 1000 mg/m2, orally administered twice a day, D1 to D14, repeated every 3 weeks
89425958|NCT05648006|Active Comparator|Capecitabine/Capecitabine+Bevacizumab|Capecitabine: 1000 mg/m2, orally administered twice a day, D1 to D14, repeated every 3 weeks Bevacizumab: 7.5 mg/kg, intravenously, once every 3 weeks.
88906862|NCT05435417|No Intervention|Actual physical measurements of the condyles on the dry mandibles|"For linear measurements, actual physical measurements will be done on the dry mandibular condyles, using digital caliper, as mentioned before.~For volumetric measurements, water displacement technique will be used. The mandibular condyle will be immersed in a graduated beaker containing water till the level of the glued gutta percha. The volume of the displaced water will be measured and will represent the actual volume of the condyle"
88906863|NCT05419570||Patients Undergoing Pancreaticoduodenectomy|
88906864|NCT05391555|Experimental|Noninteractive, then Interactive|Participants undergo the infusion under noninteractive conditions, followed by a second drug infusion under interactive conditions.
88906865|NCT05391555|Experimental|Interactive, then Noninteractive|Participants undergo the infusion under interactive conditions, followed by a second drug infusion under noninteractive conditions.
88906866|NCT05387798|Experimental|RAD011|
88906867|NCT05384457|Experimental|High intensity training (HIT)|Each participant will follow 24 therapy sessions (2 x 1.5 hours/week). The experimental group will perform a multimodal HIT protocol. Cardiorespiratory training will consist of a high-intensity interval training protocol on a cycle ergometer. After a five-minute warm-up, interval training will start, consisting of five one-minute bouts (110 RPM at 100% VO2max workload), separated by one minute of active rest (75 RPM at 50% VO2max workload). Limb strength training will consist of a circuit of three upper-body (vertical traction, chest press, arm curl) and three lower-body exercises (leg curl, leg press, leg extension) executed at 80% of the one repetition maximum. Core muscle training will consist of a circuit of six static core exercises (glute bridge, glute clam, superman back extension, adapted plank, adapted side plank, shoulder retraction with hip hinge) at 60% of the maximal voluntary contraction.
88906868|NCT05384457|Active Comparator|Moderate intensity training (MIT)|Each participant will follow 24 therapy sessions (2 x 1.5 hours/week). The control group will perform a multimodal MIT protocol. Cardiorespiratory training will consist of a moderate-intensity continuous training protocol on a cycle ergometer. After a five-minute warm up, participants start continuous training comprising of 14 minutes of moderate-intensity cycling (90RPM at 60%VO2max workload). The duration will increase weekly with 1'40'' up to 22'40''. Limb strength training will consist of a circuit of three upper-body (vertical traction, chest press, arm curl) and three lower-body exercises (leg curl, leg press, leg extension) executed at 60% of the one repetition maximum. Core muscle training will be identical to the protocol described in 'Core muscle training HIT' with the exception of the exercise intensity. Only exercises with low relative core muscle activation will be used.
88906869|NCT05320471||healthy young adults|between 20-40 years
88906870|NCT05320471||healthy older adults|between 50-75 years
88906871|NCT05306275|Experimental|CSL312 AI Abdomen|CSL312 administered subcutaneously (SC) in the abdomen via a prefilled syringe assembled to an autoinjector (AI)
88906872|NCT05306275|Experimental|CSL312 AI Thigh|CSL312 administered SC in the thigh via a prefilled syringe assembled to an AI
88906873|NCT05306275|Experimental|CSL312 AI Arm|CSL312 administered SC in the upper arm via a prefilled syringe assembled to an AI
88906874|NCT05306275|Experimental|CSL312 NSD Abdomen|CSL312 administered SC in the abdomen via a prefilled syringe assembled to a needle safety device (NSD)
88906875|NCT05306275|Experimental|CSL312 NSD Thigh|CSL312 administered SC in the thigh via a prefilled syringe assembled to a NSD
88906876|NCT05306275|Experimental|CSL312 NSD Arm|CSL312 administered SC in the upper arm via a prefilled syringe assembled to a NSD
88906877|NCT05230004|Experimental|Phase II|Phase II involves a two month home trial to determine the comfort and utility of an adjustable prosthetic system for children. Children will be fit at several different locations by their prosthetist with the adjustable socket. They will complete several questionnaires on their current device, as well as have internal socket pressures and a gait analysis completed. They will return one month later to complete the same outcome measures on their conventional device. They will also be given activity monitors to track their activity through the duration of the project.
89425959|NCT05646641|Experimental|Exercise|8 weeks of strength training.
89425960|NCT05646641|No Intervention|Control|Maintain their usual medical treatment and daily routines
89425961|NCT05645835|Experimental|intervention|Participants will engage with the digital meditation app delivering the intervention 15 min a day, five days, a week for 6 weeks.
88906878|NCT05230004|Experimental|Phase I|Phase I involves developing a final design for an adjustable, immediate fit prosthesis. We will recruit 5-10 participants age 3-12 to complete in-lab testing and evaluation of several designs. This testing will lead to the final product design to be tested in Phase II.
88906879|NCT05190744|Experimental|Polyuric subjects with Hereditary Nephrogenic Diabetes Insipidus|Polyuric subjects with hereditary nephrogenic diabetes insipidus with loss of function of AVPR2 or AQP2 will be treated with PB
89425962|NCT05645835|Active Comparator|waitlist control|Participants will be randomized to a waitlist group for six weeks. The waitlist control group will then be able to use the meditation app for six weeks as the primary intervention group
89425963|NCT05645354|Experimental|SmokefreeSGM|
89425964|NCT05645354|Active Comparator|SmokefreeTXT|
89425965|NCT05644626|Experimental|Phase 1a: Dose Escalation|Part A: Increasing dose levels of BGB-B167 monotherapy; Part B: Increasing dose levels of BGB-B167 in combination with tislelizumab (BGB-A317)
89196081|NCT00837993||Survival Analysis|Survival Analysis Based on Reclassification to a Two-tier Grading System: Review of Pathology Slides for Patients participating on Protocol COG 158.
89196082|NCT00906256|Active Comparator|AZD7295|AZD7295
89196083|NCT00906256|Placebo Comparator|Placebo capsule|Placebo
89196084|NCT00838071|Experimental|IGIV-HB Grifols|
89425966|NCT05644626|Experimental|Phase 1b: Dose Expansion|BGB-B167 alone or in combination with tislelizumab (BGB-A317)
89425967|NCT05642819||Cancer Resection|"Patients with cancer (clinical, histological, cytological or radiological evidence) planned for surgical resection of a malignancy of the oesophagus, stomach, pancreas, colon, or rectum~Aged 18-years and over~Able to give written informed consent"
89196085|NCT02539186|Experimental|platelet rich plasma|Sono-guided injection with 3cc platelet rich plasma between carpal tunnel and median nerve in intervention group.
89425968|NCT05642819||Healthy Controls|"Patients identified at surgical clinic as being planned for an open abdominal operation for a non-inflammatory, benign condition (e.g. donor nephrectomy)~Aged 18-years and over~Able to give written informed consent"
89425969|NCT05637502|Experimental|Graded Motor Imagery and Education|Participants receiving the Graded Motor Imagery programme and a therapeutic educational program
89425970|NCT05637502|Active Comparator|Education|Participants only receiving a therapeutic educational program
89425971|NCT05636995||Primary Hyperaldosteronism Diagnosed Women|Post-partum women who had a hypertensive disorder of pregnancy and a screened primary hyperaldosteronism (positive aldosterone/renin ratio).
89196086|NCT02539186|Active Comparator|splinting|The wrist night splint was firmly fixed in a neutral position to immobilize the affected wrist. Patients were ordered to wear the splint while resting at night and at least 8 hours per day during the period of study in control group.
89196087|NCT04044573|Experimental|ECHOLASER X4 Socratelite|Optic fiber of 300um will be inserted at a distance of 8-10mm from the urethra. Each ablation lasts 6 minutes. Each fiber ablates at an energy of 1800J with a power of 2-3W. Treatment lasts for about 30 minutes.
89196088|NCT02538640|Experimental|High-SDS biscuit|50 g of moist biscuit with high-SDS content and low GI with a glass of water
89196089|NCT02538640|Active Comparator|Low-SDS breakfast cereals|42 g of extruded cereals with no SDS and medium to high GI with a glass of water
89196090|NCT00902824|Active Comparator|Group A|"ADVAX at 0,1 and 2 months followed by TBC-M4 at 6 months~Number of volunteers: 12"
89007465|NCT04522271|Placebo Comparator|Placebo|Once daily oral consumption of a food-grade cornstarch that is readily digestible for approximately 5 months
89196091|NCT00902824|Active Comparator|Group B|"TBC-M4 at 0,1,6 months~Number of volunteers: 12"
89196092|NCT00902824|Placebo Comparator|Placebo|Both Groups A and B will have 4 volunteers each (8 total) that will receive a placebo.
89196093|NCT02547519|Experimental|oral insulin capsule (dose escalation using 3 dose strengths)|Dose 1 is 7.5 mg rH-insulin crystals; dose 2 is 22.5 mg rH-insulin crystals; dose 3 is 67.5 mg rH-insulin crystals. The insulin crystals are formulated together with filling substance (microcrystalline cellulose to a total weight of 200 mg) and contained in hard gelatine capsules. The study treatment will be given orally.
89196094|NCT02547519|Placebo Comparator|Placebo capsule|Daily treatment with placebo capsules containing filling substance (microcrystalline cellulose).
89196095|NCT00909376||1 - transabdominal sonography|Women who will have a transabdominal sonography done in the early second trimester.
89196096|NCT00909376||2 - transvaginal sonography|Women who will have a transvaginal sonography done in the early second trimester.
89196097|NCT02547285||Shoes characteristics in elderly people|The subjects will test different characteristics on the same shoe. A single parameter vary for each test (Different insole, heel height, stem length ...)
89196098|NCT00902902||1|
89196099|NCT00902902||2|
89196100|NCT00909454|Experimental|Daily 2000 IU vitamin D supplement|
89196101|NCT00909454|Active Comparator|Daily Vitamin D supplement 400 IU|
89196102|NCT04035070|Experimental|Root canal irrigation with co-amoxiclav-clindamycin solution|Alternate irrigation with 1 mL antibiotic-containing solution followed by 4 mL 2.5% sodium hypochlorite solution between each size instrument and the consequent one. The antibiotic-containing solution will be prepared by mixing equal quantities of 1.2 gm Co-amoxiclav solution and 600 mg Clindamycin solution at a ratio of 1:1 by volume.
89196103|NCT04035070|Experimental|Root canal irrigation with MTAD|Irrigation with 5 mL MTAD irrigating solution for 5 minutes between each size instrument and the consequent one.
89196104|NCT04035070|Active Comparator|Root canal irrigation with 2.5% sodium hypochlorite|Irrigation with 5 mL 2.5% sodium hypochlorite irrigating solution between each size instrument and the consequent one.
89196105|NCT00838149|Active Comparator|Glutamine|Glutamine would be supplemented (0.5gm/Kg ideal body weight) in the form of a water soluble commercial preparation containing 10 gm of pure L- Glutamine in the crystalline form. The patient in this group would be counseled to meet the remaining protein requirement (i.e1g/Kg/wt) by usual diet. This intervention would be made over a period of two months.
89196106|NCT00838149|Placebo Comparator|Whey Protein|"Whey Protein:~Whey protein would be supplemented (0.5gm/Kg ideal body weight) in the form of a water soluble whey protein concentrate containing 70 % protein. The patient in this group would be counseled to meet the remaining protein requirement (i.e1g/Kg/wt) by usual diet. This intervention would be made over a period of two months."
89196107|NCT02548377|Experimental|Remote ischemic preconditioning|Four 5-minute cycles of upper extremity ischemia, each separated by five minutes of reperfusion. The treatment will be carried out with a tourniquet inflated to 200 mmHg during general anaesthesia prior to flap ischemia and transfer.
89196108|NCT02548377|Sham Comparator|Sham|The tourniquet will be attached to the patient's upper extremity but never inflated.
89196109|NCT02538874|Experimental|Part A: Single Ascending Dose (SAD)|BMS-986171 or Placebo on specified days
89196110|NCT02538874|Experimental|Part B: Multiple Ascending Dose (MAD)|BMS-986171 or Placebo on specified days
89196111|NCT02538874|Experimental|Part C: Multiple Ascending Dose in Japanese subjects (J-MAD)|BMS-986171 or Placebo on specified days
89196112|NCT00906412||ET Group|Total of 25 participants with ET
89196113|NCT00906412||Controls|25 controls without ET
89196114|NCT00408421|Experimental|A|duloxetine 30 mg, daily (QD), by mouth (PO) for 1 week then duloxetine 60 mg QD, PO for 6 weeks then duloxetine 60 mg or 120 mg QD, PO for 6 weeks
89196115|NCT00408421|Placebo Comparator|B|placebo daily (QD), by mouth (PO) for 13 weeks
88906880|NCT05190744|Experimental|Polyuric subjects with Autosomal Dominant Polycystic Kidney Disease treated with Tolvaptan|Polyuric subjects with autosomal dominant polycystic kidney disease on chronic tolvaptan treatment will be treated with PB
88906881|NCT05190744|Experimental|Polyuric subject secondary to lithium administration|Polyuric subject post lithium administration will receive PB
88906882|NCT05159765|Placebo Comparator|Control|Contact lens with refractive correction, single vision optic
88906883|NCT05159765|Experimental|Treatment|Contact lens with refractive correction, multifocal optic
88906884|NCT05137080|Active Comparator|Treatment A|24mg dexamethasone i.v. perioperatively and 24mg dexamethasone i.v. on the first postoperative day
88906885|NCT05137080|Active Comparator|Treatment B|24mg dexamethasone i.v. perioperatively and placebo (isotonic saline) i.v. on the first postoperative day
88906886|NCT05137080|Placebo Comparator|Treatment C|Placebo (isotonic saline) i.v. perioperatively and placebo (isotonic saline) i.v. on the first postoperative day
88906887|NCT05099835|Active Comparator|Botulinum Toxin|injected 10 mL of 0.1% bupivacaine with 100 Botox units (BOTOX®, Allergan Inc., Irvine, CA, USA)
88906888|NCT05099835|Active Comparator|steroid|injected 10 mL of 0.25% bupivacaine with triamcinolonacetonide 4 mg/ml
89007466|NCT04520607|Experimental|Arm 1|Subjects assigned to this arm will receive one intra-articular injection of 0.07 mg lorecivivint in 2 ml vehicle (same treatment as in the parent-study) into their target knee (the same target knee injected in the parent study); performed on Day 1, at Week 48 and every 52 weeks thereafter.
89425972|NCT05636995||Control Women|Post-partum women who had a hypertensive disorder of pregnancy without underlying primary hyperaldosteronism (negative aldosterone/renin ratio)
89425973|NCT05636774|Experimental|Heart failure medication arm|Combination of Sacubitril/valsartan, Ivabradine, Ferric carboxymaltose and/or Empagliflozin
89425974|NCT05636774|Placebo Comparator|Placebo arm|Placebo tables / infusion
89425975|NCT05635617||Lower extremity fracture|High energy lower extremity fractures
89425976|NCT05627115|Experimental|Tislelizumab Response-Adapted Treatment|"All patients will receive 3 cycles of tislelizumab 200 mg (IV) every 21 days. They will then undergo a PET-CT scan (PET1).~Subsequent treatment with further tislelizumab, radiotherapy, and between 2-6 cycles of chemotherapy (Doxorubicin, Vinblastine, and Dacarbazine - AVD) is determined by the patient's stage and response at PET1."
89425977|NCT05619822|Other|TAU + waiting list|Treatment as usual
89425978|NCT05619822|Experimental|TAU + A comprehensive third-generation intervention|he protocol will bedeveloped following the three stages of recovery from trauma (Herman, 2015): first, focusing on establishing the therapeutic alliance and safety; second, focusing on recounting and re-processing the traumatic event; and third, focusing on reconnecting with others and with life despite the trauma experienced. The therapy will be administered in 11 90-minute individual sessions per week, combining strategically ACT, Mindfulness, EMDR as well as Positive Psychology interventions.
89425979|NCT05611476|Experimental|Single group|This group will receive Cognitive Muscular Therapy for low back pain
89425980|NCT05605197|Experimental|U87 CAR-T cells|The Patients are enrolled into 2 dose level cohorts in sequence
89425981|NCT05604963|Active Comparator|Group 1: Two-stage Completion Thyroidectomy|Patients randomised to this arm will undergo a 2nd operation to remove the remaining thyroid lobe.
89425982|NCT05604963|No Intervention|Group 1: Surveillance|Patients randomised to this arm will have no 2nd surgery and proceed directly to follow-up visits.
88906889|NCT05094245|Active Comparator|Stellate ganglion block|Patients underwent a stellate-ganglion block at the anterolateral aspect of the C6 vertebra. After local analgesia (lidocaine 2%), a 22-gauge Quincke needle was placed in the anterolateral aspect of the C6 vertebral body. When the needle contacted the bone, it was drawn back 1 mm. 5 mL of 0·5% ropivacaine was subsequently injected next to the stellate ganglion to produce a sympathetic block.The effect of the stellate-ganglion block on the sympathetic nervous system was confirmed by the presence of Horner's syndrome (ie, facial anhydrosis, enophthalmos, ptosis, swelling of the lower eyelid, miosis, and blood-shot conjunctiva), and an increase in the temperature of the right hand of at least 2°F from baseline.
88906890|NCT05094245|No Intervention|Conventional|Mecobalamin Tablets oral Mecobalamin Tablets tid-8
89425983|NCT05604963|Experimental|Group 2: Hemi-thyroidectomy|Patients randomised to this arm will have a single HT operation to remove thyroid lobe with the tumour.
89425984|NCT05604963|Active Comparator|Group 2: Total Thyroidectomy|Patients randomised to this arm will have a single TT operation to remove the entire thyroid gland.
89425985|NCT05603026|Active Comparator|TAVR using the self-expanding valve Evolut FX|Transcatheter aortic valve replacement (TAVR) using the bioprosthesis Medtronic Evolut FX supra-annular self-expanding valve
89536118|NCT02478827|Experimental|Processing Speed group|The neurocognitive training program will be provided by an online platform called BrainGymmer (https://www.braingymmer.com/en/brain-games/). Users will receive an account where they will only have access to the training games they have been assigned to and where their activity will be logged. One experimental group will complete the processing speed training, which involves three games: Line It Up, Sliding Search, and Bubble Math. These games are designed to engage processes involving thinking speed. Participants randomized to this cognitive training arm will complete the training games for 30 minutes per day, 5 days a week, for a total of 10 weeks
89425986|NCT05603026|Active Comparator|TAVR using the balloon-expandable valve Sapien 3 Ultra|Transcatheter aortic valve replacement (TAVR) using the bioprosthesis Edwards Sapien 3 Ultra valve
89425987|NCT05602220|Experimental|Brain training and paced breathing to stimulate alertness|
89425988|NCT05602220|Experimental|Brain training and paced breathing to relax|
89425989|NCT05600868|Active Comparator|EMDR+dual attention|.Processing the trauma with exposition and dual attention.
89425990|NCT05600868|Active Comparator|EMDR + fixed point|Processing the trauma with exposition and fixed point.
89425991|NCT05600868|Active Comparator|EMDR + exposition|Processing the trauma with exposition.
89425992|NCT05597969|Experimental|FoodCoach|"The experimental group uses the FutureMe app for 9 weeks and continue to voluntarily use it. The app has the following functionality:~Dashboard: show the Nutri-Score changes over the last 10 baskets and comparisons between the specific user and all FoodCoach app users.~Recommendations: show three recommendations regarding their food purchases and healthier product recommendations to help them achieve these recommendations.~Nutrition Analysis: show the monthly energy contribution of 7 food categories in the past 6 months.~Spending Analysis: show the monthly expense contribution of 7 food categories and 1 not categorized category in the past 6 months.~Shopping history: show their purchase history in the past 6 months, together with monthly average Nutri-Score and basket Nutri-Score if applicable~Q & A: show answers to the commonly asked questions. E.g., how is the Nutri-Score calculated?"
89425993|NCT05597969|No Intervention|Control|The control group receives no application for use. They need to finish the onboarding survey, donate their food purchase data and finish the post-study survey (voluntary). They receive no intervention while the experimental group should be actively using the FoodCoach app. The investigators will send them an analysis report of their food purchase data via email in 3 months after the intervention phase is gone. Note the intervention lasts for 9 weeks.
89425994|NCT05597306|Experimental|Part 1: VenBom Dose Escalation/De-Escalation Cohort|"Participants in this group will receive Venetoclax and Bomedemstat (VenBom) in a dose escalation/de-escalation design to determine the maximum tolerated dose (MTD). Participants will receive VenBom for 21 days on (Days 1-21) and seven days off (Days 22-28) during a 28-day cycle for three months. Doses will be administered as follows:~Dose Level -2: 0.375 mg/kg daily (d) Bomedemstat and 200 mg/d Venetoclax;~Dose Level -1: 0.75 mg/kg/d Bomedemstat and 200 mg/d Venetoclax;~Dose Level 1 (Starting): 1.5 mg/kg/d Bomedemstat and 200 mg/d Venetoclax;~Dose Level 2: 3 mg/kg/d Bomedemstat and 200 mg/d Venetoclax;~Dose Level 3: 3 mg/kg/d Bomedemstat and 400 mg/d Venetoclax.~Participants will receive three cycles of VenBom, but may continue to receive treatment as long as receiving clinical benefit or until disease progression. Participants starting at dose levels -2, -1, or 1 receive 100 mg Venetoclax on Cycle 1 Day 1."
89425995|NCT05597306|Experimental|Part 2: VenBom Expansion Cohort|Participants in this group will receive VenBom therapy at the most appropriate dose determined in Part 1. Participants will continue to receive treatment as long as receiving clinical benefit or until disease progression.
89425996|NCT05593835|Experimental|METHIS Intervention|The METHIS intervention will consist of two components. The first component is a Goal-Oriented Care (GOC) Training Program for health professionals. The training program will include the concept of personalised care, methods of goal elation, implications of GOC in healthcare practice, and how METHIS platform can be used to support the application of GOC. The training will be implemented through a blended-learning, continuous education program that will be credited by Nova University of Lisbon. The second component is a GOC information system. This will be the digital platform METHIS, which will be designed to nudge clinicians to adopt a GOC and to encourage patients and caregivers to take an active role in healthcare. The investigators will adapt an existing platform that was developed for a pilot study during the COVID-19 pandemic, that promotes care coordination, optimises disease prioritisation, and patient self-management.
89425997|NCT05593835|No Intervention|Control|"The control group in this trial will be the best usual care, using the standard Electronic Health Records available to the practice. Our understanding of what best usual care is for people with multimorbidity is informed by qualitative research in an earlier stage of this project. Our results suggest that healthcare professionals often provide disease-driven care. When faced with multiple healthcare problems, they prioritise based on 1) patient complaints; 2) which condition is less well controlled; or 3) which condition is more likely to adversely impact on patient Health Related-Quality of life. General practitioners and primary care nurses are often not familiar with the Goal-Oriented Care model. However, they already try to implement some of its principles such as identifying patient goals and supporting shared decision making."
89425998|NCT05592847|No Intervention|Usual Practice|Patients with chronic conditions slated for surgery contacted once by pre-operative nurse to discuss surgery
89425999|NCT05592847|Experimental|Nurse Navigator|Patients with chronic conditions slated for surgery contacted once by pre-operative nurse to discuss surgery, then contacted at intervals by nurse navigator study team members
89426000|NCT05592652|Other|simple post-traumatic stress disorder|Patients suffering from PTSD according to DSM-5 diagnostic features
88906891|NCT05046899|Experimental|BIOpH+ Psoriasis Medical Bath|BIOpH+ Psoriasis Medical Bath is bath. Each bath will take 20 minutes and number of bath during the entire study period is approximately 35 baths.
89426001|NCT05592652|Other|complex post-traumatic stress disorder|Patients suffering from CPTSD according to CIM-11 diagnostic features
89426002|NCT05592652|Other|volonteer trauma +|non clinical volunteer with traumatic exposure
88906892|NCT05046899|Active Comparator|Comparative device|Comparative device is Cetaphil Moisturizing Lotion. The lotion will be applied on the affected body area on the same days as the BIOpH+ Psoriasis Medical Bath is performed.
89426003|NCT05592652|Other|volonteer trauma -|non clinical volunteer without traumatic exposure
89426004|NCT05591248|Experimental|Intervention Group Virtual Reality Rehabilitation|All included patients will receive 3 - 9 sessions (3x/w) of VR rehabilitation during their stay at the intensive care unit. The games will stimulate them to move the arm(s). How long they play the game(s) is not decided in advance (patient-therapist-decision at the time of playing).
89426005|NCT05589389|Experimental|High Healthy Eating Index Diet with Minimally Processed Meat|Participants will consume a diet with a high Healthy Eating Index along with meat that is minimally processed.
89426006|NCT05589389|Experimental|High Healthy Eating Index Diet with Further Processed Meat|Participants will consume a diet with a high Healthy Eating Index along with meat that is further processed.
88906893|NCT05043415|Active Comparator|Immediate endoscopic necrosectomy|Endoscopic ultrasound (EUS)-guided drainage of the necrotic collection is performed using a lumen-apposing metal stent. Then in this group, endoscopic necrosectomy will be performed immediately following index EUS-guided drainage of the necrotic collection, during the same session
88906894|NCT05043415|Active Comparator|Step-up endoscopic intervention|Endoscopic ultrasound (EUS)-guided drainage of the necrotic collection is performed using a lumen-apposing metal stent. In this group, only EUS-guided drainage of the necrotic collection will be performed, and endoscopic necrosectomy will be performed at a separate session at a later time as needed.
88906895|NCT05010018|Experimental|Intervention|We will pilot the BUD app in 19 intervention corner stores over an 8-month period in East Baltimore. During this time, we will collect data from corner store owners, producers, whole salers, and consumers.
88906896|NCT05010018|No Intervention|Control|We will collect data from 19 control corner stores over the same 8-month period. They will not receive any form of intervention or delay intervention.
89426007|NCT05589389|Experimental|Typical Healthy Eating Index Diet with Minimally Processed Meat|Participants will consume a diet with a typical Healthy Eating Index along with meat that is minimally processed.
89007467|NCT04520607|Experimental|Arm 2|Subjects assigned to this arm will receive one intra-articular injection of 0 mg lorecivivint in 2 ml vehicle (same treatment as in the parent-study) into their target knee (the same target knee injected in the parent study) on Day 1, followed by one intra-articular injection of 0.07 mg lorecivivint in 2 ml vehicle at Week 48 and every 52 weeks thereafter.
89007468|NCT04520594|Active Comparator|Resistant Starch|Once daily oral consumption of 7.5g/m2 of an individually optimized resistant starch for approximately 6 months
89426008|NCT05589389|Experimental|Typical Healthy Eating Index Diet with Further Processed Meat|Participants will consume a diet with a typical Healthy Eating Index along with meat that is further processed.
89007469|NCT04520594|Placebo Comparator|Placebo|Once daily oral consumption of a food-grade cornstarch that is readily digestible for approximately 6 months
89426009|NCT05585697||Type 2 diabetes or control|Individuals with type 2 diabetes. Expect to include 26. Individuals without type 2 diabetes. Expect to include 26.
89426010|NCT05578898|Experimental|CLEAR CC|Patients use CLEAR CC application with Smartphone or Tablet
89426011|NCT05572333|Experimental|EP395|EP395 in repeated doses. Oral, once-daily administration of 3 EP395 capsules for 12 weeks.
89536119|NCT02478827|No Intervention|Control group|The control group will wait 10-weeks, during which they will receive treatment-as-usual (TAU), which might involve pharmacotherapy, psychotherapy, or both. After the 10-week waiting period, a post-assessment will be completed.
89007470|NCT04517435|Experimental|ME-401 + R-CHOP|Participants will receive ME-401 dose dependent on dose-escalation schedule at time of enrollment - all will receive standard dose R-CHOP. ME-401 (60 mg) will be given on days 1-4 (dose level 1) OR days 1-7 (dose level 2) of a 21 day cycle with standard dose R-CHOP x 6 cycles.
89196116|NCT00604786|Experimental|Omalizumab subcutaneous|"This active are will receive treatment with omalizumab subcutaneously at the dose currently FDA-approved for the treatment of allergic asthma. There is a weight and IgE based dosing table in the and subjects receive therapy by subcutaneous injection every 2 or 4 weeks. The lower range of dosing is 150 mg q 4weeks ( one injection) with the upper range 375 mg every 2 weeks ( three injections).~The dosing is based on IgE levels and IGE and is given by subcutaneous injection every 2 to 4 weeks"
89196117|NCT00604786|Placebo Comparator|Placebo Subcutaneous|"This placebo arm will receive identical treatment with placebo injections subcutaneously at the dose currently FDA-approved for the treatment of allergic asthma. There is a weight and IgE based dosing table in the and subjects receive therapy by subcutaneous injection every 2 or 4 weeks. The lower range of dosing is 150 mg q 4weeks ( one injection) with the upper range 375 mg every 2 weeks ( three injections).~The dosing is based on IgE levels and IGE and is given by subcutaneous injection every 2 to 4 weeks."
89426012|NCT05572333|Placebo Comparator|Placebo|Matched placebo capsule. Oral, once-daily administration of 3 placebo capsules for 12 weeks.
89426013|NCT05571995|Experimental|Intervention|The intervention group will receive TRIMOSH
89426014|NCT05571995|No Intervention|Control|The control group will receive no intervention.
89196118|NCT00902980||1. Community Based Clinics|Patient charts from community based nephrology clinics
89196119|NCT00902980||2. Regional Clinics|Patient charts from regional transplant clinics
89426015|NCT05571358|No Intervention|Control Group|Following clinical practice guidelines, subjects in the control group will receive multidisciplinary rehabilitation programmes with coordinated delivery of supervised exercise therapy, cognitive behavioural therapy (education on pain), as well as therapeutic massage to relieve low back pain during pregnancy.
89426016|NCT05571358|Experimental|Virtual Reality (Nature Trek)|"Subjects in the experimental group will receive the same treatment described for the control group.~Subjects in the experimental group will receive an additional Virtual Reality Intervention (VRi)."
89426017|NCT05569486|Experimental|Green light-emitting diode (GLED)|Subjects randomized to this arm will be exposed to GLED 2 hours a day for 10 weeks
88906897|NCT04999891||Surgical Cohort|Elderly patients aged 65 and above who are planned for hip fracture surgery.
88906898|NCT04988815|Experimental|Ropeginterferon alfa-2b|Eligible subjects will receive ropeg subcutaneously (SC) every 2 weeks at the starting dose of 250µg at week 0, 350 µg at week 2, then 500µg at a fixed dose from week 4 onwards until week 104. In patients achieving a clinical or molecular response at 24 months (week 104), treatment with ropeg will be continued until disease progression.
88906899|NCT04980378||Simplify Disc|Extended follow-up of IDE Subjects treated at two continuous levels with the Simplify Cervical Artificial Disc during IDE G150206
88906900|NCT04979572|Experimental|Part A (single dose) : Step 1 to 4: TS-172 10 mg, 30 mg, 90 mg, 270 mg|Single dose of TS-172 or placebo before breakfast
88906901|NCT04979572|Experimental|Part B (multiple dose) : Step 5: TS-172 90 mg|Multiple dose of TS-172 or placebo before breakfast and dinner
88906902|NCT04970147|Other|there are not arm for this study.|there is not a control group for this study.
88906903|NCT04938180|Experimental|Cohort A|Low-Dose AMB-05X Each subject will receive a low dose of AMB-05X every 2 weeks, for a total of 6 doses over the 12-week treatment period.
88906904|NCT04905615|No Intervention|Baseline Measures|The first two-weeks within each school children's baseline physical activity data will be collected. Children will be blinded to the data, receiving no feedback. Teachers will be instructed not to change normal school practices or encourage children's physical activity.
88906905|NCT04905615|Experimental|Data-Driven Strategy Based Intervention|During the following 2-weeks teachers will be implementing strategies to improve their class' physical activity. These are individualised strategies which will be co-developed during semi-structured interviews where teachers will discuss data visualisations with the researcher which depicts their class' physical activity over the 2-week baseline period. Teachers will then implement these strategies over the subsequent 2-weeks. During this time teachers are able to share the physical activity data with their pupils if they wish.
88906906|NCT04889300|Experimental|Best Possible Self|Positive affect and optimism will be induced through the Best Possible Self (BPS) Intervention. In the optimism intervention, participants will be asked to imagine a future in which everything went well and in which all their wishes are fulfilled. This procedure is known to reliably generate positive affect and positive future expectations (Carrillo et al., 2019). Orientated at Flink et al. (2015) the BPS condition was adapted for a pain population.
88906907|NCT04889300|Active Comparator|Typical Day|In the control condition, participants are asked to describe and visualize a typical day (TD). We adapted the TD condition in order to take possible changes in participants´ TD due to the COVID-19 pandemic into account.
88906908|NCT04873323|Experimental|TS-142 10 mg|TS-142 therapeutic dose oral tablet (low dose)
88906909|NCT04873323|Experimental|TS-142 30 mg|Description: TS-142 supratherapeutic dose oral tablet (high dose)
88906910|NCT04873323|Experimental|Moxifloxacin 400 mg|Moxifloxacin tablet
88906911|NCT04873323|Experimental|Placebo|Placebo oral tablet
88906912|NCT04834960|Other|MOV Intervention|Pre-intervention and post-intervention design
88906913|NCT04814771|Experimental|[14C] TS-142|Participants will receive oral [14C] TS-142 under fasted conditions
89426018|NCT05569486|Placebo Comparator|White light-emitting diode (WLED)|Subjects randomized to this arm will be exposed to WLED 2 hours a day for 10 weeks
89426019|NCT05563129|No Intervention|No first aid training|
89426020|NCT05563129|Experimental|First aid training|
89426021|NCT05560425|Active Comparator|Navigating College (NC) Training|Control Group
89426022|NCT05560425|Experimental|Koru Mindfulness (KM) Training|Study Group
88906914|NCT04792554||Surgical Cohort|Elderly patients aged 65 and above who are planned for major non-cardiac surgery predicted to be at least 2 hours in duration and requiring at least 1 postoperative stay in hospital.
88906915|NCT04777344|Experimental|Intervention group|The intervention group will receive the multi-component intervention (counseling with intake assessment, follow-up, help obtaining nicotine replacement therapy, and CF-specific smoke exposure education)
89426023|NCT05559879|Experimental|Cabo + Dostarlimab|Cabozantinib 40 mg by mouth every day + Dostarlimab 500 mg intravenous every 3 weeks followed by maintenance therapy: Cabozantinib 40 mg by mouth every day + Dostarlimab 1000 mg intravenous every 6 weeks
89426024|NCT05553847|No Intervention|Usual oxygen dose|A Glittre-ADL tests will be performed and the patients will use their usual fixed dose of oxygen. Pulse rate and saturation will continuously be registered during the test. Before, and after the Glittre-ADL, the patients will be asked the rate their level of dyspnea using Borg Dyspnea Scale
89426025|NCT05553847|Experimental|Automated oxygen dose|A Glittre-ADL tests will be performed and the patients will use automated oxygen titration set at an SpO2-target of 90 to 94 % and an oxygen flow of 0 - 8 liters/min. Pulse rate, oxygen flow rate and saturation will continuously be registered during the test. Before, and after the Glittre-ADL, the patients will be asked the rate their level of dyspnea using Borg Dyspnea Scale
89426026|NCT05552989||Key stakeholders of the local disaster relief community|
89426027|NCT05545527||RAPIDIRON IV iron intervention arm 1|Maternal participants in this arm were given a single dose of an IV iron formulation - ferric carboxymaltose - during pregnancy as part of their participation in the parent RAPIDIRON Trial. Participants weighing 50kg and over received a single dose having 1000mg of iron, with others receiving a lower dose as determined by a formula used by the manufacturer (20mg iron/kg body weight). This was given between 14 and 17 weeks fetal gestational age.
89426028|NCT05545527||RAPIDIRON IV iron intervention arm 2|Maternal participants in this arm were given a single dose of an IV iron formulation - iron isomaltoside - during pregnancy as part of their participation in the parent RAPIDIRON Trial. Participants weighing 50kg and over received a single dose having 1000mg of iron, with others receiving a lower dose as determined by a formula used by the manufacturer (20mg iron/kg body weight). This was given between 14 and 17 weeks fetal gestational age.
89426029|NCT05545527||RAPIDIRON active comparator arm|Maternal participants in this arm of the RAPIDIRON Trial were given ferrous sulfate tablets with 60mg elemental iron each and instructed to take two per day (one in the morning and one at night) throughout their pregnancy.
89426030|NCT05544474||Expert surgeon on radical right colectomy|Expert surgeon on radical right colectomy com pricing corresponding author/senior author from paper included in a preliminary systematic review on this topic Sica GS, Vinci D, Siragusa L, Sensi B, Guida AM, Bellato V, García-Granero Á, Pellino G. Definition and reporting of lymphadenectomy and complete mesocolic excision for radical right colectomy: a systematic review. Surg Endosc. 2022 Sep 12. doi: 10.1007/s00464-022-09548-5.
89426031|NCT05542316||Patients with a recent diagnosis of PMR|
88906916|NCT04777344|No Intervention|Control group|The control group will receive usual care plus CF-specific smoke exposure education.
88906917|NCT04753580|Experimental|group 1|healthy adult 20-35 years old
88906918|NCT04753580|Experimental|group 2|healthy elderly 65+ years old
88906919|NCT04753580|Experimental|group 3|Frail elderly 65+ years old
89426032|NCT05538091|Experimental|vismodegib + atezolizumab|"Vismodegib: fixed dose of 150 mg PO daily~Atezolizumab: fixed dose of 1200 mg Q3W (1200 mg on Day 1 of each 21-day cycle)"
89426033|NCT05536830||Participant dyads: Caregivers and Care Recipients|Participants will be recruited in pairs as caregivers and care recipients. All data collected is observational in nature.
89426034|NCT05536115||Study population|Study patients are patients with post-extraction dry socket.
89196120|NCT04034758|Placebo Comparator|Placebo capsule arm|Oral administration of 30 placebo capsule containing edible pigmented starch together with full dose of oral 5-Aminosalicylic acid(5-ASA).
89196121|NCT04034758|Active Comparator|SQIMC-md FMT arm|Oral administration of 30 SQIMC-md capsules containing 2*10^13 copies of prepared fecal microbiota lyophilized powder from multiple healthy donors' fresh feces together with full dose of oral 5-Aminosalicylic acid(5-ASA).
88906920|NCT04753268|Experimental|Treatment group: Noom Healthy Weight Program|The intervention consists of a curriculum, provided through daily articles that users are encouraged to read; logging features for weight, meals, and physical activity; in-app groups; and a virtual coach, who will communicate with participants via in-app messaging.
88906921|NCT04748965||Tibial Vessel Involvement in Patients with peripheral artery disease and CLI|The primary goal is to establish a protocol for performing optimal OCT in below-the-knee vessels. OCT images will be analyzed for lesion characteristics, lesion sizing pre- and post-intervention. This will be analyzed against QVA and IVUS (latter if applicable).
88906922|NCT04746105|Experimental|TS-142|Period in which subjects received TS-142 10 mg or The night when subjects received TS-142
88906923|NCT04746105|Experimental|Placebo|Period in which subjects received placebo or The night when subjects received matched placebo
89196122|NCT01042873|Other|Intravenous dobutamine|3 hours infusion of dobutamine
89196123|NCT01042951|Active Comparator|ShanChol Cholera Vaccine|
89426035|NCT05535140||Cancer patients who are 65 years of age or older|An online self-reported G8 screening tool. The tool will have content including: 1) the purpose and benefit of the G8, 2) explanations of each question with examples and probes to help with recall, and 3) next steps after the G8 assessment is completed and how the results might impact their cancer treatments. New established older cancer patients will be invited to interact with the tool.
89426036|NCT05533528|Active Comparator|Control|Access flap periodontal surgery
89426037|NCT05533528|Experimental|Test|Access flap periodontal surgery and periodontal granulation tissue debridement.
89426038|NCT05530993||Have considered use of PrEP|
89426039|NCT05530993||Have not considered use of PrEP|
89426040|NCT05526391|Experimental|Early PK Cohort: TAK-341 Dose 1|Participants will be randomized to receive TAK-341 at a starting Dose 1 at 4 week intervals for up to 52 weeks.
89426041|NCT05526391|Placebo Comparator|Early PK Cohort: Placebo|Participants will be randomized to receive TAK-341 placebo, up to 52 weeks.
88906924|NCT04731675|Experimental|AMB-05X|"Subjects will receive an injection of AMB-05X once every 2 weeks for 12 weeks (for 6 treatments total).~Based on ongoing review of the available safety, PK, PD, and efficacy data, the Sponsor may either increase or decrease the dose."
89196124|NCT01042951|Placebo Comparator|Placebo|
89426042|NCT05526391|Experimental|Main Cohort: TAK-341 Dose 2|Participants will be randomized to receive TAK-341 at a starting Dose 2 at 4 week intervals for up to 52 weeks.
89426043|NCT05526391|Placebo Comparator|Main Cohort: Placebo|Participants will be randomized to receive TAK-341 placebo, up to 52 weeks.
89426044|NCT05525585|Experimental|Early human milk fortification (HMF) group|A human milk fortifier will be added to the feeds between days 4 to 7, after a total feeding volume greater than 120 ml/kg/day is achieved.
89426045|NCT05525585|Active Comparator|Delayed human milk fortification (HMF) group|A human milk fortifier will be added to the feeds between days 10 to 14, after a total feeding volume greater than 120 ml/kg/day is achieved.
89426046|NCT05518188|Experimental|Treatment Arm|MELPIDA, a gene therapy product
89426047|NCT05514223||Males of couples seeking fertility treatment|The study population will consist of males of couples that visit the Center reproductive Medicine of the UMCG where a semen analysis is planned for clinical purposes.
89426048|NCT05513404|No Intervention|Breakfast only|This is an acute intervention study to compare the health benefits, in relation to changes in postprandial glucose and cognitive performance, of consumption of 3 soft fruits, raspberries, cherries, and honeyberries. It will have a randomised controlled crossover design where the volunteers will return for 4 stand-alone study sessions. All study procedures will be carried out at the Human Nutrition Unit (HNU) of the Rowett Institute. . The first study session will be an oral glucose tolerance test (OGTT). The glucose load for the OGTT in all sessions will be given as carbohydrate meal consisting of white bread, spread, low-polyphenol jam. (meal: 75g carbohydrate total). The remaining three will be intervention sessions which will be identical in all respects except for the addition of either honeyberry, cherry, or raspberry. There will be a minimum of 1 week washout period.
89426049|NCT05513404|Experimental|Honeyberry|This arm will be an oral glucose tolerance test (OGTT). The glucose load for the OGTT in all sessions will be given as carbohydrate meal consisting of white bread, spread, low-polyphenol jam. (meal: 75g carbohydrate total) with the addition of honeyberry. There will be a minimum of 1 week washout period.
89426050|NCT05513404|Experimental|Cherry|This arm will be an oral glucose tolerance test (OGTT). The glucose load for the OGTT in all sessions will be given as carbohydrate meal consisting of white bread, spread, low-polyphenol jam. (meal: 75g carbohydrate total) with the addition of cherrry. There will be a minimum of 1 week washout period.
89426051|NCT05513404|Experimental|Raspberry|This arm will be an oral glucose tolerance test (OGTT). The glucose load for the OGTT in all sessions will be given as carbohydrate meal consisting of white bread, spread, low-polyphenol jam. (meal: 75g carbohydrate total) with the addition of raspberry. There will be a minimum of 1 week washout period.
89426052|NCT05512013|Experimental|Ibuprofen|Participants will consume a single dose of ibuprofen prior to a plyometric exercise bout
89426053|NCT05512013|Experimental|Celecoxib|Participants will consume a single dose of celecoxib prior to a plyometric exercise bout
89426054|NCT05512013|Experimental|Flurbiprofen|Participants will consume a single dose of flurbiprofen prior to a plyometric exercise bout
89426055|NCT05512013|Placebo Comparator|Placebo|Participants will consume a single dose of an inert placebo prior to a plyometric exercise bout
89426056|NCT05505604|Active Comparator|PENG|Patients with hip fracture randomized to receive PENG block
89426057|NCT05505604|Active Comparator|FICB|Patients with hip fracture randomized to received FICB
89426058|NCT05504863||RAPIDIRON IV iron intervention arm 1|Maternal participants in this arm were given a single dose of an IV iron formulation - ferric carboxymaltose - during pregnancy as part of their participation in the parent RAPIDIRON Trial. Participants weighing 50kg and over received a single dose having 1000mg of iron, with others receiving a lower dose as determined by a formula used by the manufacturer (20mg iron/kg body weight). This was given between 14 and 17 weeks fetal gestational age.
89426059|NCT05504863||RAPIDIRON IV iron intervention arm 2|Maternal participants in this arm were given a single dose of an IV iron formulation - iron isomaltoside - during pregnancy as part of their participation in the parent RAPIDIRON Trial. Participants weighing 50kg and over received a single dose having 1000mg of iron, with others receiving a lower dose as determined by a formula used by the manufacturer (20mg iron/kg body weight). This was given between 14 and 17 weeks fetal gestational age.
89426060|NCT05504863||RAPIDIRON active comparator arm|Maternal participants in this arm of the RAPIDIRON Trial were given ferrous sulfate tablets with 60mg elemental iron each and instructed to take two per day (one in the morning and one at night) throughout their pregnancy.
89426061|NCT05499871|Experimental|Minimalist footwear|Transition toward a minimalist footwear.
89426062|NCT05499871|Experimental|Footstrike pattern|Transition toward a forefootstrike pattern.
88906925|NCT04715100||Experimental group|"The inclusion criteria to participate in the present study are patients: with a diagnosis of hemophilia A and B; adults; and on a prophylactic or on-demand treatment regimen with FVIII / FIX concentrates.~For their part, patients with: neurological or cognitive alterations that impede understanding of the questionnaires will be excluded from the study; Dependent patients who require help from a third person to get around; patients who have developed a hemarthros in the 4 weeks prior to the study; and those who have not signed the informed consent document.~For inclusion in the study, patients will continue to be administered the dose of FVIII / FIX concentrates, following the guidelines of the medical criteria established by their reference hematologist. Throughout this study, the medical criteria for drug treatment, the dosage, and the replacement treatment periods will not be changed."
89426063|NCT05499871|No Intervention|Control|No intervention
89426064|NCT05492331|Experimental|Music Therapy during the IUI procedure|Subjects undergoing an intrauterine insemination (IUI) procedure will experience music therapy during the procedure.
88906926|NCT04713358|Experimental|Nalmefene group|for the nalmefene group, immediately Intravenous injection of Nalmefene (0.25 g/kg, plus normal saline to 1ml) after surgery
89426065|NCT05492331|No Intervention|Standard of Care|Subjects will receive standard of care for intrauterine insemination (IUI) procedure.
88906927|NCT04713358|Placebo Comparator|Control group|Intravenous injection of normal saline 1ml immediately after surgery
88906928|NCT04705051|Experimental|Venglustat|Participants were to be treated with venglustat 15 milligrams once daily orally for 24 months or until venglustat was commercially available, whichever came first.
88906929|NCT04696952|Experimental|TS-142 10 mg|Period in which subjects received TS-142 10 mg
89426066|NCT05491005|Experimental|eHealth|
89426067|NCT05491005|Experimental|Face-to-face|
88906930|NCT04696952|Experimental|TS-142 20 mg|Period in which subjects received TS-142 20 mg
88906931|NCT04696952|Experimental|Zopiclone 7.5 mg|Period in which subjects received Zopiclone 7.5 mg
88906932|NCT04696952|Experimental|Placebo|Period in which subjects received placebo
88906933|NCT04665752||Affected Participants|Participants previously diagnosed with COVID-19.
89426068|NCT05491005|No Intervention|Healthy control group|
89426069|NCT05481177|No Intervention|Long Haul COVID|Persistent signs and/or symptoms >12 weeks post Covid-infection N = 200 evaluable subjects.
89426070|NCT05481177|No Intervention|Post COVID without LHC|No persistent signs and/or symptoms >12 weeks N = 50 evaluable subjects.
89426071|NCT05481177|Placebo Comparator|Ivabradine RCT Arms|"If POTS or IST is present for participants within either of these cohorts, then they will be assigned to one of two arms of the Ivabradine RCT [2:1 treatment:control].~RCT Arms: at least 36 evaluable subjects will be enrolled to two arms in a 2:1 ratio. More may be enrolled, depending on the number from the overall COVID-19 cohort who qualify.~IVA (Ivabradine) - at least 24 evaluable subjects Placebo - at least 12 evaluable subjects"
89426072|NCT05481086||1|Individuals with fibromyalgia syndrome
88906934|NCT04631276|Experimental|Single evaluation of H3 receptor occupancy|Subjects received single-dose of 0.1, 0.2, 0.4, 1, 2.5, 25 mg TS-091 prior to an evaluation of H3 recepto occupancy
88906935|NCT04631276|Experimental|Multiple evaluations of H3 receptor occupancy|Subjects received single-dose of 5, 12.5, 25 mg TS-091 prior to Multiple evaluations of H3 recepto occupancy
88906936|NCT04627506|No Intervention|Control Group|"Bilateral NIRS will be used to measure rSO2 intraoperatively.~In the control group, the cerebral oximetry monitor screen will be concealed, however, the recording will be continuous after verification of the signal strength and baseline value by an independent observer trained in cerebral oximetry application and unaware of the study design.~Standardized anesthesia and surgical management will be conducted according to routine institutional practice."
88906937|NCT04627506|Experimental|Study Group|"Bilateral NIRS will be used to measure rSO2 intraoperatively.~In the interventional group, an alarm threshold at 90% of the baseline rSO2 value will be established. Based on predetermined algorithm the rSO2 will be maintained at or above 90% of the baseline measurements. The intervention will be commenced within 15 seconds of the reduction in rSO2 value."
88906938|NCT04617210||Surgical Cohort|Elderly patients aged 65 and above who are planned for major non-cardiac surgery predicted to be at least 2 hours in duration and requiring at least 1 postoperative stay in hospital.
88906939|NCT04586647|Experimental|Noom Health Weight Program|
88906940|NCT04586647|No Intervention|Wait List Control|
88906941|NCT04573725|Experimental|5 mg|Period in which participants received single-dose of 5 mg TS-142 prior to bedtime
88906942|NCT04573725|Experimental|10 mg|Period in which participants received single-dose of 10 mg TS-142 prior to bedtime
88906943|NCT04573725|Experimental|30 mg|Period in which participants received single-dose of 30 mg TS-142 prior to bedtime
88906944|NCT04573725|Placebo Comparator|Placebo|Period in which participants received single placebo prior to bedtime
89426073|NCT05480982|Experimental|Cognitive functional therapy (CFT) via tele rehabilitation|"Cognitive Functional Therapy (CFT) is a physiotherapy-led intervention which has evolved from an integration of foundational behavioral psychology and neuroscience within the physiotherapy practice directed at the multidimensional biopsychosocial nature of low back pain. The clinical journey is adapted to the individual's profile following three main components: (i) making sense of pain, (ii) exposure with control and (iii) lifestyle changes.~The first 2 one-hour treatment sessions of CFT will be delivered individually and via videoconference in a weekly basis. The following one-hour treatment sessions (from 6 to 9 sessions) will be delivered in groups (up to 6 participants). One group booster session will be delivered 20 weeks after randomization"
89536120|NCT05001321||Training Group|Based on the inclusion criteria, 2000 gastric cancer patients will be recruited in the analysis. And a model will be constructed based on deep learning.
89536121|NCT05001321||Internal Validation Group|Based on the inclusion criteria, 1000 gastric cancer patients will be recruited in this group to verify the sensitivity and specificity of the constructed model.
88906945|NCT04496999|Experimental|Midostaurin with HDM201 dose escalation.|Midostaurin 50mg bid d1-28 (morning, evening) and HDM201
88906946|NCT04476225||Individuals with Hirschsprung Disease|Individuals with Hirschsprung disease
88906947|NCT04476225||Unaffected Relatives|Unaffected relatives of individuals with Hirschsprung disease
88906948|NCT04469023|Experimental|TS-142 2.5 mg|Period in which participants received multiple-dose of 2.5 mg TS-142 prior to bedtime
88906949|NCT04469023|Experimental|TS-142 5 mg|Period in which participants received multiple-dose of 5 mg TS-142 prior to bedtime
88906950|NCT04469023|Experimental|TS-142 10 mg|Period in which participants received multiple-dose of 10 mg TS-142 prior to bedtime
88906951|NCT04469023|Experimental|Placebo|Period in which participants received single placebo prior to bedtime
88906952|NCT04464421|Experimental|Contingency management (CM)|Participants will receive physical rewards urine toxicology results are positive for buprenorphine (i.e., they are adherent to Medication-Assisted Treatment (MAT)) during their first four visits after initiation of MAT.
88906953|NCT04464421|Experimental|BSM|BSM (Brief Motivational Intervention + Substance Free Activities Session + Mindfulness-Based Adherence Promotion) participants will have one-on-one behavioral intervention sessions at each of the first four visits after initiation of MAT.
89536122|NCT05001321||External Validation Group|Based on the inclusion criteria, 300 gastric cancer patients from 5 other medical centers will be recruited in this group to verify the sensitivity and specificity of the constructed model.
89536123|NCT03201679||Patients with preoperative sepsis|Sepsis defined as SIRS plus a positive culture from any site.
89196125|NCT01037023||Patients administrated Topotecan|There is only one group. This group includes patients administrated Topotecan
89196126|NCT01043107||Compuer radiaton group|
89196127|NCT01043107||control group|
89196128|NCT00909688|Experimental|1|BLI-489
89196129|NCT00909688|Placebo Comparator|2|placebo
89196130|NCT00906568||Sensitized vs non-sensitized|CF with and without SAD defined by MEF25 <50%
89196131|NCT04034836|Experimental|The scalp blocks group|The scalp blocks group will receive scalp blocks with ropivacaine, 20ml, plus 10 mg parecoxib (diluted in 2 mL NS) with epinephrine (5 ug/mL) and i.v. saline 2ml;
89196132|NCT04034836|Active Comparator|The i.v. group|The i.v. group will receive scalp blocks with ropivacaine 20ml, plus saline 2ml with epinephrine (5 ug/mL) together with 10 mg parecoxib (diluted in 2 mL NS) intravenously.
89196133|NCT04034836|Active Comparator|The control group|The control group will receive scalp blocks with ropivacaine, 20ml, plus saline 2ml with epinephrine (5 ug/mL) and i.v. saline 2ml;
89196134|NCT02806336|Experimental|Multi Modal Balance Training & Weight Loss|Supervised exercise 3 times per week for about 1 hour. The classes will consist of a group balance class (about 30 minutes), a supervised obstacle course (about 10 minutes), and lower body and core body strength exercises (about 20 minutes). Weekly nutrition sessions for individual dietary recommendations designed to produce about a 10% weight loss over the first six months of the study.
89196135|NCT02806336|Active Comparator|Multi Modal Balance Training Only|Supervised exercise 3 times per week for about 1 hour. The classes will consist of a group balance class (about 30 minutes), a supervised obstacle course (about 10 minutes), and lower body and core body strength exercises (about 20 minutes).
89196136|NCT00407797|Experimental|Pregabalin|
89196137|NCT00903292|Active Comparator|A, erlotinib|If EGFR mutation found then assigned to thyrosine kinase inhibitor (erlotinib)
89196138|NCT00903292|Active Comparator|B, pemetrexed|If EGFR wild type found then assigned to chemotherapy (pemetrexed)
89196139|NCT02539030|Active Comparator|microfracture|simple microfracture for cartilage defect of knee
89196140|NCT02539030|Experimental|modified microfracture using collagen|modified microfracture using collagen (CartiFill) for cartilage defect of knee
89196141|NCT00903526||candidemia|
89196142|NCT00906646|Experimental|Metabolic therapy|Metabolic therapy with antioxidants and cellular energisers
89196143|NCT00906646|Placebo Comparator|Placebo|Placebo tablets
89196144|NCT00903604|Experimental|AP214|Infusions of sequential ascending dosages of AP214
89196145|NCT00903604|Placebo Comparator|Placebo|Infusions of saline solution
89196146|NCT00924274|Experimental|Lifestyle counseling|
89196147|NCT00924274|Active Comparator|sunflower oil|
89196148|NCT00903838|Experimental|1|
89196149|NCT00903838|Active Comparator|2|
89196150|NCT00924430|Other|1|
89196151|NCT00924430|Other|2|
89196152|NCT03743506|Experimental|Volunteers without motor abnormalities.|The test was performed in a single, 30-minute session. The test is divided into two phases, with feedback and no feedback from the system. The order of phases was randomized. In each phase the volunteer will remain balanced on the wobble board for 15 seconds under the conditions of the phase. This test is repeated 3 times with a 30 seconds rest between them, then the next phase is performed. With feedback the volunteer can observe the system responses. Without feedback the volunteer can not observe the response of the system.
89196153|NCT00924586|Placebo Comparator|P|
89196154|NCT00924586|Experimental|E|
89196155|NCT00568126|Experimental|Maca Root|Subjects in this arm will be given 3g/day of maca root for 12 weeks
89196156|NCT00568126|Placebo Comparator|Placebo|Subjects in this arm will receive inactive placebo for 12 weeks.
89196157|NCT00903994|Other|Single Arm|Single Arm
89196158|NCT00924742|Experimental|Test drug|
89196159|NCT02539498|Active Comparator|Control|Control post menopausal women without PHPT
89196160|NCT02539498|Experimental|Experimental|Post menopausal women with PHPT followed for one year
89196161|NCT00904072||accepted|The suggestions provided by the CDSS which were accepted by the physicians.
89196162|NCT00904072||denied|The suggestions provided by the CDSS which were denied by the physicians.
89196163|NCT00904228|Experimental|Plastic Cap|Plastic lined stockinet cap (polyethylene bag)
89196164|NCT00904228|Active Comparator|Stockinet Cap|Usual practice
89536124|NCT03201679||Patients without preoperative sepsis|
89536125|NCT04996953||165 patients with insomnia|
89536126|NCT02478749|Experimental|Infant|patients aged younger than 1year
89536127|NCT02478749|Experimental|Child|patients aged 1year to 5years
89007471|NCT04488133|Experimental|Nusinersen 12 mg|Participants will receive Nusinersen 12 milligrams (mg) via intrathecal (IT) injection as loading doses on Days 1, 15, 29, and 64 followed by maintenance doses, every 4 months, on Days 183, 302, 421, 540 and 659.
89007472|NCT04473365||Without parasite|For secondary outcome: effect of co-infection with parasite on COVID-19 severity Group 1 will constitute those without parasite co-infection
89196165|NCT00924976|Experimental|1|Subjects will be offered the Steps for Achieving Financial Empowerment (SAFE) which helps facilitate a cooperative consumer-payee relationship, increase accurate knowledge about representative payeeship, promote collaborative money management and effective budgeting, and prepare mutually developed plans for carrying out the payeeship in the future.
89196166|NCT00924976|No Intervention|2|Representative payeeship as usual
89196167|NCT03824860|Experimental|Yoga Program|Eight-weeks, therapist and self-guided yoga
89196168|NCT03824860|No Intervention|Treatment as usual|Control group participants will continue to receive usual care and symptom management strategies from clinicians during the study.
89196169|NCT00906724||aerobic exercise|Aerobic exercise in Insulin Resistant Minority Adolescents
89196170|NCT01037101|Active Comparator|IVET+DCS|
89196171|NCT01037101|Experimental|VRET+DCS|
89196172|NCT01037101|Experimental|VRET+Placebo|
89196173|NCT01037101|Active Comparator|IVET+Placebo|
89196174|NCT01037101|No Intervention|Wait-List|3 weeks Wait-List
89196175|NCT00904306|Placebo Comparator|Sugar pill|6 months treatment with placebo
89196176|NCT00904306|Active Comparator|low dose|600ug/day chromium picolinate for 6 months
89196177|NCT00904306|Active Comparator|high dose chromium picolinate|1000 ug/day
89196178|NCT01788553||patients with generalized anxiety disorder|
89196179|NCT00906802|Experimental|R-Y reconstruction|the reconstruction was performed by R-Y anastomosis
89196180|NCT00906802|No Intervention|conventional reconstruction|the anastomosis was performed by B-II
89196181|NCT01040377||Inadequate initial weight loss after gastric bypass|
89196182|NCT00567892|Experimental|1. rTMS|"Stimulation Settings:~Frequency -- 1Hz on 330 sec (5 min 30 sec.) per train for the first 5 trains with the last train 350 sec. (5 min. 50 sec.) in duration Off -- 90 sec (1 min. 30 sec.) Intensity -- 110% of motor threshold Duration -- 42½ minutes (total 2000 pulses in 6 trains)"
89196183|NCT00567892|Sham Comparator|2. Sham rTMS|Sham rTMS appears identical to and mimics sounds and sensations of active magnet.
89196184|NCT00623103|Experimental|Rivastigmine capsule|Rivastigmine capsules starting at a total dose of 3 mg/day (1.5 mg twice daily orally) titrated up in 3 mg/day increments every 4 weeks to a final dose of 12 mg/day (6 mg twice daily orally). The 12 mg/day dose or the highest dose tolerated was maintained until week 76.
89196185|NCT00623103|Experimental|Rivastigmine patch|Rivastigmine patch once a day in the morning, worn for 24 hours, starting at 5 cm^2 (delivering 4.6 mg rivastigmine over a 24 hour period) for 4 weeks then titrated up to 10 cm^2 daily (delivering 9.5 mg rivastigmine over a 24 hour period). The 10 cm^2 patch or the highest well tolerated dose was maintained until week 76.
89196186|NCT01043341|Active Comparator|behavioral|the women received a folder about HPV infection and vaccines and answered a questionaire about sexual behavior, HPV infection and vaccines.
89536128|NCT02478749|Experimental|Adult|adult patients
89196187|NCT01043341|No Intervention|no intervention|the women answered a questionaire about sexual behavior, HPV infection and vaccines
89196188|NCT01043419|Experimental|LENOXe™ (xénon 100 % v/v)|Influence of LENOXe™ (xénon 100 % v/v) anesthesia on Sympathetic Nervous Activity and Security under LENOXe™ (xénon 100 % v/v) anesthesia
89196189|NCT00904384||HIV+|Patients with HIV infection living in the Autonomous Community of the Balearic Islands (CAIB), Spain
89196190|NCT00904384||Reference group|Same determinations as in HIV+ cases will be obtained in the control group of COPD patients without HIV infection as part of the study PAC-EPOC (FIS 05/2082)
89196191|NCT01037335|Placebo Comparator|control group|10 ml normal saline (NS) infiltrated into the harvest site, and 1 ml NS was administered intramuscularly.
89196192|NCT01037335|Active Comparator|intramuscular morphine|10 ml NS infiltrated into the harvest site and 5 mg morphine (1 ml) intramuscularly
89196193|NCT01037335|Active Comparator|donor site morphine|5 mg morphine (10 ml) infiltrated into the harvest site and 1 ml NS intramuscularly.
89196194|NCT00925210|Experimental|Sequential pEBUS - ENB|
89196195|NCT04604821|Experimental|Enhanced Milieu Teaching|Child-caregiver dyads receive up to 24 speech-language therapy sessions (50minutes, 2x per week for 3 months) where parents are taught by the interventionist to use Enhanced Milieu Teaching Strategies. Children and their families may continue to participate community-based educational programs.
89196196|NCT04604821|Other|Community Treatment as Usual|Child-caregiver dyads may continue to participate in community-based educational programs. Researchers provide up to 4 educational sessions to caregivers (50 minutes, every 3 weeks). During educational sessions parents are taught developmental milestones from the CDC Learn the Signs Act Early Public Health Campaign.
89196197|NCT02538952|Experimental|Xpert package|"There are three phases to this stepped-wedge trial: (1) the retrospective cohort (standard of care) phase, (2) the active comparator phase, where intensified TB case finding (ICF) interventions are in place but no Xpert device, and (3) the experimental phase of full Xpert package implementation that includes both ICF interventions and Xpert device activation. Interventions in the experimental phase therefore include: (a) adoption of the WHO-recommended 4-symptom TB screen for adults; (b) situating trained TB case-finding nurses in the 22 facilities; (c) training health facility personnel in TB diagnostic algorithms; and (d) Xpert device activation. The combination of the ICF interventions and rollout of the Xpert device is referred to as the Xpert package in this protocol."
89536129|NCT02449525|Experimental|perfusion of flaps by a bypass system|Support of perfusion of microvascular free flaps until ingrowth of vessels from the wound bed has taken place. The System works with a pressure controlled bypass to ensure low grade perfusion.
89536130|NCT02478593|Experimental|Experimental group|Group to receive educational booklet regarding risk/benefits of Benzodiazepine.
89536131|NCT02478593|No Intervention|Control group|Group to receive educational booklet regarding risk/benefits of exercise.
88906954|NCT04423939|Experimental|Hematopoietic Stem Cell Transplantation (HCT) Patients|20 HCT patients at Duke
88906955|NCT04423939|Experimental|Caregivers|20 HCT patients caregivers at Duke
89007473|NCT04473365||With parasite|For secondary outcome: effect of co-infection with parasite on COVID-19 severity Group 2 will constitute those with parasite co-infection
89426074|NCT05480982|Active Comparator|Pilates|"Participants in the comparison group will receive Pilates method using classic principles and exercises recommended by Joseph Pilates. No specific accessories or equipment will be used, allowing the exercises to be performed under any circumstances. Based on Pilates, 10 exercises were selected: Leg Pull Front, One Leg Circle, One Leg Kick, One leg stretch, Shoulder bridge, Side bend, Spine Stretch , Swimming, The hundred and The Saw. The main objective of the exercises is to improve physical capacities, including mobility, flexibility, muscle strength and activation of the power house center of force, with the therapeutic aim of a positive evolution of chronic non-specific low back pain. The one-hour sessions will be delivered once a week. Participants will be instructed to perform the set of exercises once a week without the supervision of the physiotherapist. The number of group sessions (up to 6 participants) will vary between 8 to 12."
89426075|NCT05478941|Active Comparator|Progressive Muscle Relaxation training via Zoom and Guided Imagery exposure|"A standardized protocol regarding the information on the training background is shared with participants. Then, they are invited to participate in four individual PMRT sessions (two sessions per week) deployed via Zoom.~The fifth session after a week (T1; day 7) is administered in-presence at the Virtual Reality laboratory (A10-A11)- University of Padova; here an in-imagination relaxing scenario is built up with the support of the Psychotherapist; then, participants are exposed to an in-vivo PMRT relaxing session conducted by the Psychotherapist, with the request to think about the in-imagination relaxing scenario, created before, during the progressive relaxation procedure. After two weeks (T2; day 14), at the follow-up phase, the therapist asks to recover the in-imagination relaxing scenario and relax, giving participants the time allowed for the last guided relaxing session."
89426076|NCT05478941|Experimental|Progressive Muscle Relaxation training via Zoom and personalized VR exposure|"PMRT sessions and expected time length are the same as for the first group. Differences regard the fifth session after a week (T1; day 7), where the relaxing scenario is built with the psychotherapist's support based on the VR's tools. Indeed, during the in-presence session, participants are exposed to a merged personalized relaxing VR scenario and PMRT session administered by the Oculus Quest 2 tool.~During the follow-up (T2; day 14), it is asked to recover the image and relax, making available the same time allowed for the last guided session."
89536132|NCT03199417|Experimental|Multiprofen/interventional|"A multimodal topical cream treatment with Ketoprofen, Baclofen, Amitryptiline, and lidocaine in a carrier gel. This topical formulation has been in use commercially under the trade name Multi-profen. This topical cream will be applied by the patient three times per day."
89536133|NCT03199417|Placebo Comparator|Control/Placebo Group|A identically packaged placebo cream treatment will be utilized in the control population.
88906956|NCT04416802|Experimental|PRP and Li-ESWT treatment|Participants diagnosed with erectile dysfunction will receive the combined treatment of platelet-rich plasma and low-intensity extracorporeal shockwave therapy.
88906957|NCT04401813|Experimental|IBI310|An open-label, single-arm, Ib study of the efficacy and safety of IBI310 combined with sintilimab in patients with advanced hepatocellular carcinoma
88906958|NCT04330950||Surgical Cohort|Preoperative: Battery of neurocognitive tests and questionnaires (MoCA, PHQ-9, Falls History, FIFE, STOPBANG, Nutritional Survey) Postoperative in PACU: NuDESC test Postoperative 30 days: 10 minute phone interview
89426077|NCT05478941|Experimental|Progressive Muscle Relaxation training based on audio-recording and personalized VR exposure|"A standardized protocol of information and the four PMRT sessions is administered individually based on an audio-track through the Moodle e-learning platform of the University of Padova.~During the fifth session after a week (T1; day 7), users are asked to participate in an in-presence session in which they are exposed to a merged personalized, relaxing VR scenario and a PMRT session administered based on the Oculus Quest 2 tool. The last follow-up session (T2; day 14) has the same features as the other groups."
88906959|NCT04314635|Active Comparator|TAU comparison group|TAU includes standard care modules (psychoeducation, coping, safety planning, problem solving, healthy lifestyle) administered to the teen while they are hospitalized on the inpatient unit. All teens, as part of TAU, also receive skills groups, individual treatment, and family planning meetings. All TAU families will receive a referral to an outpatient provider (standard care procedure) plus referral to specialized CHR case management services.
88906960|NCT04314635|Experimental|Brief intervention group|TAU + experimental intervention. The experimental group will receive all services provided to the TAU group (described above) and, additionally, the experimental intervention.The intervention includes 1 individual session for each teen and parent and 2 family sessions (focused on psychoeducation and motivational enhancement) with both the teen and parent, delivered during hospitalization (~45-60 minutes per session).
88906961|NCT04298853|Active Comparator|Standard|Infants randomized to the standard arm will receive morphine based on the current institutional treatment protocol: oral morphine 0.05 mg/kg/dose given every 3 hours, initiated if threshold Finnegan score is met. Once stabilized, dose will be weaned by 10% of peak dose per day until discontinuation.
88906962|NCT04298853|Experimental|Study|Infants randomized to the study arm will receive oral morphine 0.05 mg/kg/dose as needed for an elevated Finnegan score. May receive morphine as frequently as every 3 hours if needed.
88906963|NCT04238793|Experimental|Cohort 1|KLS-2031 low dose(1x10^11 VG/DRG) or Placebo
88906964|NCT04238793|Experimental|Cohort 2|KLS-2031 medium dose(1x10^12 VG/DRG) or Placebo
88906965|NCT04238793|Experimental|Cohort 3|KLS-2031 high dose(1x10^13 VG/DRG) or Placebo
88906966|NCT04232683|Experimental|Preoperative Tamsulosin|The study group will receive one oral dose .4mg of Tamsulosin prior to surgery.
88906967|NCT04232683|Placebo Comparator|Preoperative Placebo|The control group will receive one oral dose of placebo pill prior to surgery.
88906968|NCT04216810|Active Comparator|Exercise group|Exercise group
88906969|NCT04216810|Experimental|Exercise group and dry cupping|Exercise and dry cupping
88906970|NCT04201028|Experimental|Video Conferencing Health Coaching with devices|The DEV group participants will meet via the DiscoverHealth® app using their smartphone, and met 18 times with the registered dietitian (RD) to discuss exercise and diet goals. Participants in this group were provided with a blood pressure and body weight scale which connected to the CoachCare App®.
88906971|NCT04201028|Experimental|Video Conferencing Health Coaching with no devices|The NODEV group participants meet via the DiscoverHealth® app using their smartphone, and met 18 times with the registered dietitian (RD) for health coaching to discuss exercise and diet goals. Participants in this group did not receive devices.
88906972|NCT04200547|Experimental|Immunomonitoring-based follow-up|Post-operative follow-up of Crohn's disease patients will be done through the measurement of the residual rate of the drug adalimumab in the serum.
88906973|NCT04200547|Active Comparator|Standard follow-up|Post-operative follow-up of Crohn's disease patients will be based on clinical and biological parameters. This strategy is the standard strategy for post-operative follow-up of Crohn's disease patients.
88906974|NCT04184661||hypophosphatemic rickets patients|30 hypophosphatemic rickets patients older than 2 years will be included in this study
88906975|NCT04184661||controls patients|10 controls patients from pediatric nephrology unit without hypophosphatemic rickets, older than 2 years will be included in this study
88906976|NCT04177576||Patients with myeloproliferative neoplasms (MPN)|Patients diagnosed with Polycythemia Vera (PV) or Essential Thrombocythemia (ET)
88906977|NCT04112784|Experimental|INVSENSOR00039|All subjects who are enrolled into the test group and participate in data collection receive the noninvasive INVSENSOR00039 sensor.
88906978|NCT04108351|Experimental|Zopiclone|
88906979|NCT04108351|Placebo Comparator|Placebo|
88906980|NCT04101227|Experimental|Treatment Arm|AD04 (ondansetron)
88906981|NCT04101227|Placebo Comparator|Placebo Arm|Matching Placebo
88906982|NCT04096781|Experimental|Shared Decision Making Tool (SDMT)|
88906983|NCT04096781|Active Comparator|Usual Care|
88906984|NCT04049617|Experimental|Cohort 1: Evixapodlin 400 mg (Phase 1)|Participants will receive Evixapodlin 400 mg once daily for 21 days of each cycle.
88906985|NCT04049617|Experimental|Cohort 2: Evixapodlin 700 mg (Phase 1)|Participants will receive Evixapodlin 700 mg once daily for 21 days of each cycle.
88906986|NCT04049617|Experimental|Cohort 3: Evixapodlin 1000 mg (Phase 1)|Participants will receive Evixapodlin 1000 mg once daily for 21 days of each cycle.
88906987|NCT04049617|Experimental|Cohort 4: Evixapodlin 1500 mg (Phase 1)|Participants will receive Evixapodlin 1500 mg once daily for 21 days of each cycle.
89426078|NCT05477927|Experimental|CAR-T cell therapy|Dual-targeting VEGFR1 and PD-L1 CAR-T cells
89426079|NCT05472311|Other|Treat with thermal ablation|Women who screen positive for pre-cancer lesions of the cervix will be offered treatment with thermal ablation and the process of implementation evaluated using implementation science RE-AIM framework
89426080|NCT05471037|Active Comparator|Long Biliopancreatic Limb LRYGB|25 morbidly obese patients undergoing gastric bypass surgery, participating in SLIM Trial.
88906988|NCT04049617|Experimental|Cohort 5: Evixapodlin 1000 mg (Phase 1)|Participants are planned to receive Evixapodlin 1000 mg twice daily (BID) for 21 days of each cycle.
89426081|NCT05471037|Active Comparator|Short Biliopancreatic Limb LRYGB|25 morbidly obese patients undergoing gastric bypass surgery, participating in SLIM Trial.
89426082|NCT05471037|No Intervention|Control|15 normal weight control group without surgery.
89426083|NCT05464368|Experimental|Cohort 1: (A+; CDR = .5, 1; AD)|Unblinded and randomized to receive either 18F-RO948or 18F-MK6240 for PET Scan #1. PET scan #2 will be either 18F-RO948or 18F-MK6240 NOT received in PET scan #1. If a 3rdPET scanoccurs,this third scanwill always be [18F]GTP1.
89426084|NCT05464368|Experimental|Cohort 2: (A-; CDR=0; OC)|Unblinded and randomized to receive either 18F-RO948or 18F-MK6240 for PET Scan #1. PET scan #2 will be either 18F-RO948or 18F-MK6240 NOT received in PET scan#1.If a 3rdPET scan occurs, this third scan will always be [18F]GTP1.
89426085|NCT05464368|Experimental|Cohort 3: (A+; CDR = 0, .5, 1; AD)|Unblinded and randomized to receive 18F-RO948or 18F-MK6240 or [18F]GTP1for PET Scan #1. PET scan #2 will be 18F-RO948or 18F-MK6240 or [18F]GTP1NOT received in PET scan #1. PET scan # 3 will be 18F-RO948or 18F-MK6240 or [18F]GTP1NOT received in PET scan #1 or #2. Efforts will be made to include about 1/3 CDR = 0; 1/3 CDR = .5; 1/3 CDR = 1 in Cohort 3. Efforts will also be made to completethe study with about equal numbers of subjects whose PET scan #1 start with each of the three tracers.
89426086|NCT05463042|Experimental|Intermittent Hypoxia|Participants will receive intermittent hypoxia and perform balance and gait assessments before and after the intermittent hypoxia session.
89426087|NCT05463042|Sham Comparator|Normoxia (sham)|Participants will receive normoxia and perform balance and gait assessments before and after the normoxia session.
88906989|NCT04049617|Experimental|Cohort 1 Substudy: Evixapodlin 400 mg (Phase 1)|Participants will receive Evixapodlin 400 mg once daily for 21 days of each cycle.
88906990|NCT04049617|Experimental|Cohort 2 Substudy: Evixapodlin 700 mg (Phase 1)|Participants are planned to receive Evixapodlin 700 mg once daily for 21 days of each cycle.
88906991|NCT04049617|Experimental|Cohort 3 Substudy: Evixapodlin 1000 mg (Phase 1)|Participants will receive Evixapodlin 1000 mg once daily for 21 days of each cycle.
88906992|NCT04049617|Experimental|Dose Expansion (Phase 2)|Dose expansion is planned to begin when the recommended Phase 2 dose (RP2D) will be determined.
88906993|NCT04047004|Experimental|High-risk gastric cancer patients|The study population of high-risk gastric cancer patients will be offered one session of PIPAC immediately after laparoscopic removal of the stomach.
88906994|NCT03944798|Active Comparator|Surveillance Arm I|Clinical assessment and chest radiograph (CXR) every six months for two years
88906995|NCT03944798|Experimental|Surveillance Arm II|Clinical assessment and CXR every three months for two years
88906996|NCT03944798|Experimental|Surveillance Arm III|Clinical assessment and chest computed tomography (CT) every six months for two years
88906997|NCT03944798|Experimental|Surveillance Arm IV|Clinical assessment and chest CT every three months for two years
88906998|NCT03911154|Experimental|SmartSleep Continuous Fixed Interval modality|"This study uses within subject comparison. For each subject, the order of 3 SmartSleep modalities for each of the 4 nights of sleep restriction will be randomized. All subjects will receive all 3 stimulation modalities and a SHAM condition.~This study arm tests the SmartSleep Continuous Fixed Interval stimulation modality during sleep relative to the SHAM condition. The Continuous Fixed Interval is the delivery of auditory tones a 1 Hz inter-tone interval stimulation."
88906999|NCT03911154|Experimental|SmartSleep Block modality|"This study uses within subject comparison. For each subject, the order of 3 SmartSleep modalities for each of the 4 nights of sleep restriction will be randomized. All subjects will receive all 3 stimulation modalities and a SHAM condition.~This study arm tests the SmartSleep Block stimulation modality during sleep relative to the SHAM condition. The Block is the delivery of auditory tones for 5 seconds on versus 5 seconds off."
89426088|NCT05458986|Experimental|Arm 1 (educational video)|Patients watch an educational video about the importance of abnormal FIT results, the implications if follow-up colonoscopy is not completed, and demonstrate the steps to complete a colonoscopy.
89426089|NCT05458986|Active Comparator|Arm 2 (usual care)|Patients receive usual care and do not watch the educational video.
89530872|NCT02501057|Active Comparator|Clinician's Guide|"The Baseline intervention includes a brief meeting (20 minutes or less) with a clinic staff member to discuss drinking and HIV medication adherence. The clinic staff member provides feedback on the participant's drinking, helps the participant set a drinking goal, and make suggestions to help the participant reduce their drinking. Participant receives a booklet called Rethinking Drinking that includes information about alcohol and tips for cutting down on alcohol use or quitting drinking. 30- and 60-day visits last about 10 minutes each, and include a meeting with the clinic staff member again to discuss drinking and HIV medication adherence, and to get additional feedback."
88907000|NCT03911154|Experimental|SmartSleep In-Phase Adjustable modality|"This study uses within subject comparison. For each subject, the order of 3 SmartSleep modalities for each of the 4 nights of sleep restriction will be randomized. All subjects will receive all 3 stimulation modalities and a SHAM condition.~This study arm tests the SmartSleep In-Phase Adjustable stimulation modality during sleep relative to the SHAM condition. The In-Phase Adjustable is the constant stimulation with auditory tones delivered during each upstate of the slow wave."
88907001|NCT03911154|Sham Comparator|SHAM condition|"This study uses within subject comparison. For each subject, the order of 3 SmartSleep modalities for each of the 4 nights of sleep restriction will be randomized. All subjects will receive all 3 stimulation modalities and a SHAM condition.~This study arm is the SHAM condition, during which participants wore the SmartSleep device, however no auditory tones were delivered."
88907002|NCT03893435|Experimental|Sacubitril/Valsartan|In successfully revascularized post-AMI patients with LVEF ≤40% Sacubitril/Valsartan with the recommended starting dose: 24 mg/26 mg PO BID. After 2-4 weeks, the dose will be doubled to the target maintenance dose of 97 mg/103 mg PO BID (if tolerated) for 6 months.
88907003|NCT03893435|Active Comparator|Valsartan|In successfully revascularized post-AMI patients with LVEF ≤40% Valsartan with an initial dose of 40 mg PO BID, with subsequent titrations to target maintenance dose of 160 mg BID as tolerated.
88907004|NCT03853837||Prospective Fontan patients|Fontan patients to be enrolled and complete study tests/procedures
88907005|NCT03853837||Retrospective Fontan patients|Fontan patients to be retrospectively reviewed and used as control subjects
88907006|NCT03818074|Experimental|Boston Wavewriter (1000Hz) spinal cord stimulation|To investigate the response to high frequency (1000Hz) in patients who are due to have spinal cord stimulation for neuropathic back pain.
88907007|NCT03813121|Experimental|midazolam intravenous infusion|single midazolam infusion (0.02 mg/kg over 20 minutes)
88907008|NCT03813121|Placebo Comparator|placebo intravenous infusion|single placebo infusion (saline over 20 minutes)
88907009|NCT03813121|Experimental|ketamine intravenous infusion|single ketamine infusion (0.5 mg/kg over 20 minutes)
88907010|NCT03810781||Cervical Spondylotic Myelopathy (CSM)|Degenerative cervical myelopathy, encapsulates a cascade of events leading to significant degenerative changes in discs, formation of osteophytes, facet hypertrophy, calcification of the posterior longitudinal ligament and ligamentous flavum with resultant canal stenosis and segmental instability.
88907011|NCT03781778|Experimental|Group I (resistant starch foods)|Patients eat a diet consisting of resistant starch foods daily for 8 weeks.
88907012|NCT03781778|Active Comparator|Group II (foods with regular corn starch)|Patients eat a diet consisting of regular corn starch foods daily for 8 weeks.
89007474|NCT04472286||Pediatric Cancer Survivors|Children and adolescents who have completed treatment of for acute lymphoblastic leukemia (ALL) and lymphoma.
89007475|NCT04470011||Patients who initiated HIV treatment|
89196198|NCT02538952|Active Comparator|Active comparator|"There are three phases to this stepped-wedge trial: (1) the retrospective cohort (standard of care) phase, (2) the active comparator phase, where intensified TB case finding (ICF) interventions are in place but no Xpert device, and (3) the experimental phase of full Xpert package implementation that includes both ICF interventions and Xpert device activation. Interventions in the active comparator phase therefore include only: (a) adoption of the WHO-recommended 4-symptom TB screen for adults; (b) situating trained TB case-finding nurses in the 22 facilities; and (c) training health facility personnel in TB diagnostic algorithms. There is no Xpert device activation in this phase. Only standard of care microscopy-based TB diagnostic algorithms are available during this phase."
89196199|NCT02538952|No Intervention|Standard of Care|"There are three phases to this stepped-wedge trial: (1) the retrospective cohort (standard of care) phase, (2) the active comparator phase, where intensified TB case finding (ICF) interventions are in place but no Xpert device, and (3) the experimental phase of full Xpert package implementation that includes both ICF interventions and Xpert device activation. There are no interventions in the standard of care arm (retrospective cohort). There are no ICF interventions and no Xpert device activations in this phase. Only the standard of care TB case finding procedures and microscopy-based TB diagnostic algorithm are available during this phase."
89196200|NCT04015492|Experimental|BAY94-9027 / Adynovi|Treatment sequence A-B with washout before each treatment
89196201|NCT04015492|Experimental|Adynovi / BAY94-9027|Treatment sequence B-A with washout before each treatment
89196202|NCT04015570|Experimental|High Volume Plasma Exchange with SMT|"PLASMA EXCHANGE is therapeutic procedure in which blood of the patient is passed through a medical device which separates plasma from other components of blood. The plasma is removed and replaced with a replacement solution such as colloid solution (e.g., albumin and/or plasma) or a combination of crystalloid/colloid solution.Plasma exchange leads to removal of abnormal circulating plasma factor or a physiologic factor produced in excess (IG, NH3,protein bond toxins )and also exert a immunomodulatory activity.~Standard Medical Treatment (Albumin + High Caloric Diet)"
89196203|NCT04015570|Active Comparator|Standard Medical Treatment|Standard Medical Treatment (Albumin + High Caloric Diet)
89196204|NCT00904462|Experimental|Lidocaine 5% patch|Lidocaine 5% patch (Lidoderm®, Endo Pharmaceuticals Inc.), 1⅓ patches applied on each affected knee once every 24 hours
89196205|NCT00904462|Placebo Comparator|Placebo patch|Matching placebo patch, 1⅓ patches applied on each affected knee once every 24 hours
89196206|NCT00396565|Experimental|ER OROS paliperidone|Extended Release (ER) Osmotic Controlled-Release Oral Delivery System (OROS) paliperidone
89196207|NCT00396565|Placebo Comparator|Placebo|
89007476|NCT04470011||Service providers at study facilities|
89007477|NCT04468399||Patients who initiated HIV treatment|
89007478|NCT04468399||Service providers at study facilities|
89196208|NCT00396565|Active Comparator|Olanzapine|
89196209|NCT00925366|Other|Shoulder rotator cuff tear|Shoulder rotator cuff tear
89196210|NCT03224026||Fever Without Source|Clinical diagnosis of FWS (fever of less than 7 days with no cause determined by the history and the physical exam).
89196211|NCT03224026||Healthy control|Children visiting the hospital due to a non-infectious, non inflammatory etiology
89007479|NCT04459299||STEMI patients with clinical indication for primary PCI|Subjects with a clinical indication of STEMI.
89007480|NCT04443530||Coronary artery stenosis|Patients with coronary artery disease
89426090|NCT05457439|Experimental|Experimental Group|Will be evaluated at baseline and will be intervened for 7 weeks, receiving educational workshops twice a week, addressing the target behaviors. They will also be prescribed a personalized food plan, will receive daily messages through the mobile application, and will have a doubt resolution chat. They will have a digital forum to post photos and comments about their food intake, and physical activity performance, and to like and comment on other participants' photos. They will be asked to enter food records and photos of their food intake into the mobile application, for which they will receive points for performing the expected behavior in a token economy. They will have access to their data for auto-monitoring. In week 8, the experimental group will be evaluated and divided into two sub-groups. One will be completely stopped intervening (n = 25) and one will continue receiving messages through the mobile app, but will no longer have workshops and food plan prescriptions (n = 25).
89007481|NCT04421950|Active Comparator|Wild Blueberry Supplement|30 grams of wild blueberry powder per day in foods items provided to them
89007482|NCT04421950|Placebo Comparator|Placebo supplement|Food items will be provided to them without the wild blueberry power.
89007483|NCT04418596||Elite Soccer Players|Adolescent male aged 12-16 years old elite athletes that are recruited from special sport school in Leuven-Belgium and play football at a high level.
89007484|NCT04418596||Recreational Soccer players (control)|Adolescent male aged 12-16 years old recruited from ordinary school in Flanders Belgium that play soccer or any other sport recreationally with no high intensity training
89007485|NCT04398537|Experimental|5mm retraction of clip deployment apparatus|The participants in this group will have clip placement 5mm in front of the biopsy site site.
89007486|NCT04398537|Active Comparator|no retraction of clip deployment apparatus|These participants will the clip delivered at the biopsy site.
89007487|NCT04392011|Experimental|Arm 1|"Six non-naive* subjects (3 males, 3 females) will be administered a single low dose of a well-characterized kratom product (2 g) by mouth as a tea. These subjects may or may not choose to participate in Arms 2a and 2b. For subjects who will participate in Arms 2a and 2b, a washout period of 7 days will separate Arm 1 and Arm 2. Plasma will be collected from 0-120 hours and during the washout period. Urine will be collected from 0-120 hours.~*Non-naive subjects are defined as intermittent users who consume 2-8 g kratom at least once per month but no more than three times daily within the last six months prior to screening and are willing to abstain for several weeks."
89007488|NCT04392011|Experimental|Arm 2|"Arm 2 is divided into Arms 2a and 2b. Twelve non-naive subjects (6 males, 6 females) will participate in Arm 2a. Subjects who participate in this study arm will be administered an oral probe drug cocktail of dextromethorphan HBr (2 x 15 mg liquid capsules; 30 mg total) and midazolam HCl (1.25 mL of 2 mg/mL syrup; 2.5 mg total). Plasma will be collected from 0-24 hours. Urine will be collected from 0-24 hours. A washout period of 7 days will separate Arms 2a and 2b.~For Arm 2b, the same 12 subjects will be administered a combination of a well-characterized kratom product (2 g) by mouth as a tea with an oral probe drug cocktail consisting of dextromethorphan HBr (2, 15 mg liquid capsules; 30 mg total) and midazolam HCl (1.25 mL of 2 mg/mL syrup; 2.5 mg total). Plasma will be collected from 0-12 hours and during a midpoint collection within 5 days of the 24-hour blood collection. Urine will be collected from 0-24 hours."
89007489|NCT04365569|Experimental|Individualized, nutrition and physical activity intervention|Initial in-person consult with a registered dietitian, with further in-person follow-ups and monthly telephone consults
89426091|NCT05457439|No Intervention|Control Group|The control group will be evaluated at baseline and will not be intervened. Anyway, they will be evaluated at weeks 8 (as monitoring) and 15, at the end of the intervention.
89426092|NCT05443009|Active Comparator|Lidocaine|"Forty-eight (48) children will receive conventional infiltration anesthesia (buccal infiltration injection followed by complementary injections on the palatal region) with 2% lidocaine and 1:100,000 epinephrine at a dose previously calculated by weight. Two-thirds of the anesthetic will be injected into the buccal area and 1/3 into the palatal area.~Other Names: Control Group"
89007490|NCT04329429|Experimental|RC48-ADC|Participants will be treated with RC48-ADC 2.5 mg/kg, once every 2 weeks (Q2W) until investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or participant's decision to withdraw from therapy, or death (whichever occurs first)
89007491|NCT04324294|Experimental|Contrast EUS|Undergoing EUS for pancreatic indication (cyst, pancreatitis, mass)
89007492|NCT04323046|Experimental|Neoadjuvant nivolumab and adjuvant nivolumab|"NEOADJUVANT: Patients receive nivolumab IV over 30 minutes 14 days before undergoing standard of care surgical resection.~ADJUVANT MAINTENANCE: After completion of neoadjuvant infusion, patients receive nivolumab IV over 30 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
89007493|NCT04298593|Other|ECG monitoring|All patient will be under telemetry
89007494|NCT04288414||fNIRS applied|All of the participants' brain activity was evaluated with fNIRS.
89007495|NCT04283604|Experimental|ADHD with MPH|ADHD participants, taking MPH before the second session
89007496|NCT04283604|No Intervention|ADHD no MPH|ADHD participants will perform motor tests in both session, without any intervention, for evaluation of learning effect among ADHD participants.
89007497|NCT04283604|No Intervention|Healthy participants|Non-ADHD participants will serve as a control group for learning effect on motor tests
89007498|NCT04273048|Active Comparator|Diet and Exercise|Group 1 = Diet Intervention group: They will be asked to follow a personalized diet during study period and record what they eat. The meal plan for this study is Mediterranean style and nutritionally complete for 8 to 12 weeks or until oocyte retrieval procedure. Exercise Intervention: Exercise 3 times/week at a gym of their choice or at home for 8 to 12 weeks or until oocyte retrieval procedure. Exercises will be light intensity and short duration at first and will gradually increase to moderate intensity and longer duration during the first 3 weeks. They will also be encouraged to walk an average 10,000 steps per day and wear a pedometer to monitor progress.
89196212|NCT02538562||Study Population|Available tumor samples from patients with gastric or gastroesophageal junction cancer will be analyzed. No study visits or interventions are planned.
89536134|NCT02482727|No Intervention|non-occlusion training group|The control (non-occlusion training) group will follow the standard post-operative distal radius fracture rehabilitation protocol. Treatment will include passive, active assistive,active range of motion (P/AA/AROM) to wrist, forearm and hand; desensitization as needed; edema control as needed; heat/cold modalities as needed; and strengthening exercises.
89196213|NCT00925444|Experimental|FOREseal|
89196214|NCT00925444|Active Comparator|Stapling|
89196215|NCT00904774||premature neonates|gestational age less than 28 weeks
89536135|NCT02482727|Experimental|occlusion training with DELFI PTS ii tourniquet|The occlusion training group will follow the same protocol as described above but will utilize occlusion training with the strengthening exercises. Investigators will use an established occlusion training protocol already being. Intervention: occlusion training with tourniquet (DELFI PTS ii portable tourniquet system)
89536136|NCT03212131|Experimental|Normal hepatic function|Subjects with normal hepatic function
89536137|NCT03212131|Experimental|Mild hepatic impairment|Subjects with mild hepatic impairment
89007499|NCT04273048|No Intervention|Standard Care|Group 2 = Standard: They will receive standard care from the Little Rock Fertility Center.
89536138|NCT03212131|Experimental|Moderate hepatic impairment|Subjects with moderate hepatic impairment
89536139|NCT03314909|Experimental|Hemodialysis (HD)|Patients in this group would receive hemodialysis for 3 days consecutively besides conservative therapy.
89536140|NCT03314909|Experimental|Hemoperfusion (HP)|Patients in this group would receive hemoperfusion for 3 days consecutively besides conservative therapy.
89536141|NCT03314909|Experimental|HP-HD|Patients in this group would receive hemoperfusion and hemodialysis concurrent therapy for 3 days consecutively besides conservative therapy.
89196216|NCT00904852|Experimental|Tandutinib, bevacizumab, and temozolomide|tandutinib in combination with temozolomide and bevacizumab following concurrent radiation therapy and temozolomide treatment.
89196217|NCT00394771|Experimental|Low Dose DR-1031|42 days combination active tablets (20 mcg EE /150 mcg LNG) followed by 21 days combination active tablets (25 mcg EE/150 mcg LNG) followed by 21 days combination active tablets (30 mcg EE/ 150 mcg LNG) followed by 7 days of 10 mcg EE tablets.
89196218|NCT00394771|Experimental|Midrange Dose DR-1031|21 days combination active tablets (20 mcg EE /150 mcg LNG) followed by 42 days combination active tablets (25 mcg EE/ 150 mcg LNG) followed by 21 days combination active tablets (30 mcg EE/ 150 mcg LNG) followed by 7 days of 10 mcg EE tablets.
88907013|NCT03778177|Experimental|Trigeminal Neuralgia Pain Diagnosis|Healthy patients between the ages of 18-75 who have been diagnosed with moderate to severe Trigeminal Neuralgia Pain. The study team will perform transcranial electrical brain stimulation using either electrodes that are in the form of two salt-water soaked sponges attached to the head or a set of smaller gel-covered disk electrodes that fit inside the electrode holders of the EEG cap. During stimulation a weak direct or alternating current will be passed through the stimulating electrodes. Stimulation may last 20 to 30 minutes.
88907014|NCT03744117|Experimental|Intervention Arm|There is a single arm in this study. All patients will be assigned to receive the intervention, which is a palliative care consultation delivered by telemedicine.
88907015|NCT03710590|Active Comparator|Cigarette smokers|
88907016|NCT03710590|Active Comparator|Electronic cigarette users|
88907017|NCT03676725|Experimental|All subjects|All subjects get the lidocaine taste test
88907018|NCT03624816|Experimental|Restylane Defyne|injection with Restylane Defyne
88907019|NCT03624816|No Intervention|Control|no-treatment control
88907020|NCT03607825|Experimental|Neurapheresis System|CSF filtration
88907021|NCT03572985|Other|Blood alcohol concentration (BAC) level 0.025 %|Drink beverages containing alcohol calculated to have a blood alcohol concentration of 0.025%
88907022|NCT03572985|Other|BAC level 0.05 %|Drink beverages containing alcohol calculated to have a blood alcohol concentration of 0.05%
89536142|NCT03314909|No Intervention|Conservative|Patients in this group would receive basic supportive treatment, gastric lavage, glucosteroid and immunosuppressive drugs without any hemopurification.
88907023|NCT03572985|Other|BAC level 0.09 %|Drink beverages containing alcohol calculated to have a blood alcohol concentration of 0.09%
88907024|NCT03572985|Other|BAC level 0 %|Drink beverages containing non alcohol
88907025|NCT03566615|Active Comparator|Water|Residual air in the colon will be removed, water will be infused to guide insertion through an airless lumen. Infused water will be removed by suction, along with residual fecal debris, predominantly during insertion.
88907026|NCT03566615|Experimental|CAP-straight|A straight transparent cap was fitted to the colonoscope per manufacturer instruction.Residual air in the colon will be removed, water will be infused to guide insertion through an airless lumen. Infused water will be removed by suction, along with residual fecal debris, predominantly during insertion.
88907027|NCT03566615|Experimental|CAP-daisy|"A daisy cap transparent cap was fitted to the colonoscope per manufacturer instruction.Residual air in the colon will be removed, water will be infused to guide insertion through an airless lumen. Infused water will be removed by suction, along with residual fecal debris, predominantly during insertion.~Note:~IRB Approval date for the use of Endocuff at St. Barbara Hospital, Iglesias (CA), Italy, was obtained on 3/8/2017.~IRB Approval date for the use of Endocuff at Evergreen General Hospital, Taipei, Taiwan, was obtained on 3/18/2021."
88907028|NCT03548207|Experimental|JNJ-68284528|After lymphodepletion JNJ-68284528 will be administered as a single infusion.
89196219|NCT00394771|Experimental|High Dose DR-1031|21 days combination active tablets (20 mcg EE /150 mcg LNG) followed by 21 days combination active tablets (25 mcg EE/150 mcg LNG) followed by 42 days combination active tablets (30 mcg EE/ 150 mcg LNG) followed by 7 days of 10 mcg EE tablets.
89196220|NCT00394771|Active Comparator|Seasonale|84 days of combination active tablets, each containing 30 mcg EE and 150 mcg LNG, followed by 7 days of placebo tablets.
89196221|NCT00396409|Experimental|Depigold+Omalizumab|Xolair® (Omalizumab, double-blind core study period only), Depigoid® (grass/rye pollen 50/50)
89196222|NCT00396409|Experimental|Depigoid+Placebo|Depigoid® (grass/rye pollen 50/50) + Placebo
89196223|NCT02924376|Experimental|Cohort A Pemigatinib|Pemigatinib in subjects with FGFR2 translocation with a documented fusion partner in central laboratory report
89196224|NCT02924376|Experimental|Cohort B Pemigatinib|Pemigatinibin subjects with other FGF/FGFR alterations
89196225|NCT02924376|Experimental|Cohort C Pemigatinib|Pemigatinib in subjects negative for FGF/FGFR alteration
89196226|NCT03890874||First year medical students|First year medical students of jubilee mission medical college and research institute
89196227|NCT00921492|Experimental|Low-frequency electro-acupuncture|
89196228|NCT00921492|Active Comparator|Meeting a therapist - attention|
89196229|NCT02564328|Active Comparator|Intravenous stem cell transplantation|Intravenous transplantation of autologous bone marrow mesenchymal stem cell plus conventional treatment include rehabilitation
89196230|NCT02564328|No Intervention|Conventional treatment|Control group receive conventional stroke treatment that include rehabilitation
89196231|NCT03687762|Active Comparator|Cognitive Therapy (CT) Condition|"Participants randomized to this arm will be taught to recognize the relationships between thoughts, feelings, behaviors, and pain. This technique will help participants: (1) identify negative or unrealistic automatic thoughts; (2) evaluate automatic thoughts for accuracy, identify sources of distorted thoughts, recognize the connection between automatic thoughts and emotional/physical shifts; (3) challenge negative, distorted automatic thoughts via weighing the evidence; (4) develop new realistic alternative cognitive appraisals; and (5) practice applying new rational appraisals and beliefs."
89196232|NCT03687762|Active Comparator|Mindfulness Meditation (MM) Condition|Participants randomized to this arm will receive training in mindfulness meditation, specifically Vipassana, which is the form of meditation typically implemented in mindfulness research. With this technique, the emphasis is placed upon developing focused attention on an object of awareness, e.g., the breath. This focus is then expanded to include a more open, non-judgmental monitoring of any sensory, emotional, or cognitive events.
89196233|NCT03687762|Active Comparator|Activation Skills (AS) Condition|Participants randomized to this arm will be educated about the role of inactivity and behavioral avoidance in chronic pain and functioning. They will learn how to be aware of the activities they avoid because of pain, and how to set effective goals so that, step by step, they can start being more active and resume some activities they enjoyed in the past but are currently avoiding. Explanation and practice of a set of specific skills - including appropriate pacing skills - to facilitate an increase in appropriate activity level will be provided.
89196234|NCT04060836|Experimental|group A|Participants will be assigned to group A or B with a scale of 1:1 , i.e. infuse reference drug Xyntha (group A), then experimental drug (group B). All participants who completed the study will enter the prophylaxis group study.
89196235|NCT04060836|Experimental|group B|Participants will be assigned to group A or B with a scale of 1:1 , i.e. infuse experimental drug (group B), then reference drug Xyntha (group A). All participants who completed the study will enter the prophylaxis group study.
89196236|NCT00693420|Experimental|1|Bimatoprost 0.03% solution
89196237|NCT00693420|Placebo Comparator|2|Vehicle solution
89196238|NCT00742794||1|Hymenoptera sting allergic patients under immunotherapy
89196239|NCT04034524||New users of GLP1 receptor agonists (exposure)|
89196240|NCT04034524||New users of basal insulin (reference)|
89196241|NCT00925834|Placebo Comparator|Sodium chloride|"Control arm A: Hidden intracoronary infusion of 5ml sodium chloride"
89196242|NCT00925834|Experimental|Sodium chloride and verbal suggestions|"Experimental arm A: Open intracoronary infusion of 5ml sodium chloride plus the suggestion of a vasodilatory effect on coronary vessels"
89196243|NCT00925834|Active Comparator|Nitroglycerin|"Control arm B: Hidden intracoronary infusion of 0.01mg nitroglycerin in 5 ml sodium chloride"
89196244|NCT00925834|Experimental|Nitroglycerin and verbal suggestions|"Control arm B: Open intracoronary infusion of 0.01 mg nitroglycerin in 5 ml sodium chloride plus the suggestion of a vasodilatory effect on cardiac vessels"
89196245|NCT04034680|Experimental|Home care services - Intervention group|Totally 5 municipalities (25 persons with dementia) will be included in the intervention group, and will receive training in the TIME model. This includes two hours of lectures about dementia and neuropsychiatric symptoms (NPS) and three hours of training and roleplay in using the TIME model. The staff of the home care service will receive the TIME manual and access to the TIME website with access to additional educational and information files. From each municipality, three staff members, called TIME administrators, will receive additional three hours of lectures and roleplay in TIME, and will thereafter have the responsibility for performing the intervention.
88907031|NCT03532490|Active Comparator|Roflumilast 500 mcg oral tablet|500 mcg roflumilast oral tablets will be taken every other day for the first two weeks. If participant tolerates the drug, the tablet will be taken once daily.
88907032|NCT03532490|Placebo Comparator|Placebo oral tablet|500 mcg placebo oral tablets will be taken every other day for the first two weeks. If participant tolerates the drug, the tablet will be taken once daily.
88907033|NCT03520517|Experimental|BHV-0223|riluzole 40 mg sublingual tablet
88907034|NCT03479606|Experimental|Immediate Intervention|Participants will receive 24 online emotional regulation skills-training sessions twice weekly and will complete online questionnaires sent every four weeks throughout baseline, the 12-week intervention, and 12-week follow-up.
88907035|NCT03479606|Active Comparator|Waitlist Intervention|After a 12-week wait-period without any intervention, participants will receive 24 online emotion regulation skills-training sessions. Every four weeks, participants will complete online questionnaires every throughout baseline, 12-week wait-period, 12-week intervention, and 12-week follow-up.
88907036|NCT03468335|Other|Single Arm|"Cancer treatment for PDAC:~Nal-IRI (4.3 mg/ml) 70 mg/m2 as 1.5 hour infusion~5-FU 2400 mg/m2 as 46 hour infusion~Folinic acid 400 mg/m2 as 0.5 hour infusion~all on D1 of each cycle; Cycle q2w ± 5 days~Treatment until progressive disease or intolerable toxicity or withdrawal of consent."
88907037|NCT03465722|Experimental|avapritinib|300 mg PO QD
88907038|NCT03465722|Active Comparator|regorafenib|160 mg PO QD
89007500|NCT04271072||Study|"Parturients that underwent cesarean delivery and is POSITIVE for the composite outcome of either:~perinatal depression (Edinburgh postnatal depression scale >=10 during pregnancy or within 3 months after delivery), and/or~persistent pain (pain score >=3 at pelvic or lower abdominal areas at 3 months after delivery)"
89007501|NCT04271072||Control|"Parturients that underwent cesarean delivery and is NEGATIVE for the composite outcome of both:~perinatal depression (Edinburgh postnatal depression scale >=10 during pregnancy or within 3 months after delivery), AND~persistent pain (pain score >=3 at pelvic or lower abdominal areas at 3 months after delivery)"
89007502|NCT04250753||Patients with lumbar spinal stenosis|
89007503|NCT04242264|Experimental|Arm 1|Vaccine: 1 ml of saline containing10^6 or 5X10^5 cfu of the WRSs2 vaccine in 30 ml of sterile normal saline administered orally on Day 1 and Day 29. Challenge: 1 ml of S. sonnei 53G challenge in 30 ml of sterile saline administered orally on Day 57. N=40
89007504|NCT04242264|Experimental|Arm 2|Placebo + Vaccine: 30 ml of sterile normal saline placebo administered orally on Day 1 and 1 ml of saline containing 10^6 cfu of the WRSs2 vaccine in 30 ml of sterile normal saline administered orally on Day 29. Challenge: 1 ml of S. sonnei 53G challenge in 30ml of sterile saline administered orally on Day 57. N=40
89007505|NCT04242264|Placebo Comparator|Arm 3|Placebo: 31 ml of sterile normal saline placebo administered orally on Day 1 and Day 29. Challenge: 1 ml of S. sonnei 53G challenge in 30 ml of sterile saline administered orally on Day 57. N=40
89007506|NCT04185038|Experimental|ARM A (Tumor Cavity Infusion)|Patients with non-DIPG supratentorial tumors for which CAR T cells will be delivered into the tumor resection cavity
89007507|NCT04185038|Experimental|ARM B (Ventricular System Infusion)|Patients with non-DIPG either infratentorial tumors or leptomeningeal tumors for which the CAR T cells will be delivered into the ventricular system
89007508|NCT04185038|Experimental|ARM C (DIPG)|Patients with DIPG for whom CAR T cells will be delivered into the ventricular system
89007509|NCT04176939|Experimental|HZ/su Group|"Eligible adult participants with renal transplant taking daily chronic immunosuppressive therapy who had a complete 2-dose Herpes Zoster (HZ/su) vaccination course in the primary ZOSTER-041 (NCT02058589) study.~47 of these participants further received 1 or 2 additional doses of HZ/su vaccine in the revaccination phase of the current ZOSTER-073 (NCT04176939) study, first dose at Month 24 and second dose at Month 25."
89007510|NCT04170374||Patients who initiated HIV treatment|
89007511|NCT04170374||Service providers at study facilities|
89007512|NCT04168242|Experimental|Experimental arm|Patients have scalp cooling during the chemotherapy period
89007513|NCT04168242|Placebo Comparator|Control arm|Patients do not have scalp cooling during the chemotherapy period
89007514|NCT04144933|Experimental|Opioid-free General Anesthesia (OFA)|Opioid-free preoperative medications, Opioid-free pre-intubation medications, Opioid-free maintenance medication, postoperative nausea and vomiting prophylaxis.
89007515|NCT04144933|Active Comparator|Traditional Opioid-containing General Anesthesia (TOA)|Opioid-sparing preoperative medications, Opioid-containing pre-intubation medications, Opioid-containing maintenance medications, postoperative nausea and vomiting prophylaxis.
89007516|NCT04130854|Experimental|APX005M on day 3 of RT & day 3 of cycles 1-5 of mFOLFOX|On Day 3 of Cycles 1-5 of each mFOLFOX treatment, participants will receive another dose of APX005M. The sequence of administration of APX005M in combination with mFOLFOX. In Cycle 6, participants will receive only mFOLFOX. After completing the last planned dose of mFOLFOX, participants will be considered off-protocol directed therapy and undergo planned TME, per institutional standards, and proceed to the follow-up portion of this study.
89007517|NCT04130854|Active Comparator|Radiation Therapy 5Gy x 5 days, mFOLFOX|Participants randomized to Arm 2 will receive short-course RT and mFOLFOX regimen, except that participants will not receive any of the study drug. After completing the last planned dose of mFOLFOX, participants will be considered off-protocol directed therapy and undergo planned TME, per institutional standards, and proceed to the follow-up portion of this study.
89007518|NCT04124120|Experimental|Single Arterial Graft (SAG) group|Patients in this group will receive a single arterial graft which will be the left internal thoracic artery. Additional grafts used in this group will all be venous grafts.
89007519|NCT04124120|Experimental|Multiple Arterial Graft (MAG) group|Patients in the group will receive multiple arterial grafts. All patients will receive at least two arterial grafts, the left internal thoracic artery with the addition of either the right internal thoracic artery or the radial artery as the second conduit. Some patients may receive additional arterial grafts consisting of the radial artery, the right internal thoracic artery, or the right gastroepiploic artery.
89007520|NCT04106258|Experimental|low light dose|PDT is applied to the patients at low light dose : power density of 60mW/cm2 for 20 minutes
89007521|NCT04106258|Experimental|high light dose|PDT is applied to the patients at high light dose : power density of 75mW/cm2 for 20 minutes
89007522|NCT04092673|Experimental|Part 1: Sequential escalation (Completed)|eFT226 administered IV weekly in 21-day cycles; dose escalated in sequential cohorts after subjects enrolled in a given cohort have completed DLT evaluation period.
89007523|NCT04092673|Experimental|Part 2: Cohort Expansion, Monotherapy, NSCLC, KRAS (EMNK)|Cohort EMNK
89007524|NCT04092673|Experimental|Part 2: Cohort Expansion, Monotherapy, Breast, FGFR (EMBF)|Cohort EMBF
89007525|NCT04092673|Experimental|Part 2: Cohort Expansion, Monotherapy, Breast, HER2 (EMBH)|Cohort EMBH
89007526|NCT04092673|Experimental|Part 2: Cohort Expansion, Combination, Breast, Fulvestrant (ECBF)|Cohort ECBF; Combination therapy partner administered per SOC at the approved dose.
89007527|NCT04092673|Experimental|Part 2: Cohort Expansion, Combination, NSCLC, Sotorasib (ECNS)|Cohort ECNS; Combination therapy partner administered per SOC at the approved dose.
89007528|NCT04092673|Experimental|Part 2: Cohort Expansion, Combination, Breast, Fulvestrant+Abemaciclib (ECBF+A)|Cohort ECBF+A; Combination therapy partner administered per SOC at the approved dose.
89007529|NCT04092673|Experimental|Part 2: Cohort Expansion, Combination, Breast, Trastuzumab (ECBT)|Cohort ECBT; Combination therapy partner administered per SOC at the approved dose.
89007530|NCT04092673|Experimental|Part 1a: Dose Escalation, Combination, Breast|eFT226 administered IV weekly in 21-day cycles. Fulvestrant will also be given. Dose escalations per protocol.
89007531|NCT04092673|Experimental|Part 1b Dose Escalation, Combination, Breast|eFT226 administered IV every other week in 14-day cycles. Fulvestrant will also be given. Dose escalations per protocol.
89007532|NCT04092673|Experimental|Part 2 Cohort Expansion, Combination, Breast, Fulvestrant, Cyclin D1|ECBF-D1; Combination therapy partner administered per SOC at the approved dose.
89426093|NCT05443009|Experimental|Articaine|"Forty-eight (48) children will receive a single buccal infiltration injection with 4% articaine and 1:100,000 epinephrine at a dose previously calculated by weight.~Other Names: Test Group"
89426094|NCT05441449|Experimental|Arm 1: Cooling Vest|Phase 1: After satisfying bench testing criteria, AB participants will wear the wet cooling vest at maximal settings for 2 hours in the seated position in a warm thermal chamber (35°C), to determine: (1) minimum skin temperatures beneath the cooling vest and (2) subjective thermal sensation of their skin beneath the cooling vest.
89426095|NCT05441449|Experimental|Arm 2: Cooling Vest|Phase 2: Participants with Hi-SCI will wear the wet vest (experimental condition) in a warm thermal chamber (35°C) for up to 2 hours in the seated position, to determine: (1) change in Tcore and (2) perception of heat and thermal comfort.
89426096|NCT05441449|No Intervention|Arm 3: No Vest|Phase 2: Participants with Hi-SCI will wear no vest (control condition) in a warm thermal chamber (35°C) for up to 2 hours in the seated position, to determine: (1) change in Tcore and (2) perception of heat and thermal comfort.
89426097|NCT05441410|Experimental|PfSPZ-CVac/Pyramax|200.000 PfSPZ of PfSPZ Challenge NF54 will be administered by DVI along with one weight-adjusted oral dose of Pyramax each on day 1, day 6, and day 29
89007533|NCT04082572|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for 1 year in the absence of disease progression or unacceptable toxicity. Patients who do not respond to pembrolizumab and stop the treatment after 2 doses may undergo surgery within 6 months.
89007534|NCT04079751|Active Comparator|Neutral Mechanical Alignment|Total knee arthroplasty: Neutral Mechanical Alignment vs Anatomical Alignment
89007535|NCT04079751|Active Comparator|Anatomical Alignment|Total knee arthroplasty: Neutral Mechanical Alignment vs Anatomical Alignment
89007536|NCT04073225|Experimental|MindPod Dolphin Arm|Bandit the Dolphin provides an oceanic environment in which the individual's arm movements control a simulated dolphin. The neuromotor effects of this game have been designed to be used in the clinical setting to rehabilitate arm and hand function following stroke.
89007537|NCT04073225|Active Comparator|Hand Bike Arm|Pedal Exerciser, a single-component upper-arm aerobic play. This arm is innovative in its own right, by evaluating the benefits of upper arm aerobic activity on cognitive and physical health given that the vast majority of physical interventions focus on lower-extremity walking and biking exercise.
89007538|NCT04064112|Experimental|S-BLR|For S-BLR, the lower horn of the LR is recessed based on near exodeviation and the upper horn is recessed based on distant exodeviation.
89007539|NCT04064112|Active Comparator|C-BLR|For C-BLR, the LR is recessed based on distant exodeviation.
89007540|NCT04015765|Experimental|Group treatment h-APC and EMR|Standard endoscopic mucosal resection (EMR) technique will be used for primary removal of all polyps. Submucosal injection will be used to lift the polyp from the muscularis propria. Injection is used as per the current standard of care using a contrast agent and a lifting agent (e.g. NaCl 0.9% or Voluven). Snare electrocautery resection will be facilitated until complete visible removal of the complete polyp. Electrocautery snare technique is facilitated using standard microprocessor controlled electrocautery (e.g. ERBE VIO Endocut 3-1-6). Ablation of the margin after visibly complete removal of the polyp is routinely applied. For thermal ablation hybrid APC (Erbe Hybrid APC) will be applied using standard settings on the margin and resection base. Once resection and thermal ablation is considered complete the mucosal defect can be closed with clips or another preventative measure applied to reduce the risk for post-polypectomy bleeding.
89196246|NCT04034680|Active Comparator|Home care services - Control group|Totally 5 municipalities (25 persons with dementia) will be included in the Control group. The municipalities in the control group will receive the same two hours lectures about dementia and NPS as the intervention group. After the cluster RCT pilot study is ended, municipalities in the control group will receive the same three-hour lessons in the TIME as the intervention group of municipalities.
89196247|NCT00925912|Active Comparator|1|"spinal anesthesia: Active Comparator~The SA group were received a subarachnoid block with 1.5-2.0 ml of 0.5% bupivacaine."
89196248|NCT00925912|Experimental|2|Perianal block with 0.25% bupivacaine
89196249|NCT04060602|Experimental|Personalized Feedback and Education|This arm is provided personalized feedback concerning their cannabis use in addition to educational materials about risky cannabis use.
89196250|NCT04060602|Active Comparator|Education|This arm is provided educational materials about risky cannabis use.
89196251|NCT00904930||no periodontal disease|33 dental students (13 male, 20 female) with a mean age of 24.7 years (min. 19.8; max. 36.5) with no periodontal disease or dental trauma
88814680|NCT01620047|Placebo Comparator|Intravenous Fentanyl with placebo|Control group which received 0.9% normal saline delivered through a femoral nerve sheath catheter in addition to a continuous intravenous infusion of fentanyl 3 µg/ml via a PCA pump. All study drugs were continuously infused for a 24 hour period at a basal rate of 10ml/hour starting from the time the patient entered the post anesthesia care unit (PACU).
88814681|NCT00944450|Active Comparator|1|Sitagliptin anhydrous formulation
88814682|NCT00944450|Active Comparator|2|Sitagliptin monohydrate FMI formulation
88814683|NCT01706081|Experimental|Acupuncture|Patients in the acupuncture group will receive acupuncture treatment twice weekly for six consecutive weeks.
88814684|NCT01706081|Experimental|Wait-list|Patients in the wait-list control group will cross over and receive acupuncture twice weekly for 6 consecutive weeks.
88814685|NCT04358978|Active Comparator|posterior mesh no attachment|laparoscopic sacral colpopexy with no fixation of posterior mesh
88814686|NCT04358978|Active Comparator|posterior mesh attachment|laparoscopic sacral colpopexy with fixation of posterior mesh by suture
88814687|NCT01706549||Posthysterectomy pain|Observational study on posthysterectomy pain
88814688|NCT04358666|Active Comparator|surgery and focal radiosurgery of the surgical site|
88814689|NCT04358666|Active Comparator|hypofractionned radiosurgery|
88814690|NCT02982044|Experimental|Experimental-Control|"Participants will undergo all interventions, while simultaneously serving as their own within-subject control. The left side of the body will be designated experimental, and all interventions will be applied to the left arm. The right side of the body will be designated as control, and will not receive any interventions."
88814691|NCT01661621|Experimental|Group 1|Antimuscarinics (Detrusitol 4 mg QD)
88814692|NCT01661621|Experimental|Group 2|α-blockers (Doxazosin 4 mg QD)
88814693|NCT04358822|Active Comparator|30 second cord clamping|Infants in this group will receive delayed cord clamping for 30 seconds.
88814694|NCT04358822|Active Comparator|120 second cord clamping|Infants in this group will receive delayed cord clamping for 120 seconds.
88814695|NCT04354844||Cyanotic and acyanotic group|questinnaire
88814696|NCT01707095|Experimental|Bundling of cords|The cords from the camera/active electrode will be bundled together along their lengths during a laparoscopic cholecystectomy.
88814697|NCT01707095|Experimental|Unbundling of cords|The active electrode and camera cords will be place off opposite sides of the table and will not run adjacent to or in parallel with one another
88814698|NCT04355078|Experimental|Neuromuscular Training|The rehabilitation program starts two months after surgery, 45 minutes daily session, 3 times a week for 6 weeks. The involved leg is used if nothing else is stated that includes Walking on a treadmill, Squatting exercises, Single leg stance exercise Balance reach leg and arm exercises, Lunge exercises: anterior, lateral and posterior, Step-up and step down exercises, Single leg standing on balance mat, appropriate knee and hip position, Backwards and sideways walking for 5 steps on each side 1, 1 leg and 2 leg Wobble board Exercise and progress after every two weeks
88907039|NCT03425591||Cohort 1: Chronic Lymphocytic Leukemia (CLL) Participants|Participants with confirmed diagnosis of CLL will be observed to collect data on ibrutinib therapy to describe the effectiveness of ibrutinib and to provide a description of ibrutinib therapy and the first non-ibrutinib subsequent therapy in Cohort 1. The primary data source for this observational study will be the medical records of each enrolled participant.
88907040|NCT03425591||Cohort 2: Mantle-Cell Lymphoma (MCL) Participants|Participants with confirmed diagnosis of MCL will be observed to collect data on ibrutinib therapy to describe the effectiveness of ibrutinib and to provide a description of ibrutinib therapy and the first non-ibrutinib subsequent therapy in Cohort 2. The primary data source for this observational study will be the medical records of each enrolled participant.
88907041|NCT03413592|Other|Driving test|
88907042|NCT03312270|Experimental|Multimodality information Comprehension|Evaluate various aspects of multimodality presentation of materials through text-to-speech systems used by people with aphasia.
88907043|NCT03280511|Experimental|Interventional|Eligible candidates will be enrolled according to in-/exclusion criteria. Two months after colon resection or immediately after adjuvant chemotherapy (if indicated), a standard laparoscopy including peritoneal lavage, peritoneal biopsies and PIPAC treatment with oxaliplatin 92 mg/m2 will be planned. This procedure will be repeated after another 5 weeks. Follow up CTs after 12, 24 and 36 months will be planned.
88907044|NCT03267303|Experimental|TS-091 5mg|
88907045|NCT03267303|Experimental|TS-091 10mg|
88907046|NCT03267303|Placebo Comparator|Placebo|
88907047|NCT03236688||MCRPC|Metastatic Castrate Resistant Prostate Cancer (MCRPC) Patients
88907048|NCT03205423|Placebo Comparator|Gabapentin 0 mg|once daily at 8am
88907049|NCT03205423|Active Comparator|Gabapentin 1800 mg|once daily at 8am
88907050|NCT03149302|Experimental|Local neck treatment (LNT)|Cervical mobilization and specific therapeutic exercises
88907051|NCT03149302|Experimental|LNT plus sensorimotor exercises|Local neck treatment plus a tailored sensorimotor exercise program.
88907052|NCT03149302|Experimental|LNT plus balance exercises|Local neck treatment plus balance training program.
88907053|NCT03149302|Experimental|LNT plus sensorimotor/balance exercises|A combination of local neck treatment, sensorimotor control exercise, and balance exercise.
88907054|NCT03122821|Experimental|Group 1|Real Trans-cranial direct stimulation + Mental Imagery
88907055|NCT03122821|Active Comparator|Group 2|Sham Trans-cranial direct stimulation + Mental imagery
88907056|NCT03073603|Active Comparator|Drug Continuation Arm|Participants who remain on their current Disease Modifying Therapies (DMTs) without any changes. DMTs include ~14 formulations/doses of drugs approved in the US by the FDA that alter the natural history of the disease.
88907057|NCT03073603|Experimental|Drug Discontinuation Arm|Participants who will discontinue their Disease Modifying Therapies (DMTs). No other changes to their treatment occur. DMTs include ~14 formulations/doses of drugs approved in the US by the FDA that alter the natural history of the disease.
88907058|NCT03002155|Experimental|Exercise|EnhanceFitness exercise class, 1 hour, 3 times a week, duration of 12 weeks.
88907059|NCT03002155|No Intervention|Control|Usual care.
88907060|NCT02918006|Experimental|Oral Vaccine (VXA-A1.1)|Oral enteric coated vaccine tablets. Placebo (saline solution) IM injection will also be administered in this arm.
88907061|NCT02918006|Active Comparator|QIV IM Injection|A commercially available QIV will be administered at the approved dose level as the active comparator. Oral placebo tablets will also be administered in this arm.
88907062|NCT02918006|Placebo Comparator|Oral and IM Placebo|Two forms or placebos (saline IM injection and oral placebo tablets) will be administered in this arm.
88907063|NCT02917772|Experimental|Nivolumab/Ipilimumab|"Induction: Mono-Therapy with Nivolumab~If CR/PR: Nivolumab Maintenance Mono-Therapy~If SD/PD: Nivolumab/Ipilimumab Boost 1+2-Combination Therapy~If CR/PR: Nivolumab Maintenance Mono-Therapy~If SD/PD: Nivolumab/Ipilimumab Boost 3+4-Combination Therapy~If CR/PR/SD: Nivolumab Maintenance Mono-Therapy"
88907064|NCT02885324|Experimental|Cabozantinib|Cabozantininb will be taken daily at a dose of 40 mg/m2. Drug cycles will last 28 days and be continuous for up to 12 months of therapy on study.
88907065|NCT02879812|Experimental|Multi-Component Intervention|End Stage Renal Disease (ESRD) facilities will receive feedback reports containing facility specific data, an educational webinar for dialysis facility medical directors and staff, and an educational video for patients and staff.
88907066|NCT02879812|Active Comparator|Standard Care + Pamphlet|End Stage Renal Disease (ESRD) facilities will conduct usual care and receive United Network for Organ Sharing (UNOS) educational pamphlets for staff.
89196252|NCT03545256|Other|T1-N0 or T2-N0 cancers of the oral cavity|outpatient surgery for T1-N0 or T2-N0 cancers of the oral cavity or oropharynx with lymph node search
89196253|NCT00695136|Experimental|Open label single arm|Single group study of Donepezil
89426098|NCT05441410|Experimental|MVA ME-TRAP/ChAd63 ME-TRAP|MVA ME-TRAP 1.5 x 10^8 pfu will be administered intramuscularly on day 1 for priming. ChAd63 ME-TRAP 5 x 10^10 vp will subsequently administered by DVI on day 29.
89426099|NCT05441410|Placebo Comparator|Saline/placebo pill|"As placebo comparator to PfSPZ-CVac/Pyramax, saline will be administered intravenously along with an oral placebo pill on day 1, day 6, and day 29.~As placebo comparator to MVA ME-TRAP/ChAd63 ME-TRAP, saline will be administered intramuscularly on day 1 and intravenously on day 29. No placebo pill will be used to compare to the arm MVA ME-TRAP/ChAd63 ME-TRAP."
89426100|NCT05440916|Experimental|Study group|"Patients with metastatic Non-Small Cell Lung Carcinoma eligible for first line systemic treatment with chemotherapy and immune checkpoint inhibitors (PDL1 less than 50%)~Radiotherapy: palliative irradiation of 2 to 5 sites (parenchymal/bone/soft tissue metastasis and/or primary lung tumour) with fractionation: 5 fractions of 4Gy (total dose 20Gy) in one week before systemic therapy."
89426101|NCT05440916|Other|Historical cohort|"Patients with metastatic Non-Small Cell Lung Carcinoma treated with first line of systemic therapy with chemotherapy and immune checkpoint inhibitors (PDL1 less than 50%).~Radiotherapy: no radiation therapy during the first line of systemic treatment before progression of disease."
89426102|NCT05435209|Experimental|Quadrivalent HPV Vaccine|Gardasil® 0.5 mL administered intramuscularly in the deltoid or anterolateral area of the thigh
89426103|NCT05433623||Vascular Surgery Admissions|Patients who present and/or are admitted to University Hospital Limerick under the care of a Vascular Consultant.
89426104|NCT05433285|Experimental|COVID-19 Protein Subunit Recombinant Vaccine|2 doses of COVID-19 Protein Subunit Recombinant Vaccine administered with 28 days interval (0.5 mL per dose)
89426105|NCT05433285|Active Comparator|Active Comparator|2 doses of Covovax® - recombinant spike protein Nanoparticle Vaccine, administered with 28 days interval (0.5 mL per dose)
89426106|NCT05430919|Experimental|REGN5713-5714-5715|3-mAb
88907067|NCT02829099|Experimental|JNJ-64457107|In Part 1, the first cohort will receive JNJ-64457107 at a starting dose of 75 microgram per kilogram (mcg/kg). The proposed treatment schedule is intravenous (IV) dosing every 14 days. JNJ-64457107 doses will be escalated following a modified Continual Reassessment Method (mCRM); the JNJ-64457107 dose will be increased by not more than half-logarithmical (3.2-fold) dose increments. Dose escalation will continue until the maximum tolerated dose (MTD) and/or RP2D of JNJ-64457107 are defined or the maximum-administered dose (MAD) has been reached. In Part 2, subjects will receive JNJ-64457107 at the RP2D and regimen determined in Part 1.
88907068|NCT02815254|Active Comparator|Low dose exercise intervention|
88907069|NCT02815254|Experimental|High dose exercise intervention|
88907070|NCT02803853|Experimental|Intervention|The intervention is a multi-level, multi-component intervention designed to increase access to and consumption of healthier foods in Native American Communities. Intervention components will occur at the policy level; food retail outlet level; neighborhood level- schools and worksites, and household level.
89196254|NCT00905008||DES|Patients underwent percutaneous coronary intervention and received at least one drug-eluting stent during their index hospitalisation.
89196255|NCT00905008||BMS|Patients underwent percutaneous coronary intervention and received at least one uncoated stent during their index hospitalisation.
89196256|NCT02565420|Active Comparator|Lactated Ringer's solution|During the perioperative period of the colorectal, orthopedic or similar surgery the patient will receive an intervention of Lactated Ringer's solution fluids.
89426107|NCT05430919|Experimental|REGN5713-5715|2-mAb
89426108|NCT05430919|Experimental|REGN5715|1-mAb
89426109|NCT05430919|Placebo Comparator|Matching Placebo|
89426110|NCT05429983||Hypoglossal Nerve Stimulation Candidates|Participants will have a diagnosis of obstructive sleep apnea and have failed treatment with continuous positive airway pressure (CPAP). Participants will be those undergoing drug-induced sleep endoscopy (DISE) as part of routine clinical care for work up of hypoglossal nerve stimulation candidacy as a treatment for obstructive sleep apnea.
89426111|NCT05425953||Klinefelter syndrome|Patients with 47, XXY n=60
89426112|NCT05425953||Turner syndrom|Patients with 45, X n=60
89426113|NCT05425953||47, XXX|Patients with 47, XXX n=20
89426114|NCT05425953||47, XYY|Patients with 47, XYY n=20
89426115|NCT05425953||Male controls|Male controls n=80
89426116|NCT05425953||Female controls|Female controls n=80
88814748|NCT05620082||Malnourished older adults in hospital|Participants will be given oral nutritional supplementation twice per day for 4 days, in addition to normal meals, in a crossover design. The products will be offered in-between breakfast and lunch, and after dinner. Products will include traditional sip-feeds (an anonymous ready-made drink supplement, 125g, 306kcal, 18.3g protein) and a new fortified porridge (Adams Vital Nutrition Ltd. High Protein Oats, 157g, 230kcal, 15g protein).
89426117|NCT05425303||Healthy athletes|Healthy professorial team sports athletes will be monitored for the occurrence of an acute lower extremity injury during a competitive season. After the end of the season, the cohort will be divided into a healthy athlete group, athletes injured in the hamstring muscles, and athletes with other types of lower extremity injuries.
89426118|NCT05422560|Experimental|Embolization of the inferior mesenteric artery|"Only one arm: Patient followed for sigmoid/rectal cancer~Pré-Selection Preoperative consultation, first information to the patient, Validation of IC / NIC, CT-TAP available~Selection Interventional radiology consultation: Consent collection + additional exams~Inclusion V1 - D0:~Follow-up visit V2 - D2: Phone call, pain assessment and analgesic treatments collection~Follow-up visit V3 - D7: Phone call, pain assessment and analgesic treatments collection~Follow-up visit V4 - D21-D30: CT-TAP~Follow-up visit V5 - D30: Digestive surgery consultation + additionnal exams~Surgery V6 - D0: Colic surgery + additional exams~Post-surgery visit V7 - D30: Last visit, additionnal exams"
89426119|NCT05420129||MAD. Mandibular advancement Device|Patients diagnosed with Obstructive Sleep Apnea and treated with MAD
89426120|NCT05420129||CPAP. Continuous Possitive Airway Pressure|Patients diagnosed with Obstructive Sleep Apnea and treated with CPAP
89426121|NCT05418777|Experimental|TMP-SMX|Suspension with the equivalent of one DS TMP-SMX by mouth every 12 hours for 10 days
89426122|NCT05418777|Placebo Comparator|Placebo|Suspension with placebo by mouth every 12 hours for 10 days
89426123|NCT05416879||Women newly diagnosed with heart failure|
89196257|NCT02565420|Placebo Comparator|normal saline|During the perioperative period of the colorectal, orthopedic or similar surgery the patient will receive an intervention of normal saline solution.
89196258|NCT00921570|Experimental|Amlodipine|
89426124|NCT05416372|No Intervention|Control communities|Communities randomized to the control arm will receive a strengthening of the capacity to manage blood pressure at their local health center. Healthcare workers at the local health center will receive standard supplies, reference materials, and training in blood pressure measurement and management on-site. In the event of any stock-outs due to higher demand for antihypertensives during the trial implementation, the trial will temporarily provide these medications to primary health facilities until the Ministry of Health supply chain is restored. Of note, control communities will receive Religious Engagement in Health Intervention after the trial is complete.
89426125|NCT05416372|Experimental|Religious Engagement in Health Intervention communities|Communities randomized to the intervention arm will receive a strengthening of the capacity to manage blood pressure at their local health center plus Religious Engagement in Health Intervention for blood pressure (BP), which includes three evidence-based components; 1) educational sessions for Christian and Muslim leaders on religious teachings and medical aspects of BP, 2) equipping religious leaders to provide BP teaching in their communities using knowledge learned from educational sessions and through longitudinal mentorship meetings, and 3) community BP screening organized by religious leaders in partnership with local health care workers, and referrals for clinical care as needed.
88814749|NCT01623323|Other|Fluticasone|
89196259|NCT00921570|Experimental|Valsartan|
89196260|NCT00921570|Experimental|Valsartan+Amlodipine|
89426126|NCT05415176|Experimental|Taurine and Exercise (Tau+Exe)|Individuals who will receive 3g of taurine supplementation combined with physical training in the period of 16 weeks
89196261|NCT00926068|Experimental|HO/03/03 10µg|
89196262|NCT00926068|Placebo Comparator|Placebo|
89426127|NCT05415176|Experimental|Taurine (Tau)|Individuals who will receive 3g of taurine supplementation
89426128|NCT05415176|Experimental|Exercise (Exe)|Individuals who will perform a physical training and receive a placebo supplementation in the period of 16 weeks
89426129|NCT05415176|Placebo Comparator|Placebo (Cont)|Individuals who will receive a placebo supplementation in the period of 16 weeks
89426130|NCT05414292|Experimental|Drug group|Will take 1mg Rapamune (sirolimus) in oral tablet form daily for 16 weeks.
89426131|NCT05414292|Placebo Comparator|Placebo group|Will take a placebo tablet (lactose) daily for 16 weeks
89426132|NCT05408741|Experimental|Group 1 (The Intervention Group)|Participants will receive guided imagery and deep breathing technique exercises.
89426133|NCT05408741|Experimental|Group 2 ( The Control Group)|Participants will not receive any relaxation techniques. Participants will receive the current standard of care.
89426134|NCT05404048|Experimental|PD-L1 PET-imaging|The main intervention of this study is 89Zr-atezolizumab PET-scan combined with a low-dose CT-scan. The PET/CT scan will be performed before infusion of CAR T-cell therapy. In patients with an end-of-treatment F-FDG positive PET-signal a second 89Zr-atezolizumab PET/CT-scan will be performed.
88814750|NCT05620004|Experimental|Bifidobacterium Bifidum Oral Product|patients with advanced hepatocellular carcinoma who will be treate with carrilizumab and apatinib mesylate plus Bifidobacterium Bifidum Oral Product daily
88814751|NCT05620004|No Intervention|without Bifidobacterium Bifidum Oral Product|patients with advanced hepatocellular carcinoma who will be treate with carrilizumab and apatinib mesylate without Bifidobacterium Bifidum Oral Product daily
88814752|NCT02018198||Acute Respiratory Infection|Study subjects will be 1 year of age and older presenting to emergency departments, urgent care centers and primary care offices with a new onset, measured fever and new onset respiratory symptoms.
88814753|NCT02018198||Asymptomatic Cohort|Study subjects will be 1 year of age and older presenting to emergency departments, urgent care centers and primary care offices without infection.
88814754|NCT01708967|Experimental|Catheter-free method|"We explored success rate, side effects, and vital signs in patients with catether-free method.~Intervention: one-time spray of epinephrine (1cc) plus 4% lidocaine (4cc)"
88814755|NCT01708967|Experimental|Catheter insertion method|We explored success rate, side effects, and vital signs in patients with catether insertion method : use both spray and catheter
88814756|NCT01911104|Experimental|Exercise|10 weeks of aerobic exercise
88814757|NCT01911104|No Intervention|Active Control|Young athletes as a trained control
88814758|NCT03032120|Experimental|Fresh orange juice|Intervention: The subjects drank 5 mL/kg body weight of fresh-squeezed orange juice (FOJ).
88814759|NCT03032120|Experimental|Processed orange juice|Intervention: The subjects drank 5 mL/kg body weight of processed orange juice (POJ).
88814760|NCT03032120|Experimental|Control|The subjects drank 5 mL/kg body weight of control drink compounded by water mixed with sugars in a similar concentration of orange juices (5.2% of sucrose, 2.5% of fructose, 2.1% of glucose, 0.75% of citric acid, and malic acid 0.25%, flavored and colored with some drops of orange essence).
89426135|NCT05402982|Other|GROUP A|Fluid administration in the form of lactated ringer will be managed by Rohrich formula and the intraoperative fluid ratio (subcutaneous infiltration fluid plus intravenous fluid divided by total aspirate volume) will be 1.2(10). Rohrich formula represents fluid maintinance,deficit and replacement fluid ( 0.25 ml crystalloid given for each 1 ml above 4 litre of lipoaspirate).
89426136|NCT05402982|Other|GROUP B|Patients will receive fluid maintenance of lactated ringer 2 ml/kg/h, cardiometry guided SVV will be measured before and after induction then every 30 min ,it ranges between 5-15%, fluid bolus of lactated ringer 4 ml /kg over 15 min will be administered if SVV ˃ 15% .
88907071|NCT02803853|No Intervention|Control|Similar to many community- based public health research programs, the control arm will not receive any intervention components during the initial intervention period. However, after all assessments are completed they will receive a 'delayed intervention' protocol, where the community receives the intervention elements as described in the intervention arm after assessment measures have been completed.
88907072|NCT02713373|Experimental|Arm I (cetuximab and pembrolizumab)|Patients receive cetuximab IV over 120 minutes on day 1 (days 1, 7, and 14 of course 1 only) and pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for 24 months in the absence of disease progression or unacceptable toxicity. Patients may continue pembrolizumab treatment for up to 1 year if they experience disease progression.
88907073|NCT02686593|Other|Clofarabine, AraC, mitoxantrone (CLAM)|This is the single arm with the intervention using Clofarabine, AraC, Mitoxantrone
88907074|NCT02674438|Experimental|Active Intervention|"Two components to the intervention: (1) clinical algorithm for prognostication, and (2) post-discharge follow-up in the RAPID-HF clinic~Intervention #1 - Clinical algorithm: the EHMRG30-ST risk score which will be used to categorize patients as high, intermediate, or low risk. The clinical algorithm will be used to guide clinicians to decide on admission to hospital, observation during a short stay hospital admission (3 days or less), or emergency department discharge.~Intervention #2 - Referral to RAPID-HF (Rapid Ambulatory Program for Investigation and Diagnosis of HF) transitional care clinic: visit to RAPID-HF within 48-72 hours of discharge. Care provided in RAPID-HF by cardiologist + nurse for up to 30 days from date of discharge."
88907075|NCT02674438|No Intervention|Control|Usual care without access to the EHMRG30-ST scoring system, decision algorithm, or RAPID-HF clinic.
88907076|NCT02583282|Experimental|Doxycycline|Intrapleural doxycycline
88907077|NCT02583282|Active Comparator|Iodopovidine|Intrapleural iodopovidine
88907078|NCT02553941|Experimental|azacitidine, ibrutinib|Patients receive azacitidine intravenous infusion over 10-40 minutes or subcutaneous on days 1-7 or 1-5 and 8-9, and ibrutinib by mouth one daily on days 1-28. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
89426137|NCT05400486|Active Comparator|Therapeutic exercise group|1.Movements of flexion, extension, inclinations, and rotations of the cervical region at maximum amplitude and without load. 2.Neural mobilization of the cervical nerve roots. 3.Contraction of the deep muscles of the flexors, extensors, and rotators of the cervical region without performing spinal movements, using the movement of the eyes to aid in the accomplishment of these exercises. 4.Isometric contraction of the flexor muscles, inclinators, and rotators against manual resistance of the physiotherapist. 5.Isometric contraction of the cervical extensors of the cervical region against gravity. 6.Contraction of the flexor muscles, extensors, and incliners of the cervical region against the resistance of elastic bands.
89426138|NCT05400486|Experimental|Therapeutic exercise group + high frequency TENS|This group will consist of 25 participants. Initially, TENS (Endophasys® - NMS-0501, KLD Biosistemas® Equipamentos Eletrônicos Ltda) will be applied to the cervical region through 4 silicon-carbon electrodes measuring 4 x 4 cm, with a water-based gel to reduce impedance at the skin-electrode interface. Thus, TENS will be applied with a rectangular, biphasic, and symmetrical pulse, with a pulse width of 100 µm, a frequency of 100 Hz, at the maximum tolerated sensitive threshold, for 30 minutes (VANCE et al., 2012). After the application of TENS, the same program of therapeutic exercises applied in the first group will be applied, in the same sequence, evolution, times, and repetitions.
89426139|NCT05400486|Experimental|Therapeutic exercise group + Interferential|This group will consist of 25 participants. Initially, the protocol of exercises performed in the therapeutic exercise group will be applied. In sequence, the interferential current will be applied. Through the Endophasys® device - NMS-0501, KLD Biosistemas® Equipamentos Eletrônicos Ltda). Four electrodes (8x5 cm), two upper and two lower (forming a square) will be positioned around the center of the neck. The electrodes will be positioned crosswise, following the parameters: 4KHz (carrier frequency), 1/1 second (Sweep Mode), 60 Hz Amplitude of frequency modulation (AMF), 30 Hz (Delta AMF), automatic vector mode, with intensity at the motor threshold of sensation, lasting 30 minutes (Albornoz-Cabello et al., 2019).
89426140|NCT05400226|Experimental|0.32mg/kg VGT-309|Single arm in an open label study
89426141|NCT05393570|Experimental|Treatment|
89426142|NCT05393401|Experimental|VOP1k|Medical Device
89426143|NCT05391698|Experimental|Parent Training - Child Training (Group PC)|Parents of families who will be randomized in Group PC will first take part in behavioral parent training. After the completion of the parent training program and the assessment (Time 2 assessment), their children will take part in the individualized child training program.
89426144|NCT05391698|Experimental|Child Training - Parent Training (Group CP)|Children of families who will be randomized in Group CP will first take part in the individualized child training program. After the completion of the child training program and the assessment (Time 2 assessment), parents will take part in the behavioral parent training program.
89426145|NCT05389319|Experimental|Cohort 1|Prime-2-CoV_Beta, dose: 30 000 PFUs
89426146|NCT05389319|Experimental|Cohort 2|Prime-2-CoV_Beta, dose: 300 000 PFUs
88814761|NCT00535964||1|Psychologically healthy adolescents, evenly divided across the various stages of smoking uptake
88814762|NCT03031652||Enrolled group|Patients who had senile cataract and underwent phacoemulsification with topical anesthesia.
89426147|NCT05389319|Experimental|Cohort 3|Prime-2-CoV_Beta, dose: 3 000 000 PFUs
89426148|NCT05389319|Experimental|Cohort 4|Prime-2-CoV_Beta, dose: 150 000 000 PFUs
89426149|NCT05389319|Experimental|Cohort 5|Prime-2-CoV_Beta, dose: 30 000 000 PFUs
88814763|NCT01709747|Experimental|Hydromorphone Hydrochloride|Hydromorphone hydrochloride for intrathecal administration, 12 months safety evaluation
88814764|NCT05615324|Experimental|Family Talk|families will receive a manualized, family-based intervention Family Talk of approximately 8 sessions with a trained, Family Talk interventionist.
88814765|NCT05615324|No Intervention|Service as usual|Families in this arm will not receive any intervention from the research team but they may receive other services. It is likely that many will receive two sessions of talk intervention concerning parental mental health and child well-being from professionals in the mental health sector where the parent is treated.
88814766|NCT03031808|Other|Lidocaine spray|Endotracheal lidocaine spray prior to intubation
88814767|NCT03031808|Other|Muscle relaxant|Muscle relaxant prior to intubation
88814768|NCT03031808|Other|No Muscle relaxant, no Lidocaine|'No Muscle relaxant, no Lidocaine Control group
89426150|NCT05388617|Experimental|Group A|Subjects in Group A will receive up to 8 treatments with the Brera/Med 400 device on their abdomen or flanks. Subjects may receive a phone call 1 week (1-7 days) after each treatment to record side effects. Subjects will return for follow up visits at 30 and 90 days post last treatment for efficacy and side effects assessments.
88907079|NCT02546492|Experimental|Acthar|The study cohort. In this cohort Acthar gel will be administered to the enrolled patient with chrnic AMR.
88907080|NCT02527564|Experimental|Suvorexant|"50% of enrolled participants will be randomly assigned to receive double-blind suvorexant for one week, dosed at 10mg every bedtime for the first 3 nights, then increased to 20mg every bedtime for the last 4 nights.~Following the one-week double-blind, placebo-controlled phase, 100% of participants will receive open-label suvorexant for 3 months, dosed at 10mg every bedtime for the first 3 nights, then increased to 20mg every bedtime for the remainder of 3 months."
88907081|NCT02527564|Placebo Comparator|Placebo|50% of enrolled participants will be randomly assigned to receive double-blind placebo pill for one week, dosed at 10mg every bedtime for the first 3 nights, then increased to 20mg every bedtime for the last 4 nights.
88907082|NCT02282007|No Intervention|No Intervention:Control group|
88907083|NCT02282007|Experimental|Individual NPMP to the participants|This arm will receive NPMP for 6 months, individually adjusted to their problems.
88907084|NCT02179749|Active Comparator|Experimental: mifepristone 1200 mg daily|1200 mg mifepristone daily for 1-week given in conjunction with 8 weeks of standardized behavioral therapy
88907085|NCT02179749|Placebo Comparator|Placebo daily, 1-week|Placebo pills daily for 1-week given in conjunction with 8 weeks of standardized behavioral therapy
88907086|NCT02075593|Experimental|DTG/ABC/3TC|All subjects will be administered DTG 50 milligrams (mg)/ABC 600 mg/3TC 300 mg FDC tablet once daily, with or without food.
88907087|NCT02065609|Experimental|Cohort 1|89Zr-Trastuzumab Human Dosimetry and Safety
88907088|NCT02065609|Experimental|Cohort 2: Lesion Detection and Safety|HER2 Positive Lesion Detection and Safety
88907089|NCT01941108|No Intervention|Standard HIV Care Arm|Patients in the standard HIV care arm will be escorted to their first HIV care appointment at the Moore Clinic at Johns Hopkins University Hospital. They will not receive any additional intervention regarding their care after that. Participants in this arm will be followed up by the study coordinator every 3 months for 9 months.
88907090|NCT01941108|Experimental|Peer Navigation Arm|Patients in the peer navigation arm will be escorted to their first HIV care appointment at the Moore Clinic at Johns Hopkins University Hospital. They will be assigned to a peer navigator who can assist them in overcoming obstacles to their HIV care. They will be given a smartphone with specialized software to help with their navigation. Participants in this arm will be followed up by the study coordinator every 3 months for 9 months and interact with their navigator when necessary.
88907091|NCT01037816|Active Comparator|FS-67 patch|One FS-67 patch applied to target ankle every 12 hours for three days (up to 6 FS-67 patches in three days)
88907092|NCT01037816|Placebo Comparator|Placebo Patch|One placebo patch applied to target ankle every 12 hours for three days (up to 6 FS-67 patches in three days)
88907093|NCT01009138|Experimental|Diabetes-Specific CBT (DS-CBT)|Cognitive Behavioral Intervention (Group) focusing on Diabetes-Specific Problems
88907094|NCT01009138|Active Comparator|Standard Diabetes Education|Standard Diabetes Education Lessons will be given to quantify the unspecific antidepressive Effects of Participation in Group Sessions with social Contact and Acquisition of Knowledge.
88907095|NCT00641186|Experimental|Xyrem in Parkinson disease|sodium oxybate 4.5 to 9.0 gms per night
89426151|NCT05388617|Experimental|Group B|Subjects in Group B may receive up to 8 treatments with the Brera/Med 400 device on their abdomen and/or flanks. Subjects may receive a phone call 1 week (1-7 days) after each treatment to record side effects. Subjects may be asked return for follow up visits at 30 and 90 days post last treatment for efficacy and side effects assessments. Outcome measures will not be taken for subjects enrolled in this group.
89426152|NCT05387590|Other|Preventiometer Device|The Preventiometer is a physical wellness tool that assesses multiple physical wellness measures in a 60 ± 15 minutes period of time. It is intended to promote population wellness by empowering individuals to act upon the information they receive about their overall health.
89196263|NCT02710890|Experimental|Lacosamide|Up to 2 age-based Cohorts with Cohort 1 including at least 40 subjects who are >=8 to <17 years. For Cohort 2 every attempt will be made to enroll 20 subjects >= 4 to < 8 years of age, 12 subjects >= 2 to < 4 years of age and 12 subjects >= 1 month to < 2 years of age. A Data Monitoring Committee (DMC) will review the safety and tolerability data for each Cohort to make the following recommendations: the progression of the current Cohort, including intravenous (iv) infusion durations to be evaluated, and progression to initiate enrollment in the next Cohort (Cohort 2).
89196264|NCT00742950|Active Comparator|I|Nasal 2.8-mm corneal incision
89426153|NCT05385328||Healthy people|Undiagnosed persons will be evaluated by the EYEFUL system performing activities of daily living. Patterns of action will be recorded, to establish outcome measures in healthy population.
89196265|NCT00742950|Active Comparator|II|Temporal 2.8-mm corneal incision
89196266|NCT00742950|Active Comparator|III|Superior 2.8-mm corneal incision
89196267|NCT05322642|Experimental|Experimental: (UP-A)|The UP-A (Ehrenreich et al., 2008) is an emotion-focused, transdiagnostic CBT for adolescents A 10-session youth-focused programmed by adapting the core modules of UP-A, for indicated prevention and school settings.
89426154|NCT05385328||people with physical or psychological diagnoses|People with various clinical diagnoses will be evaluated by the EYEFUL system performing activities of daily living. Patterns of action will be recorded, in order to establish outcome measures in comparison with healthy population and with other diagnoses.
88814769|NCT03035474|Other|Direct & Digital|Health system engagement to improve local QI programs and patient engagement to improve self-management/medication adherence
88814770|NCT03035474|Other|Direct & Registry|Health system engagement to improve local QI programs and patient and control
89426155|NCT05384353||Healthy controls|Synaptic density PET-MR and neuropsychological testing
89426156|NCT05384353||Patients with Alzheimer's disease|Synaptic density PET-MR and additional neuropsychological testing (if necessary)
89196268|NCT05322642|Active Comparator|Active control condition|"The active control condition will be based on the 10 session of Progressive Relaxation Training programme of Bernstein and Borkovec.~It follows a similar structure as the UP-A. A group format will be used."
89426157|NCT05384353||Patients with Frontotemporal degeneration|Synaptic density PET-MR and additional neuropsychological testing (if necessary)
89196269|NCT00605176|Active Comparator|3.75% imiquimod cream|
89426158|NCT05384353||Patients with Dementia with Lewy Bodies|Synaptic density PET-MR and additional neuropsychological testing (if necessary)
89426159|NCT05384353||Patients with late-life psychiatric disorders|Synaptic density PET-MR and additional neuropsychological testing (if necessary)
89426160|NCT05377580|Placebo Comparator|Placebo|Participants will receive placebo in intravenously (IV) in Induction period. Subsequent study treatment will be determined by the participant's clinical response status at Week 12
89426161|NCT05377580|Experimental|IBI112 dose 1|Participants will receive IBI112 dose 1 intravenously (IV) in Induction Study 1. Subsequent study treatment will be determined by the participant's clinical response status at Week 12.
89426162|NCT05377580|Experimental|IBI112 dose 2|Participants will receive IBI112 dose 2 intravenously (IV) in Induction Study 1. Subsequent study treatment will be determined by the participant's clinical response status at Week 12.
89196270|NCT00605176|Active Comparator|2.5% imiquimod cream|
89196271|NCT00605176|Placebo Comparator|Placebo cream|
89196272|NCT00926146|Experimental|NCMIT|Nurse Case Management Plus Contingency Management and Tracking and the HBV vaccine
89426163|NCT05376007|Experimental|Playing serious game 'Broodles'|"The participants allocated to this group will play the newly developed serious game 'Broodles' after pre-test assessment. Children will play the serious game without the parent or the help of a caregiver. Parents and children will make complementary worksheets together and parents will read an information brochure.~Concomitant care as usual is allowed during the study.~A parent-child pair is labelled as one participant."
89426164|NCT05376007|No Intervention|Waitlist control group|"The participants allocated to this group will play the serious game 'Broodles' after follow-up assessment.~Concomitant care as usual is allowed during the study."
89426165|NCT05375214|Other|Treatment Arm|Open label study, all participants will receive novel iTBS
88814771|NCT03035474|Other|Digital & Registry|Patient engagement to improve self-management/medication adherence and control
88814772|NCT03035474|No Intervention|Registry|Control
89196273|NCT00926146|Active Comparator|SCMIT|Standard with Contingency Management and Tracking (SCMT) and HBV vaccine
89196274|NCT00743028|Experimental|1|
89196275|NCT00743028|Experimental|2|
89196276|NCT00743028|Experimental|3|
89196277|NCT00743028|Experimental|4|
89196278|NCT00743028|Experimental|5|
89196279|NCT00743028|Experimental|6|
89196280|NCT00905320|Active Comparator|Metallic Fasteners and Sutures|Laparoscopic ventral hernia repair with mesh fixation using both metallic fasteners and transabdominal sutures
89196281|NCT00905320|Experimental|Metallic Fasteners Alone|Laparoscopic ventral hernia repair with mesh fixation using metallic fasteners alone
89196282|NCT02538796|Experimental|Patients group 1|TEA + Grober Test + Task 1 + Grober Test
89196283|NCT02538796|Experimental|Patients group 2|TEA + Grober Test + Task 2 + Grober Test
89196284|NCT02538796|Experimental|Patients group 3|TEA + Grober Test + Implicit Task 3 + Grober Test
89196285|NCT02538796|Experimental|Patients group 4|TEA + Grober Test + Explicit Task 3 + Grober Test
89196286|NCT02538796|Active Comparator|Healthy volonteers group 1|TEA + Grober Test + Task 1 + Grober Test
89196287|NCT02538796|Active Comparator|Healthy volonteers group 2|TEA + Grober Test + Task 2 + Grober Test
89196288|NCT02538796|Active Comparator|Healthy volonteers group 3|TEA + Grober Test + Implicit Task 3 + Grober Test
89196289|NCT02538796|Active Comparator|Healthy volonteers group 4|TEA + Grober Test + Explicit Task 3 + Grober Test
89196290|NCT00905398|Experimental|nilotinib|single arm study
89196291|NCT00905476||NPPV|Patients with chronic respiratory failure receiving domiciliary NPPV
89196292|NCT00905710|No Intervention|1|Conventional colonoscopy
89196293|NCT00905710|Experimental|2|Colonoscopy using chromoendoscopy
89196294|NCT00926302|Experimental|Test drug|Levetiracetam one period
89196295|NCT00926302|Active Comparator|Reference drug|Keppra one period
89196296|NCT02538406||non segmental withdrawal|A standard of care colonoscopy will be done on the patient without extra time on the right side of the colon.
89196297|NCT02538406||Segmental withdrawal|A standard of care colonoscopy will be done on the patient , however the time spent in the right side of the colon will be more than half of the normal colonoscopy procedure (i.e. more than 3 minutes)
89196298|NCT00905788|No Intervention|Control Group|Embryo transfer without any intervention
89196299|NCT00905788|Experimental|Embryo Expulsion|
89426166|NCT05363397|Experimental|TBO-309 30mg (25% of target dose)|"Following randomisation, 30mg TBO-309 will be administered at the same time as the rt-PA infusion or tenecteplase bolus (as part of intravenous thrombolysis) or as soon as practical.~The allocated dose of TBO-309 will be given intravenously as follows:~20% of the dose will be administered as a bolus over approximately one minute; then~the remainder of the dose (80%) will be administered over 3 hours as an infusion~Only one dose will be administered to the patient."
89426167|NCT05363397|Experimental|TBO-309 60mg (50% of target dose)|"Following randomisation, 60mg TBO-309 will be administered at the same time as the rt-PA infusion or tenecteplase bolus (as part of intravenous thrombolysis) or as soon as practical.~The allocated dose of TBO-309 will be given intravenously as follows:~20% of the dose will be administered as a bolus over approximately one minute; then~the remainder of the dose (80%) will be administered over 3 hours as an infusion~Only one dose will be administered to the patient."
89426168|NCT05363397|Experimental|TBO-309 120mg (100% of target dose)|"Following randomisation, 120mg TBO-309 will be administered at the same time as the rt-PA infusion or tenecteplase bolus (as part of intravenous thrombolysis) or as soon as practical.~The allocated dose of TBO-309 will be given intravenously as follows:~20% of the dose will be administered as a bolus over approximately one minute; then~the remainder of the dose (80%) will be administered over 3 hours as an infusion~Only one dose will be administered to the patient."
89426169|NCT05363397|Experimental|TBO-309 180mg (150% of target dose)|"Following randomisation, 180mg TBO-309 will be administered at the same time as the rt-PA infusion or tenecteplase bolus (as part of intravenous thrombolysis) or as soon as practical.~The allocated dose of TBO-309 will be given intravenously as follows:~20% of the dose will be administered as a bolus over approximately one minute; then~the remainder of the dose (80%) will be administered over 3 hours as an infusion~Only one dose will be administered to the patient."
89426170|NCT05358509|Experimental|IV iron intervention arm 1|Intervention arm 1 involves a single dose of an IV iron formulation - ferric carboxymaltose - given during pregnancy.
89426171|NCT05358509|Experimental|IV iron intervention arm 2|Intervention arm 2 involves a single dose of an IV iron formulation - iron isomaltoside - given during pregnancy.
89426172|NCT05358509|Active Comparator|Active comparator|Participants randomly assigned to the active comparator arm will receive oral iron tablets to take daily, which is the current standard of care.
89426173|NCT05354986|Placebo Comparator|Control-Control|"Immediately after the second session of subgingival instrumentation (initial visit, RCT #1) subjects will be randomly assigned to one of two groups, test or placebo.~0-2 weeks: The control group will use three times daily a provided manual toothbrush with the placebo toothpaste (identical to the test tooth paste, but without the active ingredients), followed by the use, twice daily, of a 0.12% chlorhexidine mouth rinse.~Subjects will stop using the mouth rinse, and will start the second RCT, being randomized again, within each group of the first RCT, to the placebo or test toothpaste.~2-4 weeks: The control group will use three times daily a provided manual toothbrush with the placebo toothpaste (identical to the test tooth paste, but without the active ingredients), followed by the use, twice daily, of a 0.12% chlorhexidine mouth rinse."
89196300|NCT00927238|Experimental|XL TDR|The XL TDR is indicated for reconstruction of the disc following discectomy in skeletally mature subjects with symptomatic degenerative disc disease (DDD) of the lumbar spine at one level from L1-L5. DDD is defined as discogenic back pain with degeneration of the disc confirmed by patient history radiographic studies.
89196301|NCT00927238|Other|Outcomes from lumbar fusion study|
88907096|NCT01561482|Experimental|Metformin, Simvastatin|"Both metformin and simvastatin will be taken every day. Metformin will be taken as 1 pill in the morning and 1 pill before going to bed. Simvastatin will be taken as 1 pill before going to bed.~They will be taken until metastasis from the prostate cancer appears or until the subjects PSA has doubled from what it was before they started the study."
88907097|NCT01561586|Active Comparator|A: Weekly cisplatin with RT|Weekly cisplatin 40mg/m2 six cycles concurrent to radiation therapy
88907098|NCT01561586|Experimental|B: Tri-weekly cisplatin with RT|Tri-weekly cisplatin 75mg/m2 three cycles concurrent to radiation therapy
89426174|NCT05354986|Experimental|Control-test|"Immediately after the second session of subgingival instrumentation (initial visit, RCT #1) subjects will be randomly assigned to one of two groups, test or placebo.~0-2 weeks: The control group will use three times daily a provided manual toothbrush with the placebo toothpaste (identical to the test tooth paste, but without the active ingredients), followed by the use, twice daily, of a 0.12% chlorhexidine mouth rinse.~Subjects will stop using the mouth rinse, and will start the second RCT, being randomized again, within each group of the first RCT, to the placebo or test toothpaste.~2-4 weeks: The experimental group will use three times daily a provided manual toothbrush with the test toothpaste (Dentaid, Barcelona, Spain), followed by the use, twice daily, of a 0.12% chlorhexidine, commercially available, mouth rinse."
89426175|NCT05354986|Experimental|Test-control|"Immediately after the second session of subgingival instrumentation (initial visit, RCT #1) subjects will be randomly assigned to one of two groups, test or placebo.~0-2 weeks: The experimental group will use three times daily a provided manual toothbrush with the test toothpaste (Dentaid, Barcelona, Spain), followed by the use, twice daily, of a 0.12% chlorhexidine, commercially available, mouth rinse.~Subjects will stop using the mouth rinse, and will start the second RCT, being randomized again, within each group of the first RCT, to the placebo or test toothpaste.~2-4 weeks: The control group will use three times daily a provided manual toothbrush with the placebo toothpaste (identical to the test tooth paste, but without the active ingredients), followed by the use, twice daily, of a 0.12% chlorhexidine mouth rinse."
89426176|NCT05354986|Experimental|Test-test|"Immediately after the second session of subgingival instrumentation (initial visit, RCT #1) subjects will be randomly assigned to one of two groups, test or placebo.~0-2 weeks: The experimental group will use three times daily a provided manual toothbrush with the test toothpaste (Dentaid, Barcelona, Spain), followed by the use, twice daily, of a 0.12% chlorhexidine, commercially available, mouth rinse.~Subjects will stop using the mouth rinse, and will start the second RCT, being randomized again, within each group of the first RCT, to the placebo or test toothpaste.~2-4 weeks: The experimental group will use three times daily a provided manual toothbrush with the test toothpaste (Dentaid, Barcelona, Spain), followed by the use, twice daily, of a 0.12% chlorhexidine, commercially available, mouth rinse."
89426177|NCT05343741||Helpseeking Ecuadorian adult and adolescent clients|The participants will be adolescent (11-17 years) and adult (>18 years) clients presenting with common non-severe mental health problems who seek mental health services at the Centro de Psicología Aplicada. The CPA is an outpatient psychological service where students of the last semesters of the Clinical Psychology degree develop and practice their psychological care skills as co-therapists of professional clinical psychologists.
89426178|NCT05331521|Active Comparator|RT PCV|"Radiotherapy (RT) for over approximately 5-6 weeks:~at 50.4/54 Gy in 1.8 Gy fractions for grade II and~at 59.4 Gy in 1.8 Gy fractions for grade III gliomas~PCV cycles are 6 weeks long and given as:~Day 1: Lomustine (CCNU) at 110 mg/m2 body surface orally,~Days 8/29: Vincristine 1.4 mg/m2 i.v. (capped at 2 mg),~Days 8-21: Procarbazine 60 mg/m2 orally (capped at 100 mg)."
89426179|NCT05331521|Experimental|CETEG|"Six 42-day cycles of lomustine plus temozolomide according to the commonly used regimen:~Day 1: Lomustine (CCNU) at 100 mg/m2~Days 2-6: Temozolomide at 100 mg/m2 (cycles 1) and in 50 mg/m2 steps to 200 mg/m2 from cycle 2 on dependent on hematological toxicity"
89426180|NCT05328700|Experimental|kinesiotaping|
89426181|NCT05328700|Placebo Comparator|Tape|
89426182|NCT05327933|Experimental|Surgery plus endovascular MMA embolization|
89426183|NCT05327933|Active Comparator|Surgery alone|
89426184|NCT05327426|Experimental|fIPV-dmLT|Intradermal administration of fIPV with the addition of 0.47ug dmLT
89426185|NCT05327426|Active Comparator|fIPV|Intradermal administration of fIPV alone.
89426186|NCT05326776|Experimental|Order 1|Participants will receive 4mcg/2ml oxytocin during Session 1 and 2ml isotonic saline during Session 2, injected into the forearm.
89426187|NCT05326776|Experimental|Order 2|Participants will receive 2ml isotonic saline during Session 1 and 4mcg/2ml oxytocin during Session 2, injected into the forearm.
89426188|NCT05326646|Experimental|IBS patients|Patients suffering from IBS according to Rome IV criteria
89426189|NCT05326399||renal biopsy|Standard percutaneous biopsy has been performed in all participants. Light microscope, fluorescence microscope and electron microscope were used for assessment of kidney issue
89426190|NCT05323656|Experimental|Setanaxib 800 mg and Pembrolizumab 200 mg|Participants will be administered Setanaxib 800 mg twice daily. Participants will also be administered Pembrolizumab 200 mg intravenously every 3 weeks.
89426191|NCT05323656|Active Comparator|Placebo and Pembrolizumab 200 mg|Participants will be administered placebo throughout the 24 month treatment period. Participants will also be administered Pembrolizumab 200 mg intravenously every 3 weeks.
89196302|NCT00926614|Experimental|Pioglitizone and Atorvastatin|Pioglitazone and Atorvastatin added to standard of care Pegasys and weight based ribavirin
89426192|NCT05322512|Experimental|124I-EV|Imaging cohort All enrolled participants will be allocated to undergo three 124I-EV PET/CT scans.
89426193|NCT05322356|Experimental|Intervention|Interstitial Brachytherapy of the Prostate With Iodine 125 Implant With Target Dose Supplementation in the Tumor Volume Guided by the TRINITY® PERINE 3D system
89426194|NCT05321043|Other|Vitamin B2 labeled group|A liquid of vitamin B2 and hand sanitizer (0.12mg/mL) is marked on the patients' hands outside the endoscopy center.
89426195|NCT05317663|Experimental|Waterpipe with Health Warning Label (HWL)|All participants will complete a lab visit where they will smoke waterpipe with HWL for up to 45 minutes.
89426196|NCT05317663|Experimental|Absence of Waterpipe without Health Warning Label (HWL)|All participants will complete a lab visit where they will smoke waterpipe without HWL for up to 45 minutes.
89426197|NCT05313347||Healty Participants with varying BMI|30 healthy participants with a body mass index ranging from 17.5 to 35kg/m2.
89196303|NCT00694356|Experimental|Dalotuzumab 5 mg/kg|Participants receive dalotuzumab 5 mg/kg by intravenous (IV) infusion once each week for up to 1 year or until participant withdraws consent, experiences an adverse event (AE), progressive disease or major protocol violation, has moved or is lost to follow up.
89426198|NCT05310721|Experimental|Early time-restricted eating|Participants will eat ad libitum within an 8-hour early eating window. The first meal will be before 10 am (last meal before 18h). No calorie-containing food or beverage intake will be allowed outside the 8-hour eating window. Participants will also receive standard recommendations on healthy lifestyle based on Mediterranean dietary pattern and physical activity recommendations for weight loss and health promotion
89426199|NCT05310721|Experimental|Late time-restricted eating|Participants will eat ad libitum within an 8-hour late eating window. The first meal will be at 13h or later (last meal not before 21h). No calorie-containing food or beverage intake will be allowed outside the 8-hour eating window. Participants will also receive standard recommendations on healthy lifestyle based on Mediterranean dietary pattern and physical activity recommendations for weight loss and health promotion
89426200|NCT05310721|Experimental|Self-selected time-restricted eating|Participants will self-selecte an 8-hour eating window to eat ad libitum. No calorie-containing food or beverage intake will be allowed outside the 8-hour eating window. Participants will also receive standard recommendations on healthy lifestyle based on Mediterranean dietary pattern and physical activity recommendations for weight loss and health promotion
89426201|NCT05310721|No Intervention|Usual-care group|Participants will receive standard recommendations on healthy lifestyle based on Mediterranean dietary pattern and physical activity recommendations for weight loss and health promotion
89426202|NCT05304507|Experimental|I-PROTECT model|The I-PROTECT model is an end-user-driven intervention including evidence-based, theory-informed, and context-specific injury prevention training for youth handball, and an associated implementation strategy.
89426203|NCT05304507|Active Comparator|Control group|"Youth coaches in the control group club will be asked to use injury prevention training available in the coach education material (Ready for handball), i.e., current practice in Sweden."
89426204|NCT05298319|Experimental|Group 1|10 L/min of oxygen flow
89426205|NCT05298319|Experimental|Group 2|20 L/min of oxygen flow
89426206|NCT05298319|Experimental|Group 3|30 L/min of oxygen flow
89426207|NCT05298319|Experimental|Group 4|40 L/min of oxygen flow
89426208|NCT05298319|Experimental|Group 5|50 L/min of oxygen flow
89426209|NCT05298319|Experimental|Group 6|60 L/min of oxygen flow
89426210|NCT05295875|Experimental|ALT-801 Dose Level 1|
89426211|NCT05295875|Experimental|ALT-801 Dose Level 2|
89426212|NCT05295875|Experimental|ALT-801 Dose Level 3|
89426213|NCT05295875|Placebo Comparator|Placebo|
89426214|NCT05295810|No Intervention|Room Air|All participants will complete an active stand breathing room air with CO2 free to fluctuate
89426215|NCT05295810|Experimental|+0mmHg CO2 Clamped at baseline|All participants will complete an active stand with their CO2 held constant at baseline
89426216|NCT05295810|Experimental|+5mmHg CO2|All participants will complete an active stand breathing +5mmHg of CO2 relative to baseline
89426217|NCT05295810|Experimental|+10mmHg|All participants will complete an active stand breathing +10mmHg of CO2 relative to baseline
89426218|NCT05295810|Experimental|+10mmHg CO2 + 50mmHg O2|All participants will complete an active stand breathing +10mmHg of CO2 relative to baseline and 50mmHg of O2
89196304|NCT00694356|Experimental|Dalotuzumab 10 mg/kg|Participants receive dalotuzumab 10 mg/kg by IV infusion once each week for up to 1 year or until participant withdraws consent, experiences an AE, progressive disease or major protocol violation, has moved or is lost to follow up.
88814773|NCT01662791|Experimental|Case Group|All individuals in the Case group (i.e., only the subjects who had lost weight) were offered open-label treatment with the poorly absorbed antibiotic, rifaximin, 550 mg PO twice a day (BID) for 14 days. Subjects in the case group were in the study for 3 months.
89196305|NCT00694356|Experimental|Dalotuzumab 15 mg/kg/7.5 mg/kg|Participants receive an initial dose of dalotuzumab 15 mg/kg by IV infusion followed by a maintenance dose of dalotuzumab 7.5 mg/kg by IV infusion once every 2 weeks for up to 1 year or until participant withdraws consent, experiences an AE, progressive disease or major protocol violation, has moved or is lost to follow up.
89196306|NCT00926692||Healthy Subjects|All subjects are considered healthy
89196307|NCT00907114|Active Comparator|Ketorolac tromethamine|ocular topic ketorolac used 4 times a day during a week after panphotocoagulation
89196308|NCT00907114|Placebo Comparator|Polivynilic alcohol|ocular lubricant drops 4 times a day during one week after panphotocoagulation
89196309|NCT00692406|Experimental|Smokers not interested in quitting smoking|Smokers were scanned 24 hours after quitting smoking, and scanned after smoking as usual.
89196310|NCT00927316|Active Comparator|Active arm|E. coli 83972 bacteriuria
89196311|NCT00927316|Placebo Comparator|Placebo arm|Monitoring
89196312|NCT00926770||Pretem infants (GG < 37+0)|
89426219|NCT05295225|Active Comparator|Green Light Exposure|Subjects will complete thermal and mechanical pain threshold detection tests and Electroencephalography (EEG). After completion, subjects will be exposed to a green light-emitting diode for two hours. After exposure, thermal and mechanical pain threshold assessments and Electroencephalography (EEG) will be conducted.
88814774|NCT01662791|No Intervention|Control Group|This arm consisted of subjects with Parkinson's Disease who had not experienced significant weight loss. These patients were in the study for one day.
88814775|NCT03035240|Experimental|Financial Education Intervention|
88814776|NCT03035240|No Intervention|No Financial Education Intervention|
88814777|NCT05711225|Experimental|Experimental group|"The behavior stage was determined by applying the Stages of Change Scale (SCS) form to the pregnant women in the experimental group. The pre-test data from the women in the experimental group were obtained through the website through the Participant Introduction Form,Behavior Change Process Scale (BCPS), Self-Efficacy Scale/Encouraging Factors Scale (SES/EFS) and Decision Balance Scale (DBS) before watching the videos. In addition, FNDT was applied to women who smoked during pregnancy. Post-test data from the women in the experimental group were collected by having them fill out the postpartum part of the Participant Identification Form at the 4th week postpartum after watching the animation videos, and FNDT, SCS, BCPS/EFS and DBS forms for those who still smoke, on the website."
88814778|NCT05711225|No Intervention|Control group|"The behavior stage was determined by applying the Stages of Change Scale (SCS) form to the women participating in the control group. The pre-test data of the women participating in the control group were applied via the Participant Identification Form, FNDT, SCS, BCPS/EFS and DBS and the FNDT form to those who continued to smoke during pregnancy. Post-test data from women in the control group were collected with the postpartum part of the Participant Identification Form at 4 weeks postpartum, FNDT, SCS, BCPS/EFS and DBS for smokers."
88814779|NCT03035396|Experimental|Diassess Influenza A and B Test|
88814780|NCT03035162|Experimental|Active tDCS & PT|Dual transcranial direct current stimulation (tDCS) will be applied over the leg motor area (M1) priori to conventional physical therapy (1 hours). Anodal on affected hemisphere, Cathodal on unaffected hemisphere. Current intensity is fixed at 2 mA and current will flow continuously during 20 minutes for the active conditions. Physical therapist will give an intervention program exactly the same in all cases. The scope of intervention is administered to improve strength of weakened and postural lower limbs muscles such as trunk muscles, hip flexors/extensors/abductors, knee flexors/extensors.
88814781|NCT03035162|Active Comparator|Sham tDCS & PT|Dual transcranial direct current stimulation (tDCS) will be applied over the leg motor area (M1) priori to conventional physical therapy (1 hours). Anodal on affected hemisphere, Cathodal on unaffected hemisphere. Current intensity is fixed at 2 mA and current will flow only 2 minutes for the sham conditions. Physical therapist will give an intervention program exactly the same in all cases. The scope of intervention is administered to improve strength of weakened and postural lower limbs muscles such as trunk muscles, hip flexors/extensors/abductors, knee flexors/extensors.
88814782|NCT02245646||Control group|No indication for stapedotomy
89426220|NCT05295225|Placebo Comparator|White Light Exposure|Subjects will complete thermal and mechanical pain threshold detection tests and Electroencephalography (EEG). After completion, subjects will be exposed to a white light-emitting diode for two hours. After exposure, thermal and mechanical pain threshold assessments and Electroencephalography (EEG) will be conducted.
89196313|NCT03415464|Experimental|Functional training|15 weeks of structured exercise intervention in the form of functional training. We have divided 15 weeks into 5 cycles each cycle lasting 3 weeks. Intervention will be administered twice per week, and each session will last 45 minutes.Each 45 minutes will be further divided into 10 minutes of functional warm-up, 30 minutes of neuromuscular training (strength, agility, balance, coordination) and 5 minutes of cool down. During the 3 week period the intensity of exercise will be increased with different form of same exercise, different number of repetitions and exercise duration.
89426221|NCT05289869|Experimental|High-dose oxytocin regimen|Starting dose 6 mU/min and increased by 6 mU/min every 30 minutes until adequate contractions achieved, at the discretion of the obstetric providers.
89426222|NCT05289869|Experimental|Low-dose oxytocin regimen|Starting dose 2 mU/min and increased by 2 mU/min every 30 minutes until adequate contractions achieved, at the discretion of the obstetric providers.
89426223|NCT05289804|Experimental|Active NITESGON|One electrode each will be placed over the left and right C2 dermatomes. A constant current will be applied during the word association task.
89426224|NCT05289804|Sham Comparator|Sham NITESGON|For sham NITESGON (inactive control), placement of the electrodes will be identical to active NITESGON. Current intensity (ramp down) will gradually be reduced as soon as NITESGON reaches a current flow of 1.5 mA. The rationale behind this sham procedure is to mimic the transient skin sensation at the beginning of active NITESGON without producing any conditioning effects on the brain.
89426225|NCT05289804|Active Comparator|Active NITESGON + local anesthesia|For active NITESGON + local anesthesia (active control; local nerve anesthesia group), patients will receive NITESGON, in combination with a topical skin anesthetic (lidocaine/prilocaine cream) to reduce any potential contribution from transcutaneous stimulation of peripheral nerves. A current similar to active NITESGON will be applied.
89426226|NCT05289804|Active Comparator|Active C5/C6|For the active C5/C6 group (active control; same sensation different nerve), the electrodes will be placed over cervical nerves five and six, to mimic the sensation, but change the location. A current similar to active NITESGON will be applied.
89426227|NCT05282381||Cohort of renal transplant recipients|
89426228|NCT05281172|Experimental|Guided Self-Change therapy|
89426229|NCT05281172|Active Comparator|Psychoeducation program about healthy habits|
88814783|NCT02245646||Distortion positive|Subjects after stapedotomy perceiving sound distortions
88814784|NCT02245646||Distortion negative|Subjects after stapedotomy not perceiving sound distortions.
88814785|NCT03031886|Experimental|high GI|Cereal, milk, tea, cheese, steamed glutinous rice with chicken, carrots, bread, strawberry jam, margarine, high GI sweetener (sucrose).
89426230|NCT05278819|Experimental|upper extremity elevation|performing intervention A (5 repetitions of upper extremity elevation), and then crossed over to intervention B (5 repetitions of upper extremity with deep breathing).
89426231|NCT05278819|Experimental|upper extremity elevation with deep breathing|performing intervention B (5 repetitions of upper extremity with deep breathing), and then crossed over to intervention A (5 repetitions of upper extremity elevation).
89426232|NCT05278585||RAP TAVI group|All patients in sinus rhythm with TAVI
89426233|NCT05271864||Group A|diabetes mellites
89426234|NCT05271864||Group B|hypertension
89426235|NCT05271864||Group C|hyperlipidemia
89426236|NCT05271162|Active Comparator|Empagliflozin|Empagliflozin, 10 mg q.d; p.o
89426237|NCT05271162|Placebo Comparator|Placebo|Placebo 1 tabl q.d; p.o
89426238|NCT05268081|Experimental|Virtual specialist conferences|The group of general practices who participates in the virtual specialist conferences with endocrinologists.
89426239|NCT05268081|No Intervention|Standard of care|Receives the usual, standard practice.
89426240|NCT05259943|Placebo Comparator|Blinded Placebo|In this condition participants will receive an inert placebo once weekly for 4 weeks, but they will not know whether they receive placebo or psilocybin.
89426241|NCT05259943|Experimental|Blinded Psilocybin|In this condition participants will receive psilocybin once weekly for 4 weeks, but they will not know whether they receive placebo or psilocybin.
89426242|NCT05259943|Experimental|Open Label|In this condition participants will receive psilocybin once weekly for 4 weeks, and will be told that they are receiving psilocybin.
89426243|NCT05255952|Experimental|Patients|"3 cycles of electrical stimualtions will be done at the end of cardiac surgery, before end of surgery (patient closure), under anaesthesia.~Cardiac outcomes will be monitored"
89426244|NCT05255731|Active Comparator|Laser Group (GL)|Patients will be submitted to a low power laser application immediately after suturing of the surgical area. The radiation emission shall be conducted according to protocol.
89426245|NCT05255731|Placebo Comparator|Control Group (CG)|In these patients the investigators will use the same protocol applied in the experimental group (time and application values) but the laser device will be turn off.
89426246|NCT05255692|Experimental|Complete evaluation UDO and fMRI|Evaluation including both urodynamic evaluation and functional MRI testing
89426247|NCT05249361||Duchenne Muscular Dystrophy|Children aged 5 to 18 years with Duchenne muscular dystrophy
89426248|NCT05248789|Experimental|OH2|OH2 dosage: 1x10e7 CCID50/mL Administration：intratumoral injection Frequency：once two weeks
89196314|NCT03415464|No Intervention|Regular army training|Regular military training.
89196315|NCT03384108|Experimental|In Vivo|Infusion of 5-13C-Glutamine intravenously in healthy subjects prior to undergoing a bone marrow aspiration.
89196316|NCT03384108|Placebo Comparator|Ex Vivo|Healthy subjects will undergoing a bone marrow aspiration and then the plasma cells acquired will be cultured ex vivo in cell culture media containing 5-13C-Glutamine.
89196317|NCT03883152||Head and neck cancer|Eating difficulty is one of the most common problems for head and neck cancer (HNC), in particular, who are in advanced disease stage and receive surgery, radiation (RT) or concurrent radio-chemotherapy (CCRT) (Vissink, Burlage, Spijkervet, Jansma, & Coppes, 2003; Lazarus et al., 2014). The consequences of multi-treatment bring structural and functional changes in oral, pharynx, or larynx and influence the normal eating process (Logemann et al., 2006; Lazarus et al., 2013; Patterson, McColl, Wilson, Carding, Rapley, 2015; McLaughlin, 2014).
89196318|NCT02564094|Experimental|Epoetin beta|Participants with hematologic or solid malignancies will receive epoetin beta for a treatment period of approximately 20 weeks.
89426249|NCT05246592||Preponderant lymphatic reflux group|high ratio of axillary lymphatic reflux to axillary vein reflux
89426250|NCT05246592||Preponderant venous reflux group|low ratio of axillary lymphatic reflux to axillary vein reflux
89426251|NCT05246410|Experimental|Spot stent system|A system that loaded multi low radial force stents on one catheter.
89426252|NCT05246410|Active Comparator|Self-Expanding peripheral stent system|A conventional stent system that commonly used.
89196319|NCT00745914|Experimental|1|Pioglitazone drug 15mg daily for 3 months then 30mg for 9 months (Peroxisome Proliferator-Activated Receptor-gamma agonist)
89196320|NCT00745914|Placebo Comparator|2|placebo comparator drug 15mg daily for 3months, then 30mg for 9 months
89196321|NCT00746070||A, primary aldosteronism|patients approved to be aldosteronism
89426253|NCT05244499|Experimental|Evidence-based leadership training|The training course will take 6 months. It is divided into seven online modules. Participants join the course based on pre-structured schedule. The progress of the training course will follow specific steps to improve participants' evidence-based leadership competencies. First, each participant identifies one leadership problem on daily practice. Second, organisational data will be collected and analysed to increase the understanding of the key problem. Third, scientific literature will be searched, identified and critically appraised to find solutions. Fourth, the views of stakeholders (patients, clinicians, family members, etc.) are considered together with ethical implications. And last, all sources of information are critically appraised, new solution will be designed and implemented into the practice, and evaluated in real world context. Each module includes specific learning material. Trained tutors are responsible for mentoring each module.
89426254|NCT05244499|Active Comparator|Conventional training|The participants will join a training course with the same structure, topics, and timing as the experimental group. However, training in this group is based on independent learning methods. The participants have access to the separate learning platform, which includes reading material to be read independently. No group discussions with peers, self-reflection, assignments, or support from tutors will be offered.
89426255|NCT05244382|Experimental|Overcome group|Three-month multimodal program. Aerobic exercise will be combined with the use of TRAG (AlterG® Anti-Gravity Treadmill®), functional recovery of motor control with feedback ultrasound and occupational therapy.
89426256|NCT05244382|No Intervention|Usual treatment|Usual medical treatment for the same period of time
89426257|NCT05238246|Sham Comparator|Standard treatment group|Dental treatment was carried out with tell-show-do technique as a behavioural guidance technique.
89426258|NCT05238246|Experimental|Robot group|The robot group (RG) were treated with the robot accompaniment
89426259|NCT05237570|No Intervention|Control group|After the molar extraction, no intervention will be performed.
89426260|NCT05237570|Experimental|Interradicular septum window group|After the extraction of the molar, the maxillary sinus membrane will be elevated through a micro-window, previously done in the interradicular septum.
89426261|NCT05236842|Active Comparator|Sulthiame 100 mg|Sulthiame film-coated tablets 100 mg once daily 15 weeks
89426262|NCT05236842|Active Comparator|Sulthiame 200 mg|Sulthiame film-coated tablets 200 mg once daily 15 weeks
89426263|NCT05236842|Active Comparator|Sulthiame 300 mg|Sulthiame film-coated tablets 300 mg once daily 15 weeks
89426264|NCT05236842|Placebo Comparator|Placebo|Placebo film-coated tablets once daily 15 weeks
89426265|NCT05231486|Experimental|Cognitive Orientation to daily Occupational Performance 1|"This arm is the first group composed of four childrens who will do the CO-OP. CO-OP uses cognitive problem solving techniques to facilitate motor skill acquisition. The therapist facilitates with guided discovery the child to generate solution for problems in their performance areas.~The four patients will begin the sessions one week apart each."
89426266|NCT05231486|Experimental|Cognitive Orientation to daily Occupational Performance 2|"This arm is the second group composed of four others childrens who will do the CO-OP.~CO-OP uses cognitive problem solving techniques to facilitate motor skill acquisition. The therapist facilitates with guided discovery the child to generate solution for problems in their performance areas The four patients will begin the sessions one week apart each."
89196322|NCT00746070||B, essential hypertension|patients approved to be essential hypertension
89196323|NCT00746148|Experimental|1|Reflexology
89426267|NCT05231486|Experimental|Cognitive Orientation to daily Occupational Performance 3|"This arm is the third group composed of four others childrens who will do the CO-OP.~CO-OP uses cognitive problem solving techniques to facilitate motor skill acquisition. The therapist facilitates with guided discovery the child to generate solution for problems in their performance areas The four patients will begin the sessions one week apart each."
89426268|NCT05231486|Experimental|Cognitive Orientation to daily Occupational Performance 4|"This arm is the fourth group composed of four others childrens who will do the CO-OP.~CO-OP uses cognitive problem solving techniques to facilitate motor skill acquisition. The therapist facilitates with guided discovery the child to generate solution for problems in their performance areas The four patients will begin the sessions one week apart each."
88907099|NCT01561859|Experimental|Cognitive enhancement therapy|Cognitive Enhancement Therapy (CET) consists of approximately 60 hours of computer-assisted neurocognitive training in attention, memory, and problem-solving; and 45 social-cognitive group sessions that employ in vivo learning experiences to foster the development of social wisdom and success in interpersonal interactions. CET begins with 3 months of weekly 1-hour neurocognitive training in attention, after which patients begin the weekly 1.5-hour social-cognitive groups. Neurocognitive training then proceeds concurrently with the socialcognitive groups
89196324|NCT00746148|No Intervention|2|No intervention
89196325|NCT00746226|Active Comparator|A|Numbers 509-513, 700-709 and 900-909 Probiotic combination of L. acidophilus and B. lactis
89196326|NCT00746226|Placebo Comparator|B|"Numbers 612-624 and 800-811~Microcrystalline cellulose"
89196327|NCT00567502||1|XAGRID® (anagrelide hydrochloride)
89196328|NCT00567502||2|Xagrid + Other cytoreductive
89196329|NCT00567502||3|Other cytoreductive
89196330|NCT00746304||1|infantile esotropia
89196331|NCT00746304||2|acquired esotropia
89196332|NCT00396331|Experimental|G-CSF plus Plerixafor|
89196333|NCT00927550|Experimental|lithium plus usual care|
89196334|NCT00927550|Active Comparator|usual care without lithium therapy|
89196335|NCT00926926|Experimental|Active OTG|
89426269|NCT05231486|Experimental|Cognitive Orientation to daily Occupational Performance 5|"This arm is the fifth group composed of four others childrens who will do the CO-OP.~CO-OP uses cognitive problem solving techniques to facilitate motor skill acquisition. The therapist facilitates with guided discovery the child to generate solution for problems in their performance areas The four patients will begin the sessions one week apart each."
89426270|NCT05230940|Experimental|TURKOVAC|The dose of the TURKOVAC vaccine will be 3 μg/0.5 mL. It will be administered by injection to the left deltoid muscle of the upper arm, two doses are given 28 days apart.
89426271|NCT05230940|Active Comparator|CoronaVac|The dose of the CoronaVac vaccine will be 3 μg/0.5 mL. It will be administered by injection to the left deltoid muscle of the upper arm, two doses are given 28 days apart.
89426272|NCT05218382|Experimental|VR group|The participants will have the the virtual reality headset with immersive virtual reality.
89426273|NCT05218382|Placebo Comparator|Placeob group|The participants will have the virtual reality headset put on but blank screen.
89426274|NCT05217498|Experimental|Istradefylline+low oxygen training|"Drug: Nourianz Other Names: KW6002, Istradefylline~Participants enrolled in this study arm will ingest a 20mg tablet/day containing istradefylline starting 14 days prior to the first low oxygen therapy and continuing for 14 additional days. Participants will consume a total of 28 istradefylline tablets.~Other: low oxygen training Other Names: therapeutic intermittent hypoxia, acute intermittent hypoxia~Participants will breathe 15 episodes/session of acute low oxygen via an automated air generator system (4 sessions/week x 2 weeks). During the 90-second episodes of low oxygen, air concentrations will be continuously monitored to ensure delivery of FIO2 (fraction of inspired oxygen) = 0.10±0.02 (hypoxia) with 60-second room-air intervals (FIO2 0.21±0.02).~Throughout experimentation, blood pressure, respiratory rate, and heart rate will be monitored. We also will assess for changes in sleep quality and pain level."
88907100|NCT01561859|Active Comparator|Enriched Supportive Therapy|"Enriched Supportive Therapy is an individual approach that includes the established principles of supportive therapy previously tested by our group, which are enriched by selected practice principles from the effective Personal Therapy. These manualized supportive therapeutic practices include active listening, correct empathy, appropriate reassurance, basic psychoeducation, including computer-based educational programs, reinforcement of health-promoting initiatives, the provision of case management, and reliance on the advocacy and advice of the therapist in times of crisis."
88907101|NCT01562145||Patients with rotator cuff tears|Patients with ultrasound verified rotator cuff tears
88907102|NCT01562145||Healthy controls|Age and gender matched controls with ultrasound verified intact rotator cuff
88907103|NCT01562171|Experimental|Cooked Lentils|The study group will be asked to consume food items containing one serving of (0.3 cups) of cooked lentils per day for the first 5 days, followed by one serving of (0.6 cups) of cooked lentils per day 5 times per week (equivalent of 3 cups cooked lentils per week) for the remainder of the 12-week schedule.
88907104|NCT01562171|Active Comparator|Potato-Based Foods|The control group will be asked to consume one serving per day of potato-based foods in matrices similar to those containing lentils in the same 12-week schedule, including the smaller serving size for the first 5 days.
88907105|NCT01562184|Active Comparator|Active tDCS|Active tDCS
88907106|NCT01562184|Sham Comparator|Sham tDCS|Sham tDCS
88907107|NCT01562392|Experimental|berries and vegetables|subjects include specific berries and vegetables in the diet
88907108|NCT01562392|Placebo Comparator|control product|Control product with equivalent amounts of carbohydrates but without vegetables and berries.
88907109|NCT01562574|Experimental|Activated recombinant human factor VII|
88907110|NCT01562574|Placebo Comparator|Placebo|
88907111|NCT01562587|Experimental|Adults|
88907112|NCT01562587|Experimental|Paediatric|
88907113|NCT01562704|Experimental|paracetamol|
88907114|NCT01562704|Placebo Comparator|placebo|
88907115|NCT01562821|Experimental|Low dose|
88907116|NCT01562821|Experimental|High dose|
88907117|NCT01562821|Placebo Comparator|Placebo|
88907118|NCT01563133|Other|Lymph nodes, pancreatic masses & cysts|
89196336|NCT00926926|Placebo Comparator|Placebo|
89196337|NCT00396253|Experimental|Tenecteplase|At each treatment, subjects had 2 mL (2 mg) of tenecteplase instilled into each lumen of their HD catheter. Subjects could receive up to three treatments with tenecteplase, the first two as part of the initial treatment course and one additional treatment as part of the retreatment (RT) course. The first treatment, followed by a 1-hour dwell time, was given to all subjects at Visit 1. At the end of hemodialysis at Visit 1, eligible subjects had a second treatment instilled for an extended dwell time until the start of Visit 2 (up to 72 hours).
88907119|NCT01563263|Active Comparator|IC43 100 mcg|IC43 100 mcg intramuscular injection, IC43 is a recombinant Pseudomonas aeruginosa fusion protein
88907120|NCT01563263|Placebo Comparator|Placebo|phosphate buffered saline solution containing 0,9 % NaCL
88907121|NCT01563445|Experimental|activated recombinant human factor VII|
88907122|NCT01563445|Placebo Comparator|Placebo|
88907123|NCT01563458|Experimental|High dose|
88907124|NCT01563458|Experimental|Low dose|
88907125|NCT01563458|Placebo Comparator|Placebo|
88907126|NCT01563471|Experimental|Treatment sequence 1|
88907127|NCT01563471|Experimental|Treatment sequence 2|
88907128|NCT01563471|Experimental|Treatment sequence 3|
88907129|NCT01563471|Placebo Comparator|Treatment sequence 4|
88907130|NCT01563497|Experimental|PF-05089771 Oral Dispersion fasted|Oral dispersion TS formulation- fasted
88907131|NCT01563497|Experimental|PF-05089771 TS formulation fasted|Tablets TS formulation- fasted
88907132|NCT01563497|Experimental|PF-05089771 TS formulation fed|Tablets TS formulation- fed
88907133|NCT01563510|Experimental|Laparoscopic operation|Total laparoscopic anatomical hepatectomy were performed, combined with cholecystectomy and bile duct exploration when necessary. The intraoperative ultrasound, choledochoscope and hepatic segmental staining were used selectively.
88907134|NCT01563510|Active Comparator|Open operation|The traditional open regular hepatectomy were performed, combined with cholecystectomy and bile duct exploration when necessary. The intraoperative ultrasound and choledochoscope were used selectively.
88907135|NCT01563523|Experimental|Activated recombinant human factor VII|
88907136|NCT01563523|Placebo Comparator|Placebo|
88907137|NCT01563900|Sham Comparator|sham-CPAP group|The sham-CPAP device will be set at 4 centimeters of water pressure (cwp).
88907138|NCT01563900|Active Comparator|Auto-titration CPAP|This group will received an auto-titration CPAP, which will have a pressure range of 5 to 15 cwp. This device delivers pressure as needed by the patient at any given time while using the device.
88907139|NCT01564095|Experimental|Tacrolimus + HTK|Ex vivo Tacrolimus Rinse (20 ng/ml solved in 1000 ml HTK) of marginal liver grafts prior to implantation
88907140|NCT01564095|Placebo Comparator|HTK|Ex vivo Rinse (1000 ml HTK) of marginal liver grafts prior to implantation
88907141|NCT01564186||MulitPoint Pacing|
88907142|NCT01564186||BiV Conventional|
88907143|NCT01564238|Experimental|High calcium diets (1300 mg or higher)|
89196338|NCT00927628||Vitrectomy|Patients underwent vitrectomy with or without internal limiting membrane (ILM) peeling for an idiopathic full-thickness macular hole. Simultaneous phacoemulsification with intraocular lens implantation was performed on all phakic patients who were >40-years-of-age.
89196339|NCT00927706|Experimental|Immediate intervention|Subjects and their caregivers randomized to this arm receive the intervention immediately after baseline data is collected.
88907144|NCT01564238|Experimental|Low calcium diet (800 mg/d)|
88907145|NCT01564420||Intrathecal morphine|Patients were randomized for general anesthesia, and allocated in the control group and morphine intrathecal group.
88907146|NCT01564420||Control group|
88907147|NCT01564576|No Intervention|Conventional neuromuscular blockade|The dose of rocuronium (medication used for NMB during anesthesia)will be adjusted to maintain a depth of NMB of T1 of 10-20% as assessed by a nerve stimulator. At the end of surgery patients will receive neostigmine 2.5 mg and atropine 1 mg to reverse the effect of rocuronium. Extubation will be performed when train-of-four ratio ≥ 0.9.
88907148|NCT01564576|Experimental|Profound neuromuscular blockade|Rocuronium dose will be adjusted to maintain a depth of NMB of zero response to train of four and a post tetanic count of no more than 10 responses. At the end of surgery patients will receive a single bolus dose of 4 mg/kg sugammadex according to ideal body weight + 40%12. Extubation will be performed when train-of-four ratios ≥ 0.9.
88907149|NCT01564771||Group one|Adults ≥18 years of age with chest X-ray confirmed CAP
88907150|NCT01564823|Experimental|Metronidazole + Azathioprine.|Metronidazole, oral intake. 250 mg/8h. 3 months. Azathioprine, 2.5 mg/weight kg/day, oral intake. All study.
89196340|NCT00927706|Experimental|Delayed Intervention|Subjects and their caregivers who are randomized to this group will receive the intervention after baseline measurements are administered twice (6 weeks apart).
89196341|NCT00927004|Experimental|Etoricoxib 60 mg|
89196342|NCT00927004|Placebo Comparator|Sugar pill|
89426275|NCT05217498|Active Comparator|Placebo+low oxygen training|"This is a placebo counterpart to the istradefylline drug.~Participants enrolled in this study arm will ingest a 20mg placebo tablet/day containing dextrose starting 14 days prior to the first low oxygen therapy (LOT) and continuing for 14 additional days. Participants will consume a total of 28 placebo tablets.~Other: low oxygen training Other Names: therapeutic intermittent hypoxia, acute intermittent hypoxia~Participants will breathe 15 episodes/session of acute low oxygen via an automated air generator system (4 sessions/week x 2 weeks). During the 90-second episodes of low oxygen, air concentrations will be continuously monitored to ensure delivery of FIO2 (fraction of inspired oxygen) = 0.10±0.02 (hypoxia) with 60-second room-air intervals (FIO2 0.21±0.02).~Throughout experimentation, blood pressure, respiratory rate, and heart rate will be monitored. We also will assess for changes in sleep quality and pain level."
88907151|NCT01564823|Active Comparator|Metronidazole + Adalimumab|Metronidazole Oral Intake. 250 mg/8h. During 3 months. Adalimumab Subcutaneous 160 mg and 80 mg 2wk. Then 40 mg during 2wk as maintenance.
88907152|NCT01565005||Microcephaly|Microcephaly Intellectual abilities Cranial MRI
88907153|NCT01565005||FANCONI ANEMIA|
88907154|NCT01565239|Experimental|Fiix PT (Fiix-INR) monitoring and dosing of warfarin|The modified prothrombin time, sensitive only to factor II and X activity, will be used to monitor and dose warfarin.
88907155|NCT01565239|Active Comparator|PT (INR) monitoring and dosing of warfarin|The prothrombin time, sensitive to factors II, VII and X activity, will be used to monitor and dose warfarin.
88907156|NCT01565265|Active Comparator|GnRH agonist long protocol|Pergoveris will be administered daily from cycle day 2 to ovulation induction together with decapeptyl, which will be administered from the midluteal phase of the preceding menstrual cycle up to ovulation induction.
88907157|NCT01565265|Experimental|antagonist protocol|Pergoveris will be administered daily from cycle day 2 to ovulation induction together with Cetrotide, which will be administered from the day six up to ovulation induction.
88907158|NCT01565473||Parkinson disease patients|
88907159|NCT01565473||Healthy normal controls|
88907160|NCT01565863|Experimental|Progressive Goal Attainment Program|
88907161|NCT01565863|No Intervention|VA employment services|
88907162|NCT01566292|Experimental|BOTOX|
88907163|NCT01566344|Experimental|Routine heart failure therapy plus PVC suppression therapy|
88907164|NCT01566344|No Intervention|Routine heart failure therapy|
88907165|NCT01566357|No Intervention|Fluoride-free toothpaste|
88907166|NCT01566357|Active Comparator|Fluoride toothpaste|
88907167|NCT01566357|Active Comparator|Milk|
88907168|NCT01566357|Active Comparator|Fluoridated milk|
89426276|NCT05217498|Active Comparator|Istradefylline+SHAM|"Drug: Nourianz Other Names: KW6002, Istradefylline~This is a SHAM counterpart to low oxygen therapy.~Participants enrolled in this study arm will ingest a 20mg tablet/day containing istradefylline starting 14 days prior to the first SHAM therapy and continuing for 14 additional days. Participants will consume a total of 28 istradefylline tablets.~Participants will breathe 15 episodes/session of SHAM via an automated air generator system (4 sessions/week x 2 weeks). The system will fill reservoir bags attached to a non-rebreathing face mask. During the 90-second episodes of SHAM, air concentrations will be continuously monitored to ensure delivery of FIO2 (fraction of inspired oxygen) = 0.21±0.02 (normoxia) with 60-second room-air intervals (FIO2 0.21±0.02).~Throughout experimentation, blood pressure, respiratory rate, and heart rate will be monitored. We also will assess for changes in sleep quality and pain level."
89196343|NCT00604162|Experimental|PillCam COLON and Colonoscopy|Subjects that are indicated for colonoscopy, who are suspected or known to suffer from large bowel diseases, had capsule endoscopy with PillCam COLON after bowel preparation and before standard colonoscopy.
89196344|NCT02538328|Active Comparator|harmonic scapel|Obesity surgery cases where hamonic scalpel is used for the comparison of different surgical devices
89426277|NCT05217199||1/high risk of infants for cp|1/ high risk of infants for cp was evaulated.
89426278|NCT05215327|Experimental|Two Doses High Dose Quadrivalent Inactivated Influenza Vaccine|two doses of HD-QIV (0.7 mL; 60µg of each influenza antigen) 28-42 days apart
89426279|NCT05215327|Experimental|Two Doses Standard Dose Quadrivalent Inactivated Influenza Vaccine|receive two doses of SD-QIV (0.5 mL; 15µg of each influenza antigen) 28-42 days apart
89426280|NCT05214326||Participants with moderate to severe atopic dermatitis|Participants initiating dupilumab therapy within 30 days of enrollment, according to the treating physician's decision independently of study participation.
88907169|NCT01566357|Active Comparator|CPP-ACP|
89426281|NCT05210179|Active Comparator|TURKOVAC-Koçak|The dose of the TURKOVAC vaccine will be 3 μg/0.5 mL and will be administered by injection into the deltoid muscle.
89196345|NCT02538328|Placebo Comparator|Ligasure sealing device|Ligasure used in obesity surgery for the comparison of different surgical devices Randomly chosen cases where ligasure is used instead of hamonic scalpel in surgical procedures comparison of multiple dissectors
89426282|NCT05210179|Active Comparator|TURKOVAC-Dollvet|The dose of the TURKOVAC vaccine will be 3 μg/0.5 mL and will be administered by injection into the deltoid muscle.
89426283|NCT05207098||Neurocognitive Tests and Questionnaires|The performance-based measures will be administered with a total completion time estimated to be 90 minutes. The neurocognitive battery is similar in content and duration to multiple previous and ongoing studies being conducted by the Neurocognitive Research Lab.
89426284|NCT05200130|Active Comparator|Home exercise group|The home exercise program will be explained to the patients in the control group by the physiotherapist and the relevant brochures will be delivered to the patients. Home exercise program will take 30-45 min. İt will be applied 5 days a week for 8 weeks. Patients will receive a reminder message from the physiotherapist once a week.
89196346|NCT00396097|Active Comparator|Standard|Standard daily HGH treatment
89196347|NCT00396097|Active Comparator|Formula-based|Formula-based dose regimen
89196348|NCT00907192||Opioids|Personal Interview and Questionnaire of Advanced cancer patients, taking narcotic pain drugs (opioids).
89196349|NCT04014946|Other|ICD implantation|Implantation of a Lumax 540 single/dual chamber ICD or successor according to local practice within 3 months after enrolment. The patient will be implanted with a single or dual chamber device according to ESC guidelines.
89196350|NCT00931450|Active Comparator|Group 1|Patients receive oral exemestane and oral placebo once daily on days 1-28. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.
89196351|NCT00931450|Experimental|Group 2|Patients receive oral exemestane once daily and oral sunitinib malate once daily on days 1-28. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.
89426285|NCT05200130|Active Comparator|Manual Therapy Group|Patients in the Manual Therapy Group will receive one-to-one physiotherapy sessions in the hospital 2 days a week for 8 weeks. In these sessions, soft tissue and joint mobilizations and exercises will be applied by physiotherapist.
89426286|NCT05200130|Experimental|Telerehabilitation Supported Group|Telerehabilitation program will be applied 2 days a week for 8 weeks to patients in the telerehabilitation group. İt will take 30-45 min. A physiotherapist will meet with patients via videoconferencing over the internet and guide the program.
89196352|NCT00928330|Experimental|A|
89196353|NCT00928330|Experimental|B|
89196354|NCT00928330|Experimental|C|
89426287|NCT05199844||Group A|cardiac patients with regular heart rate
89426288|NCT05199844||Group B|cardiac patients with irregular heart rate
89426289|NCT05199454|Experimental|Exercise training|Aerobic exercise training for 12 weeks, 3 times per week, 60 minutes per session.
89426290|NCT05199454|No Intervention|Control (standards of care)|This arm will receive brochures for healthy lifestyle recommendations. No intervention will be conducted.
89426291|NCT05191979|Active Comparator|Blood volume interactions with cardiovascular adaptations|Individual differences in the time course and relationship between cardiovascular (central and peripheral) adaptations to long-term aerobic training and the concomitant blood volume changes.
89426292|NCT05191979|Active Comparator|Sex differences|Evaluate differences between genders and hormonal factors influencing individual differences (high vs. low responders) - hypothesizing that female have a blunted cardiovascular response to long-term aerobic training.
88907170|NCT01566357|Active Comparator|Fluoridated CPP-ACP|
89426293|NCT05178563|Experimental|IPT+PDT|The experimental arm consist of performing IPT in randomly assigning patients to receive local use of photodynamic therapy (PDT).
89426294|NCT05178563|Sham Comparator|; IPT+Placebo|This experimental arm consist of performing IPT in randomly assigning patients to receive sham use of photodynamic therapy(PDT).
89426295|NCT05177419|Experimental|High-dose LSD|High dose of lysergic acid diethylamide
89426296|NCT05177419|Active Comparator|Low-dose LSD|Low dose of lysergic acid diethylamide
89426297|NCT05175820||Dentists|"Graduated from the Faculty of Dentistry,~Continuing/not continuing dental education (master, doctor, doctorate) after graduation,~Working in practice or outpatient clinic, private or public hospital, private polyclinic or public health or university hospital,~Dentists who registered in Turkish Dental Association"
89426298|NCT05170633|No Intervention|Standard care|"Standard care/Control group: The nurse will receive the PRBC transfusion from the Blood~Bank. As standard care, there are no deliberate procedures for warming PRBC transfusions in this NICU. The syringe of blood may sit outside the incubator for some time and as such, will warm to the environmental ambient temperature while transfusing into the infant using a standard pump. The transfusion will be given over 4 hours, per the clinician's orders. The bedside nurse will document transfusion start and stop times, and route, on the study document at the bedside. The infant will end study participation 24 hours after the PRBC transfusion is complete to verify that all temperature data have been received and are valid."
88907171|NCT01566357|Active Comparator|Fluoride mouthrinse|
88907172|NCT01566422|Experimental|Vancomycin powder|80 randomized patients will be given vancomycin powder in the surgical sites prior to closure following spinal surgery.
88907173|NCT01566422|No Intervention|Control|80 participants who were not randomized to receive Vancomycin powder will receive no intervention at the conclusion of their surgery.
88907174|NCT01566760|Experimental|Treatment A, Cohort 1|
88907175|NCT01566760|Experimental|Treatment B, Cohort 2|
88907176|NCT01566760|Experimental|Treatment C, Cohort 1|
88907177|NCT01566760|Experimental|Treatment D, Cohort 2|
88907178|NCT01566760|Active Comparator|Treatment E, Cohort 1 and/or Cohort 2|
88907179|NCT01566890|Experimental|Regadenoson ARM|Adult subjects with sickle cell anemia will receive a regadenoson infusion with contrast-enhanced ultrasound
89426299|NCT05170633|Active Comparator|Intervention|"Intervention group: Once a nurse receives the PRBC from the Blood Bank, the nurse will~obtain a specialized tubing and use a commercial PRBC warming device, the Ranger blood warmer (3M Healthcare, Oakdale, Minnesota) to deliver the PRBC transfusion to the infant. The unit contains highly responsive aluminum heating plates that distribute heat quickly, which~responds to flow changes with even and consistent heat. The plate temperature is monitored 4 times per second and is accurate within 1°C (3M Healthcare, Oakdale, Minnesota). The Ranger blood warmer meets the American Association of Blood Bank (AABB) guidelines for warming blood. All times and information associated with the PRBC transfusion will be recorded on the bedside study document. The transfusion will be given over 4 hours, per the clinician's orders. The infant will end study participation 24 hours after the PRBC transfusion is complete to verify that all temperature data have been received and are valid."
89426300|NCT05162417|No Intervention|Control group|patient in this arm will receive scaling and root planning treatment only.
89426301|NCT05162417|Experimental|Test group (toluidine Blue O)|patients in this arm will receive Toluidine Blue O as an adjunctive to scaling and root planing.
89426302|NCT05162417|Experimental|Methylene blue|Patients will receive Methylene blue as adjunctive to scaling and root planning.
89426303|NCT05156749|Experimental|short-arm fiberglass cast|"salter harris fractures of the distal radius/forearm in children are usually treated with fiberglass long-arm casts. The investigators were able to demonstrate that in distal metaphyseal forearm fracture, treatment with a short-arm cast is not inferior to a long-arm cast.~Patients are going to receive a short-arm cast for fracture treatment."
89007552|NCT03978598|Experimental|Immediate insertion group|Immediate insertion in the first 24 hours after delivery ENG implant insertion Intervention.
89007553|NCT03978598|Active Comparator|Standard Postpartum Insertion Group|Insertion of the Etonogestrel implant 4-6 weeks postpartum Intervention.
89007554|NCT03969056|Experimental|Artificial Intelligence (AI) Activity group|Participants in this group receive an AI based intervention (automated and personalized daily step goal intervention involving a sophisticated activity analytics algorithm using advanced statistics and machine learning and message)
89007555|NCT03969056|Active Comparator|Control group|Participants in this group receive a standardized and fixed 10,000 daily steps goal intervention.
89196355|NCT00928798|Experimental|rapamycin|one facial side rapamycin and one facial side placebo
89196356|NCT00931840|Experimental|EZN-2208|"EZN-2208 will be administered as an i.v. infusion on weekly basis for 3 weeks and repeated every 28 days.~PLEASE NOTE THAT ENROLLMENT IN EXPERIMENTAL ARM (ARM A) IS COMPLETE. NO NEW PATIENT IN THIS ARM IS ALLOWED TO ENROLL."
89426304|NCT05156749|Active Comparator|long-arm fiberglass cast|"salter harris fractures of the distal radius/forearm in children are usually treated with a fiberglass long-arm cast.~Patients are going to receive a long-arm cast for fracture treatment."
89426305|NCT05152953||Persons with HIV|Persons with HIV who are currently taking antiretroviral therapy who reside in the study's target geographical areas.
89426306|NCT05152953||Pharmacy staff members|Pharmacists, pharmacy technicians, pharmacy managers, or clerks employed at a community pharmacy who would potentially be involved in program development, scheduling, financial aspects, planning or administration of long-acting injectable antiretroviral therapy in the pharmacy.
89426307|NCT05152953||Clinic staff members|Physicians, clinic managers, nurses, medical assistants, social work staff or case managers, therapists, and other clinic personnel who are involved or would potentially be involved in any aspect of long-acting antiretrovirals in the clinic facility including financial aspects, planning, scheduling patients, educating patients, ordering medication, or administering medications.
89426308|NCT05151003||Patients admitted to University Hospital San Martino, Genova, Italy|Adult patients admitted to University Hospital San Martino, Genova, Italy
89426309|NCT05149092|Placebo Comparator|Placebo (casein protein supplement)|
89426310|NCT05149092|Active Comparator|Chicken protein hydrolysate supplement|
89426311|NCT05146310|Experimental|Treated eye|Eye is treated at Baseline visit (V1)
89426312|NCT05146193||All subjects are diagnosed of having a spinal deformity|Routine care of patients with spinal deformities
89426313|NCT05122546|Experimental|Arm 2 (CBM588, nivolumab, cabozantinib S-malate)|Patients receive CBM588 PO BID, nivolumab IV over 30 minutes on day 1, and cabozantinib S-malate PO QD. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89426314|NCT05122546|Active Comparator|Arm I (nivolumab, cabozantinib S-malate)|Patients receive nivolumab IV over 30 minutes on day 1 and cabozantinib S-malate PO QD. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89426315|NCT05121272|Experimental|young men|Individuals will participate in 1 familiarization and 3 test sessions
89426316|NCT05121272|Experimental|young women|Individuals will participate in 1 familiarization and 3 test sessions
89426317|NCT05121272|Experimental|older men|Individuals will participate in 1 familiarization and 3 test sessions
89426318|NCT05121272|Experimental|older women|Individuals will participate in 1 familiarization and 3 test sessions
89426319|NCT05120115|Experimental|Weight distribution and placement|Changing where weight is distributed on belt around pelvis, specifically, bilaterally, 4th lumbar area, unilaterally on the left side. Also changing amount of weight at 0, 4, 6 and 8 kg.
88907180|NCT01566890|Other|Sickle Cell Controls ARM|Adult subjects with sickle cell anemia will receive contrast-enhanced ultrasound
88907181|NCT01566890|Other|Sickle Cell CEU ARM|Adults subjects with sickle cell anemia will receive contrast-enhanced ultrasound
88907182|NCT01566890|Other|Healthy Control ARM|Healthy African American control subjects without sickle cell anemia will receive contrast-enhanced ultrasound
88907183|NCT01566890|Other|Technique Optimization Controls|Healthy volunteers will undergo contrast-enhanced ultrasound.
88907184|NCT01566929|No Intervention|IVF only|IVFtreatment
88907185|NCT01566929|Active Comparator|Weight reduction treatment and IVF|Dietary Supplement: Low calorie diet treatment and then IVFtreatment
88907186|NCT01567072|Experimental|NSAIDs in 7 days|NSAIDs (Ibuprofen) in 7 days
88907187|NCT01567072|Active Comparator|NSAIDs in 3 days|NSAIDs (Ibuprofen) in the first 3 days and placebo in the last 4 days
88907188|NCT01567072|Placebo Comparator|Placebo|Only placebo in 7 days
88907189|NCT01567098|Experimental|SILS appendectomy|Single incision laparoscopic appendectomy
88907190|NCT01567098|Active Comparator|3 Ports appendectomy|performing appendectomy through conventional 3 incisions on the abdomen
88907191|NCT01567423|Experimental|Artesunate and Amodiaquine (ASAQ)|children receiving fixed-dose combination of artesunate and amodiaquine
88907192|NCT01567423|Active Comparator|Arthemeter and Lumefantrine (AL)|children receiving fixed-dose combination of arthemeter and lumefantrine
88907193|NCT01567631|Experimental|intrahepatic Glisson's approach|
89426320|NCT05103033|Experimental|Systems Analysis and Improvement Approach (SAIA) for mental health|Those receiving SAIA-MH will attend a 1-week in-person training for facility learning collaboratives. Following the 1-week in-person training, SAIA-MH standard operating procedures will be implemented, including: (1) structured internal/external facilitation following tablet-based guides used in pilot study (1x per week first month; 2x per week for next two months; 1x per month for remainder); (2) facilitation in the 5-step SAIA-MH improvement process.
89426321|NCT05103033|Other|Attentional Placebo Control|"Control facilities will mimic activities of the intervention group in time and contacts, but without the active ingredient of the SAIA-MH implementation strategy"
89426322|NCT05102474||Moderate to Severe Psoriasis|Moderate to severe psoriasis will be defined as affected body surface area (BSA) ≥3%.
89426323|NCT05102474||Healthy Controls|Healthy controls will be age and sex matched subjects with no prior or current history of psoriasis.
89426324|NCT05100433|Experimental|Microbiological analysis of root canals after endodontic procedures|Bacterial levels and activity in root canal samples after chemomechanical procedures and ultrasonic irrigation.
89426325|NCT05097612|Experimental|Healthy participant|This is a repeated measures design. All participants receive both the intervention and the placebo comparator.
89426326|NCT05092399||RYGB|Patients undergoing Roux-en-Y gastric bypass surgery
89426327|NCT05092399||SG|Patients undergoing Sleeve Gastrecomy surgery
89426328|NCT05082714|Experimental|tocilizumab|tocilizumab plus usual care
89426329|NCT05082714|Experimental|baricitinib|baricitinib plus usual care
89426330|NCT05075187||Participants diagnosed with Frontotemporal Dementia|Participants diagnosed with Frontotemporal Dementia
89426331|NCT05071937|Experimental|ZEN003694 + Talazoparib|"ZEN003694: 48.0 mg daily (oral) in 28-day cycles~Talazoparib: 0.75 mg daily (oral) at the same time as ZEN003694"
89426332|NCT05069051|Experimental|Belimumab|Patients obtain belimumab in combination with rituximab/venetoclax
89426333|NCT05069051|Active Comparator|Standard of Care|Patients obtain the combination rituximab/venetoclax
88907194|NCT01567631|Active Comparator|classical hepatectomy|
88907195|NCT01567787|Experimental|Proton Radiation for MPNST|Proton radiation 30 cobalt gray equivalent(CGE)at 6 CGE per fraction
88907196|NCT01567787|Experimental|Proton Radiation for neurofibromas|Proton radiation 25 cobalt gray equivalent(CGE) at 5 CGE per fraction
88907197|NCT01568190|Experimental|AVANZ|AVANZ Mites
88907198|NCT01568515|Experimental|Electronic Messages|Intervention group participants received electronic (text and/or email) reminder messages coupled with health educational messages about HPV and HPV vaccine across 7 months
88907199|NCT01568515|No Intervention|Standard of Care|Control group participants received standard of care at the student health center which included a card with their next appointment written on it.
88907200|NCT01568970|Experimental|Return to work follow-up|Regular contact between the patient and his/her caretaker at the rehabilitation center over a 6 month period, including joint communication between patient, caretaker at the rehabilitation center and stake holders such as social security office, general practitioner and workplace.
88907201|NCT01568970|Active Comparator|Standard follow-up|Standard follow-up of the patient after ended rehabilitation by the return-to-work stakeholders, ie. the general practitioner, social security office and the employer. Limited contact between the caretaker at the rehabilitation center and the patient and stakeholders.
88907202|NCT01569347||1: Cocaine users|Adults, cocaine users
88907203|NCT01569685|Active Comparator|Venlafaxine|6 months treament vith Venlafaxine (if patient has troubles sleeping in combination with Mianserine) in recommended dose in combination with Cognitive Behavioral Therapy
88907204|NCT01569685|Active Comparator|Sertraline|6 months treament vith Sertraline (if patient has troubles sleeping in combination with Mianserine) in recommended dose in combination with Cognitive Behavioral Therapy
88907205|NCT01569997|Other|Intervention group|Intervention group: nursing homes whose residents benefit from MDTM to identify the cases of dementia and to propose an adequate care project
89426334|NCT05067387|Placebo Comparator|Placebo|Oral placebo; sesame and MCT oil
89426335|NCT05067387|Experimental|20 mg THC|THC suspended in sesame oil
89426336|NCT05067387|Experimental|20 mg CBD|CBD suspended in MCT oil
89426337|NCT05067387|Experimental|20 mg THC + 20 mg CBD|THC and CBD in sesame and MCT oil
88907206|NCT01569997|No Intervention|control group|Control group: nursing homes whose residents continue to benefit from usual care
88907207|NCT01570023|No Intervention|Standard Clinical Care|Standard swallowing intervention is that which is identified by the SLP as appropriate to treat the patient's dysphagia and is in common clinical practice. Such treatment would consist of dietary or postural compensatory strategies (i.e., chin down posture while swallowing).
88907208|NCT01570023|Experimental|Standard Clinical Care Plus Isometric Lingual Exercise|Standard Clinical Care Plus 8-week Isometric Lingual Exercise Regimen. The isometric tongue exercises will be completed using the Madison Oral Strengthening Therapeutic (MOST) device. Baseline maximum lingual pressure will be obtained at the anterior and posterior sensors independently by gathering two sets of data (3 MOST device trials) at each site (anterior and posterior) that differ by less that 5%. During week one of the regimen, the target value of each repetition will be 60% of the maximum baseline pressure. For the remaining seven weeks of the program, the target value will be increased to 80% of the maximum. At weeks three, five, and seven, the baseline will be re-measured by phone and the 80% target value re-calculated.
88907209|NCT01570049|Experimental|Bendamustine|Dose of 120 mg/m2/day on Day 1 and Day 2 of each treatment cycle (every 21 days), to a maximum of 8 cycles.
88907210|NCT01570062|Active Comparator|Indoor Air HEPA Filtration|HEPA filters will be placed in participant's main living area and bedroom. Actual filtration will occur during only one of the two 7-day sampling periods.
88907211|NCT01570062|Placebo Comparator|HEPA Filtration Placebo|For one of two 7-day sampling sessions, HEPA filters placed in participants' homes will be run without an actual filter in the housing unit.
89426338|NCT05064280|Other|Cohort 1|Patients with TNBC and brain metastases
89426339|NCT05064280|Other|Cohort 2|Patients with NSCLC and brain metastases
88907212|NCT01570075|Experimental|RFA group|For RFA, we used a commercially available system with a 375-KHz computer-assisted radiofrequency generator (Elektrotom HiTT 106, Berchtold, Medizinelektronik, Germany) and an open-perfused electrode (Berchtold, Tuttlingen, Germany) of 15 cm (or 20 cm), 14 Ga, and a 15 mm (or 20 mm) active electrode tip with microbores.
89196357|NCT00931840|Experimental|Cetuximab + EZN-2208|Cetuximab will be administered as an i.v. infusion on weekly basis. EZN-2208 administered as i.v. infusion on weekly basis for 3 weeks and repeated every 28 days.
89426340|NCT05064280|Other|Cohort 3|Patients with other solid tumor types and brain metastases
89426341|NCT05064007|Experimental|1|this group will be exposed to condition A first, then B, and C
89426342|NCT05064007|Experimental|2|this group will be exposed to condition B first, then C, and A
89426343|NCT05064007|Experimental|3|this group will be exposed to condition C first, then A, and B
89426344|NCT05061030|Active Comparator|Wharton's jelly derived mesenchymal stromal cells (Protrans)|Cells are dissolved in saline and given intravenously over a period of 20-40 min. 100 million cells to subjects < 50 kg and 200 million cells to subjects 50-100 kg (>100 kg is an exclusion criterion).
89426345|NCT05061030|Placebo Comparator|Placebo|Placebo (saline) is given intravenously over a period of 20-40 min.
89426346|NCT05056948||Control|Original 3D maxillary teeth model from subjects who fulfill inclusion/exclusion criteria
89426347|NCT05056948||Test|"3D maxillary teeth model from subjects who fulfill inclusion/exclusion criteria.~The right first molar (FDI number 16) will be removed in the computer and then designed by artificial intelligence (AI) system~AI system will be trained by~different algorithms such as Group 1) Voxel-based; Group 2) View-based; Group 3) Point-based; and Group 4) Fusion methods~Group i) maxillary model only and Group ii) with antagonist model"
88814786|NCT03031886|Experimental|Low GI|Cereal, milk, tea, steamed basmati rice with chicken, spinach, bread, strawberry jam, low GI sweetener (isomaltulose).
88814787|NCT03031574|Active Comparator|Food Effect|SUVN-D4010 tablets single dose
88814788|NCT03031574|Active Comparator|Gender Effect|SUVN-D4010 tablets single dose
88814789|NCT03031574|Active Comparator|Age Effect|SUVN-D4010 tablets single dose
88814790|NCT03031418||Cohort 1|Enroll up to 500 patients to confirm performance of ExoDx Prostate IntelliScore (EPI) for men scheduled for initial biopsy. The treating physician will collect a urine sample from from a consented subject to test before their scheduled prostate biopsy (during your established clinic visit).
88820311|NCT06190405|Active Comparator|Risk-based screening by ACOG with two-step GTT|Patients at <16 weeks will be assessed for risk factors for diabetes as described by ACOG. If patients meet criteria, they will be screened with two-step screening for gestational diabetes. If patients do not meet criteria, they will not be screened until the routine timing of screening for gestational diabetes.
88820312|NCT06190392|Experimental|Modified simplified diagnostic strategy MODS|
88820313|NCT06190379|Experimental|Intervention|Essential oil blend in an inhaler stick
88820314|NCT06190379|Placebo Comparator|Placebo|blank inhaler stick
88820315|NCT06190366|Experimental|Bloodletting acupuncture at the fossa poplitea|
88820316|NCT06190366|Experimental|Bloodletting acupuncture at the regio glutaea|
88820317|NCT06190366|No Intervention|Waiting list control group|
88820318|NCT06190353|Experimental|Intervention|The experimental group which will have an immediate access to web-based psychotherapy.
88820319|NCT06190353|No Intervention|Control|A wait-list control group which have one month delayed access to intervention program.
89426348|NCT05046197||Work Package 1 - patients and carers|"Qualitative interview of 48 Patients, or their carers where the patient lacks capacity, who have had a ReSPECT form completed in the previous 6 months. To include:~12 patients living in care homes 12 patients living at home (nearing the end of their life) 12 patients living at home (not nearing the end of their life)"
89426349|NCT05046197||Work Package 1 - GPs|Qualitative interview of 30 General Practitioners who are involved in the ReSPECT process
89426350|NCT05046197||Work Package 1 - Care home managers|Qualitative interview of 24 care home managers.
89426351|NCT05046197||Work Package 2 - Focus groups/interviews (Members of the Public)|Qualitative interview of 30 members of the public with an interest in healthcare regarding attitudes to the ReSPECT process.
89426352|NCT05046197||Work Package 2 - Focus groups/interviews (Health and Social Care Professionals)|Qualitative interview of 30 Non-GP Health and Social Care Professionals regarding attitudes to the ReSPECT process.
89426353|NCT05046197||Work Package 2 - Focus groups/interviews (Faith Leaders)|Qualitative interview of 8 faith leaders regarding attitudes to the ReSPECT process.
89426354|NCT05046197||Work Package 2 - Survey (Members of the Public)|Survey of 1000 members of the public to measure public awareness and acceptability of emergency care treatment plans
89426355|NCT05046197||Work Package 2 - Survey (GPs)|Survey of 1000 GPs to measure the views of GPs nationally regarding the use of emergency care treatment plans including ReSPECT, in primary care.
89426356|NCT05046197||Work Package 3 - Patient records|Patient records of 413 patients within 12 CCGs in England who have had a ReSPECT form completed in the previous 12 months
89426357|NCT05044234|Placebo Comparator|Placebo|Participants received placebo capsules for cedirogant orally once daily (QD) for 16 weeks.
89426358|NCT05044234|Experimental|75 mg Cedirogant|Participants received 75 mg cedirogant orally once daily (QD) for 16 weeks.
89426359|NCT05044234|Experimental|150 mg Cedirogant|Participants received 150 mg cedirogant orally once daily (QD) for 16 weeks.
89426360|NCT05044234|Placebo Comparator|375 mg Cedirogant|Participants received 375 mg cedirogant orally once daily (QD) for 16 weeks.
89426361|NCT05038280|Experimental|Let's Talk about Children intervention|Teachers, students, and parents in Finland, that take part in the LTC -intervention.
89426362|NCT05038280|No Intervention|Control group|The control group includes teachers who do not use the method in their work and students and parents who do not participate in the discussions.
89426363|NCT05037799||Group 1|body-weight < 50kg
89426364|NCT05037799||Group 2|50 kg ≤ body-weight < 100 kg
89426365|NCT05037799||Group 3|100 kg ≤ body-weight < 150 kg
89426366|NCT05037799||Group 4|150 kg ≤ body-weight < 200 kg
89196358|NCT00931840|Active Comparator|Irinotecan + cetuximab|Cetuximab will be administered weekly as an i.v. infusion. Irinotecan will be administered as an i.v. infusion on Weeks 1 and 2 and repeated every 3 weeks.
89426367|NCT05036213|Active Comparator|Dietary nitrate|The active treatment, beetroot juice (BEET IT, James White Drinks, Ipswich, UK), contains 6.2mmol of inorganic nitrate. Participants will continue supplementation until they complete all testing visits.
89426368|NCT05036213|Placebo Comparator|concentrated beet root juice with depleted nitrate content|The placebo treatment is also beetroot juice provide by the same company (BEET IT, James White Drinks, Ipswich, UK), but it does not contain any inorganic nitrate. Participants will continue supplementation until they complete all testing visits.
89426369|NCT05035394|Active Comparator|Cataract surgery as stand alone|Cataract surgery as stand alone. Cataract surgery will be performed in a standardized fashion.
89426370|NCT05035394|Active Comparator|Cataract surgery in combination with Kahook Dual Blade glide goniotomy|Cataract surgery combined with Kahook Dual Blade Glide goniotomy. The goniotomy will be performed at the end of cataract surgery through the temporal cataract incision.
89426371|NCT05035394|Active Comparator|Cataract surgery in combination with iStent Inject W implantation|Cataract surgery combined with iStent Inject W. The two stents will be injected in Schlemms canal at the end of cataract surgery through the temporal cataract incision.
88820320|NCT06190327|Experimental|blended indoor and outdoor multicomponent structured exercise group|Participants will receive a 16-week blended indoor and outdoor multicomponent structured exercise program, with 2 sessions per week (90 mins/session).
88820321|NCT06190327|Active Comparator|indoor-only multicomponent structured exercise group|Participants will receive a 16-week indoor-only multicomponent structured exercise program, with 2 sessions per week (90 mins/session).
89426372|NCT05031273|Experimental|Residents moving into a congregate-living development with more features that support healthy living|Residents moving into a congregate-living development designed for older adults with more design and amenities features in the building, site, and/or neighbourhood that support physical activity, healthy eating, and social connections.
89426373|NCT05031273|No Intervention|Residents living in a standard congregate-living development|Residents living in a standard community-based congregate-living development designed for older adults.
89426374|NCT05030298|Experimental|Cohort A (stereotactic biopsy, radiosurgery, surgery)|Patients undergo MRI-guided stereotactic biopsy. Patients then undergo radiosurgery over 1 fraction. Within 14 days, patients undergo surgery. Within 4-6 weeks, patients then receive standard of care radiation therapy over 30 fraction and temozolomide daily with or without TTF at the discretion of the treating neuro-oncologist.
89426375|NCT05030298|Active Comparator|Cohort B (surgery, radiation therapy, chemotherapy)|Patients undergo surgery. Within 4-6 weeks, patients then receive standard of care radiation therapy over 30 fraction and temozolomide daily with or without TTF at the discretion of the treating neuro-oncologist.
89426376|NCT05029362|Other|Beta testing group|
89007556|NCT03951649|Experimental|Occipital Nerve block|"Trained OB/GYN providers will perform a physical exam to access location of occipital nerve injection based on palpation of bony landmarks.~Site of injection will be cleaned with an alcohol swab.~5cc of 0.5% bupivacaine will be injected into both right and left occipital nerves using a 2.5 inch 25 gauge needle. The needle will be changed between injecting sites.~After injection is completed sterile gauze will be held on injection sites for 2-3 min or until bleeding is resolved."
89007557|NCT03951649|Active Comparator|Oral Acetaminophen/Caffeine Group|Acetaminophen 650mg PO and Caffeine 100mg PO (both Level A treatments for acute headache)
89007558|NCT03949855|Experimental|Part A: Low Proteinuria Group - Belimumab and Rituximab|"Open-label pharmacokinetics (PK) phase.~Participants with low proteinuria classification will receive belimumab weekly subcutaneous injections (52 doses administered Week 0 to Week 51) and rituximab infusions at Weeks 4 and 6.~Low proteinuria classification: The excretion of ≥4 to <8 g/day of protein by the kidneys in adults. (Normal in adults: 0.15 g/day)."
89007559|NCT03949855|Experimental|Part A :High Proteinuria Group - Belimumab and Rituximab|"Open-label pharmacokinetics (PK) phase.~Participants with high proteinuria classification will receive belimumab weekly subcutaneous injections (52 doses administered Week 0 to Week 51) and rituximab infusions at Weeks 4 and 6.~High proteinuria classification: The excretion of ≥8 g/day of protein by the kidneys in adults. (Normal in adults: 0.15 g/day)."
89426377|NCT05029336|Experimental|CD3/CD19 depleted ASCT|The test article is autologous stem cell transplant with a CD3/CD19-depleted stem cell product.
89426378|NCT05020080|Experimental|ECR MEP conditioning - Stroke|MEP operant conditioning of ECR in stroke survivors
89426379|NCT05012722||Decompensated Heart Failure with reduced ejection fraction (HFrEF)|Pulse wave velocity to be measured during hospitalisation phase and repeated 4 weeks after when participant is in a stable state i.e stable (HFrEF)
89426380|NCT05012722||Decompensated Heart Failure with Preserved ejection fraction (HFpEF)|Pulse wave velocity to be measured during hospitalisation phase and repeated 4 weeks after when participant is in a stable state i.e stable (HFpEF)
89426381|NCT05012722||Acute Kidney Injury in patients with Chronic Kidney Disease stage 3a,3b or 4|Pulse wave velocity to be measured during hospitalisation phase and repeated 4 weeks after when participant is in a stable state i.e. stable Chronic Kidney Disease stage 3a, 3b and 4
89426382|NCT05003778|Active Comparator|Traditional equipment resistance and endurance training|Participants in this group undergo 6 weeks of concurrent resistance and endurance training using traditional equipment (i.e., power racks, barbells, dumbbells, etc.)
89196359|NCT00932074|Experimental|3% KP-413 Ointment|
89196360|NCT00932074|Experimental|1% KP-413 Ointment|
89426383|NCT05003778|Experimental|Minimal equipment resistance and endurance training|Participants in this group undergo 6 weeks of concurrent resistance and endurance training using minimal equipment (i.e., sandbags, resistance bands, suspension trainers, weight vests, etc.)
89426384|NCT05003778|Experimental|Minimal equipment resistance and endurance training with blood flow restriction|Participants in this group undergo 6 weeks of concurrent resistance and endurance training using minimal equipment (i.e., sandbags, resistance bands, suspension trainers, weight vests, etc.) while wearing upper- and lower-body blood-flow restriction cuffs
88907213|NCT01570075|Experimental|HR group|SR was carried out under general anesthesia using a right subcostal incision with a midline extension. Intra-operative ultrasonography was performed routinely to evaluate the tumor burden, liver remnant, and the possibility of a negative resection margin. Anatomic resection, in the form of segmentectomy and/or subsegmentectomy as described by Makuuchi et al. (16) was the preferred surgical method of liver resection. Pringle's maneuver was routinely used with a clamp and unclamp time of 10 min and 5 min, respectively; this technique was used repeatedly throughout the entire procedure.
89426385|NCT05000372||68Ga-grazytracer PET/CT in participants before immunotherapy|Participants who have not undergone immunotherapy will be injected with 2.96-3.7 MBq/kg body weight of 68Ga-grazytracer in one dose intravenously and then undergo PET/CT scan within 0.5-1 h.
88907214|NCT01570088|Active Comparator|Folic acid|
88907215|NCT01570088|Experimental|L-5-MTHF|
88907216|NCT01570088|Placebo Comparator|Placebo|
88907217|NCT01570101|Experimental|CE Marked Sapheon Closure System in GSV|"CE Marked Sapheon Closure System in closure of incompetent great saphenous veins GSV in a routine clinical setting."
88907218|NCT01570114||covered metallic stent|Endoscopically insertion of fully covered metallic stent on benign colonic strictures
88907219|NCT01570127|Experimental|Individualized Acupuncture|The patients in this group received individualized acupuncture prescribed by a certified Korean Medicine Doctor with more than 6 years of oriental medicine college education and 2 years of clinical experience. The acupuncture formulas were composed based on the pattern diagnosis, which is an unique diagnosis system of Oriental Medicine.
88907220|NCT01570127|Experimental|Standardized Acupuncture|The patients in this group received standardized acupuncture treatment using the same acupuncture points, applied by a certified Korean Medicine Doctor with more than 6 years of oriental medicine college education and 2 years of clinical experience. The acupuncture formulas were composed based on literature review of RCTs.
88907221|NCT01570127|Sham Comparator|Sham acupuncture|Non-penetrating acupuncture device, Park-sham acupuncture, was applied to the patients. The appearance of the acupuncture is same but the needles do not penetrate the skin.
88907222|NCT01570127|No Intervention|Waiting|No interventions were applied to the patients in this group. Only assessments were made at each visit.
88907223|NCT01570140||Web portal users|T2DM patients in the primary care setting, using the web portal.
88907224|NCT01570153||ADHF patients|
88907225|NCT01570166|Experimental|RFA|For RFA, we used a commercially available system with a 375-KHz computer-assisted radiofrequency generator (Elektrotom HiTT 106, Berchtold, Medizinelektronik, Germany) and an open-perfused electrode (Berchtold, Tuttlingen, Germany) of 15 cm (or 20 cm), 14 Ga, and a 15 mm (or 20 mm) active electrode tip with microbores.
89196361|NCT00932074|Placebo Comparator|Placebo|
89196362|NCT04034368|Experimental|Experimental Arm|Tenofovir alafenamide (TAF) 25 mg QD, oral administration, 48 weeks；
89196363|NCT00907270|Active Comparator|Cholecalciferol: 400 IU/day|Control: (n=50) Each subject will be evaluated after supplementation during six months with Vitamin D (Cholecalciferol: 400 IU/day)
89426386|NCT05000372||68Ga-grazytracer PET/CT in participants after immunotherapy|Participants post-immunotherapy will be injected with 2.96-3.7 MBq/kg body weight of 68Ga-grazytracer in one dose intravenously and then undergo PET/CT scan within 0.5-1 h.
89426387|NCT04984733|Experimental|Treatment|"Metronomic TMZ 50mg/m2/day orally for 3 months, then nivolumab 240mg IV until progression.~Metronomic TMZ 50mg/m2/day orally until progression then nivolumab 240mg IV until progression. Patients who progress on TMZ will start monotherapy with nivolumab.~Metronomic TMZ50mg/m2/day orally for 3 months, then nivolumab 240mg IV +/- TMZ until progression. Patients who don't progress on TMZ will commence with combination treatment; TMZ + Nivolumab at 3 mths until they progress~Metronomic TMZ 50mg/m2/day orally for 3 months, then nivolumab 240mg IV +/- TMZ until 24 months. Patients will remain on combination therapy up to a maximum of 24mths."
89426388|NCT04984421|Active Comparator|Basic|All schools will receive the HSS program. Schools randomly assigned to group 1 will receive implementation strategy bundle 1 (Basic).
89426389|NCT04984421|Experimental|Enhanced|All schools will receive the HSS program. Schools randomly assigned to group 2 will receive implementation strategy bundle 1+2 (Enhanced).
89196364|NCT00907270|Experimental|Cholecalciferol 4000 IU/day|Experimental: (n=50) Each subject will be evaluated after supplementation during six months with Vitamin D
89196365|NCT00907348|Experimental|Cohorts 1 - 2 - 3 - 4|Chemiotherapy
88820322|NCT06190327|No Intervention|control group|The control group will not receive any intervention during the whole project.
88820323|NCT06190314||patients with ischemic stroke|measure serum vitamin b12 levels
88820324|NCT06190314||patients with hemorrhagic stroke|measure serum vitamin b12 levels
89196366|NCT00375505|Experimental|Zometa|Zoledronic acid 4mg as a 15-minute infusion every 3 months for a treatment period of 24 months (total of 8 infusions).
89196367|NCT00375505|Placebo Comparator|Placebo|Placebo as a 15-minute infusion every 3 months for a treatment period of 24 months (total of 8 infusions).
89196368|NCT00928876|Experimental|Anakinra group|Anakinra 150 mg/day during four weeks
89007560|NCT03949855|Experimental|Part B: Low Proteinuria Group - Belimumab and Rituximab|"Participants in the low proteinuria classification stratification, based upon Part A, and randomized to this arm, will receive subcutaneous belimumab 400 mg (two 200 mg injections) once weekly from weeks 0-3, and then 200 mg once weekly from weeks 4-51. Participants will receive rituximab infusions at Weeks 4 and 6.~At week 30, participants will be assessed for a response to study treatment. Participants who meet at least two out of the following three criteria at week 30 will be considered to have an inadequate response to study treatment and receive a second course of rituximab (defined as 1000 mg IV given at weeks 34 and 36):~Anti-PLA2R level is ≥ 25% of baseline~Proteinuria is ≥ 50% of baseline~Serum albumin is < 2.8 g/dL"
89007561|NCT03949855|Placebo Comparator|Part B: Low Proteinuria Group - Placebo and Rituximab|"Participants in the low proteinuria classification stratification, based upon Part A, and randomized to this arm, will receive subcutaneous belimumab placebo 400 mg (two 200 mg injections) once weekly from weeks 0-3, and then 200 mg once weekly from weeks 4-51. Participants will receive rituximab infusions at Weeks 4 and 6.~At week 30, participants will be assessed for a response to study treatment. Participants who meet at least two out of the following three criteria at week 30 will be considered to have an inadequate response to study treatment and receive a second course of rituximab (defined as 1000 mg IV given at weeks 34 and 36):~Anti-PLA2R level is ≥ 25% of baseline~Proteinuria is ≥ 50% of baseline~Serum albumin is < 2.8 g/dL"
89007562|NCT03949855|Experimental|Part B :High Proteinuria Group - Belimumab and Rituximab|"Participants in the high proteinuria classification stratification, based upon Part A, and randomized to this arm, will receive subcutaneous belimumab 400 mg (two 200 mg injections) once weekly from weeks 0-3, and then 200 mg once weekly from weeks 4-51. Participants will receive rituximab infusions at Weeks 4 and 6.~At week 30, participants will be assessed for a response to study treatment. Participants who meet at least two out of the following three criteria at week 30 will be considered to have an inadequate response to study treatment and receive a second course of rituximab (defined as 1000 mg IV given at weeks 34 and 36):~Anti-PLA2R level is ≥ 25% of baseline~Proteinuria is ≥ 50% of baseline~Serum albumin is < 2.8 g/dL"
89007563|NCT03949855|Placebo Comparator|Part A :High Proteinuria Group - Placebo and Rituximab|Participants in the high proteinuria classification stratification, based upon Part A, and randomized to this arm, will receive belimumab placebo weekly subcutaneous injections (52 doses administered Week 0 to Week 51) and rituximab infusions at Weeks 4 and 6.
88820325|NCT06190301|Experimental|Intralesional Rituximab Injection|
89007564|NCT03920267|Experimental|BMS-986165 Dose 1|
89007565|NCT03920267|Experimental|BMS-986165 Dose 2|
89007566|NCT03920267|Experimental|BMS-986165 Dose 3|
89007567|NCT03918915|Experimental|Part 1: SYD-101 Dose 1; Part 2: SYD-101 Dose 1|1 drop in each eye at bedtime.
89007568|NCT03918915|Experimental|Part 1: SYD-101 Dose 1; Part 2: Vehicle|1 drop in each eye at bedtime.
89007569|NCT03918915|Experimental|Part 1: SYD-101 Dose 2; Part 2: SYD-101 Dose 2|1 drop in each eye at bedtime.
89007570|NCT03918915|Experimental|Part 1: SYD-101 Dose 2; Part 2: Vehicle|1 drop in each eye at bedtime.
89007571|NCT03918915|Placebo Comparator|Part 1: Vehicle; Part 2: SYD-101 Dose 2|1 drop in each eye at bedtime.
89007572|NCT03913455|Other|Guadecitabine and Carboplatin|Each cycle = 28 days; Subjects receive 4 cycles
89007573|NCT03896945|Placebo Comparator|Placebo|Placebo capsules will be administered orally twice a day over a 15-week period.
89426390|NCT04982250|Experimental|"Formal peer PrEP referral + HIVST delivery"|After a brief training, young female PrEP users will be encouraged to refer up to 4 peers to PrEP using strategies gained from the training, PrEP educational materials (i.e., brochures), HIVST kits (2 kits/peer = 8 kits total), and Kenya MOH-style referral cards.
89007574|NCT03896945|Experimental|AVP-786|AVP-786 capsules will be administered orally twice a day over a 15-week period.
89007575|NCT03894891|Experimental|Induction Docetaxel (T)+Cisplatin (P)+Nivolumab (N) then Radioimmunotherapy (IMRT+N) then adjuvant N|"Participants received 3 cycles of induction with docetaxel, cisplatin and nivolumab (TPN) every 3 weeks (or 21 days): docetaxel 75 mg/m2 IV day 1, cisplatin 100 mg/m2 IV day 1, and nivolumab 240 mg IV flat dose day 1.~Induction was followed by clinical and radiologic assessment of response. Participants without partial response or better based on RECIST 1.1 were offered salvage laryngectomy and/or pharyngectomy. Participants with partial or complete response per RECIST 1.1 proceeded with immunoradiotherapy concurrently with nivolumab. Intensity-modulated radiotherapy (IMRT) was preferred and proton beam radiotherapy not permitted. Nivolumab 240 mg IV flat dose day 1 was repeated every 2 weeks concurrently with IMRT (for a total of 3-4 doses).~Participants then received adjuvant nivolumab (480 mg IV flat dose day 1) every 4 weeks within 3-8 weeks from the last day of IMRT for up to 6 cycles or until disease progression or recurrence."
89007576|NCT03885648||Cases|Women's age will range 25-70 years. Cases will be women diagnosed and surgically intervened of breast cancer, stages I and II.
89196369|NCT00928876|Placebo Comparator|Placebo|Placebo during four weeks
89196370|NCT00907504|Experimental|CP-751,871 + Gemcitabine + Cisplatin|investigational arm
89196371|NCT00907504|Active Comparator|Gemcitabine + Cisplatin|standard of care
89196372|NCT00932230|Experimental|Group 1|An elastic tape that will be placed on subject's ankles to determine whether ankle proprioception is improved
89196373|NCT00929032||Liver transplant recipient|Liver transplant recipient
89196374|NCT00932308|Active Comparator|1|Western-style, high-fat, low-calcium diet (WD)
89426391|NCT04982250|No Intervention|"Informal peer PrEP referral"|Young female PrEP users will be encouraged to refer 4 peers to PrEP using informal word-of-mouth recruitment strategies and Kenya MOH-style referral cards.
89426392|NCT04979949|Active Comparator|CoronaVac|Inactivated SARS-CoV-2 virus antigen, single intramuscular injection for boosting dose.
89426393|NCT04979949|Experimental|Turkovac|Inactivated SARS-CoV-2 virus antigen, single intramuscular injection for boosting dose.
89426394|NCT04979598||Acute unilateral vestibular deafferentiation|Patients suffering from acute dizziness due to a unilateral vestibular deafferentiation.
88820326|NCT06190301|Active Comparator|Involved Site Radiation Therapy|
89007577|NCT03885648||Controls|Controls will be women surgically intervened of breast augmentation or reduction.
89007578|NCT03883490||Bicuspid Aortic valve|Patients with a bicuspid aortic valve
89007579|NCT03883490||Tri-leaflet Aortic valve|Patients with a tri-leaflet aortic valve
89007580|NCT03883412|Experimental|Exercise Alone|16 weeks of treatment
89007581|NCT03883412|Experimental|Liraglutide alone|16 weeks of treatment
89007582|NCT03883412|Experimental|Exercise + Liraglutide|16 weeks of treatment
89007583|NCT03864614|Experimental|SAGE-217|
89007584|NCT03863080|Experimental|Regimen A|RVT-1401 680 mg weekly for 6 weeks + optional open-label extension (RVT-1401, 340 mg every 2 weeks for 6 weeks)
89007585|NCT03863080|Experimental|Regimen B|RVT-1401 340 mg weekly for 6 weeks + optional open-label extension (RVT-1401, 340 mg every 2 weeks for 6 weeks)
89007586|NCT03863080|Placebo Comparator|Placebo|Placebo for 6 weeks + optional open-label extension (RVT-1401, 340 mg every 2 weeks for 6 weeks)
89007587|NCT03840837|No Intervention|Arm 1: baseline only (cross-sectional)|At baseline, all participants will undergo instrumented gait/balance testing, using a wearable sensor (Dynaport MT), and cognitive testing, using a computerized cognitive test battery (NeuroTrax Mild Cognitive Impairment & Early Dementia Battery by MindStreams). In other words, all participants will be part of arm 1.
89007588|NCT03840837|Experimental|Arm 2: rivastigmine (longitudinal)|As study intervention, a subgroup of participants will then be treated with transdermal rivastigmine patch for 12 weeks, with dose increases every 4 weeks and titration up to 13.3 mg/24h, if tolerated. For the arm 2 subgroup of participants, the same assessment that was performed at baseline (quantitative gait testing and NeuroTrax computerized cognitive test battery) will be repeated after 12 weeks, with the patient on a stable dose of transdermal rivastigmine.
89007589|NCT03834493|Experimental|Pembrolizumab + Enzalutamide|Participants receive 200 mg pembrolizumab by intravenous (IV) infusion administered on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (approximately 2 years) PLUS enzalutamide 160 mg administered orally (PO) once a day (QD) continuously until progression.
89007590|NCT03834493|Placebo Comparator|Placebo + Enzalutamide|Participants receive placebo by IV infusion administered on Day 1 Q3W for up to 35 cycles (approximately 2 years) PLUS enzalutamide 160 mg administered PO QD continuously until progression.
89007591|NCT03827057|Experimental|Reconsolidation of Traumatic Memories (RTM)|"Participants in each arm of the study will receive up to 10 90-minute manualized treatment sessions. RTM will follow a manual developed by the Research and Recognition Project, who will also train and supervise the therapists. It is anticipated that these treatments will most often be administered once per week for 10 weeks. To best meet participant needs, we will allow therapy in either arm to be massed in the pattern recently reported by Foa et al. for PE, with sessions separated by at least 24 hours over two weeks. This schedule has been used with both RTM and PE without hurting response rates, and may reduce drop-out rates. Participants who achieve remission of their PTSD before 10 sessions, measured by a PCL5 <34, can decide with their therapist whether early cessation of therapy is appropriate."
89007592|NCT03827057|Active Comparator|Prolonged Exposure (PE)|"Participants in each arm of the study will receive up to 10 90-minute manualized treatment sessions. PE will follow a manual written by the Foa and colleagues, and the therapists will be trained by expert trainers from the Center for Deployment Psychology. It is anticipated that these treatments will most often be administered once per week for 10 weeks. To best meet participant needs, we will allow therapy in either arm to be massed in the pattern recently reported by Foa et al. for PE, with sessions separated by at least 24 hours over two weeks. This schedule has been used with both RTM and PE without hurting response rates, and may reduce drop-out rates. Participants who achieve remission of their PTSD before 10 sessions, measured by a PCL5 <34, can decide with their therapist whether early cessation of therapy is appropriate."
89007593|NCT03820687|Active Comparator|Intervention Group|Participants in the intervention group will receive 3 components: 1) a bilingual, culturally tailored clinical trial educational video, 2) a low literacy booklet, and 3) support from a patient navigator to empower cancer patients to make informed decisions about cancer clinical trial participation by increasing awareness of clinical trials and MCC services, positive attitudes and intentions to consider clinical trials as an appropriate treatment option for cancer.
89007594|NCT03820687|Active Comparator|Usual Care Control Group|Participants in the usual care control group will receive a general clinical trial fact sheet.
89007595|NCT03818854|Experimental|Human Mesenchymal Stromal Cells|A single dose of 10 million cells/kg predicted body weight (PBW) Allogeneic Bone Marrow-Derived Human Mesenchymal Stromal Cells will administered intravenously over approximately 60-80 minutes.
89007596|NCT03818854|Experimental|Cell Reconstitution Media|A single dose of cell reconstitution media (1:1 mix of 5% human serum albumin and 10% Dextran 40) will administered intravenously over approximately 60-80 minutes.
89007597|NCT03808558|Experimental|TVB-2640|Patients will be administered TVB-2640 100mg/m2 orally once a day for 8 weeks.
89007598|NCT03770416|Experimental|Cohort A|Patients receive ibrutinib PO daily on days 1-28. Beginning course 1, patients also receive nivolumab IV over 1 hour on days 1 and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve at least a partial response after 6 courses may continue therapy for up to 2 years.
89007599|NCT03770416|Experimental|Cohort B|Patients receive ibrutinib PO daily on days 1-28 and nivolumab IV over 1 hour on days 1 and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve at least a partial response after 6 courses may continue therapy for up to 2 years.
89007600|NCT03762590|Experimental|Doxy.me plus Color Genomics Arm (Arm 1)|"Participants in this arm will receive genetic education through an online platform called Doxy.me~The Doxy.me session will consist of two parts: 1) a pre-recorded genetic education video 2) a live interactive video conferencing session with a GENERATE genetic counselor~After completing the Doxy.me session and post intervention questionnaires, participants will be directed to the Color Genomics study portal where they may elect to review Color Genomics' genetic education content or proceed directly to order genetic testing~Intervention is Doxy.me genetic education +/- genetic education via Color Genomics website"
89426395|NCT04975958|Experimental|DLT Observation Period I - AN2025 and Atezolizumab|During the DLT Observation I, patients will be treated with AN2025 and Atezolizumab until the patient experiences disease progression, unacceptable toxicity or withdraws consent. The starting dose of AN2025 is 50 mg. If tolerated, then a subsequent cohort will escalate to 100 mg. A dose de-escalation cohort to 80 mg may occur if the 100 mg is not well tolerated. The dose of Atezolizumab will remain constant at 1200 mg every 3 weeks (Q3W) for each dose level of AN2025 and in each cohort. Atezolizumab is administered intravenously over 60 minutes. If the first infusion is tolerated, all subsequent infusions may be delivered over 30 minutes.
89426396|NCT04975958|Experimental|DLT Observation Period II - AN0025 and Atezolizumab|During the DLT Observation II, patients will be treated with AN0025 and Atezolizumab until the patient experiences disease progression, unacceptable toxicity or withdraws consent. The starting dose of AN0025 is 250 mg. If tolerated, then a subsequent cohort will escalate to 500 mg. If 250 mg AN0025 is not tolerated, de-escalate to 125 mg. The dose of Atezolizumab will remain constant at 1200 mg Q3W for each dose level of AN0025 and in each cohort. Atezolizumab is administered intravenously over 60 minutes. If the first infusion is tolerated, all subsequent infusions may be delivered over 30 minutes.
89426397|NCT04975958|Experimental|DLT Observation Period III - AN2025, AN0025 and Atezolizumab|The DLT Observation III will be started after safety data review by the investigators and the sponsor of the double combination treatments in Observations I and II. Patients enrolled in Observation III will start with the recommended dose of AN0025 from Observation II, 1200 mg Atezolizumab, and AN2025 will start from 50 mg QD. Patients will be treated with all three study drugs until the patient experiences disease progression, unacceptable toxicity or withdraws consent. The dose of Atezolizumab will be the same (i.e., 1200 mg Q3W) regardless of dose levels of AN2025 and cohorts. Atezolizumab is administered intravenously over 60 minutes every three weeks. If the first infusion is tolerated, all subsequent infusions may be delivered over 30 minutes. The dose of AN0025 as determined in Observation II will remain constant for each dose level of AN2025 and each cohort, unless the investigators and the sponsor determine that the toxicity comes from the AN0025 + Atezolizumab combination.
89426398|NCT04975581|Experimental|Rotator cuff repair Surgery with Augmentative patch|Open rotator cuff repair Surgery with additional application of augmentative human allograft patch
89426399|NCT04975581|Active Comparator|Rotator cuff repair surgery|Open Rotator cuff repair surgery
89426400|NCT04971018|Experimental|Active ta-VNS|
89426401|NCT04971018|Placebo Comparator|Sham ta-VNS|
88907226|NCT01570166|Experimental|HR group|HR was carried out under general anesthesia using a right subcostal incision with a midline extension.Intra-operative ultrasonography was performed routinely to evaluate the tumor burden, liver remnant, and the possibility of a negative resection margin. Anatomic resection, in the form of segmentectomy and/or subsegmentectomy as described by Makuuchi et al. (16) was the preferred surgical method of liver resection. Pringle's maneuver was routinely used with a clamp and unclamp time of 10 min and 5 min, respectively; this technique was used repeatedly throughout the entire procedure. Hemostasis of the raw liver surface was done with suturing and application of fibrin glue.
88907227|NCT06310057|Experimental|Tofacitinib 10mg|All patient that fulfill the inclusion ans exclusion criteria will start at 10mg tofacitinib.
88907228|NCT06310057|Experimental|Tofacitinib 15 mg|At 3rd month, patients that do not fulfill the ASDAS major improvement criteria will get 15mg tofacitinib.
88907229|NCT06310044|Experimental|Commiphora Myrrh|50% Commiphora Myrrh
88907230|NCT06310044|Active Comparator|Sodium hypochlorite|2.5% NaOCl
88907231|NCT06310005|Experimental|SRD part: Dose group 1|Low dose.
88907232|NCT06310005|Experimental|SRD part: Dose group 2|Medium dose.
88907233|NCT06310005|Experimental|SRD part: Dose group 3|High dose.
88907234|NCT06310005|Experimental|MD part: Dose group 4|High dose.
88907235|NCT06309992|Experimental|Treatment arm|
88907236|NCT06309992|Placebo Comparator|Placebo arm|
89196375|NCT00932308|Active Comparator|2|Prudent, low-fat, calcium sufficient diet (PD)
88907237|NCT06309966|Experimental|BHV-7000 50 mg|
88907238|NCT06309966|Experimental|BHV-7000 75 mg|
88907239|NCT06309966|Placebo Comparator|Placebo|
88907240|NCT06309927|Experimental|Operative hysteroscopy|Surgical evacuation of the uterine cavity by operative hysteroscopy (tissue removal device, Truclear Mini-Elite)
88907241|NCT06309927|Active Comparator|Suction curettage|Surgical evacuation of the uterine cavity by ultrasound guided suction curettage
88907242|NCT06309914|Placebo Comparator|Placebo|One dose (1 capsule) will be consumed twice daily for 28 days. The placebo product will be rice flour (other ingredients: hypromellose, magnesium stearate and chlorophyll). Its appearance will be green/green oblong veggie capsule with white to off-white powder fill.
89196376|NCT00932386|Experimental|dexmedetomidine Hcl infusion|Dexmedetomidine is a highly selective alpha-2 adrenoreceptor agonist, which possesses hypnotic, sedative, anxiolytic, sympatholytic and analgesic properties.
88907243|NCT06309914|Experimental|Enovita Dietary Supplement|One dose (1 capsule) will be consumed twice daily for 28 days. A single dose contains: 150mg grape seed extract (Vitis vinifera L) and dried seed (cultivated), and 27.50mg 95% polyphenols.
88907244|NCT06309914|Experimental|Mirtoselect Dietary Supplement|One dose (1 capsule) will be consumed twice daily for 28 days. A single dose contains: 160mg bilberry extract (Vaccinium myrtillus L.) and 57.6mg 36% anthocyanosides.
88907245|NCT06309914|Experimental|Virtiva Dietary Supplement|One dose (1 capsule) will be consumed twice daily for 28 days. A single dose contains: 240mg Ginkgo biloba extract (leaf), 28.8mg 12% phosphatidylserine (from sunflower), and 12mg 5% ginkgo flavonglycosides.
88907246|NCT06309901||Control Group|A progressive home exercise program consisting of 3 phases was applied.
88907247|NCT06309901||FDM Group|In addition to the progressive home exercise program consisting of 3 phases, the trigger band technique of the fascial distortion model was applied around the knee.
88907248|NCT06309901||IASTM Group|In addition to the progressive home exercise program consisting of 3 phases, the IASTM was applied with Graston technique around the knee.
88907249|NCT06309888||spinal cord injury|Individuals living with a spinal cord injury
89196377|NCT00932386|Placebo Comparator|normal saline|
89196378|NCT00932464|Experimental|1|Neratinib Fasted
89196379|NCT00932464|Experimental|2|Neratinib Fed
89426402|NCT04970511|Experimental|The group I: BBAT Face-to-Face Training group|"Exercises consist of supine, sitting, standing position awareness exercises and walking exercises.~Considering eight weeks, the training is designed to progress gradually each week."
89007601|NCT03762590|Experimental|Color Genomics Only Arm (Arm 2)|"Participants in this arm will access genetic education on the Color Genomics website which includes both written information and an educational video~After accessing the Color Genomics website, participants may elect to review educational content or proceed directly to order genetic testing~Intervention is genetic education via Color Genomics website"
89007602|NCT03729518|Experimental|Arm 1|All patients will have the volume treated and radiation dose delivered to the regional lymphatics decreased according to the characteristics of the primary site and involved lymph nodes. The high risk neck will receive 50 Gy instead of 60 Gy, and the treated volume of the contralateral low risk neck will be reduced and receive only 45 Gy.
89007603|NCT03681223|Active Comparator|Restorelle® Y mesh|All subjects will be predetermined by their surgeon to undergo either a laparoscopic or robotic assisted laparoscopic sacrocolpopexy depending upon their clinical evaluation. The participants will then be randomized to Restorelle® sacrocolpopexy
89007604|NCT03681223|Experimental|Vertessa® Lite Y mesh|All subjects will be predetermined by their surgeon to undergo either a laparoscopic or robotic assisted laparoscopic sacrocolpopexy depending upon their clinical evaluation. The participants will then be randomized to Vertessa® Y sacrocolpopexy
89196380|NCT00932542|Experimental|Eutectic mixture|
89196381|NCT00932542|Placebo Comparator|placebo|
89196382|NCT00932542|Active Comparator|Medicaina|
89426403|NCT04970511|Experimental|The group II: Online BBAT training group|"Patients in the Internet-based BFT group will conduct their training with a physiotherapist to be connected via an online video conference system.~This group will be given the same training as the face-to-face BFT group."
89196383|NCT00907582|Experimental|ASCT in relapsed APL|autologous hematopoietic cell transplantation for patients with relapsed APL after achieving molecular remission
89426404|NCT04970511|No Intervention|The group III: Control group|No training will be applied to the control group patients.
89426405|NCT04968223||Patient Group|Patients with Schizophrenia
89426406|NCT04968223||Control Group|Healthy subjects without family history of psychotic illness
89426407|NCT04965961|Experimental|Recombinant human erythropoietin treatment|Participants receive intravenous injections of 9 International Units per kg bodyweight epoetin-β (NeoRecormon, Roche, Mannheim, Germany) three times per week for four weeks on non-consecutive days. Subjects receive tablets with 80mg iron (Tardyferon, Pierre Fabre Pharme GmbH, Freiburg, Germany) to ensure sufficient iron stores for the expected increase in erythropoeisis.
89426408|NCT04965961|Placebo Comparator|Control group|Participants receive intravenous injections of ~0,5 mL saline (NaCl 0,9%) three times per week for four weeks on non-consecutive days.
89426409|NCT04961762|Experimental|Navigator Program|In addition to receiving Standard Care, participants in the intervention arm will be assigned to a Homeless Outreach Counsellor. The Homeless Outreach Counsellor will connect with the participant as soon as possible during the admission and will provide support during the hospital admission and for approximately 90 days after hospital discharge.
89426410|NCT04961762|No Intervention|Standard Care|Standard Care consists of support from Care Transition Facilitators who work with patients during their hospital stay to arrange discharge plans and make follow-up arrangements. Care Transition Facilitators do not routinely work with patients after hospital discharge. As part of the routine discharge process, the health care team provides patients with medical recommendations, appointments for follow-up care as needed, a written discharge summary, and prescriptions as needed. If the patient has an identified primary care provider, a copy of the discharge summary is sent electronically to the primary care provider.
88907250|NCT06309888||non spinal cord injury|able-bodied individuals
88907251|NCT06309875|Active Comparator|Conventional|Set of specific activities carried out by the health care team by the health care team at the time of hospital discharge of HF patients: the patients with HF:
88907252|NCT06309875|Experimental|PLAN CUIDARTE|"The PLAN CUIDARTE is an intervention aimed at addressing the hospital discharge of people with HF, based on the nursing theory of transitions of Afaf Meleis(46) and under the guidelines of Robin Whittemore for the systematic development of complex interventions for experimental type research in nursing. The PLAN CUIDARTE addresses the specific educational needs of HF patients, as established by the patients with HF, as established by international accreditation standards."
88907253|NCT06309862||Patients with skin cancer eligible for dual ICI treatment.|
89426411|NCT04948918|Experimental|Distal renal denervation|The arm comprises patients undergoing distal bilateral radiofrequency renal denervation performed using Symplicity Spyral renal denervation system.
88907254|NCT06309849|Experimental|Efficacy of Physical Therapy Intervention in Cervical Angina Patients|Randomized Control Trail (RCT) will be used in the study. Participants will be dived into experimental group and control group. Each group will includes 30 participants.The physiotherapy program intervention will includes cervical traction, cervical mobilization, Sub occipital release, Muscle energy technique. and ultra sound with parameters 5 min × 3 times × 4 weeks, 1 MHz, continuous: 1.5 W/cm2; pulsed: 2.5 W/cm2, for study group.
88907255|NCT06309849|Placebo Comparator|know the effect of Physical Therapy Intervention in Cervical Angina Patients|30 participants in control.The physiotherapy program intervention will include ultrasound with parameters 5 min × 3 times × 4 weeks, 1 MHz, continuous: 1.5 W/cm2; pulsed: 2.5 W/cm2
88907256|NCT06309823|Experimental|Active treatment|
88907257|NCT06309810|Experimental|Radiotherapy|"The treatment will be administered with a TrueBeam™ (Varian Medical Systems, Palo Alto, CA, USA) linac, equipped with a Millenium 120-leaves MLC.~The target will be represented by 5 mm of the specific spinal nerve responsible for the spams. A lateral 1 mm margin will be added to the target to generate the corresponding planning treatment volume (PTV). The prescribed dose will be 45-60 Gy in a single fraction. The treatment dose will be chosen based on patients' general condition, and possibility to respect the dose limits (constraints) for the organs at risk (OARs)."
88907258|NCT06309797|Experimental|Test (HA group)|the test group were asked to brush their teeth, dip the interdental brush in HA gel, and use the dipped interdental brush.
88907259|NCT06309797|Experimental|Control Group|the control group were asked to brush their teeth and use the interdental brush for oral hygiene.
89426412|NCT04945603||Poor Grade Subarachnoid Hemorrhage|"All patients (prospective and retrospective) included will have to present a subarachnoid hemorrhage defined poor grade according to the WFNS scale due to the rupture of an intracranial aneurysm.~The patients are managed according to both most recent international guidelines on the specific disease (Stroke, May 2012) and according to national and institutional guidelines/protocols."
89426413|NCT04944173|Experimental|MRD Negative|All subjects will receive four cycles of durvalumab with SABR concurrent at cycle 2, then will be evaluated for MRD. Subjects in this arm have no detectable ctDNA at MRD landmark and will receive no further therapy.
89426414|NCT04944173|Experimental|MRD Positive, no further therapy|All subjects will receive four cycles of durvalumab with SABR concurrent at cycle 2, then will be evaluated for MRD. Subjects in this arm have detectable ctDNA at MRD landmark and are randomized to no further therapy.
89426415|NCT04944173|Experimental|MRD Positive, consolidation durvalumab|All subjects will receive four cycles of durvalumab with SABR concurrent at cycle 2, then will be evaluated for MRD. Subjects in this arm have detectable ctDNA at MRD landmark and are randomized to eight additional cycles of durvalumab
89426416|NCT04931420|Experimental|Arm A - Participants Who Receive Sequential Procedures|"If you are assigned to this arm, study doctors will sequentially remove and treat all visible cancer spots with surgery, radiation, ablation, or other procedures. These interventions might include surgical removal of the diseased part of your lung, liver, lymph nodes, and/or the lining of your belly. In addition, if surgery could not be done, we could treat these diseased spots with other modalities such as radiation and/or radiofrequency/microwave ablation.~If you're selected to be in this arm, the type of procedure you receive will vary based on your cancer and what the study doctor recommends for treatment."
89426417|NCT04931420|Other|Arm B (Control) - Participants Who Receive Standard of Care Chemotherapy|Participants in this arm receive the current standard of care chemotherapy for their specific type of gastrointestinal cancer. This treatment may include the continuation of chemotherapy and a few procedures which may improve your quality of life.
89426418|NCT04931251|Other|Financial Navigation|includes a financial toxicity screening measure (COST), baseline and post-intervention surveys, and approximately 2-6 visits with a financial navigator to identify financial assistance resources
89426419|NCT04930874|Experimental|ICU patients with COVID-19|NIRS monitoring will be performed for approximately 90 minutes at 2 mean blood pressure levels (MAP, ie 65-70 mmHg and 95-100 mmHg) within 12-48 hours and 60-84 hours after admission to the ICU for severe COVID-19 infection. Autoregulation will be assessed using Tissue Oxygenation Index values and mean arterial pressure values in a regression analysis and will be considered sufficient if the relative Pearson correlation coefficient is less than 0.3. Cerebral blood flow will be assessed by blood flow index determination after intravenous infusion of 5 mg indocyanine.
89426420|NCT04930081|Experimental|Parent Management Training|The well-researched Postivie Parenting Program (Triple P) is selected as the intervention program for the parent management training arm. It is an 8-week program that aims at equipping parents with effective parenting strategies.
89426421|NCT04930081|Experimental|Mindful Parenting Program|The Mindful Parenting program, developed by Prof Susan Bogel is selected as the intervention program for the mindful parenting arm. It is an 8-week program that trains parents in mindfulness and support them to apply mindfulness in the parenting context.
88907260|NCT06309784|Experimental|Drill Guidance System|Using a camera based system attached to a standard surgical drill the operating surgeon will use the DGS to drill with the aim of making the drilling more accurate.
89426422|NCT04930081|No Intervention|Waitlist Control Group|The waitlist control group will not receive any service until two months after the intervention arms complete their training. Depending of the availability of the program instructor, either the Parent Management Training or the Mindful Parenting program will be offered to this group.
89426423|NCT04927052|Active Comparator|Revanesse Shape + with Lidocaine|Revanesse Shape + with Lidocaine is a clear, colorless gel in 1.2 mL pre-filled syringes with 25 mg/mL of stabilized hyaluronic acid and lidocaine 0.3% w/w. Participants had 1 cheek treated with Revanesse Shape + with Lidocaine
89426424|NCT04927052|Active Comparator|Juvederm Voluma with Lidocaine|Juvederm Voluma with Lidocaine is a clear, colorless gel in 1.0 mL pre-filled syringes formulated to a concentration of 20 mg/mL of stabilized hyaluronic acid and lidocaine 0.3% w/w. Participants had 1 cheek treated with Juvederm Voluma with Lidocaine.
89426425|NCT04919265||Mother and Infant|The cohort will be followed for 2 years with 8 follow-up measurement points of the infants until the age of 1 year.
89426426|NCT04913012|Experimental|Aerobic training booster group|Will receive 12 weeks of aerobic training followed by booster sessions + standard care in the 40 follow up period
88907261|NCT06309771|Experimental|Intervention|Complex behavioral intervention based on health-related modules.
88907262|NCT06309771|No Intervention|Control|Students from the control group will follow no modules.
88907263|NCT06309758|Experimental|Participants|3 month active use of the website. Receive bi-weekly update mails to nudge participants to use the website.
88907264|NCT06309745||RPLND cohort|Patients with seminoma who are negative/low for tumour markers and unifocal ipsilateral Stage IIA or <3cm IIB will be assessed for rRPLND. Patients who are eligible for rRPLND will undergo surgery followed by adjuvant treatment or surveillance as determined by their clinical teams based on post-operative histology as per SOC. Patients who are not deemed eligible for or decline rRPLND, will be offered either BEP/EP chemotherapy or radiotherapy with or without neoadjuvant Carboplatin AUC7 and will continue to be followed in the study.
88907265|NCT06309745||Carboplatin AUC10 cohort|Patients with stage II seminoma will be offered Carboplatin AUC10. Those deemed ineligible for Carboplatin AUC10 or who decline this treatment option will be offered either BEP/EP chemotherapy or radiotherapy and will continue to be followed in the study.
88907266|NCT06309732|Experimental|GAMEC - S|Day 4 PEG Filgrastim 6mg Day 1 Actinomycin D 1mg/m2 Day 1 Methotrexate (dependent on creatinine clearance) Days 1,2, 3, 4 Etoposide 90mg/m2 Days 2, 3 Cisplatin 50mg/m2 Day 8 Cisplatin 50mg/m2 (cycle 1&2 only)
88907267|NCT06309732|Experimental|GAMEC-A|Day 1 Actinomycin-D 1m/m2 Day 2, 3 and 8 Methotrexate 8g/m2 (dependent on creatinine clearance) Day 2, 3 and 8 Cisplatin 50mg/m2 (Day 8 dose omitted from week 6 onwards) Day 1 and 2 Epirubicin 37.5mg/m2 Day 3 Pegfilgrastim 6mg Treatment given on weeks 1, 3, 6, 8 and 10.
89426427|NCT04913012|Active Comparator|Aerobic training control group|Will receive 12 weeks of aerobic training followed by standard care in the 40 follow up period
89007605|NCT03643861|Experimental|5 Fraction Breast Stereotactic Body Radiation Therapy|This study will enroll patients that have a confirmed histology of early stage breast cancer. The patient will undergo a lumpectomy and will then receive partial breast 5 fractions stereotactic body radiation therapy at a dose of 6 gy for 5 fractions for treatment. Patients will be followed for 36 total months with specific follow-ups at 3, 6, 9, 12, 18, 24, and 36 months.
89007606|NCT03631043|Experimental|Stage I (personalized vaccine)|Patients undergo collection of blood and bone marrow for making the vaccine. Patients then receive personalized vaccine SC on days 1 and 15 of cycles 1-2 and on day 1 of cycles 3-6. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
89007607|NCT03631043|Experimental|Stage II (personalized vaccine, lenalidomide)|Patients undergo collection of blood and bone marrow for making the vaccine. Patients then receive personalized vaccine SC on days 1 and 15 of cycles 1-2 and on day 1 of cycles 3-6. Patients also receive lenalidomide PO on days 1-21. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
89007608|NCT03614312||BMI 18-25 Pregnant Women|BMI 18-25 less than 36 weeks pregnant
89007609|NCT03613103|Active Comparator|Direct laryngoscopy|Intubation with direct laryngoscopy (Conventional Intubation)
89426428|NCT04913012|Experimental|Resistance training booster group|Will receive 12 weeks of resistance training training followed by booster sessions + standard care in the 40 follow up period
89426429|NCT04913012|Active Comparator|Resistance training control group|Will receive 12 weeks of resistance training followed by standard care in the 40 follow up period
89007610|NCT03613103|Experimental|Videolaryngoscopy|Intubation with videolaryngoscopy (Assisted video intubation)
89007611|NCT03609580|Experimental|1 week Pre-operative Tamsulosin administration|
89007612|NCT03609580|Experimental|3 days Pre-operative Tamsulosin administration|
89007613|NCT03602521|Experimental|BPD|Blood sample After simulating an interpersonal stress, the evolution of plasma neuropeptides level (OXT, vasopressin and opioid) of patients with a BPD
89007614|NCT03602521|Active Comparator|HC|Blood sample After simulating an interpersonal stress, the evolution of plasma neuropeptides level (OXT, vasopressin and opioid) of healthy controls (HC) patients .without any history of psychopathology
89007615|NCT03584932|Experimental|Intervention arm|Subjects participate in a youth service navigation intervention and are eligible to receive contingency management incentives.
89007616|NCT03584932|No Intervention|Control arm|Standard of care as set forth by the national HIV care guidelines.
89426430|NCT04913012|No Intervention|Control group|Will receive standard care throughout the study
89007617|NCT03583710|Experimental|Arm A (mitotane)|Patients receive mitotane PO daily on days 1-21. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity.
89007618|NCT03583710|Experimental|Arm B (mitotane, etoposide, cisplatin)|Patients receive mitotane as in Arm A. Patients also receive cisplatin IV over 2 hours on day 1 and etoposide IV over 2 hours on days 1-3. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
89007619|NCT03564093|Experimental|Dexmedetomidine|1µg/kg intranasal dexmedetomidine
89007620|NCT03564093|Placebo Comparator|Placebo|0,01ml/kg intranasal 4,5% saline
89007621|NCT03520101|Other|SAPIEN|Following the Heart Team's decision to proceed with a TAVI-ViV procedure, patients will received an Edwards (SAPIEN XT or SAPIEN 3) valve.
89007622|NCT03520101|Other|COREVALVE|Following the Heart Team's decision to proceed with a TAVI-ViV procedure, patients will received the CoreValve Evolut R or Evolut PRO valve system.
89007623|NCT03500991|Experimental|ARM A (Tumor Cavity Infusion)|"patients with supratentorial tumors for which CAR T cells will be delivered into the tumor resection cavity~Intervention: HER2-specific chimeric antigen receptor (CAR) T cell"
89007624|NCT03500991|Experimental|ARM B (Ventricular System Infusion)|"patients with either infratentorial tumors or leptomeningeal tumors for which the CAR T cells will be delivered into the fourth ventricle or lateral ventricle, respectively~Intervention: HER2-specific chimeric antigen receptor (CAR) T cell"
89007625|NCT03499587||Obese pregnant women|BMI >30 with early OB visit medical records accessible
89007626|NCT03499587||Normal weight pregnant women|BMI 18.5-25 with early OB visit medical records accessible.
89007627|NCT03483103|Experimental|Treatment|Lisocabtagene maraleucel at a dose of 100×10^6 CAR+ T cells (50×10^6 CD8+ CAR+ T cells and 50×10^6 CD4+ CAR+ T cells), will be given IV in a single-dose schedule on Day 1 (between 2 and 7 days following the completion of lymphodepleting chemotherapy).
89426431|NCT04907565||Obese patients|BMI >30kg/m2
89426432|NCT04907565||non obese patients|BMI between 18 to 29kg/m2
89426433|NCT04903925|Experimental|Group 1|All patients will undergo an impacted tooth extraction; patients allocated to group 1 will receive an antibiotic therapy with amoxicillin for 6 days (2 g/day) and a probiotic for 21 days (2 tablets/day).
89426434|NCT04903925|Placebo Comparator|Group 2|All patients will undergo an impacted tooth extraction; patients allocated to group 1 will receive an antibiotic therapy with amoxicillin for 6 days (2 g/day) and a placebo of the probiotic for 21 days (2 tablets/day).
89426435|NCT04903262|Experimental|ECCO2R|"Patients will be initially treated with standardized ventilation: volume assist/control, VT = 6 mL/kg PBW; insp. flow 50-70 L/min, I:E ratio 1:1 to 1:3; RR 20-35 bpm; PEEP according to low PEEP/ high FiO2 table. Goals: PaO2 55-80 mmHg or SpO2 88-95%; arterial pH: 7.30-7.45.~ECCO2R initiated during standardized ventilation with blood flow between 1000 and 1500 mL/min. Anticoagulation with unfractionated heparin to a target aPTT of 1.5-2.0x baseline. Target: maintain PaCO2 at baseline ± 20%.~VT initially reduced to 5 mL/kg. Sweep gas initiated and VT decreased to 4.5 then 4 mL/kg; PEEP adjusted to maintain same mean airway pressure as during standardized ventilation, provided that Pplat ≤ 25 cmH2O.~Respiratory rate decreased to 8 bpm. If PaCO2 > 75 mmHg and/or pH < 7.2, despite respiratory rate of 35/min and optimized ECCO2R, VT will be increased to the last previously tolerated VT.~Recommendation: 2 daily lung recruitment maneuvers (as per clinical practice in each center)."
89426436|NCT04903262|Active Comparator|Standard of care|"Patients will be treated with standardized ventilation: volume assist/control, VT = 6 mL/kg PBW; insp. flow 50-70 L/min, I:E ratio 1:1 to 1:3; RR 20-35 bpm; PEEP according to low PEEP/ high FiO2 table. Goals: PaO2 55-80 mmHg or SpO2 88-95%; arterial pH: 7.30-7.45.~Recommendation: 2 daily lung recruitment maneuvers (as per clinical practice in each center)."
89426437|NCT04899583|Experimental|Treatment Group|a Sirolimus Coated Balloon
89426438|NCT04899583|Active Comparator|Control Group|a Paclitaxel Coated Balloon Catheter
89426439|NCT04896827||Chronic pain|Patients with chronic pain (n=100)
89426440|NCT04896827||Healthy participants|Healthy participants (n=144)
89426441|NCT04896476|Experimental|EchoMark|All subjects will undergo a physician exam prior an arteriovenous fistula creation per the institution's standard of care. After the fistula creation is completed, but prior to closure, the EchoMark will be implanted under the outflow vein.
89426442|NCT04895631|Experimental|Fluorocholine PET Imaging|Patients will undergo a single fluorocholine PET imaging study prior to surgery.
89426443|NCT04893863|Active Comparator|Standard dressing|Topical antibiotic ointment (Polysporin™ or formulary equivalent) and non-adherent petrolatum fine-meshed gauze (ADAPTIC™) applied every Monday, Wednesday and Friday (or equivalent).
89426444|NCT04893863|Experimental|Test dressing|A 0.5 cm layer of PluroGel® followed by the above standard dressing. In addition, this will be covered with moistened gauze, kept moist twice daily. (The additional factors are the use of PluroGel® and moistened gauze. Standard dressing will continue to be used.)
89426445|NCT04888247|Experimental|Treatment|Trans-septal mitral valve replacement
89426446|NCT04885959|Placebo Comparator|Usual diet|Participants are subjected to received general dietary advice from attended nurses or physician during their antenatal visits.
89426447|NCT04885959|Experimental|PPBe Diet|Participants will receive dietary intervention which is tailored to the study objective to increase targeted bacteria of Prevotella sp and the short-chain fatty acids namely butyrate.
89426448|NCT04883476||Chronic Low Back Pain and Neck Pain|
89426449|NCT04882982|Experimental|Caria app|"The Caria app is publically available on the Apple app store. It is an interactive native app that provides education on menopause as well as symptom tracking/feedback features, social support as well as cognitive behavioral and relaxation techniques. Participants will be given an unlocked version with all content available at no charge. The app sends out occasional automated emails to users to remind of features of the app and to encourage them to return to the app. Users can opt out of reminder features."
89426450|NCT04882982|Active Comparator|Menopause education|Participants will receive educational material about menopause from the North American Menopause Society, a well respected menopause organization.
89426451|NCT04881123|Experimental|SER150|Randomized participants will receive SER150, 15 mg, orally, BID (except on Day 168 where participants will only receive a 15 mg single dose (QD) in the morning)
89426452|NCT04881123|Placebo Comparator|Placebo|Randomized participants will receive matching placebo, orally, BID (except on Day 168 where participants will only receive a 15 mg single dose (QD) in the morning)
89426453|NCT04877834|Experimental|DelanzoTMDR group|Subjects will take DelanzoTMDR 60 mg Capsule, manufactured by SAMI Pharmaceuticals (Pvt.) Ltd. after at least 10 hours' fast, with 240 mL of ambient temperature water at their scheduled dosing time-point.
89426454|NCT04877834|Active Comparator|Dexilant® Group|Subjects will take Dexilant® 60 mg Capsule, manufactured by Takeda Pharmaceutical Company Limited after at least 10 hours' fast, with 240 mL of ambient temperature water at their scheduled dosing time-point.
89426455|NCT04873128|Experimental|Healthy adults|"Healthy adults who had no infection with SARS-CoV-2 virus before or had recovered from COVID-19 and plan to take the various COVID-19 experimental vaccine candidates or had already one dose of COVID-19 vaccine and are going to have the second vaccination with a different vaccine.~Study related procedures:~1-3 days before application of the first vaccine dose (blood sample 1) 7-10 days after first dose of vaccine (blood sample 2), 1-3 days before second dose of vaccine (blood sample 3) 7-10 days after second vaccine dose (blood sample 4) 6-12 Months after second vaccine dose (blood sample 5, optional) Next Generation Sequencing (NGS) analysis and other omics analysis (transcriptomics, proteomics, metabolomics)."
89426456|NCT04873128|Experimental|COVID-19 vaccinated subjects with side effects|"COVID-19 vaccinated subjects with diagnosed central thrombosis, anaphylactic shock or other major or minor complications such as dermatitis.~Study related procedures: Blood sample will be taken without time frame 1-3 days after admission to the hospital (severe side effects) or consulting a doctor (mild side effects) (blood sample 1) during treatment (blood sample 2) After subject is recovered (blood sample 3) 6-12 Months after recovering (blood sample 4, optional) Next Generation Sequencing (NGS) analysis and other omics analysis (transcriptomics, proteomics, metabolomics)."
89426457|NCT04870957|Experimental|MBSR (mindfulness-based stress reduction)|Run-in treatment then MBSR.
89426458|NCT04870957|Experimental|PT and exercise|Run-in treatment then PT and exercise
89426459|NCT04870957|Experimental|Acupressure|Run-in treatment then Acupressure
89426460|NCT04870957|Experimental|Duloxetine|Run-in treatment then Duloxetine
89426461|NCT04870957|Experimental|MBSR then PT and exercise|Run-in treatment then 8 weeks of MBSR, and then 8 weeks of PT and exercise.
89426462|NCT04870957|Experimental|MBSR then Acupressure|Run-in treatment, then 8 weeks of MBSR, and then 8 weeks Acupressure.
89426463|NCT04870957|Experimental|MBSR then Duloxetine|Run-in treatment, then 8 weeks of MBSR, and then approximately 8 weeks of Duloxetine
89426464|NCT04870957|Experimental|PT and exercise then MBSR|Run-in treatment, then 8 weeks of PT and exercise, and then 8 weeks of MBSR.
89426465|NCT04870957|Experimental|PT and exercise then Acupressure|Run-in treatment, then 8 weeks of PT and exercise, and then 8 weeks of Acupressure
89426466|NCT04870957|Experimental|PT and exercise then Duloxetine|Run-in treatment, then 8 weeks of PT and exercise, and then approximately 8 weeks of Duloxetine
89426467|NCT04870957|Experimental|Acupressure then MBSR|Run-in treatment, then 8 weeks of Acupressure, and then 8 weeks of MBSR
89426468|NCT04870957|Experimental|Acupressure then PT and exercise|Run-in treatment, then 8 weeks of Acupressure, and then 8 weeks of PT and exercise.
89196384|NCT05277454|Experimental|HMPL-653 open-label treatment arm|"Dose-escalation Stage:~Participants will be treated with escalating doses of HMPL-653 to determine the MTD and RP2D.~Dose-expansion Stage:~Participants will be enrolled in the expansion stage to better characterize the safety, tolerability, PK variability, and preliminary efficacy of HMPL-653 in TGCT and specific advanced solid tumors."
89426469|NCT04870957|Experimental|Acupressure then Duloxetine|Run-in treatment, then 8 weeks of Acupressure, and then approximately 8 weeks of Duloxetine
89196385|NCT00907660|Active Comparator|Full Dose|Provision of 8 weight loss counseling sessions, calorie guide, pedometer, meal plan, and 2 meals per day of portion-controlled foods (shakes and entrees)
89196386|NCT00907660|Experimental|Half dose|Provision of 8 weight loss counseling sessions, calorie guide, pedometer, meal plan, and 1 meal per day of portion-controlled foods (shakes and entrees)
89196387|NCT00375427|Experimental|Every 3 months|Zoledronic acid as a 15-minute (at least) intravenous (i.v.) infusion every three months. The dose of study drug will be the same administered before the study entry, that is 4 mg or a reduced dose, i.e. 3.5 mg, or 3.3 mg or 3.0 mg. Randomized patients will receive a maximum of 4 infusions in this group.
89196388|NCT00375427|Experimental|Every 4 weeks|Zoledronic acid as a 15-minute (at least) intravenous (i.v.) infusion every 4 weeks. The dose of study drug will be the same administered before the study entry, that is 4 mg or a reduced dose, i.e. 3.5 mg, or 3.3 mg or 3.0 mg. Patients randomized to this group will receive up to 12 infusions.
89196389|NCT00929266|Experimental|1|"The choice of conducting the study in healthy volunteers and not in patients is based on the necessity to have a healthy physiological context avoiding any situation which could lead to hemolysis. As the protocol requires mobilization with a growth factor, the donors of peripheral stem cells (PSC) receive G-CSF.~Direct intravenous injection of labeled cRBC in a volume of 1 mL will be administered to the subjects."
89426470|NCT04870957|Experimental|Duloxetine then MBSR|Run-in treatment, then approximately 8 weeks of Duloxetine, and then 8 weeks of MBSR.
89426471|NCT04870957|Experimental|Duloxetine then PT and exercise|Run-in treatment, then approximately 8 weeks of Duloxetine, and then 8 weeks of PT and exercise
88907268|NCT06309719|Experimental|Test|Periodontal Access Flap (AF) + Combined Formulation of Hyaluronic acid and Polydeoxyribonucleotides (PNHA)
88907269|NCT06309719|Active Comparator|Control|Periodontal Access Flap (AF)
88907270|NCT06309706||cross-sectional|To analyze the maxillary sinus anatomy over edentulous ridges in the bilateral posterior maxillary area in Chinese patients using cone-beam computed tomography (CBCT).
88907271|NCT06309693|Active Comparator|Quadratus Lumborum Block|The QL block will be performed by the regional anesthesia team according to their standard protocol with a uniform quantity and concentration of analgesic agent (ropivacaine 60cc). Intraoperatively, patients will undergo subcutaneous injections of lidocaine (2cc per port site) at each port site. Preoperatively, patients will only receive acetaminophen and no preoperative narcotics or neuro-modulators will be administered. Intraabdominal pressure intraoperative will be standardized among surgeons (plan for 15mm Hg for port placement, then 12 mm Hg once docked). At the conclusion of each surgery, eligible patients will receive a dose of IV ketorolac. Postoperatively, patients will be prescribed a standard regimen of NSAIDs, acetaminophen and opioids. Patients will be asked to rate their pain according to the numeric pain rating scale immediately postoperatively in the PACU and patient opioid requirements while in the PACU will be reviewed in the chart.
89007628|NCT03482479|Experimental|Naltrexone Hydrochloride|Naltrexone hydrochloride for oral use, 4.5 mg per capsule, taken once a day for 6 weeks.
89007629|NCT03482479|Placebo Comparator|Placebo Comparator|Placebo to match naltrexone for oral use to be taken once a day for 6 weeks.
89426472|NCT04870957|Experimental|Duloxetine then Acupressure|Run-in treatment, then approximately 8 weeks of Duloxetine, and then 8 weeks Acupressure.
89426473|NCT04870957|Experimental|PainGuide|Run-in treatment only with no additional treatments.
89426474|NCT04868370||Multiple Sclerosis (MS)|
89426475|NCT04868370||Healthy Subject|
88907272|NCT06309693|Active Comparator|Enhanced Recovery After Surgery (ERAS) Protocol|The ERAS protocol is a multimodal approach to pain control while minimizing opioid medications. Subjects randomized to the ERAS arm will undergo the standard ERAS protocol of early postoperative ambulation, no bowel preparation, and the use of multimodal pain medications including acetaminophen and non-steroid anti-inflammatory drugs (NSAIDs). Intraabdominal pressure intraoperative will be standardized among surgeons (plan for 15mm Hg for port placement, then 12 mm Hg once docked). At the conclusion of each surgery, eligible patients will receive a dose of IV ketorolac. Postoperatively, patients will be prescribed a standard regimen of NSAIDs, acetaminophen and opioids. Patients will be asked to rate their pain according to the numeric pain rating scale immediately postoperatively in the PACU and patient opioid requirements while in the PACU will be reviewed in the chart.
88907273|NCT06309667|Experimental|Cohort A1 - Single Ascending Dose|PG-102(MG12) Dose 1 (N=8) Placebo (N=2) Subcutaneous injection
88907274|NCT06309667|Experimental|Cohort A2 - Single Ascending Dose|PG-102(MG12) Dose 2 (N=8) Placebo (N=2) Subcutaneous injection
88907275|NCT06309667|Experimental|Cohort A3 - Single Ascending Dose|PG-102(MG12) Dose 3 (N=8) Placebo (N=2) Subcutaneous injection
88907276|NCT06309667|Experimental|Cohort A4 - Single Ascending Dose|PG-102(MG12) Dose 4 (N=8) Placebo (N=2) Subcutaneous injection
88907277|NCT06309667|Experimental|Cohort A5 - Multiple Ascending Dose|PG-102(MG12) Dose 5 (N=8) Placebo (N=2) Subcutaneous injection
88907278|NCT06309667|Experimental|Cohort B1 - Multiple Ascending Dose|PG-102(MG12) Dose 1 (N=6) Placebo (N=2) Subcutaneous injection
88907279|NCT06309667|Experimental|Cohort B2 - Multiple Ascending Dose|PG-102(MG12) Dose 1~5 (N=6) Placebo (N=2) Subcutaneous injection
88907280|NCT06309667|Experimental|Cohort B3 - Multiple Ascending Dose|PG-102(MG12) Dose 1~5 (N=6) Placebo (N=2) Subcutaneous injection
88907281|NCT06309667|Experimental|Cohort B4 - Multiple Ascending Dose|PG-102(MG12) Dose 1~5 (N=6) Placebo (N=2) Subcutaneous injection
88907282|NCT06309667|Experimental|Cohort S - Multiple Ascending Dose|PG-102(MG12) Optimal Dose (N=6) Placebo (N=2) Subcutaneous injection
88907283|NCT06309654|Experimental|home-based circuit training (HBCT) protocol|Participants in the exercise group performed HBCT three times per week on non-consecutive days for 12 weeks.
88907284|NCT06309654|Sham Comparator|Standard of care (CONT)|"Providing education about the nature of OA, its progression, and strategies for symptom management.~Empowering individuals with self-management techniques, such as joint protection strategies, activity modification, and lifestyle changes (e.g., weight management, exercise)."
88907285|NCT06309641||Ferric derisomaltose|Adult patients with anemia scheduled for administration of ferric derisomaltose as prescribed in routine care.
88907286|NCT06309641||Ferric carboxymaltose|Adult patients with anemia scheduled for administration of ferric carboxymaltose as prescribed in routine care.
88907287|NCT06309641||Case reports|Patients with severe anemia who developed methemoglobinemia after intravenous administration of ferric derisomaltose.
89007630|NCT03449108|Experimental|ICI Ovarian Cancer, Sarcomas, Triple Negative Breast Cancer (LN-145-S1, nivolumab)|Ipilimumab will be administered as a single dose prior to tumor resection. Nivolumab will be administered once prior to tumor resection. Patients receive cyclophosphamide IV over 2 hours on days -7 and -6, fludarabine IV over 15-30 minutes daily on days -5 to -1, LN-145-S1 IV over 45 minutes on day 0 and aldesleukin IV over 30 minutes on days 1-4 for up to 6 doses. Within 12 weeks after receiving LN-145-S1, patients receive nivolumab IV over 30 minutes every 4 weeks in the absence of disease progression or unacceptable toxicity. The second dose will be administered prior to TIL administration and dosing will continue every 4 weeks and continued until unacceptable toxicity, progression, or start of another cancer therapy.
89007631|NCT03449108|Experimental|Thyroid Cohort (LN-145)|Patients receive cyclophosphamide IV over 2 hours on days -7 and -6, fludarabine IV over 15-30 minutes daily on days -5 to -1, autologous tumor infiltrating lymphocytes LN-145 IV over 45 minutes on day 0 and aldesleukin IV over 30 minutes on days 1-4 for up to 6 doses.
89007632|NCT03415685|Active Comparator|Group A: PicoPlus for unwanted tattoos.|Subjects receiving PicoPlus laser system treatment for unwanted tattoos.
89196390|NCT01043575|Experimental|1|Rifapentine
89196391|NCT01043575|Active Comparator|2|Rifampin
89196392|NCT00932776|Experimental|TBA|
89426476|NCT04867395|No Intervention|Usual Care|75 participants will receive standard care, consisting of verbal discharge counseling given by doctors and nurses supplemented by written instructions (all unstandardized).
89426477|NCT04867395|Experimental|Intervention group|75 participants will be randomized to receive behavioral intervention, consisting of discharge counseling using the health literacy-informed discharge instructions
89426478|NCT04862273||Native T1 CMR|Diagnostic accuracy of native T1 CMR and ATTR probability estimator are tested against the reference methods (99mTc-DPD scintigraphy, laboratory screening for multiple myeloma / AL amyloidosis; or cardiac biopsy, if noninvasive evaluation is inconclusive)
89426479|NCT04853251|Experimental|SUSVIMO|Participants will have the implant (filled prior to implantation with approximately 20 uL of the 100-mg/mL formulation of ranibizumab [approximately 2-mg dose of ranibizumab]) surgically inserted in the study eye at the Day 1 visit following their enrollment visit. After the initial fill of the implant with ranibizumab, patients will receive implant refill-exchanges at fixed 24-week intervals.
89426480|NCT04852393||Block|Patients undergoing ultrasound-guided cervical medial branch blocks as part of their usual care
89426481|NCT04844333|Experimental|Extubation under deep anesthesia|When the patient is in sedation or anesthesia state, including no body movement, bispectral index 60-70, spontaneous breathing recovery, VT ≥ 5ml / kg, respiratory rate 10-20 times / min, regular rhythm, PetCO2 < 45mmhg, regular waveform, stable circulation, the endotracheal tube is removed.
89426482|NCT04844333|No Intervention|Awake extubation|When the patient is in awake state, including bispectral index >70, spontaneous breathing recovery, VT ≥ 5ml / kg, respiratory rate 10-20 times / min, regular rhythm, PetCO2 < 45mmhg, regular waveform, the cough and swallowing reflex are obvious and the circulation is stable, the endotracheal tube is removed.
89426483|NCT04844281|Experimental|Daily Disposable Toric Contact Lens|All subjects are fit into Precision1® toric contact lenses. Subjects are requested to wear the lenses for a total of two weeks.
88820376|NCT06188598|Experimental|Time-restricted eating (TRE)|Participants in the TRE group are instructed to restrict eating to an 8-hr window but were not asked to change the type or amount of food typically consumed. The 8-hour window (e.g., 10am - 6pm) has to be the same each day starting at least 2 hours after wake and ending at least 2 hours before bed.
89196393|NCT00932776|Active Comparator|Control|
89196394|NCT00393913||Continuous Positive Airway Pressure (CPAP)|Participants will use a CPAP machine if they are found to have sleep apnea.
89426484|NCT04840381||Nonagenarians and Centenarians|Nonagenarians and Centenarians borned and living for most of their life in the Abruzzo region.
89426485|NCT04834817|Experimental|LED treatment|LED treatment with Celluma POD device after laser test area
89007633|NCT03415685|Active Comparator|Group B: PicoPlus for other dermatological conditions|Subjects receiving PicoPlus laser system treatment for unwanted benign pigmented lesions, melasma or other dermatological conditions such as skin rejuvenation.
89007634|NCT03414242|Experimental|Cervical spine musculature|
89007635|NCT03412747|Experimental|Bimekizumab Arm 1|Subjects will receive bimekizumab dose regimen 1 for 56 weeks. Subjects will receive placebo at pre-specified time-points to maintain the blinding.
89007636|NCT03412747|Experimental|Bimekizumab Arm 2|Subjects will receive bimekizumab dose regimen 1 for 16 weeks and will proceed with bimekizumab dose regimen 2 until week 56. Subjects will receive placebo at pre-specified time-points to maintain the blinding.
89007637|NCT03412747|Active Comparator|Adalimumab Arm|Subjects will receive adalimumab for 24 weeks and will then receive bimekizumab dose regimen 1 until week 56. Subjects will receive placebo at pre-specified time-points to maintain the blinding.
89007638|NCT03410992|Experimental|Bimekizumab cohort|Subjects will receive bimekizumab for 16 Weeks. Subjects who achieve certain predefined response criteria will be re-randomized to either receive bimekizumab or placebo until Week 56. Subjects who do not achieve predefined response criteria will enter the bimekizumab escape arm.
89426486|NCT04834817|No Intervention|Control|No treatment after laser test area
89426487|NCT04832750||Major Depressive Episode|At least one failed pharmaco trial in current episode
89007639|NCT03410992|Placebo Comparator|Placebo|Subjects will receive placebo for 16 Weeks. Subjects who achieve certain predefined response criteria will proceed with placebo until Week 56. Subjects who do not achieve certain predefined response criteria will enter the bimekizumab escape arm.
89426488|NCT04832750||Major Depressive Episode with comorbid Borderline Personality Disorder|At least one failed pharmaco trial in current episode
89426489|NCT04832750||Healthy Controls|No psychiatric disorders
89426490|NCT04828174|Experimental|anti-TRBC1 CAR-T cell|Administration with anti-TRBC1 CAR-T cells in the relapsed/refractory T cell hematological malignancy patients.
88820377|NCT06188598|No Intervention|Unrestricted eating|Participants are instructed to continue their diet as normal without changing the type, amount or timing of food typically consumed.
88820378|NCT06188572||Diabetes Mellitus|The study group included individuals aged 48-78 (min-max) years, diagnosed with type 2 DM in the treatment units of Harran University Training and Research Hospital.
89007640|NCT03410992|Experimental|Bimekizumab Escape arm|Subjects who do not achieve certain predefined response criteria at Week 16 or later will enter the bimekizumab escape arm and will receive open-label bimekizumab for 12 weeks.
89007641|NCT03394079|Experimental|OCT-guided|
89007642|NCT03394079|Active Comparator|IVUS-guided|
89007643|NCT03386396|Experimental|High protein/low carbohydrate|A breakfast shake will be made with high protein/low carbohydrate mixture.
89007644|NCT03386396|Experimental|High carbohydrate/low protein|A breakfast shake will be made with high carbohydrate/low protein mixture.
89426491|NCT04827563||Participants with Normal Baseline Endothelial Function|
89426492|NCT04827563||Participants with Abnormal Baseline Endothelial Function|
88820379|NCT06188572||Healthy|Age and sex homogenous healthy individuals without a diagnosis of DM were included in the control group
89007645|NCT03383445|Other|TAVR|The TAVR procedure will be performed following the standards of each participating center. No restriction or specific recommendation will be given regarding the approach, general vs. local abesthesia, Imaging guidance during the TAVR procedure, and post-procedural TAVR management.
89007646|NCT03383445|Other|SAVR|SAVR procedure will be performed using standard techniques, with no limitation in terms of type and size of the valve prosthesis or surgical procedure (e.g. enlargement of the aortic root).
89007647|NCT03370913|Experimental|valoctocogene roxaparvovec Open Label|Single administration of valoctocogene roxaparvovec at a dose of 6E13 vg/kg
89007648|NCT03364660|Experimental|Voluntary Movement Epidural Stimulation|Participants assigned to this group will receive epidural stimulation specific for voluntary movement.
89007649|NCT03364660|Experimental|Cardiovascular Epidural Stimulation|Participants assigned to this group will receive epidural stimulation specific for cardiovascular function.
89007650|NCT03364660|Experimental|Voluntary Movement ES + Stand Training|Participants assigned to this group will receive epidural stimulation specific for voluntary movement and will also receive stand training.
89426493|NCT04819503|Other|Active and then sham repetitive transcranial magnetic stimulation|"Deep rTMS is delivered with the Brainsway H7-coil (Brainsway, Jerusalem, Israel) applied via a helmet placed on the head targeting the primary motor cortex of the leg.~Sham stimulation is delivered with a sham coil placed in the helmet encasing the active rTMS coil. Sham rTMS sessions will use exactly the same parameters of stimulation as active rTMS."
89007651|NCT03364660|Experimental|Cardiovascular ES + Stand Training|Participants assigned to this group will receive epidural stimulation specific for cardiovascular function and will also receive stand training.
89007652|NCT03348150|Experimental|Gastrecomy + Cytoreductive surgery + HIPEC|Gastrectomy combined with cytoreductive surgery and HIPEC (experimental treatment)
89007653|NCT03348150|No Intervention|palliative systemic chemotherapy|Palliative systemic chemotherapy only (standard treatment)
89007654|NCT03342404|Experimental|Luspatercept (ACE-536) plus Best Supportive Care (BSC)|Arm Description: Luspatercept, subcutaneous(ly) (SC) once every 21 days
89007655|NCT03342404|Placebo Comparator|Placebo plus Best Supportive Care (BSC)|normal saline solution subcutaneous(ly) (SC) once every 21 days
89196395|NCT04437238|Experimental|Intervention - KeepWell tool|KeepWell is standalone eHealth application aimed at supporting the self-management of older adults with multimorbidity, and it has the following features: (i) lifestyle advice for any combination of the top 10 chronic conditions affecting older adults); (ii) an avatar health coach that walks users through a health prioritization and goal setting exercise; (iii) a health risk questionnaire (HRQ) covering health (chronic diseases), lifestyle (physical activity, diet, smoking, alcohol, caffeine, bladder health), and social and emotional well-being (social frailty, isolation, loneliness) dimensions; (iv) an evidence-based, customized Action plan; (v) an interactive lifestyle tracker; (vi) journaling; (vii) and a health resources library. A health coach avatar leads users through a health priority and goal setting exercise that allows them to create a customized action plan based on guideline recommendations for lifestyle changes.
89007656|NCT03329599|Experimental|Polypill|Assigned to a polypill containing 2/3 antihypertensives, a moderate/high-intensity statin and Aspirin to be taken orally, once daily in the form of a hard capsule
89007657|NCT03329599|No Intervention|Usual Care|Will continue to take separate, individual secondary preventive medications as prescribed
89007658|NCT03277612||C-Section|Infants delivered by C-section
89007659|NCT03277612||Vaginal Delivery|Infants delivered by spontaneous vaginal delivery after C-section.
89007660|NCT03277196|Experimental|Ivacaftor Arm|
89007661|NCT03277196|No Intervention|Observational Arm|
89007662|NCT03272698|Experimental|Ketamine (HIKER)|Patients in the HIKER arm will receive a single dose of ketamine 0.50 mg/kg, which is enough to achieve a full anaesthetic effect (i.e., unconsciousness mimicking the GA regimen above), on 8 successive weekdays.
89426494|NCT04819503|Other|Sham and then active repetitive transcranial magnetic stimulation|Deep rTMS is delivered with the Brainsway H7-coil (Brainsway, Jerusalem, Israel) applied via a helmet placed on the head targeting the primary motor cortex of the leg.Sham stimulation is delivered with a sham coil placed in the helmet encasing the active rTMS coil. Sham rTMS sessions will use exactly the same parameters of stimulation as active rTMS.
89426495|NCT04808570|Experimental|TQ-B3525 tablets|TQ-B3525 tablet administered orally.
89426496|NCT04799821|Experimental|Intervention|Daily walnut consumption
89426497|NCT04799821|Other|Control|No walnut consumption
89426498|NCT04798898|Experimental|Intervention (+RFA) arm|Preoperative partial RFA necrosis in the liver metastasis followed by liver resection
89426499|NCT04798898|No Intervention|Control (-RFA) arm|Liver resection
89426500|NCT04797715|Experimental|AXS-05|Up to 26 weeks in double-blind period
89426501|NCT04797715|Placebo Comparator|Placebo|Up to 26 weeks in double-blind period
89426502|NCT04794582|Active Comparator|ProGrip® Mesh reinforcement|Once the closure has been completed in 2 muscle-aponeurotic planes with continuous synthetic suture (Monomax® USP 0), the closure will be completed by placing the ProGrip® macroporous polypropylene monofilament mesh in supra-aponeurotic position using the surface with the polylactic acid microgrips, which act as Velcro, in direct contact with the superficial aponeurotic plane constituted by the aponeuroses of the greater oblique muscle and the crescentic line of the anterior rectus abdominis muscle. The polylactic acid microgrips provide immediate fixation, making additional fixation with stitches unnecessary, which makes the technique very easy to use and systematize among the different surgeons of the transplant team. The procedure is completed with the placement of a low caliber round Jackson-Pratt subcutaneous drain (10F) connected to a vacuum system that will be removed on post-transplant day 2 or 3
89007663|NCT03272698|Active Comparator|Ketamine-ECT (EAST)|Patients in the EAST arm will initially receive intravenous ketamine 0.75 mg/kg, remifentanil 1 mcg/kg (to reduce discomfort), and succinylcholine 0.75 mg/kg (for safety). Based on patients' anaesthetic response, the attending anaesthesiologist is given the freedom to vary the dose of remifentanil and succinylcholine as well as administer propofol to achieve safe and acceptable anaesthetic conditions. As per the Saskatoon Health Region's care standard, patients in the EAST arm will receive eight ECT sessions (on a bi/triweekly schedule) delivered by the attending psychiatrist with either unilateral or bilateral electrode placement and monitoring of seizure threshold by the half-age method.
89007664|NCT03235492|Experimental|SmartAlbu|If a participant agrees, after obtaining informed consent, the investigator will measure and record temperature, blood pressure, heart rate, height and weight. The participant will be given detailed instruction on how to hold the container and will be asked to spit (or deposit) their saliva up to the indicated line. The procedure will be performed twice to study the reproducibility of the test. The participant will then be asked to have a standard blood draw of 2-3 mls of blood into a vacutainer tube for analysis of HbA1c at the central lab and 1-2 mls of blood for glycated albumin for assay analysis, and a finger stick for point of care HbA1c measurement.
89007665|NCT03231657|Experimental|Incorporation of the sFlt1/P1GF ratio|"Incorporation of the ratio in the diagnosis and classification of pre-eclampsia:~sFlt1/PlGF ratio >38: pre-eclampsia risk~sFlt1/PlGF ratio >85: pre-eclampsia~ISSHP pre-eclampsia definition + ratio >210: severe PE~ISSHP pre-eclampsia definition + ratio sFlt1/PlGF ratio >600: consider deliver"
89007666|NCT03231657|No Intervention|Routine clinical practice|Criteria for the definition of PE were those of the International Society for the Study of Hypertension in Pregnancy
89007667|NCT03225482|Experimental|ME-CCT|8-week Motivationally Enhanced Compensatory Cognitive Training group
89007668|NCT03225482|Active Comparator|SC|8-week Goal-focused Supportive Contact group
89007669|NCT03213457|Placebo Comparator|Placebo|Placebo for elagolix administered twice daily (BID) plus placebo for estradiol/norethindrone acetate (E2/NETA) administered once daily (QD) for the 12-month placebo-controlled Treatment Period, followed by elagolix 200 mg BID plus E2/NETA 1 mg/0.5 mg QD for the remaining 36 months of the Treatment Period.
89007670|NCT03213457|Experimental|Elagolix / Elagolix + E2/NETA|Elagolix 200 mg BID alone for the first 6 months of the 12-month placebo-controlled Treatment Period and elagolix 200 mg BID+E2/NETA 1 mg/0.5 mg QD for the second 6 months, followed by elagolix 200 mg BID+E2/NETA 1 mg/0.5 mg QD for the remaining 36 months of the Treatment Period.
89007671|NCT03213457|Experimental|Elagolix + E2/NETA|Elagolix 200 mg BID + E2/NETA 1 mg/0.5 mg QD for the 12-month placebo-controlled Treatment Period, followed by elagolix 200 mg BID plus E2/NETA 1 mg/0.5 mg QD for the remaining 36 months of the Treatment Period.
89007672|NCT03207503||MDD patients|Participants ages 35-75 determined to be clinically depressed via structured clinical interview. No interventions will be administered as part of this study.
89196396|NCT04437238|Placebo Comparator|Control|Participants allocated to the control condition will receive care as usual but will be asked to complete the health risk questionnaire at baseline, 3- and 6-month follow-up via an online survey to collect outcomes data. The control group will receive full access to KeepWell at the conclusion of the study.
89007673|NCT03207503||non-MDD patients|Participants ages 35-75 determined to be lifetime free of psychiatric conditions as assessed by structured clinical interview. No interventions will be administered as part of this study.
89007674|NCT03198078|Experimental|Brexpiprazole|Participants were administered with brexpiprazole oral tablets, daily, dose titrated up to 0.5 mg by Day 4, 1 mg by Day 7, 2 mg by Day 14, then between 2-4 mg after Day 21 up to Week 6 with a 1 mg increase or decrease, based on the Investigator's decision.
89007675|NCT03198078|Active Comparator|Aripiprazole|Participants were administered with aripiprazole oral tablets, daily, dose titrated up to 2 mg by Day 4, 5 mg by Day 7, 10 mg by Day 14, then 10, 15 or 20 mg after Day 21 up to Week 6 with a 5 mg increase or decrease, based on the Investigator's decision.
89007676|NCT03198078|Placebo Comparator|Placebo|Participants were administered with brexpiprazole or aripiprazole matching placebo oral tablets, daily up to Week 6.
89007677|NCT03190057||Consecutive percutaneous coronary intervention|
89007678|NCT03181984|Experimental|Hemoporfin|
89196397|NCT01045837|Active Comparator|Prednisolone and Gluten free diet|Gluten free diet and prednisolone in the dose of 1 mg/kg/d over a period of 4 weeks.
89196398|NCT01045837|Placebo Comparator|Gluten free diet|Gluten free alone will be given in this group
88907288|NCT06309628||Lung Transplant patients at risk for rejection|Patients who have had a lung transplant and are getting a bronchoscopy to test for rejection will provide a breathe sample. Once their rejection results come back after their sample has been collected their breathe samples will be sorted into rejection and non-rejection groups for analysis. All patients will have the same experiences in the study.
88907289|NCT06309615||Standard of Care|Patients with a diagnosis of early-stage invasive breast cancer, post-surgery, in the process of developing a treatment plan. After a period of 2-4 weeks, patient and provider will receive the PreciseDx breast test results with follow up questionnaires to assess change in care path.
88907290|NCT06309615||Standard of Care plus PreciseDx Breast test|Patients with a diagnosis of early-stage invasive breast cancer, post-surgery, in the process of developing a treatment plan. In addition to standard of care the patient and their provider will also receive the results from the PreciseDx breast test. Questionnaires will be utilized to assess impact on decision making and planned care path.
88907291|NCT06309602|Other|Control / Standard Care|Standard care provided for patients with orders for thickened liquids.
88907292|NCT06309602|Experimental|Free Water Protocol|Standard care provided for patients with orders for thickened liquids. Additionally, participant will be allowed to have plain, un-thickened water after the following have taken place: 1) Wait 30 minutes after meal or medication administration; 2) Complete oral care according to instructions posted at bedside.
88907293|NCT06309589|Experimental|experimental group|experimental group received UDCA(Losan Pharma GmbH, registration number H20181059, 13-15 mg/day/kg) combined with Vitamin D3 (1200 IU per day) treatment for 1year
88907294|NCT06309589|No Intervention|control group|control group received UDCA(Losan Pharma GmbH, registration number H20181059, 13-15 mg/day/kg) treatment for 1 year
88907295|NCT06309576|Experimental|Fasting-refeeding cycle|Participants will be maintained in metabolic chambers and exposed to 1 day of energy balance, 2 days of fasting, and 2 days of ad-libitum refeeding.
88907296|NCT06309537||HFpEF|symptomatic patients with heart failure with preserved ejection fraction
88907297|NCT06309537||asymptomatic PH-LHD|asymptomatic left ventricular diastolic dysfunction with echocardiographic signs of pulmonary hypertension
88907298|NCT06309537||healthy volonteers|
88907299|NCT06309485|Experimental|Arm A|WGI-0301 at MTD / RP2D dose with standard dose Sorafenib
88907300|NCT06309485|Experimental|Arm B|WGI-0301 at MTD / RP2D -1 dose with standard dose Sorafenib
88907301|NCT06309485|Active Comparator|Arm C|Standard dose Sorafenib alone
88907302|NCT06309472|Experimental|Mirtazapine|Mirtazapine 30-45mg at night for 12 weeks
88907303|NCT06309472|Placebo Comparator|Placebo|Matched placebo 1-2 capsules at night for 12 weeks
88907304|NCT06309459||Low Staining|CA IX is a transmembrane protein, it exhibits cytoplasmic membrane staining. Immunohistochemically positive cells were graded as Low staining if they constituted <10% of the total.
89196399|NCT00932854|Experimental|EBUS|All patients in the trial will undergo EBUS for the diagnosis of isolated mediastinal lymphadenopathy. If this investigation is negative then the patient will be referred for mediastinoscopy.
88907305|NCT06309459||High Staining|CA IX is a transmembrane protein, it exhibits cytoplasmic membrane staining. Immunohistochemically positive cells were graded as high staining if they constituted ≥ 10%
88907306|NCT06309446|Experimental|Zoralan Wound|"At the beginning of the study, two small, superficial, abrasive wounds (approximately 1.2 cm in diameter) were induced on one volar forearm of each subject with a minimum distance of 5 cm between the wounds, using a sterile surgical hand brush.~One wound is treated with the medical device by a study nurse and covered with standard semi-occlusive wound plaster (Hansaplast Sensitive wound plaster. Topical application of appoximately 0.2g per test field (approx. 1.2cm in diameter each) once daily during a 12-day treatment period (11 treatments)."
89196400|NCT00929422||spinal cord injury 1|
89196401|NCT00929422||spinal cord injury 2|
89196402|NCT00929422||spinal cord injury 3|
89196403|NCT00929422||normal control|
89196404|NCT00932932||PWS not receiving Growth Hormone|
89426503|NCT04794582|No Intervention|Monomax® USP 0 2 planes closure|The control group will proceed according to standard clinical practice with closure using the technique in 2 muscle-aponeurotic planes with very long-term (3 months) absorbable synthetic continuous suture of poly(4-hydroxybutyrate), monofilament, elastic (Monomax® USP 0) according to the small-bites technique. In order to achieve masking of the participating subject, a small-bore (10F) Jackson-Pratt drain connected to a vacuum system will be placed in the subcutaneous space at the end of the procedure in a manner similar to the intervention group. In both treatment groups, the subcutaneous drain will be removed on post-transplant day 2 or 3.
89426504|NCT04789018||Observational (survey, virtual genetic board, interview)|Participants complete a survey about genetic knowledge and self efficacy and then attend virtual genetics board. After virtual genetics board meeting, participants complete a second survey about perceived usefulness, ease of use, acceptability, feasibility, self-efficacy and genetic knowledge. Participants may also complete a semi-structured interview after virtual genetics board.
89426505|NCT04770948|Experimental|19G|19 gauge EBUS-TBNA needle
89426506|NCT04770948|Active Comparator|22G|22 gauge EBUS-TBNA needle
89426507|NCT04765345||Vision Cohort 1|"~25 participants with the better eye Screening Visit visual acuity ETDRS letter score of 54 or more [approximate Snellen equivalent 20/80 or better] and visual field diameter 10 degrees or more in every meridian of the central field.~The better eye is defined as the eye with better Screening Visit ETDRS VA. If both eyes have the same VA (defined as the same Snellen equivalent), then the determination will be made at investigator discretion as the eye with better fixation or clearer ocular media to permit highest quality retinal imaging.~The visual field (VF) is defined as the clinically determined kinetic VF III4e performed within the last 18 months prior to or including the Screening Visit date."
88907307|NCT06309446|No Intervention|No treatment|"At the beginning of the study, two small, superficial, abrasive wounds (approximately 1.2 cm in diameter) were induced on one volar forearm of each subject with a minimum distance of 5 cm between the wounds, using a sterile surgical hand brush.~One wound is not treated but covered with standard semi-occlusive wound plaster (Hansaplast Sensitive wound plaster. Covering happens once daily during a 12-day treatment period (11 treatments)."
89196405|NCT00932932||Control subjects healthy or obese|
89426508|NCT04765345||Vision Cohort 2|"~15 participants with the better eye Screening Visit visual acuity ETDRS letter score of 19-53 [approximate Snellen equivalent 20/100 - 20/400] or (visual acuity ETDRS letter score of 54 or more [approximate Snellen equivalent 20/80 or better] and visual field diameter less than 10 degrees in any meridian of the central field).~The better eye is defined as the eye with better Screening Visit ETDRS VA. If both eyes have the same VA (defined as the same Snellen equivalent), then the determination will be made at investigator discretion as the eye with better fixation or clearer ocular media to permit highest quality retinal imaging.~The visual field (VF) is defined as the clinically determined kinetic VF III4e performed within the last 18 months prior to or including the Screening Visit date."
88907308|NCT06309433|Active Comparator|PS TKA|Patients with Posterior stabilized Total knee replacement
88907309|NCT06309433|Active Comparator|CR TKA|Patients with cruciate retaining Total knee replacement
88907310|NCT06309420|Experimental|Pixie CO2|Cryogenic treatment of warts (Carbonic ice tablet) Maximum 3 application by the technician in charge of the study Apply 15 seconds for a wart on hand or arm and 40 seconds for a wart on feet or toe
89426509|NCT04764721|Experimental|Patients enrolled in Neurocog-Covid study in Nancy hospital|Young patients (< 65 year old) who contracted VIDOC 19 and were hospitalized for less than 7 days during the first wave, and who present cognitive disorders may be definitively included in the Neurocog-Covid study if their neuropsychological assessment is abnormal. They will then have a prescription for a cerebral MRI and will be enrolled in the TEP-Covid study. If they accept, they will receive a 18F-FDG PET-CT .
89426510|NCT04760522|Experimental|WGS Diagnostic|"Both underage and adult persons (male and female) with diagnostically unsolved rare diseases who have been or are included into diagnostic care at the University Hospital Tübingen, Germany (UKT) and who are suspected of having a genetic cause of the disease.~Study related procedures: Blood sampling, anamnesis including pedigree, Next Generation Sequencing (NGS) analysis and other omics analysis (transcriptomics, proteomics, metabolomics)."
89426511|NCT04757987||Pain-free|Report persistent pain at enrolment
89426512|NCT04757987||Persistent pain|Report no pain at enrolment
89426513|NCT04757753|Experimental|ready-to-use root canal sealer: PA1704|PA1704 is used in combination with gutta percha points for the permanent obturation of root canals.
89426514|NCT04757753|Other|root canal sealer: BioRoot™ RCS|BioRoot™ RCS is used in combination with gutta percha points for the permanent obturation of root canals.
89426515|NCT04754282|Active Comparator|Traditional sitting position|Expecting women are positioned in a traditional sitting position for epidural analgesia catheter placement during labour.
89426516|NCT04754282|Experimental|Cross-legged sitting position|Expecting women are positioned in a crosse-legged sitting position for epidural analgesia catheter placement during labour.
89426517|NCT04752696|Experimental|Safety Lead-in: Onvansertib + nal-IRI + leucovorin + 5-FU|The first 3 participants will be administered onvansertib orally once a day at a dosing schedule of 12 mg/m^2 on Day 1 to Day 10 for two cycles, where each cycle is 2 weeks. Depending on the number of dose limiting toxicities (DLTs) experienced in the first 3 participants, additional participants may receive different dosing schedules, determining the dosing schedule to be used in the treatment period. Onvansertib will be administered in combination with 70 mg/m^2 nanoliposomal irinotecan (nal-IRI), 400 mg/m^2 leucovorin and 2400 mg/m^2 fluorouracil (5-FU).
89426518|NCT04752696|Experimental|Treatment Period: Onvansertib + nal-IRI + leucovorin + 5-FU|Participants will be administered onvansertib at the dosing schedule selected based on the results of the safety lead-in, in cycles of 2 weeks. Onvansertib will be administered in combination with 70 mg/m^2 nanoliposomal irinotecan (nal-IRI), 400 mg/m^2 leucovorin and 2400 mg/m^2 fluorouracil (5-FU).
89426519|NCT04749862||Breast Cancer Participants-Before Phase|Breast cancer patients (16 years old or over) who have completed active treatment will complete a series of patient reported outcomes at baseline, 3, 6 and 12 months time.
89196406|NCT00932932||PWS subjects starting Growth Hormone|
89196407|NCT00907816||intervention|PCPs at MGH who receive display of utilization and quality during computer order entry
88907311|NCT06309420|Active Comparator|Wortie®|Cryogenic treatment of wart (dimethylether-based product) Maximum 3 application by the technician in charge of the study. Apply 20 seconds for a wart on hand or arm and 40 seconds for a wart on feet or toe
88907312|NCT06309407|Experimental|Chest and Hand Dosimeters|Subjects will wear both chest and hand dosimeters during all radiation procedures performed at the Comprehensive Pain Center during the study period.
88907313|NCT06309407|Active Comparator|Chest Dosimeter|Subjects will wear only a chest dosimeter during all radiation procedures performed at the Comprehensive Pain Center during the study period.
88907314|NCT06309394|Experimental|INCB099280|Participants will be administered INCB099280 tablet orally, followed approximately 10 minutes later by an oral dose solution of radiolabeled INCB099280.
89196408|NCT00907816||control|
89196409|NCT00567268||Gabapentin|Patients taking Gabapentin
89196410|NCT00907894|Experimental|Stratum 1|
89426520|NCT04749862||Colorectal (bowel) Cancer Participants-Before Phase|Colorectal cancer patients (16 years old or over) who have completed active treatment will complete a series of patient reported outcomes at baseline, 3, 6 and 12 months time.
89426521|NCT04749862||Breast Cancer Participants-After Phase|Breast cancer patients (16 years old or over) who have completed active treatment will complete a series of patient reported outcomes at baseline, 3, 6 and 12 months time. In addition they will also complete an online symptom report from home with self-management advice (frequency of completion to be determined in phase 2)
89426522|NCT04749862||Colorectal (bowel) Cancer Participants-After Phase|Colorectal cancer patients (16 years old or over) who have completed active treatment will complete a series of patient reported outcomes at baseline, 3, 6 and 12 months time. In addition they will also complete an online symptom report from home with self-management advice (frequency of completion to be determined in phase 2)
88820380|NCT06188260|Experimental|Dry eye participants|Participants aged 20 years or above, with OSDI score between 12-32, and with either of the following positive signs: 1) corneal staining; 2) NITBUT<10s; 3) osmolarity >=308, or difference >8
88820381|NCT06188026|Experimental|Sequence 1|All participants will be exposed to both interventions in a defined sequence. OC 8 days, NNC0194-0499 4 weeks, OC/NNC0194-0499 combined 1 week.
88820382|NCT06187402|Experimental|LM-24C5 Dose Escalation|
88820383|NCT06187402|Experimental|LM-24C5 Dose Expansion|
88820384|NCT06187311|Experimental|Rivaroxaban 15mg|Subjects eligible for this clinical trial will be randomly assigned to Group 1 (15 mg of rivaroxaban) or Group 2 (20 mg of rivaroxaban) at baseline visits in a 1:1 ratio.
88820385|NCT06187311|Experimental|Rivaroxaban 20mg|Subjects eligible for this clinical trial will be randomly assigned to Group 1 (15 mg of rivaroxaban) or Group 2 (20 mg of rivaroxaban) at baseline visits in a 1:1 ratio.
88820386|NCT06187155|Experimental|INR-self management|"The participants will be responsible to monitor their INR regularly and adjust the warfarin dose by themselves accordingly, without seeking medical advice from medical personnel for 6 months.~All participants will receive full education class of minimum one-hour time and training about how to interpret INR levels and adjust their medication dose according to a pre-determined dose-INR schedule."
88820387|NCT06187155|No Intervention|Standard of care|Regular INR monitoring and seeking medical advice at Aswan Heart Centre
88820388|NCT06187038|Active Comparator|Therapeutic exercise group|The therapeutic exercise program will include warm-up, resistance, neuromuscular, mobility, and balance exercises. Over ten weeks, two sessions of the therapeutic exercise program will be carried out individually, lasting approximately 60 minutes each-a total of 20 therapeutic exercise sessions. Therapeutic exercise sessions will be carried out at least 24 hours between sessions. The therapeutic exercises will be performed in up to three sets of 8-12 repetitions or 30-60 seconds each, with rest intervals of 90 seconds between sets.
88820389|NCT06187038|Experimental|Therapeutic exercise group and pain neuroscience education program|The therapeutic exercise program will include warm-up, resistance, neuromuscular, mobility, and balance exercises. Over ten weeks, two sessions of the therapeutic exercise program will be carried out individually, lasting approximately 60 minutes each-a total of 20 therapeutic exercise sessions. Therapeutic exercise sessions will be carried out at least 24 hours between sessions. The therapeutic exercises will be performed in up to three sets of 8-12 repetitions or 30-60 seconds each, with rest intervals of 90 seconds between sets. The chronic pain neuroscience education program will be based on three domains. Making sense of pain, exposure with control, and lifestyle changes.
88820390|NCT06186765|Other|Single Arm - product does not have Communauté Européenne (CE) Mark in Europe|Observational
89426523|NCT04744298|Experimental|TheraPPP Pathway|"The investigators will perform an effectiveness-implementation hybrid study design (type 1) to evaluate the effectiveness and implementation of the TheraPPP pathway.~All mechanically ventilated patients admitted to the ICU will enter the pathway. To evaluate effectiveness the investigators will collect patient data for approximately 29 months. To assess acceptability of the pathway the investigators will conduct a survey and focus groups to clinicians who used the Pathway."
89426524|NCT04742257|Experimental|Active Stimulation|Five consecutive days of 20 minutes active stimulation with MyoRegulator® device
89426525|NCT04742257|Sham Comparator|Sham Stimulation|Five consecutive days of 20 minutes sham stimulation with MyoRegulator® device
89426526|NCT04739371|Experimental|Insulin|40 participants will receive 40 IUs of intranasal insulin about 30 minutes before consuming an ad libitum lunch.
88907315|NCT06309342|Experimental|PREVFUNKTION|Medical examination. Functional examination. Measurement of physical activity. Questionnaires on health, function and lifestyle. Feedback and advice based on medical examination. Feedback and advice based on functional examination. Functional profile. Support in setting goals for lifestyle changes.
88907316|NCT06309342|Active Comparator|Control|Medical examination. Functional examination. Measurement of physical activity. Questionnaires on health, function and lifestyle. Feedback and advice based on medical examination.
88907317|NCT06309329|Experimental|Strength at Home Parents|
88907318|NCT06309329|Active Comparator|VA treatment as usual|
88907319|NCT06309303||KD with SARS-COV-2|Subjects with Kawasaki Disease and presence of concomitant SARS-COV-2 infection
88907320|NCT06309303||KD without SARS-COV-2|Subjects with Kawasaki Disease and absence of concomitant SARS-COV-2 infection
88907321|NCT06309277|Experimental|Active|GM-1020 (oral)
88907322|NCT06309277|Placebo Comparator|Placebo|Placebo (oral)
88907323|NCT06309264|Experimental|Speech-based hearing aid fitting|Half of the study participants receive a hearing aid with gain settings determined via speech-based audiometry. Other hearing aid features such as noise reduction and directional microphones are disabled. Of this group of subjects, half are assigned to use the hearing aid daily for six weeks, while the remainder are followed for the same six-week period but use their hearing aids only to complete outcomes testing.
88907324|NCT06309264|Active Comparator|Audiogram-based hearing aid fitting|Half of the study participants receive a hearing aid with gain settings determined by applying the NAL-NL2 prescriptive formula to the pure-tone audiogram. Other hearing aid features such as noise reduction and directional microphones are disabled. Of this group of subjects, half are assigned to use the hearing aid daily for six weeks, while the remainder are followed for the same six-week period but use their hearing aids only to complete outcomes testing.
88907325|NCT06309251||Patients requiring KD|Pediatric patients with any disease which require a ketogenic diet (KD), i.e. metabolic or genetic disorder or neurological (congenital and acquired) diseases
88907326|NCT06309238|Experimental|Intensive weight loss intervention|The intensive weight loss intervention (IWL) includes total dietary replacements, behavioural support, and weight loss medication. The intervention consists of three phases: induction, weight loss continuation, maintenance, and it will lasts two years in total.
88907327|NCT06309238|Active Comparator|Bariatric surgery|Bariatric surgery: Roux-en-Y Gastric Bypass (RYGB) or Sleeve Gastrectomy (SG)
88907328|NCT06309225|Experimental|Experimental|"Cisplatin: 30-40 mg/m2/week, every week during radiation. Dose should be based on actual body weight. The first cisplatin infusion should be started within 24 hours before or after the first scheduled radiation treatment.~Intensity Modulated Radiation Therapy (IMRT) and Image-Guided Radiation Therapy (IGRT) are mandatory for this study.~55 Gy radiation in 5 weeks using 5 fractions per week + Cisplatin every week"
88907329|NCT06309212||Pre-COVID period|January 2016 to January 2020
88907330|NCT06309212||Post-COVID period|January 2021 to September 2023
88907331|NCT06309199|Experimental|Probiotics|Limosilactobacillus reuteri DSM 17938 with sunflower oil and MCT oil were packed into a container. Infants will received 5 drops per day in the morning for 60 +/- 20 days
89196411|NCT00907894|Experimental|Stratum 2|
89196412|NCT00907894|Experimental|Stratum 3|
89426527|NCT04739371|Placebo Comparator|Placebo|40 participants will receive 40 IUs of intranasal saline about 30 minutes before consuming an ad libitum lunch.
89426528|NCT04734392||Cohort A|Historical cohort 2019 + 2020
89426529|NCT04734392||Cohort B|Prospective study cohort 2020 + 2021 (TAVR implantation according new IFU)
89426530|NCT04732507|Active Comparator|One to two needle passes|Receive 1-2 needle passes for needling at each trigger point
89426531|NCT04732507|Active Comparator|Ten needle passes|Receive 10 needle passes for needling at each trigger point
89426532|NCT04732507|Active Comparator|Twenty needle passes|Receive 20 needle passes for needling at each trigger point
89426533|NCT04731857||Genetic diseases|For the retrospective data analysis, patients with genetic diseases of any age and, if available, other family members, for whom genetic analyzes were carried out between 10/2016 and 12/2020, should be included. This equates to approximately 13,000 records, minus combined analyzes in the same patient, an estimated 12,000 individuals.
89007679|NCT03165994|Experimental|APX005M with chemoradiation|"APX005M: 0.3mg/kg dose intravenously over 1 hour, every 3 weeks x 3 doses (weeks 1, 4, and 7). Treatment begins 2 weeks prior to concurrent chemoradiation (chemoRT); continues during weeks 2 and 5 of chemoRT.~Daily radiation therapy (RT): 28 fractions (28 days)~Chemotherapy: Carboplatin and paclitaxel will be given intravenously over 1 hour, once weekly, for 5 weeks (days 1, 8, 15 22, and 29 of RT). Carboplatin dose will be area under curve (AUC) 2. Paclitaxel dose will be 50mg/m2.~Surgical resection of tumor: between weeks 10-16"
89007680|NCT03131817|Experimental|PD with mood disorder or impulsivity|This is a single-center study of the neurophysiology of non-motor symptoms such as anxiety, depression, and impulsivity that are comorbid in Parkinson's Disease.
89007681|NCT03108014||Breast milk fed|Fed primarily breast fed as an infant
89007682|NCT03108014||Milk based formula fed|Fed primarily milk based formula as an infant
89007683|NCT03108014||Soy based formula fed|Fed primarily soy based formula as an infant
89007684|NCT03108001||Lean mothers|Participants that were in Glowing born from Lean mothers.
89426534|NCT04726319|Experimental|Intervention|In addition to usual care, patients will be asked to answer questions about any family history through the use of a questionnaire.
89426535|NCT04726319|No Intervention|Usual Care|Patients receive usual care, which consists of health care providers inquiring about and dealing with family history as they would in usual practice.
89426536|NCT04725812|Experimental|Eculizumab|Twelve subjects in the interventional arm will receive eculizumab at an induction dose of 900mg IV weekly (q7 days) for 4 weeks followed by a dose of 1200mg IV at week 5. Thereafter, patients will receive a maintenance dose of 1200mg IV every two weeks (q14 days). The last dose of eculizumab will be given up to 48 hours post-partum, with a dose that is dependent on the dosing schedule (i.e. whether the last dose is given within the 4-week induction period or is during the maintenance phase).
89426537|NCT04717765|Experimental|Preventive in oral mucositis caused by chemo or radiotherapy - LLL Phototherapy|"Application of LLL phototherapy from the first day until the last day, on all days that the chemo or radiotherapy treatment is administered. If the patient still shows evidence of mucositis at the end of the treatment, additional applications can be performed.~Application: in wavelength 660 nm (red), there will be 78 intra oral points, with a time of 10 seconds per point, at a power of 100 mw, totaling a power of 1J per point."
89426538|NCT04717765|Active Comparator|Preventive in oral mucositis caused by chemo or radiotherapy - Vit E|"Topical Vit. E spray, from the first day to the last day, every day that the chemo or radiotherapy treatment is administered.~Application: on the first day the professional will demonstrate the application on intra-oral mucous points. On the other days the patient will do self application, twice a day."
89426539|NCT04717765|No Intervention|Preventive in oral mucositis caused by chemo or radiotherapy - mouthwash|Oral hygiene control and mouthwash with chlorhexidine 0.12%, from the first to the last day of administration of the chemo or radiotherapy treatment. On the first day the professional will demonstrate the care. On the other days the care will be taken by the patient himself, for at least three times a day.
89426540|NCT04717765|Experimental|Curative in oral mucositis caused by chemo or radiotherapy - LLL Phototherapy|"Application of LLL phototherapy from the tenth day until the last day, on all days that the chemo or radiotherapy treatment is administered. If the patient still shows evidence of mucositis at the end of the treatment, additional applications can be performed.~Application: in wavelength 660 nm (red), there will be 78 intra oral points, with a time of 10 seconds per point, at a power of 100 mw, totaling a power of 1J per point."
89007685|NCT03108001||Overweight mothers|Participants that were in Glowing born from Overweight mothers.
89007686|NCT03108001||Obese mothers|Participants that were in Glowing born from Obese mothers.
89007687|NCT03108001||Exercise group mothers|Participants that were in Expecting born from mothers that were in the exercise group.
89007688|NCT03108001||Non Exercise group mothers|Participants that were in Expecting born from mothers that were in the non- exercise group.
89007689|NCT03105713|Experimental|Patient Safety Checklist Intervention|The intervention to be administered is a patient safety checklist (two parts) for patients to be performed on paper or electronically: a) before admission to hospital, and b) under hospital stay (discharge)
89426541|NCT04717765|Active Comparator|Curative in oral mucositis caused by chemo or radiotherapy - mucositis Vit E|"Topical Vit. E spray, application from the tenth day, and until the last day, every day that the chemo or radiotherapy treatment is administered.~Application: on the first day the professional will demonstrate the application on intra-oral mucous points. On the other days the patient will do self application, twice a day."
89426542|NCT04717765|No Intervention|Curative in oral mucositis caused by chemo or radiotherapy- mouthwash|Oral hygiene control and mouthwash with chlorhexidine 0.12%, from the tenth to the last day of administration of the chemo or radiotherapy treatment. On the first day the professional will demonstrate the care. On the other days the care will be taken by the patient himself, for at least three times a day.
89426543|NCT04717765|Experimental|Preventive osteonecrosis resulting from chemo or radiotherapy - LLL Phototherapy + extraction|"For patients who need dental extraction for the adequacy of the oral cavity. Application of LLL phototherapy on the day the dental extraction is performed and every 72hr, totaling 5 applications. It must be done at least 3 months before the beginning of the chemo or radiotherapy treatment.~Application: in wavelength 660 nm (red), alveolar ridge, 1 point per cm², with a time of 10 seconds per point, at a power of 100 mw, totaling a power of 1J per point. In wavelength 808 nm (infrared), buccal and lingual/palatal board 2 points in the length of the root, with a time of 20 seconds per point, at a power of 100 mw, totaling a power of 2J per point."
89426544|NCT04717765|Active Comparator|Preventive osteonecrosis resulting from chemo or radiotherapy - LPRF+ extraction|"For patients who need dental extraction for the adequacy of the oral cavity. LPRF placement on the day the tooth extraction is performed. The procedure must be performed at least 3 months before the start of chemo or radiotherapy treatment.~After the LPRF has been placed, the suture should be done in a way that facilitates healing for primary intention."
89426545|NCT04717765|No Intervention|Preventive osteonecrosis resulting from chemo or radiotherapy - extraction only|"For patients who need dental extraction for the adequacy of the oral cavity, the procedure must be performed at least 3 months before the start of chemo or radiotherapy treatment.~The suture should be done in a way that facilitates healing for primary intention."
89426546|NCT04717765|Experimental|Curative osteonecrosis resulting from chemo or radiotherapy - LLL Phototherapy + sequestrectomy|"Patients who have been diagnosed with bone necrosis after treatment with chemo or radiotherapy, clinical confirmation and radiography. Bone sequestrectomy, removal of necrotic tissue and application of LLL phototherapy on the day of surgery and every 72hr, totaling 5 applications. The suture should be done in a way to facilitate healing for primary intention.~Application: in wavelength 660 nm (red), alveolar ridge, 1 point per cm², with a time of 10 seconds per point, at a power of 100 mw, totaling a power of 1J per point. In wavelength 808 nm (infrared), buccal and lingual/palatal board 2 points in the length of what would be the dental root, with a time of 20 seconds per point, at a power of 100 mw, totaling a power of 2J per point."
89426547|NCT04717765|Active Comparator|Curative osteonecrosis resulting from chemo or radiotherapy - LPRF + sequestrectomy|"Patients who have been diagnosed with bone necrosis after treatment with chemo or radiotherapy, clinical confirmation and radiography. Bone sequestrectomy, removal of necrotic tissue and placement of the LPRF on the day of surgery will be performed.~After the LPRF is placed, the suture should be done in a way that facilitates healing for primary intention."
89426548|NCT04717765|No Intervention|Curative osteonecrosis resulting from chemo or radiotherapy - sequestrectomy only|"Patients who were diagnosed with bone necrosis after treatment with chemo or radiotherapy, clinical confirmation and radiography. Bone sequestrectomy and removal of necrotic tissue will be performed.~The suture should be done in a way that facilitates healing for primary intention."
89426549|NCT04716231|Experimental|Atacicept Dose 150mg|Atacicept 150mg once weekly subcutaneous (SC) injections
89426550|NCT04716231|Placebo Comparator|Placebo to match Atacicept (Part C/D)|Placebo to match Atacicept once weekly subcutaneous (SC) injection
89426551|NCT04715945||Women|12,583 women recruited when non-pregnant
89426552|NCT04715945||Children|3,158 liveborn singleton offspring of women recruited to the study
89426553|NCT04713969|Experimental|Functional dyspepsia patients before and after PPI|Pantoprazole 40mg twice daily in functional dyspepsia patients for 4 weeks
89426554|NCT04713969|No Intervention|Healthy controls before PPI|Baseline investigations
89426555|NCT04712591||Traumatic Brain Injury Patients|Traumatic brain injury (TBI) patients will be recruited and studied using electroencephalogram (EEG) to monitor their brain response to auditory and visual stimuli.
89426556|NCT04712591||Healthy Volunteers|Healthy volunteers will serve as the control group and will undergo electroencephalogram (EEG) to monitor their brain response to auditory and visual stimuli.
89426557|NCT04710602||Minimally invasive|Patients who underwent surgery with a muscle sparing, minimally invasive technique for unstable chest wall after trauma.
88907332|NCT06309199|Placebo Comparator|Placebo|Sunflower oit and MCT oil were paced into a container. Infants will received 5 drops per day in the morning for 60+/- 20 days
88907333|NCT06309160|No Intervention|Focus Groups to Inform CAST|For the year 1 development activities, the research team will conduct focus groups with administrators, special education teachers, parents, students, and pre-employment transition specialists about how to integrate plans and services across settings.
88907334|NCT06309160|Experimental|Pre-Post study of CAST|The research team will then conduct a field test of CAST in year 2, making further revisions.
88907335|NCT06309160|Active Comparator|Randomized Controlled Study of CAST|In year 3, they will use a mixed methods design using a small RCT and network analysis, oversampling African American students and students from rural areas, to evaluate CAST for improved postsecondary outcomes in employment, training, and education.
88907336|NCT06309134|Experimental|Healthy Families Bright Futures Program|This arm will complete the intervention. Assessments will occur at pre-intervention, post-intervention, and three month follow up.
88820391|NCT06186453|Experimental|Intervention group|Father-Preterm Newborn Bonding Program
88820392|NCT06186453|No Intervention|Control group|Routine nursing care will be applied
89007690|NCT03105713|No Intervention|Controls|Patients do not receive the safety checklist intervention. Care as usual.
89426558|NCT04710602||Historical control|Patients who underwent surgery with large incisions and simultaneous thoracotomy for unstable chest wall after trauma.
89426559|NCT04706429|Active Comparator|Trientine|Trientine dihydrochloride 1200 mg per day. This shall be taken orally as two Cufence 200mg hard capsules two times per day. The IMP will be dispensed to participants every 13 weeks for the duration of the study period (52 weeks).
89196413|NCT03976648|Experimental|GLPG1690 600 mg|Participants who received GLPG1690 600 milligrams (mg) in the GLPG1690-CL-204 (NCT03798366) study received GLPG1690 600 mg orally once daily up to 91 weeks.
89426560|NCT04706429|Placebo Comparator|Placebo|The placebo shall be taken orally as two capsules two times per day. This will be dispensed to participants every 13 weeks for the duration of the study period (52 weeks).
89426561|NCT04704635||Ischemic stroke/TIA|Patients with ischemic stroke or transient ischemic attack
89196414|NCT03976648|Experimental|Placebo|Participants who received placebo matched to GLPG1690 in the GLPG1690-CL-204 (NCT03798366) study received GLPG1690 600 mg orally once daily up to 91 weeks.
89426562|NCT04701021|Experimental|TENDU|Three different doses of the TENDU vaccine are to be investigated: 40, 400 and 960μg.
89426563|NCT04699227|Sham Comparator|Control group not receiving RIC|Those randomised to the control group will have the blood pressure cuff placed on the arm, but it will not be inflated.
89426564|NCT04699227|Experimental|Interventional group receiving RIC|RIC will consist of 3-4 cycles of cuff inflations to 200 mmHg for 5 min with deflation to 0 mmHg for another 5 min, which is automatically administered by the pre-programmed cuff.
89196415|NCT04014556|Active Comparator|Aflibercept plus micropulse laser (group A)|Overall 40 patients were included in the study; they were randomized into either group A (Aflibercept + Micropulse; 20 patients) or group B (Aflibercept monotherapy; 20 patients).
88907337|NCT06309134|No Intervention|Waitlist|Waitlist control. This arm will complete assessments on the same schedule as the experimental condition.
88907338|NCT06309108|Experimental|Education Group|Education group was given training with a training booklet.
89196416|NCT04014556|Active Comparator|Aflibercept monotherapy (group B)|Overall 40 patients were included in the study; they were randomized into either group A (Aflibercept + Micropulse; 20 patients) or group B (Aflibercept monotherapy; 20 patients).
89196417|NCT00929812|Active Comparator|Glucagon hydrochloride|GlucaGen® 1 mg/1 ml intramuscularly
89426565|NCT04697459|Experimental|HD-EX (patient with intradialytic exercise)|will be enrolled in a 16 week intradilatytic exercise program.
89426566|NCT04697459|No Intervention|HD (patients with standard HD)|patients with standard hemodialysis (e.g. without exercise).
89426567|NCT04694807|Experimental|Group-based Cognitive Behavioural Therapy|A group delivered treatment format of CBTgrief (12 sessions).
89426568|NCT04694807|Active Comparator|Individually delivered Cognitive Behavioural Therapy|An individual delivered treatment format of CBTgrief (12 sessions).
89426569|NCT04692259|Experimental|experimental arm|Single arm study. All patient who had an MRI performed before liver resection is included
89426570|NCT04690907|Experimental|Intervention group|Dietary intervention: Written material on healthy diet during pregnancy, 2 virtual dietary counseling sessions given by a dietician. Otherwise basic care and counseling at maternity care clinics.
89426571|NCT04690907|No Intervention|Control group|Written material on healthy diet during pregnancy, otherwise basic care and counseling at maternity care clinics.
89426572|NCT04688515|Experimental|Intervention group|Intervention group refers to mother-child dyads who will be participating in a nutrition program consisting of nutrition education and cooking sessions for 3 months.
89426573|NCT04688515|No Intervention|Comparison group|The comparison group will not receive any intervention but will be provided with the developed educational materials used in the program after the program has been completed.
89007691|NCT03069638|Experimental|Intranasal dexmedetomidine|Dexmedetomidine is given once 4 micrograms per kilogram intranasally. If the sedation is not successful another 2 microgram per kilogram intranasal dose is given. Intravenous dexmedetomidine solution is administrated intranasally with MAD nasal drug delivery device and a syringe.
89007692|NCT03069638|Active Comparator|Nitrous oxide inhalation|Dinitrousoxide (N2O) is given with Livopan administrating device. Livopan consists of 50% oxygen and 50% nitrous oxide. Gas mixture is inhaled 5 minutes before the injection procedure and during the injection procedure.
89007693|NCT02978118||Group A: Renal Cell Carcinoma|Subjects in Group A (patients with locally advanced, high grade or metastatic renal cell carcinoma starting immunotherapy) will have blood collected at baseline, at the time of a standard of care cytoreductive surgery (if applicable), 12 weeks, 24 weeks, 52 weeks and upon disease progression on treatment for analysis of peripheral blood mononuclear cells (PBMCs), circulating tumor cells (CTCs), metabolites, cytokines and angiokines. Urinary and fecal specimens will be collected at baseline, at the time of a standard of care cytoreductive surgery (if applicable), 12 weeks, 24 weeks, 52 weeks and upon disease progression. Tissue will be collected at the time of a standard of care cytoreductive surgery (if applicable).
89007694|NCT02978118||Group B: Urothelial Carcinoma|Subjects in Group B (patients with locally advanced, high grade or metastatic urothelial carcinoma starting immunotherapy) will have blood collected at baseline, at the time of a standard of care cytoreductive surgery (if applicable), 12 weeks, 24 weeks, 52 weeks and upon disease progression on treatment for analysis of peripheral blood mononuclear cells (PBMCs), circulating tumor cells (CTCs), metabolites, cytokines and angiokines. Urinary and fecal specimens will be collected at baseline, at the time of a standard of care cytoreductive surgery (if applicable), 12 weeks, 24 weeks, 52 weeks and upon disease progression. Tissue will be collected at the time of a standard of care cytoreductive surgery (if applicable).
89007695|NCT02973594|Active Comparator|Ivabradine|Patients will receive ivabradine 2.5-7.5 mg PO bid in addition to baseline maximum-tolerated beta-blocker therapy.
89007696|NCT02973594|Placebo Comparator|Placebo|Patients will receive placebo bid in addition to baseline maximum-tolerated beta-blocker therapy.
89007697|NCT02938442|Active Comparator|Control Arm|Subjects randomized to the control arm will receive SoC neoadjuvant chemotherapy starting on week 1. Doxorubicin and cyclophosphamide (AC) will be administered concurrently every two weeks for four cycles with pegfilgrastim (or equivalent growth factor) on day 2 of each AC cycle, followed by paclitaxel weekly x 12 weeks.
89196418|NCT00929812|Placebo Comparator|Placebo|1 ml NaCl 0.9%
89196419|NCT00933322|Active Comparator|ruminant TFA|In addition to the basic diet, volunteers enrich their diet with an individually calculated amount of butter containing ruminant TFA and with 15-20g rape oil for balancing the essential fatty acids.
89426574|NCT04688385|Experimental|Multipeptide Vaccine + XS 15|a personalizied multi-peptide vaccine in combination with the TLR1/2 ligand XS15 in CLL patients undergoing ibrutinib-based regimes
89426575|NCT04684459|Experimental|CAR-T cell therapy|Dual-targeting HER2 and PD-L1 CAR-T cell therapy
89426576|NCT04673760|Experimental|Arm 1: Structured specialized palliative home care|Eligible specialist palliative home care teams provide ambulant specialised palliative care as usual
89426577|NCT04673760|No Intervention|Arm 2: No care of specialist palliative home care teams at study inclusion|No care from specialist palliative home care teams at study inclusion
89426578|NCT04666090|Experimental|Carillizumab|"Preoperative neoadjuvant therapy for 2-3 cycles. Radical surgery is performed 4-6 weeks after the last dose. Postoperative radiotherapy is determined according to the clinical situation and pathological stage of the patient.~Carillizumab can be maintained for a maximum of 1 year. During the study, patients were be followed until disease progression, withdrawal of informed consent, loss of follow-up, or death."
89426579|NCT04664478||Subjects with abnormal elastogenesis|Participants with genetic variant in the connective tissue target genes
89426580|NCT04662996|Experimental|1- Chemotherapy|Intervention : one blood sample is done before beginning chemotherapy as a first treatment line for a metastatic castration resistant prostate cancer
89426581|NCT04662996|Experimental|2- Novel Hormonal Agent|Intervention : one blood sample is done before beginning a novel hormonal agent (abiraterone, enzalutamide) as a first treatment line for a metastatic castration resistant prostate cancer
89196420|NCT00933322|Active Comparator|industrial TFA|In addition to the basic diet, volunteers enrich their diet with an individually calculated amount of butter containing TFA from PHVO and with 15-20g rape oil for balancing the essential fatty acids.
89196421|NCT00933322|Placebo Comparator|without TFA|In addition to the basic diet, volunteers enrich their diet with an individually calculated amount of butter without TFA and with 15-20g rape oil for balancing the essential fatty acids.
88907339|NCT06309108|Experimental|Augmented Reality Group|Augmented reality group was given training with a augmented reality with 3DQR application.
89196422|NCT00907972|Experimental|Vitamin D3 supplementation|1000 IU/day of Vitamin D3
89196423|NCT00907972|Placebo Comparator|Placebo|Placebo
89196424|NCT03799744|Experimental|VCN-01 and Durvalumab; concomitant.|Combination VCN-01 (single iv dose) with Durvalumab, Concomitant schedule; Dose Escalation of VCN-01
89196425|NCT03799744|Experimental|VCN-01 and Durvalumab; sequential|Combination VCN-01 (single iv dose) with Durvalumab, Delayed schedule (14 days); Dose Escalation of VCN-01
89196426|NCT00933478||Patients with Patulous Eustachian Tube Dysfunction|
89196427|NCT00933556|Experimental|probiotic|subjects will be given a powder formulation of a probiotic VSL#3 to be taken once a day, at a dose of 6 gms
89426582|NCT04661683|Experimental|Exposure to Combustible Hookah Smoke|Participants will be exposed to combustible hookah smoke. To mitigate the impact of carryover effects, the exposure sessions will be separated by a minimum of 7-days.
89426583|NCT04661683|Experimental|Exposure to Electronic Hookah Aerosol|Participants will be exposed to electronic hookah aerosol. To mitigate the impact of carryover effects, the exposure sessions will be separated by a minimum of 7-days.
89426584|NCT04661683|Experimental|Exposure to Clean Air|Participants will be exposed to Clean Room Air. To mitigate the impact of carryover effects, the exposure sessions will be separated by a minimum of 7-days.
89426585|NCT04659174|Experimental|KarXT|
89426586|NCT04658342||Oral Cancer Patients|
89426587|NCT04651296|Experimental|compassion meditation|10 week, group-based manualized compassion meditation training
88907340|NCT06309108|No Intervention|Control Group|Control group was given training with a hospital routine.
88907341|NCT06309095|Experimental|1 N (Newton) torque, 250 rpm(rotary per minute) speed|The values specified in the endomotor will be used during root canal treatment. 1 N torque, 250 rpm speed
88907342|NCT06309095|Experimental|1 N torque, 350 rpm speed|The values specified in the endomotor will be used during root canal treatment. 1 N torque, 350 rpm speed
88907343|NCT06309095|Experimental|2 N torque, 250 rpm speed|The values specified in the endomotor will be used during root canal treatment. 2 N torque, 250 rpm speed
88907344|NCT06309095|Experimental|2 N torque, 350 rpm speed|The values specified in the endomotor will be used during root canal treatment. 2 N torque, 350 rpm speed
88907345|NCT06309082||Diabetic foot ulcer limb salvage group|The patient was treated without amputation
88907346|NCT06309082||Diabetic foot ulcer without limb salvage group|The treatment option for the patient was amputation
88907347|NCT06309069||Patients with CCE|CCE patients identified between 2015 and 2023
88907348|NCT06309056|Experimental|Interventional Group|
88907349|NCT06309056|No Intervention|Control Group|
88907350|NCT06309043|Experimental|HLX05|
88907351|NCT06309043|Active Comparator|EU-sourced Erbitux|
88907352|NCT06309043|Active Comparator|US-sourced Erbitux|
88907353|NCT06309043|Active Comparator|CN-sourced Erbitux|
88907354|NCT06309030|Experimental|Intervention group|
88907355|NCT06309030|Placebo Comparator|Control group|
88907356|NCT06309017|Experimental|Nutrition specialist|Participants will be assigned to this arm if the subject is determined malnourished. They will be sent to a nutrition specialist for a nutrition focused visit and will be provided standard of care intervention prior surgery.
88907357|NCT06309017|Active Comparator|Standard of Care|Participants that show no signs of malnutrition will be assigned to this arm. The subject will be provided with education and schedule of Ensure® Surgery Immunonutrition shakes for prior to surgery as per standard of care.
88907358|NCT06309004||DGBI individuals|Individuals with clinically meaningful symptom levels of DGBI, and anxiety and/or depression
88907359|NCT06309004||Healthcare professionals|Healthcare professionals (ACT therapists, health psychologists, physicians, nurses, and dietitians working with people with DGBI)
89007698|NCT02938442|Experimental|Chemo+Vaccine Arm|Subjects randomized to the chemo+vaccine arm will be immunized with P10s-PADRE in MONTANIDE™ ISA 51 VG a total of three times. The vaccine will be administered on weeks 1, 2 and 3 prior to chemotherapy. Then, they will start their SoC neoadjuvant chemotherapy on week 4. Doxorubicin and cyclophosphamide (AC) will be administered concurrently every two weeks for four cycles with pegfilgrastim (or equivalent growth factor) on day 2 of each AC cycle, followed by paclitaxel weekly x 12 weeks.
89007699|NCT02924402|Experimental|Non-CLL B Cell Malignancies (Group NHL) Part A|XmAb13676 administered IV up to 8 weeks, if receiving benefit, this can be extended at investigator's discretion
89426588|NCT04651296|Active Comparator|health education|10 week, group-based manualized health education protocol
89426589|NCT04638933||OSA patients|Patients with proven OSA (apnea-hypopnea index ≥20/h, ESS >10, age ≥18 years) and initiation of CPAP treatment
89426590|NCT04628338|Experimental|IFN-γ|100mcg IFN-γ subcutaneously three times per week (Weeks 0-7), once per week (Weeks 8-12) (or per protocol guidance based on tolerability, response, or DLI infusions)
89426591|NCT04626570|Experimental|Cognitive and Behavioural Therapy plus Management as usual|12 sessions of CBT during 18 weeks AND management of obesity with nutritional and dietary treatment as usual
89426592|NCT04626570|No Intervention|Management as usual|management of obesity with nutritional and dietary treatment as usual
89426593|NCT04622020||Adult patients with chronic neck pain (> 3 months) following whiplash injury|Cervical plexus block with local anaesthesia followed by Cervical Plexus block with depot steroids
89426594|NCT04612036||Journey II Bi-Cruciate Stabilized|Subjects who have received a Journey II Total Knee Arthroplasty with both the ACL and PCL resected
89426595|NCT04612036||Journey II Cruciate Retaining|Subjects who have received a Journey II Total Knee Arthroplasty with only the ACL resected (therefore PCL retained)
89426596|NCT04612036||Journey II Bi-Cruciate Retaining|Subjects who have received a Journey II Total Knee Arthroplasty with both the ACL and PCL retained
88907360|NCT06308991|Experimental|Yakson touch|"The Yakson method continued for 15 minutes with steady touch (5 minutes), compassionate caressing (5 minutes), and repetition of steady touch (5 minutes). In the Yakson touch method, the palms of the practitioner and all fingers were kept in close contact so that the infants did not feel pressure.~Steady touch (5 minutes): One hand rested on the chest and abdomen of the preterm infant, while the other hand supported the back and hip of the preterm infant.~Compassionate Caress (5 minutes): In the same hand position, the practitioner repeated caressing and resting for 5 minutes: Caress (1 minute), rest (30 seconds), caress (1 minute), rest (30 seconds), and caress (2 minutes). The practitioner caressed the infants' chest and belly with a 1 cm diameter clockwise circular movement every 10 seconds.~Steady touch (5 minutes): The practitioner followed the steady touch procedure as previously described."
88907361|NCT06308991|Experimental|Gentle Human Touch|While the practitioner placed one hand on the crown of the preterm infant on the eyebrow line with the fingertip touch for 15 minutes, the other hand was placed on the lower abdomen covering the waist and hip of the infant.
88907362|NCT06308991|Other|Routine Care|All infants in the control, Yakson, and GHT groups were applied swaddling as the routine practice of the clinic before and during painful procedures.
88907363|NCT06308978|Experimental|FT819|Participants with moderate to severe active SLE.
88907364|NCT06308952|Placebo Comparator|placebo group|placebo 20mg qd
88907365|NCT06308952|Active Comparator|atorvastatin group|atorvastatin 20mg qd
88907366|NCT06308939|Experimental|Eribulin Combined With Sintilimab|Eribulin: 1.4mg/m^2 day1、8，repeated every 3 week. Sintilimab: 500mg once every three weeks.
88907367|NCT06308926|Experimental|MRG-001 (Low-dose)|MRG-001 will be administered subcutaneously at 0.007 mL/kg. Patients will receive 3 injections per week every other day for a total of 2 weeks or until discharge from the ICU.
88907368|NCT06308926|Experimental|MRG-001 (High-dose)|MRG-001 will be administered subcutaneously at 0.01 mL/kg. Patients will receive 3 injections per week every other day for a total of 2 weeks or until discharge from the ICU.
88907369|NCT06308926|Placebo Comparator|Placebo|Sterile injectable saline will be administered subcutaneously at 0.01 mL/kg. Patients will receive 3 injections per week every other day for a total of 2 weeks or until discharge from the ICU.
88907370|NCT06308887|Active Comparator|Group 1|patients who had perimeniscal 5 % dextrose injection
88907371|NCT06308887|Active Comparator|Group 2|patients who had perimeniscal triamcinolone injection
88907372|NCT06308874|Experimental|Amg dose Group|Amg dose administration group
89426597|NCT04610697|Experimental|Cognitive Remediation|"Participants in the cognitive remediation condition will complete computerised exercises followed by bridging discussions delivered using tele-heath.~More details regarding treatment and control conditions will be provided following study completion to ensure participant blinding."
88907373|NCT06308874|Placebo Comparator|Amg dose Group- Placebo|Amg dose administration group- Placebo
88907374|NCT06308874|Experimental|Bmg dose Group|Bmg dose administration group
88907375|NCT06308874|Placebo Comparator|Bmg dose Group- Placebo|Bmg dose administration group- Placebo
88907376|NCT06308861|Experimental|Single administration Amg dose Group|
88907377|NCT06308861|Experimental|Single administration Bmg dose Group|
88907378|NCT06308861|Experimental|Single administration Cmg dose Group|
88907379|NCT06308861|Experimental|Single administration Dmg dose Group|
88907380|NCT06308861|Experimental|Single administration Emg dose Group|
88907381|NCT06308861|Placebo Comparator|Single administration Amg dose Group-Placebo|
88907382|NCT06308861|Placebo Comparator|Single administration Bmg dose Group-Placebo|
88907383|NCT06308861|Placebo Comparator|Single administration Cmg dose Group-Placebo|
88907384|NCT06308861|Placebo Comparator|Single administration Dmg dose Group-Placebo|
88907385|NCT06308861|Placebo Comparator|Single administration Emg dose Group-Placebo|
88907386|NCT06308861|Experimental|Multiple administration Amg dose group|
88907387|NCT06308861|Experimental|Multiple administration Bmg dose group|
88907388|NCT06308861|Experimental|Multiple administration Cmg dose group|
88907389|NCT06308861|Experimental|Multiple administration Dmg dose group|
88907390|NCT06308861|Experimental|Multiple administration Emg dose group|
88907391|NCT06308861|Placebo Comparator|Multiple administration Amg dose group - Placebo|
88907392|NCT06308861|Placebo Comparator|Multiple administration Bmg dose group - Placebo|
88907393|NCT06308861|Placebo Comparator|Multiple administration Cmg dose group - Placebo|
88907394|NCT06308861|Placebo Comparator|Multiple administration Dmg dose group - Placebo|
88907395|NCT06308861|Placebo Comparator|Multiple administration Emg dose group - Placebo|
89196428|NCT00933556|Placebo Comparator|sugar pill|placebo identical to the active product will be given
88907396|NCT06308848|Experimental|Microbiota Directed Food (MDF)|Each participant will receive 12 weeks of MDF supplement. After finishing the intervention phase, he/she will be followed-up for a 12-month period.
88907397|NCT06308848|Active Comparator|Ready-to-Use Therapeutic Food (RUTF)|Each participant will receive 12 weeks of RUTF supplement. After finishing the intervention phase, he/she will be followed-up for a 12-month period.
88907398|NCT06308822|Experimental|Treatment (erdafitinib)|Patients receive erdafitinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and MRI throughout study. Patients may also undergo blood sample collection and tumor biopsy throughout the trial.
88907399|NCT06308783|Experimental|Diaphragmatic Breathing|Diaphragmatic breathing, also known as deep breathing, is based on breathing slowly and widely, expanding the abdomen and then the ribs on inspiration and emptying as much air as possible on exhalation.
88907400|NCT06308783|Experimental|Global Postural Reeducation|Global Postural Re-education (GPR) is a technique described by Philippe Souchard that is based on the active and sustained stretching of muscle chains by performing specific postures. Breathing plays a fundamental role in the development of exercise, influencing the structures of the body and its functioning.
88907401|NCT06308783|No Intervention|Control Group|No treatment
88907402|NCT06308770|Active Comparator|Standard care|Participants will be provided with access to Versus Arthritis and Lupus UK fatigue booklets.
88907403|NCT06308770|Active Comparator|Standard care and 4 week Fatigue Management Programme (FMP)|Participants will be provided with access to Versus Arthritis and Lupus UK fatigue booklets and be randomised to a 4 week virtual FMP. They will attend live online group weekly sessions for 3 consecutive weeks followed by a review session at week 11.
88907404|NCT06308770|Active Comparator|Standard care and 7 week Fatigue Management Programme (FMP)|Participants will be provided with access to Versus Arthritis and Lupus UK fatigue booklets and be randomised to a 7 week virtual FMP. They will attend live online group weekly sessions for 6 consecutive weeks followed by a review session at week 14.
88907405|NCT06308731|Experimental|Caffeine-Based Energy Drink|12 oz Caffeine-based energy drink providing 200 mg caffeine
88907406|NCT06308731|Placebo Comparator|Placebo|12 oz placebo void of all active ingredients
88907407|NCT06308705|Other|Sera|All sera available in our biobank and originating from the Strong Treat trial will be eligible for the study, based on the availability of the baseline and the 12-month follow up serum of each included case.
88907408|NCT06308692|Other|Biological samples|Residual anonymized samples stored at -80°C at the Tropica Biobank of the DITM and for which diagnostic analysis for germ infection has previously been carried out at the DITM by blood culture and MDR surveillance in routine diagnostic rectal swab will be used.
88907409|NCT06308679|Experimental|Generic Empagliflozin 10 mg tablets|Generic Empagliflozin 10 mg tablets (test drug)
88907410|NCT06308679|Active Comparator|ARDIANCE®|ARDIANCE® (Empagliflozin 10 mg tablets (reference drug))
88907411|NCT06308640|Experimental|Fast Back Rapid Distalizer|Group 1: Consisted of 10 patients, their upper molar will be distalized with bone suppored Fast Back (Fast Back Rapid Distalizer, leone, s.p.a, Italy).
88907412|NCT06308640|Experimental|Modified Leaf Spring Self-Activated Expander|Group 2: Consisted of 10 patients, their upper molar will be distalized with bone supported modified Leaf Spring Self-Activated Expander. (Leaf Self Expander, leone, s.p.a, Italy).
88907413|NCT06308614|Experimental|Estetrol|20 mg estetrol monohydrate
88907414|NCT06308614|Placebo Comparator|Placebo|Matching Placebo
88907415|NCT06308601|Experimental|experimental group|8 sessions of laughter yoga will be applied to the experimental group.
89196429|NCT00929890|Active Comparator|Lifestyle counseling|Patients will receive dietary counseling and a general advice on physical activity
89196430|NCT00929890|Experimental|Exercise training|patients will receive dietary counseling and will be enrolled in supervised exercise training
89196431|NCT04015258|Experimental|Blueberries|Fresh blueberries purchased from local supermarket will be distributed to each participant for 1 week's consumption, 160 grams per day
89196432|NCT04015258|Experimental|Blueberry powder|Freeze-dried blueberry powder will be distributed to each participant for 1 week's consumption, 20 grams per day, equivalent to 160 grams of fresh blueberries
89196433|NCT04015258|Placebo Comparator|Blueberry components capsules|Encapsulated microcrystalline cellulose powder will be blinded as blueberry components capsules to be distributed to each participant for 1 week's consumption
89196434|NCT00933634|Experimental|electrical cardioversion|Patients were sedated with propofol and external cardioversion was performed in anteroposterior position (right sternal body at the third intercostal space-angle of the left scapula). Patients were submitted to a biphasic wave-form sequential shock of 100-150-200 J, if necessary.
89196435|NCT00933634|Active Comparator|propafenone|Propafenone (2 mg/kg bolus) was administered iv to obtain pharmacologic sinus rhythm conversion.
89196436|NCT00933712|Experimental|Dermacyd Silver Floral (Lactic Acid)|Dermacyd Silver Floral (Lactic Acid) sample will be applied like a curative. Physiologic solution and mineral oil will be also used as a control sample.
89196437|NCT00933790|Active Comparator|2EHRZ3/4HR3|Regimen 3. Intermittent - 2EHRZ3/4HR3 (E 1200mg, H 600 mg, R 450/600 mg depending on Weight <60, 600 mg for 60 kg or more, Z 1500 mg given thrice weekly)
89196438|NCT00933790|Experimental|2EHRZ7/4HR7|Regimen 1. Daily - 2EHRZ7/4HR7 (E 800 mg ,H 300 mg, R 450/600 mg depending on Weight <60, 600 mg for 60 kg or more, Z 1500 mg daily)
89196439|NCT00933790|Experimental|2EHRZ7/4HR3|Regimen 2. Part Daily - 2EHRZ7/4HR3 (E 800 mg ,H 300 mg, R 450/600 mg depending on Weight <60, 600 mg for 60 kg or more, Z 1500 mg daily in the intensive phase followed by H-600 mg ,R-450/600 mg in the continuation phase thrice weekly)
89426598|NCT04610697|Active Comparator|Active control|"Participants in the active control condition will also complete computerised exercises followed by bridging discussions delivered using tele-heath.~More details regarding treatment and control conditions will be provided following study completion to ensure participant blinding."
89426599|NCT04609683|Experimental|Hydrostasis group|"50 study subjects scheduled for an EP procedure will have AleriTM sensors on subject's bicep, forearm, or wrist, to start data collection.~Measurements will be made from the subject for a period of approximately 1 hours prior to the EP procedure. . Measurements will continue as patient is moved to the operating room. Once the EP procedure is complete, the subject will be transferred from the operating room to a hospital room, where they will stay overnight. Measurements will be made for 3-5hours post-operation.Detailed analysis will investigate how does AleriTM data correlate with known measures such as saline volume/rate, urine production volume, USG, Blood osmolality and body weight;"
89426600|NCT04607746|Experimental|Capsule|Participants will swallow the capsule for imaging prior to completing colonoscopy. Capsule swallow may be 1 day prior or 3-6 weeks prior to colonoscopy.
89426601|NCT04596670|Experimental|68Ga-ICAM1-1pep PET/CT in cancer patients before radiotherapy|"Cancer patients who have not undergone radiotherapy will be injected with 2.96 MBq/kg body weight of 68Ga-ICAM-1pep in one dose intravenously and then undergo PET/CT scan 1 h later.~Interventions:~Drug: 68Ga-ICAM-1pep Device: PET/CT"
89426602|NCT04596670|Experimental|68Ga-ICAM1-1pep PET/CT in cancer patients after radiotherapy|"Cancer patients post-radiotherapy will be injected with 2.96 MBq/kg body weight of 68Ga-ICAM-1pep in one dose intravenously and then undergo PET/CT scan 1 h later.~Interventions:~Drug: 68Ga-ICAM-1pep Device: PET/CT"
89426603|NCT04591574|Other|Intervention Group|All patients will receive a single unit red blood cell (RBC) transfusion post randomisation. Single RBC transfusions will subsequently be administered to achieve and maintain haemoglobin (Hb) concentration of 100-120g/L unitl hospital discharge. Hb measured at least weekly in hospital.
89426604|NCT04591574|Active Comparator|Usual care group|Current usual care transfusion practice, namely single RBC transfusions when Hb 70g/L or less (or modified according to clinician decision) to achieve target Hb 70-90g/L. HB measured at least weekly in hospital
89426605|NCT04590313|Active Comparator|Arthrodesis|MTPJ I Arthrodesis
89426606|NCT04590313|No Intervention|Watchful waiting|No intervention, patient information leaflet
88907416|NCT06308601|No Intervention|control group|No application will be made to the control group. After the research is completed, laughter yoga can be applied by the researcher, at the request of the experimental group, within the framework of ethical responsibilities.
88907417|NCT06308588|Experimental|Blinatumomab + Asciminib|"Participants found to be eligible to take part in this study will receive 5 cycles of blinatumomab and asciminib, followed by asciminib alone for as long as it benefits the participant.~Participants will receive blinatumomab as a continuous (non-stop) infusion on Days 4-31 of Cycle 1 and on Days 1-28 of Cycles 2-5.~Participants will take asciminib by mouth 2 times every day during this study."
88907418|NCT06308575|Experimental|Rivoceranib|Particpants will take rivoceranib by mouth 1 time each day while on study.
88907419|NCT06308562|Experimental|Fuzzy Wale Compression Stockinet|Subjects with peripheral arterial disease requiring transtibial amputation will have Fuzzy Wale Compression Stockinet applied 3-7 days pre-operatively and utilized for 4-8 weeks post operatively or until prosthetic fitting and wound has achieved full durable healing.
88907420|NCT06308562|No Intervention|Standard of care|Subjects with peripheral arterial disease requiring transtibial amputation will receive standard of care treatment compression stockinet.
88907421|NCT06308549|Experimental|Intervention|2/3 of participants will be randomised into this arm. They will receive access to MyDiaMate in the language of their participation country for 6 months.
88907422|NCT06308549|No Intervention|Care As Usual|1/3 of participants will be randomised into this arm. They will receive Care As Usual, so no intervention, for 3 months. After 3 months, they receive access to MyDiaMate, if so wished.
88907423|NCT06308536|Active Comparator|bone powder + collagen membrane|Fill the extraction socket with bone powder, and cover the extraction wound with collagen membrane.
88907424|NCT06308536|Experimental|bone powder + collagen membrane + CGF membrane|Fill the extraction socket with bone powder, and cover the extraction wound with collagen membrane and CGF membrane.
89196440|NCT02538250|Experimental|1 Nutricomp Drink Plus|Nutricomp Drink Plus
89196441|NCT00930124|Experimental|1|Group 1 will receive Conventional orthognathic surgery
89196442|NCT00930124|Active Comparator|2|Group 2 will receive distraction osteogenesis
89426607|NCT04586569|No Intervention|Standard Education|This group will receive the standard of care pre-operative education that all children get prior to ORL surgery at BCH Waltham.
88907425|NCT06308536|Experimental|bone powder mixed wih CGF gel + collagen membrane + CGF membrane|Fill the extraction socket with bone powder mixed with CGF gel, and cover the extraction wound with collagen membrane and CGF membrane.
89196443|NCT00566254|Placebo Comparator|Placebo|Participants had a starting dose of 1 mg/kg/day of placebo matching Zonisamide. Dose was titrated upwards with weekly dose increases until a dose of 8 mg/kg/day was reached at the end of the Titration Period (Week 8). Dose during the Maintenance Period remained unchanged from Week 8.
89196444|NCT00566254|Experimental|Zonisamide|Participants had a starting dose of 1 mg/kg/day of Zonisamide. Dose was titrated upwards with weekly dose increases until a dose of 8 mg/kg/day was reached at the end of the Titration Period (Week 8). Dose during the Maintenance Period remained unchanged from Week 8.
89426608|NCT04586569|Experimental|Pediatric Interactive Relational Agent (PIRA)|This group will receive the standard of care pre-operative education that all children get prior to ORL surgery at BCH Waltham and will be given access to an interactive, online educational tool for use prior to surgery. This Pediatric Interactive Relational Agent (PIRA) will be able to be accessed as many times as the family would like prior to surgery.
89426609|NCT04586530|Experimental|Memory and Attention Adaptation Training (MAAT)|"A videoconference-delivered cognitive-behavioral therapy (CBT) for treatment of chemotherapy-related cognitive dysfunction (CRCD) among cancer survivors consisting of 8 weekly 45-minute visits with a survivor workbook, that targets: 1) enhancement of survivor self-awareness of at risk situations where memory failures occur; 2) emotion regulation through modification of survivor causal attributions and negative cognitive appraisals of memory failures; and 3) training in compensatory strategies to improve performance on daily tasks for which memory."
89426610|NCT04586530|Active Comparator|Supportive Therapy (ST)|"Standard attention control condition therapy for treatment of chemotherapy-related cognitive dysfunction (CRCD) among cancer survivors consisting of 8, 45-minutes visits. ST, emphasizes non-specific psychotherapeutic factors of clinician-participant alliance: empathy, support and warmth. ST will be directed at concerns with cancer survivorship and CRCD. Clinicians will set expectations with ST participants that they will be provided validation of experience, support, and encouragement of building their own coping resources if asked directly about what to do about cognitive problems. ST emphasizes reflective listening to help deepen knowledge of the emotional experience of the participant."
89426611|NCT04581889||Children|Children from1 to 18 years, enrolled in kindergartens, primary, or secondary school located in city of Tübingen, Germany.
89426612|NCT04581889||Adult comparator|Adults of unknown status of previous SARSCoV-2 infection.
89426613|NCT04581889||Adult validation|Adults who report a history of SARS-CoV-2 infections between 1. February 2020 and the time point of sampling.
89426614|NCT04581460||Patients|Patients entered in the register of the reference Center for Hereditary Immune Deficits (CEREDIH), hospital Necker-Enfants Malades, Paris, and having reported at least one pregnancy or attempted pregnancy
89426615|NCT04580940||Subjects with complex pancreaticobiliary disease|All subjects will undergo the percutaneous transhepatic cholangiopancreatoscopy with the SpyGlass Discover System.
89426616|NCT04575883|Experimental|MedBIKE HIIT|MedBIKE HIIT Exercise Program
89426617|NCT04562051||stratified prophylaxis group|The process of stratified prophylaxis was as follows. 1) If the recipient's HBsAb level is more than 100 IU/L and the donor is HBV DNA-, the recipient will not receive any preventive measures; 2) If the recipient's HBsAb is more than 100 IU/L and the donor is HBV DNA+, the recipient receives antiviral treatment for 1 month; 3) If the recipient's HBsAb is between 10 and 100 IU/L, the recipient is treated with single dose HBIG and antiviral treatment for 1 month regardless of the donor's HBV DNA status; 4) If the recipient's HBsAb is less than 10 IU/L, the recipient will receive single dose HBIG and antiviral treatment for 1 month regardless of the donor's HBV DNA status.
89426618|NCT04562051||Routine prophylaxis group|Transplant centers adopted routine prophylaxis based on clinical experience
89426619|NCT04560582||Kidney Transplant Patients with Failed Allograft|All participants are assigned to a single cohort of kidney transplant patients with failed allograft requiring dialysis.
89426620|NCT04557176|Experimental|POC CRP-based TB screening|Participants randomized to the intervention arm will undergo POC CRP-based TB screening at study entry. Participants with elevated POC CRP levels (≥8 mg/L) will be regarded as screen-positive and will be referred for confirmatory TB testing. Participants with non-elevated POC CRP levels (<8 mg/L) will be regarded as screen-negative and will be assessed for TPT eligibility.
89426621|NCT04557176|No Intervention|Symptom-based TB screening|Participants randomized to the control arm will undergo symptom-based TB screening at study entry. Participants reporting ≥1 TB symptom (current cough, fever, night sweats, weight loss) will be regarded as screen-positive and will be referred for confirmatory TB testing, in accordance with WHO guidelines. Participants with none of the 4 TB symptoms will be regarded as screen-negative and will be assessed for TPT eligibility.
88907426|NCT06308536|Experimental|bone powder + CGF membrane|Fill the extraction socket with bone powder, and cover the extraction wound with CGF membrane.
89536800|NCT03309917|Experimental|Changes in mean arterial pressure|"The study is conducted from one hour after incision and lasts for approximately half an hour. Measurements are conducted at three levels of mean arterial pressure:~MAP set at 80-85 mmHg for 5 min.~MAP set at 70-75 mmHg for 5 min.~MAP set at 60-65 mmHg for 5 min.~Blood pressure control is by infusion of noradrenaline. When the evaluations have been conducted blood pressure control is according to clinical practice. Measurements include internal carotid artery blood flow, mean arterial pressure, heart rate, stroke volume, frontal lobe and muscle oxygenation, depth of anesthesia, and arterial and central venous blood gas variables."
88907427|NCT06308523|Experimental|AP303|
88907428|NCT06308523|Placebo Comparator|Placebo|
88907429|NCT06308510||Gastric cancer patients|Operable patients who will undergo DLS for GC. Patients will be identified from the MDT (multidisciplinary tumor board).
88907430|NCT06308510||non-cancer controls|Patients who will undergo a planned laparoscopy for bariatric or gallbladder disease
88907431|NCT06308484|Active Comparator|Active transcutaneous vagus nerve stimulation|The tVNS device consisted of two titan electrodes mounted on a gel frame and connected to a wired neurostimulation device (tVNS Health GmbH, Germany). Electrodes were placed on the cymba conchae. Stimulation intensity of 0.5 mA, delivered with a pulse width of 200-300 μs at 25 Hz.
88907432|NCT06308484|Sham Comparator|Sham transcutaneous vagus nerve stimulation|Stimulation parameters equivalent to active but sham stimulation was administered by positioning the electrodes on the central part of the left earlobe rather than the outer auditory canal, as the earlobe lacks vagus innervation.
88907433|NCT06308484|Active Comparator|Closed-loop AM-tACS increase frontal midline theta oscillation|We will deliver amplitude-modulated transcranial alternating current stimulation (AM-tACS) using two circular rubber electrodes (4 cm diameter) positioned at the Fpz and Cz locations of the international 10-20 system. The AM-tACS stimulation waveform features a carrier signal frequency of 10 kHz, an amplitude of ±1 mA, and a signal that is real-time synchronized with theta oscillations of the frontal midline. In the active condition target oscillations (frontal midline theta) will be increased.
88907434|NCT06308484|Sham Comparator|Closed-loop AM-tACS decrease frontal midline theta oscillation|Equivalent to the active comparator - except here the target oscillation will be suppressed.
88907435|NCT06308471|Experimental|Group of baby massage|Being between 28-33 weeks of gestation, Not having a congenital disease, Meeting the readiness criteria for oral feeding, Must be in the weight range of 1000-2000 grams
89196445|NCT00930202|Experimental|Conivaptan (Vaprisol)|Conivaptan (Vaprisol) will be administered in a single dose of 20 mg, mixed with 100 mL of 5% dextrose in water, and delivered over 30 minutes.
89426622|NCT04549155|Experimental|Network-guided TMS|The study comprises one arm of five sessions. In Day 1 (~1.5 hr session), participants fill forms, complete a neuropsychological test battery (NIH Toolbox, NACC UDS, BDI), and provide a saliva sample to be banked for future APOE genotype determination. On Day 2 (~1 hr session), subjects will perform an initial MRI scanning session. In this session, MRI, RSFA, DWI, and fMRI are collected so they can be used for network-based targeting. In Days 3-5 (each comprising a ~2.5 hr session) a few days later participants will undergo combined TMS-fMRI sessions. In the scanner, participants complete four fMRI runs: 2 runs using either a network-based or standard target location, counterbalanced across participants. Active and Sham TMS trials are intermixed within each run.
88907436|NCT06308471|Experimental|Group of oral stimulation (Fucile Protocol)|Being between 28-33 weeks of gestation, Not having a congenital disease, Meeting the readiness criteria for oral feeding, Must be in the weight range of 1000-2000 grams
88907437|NCT06308458|Experimental|Study Group (A)|Experimental (Breather Exerciser Trainer + conventional breathing exercises) Group 30 healthy elders will receive inspiratory muscle training by breather exerciser trainer (Gradual intensity from 2-3 rate of perceived exertion (RPE) up to reach 5-7 RPE, with gradual frequency; 1st week 8 sets of 5 repetitions '1 minute rest', 2nd week be 9 sets, and 3rd week reach 10 sets of 5 repetitions. then from 4-8 weeks 'end of study protocol' will be 10 sets of 6 repetitions with 1 minute rest between sets.), along with conventional breathing exercises (Diaphragmatic breathing, Pursed-up breathing, and Exercise connected with respiration), for 5 sessions per week for eight weeks.
88907438|NCT06308458|Other|Control Group (B)|"Control (conventional breathing exercises) Group:~30 health elders will receive conventional breathing exercises (Diaphragmatic breathing; Pursed-up breathing, Exercise connected with respiration for 5 times a week for a total 8 weeks"
88907439|NCT06308445|Experimental|Rapamycin|
89426623|NCT04546178|Experimental|PE+ intervention group|This group will participate in 15 sessions of PE+ therapy and participate in frequent symptom assessments; this is the same group of participants as the pre-intervention scores group, but they have crossed over from pre-intervention phase into intervention (active) phase.
88907440|NCT06308432|Experimental|22 degrees, 40% humidity and 50% intensity|"The room in which the 30-minute test will be performed will be at 22 degrees Celsius and 40% humidity.~The subject should perform the test at 50% of the power at which he reached his VO2max."
88907441|NCT06308432|Experimental|35 degrees, 40% humidity and 50% intensity|"The room in which the 30-minute test will be performed will be at 35 degrees Celsius and 40% humidity.~The subject should perform the test at 50% of the power at which he reached his VO2max."
88907442|NCT06308432|Experimental|35 degrees, 65% humidity and 50% intensity|"The room in which the 30-minute test will be performed will be at 35 degrees Celsius and 65% humidity.~The subject should perform the test at 50% of the power at which he reached his VO2max."
88907443|NCT06308432|Experimental|22 degrees, 40% humidity and 60% intensity|"The room in which the 30-minute test will be performed will be at 22 degrees Celsius and 40% humidity.~The subject should perform the test at 60% of the power at which he reached his VO2max."
88907444|NCT06308432|Experimental|35 degrees, 40% humidity and 60% intensity|"The room in which the 30-minute test will be performed will be at 35 degrees Celsius and 40% humidity.~The subject should perform the test at 60% of the power at which he reached his VO2max."
88907445|NCT06308432|Experimental|35 degrees, 65% humidity and 60% intensity|"The room in which the 30-minute test will be performed will be at 35 degrees Celsius and 65% humidity.~The subject should perform the test at 60% of the power at which he reached his VO2max."
89196446|NCT00930202|No Intervention|Standard Care|No intervention
89426624|NCT04546178|Active Comparator|Pre-intervention scores group (TAU)|This group will participate in symptom assessments but will not receive the PE+ intervention until the begin the active part of the trial. Participants in this group have been diagnosed with a psychotic disorder, have also experienced adversity, and use substances. This group will receive medication for psychosis as well as access to standard education programs and clinical care; thus treatment as usual (TAU).
89426625|NCT04545424|Experimental|Hypothermia + Neuromuscular blockade|Deep sedation and Neuromuscular blockade (NMB) and surface temperature management to maintain core temperature between 34 and 35°C for 48h, then rewarm to 36°C at 0.33°C per h and NMB discontinued when core temp reaches 35.5°C.
89536801|NCT03309839||neonates with cardiac surgery under cardiopulmonary bypass|
89536802|NCT03309761||Patients aged 55-60|
88907446|NCT06308406|Experimental|HRS-1167 in combination with bevacizumab in patients with recurrent ovarian cancer|
88907447|NCT06308393|Experimental|Treatment group 1|Single dose in healthy subjects
88907448|NCT06308393|Experimental|Treatment group 2|Multiple dose in healthy subjects
88907449|NCT06308393|Experimental|Treatment group 3|Multiple dose in patients
89196447|NCT00933868|Experimental|Magnesium infusion in patients breathing 100% oxygen|Patients will be given six infusions over three weeks. Each infusion will last between 4 and 10 minutes. They will then return to clinic in 1,2 and 3 months for the same tests (but no infusions will be given).
89196448|NCT00933868|Placebo Comparator|Placebo infusion|The patients will receive six placebo infusions after which they will return to clinic at one, two and three months. At the conclusion of the trial those patients who received placebo may elect to receive the active treatment in another (open label) trial that will begin shortly after this one concludes.
89196449|NCT00908206|Placebo Comparator|Placebo|Placebo to match GSK598809.
89426626|NCT04545424|Active Comparator|Usual Temperature Management|Acetaminophen and surface temperature management to maintain core temperature between 37°C and 38°C. Rewarming to 37°C for hypothermia ≤36°C with continuous renal replacement therapy.
89426627|NCT04521426||Lung Fibrosis|"probable or confirmed diagnosis of interstitial pulmonary fibrosis (IPF) or other fibrotic lung disease of unknown origin.~being listed for lung transplantation"
88820394|NCT06185725|Active Comparator|Group M-TAPA (Modified Perichondral Approach Thoracoabdominal Nerve block group)|Patients will be performed to block at the end of the surgery. Patients will be administered paracetamol 1 gr (PERFALGAN® ) IV every 8 hours in the postoperative period.. If the patient's NRS score is ≥ 4 0,5 mg/kg IV meperidine (Aldolan ampul 100 mg/2 ml) will be administered.
88820395|NCT06185725|Active Comparator|Group TAP (Transversus Abdominal Plane block group)|Patients will be performed to block at the end of the surgery. Patients will be administered paracetamol 1 gr (PERFALGAN® ) IV every 8 hours in the postoperative period.. If the patient's NRS score is ≥ 4 0,5 mg/kg IV meperidine (Aldolan ampul 100 mg/2 ml) will be administered.
88820396|NCT06185205|Experimental|Accelerated Partial Breast Irradiation (APBI)|7.5 gray (Gy) × 3 fractions via multicatheter brachytherapy
88820397|NCT06184633|Active Comparator|Intervention|Semaglutide injections + combined lifestyle intervention
88820398|NCT06184633|Placebo Comparator|Placebo|Placebo Semaglutide injections + combined lifestyle intervention
88820399|NCT06184581|Experimental|Lithium|tablet
88820400|NCT06184581|Active Comparator|Lamotrigine|tablet
88820401|NCT06184269|Active Comparator|BR1017-1A+BR1017-1B|
88820402|NCT06184269|Experimental|BR1017-1|
88820403|NCT06184256|Experimental|Core Curriculum|Participants will receive core curriculum
88820404|NCT06184256|Experimental|Core Curriculum and Group Support|Participants will receive core curriculum and group support
88820405|NCT06184256|Experimental|Core Curriculum and Behavioral Skills|Participants will receive core curriculum and behavioral skills
88820406|NCT06184256|Experimental|Core Curriculum, Behavioral Skills, and Group Support|Participants will receive core curriculum, behavioral skills, and group support
88820407|NCT06184256|Experimental|Core Curriculum and 1:1 Counseling|Participants will receive core curriculum and 1:1 counseling
88820408|NCT06184256|Experimental|Core Curriculum,1:1 Counseling, and Group Support|Participants will receive core curriculum, 1:1 counseling, and group support
88820409|NCT06184256|Experimental|Core Curriculum, 1:1 Counseling, and Behavioral Skills|Participants will receive core curriculum, 1:1 counseling, and behavioral skills
88820410|NCT06184256|Experimental|Core Curriculum, 1:1 Counseling, Behavioral Skills, and Group Support|Participants will receive core curriculum, 1:1 counseling, behavioral skills, and group support
89426628|NCT04521426||COPD standard therapy|"COPD: GOLD stage III or IV~being listed for lung transplantation~did not underwent LVR surgery or endoscopic LVR~not being treated with chronic NIV"
89426629|NCT04521426||COPD with long-term NIV|"COPD: GOLD stage III or IV~being listed for lung transplantation~did not underwent LVR surgery or endoscopic LVR~being treated with chronic NIV before lung transplantation (at least 1 months, at least 4 hours per day)."
88907450|NCT06308380|Active Comparator|Rehabilitation only|All patients who do not wish to undergo mini- invasive surgery to lengthen the calf muscles are part of the control group. They will be subjected to a specific protocol of rehabilitation exercise 3times a week for 12 weeks.
88907451|NCT06308380|Experimental|Surgery|All patients who wish to undergo mini invasive surgery to lengthen the calf muscles are part of the experimental group. they will be subjected to a specific protocol of rehabilitation exercise exercise 3times a day every day for 4weeks.
88907452|NCT06308367|Experimental|betaine|oral betaine
89426630|NCT04516993|Experimental|Tenecteplase arm|
89426631|NCT04516993|Other|Best treatment arm (e.g. Aspirin, Recombinant Tissue Plasminogen Activator, Urokinase, Thrombectomy)|The best treatment selected by local doctors
88907453|NCT06308367|Placebo Comparator|placebo|rice-flour as a placebo
89426632|NCT04514978|Experimental|Blood donation and transfusion|Donation and reinfusion of 1 unit whole blood and 130 mL packed red blood cells, respectively. Blood samples were collected at 8 weeks prior to donation for 12 subjects and 2 weeks prior to donation by 12 subjects. Blood samples were collected 3, 7, 14, 21, and 28 days after donation and 3, 6, 24 hours and 2, 3 and 6 days after reinfusion of blood.
89426633|NCT04514978|No Intervention|Control group|Blood samples collected with same frequency as described in the intervention arm.
89426634|NCT04513015|Experimental|Antioxidant diet|Group Antioxidant diet will receive 8 weeks of antioxidant dietary treatment
88907454|NCT06308354||colorectal cancer|Colorectal cancer patients are enrolled when patients were underwent surgeries.
88907455|NCT06308341|Other|Group A: (Virtual Reality technique + Motor Imagery technique + Routine Physical Therapy)|"Participants in this group will receive Virtual Reality (VR) for and Motor Imagery (MI) training with routine physical therapy for every alternate day (3 days per week) for 12 weeks. Total 45 minutes of session.~Routine physical therapy protocol will be given for 30 minutes. VR techniques for 10-15 minutes MI techniques for 05-10 minutes"
89426635|NCT04513015|Active Comparator|Normal diet|Group Normal diet will continue a normal dietetic scheme (corresponding to a isocaloric, normolipidic diet for age and sex).
89426636|NCT04506372|Experimental|Intervention group|Perioperative withdrawal of ACEI/ARB.
89426637|NCT04506372|Active Comparator|Control group|Perioperative continuation of ACEI/ARB.
89426638|NCT04495686|Experimental|Caregiver PWD-ADRD TCCI|Participants in the Caregiver PWD-ADRD telehealth care coordination intervention (TCCI) group will complete a 12-month telehealth-delivered care coordination program with an assigned dementia care coordinator.
88907456|NCT06308341|Experimental|Group B: (Virtual Reality + Routine Physical Therapy )|"The VR system consisted of a wall-mounted display, a Nintendo Wii box, a Wii remote, and a Wii Fit board. The participants will be instructed to stand on Wii Fit board while interacting with the VR system and playing the selected games.~Routine physical therapy protocol will be given for 30 minutes along with cycling and walking for 10-15 minutes.~VR techniques for 10-15 minutes."
89426639|NCT04495686|No Intervention|Caregiver for PWD-ADRD (BMT)|Participants in the Caregiver PWD-ADRD best medical treatment (BMT) group will not receive care coordination.
88907457|NCT06308341|Experimental|Group C: (Motor Imagery +Routine Physical Therapy)|"During the presentation of a video clip, patients will watch the video and afterwards try to do movement as same as shown in video.~Routine physical therapy protocol will be given for 30 minutes along with Cycling and walking for 10-15 minutes MI techniques for 10-15 minutes"
88907458|NCT06308315|Experimental|Group A (Rhythmic Training+ Routine Physical therapy)|"Rhythmic balance auditory vision training will be given thrice a week for 8 weeks. it is a 45 minute training program that consist of:~5 minute warm up activities (arm swings).~Bal-A-Vis-X training thrice a week for 20 minutes.~5-minute cool down activities.~Routine Physical therapy treatment for 15 minutes"
88907459|NCT06308315|Experimental|Group B (Strength Training+ Routine Physical Therapy)|"Strength training Program will be performed thrice a week for 8 weeks. session of 45 minute will be given to the patient. The expert managed sessions based on:~10-min warm-up activities, 25-min basic exercise 10- min cool-down activities."
88907460|NCT06308302|Experimental|Group A|Group A (Inspiratory Muscles Training +Aerobic Interval Training)
88907461|NCT06308302|Experimental|Group B|Group B (Expiratory Muscles Training +Aerobic Interval Training)
88907462|NCT06308289|Experimental|Group A|GPRM and ACBT
88907463|NCT06308289|Active Comparator|Group B|Standard Care for COPD (ACBT)
88907464|NCT06308276|Active Comparator|Group A|Brisk walking, jogging, cycling, or low-impact aerobics
88907465|NCT06308276|Active Comparator|Group B|Full body resistance exercise targeting major muscle groups, including squats, lunges, chest presses, rows, and core exercises
88907466|NCT06308263|Experimental|Period 1: Mass Balance: M1774 + [14C]M1774 microtracer|
88907467|NCT06308263|Experimental|Period 2: M1774|
88907468|NCT06308250|Experimental|GROUP A ( MIME THERAPY)|"Group A will receive mime therapy of 30 minutes with short resting intervals. Treatment will be given 5 times per week for 6 weeks. Mime therapy consist of:~Self massage of 10 minutes,~Breathing and relaxation exercises of 5 minutes,~Articulation of 5 minutes and~Facial expression exercises of 10 minutes."
88907469|NCT06308250|Experimental|GROUP B (ACTION OBSERVATION THERAPY)|"Group B will receive action observation therapy of 30 minutes with short resting interval. The treatment will be given 5 times per week for 6 weeks.~During the presentation of a video clip, patients sit relaxed in front of the computer screen while observing it.~After observing a motor act for 3 min (observation phase) patients are required to imitate what they observed for 2 min (execution phase)."
88907470|NCT06308237|Experimental|GROUP A (RESISTED EXERCISES)|Group A will receive a session of resisted exercises for 30 minutes. Treatment session will be given for 3 days per week for 12 weeks. This resisted training exercise program consist of three phases: Warm-up phase (5 minutes, after Warm-Up phase 20 minutes resisted exercise training then cooling phase (5 minutes).
88907471|NCT06308237|Experimental|GROUP B (BALANCE EXERCISES)|Group B will receive a session of Balance exercises for 30 minutes. Treatment session will be given for 3 days per week for 12 weeks. This balance exercise program consist of three phases:Warm-up phase (5 minutes), after Warm-Up phase, 20 minutes balance exercise training then cooling phase (5 minutes).
88907472|NCT06308224|Experimental|Group A (Modified-Otago Exercises)|"Participants will engage in Modified-Otago exercises for 30 minutes of moderate-intensity exercise at least three times weekly for 12 weeks.~Walking for 15 minutes~Strengthening exercises for 10 minutes~Balance exercises 20 minutes"
88907473|NCT06308224|Experimental|Group B (Tai Chi Exercises)|"Participants of the Tai Chi qigong group will participate in a 30-minute exercise class three times a week for 12 weeks.~Warm-up exercises for 10 minutes~Tai Chi Exercises for 30 minutes~Cool-down exercises for 5 minutes"
89007700|NCT02924402|Experimental|CLL/SLL (Group CLL) Part A|XmAb13676 administered IV up to 8 weeks, if receiving benefit, this can be extended at investigator's discretion
89536803|NCT00704171|Experimental|PleuraSeal|PleuraSeal Lung Sealant System
89426640|NCT04495686|Experimental|Caregiver for PWD-TBI TCCI|Participants in the Caregiver PWD-TBI telehealth care coordination intervention (TCCI) group will complete a 12-month telehealth-delivered care coordination program with an assigned dementia care coordinator.
89426641|NCT04495686|No Intervention|Caregiver for PWD-TBI (BMT)|Participants in the Caregiver PWD-TBI best medical treatment (BMT) group will not receive care coordination.
89426642|NCT04480541|Experimental|Roadmap 2.0 + Fitbit Charge 3|"Caregivers and patients download the Roadmap 2.0 mobile app on their own mobile phones or tablet to use freely throughout the 120 day study period.~Caregivers and patients receive a Fitbit wearable activitiy sensor to track activity and sleep."
89426643|NCT04478942|Active Comparator|oral misoprostol|At time of delivery, participants randomly assigned to either oral misoprostol will receive 50 mcg of Misoprostol every 4 hours up to 6 doses, OR until simplified Bishop score >6 (whichever is achieved first).
89426644|NCT04478942|Active Comparator|intravenous oxytocin|At time of delivery, participants randomly assigned to intravenous oxytocin, will be administered the drug per standard of labor and delivery titrations.
89426645|NCT04472416|No Intervention|Standardized analgesic protocol alone|Abdominal VAC dressing change using an standardized analgesic protocol alone.
89426646|NCT04472416|Experimental|VRD + standardized analgesic protocol|Abdominal VAC dressing change using standardized analgesic protocol + virtual reality device
89007701|NCT02924402|Experimental|Non-CLL B Cell Malignancies (Group NHL) Part B|XmAb13676 administered IV up to 8 weeks, if receiving benefit, this can be extended at investigator's discretion
89007702|NCT02924402|Experimental|CLL/SLL (Group CLL) Part B|XmAb13676 administered IV up to 8 weeks, if receiving benefit, this can be extended at investigator's discretion
89007703|NCT02924402|Experimental|Non-CLL B Cell Malignancies (Group NHL) Part C / Expansion|XmAb13676 administered IV up to 8 weeks, if receiving benefit, this can be extended at investigator's discretion
89426647|NCT04451161|Other|BASIS with TF-CBT|"Implementation intervention: experimental arm (Beliefs and Attitudes for Successful Implementation in Schools)~Clinical Intervention: experimental arm (Trauma-Focused CBT)"
89426648|NCT04451161|Other|AC with TF-CBT|"Implementation intervention: control arm~Clinical Intervention: experimental arm (Trauma-Focused CBT)"
89426649|NCT04451161|Other|Enhanced Treatment as Usual|"Implementation intervention: non-applicable~Clinical Intervention: control arm (Enhanced TAU)"
89536804|NCT00704171|Active Comparator|Standard of Care|Standard tissue closure techniques (control) - sutures or staples only
89536805|NCT03313973|Experimental|with self stretching same muscle|
89536806|NCT03313973|Sham Comparator|with self stretching forearm muscle|
89536807|NCT05160077|Other|Fasting|All examinations are in a fasting state.
88820411|NCT06184256|Experimental|Program Provider|Providers will deliver and evaluate one or more components of the diet or exercise interventions
88820412|NCT06183359|Experimental|The group Self-Identification Program (SIP)|"The Self-Identification Program (SIP) is a third level of third wave CBT.~It targets a correct self-identification through the of the following skills :~understand the nature and functioning of one's own mind (=conscious power, what allows the appearance of experiences);~learn to identify with the characteristics of the mind : to provide soothing (session 1), reassuring power (session 2), benevolent power (session 3), discerning power (session 4), prioritizing power (session 5), acting power (session 6), creative power (session 7), liberating power (session 8)~live better with your emotions and moods (and their dysregulation);~develop more respectful communication for oneself and others"
88820413|NCT06183359|Other|The group Acceptance and Commitment Therapy (ACT)|"The Acceptance and Commitment Therapy (ACT) is a first level of third wave CBT.~It targets the development of the following skills, consistent with the content of programs validated in the domain :~decision-making tool (matrix (session 1));~flexibility skills: defusion (session 2), Self as context (session 4), acceptance (session 4), contact with the present moment (session 5), values (session 6), valued actions (session 7), toolkit skills (session 8)."
88820414|NCT06182319|Experimental|SBO treated without NG tube|Patients who decline NG intubation will be enrolled in the trial, followed prospectively and have the same outcome measures as are acquired in the other study arms.
88820415|NCT06182319|Experimental|SBO treated with NG tube and Water-Soluble Contrast (WSC)|Patients who select NG tube treatment will be randomized into experimental and control groups. The experimental groups will have 100 cc of WSC administered in the NG tube within 2 hours of NG tube placement.
88820416|NCT06182319|Placebo Comparator|SBO Treated with NG tube and Placebo|The control group will have 100cc of saline administered via the NG tube within 2 hours of NG tube placement.
88820417|NCT06180811|Experimental|Women's Health Delaware Food Farmacy|Participants will receive medically tailored groceries (10 meals per person in the household per week from enrollment to 4 weeks after delivery) high in micronutrients that are delivered to their homes weekly. They will also interact weekly with their assigned Community Health Worker to address social needs and patient-centered goals.
88820418|NCT06180811|Active Comparator|Usual Standard of Care|Participants will receive the usual standard of care.
88907474|NCT06308211|Experimental|GROUP A (MOTOR IMAGERY+MIRROR THERAPY+ROUTINE PHYSICAL THERAPY)|"Group A will receive treatment session of 60 minutes including motor imagery for 20 minutes and mirror therapy for 20 minutes along with routine physical therapy of 20 minutes for 5 days per week for 12 weeks.In motor imagery subjects will watch the video and will be asked to close the eyes to focus and imagine how they are doing task they had previously observed 10 times and instructed to carry out the task in verbal commands given whenever necessary.~In mirror therapy,The unaffected limb will be placed in front of the mirror and patient will try to make the identical motions with the paretic limb while moving the non-paretic limb during the session and routine physical therapy includes passive and active assisted range of motion for the upper and lower extremity including the shoulder, forearm, wrist, hip, knee and ankle will be given (10 - 15 repititions)."
88907475|NCT06308211|Experimental|GROUP B (MOTOR RELEARNING PROGRAM+ROUTINE PHYSICAL THERAPY)|"GROUP B will receive treatment session of 60 minutes including motor relearning program of 40 minutes duration along with routine physical therapy of 20 minutes as explained in group A protocol. Treatment session will be given 5 days per week for 12 weeks.~Motor relearning consists of five components including analysis of task, practice of missing components, practice of task and transference of training."
88907476|NCT06308198|Experimental|Double-Blind Period: AGN-151586|Participants will receive AGN-151586 in the glabellar complex on Day 1.
88907477|NCT06308198|Placebo Comparator|Double-Blind Period: Placebo|Participants will receive Placebo in the glabellar complex on Day 1.
88907478|NCT06308198|Experimental|Open-Label: AGN-151586|Participants who meet all retreatment criteria will receive AGN-151586 in the glabellar complex on Day 43.
88907479|NCT06308185||Neonates with seizures|Newborns born at term or prematurely who have had epileptic seizures documented by electroencephalogram in the neonatal period
88907480|NCT06308172|Experimental|Single-layer|Patients who are randomized in this arm undergo a single layer-hysterotomy closure
88907481|NCT06308172|Experimental|Double-layer|Patients who are randomized in this arm undergo a double layer-hysterotomy closure
88907482|NCT06308159|Experimental|Vebeglogene autotemcel|One-time infusion of≥5×10^6/kg beta-globin lentiviral vector transduced HSCs
88907483|NCT06308133||Patients|Patients are defined as subjects affected by a hematological or non-hematological disease for which an autologous stem cells transplantation is recommended. These cases are referred as autologous use of stem cells.
88907484|NCT06308133||Stem cells donors|Stem cells donors are volunteer healthy subjects who have decided to undergo the procedures needed to collect blood stem cells. These subjects can donate their blood stem cells in favor of a blood relative or, through subscription of a specific registry (IBMDR - International Bone Marrow Donor Registry), to an unknown subject. These cases are referred as allogenic use of stem cells.
88907485|NCT06308120|Active Comparator|ION™ Endoluminal System|ION™ Endoluminal System Providers will utilize the ION™ Endoluminal System to perform a diagnostic bronchoscopy procedure
88907486|NCT06308120|Active Comparator|superDimension Navigation System and Accessories|Providers will utilize the superDimension Navigation System and Accessories to perform a diagnostic bronchoscopy procedure.
88907487|NCT06308107|Experimental|Diazoxide|IV Diazoxide as additive to hypothermic hyperkalemic cardioplegia.
88907488|NCT06308081|Experimental|Tailored|Participants in the tailored arm will receive SGM-tailored anti-vaping health messages delivered via text message
88907489|NCT06308081|No Intervention|Non-Tailored|Participants in the non-tailored arm will receive non-tailored anti-vaping health messages delivered via text message
88907490|NCT06308068|Experimental|Generic diacerein 50 mg capsule|Each subject will receive a single dose of generic diacerein 50 mg capsule, EIDAR, as a test formulation (T), or a single dose of diacerein 50 mg capsule, with 240±2 mL of ambient temperature drinking water at 30 minutes after the start of standardized HFHC breakfast. Investigational product will be provided to subject in stainless steel cup and subject will be dosed without touching the tablet. This activity will be followed by a mouth check using a tongue depressor and a flashlight to assess the compliance of dosing. The formulations will be given in a crossover fashion as per the randomization schedule. The dosing processes will be conducted under normal light condition.
88907491|NCT06308068|Active Comparator|Diacerein 50 mg capsule, ARTRODAR®|Each subject will receive a single dose of generic diacerein 50 mg capsule, , ARTRODAR®, as a reference formulation (R), with 240±2 mL of ambient temperature drinking water at 30 minutes after the start of standardized HFHC breakfast. Investigational product will be provided to subject in stainless steel cup and subject will be dosed without touching the tablet. This activity will be followed by a mouth check using a tongue depressor and a flashlight to assess the compliance of dosing. The formulations will be given in a crossover fashion as per the randomization schedule. The dosing processes will be conducted under normal light condition
88907492|NCT06307990||RTH Syndromes|Patients with THRA or THRB gene mutations
88907493|NCT06307977|No Intervention|No Intervention: CHTC as usual|Participants complete the standard Couples HIV Testing and Counseling session (CHTC).
88907494|NCT06307977|Active Comparator|Behavioral: Couples Health Project|A three-session intervention for couples addressing couples communication skills, substance use, sexual agreements. The intervention also includes couples HIV testing and counseling in the final session.
88907495|NCT06307964||Alcoholic hepatitis|Patients with histologically proven AH (after transjugular liver biopsy procedure and histological assessment).
88907496|NCT06307964||No alcoholic hepatitis|"Patients with initially suspected AH (excessive alcohol consumption and modified Maddrey score > 32) but no AH at the histological evaluation of liver biopsy.~It corresponds to patients with decompensated alcoholic liver disease but no AH."
88907497|NCT06307925|Experimental|dose-escalation phase|HC010 0.15mg/kg to 20mg/kg Q2w/28d intravenous infusion
88907498|NCT06307925|Experimental|dose expansion phase|Fixed dose of HC010 Q2w/28d intravenous infusion
88907499|NCT06307912|Placebo Comparator|Placebo group|The placebo intervention group will be shown an online educational VR video.
88907500|NCT06307912|Experimental|Nocebo group|The nocebo intervention group will be shown an online educational VR video.
88907501|NCT06307899|Experimental|Group 1|Unilateral Corner Stretching
88907502|NCT06307899|Experimental|Group 2|Manual Stretching
88907503|NCT06307899|Experimental|Group 3|PNF Stretching
88907504|NCT06307886||patients diagnosed with endometrium cancer|
88907505|NCT06307873|Active Comparator|patients undergone Sacrospinous Fixation operation|
89007704|NCT02924402|Experimental|Non-CLL B Cell Malignancies (Group NHL) Part D / Expansion|XmAb13676 administered SC up to 8 weeks, if receiving benefit, this can be extended at investigator's discretion
89007705|NCT02923193|Experimental|Lithoplasty System followed by DCB|Shockwave Lithoplasty® Peripheral Lithoplasty System is a lithotripsy-enhanced, low-pressure balloon dilatation of calcified, stenotic peripheral arteries in patients who are candidates for percutaneous therapy. lithoplasty
89007706|NCT02923193|Active Comparator|Medtronic IN.PACT (DCB)|Medronic IN.PACT Drug Coated Balloon (DBS) is indicated for percutaneous transluminal angioplasty (PTA) in patients with obstructive disease of peripheral arteries, including patients with in-stent restenosis (ISR) and arteriovenous (AV) access to help maintain hemodialysis access in patients with end-stage renal disease.
89007707|NCT02910531|Experimental|ALA supplement|"Clinical data including medical history, plain KUB x-ray and renal ultrasound, routine blood work and 24-hour urine collections for all subjects will be collected as part of normal clinical care at routine clinical visit every 4 months.~Subjects in this study arm will be taking one supplement tablet containing 1200 mg of alpha lipoic acid orally once daily for three years.~At the end of the three years of study drug treatment, all subjects will undergo a low dose non-contrast CT scan to look for a silent change in stone size."
89007708|NCT02910531|Placebo Comparator|Placebo|"Clinical data including medical history, plain KUB x-ray and renal ultrasound, routine blood work and 24-hour urine collections for all subjects will be collected as part of normal clinical care at routine clinical visit every 4 months.~Subjects in this study arm will be taking one placebo tablet containing 10 mg of sucrose orally once daily for three years.~At the end of the three years of study drug treatment, all subjects will undergo a low dose non-contrast CT scan to look for a silent change in stone size."
89007709|NCT02883062|Active Comparator|Arm A (carboplatin, paclitaxel, mastectomy, lumpectomy)|Patients receive carboplatin IV over 30 minutes Q3W and paclitaxel IV over 1 hour QW. Treatment repeats every 3 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo the collection of blood samples throughout the trial.
89196450|NCT00393523|Active Comparator|5 µg Modified Process Hepatitis B Vaccine Booster (Group 1)|"Participants had previously received a primary series of 3 doses of RECOMBIVAX HB™ (5 µg (micrograms) per dose) during the first year of life outside of the context of the study.~During this study, participants received a 5µg/0.5 ml dose of Modified Process Hepatitis B Vaccine (Booster Dose)."
89196451|NCT00393523|Active Comparator|10 µg ENGERIX-B™ Booster (Group 2)|"Participants had previously received a primary series of 3 doses of RECOMBIVAX HB™ (5 µg (micrograms) per dose) during the first year of life outside of the context of the study.~During this study, participants received a dose of 10µg/per 0.5 ml ENGERIX-B™ (Booster Dose)"
89196452|NCT00393523|Active Comparator|5 µg Modified Process Hepatitis B Vaccine Booster (Group 3)|"Participants had previously received a primary series of 3 doses of ENGERIX-B™ (10 µg (micrograms) per dose) during the first year of life outside of the context of the study.~During this study, participants received a 5µg/0.5 ml dose of Modified Process Hepatitis B Vaccine, (Booster Dose)."
89196453|NCT00393523|Active Comparator|10 µg ENGERIX-B™ Booster (Group 4)|"Participants had previously received a primary series of 3 doses of ENGERIX-B™ (10 µg (micrograms) per dose) during the first year of life outside of the context of the study.~During this study, participants received a 10µg/0.5 ml dose of ENGERIX-B™ (Booster Dose)."
89196454|NCT00393523|Experimental|5 µg Modified Process Hepatitis B Vaccine (Group 5)|"Participants did not receive a prior vaccination with a hepatitis B vaccine.~During the study, participants received a 5µg/0.5 ml dose of Modified Process Hepatitis B Vaccine."
89196455|NCT03993067|Active Comparator|Standard Treatment|Fibrin glue and Tabotamp on cut surface
89196456|NCT03993067|Experimental|Hemopatch|Hemopatch on cut surface
89196457|NCT00393367|Placebo Comparator|Saline Placebo|All subjects will receive 3 albuterol sulfate doses, 2 ipratropium bromide doses, and systemic corticosteroids. All patients will receive both the systemic corticosteroids and one dose of a mixture of albuterol and ipratropium bromide while guardians are approached for consent. Patients randomized to this placebo comparator arm will then receive 2 nebulized albuterol doses mixed with 8mL of normal saline. Finally, all patients will receive the second nebulized ipratropium dose.
89196458|NCT00393367|Experimental|Budesonide Inhalaiton Suspension|All subjects will receive 3 albuterol sulfate doses, 2 ipratropium bromide doses, and systemic corticosteroids. All patients will receive both the systemic corticosteroids and one dose of a mixture of albuterol and ipratropium bromide while guardians are approached for consent. Patients randomized to this intervention arm will then receive 2 nebulized albuterol doses mixed with 8mL of budesonide inhalation suspension (BIS). Finally, all patients will receive the second nebulized ipratropium dose.
89196459|NCT00395863|Active Comparator|MultiHance|0.5 M MultiHance at a single injection
89196460|NCT00395863|Active Comparator|Magnevist|0.5 M Magnevist at a single injection
89196461|NCT01045915|Experimental|Plasmid AMEP electrotransfer|
89196462|NCT01043731||Ginven indication for laparoscopic anterior resection|
89196463|NCT00395629|Experimental|ICL670 (Deferasirox)|Three dose cohorts: 5 mg/kg/day, 10 mg/kg/day, 15 mg/kg/day
89196464|NCT00392665|Active Comparator|Erlotinib + Bevacizumab|erlotinib plus bevacizumab
89196465|NCT00392665|Active Comparator|Erlotinib + Sulindac|erlotinib plus sulindac
89196466|NCT01046071|Experimental|transversus abdominis plane block|transversus abdominis plane block with ropivacaine
89196467|NCT01046071|Placebo Comparator|block with saline|20 ml of isotonic saline bilateral
89196468|NCT01043809|No Intervention|1|Randomly selected schools will not receive handwashing intervention
89196469|NCT01043809|Experimental|2|Randomly selected schools will get standard commercial school-based handwashing promotion
89196470|NCT01043809|Experimental|3|Randomly selected schools will receive standard commercial school-based handwashing promotion program, plus an added level of handwashing promotion (varies by country)
89196471|NCT01043887|Experimental|Patients with Moderate Hepatic Insufficiency|Patients with moderate hepatic insufficiency (a score of 7 to 9 on the Child-Pugh's scale) received a single 10 mg dose of ridaforolimus.
89196472|NCT01043887|Experimental|Healthy Control Subjects|Healthy control subjects were matched by race, age, gender, and body mass index (BMI) to the patients with moderate hepatic insufficiency. The healthy control subjects also received a single 10 mg dose of ridaforolimus.
89196473|NCT01324297||Healthy Control|Caucasian males and females between 19 and 30 years of age.
89196474|NCT01324297||First Episode Psychosis|Caucasian males and females between 19 and 30 years of age within twelve months of initial DSM IV TR diagnosis of schizophreniform psychosis, schizophrenia, schizoaffective disorder or psychotic disorder NOS.
89196475|NCT01043965|Active Comparator|Diabetes|Type 2 diabetes patients without obstructive coronary disease. Interventional group: lifestyle changes and treatment with metformin.
89196476|NCT01043965|No Intervention|Control|Control group - normal, healthy individuals.
89196477|NCT01044121|Experimental|Mattress Firmness|
89196478|NCT00622869|Experimental|Everolimus + reduced tacrolimus|Low dose tacrolimus (tacrolimus reduced) + everolimus + corticosteroids.
89196479|NCT00622869|Experimental|Tacrolimus elimination|Low-dose tacrolimus (until Month 4, then tacrolimus eliminated) + everolimus + corticosteroids.
89196480|NCT00622869|Active Comparator|Tacrolimus control|Control dose tacrolimus + corticosteroids.
89196481|NCT02548065|Active Comparator|Balneotherapy|"Daily thermal-mineral bath with mineral water named Debole of Vetriolo for a total of 12 applications carried out over a period of two weeks at Levico Terme Spa Center (Levico Terme, Italy)"
89196482|NCT02548065|Placebo Comparator|Placebo|daily thermal bath with tap water bath for a total of 12 applications carried out over a period of two weeks at Levico Terme Spa Center (Levico Terme, Italy)
89196483|NCT00395083|No Intervention|Group 1|Patients allocated to the control arm will receive standardized care that incorporates guide-line based recommendations including influenza vaccination, a short-acting bronchodilator, and either a long-acting bronchodilator or inhaled corticosteroid inhaler.
89196484|NCT00395083|Experimental|Group 2|The comprehensive group will receive an initial, intense education program with development of an action plan, and regular telephone contacts by a case manager in addition to standardized COPD care.
89196485|NCT00366457|Other|Gemcitabine, Bevacizumab and Erlotinib|single-arm, no masking
89196486|NCT00624819|Experimental|Synflorix + Infanrix + Havrix and/or Varilrix Group|This group consisted of subjects primed with Synflorix vaccine in the 10PN-PD-DIT-001 (1105553) and 007 (107046) studies. In 105553 study, subjects had been primed with 3 doses of Synflorix vaccine at 2, 3 and 4 months of age co-administered with Infanrix related vaccines. In 107046 study, subjects had received a booster dose of Synflorix vaccine at 12-18 months of age co-administered with Infanrix hexa vaccine. In this study, in the Year 4 (111347 study), subjects received at Month 48 (4 years post Dose 1 in study 105553) one additional dose of Synflorix vaccine. In addition, subjects were also offered vaccination against hepatitis A (2 doses of Havrix) and/or against varicella (a single dose of Varilrix).
89426650|NCT04447716|Experimental|Treatment (venetoclax, lenalidomide, rituximab, hyaluronidase)|Patient receive venetoclax PO QD on days 1-28. Beginning cycle 2, patients receive lenalidomide PO QD on days 1-21. Patients also receive rituximab IV on days 1, 8, 15, and 22 of cycle 2 and rituximab hyaluronidase (if no significant infusion reaction to rituximab) SC on day 1 of cycles 4, 6, 8, 10, and 12. Patients may receive rituximab IV (instead of rituximab hyaluronidase) on days 1, 8, 15, and 22 of cycles 4, 6, 8, 10, and 12 if the patient requires rituximab IV in the opinion of the treating physician. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
89426651|NCT04446000|Experimental|CSL730 (dose 1 with premedication)|administered as a single dose by subcutaneous (SC) injection or by SC infusion
89426652|NCT04446000|Experimental|CSL730 (dose 2 with premedication)|administered as a single dose by SC injection or by SC infusion
89426653|NCT04446000|Experimental|CSL730 (dose 3 with premedication)|administered as a single dose by SC injection or by SC infusion
89426654|NCT04446000|Experimental|CSL730 (dose 1 without premedication)|administered as a single dose by SC injection or by SC infusion
88907506|NCT06307873|Active Comparator|patients undergone V-notes Lateral Suspension Operation|
88907507|NCT06307847|Experimental|SP5M001 inj|SP5M001 inj 5 ml pre-filled syringe into Knee joint cavity of osteoarthritis patients
88907508|NCT06307847|Active Comparator|Synovian inj|Synovian inj 3 ml pre-filled syringe into Knee joint cavity of osteoarthritis patients
89426655|NCT04446000|Experimental|CSL730 (dose 2 without premedication)|administered as a single dose by SC injection or by SC infusion
89426656|NCT04446000|Experimental|CSL730 (dose 3 without premedication)|administered as a single dose by SC injection or by SC infusion
89426657|NCT04446000|Experimental|CSL730 (dose 4 without premedication)|administered as a single dose by SC injection or by SC infusion
89426658|NCT04446000|Experimental|CSL730 (dose 5 without premedication)|administered as a single dose by SC injection or by SC infusion
88907509|NCT06307834|Experimental|Neurofeedback - based therapy group|In this arm/group, each participant will undergo a series of ten sessions (2-3 sessions per week) over a period of 3-5 weeks. Participants will be trained in modulating their brain activation patterns by using Mental Imagery (MI) involving various hand movements. EEG will be used to record brain responses. A visual feedback will be provided during the training to help achieve specific changes in brain responses. Once an appropriate brain response is achieved, an EMG-controlled hand exoskeleton will aid in opening and closing the hand.
88907510|NCT06307834|Active Comparator|Standard Hand exercises therapy group|In this arm/group, each participant will undergo a series of ten sessions (2-3 sessions per week) over a period of 3-5 weeks. At each session, participants will practice a particular set of hand exercises. In this intervention, a variety of games, tasks, and movements will be used to improve grasping abilities. These exercises will be personalized according to each participant's interests, which will be identified through the Canadian Occupational Performance Measure and will be guided by study personnel.
88907511|NCT06307821|Experimental|Probiotics|5 billion CFU/day BC99 and protein powder; Storage: sealed, protected from light, placed in a cool and dry place.
88907512|NCT06307821|Placebo Comparator|placebo|Protein powder, 8 bags per day; Storage: sealed, protected from light, placed in a cool and dry place.
88907513|NCT06307808||Kidney transplant recipients, tacrolimus treated|Prevalent kidney transplant recipients, receiving tacrolimus as main immunosuppresant
89426659|NCT04446000|Experimental|CSL730 (dose 6 without premedication)|administered as a single dose by SC injection or by SC infusion
89426660|NCT04446000|Experimental|CSL730 (dose 7 without premedication)|administered as a single dose by SC injection or by SC infusion
89426661|NCT04446000|Placebo Comparator|Placebo|A solution matching the excipient profile of CSL730 without the active substance administered as a single dose by SC injection or by SC infusion
88907514|NCT06307808||Liver transplant recipients, tacrolimus treated|Prevalent liver transplant recipients, receiving tacrolimus as main immunosuppressant
88907515|NCT06307808||Kidney transplant recipients, belatacept treated|Prevalent kidney transplant recipients, receiving belatacept as main immunosuppressant
88907516|NCT06307795|Experimental|ANS014004 Monotherapy|"Part 1 aims to determine the safety, tolerability, maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of ANS014004.~Part 2 aims to determine the safety, tolerability and evaluate anti-tumor activity of ANS014004 as monotherapy in select solid tumors."
88907517|NCT06307782|Experimental|Total Hip Arthroplasty, whey protein intake,|"In the ERAS (Enhanced Recovery After Surgery) protocol, preoperative oral carbohydrate intake must be at least 45 g. While preparing the whey mixture, 60 grams of whey powder will be mixed into 600ml bottled water to obtain a mixture worth 200 kcal. Whey will be prepared and given by the researcher at the bedside in room air using bottled water.~In this study, by scanning the literature (13) and taking expert opinion (dietitian, anesthesiologist, orthopedic doctor), the individuals in the intervention group were given 6 hours after the surgery. It is planned to drink 600ml oral whey powder water first."
88907518|NCT06307782|Active Comparator|Total Hip Arthroplasty, water intake|600ml of water will be given 6 hours before the surgery.
88907519|NCT06307769||Geriatric Group|balance assessment
88907520|NCT06307769||Control Group|balance assessment
88907521|NCT06307756|Experimental|Music group|"Mothers will be informed about the application before the procedure. Mothers who agree to participate in the study will be asked to listen to music that relaxes them for 20 minutes a day for 4 days. The mothers' state anxiety levels and milk quantities will be evaluated before starting the application and every day during the application. Mothers' anxiety levels will be evaluated with the State Anxiety Inventory. Mothers' anxiety levels and milk quantities will be evaluated every day at 11.45 when they come to the NICU to express milk."
88907522|NCT06307756|No Intervention|Control group|"After mothers are informed about the study, mothers who agree to participate in the study will be included in the control group by randomization method. No intervention will be made to mothers in the control group. The mothers' state anxiety levels and milk quantities will be evaluated at the first meeting with the mothers and every day for four days. Mothers' anxiety levels will be evaluated with the State Anxiety Inventory. Mothers' anxiety levels and milk quantities will be evaluated every day at 11.45 when they come to the NICU to express milk."
88907523|NCT06307743|Other|RL-IPostC 30|The RL-IPostC 30 protocol involved 5 cycles of blow block and restoration, each for 30 seconds.
88907524|NCT06307743|Other|RL-IPostC 60|The RL-IPostC 60 protocol involved 5 cycles of blow block and restoration, each for 60 seconds.
88907525|NCT06307743|Other|RL-IPostC 180|The RL-IPostC 180 protocol involved 5 cycles of blow block and restoration, each for 180 seconds.
88907526|NCT06307717||volatile anaesthetic (sevoflurane, isoflurane, desflurane）|Patients receiving volatile anaesthetics received at least one volatile anaesthetic (sevoflurane, isoflurane, desflurane), and those who received non-volatile anaesthetics did not receive any volatile anaesthetic.
89536808|NCT05160077|Other|Standardised Breakfast|"Preprandial examination is in fasting state, all postprandial examinations will be conducted with standardized dietary.~30 minutes after the beginning of the preprandial examination participants receive an standardized breakfast. 270 minutes after the beginning of the preprandial examination participants receive an standardised meal."
88907527|NCT06307717||control|Patients receiving volatile anaesthetics received at least one volatile anaesthetic (sevoflurane, isoflurane, desflurane), and those who received non-volatile anaesthetics did not receive any volatile anaesthetic.
88907528|NCT06307691|Active Comparator|Control: conventional drilling|Atraumatic extraction followed by osteotomy preparation. Osteotomy site will be prepared using conventional drills. Implant placement will follow.
88907529|NCT06307691|Active Comparator|Intervention: Osseodensification|Atraumatic extraction followed by osteotomy preparation. Osteotomy site will be prepared using Densah bur. Implant placement will follow.
88907530|NCT06307678|Experimental|calcium silicate based medicament|"Root canal lengths were determined by an electronic apex locator with a 15-K file R25 and R50 Reciproc files were used at working lengths to complete the canal preparation. During instrumentation, the root canals were irrigated with 2 mL 1% NaOCl. To obtain the first samples, 3 sterile paper points were placed into the root canals beyond the 2-mm root apex and were kept in position for 60 seconds. Thereafter, the paper points were cut 4 mm from the tip30.~Afterward, root canals were dried with paper points, and calcium silicate based medicament was placed in the canals using a file at a distance of 1 or 2 mm less than the root canal length. Next, the coronal cavities were restored with temporary material.~Seven days later, the medication was mechanically removed using a master apical file. Subsequently, root canals were irrigated.The final samples were collected from the interstitial fluid of the apical tissue as previously described."
88907531|NCT06307678|Active Comparator|calcium hydroxide based medicament|"Root canal lengths were determined by an electronic apex locator with a 15-K file R25 and R50 Reciproc files were used at working lengths to complete the canal preparation. During instrumentation, the root canals were irrigated with 2 mL 1% NaOCl. To obtain the first samples, 3 sterile paper points were placed into the root canals beyond the 2-mm root apex and were kept in position for 60 seconds. Thereafter, the paper points were cut 4 mm from the tip30.~Afterward, root canals were dried with paper points, and calcium hydroxide based medicament was placed in the canals using a file at a distance of 1 or 2 mm less than the root canal length. Next, the coronal cavities were restored with temporary material.~Seven days later, the medication was mechanically removed using a master apical file. Subsequently, root canals were irrigated.The final samples were collected from the interstitial fluid of the apical tissue as previously described."
88907532|NCT06307665|Experimental|Budesonide/albuterol metered -dose inhaler (BDA MDI)|Participants will receive BDA MDI 160/180 μg (given as 2 puffs of 80/90 μg) as needed.
88907533|NCT06307665|Active Comparator|Albuterol sulfate metered-dose inhaler (AS MDI)|Participants will receive AS MDI 180 μg (given as 2 puffs of 90 μg) as needed.
88907534|NCT06307652|Experimental|balcinrenone/dapagliflozin 15 mg/10 mg|Patients will be randomized 1:1:1 to either combination of balcinrenone/dapagliflozin and matching placebo for dapagliflozin or dapagliflozin and matching placebo for balcinrenone/dapagliflozin
89196487|NCT00624819|Active Comparator|Prevenar + Infanrix + Havrix and/or Varilrix Group|This group consisted of subjects vaccinated with Prevenar vaccine in the 10PN-PD-DIT-001 (105553) and 007 (107046) studies. In 105553 study, subjects had been primed with 3 doses of Prevenar vaccine at 2, 3 and 4 months of age co-administered with Infanrix related vaccines. In 107046 study, subjects had received a booster dose at 12-18 months of age of Prevenar vaccine co-administered with Infanrix hexa vaccine. In this study, in the Year 4 111347 study, subjects had received at Month 48 (4 years post Dose 1 in study 105553) one dose of Synflorix vaccine. In addition, subjects were also offered vaccination against hepatitis A (2 doses of Havrix and/or against varicella (a single dose of Varilrix).
89196488|NCT00624819|Experimental|Prevenar + Synflorix + Infanrix + Havrix and/or Varilrix|This group consisted of subjects vaccinated with Prevenar and Synflorix vaccines in the 10PN-PD-DIT-001 (105553) and 10PN-PD-DIT-007 (107046) studies. In 105553 study, subjects had been primed with 3 doses Prevenar vaccine at 2, 3 and 4 months of age co-administered with Infanrix related vaccines. In the 107046 study, subjects had received at 12-18 months of age a booster dose of Synflorix vaccine co-administered with Infanrix hexa vaccine. In this study, in the Year 4 (111347 study), subjects had received at Month 48 (4 years post Dose 1 in study 105553) one additional dose of Synflorix vaccine. In addition, subjects were also offered vaccination against hepatitis A (2 doses of Havrix and/or against varicella (a single dose of Varilrix).
89196489|NCT00624819|Experimental|Unprimed Group|"This group consisted of subjects between, and including, 64-68 months of age at the time of additional vaccination (primed subjects) or dose 1 (unprimed subjects), and for whom the investigator believed that their parents/guardians could and would comply with the requirements of the protocol. Subjects were not previously vaccinated with any pneumococcal vaccine and received 2 doses of Synflorix vaccine at 64-68 and 66-70 months of age (at Day 0 and Month 2).~The Unprimed Group was added only in Year 4 of the study."
89196490|NCT01046149|Experimental|Breathing training|Respiratory sinus arrhythmia biofeedback-assisted deep breathing training
89196491|NCT01046149|Active Comparator|Stress management|Cognitive reconstructive strategies for stress management
89196492|NCT01049425|Active Comparator|Epirubicin and Cyclophosphamid followed by Docetaxel|4 cycles of EC on day one every three weeks followed by 4 cycles of Docetaxel on day one every three weeks
89196493|NCT01049425|Experimental|Combination of Docetaxel and Cyclophosphamid|intravenous infusion on day one every three weeks
89196494|NCT03832387|Experimental|Non-invasive mechanical ventilation|"Non-invasive ventilation (NIV) was initiated with progressive levels of inspiratory positive airway pressure and expiratory positive airway pressure until a minimum inspiratory positive airway pressure of 10-15 cmH2O and an expiratory positive airway pressure of 5-6 cmH2O were achieved in the first hour. Continuous positive airway pressure (CPAP) was initiated with a initial positive end-expiratory pressure level was 5 cmH2O, with progressive increases up to 10-15 cmH2O.~The objective pressures were set to reduce dyspnoea and respiratory mechanics, with an respiratory rate between 25 and 28 bpm. NIV/CPAP were maintained continuously (except for hygiene or oral intake) until the patient exhibited improvement from the clinical and/or gasometric perspective."
89196495|NCT03832387|Active Comparator|Venturi mask|"For oxygen therapy were used both a Venturi mask with an fraction of inspired oxygen up to 0.5 (15 L/min) and a reservoir mask connected to a high-flow flowmeter with 30 L/min of O2.~The objective oxygen therapy was to reduce dyspnoea and respiratory mechanics, with an respiratory rate between 25 and 28 bpm. Oxygen therapy was maintained continuously (except for hygiene or oral intake) until the patient exhibited improvement from the clinical and/or gasometric perspective."
89196496|NCT00838227|Experimental|One arm|Study withdrawn due to lack of funds.
89196497|NCT00827619|Other|1|single arm non-randomized post-market study
89196498|NCT04043559||patients with an acute symptomatic infarction|
89196499|NCT04043559||controls with cryptogenic stroke|
89196500|NCT00366301|Placebo Comparator|Placebo pill|Placebo pill
89196501|NCT00366301|Active Comparator|Metformin Pill|Metformin pill
89196502|NCT00366301|Active Comparator|Insulin Glargine plus placebo pill|Insulin glargine plus placebo pill
89196503|NCT00366301|Active Comparator|Insulin Glargine plus metformin pill|Insulin Glargine plus metformin pill
89196504|NCT00831207||G1|15 HIV-1+ individuals, previously untreated or without HAART for at least six months and CD4+ < 350 cells/mm3.
89196505|NCT00831207||G2|31 HIV-1+ individuals undergoing HAART without virological therapeutic failure (TF).
89196506|NCT00831207||G3|43 HIV-1+ individuals undergoing HAART with TF.
89196507|NCT00831207||G4|20 normal individuals who served as controls for serum cytokines.
89196508|NCT00831285|Experimental|tortilla with high amylose flour|
89196509|NCT00831285|Experimental|barley tortilla with low amylose flour|
89196510|NCT00831285|Experimental|barley tortilla with low amylose flour and soluble fibre|
89196511|NCT00831285|Experimental|barley tortilla with low amylose flour and insoluble fibre|
89196512|NCT00831285|Active Comparator|glucose|
89196513|NCT00831285|Experimental|barley tortilla with low amylose flour and low soluble fibre|
89426662|NCT04431869||Mothers that contract SARS-CoV-2 during pregnancy|"To evaluate evidence for in-utero vascular accidents that may manifest as intestinal atresias and limb abnormalities in the first 30 days of life as well as rates of preterm labor, fetal growth restriction and spontaneous abortions in pregnant females that contract the SARS-CoV-2 virus during gestation.~A multidisciplinary approach in conjunction with maternal fetal medicine (MFM), neonatology, and pathology will identify, and recruit infants whom were exposed to COVID-19 while in-utereo. This project will run in parallel with the institution's COVID-19 in Pregnancy Biobank that intends to obtain needed epidemiological and clinical data linked to biosamples to provide insight into SARS-CoV-2 in pregnant women and their infants. This study will request access to enrolled women infected during gestation and their neonates to assess for the conditions suggestive of in-utero vascular accidents such as intestinal atresias or limb anomalies."
89426663|NCT04431869||Infants noted to have intestinal atresias or limb anomalies|"To evaluate children identified in the neonatal intensive care unit (NICU) as having evidence of intestinal atresias or limb anomalies for potential asymptomatic carriers of COVID-19 that could have contracted the disease during the pregnancy.~Mothers of children identified will undergo SARS-CoV-2 antibody testing to identify the possibility of asymptomatic carriers which may have occurred during the pregnancy."
89426664|NCT04429087|Experimental|Arm 1: BI 764532|
89426665|NCT04429087|Experimental|Arm 2: BI 764532|
89426666|NCT04427826|Experimental|Patient admitted for acute Exacerbation of Chronic Obstructive|Patient admitted for acute Exacerbation of Chronic Obstructive Pulmonary Disease (COPD) and required NIV
89426667|NCT04424511|Placebo Comparator|Control|"Placebo mixture will be administered as a single dose in oral suspension form for children 1-11 months of age:~Single-dose of 0.5 ml / kg child weight~Participating households within villages allocated to this group will be visited quarterly (at 3-month intervals), for nine times. At the first eight of these visits, 1-11 month old eligible infants, for whom there is a consent for study drug provision, will be weighed and given a single dose of placebo mixture."
88907535|NCT06307652|Experimental|balcinrenone/dapagliflozin 40 mg/10 mg|Patients will be randomized 1:1:1 to either combination of balcinrenone/dapagliflozin and matching placebo for dapagliflozin or dapagliflozin and matching placebo for balcinrenone/dapagliflozin
88907536|NCT06307652|Active Comparator|dapagliflozin 10 mg|Patients will be randomized 1:1:1 to either combination of balcinrenone/dapagliflozin and matching placebo for dapagliflozin or dapagliflozin and matching placebo for balcinrenone/dapagliflozin
88907537|NCT06307626|Experimental|Efgartigimod arm|Participants with active, moderate-to-severe TED receiving Efgartigimod PH20 SC (subcutaneously) via pre-filled syringe (PFS)
88907538|NCT06307626|Placebo Comparator|Placebo arm|Participants with active, moderate-to-severe TED receiving Placebo PH20 SC (subcutaneously) via pre-filled syringe (PFS)
88907539|NCT06307613|Experimental|Efgartigimod arm|Participants with active, moderate-to-severe TED receiving Efgartigimod PH20 SC (subcutaneously) via pre-filled syringe (PFS)
88907540|NCT06307613|Placebo Comparator|Placebo arm|Participants with active, moderate-to-severe TED receiving Placebo PH20 SC (subcutaneously) via pre-filled syringe (PFS)
88907541|NCT06307600|Experimental|RD06-03 cell infusion|The enrolled patients will use 1 dose RD06-03 CART cell injection
88907542|NCT06307587|Active Comparator|DN group|
88907543|NCT06307587|No Intervention|Control group|
88907544|NCT06307574|Experimental|MedManage-S|Intervention group will use a smartphone application with medication reminders plus receive education with standardized information on hypertension and antihypertensive medications on the education portal. They will complete immediate outcomes assessment 4 weeks after the beginning of the intervention and follow-up outcomes 12 weeks after the beginning of intervention.
88907545|NCT06307574|Active Comparator|MedManage-P|Participants in the MedManage-P group will use a smartphone to receive education with standardized information on hypertension and antihypertensive medications on the education portal. They will complete immediate outcomes assessment 4 weeks after the beginning of the intervention and follow-up outcomes 12 weeks after the beginning of intervention.
88907546|NCT06307535|Experimental|Meaning-Centered Psychotherapy for Caregivers|Meaning-Centered Psychotherapy for Caregivers/MCP-C
88907547|NCT06307535|Active Comparator|Supportive Psychotherapy for Caregivers|Supportive Psychotherapy for Caregivers/SP-C standard of care
88907548|NCT06307522|Experimental|MRG-001 (0.005 mL/kg)|Lowest dose of dose-escalation arm
88907549|NCT06307522|Experimental|MRG-001 (0.007 mL/kg)|Intermediate dose of dose-escalation arm
88907550|NCT06307522|Experimental|MRG-001 (0.01 mL/kg)|High dose of dose-escalation arm
89196514|NCT00838305|Placebo Comparator|Placebo|drug: placebo subjects also get citalopram and placebo in a 2x2 crossover design
89426668|NCT04424511|Active Comparator|Azithromycin-biannually (Azi-biannual)|"Azithromycin or placebo will be administered as a single dose in oral suspension form for children 1-11 months of age:~Single-dose of 0.5 ml / kg child weight~Participating households within villages allocated to this group will be visited quarterly (at 3-month intervals), for nine times. At the first eight of these visits, 1-11 month old eligible infants, for whom there is a consent for study drug provision, will be weighed and given a single dose of study drug.~Azithromycin will be given at quarterly visits between January and June, and Placebo mixture will be given at quarterly visits between July and December. Azithromycin dose will be 20 mg / kg."
89426669|NCT04424511|Active Comparator|Azithromycin-quarterly|"Azithromycin will be administered as a single dose in oral suspension form for children 1-11 months of age:~Single-dose of 0.5 ml (20 mg) / kg child weight.~Participating households within villages allocated to this group will be visited quarterly (at 3-month intervals), for nine times. At the first eight of these visits, 1-11 month old eligible infants, for whom there is a consent for study drug provision, will be weighed and given a single dose of azithromycin."
89426670|NCT04412486|Experimental|Recipient of COVID-19 Convalescent Plasma (CCP) Transfusion|Transfusion of COVID-19 convalescent plasma to participants with serious or life threatening complications from COVID-19 or are at high risk to develop serious complications.
89426671|NCT04409093|Experimental|Nail bed repair with eponychial sent|
89426672|NCT04409093|Active Comparator|Nail bed repair without eponychial stent|
89426673|NCT04408521|Experimental|NEUROFEEDBACK|Participants undergo individual at home sessions of 45-minute video-replay of popular TV series while recording their 1-channel EEG using a portable system. Self-regulation of alpha rhythm is reflected in the dynamically varying opacity of the video replay window, i.e. the window would turn lighter/darker and reveal/obscure video content during episodes of low/high alpha amplitude, respectively.
89426674|NCT04408521|Placebo Comparator|CONTROL|Participants undergo individual at home sessions of 45-minute video-replay of popular TV series while recording their 1-channel EEG using a portable system. The recording is passive without real-time EEG neurofeedback (i.e. constant brightness and volume).
89426675|NCT04403295|Experimental|collaborative specialty care|In specialty collaborative care, the specialty provider team will deliver health coaching and problem-solving treatment to GWVs and recommend the primary care team make monthly optimization of analgesics.
89426676|NCT04403295|Active Comparator|e-consultation|In e-consultation the specialty provider team will make a onetime recommendation to the primary care team that the GWV locally receive health coaching and problem-solving treatment and analgesic optimization.
89426677|NCT04393259||Participants|Women attending an antenatal service using the Rainbow Clinic model of care.
89426678|NCT04388943||1|
88907551|NCT06307509||ICU patients with sepsis|Patients admitted to the Intensive Care Unit with a primary diagnosis of sepsis. They will have subcutaneous adipose tissue samples taken by needle aspiration, and blood samples taken.
88907552|NCT06307509||Surgical patients with sepsis|Patients undergoing emergency laparotomy with a diagnosis of sepsis will have subcutaneous and visceral adipose tissue samples taken intra-operatively, and blood samples taken.
88907553|NCT06306976|Other|Control Group 1|"Control group 1 patients will have no incisional hernia or prior laparotomy.~Imaging:~Ultrasound procedure will involve the following steps:~1. For control group 1 and group 2 patients, Images will be taken at two points"
88907554|NCT06306976|Other|Control Group 2|"Control group 2 patients will have no hernia and will be undergoing elective midline laparotomy.~Imaging:~Ultrasound procedure will involve the following steps:~1. For control group 1 and group 2 patients, Images will be taken at two points .~Hernia repair:~All study patients will have an open retromuscular repair with/without additional lateral~Tensiometry For all study patients, an analog spring-tensiometer will be used to assess intraoperative tension required to bring the fascia to the midline for closure."
88907555|NCT06306820|Active Comparator|Control group|Patients will receive a fixed positive end-expiratory pressure (PEEP) of 5 cmH2O.
88907556|NCT06306820|Experimental|Ultrasound group|Patients will receive ultrasound -guided lung recruitment.
88907557|NCT06306820|Experimental|PEEP IND group|Patients will receive individualized positive end-expiratory pressure (PEEP).
88907558|NCT06306677||Subjects presenting for care at Hospitals|The group is formed by subjects reporting for care at one of the four participating hospitals (China, Hong Kong SAR, Italy) who required an OPG radiographs for their routine clinical care.
88907559|NCT06306625|Experimental|Remote ischemic conditioning|A brachial cuff is positioned around one arm of the patient. Remote ischemic conditioning consists of alternating inflations and deflations of the brachial cuff. Four cycles of ischemic conditioning (5-min brachial cuff inflation at 200 millimetres of mercury (mmHg) followed by 5-min cuff deflation) are started as soon as possible after inclusion. The intervention is repeated 12 and 24 hours after inclusion.
89426679|NCT04364828|Other|Host Genome Analysis|For 150 patients from the extreme phenotypes - complementary to Whole Genome Analysis of each patient also Whole Transcriptome will performed Analysis; DNA methylation analysis using EPIC arrays will be performed in the pilot study (phase 1). Identically, in phase 2 starting from month 4, will be generated WGS, Whole transcriptome sequencing (WTS), and methylation data of the 500 patients. Epigenetic changes are likely to occur upon Corona infection. Subsequently, genome and epigenome data with RNA expression pattern will be correlated.
89426680|NCT04364828|Other|Host Response to SARS-CoV-2 Infection|Focus on longitudinal analysis of TCR repertoire of CD4+ and CD8+ T cells from blood samples (PBMCs) from clinically characterized patients (n = 24). The bulk- T-cell receptor (TCR) sequencing will be performed at different time points during the course of disease progression and recovery.
89536809|NCT05160077|Other|Standardised Breakfast and ICG|"Preprandial examination are in a fasting state, all postprandial examinations will be conducted with standardized dietary including indocyanine green (ICG) dye.~30 minutes after the beginning of the preprandial examination participants receive an standardised breakfast containing ICG. 270 minutes after the beginning of the preprandial examination participants receive an standardised meal without ICG."
89536810|NCT03313739|Experimental|Intervention group|An Educational Program
89536811|NCT03313739|No Intervention|Control group|This group(n=30) received no intervention.
88907560|NCT06306625|Other|Control group|A brachial cuff is positioned around one arm of the patient. Neither inflation nor deflation is performed.
88907561|NCT06305676||Case Group|Case group will consist of early and late disease pre-treatment Oropharyngeal Cancer cases.
89426681|NCT04364828|Other|Viral Sequence Composition|The Severe Acute Respiratory Syndrome-Corona Virus-2 (SARS-CoV-2) viral composition is determined by Next Generation sequencing (different protocols for enrichment are available, and are currently being tested to successfully analyse the virus from different isolates). It is known that SARS-CoV-2 sequence is changing at least one position every second passing from person to person. Numerous variants have been described deriving from 3 different ancestral viruses (named A, B, and C) reflecting different distributions in East Asia, Europeans and Americans. At it is anticipated that other (super)infections may add to the severity of the infection and disease course, the entire metagenome of the throat is being sequenced and analyzed as well.
89426682|NCT04354623||High Risk Subjects (n=50)|All subjects will be recruited from falls and geriatrics clinics at Vancouver General Hospital. These clinics see about 2500 patients per year and are currently used for research recruitment. Each clinic patient has gait speed measured, which will allow to recruit both high and low risk fallers. This test will allow us to recruit 50 subjects at marked risk for falls, providing us with prospectively gathered dataset of greater than 100 events, five times higher than any other sensor study.
89426683|NCT04354623||Low Risk Subjects (n=50)|We will use newspaper advertisements to recruit and then screen low risk subjects. All subjects will have a gait speed > 0.8 m/s and have had no falls in the last year.
89426684|NCT04353869||Group 1|"Patients with uncomplicated diabetes and low cardiovascular risk~During a scheduled hospitalization or consultation as part of the follow-up of their diabetes additions of biological samples, which include:~A unique venous blood sampling of 9 tubes: 4 x 7 mL EDTA (Éthylènediaminetétraacétique) tubes + 3 x 5 mL EDTA tubes + 2 x 4 mL no additive tubes (total: 51 mL) at a single time during the study and collection of 2 monovettes of 1.6 ml urine (total: 3.2 mL)."
89426685|NCT04353869||Group 2|"Patients with uncomplicated diabetes and high cardiovascular risk~During a scheduled hospitalization or consultation as part of the follow-up of their diabetes additions of biological samples, which include:~A unique venous blood sampling of 9 tubes: 4 x 7 mL EDTA tubes + 3 x 5 mL EDTA tubes + 2 x 4 mL no additive tubes (total: 51 mL) at a single time during the study and collection of 2 monovettes of 1.6 ml urine (total: 3.2 mL)."
89426686|NCT04353869||Group 3|"Patients with complicated diabetes~During a scheduled hospitalization or consultation as part of the follow-up of their diabetes additions of biological samples, which include:~A unique venous blood sampling of 9 tubes: 4 x 7 mL EDTA tubes + 3 x 5 mL EDTA tubes + 2 x 4 mL no additive tubes (total: 51 mL) at a single time during the study and collection of 2 monovettes of 1.6 ml urine (total: 3.2 mL)."
88907562|NCT06305676||Control Group|Controls will be enrolled from members of the catchment area to ensure geographic comparability of cases and controls. Controls will be matched by sex, age, race/ethnicity, and tobacco use.
88907563|NCT06305546|Experimental|group A|
88907564|NCT06305546|Experimental|GROUP B|
88907565|NCT06305546|Experimental|GROUP C|
88907566|NCT06305546|Placebo Comparator|GROUP D|
88907567|NCT06305507||Focussed therapy|laser application in focussed mode
88907568|NCT06305507||Shower laser application|laser application in shower or sweep mode
88907569|NCT06305442|Experimental|Microbiota Directed Food (MDF)|Each participant will receive 12 weeks of MDF supplement. After finishing the intervention phase, he/she will be followed-up for a 12-week period.
88907570|NCT06305442|Active Comparator|Ready-to-Use Supplementary Food (RUSF)|Each participant will receive 12 weeks of RUSF supplement. After finishing the intervention phase, he/she will be followed-up for a 12-week period.
88907571|NCT06305429|Experimental|Feasibility testing of an education program promoting effective parenting habit|Parents will receive a series of 6 short videos via Whatsapp
88907572|NCT06305416|Experimental|Ranibizumab 10mg/ml Injection (Proposed Ranibizumab Biosimilar)|Test Group of 35 adult patient with DME will get Ranibizumab (Proposed Ranibizumab Biosimilar)
88907573|NCT06305416|Active Comparator|Lucentis (Ranibizumab)|Comparator Group of 35 adult patient with DME will get Lucentis
88907574|NCT06305351|Experimental|K-757 and K-833 combination|
88907575|NCT06305351|Placebo Comparator|Placebo|
89426687|NCT04332029|Experimental|CBT + WGP + CM|The experimental intervention includes three components: 1) Cognitive Behavioral Treatment (CBT) for gradual smoking cessation; 2) Weight Gain Prevention module (WGP) and; 3) Contingency Management (CM) procedure reinforcing tobacco abstinence.
89426688|NCT04332029|Active Comparator|CBT + WGP|The active comparator will include only the first two components of the experimental intervention: 1) Cognitive Behavioral Treatment (CBT) for gradual smoking cessation and 2) Weight Gain Prevention module (WGP).
89426689|NCT04325334|Experimental|Running volume increase|Participants will be be given a running program based on their running mileage on inclusion and supported by regular contacts with the study trainer.
89426690|NCT04322929|Experimental|Oral roflumilast|Oral roflumilast 250 microgram daily will be started at the baseline visit for 4 weeks. For those who can tolerate the initial 4-week treatment, roflumilast will be increased to 500 microgram daily, allowing subsequent dose reduction back to 250 microgram daily in case of CTCAE grade 3 or 4 toxicities.
89426691|NCT04322864|Active Comparator|In-person supervised intervention|
89426692|NCT04322864|Experimental|Web-based instrument intervention|
88820419|NCT06178640|Experimental|Simvastatin 40 mg, Then ZOCOR 40 mg|Participants first received Simvastatin 40 mg film-coated tablet 1 tablet (Test product) in a fasting state. After a washout period of 1 week, they then recieved ZOCOR 40 mg film-coated tablet (Reference product) in a fasting state
89196515|NCT00838305|Experimental|mdma|drug: mdma subjects also get citalopram and placebo in a 2x2 crossover design
89426693|NCT04318977|Experimental|high-frequency repetitive transcranial magnetic stimulation|repetitive transcranial magnetic stimulation over left dorsolateral prefrontal cortex using 3000 pulses applied with 10Hz and 120% resting motor threshold
89426694|NCT04318977|Experimental|theta burst stimulation|intermittent theta burst stimulation over left dorsolateral prefrontal cortex using 600 pulses applied in trains of 10 triplets/bursts (50Hz) with 8s intertrain-interval and 120% resting motor threshold
89426695|NCT04318977|Placebo Comparator|sham rTMS|half of the patients with high-frequency repetitive transcranial magnetic stimulation and half of the patients with theta burst Stimulation with angled coil (45 degree) or sham coil
89426696|NCT04315948|Experimental|Remdesivir|"Remdesivir will be administered as a 200 mg intravenous loading dose on Day 1, followed by a 100 mg once-daily intravenous maintenance dose for the duration of the hospitalization up to a 10 days total course.~n=475"
89426697|NCT04315948|Experimental|Lopinavir/ritonavir (stopped on June 29, 2020)|"Lopinavir/ritonavir (400 lopinavir mg/100 mg ritonavir) will be administered every 12 h for 14 days in tablet form. For patients who are unable to take medications by mouth, the lopinavir/ritonavir (400 lopinavir mg/100 mg ritonavir) will be administered as a 5-ml suspension every 12 h for 14 days via a pre-existing or newly placed nasogastric tube.~n=620"
89426698|NCT04315948|Experimental|Lopinavir/ritonavir plus Interferon ß-1a (stopped on June 29)|"Lopinavir/ritonavir (400 lopinavir mg/100 mg ritonavir) will be administered every 12 h for 14 days in tablet form. For patients who are unable to take medications by mouth, the lopinavir/ritonavir (400 lopinavir mg/100 mg ritonavir) will be administered as a 5-ml suspension every 12 h for 14 days via a pre-existing or newly placed nasogastric tube.~Interferon ß1a will be administered subcutaneously at the dose of 44 µg for a total of 3 doses in 6 days (day 1, day 3, day 6).~n=620"
89426699|NCT04315948|Experimental|Hydroxychloroquine (stopped on May 24, 2020)|Hydroxychloroquine will be administered orally as a loading dose of 400 mg twice daily for one day followed by 400 mg once daily for 9 days. The loading dose of hydroxychloroquine through a nasogastric tube will be increased to 600 mg twice a day for one day, followed by a maintenance dose of 400 mg once a day for 9 days n=620
89426700|NCT04315948|Active Comparator|Standard of care alone|Standard of care alone before March, 2021.
89426701|NCT04315948|Experimental|AZD7442|"Participants randomized to the AZD7442 group will receive a total dose of 600 mg AZD7442 via a co-administered (300 mg AZD8895 and 300 mg AZD1061) single IV infusion on Day 1.~n=620"
89426702|NCT04315948|Active Comparator|Standard of care with placebo|Standard of care with placebo since April, 2021 n=620
89426703|NCT04315727|Other|Study population|"Both underage and adult persons (male and female) with diagnostically unsolved rare diseases who have been or are included into diagnostic care at the University Hospital Tübingen, Germany (UKT) and who are suspected of having a genetic cause of the disease. In addition, healthy parents of volunteers will be recruited if available to facilitate Trio studies.~Study related procedures: Blood sampling, hair collection, anamnesis including pedigree, Next Generation Sequencing (NGS) analysis and other omics analysis (transcriptomics, proteomics, metabolomics), functional cell biology studies (for example in fibroblast cultures, organoid cultivation)."
89426704|NCT04310059|Active Comparator|Folic acid 5mg|
89426705|NCT04310059|Active Comparator|Folic acid 0.5mg|
89426706|NCT04310059|Active Comparator|Materna|
89426707|NCT04304235|Active Comparator|Control|Hospital nurses will triage participants using the Emergency Triage and Treatment (ETAT) guidelines, the triage policy that is currently in place at the study hospital sites.
89426708|NCT04304235|Experimental|Intervention|Hospital nurses will triage participants using the digital triage tool (mhealth intervention).
89426709|NCT04302870|Experimental|Memantine|
89426710|NCT04302870|Experimental|Trazodone|
89426711|NCT04302870|Placebo Comparator|Placebo|
89426712|NCT04302870|Experimental|Amantadine|
89426713|NCT04294849|Experimental|Venous Thromboembolism Arm|This will be a cohort of patients age 8- ≤ 21 years old with objectively diagnosed DVT and/or PE.
88907576|NCT06305325|No Intervention|Control Group|control group received the standard care. It included antenatal classes offered at the CC clinic, which comprised of four face-to-face sessions in clinic. These classes focus on pregnancy and postpartum care including baby growth in each trimester, minor discomforts, diet, exercise, personal hygiene, complications during pregnancy, labour and delivery stages, breastfeeding, care of newborn baby, and family planning methods. The 2-3 hour long face-to-face classes are offered every week on Saturdays in the clinic
89426714|NCT04293874|Experimental|Low Omega-3LC group|Participants will consume a personalized meal plan for 2 weeks and consume an increased quantity of fish to 6 oz. wild salmon (1 steak, 6oz /steak)or 14.3 oz. (5.5 packs, 2.6 oz/pack) of chunk light tuna (1020 mg Omega-3LC/week) for 6 weeks.
89426715|NCT04293874|Experimental|High Omega-3LC group|Participants will consume a personalized meal plan for 2 weeks and consume an increased quantity of fish to 12 oz. wild salmon (2 steak,12 oz /steak)or 28.6 oz. (11 packs, 2.6 oz/pack) of chunk light tuna (2040 mg Omega-3LC/week) for 6 weeks.
89426716|NCT04290429|Experimental|SR-GI-GVHD|Analysis of patient's stool frequency, albumin serum levels and quantification of Paneth cell numbers in GI biopsies before and during teduglutide treatment.
89426717|NCT04289662|Experimental|K-924 LD|K-924 LD once daily
89426718|NCT04289662|Experimental|K-924 HD|K-924 HD once daily
89426719|NCT04289649|Experimental|K-924 LD|K-924 LD tablet once daily
89426720|NCT04289649|Experimental|K-924 HD|K-924 HD tablet once daily
89426721|NCT04289649|Active Comparator|Pitavastatin 2 mg|K-924 LD Placebo tablet once daily
89426722|NCT04289649|Active Comparator|Pitavastatin 4 mg|K-924 HD Placebo tablet once daily
89426723|NCT04281784|Experimental|EHR-based Clinician Jumpstart|The EHR-based Jumpstart Guide will be developed by extracting data from the EHR using automated methods with both inpatient and outpatient notes (e.g., progress notes, specialty consult notes, alerts and care plans) preceding the current hospitalization. It will summarize the presence/absence of POLST, advance directives and DPOA documentation and patients' code status.
89426724|NCT04281784|No Intervention|Usual Care|The clinicians (hospital teams) for patients in the control group will not receive Jumpstart guides. These subjects will receive usual care.
89426725|NCT04280692|Experimental|Group 1: PfSPZ 6,400|"Group 1 will receive a malaria infection by direct venous inoculation (DVI) with PfSPZ Challenge at a dose of 6,400 sporozoites.~Group 1 will be randomised (1:1) to receive either sub-curative Sulfadoxine-Pyrimethamine (SP) (500mg/25mg) or Piperaquine (PIP) (480mg).~Group 1 will receive a final curative treatment of Artemether-Lumefantrine (AL) with single low dose Primaquine (SLDPQ)"
89536812|NCT03309527|Experimental|e-aid Cognitive Behavior Therapy|Participants receive e-aid cognitive behavior therapy. Every week, this group will receive researcher guided individual customized sleep restriction and stimulus control therapy.
89426726|NCT04280692|Experimental|Group 1: PfSPZ 12,800|"Group 2 will receive a malaria infection by direct venous inoculation (DVI) with PfSPZ Challenge at a dose of 12,800 sporozoites~Group 2 will be randomised (1:1) to receive either sub-curative Sulfadoxine-Pyrimethamine (SP) (500mg/25mg) or Piperaquine (PIP) (480mg).~Group 2 will receive a final curative treatment of Artemether-Lumefantrine (AL) with single low dose Primaquine (SLDPQ)"
89426727|NCT04280692|Experimental|Group 3: PfSPZ 25,600|"Group 3 will receive a malaria infection by direct venous inoculation (DVI) with PfSPZ Challenge at a dose of 25,600 sporozoites~Group 3 will be randomised (1:1) to receive either sub-curative Sulfadoxine-Pyrimethamine (SP) (500mg/25mg) or Piperaquine (PIP) (480mg).~Group 3 will receive a final curative treatment of Artemether-Lumefantrine (AL) with single low dose Primaquine (SLDPQ)"
89426728|NCT04279262||Anonymised records from 6 ambulance services|The total available sample for analysis for this cohort is estimated to be at least 50,000 incidents across 6 ambulance trusts. The investigators will describe the epidemiology of CFR provision to rural health areas using an anonymised dataset.
89426729|NCT04279262||Interviews with patients (and/or relatives)|The investigators will interview about 15-20 patients (and/or relatives) who have been attended by CFRs.
89426730|NCT04279262||Interviews with CFRs|The investigators will interview about 15-20 CFRs/ CFR scheme leaders.
89426731|NCT04279262||Interviews with Ambulance staff|The investigators will interview about 15-20 ambulance staff who have experience of working with CFRs.
89426732|NCT04279262||Interviews with GPs and commisioners|The investigators will interview about 10-15 GPs and ambulance service commissioners.
89426733|NCT04276857|Other|Single arm study|All eligible patients will receive combination chemotherapy and if there i s a positive response they will undergo IRE.
89426734|NCT04273490||Hereditary hypophosphatemia|Adult persons with genetically or biochemically verified hereditary hypophosphatemia.
89426735|NCT04273490||Control|Adult control persons without disturbances in calcium, vitamin D or phosphate homeostasis matched on age, gender and menopausal status.
89426736|NCT04270617|No Intervention|Control arm|The control arm will involve usual care - 6 weeks of physical therapy, NSAIDs, and epidural steroid injections
89426737|NCT04270617|Experimental|Yoga Arm|The study arm will involve a yoga protocol devised by Eddie Stern - a renowned Ashtanga yoga practitioner, and can include NSAIDs.
89426738|NCT04268277|Experimental|Rituximab & Pembrolizumab|"Cycle 1 (21 days cycle):~Rituximab: 375 mg/m2 day 1, 8, 15 Pembrolizumab: 200 mg IV fixed dose day 2~Cycle 2-18 (21 days cycle) or until progression or non-tolerable toxicity:~Rituximab: 375 mg/m2 day 1 every second cycle Pembrolizumab: 200 mg IV fixed dose day 1"
89426739|NCT04263558|Active Comparator|LHF|Long intervention (16 sessions) High parental involvement (5 sessions) Feedback
89196516|NCT00365989|Experimental|ExAblate Enhanced Sonication Test Arm|The intervention to be administered is ExAblate Enhanced Sonication. The purpose of this study is to examine the safety profile of the ExAblate Enhanced Sonication mode to insure that no new safety issues are introduced compared to the normal focused ultrasound mode.
88907577|NCT06305325|Experimental|eHealth antenatal Coparenting Intervention|This intervention focuses on developing conflict management, problem solving, communication, and mutual support to foster positive joint parenting of an infant. A modification in the delivery of this intervention was made in the current study in order to make it deliver online. The eACoP intervention included eight antenatal videos from Feinberg's Family Foundation intervention. A website for the eACoP intervention was developed, and all the videos were uploaded to the website. These videos were 30-40 minutes each. The videos were in English and subtitles in Urdu were added to the videos. These videos were accompanied by an activity-based coparenting workbook. The coparenting workbook includes a worksheet and homework for each video and was also translated into Urdu
88907578|NCT06305312|Active Comparator|Usual Care|
88907579|NCT06305312|Experimental|Intervention|
88907580|NCT06305299|Experimental|Chimeric Antigen Receptors|blood will be collected to prepare the iC9-CAR.B7-H3 T cells. Disease-fighting T cells will be isolated and modified to prepare the iC9-CAR.B7-H3 T cells. In part 2, the iC9-CAR.B7-H3 T cells are given by infusion after completion of lymphodepletion chemotherapy.
88907581|NCT06305221|Experimental|Opioid-free group|
88907582|NCT06305221|Active Comparator|Opioid group|
88907583|NCT06305169||Referrals to endoscopy via the 2 week wait cancer pathway for all indications other than dysphagia|This group will have their serum biomarkers measured by gastropanel a commercially available blood test, along with full blood count and complete a questionnaire.
89426740|NCT04263558|Active Comparator|LHN|Long intervention (16 sessions) High parental involvement (5 sessions)
89426741|NCT04263558|Active Comparator|LLF|Long intervention (16 sessions) Low parental involvement (Brochure) Feedback
89426742|NCT04263558|Active Comparator|LLN|Long intervention (16 sessions) Low parental involvement (Brochure)
89007710|NCT02883062|Experimental|Arm B (atezolizumab, carboplatin, paclitaxel, breast surgery)|Patients receive atezolizumab IV over 30-60 minutes and carboplatin IV over 30 minutes Q3W, and paclitaxel IV over 1 hour QW. Treatment repeats every 3 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo the collection of blood samples throughout the trial.
89007711|NCT02855476||Early Pre-manifest HD|"Participants eligible are persons who meet the following criteria:~Are 18-75 years of age, inclusive, at the time of consent; and~Do not have clinical diagnostic motor features of HD, defined as Unified Huntington's Disease Rating Scale (UHDRS) Diagnostic Confidence Score < 4; and~Have CAG expansion ≥ 40; and~Have burden of pathology score, computed as (CAG - 35.5) × age, < 250"
89007712|NCT02855476||Late Pre-manifest HD|"Participants eligible are persons who meet the following criteria:~Are 18-75 years of age, inclusive, at the time of consent; and~Do not have clinical diagnostic motor features of HD, defined as Unified Huntington's Disease Rating Scale (UHDRS) Diagnostic Confidence Score < 4; and~Have CAG expansion ≥ 40; and~Have burden of pathology score, computed as (CAG - 35.5) x age, ≥ 250"
88907584|NCT06305130||Primary cohort (only one in this study)|Patient data were collected from sixteen institutions across Taiwan, encompassing 6005 patients diagnosed with UTUC between 1988 and 2023. The study included all patients who underwent RNU with curative intent. After excluding those with incomplete data, a total of 2515 eligible patients were included in the final analysis.
88907585|NCT06305117|Experimental|Participants|As this is a feasibility study, all patients included in this study will be offered the intervention.
88907586|NCT06305104|Experimental|TB subjects in 18-65 years old|140 TB subjects's left and right arms were randomly assigned to receive a single intradermal injection of 0.1 ml of the test drug (EEC,2.5 μg /ml or 5 μg /ml ) and the control drug (inoculated in both arms of the same body); all subjects were intradermally injected into the middle and lower 1/3 of the volar side of the forearm using the Mantoux method. injection. The time between skin tests on the left and right arms must be at least 30 minutes (skin test on the left arm first, then on the right arm). The follow-up visit observation point is based on the completion time of the second dose of injection.
88907587|NCT06305104|Experimental|healthy subjects in 18-65 years old|180 healthy subjects's left and right arms were randomly assigned to receive a single intradermal injection of 0.1 ml of the test drug (EEC,2.5 μg /ml or 5 μg /ml ) and the control drug (inoculated in both arms of the same body); all subjects were intradermally injected into the middle and lower 1/3 of the volar side of the forearm using the Mantoux method. injection. The time between skin tests on the left and right arms must be at least 30 minutes (skin test on the left arm first, then on the right arm). The follow-up visit observation point is based on the completion time of the second dose of injection.
88907588|NCT06305104|Experimental|non-TB subjects with lung disease in 18-65 years old|40 non-TB subjects with lung disease in 18-65 years old,each subject's left and right arms were randomly assigned to receive a single intradermal injection of 0.1 ml of the test drug (EEC,2.5 μg /ml or 5 μg /ml ) and the control drug (inoculated in both arms of the same body); all subjects were intradermally injected into the middle and lower 1/3 of the volar side of the forearm using the Mantoux method. injection. The time between skin tests on the left and right arms must be at least 30 minutes (skin test on the left arm first, then on the right arm). The follow-up visit observation point is based on the completion time of the second dose of injection.
88907589|NCT06305104|Experimental|TB subjects in 3-17 years old and 66-75 years old|Each enrolled subject received a single intradermal injection of 0.1 ml of the test drug (EEC) in one arm; the Mantoux method was used to inject intradermally into the middle and lower 1/3 of the volar side of the forearm.
88907590|NCT06305104|Experimental|non-TB subjects in 3-17 years old and 66-75 years old|Each enrolled subject received a single intradermal injection of 0.1 ml of the test drug (EEC) in one arm; the Mantoux method was used to inject intradermally into the middle and lower 1/3 of the volar side of the forearm.
88907591|NCT06305091||OBP exposed|Veterans exposed to Open Burn Pits (N=220)
88907592|NCT06305091||OBP not exposed|Veterans not exposed to Open Burn Pits (N=110)
88907593|NCT06305078|Experimental|Intervention|All will choose one of five medication experiment options to complete.
88907594|NCT06305065|Experimental|KUNWU Navigation TKA procedure|"Yuanhua Orthopaedic Robotic Systems, KUNWU, is an open-platform robotic system that does not restrict surgeons in choosing the type of prosthesis implant. It is the only Orthopaedic Robotic System in Hong Kong registered with the HK Department of Health Medical Devices Control Office (MDCO) as an open platform system. Unlike other manufacturer's implant-based robots (closed systems), Yuanhua's objective is to provide maximum flexibility in choosing the best implant for each patient. Closed system robots not only impact the surgeon's choice of implant for an individual patient but also affect the hospital's implant purchases over multiple years without any negotiation power on pricing. This business model is often referred to as a razor and razor blade model."
89007713|NCT02855476||Early Manifest HD|"Participants eligible are persons who meet the following criteria:~Are 21-75 years of age, inclusive, at the time of consent; and~Have clinical diagnostic motor features of HD, defined as UHDRS Diagnostic Confidence Score = 4; and~Have CAG expansion ≥ 40; and~Have Stage I or Stage II HD, defined as UHDRS Total Functional Capacity (TFC) scores between 7 and 13 inclusive"
89196517|NCT00702169||1|Premature and term newborn infants (male/female)
89196518|NCT00838461|Active Comparator|1|HSD-016
89196519|NCT00838461|Placebo Comparator|2|placebo
89196520|NCT01324375||THA (total hip arthroplasty)|Patients undergoing THA, preoperatively heat tested
89426743|NCT04263558|Active Comparator|SHF|Short intervention (8 sessions, group) and 8 sessions web-based High parental involvement (5 sessions) Feedback
89426744|NCT04263558|Active Comparator|SHN|Short intervention (8 sessions, group) and 8 sessions web-based High parental involvement (5 sessions)
89426745|NCT04263558|Active Comparator|SLF|Short intervention (8 sessions, group) and 8 sessions web-based Low parental involvement (Brochure) Feedback
89426746|NCT04263558|Active Comparator|SLN|Short intervention (8 sessions, group) and 8 sessions web-based Low parental involvement (Brochure)
89426747|NCT04261569|Experimental|Illuminated arm|patients with intraventricular near-infrared light illumination
89426748|NCT04261569|No Intervention|control arm|patients without any medical device
89426749|NCT04254484|Experimental|SIESTA Rehab|"Stroke floor on which nurses will be receiving training (SIESTA Rehab Education) on how to minimize nighttime disruptions and batching overnight tasks to preserve sleep for patients hospitalized on that floor. Stroke patients admitted to the SIESTA Rehab Unit will be screening for sleep disordered breathing using ApneaLink.~Patients hospitalized on this unit will be approached for consent to wear sensors and actigraphy watches during the hospital stay and after discharge."
89426750|NCT04254484|No Intervention|Control Unit|"Patients on this unit will receive usual care for stroke patients as outlined by SRALab. including routine nursing care without any intervention to promote sleep like SIESTA and routing sleep disorders screenings based on clinician judgement.~Patients hospitalized on this unit will also be approached for consent to wear sensors and actigraphy watches during the hospital stay and after discharge."
89426751|NCT04246684|Active Comparator|Control arm|In the control arm patients receive 5x5 Gy followed by 9 cycles of consolidation chemotherapy mFOLFOX6 or alternatively 6 cycles of CAPOX, followed by re-staging at week 22-24 as established as new preferred neoadjuvant regimen by the RAPIDO trial.
89426752|NCT04246684|Experimental|Experimental arm|The experimental arm starts with Fluoropyrimidin/Oxaliplatin-based CRT (1.8 Gy to 45 Gy to the primary tumor and pelvic lymph nodes; followed by sequential boost of 9 Gy to the gross tumor volume) followed by consolidation chemotherapy with 6 cycles mFOLFOX6 or alternatively 4 cycles CAPOX, followed by re-staging at week 22-24. In both arms, for patients achieving a clinical complete response (cCR), as strictly assessed by clinical investigation, endoscopy and MRI, a W&W option with close follow-up is scheduled. In case of non-complete response, immediate TME surgery is performed.
89426753|NCT04242069|Experimental|Intervention|Healthy for my Baby Intervention
89426754|NCT04242069|Other|Control|Usual care
89426755|NCT04234997|Experimental|Suvorexant 20 mg|
89426756|NCT04234997|Placebo Comparator|Suvorexant 0mg|
89426757|NCT04234373|Experimental|Low Carb dietary Intervention|
89426758|NCT04233957|Experimental|High Sodium|Consumption of an extra 3900 mg of dietary sodium per day.
89426759|NCT04233957|Placebo Comparator|Placebo|Control Condition
89196521|NCT00831363||1|minimal invasive approach
89196522|NCT00831363||2|traditional transgluteal approach
89426760|NCT04227665|Experimental|Sea level|Sea level training camp
89426761|NCT04227665|Experimental|Altitude|Altitude training camp
89426762|NCT04218201|Experimental|Subthreshold Opioid Use Disorder Prevention(STOP) Intervention|At baseline, patient participants in the STOP arm will receive the intervention components of brief advice from their PCP and a video doctor , printed educational materials, interaction with the NCM, and telephone health coaching. Brief advice will be delivered by the patient participant's PCP as part of the medical visit or via phone call. Before the encounter with the patient participant, PCPs will receive a brief printed summary report from the research staff. During the baseline visit, patient participants also meet with the research staff to view a video on tablet or desktop computer that reinforces the PCP's counseling.
89536813|NCT03309527|Active Comparator|e-aid Sleep Hygiene Education|Participants receive e-aid sleep hygiene education which consists of general sleep health education and the guidance on questionnaires. Every week, this group will receive researcher guided sleep hygiene.
89536814|NCT03313661|Experimental|Cabergoline|cabergoline 0.5 mg twice weekly within 2 hrs of awakening plus gliclazide
89196523|NCT03495505|Experimental|WiSE-CRT eligible|Patients need to meet all the inclusion and none of the exclusion criteria in order to be eligible for the study. All these patients will receive the WiSE-CRT implant.
89196524|NCT03488953|Other|Transplantation Arm|
89426763|NCT04218201|No Intervention|Enhanced Usual Care (EUC)|PCPs will conduct primary care as usual, without the support of the NCM. At the baseline visit, patient participants receive an educational pamphlet and view a short video on overdose and cancer screening. The pamphlet includes information about preventing opioid-related overdose, including how to obtain a naloxone kit. The video content will feature the health benefits of exercise. It will be viewed on a tablet or desktop computer and will be approximately 2 minutes long. All EUC patient participants receive the same video, which is not tailored to the responses given on their questionnaires. There is no study intervention after the baseline visit.
89426764|NCT04212247|Experimental|Well-being therapy|WBT will be used as the only non-pharmacological therapeutic strategy and 8 sessions will be delivered every other week with a duration of 60 minutes each. The manualized WBT will be used (Fava, 2016). Thus, the initial phase will be concerned with self-observation of psychological well-being. Once the instances of well-being will be properly recognized, the patient will be encouraged to identify thoughts, beliefs, and behaviors leading to premature interruption of well-being (intermediate phase). The final part will involve cognitive restructuring of dysfunctional dimensions of psychological well-being and meeting the challenge that optimal experiences may entail.
89426765|NCT04212247|Placebo Comparator|Control condition|The control condition will include 8 every other week sessions based on Lifestyle and well-being National Institute for health and Care Excellence (NICE) guidelines (https://www.nice.org.uk/guidance/lifestyle-andwellbeing) and on World Health Organization 12 steps to healthy eating (http://www.euro.who.int/en/ health-topics/disease-prevention/nutrition/a-healthylifestyle). These sessions will inform participants about well-being and lifestyles which can influence it.
89426766|NCT04204707||Conservative surgery|
89426767|NCT04204707||Radical surgery (segmental resection)|
89426768|NCT04197362|Experimental|ASICS Women's Gel-Venture 6 Running-Shoe|ASICS Women's Gel-Venture 6 Running-Shoe
89426769|NCT04197362|Experimental|Nike Air Max 270|Nike Air Max 270
88907595|NCT06305065|Experimental|CORI Surgical System TKA procedure|"REAL INTELLIGENCE™ CORI™ (CORI Surgical System) is a computer-assisted orthopedic surgical system. CORI Surgical System is designed to aid surgeons in planning and executing a procedure involving bone preparation for total knee arthroplasty (TKA) procedures.~CORI Surgical System is comprised of a console control unit, optical tracking camera, primary and secondary input displays (tablet and optional display monitor), and foot pedal. The CORI Surgical System software consists of a patient and user management module, a surgical planner, and an intra-operative cutting module."
89426770|NCT04197362|Experimental|La Vida+|La Vida+
89426771|NCT04196712||Coronary angiography arm|Patient undergoing invasive coronary angiography
89426772|NCT04192695|Experimental|Cytosponge|"This part of the study will have an active prospective recruitment of patients. Recruitment will involve two patient populations:~Patients with ESCC~Patients at high risk for ESCC~Following inclusion in the study, subjects will be asked to complete a behavior questionnaire, have blood collected, and undergo a Cytosponge™ procedure followed by diagnostic gastroscopy using advanced imaging with biopsies. During gastroscopy, additional tissue samples will be collected for research purposes. These samples, along with cytological specimens from the Cytosponge™, will be analyzed to assess the diagnostic accuracy of biomarkers in the diagnosis of LG-IEN, HG-IEN, and ESCC."
89426773|NCT04189406||Girls with Turner syndrome|"Girls with a pre- or perinatal diagnosis TS who are born in a medical centre in the Netherlands during the duration of the study.~The subjects will have an extra venapuncture of 3.5 mL blood at 3 and 9 months."
89426774|NCT04187404|Experimental|5-cohort study design|"Cohort 1:3-by-3 design of EO2401 in combination with nivolumab at standard dose. Three to 12 evaluable patients with adrenal carcinoma or progressive malignant pheochromocytoma/paraganglioma will be included depending on the safety profile of the administered treatments.~Cohorts 2A (previously treated patients) and 2B (previously untreated patients): evaluation of EO2401in combination with nivolumab in 33 patients with adrenal carcinoma.~Cohorts 3A (previously treated patients) and 3B (previously untreated patients) : evaluation of EO2401 combination with nivolumab in 20 patients (globally for both Cohorts 3A and 3B) with progressive malignant pheochromocytoma/ paraganglioma."
88907596|NCT06305065|Active Comparator|Conventional TKA procedure|This group will perform the standard TKA procedure.
88907597|NCT06305052|Experimental|Milk group|Olfactory and gustatory stimuli with milk in premature infants before tube feeding.
88907598|NCT06305052|Placebo Comparator|Placebo group|Olfactory and taste stimuli with double-distilled water in premature infants before tube feeding
88907599|NCT06305039|Experimental|Bilateral Cochlear Implant Users|
88907600|NCT06305039|Experimental|Unilateral Cochlear Implant Users with Single-Sided Deafness|
88907601|NCT06305039|Other|Non-Implanted Listeners with Acoustic Hearing|
88907602|NCT06305026||RA patients with concomitant fibromyalgia|
88907603|NCT06305026||RA patients without concomitant fibromyalgia|
89426775|NCT04187404|Experimental|randomized extension of Cohort 2A (3 arms): C2A-I|Randomized extension of Cohort 2A (65 patients using a 4:1:1 ratio): 43 patients belonging to this extension of Cohort 2A will be treated by EO2401 and nivolumab in combination.
89426776|NCT04187404|Experimental|randomized extension of Cohort 2A (3 arms): C2A-II|11 patients belonging to this extension of Cohort 2A will be treated by EO2401 alone.
89426777|NCT04187404|Active Comparator|randomized extension of Cohort 2A (3 arms): C2A-III|11 patients belonging to this extension of Cohort 2A who will be treated by nivolumab alone.
89426778|NCT04185545|Experimental|Immunogenicity Group - RV3 Vaccine (Bio Farma) Batch 1|3 oral doses of RV3 vaccine (Bio Farma) batch 1; administered at 0-5 days, 8-10 weeks, and 12-14 weeks of age.
89426779|NCT04185545|Experimental|Immunogenicity Group - RV3 Vaccine (Bio Farma) Batch 2|3 oral doses of RV3 vaccine (Bio Farma) batch 2; administered at 0-5 days, 8-10 weeks, and 12-14 weeks of age.
89426780|NCT04185545|Experimental|Immunogenicity Group - RV3 Vaccine (Bio Farma) Batch 3|3 oral doses of RV3 vaccine (Bio Farma) batch 3; administered at 0-5 days, 8-10 weeks, and 12-14 weeks of age.
89426781|NCT04185545|Placebo Comparator|Immunogenicity Group - Placebo|3 oral doses of Placebo; administered at 0-5 days, 8-10 weeks, and 12-14 weeks of age.
89426782|NCT04185545|Experimental|Other Efficacy Group - RV3 Vaccine (Bio Farma)|3 oral doses of RV3 vaccine (Bio Farma) administered at 0-5 days, 8-10 weeks, and 12-14 weeks of age.
89426783|NCT04185545|Placebo Comparator|Other Efficacy Group - Placebo|3 oral doses of Placebo administered at 0-5 days, 8-10 weeks, and 12-14 weeks of age.
89426784|NCT04181710|Experimental|HEMO2life|HEMO2life® will be used for ex vivo graft preservation at the dose of 1g per liter of preservation solution.
89426785|NCT04181710|Other|Control|Organ preserved in preservation solution routinely used according to the local practice
89426786|NCT04160858|Experimental|Exercise Condition|The intervention is a personalized exercise prescription based on the International Scientific Spinal Cord Injury (SCI) Exercise Guidelines. Participants begin at the Starting Level guideline: 20 min aerobic exercise, 2x/wk, at 70% of heart rate reserve (or a Borg Continuous Ratio 0-10 rating of 6), & 3 sets of 10 repetitions of strengthening exercises (each major functioning muscle group at 50-80% of 1-rep max), 2x/wk. Participants will gradually increase aerobic exercise to 30 min, 3x/wk (i.e. the Advanced Level guideline). Exercise implementation will be supported by a fitness trainer and an exercise counsellor with SCI-specific training and experience.
89426787|NCT04160858|Active Comparator|Wait-list Control|Control participants will not get an exercise prescription. They will be asked to refrain from lifestyle changes for 6 mos. After the 6-month waitlist period, Controls will receive the same resources as Exercisers.
89426788|NCT04160741|Experimental|Hot environment with radiation|"Exposure to hot environment (30°C WBGT) with radiation (800 W/m2)~Exposure for 03:20:00:~rest (two hours)~work (cycling) at 100 W (one hour)~recovery (twenty minutes)"
89536815|NCT03313661|Active Comparator|Gliclazide|gliclazide (60-120 mg) once daily
89536816|NCT03313661|No Intervention|Placebo|Placebo
89426789|NCT04160741|Experimental|Hot environment without radiation|"Exposure to hot environment (30°C WBGT) with radiation (0 W/m2)~Exposure for 03:20:00:~rest (two hours)~work (cycling) at 100 W (one hour)~recovery (twenty minutes)"
89426790|NCT04160741|Experimental|Neutral environment with radiation|"Exposure to neutral environment (20°C WBGT) with radiation (800 W/m2)~Exposure for 03:20:00:~rest (two hours)~work (cycling) at 100 W (one hour)~recovery (twenty minutes)"
89426791|NCT04160741|Active Comparator|Neutral environment without radiation|"Exposure to neutral environment (20°C WBGT) with radiation (0 W/m2)~Exposure for 03:20:00:~rest (two hours)~work (cycling) at 100 W (one hour)~recovery (twenty minutes)"
89426792|NCT04160728|Experimental|Work/ rest scenario|For every hour of work, the participants were asked to take 3-10 minutes break in the shade.
89426793|NCT04160728|Experimental|Hydration scenario|Participants were asked to consume at least 750ml of water or ice-slushies for every hour of work.
89426794|NCT04160728|Experimental|Clothing scenario|Participants were asked to wear different types of clothing during the work shift i.e. ventilated garments, white breathable coveralls, clothing with water submerged parts.
89426795|NCT04160728|Experimental|"E-carts scenario"|"Participants that were involved in manual labor by carrying heavy weights were provided with e-carts (automated carrying vehicles)"
89426796|NCT04160728|Sham Comparator|Business as usual scenario|No interference with the usual work day of the participants.
89426797|NCT04160728|Sham Comparator|Sham evaluation|Participants were monitored during a usual day of work shift while sham measurements were recorded in order for them to get familiarized with the study environment.
89426798|NCT04159389|No Intervention|traditional teaching|theoretical courses and procedural simulation on airway management during rapid sequence induction
89426799|NCT04159389|Experimental|Mental visualization|traditional teaching completed by mental visualization : theoretical courses and procedural simulation on airway management during rapid sequence induction + mental visualization (theoretical courses, audioguide for individual practice and experience sharing session)
89426800|NCT04159220|No Intervention|Control group|The transport will be released without a clamping of endotracheal tube before each disconnection from ventilator.
89426801|NCT04159220|Experimental|Clamping group|The transport will be released with a clamping of endotracheal tube before each disconnection from ventilator.
89426802|NCT04155281||suspicion of intoxication|New Psychoactive Substances research in urine
89426803|NCT04154865|Experimental|Enrolled, eligible|Single arm for eligible subjects
89426804|NCT04153838||Children|A group of 'typically' developing children (aged between 6 years and 16 years 11 months) from the general paediatric population will be recruited; with the sample distributed evenly across 6 age bands (i.e. ages 6-7 years, 8-9 years, 10-11 years, 12-13 years, 14-15 years, and 16 years+).
89426805|NCT04151472|Experimental|90mg Idebenone|Placebo by mouth, three times a day for 1 months； Idebenone 30mg table by mouth, three times a day for next 3 months
89426806|NCT04151472|Experimental|270mg Idebenone|Placebo by mouth, three times a day for 1 months； Idebenone 90mg table by mouth, three times a day for next 3 months
89426807|NCT04151472|Placebo Comparator|Placebo|Placebo by mouth, three times a day for 4 months
88907604|NCT06305013||Participant of simulation course organised by Department of Simulation medicine|Participant of simulation course organised by Department of Simulation medicine
89426808|NCT04151433|Active Comparator|The combined technique|First step consisting of stripping the cyst wall for 80% of the surface, followed by a second step consisting of ablation of the remaining 20% cyst surface.
89426809|NCT04151433|Active Comparator|CO2 laser vaporization only|CO2 laser vaporization only of the complete inner cystic wall after drainage of the cyst content, irrigation and inspection of its inner wall. Ablation of the inner cyst wall using the CO2 laser (Lumenis). Power settings of 30-55W for CO2 laser beam and 6-10W for CO2 fibre are used. The laser should be on the ablate function to widen the beam (e.g. Surgitouch modus). The laser should be applied in Surgitouch modus so that it can ablate the cyst surface while preserving the underlying healthy tissue.
89426810|NCT04147247|Experimental|1.0 milligram/kilogram BI 905681|Subjects received an intravenous infusion of 1.0 milligram/kilogram BI 905681 on day 1 of each cycle (1 cycle = 21 days). Patients may continue on treatment for unlimited cycles, until criteria for stopping treatment are met.
89426811|NCT04147247|Experimental|2.5 milligram/kilogram BI 905681|Subjects received an intravenous infusion of 2.5 milligram/kilogram BI 905681 on day 1 of each cycle (1 cycle = 21 days). Patients may continue on treatment for unlimited cycles, until criteria for stopping treatment are met.
89426812|NCT04147247|Experimental|5.0 milligram/kilogram BI 905681|Subjects received an intravenous infusion of 5.0 milligram/kilogram BI 905681 on day 1 of each cycle (1 cycle = 21 days). Patients may continue on treatment for unlimited cycles, until criteria for stopping treatment are met.
89426813|NCT04147247|Experimental|7.0 milligram/kilogram BI 905681|Subjects received an intravenous infusion of 7.0 milligram/kilogram BI 905681 on day 1 of each cycle (1 cycle = 21 days). Patients may continue on treatment for unlimited cycles, until criteria for stopping treatment are met.
89426814|NCT04147247|Experimental|8.5 milligram/kilogram BI 905681|Subjects received an intravenous infusion of 8.5 milligram/kilogram BI 905681 on day 1 of each cycle (1 cycle = 21 days). Patients may continue on treatment for unlimited cycles, until criteria for stopping treatment are met.
89426815|NCT04144907|Experimental|Phenylalanine intake|
89426816|NCT04138589||CF patients aged 6-18 years homozygeous for delta F508|CF patients aged 6-18 years homozygeous for delta F508 starting with lumacaftor/ ivacaftor or tezacaftor/ ivacaftor
89196525|NCT01046227||Serology after Novel H1N1 vaccination|This study is designed to investigate the antibodies titers before and after the novel H1N1 influenza vaccination in pediatric haemato-oncology patients.
89536817|NCT00703781|Experimental|Bromfenac|Bromfenac Ophthalmic Solution 0.09%, Dosed 1 Drop Daily
89536818|NCT00703781|Placebo Comparator|Placebo|Placebo, Dosed 1 Drop Daily
89536819|NCT03313583||Blood product recipients|All patients who received at least one blood product on the day of the study
89536820|NCT02468609|Other|Ultralow-Dose-CT|Additional Ultralow-Dose-CT of the chest
89536821|NCT03313505||Patients who had been tested for S100B protein|
89426817|NCT04136769|Experimental|Intervention|"After trial enrolment, patients undergo visceral debranching.~After visceral debranching, patients proceed to neoadjuvant chemotherapy. The therapy as such is not a formal part of the trial protocol. The specific chemotherapy regimen and its duration are decided individually by treating physicians.~Tumor resection should be performed two to four weeks after completion of chemotherapy. Prior to resection, re-staging and verification of vascular reconstruction patency are carried out. The specific procedure for tumor resection and intestinal tract reconstruction is at the choice of the treating surgeon. It should follow oncological principles and aim at complete removal of the tumor and regional lymph nodes. Usually, resection will be done as pancreatoduodenectomy with or without distal gastrectomy (Whipple's procedure or pylorus-preserving Whipple's procedure), distal pancreatectomy with splenectomy, or total pancreatectomy with splenectomy."
89426818|NCT04132284|Experimental|DBT IOP plus DBT PI|Standard Dialectical Behavior Therapy (DBT) delivered in the context of an intensive outpatient program (DBT IOP) for adolescents plus an 8-10 session DBT-based parenting intervention (DBT PI)
89426819|NCT04132284|Active Comparator|DBT IOP alone|No parenting intervention provided beyond what is part of the DBT IOP treatment as usual.
89426820|NCT04130438|Active Comparator|Beta Blocker (nebivolol)|
89426821|NCT04130438|Active Comparator|Calcium Channel Blocker (diltiazem)|
89426822|NCT04130438|Placebo Comparator|Placebo|
89426823|NCT04128722|Experimental|Sirolimus 1mg/mL|Application of 1 mg/mL sirolimus solution, 0.5 mL to 1 mL according to the size of the lesion, once daily, on lingual microcystic lymphatic malformation, the experimental intervention versus usual care (no treatment), the control condition.
89426824|NCT04128722|No Intervention|Control condition|Usual care, i.e. no intervention
89426825|NCT04120805|Experimental|Group 1 (Hemostatic Agents Plus +)|
88907609|NCT06304987|Experimental|CRT+PD-1 inhibitor+PCSK9 inhibitor|Receive long-course radiotherapy in weeks 1-5: 50 Gy/25 f, 2 Gy/day, days 1-5/week; for 5 consecutive weeks; Simultaneously receive 30 days of capetabine treatment at weeks 1-2, weeks 3-5, and weeks 6-8, 825-1000mg/m2, bid, po, days 1-5/week; PD-1 inhibitor: 200mg, iv.gtt, single dose Infusion, a cycle of 21 days, a total of 3 cycles. Carry out at 2 weeks (days 8-14), 5 weeks (days 29-35), and 8 weeks (days 50-56) after the start of radiotherapy; PCSK9 inhibitor: 600 mg, subcutaneous injection, 1, 7 weeks.
89426826|NCT04120805|Active Comparator|Group 2 (Hemostatic Agents Negative -)|No Hemostatic Agent
89426827|NCT04119180|Experimental|Sedation|The child receives sedatives approved for use in an outpatient setting, directed by a doctor, to accomplish the dental treatment.
89426828|NCT04119180|Other|Control|The child does not receive sedatives. As s/he exhibits negative behavior for the dental procedure, s/he will be restrained by a family member and dental team.
89426829|NCT04110730|Experimental|3D Prostheses Users|Children with unilateral congenital upper-limb reductions
89426830|NCT04110730|Active Comparator|Typically Developing Children|Age- and sex-matched control group of typically developing children.
89426831|NCT04107857||Smoking Cessation|"Patients enter the program through clinic appointments or community outreach programs.~Patients will be given brief advice to quit smoking and referral options to receive evidence-based treatment through Missouri/Illinois Quitlines, Smokefree.TXT, or smokefree.gov dependent on the patient's preference for counseling~Patient can also be prescribed smoking cessation pharmacotherapy"
89426832|NCT04106518||cirrhosis|Patients with alcoholic liver disease without alcoholic hepatitis
89196526|NCT04044339|Experimental|TD-5202 for SAD (Part A)|6 out of 8 subjects per cohort (up to 4 cohorts) will be randomized to receive TD-5202
89196527|NCT04044339|Placebo Comparator|Placebo for SAD (Part A)|2 out of 8 subjects per cohort (up to 4 cohorts) will be randomized to receive placebo
89196528|NCT04044339|Experimental|TD-5202 for MAD (Part B)|6 out of 8 subjects per cohort (up to 3 cohorts) will be randomized to receive TD-5202
89426833|NCT04106518||severe alcoholic hepatitis|Patients with severe alcoholic hepatitis ( Maddrey score ≥32)
89196529|NCT04044339|Placebo Comparator|Placebo for MAD (Part B)|2 out of 8 subjects per cohort (up to 3 cohorts) will be randomized to receive placebo.
89426834|NCT04106518||non-severe alcoholic hepatitis|Patients with non-severe alcoholic hepatitis (Maddrey score <32)
89426835|NCT04104607|Experimental|CC-1 therapy|Infusion of CC-1 over 24 hours for 7 days with possible intra-patient dose-escalation. In case of clinical benefit, additional cycles with a total of up to six are possible.
89426836|NCT04104555|Active Comparator|Usual supportive care - exercises and footwear advice|"OSTRICH main trial:~Participants will be offered an exercise programme and advice regarding footwear. The treating clinician will be able to prescribe appropriate exercises from a menu of exercises."
89426837|NCT04104555|Experimental|Prefabricated, off-the-shelf orthoses|"OSTRICH main trial:~A pair of prefabricated, off-the-shelf orthoses (i.e. mass produced to a generic shape but can be adapted by a clinician) plus an exercise programme and advice regarding footwear. The treating clinician will be able to prescribe appropriate exercises from a menu of exercises."
89426838|NCT04104555|Experimental|Signposting to multimedia|OSTRICH 'signposting to multimedia' Study within a trial (SWAT) Participants will be given signposting information to the multimedia trial information resources in the participant information sheet which is included in the OSTRICH recruitment pack.
89426839|NCT04104555|No Intervention|Standard written information only|OSTRICH signposting to multimedia' Study within a trial (SWAT) Participants will receive the standard written information sheet only. This will not include signposting to the multimedia trial information resources, in the OSTRICH recruitment pack.
89426840|NCT04104555|Experimental|Birthday card|OSTRICH Birthday card study within a trial (SWAT) Participants will be sent a birthday card on or shortly before their birthday from the OSTRICH study team to encourage completion of questionnaires.
89426841|NCT04104555|No Intervention|No birthday card|OSTRICH Birthday card study within a trial (SWAT) Participants will not be sent a birthday card during the trial.
89426842|NCT04090177|Experimental|Intervention-TEAM Wheels|The treatment group will receive the TEAM Wheels program over a 4-week period. Session 1 will be virtually delivered via MS Teams teleconference. The peer trainer is an experienced MWC user trained to deliver the TEAM Wheels program. At least 2 peers will be trained at each site to offer multiple trainer attributes; a male and female, one being at least 50 years old. Participants will pre-select a peer trainer from a biosketch to optimize training effect (e.g., preference for age, sex factors); comparability in age has been identified as preferential among older adults and influential to self-efficacy. After Session 1, participants engage in 4 weeks of eHealth home program training. They are instructed to practice for 75-150 minutes/week. Consistent with motor learning principles, we encourage training in 15-30 minute blocks 1-2 times/day, 3-5 days/week. The peer trainer arranges the remaining two virtual teleconference sessions with the participant, about 1 week apart.
89536822|NCT03313505||Patients who have benefited from another strategy|
88907610|NCT06304987|Active Comparator|CRT+PD-1 inhibitor|Receive long-course radiotherapy in weeks 1-5: 50 Gy/25 f, 2 Gy/day, days 1-5/week; for 5 consecutive weeks; Simultaneously receive 30 days of capetabine treatment at weeks 1-2, weeks 3-5, and weeks 6-8, 825-1000mg/m2, bid, po, days 1-5/week; PD-1 inhibitor: 200mg, iv.gtt, single dose Infusion, a cycle of 21 days, a total of 3 cycles. Carry out at 2 weeks (days 8-14), 5 weeks (days 29-35), and 8 weeks (days 50-56) after the start of radiotherapy.
89536823|NCT03313427|Experimental|Intervention|Usual care Early physical therapy intervention at the UCIN and after discharge, at home; based on the family-centered model.
89196530|NCT00391807|Experimental|study drug|Norethindrone/Ethinyl Estradiol
89536824|NCT03313427|Other|Control|Usual care
89536825|NCT03309293|Other|controls|biological samples bank
89536826|NCT03309293|Experimental|cases|
89536827|NCT03313349|Other|Usual Provision (UP)|"Usual Provision~Psychotherapy: 1. cognitive therapy 2.family intervention"
88820420|NCT06178640|Active Comparator|ZOCOR 40 mg, Then Simvastatin 40 mg|Participants first received ZOCOR 40 mg film-coated tablet 1 tablet (Reference product) in a fasting state. After a washout period of 1 week, they then recieved Simvastatin 40 mg film-coated tablet (Test product) in a fasting state.
88820421|NCT06177795|No Intervention|Penn: Control|Clinics randomized to the control arm will receive standard of care.
88820422|NCT06177795|Experimental|Penn: Intervention|Clinics randomized to the intervention arm will receive the toolkit of clinician and patient facing nudges. Patient nudges will be post-visit text message reminders (standard messaging content). Clinician nudges will be default pended orders.
88820423|NCT06177795|Experimental|Penn: High Risk Intensification|Patients in the intervention clinics identified as high risk for noncompletion of mammogram will be randomized 1:1 to receive the high risk intensification arm or remain in the standard intervention arm. Patients in the high risk intensification arm will receive an additional bidirectional texting component.
88820424|NCT06177795|No Intervention|UH: Control|Primary care providers randomized to the control arm will receive standard of care.
88820425|NCT06177795|Experimental|UH: Intervention|Primary care providers randomized to the intervention arm will receive default pended orders for a mammogram.
88820426|NCT06176183|Other|Cohort I of patients|Individuals who undergo the conventional arthroscopic meniscus repair procedure
88820427|NCT06176183|Other|Cohort II of patients|Patients who receive the supplementary fibrin clot augmentation during the arthroscopic meniscus repair operation.
88820428|NCT06170645|Experimental|Patients with active tVNS|Patients consulting on St Etienne hospital and suffering from fibromyalgia and long Covid will be included.
88820429|NCT06170645|Sham Comparator|Patients with sham tVNS|Patients consulting on St Etienne hospital and suffering from fibromyalgia and long Covid will be included.
88820431|NCT06158581|Experimental|The Emotion Awareness and Skills Enhancement|EASE is a 16-session mindfulness-based intervention (MBI). It emphasizes a small set of core concepts (i.e., mindfulness practices, distress tolerance, encouraging helpful thoughts, self-compassion) that are repeated with consistent language throughout. Emphasis is placed on increasing awareness of gradients of emotional arousal.
88820432|NCT06158581|Active Comparator|The Unified Protocol|UP is a 12-21 session cognitive behavioral therapy (CBT) based treatment. In this study, there will be 16 sessions. UP is focused on identifying emotions and building new coping strategies. It is customizable to meet the needs of the individual.
88820433|NCT06158555|Experimental|Single Arm|Patients will receive fluid and vasopressor challenges and the macro and microvascular responses will be recorded using the IKORUS monitor alongside conventional haemodynamic monitoring
88820434|NCT06158295|Experimental|Walking apnea at Low Lung Volume|Participants walk at 5,5 km/h on treadmill for 6 minutes. Participants in the experimental group will perform intermittent apneas at low lung volume with a density of 15 seconds, followed by a normal breath of 10 seconds (15 cycles of 15s apnea - 10s normal breathing, until completing the 6 minutes).
88820435|NCT06158295|No Intervention|Walking at normal breathing|Participants walk at 5,5 km/h on treadmill for 6 minutes. Participants in the control group will remain breathing normally for these 6 minutes.
88820436|NCT06158282|Experimental|Walking apnea at High Lung Volume|Participants walk at 5,5 km/h on treadmill for 6 minutes. Participants in the experimental group will perform intermittent apneas at high lung volume with a density of 15 seconds, followed by a normal breath of 10 seconds (15 cycles of 15s apnea - 10s normal breathing, until completing the 6 minutes)
88820437|NCT06158282|No Intervention|Walking at normal breathing|Participants walk at 5,5 km/h on treadmill for 6 minutes. Participants in the control group will remain breathing normally for these 6 minutes.
88820438|NCT06158256|Experimental|Static apnea at low Lung Volume|Participants will remain at rest in the supine position for 6 minutes. Participants in the experimental group will perform intermittent apneas at low lung volume with a density of 30 seconds, followed by a normal breath of 10 seconds (9 cycles of 30s apnea - 10s normal breathing, until completing the 6 minutes).
88820439|NCT06158256|No Intervention|Static at normal breathing|Participants will remain at rest in the supine position for 6 minutes. Participants in the control group will remain breathing normally for these 6 minutes.
88820440|NCT06158204|Experimental|Immediate intervention|Participants will receive the 8-week intervention first, followed by 8 weeks of observation-only
88820441|NCT06158204|Active Comparator|Delayed intervention|Participants will receive the 8-week intervention after 8 weeks of observation-only
88820442|NCT06156163|Experimental|Perturbation Group|Exercise program with progressive perturbation conditions
88820443|NCT06156163|Active Comparator|Exercise Group|Exercise program
88820444|NCT06155669|No Intervention|Standart Group|Participants will be selected from patients diagnosed with tension-type headache according to the International Classification of Headache Disorders, third edition (ICHD-3) criteria. All selected participants will be administered 25 mg of dexketoprofen.
88820445|NCT06155669|Experimental|Virtual Reality|Participants will be selected from patients diagnosed with tension-type headache according to the International Classification of Headache Disorders, third edition (ICHD-3) criteria. Selected participants, in addition to being administered 25 mg of dexketoprofen, will also use virtual reality goggles.
88820446|NCT06152419|Experimental|Interrogated patients|Patients will be asked to complete questionnaires to evaluate the quality and the impact of the video and to assess the need for additional information. Patients will be recruited at the first consultation at the radiotherapy department or at one of the first radiotherapy sessions. In addition, focus groups will be organised to assess whether this video meets the patients' needs.
88820447|NCT06150677|Experimental|Static apnea at High Lung Volume|Participants will remain at rest in the supine position for 6 minutes. Participants in the experimental group will perform intermittent apneas at high lung volume with a density of 30 seconds, followed by a normal breath of 10 seconds (9 cycles of 30s apnea - 10s normal breathing, until completing the 6 minutes).
89536828|NCT03313349|Other|Enhanced/Need-Based Provision (ENP)|"Enhanced/need-based Provision~Psychotherapy: 1.cognitive therapy 2.family intervention"
89536829|NCT00703157|Active Comparator|1|Arm 1: Catheter Ablation
89007714|NCT02855476||Moderate Manifest HD|"Participants eligible are persons who meet the following criteria:~Are 21-75 years of age, inclusive, at the time of consent; and~Have clinical diagnostic motor features of HD, defined as UHDRS Diagnostic Confidence Score = 4; and~Have CAG expansion ≥ 40; and~Have Stage III HD, defined as UHDRS TFC scores between 3 and 6, inclusive"
89536830|NCT00703157|Active Comparator|2|Arm 2: Surgical Ablation.
89536831|NCT03309215|Experimental|Patients with nickel allergy|Experimental stimulation with nickel discs
88820448|NCT06150677|No Intervention|Static at normal breathing|Participants will remain at rest in the supine position for 6 minutes. Participants in the control group will remain breathing normally for these 6 minutes
89536832|NCT03309215|Experimental|Persons without nickel allergy|Experimental stimulation with nickel discs
89426843|NCT04090177|No Intervention|Control-Wait List|"The control group receives no specific intervention over the course of the 4-week period. This reflects usual practice/typical experience of a MWC user in their provincial context. Control group participants placed on the wait-list will receive the TEAM Wheels program following completion of the study (i.e. after post-treatment data collection). The site Research Coordinator/Assistant will make telephone or email contact with control group participants at the end of weeks 2 and 4 during the study period to deter attrition/drop-out. When contact is made at week 4, the Research Coordinator will schedule an appointment for post-treatment data collection (week 7). Any formal MWC training received during the wait-list period will be documented for potential post-hoc analysis as a confounding variable; research evidence and investigators' clinical experience confirm that in all 3 provinces formal training is not provided once MWC users are discharged from hospital."
89426844|NCT04089696|Experimental|ExSpiron|10 patients with ALS
89426845|NCT04086875|Experimental|Phase 1 (focus groups)|Participants attend focus groups on adherence to hormone therapy.
89426846|NCT04086875|Experimental|Phase II Group 1 (text messages)|Participants receive text messages twice weekly for 6 months to remind and motivate participants about AHT adherence.
89426847|NCT04086875|Active Comparator|Phase II Group II (usual care)|Participants receive usual care.
89196531|NCT00624585|Experimental|Dasatinib Dose Escalation|Patients will be started on dasatinib at a continuous oral daily dose of 100 mg per day. At 8 weeks, if the initial dose is well tolerated and patient has not achieved a partial response, the dose may be increased to 150 mg per day. All patients will be followed per protocol for a total core period of 16 weeks from the first dose. Responding patients will continue dasatinib treatment for up to 48 weeks in the absence of treatment failure, disease progression, limiting toxicity or death. Patients continuing after 48 weeks will be enrolled in a separate extension study for future follow up.
89196532|NCT01046305||Part 1: Interview & Questionnaires|Patients interviews and questionnaires about CML symptoms once.
89426848|NCT04083118||Bicuspid aortic valve|80 patients with bicuspid aortic valve with or without an aortic aneurysm
89426849|NCT04083118||controls|20 healthy volunteer controls age and sex matched to 20 of the bicuspid aortic valve patients
89426850|NCT04080167|Other|Arm 1 (InCharge Health app)|Patient receives the InCharge Health app for 6 months
89426851|NCT04080167|Other|Arm 2 (HU Toolbox app)|Provider receives the HU Toolbox app for 9 months
89426852|NCT04075331|Experimental|Mepolizumab|Mepolizumab
89426853|NCT04075331|Placebo Comparator|Placebo|Saline solution
89426854|NCT04070378|Experimental|Open-label Treatment|This is an open-label pilot study designed to explore whether daratumumab may have a clinically meaningful effect in patients with mild to moderate Alzheimer's disease. During the treatment phase, eligible subjects will receive daratumumab SC 1800 mg (daratumumab 1800 mg with rHuPH20 30,000 units) subcutaneous infusion over 3-5 minutes (15 mL) once weekly for 8 weeks followed by daratumumab SC 1800 mg every 2 weeks for 16 weeks.
89426855|NCT04069754|Experimental|Adapted Passport to Freedom Intervention Arm|The intervention consists of 5 weekly, 90 minute group sessions that cover topics such as mindfulness, health, healthy relationships, family matters, and reflections
88907613|NCT06304961|Experimental|Tozorakimab Dosage form A (Test)|Participants will receive a single dose of Tozorakimab Dosage form A via subcutaneous (SC) injection.
88907614|NCT06304961|Experimental|Tozorakimab Dosage form B (Reference)|Participants will receive a single dose of Tozorakimab Dosage form B via SC injection.
88907615|NCT06304935|Other|One Group of pt used one tonsillar bed (tested) side other tonsillar bed (control)|In the same Group one of tonsillar bed randamly injected with injectable platelet rich fibrin and other side as control and compare in post tonsillectomy healing, pain and hemostasis
88907616|NCT06304896|Active Comparator|The Cardioprotective Group (CPG)|50 patients will receive a low-dose Beta-blockers in the form of Carvedilol 6.25 mg PO twice daily, a low-dose ACE inhibitors in the form of Ramipril 2.5 mg PO once daily, and a statin in the form of rosuvastatin 20 mg oral tablets.
88907617|NCT06304896|Active Comparator|The Immunomodulatory Group (IMG)|50 patients will receive Colchicine 0.6 PO once daily.
88907618|NCT06304896|Placebo Comparator|The Placebo Control Group (PCG)|50 patients will receive a placebo as a control group.
88907619|NCT06304883|Experimental|Experimental: ALZ-801|ALZ-801 265 mg BID tablet orally. Subjects will take one 265 mg tablet of ALZ-801 in the evening during the first 4 weeks of the study; thereafter, they will take one 265 mg tablet BID.
88907620|NCT06304805|Experimental|Group A|cycle 1: treatment drug + fasted cycle 2: reference drug + fasted cycle 3: treatment drug + food
88907621|NCT06304805|Experimental|Group B|cycle 1: reference drug + fasted cycle 2: treatment drug + food cycle 3: treatment drug + fasted
88907622|NCT06304805|Experimental|Group C|cycle 1: treatment drug + food cycle 2: treatment drug + fasted cycle 3: reference drug + fasted
89426856|NCT04068454|Active Comparator|classical rehabilitation group|
89426857|NCT04068454|Experimental|virtual reality group|
88907623|NCT06304805|Experimental|Group D|cycle 1: treatment drug + food cycle 2: reference drug + fasted cycle 3: treatment drug + fasted
88907624|NCT06304805|Experimental|Group E|cycle 1: reference drug + fasted cycle 2: treatment drug + fasted cycle 3: treatment drug + food
88907625|NCT06304805|Experimental|Group F|cycle 1: treatment drug + fasted cycle 2: treatment drug + food cycle 3: reference drug + fasted
88907626|NCT06304792|Experimental|Immediate FET in a stimulated or programmed cycle|Stimulated or programmed cycle FET is performed in the first cycle following failed fresh embryo transfer or freeze all.
88907627|NCT06304792|No Intervention|Postponed FET in a stimulated or programmed cycle|Stimulated or programmed cycle FET is performed at least one full menstrual, or one hormonal replacement treatment (HRT) cycle in case of oligo-anovulation, after the fresh embryo transfer or freeze-all cycle
88907628|NCT06304779|Placebo Comparator|Control group|Patients receive an equivalent volume of normal saline at anesthesia induction and throughout the perioperative period until 24 hours postoperatively.
88907629|NCT06304779|Experimental|Lidocaine group|Patients receive a loading dose of 1.5 mg/kg 2% lidocaine at anesthesia induction, followed by continuous intravenous infusion at 1.5 mg/kg/h until 24 hours postoperatively.
88907630|NCT06304766|Active Comparator|Open ablation|Laparotomy performed for open ablation of the tumor
88907631|NCT06304766|Experimental|Laparoscopic ablation|Ablation of the tumor performed by laparoscopic approach
88907632|NCT06304753|Experimental|Remote Monitoring|"Patients with chronic heart failure with low ejection fraction who was hospitalized due to decompensation of their condition. Their condition should be stabilized and blood pressure and renal function (Potassium level and eGFR) should be sufficient for titration of drugs. They should also have a smartphone with internet access.~Follow-up and management of heart failure medications provided by specialists at participating institutions. Doses of oral heart failure medications optimized within 6 weeks, provided clinical assessments and laboratory measures indicate that it is safe to increase doses."
88907633|NCT06304753|No Intervention|Usual Care|"Patients with chronic heart failure with low ejection fraction who was hospitalized due to decompensation of their condition. Their condition should be stabilized and blood pressure and renal function (Potassium level and eGFR) should be sufficient for titration of drugs. They should also have a smartphone with internet access.~Follow-up and management of heart failure medications provided by the patient's general physician and/or cardiologist according to local medical standards"
88907634|NCT06304727||enteral feeding group|Infants < 1 year old with bronchiolitis and exclusive nutritional impairment who underwent short-term enteral feeding and monitoring in the emergency room according to the 2022-2024 seasons protocol
88907635|NCT06304714||Patient from french Guiana|15 patients suffering from envenomation by Bothrops bites endemic to French Guiana
88907636|NCT06304714||Patient from Martinique|15 patients suffering from envenomation by Bothrops Lanceolatus bites endemic to Martinique.
88907637|NCT06304701|Experimental|Experimental arm : Adults with autism spectrum disorder|All of the interventions described below
88907638|NCT06304701|Active Comparator|Control arm : Adults with typical development|All of the interventions described below
88907639|NCT06304688|No Intervention|Control Group|The control group (CG) will not undergo treatment, which will be evaluated in the pre- and post-phase of the study. Participants assigned to this group will receive general advice on the positive effects of regular physical activity, and they will be given the guide of recommendations for the promotion of physical activity.
88907640|NCT06304688|Experimental|Experimental Group|The experimental group (EG), after an initial evaluation, will be subjected to a physical training program based on the yoga method, for 12 weeks with 2 weekly sessions (Tuesday and Thursday), with a duration of 45 minutes per session. Once the intervention is finished, you will undergo a final evaluation again to see if there is a difference or not with the results obtained at the beginning.
89196533|NCT01046305||Part 2: Symptoms Rating|Importance of symptoms to CML patients rated by physicians, nurses, patients, and caregivers.
89196534|NCT01046305||Part 3: MDASI-CML Questionnaires|Patients questionnaires about CML symptoms over 1 year using M. D. Anderson Symptom Inventory (MDASI) module (the MDASI-CML)
88907643|NCT06304649|Experimental|Cast21 Short Arm Product|
89196535|NCT00831519||Macrosomial, GD|
89196536|NCT00831519||Macrosomial, control|
89196537|NCT01046383|Experimental|IMN1207|"Dietary Supplement: IMN1207~Stratum A: CRP <40 mg/L and WBC < 11x109/L (i.e. subjects with relatively low levels of inflammation).~Stratum B: CRP ≥ 40 mg/L and/or WBC ≥ 11x109/L (i.e. subjects with relatively high levels of inflammation."
89426858|NCT04064567|Active Comparator|Enhanced Standard of Care|PrEP education and referral to a community-based PrEP provider (enhanced standard of care)
89426859|NCT04064567|Experimental|Community Health Worker Involved Enhanced Standard of Care|PrEP education, referral to a community-based PrEP provider, and referral to a CHW who will facilitate access to community-based PrEP and other healthcare and social-support services.
89426860|NCT04061876|Experimental|Ruxolitinib combined with Corticosteroids|Participants began oral administration of ruxolitinib at 5 mg QD; Methylprednisolone: 1mg/kg/d , iv or iv gtt for at leas 5 days, then taper according to the clinical response.
89426861|NCT04061876|Active Comparator|Corticosteroids|Methylprednisolone: 2mg/kg/d , iv or iv gtt for at least 1 week, then taper according to the clinical response.
89426862|NCT04058457||STN DBS|Patients planned to undergo deep brain stimulation of the subthalamic nucleus
89426863|NCT04058457||GPi DBS|Patients planned to undergo deep brain stimulation of the globus pallidus interna
89426864|NCT04058457||VIM DBS|Patients planned to undergo deep brain stimulation of the ventral intermediate nucleus of thalamus.
89426865|NCT04048759|Other|Remote Low|
89426866|NCT04048759|Other|Remote High|
89426867|NCT04048759|Other|Personal Coach|
89426868|NCT04046796||Healthy twin|
89426869|NCT04046796||Effected Twin|Twin with unclear rare diseases, clinically characterized in the context of outpatient/ inpatient standard care at the University Hospital Tübingen (UKT) or cooperating location.
89426870|NCT04037527|Experimental|Neoadjuvant Chemotherapy Plus Radiation Therapy|Up to 6 cycles (once a week) of chemotherapy with a 3+3 dose escalating plan (from 100 mg to 300 mg for Gemcitabine; 10 mg to 25 mg for Docetaxel) along with radiation (five days a week) for up to 6 weeks.
89426871|NCT04027374||Fetal surgery group|Newborns after successful fetal surgery for MMC, delivered by elective c-section at weeks 35;0 - 37;0.
89426872|NCT04027374||Glucocorticoid control group|Healthy newborns after exposure to synthetic glucocorticoids for lung maturity during pregnancy, delivered by elective c-section between 35;0 - 40;0 weeks, matched for child sex with group 1. This group is needed to control for the effects of sGC exposure.
89426873|NCT04027374||Healthy controls|Healthy newborns, uncomplicated pregnancy, delivered at term by elective c-section between 36;0 - 39;0 weeks. Matched for child sex with group 1.
89426874|NCT04027296||suspected COPD|Patients aged ≥ 35yo and ≥10Pack.Year
89426875|NCT04027101|Experimental|Experimental group|Oral baricitinib 4mg/day for 12 weeks. Then, at week 12, if PMR-AS≤10, patients will receive baricitinib 2 mg for 12 weeks. If PMR-AS ≤10, the patients will not receive any treatment until W24 At W24, if PMR-AS>10, they will receive GCs according to the PMR-AS (PMR-AS<10: no GCs, PMR-AS between 10-20: 10mg/day, PMR-AS between 21-30: GCs at 15mg/d and if PMR-AS> 30: 20mg/d or more according to investigator's opinion). Dosage of GCs will be decreased (1 mg every week) or increased according to PMR-AS (PMR-AS < 10: decrease, PMR-AS > 20 increase, 10 ≤ PMR-AS ≤ 20: stable dose) according to investigator's opinion.
89426876|NCT04027101|Placebo Comparator|Control group|Oral placebo every day during 3 months (W12). Then, at week 12, if PMR-AS ≤10, placebo for 12 weeks. If PMR-AS ≤10, the patients do not receive any treatment until a flare. If PMR-AS>10, they will receive GCs according to the PMR-AS (PMR-AS<10: no GCs, PMR-AS between 10-20: 10mg/day, PMR-AS between 21-30: GCs at 15mg/d and if PMR-AS> 30: 20mg/d or more according to investigator's opinion). Dosage of GCs will be decreased (1mg every week) or increased according to PMR-AS (PMR-AS < 10: decrease, PMR-AS > 20 increase, 10 ≤ PMR-AS ≤ 20: stable dose) and according to investigator's opinion.
89426877|NCT04009421||High and low coronary artery plaque burden|Patients with high plaque burden defined as plaque in >=4 segments of the coronary tree and low plaque burden as plaque in <4 segments of the coronary tree assessed by postprocessing of CT coronary angiography images and cardiovascular events and mortality.
89426878|NCT04007367|Experimental|Open-Label Phase: SAGE-217|Participants self-administered SAGE-217, 30 milligrams (mg), oral capsule, once daily (QD) in the evening from Day 1 to Day 14.
89426879|NCT04007367|Placebo Comparator|Double-Blind Phase: Placebo|Following the OL Phase, participants who exhibited a Hamilton Rating Scale for Depression (HAM-D) response, defined as a greater than or equal to (≥) 50% reduction from baseline in HAM-D total score were to be randomized to receive SAGE-217 matching placebo capsule, orally, QD, in the evening, in a total of five, 14-day treatment periods, each separated by a 6-week follow-up period during the 40-week DB Phase of the study. However, no participants were randomized to receive SAGE-217 matching placebo due to early study termination.
89426880|NCT04007367|Experimental|Double-Blind Phase: SAGE-217|Following the OL Phase, participants who exhibited a HAM-D response defined as a ≥ 50% reduction from baseline in HAM-D total score to SAGE-217 were randomized to receive SAGE-217, 30 mg, oral capsule, QD, in the evening, up to study termination date (i.e., up to approximately 22 weeks) during the DB Phase of the study.
89426881|NCT03997552|Experimental|Non-incised papillae surgical approach (NIPSA)|To access the defect, a single horizontal or oblique apical incision will be made in the mucosa located on the bony cortex, far from the marginal tissues and apically to the edge of the bony crest delimiting the defect. The incision will be extended mesiodistally as necessary to allow access to the defect and correct debridement of the granulation tissue. The tissue coronal to the incision will be raised full thickness, trying to maintain the preoperative papillae architecture intact. The granulation tissue and epithelium of the pocket will be eliminated. The affected root will be scaled and planed, and calculus eliminated. Once the defect will be debrided, the enamel matrix derivates will be applied. Then the incision line will be sutured by a double suture line to facilitate closing without tension: The first with internal horizontal mattress sutures to approximate the connective tissue of both edges of the mucosal incision, and the second with single interrupted sutures.
89426882|NCT03997552|Active Comparator|marginal approach by palatal incision|A small incision in the palatal aspect and a limited papila elevation to the buccal aspect will be made for treating isolated periodontal defect. Enamel matrix derivates will be applied on the debrided root surfaces.
89426883|NCT03997552|Active Comparator|Minimally invasive surgical technique (MIST)|The incision of the defect-associated papilla will be performed according to the principles of the papilla preservation techniques. Enamel matrix derivates will be applied on the debrided root surfaces. Stable primary closure of the flaps will be obtained with internal modified mattress sutures.
89426884|NCT03992430|Experimental|Part 1: Eteplirsen|Participants will receive eteplirsen 100 mg/kg once weekly for at least 4 weeks, followed by eteplirsen 200 mg/kg once weekly for at least 4 weeks.
89426885|NCT03992430|Active Comparator|Part 2: Eteplirsen 30 mg/kg|Randomized participants will receive eteplirsen 30 mg/kg once weekly for up to 144 weeks.
89426886|NCT03992430|Experimental|Part 2: Eteplirsen 100 mg/kg|Randomized participants will receive eteplirsen 100 mg/kg once weekly before the selection of the high dose occurs and then will receive the selected high dose once weekly for up to 144 weeks.
89426887|NCT03992430|Experimental|Part 2: Eteplirsen 200 mg/kg|Randomized participants will receive eteplirsen 200 mg/kg once weekly before the selection of the high dose occurs and then will receive the selected high dose once weekly for up to 144 weeks.
89426888|NCT03979885|Other|Goal-Directed Incentives|
89426889|NCT03979885|Other|Outcome-Based Incentives|
89426890|NCT03979885|Other|Enhanced Usual Care|
89426891|NCT03972072|Experimental|Single Intervention Arm|daily imaging for MR-IGRT once weekly offline plan adaptation subjective/objective LENT-SOMA xerostomia-evaluation including flow measurements at baseline, 6 month-, 12 month- and 24 month-follow up EORTC-QoL questionnaires at baseline, 6 month-, 12 month- and 24 month-follow up
89426892|NCT03967717||Patients with edematous states|Patients with edematous states receive standard of care diuretic.
89426893|NCT03966014|Active Comparator|EM-amoxicillin 3 x 10 days|
88907644|NCT06304636|Experimental|Part 1 Descartes-15 with lymphodepletion|Intra-patient dose escalation arm with three dose levels over the course of six infusions of cell product. Patients will receive lymphodepletion prior to initiating cell therapy.
88907645|NCT06304636|Experimental|Part 2 Arm 1 Descartes-15 with lymphodepletion|Descartes-15 infusions at the maximum tolerated dose level from Part 1. Patients will receive lymphodepletion prior to initiating cell therapy.
88907646|NCT06304636|Experimental|Part 2 Arm 2 Descartes-15 without lymphodepletion|Descartes-15 infusions at the maximum tolerated dose level from Part 1. Patients will not receive lymphodepletion prior to initiating cell therapy.
88907647|NCT06304623|Experimental|SVF cells treatment|40 subjects were treated with autologous SVF intravenous treatment.
88907649|NCT06304597|Experimental|Durvalumab-680LT and nivolumab-800CW|"Study procedure 1: Combined intravenous tracer administration with 15mg IMFINZI and 15mg OPDIVO followed by fluorescence molecular endoscopy~Study procedure 2: Combined intravenous tracer administration with 15mg IMFINZI and 15mg OPDIVO followed by fluorescence molecular endoscopy"
88907650|NCT06304571|Experimental|HC006 Dose Escalation|
88907651|NCT06304571|Experimental|HC006 Dose Expansion|
88907652|NCT06304558|Experimental|Intervention|"T The total number of sessions to be conducted for each patient will be 10 sessions, spread over 5 weeks, which means a frequency of twice a week.~Each NESA microcurrent session will last 60 minutes. A maximum time of 15 minutes will be allowed for connecting the patient at the beginning and for removing the device at the end.~During the 10 sessions of the treatment, the programming will evolve to optimize the response.~The directing electrode will be located throughout the treatment between the spinous processes of C6 and C7 to act generally on the individual, and in later sessions, the electrode will be placed in the abdominal area to cover the hypogastric plexus and at S2-S3 to influence the sacral plexus.~The intensity will be set to Low (3 volts) in all sessions, following the Arndt-Schulz law. The other device parameters range between 100-900 microamperes and between 1.14 and 14.29 hertz, and are preset by each program"
88907653|NCT06304558|Placebo Comparator|Placebo|Non-active Non-invasive Neuromodulation (NESA)
88907654|NCT06304506|Experimental|Young obese men|BMI [30, 40] Age [18, 35]
88907655|NCT06304506|Experimental|Young healthy men|BMI [20, 25] Age [18, 35]
88907656|NCT06304506|Experimental|Old healthy men|BMI [20, 25] Age [60, 75]
88907657|NCT06304493|Experimental|"Alarm ON Cohort"|"The ON cohort will receive the standard-of-care instructions for IS and information about the auditory and visual reminders. The ON cohort patients will receive audible and visual signals from the InSee monitor attached to their incentive spirometer every 20 minutes and upon successfully reaching certain achievements."
88907658|NCT06304493|Placebo Comparator|"Alarm OFF Cohort"|"The OFF cohort will receive only the standard-of-care instructions for IS. The OFF patients will receive no signals from the InSee monitor attached to their incentive spirometer."
88907659|NCT06304480|Experimental|100g fermented Tofu|Participants will consume 100 g Miso fermented tofu per day which may be consumed any way i.e. fried, grilled, baked, etc to taste or prepared from the list of recipes provided.
88907660|NCT06304480|No Intervention|Control|Participants will consume their regular diet
88907661|NCT06304467|No Intervention|Treatment As Usual (TAU)|Study Subjects randomized to treatment as usual (TAU) will not receive an intervention. They will continue with follow-up visits in the outpatient clinic as part of standard of care. .
89196538|NCT01046383|Placebo Comparator|Casein|"Dietary Supplement: Casein.~Stratum A: CRP <40 mg/L and WBC < 11x109/L (i.e. subjects with relatively low levels of inflammation).~Stratum B: CRP ≥ 40 mg/L and/or WBC ≥ 11x109/L (i.e. subjects with relatively high levels of inflammation."
89196539|NCT00838617||Participants with ALS|Participants diagnosed with ALS.
89426894|NCT03966014|Active Comparator|EM-amoxicillin 3 x 14 days|
89426895|NCT03966014|Active Comparator|EM-amoxicillin 2 x 14 days|
89426896|NCT03966014|Other|Controls|
89426897|NCT03962452|Other|Mitochondrial disease|Unresolved index patients with suspected mitochondrial disease
89426898|NCT03941886|No Intervention|Non-intervention group|Participants receive routine prenatal care
89426899|NCT03941886|Experimental|Intervention group|Participants receive first-trimester screening for preterm-preeclampsia by the Bayes based method followed by commencement of low-dose aspirin prophylaxis in high-risk women.
89426900|NCT03934866||Group A (LDCT)|"25,000 individuals who are at high-risk for lung cancer due to a significant smoking history.~Participants will receive at least 1 LDCT scan at baseline."
89426901|NCT03934710|Placebo Comparator|Placebo|Placebo
89426902|NCT03934710|Experimental|Serotonin agonist 13ug|13ug of serotonin agonist
89426903|NCT03934710|Experimental|Serotonin agonist 26ug|26ug of serotonin agonist
89426904|NCT03929926|Active Comparator|Group 1 (usual care)|receive usual care
89426905|NCT03929926|Experimental|Group II (outreach contact)|Patients receive educational materials in the mail about lung cancer screening with a cover letter from their physician. A week later, they receive a phone call from the study staff to assess their eligibility. Eligible and interested patients receive an office visit at the JLCSP for shared decision-making and possible lung cancer screening.
89426906|NCT03929926|Experimental|Group III (outreach + Decision Counseling Program)|Patients receive educational materials in the mail about lung cancer screening with a cover letter from their physician. A week later, they receive a phone call from the study staff to assess their eligibility. Patients then undergo a decision counseling session through a semi-structured Decision Counseling Program that includes a review of the mailed educational materials and completion of an interactive exercise intended to clarify personal preference related to screening options (to have LDCT or not to have LDCT). Patients interested in screening schedule an office visit at JLCSP for possible screening or are referred to their primary care physician for consultation.
89426907|NCT03914547|Experimental|REDCHiP intervention arm|REDCHiP uses 10- video-based telemedicine sessions to deliver T1D education, behavioral parent training, and problem-solving to enhance parents' knowledge and skills. Sessions last about 45-60 minutes each.
89426908|NCT03914547|Active Comparator|Attention Control arm|ATTN uses 10- video-based telemedicine sessions to deliver general patient education specific to young children. Similar to REDCHiP, all ATTN sessions last 45-60 minutes.
89426909|NCT03900650|Experimental|Alcoholic beverage, High Provocation Manipulation|Participants will receive a dose of alcohol mixed in fruit juice designed to achieve a peak breath alcohol concentration of .08%. Participants then receive an experimental manipulation designed to evoke negative emotions such as frustration.
89426910|NCT03900650|Experimental|Non-alcoholic beverage, High Provocation Manipulation|Participants will receive a beverage that does not contain alcohol (fruit juice only). Participants then receive an experimental manipulation designed to evoke negative emotions such as frustration.
88907662|NCT06304467|Experimental|Contingency Management (CM)|Study subjects who have received a liver transplant and have been randomized to the treatment arm will receive contingency management, a positive reinforcement behavioral treatment with escalating rewards for consecutive either negative urine and blood tests (or lower value of metabolites than the previous week for PeTH) depending on which results are received first, capped at a maximum of $80 (in the form of a gift card) at the week 10 visit.
88907663|NCT06304454|Experimental|Cognitive and emotional board games|An experimental group that will carry out the cognitive and emotional game program in the classroom implemented by the teachers of the participating centers.
88907664|NCT06304454|Active Comparator|Motor/Luck board games|A control group that will be on board games that do not directly activate cognitive and emotional processes. These games are classified as motor or luck board games.
88907665|NCT06304441|Experimental|Group A|Intra-pemetrexed plus third-generation small molecule TKI drugs (e.g. 'osimertinib')
88907666|NCT06304441|Active Comparator|Group B|Third-generation small molecule TKI drugs (e.g. 'osimertinib') alone
88907667|NCT06304428|Active Comparator|Deprescribing Care Model|In this pragmatic, cluster randomized crossover trial 42 Skilled Nursing Facilities (SNF) will each receive 6 months of each care model in random sequence. All patients with OP fracture admitted to the SNF within the intervention time period will receive the full designated care model, even if their stay in the SNF extends into the next intervention period.
88907668|NCT06304428|Active Comparator|Bone Heath Service Model|In this pragmatic, cluster randomized crossover trial 42 Skilled Nursing Facilities (SNF) will each receive 6 months of each care model in random sequence. All patients with OP fracture admitted to the SNF within the intervention time period will receive the full designated care model, even if their stay in the SNF extends into the next intervention period.
88907669|NCT06304428|Active Comparator|Injury Prevention Service Model|In this pragmatic, cluster randomized crossover trial 42 Skilled Nursing Facilities (SNF) will each receive 6 months of each care model in random sequence. All patients with OP fracture admitted to the SNF within the intervention time period will receive the full designated care model, even if their stay in the SNF extends into the next intervention period.
88907670|NCT06304415||Working General Population|Consenting hospital staff are recruited to this study. Blood test and questionnaires are taken at baseline. Prospective follow-up of cardiovascular events are undertaken.
89007715|NCT02855476||Advanced Manifest HD|"Participants eligible are persons who meet the following criteria:~Are 21-75 years of age, inclusive, at the time of consent; and~Have clinical diagnostic motor features of HD, defined as UHDRS Diagnostic Confidence Score = 4; and~Have CAG expansion ≥ 40; and~Have Stage IV HD, defined as UHDRS TFC scores between 0 and 2, inclusive"
89196540|NCT04044261|Experimental|Study Arm|Single open-label study arm. All participants are enrolled into this arm.
89196541|NCT00838773|Experimental|YMSM|Young Men Who Have Sex with Men
89196542|NCT00838773|Experimental|YHA|Young Heterosexual Adults
89196543|NCT00838773|Experimental|ROMA|Gypsies (Bulgarian)
89196544|NCT00838773|No Intervention|Control|All study participants (including those in control condition networks) receive HIV/AIDS/STD risk reduction counseling at baseline, as well as testing and treatment or treatment referral for STDs and HIV infection. STD/HIV testing and treatment or treatment referral are provided at each followup point. This constitutes the control intervention.
88907671|NCT06304402|Experimental|Proprioceptive Neuromuscular Facilitation Stretching|Proprioceptive Neuromuscular Facilitation Stretching Group participants will undergo one session of PNF posterior shoulder stretching exercise in the modified sleeper position.
88907672|NCT06304402|Experimental|The Percussive Massage Treatment|The Percussive Massage Treatment Group participants will receive a 5-minute massage on the posterior deltoid area.
88907673|NCT06304389|Experimental|Patients with refractory epilepsy|Patients will not receive any drugs, but will participate to experiments involving electroencephalograpy, pupillometry and light administration.
88907674|NCT06304389|Experimental|Healthy subjects|Subjects will not receive any drugs, but will participate to experiments involving electroencephalograpy, pupillometry and light administration.
88907675|NCT06304376|Other|study group|This study group contains of patient who had alveolar cleft, indicated for late secondary alveolar grafting
88907676|NCT06304363|Experimental|Physical activity|Patients are encouraged to participate in physical exercise at the psychiatric unit
88907677|NCT06304350|Experimental|Combination of pembrolizumab and platinum containing dual drugs|After 2 courses of treatment with pembrolizumab combined with platinum containing dual drugs (albumin paclitaxel+carboplatin), surgery was performed, and postoperative pembrolizumab immunomaintenance therapy continued
88820449|NCT06149598|Experimental|Coughing at the time of first biopsy|Patients are asked to cough during the first biopsy. They should not cough during the second biopsy, and no additional interventions will be performed during the second biopsy.
88820450|NCT06149598|Active Comparator|Coughing at the time of second biopsy|Patients are asked to cough during the second biopsy. They should not cough during the first biopsy, and no additional interventions will be performed during the first biopsy.
89007716|NCT02855476||Incomplete Penetrance HD|"Participants eligible are persons who meet the following criteria:~Are 18-75 years of age, inclusive, at the time of consent; and~Have CAG expansion of 36-39"
89196545|NCT00838851|Experimental|CCRE|
88820451|NCT06149338|Experimental|Patients being intubated using Macintosh laryngoscope|
88820452|NCT06149338|Experimental|Patients being intubated using Vie Scope laryngoscope|
88820453|NCT06147609|Active Comparator|children with lower lingual holding arch space maintainer|non functional fixed space maintainer used in the mandibular arch to maintain arch length by prevention of mesial movement of permanent first molar
88820454|NCT06147609|Active Comparator|children with removable partial denture space maintainer|functional Removable space maintainer that not only maintain the mesiodistal space, but vertical dimension and masticatory function is also assured
89426911|NCT03900650|Experimental|Alcoholic beverage, Low provocation manipulation|Participants will receive a dose of alcohol mixed in fruit juice designed to achieve a peak breath alcohol concentration of .08%. Participants receive an experimental manipulation designed to evoke positive emotions.
88907678|NCT06304337|No Intervention|Ordinary oral cushion set|Before anesthesia induction, patients in the experimental group received 5-6L/min of oxygen for about 1min through the endoscopic bite connecting oxygen supply device, and patients in the control group inhaled 5-6L/min of oxygen for about 1min through the nasal catheter.Both groups were anesthetised with propofol 3mg/Kg and sufentanil 7ug.Sufentanil was given at the beginning of pre-oxygen inhalation, and propofol was given 1min later. After the subjects achieved sufficient sedation (about BIS40), The ordinary endoscopic bite group began to perform endoscopic operation after sufficient sedation was achieved,In both groups, 5mg/Kg/h propofol was continuously pumped to maintain anesthesia until completion of the examination.
89426912|NCT03900650|Experimental|Non-alcoholic beverage, Low provocation manipulation|Participants will receive a beverage that does not contain alcohol (fruit juice only). Participants then receive an experimental manipulation designed to evoke positive emotions.
89426913|NCT03896854|Experimental|CD19 positive relapsed or refractory acute myeloid leukemia|MICM typing confirmed CD19 positive relapsed and refractory acute myeloid leukemia
89426914|NCT03890120|Experimental|Cilofexor 100 mg (Blinded Phase)|Participants received cilofexor 100 mg tablet, orally, once daily for up to 100.3 weeks.
89426915|NCT03890120|Placebo Comparator|Placebo (Blinded Phase)|Participants received placebo to match cilofexor 100 mg tablet, orally, once daily for up to 98.1 weeks.
89426916|NCT03890120|Experimental|Cilofexor From Cilofexor 100 mg (OLE Phase)|Participants who received cilofexor in blinded phase and had entered the open-label extension (OLE) phase received open-label cilofexor 100 mg tablet, orally, once daily for up to 44.7 weeks.
89426917|NCT03890120|Experimental|Cilofexor From Placebo (OLE Phase)|Participants who received placebo in blinded phase and had entered the OLE phase received open-label cilofexor 100 mg tablet, orally, once daily for up to 45.0 weeks.
89426918|NCT03867370|Experimental|Group A|During the neoadjuvant period, the patients will receive a single dose JS001 intravenous infusion of 480 mg. After the operation, the patients will receive JS001 240 mg Q3W for up to 48 weeks.
89426919|NCT03867370|Experimental|Group B (Toripalimab, Lenvatinib)|During the neoadjuvant period, the patients will receive a single dose JS001 intravenous infusion of 480 mg in combination with oral lenvatinib at a starting dose of 8 or 12 mg once a day. After the operation, the patients will receive JS001 240 mg Q3W and lenvatinib for up to 48 weeks.
89426920|NCT03867370|Active Comparator|Group C (Toripalimab, Lenvatinib)|During the neoadjuvant period, the patients will receive a single dose JS001 intravenous infusion of 480 mg in combination with oral lenvatinib at a starting dose of 8 or 12 mg once a day. After the operation, the patients will receive JS001 240 mg Q3W for up to 48 weeks.
88907679|NCT06304337|Experimental|New oropharyngeal airway group|Before anesthesia induction, patients in the experimental group received 5-6L/min of oxygen for about 1min through the endoscopic bite connecting oxygen supply device, and patients in the control group inhaled 5-6L/min of oxygen for about 1min through the nasal catheter.Both groups were anesthetised with propofol 3mg/Kg and sufentanil 7ug.Sufentanil was given at the beginning of pre-oxygen inhalation, and propofol was given 1min later. After the subjects achieved sufficient sedation (about BIS40), the new oropharyngeal airway group was placed into the oropharyngeal airway through the endoscopic bite and then began gastroscopy,In both groups, 5mg/Kg/h propofol was continuously pumped to maintain anesthesia until completion of the examination
88907680|NCT06304324|Placebo Comparator|Sham Block|0.2% ropivacaine for popliteal nerve block
88907681|NCT06304324|Active Comparator|Dexamethasone|0.1mg/kg dexamethasone added to 0.2% ropivacaine for popliteal nerve block
88907682|NCT06304324|Active Comparator|Dexmedetomidine|0.5ug/kg dexmedetomidine added to 0.2% ropivacaine for popliteal nerve block
88907683|NCT06304311|Active Comparator|Routine Obstetrics care (Control)|Participants in the control arm received routine obstetrics care, which typically includes standard prenatal care, monitoring during labor, and delivery management according to established hospital protocols. There were no additional interventions or techniques implemented beyond standard practice for managing labor and delivery.
88907684|NCT06304311|Experimental|Routine Obstetrics care & Lamaze breathing techniques and backside massage (Interventional group)|Participants in the experimental arm received routine obstetrics care, similar to the control group, along with additional interventions of Lamaze breathing techniques and backside massage. Lamaze breathing techniques were taught to participants during antenatal classes or individual sessions, focusing on deep breathing, relaxation, and pain management strategies during labor. Backside massage was administered by trained personnel using gentle, rhythmic strokes on the lower back to alleviate discomfort and promote relaxation during labor. These interventions were integrated into the labor and delivery process alongside routine obstetrics care.
88907685|NCT06304298|Active Comparator|Sham blocks|iPACK block with 20ml of 0.9% sodium chloride
88907686|NCT06304298|Active Comparator|iPACK block|iPACK block with 20ml 0f 0.2% ropivacaine
88907687|NCT06304285|Experimental|Acupuncture group|The subjects received acupuncture treatment at the following points: Tianshu, Zusanli, Hegu, Taichong, Shangjuxu, Jigou, Zhaohai, Lanwei and shousanli.
88907688|NCT06304285|Sham Comparator|control group|Treatment with comfort needle and comfort embedding needle
89196546|NCT00831597|Experimental|Bendamustine with rituximab|All patients received combination bendamustine with rituximab
89196547|NCT00622635|Experimental|Indacaterol 300 μg - placebo to indacaterol - salmeterol 50 μg|In treatment period 1, patients received indacaterol 300 μg once daily for 14 days via single-dose dry-powder inhaler (SDDPI); in treatment period 2, patients received placebo to indacaterol once daily for 14 days via SDDPI; and in treatment period 3, patients received salmeterol 50 μg twice daily for 14 days via multi-dose dry-powder inhaler (MDDPI). There was a washout period of 14 days between each treatment period. Indacaterol and placebo to indacaterol were administered double-blind; salmeterol was administered open-label. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
89536143|NCT03211819|Experimental|computer guided placement|"In the test group, the computer guided surgical guide manufactured using zenith 3D printer (Dentis, Daegu, Korea) will be used for implant drilling and placement (s-Clean Tapered Implants, Dentis Co., Ltd., Woram-Dong, Dalseo-Gu, Daegu, South Korea) following the manufacture's instructions.~Then in implants with primary stability > 35 Ncm2, the final abutment will be placed and any further adjustment would be done immediately in the lab and repositioned in place. Then the vacuum stent will be checked in its place again intraorally, then a chair side tooth coloured autopolymerizing resin (Structur 2 SC / QM,VOCO GmbH, Germany) will be injected into the vacuum sheet corresponding to the implant site to construct the temporary crown."
88907689|NCT06304272|Experimental|Irrigating Traumatic Wound with Drinking Water|In drinking water arm, acute traumatic wound will be cleaned with drinking water. Bacteriological safety of the drinking water will be ensured by testing water.
88907690|NCT06304272|Experimental|Irrigating Traumatic Wound with Normal Saline|In normal saline arm, acute traumatic wound will be cleaned with normal saline.
89196548|NCT00622635|Experimental|Placebo to indacaterol - salmeterol 50 μg - indacaterol 300 μg|In treatment period 1, patients received placebo to indacaterol once daily for 14 days via single-dose dry-powder inhaler (SDDPI); in treatment period 2, patients received salmeterol 50 μg twice daily for 14 days via multi-dose dry-powder inhaler (MDDPI); and in treatment period 3, patients received indacaterol 300 μg once daily for 14 days via SDDPI. There was a washout period of 14 days between each treatment period. Indacaterol and placebo to indacaterol were administered double-blind; salmeterol was administered open-label. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
89199188|NCT05953987|Experimental|aerobic exercise (EX)|The participant underwent aerobic exercises, either by running on a treadmill or on a regular floor surface. Each training session began with a 5-minute warm-up comprising stretching exercises. In weeks 1-4, moderate intensity was maintained, targeting 40-50% of the heart rate reserve (HRR) for a duration of 60 minutes. From weeks 5-8, the intensity increased to the range of 51-60% of the heart rate reserve, and a 5-minute cool down was added.
88907694|NCT06304246||Labor Pain Group (LPG)|LPG; pregnant women who will undergo emergency C-section with labor pain. Labor pain will be defined as having 3 or more regular uterine contractions in 20 minutes or &gt;120 Montevideo units of uterine performance observed during non-stress testing (NST) conducted at the Obstetrics Clinic.
88907695|NCT06304246||No Pain Group (NPG)|NPG; pregnant women who will undergo elective C-section without labor pain.
88907696|NCT06304233||Diagnosed with Schizophrenia|Patients with a ICD-10 diagnosis of Schizophrenia will undergo investigations to assess cardiac function, cardiovascular disease risk factors and DISC1 mRNA expression. Participants eligible for MRI will be invited to undergo cardiac MRI in addition to echocardiography.
88907697|NCT06304233||No mental health diagnosis|Participants without a mental health diagnosis will be randomly selected from an existing population registered in the HUNT data and biobank for whom, echocardiographic data and biological samples are available.Those enrolled as controls will be invited to participate in the cardiac MRI portion of the study.
88907698|NCT06304220|Active Comparator|Group DSG: Desogestrel|Desogestrel Cerazet® 75 mg/day orally from the first day of controlled ovarian hyperstimulation (COH) until the day of trigger with agonist (GnRH-a).
88907699|NCT06304220|Active Comparator|Group MPA: Medroxyprogesterone|Medroxyprogesterone acetate Progevera® 10 mg/day orally from the first day of controlled ovarian hyperstimulation (COH) until the day of trigger with agonist (GnRH-a).
89426921|NCT03866525|Experimental|Dose escalation and dose expansion|"A 3+3 dose-escalation strategy is used in the phase 1 part and 3 dose levels (10e6, 10e7 and 10e8 CCID50/mL) of OH2 are assessed as single agent and in combination with HX008. The recommended dose levels are then determined and adopted in the phase 2 part for dose-expansion.~In the phase 2 dose-expansion part, OH2 will be delivered as single agent in cohort 1, in combination with irinotecan in cohort 2, in combination with HX008 in cohort 3 and 4. There are no comparator arms for these cohorts."
89007717|NCT02855476||Juvenile Manifest HD|"Participants eligible are persons who meet the following criteria:~Are ≥11 years of age at the time of consent; and~Have clinical diagnostic features of juvenile HD, defined as UHDRS Diagnostic Confidence Score = 4 aged ≤20 years; and~Have CAG expansion ≥ 40"
89007718|NCT02855476||Healthy Control|"Participants eligible are persons who meet the following criteria:~Are 18-75 years of age, inclusive, at the time of consent; and~Have no known family history of HD; or~Have known family history of HD but have been tested for the huntingtin gene CAG expansion and are not at genetic risk for HD (CAG < 36)."
89007719|NCT02808650|Experimental|Treatment (prexasertib)|Patients receive prexasertib IV over 60 minutes on days 1 and 15. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
89007720|NCT02727803|Experimental|Myeloablative regimen 1|"Patients receive anti-thymocyte globulin IV over 4 hours on days -9 and -8, fludarabine phosphate IV over 1 hour, clofarabine IV over 1 hour, and busulfan IV over 3 hours on days -7 to -4. Patients undergo TBI on day -3.~UMBILICAL CORD BLOOD TRANSPLANT: Patients undergo umbilical cord blood transplantation on day 0.~NK CELLS INFUSION: Patients receive NK cells IV over 30 minutes between days 30-180."
89007721|NCT02727803|Experimental|Non-myeloablative regimen 2|"Patients with CD20 positive malignancies receive rituximab IV over 6 hours on day -9. Patients receive anti-thymocyte globulin IV over 4 hours on days -8 and -7, fludarabine phosphate IV over 1 hour on days -6 to -3, and cyclophosphamide IV over 3 hours on day -6 and undergo TBI on day -1 at the discretion of the investigator(s).~UMBILICAL CORD BLOOD TRANSPLANT: Patients undergo umbilical cord blood transplantation on day 0.~NK CELLS INFUSION: Patients receive NK cells IV over 30 minutes between days 30-180."
89007722|NCT02727803|Experimental|Reduced intensity regimen 3|"Patients receive anti-thymocyte globulin IV over 4 hours on days -7 and -6, fludarabine phosphate IV over 1 hour on days -5 to -2, and melphalan IV over 30 minutes on day -2.~UMBILICAL CORD BLOOD TRANSPLANT: Patients undergo umbilical cord blood transplantation on day 0.~NK CELLS INFUSION: Patients receive NK cells IV over 30 minutes between days 30-180."
89007723|NCT02636998||Normal weight|BMI <85th percentile
89007724|NCT02636998||Obese|BMI > 95th percentile
89007725|NCT02630693|Active Comparator|Palbociclib (100mg)|Palbociclib 100mg PO daily plus Fulvestrant or Tamoxifen or another Aromatase Inhibitor at the standard doses/schedules
89007726|NCT02630693|Active Comparator|Palbociclib (125mg)|Palbociclib 125mg PO daily 3 out of 4 weeks plus Fulvestrant or Tamoxifen or another Aromatase Inhibitor at the standard doses/schedules
89007727|NCT02626338|Experimental|Arm A|"Mitoxantrone~Cytarabine~Crenolanib"
89007728|NCT02626338|Experimental|Arm B|"Fludarabine~Cytarabine~G-CSF~Idarubicin~Crenolanib"
89007729|NCT02626338|Experimental|Arm C|"Mitoxantrone~Etoposide~Cytarabine~Crenolanib"
89007730|NCT02622100||Bioresorbable Vascular Scaffold|
89426922|NCT03859921|Experimental|Dydrogesterone group|Oral dydrogesterone 10mg tds will be given for two weeks from the next day of the LH surge or hCG induced ovulation.
89426923|NCT03859921|Placebo Comparator|Placebo group|Placebo will be given given for two weeks from the next day of the LH surge or hCG induced ovulation.
89426924|NCT03859895||Observational (without bone scan)|Former Observational Arm participants of the ZiPP trial.
89426925|NCT03859895||Observational (with bone scan)|Former Interventional Arm participants of the ZiPP trial.
89426926|NCT03857672|Experimental|Hypnotic Cognitive Therapy (HYPNOCT)|The HYPNOCT arm will use hypnotic strategies and suggestions for identifying adaptive cognitions and for making adaptive changes in cognitions more integrated into the participant's belief system (note that traditional CT uses purposeful argument and logic to make these changes; in this condition the investigators add a hypnotic automaticity to this process). Thus, HYPNOCT is a hybrid intervention that overlaps with both hypnosis and CT. The participant will relax in a comfortable position and listen to the clinician speak. However, unlike standard hypnosis for pain, the post-induction suggestions will focus on changes in cognitive content and processes (as opposed to changes in sensory experience). The participants will undergo 6 weekly sessions each lasting 30-40 minutes.
89426927|NCT03857672|No Intervention|Usual Care|The study therapist will notify participants assigned to Usual Care via the participant's preferred mode of communication (phone, U.S. mail, or email). People assigned to usual care will be encouraged to continue using the health care services available to them to address their pain. The study therapist will emphasize the importance of completing the outcome assessments. The treatments usual care participants actually received will be assessed at 6 and 12 weeks.
89199189|NCT05953987|Other|sedentary control (CON)|The participant did not engage in the aerobic exercise training protocol or receive any form of supplementation during the study trial.
89426928|NCT03851419||People living with HIV|People living with HIV (ART naive or on ART)
89426929|NCT03851419||People not infected with HIV|HIV-negative people. Each participant is matched for age, sex and location to a study participant living with HIV
89426930|NCT03848325|Experimental|Sleep deprivation|All subjects will be provided an 8 hour opportunity for sleep (Night 1) followed by outcome assessment the next morning (Day 1). They will then be kept awake the subsequent 24 hours including Night 2, followed by outcome assessment the following morning (Day 2).
89007731|NCT02603146|Experimental|Hydroxychloroquine Group|Subjects randomized to hydroxychloroquine (HCQ). Subjects will receive 200-400 mg of HCQ (1-2 pills), based upon ideal body weight (IBW), taken daily for 12 months.
89426931|NCT03844412|Active Comparator|peripheral treatment|5% lidocaine/5 mg/ml 0.02% estradiol compound cream
89426932|NCT03844412|Active Comparator|central treatment|tricyclic antidepressant nortriptyline pill
89426933|NCT03844412|Active Comparator|combined peripheral and central treatments|5% lidocaine/5 mg/ml 0.02% estradiol compound cream and tricyclic antidepressant nortriptyline pill
89426934|NCT03844412|Placebo Comparator|placebo|placebo cream and placebo pill
89426935|NCT03826875|Experimental|Treatment|Patients randomized to the fluoxetine treatment group will be initially prescribed fluoxetine 20mg/day for a period of one year.
89426936|NCT03826875|Placebo Comparator|Placebo|Patients randomized to the placebo group will be initially prescribed placebo 20mg/day for a period of one year.
89426937|NCT03819361||Suspected OSA|
89426938|NCT03807076|Other|GIP-A|Infusion of GIP-A alone as a study tool.
89426939|NCT03807076|Placebo Comparator|Placebo|Saline
88907700|NCT06304207|No Intervention|Control|Control group participants will only be seen during the outcomes assessments at the MGH Institute of Health Professions at times 0, 1, and 2, but will receive no active supervised intervention. Control group participants will go home with discharge instructions to maintain a home exercise routine provided to them at discharge. Bi-weekly check in phone calls from the study team will continue to ensure participant engagement in the study. During the phone calls, participants will be encouraged to keep a log of their weekly activities in a journal.
88907701|NCT06304207|Experimental|Onsite Pulmonary Rehab|Supervised pulmonary rehabilitation including exercise training, activity counselling, and education provided onsite.
89199190|NCT05953948|Experimental|Intelligent case manage platform (ICMP) and self-management program|The experimental group received ICMP information. They could interact with the care manager via chatbot. The ICMP was established with information related to care instruction after liver transplantation.
89199191|NCT05953948|No Intervention|usual care|Participants in the control only received the usual care that included wound care, medication, and infection control.
89426940|NCT03802591|Experimental|CS1001 monoclonal antibody|in combination with Oxaliplatin and Capecitabine
89426941|NCT03802591|Placebo Comparator|CS1001 placebo|in combination with Oxaliplatin and Capecitabine
89426942|NCT03793114|Experimental|Detectable levels of adrenal hormones|Patients with detectable serum levels of adrenal hormones will go through cosyntropin stimulation testing.
89426943|NCT03793114|Active Comparator|Controls with undetectable hormone levels|Twenty patients without detectable serum levels of adrenal hormones will serve as controls in cosyntropin stimulation testing.
89426944|NCT03793114|No Intervention|Undetectable levels of adrenal hormones|Patients without detectable serum levels of adrenal hormones. Cosyntropin stimulation testing will not be performed.
89426945|NCT03793114|Other|Congenital adrenal hyperplasia (CAH) control group|Mapping adrenal steroid profile in patients with congenital adrenal hyperplasia (CAH) with confirmed total deficiency of 21-hydroxylase.
89426946|NCT03793114|Other|Bilaterally adrenalectomized control group|Mapping adrenal steroid profile in patients who are bilaterally adrenalectomized.
89426947|NCT03793114|Experimental|Diurnal variation in residual adrenocortical hormone levels|Patients with detectable serum levels of adrenal hormones will go through a 30-hour ambulatory sampling of interstitial fluid for mapping of any diurnal variation in endogenous adrenocortical secretion.
89426948|NCT03793114|Experimental|Repeated cosyntropin testing in newly diagnosed patients|Newly diagnosed patients will be invited to go through repeated cosyntropin testing to delineate the natural progression of adrenocortical failure.
89426949|NCT03793114|Active Comparator|Cardiovascular and inflammatory biomarkers|Compare cardiovascular and inflammatory biomarker profiles in patients with and without residual production of adrenocortical steroids
89426950|NCT03783689|Active Comparator|Group 1 (Treatment)|Subjects in Group 1 will have Leads placed in the residual limb in the upper leg. These subjects will then use the SPRINT Peripheral Nerve Stimulation (PNS) System and will receive electrical stimulation for 8 weeks.
89426951|NCT03783689|Sham Comparator|Group 2 (Control)|Subjects in Group 2 will have Leads placed in the residual limb in the upper leg. These subjects will then use the SPRINT Peripheral Nerve Stimulation (PNS) System and receive 8 weeks of sham stimulation. Subjects will then have the option to crossover and receive stimulation therapy.
89426952|NCT03771664|Placebo Comparator|Placebo|Participants received SAGE-217 matching placebo capsules (single-blind), orally, once daily prior to Day 1 (Days -2 and -1) followed by self-administration of SAGE-217 matching placebo capsules, orally, once daily for 12 days. Thereafter participants received SAGE-217 matching placebo capsules, orally, once daily, 30 minutes prior to lights out [polysomnography (PSG)] on Days 13 and 14 (double-blind). Thereafter participants self-administered SAGE-217 matching placebo capsules (single-blind), orally, once daily on Days 15 to 21.
89426953|NCT03771664|Experimental|SAGE-217|Participants received SAGE-217 matching placebo capsules (single-blind), orally, once daily prior to Day 1 (Days -2 and -1) followed by self-administration of SAGE-217, 30 milligrams (mg) capsules, orally, once daily for 12 days. Thereafter participants received SAGE-217, 30 mg capsules, orally, once daily, 30 minutes prior to lights out (PSG) on Days 13 and 14 (double-blind). Thereafter participants self-administered SAGE-217 matching placebo capsules (single-blind), orally, once daily on Days 15 to 21.
89426954|NCT03762447|Experimental|INCB086550|
89426955|NCT03753074|Experimental|Treatment Arm A (TAF)|390 subjects administered Tenofovir Alafenamide 25 mg once daily
89426956|NCT03753074|No Intervention|Treatment Arm B (Best supportive care)|"390 subjects received best supportive care~During treatment period, among treatment arm B, subjects who are indicated for antiviral treatment will be treated with TAF as follows:~Based on the AASLD 2018 Guidelines of CHB (ALT 70≥ for male, 50≥ for female)~40≤ALT levels<70 IU/L (males) or 40≤ ALT levels<50 IU/L (females) with evidence of significant fibrosis(F2; ≥7.2 kPa) as measured by either liver biopsy, Fibroscan or MR elastograpy performed within 3 months.~If they were clinically judged to have cirrhosis by investigators and confirmed with Fibroscan (≥ 12.0 kPa)."
89426957|NCT03752411|Experimental|Research Bottle|This group will have medication dispensed in a research bottle.
89426958|NCT03752411|Placebo Comparator|Regular prescription Bottle|This group will have medication dispensed in a regular prescription bottle
89426959|NCT03743415|Experimental|Handbook|The Symptom Management and Survivorship Handbook is a self-care management handbook with each symptom chapter presented in an identical format: what the symptom is, how people describe the symptom, the causes of the symptom, strategies for managing the symptom and resources. The Handbook is available in English and Spanish. Each weekly call will begin with the symptom assessment. For each symptom rated at 4 or higher on a 0-10 scale of severity, the survivors will be referred for symptom self-management. During weeks 2-12, Handbook use since the last call (intervention enactment) and symptoms will be assessed. During weekly calls to caregivers, the caregivers will be notified of symptoms above threshold experienced by survivors and directed to the Handbook. During weeks 2-12, Handbook use and symptoms are assessed, a summary of survivors' symptoms provided. Calls will last about 10 minutes.
89196549|NCT00622635|Experimental|Salmeterol 50 μg - indacaterol 300 μg - placebo to indacaterol|In treatment period 1, patients received salmeterol 50 μg twice daily for 14 days via multi-dose dry-powder inhaler (MDDPI); in treatment period 2, patients received indacaterol 300 μg once daily for 14 days via single-dose dry-powder inhaler (SDDPI); and in treatment period 3, patients received placebo to indacaterol once daily for 14 days via SDDPI. There was a washout period of 14 days between each treatment period. Indacaterol and placebo to indacaterol were administered double-blind; salmeterol was administered open-label. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
89196550|NCT00622635|Experimental|Placebo to indacaterol - indacaterol 300 μg - salmeterol 50 μg|In treatment period 1, patients received placebo to indacaterol once daily for 14 days via single-dose dry-powder inhaler (SDDPI); in treatment period 2, patients received indacaterol 300 μg once daily for 14 days via SDDPI; and in treatment period 3, patients received salmeterol 50 μg twice daily for 14 days via multi-dose dry-powder inhaler (MDDPI). There was a washout period of 14 days between each treatment period. Indacaterol and placebo to indacaterol were administered double-blind; salmeterol was administered open-label. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
89196551|NCT00622635|Experimental|Indacaterol 300 μg - salmeterol 50 μg - placebo to indacaterol|In treatment period 1, patients received indacaterol 300 μg once daily for 14 days via single-dose dry-powder inhaler (SDDPI); in treatment period 2, patients received salmeterol 50 μg twice daily for 14 days via multi-dose dry-powder inhaler (MDDPI); and in treatment period 3, patients received placebo to indacaterol once daily for 14 days via SDDPI. There was a washout period of 14 days between each treatment period. Indacaterol and placebo to indacaterol were administered double-blind; salmeterol was administered open-label. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
89199192|NCT05953922|Active Comparator|treatment group|The treatment group will engage in transcutaneous electrical stimulation (TENS) and core stability exercises for three sessions each week for four weeks.
88820480|NCT06113913|Experimental|Interventional comparator (SC infliximab, bi-weekly)|Participants will switch from an optimized dose of intravenous infliximab to subcutaneous infliximab. This means the participants will inject 120 mg subcutaneous infliximab every other week.
89426960|NCT03743415|Experimental|TIP-C plus Handbook|Each survivor and caregiver will receive one 40-minute telephone call per week for 12 weeks. The Telephone Interpersonal Counseling (TIP-C) intervention 8-week protocol is the same for both survivor and caregiver. During weekly contacts, the counselors target social support behaviors using interpersonal communications techniques. Counselors can personalize the counseling intervention for the specific needs or interests as expressed during sessions while still adhering to a structured protocol. The final 4 weeks will be Handbook only.
89426961|NCT03739853|Active Comparator|Standard care|Control 'step-up' therapy in the cohort (MONITOR-PsA study). Therapy for the cohort is defined by standard NHS practice following international recommendations and National requirements for the prescription of biologic therapy[19-22]. Commonly Initial therapy will be with methotrexate alone (15mg/week rising to 25mg/week as tolerated by week 8 of therapy) unless this is contraindicated. In cases of non-response or intolerance to methotrexate, participants will have an alternative DMARD (most commonly sulfasalazine or leflunomide) added or switched to. In cases of failure of two DMARDs, treatment can be escalated to biologic therapy as per National Institute for Health and Clinical Excellence (NICE) recommendations. If the requisite disease activity is not met or if there are contraindications to biologics, alternative DMARD combinations will be used.
89536833|NCT03309059|Placebo Comparator|water and soap|Will be composed of elderly patients who present with fecal and / or urinary incontinence and who, therefore, need to implement measures to prevent the development of IAD with the use of soap and water in the area and subsequent diaper placement disposable. This type of procedure is standardized in the medical clinic wards of the hospital under study, and for this reason, it was defined as control.
89196552|NCT00622635|Experimental|Salmeterol 50 μg - placebo to indacaterol - indacaterol 300 μg|In treatment period 1, patients received salmeterol 50 μg twice daily for 14 days via multi-dose dry-powder inhaler (MDDPI); in treatment period 2, patients received placebo to indacaterol once daily for 14 days via single-dose dry-powder inhaler (SDDPI); and in treatment period 3, patients received indacaterol 300 μg once daily for 14 days via SDDPI. There was a washout period of 14 days between each treatment period. Indacaterol and placebo to indacaterol were administered double-blind; salmeterol was administered open-label. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
88907702|NCT06304207|Experimental|Telehealth Pulmonary Rehab|Supervised pulmonary rehabilitation including exercise training, activity counselling, and education provided remotely using Zoom videoconferencing technology.
89196553|NCT00391027|Active Comparator|Insulin Glargine (Lantus®)|
89536834|NCT03309059|Active Comparator|zinc oxide|will be composed of elderly patients who present with fecal and / or urinary incontinence and who, therefore, need to implement measures to prevent the development of IAD with the use of soap and water sanitation and application of zinc oxide . The patient presenting with urinary and / or fecal eliminations will undergo such intervention and then the placement of the disposable diaper used by the hospital.
88907703|NCT06304194|Other|Patients with suspected diagnostic onco-hematologic/immunologic disease|"All patients with suspected diagnostic onco-hematologic, onco-immunologic, and hematologic disease at onset or relapse.~Patients undergo several procedures to complete the diagnostic process and eventually the staging of the disease"
88907704|NCT06304181|Experimental|Paracetamol and Mannitol Injection group|Paracetamol and Mannitol Injection 500mg was given intravenously 30 minutes before the end of the operation
88907705|NCT06304181|Active Comparator|Parecoxib group|40mg of parecoxib was given intravenously 30min before the end of the operation
88907706|NCT06304168||Observational|Patients undergo blood, urine, and/or residual tissue sample collection and have their medical records reviewed on study.
88907707|NCT06304129|Experimental|Blood ponction|All patients are in the experimental group
88907708|NCT06304077|Experimental|forest|virtual reality (VR) assisted gait therapy in a forest landscape
88907709|NCT06304077|Experimental|urban|virtual reality (VR) assisted gait therapy in a urban landscape
88907710|NCT06304077|Experimental|rural|virtual reality (VR) assisted gait therapy in a rural landscape
88907711|NCT06304077|No Intervention|control|standard gait therapy
88907712|NCT06304051|Active Comparator|Intermittent Oro-esophageal Tube Feeding|the nasogastric tube was removed, and Intermittent oro-esophageal tube feeding was initiated for nutrition support within 4 hours after completing the admission assessment, following the standard Intermittent oro-esophageal tube feeding procedure.
88907713|NCT06304051|Active Comparator|Nasogastric Tube|This group was provided with nutrition support by the indwelling nasogastric tube. The entire feeding process strictly followed the standardized procedure for nasogastric feeding.
88907714|NCT06304038||Vaccinated subjects|Healthcare workers that received quadrivalent split inactivated non-adjuvanted flu vaccine Fluarix Tetra in a single administration
88907715|NCT06304038||Unvaccinated subjects|Healthcare workers that did not received flu vaccine
88907716|NCT06304025|Experimental|Thawed allogeneic WJ-MSCs|Administration intravenously of 1x106 cells/kg weight of thawed allogeneic WJ-MSCs
88907717|NCT06304025|Experimental|Expanding allogeneic WJ-MSCs|Administration intravenously of 1x106 cells/kg weight of expanding allogeneic WJ-MSCs
89426962|NCT03739853|Experimental|Combination csDMARD|Arm 2 - Combination DMARD arm. All participants will be prescribed methotrexate with an additional DMARD (either sulfasalazine or leflunomide) at baseline. Response will be assessed after 12 weeks of therapy using the Minimal Disease Activity (MDA) criteria. Participants who achieve the MDA criteria by week 12 on this combination therapy will continue . Participants who show a significant response by in week 12 (a reduction in tender and swollen joint counts of at least 20%) but do not yet meet the MDA criteria should continue on this therapy for an additional 12 weeks before review. Participants failing to show significant response (reduction in joint counts by less than 20%) by week 12 on this combination therapy or those failing to meet MDA criteria by week 24 will be eligible for rescue therapy
88907720|NCT06303921|Experimental|11C-M503 PET|Participants will undergo 11C-M503 PET scan, they may also have a brain MRI and Amyloid PET scan as well as neurological assessments.
88907721|NCT06303895|Experimental|routine treatment+swallowing rehabilitation training+acupuncture therapy|The group was given routine treatment and swallowing rehabilitation training. Moreover, the experimental group was given acupuncture therapy.
88907722|NCT06303895|Active Comparator|routine treatment+swallowing rehabilitation training|The control was given routine treatment and swallowing rehabilitation training
88907723|NCT06303869|Experimental|Deep Brain Stimulation of the Motor Thalamus|Individuals who have speech and motor deficits due to a stroke.
88907724|NCT06303856|Experimental|Active Breathing Exercises|The observation group is the only group of the participants.The elderly individuals will be arranged to undergo a continuous three-week (21 days) duration of Active Breathing Exercises, with weekends off and training conducted only on weekdays. Apart from this,we require participants to only engage in daily activities and avoid strenuous and dangerous behaviors.
88907725|NCT06303843|Experimental|Intervention group|Transfer to the operating theatre with an electric ride-on car
88907726|NCT06303843|No Intervention|Controlled group|Transfer to the operating theatre with a paediatric trolley
88907727|NCT06303830|Active Comparator|Control group|Sodium nitrate, once a day for 14 days
88907728|NCT06303830|Experimental|Bariatric group|Sodium nitrate, once a day for 14 days
88907729|NCT06303804|Experimental|Educational videos arm|
88907730|NCT06303778|Active Comparator|Standard Care|Participants assigned to the standard care condition will receive standard MAUD care delivered by their CPSs and will not receive access to SD-App. Three medications, naltrexone, disulfiram, and acamprosate, have been approved by the Federal Drug Administration and topiramate has been recommended by the VA/DoD clinical practice guidelines for SUD. MAUD includes these four medications. All medication decisions will be between the CPS and the Veteran and not influenced by study participation.
88907731|NCT06303778|Experimental|Combined MAUD+SD-App|In addition to standard MAUD care, participants assigned to the MAUD+SD-App condition will receive access to the Stand Down app at randomization.
88907732|NCT06303765|Experimental|PReDAS intervention|All participants will receive the PReDAS intervention during the study. As per concurrent multiple baseline designs, each participant will be randomized as to WHEN they receive the PReDAS during the 6 month study period. Baseline lengths will vary from 2 to 5 months.
88907733|NCT06303752|Experimental|Autologous ADRC|Allocated patients will be treated for the fistula by combined surgical debridement of the fistula tract, closure of the internal orifice and injection of 30 ml lipoaspirate around the entire length of the fistula tract. Lipoaspirate will be harvested from the anterior abdominal wall under the same operation. Two hours later, the patient will receive injection of 5 ml suspension including 30 million autologous adipose-derived regenerative cells ADRC and injected at the same site of the lipoaspirate injection.
89007732|NCT02603146|Placebo Comparator|Placebo Group|Subjects randomized to placebo HCQ. Subjects will receive 200 - 400 mg of HCQ placebo (1-2 pills), based upon IBW, taken daily for 12 months.
89196554|NCT00391027|Active Comparator|Inhaled Human Insulin (Exubera®)|
89007733|NCT02579720||Group 1: Pollinex® Quattro Patients|Patients treated with Pollinex® Quattro
89196555|NCT00622401|Experimental|Group 1|Dendritic Cell/Tumor Fusion Vaccine Only
89426963|NCT03739853|Experimental|Early TNF inhibition|Early biologic arm. All participants will be prescribed methotrexate (given weekly) with a TNF inhibitor (adalimumab given every two weeks) at baseline. Treatment with TNF inhibitor will be continued until week 24 at which time the TNF inhibitor will be tapered to week 32. The TNF inhibitor will be stopped completely after week 32 and participants will continue on methotrexate. In case of flare of disease, participants will be eligible for rescue therapy
89426964|NCT03733184||The Christie NHS FT|Patients treated by Cytoreduction and Heated Intraperitoneal Surgery at The Christie NHS Foundation Trust (one of the two initial, primary treatment centres) for Colorectal Peritoneal Metastasis.
89426965|NCT03733184||Hampshire Hospitals NHS FT|Patients treated by Cytoreduction and Heated Intraperitoneal Surgery at Hampshire Hospitals NHS Foundation Trust (one of the two initial, primary treatment centres) for Colorectal Peritoneal Metastasis.
89426966|NCT03731572|Experimental|Power Training|Hip abductor-adductor resistance exercises at 75% maximum strength and maximum execution speed, 3, 1-hour training sessions per week for 12 weeks.
89426967|NCT03731572|Active Comparator|Strength Training|Hip muscle abductor-adductor resistance exercises at maximum strength at reduced execution speed (2s concentric/3s eccentric), 3, 1-hour training sessions per week for 12 weeks.
89426968|NCT03722693||Experimental group|Experimental group included subacute stroke patients with initial wrist extension. Each participant will receive 28 therapy sessions in total, that are divided into four blocks of 7 sessions. During the first 7 sessions the participant will receive standard care treatment (S), this block will be followed by first Functional electrical stimulation based treatment (FES intervention) block with 7 sessions of protocol A (AUTO or FUNCTION). Third block will consider additional 7 sessions of standard care (S). Fourth block will include 7 sessions of Functional electrical stimulation based treatment (FES intervention) with other type of treatment B (FUNCTION or AUTO).
89426969|NCT03707834|No Intervention|WIC Standard Care (SC)|Participants assigned to the WIC standard care arm will receive usual care offered to pregnant women at WIC.
89426970|NCT03707834|Experimental|Antenatal Obesity Treatment (AO)|The AO arm consists of a multi-component, theory- and evidence-based intervention and includes weight-related behavior change through goal setting and self-monitoring, behavioral skills training, interpersonal support, and social modeling strategies.
89426971|NCT03706677|Active Comparator|CRYO group|"Within the CRYO arm the ablation will be performed using the Arctic Front Advance Cardiac CryoAblation Catheter, including next generation systems as applicable and approved by Medtronic for the trial.~Intervention performed: Cryoballoon ablation; Cryoballoon (Arctic Front Advance Cryoballoon)"
89196556|NCT00622401|Experimental|Group 2|Dendritic Cell/tumor fusion vaccine and low dose IL-12
89196557|NCT00622401|Experimental|Group 3|Dendritic Cell/tumor fusion vaccine and higher dose IL-12
89196558|NCT00827853|Experimental|1|Conventional angioplasty balloon post-dilation of nitinol self expanding stents
89007734|NCT02579720||Group 2: Control Patients|Patients who decided to use only anti-allergic drugs during the grass pollen season
89196559|NCT00827853|Experimental|2|Cryoplasty balloon post-dilation
89199193|NCT05953922|No Intervention|control group|The transcutaneous electrical stimulation nerve stimulation will be administered to the control group just for three sessions each week for four weeks.
89426972|NCT03706677|Active Comparator|RF group|"Within the RF arm the ablation will be performed using a catheter out of the ThermoCool Smarttouch catheter family, including next generation contact force systems as applicable.~Intervention performed: Radiofrequency ablation; Radiofrequency Catheter (ThermoCool Smarttouch)"
89426973|NCT03680963|Experimental|Non-invasive strategy|Non-invasive strategy consisting of blood pressure monitoring by non-invasive automated cuff measurements
89426974|NCT03680963|Other|Control strategy|Usual strategy of systematic indwelling arterial catheter insertion in the early hours of acute circulatory failure
89426975|NCT03672175|Placebo Comparator|SAGE-217 Matched Placebo|Participants self-administered SAGE-217 matched placebo capsules, orally, once daily in the evening with food for 14 days.
89426976|NCT03672175|Experimental|SAGE-217 20 mg|Participants self-administered SAGE-217 20 milligrams (mg) capsules, orally, once daily in the evening with food for 14 days.
89426977|NCT03672175|Experimental|SAGE-217 30 mg|Participants self-administered SAGE-217 30 mg capsules, orally, once daily in the evening with food for 14 days.
89426978|NCT03670524|Experimental|Targeted neighborhoods for Greenness|Using greenness as a therapeutic intervention, we will plant shrubs, grasses, young and mature trees (40-50 ft in height), so that we can evaluate changes in health and pollution, 2 years after planting.
89196560|NCT04018365|Experimental|Treatment of empagliflozin|Empagliflozin 10 mg is to be continuously administered once daily for 12 weeks. Measure an HbA1c level after 12 weeks and determine the dose (Week 13 to Week 24). In case of <7.0%, 10 mg will be continued: in case of >=7.0%, it will be increased to 25 mg.
89426979|NCT03670524|No Intervention|Control Group|No intervention
89426980|NCT03653832|Experimental|Dexmedetomidine Group|For dexmedetomidine, the regimen will follow the manufacturer's guidance and regimens used in previous trials. Dexmedetomidine will be up and down titrated against sedation targets set by clinical staff and reviewed at regular intervals, and documented at least daily. No loading dose will be administered. The starting dose will be 0.7µg.kg-1.hour-1 titrated to a maximum dose 1.4µg.kg-1 hour-1. Lower starting doses will be used at clinical discretion for patients with cardiovascular instability.
89426981|NCT03653832|Experimental|Clonidine Group|For clonidine, the regimen is designed to be equipotent with dexmedetomidine based on known pharmacokinetics and pharmacodynamics. The chosen regimen is similar to that currently used in many UK ICUs as part of routine 'off label' practice. Clonidine will be up and down titrated against sedation targets set by clinical staff and reviewed at regular intervals, and at least daily. No loading dose will be administered. The starting dose will be 1.0µg.kg-1.hour-1 titrated to a maximum dose of 2µg.kg-1.hour-1. Lower starting doses will be used at clinical discretion for patients with cardiovascular instability.
89426982|NCT03653832|Active Comparator|Usual Care (Propofol) Group|Usual Care Group : Patients will continue to receive intravenous propofol according to usual current care . The sedation targets, weaning, and sedation discontinuation procedures will follow the same clinical targets as for the clonidine and dexmedetomidine groups.
89426983|NCT03650712|Other|frequently sampled oral glucose tolerance testing|frequently sampled oral glucose tolerance testing will be performed in a one-time cross sectional visit
89426984|NCT03650712|Other|Frequently sampled oral glucose tolerance testing anc CGM|frequently sampled oral glucose tolerance testing will be performed in a one-time cross sectional visit + continuous glucose monitor will be placed after the visit and mailed back
89426985|NCT03650712|Other|frequently sampled oral glucose tolerance testing and DXA|frequently sampled oral glucose tolerance testing will be performed in a one-time cross sectional visit + a DXA scan will be done at the same visit
89426986|NCT03650712|Other|frequently sampled oral glucose tolerance testing, CGM & DXA|frequently sampled oral glucose tolerance testing will be performed in a one-time cross sectional visit + continuous glucose monitor will be placed after the visit and mailed back + a DXA scan will be done at the same visit
88820481|NCT06113913|Active Comparator|Intravenous comparator (IV infliximab, optimized dosing schedule)|Participants not willing to switch will continue treatment with intravenous infliximab at the same dosing schedule as before.
89196561|NCT00839007|Experimental|A|Dose 1 of CD-NP
89426987|NCT03643276|Active Comparator|pB: early (non-)HR-standard/MR-standard|"Induction (5 wks): Protocol IA with prednisolone, vincristine, daunorubicin, pegaspargase, IT methotrexate (MTX)~Consolidation (6 w/4 w): Consolidation extended (control arm of randomization R-eHR) with cyclophosphamide, cytarabine, 6-mercaptopurine (6-MP), IT MTX, dexamethasone, vincristine, pegaspargase or Consolidation short (standard arm of early non-HR group) with cyclophosphamide, cytarabine, 6-mercaptopurine, IT MTX~Extra-compartment phase (8 wks): Protocol M with 6-MP, HD-MTX, IT MTX~Reinduction (6 wks): Protocol II with dexamethasone, vincristine, doxorubicin, pegaspargase, IT MTX, cyclophosphamide, tioguanine, cytarabine~Maintenance (until 2 years after initial diagnosis): 6-MP, MTX [without preceding blinatumomab (control arm of randomization R-MR)]~Erwinase is given in case of allergy to pegaspargase."
88820482|NCT06111014|Experimental|Open Label|Latozinemab (AL001) administered by IV infusion over 60 minutes, q4w
88820483|NCT06107998|Experimental|Stethoscope|Patients whose endotracheal tube cuff is inflated via a stethoscope
89196562|NCT00839007|Experimental|B|Dose 2 of CD-NP
89007735|NCT02532621|Experimental|Venous InterGraft Connector (VIG)|This is a nonrandomized, single-arm study: All enrolled patients are assigned to the same treatment: AVG implantation using a VIG (study device) to create the venous anastomosis and standard suturing to create the arterial anastomosis of the implanted AVG.
89007736|NCT02484859|Active Comparator|remifentanil|Following an intravenous bolus dose of 0.5 µg/kg remifentanil administered just before the induction of anaesthesia, patients will receive an intravenous infusion of remifentanil at a dose of 0.25-0.5 µg/kg/min throughout the surgery. The rate of infusion will be adjusted to maintain a mean blood pressure within %70-80 of the baseline value. At the end of the surgery, the rate of infusion will be decreased to 0.05 µg/kg/min, and continued until the patient is extubated.
89007737|NCT02484859|Active Comparator|tramadol + metoprolol|Just before the induction of anaesthesia, an intravenous infusion of 1 mg/kg of tramadol in 100 ml isotonic fluid will be started. The infusion will be completed in 30 minutes using a perfusor. Additionally, following the administration of the neuromuscular blocking agent, 0.1 mg/kg of intravenous metoprolol will be administered within 5 minutes.
89007738|NCT02482870|Active Comparator|Macintosh|Patients scheduled for general anesthesia during the study period, who had been intubated with Macintosh laryngoscope first and then with KingVision videolaryngoscope.
89007739|NCT02482870|Active Comparator|KingVision|Patients scheduled for general anesthesia during the study period, who had been intubated with King Vision videolaryngoscope first and then with Macintosh laryngoscope.
89007740|NCT02482168|Experimental|APX005M every 3 week|Subjects receive APX005M intravenously every 3 week until disease progression, unacceptable toxicity or death.
89007741|NCT02482168|Experimental|APX005M every 2 week|Subjects receive APX005M intravenously every 2 week until disease progression, unacceptable toxicity or death.
89007742|NCT02482168|Experimental|APX005M every 1 week|Subjects receive APX005M intravenously every 1 week until disease progression, unacceptable toxicity or death.
89007743|NCT02452918|Experimental|Oritavancin 1200 mg Without Concomitant Warfarin Therapy|Oritavancin as a single 1200 mg IV dose administered over 3 hours in participants with ABSSSI who were not on concomitant warfarin therapy
89007744|NCT02452918|Experimental|Oritavancin 1200 mg With Concomitant Warfarin Therapy|Oritavancin as a single 1200 mg IV dose administered over 3 hours in participants with ABSSSI who were on concomitant warfarin therapy at a standard dose and dosing schedule
89007745|NCT02431507|Experimental|Treatment Arm with Magnetic Apnea Device|The treatment arm with magnetic apnea device includes: surgical implantation of the magnetic apnea device(MAGNAP) to treat obstructive sleep apnea in each eligible enrolled subject . A custom fitted external brace will be created for wear throughout the 13 months of treatment and evaluated for improvement of symptoms..
89007746|NCT02414867||1|Normal weight mothers
89007747|NCT02414867||2|Overweight/Obese mothers
89007748|NCT02412787|Experimental|Idursulfase-IT|Participants will receive 10 milligrams (mg) of idursulfase-IT intrathecally via intrathecal drug delivery device (IDDD) or lumbar puncture (LP) once every 28 days along with standard-of-care therapy with Elaprase for 480 weeks. Participants who are younger than 3 years of age will receive an adjusted dose of 7.5 mg (greater than [>] 8 months to 30 months of age) and 10 mg (>30 months to 3 years of age) of idursulfase-IT.
89196563|NCT00839007|Experimental|C|Dose 3 of CD-NP
89196564|NCT00839007|Experimental|D|Dose 4 of CD-NP
89196565|NCT00839007|Experimental|E|Dose 5 of CD-NP
89196566|NCT00839007|Experimental|F|Dose 6 of CD-NP
89196567|NCT00839007|Placebo Comparator|G|Placebo
89196568|NCT00621621|Experimental|Freezor Catheter for AVNRT|Subjects with Atrio Ventricular Reentrant Tachycardia (AVNRT)will be treated with cryo (freezing) energy to ablate the slow pathway causing the arrythmia.
89199194|NCT05953909||Eribulin-Based Regimen|Not Applicable since observational study
89426988|NCT03643276|Experimental|pB: early HR-exp./MR-standard|"Induction (5 w): Protocol IA with prednisolone, vincristine, daunorubicin, pegaspargase, IT MTX~Consolidation (6 w): Consolidation extended+BZM (experimental arm of randomization R-eHR) with cyclophosphamide, cytarabine, 6-MP, IT MTX, dexamethasone, vincristine, pegaspargase, bortezomib (given at 1.3 mg/m²/dose on days 50, 53, 56 and 59)~Extra-compartment phase (8 wks): Protocol M with 6-MP, HD-MTX, IT MTX~Reinduction (6 wks): Protocol II with dexamethasone, vincristine, doxorubicin, pegaspargase, IT MTX, cyclophosphamide, tioguanine, cytarabine~Maintenance (until 2 yrs after initial diagnosis): 6-MP, MTX [without preceding blinatumomab (control arm of randomization R-MR)]~Erwinase is given in case of allergy to pegaspargase."
89426989|NCT03643276|Experimental|pB: early (non)HR-standard/MR-exp.|"Induction (5 w): Protocol IA with prednisolone, vincristine, daunorubicin, pegaspargase, IT MTX~Consolidation (6 w/4 w): Consolidation extended (control arm in randomization R-eHR) with cyclophosphamide, cytarabine, 6-MP, IT MTX, dexamethasone, vincristine, pegaspargase or Consolidation short (standard arm of early non-HR group) with cyclophosphamide, cytarabine, 6-mercaptopurine, IT MTX~Extra-compartment phase (8 w): Protocol M with 6-MP, HD-MTX, IT MTX~Reinduction (6 w): Protocol II with dexamethasone, vincristine, doxorubicin, pegaspargase, IT MTX, cyclophosphamide, tioguanine, cytarabine~Blinatumomab (4 w): 1 cycle blinatumomab given at 15 µg/m²/day for 28 days (experimental arm of randomization R-MR)~Maintenance (until 2 yrs after initial diagnosis): 6-MP, MTX~Erwinase is given in case of allergy to pegaspargase."
89426990|NCT03643276|Experimental|pB: early HR-exp./MR-exp.|"Induction (5 w): Protocol IA with prednisolone, vincristine, daunorubicin, pegaspargase, IT MTX~Consolidation (6 w): Consolidation extended+BZM (experimental arm of randomization R-eHR) with cyclophosphamide, cytarabine, 6-MP, IT MTX, dexamethasone, vincristine, pegaspargase, bortezomib (given at 1.3 mg/m²/dose on days 50, 53, 56 and 59)~Extra-compartment phase (8 w): Protocol M with 6-MP, HD-MTX,IT MTX~Reinduction (6 weeks): Protocol II with dexamethasone, vincristine, doxorubicin, PEG-L-asparaginase, IT MTX, cyclophosphamide, tioguanine, cytarabine~Blinatumomab (4 w): 1 cycle blinatumomab given at 15 µg/m²/day for 28 days (experimental arm of randomization R-MR)~Maintenance phase (until 2 yrs after initial diagnosis): 6-MP, MTX~Erwinase is given in case of allergy to pegaspargase."
89007749|NCT02379520|Experimental|Group A|HPV Specific T Cells
89007750|NCT02379520|Experimental|Group B|HPV Specific T Cells plus lymphodepletion (Cytoxan and Fludarabine) and nivolumab
89196569|NCT00621621|Other|External Data Supporting the Study|This arm was taken from pier reviewed published reports that include adult subjects ablated with the Freezor catheter for AVNRT.
89531075|NCT02498249|Experimental|Experimental: low level laser therapy (LLLT)|"For the LLLT irradiation, a paper template with 9 points (area of 1cm and a distance from center to center of 1 cm) will be used, distributed in three columns and three lines. The central point of the template will be positioned above the medium point of a line traced between the acromion and the spinous process of the seventh cervical vertebra, where the treatment should be close to the fixation point of the EMG electrode. The application point of the LLLT was determined by the location of the innervation point of the upper trapezius muscle.~Individuals will be subject to application of low level laser with a total dose of 18 J"
89196570|NCT00828087|Experimental|Everolimus Arm|Everolimus Eluting Coronary Stent System
89196571|NCT00828087|Active Comparator|non drug eluting stent Arm|cobalt chromium balloon expandable stent
89196572|NCT00828165|Experimental|ARRY-300|
89196573|NCT00828165|Placebo Comparator|Placebo|Placebo
88820484|NCT06107998|Active Comparator|Audible leak/Balloon palpation|Patients whose endotracheal tube cuff is inflated via audible leak/balloon palpation method.
88820485|NCT06107049|Active Comparator|Probiotic group|Participants in the probiotic group received 3g of BLa80 product per day.
88820486|NCT06107049|Placebo Comparator|Placebo group|Participants in the placebo group received 3g of maltodextrin per day.
89196574|NCT00839085|No Intervention|1|normal procedure of CABG
89426991|NCT03643276|Active Comparator|pB: early (non-)HR-standard/HR-standard|"Induction (5 w): as in other pB arms~Consolidation (6 w/4 w): Consolidation extended (control arm in randomization R-eHR) with cyclophosphamide, cytarabine, 6-MP, IT methotrexate, dexamethasone, vincristine, pegaspargase or Consolidation short (standard arm of early non-HR group) with cyclophosphamide, cytarabine, 6-MP, IT MTX~Intensified consolidation (3x5 d): Block HR-1' followed by HR-2' and HR-3' (control arm in randomization R-HR) with dexamethasone, vincristine, vindesine, daunorubicin, HD-MTX, IT MTX, HD-cytarabine, cyclophosphamide, ifosfamide, pegaspargase, etoposide~Reinduction (3x4 w): Protocol III given 3 times with dexamethasone, vincristine, doxorubicin, pegaspargase, IT MTX, cyclophosphamide, tioguanine, cytarabine~Maintenance (until 2 yrs after init. diagnosis): 6-MP, MTX~Erwinase is given in case pegaspargase allergy. Pts with poor response to intensified consolidation receive Myocet-FLA (Myocet, fludarabine, HD-cytarabine, IT-MTX)."
89426992|NCT03643276|Experimental|pB: early HR-exp./HR-standard|"Induction (5 w): as in other pB arms~Consolidation (6 w): Consolidation extended+BZM (experimental arm of randomization R-eHR) with cyclophosphamide, cytarabine, 6-MP, IT MTX, dexamethasone, vincristine, pegaspargase, bortezomib (1.3 mg/m²/dose on days 50, 53, 56 and 59)~Intensified consolidation (3x5 d): Block HR-1' followed by HR-2' and HR-3' (control arm in randomization R-HR) with dexamethasone, vincristine, vindesine, daunorubicin, HD-MTX, IT MTX, HD-cytarabine, cyclophosphamide, ifosfamide, pegaspargase, etoposide~Reinduction (3x4 w): as in arm pB: early (non-)HR-standard/HR-standard~Maintenance (until 2 yrs after initial diagnosis): 6-MP, MTX~Erwinase is given in case of allergy to pegaspargase. Pts with poor response to intensified consolidation receive Myocet-FLA (Myocet, fludarabine, HD-cytarabine, IT-MTX)"
89426993|NCT03643276|Experimental|pB: early (non-)HR-standard/HR-exp.|"Induction (5 w): as in other pB arms~Consolidation (6 w/4 w): Consolidation extended (control arm in randomization R-eHR) with cyclophosphamide, cytarabine, 6-MP, IT MTX, dexamethasone, vincristine, pegaspargase or Consolidation short (standard arm of early non-HR group) with cyclophosphamide, cytarabine, 6-MP, IT MTX~Intensified consolidation (1x5 d + 2x28 d): Block HR-1' with dexamethasone, vincristine, HD-MTX, IT MTX, HD-cytarabine, cyclophosphamide, pegaspargase followed by 2 cycles blinatumomab at 15 µg/m²/day for 28 days per cycle plus 2x2 doses IT MTX (experimental arm of randomization R-HR)~Reinduction (3x4 weeks): as in arm pB: early (non-)HR-standard/HR-standard~Maintenance (until 2 yrs after init. diagnosis): 6-MP, MTX~Erwinase is given in case of pegaspargase allergy. Pts with poor response to intensified consolidation receive Myocet-FLA (Myocet, fludarabine, HD-cytarabine, IT-MTX)"
89536835|NCT03309059|Experimental|Non-Irritant Barrier Film|will be composed of the elderly patients who present fecal and / or urinary incontinence and that, therefore, it is necessary to implement measures to prevent the development of ICD with the use of soap and water hygiene and application of Non Irritant Barrier Film. The patient who presents with urinary and / or fecal eliminations will undergo this intervention and then the placement of the disposable diaper used by the hospital.
89196575|NCT00839085|Active Comparator|2: GSE|100 mg GSE every 6h /Po, starting one day before surgery (4 doses in 24h)
89196576|NCT00839085|Active Comparator|3: Vit C|25 mg/kg through pump
89199195|NCT05953909||nab-paclitaxel based regimen|Not Applicable since observational study
89199196|NCT05953909||Other Chemotherapy Regimen|Not Applicable since observational study
89426994|NCT03643276|Experimental|pB: early HR-exp./HR-exp.|"Induction (5 w): as in other pB arms~Consolidation (6 w): Consolidation extended+BZM (experimental arm of randomization R-eHR) with cyclophosphamide, cytarabine, 6-MP, IT MTX, dexamethasone, vincristine, pegaspargase, bortezomib (1.3 mg/m²/dose on days 50, 53, 56 and 59)~Intensified consolidation (1x5 d + 2x28 d): Block HR-1' with dexamethasone, vincristine, HD-MTX, IT MTX, HD-cytarabine, cyclophosphamide, pegaspargase followed by 2 cycles blinatumomab at 15 µg/m²/day for 28 days per cycle plus 2x2 doses IT MTX (experimental arm of randomization R-HR)~Reinduction (3x4 weeks): as in arm pB: early (non-)HR-standard/HR-standard Maintenance (until 2 yrs after initial diagnosis): 6-MP, MTX~Erwinase is given in case of allergy to pegaspargase. Pts with poor response to intensified consolidation receive Myocet-FLA (Myocet, fludarabine, HD-cytarabine, IT-MTX)"
89536836|NCT03313271||a cohort of patients with lymphoma in China|establish a cohort of patients with lymphoma in China and follow up the patients for a long period of time
89536837|NCT03308981|Experimental|REThink therapeutic online game|REThink group will play twice the seven levels of the game, divided into seven modules.
89196577|NCT00831909||1|All NSCLC patients attending the responsible department of treating this type of patients (e.g. Oncology Department, Pneumology Department) for the first time (regardless of whether the patient is diagnosed with locally, advanced or metastatic disease) at the participating sites from the first of January 2009 to the end of March 2009. Patients diagnosed, or even treated, in other departments within the same hospital or in another hospital are susceptible to be included in the study if full access to the patient's medical record is made available.
88907734|NCT06303752|Experimental|allogenic ADRC001|Allocated patients will be treated for the fistula by combined surgical debridement of the fistula tract, closure of the internal orifice and injection of 30 ml lipoaspirate around the entire length of the fistula tract. Lipoaspirate will be harvested from the anterior abdominal wall under the same operation. Two hours later, the patient will receive injection of 5 ml suspension including 30 million cultured allogenic adipose-derived regenerative cells ADRC001 and injected at the same site of the lipoaspirate injection.
88907735|NCT06303739|Experimental|Single Psilocybin Treatment|Participants will be administered one dose of a 25mg capsule of psilocybin. This will be administered one time.
89196578|NCT02549313||position changes of head with brain lesion|patient with position changes of the head: registration of blood flow changes induced when the patient's head will be tilted at 0 ° (that is to say flat), 15 ° and 30 °.
88907736|NCT06303739|Active Comparator|Two Psilocybin Treatments|Participants will be administered one dose of a 25mg capsule of psilocybin. Two weeks later, the participant will be administered one more dose of a 25mg capsule of psilocybin.
88907737|NCT06303726|Active Comparator|Single bundle ACL reconstruction|In this group we chose to do surgery of ACL reconstruction with single bundle (patellar ligament).
88907738|NCT06303726|Active Comparator|Double bundle ACL reconstruction|In this group we chose to do surgery of ACL reconstruction with double bundle - hamstring ligament.
89196579|NCT00828243||Genetic association|Infants with and without neonatal respiratory distress syndrome undergo surfactant gene sequencing to identify genomic variants associated with neonatal respiratory distress syndrome
89196580|NCT00828243||Nutrient|To newborn infants with respiratory distress syndrome, we administer stable isotopically labeled nutrients (precursors of surfactant phospholipids or proteins) to permit mass spectrometry-based comparison of surfactant phospholipid and protein turnover.
89196581|NCT00839163|Experimental|Arm 1|
89196582|NCT00839163|Experimental|Arm 2|
89196583|NCT00839163|Experimental|Arm 3|
89196584|NCT00839163|Experimental|Arm 4|
89196585|NCT00839163|Active Comparator|Arm 5|
89007751|NCT02356653|Experimental|Expanded access to CliniMACs device for T cell depletion|access for patients who lack a fully HLA matched sibling, and who are candidates for allogeneic hematopoietic stem cell transplant (HSCT). These patients have a serious or immediately life-open protocols that utilize CliniMACs technology for T depletion. Subjects will undergo transplant of stem cells with CD3+/CD19+ depletion.
89196586|NCT02549001|Experimental|P-3058 10%|P-3058 10%
89196587|NCT02549001|Placebo Comparator|vehicle of P-3058 10%|vehicle of P-3058 10%
89196588|NCT02549001|Active Comparator|amorolfine 5%|Loceryl®
89196589|NCT00621543|Experimental|Observation- All subjects|Women choosing intra-uterine contraception after medical abortion.
89196590|NCT00832065||Patients With Sleep Apnea and Low Testosterone|Adult male patients between 18-70 years of age with nely diagnosed OSAS documented by all night polysomnography(PSG)
89007752|NCT02342691|Experimental|BLXA4-ME oral rinse|The topical oral rinse dosage form of BLXA4-ME (also known as ClinRinse-1) will consist of drug substance prepared at a concentration of 1.0 μM in an aqueous vehicle solution
89007753|NCT02342691|Placebo Comparator|Placebo oral rinse|The placebo preparation will consist of formulated oral rinse without BLXA4-ME and will be identical to the test rinse in color, appearance and taste
89007754|NCT02342691|No Intervention|No Rinse Control|The no-rinse control group will use no oral rinse, in order to assess the effect of the rinsing action independent of the active ingredients
89007755|NCT02332902|Experimental|Intervention|This is a single arm intervention using Everolimus
89007756|NCT02324608|Experimental|Treatment (cetuximab)|Patients receive cetuximab IV over 60-120 minutes once weekly for 8 weeks.
89426995|NCT03643276|Other|pB: early non-HR/SR|"Induction (5 w): Protocol IA with prednisolone, vincristine, daunorubicin, pegaspargase, IT MTX~Consolidation (4 w): Consolidation short with cyclophosphamide, cytarabine, 6-mercaptopurine, IT MTX~Extra-compartment phase (8 w): Protocol M with 6-MP, HD-MTX, IT MTX~Reinduction (6 w): Protocol II with dexamethasone, vincristine, doxorubicin, pegaspargase, IT MTX, cyclophosphamide, tioguanine, cytarabine~Maintenance (until 2 yrs after initial diagnosis): 6-MP, MTX~Erwinase is given in case of allergy to pegaspargase."
89426996|NCT03643276|Active Comparator|T: early non-SR-standard/(non-)HR|"Induction (5 w): Protocol IA-Dexa with prednisolone/dexamethasone, vincristine, daunorubicin, pegaspargase, IT MTX or Protocol IA-CPM with prednisolone instead of dexamethasone and additional CPM~Consolidation (4 w): Protocol IB regular (control arm in randomization. R-T) with cyclophosphamide, cytarabine, 6-mercaptopurine, IT MTX~non-HR extra-compartment phase and reinduction: as in arm pB: early non-HR/SR~HR intensified consolidation and reinduction: as in arm pB: early (non-)HR-standard/HR-standard~Maintenance (until 2 yrs after initial diagnosis): 6-MP, MTX~Erwinase is given in case of allergy to pegaspargase. Pts with poor response to intensified consolidation receive Myocet-FLA (Myocet, fludarabine, HD-cytarabine, IT-MTX)"
89007757|NCT02323867|Experimental|Alpha Beta Total Body Irradiation - total body irradiation (TBI) first|"Alpha Beta Total Body Irradiation - TBI first Day Treatment~11 Anti-thymocyte globulin (ATG)~10 ATG~9 ATG~8 TBI~7 TBI~6 TBI~5 Thiotepa~4 Thiotepa~3 Cyclophosphamide~2 Cyclophosphamide~1 Rest 0 Transplant with alpha beta T cell depleted stem cells"
89007758|NCT02323867|Experimental|Alpha Beta Total Body Irradiation - TBI last|"Alpha Beta Total Body Irradiation - TBI last Day Treatment~9 ATG~8 ATG~7 Thiotepa + ATG~6 Thiotepa~5 Cyclophosphamide~4 Cyclophosphamide~3 TBI~2 TBI~1 TBI 0 Transplant with alpha beta T cell depleted stem cells"
89007759|NCT02323867|Experimental|Alpha Beta Non-irradiation regimen|"Alpha Beta Non-irradiation regimen Day Treatment~9 Busulfan + ATG~8 Busulfan + ATG~7 Busulfan +ATG~6 Busulfan~5 Thiotepa~4 Thiotepa~3 Cyclophosphamide~2 Cyclophosphamide~1 0 Transplant with alpha beta T cell depleted stem cells"
89007760|NCT02305654|Active Comparator|Arm A - Standard Surgery (ILND)|"Part of randomisation 1.~The total treatment duration (Inguinal Lymph Node Dissection (ILND)) is estimated to be over 1 day for those patients allocated to Arm A - standard surgery."
89007761|NCT02305654|Experimental|Arm B - neoadjuvant chemotherapy|"Part of randomisation 1.~Patients will receive up to 4 cycles of Paclitaxel, Ifosfamide, and Cisplatin (TIP).~Administration on an outpatient basis:~Paclitaxel 175 mg/m2, day 1, Ifosfamide 900 mg/m2, days 2-5, Cisplatin 15 mg/m2, days 1-5~Administration on an inpatient basis:~Paclitaxel 175 mg/m2, day 1, Ifosfamide 1200 mg/m2, days 1-3, Cisplatin 25 mg/m2, days 1-3"
89007762|NCT02305654|Experimental|Arm C - neoadjuvant chemoradiotherapy|"Part of randomisation 1.~Radiotherapy dose is 45Gy in 25 fractions over 5 weeks using 6-10 MV photons to all regions.~Concurrent cisplatin 40mg/m2 will be given weekly, subject to GFR>45mls/min."
89007763|NCT02305654|Experimental|Arm P - prophylactic PLND|"Part of randomisation 2.~Prophylactic pelvic lymph node dissection (PLND) - The total treatment duration is estimated to be over 1 day.~Patients who have NOT received neoadjuvant chemoradiotherapy will receive adjuvant chemoradiotherapy:~Cisplatin 40mg/m2 will be given weekly, subject to GFR>45mls/min.~Groin: One or both groins may be boosted up to 54Gy in 25 fractions. An IMRT boost of up to 57 Gy can be given to recurrent or residual macroscopic tumour~Pelvis: the dose is limited to 45Gy unless IMRT is available. An IMRT boost of up to 54Gy in 25 fractions is applied to:~Any macroscopic tumour or pathological lymph nodes~Electively to external iliac nodes in patient with high disease burden~Patients who have had neoadjuvant chemoradiotherapy will have prophylactic PLND alone."
89007764|NCT02305654|No Intervention|Arm Q - Surveillance no prophylactic PLND|"no prophylactic PLND Part of randomisation 2.~For patients who have NOT received neoadjuvant chemoradiotherapy:~Groin: One or both groins may be boosted up to 54Gy in 25 fractions. An IMRT boost of up to 57 Gy can be given to recurrent or residual macroscopic tumour~Pelvis: the dose is limited to 45Gy unless IMRT is available. An IMRT boost of up to 54Gy in 25 fractions is applied to:~Any macroscopic tumour or pathological lymph nodes Electively to external iliac nodes in patient with high disease burden"
89007765|NCT02229084|Experimental|Part 1 - Chemovax Schedule A|Feasibility - Chemovax schedule A: Subjects will receive the first cycle of chemotherapy along with the first injection of P10s-PADRE/MONTANIDE™ ISA 51 VG vaccine on week 1, the subsequent two injections of the vaccine one week apart (week 2 and 3), second cycle of chemotherapy on week 4, and subsequent cycles of chemotherapy every 21 days (week 7,10,13,16,19,22).
89007766|NCT02229084|Experimental|Part 1 - Chemovax Schedule B|Feasibility - Chemovax Schedule B: Subjects will receive the first cycle of chemotherapy on week 1, the first injection of P10s-PADRE/MONTANIDE™ ISA 51 VG vaccine on week 2, the subsequent two injections of the vaccine one week apart (week 3 and 4), second cycle of chemotherapy on week 4 (along with second vaccine injection) and subsequent cycles of chemotherapy every 21 days (week 7,10,13,16,19,22).
89007767|NCT02229084|Experimental|Part 1 - Chemovax Schedule C|Feasibility - Chemovax Schedule C: Subjects will receive three weekly injections of P10s-PADRE/MONTANIDE™ ISA 51 VG vaccine (week 1,2,3), then first cycle of chemotherapy (week 4), and subsequent cycles of chemotherapy every 21 days (week 7,10,13,16,19,22,25).
89007768|NCT02229084|Experimental|Part 1 - Chemovax Schedule D|Feasibility - Chemovax Schedule D: Subjects will receive the first injection of vaccine on week 1, the subsequent two injections of the P10s-PADRE/MONTANIDE™ ISA 51 VG vaccine one week apart (week 2 and 3), the first cycle of chemotherapy on week 2 (along with second vaccine injection) and subsequent cycles of chemotherapy every 21 days (week 5,8,11,14,17,20,23).
89007769|NCT02229084|Experimental|Part 1 - Chemovax Schedule E|Feasibility - Chemovax Schedule E: Subjects will receive the first injection of vaccine on week 1, the subsequent two injections of the P10s-PADRE/MONTANIDE™ ISA 51 VG vaccine one week apart (week 2 and 3), the first cycle of chemotherapy on week 3 (along with third vaccine injection) and subsequent cycles of chemotherapy every 21 days (week 6,9,12,15,18,21,24).
89007770|NCT02229084|Experimental|Part 2 - Chemovax Schedule C|Primary Efficacy - Chemovax Schedule C: Subjects will receive three weekly injections of P10s-PADRE/MONTANIDE™ ISA 51 VG vaccine (week 1,2,3), then first cycle of chemotherapy (week 4), and subsequent cycles of chemotherapy every 21 days (week 7,10,13,16,19,22,25).
89007771|NCT02229084|Experimental|Part 3 - Chemovax Schedule C|Expanded Efficacy - Chemovax Schedule C: Subjects will receive three weekly injections of P10s-PADRE/MONTANIDE™ ISA 51 VG vaccine (week 1,2,3), then first cycle of chemotherapy (week 4), and subsequent cycles of chemotherapy every 21 days (week 7,10,13,16,19,22,25).
89007772|NCT02213497|Experimental|Dose Escalation of Neoadjuvant Proton Radiotherapy in Esophageal Cancer|Patients with esophageal cancer to be treated with concurrent preoperative chemoradiation with carboplatin and paclitaxel.
89007773|NCT02153307|Experimental|Implantable loop recorders Reveal ICM LINQ®,|
89007774|NCT02138721|No Intervention|No local treatment|Routine care in metastatic prostate cancer.
89007775|NCT02138721|Experimental|Local treatment|Radical Prostatectomy (RP) + routine care in metastatic prostate cancer.
89007776|NCT02038660||Patients with coronary artery disease|
89007777|NCT01897168||No grouping|
89007778|NCT01822067||Normal weight- Non Maternal obesity|Full-term neonates at 2 weeks of age born to normal weight mothers
89007779|NCT01822067||Obese- Obese Mothers|Full-term neonates at two weeks of age born of obese mothers
89007780|NCT01822054||Normal weight|
89007781|NCT01822054||Obese|
89007782|NCT01800760|Experimental|No groups|
89007783|NCT01750073|Experimental|Treatment (chemotherapy, surgery, post-operative therapy)|See Detailed Description
89196591|NCT00832143|No Intervention|1|Usual Care
89196592|NCT00832143|Experimental|2|Referral Card with one-to-one counseling
89196593|NCT00623805|Active Comparator|Bevacizumab+capecitabine+oxaliplatin|Participants received bevacizumab 7.5 mg/kg intravenously (IV) on Day 1 of each 3-week cycle + oxaliplatin 130 mg/m^2 IV on Day 1 of each 3-week cycle + capecitabine 1000 mg/m^2 orally twice a day on Days 1-14 of each 3-week cycle until disease progression.
89536838|NCT03308981|Active Comparator|REBE group|Participants will follow 7 modules, structured based on the strategies practiced in each of the REThink level.
88907739|NCT06303713|Experimental|Phase 1A: Dose Escalation|"Participants will be enrolled in a 3+3 dose escalation design to establish a maximum tolerated dose (MTD) of carboplatin, starting at Dose Level 1 and escalating to Dose Level 2 or 3.~Baseline visit.~Day 1 of Cycles 3 and 5: Tumor assessment radiologic scans.~Cycle 1 through End of Treatment:~Days 1 and 22 of 42-day cycle: Predetermined dose of carboplatin every 3 weeks for a maximum of up to 6 cycles.~Day 2 of 42-day cycle: Predetermined dose of 177Lu-PSMA-617 every 6 weeks for a maximum of up to 6 cycles.~End of treatment visit.~Follow up visits in-office or via telephone. If 0 out of 3 participants experience a dose-limiting toxicity (DLT), the study will proceed to the next dose level. If 1 or more participants experience a DLT, this dose level is declared the MTD and study will not proceed to expansion. If 1 out of 6 participants at the highest dose level experience DLTs, this is the recommended Phase 1B dose."
88907740|NCT06303713|Experimental|Phase 1B: Dose Expansion|"19 additional participants will be enrolled at the RP2D of carboplatin and will complete:~Baseline visit.~Day 1 of Cycles 3 and 5: Tumor assessment radiologic scans.~Tumor biopsy at baseline and at 12 weeks.~Cycle 1 through End of Treatment:~Days 1 and 22 of 42 day cycle: Predetermined dose of carboplatin every 3 weeks for a maximum of up to 6 cycles.~Day 2 of 42 day cycle: Predetermined dose of 177Lu-PSMA-617 every 6 weeks for a maximum of up to 6 cycles.~End of treatment visit.~Follow up visits in-office or via telephone."
88907741|NCT06303700||adolescents|from both sex, age ranged from twelve to seventeen years old, free from mobility disability and Severe cognitive impairment
88907742|NCT06303700||youth|from both sex, age ranged from twenty to twenty-two years old, free from mobility disability and Severe cognitive impairment
88907743|NCT06303700||geriatrics|from both sex, age ranged from sixty to eighty years old, free from mobility disability and Severe cognitive impairment
88907744|NCT06303687|Experimental|VR-PAT|Participant wears the Pico Neo 3 Pro Eye headset and actively plays the VR-PAT game while also wearing the fNIRS, during their clinically scheduled burn dressing change.
88907745|NCT06303687|No Intervention|Control|Participant wears the fNIRS and can engage in standard distraction techniques, during their clinically scheduled burn dressing change.
88907746|NCT06303674|Experimental|Physical activity with engaging cognitively|This experimental condition involves engaging in physical activity interspersed with rest periods based on cognitive tasks.
88907747|NCT06303674|Experimental|Physical activity without engaging cognitively|This experimental condition involves engaging in physical activity interspersed with rest periods (without cognitive tasks).
88907748|NCT06303674|No Intervention|Cognitively engaging control conditions|In this condition, participants will be suggested to watch a video while seating/resting for 10 minutes.
88907749|NCT06303661|Experimental|RF and SWT|The treatment will be carried out through the application of monopolar non-ablative radiofrequency (IBRAMED, Amparo, São Paulo, Brazil - model NÈARTEK) associated with electromagnetic low-intensity shock wave therapy (IBRAMED, Amparo, São Paulo, Brazil - model THORK) on the fibrotic plaque in the penis, 2 to 5 times a week, according to the patient's availability, totaling 24 sessions.
88907750|NCT06303648|Experimental|Cohort 1|50 mg x 1 dose
88907751|NCT06303648|Experimental|Cohort 2|100 mg x 1 dose
88907752|NCT06303648|Experimental|Cohort 3|150 mg x 1 dose
88907753|NCT06303648|Experimental|Cohort 4|200 mg x 1 dose
88907754|NCT06303622|Experimental|MRUS arm|Targeted biopsies will be performed by software-assisted MRI-ultrasound fusion registration . Software-based fusion targeted biopsy of 4 cores per target followed by 12-core systematic biopsy will be performed. The fusion or overlay of 3D MRI and USG images create a detailed 3D prostate image with both targeted and systematic biopsy core locations recorded.
88907755|NCT06303622|Active Comparator|COG arm|The biopsy operator reviews the MR images and creates a mental three-dimensional representation of the prostate and the lesion within it to guide biopsy. Cognitive registration is a visual guidance technique in which the surgeon samples a visually estimated location on transrectal ultrasound (TRUS) corresponding to the MRI suspicious regions. Cognitive-guided biopsy is performed by taking 4 cores from each target followed by 12-core systematic biopsies.
88907756|NCT06303596|Experimental|Experimental: Experimental group|"The experimental group would receive standard psychiatric treatment.~Additionally, the experimental group would be provided with a 16-session hippotherapy program for 8 weeks, as an adjuvant to standard psychiatric treatment."
88907757|NCT06303596|Other|Other: Control group|The control group would receive only standard psychiatric treatment.
89536839|NCT03308981|No Intervention|Wait-list|Participants will not receive any intervention.
88907758|NCT06303583|Experimental|IO|chemoradiotherapy sequential tislelizumab
88907759|NCT06303570|Experimental|CBL-514 injection|Eligible participants will receive CBL-514 administered in doses ranging from 1 mL to a maximum of 20 mL per lipoma, with treatments scheduled at intervals of approximately 4 weeks, up to 5 treatments.
88907760|NCT06303570|Placebo Comparator|0.9% Sodium Chloride|Eligible participants will receive 0.9% Sodium Chloride administered in doses ranging from 1 mL to a maximum of 20 mL per lipoma, with treatments scheduled at intervals of approximately 4 weeks, up to 5 treatments.
89536840|NCT02469545|Active Comparator|SSRI and probiotic|Administering antidepressant drug (SSRI - selective serotonin reuptake inhibitor: Escitalopram or Sertraline) and probiotic (Lactobacillus Plantarum 299v) to a group of patients diagnosed with depression (n=30).
89007784|NCT01723774|Experimental|Arm 1: PIK3CA Wild Type Cohort|"Tumor biopsy for testing/research at baseline and Cycle 1 Day 15~Cycle 0 is 28 days of anastrozole PO daily and, if premenopausal, goserelin SC every 28 days.~Cycles 1-5: PD 0332991 combined with anastrozole (and goserelin if premenopausal) is to be (4) 28-day cycles followed by a 5th cycle of 10-12 days duration consisting of daily PD 0332991 and anastrozole (last dose day before surgery)~Standard surgery will be performed per institutional standards 2-4 weeks following the completion of Cycle 4 in those who did not receive Cycle 5. In patients who receive Cycle 5, surgery occurs on Day 11, 12, or 13 of Cycle 5.~Patients who derived benefit from the therapy have the option of taking PD 0332991 in combination with endocrine therapy for 23 cycles after surgery and adjuvant chemotherapy and radiation if indicated. It should be re-started at least 4 weeks after the completion of chemotherapy and radiation therapy if these treatments were planned."
89007785|NCT01723774|Experimental|Arm 2: PIK3CA Mutant Type Cohort|"Tumor biopsy for testing/research at baseline and Cycle 1 Day 15~Cycle 0 is 28 days of anastrozole PO daily and, if premenopausal, goserelin SC every 28 days.~Cycles 1-5: PD 0332991 combined with anastrozole (and goserelin if premenopausal) is to be (4) 28-day cycles followed by a 5th cycle of 10-12 days duration consisting of daily PD 0332991 and anastrozole (last dose day before surgery)~Standard surgery will be performed per institutional standards 2-4 weeks following the completion of Cycle 4 in those who did not receive Cycle 5. In patients who receive Cycle 5, surgery occurs on Day 11, 12, or 13 of Cycle 5.~Patients who derived benefit from the therapy have the option of taking PD 0332991 in combination with endocrine therapy for 23 cycles after surgery and adjuvant chemotherapy and radiation if indicated. It should be re-started at least 4 weeks after the completion of chemotherapy and radiation therapy if these treatments were planned."
89007786|NCT01723774|Experimental|Arm 3: Endocrine Resistant Cohort|"Tumor biopsy for testing/research at baseline and Cycle 1 Day 15~Cycles 1-5: PD 0332991 combined with anastrozole (and goserelin if premenopausal) is to be (4) 28-day cycles followed by a 5th cycle of 10-12 days duration consisting of daily PD 0332991 and anastrozole (last dose day before surgery)~Standard surgery will be performed per institutional standards 2-4 weeks following the completion of Cycle 4 in those who did not receive Cycle 5. In patients who receive Cycle 5, surgery occurs on Day 11, 12, or 13 of Cycle 5.~Patients who derived benefit from the therapy have the option of taking PD 0332991 in combination with endocrine therapy for 23 cycles after surgery and adjuvant chemotherapy and radiation if indicated. It should be re-started at least 4 weeks after the completion of chemotherapy and radiation therapy if these treatments were planned."
89007787|NCT01674140|Placebo Comparator|Arm I|Patients receive an approved endocrine therapy comprising tamoxifen citrate*, goserelin acetate** or leuprolide acetate**, or an aromatase inhibitor (anastrozole, letrozole, or exemestane) for 2-5 years. Patients also receive a placebo PO daily for 1 year in the absence of disease progression or unacceptable toxicity.
89007788|NCT01674140|Experimental|Arm II|Patients receive an approved endocrine therapy regimen as in arm I. Patients also receive everolimus PO daily for 1 year in the absence of disease progression or unacceptable toxicity.
89007789|NCT01433198|Active Comparator|Aquatic exercise group|
89007790|NCT01433198|No Intervention|Control group|
89007791|NCT01356628|Experimental|PD-0332991|PD-0332991 in the Treatment in Patients with Advanced Hepatocellular Carcinoma
89007792|NCT01294072|Experimental|Arm 1: Curcumin alone|Subjects take curcumin orally.
89007793|NCT01294072|Experimental|Arm 2: Curcumin with plant exosomes|Subjects take curcumin conjugated with plant exosomes.
89196594|NCT00623805|Experimental|Bevacizumab(B)+capecitabine(C)+oxaliplatin followed by B+C|Participants received bevacizumab 7.5 mg/kg intravenously (IV) on Day 1 of each 3-week cycle + oxaliplatin 130 mg/m^2 IV on Day 1 of each 3-week cycle + capecitabine 1000 mg/m^2 orally twice a day on Days 1-14 of each 3-week cycle for 6 cycles followed by bevacizumab 7.5 mg/kg intravenously (IV) on Day 1 of each 3-week cycle + capecitabine 1000 mg/m^2 orally twice a day on Days 1-14 of each 3-week cycle until disease progression.
89196595|NCT02548923|Active Comparator|dexmedetomidine group|Patients who received dexmedetomidine for sedation
89196596|NCT02548923|No Intervention|propofol group|Patients who received propofol for sedation
89196597|NCT04043871||Patients with renal insufficiency|
89196598|NCT00832221|Active Comparator|1|
89196599|NCT00832221|Active Comparator|2|
89196600|NCT00828399|Experimental|Glutamine|
89007794|NCT01294072|Experimental|Arm 3: no treatment|subjects will not take curcumin or plant exosomes
89007795|NCT01131117||Pregnant women|
89007796|NCT01087554|Experimental|Arm A: Vorinostat + Sirolimus|"Escalation Phase: Vorinostat starting dose 100 mg by mouth on Days 7 - 28 of Cycle 1; For all other cycles, dose of 100 mg Days 1-28.~Expansion Phase starting dose: MTD from Escalation Phase.~Escalation Phase: Sirolimus starting dose1 mg by mouth on Days 1 - 28.~Expansion Phase starting dose: MTD from Escalation Phase."
89007797|NCT01087554|Experimental|Arm B: Vorinostat + Everolimus|"Escalation and Expansion Phase: Vorinostat dose 300 mg by mouth on Days 7 - 28. Rest of cycles: 300 mg by mouth on Days 1 - 28.~Escalation Phase: Everolimus starting dose 5 mg by mouth on Days 1 - 28.~Expansion Phase: MTD from Escalation Phase."
89007798|NCT01087554|Experimental|Arm C: Vorinostat + Temsirolimus|"Escalation and Expansion Phase: Vorinostat dose 300 mg by mouth on Days 7 - 28. Rest of cycles: 300 mg by mouth on Days 1 - 28.~Escalation Phase: Temsirolimus starting dose 12.5 mg by vein on Days 1, 8, 15, 22.~Expansion Phase: MTD from Escalation Phase."
89007799|NCT00920582|Experimental|Herold Regimen|14-day cycle of teplizumab consisting of daily IV doses of 51 µg/m2, 103 µg/m2, 207 µg/m2, and 413 µg/m2 on Study Days 1-4, respectively, and one dose of 826 µg/m2 on each of Study Days 5-14. Repeat at Week 26
89007800|NCT00920582|Experimental|33.3% Herold Regimen|Subjects received a 14-day cycle of teplizumab consisting of daily IV doses of 17 µg/m2, 34 µg/m2, 68 µg/m2, and 136 µg/m2 on Study Days 1-4, respectively, and one dose of 273 µg/m2 on each of Study Days 5-14. Repeat at Week 26
89007801|NCT00920582|Experimental|Curtailed Herold Regimen|Subjects received a 6 day cycle of teplizumab consisting of daily IV doses of 51 µg/m2, 103 µg/m2, 207 µg/m2, and 413 µg/m2 on Study Days 1-4, respectively, and one dose of 826 µg/m2 on each of Study Days 5-6, followed by 8 days of IV placebo (Study Days 7-14). Repeat at Week 26
89007802|NCT00920582|Placebo Comparator|Placebo|14-day cycle of placebo consisting of daily IV doses. Repeat at Week 26
89007803|NCT00898638||Healthy Volunteers|Non-tumor volunteers will be asked to participate at the time that they are attending a head and neck cancer screening clinic or at the time they are accompanying a patient to their appointment at the head and neck clinic. Intake sheets and biological specimens contributed by volunteers will be coded at the time of collection so that no identifiers are obtained. These specimens will not be linked to identifiers.
89007804|NCT00898638||Head and Neck Tumor patients|Eligible patients will be identified at the Vanderbilt Head & Neck Clinic by clinical and research staff. An appropriately trained staff member will discuss the protocol with the patient (including, risks, benefits, alternatives, etc.).
89007805|NCT00735423||No groups|IDE used for outcome measurement not intervention
89007806|NCT00722527||Affected Population|Subjects with an elevated hemoglobin concentration or an elevated platelet count
89007807|NCT00616395||no grouping|IDE used for outcome measurement not for an intervention.
89007808|NCT00439049||A|Cocaine Dependent Subjects
89007809|NCT00254423|Experimental|Arm A (once daily dasatinib)|Patients receive dasatinib PO QD for up to 15-18 years.
89007810|NCT00254423|Experimental|Arm B (twice daily dasatinib)|Patients receive dasatinib PO BID for up to 15-18 years.
89007811|NCT04720092|Experimental|Treatment A-B|Subjects received a single oral dose of 10 mg rivaroxaban tablet in the fasted state on Day 1 (Treatment A) during intervention period 1; and then a single oral dose of 10 mg rivaroxaban oral suspension in the fasted state on Day 1 (Treatment B) during intervention period 2. A wash-out of at least 7 days was maintained between the treatments.
89007812|NCT04720092|Experimental|Treatment B-A|Subjects received a single oral dose of 10 mg rivaroxaban oral suspension in the fasted state on Day 1 (Treatment B) during intervention period 1; and then a single oral dose of 10 mg rivaroxaban tablet in the fasted state on Day 1 (Treatment A) during intervention period 2. A wash-out of at least 7 days was maintained between the treatments.
89007813|NCT00221702|Experimental|A|Peg Intron 100 mcg SC/week for 36 months
89007814|NCT00221702|Active Comparator|B|Intron A 3 X 3 MIU, weekly, sc, for 18 months
89196601|NCT00828399|Placebo Comparator|Whole protein|
89426997|NCT03643276|Experimental|T: early non-SR-exp/(non-)HR|"Induction (5 w): Protocol IA-Dexa with prednisolone/dexamethasone, vincristine, daunorubicin, pegaspargase, IT MTX or Protocol IA-CPM with prednisolone instead of dexamethasone and additional CPM~Consolidation (6 w): Protocol IB long (experimental arm in randomization R-T) with cyclophosphamide, cytarabine, 6-mercaptopurine, IT MTX~non-HR extra-compartment phase and reinduction: as in arm pB: early non-HR/SR~HR intensified consolidation and reinduction: as in arm pB: early (non-)HR-standard/HR-standard~Maintenance (until 2 yrs after initial diagnosis): 6-MP, MTX~Erwinase is given in case of allergy to pegaspargase. Pts with poor response to intensified consolidation receive Myocet-FLA (Myocet, fludarabine, HD-cytarabine, IT-MTX)"
89536144|NCT03211819|Active Comparator|free hand placement|in the control group, the implant will be placed it the socket using free hand technique and according to the manufacturing instruction's (s-Clean Tapered Implants, Dentis Co., Ltd., Woram-Dong, Dalseo-Gu, Daegu, South Korea) . The implants will be placed guided by the socket of the root. Then in implants with primary stability > 35 Ncm2, the final abutment will be placed and any further adjustment would be done immediately in the lab and repositioned in place. Then the vacuum stent will be checked in its place again intraorally, then a chair side tooth coloured autopolymerizing resin (Structur 2 SC / QM,VOCO GmbH,Germany)will be injected into the vacuum sheet corresponding to the implant site to construct the temporary crown.
88907761|NCT06303557|Active Comparator|Preoperative Erector Spinae Plane Block|In the preoperative period, under general anesthesia, after the linear ultrasound (US) probe will be placed 2-3 cm lateral to the L3 spinous process, 15 ml of 0.25% bupivacaine will be injected into the interfacial space below the erector spinae muscle, above the transverse process. The same ESPB procedure was performed on the other side. In total, 40 ml of 0.25% bupivacaine was administered.
88907762|NCT06303557|Active Comparator|Postperative Erector Spinae Plane Block|In the postoperative period, under general anesthesia, after the linear ultrasound (US) probe will be placed 2-3 cm lateral to the L3 spinous process, 15 ml of 0.25% bupivacaine will be injected into the interfacial space below the erector spinae muscle, above the transverse process. The same ESPB procedure was performed on the other side. In total, 40 ml of 0.25% bupivacaine was administered.
88907763|NCT06303544|Experimental|Wedge 1|Four villages of 12 will be randomized into Wedge 1. Four of the remaining 8 villages will be randomized to Wedge 2. The remaining 4 villages will be Wedge 3.
88907764|NCT06303544|No Intervention|Wedge 2|While Wedge 1 is undergoing intervention, Wedges 2 & 3 will act as controls.
88907765|NCT06303544|No Intervention|Wedge 3|While Wedge 1 is undergoing intervention, Wedges 2 & 3 will act as controls.
88907766|NCT06303531|Active Comparator|Eurofer|Ferrous Fumarate - 300 mg
88907767|NCT06303531|Active Comparator|FeraMAX|Polysaccharide Iron - 150mg
88907768|NCT06303531|Active Comparator|EBMfer|Ferrous Ascorbate - 100 mg
89196602|NCT04044027|No Intervention|Control Group|
88907769|NCT06303518|Experimental|High normal ETCO2, Normal ETCO2, Low normal ETCO2|All patients will receive same interventions, in a randomised order.
88907770|NCT06303518|Experimental|High normal ETCO2, Low normal ETCO2, Normal ETCO2|All patients will receive same interventions, in a randomised order.
88907771|NCT06303518|Experimental|Low normal ETCO2, Normal ETCO2, High normal ETCO2|All patients will receive same interventions, in a randomised order.
88907772|NCT06303518|Experimental|Low normal ETCO2, High normal ETCO2, Normal ETCO2|All patients will receive same interventions, in a randomised order.
89196603|NCT04044027|Experimental|Intervention Group|
89536145|NCT05713487|Experimental|preventive treatment group|
89536146|NCT05713487|No Intervention|control group|
88907773|NCT06303518|Experimental|Normal ETCO2, Low normal ETCO2, High normal ETCO2|All patients will receive same interventions, in a randomised order.
89196604|NCT00839397|Other|Paroxetine|A 52-week, non-comparative, uncontrolled study (However, the baseline phase is single blind)
88907774|NCT06303518|Experimental|Normal ETCO2, High normal ETCO2, Low normal ETCO2|All patients will receive same interventions, in a randomised order.
88907775|NCT06303505|Experimental|Platinum resistant ovarian cancer|
89196605|NCT04043715|Other|Comparison of transcutaneous & epidural stimulation|Comparison of transcutaneous vs epidural electrical stimulation
89196606|NCT00828477|Active Comparator|1|Xibrom (bromfenac)
89196607|NCT00828477|Active Comparator|2|Nevanac (nepafenac)
89196608|NCT00621309|Active Comparator|1|Subjects are given 300 mg / 7 days of rifampicin to induce CYP3A4. Midazolam clearance is measured on the 8th day.
89196609|NCT00621309|Active Comparator|2|Sulforaphane (SFN), a natural product derived from broccoli sprouts, is utilized as a putative inhibitor of ligand (Rifampin) activation of the Pregnane X-receptor. In this arm, both SFN (putative inhibitor of ligand binding to PXR) and Rifampin (strong activating ligand of PXR) are given together.
89196610|NCT00621309|Active Comparator|3|This arm involves the administration of Sulforaphane (SFN) alone, in the absence of the PXR ligand, rifampicin. The hypothesis is that SFN will have no effect on the expression of PXR-regulated genes. Alternatively, it is possible that SFN could inhibit as yet unidentified endogenous ligands to the PXR receptor, thereby causing down-regulations of genes regulated wholely or in part by PXR. SFN is administered as a broccoli sprout extract at a dose rate of 75 mg (~420 umoles) per day for 7 days.
89196611|NCT00832611|Experimental|Experimental: Group A Anastomotic Coupler|Device: ROX Anastomotic Coupler System (ACS). The ACS will be used to create an arteriovenous fistula in the iliac region (between the iliac artery and vein).
89196612|NCT04018521|Active Comparator|Parent Connectors|trained and supervised PPNs deliver weekly telephone-based support for six to nine months to parents or caregivers of all newlyenrolled youth or young adults (Y/YA) in FEP services
89196613|NCT04018521|Active Comparator|Usual Care|Coordinated Specialty Care (CSC)
89196614|NCT00832689|Experimental|1|
89196615|NCT00567190|Experimental|Pertuzumab + Trastuzumab + Docetaxel|Participants randomized to this arm received pertuzumab 420 milligrams (mg) intravenously (IV) once every 3 weeks (q3w) and trastuzumab 6 milligrams per kilogram (mg/kg) IV q3w, plus docetaxel 75 milligrams per square metre of body surface (mg/m^2) IV q3w (for at least 6 cycles; 1 cycle was 21 days). After Cycle 6, continuation of docetaxel treatment was at the discretion of the participant and treating physician. Participants remained in the treatment phase of the study until investigator-assessed radiographic or clinical evidence of disease progression, unmanageable toxicity, or study termination and were followed for survival until death, loss to follow-up, withdrawal of consent, or study termination.
89196616|NCT00567190|Placebo Comparator|Placebo + Trastuzumab + Docetaxel|Participants randomized to this arm received placebo IV q3w and trastuzumab 6 mg/kg IV q3w, plus docetaxel 75 mg/m^2 IV q3w (for at least 6 cycles; 1 cycle was 21 days). After Cycle 6, continuation of docetaxel treatment was at the discretion of the participant and treating physician. Participants remained in the treatment phase of the study until investigator-assessed radiographic or clinical evidence of disease progression, unmanageable toxicity, or study termination and were followed for survival until death, loss to follow-up, withdrawal of consent, or study termination.
89196617|NCT00922389|Experimental|G-CSF + Stem cells|
89196618|NCT00922389|Other|No stem cell group|
89536841|NCT02469545|Placebo Comparator|SSRI and placebo of probiotic|Administering antidepressant drug (SSRI - selective serotonin reuptake inhibitor: Escitalopram or Sertraline) and placebo of probiotic (crystalline cellulose powder) to a group of patients diagnosed with depression (n=30).
88907776|NCT06303505|Experimental|Non small cell lung cancer-adenocarcinoma|
88907777|NCT06303492|Experimental|Gastric ultrasound (GUS) group|Aspiration risk assessment using GUS in addition to the standard clinical assessment.
88907778|NCT06303492|No Intervention|Control|Aspiration risk assessment only by standard clinical assessment, and no GUS
88907779|NCT06303479|Experimental|Instrumental breathing exercise group|Instrumental breathing exercise group consisting of 13 healthy adults between the ages of 18-30
88907780|NCT06303479|Experimental|Non-Instrumental breathing exercise group|Non-Instrumental breathing exercise group consisting of 13 healthy adults between the ages of 18-30
88907781|NCT06303466||Danish Fabry Patients|Patients with a genetically-verified diagnosis of Fabry Disease.
88907782|NCT06303453|Experimental|GROUP A (BALANCE EXERCISES)|Group A will receive a session of balance exercises for 45 minutes.Treatment session will be given for 3 days per week for 8 weeks.This balance exercise program consist of three phases.Warm-up phase(5 minutes,after warm-up phase 35 minutes balance exercises then cooling phase (5 minutes).
88907783|NCT06303453|Experimental|GROUP B (RESISTED EXERCISES)|Group B will receive a session of resisted exercises for 45 minutes.Treatment session will be given for 3 days per week for 8 weeks.This resisted exercises program consist of three phases.Warm-up phase(5 minutes,after warm-up phase 35 minutes balance exercises then cooling phase (5 minutes).
88907784|NCT06303440|Other|Group A (Routine Physical Therapy+ Balance Training)|"The children will be provided with Routine Physical Therapy and Balance Training.~Balance exercises will be provided for 15 minutes and 30 minutes of Routine physical therapy will be as strengthening and stretching exercises."
88907785|NCT06303440|Experimental|Group B (Virtual Reality + Routine Physical Therapy)|The VR system consisted of a wall-mounted display, a Nintendo Wii box, a Wii remote, and a Wii Fit board. The participants will be instructed to stand on Wii Fit board while interacting with the VR system and playing the selected games and routine physical therapy of 30 minutes will be provided.
88907786|NCT06303440|Experimental|Group C (Motor Imagery+ Routine Physical Therapy)|During the presentation of a video clip, patients will watch the video and afterwards try to do movement as same as shown in video
88907787|NCT06303427|Experimental|Group A: (Modified constraint-induced movement therapy + electrical stimulation)|"Group A will include 17 participants. The participants in this group will receive a 60-minute session daily. Each participant will perform 96 sessions (6 times per week over 16 weeks) for 60 minutes daily.~Electrical stimulation for 20 minutes~Routine physical therapy for 10 minutes~Modified constraint-induced movement therapy for 30 minutes."
88907788|NCT06303427|Experimental|Group B: (Modified constraint-induced movement therapy)|"17 participants will be included in this group. The participants in this group will also receive a 60-minute session daily (6 times per week over 19 weeks).~Routine physical therapy for 10 minutes.~Modified constraint-induced movement therapy for 50 minutes."
88907789|NCT06303414||Carotid Endarterectomy (CEA)|Patients who are treated with CEA.
88907790|NCT06303414||Carotid Artery Stenting (CAS)|Patients who are treated with CAS.
88907791|NCT06303414||Hybrid Surgery|Patients who are treated with Hybrid Surgery.
88907792|NCT06303401|Experimental|SI joint thrust Manipulation|The patient was supine and the therapist stood contralateral to the side which was to be manipulated. The patient was passively moved into side bending toward the side to be manipulated. The therapist passively rotated the patient, and then delivered a quick thrust to the Anterior Superior Iliac Spine (ASIS) in a posterior and inferior direction
89426998|NCT03643276|Other|T: early SR/non-HR|"Induction (5 w): Protocol IA-Dexa with prednisolone/dexamethasone, vincristine, daunorubicin, pegaspargase, IT MTX~Consolidation (4 w): Protocol IB regular with cyclophosphamide, cytarabine, 6-mercaptopurine, IT MTX~Extra-compartment phase (8 w): Protocol M with 6-MP, HD-MTX, IT MTX~Reinduction (6 w): Protocol II with dexamethasone, vincristine, doxorubicin, pegaspargase, IT MTX, cyclophosphamide, tioguanine, cytarabine~Maintenance (until 2 yrs after initial diagnosis): 6-MP, MTX~Erwinase is given in case of allergy to pegaspargase."
88907793|NCT06303401|Active Comparator|Pelvic Stabilization Exercises|Heating pad for 10- 15 mints Pelvic stabilization exercises. Bridging (3 sets x 10 reps with 10 secs hold), Pelvic Tilt exercise (3 sets x 10 reps with 10 secs hold), Bird-Dog Exercise (3 sets x 10 reps with 10 secs hold), clamshell Exercise (3 sets x 10 reps with 10 secs hold).
88907794|NCT06303388|Experimental|Egoscue Exercise|"• The Egoscue exercise comprise of 10 exercises which Included~Static back alone and with breathing.~Abdominal contraction while in the static back position.~abductor press~overhead extension~elbow curls on a wall~static wall~upper spinal twist 8 pelvic tilts~9.supine groin progressive 10.air bench exercises."
88907795|NCT06303388|Active Comparator|Bruegger's Exercise|"steps include in Breugger's Exercise~Sit with your buttocks at the edge of a chair.~Spread your legs apart slightly.~Turn your toes out slightly.~Rest your weight on your legs/feet & relax your abdominal muscles.~Tilt your pelvis forward (i.e. arch your lower back) while lifting your chest up~Rotate your arms outward while turning your palms up.~Hold your head high in the air, with a slight arch in the neck. The patient is to slowly exhale by breathing out through their lips while actively externally rotating their arms and spreading their fingers. The patient is to perform this exercise once or twice every 20-30 minutes of prolonged sitting and held in this position for 30-60 seconds"
89426999|NCT03643224|Experimental|Experimental|Radiofrequency Ablation. Catheter ablation to treat persistent atrial fibrillation using temperature-controlled ablation catheter
88907796|NCT06303375|Experimental|Kinesio taping along with conventional physical therapy|treatment with moist hot pack along with stretching of tight erector spinae, hip flexors and strengthening of weak abdominals and gluteal muscles along with Kinesiotaping using inhibition and facilitation technique for LCS.
88907797|NCT06303375|Active Comparator|conventional physical therapy|Treatment with moist hot pack along with stretching of tight erector spinae, hip flexors and strengthening of weak abdominals and gluteal muscles.
88907798|NCT06303362|Experimental|Elastic band excercises|Elastic band excercises and stretching is given to shoulder muscles (deep neck flexors, pectoralis major and minor, rhomboids and trapezius)
88907799|NCT06303362|Active Comparator|strengthening with conventional physical therapy|strengthening with conventional physicaltherapy is given to shoulder muscles (deep neck flexors, pectoralis major and minor, rhomboids and trapezius)
88907800|NCT06303336|Experimental|NMES with Dynamic Bracing|The NMES targeting the hip adductors, the knee flexor muscles and the ankle & foot muscles, along with dynamic bracing
88907801|NCT06303336|Experimental|NMES without Dynamic Bracing|Neuromuscular Electrical Stimulator targeting the lower extremity
88907802|NCT06303336|Experimental|Dynamic Bracing Only|Dynamic Bracing of lower extremity
88907803|NCT06303323|Experimental|Qigong Exercise|Baduanjin Exercise will be performed which consists of 8 standing postures. At least 30 minutes per time. 10-13 min for a set of Badaunjin
88907804|NCT06303323|Experimental|Wu Dang Tai Chi|Wu Dang 13 form postures will be performed. Initially, each posture will be performed 3 times then progressively increase to more according to the patient's discomfort.
88907805|NCT06303310|Experimental|Group A|Group A will receive gaze stability exercises consist of 5 structured components for 20 minutes and the routine physical therapy consisting of balance exercises of 20 minute for 5 days a week for 4 weeks.
88907806|NCT06303310|Experimental|Group B|Group B will receive optokinetic exercises for 20 minutes and the routine physical therapy consisting of balance exercises of 20 minute for 5 days a week for 4 weeks.
88907807|NCT06303297|Experimental|REFLEXOLOGY|
88907808|NCT06303297|Active Comparator|GENERALIZED STRETCHING|
88907809|NCT06303271|Experimental|Vagus Nerve Stimulation (VNS) and Caw Thorne Cooksey|Group will receive intervention of 30 minutes daily for 4 weeks (16 sessions).
88907810|NCT06303271|Active Comparator|Caw Thorne Cooksey|Group will receive intervention of 30 minutes daily for 4 weeks (16 sessions).
88907811|NCT06303258|Experimental|Core Stabalization Exercises Group|This Group will receive core stability exercises 3 sessions per week for 4 weeks and basic antenatal education.
88907812|NCT06303258|Experimental|Generalized Exercise Group|This Group will receive generalized supervised antenatal exercises that are covered in three phases and basic antenatal education. There will be 3 sessions per week for 10weeks conducted for generalized antenatal exercises including Aerobics, Endurance and Pelvic Floor Muscle Training.
88907813|NCT06303258|No Intervention|Control Group|Basic Antenatal Education for Lumbopelvic Pain Prevention
88907814|NCT06303245|Experimental|ABDOMINAL BINDERS|
88907815|NCT06303245|Active Comparator|TENS|
88907816|NCT06303232|Experimental|MANUAL LYMPHATIC DRAINAGE|
88907817|NCT06303232|Active Comparator|THERAPEUTIC ULTRASOUND|
88907818|NCT06303219|Experimental|TRADITIONAL MODERATE INTENSITY TRAINING|
88907819|NCT06303219|Active Comparator|HIGH INTENSITY INTERVAL TRAINING|
88907820|NCT06303206|Experimental|Home Blood Pressure Telemonitoring (HBPT) + Case Management (CM)|This group will be asked to follow home BP monitoring as per instructions. Results will be transmitted and telemonitored using an app, where case managers (designated pharmacists) will monitor BP values to provide counselling for medication adherence and behavioural support and review telemonitored BP summaries and adjust BP medications according to protocol. Case management teams will contact participants at baseline and every month until the end of the study, or more frequently if BP is uncontrolled.
88907821|NCT06303206|No Intervention|Usual Care|This group will receive usual care by their primary care provider and provided with hypertension education materials similar to the intervention group. Participants will receive the same home BP monitor to encourage monitoring of home BP based on hypertension guideline recommendations. Home BP readings will tele-transmit via the app for study purposes, but not made available to the case managers or primary care providers, except if necessary for safety reasons, or at the discretion of the data safety monitoring physician.
89196619|NCT00922389|Active Comparator|Standerd theraphy|Any therapy for diabetic foot CLI which is routinely practiced and accepted in India
89196620|NCT00691938|Experimental|Level 1|"LBH589 10 mg/day three times a week on nonconsecutive days in a 28 day cycle.~Decitabine 20 mg/m^2 IV on days 1-5 in a 28 day cycle."
89196621|NCT00691938|Experimental|Level 2|"LBH589 15 mg/day three times a week on nonconsecutive days in a 28 day cycle.~Decitabine 20 mg/m^2 IV on days 1-5 in a 28 day cycle."
89196622|NCT00691938|Experimental|Level 3|"LBH589 20 mg/day three times a week on nonconsecutive days in a 28 day cycle.~Decitabine 20 mg/m^2 IV on days 1-5 in a 28 day cycle."
89196623|NCT00691938|Experimental|Level 4|"LBH589 30 mg/day three times a week on nonconsecutive days in a 28 day cycle.~Decitabine 20 mg/m^2 IV on days 1-5 in a 28 day cycle."
89196624|NCT00691938|Experimental|Level 5|"LBH589 40 mg/day three times a week on nonconsecutive days in a 28 day cycle.~Decitabine 20 mg/m^2 IV on days 1-5 in a 28 day cycle."
89196625|NCT00691938|Experimental|Level 5B|"LBH589 40 mg/day three times a week on nonconsecutive days for the first 2 weeks in a 28 day cycle.~Decitabine 20 mg/m^2 IV on days 1-5 in a 28 day cycle."
89196626|NCT00691938|Experimental|Phase II|"LBH589 will be given in the dose and in the schedule that was found to work in the Phase I portion which was Level 5B.~Decitabine 20 mg/m^2 IV on days 1-5 in a 28 day cycle."
89196627|NCT00365365|Experimental|Stratum 1 (AC->T + bevacizumab)|"HER2-negative participants administered~doxorubicin and cyclophosphamide (AC) + bevacizumab for 4 cycles followed by~docetaxel (T) + bevacizumab for 4 cycles followed by~bevacizumab maintenance therapy for total of 52 weeks from date of first dose regardless of number of doses received or missed"
89196628|NCT00365365|Experimental|Stratum 2 (TAC + bevacizumab)|"HER2-negative participants administered~docetaxel, doxorubicin, cyclophosphamide (TAC) + bevacizumab for 6 cycles followed by~bevacizumab maintenance therapy for total of 52 weeks from date of first dose regardless of number of doses received or missed"
89427000|NCT03641287|Experimental|Arm I (aerobic exercise)|Participants meet with exercise physiologist for 1, 60 minute session. Participants then receive individualized exercise prescription with goal of moderate aerobic exercise over 150 minutes per week at home for up to 24 weeks. Participants also receive telephone-based motivational support by exercise physiologist weekly for 24 weeks.
89427001|NCT03641287|Active Comparator|Arm II (habitual level of physical activity)|Participants maintain habitual levels of physical activity and receive general education material about ovarian cancer and survivorship for 24 weeks. After 24 weeks, participants are offered exercise intervention.
89427002|NCT03624400|Experimental|Internet-based CBT-I|N= 120 participants are offered Internet-based Cognitive behaviour therapy for insomnia (CBT-I)
89427003|NCT03624400|Active Comparator|Internet-based psychoeducation|N= 120 participants are offered Internet-based psychoeducation about sleep problems in ASD.
89427004|NCT03617471|Experimental|Paracetamol oral tablets 1g tid|Patients received paracetamol one gram three times daily. Venopuncture for PK profiling
89427005|NCT03617471|Experimental|Paracetamol oral granules 1g tid|Patients received paracetamol one gram three times daily. Venopuncture for PK profiling
89427006|NCT03614858|Experimental|Cohort 1|Experimental: Cohort 1 Intervention: Biological: CART-19/22 This cohort will determine the safety and efficacy of targeted CD19/CD22 chimeric Antigen Receptor Engineered T Cell Immunotherapy (CART) in the Treatment of CD19/CD22 Positive Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia.
89427007|NCT03611595|Experimental|Cabozantinib and 13-cis-retinoic acid|Cabozantinib will be given orally once every day with cycles repeated every 4 weeks (28 days, +/- 3 days), with no rest periods between cycles, combined with 13-cis-retinoic acid at 80mg/m2/dose twice daily for two consecutive weeks (14 days) out of every four weeks (28 days, +/- 3 days).
89427008|NCT03611309|Experimental|Surgeon-palliative care team co-management|In the Surgeon-palliative care team co-management arm, all patients receive the surgical care of surgeon alone management, which includes surgeon and the surgical team. In addition to this surgeon alone care, palliative care will also be provided by a specialist team. For patients in this arm, patients and/or family members will be seen by the palliative care team: (1) in an outpatient setting prior to surgery, (2) in the hospital within 72 hours of their initial surgery and as needed afterwards, and (3) via phone on in-clinic (per patient preference) on an at least monthly basis and/or as needed for 12 weeks following surgery.
89427009|NCT03611309|Other|Surgeon alone management|The surgeon and surgical team will manage symptoms, psychosocial support, and prognostic related communication. The surgeon and surgical team care for the patient and their family both prior to and following surgery. The surgeon team is given guidelines published by the National Cancer Coalition Network as to when palliative care specialist consultation is recommended
89427010|NCT03595267||Rural and Remote Indigenous Communities|Point-of-care screening for Chronic Kidney Disease, Diabetes, and Hypertension will be administered in rural and remote communities in Manitoba, British Columbia, Alberta, Saskatchewan, and Ontario.
88907822|NCT06303167|Experimental|Treatment (osimertinib)|Patients receive osimertinib (AZD9291) PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo radiologic evaluation throughout the trial, ECHO or MUGA during screening, and biopsy and collection of blood samples on trial and at end of treatment.
88907823|NCT06303154|Experimental|Mobiderm Intimate Bra group|All the patients will wear MOBIDERM Intimate bra composed of a bra and a MOBIDERM pad
88907824|NCT06303141|Other|Closed Chain Exercises|Group A, serving as the control group, will undergo a structured rehabilitation regimen comprising closed chain exercises, icing, and bracing. The exercise component will focus on enhancing proprioception and strengthening the ankle joint. Participants will perform exercises including open eyes and closed eyes across arm movements for three sets lasting 60 seconds each, lateral step down exercises for three sets of 6-12 repetitions, semi-squat exercises for three sets of 6-12 repetitions, and Thera-band isometric exercises for three sets of 10-15 seconds each. These exercises are designed to promote ankle stability, improve range of motion, and enhance muscle strength. Additionally, icing and bracing will be utilized to reduce inflammation and provide external support to the injured ankle.
88907825|NCT06303141|Experimental|Neuromuscular training|Group B, designated as the experimental group, will undergo a comprehensive rehabilitation protocol combining neuromuscular training with closed chain exercises, icing, and bracing. The exercise regimen will target proprioception, neuromuscular control, and ankle stability. Participants will engage in a series of exercises including single leg raises for three sets lasting 30 seconds each, ankle eversion/inversion exercises for three sets of 25 repetitions, double hopping in place then out of place for three sets of 30 seconds, reaching exercises with feet and hands for three sets lasting 30-60 seconds each, and wobble board exercises for three sets lasting 30-60 seconds each. These exercises are aimed at improving balance, coordination, and muscle strength around the ankle joint. The addition of neuromuscular training enhances the proprioceptive feedback and control, which is crucial for injury prevention and functional recovery in athletes with ankle sprains.
89007815|NCT04615702||application of recent guidelines in the management of acute biliary pancreatitis|all patients subjected to the following: Confirmation of the diagnosis of acute pancreatitis, Diagnosis of the cause either biliary or not, Severity scoring and Evidence based management regarding Initial management, Intervention as indicated, Prevention of recurrence and Follow up
89007816|NCT04615585|Experimental|Aloe Vera + Scaling and root planing|
89007817|NCT04615585|Active Comparator|Scaling and root planing|
89007818|NCT04615468|Experimental|TQ-B3525 tablets|TQ-B3525 tablet administered orally.
89427011|NCT03586284|Active Comparator|Oral Valganciclovir|Oral Valganciclovir 900mg PO BID Topical placebo solution, 1 drop applied 6 times daily
89007819|NCT04615858|Active Comparator|Genepro Generation 3|1 scoop, 11g, Genepro Generation 3 Protein daily will be used by Group A (20 participants) 10 male, 10 female participants 6 months post bariatric surgery.
89007820|NCT04615858|Active Comparator|Whey Protein|1 scoop, 30g, Whey Protein daily will be used by Group B (20 participants) 10 male, 10 female participants 6 months post bariatric surgery.
89007821|NCT04615351|Active Comparator|Metformin|Metformin 500 mg to be taken twice per day for two weeks and then metformin 1000 mg PO twice daily after tolerating the lower dose
89427012|NCT03586284|Active Comparator|Topical Ganciclovir 2%|Topical Ganciclovir 2% solution, 1 drop applied 6 times daily Placebo pills PO BID
89427013|NCT03586284|Placebo Comparator|Placebo|Topical placebo solution, 1 drop applied 6 times daily Placebo pills PO BID
89007822|NCT04615351|No Intervention|Routine Care|Discharge information about maintaining a healthy diet
89007823|NCT04615156|Experimental|Evaluation for adverse events from 18F-2-fluoro-2-deoxy-D-glucose produced by a new manufacturer|
89007824|NCT04615312|Experimental|a CDK4 / 6 inhibitor and a MEK inhibitor|Participants will receive a CDK4 / 6 inhibitor and a MEK inhibitor treatment
89007825|NCT04614961||Patients with overweight, obesity or after bariatric surgery|Patients with overweight, obesity or after bariatric surgery
89007826|NCT04618666|Experimental|laparoscopic and open appendectomy|comparative study between laparoscopic and open appendectomy
89007827|NCT00251121|Experimental|Atrial pacing|Diagnostic pacing in right heart atrium in order to unmask reentry tachycardia
89007828|NCT04614883|Other|Asymptomatic patients or Healthy volunteers|Patient with no symptom of COVID-19 infection but for whom a PCR test needs to be done because he has been in contact with a COVID-19 positive person
89007829|NCT04614883|Other|Symptomatic patients with positive PCR|Patients with symptoms of COVID-19 and whose PCR result is positive
89007830|NCT04614883|Other|Symptomatic patients with negative PCR but with seroconversion within 4 to 8 weeks|Patients with symptoms of COVID-19 and whose PCR result is negative at inclusion but presents a seroconversion within 4 to 8 weeks post inclusion
89007831|NCT04614727|Experimental|polymeric nano calcium fluoride containing varnish, NANO SEAL.|
89427014|NCT03575429|Active Comparator|Engagement Intervention|Family navigators will engage families to access resources and support when they first learn their child has signs of autism spectrum disorder (ASD) using an intervention that integrates motivational interviewing (MI) and problem-solving education (PSE). The family navigator will meet with parents for up to 6 individual MI+PSE sessions for each 3-month stage of intervention.
89536147|NCT04990557|Experimental|A - Two cycles|"Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) and ACE2 gene will be knocked out by CRISPR Cas9 in the laboratory (PD-1/ACE2 Knockout T cells). The lymphocytes will be selected and expanded ex vivo and infused back into patients.~A total of 1 x 10^7/kg PD-1and ACE2 Knockout T cells will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third. Patients will receive a total of two cycles of treatment."
89007832|NCT04614727|Other|Casein Phosphopeptide Amorphous Calcium Phosphate Containing Fluoride Varnish,MI varnish|CPP-ACP with 5%NaF
89007833|NCT04614415|Experimental|Treatment group|group 1 will be treated with autocrosslinked Hyaluronic acid
89007834|NCT04614415|Placebo Comparator|control group|group 2 treated with placebo (isotonic saline solution).
89007835|NCT04614376||Control Group|The control group participants have not been diagnosed with mild cognitive impairment or Alzheimer's disease within the past 5 years. There are no interventions to this group.
89007836|NCT04614376||Case Group|The case group participants have been diagnosed with mild cognitive impairment or Alzheimer's disease within the past 5 years. There are no interventions to this group.
89199197|NCT05953896|Experimental|Hyaluronic acid gel|will include 10 patients undergoing non invasive reconstruction of interdental papilla using injectable Hyaluronic acid gel
89427015|NCT03575429|Active Comparator|Engagement + Coaching Intervention|Family navigators will engage families to access resources and support when they first learn their child has signs of autism spectrum disorder (ASD) using an intervention that integrates MI+PSE. Family navigators will also coach families to embed intervention strategies for toddlers with ASD in everyday activities using the Early Social Interaction (ESI) model. ESI teaches parents how to support their child's social communication, language, play and behaviors in everyday routines, activities, and places. The family navigator will meet with parents for 12 weekly home visits for each 3-month stage of intervention.
89427016|NCT03571321|Experimental|Ruxolitinib|"Participants will receive ruxolitinib in addition to standard chemotherapy.~Standard Chemotherapy Consists of:~Remission consolidation therapy (lasting 8 weeks)~Interim Maintenance (lasting 8 weeks)~Delayed Intensification (lasting 8 weeks~Maintenance Therapy (12 week courses/84 day cycles lasting 2-3 years)~Prior to study entry, patients must have completed a 4-drug induction therapy regimen with intrathecal chemotherapy (modified Berlin-Frankfurt-Münster (aBFM) regimen or equivalent) as per the institution standard of care."
89427017|NCT03569878|Experimental|Peer-Integrated Multidisciplinary Collaborative Care|The peer-integrated collaborative care intervention includes front-line trauma center staff (e.g., nursing and masters in social work), joined by injured peer interventionists and supervised by an MD (psychiatrist). The collaborative care team will provide case management, behavioral intervention elements, psychopharmacologic medication recommendations as well as 24/7 cell phone coverage for approximately 6 months post-injury. The intervention will be supported by a novel emergency department health information technology platform.
89427018|NCT03569878|Active Comparator|Trauma surgery team notification|Trauma surgery team notification of patient emotional distress, with recommendation for mental health inpatient consultation will be the comparator condition.
89427019|NCT03564275|Experimental|Prospective Treatment Group|Proton Boost
89427020|NCT03564275|No Intervention|Retrospective Comparison Group|Retrospective patients previously treated with standard of care photon therapy. There is no patient interaction with this group. Data collection from medical records only.
89427021|NCT03564236|Active Comparator|Standard Care|"Standard care is provided according to our local COPD exacerbation protocol. All patients are treated with:~oral prednisolone 40 mg/day for 5 days;~antibiotics prescribed according to the following criteria: fever (body temperature > 38.5 degrees Celsius), elevated C-reactive protein (CRP) >50, change in sputum colour, and/or according to the physician's decision of severe illness, and/or in all patients with a FEV1 <30% of predicted;~high dose inhaled corticosteroids, beta-agonists and or anticholinergics.~Oxygen will be prescribed in all patients through a standard low flow system in order to maintain an adequate arterial oxygen saturation (Sa,O2) Patients will be discharged with regular low flow oxygen once they fulfil the criteria for long-term oxygen therapy."
89427022|NCT03564236|Experimental|Nasal High Flow Therapy|"In addition to the standard care described above, patients in the intervention group will be treated with:~nHFT, set at 30-50 L/min flow with oxygen to achieve an adequate oxygen saturation. nHFT is prescribed for at least 6 hours, but patients are stimulated to use the device as much as possible during the hospital stay.~During periods without HFT through a standard low flow system, to maintain an adequate arterial oxygen saturation (Sa,O2) (between 90-92% if patients are concomitantly hypercapnic, and between 90-95% if patients are normocapnic). Flow rates are titrated accordingly.~After discharge patients in the nHFT arm will continue the prescribed therapy at home for 90 subsequent days."
89427023|NCT03549403|Experimental|Patient-centered telephone education|Patients receive the preoperative call home one week before the day surgery and postoperatively 3-8 days after the day surgery. On the day of surgery patients receive current education.
89427024|NCT03549403|No Intervention|Current education practice|Patient´s education is implemented in accordance with current practice, where day surgery adult patients receive preoperative education over the phone one week prior to day surgery and postoperative education during on the day of surgery.
89536842|NCT03308747|Experimental|High systemic inflammation|Individuals assigned in the high systemic inflammation group will be characterized by IL6: ≥ 1.7 pg/ml and hs-CRP: > 2.0 mg/L.
89196629|NCT00365365|Experimental|Stratum 3 (TCH + bevacizumab)|"All HER2-positive participants administered~docetaxel, carboplatin, trastuzumab (TCH) + bevacizumab for 6 cycles followed by~bevacizumab and trastuzumab maintenance therapy for total of 52 weeks from date of first dose regardless of number of doses received or missed"
89196630|NCT02564874|Experimental|Savory snack|1-2 assigned snacks to be taken in determined portions equivalent to 15% of dietary energy intake, chosen from 9-point hedonic preferences questionnaire completed by participant (chips, pretzels, etc.)
89196631|NCT02564874|Experimental|Sugary beverage|1-2 soda-based drinks/juice to be taken in determined portions equivalent to 15% of dietary energy intake, chosen from 9-point hedonic preferences questionnaire completed by participant (coke, sprite, etc.)
89196632|NCT01046461|Experimental|Ramosetron, Aprepitant, Dexamethasone|
89196633|NCT00623727|Experimental|rFVIII-FS/pegylated liposomes (BAY79-4980)|35 IU/kg body weight of BAY79-4980 1x/week plus 2 dummy injections/week (dummy = rFVIII (recombinant factor VIII)-FS (formulated with sucrose) excipient reconstituted in WFI (sterile water for injection))
89196634|NCT00623727|Active Comparator|rFVIII-FS/WFI (BAY14-2222)|25 IU/kg body weight of rFVIII-FS 3x/week (employing 1 percent POPC (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine)-alone liposome (rFVIII-FS-POPC) as blinding agent used for first weekly injection and rFVIII-FS in WFI for 2nd and 3rd injection)
89196635|NCT00933946|Experimental|Dermacyd Silver Frutal (Lactic Acid)|Dermacyd Silver Frutal (Lactic Acid) sample will be applied like a curative. Physiologic solution and mineral oil will be also used as a control sample.
89536843|NCT03308747|Active Comparator|Low systemic inflammation|Individuals assigned in the high systemic inflammation group will be characterized by IL6: < 1.7 pg/ml and hs-CRP: < 1.0 mg/L.
89536844|NCT02469467|Experimental|VS-505|750 mg capsule
88907826|NCT06303141|Experimental|Mobilization with movement|Group C, designated as an experimental group, will undergo a unique intervention combining mobilization with movement techniques, closed chain exercises, icing, and bracing. The focus of this intervention is to address joint dysfunctions and pain modulation while improving range of motion (ROM) in athletes with ankle sprains. Participants will receive joint mobilization with movement techniques, following the Mulligan approach, aimed at restoring normal joint mechanics and function. The protocol will involve three sets of six oscillations or glides each, targeting specific joint restrictions and impairments associated with ankle sprains. By integrating manual therapy with exercise and adjunct modalities like icing and bracing, this comprehensive approach aims to optimize joint function, reduce pain, and enhance overall rehabilitation outcomes in professional athletes with ankle injuries.
88907827|NCT06303102|Experimental|Experimental|Experimental Group A (Manual PT/ Conventional PT Treatment + Segmental and Pursed Lip Breathing Exercise)
88907828|NCT06303102|Other|Controlled|Group B (Manual PT/Conventional PT Treatment)
88907829|NCT06303089||Questionnaires assessed Chronic Kidney Disease patients|"Participants who met the inclusion criteria below will be invited to fill in tobacco exposure questionnaires, smokers will be invited to complete smoking cessation questionnaires set.~Participants aged 18 years or older;~Participants with a confirmed diagnosis of Chronic Kidney Disease;"
88907830|NCT06303076|Experimental|Tizanidine Group|Participants will be asked to ingest Tinazidine, orally at home immediately before going to bed to sleep. Initially, the patients will be asked to ingest 2 mg HS, and it will be titrated up by 2 mg every 4 days, as per response and tolerability, up to a maximum dose of 0.1 mg/kg/HS.
88907831|NCT06303076|Active Comparator|Zolpidem Group|Participants will be asked to ingest Zolpidem 10 mg HS, orally at home before bedtime.
88907832|NCT06303063|Experimental|SINOMED IAS Stent System|The SINOMED IAS Stent System is intended for use with occlusive devices in the treatment of intracranial aneurysms.
88907833|NCT06303063|Active Comparator|Neuroform Atlas Stent System|The Neuroform Atlas Stent System is intended for use with occlusive devices in the treatment of intracranial aneurysms.
88907834|NCT06303050|Experimental|Mental Imagery with task Oriented training group|Participants will perform warm-up exercise for 5 minutes to prepare the body for functional task and to improve overall performance.
88907835|NCT06303050|Active Comparator|Task Oriented training group|Task oriented training In standing, forward stepping and sideward stepping, reaching in standing, Transition from sit to stand, Walk then back to sit, Walk with even steps, Walk with carrying objects.
88907836|NCT06303037|Experimental|Group L|Low-dose esketamine
88907837|NCT06303037|Experimental|Group M|Medium dose esketamine
88907838|NCT06303024|Experimental|personalized combined physical and cognitive intervention|The exercise intervention will be aerobic and performed on a stationary bicycle and will comply with the basic principle of progressive overload, combined with a computer based cognitive rehabilitation program carried out twice a week for 12 weeks, using the Rehacom software.
88907839|NCT06303011|Experimental|Group: A|TENS on sacral areas with Abdominal Massage
89536845|NCT03313193|Experimental|Arm A|Acupressure for Children in Treatment for a Childhood Cancer + usual care
88907840|NCT06303011|Active Comparator|Group: B|TENS on para sacral area with Abdominal Massage
88907841|NCT06302998|Experimental|DEX-PRESSIN|This group will receive vasopressin as the first-line vasopressor. DEX will be started after hemodynamic stabilization if the heart rate is >90 beats per minute (bpm). NE infusion will be the second-line vasoactive drug.
88907842|NCT06302998|Active Comparator|Standard-of-care group|This group will receive conventional treatment according to the Surviving Sepsis Campaign 2021 guidelines. This group will receive vasopressin as the second line after NE and will not receive dexmedetomidine.
89007837|NCT04614688|Experimental|Patient Education Group|Patients in this group will undergo the standard physician-led informed consent process and then be provided with an interactive patient education platform for hysteroscopy on a tablet available in the clinic for up to one hour of time. After the patient has explored the patient education platform, they will be given a post-consent survey which will measure their understanding of the surgery, their readiness for the surgery, and their satisfaction with the consent process.
89196636|NCT01046539|Active Comparator|RDC-0313 + Buprenorphine|Cohort 1 (1 and 4 mg) + 8 mg Cohort 2 (dependent on Cohort 1 results)
89196637|NCT01046539|Placebo Comparator|Placebo|
89196638|NCT04015024|Experimental|SKLB1028 150mg bid|Repeated oral administration until there is no longer clinical benefit from therapy,or until unacceptable toxicity occurs.
89196639|NCT04015024|Experimental|SKLB1028 200mg bid|Repeated oral administration until there is no longer clinical benefit from therapy,or until unacceptable toxicity occurs
89196640|NCT04015024|Experimental|SKLB1028 300mg qd|Repeated oral administration until there is no longer clinical benefit from therapy,or until unacceptable toxicity occurs
89196641|NCT01044199|Experimental|1: Pre-EP ID|Group of participants receiving PCEC rabies vaccine intradermally with the Pre-Exposure schedule.
89196642|NCT01044199|Active Comparator|2: Pre-EP IM|Group of participants receiving PCEC rabies vaccine intramuscular with the Pre-Exposure schedule.
89196643|NCT01044199|Experimental|3: Booster ID|Group of participants receiving PCEC rabies vaccine intradermally with the Booster schedule.
89531076|NCT02498249|Placebo Comparator|Experimental: Placebo low level laser therapy (PLLLT)|"For the PLLLT irradiation, a paper template with 9 points (area of 1cm and a distance from center to center of 1 cm) will be used, distributed in three columns and three lines. The central point of the template will be positioned above the medium point of a line traced between the acromion and the spinous process of the seventh cervical vertebra, where the treatment should be close to the fixation point of the EMG electrode. The application point of the PLLLT was determined by the location of the innervation point of the upper trapezius muscle.~Individuals will be subject to application of low level laser with a total dose of 0 J"
89007838|NCT04614688|No Intervention|Standard Consent Group|Patients in this group will undergo the standard physician-led informed consent process only. After they have consented to the surgery, they will be given a post-consent survey which will measure their understanding of the surgery, their readiness for the surgery, and their satisfaction with the consent process.
89007839|NCT00412685||TGA group|The TGA group consists of 15 patients treated withMustard or Senning procedures for surgical repaired of D-TGA atrial switch operation.
89196644|NCT01044199|Active Comparator|4: Booster IM|Group of participants receiving PCEC rabies vaccine intramuscular with the Booster schedule.
89196645|NCT00908284|Active Comparator|Control Group|Participants will take part in a 12-week control group.
89196646|NCT00908284|Experimental|Exercise Program|Participants will take part in a 12-week exercise program.
89196647|NCT00839709||depletion immunosuppression|
89196648|NCT00839709||no depletion immunosuppression|
89196649|NCT00930358|Experimental|MEOPA|MEOPA : equimolar nitrous oxide/oxygen mixture
89196650|NCT00930358|Active Comparator|General anesthesia|Gold standard
88907843|NCT06302985|Experimental|ICG for CLMs|"Preoperative preparation ICG solution dissolved in 5ml of normal saline (dose 0.5mg/kg) was inhaled 30 minutes before surgery.~Operation method After entering the chest cavity, the fluorescence endoscope was switched to the fluorescence display mode, and the fluorescence-stained normal lung tissue and non-stained lesion tissue could be clearly displayed through the display screen, and the external boundary of the lesion was marked with an electric hook. The mediastinal pleura and pulmonary pleura were opened along the boundary of the lesion, and the lung tissue was split along the gap between the lesion and the lung tissue with an electric coagulation hook and an ultrasonic knife, and the lesion arteries and bronchi were freed. Smaller blood vessels could be cut by Ligasure or ultrasonic knife directly, and thicker blood vessels and bronchi should be cut by Hemolock until the lesion resection was completed."
89007840|NCT00412685||TOF group|The TOF group consists of 15 patients with surgically corrected TOF.
89196651|NCT00832845|Experimental|CBSST plus treatment as usual|Subject randomized to the CBSST Group arm will attend 2 hour weekly Cognitive Behavioural Social Skills therapy sessions for 9 months. They will also be attending follow-up assessments q 4 months.
89196652|NCT00832845|Active Comparator|Treatment as Usual Group|Subjects randomized to the Treatment as Usual Group Arm will continue with their regular psychiatric treatment for 1 year. Like the CBSST Group Arm, they will have follow up assessments q 4 months. After completing the Treatment as Usual Group arm, they will automatically continue on with the CBSST Group Arm.
89196653|NCT00930436|Active Comparator|Saline infusion|Saline will be given as an active control agent to compare with sodium bicarbonate. Each bag of solution will be blinded, and given in the same manner.
89196654|NCT00930436|Experimental|Sodium Bicarbonate|Infusion of sodium bicarbonate will be given prior to,during and after the contrast agent for a total of 6 to 10 hours
89196655|NCT00372775|Experimental|Sunitinib|
89196656|NCT00832923|No Intervention|Routine IMPACT DC care|Participants receive standard asthma education as routine for IMPACT DC
89196657|NCT00832923|Experimental|Enhanced care PEPAC Intervention|
89196658|NCT00936676||Rasagiline mesylate|Enrollment by invitation to participates from the ADAGIO trial
89196659|NCT00839787|Experimental|Morphine|Morphine Sulfate: If weight is <50 Kg; Morphine 0.1mg/kg IV to a maximum of 10mg can be given; if weight ≥ 50 Kg a maximum of 10mg can be given.
89196660|NCT00839787|Placebo Comparator|Placebo|Normal saline
89196661|NCT01044355|Active Comparator|auto-titrating|Patients being treated for 6 weeks with auto-titrating continuous airway pressure.
89196662|NCT01044355|Active Comparator|Fixed|Patients receiving 6 weeks of treatment with fixed continuous positive airway pressure.
89196663|NCT01049659|Other|neuropsychological tests|neuropsychological assessment of children around their second birthday
89196664|NCT00936754|Experimental|Treatment|Single administration of 500 mg of encapsulated brown seaweed powder, taken 30 minutes before test meal
89196665|NCT00936754|Placebo Comparator|Placebo|Single administration of encapsulated placebo, taken 30 minutes before test meal
89196666|NCT00372697|Experimental|Octreotide 30 mg every 21 days|Patients received octreotide 30 mg every 21 days intramuscularly (im) for 6 months, a total of 8 doses. At each study visit, octreotide was administered only after completion of all scheduled efficacy and safety evaluations for that visit. Octreotide was injected im into the right or left gluteal regions. The injections were initially administered by a trained and authorized member of the investigational team. When no study visit at the investigational site was required, the injections were given by a trained nurse or the family doctor.
89196667|NCT00372697|Experimental|Octreotide 60 mg every 28 days|Patients received octreotide 60 mg every 28 days intramuscularly (im) for 6 months, a total of 6 doses. Octreotide mg was administered as two 30 mg injections. At each study visit, octreotide was administered only after completion of all scheduled efficacy and safety evaluations for that visit. Octreotide was injected im into the right or left gluteal regions. The injections were initially administered by a trained and authorized member of the investigational team. When no study visit at the investigational site was required, the injections were given by a trained nurse or the family doctor.
89196668|NCT04014478|Experimental|Endovascular Denervation|
89196669|NCT00934336|Experimental|preprandial injection|pre-prandial injection of an ultra-fast-acting analog during 3 months, then post-prandial injection of an ultra-fast-acting analog during 3 other months.
89196670|NCT00934336|Experimental|post-prandial injection|post-prandial injection of an ultra-fast-acting analog during 3 months then pre-prandial injection of an ultra-fast-acting analog during 3 other months.
89196671|NCT00934414|Experimental|Smokers|
89196672|NCT00934414|Experimental|Non-Smokers|
89196673|NCT00930514|Active Comparator|Rituximab IV 375 mg/m^2 (Stage 1: Cohort A)|
89196674|NCT00930514|Active Comparator|Rituximab IV 375 mg/m^2 (Stage 2: Cohort E)|
89196675|NCT00930514|Experimental|Rituximab SC 1400 mg (Stage 2: Cohort F)|
89196676|NCT00930514|Experimental|Rituximab SC 375 mg/m^2 (Stage 1: Cohort B)|
89196677|NCT00930514|Experimental|Rituximab SC 625 mg/m^2 (Stage 1: Cohort C)|
89196678|NCT00930514|Experimental|Rituximab SC 800 mg/m^2 (Stage 1: Cohort D)|
89196679|NCT00936988|Experimental|cinacalcet|
89196680|NCT00934492|Active Comparator|Cotrimoxazole dispersible tablet|Children between 2-6 months will receive single dispersible tablet of 120mg,daily while children over 6 months to 5 years will receive 240 mg dispersible tablet daily for six months.
89196681|NCT00934492|Placebo Comparator|Placebo dispersible tablet|Children between 2-6 months will receive single dispersible Placebo tablet of 120mg,daily while children over 6 months to 5 years will receive 240 mg dispersible Placebo tablet daily for six months.
89536846|NCT03313193|No Intervention|Arm B|Usual care alone
89196682|NCT00930592||Children with Psoriasis|Children and adolescents from 10-17 years of age with moderate to severe psoriasis.
89196683|NCT00930592||Control: children with warts|Children and adolescents from 10-17 years of age with warts.
89196684|NCT00934570|Active Comparator|Metformin, Standard exercise|Lifestyle intervention with metformin and standard exercise program.
89196685|NCT00934570|Placebo Comparator|Placebo, Standard exercise|Lifestyle intervention with placebo and standard exercise program
88907844|NCT06302972|Experimental|IASTM and CCEP|"Instrument Assisted Soft Mobilization Technique; For pectoralis major:~Subjects will be asked to lay supine with their thorax front side exposed. In abduction, restriction or adhesions will be located using scanning and gel will be applied. IASTM also address soft tissue restrictions and pain in levator scapulae, suboccipital muscles and sternocleidomastoid muscle.~The CCEP will be designed in three phases, including initial, improvement, and maintenance.. The exercises in appropriate muscles in correct alignment during the movement pattern, the protocol focused on improving sustained postures.~Exercises in initial phase protocol from 10 s hold x7 to 15 s hold x 10 from roller Exercises in improvement phase protocol from 10 repetition x 5 to 15 repetition x 6 from dumbbell , thera band, swiss ball and balance board"
88907845|NCT06302972|Active Comparator|Comprehensive Corrective Exercise Program.Type|"The CCEP will be designed in three phases, including initial, improvement, and maintenance. Exercises are progressed in frequency and intensity during these phases, as long as the movements are performed in a good quality. The exercises in appropriate muscles in correct alignment during the movement pattern, the protocol focused on improving sustained postures. This goal was addressed in the improvement phase when necessary tissue adaptations occurred by increasing the load of exercises. In the maintenance phase, the participant continued to do the exercises and maintain the training adaptations for two weeks. The exercises will be the same as the improvement phase without any progression in intensity and frequency.~Exercises in initial phase protocol from 10 s hold x7 to 15 s hold x 10 from roller Exercises in improvement phase protocol from 10 repetition x 5 to 15 repetition x 6 from dumbbell , thera band, swiss ball and balance board"
89536148|NCT04990557|Experimental|B- Two cycles|"Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) and ACE2 gene will be knocked out by CRISPR Cas9 in the laboratory (PD-1/ACE2 Knockout T cells). The lymphocytes will be selected and expanded ex vivo and infused back into patients.~A total of 1 x 10^7/kg PD-1 and ACE2 Knockout T cells will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third. Patients will receive a total of two cycles of treatment.~A total of 2 x 10^7/kg PD-1and ACE2 Knockout T cells will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third. Patients will receive a total of two cycles of treatment."
89536149|NCT04990557|Experimental|C- Two cycles|"Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) and ACE2 gene will be knocked out by CRISPR Cas9 in the laboratory (PD-1/ACE2 Knockout T cells). The lymphocytes will be selected and expanded ex vivo and infused back into patients.~A total of 4 x 10^7/kg PD-1 and ACE2 Knockout T cells will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third. Patients will receive a total of two cycles of treatment."
89536150|NCT02478437|Active Comparator|Group 1|Conventional radiofrequency ablation (RFA) Following ablation, 0.5 cc of 0.5% bupivacaine will be injected to provide post procedure analgesia.
88907849|NCT06302946|Experimental|experimental group|will receive neuromuscular stimulation , mindfulness breathing and traditional physiotherapy program
88907850|NCT06302946|Active Comparator|control group|the control group will stick to the traditional physiotherapy program only.
89196686|NCT00934570|Active Comparator|Metformin, Intensive exercise|Lifestyle intervention with metformin and intensive exercise
89196687|NCT00934570|Placebo Comparator|Placebo, Intensive exercise|Lifestyle intervention with placebo and intensive exercise program.
89196688|NCT00937066||1|Adult patients 18-65 years with moderate to severe uncontrolled asthma
88907851|NCT06302933|Other|Children enrolled in Pediacam III ANRS12225 cohort|
88907852|NCT06302920|Active Comparator|Kinesiotaping group|Patients will be divided into 2 groups according to the random numbers table, and both groups will receive a conventional physical therapy and rehabilitation program and nutritional support. Afterwards, edema-reducing kinesiotaping will be applied to one group.
89196689|NCT03702634|No Intervention|Control (Usual Care)|Surrogate will receive usual care in the hospital, which could include visits from the unit chaplain or other staff from the spiritual care department.
88907853|NCT06302920|No Intervention|Control group|Patients will be divided into 2 groups according to the random numbers table, and both groups will receive a conventional physical therapy and rehabilitation program and nutritional support.
89196690|NCT03702634|Experimental|Intervention|Spiritual Care Assessment and Intervention (SCAI) framework
89196691|NCT00934726||1 group, schizophrenia patients|Patients with schizophrenia according to ICD-10(diagnostic and statistical manual of mental disorders)
89196692|NCT00930670|Experimental|Rosuvastatin-omeprazole|Rosuvastatin-omeprazole
88907854|NCT06302907|Active Comparator|Buffered LA|AA buffered 2% lidocaine with 1:80000 epinephrine and sodium bicarbonate 8.4% was used for one site
88907855|NCT06302907|Active Comparator|Unbuffered LA|an unbuffered 2% lidocaine with 1: 80000 epinephrine for the other site at the same appointment.
88907856|NCT06302894|No Intervention|Control group|Internet addiction scale, family harmony scale and loneliness scale for children will be applied to the control group after 6 weeks without any intervention.
89196693|NCT00930670|Experimental|Rosuvastatin-pantoprazole|Rosuvastatin 20 mg for 1 month, then rosuvastatin 20 mg and pantoprazole 40 mg for 11 months
89196694|NCT00930670|Experimental|Rosuvastatin-esomeprazole|Rosuvastatin 20 mg for 1 month, then rosuvastatin 20 mg and esomeprazole 40 mg for 11 months
89196695|NCT00930670|Active Comparator|Rosuvastatin-ranitidine|Rosuvastatin 20 mg for 1 month, then rosuvastatin 20 mg and ranitidine 300 mg for 11 months
89196696|NCT00930670|Experimental|Atorvastatin-omeprazole|Atorvastatin 80mg for 1 month, then atorvastatin 80 mg and omeprazole 20 mg for 11 months
89196697|NCT00930670|Experimental|Atorvastatin-pantoprazole|Atorvastatin 80mg for 1 month, then atorvastatin 80 mg and pantoprazole 40mg for 11 months
89196698|NCT00930670|Experimental|Atorvastatin-esomeprazole|Atorvastatin 80mg for 1 month, then atorvastatin 80 mg and esomeprazole 40 mg for 11 months
89196699|NCT00930670|Active Comparator|Atorvastatin-ranitidine|Atorvastatin 80mg for 1 month, then atorvastatin 80 mg and ranitidine 300mg for 11 months
89196700|NCT00934804|Experimental|Comparative Diagnostic system|Galilei dual Scheimpflug analyzer
89196701|NCT00934882|Experimental|Arm 1|
89196702|NCT00937144|Experimental|viagra|viagra versus placebo will be given to patients with sickle cell anemia
89196703|NCT00937144|Placebo Comparator|placebo|viagra versus placebo will be given to patients with sickle cell anemia
89196704|NCT04014400|Experimental|Suprathel|Once hemostasis is obtained, the Suprathel material will be handled with a new pair of sterile gloves. It will be cut so that the material extends 1-2 cm beyond the donor site margins, then applied to the donor site. The Suprathel will be secured with a protective layer of Rylon extending 1-2 cms beyond the margins of the Suprathel. The primary dressing will be covered with cotton gauze (4x4 fluff gauze pads) and wrapped with rolled gauze). The outer dressing will be changed 7-10 days post-op. The Suprathel and Rylon will remain in place until they can be easily peeled off. To facilitate the pain-free and easy removal of the primary Suprathel dressing, practioners will apply Vaseline or lotion to saturate and loosen the material. The patients will be followed on average about once per week in an outpatient clinic until the Suprathel (and Rylon) are removed, but they may continue to be seen until the STSG is fully healed.
89196705|NCT04014400|Active Comparator|Xeroform|After hemostasis occurs, the Xeroform dressing will be handled with a new pair of sterile gloves and cut so that the material extends 1-2 cm beyond the donor site margins, then applied to the donor site. The primary dressing will be covered with cotton gauze (4x4 fluff gauze pads) and wrapped with rolled gauze (Kerlix). The outer dressing will be changed 7-10 days post-op. The Xeroform will remain in place until it can be easily peeled off. To facilitate the pain-free and easy removal of the Xeroform dressing, practioners may apply Vaseline or lotion to saturate and loosen the material. The patients will be followed on average about once per week in an outpatient clinic until the Xeroform is removed, but they may continue to be seen until the STSG is fully healed.
89196706|NCT00931060|Experimental|Branched chain amino acids|Patients with cirrhosis. Healthy subjects age and sex matched
89196707|NCT00937456|Experimental|Laparoscopically-assisted esophagectomy|Laparoscopically-assisted esophagectomy: standard abdominal procedure of gastric mobilisation but through laparoscopic route. Right thoracotomy as usual.
89007841|NCT00412685||Control group|The control group C consists of 15 control subjects (AH) with normal Doppler Echocardiographic echocardiographic examinations.
89196708|NCT00937456|Active Comparator|Open esophagectomy|Conventional open esophagectomy: Esophagectomy with extended 2-field lymphadenectomy through laparotomy and right thoracotomy (Ivor-Lewis standard procedure)
89007842|NCT04614298|Experimental|KHK4827 210 mg SC (Subcutaneous)|Single SC administration
89007843|NCT04614298|Placebo Comparator|Placebo SC|Single SC administration
89007844|NCT04613986|No Intervention|Standard|Standard of care according to our current in house SOP
89007845|NCT04613986|Experimental|Treatment|Standard of care according to our current in house SOP + Therapeutic Plasmaexchange (d1, 3, 5)
89007846|NCT04614259|Experimental|intravenous analgesia|
89007847|NCT04614259|Experimental|infraorbital nerve block|
89007848|NCT00251160|Active Comparator|ETAC|
89007849|NCT00251160|Active Comparator|Open ICS|
89007850|NCT04613908|Active Comparator|standard care or usual rehabilitation|It will consist of the usual treatment performed by the intensive care physiotherapist, it will be applied every day that the study lasts.
89007851|NCT04613908|Experimental|neuro muscular electro stimulation|They received 5 sessions per week (except weekends) of neuromuscular electrostimulation of 30 minutes duration. Also, every day that the study is carried out in the morning and in the afternoon, the subjects will receive the usual treatment performed by the intensive care physiotherapist.
89007852|NCT04613908|Experimental|early mobilization protocol|Throughout the duration of the study, an early mobilization protocol will be applied to apply a specific treatment based on different levels of treatment for each subject of the group; It differs from the usual procedure in protocolized progression according to the objectives reached by the patient, unlike the usual treatment, where the progression is in accordance with the clinical criteria of the treatment professional.
89007853|NCT04614181|Experimental|Carbohydrate and protein loading|Nestle Resource drink
89007854|NCT04614181|Active Comparator|Usual care|Usual fracture care as determined by clinical team
89007855|NCT00412802|Experimental|1|dose adaptation of Enoxaparine at the renal deficient patients
89007856|NCT00412802|Active Comparator|2|No dose adaptation of Enoxaparine at renal normal patients
89007857|NCT00563524|Placebo Comparator|1|
89007858|NCT04613869|Experimental|High-dose esketamine group|After the operation, 5 mg esketamine was injected intravenously for postoperative analgesia. PCIA formula: hydromorphone 6mg + esketamine 45mg + tropisetron 10mg into 0.9% sodium chloride injection 100ml, the first dose is 20ug/kg , Background dose 2ug/kg/h, single dose 4ug/kg/time
89007859|NCT04613869|Experimental|Low-dose esketamine group|After the operation, esketamine 2.5mg was injected intravenously for postoperative analgesia. PCIA formula: hydromorphone 6mg + esketamine 22.5mg + tropisetron 10mg into 0.9% sodium chloride injection 100ml, the first dose is 20ug/ kg, background dose 2ug/kg/h, single dose 4ug/kg/time
89007860|NCT04613869|Placebo Comparator|Control group|PCIA formula: 6mg of hydromorphone + 10mg of tropisetron into 100ml of 0.9% sodium chloride injection, the first dose is 20ug/kg, the background dose is 2ug/kg/h, and the single dose is 4ug/kg/time.
89007861|NCT00251355|Experimental|5-FU/gemcitabine/RT|
89007862|NCT02962388|Active Comparator|Reference therapy arm|Best Available Therapy (BAT) in second line, after hydroxyurea. BAT restricted to anagrelide or IFNα/ PegIFNα in the study, according to the investigator decision
89007863|NCT02962388|Experimental|Investigational therapy arm|"Ruxolitinib JAKAVI® Starting dose 10 mg BID, orally. To be increased or decreased (5 or 10 mg steps) per standardized dosing paradigm.~Maximum dose 25 mg BID."
89007864|NCT04613167|Experimental|Alirocumab|The first group of patients will receive 150 mg of alirocumab every two weeks subcutaneously for 6 months
89007865|NCT04613167|Experimental|Evolocumab|the second group of patients will receive evolocumab 140 mg every two weeks subcutaneously for 6 months
89007866|NCT04613167|Experimental|Control group|Control group will be included in the treatment after 6 months. During this time, the control group will not receive treatment with alirocumab or evolocumab, only standard guidelines-based treatment
89007867|NCT04613245||Patient with asthma|
89007868|NCT04613284|Experimental|Endostar combined Radiation|
89007869|NCT04613401||VAD-patients with Telemonitoring|
89007870|NCT00563602|Active Comparator|2|Standard Therapy: Endoscopic ligation (LEV) + Nadolol + Isosorbide mononitrate (MNI)(drugs carefully titrated until achieve maximum tolerated dose)
89007871|NCT00563602|Experimental|1|"Hemodynamic guided therapy:~1) LEV + Nadolol. HVPG measurement: if response, no changes, if not, switch to 2) LEV + Nadolol + MNI. HVPG measurement: if response, no changes, if not, switch to: 3) LEV + Nadolol + Prazosin. (drugs carefully titrated until achieve maximum tolerated dose)"
89007872|NCT00563641|Experimental|1|Early NCPAP plus very early surfactant
89007873|NCT00563641|Active Comparator|2|NCPAP alone
89007874|NCT00248118|Active Comparator|Active medication|300mg bupropion HCL
89007875|NCT00248118|Placebo Comparator|Placebo|Placebo pill
89007876|NCT00221897||Healthy individuals|healthy controls with or without myopia
89007877|NCT00221897||Persons at risk for or with primary open angle glaucoma|with or without myopia with a diagnosis of glaucoma, glaucoma suspect and ocular hypertension
89007878|NCT04612894|Experimental|Neoadjuvant Camrelizumab + Apatinib|Apatinib 250mg, po qd, and Camrelizumab 200mg, iv q2w as neoadjuvant treatment. 28 days as one cycle, for at least two cycles.
89007879|NCT04612777|Experimental|Opening Doors to Recovery|Participants will receive services from the team of three ODR navigators: one professional social worker, one navigator who is a family member of someone with SMI, and one peer navigator with lived experience.
89007880|NCT04612777|Active Comparator|Intensive Case Management or Case Management|Participants randomized to the control group will either receive standard services of Intensive Case Management or Case Management, depending on the services that are available in their county.
89196709|NCT04014010||Cohort|Patients ages ≥ 45 receiving their index (i.e. first) non-cardiac surgery with an overnight stay at the Nova Scotia Health Authority Queen Elizabeth II (QEII) hospitals (Victoria General and Halifax Infirmary) Halifax, Canada, from January 1, 2013 to December 1, 2017 will be included. Patients under going cardiac surgery or deceased organ donation will be excluded. Patients without an electronic anesthetic record during surgery will also be excluded. Preliminary analysis of the intraoperative database estimates approximately 35,000 patients in this cohort.
89196710|NCT03743272||Liver condition|Participants who have a history of of liver disease
89536151|NCT02478437|Active Comparator|Group 2|Cooled radiofrequency ablation (CRFA) Following ablation, 0.5 cc of 0.5% bupivacaine will be injected to provide post procedure analgesia.
89536152|NCT03201835|Experimental|PNL-THC:CBD soft gelatin capsule|3 soft capsules, containing a total of 10.8 mg THC and 10 mg CBD (Each capsule contains 3.6 mg THC and 3.3 mg CBD)
89536153|NCT03201835|Experimental|P-PNL-THC:CBD soft gelatin capsule|2 soft capsules containing a total of 7.2 mg THC, 6.7 mg CBD and 20 mg piperine (Each capsule contains 3.6 mg THC, 3.3 mg CBD and 10 mg piperine)
89196711|NCT03743272||Healthy volunteers|Participants who have do not have a diagnosed liver condition and are in general good health
89536154|NCT03201835|Experimental|CBD hard capsule dose 1|1 hard capsule containing 10 mg CBD
89536155|NCT03201835|Experimental|CBD hard capsule dose 2|1 hard capsule containing 100 mg CBD
89536156|NCT03201835|Active Comparator|Sativex®|spray X 4 actuations, Each 100 μL spray contains 2.7 mg THC and 2.5 mg CBD, total per administration: 10.8 mg THC and 10 mg CBD
89536157|NCT03074721|Other|PCI with PCI Suite Software|
89536158|NCT03074721|Other|conventional PCI|
89536159|NCT03314831||Sepsis|Patients with sepsis or septic shock admitted on Intensive Care Unit.
89536160|NCT03314831||Systemic Inflammatory Response Syndrome|Patients with Systemic Inflammatory Response Syndrome non-infectious etiology.
88907857|NCT06302894|Experimental|Experimental group|"In order to reduce problematic internet use and protect the experimental group from addiction, different online applications and trainings based on the Health Belief Model, enriched with web 2.0 technologies, will be provided and followed every week (6 weeks in total).~At the end of 6 weeks, the internet addiction scale, family harmony scale and loneliness scale for children will be administered."
88907858|NCT06302881||low TSR and high TSR group|The assessment of the tumor-stroma ratio (TSR) entailed measuring the percentage of tumor and stroma constituents. Based on earlier research, 5/5 was deemed as ideal threshold of TSR measurement.
88907859|NCT06302868|Active Comparator|Telemedicine-based Virtual Reality Exposure Therapy|This group will receive exposure therapy in a telemedicine-based Virtual Reality Clinic using virtual reality snakes, dogs, or spiders. The VR stimuli range from small to medium to large and have four activity levels: idle, calm, energetic, and aggressive.
88907860|NCT06302868|Active Comparator|Standard Telemedicine Exposure Therapy|This group will receive exposure therapy via Doxy.me telemedicine platform using photos and videos of snakes, dogs, or spiders. The photo/video stimuli range from small to medium to large and have four activity levels: idle, calm, energetic, and aggressive.
88907861|NCT06302855|Active Comparator|dental visit invited|Patients will only be invited or asked to schedule a complimentary periodontal check-up visit without any previous assessment.
88907862|NCT06302855|Experimental|dental visit recommended based on dental expertise|Patients' oral cavities will be photographed. Based on the remote assessment of periodontitis risk conducted by the same periodontist from the Division of Regenerative Dental Medicine and Periodontology at the University Clinic of Dental Medicine, patients will be invited or asked to schedule a complimentary periodontal check-up visit at the CUMD. The appointment will be arranged directly at the diabetologist's office.
88907863|NCT06302842|Experimental|Before and after treatment|"Nutraceutical (Bioritmon Immuno Defend), one oral preparation daily for 24 days.~Immunological parameters are investigated before and after the treatment."
88907864|NCT06302829|Experimental|Intramuscular Electrical stimulation|Myofascial trigger point would be targeted by direct intramuscular electrical stimulation by using direct electrode placement method, where anode pole and the cathode pole of the stimulator connected to the needles of the MTrPs of the shoulder girdle muscles using the alligator clip connector in which both electrodes are on the muscle belly in which anode pole at proximal end and cathode pole at the distal end along the musculotendinous junction. The special programmed comfy stim (a double channeled multipurpose electrical stimulator) was used to deliver electrical impulses with following parameters; pulse duration 80µs, frequency 100HZ, and time duration for 10 min
88907865|NCT06302829|Active Comparator|Dry Needling|DN for the MTrPs will be performed over the identified trigger points locations at a suitable angle. The needles of suitable length and thickness (30-mm), depending on the depth of the MTrPs location inserted into the shoulder girdle muscles to deactivate the active MTrPs. Subsequently, the inserted needles moved to-and-fro direction to elicit the local twitch responses, which further reaffirms the ideal placement of needle into the MTrPs. After the twitch response obtained, the dry needles were kept within the muscles approximately for 10 minutes. Dry needling was performed subscapularis, latissimus dorsi, supraspinatus, deltoid, teres minor.
88907866|NCT06302816|Experimental|TUPLER exercises|
88907867|NCT06302816|Active Comparator|SCOOP EXERCISES|
88907868|NCT06302803|Experimental|The mTRE group|Participants in the mTRE group will be instructed to eat during a window of 8 h (8 am to 4 pm) 5 days and fast (approximately 500-600 kcal per day) 2 days per week.
89536161|NCT03314831||No inflammation|Patients without systemic inflammation.
88907869|NCT06302803|Experimental|The CR group|Participants will follow receive a diet of 1500-1800kcal/d for men and 1200-1500kcal/d for women, without restriction on eating time.
89427025|NCT03531073||Standard care cohort|This study is observational. Patients will receive standard treatment as given in usual clinical practice with no intervention as part of the study. As per current clinical practice guidelines and UK reimbursement rules for biologics in PsA, patients will receive a pragmatic treat to target approach using step up standard therapies. Patients will usually receive methotrexate first line, initially 15mg ow increasing to 25mg ow as tolerated. In case of non-response, an additional DMARD will be used (sulfasalazine up to 3g daily or leflunomide 20mg od). If two DMARDs are failed and patients are eligible for biologic therapy under UK National Institute of Health and Clinical Excellence (NICE) guidance, then biologics will be used.
89427026|NCT03524118|Experimental|Panel A: Pre-term clesrovimab Dose 1|Pre-term infants will receive clesrovimab Dose 1 via intramuscular (IM) injection and will be followed for up to 365 days.
89427027|NCT03524118|Experimental|Panel B: Pre-term clesrovimab Dose 2|Pre-term infants will receive clesrovimab Dose 2 via IM injection and will be followed for up to 365 days.
89427028|NCT03524118|Experimental|Panel C: Pre-term clesrovimab Dose 3|Pre-term infants will receive clesrovimab Dose 3 via IM injection and will be followed for up to 365 days.
89427029|NCT03524118|Experimental|Panel D1: Pre-term clesrovimab Dose 4|Pre-term infants enrolled prior to AM4 will receive clesrovimab Dose 4 via IM injection and will be followed for up to 365 days.
89427030|NCT03524118|Experimental|Panel D2: Pre-term clesrovimab Dose 4|Pre-term infants enrolled after AM4 will receive clesrovimab Dose 4 via IM injection and will be followed for up to 545 days.
89427031|NCT03524118|Experimental|Panel E1: Full-term clesrovimab Dose 4|Full-term infants enrolled prior to AM4 will receive clesrovimab Dose 4 via IM injection and will be followed for up to 365 days.
88820487|NCT06104449|Experimental|MK-5684|Participants receive MK-5684 5 mg by oral tablets twice daily plus dexamethasone 1.5 mg by oral tablets and fludrocortisone acetate 0.1 mg oral tablet once daily continuously until progression. Hydrocortisone up to 100 mg oral dose will also be provided to participants for use as rescue medication.
88820488|NCT06089694||All Enrolled Subjects|In-clinic Testing Visit: All enrolled subjects will have a Holter recorder, capnography monitor and SpO2 sensor applied and will undergo various breathing/exercise activities. Subjects will go home connected to the Holter recorder for 24 hours for collection of ambulatory data.
88820489|NCT06088004|Experimental|ABO2011 Injection|
88820490|NCT06087445|Experimental|NeuroLife EMG-FES Sleeve System|The NeuroLife EMG-FES System is a completely non-invasive system (surface electrodes only, no implantable components) worn on the forearm of participants and has up to 160 electrodes that can record electromyography (EMG), or muscle activity, and also electrically stimulate (FES) muscles. Using this combined, closed-loop technology participants will complete a 12-week protocol with a study therapist practicing functional activities using their hand/forearm while wearing the NeuroLife EMG-FES Sleeve System.
89196712|NCT00935116|Active Comparator|etoricoxib|"G1 (CONTROL): Oral NSAID (diclofenac, three times a day) administrated pre-operatively and for 3 days after surgery.~G2: Etoricoxib 120 mg, pre and post-operatively for 3 days after surgery"
88820492|NCT06085391|Experimental|REThink game|Each recruited participant randomized in the experimental group will receive the REThink game app.
88820493|NCT06085391|Active Comparator|MoodWheel|The participants randomized in the control group will complete the MoodWheel app.
88820494|NCT06085391|Experimental|PsyPills|Participants from experimental group who do not respond to REThink game alone will receive the PsyPills app
88820495|NCT06082440|Experimental|Human Umbilical Mesenchymal Stem Cells|Participants received a single administration for Human Umbilical Mesenchymal Stem Cells during the treatment period.The specification is 2.5 × 10^7cells/2ml suspension/branch.
88820496|NCT06077968||Vaccinated|Patients will be considered vaccinated if they have documented evidence of receiving ABRYSVO ≥30 days before index date (i.e., defined as the date of hospitalization or Emergency Department (ED) admission.)
88907870|NCT06302803|No Intervention|Control|usual health care
89427032|NCT03524118|Experimental|Panel E2: Full-term clesrovimab Dose 4|Full-term infants enrolled after AM4 will receive clesrovimab Dose 4 via IM injection and will be followed for up to 545 days.
89427033|NCT03524118|Placebo Comparator|Placebo|Pre-term infants will receive placebo via IM injection.
89427034|NCT03522545|Experimental|Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal|Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs) isolated from hematogenous bone marrow
88820497|NCT06077968||Unvaccinated|Patients will be considered unvaccinated if they do not have documented evidence of receiving ABRYSVO.
88820498|NCT06077643||Exchange group|Each patient will participate in a cycle of four sessions, over four months. Each will be carried out with five patients, in order to facilitate exchanges. The aim is to organize eight groups that will each complete a cycle. This will allow to include about forty patients in the study.
88820499|NCT06077643||Control group|"Patients who don't want to participate in the exchange groups but agree to be included in the control group. They will have to complete the quality of life questionnaires four months apart.~Estimation of 10 patients included."
88820500|NCT06074926|Experimental|Group 1 - Intervention|Participants will attend two laboratory visits and complete a 3-week intervention, which consists of interactive parent-child activities (~45 min of interactive activities/week) that pair tasting an assigned target vegetable with positive parent-child interactions. Positive interactions will be promoted via positive parenting prompts embedded in the activity instructions (e.g., prompts promoting child-directed play).
88820501|NCT06074926|Experimental|Group 2 - Control|Participants will attend the same two laboratory visits and complete a 3-week intervention, which consists of only individual taste exposures to their target vegetable.
88820502|NCT06071793|Experimental|All participants|Patients to receive mobility interventions from trained family members
88820504|NCT06066567|Experimental|Experimental: treatment group|
88820505|NCT06066567|Active Comparator|control group|
88820506|NCT06065098|Experimental|Community health worker-led implementation strategy:|Individual coaching sessions; healthcare navigation; healthcare at community settings; church-based nutrition education and exercise programs; and self-monitoring of BP.
88907871|NCT06302790|Active Comparator|Molli Suit Apply Group (Device On)|Evaluations will be made before the children are dressed in the Mollii Suit, and the evaluations will be repeated after the children are dressed and practiced for 60 minutes.
89196713|NCT00931138|Active Comparator|Arm1 = Aracytine + Daunorubicin|Aracytine : 200 mg/m2 d1-d7 Daunorubicin : 80 mg/m2 d1-d3
89196714|NCT00931138|Active Comparator|Arm 3 = Aracytine And Idarubicin|Aracytine : 200 mg/m2 d1-d7 Idarubicin : 12 mg/m2 d1-d4
89196715|NCT00931138|Active Comparator|Arm 2 = Aracytine And Idarubicin|Aracytine : 200 mg/m2 d1-d7 Idarubicin :12 mg/m2 d1-d3
89196716|NCT04014088|Active Comparator|helmet CPAP|helmet CPAP administer to patient diagnosed as acute cardiogenic pulmonary edema
89196717|NCT04014088|Active Comparator|facemask CPAP|facemask CPAP administer to patient diagnosed as acute cardiogenic pulmonary edema
88907872|NCT06302790|Placebo Comparator|Mollii Suit Placebo Group (Device Off)|Evaluations will be made before the children are dressed in the Mollii Suit, and the evaluations will be repeated after the children are dressed and applied for 60 minutes with the device in off mode.
89196718|NCT00935194|Experimental|blank|do not take antiviral therapy
88907873|NCT06302790|No Intervention|Control Group|Children will be evaluated and the evaluations will be repeated 60 minutes later.
88907874|NCT06302764||Polish Medical Staff|Medical doctors, and emergency staff (paramedics), involved in treating life-threatening conditions
88907875|NCT06302764||Ukrainian Medical Staff|Medical doctors, and emergency staff (paramedics), involved in treating life-threatening conditions
88907876|NCT06302764||Portuguese Medical Staff|Medical doctors, and emergency staff (paramedics), involved in treating life-threatening conditions
88907877|NCT06302764||Spanish Medical Staff|Medical doctors, and emergency staff (paramedics), involved in treating life-threatening conditions
88907878|NCT06302738||Non-dipper pattern at 24-hour BP monitoring|Defined as a nocturnal decrease systolic and/or in diastolic BP values <10% compared to the corresponding daytime values;
88907879|NCT06302725|Experimental|Vaginal self sampling detecting HPV|
89196719|NCT00935194|Experimental|Oseltamivir|antiviral therapy
89196720|NCT00935194|Experimental|chinese medicinary herbs|antiviral therapy
89196721|NCT00935194|Experimental|oseltalmivir and chinese medicinal herbs|combination antiviral therapy
89196722|NCT00937534|Active Comparator|Part A|Young male healthy volunteer
89196723|NCT00937534|Active Comparator|Part B|Elderly male healthy volunteer
89196724|NCT00690378|Experimental|1|NXL/104 ceftazidime
89196725|NCT00690378|Active Comparator|2|comparator 4 x daily
89196726|NCT00937612|Experimental|concurrent chemoradiation|patients who has 3 or more minor risk factors of recurrence, and will receive postoperative chemoradiation.
89196727|NCT00574275|Placebo Comparator|Placebo and Gemcitabine|Participants with metastatic pancreatic cancer administered Placebo and 1000 mg/m^2 Gemcitabine.
89196728|NCT00574275|Experimental|Aflibercept and Gemcitabine|Participants with metastatic pancreatic cancer administered 4 mg/kg Aflibercept and 1000 mg/m^2 Gemcitabine.
89196729|NCT00931216|Experimental|Integrated ANC, PMTCT and HIV Services|HIV care and treatment services are integrated into antenatal care (ANC) services for women testing positive within the ANC at this facility.
89196730|NCT00931216|No Intervention|Non-Integrated Services|Women testing positive in the ANC department are referred for care at the HIV clinic. HIV care and treatment services are not provided within the ANC at facilities randomized to this arm.
89196731|NCT00937690||infrared imaging of cutaneous lesions|patients and volunteers with cutaneous lesions, with and without clinically detectable melanoma, and with one or more palpable cutaneous lesions
89196732|NCT00743418|Other|1|Healthy controls Mini Mental State evaluation score >28/30
89196733|NCT00743418|Other|2|Mild Cognitive Impairment: Mini Mental State Evaluation Score (MMSE)=26-28/30
89196734|NCT00743418|Other|3|Mild Dementia: Mini Mental State Evaluation Score (MMSE)=21-25/30
89196735|NCT00935350|Placebo Comparator|1|Control White bread containing 50g available carbohydrate
89196736|NCT00935350|Placebo Comparator|2|White bread and milk control
89196737|NCT00935350|Placebo Comparator|3|Granola control
89196738|NCT00935350|Placebo Comparator|4|Cornflakes and milk control
89196739|NCT00935350|Placebo Comparator|5|White rice control
89196740|NCT00935350|Placebo Comparator|6|Fruit yogurt control
89196741|NCT00935350|Placebo Comparator|7|Turkey dinner control
89196742|NCT00935350|Experimental|8|Granola
89196743|NCT00935350|Experimental|9|Cornflakes and milk
89196744|NCT00935350|Experimental|10|White Rice
89196745|NCT00935350|Experimental|11|Fruit yogurt
89196746|NCT00935350|Experimental|12|Turkey dinner
88820507|NCT06065098|Experimental|Group-based Education Strategy|Group-based education sessions; information on primary care physicians; and instruction on self-monitoring of BP.
88820510|NCT06061588|No Intervention|The case group|Included in the case group, patients diagnosed with migraine and experiencing headache will receive standard treatment, consisting of 50 mg of dexketoprofen within 150 cc of normal saline.
88820511|NCT06061588|Experimental|The control group|The control group, in addition to standard treatment, will be treated with virtual reality therapy using VR goggles, which will create a virtual environment simulating moonlight by the dark seaside or a campfire ambiance with classical music (calm, slow, and soothing).
88820512|NCT06061575|Other|Acetaminophen|Adult patients diagnosed with sepsis according to the latest current guidelines, who have agreed to participate in the study or have provided consent by their relatives, and received 1g of acetaminophen for fever management.
88820513|NCT06061575|Other|Ibuprofen|Adult patients diagnosed with sepsis according to the latest current guidelines, who have agreed to participate in the study or have provided consent by their relatives, and received 400 mg of ıbuprofen for fever management.
88820514|NCT06060405|Experimental|Durvalumab and Oleclumab|Durvalumab, 1500 mg x 1 dose and oleclumab 3000 mg x 2 doses every 2 weeks prior to surgical resection.
88820515|NCT06053736|Experimental|REVIVE™ Toric Soft Contact Lenses|
88820516|NCT06051123|Experimental|Experimental Group|Participants in this group will be randomized to receive a probiotic formulation for 24 weeks.
88820517|NCT06051123|Placebo Comparator|Control Group|Participants in this group will be randomized to receive a placebo for 24 weeks.
88820518|NCT06049108|Experimental|[14C]-LY3871801|Single dose of [¹⁴C]-LY3871801 administered orally
88820519|NCT06045910|Experimental|Safety Lead-In Phase|
88820520|NCT06045910|Experimental|Dose Expansion Phase|
88820521|NCT06044441|Experimental|ENABLE-SG (immediate group)|"Participants will receive the ENABLE-SG model immediately (six sessions for patients and four sessions for caregivers) at an approximately weekly interval.~Interventions: ENABLE-SG model"
88820522|NCT06044441|Other|Wait-list control|"6-month wait-list control. Participants will receive the ENABLE-SG model six months after baseline (six sessions for patients and four sessions for caregivers) at an approximately weekly interval.~Interventions: ENABLE-SG model"
88820523|NCT06035874|Active Comparator|Bem group|Patient will get Bempedoic acid along with the standard of Care
88820524|NCT06035874|No Intervention|Control Group|Patient will get the standard of Care as per routine practice
88820525|NCT06033209|Experimental|Part A Intramuscular (IM) safety with dose finding - Group 1|
88820526|NCT06033209|Experimental|Part A IM safety with dose finding - Group 2|
88820527|NCT06033209|Experimental|Part A IM safety with dose finding - Group 3|
88820528|NCT06033209|Experimental|Part A IM safety with dose finding - Group 4|
88820529|NCT06033209|Experimental|Part A IM safety with dose finding - Group 5|
88820530|NCT06033209|Experimental|Part A IM safety with dose finding - Group 6|
88820531|NCT06033209|Experimental|Part A Subcutaneous (SC) safety with dose finding - Group 7|
88820532|NCT06033209|Experimental|Part A SC safety with dose finding - Group 8|
88820533|NCT06033209|Experimental|Part A SC safety with dose finding - Group 9|
88820534|NCT06033209|Experimental|Part A SC safety with dose finding - Group 10|
88820535|NCT06033209|Experimental|Part A SC safety with dose finding - Group 11|
88820536|NCT06033209|Experimental|Part A SC safety with dose finding - Group 12|
88820537|NCT06033209|Experimental|Part B IM Immunogenicity - Group 13|
88820538|NCT06033209|Experimental|Part B SC Immunogenicity - Group 14|
88820539|NCT06033209|Experimental|Part B Immunogenicity - Group 15|Group 15 N332-GT5 gp140 with SMNP dose and route (SC or IM) is To Be Determined (TBD) based on groups 6 and 12 (Part A).
89427035|NCT03522545|Placebo Comparator|Placebo|Placebo for Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs)
89427036|NCT03516617|Experimental|Arm A (acalabrutinib)|Patients receive acalabrutinib PO BID on days 1-28. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive acalabrutinib PO BID on days 1-84. Treatment repeats every 84 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients may continue treatment with acalabrutinib If MRD negative CR/CRi is not achieved after 12 cycles.
89427037|NCT03516617|Experimental|Arm B (acalabrutinib, obinutuzumab)|Patients receive acalabrutinib PO BID on days 1-28 and obinutuzumab IV on days 1, 2, 8, and 15 of cycle 1 and days 1 of subsequent cycles. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive acalabrutinib PO BID on days 1-84. Treatment repeats every 84 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients may continue treatment with acalabrutinib If MRD negative CR/CRi is not achieved after 12 cycles.
89427038|NCT03516617|Active Comparator|Arm C (observation)|Patients will be observed every 6 months for up to 2 years.
88907880|NCT06302673|Experimental|Laserpuncture with standard antiemetic therapy (ondansentron 4 mg iv)|Laserpuncture : using RJ Laser with Nogier B wave setting, frequency 584 Hz, power 50 mW, wavelength 785 nm, and energy of 2 Joules at each acupuncture point ( PC6 Neiguan and CV12 Zhongwan)
88907881|NCT06302673|Sham Comparator|Sham Laserpuncture with standard antiemetic therapy (ondansentron 4 mg iv)|Sham Laserpuncture : using RJ Laser with Nogier B wave setting, frequency 584 Hz, power 50 mW, wavelength 785 nm, and energy of 2 Joules at each acupuncture point ( PC6 Neiguan and CV12 Zhongwan). The laser is turned on but not activated
89196747|NCT00935350|Placebo Comparator|13|White Bread
89427039|NCT03506945|Experimental|mPEP|Behavioral Activation Therapy - Increase engagement in pleasant activities as a mechanism for reducing distress and improving overall well-being. Participants will use an online web tool to select and schedule activities they deem will be rewarding and fulfilling. They will then track their engagement in these activities on a weekly basis.
89427040|NCT03506945|Active Comparator|Bibliotherapy|Bibliotherapy - Develop improved coping and problem-solving skills. Participants will receive bibliotherapy handouts describing various means of managing their distress and solving caregiving-related problems.
89427041|NCT03462329|Active Comparator|patients with erythema migrans|Patients will be treated with antibiotics for Lyme disease.
89427042|NCT03462329|No Intervention|controls|Control subjects will not be given antibiotics.
89427043|NCT03678350|Experimental|Treatment (porfimer sodium, IO-PDT)|Participants receive porfimer sodium IV over 3-5 minutes and receive IO-PDT via a light dosimetry system 24-48 hours later.
88907882|NCT06302660||Oesophageal adenocarcinoma survivors|100 disease free survivors who underwent multimodality treatment for oesophageal adenocarcinoma and are >1 year post oesophagectomy
88907883|NCT06302621|Experimental|DOSE ESCALATION PHASE 1A PEMIGATINIB + AFATINIB|"In the phase 1a dose escalation study participants with FGFR-altered refractory advanced solid tumors will be enrolled.~This research study involves the study drugs Afatinib and Pemigatinib."
89196748|NCT00935350|Placebo Comparator|14|White bread
89196749|NCT00935350|Experimental|15|Granola
89196750|NCT00839865|Experimental|herb ointment dressing change group|This group of patients in the ointment dressing every 2 days until Wound Healing or 6 months
89196751|NCT00839865|No Intervention|Conventional dressing change group|This group of patients in the Conventional dressing every 2 days until Wound Healing or 6 months
89196752|NCT02564640|Active Comparator|videolaryngoscope|patients intubated by using the videolaryngoscopy
89196753|NCT02564640|Active Comparator|Macintosh laryngoscope|patients intubated by using the Macintosh laryngoscope
89196754|NCT00839943|Active Comparator|ozone|obese vs non-obese women
89196755|NCT00839943|Active Comparator|air|obese vs non obese women
89196756|NCT00746382|Active Comparator|1|Roflumilast cream 0.5%
89196757|NCT00746382|Placebo Comparator|2|Placebo cream
89196758|NCT00833001||1|GYNECARE PROLIFT+M* Pelvic Floor Repair System
89199198|NCT05953896|Active Comparator|Multilayer L-PRF|will include 10 patients undergoing minimally invasive surgery for reconstruction of interdental papilla using multilayer L-PRF membranes
89199199|NCT05953883|Experimental|Interventional|
89427044|NCT03442101||Treatment group|These participants are newly diagnosed with psychosis.
89427045|NCT03437421|Experimental|Type II diabetic patients|3 month Vitamin D3 (cholecalciferol) supplementation in patients with vitamin D deficiency, based on 25-OH-D3 dosage.
89427046|NCT03437421|Experimental|Type I diabetic patients|3 month Vitamin D3 (cholecalciferol) supplementation in patients with vitamin D deficiency, based on 25-OH-D3 dosage.
89531077|NCT02498171|Experimental|Intrathecal morphine with fentanyl|Single shot of intrathecal morphine 100mcg mixed with 25mcg of fentanyl and filled up to make a 2ml solution. This would then be injected into the subarachnoid space through L2-3 or L3-4 following standard procedures.
89427047|NCT03437265|Experimental|PLENVU powder for oral solution|"Dose 1: Oral administration of 1 sachet (115.96 g) PLENVU Dose 1, reconstituted with water and made up to 473 mL and 473 mL of additional water to be consumed; both to be consumed over a period of 60 min after the start of Dose 1.~Dose 2: Oral administration of 2 sachets (101.91 g) comprising PLENVU Dose 2, reconstituted with water and made up to 473 mL and 473 mL of additional water to be consumed; both to be consumed over a period of 60 min after the start of Dose 2.~Additional water was permitted ad libitum during and after each dose."
89427048|NCT03414424|Experimental|All subjects|All subjects undergo same full protocol, including CES at rest and CES plus active hand or wrist movements.
89427049|NCT03407768|Other|Individualized interventions|Exercise, Yoga, massage therapy, acupuncture, and others
89427050|NCT03401294|Other|Single arm|FOLFOXIRI and Bevacizumab
89427051|NCT03349476|Experimental|MFAM|"The mFAM Workstation is a computerized system used to reconstruct the shape of the left atrium of the heart, by fitting a parametric shape model to points data acquired by a catheter.~The mFAM Workstation uses recorded catheter positions and other data inputs collected from various types of multi-electrode catheters and generates output data files that can be displayed as a 3D anatomic structure."
89427052|NCT03337932|Active Comparator|MEM-7 days doxycycline|
89427053|NCT03337932|Active Comparator|MEM-14 days doxycycline|
89427054|NCT03337932|Placebo Comparator|Controls|
88907884|NCT06302621|Experimental|COH 1: EXP PHASE 1B COHORT 1 MTD/RP2D PEMIGATINIB + AFATINIB FGFR INHIBITOR-NAIVE|"In the phase Ib dose expansion study, patients with FGFR-altered cholangiocarcinoma will be recruited into 2 cohorts: FGFR inhibitor-naïve cholangiocarcinoma and FGFR-inhibitor-pretreated and resistant cholangiocarcinoma. Cohort 1 will enroll patients with FGFR inhibitor-naïve cholangiocarcinoma.~This research study involves the study drugs Afatinib and Pemigatinib."
89199200|NCT05953857||Untreated|Not treated with TKI
89427055|NCT03312634|Experimental|Palovarotene Chronic/Flare-Up Regimen|Participants received 5 mg palovarotene once daily for up to 48 months; and 20 mg palovarotene once daily for 28 days, followed by 10 mg for 56 days for flareups. (Dosing was adjusted for weight in skeletally immature subjects.)
89427056|NCT03305458|Active Comparator|Treatment as usual|Trauma Focused Cognitive Behavioral Therapy
89427057|NCT03305458|Experimental|Tablet-Facilitated TF-CBT|Standard treatment with the addition of in-treatment/session iPad activities
89427058|NCT03304665||Healthy Volunteers|Healthy Volunteers
89427059|NCT03289936|Experimental|Start ventilation with NIPPV|Alternatively vented with NIPPV and SNIPPV
89427060|NCT03289936|Experimental|Start ventilation with SNIPPV|Alternatively vented with SNIPPV and NIPPV
89427061|NCT03284931|Experimental|SAGE-217 high dose|SAGE-217
89427062|NCT03284931|Experimental|SAGE-217 low dose|SAGE-217
89427063|NCT03284931|Placebo Comparator|Placebo|Placebo
89196759|NCT04060368|Experimental|ESG Stitch® system + Lifestyle modifications|Endoscopic technique defined as a gastric restriction by means of continuous sutures of the entire gastric wall of the antrum and body, transmurally, in order to simulate a gastric sleeve, in the same way as sleeve gastrectomy surgery. Gastroplasty is performed using an endoscopic suture system (OverStitch, Apollo Endosurgery Inc., Austin, Texas, USA) inserted into a dual-channel endoscope (GIF-2T160, Olympus Medical Systems Corp., Tokyo, Japan).
89196760|NCT04060368|Active Comparator|LSG + Lifestyle modifications|Minimally invasive surgical technique defined as a gastric restriction by means of an excision approximately 80% of the stomach along the greater curvature.
89196761|NCT00828867|Experimental|Cohort 1|100mg
89196762|NCT00828867|Experimental|Cohort 2|200mg
89196763|NCT00828867|Experimental|Cohort 3|400mg
89196764|NCT00828867|Experimental|Cohort 4|800mg
89196765|NCT00828867|Experimental|Cohort 5|1500mg
89196766|NCT00828867|Experimental|Cohort 6|2000mg
89196767|NCT00828867|Experimental|Cohort 7|800mg with food
89196768|NCT00828867|Experimental|Cohort 8|3000mg
89196769|NCT00828867|Experimental|Cohort 9|4000mg
89196770|NCT00746460|Experimental|A|Behavioral
89196771|NCT00567112|Experimental|DFC (fasted)|
89196772|NCT00567112|Experimental|OCT (fasted)|
89196773|NCT00567112|Experimental|OCT (after meal)|
89196774|NCT00567112|Active Comparator|OCT (before meal)|
89196775|NCT00829101||1 One-stage repair|A consecutive group of children born with unilateral cleft lip and palate from the south region of Sweden, in all 10 children, who have had a primary palatal surgery at 12 months of age.
89196776|NCT00829101||2 Two-stage repair, early closure|A consecutive group of children born with unilateral cleft lip and palate from the western region of Sweden, in all 10 children, who have had a two-stage palatal surgery, with soft palate closure at 4-6 months and repair of the hard palate at 12 months of age.
88907885|NCT06302621|Experimental|COH 2: EXP PHASE 1B COHORT 2 MTD/RP2D PEMIGATINIB + AFATINIB FGFR INHIBITOR-PRETREATED|"In the phase Ib dose expansion study, patients with FGFR-altered cholangiocarcinoma will be recruited into 2 cohorts: FGFR inhibitor-naïve cholangiocarcinoma and FGFR-inhibitor-pretreated and resistant cholangiocarcinoma. Cohort 2 will enroll patients with FGFR-inhibitor-pretreated and resistant cholangiocarcinoma.~This research study involves the study drugs Afatinib and Pemigatinib."
88907886|NCT06302608|Experimental|Dose level 1|Dose level 1 will be administered
88907887|NCT06302608|Experimental|Dose level 2|Dose level 2 will be administered
88907888|NCT06302595|Experimental|MRI-guided prostate biopsy|Participants who receive biopsy under MRI-guidance and a needle holder frame.
88907889|NCT06302582|Experimental|Platelet-rich plasma (PRP) combined with human umbilical cord mesenchymal stem cells (huMSCs)|Inject 3ml PRP+huMSCs (5 × 106) into the edge and bottom of the wound, with 0.5 ml at each point and a distance of approximately 1-3 cm between each point. Then, apply autologous PRP gel (PRP+thrombin mixture, 2ml) evenly on the wound, with a thickness of about 2mm.
88907890|NCT06302582|Other|Control group|Standard therapy
88907891|NCT06302478|Experimental|5E Program|Participants in the 5E program group will receive 7-day nursing interventions.
88907892|NCT06302478|No Intervention|Usual Care|Participants in the control group will receive 7-day usual care interventions, including health education regarding signs and symptoms of venous thromboembolism and IPC use if the participants experienced muscle power as grade 0.
88907893|NCT06301932||Epidural analgesia|Group of the patients received epidural analgesia
88907894|NCT06301932||Non epidural analgesia|Group of the patients who did not received epidural analgesia
88907895|NCT06301919||Included patients|All patients referred to our hospital and treated by TAE with NBCA, based on clinical decisions in emergency and CT scan.
88907896|NCT06301763|Experimental|Intermittent Oral-esophageal Tube Feeding|During the 15-day treatment, both groups of patients are hospitalized, while conventional care and enteral nutrition support are provided to the two groups. Specifically, conventional care includes health education, dietary adjustments, nasopharyngeal hygiene, management of risk factors (blood pressure and lipid control, etc.), exercise rehabilitation, and psychological support. The frequency and content of these interventions are arranged based on health condition. The observation group receives IOE for enteral nutrition support.54 cm.
88907897|NCT06301763|Active Comparator|nasogastric tube feeding|During the 15-day treatment, both groups of patients are hospitalized, while conventional care and enteral nutrition support are provided to the two groups. Specifically, conventional care includes health education, dietary adjustments, nasopharyngeal hygiene, management of risk factors (blood pressure and lipid control, etc.), exercise rehabilitation, and psychological support. The frequency and content of these interventions are arranged based on health condition.The control group receives NGT for enteral nutrition support
88907898|NCT06301750|Experimental|Intermittent Oral-esophageal Tube Feeding group|This group is hospitalized, while conventional care and enteral nutrition support are provided to the two groups. The Intermittent Oral-esophageal Tube Feeding group receives Intermittent Oral-esophageal Tube Feeding for enteral nutrition support
88907899|NCT06301750|Active Comparator|Nasogastric tube group|This group is hospitalized, while conventional care and enteral nutrition support are provided to the two groups. The Nasogastric tube group receives Nasogastric Tube Feeding for enteral nutrition support
88907900|NCT06301724|Experimental|Stellate ganglion block|the patients were provided with stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g)
88907901|NCT06301724|Placebo Comparator|Injection|the patients were provided with injection, which was with the same procedure of stellate ganglion block but no drugs.
88907902|NCT06301711|Experimental|Rehabilitation therapy+Stellate ganglion block|"The study lasted 10 days for each patient. During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.~Based on the invention above, the patients in the observation group were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g)."
88907903|NCT06301711|Active Comparator|Rehabilitation therapy|The study lasted 10 days for each patient. During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.
88907904|NCT06301698|Experimental|Comprehensive rehabilitation+Stellate ganglion block|Patients enrolled are firstly numbered for privacy with software and divided into the observation group and the control group with. Additionally, the staffs involved in assessment would not participate in the intervention of the study. The treatment lasts 10 days.
88907905|NCT06301698|Active Comparator|Comprehensive rehabilitation|Patients enrolled are firstly numbered for privacy with software and divided into the observation group and the control group with. Additionally, the staffs involved in assessment would not participate in the intervention of the study. The treatment lasts 10 days.
88907906|NCT06301685|Experimental|Routine therapy+Stellate ganglion block|"The study lasts 10 days for each patient. During the treatment, All the participants are provided with the routine rehabilitation therapy.~Based on the invention above, the patients were provided with stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g)"
88907907|NCT06301685|Placebo Comparator|Routine therapy+Placebo|The study lasts 20d for each patient. During the treatment, All the participants are provided with the routine rehabilitation therapy and placebo injection.
89199201|NCT05953857||Treated|Treated with TKI
89199202|NCT05953805||Patients With iPads|Patients who have been assigned an iPad to complete their PPI sessions remotely
88907908|NCT06301672|Experimental|Intermittent Oral-esophageal Tube Feeding|During the 15-day treatment, both groups of patients are hospitalized, while conventional care and enteral nutrition support are provided to the two groups. Specifically, conventional care includes health education, dietary adjustments, nasopharyngeal hygiene, management of risk factors (blood pressure and lipid control, etc.), exercise rehabilitation, and psychological support. The frequency and content of these interventions are arranged based on the patients; health condition. The observation group receives Intermittent Oro-esophageal Tube Feeding for enteral nutrition support
89427064|NCT03279471|Experimental|CBT/BIACA|These participants will receive CBT treatment using Behavioral Interventions for Anxiety in Children with Autism (BIACA). BIACA is an anxiety treatment package designed for children with ASD that includes elements of CBT and social skills training.
89427065|NCT03279471|Active Comparator|Sertraline|These participants will receive sertraline
89427066|NCT03279471|Placebo Comparator|Pill Placebo|These individuals will receive a pill placebo.
89427067|NCT03276195||Familial TSC and families|Individuals with familial TSC including those with a clinical diagnosis but no genetic confirmation and individuals with a genetic diagnosis
89427068|NCT03276195||Sporadic TSC and families|Individuals with sporadic TSC including those with a clinical diagnosis but no genetic confirmation and individuals with a genetic diagnosis
89427069|NCT03275493|Experimental|Experimental: Cohort 1|This cohort will determine the safety and efficacy of humanized CD19 CAR-T cells for CD19+ acute lymphoblastic leukemia
89427070|NCT03275493|Experimental|Experimental: Cohort 2|This cohort will determine the safety and efficacy of humanized CD19 CAR-T cells with CRS suppression technology for CD19+ acute lymphoblastic leukemia.
89427071|NCT03231878|Active Comparator|Active|
89427072|NCT03231878|Placebo Comparator|Placebo|
88907909|NCT06301672|Active Comparator|Nasogastric Tube Feeding|During the 15-day treatment, both groups of patients are hospitalized, while conventional care and enteral nutrition support are provided to the two groups. Specifically, conventional care includes health education, dietary adjustments, nasopharyngeal hygiene, management of risk factors (blood pressure and lipid control, etc.), exercise rehabilitation, and psychological support. The frequency and content of these interventions are arranged based on the patients; health condition.The control group receives nasogastric tube for enteral nutrition support
88907910|NCT06301633|Experimental|Intermittent Oro-esophageal Tube Feeding+comprehensive rehabilitation therapy|Study lasts 15 days for each patient. The patients were given comprehensive rehabilitation therapy. The observation group was provided the support of enteral nutrition by Intermittent Oro-esophageal Tube Feeding.
89427073|NCT03229083|Experimental|Use of Carevive software|Reporting and management of side effects from oral targeted therapy or immunotherapy, through Carevive software, in patients who have advanced Renal Cell Carcinoma (RCC).
89427074|NCT03218748|Experimental|Honest, Open, Proud|"The group program is about disclosure versus secrecy of one's mental illness. The groups are facilitated by two peers (soldiers with lived experience of mental illness). Each group runs for three weeks, one meeting per week, and two hours per meeting. There is one 2-hour booster session in week 6.~Fidelity to manual: rated by a research assistant who is present during the group session"
89427075|NCT03218748|No Intervention|Control group|Treatment as usual (TAU)
89427076|NCT03212378||CHIP 1 - low risk patients|
89427077|NCT03212378||CHIP 2 - medium risk patients|
88907911|NCT06301633|Active Comparator|Nasogastric Tube Feeding+comprehensive rehabilitation therapy|Study lasts 15 days for each patient. The patients were given comprehensive rehabilitation. The observation group was provided the support of enteral nutrition by Nasogastric Tube Feeding.
89196777|NCT00829101||3 Two-stage repair, delayed closure|A consecutive group of children born with unilateral cleft lip and palate from the western region of Sweden, in all 10 children, who have have had a two-stage palatal surgery, with soft palate closure at 4-6 months and repair of the hard palate at 36 months of age.
89196778|NCT01742832|Active Comparator|Vilazodone|A fixed dose titration (with doses ranging from 10mg to 40mg/day) will be used. Subjects will take 10mg/day for 1 week, 20mg/day for 1 week and then 40mg/day.
89199203|NCT05953805||Patients Without iPads|Patients who will continue to attend the classic face to face PPI meetings
89427078|NCT03212378||CHIP 3 - high risk patients|
89427079|NCT03193281|Other|Dasatinib|"All patients will begin the study on dasatinib treatment (Sprycel® 100mg once daily oral administration). Those who reach MR3.0 at 12 months (end of Study Stage 1) and achieve a confirmed result at 13 months, will switch to imatinib treatment (Imatinib-AFT 400mg once daily oral administration) for the next 24 months (Study Stage 2).~Patients who do not achieve a confirmed MR3.0 result at 13 months will not be eligible to switch to imatinib treatment and will remain on dasatinib treatment, as per Study Stage 1.~Patients will be assessed on a 3-monthly basis throughout the study. Those who discontinue dasatinib treatment during the study for reasons other than the planned treatment switch to imatinib at 13 months, will also be followed up every 3 months."
89427080|NCT03181867|Experimental|1/Localized High Risk|18F-DCFPyL PET/CT imaging, unlabeled PSMA-11 (optional) and possible prostatectomy
89427081|NCT03181867|Experimental|2/biochemical recurrence (bcr)|18F-DCFPyL PET/CT imaging, unlabeled PSMA-11 (optional)
89427082|NCT03157934||Primary CSC (Comprehensive Stroke center) admission|Patients with primary admission to endovascular-ready hospital (comprehensive stroke center)
89427083|NCT03157934||Primary non-CSC (non-Comprehensive Stroke Center) SU (Stroke Unit) admission|Patients with primary admission to non-endovascular-ready hospital with (regional/local) stroke unit
89427084|NCT03157934||Non-acute stroke hospital admission|Patients with primary admission to non-acute stroke-ready hospital
89427085|NCT03150173|Experimental|O-BMT (onsite treatment)|Over 2 weeks at the syringe-exchange program, participants in the O-BMT arm will see a buprenorphine provider twice, receive weekly blister packs of medication, and then their care will be transferred to a community health center for maintenance buprenorphine treatment
89427086|NCT03150173|Active Comparator|Enhanced Referral|In the control arm, participants will receive enhanced referral to a community health center for maintenance buprenorphine treatment
89427087|NCT03104153|No Intervention|Output-based|
89427088|NCT03104153|Active Comparator|Early-removal|
89427089|NCT03053973|Experimental|NIV directly started arm|Patients randomised to this arm will start noninvasive ventilation after baseline measurements are performed.
89196779|NCT01742832|Placebo Comparator|Citalopram|For those assigned to citalopram, the dose of citalopram will be maximized to 40mg/day. For those assigned to vilazodone, their citalopram dose will be maintained at 20mg/day for 1 week, then reduced to 10mg/day for 1 week, then switched to vilazodone 10mg/day.
88907912|NCT06301620|Experimental|Routine rehabilitation treatment+Intra-articular Injection|The patients receive a 15-day treatment and are required to stay in the hospital during this period. Patients in the experimental group are given routine rehabilitation treatment and intra-articular injections. Lidocaine is used as the injected medication at a dose of 2ml, administered once every 5 days for a total of three injections.
88907913|NCT06301620|Active Comparator|Routine rehabilitation treatment|The patients receive a 15-day treatment and are required to stay in the hospital during this period. Patients are given routine rehabilitation treatment.
88907914|NCT06301607|Experimental|Intermittent Oro-esophageal Tube Feeding+comprehensive rehabilitation therapy|"Assigned randomly before the treatment, all patients were provided with comprehensive rehabilitation therapy as follows:~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training.~The group was given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure. The feeding content was formulated by the nutritionists based on the condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups"
88907915|NCT06301607|Active Comparator|Nasogastric Tube Feeding+comprehensive rehabilitation therapy|"Assigned randomly before the treatment, all patients were provided with comprehensive rehabilitation therapy as follows:~Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training.~Besides, the group was given enteral nutritional support with Nasogastric Tube according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements."
88907916|NCT06301594|Experimental|the observation group|The observation group is the only group of the participants.The elderly individuals will be arranged to undergo a continuous three-week (21 days) duration of systematic simple swallowing training, with weekends off and training conducted only on weekdays, two sessions per day, each lasting 15-30 minutes. Each training session will be conducted approximately one hour prior to meals. Apart from this,we require participants to only engage in daily activities and avoid strenuous and dangerous behaviors
88907917|NCT06301477|Active Comparator|Resistant Starch|Once daily oral consumption of either 7.5g/m2 or 5.0g/m2 (body surface area) of a resistant starch for 48 weeks that is individually optimized at 24 weeks.
88907918|NCT06301477|Placebo Comparator|Placebo|Once daily oral consumption of a readily digestible food-grade cornstarch that resembles the study product in appearance, smell and taste for 48 weeks
88907919|NCT06301360|Experimental|I-EAET with therapist support|I-EAET is a 10 week treatment intervention combining principles from emotion focused therapies and neuroscience. Main components include psychoeducation on the body-mind connection, anxiety regulation with self-compassion exercises and different techniques for emotional exposure and processing. Participants have help from a therapist giving feedback.
88907920|NCT06301360|Active Comparator|I-EAET without therapist support|I-EAET is a 10 week treatment intervention combining principles from emotion focused therapies and neuroscience. Main components include psychoeducation on the body-mind connection, anxiety regulation with self-compassion exercises and different techniques for emotional exposure and processing. Participants works on their own and have only technical support.
88907921|NCT06300684|Experimental|CBT-i|The CBT-i group consists of participants who will receive Cognitive Behavioral Therapy for Insomnia (CBTi) over 4 weeks (1 session per week). This intervention involves structured sessions aimed at addressing maladaptive sleep behaviors and promoting healthy sleep habits. Participants in this group will engage in cognitive restructuring, relaxation techniques, and sleep hygiene education to improve sleep quality and duration. The goal of CBTi is to modify behaviors and thoughts that contribute to insomnia, leading to more restful and consolidated sleep patterns.
88907922|NCT06300684|No Intervention|Sleep Hygiene|The Sleep Hygiene group consists of participants who will not receive any specific therapeutic intervention. Instead, participants in this group will receive basic sleep hygiene education, which includes general recommendations and guidance on healthy sleep habits, which does not involve a structured therapeutic intervention.
88907923|NCT06300645|Experimental|SPLATT|Children with congenital talipes who have been treated with split tibialis anterior tendon transfer to peroneus brevis
88907924|NCT06300645|Experimental|TATT|Children with congenital talipes who have been treated with total ribialis anterior tendon transfer to lateral cuneiform
88907925|NCT06300567||patients with unconcluded diagnosis for cystic fibrosis|"symptomatic patientscarrying 2 variants of CFTR, including at least 1 non CF causing~patients not concluded at neonatal screening of Cystic Fibrosis"
88907926|NCT06300424|Experimental|Almonertinib and Chemo-immunotherapy|6 weeks of almonertinib followed by 3 cycles of neoadjuvant adebrelimab (1200mg every 3 weeks) with nab-paclitaxel and carboplatin (nab-paclitaxel 135 mg/m2, d1 and d8, and carboplatin AUC 5, d1 every 3 weeks) will be administered before surgery, followed by optional adjuvant treatment including EGFR-TKIs up to 3 years or immunotherapy for up to 1 year or till disease progression or unacceptable toxicity.
89427090|NCT03053973|Other|NIV postponed arm|Patients randomised to this arm will, after baseline measurements have been done, first be followed for 3 months while on standard care, and thus serve as the control arm. After this 3 months period, measurements are repeated and patients will also be initiated on noninvasive ventilation.
89427091|NCT03052036|Other|Invasive Treatment|Coronary angiography with a view to coronary revascularisation
89427092|NCT03052036|Other|Optimal Medical Therapy|Patients to be treated with guideline recommended secondary prevention therapy including antiplatelet therapy, statins, ACE inhibitors, betabloackers
89427093|NCT03051984|Experimental|NMES|Neuromuscular electrical stimulation (NMES) will be administered for 5 weeks post-TKA in the quadriceps of the surgical leg. Treatment will occur 5 days per week, twice daily for 45 minutes on each occasion.
89427094|NCT03051984|No Intervention|Control|No intervention will be administered during the 5 weeks post-TKA in the surgical leg.
88907927|NCT06300398|Experimental|Part A: Single Ascending Dose (SAD)|Single oral doses (6 dose cohorts) of IAMA-6 liquid suspension or placebo-to-match IAMA-6 liquid suspension in fasted participants
88907928|NCT06300398|Experimental|Part B: Food Effect (FE)|Single oral dose (1 dose cohort) of IAMA-6 liquid suspension in fed participants
88907929|NCT06300398|Experimental|Part C: Multiple Ascending Dose (MAD)|Multiple oral doses (3 dose cohorts) of IAMA-6 liquid suspension or placebo-to-match IAMA-6 liquid suspension for 7 days in fasted or fed participants
88907930|NCT06300229|Active Comparator|Denosumab|Subcutaneous injection with 60 mg Denosumab once
88907931|NCT06300229|Placebo Comparator|Placebo|Subcutaneous injection with NaCl once
88907932|NCT06300099|Active Comparator|Dexamethasone|Dexamethasone injection
88907933|NCT06300099|Active Comparator|Dexmedetomidine|Dexmedetomidine injection.
88907934|NCT06299943|Experimental|Target Biofeedbak gait training|Patients in this group receive, in addition to conventional therapy, biofeedback gait training by selected biomechanical (Staince or single support phase, range of motion at joint or EMG amplitude) gait parameter. Training takes place 8-12 times over three weeks. The duration of each workout varies from 10 to 30 minutes.
88907935|NCT06299943|Experimental|Target Biofeedbak gait training-2|Patients in this group receive, in addition to conventional therapy, biofeedback gait training by selected biomechanical (Staince or single support phase, range of motion at joint or EMG amplitude) gait parameter. Training takes place 8-12 times over three weeks. The duration of each workout varies from 10 to 30 minutes.
88907936|NCT06299891|Experimental|Drug Intervention|Active drug dose escalation and adjustment: The drug had been used in adolescents with obesity before. For this trial, the FDA approved dose titration will be followed until the highest tolerable dose is reached.
88907937|NCT06299891|Placebo Comparator|Placebo|Matching placebo using capsules matching the appearance of the active drug.
89427095|NCT03049007||Partner|Spousal bereaved individuals (age 25-85) in the Central Denmark Region identified through a data extraction of the Danish Civil Registration System (CPR) every sixth week over a period of one year. The group will complete a survey at respectively 2 (T1), 6 (T2), 11 (T3), 18 (T4), and 26 (T5) months post-loss as well as 3, 4, 5 and 6 years post loss.
89427096|NCT03049007||Child|Parental bereaved individuals (age 18 or above) that are children of the partner group. The group will complete a survey at respectively 2 (T1), 6 (T2), 11 (T3), 18 (T4), and 26 (T5) as well as 3, 4, 5 and 6 years post loss.
88907940|NCT06299553||Single group/cohort|Patients with DLBCL R/R disease non-transplant eligible
88907941|NCT06299527|Experimental|Synchronous Exercise Group|Synchronous telerehabilitation was performed via videoconference. Patients were taken to video conference calls accompanied by a researcher and supervisor. Participants were to perform their exercises simultaneously under the guidance of the researcher. Participants were taken to video conference calls in groups of 5 with similar functional levels. Each session lasts an average of 45 minutes. It was last. The start and end date of the exercise program, the number of repetitions for each exercise, the number of sets, daily repetitions, rest time between sets and the order of the exercises were determined by the researcher.
88907942|NCT06299527|Active Comparator|Asynchronous Exercise Group|Asynchronous telerehabilitation was carried out through the mobile application. Researchers created a record for each participant in the mobile application with the personal information of the participants. Participants were logged in to the application with an account address and password created for them. The mobile application was supervised and followed by a researcher. The principal researcher prepared an exercise program specifically for each participant. He sent the exercise program he had prepared to the relevant participants through the application. In the mobile application, all exercises are explained in video and writing.
89427097|NCT03011710|Experimental|E-cigarette with nicotine|Nicotine level: 6 mg/ml
89427098|NCT03011710|Experimental|E-cigarette without nicotine|Nicotine level: 0 mg/ml
88907943|NCT06299514|Active Comparator|Pharmacological Therapy|Patients randomized to pharmacology rate control will receive guideline-directed HF management across all ranges of LVEF, including appropriate rate control medications. ICD will be inserted in those patients who have LVEF ≤35%
89196780|NCT00833079|Experimental|Tacrolimus 0.1% Taro|Tacrolimus 0.1% manufactured by Taro applied for 14 days
89427099|NCT03011710|Experimental|Conventional cigarette|Nicotine content: 0,5mg
89196781|NCT00833079|Active Comparator|Protopic - Tacrolimus 0.1%|Protopic, Tacrolimus 0.1% applied for 14 days
88907944|NCT06299514|Experimental|P&A-BiVP|Patients randomized to P&A-BiVP will receive a cardiac resynchronization therapy (CRT) pulse generator, and ICD if LVEF ≤35% within 10 working days of randomization. Catheter AVNA will be performed within 4 weeks.
88907945|NCT06299514|Experimental|P&A-CSP|Patients randomized to P&A-CSP will receive a CSP and ICD if LVEF ≤35% within 10 working days of randomization. Catheter AVNA will be performed within 4 weeks.
88907946|NCT06299345|Sham Comparator|control group (CG)|Physically performed the task once per session. No MI. The physical task is a mirror tracing game that requires participants to trace a star shape viewed through a mirror, going as fast as possible while staying within the lines.
88907947|NCT06299345|Experimental|low-dose group (LD)|In addition to physically performing the motor task once in session 1, then they performed MI for 6 minutes (2 min x 3 sets) per session. MI for this study took the form of non-guided first-person mental practice. First-person imagery was explained to each participant where they imagined performing the target skill through their own eyes rather than if they were a bystander watching someone else do the task (third person).
88907948|NCT06299345|Experimental|high-dose group (HD)|In addition to physically performing the motor task once in session 1, then MI for 12 minutes (2 min x 6 sets) per session. The MI technique was the same as the LD group.
88907949|NCT06299137|No Intervention|Control|Usual care. No changes made or recommended to patients randomized to the control arm.
88907950|NCT06299137|Experimental|Intervention arm (Undergoes SAPB)|Patients randomized to this arm will receive the Serratus Anterior Plane block.
88907951|NCT06298825||sarcopenia|Acute decompensated heart failure with sarcopenia. Sarcopenia will be defined using the Asian Working Group for Sarcopenia (AWGS) criteria in the study. According to the guidelines, we can define participants as having sarcopenia when low muscle strength or physical performance coexisted with low skeletal muscle mass. We will define low muscle strength as handgrip strength <26kg for men and <18 kg for women, low physical performance as a walk speed of <1.0m/s for both sexes. We can use bioelectrical impedance analysis to measure the appendicular skeletal muscle mass. The appendicular skeletal muscle mass index (ASMI) is calculated as the sum of muscle mass in the extremities divided by the height squared (kg/m2). The cut-off values of <7.00 kg/m2 for men and <5.70 kg/m2 for women will be used.
88907952|NCT06298825||Non-sarcopenia|Acute decompensated heart failure without sarcopenia
88907953|NCT06298760|Experimental|Knee Massage With Black Cumin Oil Group|Necessary explanations were made to the patients in this group. Before application, 5 drops of black cumin oil were applied to the patient's knee for 20 minutes. waited. After making sure that there was no allergy, both knees were massaged with oil for a total of 30 minutes.
88907954|NCT06298760|Placebo Comparator|Placebo Knee Massage Application Group|Patients in this group received a 30-minute knee massage with pure petroleum jelly.
89196782|NCT00833079|Placebo Comparator|Vehicle|Tacrolimus vehicle applied for 14 days
89196783|NCT00935506|Experimental|Clopidogrel + Aspirin|
89196784|NCT00833157|Experimental|Glucosamine|
89196785|NCT00833157|Experimental|Ibuprofen|
89196786|NCT00833157|Placebo Comparator|Placebo|
89196787|NCT00833235||Patients with dry eye|No treatment is prescribed for the study. Patient dry eye progression will be followed for up to 60 months. Patients may use artificial tears to treat their dry eye symptoms.
89196788|NCT00833235||Patients with no history of dry eye|No treatment is prescribed for this control group. Patients will be followed for up to 60 months. If needed, patients may use artificial tears.
89196789|NCT00935662|Experimental|AZD8329|AZD8329 oral solution
89196790|NCT00935662|Placebo Comparator|Placebo|Placebo for AZD8329 oral solution
89196791|NCT00931372|Experimental|Sequence 1: AVE0010/Placebo|"Period 1: lixisenatide 20 µg in 200 µL, one single dose~Period 2: placebo 200 µL, one single dose"
89196792|NCT00931372|Experimental|Sequence 2: Placebo/AVE0010|"Period 1: placebo 200 µL, one single dose~Period 2: lixisenatide 20 µg in 200 µL, one single dose"
89196793|NCT00935740||Age-Matched Healthy Controls|Age-Matched Healthy Controls
89196794|NCT00935740||Heart Failure|Subjects with LVEF < 40%
89196795|NCT00829257|Experimental|Fine particle steroid inhaler|HFA-BDP plus Fluticasone/Salmeterol Combination
89196796|NCT00829257|Active Comparator|Coarse Particle Inhaler|FP plus Fluticasone/Salmeterol combination
89196797|NCT01618656|Active Comparator|PF-04457845|2/3 of subjects will be randomized to fatty acid amide hydrolase (FAAH) inhibitor 4mg
89196798|NCT01618656|Placebo Comparator|Placebo (sugar pill)|1/3 of subjects will be randomized to placebo
89196799|NCT03978832|Experimental|Oral Risperidone followed by PERSERIS|All subjects will receive 2 SC injections of PERSERIS at each study visit every 28 days for a total of 4 visits of 2 injections each. The first 3 visit injections will be administered in the abdomen and the final visit injections will be administered in the back of the upper arm.
89196800|NCT00840255|Active Comparator|Breif Behavioral Treatment of Insomnia|Effective behavioral insomnia treatments are typically delivered over an 8-week period. This format may not be easily exportable to primary and community care settings where military returnees and veterans seek help. The goal here is to test the effects of a 4-week behavioral treatment that targets chronic insomnia (lasting >1 month) in service members returning from Operation Iraqi Freedom (OIF) and Operation Enduring Freedom (OEF), and who present with the typical psychiatric comorbidities associated of combat-related anxiety and mood disorders and stress reactions.
89427100|NCT03011710|Placebo Comparator|Cigarette tip|Placebo device
89531078|NCT02498171|Active Comparator|Intrathecal morphine with bupivacaine|Single shot of intrathecal morphine 100mcg mixed with 2.5mg of spinal bupivacaine and filled up to make a 2ml solution.This would then be injected into the subarachnoid space through L2-3 or L3-4 following standard procedures.
89196801|NCT00840255|Other|Information Control|This arm of the study does not receive the Brief Behavioral Treatment for Insomnia. This arm will act as the control arm.
89196802|NCT00840333|Experimental|1|CF PATIENTS 6-11 YEARS OF AGE
89196803|NCT00840333|Experimental|2|CF PATIENTS 12-16 YEARS OF AGE
89196804|NCT00840489|Experimental|Ribavirin|Ribavirin 1000-1200 mg qd
89196805|NCT00840489|Active Comparator|Colchicine|Colchicine 0.5 mg bd
89196806|NCT00743496|Experimental|Group 1|Participants who consent to the study will receive Anti-GD2 antibody.
88907955|NCT06298760|Experimental|Foot Reflexology Group With Black Cumin Oil|Patients in this group underwent foot reflexology with pure black cumin oil for 40 minutes on both feet.
88907956|NCT06298760|Placebo Comparator|Placebo Foot Reflexology Group|Patients in this group underwent foot reflexology with vaseline for 40 minutes on both feet.
88907957|NCT06298760|No Intervention|Control Group|No intervention was performed on patients in this group. Followed for 6 weeks. Face-to-face meetings were held once a week.
88907958|NCT06298682||subjects without known pathologies|
88907959|NCT06298539||Obesity|BMI > 30 kg/m2
88907960|NCT06298539||Healthy weight|BMI range: 19 - 29 kg/m2
88907961|NCT06298526||women with anorexia nervosa|DSM-V criteria for anorexia nervosa must be satisfied
88907962|NCT06298526||healthy weight women|BMI range: 19-29 kg/m2
88907963|NCT06297967|Experimental|Acetic Acid|Topic application of a Acetic Acid 2% solution for 15 min, typically administered every 24h. The frequency of the treatments may be modified according to the evolution of the lesion at the discretion of the nurse in charge of the treatments
88907964|NCT06297967|Active Comparator|Control group|Topic application of Prontosan® for 15 min, typically administered every 24h. The frequency of the treatments may be modified according to the evolution of the lesion at the discretion of the nurse in charge of the treatments
88907965|NCT06297772|Active Comparator|Flu-Bu4|Preconditioning with Flu-Bu4 without decitabine for patients with AML-MR
89196807|NCT00937846|Experimental|GSK1034702|Single oral 5 mg dose in liquid formulation
89196808|NCT00833391|Experimental|GSK1838262 arm|Each subject will participate in five dosing sessions separated by at least seven days. Subjects will receive a single dose of current formulation of GSK1838262 or one of the four new formulations of GSK1838262 at each dosing session in random sequence.
89196809|NCT04044105|No Intervention|No Education|Patients in this arm receive no education regarding how to dispose of their opiate medication
89196810|NCT04044105|Experimental|Pamphlet education|Patients receive an educational pamphlet only, to be given at the preoperative teaching class, prior to their standard 3-week postoperative clinic appointment, and prior to their standard 6-week postoperative clinic appointment.
89196811|NCT04044105|Experimental|Pamphlet education + texts|Patients receive an educational pamphlet, to be given at the preoperative teaching class, prior to their standard 3-week postoperative clinic appointment, and prior to their standard 6-week postoperative clinic appointment. In addition, 3 automated text messages sent at those same time points.
89196812|NCT00829335||HCC patients|According with the investigators previously reported selection flow-chart , patients suitable for surgical approach were those with HCC without ascites, without or with esophageal varices for which preoperative endoscopic eradication could be carried out successfully, and with serum bilirubin level lower than 1.5 mg/dl. Potential candidates to systematic segmental or subsegmental resection by IOUS-guided finger compression were considered patients with single HCC located in one or 2 adjacent segments without portal thrombosis, and anyway not demanding for its complete removal a sectional resection or wider.
89196813|NCT02547051|Experimental|Food allergy and vocal cord tension|To determine if dietary allergen responses and frequency and severity of vocal cord tension.
89196814|NCT00840567|Other|Healthy Volunteers|To obtain a one time skin sample (4 ml skin punch biopsy) and one time blood sample (1 teaspoon)
89531079|NCT05035875||40 COPD patients|all participants were subjected to : history - clinical examination - spirometry - ultrasound evaluation of diaphragmatic function
89531080|NCT05035875||40 healthy individuals|all participants were subjected to : history - clinical examination - spirometry - ultrasound evaluation of diaphragmatic function
88907966|NCT06297772|Experimental|Dec-Flu-Bu4|Preconditioning with Flu-Bu4 and decitabine for patients with AML-MR
88907967|NCT06297499|Experimental|Treatment Group 1. Pre-Intrathecal|Patients will receive an IV solution of 8mg ondansetron (4ml) within 30 minutes of the standard-of-care anesthetic treatment (intrathecal morphine administration) followed by a placebo treatment of an IV solution of 4ml 0.9% saline administered at the time of umbilical cord clamping.
88907968|NCT06297499|Active Comparator|Treatment Group 2 Cord clamping|Patients will receive a placebo treatment of an IV solution of 4ml 0.9% saline administered within 30 minutes of the standard-of-care anesthetic treatment (intrathecal morphine administration) followed by an IV solution of 8mg ondansetron (4ml) administered at the time of umbilical cord clamping.
88907969|NCT06297447|Active Comparator|"Usual care"|"Usual Care: The control group receives unrestricted usual care. It could include a patient interview with individual goal setting and subsequent rehabilitation using cardio and strengthening exercises towards achieving the determined goals. It will be delivered by an authorized physiotherapist, and the intervention is determined by patient preferences, physiotherapist's clinical reasoning, and available resources."
89196815|NCT00840567|Other|Patients with benign, inherited hematologic disease|To obtain a one time skin sample (4 ml skin punch biopsy) and one time blood sample (1 teaspoon)
89196816|NCT00829569|Experimental|Intralipid with/without Omegaven|Lipid infusion with/without marine n-3 fatty acids
89196817|NCT02548767|Experimental|HFCS-EB|Consume 3 servings/day of high fructose corn syrup (HFCS)-sweetened beverage along with the provided energy-balanced diet. The 3 HFCS-sweetened beverages will contain 25% of energy requirement and the remainder of the provided diet will contain 75% of energy requirement. All and only the provided beverage and diet will be consumed for eight weeks.
89196818|NCT02548767|Placebo Comparator|Asp-EB|Consume 3 servings/day of aspartame-sweetened beverage along with the provided energy-balanced diet. The 3 aspartame-sweetened beverages will contain 0% of energy requirement and the remainder of the provided diet will contain 100% of energy requirement. All and only the provided beverage and diet will be consumed for eight weeks.
89427101|NCT03000569|Experimental|Part A: Antiparkinsonian Agent(s) Followed by SAGE-217|Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14.
89427102|NCT03000569|Experimental|Part B: Antiparkinsonian Agent(s) + SAGE-217|Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food.
89427103|NCT02997761|Experimental|Treatment (ibrutinib, blinatumomab)|"INDUCTION THERAPY: Patients receive ibrutinib PO QD on days 1-49 of course 1 and days 1-42 of course 2, and blinatumomab IV on days 8-35 of course 1 and days 1-28 of course 2 in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION THERAPY: Patients with CR/CRi after Induction Therapy receive ibrutinib PO QD on days 1-42 and blinatumomab IV on days 1-28. Treatment repeats every 42 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive ibrutinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
89427104|NCT02961348|Active Comparator|Early start of NOAC|Day 1 to day 4 after ischemic stroke onset
89427105|NCT02961348|Active Comparator|Late start of NOAC|Day 5 to day 10 after ischemic stroke onset
89427106|NCT02949921|Experimental|"Grade 4 Hands group"|"Grade 4 Hands group will be subjects with hand grading of grade 4 (very severe loss of fatty tissue, marked visibility of veins and tendons in the dorsal hand). Grade 4 Hands group subjects will receive Radiesse injectable implant and 2% lidocaine HCL up to 3 cc (2 syringes) per hand per treatment. Subjects in Grade 4 Hands group can have up to three retreatments over an 18 month period."
89427107|NCT02949921|Experimental|"Grade 2 or 3 Hands group"|"Grade 2 or 3 Hands group will be subjects with hand grading of grade 2 or grade 3 (moderate to severe loss of fatty tissue, mild to moderate visibility of veins and tendons in the dorsal hand). Grade 2 or 3 Hands group subjects will receive Radiesse injectable implant and 2% lidocaine HCL up to 3 cc (2 syringes) per hand per treatment. Subjects in Grade 2 or 3 Hands group can have up to three retreatments over an 18 month period."
89427108|NCT02935205|Experimental|Treatment (enzalutamide, indomethacin)|Patients receive enzalutamide PO QD and indomethacin PO BID or QD. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
89427109|NCT02914912||GALS symptomatic patients group|Patents With symptoms of chronic mesenteric ischemia shall be investigated with GALS.
89427110|NCT02872532|Experimental|Testicular tissue|Children faced with a fertility threatening diagnosis or treatment plan will be offered testicular tissue cryopreservation, particularly if pre-pubescent and without other options to preserve fertility.
89427111|NCT02860091||Ropivacaine infusion|Patients receiving continuous ropivacaine infusion for approximately 7 days via paravertebral nerve block or erector spinae catheter managed according to existing institutional protocols.
89427112|NCT02844049|Active Comparator|Deep Brain Stimulation|DBS surgical procedure scheduled and realized
89427113|NCT02844049|No Intervention|Control group|medical treatment (psycho- and pharmaco-therapy) will continue to be given and optimized according to the defined BMT strategies and criteria
89427114|NCT02835222|Experimental|Arm 2 (Selinexor) cytarabine, daunorubicin and selinexor|"INDUCTION: Cytarabine IV on days 1-7, daunorubicin hydrochloride IV on days 1-3, and selinexor PO twice weekly from day 1. Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.~RE-INDUCTION: Disease has not responded receive cytarabine IV on days 1-5, daunorubicin hydrochloride IV on days 1-2, and selinexor PO twice weekly. Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: In remission receive cytarabine IV every 12 hours for a total 6 doses days 1-3, and selinexor PO twice weekly from day 1. Treatment repeats every 42 days for up to 3 courses in the absence of disease progression or unacceptable toxicity."
89007881|NCT04612543|Active Comparator|Genial Posterior Composite with Polyethylene fiber|The enamel and dentin were conditioned with bonding procedure.After bonding procedures, remaining tooth composite resin walls were created and cured for 20 s. Prepared ribbond fiber pieces, 2-mm-wide approximately 12mm-long, (Ribbond Thinner, Higher, Modulus - Ribbond Inc,Seattle) were wetted with an unfilled resin for 2 minutes at a non-light environment. The inner surfaces of the prepared class I cavity were lined with flowable resin. After removing the excess resin, pre-wetted polyethylene fiber was condensed circumferentially and embedded with a hand instrument into the bed of unpolymerized flowable composite and then polymerized for 20 seconds with Light Emitting Diodes. After curing for 20 s, composite resin was applied to the rest of the cavity incrementally, each increment was cured for 20 seconds. Finally, the restoration was shaped with finishing diamonds and silicon instruments.
89007882|NCT04612543|Active Comparator|Genial Posterior Composite|The enamel and dentin were conditioned with bonding procedure using an applicator, left undisturbed for five to 10 seconds, and then dried thoroughly for five seconds with oil-free air under air pressure, Genial Direct Posterior resin was applied with the incremental technique (2 mm thick layers) and light-cured for 20 seconds. Finally, the restoration was shaped with finishing diamonds and silicon instruments
89007883|NCT02961387|Experimental|Hydrogen generator treatment|Inhalation of hydrogen-oxygen mixed gas.
89531081|NCT03120533|Experimental|Treprostinil|the participant will receive 10 days of iontophoresis of treprostinil on a first site, each day the same site.
89531082|NCT03120533|Placebo Comparator|Placebo|the participant will receive 10 days of iontophoresis of NaCl on a second site, but the same time than treprostinil
89007884|NCT02961387|Sham Comparator|Oxygen-making machine treatment|Inhalation of oxygen.
89007885|NCT00221975|Active Comparator|Lithium + Divalproex + Lamictal|Lithium monotherapy was initiated at 450 mg once daily and titrated slowly over 3 weeks to a minimum blood level of 0.5 mEqlL. Divalproex was then initiated at 250 mg twice daily and increased slowly over 5 weeks to a minimum blood level of 50 μg/mL. Patients meeting the criteria of being non-responsive to lithium plus divalproex were randomly assigned to receive lamotrigine or placebo. Patients randomized to the lamotrigine group were titrated up to a minimum dose of 150 mg and maximum dose of 200 mg per day.
89007886|NCT00221975|Placebo Comparator|Lithium + Divalproex + Placebo|Lithium monotherapy was initiated at 450 mg once daily and titrated slowly over 3 weeks to a minimum blood level of 0.5 mEqlL. Divalproex was then initiated at 250 mg twice daily and increased slowly over 5 weeks to a minimum blood level of 50 μg/mL. Patients meeting the criteria of being non-responsive to lithium plus divalproex were randomly assigned to receive lamotrigine or placebo. Patients randomized to the placebo group were giving matching placebo.
89007887|NCT04612582|Experimental|Group1|Group1 is the AL amyloidosis patients who have bortezomib-thalidomide-dexamethason-based regimens for their treatment.
89007888|NCT04612582|Experimental|Group2|Group2 is the AL amyloidosis patients who have bortezomib-cyclophosphamide-dexamethason-based regimens for their treatment.
89007889|NCT04612855||Painful post-traumatic trigeminal nerve injuries|Patients presenting with painful post-traumatic trigeminal nerve injuries according to the recent ICOP criteria.
89007890|NCT04612855||Non-painful post-traumatic trigeminal nerve injuries|Patients presenting with non-painful post-traumatic trigeminal nerve injuries according to the recent ICOP criteria.
89007891|NCT04612855||Temporary nerve injuries|Patients with a trigeminal nerve injury with symptom resolution within 3 months after data of trauma.
89007892|NCT04612855||Persistent nerve injuries|Patients with a trigeminal nerve injury and complaints persisting longer than 3 months after the trauma.
89007893|NCT00222014|Experimental|1|TIPS réalisé avec prothèse couverte de PTFE
89007894|NCT00222014|Active Comparator|2|Paracenthese and albumine perfusion
89007895|NCT04612426|Experimental|Brain-computer Interface-Pedaling Training System|
89007896|NCT04612426|Sham Comparator|Traditional Pedaling Training System|Patients wear the same EEG equipment that only collect data, but not guide training.
89007897|NCT04612504|Experimental|SynOV1.1 Injection|
89007898|NCT04612270|Experimental|Participants for blood collection|The blood samples of all participants will be treated equally according to the study protocol. No intervention in-vivo.
89007899|NCT00222053|No Intervention|1|No specific intervention
89007900|NCT00222053|Active Comparator|2|Biphosphonates
89007901|NCT00222053|Experimental|3|Thalidomide
89007902|NCT04611958|Experimental|Bupivacaine arm|Participants undergoing ERCP as part of routine clinical care will be consented for this study.
89007903|NCT04611646|Experimental|Heat-suit training|Low-intensity endurance training with heat suit
89007904|NCT04611646|Other|Non-heat-suit training|Low-intensity endurance training without heat suit
89007905|NCT04611724|Experimental|FOLFIRINOX|oxaliplatin 85 mg/m2 IV over 2 hours leucovorin 400 mg/m2 over 2 hours irinotecan 150 mg/m2 over 90 min, 5-FU continuous infusion 2400 mg/m2 continuous infusion over 46 hours
89007906|NCT00563836|Experimental|1|
89007907|NCT04611685|Experimental|NSAIDs|Parecoxib (iv.) for once & Loxoprofen (po.) for routine use during the first 3 postop. days.
89007908|NCT04611685|Active Comparator|Tramadol|Tramadol (im.) for once & Tramcontin (po.) for routine use during the first 3 postop. days.
89007909|NCT04611412||1 group|Group I consisted of 17 people (16.83%) with a uniform type of obesity
89007910|NCT04611412||2 group|Group II included 38 children with AO, and 20 of them had normal BLOOD pressure
89007911|NCT00222248|Experimental|Pelvic floor muscle training|Weekly group session of education and exercise to music incorporating pelvic floor muscle training incorporating motor control, strength, endurance, power and functional training in a variety of different positions.
89007912|NCT00222248|Active Comparator|Bladder training|Weekly group session of education regarding deferral techniques, timed voiding parameters and gentle exercise to music.
89007913|NCT00248235|Experimental|PRET|Progressive Resistance Exercise Training: upper extremity 6-8 exercises
89007914|NCT00248235|Active Comparator|Standard Care|Standard Care: physical therapy - range of motion, 6-8 strengthening exercises
89007915|NCT00563914|Experimental|1|
89007916|NCT00563914|Active Comparator|2|
89007917|NCT00563953|Experimental|1|Primary chemotherapy regimen consisting of four cycles of pegylated-liposomal doxorubicine at 35 mg/m² IV plus CPM 600 mg/m² on Day 1 every 4 weeks followed by paclitaxel 80 mg/m²/week for 12 weeks before surgery.
89007918|NCT00563992|Experimental|1|Participants will take lithium for 12 months
89007919|NCT00563992|Experimental|2|Participants will take valproate for 12 months
89007920|NCT04611373|Experimental|A|Acetazolamide tablet 25mg/ tablet, 2 tablets a day; Levamisole 25mg/ tablet, 6 tablets/day continuous medication; Continue treatment until the disease progresses
89007921|NCT04611256|Experimental|MSC transfusion|
89007922|NCT04611256|Active Comparator|Control|
89199204|NCT05953805||Staff|Staff who will give their opinions on the use of iPads against normal PPI methods
89427115|NCT02835222|Active Comparator|Standard of Care - Cytarabine and daunorubicin|"INDUCTION: Cytarabine IV on days 1-7, daunorubicin hydrochloride IV on days 1-3. Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.~RE-INDUCTION: Disease has not responded receive cytarabine IV on days 1-5, daunorubicin hydrochloride IV on days 1-2. Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: In remission receive cytarabine IV every 12 hours for a total 6 doses days 1-3. Treatment repeats every 42 days for up to 3 courses in the absence of disease progression or unacceptable toxicity."
89427116|NCT02817230||Patients|Patients referred to the out-patient clinic with LDL levels >4.9 mmol/l
89427117|NCT02817230||Controls|Matched normocholesterolemic control subjects
88907970|NCT06297447|Experimental|PNE4Adults - pain science education|"PNE4Adults: In this group, the participants will receive an add-on individualized PSE in addition to the usual care with the PNE4Adults resource. The PNE4Adults session will follow the developed manual (http://www.paininmotion.be/pne4kids) and will be delivered by a physiotherapist in two sessions of each 30-45 minutes, shortly following the first meeting. Firstly, the function of a normal pain system is introduced, with examples of the pain being overly or under protective. Then, the patient teaches back giving the therapist the opportunity to evaluate the understanding and, if necessary, repeat essential key messages. Secondly, the sensitized pain system is explained. Thirdly, the subject is asked to reflect on this new information in relation to his/her own situation. Subsequently, the new knowledge is integrated in usual care with any additional measures that need to be included, e.g., graded exposure, stress relief, graded activity, and cognitive therapies."
88907971|NCT06297304|Experimental|Physical Activity Intervention|One arm : all volunteers will receive an intervention program based on sedentary behavior reduction and physical activity promotion.
88907972|NCT06297122||Patients|"All consecutive children under the age of 18 years with community-acquired or healthcare-associated severe Group A Streptococcus (GAS) infections admitted to Necker hospital between January 1, 2018, and December 31, 2023. Among GAS infections, invasive and probable invasive GAS illnesses will be distinguish.~Invasive GAS infection will be defined as: isolation by culture or polymerase chain reaction of GAS from a normally sterile site; or isolation of GAS from a sterile or non-sterile site accompanied by necrotizing fasciitis or streptococcal toxic shock syndrome.~Probable invasive GAS will be defined as acute infections with GAS isolated from a non-sterile site, which includes sputum, otorhinolaryngology surgical specimens (mastoiditis, ethmoiditis, pharyngeal abscess) accompanied with one or more of the following severity criteria:intravenous antibiotics;surgery; and/or admission to the pediatric intensive care unit."
88907973|NCT06296446||people with fibromyalgia|People with fibromyalgia in Poland. The study does not include any intervention. The collected data, in a cross-sectional study, are intended to assess the functioning and disability of people with fibromyalgia using standardized questionnaires such as: WHODAS 2.0, FIQ, BDI.
88907974|NCT06295965||Observational|Patients undergo blood sample collection and complete surveys on study. Patients' medical records are also reviewed.
88907975|NCT06295705|Experimental|Hip-Hop Dance|The program will be a 7-week occupational therapy led dance program utilizing hip-hop dance as an intervention. Subjects with ASD will dance for 1 time a week for 60 minutes, ending with a dance showcase on the final week.
88907976|NCT06295614|Experimental|All participants|"All participants enrolled in the study will receive the same intervention.~The first year of the study consists of the following phases: enrolment, baseline assessments, surgical implantation of the ARC-IM stimulation device, configuration sessions for stimulation, in-clinic and at-home rehabilitation, and a home-use phase. It is followed by 3 years of safety follow-up.~Assessments will be planned throughout the course of the study and at baseline, the end of the optimization phase, the end of the rehabilitation phase, and after 12 months post-surgery."
88907977|NCT06294860||Hormone replacement therapy with rhGH|Each subject will be treated with hormone replacement therapy with rhGH with a dose of 0.025-0.035 mg/kg body weight per day (or 0.7-1.0 mg/ m2 body surface area per day) for a period of 6 months.
88907978|NCT06294821|Active Comparator|4-aminopyridine|Study drug: dalfampridine (generic) 10mg ER capsule
88907979|NCT06294821|Placebo Comparator|Placebo|Placebo-1 capsule
88907980|NCT06294613|Other|vitreoretinal surgery supported by Luca System|
88907981|NCT06293248|No Intervention|Control group|Patients in this group received routine care and no music application was performed.
89007923|NCT04611061||ARVI and influenza prophylaxis with Kagocel|"Prophylaxis according to routine practice and instructions for medical use of Kagocel.~Group of patients receiving Kagocel for prevention of ARVI and influenza"
89007924|NCT04611061||ARVI and influenza prophylaxis without any antiviral medicines|Group of patients receiving no any antiviral medicines for prevention of ARVI and influenza
89007925|NCT04610983|Experimental|Control|Control 2 * Gel Encapsulated Algal Oil Capsules (each containing 200mg DHA) Total dose of 400mg DHA.
89007926|NCT04610983|Experimental|Treatment 1 - Semi-Solid food matrix|Vegetable encapsulated algal oil integrated with a semi-solid food product (soup) to deliver 400 mg DHA.
89427118|NCT02807805|Experimental|Treatment (abiraterone acetate, niclosamide, prednisone)|Patients receive abiraterone acetate PO QD, niclosamide PO BID and prednisone PO BID. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.
89427119|NCT02783092|Experimental|Cannabidiol|Concentration unit: 200mg/ml; 5 - 25 mg/Kg/day ; Oral solution
89427120|NCT02783092|Placebo Comparator|Placebo|Oral solution
89531083|NCT03096951|Experimental|Prehabilitation group|Preoperative and postoperative telerehabilitation
89427121|NCT02780128|Other|Molecular Analysis|All participants with relapsed or refractory neuroblastoma will have a tumor biopsy to identify genetic mutations. There is no drug given in this arm of the trial.
88907982|NCT06293248|Experimental|Experimental group|"The patient information form, vital signs registration form, and state-trait anxiety scale were administered to the patients in the music group while they were in the ward before being sent to the CAG laboratory. Afterward, Rast, Acemasiran, and Huseyni music from Classical Turkish Music modes were optionally offered to the patients, and before the CAG procedure (while the patient was waiting for the procedure in the CAG laboratory), the music preferred by the patients was played with headphones for 15-20 minutes in order not to disturb other patients. After CAG, 15 minutes after the patient arrived at the service, he listened to music for 15-20 minutes. Then, the vital signs registration form, state-trait anxiety scale, Perianesthesia Comfort Scale-PCS and Patient Satisfaction Survey on Nursing Care Quality (PSSNCQ) were applied."
88907983|NCT06292663|Experimental|Intervention|Patients allocated to this group are getting the standard information from their anesthesiologist and a supplement of information via. a Virtual Reality (VR) headset. The information they get through the VR headset is about their course on the day of their surgery.
88907984|NCT06292663|No Intervention|Control Group|Patients allocated to this group are only getting standard information from their anesthesiologist.
88907985|NCT06292013|Experimental|Lepodisiran Sodium|Lepodisiran sodium administered subcutaneously (SC).
88907986|NCT06292013|Placebo Comparator|Placebo|Placebo administered SC.
88907987|NCT06291194|Experimental|Test group(AJU-S56 5%)|QID(4 times in a day) for 24 Weeks after Randomization
88907988|NCT06291194|Placebo Comparator|Placebo group(Vehicle)|QID(4 times in a day) for 24 Weeks after Randomization
88907989|NCT06290830|Experimental|Abdominal massage group|Abdominal massage is demonstrated by the researchers to a female student with functional constipation. The student will apply exfoliation (superficial and deep), petrissage, and vibration massage movements for about 15 minutes twice a day in the morning and evening hours and at least 30 minutes after the nutritional meal, 5 days a week, for a total of 12 weeks.
88907990|NCT06290830|Experimental|Kegel Exercises group|In this group students will perform Kegel exercises; 2 times a day in the morning and evening hours, 5 days a week, for a total of 12 weeks.
88907991|NCT06290830|Experimental|Both abdominal massage and kegel exercises to gether|students will perform both abdominal massage and kegel exercises to gether for a total of 12 weeks
88907992|NCT06290830|No Intervention|Control group|No intervention
88907993|NCT06290232|Experimental|Fetoscopic Laser Photocoagulation Surgery|Pregnant individuals diagnosed with type II vasa previa will undergo fetoscopic laser photocoagulation.
88907994|NCT06290115||Case group: NSSI patient group|"Patients who meet the diagnostic criteria in DSM-5 and are clinically diagnosed as NSSI;~Age range: 15-25 years old;~Clear consciousness, normal speech function, able to communicate in Chinese and reading chinese;"
88907995|NCT06290115||Control group 1: non-NSSI patients|"psychiatric outpatients or inpatients can read and understand the contents of the questionnaire;~Patients who do not meet the diagnostic criteria in DSM-5 and are clinically diagnosed as NSSI.~Age range: 15-25 years old;~Clear consciousness, normal speech function, able to communicate in Chinese and reading chinese;"
88907996|NCT06290115||Control group 2: healthy group|"No mental illness;~Age range: 15-25 years old;~Clear consciousness, normal speech function, able to communicate in Chinese and reading chinese;"
88907997|NCT06289153|Experimental|Internal Brace|Patients will undergo ACL Reconstruction (ACLR) with an internal brace. At 6 months post-operation patients will fill out clinical outcome surveys. At the routine 1 year postoperative visit, all patients will fill out clinical outcome surveys and undergo MRI evaluation of the knee.
88907998|NCT06289153|Active Comparator|Standard ACLR|Patients will undergo ACLR without an internal brace. At 6 months post-operation patients will fill out clinical outcome surveys. At the routine 1 year postoperative visit, all patients will fill out clinical outcome surveys and undergo MRI evaluation of the knee.
88907999|NCT06288217|Experimental|Paired nTVNS Stimulation|"Non-invasive electrical stimulation of the trigeminal and vagus nerves will be delivered by the NeuraStasis Stimulator System. The non-invasive Stimulation Electrode is positioned on the head (forehead and in the ear). The operator controls the stimulation delivery through the accompanying Controller.~Rehabilitation sessions begin with a stimulation tolerability assessment where the dose of therapy is selected. A 15-minute priming stimulation is delivered next, followed by the standard of care rehabilitation over the remaining session. During this rehabilitation paired nTVNS is delivered with repetitive motions."
88908000|NCT06288217|Sham Comparator|Sham Stimulation|"For the active shame comparator group, the non-invasive Stimulation Electrode is positioned on the head (forehead and in the ear) as in the experimental group. The operator controls the stimulation delivery through the accompanying Controller.~Rehabilitation sessions begin with a stimulation tolerability assessment where the dose of therapy is selected. A sham stimulation dosage will follow for the remaining procedure, including the priming stimulation, period and the standard of care rehabilitation"
88908001|NCT06288035|Experimental|At-night oral dexamethasone|Patients in the intervention group will receive oral 8 mg dexamethasone at night before surgery. The time of dexamethasone administration will be recorded.
88908002|NCT06288035|Active Comparator|At-induction dexamethasone|Patients in the control group will receive intravenous 8 mg dexamethasone just before or at the induction of anesthesia. The dexamethasone ampule will be diluted in a 10 ml syringe and given in at least one minute to avoid unpleasant sensations in injection.
89007927|NCT04610983|Experimental|Treatment 2 - Solid food matrix|Vegetable encapsulated algal oil integrated with a solid food product (extruded snack) to deliver 400 mg DHA.
89007928|NCT04611178||CIV-ABAO|CIV-ABAO
89196819|NCT02548767|Experimental|HFCS-AL|Consume 3 servings/day of high fructose corn syrup (HFCS)-sweetened beverage along with the provided ad libitum diet. The 3 HFCS-sweetened beverages will contain 25% of energy requirement and the remainder of the provided diet will contain approximately 125% of energy requirement. All the provided beverage will be consumed for eight weeks. Only the provided beverage and diet will be consumed for eight weeks. The provided diet will be consumed ad libitum and the uneaten portions will be returned to study staff.
89199205|NCT05953792||thoracic kyphosis|patients with their kyphotic apex located at T10 or above
89199206|NCT05953792||thoracolumbar kyphosis|patients with their kyphotic apex located below T10
89427122|NCT02780128|Experimental|Group 1: ALK|"Qualified participants whose tumors show certain mutations in the anaplastic lymphoma kinase (ALK) pathway (based on genetic sequencing results) will receive a combination therapy of ceritinib and ribociclib, to be administered orally in 28-day cycles.~Two different doses of ceritinib and three different doses of ribociclib will be evaluated. Once the investigators have identified the highest safe dose of both drugs that can be given at the same time, additional participants will be enrolled in the study at this dose level.~It is possible that if starting at a lower dose, participants may take a higher dose once that dose has been deemed safe."
89427123|NCT02775851|Experimental|Cohort A (pembrolizumab, surgery)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 3 cycles. Patients with potentially resectable disease undergo surgery. Patients with tumor progression and unresectable disease may receive one additional cycle of pembrolizumab. Patients undergo CT scan and may undergo PET and MRI throughout the study. Patients also undergo blood sample collection at screening and tumor biopsy throughout the study.
89427124|NCT02775851|Experimental|Cohort B (pembrolizumab)|Patients with unresectable disease receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 34 cycles in the absence of disease progression or toxicity. Patients undergo CT scan and may undergo PET and MRI throughout the study. Patients also undergo blood sample collection at screening and tumor biopsy throughout the study.
89427125|NCT02734719|Experimental|Group treated with Bonestim|The experimental group will be treated with the electrical stimulation device Bonestim.
89427126|NCT02733159|Experimental|Pembrolizumab|Pembrolizumab: 200 mg Q3W, intravenous administration for a maximum of 2 years, or until progression or unacceptable toxicity.
88820540|NCT06031272|Experimental|Arm A: 30 mg/kg 3BNC117-LS-J + 10 mg/kg 10-1074-LS-J|Participants will receive 30 mg/kg 3BNC117-LS-J and 10 mg/kg 10-1074-LS-J, administered as two intravenous (IV) infusions at Step 1 entry (Day 0). Participants will discontinue ART on Day 2.
89007929|NCT00222326|Experimental|Pelvic floor muscle training|Pelvic floor muscle training: clinic and rooms exercise training
89007930|NCT00222326|No Intervention|Usual care|Usual care as provided by the surgeon and hospital staff
89007931|NCT00564031|Placebo Comparator|1|
89007932|NCT00564031|Experimental|2|
89007933|NCT00564031|Experimental|3|
89007934|NCT00564031|Experimental|4|
89531084|NCT03096951|Active Comparator|Rehabilitation group|Postoperative telerehabilitation
88908003|NCT06287775|Experimental|Phase I (iadademstat, atezolizumab, durvalumab)|Patients in Phase I receive iadademstat PO on days 1, 8, 15, and 22 or days 1 and 15 of each cycle. Patients also continue receiving their initial ICI treatment, either atezolizumab IV over 30-60 minutes on day 1 of each cycle or durvalumab IV over 60 minutes on day 1 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo MUGA or ECHO, brain MRI or brain CT during screening, and CT scans and blood sample collection throughout the trial. Patients may also undergo an optional tumor biopsy on study.
88908004|NCT06287775|Active Comparator|Phase II Arm II (atezolizumab, durvalumab)|Patients in Phase II Arm II continue receiving their initial ICI treatment, either atezolizumab IV over 30-60 minutes on day 1 of each cycle or durvalumab IV over 60 minutes on day 1 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo MUGA or ECHO, brain MRI or brain CT during screening, and CT scans and blood sample collection throughout the trial. Patients may also undergo an optional tumor biopsy on study.
88908005|NCT06287775|Experimental|Phase II, Arm I (iadademstat, atezolizumab, durvalumab)|Patients in Phase II Arm I receive iadademstat PO on days 1, 8, 15, and 22 or days 1 and 15 of each cycle. Patients also continue receiving their initial ICI treatment, either atezolizumab IV over 30-60 minutes on day 1 of each cycle or durvalumab IV over 60 minutes on day 1 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo MUGA or ECHO, brain MRI or brain CT during screening, and CT scans and blood sample collection throughout the trial. Patients may also undergo an optional tumor biopsy on study.
88908006|NCT06286553|Experimental|Trunk Exercise and Inspiratory Muscle Training Group (IMT+TEG)|The Trunk Exercise and Inspiratory Muscle Training Group (IMT+TEG) will follow a comprehensive, 12-week therapeutic exercise program that involves progressive strengthening exercises specifically targeting the trunk and pelvic floor muscles, functional retraining exercises, and additional exercises focusing on strengthening the inspiratory muscles (Inspiratory Muscle Training - IMT).
88908007|NCT06286553|Active Comparator|Trunk Exercise Group (TEG)|The Trunk Exercise Group (TEG) will partake in a comprehensive 12-week therapeutic exercise program that involves progressive strengthening exercises specifically targeting the trunk and pelvic floor muscles, alongside functional retraining exercises.
88908008|NCT06286553|Active Comparator|Control group (CG)|The control group (CG) will receive general management information for DRA, and written instructions for engaging the deeper abdominals and pelvic floor muscles, accompanied by an educational exercise session. Participants will be encouraged to perform these contractions regularly, without guidance or supervision.
88908009|NCT06286098|Experimental|(Alpha lipoic acid) Active Group|"Alpha Lipoic Acid orally along with the standard care of therapy for a duration of 6 months.~Dose: 600 mg once daily."
88908010|NCT06286098|Placebo Comparator|(Placebo) Control Group|"Placebo along with the standard care of therapy for a duration of 6 months.~Dose: One Tablet daily."
88908011|NCT06286033|Experimental|Part 1: Single Ascending Dose (SAD)|Participants will receive a range of doses of AG-181 or placebo, orally, once on Day 1. AG-181 will be given under fasted conditions.
88908012|NCT06286033|Experimental|Part 2: Multiple Ascending Dose (MAD)|Participants will receive a range of doses of AG-181 or placebo twice daily (BID) for 13 days and a single dose on Day 14 under fasted conditions.
88908013|NCT06286033|Experimental|Part 3: Food Effect|Participants will receive a single dose of AG-181 orally, once on Day 1 of the fasted phase, followed by an additional single dose administered on Day 1 of the phenylalanine (Phe)-restricted diet phase and Day 1 of the high-fat meal phase.
88908014|NCT06285825|Experimental|Emapalumab|"If you are found to be eligible to take part in this research study, you will be assigned to 1 of 2 dose levels of emapalumab, based on when you enroll on the study. Up to 16 participants will receive each dose level of the study drug.~The first group of 5 participants will be enrolled at the lower dose level.~Depending on the safety data seen in this first group, the next 11 participants will be enrolled at the lower dose.~After reviewing the early safety data from that first group of 16 participants, the study team will enroll the next 5 participants at the higher dose level and be checked for serious side effects.~Depending on the safety information from the first 5 participants in the higher dose level group, the other 11 will then be enrolled."
88908015|NCT06285058||Training dataset|patients who were diagnosed with non-small cell carcinoma and undergo surgery after neoadjuvant chemoimmunotherapy treatment at hospital 1 (Tongji Medical College Affiliated Union Hospital)
88908016|NCT06285058||test dataset|patients who were diagnosed with non-small cell carcinoma and undergo surgery after neoadjuvant chemoimmunotherapy treatment at hospital (Zhengzhou University First Affiliated Hospital, Yichang Central Hospital, Anyang Cancer Hospital)
88908017|NCT06284720|Experimental|Experimental: real tACS|5 sessions of gamma tACS (40 Hz) at 2 mA over the Precuneus
88908018|NCT06284720|Sham Comparator|Placebo Comparator: sham tACS|5 sessions of sham over the Precuneus
88908019|NCT06279663|Active Comparator|PCI|complete revascularization
88908020|NCT06279663|Active Comparator|CABG|
88908021|NCT06278779|Active Comparator|Esketamine group|"Dosing of esketamine intranasal spray will be guided by the Spravato® Product Information. This involves a starting dosage of 28 or 56 mg, with dose adjustment up to 84 mg as required to optimise response. Dose adjustments will be based on effectiveness and tolerability to the previous dose. The recommended treatment protocol is twice per week for 4 weeks, then weekly in weeks 5-8, then option of weekly-fortnightly maintenance treatment for responders. After week 8, patients may continue treatment as guided by the ketamine clinic psychiatrist."
88908022|NCT06278779|Active Comparator|Racemic ketamine|"Treatment administration will follow standard clinical practice in the recruiting clinic, with a recommendation to follow an evidence-based and established dose-optimising approach, given by injection, twice per week for 4 weeks, then the frequency of further treatments (week 5 - month 6) will be based on the clinical judgement of the ketamine clinic psychiatrist.~Dosing will be adjusted by the ketamine clinic psychiatrist, based on clinical response, safety and tolerability. The psychiatrist will review the patient before each treatment, over the first 4 weeks, to judge the dose level required.~Typically, dosing will begin at the standard dose of 0.5 mg/kg and adjusted using an ascending dose titration schedule if the patient has not shown clinical response and if side effects are adequately tolerated.~."
88908023|NCT06278519|Experimental|Blood and urinary collection, cardiac MRI|Blood and urinary collection, cardiac MRI at inclusion during acute phase of STEMI, and one year after inclusion visit.
89196820|NCT02548767|Placebo Comparator|Asp-AL|Consume 3 servings/day of aspartame-sweetened beverage along with the provided ad libitum diet. The 3 aspartame-sweetened beverages will contain 0% of energy requirement and the remainder of the provided diet will contain approximately 125% of energy requirement. All the provided beverage will be consumed for eight weeks. Only the provided beverage and diet will be consumed for eight weeks. The provided diet will be consumed ad libitum and the uneaten portions will be returned to study staff.
89007935|NCT04610437|Active Comparator|intramedullary reabsorbable fixation system PLLA.|Arthrodesis interphalangeal with intramedullary reabsorbable fixation system PLLA.
89007936|NCT04610437|Placebo Comparator|K-wire|Arthrodesis interphalangeal with kirschner wire
89007937|NCT02961426|Experimental|sofosbuvir + ravidasvir|12 weeks for non-cirrhotic patients, 24 weeks for cirrhotic patients
89196821|NCT00840645|Experimental|1. YM178|
89196822|NCT00566722|Experimental|Open Label|
88820541|NCT06031272|Placebo Comparator|Arm B: Placebo|Participants will receive dose-volume equivalent placebo IV infusions for both 3BNC117-LS-J and 10-1074-LS-J at Step 1 entry (Day 0). Participants will discontinue ART on Day 2.
88820542|NCT06029998|Experimental|Bortezomib|bortezomib starting at a dose of 1.3 mg per square meter of the body-surface area (BSA) subcutaneously on days 1, 4, 8, and 11 in a 21-day cycle.
88820543|NCT06029153|Experimental|Middle meningeal artery embolization|Middle meningeal artery embolization with coil.
88820544|NCT06026852|Other|Patients|Patients admitted to the ICU who are treated with piperacillin-tazobactam or meropenem.
88820545|NCT06026852|Other|Physicians|Physicians in training or consultants who care for patients that are included in the study.
88820546|NCT06025669|Experimental|Nap rested and nap restriction|There are two conditions in the single-arm, that is, the nap rested condition and the nap restriction condition. The sequence of two conditions is randomized.
88820547|NCT06023576|Experimental|standard-of-care antihypertensive medications|This will consist of treatment with antihypertensive medications titrated every 4 weeks for the first 3 months, and then every 3 months in months 4-12. All participants will be provided with dietary (e.g., 1500mg/d sodium restriction) and lifestyle recommendations as background therapy for optimizing HTN control.
88820548|NCT06023576|Experimental|higher dose antihypertensive medications|Patients randomized to intensive SBP control will be treated to achieve an SBP goal <120 mm Hg, and patients randomized to standard SBP control will be treated to achieve an SBP goal <140 mm Hg. Antihypertensive medications will be titrated on the basis of seated blood pressure measurements obtained after a 5-min rest period. All participants will be provided with dietary (e.g., 1500mg/d sodium restriction) and lifestyle recommendations as background therapy for optimizing HTN control.
88820549|NCT06023329|Experimental|Group1|
88820550|NCT06023329|Placebo Comparator|Group 2|
88820551|NCT06017427||Patients suffering from severe recurrent CRSwNP and treated with Dupilumab|Patients suffering from severe recurrent CRSwNP despite having benefited from the appropriate medical and surgical treatment and treated with Dupilumab for 6 months
88820552|NCT06008860|Other|Primary Cohort - Azelastine|This is a double-blind clinical trial. All subjects will be sent an instructional video and be given written instructions which will educate them on how to use the drug or placebo nasal spray. Patients will follow the dosing instructions for Astepro® 0.15% nasal spray.
88820553|NCT06008860|Placebo Comparator|Primary Cohort - Placebo|This is a double-blind clinical trial. A Placebo will be provided by Bayer which features similar color and packaging. Both groups will also undergo recommendations for supportive care, which will be standardized. Any patients who develop severe disease will be given instructions for escalation of care.
88820554|NCT06008821|Experimental|Intervention Group|Bilateral, single level, paravertebral blockade with 0.25% ropivicaine
88820555|NCT06008821|Sham Comparator|Control Group|Bilateral, single level, subcutaneous sham block with normal saline
88820556|NCT06008730|Experimental|Treatment (proton beam radiation therapy)|Patients undergo radiation treatment planning and then undergo proton beam radiation therapy on study. Patients also undergo collection of blood samples.
88820557|NCT06004206|Experimental|nPSV first|Patients will follow the pattern: nPSV -> PSV -> nPSVo -> PSVo
88820558|NCT06004206|Experimental|PSV first|Patients will follow the pattern: PSV -> nPSV -> PSVo -> nPSVo
88820559|NCT06001658|Experimental|Gemcitabine, Cisplatin and Pembrolizumab|
88820560|NCT06000332|Experimental|InogenOne Rove 6 Portable Oxygen Concentrator|InogenOne Rove 6 Portable Oxygen Concentrator
88820561|NCT05997888|Experimental|At-Home Strength Training Group|Participants in this arm will undergo an in-person meeting before the start of the study to meet each other, go over movements to minimize risk of injury, and to discuss intervention logistics. Then, for six weeks, participants will be sent five workouts at the start of each week (Monday). Participants will choose 2 or 3 to complete on their own. Additionally, participants will have a weekly Zoom meeting in which 30 minutes will be dedicated to exercising, and 30 minutes will be for group counseling.
88820562|NCT05997888|No Intervention|Wait-List Control Group|This will be a wait-list control group. Participants at the end of the study will have the option to complete the full, partial, or none of the intervention.
88820563|NCT05991349|Experimental|IBI129|IBI129
88820564|NCT05986890|Other|Roux-en-Y Bypass|laparoscopic Roux-en-Y (R-Y) procedure is a well-established procedure, commonly utilized in the setting of bariatric- and gastric cancer surgery. The procedure establishes intestinal continuity that bypasses the distal stomach and duodenum. This is achieved by dividing the jejunum 30-40 cm distal to the ligament of Treitz, bringing the distal end of jejunum up anterior to the transverse colon to be anastomosed to the back wall of the stomach (forming the Roux-limb). The proximal cut end of jejunum then gets anastomosed to the downstream roux-limb (forming the Y-limb). The benefits of this reconstruction include less chance of gastric contents travelling into the afferent limb and similarly, avoiding bile reflux from the afferent limb with associated bile gastritis.
89427127|NCT02731612|Experimental|Lurasidone|Lurasidone 20 - 80 mg / day added to current treatment for 6 weeks.
89427128|NCT02731612|Placebo Comparator|Placebo|Placebo added to current treatment for 6 weeks
89427129|NCT02721719||Healthy Adults|[Not receiving Vedolizumab] Healthy adults who have not donated blood within the past two months and who have no history of blood-borne diseases.
89427130|NCT02721719||Adults with no Inflammatory Bowl Disease|[Not receiving Vedolizumab] Adult patients undergoing endoscopy for indications other than Inflammatory Bowel Disease or other inflammatory conditions of the bowel (such as colon cancer screening or polypectomy)
89427131|NCT02721719||Donors with Ulcerative Colitis|[Set to receive Vedolizumab] Adults with an established diagnosis of UC (≥ 6 months preceding involvement in study) who are both scheduled for an endoscopy and are about to receive Vedolizumab treatment (standard of care).
89007938|NCT04610359|Experimental|Stem cell group|Interstitial cystitis patients who receive submucosal injection of hESC-MSCs
89427132|NCT02696876|Active Comparator|Control group|Patients in this group will received conventional microfracture treatment as indicated for isolated cartilage defects and defined by the inclusion criteria.
89427133|NCT02696876|Experimental|Intervention group|Patients in this group will also receive microfracture for the treatment of isolated cartilage defects in combination with arthroscopic synovial brushing to access and release synovial MSCs into the joint space.
89007939|NCT04610281|No Intervention|Control|"Wards without the Inner Garden biofeedback tool"
89427134|NCT02683486|Experimental|Activities of daily living on iO2t|Patients will complete simulated activities of daily living on intelligent oxygen therapy (an auto-titrating oxygen system)
89427135|NCT02683486|Active Comparator|Activities of daily living on LTOT|Patients will complete activities of daily living on their usual long-term oxygen therapy.
89427136|NCT02642172|Experimental|ITF (Inulin/OFS 75/25)|16 gram/day of ITF (Inulin/OFS 75/25)
89007940|NCT04610281|Experimental|Inner Garden|"Wards with the Inner Garden biofeedback tool"
89007941|NCT04610008||APON|Retrospective review of routine clinical images from patients with an acquired pit of the optic nerve (APON), and a documented diagnosis of primary open angle glaucoma or normal tension glaucoma
89427137|NCT02642172|Placebo Comparator|placebo|16 gram/day of maltodextrin (placebo)
89427138|NCT02612662|Experimental|Cohort 1|Subjects will be fasted for at least 10 hours before dosing and until 4 hours after dosing of a single dose of AZD4076 tetracosasodium or placebo (high doses may be fractionated)
89427139|NCT02612662|Experimental|Cohort 2|Subjects will be fasted for at least 10 hours before dosing and until 4 hours after dosing of a single dose of AZD4076 tetracosasodium or placebo (high doses may be fractionated)
88820565|NCT05986890|Other|Gastrojejunostomy|surgical gastrojejunostomy, a procedure dating back to the late 1800's.5 This surgical bypass consists of connecting the stomach to a loop of proximal small bowel, thus bypassing any duodenal or distal gastric obstruction.
88820566|NCT05980559|Experimental|One Group|Patients will be injected with 50 MU of botulinum toxin and Surface qualitative Electromyography, maximum bite force and visual pain scale will be taken before and after 1, 3 months
88820567|NCT05980013|Experimental|Supine Donation Position|
89427140|NCT02612662|Experimental|Cohort 3|Subjects will be fasted for at least 10 hours before dosing and until 4 hours after dosing of a single dose of AZD4076 tetracosasodium or placebo (high doses may be fractionated)
89427141|NCT02612662|Experimental|Cohort 4|Subjects will be fasted for at least 10 hours before dosing and until 4 hours after dosing of a single dose of AZD4076 tetracosasodium or placebo (high doses may be fractionated)
89427142|NCT02612662|Experimental|Cohort 5|Subjects will be fasted for at least 10 hours before dosing and until 4 hours after dosing of a single dose of AZD4076 tetracosasodium or placebo (high doses may be fractionated)
89427143|NCT02612662|Experimental|Cohort 6|Subjects will be fasted for at least 10 hours before dosing and until 4 hours after dosing of a single dose of AZD4076 tetracosasodium or placebo (high doses may be fractionated)
89427144|NCT02611167|Experimental|Bone marrow-derived MSC transplantation (1 x 10 6 MSC/kg)|Allogeneic bone marrow-derived MSCs will be delivered intravenously.
88820568|NCT05980013|Experimental|Reclined Donation Position|
88820569|NCT05972733|Experimental|Open Arm Study|One dose given to all participants
89007942|NCT04610008||No APON control|Retrospective review of routine clinical images from patients with NO acquired pit of the optic nerve (APON), and a documented diagnosis of primary open angle glaucoma or normal tension glaucoma
89427145|NCT02611167|Experimental|Bone marrow-derived MSC transplantation (3 x 10 6 MSC/kg)|Allogeneic bone marrow-derived MSCs will be delivered intravenously.
89427146|NCT02611167|Experimental|Bone marrow-derived MSC transplantation (6 x 10 6 MSC/kg)|Allogeneic bone marrow-derived MSCs will be delivered intravenously.
89427147|NCT02611167|Experimental|Bone marrow-derived MSC transplantation (10 x 10 6 MSC/kg)|Allogeneic bone marrow-derived MSCs will be delivered intravenously.
89427148|NCT02594072|Experimental|SABR with androgen suppression|Stereotactic ablative radiotherapy (SABR) with a prescribed dose of 36.25 Gy in 5 fractions over 5 weeks (one treatment day per week). Zoladex ® for androgen suppression, taken for 6 months for patients with intermediate-risk prostate cancer, 18 months for patients with high-risk prostate cancer.
89427149|NCT02594072|Active Comparator|EBRT with androgen suppression|Conventional external beam radiation therapy (EBRT) with a prescribed dose of 73.68 Gy in 28 fractions (5 treatment days per week over 5.5 weeks). Zoladex ® for androgen suppression, taken for 6 months for patients with intermediate-risk prostate cancer, 18 months for patients with high-risk prostate cancer.
89427150|NCT02541955|Active Comparator|40 Units|40 units of Acthar per week
89007943|NCT04610164|Experimental|Group 1: TXA group|Patient will receive 1 gram intravenous TXA prior to surgery
89007944|NCT04610164|No Intervention|Group 2: Control Group|Patient will not receive TXA prior to surgery
89427151|NCT02541955|Active Comparator|80 Units|80 units of Acthar twice per week
89427152|NCT02530177||Patients having CYTOTOXIC CHEMOTHERAPY|Participants will undergo study related assessments and the appropriate HRQoL questionnaires will be administered. Baseline and follow-up clinical assessments will be performed, preferably when the patient presents to the clinic for (clinically indicated) standard-of-care visits. Initially, these visits will be coinciding with the appropriate chemotherapy dosing cycles (as applicable to select study cohorts), and subsequently they will be performed during the standard-of-care follow-up visits.
89427153|NCT02530177||Patients having ENDOCRINE THERAPY|Participants will undergo study related assessments and Medical and Personal History Questionnaire data collection forms and the appropriate HRQoL questionnaires, will be administered. Baseline and follow-up clinical assessments will be performed, preferably when the patient presents to the clinic for standard-of-care visits. Initially, these visits will be coinciding with the appropriate therapy and subsequently they will be performed during the standard-of-care follow-up visits.
89427154|NCT02530177||COMPARATOR (menopausal women)|Menopausal women will include unrelated visitors accompanying breast cancer patients (e.g. friends) attending the breast medicine or dermatology clinics, or female employees of MSKCC. There will be no follow-up visits (after baseline) for participants in the comparator cohort.
89531085|NCT03120767|Experimental|Condition 1|enrolled in the Risk and Resilience course during Fall 2017 and directly encouraged to participate in the Founders Living and Learning Community wellness activities for the Fall of 2017 (Coordinated Wellness Programming)
89531086|NCT03120767|Active Comparator|Condition 2|enrolled in the Risk and Resilience course in Spring 2018, and not directly encouraged to participate in the WIN Living and Learning Community wellness activities
89007945|NCT04610086||False positive FIT|Participants in the colorectal cancer screening program, with a positive FIT and with a normal colonoscopy
89007946|NCT04610086||Polyps|Participants in the colorectal cancer screening program, with a positive FIT and diagnosed of colorectal polyps in the colonoscopy
89427155|NCT02498132|Experimental|Behavioral Activation|Behavioral Activation will be administered via Moodivate will mirror the core BA components outlined above. Moodivate will also be modified for a mobile environment in key ways, with the most salient being: 1) Elimination of the need for a therapist: By eliminating the need for a therapist, we will be able to reach a broad patient/consumer base that may not utilize traditional therapy resources and will combat the primary barrier to PCPs recommending psychotherapy to their patients with elevated depressive symptoms and 2) Elimination of paper forms: By eliminating paper forms, we will increase the sensitivity of BA to motivational and organizational deficits frequently observed in patients with elevated depressive symptoms while also increasing treatment fidelity by prompting the patient to complete activities at scheduled times and giving the patient reinforcement for completing activities.
89427156|NCT02498132|Active Comparator|Cognitive Based Therapy|Moodkit will be used to administer cognitive based therapy which is commonly compared to behavioral activation.
89427157|NCT02498132|Active Comparator|Treatment as Usual|TAU will be provided to individuals. These subject will be provided with therapy but will not utilize a mobile application.
89427158|NCT02486133|Experimental|A: boosted darunavir (bDRV) plus dolutegravir (DTG; 2DR)|Prezista & Norvir & Tivicay
89427159|NCT02486133|Active Comparator|B: bDRV plus 2 nucleoside reverse-transcriptase inhibitors (NRTIs; 3DR)|Prezista & Norvir & Truvada or Prezista & Norvir & Kivexa or Prezista & Norvir & Descovy
89427160|NCT02457442|Active Comparator|PR1|(Arm closed in May 2022) Propofol-Remifentanil: Prop high, Remi low. Changing Remi (up-and-down)
89427161|NCT02457442|Active Comparator|PR2|(Arm closed in May 2022) Propofol-Remifentanil: Prop low, Remi high. Changing Prop (up-and-down)
89427162|NCT02457442|Active Comparator|SR1|(Arm closed in May 2022) Sevoflurane-Remifentanil: Sevo high, Remi low. Changing Remi (up-and-down)
89427163|NCT02457442|Active Comparator|SR2|(Arm closed in May 2022) Sevoflurane-Remifentanil: Sevo low, Remi high. Changing Sevo (up-and-down)
89427164|NCT02457442|Active Comparator|SPR1|(Arm closed in October 2023) Sevoflurane-Propofol-Remifentanil: Sevo plus Remi intermediate, Remi intermediate; changing Propofol.
89007947|NCT04610086||Colorectal cancer|Participants in the colorectal cancer screening program, with a positive FIT diagnosed by colorectal cancer
89196823|NCT00691704|Experimental|High-risk Multiple Myeloma|Lenalidomide Induction (with Low Dose Dexamethasone) Therapy Followed by Low Dose Melphalan, Prednisone, Lenalidomide and Bortezomib Sequential Maintenance Therapy
89427165|NCT02457442|Active Comparator|SPR2|(Arm closed in October 2023) Sevoflurane-Propofol-Remifentanil: Sevo plus Remi intermediate, Remi intermediate; changing Sevoflurane.
89007948|NCT04610203|Placebo Comparator|Glucose|Glucose - 50 g
89007949|NCT04610203|Experimental|Nutralys S85 Plus 25 g|Nutralys S85 Plus Pea Protein 25 g + 50 g Glucose
89196824|NCT00833625|Experimental|PET/CT Scan + Biomarkers Testing|"PET/CT scan with fluorodeoxyglucose (FDG) solution by vein, scan done 10-14 days after beginning chemotherapy and radiation (chemoradiation).~Tissue obtained at MDACC during previous biopsy and at time of post chemoradiation surgery will be used for biomarker analysis."
89196825|NCT00829647|Experimental|combination dasatinib plus lenalidomide|dasatinib 70 mg po daily plus lenalidomide 2.5 md po daily
89196826|NCT02564406|Experimental|hypercapnic patients|patients with acute hypercapnic respiratory failure due to exacerbation of chronic obstructive pulmonary disease, refused endotracheal intubation after failing NIV and were treated withLow flow etracorporeal CO2 removal
89196827|NCT00935896|No Intervention|high VT group|
89196828|NCT00935896|Experimental|Low tidal volume|
89196829|NCT00829725|Active Comparator|screws-internal fixation|3-4-screws-internal fixation
89427166|NCT02427854|No Intervention|No training|Incidence of obstetric perineal injuries in the participating hospitals before implementation of the manual perineal protection method.
88908024|NCT06277349|Other|Non toric multifocal IOL combined with corneal incisional surgery|Non-toric Multifocal IOL (Rayner) - Model M-Flex 630F - CE marked since 2006 (in routine use). Surgery is performed under topical anaesthesia. Preoperatively, the horizontal meridian will be marked in the sitting position with a blue marking pen or insulin syringe at the limbus. The temporal self sealing incision, injection of viscoelastic substance, capsulorhexis, phacoemulsification, irrigation/aspiration of cortical material and injection of viscoelastic substance into the capsular bag are performed as standard procedure. Corneal limbal relaxing incisions (LRI) according to the Donnenefeld nomogram will be performed combined with standard non-toric multifocal IOL.
88908025|NCT06277349|Other|Toric multifocal IOL alone|Toric Multifocal IOL (Rayner) - Model M-Flex T 588 or 638 - CE marked since January 2007. Surgery is performed under topical anaesthesia. Preoperatively, the horizontal meridian will be marked in the sitting position with a blue marking pen or insulin syringe at the limbus. The temporal self sealing incision, injection of viscoelastic substance, capsulorhexis, phacoemulsification, irrigation/aspiration of cortical material and injection of viscoelastic substance into the capsular bag are performed as standard procedure. The multifocal toric IOL will be implanted.
88908026|NCT06277063|Experimental|Acute exacerbation experimental group|VAS pain intensity will be assessed at the onset of headache, and patients will receive nVNS for half an hour within 20 minutes of the onset, and post-treatment evaluation results will be recorded immediately after treatment, 2 hours, 8-12 hours, 24 hours, and 36-48 hours. During the course of treatment and intervention, a 20-minute ECG closed-loop assessment test will be performed before admission and after return. The procedure included: 5 minutes of rest (i.e. no vagal stimulation), 10 minutes of vagal stimulation, 5 minutes of rest(5-10-5), a total of 20 minutes of ECG, and real-time extraction of heart rate and sex data. Neck electromyography before and after intervention was also used as an auxiliary indicator.
88908027|NCT06277063|Sham Comparator|Acute exacerbation control group|VAS pain intensity will be assessed at the onset of headache, and patients will receive sham-nVNS for half an hour within 20 minutes of the onset, and post-treatment evaluation results will be recorded immediately after intervention, 2 hours, 8-12 hours, 24 hours, and 36-48 hours. During the course of intervention, a 20-minute ECG closed-loop assessment test will be performed before admission and after return. The procedure included: 5 minutes of rest (i.e. no vagal stimulation), 10 minutes of vagal stimulation, 5 minutes of rest, a total of 20 minutes of ECG, and real-time extraction of heart rate and sex data. Neck electromyography before and after intervention was also used as an auxiliary indicator.
88908028|NCT06277063|Experimental|Seizure prevention experimental group|The total course of intervention will be 8 weeks. Two 20-minute (5-10-5) closed-loop vagal - ECG/EMG measurements will be required before and after the intervention. Subjects will be required to keep a headache diary for 4 weeks at baseline before the intervention. The time of onset, duration, pain intensity (as measured by visual analogue scale (VAS)), accompanying symptoms, and medication use will be recorded. According to the randomized group, nVNS intervention will be carried out at home for 8 weeks, twice a day (7:00-8:00 in the morning and 19:00-20:00 in the evening). After the intervention, headache diary will be still needed to fill out, and the content will be the same as above. Headache diaries will be collected at 4-week intervals from week 4 to week 20.
88908029|NCT06277063|Sham Comparator|Seizure prevention control group|The total course of intervention will be 8 weeks. Two 20-minute (5-10-5) closed-loop vagal - ECG/EMG measurements will be required before and after the intervention. Subjects will be required to keep a headache diary for 4 weeks at baseline before the intervention. The time of onset, duration, pain intensity (as measured by visual analogue scale (VAS)), accompanying symptoms, and medication use will be recorded. According to the randomized group, sham-nVNS intervention will be carried out at home for 8 weeks, twice a day (7:00-8:00 in the morning and 19:00-20:00 in the evening). After the intervention, headache diary will be still needed to fill out, and the content will be the same as above. Headache diaries will be collected at 4-week intervals from week 4 to week 20.
88908030|NCT06276361|Experimental|Cohort 1/2|Patient will recieve oral risperidone for one week followed by a single IM injection of Risperidone QUAR out of two possible formulations (F1/F2) with a level 1 dose.
88908031|NCT06276361|Experimental|Cohort 1a/2a|Patient will recieve oral risperidone for one week followed by a single IM injection of Risperidone QUAR out of two possible formulations (F1/F2) with a level 2 dose.
88908032|NCT06276361|Experimental|Cohort 1b//2b|Patient will recieve oral risperidone for one week followed by a single IM injection of Risperidone QUAR out of two possible formulations (F1/F2) with a level 3 dose.
88908033|NCT06276361|Experimental|Cohort 1c/2c|Patient will recieve oral risperidone for one week followed by a single IM injection of Risperidone QUAR out of two possible formulations (F1/F2) with a level 3 dose.
89007950|NCT04610203|Experimental|Nutralys S85 Plus 50 g|Nutralys S85 Plus Pea Protein 50 g + 50 g Glucose
89427167|NCT02427854|Active Comparator|Education by animated training video|Incidence of obstetric perineal injuries in the participating hospitals, after the delivery unit staff has been educated and trained to a perineal support by an animated training video only.
89196830|NCT00829725|Experimental|TARGON FN|"The Targon FN implant consists of a small side plate with six locking screw ports. The two distal holes are used to fix the plate to the lateral cortex of the femur with angle stable 4.5 mm cortical screws. The proximal holes allow the implementation of up to four TeleScrews which cross the fracture site. These 6.5 mm screws are dynamic and allow therewith the collapse of the fracture at the femoral neck. The sliding during the collapse occurs within these screws so that a protrusion of the screws in the lateral soft tissue is prevented"
89427168|NCT02427854|Active Comparator|Interactive hands on bedside training|Incidence of obstetric perineal injuries in the participating hospitals, after the delivery unit staff has been educated and trained to a perineal support by an animated training video and additionally by an interactive hands-on bedside training.
89427169|NCT02407691|Experimental|Primary Care 101 Enhanced guideline|Primary Care 101 guideline with enhanced mental health
88908034|NCT06275087|Experimental|TIVA group|"The study involves patients in an operating room undergoing standard procedures. The induction procedure for anesthesia is the same for both groups, using sufentanil, propofol, and cisatracurium.~In the TIVA group, anesthesia is maintained with continuous propofol infusion and intermittent cisatracurium doses, guided by neuromuscular and electroencephalogram monitoring. At the end of surgery, neuromuscular block is reversed, and extubation occurs when the train-of-four (TOF) index is over 90%.~Muscle strength and bite force are measured at different intervals before and after anesthesia, using specific instruments. Additionally, patients fill out the Quality of recovery-40 (Qor-40) questionnaire at various time points to assess the quality of recovery after surgery and anesthesia."
88908035|NCT06275087|Active Comparator|Volatile group|In the volatile group, anesthesia is maintained with inhaled sevoflurane and intermittent cisatracurium doses. Cisatracurium is repeated based on TOF ratio, and anesthesia depth is controlled by BIS, maintaining values between 25 and 50. Drug doses are adjusted according to TOF and BIS values.
88908036|NCT06274814|Active Comparator|Rhomboid intercostal block|23 patients the rhomboid intercostal block (RIB) Group A
88908037|NCT06274814|Active Comparator|RISS Rhomboid intercostal block combined with the sub-serratus plane block|23 patients the RIB combined with the sub-serratus plane block (RISS) Group B
88908038|NCT06274814|No Intervention|No block intervention|"routine IV analgesia 23 patients no block intervention was performed. The anesthetic dose was adjusted to maintain blood pressure within 20% of the baseline value. An additional dose of intravenous fentanyl (0.1 µg kg-1 min-1) was injected as needed.~Group C"
89196831|NCT00746538|Experimental|1|metallic stent group
89196832|NCT00746538|Active Comparator|2|plastic stent group
89196833|NCT00829881|Placebo Comparator|1|Participants will receive a placebo capsule, administered orally, once per study visit.
88908042|NCT06273293|Other|Percutaneous coronary intervention (PCI) and guide wire post PCI in multivessel patients|
88908043|NCT06273124|Experimental|SteadiSet Extended Wear Infusion Set|Each participant will be asked to wear the Investigational Extended Wear Infusion Set for up to 168 hours for 12 consecutive wear periods with the Tandem t:slim X2 insulin pump with Control-IQ technology, and wearing the Dexcom G6 sensor.
88908044|NCT06272630|Experimental|DWJ1464|UCDA 100 mg, TID
88908045|NCT06272630|Placebo Comparator|Placebo of DWJ1464|Placebo of DWJ1464, TID
89196834|NCT00829881|Experimental|2|Participants will receive a betahistine capsule, administered orally, once per study visit.
89196835|NCT02563314|Experimental|intervention|
89196836|NCT02563314|Other|control|
89536847|NCT03308591|Experimental|NACT|The patients will receive 2 courses of platinum based chemotherapy before surgery, 2-3 weeks after each course, doctors will appraise the effect of the chemotherapy. Patients who are sensitive to the treatment will undergo radical hysterectomy and pelvic lymph node dissection 3 weeks after chemotherapy. And 2-3weeks after the surgery, patients will receive adjuvant chemotherapy according to the pathological risk factors.
89427170|NCT02407691|Active Comparator|Standard of care|Primary Care 101 standard version guideline
89427171|NCT02391519||High Altitude (3000 m)|Collection of myometrial, cord blood, and placental tissue samples from women at high altitude (Summit County) and low altitude (Denver) in Colorado in order to determine if residence at altitude during pregnancy changes the vasoreactivity of myometrial arteries (MA).
89427172|NCT02391519||Low Altitude (1600 m)|Collection of myometrial, cord blood, and placental tissue samples from women at high altitude (Summit County) and low altitude (Denver) in Colorado in order to determine if residence at altitude during pregnancy changes the vasoreactivity of myometrial arteries (MA).
89427173|NCT02347111|Experimental|flecainide 1st|flecainide x 6 months, then crossover to sotalol x 6 months
89427174|NCT02347111|Experimental|sotalol 1st|sotalol x 6 months, then crossover to flecainide x 6 months
89427175|NCT02323945|Active Comparator|AIH/Walk|Subjects with chronic, motor-incomplete SCI receive acute intermittent hypoxia (AIH) with walking practice, then AIH with strength practice and compare their efficacy on enhancing strength and/or walking performance.
89536848|NCT03308591|Active Comparator|PST|The patients in this group will undergo radical hysterectomy and pelvic lymph node dissection directly, and 2-6 weeks after the surgery, they will receive adjuvant chemotherapy according to the pathological risk factors.
88908046|NCT06272487|Experimental|Zilebesiran|Participants will receive zilebesiran on Day 1 of the 6-month double-blind (DB) treatment period. Participants must be on stable doses of at least 2, but not more than 4, antihypertensive medications for at least 30 days prior to screening and plan to remain on stable doses of these medications during screening and through the DB treatment period.
88908047|NCT06272487|Placebo Comparator|Placebo|Participants will receive placebo on Day 1 of the 6-month DB treatment period. Participants must be on stable doses of at least 2, but not more than 4, antihypertensive medications for at least 30 days prior to screening and plan to remain on stable doses of these medications during screening and through the DB treatment period.
88908048|NCT06272045|Experimental|Enriched home visiting|
88908049|NCT06272045|Active Comparator|Routine home visiting|
89196837|NCT00840723||Current smokers|Current cigarette smokers with no other illness
88908050|NCT06271785|Experimental|HR-EEG recording|
88908051|NCT06270719||Delandistrogene Moxeparvovec|Participants were either (1) prescribed delandistrogene moxeparvovec commercially as part of clinical care prior to entry into this trial or (2) previously received delandistrogene moxeparvovec through participation in select SRP-9001 studies.
88908052|NCT06270719||Standard of Care|Participants unexposed to DMD gene therapy receiving standard of care therapy (chronic glucocorticoid treatment) that does not include delandistrogene moxeparvovec or other DMD gene therapies.
88908053|NCT06270082|Experimental|IK-595|Dose Escalation and Dose Expansion
88908054|NCT06270030|Experimental|LNZ101 (Aceclidine /Brimonidine) ophthalmic solution|Drug: Aceclidine/Brimonidine ophthalmic solution Other Names: LNZ101
88908055|NCT06270030|Experimental|LNZ100 (Aceclidine) ophthalmic solution|Drug: Aceclidine ophthalmic solution Other Names: LNZ100
88908056|NCT06270030|Placebo Comparator|Placebo (Vehicle) ophthalmic solution|Drug: Placebo (Vehicle) ophthalmic solution Other Names: NA
88908057|NCT06269133||Study Patients|Patients who have received cemiplimab in combination with platinum-doublet chemotherapy for the 1L treatment of aNSCLC in the US with no documented EGFR, ALK and ROS1 variants as described in the protocol.
88908058|NCT06269094|Experimental|CGM|
88908059|NCT06266728|Experimental|Total 30 for astigmatism contact lenses|Total30 for Astigmatism Monthly Replacement Contact Lenses
88908060|NCT06266338|Experimental|Pembrolizumab and Lenvatinib Arm|"Pembrolizumab 200 mg q 3 weeks IV Lenvatinib 20 mg PO QD Continue q3 weeks~Pembrolizumab and Lenvatinib will be given together in this trial for a maximum of 2 years i.e. a total of 35 cycles of pembrolizumab with the q3 week dosing and Lenvatinib daily. Participants who complete study intervention after 2 years of pembrolizumab and lenvatinib are eligible for up to 1 year of additional pembrolizumab and lenvatinib (second course) upon experiencing disease progression."
89196838|NCT00840723||Healthy controls|Healthy non smokers
88820570|NCT05972213||Longitudinal group|"25 patients anticipated. Patients with :~Uncontrolled asthma: ACT score < 20 and/or at least one exacerbation in the last 6 months~Naïve biotherapy~Indication for initiation of biotherapy according to the referring pulmonologist (omalizumab, mepolizumab, benralizumab, dupilumab)"
89427176|NCT02323945|Active Comparator|AIH/Strength|Subjects with chronic, motor-incomplete SCI receive AIH with strength practice, then AIH with walking practice and compare their efficacy on enhancing strength and/or walking performance.
89427177|NCT02320929|Experimental|Intraoperative irrigation only|The infected tendon sheath is irrigated intraoperatively, the catheter is removed, and small rubber srains are left in small incisions.
89427178|NCT02320929|Active Comparator|Intra- and postoperative irrigation|The infected tendon sheath is irrigated intraoperatively, the catheter is kept in place, the irrigation is continued postoperatively 3 times a day for 3 days.
89427179|NCT02315768|Experimental|GA101+ibrutinib|"Ibrutinib 420 mg (140 mg capsules 3 times) orally once daily for up to 6 cycles.~GA101 (Obinutuzumab) by Intravenous infusion for up to 6 cycles (28 day cycles) as follows:~Cycle 1, Day 1,100 mg GA101 obinutuzumab will be administered.~Cycle 1, Day 2, 900 mg of GA101 obinutuzumab will be administered.~Cycle 1, Days 8 and 15,1,000 mg of GA101 obinutuzumab will be administered.~Cycles 2-6, Day 1, 1,000 mg of GA101 obinutuzumab will be administered."
89427180|NCT02315716|Experimental|Consolidation with 4 cycles of CarCyDex|Patients responding to induction treatment will receive 4 further cycles of Carfilzomib, Cyclophosphamide and Dexamethasone (CarCyDex) treatment followed by 18 months of maintenance carfilzomib
89427181|NCT02315716|Active Comparator|Autologous Stem Cell Transplant (ASCT)|Patients responding to induction treatment will receive a melphalan conditioned autologous stem cell transplant followed by 18 months of maintenance carfilzomib
89536849|NCT03312959|Experimental|hyperbaric bupvacaine group|Peribulbar block will be performed using a total volume of 7 ml 6ml hyperbaric bupivacaine 0.5% + hyaluronidase (50 IU) in 1ml saline
89196839|NCT00936130||Lifestyle counseling|This group will be comprised of participants on a low calorie diet program.
89427182|NCT02306382|Experimental|ultrasonography, abscess|The experimental group will be treated after examination with 3D ultrasonography. Follow up after two months and one year.
89427183|NCT02306382|Other|Control group with clincial inscision|The control group will have drainage of their perianal abscess in the OR without ultrasound. Follow-up after two months and one year.
89427184|NCT02302833|Experimental|Treatment (cabozantinib s-malate)|Patients receive cabozantinib s-malate PO QD on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
88908061|NCT06265701|Experimental|Derailment-Focused Reflective Journaling Condition|Participants will be tasked with engaging in a 5-session journaling intervention where participants reflect on core aspects about their (participants') selves within traditional developmental stages (e.g., first semester in college, early childhood, etc.).
88908062|NCT06265701|Placebo Comparator|Everyday Tasks Reflective Journaling Condition|Participants will be tasked with engaging in a 5-session journaling intervention where they (participants) reflect on everyday tasks (e.g., their last trip to the grocery store, the last movie they saw, etc.).
88908063|NCT06264570|Experimental|B-TMG experimental group|Subjects with normal COMT gene and MTHFR gene polymorphism
88908064|NCT06264570|Experimental|B-SAM experimental group|Subjects with COMT gene polymorphism or normal COMT gene and normal MTHFR gene
88908065|NCT06264570|Placebo Comparator|B-TMG placebo group|Subjects with normal COMT gene and MTHFR gene polymorph polymorphism ysm
88908066|NCT06264570|Placebo Comparator|B-SAM placebo group|Subjects with COMT gene polymorphism or normal COMT gene and normal MTHFR gene
88908067|NCT06263465|Experimental|Lactobacillus cispatus|10^9 cfu,5 days
88908068|NCT06263465|Placebo Comparator|Placebo|0 cfu,5 days
88908069|NCT06263153|Experimental|Treatment (futibatinib, durvalumab, radical cystectomy)|Patients receive futibatinib PO QD on days 1-28 and durvalumab IV over 60 minutes on day 1 of each cycle. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo radical cystectomy within 4-12 weeks. Patients also undergo CT and MRI during screening and on the trial and also undergo blood sample collection on the trial.
88908070|NCT06262932|Active Comparator|Repeated amiodarone bolus dosing regimen|An Initial 150 mg IV amiodarone bolus should be given over a 15-minute period. If the heart rate is still over 110 minutes after the initial treatment, provide an additional 150 mg IV amiodarone bolus over a 15-minute period. During the first 24 hours, this bolus may be administered up to three times in total. Within 24 hours of finishing the first bolus dosage, 900 mg of amiodarone will be administered intravenously.
88908071|NCT06262932|Active Comparator|Standard dosing regimen|An Initial 150 mg IV amiodarone bolus should be given over a 15-minute period, then a 24-hour amiodarone loading infusion 900 mg over 24 hours
88908072|NCT06262659||group fistula|"Preoperative age, gender, weight, height, body mass index, diabetes mellitus, hypertension, asthma, smoking status, postoperative chest pain, intraoperative AVF flow, AVF depth, AVF vascular diameter, and postoperative 6th-week Doppler ultrasonography measurements of AVF flow, AVF depth, and AVF vascular diameter will be recorded for the patients included in the study. Maturation assessment will be made based on these results.~AVF flow measurement will be performed intraoperatively and at the 6th week postoperatively using Doppler ultrasonography (B-Mode and duplex ultrasound on the LOQIC; GE Healthcare Technologies, Milwaukee, Wisconsin, United States). For each patient, AVF flows will be recorded by taking at least 3 measurements of AVF flow, depth, and vascular diameters at 2, 5, 10, and 15 cm proximal to the AVF anastomosis, and arithmetic averages will be calculated."
88908073|NCT06261905|Active Comparator|Calcitriol|Subjects with OUD will receive a baseline MRI. On the night before and day of testing, subjects with OUD will receive two doses of calcitriol (3.0mcg total), followed by PHNO injection and PET Scan for the calcitriol condition. All subjects will complete the study with both active calcitriol and a placebo control and the order these interventions are received will be randomized.
88908074|NCT06261905|Placebo Comparator|Placebo|Subjects with OUD will receive a baseline MRI. On the night before and day of testing, subjects with OUD will receive two doses of an inactive placebo, followed by PHNO injection and PET Scan for the placebo condition. All subjects will complete the study with both active calcitriol and a placebo control and the order these interventions are received will be randomized.
89196840|NCT00936130||Weight Loss Surgery|This group will be comprised of participants having weight loss surgery: Roux-en-Y gastric bypass, gastric banding, or sleeve gastrectomy.
89196841|NCT00829959||Genetic Counseling|Women referred to the Clinical Cancer Genetics Program for discussion of Hereditary Breast And Ovarian Syndrome (HBOC).
89196842|NCT00921648||Mr Q, 40 years old|Dementia, sensory aphasia, irritability, hallucination MRI showed cortical lesion, mesial temporal lobe atrophy.
89196843|NCT00921648||Mr Guo,35 years old|Dementia, sensory aphasia, tremor, gait disturbance MRI showed cortical lesion, enlarged ventricle, white matter lesion, cerebral atrophy
89196844|NCT00921648||Mr Zhang,40 years old|Dementia, apraxia of speech, gatism , irritability, insomnia, gait disturbance MRI showed white matter lesion, cerebral atrophy.
89196845|NCT00921648||Mr Liu,40 years old|Dementia, apraxia of speech, irritability, insomnia MRI showed normal.
89196846|NCT00921648||Mr Zhang,54 years old|Dementia, apraxia of speech MRI showed white matter lesion, cerebral atrophy.
89196847|NCT04016727|Experimental|PRP group|patients in which 60 units of prp was injected
89196848|NCT04016727|No Intervention|Control group|patients not given any intervention
89196849|NCT04014244|Experimental|Corticosteroids vs. Dextrose|In the first part of the study examiner will randomize substance for left hand infiltration using a dice (odd number - corticosteroids; even number - 5% glucose). Right hand will be infiltrated with the remaining substance.
89196850|NCT04014244|Experimental|Corticosteroids or Dextrose vs. Surgery|In the second part of the study examiner will randomize treatment procedure for left hand using a dice (odd number - corticosteroids or 5% glucose; even number - surgery). Substance for injection will be determined according to the results of the first part of the study - more effective one, or in case of non-inferiority 5% glucose will be used. Surgical release will be performed by the same plastic surgeon. Both treatments will be performed maximally 2 months after diagnosis, with maximum period between them of 1 week.
89196851|NCT00834015|Other|Experimental|combined strength and aerobic training
89536850|NCT03312959|Active Comparator|isobaric bupvacaine group|Peribulbar block will be performed using a total volume of 7 ml 6ml isorbaric bupivacaine 0.5% + hyaluronidase (50 IU) in 1ml saline
89007951|NCT04609969|Experimental|Comparison between RT-qPCR and COVID-VIRO® results on nasopharyngeal swab specimens|Two concurrent nasopharyngeal swab specimens are collected for each participant. Comparison between RT-qPCR and COVID-VIRO® results of RT-qPCR positive patients is used to assess COVID-VIRO® sensitivity. Conversely, comparison between RT-qPCR and COVID-VIRO® results of RT-qPCR negative patients is used to assess COVID-VIRO® specificity.
89007952|NCT04610125|Experimental|Auto CAR-T|Patients will be treated with Auto CAR-T cells
89007953|NCT04610242|Experimental|Experimental group|Patients undergo diagnostic tests before the initial infusion of rituximab, including skin prick tests, intradermal tests, and challenge tests successively. If the skin test shows a positive result, the patient will receive desensitization procedure, and if the skin test is negative, the challenge test will be done, meaning normal infusion of rituximab according to manufacturer instructions. All the HSRs in the process of desensitization or normal infusion will be recorded. Peripheral blood will be drawn from all the subjects during their infusion to investigate the mechanism of HSRs to rituximab.
89007954|NCT00564148|Experimental|A,1, II|
89007955|NCT04609540||Pyrotinib and Trastuzumab group|Dual anti-HER2 therapy (pyrotinib and trastuzumab) and chemotherapy
89007956|NCT00564187|Active Comparator|1|"Until 6 weeks: 150mg/day, then a dosage adjustment according to the blood pressure(normalized: DBP<90mmHg, responding non normalized:DBP≥90mmHg and a decrease of DBP≥10mmHg, non responding: decrease of DBP<10mmHg and DBP≥90mmHg) for the period between 6 and 12 weeks:~• 150mg/day for normalized patients and patients responding non normalized randomized in the group A"
89007957|NCT00564187|Active Comparator|2|• Or 300 mg/day for non responding patients and responding patients non normalized randomized in the group B
89007958|NCT04609462|Active Comparator|Conventional oxygen therapy (COT) group|Oxygen therapy will be delivered by conventional nasal cannula / prongs, venturi mask, or mask with reservoir, with flows between 3 and 15 liters / minute, to ensure SpO2 ≥ 92%.
89007959|NCT04609462|Experimental|High-flow nasal cannula (HFNC) group|Breathing support with High-Flow oxygen therapy, flow will be initiated between 50 and 60 liters / minute. FiO2 60% to 100% with the objective of reaching SpO2 ≥ 92%. Adequate wetting of the system should be ensured according to the recommendations of the HFNC device manufacturer. FiO2 may be decreased gradually according to the patient's individual condition, trying to maintain SpO2 ≥ 92%.
89007960|NCT04609267|Experimental|Paper Baseline|Half of the participants will complete the PHQ-9 in the traditional paper format at their first appointment. At their second appointment 1-month later, they will complete the PHQ-9 on the Mirror device equipped with Amazon Alexa.
89007961|NCT04609267|Experimental|Mirror Baseline|Half of the participants will complete the PHQ-9 on the Mirror device equipped with Amazon Alexa at their first appointment. At their second appointment 1-month later, they will will complete the PHQ-9 in the traditional paper format.
89007962|NCT04609384||Prior to installation of device|Health care workers who perform the surgical rub prior to installation of the device that should increase the time spend on surgical rub.
89007963|NCT04609384||Post device installation|Health care workers who perform the surgical rub following installation of the device that should increase the time spend on surgical rub.
89007964|NCT04609150||Multiple myeloma patients with vertebral fractures|Patients followed for multiple myeloma in the Lariboisière/Saint-Louis/Fernand-Widal hospital group, with vertebral fractures treated by vertebroplasty from January 2017 to December 2021, with recent clinical and biological data available at the time of imaging and fracture events
89007965|NCT00564343||ChSt, water training, Observation|Subjects suffer from chronic hemiplegia (a year or more post stroke) that upon questioning was judged to meet the following inclusion criteria: (a) able to stand independently 90 seconds; (b) able to walk 10 meters (with cane if necessary); (c) able to understand verbal instructions. The exclusion criteria will be: (a) Serious visual impairment; (b) Inability to ambulate independently (cane acceptable, walker not). (c) Severely impaired cognitive status (score less then 24 in Mini Mental State Examination). (d) Persons with impaired communication capabilities.
89007966|NCT00564382|Other|1|Patients with ACS in the emergency department and primary tests (ECG, TNT) negative for myocardial ischemia
89007967|NCT00564460|Active Comparator|1|Finasteride 5 mg PO once daily for 8 weeks prior to TURP
89007968|NCT00564460|Placebo Comparator|2|Placebo
89427185|NCT02290782|Experimental|Intraoperative radiotherapy (IORT)|"IORT (20Gy) as intervention will be given during breast conserving surgery. If risk factors (Tumor > 3.5 cm, lobular cancer, resection margin < 2 mm*, L1, pN+ mulitfocal/multicentric, EIC, negative hormone receptors) are present, external beam radiotherapy will be added.~* In case of positive margins (<2 mm resection margin) a re-resection should be done"
89007969|NCT04609033|Active Comparator|bupivacaine group|
89007970|NCT04609033|Active Comparator|bupivacaine + morphine|
89007971|NCT04609033|Active Comparator|bupivacaine + morphine + ketamine|
89007972|NCT04609033|Placebo Comparator|isotonic saline|
89007973|NCT00222716|Experimental|Structured|Behavioral Intervention: Structured counseling behavioral intervention focused on problem solving.
89007974|NCT00222716|No Intervention|Usual Care|Control arm
89007975|NCT00222716|Experimental|Inidividualized|Behavioral Intervention: Individualized nurse counseling behavioral intervention focused on problem-solving
89196852|NCT03886974||Adults with type 1 diabetes|People with T1D who are 18 years or older.
89196853|NCT03886974||Parents of adults with type 1 diabetes|Parents who have adult children with type 1 diabetes.
88820571|NCT05972213||Cross-sectional group|"80 patients anticipated.~Patient on biotherapy (omalizumab, mepolizumab, benralizumab, dupilumab) for at least 6 months.~Controlled asthma (ACT > 20 and no exacerbation for 6 months) or uncontrolled asthma (ACT < 20 and/or at least 1 exacerbation for 6 months)."
88908075|NCT06260891|Experimental|Dose 1: Zinc 25 mg/day|25 mg of zinc as zinc gluconate taken orally once a day
88908076|NCT06260891|Experimental|Dose 2: Zinc 40 mg/day|40 mg of zinc as zinc gluconate taken orally once a day
88908077|NCT06260709|Experimental|NNC6019-0001|Participants will receive NNC6019-0001 intravenously every 4 weeks added to the standard of care until Week 140.
89427186|NCT02274116|Active Comparator|Intermittent Hypoxia (AIH)|"Subjects with chronic, motor-incomplete SCI will breath mild bouts of low oxygen.~Intervention: AIH - Intermittent Hypoxia - hypoxia air mixture Dosage: 10% oxygen Frequency: 1.5 minutes bouts of low oxygen with 1.0 minute intervals of room air Duration: 38 minutes"
89427187|NCT02274116|Sham Comparator|Intermittent Room Air (SHAM)|"Subjects with chronic, motor-incomplete SCI will breath mild bouts of room air.~Intervention: SHAM - Intermittent Room Air - room air mixture Dosage: 21% oxygen Frequency: 1.5 minutes bouts of room air with 1.0 minute intervals also of room air Duration: 38 minutes"
89427188|NCT02270476||Early diagnosed (ED)|Children diagnosed with CF in the first 4 months of life.
89427189|NCT02270476||Late diagnosed (LD)|Children diagnosed with CF after the first 4 months of life.
89427190|NCT02205359|Experimental|aCRT ON|The aCRT algorithm has been developed to provide RV-synchronized LV pacing when intrinsic AV conduction is normal or BiV pacing otherwise
89427191|NCT02205359|Active Comparator|aCRT OFF|Standard CRT
89427192|NCT02183883|Experimental|Afatinib|Afatinib, tablet, 40mg, 30mg, 20mg, OD, taken until progression, unacceptable toxicity, intercurrent illness, patient/clinician decision
89427193|NCT02131584|Experimental|Supportive care (ruxolitinib phosphate)|Patients receive ruxolitinib phosphate PO BID (approximately 12 hours apart) for up to 2 years in the absence of disease progression or unacceptable toxicity.
89427194|NCT02116140|Experimental|[C11]Acetate HED PET|"AMEND is a single centre substudy of the ADVENT-HF trial. This substudy is a clinical physiologic proposal designed to determine the effects of long-term (6 months) ASV on cardiac energetics and SN function in patients with chronic stable HF and sleep apnea extending our previous evaluation of short-term CPAP in patients with OSA and HF.~All subjects consenting to the ADVENT primary trial will be eligible to participate in the substudy.~Substudy consenting patients will have [11C]acetate and [11C]HED PET imaging; HR variability; plasma norepinephrine (NE) levels, urine normetanephrine levels within 2 weeks of the sleep study. Baseline measurements will be repeated after 6 months in all patients."
89427195|NCT02088645|Experimental|Phase 0: One arm; Phase I: One arm|"Phase 0: 6 patients, intravenous application of 2 x 1 gigabequerel (GBq) 177Lu-PP-F11N with and without Physiogel (crossover)~Phase I: expected 12 - 18 patients, intravenous application of max. 6 x 7-8 GBq 177Lu-PP-F11N (increasing number of applications by one in groups of three patients). All patients with or without Physiogel, depending on the results of the phase 0 study."
88908082|NCT06259825|Placebo Comparator|Control Chicken-meat and Control Eggs|Consumption of at least 4 portions of standard chicken-meat and at least 4 standard eggs per week, for 4 months.
89427196|NCT02064309|Experimental|Human islets in Beta-Air device|
89427197|NCT02062346|Placebo Comparator|Placebo|Saline placebo
88908083|NCT06259825|Experimental|Omega-3 Chicken-meat and Omega-3 Eggs|Consumption of at least 4 portions of omega-3-PUFA enriched chicken-meat and at least 4 omega-3-PUFA enriched eggs per week, for 4 months.
89427198|NCT02062346|Experimental|BQ123|Intravenous infusion of BQ123 1000nmol/min for 15min
88908084|NCT06259682|Other|Intervention arm|Only one arm, all participants are given the treatment
88908085|NCT06259422|Other|Iohexol in addition to 125I-iothalamate and 131I-hippuran|In this clinical trial, patients receiving 125I-iothalamate and 131I-hippuran during routine clinical care, will also receive iohexol. This allows us to determine the mGFR using both methods in the same patient, and compare both methods in terms of accuracy and precision.
88908086|NCT06257277||Patients require GBCA-enhanced MRI|Patients who are scheduled to undergo magnetic resonance imaging (MRI) with gadolinium-based contrast agent (GBCA) enhancement as per routine clinical practice.
88908087|NCT06256848|Experimental|rehabilitation treatment+ Myofascial Release group|Study lasts 21 days for each patient. All patients are given rehabilitation treatment.The experimental group was given the Myofascial Release Therapy, five days a week, once a day, for 30-60 minutes each time.
88908088|NCT06256848|Active Comparator|rehabilitation treatment group|Study lasts 21 days for each patient. All patients are given rehabilitation treatment, five days a week, once a day, for 30-60 minutes each time.
88908089|NCT06253572|Experimental|1|Education
88908090|NCT06253364||Liver resection group|No adjuvant therapy after hepatectomy.
88908091|NCT06253364||Adjuvant PD-1 group|Adjuvant therapy with PD-1 monoclonal antibody after hepatectomy
88908092|NCT06253364||Adjuvant PD-1 plus Lenvatinib group|Adjuvant therapy with PD-1 monoclonal antibody combined with lenvatinib after hepatectomy.
89427199|NCT02062346|Experimental|BQ123/788|Intravenous infusion of BQ123 1000nmol/min and BQ788 300nmol/min
88908093|NCT06252883|Experimental|GROUP A (intervention group)|"Parents in this group will receive bedside video call 2-3 days a week in addition to the routine NICU phone update and/or bedside update using the NICU iPad w/ Doximity app."
88908094|NCT06252883|No Intervention|Group B (control group)|Parents in this group will receive the routine phone and/or bedside updates done in our NICU already without the intervention (serial video calls).
88908095|NCT06249906|Active Comparator|Commercial bone implant product Group|Bone repair products in the market such as artificial bones and allogeneic bones.
88908096|NCT06249906|Experimental|Mirco-structured Bioceramic Group|β-Tricalcium phosphate (β-TCP) is a material with excellent biocompatibility and osteoinduction and bone guidance properties, which can provide mechanical strength equal to or better than that of human cancellous bone.
88908097|NCT06249087|Experimental|the observation group|"Assigned randomly before the treatment, all patients were provided with comprehensive rehabilitation therapy as follows:~Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training.~The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure. The feeding content was formulated by the nutritionists based on the condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups"
88908098|NCT06249087|Active Comparator|the control group|"Assigned randomly before the treatment, all patients were provided with comprehensive rehabilitation therapy as follows:~Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training.~Besides, the control group was given enteral nutritional support with Nasogastric Tube according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements."
88908099|NCT06248892|Experimental|The observation group|"Assigned by the random number table. During the treatment, all patients were provided with comprehensive rehabilitation therapy.~Besides, the observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube Feeding according to the relevant guidelines."
88908100|NCT06248892|Active Comparator|The control group|"Assigned by the random number table. During the treatment, all patients were provided with comprehensive rehabilitation therapy.~Besides, the control group was given enteral nutritional support with nasogastric tube according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation."
88908101|NCT06246227||High Risk Melanoma Patients|Patients followed-up for Melanoma, Clinical Stages IIB - III and Resected Stage IV
89427200|NCT02062346|No Intervention|Assessment of forearm vascular function|Response of forearm blood flow to endothelium-dependent and endothelium-independent vasodilators
89427201|NCT02047084||Theraskin, Apligraf|Theraskin used every other week x 4 Apligraf used weekly x 8
89427202|NCT02047084||Venous leg ulcers|Theraskin and Apligraft
89427203|NCT02004834|Active Comparator|0,5% levobupivacaine with 2% lidocaine|7,0 ml.of mixture 0,5% levobupivacaine with 2% lidocaine are given per level Th2,Th3,Th4 for ultrasound guided paravertebral blocks in breast surgery
89427204|NCT02004834|Active Comparator|0,5% levobupivacine|7,0 ml. 0,5% levobupivacaine are given per level Th2,Th3,Th4, given for ultrasound guided paravertebral blocks in breast surgery
88908102|NCT06242691|Experimental|Part 1: MK-1200|In Part 1, participants will receive escalating doses of MK-1200 via intravenous (IV) infusion every 2 weeks (Q2W) until any discontinuation criteria are met.
89427205|NCT01979536|Experimental|Arm BV (brentuximab vedotin, combination chemotherapy)|"COURSE A (CYCLES 1, 3, AND 5): Patients receive brentuximab vedotin IV over 30 minutes on day 1, dexamethasone PO BID or IV on days 1-5, ifosfamide IV over 60 minutes on days 1-5, methotrexate IV over 3 hours on day 1, cytarabine IV over 1-30 minutes every 12 hours for 4 doses on days 4 and 5, and etoposide IV over 2 hours on days 4 and 5.~COURSE B (CYCLES 2, 4, AND 6): Patients receive brentuximab vedotin, dexamethasone, and methotrexate as in Arm BV, Course A. Patients also receive cyclophosphamide IV over 15-30 minutes on days 1-5 and doxorubicin hydrochloride IV over 1-15 minutes on days 4 and 5."
89427206|NCT01979536|Experimental|Arm CZ (crizotinib, combination chemotherapy)|"COURSE A (CYCLES 1, 3, AND 5): Patients receive crizotinib PO BID on days 1-21 and dexamethasone, ifosfamide, methotrexate, cytarabine, and etoposide as in Arm BV, Course A.~COURSE B (CYCLES 2, 4, AND 6): Patients receive crizotinib PO BID as in Arm CZ, Course A and dexamethasone, cyclophosphamide, methotrexate, and doxorubicin hydrochloride as in Arm BV, Course B."
89427207|NCT01880723|Experimental|Albuterol|2.5 mg diluted in 3mL normal saline nebulized using a Power Neb2 nebulizer
89427208|NCT01880723|Placebo Comparator|Saline (healthy only)|nebulized 3 ml normal saline using a Power Neb2 nebulizer
88908103|NCT06242691|Experimental|Part 2: MK-1200 Cohort A|In Part 2, participants in Cohort A will receive either Dose 1 or Dose 2 of MK-1200 via IV infusion Q2W until any discontinuation criteria are met.
88908104|NCT06242691|Experimental|Part 2: MK-1200 Cohort B|In Part 2, participants in Cohort B will receive Dose 1 of MK-1200 via IV infusion Q2W until any discontinuation criteria are met.
88908105|NCT06242587|Active Comparator|Group Pericoccygeal block|Patients undergoing pericoccygeal block
88908106|NCT06242587|Active Comparator|Group Impar ganglion block|Patients undergoing impar ganglion block
88908107|NCT06241534|Experimental|Recordings Group|Cardiac rehabilitation supplemented by relaxation-therapeutic recordings
88908108|NCT06241534|Experimental|VR Group|Cardiac rehabilitation supplemented by VR therapy
88908109|NCT06241534|Active Comparator|Control Group|Cardiac rehabilitation supplemented by Schultz Autogenic Training
88908110|NCT06241014|Experimental|Group A: Group A will be treated with mulligan mobilizations and Sling exercises.|Group A: In this group, Subjects will be treated with Mulligan mobilizations along with sling exercises. Mulligan mobilizations include SNAGs. Participants will receive 3 sets of mulligan mobilization techniques per session, each set involving 10 times repetition of the exercise. The interval between the sets will be 15 to 20 seconds. The technique will be repeated total of six times, having two sessions per week for 3 weeks. The sling exercise program will also be applied for 3 weeks, 2 times a week for 20 minutes per day.
88908111|NCT06241014|Active Comparator|Group B: Group B will be treated with mulligan mobilizations alone.|Group B: In this group, Subjects will be treated with Mulligan mobilizations and sling exercises. Mulligan mobilizations include SNAGs. Participants will receive 3 sets of mulligan mobilization techniques per session, each set involving 10 times repetition of the exercise. The interval between the sets will be 15 to 20 seconds. The technique will be repeated a total of six times, having two sessions per week for 3 weeks.
88908112|NCT06240117|Experimental|Standard of care with intraoperative cell salvage|Participants for elective surgery with anemia randomized to standard of care with intraoperative cell salvage.
88908113|NCT06240117|No Intervention|Standard of care without intraoperative cell salvage|Standard of care for cesarean sections as per the policy of the anesthesiology department.
88908114|NCT06239766||Non-Cisgender Adults Considering Chest Masculinization Surgery|Persons assigned female or intersex at birth who identify as TGD and are considering gender-affirming chest masculinization surgery.
88908115|NCT06239558||South Asian Service Users|Service users who identify themselves as South Asian will be invited to participant in a semi-structured interview and/or a focus group. The interview will be used to identify lived experiences of the barriers and enablers to cardiac rehabilitation, relating to uptake, adherence or completion. The focus group will be used to collaboratively generate adaptations to CR services which could be implemented to overcome the barriers, and enhance the enablers, identified during the interviews.
89427209|NCT01824836|Experimental|Supportive care (anastrozole)|Patients receive anastrozole PO QD for 12 months.
89427210|NCT01798992|No Intervention|Non-failing control|Patients with normal ejection fraction who underwent a single myocardial biopsy and received no β-blocker therapy
89427211|NCT01798992|Active Comparator|Metoprolol succinate|Idiopathic dilated cardiomyopathy patients randomized to metoprolol succinate titrated to a goal of 200 mg by mouth daily for 18 months
89427212|NCT01798992|Active Comparator|Metoprolol succinate + doxazosin|Idiopathic dilated cardiomyopathy patients who were randomized to receive metoprolol succinate and doxazosin titrated to a goal of 200 mg and 8 mg by mouth daily for 18 months
89427213|NCT01798992|Active Comparator|Carvedilol|Idiopathic dilated cardiomyopathy patients who were randomized to receive carvedilol titrated to a goal of 25 mg by mouth twice daily for 18 months
89427214|NCT01746836|Experimental|Ponatinib hydrochloride|Patients receive ponatinib hydrochloride PO QD. Treatment continues for up to 5 years in the absence of disease progression or unacceptable toxicity.
89427215|NCT01697930|Experimental|[18F] 4-L-Fluoroglutamine (2S,4R)|This pilot, first in-human microdose PET trial of the positron-emitting agent [18F] 4-L-Fluoroglutamine (2S,4R) will be an open-label study. The [18F] 4-L-Fluoroglutamine (2S,4R) agent will be administered by bolus intravenous injection. In all study patients, the pharmacokinetics, metabolism, and biodistribution of [18F] 4-L-Fluoroglutamine (2S,4R) will be evaluated by non-invasive blood- and PET-based assays, at multiple time points (see Table 1,) during one day. Eligible patients optionally can participate in the study twice, on a separate date, receiving a second radiotracer microdose of [18F] 4-L-Fluoroglutamine (2S,4R), followed by non-invasive blood- and PET-based assays. At the discretion of the investigator, scan 3 can be waived.
89427216|NCT01662453||SUDEP Group|The SUDEP group refers to epileptic patients that had a sudden unexplained death; excludes trauma, drowning, status epilepticus, or other known cause, but there is often evidence of an associated seizure.
89427217|NCT01662453||Control Group|We will recruit living patients with epilepsy for the control group. In particular, epileptic patients with Dravet Syndrome of Idic 15.
89427218|NCT01619917|Active Comparator|Proximal|location of the scar proximal to heart
89427219|NCT01619917|Experimental|Distal|location of scar distal to heart
88908116|NCT06239558||Cardiac Rehabilitation Healthcare Professionals|The rehabilitation healthcare professionals will be invited to participant in a semi-structured interview and/or a focus group. The interviews will be used to explore their the perceptions of barriers and enablers and knowledge around the cultural requirements of South Asian service users.
88908117|NCT06239558||Key stakeholders|Key stakeholders relating to cardiac rehabilitation, University Hospitals of Leicester (UHL) NHS Trust, and/or South Asian communities will be invited to participate in the focus group, helping to generate adaptations to CR services.
88908118|NCT06239389|Active Comparator|hydroxyurea|Hydroxyurea is available in oral dosage form which is capsule. frequency: once a day duration: at every 24 hours dose: 15/mg/kg/day.
88908119|NCT06239389|Experimental|Thalidomide|Thalidomide is available in oral dosage form which is capsule. frequency: once a day at night duration: at every 24 hours dose:50 mg / day (in patients >10-13 years) while the adult dose was 100 mg /day (age >13 Years)
88908120|NCT06238440|Other|Control|In the control group (CG), a conventional physiotherapy program will be implemented for 2 weeks. A 10-session treatment will be completed using thermal and electrical agents specified in the program prescribed by the physiotherapist.
88908121|NCT06238440|Experimental|Splint|In the Splint (SP) group, in addition to the 10-session conventional physiotherapy program, individuals will be instructed to use the splint prescribed by the physician for 2 weeks.
88908122|NCT06238440|Experimental|Rigid taping|In the Rigid taping (RB) group, along with the 10-session conventional physiotherapy program, a rigid strapping application will be performed by an experienced researcher at the end of each physiotherapy session, five days a week.
88908123|NCT06238440|Experimental|Kinesiotape|In the Kinesiotape (KT) group, in addition to the 10-session conventional physiotherapy program, kinesiotape application will be carried out by a certified researcher. To ensure homogeneity, individuals in both strapping groups will be asked to remove the tape before coming to treatment and reapply it at the end of the session.
88908124|NCT06237855|No Intervention|Standard of Care|Drain removal will occur during clinic visit by provider per standard of care procedure.
88908125|NCT06237855|Experimental|Self-drain removal training|"Subjects will remove drain at home Training will consist of a detailed online video of a provider instructing how to remove the drain and practicing on a model created specifically to mimic the following actions during drain self-removal:~Tension required to remove the drain~Placing and taping gauze after suture and drain removal"
88908126|NCT06237829|Experimental|Identifying and synthesizing high-contrast tactile materials without physical features|Beyond the few materials investigators previously identified, it is unknown which materials are useful for creating tactile sensations. Common material properties such as a friction coefficient or hydrophilicity are insufficiently detailed to accurately predict friction forces-the basis of tactile stimuli. The investigators will use expertise in connecting tactile sensations with chemical structure through mechanical testing, theory, and human testing. The investigators' goal is to identify materials that lead to high tactile contrast without relying on physical features. (Tactile contrast is defined by the investigators as large differences in friction which are easily distinguishable by humans during free tactile exploration.)
88908127|NCT06237829|Experimental|Building tactile aids with designer materials for plots, games, and object labeling|Investigators will build static tactile aids with designer materials, i.e., silanes and polymers coatings. These aids will be a mathematical plot, a board game, and simulated money. Investigators will compare the speed, accuracy, and amount of information of hybrid tactile aids made from designer materials and physical features to traditional tactile aids made only with bumps.
89196854|NCT03886974||Healthcare providers managing patients with type 1 diabetes|Licensed healthcare providers who are managing patients with T1D (whether in adult or pediatric practice).
89196855|NCT02548611|Experimental|Prasugrel|single-dose loading with 60 mg of prasugrel pre PCI
89196856|NCT02548611|Active Comparator|Clopidogrel|loading with 600 mg of clopidogrel pre PCI
89427220|NCT01570868|Experimental|Ponatinib 45 mg|Ponatinib at a dose of 45 mg orally, once daily. If a dose is missed or vomited, the next dose should not be increased to account for missing a dose. Total duration of therapy 3 to 5 years.
89427221|NCT01570868|Experimental|Ponatinib 30 mg|Ponatinib at a dose of 30 mg orally, once daily. If a dose is missed or vomited, the next dose should not be increased to account for missing a dose. Total duration of therapy 3 to 5 years.
89427222|NCT01550536|Experimental|Training|Sedentary women who exercised <2 hours per week and who had never engaged in a regular exercise program were enrolled in an exercise training intervention, following baseline measurements. See intervention below.
89427223|NCT01550536|No Intervention|Active|Postmenopausal women who exercised >5 hours per week and had been doing so for at least the past 10 years. These women were asked to maintain their normal activity habits for the duration of the study.
88908128|NCT06237829|Experimental|Optimal design of bumps and designer materials in tactile aids|Reflecting the lack of standardized methods or benchmarks for tactile technologies, the known limits of tactile sensitivity was narrowed from millimeters, microns, to nanometers within the last 10 years by use of metal wires, wrinkled plastics, and silanes, respectively. Investigators will determine the optimal design of traditional bumps which yields the highest tactile stimulus in the smallest area. Investigators expect to find that current bumps are larger than necessary, and that the same information could be placed into a smaller area (higher information density). Then, investigators will augment bumps with designer materials to increase the tactile stimulus from a bump, thereby permitting even smaller bumps to increase information density. Beyond optimal design methods, the investigators' quantitative methods, enabled by making the mechanical stimulus the dependent variable, also serve as benchmarks between tactile aids.
88908129|NCT06234488||Transgender and Gender-Diverse Persons with Breast Cancer|Patients who had a breast cancer diagnosis (including those with ductal carcinoma in situ (DCIS)), who were age ≥18 years at the time of diagnosis and identify as a gender and/or sex that is different from their sex assigned at birth (e.g., transgender, nonbinary, genderqueer, etc.) between 1/1/1990 - 7/1/2023.
88908130|NCT06233071|Experimental|Sequence 1-Drospirenone+ Ethinyl Estradiol test product and then reference product|Participants will receive treatment 1 in period 1 and treatment 2 in period 2. Where treatment 1= Drospirenone (3 mg) + Ethinyl Estradiol (0.02 mg) test product, treatment 2= Drospirenone (3 mg) + Ethinyl Estradiol (0.02 mg) reference product.
88908131|NCT06233071|Experimental|Sequence 2-Drospirenone+ Ethinyl Estradiol reference product and then test product|Participants will receive treatment 2 in period 1 and treatment 1 in period 2. Where treatment 1= Drospirenone (3 mg) + Ethinyl Estradiol (0.02 mg) test product, treatment 2= Drospirenone (3 mg) + Ethinyl Estradiol (0.02 mg) reference product.
88908132|NCT06230692|Experimental|Inspiratory Muscle Training (IMT)|Participants will be asked to perform inspiratory muscle training (breathing exercise) 5 days per week for 6 weeks at home.
88908133|NCT06230666|Experimental|Single-isocenter SBRT|SBRT using a single-isocenter treatment plan
88908134|NCT06230666|Active Comparator|Multiple-isocenter SBRT|SBRT using multiple treatment plans
88908135|NCT06229392|Experimental|Intratumoral influenza vaccine|
88908136|NCT06226688|Experimental|Affected arm at the same side of mastectomy|There is 2 arms Arm1:-arm at side of mastectomy without lymphedema trained by biofeedback
88908137|NCT06226688|Experimental|2 arms one trained by biofeedback and other control without biofeedback|Arm2:-arm at side of mastectomy on other group but not trained with biofeedback Training using shoulder ladder ,shoulder wheel ,shoulder mobilization and IPC
88908138|NCT06224049|Experimental|hNeo-T|The escalating doses of hNeo-T in this study will be 5*10^7 cells and1*10^8 cells.
88908139|NCT06223503|Experimental|Telehealth Transitional Pain Service + Standard Postoperative Follow-Up Care|Telehealth Transitional Pain Service + Standard Postoperative Follow-Up Care
88908140|NCT06223503|Active Comparator|Standard Follow Up Care|Standard Follow Up Care
88908141|NCT06219980|Experimental|treatment group|
88908142|NCT06219577|Other|Systane Complete Multi-Dose PF|
88908143|NCT06219577|Other|Walgreen's Lubricant Balance|
88908144|NCT06216704||Cystic Fibrosis|"This group will be 36 adolescents, ages 13-20 years old, who have been diagnosed with cystic fibrosis.~All participants will have a two study visits approximately one year apart during which the listed diagnostic testing will be performed."
88908145|NCT06216704||Control|"Controls will be matched for age, Tanner staging, BMI percentile, and ancestry.~All participants will have a two study visits approximately one year apart during which the listed diagnostic testing will be performed."
88908146|NCT06215261|Experimental|Methylone|
88908147|NCT06215261|Placebo Comparator|Placebo|
88908148|NCT06211075|Experimental|Intervention Group|The intervention will be delivered remotely via zoom or google meets, guided by Overcome coaches. Coaches are trained over two days via training slides, role plays and feedback. The intervention includes CBT-I and Motivational Interviewing.
88908149|NCT06211075|No Intervention|Waitlist Control Group (WLC/WLCG)|Participants will receive the same benefits from the intervention after the end of the main study or after the last participant in the experimental group is interviewed at the post-intervention interview.
88908150|NCT06207513|Experimental|Intervention I group|Patient intubated with an endotracheal tube and on a mechanical ventilator will receive endotracheal suctioning procedure using a single-used open endotracheal suction catheter that is used only for one-time suctioning attempt and discarded after each endotracheal suction cycle. A new catheter will be used for each endotracheal suctioning procedure.
89196857|NCT00743886|Placebo Comparator|2|saline
89196858|NCT00743886|Experimental|1|Plasma Rich in Growth Factors (PRGF)
89427224|NCT01415752|Experimental|Arm A|Patients receive induction therapy comprising rituximab IV on day 1 and bendamustine hydrochloride IV over 60 minutes on days 1-2. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then proceed to arm E.
89427225|NCT01415752|Experimental|Arm B|Patients receive induction therapy comprising bortezomib IV subcutaneously (SC) on days 1, 4, 8, and 11 and rituximab and bendamustine hydrochloride as patients in arm A. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then proceed to arm F.
89427226|NCT01415752|Experimental|Arm C|Patients receive induction therapy comprising rituximab and bendamustine hydrochloride as patients in arm A. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then proceed to arm G.
89427227|NCT01415752|Experimental|Arm D|Patients receive bortezomib, rituximab, and bendamustine hydrochloride as patients in arm B. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then proceed to arm H.
89427228|NCT01415752|Experimental|Arm E|Patients receive consolidation therapy comprising rituximab IV on day 1. Courses repeat every 8 weeks for 2 years in the absence of disease progression or unacceptable toxicity.
88908151|NCT06207513|Experimental|Intervention II group|Patient intubated with an endotracheal tube and on a mechanical ventilator will receive endotracheal suctioning procedure using an open endotracheal suction catheter that is used multiple times during a 12-hour nursing shift. Flushing of the suctioning circuit will be performed with 40 ml of chlorhexidine gluconate 0.2% after every endotracheal suction procedure
89427229|NCT01415752|Experimental|Arm F|Patients receive consolidation therapy comprising rituximab IV on day 1. Courses repeat every 8 weeks for 2 years in the absence of disease progression or unacceptable toxicity.
89427230|NCT01415752|Experimental|Arm G|Patients receive consolidation therapy comprising lenalidomide orally (PO) daily on days 1-21 every 4 weeks and rituximab IV every 8 weeks for 2 years in the absence of disease progression or unacceptable toxicity.
89427231|NCT01415752|Experimental|Arm H|Patients receive consolidation therapy comprising lenalidomide PO daily on days 1-21 every 4 weeks and rituximab IV every 8 weeks for 2 years in the absence of disease progression or unacceptable toxicity.
88908152|NCT06207513|Other|Control group|Patients intubated with an endotracheal tube and on a mechanical ventilator will receive standard care. This is the endotracheal suctioning procedure using an open endotracheal suction catheter that is used multiple times during a 12-hour nursing shift. Flushing of the suctioning circuit is standardised performed using normal saline after every endotracheal suction procedure.
88908153|NCT06207344|Active Comparator|Dexmedetomidine and propofol|After anesthesia induction, dexmedetomidine was infused intravenously at 1 μg/kg within 15 min, then infused at 0.3 μg/kg/h until 30 min before the end of the operation. Propofol was infused intravenously at 4-12mg/kg/h to maintain the depth of anesthesia (patient state index between 25-50 monitored by Masimo SedLine).
88908154|NCT06207344|Experimental|Dexmedetomidine and desflurane|After anesthesia induction, dexmedetomidine was infused intravenously at 1 μg/kg within 15 min, and then infused at 0.3 μg/kg/h until 30 min before the end of the operation. At the same time, 2.5%-8.5% desflurane was used to maintain the depth of anesthesia (patient state index between 25-50 monitored by Masimo SedLine).
89427232|NCT01415648|Experimental|open NIRS|continuous per operative cerebral oximetry monitoring (using INVOS™ cerebral oximeter) associated with hemodynamic optimisation algorithm (excluding norepinephrine) if cerebral oximetry decrease more than 15% under the preoperative baseline
89427233|NCT01415648|Sham Comparator|Blinded NIRS|Continuously monitored with cerebral oximeter but this latter is blinded to the medical team, the alarm switch off , and patients are managed with the standard care of the centre
89427234|NCT01391962|Experimental|Part I|Patients will be randomized to receive cediranib (30 mg) or sunitinib malate (37.5 mg) orally, once a day in 28-day cycles
89427235|NCT01391962|Experimental|Part II|At the time of disease progression, patients will cross over to the other treatment arm after a 2-week wash-out period
89427236|NCT01288560|Active Comparator|Advanced cardiac imaging (PET/CT or CMR)|Patients will undergo cardiac imaging as evaluation of heart failure using 1 of the following alternate/advanced imaging modalities: Positron Emission Tomography (PET/CT), Cardiac Magnetic Resonance (CMR)
88908155|NCT06207331|Experimental|Dexmedetomidine 0.5 μg/kg|Participants inhale 0.5 μg/kg dexmedetomidine prepared in 2 ml 0.9% saline.
88908156|NCT06207331|Experimental|Dexmedetomidine 1 μg/kg|Participants inhale 1 μg/kg dexmedetomidine prepared in 2 ml 0.9% saline.
88908157|NCT06207331|Placebo Comparator|Placebo|Participants inhale 2 ml atomized 0.9% saline.
88908158|NCT06207149|Experimental|Intervention|Participants will attend an advocacy program.
88908159|NCT06207149|Active Comparator|Waitlist-Control Group|Participants will receive the written materials of the advocacy program. After completing the intervention group completes the advocacy program, the waitlist-control group participants will be able to participate in the advocacy program.
89427237|NCT01288560|Active Comparator|Standard cardiac imaging (SPECT)|Patients will undergo standard cardiac imaging procedures for evaluation of heart failure such as single photon emission computed tomography (SPECT).
89427238|NCT01251965|Experimental|Ruxolitinib 50 mg BID|Phase I - Starting dose of Ruxolitinib 50 mg by mouth twice a day for 28 day cycle.
89427239|NCT01251965|Experimental|Ruxolitinib 100 mg BID|Phase I dose of Ruxolitinib 100 mg by mouth twice a day for 28 day cycle.
89427240|NCT01251965|Experimental|Ruxolitinib 200 mg BID|Phase I dose of Ruxolitinib 200 mg by mouth twice a day for 28 day cycle.
89427241|NCT01239693|Active Comparator|IFA group|Women during pregnancy: 1 tablet of iron+ folate daily until delivery (60 mg iron + 400 ug folic acid) Women during lactation (from delivery to 6 months post-partum): 1 daily tablet of calcium (200 mg), akin to placebo Children from 6 to 18 months of age: None
89427242|NCT01239693|Active Comparator|MMN group|Women during pregnancy: 1 tablet of multiple micronutrients daily until delivery Women during lactation (from delivery to 6 months post-partum): 1 daily tablet of multiple micronutrients' Children from 6 to 18 months of age: None
89427243|NCT01239693|Experimental|LNS group|Women during pregnancy: 1 sachet of LNS-P&L (20 g of LNS) daily until delivery Women during lactation (from delivery to 6 months post-partum): 1 daily sachet of LNS-P&L (20 g of LNS) Children from 6 to 18 months of age: 2 daily sachet of LNS-20gM (20 g of LNS)
89427244|NCT01224886|Experimental|Sedentary obese|
89427245|NCT01224886|Experimental|Sedentary normal weight|
88908160|NCT06205381|Experimental|AV078|"In part A, a single ascending doses of AV078 oral solution will be investigated in separate cohorts. The starting dose will be 0.5 mg and ascending doses will be determined based on data from previous cohorts.~In Part B, multiple ascending doses of AV078 oral solution will be administered once daily for 14 days. Dose levels will be determined based on data from the single ascending dose study and previous cohorts in the multiple ascending dose study.~In Part C the effect of food (fasting or high calorie) on the pharmacokinetics of a single dose of AV078 will be investigated. The dose will be determined from Part A of the study."
88908161|NCT06205381|Placebo Comparator|Placebo|"In Part A, placebo oral solution (containing no active ingredient) will be administered once.~In Part B, placebo oral solution (containing no active ingredient) will be administered once daily for 14 days."
88908162|NCT06205381|Other|Itraconazole|In Part D, 200 mg itraconazole will be administered as an oral capsule once daily for 9 days, to investigate the effect of itraconazole on the pharmacokinetics of AV078.
89007976|NCT04608565|Other|Remote biomonitoring sensor device|250 readings for a power of 80% and to detect a 5% difference in measurements with 95% confidence interval from mothers and newborns was ascertained. Once 3 probes were strapped (radiant warmer, RBM device and multichannel), a waiting period of 10 minutes for temperature stabilization was given. First RBM device & multichannel probe provided readings continuously (every few seconds); Then radiant warmer probe and manual thermometer readings were taken every 15 minutes for 5 timings: 0, 15, 30, 45 and 60 minutes. Participant safety for newborns was ensured following routine appropriate care protocols.
89007977|NCT00222755|Experimental|1|Behavioral Care Management
89007978|NCT00222755|No Intervention|2|Usual Care
89007979|NCT04608760|Active Comparator|Meksibel|Intravenous 0.1 30 minutes before the procedure and 0.1 once a day for 3 days after the procedure
89007980|NCT04608760|Active Comparator|Indometacin|Into the rectum 1 hour before the procedure and 1 candle 1 time a day for 3 days after the procedure
89007981|NCT04608760|Active Comparator|Meloksicam|Intravenous 15 mg 30 minutes before the procedure and 15 mg once a day for 3 days after the procedure
89007982|NCT04608760|Active Comparator|Oktride|Intravenous 3 ml 30 minutes before the procedure and 3 ml once a day for 3 days after the procedure
89007983|NCT04608370|Experimental|Active tPBM session group|Participants in the active tPBM group will take active tPBM session, which include 12 minutes active tPBM by a 1064nm laser to the left forehead , 6 minutes resting-state fNIRS measurement, and 8 minutes digital n-back task-an ubiquitous cognitive task for working memory.
89007984|NCT04608370|Active Comparator|Sham tPBM session group|Participants in the sham tPBM group will take sham tPBM session, which include 12 minutes sham tPBM by a 1064nm laser to the left forehead , 6 minutes resting-state fNIRS measurement, and 8 minutes digital n-back task-an ubiquitous cognitive task for working memory.
89427246|NCT01224886|No Intervention|Athletes|
89427247|NCT01223248|Experimental|stereotactic IGIMRT using a single dose of 24 Gy|This is a phase III, multicenter, randomized, study comparing two dosing schedules for hypofractionated image-guided radiation therapy to bone, spine, soft tissue, and lymph nodes in patients with metastatic disease
89427248|NCT01223248|Experimental|stereotactic IGIMRT 27 Gy in 3 fractions|This is a phase III, multicenter, randomized, study comparing two dosing schedules for hypofractionated image-guided radiation therapy to bone, spine, soft tissue, and lymph nodes in patients with metastatic disease
89427249|NCT01190644|Experimental|Sotatercept|Participants will receive a single 35 mg dose of sotatercept by subcutaneous (SC) injection on Day 1, Day 43, and Day 85.
89427250|NCT01187485|Experimental|Androderm® 2.5mg|Study subjects will be randomized to one of the study arms: 2.5 mg of Androderm®.
89427251|NCT01187485|Experimental|Androderm® 5.0 mg|Study subjects will be randomized to one of the study arms: 5.0 mg of Androderm®.
89007985|NCT04608526||Group 1|Patients without deep dentin caries / apical rarefying osteitis
89007986|NCT04608526||Group 2|Patients with deep dentin caries / apical rarefying osteitis on the right or left sides
89007987|NCT04608526||Group 3|Patients with deep dentin caries / apical rarefying osteitis on either the right and left side
89007988|NCT04608253||All enrolled subjects received an 11C-choline PET/CT prior to enrollment.|Patients with biochemically proven primary hyperparathyroidism who underwent parathyroid surgery after localization by means of 11C-choline PET/CT and negative or discordant first-line imaging
89427252|NCT01187485|Experimental|Androderm® 7.5mg|Study subjects will be randomized to one of the study arms: 7.5 mg of Androderm®.
89427253|NCT01187472||Treated subjects|Subjects treated on a previous study of locally advanced head and neck cancer
89427254|NCT01185158|Experimental|ZD1839 (IRESSA) 250mg|ZD1839(IRESSA) 250mg orally (po) daily
89427255|NCT01177761|Active Comparator|exercise|endurance,balance, power, resistance type exercise
89427256|NCT01177761|No Intervention|sedentary control|Subjects were instructed to do not relevantly change their lifestyle
89427257|NCT01085864||Patients with lung nodules on CT scan.|Patients with lung nodules on CT scan.
89427258|NCT01085617|Active Comparator|B1 - Standard therapy|Standard chemotherapy for precursor B-cell ALL
89427259|NCT01085617|Experimental|B2 - Rituximab|Standard chemotherapy for precursor B-cell ALL plus weekly rituximab infusions during phase 1 induction
89427260|NCT01085617|Active Comparator|T1 - Standard therapy|Standard chemotherapy for T-cell ALL
89427261|NCT01085617|Experimental|T2 - Nelarabine|Standard chemotherapy for T-cell ALL plus an additional course of treatment with nelarabine following phase 2 induction
89427262|NCT01085617|Active Comparator|P1 - standard palifermin|6 doses of palifermin before/after myeloablative stem cell transplant (randomisation closed due to lack of clinical relevance in 2016)
89007989|NCT04608175|Experimental|Acupuncture group|"The experimental group will receive the standard treatment administered in these cases (analgesic regimen and nursing care procedures), in addition to the following acupuncture therapy.~In the first visit (preoperative), the anamnesis and energy diagnosis of each patient will be carried out following the practices of Traditional Chinese Medicine (TCM) to design a personalized treatment based on the patient's medical history. A treatment of approximately 10 to 12 acupuncture points will be designed considering the TCM diagnosis and medical history of each patient. Both TCM diagnosis and the points used will be reassessed in each session. The points belonging to the upper extremity of the affected breast will be treated on the contralateral side, taking care not to insert any needle in the limb on the affected side. No points in the operated region will be used."
89427263|NCT01085617|Experimental|P2 - collapsed palifermin|1 x large dose of palifermin before myeloablative stem cell transplant and 3 low doses after transplant (randomisation closed due to lack of clinical relevance in 2016)
89007990|NCT04608175|No Intervention|Control group|The control group will only receive standard care procedures (analgesic regimen and nursing care procedures), although they will have the same follow up visits as the patients in the intervention group to facilitate analysis of the study variables.
89007991|NCT04608097|Experimental|Simple cognitive task intervention|"A memory cue followed by playing the computer game Tetris (on own smartphone) with mental rotation instructions for ca. 12 minutes."
89007992|NCT04608097|Placebo Comparator|Attention placebo|A memory cue followed by listening to a podcast (on own smartphone) for ca. 12 minutes.
89007993|NCT04607902|Active Comparator|Supportive Therapy SSI (ST-SSI)|The web-based supportive therapy (ST-SSI) intervention, called the Sharing Feelings Intervention, is designed to mimic supportive therapy (ST). The goals of the ST intervention are to encourage participants to identify and express feelings to close others; the intervention does not teach or emphasize specific skills or beliefs. In previous clinical trials, ST has resulted in significantly fewer reductions in youth internalizing problems compared to cognitive-behavioral and growth mindset interventions. The ST-SSI is designed to control for nonspecific aspects of intervention, including engagement in a computer program. It includes the same number of reading and writing activities as the other SSIs.
89007994|NCT04607902|Experimental|Behavioral Activation SSI (BA-SSI)|The BA-SSI include 5 elements: (1) An introduction to the program's rationale: that engaging in value-based activities can combat sad mood and low self-esteem; (2) Psychoeducation about depression, including how behavior shapes feelings and thoughts; (3) A life values assessment, where youth identify key areas from which they draw enjoyment and meaning; (4) Creation of an activity hierarchy, where youth identify and personalize (in guided exercises) 3 activities to target for change; and (5) An exercise in which youths write about benefits that might result from engaging in each activity; an obstacle that might keep them from doing the activities; and a strategy for overcoming identified obstacles.
89007995|NCT04607902|Experimental|Growth Mindset SSI (GM-SSI)|"Program includes: An introduction to the brain and a lesson on neuroplasticity; Testimonials from older youths who describe their views that traits are malleable Further stories by older youths, describing times when they used growth mindsets to persevere during social/emotional setbacks; Study summaries noting how/why personality can change; And an exercise in which youths write notes to younger students, using scientific information to explain people's capacity for change."
89007996|NCT00251628|Active Comparator|Group A|
89007997|NCT00251628|Active Comparator|Group B|
89007998|NCT00251628|Experimental|Group C|
89007999|NCT04608058|Experimental|Intervention|"At first, participants' demographic data, the levels of self-management, and HbA1c were documented at the commencement of the study. Then, asynchronous Diabetes self-management training, using digital storytelling was made available to this group. Post-test data were collected 3 months after the pretest."
89008000|NCT04608058|Experimental|No Intervention|"At first, participants' demographic data, the levels of self-management, and HbA1c were documented at the commencement of the study. Then, the control group received the clinics' routine training. Post-test data were collected 3 months after the pretest."
89008001|NCT04607707||Postmenopausal Women|Participants who sign an informed consent will be asked to complete study questionnaires at a single visit that coincides with a normal healthcare visit. No other study procedures will be performed.
89008002|NCT00564538|Experimental|1|Patients in arm 1 will receive induction with thymoglobulin at time of transplant with delayed initiation of tacrolimus
89008003|NCT00564538|Active Comparator|2|patients in arm 2 will not receive thymo induction at time of transplant and will have immediate initiation of tacrolimus
89008004|NCT04607824||Duchenne Muscular Dystrophy group|Forty-five male subjects were included in the Duchenne Muscular Dystrophy (DMD) group and they were assessed for twenty minutes at rest sitting, and then five minutes whilst performing the maze task on a computer.
89008005|NCT04607824||Typical Development group|Forty-five male subjects were included in the healthy Typical Development (TD) control group and they were assessed for twenty minutes at rest sitting, and then five minutes whilst performing the maze task on a computer
89008006|NCT04607863||Low back pain|Patients with low back pain
89008007|NCT04607863||No low back pain|No low back pain patients
89008008|NCT04607785|Active Comparator|Miswak mouthwash group|Miswak sticks were bought from local markets, Baghdad, Iraq, washed with cold water and dried then crushed into powder. Later,7 grams of the miswak powder weighted and added to 350 ml of distilled water (D.W.) in a conical flask for 24 hours. Finally, the solution then filtered and stored in tightly closed bottles in a cool place.9
89008009|NCT04607785|Other|Chlorhexidine mouthwash group|0.12% chlorhexidine gluconate mouthwash for seven days
89008010|NCT04607629|Experimental|Genolar® + Symbicort®|omalizumab & inhalation of budesonide+formoterol
89008011|NCT04607629|Active Comparator|Xolair® + Symbicort®|omalizumab & inhalation of budesonide+formoterol
89427264|NCT00849290|Experimental|APC8015F|
89427265|NCT00674479|Experimental|INCB018424|The starting dose of INCB018424 will be 25 mg by mouth twice daily.
89427266|NCT00606866|Placebo Comparator|I|placebo pill
89427267|NCT00606866|Active Comparator|II|Sorafenib, 200 mg bid
89427268|NCT00606866|Active Comparator|III|Sorafenib, 400 mg bid
89427269|NCT00594542|Experimental|0.5% lidocaine group|Group that receives 0.5% lidocaine with 1:200,000 epinephrine
89008012|NCT04607473|Experimental|ABUS|ABUS is performed by experienced technicians using a GE inveniaTM. Each breast is imaged in three views with an automated 15.4-cm 14-6-MHz linear- array transducer, which acquires up to 1000 two-dimensional images in the transverse plane, imaging the breast in three parts: the central (anteroposterior), lateral, and medial portions of the breast. To ensure inclusion of all breast tissue, particularly in participants with very large breasts, additional views are obtained as deemed necessary by the technician to cover the entirety of the breast.
89008013|NCT05558852|Experimental|Meshless Approach|Laparoscopic Sacrocolpopexy in central or anterior compartment prolapse.
89008014|NCT04607512|Experimental|Telaglenastat|800 mg telaglenastat (4 x 200 mg tablets) administered twice daily (BID) on Days 1 3, with a single dose administered on the morning of Day 4
89008015|NCT04607512|Placebo Comparator|Telaglenastat Placebo|800 mg placebo (4 x 200 mg tablets) administered twice daily (BID) on Days 1 3, with a single dose administered on the morning of Day 4
89008016|NCT04607512|Active Comparator|Moxifloxacin|Single dose of 400 mg moxifloxacin (1 x 400 mg tablet) administered on the morning of Day 4
89008017|NCT04607239|Experimental|Telemonitoring|"In addition to the usual care, this group benefits from a weekly telephone call by the Clinical Research Associate (CRA) for the collection of home blood pressure measurements (which the patient measures twice a day everyday), for therapeutic education, and for treatment compliance assessment.~This group will also benefit from a monthly call by the attending physician for treatment titration and side effects check."
89008018|NCT04607239|Other|Conventional|"This group will benefit form the usual care without any phone calls for therapeutic education, treatment compliance assessment, treatment titration or side effects check.~The usual care includes attending the follow up visits after inclusion at Day 90 (D-90) & Day 180 (D-180) for face to face consultation with the attending physician."
89008019|NCT04607395||pre-operative radiographs of deep carious lesion|
89196859|NCT00830193|Active Comparator|N-acetylcysteine|Intravenous fluid administration was administered as soon as possible following randomization (not to exceed 12 hours prior to anticipated contrast exposure) and continued for 12 hours post CT. Patients randomized to the experimental arm received intravenous normal saline plus NAC 10 grams IV (5 g pre and 2.5 g at 6 and 12 hours post-exposure) for a total of 3 doses.
89196860|NCT00830193|Placebo Comparator|Placebo|Intravenous fluid administration was administered as soon as possible following randomization (not to exceed 12 hours prior to anticipated contrast exposure) and continued for 12 hours post CT. Medication packages were prepared and dispensed by pharmacy and included three premixed and prepackaged minibags containing either 5 g in 100 cc D5W (pre-CT dose) or 2.5 g in 50 cc D5W (post-CT doses). The placebo was D5W and was colour and consistency matched by pharmacy. Patients randomized to placebo received intravenous normal saline plus 3 doses of placebo.
89427270|NCT00594542|Experimental|1.0% lidocaine group|Group that receives 1.0% lidocaine with 1:100,000 epinephrine
89427271|NCT00580580|Active Comparator|1 Intravenous Optison Followed by Contrast Pulse Sequencing|"Administration of Optison (0.1-0.4 mL) intravenously followed by Contrast Pulse Sequencing to image both the coronary and carotid arteries.~Use will depend on availability of the contrast for the given study Optison will not be used on patients with blood allergies or Jehovah Witnesses"
89427272|NCT00580580|Active Comparator|2 Intravenous Definity followed by Contrast Pulse Sequencing|Intravenous injection of Definity (0.05-0.20 mL) followed by Contrast Pulse Sequencing to image both coronary and carotid arteries
89427273|NCT00580580|Active Comparator|3 Intravenous PESDA followed by Contrast Pulse Sequencing|Intravenous injection of PESDA at a rate of 0.05-0.20 mL followed by Contrast Pulse Sequencing image of coronary and carotid arteries PESDA will be used exclusively in patients who are eligible for other IRB studies
89427274|NCT00564291||1|Healthy volunteers
89427275|NCT00564291||2|CSME secondary to diabetic retinopathy
89427276|NCT00564291||3|ARMD with CNV before and after therapy
89427277|NCT00564291||4|ARMD atrophic
89427278|NCT00564291||5|Retinal vein occlusion
89427279|NCT00564291||6|retinitis pigmentosa
89427280|NCT00564291||7|vitreoretinal proliferation
89427281|NCT00542451|Experimental|Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer|80 mg of paclitaxel per square meter of body-surface area weekly for 12 weeks and a loading dose of 4 mg of intravenous trastuzumab per kilogram of body weight on day 1, followed by 2 mg per kilogram weekly, for a total of 12 doses. After the completion of 12 weeks of treatment with Trastuzumab, the dosing of Trastuzumab could be continued on a weekly basis, or the regimen could be changed to 6 mg per kilogram every 3 weeks for 40 weeks to complete a full year of intravenous treatment with trastuzumab.
89427282|NCT00478712||Families with Hirschsprung Disease|Individuals with Hirschsprung disease and their affected and unaffected relatives.
89427283|NCT00397163|Active Comparator|Remote preconditioning|Simultaneous inflation (5min) and deflation (5min) of cuffs placed on upper arm and thigh - cycle repeated 2 times
88908163|NCT06205381|Other|Midazolam and fexofenadine|In Part E, 2.5 mg midazolam will be administered as an oromucosal solution and 120 mg fexofenadine will be administered as an oral tablet on day 1 and day 18, to investigate the effect of AV078 on the pharmacokinetics of midazolam and fexofenadine.
88908164|NCT06205251|Experimental|Inspiratory Muscle Training (IMT)|Participants will be asked to perform inspiratory muscle training (breathing exercise) 5 days per week for 6 weeks at home.
89196861|NCT00746772|Active Comparator|1|Patients with oral lichen planus
89427284|NCT00397163|Placebo Comparator|Placebo|Deflated cuffs placed on upperarm and thigh for 20 minutes
89427285|NCT00368082|Experimental|TGFbeta resistant LMP-specific CTLs|"CTLs be given by intravenous injection over 1-10 minutes through either a peripheral or a central line.~If patients with active disease have stable disease or a partial response at their 6 week or subsequent evaluations they will be eligible to receive up to 6 additional doses of CTLs at 1-2 monthly intervals-each of which will consist of the same cell number as their second injection."
89427286|NCT00336232|Experimental|Diet Intervention|28 day diet low vitamin K, 28 day diet high vitamin K
89427287|NCT00131235|Placebo Comparator|Control|Standard antenatal care as described in intervention
89427288|NCT00131235|Experimental|Monthly SP|Standard antenatal care + monthly intermittent presumptive treatment of malaria with sulfadoxine pyrimethamine, as described in intervention
88908165|NCT06204159|Experimental|End Hole Catheter followed by TriNav Catheter|"FDA approved catheter~Randomization End Hole catheter then TriNav catheter"
88908166|NCT06204159|Experimental|TriNav Catheter followed by End Hole Catheter|"FDA approved catheter~Randomization TriNav catheter then End Hold catheter"
88908167|NCT06200987|Experimental|Intervention|The group randomized to use the vibrator for 9 months
88908168|NCT06200987|No Intervention|Controls|Usual standard treatment
89427289|NCT00131235|Experimental|AZI-SP|Standard antenatal care + monthly intermittent presumptive treatment of malaria with sulfadoxine pyrimethamine + two presumptive treatments of sexually transmitted infections and malaria with azithromycin, as described in intervention
89427290|NCT00014859||Population-based cohort|Descriptive cohort of population-based DNA samples from the newborn screening program in Missouri with vital statistics based, linked phenotype data
89427291|NCT00014859||Trio sequencing cohort|Affected infant/child (term or near term infant with progressive respiratory distress or other rare pulmonary phenotype or older child with interstitial lung disease or other rare pulmonary phenotype) and parents
89196862|NCT00746772|Placebo Comparator|2|Patients with oral lichen planus
89196863|NCT00938080|Experimental|AG013: one mouth rinse/day|
89196864|NCT00938080|Experimental|AG013: three mouth rinses/day|
89196865|NCT00938080|Experimental|AG013: six mouth rinses/day|
89196866|NCT00938080|Placebo Comparator|one mouth rinse/day|
89196867|NCT00938080|Placebo Comparator|three mouth rinses/day|
89196868|NCT00938080|Placebo Comparator|six mouth rinses/day|
88908169|NCT06199986|Experimental|ADT Order Check Attestation (Or)|"Study staff will place a Living Well ADT health factor in the electronic medical record for patients already receiving ADT, and whose clinic visits the study team have confirmed to be targets for ADT de-implementation. Health factors will be entered as eligible clinic visits are identified. This health factor combined with a low PSA level (most recent PSA < 2) will trigger the ADT Order Check Attestation Intervention (Or) when the provider participant places an order for ADT (e.g., Lupron, Eligard, Goserelin, and Zoladex). Provider participants may override the order check by entering text indicating the reason and continue with the ordering process."
88908170|NCT06199986|Experimental|Provider Script (Sc)|Study staff will enter an electronic health record progress note approximately one business day prior to a target low-value ADT clinic visit from a patient already receiving ADT. The note will include scripted talking points for the provider participant to help with discussion and recent PSA levels and can be edited, signed, or deleted by the provider, giving a quick and simple way to document the discussion. The progress note will prompt provider participants to indicate whether a patient prefers to continue or discontinue ADT. The progress note will include links to a patient-facing clinic handout which will be posted on an external website. Provider participants may modify, ignore, or delete the progress note.
88908171|NCT06199986|No Intervention|Control|The study team will match up to 8 sites (i.e., medical centers) to the 4 randomized sites as contemporary controls where no interventions have been deployed to compare the primary outcome of interruption of low-value ADT injections. Low-value ADT injections, eligible clinic visits, and primary outcomes for a matched 6-month period will be ascertained through chart review and compared to intervention site primary outcomes.
88908172|NCT06199830||cough variant asthma|(1) chronic cough (≥8 weeks) as the sore or predominant symptom; (2) variable airway limitation evaluated by BHR test; (3) a positive response to anti-asthma therapy; (4) No other causes of chronic cough.
88908173|NCT06199830||chronic cough|(1) chronic cough (≥8 weeks) as the sore or predominant symptom; (2) without radiographic evidence of lung disease; (3) with no fever, blood-stained sputum or other active respiratory injection;
88908174|NCT06196814|Experimental|Cohort of EGFR Sensitve Mutant NSCLC|Efficay, Satety and Dose Escalation of AK112 plus Platinum-based Chemotherapy for EGFR Sensitive mutant NSCLC who Failed from First-Line Osimertinib.
88908175|NCT06196814|Experimental|Cohort of ALK Fusion NSCLC|Efficay and Satety of PD-1/VEGR bispecific antibodies (AK112) plus Platinum-based Chemotherapy for ALK fusion NSCLC who Failed from First-Line Osimertinib.
88908176|NCT06196814|Experimental|Cohort of ROS1 Fusion NSCLC|Efficay and Satety of PD-1/VEGR bispecific antibodies (AK112) plus Platinum-based Chemotherapy for ROS1 fusion NSCLC who Failed from First-Line Crizotinib.
88908177|NCT06196372|Experimental|Experimental: Intervention|An online mindfulness nursing support program (MenoMind) was applied to this group for 8 weeks and lasting an average of 50 minutes.
88908178|NCT06196372|No Intervention|Control|The control group received no intervention and the women were left to routine clinical care.
88908179|NCT06195930|Experimental|Overall study|At Visit 1 participants will receive 1x 5 mg Vericiguat (BAY1021189) tablet daily (on top of standard of care) for at least 14 days to max 18 days (+4 days time window allowed)
88908180|NCT06194305|Experimental|CBIT group|Participants with chronic TICs
88908181|NCT06193486|Experimental|Dose Escalation|"Participants will undergo leukapheresis followed by lymphodepletion and infusion of MSGV1-PSCA-8T28Z. The lymphodepletion regimen includes cyclophosphamide (500 mg/m2) and fludarabine (30 mg/m2) administered over 3 days (Days -5, -4, -3). The standard 3+3 design will be used to guide dose escalation/de-escalation decisions based on the cumulative number of patients who experience a dose limiting toxicity (DLT) at the current dose. The first cohort of 3 patients will be treated at dose level 1.~The target maximum doses infused at each dose level is:~Dose Level 1: 1x10^5 cells/kg Dose Level 2: 3x10^5 cells/kg Dose Level 3: 1x10^6 cells/kg Dose Level 4: 3x10^6 cells/kg Dose Level 5: 1x10^6 cells/kg"
88908182|NCT06193486|Experimental|Dose Expansion|Participants will undergo leukapheresis followed by lymphodepletion and infusion of MSGV1-PSCA-8T28Z. Lymphodepletion will include 3 days of treatment with fludarabine (30 mg/m^2) and cyclophosphamide (500 mg/m^2) prior to study day 0. Participants will then receive MSGV1-PSCA-8T28Z at the dose level determined to be the Maximum Tolerated Dose (MTD) in the dose escalation portion of the study.
88908183|NCT06193239|Experimental|OWL-EVO1|"After confirming full eligibility, individuals will all be administered the OWL-EVO1 probe intravenously.~This includes:~Patients diagnosed with histopathologically confirmed lung cancer.~Individuals with a CT-proven absence of lung cancer, including those with relevant comorbidities and risk factors such as smoking, COPD, asthma, extrapulmonary malignant tumours, active lung infection/inflammation and other chronic respiratory diseases."
89008020|NCT04607278|Experimental|Probiotic|Oral probiotic supplementation (Pro-Probiotic) was provided by iHealth; Cromwell, USA. Each sachet included a 1×1010 CFUs dose of four viable microbial cell preparation strains: there are two strains of lactobacillus genus (Lactobacillus acidophillus L1 (2.9×109) and Lactobacillus rhamnosus liobif (2.9×109)), Bifidobacterium longum (2.9×109) and Saccharomyces boulardii (1.3×109). Each participant took a total daily dose of 4×1010 CFUs.
89196869|NCT00834327|Experimental|1|aplindore 0.05 mg MR total daily dose
89196870|NCT00834327|Experimental|2|aplindore 0.1 mg MR total daily dose
89196871|NCT00834327|Experimental|3|aplindore 0.25 mg MR total daily dose (to include short titration)
89196872|NCT00834327|Experimental|4|aplindore 0.5 mg MR total daily dose (to include short titration)
89196873|NCT00834327|Placebo Comparator|5|Placebo
89196874|NCT02563938|Experimental|AK001|Up to six single ascending doses of AK001.
89427292|NCT04161638|Experimental|High Blood Pressure|Ambulatory BP measurement was used to confirm the laboratory BP group classification according to the European Society of Hypertension. Participants were placed in the high blood pressure (HBP) group if they met any of the following criteria: 1) 19-hour average systolic BP/diastolic BP (SBP/DBP) > 130/80 mmHg, 2) daytime (awake) average SBP/DBP > 135/85 mmHg, or 3) nighttime (sleep) average SBP/DBP > 120/70 mmHg.
89427293|NCT04161638|Experimental|Normal Blood Pressure|Participants were placed in the normal BP (NBP) group if they met all of the following criteria: 1) 19-hour average SBP/DBP < 130/80 mmHg, 2) daytime (awake) average SBP/DBP < 135/85 mmHg, and 3) night-time (asleep) average SBP/DBP <120/70 mmHg.
89427294|NCT00157248|Experimental|dabigatran etexilate, 150 mg once daily|dosage used at study start
89427295|NCT00157248|Experimental|dabigatran etexilate, 150 mg twice daily|dosage used at study start
89427296|NCT00157248|Experimental|dabigatran etexilate, 300 mg once daily|dosage used at study start
89427297|NCT00157248|Experimental|dabigatran etexilate, 300 mg twice daily|dosage used at study start
89427298|NCT02504580|Experimental|Part A, Cohort A|HTX-011 (bupivacaine/meloxicam), 200 mg/6 mg by injection.
88908184|NCT06191978|Experimental|ASTX727/venetoclax|"On Days 1-5 of Cycle 1, you will take ASTX727 by mouth with a glass of water. Participants must fast (not eat or drink anything but water, black coffee, or tea) for at least 2 hours before and for 2 hours after taking ASTX727. For 4 hours before dosing and 4 hours after dosing, participants should not take antacids or any other medicine that can change the amount of acid in your stomach.~Days 1-21 or 1-28 depending on dose level, of all cycles beginning with Cycle 2. The study doctor will tell participants which of these schedules participants will follow. Venetoclax should be taken with water and a meal at around the same time each day."
88908185|NCT06191315|Experimental|Dupilumab (double-blind period)|Dupilumab subcutaneous injection as per protocol
88908186|NCT06191315|Placebo Comparator|Placebo|Placebo matching dupilumab subcutaneous injection as per protocol
88908187|NCT06189508|Experimental|A: Single NXT007 SC Injection Into Abdomen|
88908188|NCT06189508|Experimental|B: Single NXT007 SC Injection Into Upper Arm|
89427299|NCT02504580|Experimental|Part A, Cohort B|HTX-011(bupivacaine/meloxicam), 400 mg/12 mg by injection.
89427300|NCT02504580|Experimental|Part A, Cohort C|HTX-011 (bupivacaine/meloxicam), 200 mg/6 mg by instillation.
88908189|NCT06189508|Experimental|C: Single NXT007 SC Injection Into Thigh|
88908190|NCT06189508|Experimental|D: Single NXT007 IV Infusion|
89008021|NCT04607278|Active Comparator|Prebiotic|The prebiotic (Inulin) was made up of inulin from the chicory plant and provided by the Fibrelle (Belgium) company. Five grams packs were given to the participants in boxes. Each participant was requested to take a total daily 10 g dose.
89008022|NCT04607278|Placebo Comparator|Placebo|It was composed of maltodextrin, and provided by the manufacturer Fibrelle; (Belgium). The prescription was similar to probiotics or prebiotics groups.
89008023|NCT00564577|Other|CFA/I and CS17 challenge strain|Colonization factor antigen (CFA/I) and CS17 challenge strainAscending dose finding study in 5-10 subjects per dose; to identify the dose able to give a diarrheal attack rate greater than or equal to 80%.
89427301|NCT02504580|Experimental|Part A, Cohort D|HTX-011 (bupivacaine/meloxicam), 400 mg/12 mg by instillation.
89427302|NCT02504580|Experimental|Part A, Cohort E|HTX-011 (bupivacaine/meloxicam), 400 mg/12 mg by injection and instillation (combination).
89427303|NCT02504580|Placebo Comparator|Part A, Cohort F|Saline placebo by injection.
89427304|NCT02504580|Experimental|Part B, Cohort A|HTX-011A (bupivacaine/meloxicam), 200 mg/6 mg by injection.
89427305|NCT02504580|Experimental|Part B, Cohort B|HTX-011A (bupivacaine/meloxicam) 400 mg12 mg by injection.
89427306|NCT02504580|Experimental|Part B, Cohort C|HTX-011B (bupivacaine/meloxicam), 200 mg/6 mg by injection.
89427307|NCT02504580|Experimental|Part B, Cohort D|HTX-011B (bupivacaine/meloxicam), 400 mg/12 mg by injection.
89427308|NCT02504580|Placebo Comparator|Part B, Cohort E|Saline placebo by injection.
89427309|NCT02504580|Experimental|Part C, Cohort A|HTX-002, 200 mg by injection or instillation.
89427310|NCT02504580|Experimental|Part B, Cohort F|HTX-002, 400 mg by injection or instillation.
89427311|NCT02504580|Experimental|Part C, Cohort B|HTX-011B (bupivacaine/meloxicam), 200 mg/6 mg by instillation.
89427312|NCT02504580|Experimental|Part B, Cohort G|HTX-011B (bupivacaine/meloxicam), 400 mg/12 mg by instillation.
89427313|NCT02504580|Placebo Comparator|Part C, Cohort C|Saline placebo by instillation.
89427314|NCT02504580|Active Comparator|Part C, Cohort D|Bupivacaine HCI (Marcaine), 75 mg by injection.
88908191|NCT06185244|Experimental|Therapist-supported internet delivered trauma-focused CBT|Therapist-supported internet delivered trauma-focused CBT. The protocol mirrors the exact content of first-line treatment for children with PTSD but is delivered through a digital platform and will comprise of text-based material as well as audio files and video illustrations in an age-appropriate manner that the participant gains access to sequentially. iTF-CBT will be therapist-assisted, and each participant will have a designated therapist to guide them through treatment. Treatment will span over 12 weeks and integrates cognitive, behavioral, interpersonal, and family therapy principles as well as trauma interventions. Parallel to the child's treatment, the caregivers are provided the same components and parenting practices, and joint child-parent activities are included. Participants will have access to a therapist that will guide them through treatment in a text based format.
88908192|NCT06185244|Active Comparator|Therapist-supported psychoeducation and stress management|Therapist-supported CBT internet-delivered treatment comprising psychoeducation about PTSD, relaxation/stress management techniques and relapse prevention. The treatment will be delivered in a digital platform for twelve weeks. Participants will have access to a therapist that will guide them through treatment in a text-based material as well as audio files and video illustrations in an age-appropriate manner that the participant gains access to sequentially.
88908193|NCT06180655|Experimental|Diabetes Self-Management Education and Support (DSMES) plus Tai Chi Easy (TCE)™|Participants will be asked to attend 45 minutes of DSMES and 45 min of TCE twice a week for 6 weeks. All classes will be recorded and available online and can viewed at a time when it is most convenient to accommodate working adults.
89196875|NCT02563938|Placebo Comparator|Saline Solution|Saline solution will be administered as a single infusion.
89196876|NCT00938158|Experimental|Stage 1 normal renal function|Subject with estimated glomerular filtration rate (GFR) greater than 80 milliliter per minute (mL/min)
88908194|NCT06180590||Vosevi Group|Patients are administrated with once-daily oral Vosevi (Sofosbuvir/Velpatasvir/Voxilaprevir: 400mg/100mg/100mg)
88908195|NCT06180590||Sofosbuvir/Velpatasvir combined with ribavirin Group|Patients are administrated with once-daily oral Sofosbuvir/Velpatasvir (400mg/100mg) combined with ribavirin（500mg）twice a day
88908196|NCT06180122|Other|Symptomatic Group|Participants who are suffer from unexplained left leg swelling.
88908197|NCT06180122|Other|Asymptomatic Group|Participants who do not suffer from unexplained left leg swelling
88908198|NCT06176404|Active Comparator|The comparison group|"The study lasted 20d for each patient. During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.~Particularly, due to dysphagia, the patients enrolled might face difficulty in eating. For patients who were able to finish intake via mouth by compensatory means, the consistency, type, and size of food bolus was arranged. For those who cannot acquire sufficient nutrition through oral intake, the nasogastric tube feeding (NGT) was provided."
88908199|NCT06176404|Experimental|The observation group|"The study lasted 20d for each patient. During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.~Particularly, due to dysphagia, the patients enrolled might face difficulty in eating. For patients who were able to finish intake via mouth by compensatory means, the consistency, type, and size of food bolus was arranged. For those who cannot acquire sufficient nutrition through oral intake, the nasogastric tube feeding (NGT) was provided.~Based on the invention above, the patients in the observation group were provided with SGB, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g)."
88908200|NCT06174649|No Intervention|Standard of Care|When a blood culture growing GNB is randomized standard of care arm the positive blood cultures will be characterized using standard of care antimicrobial susceptibility testing (AST)
88908201|NCT06174649|Active Comparator|Reveal|When a blood culture growing GNB is randomized to the Reveal arm, the positive blood culture will be characterized using Reveal, a rapid AST, and the standard of care AST.
88908202|NCT06173804|Experimental|Lifestyle intervention group|The study team will assess improvements in physical function assessed by the short physical performance battery and other health-related measures (diabetes knowledge, self-efficacy, social support, physical activity, diet consumption, HbA1c, and quality of life).
89427315|NCT02504580|Experimental|Part D, Cohort A|HTX-011B (bupivacaine/meloxicam), 400 mg/13 mg via a combination of injection and instillation.
89427316|NCT02504580|Experimental|Part E, Cohort A|HTX-009, 12 mg by injection and instillation (combination).
89196877|NCT00938158|Experimental|Stage 1 moderate/severe renal function|Subject with estimated GFR >= 20 mL/min and less than 50 mL/min
89196878|NCT00938158|Experimental|Stage 2 normal renal function|Subject with GFR greater than 80 mL/min
89196879|NCT00938158|Experimental|Stage 2 moderate renal impairment|Subject with estimated GFR >= 30 mL/min and less than 50 mL/min
89196880|NCT00938158|Experimental|Stage 2 subjects requiring hemodialysis|Subjects who require hemodialysis
89196881|NCT00938158|Experimental|Stage 2 severe renal impairment not requiring hemodialysis|Subjects with GFR less than 30 mL/min
89427317|NCT02504580|Experimental|Part F, Cohort A|HTX-011B (bupivacaine/meloxicam), 300 mg/9 mg by instillation.
89196882|NCT00938158|Experimental|Stage 2 mild renal impairment|Subjects with GFR >= 50 mL/min and <= 80 mL/min
89427318|NCT02504580|Experimental|Part F, Cohort B|Bupivacaine HCI (Marcaine), 75 mg by injection.
89427319|NCT02504580|Placebo Comparator|Part F, Cohort C|Saline placebo by injection.
89427320|NCT02235402|Experimental|Lacidipine|
89427321|NCT02235402|Active Comparator|Bendrofluazide|
89427322|NCT02235402|Placebo Comparator|Placebo|
89427323|NCT02501304|Experimental|ReVENT Sleep Apnea System|All patients will be implanted with the ReVENT Sleep Apnea System
89427324|NCT02484378|Experimental|CER-001|CER-001 infusion
89427325|NCT02484378|Placebo Comparator|Placebo|Placebo infusion
89427326|NCT02235480|Experimental|Tazarotene Gel|once daily
89427327|NCT02235480|Placebo Comparator|Placebo Gel|once daily
89427328|NCT02235558|Experimental|Verapamil|Super-selective intra-arterial administration of 10 mg verapamil immediately following successful intra-arterial thrombolysis
89427329|NCT02235636||Laparoscopic group|
89196883|NCT00840957||A|Rhumatoid arthritis patient currently receiving infliximab
89427330|NCT02235636||Robotic group|
89427331|NCT02235714||Tetraplegia|Individuals with chronic tetraplegia
89427332|NCT02235714||Asthma|Individuals with mild asthma
89427333|NCT02235714||Able-bodied controls|Age matched able-bodied (AB) controls with no history of lung disease
89427334|NCT04237350||severe visual impairment group|"The severe visual impairment group is defined as the BCVA of at least one eye outside the 99% referenced range or worse than light perception with structural abnormalities or other examination results."
88908203|NCT06172933|Experimental|Move with Meaning|In Move with Meaning, participants will engage in twice weekly, interactive text message sessions, which are accompanied by audio content to promote engagement in the program. In the first session of each week, participants will review their physical activity goal and positive psychology topic from last week, then learn about a new positive psychology and physical activity topic and ultimately set a new physical activity goal for the week. In the second session, participants will either be reminded of the content of the audio file and the goal they set earlier that week. The program will run for eight weeks.
88908204|NCT06172933|No Intervention|Wait-list control|Participants in the wait-list control condition will engage in usual medical care for eight weeks, then will complete the Move with Meaning program.
88908205|NCT06172478|Experimental|HER3-DXd Monotherapy|Participants with locally advanced or metastatic cancer (melanoma, head and neck, and gastric cancer) will receive an intravenous infusion of HER3-DXd monotherapy 5.6 mg/kg every 3 weeks (Q3W).
88908206|NCT06172296|Active Comparator|Arm A (SOC treatment)|See detailed description
88908207|NCT06172296|Experimental|Arm B (Dinutuimab in induction)|See detailed description
88908208|NCT06172114|Active Comparator|Control group (C)|Xenograft + resorbable collagen membrane
88908209|NCT06172114|Experimental|Test group (T)|Xenograft combined with L-PRF + resorbable collagen membrane
88908210|NCT06170970|Experimental|solriamfetol then placebo first|Four weeks of treatment with solriamfetol followed by one week of washout and four weeks of treatment with placebo
88908211|NCT06170970|Experimental|placebo then solriamfetol first|Four weeks of treatment with placebo followed by one week of washout and four weeks of treatment with solriamfetol
88908212|NCT06170567|Experimental|Students' course success|The effect of puzzles on students' course success
88908213|NCT06170567|Experimental|Student scores|The effect of puzzles on students' course success
88908214|NCT06168578||Group I (ARM-): After intubation, 5 cmH2O PEEP will be applied until the end of the operation|"First ONSD measurement will be performed 5 minutes after intubation with the patient in supine position (T0)~A second ONSD measurement will be performed 10 minutes after intubation with the patient in supine position. (T1)~ONSD will be measured for the third time 5 minutes after pneumoperitoneum is established with 12-13 mmHg. (T2)~At 10 minutes of Trendelenburg position (45⁰), ONSD will be measured for the fourth time (T3).~In Trendelenburg position (45⁰), ONSD will be measured for the fifth time after removal of the uterus. (T4)~After the supine position is assumed before extubation and pneumoperitoneum is terminated, ONSD will be measured for the sixth time before the neuromuscular blocker is reversed. (T5)"
89196884|NCT00743964|Experimental|ECX|Epirubicin, cisplatin and capecitabine combination chemotherapy will be administered.
89427335|NCT04237350||likely healthy group|"For the likely healthy group, the visual acuity of both eyes is in the 95% referenced range with no structural abnormalities.~The referenced range could be found in the following publication:~Mayer, DL., et al. Monocular acuity norms for the Teller Acuity Cards between ages one month and four years. Investigative Ophthalmology & Visual Science. 36(3):671 (1995)"
89427336|NCT04237350||mild visual impairment group|"The mild visual impairment group is defined as the BCVA in the 99% referenced range in both eyes with abnormalities of structure or other examination results."
88908215|NCT06168578||Group II (ARM+): After intubation, 5 cmH2O PEEP will be applied until the end of the operation|"ONSD will be measured 5 minutes after intubation with the patient in supine position (T0)~ARM will be applied 10 minutes after intubation, and ONSD will be measured for the second time when the peak pressure is reached. (T1)~ONSD will be measured for the third time 5 minutes after pneumoperitoneum is established with 12-13 mmHg. (T2)~At 10 minutes of Trendelenburg position (45⁰), ONSD will be measured for the fourth time (T3).~Trendelenburg position (45⁰), ARM will be applied after the uterus is removed, and ONSD will be measured for the fifth time when the peak pressure is reached. (T4)~After the supine position is assumed before extubation and pneumoperitoneum is terminated, ONSD will be measured for the sixth time before the neuromuscular blocker is reversed. (T5)"
89196885|NCT00743964|Active Comparator|CX|Cisplatin and capecitabine combination chemotherapy will be administered.
89196886|NCT00939406|No Intervention|Control|Control group consists of subjects randomized to the control arm who will receive lumbar decompression surgery (laminotomy or laminectomy) alone
89196887|NCT00939406|Experimental|Hyalospine|Intervention group consists of subjects randomized to the treatment arm who will receive lumbar decompression surgery (laminotomy or laminectomy) and HyaloSpine.
89196888|NCT00830271|Experimental|Vicryl plus/Monocryl plus|"Vicryl plus and Monocryl plus is the active comparator arm. These are the active sutures, coated with triclosan antiseptic, being used in the closure of skin and subcutaneous tissues after breast cancer surgery."
89196889|NCT00830271|Placebo Comparator|vicryl/monocryl|"Plain Vicryl or Monocryl suture currently the standard which are not coated with triclosan, serve as the control."
89196890|NCT02563236|Experimental|Parabolic flight and Augmented Reality interface alignments|
89427337|NCT04220112|Experimental|Real Time Functional MRI (rt-fMRI)|Real-time fMRI (rt-fMRI) neurofeedback (focused on amygdala down-regulation) intervention
89427338|NCT04220112|Sham Comparator|Sham|Sham-controlled group
89427339|NCT04214418|Experimental|Phase 1: MTD|"Subjects will be treated with combination therapy at the designated dose levels:~Dose 1 - Hydroxychloroquine 600mg twice per day, Cobimetinib 40mg, no Atezolizumab Dose 2 - Hydroxychloroquine 600mg twice per day, Cobimetinib 40mg, Atezolizumab 840mg Dose 3 - Hydroxychloroquine 600mg twice per day, Cobimetinib 60mg, Atezolizumab 840mg"
89427340|NCT04214418|Experimental|Phase 2: Cohort 1|Advanced Pancreatic Adenocarcinoma (N = 23-67) subjects will receive study treatment based on the MTD determined from Phase 1
89427341|NCT04214418|Experimental|Phase 2: Cohort 2|Advanced Colorectal Adenocarcinoma (N = 20-34) subjects will receive study treatment based on the MTD determined from Phase 1
89427342|NCT04214418|Experimental|Phase 2: Cohort 3|Histology Agnostic Adenocarcinoma (N = 23-56) subjects will receive study treatment based on the MTD determined from Phase 1
89427343|NCT02233608|No Intervention|Usual Care|The usual care group will receive generic pelvic floor muscle exercise (PMFX) instructions and demonstrations by the research coordinator at the initial post-operative time point. This will include instruction on how to engage the pelvic floor and specific PFMX prescription. Repetition volume will start at 20 repetitions per day during weeks 1-2; 60/day during weeks 3-4; and 90/day during weeks 5-6, and 100+/day for weeks 7-26. The total number of repetitions will be divided equally between rhythmic (contract and relaxed over one second) and sustained contractions (contract and hold for up to 10 seconds).
89427344|NCT02233608|Experimental|Advanced Pelvic Floor Exercise (APFX)|Participants in this group will receive detailed week-by-week description of the program. The program progresses participants through stages of training every two weeks, starting the introduction of basic PFMX, and slowly incorporates Pfilates and Hypopressives exercises until week 8, where patients will maintain the final stage of training until week 26 or urinary incontinence is completely resolved.
89427345|NCT02233686|Experimental|XEN-D0501|4mg BID Days 1-13, 4mg once daily (OD) Day 14
89427346|NCT02233686|Placebo Comparator|Placebo to Match|BID Days 1-13, once daily (OD) Day 14
89427347|NCT02233764|Experimental|FeZnPM|The FeZnPM arm will consume iron- and zinc-biofortified pearl millet (ICTP8203-Fe).
89427348|NCT02233764|Active Comparator|CtrlPM|The CtrlPM arm will consume conventional pearl millet three times per day, six days per week, for 9 months. Children are anticipated to consume 25-30 grams of the pearl millet at each feeding. The pearl millet will be prepared using a variety of recipes such as porridges, breads, and biscuits.
89427349|NCT02233920||Chronic obstructive bronchitis patients|
89427350|NCT02234076|Experimental|VRET|"Virtual Reality Exposure Therapy (VRET)~The experimental treatment VRET is offered with the Multi-Modal Memory Restructuring System (3MR system) and a therapy manual. Participants can use this system at home. Note: The 3MR system is offered via a computer screen, no head-mounted display (HMD) equipment is used in this study."
89427351|NCT02234076|Active Comparator|TAU|Treatment As Usual
89427352|NCT02471898|Experimental|HTX-011|Evaluate the analgesic efficacy of HTX-011
89427353|NCT02471898|Placebo Comparator|Placebo|Saline
89196891|NCT00830349|Experimental|1|Risperidone 1 mg Tablets
89427354|NCT01626378|Experimental|TRx0237 200 mg/day group|
89427355|NCT01626378|Placebo Comparator|Placebo|
89427356|NCT02263404|Experimental|Deep Brain Stimulation|DBS Implant and stimulation Intervention: Device: Deep Brain Stimulation
89427357|NCT02234154|Other|TOPS System|Post Marketing Study
89427358|NCT02235948|Experimental|folic acid|folic acid supplementation placebo controlled
89427359|NCT02236026|Experimental|Supratherapeutic dose of Nestorone|Subjects will be randomized to a treatment sequence on Day 1 of Treatment Period 1, prior to administration of investigational product, according to a randomization schedule provided by the Sponsor
89427360|NCT02236026|Placebo Comparator|Placebo|Subjects will be randomized to a treatment sequence on Day 1 of Treatment Period 1, prior to administration of investigational product, according to a randomization schedule provided by the Sponsor
89427361|NCT02236026|Experimental|Moxifloxacin|Subjects will be randomized to a treatment sequence on Day 1 of Treatment Period 1, prior to administration of investigational product, according to a randomization schedule provided by the Sponsor
89427362|NCT02236104|Experimental|cough assist session|Mechanical insufflation-exsufflation contains 15 cycles durea 2-3 seconds. pressure level fixed +/-30 cm H2O.
89427363|NCT03973866|Experimental|Alfapump|Implantation of Alfapump
89427364|NCT03970902||Integrated Osteoporosis Care|Group of formal and informal primary caregivers and non-institutionalized postmenopausal women with osteoporosis in whom a complex patient-tailored intervention is provided.
89427365|NCT03970902||Care As Usual|Group of formal and informal primary caregivers and non-institutionalized postmenopausal women with osteoporosis receiving care as usual for the management of osteoporosis.
89196892|NCT00830349|Active Comparator|2|Risperdal® 1 mg Tablets
89196893|NCT00746850|Experimental|H|early LC within 72 hours after the diagnosis with H (Harmonic)
89196894|NCT00746850|Active Comparator|MD|early LC within 72 hours after the diagnosis with MD (Monopolar Diathermy)
89196895|NCT00830427|Experimental|PF-00610355|
89427366|NCT02236182|Experimental|Ipratropium Bromide low|delivered via RESPIMAT®
89427367|NCT02236182|Experimental|Ipratropium Bromide high|delivered via RESPIMAT®
89427368|NCT02236182|Placebo Comparator|Placebo|delivered via RESPIMAT®
89427369|NCT03010904|Experimental|pasteurized milk|milk that has undergone pasteurization treatment
89427370|NCT03010904|Experimental|homogenized pasteurized milk|Milk that has undergone homogenization and pasteurization treatment
88908216|NCT06167746|Active Comparator|Digital Health Information (DHI)|Digital health information is delivered through a website tailored with care transitions and self-care information for all participants over the 6-month study.
88908217|NCT06167746|Experimental|Virtual Health Coaching + DHI|Study participants in the intervention group will receive 10-session virtual health coaching intervention sessions delivered over 6 months.
88908218|NCT06167304|Experimental|Technology-implemented exercise therapy|Therapy plans performed at home overseen by a remote physical therapist via SimpleTherapy. Allocation to this group will require using smart devices or a computer/laptop to receive care. Remote visits with a PT typically last 45min long and home exercises suggested by the app are self-paced.
88908219|NCT06167304|Active Comparator|Traditional Physical Therapy|Participants will be prescribed an exercise plan by a physical therapist as normally would occur as part of standards of care outside the context of a research study. In-person assessments and at-home exercise suggestions will be decided by the physical therapist. Duration of PT appointments is typically 45 minutes long two times per week and are supplemented by PT recommended self-paced at-home exercises.
88908220|NCT06165757|Experimental|noise on pain|Comparison of pain sensitivity before and after hearing noise among 15 subjects in each group.
89427371|NCT03010904|Experimental|UHT milk|Milk that has undergone homogenization and ultra high temperature treatment
89427372|NCT04453280||Cohort 1 - Prague and Central Bohemian Region|A population cohort of cured patients based on epidemiologically defined demographic parameters - Prague and Central Bohemian Region population
88908221|NCT06165562|Experimental|Pressure Supporting Ventilation (PSV) and EEG-guided Emergence group|"Pressure support ventilation will be applied from the start of subcutaneous suture until extubation. At the end of surgery, sevoflurane will be discontinued, and the attending anesthesiologist will perform tracheal extubation after observing the 'zipper opening' pattern on the EEG spectrogram, indicating the patient's recovery of consciousness. For safety reason, extubation will also be guided by the following processed EEG indices thresholds:~95% spectral edge frequency (SEF) ≥ 23~Patient state index (PSI) ≥ 64"
89196896|NCT00830427|Experimental|PF - 00610355|
89196897|NCT00830427|Placebo Comparator|Placebo|
89196898|NCT02563158|No Intervention|Hx with hepatic inflow occlusion|Hepatectomy is carried out using Pringle maneuver in cycles of 15 minutes clamping + 5 minutes unclamping of the hepatoduodenal ligament.
89196899|NCT02563158|Experimental|Hx with non-occlusion technique|Hepatectomy without hepatic inflow occlusion (non-occlusion technique)
89196900|NCT00841113|Experimental|1 Abarelix|Investigative drug
89196901|NCT00841113|Active Comparator|2 Goserelin plus bicalutamide|Standard therapy
89196902|NCT00741546||A|Patients referred for cardiac surgery intervention
89427373|NCT04453280||Cohort 2 - South Moravian Region|A population cohort of cured patients based on epidemiologically defined demographic parameters - South Moravian Region population.
89427374|NCT04453358|Active Comparator|Interactive coaching|Airway clearance therapy using goal setting and interactive feedback.
89427375|NCT04453358|Active Comparator|Standard of care coaching|Standard of care airway clearance therapy.
89427376|NCT01328756|Experimental|Lisdexamfetamine Dimesylate|
89427377|NCT03466580|Experimental|Intervention|('Standard' specialized palliative care +) The Carer Support Needs Assessment Tool (CSNAT) intervention.
89427378|NCT03466580|No Intervention|Control|('Standard' specialized palliative care). No intervention offered.
89427379|NCT03130322|Experimental|NightPP|Participants of the NightPP will be subjected to one MRI session and two MEG recording sessions: the first one before a physical practice session of the two motor tasks investigated in the study, and second MEG session right after practice.
89427380|NCT03130322|Experimental|NightMI|Participants of the NightMI will be subjected to one MRI session and two MEG recording sessions: the first one before a motor imagery practice session of the two motor tasks investigated in the study, and second MEG session right after practice.
89427381|NCT03130322|Experimental|NightCtrl|Participants of the NightCtrl will be subjected to one MRI session and two MEG recording sessions: the first one before a mental rotation practice session, a second MEG session right after practice,and second MEG session right after practice.
89427382|NCT03130322|Experimental|Day|Participants of the NightMI will be subjected to one MRI session and two MEG recording sessions: the first one before a motor imagery practice session of the two motor tasks investigated in the study, and second MEG session right after practice.
89427383|NCT03466268|Experimental|Dose escalation study of Glumetinib|To determine the maximum tolerated dose (MTD) of Glumetinib
89427384|NCT02206334|Experimental|Stereotactic Body Radiation Therapy (SBRT)|Patients undergo 3-5 fractions of image-guided stereotactic body radiation therapy to all existing metastases over 1-3 weeks with at least 40 hours between treatments for an individual metastasis.
88908222|NCT06165562|Active Comparator|Conventional Emergence group|Conventional full-awake extubation will be performed based on the routine practice of our institution. At the end of surgery, sevoflurane will be stopped, and the attending anesthesiologist will lead the emergence process, allowing the patient to breathe spontaneously and providing intermittent manual assistance if necessary. Extubation will be performed when the patient meets the following criteria: obeys commands such as eye-opening or hand-grip, tidal volume > 5 ml/kg, end-tidal carbon dioxide < 45 mmHg, spontaneous respiratory rate 10 to 20 breaths/min.
88908223|NCT06165016|Experimental|Far red light therapy|Subgroup of participants receiving the 670 nm far red light device
88908224|NCT06165016|Sham Comparator|Sham therapy|Subgroup of participants receiving the sham light device, far red light device covered with blue filter paper to block 670 nm light, resulting in mean power generated of 0.24 mW/cm2, compared to 26.3 mW/cm2 for the intervention, a 100-fold difference.
88908225|NCT06164392|Experimental|Neuroma ICG|Subjects will receive Intravenous ICG to generate a Fluorescence Angiogram of the Neuroma
88908226|NCT06162806|Active Comparator|Group A|This group of patients will receive ultrasound guided caudal epidural block using 1ml/kg of Bupivacaine +0.5ulkg fentanyl
88908227|NCT06162806|Experimental|Group B|This group of patients will receive ultrasound guided caudal epidural block with 50 mg of magnesium added to (1ml/kg Bupivacaine+0.5ulkg fentanyl)bi-mixture
88908228|NCT06162715|Experimental|Tirzepatide Group|Patients will receive Tirzepatide beginning 12 months after undergoing Roux-en-Y Gastric Bypass following an adaptive modified dose titration protocol to a maximum dose of 15 mg weekly.
88908229|NCT06162715|Placebo Comparator|Control|Patients in this group will receive a placebo but will follow the same protocol as patients in the Tirzepatide group.
88908230|NCT06161805|Experimental|Esketamine|Esketamine dosing regimen is set at 0.1 mg/kg/h as starting dosage. Dosage will be gradually increased based on heart rate, oxygen saturation, blood pressure and side effects (e.g. nausea and dissociative effects) during a period of 8 hours to a maximum of 0.5 mg/kg/h (in steps of 0.1-0.3-0.5 mg/kg/hour).
88908231|NCT06161805|Placebo Comparator|Placebo|8 hours infusion with saline (NaCl 0.9%)
89427385|NCT05326178|Experimental|General information about depression|Exposure to general information about depression
89427386|NCT05392634|Active Comparator|Amoxicillin/ Cefuroksim|standard antibiotic prophylaxis 24 hours
89427387|NCT05392634|Experimental|Meropenem|preventive antibiotic therapy within 5 days from the date of the skin incision
89427388|NCT05391386|No Intervention|conventional|
89427389|NCT05391386|Experimental|modified|
89427390|NCT03466190|Experimental|Custom made PEEK plate fixation|Open Reduction Internal Fixation using Custom made PEEK plates.
89427391|NCT03466190|Active Comparator|Titanium plate fixation|Open Reduction Internal Fixation using conventional titanium plating system.
89427392|NCT03922308|Placebo Comparator|Standard of Care (SoC) + Placebo|Participants received SoC daily PEX followed by placebo immediately and 12 +/- 1 hours after completion of PEX until remission was achieved (up to approximately 6 months).
89427393|NCT03922308|Experimental|SoC + SHP655 + Placebo|Participants received SoC daily PEX and SHP655 40 +/- 4 international units per kilogram (IU/kg), IV injection, QD, immediately after PEX and placebo 12 +/- 1 hours after completion of PEX until remission was achieved (up to approximately 6 months).
89427394|NCT03922308|Experimental|SoC + SHP655|Participants received SoC daily PEX and SHP655 40 +/- 4 IU/kg, IV injection, BID, immediately after PEX and 12 +/- 1 hours after completion of PEX until remission was achieved (up to approximately 6 months).
89427395|NCT02263482|Other|Control group|patients awaiting for evaluation to cardiac rehabilitation or transplantation
89427396|NCT02263482|Experimental|moderate-intensity group|Patients will be submitted to a 8-weeks training program, with inspiratory muscle trained at 30% of the maximal inspiratory pressure (30 minutes/session/7 days/week) and peripheral muscle trained with upper and lower exercises (50% of the 1-maximum repetition test).
88908232|NCT06160609|Experimental|Belantamab mafodotin + GSK3174998|
88908233|NCT06158620|Experimental|Sprix|"Phase I will consist of a single-arm open label pilot study. Prior to the initiation of a large-scale randomized trial, we propose a single-arm open label pilot study to evaluate the feasibility, practicality, and qualitative outcomes of utilizing intra-nasal ketorolac in patients with indwelling ureteral stents. We seek to enroll 20 patients for the initial pilot.~Phase II will consist of a randomized trial comparing intranasal ketorolac to Diclofenac, a commonly used oral NSAID. , Diclofenac potassium. Following ureteroscopy and stent placement, patients will receive standard of care medications to mitigate post operative pain and stent discomfort, and will be randomized to receive either as needed intra-nasal ketorolac or oral diclofenac. We seek to enroll and randomize 60 patients in a 1:1 fashion. Analysis will be intention to treat."
88908234|NCT06158620|Active Comparator|Diclofenac|Phase II will consist of a randomized trial comparing intranasal ketorolac to Diclofenac, a commonly used oral NSAID. , Diclofenac potassium. Following ureteroscopy and stent placement, patients will receive standard of care medications to mitigate post operative pain and stent discomfort, and will be randomized to receive either as needed intra-nasal ketorolac or oral diclofenac. We seek to enroll and randomize 60 patients in a 1:1 fashion. Analysis will be intention to treat.
88908235|NCT06157892|Experimental|Dose Escalation - Previously treated advanced GC/GEJC or breast cancer|disitamab vedotin + tucatinib
88908236|NCT06157892|Experimental|Cohort A monotherapy - HER2-low 2L or 3L breast cancer|disitamab vedotin monotherapy
88908237|NCT06157892|Experimental|Cohort A - HER2-low 2L or 3L breast cancer|disitamab vedotin + tucatinib
88908238|NCT06157892|Experimental|Cohort B monotherapy - HER2+ 3L or higher breast cancer|disitamab vedotin monotherapy
88908239|NCT06157892|Experimental|Cohort B - HER2+ 3L or higher breast cancer|disitamab vedotin + tucatinib
88908240|NCT06157892|Experimental|Cohort C monotherapy - HER2-low 2L GC/GEJC|disitamab vedotin monotherapy
88908241|NCT06157892|Experimental|Cohort C - HER2-low 2L GC/GEJC|disitamab vedotin + tucatinib
89196903|NCT00830505|Experimental|1: fluticasone/salmeterol|2 puffs twice a day for 2 weeks
89196904|NCT00830505|Active Comparator|2: fluticasone|2 puffs twice a day for 2 weeks
89196905|NCT00566020|Experimental|Lamotrigine|study drug
89196906|NCT02563782|Sham Comparator|Control group|Sham surgery and placebo immunosuppressive therapy (IMT)
89196907|NCT02563782|Active Comparator|Active Group|Sub-retinal transplantation of MA09-hRPE cells and IMT
89196908|NCT00841191|Experimental|Siltuximab 2.8 mg/kg (Cohort 1)|
89196909|NCT00841191|Experimental|Siltuximab 5.5 mg/kg (Cohort 2)|
89196910|NCT00841191|Experimental|Siltuximab 11 mg/kg (Cohort 3)|
89196911|NCT00841191|Experimental|Siltuximab 15 mg/kg (Cohort 4)|
89196912|NCT00841191|Experimental|Siltuximab 15 mg/kg (Expansion Cohort 5)|
89196913|NCT00841191|Experimental|Siltuximab 15 mg/kg (Ovarian Cancer Cohort 6)|
89196914|NCT00841191|Experimental|Siltuximab 15 mg/kg (KRAS Mutant Tumors Cohort 7)|
89196915|NCT00741624|Experimental|1|bilateral post refractive surgery subject
89196916|NCT00830583|Other|1|pompe's disease suspected patient
89196917|NCT00843453|Other|1|Comparison of serum vitamin and B12 concentrations of PPI and non-PPI groups
89196918|NCT00843453|Experimental|2|Comparison of baseline and end of treatment serum vitamin B12 and MMA concentrations.
89196919|NCT00921726|Experimental|1|Participants will receive treatment in the following order: Study Regimens A, B, C, D
89536851|NCT03308357||All six subjects|2 patients with ulcerative colitis; one with active disease and one in remission. 2 patients with Crohn's disease; one with active disease and one in remission. 2 healthly controls. Single blood sample from each participant, serum collected, that serum will be spiked with known concentrations of the originator infliximab and the biosimilar infliximab and then run on a range of assays to measure infliximab drug concentrations
89008024|NCT04719975|Experimental|Mental Fatigue (Stroop) - Chair task|Participants will be performing the Chair Task (150 submaximal dynamic knee extensions at 50% of their maximal voluntary contraction (MVC)) when mentally fatigued. A 60 minute variant of the Stroop task will be used to induce the mental fatigue. During the whole trial EEG will be measured.
89196920|NCT00921726|Experimental|2|Participants will receive treatment in the following order: Study Regimens B, A, C, D
89196921|NCT00938236|Other|Inhaled cyclosporine|Extended access to inhaled cyclosporine for patients from treatment and control arms of Phase 3 study CIS001
89196922|NCT02546739|Experimental|Experimental: 1|Acute lymphoblastic leukemia treated with chimeric antigen receptor modified T cells(Anti-CD19-CAR) targeting CD19.
89196923|NCT02546739|Experimental|Experimental: 2|Chronic lymphoblastic leukemia with chimeric antigen receptor modified T cells(Anti-CD19-CAR) targeting CD19.
89427397|NCT02263482|Active Comparator|low-intensity group|Patients will be submited to a 8 weeks training program, with inspiratory muscle trained at 15% of the maximal inspiratory pressure (30 minutes/session/7 days/week) and peripheral muscle trained with exercises of upper limbs and lower limbs (0,5 Kg each).
89536852|NCT03312725||Patients with ruptured or unruptured intracranial aneurysms.|
88908242|NCT06156228|Experimental|Multilevel Intervention|The Multilevel Intervention condition will receive tailored and targeted messages about vaccination. Health educators will also deliver motivational interview sessions to patients eligible to receive the vaccines during the first 6 months of the study. To supplement these encounters, health educators will also send patients mail, emails and/or text message-based informational materials (including videos, testimonials, and resources) that reinforce the benfits of vaccines.
88908243|NCT06156228|No Intervention|Standard Clinical Practice|Standard clinical practice consisting of generic patient outreach to promote vaccine uptake among Latino patients.
88908244|NCT06155305||Breast cancer patients|Patients diagnosed with breast cancer undergo biopsy before initiating neoadjuvant therapy.
88908245|NCT06152549||MACE First Group|This group (N=250) will be presented with the Maltreatment and Abuse Chronology of Exposure (MACE) scale toward the beginning of the session and the Math/Verbal Test toward the end.
88908246|NCT06152549||Standardized Test Questions First Group|This group (N=250) will be presented with the standardized test questions (Math/Verbal) toward the beginning of the session and the Maltreatment and Abuse Chronology of Exposure (MACE) scale toward the end.
88908247|NCT06150924|Experimental|Part A - Cohort 1|
88908248|NCT06150924|Experimental|Part A - Cohort 2|
88908249|NCT06150924|Experimental|Part B - Open Label|
88908250|NCT06149312|Experimental|Advance Care Planning Intervention|Patients from experimental arm will benefit from a Standardized Advance Care Planning interview alone or in the presence of relatives within 3 days after randomization.
88908251|NCT06149312|No Intervention|Standard cares|Patients from control arm will be treated without specific intervention, which does not exclude the possibility of resorting to non standardized advance care planning interviews with an oncologist or a physician specialized in palliative care.
88908252|NCT06144489|Active Comparator|Low Dose|Low dose (3g) of Vistula tart cherry, freeze dried. 60-78 mg of anthocyanins, 8.07 kcal and had a macronutrient content of 1.215 g, 0.003 g, 0.042 g, for carbohydrates, fat and protein, respectively.
88908253|NCT06144489|Active Comparator|High Dose|High dose (6g) of Vistula tart cherry, freeze dried. 120-156 mg of anthocyanins, 16.14 kcal with 2.43 g, 0.006 g, 0.08 g for carbohydrates, fat and protein, respectively.
88908254|NCT06144489|Placebo Comparator|Placebo|Matched with the active low dose, this placebo was matched for calorific content.
88908255|NCT06143956|Experimental|LY3305677 Obesity ISA OXA1|"Participants will receive LY3305677 or placebo subcutaneously (SC).~Each ISA will detail the intervention specific analysis."
88908256|NCT06143956|Experimental|LY3841136 Obesity ISA LAA1|"Participants will receive LY3841136 or placebo SC.~Each ISA will detail the intervention specific analysis."
88908257|NCT06142682|Experimental|CIDEXEL|MED-EL Cochlear Implant Mi1250 +FLEX28 DEX (CIDEXEL)
88908258|NCT06140836|Experimental|Arm A|
88908259|NCT06140836|Active Comparator|Arm B|
88908260|NCT06140134||Intrahepatic cholangiocarcinoma listed for liver transplant|Listed patients enrolled with diagnosis of intrahepatic cholangiocarcinoma will be enrolled on an intent to treat basis with comparison between patients receiving transplant versus those who expire or are removed from the waitlist.
88908261|NCT06139536|Experimental|A/ Standard 3+3 1.0mg/kg of BAT4706 with 300mg of BAT1308|"Drug: BAT4706 injection, Dosage: 1.0mg/kg, Frequency: once every 3 weeks, Duration: 3 month.~Drug: BAT1308 injection, Dosage: 300mg, Frequency: once every 3 weeks, Duration: 1 year."
88908262|NCT06139536|Experimental|B/ Standard 3+3 2.0mg/kg of BAT4706 with 300mg of BAT1308|"Drug: BAT4706 injection, Dosage: 2.0mg/kg, Frequency: once every 3 weeks, Duration: 3 month.~Drug: BAT1308 injection, Dosage: 300mg, Frequency: once every 3 weeks, Duration: 1 year."
88908263|NCT06139536|Experimental|C/ Standard 3+3 3.0mg/kg of BAT4706 with 300mg of BAT1308|"Drug: BAT4706 injection, Dosage: 3.0mg/kg, Frequency: once every 3 weeks, Duration: 3 month.~Drug: BAT1308 injection, Dosage: 300mg, Frequency: once every 3 weeks, Duration: 1 year."
88908264|NCT06139536|Experimental|D/ Standard 3+3 6.0mg/kg of BAT4706 with 300mg of BAT1308|"Drug: BAT4706 injection, Dosage: 6.0mg/kg, Frequency: once every 3 weeks, Duration: 3 month.~Drug: BAT1308 injection, Dosage: 300mg, Frequency: once every 3 weeks, Duration: 1 year."
88908265|NCT06139536|Experimental|E/ Standard 3+3 10.0mg/kg of BAT4706 with 300mg of BAT1308|"Drug: BAT4706 injection, Dosage: 10mg/kg, Frequency: once every 3 weeks, Duration: 3 month.~Drug: BAT1308 injection, Dosage: 300mg, Frequency: once every 3 weeks, Duration: 1 year."
88908266|NCT06139263|Active Comparator|Control Group|All individuals participating in the study will receive a conventional treatment program 4 days a week. In the conventional treatment program, heat will be applied to the neck area for 20 minutes and TENS (100 Hz) will be applied to the painful area. Additionally, patients will be given joint range of motion (ROM) exercises under the supervision of a physiotherapist. Patients will be asked to perform ROM exercises in 2 sets of 10 repetitions, holding for 2 seconds at the end point in all directions. As a strengthening exercise, isometric exercises will be given in the flexion extension, right and left lateral flexion directions by waiting for 6 seconds at the end point. Isometric exercises will be performed in 2 sets of 10 repetitions with 1 minute rest between sets.
88908267|NCT06139263|Experimental|Vibration Group|Vibration application will be applied to the individuals in this group in addition to conventional methods. Vibration application will be applied to the trapezius, levator scapula and cervical paravertebral muscles with a percussion massage gun (Compex Fix 2.0) along the origo-insersio line for 3 minutes for each muscle group. Vibration application will be made with the soft head of the percussion massage gun. Vibration therapy will be applied 3 days a week for 3 weeks.
89427398|NCT02263560||Post-stroke patients|Patients who experienced stroke and who already recover gait abilities.
89427399|NCT02263560||Control population|Participants matching the criterion (age and gender) of the patients' group.
89427400|NCT02264808||Developmental outcomes|A developmental assessment (Bayley-III) of children 18-20 months who already enrolled in Florida Neonatal Neurologic Network. As part of this previous study, these children were born with Hypoxic Ischemic Encephalopathy (HIE) and underwent therapeutic cooling after birth.
89536853|NCT03308279||Asinthomatic|The only group evaluated
89196924|NCT02546739|Experimental|Experimental: 3|Non-hodgkin lymphoma treated with chimeric antigen receptor modified T cells(Anti-CD19-CAR) targeting CD19.
89196925|NCT00744198|Active Comparator|1|Autologous sling
89196926|NCT00744198|Active Comparator|2|Synthetic sling
89196927|NCT00744198|Active Comparator|3|Biological sling
89196928|NCT04013776|Active Comparator|Phosphate supplemented diet|All participants will undergo phosphate testing after following a phosphate supplemented diet for 5 days
89196929|NCT04013776|No Intervention|Low phosphate diet|All participants will undergo phosphate testing after following a low phosphate diet for 5 days
89196930|NCT00741702|Experimental|Intervention group|A home care nurse followed a predefined treatment algorithm of pharmacologic antihypertensive therapy.
89196931|NCT00741702|No Intervention|Control group|Treatment decisions were made by each subject's primary care physician. Participants in this group received usual care.
89196932|NCT00841347|No Intervention|1|Study of habitual sleep length on non obese teen group
89196933|NCT00841347|Experimental|2|Study of habitual sleep length period followed by extended sleep length period on obese teen group
89196934|NCT00841347|Experimental|3|Study of extended sleep length period followed by habitual sleep length period on obese teen group
89196935|NCT00936286|Experimental|Respiratory Muscle Training|
89196936|NCT00741780||G-CSF plus plerixafor|Participants in AMD3100-3102 (NCT00103662) who underwent mobilization with granulocyte colony-stimulating factor (G-CSF) and received plerixafor prior to undergoing apheresis.
89196937|NCT00741780||G-CSF plus placebo|Participants in AMD3100-3102 (NCT00103662) who underwent mobilization with granulocyte colony-stimulating factor (G-CSF) and received placebo prior to undergoing apheresis.
89196938|NCT00936442||Group A|Standard treatment: 12-month follow-up of anastrozole treatment according to SmPC and current clinical practice.
89196939|NCT00936442||Group B|Standard treatment + educational material: 12-month follow-up of anastrozole treatment according to SmPC and current clinical practice plus reception of educational material on regular basis.
89196940|NCT00744354|Experimental|Non-Randomized Open Label Single Arm|Phase 1 dose escalation trial of vorinostat in combination with bortezomib and pegylated liposomal doxorubicin hydrochloride.
89196941|NCT00936520|Experimental|Dose 1|SAR 1118 dose 0.1%
89196942|NCT00936520|Experimental|Dose 2|SAR 1118 dose 1.0%
89196943|NCT00936520|Experimental|Dose 3|SAR 1118 dose 5.0%
89196944|NCT02564562|Experimental|Treatment|Radiolabeled PF-06463922 in healthy volunteers
89196945|NCT00841425||Swimmers|
89196946|NCT05311566|Experimental|Patients with primary IB2-IIIB cervical cancer|Patients with primary IB2-IIIB cervical cancer, including squamous carcinoma, adenocarcinoma, and adenosquamous carcinoma.
89196947|NCT00564070|Active Comparator|Enhanced treatment as usual|Enhanced treatment as usual plus single-session life-steps treatment
89427401|NCT01593228|Experimental|1|"Patients receiving iniparib alone or in combination with other anti-cancer agents as defined by the parental study. Interventions:~Drug: Iniparib monotherapy~Drug: Iniparib + gemcitabine + carboplatin~Drug: Iniparib + topotecan~Drug: Iniparib + irinotecan~Drug: Iniparib + paclitaxel~Drug: Iniparib + liposomal doxorubicin + carboplatin"
89427402|NCT02264886|Experimental|Arm 1: Stereotactic body radiation therapy|"Radiotherapy will consist of stereotactic body therapy, to be given over five fractions, delivered once daily or once every other day for a period of one to two weeks, for a total of five treatments.~All patients will undergo MRI simulation in positioning appropriate for the specific treatment site. When medically feasible and applicable, patients will be simulated with IV and small bowel contrast (for non-thorax cases)."
89427403|NCT02264964|Experimental|internal jugular vein catheterization|900 patients will be received temporary central vena catheterization in right internal jugular vein with non-cuff GamCath® catheter.They will undergo AVF creation.
89427404|NCT02264964|Experimental|femoral vein catheterization|500 patients will be received temporary central vena catheterization in femoral vein with non-cuff GamCath® catheter, which are unsuitable for right internal jugular vein catheterization.They will undergo AVF creation.
89427405|NCT02263638|Experimental|Anakinra|One daily subcutaneous injection of a fixed dose of 100 mg will be administered at a fixed time by a nurse during a five day period
89427406|NCT02236260|Active Comparator|Local anesthesia alone|
89427407|NCT02236260|Experimental|Local Anesthesia + Electroacupuncture|
89427408|NCT02263716||Accelerometer|Utilize accelerometers to measure activity in a diverse population of patients with medical or surgical critical illness.
89427409|NCT01555554|Experimental|Propranolol Hydrochloride|
89427410|NCT01555554|Placebo Comparator|Placebo Group|
89427411|NCT03135600|Experimental|Normal|The participants from this group are healthy people.
89427412|NCT03135600|Experimental|ACLD|The participants from this group suffer from anterior cruciate ligament injury.
89427413|NCT01435044|Experimental|SOF+RBV 12 Weeks|Participants were randomized to receive sofosbuvir plus RBV plus placebo to match GS-0938 for 12 weeks.
89427414|NCT01435044|Experimental|SOF+RBV 24 Weeks|Participants were randomized to receive sofosbuvir plus RBV plus placebo to match GS-0938 for 24 weeks.
89427415|NCT01435044|Experimental|GS-0938 Alone|Participants were randomized to receive GS-0938 plus placebo to match sofosbuvir for up to 24 weeks.
89427416|NCT01435044|Experimental|GS-0938+SOF|Participants were randomized to receive GS-0938 plus sofosbuvir for up to 24 weeks.
89427417|NCT01435044|Experimental|GS-0938+SOF+RBV|Participants were randomized to receive GS-0938 plus sofosbuvir plus RBV for up to 24 weeks.
89427418|NCT01435044|Experimental|Placebo|Deferred start group: Participants were randomized to receive placebo to match GS-0938 plus placebo to match sofosbuvir for 24 Weeks.
89427419|NCT01435044|Experimental|Retreatment Group - SOF+RBV 24 Weeks|After discontinuing a regimen containing GS-0938, participants received sofosbuvir plus RBV for up to 24 weeks.
89427420|NCT01434498|Active Comparator|Arm 1|GS-5885, GS-9451, tegobuvir (GS-9190), and Copegus® for 24 weeks
89427421|NCT01434498|Active Comparator|Arm 2|GS-5885, GS-9451, tegobuvir (GS-9190), and a placebo matching ribavirin for 24 weeks
89427422|NCT01434498|Active Comparator|Arm 3|GS-5885, GS-9451, a placebo matching tegobuvir, and Copegus® for 24 weeks
89427423|NCT03735966|Experimental|Pyrotinib plus trastuzumab and docetaxel and carboplatin|Pyrotinib + trastuzumab + docetaxel+carboplatin
89427424|NCT01554696|Experimental|ASP015K lowest dose|ASP015K lowest dose daily in addition to concomitant weekly oral methotrexate
89427425|NCT01554696|Experimental|ASP015K low dose|ASP015K low dose daily in addition to concomitant weekly oral methotrexate
89427426|NCT01554696|Experimental|ASP015K medium dose|ASP015K medium dose daily in addition to concomitant weekly oral methotrexate
89427427|NCT01554696|Experimental|ASP015K high dose|ASP015K high dose daily in addition to concomitant weekly oral methotrexate
89427428|NCT01554696|Placebo Comparator|Placebo|Placebo daily in addition to concomitant weekly oral methotrexate
89427429|NCT02236416|Experimental|Intervention group|Physical exercise
89427430|NCT02236416|Other|Control group|Posture Education/Unchanged condition
89427431|NCT02236494|Active Comparator|General Health Information Pamphlet|This group will not receive a brief intervention in the ED. They will receive a pamphlet with general health information for older adults, as well as contact information for an outpatient alcohol treatment center where they have the option to follow-up for alcohol treatment at their discretion. The patient's readiness to change their alcohol habits will be measured using a 1-10 scale with a visual cue.
89427432|NCT02236494|Experimental|Brief Negotiated Interview|The BNI will follow standard steps (7, 63): 1. The research assistant (RA) will ask permission to discuss the patient's alcohol use with them. 2. They will provide feedback regarding the patient's alcohol use, and will review guidelines drinking in older adults. Where relevant, the RA will discuss how the patient's current visit may relate to their alcohol use. 3. The RA will assess the patient's readiness to change using a 1-10 scale, and will enhance motivation. 4. The RA will negotiate a goal for the patient's drinking and give advice. The patient will be asked to sign a drinking agreement.
89427433|NCT02265120|Experimental|primary care providers by region|A questionnaire will be given to a randomized sample of primary care providers who care for patients in the 194 federally designated regions of Primary Care provider shortage within California will be studied.
89427434|NCT02265198||PC Group|patients with Pulmonary Contusion on chest computed tomography (CT)
89427435|NCT02265198||Control Group 1|Uninjured patients undergoing elective surgical procedures that will require intubation and mechanical ventilation
88908268|NCT06133517|Experimental|Single Arm|Patients who are eligible to participate in the study will receive 3 cycles of sacituzumab govitecan, zimberelimab and domvanalimab every 3 weeks prior to cystectomy, unless there are signs of unacceptable toxicity, progressive disease, or the patient requests withdrawal from the study. Patients who do not achieve a pCR or that achieving a pCR still have positive ctDNA will also complete an adjuvant phase of the study consisting of 12 additional cycles of zimberelimab and domvanalimab after cystectomy.
88908269|NCT06133426|Other|Cohort group|"Patients will be used a connected scale during the duration of their participation in the study.~Patients will be invited to use the scale once a day. Patient's data will be accesible by medical team via a specific remote plateform.~Alert will be generated according to the evolution of clinical data, permetting a early patient management by the medical team."
88908270|NCT06133413|No Intervention|Standard of care group|Standard follow-up
88908271|NCT06133413|Experimental|Connected scale group|Standard follow up + Use weekly of Body Comp Pro connected scale, associated with a remote monitoring by medical team allowing alert generation and early intervention
88908272|NCT06131840|Experimental|SGN-CEACAM5C|SGN-CEACAM5C monotherapy
88908273|NCT06131541|Experimental|Group I: autogenous bone graft group|11 subjects will be assigned to receive alveolar ridge splitting in combination with autogenous bone graft associated with immediate implant placement
88908274|NCT06131541|Experimental|Group II: autogenous tooth graft group|11 subjects will be assigned to receive alveolar ridge splitting in combination with undemineralized autogenous tooth graft associated with immediate implant placement
89427436|NCT02265198||Control Group 2|Trauma patients without chest injury who are mechanically ventilated
89427437|NCT02265198||MICU group|Patients in the Medical ICU who are mechanically ventilated with acute respiratory failure
89427438|NCT02265276|Active Comparator|Saroglitazar Group|Tab Saroglitazar 4 mg oral daily fixed dose for 24 weeks
89427439|NCT02265276|Placebo Comparator|Pioglitazone Group|Tab Pioglitazone 30 mg daily fixed dose for 24 weeks
89427440|NCT02263872|Experimental|Minocycline|Minocycline 200mg perday
89427441|NCT02263872|Placebo Comparator|comparison group with placebo|Placebo provide
89427442|NCT02265354|Experimental|Collective-Intelligence computer tailored health communication|Smokers will have access to all Decide2quit.org website functions and will receive 4 tailored emails per week based on a collective intelligence recommender systems algorithm for up to 6 months
89427443|NCT02265354|Active Comparator|Rule-based computer tailored health communication|Smokers will have access to all Decide2quit.org website functions and will receive 4 tailored emails per week based on a rule-based algorithm for up to 6 months
89531087|NCT03120767|No Intervention|Condition 3|a control group that receives none of the interventions during the first year. This group will instead receive an online pamphlet that contains a number of wellness tips and advice for first-year students. Condition 3 participants have access to the WIN Living and Learning Community wellness activities in Fall of 2017 and Spring of 2018, but are not directly encouraged to participate.
88908277|NCT06131372|Experimental|CagriSema 2.4 mg/2.4 mg|Participants will receive 2.4 milligram (mg) cagrilintide and 2.4 mg semaglutide subcutaneously once-weekly after a dose escalation period of 16 weeks during the maintenance period for 10 weeks.
89536162|NCT03199495|Experimental|electroacupuncture|Participants were randomized divided into experimental and control groups .Acupuncture included Hegu (LI 4), Neiguan (PC6), Zusali (ST 36), Shanjuxu (ST37), Xiajuxu (ST39), Taichong (LR3) and Taibai(SP3) on both hands and legs. Acupuncture included Hegu (LI 4) and Neiguan (PC6), Zusali (ST 36) and Taichong (LR3) with electrical stimulation were conducted. The frequency of electrical stimulation was 2 Hz and the intensities of the stimulation was below 9.8 mA for 15 minutes.After 15 minutes treatment, acupuncture were removed and after 15 minutes the investigators stated to evaluate.
88908278|NCT06131372|Experimental|Semaglutide 2.4 mg|Participants will receive semaglutide 2.4 mg and placebo matched to cagrilintide subcutaneously once-weekly after a dose escalation period of 16 weeks during the maintenance period for 10 weeks.
88908279|NCT06131372|Experimental|Cagrilintide 2.4 mg|Participants will receive cagrilintide 2.4 mg and placebo matching to semaglutide subcutaneously once-weekly after a dose escalation period of 16 weeks during the maintenance period for 10 weeks.
88908280|NCT06131372|Placebo Comparator|Placebo|Participants will receive 2.4 mg placebo matched to cagrilintide and placebo matched to semaglutide subcutaneously once weekly for 26 weeks.
88908281|NCT06130540|Experimental|Secukinumab: Giant Cell Arteritis (GCA)|
88908282|NCT06130540|Experimental|Secukinumab: Polymyalgia Rheumatica (PMR)|
88908283|NCT06129422|Experimental|NMK89|Patients will receive a single infusion of NMK89
88908284|NCT06128746|Experimental|Interventional rTMS group|The intervention group will receive 1 Hz active rTMS during treatment, lasting for 20 minutes, follow up by 30 minutes of intensive limb training.
88908285|NCT06128746|Sham Comparator|Sham rTMS group|The sham group will not receive any Hz of rTMS during treatment, also lasting for 20 minutes with 30 minutes of intensive limb training afterwards.
88908286|NCT06126887|Experimental|Incrediwear Daytime|Incrediwear back brace worn 7AM-7PM (against skin)
88908287|NCT06126887|Sham Comparator|Incrediwear Sham Daytime|Incrediwear sham back brace worn 7AM-7PM (against skin)
88908288|NCT06126887|Placebo Comparator|Control Daytime|Standard-issue brace (e.g. Horizon Lumbar Brace (Aspen Medical Products, LLC)) worn 7AM-7PM
88908289|NCT06126887|Active Comparator|Incrediwear 24 hour|Incrediwear back brace worn 7AM-7PM (against skin). Incrediwear waist sleeve worn 7PM-7AM (against skin)
88908290|NCT06126315|Experimental|alcar 1.5 g|2 pockets of ALCAR will be administered t.i.d for 48 weeks. Total daily dosage: 1.5 g
88908291|NCT06126315|Experimental|alcar 3 g|2 pockets of ALCAR will be administered t.i.d for 48 weeks. Total daily dosage: 3 g
88908292|NCT06126315|Placebo Comparator|placebo|2 pockets of placebo will be administered t.i.d for 48 weeks.
88908293|NCT06124846|No Intervention|control|Age- and sex-matched adolescents with no lifetime history of cannabis use will also complete the protocol.
88908294|NCT06124846|Experimental|CB-Abst|adolescents ages 15-18 years old with CUD use randomized to CB-Abst
88908295|NCT06124846|Experimental|CB-MON|adolescents ages 15-18 years old with CUD use randomized to CB-Mon
88908296|NCT06124144|Experimental|Oleylphosphocholine capsules (IMP) oral administration|Participants will receive once Oleylphosphocholine (capsule/s) orally as a single dose under fed conditions.
88908297|NCT06122441|Experimental|Complex lifestyle intervention|Receives a complex lifestyle intervention, a wrist-worn activity tracker, and access to national recommendations on physical activity.
88908298|NCT06122441|Active Comparator|Active control|Receives a wrist-worn activity tracker and access to national recommendations on physical activity.
88908299|NCT06122181|Experimental|HS-10384|Multiple ascending doses of HS-10384 orally
88908300|NCT06122181|Placebo Comparator|Placebo|Multiple ascending doses of HS-10384 placebo orally
88908301|NCT06121609|Experimental|0-3 years group|Age:<48 months
88908302|NCT06121609|Experimental|4-6 years group|Age: ≥48 and <84 months
88908303|NCT06121609|Experimental|7-12 years group|Age: ≥84and <156 months
88908304|NCT06121492|Experimental|Branched-chain amino acid|In the branched-chain amino acid (BCAA group), participants will receive oral BCAA for 24 weeks, with a daily dosage of approximately 13.68 g/day. Each sachet of BCAA will contain 6.84 g of BCAA (valine 1.82 g, leucine 3.29 g, isoleucine 1.72 g), total protein 17.08 g, carbohydrates 25.48 g, fat 5.66 g, providing 221.2 kcal of energy. Each sachet weighs 52 g and should be mixed with 150 ml of water. Participants will consume 2 sachets daily, one after breakfast and one after dinner.
89196948|NCT00564070|Experimental|CBT-AD|Enhanced treatment as usual plus multiple-session CBT treatment (CBT-AD)
89427444|NCT02265432|Experimental|Mobile technology intervention|"General physical activity educational materials~Wearable activity tracking devices to enable the intervention participants to self-monitor their physical activity behavior and receive real-time feedback~Access to an online map of Singapore providing location based information about leisure time physical activity opportunities~Personalized text messages which include, educational information, tailored theory-based motivational messages, as well as compliance enhancing reminders"
89427445|NCT02265432|Other|Control|1.General physical activity educational materials
89427446|NCT02261376|Experimental|Caucasian men, aged 18-55 years|
88908305|NCT06121492|Placebo Comparator|Placebo|In the placebo group, BCAA will be replaced with maltodextrin. Each sachet of the placebo will contain a total of 5.93 g of protein, 35.87 g of carbohydrates, 6.00 g of fat, providing 221.2 kcal of energy. Like the BCAA sachets, each placebo sachet will weigh 52 g and should be mixed with 150 ml of water. Participants in the placebo group will consume 2 sachets daily, one after breakfast and one after dinner.
89427447|NCT02261376|Experimental|Caucasian men, aged 65 years or older|
89427448|NCT02261376|Experimental|Japanese men, aged 18-55 years|
89427449|NCT02261376|Experimental|Caucasian women, aged 18-55 years|
89427450|NCT02261454|No Intervention|No gum chewing|Usual pharmacologic treatment and post-operative care (e.g. daily visits by surgical team, antibiotics where appropriate, mobilization, advancement of diet as tolerated). Analgesia and anti-emetics will be provided (both oral and intravenous) as needed.
89536854|NCT03312647||Latent tuberculosis infection|Identified subjects with latent tuberculosis infection (LTBI) using whole-blood interferon-r release assays. All enrolled subjects were treated with one of the recommended regimens for LTBI treatment: 9 months of isoniazid, 4 months of rifampin and 3 months of isoniazid plus rifampin. Blood, urine sampling, and monitoring frequencies of adverse reactions of anti-TB drugs were performed.
88908306|NCT06121050|Experimental|Pet visit|Intensive care patients visited by their pets for 20 minutes
88908307|NCT06120790||Patients with Tracheostomies|Patients with openings in their airways (i.e. tracheostomies)
88908308|NCT06119594|No Intervention|Standard follow-up group|Routine care
88908309|NCT06119594|Experimental|Connected scale group|Routine care + use of connected scale during 6 months
88908310|NCT06119451|Experimental|Interventional Group|Participants who will be given both educational video and traditional music therapy 3 times a week for 4 weeks in a row. This group will get Maslach Burnout Inventory, Heart Rate Variability, IgA, T cell regulator, cortisol, and endorphine score evaluated before, in the middle, right after finishing intervention, and 2 weeks after intervention.
88908311|NCT06119451|No Intervention|Control group|Participants who will be given only educational video. This group will get Maslach Burnout Inventory, Heart Rate Variability, IgA, T cell regulator, cortisol, and endorphine score evaluated before, in the middle, right after finishing intervention, and 2 weeks after intervention.
88908312|NCT06118255|Experimental|Fenfluramine Open-label|All study participants will initiate fenfluramine hydrochloride (HCl) treatment at 0.2 mg/kg/day in the Dose-Finding Period and may be up-titrated to a maximum of 0.8 mg/kg/day based on the Investigators discretion. The dose of fenfluramine HCl can be flexibly titrated during the Maintenance Period. Study participants, who discontinue early will participate in the Taper Period. All participants will complete an End of Treatment (EOT) Visit.
88908313|NCT06117735|Experimental|PTFE covered stent|Use the experimental device, PTFE covered stent to treat protal hypertension.
88908314|NCT06117423|Other|No administration of adalimumab-680LT|Patients did not receive adalimumab-680LT, but underwent a Fluorescence Molecular Imaging procedure to serve as a control group and compare results with patients receiving the tracer
88908315|NCT06117423|Experimental|4.5 mg adalimumab-680LT|Patients received 4.5 mg adalimumab-680LT and underwent a Fluorescence Molecular Imaging procedure
88908316|NCT06117423|Experimental|15 mg adalimumab-680LT|Patients received 15 mg adalimumab-680LT and underwent a Fluorescence Molecular Imaging procedure
88908317|NCT06117423|Experimental|25 mg adalimumab-680LT|Patients received 25 mg adalimumab-680LT and underwent a Fluorescence Molecular Imaging procedure
88908318|NCT06117423|Experimental|>14 weeks of adalimumab therapy + optimal dose adalimumab-680LT|Patients who received the optimal dose during the first Fluorescence Molecular Imaging procedure are invited for a second procedure after at least 14 weeks of adalimumab therapy. They will receive the optimal dose adalimumab-680LT and will undergo another Fluorescence Molecular Imaging procedure
88908319|NCT06116760|Experimental|Anodal Occipital tDCS + audio-visual training|Anodal tDCS on ipsilesional occipital cortex. Anode electrode placed on O1/O2 (10-20 EEG system) and reference electrode placed on the contralateral forehead. Stimulation delivered at 2mA during the first 30 minutes of the audio-visual training.
88908320|NCT06116760|Experimental|Anodal Parietal tDCS + audio-visual training|Anodal tDCS on ipsilesional posterior parietal cortex. Anode electrode placed on P3/P4 (10-20 EEG system) and reference electrode placed on the contralateral forehead. Stimulation delivered at 2mA during the first 30 minutes of the audio-visual training.
88908321|NCT06116760|Sham Comparator|Sham tDCS + audio-visual training|Arm 3: sham tDCS. Half of participants with Group 1 montage, the other half with Group 2 montage. Stimulator is turned off after 30s of the audio-visual training.
88908322|NCT06116526|Experimental|Dupilumab - discontinuation|Participants will discontinue their dupilumab treatment for atopic dermatitis.
88908323|NCT06116526|Experimental|Dupilumab - dose reduction|Participants whose standard dupilumab dosing for atopic dermatitis is 200 mg or 300 mg every 2 weeks will decrease drug administration to every 4 weeks, and participants whose standard dupilumab dosing is 200 mg or 300 mg every 4 weeks will decrease administration to every 8 weeks.
88908324|NCT06116526|Experimental|Dupilumab - standard dosing|"Participants will continue to receive standard maintenance dupilumab dosing for atopic dermatitis according to FDA labeling, as indicated below.~Infants ≥6 months and Children <6 years:~5 to <15 kg: 200 mg every 4 weeks. 15 to <30 kg: 300 mg every 4 weeks~Children ≥6 years and Adolescents ≤17 years:~15 to <30 kg: 300 mg every 4 weeks 30 to <60 kg: 200 mg every other week~≥60 kg: 300 mg every other week"
88908325|NCT06116071||GD subjects with normal growth rate and no bone involvement|No drug interventions.
88908326|NCT06116071||GD type 1 subjects with evidence of bone involvement|No drug interventions.
88908327|NCT06116071||GD type 3 subjects|No drug interventions.
88908328|NCT06116071||Non-GD age and gender-matched controls with normal growth rate and no known bone complications|No drug interventions.
88908329|NCT06114862|No Intervention|Control|Of the individuals identified in the screener survey endorsing past year mental health symptoms, half will be randomized into the control group. The control group will not be contacted. The investigators will passively monitor their posts on RallyPoint for the duration of the study (6 months).
89008025|NCT04719975|Placebo Comparator|Control Task (Documentary) - Chair Task|In the control task subjects will have to watch a documentary on the same computer screen as that used for the experimental trial. These documentaries are chosen based on their emotionally neutral, yet engaging content. This will be followed by the Chair Task, During the whole trial EEG will be measured.
89196949|NCT00835029|Active Comparator|Clotrimazole varnish|Clotrimazole in a slow release varnish treatment
89196950|NCT00835029|Active Comparator|Clotrimazole troches|Clotrimazole troches 10 mgx5 day for treatment of denture associated candiad infection
89427451|NCT02261454|Active Comparator|Gum chewing|"Usual pharmacologic treatment and post-operative care (e.g. daily visits by surgical team, antibiotics where appropriate, mobilization, advancement of diet as tolerated). Analgesia and anti-emetics will be provided (both oral and intravenous) as needed.~Intervention: 1 piece of sugarless gum to be chewed three times daily for 1 hour each."
89427452|NCT02261532|Experimental|TAS-102|
89427453|NCT01535508|Experimental|Liquid Vitamin D|
88908330|NCT06114862|Experimental|Intervention|Of the individuals identified in the screener survey endorsing past year mental health symptoms, half will be randomized into the intervention group. Participants in the intervention group will be recruited using a banner or pop-up message on their RallyPoint homepage or through a message on the RallyPoint site which will ask them if they have time to answer a few questions about their experiences on the RallyPoint site. If participants decline to answer these questions, a message will appear stating that they will be contacted again later, and the investigators will wait several days before contacting the potential participant again. After three attempts, participants will not be re-contacted. Participants' posts on RallyPoint will be passively monitored for 6 months after completing the intervention.
88908331|NCT06113679|Active Comparator|Active|
88908332|NCT06113679|Sham Comparator|Sham|
89427454|NCT01423110|Experimental|BYM338|
89427455|NCT01423110|Placebo Comparator|Placebo|
88908333|NCT06112418|No Intervention|Risk Factor-Based Care|The risk factor-based care group will be managed by their usual care providers, with an initial pre-randomization assessment of current treatment by a centralized cardiology team to optimize care relative to primary prevention guidelines. During the trial, the centralized cardiology team will monitor the provision of medications prescribed and lab values relative to guidelines, and provide feedback and education to site investigators to support optimization. CCTA results will be centrally archived and will remain blinded to the usual care provider until the end of the study.
89427456|NCT01420770|Experimental|SAR02503 300 mg qd|daily X 28 days
89427457|NCT01420770|Experimental|SAR302503 400 mg qd|daily X 28 days
89427458|NCT01420770|Experimental|SAR302503 500 mg qd|daily X 28 days
89427459|NCT01529424|Experimental|Group 1|Non-extensive PK/non post-prandial
89427460|NCT01529424|Experimental|Group 2a|Extensive PK
89427461|NCT01529424|Experimental|Group 2b|Post-prandial assessment
89427462|NCT01529424|Experimental|Group 3|Stable dose of fibrate
89427463|NCT01529424|Experimental|Group 4|Fredrickson Type 1 dyslipidemia
89427464|NCT02637960|Experimental|Fedovapagon 2 mg|One daily dose of 2 mg fedovapagon for 12 weeks
89427465|NCT02637960|Experimental|Placebo matched to fedovapagon|One daily dose of placebo (matched to fedovapagon) for 12 weeks
89427466|NCT01523184|Placebo Comparator|Placebo Capsule|Placebo Capsules
89427467|NCT01523184|Active Comparator|YKP10811 Drug Product Capsule, 10 mg|
89427468|NCT01523184|Active Comparator|YKP10811 Drug Product Capsule, 20 mg|
89427469|NCT01523184|Active Comparator|YKP10811 Drug Product Capsule, 30 mg|
89427470|NCT02261610|Experimental|clinical group|In the first group of patients, the use of antibiotics will be guided by clinical (clinical group).
89427471|NCT02261610|Other|PCT group|In the second group, the use of antibiotics will be guided by the algorithm (PCT group).
89427472|NCT01416402|Other|Arhalofenate with febuxostat and colchicine|
88908334|NCT06112418|Experimental|Cleerly Stage-Based Care|The Cleerly Stage-Based Care group will receive personalized care centrally managed by a remote cardiologist-led team. They will also receive an initial pre-randomization assessment of current treatment by a centralized cardiology team to optimize care relative to primary prevention guidelines. Cleerly CAD Staging System results will be discussed with participants and serve as the basis for standardized algorithm-supported pharmacotherapy & education, which will be intensified if plaque burden has progressed at 24 months.
88908335|NCT06109181|Experimental|LX2020|Single ascending dose of LX2020, with a starting dose of 2.0 x10^13 gc/kg, in multiple cohorts
89427473|NCT01414920|Placebo Comparator|Placebo QD|
89427474|NCT01414920|Experimental|TAK-875 25 mg QD|
89427475|NCT01414920|Experimental|TAK-875 50 mg QD|
89427476|NCT01414920|Experimental|Sitagliptin 100 mg QD|
89427477|NCT01414920|Experimental|TAK-875 25 mg QD + Sitagliptin 100 mg QD|
89427478|NCT01414920|Experimental|TAK-875 50 mg QD + Sitagliptin 100 mg QD|
89427479|NCT01517880|Experimental|6,000 mg SA-ER|Subjects will receive this dose for the duration of the study (total study duration of 48 weeks).
89427480|NCT01517880|Placebo Comparator|Placebo|Subjects will be randomized to the placebo arm for the first 24 weeks of the study. Then, subjects in this arm will be re-randomized into either the 3,000 mg per day or 6,000 mg per day arm for the remaining 24 weeks of the study (48 weeks total study duration).
89427481|NCT01517880|Experimental|3,000 mg SA-ER|Subjects will receive this dose for the duration of the study (total study duration of 48 weeks).
89427482|NCT01412034|Experimental|CER-001|Open label single arm study of CER-001
88908336|NCT06108297|Experimental|Lithium|Lithium capsules titrated to 30-45mg/day based on individual patient subjective benefits and tolerability.
88908337|NCT06108063|Experimental|Losartan (investigational)|Losartan 12.5 mg, PO, BID, for four weeks post-TKA surgery (on Days 1 through 28, starting the day after surgery).
88908338|NCT06108063|Placebo Comparator|Placebo (control)|Losartan Placebo 12.5 mg, PO, BID, for four weeks post-TKA surgery (on Days 1 through 28, starting the day after surgery).
88908339|NCT06107764|Active Comparator|Intermittent theta burst stimulation (iTBS)|Participants complete MRI scanning and cognitive testing followed by rTMS (iTBS pattern) followed by repeat cognitive testing and MRI scanning
88908340|NCT06107764|Active Comparator|continuous theta burst stimulation (cTBS)|Participants complete MRI scanning and cognitive testing followed by rTMS (cTBS pattern) followed by repeat cognitive testing and MRI scanning
88908341|NCT06107764|Sham Comparator|sham rTMS|Participants complete MRI scanning and cognitive testing followed by sham rTMS followed by repeat cognitive testing and MRI scanning
88908342|NCT06107712|Experimental|Online yoga exercise group|Online yoga practice was implemented in a calm and quiet environment in the individuals' own home or dormitory in a way that they could participate online.
88908343|NCT06107712|Active Comparator|Face-to-face yoga exercise group|Face-to-face yoga practice was carried out at therapeutic exercise laboratory at Marmara University Health Sciences Faculty.
88908344|NCT06107712|No Intervention|control|Participants in the control group who continued their routine activities for six weeks after the initial evaluation and did not participate in any exercise, yoga, etc. program were included in the second evaluation.
88908345|NCT06106412|Experimental|GROUP 1 IONOMYCIN SIGMA|The oocytes obtained from the patients allocated to this group will be subdivided again in two groups Group 1a: Oocytes treated with SIGMA ionomycin (treatment). Group 1b: Oocytes that will not be treated with any activator (Control).
89427483|NCT02261688|Other|Subjects in study|All subjects in study are in a cross-over study with 3 interventions sequentially (low salt diet, low salt diet + IV normal saline, liberal salt diet)
89427484|NCT02263950|Experimental|LON002|(Artemether sublingual spray)
89427485|NCT02261844|Experimental|resveratrol|Resveratrol 1 g daily for 10 days
89427486|NCT02261844|Placebo Comparator|Placebo|Placebo 1 pill daily for 10 days
89427487|NCT02261922|Experimental|ticagrelor|ticagrelor treatment
89427488|NCT02261922|Active Comparator|prasugrel|prasugrel treatment
89427489|NCT02264028|Active Comparator|[14C]-DK-AH 269 CL intravenous|
89427490|NCT02264028|Experimental|[14C]-DK-AH 269 CL oral|
88908346|NCT06106412|Active Comparator|GROUP 2 A23187|The oocytes obtained from the patients allocated to this group will be subdivided again in two groups Group 2a: Oocytes treated with A23187 (treatment). Group 2b: Oocytes that will not be treated with any activator (Control).
88908347|NCT06105021|Experimental|Dose Escalation|Subjects will be given a one-time infusion of AFNT-211 starting at dose level 1 and monitored for 28 days (DLT period). Each cohort will enroll 2-4 subjects at different dose levels for a total of 20 subjects in the escalation portion. The optimal biological dose and recommended phase 2 dose will be determined.
89196951|NCT02562768|Experimental|LY3154207|LY3154207 administered orally once daily in multiple-ascending dose cohorts for 14 days.
89196952|NCT02562768|Placebo Comparator|Placebo|Placebo matching LY3154207 administered once daily for 14 days.
89427491|NCT02264106|Experimental|Lefradafiban tablet with pantoprazole|
89427492|NCT02264106|Active Comparator|Lefradafiban tablet|
89427493|NCT02264106|Experimental|Lefradafiban double chamber sachet with pantoprazole|
89427494|NCT02264106|Active Comparator|Lefradafiban double chamber sachet|
89427495|NCT02262156|Experimental|Cognitive behavioral Therapy|"CBT program to be used in group modality that focused on managing symptoms of depression in patients with epilepsy.~12 CBT sessions, consisting of one weekly 90-minute session for 12 consecutive weeks."
89427496|NCT02262156|Active Comparator|Selective serotonin euptake inhibitor|Patients will receive a SSRI (sertraline or citalopram) for 12 weeks. Dose will be adjusted every 4 weeks according to medical criteria.
89427497|NCT02612922|Active Comparator|Nitazoxanide|Two Nitazoxanide 300 mg tablets orally twice daily (b.i.d.) for 5 days
89427498|NCT02612922|Placebo Comparator|Placebo|Two Placebo tablets orally twice daily (b.i.d.) for 5 days
89427499|NCT01516476|Experimental|Liraglutide Arm|
89427500|NCT01516476|Placebo Comparator|Placebo Arm|
89427501|NCT01516476|Experimental|RO6807952 Arm 1|
88908348|NCT06105021|Experimental|Dose Expansion: PDAC|20 subjects with pancreatic ductal adenocarcinoma will be given a one-time infusion of AFNT-211 at the optimal biological dose / recommended phase 2 dose determined in the escalation portion. Subjects will be monitored for safety for 28 days.
89427502|NCT01516476|Experimental|RO6807952 Arm 2|
88908349|NCT06105021|Experimental|Dose Expansion: CRC|20 subjects with colorectal carcinoma will be given a one-time infusion of AFNT-211 at the optimal biological dose / recommended phase 2 dose determined in the escalation portion. Subjects will be monitored for safety for 28 days.
88908350|NCT06105021|Experimental|Dose Expansion: NSCLC|20 subjects with non-small cell cancer will be given a one-time infusion of AFNT-211 at the optimal biological dose / recommended phase 2 dose determined in the escalation portion. Subjects will be monitored for safety for 28 days.
89427503|NCT01516086|Experimental|Fluticasone Propionate (FP) - arm 1|FP BID (twice daily)
88908351|NCT06105021|Experimental|Dose Expansion: Adv Solid Tumors|20 subjects with solid tumors will be given a one-time infusion of AFNT-211 at the optimal biological dose / recommended phase 2 dose determined in the escalation portion. Subjects will be monitored for safety for 28 days.
88908352|NCT06101654||Healthy Adult Volunteers|Minimum of ten (10) subjects meeting the eligibility criteria.
88908353|NCT06101173|Experimental|Experimental vaccine group A, Low dose, Intramuscular injection (IM)|1 dose of Low-adjuvant dose VLP-Polio vaccine on Visit 1
88908354|NCT06101173|Active Comparator|Control vaccine group A, IM|1 dose of IPOL vaccine on Visit 1
88908355|NCT06101173|Experimental|Experimental vaccine group B, Medium dose, Intramuscular injection (IM)|1 dose of Medium dose VLP-Polio vaccine on Visit 1
88908356|NCT06101173|Active Comparator|Control vaccine group B, IM|1 dose of IPOL vaccine on Visit 1
88908357|NCT06101173|Experimental|Experimental vaccine group C, High dose, Intramuscular injection (IM)|1 dose of High dose VLP-Polio vaccine on Visit 1
88908358|NCT06101173|Active Comparator|Control vaccine group C, IM|1 dose of IPOL vaccine on Visit 1
88908359|NCT06101134|Experimental|Cohort 1: Metastatic Melanoma|
89427504|NCT01516086|Experimental|Fluticasone propionate (FP) - arm 2|FP BID
89427505|NCT01516086|Experimental|Fluticasone Propionate (FP) - arm 3|FP BID
88908360|NCT06101134|Experimental|Cohort 2: Resected Melanoma|
89427506|NCT01516086|Experimental|FLuticasone Propionate (FP) - Arm 4|FP BID
89427507|NCT01516086|Experimental|Fluticasone Propionate (FP) - Arm 5|FP BID
89427508|NCT01516086|Placebo Comparator|Placebo - Arm 6|Placebo inhalation solution
89427509|NCT02265666|Experimental|BIIL 284 BS Tablet FF|
89427510|NCT02265666|Active Comparator|BIIL 284 BS tablet C|
89427511|NCT03135756||Depression and anxiety symptoms|
89427512|NCT03135756||Healthy controls|
89427513|NCT01497834|Experimental|Daclatasvir + Asunaprevir|
88908363|NCT06099379|Experimental|CBD:THC Group 1|"Group will receive four doses of CBD:THC ratio (20:20 mg, 40:20 mg, 80:20 mg and 120:20 mg) and a control product CBD:THC ratio (0:20 mg).~Group will attend a total of five study visits (one for each study product) with at least 1 week between each visit.~The order in which the study products will be administered depend on the randomization sequence."
89427514|NCT02262234|Experimental|Education Program Type 1|
89427515|NCT02262234|Experimental|Education Program Type 2|
89427516|NCT02262312||Patients with myelodysplastic syndrome|Patients with myelodysplastic syndrome among these include also patients with chronic myelomonocytic leukemia with myelodysplasia, patients with acute myeloid leukemia progressed from myelodysplastic syndrome and patients with myelodysplastic/myeloproliferative neoplasm, unclassifiable
89427517|NCT02265822|Experimental|melatonin|0.5 mg/kg (max 20 mg) oral melatonin premedication will be administered approximately 40 min before the induction of general anaesthesia with propofol. The melatonin will be prepared in a fixed volume of 5 ml adding water in a syringe without needle.
89427518|NCT02265822|Active Comparator|midazolam|0.5 mg/kg (max 20 mg) oral midazolam premedication will be administered approximately 40 min before the induction of general anaesthesia with propofol. The melatonin will be prepared in a fixed volume of 5 ml adding 5% dextrose in a syringe without needle.
89427519|NCT01491516|Experimental|Investigational|
89427520|NCT02265900|Active Comparator|Exercise 1|One type of exercise
89427521|NCT02265900|Placebo Comparator|Exercise 2|A different type of exercise
89427522|NCT02265978|Experimental|CopeSmart|
89427523|NCT02265978|No Intervention|Control|
89427524|NCT01385592|Experimental|AFQ056 100 mg|
89196953|NCT00843609|Experimental|Continuous glucose monitoring|Continuously wearing the FreeStyle Navigator continuous glucose monitor, displaying real-time glucose values and sounding alarms
89008026|NCT04719975|Experimental|Mental Fatigue (Stroop) - Bike Task|Participants will be performing the Bike Task (a 9 min cycling task performed at 45 rpm with intensity being constant and will be 10% below VT) when mentally fatigued. A 60 minute variant of the Stroop task will be used to induce the mental fatigue. During the whole trial EEG will be measured.
89196954|NCT00843609|No Intervention|Control|Using SMBG with standard routine instructions
89196955|NCT00744510|Experimental|1|Reflexology
89196956|NCT00744510|No Intervention|2|
89196957|NCT00940186||pikamilone|
89196958|NCT00940186||dosage|low dosage group: administrate pikamilone tablet 50 mg; middle dosage group: administrate pikamilone tablet 100 mg; hige dosage group: administrate pikamilone tablet 200 mg.
88908364|NCT06099379|Experimental|CBD:THC Group 2|"Group will receive four doses of CBD:THC ratio (20:20 mg, 40:20 mg, 80:20 mg and 120:20 mg) and a control product CBD:THC ratio (0:20 mg).~Group will attend a total of five study visits (one for each study product) with at least 1 week between each visit.~The order in which the study products will be administered depend on the randomization sequence."
88908365|NCT06099379|Experimental|CBD:THC Group 3|"Group will receive four doses of CBD:THC ratio (20:20 mg, 40:20 mg, 80:20 mg and 120:20 mg) and a control product CBD:THC ratio (0:20 mg).~Group will attend a total of five study visits (one for each study product) with at least 1 week between each visit.~The order in which the study products will be administered depend on the randomization sequence."
88908366|NCT06099379|Experimental|CBD:THC Group 4|"Group will receive four doses of CBD:THC ratio (20:20 mg, 40:20 mg, 80:20 mg and 120:20 mg) and a control product CBD:THC ratio (0:20 mg).~Group will attend a total of five study visits (one for each study product) with at least 1 week between each visit.~The order in which the study products will be administered depend on the randomization sequence."
88908367|NCT06099379|Experimental|CBD:THC Group 5|"Group will receive four doses of CBD:THC ratio (20:20 mg, 40:20 mg, 80:20 mg and 120:20 mg) and a control product CBD:THC ratio (0:20 mg).~Group will attend a total of five study visits (one for each study product) with at least 1 week between each visit.~The order in which the study products will be administered depend on the randomization sequence."
88908368|NCT06096545|Active Comparator|Group 1 = Fine needle aspiration biopsy|In Group A, patients with axillary metastasis identified by FNAB were subjected to repeat ultrasound-guided FNAB after completion of neoadjuvant treatment, The obtained biopsies were sent for histopathological evaluation without revealing patient names to avoid influencing the research results, and the surgical team was not informed of the biopsy results. During surgery, both dyed lymph nodes and clipped lymph nodes were excised for SLNB and assessed by frozen section evaluation.
88908369|NCT06096545|Active Comparator|Group 2 = Core biopsy|in Group B, patients with axillary metastasis identified by CNB underwent repeat biopsy using the same method after completing neoadjuvant treatment.The obtained biopsies were sent for histopathological evaluation without revealing patient names to avoid influencing the research results, and the surgical team was not informed of the biopsy results. During surgery, both dyed lymph nodes and clipped lymph nodes were excised for SLNB and assessed by frozen section evaluation.
88908370|NCT06094894|Experimental|Sucralose|The intervention will consist of capsules filled with pure sucralose. Each capsule will contain 90 mg of sucralose. Participants will be asked to consume one capsule in each meal (three per day) to achieve an ingestion of 270 mg of sucralose, this quantity corresponds approximately to the 30% of the acceptable daily intake (ADI) of sucralose for a lean person. This was calculated based on the ADI established by the joint FAO/WHO expert committee on food additives (JECFA) of 15 mg per kg of body weight per day of sucralose.
88908371|NCT06094894|Placebo Comparator|Placebo|The intervention will consist of capsules filled with placebo (cornstarch). Each capsule will contain 90 mg of cornstarch. Participants will be asked to consume one capsule in each meal (three per day) in order to achieve an ingestion of 270 mg of placebo, this quantity is in order to match the sucralose consumed in the intervention group.
88908372|NCT06094036|Other|weekly physical activity volume performed above 600 MET·minutes/week|Exercise program requiring clear definition of modality, intensity, frequency, duration and progression of exercise, tailored on patient's clinical conditions and goals.
88908373|NCT06094036|Other|weekly physical activity volume performed below 600 MET·minutes/week|Exercise program requiring clear definition of modality, intensity, frequency, duration and progression of exercise, tailored on patient's clinical conditions and goals.
88908374|NCT06091982||AKI-RRT|Post cardiovascular surgery patients with condition of acute kidney injury postoperative; and with an exposure of renal replacement therapy (intermittent haemodialysis or continuous renal replacement therapy) which is indicated postoperatively.
88908375|NCT06091982||AKI non RRT|Post cardiovascular surgery patients with condition of acute kidney injury postoperative; but without exposure of renal replacement therapy.
88908376|NCT06091514|Other|Cohort group|"Patients will be followed during a period ranging from 3 to 12 months depending on his period at risk of AF. This period will be defined at the inclusion visit. During this period, the patient will be followed as part of usual care, considering the medical informations given by the ILR device already implanted.~During this period, the patient will have to wear the watch permanently outside charging time. Moreover, he will have to realize ECG measurement when the Medical Watch will indicate it. The patient could also trigger an ECG measurement if he feels the need."
89196959|NCT00940186||tablet|
89536855|NCT02469311|Sham Comparator|Primary Control TKA|Patients undergoing a first or primary total knee arthroplasty will be randomized to the intervention of Standard of care bathing with antibacterial soap and water.
89196960|NCT00835107|Experimental|Ziprasidone|
89196961|NCT00835107|Placebo Comparator|Sugar pill|
89196962|NCT02562846||ECT patients|Depressive patients receiving electroconvulsive therapy.
89196963|NCT00843765|Active Comparator|TCM integrated group|800 patients with acupuncture, massage and basic Chinese medicine treatment
89196964|NCT00843765|Active Comparator|Western Medicine group|400 patients with modern rehabilitation techniques and Western Medicine basic treatment
89008027|NCT04719975|Placebo Comparator|Control task (Documentary) - Bike Task|In the control task subjects will have to watch a documentary on the same computer screen as that used for the experimental trial. These documentaries are chosen based on their emotionally neutral, yet engaging content. This will be followed by the Bike Task, During the whole trial EEG will be measured.
89008028|NCT00564616|Placebo Comparator|voice group|"the voice group received voice CPR instruction via a voice-only cell phone"
89008029|NCT00564616|Experimental|video group|"the video group received interactive voice and video instruction via a video cell phone"
89427525|NCT01385592|Placebo Comparator|Placebo|
89427526|NCT02262390|Active Comparator|Standard of Care|Partner notification slip is given to the pregnant female participant on the day she receives her syphilis test results to give to their sexual partner encouraging them to come to the STI clinic and be screened for syphilis. The partner notification slip will have a code number, but no identifiable features (no names).
89008030|NCT00564655|Active Comparator|1|Patients in the control group will receive localized infiltration of local anesthesia at the beginning of the procedure as is current standard practice.
89008031|NCT00564655|Experimental|2|Patients in the experimental group will receive a regional anesthetic blockade of the anterior abdominal wall via the transversus abdominis plane.
89008032|NCT04719546||NEC Group|All Premature Neonates born in Nancy and Lyon over 10 years and presenting with Necrotizing Enterocolitis
89008033|NCT04719546||Control Group|All Premature Neonates born in Nancy and Lyon over 10 years without Necrotizing Enterocolitis throughout the neonatal period
89008034|NCT04607083||Patients with at least one diminutive rectosigmoid polyp|"Consecutive adult (>18 years) outpatients undergoing elective colonoscopy, in which at least one diminutive (<5 mm) rectosigmoid polyp is detected.~Exclusion criteria:~patients with CRC history or hereditary polyposis syndromes or hereditary non-polyposis colorectal cancer~patients with inadequate bowel preparation~patients in which caecal intubation was not achieved or scheduled for partial examinations~polyps could not be resected due to ongoing anticoagulation preventing resection and pathologic assessment~patients undergoing urgent colonoscopy."
89008035|NCT04606615||Adults: AD + FA|Adults: atopic dermatitis and food allergy to peanut
89008036|NCT04606615||Adults: AD - FA|Adults: atopic dermatitis and no food allergy
89008037|NCT04606615||Adults: NC|Adults: Normal Control
89008038|NCT04606615||Children: AD+ Peanut|Children: atopic dermatitis and food allergy to peanut
89008039|NCT04606615||Children: AD + Milk|atopic dermatitis and food allergy to milk
89008040|NCT04606615||Children: AD + Egg|atopic dermatitis and food allergy to egg
89008041|NCT04606615||Children: AD only|atopic dermatitis and no food allergy
89008042|NCT04606615||Children: NC|Normal Control
89008043|NCT04606849|Other|Physician Survey|A modified version of a previously validated REDCap questionnaire will be administered to Instacare clinicians in the cluster where ePNa-CheXED was deployed via email at 6 months after ePNa-CheXED implementation. Our questionnaire includes questions on respondent demographics and Likert-style questions about respondents' experiences with ePNa. We will validate our modified questionnaire by calculating component loadings and Cronbach Alphas (i.e., internal consistency) of Likert questions loading onto the same components
89008044|NCT04606849|Other|Adapt ePNa-CheXED for InstaCares|"Adapt ePNa-CheXED for Instacares and after in silico testing, pilot it among super user clinicians during Instacare shifts and assess its usability. ePNa needs adaptation for more limited patient data available in Instacare clinics, calibration of severity measures for lower observed mortality, and a chest imaging prompt in patients with pneumonia signs and symptoms. ePNa-CheXED will incorporate Stanford University's artificial intelligence CheXED model to provide electronic classification of chest images in <1 second for elements of pneumonia diagnosis and treatment (radiographic pneumonia, single vs multiple lobes, and pleural effusion)."
89008045|NCT01580722|Other|early|patients underwent < 8 weeks reconstruction after injury
89008046|NCT01580722|Other|delay|patients underwent > 8 weeks reconstruction after injury
89008047|NCT04606810|Active Comparator|Arm1, Participants received the multidisciplinary educational intervention at baseline|Participants in arm1 received the usual care plus the multidisciplinary educational intervention consisting of an educational DVD followed by a teleconference at baseline.
89008048|NCT04606810|Other|Arm2, Participants in arm2 received the educational intervention after 3 months|Participants in group 2 first received usual care, and after 3 months were offered the multidisciplinary educational intervention.
89196965|NCT00843921|Experimental|Carbaglu|Investigate whether a 3-day treatment with NCG can improve or restore urea genesis capacity in patients with NAGS, CPSI, or OTC deficiency or PA or MMA using surrogate markers: [13C] label incorporation into urea and plasma levels of ammonia, urea nitrogen (BUN) and amino acids
89427527|NCT02262390|Active Comparator|SMS reminders and notification slip for partner screening|Participants will receive weekly SMS reminders to encourage their partners to attend the STI clinic for syphilis testing for up to 8 weeks after initial positive syphilis test for the participant. The participant ID number will be written on both the notification paper which partners should bring in with them and on the SMS reminders.
89196966|NCT00690612|Experimental|1|investigator determines efficacious dose based on child's BP response.
89536856|NCT02469311|Active Comparator|Primary Treatment TKA|Patients undergoing a first or primary total knee arthroplasty will be randomized to the intervention of chlorhexidine impregnated cloths.
89008049|NCT04606888|Experimental|Transcutaneous electrical acupoint stimulation group|Transcutaneous electrical acupoint stimulation group patients received Transcutaneous electrical acupoint stimulation (Neiguan [PC6], Yintang [GV 29], Zusanli [ST36]) for 30 min before the induction of anaesthesia until the end of the surgery and the night before operation, the first, second and third night after operation 30 min once a day with an altered frequency 2/100 Hz, disperse-dense waves, adjusted electricity intensity which was less than 10 mA.
89008050|NCT04606888|No Intervention|Control group|In Control group, except the electronic stimulation was not applied, the treatment was the same as the Transcutaneous electrical acupoint stimulation group.
89008051|NCT04606654|Experimental|Handgrip strength training with Blood flow restriction|"Three sessions per week will be given to individual subject. and training will be with Blood flow restriction.~Subjects will be followed for two weeks for;~Hand grip strength~Forearm circumference"
89536857|NCT02469311|Active Comparator|Revision Treatment TKA|Patients undergoing a second or subsequent or a revision total knee arthroplasty will be randomized to the intervention of a chlorhexidine impregnated cloths.
89008052|NCT04606654|Active Comparator|Handgrip strength training without Blood flow restriction|"Three sessions per week will be given to individual subject and training will be without Blood flow restriction.~Subjects will be followed for two weeks for;~Hand grip strength~Forearm circumference"
89008053|NCT04606147|Experimental|Group 1 ((Serratus Anterior Plane Block SAPB)) N=3o|Patients received Ultrasound guided Serratus Anterior Plane Block preoperative with injection of 30 ml levobupivacaine 0.25%. Then patients were transferred to the operating room.
89008054|NCT04606147|Experimental|Group 2 ((Erector Spinae Plane Block ESPB)) N=3o|Patients received Ultrasound guided erector spinae plane block with injection of 30 ml levobupivacaine 0.25%. Then patients were transferred to the operating room.
89427528|NCT02262390|Active Comparator|Phone call reminders and notification slip for partner scree|Participants will receive weekly phone call reminders to encourage their partners to attend the STI clinic for syphilis testing for up to 8 weeks after initial positive syphilis test for the participant. The participant ID number will be written on both the notification paper which partners should bring in with them and be given to the participant when the nurse calls.
89427529|NCT02262468||MOM total hip replacements|all patients with MOM 36mm hip replacements
89427530|NCT02607930|Experimental|B/F/TAF|B/F/TAF + ABC/DTG/3TC placebo administered without regard to food for at least 144 weeks.
89427531|NCT02607930|Active Comparator|ABC/DTG/3TC|ABC/DTG/3TC + B/F/TAF placebo administered without regard to food for at least 144 weeks.
89427532|NCT02607930|Experimental|Open-label Phase B/F/TAF to B/F/TAF|After Week 144, participants will continue to take their blinded study drug and attend visits every 12 weeks until the End of Blinded Treatment Visit. Following the End of Blinded Treatment Visit, participants will be given the option to receive open-label (OL) B/F/TAF for 96 weeks. After the Week 96 OL Visit, participants in a country where B/F/TAF is not commercially available will be given the option to continue OL B/F/TAF until the product becomes accessible through an access program or until Gilead elects to discontinue the study in that country, whichever occurs first.
89536858|NCT02469311|Sham Comparator|Revision Control TKA|Patients undergoing a second or revision total knee arthroplasty will be randomized to the intervention of Standard of care bathing with antibacterial soap and water.
89008055|NCT04606225|Experimental|Losartan group|Drug: Losartan
89008056|NCT04606225|Placebo Comparator|Placebo group|Drug: Placebo Oral Tablet
89008057|NCT05528549|Experimental|Dynamic Exercise|The investigators will look at leg blood flow during a seated leg-kicking test that is similar to biking. Leg blood flow will be measured in both the active and inactive legs. These measurements will be taken to examine how blood is directed (or controlled) during exercise.
89008058|NCT05528549|Experimental|Static Exercise|The investigators will look at blood pressure responses to a sustained leg kick. Blood pressure should increase during the sustained contraction for people without Down syndrome.
89427533|NCT02607930|Experimental|Open-label Phase ABC/DTG/3TC to B/F/TAF|After Week 144, participants will continue to take their blinded study drug and attend visits every 12 weeks until the End of Blinded Treatment Visit. Following the End of Blinded Treatment Visit, participants will be given the option to receive OL B/F/TAF for 96 weeks. After the Week 96 OL Visit, participants in a country where B/F/TAF is not commercially available will be given the option to continue OL B/F/TAF until the product becomes accessible through an access program or until Gilead elects to discontinue the study in that country, whichever occurs first.
88908377|NCT06089122|Experimental|IVIG|Patients with primary immunodeficiency will switch to Shu Yang IVIG and optimize the posology to IgG 300 to 600 mg every 21 or 28 days in a run-in period of 2 to 6 administrations, aiming at keeping the IgG trough levels above 5 g/L. In the one-year test period, the patients will receive the test IVIG at the same dose/intervals of the optimization. However, the IgG trough levels will be monitored every visit, and new adjustments/dose optimization will be performed whenever needed to keep the IgG trough levels above 5g/L.
88908378|NCT06088732|Experimental|Session 1|Exercise (30 min on bicycle ergometer at 60% peak power output) and a single oral dose 800mg of ibuprofen
88908379|NCT06088732|Active Comparator|Session 2|Exercise (30 min on bicycle ergometer at 60% peak power output) and matching placebo
88908380|NCT06088732|Active Comparator|Session 3|30 minutes rest (sitting in chair) and a single oral dose 800mg of ibuprofen
88908381|NCT06088732|Placebo Comparator|Session 4|30 minutes rest (sitting in chair) and matching placebo
88908382|NCT06087081|Experimental|Group A|Baseline treatment along with Mill's manipulation
88908383|NCT06087081|Experimental|Group B|Baseline Treatment along with Mill's manipulation and Mulligan's pain relief phenomena
88908384|NCT06083662|Experimental|A arm|Neratinib + herzuma
88908385|NCT06081075||Acutely ill neonates with suspected genetic condition, without a clear non-genetic aetiology|
88908386|NCT06079671|Experimental|Volrustomig|Volrustomig
88908387|NCT06079671|Placebo Comparator|Placebo|Placebo
89536163|NCT03199495|Sham Comparator|sham electroacupuncture|Participants were randomized divided into experimental and control groups. The Vaccaria Seeds (scientific name:Vaccaria segetalis) will be applied in control group. Vaccaria Seed is a spherical, smooth and hard seed, which is commonly used on ear acupuncture point. In control group, Vaccaria Seeds will be secured on the acupuncture point the same as experimental group, and coverd by transcutaneous electrical nerve stimulation (TENS), which is actually not turned on. The intervention will last for 15 minutes.After 15 minutes treatment, acupuncture were removed and after 15 minutes the investigators stated to evaluate.
88908389|NCT06078176|Experimental|Bowel emptying|Study participants will act as their own controls, first providing data using their usual digital rectal stimulation intervention for bowel care, then providing data using electrical stimulation for bowel care.
88908390|NCT06074744|Active Comparator|Intervention group: SSNB + IPACK (group 1)|"Subsartorial Nerve Block:~15ml bupivacaine 0.5% + clonidine 1mcg/kg for prolongation of the block effect~anatomic landmarks: proximal adductor channel, intersection of the medial borders of the sartorius muscle and the adductor longus, guided by ultrasound control~no patch to puncture site to not jeopardise the surgeon's blinding~IPACK: 15ml bupivacaine 0.5% after completion of the femoral preparation"
88908391|NCT06074744|Active Comparator|Control group: FNB + IPACK (group 2)|"Femoral Nerve Block:~15ml bupivacaine 0.5% + clonidine 1mcg/kg for prolongation of the block effect~anatomic landmarks: lateral to the femoral artery,level of the femoral crease (proximal to the vascular outlet of the deep artery of the thigh), femoral nerve lies on the surface of the iliopsoas muscle and is covered by the fascia iliaca, guided by ultrasound control~no patch to puncture site to not jeopardise the surgeon's blinding~IPACK: 15ml bupivacaine 0.5% after completion of the femoral preparation"
88908392|NCT06074536|Experimental|Interventional arm|The recruited GPs will be randomized into 2 parallel groups (interventional and control). Following this randomization, the GPs from the interventional group will undergo face-to-face training to the patient-centered approach.
88908393|NCT06074536|No Intervention|Control arm|The GPs of the control group will take care the patient according to current screening recommendations and procedures organized by the colorectal cancer (CCR) mass screening.
89008059|NCT04606108|Experimental|Experimental|camrelizumab in combination with Liposome doxorubicin and Ifosfamide intervention
89427534|NCT02264184|Experimental|Tamsulosin + Paroxetine|"Tamsulosin: q.d on day 1~Paroxetine: higher dose q.d. on days -7 to 2 q.d., lower dose on days -10 to -8 and 3 to 5"
89536164|NCT03071367|Experimental|Clinical Simulation|
89536165|NCT03071367|No Intervention|Classical Learning|
89196967|NCT02546505|No Intervention|Control|The current situation with current way brands show or not nutritional information on Front of Pack (FoP) - without consumer information
88908394|NCT06071442|Experimental|Part 1: Vemircopan, Metformin and Rosuvastatin|"Participants will receive Vemircopan, Metformin and Rosuvastatin in a fixed sequence over 2 periods.~Period 1 (8 days): Participants will receive a single dose of metformin on day 1 and a single dose of rosuvastatin on day 4.~Period 2 (12 days): Participants will receive vemircopan twice daily from day 1 to day 11. On day 5, participants will receive metformin co-administered with vemircopan. On day 8, participants will receive rosuvastatin co-administered with vemircopan.~There will be a washout period of at least 4 days between the dose of rosuvastatin in Period 1 and the first dose of vemircopan in Period 2."
88908395|NCT06071442|Experimental|Part 2: Vemircopan and LNG/EE-Containing OCs|"Participants will receive Vemircopan and LNG/EE-Containing OCs in a fixed sequence over 2 periods.~Period 1 (7 days): Participants will receive a single dose of OC, consisting of LNG and EE on day 1.~Period 2 (10 days): Participants will receive multiple doses of vemircopan from day 1 to day 9. On day 5, participants will receive a single dose of OC co-administered with vemircopan.~There will be a washout period of at least 7 days between the dose of OC in Period 1 and the first dose of vemircopan in Period 2."
88908396|NCT06071442|Experimental|Part 3: Vemircopan and Carbamazepine|"Participants will receive Vemircopan and Carbemazepine in a fixed sequence over 2 periods.~Period 1 (4 days): Participants will receive a single oral dose of vemircopan on day 1.~Period 2 (22 days): Participants will receive carbemazepine twice daily from day 1 to day 21. On day 19, participants will receive a single oral dose of vemircopan co-administered with carbamazepine.~There will be a washout period of at least 4 days between the dose of vemircopan in Period 1 and the first dose of carbamazepine in Period 2."
88908397|NCT06068166|Experimental|GDMT plus TEA|"The patients received maximally tolerated guideline-directed medical therapy (GDMT) plus TEA.~Thoracic epidural anesthesia (TEA), the infusion of anesthetic agents (eg, lidocaine or ropivacaine) into the epidural space, is used to achieve sympathetic block at the T1 to T4 levels in thoracic and abdominal surgical procedures."
88908398|NCT06068166|Active Comparator|GDMT|The patients received maximally tolerated GDMT.
88908399|NCT06067230|Experimental|Part A: mRNA-1345 Dose 1|Single injection of mRNA-1345 administered intramuscularly (IM) on Day 1.
88908400|NCT06067230|Experimental|Part A: mRNA-1345 Dose 2|Single injection of mRNA-1345 administered IM on Day 1.
88908401|NCT06067230|Experimental|Part B: mRNA-1345 Dose 2|Two injections of mRNA-1345 administered IM on Day 1 and Day 57.
89536166|NCT02478515|Experimental|Intraviteal Ranibizumab 0.5mg|Intraviteal Ranibizumab 0.5mg
89536167|NCT02448199|Experimental|Kit 1 ( ML + CG ) + P|One sachet meloxicam and glucosamine and 1 placebo tablet once a day for 12 weeks One sachet
88908404|NCT06065735|Experimental|Paroxetine|
88908405|NCT06065709|Experimental|Mindfulness breath awareness meditation group|"Mindfulness breath awareness meditation will be performed nine times in total, once every eight hours within 72 hours, to the pregnant woman who is hospitalised in the perinatology service of the hospital with the diagnosis of preeclampsia. Each session will last 30 minutes.~A 4-stage mindfulness breath awareness meditation includes the following stages:~Stage 1 - Body Harmony. Stage 2 - Counting as you Exhale Stage 3 - Counting while Breathing Stage 4 - Sit Still and Witness."
88908406|NCT06065709|No Intervention|control group|only mindfulness breath awareness meditation will not be applied to the control group.
89196968|NCT02546505|Experimental|Intervention n°1|Introduction of a Front-of-pack nutrition label (5-CNL) on selected categories of foods. No additional consumer information
89196969|NCT02546505|Experimental|Intervention n°2|Introduction of a Front-of-pack nutrition label (5-CNL) on selected categories of foods. Additional consumer information specifically targeting nutritional information and explaining the 5-CNL will be performed (this information will consist in a concept shown to respondents before the shopping session).
88908407|NCT06064643||Survey Arm|All participants will be asked to complete an online survey
88908408|NCT06064643||Interview Arm|A sample of the survey group will be asked to take part in a single qualitative interview
88908409|NCT06064643||Bleed Diary Arm|A sample of the survey group will be asked to take part in a 30 day bleed diary
88908410|NCT06064006|Experimental|NNC0487-0111|Participants will be randomized to receive NNC0487-0111. The study will be conducted in 3 parts. Part A: Single ascending dose (SAD) Part B and C: Multiple ascending dose (MAD)
89536168|NCT02448199|Active Comparator|Kit 2 ( ML + P)|One tablet of meloxicam and one sachet of placebo once per day for 12 weeks
89536169|NCT02448199|Active Comparator|Kit 3 ( P+ GC)|One sachet of glucosamine and one tablet placebo once a day for 12 weeks
89196970|NCT00841503||12 healthy volunteers|Healthy volunteers are randomized to 1 of 4 products over 4 weekly visits: i)buckwheat crackers;ii)crackers without buckwheat; iii)oral glucose; iv) oral sugar substitute, followed by 7 days of buckwheat crackers.
89196971|NCT00841503||12 Participants with Type 2 diabetes|Volunteers with type 2 diabetes are randomized to 1 of 4 products over 4 weekly visits: i)buckwheat crackers;ii)crackers without buckwheat; iii)oral glucose; iv) oral sugar substitute, followed by 7 days of buckwheat crackers.
89196972|NCT00742014|Experimental|1|
89196973|NCT00742092|Experimental|1|miglustat
89196974|NCT00742092|Placebo Comparator|2|placebo
89196975|NCT00841581|Experimental|Lucentis|"All patients receive iL for for first 6 months of study. At 6 months - patients are classified as responders or non-responders. Responders receive iL PRN based on OCT,clinical exam etc. Non-responders are seen again at 12 months for repeat investigations."
89196976|NCT00742248|Active Comparator|A|Formoterol pMDI
88908411|NCT06064006|Placebo Comparator|Placebo|Participants will be randomized to receive Placebo. The study will be conducted in 3 parts. Part A: Single ascending dose (SAD). Part B and C: Multiple ascending dose (MAD).
88908412|NCT06061341||TruGraf|Group who will have immunosuppression (IS) assessed utilizing TruGraf Liver Gene Expression test to serially monitor liver transplant recipients with autoimmune disease and alter IS based on these results.
88908413|NCT06061341||Matched historical control group|Group who will have immunosupression (IS) assessed utilizing traditional clinical parameters for IS management.
88908414|NCT06058611|Experimental|Intervention group 1 (GI1)|Intervention group 1 (IG1) will carry out personalised and adapted computerised cognitive stimulation (CE) through the stimulus platform; 30 minutes/day, 5 days/week, 8 weeks; 40 sessions. The following will be worked on: memory, orientation, language, praxis, gnosis, calculation, perception, logical reasoning, attention-concentration and executive functions.
88908415|NCT06058611|Experimental|Intervention group 2 (GI2)|"Intervention group 2 (IG2) will perform between 2 and 5 cognitively stimulating leisure activities for 8 weeks. These leisure activities will be selected from the adapted version of the Karp et al. 2006 questionnaire (Karp et al., 2006) taking into account the three components of leisure activities (mental, physical and social). The questionnaire contains 29 activities.~In addition to indicating which cognitively stimulating leisure activities they perform on a weekly basis, participants in IG2 will indicate their daily frequency (< 30 min, 30min-1 hour, 1-2 hours, > 2 hours), commenting on whether they have carried them out individually or in a group. It will also be taken into account whether these activities were previously carried out according to their stage of life."
88908416|NCT06058611|No Intervention|Control Group (CG)|The control group (CG) will not receive any intervention during the study period.
88908417|NCT06057909||Lewy Body Disease Group|Subjects identified by their physician with a diagnosis of Lewy body disease will have a physical and neurological exam, MRI of brain, electroencephalography (EEG), and electromyography (EMG).
88908418|NCT06057909||Alzheimer Disease Group|Subjects identified by their physician with a diagnosis of Alzheimer will have a physical and neurological exam, MRI of brain, electroencephalography (EEG), and electromyography (EMG).
89196977|NCT00742248|Active Comparator|B|Formoterol dry powder
89196978|NCT00742248|Placebo Comparator|C|Placebo pMDI DPI
89196979|NCT04249167|Experimental|Treatment (cryoablation, atezolizumab, nab-paclitaxel)|Patients undergo cryoablation of the primary tumor over about 1 hour. After 2-3 weeks, patients receive atezolizumab IV on days 1 and 15 and nab-paclitaxel IV on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89196980|NCT00744588||alcohol dependence|Alcohol-dependent subjects currently being treated in an inpatient treatment facility.
89196981|NCT00621153|Active Comparator|1|Candesartan cilexetil 16mg monotherapy
89196982|NCT00621153|Experimental|2|Candesartan cilexetil 16mg/HCT combination therapy
89196983|NCT00621153|Active Comparator|3|candesartan cilexetil 32mg monotherapy
89196984|NCT00621153|Experimental|4|Candesartan Cilexetil 32 mg/HCT combination therapy
89196985|NCT03883854||1 group|"Complete iron profile~serum iron~serum ferritin~total iron binding capacity~transferrin saturation (TSAT)"
88908419|NCT06057909||Healthy Control Group|Subjects identified as a health individual will have a physical and neurological exam, MRI of brain, electroencephalography (EEG), and electromyography (EMG).
88908420|NCT06055959|Experimental|Zilucoplan Arm|Study participants will receive zilucoplan in pre-defined dose based on their weight.
88908421|NCT06055842|Active Comparator|lateral incisor group|Patients having two mandibular implants in lateral incisor positions.
89196986|NCT02546427|Experimental|Treatment|"Step 1: Pelvic Lymph Node Irradiation~Helical TomoTherapy (HT): 41.25 Gy in 15 fractions of 2.75 Gy each~Step 2: Treat boost volume to prostate and seminal vesicles~Acceptable treatment modalities:~CyberKnife SBRT: 19 Gy in 2 fractions of 9.5 Gy each with SBRT~Permanent prostate implant (PPI):~108 Gy for low dose rate PPI with I-125 90 Gy for low dose rate PPI with Pd-103 HDR brachytherapy: 15 Gy in one fraction for HDR"
89196987|NCT00747084|Experimental|Arm 1: Study Treatment|Study Treatment: warm water loading of the sigmoid colon and warm water irrigation for dealing with colonic spasms.
89196988|NCT00747084|No Intervention|Arm 2: Control Treatment|Control Treatment: no water loading and waiting for spasms to subside.
89196989|NCT00835419|Experimental|1|P276-00 investigational product (small molecule Cdk 4-D1, Cdk1-B and Cdk9-T inhibitor)
89008060|NCT04719507|Experimental|erector spinae arm|ultrasound guided erector spinae block
89427535|NCT02264184|Active Comparator|Tamsulosin|Tamsulosin: q.d on day 1
89427536|NCT02268162|No Intervention|Routine Bronchoscopy|Participants in the group will receive routine bronchoscopy.
89427537|NCT02268162|Experimental|Routine Bronchoscopy with a guiding equipment|Participants in the group will receive routine bronchoscopy combined with a guiding equipment. These guiding equipments include virtual bronchoscopic navigation(VBN), endobronchial ultrasonography with a guide sheath(EBUS-GS) and fluoroscopy.
89427538|NCT02268162|Experimental|Routine Bronchoscopy with two or more guiding equipments|Participants in the group will receive routine bronchoscopy combined with two or more guiding equipments. These guiding equipments include virtual bronchoscopic navigation(VBN), endobronchial ultrasonography with a guide sheath(EBUS-GS) and fluoroscopy.
89427539|NCT02264262|Experimental|Sympathetic nerve activity|Healthy volunteers will undergo microneurography, and non invasive sympathetic nerve activity by EKG analysis at baseline and in response to stress.
89427540|NCT02264340|Active Comparator|Control|Relaxation technique
89427541|NCT02264340|Experimental|Experimental|Combined treatment
89427542|NCT02266056|Experimental|Deep neuromuscular relaxation|
89427543|NCT02266056|Active Comparator|Moderate neuromuscular relaxation|
89427544|NCT01482390|Experimental|TVR (12 Weeks), MCB (24 Weeks), PEG-IFN/RBV (24 Weeks)|Twelve weeks of therapy with MCB, TVR, and PEG-IFN/RBV, followed by 12 weeks of therapy with MCB and PEG-IFN/RBV (total treatment duration of 24 weeks).
89427545|NCT01482390|Experimental|TVR (12 Weeks), MCB (24 Weeks), PEG-IFN/RBV (48 Weeks)|Twelve weeks of therapy with MCB, TVR, and PEG-IFN/RBV, followed by 12 weeks of therapy with MCB and PEG-IFN/RBV and then 12 weeks of therapy with PEG-IFN/RBV (total treatment duration of 48 weeks).
89427546|NCT01482390|Experimental|TVR, MCB, Placebo MCB( each for 12Weeks),PEG-IFN/RBV(48 Weeks)|Twelve weeks of therapy with MCB, TVR, and PEG-IFN/RBV, followed by 12 weeks of therapy with placebo matching to MCB and PEG-IFN/RBV, and then 24 weeks of therapy with PEG-IFN/RBV (total treatment duration of 48 weeks).
88908422|NCT06055842|Active Comparator|canine group|Patients having two mandibular implants in canine positions
89196990|NCT00747162|Experimental|1|We will use The INVOS cerebral oximeter to determine oxygen content in the healthy muscle. In addition, we will use a the DermaSpectrometer to determine if there are differences in our readings according to skin color.
89427547|NCT01482390|Active Comparator|TVR(12 Weeks), Placebo MCB (24 Weeks), PEG-IFN/RBV(48 Weeks)|Twelve weeks of therapy with placebo matching to MCB, TVR, PEG-IFN/RBV, will be followed by 12 weeks of therapy with placebo matching to MCB along with PEG-IFN/RBV , following 24 weeks of therapy with PEG-IFN/RBV (total treatment duration of 48 weeks).
89427548|NCT04476342|Experimental|MICPB group|The experimental group is minimal invasive cardiopulmonary bypass (MICPB) group, with built-in micro-thrombotic oxygenator and mini cardioplegia (MP) formula (15ML15% KCl+10ml compound potassium, calcium and magnesium +25ml normal saline).
89427549|NCT04476342|No Intervention|CCPB group|The control group was conventional cardiopulmonary bypass (CCPB) group, using ordinary oxygenator, microemboli filter, and 4:1 cardioplegia solution.
89427550|NCT02268240|Experimental|Experimental|Stepped Care
88908423|NCT06054867|Experimental|Aquablation|
89427551|NCT02268240|No Intervention|Control|Usual Care
89427552|NCT02268318|Experimental|1-Fermented Dairy Product with Phytosterols (test)|one arm active = 1 bottle of dairy product/day with 1,6g of phytosterols
89427553|NCT02268318|Placebo Comparator|2-Fermented dairy Product with No Phytosterols (control)|one arm control product= 1 bottle of dairy product/day with no Phytosterols
88908424|NCT06051214|Experimental|Thrombogram|Blood sampling every month for 12 months
89427554|NCT01478178|Experimental|VAL-083 (Dianhydrogalactitol)|VAL-083 given by intravenous infusion with a starting dose of 1.5 mg/m2 IV. Escalating doses to be administered in sequential dose cohorts.
89427555|NCT01366014|Experimental|ARRY-371797|
89427556|NCT01366014|Active Comparator|Oxycodone HCl ER|
89427557|NCT01366014|Placebo Comparator|Placebo|
89427558|NCT01475058|Experimental|Treatment (T cell therapy)|Patients undergo one IV infusion of donor-derived CD8+ central memory-derived CMV/CD19 or EBV/CD19 bi-specific T cells, at least 30 days after HCT.
89427559|NCT01361802|Active Comparator|Ambroxol Spray 2.5mg|Ambroxol Spray Low Dose
89427560|NCT01361802|Active Comparator|Ambroxol Spray 5mg|Ambroxol Spray Medium Dose
89427561|NCT01361802|Active Comparator|Ambroxol Spray 10mg|Ambroxol Spray High dose
88908426|NCT06048159|Experimental|High Definition tACS with Short-term Memory Focused Speech Therapy|High-Definition-tACS will be delivered via a battery operated alternating current stimulator (Soterix) using two 3x1 center-surround montages.The current is turned on and increased in a ramplike fashion over approximately 30 seconds. Participants will undergo tACS stimulation for 20-minutes with 2 milliampere (mA) peak-to-peak intensity. Stimulation will be maintained no longer than 20 minutes. This will be paired with short-term memory focused speech therapy.
89008061|NCT04719507|Experimental|thoracic paravertebral arm|ultrasound guided thoracic paravertebral block.
89196991|NCT00574119|Experimental|Results with spironolactone|patients with heart failure due to nonischemic dilated cardiomyopathy will be studied by 11C acetate positron emission tomography and magnetic resonance imaging using vasodilator and gadolinium to judge myocardial blood flow, before and after 6 months' treatment with spironolactone.
89427562|NCT01361802|Placebo Comparator|Placebo Spray|Placebo Spray
89427563|NCT01235754|Placebo Comparator|placebo gel|placebo transdermal gel
89008062|NCT04719507|Active Comparator|drug arm|pethidine (1 mg/kg ) once
89008063|NCT04605757||Patients with acute respiratory failure due to SARS-COV-2|Patients admitted to hospital with acute respiratory failure due to SARS-COV-2 infection causing pneumonia
89008064|NCT04605835||Main group|484 children with congenital obstructive uropathies
89008065|NCT04605952||SARS-CoV-2 IgG antibody positive between 28th June to 15th July 2020|As a serosurveillance measure, 3296 asymptomatic employees of an industrial workforce Jamshedpur (India) were tested for SARS-CoV-2 IgG antibodies specific for the spike subunit antigen by the ErbaLisa COVID-19, Erba Corporate Services (United Kingdom) between 28th June and 15th July 2020. All those who initially tested SARS-CoV-2 IgG antibody positive were retested at 45-65 days
89008066|NCT04605640|Experimental|Weight Management Intervention|During a 12-month period, participants will attend a total of 22 diet improvement sessions, each of which will last approximately 1 hour. Twelve sessions will be held in the first 5 months and will be focused on safe and efficient weight loss. The participants will learn to create a personalized weight loss diet from their kitchen based on their diet practice and food preference. The next 10 sessions will be held in the last 7 months and will be focused on weight maintenance and healthy eating. The participants will build skills to select foods and create meals that prevent them from overeating. Participants will be followed by daily self-weighing for 1 year after intervention.
89008067|NCT04605562|Experimental|IC+CCRT with palbociclib|If patients were non-Immune Subtype.
89008068|NCT04605562|Experimental|IC+CCRT with galunisertib and PD-1 blocking antibody|If patients were Evaded Immune Subtype.
89008069|NCT04605562|Experimental|IC+CCRT with PD-1 blocking antibody|If patients were Active Immune Subtype.
89008070|NCT00248586|Experimental|Standard CBT (S-CBT)|
89008071|NCT00248586|Experimental|Minimal contact CBT (MC-CBT)|
89008072|NCT00248586|No Intervention|Control|
89008073|NCT00402857|Experimental|1|Participants will receive the Incredible Years Program, a group parenting intervention
89008074|NCT00402857|Other|2|Participants assigned to the waitlist condition will receive the Incredible Years Program after a 1-year waiting period
89008075|NCT04605523||Patients with Ataxia Telangiectasia|
89008076|NCT04605523||Healthy controls|
89008077|NCT04605601|Experimental|Study Group|
89008078|NCT04605601|Other|Control Group|
89008079|NCT04605367|Experimental|100% PP, a-TDCS|"After the pre-test:~repetition of the correct sequence as many times as possible (12 blocks of 30s).~After the post-test:~Anodal stimulation (intensity : gradual increase for 30s until 1mA, will remain constant for 15min, gradual decrease for 30s until 0mA ;current density : 0.04 mA/cm²."
89008080|NCT04605367|Experimental|100% PP, sham TDCS|"After the pre-test :~physical repetition of the correct sequence as many times as possible, during 12 blocks of 30s.~After the post-test : sham stimulation (gradual increase in current for 30 seconds until 1mA, immediately followed by a gradual decrease for 30 s until 0mA."
89008081|NCT04605367|Experimental|100% MP, a-TDCS|"After the pre-test :~mental repetition of the correct sequence as many times as possible, during 12 blocks of 30s.~After the post-test:~Anodal stimulation (intensity : gradual increase for 30s until 1mA, will remain constant for 15min, gradual decrease for 30s until 0mA ;current density : 0.04 mA/cm².)"
89427564|NCT01235754|Experimental|testosterone gel|transdermal testosterone gel
89427565|NCT04477122|Experimental|Blue|Four sessions (one per week along one month) of manual therapy (25 minutes of massage on temporal, masseter and pterygoid muscles and 5 minutes of joint passive mobilization) and 3 minutes (2000 shots approximately) of extracorporeal radial shock waves therapy on painful points of masseter and temporal muscles at 2 bars and 10 Hertzs. Participants will wear splint 23 hours/day
89008082|NCT04605367|Experimental|100% MP, sham TDCS|"After the pre-test :~mental repetition of the correct sequence as many times as possible, during 12 blocks of 30s.~After the post-test : sham stimulation (gradual increase in current for 30 seconds until 1mA, immediately followed by a gradual decrease for 30 s until 0mA."
89196992|NCT00844077||Barrett's metaplasia|Barrett's intestinal metaplasia, confirmed via pathology, undergoing standard of care endoscopic screening.
89196993|NCT00841737|Experimental|Psychoeducational group intervention|Psychoeducational group received weekly a psychoeducational intervention during a period of 12 weeks run by a nurses.
88908427|NCT06048159|Sham Comparator|Sham-High Definition tACS with Short-term Memory Focused Speech Therapy|High-Definition-tACS will be delivered via a battery operated alternating current stimulator (Soterix) using two 3x1 center-surround montages. The current is turned on and increased in a ramplike fashion for 10 to 30 seconds and then ramped down. In this way, the participants experience the same initial sensations (mild tingling) as the active tACS groups. This will be paired with short-term memory focused speech therapy.
88908428|NCT06048042|Experimental|Autogenous Demineralized Dentin Graft|An Autogenous Demineralized Dentin Graft will be prepared from the participant's freshly extracted teeth and placed in the intrabony defect following the modified minimally invasive surgical technique.
88908429|NCT06048042|Active Comparator|Autogenous bone Graft|An Autogenous Bone Graft will be harvested from the retromolar area and placed in the intrabony defect following the modified minimally invasive surgical technique.
88908430|NCT06047457|Experimental|"Dysport® dose A"|"Participant will receive four treatment cycles, each separated by an interval of 12 weeks.~Double-blind placebo-controlled (DBPC) Phase: Dysport® dose A administered intramuscularly on Day 1 and Week 12.~Extension Phase: Dysport® dose A administered intramuscularly at Week 24 and Week 36 (final follow-up at Week 48)"
88908431|NCT06047457|Experimental|"Dysport® dose B"|"Participant will receive four treatment cycles, each separated by an interval of 12 weeks.~DBPC Phase: Dysport® dose B administered intramuscularly on Day 1 and Week 12.~Extension Phase: Dysport® dose B administered intramuscularly at Week 24 and Week 36 (final follow-up at Week 48)"
88908432|NCT06047457|Placebo Comparator|"Placebo - Dysport dose A"|"Participant will receive four treatment cycles, each separated by an interval of 12 weeks.~DBPC Phase: Placebo dose A administered intramuscularly on Day 1 and Week 12.~Extension Phase: Dysport® dose A administered intramuscularly at Week 24 and Week 36 (final follow-up at Week 48)."
88908433|NCT06047457|Placebo Comparator|"Placebo - Dysport dose B"|"Participant will receive four treatment cycles, each separated by an interval of 12 weeks.~DBPC Phase: Placebo dose B administered intramuscularly on Day 1 and Week 12.~Extension Phase: Dysport® dose B administered intramuscularly at Week 24 and Week 36 (final follow-up at Week 48)."
88908434|NCT06047444|Experimental|"Dysport® dose A"|"Participant will receive four treatment cycles, each separated by an interval of 12 weeks.~Double-blind placebo-controlled (DBPC) Phase: Dysport® dose A administered intramuscularly on Day 1 and Week 12.~Extension Phase: Dysport® dose A administered intramuscularly at Week 24 and Week 36 (final follow-up at Week 48)"
88908435|NCT06047444|Experimental|"Dysport® dose B"|"Participant will receive four treatment cycles, each separated by an interval of 12 weeks.~DBPC Phase: Dysport® dose B administered intramuscularly on Day 1 and Week 12.~Extension Phase: Dysport® dose B administered intramuscularly at Week 24 and Week 36 (final follow-up at Week 48)"
88908436|NCT06047444|Placebo Comparator|"Placebo - Dysport dose A"|"Participant will receive four treatment cycles, each separated by an interval of 12 weeks.~DBPC Phase: Placebo dose A administered intramuscularly on Day 1 and Week 12~Extension Phase: Dysport® dose A administered intramuscularly at Week 24 and Week 36 (final follow-up at Week 48)"
88908437|NCT06047444|Placebo Comparator|"Placebo - Dysport dose B"|"Participant will receive four treatment cycles, each separated by an interval of 12 weeks.~DBPC Phase: Placebo dose B administered intramuscularly on Day 1 and Week 12.~Extension Phase: Dysport® dose B administered intramuscularly at Week 24 and Week 36 (final follow-up at Week 48)."
88908438|NCT06047093|Experimental|HBsAg <100 IU/ml|Patients chronically mono-infected with HBV, whose HBsAg is less than 100 IU/ml (patients treated or not with NA)
88908439|NCT06047093|Experimental|HBsAg between 100 and 3000 IU/ml|Patients chronically mono-infected with HBV, with HBsAg levels >100 and <3000 IU/ml (patients treated or not with NA).
88908440|NCT06047093|Experimental|HBsAg ≥ 3000 IU/ml|Patients chronically mono-infected with HBV, with HBsAg levels ≥ 3000 IU/ml (patients treated or not with NA).
88908441|NCT06047093|Experimental|Loss of HBsAg (spontaneously or under NA)|"Patients with loss of HBsAg (spontaneously or under NA). This group will allow comparison of the HBsAg loss immuno-virological profile with that of patients with active infection and varying levels of HBsAg (groups 1-3 and 5) and aid in identifying of predictors of functional cure. The identification of determinants of HBV functional cure is fundamental and is comparable to investigations that have been carried out in HIV-infected elite controllers."
88908442|NCT06047093|Experimental|Patients co-infected with HBV and HDV|Patients co-infected with HDV (positive HDV viral load), regardless of HBsAg level (presence or absence of HBV or HDV treatment)
88908443|NCT06046703||Vegan|Pregnant women with a strict plant-based diet
88908444|NCT06046703||Omnivorous|Pregnant women with an omnivorous diet.
88908445|NCT06046534||Cohort|SLE patients who participated in the anifrolumab EAPs (AMANA or ATUc).
88908446|NCT06046066|Experimental|Dose Escalation|NM6603, administered orally every day in 28-day cycles
88908447|NCT06045559||S(Sevoflurane)|Anesthesia induction for all patients will be performed with 2 mg/kg propofol and 2 µg/kg fentanyl. Following loss of eyelash reflex, 1.2 mg/kg rocuronium will be administered intravenously to all patients. Anesthesia will be maintained with sevoflurane, with a BIS value between 40-50 and a minimal alveolar concentration (MAC) value between 1-1.5.
88908448|NCT06045559||D(Desflurane)|Anesthesia induction for all patients will be performed with 2 mg/kg propofol and 2 µg/kg fentanyl. Following loss of eyelash reflex, 1.2 mg/kg rocuronium will be administered intravenously to all patients. Anesthesia will be maintained with desflurane, with a BIS value between 40-50 and a MAC value between 1-1.5.
89196994|NCT00841737|Active Comparator|Control group|Individual conventional care
89196995|NCT00705614||Remicade Group|Particpiants with no prior exposure to Remicade, who at the time of enrollment are scheduled to receive Remicade within 30 days of the Baseline Visit. Participants who start on Remicade will constitute the Remicade Group, regardless of whether they continue with Remicade or switch to another treatment.
89427566|NCT04477122|Placebo Comparator|Red|Four sessions (one per week along one month) of manual therapy (25 minutes of massage on temporal, masseter and pterygoid muscles and 5 minutes of joint passive mobilization) and 3 minutes of placebo extracorporeal radial shock waves therapy on painful points of masseter and temporal muscles. Participants will wear splint 23 hours/day
89427567|NCT02266290|Experimental|Kinesio-Tape group|In this study, Sport tex® kinesiotape over lateral ankle (6cm*2.5m) is used.
89427568|NCT02266290|Placebo Comparator|Placebo Tape Group|In the placebo group, Pretape Cramer® (100% cotton, 1.25cm*10m) was used. With patient in the same position described above, horizontal strips were placed covering the sural region with no defined direction.
89427569|NCT04476264||transscleral IOL fixation|the use of a novel adjustable single 8-0 polypropylene suture for scleral fixation without conjunctival dissection
88908449|NCT06045559||P(Propofol)|Anesthesia induction for all patients will be performed with 2 mg/kg propofol and 2 µg/kg fentanyl. Following loss of eyelash reflex, 1.2 mg/kg rocuronium will be administered intravenously to all patients. Propofol was administered intravenously at a rate of 6-12 mg/kg/min to maintain anesthesia, keeping the BIS value between 40-50.
89427570|NCT02264496|No Intervention|Control|Standard pre-operative care
89427571|NCT02264496|Experimental|Exercise|A 2-4 week low volume, moderate intensity, supervised, one to one, individualised exercise programme. '
89427572|NCT03135444|Experimental|Provider Field Test|15 providers will be given an initial version of the PSA TOOL, over a 4 week period, they will be able to provide feedback on the tool. This will be used to revise the screening decision aid. Informal interviews with providers will also be conducted by a member of the study team to obtain feedback about ease of use and usefulness of the tool.
89427573|NCT03135444|Experimental|Patient test of revised PSA TOOL|150 patients will be asked to use the revised PSA TOOL. Pre- and Post-tests will be given to see if the tool changed the knowledge that patients have an option to be screened for prostate cancer and of specific factors to be considered in the screening decision. Informal interviews with patients who are exposed to the tool will also be conducted by a member of the study team to obtain feedback on issues addressed by the survey questions.
88908454|NCT06044025|Experimental|Metformin + Turmeric|"Each subject will begin using metformin and turmeric within 7 days of consent. Subjects will start with metformin 500 mg by mouth (po) two times daily (bid) with meals for 14 days. Metformin titration will then increase to 850 milligram (mg) po bid for 14 days before increasing titration to a desired dosage of 1,000 mg po bid. For those subjects currently taking Metformin, they will continue current dose (if 1,000 mg po bid) or titrate dose as just described until maximum dose is achieved.~After two weeks of metformin titration, each subject will start with 1,500 mg turmeric po daily with meals. Dose can be temporarily reduced to 1,000 mg po daily for those who report GI discomfort. If GI discomfort has resolved within one month of the dose reduction, subjects will resume 1,500 mg po daily. If GI discomfort has not resolved the participant may be insturcted to stop taking the study treatment and be removed from the study."
89427574|NCT01355406|Other|PAD|This is a prospective single-arm multi-center clinical trial designed to evaluate the safety and efficacy of the Flexible Stenting Solutions Flext Stent® Femoropopliteal stenting system in subjects with lower limb peripheral arterial desease (PAD). Subjects targeted for enrollment must have a single de-novo lesion located in the superficial femoral artery and/or proximal popliteal artery with at > 70% stenosis. Subjects must meet all enrollment criteria and provide written informed consent prior to participation in the study.
89427575|NCT02266368|No Intervention|Control group|This arm will include patients with non-coated stents
89427576|NCT02266368|Active Comparator|Antimicrobeal group|This arm will include patients with antimicrobeal coated stents
89536170|NCT03071289|Active Comparator|The control group (Group A)|In Group A, adjuvant radio-chemotherapy is applied. The radiotherapy is performed according to Radiation Method A. The regimen of chemotherapy is cisplatin 30mg/m2 every week.
88908455|NCT06043193||Major subjects, suffering from metastatic neuroendocrine tumours|Major subjects, suffering from metastatic neuroendocrine tumours, for whom the indication for treatment by vectorized internal radiotherapy is decided in a multidisciplinary consultation meeting (National Reference Network for the management of Neuro-Endocrine Tumors) and who will be treated in one of the 5 centers in the AURA region
88908456|NCT06042335|Experimental|DAISe EZ|Mechanical thrombectomy utilizing the DAISe Thrombectomy System, consisting of the DAISe Thrombectomy Device and DAISe Delivery Catheter, used with aspiration.
88908457|NCT06042270|Placebo Comparator|Placebo|10 participants will be given rice-flour as a placebo
88908458|NCT06042270|Active Comparator|Betaine|10 participants will be given betaine
88908459|NCT06040970|Experimental|ovarian cancer arm|DEC 3+3 dose expansion of Sacituzumab Govitecan in Combination with Cisplatin
88908460|NCT06040970|Experimental|endometrial cancer arm|DEC 3+3 dose expansion of Sacituzumab Govitecan in Combination with Cisplatin
88908461|NCT06040138||Patients with prolonged weaning|Patients who have failed more than 3 spontaneous breathing trials, in pressure support ventilation, with hemodynamic and metabolic stability, and a regular and stable ventilatory pattern.
88908462|NCT06038929|Experimental|vagal nerve stimulant|The aim is to measure gastric emptying and gastric accommodation in response to a caloric meal before and 3 months after activation of VNS. Therefore, prior to surgery, subjects will undergo combined gastric emptying/accommodation test. Subsequently, participants will undergo a second identical study approximately 3 months after insertion of the VNS.
88908463|NCT06038643|Experimental|Intervention|Social motivation intervention, self-transcendence daily messages, and daily accelerometry.
88908464|NCT06038643|Active Comparator|Active Control|Daily accelerometry.
88908465|NCT06037330|Experimental|Nalbuphine group|40 mg of nalbuphine was diluted into 50 mL solution, the load dose was 0.1mg/kg, the maintenance dose was 0.04-0.08mg/kg/h, the CPOT score was <2, and the daily maximum dose was 160mg.
88908466|NCT06037330|Active Comparator|Sufentanil group|0.1mg of sufentanil was diluted into 50 mL solution, the loading dose was 0.2-0.5μg/kg, the maintenance dose was 0.2-0.3μg/kg/h, and the CPOT score was <2 points.
88908469|NCT06033820|Experimental|ZR2-ICE Group|All patients will receive 3 cycles of ZR2-ICE immunochemotherapy every three weeks.
88908470|NCT06032468|Experimental|Rehabilitation with ARC Intellicare Device|rehabilitation exercise for 8 weeks using wearable devices
88908471|NCT06032468|Active Comparator|Rehabilitation with exercise sheet|rehabilitation exercise for 8 weeks using rehabilitation exercise sheets
88908472|NCT06030739|No Intervention|Usual Care|No letter
88908473|NCT06030739|Experimental|Standard Letter|This group will receive a standard letter on the benefits of influenza vaccination without behavioral economic enhancement
88908474|NCT06030739|Experimental|Repeated Letter|The standard letter sent out two times instead of once
88908475|NCT06030739|Experimental|Cardiovascular Gain-Framing Letter|Text added to the standard letter highlighting potential cardiovascular benefits of influenza vaccination
88908476|NCT06030739|Experimental|Respiratory Gain-Framing Letter|Text added to the standard letter highlighting potential respiratory disease-related benefits of influenza vaccination
88908477|NCT06030739|Experimental|Implementation Intention Prompt Letter|Implementation intention prompt added to the standard letter
88908478|NCT06030739|Experimental|Loss-Framing Letter|Text added to the standard letter highlighting potential risks of not receiving influenza vaccination
88908479|NCT06030726|No Intervention|Usual Care|No letter
88908480|NCT06030726|Experimental|Standard Letter|This group will receive a standard letter on the benefits of influenza vaccination without behavioral economic enhancement
88908481|NCT06030726|Experimental|Repeated Letter|The standard letter sent out two times instead of once
88908482|NCT06030726|Experimental|Cardiovascular Gain-Framing Letter|Text added to the standard letter highlighting potential cardiovascular benefits of influenza vaccination
88908483|NCT06030726|Experimental|Respiratory Gain-Framing Letter|Text added to the standard letter highlighting potential respiratory disease-related benefits of influenza vaccination
88908484|NCT06030726|Experimental|Implementation Intention Prompt Letter|Implementation intention prompt added to the standard letter
88908485|NCT06030726|Experimental|Loss-Framing Letter|Text added to the standard letter highlighting potential risks of not receiving influenza vaccination
88908486|NCT06029309|Experimental|Zanu-Tafa Phase 1 Group|"Participants in this group will receive combination therapy of Zanubrutinib (Zanu) and Tafasitamab (Tafa) for up to 24 cycles, followed by maintenance therapy with Zanubrutinib until progression. Each cycle is 28 days in length. Combination therapy will be administered via induction phases as follows:~Early induction - cycles 1 to 3 (12 weeks)~Late induction - cycles 4 to 12 (36 weeks)~Extended induction - cycles 13-24 (48 weeks)~Subsequent maintenance Zanu therapy may last up to 2 years. Total study participation is up to four (4) years."
88908487|NCT06029309|Experimental|Zanu-Tafa Phase 2 Group|"Participants in this group will receive the combination therapy of Zanubrutinib (Zanu) at the recommended phase 2 dose (RP2D) determined during Phase 1, and Tafasitamab at standard doses, followed by maintenance therapy with Zanubrutinib until progression.. Combination therapy will be administered via induction phases as follows:~Early induction - cycles 1 to 3 (12 weeks)~Late induction - cycles 4 to 12 (36 weeks)~Extended induction - cycles 13-24 (48 weeks)~Subsequent maintenance Zanu therapy may last up to 2 years. Total study participation is up to four (4) years."
88908488|NCT06027255|Other|Post- COVID 19 POTS patients|Inflammatory markers IL-6,Cytokines (IL-17, and IFN-ɣ), Autonomic symptoms assessment questionnaire (COMPASS 31): In post-COVID-19 POTS (cases).
88908489|NCT06027255|Other|POTS patients|Inflammatory markers IL-6,Cytokines (IL-17, and IFN-ɣ), Autonomic symptoms assessment questionnaire (COMPASS 31):Gender, age, and BMI-matched: patients with diagnosis of POTS
88908490|NCT06027255|Other|Post- COVID 19 POTS patients with Controls|Inflammatory markers IL-6,Cytokines (IL-17, and IFN-ɣ), Autonomic symptoms assessment questionnaire (COMPASS 31):Gender, age, and BMI-matched: Controls are :COVID-19 infected without sequelae
88908491|NCT06024941|Experimental|Radiation|Radiation to one progressive lesion
88908492|NCT06024382|Experimental|twin block|group treated with twin block only
88908493|NCT06024382|Experimental|twin block combined with low level laser|group treated with twin block combined with low level laser therapy
89536171|NCT03071289|Experimental|The experiment group (Group B)|In Group B, adjuvant radio-chemotherapy is applied. The radiotherapy is performed according to Radiation Method B. The regimen of chemotherapy is cisplatin 30mg/m2 every week.
89536172|NCT05713409||Adult patients with an established diagnosis of CD going through ileocecal resection|
89196996|NCT00705614||Standard Therapy Group|Participants who are being treated with standard therapy and are not adequately maintained and will be offered an alternative treatment that does not include Remicade. Standard therapy participants must not have previously received Remicade.
88908494|NCT06022406|Experimental|FMT capsules|"10 participants taking FMT. The study product consists of fecal microbiota capsules prepared by Dr. Silverman's team in London, Ontario, Canada. Dr. Silverman has received approval from Health Canada to evaluate FMT in patients with metastatic malignant melanoma or with fatty liver within a clinical trial setting (CTA control nos. 235387and 195078 respectively).~Approximately 30 to 40 capsules will be prepared from 80-100g of healthy human feces from a single healthy donor and administered as a single dose. Capsules will be prepared by a modified method as described by Kao et al, 201747,48 (see Investigator brochure)."
88908495|NCT06022406|Placebo Comparator|Placebo capsules|10 participants taking Placebo. Placebo capsules contain microcrystalline cellulose, for equivalence in weight and color that will be encapsulated in gelatin capsules. Each capsule will be filled with approximatively 5.5g of microcrystalline cellulose, and encapsulated in size 0 and size 00 capsules.
88908496|NCT06019598|Experimental|Licorice|2 weeks of licorice corresponding to 20 mg of glycyrrhizic acid followed by 2 weeks of licorice corresponding to 50 mg of glycyrrhizic acid.
88908497|NCT06019078||Prospective Cohort|Patients admitted to participating ICUs who meet inclusion criteria monitored by 4 channel pEEG.
89427577|NCT02266446|Experimental|Attention & Interpretation Modification|The final product will be web-delivered, so it may be completed at the clinic or home. Treatment will consist of 8, 30-minute, twice-weekly sessions designed to: a) decrease attention bias to threat and b) extinguish threat interpretations/reinforce benign interpretations of ambiguity. Attention bias will be modified via a dot probe task that increases attentional control by directing attention away from threat faces via probe location. Patients will complete 256 trials per session. Interpretation bias will be modified via a word-sentence association task which provides positive feedback when participants endorse benign interpretations of ambiguous sentences and negative feedback for threat interpretations. Participants will complete 150 training trials per session
89427578|NCT02268630||Group A|Patients treated with Warfarin for VTE
88908498|NCT06019078||Retrospective Cohort|Patients admitted to participating ICUs who meet inclusion criteria not monitored by 4 channel pEEG.
88908499|NCT06018558|Experimental|Phase1 Dose Escalation- Low Dose (2.5×10E10 vg/mL):|Low Dose (2.5×10E10 vg/mL): Subjects will receive a subretinal injection of OCU410 in the low dose concentration.
88908500|NCT06018558|Experimental|Phase1 Dose Escalation- Medium Dose (5×10E10 vg/mL):|Medium Dose (5×10E10 vg/mL): Subjects will receive a subretinal injection of OCU410 in the medium dose concentration.
88908501|NCT06018558|Experimental|Phase1 Dose Escalation- High Dose (1.5×10E11 vg/mL):|High Dose (1.5×10E11 vg/mL): Subjects will receive a subretinal injection in the high dose concentration.
88908502|NCT06018558|Experimental|Phase 2 Dose Expansion: Maximum tolerated dose (MTD) from Phase 1-Randomized Arm|Maximum tolerated dose (MTD) from Phase 1: Subjects will receive a subretinal injection in the MTD concentration.
89427579|NCT02268630||Grup B|Patients treated with Rivaroxaban for VTE
89427580|NCT01234038|Experimental|Part 1 Cohort 1|
88908503|NCT06018558|Experimental|Phase 2 Dose Expansion: Lower Dose from Phase 1-Randomized Arm|Subjects will receive a subretinal injection of OCU410 in a Lower Dose concentration.
88908504|NCT06018558|No Intervention|Control Arm|No Intervention Control Arm: Subject will not receive any active study intervention
88908505|NCT06017557|Experimental|Clinical Stage III-IV Ovarian Cancer|individuals who have been diagnosed or are suspected to have Clinical Stage III-IV Ovarian Cancer and CT and MRI have most commonly been used to identify sites and amounts of tumors in the abdomen and can help determine if these tumors can be safely removed by surgery. However, these imaging methods are only a prediction, and sometimes a diagnostic laparoscopy (putting a camera in the abdomen to look at all sites of disease) is performed to help this decision process.
88908506|NCT06015516|Experimental|Treatment Test: Oral minoxidil 1 mg tablets|Participants will be administered one tablet of oral minoxidil 1mg once a day, orally, after fasting for at least 10 hours, with 240 mL or 8 Oz. of water, and fasting for a further 5 hours.
89427581|NCT01234038|Experimental|Part 1 Cohort 2|
88908507|NCT06015516|Active Comparator|Treatment Reference: Regaxidil 20 mg/ml (2%) topical solution|Participants will be administered topically on the scalp after fasting for at least 10 hours pre-dose and 5 hours post-dose. After the administration subject should not wash her head for at least 5 hours. Each one mL dose of 2% topical minoxidil will be carefully measured to provide 20 mg of minoxidil using the syringe provided with each bottle.
88908508|NCT06015477|Experimental|ticagrelor monotherapy group|Ticagrelor monotherapy (starting dose of ticagrelor was a single loading dose of 180mg (90mg x 2 tablets) and thereafter 1 tablet (90mg) each time, twice daily.). After 1 month, continuation to ticagrelor monotherapy for 1 year.
88908509|NCT06015477|Active Comparator|Dual Antiplatelet Therapy group|Clopidogrel 75mg + Aspirin 100mg 1 month, after 1 month, change to aspirin 100mg 1 year.
88908510|NCT06013319|Experimental|Esmolol group|Patients with ARDS who require mechanical ventilation after adequate disease assessment and whose heart rate continues to be ≥95 beats/min, but ≤120 beats/min within 24 hours after diagnosis, for at least 10 minutes without changing the dosage of catecholamine, were diagnosed as atrial fibrillation, atrial flutter or sinus tachycardia. The primary treatment is maintained while the esmolol load dose is administered and the maintenance dose is pumped continuously until the patient's heart rate is maintained between 80 and 94 beats per minute.
88908511|NCT06013319|No Intervention|Control group|Patients with ARDS who need mechanical ventilation after adequate condition assessment and whose heart rate continues to be ≥95 beats /min but ≤120 beats /min after optimal hemodynamic treatment within 24 hours after diagnosis were randomly included in the control group. Routine mechanical ventilation, full sedation and analgesia, maintain RASS score 0-2 points; The target tidal volume is 6ml/kg, and the ventilator parameters should be adjusted in time according to the blood gas analysis. Hypotensive patients with sufficient blood volume should be pumped with pressor drugs. Timely sputum suction, airway management, eliminate fever, asthma, pain and other stimulation caused by the heart rate is too fast.
88908512|NCT06013137|Experimental|Experimental|This group will have access to the Therabot smartphone application. They will interact with the generative chatbot daily to discuss their mental health. Each participant in this group will have some benchmark symptoms of depression, anxiety, or eating disorders. They will fill out questionnaires every 4 weeks to describe changes in symptoms.
88908513|NCT06013137|No Intervention|Control|This group will not have access to the Therabot App. They will fill out questionnaires every 4 weeks to describe changes in symptoms. Each participant in this group will have some benchmark symptoms of depression, anxiety, or eating disorders.
88908514|NCT06012851|Experimental|Mobile BPT with in-the-moment feedback|Participants will be randomized multiple times per day to receive either a push notification related to parenting behavior or no push notification.
88908515|NCT06012435|Experimental|Experimental Arm|sigvotatug vedotin monotherapy
88908516|NCT06012435|Active Comparator|Control Arm|Docetaxel monotherapy
88908517|NCT06011408|Other|Taking antipsychotic medication with Tardive Dyskinesia|
88908518|NCT06011408|Other|Taking antipsychotic medication without Tardive Dyskinesia|
88908519|NCT06010355|Experimental|Arm I (Aim 1) (focus group)|Participants participate in a focus group over 1 hour in support of the development of a culturally tailored educational video on study.
88908520|NCT06010355|Experimental|Arm II (Aim 2) (video, interview)|Participants watch a culturally tailored educational video over 3-5 minutes and then immediately undergo an interview in support of the refinement of a culturally tailored educational video on study.
88908521|NCT06010355|Experimental|Arm III (Aim 3) (video, test)|Participants watch a culturally tailored educational video over 3-5 minutes and complete a brief test pre- and post-video over 30 minutes on study.
88908522|NCT06006689|Placebo Comparator|Placebo group|Qishen Yiqi Dripping Pills placebo, 3 bags, take orally after meals, 3 times a day
88908523|NCT06006689|Experimental|Low dose group|Low dose Qishen Yiqi Dripping Pills, 3 bags, take orally after meals, 3 times a day
88908524|NCT06006689|Experimental|High dose group|High dose Qishen Yiqi Dripping Pills, 3 bags, take orally after meals, 3 times a day
89427582|NCT01234038|Experimental|Part 2 Arm A|
89427583|NCT01234038|Experimental|Part 2 Arm B|
89427584|NCT01233960|Experimental|Prochymal|Infusions of Prochymal on days 42-45, 84-87, and 126-129 after first infusion in Protocol 603. Each infusion of PROCHYMAL (remestemcel-L) will contain 200 million cells.
89427585|NCT02268708||COPD|"Patients:~>18 years old COPD: FEV/FEV1<80% in respiratory evaluation who have un oncological pulmonary resection in Cochin Hospital Paris France"
88908525|NCT06006585|Experimental|BI 771716 low dose treatment group (Single rising dose (SRD part))|
88908526|NCT06006585|Experimental|BI 771716 treatment group (multiple dose (MD part))|
88908527|NCT06006585|Experimental|BI 771716 medium dose treatment group (SRD part)|
88908528|NCT06006585|Experimental|BI 771716 high dose treatment group (SRD part)|
89427586|NCT01229982|Experimental|L-PPDS|
89536173|NCT03199183||Takayasu arteritis|All recruited Takayasu arteritis patients.
89536174|NCT03314675|Other|CRT-D Measurements|Pre-specified measurements and additional follow-ups
89536175|NCT03199105|Experimental|preoperative education and tetracaine|
89427587|NCT02264652|Experimental|HD Transcranial Direct Stimulation|Genuine cathodal HD-tDCS approximately 2mA will be delivered through High-Definition electrodes that will be arranged on the skull according to a 4x1-ring configuration with the central cathodal electrode placed over the identified target and surrounding return electrodes forming approximately a 5-cm radius ring.
89427588|NCT01226628|Experimental|Cohort A|Phase 1: 3 patients will receive 60,000 human umbilical tissue-derived cells (hUTC)
89008083|NCT04605367|Experimental|50% MP and 50% PP, a-TDCS|"After the pre-test :~mental repetition of the correct sequence as many times as possible, during 6 blocks of 30s. Then physical repetition of the correct sequence as many times as possible, during 6 blocks of 30s.~After the post-test : they will receive the real stimulation. Anodal stimulation (intensity : gradual increase for 30s until 1mA, will remain constant for 15min, gradual decrease for 30s until 0mA ;current density : 0.04 mA/cm²."
89008084|NCT04605367|Experimental|50% MP and 50% PP, sham TDCS|For both tasks, the training modalities are the same. After the pre-test, this group will have to mentally repeat the correct sequence as many times as possible, during 6 blocks of 30s. Then they will have to physically repeat the correct sequence as many times as possible, during 6 blocks of 30s. After this training, they will perform the post-test. And immediately after the post-test, they will receive the sham stimulation. The sham stimulation will be consisted of a gradual increase in current for 30 seconds until 1mA, immediately followed by gradual decrease for 30 s until 0mA.
89008085|NCT04605367|No Intervention|No practice, No stimulation|After the pre-test, this group will read an article for 12 minutes. After this training, they will perform the post-test. Immediately after this, they will read another article during 15 minutes.
89008086|NCT04605289|Experimental|Group I (study group)|Scaling and root planing + intra-pocket application of 2% Cymbopogon citratus (lemon-grass) gel
89427589|NCT01226628|Experimental|Cohort B|Phase 1: 3 patients will receive 120,000 hUTC
89427590|NCT01226628|Experimental|Cohort C|Phase 1: 3 patients will receive 300,000 hUTC
89427591|NCT01226628|Experimental|Cohort D|Phase 1: 3 patients will receive 560,000 hUTC
89427592|NCT01226628|Experimental|Cohort E|Phase 1: 6 patients will receive 300,000 hUTC
89427593|NCT01226628|Experimental|Cohort F|Phase 1: 6 patients will receive either 60,000 or 300,000 hUTC
89427594|NCT01226628|Experimental|Cohort G|Phase 1: 6 patients will receive either 60,000 or 300,000 hUTC
89008087|NCT04605289|Placebo Comparator|Group II (control group)|Scaling and root planing +intra-pocket application of placebo gel
89008088|NCT04605133||ARDS|Patients with mild or severe ARDS necessitating of prone position during mechanical ventilation
89008089|NCT04605250|Other|Adults undergoing abdominal surgery with laparotomy|Respiratory variability before and after abdominal surgery
89427595|NCT01226628|Experimental|Phase 2a|Up to 38 patients will receive one of two optimal doses as selected from the Phase 1 portion of the study
89427596|NCT01225380|Experimental|Arm 1|GS-9190 and GS-9256 in combination with Pegasys® and Copegus® for 16 or 24 weeks; Pegasys® and Copegus® may be continued for up to 48 weeks total duration depending on individual response to therapy
89427597|NCT01225380|Experimental|Arm 2|GS-9256 (active) and placebo matching GS-9190 in combination with Pegasys® and Copegus® for 24 weeks; Pegasys® and Copegus® may be continued for up to 48 weeks total duration depending on individual response to therapy
89427598|NCT01225380|Placebo Comparator|Arm 3|Placebo matching GS-9190 and placebo matching GS-9256 in combination with Pegasys® and Copegus® for 24 weeks; Pegasys® and Copegus® will be continued for up to 48 weeks total duration
88908529|NCT06006273|Experimental|Arm A: Dose expansion-Ewings sarcoma|The first group of participants in this phase will receive the highest dose of eribulin. Each group of participants enrolled after that will receive a slightly lower dose of the drug. Participants in this phase will be enrolled in 1 of 3 treatment arms, based on their disease type, and will receive the recommended dose combination found in the Dose Escalation phase.
88908530|NCT06006273|Experimental|Arm B: Dose expansion -Rhabdomyosarcoma|The first group of participants in this phase will receive the highest dose of eribulin. Each group of participants enrolled after that will receive a slightly lower dose of the drug. Participants in this phase will be enrolled in 1 of 3 treatment arms, based on their disease type, and will receive the recommended dose combination found in the Dose Escalation phase.
88908531|NCT06006273|Experimental|Arm C: Dose expansion- other solid tumor histologies|The first group of participants in this phase will receive the highest dose of eribulin. Each group of participants enrolled after that will receive a slightly lower dose of the drug. Participants in this phase will be enrolled in 1 of 3 treatment arms, based on their disease type, and will receive the recommended dose combination found in the Dose Escalation phase.
88908532|NCT06006273|Experimental|Arm D: Dose finding levels 0,-1 and -2|The first group of participants in this phase will receive the highest dose of eribulin. Each group of participants enrolled after that will receive a slightly lower dose of the drug. Participants in this phase will be enrolled in 1 of 3 treatment arms, based on their disease type, and will receive the recommended dose combination found in the Dose Escalation phase.
88908533|NCT06005493|Experimental|Module 1: AZD5863 Monotherapy Intravenous (IV)|Module 1: AZD5863 Intravenous (IV) Monotherapy
88908534|NCT06005493|Experimental|Module 2: AZD5863 Monotherapy Subcutaneous (SC)|Module 2: AZD5863 Subcutaneous (SC) Monotherapy
88908535|NCT06004063|Experimental|Enteral nutrition (EN)-Group 1|Participants will receive enteral feeding (directly into the stomach) based on your ability to receive your daily caloric needs by mouth. Participants will be monitored by a dietician and may receive feeding by vein to achieve caloric goals.
88908536|NCT06004063|Active Comparator|Standard care parenteral nutrition (PN)-Group 2|Participants will receive the standard of care. Participants will be monitored by a dietician to see if the participants are able to receive your daily caloric needs by mouth. Some participants may be able to receive oral dietary supplements, but if this is not possible or not enough, participants will begin receiving standard of care feeding by vein.
88908537|NCT06003842|Active Comparator|control group|The exercise program to be given to the participants consists of stretching, strengthening and postural exercises for the muscles in the neck-back region. While doing the posture exercises, the participants will be asked to do the exercises in front of the mirror in order to correct the wrong postural posture and to provide relaxation.
88908538|NCT06003842|Experimental|taping group|In addition to the exercises, the Kinesio® Tex taping application will remain on the body for 4 days, and then it will be applied 6 times in total, with a 3-day break.
89427599|NCT01349868|Experimental|PT005 MDI (Dose 1)|PT005 MDI (Dose 1)
89427600|NCT01349868|Experimental|PT005 MDI (Dose 2)|PT005 MDI (Dose 2)
89427601|NCT01349868|Experimental|PT005 MDI (Dose 3)|PT005 MDI (Dose 3)
89427602|NCT01349868|Placebo Comparator|Placebo MDI|Placebo MDI
89427603|NCT01349868|Active Comparator|Formoterol Fumarate 12 μg (Foradil® Aerolizer®)|Formoterol fumarate inhalation powder 12 μg
89427604|NCT01349868|Active Comparator|Formoterol Fumarate 24 μg (Foradil® Aerolizer®)|Formoterol fumarate inhalation powder 24 μg
89427605|NCT01348152|Placebo Comparator|Placebo|Placebo TID
89427606|NCT01348152|Experimental|DAIKENCHUTO (TU-100) 15 g/day|TU-100 5g TID
89427607|NCT01461954|Experimental|FST-100|
89427608|NCT01461954|Placebo Comparator|FST-100 Vehicle|
89427609|NCT02266524|Experimental|Tamsulosin hydrochloride, very low dose|
89427610|NCT02266524|Experimental|Tamsulosin hydrochloride, low dose|
89427611|NCT02266524|Experimental|Tamsulosin hydrochloride, medium dose|
89427612|NCT02266524|Experimental|Tamsulosin hydrochloride, high dose|
89427613|NCT01336686|Experimental|Arhalofenate 400 mg|
89427614|NCT01336686|Experimental|Arhalofenate 600 mg|
89427615|NCT01336686|Placebo Comparator|Placebo|
89427616|NCT02266602|Other|Treatment|Patients treated with intraoperative radiation therapy at the time of partial mastectomy.
88908539|NCT06003530|Experimental|Low dose hOMSC200|Administration of low dose hOMSC200 in addition to routine standard of care
88908540|NCT06003530|Experimental|High dose hOMSC200|Administration of high dose hOMSC200 in addition to routine standard of care
88908541|NCT06003530|Placebo Comparator|Placebo|Administration of placebo in addition to routine standard of care
88908542|NCT06003231|Experimental|Disitamab vedotin monotherapy|Disitamab vedotin monotherapy
89427617|NCT01221246|Experimental|GM602|First 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 320 mg/dose of GM602 or placebo in a 2:1 ratio, then the next 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 480 mg/dose of GM602 or placebo in a 2:1 ratio. Concurrently, 18 severe patients will be randomized in the same manner. Total 12 moderate and 12 severe patients will receive GM602.
89427618|NCT01221246|Placebo Comparator|Placebo Comparator|First 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 320 mg/dose of GM602 or placebo in a 2:1 ratio; then the next 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 480 mg/dose of GM602 or placebo in a 2:1 ratio. Concurrently, 18 severe patients will be randomized in the same manner. Total 6 moderate and 6 severe patients receive Placebo.
89427619|NCT01205334|Experimental|Autologous CMV-specific CTL|"The patient will receive one of the following doses:~1.5x10^7 cells/m2~4.5x10^7 cells/m2~1.5x10^8 cells/m2"
89427620|NCT01455090|Experimental|Group 1:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(75mg)|"BMS-650032 200 mg tablet by mouth twice daily for 24 Weeks~BMS-790052 60 mg tablet by mouth once daily for 24 Weeks~BMS 791325 75 mg table by mouth twice daily for 24 Weeks"
89427621|NCT01455090|Experimental|Group 2:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(75mg)|"BMS-650032 200 mg tablet by mouth twice daily for 12 Weeks~BMS-790052 60 mg tablet by mouth once daily for 12 Weeks~BMS 791325 75 mg table by mouth twice daily for 12 Weeks"
89536176|NCT03199105|Experimental|tetracaine|
89427622|NCT01455090|Experimental|Group 3:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(150mg)|"* Contingent upon review of safety data from all available treated subjects from Groups 1 and 2~BMS-650032 200 mg tablet by mouth twice daily for 24 Weeks~BMS-790052 60 mg tablet by mouth once daily for 24 Weeks~BMS 791325 150 mg table by mouth twice daily for 24 Weeks"
89427623|NCT01455090|Experimental|Group 4:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(150mg)|"* Contingent upon review of safety data from all available treated subjects from Groups 1 and 2~BMS-650032 200 mg tablet by mouth twice daily for 12 Weeks~BMS-790052 60 mg tablet by mouth once daily for 12 Weeks~BMS 791325 150 mg table by mouth twice daily for 12 Weeks"
89427624|NCT01455090|Experimental|Group 5:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg)|"* Genotype 1 treatment-naive subjects~BMS-650032 200 mg tablet by mouth twice daily for 12 Weeks~BMS-790052 30 mg tablet by mouth twice daily for 12 Weeks~BMS 791325 75 mg table by mouth twice daily for 12 Weeks"
88908543|NCT06003205|Other|Wearable bioimpedance sensor|All subjects will use the investigational device and undergo several interventions: lower body negative pressure (3-40 minutes at 30 mmHg), posture intervention, and pressure intervention.
88908544|NCT06003179|Active Comparator|Cyclophosphamide and fludarabine, standard dose|Fludarabine 25mg/m2 Cyclophosphamide 250mg/m2 Days -4, -3, -2
88908545|NCT06003179|Experimental|Cyclophosphamide and fludarabine, standard dose with radiation|Fludarabine 25mg/m2 Cyclophosphamide 250mg/m2 Days -6, -5, -4 2 Gy in 2 Fractions Days -3, -2
88908546|NCT06003179|Experimental|Cyclophosphamide (intermediate dose) and fludarabine|Fludarabine 25mg/m2 Cyclophosphamide 500mg/m2 Days -4, -3, -2
88908547|NCT06003179|Experimental|Cyclophosphamide (intermediate dose) and fludarabine with radiation|Fludarabine 25mg/m2 Cyclophosphamide 500mg/m2 Days -6, -5, -4 2 Gy in 2 Fractions Days -3, -2
88908548|NCT06003179|Experimental|Cyclophosphamide (high dose) and fludarabine|Fludarabine 25mg/m2 Cyclophosphamide 750mg/m2 Days -4, -3, -2
88908549|NCT06003179|Experimental|Cyclophosphamide (high dose) and fludarabine with radiation|Fludarabine 25mg/m2 Cyclophosphamide 750mg/m2 Days -6, -5, -4 2 Gy in 2 Fractions Days -3, -2
88908550|NCT06003114||First-line patients on Palbociclib|Participants taking oral palbociclib as prescribed in first-line treatment
88908551|NCT06001385|Experimental|Regimen A (MAC: Busulfan and Fludarabine, PBSC HCT; Reduce Dose PTCy|"Patients Receive:~Patients receive:~Busulfan (≥ 9 mg/kg total dose) IV or PO on days -6 to -3 Fludarabine (150 mg/m2 total dose) IV on days -6 to -2~Patients receive a peripheral blood stem cell (PBSC) graft infusion from a mismatched unrelated donor on Day 0.~Patients receive a reduced dose of cyclophosphamide (25mg/kg per dose) on Day 3 and Day 4 post-transplant.~First 20 patients with a 4-6/8 mismatched unrelated donor will receive an alternate dose of post-transplant cyclophosphamide of 37.5 mg/kg on Days 3 and Day 4 post-transplant."
88908552|NCT06001385|Experimental|Regimen B (MAC: Fludarabine and TBI, PBSC HCT; Reduce Dose PTCy|"Patients receive:~Fludarabine (90 mg/m2 total dose) IV on days -7 to -5 Total body irradiation (TBI) (1200 cGy total dose) on days -4 to -1~Patients receive a peripheral blood stem cell (PBSC) graft infusion from a mismatched unrelated donor on Day 0.~Patients receive a reduced dose of cyclophosphamide (25mg/kg per dose) on Day 3 and Day 4 post-transplant.~First 20 patients with a 4-6/8 mismatched unrelated donor will receive an alternate dose of post-transplant cyclophosphamide of 37.5 mg/kg on Days 3 and Day 4 post-transplant."
88908553|NCT06001385|Experimental|Regimen C (RIC: Fludarabine and Busulfan; PBSCT HCT; Reduced Dose PTCy|"Patients receive:~Fludarabine (150-180 mg/m2 total dose) IV on days -6 to -2 Busulfan (less than or equal to 8 mg/kg PO or 6.4 mg/kg IV) on days -5 and -4~Patients receive a peripheral blood stem cell (PBSC) graft infusion from a mismatched unrelated donor on Day 0.~Patients receive a reduced dose of cyclophosphamide (25mg/kg per dose) on Day 3 and Day 4 post-transplant.~First 20 patients with a 4-6/8 mismatched unrelated donor will receive an alternate dose of post-transplant cyclophosphamide of 37.5 mg/kg on Days 3 and Day 4 post-transplant."
88908554|NCT06001385|Experimental|Regimen D (RIC: Fludarabine and Melphalan; PBSCT HCT; Reduced Dose PTCy|"Patients receive:~Fludarabine (125-150 mg/m2 total dose) IV on days -7 to -3 Melphalan (100-140 mg/m2) IV on day -1~Patients receive a PBSC graft infusion from a mismatched unrelated donor on Day 0.~Patients receive a reduced dose of cyclophosphamide (25mg/kg per dose) on Day 3 and Day 4 post-transplant.~First 20 patients with a 4-6/8 mismatched unrelated donor will receive an alternate dose of post-transplant cyclophosphamide of 37.5 mg/kg on Days 3 and Day 4 post-transplant."
88908555|NCT06001385|Experimental|Regimen E (NMA: Fludarabine, Cyclophosphamide, and TBI; PBSCT HCT; Reduced Dose PTCy|"Patients receive:~Fludarabine (150mg/m2 total dose) IV on days -6 to -2 Cyclophosphamide (29-50mg/kg) IV on days -6 and -5 TBI (200cGy) on day -1~Patients receive a PBSC graft infusion from a mismatched unrelated donor on Day 0.~Patients receive a reduced dose of cyclophosphamide (25mg/kg per dose) on Day 3 and Day 4 post-transplant.~First 20 patients with a 4-6/8 mismatched unrelated donor will receive an alternate dose of post-transplant cyclophosphamide of 37.5 mg/kg on Days 3 and Day 4 post-transplant."
89427625|NCT01455090|Experimental|Group 6:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg)|"* Genotype 1 treatment-naive subjects~BMS-650032 200 mg tablet by mouth twice daily for 12 Weeks~BMS-790052 30 mg tablet by mouth twice daily for 12 Weeks~BMS 791325 150 mg table by mouth twice daily for 12 Weeks"
89536177|NCT05713331|Experimental|CLS-R|Web-based remote training for school mental health providers
88908556|NCT05999682|Experimental|apigenin|Intragastric tube injection of ground apigenin tablet 50 mg with 5 ml of sterilized water + conventional standardized treatment, for 4 consecutive days.
88908557|NCT05999682|Placebo Comparator|sterilized water|Gastric tube injection of 5 ml of sterilized water for injection + conventional standardized treatment, for 4 consecutive days.
88908558|NCT05999357|Experimental|adult patients with KRAS G12C+ NSCLC and brain metastases|"Cohort A: adult patients with KRAS G12C+ NSCLC and untreated asymptomatic BM Cohort B: Adult patients with KRAS G12C+ NSCLC and treated asymptomatic BM~JDQ443 200 mg BID until unacceptable toxicity or disease progression"
89008090|NCT00564772|Experimental|single arm|all subjects dosed the same
89427626|NCT01455090|Experimental|Group 7:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg)|"* Genotype 4 treatment-naive subjects~BMS-650032 200 mg tablet by mouth twice daily for 12 Weeks~BMS-790052 30 mg tablet by mouth twice daily for 12 Weeks~BMS 791325 75 mg table by mouth twice daily for 12 Weeks"
89427627|NCT01455090|Experimental|Group 8:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg)|"* Genotype 4 treatment-naive subjects~BMS-650032 200 mg tablet by mouth twice daily for 12 Weeks~BMS-790052 30 mg tablet by mouth twice daily for 12 Weeks~BMS 791325 150 mg table by mouth twice daily for 12 Weeks"
89427628|NCT01455090|Experimental|Group 9:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg)|"* Genotype 1 treatment-null/non-responder subjects~BMS-650032 200 mg tablet by mouth twice daily for 12 Weeks~BMS-790052 30 mg tablet by mouth twice daily for 12 Weeks~BMS 791325 75 mg table by mouth twice daily for 12 Weeks"
89427629|NCT01455090|Experimental|Group10:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg)|"* Genotype 1 treatment-null/non-responder subjects~BMS-650032 200 mg tablet by mouth twice daily for 12 Weeks~BMS-790052 30 mg tablet by mouth twice daily for 12 Weeks~BMS 791325 150 mg table by mouth twice daily for 12 Weeks"
89427630|NCT01455090|Experimental|Group11:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg)|"* Genotype 1 treatment-null/non-responder subjects~BMS-650032 200 mg tablet by mouth twice daily for 24 Weeks~BMS-790052 30 mg tablet by mouth twice daily for 24 Weeks~BMS 791325 75 mg table by mouth twice daily for 24 Weeks"
89427631|NCT01455090|Experimental|Group12:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg)|"* Genotype 1 treatment-null/non-responder subjects~BMS-650032 200 mg tablet by mouth twice daily for 24 Weeks~BMS-790052 30 mg tablet by mouth twice daily for 24 Weeks~BMS 791325 150 mg table by mouth twice daily for 24 Weeks"
89427632|NCT01455090|Experimental|Grp13:BMS-650032(200mg)+BMS-790052(30mg)+BMS-791325(75mg)+RBV|"* Genotype 1 treatment-naive subjects~BMS-650032 200 mg tablets orally twice daily 12 weeks~BMS-790052 30 mg tablets orally twice daily 12 weeks~BMS-791325 75 mg tablets orally twice daily 12 weeks~Ribavirin (RBV) tablets orally weight based dosing daily 12 weeks [if subject is < 75 kg: 1000 mg per day orally (2 x 200 mg tablets in AM and 3 x 200 mg tablets in PM), or if ≥ 75 kg: 1200 mg per day orally (3 x 200 mg tablets in AM and 3 x 200 mg tablets in PM]"
89427633|NCT03135366|Active Comparator|Standard of Care (Control)|
88908559|NCT05997082|Experimental|Participants in the intervention|Participants in the intervention will participate in the 6-week mindfulness self-compassion course delivered online.
89427634|NCT03135366|Experimental|Keheala Intervention (Treatment)|The intervention consisted of a daily request for self-verification of medication adherence, access to a supporter via a chat client, and information about TB.
89427635|NCT01449162|Experimental|Masitinib as add-on to oral corticosteroids|Participants receive masitinib (6 mg/kg/day), given orally twice daily, as add-on to oral corticosteroids
89427636|NCT01449162|Placebo Comparator|Placebo as add-on to oral corticosteroids|Participants receive placebo (6 mg/kg/day), given orally twice daily, as add-on to oral corticosteroids
89427637|NCT02056782|Experimental|Dociparstat|"The following induction regimen was administered:~Cytarabine (100 mg/m2/day) via continuous intravenous (IV) infusion 24 hours daily for 7 days.~Idarubicin (12 mg/m2/day) IV on Days 1, 2, and 3.~Dociparstat (4 mg/kg) given over 5 minutes IV, immediately after the idarubicin dose on Day 1, followed by a continuous IV infusion (0.25 mg/kg/hr for 24 hours daily) for a total of 7 days."
88908560|NCT05996185|Experimental|Mogamulizumab + DA-EPOCH|"All subjects are scheduled to receive six cycles of DA-EPOCH + Mogamulizumab~Cycle 1: Mogamulizumab on days 1,8,15, of a 21-day cycle with DA-EPOCH on day 1.~Cycle 2 onwards: Mogamulizumab on day 1 with DA-EPOCH~Mogamulizumab will be administered modified to a 21-day cycle in combination with chemotherapy. Subjects will receive 1.0 mg/kg of mogamulizumab as an IV infusion over at least 1 hour on Days 1, 8, 15 of the first cycle and Day 1 for the subsequent cycles. This dosing regimen will ensure the first 4 doses are given weekly at a dose of 1 mg/kg. Subsequent dosing will occur on a 21-day schedule to coincide with the frequency of administration of DA-EPOCH to allow for simpler co-administration of the study drugs."
88908561|NCT05995678|Experimental|STEP-Home-SP + Usual Care|The core skills of emotional regulation and problem solving are introduced and integrated throughout all Veteran-specific reintegration content modules for practice and repetition for 12 weeks. Attention training augments emotional regulation and problem solving core skills and is interspersed throughout group and individual sessions. Additional 30-minute individual skill building and goal setting sessions occur ~4-6 times based on individual Veteran needs
88908562|NCT05995678|Active Comparator|Usual Care|UC will include the Transition Assistance Program (TAP) as scheduled by DOD prior to military separation, VA Solid Start post-separation, and educational augmentation post-separation.
88908563|NCT05995275|Experimental|mRNA-1769 Dose A|Participants will receive intramuscular (IM) injection of mRNA-1769 at Dose A on Day 1 and Day 29.
88908564|NCT05995275|Experimental|mRNA-1769 Dose B|Participants will receive IM injection of mRNA-1769 at Dose B on Day 1 and Day 29.
88908565|NCT05995275|Experimental|mRNA-1769 Dose C|Participants will receive IM injection of mRNA-1769 at Dose C on Day 1 and Day 29.
88908566|NCT05995275|Placebo Comparator|Placebo|Participants will receive IM injection of placebo matched to mRNA-1769 on Day 1 and Day 29.
88908567|NCT05994898||UHFUS|Pulmonary nodules were detected by UHFUS method.
88908568|NCT05994898||Palpation|Pulmonary nodules were detected by palpation method.
89427638|NCT01469832|Experimental|Subretinal injection of MA09-hRPE|"Cohort 1 50,000 cells~Cohort 2 100,000 cells~Cohort 2a Better Vision 100,000 cells~Cohort 3 150,000 cells~Cohort 4 200,000 cells"
89427639|NCT04475484||School-age children|School-age children from primary school to high school (about age 6 to 18) in the Academy of Lyon
89427640|NCT01198626|Experimental|JNJ-32729463|
89427641|NCT01198626|Active Comparator|moxifloxacin|
89427642|NCT01198626|Experimental|JNJ-32729463 Open-Label|subjects with suspected or confirmed S. aureus CABP may be entered into an open-label JNJ 32729463 treatment group at selected study sites
88908569|NCT05993234||Trastuzumab deruxtecan (T-DXd)|Participants with HER2-positive gastric or gastroesophageal junction adenocarcinoma who will be treated with trastuzumab deruxtecan and part of the enrolled participants will receive conventional therapy. The participants on conventional therapy will be analyzed for exploratory purposes only.
89008091|NCT00564811|No Intervention|G1|
89008092|NCT00564811|Experimental|G2|
89008093|NCT00564967|Experimental|1|CBT via the Internet
89427643|NCT01194960|Active Comparator|Docetaxel Alone|Subjects will receive 10 cycles of Docetaxel alone until toxicity or progression.
89427644|NCT01194960|Experimental|TroVax plus Docetaxel|Subjects will receive both TroVax plus 10 cycles of Docetaxel.
89427645|NCT02266680|Experimental|Yoga Treatment Group|BFY will be taught by a trained yoga instructor. Group sessions will be offered twice a week for 60 minutes each (i.e., a total of 2 hours per week), for 8 weeks.
89427646|NCT02266680|No Intervention|Waitlist Group|Waitlisted participants will receive BFY at the next available group after their waitlist period is completed
89427647|NCT01331850|Experimental|Previous null responders (Cohort B): Group 4|Patients in all groups will receive danoprevir 100 mg twice a day and ritonavir 100 mg twice a day for 24 weeks. In addition, Group 4 will receive RO5024048 1000 mg twice a day and Copegus 1000 mg or 1200 mg twice a day for 24 weeks.
89427648|NCT01331850|Experimental|Previous null responders (Cohort B): Group 5|Patients in all groups will receive danoprevir 100 mg twice a day and ritonavir 100 mg twice a day for 24 weeks. Group 5 will receive RO5024048 1000 mg twice a day, Pegasys 180 microgram subcutaneously once weekly and Copegus 1000 mg or 1200 mg twice a day for 24 weeks.
89536178|NCT05713331|Active Comparator|CLS|In-person training for school mental health providers
88908570|NCT05990946|Experimental|Intervention Group|Participants randomized to the intervention group will complete ePRO symptom severity scores on the PSA-Lung questionnaire via the smartphone app on discharge and post-discharge days 3, 7, 14, 21, 28. Alerts are triggered if any of 5 core symptoms scored ≥4, prompting remote clinician feedback and guidance on symptom management.
88908571|NCT05990946|No Intervention|Control Group|Participants randomized to the control group will complete ePRO symptom severity scores on the PSA-Lung questionnaire via the smartphone app on discharge and post-discharge days 3, 7, 14, 21, 28, without clinician alerts.
88908572|NCT05989022|Other|Imaging Breast Diagnostic|Imaging breast diagnostic where patients receive both modalities MRI and B-CT to compare the resolution of the two different diagnostic devices in the same patient
88908573|NCT05988203|Experimental|SSA - BNT166a|Escalating dose levels
88908574|NCT05988203|Experimental|SSB - BNT166a|One dose level
88908575|NCT05987449|Experimental|NXT007 Dose Escalation|
88908576|NCT05979922|Experimental|Caring Mind mobile app|Participants will receive the Caring Mind mobile app containing the Mindfulness-based Cognitive Coping program.
88908577|NCT05979922|Active Comparator|Traditional educational program|Participants will receive a traditional educational/resources program, containing a downloadable workbook and online resources.
88908578|NCT05978232|Experimental|Navigator-Assisted Hypofractionation (NAVAH)|"This pilot cohort study is designed as follows:~Navigator discussion with patients prior to the start of radiation therapy simulation (15-30 minutes).~Navigator administration of survey with patients after completion of radiation therapy simulation but before the start of radiation therapy (30-45 minutes)~Navigator administration of post-treatment survey and financial toxicity survey instrument after the completion of radiation therapy (60 minutes)."
88908579|NCT05977933||PAH Patients|Pulmonary hypertension (PH) is associated with worsening breathlessness and exercise capacity, right-heart failure, and adverse outcomes including increased mortality. Moreover, PH disease progression can be rapid; pharmaceutical intervention in early-stage PH can improve symptoms and functional capacity, and delayed diagnosis and treatment of PH likely reduces survival.
88908580|NCT05977712||CIRCAME|This is the full cohort of patients that compose the CIRCAME study (N estimated = 1500)
88908581|NCT05977712||CIRCAME-EYE ancillary study|Patients from CIRCAME seen at the Fernand-Widal hospital who will also undergo an eye examination (CIRCAME-EYE, N estimated = 1100, a sub-group of CIRCAME)
88908582|NCT05973708|Active Comparator|Group A: Clamshell Exercise|"Group B will be given frog pumps exercises in their regular training program.~These exercises are given as:~In (0-2) week ,2 sets 10 repetitions~In (2-4)week, 3 sets of 10 repetitions~In (4-6)week, 3 sets of 15 repetitions"
88908583|NCT05973708|Active Comparator|Group B: Frog Pump Exercise|"Group B will be given frog pumps exercises in their regular training program.~These exercises are given as:~In (0-2) week ,2 sets 10 repetitions~In (2-4)week, 3 sets of 10 repetitions~In (4-6)week, 3 sets of 15 repetitions"
88908584|NCT05973695|Active Comparator|Group A: Clamshell Exercise|Group A will be treated with baseline treatment and clamshell exercises. Lie on your side with your knees slightly bent and with one leg on top of the other. Keep your feet together and lift your top knee until its parallel with your hip. Lower your knee back to the initial position, repeat, and then switch sides. In 1st week 1 sets 10 repetitions. In 2nd week 2 sets of 10 repetitions. In 3rd and 4th week and onwards 3 sets of 10 repetitions.
88908585|NCT05973695|Active Comparator|Group B: Gluteal Bridge exercise|Group B will be treated with baseline treatment and Gluteal Bridge exercises. Start flat on your back with your legs bent at a 90-degree angle and feet placed flat on the ground. Make sure your toes are turned outward at 45-degree angles and your knees are facing in the same direction as your toes. Drive down through your feet and push your hips up. You should feel this variation fatiguing the outer portion of your thighs. Make sure you keep your knees over your toes throughout the entire movement. Don't let them move forward over the toes. In a controlled motion, let your hips sink back down toward the ground. This completes 1 repetition. Perform 3 sets of 15 repetitions, or 3 rounds of a 30-second hold.
88908586|NCT05973682|Experimental|Group A: post isometric relaxation and ConVentional treatment.|Post Isometric Relaxation: The term refers to the effect of subsequent relaxation experienced by a muscle or group of muscles, after brief periods during which an isometric contraction has been performed. Post isometric relaxation technique was applied to levator scapulae for 5 repetition using 20% of maximal isometric contraction for 7-10 sec. with complete relaxation of all element, the stretch is maintained for 30 sec.
89008094|NCT00564967|Experimental|2|15 weeks, CBT group therapy, 1 session/week (2.5 hours).
89008095|NCT03454243|Experimental|RXDX-106|
89427649|NCT01331850|Experimental|Previous null responders (Cohort B): Group 6|Patients in all groups will receive danoprevir 100 mg twice a day and ritonavir 100 mg twice a day for 24 weeks. Group 6 will receive RO5024048 1000 mg twice a day, Pegasys 180 microgram subcutaneously once weekly and Copegus 1000 mg or 1200 mg twice a day for 24 weeks. In addition, patients in Group 6 will receive another 24 weeks of Pegasys plus Copegus treatment.
89008096|NCT05506163||Training set|The whole cohort is randomly assigned to a training cohort and validation cohort.
89008097|NCT05506163||validation set|The whole cohort is randomly assigned to a training cohort and validation cohort.
89008098|NCT04604977|Other|Mindfulness by Smartphone|an approach that is alternative to current practice, particularly as far as reducing face-to-face hospital visits taking advantage of facilities offered by new technologies, besides including innovative and emerging treatment choices, namely a behavioural approach base on mindfulness
89008099|NCT04604938|Experimental|Losartan group|Drug: Losartan
89008100|NCT04604938|Placebo Comparator|Placebo group|Drug: Placebo Oral Tablet
89008101|NCT04604626||Population 1|Adults and children with severe obesity ie (BMI> 35 kg / m² for adults and Z BMI score> 3DS for age and sex for children) and / or eating disorders with genetic diagnosis as part of care.
89008102|NCT04604626||Population 2|Adults and children with obesity and / or eating disorders hypothalamic lesion (craniopharyngioma example).
89008103|NCT04604587|Experimental|amyloid PET、T807 PET|PET/CT
89427650|NCT01331850|Experimental|Previous partial responders (Cohort A): Group 1|Patients in all groups will receive danoprevir 100 mg twice a day and ritonavir 100 mg twice a day for 24 weeks. In addition, Group 1 will receive RO5024048 1000 mg twice a day and Copegus 1000 mg or 1200 mg twice a day for 24 weeks.
89008104|NCT00565123|Experimental|Group A|Experimental dosage
89008105|NCT00565123|Active Comparator|Group B|Classical dosage
89008106|NCT05467943|Experimental|Cohort 1 based on the EZH2 mutations|MT patients with R/R FL; planned enrollment number: 19;
89427651|NCT01331850|Experimental|Previous partial responders (Cohort A): Group 2|Patients in all groups will receive danoprevir 100 mg twice a day and ritonavir 100 mg twice a day for 24 weeks. In addition, Group 2 will receive Pegasys 180 microgram subcutaneously once weekly and Copegus 1000 mg or 1200 mg twice a day for 24 weeks.
89008107|NCT05467943|Experimental|Cohort 2 based on the EZH2 mutations,|WT patients with R/R FL; planned enrollment number: 20;
89008108|NCT04604392|Experimental|Tooth tissue-borne (KBME) expander|In this tooth tissue-borne appliance, the occlusal surfaces of the molar and premolar teeth and half of the palatinal and buccal surfaces are covered with heat polymerized acrylic. Hyrax expansion screw is in the midline, as far as possible to the palate positioned close and parallel.
89008109|NCT04604392|Experimental|Tooth-borne (Hyrax) expander|In this tooth-borne expansion appliance, orthodontic bands are placed on the right and left 1st premolar and 1st molar teeth of the patients and the bands are soldered to the Hyrax expansion screw. The expansion screw is in the midline, as far as possible to the palate positioned close and parallel.
89008110|NCT04604392|Experimental|Bone-borne (MIDME) expander|This bone-borne expander includes 2 mini-screws with a diameter of 1.6 mm and a length of 10 mm on the right and left sides, coinciding between the roots of the 2nd premolar and 1st molar teeth in addition to the hyrax expansion screw.
89008111|NCT04604470||Standard treatment|Chemotherapy Chemoradiotherapy Radiotherapy Immunotherapy Or a combination of above
89008112|NCT04604470||ImmunoSABR treatment|"SABR combined immunotherapy~Radiotherapy combined immunotherapy"
89008113|NCT05439707|Experimental|Experimental group|The transaricular vagus nerve stimulator was placed in the left ear trunk, which is dominated only by the auricular branch of the vagus nerve. Continuous stimulation was performed at a frequency of 25Hz with pulse width of 300 μs. The stimulation was adjusted to be higher than the perception threshold and lower than the pain threshold. Each stimulation lasted for 30 minutes, three times per day (morning, noon, evening), from 1 day before surgery to 7 days after surgery, and the treatment lasted for 9 consecutive days.
89008114|NCT05439707|Sham Comparator|Control group|The transaricular vagus nerve stimulator was placed in the same position as the experimental group, covered with an insulating film and placed at the site of the stimulation, so that the patient could not actually receive the electrical stimulation. Continuous stimulation was performed at a frequency of 25Hz and pulse width of 300 μs, and the stimulation was adjusted to be higher than the perception threshold and lower than the pain threshold. Each stimulation lasted for 30 minutes, three times per day (morning, noon, evening), from 1 day before surgery to 7 days after surgery, for 9 consecutive days.
89008115|NCT04603885|Experimental|Aerobic exercise group|Aerobic exercise will be measured with a Polar United fitness watch. Heart rate during exercise will be measured using a Polar United fitness watch, which has been validated for monitoring moderate and high intensity physical activity.
89196997|NCT00705614||Switched to Remicade Group|Participants who started in the Standard Therapy Group but switched over to Remicade sometime during the follow-up period. Participants who switch to Remicade are evaluated in the Standard Therapy group until the time of the switch and are evaluated in the Switched to Remicade group thereafter.
89008116|NCT04603885|Placebo Comparator|Attention control group|The time-equivalent, stretching movements will serve as the placebo exercise condition in this proposed study. Previous research has shown that stretching could reduce attrition and patient dissatisfaction and better ensure allocation concealment. Following baseline measures, a student will demonstrate the use of a Polar United fitness watch and stretching movements via zoom from week 3 to week 5. Starting on week 3, participants will perform the prescribed stretching exercise 3 times a week, maintaining heart rate below 40% of heart rate reserve during exercise.
89008117|NCT04603768|Experimental|Theraband exercises|Group A: baseline physical therapy treatment along with theraband exercises
89008118|NCT04603768|Experimental|Co-contraction exercises|Group B: baseline physical therapy treatment along with co-contraction exercises
89008119|NCT04603768|Experimental|isometric exercises|Group C: baseline physical therapy treatment along with isometric exercises
89008120|NCT04603963|No Intervention|group control|alternate exercises: in one day breathing exercises, active or with a load of large muscle groups (according to tolerance) with a maximum limit of 2 kg, sedation out of bed, walking. On another day aerobic exercise with cycle ergometer limited to 30 minutes.
89427652|NCT01331850|Experimental|Previous partial responders (Cohort A): Group 3|Patients in all groups will receive danoprevir 100 mg twice a day and ritonavir 100 mg twice a day for 24 weeks. Group 3 will receive RO5024048 1000 mg twice a day, Pegasys 180 microgram subcutaneously once weekly and Copegus 1000 mg or 1200 mg twice a day for 24 weeks.
89008121|NCT04603963|Experimental|intervention group|He received the same intervention as the control group, associating respiratory muscle training 1 time a day with power breathe 3 series of 10 repetitions (started with 30% of the Pimax value) with readjusted load every 7 days.
89008122|NCT04603729|Active Comparator|group 1 dexamethasone|participants will receive dexamethasone 8mg/day Intravenous for 5 days
89008123|NCT04603729|Active Comparator|group 2 methylprednisolone|participants will receive methylprednisolone 1mg/kg/day intravenous for 5 days
89008124|NCT04604080||single group|Respondents will be given survey form, filled and will be collected back
89008125|NCT04603534|Experimental|Intervention group|
89008126|NCT04603378|Other|KB195|
89008127|NCT04603378|Other|Polydextrose|
89427653|NCT02264730|Experimental|Clot Foam|Application of Clotfoam
89427654|NCT01328808|Experimental|group 2 Pain management|"In preterm and term neonates with a GA of 28 weeks or more a 15 mg/kg dose of APAP will be given every 8 hrs by an intravenous infusion over 30-minute.~In preterm and term neonates with a GA of less than 28 weeks 15 mg/kg dose of APAP will be given every 12 hrs by an intravenous infusion over 30-minute"
89427655|NCT01968590|Active Comparator|cholecalciferol 600 IU|cholecalciferol in Ddrops form at either 600 International units per day versus 4,000 IU per day
89427656|NCT01968590|Active Comparator|cholecalciferol 4,000 IU|Cholecalciferol at 4,000 IU per day in the form of liquid Ddrops
89008128|NCT04603378|Other|Pullulan|
89008129|NCT04603378|Other|Maltodextrin|
89008130|NCT04603573|Experimental|(intervention)|Fluoride varnish (3M Clinpro White Varnish 5% sodium fluoride). Group (1)
89008131|NCT04603573|Active Comparator|comparator|Resin based fissure sealant (3M Clinpro Sealant, light cure, low viscosity, fluoride release).group (2)
89008132|NCT00565201|Experimental|Botox and Rehab|"Patients will receive BOTOX® (100 to 360 U) injected into the any of the following muscles: 30-100U in the Flex. Dig. Sublimes (3 sites), 30-100U in the flex. Carpi Rad. (3 sites), 30- 100 U flex Carpi Ulnaris (3 sites), 30-100 U in the flex Dig Superficiali ( 3 sites), 25U Prontator Teres (1 site), 25 U Brachioradialis (1 site).~Physical Rehabilitation: One hour session divided into 3 categories of treatment - 1.) Pre-functional/modalities for a general guideline of treatment; 2.)Repetitive task practice and strengthening; 3.)Functional activities - ADL and IADLs."
89008133|NCT00565201|Placebo Comparator|Placebo and Rehab|Patients will placebo saline (100 to 360 U) injected into any of the following muscles: 30-100U in the Flex. Dig. Sublimes (3 sites), 30-100U in the flex. Carpi Rad. (3 sites), 30- 100 U flex Carpi Ulnaris (3 sites), 30-100 U in the flex Dig Superficiali ( 3 sites), 25U Prontator Teres (1 site), 25 U Brachioradialis (1 site) followed by Physical Rehabilitation: One hour session divided into 3 categories of treatment - 1.) Pre-functional/modalities for a general guideline of treatment; 2.)Repetitive task practice and strengthening; 3.)Functional activities - ADL and IADLs.
89008134|NCT05361824|Experimental|Ketorolac|Ketorolac 30mg 8 hourly for 48 hours post-operatively
89008135|NCT05361824|Active Comparator|Paracetamol|Paracetamol 1gm 6 hourly for 48 hours post-operatively
89008136|NCT04603612|Other|NMIBC patients|Patients with diagnosed bladder tumors seen the urology department (Urology and Nephrology Center, Mansoura University, Egypt) will be assessed for eligibility to the study and inclusion criteria. Patients who are meeting these criteria will be asked to participate in this prospective study and will be provided with an informed consent form. Study participants will be enrolled, and the appropriate scheduled procedures will be performed.
89008137|NCT04603222|Experimental|Treatment Group|Group treating blepharitis with SUMMIT BRUSH and Ocusoft Lid Scrub Original Foaming Eyelid Cleanser once a day
89008138|NCT04603222|Active Comparator|Control Group|Group treating blepharitis with Ocusoft Lid Scrub Original Foaming Eyelid Cleanser once a day
89008139|NCT04603339|Experimental|Intervention Arm|Single arm trial, all participants will receive the intervention
89008140|NCT05314829||Study group|Data will be collected from 2 child advocacy centers
89008141|NCT04603456|Experimental|Probiotic Group|consisted of 15 cases who received probiotics only. A drug called Lacteol fort (Rameda Company) . A sachet was taken once daily for three months. Each sachet contains 10 billions lactobacilli.
89008142|NCT04603456|Experimental|SLIT Group|included 15 children who received SLIT for 6 months. Standardized Timothy Grass Pollen (Phleum pratense)
89196998|NCT00844155|Active Comparator|A.Oseltamivir 75 mg dose|Patients will be randomized to two groups (group A) to receive oseltamivir at 75 mg, or (group B) to receive the drug at 150 mg in the fasting or fed state.
89427657|NCT03466034||Endometriod|Type I (endometrioid and mucinous carcinomas) - Magnetic Resonance Imaging (MRI) with 100% Oxygen.
89427658|NCT03466034||Serous|Type II (serous and clear cell carcinomas) - Magnetic Resonance Imaging (MRI) with 100% Oxygen.
89427659|NCT02266836|Experimental|MyndMove|The MyndMove system is a neuromodulation device that delivers short electrical pulses to stimulate muscle contractions and enhance motor recovery following Stroke or Spinal Cord Injury. MyndMove delivers therapeutic stimulation sequences called protocols, which are coded therapeutic algorithms which assist muscle movement allowing the brain and central nervous system to be retrained restoring voluntary reaching and grasping functions lost following neurological injury. The MyndMove system comprises the hardware device, stimulation electrodes and cables, hand and foot switches, and integrated software.
88908587|NCT05973682|Active Comparator|Group B: Conventional treatment|hot pack and TENS at neck area for 10 mint upper trapezius, levator scapulae and pectoralis stretching 3 times with 30-second hold. static stretching exercises, two sessions per week for 3 weeks were given to each patient
88908588|NCT05970497|Experimental|Dose escalation of KB707 by intratumoral (IT) injection in solid tumors|Dose escalation of single-agent KB707 in 3 cohorts to treat superficial solid tumors
88908589|NCT05970497|Experimental|Dose expansion of KB707 by IT injection|Single-agent KB707 in superficial and deep/visceral solid tumors
88908590|NCT05970003|Active Comparator|Group A: Copenhagen exercise|"Group A will receive the Copenhagen exercise, also known as the adductor strengthening protocol, is a dynamic and high-intensity exercise. It doesn't require any special equipment and can be done in any training center.~There are 3 different levels of exercise were performed by players.~Level 1: Side-lying hip adduction exercise.~Level 2: Copenhagen adduction exercises while both arms support at the knee.~Level 3: Copenhagen adduction exercise - primary support at the ankle and minor support at the knee."
88908591|NCT05970003|Active Comparator|Group B : Holmich Exercises|"Group B will receive Holmich continues to provide the strongest evidence for the efficacy of exercise as an ARGP treatment.~The Holmich treatment protocol exercise includes static and dynamic and/or isometric and isotonic strengthening exercises for hip adductors and abductors and also for abdominal muscles.~There are 6 Different types of exercises were performed by players who were a participant with 3 sets of 10 repetitions with 15 sec recovery period."
88908592|NCT05968898|No Intervention|Usual care (clinician assessment)|In the usual care arm, clinicians will evaluate individuals with indeterminate pulmonary nodules as part of routine clinical care. No specific guidance regarding pulmonary nodule risk stratification will provided to evaluating clinicians.
88908593|NCT05968898|Experimental|Clinician assessment + CAD-based risk stratification|In the experimental arm, evaluating clinicians will receive a Lung Cancer Prediction report from an artificial intelligence radiomics-based computer-aided diagnosis tool for risk stratification of pulmonary nodules.
88908594|NCT05963555|Experimental|Whole-Body Photobiomodulation|Light therapy in both the visible and near-infrared range (non-UV) applied to the whole body in a light pod or bed.
88908595|NCT05963555|Experimental|Dry Float|Simulates the effects of traditional Float-REST therapy. Instead of contact with salt water, the dry float system has a very thin membrane that cradles the body and provides a warm sensation, similar to that experienced in a traditional flotation tank.
88908596|NCT05963555|Experimental|Localized Photobiomodulation|Light therapy in both the visible and near-infrared range (non-UV) applied locally to only a specific body region.
88908597|NCT05963555|No Intervention|Control|Participants in the control group will be asked to keep their normal daily routine.
88908598|NCT05963542|Experimental|ACT + sound therapy group|"The combined treatment group will receive Internet-delivered guided self-help tinnitus treatment based on ACT combined with customized sound therapy.~The online ACT program includes 8 modules of structured self-help material over 8 weeks. Each module includes information, exercises, and homework. The self-help material covers the six core processes of ACT: acceptance, cognitive defusion, being present, self-as-context, values, and committed action, emphasizing psychological flexibility.~Customized sound therapy will be provided by the Fudan Tinnitus Relieving System (FTRS) app. Participants will listen to tailor-made music through the app for more than two hours per day."
88908599|NCT05963542|Active Comparator|sound therapy group|The single treatment group will receive customized sound therapy provided by the FTRS app for more than two hours per day.
88908600|NCT05962606|Experimental|AON-D21 plus Standard of Care|Sterile liquid formulation of AON-D21 in 4% mannitol + 0.05% EDTA in glass vials. It will be administered intravenously, for up to 10 days plus Standard of Care therapy for severe community-acquired pneumonia as per local guidelines.
88908601|NCT05962606|Placebo Comparator|Placebo plus Standard of Care|Sterile liquid formulation of 5% glucose solution in matched glass vials with a 1.5 mL fill volume. It will be administered intravenously, for up to 10 days plus Standard of Care therapy for severe community-acquired pneumonia as per local guidelines.
88908602|NCT05960461|Experimental|FMF (Families Moving Forward) Connect Pro with ECHO implementation|Mental health providers are trained in FMF Connect Pro with ECHO (Extension of Community Healthcare Outcomes) tele-mentoring. FMF Connect Pro teaches mental health providers how to do routine screening of prenatal alcohol exposure, diagnose fetal alcohol spectrum disorders (FASD), and support caregivers in using the FMF Connect app. The FMF Connect Pro Dashboard organizes intervention content for providers and includes tools for client progress monitoring. In this arm, providers receive training in FMF Connect Pro through 13 bi-weekly ECHO tele-mentoring sessions. Each ECHO session involves brief didactic presentations by Hub Team members on FASD-informed care principles and FMF Connect content and case-based discussions and recommendations by Spoke Sites.
89008143|NCT04603456|Experimental|Combined treatment Group|included 15 children who received probiotics and SLIT. A drug called Lacteol fort was administered A sachet was taken once daily for 3 months . Standardized Timothy Grass Pollen was taken for 6 months
89008144|NCT04603105||Single Study Cohort|Patients will be recruited from the main study after being determined to having COVID-19 and Cancer
89427660|NCT01325688|Experimental|Group 1|PEP005 0.05% gel applied and occluded with an aluminium disk for up to three consecutive days
89427661|NCT01325688|Experimental|Group 2|PEP005 0.05% Gel applied and occluded with an OpSite(TM) disk up to three consecutive days
89427662|NCT01325688|Experimental|Group 3|PEP005 0.05% applied with no occlusion for up to three consecutive days
89427663|NCT01318434|Experimental|EB-1010 25 mg BID|Experimental Active
89427664|NCT01318434|Experimental|EB-1010 50 mg BID|Experimental Active
89008145|NCT04602676|Experimental|Diarrheal Assessment with DEP, then diarrheal assessment|Participants will go through a 4 week period where clinicians will use a rehydration calculator application with the DEP algorithm. After a washout period of 1 week, they will go through a 4 week period where clinicians will use a rehydration calculator application.
89427665|NCT01318434|Active Comparator|SSRI/SNRI|Active Comparator
89427666|NCT01318434|Placebo Comparator|EB-1010 0 mg BID|Placebo comparator
89427667|NCT03465956|Other|Laparoscopic Sleeve Gastrectomy|Laparoscopic sleeve gastrectomy for patients with morbid obesity using the gastro-intestinal anastomosis stapler.
89427668|NCT03465800|Active Comparator|Self-Monitoring|Participants self-monitor their physical activity
89427669|NCT03465800|Experimental|Daily Incentives|daily payments for physical activity
88908603|NCT05960461|Experimental|FMF (Families Moving Forward) Connect Pro with Self-directed materials|Mental health providers are trained in FMF Connect Pro with self-directed materials. FMF Connect Pro teaches mental health providers how to do routine screening of prenatal alcohol exposure, diagnose fetal alcohol spectrum disorders (FASD), and support caregivers in using the FMF Connect app. The FMF Connect Pro Dashboard organizes intervention content for providers and includes tools for client progress monitoring. In this arm, mental health providers will access similar didactic content as ECHO participants, but in an asynchronous format on the FMF Connect Pro Dashboard. This will include pre-recorded videos, activities, and additional resources for further learning.
88908604|NCT05960461|No Intervention|Waitlist Comparison Group|The waitlist comparison group will receive FMF Connect Pro via Self-directed materials after completing assessments at the 6-month timepoint.
88908605|NCT05959655||Glean Urodynamics System|Wireless, catheter-free urodynamics system
89427670|NCT03465800|Experimental|Delayed Lump Sum Incentives|lump sum payments for physical activity
88908606|NCT05957393|Experimental|Quantity (present) x Quality (present)|Participants will receive a social norm-based message (for quantity) and will learn the AIMS method, a trust-building method using presumptive language (for quality).
88908607|NCT05957393|Experimental|Quantity (present) x Quality (absent)|Participants will receive a social norm-based message (for quantity).
88908608|NCT05957393|Experimental|Quantity (absent) x Quality (present)|Participants will learn the AIMS method, a trust-building method using presumptive language (for quality).
88908609|NCT05957393|Experimental|Quantity (absent) x Quality (absent)|Control: Participants in this condition will receive general information about vaccines, including vaccine principles, uptake barriers, and guidelines. This information will come directly from the CDC's Advisory Committee on Immunization Practices (ACIP) website.
88908610|NCT05956626|Experimental|Experimental: Phase1 Dose Escalation- Low Dose (3.75×10E10 vg/mL):|Low Dose (3.75×10E10 vg/mL): Subjects will receive a subretinal injection of 200 µL of OCU410ST in the low dose concentration.
88908611|NCT05956626|Experimental|Experimental: Phase1 Dose Escalation- Medium Dose (7.5×10E10 vg/mL):|Medium Dose (7.5×10E10 vg/mL): Subjects will receive a subretinal injection of OCU410ST in the Medium dose concentration.
88908612|NCT05956626|Experimental|Experimental: Phase1 Dose Escalation- High Dose (2.25×10E11 vg/mL):|High Dose (2.25×10E11 vg/mL): Subjects will receive a subretinal injection of OCU410ST in the high dose concentration.
88908613|NCT05956626|Experimental|Experimental: Phase 2 Dose Expansion: Dose 1 from Phase 1-Randomized Adult Arm|Subjects will receive a subretinal injection of OCU410ST with Maximum tolerated dose (MTD) from Phase 1.
88908614|NCT05956626|Experimental|Experimental: Phase 2 Dose Expansion: Dose 1 from Phase 1-Randomized Pediatric Arm|Subjects will receive a subretinal injection of OCU410ST with Maximum tolerated dose (MTD) from Phase 1.
88908615|NCT05956626|Experimental|Experimental: Phase 2 Dose Expansion: Dose 2 from Phase 1-Randomized Adult Arm|Subjects will receive a subretinal injection of OCU410ST with Lower Dose than Maximum tolerated dose (MTD) from Phase 1
88908616|NCT05956626|Experimental|Experimental: Phase 2 Dose Expansion: Dose 2 from Phase 1-Randomized Pediatric Arm|Subjects will receive a subretinal injection of OCU410ST with Lower Dose than Maximum tolerated dose (MTD) from Phase 1
88908617|NCT05956626|No Intervention|No Intervention- Randomized Control Adult Arm|No Intervention Control Arm: Subject will not receive any active study intervention
88908618|NCT05956626|No Intervention|No Intervention- Randomized Control Pediatric Arm|No Intervention Control Arm: Subject will not receive any active study intervention
88908619|NCT05956535||AONDA contact lenses|Lotrafilcon A contact lenses worn therapeutically as a bandage lens in a continuous wear (CW) modality (lenses worn continuously including overnight) as instructed by the eye care professional.
88908620|NCT05956535||PV2 contact lenses|Balafilcon A contact lenses worn therapeutically as a bandage lens in a continuous wear (CW) modality (lenses worn continuously including overnight) as instructed by the eye care professional.
89427671|NCT04475094||COHORT|All patients will have had a clinically-indicated PET revealing at least one reversible perfusion defect followed by a research-indicated cardiac PET study between 3 and 8 weeks post-successful coronary artery stenting.
88908621|NCT05953610|Experimental|Acetazolamide|Treatment with acetazolamide 500 mg nightly for 1 month.
88908622|NCT05953610|Experimental|Acetazolamide/Eszopiclone|Treatment with acetazolamide 500 mg and eszopiclone 3 mg nightly for 1 month.
88908623|NCT05952869|Experimental|MK-0616|Participants will receive 20 mg of MK-0616 orally once daily (QD) for up to 52 weeks.
88908624|NCT05952869|Placebo Comparator|Placebo|Participants will receive MK-0616-matching placebo orally QD for up to 52 weeks.
88908625|NCT05952804|Experimental|Arm I (therapeutic immune globulin)|Patients receive IGRT with IVIG within 14 days prior to CD19 CAR-T treatment. Patients then undergo CD19 CAR-T therapy. Patients receive IVIG monthly, starting 28 days after CD19 CAR-T therapy for 4 months in the absence of unacceptable toxicity. Patients also undergo blood sample collection throughout the study.
89536179|NCT03074799|Active Comparator|TST-based Screening (Child contacts)|In the control clinics, decision regarding IPT will be made based on TST results, as is now the standard of care in this South African health district. In this setting, all TST negative children are initiated on IPT by the nurse at the local clinic. TST positive children are all referred to the district hospital for further evaluation of TB disease regardless of clinical symptoms. Again, clinical outcome data will be obtained from patient records and the same longitudinal child contact register.
89196999|NCT00844155|Active Comparator|B. Oseltamivir 150mg|Patients will be randomized to groups (group A) to receive oseltamivir at 75 mg, or group B to receive the drug at 150 mg in the fasting or fed state.
89536859|NCT02469311|Sham Comparator|Primary Control THA|Patients undergoing a first or primary total hip arthroplasty will be randomized to the intervention of Standard of care bathing with antibacterial soap and water.
89536860|NCT02469311|Active Comparator|Primary Treatment THA|Patients undergoing a first or primary total hip arthroplasty will be randomized to the intervention of chlorhexidine impregnated cloths.
88908626|NCT05952804|Placebo Comparator|Arm II (normal saline)|Patients receive placebo with normal saline IV within 14 days prior to CD19 CAR-T treatment. Patients then undergo CD19 CAR-T therapy. Patients receive normal saline monthly, starting 28 days after CD19 CAR-T therapy for 4 months in the absence of unacceptable toxicity. Patients also undergo blood sample collection throughout the study.
88908627|NCT05952388|No Intervention|Behavioral Patient Care|Chart review
88908628|NCT05949255|Experimental|Probiotic|Subjects will receive a probiotic supplement to take by mouth daily.
88908629|NCT05949255|Placebo Comparator|Placebo|Subjects will receive a placebo to take by mouth daily.
88908630|NCT05949190|Experimental|M-RUSF+ (Maternal Ready-to-Use Supplementary Food + DHA/EPA/choline) and CBT|"Factorial 1. A daily dose of 500mg DHA, 500mg EPA, and 550mg choline will be added to the maternal balanced energy-protein RUSF. One sachet (daily dose) will provide 520 Kcal, 18g protein, and the same quantities of micronutrients as the United Nations International Multiple Micronutrient Antenatal Preparation (UNIMMAP) for women. M-RUSF+ will be vacuum sealed and packaged in foil sachets containing 100g of food.~Factorial 2. Among participants randomized to receive M-RUSF+ vs. M-RUSF, those who develop ante- or postpartum depression will receive 6 sessions of CBT adopted for use in illiterate populations will be provided."
88908631|NCT05949190|Experimental|M-RUSF+ (Maternal Ready-to-Use Supplementary Food + DHA/EPA/choline) and no CBT|"Factorial 1. A daily dose of 500mg DHA, 500mg EPA, and 550mg choline will be added to the maternal balanced energy-protein RUSF. One sachet (daily dose) will provide 520 Kcal, 18g protein, and the same quantities of micronutrients as the UNICEF/World Health Organization/United Nations multiple micronutrient supplement for pregnant/lactating women. M-RUSF+ will be vacuum sealed and packaged in foil sachets containing 100g of food.~Factorial 2. Participants who develop ante- or postpartum depression will not receive CBT."
88908632|NCT05949190|Experimental|M-RUSF (Maternal Ready-to-use Supplementary Food without DHA/EPA/choline and CBT|"Factorial 1. M-RUSF will be similar to M-RUSF+, except it will not contain added DHA or EPA, and will only contain 5mg of added choline to help with flavor masking. One sachet (daily dose) will provide 520 Kcal, 18g protein, and the same quantities of micronutrients as the UNIMMAP for pregnant/lactating women. M-RUSF+ will be vacuum sealed and packaged in foil sachets containing 100g of food.~Factorial 2. Participants who develop ante- or postpartum depression will receive 6 sessions of CBT adopted for use in illiterate populations will be provided."
88908633|NCT05949190|Experimental|M-RUSF (Maternal Ready-to-use Supplementary Food without DHA/EPA/choline and no CBT|"Factorial 1. M-RUSF will be similar to M-RUSF+, except it will not contain added DHA or EPA, and will only contain 5mg of added choline to help with flavor masking. One sachet (daily dose) will provide 520 Kcal, 18g protein, and the same quantities of micronutrients as the UNIMMAP for pregnant/lactating women. M-RUSF+ will be vacuum sealed and packaged in foil sachets containing 100g of food.~Factorial 2. Participants who develop ante- or postpartum depression will not receive CBT."
88908634|NCT05948826|Experimental|Monotherapy Dose Dose Finding - Part 1|TORL-3-600
88908635|NCT05948826|Experimental|Expansion as Monotherapy - Part 2|TORL-3-600
88908636|NCT05946941|Experimental|Deucravacitinib, Dose 1|
88908637|NCT05946941|Experimental|Deucravacitinib, Dose 2|
88908638|NCT05946941|Placebo Comparator|Placebo, followed by Deucravacitinib Dose 1 or Dose 2|
88908639|NCT05942469|Experimental|FOREST + Assessments|READI staff will participate in Monthly Skill Sessions and complete FOREST content modules in the Learning Management System (LMS). Staff will also be invited to complete annual assessments for primary and secondary outcome measures, as well as annual interviews and focus groups to gather feedback on progress, implementation, and content.
88908640|NCT05939947|Experimental|ALE.F02|Patients will receive 3 doses of ALE.F02 administered once every second week as a continuous intravenous (IV) infusion to a total of 3 doses.
88908641|NCT05939947|Placebo Comparator|Placebo|Patients will receive 3 doses of matching placebo administered once every second week as a continuous intravenous (IV) infusion to a total of 3 doses.
88908642|NCT05937087||TOC community advisory research team|Participants were given a pre-and post community engagement survey.
88908643|NCT05936528|Experimental|Lactoferrin|Lactoferrin 100 mg sachets with a dose of 200 mg (2 sachets) orally twice daily (400 mg per day) In addition to standard of care
88908644|NCT05936528|No Intervention|Placebo|Standard of care only no intervention by lactoferrin
88908645|NCT05934981|Experimental|Low Pressure and warm and humidified CO2 insufflation|Low pressure pneumoperitoneum and use warm and humidified CO2 insufflation
88908646|NCT05934981|Active Comparator|Low Pressure|Low pressure pneumoperitoneum
88908647|NCT05934487|Experimental|Randomized Arm- Treatment Arm|"All subjects will receive the Cordella Sensor.~Clinicians will manage the subjects to target PAP per protocols specific Treatment Guidelines and according to Guideline-Directed Medical Therapy."
88908648|NCT05934487|Experimental|Randomized Arm- Active Control Arm|"All subjects will receive the Cordella Sensor.~Clinicians will manage subjects using the subjects daily data trends (BP, weight, HR, SpO2 symptoms) according to Guideline Directed Medical Therapy."
88908649|NCT05934487|Experimental|Randomized Arm- Crossover Arm|"All subjects will receive the Cordella Sensor.~At least 12 months following implant and following an adjudicated HFH, subjects in the Active Control Arm can qualify to crossover to the Crossover Arm and both patients and clinicians would then be unmasked to PAP. Clinicians will then manage the subjects to target PAP per protocols specific Treatment Guidelines and according to Guideline-Directed Medical Therapy."
88908650|NCT05934487|Experimental|Single Arm- Clinician-Directed Patient Self-Management Arm|"All subjects will receive the Cordella Sensor.~Subjects will self-manage their Loop diuretics per protocol specific Clinician-Directed Patient Self-Management Treatment Guidelines and Clinicians will manage the patients according to Guideline-Directed Medical Therapy."
88908651|NCT05934487|Experimental|Single Arm- Clinician Management Arm|"All subjects will receive the Cordella Sensor.~Clinicians will manage the subjects to target PAP per protocols specific Treatment Guidelines and according to Guideline-Directed Medical Therapy."
89008146|NCT04602676|Experimental|Diarrheal Assessment, then Diarrheal assessment with DEP|Participants will go through a 4 week period where clinicians will use a rehydration calculator. After a washout period of 1 week, they will go through a 4 week period where clinicians will use a rehydration calculator application with the DEP algorithm.
89197000|NCT00835653||1|patients with a carpal tunnel syndrome
89197001|NCT00835653||2|patients without a carpal tunnel syndrome
88908652|NCT05934136|Experimental|My Healthy Brain 1|My Healthy Brain 1 is an 8-week group program delivered via 90-minute Zoom meetings led by a clinical psychologist. It provides education on the link between dementia and lifestyle factors, including poor exercise, sleep, diet/nutrition, mental and social stimulation, alcohol, and smoking. My Healthy Brain 1 participants learn evidence-based mindfulness and behavior change skills to address common barriers to healthy habits, such as stress and setting achievable goals. My Healthy Brain 1 participants wear an activity watch to monitor lifestyle changes during the program.
88908653|NCT05934136|Active Comparator|My Healthy Brain 2|My Healthy Brain 2 condition controls for the effect of time spent and support/feedback from the group and interventionist. Participants in My Healthy Brain 2 will receive education on lifestyle, brain health, and cognitive decline symptoms in addition to usual care as determined by their medical team. Each weekly session will focus on a different topic: 1) lifestyle and brain health, 2) physical activity, 3) sleep, 4) nutrition, 5) medical adherence, 6) cognitive health, 7) social support, and 8) a program overview. My Healthy Brain 2 is conducted in the same format as My Healthy Brain 1 (8 weekly Zoom sessions, 90 minutes each), but does not include behavior change strategies. My Healthy Brain 2 participants wear an activity watch to monitor lifestyle changes during the program.
88908654|NCT05933070|Experimental|Schedule of Assessments|"INKmune therapy will be administered by a slow intravenous injection via conventional blood giving set. Patients will receive 3 weekly IV doses of INKmune on Day 1, 8, and 15.~In Cohort 1, the initial planned dose is 1 x 10^8 INKmune;~In Cohort 2, the weekly dose will increase to 3 x 10^8 INKmune;~In Cohort 3, the weekly dose will increase to 5 x 10^8 INKmune."
89197002|NCT00620763|Experimental|A|Dietary Intervention: High meat and high acid load diet followed by low meat and low acid load diet
89197003|NCT00620763|Experimental|B|Dietary Intervention: Low meat and low acid load diet followed by high meat and high acid load diet
89197004|NCT05670938||Non-seminomatous germ cell tumours, stage I low risk|No lymphadenopathy or metastases on the postoperative scan. Three consecutive blood drawings with normal tumour markers. Patients undergoing lymph node dissection as a second curative operation after an orchiectomy, can also be included in case that the postoperative scan shows no residual disease or metastases.
89197005|NCT05670938||Non-seminomatous germ cell tumours, stage I high risk|"After completion of one cycle of Bleomycin, etoposide and platinum (BEP). Biochemical remission at completion of chemotherapy, meaning three consecutive blood drawings with normal tumour markers.~No lymphadenopathy or metastases on the CT scan after completion of chemotherapy."
89197006|NCT05670938||Seminomatous germ cell tumours (after chemotherapy) with complete remission.|"Biochemical remission at completion of chemotherapy, meaning three consecutive blood drawings with normal tumour markers.~No lymphadenopathy or metastases on the CT scan after completion of chemotherapy."
89197007|NCT05670938||Non-seminomatous germ cell tumours (after chemotherapy) with complete remission.|"Biochemical remission at completion of chemotherapy, meaning three consecutive blood drawings with normal tumour markers.~No lymphadenopathy or metastases on the CT scan after completion of chemotherapy."
89197008|NCT00835809||Acute respiratory diseases.|Patient admit in emergency or intensive care unite with acute respiratory insufficiency.
89197009|NCT00844233|Experimental|1|Irinotecan Bead
89197010|NCT00841893|Experimental|1|Mustard
89197011|NCT00841893|Experimental|2|Placebo
89197012|NCT00844311|Active Comparator|Control arm|150 iu/day of rFSH alone
89197013|NCT00844311|Experimental|hCG low dose|150 iu/day of rFSH + 50 iu/day of hCG from stimulation day 1
89197014|NCT00844311|Experimental|hCG medium dose|150 iu/day of rFSH + 100 iu/day of hCG from stimulation day 1
89197015|NCT00844311|Experimental|hCG high dose|150 iu/day of rFSH + 150 iu/day of hCG from stimulation day 1
89197016|NCT02547597|Experimental|Carvedilol|Carvedilol 25 mg twice a day
88908671|NCT05931835|Experimental|Catheter-ablation and closure procedures arm|Subjects entitled to undergo a catheter-based ablation treatment for typical atrial flutter or atrial fibrillation and subjects entitled to undergo a left atrial appendage/atrial septal defect closure procedure
88908672|NCT05929794|Active Comparator|Micropatch application + metronidazole 0.75% topical gel|Participants will have pre-treatment micropatch application followed by metronidazole 0.75% topical gel
88908673|NCT05929794|Active Comparator|Metronidazole 0.75% topical gel|Participants will have metronidazole 0.75% topical gel applied without the pre-treatment micropatch application
88908674|NCT05929794|Active Comparator|Micropatch application + metronidazole 0.75% topical cream|Participants will have pre-treatment micropatch application followed by metronidazole 0.75% topical cream
88908675|NCT05929794|Active Comparator|Metronidazole 0.75% topical cream|Participants will have metronidazole 0.75% topical cream applied without the pre-treatment micropatch application
88908676|NCT05928637|Experimental|Sequence 1|"Period 1: oral dose of D745 1 tablet.~Period 2: multiple oral dose of 1 tablet of D759 and 2 tablets of D150.~Period 3: multiple oral dose of 1 tablet of D745, 1 tablet of D759, and 2 tablets of D150."
88908677|NCT05928637|Experimental|Sequence 2|"Period 1: oral dose of D745 1 tablet.~Period 2: multiple oral dose of 1 tablet of D745, 1 tablet of D759, and 2 tablets of D150.~Period 3: multiple oral dose of 1 tablet of D759 and 2 tablets of D150."
88908678|NCT05928637|Experimental|Sequence 3|"Period 1: multiple oral dose of 1 tablet of D759 and 2 tablets of D150.~Period 2: oral dose of D745 1 tablet.~Period 3: multiple oral dose of 1 tablet of D745, 1 tablet of D759, and 2 tablets of D150."
89427672|NCT05229692|Experimental|NEUBIE|"Experimental group will receive rehabilitation training with the NEUBIE for 6 weeks post-operative. Training will occur at Neufit 2x a week from week 1-5, and will be administered by NeuFit clinic staff. Exercises and ability to complete exercises will be recorded by NeuFit staff in standardized clinic evaluation forms.~Participants will undergo will undergo both active muscle tests and body analysis tests.~Measurements will be taken at The Piazza Center by clinic staff prior to surgery at 2,4,6,8, and 12 weeks post-operative. Measurements will be used to demonstrate milestones of functional recovery, comparable between subjects by weeks achieved."
89427673|NCT05229692|No Intervention|Control|"Control group will receive current post-operative standard of care for abdominoplasty, which includes using an abdominal binder, rest and minimal activity for 6 weeks.~Participants will undergo both active muscle tests and body analysis tests. Measurements will be taken at The Piazza Center by clinic staff prior to surgery at 2,4,6,8, and 12 weeks post-operative. Measurements will be used to demonstrate milestones of functional recovery, comparable between subjects by weeks achieved."
89427674|NCT01314222|Other|Arm 1: BMS-954561 40mg or 80mg|"BMS-954561 40mg or 80mg TID to Placebo OR Placebo to 40mg or 80mg TID~Active to Placebo or Placebo to Active (cross-over)"
89427675|NCT01314222|Other|Arm 2: BMS-954561 150mg or 300mg|"BMS-954561 150mg or 300mg TID to Placebo OR Placebo to 150mg or 300mg TID~Active to Placebo or Placebo to Active (cross-over)"
89427676|NCT01314222|Other|Arm 3: Pregabalin 100mg|"Pregabalin 100mg TID to Placebo OR Placebo to 100mg TID~Active to Placebo or Placebo to Active (cross-over)"
89427677|NCT01309932|Experimental|A1: pegIFNλ+BMS-790052+Placebo for BMS-650032+Ribavirin|Part A
89427678|NCT01309932|Experimental|A2: pegIFNλ+BMS-650032+Placebo for BMS-790052+Ribavirin|Part A
89427679|NCT01309932|Active Comparator|A3: pegIFNα-2a+PBO for BMS-790052+PBO for BMS-650032+RBV|Part A
89427680|NCT01309932|Experimental|A4: pegIFNλ+BMS-790052+BMS-650032+Ribavirin (24 weeks)|Part B
89427681|NCT01309932|Experimental|A5: pegIFNλ+BMS-790052+BMS-650032+Ribavirin (16 weeks)|Part B
88908679|NCT05928637|Experimental|Sequence 4|"Period 1: multiple oral dose of 1 tablet of D745, 1 tablet of D759, and 2 tablets of D150.~Period 2: multiple oral dose of 1 tablet of D759 and 2 tablets of D150.~Period 3: oral dose of D745 1 tablet."
88908680|NCT05928637|Experimental|Sequence 5|"Period 1: multiple oral dose of 1 tablet of D745, 1 tablet of D759, and 2 tablets of D150.~Period 2: oral dose of D745 1 tablet.~Period 3: multiple oral dose of 1 tablet of D759 and 2 tablets of D150."
88908681|NCT05928637|Experimental|Sequence 6|"Period 1: multiple oral dose of 1 tablet of D745, 1 tablet of D759, and 2 tablets of D150.~Period 2: multiple oral dose of 1 tablet of D759 and 2 tablets of D150.~Period 3: oral dose of D745 1 tablet."
88908682|NCT05928130|Experimental|Volume Training Group|Participants in this group will undergo a plyometric training protocol at a known effective volume that is expected to induce changes in lower limb strength, power, and muscle activity.
88908683|NCT05928130|Experimental|Reduced Volume Training Group|Participants in this group will undergo a plyometric training protocol at a lower volume than the Volume Training Group, aiming to determine if a lower volume still leads to significant improvements in lower limb strength, power, and muscle activity.
88908684|NCT05928130|No Intervention|Control Group|Participants in this group will not undergo any plyometric training and will serve as a comparison to assess the natural progression of lower limb strength, power, and muscle activity without intervention.
88908685|NCT05927532|Experimental|Argyle Fistula Cannula Subjects|All subjects enrolled in the study and treated with the Argyle Safety Fistula Cannula with Anti-reflux Valve
88908686|NCT05925972|Active Comparator|Grup ESP|The group to which erector spina plane block will be applied
88908687|NCT05925972|Active Comparator|Grup OSTAP|The group to which oblique subcostal transversus abdominis plane block will be applied
89427682|NCT01309932|Experimental|A6: pegIFNλ+BMS-790052+BMS-650032+Placebo for RBV (24 weeks)|Part B
89427683|NCT01309932|Experimental|A7: pegIFNλ+BMS-790052+BMS-650032+Placebo for RBV (16 weeks)|Part B
89427684|NCT01846286||Newly Diagnosed HNC|For AIM 2 and AIM3, Newly diagnosed and previously untreated patients with locoregional squamous cell carcinoma of the head and neck recruited at MD Anderson: Pain assessed at baseline, weekly during treatment, and during clinic visits (every 6-8 weeks) for a period of 3 months after treatment. Quantitative sensory testing performed at baseline and at 3 months from completion of treatment to determine nociceptive versus neuropathic component.
89427685|NCT01733888|Active Comparator|Office Bleaching|Fluorosed teeth will be bleached using 35 % Hydrogen Peroxide (Pola Office, SDI, Australia) according to manufactures´ instruction.
89427686|NCT01733888|Experimental|Resin Infiltration|"White spots in fluorosed teeth will be infiltrated using the resin infiltrant Icon (DMG, Hamburg, Germany) according to manufactures´ instructions."
88908688|NCT05925504|Experimental|Luspatercept|open-label, single-arm
88908689|NCT05924789||Cohort A|120 patients with histological diagnosis of gastric and gastroesophageal junction cancer.
88908690|NCT05924789||Cohort B|80 patients histological diagnosis of pancreatic cancer.
88908691|NCT05924152|Active Comparator|Treatment A|Treatment A: A single oral dose of adagrasib 400 mg (2 × 200-mg tablets) on Day 1;
88908692|NCT05924152|Active Comparator|Treatment B|"Treatment B: A single oral dose of eltrombopag 75 mg~(1 × 75-mg tablet) plus adagrasib 400 mg (2 × 200-mg tablets) on Day 8."
88908693|NCT05923359|Experimental|Apple Watch Intervention Group|Participants will be asked to wear an Apple Watch and use the Mayo Clinic ECG Study App to collect and share data with the study team.
88908694|NCT05923359|No Intervention|Control Group|Participants will receive usual care.
88908695|NCT05922930|Experimental|TROP2-CAR-NK|"Participants will receive 1 dose of TROP2-CAR-NK and will visit the study clinic up to 16 times to have tests and procedures (such as blood draws, biopsies, and CT scans).~Participants will receive lymphodepleting chemotherapy (cyclophosphamide and fludarabine) for 3 days in a row. Participants will receive cyclophosphamide and fludarabine by vein over about 3 hours total."
89197017|NCT02547597|Active Comparator|Atenolol|Atenolol 50 mg twice a day
89197018|NCT00844389|Active Comparator|NIR light|Group of patients stimulated with near to infrared light daily stimulation
89197019|NCT00844389|Placebo Comparator|Green light|Group of patients stimulated with green light.
89197020|NCT02567474|No Intervention|control|no intervention
89197021|NCT02567474|Experimental|intervention|self management intervention based on 5A model
88908696|NCT05920096|Experimental|Intervention|A diabetes specialist nurse-led multi-component smoking cessation intervention tailored for individuals with diabetes based on evidence and theory and guided by the 5A's and 5R's framework for smoking cessation The intervention consists of three to four (30-60 minutes) smoking cessation support sessions which are to be delivered by the two diabetes specialist nurses at the Diabetes Education Unit during the study period (12 weeks). As part of the first session, participants will also be shown three very brief video clips in which a person living with diabetes explains the serious health problems he suffered from (when smoking and having diabetes). Participants will also receive a six-week supply of Nicotine Replacement Therapy (NRT) - nicotine patch and/or nicotine spray.
88908697|NCT05920096|Active Comparator|Control|Active referral to the Health Promotion and Disease Prevention Directorate's one-to-one general stop-smoking service. This counseling service is provided every fortnight within Mosta, Floriana, or Paola health centres. The number of counseling sessions (lasting around 20 minutes each) provided during the study period (12 weeks) will be based on the client's needs.
88908698|NCT05917470|Experimental|Dose Level 1: 40mg|40mg of single agent ONCT-534 to be administered daily in oral tablets
88908699|NCT05917470|Experimental|Dose Level 2: 80mg|80mg of single agent ONCT-534 to be administered daily in oral tablets
88908700|NCT05917470|Experimental|Dose Level 3: 160mg|160mg of single agent ONCT-534 to be administered daily in oral tablets
88908701|NCT05917470|Experimental|Dose Level 4: 300mg|300mg of single agent ONCT-534 to be administered daily in oral tablets
88908702|NCT05917470|Experimental|Dose Level 5: 600mg|600mg of single agent ONCT-534 to be administered daily in oral tablets
88908703|NCT05917470|Experimental|Dose Level #1|Recommended Phase 2 dose level #1 of single agent ONCT-534 to be administered daily in oral tablets
88908704|NCT05917470|Experimental|Dose Level #2|Recommended Phase 2 dose level #2 of single agent ONCT-534 to be administered daily in oral tablets
88908705|NCT05917327|Experimental|MEX-CD1 Low volume CVVHD|"Patients enrolled in the treatment arm will receive MEX-CD1 treatment depending on the severity of their symptoms in addition to standard of care:~Patients with moderate liver injury not requiring extracorporeal blood epuration therapies as standard of care: 5 treatments with MEX-CD1 on consecutive days~Patients requiring extracorporeal blood epuration therapies as standard of care: 10 treatments with MEX-CD1 on consecutive days"
88908706|NCT05916833|Experimental|hypopressive breathing technique|"These exercises involved sucking in the abdomen and opening the ribs by engaging the accessory inspiratory muscles, such as the serratus anterior, external intercostalis, scalenes, and sternocleidomastoid, while maintaining the glottis closed, a process known as diaphragmatic suction."
88908707|NCT05916833|Experimental|noble technique|The Noble technique is (partially sitting up while manually flexing the rectus Abdominis muscles.
88908708|NCT05913401|Experimental|Aerobic Exercise|Exercise sessions will be 20 minutes of moderate-intensity aerobic exercise on a treadmill. A treadmill is located on D1A within the space shared by the Butler Hospital TMS Clinic and the COBRE-support Neuromodulation Research Facility. A research staff member will monitor their heart rate and blood pressure to ensure safety and that activity is occurring at a moderate intensity (i.e., 64-76% of age predicted maximal heart rate). Participants will be asked to rate their affect and rating of perceived exertion (RPE) during exercise sessions. Sessions will include a 5-min warm-up and a 5-min cool-down to ensure safe exercise procedures. Participants will be asked to answer questions about affect before, during, and after exercise. These sessions will be supervised (i.e., they provide onsite coverage) by an exercise physiologist or medical staff member (e.g., nurse or physician) to ensure safety.
88908709|NCT05913401|Other|Video Condition|In this condition, participants will be asked to sit and watch various documentaries or educational videos on topics NOT related to physical activity. These will last approximately 20 minutes and will occur before each TMS session.
88908710|NCT05912166|Experimental|Wakeful Spanish|Wakeful Spanish is the Spanish-language version of Wakeful, developed at Northwestern University. It is a self-directed 9-week digital mindfulness course closely aligned with traditional 8-week Mindfulness-based Stress Reduction (MBSR) programs.
88908711|NCT05910554|Active Comparator|Active|Patients randomized to metformin will be assigned the active arm.
88908712|NCT05910554|Placebo Comparator|Placebo|Patients randomized to cellulose will be assigned the placebo arm.
88908713|NCT05902806|Experimental|Comparison of current tube feed to intervention feed with upgraded composition|Subjects will use their own current practice tube feed for 1 week (baseline period) and will switch to the intervention tube feed with an upgraded composition with a comparable energy density and fiber content as their current tube for 2 weeks (intervention period). Since four different products will be evaluated (product A-D), there will be 4 study groups
89427687|NCT01733888|Experimental|Resin Infiltration twice|"White spots in fluorosed teeth will be infiltrated using the resin infiltrant Icon (DMG, Hamburg, Germany) according to manufactures´ instructions. Here, the infiltrant Icon is applied twice."
89427688|NCT01733888|Experimental|Office Bleaching + Resin Infiltration|Fluorosed teeth will be bleached using 35 % Hydrogen Peroxide (Pola Office, SDI, Australia). After a 20 day wash over period, these teeth will be treated with the resin infiltration intervention (Icon, DMG, Hamburg, Germany).
89427689|NCT01181622|Experimental|denufosol tetrasodium Inhalation Solution|
89427690|NCT01181622|Placebo Comparator|Placebo|
89427691|NCT01101594|Experimental|hLL1-DOX|4 Different dose levels of hLL1-DOX will be studied in groups of 3-6 patients. Once an optimal dose has been found, up to additional 30 patients will be studied at that dose level.
89427692|NCT01304862|Experimental|Self-management intervention|
89427693|NCT01304862|Active Comparator|Educational Videos about Healthy Living|
89427694|NCT05386628|Active Comparator|control group|Conventional physiotherapy program (joint movement exercises, local relaxation techniques, etc.) will be applied to the participants in this group.
89008147|NCT04602832|Experimental|ENHANCE Treatment Group|The ENHANCE program was tailored to address the current health and well-being challenges faced by individuals living in the COVID-19 pandemic. The contents of each week will focus on a new evidenced-based principle that has been shown in research to decrease negative thinking and emotions, as well as increase positive thinking, emotions, and overall physical and mental health and well-being. Each week participants will focus on the skills and methods of implementing happiness and well-being into their daily routine.
89008148|NCT04602832|No Intervention|Wait-List Control Group|Over the course of the study, participants will be asked to refrain from accessing the ENHANCE program materials to ensure the integrity of the research design. At the end of the study duration, participants will receive the full ENHANCE program.
89008149|NCT05285501|Experimental|Virtual Therapeutic Garden|"Twice a week, for a 4 consecutive weeks:~8 sessions of general fitness training (40 minutes each) 8 sessions of VRTierOne therapy (20 minutes each)"
89008150|NCT05285501|Active Comparator|Control|"Twice a week, for a 4 consecutive weeks:~8 sessions of general fitness training (40 minutes each) 8 sessions of group relaxation and psychoeducation (20 minutes each)"
89008151|NCT04602910|Experimental|the phases of planning and acting|Each part of the website page was assessed for comprehensibility and usability by patients. Health care providers were asked to assess the acceptability of the website. A 5-point Likert scale was used for patient and health care provider ratings for each item. If the score were less than 3, then we would modify the website content based on the user feedback from patients and health care providers
89008152|NCT00248976|No Intervention|1|This is the control group, which will be monitor. No intervention will be delivered to this group.
89008153|NCT00248976|Experimental|2|This group received the experimental intervention. This is an intervention based on feedback of individualized risk profiles framed as the opportunity to reduce one's biologic age. Net-present value of individual health behaviors in years.
89008154|NCT04602715|Experimental|MET-2 20 g|Loading dose of MET-2 is administered for the first two days, followed by a regular, daily dose for the duration of the study (6 weeks total).The loading dose will consist of 5 g of MET-2 in the form of ten capsules orally on day one and on day two. The regular daily dose will consist of 1.5 g MET-2 in the form of three MET-2 capsules taken once daily, excluding days where they take the booster (same as loading dose).
89427695|NCT05386628|Experimental|Manual lymphatic drainage group|In addition to the conventional physiotherapy program, manual lymphatic drainage (including upper limb extremity and anterior/posterior axillar-axillar anastomoses and axilla-inguinal anastomosis) will be applied to the participants in this group.
89008155|NCT04602715|Placebo Comparator|Placebo|Loading dose of placebo is administered for the first two days, followed by a regular, daily dose of placebo for the duration of the study (6 weeks total).The loading dose will consist of ten capsules of placebo (which match the MET-2 capsules in appearance and weight) taken orally on day one and on day two. The regular daily dose will consist of three placebo capsules taken once daily, excluding days where they take the booster (same as loading dose).
89008156|NCT04602403|Placebo Comparator|placebo group|people who given placebo to become agroup of comparison with the other group
89008157|NCT04602403|Active Comparator|tamsulosin group|people who given tamsulosin to know the effect on ureteroscopy and compare with the control group
89008158|NCT00565240|Experimental|Oral Contraceptive|
89008159|NCT00565240|Experimental|Contraceptive Ring|
89008160|NCT00565240|Experimental|Aromatase Inhibitors|
89008161|NCT00565240|No Intervention|Control|
89427696|NCT05386628|Experimental|Myofascial relasing group|In addition to the conventional physiotherapy program, myofascial chain relasing techniques will be applied to the participants in this group.
89427697|NCT05386628|Experimental|Lymphatic drainage and myofascial releasing group|In addition to the conventional physiotherapy program, manual lymphatic drainage (including upper limb extremity and anterior/posterior axillar-axillar anastomoses and axilla-inguinal anastomosis) and myofascial chain relasing techniques will be applied to the participants in this group.
89427698|NCT04475172|Experimental|Fusio™ Flowable Self-Adhesive Flowable Composite|"2-Cavity preparation steps:~patients will be given local anesthesia as required,the operative field will be isolated with rubber dam before starting.~Conventional design Class V cavity will be prepared on the buccal surface of tooth by No. #330 bur (0.8 mm in diameter and 1.6 mm in length) , tooth surfaces will be kept moist to protect them against dehydration.~2% chlorhexidine gluconate disinfecting solution .~wash the dentin surface with water spray and air dry with maximum air pressure for 5 s.~A) Intervention: Fusio™ Flowable (Self adhesive flowable composite):~Simply syringe into the preparation 1 mm increments, agitate with tip or brush for 20 s, and light-cure.No need for an etchant or an adhesive."
89427699|NCT04475172|Active Comparator|Conventional flowable composite [Tetric Evo Flow (FF)].|"Tetric Evo Flow (Conventional flowable composite):~After cleaning cavities, apply conditioning material (phosphoric acid etching 37% ) and apply bonding agent (ExciTE® F) according to the instructions for use of the product.~Apply Tetric EvoFlow in layers of 1mm. Polymerize each layer separately following the instructions for use of this product. . Hold the light emission window as closely as possible to the surface of the restorative material.~All 20 Class V restorations will be prepared, restored, finished, and polished by one operator. Each of the 10 patients had one (FL) restoration and the other restoration will be filled with (FF)."
89427700|NCT05385770|Active Comparator|AZM Xmg|1. AZM Xmg (4 weeks) Non-responder -> AZM Xmg (8 weeks)
89427701|NCT05385770|Active Comparator|AZM X'mg|1. AZM X'mg (4 weeks) Non-responder -> AZM X'mg (8 weeks)
89008162|NCT00565279|Experimental|ASF1057|
89427702|NCT05385770|Active Comparator|AML Ymg|1. AML Ymg (4 weeks) Non-responder -> AML Ymg (8 weeks)
89427703|NCT05385770|Active Comparator|AML Y'mg|1. AML Y'mg (4 weeks) Non-responder -> AML Y'mg (8 weeks)
89427704|NCT05385770|Active Comparator|AZM/AML X/Ymg|"AZM Xmg (4 weeks) Non-responder -> AZM Xmg + AML Ymg (8 weeks)~AML Ymg (4 weeks) Non-responder -> AZM Xmg + AML Ymg (8 weeks)"
89427705|NCT05385770|Active Comparator|AZM/AML X'/Ymg|"AZM X'mg (4 weeks) Non-responder -> AZM X'mg + AML Ymg (8 weeks)~AML Ymg (4 weeks) Non-responder -> AZM X'mg + AML Ymg (8 weeks)"
89427706|NCT05385770|Active Comparator|AZM/AML X/Y'mg|"AZM Xmg (4 weeks) Non-responder -> AZM Xmg + AML Y'mg (8 weeks)~AML Y'mg (4 weeks) Non-responder -> AZM Xmg + AML Y'mg (8 weeks)"
89427707|NCT05385770|Active Comparator|AZM/AML X'/Y'mg|"AZM X'mg (4 weeks) Non-responder -> AZM X'mg + AML Y'mg (8 weeks)~AML Y'mg (4 weeks) Non-responder -> AZM X'mg + AML Y'mg (8 weeks)"
88908716|NCT05901831|Experimental|Finerenone arm|Participants with eGFR ≥25 to <60 mL/min/1.73 m^2 at Screening visit will take Finerenone Dose A. Participants with eGFR ≥60 mL/min/1.73 m^2 at Screening visit will take Dose B. Up-titration and down-titration of study intervention will be based on local potassium and kidney function (eGFR) values. Treatment duration is 6 months.
88908717|NCT05901831|Placebo Comparator|Placebo arm|Participants will take Finerenone matching placebo for 6 months.
88908718|NCT05900895|Experimental|Treatment Arm|Participants receive 2 cycles of olaparib in combination with 17b-estradiol and then continue to be treated with single-agent 17b-estradiol until disease progression.
88908719|NCT05899049|Experimental|Pembrolizumab + Belzutifan + Lenvatinib|Participants will receive pembrolizumab 400 mg PLUS belzutifan 120 mg PLUS lenvatinib 20 mg. Pembrolizumab will be administered intravenously (IV) once every 6 weeks (Q6W) for up to 18 administrations (up to ~2 years). Belzutifan and lenvatinib will be administered orally once daily (QD) until progressive disease or discontinuation.
88908720|NCT05899049|Experimental|Pembrolizumab/Quavonlimab + Lenvatinib|Participants will receive pembrolizumab/quavonlimab (co-formulation of pembrolizumab 400 mg and quavonlimab 25 mg) PLUS lenvatinib 20 mg. Pembrolizumab/quavonlimab will be administered IV Q6W for up to 18 administrations (up to ~2 years). Lenvatinib will be administered orally QD until progressive disease or discontinuation.
88908721|NCT05899049|Active Comparator|Pembrolizumab + Lenvatinib|Participants will receive pembrolizumab 400 mg PLUS lenvatinib 20 mg. Pembrolizumab will be administered IV Q6W for up to 18 administrations (up to ~2 years). Lenvatinib will be administered orally QD until progressive disease or discontinuation.
88908722|NCT05898620|Experimental|Low Dose|Dose Level 1
88908723|NCT05898620|Experimental|High Dose|Dose Level 2
89536861|NCT02469311|Sham Comparator|Revision Control THA|Patients undergoing a second or revision total hip arthroplasty will be randomized to the intervention of Standard of care bathing with antibacterial soap and water.
88908725|NCT05896709|Experimental|MK-RS|Patients' embryos will be selected by MK-RS integrative analytical method.
88908726|NCT05896709|No Intervention|Conventional|Patients' embryos will be selected by conventional method (i.e by embryologists).
88908727|NCT05893862|Experimental|Sequence 1: MK-8189 (Treatment A)→Moxifloxacin (Treatment B)→Placebo (Treatment C)|Participants receive a sequence of Treatment A in Period 1 followed by Treatment B in Period 2 followed by Treatment C in Period 3; there will be a 5-day washout between periods. Treatment A consists of MK-8189 administered orally at 48 mg on Day 1 and 80 mg on day 2. Treatment B consists of placebo administered orally on Day 1 and moxifloxacin administered orally at 400 mg on Day 2. Treatment C consists of placebo administered orally on Day 1 and Day 2.
88908728|NCT05893862|Experimental|Sequence 2: Moxifloxacin (Treatment B) →Placebo (Treatment C) →MK-8189 (Treatment A)|Participants receive a sequence of Treatment B in Period 1 followed by Treatment C in Period 2 followed by Treatment A in Period 3; there will be a 5-day washout between periods. Treatment B consists of placebo administered orally on Day 1 and moxifloxacin administered orally at 400 mg on Day 2. Treatment C consists of placebo administered orally on Day 1 and Day 2. Treatment A consists of MK-8189 administered orally at 48 mg on Day 1 and 80 mg on Day 2.
88908729|NCT05893862|Experimental|Sequence 3: Placebo (Treatment C) →MK-8189 (Treatment A) →Moxifloxacin (Treatment B)|Participants receive a sequence of Treatment C in Period 1 followed by Treatment A in in Period 2 followed by Treatment B in Period 3; there will be a 5-day washout between periods. Treatment C consists of placebo administered orally on Day 1 and Day 2. Treatment A consists of MK-8189 administered orally at 48 mg on Day 1 and 80 mg on Day 2. Treatment B consists of placebo administered orally on Day 1 and moxifloxacin administered orally at 400 mg on Day 2.
88908730|NCT05893862|Experimental|Sequence 4: Moxifloxacin (Treatment B) → MK-8189 (Treatment A) → Placebo (Treatment C)|Participants receive a sequence of Treatment B in Period 1 followed by Treatment A in Period 2 followed by Treatment C in Period 3; there will be a 5-day washout between periods. Treatment B consists of placebo administered orally on Day 1 and moxifloxacin administered orally at 400 mg on Day 2. Treatment A consists of MK-8189 administered orally at 48 mg on Day 1 and 80 mg on Day 2. Treatment C consists of placebo administered orally on Day 1 and Day 2.
88908731|NCT05893862|Experimental|Sequence 5: MK-8189 (Treatment A) →Placebo (Treatment C) →Moxifloxacin (Treatment B)|Participants receive a sequence of Treatment A in Period 1 followed by Treatment C in Period 2 followed by Treatment B in Period 3; there will be a 5-day washout between periods. Treatment A consists of MK-8189 administered orally at 48 mg on Day 1 and 80 mg on Day 2. Treatment C consists of placebo administered orally on Day 1 and Day 2. Treatment B consists of placebo administered orally on Day 1 and moxifloxacin administered orally at 400 mg on Day 2.
88908732|NCT05893862|Experimental|Sequence 6: Placebo (Treatment C) →Moxifloxacin (Treatment B) → MK-8189 (Treatment A)|Participants receive a sequence of Treatment C in Period 1 followed by Treatment B in Period 2 followed by Treatment A in Period 3; there will be a 5-day washout between periods. Treatment C consists of placebo administered orally on Day 1 and Day 2. Treatment B consists of placebo administered orally on Day 1 and moxifloxacin administered orally at 400 mg on Day 2. Treatment A consists of MK-8189 administered orally at 48 mg on Day 1 and 80 mg on Day 2.
88908733|NCT05893537|Active Comparator|CT1812 200 mg|Drug: CT1812 Active Study Drug
88908734|NCT05893537|Placebo Comparator|Placebo|Placebo
88908735|NCT05889624|Experimental|CBT while taking a clinically-prescribed, pill-based prevention therapy (amitriptyline)|This intervention consists of Cognitive Behavioral (CBT), a mind and body based intervention using education on gate control theory of pain, behavioral strategies such as muscle relaxation, activity pacing, and cognitive strategies including distraction, problem solving, and using calming self-statements. This arm will also take a daily oral dose of Amitriptyline, which will be clinically prescribed and managed by the patient's headache provider.
89427708|NCT02269020|Experimental|3 patients cancer of the epi larynx|"3 patients with squamous cell carcinoma of the epi-larynx~Intervention: Neck Dissection"
89427709|NCT05385380|Experimental|Safe motherhood Promotion(Educational, Counselling & Training) and maternity waiting homes upgrading|"Improving the quality of maternal health services in health centers (training for midwives in basic emergency obstetric care and upgrading maternity waiting homes to the level to provide basic accommodation to address access-related barriers~Training community health workers with the aim of improving their knowledge about safe motherhood and about how to prepare a birth plan, including stays in maternity waiting homes~Training pregnant women"
89427710|NCT05385380|No Intervention|Comparison|The current standard service package
89008163|NCT00565279|Placebo Comparator|ASF1057 placebo|
89427711|NCT02264418|Experimental|ODM 203|Oral capsules given once daily dosage 50-800mg
89427712|NCT02264418|Experimental|ODM-203|Oral tablets given once daily 200-1600mg
89427713|NCT04474548|Experimental|Ultrasound|"For participants randomly assigned to ultrasound use, a bedside ultrasound will be performed using the trans-abdominal probe during and/or immediately after placement of the IUD. The distance from the IUD arms to the fundus will be measured with the ultrasound, and the IUD will be defined as being in place when the distance from the top of the IUD to the fundus is measured to be 3mm or less. If the distance is greater than 4mm, the provider may reposition the IUD manually or with a ring forceps."
89427714|NCT04474548|No Intervention|No ultrasound|For participants randomly assigned to no ultrasound use, provider will insert the IUD with a ring forceps and will use palpation of the fundus to determine whether or not the IUD is likely in place.
89427715|NCT04474626|Experimental|ISOQUERCETIN|"The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits~- ISOQUERCETIN: Oral Study Drug, 1 time per day, per predetermined dosed per 28 treatment cycle.~This will continue for up to 337 days."
89427716|NCT01094496|Experimental|CDX-1307 Vaccine Regimen|Chemotherapy with CDX-1307 vaccine regimen (neoadjuvant phase), followed by bladder removal surgery (cystectomy). CDX-1307 vaccine regimen will continue to be given for up-to 1 year post-surgery (adjuvant/long-term follow-up phase).
89427717|NCT02736188|Experimental|Drug: Aceneuramic Acid Extended-Release Tablets|Participants will take 4 tablets (500 mg Ace-ER each for 2 g per dose) orally 3 times per day (TID).
89427718|NCT02269176|Experimental|Telmisartan|Low dose of telmisartan, uptitrated to high dose in case no sufficient effect is observered
89427719|NCT02269176|Active Comparator|Losartan|Low dose of losartan, uptitrated to high dose in case no sufficient effect is observered
89427720|NCT02269254|Experimental|Persona PS|Total Knee Replacement with Persona PS Knee Prosthesis by Zimmer
89427721|NCT02269254|Active Comparator|NexGen PS|Total Knee Replacement with NexGen PS Knee Prosthesis by Zimmer
89427722|NCT03135288|Experimental|Cell-phone assisted|will be advised that they are going to receive a reminder of their postpartum family planning visit 5 weeks after the delivery (one week before the scheduled visit) and a phone call 48 hours before the scheduled visit. They will also receive two follow-up phone calls to answer any questions and to remind them with the follow-up visits after insertion. Woman will be given a referral card to the outpatients' family planning clinic denoting her study group and serial number and with a specific date for postpartum family planning visits. They will be also provided with a cell phone number working 7 days a week to answer any query or questions regarding her family planning program.
89427723|NCT03135288|No Intervention|control group|will receive the same above adequate counseling with referral card but without any phone assistance
89427724|NCT02266992|Experimental|Fluenz Tetra|Live attenuated influenza vaccine- Fluenz tetra. Intra-nasal administration of 0.2ml (0.1ml in each nostril).
89427725|NCT02522546||nasopharyngeal swab|Children ages 1-5 years and their household contacts
89427726|NCT01094262|Experimental|JNJ-42160443 (lower dose)|
89427727|NCT01094262|Experimental|JNJ-42160443 (higher dose)|
89427728|NCT01094262|Active Comparator|Oxycodone CR (standard pain medication)|
89427729|NCT01094262|Placebo Comparator|Placebo|
89427730|NCT03441542|Experimental|Data-assisted Case Navigation|Patients are recruited and consented into the study by the patient navigator after which the navigator provides assistance with scheduling, reminders, and transportation. The navigator is also charged with responding to patient questions, and monitoring and documenting if and when patients achieve HCV care milestones. Each month, the project will update the Grady Liver Clinic HCV patient registry, to generate information about the patient's HCV care progress and use this information to develop instructions sheets regarding the expected care milestones to be achieved that month for each patient. During the month, the navigator will participate in project meetings and report on milestone achievement and barriers for patients assigned to the experimental arm of the study.
89008164|NCT00565279|Placebo Comparator|ASF1057 Vehicle|
89008165|NCT04602637||P1|
89008166|NCT04602637||P2|
89008167|NCT04602637||P3|
89427731|NCT03441542|Active Comparator|Standard of Care|Patients are recruited and consented into the study by the patient navigator at which time they will be reminded of their infection, consequences of untreated disease, and the availability of study sponsored antiviral treatment should they seek it. Patients will not be subsequently contacted by the study. Patients who seek treatment without patient navigation services will receive the same study provided HCV pre-treatment care and study provided treatment drugs when indicated. Self-referral to care and antiviral therapy when indicated are known to be effective in curing HCV among some patients, this arm is classified as an active comparator.
88908736|NCT05889624|Experimental|CBT alone|This intervention arm consists of 6 Cognitive Behavioral Therapy (CBT), a mind and body based intervention using education on gate control theory of pain, behavioral strategies such as muscle relaxation, activity pacing, and cognitive strategies including distraction, problem solving, and using calming self-statements.
89427732|NCT02267070|Experimental|Cognitive Training and Exercise|24 weeks of systematic computerized cognitive training, 4 hours per week, plus aerobic exercise, four 30 minute sessions per week. The first 12 weeks involves neurocognitive training, using auditory training exercises from Posit Science Brain HQ. The 2nd 12 weeks involves social cognitive training, using the Posit Science SocialVille modules. Aerobic exercise occurs as two 30-minute sessions at the clinic and two at home weekly. Intensity of aerobic exercise is tailored to maintain an individualized target heart rate zone and is monitored by a heart rate recorder. A weekly one-hour Bridging Skills Group is designed to aid generalization of training to everyday life situations. All members receive individual case management and supportive psychotherapy, and family psychoeducation.
88908737|NCT05889117|Experimental|Waitlist-control-treatment-group|After a 2-week control waitlist period, patient receive 30 treatments.
89427733|NCT02267070|Active Comparator|Cognitive Training|24 weeks of systematic computerized cognitive training, 4 hours per week, plus aerobic exercise, four 30 minute sessions per week. The first 12 weeks involves neurocognitive training, using auditory training exercises from Posit Science Brain HQ. The 2nd 12 weeks involves social cognitive training, using the Posit Science SocialVille modules. A weekly one-hour Bridging Skills Group is designed to aid generalization of training to everyday life situations. All members receive individual case management and supportive psychotherapy, and family psychoeducation.
89427734|NCT05626842|Experimental|Single-arm|Single-arm real-world evaluation with a matched control group from comparable GP practices
89427735|NCT04632134|Experimental|Transcutaneous vagal nerve stimulation (tVNS)|"After positioning the tVNS electrodes in the right ear but without delivering tVNS (Sham tVNS), above mentioned signals will be recorded for 10 minutes while supine, for 15 minutes during 75° head-up tilt.~The same protocol will be performed during active tVNS.~The tVNS will be performed while 15 minutes in supine position and during 75°head-up Tilt.~Thereafter, every patient will be provided with a Nemos© device and electrodes for home daily stimulation. Daily stimulation will consist of 4 hours of stimulation organized as 4 sessions each lasting 1 hour, to be applied at the patient's convenience."
89427736|NCT04476186|Active Comparator|treatment group|200 mg of oral acyclovir 5 timed per day for 5 days per week for maximum 1 month
89427737|NCT04476186|Placebo Comparator|controlled group|KOH 10 % solution local application with apiece of cotton 2 time per day maximum for 1 month
89427738|NCT03440216|Experimental|Sampling if GFR = or > 30 mL/min|"Note: GFR = Glomerular Filtration Rate~Patients with a normal of moderately decreased renal function~Temocillin: 6 g in continuous infusion over 24 h;~Ceftriaxone: bolus 2 g (in 30 min) every 12h~Meropenem: prolonged infusion (3 h) of 2 g every 8h~Blood sampling for antibiotic (temocillin, ceftriaxone or meropenem) pharmacokinetic analysis / Tissue sampling (lung) for determination of antibiotic content when possible / Collection of fluid samples (bronchoalveolar lavage, drainage fluid) for determination of antibiotic concentration when possible"
89427739|NCT03440216|Experimental|Sampling if GFR < 30 mL/min|"Patients with severe renal insufficiency or hemodialysis:~Temocillin: 6 g in continuous infusion over 24 h;~Ceftriaxone: bolus 2 g (in 30 min) every 12h~Meropenem: prolonged infusion (3 h) of 2 g every 8h~Blood sampling for antibiotic (temocillin, ceftriaxone or meropenem) pharmacokinetic analysis / Tissue sampling (lung) for determination of antibiotic content if possible / Collection of fluid samples (bronchoalveolar lavage, drainage fluid) for determination of antibiotic concentration if possible"
89427740|NCT01166412|Active Comparator|Dose level AG1000-6.5|
89427741|NCT01166412|Active Comparator|Dose level AG1000-12.5|
89427742|NCT04475796|Active Comparator|Early group|
89427743|NCT04475796|Active Comparator|Delayed group|
89427744|NCT05370716|Experimental|Group A|Pregabalin + Polmacoxib
89427745|NCT05370716|Active Comparator|Group B|Polmacoxib
89427746|NCT05370716|Active Comparator|Group C|Pregabalin
89427747|NCT05626764||Immune checkpoint inhibitors|Any immunotherapy by immune checkpoint inhibitor molecule in combination or monotherapy, associated or no with any other cancer treatment such as chemotherapy, targeted therapy, radiotherapy, etc.
89427748|NCT05626764||CAR-T cells|Transplantation of recombined autologous immune T-cells
89427749|NCT03382496||Lung Cancer patients in France|Lung Cancer patients treated by nivolumab in real life condition in France from October 2016 to October 2017
89427750|NCT05158244|Experimental|PF-07081532|multiple dosing, once-daily for 42 days
89427751|NCT05158244|Placebo Comparator|Placebo|multiple dosing, once-daily for 42 days
89427752|NCT02269410|Active Comparator|GBP-SPS|GBP Standard PRO-S (0.8g protein/kg ideal body weigh/day)
88908738|NCT05886894||Air Optix plus HydraGlyde Multifocal Daily Wear|Lotrafilcon B multifocal soft contact lenses with comfort additive worn in both eyes and removed daily for cleaning and disinfection
88908739|NCT05886894||Air Optix plus HydraGlyde Multifocal Extended Wear|Lotrafilcon B multifocal soft contact lenses with comfort additive worn in both eyes worn on an extended wear basis. Extended wear is defined as up to 6 days continuous wear (including while sleeping/overnight).
88908740|NCT05886894||Biofinity Multifocal Daily Wear|Comfilcon A multifocal soft contact lenses worn in both eyes and removed daily for cleaning and disinfection
88908741|NCT05886894||Biofinity Multifocal Extended Wear|Comfilcon A multifocal soft contact lenses worn in both eyes worn on an extended wear basis. Extended wear is defined as up to 6 days continuous wear (including while sleeping/overnight).
88908742|NCT05886881||Air Optix Aqua Sphere|Lotrafilcon B spherical soft contact lenses worn in both eyes on an extended wear basis. Extended wear is defined as up to 6 days continuous wear (including while sleeping/overnight).
89427753|NCT02269410|Experimental|GBP-HPS|GBP High PRO-S (1.2g protein/ kg ideal body weight/ day)
89427754|NCT02269410|Active Comparator|VSG-SPS|VSG Standard PRO-S (0.8g protein/kg ideal body weigh/ day)
89427755|NCT02269410|Experimental|VSG-HPS|VSG High PRO-S (1.2g protein/ kg ideal body weight/ day)
89427756|NCT05156918|Experimental|Exercise Group|Exercise group participants will perform supervised high intensity exercise three times per week at the LLU department of physical therapy laboratory utilizing treadmills, stationary bicycles, and rowing machines.
89427757|NCT05156918|Active Comparator|Control Group|Control group participants will make no modifications to regular diet or exercise habits for 30 days.
89427758|NCT01038804|Experimental|A. YM155 plus docetaxel|
89427759|NCT01038804|Active Comparator|B. docetaxel alone|
89427760|NCT03465566||Children with BECTS|"Children with active BECTS according to state-of-the-art diagnostic criteria of ILAE (International League Against Epilepsy). Eligible subjects will be recruited at their first clinical observation in the epilepsy centers involved in the study.~All subjects will perform five diagnostic evaluations named:~IDS (Intelligence and Development Scale) MMSPE (Mini Mental State Pediatric Examination) CDI 2 (Children Depression Inventory 2) CBCL (Child Behavior Check List) Tests of facial expression evaluation"
89427761|NCT03465566||Healthy children|"Healthy controls matched for sex, age range, and education with no family history for epilepsy or other neuropsychiatric disorders.~All subjects will perform the following tests:~MMSPE (Mini Mental State Pediatric Examination) CDI 2 (Children Depression Inventory 2) CBCL (Child Behavior Check List) Tests of facial expression evaluation"
89427762|NCT05118776|Experimental|ASC40|ASC40 tablets 100mg/m^2 and bevacizumab 10mg/kg.
89427763|NCT05118776|Placebo Comparator|Placebo|Placebo and bevacizumab 10mg/kg.
89427764|NCT02269566|Active Comparator|Allergen extract|0.1 ml of allergen extracts
89427765|NCT02269566|Placebo Comparator|Placebo|Normal saline, 0.1 ml
89427766|NCT02269644|Experimental|Dalbavancin|Dalbavancin randomized subjects will receive one dose of dalbavancin 1500 mg IV over 30 minutes on Day 1 plus azithromycin 500 mg IV on Day 1. Dalbavancin dose will be adjusted for subjects with significant renal insufficiency who are not receiving regular hemodialysis. All patients in the dalbavancin group will receive placebo linezolid infusions or tablets to maintain the blinding. Dalbavancin dose will be adjusted for subjects with significant renal insufficiency who are not receiving regular hemodialysis
89427767|NCT02269644|Active Comparator|Linezolid|Linezolid randomized subjects will receive linezolid 600 mg every 12 hours for a minimum of 10 days, and a maximum of 14 days. All patients will receive at least one IV dose of linezolid initially plus azithromycin 500 mg IV only on Day 1. Subjects then may then be switched to oral linezolid at the discretion of the investigator, if clinical improvement in the signs and symptoms of pneumonia is observed, to complete the 10-14 day course of therapy,. No dose adjustment is required for renal insufficiency.
89427768|NCT02269644|Other|Linezold Placebo IV and Oral Capsules|Dalbavancin randomized subjects after the 1st dose on Day 1 will receive placebo linezolid every 12 hours for a minimum of 10 days and a maximum of 14 days. Dalbavancin randomized subjects may be switched to oral linezolid placebo therapy to complete the 10-14 day course of therapy.
89427769|NCT02269644|Other|Azithromycin|Dalbavancin and linezolid randomized subjects on Day 1, 1st dose will also receive 500 mg of IV azithromycin
89427770|NCT02269722|Experimental|Short Clamp time|Radial clamp applied at full pressure for 20 minutes. At the end of 20 minutes, the clamp will be loosened ¼ turn every 5 minutes over 20 minutes and then removed.
89427771|NCT02269722|Experimental|Long Clamp Time|Radial clamp applied at full pressure for 60 minutes. At the end of 60 minutes, the clamp is to be loosened and removed under the same instruction as those patients in arm one.
89427772|NCT03367988|Experimental|Opioid-free Anesthesia|Patients will receive no intraoperative narcotics as part of their anesthesia regimen
89427773|NCT03367988|Active Comparator|Opioid Anesthesia|Patients will receive intraoperative narcotics as part of their anesthesia regimen
89427774|NCT03465488|Experimental|Subjects|All participants that meet all inclusion criteria and none of the exclusion criteria will be enrolled in the study and receive a subject identifier (SubjectID). At baseline, all participants will receive a single treatment of albendazole 400mg and their stool will be examined for helminth eggs. Two to three weeks after treatment a follow-up examination of their stool is performed.
89427775|NCT02267304|Experimental|Morphine/placebo/naxolone|
89427776|NCT02267304|Experimental|Naxolone/morphine/placebo|
89427777|NCT02267304|Experimental|placebo/naxolone/morphine|
89427778|NCT03465410|Active Comparator|GROUP I Standard adjustment|Standard dosage of Tacrolimus
89427779|NCT03465410|Experimental|GROUP II Bayesian prediction adjustment|Bayesian prediction Tacrolimus dosage
89427780|NCT04475874|Active Comparator|supervised stretching exercises :group A|The intervention group A practiced a 30 to 45-minute supervised active stretching program three times a week for four weeks
89427781|NCT04475874|Active Comparator|non-supervised active stretching home program: group B|practiced non-supervised active stretching home program
89427782|NCT04475874|No Intervention|Standard of care: group c|control group
89427783|NCT05332418|Experimental|study group|the study group received the same exercise training program in addition to electromagnetic field therapy, three times per week for four weeks
89427784|NCT05332418|Experimental|control group|the control group which received the selected exercise program
89427785|NCT02522234|Experimental|F-627 240 µg/kg|"F-627 at the dose of 240 mcg/kg administered by s.c. injection on Day 2 of each cycle for up to 6 cycles.~Chemotherapy (docetaxol, doxorubicin and cyclophosphamide) administered by intravenous injection on Day 1 of each cycle for up to 6 cycles."
89427786|NCT02522234|Experimental|F-627 320 µg/kg|"F-627 at the dose of 320 mcg/kg administered by s.c. injection on Day 2 of each cycle for 6 cycles.~Chemotherapy (docetaxol, doxorubicin and cyclophosphamide) administered by intravenous injection on Day 1 of each cycle for up to 6 cycles."
89008168|NCT04602442|Experimental|EXO-1|Participants (n=30) in this group will receive standard therapy and exosomes of the first type.
89427787|NCT03465332||Lung specialist|Approximately 30 lung specialists in Germany with a sufficient number of COPD subjects under supervision will be enrolled in the study to document physician's attitudes on COPD diagnosis and therapy, and to document data on about 250 subjects with COPD.
89427788|NCT03465332||Subjects with COPD|Data from approximately 250 subjects with COPD under supervision of lung specialists enrolled in the study will be analyzed.
89427789|NCT00154284|Active Comparator|Everolimus (Certican) with Cyclosporine (Neoral) Continuation|Patients were treated with everolimus and cyclosporine for 3 months post-transplantation. Everolimus (Certican) was administered orally, in two divided doses (b.i.d), and at the same time as Cyclosporine (Neoral). Everolimus (Certican) dose was adjusted in order to maintain a trough level between 3 and 8 ng/mL until randomization. After randomization the target trough range remained at 3 - 8 ng/mL in the cyclosporine (Neoral) continuation groups for a period of 9 months. Each patient was administered i.v. prednisone (or equivalent) pre- or intra-operatively according to center practice.
89427790|NCT00154284|Experimental|Everolimus (Certican) with Cyclosporine (Neoral) Withdrawal|Patients were treated with everolimus and cyclosporine for 3 months post-transplantation. Everolimus (Certican) was administered orally, in two divided doses (b.i.d), and at the same time as Cyclosporine (Neoral). Everolimus (Certican) dose was adjusted in order to maintain a trough level between 3 and 8 ng/mL until randomization. Therefore, patients were randomized to cyclosporine withdrawal over a period of 1 month (±1 week) in study A2419 (NCT00154284) and over 3 months (±1 week) in study A2423 (NCT00170807). After randomization, final target trough range for everolimus was 8 - 12 ng/mL. Each patient was administered i.v. prednisone (or equivalent) pre- or intra-operatively according to center practice.
89427791|NCT01293552|Placebo Comparator|Control|blank vehicle formulation
89427792|NCT01293552|Experimental|Dose 1|Dose 1
89427793|NCT01293552|Experimental|Dose 2|Dose 2
89427794|NCT01293552|Experimental|Dose 3|Dose 3
89427795|NCT01293552|Experimental|Dose 4|Dose 4
89197022|NCT00835887|Experimental|1|Treatment with low dose flavanoids
89427796|NCT04973306|Experimental|Neoadjuvant chemoradiotherapy combined with anti-PD-1 antibody|Neoadjuvant chemoradiotherapy (NCRT) combined with tislelizumab is performed followed by Ivor-Lewis or Mckeown esophagectomy in enrolled patients.
89427797|NCT04973306|Active Comparator|Neoadjuvant chemoradiotherapy|Neoadjuvant chemoradiotherapy (NCRT) is performed followed by Ivor-Lewis or Mckeown esophagectomy in enrolled patients.
89427798|NCT04438746|Experimental|Group receiving CBAT|
89427799|NCT04438746|Placebo Comparator|Group receiving general emotion training|
89427800|NCT01037166|Experimental|Entecavir (0.5 mg)|
89427801|NCT01037166|Experimental|Entecavir (1mg)|
89427802|NCT03134976||Salvage Larynx|The first group includes subjects with cancer of the voice box (laryngeal squamous cell carcinoma) that has already been treated by either chemotherapy or radiation. This group will be treated using the standard of care, which includes starting thyroid hormone replacement therapy (levothyroxine) after surgery.
89536862|NCT02469311|Active Comparator|Revision Treatment THA|Patients undergoing a second or subsequent or a revision total knee arthroplasty will be randomized to the intervention of chlorhexidine impregnated cloths.
89427803|NCT03134976||Non-Salvage Larynx|The second group of subjects will consist of patients who have head and neck cancer of sites other than the voice box (larynx) without prior exposure to radiation or chemotherapy who are undergoing flap reconstruction surgery. This group will not be treated with levothyroxine so long as the subject has normal thyroid function. If a subject is hypothyroid, then thyroid hormone replacement will be given as a part of routine clinical care.
89427804|NCT04491032|Active Comparator|Low Volume|Caudal anesthesia will be performed with 0.8 ml/kg of the local anesthetic solution
89427805|NCT04491032|Active Comparator|High Volume|Caudal anesthesia will be performed with 1.25 ml/kg of the local anesthetic solution
89427806|NCT02269800|Experimental|Benzalkonium chloride solution|Tid, for 7 days.
89427807|NCT02269800|Active Comparator|Normal saline|Tid, for 7 days.
89427808|NCT04487756|Experimental|Atezo+DCvac|"- Induction (4 cycles, every 3 weeks): Carboplatin area under the curve (AUC) 5 (5 mg per milliliter per minute, administered intravenously on day 1 of each cycle) and etoposide (100 mg per square meter of body-surface area, administered intravenously on days 1 through 3 of each cycle) Atezolizumab, 1200 mg administered intravenously every 3 weeks on day 1 of each cycle)~- Maintenance (only patients without PD after 4 induction cycles, up to PD): Atezolizumab iv (1200 mg/IV on day 1 every 3 weeks) DCV intradermally (max. 6 doses) on weeks 1, 3, 6, 9, 21, 33."
89427809|NCT02269878||people with MPM with Thymine/Thymine,Thymine/cytosine genotype|according to Single nucleotide polymorphism analysis of rs 763110, people have one of the following genotypes, Thymine/Thymine,Thymine/Cytosine,Cytosine/Cytosine. we will assign Thymine/Thymine, Thymine/Cytosine to group one and Cytosine/Cytosine to group two. for rs 1800682 people will have one of the following genotypes Adenine/Adenine, Adenine/Guanine or Guanine/Guanine.
89427810|NCT02269878||people with MPM, Cytosine/Cytosine genotype|according to Single nucleotide polymorphism analysis of rs 763110, people have one of the following genotypes, Thymine/Thymine,Thymine/Cytosine,Cytosine/Cytosine. we will assign Thymine/Thymine, Thymine/Cytosine to group one and Cytosine/Cytosine to group two. for rs 1800682 people will have one of the following genotypes Adenine/Adenine, Adenine/Guanine or Guanine/Guanine.
89427811|NCT02269956|Active Comparator|Intervention|The 2 NH's not used in the focus groups will receive the intervention, a 12-week feasibility study. At baseline, weeks 6 and 12, dementia feeding skills knowledge and self-efficacy tests will be administered, meal observations of nursing staff assisting PWD with meals will be video recorded for 3 meals over 2 days at baseline and again at week 6 and 12, and a medical record review will be conducted. After baseline data is collected, the training program will be delivered in 5 weekly modules with group coaching sessions completed the same week.
89427812|NCT02269956|No Intervention|Focus Groups|Year 1 focus groups will aim to identify how nursing staff feel about usual interventions for feeding behaviors of PWD and staff responses when a PWD displays difficult eating behaviors. Year 2 focus groups will evaluate the revised dementia feeding skills training program, the coaching interventions, and case scenarios, and indicate how realistic and compatible the intervention is with their work environment.
89427813|NCT02270112||Paroxysmal Af|No Intervention is planned. All patients receive a 5 Minute ECG and have their pulse recordes by an iPhone.
89427814|NCT01281462|Experimental|Ceftaroline fosamil and NXL104 (q8h)|
89427815|NCT01281462|Experimental|Ceftaroline fosamil and NXL104 (q12h)|
89427816|NCT01281462|Active Comparator|Doripenem|
89427817|NCT01268280|Experimental|Treatment Sequence 1|Dosing Period 1 Placebo; Dosing Period 2 CK-2017357 250 mg; Dosing Period 3 CK-2017357 500 mg
89427818|NCT01268280|Experimental|Treatment Sequence 2|Dosing Period 1 Placebo; Dosing Period 2 CK-2017357 500 mg; Dosing Period 3 CK-2017357 250 mg
89427819|NCT01268280|Experimental|Treatment Sequence 3|Dosing Period 1 CK-2017357 250 mg; Dosing Period 2 Placebo; Dosing Period 3 CK-2017357 500 mg
89427820|NCT01268280|Experimental|Treatment Sequence 4|Dosing Period 1 CK-2017357 250 mg; Dosing Period 2 CK-2017357 500 mg; Dosing Period 3 Placebo
89427821|NCT01268280|Experimental|Treatment Sequence 5|Dosing Period 1 CK-2017357 500 mg; Dosing Period 2 Placebo; Dosing Period 3 CK-2017357 250 mg
89427822|NCT01268280|Experimental|Treatment Sequence 6|Dosing Period 1 CK-2017357 500 mg; Dosing Period 2 CK-2017357 250 mg; Dosing Period 3 Placebo
89427823|NCT04453124|No Intervention|Soap and Water|Standard of care using soap and water
89427824|NCT04453124|Experimental|Ficus Septica Sap|Ficus Septica Sap, topical cream, 50ul, daily, for 2 days
89427825|NCT04453124|Active Comparator|Chlorhexidine (Topical)|Chlorhexidine, topical solution, 50ul, daily, for 2 days
89427826|NCT02267460|Active Comparator|AA4500 with investigator modeling and vacuum therapy|AA4500 with investigator modeling and home use of the ErecAid® Esteem® Manual Vacuum Therapy System.
89427827|NCT02267460|Active Comparator|AA4500 without investigator modeling/with vacuum therapy|AA4500 without investigator modeling but with home use of the ErecAid® Esteem® Manual Vacuum Therapy System.
89427828|NCT04453514|Experimental|Trauma-informed yoga video recording|Participants will complete a single trauma-informed yoga practice using a 45-minute guided video recording.
89427829|NCT01024062|Experimental|Paclitaxel|
89427830|NCT04453436||Virologic failure|Viral load above detection limits at window period
89427831|NCT04453436||Virologic Success|Viral load bellow detection limits at window period
89427832|NCT02267616|Experimental|Continued Use Implant Group|Woman randomly assigned to the continued use of their Etonogestrel Implant will continue to use their Etonogestrel Implant for contraception past FDA-approved duration of 36 months.
89427833|NCT02267616|Active Comparator|New Implant Group|Woman randomly assigned to the new Etonogestrel Implant will have their existing Etonogestrel Implant removed and a new implant placed.
89427834|NCT02267616|No Intervention|Observational Continued Use Group|Women who refuse randomization will have an option of continuing to use their existing Etonogestrel Implant beyond the FDA-approved duration (36 months).
89427835|NCT03465176|Experimental|Intervention|The women in this arm will receive an essential oil blend to inhale each afternoon for two weeks.
89427836|NCT03465176|Placebo Comparator|Control|The women in this arm will receive an odorless vegetable based oil to inhale each afternoon for two weeks as a control/placebo.
89427837|NCT02267694|Other|Black raspberry powder|Black raspberry powder 25 grams once daily for 4 weeks. If tolerated, will increase to 25 grams twice a day for another 20 weeks. Total length of active treatment 24 weeks.
89427838|NCT05232734|Experimental|Oral caffeine group|Patients in this arm will receive treatment with oral caffeine
89427839|NCT05232734|Placebo Comparator|Control group|Patients in this group will receive syrup BP (placebo)
89427840|NCT02270346|Active Comparator|Treatment group|Intervention: Treatment group received inspiratory muscle training (IMT) using POWERbreathe Classic threshold loading device.
89427841|NCT02270346|Sham Comparator|Control group|Sham: Control group received sham inspiratory muscle training (IMT) using POWERbreathe Classic threshold loading device .
89427842|NCT02270502||Adult patients on the SICU|Adult patients on the surgical intensive care unit (SICU), within 72 hours of admission to the SICU and until SICU discharge. Ultrasound Philips CX50, Frailty Index questionnaire and muscle strength tests.
89427843|NCT01023204|Experimental|Paclitaxel|
88908743|NCT05886881||Air Optix plus HydraGlyde Sphere|Lotrafilcon B multifocal soft contact lenses with comfort additive worn in both eyes on an extended wear basis. Extended wear is defined as up to 6 days continuous wear (including while sleeping/overnight).
89427844|NCT04453748||COVID-19 convalescents|People who recovered from COVID-19: have no symptoms and no SARS-Cov2 RNA in PCR
89427845|NCT04475562|Other|COVID-19 suspected|Participants were recruited at the outpatient clinic for MUMC+ employees with COVID-19 symptoms or at the nursing unit where a SARS-CoV-2 patient was admitted.
89427846|NCT04460456|Experimental|SBT6050 Monotherapy|Escalating doses of SBT6050 in Part 1 followed by expansion in Part 2 at the recommended dose determined in Part 1.
89427847|NCT04460456|Experimental|SBT6050 and pembrolizumab|Escalating doses of SBT6050 in combination with pembrolizumab in Part 3 followed by expansion in Part 4 at the recommended dose determined in Part 3.
89427848|NCT04460456|Experimental|SBT6050 and cemiplimab|SBT6050 in combination with cemiplimab in Part 5 at the recommended dose determined in Parts 1 and 3.
89427849|NCT03468452||Early extubation|The endotracheal tube is removed in the operation room, and no suction support is required after surgery.
89427850|NCT03468452||late extubation|"Take the tracheal tube back to the ward for respiratory support or removal of air.~The catheter is inserted again within 48h."
89427851|NCT01022970|Placebo Comparator|Placebo|
89427852|NCT01022970|Active Comparator|QAX576|
89427853|NCT02735096|Experimental|Vestibular Patients for EquiCue Testing|Subjects with vestibular deficiency will try the intraoral electronic balance aid to see whether there is improvement in balance.
89427854|NCT02267928|Experimental|Check/Experience|Participants are asked to check the symptoms that they have experienced in the last 6 weeks.
88908744|NCT05886881||Air Optix plus HydraGlyde Toric|Lotrafilcon B toric soft contact lenses with comfort additive worn in both eyes on an extended wear basis. Extended wear is defined as up to 6 days continuous wear (including while sleeping/overnight).
89197023|NCT00835887|Experimental|2|Treatment with high dose flavanoids
89197024|NCT00738218|Other|MDCT|Single Arm study. All patients underwent MDCT.
89197025|NCT00842049|Experimental|Study|Insertion of lumbar drain
89197026|NCT00842049|Other|Control|Normal clinical management without lumbar drain
89197027|NCT04062500||Patients with heart failure|patients treated in the hospital for acute heart failure in China
89197028|NCT00835965|Active Comparator|Active Comparator|Patients receive aprepitant and dexamethasone for prevention of postoperative nausea and vomiting
89197029|NCT00835965|Placebo Comparator|Placebo Comparator|Patients receiving aprepitant and placebo dexamethasone for prevention of postoperative nausea and vomiting
89197030|NCT02567786|Active Comparator|Fresh Frozen Plasma|The priming of the CPB oxygenator will be done with 15 ml/kg of FFP in addition to packed red blood cells.
89427855|NCT02267928|Experimental|Un-check/Experience|Participants are asked to un-check the symptoms that they have experienced in the last 6 weeks.
89197031|NCT02567786|Active Comparator|Plasmalyte|The priming of the CPB oxygenator will be done with 15 ml/kg of Plasmalyte in addition to packed red blood cells.
89197032|NCT05667740|Experimental|Gamma-PN3|"Inactivated whole-cell pneumococcal vaccine at 50, 250 or 1000 mcg of protein content.~One dose on Day 1 and second dose Day 29"
89427856|NCT02267928|Experimental|Check/Not Experienced|Participants are asked to check the symptoms that they have NOT experienced in the last 6 weeks.
89427857|NCT02267928|Experimental|Un-check/Not Experienced|Participants are asked to un-check the symptoms that they have NOT experienced in the last 6 weeks.
88908745|NCT05886881||Biofinity Sphere|Comfilcon A spherical soft contact lenses worn in both eyes on an extended wear basis. Extended wear is defined as up to 6 days continuous wear (including while sleeping/overnight).
88908746|NCT05886881||Biofinity Toric|Comfilcon A toric soft contact lenses worn in both eyes on an extended wear basis. Extended wear is defined as up to 6 days continuous wear (including while sleeping/overnight).
88908747|NCT05886816|Experimental|Mito-MES|MitoQ pills 20 mg orally daily taken during the study and initiated within 3 days post exposure.
88908748|NCT05886816|Placebo Comparator|Control group|Placebo pills orally daily taken during the study and initiated within 3 days post exposure.
89197033|NCT05667740|Placebo Comparator|Placebo|Saline on Day 1 and second dose Day 29
89197034|NCT05667740|Active Comparator|Prevenar-13|Licensed pneumococcal vaccine on Day 1 and saline on Day 29
89197035|NCT05667740|Active Comparator|Pneumovax-23|Licensed pneumococcal vaccine on Day 1 and saline on Day 29
89197036|NCT00842205|Active Comparator|1 HCV positive pts|"Patients with chronic HCV infection undergoing liver biopsy followed by antiviral treatment.~peg-IFN alfa 2a 180ug s.c. QW + ribavirin 1000-1200mg p.o. daily 48weeks or peg-IFN alfa 2b 1.5 ug/kg s.c. QW + ribavirin 100-1200mg p.o. daily 48 weeks"
89197037|NCT00842205|No Intervention|2 Other liver disease|pts. with NASH (or other liver disease) undergoing liver biopsy.
89197038|NCT00738296|Active Comparator|A|Group A: Comparator
89197039|NCT00738296|Active Comparator|B|Group B: Comparator
89197040|NCT00738296|Experimental|C|Group C: Drug
88908749|NCT05886049|Experimental|Treatment (revumenib, daunorubicin, cytarabine)|See Detailed Description.
89197041|NCT00844701||Non-smoker|Non-smoking control
89197042|NCT00844701||Nicotine Dependent Smoking Group|current smokers
89197043|NCT00836043||Group 1|
89197044|NCT02567396|Experimental|Treatment (talazoparib)|Patients receive talazoparib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89197045|NCT02547831||Observational approach|Patients will be placed on wait and see approach and then shifted to specific treatment in case of progression
89197046|NCT00738452|Experimental|Treatment (chemo, monoclonal antibody therapy, radiation)|CHEMORADIOTHERAPY: Patients undergo external beam radiation therapy 5 days a week for 45 days. Beginning within 24 hours of the start of radiation therapy, patients receive paclitaxel IV over 1 hour and carboplatin IV over 30 minutes on days 1, 8, 15, 22, 29, and 36 OR cisplatin IV over 60 minutes on days 1, 8, 29, and 36 and etoposide IV over 60 minutes on days 1-5 and 29-33. CONSOLIDATION RADIOIMMUNOTHERAPY: Beginning 6-10 weeks after completion of chemoradiotherapy, patients with stable disease, partial response, or complete response receive a therapeutic dose of yttrium Y 90 anti-CEA monoclonal antibody cT84.66 IV. Treatment continues in the absence of disease progression or unacceptable toxicity.
89197047|NCT00836121||tumor|
89197048|NCT05667428|Experimental|Leprorelin group|Leprorelin was given subcutaneously before each cycle of chemotherapy.
89197049|NCT05667428|Placebo Comparator|Control group|Normal salinewas given subcutaneously before each cycle of chemotherapy.
89197050|NCT00844779||T|(n=30): without central adiposity, without insulin resistance, operated for cholecystectomy or a benign liver tumor.
89197051|NCT00844779||A|(n=30): with central adiposity, insulin resistance and hepatic steatosis (histology).
89197052|NCT00844779||B|(n=30): with central adiposity, insulin resistance and steatohepatitis ± hepatic fibrosis (histology).
89197053|NCT05664542|Experimental|ESPB group|this group will receive ESPB using ropivacaine and dexmedetomidine
89197054|NCT05664542|No Intervention|Control group|this group will not receive any block
89197055|NCT00562978|Experimental|Zevalin 1000 cGy + VP-16 40 mg/kg + Cytoxan 100 mg/kg|"Preparation for AHSCT: Peripheral blood stem cells (PBSCs) are collected via leukapheresis. Samples are analyzed by cytogenetic studies, immunophenotyping, and gene rearrangement. Patients with an adequate number of collected CD34-positive cells (≥ 3 times 10^6 /kg) proceed to radioimmunotherapy.~Radioimmunotherapy: Patients receive yttrium Y 90 ibritumomab tiuxetan and undergo bone marrow biopsy and dose estimation.~Chemotherapy: Patients receive etoposide IV and cyclophosphamide IV~AHSCT: Patients undergo reinfusion of PBSCs.~Growth factor therapy: Patients receive filgrastim (G-CSF) IV. Treatment continues in the absence of disease progression or unacceptable toxicity."
89197056|NCT00562978|Experimental|Zevalin 1000 cGy + VP-16 60 mg/kg + Cytoxan 100 mg/kg|"Preparation for AHSCT: Peripheral blood stem cells (PBSCs) are collected via leukapheresis. Samples are analyzed by cytogenetic studies, immunophenotyping, and gene rearrangement. Patients with an adequate number of collected CD34-positive cells (≥ 3 times 10^6 /kg) proceed to radioimmunotherapy.~Radioimmunotherapy: Patients receive yttrium Y 90 ibritumomab tiuxetan and undergo bone marrow biopsy and dose estimation.~Chemotherapy: Patients receive etoposide IV and cyclophosphamide IV~AHSCT: Patients undergo reinfusion of PBSCs.~Growth factor therapy: Patients receive filgrastim (G-CSF) IV. Treatment continues in the absence of disease progression or unacceptable toxicity."
89197057|NCT00921206|Active Comparator|VAX102 given i.m.|Universal influenza candidate vaccine
89197058|NCT00921206|Active Comparator|VAX102 given s.c.|Universal influenza candidate vaccine
89197059|NCT00842439|Experimental|Cognitive Behavioral Intervention (CBI)|Participants will meet with an interventionist once a week for 12 weeks. They will discuss the child's behavior, will learn coping skills and how to deal with other people.
88908750|NCT05884073|Experimental|Circuit-based resistance exercise|12-week, supervised twice weekly circuit-based resistance training program.
89008169|NCT04602442|Experimental|EXO-2|Participants (n=30) in this group will receive standard therapy and exosomes of the second type.
89197060|NCT00842439|Experimental|Nutritional Supplements (NUT)|Participants will be asked to take omega-3 supplements, multivitamin tablets, and calcium tablets every day for 12 weeks.
89197061|NCT00842439|Experimental|CBI + NUT|Participants will receive both the cognitive behavioral intervention and the nutritional supplements.
89197062|NCT00842439|No Intervention|No intervention|Participants will not be asked to come for sessions or any other intervention. They will receive a list of the types of help that are available if they are interested in following up on their own.
89197063|NCT00940264||Given indication for cholecystectomy|
89197064|NCT04013230|Active Comparator|Usual care|Usual care according to regular treatment routines at the clinic.
89197065|NCT04013230|Active Comparator|Web-COP|Usual care plus group sessions and a web-based treatment program
89427858|NCT01022346|Placebo Comparator|Placebo|Placebo matched to RO5217790 will be administered subcutaneously on Days 1, 8, and 15.
89427859|NCT01022346|Experimental|RO5217790|RO5217790 will be administered at a dose of 5*10^7 plaque forming unit (pfu) subcutaneously on Days 1, 8, and 15.
89427860|NCT04890314||Active Surveillance (AS)|Doctor will monitor the patient without directly treating the cancer.
89427861|NCT04890314||Stereotactic Body Radiation Therapy (SBRT)|Radiation treatment of prostate cancer requiring less than 2 weeks of treatment.
89427862|NCT04890314||Intensity-Modulated Radiation Therapy (IMRT)|Radiation treatment of prostate cancer requiring more than 2 weeks of treatment.
89427863|NCT04890314||Partial Gland Ablation (PGA)|Prostate cancer treatment that involves only treating part of the prostate that has cancer. Examples include, but are not limited to, high intensity focused ultrasound (HIFU) and cryotherapy.
89427864|NCT04890314||Radical Prostatectomy (RP)|Prostate surgery that removes the whole prostate.
89427865|NCT04880096||chronic pain patients|All adult patients followed-up in participating pain clinics
89427866|NCT04475406|Sham Comparator|Control group|Standard implant, intra-bone length ≥8 mm (30 implants)
89427867|NCT04475406|Active Comparator|Test group|Extra Short implant, intra-bone length ≤6 mm (30 implants)
89427868|NCT02522390||Nutrition Researcher Cohort|This cohort study is an observational, one-group study. The intervention consists of research activities that participants are asked to perform throughout the cohort, including the use of do-it-yourself devices, filling out online-questionnaires and sample collection with supplied kits for the analysis of various health parameters. The frequency with which participants are asked to measure these health parameters varies, ranging from once to weekly.
89427869|NCT02268006|Other|IMRT-SIB|
89427870|NCT03462212|Other|Standard treatment|Carboplatin AUC 5 + Paclitaxel 175 mg/mq d 1 q 21 for 6 cycles + Bevacizumab 15 mg/kg d 1 q 21 days for 22 cycles (in combination and maintenance)
89427871|NCT03462212|Experimental|Carboplatin + Paclitaxel + Bevacizumab + Rucaparib|Carboplatin AUC 5 + Paclitaxel 175 mg/mq d1 q 21 days for 6 cycles + Bevacizumab 15 mg/kg d1 q 21 for 22 cycles (in combination and maintenance) + Rucaparib at the dose defined by the Phase I study continuously for 2 years (Rucaparib only in maintenance)
89427872|NCT03462212|Experimental|Carboplatin + Paclitaxel + Rucaparib|Carboplatin AUC 5 + Paclitaxel 175 mg/mq d1 q 21 days for 6 cycles + Rucaparib 600 mg BID continuously for 2 years (Rucaparib only as maintenance).
89427873|NCT01152216|Experimental|Dimebon|
89427874|NCT01016808|Experimental|Q8003 12 mg/8 mg|Combination
89427875|NCT01016808|Active Comparator|Morphine sulfate 12 mg|Single component
89427876|NCT01016808|Active Comparator|Oxycodone HCl 8 mg|Single component
89427877|NCT04452968|Experimental|intermittent fasting|"Daily caloric requirement was calculated using basal metabolic rate (BMR) calculator. All women were directed to decrease calorie intake by 500 calories.~Women were told about timed restricted feeding. They were required to fast for 16 hours and consume their allotted calories during the remaining 8 hours."
89427878|NCT04452968|Active Comparator|caloric restriction|Daily caloric requirement was calculated using basal metabolic rate (BMR) calculator. All women were directed to decrease calorie intake by 500 calories.
89427879|NCT03462134||Survey amongst orthopaedic surgeons|Selected of 20 patients from the Escape trial (NCT01850719)
89427880|NCT03462056|Experimental|CF Ready to Use Supplemental Food.|Participants will receive Cystic Fibrosis Ready to Use Supplemental Food sufficient to provide approximately 20% of estimated daily caloric needs up to 500kcal of total calories, 18.5 grams of protein and 28g of fat. The supplement is also optimized to provide excellent protein quality and optimal polyunsaturated fatty acid composition
89427881|NCT01014078|Experimental|Azithromycin Ophthalmic Solution, 1%|
89427882|NCT01014078|Placebo Comparator|Placebo|
89427883|NCT02522078|Active Comparator|Dry Misoprostol|400 µg of dry misoprostol
89427884|NCT02522078|Experimental|Wet misoprostol|400 µg of wet misoprostol
89427885|NCT01146522|Experimental|LCQ908|
89427886|NCT01146522|Placebo Comparator|Placebo|
89427887|NCT03461822||SRT in primary-inoperable solid tumors|stereotactic radiotherapy in hypofractionated regimes in 1-5 fractions in primary-inoperable solid tumors
89427888|NCT03461822||Classic radiotherapy in primary-inoperable solid tumors|Classic radiotherapy in 1.8-2.0 Gy per fraction in primary-inoperable solid tumors
89427889|NCT03461822||SRT in oligometastatic cancer|stereotactic radiotherapy in hypofractionated regimes in 1-5 fractions in oligometastatic cancer
89427890|NCT03461822||Classic radiotherapy in oligometastatic cancer|Classic radiotherapy in 1.8-2.0 Gy per fraction in oligometastatic cancer
89427891|NCT03468374|Active Comparator|Lymphoscintigraphy|Nuclear Medicine diagnostic device using radioactive material
89427892|NCT03468374|Active Comparator|Single Photon Emission Tomography|Nuclear Medicine diagnostic device using fusion technique between SPECT and CT
89427893|NCT00911274|Experimental|Test (mycophenolate mofetil) First|Mycophenolate Mofetil 250 mg Capsule dosed in first period followed by CellCept® 250 mg Capsule dosed in second period.
89427894|NCT00911274|Active Comparator|Reference (CellCept®) First|CellCept® 250 mg Capsule dosed in first period followed by Mycophenolate Mofetil 250 mg Capsule dosed in second period.
89427895|NCT03468296|Experimental|Continued Q2 Week Treatment|Will receive intravitreal aflibercept (2.0mg) injections for an additional four consecutive 2 week intervals at weeks 18, 20, 22, and 24
89197066|NCT00842595|Experimental|R NIMP|(Mabthera®) Rituximab IV 375 mg/m²day 1 (Navelbine ®)Vinorelbine IV 25mg/m² day 1 and day 5 (Novantrone®)Mitoxantrone IV 10 mg/m² day 1 (Holoxan®)Ifostamide IV 1000 mg/m²day 1 to day 5 (Cortancyl®)prednisone oral day 1 to day 5
89427896|NCT03468296|Active Comparator|Treat-And-Extend Treatment|Will receive intravitreal aflibercept (2.0mg) injections on a treat-and-extend basis through week 24 with a minimum inter-treatment interval of q4 weeks.
89427897|NCT05238636||Stretta|Patients that have undergone or are to undergo the Stretta procedure
89427898|NCT05238636||LINX|Patients that have undergone or are to undergo the LINX device
89427899|NCT05238636||Laparoscopic fundoplication|Patients that have undergone or are to undergo laparoscopic fundoplication.
89427900|NCT01130142|Active Comparator|Arm 1 (Phase 2)|IPI-926 in combination with gemcitabine
89427901|NCT01130142|Placebo Comparator|Arm 2 (Phase 2)|Placebo in combination with gemcitabine
89427902|NCT03464864|Experimental|Treprostinil Inhalation Powder 30 mcg|
89427903|NCT03464864|Experimental|Treprostinil Inhalation Powder 60 mcg|
89427904|NCT03464864|Experimental|Treprostinil Inhalation Powder 90 mcg|
89427905|NCT03464864|Experimental|Treprostinil Inhalation Powder 120 mcg|
89427906|NCT03464864|Experimental|Treprostinil Inhalation Powder 150 mcg|
89427907|NCT03464864|Experimental|Treprostinil Inhalation Powder 180 mcg|
89427908|NCT03464864|Experimental|Treprostinil Inhalation Powder 240 mcg|
89427909|NCT03464864|Experimental|Treprostinil Inhalation Powder 300 mcg|
89427910|NCT03468140|Experimental|Current end stage liver disease patients|Eculizumab
89427911|NCT03468140|Other|Historical controls|The Ochsner database will be used to obtain 5 historical matches for each study participant. Matching criteria for each patient will include: 1) gender; 2) (MELD) Score ± 5; 3) age ± 5 years; 4) body mass index (BMI) ± 5 kg/m2; 5) donor macrosteatosis ± 5%; and 6) CIT± 3 hours.
89427912|NCT03129932|Active Comparator|gluten phase|volunteers will receive 2 corn muffins containing12g of gluten/muffin to be consumed daily for 4 weeks
89427913|NCT03129932|Placebo Comparator|Placebo phase|volunteers will receive 2 corn muffins without gluten/muffin to be consumed daily for 4 weeks
89427914|NCT01009242|Experimental|0.1mg/kg and 1mg/kg CDP6038 IV and Placebo IV|Cohort 1, Group 1 will compare 0.1mg/kg, 1mg/kg CDP6038 and placebo IV.
89427915|NCT01009242|Experimental|1 mg/kg CDP6038 SC and Placebo SC|Cohort 1, Group 2 will compare 1mg/kg CDP6038 and placebo sc.
89427916|NCT01009242|Experimental|Optimized CDP6038 SC|Cohort 2, Group 3 will compare optimized sc doses of CDP6038 based on outcome of Cohort 1 with placebo.
89427917|NCT03464786|Experimental|absorbable collagen membrane|Subjects randomized in this arm will receive Lando® absorbable collagen membrane after tooth extraction.
89427918|NCT03464786|Active Comparator|Bio-Gide resorbable bilayer membrane|Subjects randomized in this arm will receive Bio-Gide resorbable bilayer membrane after tooth extraction.
89427919|NCT02272296|Active Comparator|Jet Injector_main study|Administration of insulin or placebo injection in main study
89427920|NCT02272296|Placebo Comparator|conventional pen, NovoPen IV|Administration of insulin or placebo injection in main study
89427921|NCT02272296|Active Comparator|jet injector_sub study|Administration of insulin or placebo injection in sub study
89427922|NCT03468062|Experimental|Dexmedetomidine|0.5 mg/kg of dexmedetomidine (Precedex; Hospira, Lake Forest, IL) is mixed in normal saline 100mL and administered for 5 minutes after anesthetic induction.
89427923|NCT03468062|Placebo Comparator|Placebo|Only normal saline 100mL is administered for 5 minutes after anesthetic induction.
89427924|NCT01008852|Experimental|Treatment Group 1|
89427925|NCT01008852|Experimental|Treatment Group 2|
89008170|NCT04602442|Placebo Comparator|Placebo|Participants (n=30) in this group will receive standard therapy and inhalation placebo solution.
89197067|NCT04013698|Experimental|PEEP level 5 cmH2O to 15 cmH2O|
89197068|NCT04013698|Experimental|PEEP level 15 cmH2O to 5 cmH2O|
89197069|NCT00845091|Experimental|Exercise|moderate-intensity, low-impact, supervised, aerobic exercise
89197070|NCT00845091|Active Comparator|Heart Healthy Education|Educational topics on heart health (e.g., nutrition, smoking, sleep)
89427926|NCT01008852|Experimental|Treatment Group 3|
89427927|NCT01008852|Experimental|Treatment Group 4|
89427928|NCT01008852|Placebo Comparator|Treatment Group 5|
89427929|NCT03464708|Experimental|HMB|HMB 3 g/day until hospital discharge or 28-days (whichever comes first). HMB to be provided in powder form and administered via enteral feeding tube whilst in the ICU and orally once able to eat and drink.
89427930|NCT03464708|Placebo Comparator|Placebo|Placebo (lactose) 3 g/day until hospital discharge or 28-days (whichever comes first). Placebo to be provided in powder form and administered via enteral feeding tube whilst in the ICU and orally once able to eat and drink.
89427931|NCT03464552|Active Comparator|Celecoxib group|will receive oral Celecoxib 200 mg capsule (Celebrex®200, Pfizer, USA) once 3 hours before the colposcopic guided biopsy
89427932|NCT03464552|Placebo Comparator|Placebo group|will receive oral placebo capsule once 3 hours before the colposcopic guided biopsy
89427933|NCT05628558||GIDEMHA-1|"First descriptive cohort of the study with patients with mild/moderate hemophilia A retrospectively enrolled for data soon recorded in medical files during the period 2010-2020 in 4 French hemophilia treatment centers (Angers, Caen, Nantes and Rennes).~All these patients received desmopressin with FVIII levels measurements pre/post desmopressin infusion.~Actual number of patients: 429"
89427934|NCT05628558||GIDEMHA-2|"Replication cohort including patients with mild/moderate hemophilia A retrospectively enrolled for data soon recorded in medical files:~during the period 2020-2023 by the initial 4 hemophilia treatment centers (Angers, Caen, Nantes and Rennes)~during the period 2010-2023 by 2 other hemophilia treatment centers (Brest and Tours).~All these patients received desmopressin with FVIII levels measurements pre/post desmopressin infusion.~Anticipated number of patients : 371"
89427935|NCT03461588|Active Comparator|Free-breathing|standard treatment
89427936|NCT03461588|Experimental|Deep inspiratory breath-holding|new technique
89427937|NCT05628480||POD group|According to RASS and CAM-ICU scales, patients who suffer from post-cardiac surgery delirium in ICU will be include into POD group
89427938|NCT05628480||Non-POD group|According to RASS and CAM-ICU scales，patients who do not judge as post-cardiac surgery delirium in ICU will be include into non-POD group
89427939|NCT03461510|Experimental|Type 2 Diabetes|Hyperglycemic clamp and Hyperinsulinemic Euglycemic clamp
89427940|NCT03461510|No Intervention|Lean Control|Controls do not undergo Hyperglycemic clamp and Hyperinsulinemic Euglycemic clamp
89427941|NCT03461510|No Intervention|Obese Control|Controls do not undergo Hyperglycemic clamp and Hyperinsulinemic Euglycemic clamp
89427942|NCT05232474|Other|Control group: no access to KomPas+|Therapists in the control group will not have access to KomPas+ and will continue to deliver usual care by using the KNGF guideline. They will also maintain access to KomPas. As with KomPas+, therapists are free to choose whether to use KomPas or not. The use of KomPas will also be encouraged.
89427943|NCT05232474|Experimental|Experimental group: access to KomPas+|KomPas+ will be implemented within the experimental group. The use of KomPas+ in the physiotherapeutic treatment of patients with intermittent claudication will not be mandatory but will be encouraged through an implementation strategy. Therapists are free to choose whether to use it or not.
89427944|NCT03461432|Experimental|Personalised Cognitive Remediation Therapy (pCRT)|A case-control study design with pre- and post-therapy assessment, comparing a group of participants with schizophrenia who received standard CRT, with a similar group of participants receiving pCRT.
89427945|NCT01007292|Experimental|YM155 plus rituximab|
89427946|NCT03464474|Experimental|Assessment of inflammation grade|Colonic biopsies will be acquired. Biopsies from all patients will be examined using digital holographic microscopy as well as performing a histopathological analysis using the Nancy-score (Goldstandard).
89427947|NCT03467984|Experimental|LBVE|Infants will receive a 0.5mL intramuscular injection of LBVE at 6,10 and 14 weeks of age
89427948|NCT03467984|Active Comparator|Prevnar13|Infants will receive a 0.5mL intramuscular injection of Prevnar13 at 6,10 and 14 weeks of age
89427949|NCT03887208|Experimental|Autologous adipose derived stem cells|Autologous ADSC injection combined with laser therapy of the skin.
89427950|NCT03887208|Placebo Comparator|Placebo - Normal saline injection|Normal sline injection combined with laser therapy of the skin.
89427951|NCT03467828|Experimental|Study Group|Infants diagnosed with BPD.
89427952|NCT03467828|No Intervention|Control Group|Infants born in similar gestational week and birth weight but not diagnosed with BPD.
89427953|NCT01005108|Experimental|placebo pill|
89427954|NCT01005108|Experimental|placebo accupuncture|
89427955|NCT01005108|Experimental|accupuncture|
89427956|NCT01005108|Experimental|gabapentin|
89427957|NCT00905346|Experimental|Test First|Topiramate Capsules 25 mg
89427958|NCT00905346|Active Comparator|Reference First|Topamax® 25 mg Capsule
89427959|NCT03464240|Active Comparator|Glucose|50 grams glucose in 50 ml water
89427960|NCT03464240|Placebo Comparator|Water|50 ml water
89427961|NCT00903552|Experimental|Low Dose|
89427962|NCT00903552|Placebo Comparator|PBS|
89427963|NCT00903552|Experimental|High Dose|
89427964|NCT03461198|Experimental|Treatment|Restylane® Silk to a defined area of mid to low cheeks.
89427965|NCT00902928|Experimental|1. YM150, Dose X, twice daily|
89427966|NCT00902928|Experimental|2, YM150, Dose X, once daily|
89427967|NCT00902928|Experimental|3. YM150, Dose Y, twice daily|
89427968|NCT00902928|Experimental|4. YM150, Dose Y, once daily|
89427969|NCT00902928|Active Comparator|5. Enoxaparin|
89427970|NCT03464162|Experimental|Social Network Meetings Group|"This arm will receive Social Network Meetings for a 6 month period. Meetings may occur as often as 3 times a week when there is a crisis or more commonly would occur once every other week. These meetings will last between 60 and 90 minutes and will take place for however long the clients and their social networks would like within the project period. Ideally, each client and his/her Social Network would participate in 4 meetings during the 6 month period. This group would continue to receive care as usual with the addition of these meetings.~*Final sample in this arm was N=3."
89427971|NCT03464162|No Intervention|No Social Network Meetings Group|"This arm will not receive the Social Network Meetings intervention. Clients in this arm will participate in the study for 6 months and receive care as usual during this time.~*Final sample in this arm was N=1."
89427972|NCT03464162|Other|Social Network Members|"This arm is comprised of individuals who are social network members of clients who are receiving the Social Network Meetings intervention.~*Final sample in this arm was N=3 (social network members of arm 1)."
89427973|NCT03467672||Infected patients|
89427974|NCT03467672||Control group|
89536863|NCT02469233|Experimental|TranS-C|The Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C) is comprised of cross-cutting interventions, 'core modules' and 'optional modules'. TranS-C is derived and adapted from our previous disorder-focused research, firmly grounded in basic science and treatment literature.
89427975|NCT03464006|Experimental|Online Support Module|Patients in the online support module group will receive a tablet which has the developed peripheral arterial disease platform installed on it. The platform helps the patient to monitor factors related to their peripheral arterial disease such as exercise, smoking, and diet and helps them to track and modify these behaviours.
89427976|NCT03464006|Active Comparator|Standard of Care|Patients in this arm will receive the standard of care as provided by the institution.
89427977|NCT03467594|Experimental|Intervention arm|"8 week workplace based exercise programme, 3 exercise sessions each week. Exercises will be conducted in an interval training format (60 second exercise bursts, followed by 75 seconds rest). The exercise bursts are designed to elicit ≥85% of participants age predicted maximum heart rate and will be tailored to each individuals fitness level and ability. Exercise sessions will be supervised and conducted in groups, with the option to request individual one-to-one sessions if preferred.~Outcome measures assessed at baseline and follow-up (8 weeks)"
89427978|NCT03467594|No Intervention|Control|Outcome measures only at baseline at follow-up (8 weeks)
89427979|NCT02522156|Experimental|Looming Vulnerability Induction|"Four audiotape-guided imagery exercises, each lasting about 3 minutes:~Conveyor Belt: Places the participants in a dimly-lit factory, in which they are being carried along faster and faster on a conveyor belt as they smoke. This conveyor belt is described as ultimately leading to the diagnosis of lung cancer.~Office Building: Places participants in an office all alone, watching calendar pages fly off the wall. As participants smoke and time progresses, participants are meant to feel their lungs withering away and their heart beat becoming weaker and weaker.~Train Tracks: Set in the open plains on top of a set of railroad tracks. As participants smoke, a train heading directly towards them gains speed.~Clock Ticking: In this timing exercise, participants are instructed to imagine terrible health consequences related to smoking coming closer and closer to them as they smoke. Participants are asked to keep track of time for a period of three minutes."
89427980|NCT02522156|Placebo Comparator|Control|"Four audiotape-guided imagery exercises, as follows:~Escalator (parallel to conveyor belt above): Takes place in an empty mall in the morning. The participants imagine they are slowly and steadily being carried by the escalator until they reach the top.~Metro (parallel to office building): Involves riding public transportation while reading a magazine, steadily flipping the pages.~Driving (parallel to Train Tracks): Involves driving a car. The car in this case moves steadily with no traffic hindrances that would cause a reduction of speed.~Human Clock (parallel to Clock Ticking): Another timing exercise. In this case, the participants receive instruction to pretend they are a human clock."
89427981|NCT05628168|Experimental|Group A|The NMG received three sessions/week for 4 weeks with each session lasting for 30 min including slider and tension neurodynamic techniques.
89427982|NCT05628168|Active Comparator|Group B|The participants only received a selected therapy program similar to the NMG with no change in duration.
89427983|NCT02522000||Patients with functional dyspepsia|
89427984|NCT02522000||Healthy controls|
89427985|NCT01002924|Experimental|All Participants|All participants invited to enroll on study will receive EC145 (vintafolide) 2.5 mg by intravenous bolus on Monday, Wednesday, and Friday of Weeks 1 and 3 in each 4-week cycle.
89427986|NCT03461042|Experimental|Arm R|Co-administer following medication for 12 weeks since informed consent; R group: taking capsule of Ramelteon 8mg once daily before sleeping.
89427987|NCT03461042|Placebo Comparator|Arm PL|Co-administer following medication for 12 weeks since informed consent; Placebo group: taking capsule of Placebo once daily before bedtime.
89427988|NCT01130064|Experimental|QAX576|QAX576
89427989|NCT01130064|Placebo Comparator|Placebo|Placebo
89427990|NCT01129674|Active Comparator|Standard of Care|
89427991|NCT01129674|Experimental|LY2140023|"20mg, 40mg or 80mg~After 104 weeks, patients have the option to continue on treatment until the end of the study"
89197071|NCT00938626|Experimental|Armed-activated T cells/Immunotherapy|At least 1-3 weeks after the second infusion, patients receive high-dose chemotherapy and then undergo autologous peripheral blood stem cell transplantation. Patients then undergo leukapheresis for G-CSF-mobilized autologous T-cells.
89197072|NCT05193344|Experimental|Digital solution group|Participants will be instructed to download a remote symptom monitoring and lifestyle-changing mobile application to which they will have access for 12 months. The program aims to provide remote symptom monitoring by having participants enter data (on diet, exercise, weight, etc) and answer questionnaires via the SidekickHealth platform, and to empower positive lifestyle changes. Beyond this, all patients in the interventional arm will also receive standard of care as defined below for the control arm.
89197073|NCT05193344|Active Comparator|Standard of care - control group|All participants in the control arm will receive best medical therapy including start or optimization of secondary preventive pharmacotherapy, and advise on modifiable risk factors. The participants in the control arm will also receive an information leaflet about relevant lifestyle modifications for HF. After the baseline measurements and data collection, there will be scheduled visits to a health care provider at 3, 6, and 12 months.
89197074|NCT00842673|Experimental|1|30 mg ST101
89197075|NCT00842673|Experimental|2|90 mg ST101
89197076|NCT00842673|Experimental|3|180 mg ST101
89197077|NCT00842673|Placebo Comparator|4|Placebo
89197078|NCT04013308|Experimental|10 iontophoresis treatments with potassium iodide|
89197079|NCT04013308|No Intervention|10 iontophoresis treatments with placebo|
89197080|NCT00836199|Placebo Comparator|Placebo vaccine|
89197081|NCT00836199|Experimental|NicVAX vaccine|
89427992|NCT03129854|Experimental|experimental group|Prostate cryotherapy plus ADT
89427993|NCT03129854|No Intervention|control group|standard of care ADT continually
89427994|NCT03928392|Experimental|SCUBA Dive with OT|Two SCUBA dives in conjunction with occupational therapy intervention. The occupational therapy intervention will take place on the beach or on the boat before/after the SCUBA dive. The intervention will consist of learning 3 different breathing techniques. Participants will also be educated about mindfulness principals. Additionally, participants will complete journaling activities between dives.
89427995|NCT03928392|Active Comparator|SCUBA Dive without OT|The group will engage in two SCUBA dives.
89427996|NCT05045378|Active Comparator|1. Two 0.045mg/kg midazolam infusions|Two 0.045mg/kg midazolam infusions as active placebo
89427997|NCT05045378|Experimental|2. First 0.045mg/kg midazolam infusion and Second 0.5mg/kg ketamine infusion|Single ketamine infusion + Single midazolam placebo infusion
89427998|NCT05045378|Experimental|3. Two 0.5mg/kg ketamine infusions|Repeated (Two) ketamine infusions: Two 0.5mg/kg ketamine infusions
89427999|NCT03460964|Experimental|Patients with Diabetes|All participants will receive a minimum of 2 doses of pilocarpine 0.1 mL gel, applied to the skin via the glucose sensor to induce sweat. Glucose will be measured with both an adhesive (needle-free) glucose sensor and a glucometer, at fasting, and time points ranging from 15 to 200 minutes after consuming a standardized meal. There are no other interventions.
89428000|NCT03460886|Experimental|Bihemispheric stimulation|"Anodal stimulation on ipsilesional leg motor primary cortex and supplementary motor area~Anodal stimulation on contralesional leg motor primary cortex and supplementary motor area Subject walks on treadmill for 10 minute during stimulation."
89428001|NCT03460886|Experimental|Ipsilesional stimulation|"Anodal stimulation on ipsilesional leg motor primary cortex and supplementary motor area~Sham on contralesional leg motor primary cortex and supplementary motor area Subject walks on treadmill for 10 minute during stimulation."
89428002|NCT03460886|Experimental|Contralesional stimulation|"Sham stimulation on ipsilesional leg motor primary cortex and supplementary motor area~Anodal stimulation on contralesional leg motor primary cortex and supplementary motor area Subject walks on treadmill for 10 minute during stimulation."
89428003|NCT03460886|Active Comparator|Sham|"Sham stimulation on ipsilesional leg motor primary cortex and supplementary motor area~Sham stimulation on contralesional leg motor primary cortex and supplementary motor area Subject walks on treadmill for 10 minute during stimulation."
89428004|NCT03460808|Experimental|atorvastatin, acetylcysteine & danazol|atorvastatin 20mg qd po plus acetylcysteine 400mg tid po plus danazol 200mg bid po for 12 weeks
89428005|NCT04956926|Experimental|JS201|
89428006|NCT03463772|Active Comparator|standard IVF|On the Day2/3 of the menstrual cycle, qualified participants will be randomized into either of two groups. Participants in group A will receive standard IVF procedure. Other standard assisted reproductive treatments are similar and parallel between two groups.
89428007|NCT03463772|Active Comparator|In vitro maturation|On the Day2/3 of the menstrual cycle, qualified participants will be randomized into either of two groups. Participants in group B will receive IVM procedure.Other standard assisted reproductive treatments are similar and parallel between two groups.
89428008|NCT05169762||transgender women|transgender women eligeble to start gender affirming hormone treatment
89428009|NCT04946630|Experimental|Seretide Evohaler forte according to SmPc|Single dose inhalation of fluticasone propionate/salmeterol 250 µg/25 µg administered via the Evohaler in accordance with instruction in the SmPC for Seretide Evohaler forte.
89428010|NCT04946630|Experimental|Whole lung exposure|Single dose of fluticasone propionate/salmeterol 250 µg/25 µg administered via the PreciseInhale system set up for whole lung exposure. The entire 300 mL aerosol volume produced by the single dose from the inhaler will be inhaled at a flow rate in accordance with instructions for the Evohaler.
89428011|NCT04946630|Experimental|Alveolar bolus/ Breath hold exposures|A subdivided dose of fluticasone propionate/salmeterol 250 µg/25 µg administered via the PreciseInhale system set up for six repetitive 70 mL Alveolar bolus/ Breath hold exposures. Each 70 mL bolus will be extracted from a freshly generated volume of 300 mL aerosol produced by actuation of a single dose from the inhaler.
89428012|NCT04946630|Experimental|Bronchial bolus/ Breath hold exposures|A subdivided dose of fluticasone propionate/salmeterol 250 µg/25 µg administered via the PreciseInhale system set up for six repetitive 70 mL Bronchial bolus/ Breath hold exposures. Each 70 mL bolus will be extracted from a freshly generated volume of 300 mL aerosol produced by actuation of a single dose from the inhaler.
89428013|NCT05164302|Experimental|Group A: LO1 point (Tooth)|Participant received auricular acupuncture and sham acupuncture at LO1 point in each side of the ear. In each session, temperature of skin surface at the pinna and lower jaw will be recorded.
89428014|NCT05164302|Experimental|Group B: LO3 point (Jaw)|Participant received auricular acupuncture and sham acupuncture at LO3 point in each side of the ear. In each session, temperature of skin surface at the pinna and lower jaw will be recorded.
89428015|NCT00900900|Experimental|Dehydroepiandrosterone (DHEA)|
89428016|NCT00900900|Experimental|Pregnenolone|
89428017|NCT00900900|Placebo Comparator|Placebo|
89428018|NCT03460730|Experimental|Immunised children|Single 0.5 ml sub-cutaneous dose of 23-valent pneumococcal polysaccharide vaccine (Pneumovax)
89428019|NCT05627778|Experimental|68Ga-PSMA-11 and 68Ga-P15-041 PET/ CT scan|Patients of Prostate cancer PET/CT imaging: In two consecutive days each patient underwent a PET/ CT scan after intravenous administration of 68Ga- PSMA-11 and 68Ga-P15-041, respectively.
89428020|NCT01120470|Experimental|OGX-427 and Prednisone|OGX-427: Starting within 5 days of randomization, three loading doses at 600 mg IV within the first 10 days of initiating treatment, followed by weekly doses of 1000 mg IV Prednisone: 5 mg BID orally starting within 4 days following randomization and at least 24 hours prior to first loading dose of OGX-427
89428021|NCT01120470|Active Comparator|Prednisone|"Control Arm:~Prednisone: 5 mg BID orally starting within 4 days following randomization"
89428022|NCT00997152|Experimental|Dose 1 JTT-654|
89428023|NCT00997152|Experimental|Dose 2 JTT-654|
89428024|NCT00997152|Placebo Comparator|Placebo|
89428025|NCT00993018|Experimental|JNJ-42160443 (1 mg)|JNJ-42160443 1 mg will be administered as a single, subcutaneous injection every 28 days for up to first 52 weeks in the blinded fashion and then every 28 days for up to an additional 52 weeks in the open-label fashion.
89428026|NCT00993018|Experimental|JNJ-42160443 (3 mg)|JNJ-42160443 3 mg will be administered as a single, subcutaneous injection every 28 days for up to first 52 weeks in the blinded fashion and then every 28 days for up to an additional 52 weeks in the open-label fashion.
89428027|NCT00993018|Experimental|JNJ-42160443 (10 mg)|JNJ-42160443 10 mg will be administered as a single, subcutaneous injection every 28 days for up to first 52 weeks in the blinded fashion and then every 28 days for up to an additional 52 weeks in the open-label fashion.
89428028|NCT00993018|Placebo Comparator|Placebo|Placebo will be administered as a single, subcutaneous injection every 28 days for up to 52 weeks.
89428029|NCT01117584|Experimental|ASP1941 lowest dose|oral tablet
89428030|NCT01117584|Experimental|ASP1941 low dose|oral tablet
89428031|NCT01117584|Experimental|ASP1941 high dose|oral tablet
89428032|NCT01117584|Experimental|ASP1941 highest dose|oral tablet
89428033|NCT01117584|Placebo Comparator|Placebo|oral tablet
89428034|NCT03135054|Experimental|Combination|"Quizartinib is a second generation FLT3 inhibitors.The starting dose of quizartinib will be 30 mg/day oral unless the patients are taking a strong CYP3A4 inhibitor in which case the dose will be 20 mg /day. Quizartinib should be taken continuously throughout the treatment period unless there is no evidence of response at first assessment on day 28 or progressive disease at any time during the treatment.~Omacetaxine Mepesuccinate will be given at 1.5 mg/m2/day (maximum dose 3 mg) for 7 days (concurrently with quizartinib) in 28-day cycle."
89428035|NCT00991068|Experimental|Synera|Synera topical patch
89428036|NCT01328444|Experimental|GSK 573719 + GW642444 125/25|125mcg/25mcg nDPI
89428037|NCT01328444|Experimental|GSK 573719 +GW642444 62.5/25|62.5mcg/25mcg nDPI
89428038|NCT01328444|Experimental|GSK 573719 125|125mcg nDPI
89428039|NCT01328444|Experimental|GSK 573719 62.5|62.5 mcg nDPI
89428040|NCT01328444|Experimental|GW 642444 25|25mcg nDPI
89428041|NCT01328444|Placebo Comparator|Plb|Plb nDPI
89428042|NCT01114698|Experimental|JNJ26489112|
89428043|NCT01114698|Active Comparator|Venlafaxine XR|
89428044|NCT01114698|Placebo Comparator|Placebo|
89428045|NCT01114308|Experimental|Probuphine|Patients are first inducted on SL BPN then switched to 4 buprenorphine implants
89428046|NCT01114308|Placebo Comparator|placebo implant|patients are first inducted on SL BPN then switched to 4 placebo implants
89428047|NCT01114308|Active Comparator|sublingual buprenorphine|patients are inducted on SL BPN, then continue on SL BPN
89428048|NCT05469126|Experimental|LY3502970 alone (Period 1)|LY3502970 administered orally.
89428049|NCT05469126|Experimental|Clarithromycin + LY3502970 (Period 2)|Clarithromycin administered orally in combination with LY3502970 given orally.
89428050|NCT04905836|Experimental|COVI-MSC|Subjects will receive intravenous infusions of COVI-MSC (two vials or a total of ≈ 30 million cells) on Day 0, Day 2, and Day 4
89428051|NCT04905836|Placebo Comparator|Placebo|Subjects will receive intravenous infusions of placebo (two vials) on Day 0, Day 2, and Day 4
89428052|NCT00887250|Placebo Comparator|1|Placebo
89428053|NCT00887250|Experimental|2|Losartan 50 mg for 12 weeks
89428054|NCT00887250|Experimental|3|Losartan 50 mg titrated to 100 mg after 6 weeks
89428055|NCT04859192|Experimental|study group|For 6 weeks, students in study group will receive their routine flipped classroom in addition to gamified activities that they are required to complete before class session.
89428056|NCT04859192|No Intervention|control group|The control group will not receive any intervention only their routine flipped classroom education
89428057|NCT03463616||CT abdomen|Patients who had a CT abdomen as primary work-up before treatment planning for rectal cancer.
89428058|NCT03463616||MRI Abdomen|Patients who had a MRI abdomen as primary work-up before treatment planning for rectal cancer.
89428059|NCT00990912|Experimental|Carboplatin|
89428060|NCT00990912|Experimental|Irinotecan (12 (9) mg/m²/day)|
89428061|NCT00990912|Active Comparator|Irinotecan (10 (10) mg/m²/day|
89428062|NCT00886470|Experimental|ST266 1|Topical treatment every other day
89428063|NCT00886470|Experimental|ST266 2|Topical treatment every 4th day
89428064|NCT00886470|Experimental|ST266 3|Topical treatment every 7th day
89536864|NCT02469233|Active Comparator|UC-DT|Usual Care, Delayed Treatment (DT) is comprised of a case manager who co-ordinates care and refers each client for a medication review and to rehabilitation programs. At the end of 6-months in UC-DT, the participants will receive TranS-C.
88908751|NCT05884073|Experimental|Circuit-based resistance exercise plus home-based walking|12-week, supervised twice weekly circuit-based resistance training program plus home-based (unsupervised) brisk walking/light jogging program 3 days/week.
88908752|NCT05884073|Active Comparator|Home-based walking|12-week self-paced walking at home (unsupervised) 3 days/week.
88908753|NCT05883540|Experimental|treatment arm|Subjects in the treatment arm will receive 100 μg LSD (first session) and 100 or 200 μg LSD (second session) per os.
88908754|NCT05883540|Active Comparator|control arm|Subjects in the control arm will receive 25 μg LSD (first session) and 25 μg LSD (second session) per os.
88908755|NCT05882305|Experimental|KSD-101|Biological: Dendritic Cell Vaccine( (Autologous monocyte-derived DCs pulsed withEBV-associated antigen) Patients will receive approximately （2.5-10）x10^6 DC vaccine via subcutaneous injections bi-weekly,totally 3-5 times.
88908756|NCT05881174|Active Comparator|Newly untreated diagnosed PTSD patients without medications|Newly untreated diagnosed PTSD patients who have not yet received any PTSD treatment for a 2-week therapy of acupuncture
88908757|NCT05881174|Active Comparator|Newly diagnosed PTSD patients on pharmacological therapy|Newly diagnosed PTSD patients on pharmacological therapy for a 2-week therapy of acupuncture
88908758|NCT05881174|Active Comparator|Newly diagnosed PTSD patients with or without medications with mild traumatic brain injury|Newly diagnosed PTSD patients with or without medications having mild traumatic brain injury for a 2-week therapy of acupuncture
88908759|NCT05880628||Any patient with aneurysmal or simple bone cyst who benefit a sclerotherapy by Discogel®|"Any patient with aneurysmal or simple bone cyst who benefit a sclerotherapy by Discogel® will be included.~Analysis datas of medical record."
88908760|NCT05880108|Experimental|Weight Loss|Participants will be asked to participate in a 1x/week center-based nutrition diet class, 2x/week center-based exercise classes, and 1x/week exercise session conducted on their own for 12 weeks.
88908761|NCT05880108|Active Comparator|Weight Stability|Participants will be asked to participate in a 1x/week center-based health education class, 2x/week center-based stretching/balance classes, and 1x/week stretching/balance session conducted on their own for 12 weeks.
88908762|NCT05878964||Group 1|All patients affected by solid tumors already in treatment with anti-PD1/PDL1 or cyclin-dependent kinase (CDK) inhibitors.
88908763|NCT05878964||Group 2|All patients affected by solid tumors already eligible for treatment with anti-PD1/PDL1 or cyclin-dependent kinase (CDK) inhibitors.
88908765|NCT05872867|Experimental|Dose escalation (Stage 1)|WM-A1-3389 administered intravenously, weekly for 21 days of each cycle
88908766|NCT05872867|Experimental|Dose escalation (Stage 2)|WM-A1-3389 administered intravenously, weekly for 21 days of each cycle Pembrolizumab 200 mg administered intravenously, every 3 weeks for 21 days of each cycle
88908767|NCT05872763||Retrospective cohort (Cohort 1)|All cases of unresectable stage IIIB/IIIC/IV NSCLC newly diagnosed between January 2020 and the date of the study initiation will be collected. All these participants will be followed up until death or lost-to-follow-up or until 12 months after the last participant is enrolled in cohort 2 in the study.
88908768|NCT05872763||Prospective cohort (Cohort 2)|The prospective enrollment of new cases of unresectable stage IIIB/IIIC/IV NSCLC will end up to 1 year after the first patient is enrolled (FPI) in Cohort 2.
88908769|NCT05871970|Experimental|TARA-002|TARA-002 is a lyophilized biological preparation for injection containing cells of Streptococcus pyogenes (Group A, type 3) Su strain treated with benzylpenicillin.
88908770|NCT05871268|Experimental|Physician Awareness|The physician will have access to the pre-visit Control Preference Scale survey results for women assigned to this group.
88908771|NCT05871268|Active Comparator|Usual Care|The physician will not have access to the pre-visit Control Preference Scale survey results for women assigned to this group.
89428065|NCT03460574|Experimental|INFORMATION|"Participants in this condition receive a manipulation suggesting that the performance test TEMINT, they previously worked on, has been shown to be highly relevant for daily life and professional success. We anticipated that after receiving this fake information about the TEMINT, it would be difficult for participants to engage in cognitive immunization processes because the validity and utility of the expectation-disconfirming experience is explicitly highlighted."
89428066|NCT03460574|Experimental|SALIENCE|Participants in this condition are asked to think about how well they performed on this really difficult performance test. We anticipated that this manipulation would enhance expectation change, as the salience of the expectation-disconfirming experience was explicitly increased.
89428067|NCT03460574|Experimental|ATTENTION|Before working on the performance test, participants in this conditions receive the instruction to attentionally focus on their personal result in the performance test. Further, they are asked to specify what would be personally good result for them. We anticipated that after receiving this instruction, the expectation-disconfirming performance feedback should be salient for the participants, hence making it difficult for them to engage in cognitive immunization strategies.
89428068|NCT03460574|Experimental|CONTROL|Participants in this condition receive no further information. Therefore, they are passing through the standard procedure of the previously developed experimental paradigm.
89428069|NCT00973284|Experimental|Norwalk VLP Vaccine 100 µg|Norwalk Virus-like Particle (VLP) Vaccine 100 µg, dry powder, intranasally using a delivery device with a puff of air, 50 µg in each nostril, on Days 0 and 21 in the Vaccination Stage. Norwalk Virus, 48 Reverse Transcription Polymerase Chain Reaction (RT-PCR) units, solution, orally, on Day 42 in the Challenge Stage.
89428070|NCT00973284|Placebo Comparator|Placebo|Norwalk VLP placebo-matching vaccine, dry powder, intranasally using a delivery device with a puff of air, 50 µg in each nostril, on Days 0 and 21 in the Vaccination Stage. Norwalk Virus, 48 RT-PCR units, solution, orally, on Day 42 in the Challenge Stage.
89428071|NCT03893162|Experimental|"Multi-strain probiotic BioKult"|4 capsules daily for 8 weeks
89428072|NCT03893162|Placebo Comparator|Placebo|4 capsules daily for 8 weeks
89428073|NCT02599402|Experimental|Combination therapy: Nivolumab + Ipilimumab|Nivolumab + Ipilimumab specified dose on specified days
89008171|NCT00249015|Experimental|1|Combined Aerobic and Resistance Exercise Program: perform three exercise sessions per week consisting of about 25-30 minutes of aerobic exercise at a moderate-to-vigorous intensity as well as some weight training consisting of two sets of 8-12 repetitions of 9-10 different exercises. For the aerobic exercise, participant can choose from different exercise equipment such as a treadmill or stationary bicycle.
89428074|NCT02599402|Experimental|Monotherapy: Nivolumab|Nivolumab specified dose on specified days
89428075|NCT00879762|Experimental|Group A: High Dose|Single high dose of IMVAMUNE® (5x10^8 TCID50, consisting of two 0.5 mL injections) vaccine on Day 0 and a single saline placebo dose (single 0.5 mL injection) on Day 28 to match the two dose regimen of Group B.
89428076|NCT00879762|Active Comparator|Group B: Standard Dose|Standard two dose regimen of IMVAMUNE® (1x10^8 TCID50) vaccine on Day 0 (consisting of 0.5 mL injection of vaccine and 0.5 mL injection of saline placebo) and Day 28 (single 0.5 mL injection of vaccine).
89008172|NCT00249015|Active Comparator|2|Moderate Aerobic Exercise Group: perform three exercise sessions per week consisting of about 25-30 minutes of aerobic exercise at a moderate-to-vigorous intensity. Again, participant can choose from different exercise equipment.
89428077|NCT03463538|Active Comparator|Arthroscopic capsular release|Surgical release performed under general anesthetic
89428078|NCT03463538|Active Comparator|Hydro-dilatation|injection of water under local anesthetic in to shoulder joint
89428079|NCT05212194|Other|Post spinal puncture headache|the patients who developed post spinal puncture headache
88908772|NCT05867173|Experimental|Intervention to assess CI|To develop new programming strategies for individuals that will improve performance for a wider range of cochlear implant people
88908773|NCT05864027|Experimental|Peer-led Oral Health Recovery educational group|
88908774|NCT05864027|Active Comparator|Educational Video|
88908775|NCT05863351|Active Comparator|Arm I (usual care)|Patients receive standard of care systemic therapy on study. Patients undergo CT or MRI throughout the trial.
88908776|NCT05863351|Experimental|Arm II (SAbR, usual care)|Patients undergo repeated SAbR until progression and then receive standard of care systemic therapy on study. Patients undergo CT or MRI throughout the trial.
88908777|NCT05859724|Placebo Comparator|Placebo|Placebo (for NM26-2198) for subcutaneous (SC) injection in healthy volunteers (HVs) on Day 1 (SAD Cohorts) and on Days 1, 8, 15, and 22 (MAD Cohorts)
88908778|NCT05859724|Experimental|NM26-2198|NM26-2198 10mg, 50mg, 150mg, 300mg, 400mg, 600mg, and 900mg for SC injection in HVs on Day 1 (SAD Part A); NM26-2198 150mg, 300mg, and 600mg for SC injection in patients with AD (MAD Part B); NM26-2198 150mg and 300mg for SC injection in HVs on Days 1, 8, 15, and 22 (MAD Part C)
88908779|NCT05859698|Experimental|Valbenazine|Valbenazine administered once daily for 24 weeks.
88908780|NCT05858879|Active Comparator|Notification with a CAC image|Notification of presence of CAC with a CT scan image
89428080|NCT03460496|Experimental|APN-led Intervention|"Intervention group being provided with the interventions described below.~Advanced practice nurses' interventions~Neonatologists: neonatal outpatient consultation~psychological support~lactation consultant~physiotherapeutic interventions~collaboration with social workers~music therapy~close collaboration with other health care professionals~interprofessional roundtable meetings"
89428081|NCT03460496|No Intervention|Control, Standard Care|Control group receiving standard care
89428082|NCT01101906|Experimental|Arm A: OSI-906|150 mg BID
89428083|NCT01101906|Placebo Comparator|Arm B: Placebo|Placebo BID
89428084|NCT04778384|Experimental|Intervention Group|30 patients receive micro-training based on a checklist & targeted discussion / dismantling of patient-related barriers based on the answers in the second part of the questionnaire (BQII Barriers Questionnaire)
89428085|NCT04778384|Sham Comparator|Control Group|30 patients receive a sham intervention: an unstructured conversation is carried out. Patient questions are answered correctly, but there is no training, rather patient information.
89428086|NCT00879606|Experimental|1|Participants will be randomized to receive ALT-836.
89428087|NCT00879606|Placebo Comparator|2|Patients will be randomized to receive placebo.
89428088|NCT04768166|Experimental|Evaluate the safety of Miglustat administration in subjects with Spastic Paraplegia 11|100 mg of Miglustat, 3 caps per day for first 4 weeks; 100 mg of Miglustat, 6 caps per day for 8 weeks
89428089|NCT04822090||Group I|HHA patients with acute symptomatic HPV-B19 infection
89428090|NCT04822090||Group II|HHA patients without acute symptomatic HPV-B19 infection
89428091|NCT00962832|Placebo Comparator|Part 1 - Placebo intravenously|Participants received placebo intravenously every 4 weeks for 24 weeks.
89428092|NCT00962832|Experimental|Part 1 - Rontalizumab 750 mg intravenously|Participants received rontalizumab 750 mg intravenously every 4 weeks for 24 weeks.
89428093|NCT00962832|Placebo Comparator|Part 2 - Placebo subcutaneously|Participants received placebo subcutaneously every 2 weeks for 24 weeks.
89197082|NCT05280262|Other|Group 1 Asymptomatic|"Group 1 - Prospective cohort of children and young adults enrolled at diagnosis and followed longitudinally~Patients will be evaluated at 5 time-points (Baseline - Follow Up 1-4 [FU1-4]) during therapy using a computer-based short age-appropriate neurocognitive test battery (CogState) and paired CSF samples taken at the time of routine scheduled lumbar punctures. In addition one saliva sample (or stored DNA from a remission bone marrow sample extracted during routine trial procedures) will be collected as a source of germline DNA and a clinical report form will be completed at study entry and at completion of the study. CSF samples will be collected at the time of the patient's scheduled therapeutic treatment with no additional sampling."
89428094|NCT00962832|Experimental|Part 2 - Rontalizumab 300 mg subcutaneously|Participants received rontalizumab 300 mg subcutaneously every 2 weeks for 24 weeks.
89428095|NCT00962832|Experimental|Part 3 - Rontalizumab 750 mg intravenously|Participants received rontalizumab 750 mg intravenously every 4 weeks for 120 weeks.
89428096|NCT03463382|Active Comparator|ESP Group|"Erector Spinae Plane Block Group~Block Drug: 0,25% bupivacaine 0,5ml/kg (max.20ml) were used for blocks"
89428097|NCT03463382|Active Comparator|QLB Group|"Quadratus Lumborum Block Group~Block Drug: 0,25% bupivacaine 0,5ml/kg (max.20ml) were used for blocks"
89428098|NCT04427566|Experimental|Radiation Arm|Each subject will receive a dose of whole lung radiation. A second optional dose of 80 cGy may be delivered if no improvement after 3-10 days.
89428099|NCT04452812|Experimental|Convalescent plasma|"Best available treatment + convalescent plasma~Best available treatment: hemodynamic support, oxygen supplementation, antibiotic therapy (if required), and individualized treatment judged by the attending physician.~Plasma will be split by aliquots of 200 ml for its storage on -60 celsius degrees until it's used. After defrosting, it will be administered on 2 200 ml separated doses on a 12 hours interval."
89428100|NCT04452812|Placebo Comparator|Best available treatment|"Best available treatment + Placebo (0.9% saline solution)~Best available treatment: hemodynamic support, oxygen supplementation, antibiotic therapy (if required), and individualized treatment judged by the attending physician.~Placebo will consist on 2 doses of 200 ml of 0.9% saline solution separated on a 12 hour interval."
89428101|NCT00879138|Placebo Comparator|Sugar pill|
89428102|NCT00879138|Experimental|VA106483 2 mg|
89428103|NCT00879138|Experimental|VA106483 4 mg|
89428104|NCT00879138|Experimental|VA106483 8 mg|
89428105|NCT04821700||Patients with Carotid stenosis|Ischemic stroke patients with atrial fibrillation and carotid stenosis
89428106|NCT04821700||Patients without Carotid stenosis|Ischemic stroke patients with atrial fibrillation without carotid stenosis
89428107|NCT04452734|Active Comparator|Control Group|
89428108|NCT04452734|Experimental|Study Group|
89428109|NCT00876798|Experimental|1|Lixivaptan
89428110|NCT00876798|Placebo Comparator|2|Placebo
89428111|NCT04814836|Other|Group I|Total-etch mode with 35% phosphoric acid
89428112|NCT04814836|Other|Group II|Selective-etch mode with 35% phosphoric acid
89428113|NCT04814836|Other|Group III|Total-etch mode with laser (Er,Cr:YSGG)
89428114|NCT04814836|Other|Group IV|Selective-etch mode with laser (Er,Cr:YSGG)
89428115|NCT04814836|Other|Group V|Self-etch mode
89428116|NCT03460418||Multiloc nail|Fracture treated with a Multiloc nail (patients treated between 2012 and 2017)
89428117|NCT03460418||Philos plate|Fracture treated with a Philos plate (patients treated between 2012 and 2017)
89428118|NCT03460418||arthroplasty|Fracture treated by arthroplasty (patients treated between 2012 and 2017)
89428119|NCT03460340|Experimental|FM group|patients diagnosed with Fibromyalgia receiving dTMS treatment.
89428120|NCT03460340|Sham Comparator|placebo group|patients diagnosed with Fibromyalgia receiving sham- treatment.
89428121|NCT03463226||Low testosterone|"Patients with HF and testosterone deficiency.~Cardiopulmonary exercise test~Muscle Sympathetic Nerve Activity~Dual-energy X-ray absorptiometry~Venous occlusion plethysmography~Blood sample collection~Dynamometers for Handgrip Strength"
89428122|NCT03463226||Normal testosterone|"Patients with HF and normal plasma levels of testosterone.~Cardiopulmonary exercise test~Muscle Sympathetic Nerve Activity~Dual-energy X-ray absorptiometry~Venous occlusion plethysmography~Blood sample collection~Dynamometers for Handgrip Strength"
89428123|NCT00875160|Experimental|AT2101|
88908781|NCT05858879|Active Comparator|Notification without a CAC image|Notification of presence of CAC without a CT scan image
88908782|NCT05858879|Placebo Comparator|Usual care|Usual care
89428124|NCT04814290||living liver donors|cases already underwent hepatectomy for living-donor liver transplantation.
89428125|NCT04814290||matched controls|healthy persons who attended the preoperative clinic while preparing for donation but were rejected because of an ABO blood group mismatch.
89428126|NCT00872430|Active Comparator|Placebo/Laxative tea crossover|This arm received placebo in the first period and laxative tea in the second period (after washout period of 9 days).
89428127|NCT00872430|Active Comparator|Laxative tea/Placebo crossover|This arm received laxative tea in the first intervention period and placebo in the second intervention period (after washout period of 9 days).
89428128|NCT05617222|Active Comparator|Bed rest- Control|One leg will be subjected to disuse by bed rest and will not receive further treatment during the bed rest period.
89428129|NCT05617222|Experimental|Bed rest + NMES|One leg will be subjected to disuse by bed rest and will in addition receive neuromuscular electrical stimulation of the quadriceps muscle 3 times/day.
89428130|NCT04821388|Experimental|intended to use Rontis DCB for treatment of lesions in the femoropopliteal arteries.|
89428131|NCT00872196|Other|1 - Follow-up Study|This is a follow-up study with no treatment and only samples being collected.
89428132|NCT04813978|No Intervention|Group B (control)|Head phone will be placed and music will not be played, will get normal nursing care
89428133|NCT04813978|Experimental|Group A (music intervention)|For the interventional group, in addition to normal nursing care, patients will listen to instrumental relaxing music genre consist of pitch, rhythm and tone color for 30 minutes pre-operatively, using mp3 player and over-ear headphones to reduce outside interference, at a volume of the patient's preference.
89428134|NCT00871182|Experimental|PT001 18 mcg|Inhaled PT001 18 mcg
89428135|NCT00871182|Experimental|PT001 36 mcg|Inhaled PT001 36 mcg
88908783|NCT05857527|Experimental|Soterix taVNS stimulation using EMG sensors|We will trial use of a new taVNS unit that uses automated EMG sensors to trigger stimulation and an optional Bluetooth manual trigger. This experimental device will be used to during CIMT rehabilitation treatment to pair stimulation with active movement.
88908784|NCT05856448|Experimental|GLPG3667 - Treatment A|Participant will receive a dose A of GLPG3667 capsules orally once daily (q.d.) for 48 weeks.
88908785|NCT05856448|Experimental|GLPG3667 - Treatment B|Participant will receive a dose B of GLPG3667 capsules orally (q.d.) for 48 weeks.
89428136|NCT00871182|Experimental|PT001 72 mcg|Inhaled PT001 72 mcg
89428137|NCT00871182|Experimental|PT001 144 mcg|Inhaled PT001 144 mcg
89428138|NCT00871182|Placebo Comparator|Inhaled Placebo|Inhaled Placebo
89428139|NCT00871182|Active Comparator|Tiotropium Handihaler|Tiotropium 18 mcg administered via Handihaler
89428140|NCT04821232|Experimental|interventional|"Students in the intervention group will be given a total of 120 minutes out of 40 minutes, and 24 sessions of yoga for 8 weeks, 3 days a week. The researcher who will make yoga with each student will be sent videos on the online platform, including a yoga introduction and a full yoga session with the students after a yoga session. The students were asked to do yoga 3 times a week in accordance with the video and the researcher will be called twice a week to get information about the process. Content of education;~Breath Awareness Training (10 minutes)~Asanas (20 minutes) I. Don't bend sideways in Mountain Pose ii. Warrior Pose iii. Bridge Pose iv. Happy Baby Pose~v. Fixed Butterfly / Angel Pose vi. Wide sitting in Angel Pose vii. Cat Pose Tiger Breath viii. Cow-downward dog, ix. Plank x. Cobra c. Mudra and meditation (10 minutes) will be practiced."
89428141|NCT04821232|Other|Control groups|No intervention will be applied to students in the control group.
89428142|NCT04814056|Experimental|Afatinib treatment group|This is an open-label, sing-arm phase IV clinical study
89428143|NCT04813744|Experimental|Investigation of atraumatic restorative treatment in adults with a high risk of caries|The study group included a total of 25 healthy individuals with high caries risk who had molar teeth in their mouth with 3-4 mm depth occlusal dentin caries. In the clinical study, the infected and demineralized dentin was cleaned manually with a sterile excavator. The dentin sample was taken from the last removable and affected dentin layer at the cavity floor by one excavation for microbiological assessment. The teeth were restored with a conventional glass ionomer cement. In the 6th month, restorations were removed by using low-speed round steel bur, and the dentin samples were removed with an excavator from the cavity floor to repeat the microbiological assessment. In the first week and 6th month of atraumatic restorative treatment, the impressions were taken from the restored teeth to prepare replicas. The replicas of the twenty teeth out of 25 were randomly selected to evaluate of marginal adaptation under scanning electron microscopy.
89428144|NCT05627310||Training Cohort|Nasopharyngeal endoscopic images collected from 8 hospitals all over China
89428145|NCT05627310||Validation Cohort|Nasopharyngeal endoscopic images collected from 8 hospitals all over China
88908786|NCT05856448|Placebo Comparator|Placebo|Participant will receive placebo matched to GLPG3667 capsules orally q.d for 48 weeks.
88908787|NCT05849441|Experimental|Online mindfulness intervention|Participants will have access to the intervention between pre-test and post-test assessments. The intervention, Aware Program, is an online mindfulness education program for adolescents with 22q11DS designed to enhance their coping skills and ability to manage stress and anxiety in healthy ways.
89428146|NCT05627310||Testing Cohort|Nasopharyngeal endoscopic images prospectively collected from 8 hospitals all over China
89428147|NCT05617144|Experimental|Treatment|
89428148|NCT05627154|Placebo Comparator|Placebo only|Participants randomised to the Placebo condition will be taking a lactose placebo capsule daily for 14 days.
89428149|NCT05627154|Experimental|Citalopram only|Participants randomised to the Citalopram only condition will be taking 20mg of citalopram in capsule form daily for 14 days.
89428150|NCT05627154|Experimental|Citalopram and Behavioural Activation|Participants randomised to the Citalopram only condition will be taking 20mg of citalopram in capsule form daily for 14 days. Over the two weeks of taking citalopram, they will also receive ~3h of behavioural activation therapy split into 3 sessions.
89428151|NCT04427176||Nurses|"Nursing staff working 8 or 12 hours a day for 2 consecutive days in a COVID unit at the hospital of Saint Etienne will be included.~They will be wear ARFC mask."
89428152|NCT04813666|Active Comparator|TB group|
89428153|NCT04813666|Placebo Comparator|Non TB group|
89428154|NCT04766346|Experimental|Nutritional Supplement|The NS is a fortified cow's milk-based product provided in powdered form.
89428155|NCT04813588|Experimental|Pantomimng|In experimental group pantomiming treatment will be administered
89428156|NCT04813588|Active Comparator|Easy onset|In active comparator group easy onset method will be administered
89428157|NCT05379816|No Intervention|conservative treatment|analgesics are used for PTPS
89428158|NCT05379816|Active Comparator|Interventional treatment|perineural injection
89428159|NCT05378022|Placebo Comparator|Control|"Control group receives the routine treatment and uses 0.9% NaCl physiological saline:~Routine treatment is as follows:~Oral administrative drugs: antipyretic paracetamol (Efferegant®); expectorant Carbocysteine (Carbothiol®); antiviral Oseltamivir phosphate (Tamiflu®); antibiotics e.g. cefotaxim (Goldcefo®), Amoxicillin / clavulanic acid (Augmentin®) based on the results of antibiotic susceptibility test.~Aerosol therapy: bronchodilator e.g. salbutamol (Ventolin ®️inhaler) or budesonide (Pulmicort ®️Respules)."
89428160|NCT05378022|Experimental|Navax|"Navax group receives the routine treatment and uses NaCl 0.9% plus B. subtilis and B. clausii at 5 billion CFU/5 mL (LiveSpo®️ Navax):~Routine treatment is as follows:~Oral administrative drugs: antipyretic paracetamol (Efferegant®); expectorant Carbocysteine (Carbothiol®); antiviral Oseltamivir phosphate (Tamiflu®); antibiotics e.g. cefotaxime (Goldcefo®), Amoxicillin / clavulanic acid (Augmentin®) based on the results of antibiotic susceptibility test.~- Aerosol therapy: bronchodilator e.g. salbutamol (Ventolin ®️inhaler) or budesonide (Pulmicort ®️Respules)."
89428161|NCT04820608|Experimental|Customized, transepithelial cross-linking|All study patients will be treated according to the customized remodeled vision protocol
89428162|NCT00957918|Experimental|Nicotine|Active drug is nicotine dihydrate bitartrate, provided as an oral capsule at escalating doses, 1 mg to 6 mg, once every 6 hours
89428163|NCT00957918|Placebo Comparator|placebo|Subjects in this arm receive placebo capsules orally
89428164|NCT04360720|No Intervention|Dual Antiplatelet Therapy|"Subjects randomized to Dual Antiplatelet Therapy Control Group will be treated with a regimen of acetylsalicylic acid combined with ticagrelor or prasugrel for 12 months.~Acetylsalicylic acid (100 mg/day) + ticagrelor (90 mg twice daily) Or Acetylsalicylic acid (100 mg/day) + prasugrel (10 mg once daily)"
89428165|NCT04360720|Experimental|Antiplatelet Monotherapy|"All subjects randomized to Monotherapy Group will have acetylsalicylic acid discontinued immediately after randomization.~Subjects randomized to Monotherapy Group will be treated with ticagrelor or prasugrel alone for 12 months.~Ticagrelor alone (90 mg twice daily) Or Prasugrel alone (10 mg once daily)"
89428166|NCT04474236||COVID-19 patients|Adult (> 18 years) with Proven COVID-19 (specific PCR from respiratory track sample)
88908788|NCT05849441|No Intervention|Wait-List Control|Participants will not have access to the online mindfulness intervention between the pre-test and post-test assessments. After completing the post-test questionnaires, participants in the wait-list control group will receive access to the online mindfulness intervention (Aware Program).
88908789|NCT05847673|Experimental|Arm I (EQQUAL A)|Participants receive self-guided online EQQUAL A program on study. Participants also receive motivational messages and smoking cessation information via text messages.
88908790|NCT05847673|Active Comparator|Arm II (EQQUAL B)|Participants receive self-guided online EQQUAL B program on study. Participants also receive motivational messages and smoking cessation information via text messages.
89428167|NCT02734862|Experimental|Group 1|"Subjects in the CD101 IV treatment group 1 (Part A Only - up to 30 mITT subjects) will receive CD101 IV 400 mg on Day 1 and Day 8, with an optional dose of 400 mg on Day 15 (for all subjects) and an optional dose of 400 mg on Day 22 (only for subjects with IC), if needed.~Daily intravenous placebo infusion when not administered CD101. Daily oral placebo as step down."
89428168|NCT02734862|Active Comparator|Group 3|"Subjects in the caspofungin group will receive IV caspofungin (a single 70 mg loading dose on Day 1 followed by 50 mg once daily) for ≥3 days up to a maximum of 21 days for subjects with candidemia only and up to a maximum of 28 days for subjects with IC (with or without candidemia).~After ≥3 days of IV therapy, subjects in the caspofungin group can be switched to oral step-down therapy of fluconazole (a loading dose of 800 mg [4 capsules] on the first day followed by 400 mg [2 capsules]/day thereafter). After switch to oral step down before Day 8, subjects in the caspofungin group will receive IV placebo on Day 8 to preserve the study blind."
88908794|NCT05841810|Experimental|Stage 1 mHealth Outreach|
88908795|NCT05841810|Experimental|Stage 2 mHealth Outreach|
88908796|NCT05841810|No Intervention|Stage 1 Standard of Care|
88908797|NCT05841810|No Intervention|Stage 2 Standard of Care|
88908798|NCT05841810|Experimental|Stage 2 mHealth Outreach + Care Coordination|
88908799|NCT05841628|Experimental|Port wine stain|The port wine stain will be treated with the DermaV laser. Within the single port wine stain, one area will be treated with standard settings (single pulse high fluence). Four other areas will be treated with multi-pulse low fluence settings. A sixth area will be an untreated control.
88908800|NCT05841615|Sham Comparator|PVI alone|Participants only experience PVI operations
88908801|NCT05841615|Experimental|PVI and RDN|Participants experience both PVI and RDN operations
88908802|NCT05841511|Experimental|Immediate treatment group|"The immediate treatment group will receive the intervention in the first time period, while the wait-list control group will receive the intervention program during the second time period. Baseline and outcome evaluation will be accessed at three-time points: baseline assessment (1st week), assessment 1-midway (5th week), and assessment 2-final (10th week) in this study.~To establish and develop an efficient program, several theories were implemented into the intervention design to address handwriting problems in children with ASD, including psycho-geometric theory, motor learning theory, and cognitive training theories. The intervention will be delivered in thirty-six activities for visual perceptual, fine motor, and visual motor integration skill training integrated with the unique properties of the Chinese writing system. A total of 12 hours of intervention program will be conducted in eight sessions within four weeks."
88908803|NCT05841511|Experimental|Wait-list control group|"The immediate treatment group will receive the intervention in the first time period, while the wait-list control group will receive the intervention program during the second time period. Baseline and outcome evaluation will be accessed at three-time points: baseline assessment (1st week), assessment 1-midway (5th week), and assessment 2-final (10th week) in this study.~To establish and develop an efficient program, several theories were implemented into the intervention design to address handwriting problems in children with ASD, including psycho-geometric theory, motor learning theory, and cognitive training theories. The intervention will be delivered in thirty-six activities for visual perceptual, fine motor, and visual motor integration skill training integrated with the unique properties of the Chinese writing system. A total of 12 hours of intervention program will be conducted in eight sessions within four weeks."
88908804|NCT05838599|Experimental|Topical IMQ and localized RT|After the initial study visit, patients will immediately begin use of imiquimod cream at designated lesions (those with combined size >50cm2) nightly for 5 consecutive days a week over 6 weeks. One week into the imiquimod treatment course, radiation therapy will be administered at Northwestern Medicine by radiation oncologists familiar with MF in 2 fractions of 4 Gy (total 8 Gy) over 2 days to the same designated lesions.
88908805|NCT05837260||Cohort 1|Patients with newly diagnosed iodine refractory thyroid cancer on surveillance
88908806|NCT05837260||Cohort 2|Patients with locally advanced and / or metastatic (Stage 3 & 4) medullary thyroid cancer
88908807|NCT05837260||Cohort 3|Patients with iodine refractory thyroid cancer or advanced/metastatic unresectable MTC due to commence systemic treatment or already on systemic treatment
88908808|NCT05837260||Cohort 4|Patients with newly diagnosed anaplastic thyroid cancer
88908809|NCT05837247|Experimental|Game-based telerehabilitation exercises|The telemonitoring-supported program will be conducted with a smartphone application synchronously. The participants will be monitored by the investigators using an online communication application during exercise sessions.
88908810|NCT05837169|Experimental|Intervention group|The MBSR program will be offered through the Zoom platform. It consists of a total of 8 weekly sessions, with an approximate duration of 2 hours per session. During these sessions, patients will be instructed in exercises to promote mindfulness, including body awareness (body scan), gentle yoga exercises, and meditation. Additionally, a digital manual will be delivered with exercises that can be done at home, 8 audios with guided exercises and a video with balance and flexibility postures. Patients will be instructed to practice mindfulness exercises at least twice a day, lasting approximately 20 min per exercise, to cultivate the incorporation of meditation into their daily lives.
88908811|NCT05837169|No Intervention|Wait-list control group|
88908812|NCT05836987|Experimental|AFSW Guided DOAC|All participants randomized to the experimental arm will be provided with an AFSW that will be linked to the participants Apple watch and the secure REACT-AF app within the Eureka cloud. The AFSW will intermittently and passively assess for rhythm irregularities consistent with AF and notify the wearer and coordinating center if a threshold AF event has occurred.
88908813|NCT05836987|Active Comparator|Continuous DOAC therapy|All participants randomized to the control arm will remain on previously prescribed FDA-approved DOAC regimen as indicated by current practice standards. These participants will continuously take DOAC through the course of the study as prescribed by the participants primary physician unless otherwise contraindicated. Participants in the control arm will also use the REACT-AF mobile app within the Eureka platform via Apple watch for study follow-up activities, but the participants will not receive an AFSW and any personally owned Apple Watch will not be loaded with the customized REACT-AF detection algorithm nor participant notification apps.
88908814|NCT05836974|Experimental|Ex-utero cord blood collection|Ex-utero cord blood collection
89428169|NCT02734862|Experimental|Group 2|"Subjects in the CD101 IV treatment group 2 (Part B Only - up to 30 mITT subjects) will receive CD101 IV 400 mg on Day 1 and Day 8, with an optional dose of 200 mg on Day 15 (for all subjects) and an optional dose of 200 mg on Day 22 (only for subjects with IC), if needed.~Daily intravenous placebo infusion when not administered CD101. Daily oral placebo as step down."
89428170|NCT00818844|Experimental|Nepafenac|Nepafenac 0.1% dosed topically TID for 3 months after Epiretinal Membrane (ERM) Surgery
89428171|NCT00818844|Placebo Comparator|BSS|BSS dosed topically TID for 3 months after Epiretinal Membrane (ERM) Surgery
89428172|NCT00862524|Experimental|ARRY-334543 + gemcitabine|
88908815|NCT05836974|Active Comparator|In-utero cord blood collection|In-utero cord blood collection
89428173|NCT03460262|Active Comparator|Standard dressing-Cutiplast®|
89428174|NCT03460262|Experimental|Negative pressure wound therapy-PICO®|
89428175|NCT04427644||Complication positive|Patients with perioeprative complications after laparascopic sleeve gastrectomy before discharge (wound complications, thromboembolic events, staple line leakage, splenic infarction proven by imaging modalities, bleeding detected due to low hemoglobin and hematocrit values during follow-up, acute renal failure due to deterioration in biochemical parameters)
89428176|NCT04427644||Complication negative|Patients without perioeprative complications after laparascopic sleeve gastrectomy before discharge
89428177|NCT04427644||BMI 40 - 45 kg/m2|Operated patients preoperative BMI values between 40 - 45 kg/m2
89428178|NCT04427644||BMI 45 - 50 kg/m2|Operated patients preoperative BMI values between 45 - 50 kg/m2
89428179|NCT04427644||BMI over 50 kg/m2|Operated patients preoperative BMI values 45 - 50 kg/m2
89428180|NCT04427644||Clavien Dindo Major Complications|"Any deviation from the normal postoperative course without the need for pharmacological treatment or surgical, endoscopic and radiological interventions Acceptable therapeutic regimens are: drugs as antiemetics, antipyretics, analgesics, diuretics and electrolytes and physiotherapy This grade also includes wound infections opened at the bedside~Requiring pharmacological treatment with drugs other than such allowed for grade I complications. Blood transfusions, antibiotics and total parenteral nutrition are also included"
89428181|NCT04427644||Clavien Dindo Minor Complciations|3. Requiring surgical, endoscopic or radiological intervention 3a Intervention under regional/local anaesthesia 3b Intervention under general anaesthesia 4. Life-threatening complication requiring intensive care/intensive care unit management 4a Single-organ dysfunction 4b Multi-organ dysfunction 5. Patient demise
89428182|NCT00858702|Experimental|1|olmesartan medoxomil tablets and a CCB tablet (of the dihydropyridine class), once daily for 8 weeks
89428183|NCT00858702|Experimental|2|olmesartan medoxomil and a diuretic tablet (of the thiazide class)
89428184|NCT03460184||G.A Group A|Group A: n= 30 Parturiant patients will receive general anesthesia. General anesthesia will be conducted After pre-oxygenation for 3-5 minutes. 5% thiopental (5 mg/kg) will be administered intravenously over 30s, followed by succinylcholine 1.5 mg/kg. After tracheal intubation, the patients will be ventilated with 100% oxygen. isoflurane 0.8% will be added, to maintain the anesthesia. Further neuromuscular block will be maintained by using atracurium as needed. After delivery of the fetus, fentanyl IV will be given 1ug/kg as analgesia and 20 IU oxytocin will be given by intravenous infusion .Reverse neuromuscular blockade as necessary at completion of surgery. Extubate when the patient is awake, the anesthesia is adequately reversed, and the patient is following commands
89428185|NCT03460184||Spinal A Group B|"Group B: n= 30 Parturiant patients will receive spinal anesthesia. In the sitting position and after complete aseptic precaution are taken, 2-3 ml of Lidocaine will be injected subcutaneously, spinal anesthesia will be performed at interspace L3-4 or L4-5, either via midline or paramedian approaches using 22 guage Quinke needle with the bevel directed laterally. 2.5 ml of hyperbaric bupivacaine 0.5% in addition to 25 μg fentanyl (0.5 ml) will be injected into the subarachnoid space after successful dural puncture and confirmation by barbotage.~The patient will be put flat in the supine position with left uterine displacement using wedge under the right loin and the surgeon will be allowed to sterilize and wrap the field after confirmation of the solidity of the block its level.~All patiens will be observed for cardiac complications in the form of non-fatal MI, arrhythmias and sudden cardiac death until discharged after at least 72h."
89428186|NCT04427332||Covid19 infection related patients|"All subjects that had access to the nasopharyngeal swabs service of the hospital for the detection of the Sars-CoV-2 virus, both hospitalized and discharged from the hospital and not hospitalized, from mid-May to the end of June 2020, will be consecutively enrolled. It is assumed that 500 people will be recruited."
88908816|NCT05836584|Experimental|Arm A (chemotherapy, atezolizumab)|"NEOADJUVANT THERAPY: Patients receive physician's choice of chemotherapy regimen consisting of FLOT or mFOLFOX or CAPOX in addition to atezolizumab IV on study.~SURGERY: Patients undergo surgery with lymphadenectomy on study.~ADJUVANT THERAPY: Patients receive FLOT, mFOLFOX, or CAPOX and atezolizumab IV as in neoadjuvant therapy and then receive atezolizumab IV alone.~Patients also undergo CT or MRI throughout the trial. Patients may optionally undergo PET/CT and/or collection of blood samples throughout the trial. Patients may also undergo ECHO throughout the trial as clinically indicated."
88908817|NCT05836584|Experimental|Arm B (atezolizumab)|"NEOADJUVANT THERAPY: Patients receive atezolizumab IV on study.~SURGERY: Patients undergo surgery with lymphadenectomy on study.~ADJUVANT THERAPY: Patients receive atezolizumab IV on study.~Patients also undergo CT or MRI throughout the trial. Patients may optionally undergo PET/CT and/or collection of blood samples throughout the trial. Patients may also undergo ECHO throughout the trial as clinically indicated."
88908818|NCT05836129|Experimental|TM Group|The intervention used for this group is instruction in the Transcendental Meditation practice. It is a four day course of instruction with 1.5 hours of instruction over four consecutive days, followed by an additional 1.5 hours of instruction ten days later.
88908819|NCT05836129|Active Comparator|Active Control Group|This group will be offered an online stress reduction course consisting of two 20-60 minute classes for the first month of the trial.
88908820|NCT05835687|Experimental|Arm A (relapsed/refractory CNS tumors)|Patients with B7-H3-positive relapsed/refractory non-brainstem primary CNS tumors.
88908821|NCT05835687|Experimental|Arm B (brainstem high-grade neoplasms)|Patients with high-grade neoplasms
89428187|NCT04735172|Experimental|de novo PD patients|"Patients will be included:~suffering from idiopathic Parkinson's disease according to UKPDSBB criteria (Gibb & Lees, 1988; Hughes et al., 1992),~the stage of the disease is I-II according to the Hoehn and Yahr scale,~which do not receive dopaminergic treatment,~duration of disease development: 5 years,~without major cognitive impairment (Moca > 24)~men or women aged 18 to 75,~having understood and signed the informed consent form,~members of a social security scheme."
89428188|NCT04735172|Experimental|control subjects|"subjects male or female aged 18 -75 years~subjects affiliated to a social security scheme.~volunteers who have given their written consent. They will be matched to de novo PD patients according to age, sex and level of education."
89428189|NCT00817986|Experimental|Arbaclofen placarbil 20 mg|Arbaclofen placarbil 20 mg, BID, for 14 days including the taper period.
89428190|NCT00817986|Placebo Comparator|Placebo for Arbaclofen placarbil|Placebo for 14 days
89428191|NCT00817986|Experimental|Arbaclofen placarbil 30 mg|Arbaclofen placarbil 30 mg, BID, for 14 days including the taper period.
89428192|NCT00817986|Experimental|Arbaclofen placarbil 40 mg|Arbaclofen placarbil 40 mg, BID, for 14 days including the taper period.
89428193|NCT04188080|Experimental|Jarlsberg cheese starting dose|The participants obtaining an Osteocalcin increase > 10% during the previous 6 weeks intake of Jarlsberg cheese, will get a percent reduction in the daily cheese-dose equal to the increase in the Osteocalcin level
89428194|NCT02598934|Experimental|Ibandronate Group 1|Participants will receive a 6-month regimen with oral ibandronate, 150 mg once monthly. Group 1 will receive a physician consultation after 4 months of treatment to review bone turnover test results.
89428195|NCT02598934|Experimental|Ibandronate Group 2|Participants will receive a 6-month regimen with oral ibandronate, 150 mg once monthly. Group 2 will not receive a physician consultation.
89428196|NCT00817362|Experimental|IPI-504 and Trastuzumab|"IPI-504 IV infusion 300 mg/m2 once weekly in combination with trastuzumab infusion every 3 weeks. (Continuous schedule)~Three week cycle with IPI-504 twice per week for 2 weeks and trastuzumab once per cycle followed by one week without treatment.~Trastuzumab IV infusion 8 mg/kg as the first dose of trastuzumab, followed by trastuzumab 6 mg/kg every 3 weeks. Subjects whose last dose of trastuzumab was <4 weeks prior to study entry will receive 6 mg/kg as the first dose of trastuzumab. For all additional cycles in Stage 1, trastuzumab will be administered with the first dose of IPI-504.~IPI-504 and trastuzumab will be administered for all cycles. Until progression or unacceptable toxicity develops."
89428197|NCT04176848|Experimental|CFI-400945 + Durvalumab|
89428198|NCT00945672|Experimental|PF-04360365 10 mg/kg|
89428199|NCT00945672|Experimental|PF-04360365 7.5 mg/kg|
89428200|NCT00945672|Placebo Comparator|placebo|
89428201|NCT04163978|Experimental|Nitric oxide releasing solution (NOSi)|DailyTopical sinus irrigation delivery of 240mL NOSi
89428202|NCT04163978|Active Comparator|Budesonide -saline|Daily Topical sinus irrigation delivery of 240 mL of 1 mg Budesonide-saline
89428203|NCT00811902|Experimental|Nerispirdine 50mg|Nerispirdine 50mg once daily for 14 weeks
89428204|NCT00811902|Experimental|Nerispirdine 100mg|Nerispirdine 100mg once daily for 14 weeks
89428205|NCT00811902|Experimental|Nerispirdine 200mg|Nerispirdine 200mg once daily for 14 weeks
89428206|NCT00811902|Placebo Comparator|Placebo|Placebo for Nerispirdine once daily for 14 weeks
89428207|NCT02598622|Experimental|Acetyl-L-Carnitine only|The first 15 subjects participating in this study will receive Acetyl-L-Carnitine and pharmacokinetic testing will be done.
89428208|NCT02598622|Experimental|Acetyl-L-Carnitine or Placebo|Subjects 16-30 will be randomized to receive drug or placebo.
89428209|NCT03460028|Experimental|Yoga Condition|Participants randomized to the Yoga Condition will participate in a specialized yoga intervention.
89428210|NCT03460028|No Intervention|Wait-List Control Condition|Participants randomized to the Wait-List Control Condition will participate in a specialized yoga intervention once the Yoga Condition has completed their assigned intervention.
88908822|NCT05835284||Single Arm|Enrolled subjects will receive a non-diagnostic CT scan on the pre-market, investigational Edge-on Silicon Photon Counting CT device.
89428211|NCT03463070|Active Comparator|preoperative misoprostol group|70 women who received 600 mg misoprostol rectally preoperatively before cesarean section
89428212|NCT03463070|Active Comparator|postoperative misoprostol group|70 women who received 600 mg misoprostol postoperatively at operating theatre after cesarean section
89428213|NCT00809562|Experimental|1|
88908823|NCT05831839|Other|Cognitive training 1|Randomized wait-list controlled pilot trial
88908824|NCT05831839|Other|Cognitive training 2|Randomized wait-list controlled pilot trial
89428214|NCT00809562|Placebo Comparator|2|
89428215|NCT00807612|Experimental|Part 1 Cohort 1|AMG 479 at 18 mg/kg in combination with paclitaxel/carboplatin for 4 to 6 cycles followed by AMG 479 at 18 mg/kg monotherapy for 24 months from study day 1
89428216|NCT00807612|Experimental|Part 1 Cohort 2|AMG 479 at 12 mg/kg in combination with paclitaxel/carboplatin for 4 to 6 cycles followed by AMG 479 at 12 mg/kg monotherapy for 24 months from study day 1
89428217|NCT00807612|Experimental|Part 2|"AMG 479 in combination with paclitaxel/carboplatin for 4 to 6 cycles followed by AMG 479 monotherapy for 24 months from study day 1~(AMG 479 dose in Part 2 will be the final AMG 479 dose from Part 1)"
89428218|NCT03462992||FIT-positive individuals|Patients being positive to an FIT test performed in the context of the Flemish (Northern Belgium) colorectal cancer screening campaign. These patients are male and female between 56 and 74 years old.
89428219|NCT00805818|Experimental|NNZ-2566|20 mg/kg intravenous bolus infusion over 10 minutes followed by a continuous intravenous infusion of 1 mg/kg/h (Cohort 1, n=20), 3 mg/kg/h (Cohort 2, n=20) or 6 mg/kg/h (Cohort 3, n=133) intravenous infusion for a total of 72 consecutive hours.
88908825|NCT05830305|Active Comparator|Mobile health intervention|Subjects will enter their home BP measurements into a mobile stroke App (WeRISE) daily, and the study team will regularly review the BP measurements through a backend system. A protocol-based intervention via phone calls, which includes anti-hypertensive drug adjustment and reinforcement of lifestyle modification, will be implemented.
88908826|NCT05830305|No Intervention|Usual care|Subjects will have their hypertension managed by their respective treating physicians.
88908827|NCT05827055|Experimental|Proglumide TID with Gemcitabine and Nab-Paclitaxel|Proglumide given three times a day with gemcitabine and nab-paclitaxel
89428220|NCT00805818|Placebo Comparator|Sodium Chloride (0.9%) for Injection|Intravenous bolus infusion over 10 minutes followed by a continuous intravenous infusion (Cohort 1, n=10), (Cohort 2, n=10) or (Cohort 3, n=67) intravenous infusion for a total of 72 consecutive hours.
89428221|NCT04566068|Experimental|Intervention- Adapted Virtual Insomnia Program|4 sessions (approximately 45 min/each, weekly) plus 3 check-ins (approximately 15 min/each, between-sessions) delivered virtually. Sessions are modeled after a published, evidence-based CBT-I protocol and adapted to target needs and preferences identified by cancer survivors. Interventionists will participate in weekly supervision. Approximately half of participants will be asked to wear sleep trackers for one-week prior to starting the intervention (T0) and one-week after completing the intervention (T1).
89428222|NCT04566068|Placebo Comparator|Control- Enhanced usual care|Enhanced usual care. Referral to the Massachusetts General Hospital Behavioral Sleep Medicine service plus an educational handout on the topic of sleep hygiene.
89428223|NCT00805350|Experimental|Eplivanserin|Eplivanserin 5 mg/day
89428224|NCT00805350|Placebo Comparator|Placebo|Placebo of Eplivanserin 5 mg/day
89428225|NCT04549298||Patients with grade 2 and 3 LV diastolic dysfunction|Patients with high filling pressure
89428226|NCT04549298||Patients with normal and grade 1 LV diastolic dysfunction|Patients with normal filling pressure
89428227|NCT00801060|Experimental|Treatment Group A|"FCR + Lumiliximab (L)~L (Lumiliximab): Day 2 50 mg/m2, Day 4 450 mg/m2, for the first week, then single doses of 500 mg/m2 every four weeks, for 21 weeks.~F (Fludarabine): 25 mg/m2 daily, every four weeks for 21 weeks~C (Cyclophosphamide): 250 mg/m2 daily, every four weeks for 21 weeks~R: (Rituximab): Day 1 50 mg/m2, Day 3 325 mg/m2, for the first week, then single doses of 500 mg/m2 every four weeks, for 21 weeks"
89428228|NCT00801060|Active Comparator|Treatment Group B|"FCR~F (Fludarabine): 25 mg/m2 daily, every four weeks for 21 weeks~C (Cyclophosphamide): 250 mg/m2 daily, every four weeks for 21 weeks~R: (Rituximab): Day 1 50 mg/m2, Day 3 325 mg/m2, for the first week, then single doses of 500 mg/m2 every four weeks, for 21 weeks"
89428229|NCT03462836|Experimental|IV ketamine/lidocaine/IV PCA (MA) group|In addition to basic anesthetic methods, multimodal analgesia with IV ketamine, lidocaine and IV PCA apply
89428230|NCT03462836|Active Comparator|IV PCA only (CA) group|In addition to basic anesthetic methods, only IC PCA apply for pain control
89428231|NCT00849576|Active Comparator|Regular Human Insulin|Single Injection
89428232|NCT00849576|Active Comparator|Inuslin Lispro (90%)|Single Injection
89428233|NCT00849576|Experimental|Insulin VIAject™ (75%)|Single Injection
89428234|NCT00849576|Experimental|Insulin VIAject™ (90%)|Single injection
89428235|NCT02521922|Experimental|VSP Study Participants|Vital Signs Patch system study participants. Each study participant will receive the VSP System - NEHB Configuration and then the VSP System - PAL Configuration. Vital signs will be taken and adhesive will be assessed for each participant for each configuration.
89428236|NCT00842088|Experimental|Active|
89428237|NCT00842088|Placebo Comparator|Placebo|
89428238|NCT03457688|Active Comparator|prebiotic inulin-type fructans|
89428239|NCT03457688|Placebo Comparator|placebo maltodextrin|
89428240|NCT03462602|Experimental|NGT group|NGT group
89428241|NCT03462602|Experimental|non-NGT group|non-NGT group
89428242|NCT00841698|Experimental|Paroxetine|Paroxetine HCl 40 mg Tablet (test) dosed in first period followed by Paxil® 40 mg Tablet (reference) dosed in second period
89428243|NCT00841698|Active Comparator|Paxil®|Paxil 40 mg Tablet (reference) dosed in first period followed by Paroxetine HCl 40 mg Tablet (test) dosed in second period
89428244|NCT03457610|Experimental|Speech and language intervention|
89428245|NCT04383002|No Intervention|Standard of Care (control)|Patients will receive standard of care therapy
89428246|NCT04383002|Experimental|Inhaled Nitric Oxide|
89428247|NCT00841542|Experimental|Amlodipine Besylate|Amlodipine Besylate 10 mg tablet (test) dosed in first period followed by Norvasc® 10 mg tablet (reference) dosed in second period
89428248|NCT00841542|Active Comparator|Norvasc®|Norvasc® 10 mg tablet (reference) dosed in first period followed by Amlodipine Besylate 10 mg tablet (test) dosed in second period
89428249|NCT03462524||Neoadjuvant chemotherapy|
89428250|NCT03462524||Neoadjuvant chemoradiation|
88908828|NCT05827055|Experimental|Placebo TID with Gemcitabine and Nab-Paclitaxel|Placebo given three times a day with gemcitabine and nab-paclitaxel
88908829|NCT05822791||ECG-Detected AF|Patients with atrial fibrillation detected on 12-lead ECGs done post-stroke
88908830|NCT05822791||Device-Detected AF|Patients with atrial fibrillation detected on prolonged Holter monitoring lasting at least 7 days.
88908831|NCT05822583|Experimental|active treatment group|Active treatment group (IV abatacept infusion, 10 mg/kg up to 1750 mg) + baseline IM
88908832|NCT05822583|Placebo Comparator|Control group|Placebo group (IV infusion of normal saline) + baseline IM
88908833|NCT05822544|Experimental|Oral Solution|Oral solution of TLC-6740
88908834|NCT05822544|Placebo Comparator|Placebo|Oral dose of TLC-6740 placebo-to-match
88908835|NCT05822544|Experimental|Tablet|Tablet formulation of TLC-6740
88908836|NCT05822544|Experimental|Drug Metabolizing Enzyme|Oral dose of omeprazole, voriconazole, or itraconazole
88908837|NCT05821426|Experimental|eTrieve PE Kit|
88908838|NCT05820646|Experimental|Patients with necrotic mandibular premolars will be treated with boswellia sacra|25-45 years old patients with necrotic single rooted mandibular premolar with single canal with periapical lesion will be treated with boswellia sacra as an intracanal medicament for 3 days
89428251|NCT03623750|Experimental|EGFR-TK Inhibitor plus EGF-PTI|Elegile patients will receive a single pre-treatment low dose of intravenous cyclophosphamide 200mg/m2 before experimental treatment starts. Daily oral therapy with afatinib according to the SmPC of the product in nominal treatment cycles of 21 days followed by immunisation with EGF-PTI.
88908839|NCT05820646|Experimental|Patient with necrotic mandibular premolar will be treated with boswellia sacra|25-45 years old patients with necrotic single rooted mandibular premolar with single canal with periapical lesion will be treated with boswellia sacra as an intracanal medicament for 7 days
88908840|NCT05820646|Active Comparator|Patients with necrotic mandibular premolar will be treated with calcium hydroxide|25-45 years old patients with necrotic single rooted mandibular premolar with single canal with periapical lesion will be treated with calcium hydroxide as an intracanal medicament for 7 days
88908841|NCT05819944||Pathway 1- Diagnostic case control study undertaken in a secondary care population|evaluates whether the technology can distinguish between people with asthma and healthy volunteers, and other respiratory conditions in a well characterised secondary care population;
88908842|NCT05819944||Pathway 2- Prospective diagnostic study undertaken in a primary care population|assesses whether the technology can accurately diagnose asthma (either independently or alongside current diagnostic tests) in a primary care population of patients where there is a clinical suspicion of asthma;
88908843|NCT05819944||Pathway 3- A phenotypic characterisation study undertaken in participants with confirmed asthma|explores the ability of the technology to identify clinically important phenotypic characteristics which are difficult to measure in primary care and/or significantly impact on patient management and treatment;
88908844|NCT05819866|Active Comparator|Leriglitazone|Leriglitazone Treatment
88908845|NCT05819866|Placebo Comparator|Placebo|Placebo
88908846|NCT05819541|Experimental|High-dose oral montelukast plus standard treatment|Escalating dose-levels of oral montelukast between 2 mg/kg and 3 mg/kg determined by pharmacokinetic-guided dose modeling, added to standard, guideline-based treatment (systemic corticosteroid, inhaled albuterol, and possible treatment adjuncts such as IV magnesium, determined by evidence-based asthma clinical practice guideline).
88908847|NCT05819541|Placebo Comparator|Identical placebo plus standard treatment|Guideline-based treatment (systemic corticosteroid, inhaled albuterol, and possible treatment adjuncts such as IV magnesium, determined by evidence-based asthma clinical practice guideline).
88908848|NCT05817058|Experimental|Treatment of escalating doses of AFM28|AFM28 first in human starting dose will be 25 mg i.v.
88908849|NCT05817045|Active Comparator|Active|"RD-X19 Active Device~Investigational device that uses safe electromagnetic energy to target the oropharynx."
88908850|NCT05817045|Sham Comparator|Sham|"RD-X19 Sham Device~Investigational device that uses safe electromagnetic energy to target the oropharynx but at energy levels with a lower inactivation potential against SARS-CoV2 in vitro."
88908851|NCT05816707|Other|Control|extraction socket .
88908852|NCT05816707|Active Comparator|PRF Group|extraction socket and PRF
88908853|NCT05816707|Active Comparator|Curcuma Longa Group|Extraction Socket and Curcuma Longa
88908854|NCT05811897|Experimental|Self-Managed Online Treatment|Participants manage their treatment online without the assistance of a therapist.
88908855|NCT05811897|Active Comparator|Therapist-Assisted Online Treatment|Participant will be assisted through the process by a therapist who will provide support and encouragement for 15-20 minutes of contact per week for the duration of the treatment. Supportive contacts are not psychotherapy. They are intended to answer questions about the content of the platform, to review adherence to the exercises and to provide encouragement; they also allow for the rapid identification and referral of participants in case of need (e.g., suicidal crisis).
88908856|NCT05809752|Experimental|Dendritic Cell (DC) Vaccine dose escalation|HER2/3 peptide-pulsed DC1 will be administered intrathecally (IT) weekly for 6 doses /cycle for a maximum of two cycles, and then re-staged. If there are sufficient DC1s this may be continued weekly thereafter. There are 1 safety cohort (1 million DCV cells) and 3 escalating doses (2 million, 10 million and 50 million DCV cells) possible.
88908857|NCT05809531|Experimental|Pegcetacoplan administered subcutaneously|Pegcetacoplan administered subcutaneously twice weekly according to protocol defined dosing regimen
88908858|NCT05807581|No Intervention|Biomarkers|
88908859|NCT05807581|Active Comparator|physical activity|
88908860|NCT05807581|No Intervention|sedentary|
88908861|NCT05807581|Active Comparator|iTBS active|
88908862|NCT05807581|Sham Comparator|iTBS sham|
88908863|NCT05807412|Experimental|Experimental half|Each subject will be randomized to have either their right forehead or left forehead treated with 4 units or 0.1 cc of prabotulinumtoxinA 2.5 cm above the orbital rim.
88908864|NCT05807412|Active Comparator|Comparator half|Each subject will be randomized to have either their right forehead or left forehead treated with 4 units or 0.1 cc of onabotulinumtoxinA 2.5 cm above the orbital rim.
88908865|NCT05805176|Experimental|ADHD Therapy|
88908866|NCT05803421|Experimental|Orforglipron|Participants will receive escalated doses of orforglipron orally.
88908867|NCT05803421|Active Comparator|Insulin Glargine|Participants will receive insulin glargine subcutaneously (SC). Doses will be individualized and titrated according to a treat-to-target algorithm.
88908868|NCT05803382|Experimental|Treatment (ZEN003694, capecitabine)|Patients receive ZEN003694 PO QD and capecitabine PO BID 2 weeks on, 1 week off during each treatment cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT or MRI, PET/CT, and collection of blood samples throughout the trial. Patients may also undergo biopsies during screening and while on the study.
89428252|NCT00840840|Experimental|1|
89428253|NCT00840840|Active Comparator|2|
89428254|NCT03595982|Experimental|Procardia XL 30 mg|Procardia XL 30 mg XL Q 12h - When a patient's BP is persistently elevated after a dose of 30 mg of Procardia XL, the dose is increased to 60 mg Procardia XL divided in 2 doses of 30 mg given 12h apart.
89428255|NCT03595982|Active Comparator|Procardia XL 60 mg|Procardia XL 60 mg Q 24h - When a patient's BP is persistently elevated after a dose of 30 mg of Procardia XL, the dose is increased to 60 mg Procardia given once a day.
89428256|NCT00944970|Other|binodenoson then adenosine|binodenoson (experimental); adenosine (active comparator)
89428257|NCT00944970|Other|adenosine then binodenoson|adenosine (active comparator); binodenoson (experimental)
89428258|NCT00944970|Active Comparator|adenosine then adenosine|
89428259|NCT03456206||"Diet, Cancer and Health cohort"|"Participants from the Diet, Cancer and Health (DCH) cohort with no CID diagnosis at entry to the DCH study. The number of persons developing a CID (defined as at least one of the mentioned CIDs) during follow up (1993/1997 - 2018) and the number of persons not developing a CID will be investigated.~Based on the participants reporting of dietary habits in the Food Frequency Questionnaire (FFQ) from the DCH study, the exposure intake of red and processed meat and fibres will be investigated in both CID cases and non-cases.~Other exposure variables are Lifestyle factors independently or combined and are also obtained from the data in the DCH cohort."
89428260|NCT00840216|Experimental|1|
89428261|NCT00840216|Active Comparator|2|
89428262|NCT03462446||Treatment group with Rivaroxaban|Patients treated with Rivaroxaban
89428263|NCT03462446||Control group with VKAs|Patients treated with VKAs. This control group will be subsequently divided based on the TTR value in the last 6 months (below 65% and above 65%).
89428264|NCT03455816|Experimental|Group that uses the Social Diabetes App (research group)|This group use the App Social diabetes with the glucometer Glucomen Areo to monitoring the glucemia during 6 month
89428265|NCT03455816|Active Comparator|Usual clinical monitoring group (control group)|This group does not use the App. This group have an intermediate visit at 3 months with de doctor to see blood glucose self-monitoring and propose adjustments
89428266|NCT00944892|Experimental|Dose 1|
89428267|NCT00944892|Experimental|Dose 2|
89428268|NCT00944892|Experimental|Dose 3|
89428269|NCT00944892|Placebo Comparator|Placebo|
89428270|NCT00939276|Experimental|NEVANAC|One drop instilled in the study eye 3 times daily (morning, midafternoon, and bedtime) beginning the day before surgery, continuing on the day of surgery and through the first 90 days following surgery
89428271|NCT00939276|Placebo Comparator|Nepafenac Vehicle|One drop instilled in the study eye 3 times daily (morning, midafternoon, and bedtime) beginning the day before surgery, continuing on the day of surgery and through the first 90 days following surgery
89428272|NCT03455660||Pre-January 2015|Patients who underwent cesarean delivery between February 2013 and December 2014.
89428273|NCT03455660||Post-January 2016|Patients who underwent cesarean delivery between February 2016 and December 2017.
89428274|NCT03449186||Pregnancy group|Women, who were in their second trimester (weeks 16-24) or third trimester (weeks 25-34)selected for the study. Saliva and GCF samples were collected and clinical periodontal measurements were made gently
89428275|NCT03449186||Postpartum group|Postpartum women 6 months after giving birth recalled. Saliva and GCF samples were collected and clinical periodontal measurements were made.
89428276|NCT00838890|Active Comparator|Cdc7-inhibitor (A)|
89428277|NCT00838890|Active Comparator|Cdc7-inhibitor (B)|
89428278|NCT03455426|Experimental|letrozole group|letrozole 5mg/day starting from day 3 of menstrual cycle for 5 days
89428279|NCT03455426|No Intervention|natural cycle group|
89428280|NCT00794586|Experimental|FTI 80mg/20mg BID|Fosfomycin/Tobramycin combination 80mg/20 mg inhaled twice daily
88908869|NCT05802264|Experimental|Part A Healthy Volunteer|Subjects will be assigned to one of six planned dose cohorts and receive single doses of ABCI (0.5mg, 1.0mg, 2.0mg, 4.0mg, 6.0mg, 10.0mg). In each cohort, six subjects will receive ABCI and 2 will receive placebo
88908870|NCT05802264|Experimental|Part B Healthy Volunteer|Subjects will be assigned to one of three planned dose cohorts and receive a loading dose and multiple ascending doses of ABCI (loading dose 1.5mg/0.5mg daily, loading dose 6.0mg/2.0 daily, loading dose 10.0mg/4.0mg daily). In each cohort, six subjects will receive ABCI and 2 will receive placebo.
89008173|NCT00249015|Experimental|3|High Aerobic Exercise Group: perform three exercise sessions per week consisting of about 45-60 minutes of aerobic exercise at a moderate-to-vigorous intensity. Again, participant can choose from different exercise equipment.
89008174|NCT04602247|Experimental|SIC|100 mg sodium iron chlorophyllin (SIC) containing 6 mg 57 Fe.
89428281|NCT00794586|Experimental|FTI 160mg/40mg BID|Fosfomycin/Tobramycin combination 160 mg/40 mg inhaled twice daily
89428282|NCT00794586|Placebo Comparator|Placebo A BID|Placebo A inhaled twice daily
89008175|NCT04602247|Experimental|SIC + AA combined|100 mg sodium iron chlorophyllin (SIC) containing 6 mg 57 Fe given with 40 mg Ascorbic Acid
89428283|NCT00794586|Placebo Comparator|Placebo B BID|Placebo B inhaled twice daily
89428284|NCT00794430|Experimental|V3381|V3381: titrated from 100 mg bid to maximum 400 mg bid over 4 weeks followed by maintenance phase at highest tolerated dose. Total duration of treatment 13 weeks.
89428285|NCT00794430|Placebo Comparator|Placebo|Placebo to match V3381, 100 mg, given according to the same regimen.
89428286|NCT00791154|Active Comparator|ARM B|Blinded AMG 102 study drug and carboplatin or cisplatin and etoposide
89428287|NCT00791154|Placebo Comparator|ARM C|Blinded placebo and carboplatin or cisplatin and etoposide
89428288|NCT00791154|Active Comparator|ARM A|Blinded AMG 479 study drug and carboplatin or cisplatin and etoposide
89428289|NCT00938652|Active Comparator|Arm G/C|gemcitabine/carboplatin on Days 1 and 8 of 21-day cycle(s)
89428290|NCT00938652|Experimental|Arm G/C/I|gemcitabine/carboplatin on Days 1 and 8, plus iniparib on Days 1, 4, 8, and 11 of 21-day cycle(s)
89428291|NCT03550352|Experimental|1) THC and CBD combined|TN-TC11M2 oral capsules (THC 2.5 mg / CBD 2.5 mg)
89428292|NCT03550352|Experimental|2) CBD alone|TN-C200M2 oral capsules (CBD 200 mg)
89008176|NCT04602247|Active Comparator|FeSO4|6mg of FeSO4 given as 4 mg 56Fe and 2mg 58Fe
89008177|NCT04602247|Active Comparator|FeSO4 + AA combined|6mg of FeSO4 given as 4 mg 56Fe and 2mg 58Fe along with 40 mg Ascorbic Acid
89428293|NCT04266158|Active Comparator|MyoPro 2 Motion-G-orthosis-None|Following screening, all subjects receive 2 education sessions, during which they are trained on the donning and use of the MyoPro 2 Motion-G, Comfy Splint orthosis, and no device, all on the affected UE. The presentation and training on these interventions is non-randomized and administered to all subjects. After these training sessions, all subjects complete a battery of three tests while wearing one of the two devices, or no device. The order in which the tests are administered is randomized.
89428294|NCT04266158|Active Comparator|Comfy Splint|Following screening, all subjects receive 2 education sessions, during which they are trained on the donning and use of the MyoPro 2 Motion-G, Comfy Splint orthosis, and no device, all on the affected UE. The presentation and training on these interventions is non-randomized and administered to all subjects. After these training sessions, all subjects complete a battery of three tests while wearing one of the two devices, or no device. The order in which the tests are administered is randomized.
89536865|NCT03308201|Experimental|Hemay022 and Exemestane|"Part one: Hemay022 in combination with exemestane will be taken orally once daily. Planned dose escalation of Hemay022 will be 200mg, 300mg,400mg or 500mg daily for 28 days.~Part two: Hemay022 in combination with exemestane will be taken in OTR dose until disease progression, intolerable toxicity or death."
89008178|NCT04602247|Experimental|EP + FeSO4 combined|100 mg of Chlorophyllin without the Magnesium central atom along with 6 mg FeSO4 as 54 Fe
89008179|NCT04602247|Experimental|EP + FeSO4 + AA combined|100 mg of Chlorophyllin without the Magnesium central atom along with 6 mg FeSO4 as 54 Fe along with 40 mg of Ascorbic Acid
88908871|NCT05802264|Experimental|Part C People with Cystic Fibrosis|Subjects will be assigned to one of two planned dose cohorts of ABCI (loading dose 6.0mg/2.0mg daily, loading dose 10.0mg/4.0mg daily) for a total of 28 days of open-label study drug administration. Up to 20 subjects with CF, including 2 sentinels subjects not on cystic fibrosis transmembrane conductance regulator (CFTR) modulators will be enrolled. The 2 sentinel subjects will receive the medium dose/regimen. If the medium dose/regimen is tolerated, the remaining subjects with CF will receive the high dose/regimen of ABCI and may be either on CFTR modulators or not on CFTR modulators.
88908872|NCT05800821||Patients with reduced cerebrovascular reserve|
88908873|NCT05800821||Patients with sufficient cerebrovascular reserve|
88908874|NCT05799703|Active Comparator|Group (A)|will receive RES in addition to the traditional exercise program.
88908875|NCT05799703|Active Comparator|Group (B)|will receive KT in addition to the traditional exercise program.
89197083|NCT05280262|Other|Group 2 Symptomatic|"Group 2 - Children and young adults with Stroke-like syndrome/PRES and /or seizures (SPS)~Following a diagnosis of SPS, patients and their families can be approached for informed consent to enter this study within 4 weeks following SPS event. If consent is obtained, patients will be evaluated at up to 7 timepoints, or until end of treatment, using a computer-based short age-appropriate neurocognitive test battery (CogState) and paired CSF samples taken at the time of routine scheduled lumbar punctures. Follow up visit 2 will take place at 12 months, with Follow up 3-7 [FU3-7] scheduled at 6 monthly timepoints. CSF samples will be collected at the time of the patient's scheduled therapeutic treatment with no additional sampling."
89536180|NCT03074799|Experimental|Symptom -based Screening(Child Contacts)|In the intervention clinics, decisions regarding IPT will be made on a clinical basis. If the child is symptomatic, they will be referred to the hospital for further evaluation of TB disease including both chest X-ray and testing of either sputum or swallowed sputum. If the child is asymptomatic, the TB nurse at the local clinic will initiate them on weight-appropriate dosing of IPT. Children will be followed at least monthly for the duration of the six month course of isoniazid, as is standard of care in South Africa at this time. Clinical outcome data will be obtained from patient records and implementation of a contact register aimed at improving longitudinal care of children on isoniazid preventive therapy.
89197084|NCT02547753||Transplanted group|patients who are kidney receptors for at least 6 months and need tooth extraction
89197085|NCT02547753||Control group|healthy patients who need tooth extraction
89536181|NCT03199027|No Intervention|Clinic-based Care|Clinic-based care is the current Standard-of-Care whereby newly initiated ART patients attend the ART clinic.
89536182|NCT03199027|Experimental|Adherence Club Care|Adherence club care involves referral to community-based ART services in the form of Adherence clubs, which are led by community health workers and supported by ART clinic nurses.
89536183|NCT02482649|Experimental|EAA/T|EAA/TEquine-Assisted Activities and Therapy) bi-weekly for 12eeks
89536184|NCT02482649|Active Comparator|Drugs|Methylphenidate or Atomoxetine
89197086|NCT04013386|Active Comparator|Aprepitant/Dexamethasone Group|
89197087|NCT04013386|Active Comparator|Mertazepine /Dexamethasone Group|
89197088|NCT04013386|Active Comparator|Dexamethasone Group|
88908876|NCT05798130||Oxygen Extraction Rate < 30% Group|Oxygen Extraction Rate < 30%
88908877|NCT05798130||Oxygen Extraction Rate ≥ 30% Group|Oxygen Extraction Rate ≥ 30%
89197089|NCT02567084|Other|"CERAMENT™ |BONE VOID FILLER"|"Intraoperativ application of medical device: CERAMENT™ |BONE VOID FILLER 5cc/10cc/18cc"
89197090|NCT00940420|Experimental|A|
89197091|NCT00940420|Experimental|B|
89197092|NCT00845169|Experimental|Diesel Exposure|1 hour exposure to diesel exhaust at 300 µg/m3 during intermittent exercise
89197093|NCT00845169|Experimental|Air Exposure|1 hour exposure to filtered air during intermittent exercise
89197094|NCT00842907|Active Comparator|oral isotretinoin|Twelve subjects will be treated with oral isotretinoin 20.0 mg, once a day, every other day, for 24 weeks.
89197095|NCT00842907|Active Comparator|tretinoin|Twelve patients will be treated with 0,05% tretinoin cream applied on face and forearms at night and moisturizer broad-spectrum sunscreen twice a day.
89197096|NCT05181488|Experimental|IORT group|Intraoperative radiation therapy of 10 Gy delivered during surgery followed by adjuvant gemcitabine chemotherapy
89197097|NCT05180396||Cases with the diagnosis of Heart Failure (Acute and Chronic)|Application of a questionnaire consisting of different questions to patients.
89197098|NCT04013074|Experimental|TIPS+Standard Medical Treatment|TIPS along with standard medical therapy only included as per requirement nutritional therapy (high calorie intake- 2400 Kcal/ day) as and when required LVP and albumin infusion and diuretics.
89536185|NCT03198637|Experimental|Monitoring|Neuromuscular Blockade's monitoring
89536186|NCT03198637|Active Comparator|Clinical assessment|No active monitoring of cisatracurium
88908878|NCT05798026|Experimental|EU103: Dose Escalation Cohort|Participants with advanced solid tumors will receive EU103 intravenously once every 3 weeks (3 weeks = 1 cycle) with escalating doses starting from 1 milligrams per kilogram (mg/kg) for each cohort and increasing to 3, 6, 12 or 24 mg/kg until disease progression, unacceptable toxicities or death, withdrawal of consent, end of study, or physician's decision, whichever occurs first.
89197099|NCT04013074|Active Comparator|Standard Medical Treatment|standard medical therapy only included as per requirement nutritional therapy (high calorie intake- 2400 Kcal/ day) as and when required LVP and albumin infusion and diuretics.
89197100|NCT00620373|Experimental|Mammography and Molecular Breast Imaging|Participants underwent conventional mammography and molecular breast imaging after a 740-millibecquerel (mBQ) (20-mCi) Technetium (99mTc) sestamibi injection.
89197101|NCT02567318|Experimental|MRI-scan|All study participants will complete a MRI-scan of the brain
89197102|NCT03360292|Experimental|Higher target range|Infants will be targeted to 92-97% oxygen saturation
89197103|NCT03360292|No Intervention|Standard target range|Infants will be targeted to 90-95% oxygen saturation, which is the range used as routine in the Neonatal Unit involved in the study
89197104|NCT00940654||Patients with fever|
89197105|NCT00940654||Patients without any fever|
89197106|NCT00845247|Placebo Comparator|Control|Control group patients will receive usual medical plus usual supportive treatment.
89197107|NCT00845247|Active Comparator|Case management|Intervention group patients are offered the support of a nurse case manager throughout their course of treatment.
88908879|NCT05798026|Experimental|EU103: Dose Escalation Cohort 1|1 mg/kg
88908880|NCT05798026|Experimental|EU103: Dose Escalation Cohort 2|3 mg/kg
88908881|NCT05798026|Experimental|EU103: Dose Escalation Cohort 3|6 mg/kg
88908882|NCT05798026|Experimental|EU103: Dose Escalation Cohort 4|12 mg/kg
88908883|NCT05798026|Experimental|EU103: Dose Escalation Cohort 5|24 mg/kg
88908884|NCT05798026|Other|Backfill cohort|Additional subjects can be registered at doses confirmed to be safety
88908885|NCT05796375|Active Comparator|Frequent Cystoscopy|Cystoscopy is conducted at 6, 12, 18, and 24 months for patients undergoing surveillance for low grade intermediate-risk non-muscle invasive bladder cancer
89008180|NCT04601896||Live patients admitted for Refractory Cardiac Arrest with ECMO|
89008181|NCT04601896||Live patients quality of life admitted for Refractory Cardiac Arrest without ECMO|
89428295|NCT04266158|Active Comparator|No Splint|Following screening, all subjects receive 2 education sessions, during which they are trained on the donning and use of the MyoPro 2 Motion-G, Comfy Splint orthosis, and no device, all on the affected UE. The presentation and training on these interventions is non-randomized and administered to all subjects. After these training sessions, all subjects complete a battery of three tests while wearing one of the two devices, or no device. The order in which the tests are administered is randomized.
89428296|NCT00928590|Experimental|DuoTrav APS|Travoprost/Timolol Maleate Fixed Combination solution, 1 drop in the study eye(s) once daily, at 9 AM, for 12 months
89428297|NCT03512756|Experimental|Part 1 and Part 2 SM-88 Arm|"(Part 1 enrollment complete) SM-88 used with MPS (methoxsalen, phenytoin and sirolimus)~(Part 2 actively enrolling) SM-88 (920 mg per day) used with MPS (methoxsalen, phenytoin and sirolimus) will be administered to 125 evaluable subjects until unacceptable toxicity, disease progression, or any of the treatment discontinuation criteria are met."
89428298|NCT03512756|Experimental|Physician's Choice|Physician's Choice therapy will be administered for a total of 125 evaluable subjects until unacceptable toxicity, disease progression, or any of the treatment discontinuation criteria are met.
89428299|NCT03453398|Experimental|Group 1|Shifts over 24-hours, shift cycle of 5 days (morning, afternoon, night, night off, rest).
89428300|NCT03453398|Experimental|Group 2|Shifts over 24-hours, shift cycle of 10 days (morning, morning, afternoon, afternoon, rest, night, night, night off, rest, rest).
89428301|NCT03453398|Active Comparator|Group 3|Only diurnal shifts, shift cycle of 5 days (morning, afternoon, morning, afternoon, morning, rest, rest).
89428302|NCT00836706|Experimental|Clarithromycin (test)|Clarithromycin 500 mg Tablet (test) dosed in first period followed by Biaxin® 500 mg Tablet (reference) dosed in second period
89428303|NCT00836706|Active Comparator|Biaxin®|Biaxin® 500 mg Tablet (reference) dosed in first period followed by Clarithromycin 500 mg Tablet (test) dosed in second period
89428304|NCT00836472|Experimental|Glyburide Metformin|Glyburide Metformin 5/500 mg Film-Coated Tablet (test) dosed in first period followed by Glucovance® 5/500 mg Tablet (reference) dosed in second period
89428305|NCT00836472|Active Comparator|Glucovance®|Glucovance® 5/500 mg Tablet (reference) dosed in first period followed by Glyburide Metformin 5/500 mg Film-Coated Tablet (test) dosed in second period
89428306|NCT03452462|Experimental|Direct His Bundle Pacing|Pacing from the His bundle lead
89428307|NCT03452462|Active Comparator|Biventricular Pacing|Pacing from the right ventricular and coronary sinus leads
89428308|NCT03451760|Experimental|Feru-guard|Over a 12 week period participants will take two 280 mg hard gel capsules of Feru-guard 100M per day (1 capsule am, 1 capsule pm). One capsule will be taken in the morning with a meal and one capsule will be taken in the afternoon with a meal. Each capsule contains 180.32 mg ferulic acid and 20.02 mg of Angelica archangelica. Total daily dose will be 560mg of Feru-guard 100M, with 360.64 mg of ferulic acid and 40.04 mg of Angelica archangelica.
89428309|NCT03451760|Placebo Comparator|Placebo|Over a 12 week period participants will take two 280 mg hard gel capsules of a placebo per day (1 capsule am, 1 capsule pm). One capsule will be taken in the morning with a meal and one capsule will be taken in the afternoon with a meal.Total daily dosage will be 560mg of a maltodextrin, calcium stearate, and vanilla food flavor mixture.
89428310|NCT03134664|Experimental|Experimental group|Patients with femoral neck fractures are randomly assigned to undergo femoral head replacement via the SuperPATH approach in the experimental group.
89428311|NCT03134664|Experimental|Control group|Patients with femoral neck fractures are randomly assigned to undergo femoral head replacement via the conventional posterior approach in the control group.
89428312|NCT04184336||Persons of all ages|Persons of all ages admitted between January 1, 2016 and December 31, 2022 with a positive result of Neisseria meningitidis isolated or detected by PCR from a normal sterile site, such as blood, CSF, joint fluid, pleural, peritoneal, pericardial fluid or tissue biopsy
89428313|NCT04473846|Experimental|PF group|The first group will undergo general anesthesia using Fentanyl and Propofol.
89428314|NCT04473846|Experimental|PFK group|The second group will receive a mixture that consists of Fentanyl, Propofol, and Ketamine. In addition, Lidocaine will be added to reduce the pain on injection caused by Propofol.
89428315|NCT03448874|Experimental|Seal-G MIST System|Seal-G MIST System is a surgical sealant that will be applied adjunctively to standard closure techniques for reinforcement and protection of gastrointestinal anastomoses.
89428316|NCT03448874|No Intervention|Standard of care|Patients in the control arm will receive the standard of care [SOC] for colorectal resection surgery with primary anastomosis (no additional intervention)
88908886|NCT05796375|Experimental|Xpert Urine Test|Xpert arm includes urine testing using the Xpert Bladder Cancer Monitor urine test at 6 and 18 months. Cystoscopy is conducted at 12 and 24 months for patients undergoing surveillance for low grade intermediate-risk non-muscle invasive bladder cancer
88908887|NCT05796375|Experimental|EpiCheck Urine Text|EpiCheck arm includes urine testing using the Bladder EpiCheck urine test at 6 and 18 months. Cystoscopy is conducted at 12 and 24 months for patients undergoing surveillance for low grade intermediate-risk non-muscle invasive bladder cancer.
88908888|NCT05794828|Experimental|Erector Spinae Plane Block (ESP) administration|Patients with the listed diagnoses will be offered and then consented for an ESPB under ultrasound guidance.
89428317|NCT05381532|Experimental|Chronic variable sleep deficiency - follicular phase|This will be the first of four arms of controlled sleep manipulation. Participants randomized to this arm will be studied on a chronic variable sleep deficiency schedule during the follicular phase of their menstrual cycle. The exact sleep schedule is not provided in order to keep participants blinded to sleep conditions.
89536866|NCT03308201|Experimental|Hemay022 and Letrozole|Part two: Hemay022 in combination with letrozole will be taken in OTR dose until disease progression, intolerable toxicity or death.
88908889|NCT05791617||Cases (Ischemic stroke)|Left and right middle cerebral artery ischemic stroke Patients presenting with acute onset focal neurological deficits and DWI-MRI evidence of an acute brain infarct of the left or right middle cerebral artery ischemic stroke.
88908890|NCT05791617||Controls (TIA)|Patients with acute focal neurological symptoms without brain infarct on MRI. Patients presenting with acute onset focal neurological deficits presumed to be of vascular origin, WITHOUT DWI-MRI evidence of an acute brain infarct.
89428318|NCT05381532|Experimental|Chronic variable sleep deficiency - luteal phase|This will be the second of four arms of controlled sleep manipulation. Participants randomized to this arm will be studied on a chronic variable sleep deficiency schedule during the luteal phase of their menstrual cycle. The exact sleep schedule is not provided in order to keep participants blinded to sleep conditions.
89428319|NCT05381532|Experimental|Control sleep - follicular phase|This will be the third of four arms of controlled sleep manipulation. Participants randomized to this arm will be studied on a control sleep schedule during the follicular phase of their menstrual cycle. The exact sleep schedule is not provided in order to keep participants blinded to sleep conditions.
89428320|NCT05381532|Experimental|Control sleep - luteal phase|This will be the fourth of four arms of controlled sleep manipulation. Participants randomized to this arm will be studied on a control sleep schedule during the luteal phase of their menstrual cycle. The exact sleep schedule is not provided in order to keep participants blinded to sleep conditions.
89428321|NCT03129698|Other|Formerly Arm Label|Apatinib 250mg daily
89428322|NCT04473456|No Intervention|Serial arm|In the serial group, all colonoscopies will be performed by the same endoscopist. EGDs are performed by the attending endoscopist on the day of the procedure.
89428323|NCT04473456|Active Comparator|Simultaneous arm|In the simultaneous group, all colonoscopies will be performed by the same endoscopist. EGDs are performed by the attending endoscopist on the day of the procedure.
89428324|NCT03263078|Experimental|TIVA with Propofol in free flap surgery|Total intravenous anesthesia(TIVA) with Propofol
89428325|NCT03263078|Active Comparator|Sevoflurane in free flap surgery|Inhalation anesthesia with Sevoflurane
89428326|NCT05349006|Experimental|Azathioprine|"Azathioprine, dose related to weight (100 mg for <50 kg, 150 mg 50-100 kg, 200 mg for >100 kg), oral, daily~Associated to oral corticosteroid, prednisone : 40 mg per day during three months, and progressively tapered during three months until stop (- 30 mg during 15 days, 20mg during 15 days, 15 mg during 15 days, 10 mg during 15 days, 5 mg during 15 days and introduction of hydrocortisone 20 mg + Stop prednisone; hydrocortisone 20mg during 15 days, Stop hydrocortisone)"
89428327|NCT05349006|Placebo Comparator|Placebo|"Placebo, once a day, oral, number of caps related to weight~Associated to oral corticosteroid: prednisone 40 mg per day during three months and progressively tapered during three months until stop (- 30 mg during 15 days, 20mg during 15 days, 15 mg during 15 days, 10 mg during 15 days, 5 mg during 15 days and introduction of hydrocortisone 20 mg + Stop prednisone; hydrocortisone 20mg during 15 days, Stop hydrocortisone)"
89428328|NCT03450980|Other|EyeTurn App|All participants will have their eye alignment measured with both the experimental device (EyeTurn app) and the clinical gold standard tests or ground truth (simulated strabismus gaze angles).
88908891|NCT05789485|Experimental|90 min/wk|AT will consist of individualized walking delivered up to 7 times per week to achieve a cumulative total duration of: Arm 1: 90 min/wk. AT therapy within each arm will follow a non-linear (i.e., AT dose is continually altered and progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period) dosing schedule delivered during chemotherapy. Supervised AT will be monitored using TeleEx.
89428329|NCT01984502|Experimental|Radiation|CyberKnife Accelerated Hemilarynx Stereotactic Radiotherapy
89428330|NCT00785226|Experimental|RDEA119 with Sorafenib|Total daily doses of RDEA119 from 10 mg/day to 100 mg/day and sorafenib from 400 mg/day to 800 mg/day.
89428331|NCT05322278||Double-Embryo transfer in ICSI|
88908892|NCT05789485|Experimental|150 mins/wk|AT will consist of individualized walking delivered up to 7 times per week to achieve a cumulative total duration of: Arm 1: 90 min/wk. AT therapy within each arm will follow a non-linear (i.e., AT dose is continually altered and progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period) dosing schedule delivered during chemotherapy. Supervised AT will be monitored using TeleEx.
88908893|NCT05789485|Experimental|300 mins/wk|AT will consist of individualized walking delivered up to 7 times per week to achieve a cumulative total duration of: Arm 1: 90 min/wk. AT therapy within each arm will follow a non-linear (i.e., AT dose is continually altered and progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period) dosing schedule delivered during chemotherapy. Supervised AT will be monitored using TeleEx.
88908894|NCT05786209|Experimental|Whole-body Balm + Wash and Shampoo|Parent participant will be instructed to apply the whole-body balm on the newborn baby's whole body (excluding the mouth, eyes, diaper area, and scalp) two times per day (morning and evening), and to cleanse the newborn baby with the wash and shampoo at least once per week and no more than three times per week up to Day 28.
88908895|NCT05784272||Initiators|These will be the participants who initiate into phase IV cardiac reahb
89428332|NCT00920946|Placebo Comparator|Placebo|
89428333|NCT00920946|Experimental|Dimebon|
89428334|NCT04686422|Experimental|Tetric PowerFill Class I and II restorations|
89428335|NCT02598388|Experimental|Part 1 (US Participants)|Participants will receive MVA-BN-Filo or placebo on Day 1 followed by Ad26.ZEBOV or placebo on Day 15.
88908896|NCT05784272||Non-initiators|These will be the participants who do not initiate into phase IV cardiac reahb
88908897|NCT05779241|Experimental|LYN-005 Containing 15-mg Risperidone|During the run-in period (Day -7 to Day -1), participants receive Risperdal® (IR risperidone) daily. During the treatment period, participants receive 5 weekly doses of LYN-005 15 mg (Days 1, 8, 15, 22, and 29) and Risperdal 1 mg from Day 1 to Day 7.
89428336|NCT02598388|Experimental|Part 2 Group 1 (African Participants)|Participants will receive Ad26.ZEBOV or placebo on Day 1 followed by MVA-BN-Filo or placebo on Day 29.
89428337|NCT02598388|Experimental|Part 2 Group 2 (African Participants)|Participants will receive MVA-BN-Filo or placebo on Day 1 followed by Ad26.ZEBOV or placebo on Day 15.
89428338|NCT00836004|Experimental|Clindamycin (test)|Clindamycin 300 mg Capsule (test) dosed in first period followed by Cleocin® 300 mg Capsule (reference) dosed in second period
89428339|NCT00836004|Active Comparator|Cleocin® (reference)|Cleocin® 300 mg Capsule (reference) dosed in first period followed by Clindamycin 300 mg Capsule (test) dosed in second period
88908898|NCT05779241|Experimental|LYN-005 Containing 45-mg Risperidone|During the run-in period (Day -7 to Day -1), participants receive Risperdal® (IR risperidone) daily. During the treatment period participants receive 5 weekly doses of LYN-005 45 mg (Days 1, 8, 15, 22, and 29) and Risperdal 3 mg from Day 1 to Day 7.
89428340|NCT00917826|Experimental|Arginine Butyrate + Ganciclovir/Valganciclovir|
89428341|NCT03102320|Experimental|Cholangiocarcinoma|"Safety lead-in phase will determine the MTD of anetumab ravtansine administered in combination with cisplatin. Please note the study is no longer recruiting for the cholangiocarcinoma safety lead-in phase.~During the main study phase anetumab ravtansine will be administered at the determined MTD in combination with cisplatin. Please note the main study phase for cholangiocarcinoma will no longer be going ahead."
89428342|NCT03102320|Experimental|Adenocarcinoma of the pancreas|Safety lead-in phase will determine the MTD of anetumab ravtansine administered in combination with gemcitabine During the main study phase, anetumab ravtansine will be administered at the determined MTD in combination with gemcitabine
89428343|NCT03102320|Experimental|Other solid tumors|(Non-small cell adenocarcinoma of the lung (NSCLC adenocarcinoma), Adenocarcinoma of the breast - triple negative (TNBC), Gastric adenocarcinoma including gastroesophageal junction (GEJ Cancer, Thymic carcinoma) During the main study phase, anetumab ravtansine will be administered at dose of 6.5 mg/kg in solid tumors
89428344|NCT00835692|Experimental|Clarithromycin Tablets|Clarithromycin 500 mg Tablet (test) dosed in first period followed by Biaxin® 500 mg Tablet (reference) dosed in second period
89428345|NCT00835692|Active Comparator|Biaxin® Tablets|Biaxin® 500 mg Tablet (reference) dosed in first period followed by Clarithromycin 500 mg Tablet (test) dosed in second period
89428346|NCT00835614|Experimental|1|
89428347|NCT00835614|Active Comparator|2|
89428348|NCT04812886|Experimental|Epidemiological study|
89428349|NCT03448562|Experimental|Study Group|CPVI plus electrophysiologic substrate ablation in the left atrium during sinus rhythm (STABLE-SR)
89428350|NCT03448562|Active Comparator|Control Group|CPVI alone
89428351|NCT04819750|Active Comparator|MusicCare® device|The device is a touch tablet with a headset that allows noise reduction. The patient can choose the music they prefer. The selected U-shaped sequence uses the principles of hypnoanalgesia to accompany the patient into a state of deep relaxation.
89428352|NCT04819750|Placebo Comparator|Headphones with noise reduction|Headphones with noise reduction without music
89428353|NCT00835536|Experimental|1|
89008182|NCT04602130|Experimental|Massage|Massages were performed starting from the face, focused on the newborns forehead, and then around the eyes and cheeks with gentle touches. Then, newborns' chest area and the upper and lower extremities were massaged. Finally, newborns'were placed prone position and the back was massaged. Nurses recorded newborns' physiological measurements (pulse, respiration, oxygen saturation and body temperature) on the Newborn Follow-up Form.
89428354|NCT00835536|Active Comparator|2|
89428355|NCT05321966|Experimental|Visual Education Group|The intervention group watched three episodes of a training video a week for 12 weeks. Each session started 90 minutes after the HD treatment
89008183|NCT04602130|Experimental|Sponge Bathing|In the sponge bathing group, the newborns' eyes, faces (outward from the midline), around the ear and the back of the ear were wiped from the inside out with cotton wipes and dried. Then, the chest area and arms, abdomen and back, legs and feet, respectively, were wiped and dried. Finally, the genital area was cleaned, before diapering the newborn. Nurses recorded newborns' physiological measurements (pulse, respiration, oxygen saturation and body temperature) on the Newborn Follow-up Form
89008184|NCT04602130|Experimental|Tub bathing|In the tub bathing group, before being immersed in the tub, the newborns' faces and heads were cleaned outwards from the midline and dried. Then, the neck, chest, arms, back, legs and genital area were soaped, before the full body was rinsed and dried. Finally, umbilical cord care was performed, and the baby was diapered. Nurses recorded the newborns' physiological measurements (pulse, respiration, oxygen saturation and body temperature) on the Newborn Follow-up Form.
89428356|NCT05321966|No Intervention|no intervention|No intervention was made to the individuals in the control group.
89428357|NCT04812574|Experimental|Hypertonic Saline (10%) Injection|Periurethral hypertonic saline (10%) injection was performed in female patients with Stress Urinary Incontinence or Stress-Predominant Mixed Urinary Incontinence.
89428358|NCT05321732|Experimental|Intervention: DWP16001 A mg|
89428359|NCT05321732|Experimental|Intervention: DWC202010 B mg|
89428360|NCT05321732|Experimental|Intervention: DWP16001 A mg + DWC202010 B mg|
89428361|NCT04586556|Experimental|Artificial intelligence for real-time detection and monitoring of colorectal polyps|A standard colonoscopy will be performed according to the standard of routine care. All optically diagnosed polyps will be removed and sent to the CHUM pathology laboratory for histopathological evaluation according to institutional standards. The AI system will capture video of the procedure in real time, and provide additional information on the detection of polyps, follow-up and prediction of pathology. The full-length colonoscopy videos will be annotated for the exact time of the identification of the anatomical landmarks, polyps, also for polyp- and procedural-related characteristics.
89428362|NCT04819672|Experimental|Low Intensity Training associated with Partial Blood Flow|In the experimental group, a cuff with compression at 60% of the pressure required for total arterial occlusion will be placed, 16 treatment sessions in 8 weeks: warm-up, stretching of the lower limbs, strengthening of the quadriceps (knee extension and squat). The cuff with partial blood flow restriction will be used during knee extension and squat exercises.
89428363|NCT04819672|Sham Comparator|Low Intensity Training associated with Partial Blood Flow-Sham|In the sham group, the cuff will be placed, but there will be no arterial occlusion pressure, 16 treatment sessions in 8 weeks: warm-up, stretching of the lower limbs, strengthening of the quadriceps (knee extension and squat). The cuff without partial blood flow restriction will be used during knee extension and squat exercises.
89428364|NCT04819516|Experimental|HIFU with REGOTORI|
89536867|NCT03308201|Experimental|Hemay022 and Fulvestrant|Part two: Hemay022 in combination with fulvestrant will be taken in OTR dose until disease progression, intolerable toxicity or death.
89428365|NCT05321654|Experimental|Posture Education (PE) Group|PE group members received a 20-minute in-person one-on-one standardized educational session by a research team member in the laboratory on the following topics: health risks associated with forward head posture; postural guidelines for using mobile electronic devices, desktop computers, and laptop computers; as well as rest break guidelines. Participants were asked to adhere to the postural guidelines provided in the educational session for the next 4 weeks.
89428366|NCT05321654|Experimental|Self-Myofascial Release + Stretching (SMRS) Group|This group applied self-myofascial release (SMR) to their thoracic spine with a myofascial roller for 30 sec., then 6 repetitions of myofascial rolling for 90 sec. They applied SMR for 30 sec. to their neck flexors and extensors using their fingertips. They applied SMR to the upper trapezius and pectoralis for 30 sec using a soft tissue mobilization tool. For the first 2 weeks, they performed SMR 3x/wk. During wks. 3 and 4, they progressed SMR to 5 days/wk. Group members also performed stretching to these same muscles after SMR 3 days/wk for the first 2 weeks of the study, progressing to 5 days/wk during weeks 3 and 4.
89428367|NCT05321654|Experimental|Self-Myofascial Release + Stretching + Strengthening (SMRSS) Group|This group performed the same protocol as SMRS group, as well as include the following strengthening exercises: the supine chin tuck (SCT), upper thoracic-lower cervical extension (UTLCE) using an exercise band that provided 5.5 pounds of resistance, and a single-arm row with trunk rotation (SARTR) using exercise tubing that provided 20 pounds of resistance. The SCT was progressed in 3 phases: Week 1: chin tuck held 2 sec., 5 reps. Week 2: same as week 1, but included us of a towel roll placed under the head. Wks. 3 and 4: chin tuck with head lift 1 in., 2 sec. hold. UTLCE: neck extension with exercise band, held 2 sec. SARTR: single arm row with trunk rotation was performed in a controlled and fluid manner using a self-selected speed. The UTLCE and SARTR were performed with 1 X 10 reps for wks 1-2 and progressed to 2 X10 reps in wks 3-4. Strengthening exercises were performed 3x/wk. for 4 wks.
89428368|NCT05321654|No Intervention|Control Group (CG)|Participants in the CG did not receive an intervention.
88908899|NCT05776966|Experimental|Gender-specific digital intervention plus treatment as usual (GSDI+TAU)|GSDI + TAU includes the addition of a gender-specific digital intervention (GSDI) to treatment as usual. The GSDI has a web-based component and a mobile component. The web-based portion of the GSDI includes: (1) gender-specific psychoeducation on substance use disorders, (2) specific education on opioid use disorder, including information about medication treatment for opioid use disorder, and (3) information on relapse-prevention skills. Participants complete the web-based portion immediately after completing baseline assessments. The mobile component includes three parts: (1) weekly self-report surveys of opioid and other substance use and medication adherence, (2) weekly skills-practice exercises, and (3) daily motivational messages encouraging self-care. Participants engage with the mobile component after completing the web-based portion until the end of the study (12 weeks).
88908900|NCT05776966|Other|Treatment as usual (TAU)|TAU for opioid use disorder consists of a mix of medication treatment and individual and group therapy services across various levels of care: inpatient, residential, and outpatient. Residential treatment is for adults who have completed detoxification and require additional treatment in a structured environment. Inpatient treatment includes short-term care and detoxification treatment and incorporates a combination of group, family, and individual therapy targeted at medical stabilization, reducing the severity of the patient's symptoms, and providing resources and ongoing support to prevent relapse. Outpatient treatment is focused on comprehensive evaluation and stabilization.
88908901|NCT05776316|Experimental|IHRI|Integrated harm reduction intervention (IHRI) program tailored specifically for highly marginalized Black and Latinx people who use drugs (PWUDs). The IHRI lasts 8 weeks in duration, with the first 4 weeks consisting of weekly education lessons provided by the IHRI care coordinator. The subsequent 4 weeks will involve individualized identification of vulnerabilities in the social determinants of health (SDOH) for the purposes of making informed referrals to relevant partnering social service organizations. Participants will also be exposed to service encounters through mobile vans in which staff offer information to PWUD on syringe exchange, clean user kits, naloxone use, and fentanyl strip distribution.
88908902|NCT05776316|No Intervention|HR SAU|Harm reduction services as usual (HR SAU). Participants will be exposed to service encounters through the mobile vans in which staff offer information to PWUD on syringe exchange, clean user kits, naloxone use, and fentanyl strip distribution.
88908903|NCT05775406|Experimental|Phase 1 Dose Escalation Arm A in patients with R/R Solid Tumors and Lymphomas|KT-253 dosed intravenous (IV) once every three weeks in 21-day cycles
88908904|NCT05775406|Experimental|Phase 1 Dose Escalation Arm B in patients with R/R High Grade Myeloid Malignancies and ALL|KT-253 dosed IV once every three weeks in 21-day cycles
88908905|NCT05775289|Experimental|Arm A: Tobemstomig + Platinum-Based Chemotherapy|"Participants with non-squamous (NSQ) NSCLC will receive induction treatment with blinded tobemstomig in combination with pemetrexed and carboplatin, all on Day 1 every 3 weeks (Q3W) for four 21-day cycles, followed by Q3W maintenance therapy with blinded tobemstomig together with pemetrexed until disease progression or treatment discontinuation.~Participants with squamous (SQ) NSCLC will receive blinded tobemstomig in combination with paclitaxel and carboplatin, all on Day 1 Q3W for four 21 day cycles, followed by blinded tobemstomig (on Day 1) Q3W until disease progression or treatment discontinuation."
88908906|NCT05775289|Active Comparator|Arm B: Pembrolizumab + Platinum-Based Chemotherapy|"Participants with NSQ NSCLC will receive induction treatment with blinded pembrolizumab in combination with pemetrexed and carboplatin, all on Day 1 Q3W for four 21-day cycles, followed by a maintenance therapy with blinded pembrolizumab together with pemetrexed Q3W until disease progression or treatment discontinuation.~Participants with SQ NSCLC will receive blinded pembrolizumab in combination with paclitaxel and carboplatin, all on Day 1 Q3W for four 21-day cycles, followed by blinded pembrolizumab (on Day 1) Q3W until disease progression or treatment discontinuation."
88908907|NCT05775159|Experimental|Cohort 1A|Volrustomig monotherapy
88908908|NCT05775159|Experimental|Cohort 1B|Volrustomig combination with bevacizumab
88908909|NCT05775159|Experimental|Cohort 1C|Volrustomig combination with lenvatinib
88908910|NCT05775159|Experimental|Cohort 2A|Rilvegostomig combination with Gemcitabine and Cisplatin
88908911|NCT05775159|Experimental|Cohort 2B|Volrustomig combination with Gemcitabine and Cisplatin
88908912|NCT05775159|Experimental|Cohort 1D|Volrustomig combination with rilvegostomig and bevacizumab
88908913|NCT05775159|Experimental|Cohort 1E|Rilvegostomig combination with bevacizumab
88908914|NCT05775081|Experimental|Treated Dentine Matrix (TDM)|Participants treated with TDM paste
89428369|NCT04819984|Experimental|Continuous PtC02 evaluation|Continuous PtC02 measured by TCM5 monitor during ventilatory weaning test of 30 minutes when available
89428370|NCT04356664|No Intervention|Frozen embryo transfer with Hormonal Replacement Therapy (HRT)|Patient will received usual Hormonal Replacement Therapy for a Frozen embryo transfer composed of estrogens and progestins.
89428371|NCT04356664|Experimental|Frozen embryo transfer with HRT and GnRH agonist|Patient will received 1 or 2 injection of GnRH agonist priori to usual Hormonal Replacement Therapy for a Frozen embryo transfer composed of estrogens and progestins.
89428372|NCT04037072|Experimental|Mitomycin C|Cotton swab or strip of 2x2 cotton gauze soaked with 0.4mg/mL Mitomycin C
89428373|NCT04037072|Placebo Comparator|Control|Cotton swab or strip of 2x2 cotton gauze soaked with Normal saline
89008185|NCT04602130|No Intervention|Control|The newborns in the control group did not undergo any intervention other than standard clinical practices. All physiological measurements (pulse, respiration, oxygen saturation and body temperature) were performed by nurses and recorded on the Newborn Follow-up Form.
89428374|NCT05616988|Experimental|Experimental Group|The experimental group will consist of 20 patients with an indication for reconstruction using autologous tissues (DIEP, FALD) and 20 patients with an indication for reconstruction using the immediate prosthesis technique who will carry out the psychological-clinical intervention focusing on expressive writing about their experience of the surgical treatment.
89428375|NCT05616988|No Intervention|Control Group|The control group will consist of 20 patients with an indication for reconstruction using autologous tissues (DIEP, FALD) and 20 patients with an indication for reconstruction using the immediate prosthesis technique who will not undergo any kind of psychological-clinical intervention and will be able to apply for the latter at the end of the research.
88908915|NCT05775081|Experimental|Platelet Rich Fibrin (PRF)|Participants treated with PRF
89428376|NCT04549194|Experimental|Tyrosine - External Operation|1-month L-Tyrosine treatment following 4-month external operation
89428377|NCT04549194|Experimental|Placebo - External Operation|1-month Placebo treatment following 4-month external operation
89428378|NCT04549194|Experimental|Tyrosine - Rear Base|1-month L-Tyrosine treatment following 4 months at rear base
89428379|NCT04549194|Experimental|Placebo - Rear Base|1-month Placebo treatment following 4 months at rear base
89428380|NCT04819438|Experimental|Riluzole orodispersible film (Test)|The subjects will be treated with one orodispersible film containing 50 mg of riluzole in two out of the four study periods according to the randomisation sequence
88908916|NCT05774184|Active Comparator|Barzolvolimab (CDX-0159)|300 mg subcutaneous administration every 4 weeks through week 24
88908917|NCT05774184|Placebo Comparator|Placebo then barzolvolimab (CDX-0159) 300mg|Matching placebo subcutaneous administration every 4 weeks through week 16, then 300mg subcutaneous administration every 4 weeks through week 24
89428381|NCT04819438|Active Comparator|Rilutek® (Reference)|The subjects will be treated with one film-coated table containing 50 mg of riluzole in two out of the four study periods according to the randomisation sequence
89428382|NCT03448484|Experimental|Intervention|Intervention (agriculture-focused package + nutrition-sensitive and nutrition-specific interventions=integrated package)
89428383|NCT03448484|Other|Control|Control (agriculture-focused package)
89428384|NCT04542096||Group1|Patients receiving invasive respiratory therapy (intubated)
89428385|NCT04542096||Group2|Patients receiving non-invasive respiratory therapy.
89428386|NCT03448328|Experimental|Pea Protein|NUTRALYS pea protein supplement
89428387|NCT03448328|Experimental|Whey Protein|Whey protein supplement
89428388|NCT03448328|Active Comparator|Apple juice|Apple juice
89428389|NCT03865316|Experimental|SedLine Vs Comparator Test Group|
89428390|NCT02598076|Active Comparator|control|Group will receive standard treatment for psychogenic non-epileptic seizures. They will undergo an initial clinic visit with a neuropsychiatrist and neurologists. They will not undergo any subsequent motivational interview. Following the initial clinic visit, all subjects with ongoing seizures will either be scheduled for ongoing psychotherapy for treatment of PNES at Brigham and Women's Hospital or referred to a local psychotherapist according to their preference.
89428391|NCT02598076|Experimental|MI|"Group will receive an initial clinic visit with a neuropsychiatrist and neurologists, identical to the initial clinic visit for the control group. In addition they will receive 1 session of motivational interviewing immediately following the initial clinic visit. These patients will be questioned using standardized motivational interviewing techniques by the study author who is a board certified neurologist and who has formal training and certification in motivational interviewing.~Following the initial clinic visit, all subjects with ongoing seizures will either be scheduled for ongoing psychotherapy for treatment of PNES at Brigham and Women's Hospital or referred to a local psychotherapist according to their preference (identical treatment in control and MI arms)."
89428392|NCT03776630|Other|Control|Patients undergoing surgery for benign pelvic lesions
89428393|NCT03776630|Other|Ovarian Cancer|
89428394|NCT03776630|Other|Endometrial Cancer|
89428395|NCT03448172|Experimental|Investigational Product|[14C]PF-05221304
89428396|NCT04819828|Experimental|Tamsulosin|At the end of the ESWL session, the patients received standard treatment for analgesia consisting of oral diclofenac (75 mg/12 h) as needed plus oral tamsulosin (0.4 mg/day) for eight weeks.
89428397|NCT04819828|Active Comparator|Control|At the end of the ESWL session, the patients received standard treatment for analgesia consisting of oral diclofenac (75 mg/12 h) as needed
89428398|NCT02602288|Experimental|AAR+Behavioral Intervention (EXP)|Ask Advise Refer (AAR): WIC clinic staff ask about children's secondhand smoke exposure (SHSe), advise about harms of SHSe, and refer to smoking cessation resources. Telebased tobacco counseling: Telephone counseling to promote parent's smoking cessation and behaviors to protect children from secondhand tobacco smoke. Mobile phone smoking cessation application: Smartphone based application to support smoking cessation efforts. Nicotine polacrilex: Over the counter nicotine replacement therapy in gum or lozenge form.
89428399|NCT02602288|Active Comparator|AAR+Attention Control Intervention (CTL)|Ask Advise Refer (AAR): WIC clinic staff ask about children's secondhand smoke exposure (SHSe), advise about harms of SHSe, and refer to smoking cessation resources. Telebased nutrition counseling: Telephone counseling to promote nutritious eating practices in the family. Mobile phone nutrition application: Smartphone based application to support healthy eating habits
89428400|NCT05321186|Other|minimally invasive spinopelvic fixation.|"the arm will include skeletally mature patients (between the age of 18-60) presenting with sacral fractures (provided that the fracture line passes below the level of S2) associated with lumbosacral instability) with the following inclusion and exclusion criteria.~Inclusion criteria:~Unilateral or bilateral L5-S1 facet fractures (AO classification type C1 and C2)~Spinopelvic dissociation (AO type C3)~Traumatic lumbosacral dislocation~Exclusion criteria:~unwillingness to participate in the study~pathological fractures~other medical comorbidities that preclude surgical intervention."
89428401|NCT03745352|Experimental|Arm A (pevonedistat, azacitidine)|Patients receive pevonedistat intravenously (IV) over 60 minutes on days 1, 3, and 5 and azacitidine IV over 10-40 minutes or subcutaneously (SC) on either days 1-7, or days 1-5 and 8-9, or days 1-6 and 8. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89428402|NCT03745352|Active Comparator|Arm B (azacitidine)|Patients receive azacitidine IV or SC as in Arm A. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89428403|NCT04427410||pregnancy|
89428404|NCT04427410||postpartum|
89428405|NCT05321030||Smartphone addict|
89428406|NCT05321030||Smartphone non addict|
89428407|NCT03129308||HIV infected patients|4.5 ml of blood will be collected during a routine medical check-up.
89428408|NCT03129308||HIV negative control patients|4.5 ml of blood will be collected during a routine medical check-up.
89428409|NCT03740126|Experimental|Arm A, PET/CT|18F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose positron emission tomography with computed tomography (FDG PET/CT) replacing computed tomography (CT) at months 6, 12, 18 and 24, otherwise as B with CT scan months 9, 15 and 21. Quality of life assessment and liquid biopsy every 3 months for later analysis.
89428410|NCT03740126|No Intervention|Control arm B|CT-scan and clinical evaluation every 3 months. Quality of life assessment and liquid biopsy at every 3 months for later analysis.
89428411|NCT05617690|Experimental|Cyclopol group|
89428412|NCT05617690|Active Comparator|Propofol group|
89428413|NCT03448094|Experimental|Resveratrol|500mg of Veri-te Resveratrol (consumed as two 250mg tablets, at two timepoints each day).
89428414|NCT03448094|Placebo Comparator|Placebo|Matched placebo capsules (1 capsule consumed at two timepoints each day).
89428415|NCT04819204|Experimental|GnRH antagonist alone|Intervention: Cetrorelix acetate (Cetrotide)
89428416|NCT04819204|Experimental|GnRH antagonist + Testosterone add-back|Intervention: Cetrorelix acetate (Cetrotide) + Testosterone gel (Androgel)
89428417|NCT04819048|Experimental|Low-Level Laser Therapy+acupuncture|"The laser light will be applied in 6 points on the affected side: anterior to the mandibular condyle and intraauricular toward the temporomandibular joint; 2 points irradiation on the superficial masseter muscle and 2 points on the anterior temporal muscle bundle. Each point will be irradiated for 30 seconds for a total of 180 seconds.~After LLLT irradiation,the following acupuncture points will be selected: Jiache,Xiaguan,Quanliao,Baihui,Fengchi, Hegu.The needles will be inserted and rotated manually with a frequency of about 100 turns per minute clockwise and counterclockwise ,as above vertically into a depth of 25-30 mm to achieve the proper feel called Deqi in every point on the affected side, and then the needles will be retained for 30 minutes."
89428418|NCT04819048|Active Comparator|Low-Level Laser Therapy|The laser light will be applied in 6 points on the affected side: anterior to the mandibular condyle and intraauricular toward the temporomandibular joint; 2 points irradiation on the superficial masseter muscle and 2 points on the anterior temporal muscle bundle. Each point will be irradiated for 30 seconds for a total of 180 seconds.
89428419|NCT02807454|Experimental|Daratumumab Plus Durvalumab Treatment|"Intravenous (IV) durvalumab at 1500mg on Day 1 or 2 of a 28-day cycle~IV daratumumab at 16mg/kg on days 1, 8, 15 and 22 at cycles 1-2; on days 1 and 15 at cycles 3-6; and on day 1 from cycle 7 onward"
89428420|NCT02807454|Experimental|Pomalidomide+ Daratumumab+ Durvalumab+ Dexamethasone Treatment|"Intravenous (IV) durvalumab at 1500mg on Day 1 or 2 of a 28-day cycle~IV daratumumab at 16mg/kg on days 1, 8, 15 and 22 at cycles 1-2; on days 1 and 15 at cycles 3-6; and on day 1 from cycle 7 onward~oral POM at 4mg/day on days 1 to 21~oral/IV dex at 40mg/day (>75 years old) or 20mg/day (>75 years old) on days 1, 8, 15 and 22"
89428421|NCT03718286|Experimental|Alirocumab|
89428422|NCT03718286|Sham Comparator|Sham Control|
89428423|NCT04819126|Experimental|Nintendo Wii Virtual Reality Application In Older People With Alzheimer's Dementia|"The study included a total of 32 volunteers between the ages of 65-80, who stayed in Karaman Ahmet Mete Nursing Home, Elderly Care and Rehabilitation Center, with mild or moderate Alzheimer's dementia diagnosed by a neurologist. As a result of the power analysis, it was calculated that at least 16 individuals could be included in each group (at least 32 individuals in total). Randomization was performed by the sealed-envelope method. According to this method, 4 females and 12 males were determined to be in the control group, while 5 females and 11 males were determined to be in the training group.~The evaluation was completed before the intervention. The same evaluation was conducted after 6 weeks.~The training group was trained with games from different categories such as balance and aerobic exercises with a Nintendo Wii virtual reality device 2 times a week for a period of 6 weeks, with 1 session lasting for 30 minutes, and each patient was trained with the same games."
89428424|NCT04819126|No Intervention|Older People With Alzheimer's Dementia|In the control group, no application was performed during this period, and routine medical treatments were continued. The training group was evaluated before and after the training, while the control group was re-evaluated at the end of the 6th week after the first evaluation. After the study was completed, the volunteers from the control group were also given training.
89428425|NCT05320874|Experimental|KM257|KM257 Bispecific antibody
89428426|NCT02597920||Switch patients / A|Patients with non-valvular atrial fibrillation (NVAF), currently on Vitamin K Antagonist (VKA) therapy, who are switched to Pradaxa.
89428427|NCT02597920||New AF patients / B|Newly diagnosed NVAF patients who are treated with VKA or Pradaxa (VKA : Pradaxa = 1:1).
88908918|NCT05772546|Experimental|Group A - Avatromopag|"30 participants will be randomized into a 1:1 fashion and will be stratified based on the number of cytotoxic agents in the patient's chemotherapy regimen. Participants will complete study procedures as outlined:~Lead-In Period (Day 1 - 15)~Pre-determined dose of Avatrombopag 1x daily.~Participants failing to achieve a platelet count ≥100,000/µL within 2 weeks will be considered a treatment failure (and will proceed to the end-of-study visit).~On-Cycle Period (Day 15 - up to Week 6)~• Pre-determined dose of Avatrombopag 1x daily.~Follow-up Period~End of Treatment on-site visit.~Follow-up visit 30-42 days after End of Treatment visit."
89428428|NCT05320640|Experimental|Experimental arm|"Drug: Chidamide10mg/day, day1-4; 20mg/day, day8, 11, 15, 18. Drug: Decitabine10mg/day, day1-5. Drug: Immune Checkpoint Inhibitors（anti-PD1/PD-L1/CTLA4 antibodies）. Physicians will decide which ICIs will be used during treatment.~Every 3 weeks."
89428429|NCT00835146|Experimental|1|
89428430|NCT00835146|Active Comparator|2|
89428431|NCT04819282||One group|Physical performance was evaluated with the Senior Fitness Test in one group of geriatric individuals.
89428432|NCT04818736|Experimental|COVID-19|mRNA-1273 vaccine
89428433|NCT04818736|Experimental|Control|Usual care
89536868|NCT03308123||Health Care Professionals|Health care professionals
89536869|NCT03308123||Carers of hip-fracture patients with moderate/severe|Carers of hip-fracture patients with moderate/severe
88908919|NCT05772546|Active Comparator|Group B - Matching Placebo|"30 participants will be randomized into a 1:1 fashion and will be stratified based on the number of cytotoxic agents in the patient's chemotherapy regimen. Participants will complete study procedures as outlined:~Lead-In Period (Day 1 - 15)~Pre-determined dose of matching placebo 1x daily.~Participants failing to achieve a platelet count ≥100,000/µL within 2 weeks will be considered a treatment failure (and will proceed to the end-of-study visit).~On-Cycle Period (Day 15 - up to Week 6)~• Pre-determined dose of matching placebo 1x daily.~Follow-up Period~End of Treatment on-site visit.~Follow-up visit 30-42 days after End of Treatment visit."
88908920|NCT05772130|Active Comparator|Arm I (usual care)|Patients receive a family letter and their genomic test report to share with at-risk first degree relatives on study.
89008186|NCT04602052|Active Comparator|Medical arm|Those who choose medical abortion receive mifepristone 200 mg on day 1 and are appointed to return to SPHMMC 24-48 hours later for admission and misoprostol administration.
89428434|NCT04472520|Experimental|Subject getting an ECG|Subjects getting an ECG will have AliveCore tracings obtained in 3 configurations; between right hand and left hand, between left hand and left lower leg (thigh, calf, and foot) and between right hand and left lower leg (thigh, calf, and foot).These configurations will be obtained with the participant lying in bed and in a sitting position.
89428435|NCT01235234|Experimental|CF101 0.1 mg|Subjects were randomized to receive CF 101 0.1mg, orally, twice daily for 24 weeks
89428436|NCT01235234|Experimental|CF101 1 mg|Subjects were randomized to receive CF 101 1.0mg, orally, twice daily for 24 weeks
89428437|NCT01235234|Placebo Comparator|Placebo|Subjects were randomized to receive matching placebo, orally, twice daily for 24 weeks
89428438|NCT04811326|Active Comparator|NB-UVB radiation|will expose to 2 sessions/week of NB-UVB radiation, for 3 months.
89428439|NCT04811326|Active Comparator|Latanoprost|latanoprost 0.005%, will be applied after microneedling, by using 1.5-2 mm needle length dermapen, of vitiligenous patches. The procedure will be repeated once weekly for 3 months (12 sessions).
89428440|NCT04811326|Active Comparator|latanoprost + NB-UVB|(latanoprost + NB-UVB group): latanoprost 0.005%, will be applied after microneedling of vitiligenous patches in the same day of NB-UVB sessions in the same manner of group 2.
89428441|NCT04811326|No Intervention|healthy individuals|healthy individuals as control group
89428442|NCT00834990|Experimental|1|
89428443|NCT00834990|Active Comparator|2|
89428444|NCT05320562|No Intervention|Control group|Participants underwent 3 exercise sessions for 60 minutes each. Exercise program was created to improve range of motion and muscle strength. Participants executed active exercise in lying, sitting, and standing positions, isometric exercise, exercise with resistance band. All exercises were repeated 12 times in 3 sets and depending on the capacity of the subject. Breaks between sets 10 sec.
89428445|NCT05320562|Sham Comparator|Sham taping|Participants underwent 3 exercise sessions for 60 minutes each. Exercise program was created to improve range of motion and muscle strength. Participants executed active exercise in lying, sitting, and standing positions, isometric exercise, exercise with resistance band. All exercises were repeated 12 times in 3 sets and depending on the capacity of the subject. Breaks between sets 10 sec.
89428446|NCT05320562|Experimental|Kinesio taping|Participants underwent 3 exercise sessions for 60 minutes each. Exercise program was created to improve range of motion and muscle strength. Participants executed active exercise in lying, sitting, and standing positions, isometric exercise, exercise with resistance band. All exercises were repeated 12 times in 3 sets, 10 s breaks between sets.
89428447|NCT02597452|Other|intelligent Breast Exam, iBE|Single Arm: Additional breast exam by a FDA approved hand-held intelligent breast exam device and a clinical breast exam during their scheduled breast screening appointment. No return visit required for participation.
89428448|NCT04483050|Experimental|experimental group|
89428449|NCT05320484|Experimental|clinical pilates exercises|clinical pilates exercises applied to 1st group,for 3 days / week for 6 weeks.
89428450|NCT05320484|Other|classical posture exercises|classical postural exercises applied to 2 nd group,for 3 days / week for 6 weeks.
89428451|NCT04479072|Active Comparator|Intervention Arm|60 subjects will be randomly assigned to this arm. The subjects in this arm will receive a daily dose of aspirin 81 mg.
89428452|NCT04479072|Placebo Comparator|Placebo Arm|60 subjects will be randomly assigned to this arm. The subjects in this arm will receive a daily dose of a placebo pill
89428453|NCT04479072|No Intervention|Observational Arm|60 subjects will be placed in the observational arm. These subjects will not receive any intervention but will be followed and asked to return at the same time interval as the other 2 groups.
89428454|NCT04817878||Late preterm infant group|Gestational age 33 weeks-36 weeks
89428455|NCT04817878||Very premature infant group|Gestational age 28 weeks-32 weeks
89428456|NCT04817878||Super preterm infant group|Gestational age less than 28 weeks
89428457|NCT05320328||1|The study group (A) will receive radio frequency ablation followed by uncovered Self expandable metal stent/Plastic stent placement (one or more)at same procedure.
89428458|NCT05320328||2|The control group (B) will receive uncovered Self expandable metal stent / Plastic stent (one or more) placement.
89428459|NCT03036202||one group|All patients treated for cardiac arrest, meeting our inclusions criteria will be enrolled in the study. No interventions regarding the national guidelines will be jeopardized, as the plasma concentration following a single dose of epinephrine will be measured in all patient.
89428460|NCT03035968|Experimental|Vojta arm|Patients in the interventional arm are treated with Vojta therapy from randomization until discharge.
89428461|NCT03035968|Active Comparator|conventional physiotherapy arm|Patients in this control arm are treated with conventional physiotherapy for motor improvement from randomization until discharge.
89428462|NCT03245918|Other|Aprepitant Capsule Study Period #1|
89428463|NCT03245918|Other|Aprepitant Oral Suspension Study Period#1|
89428464|NCT00834756|Experimental|Azithromycin|Azithromycin 600 mg tablet (test) dosed in first period followed by Zithromax® 600 mg tablet (reference) dosed in second period
89428465|NCT00834756|Active Comparator|Zithromax®|Zithromax® 600 mg tablet (reference) dosed in first period followed by Azithromycin 600 mg tablet (test) dosed in second period
89428466|NCT00828854|Experimental|Entinostat 5 mg + AI|Entinostat 5 mg tablet orally every week on Days 1, 8. 15 and 22 of each 28-day treatment cycle in combination with continued treatment with AI therapy at labeled dose and schedule until disease progression or unacceptable toxicity.
89428467|NCT04810936|Experimental|Early ONS intervention group|Patients in early ONS intervention group will receive nutritional counseling (follow-up visits once a week during radiotherapy and at the 1st and 3rd months after radiotherapy) and ONS intervention in the beginning of radiotherapy. The ONS is prescribed to increase oral intake of patients and to ensure total energy supply is more than 30 kcal/kg/day and protein intake more than 1.2 g/kg/day.
89428468|NCT04810936|No Intervention|Standard nutrition intervention group|Patients in standard nutrition intervention group will receive nutritional counseling (follow-up visits once a week during radiotherapy and at the 1st and 3rd months after radiotherapy).
88908921|NCT05772130|Experimental|Arm II (provider-mediated contact)|Patients receive a family letter and their genomic test report to share with at-risk first degree relatives and relatives also receive provider-mediated contact to discuss genetic results on study.
89197110|NCT00845325|Active Comparator|Group One|"The first group (early motion) will have a bulky dressing placed at the time of surgery. They will be instructed to remove the dressing on the first postoperative day and to place a band-aid over the incision. A set of non-weight bearing stretching exercises will be explained on the day of surgery and instructions with diagrams sent home with the patient. They will begin these exercises on the day after surgery and perform them three times daily for two weeks. The patients will have no restrictions concerning activity or return to work."
88908922|NCT05769556|Experimental|Group A|will receive brain gym exercises and physiotherapy .
88908923|NCT05769556|Active Comparator|Group (B)|will receive physiotherapy alone.
89197111|NCT00845325|Other|Behavorial Control Group Two|The second group will have wrist immobilization splints placed at the time surgery. The thumb and fingers will not have limited motion in this splint. Due to the splint placement, the patients will be restricted from using that hand during its implementation. One week following surgery the splint will be removed and the patient will be instructed to begin activity without restriction.
89197112|NCT00940732|Experimental|Destigmatisation and Mental Health Literacy|
89197113|NCT00940732|Experimental|Help-seeking list|
89197114|NCT00940732|Experimental|Feedback|
89197115|NCT00940732|No Intervention|Control|
89197116|NCT02567006|Active Comparator|Short Message Service (SMS) group|Receiving SMS message reminders 1 week before scheduled vaccination
89197117|NCT02567006|Placebo Comparator|Usual care|Not receiving SMS messages
89197118|NCT00843063|Active Comparator|pantoprazole|pantoprazole 20 mg om and matching placebo nocte
89197119|NCT00843063|Active Comparator|famotidine|Famotidine 40 mg om and nocte
89197120|NCT04013464|Experimental|MDD and Health Control|MDD in open label
89197121|NCT04043247|Sham Comparator|Control Group|Same as TEAS group but without electrical stimulation
89197122|NCT04043247|Experimental|TEAS Group|Bilateral Neiguan and Zusanli acupuncture points, 2/10Hz Dense wave , 6-9mA,30min
89197123|NCT04012918|Experimental|A.I. + Capeciabine|Patients will receive Capecitabine 625 mg/m2 bid PO for 14 days to be repeated every 21 days until progression in combination with aromatase inhibitor if postmenopausal, addition of LHRH agonist will be added if premenopausal.
89197124|NCT04012918|Active Comparator|A.I|Patients will receive aromatase inhibitors ( letrozole 2.5 mg PO per day or Anastrozole 1 mg PO per day or aromasin 25 mg PO per day) if post-menopausal, if premenopausal leutnising hormone releasing hormone (LHRH) agonist will be added to the aromatase inhibitor.
89197125|NCT04062578|Experimental|CD Oliver|Female first team players of the club that plays in the National Second Division league.
89197126|NCT04062578|Active Comparator|SD Huesca|Female first team players who play in the Aragonese Territorial First league
89197127|NCT05131490|Experimental|Experimental|Experimental group intervention consists two months a mobile application intervention developed for gynecological cancer patients receiving chemotherapy
89197128|NCT05131490|No Intervention|No intervention|Control group receive routine care.
89197129|NCT00939718|Active Comparator|Vitamin B12 with antidepressants|Subjects in this arm will receive vitamin B12 supplement (injectable)along with their routine antidepressant treatment as prescribed by their primary physicians. subjects will be blind to their arm allocation and will receive injections in a concealed manner with injection vials covered with foil.
88908924|NCT05765344|Experimental|Bulevirtide (BLV), Moderate Hepatic Impairment|"Participants with moderate hepatic impairment will receive BLV 2 mg injection once daily for 6 days starting on Day 1.~Following completion and evaluation of pharmacokinetics (PK) and safety data, additional participant groups and BLV doses may be initiated."
88908925|NCT05765344|Experimental|BLV, Severe Hepatic Impairment|"Participants with severe hepatic impairment will receive BLV 2 mg injection once daily for 6 days starting on Day 1.~Following completion and evaluation of PK and safety data, additional participant groups and BLV doses may be initiated."
88908926|NCT05765344|Experimental|BLV, Normal Hepatic Function (Matched Control Participants)|Participants with normal hepatic function will receive BLV 2 mg once daily for 6 days.
88908927|NCT05762796|No Intervention|Healthy Controls|Never-concussed age-and gender-matched healthy controls will not receive any intervention. Behavioral and neuroimaging measurements will be administered only once, at the initial visit.
89008187|NCT04602052|Experimental|Surgical arm|Those who chose surgical abortion are given mifepristone 200 mg with or without laminaria and appointed to return the next day for surgical abortion.
89197130|NCT00939718|Placebo Comparator|Placebo injections dextrose water|Subjects in this arm will receive placebo injections which will contain only dextrose water. They will also receive 6 injections on a weekly basis and the injection vials will be covered with foil to ensure masking.
89197131|NCT00843141|Experimental|cognitive computerized training|cognitive computerized training utilizing executive attention tasks
89197132|NCT00843141|Active Comparator|simple cognitive computerized training|simple computerized cognitive program utilising simple reaction time tasks that do not challenge executive attention
89197133|NCT04062968|Experimental|Video education|"Women randomized to the intervention group (video education) will view the prenatal screening video made by the Genetic Support Foundation and the Washington Department of Health, the 4.5 minute video How to Decide About Prenatal Genetic Testing, available at: https://www.geneticsupportfoundation.org/genetics-and-you/pregnancy-and-genetics/prenatal-genetic-testing-videos .7 They will then complete the study related surveys at their initial obstetric visit."
89197134|NCT04062968|No Intervention|Usual care|Women randomized to the control group will receive routine prenatal care with no additional study intervention other than completion of the study related surveys at baseline (initial prenatal testing).
89428469|NCT04810468|Other|Children in primary school|anthropometric measurment will take from each participiant in study to asses wheight ,height ,BMl and also use aquestionnaire yo asses the Sociodemographic data,dietary habits ,hygiene information
88908928|NCT05762796|Experimental|tDCS in Youth with mild traumatic brain injury|"Behavioral as well as neuroimaging measurements will be administered at the final post-anodal transcranial direct current stimulation (tDCS), final post-sham tDCS, and at 30-day follow-up visits.~tDCS will be administered after the initial behavioral and neuroimaging testing. Ten sessions of 1.5 mA real tDCS and 10 sessions of sham tDCS will be administered using Neurocom (Germany) DC stimulator and two 5x7 electrodes, moistened in saline solution, to 10 participants with mTBI following a cross-over design with a 2-week washout period. The location of the brain regions will be determined using either the Transcranial Magnetic Stimulation Neuronavigation or Brainsight Neuronavigation system. The anode will be placed over pre-determined brain regions, whereas the cathode will be placed either over Fp2 (contralateral supraorbital) or other suitable reference areas."
88908929|NCT05761301|Experimental|Part A: ALN-KHK|Participants will be administered a single dose of ALN-KHK.
88908930|NCT05761301|Placebo Comparator|Part A: Placebo|Participants will be administered a single dose of placebo.
88908931|NCT05761301|Experimental|Part B: ALN-KHK|Participants will be administered a multiple doses of ALN-KHK.
88908932|NCT05761301|Placebo Comparator|Part B: Placebo|Participants will be administered a multiple doses of placebo.
88908933|NCT05758597|Experimental|Remazolam besylate group|The remimazolam besylate treatment group was given remimazolam besylate 0.1-1mg/kg/h to maintain the target RASS score.
88908934|NCT05758597|Active Comparator|Midazolam group|The midazolam treatment group was given midazolam 0.05-0.2 mg/kg/h to maintain the target RASS score.
89197135|NCT00938938|Experimental|Press guide plus press release|Participants in the intervention group will receive a press guide (a one-page summary of study findings written by the investigators) in addition to the journal's full narrative press release for the selected article, a copy of the article's abstract, and a link to the full text of the journal article.
89197136|NCT00938938|No Intervention|Press release only|Participants in the control group will receive the journal's full narrative press release for the selected article, a copy of the article's abstract, and a link to the full text of the journal article.
88908937|NCT05757284||patients with unilateral or bilateral, primary or secundary LLL|
88908938|NCT05757284||healthy controls|
88908939|NCT05756153|Experimental|GFH925+Cetuximab|
88908940|NCT05754034|Experimental|High flow oxygen|Heated and humidified oxygen delivered via high flow oxygen device through nasal cannula, up to 60 liters per minute of flow.
89197137|NCT00843219||PET/CT Scan|
88908941|NCT05754034|Active Comparator|Standard flow oxygen|Oxygen delivered via standard oxygen devices at standard flows up to 15 liters per minute: nasal cannula, face mask, or nonrebreather mask.
88908942|NCT05753189|Experimental|Combination ophthalmic solution (LNZ101) dosed bilaterally|LNZ 101: Aceclidine/Brimonidine Ophthalmic Solution
88908943|NCT05753189|Placebo Comparator|Placebo (Vehicle) ophthalmic solution dosed bilaterally|Placebo: Proprietary Vehicle Ophthalmic Solution
88908944|NCT05753189|Experimental|Aceclidine ophthalmic solution dosed bilaterally|LNZ 100: Aceclidine ophthalmic solution
88908945|NCT05751759|Experimental|Cohort 1|8 participants with mild hepatic impairment (Child-Pugh A) will be given Dose A of mitiperstat.
88908946|NCT05751759|Experimental|Cohort 2|8 participants with moderate hepatic impairment (Child-Pugh B) will be given Dose A of mitiperstat.
88908947|NCT05751759|Experimental|Cohort 3|6-8 participants with severe hepatic impairment (Child-Pugh C) will be given Dose A of mitiperstat.
88908948|NCT05751759|Experimental|Cohort 4|8-12 participants with normal hepatic function will be given Dose A of mitiperstat.
88908949|NCT05749029|Experimental|Intervention|
88908950|NCT05749029|No Intervention|Waitlist Control|Control participants will receive no intervention during the study but will be given the option of accessing the online self-compassion intervention after the study is complete.
88908951|NCT05748665|Experimental|remimazolam|remimazolam induction
88908952|NCT05748665|Active Comparator|etomidate|etomidate induction
88908953|NCT05741437|Experimental|Sequence 1|"Period 1: D745, D150 - A single oral dose of 2 tablets under food intake condition~Period 2: CKD-378 - A single oral dose of 1 tablet under food intake condition"
88908954|NCT05741437|Experimental|Sequence 2|"Period 1: CKD-378 - A single oral dose of 1 tablet under food intake condition~Period 2: D745, D150 - A single oral dose of 2 tablets under food intake condition"
88908955|NCT05740007|Experimental|IW-3300 100 µg|IW-3300 at 100 µg rectal foam administered daily for 12 weeks
88908956|NCT05740007|Experimental|IW-3300 300 µg|IW-3300 at 300 µg rectal foam administered daily for 12 weeks
88908957|NCT05740007|Placebo Comparator|Placebo|Placebo rectal foam administered daily for 12 weeks
89197138|NCT02568098|Experimental|TMEC-14-022 (OxTREC 39-14)|Subjects had previously taken drug CQ and PQ
89197139|NCT02568098|Experimental|TMEC 12-004 (OxTREC 58-11)|Subjects had previously taken drug PQ and DHA-PQP
89536870|NCT03308123||Discharged hip-fracture patient with memory difficulty|Discharged hip-fracture patient with memory difficulty
88908958|NCT05737745|No Intervention|Usual care|Endometrial cancer survivors will receive standard survivorship care including a one-time educational newsletter about survivorship physical activity and nutrition recommendations. Fitbits will be given to track physical activity.
89197140|NCT02568098|Experimental|New subject|"Subjects who not previously participated in study TMEC 12-004 (OxTREC ref. 58-11) and study TMEC 14-022 (OxTREC ref. 39-14)."
89197141|NCT02732626|Active Comparator|pulmonary vein isolation alone|patients randomized to this group receive stand alone pulmonary vein isolation regardless to their left atrial voltage map
89197142|NCT02732626|Experimental|pulmonary vein isolation + low voltage area guided ablation|patients randomized to this group receive pulmonary vein isolation + low voltage area guided linear substrate modification in the case if there are any
89197143|NCT00836667|Experimental|1|
88908959|NCT05737745|Experimental|FitEx-ECS|Endometrial cancer survivors and their support team members (as a group of one survivor and their team) will complete the FitEx-ECS intervention program, with a focus on walking. Fitbits will be given to track physical activity.
88908960|NCT05737745|Experimental|FitEx-ECS+ Yoga|Endometrial cancer survivors and their support team members (as a group of one survivor and their team) will complete the FitEx-ECS+yoga intervention program, with a focus on postures, breathwork, and mindfulness. Fitbits will be given to track physical activity.
89536187|NCT02635347|Experimental|Remote Ischemic Conditioning (RIC) group|Participants will receive RIC during transplant and the initial four post-transplant days. During transplant: first intervention after induction of anesthesia but before commencing surgery and the second at the conclusion of the procedure. After transplant: RIC applied daily during the first four consecutive postoperative days. Pneumatic tourniquet will be used to induce RIC
89536188|NCT03314597|Active Comparator|Balance exercise group|Each of the ten sessions was composed of 45 minutes of balance exercises, each treatment being followed by a 15-min final phase of lower limb stretching, performed with the assistance of a physiotherapist. Sessions were repeated two or three times a week, with at least one rest day between one session and the next, over four successive weeks. Each patient was treated on-phase, at the same time of the day across sessions.
89536189|NCT03314597|Experimental|Mobile platform exercise group|Each of the ten sessions was composed of 45 minutes mobile platform training, each treatment being followed by a 15-min final phase of lower limb stretching, performed with the assistance of a physiotherapist. Sessions were repeated two or three times a week, with at least one rest day between one session and the next, over four successive weeks. Each patient was treated on-phase, at the same time of the day across sessions.
89536190|NCT03211429|Active Comparator|Cognitive behavioural therapy|The program aims to teach participants how to deal with their concerns about falls and related avoidance of activity, in order to increase their physical, social and functional activities. The cognitive behavioural intervention program, provides by psychologists, consists of eight group sessions, 60 minutes each. During each session a main theme is addressed. The themes of the program are: concerns about falls; thoughts about falling; physical exercise; asserting oneself; overcoming personal barriers; safe behaviour; and managing concerns about falls.
89536191|NCT03211429|Active Comparator|Tai chi|Subjects in the Tai Chi group undertook supervised Tai Chi training in the Yang style of 24 movements, for one hour, once a week for 8 weeks. The first 5 min was allocated for warm-up, with the rest of the time for Tai Chi practice.
89536871|NCT03312413|Experimental|Dexmedetomidine low dose group|Patients in this group are received dexmedetomidine hydrochloride iv infusion of 0.2μg·kg-1·h-1 from incision to 20-30 minutes before the end of surgery
88908972|NCT05735119||Subscapularis Tendon Injuries|Tapestry Biointegrative Implant
88908973|NCT05734625|Experimental|Greater Occipital Nerve block group|Subjects will receive bilateral greater occipital nerve blocks for a total of 2 blocks
88908974|NCT05734625|Experimental|Multiple Peripheral Nerve block group|Subjects will receive 10 nerve blocks to include bilateral greater occipital, lesser occipital, auriculotemporal, supraorbital and supratrochlear nerves.
88908975|NCT05731037|Active Comparator|Short restitution group (SR)|Resistance training for knee extensors three training session per week.
88908976|NCT05731037|Experimental|Extended restitution group (ER)|Resistance training for knee extensors on training session per week (greater restitution from loading).
88908977|NCT05727462|Experimental|Manual Therapy with TECAR|Participants allocated to this group received 15 sessions of a manual therapy protocol applied by two resistive TECAR bracelet electrodes (one in each hand).
88908978|NCT05727462|Active Comparator|Manual Therapy without TECAR bracelet electrodes|Participants allocated to this group received the same Manual Therapy protocol without the resistive TECAR bracelet electrodes
88908979|NCT05726383|Experimental|Treatment Arm - Iscador*P|Each Iscador® P therapy begins with a dose finding phase related to the drug' immunogenicity. In this phase, gradually increasing doses are used to determine the optimum individual dose response of the patient and to prevent excessive toxicity. The Iscador® P will be administered three times per week by subcutaneous injections (M,W,F) into the subcutaneous tissue of the thigh or abdomen. Treatment is administered according to a series of escalating doses that are given each of the three days in a week for 7 doses. There are 3 different series (Series 0, 1, and 2) and there are 7 dose vials in each series. Once the patient has reached their maximum tolerated dosing series, that series is used as the treatment regimen for the remaining weeks to a total duration of 52 weeks (13 cycles) or until disease progression. Each cycle is 4 weeks.
88908980|NCT05721573|Active Comparator|0.5 mg/kg ABC008|"Part A - ABC008 N=12~Part B - ABC008 N= 67"
88908981|NCT05721573|Active Comparator|2.0 mg/kg ABC008|"Part A - ABC008 N=12~Part B - ABC008 N= 67"
88908982|NCT05721573|Placebo Comparator|Placebo|"Part A - Placebo N= 6~Part B - Placebo N= 67"
88908983|NCT05720949|No Intervention|Group 1 - Control|Patients randomized to this group will receive an adductor canal block (ACB) and Infiltration between the Popliteal Artery and Capsule of the Knee (IPACK) nerve block.
88908984|NCT05720949|Experimental|Group 2 - Intervention|"Patients randomized to this group will receive an adductor canal block (ACB), Infiltration between the Popliteal Artery and Capsule of the Knee (IPACK) nerve block, and the genicular nerve block (intervention).~The genicular nerve block is a total of 20cc of 0.25% bupivacaine with 2mg of preservative free dexamethasone applied to the superomedial genicular nerve, superolateral genicular nerve, inferomedial genicular nerve, and nerve to vastus intermedius."
88908985|NCT05719883|Experimental|Maurora® Sirolimus Eluting Stent System|Device: Maurora® Sirolimus Eluting Stent System A sirolimus eluting intracranial stent system with platform is made of L605 CoCr alloys.
88908986|NCT05719883|Active Comparator|APOLLO™ Intracranial Stent System|Device: Apollo Intracranial Stent System A 316L stainless steel balloon-expandable intracranial stent system.
89197144|NCT00836667|Active Comparator|2|
89197145|NCT00940030|Experimental|MBP+enema|mechanical bowel preparation and enema
89197146|NCT00940030|Active Comparator|enema|
89197147|NCT00845559|Experimental|Exenatide|Subjects randomized to treatment will receive a four month supply of exenatide.
89197148|NCT00845559|No Intervention|No Treatment|
89197149|NCT00939016|Active Comparator|High SD/ Low DR|This group contains females that exhibit characteristics of high social desirability and low dietary restraint.
89428470|NCT05308082|Experimental|Intervention group|It is proposed to have 70 participants who meet the inclusion criteria in the intervention group. Dance movement therapy will be delivered as an intervention, which consists of six sessions: (1) Movement for Self-expression, (2) Movement for Emotional Health I, (3) Movement for Emotional Health II, (4) Movement for Connection & Creativity, (5) Embracing your Dancing Child, and (6) Movement for Self-compassion.
89428471|NCT05308082|No Intervention|Active control group|It is proposed to have 70 participants who meet the inclusion criteria in the active control group. Health talk will be delivered to participants which will match the length of contact and interval of contact of that in the intervention group.
89428472|NCT00834522|Experimental|Granisetron|Granisetron 2 x 1 mg Tablet (test) dosed in first period followed by Kytril® 2 x 1 mg Tablet (reference) dosed in second period
89428473|NCT00834522|Active Comparator|Kytril®|Kytril® 2 x 1 mg Tablet (reference) dosed in first period followed by Granisetron 2 x 1 mg Tablet (test) dosed in second period
89008188|NCT04602208||Focal HIFU for primary localized prostate cancer|Between November 2009 and December 2016, at Edouard Herriot Hospital (Lyon, France), 146 consecutive patients were treated with focal HIFU for primary localized prostate cancer. Focal therapy was offered for low or intermediate risk disease (inclusion criteria: one tumor localized by systematic and targeted biopsies based on MRI findings, Gleason ≤7). Treatment failure was defined as local or systemic salvage treatment, a positive biopsy Gleason score of 7 or greater in-field or out-of-field in nontreated patients, prostate cancer metastasis or prostate cancer specific death.
89197150|NCT00939016|Active Comparator|High SD/ High Dr|This group contains females that exhibit characteristics of high social desirability and high dietary restraint.
89428474|NCT04818190|No Intervention|DIEP reconstruction, no neurotization|DIEP reconstruction No sensory neurotization
89428475|NCT04818190|Experimental|DIEP reconstruction, neurotization|DIEP reconstruction With sensory neurotization
89428476|NCT04810312|Experimental|Intervention group|Back extensor strengthening with oral protein supplementation
89428477|NCT00834444|Experimental|1|
89428478|NCT00834444|Active Comparator|2|
89428479|NCT05174858|Experimental|Device under investigation|intra-alveolar placement of the hemostatic dressing ETIK COLLAGENE immediately after tooth extraction.
89197151|NCT00939016|Active Comparator|Low SD/ High DR|This group contains females that exhibit characteristics of low social desirability and high dietary restraint.
89197152|NCT00939016|Active Comparator|Low SD/ Low DR|This group contains females that exhibit characteristics of low social desirability and low dietary restraint.
89197153|NCT02567240|Experimental|Carbon monoxide-bubbled mediums|Islets will be harvested with Carbon monoxide-saturated mediums
89428480|NCT05174858|Other|Comparator|the alveolus is left empty after tooth extraction.
89428481|NCT05265572|Experimental|Intervention group|The group that will receive the intervention to apply
89428482|NCT05265572|No Intervention|Control group|The group that will not receive the intervention
89428483|NCT00834132|Experimental|Azithromycin|Azithromycin 600 mg tablet (test) dosed in first period followed by Zithromax® 600 mg tablet (reference) dosed in second period
89428484|NCT00834132|Active Comparator|Zithromax®|Zithromax® 600 mg tablet (reference) dosed in first period followed by Azithromycin 600 mg tablet (test) dosed in second period
89428485|NCT05265104|Experimental|SDF with stainless steel crown|mixture of silver , diamine and fluoride applied using a brush to the caries in the primary molar , it is used to arrest the progress of the carious lesion
89428486|NCT05265104|Experimental|Diode laser with stainless steel crown|Diode laser beam is used to sterilize the carious lesions to arrest the progress of the dental caries
89428487|NCT05265104|Active Comparator|Control, stainless steel crown only|stainless steel crown is cemented on the carious primary molar to arrest the progress of the caries, by isolating the tooth from the surrounding bacteria, this is the concept of the Hall technique.
89428488|NCT02988830|Experimental|Chronic lumbar pain|
89428489|NCT03447548|Experimental|Processing speed training|Neurofeedback processing speed training
89428490|NCT03447548|Active Comparator|Active control|Computer games
89428491|NCT00833586|Experimental|Terbinafine|Terbinafine HCl 250 mg Tablet (test) dosed in first period followed by Lamisil® 250 mg Tablet (reference) dosed in second period
89428492|NCT00833586|Active Comparator|Lamisil®|Lamisil® 250 mg Tablet (reference) dosed in first period followed by Terbinafine 250 mg Tablet (test) dosed in second period
89428493|NCT03712358|Experimental|Cohort 0 (PVSRIPO)|A single dose of PVSRIPO into a single lesion.
89428494|NCT03712358|Experimental|Cohort 1 (PVSRIPO)|A single dose of PVSRIPO into 2 different lesions, 21 days apart, when applicable per dose escalation guidelines.
89428495|NCT03712358|Experimental|Cohort 2 (PVSRIPO)|A single dose of PVSRIPO into 3 different lesions, 21 days apart, when applicable per dose escalation guidelines.
89428496|NCT03712358|Experimental|Cohort 3 (PVSRIPO)|A single dose of PVSRIPO into 3 different lesions, 21 days apart, when applicable per dose escalation guidelines.
88908987|NCT05718947||MS scan cohort|10 patients with a known clinical diagnosis of relapsing remitting MS according to the 2017 McDonald criteria between ages of 18-65 years, who had a new lesion on their clinical brain MRI in the prior 15 months. The investigators intend to include patients on low-efficacy medication (interferon β, peginterferon, glatiramer acetate, teriflunomide) as well as patients on high-efficacy medication (natalizumab, ocrelizumab, alemtuzumab, fingolimod) to have a varied and representative study population.
88908988|NCT05718297|Experimental|Experimental arm|Brigatinib 180 mg once daily p.o., with seven day lead-in at 90 mg once daily, for 3 years or until progression of disease, or unacceptable toxicities or withdrawal of consent
88908989|NCT05718297|Active Comparator|Control arm|Patients in the control arm will be observational, or, as per investigators choice, patients may receive durvalumab, administered within the label in the respective country.
88908990|NCT05715463|Other|Arm 1|Arm 1 is the control arm which will receive the standard of care resource sheets.
88908991|NCT05715463|Experimental|Arm 2|Arm 2 will receive the assistance of a community resource specialist (CRS)- an individual without formal medical training with community-based expertise.
89428497|NCT03712358|Experimental|Cohort 4 (PVSRIPO)|A single dose of PVSRIPO into a single lesion, followed by PVSRIPO injected into up to 6 lesions at Day 10 and every 21 days thereafter.
88908992|NCT05715463|Experimental|Arm 3|Arm 3 will receive the assistance of a bilingual (English and Spanish) nurse patient navigator with nursing training and additional rheumatology-specific training.
88908993|NCT05715346|Experimental|LEV102 Topical Gel, 2.0%|
88908994|NCT05715346|Experimental|LEV102 Topical Gel, 1.0%|
88908995|NCT05715346|Placebo Comparator|Vehicle|
89428498|NCT02605954|Experimental|E/C/F/TAF|Participants will switch to E/C/F/TAF FDC and receive treatment for 48 weeks.
89428499|NCT02605954|Active Comparator|ABC/3TC+3rd Agent|"Participants will maintain prior regimen of ABC/3TC plus a third antiretroviral agent for 24 weeks followed by a delayed switch to E/C/F/TAF FDC.~Note: the prior regimen is determined by the participant's clinician (prior to entry into the study) and will consist of one of the third antiretroviral agents listed."
89428500|NCT00780000|Experimental|A1|
88908996|NCT05714982|Experimental|Label with text health warning|Labels with e-cigarette health warning that include text about health harms of vaping will be applied to participants' vaping devices and refills.
88908997|NCT05714982|Experimental|Label with pictorial health warning|Labels with e-cigarette health warning that include the same text about health harms of vaping and corresponding pictorial images will be applied to participants' vaping devices and refills.
88908998|NCT05714982|Other|Label with neutral statements about vaping|Labels with neutral statements about vaping will be applied to participants' vaping devices and refills.
89197154|NCT02567240|No Intervention|Normal mediums|Islets will be harvested with regular mediums
89197155|NCT00940810|Experimental|PDD procedure|
89428501|NCT03447470|Experimental|Monotherapy RXC004 - Module 1|Patients will be given RXC004 at a specified dose level and reviewed for Dose Limiting Toxicities. Once the DLT period is complete RXC004 will be given at a higher dose until MTD is reached.
89428502|NCT03447470|Experimental|Combination RXC004 plus Nivolumab - Module 2|Patients will be given RXC004 at specific doses in combination with a standard dose of Nivolumab and reviewed for Dose Limiting Toxicities. Once the DLT period is complete, RXC004 will be given at a higher dose until MTD is reached.
89428503|NCT03447470|Experimental|Intermittent schedules of monotherapy RXC004 - Module 3|Patients will be given RXC004 at specific doses. One group will be treated for 4 days, followed by 3 days off; repeated weekly for 21 days. A second group will be treated for 2 weeks at the same dose, followed by 1 week off for 21 days.
89428504|NCT03447392|Experimental|patient education and Chinese medicine|1-hour, one-on-one teaching session with a educator to the standard discharge education of Integrated Traditional and Western Medicine
89428505|NCT03447392|No Intervention|patient education|no discharge education
89428506|NCT00765804|Active Comparator|Low Dose: DP 7.5 mA-min at 2.5 mA|Ocular Iontophoresis with EGP-437 (dexamethasone phosphate ophthalmic solution 40 mg/mL) 7.5 mA-min at 2.5 mA
89428507|NCT00765804|Active Comparator|High Dose: DP 10.5 mA-min at 3.5 mA|Ocular Iontophoresis with EGP-437 (dexamethasone phosphate ophthalmic solution 40 mg/mL) 10.5 mA-min at 3.5 mA
89197156|NCT00940810|Active Comparator|Conservative Care|
89197157|NCT00843297|Active Comparator|CG|Coolgard: invasive Cooling
89197158|NCT00843297|Active Comparator|AS|ArcticSun: Surface-Cooling
89197159|NCT00843297|Sham Comparator|UnCOOL|No Cooling-Therapy due to non-operational cooling-devices
89197160|NCT05107778|Experimental|Queue ASC42 10mg|ASC42 10mg, ih PEG-IFN α-2a and ETV for 12 weeks.
89197161|NCT05107778|Experimental|Queue ASC42 15mg|ASC42 15mg , ih PEG-IFN α-2a and ETV for 12 weeks.
89197162|NCT05107778|Placebo Comparator|Queue Placebo|Placebo, ih PEG-IFN α-2a and ETV for 12 weeks.
89197163|NCT00372619|Experimental|Clofarabine 40 mg/m² to assess feasibility in ALL patients.|Clofarabine 40 mg/m² to assess feasibility in ALL patients. Patients receive Cycle 1 (14-42 days) Cytarabine IT (aged based dosage 1-1.99 30 mg, 2-2.99 50 mg, ≥ 3 years 70 mg on Day 0, Clofarabine IV (dosage 40 mg/m2/dose) on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Cycle 2 (14-42 days) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 40 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Maintenance cycles 1-10 (14-42 days each) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 40 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5.
89197164|NCT00372619|Experimental|Clofarabine 40 mg/m² to assess feasibility in AML patients.|Clofarabine 40 mg/m² to assess feasibility in AML patients. Patients receive Cycle 1 (14-42 days) Cytarabine IT (aged based dosage 1-1.99 30 mg, 2-2.99 50 mg, ≥ 3 years 70 mg on Day 0, Clofarabine IV (dosage 40 mg/m2/dose) on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Cycle 2 (14-42 days) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 40 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Maintenance cycles 1-10 (14-42 days each) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 40 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5.
89197165|NCT00372619|Experimental|Clofarabine 52 mg/m² to assess feasibility in ALL patients.|Clofarabine 52 mg/m² to assess feasibility in ALL patients. Patients receive Cycle 1 (14-42 days) Cytarabine IT (aged based dosage 1-1.99 30 mg, 2-2.99 50 mg, ≥ 3 years 70 mg on Day 0, Clofarabine IV (dosage 52 mg/m2/dose) on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Cycle 2 (14-42 days) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 52 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Maintenance cycles 1-10 (14-42 days each) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 52 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5.
89197166|NCT00372619|Experimental|Clofarabine 52 mg/m² to assess efficacy in ALL patients.|Clofarabine 52 mg/m² to assess efficacy in ALL patients. Patients receive Cycle 1 (14-42 days) Cytarabine IT (aged based dosage 1-1.99 30 mg, 2-2.99 50 mg, ≥ 3 years 70 mg on Day 0, Clofarabine IV (dosage 52 mg/m2/dose) on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Cycle 2 (14-42 days) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 52 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Maintenance cycles 1-10 (14-42 days each) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 52 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5.
89197167|NCT00372619|Experimental|Clofarabine 52 mg/m² to assess feasibility in AML patients.|Clofarabine 52 mg/m² to assess feasibility in AML patients. Patients receive Cycle 1 (14-42 days) Cytarabine IT (aged based dosage 1-1.99 30 mg, 2-2.99 50 mg, ≥ 3 years 70 mg on Day 0, Clofarabine IV (dosage 52 mg/m2/dose) on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Cycle 2 (14-42 days) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 52 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Maintenance cycles 1-10 (14-42 days each) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 52 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5.
89197168|NCT00372619|Experimental|Clofarabine 52 mg/m² to assess efficacy in AML patients|Clofarabine 52 mg/m² to assess efficacy in AML patients. Patients receive Cycle 1 (14-42 days) Cytarabine IT (aged based dosage 1-1.99 30 mg, 2-2.99 50 mg, ≥ 3 years 70 mg on Day 0, Clofarabine IV (dosage 52 mg/m2/dose) on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Cycle 2 (14-42 days) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 52 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Maintenance cycles 1-10 (14-42 days each) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 52 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5.
89197169|NCT00372619|Experimental|Clofarabine 52 mg/m² to assess efficacy - ambiguous lineage pt|Clofarabine 52 mg/m² to assess efficacy in acute leukemia of ambiguous lineage patients. Patients receive Cycle 1 (14-42 days) Cytarabine IT (aged based dosage 1-1.99 30 mg, 2-2.99 50 mg, ≥ 3 years 70 mg on Day 0, Clofarabine IV (dosage 52 mg/m2/dose) on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Cycle 2 (14-42 days) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 52 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Maintenance cycles 1-10 (14-42 days each) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 52 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5.
89197170|NCT02546115|Active Comparator|Intervention|standard practice (structured rehabilitation programme) + TNS
89197171|NCT02546115|Active Comparator|control|standard practice (structured rehabilitation programme)
89197172|NCT04477616|Experimental|Experimental: Experimental/PEG-rhG-CSF|patients received a single dose of 6mg of PEG-rhG-CSF(pegfilgrastim), as a single subcutaneous injection on day 7 (chemotherapy day was recorded as day 1). If WBC >= 15 x 10^9/L in the first chemotherapy cycle, then 3mg PEG-rhG-CSF will be used in the second chemotherapy cycle.
89197173|NCT04477616|Active Comparator|Comparator: Comparator/PEG-rhG-CSF|patients received a single dose of 6mg of PEG-rhG-CSF(pegfilgrastim), as a single subcutaneous injection on day 3 (chemotherapy day was recorded as day 1). If WBC >= 15 x 10^9/L in the first chemotherapy cycle, then 3mg PEG-rhG-CSF will be used in the second chemotherapy cycle.
89197174|NCT00851175|No Intervention|1|forearm bloodflow after 2,3, and 5 minutes of forearm ischemia
89197175|NCT00851175|Active Comparator|2|forearm bloodflow after 2,3, and 5 minutes of forearm ischemia with concommitant administration of caffeine (90 ug/min/100ml forearm volume) into the brachial artery of the experimental (=non dominant) arm
89197176|NCT00851175|Experimental|3|forearm bloodflow after 2,3, and 5 minutes of forearm ischemia after 7 days oral treatment with rosuvastatin 1dd 20mg
89008189|NCT04602013|Experimental|Immunotherapy combined with chemoradiotherapy|"Immunotherapy combined with chemoradiotherapy~Sintilimab Body weight <60kg: 3mg/kg IV Q3W; Body weight ≥60kg: 200mg IV Q3W.~Chemotherapy drugs include cisplatin and albumin-bound paclitaxel for injection Paclitaxel for injection (albumin-bound type) dose: 3 dose groups (di=260 mg/m2, di-1=220 mg/m2, di-2=180 mg/m2).~Dosing on the first day, one cycle every three weeks, a total of 2 cycles. Cisplatin (25mg/m2 IV D1-3 Q3W)~Radiotherapy The total dose is 60-66 Gy, divided into 30-33 times (2.0 Gy/f, 5 f per week)."
89008190|NCT04601701|Experimental|CRVO: Bevacizumab and intravitreal Dexamethasone.|Participants with CRVO will receive a combination of Bevacizumab and intravitreal Dexamethasone.
89197177|NCT00851175|Active Comparator|4|forearm bloodflow after 2,3, and 5 minutes of forearm ischemia after 7 days oral treatment with rosuvastatin 1dd 20mg with concommitant administration of caffeine (90 ug/min/100ml forearm volume) into the brachial artery of the experimental (=non dominant) arm
89197178|NCT04043013|Active Comparator|Mini-Taurus® (Rocky Mountain©) Brackets|"Brackets Mini-Taurus® (Rocky Mountain©) with:~ORTHODONTIC BRACKET PRESCRIPTION Canines 0º First Premolar 0º Second Premolar 0º First Molar 0º"
89197179|NCT04043013|Active Comparator|Smart Clip® SL3 High Torque (3M Unitek©)|"Brackets Smart Clip® SL3 High Torque (3M Unitek©) with:~ORTHODONTIC BRACKET PRESCRIPTION~Canines +6º First Premolar -4º Second Premolar -4º First Molar -14º"
89197180|NCT04043013|Active Comparator|Tip-Edge Plus® (TP Orthodontics©)|"Brackets Tip-Edge Plus® (TP Orthodontics©) with:~ORTHODONTIC BRACKET PRESCRIPTION~Canines -4º First Premolar -7º Second Premolar -7º First Molar 0º -14º -11º -14º"
89197181|NCT04043013|Active Comparator|Victory® (3M Unitek©)|"Brackets Victory® (3M Unitek©) with:~ORTHODONTIC BRACKET PRESCRIPTION~Canines 0º First Premolar -7º Second Premolar -7º First Molar -14º"
89197182|NCT00845637|Active Comparator|Eggplant extract|
89197183|NCT00845637|Placebo Comparator|Placebo|
89197184|NCT03992833|Experimental|lung cancer screening|"Participants will undergo a chest CT scan in the Department of Radiology at Tianjin Cancer Hospital. All scans will be performed using the same CT system: Definition AS. Two readings of the images will be performed. In the first image reading, the CT images will be read by specially trained Chinese resident radiologist and checked by one of two senior Chinese radiologists. Lung Cancer Screening (version 2. 2018) Guidelines of the National Comprehensive Cancer Network (NCCN) will be used for the management of lung nodules. This guideline recommends management of lung nodules based on diameter. In the second reading, a semi-automated volumetry software will be used to measure the volume and evaluate the other parameters of lung nodules.~At baseline and one year after baseline, data about general characteristics, risk factors of lung cancer, and health status of the participants will be collected."
89197185|NCT02566226|Placebo Comparator|Bupivacaine with normal saline|
89197186|NCT02566226|Active Comparator|Bupivacaine with intrathecal morphine|
89197187|NCT00837057|Other|early crrt, late crrt|
89197188|NCT00837135|Experimental|All Subjects|Screening for Eligibility into Trial
89197189|NCT00837135|Experimental|ARM A|GI-4000 Vaccine
89197190|NCT00837135|Experimental|ARM B|GI-4000 Vaccine + Activated T Cells
89197191|NCT00837135|Experimental|After GI-4000 Vaccine #4|GI-4000 Monthly - For those with incomplete removal of tumor GI-4000 Monthly + Chemotherapy - For those with complete removal of tumor
89197192|NCT03896048||Successful extubation|
89197193|NCT03896048||Failed extubation|Failed extubation will be defined as a patient who in the first 48 hours after extubation are reintubated, have unplanned non-invasive ventilation (NIV) or who have a tracheostomy.
89197194|NCT00845715|Other|Early motion|
89197195|NCT00845715|Other|Standard motion|
89197196|NCT02546349|Experimental|high eNO: ICS/LABA|patients with eNO >=23.5 ppb, receive inhaled corticosteroid (ICS)/long-acting beta2 agonist (ICS/LABA) of fluticasone/salmeterol 250/25 mcg/puff, 2 puffs bid.
89197197|NCT02546349|Active Comparator|high eNO: LAMA|patients with eNO >=23.5 ppb, receive long acting muscarinic antagonist (LAMA) of tiotropium 2 inhalations 2.5 mcg/inhalation, once daily
89197198|NCT02546349|Experimental|Low eNO: ICS/LABA|patients with eNO < 23.5 ppb, receive fluticasone/salmeterol 250/25 mcg/puff, 2 puffs bid
89197199|NCT02546349|Active Comparator|Low eNO: LAMA|patients with eNO < 23.5 ppb, receive tiotropium 2 inhalations 2.5 mcg/inhalation, once daily
89197200|NCT00851487|Experimental|Amoxicillin|Oral amoxicillin in the dose of 15 mg/kg/dose 8 hourly was given as an active drug
89197201|NCT00851487|Placebo Comparator|Placebo|The placebo was similar in colour, consistency and volume as oral amoxicillin
89197202|NCT00622167|Other|1|All patients will receive integrated backscatter IVUS and dual source CT.
89197203|NCT04042857|Experimental|Next Science|Patients will apply Next Science treatment to the study target hallux nail for 48 weeks daily.
89197204|NCT04235907|Active Comparator|Traditional Physical Therapy|Patients will be given a prescription to see a physical therapist and a paper-based rehabilitation protocol. Patients will be allowed to receive physical therapy at a location of patients' choosing. This arm represents the current standard of care.
89197205|NCT04235907|Active Comparator|Telerehabilitation|Patients will be given access to a website containing instructions with pictures and videos for the exercises patients are to complete as part of patients' rehabilitation. Patients will not be given a prescription to physical therapy. Patients in this group will receive weekly calls from a physical therapist during weeks 6-12 post-operatively.
89197206|NCT00562354|Experimental|1|Stratum 1: >= 65 years of age
89197207|NCT00562354|Experimental|2|Stratum 2: 50 to 64 years of age
89197208|NCT00372385|Placebo Comparator|PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week|Placebo (PBO) matched to telaprevir tablet orally thrice daily for 12 weeks in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (RBV) orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (<) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (>=) 75 kg, for 48 weeks.
89197209|NCT00372385|Experimental|Telaprevir 12 Week +Peg-IFN-alfa-2a,RBV 24 Week|Single loading dose of telaprevir 1250 mg tablet orally on Day 1 followed by 750 mg telaprevir tablet orally thrice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 24 weeks.
89197210|NCT00372385|Experimental|Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 12 Week|Single loading dose of telaprevir 1250 mg tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 12 weeks.
89197211|NCT00372385|Experimental|Telaprevir 12 Week+Peg-IFN-alfa-2a 12 Week|Single loading dose of telaprevir 1250 mg tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection, for 12 weeks.
89197212|NCT03830281|Active Comparator|Insulin Lispro (Humalog)|Participants received individual dose of 100 U/mL insulin lispro (Humalog) by CSII; where mealtime boluses were delivered 0 to 2 minutes prior to the start of each meal, with basal infusion rates 24 hours/day, and correction boluses as necessary.
89197213|NCT03830281|Experimental|Ultra-Rapid Lispro|Participants received individual dose of 100 units per milliliter (U/mL) ultra rapid lispro by continuous subcutaneous insulin infusion (CSII); where mealtime boluses were delivered 0 to 2 minutes prior to the start of each meal, with basal infusion rates 24 hours/day, and correction boluses as necessary.
89197214|NCT00563368|Experimental|VI-0521 Top|VI-0521; high dose phentermine/topiramate
89197215|NCT00563368|Experimental|VI-0521 Mid|VI-0521; mid dose phentermine/topiramate
89197216|NCT00563368|Active Comparator|TPM 46|mid dose topiramate
89197217|NCT00563368|Active Comparator|TPM 92|high dose topiramate
89197218|NCT00563368|Active Comparator|PHEN 7.5|mid dose phentermine
89197219|NCT00563368|Active Comparator|PHEN 15|high dose phentermine
89197220|NCT00563368|Placebo Comparator|Placebo|
89197221|NCT02535013|Placebo Comparator|Control|No intervention during the perioperative period. Perform lung ultrasound twice only for the diagnostic purpose at the end of surgery and 6 to 12 hours after surgery in the intensive care unit.
89197222|NCT02535013|Active Comparator|Ultrasound|Perform lung ultrasound three times during the perioperative period; after the induction of general anesthesia, at the end of surgery, and 6 to 12 hours after surgery in the intensive care unit. According to the lung ultrasound finding, conduct appropriate interventions such as, alveolar recruitment maneuver for atelectasis, or chest tube insertion for pneumothorax.
89197223|NCT00390013|Active Comparator|Gabapentin|Gabapentin (Neurontin) titration and dosing for total of 8 weeks (Cross over)
89197224|NCT00390013|Placebo Comparator|Placebo oral capsule|Placebo titration and dosing for total of 8 weeks (Cross over)
89197225|NCT00561652|Active Comparator|Education + exercise|Education was provided in four, 1-hour sessions to improve patients' understanding of their back problem, reduce unwarranted concern about serious outcomes, & empower them to maintain normal activities & reduce risk of future back problems. Patients were taught that recovery depends on moving & restoring normal function & fitness. Patients were shown stretching & strengthening exercises to perform daily at home to enhance mobility & increase trunk endurance while minimizing spinal load. At follow-up, therapists reviewed exercise form & adherence. Participants allocated to no chiropractic care also were scheduled for 10 weekly 10-15 minute sessions to equalize provider attention vs. the group also receiving chiropractic care & not to provide education, exercise instruction, or therapy.
89197226|NCT00561652|Experimental|Education + exercise + chiropractic|In addition to education & exercise, all participants in this arm will be assigned chiropractic treatment. A minimum of 4 & up to 12 treatments will be provided over 6 weeks, based on patient response (i.e. treatments stopped if symptoms resolve). Each treatment visit will last 10-20 minutes. After 6 weeks, if the treating chiropractor determined that the patient's LBP was continuing to improve but hadn't reached therapy goals defined at baseline, the patient could receive up to 12 additional treatments over the next 6 weeks. Chiropractic treatment was delivered following standardized protocols. Treatment consisted of manual therapies, including SMT and mobilization techniques, with the assistance of light soft tissue techniques as indicated to facilitate the SMT.
89428508|NCT00765804|Placebo Comparator|Placebo: 10.5 mA-min at 3.5 mA|Ocular Iontophoresis with Placebo (sodium citrate buffer solution 100 mM at 10.5 mA-min at 3.5 mA)
89428509|NCT03447236|Experimental|Feuerstein Program|All subjects participating in the Feuerstein Program will be evaluated by anatomical and functional MRI as well as computerized cognitive assessment prior to and following intervention as outlined in the protocol.
89428510|NCT00764634|Placebo Comparator|1 Placebo|
89428511|NCT00764634|Active Comparator|2 rBV A/B Vaccine|
89428512|NCT00764634|Placebo Comparator|3 Placebo|
89008191|NCT04601701|Active Comparator|CRVO: Bevacizumab|Participants with CRVO will receive a combination of Bevacizumab only.
89428513|NCT00764634|Active Comparator|4 rBV A/B Vaccine|
89428514|NCT03447158|Experimental|15% Dextrose group|4.5cc 15% dextrose and 0.5cc 1% xylocaine was injected into inflamed subacromial bursa under sonographically guidance
89428515|NCT03447158|Placebo Comparator|control group|4.5cc normal saline and 0.5cc 1% xylocaine was injected into inflamed subacromial bursa under sonographically guidance
89428516|NCT03443804|Experimental|Test(DW1401)|tid PO, DW1401+Placebo of Stillen tab.
89428517|NCT03443804|Active Comparator|Reference(Stillen tab.)|tid PO, Stillen tab.+Placebo of DW1401
89428518|NCT04830904|Experimental|Use of lycra garments|the subjects are assessed with and without wearing the device
89428519|NCT03443726|Experimental|Infiltrative technique|Patients in this arm will have buccal and lingual infiltrative anesthesia with 4% articaine 1:100.000 epinephrine for third molar extraction.
89428520|NCT03443726|Active Comparator|Nerve block technique|Patients in this arm will have inferior alveolar nerve and buccal nerve block with 4% articaine 1:100.000 epinephrine for third molar extraction.
89428521|NCT04336956||hospitalized children with Covid19|- Children < 18 years old Patients under 18 years old, admitted in French pediatric wards with a confirmed COVID-19 infection on Nasal and pharyngeal swab specimens or blood samples tested positive for 2019-nCoV nucleic acid using real-time reverse-transcriptase polymerase-chain-reaction (RT- PCR) assay; or on typical chest CT signs
89428522|NCT04830670||Large sinus|same patient, sinus width > 12mm measured at 10mm from the alveolar crest at the planned implant site
88908999|NCT05713903|Experimental|Laparoscopic right colectomy|In laparoscopic right colectomy subgroup, the patient will be placed in a lithotomy position. Entrance in the peritoneal cavity will be completed via the open Hasson method. Overall, 4 ports will be used: 10mm at the umbilicus for optical entry, 12mm in the left midclavicular line below the umbilicus as the main working port, 5mm at the McBurney point, and 5mm between the umbilicus and the xiphoid process. Dissection of the peritoneal fold, under the terminal ileum, will be performed based on the medial to lateral approach. Similar to the open approach, the ileocolic vessels, as well as the right branches of the middle colic will be ligated at their origin for cecal and proximal ascending tumors. For hepatic flexure cancers, the medial colic vessels will be ligated. The ileocolic anastomosis will be completed either intracorporeally or extracorporeally, using staples or sutures.
88909000|NCT05713903|Active Comparator|Open right colectomy|In the open right colectomy group, the operation will start with a midline incision and dissection based on the lateral to medial approach. The lateral peritoneal fold along Toldt's line will be incised and the ascending colon will be mobilized from the retroperitoneum according to the embryological dissection planes. Dissection will continue until the anterior surface of the superior mesenteric vessels at the third duodenal part. Ileocolic and right colic vessels will be ligated at their origins. For hepatic flexure tumors, the middle colic vessels will be also ligated at their origin. The ileocolic anastomosis will be performed using an automatic stapler. The anastomosis will be completed either with staples or sutures.
88909001|NCT05712668|Active Comparator|Standard Pre-operative Counseling|Participants will receive standard counseling.
88909002|NCT05712668|Experimental|Standard Pre-operative Counseling plus Asynchronous Telemedicine|Participants will receive standard counseling plus access to a 5 minute video reviewing their in-office counseling.
88909003|NCT05709873|Experimental|Imagery rehearsal therapy (IRT)|Participants randomized to this group will receive 7 sessions of IRT.
88909004|NCT05709873|Experimental|Imagery rehearsal therapy and targeted dream control (IRT+TDC)|Participants randomized to this group will receive 7 sessions of IRT+TDC.
88909005|NCT05707676|Experimental|Dose Escalation|"Up to 9 dose cohorts will be sequentially enrolled in the dose escalation part using an accelerated titration combined with the standard BOIN dose escalation algorithm approach."
88909006|NCT05707676|Experimental|Single Drug Expansion|To further evaluate the safety, tolerance and preliminary clinical efficacy of LB4330 single drug in specific tumor species, the planned expanded cohort and number of subjects are as follows: Cohort A: LB4330 single drug therapy, 10 patients with advanced gastric and gastroesophageal junction adenocarcinoma with Claudin 18.2 expression;Cohort B: LB4330 single drug therapy, 5 patients with advanced pancreatic ductal adenocarcinoma with Claudin 18.2 expression; Cohort C: LB4330 single drug therapy, other advanced solid tumor patients with Claudin 18.2 expression, a total of 8-15 cases.
88909007|NCT05706701|Experimental|Nicotine vaping group visit 1|Subjects will receive the either free-base or protonated form of four nicotine fluxes: 9, 18, 27, 35 μg/sec at their first of two visits. In the first visit, participants will use the ENDS device with one nicotine form and four fluxes in random order. Participants will be instructed to attend the lab for a second visit, to test the four fluxes but with the other nicotine form.
89428523|NCT04830670||narrow sinus|same patient, sinus width < 12mm measured at 10mm from the alveolar crest at the planned implant site
89428524|NCT04426864|Active Comparator|Supervised Aerobic Plus Stretching Exercises Group|The participants were instructed to perform the walking exercise at their target HR on a treadmill and stretching exercises before and after the exercise program in the Sports Rehabilitation Unit of Pamukkale University.
89428525|NCT04426864|Experimental|Supervised Resistance Plus Stretching Exercises Group|The participants were instructed to perform resistance exercises using weight machines and stretching exercises before and after the exercise program in the Sports Rehabilitation Unit of Pamukkale University.
89428526|NCT04426864|Experimental|Home-based Stretching Exercises Group|The participants were instructed to perform the stretching exercises at home.
89428527|NCT04810000||Group A|Group A ( Tourniquet release before wound closure and hemostasis ensured )
89428528|NCT04810000||Group B|Group B ( Tourniquet release after wound closure )
89428529|NCT03447080|Other|Control 1|White bread
89428530|NCT03447080|Other|Control 2|White bread
89428531|NCT03447080|Experimental|Rice bran soybean milk|White Bread with 195ml of rice bran soybean mil
89428532|NCT03447080|Experimental|Soybean milk|White Bread with 195ml of soybean milk
89428533|NCT00760344|Experimental|SYR-472 3.125 mg QD|(with lifestyle modification and/or metformin stable dose therapy)
89428534|NCT00760344|Experimental|SYR-472 12.5 mg QD|(with lifestyle modification and/or metformin stable dose therapy)
89428535|NCT00760344|Experimental|SYR-472 50 mg QD|(with lifestyle modification and/or metformin stable dose therapy)
89428536|NCT00760344|Experimental|SYR-472 100 mg QD|(with lifestyle modification and/or metformin stable dose therapy)
89428537|NCT00760344|Placebo Comparator|Placebo QD|(with lifestyle modification and/or metformin stable dose therapy)
89197227|NCT00697346|Experimental|Part 1: PIC Dose Escalation|Alisertib 25 or 35 mg, Powder-in-Capsule (PIC) formulation, orally, once daily (QD) for 21 days followed by a 7-day recovery period in 28-day cycles or alisertib 35, 45, 65 or 90 mg PIC, orally, (QD for 14 days followed by a 14-day recovery period in 28-day cycles, until disease progression or unacceptable alisertib-related toxicity (up to 14 cycles). All participants received an initial starting dosage of alisertib PIC 25 mg, orally, twice daily (BID) on Day 1 (loading dose), followed by their respective dosage assignment.
89428538|NCT00760344|Active Comparator|Sitagliptin 100 mg QD|(with lifestyle modification and/or metformin stable dose therapy)
89428539|NCT03443570|Experimental|combination treatment group|100 enrolled patients are randomly picked up to take rituximab in combination with bortezomib at the indicated dose
89428540|NCT03443570|Active Comparator|control group|100 enrolled patients are randomly picked up to take rituximabalone at the indicated dose
89428541|NCT01695980|Experimental|LMA with modified retractor|LMA with modified retractor
89428542|NCT01695980|Active Comparator|ETT with non modified retractor|ETT with non modified retractor
89428543|NCT02718404|Experimental|MR-HIFU Treatment|"The Philips MR-HIFU Sonalleve System integrates a high intensity phased array focused ultrasound transducer with a 3 Tesla Magnetic Resonance (MR) imaging system and electromechanical transducer positioning system to deliver spatially and temporally controlled ultrasound energy and thermal heat to tissues non-invasively.~At HIFU day (day 0) before treatment patient will be performed a bone lesion MRI and a functional brain MRI.~During the treatment procedure, an intravenous catheter will deliver MR contrast media and medications (such as sedation and analgesics if required) within the MR room.~Following the MR-HIFU procedure, a set of MR images of the target region will be acquired with the use of a MR contrast agent, together with a functional brain MRI."
89428544|NCT03443492|Experimental|SLOG|800 mg/m2 gemcitabine at a fixed rate of 10 mg/m2/min followed by a 2-hour intravenous infusion of oxaliplatin on day 1 plus twice daily oral S-1 80-120 mg/day (based on BSA) and oral leucovorin 30 mg twice a day on day 1 to day 7, every 14 days as a cycle
89428545|NCT03443492|Experimental|mFOLFIRINOX|oxaliplatin at a dose of 85 mg/m2, given as a 2-hour infusion, with the addition, after 30 minutes, of irinotecan at a dose of 150 mg/m2, given as a 90-minute infusion. The treatment was immediately followed by a continuous intravenous infusion via central venous catheter of leucovorin 400 mg/m2 given as a 2-hour infusion and 5-FU 2400 mg/m2 over a 46-hour period on day 1 every 14 days/cycle.
89197228|NCT00697346|Experimental|Part 1: ECT Dose Escalation|Alisertib 40 mg, Enteric-coated Tablet (ECT) formulation, orally, QD for 14 days followed by a 14-day recovery period in 28-day cycles, or alisertib 30, 40 or 50 mg ECT, orally BID for 7 days followed by a 14-day recovery period in 21-day cycles, until disease progression or unacceptable alisertib-related toxicity (up to 15 cycles).
89428546|NCT03497520|Experimental|scoliosis patients|scoliosis patients who have cobb angle over 10 degree perform asymmetric spinal stabilization exercise
89428547|NCT03446924|Placebo Comparator|Control|The control group will be given a single dose of 1.5 g rice flour in capsule form (250 mg / capsule). The gelatine capsules (MyProtein, Northwich, UK) used are identical to those used in the treatment group. Capsules are prepared by the investigatory team using good hygiene practice in the research kitchen of the School of Sport, Exercise and Rehabilitation (University of Birmingham).
89428548|NCT03446924|Active Comparator|Treatment|"The treatment group will be given a single dose of 1.5g phosphatidic acid in capsule form (250 mg / capsule). Capsules are prepared by the investigatory team using good hygiene practice in the research kitchen of the School of Sport, Exercise and Rehabilitation (University of Birmingham).~PA is considered a dietary supplement ingredient according to the US FDA. The source of PA will be a commercial available soy-derived PA (Mediator®, Chemi Nutra, White Bear Lake, MN). The safety of Mediator® Soy-PA has been thoroughly demonstrated in humans. Mediator® Soy-PA does not contain any compounds with narcotic, psychotropic or pharmaceutical effects and is in compliance with banned substances requirements as espoused by the World Anti-Doping Agency. Mediator® Soy-PA is not a medicinal product."
88909008|NCT05706701|Experimental|Nicotine vaping group visit 2|The same subjects from visit 1 will receive the either free-base or protonated form of four nicotine fluxes: 9, 18, 27, 35 μg/sec at their second study visit, using the opposite nicotine form that was used during the first visit.
89197229|NCT00697346|Experimental|Part 2: PTCL|Participants with peripheral T-cell lymphoma (PTCL) received alisertib 50 mg ECT, orally, BID for 7 days followed by a 14-day recovery period in 21-day cycles, until disease progression or unacceptable alisertib-related toxicity (up to 2 cycles).
89197230|NCT00562120|Placebo Comparator|Placebo|
89197231|NCT00562120|Active Comparator|Allegra|
89197232|NCT00562120|Active Comparator|Allegra-D|
89428549|NCT03134508||pregnant IBD women treated|pregnant IBD women treated by antiTNFα
89197233|NCT00562120|Experimental|PF-03654746|
89197234|NCT00941044|Experimental|non-invasive NAVA|application of non-invasive neurally adjusted ventilatory assist in healthy volunteers
89197235|NCT00939172|Experimental|TTP607|
89428550|NCT03134508||pregnant IBD women not treated|pregnant IBD women not treated by antiTNFα
89428551|NCT00724698||Group|Patients diagnosed with Allergic Rhinitis or Chronic Idiopathic Urticaria
89428552|NCT00830154|Experimental|1|0.30 mg pagoclone BID
89428553|NCT00830154|Experimental|2|0.60 mg pagoclone BID
89428554|NCT00830154|Placebo Comparator|3|placebo
89428555|NCT00826982||Pancreatic Cancer|
89428556|NCT00722592|Experimental|Vintafolide + PLD|Participants receive vintafolide 2.5 mg intravenous (IV) bolus on Days 1, 3, 5, 15, 17, and 19 and Pegylated Liposomal Doxorubicin (PLD) weight-based dose, IV on Day 1 of each 4-week cycle.
89428557|NCT00722592|Active Comparator|PLD Alone|Participants receive PLD on Day 1 of each 4-week cycle.
89428558|NCT00829998|Experimental|Zaleplon|Zaleplon 10 mg Capsule (test) dosed in first period followed by Sonata® 10 mg Capsule (reference) dosed in second period
89428559|NCT00829998|Active Comparator|Sonata®|Sonata® 10 mg Capsule (reference) dosed in first period followed by Zaleplon 10 mg Capsule (test) dosed in second period
89428560|NCT02551718|Experimental|Treatment (chemosensitivity testing, chemotherapy)|Leukemia cells purified from blood or bone marrow samples are analyzed for sensitivity to individual drugs and drug combination and by next generation sequencing.
88909009|NCT05706493|Other|Non-surgical periodontal treatment|assessment of different periodontal parameters and gingival crevicular fluid sampling will be done then non surgical periodontal treatment will be performed then after 3 months re assessment of the periodontal parameters and gingival crevicular fluid sampling will be done
88909010|NCT05706480||Periodontally clinically healthy patients|In Periodontally clinically healthy patients fulfilling the eligibility criteria. The gingival tissue thickness will be measured using probe-colored periodontal probes (CPP), standard periodontal probes (SPP) and transgingival sounding with an endodontic file (ISO #20), visual judgment using photographs will be done to the three assessment methods
88909011|NCT05706116|Experimental|Trichuris trichiura Egg Inoculum 150 eggs|150 Trichuris trichiura eggs
88909012|NCT05706116|Experimental|Trichuris trichiura Egg Inoculum 300 eggs|300 Trichuris trichiura eggs
88909013|NCT05706116|Experimental|Trichuris trichiura Egg Inoculum 450 eggs|450 Trichuris trichiura eggs
88909014|NCT05702021|Experimental|Science of Service Laboratory implementation strategy|The Science of Service Laboratory implementation strategy consists of: didactic training (contingency management workshops; monthly contingency management coaching calls), performance feedback (practice sessions and electronic medical record feedback); and facilitation (monthly facilitation calls).
88909015|NCT05702021|No Intervention|Stepped wedge comparator|Our hybrid trial uses a unidirectional crossover stepped wedge design. All sites cross over in the same direction from usual care to intervention. All sites therefore act as their own comparison prior to the sequential roll-out of the implementation strategy.
88909016|NCT05700435|Experimental|Randomization|At two study sites, we will randomly assign participants to the VTC/in-person group or CBT group using a ratio of 2:1 to assign participants to the VTC/in-person or CBT training modalities. We anticipate 84 participants (42 per site) will be assigned to the CBT modality and 168 (84 per site) will be assigned to the VTC/in-person modality.
88909017|NCT05700435|Active Comparator|Self-selection|At two study sites, participants will be able to self-select which SMART training modality they will complete (VTC/in-person or CBT).We aim to recruit 250 participants in the self-selection arm.
89428561|NCT00722358|Active Comparator|BMS-650032|
89428562|NCT00722358|Placebo Comparator|Placebo|
89428563|NCT00719550|Placebo Comparator|Phase 2 Arm C|AMG 102 placebo plus ECX
89428564|NCT00719550|Other|Phase 1b|Phase 1b dose study with open-labe AMG 102 at 15mg/kg de-escalating to 7.5mg/kg and 5mg/kg if needed.
89428565|NCT00719550|Active Comparator|Phase 2 Arm B|AMG 102 at 7.5mg/kg plus ECX
89428566|NCT00719550|Active Comparator|Phase 2 Arm A|AMG 102 at 15mg/kg plus ECX
89428567|NCT03443258|Experimental|Intervention Group (IG)|Patients receive needs assessment tool integrated in nursing consultation in accordance with requirements by Danish Health and Medicine Board follow-up program for HNC patients. The consultation consists of 6 steps 1. Welcoming patient; 2. Introducing patient to assessment tool; 3. Discuss symptoms and concerns patient wishes to discuss; 4. Follow up on patients symptoms, concerns and emotional reactions/problems; 5. Accompany/support patient during appointment with surgeon and in cooperation with patient and surgeon ensure that problems arising from the tool needing medical attention are focused on; 6. Continue the consultation after appointment with surgeon; refer patient to multi-disciplinary team members when needed
89428568|NCT03443258|No Intervention|Control Group (CG)|CG will receive standard care according to the Danish Health and Medicine Board's follow-up program for HNC patients. At present this is done by a staff nurse interviewing the patient, who is a member of the rehabilitation team who perform nursing consultations. The interview takes place after the appointment with the surgeon. The nurse refers the patient to physical rehabilitation if needed
89428569|NCT04256304|Experimental|Intervention group|"Personalized Health Engagement Plan group~First face-to-face session (Motivational interviewing) + Pre-tests~Patient Health Engagement Scale~Assessment Scale for Treatment Adherence in Type 2 Diabetes Mellitus~The Diabetes Management Self-Efficacy Scale for Patients with Type 2 Diabetes Mellitus~Phone call coaching~A set of personalized home-based exercises~Second face-to-face session (Motivational interviewing) + Post-tests"
89536872|NCT03312413|Experimental|Dexmedetomidine median dose group|Patients in this group are received dexmedetomidine hydrochloride iv infusion of 0.5μg·kg-1·h-1 from incision to 20-30 minutes before the end of surgery
88909018|NCT05699785|Experimental|patients on antiretroviral therapy with second generation anti-integrase drugs in triple therapy|
88909019|NCT05699785|Experimental|patients on antiretroviral therapy with second generation anti-integrase drugs in dual therapy|
88909020|NCT05691504|Experimental|Treatment (pelcitoclax, cobimetinib)|Patients receive APG-1252 IV Q7D. Patients also receive cobimetinib PO QD on days 1-21 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo biopsy and collection of blood on study and undergo CT and/or MRI throughout the trial. Patients undergo ECHO or MUGA during screening and on study.
88909021|NCT05690230|Experimental|Intervention 1: Virtual reality|
88909022|NCT05690230|No Intervention|Control 1|Standard of care without change, in parallel with intervention 1: Virtual reality.
88909023|NCT05690230|Experimental|Intervention 2: Environmental changes|
88909024|NCT05690230|No Intervention|Control 2|Standard of care without change, in parallel with intervention 2: Environmental changes.
88909025|NCT05688293|Active Comparator|Connective tissue graft|Patients will receive non-surgical periodontal treatment and connective tissue graft using tunneling technique
88909026|NCT05688293|Active Comparator|Free gingival Graft|Patients will receive non-surgical periodontal treatment and partially de-epithelized free gingival graft
88909027|NCT05688293|Active Comparator|Non surgical procedure|Patients will receive non-surgical periodontal treatment only
88909028|NCT05687058|Experimental|Empagliflozin 25 mg thrice-weekly post-hemodialysis dosing|All participants undergoing thrice-weekly hemodialysis (HD) on the Monday-Wednesday-Friday (MWF) schedule will be assigned to the empagliflozin 25 mg thrice-weekly post-hemodialysis dosing arm (Group I).
88909029|NCT05687058|Experimental|Empagliflozin 10 mg daily dosing|Patients undergoing thrice-weekly hemodialysis (HD) on the Tuesday-Thursday-Saturday (TTS) schedule, patients on twice-weekly HD, or patients on peritoneal dialysis will receive empagliflozin 10 mg daily (Group II).
89428570|NCT04256304|No Intervention|Control group|"First meeting (Pre-tests)~Patient Health Engagement Scale~Assessment Scale for Treatment Adherence in Type 2 Diabetes Mellitus~The Diabetes Management Self-Efficacy Scale for Patients with Type 2 Diabetes Mellitus~Second meeting (Post-tests)~Patient Health Engagement Scale~Assessment Scale for Treatment Adherence in Type 2 Diabetes Mellitus~The Diabetes Management Self-Efficacy Scale for Patients with Type 2 Diabetes Mellitus"
89428571|NCT03443180|Other|Dietary intervention|Participants will be asked to remove food containing gluten and ATI from their diets for 4 weeks.
89197236|NCT01563016|Experimental|Glucose & Depleting|participants will perform in a depleting task and receive a glucose drink
89197237|NCT01563016|Placebo Comparator|Glucose & non-depleting|participants will perform in a non-depleting task and receive a glucose drink
88909032|NCT05683639|No Intervention|Standard protocol|The standard protocol comprises no heating of the aspiration needle.
88909033|NCT05683639|Experimental|Warming protocol|The aspiration needle will be warm-up overnight the day before the oocyte pick-up procedure
88909034|NCT05679258|Experimental|HLX15 group|Recombinant anti-CD38 fully human monoclonal antibody injection developed by Shanghai Henlius Biotech, Inc.
89428572|NCT04254354||transgender men|no intervention
88909035|NCT05679258|Active Comparator|US-sourced DARZALEX® group|Daratumumab injection
88909036|NCT05679258|Active Comparator|CN-sourced DARZALEX® group|Daratumumab injection
88909037|NCT05679258|Active Comparator|EU-sourced DARZALEX® group|Daratumumab injection
88909038|NCT05678179|Experimental|Telehealth|
88909039|NCT05678179|Active Comparator|In Person (Face-2-Face)|
89197238|NCT01563016|No Intervention|Placebo & depleting|participants will perform in a depleting task and receive a placebo drink
89428573|NCT05018702|Experimental|ARX788|
89197239|NCT01563016|No Intervention|Placebo & non depleting|participants will perform in a non depleting task and receive a placebo drink
89197240|NCT00561730||Pantoprazole|All patients enrolled
89197241|NCT00697112||A|
89197242|NCT00621855|Experimental|Dabigatran etexilate 50mg|twice daily dosing,
89428574|NCT05016518|Experimental|Propofol group|Propofol based total intravenous anesthesia
89428575|NCT05016518|Active Comparator|Remimazolam group|Remimazolam based total intravenous anesthesia
88909040|NCT05671757|Experimental|4 mg/kg Cohort|This cohort will receive intravenous (IV) administration of 4 mg/kg daratumumab administered weekly for 8 doses (weeks 0 through 7). Post-treatment follow-up visits will occur at weeks 9, 12, 18, 24, 36, and 48
89197243|NCT00621855|Experimental|Dabigatran etexilate 75mg|twice daily dosing, patients with moderate renal impairment allocated 50mg bid
88909041|NCT05671757|Experimental|8 mg/kg Cohort|This cohort will receive intravenous (IV) administration of 8 mg/kg daratumumab administered weekly for 8 doses (weeks 0 through 7). Post-treatment follow-up visits will occur at weeks 9, 12, 18, 24, 36, and 48
88909042|NCT05671757|Experimental|16 mg/kg Cohort|This cohort will receive intravenous (IV) administration of 16 mg/kg daratumumab administered weekly for 8 doses (weeks 0 through 7). Post-treatment follow-up visits will occur at weeks 9, 12, 18, 24, 36, and 48
88909043|NCT05670912|Experimental|active group|Take 2 tablets each time (study drug), 3 times a day, a total of 0.9g per day. Take it with warm water half an hour before meals.
89197244|NCT00621855|Experimental|Dabigatran etexilate 110mg|twice daily dosing, patients with moderate renal impairment allocated 75mg bid
89197245|NCT00621855|Experimental|dabigatran etexilate 150mg|twice daily dosing, patients with moderate renal impairment allocated 110mg bid
88909044|NCT05670912|Placebo Comparator|control group|Take 2 tablets of the control drug (placebo) each time, 3 times a day, 0.9g a day. Take it with warm water half an hour before meals.
88909045|NCT05669729||VPRIV® Home Infusion|Participants diagnosed with Gaucher disease will receive VPRIV® home infusion, administered by their caregivers and home infusion nurses will participate in the survey and complete the non-nominative web-based questionnaires on Day 1.
88909046|NCT05666245|Other|Donors|Donors are persons naturally infected with influenza.
88909047|NCT05666245|Experimental|Intervention Recipients|Intervention recipients are participants who do not have influenza and will use personal protective equipment.
88909048|NCT05666245|No Intervention|Control Recipients|Control recipients are participants who do not have influenza and will not be using personal protective equipment.
88909049|NCT05664763|Experimental|Cannabis use disorder|CUD participants participants undergo neuroimaging, cognitive testing, and EEG at baseline and following cannabis abstinence at 4 weeks follow-up. Participants will receive motivational enhancement and contingency management during the 4-week abstinence period.
88909050|NCT05664763|Experimental|Healthy control|Healthy control participants undergo neuroimaging, cognitive testing, and EEG at baseline.
88909051|NCT05663931|Experimental|DM Discharge Toolkit|Up to 60 participants will be recruited for the intervention group. Participants will receive the current standard of care DM education for insulin at Northwestern Memorial Hospital and the adjunctive education with the DM Discharge Toolkit.
88909052|NCT05663931|No Intervention|Current Standard of Care Discharge DM Training|Up to 60 participants will be recruited for the control group. Participants will receive the current standard of care DM education for insulin use during current discharge care processes at Northwestern Memorial Hospital.
88909053|NCT05662033|Experimental|Part 1 (SAD): Cohort 1|6 Healthy subjects will receive a single oral dose A of AZD6793 and 2 healthy subjects will receive placebo
88909054|NCT05662033|Experimental|Part 1 (SAD): Cohort 2|6 Healthy subjects will receive a single oral dose B of AZD6793 and 2 healthy subjects will receive placebo
88909055|NCT05662033|Experimental|Part 1 (SAD): Cohort 3|6 Healthy subjects will receive a single oral dose C of AZD6793 and 2 healthy subjects will receive placebo
88909056|NCT05662033|Experimental|Part 1 (SAD): Cohort 4|6 Healthy subjects will receive a single oral dose D of AZD6793 and 2 healthy subjects will receive placebo
88909057|NCT05662033|Experimental|Part 1 (SAD): Cohort 5|6 Healthy subjects will receive a single oral dose E of AZD6793 and 2 healthy subjects will receive placebo
88909058|NCT05662033|Experimental|Part 2 (MAD): Cohort 1|6 Healthy subjects will receive dose W of AZD6793 and 2 healthy subjects will receive placebo once daily on Day 1 and 8 and twice daily on Day 3 to Day 7
88909059|NCT05662033|Experimental|Part 2 (MAD): Cohort 2|6 Healthy subjects will receive dose X of AZD6793 and 2 healthy subjects will receive placebo once daily on Day 1 and 8 and twice daily on Day 3 to Day 7
88909060|NCT05662033|Experimental|Part 2 (MAD): Cohort 3|6 Healthy subjects will receive dose Y of AZD6793 and 2 healthy subjects will receive placebo once daily on Day 1 and 8 and twice daily on Day 3 to Day 7
88909061|NCT05662033|Experimental|Part 2 (MAD) : Cohort 4|6 Healthy subjects will receive dose Z of AZD6793 and 2 healthy subjects will receive placebo once daily on Day 1 and 8 and twice daily on Day 3 to Day 7
88909062|NCT05662033|Experimental|Part 3: Treatment sequence 1|Subjects will receive a single oral dose of test formulation AZD6793 in fasted state, test formulation AZD6793 in fed state following reference formulation AZD6793 in fasted state once on Day 1 of each treatment period.
89197246|NCT00621855|Placebo Comparator|placebo|matched placebo
89197247|NCT04012762|Active Comparator|Moderate-intensity group|WBVT application was 2-4 mm for vibration amplitude value and 25 Hz for training frequency in moderate-intensity group.
89197248|NCT04012762|Active Comparator|Vigorous-intensity group|WBVT application was 2-4 mm for vibration amplitude value and 40 Hz for training frequency in vigorous-intensity group.
89197249|NCT04258280|Active Comparator|Usual Care|
89197250|NCT04258280|Experimental|Enhanced Care|
89197251|NCT00940966|Experimental|energy restricted very-low carbohydrate|non-energy restricted ketogenic diet .
89197252|NCT00940966|Active Comparator|ADA diet|standard ADA diet
89197253|NCT00940966|Active Comparator|low glycemic index|restricted ketogenic diet
89197254|NCT00851565|Active Comparator|1|Patients with Crohn's disease with secondary loss of response to infliximab.
89197255|NCT00851565|Active Comparator|2|Patients with Crohn's disease with secondary loss of response to infliximab.
89008192|NCT05233748|Experimental|Stochastic Resonance (SR)|During this condition, participants will walk on the treadmill while receiving SR stimulation at their individual optimal intensity (SR) with and without visual perturbations.
89008193|NCT05233748|No Intervention|No Stochastic Resonance (noSR)|During this condition, participants will walk on the treadmill while receiving no SR stimulation (noSR) with and without visual perturbations.
89008194|NCT04601662|Experimental|Corticision|Patients in this group will be subjected to corticision to accelerate orthodontic movement
89008195|NCT04601662|Active Comparator|Traditional treatment|Patients in this group will undergo normal traditional treatment without any acceleration method.
89008196|NCT04601545|Experimental|VR therapy group|Pulmonary rehabilitation supplemented by VR therapy
89008197|NCT04601545|Active Comparator|Active Control Group|Pulmonary rehabilitation supplemented by Schultz Autogenic Training
89008198|NCT00565318|Active Comparator|A|
89008199|NCT00565318|Placebo Comparator|B|
89008200|NCT00249054|Active Comparator|ASR hip prosthesis|DuPuy ASR hip prosthesis
89008201|NCT00249054|Active Comparator|ReCap hip prosthesis|Biomet ReCap hip prosthesis
89008202|NCT00565357|Experimental|E|
89008203|NCT00565357|No Intervention|C|
89008204|NCT05201144|Active Comparator|Sildenafil citrate|Sildenafil citrate 1mg/kg every 8 hours (PO or NG) for up to 14 days
89536192|NCT03211429|Active Comparator|Postural control exercise|Individually adjusted progressive and specific postural control training, provided by physiotherapists for one hour, one time per week for 8 weeks. The exercise is progressive and specific to functional postural control tasks. It comprises elements that represent activities included in, and required for, independent daily living, such as maintaining balance when sitting, standing and walking; and also reacting to loss of balance.
89008205|NCT05201144|Placebo Comparator|Placebo|Equivalent volume of Ora-sweet©/Ora-plus© every 8 hours (PO or NG) for up to 14 days
89008206|NCT04601389|Experimental|"GNR-044 (JSC GENERIUM, the Russian Federation)"|150 mg of omalizumab was subcutaneously injected once in the deltoid muscle area
89008207|NCT04601389|Active Comparator|Xolair® (Novartis Pharma AG, Switzerland)|150 mg of omalizumab was subcutaneously injected once in the deltoid muscle area
89008208|NCT04600843|Experimental|Physical therapy with Patient education|Treated with proper physical therapy treatment protocol according to patient presenting condition and patient education manual
89008209|NCT04600843|Experimental|Physical Therapy without patient Education|Treated with proper physical therapy treatment protocol according to patient presenting condition
89008210|NCT00565396|Active Comparator|1|Fosinopril 10mg/day(oral)
89008211|NCT00565396|Active Comparator|2|Fosinopril 20mg/day(oral)
89008212|NCT00565396|Active Comparator|3|Losartan 50mg/day(oral)
89008213|NCT00565396|Active Comparator|4|Losartan 100mg/day(oral)
89008214|NCT04600765|Active Comparator|Diet Before|Typical diet contaminated with Bisphenol A. Patient assigned to this arm will consume a typical American diet as defined by USDA.
89197256|NCT00561574|Experimental|Esmirtazapine 1.5 mg|Participants receive esmirtazapine 1.5 mg tablets, one tablet administered orally once daily for up to 52 weeks
89197257|NCT00561574|Experimental|Esmirtazapine 3.0 mg|Participants receive esmirtazapine 3.0 mg tablets, one tablet administered orally once daily for up to 52 weeks
89536193|NCT02478281|Experimental|Methylene Blue Injection, USP|Single dose of Methylene Blue Injection, USP at a dose of 1 mg/kg solution per kg given intravenously over a period of approximately 5 minutes.
89008215|NCT04600765|Active Comparator|Diet After|Bisphenol A reduced. Patient assigned to this arm will consume a diet analogous to atypical American diet as defined by USDA, but with known Bisphenol A sources reduced or eliminated.
89008216|NCT04601116|Active Comparator|Atorvastatin 80 Mg Oral Tablet|Atorvastatin 80 mg tablets per day for 2 years
89008217|NCT04601116|Placebo Comparator|Placebo|Placebo tablets 1 per day for 2 years.
89008218|NCT04600687|Experimental|Intervention Arm|Participants will be enrolled in a single arm with a cross over design. Each participant will receive both placebo tablets about 30 minutes apart. Questionnaires will be completed prior to and after each placebo tablet is swallowed.
89008219|NCT04600726||older adults with known mild NCD|Older adults with known mild neuro-cognitive disorders
89008220|NCT04600726||older adults with non-communicable diseases|older adults with non-communicable diseases such as diabetics, hypertension and chronic obstructive airway diseases
89008221|NCT04600726||Older adults with healthy condition|Older adults who are free from neuro-cognitive disorders and non-communicable diseases
89008222|NCT04600453|Experimental|Training group|"Multicomponent exercise group (intervention): The intervention will consist of a multicomponent exercise training programme24, which will be composed of supervised progressive resistance exercise training, balance-training and walking for 4 consecutive days. During the training period, patients will be trained in 20 min sessions twice a day (morning and evening).~The supervised multicomponent exercise training programme will be comprised of upper and lower body strengthening exercises, tailored to the individual's functional capacity, using weight machines and aiming for 2-3 sets of 8-10 repetitions at an intensity of 40-60 % of 1RMcombined with balance and gait retraining exercises that progressed in difficulty and functional exercises, such as rises from a chair. The second part of the session will consist of functional exercises such as knee extension and flexion, hip abduction, balance movements, and daily walking in the hospital."
89008223|NCT04600453|No Intervention|Usual care group|Usual care
89008224|NCT04600297|Experimental|3D printed resin composite posterior FDP|Three units posterior fixed dental prosthesis made with 3D printed resin composite material
89008225|NCT04600024||Piriformis syndrome group|Patients who were diagnosed as PS by diagnostic injection with ultrasound guidance
88909063|NCT05662033|Experimental|Part 3: Treatment sequence 2|Subjects will receive a single oral dose of test formulation AZD6793 in fed state, reference formulation AZD6793 in fasted state following test formulation AZD6793 in fasted state once on Day 1 of each treatment period.
88909064|NCT05662033|Experimental|Part 3: Treatment sequence 3|Subjects will receive a single oral dose of reference formulation AZD6793 in fasted state, test formulation AZD6793 in fasted state following test formulation AZD6793 in fed state once on Day 1 of each treatment period.
88909065|NCT05661916|Experimental|ALN-TTRSC04|Participants will be administered a single dose of ALN-TTRSC04.
88909066|NCT05661916|Placebo Comparator|Placebo|Participants will be administered a single dose of placebo.
88909067|NCT05661201|Experimental|Dose Level 1: NEROFE with doxorubicin|weekly doses of NEROFE at 96 mg/m2, intravenously over 60 minutes
88909068|NCT05661201|Experimental|Dose level -1: Nerofe with doxorubicin|weekly doses of NEROFE at 48 mg/m2, intravenously over 60 minutes
88909069|NCT05661201|Experimental|Dose level 2: Nerofe with doxorubicin|weekly doses of NEROFE at 192 mg/m2, intravenously over 60 minutes
88909070|NCT05661201|Experimental|Dose Level 3: Nerofe with doxorubicin|weekly doses of NEROFE at 288 mg/m2, intravenously over 60 minutes
88909071|NCT05660369|Experimental|Safety Run-In Phase|"Participant enrollment will be staggered by 30 days for up to 3 participants.~Participants will receive 1 infusion of CARv3-TEAM-E.~Phase will be expanded up to 6 participants if any Dose-Limiting Toxicities DLTs occur.~After all participants have been enrolled, there will be an evaluation made by the Data Safety Monitoring Board (DSMB) and the FDA to determine the safety of enrollment into additional arms."
88909072|NCT05660369|Experimental|Arm 1: Recurrent Glioblastoma (GBM), EGFRvIII Positive|"Participants will undergo a leukapheresis procedure, or collection of mononuclear T cells via peripheral blood draw.~CARv3-TEAM-E will be administered 1x weekly for 6 doses on Days 0, 7, 14, 21, 28, and 36.~Participants will be followed for 2 years post-treatment."
88909073|NCT05660369|Experimental|Arm 2: Newly Diagnosed GBM, EGFRvIII Positive|"Participants will undergo a leukapheresis procedure, or collection of mononuclear T cells via peripheral blood draw.~CARv3-TEAM-E will be administered 1x weekly for 6 doses on Days 0, 7, 14, 21, 28, and 36.~Participants will be followed for 2 years post-treatment."
88909074|NCT05660369|Experimental|Arm 3: Recurrent GBM, EGFRvIII Negative|"Participants will undergo a leukapheresis procedure, or collection of mononuclear T cells via peripheral blood draw.~CARv3-TEAM-E will be administered 1x weekly for 6 doses on Days 0, 7, 14, 21, 28, and 36.~Participants will be followed for 2 years post-treatment."
88909075|NCT05658003|Experimental|[177Lu]Lu-PSMA-617|Participants will receive 7.4 GBq (200 mCi) +/- 10% [177Lu]Lu-PSMA-617 once every 6 weeks for 6 cycles. Best supportive care, including ADT may be used.
88909076|NCT05658003|Active Comparator|Androgen receptor-directed therapy (ARDT)|For participants randomized to the ARDT arm, the change of ARDT treatment will be administered per the physician's orders. Best supportive care, including ADT may be used.
88909077|NCT05656040|Experimental|Part 1: MK-2060|MK-2060 administered as a single subcutaneous dose of 30 mg on Day 1
88909078|NCT05656040|Placebo Comparator|Part 1: Placebo|Placebo (normal saline) administered as a single subcutaneous dose on Day 1
88909079|NCT05656040|Experimental|Part 2: MK-2060|MK-2060 administered as multiple subcutaneous doses on Days 1, 2, 3, 4, 8, 15, and 22.
88909080|NCT05656040|Placebo Comparator|Part 2: Placebo|Placebo (normal saline) administered as multiple subcutaneous doses on Days 1, 2, 3, 4, 8, 15, and 22.
88909081|NCT05656040|Experimental|Part 3: MK-2060|MK-2060 administered as a single subcutaneous dose on Day 1
88909082|NCT05655793||With Neurodegeneration|Includes patients with mild cognitive impairment and dementia
88909083|NCT05655793||Without Neurodegeneration|Includes healthy controls and patients with subjective cognitive decline
88909084|NCT05655754|Active Comparator|Methohexital|"Initial dose: methohexital 1 mg/kg (≙ 80 mg methohexital in a subject with 80 kg). If sufficient hypnosis is not achieved with the initial dose further doses of 10 mg methohexital will be administered until sufficient depth of anesthesia according to defined criteria is achieved. Criteria for sufficient depth of anesthesia will be comprised by a) the abolition of the eye-lash reflex b) absence of motor reaction upon inflation of the tourniquet.~Maintenance dose: none (The drug combination is injected in order to initiate anesthesia) Route of administration: intravenous Duration: few seconds to initiate anesthesia. The procedure will be repeated for each ECT session."
88909085|NCT05655754|Active Comparator|Ketofol|"Esketamine and propofol will be prepared shortly before injection by the nurse anesthetist as follows: 4 ml esketamine 25mg/ml, 6ml NaCl (0,9%), 10ml propofol (10mg/ml). The stability of ketamine-propofol mixtures (undiluted, 50:50 ratio) in one syringe has been documented for up to 3 hours.~Initial dose: esketamine 0,5 mg/kg + propofol 0,5 mg/kg (≙ 40 mg esketamine + 40 mg propofol in a subject with 80 kg). If sufficient hypnosis is not achieved with the initial dose further doses of 5mg esketamine and 5 mg propofol will be administered until a sufficient depth of anesthesia is achieved.~Maintenance dose: none (The drug combination is injected in order to initiate anesthesia) Route of administration: intravenous Duration: few seconds to initiate anesthesia. The procedure will be repeated for each ECT session"
88909086|NCT05655182|Experimental|Group 1, infants (age 18-59 months), RSV+, BLB201 10^6 PFU|6 RSV seropositive participants will be administered 10^6 PFU BLB-201 by intranasal route on Day 1
88909087|NCT05655182|Placebo Comparator|Group 1, infants (age 18-59 months), RSV+, Placebo|4 RSV seropositive participants will be administered placebo by intranasal route on Day 1
88909088|NCT05655182|Experimental|Group 2, infants (age 18-59 months), RSV+, BLB201 10^7 PFU|6 RSV seropositive participants will be administered 10^7 PFU BLB-201 by intranasal route on Day 1
89428576|NCT04288622|Experimental|ESM-derived personalised feedback (ESM-F) group|Participants will be required to participate in an ESM data collection procedure. Participants will be required to complete a beep-questionnaire 3 days a week, over a 6-week period. The mobile app will be programmed to emit a beep 10 times per day at random intervals between 7.30 and 22.30. At each beep, participants will use the app to digitally complete a brief beep-questionnaire, which covers current affect, current context and activities. Moreover, participants will receive weekly standardized feedback on personalized patterns of positive affect.
89197258|NCT00619827|Experimental|300 IR|300 IR grass pollen allergen extract tablet
89536194|NCT02482337|Experimental|POEM procedure|Patients who underwent POEM
89536195|NCT03074565|Experimental|Ultrasonic alone|Sanative therapy using ultrasonic instrumentation only.
88909089|NCT05655182|Placebo Comparator|Group 2, infants (age 18-59 months), RSV+, Placebo|4 RSV seropositive participants will be administered placebo by intranasal route on Day 1
88909090|NCT05655182|Experimental|Group 3, children (age 8-24 months), RSV+ or RSV-, BLB201 10^6 PFU|16 participants will be administered BLB201 10^6 PFU by intranasal route on Day 1
88909091|NCT05655182|Placebo Comparator|Group 3, children (age 8-24 months), RSV+ or RSV-, Placebo|8 participants will be administered placebo by intranasal route on Day 1
88909092|NCT05655182|Experimental|Group 4, children (age 6-24 months), RSV+ or RSV-, BLB201 10^7 PFU|32 participants will be administered BLB201 10^7 PFU by intranasal route on Day 1
88909093|NCT05655182|Active Comparator|Group 4, children (age 8-24 months), RSV+ or RSV-, Placebo|16 participants will be administered placebo by intranasal route on Day 1
89197259|NCT00619827|Placebo Comparator|Placebo|Placebo tablet
89536196|NCT03074565|Active Comparator|Ultrasonic+|Sanative therapy using ultrasonic plus hand instrumentation.
89197260|NCT05633732||Standardized View Group|The echocardiography view images of patients in this group are standardized.
89197261|NCT00848055|Experimental|arm 1|AbGn168 cohort 1
89197262|NCT00848055|Experimental|arm 2|AbGn168 cohort 2
89197263|NCT00848055|Experimental|arm 3|AbGn168 cohort 3
89197264|NCT00848055|Experimental|arm 4|AbGn168 cohort 4
89197265|NCT00848055|Experimental|arm 5|AbGn168 cohort 5
89197266|NCT00848055|Experimental|arm 6|AbGn168 cohort 6
89197267|NCT00848055|Experimental|arm 7|AbGn168 cohort 7
89197268|NCT00848055|Experimental|arm 8|AbGn168 cohort 8
89197269|NCT00687804|Experimental|Ranibizumab 0.5 mg|"Ranibizumab 0.5 mg was administered monthly by intravitreal injection in the study eye for 3 months. After the third injection, treatment was suspended if either one of the following criteria was met:~Improvement in best corrected visual acuity (BCVA) could not be attributed to treatment at the last 2 visits, in the opinion of the investigator, or BCVA > 84 letters (approximate Snellen equivalent of 20/20) was observed at the last 2 last visits.~Patients also received sham laser treatment on Day 1 and subsequently at intervals of at least 3 months, if deemed necessary by the evaluating physician.~Active/sham laser treatment was always administered before (sham) intravitreal injections. The minimum interval between the 2 treatments was 30 minutes.~In the extension study at the investigator's discretion, patients received open-label ranibizumab 0.5 mg intravitreal injections once a month until stable vision was reached (a maximum of 24 injections) and could receive laser therapy."
89197270|NCT00687804|Experimental|Ranibizumab 0.5 mg + laser|"Ranibizumab 0.5 mg was administered monthly by intravitreal injection in the study eye for 3 months. After the third injection, treatment was suspended if either one of the following criteria was met:~Improvement in best corrected visual acuity (BCVA) could not be attributed to treatment at the last 2 visits, in the opinion of the investigator, or BCVA > 84 letters (approximate Snellen equivalent of 20/20) was observed at the last 2 last visits.~Patients also received active laser treatment on Day 1 and subsequently at intervals of at least 3 months, if deemed necessary by the evaluating physician.~Active/sham laser treatment was always administered before (sham) intravitreal injections. The minimum interval between the 2 treatments was 30 minutes.~In the extension study at the investigator's discretion, patients received open-label ranibizumab 0.5 mg intravitreal injections once a month until stable vision was reached (a maximum of 24 injections) and could receive laser therapy."
89197271|NCT00687804|Active Comparator|Laser|"Laser photocoagulation treatment was administered on Day 1 and at intervals of at least 3 months, if deemed necessary by the physician. Patients also received monthly sham intravitreal injection in the study eye for 3 consecutive months. After the third injection, treatment was suspended if either one of the following criteria was met:~Improvement in best corrected visual acuity (BCVA) could not be attributed to treatment at the last 2 visits, in the opinion of the investigator, or BCVA > 84 letters (approximate Snellen equivalent of 20/20) was observed at the last 2 last visits.~Active/sham laser treatment was always administered before (sham) intravitreal injections. The minimum interval between the 2 treatments was 30 minutes.~In the extension study at the investigator's discretion, patients received open-label ranibizumab 0.5 mg intravitreal injections once a month until stable vision was reached (a maximum of 24 injections) and could receive laser therapy."
89197272|NCT00848133|Active Comparator|mini-midvastus|
89197273|NCT00848133|Active Comparator|mini-subvastus|
89197274|NCT02568020|No Intervention|low-protein diet(LPD)|All patients will be treated with a LPD containing 0.6g protein/kg BW per day and 120-125 kJ/kg BW per day.The patients will be followed-up for one year. The patients will come to the hospital every 4 weeks.
89536197|NCT02482415|Experimental|Intervention|Family caregivers were invited to meet in a group for 2 hours once a week for 3 weeks. Each meeting had a specific topic presented by a health care professional of the palliative care team (physician, nurse and social worker). The meetings addressed multi-dimensional issues in dialogue with the participants. A nurse acted as group leader and participated in all meetings. The intervention included both supportive and educational components. Each meeting began with a presentation based on a specific topic (palliative care, practical care and emotional reactions). This was followed by reflection and conversation, and finally a relaxation exercise
89536198|NCT02482415|No Intervention|Control|
89536199|NCT03209947|Experimental|Ulnar nerve ultrasound|
89536200|NCT02478125|Active Comparator|burixafor hydrobromide|Four daily doses of burixafor hydrobromide alone
89536201|NCT02478125|Active Comparator|G-CSF|G-CSF will be given as a daily subcutaneous (SC) injection beginning 4 days prior to Burixafor hydrobromide and continuing through the 4 days of Burixafor hydrobromide treatment
88909094|NCT05655182|Experimental|Group 6, children (age 8-24 months), RSV+ or RSV-, BLB201 10^7 PFU|30 participants will be administered BLB201 10^7 PFU by intranasal route on Day 1 and Day 57
88909095|NCT05655182|Placebo Comparator|Group 6, children (age 8-24 months), RSV+ or RSV-, Placebo|15 participants will be administered Placebo by intranasal route on Day 1 and Day 57
88909096|NCT05652400||Individuals diagnosed with HIV infection|People with HIV
89197275|NCT02568020|Experimental|LPD+KA|LPD+KA group will be supplemented with keto-amino acids (Ketosteril®, Fresenius Kabi) at a dosage of one tablet/5kg ideal body weight/day, divided into three doses taken during meals.The patients will be followed-up for one year. The patients will come to the hospital every 4 weeks.
89197276|NCT00848445|Experimental|APP and VRR on|APP and VRR turned on at 2 week visit
89428577|NCT04288622|No Intervention|ESM group|Participant will be required to participate in the same ESM data collection procedure as the ESM-F group. The personalised feedback report will be given to the participant after the whole study period (32 weeks) instead of weekly during data collection process.
89197277|NCT00848445|Active Comparator|APP and VRR off|APP and VRR turned off
89428578|NCT04288622|No Intervention|Control (CON) group|Participants will not be required to participate in the 6-week ESM data collection procedure. They will also receive the personalised feedback report based on the ESM data collected at baseline and week 7.
89428579|NCT05389020|Experimental|Intervention group|70 minutes course using newly developed real-size infant's arm and leg manikin
89428580|NCT05389020|No Intervention|Control group|70 minutes course using conventional manikin
89428581|NCT00718692|Experimental|1|Patients treated with Sym001
89428582|NCT05127356||Laser fluorescence|"DIAGNOdent is a laser fluorescence device that detects and quantify stages of development of incipient carious lesions~0-4 healthy tooth structure; 5-10 Outer half enamel caries; 11-20 Inner half enamel caries; 21+ Dentin caries"
89536873|NCT03312413|Experimental|Dexmedetomidine high dose group|Patients in this group are received dexmedetomidine hydrochloride iv infusion of 0.7μg·kg-1·h-1 from incision to 20-30 minutes before the end of surgery
89197278|NCT02563704|Active Comparator|ARTES|"Injectable Artesunate.Each vial contained 60 mg anhydrous artesunic acid, which was dissolved in 1 ml of 5% sodium bicarbonate (provided with the drug) and then mixed with 5 ml saline solution (provided with the drug) before injecting into an indwelling intravenous catheter.~Patients received 2.4 mg/kg bw of parenteral artesunate at H0, H12, H24 and thereafter once daily, for a minimum of 24 hours.~Patients exited from the protocol if they had clinically recovered and parasitaemia was negative."
89197279|NCT02563704|Active Comparator|QLD|"Injectable quinine. Each vial contained 250 mg or 500 mg QB.~Patients received a loading dose of 16.6 mg/kg bw of QB by intravenous (IV) infusion over 4 hours followed 8 hours after the start of the loading dose, with a maintenance dose of QB at 8.3 mg/kg bw over 4 hours every 8 hours diluted in 10 ml/kg bw of 10% dextrose solution.~Patients received a minimum of 24 hours of parenteral treatment and exited from the protocol if they had clinically recovered and parasitaemia was negative."
89536874|NCT03312413|Placebo Comparator|Control group (normal saline group)|Patients in this group are received saline iv infusion of 5mL·h-1 from incision to 20-30 minutes before the end of surgery
88909097|NCT05646381|Experimental|Pelacarsen (TQJ230) 80mg|Pelacarsen (TQJ230) 80 mg prefilled syringe injected monthly, administered subcutaneously
88909098|NCT05646381|Placebo Comparator|Matching placebo|Placebo to match pelacarsen (TQJ230) prefilled syringe injected monthly, administered subcutaneously
88909099|NCT05644977|Experimental|Cohort 1: Emraclidine Dose 1|Participants will receive emraclidine dose 1 or emraclidine-matching placebo tablets, orally, once daily (QD) up to Day 14.
88909100|NCT05644977|Experimental|Cohort 2: Emraclidine Dose 2|Participants will receive emraclidine dose 2 or emraclidine-matching placebo tablets, orally, QD up to Day 14.
88909101|NCT05644977|Experimental|Cohort 3: Emraclidine Dose 3|Participants will receive emraclidine dose 3 or emraclidine-matching placebo tablets, orally, QD up to Day 14.
88909102|NCT05644977|Experimental|Cohort 4: Emraclidine Dose 4|Participants will receive emraclidine dose 4 or emraclidine-matching placebo tablets, orally, QD up to Day 14.
88909103|NCT05644977|Experimental|Cohort 5: Emraclidine Dose 5|Participants will receive emraclidine dose 5 or emraclidine-matching placebo tablets, orally, QD up to Day 14.
89428583|NCT05127356||Visual examination|"ICDAS II~Code 0: Sound tooth surface; Code 1: First visual change in enamel; Code 2:Distinct visual change in enamel when viewed wet; Code 3: Localized enamel breakdown due to caries with no visible dentin; Code 4: Underlying dark shadow from dentin with or without localized enamel breakdown; Code 5: Distinct cavity with visible dentin; Code 6: Extensive distinct cavity with visible dentin."
89428584|NCT04234490||Patient|Patients who are receiving Home Parenteral Support (HPN) (artificially fed through a vein) due to intestinal failure
89428585|NCT04234490||Carer|Family member or carer of patient who is receiving Home Parenteral Support
89428586|NCT03446534|Experimental|Amoxicillin|Amoxicillin 100mg/ml mixture (Imacillin), 0.25ml/kg every 8 hours for 7 days.
89428587|NCT03446534|Placebo Comparator|Placebo|Placebo mixture 0.25ml/kg every 8 hours for 7 days
89428588|NCT00829764|Experimental|1|Doxycycline Monohydrate
88909104|NCT05644457||Patients receiving systemic therapies for cancers of the head and neck|Patients undergoing systemic therapy for recurrent, metastatic, or locally advanced cancer of the head and neck not suitable for treatment with curative intent. A biological research study involving the collection of blood, tumour tissue, saliva, and other body fluids routinely examined during cancer care (e.g. cerebrospinal fluid (CSF), ascites, urine, stool or pleural fluids).
88909105|NCT05644158|Active Comparator|Exercise group|Patients with intermittent claudication will receive conservative treatment with monitored exercise training for a total of 12 weeks (home-based training, minimum of three times a week, documented by using a diary with documentation of the type, the intensity and the duration of the training as well as by using a physical activity monitoring system (Move 4, Karlsruhe, Germany).
88909106|NCT05644158|Active Comparator|Revascularization group|will receive revascularization of the underlying atherosclerosis lesion of the superficial femoral artery. Depending on the exact morphology of the lesion, patients with short superficial femoral artery lesions (<25 cm) will be subdivided into group 2A with endovascular treatment and patients with long superficial femoral artery lesions (>25 cm) will be subdivided into group 2B with open surgical treatment
89428589|NCT00829764|Active Comparator|2|Vibramycin Monohydrate®
89428590|NCT00718224|Experimental|Semuloparin|"Semuloparin sodium 20 mg (10 mg if Severe Renal Impairment [SRI]) once daily for 7-10 days with an initial dose given 8 hours after surgery~To maintain the blind, placebo for Enoxaparin sodium:~12 and 24 hours after surgery, then once daily if no SRI~12 hours after surgery only if SRI"
89428591|NCT00718224|Active Comparator|Enoxaparin|"Enoxaparin sodium 30 mg twice daily (20 mg once daily if Severe Renal Impairment [SRI]) for 7-10 days with an initial dose given 12 hours after surgery~Placebo for Semuloparin sodium 8 hours after surgery to maintain the blind"
89428592|NCT03129542|Active Comparator|Midodrine Hydrochloride 10 milligrams|Three doses of oral midodrine every 8 hours will be administered in addition to usual care for sepsis. Participants randomized to the intervention group will receive a total of 3 doses of midodrine 10 milligrams every 8 hours by mouth in the form of a tablet encapsulated in order to be identical to placebo. Participants will receive treatment for a total of 16 hours, beginning with the first dose.
88909107|NCT05644158|No Intervention|Healthy control group|Patients undergoing surgery for symptomatic varicose veins with excluded PAD will serve as a control group.
88909108|NCT05642455|Experimental|Afamitresgene autoleucel|
89428593|NCT03129542|Placebo Comparator|Placebo oral capsule|For participants randomized to the placebo arm, an identical appearing capsule containing only Lactose Monohydrate powder will be administered every 8 hours for a total of 3 doses.
88909109|NCT05640700||Controls|Healthy women without HPV in their cervical and vaginal sample
88909110|NCT05640700||Women with HPV|Women with HPV, with or without cervical intraepithelial neoplasia or carcinoma
88909111|NCT05639894|Experimental|Group 1: Sentinel and Main Cohorts|1 injection of RSV mRNA LNP CL-0059 vaccine (Low dose) via intramuscular injection
89428594|NCT03129230|Experimental|Free nonvascularized fibula autograft|Sixteen pediatric patients before epiphyseal closure were treated with free nonvascularized fibula autograft after resections of tumor-like lesions in the femoral neck.
89428595|NCT04799028|Active Comparator|Traditional children's fortified cow's milk|
89428596|NCT04799028|Experimental|New toddler milk with synbiotics and fat blend|
89428597|NCT04799028|Other|Toddlers consuming habitual diet|
89428598|NCT03129074|Experimental|Varlitinib given in combination with capecitabine|"PO varlitinib 300 mg BID~PO capecitabine 1000 mg/m2 BID"
89428599|NCT03446378|Experimental|Anodal tDCS + physical therapy|tDCS will be applied with duration of 20 minutes, intensity of 2 mA where anodal electrode will be on the affected hemisphere and the cathodal electrode, on the contralateral supraorbital region. After tDCS, patients will be submitted to 40 minutes of physical therapy protocol. Experimental sessions will be repeated five times per week to complete 10 sessions
89428600|NCT03446378|Experimental|Cathodal tDCS + physical therapy|tDCS will be applied with duration of 20 minutes, intensity of 2 mA where cathodal electrode will be on the affected hemisphere and the anodal electrode, on the contralateral supraorbital region. After tDCS, patients will be submitted to 40 minutes of physical therapy protocol. Experimental sessions will be repeated five times per week to complete 10 sessions
89428601|NCT03446378|Sham Comparator|Sham tDCS + physical therapy|tDCS will be applied with duration of 20 minutes, intensity of 2 mA where anodal electrode will be on the affected hemisphere and the cathodal electrode, on the contralateral supraorbital region. Sham tDCS will be performed by ramping current flow for the first 10 seconds of stimulation, but switching the stimulator off after 30 seconds After tDCS, patients will be submitted to 40 minutes of physical therapy protocol. Experimental sessions will be repeated five times per week to complete 10 sessions
88909112|NCT05639894|Experimental|Group 2: Sentinel and Main Cohorts|1 injection of RSV mRNA LNP CL-0137 vaccine (Low dose) via intramuscular injection
88909113|NCT05639894|Experimental|Group 3: Sentinel and Main Cohorts|1 injection of RSV mRNA LNP CL-0059 vaccine (Medium dose) via intramuscular injection
88909114|NCT05639894|Experimental|Group 4: Sentinel and Main Cohorts|1 injection of RSV mRNA LNP CL-0137 vaccine (Medium dose) via intramuscular injection
88909115|NCT05639894|Experimental|Group 5: Sentinel and Main Cohorts|1 injection of RSV mRNA LNP CL-0059 vaccine (High dose) via intramuscular injection
88909116|NCT05639894|Experimental|Group 6: Sentinel and Main Cohorts|1 injection of RSV mRNA LNP CL-0137 vaccine (High dose) via intramuscular injection
89428602|NCT03450044|Experimental|Vaccinated|Transfer of autologous dendritic cells interspersed with chemotherapy doses
89428603|NCT03450044|No Intervention|Control|Control patients who follow their basic treatment with chemotherapy with the A/C scheme
88909117|NCT05639894|Placebo Comparator|Group 7: Main, Sentinel and Booster Cohorts|1 injection of placebo via intramuscular injection
89428604|NCT03449966|Experimental|Target biopsy under pCLE|(Cellvisio® with confocal minoprobe™, Mauna Kea Technologies, France)
89428605|NCT03449966|Active Comparator|Random biopsy at cancer lesion under WLE|WLE (GIF-HQ290, Olympus, Japan) group
89428606|NCT04451486|Experimental|Treatment dose 1|1x10*5 CD61-Lin- cells /0.25mL DPBS
89428607|NCT04451486|Experimental|Treatment dose 2|1x10*6 CD61-Lin- cells /0.25mL DPBS
89428608|NCT04451486|Experimental|Treatment dose 3|1x10*7 CD61-Lin- cells /0.25mL DPBS
89428609|NCT03446300||college student population|
89428610|NCT03446300||working population|
89428611|NCT03446300||aged more than 50 years old population|
89428612|NCT03443102||SARS survivors|First-line HCWs infected during the SRAS-CoV pandemic in Peking University People's Hospital, China. Diagnose was further confirmed by SARS-CoV seropositive results.
89428613|NCT03443102||Controls|"Coworkers of the infected HCWs, who also exposed to SARS patients or specimens. Infection was further excluded by SARS-CoV seronegative results.~Healthy controls matched for age, sex and disease condition, but without exposures to SARS virus."
89428614|NCT03446222|Active Comparator|Catheter Ablation|Catheter based radiofrequency ablation with wide antral circumferential PVI and isolation of posterior wall will be performed. Mitral and cavo-tricuspid isthmus ablation will be done only if such isthumus dependent flutters are documented prior to / during the procedure.
89428615|NCT03446222|Active Comparator|Mini-maze surgical procedure|Wolf Mini-maze surgical ablation along with left atrial appendage ligation will be performed.
89428616|NCT03449810|Experimental|DSE plus MET (group A)|"The DSE will consist of seven exercise activities that will be administered at random viz; 1. Bridging 2. Supine twist stretch 3. Double leg knee to chest stretch 4. Plank heel raise 5. Ball squat 6. Leg press on ball 7. Hip Lifts.~The MET procedure will involve a total of 5-10 contralateral isometric voluntary contractions that will be resisted by force equal to the participant's for 30 seconds with 5 seconds rest between contractions (corresponding to 20-30%)."
89428617|NCT03449810|Active Comparator|DSE only (group B)|The DSE will consist of seven exercise activities that will be administered at random viz; 1. Bridging 2. Supine twist stretch 3. Double leg knee to chest stretch 4. Plank heel raise 5. Ball squat 6. Leg press on ball 7. Hip Lifts.
88909121|NCT05636592||Standard programme group|Standard programme group, immunotherapy alone
88909122|NCT05636592||controlled programme group|controlled programme group, statin combined with immunotherapy
88909123|NCT05636111|Experimental|Dose Escalation and Dose Expansion|Pariticipants will be assigned to a dose level of combined paclitaxel, bevacizumab, and lurbinectedin
88909124|NCT05634057|Experimental|Anisodamine hydrobromide combined with heparin|Anisodamine hydrobromide injection + low molecular weight heparin + basic treatment: The dosage of scopolamine butylbromide is 2.0mg/(kg*d), administered via a micro-pump at a constant rate, continuously for 3 days. The dosage range for low molecular weight heparin is limited to 3000-6000U, administered subcutaneously once daily, continuously for 3 days.
88909125|NCT05634057|No Intervention|conventional therapy|Conventional treatment includes shock treatment, eliminating the cause of the condition, actively treating the primary disease, replenishing blood volume, correcting acid-base imbalances, using vasoactive drugs to maintain blood pressure, and advanced life support as needed, such as the use of a ventilator and bedside blood filtration for organ support.
88909126|NCT05631483|Experimental|DAISe|DAISe Thrombectomy Device
88909127|NCT05628259|Experimental|Intervention Group|A motivational interview (MI) program based on the telenursing approach was applied to the individuals in the experimental group. In this study, the MI procedure includes eight sessions in total, with four sessions of motivational interviews by phone in the first month of the intervention and four sessions of motivational interviews by phone in the next two months for each individual. Pre-tests were collected in the first month. Afterwards, MI intervention was applied for three months. This intervention was applied to the experimental group in addition to the routine care provided by the hospital. MI application took an average of 45-60 minutes via phone call.
89428618|NCT03449810|Active Comparator|Standard Physiotherapy Treatment (group C)|This group will involve classical massage, therapeutic exercises (strengthening spinal and abdominal muscles) and a combination of interferential therapy and therapeutic ultrasound (INF/UTS) applied to the lumbosacral region. The participants will be asked to perform the therapeutic exercises once a day at home.
89428619|NCT05121506|Experimental|CBD and THC with GT4 technology|
89428620|NCT03449654|Other|Liraglutide|
89428621|NCT03449654|Other|placebo|
89428622|NCT03388008|Active Comparator|Standard of care|Tacrolimus + Mycophenolate mofetil + prednisone from day 0 through day 365
89428623|NCT03388008|Experimental|Belatacept-based immunosuppression|Belatacept + Tacrolimus + prednisone from day 0 through day 89, then Belatacept + Mycophenolate mofetil + prednisone from day 90 through day 365
89428624|NCT00710580|Experimental|A|
89428625|NCT00710580|Active Comparator|B|
89428626|NCT00710580|Placebo Comparator|C|
89428627|NCT05112380||Sedentary adults|"Do not practice overhead sport~No pain or history of shoulder pain"
89428628|NCT05112380||Overhead athletes|"Practice an overhead sport at least five hours a week~No pain or history of shoulder pain"
88909128|NCT05628259|No Intervention|Control Group|The control group received routine nursing care in the diabetes policlinic.
88909129|NCT05625906|Experimental|Intervention group|will receive a multi-media experiential training programme.
88909130|NCT05625906|No Intervention|control group|will NOT receive a multi-media experiential training programme
88909131|NCT05625633|Experimental|HPV Vaccine|0.5-mL suspension of 9-valent Gardasil vaccine administered as intramuscular injection at weeks 0, 4, and 20
88909132|NCT05625633|Placebo Comparator|Placebo|0.5-mL normal saline administered as intramuscular injection at weeks 0, 4, and 20
88909133|NCT05624788||Specialist Referral: Neurology|
88909134|NCT05624788||Specialist Referral: Ophthalmology|
88909135|NCT05624788||Specialist Referral: Oncology|
88909136|NCT05622500|Experimental|Best endovenous reconstruction + best medical treatment (compression +/- anti-thrombotic therapy).|The intervention arm consists of participants undergoing best endovenous reconstruction under the guidance of intra-vascular ultrasound in addition to best medical treatment (compression +/- antithrombotic therapy).
88909137|NCT05622500|Active Comparator|Best medical treatment alone (compression +/- anticoagulation).|The comparator arm will consist of participants receiving best medical treatment alone.
89197280|NCT02563704|Active Comparator|QNLD3|"Injectable quinine. Each vial contained 250 mg or 500 mg QB.~Patients received 8.3 mg/kg bw of QB over 4 hours by IV infusion every 8 hours diluted in 10 ml/kg bw of 10% dextrose solution.~Patients received a minimum of 24 hours of parenteral treatment and exited from the protocol if they had clinically recovered and parasitaemia was negative."
88909138|NCT05622305|Experimental|Online 1-Day CBT-Based Workshop|Participants assigned to the treatment arm will attend a day long CBT-based workshop delivered online by two trained public health nurses in addition to receiving usual care.
89428629|NCT03446144|Experimental|IONIS-FB-Lrx|
89428630|NCT03446144|Placebo Comparator|Placebo (sterile saline 0.9%)|
89428631|NCT00829686|No Intervention|No intervention|No antibiotic
88909139|NCT05622305|No Intervention|Treatment as Usual|Participants assigned to the control arm will continue to receive standard postnatal care from their healthcare providers.
88909140|NCT05620173|Experimental|Vedea Amblyopia Therapy (VAT) then Vedea Amblyopia Therapy|"Children in this intervention arm will use the VAT for 16 weeks.~After the initial 16 weeks of treatment these children will be allowed to use the VAT for another 16 weeks."
89008226|NCT04600024||Age and sex match control group|Patients who were excluded from the diagnosis of PS and had anteroposterior (AP) direct radiographic imaging
89428632|NCT00829686|Active Comparator|Septra DS|Septra DS (800/160) two pills PO BID x 7 days
89428633|NCT00829530|Experimental|1|
89428634|NCT00829530|Active Comparator|2|
89428635|NCT01377194|Experimental|1|40mg Levomilnacipran ER
89428636|NCT01377194|Experimental|2|80mg of Levomilnacipran ER
89428637|NCT01377194|Placebo Comparator|3|Placebo
89428638|NCT00829452|Experimental|1|
89428639|NCT00829452|Active Comparator|2|
89428640|NCT00829374|Experimental|1|Dimebon, 5 mg orally three times daily
89428641|NCT00829374|Experimental|2|Dimebon, 20 mg orally three times daily
89428642|NCT00829374|Placebo Comparator|3|Placebo orally three times daily
89428643|NCT03449420||Post Partum Hemorrhage|Patients presenting with a post partum hemorrhage. A thromboelastography analysis is realized at discretion of the anesthesiologist in charge
89428644|NCT00747318|Experimental|1|
89428645|NCT00746616|Experimental|1|Hip resurfacing devices in the young, active patient with advanced hip disease instead of traditional total hip arthroplasty.
89428646|NCT00744276|Active Comparator|1|
89428647|NCT00744276|Active Comparator|2|
89428648|NCT00744276|Active Comparator|3|
89428649|NCT00744276|Placebo Comparator|4|
89428650|NCT00744276|Placebo Comparator|5|
89428651|NCT00744276|Placebo Comparator|6|
89428652|NCT00697710|Experimental|Cohort A|50 mg S-777469 or Placebo, BID
89428653|NCT00697710|Experimental|Cohort B|200 mg S-777469 or Placebo, BID
89428654|NCT00697710|Experimental|Cohort C|800 mg S-777469 or Placebo, BID
89428655|NCT03438344|Experimental|Arm I (CMV-MVA triplex vaccine)|Patients receive multi-antigen CMV-modified vaccinia Ankara vaccine via injection on days 28 and 56 post-HCT.
89428656|NCT03438344|Placebo Comparator|Arm II (placebo)|Patients receive placebo via injection on days 28 and 56 post-HCT.
89428657|NCT00743184|Placebo Comparator|Placebo + Placebo|Participants will receive Placebo + Placebo on Days 0 and 14 of each 6-month course.
89428658|NCT00743184|Experimental|15 mg Ozarelix + 15 mg Ozarelix|Participants will receive 15 mg Ozarelix + 15 mg Ozarelix on Days 0 and 14 of each 6-month course.
89428659|NCT00743184|Experimental|30 mg Ozarelix + 15 mg Ozarelix|Participants will receive 30 mg Ozarelix + 15 mg Ozarelix on Days 0 and 14 of each 6-month course.
89428660|NCT00742716|Experimental|CTA018 Injection low dose|Low dose IV 3 times a week for 4 weeks
89428661|NCT00742716|Experimental|CTA018 Injection low to mid dose|low to mid dose IV 3 times a week for 4 weeks
89428662|NCT00742716|Experimental|CTA018 Injection mid to high dose|mid to high dose IV 3 times a week for 4 weeks
89428663|NCT00742716|Experimental|CTA018 Injection high dose|high dose IV 3 times a week for 4 weeks
89428664|NCT03446066||case group|20 cases suffering from excessive daytime sleepiness (4 females and 16 males) with their age range 32-58yrs and BMI range is 24.97-39.06 kg/m2
89428665|NCT03446066||control group|20 healthy subjects (5 females and 15 males) with their age range 31-55yrs and BMI range is 23.40-43.0 kg/m2
89428666|NCT04640402|Experimental|Low-dose vaccine (18-59 years) & Two dose regimen|two doses of low-dose Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21.
89428667|NCT04640402|Experimental|Low-dose vaccine (18-59 years) & Three dose regimen|three doses of low-dose Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 14, 28.
89428668|NCT04640402|Experimental|High-dose vaccine (18-59 years) & Two dose regimen|two doses of high-dose Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21.
89428669|NCT04640402|Experimental|High-dose vaccine (18-59 years) & Three dose regimen|three doses of high-dose Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 14, 28.
89428670|NCT04640402|Experimental|Low-dose vaccine (60-85 years) & Two dose regimen|two doses of low-dose Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21.
89428671|NCT04640402|Experimental|Low-dose vaccine (60-85 years) & Three dose regimen|three doses of low-dose Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 14, 28.
89428672|NCT04640402|Experimental|High-dose vaccine (60-85 years) & Two dose regimen|two doses of high-dose Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21.
89428673|NCT04640402|Experimental|High-dose vaccine (60-85 years) & Three dose regimen|three doses of high-dose Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 14, 28.
89428674|NCT04640402|Placebo Comparator|Low-dose placebo (18-59 years) & Two dose regimen|two doses of placebo at the schedule of day 0, 21.
89428675|NCT04640402|Placebo Comparator|Low-dose placebo (18-59 years) & Three dose regimen|three doses of placebo at the schedule of day 0, 14, 28.
89428676|NCT04640402|Placebo Comparator|High-dose placebo (18-59 years) & Two dose regimen|two doses of placebo at the schedule of day 0, 21.
89428677|NCT04640402|Placebo Comparator|High-dose placebo (18-59 years) & Three dose regimen|three doses of placebo at the schedule of day 0, 14, 28.
89428678|NCT04640402|Placebo Comparator|Low-dose placebo (60-85 years) & Two dose regimen|two doses of placebo at the schedule of day 0, 21.
89428679|NCT04640402|Placebo Comparator|Low-dose placebo (60-85 years) & Three dose regimen|three doses of placebo at the schedule of day 0, 14, 28.
89428680|NCT04640402|Placebo Comparator|High-dose placebo (60-85 years) & Two dose regimen|two doses of placebo at the schedule of day 0, 21.
89428681|NCT04640402|Placebo Comparator|High-dose placebo (60-85 years) & Three dose regimen|three doses of placebo at the schedule of day 0, 14, 28.
88909141|NCT05620173|Active Comparator|Occlusion therapy then Vedea Amblyopia Therapy (VAT)|"Children in this intervention arm will adhere to a 'care as usual' regimen consisting of occlusion therapy as prescribed by their health care provider. They will do so for 16 weeks.~After the initial 16 weeks of treatment these children will crossover into the experimental arm to examine if they are still responsive to the VAT after already completing 16 weeks of traditional treatment."
89197281|NCT02563704|Active Comparator|QNLD2|"Injectable quinine. Each vial contained 250 mg or 500 mg QB.~Patients received 12.5 mg/kg bw of QB over 4 hours by IV infusion every 12 hours diluted in 10 ml/kg bw of 10% dextrose solution.~Patients received a minimum of 24 hours of parenteral treatment and exited from the protocol if they had clinically recovered and parasitaemia was negative."
89428682|NCT00740610|Experimental|Cohort 1|22 subjects to receive 1 mg GS-9450 for 4 weeks
89428683|NCT00740610|Experimental|Cohort 2|22 subjects to receive 5 mg GS-9450 for 4 weeks
89428684|NCT00740610|Experimental|Cohort 3|22 subjects to receive 10 mg GS-9450 for 4 weeks
88909142|NCT05619718|Experimental|Treatment|Treatment group will receive Awareness, Courage, and Love Groups for loneliness.
88909143|NCT05619718|Active Comparator|Control|Control group will receive treatment as usual in the form of Mutual Help Meetings.
88909144|NCT05615857|No Intervention|Colonoscopy without Endocuff|No Endocuff inserted proximally to colonoscope and use of retroflexion
88909145|NCT05615857|Experimental|Colonoscopy with Endocuff|Endocuff inserted proximally to colonoscope, no use of retroflexion
89197282|NCT05616416||All ED Patient|All patients visited the emergency department during the period.
89428685|NCT00740610|Experimental|Cohort 4|22 subjects to receive 40 mg GS-9450 for 4 weeks
89428686|NCT00740610|Placebo Comparator|Cohort 5|22 subjects to receive placebo to match GS-9450 for 4 weeks
89428687|NCT03442790|Experimental|Agitated Saline Method|The proper placement of the central venous line will be confirmed using agitated saline under ultrasound vision
89428688|NCT03442790|Active Comparator|Chest X-Ray Confirmation|The proper placement of the central venous line will be compared with chest x-ray obtained in supine position after central line placement
89428689|NCT03445910|Experimental|Human chorionic gonadotrophin|The hCG Group included 50 patients who had an intrauterine injected of 500 IU of hCG on the day of ovum pick-up
89428690|NCT03445910|No Intervention|control|The Control Group included 50 patients who went through the ICSI conventional protocol without intrauterine injection.
89428691|NCT00823992|Placebo Comparator|placebo|
89428692|NCT00823992|Experimental|taspoglutide|
89428693|NCT03442712|Active Comparator|Treatment arm 1|"Auricular acupressure (AA) plus smartphone App:~Semen Vaccaria laccaria will be applied on one ear only, and seed plasters will be changed every 3 days to 4 days to the opposite ear. Subjects will be requested to apply pressure on the acupoints thrice per day. The subjects will install the smartphone App specifically designed for this study. The App will send out regular AA reminders to the subjects. The total treatment period will be 8 weeks."
89428694|NCT03442712|Active Comparator|Treatment arm 2|The participants will only receive AA treatment and are required to perform daily self-administered seeds pressing.
89428695|NCT03442712|No Intervention|Treatment arm 3|The participants in the waitlist control group will maintain their usual dietary and exercising patterns.
89428696|NCT03442634|Experimental|Early Hydration Group|this study group will get 200 ml of sugar free water within 1 hour after cesarean section followed by oral hydration as per patients' desire then starting semisolid and solid foods when patients are open bowel Intervention: Early Oral Hydration
89428697|NCT03442634|Active Comparator|Traditional Hydration Group|this study group will get 200 ml of sugar free water after 6 hours after cesarean section followed by oral hydration as per patients' desire then starting semisolid and solid foods when patients are open bowel Intervention: Traditional Oral Hydration
88909146|NCT05615389|Experimental|Medicinal Cannabis C12T12|C12T12 Ruby Balanced Oil (Cannatrek Ltd, Australia). 12.5mg/ml CBD and 12.5mg/ml THC in sunflower oil.
89197283|NCT05279950|Active Comparator|Piezoelectric|Full-mouth ultrasonic debridement will be performed with a ultrasonic tip (vibration frequence >18 kHz) powered by a piezoelectric device
89197284|NCT05279950|Experimental|Magnetostrictive|Full-mouth ultrasonic debridement will be performed with a ultrasonic tip (vibration frequence >18 kHz) powered by a magnetostrictive device.
89428698|NCT00823680|Placebo Comparator|Placebo|
89428699|NCT00823680|Experimental|RO5027838 200mg|
89428700|NCT00823680|Experimental|RO5027838 50mg|
89428701|NCT00823680|Experimental|RO5093151 10mg|
89428702|NCT00823680|Experimental|RO5093151 400mg|
89428703|NCT03109496||OME Patients|Suffer from chronic Otitis Media with Effusion (OME) for at least 3 months and undergo ventilation tube placement.
89428704|NCT03109496||Healthy Control|Undergo surgery that gives access to the middle ear space (e.g. cochlear implant surgery) or adenoids, in absence of upper respiratory tract infections.
89428705|NCT04619732|Experimental|Marginal Kidneys|"Transplant patients receiving kidneys from deceased marginal donors: aged >= 60, or >= 50 with comorbid renal impairment, hypertension, or cerebrovascular disease.~Following consent, kidneys will be cold perfused with preserving solution for 2-4 hours as per standard of care at the study centre. During this period, the kidneys will be monitored for creatinine, glucose, and lactate concentrations using three microdialysis probes placed into the tissue, the vein, and the ureter. Data will be blinded to clinicians.~The probes will be removed at the end of the perfusion period and the organs will be transplanted or discarded according to clinical protocol. If transplanted, the study will monitor the patient's recovery for the first 30 days."
89428706|NCT04600076|Experimental|BabyCenter site and the community group|
89428707|NCT00646542|Experimental|1|
89428708|NCT00646542|Placebo Comparator|2|
89428709|NCT03445676|No Intervention|Usual Care|Study personnel silently observe and record what the healthcare worker does at each hand hygiene opportunity without direction to the healthcare worker
89428710|NCT03445676|Experimental|ABHR directly on gloves|Healthcare worker will be directed by study personnel to use alcohol-based hand rub (ABHR) to cleanse gloves at each hand hygiene opportunity
89428711|NCT03445676|Placebo Comparator|Ideal Standard|Healthcare worker will be directed by study personnel to remove gloves, perform hand hygiene and replace gloves at each hand hygiene opportunity
89428712|NCT03442478|Experimental|2D/3D Tomosynthesis|2D/3D Tomosynthesis images will be obtained in addition to standard mammographic images.
89428713|NCT04198740||Control group|Healthy, normal ocular surface
89428714|NCT04198740||Dry eye syndrome|"Patients suffering from either:~Lacrimal insufficiency~Anterior blepharitis~Posterior blepharitis~Sjögren syndrome"
89428715|NCT04198740||Allergic conjunctivitis|Patients suffering from allergic conjunctivitis
89428716|NCT04198740||Mucous membrane pemphigoid|Patients suffering from mucous membrane pemphigoid
89428717|NCT04198740||Infectious keratoconjunctivitis|"Patients suffering from keratitis and/or conjunctivitis of various etiology:~Viral~Bacterial~Fungal~Acanthamoeba"
89428718|NCT03445598|Experimental|Interactive CCBT group|This group receives Interactive and Personalized CCBT
89428719|NCT03445598|Active Comparator|Limited CCBT control group|This group receives Feature-limited CCBT
89428720|NCT03445598|Other|Waitlist control group|This group receives waitlist control
89428721|NCT03445442||Group 1|Sacrocolpopexy (SCP)
89428722|NCT03445442||Group 2|Native tissue repair surgery (NTR)
89428723|NCT03445442||Group 3|Vaginal mesh repair surgery (VMR)
89428724|NCT03442244|Experimental|LEO 90100 foam|Each subject has each of the 2 investigational products applied at the same time on 2 sites on the back. The location on which the treatments are applied is randomised in a double-blinded manner LEO 90100 foam contains Calcipotriol hydrate 52.2 μg/g (equivalent to 50.0 μg/g calcipotriol) plus Betamethasone dipropionate 0.643 mg/g
89197285|NCT00939250|Experimental|Diabetes and depression intervention|Measurement based care for diabetes and depression, disease self management for diabetes and depression
89197286|NCT00939250|Active Comparator|Diabetes intervention|Measurement based care for diabetes, disease self management for diabetes
89536875|NCT02722967|Experimental|Aripiprazole + IEM|Subjects will receive an intervention consisting of a drug-device combination that consists of an aripiprazole tablet with a tiny sensor embedded within it referred to as an Ingestible Event Marker (IEM) . They will discontinue their normally prescribed oral aripiprazole tablets and will take the aripiprazole(2, 5, 10, 15, 20, or 30 mg) + IEM once daily for the 8-week assessment period for this trial.
89197287|NCT00744666|Experimental|1|Patients receive Prednisolone 1% 1gtt qid x 4 weeks. If the intraocular pressure (IOP) after the 4 weeks is > or equal to 21 mmHg, then IVTA will be withheld. If the IOP < 21mmHg, then patients will receive an injection of IVTA.
89197288|NCT00744666|No Intervention|2|Patients will receive an injection of IVTA (no trial of Prednisolone gtts is given).
88909147|NCT05615389|Experimental|Medicinal Cannabis C20T5|C20T5 Ruby CBD Oil (Cannatrek Ltd, Australia). 20mg/ml CBD and 5mg/ml THC in sunflower oil.
88909148|NCT05614102|Experimental|Dose escalation of BAY2965501|For escalation part, different dose levels of BAY2965501 are planned.
89197289|NCT00851955||1. Normal pancreas patients|Patients with no documented clinical history of pancreatic diseases supported by at least 1 negative imaging test (EUS, CT scan or MRI).
89197290|NCT00851955||2. Chronic pancreatitis patients|Patients with documented diagnosis of moderate to advanced chronic pancreatitis supported by at least 1 positive imaging test (EUS,CT scan or MRI).
89197291|NCT00851955||3. Pancreatic cancer patients|Patients with documented tissue diagnosis (or clinical suspicion) of Pancreatic Cancer.
89197292|NCT04013620|Experimental|transient belatacept|
89197293|NCT02562222|Experimental|anodal tDCS on M1|anodal tDCS on left primary motor cortex
89197294|NCT02562222|Experimental|cathodal tDCS on M1|cathodal tDCS on left primary motor cortex
89197295|NCT02562222|Experimental|anodal tDCS on V1|anodal tDCS on visual cortex
89197296|NCT02562222|Experimental|cathodal tDCS on V1|cathodal tDCS on visual cortex
89197297|NCT02562222|Experimental|anodal tDCS on M1 and cathodal on V1|dual tDCS - anodal tDCS on left primary motor cortex and cathodal on visual cortex
89197298|NCT02562222|Experimental|cathodal tDCS on M1 and anodal on V1|dual tDCS - cathodal tDCS on left primary motor cortex and anodal on visual cortex
89197299|NCT02562222|Sham Comparator|sham tDCS|sham tDCS
89197300|NCT04012684|Experimental|rTMS: left first|One-session rTMS is applied to left IFG. Pre-stimulation and post-stimulation MMN is recorded and compared. After at least two weeks, one-session rTMS is applied to right IFG. Pre-stimulation and post-stimulation MMN is recorded and compared as well.
89197301|NCT04012684|Experimental|rTMS: right first|"One-session rTMS is applied to right IFG. Pre-stimulation and post-stimulation MMN is recorded and compared. After at least two weeks, one-session rTMS is applied to left IFG. Pre-stimulation and post-stimulation MMN is recorded and compared as well.~After at least two weeks, stimulations of the same parameters are given over left IFG. Pre-stimulation and post-stimulation MMN is recorded and compared as well."
89197302|NCT04012684|Sham Comparator|Sham: left first|One-session sham stimulation is applied to left IFG. Pre-stimulation and post-stimulation MMN is recorded and compared. After at least two weeks, one-session sham stimulation is applied to right IFG. Pre-stimulation and post-stimulation MMN is recorded and compared as well.
89197303|NCT04012684|Sham Comparator|Sham: right first|One-session sham stimulation is applied to right IFG. Pre-stimulation and post-stimulation MMN is recorded and compared. After at least two weeks, one-session sham stimulation is applied to left IFG. Pre-stimulation and post-stimulation MMN is recorded and compared as well.
89536876|NCT04442633|Active Comparator|conventional therapy|topical corticosteroid plus antifungal
89536877|NCT04442633|Experimental|Glutamine with a topical corticosteroid plus antifungal|Glutamine therapy in combination with a topical corticosteroid plus antifungal
88909149|NCT05614102|Experimental|Dose expansion of BAY2965501|For expansion part, specific tumor types are recruited (non-small cell lung cancer (NSCLC) and gastric/gastroesophageal junction (GEJ) adenocarcinoma).
88909150|NCT05614102|Experimental|Dose escalation of BAY2965501+pembrolizumab|For escalation part different dose levels of BAY2965501 are planned in combination with 200mg pembrolizumab. BAY2965501 will be taken daily in combination with 200mg pembrolizumab every 3 weeks.
89197304|NCT05051228||GEAR cohort|This is a noninvasive study that screens healthy and non-healthy volunteers for cardiovascular disease.
89197305|NCT00944788|Experimental|qi-gong|
89428725|NCT03442244|Placebo Comparator|Vehicle foam|"Each subject has each of the 2 investigational products applied at the same time on 2 sites on the back. The location on which the treatments are applied is randomised in a double-blinded manner.~Foam vehicle does not contain active ingredients"
89428726|NCT02064387|Experimental|Schedule 1 Part 1|Participants will receive GSK2857916 intravenously over 60 minutes (one dose) every 3 weeks (21 day cycle) for a maximum of 16 cycles.
89428727|NCT02064387|Experimental|Schedule 2 Part 1|Participants may receive GSK2857916 intravenously over 60 minutes (one dose) once weekly for three consecutive weeks followed by 1 week of rest (28 day cycle) for a maximum of 16 cycles.
89428728|NCT02064387|Experimental|Schedule 1 Part 2|Participants will receive the dose and schedule of GSK2857916 evaluated in Part 1 that is selected for further evaluation in Part 2 for up to 16 cycles.
88909151|NCT05614102|Experimental|Dose expansion of BAY2965501 +pembrolizumab|For expansion part, specific tumor types are recruited (non-small cell lung cancer (NSCLC) and gastric/gastroesophageal junction (GEJ) adenocarcinoma). BAY2965501 will be taken daily in combination with 200mg pembrolizumab every 3 weeks.
88909152|NCT05614089|Experimental|Glargine|Insulin glargine (long-acting insulin analogue)
88909153|NCT05614089|Active Comparator|NPH or premixed 70/30 (human insulin)|NPH or premixed 70/30 (human insulin)
88909154|NCT05608408|Experimental|Site 1, then SOC, then site 2, then SOC, then site 3, then SOC, then site 4, then SOC, then site 1|
89428729|NCT02064387|Experimental|Schedule 2 Part 2|Participants may receive the dose and schedule of GSK2857916 evaluated in Part 1 that is selected for further evaluation in Part 2 for a maximum of 16 cycles.
89428730|NCT04896944||ICU Centre Hospitalier de Saint Denis|
89428731|NCT04896944||ICU Hôpital Ambroise Paré Boulogne|
89428732|NCT03442166|Active Comparator|LED group|The patients (n=17) will receive daily intra and extra oral LED applications from the immediate postoperative period up to 7 days after the surgical procedure. The LED irradiation will be performed in two areas, one intra and one extra oral. The LED to be used in the intraoral site will be red, 660+/-20nm wavelength, 5 mW power, 2.7J/cm2 energy density for 7 min, 2J energy per point, knowing that the 6 irradiated spots will have 12J in total. In the extra oral site the infra-red LED will be used, 850+/-20nm wavelength, power of 5mW, 3.8J/cm2 of energy density for 10 min, 3J of energy per point, knowing that 36 will be irradiated, so we will have 108J in total.
88909155|NCT05608408|Experimental|Site 1, then SOC, then site 2, then SOC, then site 3, then SOC, then site 4, then SOC, then site 2|
88909156|NCT05608408|Experimental|Site 1, then SOC, then site 2, then SOC, then site 3, then SOC, then site 4, then SOC, then site 3|
88909157|NCT05608408|Experimental|Site 1, then SOC, then site 2, then SOC, then site 3, then SOC, then site 4, then SOC, then site 4|
88909158|NCT05608005|Experimental|Group 1|2 doses, 21 days apart, of Panblok H7 dose 1 + MF59
88909159|NCT05608005|Experimental|Group 2|2 doses, 21 days apart, of Panblok H7 dose 2 + MF59
88909160|NCT05608005|Active Comparator|Group 3|2 doses, 21 days apart, of Panblok H7 dose 3 unadjuvanted
88909161|NCT05604222|Experimental|Mirabegron|Mirabegron for 8 weeks
88909162|NCT05604222|Experimental|Mirabegron plus Brief Behavioral Treatment for Insomnia (BBTI)|Mirabegron for 8 weeks and a 4 week behavioral intervention for insomnia
88909163|NCT05602207|Experimental|Abrocitinib 100 mg tablet (marketed drug)|
88909164|NCT05601973|Experimental|Treatment Arm|Amivantamab (fixed dose of 1750 mg (or 2100 mg, i.v. every 3 weeks, until disease progression, or intolerable toxicity) PLUS Lazertinib (240 mg, orally, once daily, until disease progression or intolerable toxicities) PLUS Bevacizumab (Zirabev® is administered at a dose of 15mg/kg, i.v. every 3 weeks, until disease progression, or intolerable toxicity).
89428733|NCT03442166|Sham Comparator|Sham group|Patients (n=17) will be treated in the same way as the LED group. The person in charge of the application will simulate the intraoral and extraoral irradiation by positioning the LED in the same locations described for the LED group, but the equipment will be kept off. So that the patient does not identify the sound of activation of the device (beep), it will be recorded, and connected at the time of application.
89428734|NCT01328366||Participants with severe psoriasis|The participants had severe disease as defined by a total Psoriasis Area Severity Index (PASI) of 10 or more and a Dermatology Life Quality Index (DLQI) of more than 10 and had not responded to standard systemic therapies.
89428735|NCT03437954|Other|Standard soft diet|
89428736|NCT03437954|Other|Non-restricted diet|
89428737|NCT03437876|Experimental|patients with HBV induced cirrhosis|patients with HBV induced cirrhosis will be recruited for study, which involved a 4 times intestinal microbiota transplant and the time interval is generally 2 weeks.
89428738|NCT04452266||case group|Women with Lynch Syndrome and endometrial Cancer matched on age of endometrial cancer diagnosis
89428739|NCT04452266||control group|Women with Lynch Syndrome, without Cancer at Lynch Syndrome Diagnostic matched on their age at Lynch Diagnostic
89428740|NCT03442010||People with adverse drug event|People with adverse drug event
89428741|NCT03442010||People without adverse drug event|People without adverse drug event
89428742|NCT02063139|Experimental|Flutiform 50/5 ug (2 puffs bid) pMDI|Flutiform 50/5 ug (2 puffs bid) pMDI
89428743|NCT02063139|Active Comparator|Fluticasone 50 ug (2puffs bid) pMDI|Fluticasone 50 ug (2puffs bid) pMDI
89428744|NCT02063139|Other|Beclometasone Autohaler 50 ug (2 puffs bid)|Active control
89428745|NCT03441932|Active Comparator|Dysphagia screening failed arm|"Subjets within the this arm will have FEES with videotaping of pharyngeal phase after giving subjects a standardised food consisting of thin Puree. An ENT resident blinded to the result of the screening test will do this intervention"
89428746|NCT03441932|Active Comparator|Dysphagia screening passed arm|"Subjets within the this arm will have FEES with videotaping of pharyngeal phase after giving subjects a standardised food consisting of thin Puree. An ENT resident blinded to the result of the screening test will do this intervention"
89428747|NCT04452110||Group I|In volunteers in Group 1, values obtained using a linear probe will be compared.
89428748|NCT04452110||Group II|In volunteers in Group 2, values obtained using a hockey stick probe will be compared.
89428749|NCT00690456|Experimental|Rimonabant|Rimonabant 20 mg once daily on top of metformin
89428750|NCT00690456|Placebo Comparator|Placebo|Placebo (for Rimonabant) once daily on top of metformin
89428751|NCT03445364|Active Comparator|Low coronary injection-pressure, 200 psi|"Patients with STEMI who undergo Primary PCI with the use of low intracoronary dye injection pressure (of 200 psi), by using ACIST automated injector. Patients will recieve bare-metal stents at the courtasy of the interventional cardiologist, only in infarct-related artery.~Use of different injection pressure during primary PCI"
89428752|NCT03445364|Active Comparator|High coronary injection-pressure,550 psi|"Patients with STEMI who undergo Primary PCI with the use of higher intracoronary dye injection pressure (of 500 psi), by using ACIST automated injector. Patients will recieve bare-metal stents at the courtasy of the interventional cardiologist, only in infarct-related artery.~Use of different injection pressure during primary PCI"
89428753|NCT03441854||HFNC group|The investigators will prospectively include 30 patients admitted to 13- bed PICU after liver transplantation and treated with HFNC oxygen delivery after extubation.
89428754|NCT03441854||Control Group|For each study group patient, a match control subject (matching criteria: age ± 10%, PaO2/FiO2 ± 30, diagnosis, Model for End-Stage Liver Disease (MELD) ± 10%) will be chosen from a group of 70 patients treated with conventional oxygen delivery (Venturi Mask) during the previous 2 years.
89428755|NCT03437642||Tako-Tsubo - STP|Short term psychotherapy + Classic cardiological therapy
89428756|NCT03437642||Tako-Tsubo - Control|Classic cardiological therapy only
89428757|NCT03437642||Oncologic - STP|Short term psychotherapy + Classic oncological therapy
89428758|NCT03437642||Oncologic - Control|Classic oncological therapy only
88909165|NCT05599945|Experimental|Single Dose 1: NNC0581-0001 10 milligram (mg)|Participants will receive a single dose of NNC0581-0001 10 mg or matching placebo injection subcutaneously.
89428759|NCT03437642||AMI - STP|Short term psychotherapy + Classic cardiological therapy
88909166|NCT05599945|Experimental|Single Dose 2: NNC0581-0001 30 mg|Participants will receive a single dose of NNC0581-0001 30 mg or matching placebo injection subcutaneously.
88909167|NCT05599945|Experimental|Single Dose 3: NNC0581-0001 90 mg|Participants will receive a single dose of NNC0581-0001 90 mg or matching placebo injection subcutaneously.
89428760|NCT03437642||AMI - Control|Classic cardiological therapy only
89428761|NCT03437642||Healthy Subjects|No therapy
89428762|NCT01370499|Experimental|LY2216684 + SSRI|"LY2216684: 12 milligrams (mg) or 18 mg, administered orally, once daily for 52 weeks, adjunctive to a selective serotonin reuptake inhibitor (SSRI).~During the open-label phase, all participants started at the 12 mg dose and could have the dose increased to 18 mg after the first week of treatment. During the first 12 weeks, participants were allowed (at scheduled or unscheduled visits) to decrease their dose to 12 mg based on response. After a decrease in dose to 12 mg, participants could have had an increase back up to 18 mg at any scheduled visit based on response and tolerability. After 12 weeks of treatment, participants maintained a stable dose.~Open-label treatment was followed by a 1-week abrupt discontinuation phase. Participants who either completed study visits through Week 52 or discontinued early from the study for any reason returned 1 week later for follow-up visit. Participants did not receive LY2216684 but continued their SSRI treatment at a stable dose."
89428763|NCT04070196|Other|Leucocyte testing|The PD effluent will be sent to the laboratory for leucocyte testing for patients presented with suspected PD peritonitis.
89428764|NCT03445286|Experimental|Silver Diamine Fluordie Application|This group will receive Silver Diamine Fluoride (SDF) application once every week within three weeks period
89428765|NCT03445286|Placebo Comparator|Normal Saline|This control group will receive normal saline application once a week within a a three-week period
89428766|NCT00626106|Placebo Comparator|Placebo|
89428767|NCT00626106|Active Comparator|Investigational Product|
88909168|NCT05599945|Experimental|Single Dose 4: NNC0581-0001 250 mg|Participants will receive a single dose of NNC0581-0001 250 mg or matching placebo injection subcutaneously.
88909169|NCT05598567||TCI Group|"Anesthesia induction will be provided by infusion of Propofol and Remifentanil with an infusion pump device called TCI (target controlled infusion). When the bispectral index (processed EEG) levels drop below 60, rocuronium will be administered at a dose of 0.6 mg/kg, and 3 minutes after that, endotracheal intubation will be performed. Propofol and Remifentanil infusion and TCI-TIVA will be continued in the maintenance of anesthesia.~Basal values of CK, CK-MB, Troponin-I will be studied in the preoperative period. In the postoperative period, CK, CK-MB, Troponin-I values will be studied 2 times; immediately at the end of the operation and in the 8th hour from the end of the operation."
88909170|NCT05598567||Sevoflurane Group|"Anesthesia induction will be provided by administration of propofol 2 mg/kg, remifentanil 1 mcg/kg . When the processed EEG levels drop below 60, rocuronium will be administered at a dose of 0.6 mg/kg. 3 minutes after that, endotracheal intubation will be performed. Conventional balanced inhalation-intravenous anesthesia will be provided by administering remifentanil at 0.05 mcg/kg/min and sevoflurane 2% in the maintenance of anesthesia.~Basal values of CK, CK-MB, Troponin-I will be studied in the preoperative period. In the postoperative period, CK, CK-MB, Troponin-I values will be studied 2 times; immediately at the end of the operation and in the 8th hour from the end of the operation."
88909171|NCT05597540|Experimental|7 day-duration antibiotic treatment|
88909172|NCT05597540|Active Comparator|14 day-duration antibiotic treatment|
89428768|NCT00626106|Other|Roll-over|
89428769|NCT03437408|Experimental|Mapping and ablation|Automated Substrate maps with different pacing modes. Validation of collected substrate. Data collection during ablation
89428770|NCT02064465|Experimental|Lamotrigine Dispersable/Chewable|lamotrigine dispersible/chewable tablet 100mg
89428771|NCT02064465|Experimental|Lamotrigine Compressed|lamotrigine compressed tablet 100mg
89428772|NCT04530656|Experimental|Middle-dose vaccine (18-55 years) & Two dose regimen|Two doses of middle-dose experimental vaccine at the schedule of day 0, 28.
89428773|NCT04530656|Experimental|Middle-dose vaccine (> 55 years) & Two dose regimen|Two doses of middle-dose experimental vaccine at the schedule of day 0, 28.
89428774|NCT04530656|Experimental|High-dose vaccine (18-55 years) & Two dose regimen|Two doses of high-dose experimental vaccine at the schedule of day 0, 28.
89428775|NCT04530656|Experimental|High-dose vaccine (> 55 years) & Two dose regimen|Two doses of high-dose experimental vaccine at the schedule of day 0, 28.
89197306|NCT00944788|No Intervention|Usual care|
89197307|NCT00749112|Experimental|A|
89428776|NCT04530656|Experimental|High-dose vaccine (18-55 years) & Three dose regimen|Three doses of high-dose experimental vaccine at the schedule of day 0, 14, 28.
89428777|NCT04530656|Experimental|High-dose vaccine (> 55 years) & Three dose regimen|Three doses of high-dose experimental vaccine at the schedule of day 0, 14, 28.
89428778|NCT04530656|Placebo Comparator|Middle-dose placebo (18-55 years) & Two dose regimen|Two doses of middle-dose placebo at the schedule of day 0, 28.
89428779|NCT04530656|Placebo Comparator|Middle-dose placebo (> 55 years) & Two dose regimen|Two doses of middle-dose placebo at the schedule of day 0, 28.
89428780|NCT04530656|Placebo Comparator|High-dose placebo (18-55 years) & Two dose regimen|Two doses of high-dose placebo at the schedule of day 0, 28.
89428781|NCT04530656|Placebo Comparator|High-dose placebo (> 55 years) & Two dose regimen|Two doses of high-dose placebo at the schedule of day 0, 28.
89428782|NCT04530656|Placebo Comparator|High-dose placebo (18-55 years) & Three dose regimen|Three doses of high-dose placebo at the schedule of day 0, 14, 28.
89428783|NCT04530656|Placebo Comparator|High-dose placebo (> 55 years) & Three dose regimen|Three doses of high-dose placebo at the schedule of day 0, 14, 28.
89428784|NCT00690066|Experimental|Prochymal|PROCHYMAL®
89428785|NCT00690066|Placebo Comparator|Placebo|Placebo
89428786|NCT01370265|Active Comparator|Regadenoson, then Adenosine|Regadenoson (0.4 mg/5 ml IV) was administered intravenously over 10 seconds, followed immediately by saline flush and N-13 ammonia (10-20 MCi) injection and an additional saline flush in the first intervention period. Adenosine (140 μg/kg/min) was administered intravenously over 6 minutes in the second intervention period (after washout period). Three minutes after the start of adenosine infusion, N-13 ammonia (10-20 mCi) was administered.
89428787|NCT01370265|Active Comparator|Adenosine, then Regadenoson|Adenosine (140 μg/kg/min) was administered intravenously over 6 minutes in the first intervention period. Three minutes after the start of adenosine infusion, N-13 ammonia (10-20 mCi) was administered. After a washout period, Regadenoson (0.4 mg/5 ml IV) was administered intravenously over 10 seconds, followed immediately by saline flush and N-13 ammonia (10-20 MCi) injection and an additional saline flush in the second intervention period.
88909173|NCT05596799|Experimental|Facing Eating Disorder Fears Condition|Participants will complete 1 session of education about the treatment. After completion of treatment education and baseline questionnaires, participants will complete sessions 2 through 12 of virtual treatment for anorexia nervosa and mobile assessments.
88909174|NCT05596799|No Intervention|Treatment as Usual|Participants will complete baseline measures, mobile assessments and treatment as usual.
88909175|NCT05594862|Active Comparator|Lipogems|surgical drainage with cone fistulectomy + infiltration of micro-fractured autologous adipose tissue at the level of the internal orifice
88909176|NCT05594862|No Intervention|Placebo|surgical drainage with cone fistulectomy + infiltration of physiological solution and suture point positioning at the internal orifice level
89428788|NCT00734292|Placebo Comparator|I|"Period 1 Treatment Regimen A: FlutiForm 250/10 ug~Period 2 Treatment Regimen B: FlutiForm 100/10 ug~Period 3 Treatment Regimen C: placebo"
88909177|NCT05593432|Experimental|Ruxolitinib cream|Ruxolitinib 1.5% cream BID for 16 weeks, followed by ruxolitinib cream BID 16-week open-label extension.
88909178|NCT05593432|Placebo Comparator|Vehicle Cream|Vehicle cream BID for 16 weeks, followed by ruxolitinib 1.5% cream BID in a 16-week open-label extension.
88909179|NCT05593029|Experimental|SEP-363856 & ADT (Antidepressant Therapy)|
88909180|NCT05593029|Placebo Comparator|Placebo & ADT (Antidepressant Therapy)|
88909181|NCT05591573|Experimental|Low glycemic index drink|Fruit drink containing low glycemic index sugar.
88909182|NCT05591573|Experimental|High glycemic index drink|Fruit drink containing high glycemic index sugar.
88909183|NCT05588895|Experimental|Notification|The notification arm will have its CT scans interpreted and reported according to standard clinical practice. A standardized notification message using the EHR will be sent to the patient's Stanford affiliated non-EP cardiologist, if present, or the primary care clinician if there is no non-EP cardiologist. After a two week delay from notifying the patient's non-EP cardiologist or PCP, a standardized notification message will be sent to the patient. The message will include an image of the CAC from the chest CT. All communications will be signed by the Principal Investigator. Any treatment decisions will be made by the patient and their clinician.
89428789|NCT00734292|Placebo Comparator|II|"Period 1 Treatment Regimen B: FlutiForm 100/10 ug~Period 2 Treatment Regimen C: placebo~Period 3 Treatment Regimen A: FlutiForm 250/10 ug"
89428790|NCT00734292|Placebo Comparator|III|"Period 1 Treatment Regimen C: placebo~Period 2 Treatment Regimen A: FlutiForm 250/10 ug~Period 3 Treatment Regimen B: FlutiForm 100/10 ug"
89428791|NCT03437096|Other|venipuncture pain|pain during venipuncture
89428792|NCT00687882|Experimental|Intervention: A|Patients with non-occlusive thrombus or resolved thrombosis at 6 weeks.
89428793|NCT00687882|Active Comparator|B|Patients with non-occlusive thrombus or resolved thrombosis at 6 weeks.
89008227|NCT05154461|Experimental|GLP-1 in relation to the 2 major BHB release sites|The magnitude of plasma GLP-1 following an OGTT (75g glucose per os) when beta-hydroxybutyrate (BHB) is released either at an upper gastrointestinal site (alginate encapsulation), or at distal gastrointestinal site (pea-protein encapsulation). BHB is given per-os in a single dose of 18g, plus 2 g encapsulation material; totally 20 g.
89428794|NCT00687882|Other|Parallel Cohort: Persistent Occlusive Thrombosis|Patients with completely occlusive thrombosis at 6 weeks.
89428795|NCT00687882|Other|Parallel Cohort: Persistent Antiphospholipid Antibody|Patients with persistent Positive Antiphospholipid Antibody at 6 weeks.
89428796|NCT02064543||ADPM and GAITRite|mobility assessments (ADPM, GAITRite) measuring gait parameters
89428797|NCT02064621|Experimental|C(Candesartan 32mg)|Candesartan 32mg 1T, PO, QD for 9days
89428798|NCT02064621|Experimental|B(Candesartan 32mg/Amlodipine 10mg)|Candesartan 32mg 1T, PO, QD for 9days/Amlodipine 10mg 1T, PO, QD for 9days
89428799|NCT03441698|Experimental|Genuine acupuncture (A)|Genuine acupuncture (A) with neutral communication (A1) or positive communication (A2)
89428800|NCT03441698|Placebo Comparator|Sham Acupuncture (B)|Sham acupuncture (B) with neutral communication (B1) or positive communication (B2)
89428801|NCT03441698|Active Comparator|Rest (C)|Rest (C) with neutral communication (C1) or positive communication (C2)
89428802|NCT03441620|Placebo Comparator|Control|Calorie and fiber-matched control powder
89428803|NCT03441620|Experimental|Strawberry one serving|Freeze-dried powder equivalent to one serving fresh strawberries per day.
89428804|NCT03441620|Experimental|Strawberry two-half servings|Freeze-dried powder equivalent to 2.5 serving fresh strawberries per day.
88909184|NCT05588895|No Intervention|Usual Care|"The usual care arm will have its CT scans interpreted and reported according to standard clinical practice. This may mention the presence of CAC in the official radiology imaging report, per usual practice. The usual care arm will not receive any notification beyond this standard of care.~We intend to notify patients in the usual care arm at the end of 6 months if we determine that notification is effective at increasing statin rates."
88909185|NCT05586139|Experimental|Microbiome-directed food (MDF) - MAM|Each (MAM) child will receive a daily ration of MDF corresponding to his weight, for maximum 12 weeks
89008228|NCT00565474|Active Comparator|1|fluvastatin 40mg b.i.d.
89428805|NCT00684918|Experimental|Experimental|In the Pilot Schedule portion of the study 3 hour vs 24 hour infusion schedules of obatoclax.
88909186|NCT05586139|Active Comparator|Ready-to-use supplementary food (RUSF)|Each (MAM) child will receive a daily ration of MDF corresponding to his weight, for maximum 12 weeks
89428806|NCT03445208|Experimental|Cohort 1|BMI 18.0 to ≤ 25.0
89428807|NCT03445208|Experimental|Cohort 2|BMI >25.0 to ≤ 30.0
89428808|NCT03445208|Experimental|Cohort 3|BMI >30.0 ≤ 40.0
88909187|NCT05586139|Experimental|Microbiome-directed food (MDF) - SAM|Each (SAM) child will receive a daily ration of MDF corresponding to his weight, for maximum 12 weeks of supplementation.
89008229|NCT00565474|Placebo Comparator|2|Placebo b.i.d.
89008230|NCT00252486|Placebo Comparator|Flax oil, placebo oil|
89428809|NCT00726648|Experimental|1|
89428810|NCT00726648|Experimental|2|
89428811|NCT00726648|Experimental|3|
89428812|NCT00726648|Experimental|4|
89428813|NCT00726648|Placebo Comparator|5|
88909188|NCT05586139|Active Comparator|Ready-to-use therapeutic food (RUTF)|Each (SAM) child will receive a daily ration of RUTF corresponding to his weight, for maximum 12 weeks of supplementation
88909189|NCT05584215|Experimental|Treatment|Treatment group will receive cognitive behavioural therapy informed groups for psychosis.
88909190|NCT05584215|No Intervention|Control|Control group will be put on a waitlist to receive cognitive behavioural therapy informed groups for psychosis.
88909191|NCT05583955|Experimental|Active|Escalating doses of NOE-105 capsules
88909192|NCT05583955|Placebo Comparator|Placebo|Escalating doses of matching placebo
88909193|NCT05579431|Experimental|Part A|Participants grouped in different cohorts will receive a single ascending dose of VX-634.
88909194|NCT05579431|Placebo Comparator|Placebo Part A|Participants will be randomized to receive placebo matched to VX-634.
88909195|NCT05579431|Experimental|Part B|Participants grouped in different cohorts will receive multiple doses of VX-634.The dose levels will be determined based on the data from Part A.
88909196|NCT05579431|Placebo Comparator|Placebo Part B|Participants will be randomized to receive placebo matched to VX-634.
88909197|NCT05577546|Experimental|Brace group|"Fifteen patients with AIS will be included in this group. The scoliosis brace, whose characteristics are described below under the Brace heading, will be worn by the patient for 12 weeks. Although the daily brace wearing time varies between 20-23 hours, depending on the patient, it will be determined according to the physician's recommendation. Compliance regarding the brace will be monitored from the parent-controlled charts where the daily wearing time is recorded by the patient"
88909198|NCT05577546|Experimental|Brace and Schroth exercise group|Fifteen patients with AIS will be included in this group, they will be treated by brace and exercise during 12 weeks. The same brace treatment protocol as the brace group will be applied for this group. Additionally, Schroth Three-Dimensional Scoliosis Exercise Treatment will be applied to this group by the researcher physiotherapist at the brace center. Exercise therapy will be carried out at the brace center once a week with the researcher physiotherapist, and 45 min a day, 4 days a week in the form of home exercises. The number of exercise sets and repetitions will be determined by the researcher physiotherapist according to the patient, considering deformity severity and flexibility, generalized joint hypermobility, bone maturation, menarche status and the risk of progression. Compliance with the home exercise program (frequency and duration) will be recorded by the patients in a home exercise diary for 12 weeks.
89428814|NCT02067897||Vandenbos procedure (skinfold excision)|Participants in this cohort will undergo with Vandenbos procedure (skinfold excision) for one or more ingrown toenails. This surgery will be formed as an day procedure under general anesthetic.
89428815|NCT03445052|Experimental|2018 XPAND Intervention Arm|This group will receive the personalised adherence intervention in 2018 in addition to routine clinical care.
89008231|NCT04600492|Active Comparator|Active Comparator: Active drug group Riociguat|Riociguat 0.5mg、1.0mg、2.5mg
89428816|NCT03445052|No Intervention|2018 XPAND Control Arm|This group will receive routine clinical care and act as the control group for the primary objective: To compare the mean daily dose of UVR (SEDs) reaching the face between the intervention group and control group over a 3 week period in June to July (follow-up 1). This group will receive the intervention in 2019, to allow within group change to be assessed.
89008232|NCT04600492|Placebo Comparator|Placebo group|Placebo 0.5mg、1.0mg、2.5mg
89008233|NCT04600063|Other|Conventional procedure|In the conventional procedure group, first, the pancreatic body and tail and spleen are mobilized (mandatory procedure), and the regional lymph nodes of the body and tail of the pancreas, such as the hepatoduodenal mesentery (No12 lymph node) and the common hepatic artery perimeter (No8), are removed. (Recommended procedure) and dissection of lymph nodes (No14p) around SMA (Recommended procedure), and after dissection of the gastro-splenic ligament and pancreas, transection of the splenic vein at the end of the resection procedure (required procedure) . However, in order to prevent bleeding and secure a safe field of view, early pancreatotomy is allowed.
89008234|NCT04600063|Experimental|Isolation procedure (RAMPS procedure)|In the Isolation procedure group, the transection of the root of the splenic artery and the pancreatic transection are performed first, followed by the transection of the splenic vein (mandatory procedure). At that time, the branch from the splenic artery (dorsal pancreatic artery), the branch to the splenic vein (left gastric vein, inferior mesenteric vein), and short gastric arteriovenous are also disconnected as soon as possible (recommended procedure). An operation to lift up the pancreatic neck from the dorsal portal vein or superior mesenteric artery to expose the splenic vein (so-called tunneling) is allowed. After that, lymph node dissection such as hepatoduodenal mesentery (No12), common hepatic artery perimeter (No8), lymph node dissection around SMA (No14p) was performed (recommended procedure), and at the end of the resection operation, the pancreas body/tail and spleen are mobilized and removed (required procedure).
89008235|NCT04599985|Experimental|Star excursion balance training (SEBT)|Received star excursion balance training (SEBT) program. Performed 3-trials in all 8 directions of the SEBT grid.
89008236|NCT04599985|Active Comparator|Simplified star excursion balance training (SSEBT)|Received simplified star excursion balance training (SSEBT) program. Performed 3-trials in all 3 directions of SSEBT grid.
89008237|NCT04599673|Experimental|AMNIOGEN|Intraoperative1 kit of AMNIOGEN injection into shoulder joint after RCT repair.
89008238|NCT04599673|Placebo Comparator|Normal saline|Intraoperative 10 ml of normal saline injection into shoulder joint after RCT repair.
89428817|NCT03559959|Experimental|$0 price|Vouchers for HIV self-testing kits: Individuals will receive a voucher that can be used to redeem an HIV self-testing kit free of charge.
89428818|NCT03559959|Experimental|$0.5 price|Vouchers for HIV self-testing kits: Individuals will receive a voucher that can be used to purchase an HIV self-testing kit at the price of $0.5.
89428819|NCT03559959|Experimental|$1 price|Vouchers for HIV self-testing kits: Individuals will receive a voucher that can be used to purchase an HIV self-testing kit at the price of $1.
89428820|NCT03559959|Experimental|$2 price|Vouchers for HIV self-testing kits: Individuals will receive a voucher that can be used to purchase an HIV self-testing kit at the price of $2.
89428821|NCT03559959|Experimental|$3 price|Vouchers for HIV self-testing kits: Individuals will receive a voucher that can be used to purchase an HIV self-testing kit at the price of $3.
89428822|NCT04414826|Active Comparator|Mindfulness + Compassion (MC) Intervention|Subjects assigned to this condition will participate in an hour-long, one-session telehealth intervention teaching both mindfulness and compassion skills.
89428823|NCT04414826|Active Comparator|Mindfulness Alone (MO) Intervention|Subjects assigned to this condition will participate in an hour-long, one-session telehealth intervention teaching mindfulness skills alone.
89428824|NCT04414826|Placebo Comparator|Waitlist Control (WL)|Those in the wait-list control condition will wait one week and complete a one-week follow-up assessment before being randomized to one of the two intervention conditions.
89428825|NCT02280720|Active Comparator|CoCr-BAS|Stenting using Optimax™ cobalt-chromium alloy platform with a titanium-nitride-oxide coating
88909199|NCT05577546|No Intervention|Healthy control group|Fifteen healthy volunteers between the ages of 10-18 will be included in this group. No intervention will be applied to this group and they will only be assessed, and their findings obtained from the gait analysis will compare with the patient groups.
88909200|NCT05576805||Cohort 1: Resistant, Refractory, or Intolerant (RRI) to Anti-CMV Treatment|Participants who had an SOT after January 1, 2016 and must have developed post-transplant CMV infection and were subsequently characterized as RRI to currently available anti-CMV treatment at least 12 months before enrollment in the study will be observed in this retrospective study for 24 months.
88909201|NCT05576805||Cohort 2: Pre-emptive CMV Treatment|Participants who had an SOT after January 1, 2019, and who were preemptively treated for CMV at least 12 months before enrollment in the study will be observed in this retrospective study for 24 months.
88909202|NCT05575375|Experimental|Values Affirmation + Usual Care|
88909203|NCT05575375|Other|Usual Care|
88909204|NCT05575180|Experimental|Methazolamide|Drug: Methazolamide Dose: 100 mg b.i.d Duration: 2 days prior to testing + 1 hr prior to testing start Form: Oral
88909205|NCT05575180|Active Comparator|Acetazolamide|Drug: Acetazolamide Dose: 250 mg t.i.d Duration: 2 days prior to testing + 1 hr prior to testing start Form: Oral
88909206|NCT05575180|Placebo Comparator|Placebo|Drug: Placebo (microcrystalline cellulose) Dose: 250 mg t.i.d Duration: 2 days prior to testing + 1 hr prior to testing start Form: Oral
88909207|NCT05575011|Experimental|Part A: Cohort 1: BIIB115 Dose 1|Participants will receive a single dose of BIIB115, Dose 1, via IT bolus injection, on Day 1.
88909208|NCT05575011|Experimental|Part A: Cohort 2: BIIB115 Dose 2|Participants will receive a single dose of BIIB115, Dose 2, via IT bolus injection, on Day 1.
88909209|NCT05575011|Experimental|Part A: Cohort 3: BIIB115 Dose 3|Participants will receive a single dose of BIIB115, Dose 3, via IT bolus injection, on Day 1.
89428826|NCT02280720|Active Comparator|PtCr-EES|Stenting using PROMUS Element™ Plus durable polymer everolimus-eluting stent built on a platinum-chromium platform.
89428827|NCT02068053|Experimental|Arm A - BMS-986020|600 mg (approximately 80 micro Curie) of [14C] BMS-986020 Single Dose for 1 Day (Day 1) orally
89428828|NCT02280798||pilot study|"A total of 5 volunteers from our egg donation program were included in the study with 4 endometrial biopsies for each one after 4 diferente protocols~Endometrial biopsy after Stimulated cycle~Endometrial biopsy after Natural Cycle~Endometrial biopsy after Natural modified cycle: the biopsy is taken seven days after the hCG~Endometrial biopsy after Hormone Replacement Therapy Cycle"
89428829|NCT03444974|Active Comparator|Patient therapy group|"Adolescents with substance use disorders~Receiving an adapted treatment according to the MATRIX-A therapy"
89428830|NCT03444974|Active Comparator|Parental therapy group|"Parents of adolescents with substance use disorders~Receiving an adapted treatment according to the MATRIX-A therapy"
89428831|NCT03444974|No Intervention|Patient waiting list group|"Adolescents with substance use disorders~On the waiting list for receiving a MATRIX-A therapy"
88909210|NCT05575011|Experimental|Part A: Cohort 4: BIIB115 Dose 4|Participants will receive a single dose of BIIB115, Dose 4, via IT bolus injection, on Day 1.
88909211|NCT05575011|Placebo Comparator|Part A: Cohorts 1-4: BIIB115-Matching Placebo|Participants will receive a single dose of BIIB115-matching placebo, via IT bolus injection, on Day 1.
88909212|NCT05575011|Experimental|Part B: Cohort 5: BIIB115 Dose 3|Pediatric SMA participants previously treated with onasemnogene abeparvovec will receive two doses of BIIB115, Dose 3, via IT bolus injection at two separate time points.
88909213|NCT05575011|Experimental|Part B: Cohort 6: BIIB115 Dose 4|Pediatric SMA participants previously treated with onasemnogene abeparvovec will receive two doses of BIIB115, Dose 4, via IT bolus injectionat two separate time points.
88909214|NCT05574400|Placebo Comparator|Control|Prepared intravenous piggyback solution of 5 percent dextrose water at multiple postoperative time points over a 30-minute infusion period.
89428832|NCT03444974|No Intervention|Parental waiting list group|"Parents of adolescents with substance use disorders~On the waiting list for receiving a MATRIX-A therapy"
89428833|NCT03444974|No Intervention|control group|"Adolescents with no history of substance use disorders~no other intake of psychotropic substances such as psychotropic medication"
89428834|NCT02068131|Experimental|Novaferon+ xeloda|"Capecitabine for 2 weeks straight (Days 1-14) followed by 1 week without capecitabine (Days 15-21).~Recombinant anti-tumor and anti-virus protein for injection(Novaferon), three times per week."
89428835|NCT02068209|Active Comparator|Tramadol|Patients will receive Tramadol 50mg 1 hour before outpatient hysteroscopy
89428836|NCT02068209|Placebo Comparator|Placebo|Patients will receive a placebo 1 hour before the procedure.
89428837|NCT00680784|Experimental|HKT-500 Ketoprofen Topical Patch|Randomized, double-blind, placebo-controlled, multicenter study in men and women 18 years of age or older who have a painful, acute, benign, ankle sprain of the lateral ligament(s) within the previous 48 hours.
89428838|NCT00680784|Placebo Comparator|Placebo Patch|Treatment with placebo patch
89428839|NCT04404218|Experimental|Açaí palm berry extract|Açaí palm berry extract is a powerful antioxidant with no known side-effects and is widely consumed in Brazil. Açaí palm berry chemical composition has been established and includes several antioxidants - gallic acid, catechin, chlorogenic acid, caffeic acid, p-coumaric acid, epicatechin, orientin, cyanidin-3-0-glucoside, luteolin and apigenin. Orientin is the most concentrated compound (7,96mg/g) and this compound is able to modulate the NLRP3 inflammasome.
89428840|NCT04404218|Placebo Comparator|Placebo arm|This study will be double-blinded and placebo-controlled. To ensure double-blinding, placebo and active compound capsules will be over-encapsulated with DBCAPS® capsules, which were developed with a tamper-evident design to address the clinical trial challenges of testing without bias. These capsules are made of gelatin and have no interaction with bioavailability.
88909215|NCT05574400|Experimental|Low-dose Caffeine|Prepared intravenous low-dose caffeine citrate (1.5 mg/kg) at multiple postoperative time points over a 30-minute infusion period.
88909216|NCT05574400|Experimental|High-dose Caffeine|Prepared intravenous high-dose caffeine citrate (3 mg/kg) at multiple postoperative time points over a 30-minute infusion period.
88909217|NCT05574296|Experimental|Usual care + H2 therapy|Hydrogen administered via mechanical ventilator and sweep gas into ECMO membrane for 72 hours
88909218|NCT05574296|Active Comparator|Usual care|The current standard of care.
88909219|NCT05573893||Cohort 1|Cohort 1 containing patients with documented HER2-positive unresectable or metastatic BC receiving T-DXd for 2L treatment in line with the applicable summary of product characteristics (SmPC) within routine clinical practice.
88909220|NCT05573893||Cohort 2|Cohort 2 containing patients with documented HER2-low unresectable or metastatic BC receiving T DXd treatment in line with the applicable summary of product characteristics (SmPC) within routine clinical practice.
88909221|NCT05573555|Experimental|ARV-471 in combination with Ribociclib|ARV-471 administered orally QD continuously and Ribociclib administered orally QD consecutively for 21 days followed by 7 days off treatment on 28-day cycles
88909222|NCT05571683||recovered from covid-19, 2 l/min oxygen support|20 patients, who recovered from COVID-19 will be supported with 2 l/min oxygen during the operation under the drapes. Electrocardiography, pulse oximetry, non-invasive blood pressure, end-tidal carbon dioxide and cerebral oximetry will be monitored and optic nerve sheath diameter will be measured before and after surgical procedure. All measurements except optic nerve sheath diameter will be recorded and repeated at 5 minute intervals throughout the operation.
88909223|NCT05571683||no covid anamnese, 2 l/min oxygen support|20 patients with no COVID-19 anamnese will be supported with 2 l/min oxygen during the operation under the drapes. Electrocardiography, pulse oximetry, non-invasive blood pressure, end-tidal carbon dioxide and cerebral oximetry will be monitored and optic nerve sheath diameter will be measured before and after surgical procedure. All measurements except optic nerve sheath diameter will be recorded and repeated at 5 minute intervals throughout the operation.
88909224|NCT05571683||recovered from covid-19, 4 l/min oxygen support|20 patients, who recovered from COVID-19 will be supported with 4 l/min oxygen during the operation under the drapes. Electrocardiography, pulse oximetry, non-invasive blood pressure, end-tidal carbon dioxide and cerebral oximetry will be monitored and optic nerve sheath diameter will be measured before and after surgical procedure. All measurements except optic nerve sheath diameter will be recorded and repeated at 5 minute intervals throughout the operation.
88909225|NCT05571683||no covid anamnese, 4 l/min oxygen support|20 patients with no COVID-19 anamnese will be supported with 4 l/min oxygen during the operation under the drapes. Electrocardiography, pulse oximetry, non-invasive blood pressure, end-tidal carbon dioxide and cerebral oximetry will be monitored and optic nerve sheath diameter will be measured before and after surgical procedure. All measurements except optic nerve sheath diameter will be recorded and repeated at 5 minute intervals throughout the operation.
88909226|NCT05571462||Activity monitor group|No intervention will be applied. All patients will have activity monitors placed at the distal part of the femur and on the torso. Normal rehabilitation will be performed as usual.
89428841|NCT02068287|Experimental|ESMOLOL|Resuscitated, hyperkinetic septic shock patients are treated with esmolol in order to reduce heart rate of 20% during 6 hours. During the intervention period, multimodal macro and micro hemodynamic data are recorded.
89428842|NCT03444896|Experimental|Acupuncture group|
88909227|NCT05570344|Active Comparator|Enrolment in rTMS sessions alone|All study participants will be scheduled to receive 30 sessions of rTMS treatment for 6 weeks as pre-established by the Alberta Health Services Strategic Clinical Network for Addiction and Mental Health and Nova Scotia Health.
88909228|NCT05570344|Experimental|Enrolment in rTMS sessions plus Text4Support|Participants in the rTMS plus Text4Support group of the study would be assisted by a study team member assigned that purpose to register onto the Text4Support program. The process would require all participants to input their phone numbers into the Text4Support platform that will be used to deliver the daily messages. Starting a day after enrollment, participants will receive daily supportive text messages designed by mental health therapists, clinical psychologists, psychiatrists, and mental health service users. These messages are based on cognitive behavior therapy principles crafted to enhance positively the mood of its users with depressive symptoms and other related mental health problems of concern. The messages will be pre-programmed into a software program that will deliver the messages to participants automatically to the participants' mobile phones at 10 AM (Mountain Time) and 12 PM (Atlantic Time), and each participant will receive these messages continuously for 6 weeks.
89197308|NCT00848679|Active Comparator|Epidural lidocaine|30 women to receive 5 x 5mL boluses of epidural lidocaine 2%. 10 pre-eclampsia, 10 term pregnancy, 10 non-pregnant.
89428843|NCT03444896|Placebo Comparator|Sham acupuncture group|
89428844|NCT02068365|Other|Pegyinterferon-alfa-2a|Pegyinterferon-alfa-2a 180mcq weekly for 48 weeks
89428845|NCT02280876|Active Comparator|1 - Andrographis paniculata p/st extract|1 - Andrographis paniculata extract. Active comparator, consists of 15 adult patients with active Recurrent Remitting Multiple Sclerosis, randomly assigned, taking the active test product (Andrographis paniculata p/st extract, oral lozenges, one BID, for 12 months), in addition to base medication (Interferon).
89197309|NCT00848679|Placebo Comparator|Epidural saline|30 women to receive 5 x 5 mL boluses of epidural saline. 10 pre-eclamptics, 10 normal term pregnancy, 10 non-pregnant
89428846|NCT02280876|Placebo Comparator|2 - Excipients|2 - Excipients. Placebo comparator, consists of 15 adult patients with active Recurrent Remitting Multiple Sclerosis, randomly assigned, taking the placebo formulation (Only the excipients of the active test product, in oral lozenges of same shape, one BID, for 12 months), in addition to base medication (Interferon).
89428847|NCT03444818|Experimental|[14C]-E6007|Participants will receive a single oral dose of 60 milligrams (mg) of [14C]-E6007.
89428848|NCT02068521|Experimental|Treatment naive subjects with GHD|Up to 100 new treatment naïve subjects with GHD will receive somavaratan 3.5mg/kg twice monthly.
89428849|NCT02068521|Experimental|Subjects who have completed a somavaratan study|All subjects after participation in (12VR2) or participation in the 14VR4 protocols have the option to receive somavaratan 3.5mg/kg twice monthly.
89428850|NCT04367870||Non immune patient|Patients with a negative SARS-CoV-2 immunoassay
89428851|NCT04367870||Immune patient|Patients with a positive SARS-CoV-2 immunoassay
88909229|NCT05559021|Experimental|Myofascial Treatment Approach|"Patients will have 1 session per week, during 4 weeks, making 4 sessions in total. Each session will last 30 minutes. Each session consists of:~Transverse planes in the thoracolumbar fascia and abdomen: The physical therapist place his hands facing each other so that one hand is between the tables and the patient's thoracolumbar fascia and the other on the abdomen~Transverse planes at C7-D3 and sternum: The physical therapist, places one hand between the table and the patient's first 4 thoracic vertebrae (C7-T4) and the other on the sternum.~Suboccipital inhibition: the physical therapist, places his hands under the patient's head transversely between the occipital and the spinous process of C2. After, the head is lowered in such a way that the occipital bone rests on the tenar eminences and a slight traction is maintained cranially."
88909230|NCT05559021|Experimental|Mobilization Approach.|"Patients will have 1 session per week, for 4 weeks, which means 4 sessions in total. Each session will last 30 minutes. Each session consists of:~Postero-anterior cervical sliding: the patient's cervical vertebrae will be evaluated with the 4 degrees of postero-anterior sliding, and the pain at each vertebral level is recorded. Then, the most painful vertebra previously detected will be treated.~Postero-anterior lumbar slippage: the patient's lumbar vertebrae will be evaluated with the 4 degrees of postero-anterior slippage, and the pain at each vertebral level is recorded. Afterwards, the most painful vertebra previously detected will be treated.~Postero-anterior dorsal slippage: the patient's dorsal vertebrae will be evaluated with the 4 degrees of postero-anterior slippage, and the pain at each vertebral level is recorded. Then, Afterwards, it will treat during the most painful vertebra previously detected."
88909231|NCT05549908|Experimental|Experimental 4 doses|Inoculate experimental vaccine according to 2-1-1 immunization procedure
88909232|NCT05549908|Experimental|Experimental 5 doses|Inoculate experimental vaccine according to 1-1-1-1-1 immunization procedure
88909233|NCT05549908|Active Comparator|SPEEDA® 4 doses|Inoculate SPEEDA® according to 2-1-1 immunization procedure
88909234|NCT05548660|Experimental|PGx-guided|Pharmacogenetic testing using a 16 gene panel with a pharmacist consult providing genotype-guided recommendations for post-surgery analgesic selection based on CYP2D6 and CYP2C9 results. Pharmacist recommendations for all 16 gene results will also be provided in a detailed note.
88909235|NCT05548660|Other|Usual care|Pharmacogenetic testing using a 16 gene panel. Post-surgery analgesic selection will be based on usual care (not the PGx results). Pharmacist recommendations for all 16 gene results will be provided in a detailed note with a delayed return of results (30 days post surgery)
88909236|NCT05547906|Experimental|ASCA101 IV|The study drug, ASCA101(300mg/vial), will be reconstituted in water for injection and diluted with saline to a dose calculated according to individual body surface area or body weight.
88909237|NCT05546814|Experimental|Sodium algorithm|Starting at 2 weeks of age, the sodium algorithm group will be started based on their sodium levels. This will be adjusted weekly based on weight gain and sodium levels.
88909238|NCT05546814|No Intervention|Control|Subjects will be cared for by current protocols
88909239|NCT05545371|Experimental|4 doses|Inoculate rabies vaccine according to 1-1-1-1 immunization procedure
88909240|NCT05545371|Experimental|5 doses|Inoculate rabies vaccine according to 1-1-1-1-1 immunization procedure
88909241|NCT05544864|Other|homogenous|Stratification - homogenous pattern
89428852|NCT02068677|Other|sympathetic response|This group will be composed of subjects who experience a heart rate and/or Blood Pressure change during injection.
88909242|NCT05544864|Other|heterogenous|Stratification - homogenous pattern
89428853|NCT02068677|Other|no sympathetic response|This group will be made up of subjects that do not experience a vital sign change with injection for CPN.
89428854|NCT01973166|Experimental|Picosecond Q-switched Laser Treatment|Picosecond Q-switched Nd:YAG (1064 nm and 532 nm) laser
89428855|NCT01973166|Active Comparator|Nanosecond Q-switched Laser Treatment|Nanosecond Q-switched Nd:YAG (1064 nm and 532 nm) laser
89428856|NCT03789279||Distal transradial arterial access|Patients undergoing invasive coronary angiography via the distal radial approach (anatomical snuffbox)
89428857|NCT00680472|Active Comparator|A,1 HKT-500 Ketoprofen Topical Patch|A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Two-Week Study to Assess the Efficacy and Safety of HKT-500 in Subjects with Acute Shoulder Pain
89428858|NCT00680472|Placebo Comparator|A,2 Placebo Patch|Treatment with placebo patch
89428859|NCT05575401|Active Comparator|Tonsillectomy +/- adenoidectomy|Participants will undergo extracapsular tonsillectomy +/- adenoidectomy.
89428860|NCT05575401|Experimental|Tonsillectomy +/- adenoidectomy with lateral pharyngoplasty|Participants will undergo extracapsular tonsillectomy +/- adenoidectomy and lateral pharyngoplasty.
88909243|NCT05543616|Experimental|3 microgram dose, 6 Months to <2 Years (Substudy A, Phase 1)|Injection in the muscle at 0-, 3-, and 11-weeks and approximately 6-months post-Dose 3
88909244|NCT05543616|Experimental|6 microgram dose, 6 Months to <2 Years (Substudy A, Phase 1)|Injection in the muscle at 0-, 3-, and 11-weeks and approximately 6-months post-Dose 3
88909245|NCT05543616|Experimental|10 microgram dose, 6 Months to <2 Years (Substudy A, Phase 1)|Injection in the muscle at 0-, 3-, and 11-weeks and approximately 6-months post-Dose 3
88909246|NCT05543616|Experimental|Selected dose, 6 Months to <2 Years (Substudy A, Phase 2/3, Group 1) - 0/8 week schedule|Injection in the muscle at 0- and 8-weeks
88909247|NCT05543616|Experimental|Selected dose, 6 Months to <2 Years (Substudy A, Phase 2/3, Group 2) - 0/8 week schedule|Injection in the muscle at 0- and 8-weeks
88909248|NCT05543616|Experimental|3 microgram dose, 6 Months to <4 Years 6 Months (Substudy B, Group 1)|Injection in the muscle, 2 doses 2 months apart
88909249|NCT05543616|Experimental|3 microgram dose, 6 Months to <5 Years (Substudy B, Group 2)|Injection in the muscle, 1 dose
88909250|NCT05543616|Experimental|3 microgram dose, 6 Months to <5 Years (Substudy B, Group 3)|Injection in the muscle, 1 dose
88909251|NCT05543616|Experimental|6 microgram dose, 6 Months to <2 Years (Substudy C, Phase 1)|Injection in the muscle, 1 dose
88909252|NCT05543616|Experimental|10 microgram dose, 6 Months to <2 Years (Substudy C, Phase 1)|Injection in the muscle, 1 dose
88909253|NCT05543616|Experimental|10 microgram dose, 5 to <12 Years (Substudy D, Group 1)|Injection in the muscle, 1 dose
88909254|NCT05543616|Experimental|10 microgram dose, 5 to <12 Years (Substudy D, Group 2)|Injection in the muscle, 1 dose
88909255|NCT05543616|Experimental|10 microgram dose, 5 to <12 Years (Substudy D, Group 3)|Injection in the muscle, 1 dose
88909256|NCT05543616|Experimental|3 microgram dose, 2 Years to <4 years 3 months (Substudy A, Phase 1)|Injection in the muscle at 0-, 3-, and 11-weeks and approximately 6-months post-Dose 3
88909257|NCT05543616|Experimental|6 microgram dose, 2 Years to <4 years 3 months (Substudy A, Phase 1)|Injection in the muscle at 0-, 3-, and 11-weeks and approximately 6-months post-Dose 3
88909258|NCT05543616|Experimental|10 microgram dose, 2 Years to <4 years 3 months (Substudy A, Phase 1)|Injection in the muscle at 0-, 3-, and 11-weeks and approximately 6-months post-Dose 3
88909259|NCT05543616|Experimental|6 microgram dose, 2 Years to <5 Years (Substudy C, Phase 1)|Injection in the muscle, 1 dose
88909260|NCT05543616|Experimental|10 microgram dose, 2 Years to <5 Years (Substudy C, Phase 1)|Injection in the muscle, 1 dose
88909261|NCT05543616|Experimental|3 microgram dose, 6 Months to <2 Years (Substudy A, Phase 2/3, Group 3) - 0/3/11 week schedule|Injection in the muscle at 0-, 3-, and 11-weeks
88909262|NCT05543616|Experimental|Selected dose, 2 to <5 Years (Substudy A, Phase 2/3, Group 4) - Single dose|Injection in the muscle, 1 dose
88909263|NCT05543616|Experimental|Selected dose, 2 to <5 Years (Substudy A, Phase 2/3, Group 5) - Single dose|Injection in the muscle, 1 dose
88909264|NCT05543616|Experimental|3 microgram dose, 2 Years to <5 Years (Substudy E, Group 1)|Injection in the muscle, 1 dose
88909265|NCT05543616|Experimental|10 microgram dose, 5 Years to <12 Years (Substudy E, Group 2)|Injection in the muscle, 1 dose
88909266|NCT05539430|Experimental|Experimental LB1908|Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells
88909267|NCT05538806||Group 1|all patients will receive routine clinical care and TTFields
88909268|NCT05538663|Experimental|Arm A|Gemcitabine + Docetaxel
88909269|NCT05538663|Experimental|Arm B|BCG
88909270|NCT05538247|Experimental|S. boulardii CNCM I-745 Group|Subjects will receive Indomethacin from day 2 to day 7 and S. boulardii CNCM I-745 from day 1 to day 14
88909271|NCT05538247|Placebo Comparator|Placebo Group|Subjects will receive Indomethacin from day 2 to day 7 and Placebo from day 1 to day 14
88909272|NCT05537896|Experimental|Xerava|Eravacycline- 1 mg/kg actual body weight IV Infusion over 60 minutes every 12 hours
88909273|NCT05537220|Experimental|Group 1 - N-acetylcysteine|This is the intervention group. Patients in this group will be receiving 1800 mg of N-acetylcysteine in the form of 3 effervescent 600 mg tablets dissolved in water twice a day for 45 months.
88909274|NCT05537220|Placebo Comparator|Group 2 - Placebo|Patients in the placebo group will receive identical effervescent tablets lacking active drug.
88909275|NCT05532046|Experimental|Treatment arm 1|Participants will receive BAY2413555 for 28 days (Part A: 14 days and Part B: 14 days).
88909276|NCT05532046|Experimental|Treatment arm 2|Participants will receive BAY2413555 for 28 days (Part A: 14 days and Part B: 14 days).
88909277|NCT05532046|Placebo Comparator|Placebo|Participants will receive placebo to BAY2413555 for 28 days (Part A: 14 days and Part B: 14 days).
88909278|NCT05531656|Active Comparator|CT1812 100 mg|CT1812 at a dose of 100 n=180 group
88909279|NCT05531656|Active Comparator|CT1812 200 mg|CT1812 at a dose of 300mg, n=180 group
88909280|NCT05531656|Placebo Comparator|Placebo|Placebo, n=180 group
88909281|NCT05530421|Experimental|XVenD Group|"Participants will receive XVenD combination therapy of Selinexor (X), Venetoclax (Ven) and Dexamethasone (D) orally during each 28-day cycle. Doses will be administered as follows:~Cycle 1 Days 1 to 7:~Venetoclax 400 mg orally (PO), Days 1-7~Dexamethasone 40 mg PO, Day 1~Cycle 1 Days 8 to 28:~Venetoclax 800 mg PO, Days 8-28~Dexamethasone 40 mg PO, Days 8, 15, and 22~Cycles 2 to 4:~Selinexor 80 mg PO, Days 1, 8, 15, and 22~Venetoclax 800 mg PO, Days 1-28~Dexamethasone 40 mg PO, Days 1, 8, 15, and 22~Cycle 5 and beyond:~Selinexor 80 mg PO, Days 1, 8, 15, and 22~Venetoclax 800 mg PO, Days 1-28~Dexamethasone 20 mg PO, Days 1, 8, 15, and 22~Selinexor dose will be reduced to 60 mg for remaining participants if after the first 6 participants complete the first cycle and 2 or more out of these first 6 participants experience dose-limiting toxicities (DLTs)."
89428861|NCT03444662|Placebo Comparator|Placebo|Intervention: Dietary Supplement: Placebo supplement
89197310|NCT02567864|Experimental|Healthy Beat Accupunch|The HBA exercise program includes: 1) warm-up: 5 slow and gentle exercises to regulate qi, loosen up the body, and elevate the energy for a safe transition to the next phase, 2) accupunch: 14 low-to-medium speed exercises to punch the 14 meridians to enhance the cardiovascular-respiratory workout, and 3) relaxation: 5 low-speed, muscle relaxing exercises with deep breaths to sooth the body and mind. It is conducted 3 times per week and 40 minutes per practice.
89197311|NCT02567864|Active Comparator|control|The control group maintains daily activities.
89197312|NCT04012606|Experimental|TORIPALIMAB|
89197313|NCT04012606|Active Comparator|Chemotherapy|
89197314|NCT00744744||Survey|
89197315|NCT00944866||RA with drug|
88909282|NCT05526521|Experimental|Dupilumab|Administered subcutaneously (SC) every 4 weeks (Q4W) or every 2 weeks (Q2W) with or without an initial loading dose based on weight and age
88909283|NCT05526144|Placebo Comparator|Placebo group|Placebo group will receive placebo tablets
88909284|NCT05526144|Active Comparator|Study group|Study group will receive Synthroid (Levothyroxine) 25, 50, or 75 mcg daily
88909285|NCT05522244|No Intervention|standard CTA|Standard CTA performed as standard of care for Stroke Workup
88909286|NCT05522244|Experimental|extended CTA|The standard CTA will be extended 6 cm below the carina
88909287|NCT05521906|Experimental|Treatment Condition|The PRYSHM program is theoretically grounded, follows best practices for effective health behavior prevention, and includes nine, one hour sessions co-facilitated by 2 LGBTQ+ adults.
88909288|NCT05521906|No Intervention|Control|Check-ins/provision of resources
88909289|NCT05521022|Experimental|Part 1 AT-02|Part 1 enrolling Healthy Volunteers (Randomised, Double-blind) Drug: AT-02 Dosage: 30mg to 1000mg Dosage Form & Route of Admin: Solution for IV Infusion
88909290|NCT05521022|Placebo Comparator|Part 1 Placebo|Part 1 enrolling Healthy Volunteers (Randomised, Double-blind) Dosage Form & Route of Admin: Normal Saline Solution for IV Infusion
88909291|NCT05521022|Experimental|Part 2 AT-02|Part 2 enrolling Systemic Amyloidosis Participants (Single-Arm, Open-label) Drug: AT-02 Dosage: 300mg to 4000mg Frequency: Single Dose Dosage Form & Route of Admin: Solution for IV Infusion
88909292|NCT05521022|Experimental|Part 3 AT-02|Part 3 enrolling Systemic Amyloidosis Participants (Single-Arm, Open-label) Drug: AT-02 Dosage: Dose levels will be determined by the SRC. The starting dose in Part 3 will be determined by the SRC based on all available safety, tolerability, PK, and PD data from all prior cohorts Frequency: Multiple Doses Dosage Form & Route of Admin: Solution for IV Infusion
88922204|NCT05651516|Experimental|Tau PET/CT|"PET/CT imaging will be used to evaluate the uptake of tau in the brain using the investigational radiotracer [18F]PI-2620. Each subject will have one [18F]PI-2620 positron emission tomography/computed tomography (PET/CT) scan performed.~Participants will undergo approximately 30 minutes of static PET scanning of the brain and body starting approximately 45 minutes post injection of [18F]PI-2620. All images will be corrected for scatter and measured photon attenuation and reconstructed using standard reconstruction techniques. Standardized uptake value ratio (SUVr), the ratio of regional to reference uptake, will be calculated with cerebellum as reference, where NFTs are generally not present in neurodegenerative disorders, hence likely not in OUD.~Subjects in all three groups undergo a brain MRI including a structural MRI functional reactivity to an episodic memory task, and undergo a comprehensive neurocognitive battery."
89197316|NCT00944866||RA without drug|
89197317|NCT02545959|Active Comparator|Control group|receive a single pulse of methylprednisolone IV (120mg)
89197318|NCT02545959|Experimental|Rituximab IT group|receive a single intrathecal infusion of rituximab (with IV methylprednisolone 120mg to avoid side effect)
89197319|NCT02545959|Experimental|Rituximab IT + IV group|receive Rituximab IT as previous and Rituximab IV (375mg/m2) the same day
89197320|NCT04012528||"the before group"|75 teenagers after scoliosis surgery before ERAS program implementation
89197321|NCT04012528||"the after group"|75 teenagers after scoliosis surgery after ERAS program implementation
89197322|NCT04062110|Active Comparator|Long plaster casts for type AO 2R3A2.2|Closed reduction of the fracture and immobilization with long plaster casts (above-elbow, Long plaster casts).
89197323|NCT04062110|Active Comparator|Short plaster casts for type AO 2R3A2.2|Closed reduction of the fracture and immobilization with short plaster casts (below-elbow, Short plaster casts)
89197324|NCT00747630|Experimental|Intervention|The group selected to watch the video.
89197325|NCT02545647|No Intervention|Standard RYGB|65 patients undergo a standard Roux-en-Y gastric bypass
89197326|NCT02545647|Active Comparator|Banded RYGB|65 patients undergo a banded RYGB (BRYGB)
89197327|NCT00744900|Experimental|A|
89197328|NCT00727090|Experimental|1|Conivaptan in addition to usual care at the discretion of the attending medical staff
89197329|NCT00727090|No Intervention|2|Usual care by the attending physician staff
89197330|NCT00852033|No Intervention|1|Assessment Group (no intervention)
89197331|NCT00852033|Active Comparator|2|Brief Motivational Intervention (BMI)
89197332|NCT00852033|Active Comparator|3|Parent Based Intervention (PBI)
89197333|NCT00852033|Active Comparator|4|BMI and TBI
89197334|NCT05048654||Group A: Retrospective|Retrospectively, there will be an abstract of AMH and FSH from survivors seen at CHCO and UCH from October 1st, 2016 to September 31st, 2019 and assess time points.
89008239|NCT04599595||Multiple Scerosis (MS) Group|This group will be composed by 150 MS patients who, consecutively, from the start of the study, will refer to the MS clinic of the Neurology Unit of the Ferrara University Hospital, Italy. The first 50 patients with a PACQoL score ≥ 32 will be asked to be willing to enter the next phase of the study that continues at the Coloproctological Outpatient Clinic of Ferrara University Hospital, Italy with an appointment provided by the neurologist with a pre-established schedule (with written consent).
89428862|NCT03444662|Experimental|Cognizin and Omega-3|Intervention: Dietary Supplement: Citicoline and Omega-3 supplement
89428863|NCT03444662|Experimental|Omega-3|Intervention: Dietary Supplement: Omega-3 supplement
89428864|NCT02068755||Cardiac surgery|Patients who have undergone cardiac surgery
89428865|NCT03444506|Placebo Comparator|Placebo nasal spray|Placebo nasal spray - 2 sprays per nostril, BID
89428866|NCT03444506|Experimental|Molo 1 (also referred as GSP 301-2 NS)|Fixed Dose Combination of Molo nasal spray (olopatadine hydrochloride 665 mcg and mometasone furoate 25 mcg nasal spray) - 2 sprays per nostril, BID
89428867|NCT03444506|Experimental|Molo 2 (also referred as GSP 301-1 NS)|Fixed Dose Combination of Molo nasal spray (olopatadine hydrochloride 665 mcg and mometasone furoate 50 mcg nasal spray) - 2 sprays per nostril, QD
89428868|NCT03444506|Active Comparator|DYMISTA nasal spray|Fixed Dose Combination of azelastine hydrochloride 137 mcg and fluticasone propionate 50 mcg nasal spray - 1 spray per nostril, BID
89428869|NCT03444506|Active Comparator|PATANASE nasal spray|Olopatadine hydrochloride 665 mcg nasal spray - 2 sprays per nostril, BID
89428870|NCT02065947|Active Comparator|general anesthesia|fentanyl 0,05 - 0.1 mg/h, propofol 150 - 200 mg, atracurium
89428871|NCT02065947|Experimental|paravertebral block|a mixture of 10 ml bupivacaine 0.5% plus 20 ml lidocaine 2% with adrenaline 1:200,000, ketamine bolus 0.5 mg/kg, midazolam 2-3 mg and continuous propofol using target-controlled infusion (TCI) system aiming at effect site concentration (Ce) of 1-1.5 mcg/mL
89428872|NCT03436706||Participants|The cohort will consist of male and female children ages 11-12 accompanied by a participating parent over the age of 18 years. The family income of participants in this cohort cannot exceed 200% of the federal poverty level established in 2018.
89428873|NCT02068833||Gastrectomy|Subjects in this group will undergo a gastrectomy only.
89428874|NCT02068833||BPD-DS|Subjects in this group will undergo a BPD-DS surgery.
89428875|NCT02068911||Monitoring of ETCO2 and PTCO2|All neuromuscular patients
89428876|NCT02068989||Stress Hyperglycemic Group|Repeat HbA1C in 1 year
89428877|NCT02068989||Euglycemic Group|Repeat HbA1C in 1 year
89428878|NCT03436628|Experimental|App Use|Kids (10-15 years old) with type 1 diabetes and one of their parents will receive the MyT1DHero app to use for a 3-month period. Participants are urged to use the app four times each day.
89428879|NCT03129464|Experimental|Cold Therapy|Patients undergoing total laparoscopic hysterectomy will receive routine pre-operative multi-modal analgesia regimen and well as routine post-operative analgesia with instructions for dosing. Intervention will include the patient being asked to use a reusable cold gel pack to deliver cold therapy to their abdominal incisions every 6 hours for the first 72 hours.
89428880|NCT03129464|No Intervention|Control|Patients undergoing total laparoscopic hysterectomy will receive routine pre-operative multi-modal analgesia regimen and well as routine post-operative analgesia with instructions for dosing. They will not receive any additional intervention.
89428881|NCT02066025||group_0|Women with negative mammography (BIRADS 1-2), as negative controls.
89428882|NCT02066025||group_1|Women with positive biopsy for (ID, IL, DCIS) as patients.
89428883|NCT02066025||group_2|Women with positive mammography (BIRADS 3-4-5-6), and a negative biopsy diagnosis for breast cancer (ID, IL, DCIS) will be enrolled as benign (ADH, ALH, LCIS, fibroadenoma, fibrocystic changes (including sclerosing adenosis), Benign papillaoma, normal breast) as benigns.
89428884|NCT03436472|Experimental|dexmedetomidine group|For patients who were not intubated, dexmedetomidine was infused at a rate of 0.1 microgram/kg per hour from study recruitment on the day of surgery until 8:00 am on the first day after surgery. For patients who were intubated and mechanically ventilated, dexmedetomidine infusion was started after the Richmond Agitation Sedation Scale was -2 or higher after intensive care unit admission until 8:00 am on the first day after surgery.
89428885|NCT03436472|Placebo Comparator|placebo group|Normal saline was infused in the same rate for the same duration as that in the placebo group.
89428886|NCT02064699||CMV infection|Renal transplant recipient immunized against the Cytomegalovirus
89428887|NCT02066103|Experimental|Treatment|
89428888|NCT02521688||Group I (PTD + CP)|include ten mothers exhibiting spontaneous preterm delivery with moderate to severe chronic periodontitis +incisional biopsy from placenta and GCF sample
89428889|NCT02521688||Group II (TD + CP)|include ten mothers exhibiting spontaneous term delivery with moderate to severe chronic periodontitis+incisional biopsy from placenta and GCF sample
89428890|NCT02521688||Group III (PTD + HP)|include tenmothersexhibiting spontaneous preterm delivery with healthy periodontium +incisional biopsy from placenta and GCF sample
89428891|NCT02521688||Group IV (TD + HP)|ten mothersexhibiting spontaneous term delivery with healthy periodontium(Armitage GC. 1999)+ incisional biopsy from placenta and GCF sample
89428892|NCT02066259||healthy_0|healthy, people with normal (negative) colonoscopy results.
89428893|NCT02066259||patient_1|people with biopsy/surgery verified carcinoma of the colon, either an Adenocarcinoma, or carcinoma in situ
89428894|NCT02066259||benign_2|people with biopsy verified benign polyps of the colon one of the following - Villus adenoma, Tubular adenoma, Low grade dysplasia, Intermediate grade dysplasia, High grade dysplasia, Severe dysplasia
89428895|NCT04809532|Experimental|Group A|Transverse abdominis plane (TAP ) block via 20ml 0.25% bupvicaine on both sides of midline will be given at end of surgery
89428896|NCT04809532|No Intervention|Group B|At the end of surgery, no additional intervention will be done.
89428897|NCT03444428||Non Invasive Ventilation|"Age, height, weight~History and Physical Examination~Evaluation of dyspnoea: mMRC, Borg scale (Seated-Supine)~Amyotrophic lateral sclerosis functional rating scale (ALSFRS-R)~Sleep-Disordered Breathing in Neuromuscular Disease Questionnaire (SiNQ-5)~24h Blood Pressure monitor~Spirometry - FEV1 and FVC~Respiratory muscle strength - MIP, MEP, and SNIP~Arterial Blood Gases~Carotid-femoral pulse wave velocity~Breath CO exhale"
88909293|NCT05518682|Experimental|Single study arm|The Lenire device is CE marked in Europe and intended to reduce the symptoms of tinnitus. It comprises a handheld controller and an intra-oral device called a Tonguetip® Intra-Oral Device (IOD), which delivers gentle electrical stimulation to the tongue, and also comprises of a set of wireless consumer headphones that deliver audio stimulation. The sound and tongue stimulus parameters such as stimulus rate, stimulus intensity, and the timing relationship between the auditory and somatosensory stimulus events are grouped into stimulation Parameter Sets (PS). PS1 is used during the first 6-weeks of stimulation and PS4 is used during the second 6-weeks of stimulation, similar to what is routinely used for tinnitus individuals in Europe. For this study, the device software has been modified to allow users to adjust the headphone volume to a level that is comfortable and clearly audible instead of a preset volume with limited adjustments based on the patient's audiogram.
89428898|NCT03444428||Without Non Invasive Ventilation|"Age, height, weight~History and Physical Examination~Evaluation of dyspnoea: mMRC, Borg scale (Seated-Supine)~Amyotrophic lateral sclerosis functional rating scale (ALSFRS-R)~Sleep-Disordered Breathing in Neuromuscular Disease Questionnaire (SiNQ-5)~24h Blood Pressure monitor~Spirometry - FEV1 and FVC~Respiratory muscle strength - MIP, MEP, and SNIP~Arterial Blood Gases~Carotid-femoral pulse wave velocity~Breath CO exhale"
89428899|NCT02069067||Advanced cancer patients with pain|
89428900|NCT03436316|Experimental|SAD Cohort 1 (Part 1)|6 Participants will receive AZD8154 (single inhaled small particle dose 1) and 2 participants will receive placebo.
89428901|NCT03436316|Experimental|SAD Cohort 2 (Part 1)|6 Participants will receive AZD8154 (single inhaled small particle dose 2) and 2 participants will receive placebo.
88909294|NCT05518071|Experimental|Cohort 1 - N=4 (0.05mg/kg, 2-4h before intervention)|
89428902|NCT03436316|Experimental|SAD Cohort 3 (Part 1)|6 Participants will receive AZD8154 (single inhaled small particle dose 3) and 2 participants will receive placebo.
89428903|NCT03436316|Experimental|SAD Cohort 4 (Part 1)|6 Participants will receive AZD8154 (single inhaled small particle dose 4) and 2 participants will receive placebo.
89428904|NCT03436316|Experimental|SAD Cohort 5 (Part 1)|"6 Participants will receive AZD8154 (single inhaled small particle dose 5) and 2 participants will receive placebo.~Participants in this Cohort will return for a second Treatment Period after a minimum washout period of 7 to 14 days. All 6 subjects will receive an inhaled dose of AZD8154 (large particle size)."
89428905|NCT03436316|Experimental|SAD Cohort 6 (Part 1)|6 Participants will receive AZD8154 (single inhaled small particle dose 6) and 2 participants will receive placebo.
89428906|NCT03436316|Experimental|Cohort 1 (Part 2)|All participants in this cohort will receive single IV dose of AZD8154 in Treatment Period 1 and then after washout period, will receive inhaled AZD8154 (small particle size) in Treatment Period 2.
88909295|NCT05518071|Experimental|Cohort 2 - N=4 (0.05mg/kg, 14-24h before intervention)|
89197335|NCT05048654||Group B: Prospective|Prospectively, survivors will be evaluated by a member of the FPRLE team in the outpatient clinic at 12 months post-therapy completion and every 6 months to 36 months as part of clinical care. Per standard of care AMH and FSH will be drawn at each time point.
89197336|NCT00944944||Gyn Pts with lymphedema|
89197337|NCT00944944||Gyn Pts without Lymphedema|
89197338|NCT00848835||control|all patients in the control group
89197339|NCT00950014|Experimental|Percentage format only|Numbers are presented in percentage format (e.g., 35%, 0.2%) only.
89197340|NCT00950014|Experimental|Fixed frequency format only|Numbers are presented in fixed frequency format only (5 out of 1000, 0.6 out of 1000). Denominators remains the same for each number.
89197341|NCT00950014|Experimental|Variable frequency format|Frequency denominators are adjusted to keep the numerator greater than 1, so they may change throughout the survey (e.g., 6 out of 1000, 42 out of 100)
89197342|NCT00950014|Active Comparator|Fixed combination format|Numbers are presented with both percentages and frequencies, and frequency denominators remain fixed (e.g., _ out of 1000).
89197343|NCT00950014|Experimental|Variable combination format|Numbers are presented with both percentages and frequencies, but frequency denominators may vary (e.g., _ out of 1000, _ out of 100).
89197344|NCT00855621|Active Comparator|Single microelectrode|Surgical procedure performed using single microelectrode recording guidance intraoperatively
89197345|NCT00855621|Active Comparator|Multiple microelectrode|Surgical procedure performed using multiple microelectrode recording guidance intraoperatively
89197346|NCT00689052|Experimental|Pramipexole ER|0.75 mg to 4.5 mg tablets of Pramipexole ER, once daily in the evening
89197347|NCT00689052|Placebo Comparator|Placebo|Placebo tablets, once daily in the evening
89197348|NCT04012450|Active Comparator|Epidural Anesthesia|Women in labor receiving epidural anesthesia
89197349|NCT04012450|Active Comparator|Spinal-epidural|Women in labor receiving spinal-epidural anesthesia
89197350|NCT00945022|Experimental|Lipsus|
89197351|NCT02565212|Experimental|GROUP 1|montelukast sodium and mometasone
89197352|NCT02565212|Active Comparator|Group 2|montelukast
89197353|NCT02565212|Active Comparator|Group 3|mometasone furoate
89197354|NCT00848913|Active Comparator|Rehabilitation without strength training|Basic mobility and exercise therapy without strength training following a guideline with 12 specific exercises, progressed individually.
89197355|NCT00848913|Experimental|Rehabilitation with strength training|Basic mobility and exercise therapy following a guideline with 12 specific exercises, progressed individually, and supplemented with progressive knee-extension strength training (10RM) of fractured limb every day during admission.
89197356|NCT03891836||medical students|All students from the chosen classes in each study year will be invited to complete self-administered questionnaire
89197357|NCT00747708|Experimental|Peripheral|Patients are randomised in a 1:1 ratio to receive granulocyte-colony stimulating factor (G-CSF) or placebo injection
89197358|NCT00747708|Experimental|Percutaneous intracoronary injection|All patients will receive granulocyte-colony stimulating factor injections followed by a bone marrow aspiration. Patients will be randomised in a 1:1 ratio to receive intracoronary injections of bone marrow derived stem/progenitor cells or placebo infusion through a percutaneous route
89197359|NCT00747708|Experimental|Percutaneous intramyocardial injection|All patients will receive granulocyte-colony stimulating factor injections followed by a bone marrow aspiration. Patients will be randomised in a 1:1 ratio to receive intramyocardial injections of bone marrow derived stem/progenitor cells or placebo infusion through a percutaneous route
89197360|NCT05602064|Experimental|Group I (Ibuprofen)|"Participants will receive ibuprofen 100 mg/5 ml (BRUFEN®, Kahira Pharmaceuticals & Chemical Industries Co.) The solution will be administered Once, 1 hour prior to the local anesthesia administration.~The participant will receive a weight-dosed volume Effective dosages range from 10 mg/kg/day to a maximum of 40 mg/kg/day"
89197361|NCT05602064|Experimental|Group II (Paracetamol)|"Participants will receive paracetamol 250 mg/5 ml (CETAL®, EGYPTIAN INT. PHARMACEUTICAL INDUSTRIES CO.) The solution will be administered once, 1 hour prior to the local anesthesia administration.~The participant will receive a weight-dosed volume Effective dosages are between 15-20mg/kg/day to a maximum of 60 mg/kg/day"
89428907|NCT03436316|Experimental|MAD Cohort 1 (Part 3)|6 Participants will receive AZD8154 (single inhaled dose 8) and 2 participants will receive placebo on Day 1. Participants will then receive multiple dosing of AZD8154 (inhaled dose 8) or placebo once daily from Day 4 to Day 12.
89428908|NCT03436316|Experimental|MAD Cohort 2 (Part 3)|6 Participants will receive AZD8154 (single inhaled dose 9) and 2 participants will receive placebo on Day 1. Participants will then receive multiple dosing of AZD8154 (Inhaled dose 9) or placebo once daily from Day 4 to Day 12.
88909296|NCT05518071|Experimental|Cohort 3 - N=4 (0.10mg/kg, 2-4h before intervention)|
88909297|NCT05518071|Experimental|Cohort 4 - N=4 (0.1mg/kg, 14-24h before intervention)|
88909298|NCT05518071|Experimental|Expansion cohort - N=4 (optimal dose, optimal dose-interval)|
88909299|NCT05515679|Experimental|Treatment|BRAIN Intervention
88909300|NCT05515341||Medical Device Therapy/Procedure for Chronic Pain|
88909301|NCT05513872|Experimental|Condition #1|NRT Sampling = On Behavioral Counseling = Practice Quitting
88909302|NCT05513872|Experimental|Condition #2|NRT Sampling = Off Behavioral Counseling = Practice Quitting
88909303|NCT05513872|Experimental|Condition #3|NRT sampling = On Behavioral counseling = Motivational Interviewing
88909304|NCT05513872|Experimental|Condition #4|NRT sampling = Off Behavioral counseling = Motivational Interviewing
88909305|NCT05507983|Experimental|Tranexamic acid arm|"Tranexamic acid 1500 mg dissolved in 100 ml sodium chloride, once, directly after anesthetizing the participant.~In participants with renal insufficiency (creatinine >120 umol/L) the dose will be reduced to 1000 mg."
88909306|NCT05507983|Placebo Comparator|Placebo arm|100ml sodium chloride 0.9%, once, directly after anesthetizing the participant.
88909307|NCT05506943|Experimental|CTX-009 plus Paclitaxel|
89008240|NCT00565513|Other|A|cord blood and maternal milk tests
89428909|NCT03436316|Experimental|MAD Cohort 3 (Part 3)|6 Participants will receive AZD8154 (single inhaled dose 10) and 2 participants will receive placebo on Day 1. Participants will then receive multiple dosing of AZD8154 (inhaled dose 10) or placebo once daily from Day 4 to Day 12.
89428910|NCT04809142|Experimental|TQB2450+Anlotinib|TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle ,Anlotinib capsules 12 mg given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
89428911|NCT04809142|Active Comparator|Chemotherapy|Capecitabine tablets combined with oxaliplatin injection or gemcitabine hydrochloride injection. Each cycle is 3 weeks.
89428912|NCT02064777|Experimental|Tacrolimus|
89428913|NCT03444350|Active Comparator|Control group|SRP plus placebo
89428914|NCT03444350|Experimental|Gaseous ozone group|SRP plus gaseous ozone [1 W (100 mJ, 10 Hz)]
89428915|NCT02066337|Placebo Comparator|placebo gel|scaling and root planing with placebo gel
89428916|NCT02066337|Active Comparator|Ozonated olive oil gel|scaling and root planing with Ozonated olive oil gel
89428917|NCT03436394|Experimental|Evobrutinib: Normal Renal Function|Subjects with estimated glomerular filtration rate (eGFR) greater than or equal to (>=) 90 milliliter per minute per 1.73 meter square (mL/min/1.73 m^2) will receive a single oral dose of evobrutinib under fasting conditions.
89428918|NCT03436394|Experimental|Evobrutinib: Severe Renal Impairment|Subjects with eGFR less than (<) 30 mL/min/1.73 m^2 will receive a single oral dose of evobrutinib under fasting conditions.
89428919|NCT03436394|Experimental|Evobrutinib: Moderate Renal Impairment|Subjects with eGFR >= to 30 mL/min/1.73 m^2 and < 60 mL/min/1.73 m^2 will receive a single oral dose of evobrutinib under fasting conditions.
89197362|NCT05602064|Placebo Comparator|Group III (Placebo)|The placebo solution will be freshly prepared by an assistant in a manner to match the color and odor of the analgesics
89197363|NCT02565134|Experimental|PAC-14028 cream 0.1%|PAC-14028 cream 0.1%, Twice daily for 4 weeks
89197364|NCT02565134|Experimental|PAC-14028 cream 0.3%|PAC-14028 cream 0.3%, Twice daily for 4 weeks
89197365|NCT02565134|Experimental|PAC-14028 cream 1.0%|PAC-14028 cream 1.0%, Twice daily for 4 weeks
89197366|NCT02565134|Placebo Comparator|PAC-14028 cream vehicle|PAC-14028 cream vehicle, Twice daily for 4 weeks
89197367|NCT00747942|No Intervention|A|exercise referral to lifestyle activities at the level of moderate intensity without support
89428920|NCT03436394|Experimental|Evobrutinib: Mild Renal Impairment|Subjects with eGFR >= to 60 mL/min/1.73 m^2 and < 90 mL/min/1.73 m^2 will receive a single oral dose of evobrutinib under fasting conditions.
89197368|NCT00747942|Active Comparator|B|Exercise referral combined with individual support, access to structured group exercise programs, and motivational support
89197369|NCT00560950|Experimental|1st Revaccination Group|
89197370|NCT00560950|Experimental|2nd Revaccination Group|
89197371|NCT02562144|Experimental|Xylocaine spray|
89197372|NCT02562144|Placebo Comparator|Placebo|
89428921|NCT03441386|Experimental|Cognitive Study|Cognitive Responses was analyzed after different intensities physical exercise sessions.
89428922|NCT02069145|Experimental|Drug: OMP-54F28, with Sorafenib|
89428923|NCT04830358|Experimental|EuPCV15|Single dose of Pneumococcal Conjugate Vaccine will be administered intramuscularly at Day 0.
89428924|NCT04830358|Active Comparator|Prevenar13|Single dose of Pneumococcal Conjugate Vaccine will be administered intramuscularly at Day 0.
89428925|NCT03436160|Experimental|WR826647|100 mcg Carbon-14 radio labeled WR826647 administered via IV
89428926|NCT03436160|Experimental|WR909388|100 mcg Carbon-14 radio labeled WR909388 administered via IV
89428927|NCT03436160|Experimental|WR909390|100 mcg Carbon-14 radio labeled WR909390 administered via IV
88909308|NCT05506943|Active Comparator|Paclitaxel|Patients randomized to receive paclitaxel only have the option to crossover to the CTX-009 plus paclitaxel arm after documented disease progression per RECIST v1.1.
88909309|NCT05499663|Experimental|POSTHOC app|
89197373|NCT02562300|Active Comparator|Sublingual misoprostol|The patients in this arm received 400 micrograms of sublingual misoprostol, immediately after delivery of the neonate.
89197374|NCT02562300|Active Comparator|oxytocin|The patients in this arm received 20 IU oxytocin dissolved in 1 L of Lactated Ringer's or glucose solution) at the rate of 125 ml /h , immediately after delivery of the neonate.
89197375|NCT00945178|Experimental|Part A: A|AZD1386
88909310|NCT05499663|No Intervention|Control|
88909311|NCT05496686|Experimental|225Ac-MTI-201 4.7 microCi|Cohort 1: Participants were administered a single dose of 4.7 microCi of 225Ac-MTI-201 via intravenous catheter, with up to 3 years of follow-up.
89197376|NCT00945178|Experimental|Part A: B|Placebo for AZD1386
88909312|NCT05496686|Experimental|225Ac-MTI-201 9.5 microCi|Cohort 2: Participants were administered a single dose of 9.5 microCi of 225Ac-MTI-201 via intravenous catheter, with up to 3 years of follow-up.
88909313|NCT05496686|Experimental|225Ac-MTI-201 19 microCi|Cohort 3: Participants were administered a single dose of 19 microCi of 225Ac-MTI-201 via intravenous catheter, with up to 3 years of follow-up.
89197377|NCT00945178|Experimental|Part B: A|Naproxen
89197378|NCT00945178|Experimental|Part B: B|Placebo for Naproxen
89197379|NCT00749346|Experimental|A|Treatment with concomitant Alimta and NovoTTF-100L
89197380|NCT00945412|Experimental|Micropolysaccharide Hemospheres (MPH)|
89197381|NCT00945412|Active Comparator|Electrocautery|
89197382|NCT00749424|Experimental|1|crushing technique
89197383|NCT00749424|Active Comparator|2|provisional T stenting technique
89428928|NCT04830280|Active Comparator|Posterior quadratus lumborum block|
89428929|NCT04830280|Sham Comparator|control group|
89197384|NCT00945568|Experimental|Aminolaban EN|Aminoleban EN™ was administered at a dose of 100 g per day commencing two weeks prior to surgery. A 100 g dose of Aminoleban EN™ contains 13.0 g of free amino acids, 13.0 g of gelatin hydrolysate, 1.0 g of casein, 62.1 g of carbohydrate, 7.0 g of lipid, glycyrrhizin, and other components, producing 420 kcal. The AEN group included 40 patients who were administered 100 g of Aminoleban EN™ as 50 g during the day and 50 g as a late evening snack.
88909314|NCT05496686|Experimental|225Ac-MTI-201 38 microCi|Cohort 4: Participants were administered a single dose of 38 microCi of 225Ac-MTI-201 via intravenous catheter, with up to 3 years of follow-up.
88909315|NCT05496686|Experimental|225Ac-MTI-201 76 microCi|Cohort 5: Participants were administered a single dose of 76 microCi of 225Ac-MTI-201 via intravenous catheter, with up to 3 years of follow-up.
88909316|NCT05496686|Experimental|225Ac-MTI-201 152 microCi|Cohort 6: Participants were administered a single dose of 152 microCi of 225Ac-MTI-201 via intravenous catheter, with up to 3 years of follow-up.
88909317|NCT05496686|Experimental|225Ac-MTI-201 254 microCi|Cohort 7: Participants were administered a single dose of 254 microCi of 225Ac-MTI-201 via intravenous catheter, with up to 3 years of follow-up.
88909318|NCT05496686|Experimental|225Ac-MTI-201 424 microCi|Cohort 8: Participants were administered a single dose of 424 microCi of 225Ac-MTI-201 via intravenous catheter, with up to 3 years of follow-up.
88909319|NCT05496686|Experimental|225Ac-MTI-201 564 microCi|Cohort 9: Participants were administered a single dose of 564 microCi of 225Ac-MTI-201 via intravenous catheter, with up to 3 years of follow-up.
88909320|NCT05496686|Experimental|225Ac-MTI-201 750 microCi|Cohort 10: Participants were administered a single dose of 750 microCi of 225Ac-MTI-201 via intravenous catheter, with up to 3 years of follow-up.
88909321|NCT05496686|Experimental|225Ac-MTI-201 998 microCi|Cohort 11: Participants were administered a single dose of 998 microCi of 225Ac-MTI-201 via intravenous catheter, with up to 3 years of follow-up.
88909322|NCT05496686|Experimental|225Ac-MTI-201 1327 microCi|Cohort 12: Participants were administered a single dose of 1327 microCi of 225Ac-MTI-201 via intravenous catheter, with up to 3 years of follow-up.
88909323|NCT05491616|Experimental|Nivolumab q4w|patients will receive Nivolumab at 480mg Q4W starting 10-14 weeks
88909324|NCT05487456|Active Comparator|P4M3 CA35|Ad libitum use of P4M3 using CA35 Cartridges
88909325|NCT05487456|Active Comparator|P4M3 CM35|Ad libitum use of P4M3 using CM35 Cartridges
88909326|NCT05487456|Active Comparator|Cigarette|Ad libitum use of subject's own preferred CIG brand
88909327|NCT05487456|Active Comparator|Smoking Abstinence|Smoking abstinence
88909328|NCT05478304|Experimental|Treatment|LAAE using the AtriClip concomitant to and at the time of planned cardiac surgery
88909329|NCT05478304|No Intervention|Control|No LAAE concomitant to and at the time of planned cardiac surgery
88909330|NCT05477485|Other|Usual Care|Usual Care participants will receive standard state-level care for missing ART prescription refill(s) for Virginia Medicaid enrollees with HIV.
88909331|NCT05477485|Experimental|AIMS program - patient|Participants will receive patient-level support. Support will come from the participant's provider, pharmacy, managed-care organization or the community.
88909332|NCT05475171|Experimental|MGD019|Participants will receive MGD019 by vein over about 30 minutes on Day 1 of each cycle
88909333|NCT05473403|Experimental|Corticosteroid therapy|Prednisone or Prednisolone or Methylprednisolone : Patient with ASAIH will be treated in oral or intravenous (IV) with high doses ( ≥ 1mg/kg/day) of corticosteroids (Prednisone or Prednisolone or Methylprednisolone) until relapse (confirmed by blood tests and clinical status) requiring an emergency Liver Transplantation (LT) or death.
88909334|NCT05473403|No Intervention|Patient without corticosteroid therapy|Patient not treated will undergo to emergency Liver Transplantation (LT) or death.
89428930|NCT03444272|Experimental|Hepatitis C Treatment|HCV Treatment (Sofosbuvir and Daklatasuvir)
89428931|NCT03444272|No Intervention|Supportive treatment|supportive liver therapy
88909335|NCT05472402|Experimental|LADIES online intervention (R33 phase)|Participants will include 30 women who will be randomized to receive six (6) months of online group-based intervention sessions that teach participants how to increase physical activity levels.
88909336|NCT05472402|Placebo Comparator|LADIES online control (R33 phase)|Participants will include 30 women who will be randomized to receive self-guided materials that teach participants how to increase physical activity levels. Placebo comparator participants will receive their materials via the online platform.
88909337|NCT05469802|Experimental|PIZV 0.5 mL|Participants will receive PIZV 0.5 mL injection, IM, once on Day 1 (first dose) and Day 29 (second dose).
88909338|NCT05469802|Placebo Comparator|Placebo 0.5 mL|Participants will receive a placebo injection, IM, once on Day 1 (first dose) and Day 29 (second dose).
88909339|NCT05469139||Portable MRI group|Patients on ECMO who undergo portable MRI to assess brain injury within 24-48 hours of ECMO initiation
88909340|NCT05468580|Active Comparator|endoscopic Coeliac Artery Release (eCAR)|Patients randomized in the Intervention Group.
88909341|NCT05468580|Sham Comparator|Sham Operation|Patients randomized in the Sham group.
88909342|NCT05467176||Participants with Prostate Cancer|Patients with prostate cancer who are initiating treatment or have initiated treatment with ORGOVYX (per label instructions) within 1 month prior to enrollment and who remain on treatment at the time of enrollment.
88922205|NCT05650866|Experimental|Implanted group|The study device will be implanted during the ongoing prostatectomy surgery. Participants will then be asked to activate it everyday.
89428932|NCT03347331|Experimental|Input function group|Each subject underwent a 90 min acquisition PET scan with concomitant arterial blood sampling
89428933|NCT03347331|Experimental|Test-retest group|Each subject underwent 2 PET scans distant from 1 to 3 weeks
89428934|NCT04873700||All Participants|Participants diagnosed with moderate to severe UC or CD will be observed on Day 1 for cross-sectional evaluation of disease activity, treatment patterns, burden of disease and quality of life along with retrospective data collection for previous 3 years prior to Day 1 to assess the IBD treatments and use of other healthcare resources related with the management of UC and CD.
89428935|NCT04829734|Experimental|Active PBMT-sMF|Active PBMT-sMF will be applied two times a week (three to four days apart), for three consecutive weeks, yielding six treatment sessions.
89428936|NCT04829734|Placebo Comparator|Placebo PBMT-sMF|Placebo PBMT-sMF will be applied two times a week (three to four days apart), for three consecutive weeks, yielding six treatment sessions.
89428937|NCT04816786||Group 1: Admitted to ICU and died during the hospital stay.|
89428938|NCT04816786||Group 2: Admitted to ICU was were discharged.|
89428939|NCT05056532||patients|Maximal mouth pressure will be evaluated for determine respiratory muscle strength, m. pectoralis, m. serratus anterior, m. sternocloideumasteoideus and quadriceps muscles strengths will be measured to evaluate accessory respiratory muscle strength, London chest activity of daily living scale will be done for assessment of dyspnea and six minute walk test will be used for determination of functionally capacity
89428940|NCT05056532||Control group|Maximal mouth pressure will be evaluated for determine respiratory muscle strength, m. pectoralis, m. serratus anterior, m. sternocloideumasteoideus and quadriceps muscles strengths will be measured to evaluate accessory respiratory muscle strength, London chest activity of daily living scale will be done for assessment of dyspnea and six minute walk test will be used for determination of functionally capacity
89428941|NCT03035812|Experimental|Alkali|Patients in whom an oral alkalinization whatever the formulation
88909343|NCT05463406|Experimental|The PLUS algorithm|"The PLUS clinical management algorithm:~EDs having switched to the intervention period (intervention group) will manage their patients using the PLUS algorithm.~The PLUS algorithm starts with a validated pneumonia clinical prediction score (score of Van Vugt), followed by LUS. In case of positive results of any of these tests, PCT is measured to identify patients who will most likely benefit from antibiotics. A validated clinical severity score will ensure the safety of the intervention in those with discordant results (LUS consolidation and low PCT)."
88909344|NCT05463406|Other|Usual care|Usual care: management as usual
89428942|NCT03109652|Active Comparator|IV TXA alone|One ampule of 500mg/ml tranexamic acid(TXA) inj is injected intravenously during operation after box cutting procedure(before tourniquet deflation). Additionally, 1 ampule of TXA is administrated 3 hours after first injection on the day of operation.
89428943|NCT03109652|Experimental|IV TXA and Oral TXA 5 days|"One ampule of 500mg/ml tranexamic acid(TXA) inj is injected intravenously during operation after box cutting procedure(before tourniquet deflation). Additionally, 1 ampule of TXA is administrated 3 hours after first injection on the day of operation.~Two 250mg capsules of oral TXA(Transamin Cap) is given three times a day, 30 minutes after each meal, from postoperative day 1 to day 5."
88909345|NCT05462288||Patient Group|
88909346|NCT05462223|Experimental|Alucent VRS for Treatment of Atherosclerotic Lesions|"Alucent Vessel Restoration System for AVF (VRS-AVF) consists of the following components:~VRS 10-8-10 Dimer Coated Balloon Catheter for AVF~VRS Light Fiber~VRS Light Source"
88922206|NCT05650866|No Intervention|Control group|Participants in the control group will undergo standard prostatectomy and will not be implanted with the study device.
89008241|NCT00565552|Active Comparator|1|Each patient uses the silicone gel on one half of the scar, leaving the other one blank as an internal control.
89008242|NCT00414687|Experimental|Arm 1|
89428944|NCT03109652|Experimental|IV TXA and Oral TXA 2 days|"One ampule of 500mg/ml tranexamic acid(TXA) inj is injected intravenously during operation after box cutting procedure(before tourniquet deflation). Additionally, 1 ampule of TXA is administrated 3 hours after first injection on the day of operation.~Two 250mg capsules of oral TXA(Transamin Cap) is given three times a day, 30 minutes after each meal, from postoperative day 1 to day 2."
89428945|NCT04830046||Multiple Myeloma-MM patients|People with Multiple Myeloma-MM receiving covid 19 vaccine
89428946|NCT04830046||Waldenstrom's macroglobulinemia-WM patients|People with Waldenstrom's macroglobulinemia-WM receiving covid 19 vaccine categorized by treatment naïve, actively receiving BTK inhibitor,currently or previously treated.
89428947|NCT05566353|Experimental|Patients followed at the implantation reference centers|Patients eligible for implant processor renewal in 2 years and corresponding to inclusion criteria will be enrolled during their routine check-up appointment at the implantation reference centers of the University Hospitals of Montpellier and Toulouse. Patients will be their own controls through the use of their medical history data.
89428948|NCT03444194|Experimental|Biopsi arm|
89428949|NCT02069223|Active Comparator|Gastrectomy|Subjects in this group will undergo a gastrectomy as their first surgery with a BPD-DS 1-year later.
89008243|NCT04599244|Experimental|emergency pulpotomy|intervention arm
89428950|NCT02069223|Active Comparator|BPD-DS|Subjects in this group will undergo a BPD-DS as their first surgery with a gastrectomy 1-year later.
89428951|NCT02069223|Active Comparator|Gastrectomy+BPD-DS|Subjects in this group will undergo a gastrectomy AND a BPD-DS concomitantly. They will then be closely monitored for the remainder of the study.
89428952|NCT02069301|Experimental|Integrated Depression/Microfinance Group|LIFE-DM is a Depression and Microfinance integrated program using behavior activation and problem solving therapy applied to both depression and livelihood. Livelihood support include microfinance loans, personal finance, and income-generation skills.
89428953|NCT02069301|Other|Treatment as Usual|Currently treatment as usual in this province includes national guidelines for antidepressant care for depression and referral for microfinance/livelihood programs
89428954|NCT03035656|Experimental|Experimental|Administration of epidural Ropivaciane
89428955|NCT03035656|Placebo Comparator|Control|Administration of saline
89428956|NCT02066493||conservative management|neither surgical nor endovascular management
89428957|NCT02066493||endovascular management|endovascular management
89428958|NCT02066493||surgical management|surgical management
88909347|NCT05460468|Experimental|TMS-AD|The study comprises one arm of four sessions. On Day 1 (~2 hr session), participants fill forms, complete a neuropsychological test battery (NIH Toolbox, NACC UDS, BDI), and provide a saliva sample to be banked for future APOE genotype determination. On Day 2 (~2 hr session), subjects will perform an initial MRI scanning session. In this session, MRI, RSFA, DWI, and fMRI are collected so they can be used for network-based targeting. On Days 3 participants will undergo a combined TMS-fMRI session (~2 hr session). On Day 4 participants wil undergo a combined TMS-EEG session(~2 hr session).
88922207|NCT05649943|Other|APA + ADT + RP/RT|Apalutamide 240 mg, four 60 mg tablets as an oral single daily dose, according to clinical practice, plus Androgen Deprivation Therapy (ADT) plus clinician-driven choice local treatment with Radiotherapy or Radical Prostatectomy, six months after starting treatment with apalutamide
88922208|NCT05649943|Other|APA + ADT|Apalutamide 240 mg, four 60 mg tablets as an oral single daily dose, according to clinical practice, plus Androgen Deprivation Therapy (ADT)
89197385|NCT00945568|No Intervention|Control|The patients were divided into two groups including one group administered Aminoleban (the AEN group) and a control group given no additional dietary supplementation. The total caloric energy intake per day during the study period was assumed to be equal to Aminolaban EN group.
89008244|NCT04599244|Active Comparator|complete pulp extirpation|control arm
89197386|NCT02562690||Acute Coronary Syndrome|"Patients with acute chest pain and persistent ST-segment elevation or new left bundle branch block on the 12 lead ECG. This is termed ST-segment Elevation Myocardial Infarction (STEMI).~Patients with acute chest pain but without persistent ST-segment elevation. These patients, based on the measurement of cardiac biomarker values (troponin), will be further classified as Non-ST-segment Elevation Myocardial Infarction (NSTEMI) or unstable angina.~Where possible, all patients will have tests of thrombotic status including thrombin generation assays, TEG and GTT."
89197387|NCT00950092|Other|Treatment|
89197388|NCT00576758|Experimental|Obinutuzumab|Participants received 1000 mg obinutuzumab intravenous (IV) infusion once a week on Days 1, 8, 15, and 22 in the Induction Period. 2 months following the last infusion, participants without disease progression, were eligible to receive a 1000 mg IV infusion every two months for 2 years in the Extension Period. All participants received oral acetaminophen/ paracetamol (1000 mg) and an antihistamine such as diphenhydramine (50-100 mg), 30-60 minutes prior to each infusion.
89197389|NCT00576758|Active Comparator|Rituximab|Participants received 375 mg/m^2 rituximab IV infusion once a week on Days 1, 8, 15 and 22 in the Induction Period. 2 months following the last infusion, participants without disease progression were eligible to receive a 375 mg/m^2 rituximab IV infusion once every two months for 2 years in the Extension Period. All participants received oral acetaminophen/ paracetamol (1000 mg) and an antihistamine such as diphenhydramine (50-100 mg), 30-60 minutes prior to each infusion.
89197390|NCT00923676|Active Comparator|Fenofibrate|Fenofibrate pills
89197391|NCT00923676|Active Comparator|Rosuvastatin|Rosuvastatin pills
89197392|NCT00923676|Active Comparator|fenofibrate + rosuvastatin|fenofibrate pills + rosuvastatin pills
89536878|NCT03307811|Experimental|22 gauge needle liver biopsy|EUS-LB will be performed using a 22 g FNB needle. Specimens obtained from each pass will be placed in a separate biopsy jar. If the third pass does not result in sufficient diagnostic material, a 19 G will be used. A maximum of 3 passes will be made using the alternate needle. The total number of passes with the 22 G needle and the 19 G needle is 6. Data will be collected about the procedure and the performance of the needles for each procedure.
88909348|NCT05458674|Experimental|Tucatinib/Eribulin/Trastuzumab|"The initial dose of trastuzumab will be given as a loading dose of 8 mg/kg intravenously (IV), unless trastuzumab was administered within the prior 4 weeks, then the initial dose of trastuzumab will be administered at a dose of 6 mg/kg. Each trastuzumab dose is given once every 21 days, except in specific circumstances where it may be given weekly to compensate for modifications in treatment schedule~Tucatinib 300 mg orally twice daily (PO BID) every day (Days 1-21) of each 21-day cycle using a modified schedule of events. Subcutaneous trastuzumab is given only once every three weeks as there is no allowance for weekly dosing.~Eribulin will be given at a dose of 1.4 mg/M2 intravenously over a 2-5 minute period on days 1 and 8 of each 21-day cycle."
88909349|NCT05458323|Experimental|Free near and distance glasses|All participants randomised to the intervention group will be provided with free near and/or distance spectacles based on the results of refraction. Glasses will be provided at the time of enrolment into the study. The participants will be asked to choose from an assortment of 20 frames. Participants will be asked to report to the study team member in case of any issue with spectacles or if spectacles are lost or broken. Replacement glasses will be provided in case of broken or lost spectacles whenever required. Participants will undergo annual eye exams and refraction, and change of glasses will be prescribed as needed.
89428959|NCT03441230|Active Comparator|Circumference of 13 cm, sphere form (diameter of 4 cm)|
89428960|NCT03441230|Active Comparator|Circumference of 13 cm, cylinder form, length 11 cm|
89428961|NCT03441230|Active Comparator|Circumference of 16 cm, sphere form (diameter of 5 cm)|
89428962|NCT03441230|Active Comparator|Circumference of 16 cm, cylinder form, length 11 cm|
89428963|NCT03441230|Active Comparator|Circumference of 16 cm, cylinder form, length 18 cm|
89428964|NCT03441230|Active Comparator|Circumference of 19 cm, sphere form (diameter of 6 cm)|
88909350|NCT05458323|No Intervention|Control-No treatment|All participants randomised to the control group will receive a prescription for spectacles and given free near and/or distance glasses as needed at study close out.
88909351|NCT05457959|Placebo Comparator|Cohort I Arm A (ppDC, placebo)|Patients undergo leukapheresis 10 days prior to first injection. Patients receive ppDC ID in both arms with poly ICLC IM on day -10 and placebo IV on day -9 prior to standard of care surgical resection.
88909352|NCT05457959|Placebo Comparator|Cohort I Arm B (placebo, nivolumab, ipilimumab)|Patients undergo leukapheresis 10 days prior to first injection. Patients receive placebo ID in both arms with poly ICLC IM on day -10 and nivolumab IV and ipilimumab IV on day -9 prior to standard of care surgical resection.
88909353|NCT05457959|Experimental|Cohort I Arm C (ppDC, nivolumab, ipilimumab)|Patients undergo leukapheresis 10 days prior to first injection. Patients receive ppDC ID divided in both arms with poly ICLC IM on day -10 and nivolumab IV and ipilimumab IV on day -9 prior to standard of care surgical resection.
88909354|NCT05457959|Experimental|Cohort II Arm A (ppDC, placebo)|Within 30 days of surgical resection, patients receive ppDC ID in both arms with poly ICLC IM and placebo IV on day 1 of each cycle. Treatment repeats every 2 weeks for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Post-treatment, patients may receive nivolumab IV on day 1 of each cycle. Cycles repeat every 4 weeks for up to 24 months following surgical resection in the absence of disease progression or unacceptable toxicity.
88909355|NCT05457959|Placebo Comparator|Cohort II Arm B (placebo, nivolumab)|Within 30 days of surgical resection, patients receive placebo ID in both arms with poly ICLC IM and nivolumab IV on day 1 of each cycle. Treatment repeats every 2 weeks for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Post-treatment, patients may receive nivolumab IV on day 1 of each cycle. Cycles repeat every 4 weeks for up to 24 months following surgical resection in the absence of disease progression or unacceptable toxicity.
88909356|NCT05457959|Experimental|Cohort II Arm C (ppDC, nivolumab)|Within 30 days of surgical resection, patients receive ppDC ID in both arms with poly ICLC IM and nivolumab IV on day 1 of each cycle. Treatment repeats every 2 weeks for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Post-treatment, patients may receive nivolumab IV on day 1 of each cycle. Cycles repeat every 4 weeks for up to 24 months following surgical resection in the absence of disease progression or unacceptable toxicity.
88909357|NCT05456880|Experimental|BEAM-101|BEAM-101 manufactured with autologous CD34+ hematopoietic stem cells collected by plerixafor mobilization and edited ex vivo. No maximum dose has been set for BEAM-101; all of the gene edited cells that pass release specifications will be administered to the patient. BEAM 101 will be administered as a single dose by IV infusion.
88909358|NCT05456191|Experimental|Asciminib|Participants will receive asciminib 80 mg QD
88909359|NCT05456191|Active Comparator|Nilotinib|Participants will receive nilotinib 300 mg BID
89197393|NCT00950326|Active Comparator|B1-Physio|In Group B1, patients will be given physiotherapy of the hip or knee joint three times a week
89197394|NCT00950326|Experimental|A1 Hydro|In this group patients will receive a specific hydrotherapeutic procedure in the form of alternate cold and warm thigh affusions ( pouring on water) which will consist of repeated cold and warm water stimulation of the knee and hip region.
89428965|NCT03441230|Active Comparator|Circumference of 19 cm, cylinder form, length 11 cm|
89428966|NCT03441230|Active Comparator|Circumference of 22 cm, sphere form (diameter of 7 cm)|
89428967|NCT03441230|Active Comparator|Circumference of 25 cm, sphere form (diameter of 8 cm)|
89428968|NCT03441230|Active Comparator|Circumference of 28 cm, sphere form (diameter of 9 cm)|
89428969|NCT03441074|Experimental|Intervention Group|Patients randomly assigned to intervention group will get enhanced olfactory stimuli during the perioperative period
89428970|NCT03441074|No Intervention|Non-intervention Group|Patients randomly assigned to non-intervention group will not get any olfactory stimuli during the perioperative period
89428971|NCT02069535|Experimental|AVANZ Cupressus|AVANZ Cupressus
89428972|NCT04829032||Hartmann's procedure|Evaluate the role of Hartmann's procedure in emergency setting for left-sided acute surgical colonic disease (perforated diverticulitis with purulent or fecal peritonitis; colon cancer perforation-obstruction; ischemic colitis; abdominal trauma).
89428973|NCT04829032||Colonic resection with primary anastomosis|Evaluate the role of colonic resection with primary anastomosis in emergency setting for left-sided acute surgical colonic disease (perforated diverticulitis with purulent or fecal peritonitis; colon cancer perforation-obstruction; ischemic colitis; abdominal trauma).
89428974|NCT03444116||Cases (+FDO)|Patients who underwent an FDO
89428975|NCT03444116||Controls (-FDO)|Same as cases but did not undergo an FDO
88909360|NCT05453968|Experimental|Berotralstat|Berotralstat administered once daily in 4 dose cohorts determined by participant weight. Cohorts 1 and 2 will enroll in parallel. After 4 participants from Cohort 1 and 2, with ≥ 2 subjects from Cohort 2, have reached Week 2, Cohort 3 will open for enrollment. Cohort 4 will open for enrollment, after ≥ 4 subjects in Cohort 3 have reached Week 2. Prior to dosing Cohort 3 and 4, available PK and safety data will be reviewed to confirm it is safe to proceed and the appropriate weight bands for each. BioCryst will notify sites when Cohorts 3 and 4 are open for enrollment.
88922211|NCT05640778|Experimental|neoadjuvant endocrine therapy|CDK4/6 inhibitor combined with aromatase inhibitor
89428976|NCT02069613||Mild traumatic brain injury (mTBI)|Patients admitted to Huntington Memorial Hospital (HMH), Pasadena CA, Emergency Department (ED) diagnosed with mTBI by history (alteration of consciousness, post-traumatic amnesia, loss of consciousness) and normal brain computed tomography (CT).
89428977|NCT02069613||Control|Patients admitted to HMH ED for minor extremity trauma (sprains) and no evidence of mTBI
89428978|NCT04829266|Experimental|process simulation group|an experimental group with process simulation with elements of relaxation
89428979|NCT04829266|Experimental|outcome simulation group|an experimental group with outcome simulation with elements of relaxation
89428980|NCT04829266|Other|control group|a control group with no process and outcome simulations, but with elements of relaxation
89428981|NCT03443960|Experimental|Treatment A (TNX-102 SL)|2 x TNX-102 SL (cyclobenzaprine HCl sublingual tablets) 2.8 mg once daily for 20 consecutive days
89428982|NCT03443960|Active Comparator|Treatment B (AMRIX)|1 x AMRIX ER capsule 30 mg once daily for 20 consecutive days
89428983|NCT02069691|Experimental|virtual reality-cycling training system|
89428984|NCT03035734|Active Comparator|A|Single oral dose BMS-986141 Form A tablet under fasting conditions
89428985|NCT03035734|Experimental|B|Single oral dose BMS-986141 Form B tablet (low-dose) under fasting conditions
89428986|NCT03035734|Experimental|C|Single oral dose BMS-986141 Form B tablet (high-dose) under fasting conditions
89428987|NCT03035734|Experimental|D|Single oral dose BMS-986141 Form B tablet (high-dose) under fed conditions
89428988|NCT05616754|Experimental|Test group|People more than 4 months after completing basic immunization with recombinant novel coronavirus protein vaccine (CHO cells)
89428989|NCT05616754|Active Comparator|control group|People more than 4 months after completing basic immunization with recombinant novel coronavirus protein vaccine (CHO cells)
88909361|NCT05452720|Experimental|Experimental Arm|This is a single-arm study. All participants in this study will undergo implantation with MASA Valve.
88909362|NCT05447663|Experimental|Siremadlin (HDM201)|Participants with AML post allogeneic stem cell transplantation (allo-SCT) will receive siremadlin monotherapy in part 1 and siremadlin monotherapy as well as in combination with donor lymphocyte infusion in part 2
88909363|NCT05445037|Experimental|Continuos Monitoring|Continuos monitoring will be done with clearsight continuously assessing blood pressure, cardiac output and heart rate; NIRS electrode to access cerebral O2 saturation, peripheral O2 saturation, BIS value and axillary temperature.
88909364|NCT05445037|Experimental|Standard monitoring|Standard monitoring will be done with non-invasive
88909365|NCT05443724|Experimental|CVL-231 30 mg|Participants will receive CVL-231 30 milligrams (mg) tablet, once daily for 52 weeks.
88909366|NCT05442632|Experimental|Experimental: 1|durg：Hetrombopag 5mg，once daily，oral
88909367|NCT05442632|Experimental|Experimental: 2|Ndurg： Placebo 5mg，once daily，oral
88909368|NCT05438420|Experimental|Dose escalation of Q702 in combination with fixed dose of pembrolizumab|Give one week on/one week off at selected dose level
88909369|NCT05438420|Experimental|Dose expansion of Q702 in combination with fixed dose of pembrolizumab|Give intravenously once every three week at 200 mg
88909370|NCT05436834|Experimental|mRNA-1273.214|"Part 1: Participants who have not been previously vaccinated against SARS-CoV-2, will receive 2 intramuscular (IM) injections of 25 microgram (μg) mRNA-1273.214 on Day 1 and Day 29.~Part 2: Participants who have previously been vaccinated with a mRNA-1273 primary series, will receive a single IM booster dose (BD) of 10 μg mRNA-1273.214 at least 4 months after the last dose on BD Day 1."
88909371|NCT05435027|Experimental|GRT-R914, HIV-negative (Part A)|Participants in this ≥18 to 65-year-old Part A are naïve to SARS-CoV-2 (Cohorts A1, A2, and A3) or SARS-CoV-2 convalescent (Cohorts A4, A5, A6). Cohorts will receive doses of GRT-R914 administered as prime and boost on Days 1 and Day 29, or as boost 6 months after primary SARS-CoV-2 infection.
88909372|NCT05435027|Experimental|GRT-R912, HIV-negative (Part B)|Participants in this ≥18 to 65-year-old Part B are naïve to SARS-CoV-2 (Cohorts B1, B2) or SARS-CoV-2 convalescent (Cohorts B3, B4). Cohorts will receive doses of GRT-R912 administered as prime and boost on Days 1 and 29, or as boost 6 months after primary SARS-CoV-2 infection. Parts B, C, and D will be run in parallel.
88909373|NCT05435027|Experimental|GRT-R912 or GRT-R914, People Living with HIV (PLWH) (Part C)|Participants in this ≥18 to 65-year-old Part C are people living with HIV but naïve to SARS-CoV-2 (Cohorts C1, C4) or living with HIV but SARS-CoV-2 convalescent (Cohorts C2, C3, C5, C6). Cohorts will receive doses of GRT-R912 or GRT-R914 administered as prime and boost on Days 1 and 29, or as boost 6 months after primary SARS-CoV-2 infection. Parts B, C, and D will be run in parallel.
88909374|NCT05435027|Experimental|GRT-R918, HIV-negative and PLWH, With and Without Prior Vaccination (Part D)|Participants will be ≥18 and <60 years or ≥60 years, HIV-Negative and PLWH with no prior vaccination to SARS-CoV-2 (Cohorts D1, D2, D5, D6) or with prior vaccination to SARS-CoV-2 (Cohorts D3, D4, D7, D8). Cohorts will receive doses of GRT-R918 administered as prime and boost on Days 1 and 29, or as boost ≥2 months after prior SARS-CoV-2 vaccination. Parts B, C, and D will be run in parallel.
89428990|NCT05616754|Experimental|Observation group|People over 4 months after completing basic immunization with COVID-19 mRNA vaccine
89428991|NCT03440996|Experimental|Clinpro™ 5000|Participants will use Clinpro™ 5000 to brush their teeth for two minutes twice daily for 4 months.
89428992|NCT03440996|Experimental|Clinpro™ Tooth Crème|Participants will use Clinpro™ Tooth Crème to brush their teeth for two minutes twice daily for 4 months.
89428993|NCT03440996|Active Comparator|MI-Paste Plus|Participants will use MI-Paste Plus to brush their teeth for two minutes twice daily for 4 months.
89428994|NCT04762576||Cardiac Surgical Patients|All consenting adults undergoing cardiac surgery at Toronto General Hospital.
89428995|NCT03440840|Experimental|Computer Training with active tDCS|Participants randomized to this arm will receive computer-based cognitive training using a car racing game with active transcranial direct current stimulation (tDCS).
89428996|NCT03440840|Active Comparator|Computer Training with sham tDCS|Participants randomized to this arm will receive computer-based cognitive training using a car racing game with sham transcranial direct current stimulation (tDCS).
89428997|NCT03440840|Placebo Comparator|Computer Training with or without tDCS|Participants in this arm will watch educational videos as a comparator to computer training with the car racing game (watching educational videos).
89428998|NCT03440762|Other|AF awareness education|AF awareness education face to face
89428999|NCT04808830||Pulmonary arterial hypertension|Adult patients with pulmonary arterial hypertension
88922212|NCT05639634|Experimental|Chlorella Supplementation and Exercise|Supplementation with Chlorella (1.5 g/d) with a physical exercise program for 12 weeks
89429000|NCT03436004|Experimental|Experimental|Colonoscopy with specific device with CE marking (Endocuff Vision)
89429001|NCT03436004|Active Comparator|Active Comparator|Colonoscopy with standard device of the center
89197395|NCT00950326|Active Comparator|C- Hydro & Physiotherapy|Patients with active osteoarthritis of the hip or knee will receive specific, joint-related hydrotherapy in the form of a (daily) alternate cold and warm thigh affusions as well as joint-specific physiotherapy (three times a week).
89008245|NCT04599283|Active Comparator|Symptomatic|"You have to be a male patient.~You must have a smartphone (iPhone or Android).~You are at least 35 years old and have already been diagnosed with BPH or Overactive Bladder (OAB) condition OR you are presenting at least one of the following BPH / OAB symptoms:~1. Frequent or urgent need to urinate 2. Increased frequency of urination at night (nocturia) 3. Difficulty starting urination 4. Weak urine stream or a stream that stops and starts 5. Dribbling at the end of urination 6. Inability to completely empty the bladder 7. Experience urge incontinence - the involuntary loss of urine immediately following an urgent need to urinate"
89008246|NCT04599283|Active Comparator|Asymptmatic|"You have to be a male patient.~You must have a smartphone (iPhone or Android).~You are at least 18 years old and have not been diagnosed with BPH or OAB, and you are not presenting any of the above symptoms."
89197396|NCT00745446|Experimental|1|1 hour exposure to filtered air
89429002|NCT04808128|Experimental|Drink A + SC|In t0 the group will receive 250 ml XL energy drink + 20 gr sucrose.
89429003|NCT04808128|Active Comparator|Drink B + SC|In t0 the group will receive 250 ml Fanta soft drink + 20 gr sucrose.
89197397|NCT00745446|Experimental|2|1 hour exposure to diesel exhaust (300mcg/m3)
89197398|NCT00745446|Experimental|3|1 hour exposure to filtered diesel exhaust
89197399|NCT00921284|Placebo Comparator|Placebo|patients will receive a closed-loop administration of propofol and remifentanil according to bispectral level and a placebo
89197400|NCT00921284|Experimental|dexmedetomidine|patients will receive a closed-loop administration of propofol and remifentanil according to bispectral level and dexmedetomidine
89197401|NCT00748020|Active Comparator|group 1|Erythematogenic irradiation scheme
89197402|NCT00748020|Active Comparator|group 2|Suberythematogenic irradiation scheme
89197403|NCT00749502|Experimental|Part A-Dose escalation and confirmation|
89197404|NCT00749502|Experimental|Part B - Prostate/Ovarian Cancer Cohort|
89197405|NCT00749502|Experimental|Part C - T-PLL/CLL cohort|
89197406|NCT00749502|Experimental|Part D - CRC, endometrial, breast, and ovarian cancer cohort|
89197407|NCT00560794|Experimental|Blinatumomab|Participants received blinatumomab as continuous intravenous infusion at constant flow rate over 4 weeks followed by a 2 week treatment-free period (defined as one treatment cycle), for up to a maximum of 10 cycles. The initial dose was 15 μg/m^2/day. A dose increase to 30 μg/m^2/day was permitted with evidence for insufficient response to blinatumomab treatment.
89197408|NCT00749736|Active Comparator|1|4000 IU of cholecalciferol per day
89429004|NCT04808128|Active Comparator|Drink C + SC|In t0 the group will receive 250 ml soda water + 47 gr sucrose.
89429005|NCT04808128|Experimental|Drink A + CC|In t0 the group will receive 250 ml XL energy drink + 20gr complex carbohydrates from one slice of bread (30g) and one spoon of hummus.
89197409|NCT00749736|Active Comparator|2|1 mcg of doxercalciferol per day.
89197410|NCT00749736|Placebo Comparator|3|placebo for six months
89197411|NCT00950404|Active Comparator|Viagra 50 mg tablet, administered with water.|
89197412|NCT00950404|Experimental|Formulation B ODT tablet 50 mg, administered without water.|
89197413|NCT00950404|Experimental|Formulation C ODT tablet 50 mg, administered without water.|
89197414|NCT00950404|Experimental|Formulation D ODT tablet 50 mg, administered without water.|
89197415|NCT00749814|Experimental|A|Study group will receive melatonin.
89197416|NCT00749814|Placebo Comparator|B|Placebo
89197417|NCT00749814|No Intervention|C|No intervention control group.
89197418|NCT00950482|Active Comparator|TA|Active TA
89197419|NCT00950482|Active Comparator|AA|Alternative Acupuncture
89197420|NCT00950482|Active Comparator|WC|Waiting Group
89197421|NCT00748176||A|
89197422|NCT00941122||MRSA/VRE patients|patients known to be colonized with MRSA/VRE
89197423|NCT02565758|Experimental|Arm A4 (ABBV-085)|ABBV-085 administered on at 28 day cycle and enrolling at MD Anderson
89197424|NCT02565758|Experimental|Arm A3 (ABBV-085)|ABBV-085 will be administered at every cycle (28-day cycles).
89197425|NCT00950560||inpatient|
89197426|NCT00950560||outpatient|
89197427|NCT00950560||emergency patient|
89197428|NCT04159922||Type 2 diabetic patients with foot wounds|
89197429|NCT00941200||Blood collection|
89197430|NCT00945880|Experimental|Experimental Group|clemizole hydrochloride, 100mg, BID
88909375|NCT05432804|Active Comparator|Group I (temozolomide)|Patients receive temozolomide PO on days 1-5 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo MRI throughout the study and blood sample collection while on study.
88909376|NCT05432804|Experimental|Group II (temozolomide, selinexor)|Patients receive temozolomide PO on days 1-5 of each cycle and selinexor PO on days 8 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo MRI throughout the study and blood sample collection while on study.
88909377|NCT05429645|Experimental|3-dimensional guidance technique|3-dimensional (3D) guidance technique to position the heart probes in the setting up of a pace maker
88909378|NCT05428605|Experimental|GEM patients|
88909379|NCT05428384||mono arm|Each subject will have at baseline and at 3 month follow-up CardioMEMS readings paired with cardiac MRI scans and measurements completed for each subject will be under nominally the same conditions.
88909380|NCT05427916|Experimental|Negative Pressure Wound Therapy|Negative pressure to the incision site and managing exudate generated by the incision.
88909381|NCT05427916|Active Comparator|Optifoam|This foam is standard of care and is currently stocked by the operating rooms at Mount Sinai hospital and indicated for use in high risk wounds
88909382|NCT05426837|Placebo Comparator|Health Education Training|Health Education Training (HET) control condition covers standard healthy lifestyle behaviors as well as broad coping strategies to address stress. HET is a fully computerized 1-hour control condition focused on increasing healthy behaviors and decreasing unhealthy behaviors. Content includes healthy eating, hydration, sleep and rest, exercise, stress management as well as other healthy lifestyle tips. The HET protocol has been used in prior studies as a control condition for CSI to account for intervention modality and time (e.g. Schmidt et al., 2014). HET is perceived positively, with high rates of acceptability. Importantly, HET is inert with respect to the proposed mechanism of action (PB/TB) (Schmidt et al., 2014; Schmidt et al., 2007; Short et al., 2015). Also, home practice will be prescribed to match the procedures used in CSI and practice forms are provided wherein participants will self-monitor some of the behaviors addressed in HET.
88909383|NCT05426837|Active Comparator|Combatting Social Isolation|"Combating Social Isolation (CSI). CSI and a similar version of this intervention called Building Stronger Allies, has gone through a rigorous treatment development phase, pilot RCT, and larger RCTs (Schmidt et al., 2014; Schmidt et al., 2017; Schmidt et al., 2007; Norr et al., 2017; Short et al., 2015; Short et al., 2017a; Schmidt et al., submitted for publication). CSI is a transdiagnostic cognitive behavioral therapy (CBT)-based protocol designed to address elevated perceived burdensomeness (PB) and thwarted belongingness (TB). The CSI intervention was designed in consultation with clinicians experienced in treating individuals dealing with issues related to PB/TB. CSI is a fully computerized, 1-hour intervention. The latest version of CSI uses Vyond software for video animation and audio narration throughout, as well as interactive features (e.g., brief quizzes to promote comprehension). Procedures draw heavily on standard CBT techniques."
88909384|NCT05425979|Active Comparator|Mepivacaine group|Subjects will receive an ultrasound-guided peripheral nerve block at the ankle with mepivacaine prior to undergoing foot surgery
88922213|NCT05639634|Experimental|Chlorella Supplementation|Supplementation with Chlorella (1.5 g/d) only for 12 weeks. No exercise programme
89429006|NCT04808128|Active Comparator|Drink B + CC|In t0 the group will receive 250 ml Fanta soft drink + 20gr complex carbohydrates from one slice of bread (30g) and one spoon of hummus.
89429007|NCT04808128|Active Comparator|Drink C + CC|In t0 the group will receive 250 ml soda water + 27gr sucrose + 20gr complex carbohydrates from one slice of bread (30g) and one spoon of hummus.
89429008|NCT04427878|Experimental|patients with Covid-19|
89536879|NCT03312335|Experimental|Low-dose Aldesleukin (Proleukin®)|
89429009|NCT03440684|Experimental|Healthy individuals|Forty-one healthy individuals were volunteer to participate in the study and 39 of them had no neurological disease, were from 18 to 65 years old, and had no upper extremity injuries. And they have joined to exercise training during 6 weeks.
89429010|NCT04816942|Experimental|Convalescent Plasma|Patients receiving Two units of ABO compatible COVID-19 convalescent plasma will be administered.P
89429011|NCT03443882|Active Comparator|Astaxanthin formulation #1|capsules
89429012|NCT03443882|Active Comparator|Astaxanthin formulation #2|tablets
88909385|NCT05425979|Active Comparator|Bupivacaine group|Subjects will receive an ultrasound-guided peripheral nerve block at the ankle with bupivacaine prior to undergoing foot surgery
88909386|NCT05425615|Experimental|Active TMS|Deymed DuoMag XT-35 rTMS system (DM-XT35) connected to a 70-mm figure-of-eight coil with built-in cooling fans (also known as an air-cooled coil) will be used for delivering active repetitive or rapid TMS to the target site.
88909387|NCT05425615|Active Comparator|Control TMS|Deymed DuoMag XT-35 rTMS system (DM-XT35) connected to a 70-mm figure-of-eight coil with built-in cooling fans will be used for delivering active repetitive or rapid TMS to the control site.
89429013|NCT03443882|Active Comparator|Astaxanthin formulation #3|powder
89429014|NCT03443882|Experimental|Astaxanthin formulations|fast condition
89429015|NCT04797988|Experimental|eon FR 1064 nm Device|Patient will be treated with the eon FR 1064 nm device.
89429016|NCT04451174|Experimental|Treatment|Prednisone 40 mg days 1 to 4. Then Prednisone 20 mg days 5 to 8.
89429017|NCT04451174|No Intervention|Control|
89429018|NCT04807426|Active Comparator|Multi Sensory stimulation exercises|only Multisensory stimulation Exercises
88909388|NCT05425615|Sham Comparator|Sham TMS|Deymed DuoMag XT-35 rTMS system (DM-XT35) connected to a 70-mm figure-of-eight coil with built-in cooling fans will be used for delivering sham repetitive or rapid TMS to the control or target site.
88909389|NCT05424276|Experimental|50mg IkT-148009|This arm will consist of thirty (30) patients on 50mg of active treatment.
88909390|NCT05424276|Experimental|100mg IkT-148009|This arm will consist of thirty (30) patients on 100mg of active treatment.
88909391|NCT05424276|Experimental|200mg IkT-148009|This arm will consist of thirty (30) patients on 200mg of active treatment.
88909392|NCT05424276|Placebo Comparator|Placebo|This arm will consist of thirty (30) patients on placebo.
88909393|NCT05423145|Experimental|acupressure intervention|Receives access to the acupressure intervention
88909394|NCT05423145|No Intervention|wait list control|No access to the acupressure intervention during the study period
88922214|NCT05639634|Placebo Comparator|Placebo Supplementation and Exercise|Supplementation with Placebo - microcrystalline cellulose (1.5 g/d) with a physical exercise program for 12 weeks
89429019|NCT04807426|Experimental|Task Oriented Exercises|Task-oriented exercises without Multisensory stimulation Exercises
89429020|NCT04807426|Experimental|Task oriented exercises and Multisensory stimulation exercises.|Task-oriented exercises with Multisensory stimulation Exercises
89429021|NCT03433430|Other|truSculpt|truSculpt treatment
89536202|NCT02478125|Experimental|Docetaxel|"Investigators will administer a single 75 mg/m2 IV dose of docetaxel. Twenty-one days later investigators will re-treat enrolled men with the optimal mobilization strategy + docetaxel IV.~The second dose of docetaxel being given in combination with the optimal mobilization strategy will be chosen according to a standard 3+3 dose escalation schema, in which the dose of bruixafor +/- G-CSF will be held constant and the dose of docetaxel will escalate between three dose-levels: 1) docetaxel 30 mg/m2 IV, 2) docetaxel 60 mg/m2 IV, and 3) docetaxel 75 mg/m2"
88909395|NCT05422690|Experimental|gemcitabine, cisplatin and Durvalumab chemotherapy with Yittrium-90|single arm - Induction Gemcitabine, Cisplatin and Durvalumab Triplet Chemotherapy followed by Gemcitabine, Cisplatin in combination with yttrium-90 (Y-90) Radioembolization
88909396|NCT05421858|Experimental|Fosmanogepix (PF-07842805) IV/oral|"Fosmanogepix will be administered as an Intravenous (IV) infusion given directly into a vein in the arm. There is an option to switch from the IV infusion to the oral form of fosmanogepix which is taken by mouth.~Matching placebos for caspofungin and fluconazole will also be administered (a placebo does not have any medicine in it but looks just like the caspofungin and fluconazole)."
88909397|NCT05421858|Active Comparator|Caspofungin IV/ Fluconazole oral|"Caspofungin will be administered as an intravenous (IV) infusion given directly into a vein in the arm. There is an option to switch from the IV infusion to oral fluconazole which is taken by mouth.~Matching placebos for fosmanogepix will also be administered (a placebo does not have any medicine in it but looks just like the medicine fosmanogepix being studied)."
88909398|NCT05421429|Experimental|KN057 (Cohort 1：HA/HB)|Injection, once a week
88909399|NCT05421429|Experimental|KN057 (Cohort 2：HA/HB)|Injection, once a week
88909400|NCT05421429|Experimental|KN057 (Cohort 3：HA/HB)|Injection, once a week
88909401|NCT05421429|Experimental|KN057 (Cohort 4：HAW/HBW)|Injection, once a week
88909402|NCT05421377||lymph node dissection for treatment of urogenital, gynaelogical or skin cancer|Patients with any type of skin melanoma (at the level of the lower limb), urogenital or gynaecological cancer scheduled for lymph node dissection
88909403|NCT05420207||MSM patients|
88909404|NCT05420207||Physician treating MSM patients|
88909405|NCT05419375|Other|Non-Small Cell Lung Cancer (NSCLC)|Participants with NSCLC will be screened for biomarker eligibility for a linked Roche study.
88909406|NCT05419050|Experimental|treatment|treatment arm
88909407|NCT05412576|Experimental|IVL0.5 group|At the beginning of surgery, lidocaine 0.5mg/kg per hour will be continuously infused (using ideal body weight) and stopped at the end of the procedure.
88909408|NCT05412576|Experimental|IVL1.0 group|At the beginning of surgery, lidocaine 0.5mg/kg per hour will be continuously infused (using ideal body weight) and stopped at the end of the procedure.
88909409|NCT05412576|Experimental|IVL1.5 group|At the beginning of surgery, lidocaine 0.5mg/kg per hour will be continuously infused (using ideal body weight) and stopped at the end of the procedure.
88909410|NCT05412576|Placebo Comparator|Placebo group|At the beginning of surgery, in the placebo group, the same dose of normal saline as the experimental groups will be given until the procedure is over.
88909411|NCT05411718|Experimental|Naproxen|Participants will take two (2) naproxen matching capsules by mouth 1 time every day, at about the same time each day
88909412|NCT05411718|Active Comparator|Aspirin|Participants will take two (2) aspirin matching capsules by mouth 1 time every day, at about the same time each day
88909413|NCT05407324|Experimental|CORT113176 (Dazucorilant) 300 mg|300 mg of dazucorilant will be administered once daily.
88909414|NCT05407324|Experimental|CORT113176 (Dazucorilant) 150 mg|150 mg of dazucorilant will be administered once daily.
88909415|NCT05407324|Placebo Comparator|Placebo (matched to study drug)|Placebo will be administered once daily.
88909416|NCT05407285|Experimental|0 mg CBD, ingested placebo|Ingested placebo containing 0 mg CBD. Group will attend a total of five study visits (one for each study product) with at least 1 week between each visit. The order in which the study products will be administered depend on the randomization sequence.
88909417|NCT05407285|Experimental|20 mg CBD, ingested CBD|Ingested cannabis containing 20 mg CBD. Group will attend a total of five study visits (one for each study product) with at least 1 week between each visit. The order in which the study products will be administered depend on the randomization sequence.
88909418|NCT05407285|Experimental|50 mg CBD, ingested CBD|Ingested cannabis containing 50 mg CBD. Group will attend a total of five study visits (one for each study product) with at least 1 week between each visit. The order in which the study products will be administered depend on the randomization sequence.
88909419|NCT05407285|Experimental|100 mg CBD, ingested CBD|Ingested cannabis containing 100 mg CBD. Group will attend a total of five study visits (one for each study product) with at least 1 week between each visit. The order in which the study products will be administered depend on the randomization sequence.
88909420|NCT05407285|Experimental|200 mg CBD, ingested CBD|Ingested cannabis containing 200 mg CBD Group will attend a total of five study visits (one for each study product) with at least 1 week between each visit. The order in which the study products will be administered depend on the randomization sequence.
89536203|NCT03070197||Case/CHD with deleterious mutations|Participants with CHD with damaging de novo mutations or stringently defined deleterious missense mutations) on whole exome sequencing or whole genome sequencing
88909421|NCT05406830|Experimental|Verum acupuncture (VA)|Participants will be treated by real manual acupuncture and usual care. They will be treated twice a week for 8 weeks, to fulfill a 16-session treatment course. Each acupuncture treatment session for patients will be 30 minutes in duration.
88909422|NCT05406830|Sham Comparator|Sham acupuncture (SA)|Participants will be treated by non-penetrating sham acupuncture and usual care. They will be treated twice a week for 8 weeks, to fulfill a 16-session treatment course. Each acupuncture treatment session for patients will be 30 minutes in duration.
88909423|NCT05405114|Experimental|HU-non-eligible - NDec plus placebo|HU-non eligible patients randomised to treatment with NDec on one day and placebo on the other day
88909424|NCT05405114|Experimental|HU-non-eligible - NDec plus NDec|HU-non eligible patients randomised to treatment with NDec on both days
88909425|NCT05405114|Placebo Comparator|HU-non-eligible - Placebo plus placebo|HU-non eligible patients randomised to treatment with placebo on both days
88909426|NCT05405114|Experimental|HU-active - NDec plus placebo|HU-active patients randomised to treatment with NDec on one day and placebo on the other day
88909427|NCT05405114|Experimental|HU-active - NDec plus NDec|HU-active patients randomised to treatment with NDec on both days
88909428|NCT05405114|Active Comparator|HU-active - HU|HU-active patients randomised to continue on open-label HU treatment
88909429|NCT05404880||EDWARDS INSPIRIS RESILIA Aortic Valve|Subjects who were treated with the INSPIRIS RESILIA aortic heart valve.
88909430|NCT05401253||Adequate physical activity group|At least 600 met-minutes /week for five or more days of walking, moderate and strenuous physical activity per week.
89429022|NCT04828720|Active Comparator|PRF group|"The PRF was prepared according to Choukroun et al. [5] immediately before surgery, a 10 ml blood sample was taken by venipuncture of the antecubital vein without anticoagulant. The tubes were centrifuged immediately by a dedicated centrifuge at 3,000 rpm for 10 minutes.~A structured fibrin clot was produced by such preparation protocol in the middle of the tube, with the erythrocytes at the bottom and acellular plasma at the top. Following elimination of acellular plasma, a sterile scissors was used to separate the PRF from the erythrocytes. A membrane of PRF was formed by squeezing it gently between two pieces of gauze. Folding of the membrane was performed to achieve the required thickness (1.0 mm) with accurate trimming to match the palatal wound. The obtained membrane was then placed at the palatal donor site and compressed with gauze. Then, it was secured with 3-0 black plaited silk and a stent was placed."
89429023|NCT04828720|Placebo Comparator|Control group|the palatal wounds in control group were managed by compressing the donor site with gauze and periodontal pack was placed. Patients in control group used a soft stent to protect the palatal donor wound site . Patients were instructed firmly not to shatter the stent for 1 week. The stent was removed and reseated only by the operator during the application of medications and collection of smears. One week postoperatively, the protective stents were discontinued.
89429024|NCT04828720|Experimental|ozonated group|the palatal wound in ozanaited group will be painted by ozainated oil 2ml daily for 1 week, Patients used a soft stent to protect the palatal donor wound site . Patients were instructed firmly not to shatter the stent for 1 week. The stent was removed and reseated only by the operator during the application of medications and collection of smears. One week postoperatively, the protective stents were discontinued.
89429025|NCT03435770|Experimental|EUSRA RFA needle|This procedure is very similar to the standard technique of EUS-guided fine needle aspiration. All patients would undergo EUS with a linear array or therapeutic echoendoscope. The location and size of the lesion would be assessed for suitability of treatment. After locating the lesion, the EUSRA RFA needle would be inserted to the centre of the lesion. RFA would then be initiated and hyperechoic interferences would be observed around the electrode signifying heating of the tissue.
88909431|NCT05401253||Insufficient physical activity group|Less than 600 met-minutes /week for five or more days of walking, moderate and strenuous physical activity per week.
89429026|NCT04828876|Experimental|Yoga practice|The yoga practice will be held 2 days a week for 6 weeks, a total of 12 sessions. Each session is set as one hour
89429027|NCT04828876|No Intervention|Control group|Routine maintenance will be applied
89429028|NCT03440606|Experimental|MCAT Supervision Group|The 6-week 3-hour Mindful-Compassion Art Therapy (MCAT) supervision will include intervention elements of brief psycho-education, weekly mindfulness mediation that serve as a foundation to foster creative art making, reflective writing, group sharing and discussion.
89429029|NCT03440606|Experimental|Waitlist Control Group|Those assigned to the waitlist control group will not receive Mindful-Compassion Art Therapy (MCAT) supervision until approximately 1.5 month later; equivalent intervention and assessment procedures will be administered.
89429030|NCT04828798|Active Comparator|Directional deep brain stimulation|Deep brain stimulation delivered in a directional manner within an axial plane
88909435|NCT05397470|Experimental|Part A: Placebo-controlled treatment period: Losmapimod|Participants will be randomized to receive losmapimod.
88909436|NCT05397470|Placebo Comparator|Part A: Placebo-controlled treatment period: Placebo|Participants will be randomized to receive placebo
88909437|NCT05397470|Experimental|Part B: Open-label extension|Participants will receive losmapimod, upon completion of all assessments for Part A.
88909438|NCT05396911|Experimental|Youth Brief Tobacco Intervention + Automated Text Messaging|
88909439|NCT05396911|Experimental|Youth Brief Tobacco Intervention|
88909440|NCT05396911|Experimental|Automated Text Messaging|
88909441|NCT05396911|No Intervention|No Treatment Control|
88909442|NCT05396833|Experimental|Part A1: M1774 and M4076|
88909443|NCT05396833|Experimental|Part A1.1: M1774 and M4076|Assessment of the Effect of Food (Low-fat Meal) on the PK of M4076 Monotherapy Followed by Treatment with M1774 in Combination with M4076
88909444|NCT05396833|Experimental|Part A2: M1774 and M4076|ATM in prostate cancer (Part A2)
88909445|NCT05396833|Experimental|Part A3: M1774 and M4076|ARID1A in endometrial cancer (Part A3
89429031|NCT04828798|Active Comparator|Nondirectional deep brain stimulation|Deep brain stimulation delivered in a nondirectional manner within an axial plane
89429032|NCT04828642|Active Comparator|Supplementation group|Antioxidant vitamins (Vitamin C (1000 mg) + Vitamine E (235 mg))
88909446|NCT05396833|Experimental|Part A2/A3: M1774 and M4076|Tablet formulation (TF1, test) compared to a capsule formulation (reference)
88909447|NCT05396833|Experimental|Part B1: M1774 and Avelumab|
88909448|NCT05396248|Experimental|Experimental Group|The experimental group will receive memory retraining exercises administered on a laptop computer twice a week for five weeks (10 training sessions).
88909449|NCT05396248|Placebo Comparator|Placebo Control Group|The placebo control group will receive placebo memory exercises administered on a laptop computer twice a week for five weeks (10 placebo control sessions).
88909450|NCT05393622|Experimental|Intervention, Placement of Device & Stimulation|Placement of neurostimulation device & stimulation of prefrontal cortex target
88909451|NCT05393180|Other|Hybrid Convergent|"Once the procedure intra-op exclusion conditions have been evaluated, the Epicardial linear lesions will be created endoscopically using the EPi-Sense®-Guided Coagulation System or EPi-Sense ST™ Coagulation System throughout the posterior left atrium and along the pericardial reflections from a trans-diaphragmatic or sub-xyphoid access without any chest incisions. An endocardial ablation catheter will be used to complete the isolation of the pulmonary veins and create a cavotricuspid lesion to prevent typical atrial flutter.~Posterior and other linear lesions such as a roof lesion and mitral valve isthmus lesion will not be created during the endocardial component of the convergent procedure.~Once the study lesion pattern has been created by coagulating cardiac tissue using the EPi-Sense®- Guided Coagulation System or EPi-Sense ST™ Coagulation System and the endocardial ablation catheter, the pulmonary veins must be evaluated for entrance and/or exit block to confirm isolation."
88909452|NCT05390840|Experimental|Part 1 (MG-O-1002)|Drug: MG-O-1002; Dose level: 0.8%; Dosage form: ophthalmic solution; Route of administration: topical ocular
88909453|NCT05390840|Placebo Comparator|Part 2 (MG-O-1002 or Placebo)|"Arm 1:~Drug: MG-O-1002; Dose level: 0.8%; Dosage form: ophthalmic solution; Route of administration: topical ocular~Arm 2:~Drug: Placebo; Dosage form: ophthalmic solution; Route of administration: topical ocular"
88909454|NCT05387941|Experimental|Dexamethasone treated infants|15 infants that receive dexamethasone eye drops for treatment of retinopathy of prematurity will be included, and both serum and saliva samples will be collected in order to find out the pharmacokinetic properties of dexamethasone in eye drops according to a pre-specified sampling scheme specifically designed for this purpose by experts in pediatric pharmacokinetics.
88909455|NCT05387616|Experimental|Copanlisib + Obinutuzumab|
88909456|NCT05386914|Experimental|Carrier APOE4|
88909457|NCT05386914|Other|Non-Carrier APOE4|
88909458|NCT05385575|Experimental|Cohort 1|Participant will receive 0.1mg of single dose by subcutaneous injection of KN056
88909459|NCT05385575|Experimental|Cohort 2|Participant will receive 0.3mg of single dose by subcutaneous injection of KN056
88909460|NCT05385575|Experimental|Cohort 3|Participant will receive 1.0mg of single dose by subcutaneous injection of KN056 or placebo
88909461|NCT05385575|Experimental|Cohort 4|Participant will receive 3.0mg single subcutaneous dose of KN056 or placebo
88909462|NCT05385575|Experimental|Cohort 5|Participant will receive 6.0mg of single dose by subcutaneous injection of KN056 or placebo
88909463|NCT05385575|Experimental|Cohort 6|Participant will receive 12.0mg of single dose by subcutaneous injection of KN056 or placebo
89429033|NCT04828642|Placebo Comparator|Placebo group|Placebo supplementation with the same aspect as supplementation
89429034|NCT03433352||Control group|30 healthy volunteers were included in the healthy control group
89429035|NCT03433352||Recrudescence group|30 GD patients who received recurrence within 2 years after treatment with Methimazole Pill or propylthiouracil pill
89429036|NCT03433352||No recrudescence group|30 GD patients who did not receive recurrence within 2 years after treatment with Methimazole Pill or propylthiouracil pill
88909464|NCT05385575|Experimental|Cohort 7|Participant will receive 18.0mg of single dose by subcutaneous injection of KN056 or placebo
88909465|NCT05383170|Experimental|Arm A: advanced or metastatic HNSCC|The safety and tolerability of CyPep-1 in combination with pembrolizumab will be evaluated in a cohort of 30 subjects in total with advanced or metastatic HNSCC. CyPep-1 will be administered every 2 weeks (Q2W) and pembrolizumab will be administered following a Q6W schedule as per standard of care (SoC).
89429037|NCT04828564|Experimental|Ribavirin Arm|"Ribavirin dosage: 200 mg oral ribavirin capsules for 5 days~Regimen: 1200 mg loading dose on day-1 (three capsules in the morning and three capsules in the evening) followed by 800 mg/day maintenance dose (two capsules in the morning and two capsules in the evening) on day-2 to day-5."
89429038|NCT04828564|Active Comparator|Favipiravir Arm|"Favipiravir dosage: 200 mg oral favipiravir tablets for 5 days~Regimen: 2x1600 mg loading dose on day-1 (eight tablets in the morning and eight tablets in the evening) followed by 2x600 mg maintenance dose (three tablets in the morning and three tablets in the evening) on day-2 to day-5."
88909466|NCT05383170|Experimental|Arm B: advanced or metastatic melanoma|The safety and tolerability of CyPep-1 in combination with pembrolizumab will be evaluated in a cohort of 30 subjects in total with advanced or metastatic melanoma. CyPep-1 will be administered every 2 weeks (Q2W) and pembrolizumab will be administered following a Q6W schedule as per standard of care (SoC).
88909467|NCT05383170|Experimental|Arm C: advanced or metastatic TNBC|The safety and tolerability of CyPep-1 in combination with pembrolizumab will be evaluated in a cohort of 30 subjects in total with advanced or metastatic TNBC. CyPep-1 will be administered every 2 weeks (Q2W) and pembrolizumab will be administered following a Q6W schedule as per standard of care (SoC).
88909468|NCT05381909|Experimental|Phase 1a: Dose Escalation Part A|Participants will receive escalating doses of BGB-24714 as monotherapy
89429039|NCT04449692|Experimental|80 µg s.c. dasiglucagon|80 µg of dasiglucagon will be administered subcutaneously when plasma glucose levels reach 4.5 mmol/l
88909469|NCT05381909|Experimental|Phase 1a: Dose Escalation Part B|Participants will receive increasing dose levels of BGB-24714 in combination with paclitaxel
88909470|NCT05381909|Experimental|Phase 1a: Dose Escalation Part C|Participants will receive increasing dose levels of BGB-24714 in combination with chemoradiation
88909471|NCT05381909|Experimental|Phase 1a: Dose Escalation Part D|Participants will receive increasing dose levels of BGB-24714 in combination with chemoradiation
89197431|NCT04061174|Experimental|Shoulder stabilization exercise and office exercise training|Shoulder stabilization exercises will be given to the experimental group participants individually during 8 weeks. Exercises will be done 3 times a week and each exercise will be performed with 10 repetitions, 3 sets and 60-90 seconds rest between sets. Also experimental group participants will do office exercise training that given to other group participants.
89429040|NCT04449692|Experimental|120 µg s.c. dasiglucagon|120 µg of dasiglucagon will be administered subcutaneously when plasma glucose levels reach 4.5 mmol/l
89429041|NCT04449692|Active Comparator|15 g oral carbohydrate (dextrose tablets)|15 g of oral carbohydrate (dextrose tablets) will be administered when plasma glucose levels reach 4.5 mmol/l
88909472|NCT05381909|Experimental|Phase 1a: Dose Escalation Part A-CN|Participants will receive escalating doses of BGB-24714 as monotherapy in mainland China
88909473|NCT05381909|Experimental|Phase 1a: Dose Escalation Part E|Participants will receive increasing dose levels of BGB-24714 in combination with chemoradiation in mainland China
88909474|NCT05381909|Experimental|Phase 1b: Dose Expansion|BGB 24714 will be administered in combination with paclitaxel or docetaxel in participants with selected solid tumors.
88909475|NCT05373862|Experimental|Globe-Shaped, High-Density, Multi-Electrode Mapping Catheter|Participants with cardiac arrhythmias/ablation history who are scheduled to have a clinically-indicated catheter mapping and ablation procedure of arrhythmia management for atrial and ventricular procedures will be using multi-electrode mapping catheter.
88909476|NCT05369832|Experimental|Cohort 1 - Advanced therapy-naive|
88909477|NCT05369832|Experimental|Cohort 2 - Advanced therapy-exposed|
88909478|NCT05368207|Experimental|Pembrolizumab|Pembrolizumab will be given as an intravenous infusion at 200 mg, every 6 weeks, for 6 cycles.
88909479|NCT05365087||TS Cohort|Patients who chose the Transoral Fundoplication (TF) prior to the Laparoscopic Sleeve Gastrectomy (LSG) procedure.
88909480|NCT05365087||RNY Cohort|Patients who chose the Laparoscopic Roux-enY Gastric Bypass procedure.
88909481|NCT05365087||LSG Cohort|Patients with no evidence of GERD who undergo LSG and complete standard surveillance endoscopy
88909482|NCT05364879|Experimental|Intervention|Circuit-based prehabilitation exercise intervention
88909483|NCT05363982|Active Comparator|Transcranial Photobiomodulation (tPBM) Treatment|Transcranial Photobiomodulation--a noninvasive intervention in which near-infrared light is applied to forebrain.
88909484|NCT05363982|Sham Comparator|Placebo/ Sham Treatment|The sham treatment will mimic the tPBM procedure, while delivering no light.
88909485|NCT05363280|Experimental|OBD finding cohort at low dose|Subject in low dose group will receive AL8326 orally in each cycle until intolerable toxicity or disease progression or withdrawal . 6-12 subjects are in this group. Efficacy, safety and PK will be evaluated and compared within 3 different dosing group to define the final OBD.
88909486|NCT05363280|Experimental|OBD finding cohort at middle dose|Subject in middle dose group will receive AL8326 orally in each cycle until intolerable toxicity or disease progression or withdrawal . 6-12 subjects are in this group. Efficacy, safety and PK will be evaluated and compared within 3 different dosing group to define the final OBD.
88909487|NCT05363280|Experimental|OBD finding cohort at high dose|Subject in high dose group will receive AL8326 orally in each cycle until intolerable toxicity or disease progression or withdrawal . 6-12 subjects are in this group. Efficacy, safety and PK will be evaluated and compared within 3 different dosing group to define the final OBD.
88909488|NCT05361967||ATK: Above-The-Knee|Subjects with claudication (Rutherford 3) or CLTI (Rutherford 4 or 5), who have undergone an endovascular procedure utilizing adjunctive therapies, other than balloon angioplasty alone, which are then followed by PTA and IVUS, and have an arterial dissection requiring repair. ATK subjects will have baseline lesions in the superficial femoral and/or proximal popliteal arteries.
88909489|NCT05361967||BTK: Below-The-Knee|Subjects with CLTI (Rutherford 4 or 5), who have undergone an endovascular procedure utilizing adjunctive therapies, other than balloon angioplasty alone, which are then followed by PTA and IVUS, and have an arterial dissection requiring repair. BTK subjects will have baseline lesions in the mid/distal popliteal, peroneal and/or tibial arteries.
88909490|NCT05361473|Active Comparator|The NeoHilda Point of care method|Evaluating baby including lactate dehydregenase Levels measured in umbilical core blood using the fast point of care method called Neo Hilda
88909491|NCT05361473|Sham Comparator|No Measurement of LDH|Evaluating baby without Lactate dehydrogenase result
88909492|NCT05357651|Experimental|Dose Escalation|Up to 9 dose cohorts will be sequentially enrolled in the dose escalation part using an accelerated titration combined with the standard 3+3 dose escalation algorithm approach.
89429042|NCT04798300|Other|tested material|Newly Introduced Gradient Monolithic Zirconia (Intervention)
89429043|NCT04798300|Active Comparator|comparator material|Full Strength Monolithic Zirconia (Comparator)
89429044|NCT05619406|Active Comparator|Control|The Control Group will be screened at baseline and be informed of their risk factors. They will be counselled to consult their provider following baseline risk factor assessment but this advice will not be reinforced by exposure to the app, stroke video, or module content. At the end of the study (EOS), they will complete a questionnaire to assess possible contamination with the intervention.
89429045|NCT05619406|Experimental|Intervention|The riskometer app will be administered one-on-one to the participants using a smartphone and eventually score and assess them using the global risk score
89429046|NCT03435302|Experimental|Temozolomide Plus Cisplatin|per os 200 mg/m^2/d temozolomide on days 1 to 5 plus i.v. 75 mg/m^2 cisplatin divided into 3 days,which was repeated every 3 weeks for six cycles
89429047|NCT03435302|Active Comparator|High-Dose IFN-a2b|Participants will be treated with i.v. 15×10^6U/m^2/d IFN-a2b on days 1 to 5 each week for 4 weeks, followed by s.c. 9×10^6U IFN- a2b three times per week for 48 weeks.
89429048|NCT04973150|Experimental|the children were given gauze covering training in one eye or both eyes|According to the operation method, the children were given gauze covering training in one eye or both eyes.
89429049|NCT04973150|No Intervention|Using regular tablet computer to play cartoon animation video|
88909493|NCT05357651|Experimental|Safety Expansion|2-3 doses were initially selected for safety expansion, with patients with advanced solid tumors as the main research population. Each dose cohort is expected to enroll 9-12 patients.
88909494|NCT05357651|Experimental|Exploratory Expansion|The Cohort Exploratory Expansion will enroll subjects by cohort at the RP2D dose, and a total of 4 cohorts (cohorts A, B, C, D) are expected.
88909495|NCT05353985|Placebo Comparator|Cohort 1: TAK-062 Placebo + SIGE Gluten-Bar|TAK-062 placebo-matching 4 tablets, orally, taken within pre-determined time before the start of a meal and SIGE gluten bar, orally, with a meal, at protocol defined timepoints, for up to 24 weeks.
88909496|NCT05353985|Experimental|Cohort 1: TAK-062 Dose 1 + SIGE Gluten-Bar|TAK-062 Dose 1, 4 tablets, orally, taken within pre-determined time before the start of a meal and SIGE gluten bar, orally, with a meal, at protocol defined timepoints, for up to 24 weeks.
88909497|NCT05353985|Placebo Comparator|Cohort 2: TAK-062 Placebo + SIGE Gluten-Bar|TAK-062 placebo-matching 4 tablets, orally, taken within pre-determined time before the start of a meal and SIGE gluten bar, orally, with a meal, at protocol defined timepoints, for up to 24 weeks.
88909498|NCT05353985|Experimental|Cohort 2: TAK-062 Dose 2 + SIGE Gluten-Bar|TAK-062 Dose 2, 4 tablets, orally, taken within pre-determined time before the start of a meal and SIGE gluten bar, orally, with a meal, at protocol defined timepoints, for up to 24 weeks.
88909499|NCT05353985|Experimental|Cohort 2: TAK-062 Dose 3 + SIGE Gluten-Bar|TAK-062 Dose 3, 4 tablets, orally, taken within pre-determined time before the start of a meal and SIGE gluten bar, orally, with a meal, at protocol defined timepoints, for up to 24 weeks.
89429050|NCT04807192|Experimental|Arm 1: SBRT|
89429051|NCT04807192|Experimental|Arm 2: CMP-001 + SBRT|
89429052|NCT04798222|Experimental|Group 1: Treatment Sequence ABECD|Participants will receive a single oral dose of Treatments A, B, E, C, and D in Treatment periods 1 to 5 on Day 1 of the study.
89429053|NCT04798222|Experimental|Group 1: Treatment Sequence BACED|Participants will receive a single oral dose of Treatments B, A, C, E, and D in Treatment periods 1 to 5 on Day 1 of the study.
89429054|NCT04798222|Experimental|Group 1: Treatment Sequence CDBEA|Participants will receive a single oral dose of Treatments C, D, B, E, and A in Treatment periods 1 to 5 on Day 1 of the study.
89429055|NCT04798222|Experimental|Group 1: Treatment Sequence EADBC|Participants will receive a single oral dose of Treatments E, A, D, B, and C in Treatment periods 1 to 5 on Day 1 of the study.
89429056|NCT04798222|Experimental|Group 2: Treatment Sequence AFHG|Participants will receive a single oral dose of Treatments A, F, H, and G in Treatment periods 1 to 4 on Day 1 of the study.
89429057|NCT04798222|Experimental|Group 2: Treatment Sequence FGAH|Participants will receive a single oral dose of Treatments F, G, A, and H in Treatment periods 1 to 4 on Day 1 of the study.
89429058|NCT04798222|Experimental|Group 2: Treatment Sequence GHFA|Participants will receive a single oral dose of Treatments G, H, F, and A in Treatment periods 1 to 4 on Day 1 of the study.
89429059|NCT04798222|Experimental|Group 2: Treatment Sequence HAGF|Participants will receive a single oral dose of Treatments H, A, G, and F in Treatment periods 1 to 4 on Day 1 of the study.
89429060|NCT03433196|Experimental|HS-25 and Atorvastatin|HS-25 20mg, Atorvastatin 10mg, Placebo of Atorvastatin 1 tablet
89429061|NCT03433196|Active Comparator|Atorvastatin|Atorvastatin 20mg, Placebo of HS-25 2 tablets
89536204|NCT03070197||Control/CHD without deleterious mutations|Participants with CHD without damaging de novo mutations or stringently defined deleterious missense mutations) on whole exome sequencing or whole genome sequencing
89536205|NCT02448121|Experimental|Autologous bone marrow stem cell graft|Autologous bone marrow stem cell implantation
89536206|NCT02478047|Active Comparator|only antiemetic|The participants in the control group received standard antiemetic alone. Standard antiemetic for all groups is based on American Society of Clinical Oncology cClinical pPractice gGuideline. The 5-hydroxytryptamine-3 (5-HT3) antagonist (Ramosetron, Tropisetron) and dexamethasone are administered before the chemotherapy treatment.
89536207|NCT02478047|Experimental|Matching points ST36+CV12|
89536208|NCT02478047|Experimental|Matching points PC6+CV12|
89536209|NCT02478047|Experimental|Matching points CV3+CV12|
89429062|NCT02792829|Experimental|Lenvatinib 11 mg (suspension formulation)|"Arm 1 will have 2 sequences:~Sequence 1 - Treatment Period 1: 11 mg suspension (2 capsules, 1 x 10 mg and 1 x 1 mg); Treatment Period 2: 11 mg capsules (2 capsules, 1 x 10 mg and 1 x 1 mg)~Sequence 2 - Treatment Period 1: 11 mg capsules (2 capsules, 1 x 10 mg and 1 x 1 mg); Treatment Period 2: 11 mg suspension (2 capsules, 1 x 10 mg and 1 x 1 mg)"
89429063|NCT02792829|Experimental|Lenvatinib 11 mg (2 vs 5 capsules)|"Arm 2 will have 4 sequences:~Sequence 3 - Treatment Period 1: 11 mg suspension (5 capsules, 2 x 4 mg and 3 x 1 mg) WATER; Treatment Period 2: 11 mg suspension (2 capsules, 1 x 10 mg and 1 x 1 mg) APPLE JUICE~Sequence 4 - Treatment Period 1: 11 mg suspension (5 capsules, 2 x 4 mg and 3 x 1 mg capsules) APPLE JUICE; Treatment Period 2: 11 mg suspension (2 capsules, 1 x 10 mg and 1 x 1 mg capsules) WATER~Sequence 5 - Treatment Period 1: 11 mg suspension (2 capsules, 1 x 10 mg and 1 x 1 mg capsules) WATER; Treatment Period 2: 11 mg suspension (5 capsules, 2 x 4 mg and 3 x 1 mg capsules) APPLE JUICE~Sequence 6 - Treatment Period 1: 11 mg suspension (2 capsules, 1 x 10 mg and 1 x 1 mg capsules) APPLE JUICE; Treatment Period 2: 11 mg suspension (5 capsules, 2 x 4 mg and 3 x 1 mg capsules) WATER"
89008247|NCT04599322|Experimental|Bilateral dry needling in Flexor Brevis Digitorum in subjects with latent trigger point|Bilateral dry needling in Flexor Brevis Digitorum in subjects with latent trigger point
89429064|NCT02792829|Experimental|Lenvatinib 23 mg|"Arm 3 will have 2 sequences:~Sequence 7 - Treatment Period 1: 23 mg suspension (5 capsules, 2 x 10 mg and 3 x 1 mg capsules) taken 23 hours after preparation; Treatment Period 2: 23 mg suspension (5 capsules, 2 x 10 mg and 3 x 1 mg capsules) taken 2 hours after preparation~Sequence 8 - Treatment Period 1: 23 mg suspension (5 capsules, 2 x 10 mg and 3 x 1 mg capsules) taken 2 hours after preparation; Treatment Period 2: 23 mg suspension (5 capsules, 2 x 10 mg and 3 x 1 mg capsules) taken 23 hours after preparation"
89008248|NCT04599205|Experimental|Microneedling group A|"Patients will be subjected to the following:~Combined laser (power=3.6 mJ) and topical tranexamic acid (TXA) (one finger unit) gel on the right half of the face.~Combined microneedling (by dermapen) and topical TXA gel only on the left half. Self application of topical TXA gel (2 finger units) on both sides on daily base."
89008249|NCT04599205|Experimental|Laser group B|"Patients will be subjected to the following:~Combined laser(power=3.6 mJ) and topical TXA gel (one finger unit) on the right half.~Laser (power=3.6 mJ) only on the left one."
89008250|NCT04599205|Experimental|Gel group C|patients will be subjected to: Daily application of topical TXA gel (2 finger units) on both face sides.
89429065|NCT04451096|Active Comparator|Probiotic with prebiotic|Drug: Probiotic sachet containing granulated multiple strains of Lactobacillus and Bifidobacterium, granulated fermented milk, lactose, fructo-oligosaccharide (FOS) with orange flavouring.
89429066|NCT04451096|Placebo Comparator|Placebo|Drug : Placebo sachet of granulated milk, lactose and orange flavouring, without FOS or microbial cells which appeared similar to the probiotics
89429067|NCT04828252|Experimental|808nm|The wavelength of this experimental group was 808nm, total power: 3.6W, 15 minutes a session, 3 times a week for 8 weeks
89429068|NCT04828252|Active Comparator|660nm|The wavelength of this experimental group was 660nm, total power: 3.6W, 15 minutes a session, 3 times a week for 8 weeks
89429069|NCT04828252|Placebo Comparator|Control|The wavelength of control group, total power: 0.0072W, 15 minutes a session, 3 times a week for 8 weeks
89429070|NCT04797676||EUS-FNB group|Each patient participated in the EUS-FNB group and the surgery group. The procedure of EUS-FNB with wet suction technique is as follow: before the needle was inserted into the biopsy channel, the stylet was removed, and the needle was flushed with saline solution until the fluid dripped out of the needle tip. The air column was replaced with the fluid. A 10-mL syringe was prefilled with 2 mL of saline solution, and the valve was closed. The syringe was loaded to the 5-mL position (i.e. a 3-mL vacuum) and then attached to the proximal port and used for biopsy after inserting into the biopsy channel and puncturing the lesion. Each patient was performed 1-2 passes to obtain specimens for subsequent experiments.
89008251|NCT04599127|Experimental|Mobilization with movement|Mobilization with movement on the shoulder abduction and external rotation
89008252|NCT04599127|Placebo Comparator|Conventional physical therapy|Postural correction exercise and muscle strengthening of the rotator cuff muscle and surrounding muscle on the subacromial region
89008253|NCT04598737|Experimental|Ultra-translucent multilayer zirconia|Ultra-translucent multilayer zirconia laminate veneer treatment
89008254|NCT04598737|Experimental|Lithium disilicate|Lithium disilicate laminate veneer treatment
89008255|NCT00252525||Group 1|This is an observational study of patients who are enrolled in the ongoing randomized clinical trial AGlycemic Control and Complications in Diabetes Mellitus Type 2@.
89008256|NCT04598971||Cystitis|Patients with lower UTI will be included in this group
89008257|NCT04598971||Pyelonephritis|Patients with higher UTI will be included in this group
89008258|NCT00565591|Placebo Comparator|Dose escalation|
89008259|NCT00565630|Experimental|1|Vigamox via the experiemntal device
89008260|NCT00565630|Active Comparator|2|Vigamox drops from the commercially available bottles
89429071|NCT04797676||surgery group|Each patient participated in the EUS-FNB group and the surgery group. The patient underwent EUS-FNB with wet suction technique first, followed by surgery (palliative surgery without excising tumor is not included) for pancreatic cancer. According to the size of the specimen, 0.5cm3-1cm3 tumor specimen was used for subsequent experiments.
89429072|NCT02069769|Experimental|communication with oncology team|oncology team will be prompted to contact family caregiver and/or patient twice weekly while the patient is receiving hospice care.
89008261|NCT05011526|Experimental|MVC-COV1901|S-2P protein with CpG and Aluminum Hydroxide/0.5mL
89008262|NCT05011526|Experimental|AZD1222|ChAdOx1 nCoV-19 vaccine
89008263|NCT00565786||ArCom® Polyethylene|ArCom® Polyethylene
89008264|NCT00565786||ArComXL® Polyethylene|ArComXL® Polyethylene
89008265|NCT00565942|Active Comparator|Usual care|Treatment as usual coordinated by general practitioners in primary care.
88909500|NCT05353985|Placebo Comparator|Cohort 2: TAK-062 Placebo + Gluten-free SIGE Bar|TAK-062 placebo-matching 4 tablets, orally, taken within pre-determined time before the start of a meal and gluten-free SIGE bar, orally, with a meal, at protocol defined timepoints, for up to 24 weeks.
88909501|NCT05353985|Experimental|Cohort 2: TAK-062 Dose 1 + Gluten-free SIGE Bar|TAK-062 Dose 1, 4 tablets, orally, taken within pre-determined time before the start of a meal and gluten-free SIGE bar, orally, with a meal, at protocol defined timepoints, for up to 24 weeks.
88909502|NCT05353985|Experimental|Cohort 2: TAK-062 Dose 2 + Gluten-free SIGE Bar|TAK-062 4 tablets, orally, taken within pre-determined time before the start of a meal and gluten-free SIGE bar, orally, with a meal, at protocol defined timepoints, for up to 24 weeks.
89429073|NCT04450862|Experimental|Intervention arm|Participants randomised to the intervention arm will receive a CBT informed, self-help intervention for anxiety in PH. This will be based on the four factor model, which is a trans-diagnostic approach to help understanding and identify behaviour change methods (Padesky & Mooney, 1990).
88909504|NCT05346640|Experimental|Functional electrical stimulation in individuals with foot drop|Comparison of kinematics in stimulated and unstimulated gait using functional electrical stimulation in individuals with foot drop as a result of a neurological dysfunction
88909505|NCT05346367|Active Comparator|SRT (stereotactic radiotherapy)|stereotactic radiotherapy in 1 or 3 fractions of 8 Gy up to 15-24 Gy
89429074|NCT04450862|No Intervention|Control arm|A waiting-list will be used as a control condition. If the self-management intervention is found to be acceptable and not associated with any risk, then participants in the control condition will receive the intervention.
89429075|NCT02066571|Other|droxidopa, then sugar pill|Droxidopa will be titrated over a 2-week period up to 300 mg twice daily (600 mg total daily dose). Subjects will be titrated to highest tolerated dose and will continue on that dose for two weeks. Then, the subject will start sugar pills.
89429076|NCT02066571|Other|sugar pill, then droxidopa|Subject will be be on sugar pill for 5 weeks (4 weeks of placebo treatment and one week of wash-out or sugar pills). Then, droxidopa will be titrated over 2 week period up to 300 mg twice daily (600 mg total daily dose). Subjects will be titrated to highest tolerated dose and will continue on that dose for two weeks.
89429077|NCT03433118|Experimental|Acupuncture|Acupuncture administered by specially-trained therapeutic radiographers to patients attending the UCH radiotherapy department for radiotherapy intended to be curative of their cancer
89429078|NCT03433118|No Intervention|Standard care|Standard care for patients attending the UCH radiotherapy department for radiotherapy intended to be curative of their cancer
89429079|NCT02066649|Active Comparator|Carvedilol|Initiating patient on carvedilol after diagnosis of varices made on endoscopy
89429080|NCT02066649|Active Comparator|Variceal Band Ligation|performing variceal band ligation during endoscopy on patient after diagnosis of esophageal varices made on endoscopy
89429081|NCT02066649|Active Comparator|Combination Group (Carvedilol + Variceal band ligation)|once patient has confirmed large esophageal varices on endoscopy, he/she will be started on carvedilol (post-procedure) in addition to having variceal band ligation performed during endoscopy
88909506|NCT05346367|Experimental|fSRT (hypo fractionated stereotactic radiotherapy)|hypo fractionated stereotactic radiotherapy in 5 fractions of 7 Gy up to 35 Gy. Brain stem metastases 5 fractions of 6 Gy up to 30 Gy
88909507|NCT05345392|Active Comparator|Mindfulness-Based Intervention (MBI)|The MBI is based on mindfulness-based stress reduction and mindfulness-based cognitive therapy, borrowing publicly available materials from the Mindfulness in Schools Program and Acceptance and Commitment Therapy. The MBI consists of 8 weekly groups, 45-60 minutes in length, and include 3-8 youth. Group content will consist of brief, age-appropriate mindfulness practices, videos, and discussions to engage participants. Parents will be involved at the beginning of each session and will receive a handout detailing session content. Each week will focus on a different aspect of mindfulness: introduction to mindfulness, attention, being with internal experiences, the stories minds tell, watching thought traffic, waking up to now, flow, and wrap-up/mindfulness in daily life. A home practice given each week will be discussed at the next group. Groups will be taught by two trained instructors with an ongoing mindfulness practice, who have training and experience teaching mindfulness to youth.
88922215|NCT05639634|Placebo Comparator|Placebo Supplementation|Supplementation with Placebo - microcrystalline cellulose (1.5 g/d) only for 12 weeks. No exercise programme
88922216|NCT05637944||intubated within day 7th|patients needing oro-tracheal intubation within day 7th from admission.
88922217|NCT05637944||non intubated within day 7th|patients not requiring intubation within day 7th from admission
89429082|NCT02070003|Experimental|Motivational Interviewing and Physician Guided Opioid Weaning|Patients will go through motivational interviewing with the study physician via phone once a week for 7 weeks, and once a month up to a year as applicable, until patient completes the protocol.
89429083|NCT02070003|No Intervention|Usual Care|
89429084|NCT04807270|Active Comparator|T-LAB / PRP KIT|In the first group, Platelet-rich plasma (PRP) prepared with T-LAB / PRP KIT injection in 3 sessions will be applied.
89429085|NCT04807270|Active Comparator|T-LAB / PRP INJECTION SYRINGE|In the first group, Platelet-rich plasma (PRP) prepared with T-LAB / PRP INJECTION SYRINGE injection in 3 sessions will be applied.
89429086|NCT04807270|Active Comparator|SALINE|In the first group, Platelet-rich plasma (PRP) prepared with SALINE injection in 3 sessions will be applied.
89429087|NCT03432962||Food code group|The participants freely selected foods from the online dietary assessment tool to record what they had eaten over the last 24h. They then provided information on brand details. The recalls were recoded to take into account all branded items and then recoded again to take represent all generic (ie. no brands) foods.
89429088|NCT02070081|Experimental|Surgery|
89429089|NCT03435068|Experimental|Ceramic rotary bur|For the ceramic bur group(Meisenger gingivectomies, ceramic rotary burs were used with 400-rpm rotary systems and with no serum irrigation, per the manufacturer's recommendation.
89008266|NCT00565942|Active Comparator|Integrative care|Selected complementary therapies (Swedish massage therapy, manual therapy/naprapathy, shiatsu, acupuncture and qigong) added to usual care.
89429090|NCT03435068|Experimental|Diode laser|In the laser group (LG), a diode laser was applied to the operation sites in accordance with the manufacturer's guidelines (2.8 W continuous wave mode, wavelength 980 nm). The fiber optic laser tip had a 320-μm diameter with a 2.8 W output power. The laser never made contact with the gingival tissue. The practice distance did not affect the laser spot size, which was 0.5 cm-1 cm. Smoke associated with the laser application was aspirated from the surgical site.
89429091|NCT03435068|Active Comparator|Scalpel|In the scalpel group following the local anesthetic administration, the gingivectomy was performed with a #15 scalpel. Subsequent to the operation, the borderline of gingiva was determined via the use of a pointer dental tweezers, and excessive gingival tissue was then removed with Gracey curettes
89429092|NCT02070159|Active Comparator|Clopidogrel 600 mg|Patients administer conventional loading dose of clopidogrel 600 mg as active comparators.
89429093|NCT02070159|Experimental|Prasugrel 30 mg|Patients administer lower loading dose of prasugrel 30 mg.
89429094|NCT02070159|Active Comparator|Prasugrel 60 mg|Patients administer conventional loading dose of prasugrel 60 mg as active comparators.
88909508|NCT05345392|Active Comparator|Health and Wellness Intervention (HWI)|The control intervention, Health and Wellness Intervention (HWI), is a manualized intervention that's inspired by the Health Enhancement Program that has been adapted for youth 11-14 years old, using brief, engaging, and age-appropriate activities to address topics related to physical and mental health. HWI consists of 8 weekly groups, 45-60 minutes in length, and include 3-8 youth. Parents will be involved at the beginning of each session and will receive a handout detailing session content. HWI will include the following modules: stress management, social support, strengths and values, sleep health, nutrition, and exercise. As with the MBI, a home practice given each week will be discussed at the next group. Groups will be taught by two trained instructors without extensive mindfulness practice or training. The intervention will be matched on time and social interaction, but the HWI will not contain any mindfulness or cognitive behavioral therapy (CBT) components.
88909509|NCT05343598|Active Comparator|Active cerebellum rTMS|Cerebellar targeted iTBS, twice daily, one week.
89429095|NCT03434990|Experimental|Spinal manipulation/myofascial release|2x/week, for 3 weeks, performed by a chiropractor. Sessions will last 20 minutes, with 1 individual per session. Myofascial release will be done on paravertebral muscle (Erector spinae, quadratus lumborum) and on gluteus maximus and piriform muscles, the pressure will depend of pain tolerance of each subject. After this procedure, the spinal manipulation will be performed on the sacroiliac join and on the lumbar vertebrae with less mobility.
89429096|NCT03434990|Active Comparator|Spinal manipulation|2x/week, for 3 weeks, performed by a chiropractor. Sessions will last 20 minutes, with 1 individual per session. The spinal manipulation will be performed on the sacroiliac join and on the lumbar vertebrae with less mobility.
88909510|NCT05343598|Sham Comparator|Sham cerebellum rTMS|Cerebellar targeted sham iTBS, twice daily, one week.
88909511|NCT05342883|Other|Experimental: Resection, GammaTile and Stupp Protocol|Resection, Gamma Tile and Stupp Protocol
88909512|NCT05337735|Experimental|XmAb20717|Participants will receive XmAb20717 by vein over 1 hour on Days 1 and 15 of each cycle.
88909513|NCT05333016|Experimental|Multimodal Exercise Intervention|12-week, twice weekly partner-based multimodal exercise program
89429097|NCT03128762||Cases|"Patients in this group are asthmatic (see inclusion/exclusion) criteria.~Intervention: ILC2 levels in blood"
89429098|NCT03128762||Controls|"Controls are non-asthmatic subjects that are age and gender matched to asthma cases.~Intervention: ILC2 levels in blood"
88909516|NCT05329194|Experimental|Tezepelumab|Participants will be receiving 210 mg of tezepelumab every 4 weeks (Q4W) from Week 0 until Week 48.
88909517|NCT05327686|Active Comparator|Arm I (standard of care immunotherapy)|Patients receive one of the following immunotherapy regimens per physician discretion: nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes every 3 weeks for 4 doses followed by nivolumab IV over 30 minutes every 2 or 4 weeks; pembrolizumab IV over 30 minutes every 3 or 6 weeks and axitinib PO BID; avelumab IV over 60 minutes every 2 weeks and axitinib PO BID; nivolumab IV over 30 minutes every 2 or 4 weeks and cabozantinib PO QD; OR pembrolizumab IV over 30 minutes every 3 or 6 weeks and lenvatinib PO QD. Treatment with immunotherapy continues in the absence of disease progression or unacceptable toxicity.
88909518|NCT05327686|Experimental|Arm II (SABR, standard of care immunotherapy)|Patients undergo SABR on 3 different days over 1-3 weeks and receive immunotherapy as in Arm I.
89536210|NCT04996485|Experimental|Experimental group №1 (Secukinumab )|Secukinumab - subcutaneous injections into the shoulder according to the schedule of 0,1,2,3 weeks, then injections 1 time in 3 months up to 52 weeks of therapy.
88909520|NCT05326230|Experimental|Renal Denervation|Renal Angiogram and Renal Denervation (PRDS-001- Paradise™ System)
88909521|NCT05326230|Sham Comparator|Sham Control|Renal Angiogram
88909522|NCT05324969|Experimental|MM-based MI group|Intervention group parents will receive 9 intervention sessions every other week by trained staff via 9 online sessions via Zoom or phone calls. Each intervention session will last 30-40 minutes. Intervention group parents will receive 3 text messages per week. No in-person contacts will be conducted without MSU department permission. All assessments will be delivered remotely with guided phone calls or zoom conference. The assessment of dyads' BMI, %BF, and WC will be obtained remotely from the parents using the scale and measuring tape delivered to their home.
88909523|NCT05324969|Other|Control group|Control group parents will receive a total of 9 emailed packets of educational materials (without information related to the mindfulness-based motivational interviewing [MM-based-MI]). The pre and post assessments will be collected the same way as the participants at intervention group.
88922218|NCT05631964|Experimental|Study treatment|Participants receive BL-M07D1 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
88922219|NCT05631548|Experimental|iTBS to dmPFC, Then Sham iTBS|
88922220|NCT05631548|Sham Comparator|Sham iTBS, Then iTBS to dmPFC|
89429099|NCT04797598|Active Comparator|Virtual Reality group|In this group patients will be treated with virtual reality . This group will receive therapy session for 1 hour, two times in a week and for 12 weeks, total session will be 24. The virtual reality group will receive 30 minutes virtual reality training and 30 minutes conventional treatment.
89429100|NCT04797598|Active Comparator|Cyclic training group|In this group patients will be treated with cyclic training . This group will receive therapy session for 1 hour, two times in a week and for 12 weeks, total session will be 24. The cyclic training group will receive 30 minutes cyclic training and 30 minutes conventional treatment
88909524|NCT05323955|Experimental|Experimental Group|"Trastuzumab/pertuzumab + tucatinib or T-DM1 + tucatinib~300mg of tucatinib taken orally twice a day. Taken on Days 1-21 of a 21 Day cycle (3 Weeks).~Trastuzumab/Biosimilar administered per current package insert based on site standard of care guidelines~Pertuzumab or Biosimilar administered per current package insert based on site standard of care guidelines~Trastuzumab Emtansine (T-DM1) administered per current package insert based on site standard of care guidelines"
88909525|NCT05320549|Experimental|Exercise|Participants have the opportunity to engage in face-to-face and/or online exercise classes
88909526|NCT05320549|No Intervention|Usual care control|Participants continue to engage with usual care provided on discharge from the hospital.
89429101|NCT04827628|Experimental|Obese with Oryza sativa extract|The group with a body mass index of more than 25 kg/m2 that receive the Oryza Sativa Extract
89429102|NCT04827628|Active Comparator|Obese with control|The group with a body mass index of more than 25 kg/m2 that receive the citric acid and sorbitol mixture
88909527|NCT05320367|Experimental|CBD (Group 1)|"Group will receive four CBD doses (5 mg, 17 mg, 50 mg and 100 mg), and placebo (0 mg).~Group will attend a total of five study visits (one for each study product) with at least 1 week between each visit.~The order in which the study products will be administered depend on the randomization sequence"
89008267|NCT04598542|Experimental|TA injection followed by LOR injection|IA injection of TA into the right knee, followed by IA injection of LOR into the same knee 7 days later.
89429103|NCT04827628|Active Comparator|Normal Body Mass Index|The group with a body mass index of less than 25 kg/m2 that receive the citric acid and sorbitol mixture
89429104|NCT02066805||Cohort 1|
89429105|NCT03128684|Experimental|Small Green Lentil Muffin|
89429106|NCT03128684|Experimental|Split Red Lentil Muffin|
88909528|NCT05320367|Experimental|CBD (Group 2)|"Group will receive four CBD doses (5 mg, 17 mg, 50 mg and 100 mg), and placebo (0 mg).~Group will attend a total of five study visits (one for each study product) with at least 1 week between each visit.~The order in which the study products will be administered depend on the randomization sequence"
88909529|NCT05320367|Experimental|CBD (Group 3)|"Group will receive four CBD doses (5 mg, 17 mg, 50 mg and 100 mg), and placebo (0 mg).~Group will attend a total of five study visits (one for each study product) with at least 1 week between each visit.~The order in which the study products will be administered depend on the randomization sequence."
89429107|NCT03128684|Placebo Comparator|Wheat Muffin|
89429108|NCT03128684|Experimental|Small Green Lentil Chili|
88909530|NCT05320367|Experimental|CBD (Group 4)|"Group will receive four CBD doses (5 mg, 17 mg, 50 mg and 100 mg), and placebo (0 mg).~Group will attend a total of five study visits (one for each study product) with at least 1 week between each visit.~The order in which the study products will be administered depend on the randomization sequence."
88909531|NCT05320367|Experimental|CBD (Group 5)|"Group will receive four CBD doses (5 mg, 17 mg, 50 mg and 100 mg), and placebo (0 mg).~Group will attend a total of five study visits (one for each study product) with at least 1 week between each visit.~The order in which the study products will be administered depend on the randomization sequence."
88909532|NCT05319730|Active Comparator|Paclitaxel or irinotecan|Participants receive paclitaxel 80-100 mg/m^2 intravenously (IV) on days 1, 8, and 15 every 28-day cycle until progressive disease (PD) or discontinuation, or irinotecan 180 mg/m^2 IV on day 1 of every 14-day cycle until PD or discontinuation.
89008268|NCT04598542|Experimental|LOR injection followed by TA injection|IA injection of LOR into the right knee, followed by IA injection of TA into the same knee 7 days later.
89429109|NCT03128684|Experimental|Split Red Lentil Chili|
89429110|NCT03128684|Placebo Comparator|Rice Chili|
89429111|NCT03109340|Active Comparator|Supervised treadmill group|a. Supervised treadmill group (Group I): The participants were instructed walking exercise at their target heart rate on a treadmill in Sports Rehabilitation Unit of Pamukkale University.
89429112|NCT03109340|Experimental|ECE PEDO pedometer group|b. ECE PEDO® pedometer group (Group II): Participants were given the walking program with ECE PEDO giving audible feedback in case of any deviation from their target range of steps per minute.
89429113|NCT02070393|Experimental|Radiation Treatment using Protons|14 -24 Radiation Treatments (typically 1.5 - 1.8 cobalt-Gray equivalent per fraction for 14-24 treatments).
89429114|NCT03432884|Experimental|Part A: BGB-3111|
89429115|NCT03432884|Placebo Comparator|Part A: Placebo|
89429116|NCT03432884|Experimental|Part B: BGB-3111, Placebo, and Moxifloxicin|
89429117|NCT02066961||Cohort 1|Subjects with biochemical failure experience after primary treatment and have high-risk disease
89429118|NCT02066961||Cohort 2|Subjects with a medical diagnosis of castration-resistant prostate cancer
89429119|NCT02066961||Cohort 3|Subjects with an initial diagnosis of metastatic prostate cancer
89429120|NCT04806880||users|Users of web-application
89429121|NCT03440294|Other|with neoprene suit and life jacket|"Realization of the following examinations WITH neoprene suit and life jacket :~resting standard spirometry~maximum exercise testing. No drug and no placebo will be used in this arm."
89429122|NCT03440294|Other|without neoprene suit and life jacket|"Realization of the following examinations WITHOUT neoprene suit and life jacket :~resting standard spirometry~maximum exercise testing. No drug and no placebo will be used in this arm."
89429123|NCT04827784|Experimental|Auriculotemporal Nerve Block Administration|A total of 3 doses of Auriculotemporal Nerve Block (ATNB) were administered to involved participants. Local anesthetic solutions containing Articaine Hydrochloride (80 mg / 2 ml) and epinephrine bitartrate (0.02 mg / 2 ml) were used for ATNB application. The injections were repeated on follow-up visits in the first and fourth weeks. The maximal mouth opening amounts, pain intensity values (via VAS scale), and self-reported outcomes were evaluated at the pre-injection, first week, fourth week, and sixth-month follow-up controls.
89429124|NCT03986996|Active Comparator|Group 1 -Amoxycillin Doxycyclin and metronidazole|triple therapy with amoxicillin, metronidazole and tetracycline twice daily, for 2 weeks.
89429125|NCT03986996|Experimental|Group 2 -Amoxycillin and Doxycyclin|double therapy with Amoxycillin and Doxycyclin twice daily, for 2 weeks.
89429126|NCT04827472|Experimental|Part1(Cohort1) : DWJ1521 Amg|
89429127|NCT04827472|Experimental|Part1(Cohort2) : DWJ1521 Bmg|
89429128|NCT04827472|Experimental|Part1(Cohort3) : DWJ1521 Cmg|
89429129|NCT04827472|Experimental|Part1(Cohort4) : DWJ1521 Dmg|
89429130|NCT04827472|Experimental|Part2 : DWJ1521 Xmg|
89429131|NCT04827472|Experimental|Part2 : DWP14012 Tablet|
89429132|NCT02067117|Experimental|influenza split vaccine|
89429133|NCT03440138||University Hospital Zurich|
89429134|NCT03440138||St Pierre University Hospital, Brussels, Belgium|
89429135|NCT03440138||Sana Klinikum, Offenbach, Germany|
89429136|NCT03440138||Complutense University of Madrid, Spain|
89429137|NCT03440138||Musgrove Park Hospital, Taunton, UK|
89429138|NCT03440138||University of Gothenburg, Sweden|
89429139|NCT03440138||AZ Sint-Jan Hospital in Bruges, Belgium|
89429140|NCT03440138||Bristol|
89429141|NCT03440138||Cleveland Clinic, Weston, Florida, USA|
89429142|NCT03440138||Oswaldo Cruz German Hospital, Sao Paolo, Brazil|
89429143|NCT03440138||Clínica Las Condes, Santiago, Chile|
89429144|NCT03440138||Brown University, Providence Rhode Island|
89429145|NCT03440138||Fresno Bariatric, CA, USA|
89429146|NCT03440138||Rijnstate Hospital, Arnhem, The Netherlands|
89429147|NCT03440138||CHU Nice, France|
89429148|NCT03440138||Claraspital Basel, Switzerland|
89429149|NCT03440138||Gastro-Obeso-Center Advanced Med Inst, Brazil|
89429150|NCT03440138||Hospital Dipreca Santiago Región Metropolitana , Chile|
89429151|NCT03440138||Medical University Wien, Austria|
89429152|NCT04796428|Active Comparator|canagliflozin|100 mg (or 50/850 mg and 50/1000 mg of the fixed association with metformin) or 300 mg (or the 150/850 mg and the 150/1000 mg fixed association with metformin).
89429153|NCT04796428|Active Comparator|dapagliflozin|10 mg (or 5/850 mg and 5/1000 mg of the fixed association with metformin; or 10/5 mg of the fixed dapagliflozin / saxagliptin combination)
89429154|NCT04796428|Active Comparator|empagliflozin|10 mg (or 5/850 mg and 5/1000 mg of the fixed association with metformin; or 5/5 mg of the empagliflozin / linagliptin combination) or 25 mg (or the 12.5/850 mg and the 12.5/1000 mg fixed association with metformin; or the 12.5/5 mg empagliflozin / linagliptin combination).
89429155|NCT02867592|Experimental|Treatment (cabozantinib s-malate)|Patients receive cabozantinib-s-malate orally (PO) on a continuous dosing schedule using a dosing nomogram on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89429156|NCT02070471|Experimental|LC28-0126 Dose A|LC28-0126 Dose A
89429157|NCT02070471|Experimental|LC28-0126 Dose B|LC28-0126 Dose B
89429158|NCT02070471|Experimental|LC28-0126 Dose C|LC28-0126 Dose C
89429159|NCT02070471|Placebo Comparator|Placebo|Placebo
89429160|NCT03440060|No Intervention|standard group|participants receive systematically empiric antibiotic therapy on admission with amoxicillin- acid clavulanic or levofloxacin in case of allergy
89429161|NCT03440060|Active Comparator|Procalcitonin group|participants receive antibiotics only if the procalcitonin value is at or greater than 0.25 ng/ml
89429162|NCT02067195|Active Comparator|Guideline Hydration|No hydration for patients without chronic kidney disease(CrCl<60ml/min),or Receiving hydration with a 1 mL/kg bolus of intravenous isotonic saline (0.9% sodium chloride) after diagnosis of chronic kidney disease until 24 hours after PCI. Hydration rate was reduced to 0.5 mL/kg per hour in patients with New York Heart Association class III or KillipⅡ/Ⅲ.
89429163|NCT02067195|Active Comparator|Adequate Hydration|Receiving hydration with a 3 mL/kg.hour bolus of intravenous isotonic saline (0.9% sodium chloride) from randomization to the end of the procedure, the measurement of LVEDP was conducted after the procedure, a sliding-scale hydration was employed in the LVEDP-guided hydration arm that was based on LVEDP for 2 hours: 5 ml/kg/hr for LVEDP <13 mmHg, 3 ml/kg/hr for LVEDP 13-18 mmHg, and >1.5 ml/kg/hr for LVEDP >18 mmHg, whereas,0.5 ml/kg/hr for LVEDP >20 mmHg, continue hydration with a 1 mL/kg until 24 hours after procedure. Hydration rate was reduced to 0.5 mL/kg per hour in patients with New York Heart Association class III or KillipⅡ/Ⅲ.
89429164|NCT02070627|Experimental|NIRF-C and IOC|Each enrolled subject will undergo injection with indocyanine green (ICG), intraoperative near infrared fluorescence cholangiography (NIRF-C) and standard of care intraoperative cholangiography.
89429165|NCT03432728||S-ECC|Children in their fifth year of life with severe early childhood caries Children selected will require complete dental rehabilitation under general anesthesia All enrolled children will receive treatment of all dental carious lesions under general anesthesia
89429166|NCT03432728||Control|Children age and sex matched with the S-ECC group who are free of dental caries
89429167|NCT02064933||Retrospective Cohort (Longitudinal Analysis)|Participants with WAS treated at consortium centers since 1990 who have received transplant (Stratum A) or gene therapy (Stratum B)
89429168|NCT02064933||Prospective Cohort (Longitudinal Analysis)|Participants treated at consortium centers since 1990 who will receive transplant (Stratum A) or gene therapy (Stratum B)
89429169|NCT02064933||Cross-Sectional Cohort (Cross-sectional Analysis)|Living participants with WAS who have received transplant (Stratum A) or gene therapy (Stratum B) at Consortium Centers 1990-Present And >= 2 Years Post-Transplant
89429170|NCT04450784||Secondary Acute Myeloid Leukemias (AML) of the child|
89429171|NCT04450160|Placebo Comparator|Standard of Care|Current GBM Treatment of surgery, radiation and chemotherapy with temozolomide.
89429172|NCT04450160|Experimental|AEO with Standard of Care|Anhydrous Enol-Oxaloacetate added to the Standard of Care (surgery, radiation and chemotherapy with temozolomide).
89429173|NCT02067351|Experimental|Mindfulness Intervention|Mindfulness intervention
89429174|NCT03434756|Experimental|Propioceptive Training|
89429175|NCT04745936|Experimental|C-curve group (group C)|In group C, stylet curvature is made similar to the natural curvature of endotracheal tube.
89429176|NCT04745936|Active Comparator|Hockey stick curve group (group H)|In group H, stylet curvature is made similar to hockey stick shape.
89429177|NCT02070783|Experimental|ARA290|11-amino acid, linear peptide ARA290; intravenous injection with 2 mg ARA290 (single dosage).
89429178|NCT02070783|Placebo Comparator|Placebo|saline (NaCl 0.9%)
89429179|NCT03432572|Experimental|pyridium|Group A will take 200 mg of oral Pyridium 1 hour before surgery and then the urine jets will be evaluated on cystoscopy in the operating room during a gynecological procedure.
89429180|NCT03432572|Active Comparator|riboflavin|Group B will take 400 mg of riboflavin 1 hour before surgery and then the urine jets will be evaluated on cystoscopy in the operating room during a gynecological procedure.
89197432|NCT04061174|Experimental|Office exercise training|"Office-based stretching exercises will be given to other group 3 sets will be applied by waiting 15 seconds for increasing range of motion of back, shoulder and neck joints.~In addition, isometric exercises and scapula stabilization exercises will be given to strengthen the shoulder muscles and participants will do these exercises 3 times a week and once a day in 10 repetitions (10-15 seconds) and 3 sets. Each set will be given a rest of 60-90 seconds. Total time will be 10-15 minutes.Office exercise training will last a total of 8 weeks."
89197433|NCT00950638|Active Comparator|dose comparison|
89197434|NCT00950638|Active Comparator|Dose comparison|
89197435|NCT02565290|Active Comparator|Omega-3|2 capsules of omega 3 - 2 times a day
89197436|NCT02565290|Placebo Comparator|Soy oil|2 capsules of soy oil - 2 times a day
89197437|NCT00941278|Experimental|PH-10 Treatment|
89197438|NCT00619359|Experimental|1|Arm 1: study medication
89197439|NCT00619359|Active Comparator|2|Arm 2: Active comparator
89197440|NCT00950716|Active Comparator|Usual care|The 'control arm' will receive standard usual care with clinicians' follow-up and referral with education to diabetes nurses if deemed necessary at in-charge clinicians' discretion.
89197441|NCT00950716|Active Comparator|Patient Peer Support and Empowerment|30 mentors are themselves diabetes patients who have good self care and are motivated to support their peers. The mentors will be trained to deliver peer support intervention under supervision by a program manager. The 300 diabetes patients (mentees) randomized to the peer support group are the intervention targets of these 30 mentors. Telephone-Linked-Communication (TLC) system will be a tool of the mentors for education to the mentees. TLC system utilizes an automatic, interactive, computer-controlled telephone system to monitor and promote diabetes self-management.
89197442|NCT00848991|Active Comparator|Precedex|In the operating room routine anesthesia monitors will be placed and vital signs will be recorded continuously using data collection software. A routine propofol anesthetic will be administered to subjects randomized to the control group or a Precedex infusion with propofol for subjects randomized to the treatment group. Precedex infusion will be started after induction of general anesthesia. Vital signs (SBP, DBP, MAP) will be recorded continuously throughout the surgery. At the end of the case subjects will be extubated and the blinded observer will assess emergence from anesthesia based on hemodynamic stability and tolerance of the endotracheal tube. Videotaping of emergence will be used to assist in the evaluation of emergence of anesthesia and extubation.
89197443|NCT00848991|Active Comparator|Propofol|Propofol for emergence from anesthesia
89197444|NCT00941434|Experimental|RUTF|Children with Severe malnutrition will be treated with Ready to use therapeutic food (RUTF) till their weight for age z scores are no longer in severe malnutrition group
89197445|NCT00950794|Active Comparator|Hokunalin(tulobuterol) tape|Hokunalin(tulobuterol) tape: long-acting Beta2-agonist
89197446|NCT00950794|Experimental|Salmeterol(408DP-02)|Salmeterol(408DP-02)：long-acting Beta2-agonist
89197447|NCT00951028|Active Comparator|Enhanced treatment as usual|Participants will receive the life-steps intervention and treatment as usual.
89197448|NCT00951028|Experimental|CBT for adherence and depression (CBT-AD)|Participants will receive the life-steps and CBT-AD interventions.
89429181|NCT03432572|Placebo Comparator|thiamine|Group C will take the placebo (50 mg of thiamine) 1 hour before surgery and then the urine jets will be evaluated on cystoscopy in the operating room during a gynecological procedure.
89197449|NCT00951028|Active Comparator|ISP for adherence and depression (ISP-AD)|Participants will receive the life-steps and ISP-AD interventions.
89197450|NCT00849069|Experimental|Group A|
89429182|NCT03379077|Experimental|LTP Plus Supported Implementation|LTP Plus Supported Implementation group participants will receive intervention by trained LHWs of HANDS, co-facilitated and supervised by senior trained PILL researchers, expert in delivering LTP plus intervention
89429183|NCT03379077|Active Comparator|LTP Plus|Participants in LTP Plus arm will receive LTP plus intervention by trained LHWs of Health and Nutrition Development Society (HANDS).
89429184|NCT03439904|Experimental|pharmaceutical care intervention group|Patients will receive individualized pharmaceutical care in addition to usual medical care
89429185|NCT03439904|No Intervention|control group|Patients will receive usual medical care
89429186|NCT02260323|Experimental|patient-tailored anti-arthritis herbs|patient use tailored anti-arthritis herbs
89197451|NCT00849069|Active Comparator|Group B|
89197452|NCT00849303|Experimental|earlier gait-oriented rehabilitation|Patients practise walking every workday for 60 min (actual 30min) either on a treadmill or on a gait trainer for four weeks, and receive also other physiotherapy 60 min daily.
89197453|NCT00849303|Active Comparator|later gait-oriented rehabilitation|Patients practise walking every workday for 60 min (actual 30min) either on a treadmill or on a gait trainer for four weeks, and receive also other physiotherapy 60 min daily.
89197454|NCT00941590||Patients with tick borne encephalitis.|
89197455|NCT04042545|Experimental|inhaled THC/CBD (PPP001)|PPP001 (cannabis dosing capsule with THC/CBD) inhalation with a device
88909533|NCT05319730|Experimental|Pembrolizumab + MK-4830 + paclitaxel or irinotecan|Participants receive pembrolizumab 200 mg IV once every 3 weeks (Q3W) for up to 35 cycles (cycle=21 days) or until PD or discontinuation + MK-4830 800 mg IV Q3W up to 35 infusions + paclitaxel 80-100 mg/m^2 IV on days 1, 8, and 15 every 28-day cycle until PD or discontinuation or irinotecan 180 mg/m^2 180 mg/m^2 on day 1 every 14-day cycle until PD or discontinuation.
88909534|NCT05319730|Experimental|Pembrolizumab + MK-4830 + lenvatinib|Participants receive pembrolizumab 200 mg IV Q3W up to 35 cycles (cycle=21 days) until PD or discontinuation + MK-4830 800 mg IV Q3W up to 35 infusions + lenvatinib 20 mg oral administration every day until PD or discontinuation.
89429187|NCT02260323|Active Comparator|patient-tailored DMARDs|Patients use tailored DMARDs
89429188|NCT03803592|Experimental|Dyadic MCS program|"Participants from the experimental group will receive a dyadic multisensory and cognitive stimulation (MCS) programme.~The MCS program is a 15- week program. In the first 4 weeks, participants will attend the center-based Face-to-face (FTF) session twice a week (8 sessions), while in the remaining week (5th-15th Week), home-based sessions will be delivered by the caregivers with the PWD at home and was suggested to deliver the intervention 3 times/week at home. The home-based sessions will be supplemented with weekly telephone follow-up and two FTF sharing sessions over the intervention period."
89429189|NCT03803592|No Intervention|Control group|Participants from the control group will receive usual care and no intervention will be received.
89429190|NCT02067429|Experimental|Toric Intraocular lens|Toric intraocular lens implantation during standard cataract surgery
89429191|NCT02067429|Experimental|Limbal Relaxing Incisions|Limbal relaxing incisions during standard cataract surgery
89429192|NCT03434600|Active Comparator|Oxford|Patients receiving an Oxford UKA, which is the standard treatment for patients with medial osteoarthritis of the knee at our department.
89429193|NCT03434600|Experimental|Sigma|Patients receiving a Sigma UKA, which is the experimental treatment.
88909535|NCT05319730|Experimental|MK-2870|Participants will receive 4 mg/kg of MK-2870 via IV infusion on Days 1, 15, and 29 of each 42-day cycle until discontinuation.
88909536|NCT05319353|Experimental|Cohort 1: Maribavir 400 or 200 mg|Participants with greater than or equal to (>=) 12 to less than (<) 18 years of age will receive maribavir 400 milligrams (mg) (2*200 mg tablets) twice daily (BID) based on body weight >= 25 kilogram (kg) or 200 mg tablet BID based on body weight 10 to < 25 kg orally for up to 8 weeks treatment period (Day 0/Week 0 to Day 56/Week 8). The dosing regimen will be based on the participant's body weight and may be updated over the course of the study based on the internal interim analyses on PK, safety, and tolerability of at least 5 participants in each cohort.
88909537|NCT05319353|Experimental|Cohort 2: Maribavir 400 or 200 mg|Participants with >= 6 to < 12 years of age will receive maribavir 400 mg (2*200 mg tablets) BID based on body weight >= 25 kg or 200 mg tablet BID based on body weight 10 to < 25 kg orally for up to 8 weeks treatment period (Day 0/Week 0 to Day 56/Week 8). The dosing regimen will be based on the participant's body weight and may be updated over the course of the study based on the internal interim analyses on PK, safety, and tolerability of at least 5 participants in each cohort.
88909538|NCT05319353|Experimental|Cohort 3: Maribavir|Participants with 0 to < 6 years of age will receive maribavir based on PK modeling.
88909539|NCT05318937|Experimental|SAGE-718|Participants will receive SAGE-718 capsules, orally, once daily in the morning for 42 days.
88909540|NCT05318937|Placebo Comparator|Placebo|Participants will receive SAGE-718-matching placebo capsules, orally, once daily in the morning for 42 days.
88909541|NCT05318573|Experimental|Safety Run-in Phase|FF-10832 in combination therapy with pembrolizumab; FF-10832 will be dosed at 40 mg/m2 with a fixed dose of pembrolizumab (200 mg)
88909542|NCT05318573|Experimental|Urothelial Monotherapy - FF-10832 Expansion Phase|FF-10832 will be dosed at 40 mg/m2
88909543|NCT05318573|Experimental|Urothelial Combination - FF-10832 + pembrolizumab Expansion Phase|FF-10832 in combination therapy with pembrolizumab; FF-10832 will be dosed at 40 mg/m2 with a fixed dose of pembrolizumab (200 mg)
89197456|NCT04042545|Placebo Comparator|Placebo|Placebo inhalation with a device
89197457|NCT00951106|Experimental|Pyrimethamine/sulfdoxine (Fansidar)|Pyrimethamine/sulfdoxine (Fansidar)
89197458|NCT00852267|Active Comparator|High CHO, High SatFat Diet|
89197459|NCT00852267|Experimental|Low CHO, High SatFat Diet|
89429194|NCT02280954|Experimental|ICG injection group|This group will receive a single dose of ICG, infused over 40 minutes. During surgery, they will be imaged with a camera and an imaging probe the investigators have developed.
89429195|NCT02070861|Experimental|Comparing cardiac output changes|"Explore the relationship between changes in cardiac output measured with eosophagal Doppler, the volume-clamp-method and exhaled CO2 during ventricular pacing and passive leg raise.~Measurements with the volume-clamp-method were aborted due to technological difficulties."
88909544|NCT05318573|Experimental|NSCLC Monotherapy - FF-10832 Expansion Phase|FF-10832 will be dosed at 40 mg/m2
88909545|NCT05318573|Experimental|NSCLC Combination - FF-10832 + pembrolizumab Expansion Phase|FF-10832 in combination therapy with pembrolizumab; FF-10832 will be dosed at 40 mg/m2 with a fixed dose of pembrolizumab (200 mg)
88909546|NCT05317858|Experimental|Pembrolizumab with Exablate BBBD|Using Exablate Model 4000 Type 2 for the treatment of NSCLC brain metastases in subjects who are undergoing planned pembrolizumab monotherapy.
88909547|NCT05317858|Active Comparator|Control Arm (Pembrolizumab only)|subjects will undergo planned pembrolizumab monotherapy.
88909548|NCT05315232||Qualitative assessment|Survey (using validated quality of life assessment questionnaires) and one to one interviews of people and family members living with Glanzmanns Thrombasthenia
89197460|NCT00852267|Experimental|Low CHO, Low SatFat Diet|
89197461|NCT00372229|Experimental|Valganciclovir Cytomegalovirus (CMV) Prophylaxis|
89197462|NCT00372229|Active Comparator|Pre-emptive CMV Therapy|
89197463|NCT05301010|Experimental|Faceptor + Docetacel|Patients received a loading dose of Faceptor 8 mg/kg IV + docetaxel 75 mg/m^2 IV on Cycle 1 followed by Faceptor 6 mg/kg IV + docetaxel 75 mg/m^2 IV on the next 5 cycles (each cycle is 21 days)
89429196|NCT03432416|Experimental|Regimen 1: Continuous Usage|Contraceptive vaginal ring delivering a daily dose of Nestorone® and estradiol (NES-E2 CVR) worn continuously for 91 days.
89429197|NCT03432416|Experimental|Regimen 2: Cyclical Usage|Contraceptive vaginal ring delivering a daily dose of Nestorone® and estradiol (NES-E2 CVR) worn for 91 days, but is removed for 2 days each month (days 29-30, 59-60, and 90-91).
89197464|NCT05301010|Active Comparator|Herceptin + Docetacel|Patients received a loading dose of Herceptin 8 mg/kg IV + docetaxel 75 mg/m^2 IV on Cycle 1 followed by Herceptin 6 mg/kg IV + docetaxel 75 mg/m^2 IV on the next 5 cycles (each cycle is 21 days)
89429198|NCT02281032|Other|interRAI Palliative Care|"15 experimental nursing homes:~Caregivers of 15 participating nursing homes receive a training about the interRAI PC and the BelRAI webapplication~Caregivers of 15 experimental nursing homes fill out the interRAI PC multidisciplinary every three months during one year for all nursing home residents with palliative care needs. Based on the results (Client Assessment Protocols and Scales) of the interRAI PC instrument, care plans are being evaluated, adapted and designed."
89429199|NCT02281032|No Intervention|No interRAI Palliative Care|"15 control nursing homes:~- Caregivers of control nursing homes do not receive the intervention and provide care as usual"
89429200|NCT02070939|Experimental|SAD cohorts 1-7 Experimental Arm|
89197465|NCT00855777|Experimental|Etoricoxib|Etoricoxib 120 mg/day x 3 days
89429201|NCT02070939|Placebo Comparator|SAD Cohorts 1-7 Placebo Arm|
89429202|NCT02070939|Experimental|MAD cohorts 2-6 Experimental Arm|
89429203|NCT02070939|Placebo Comparator|MAD cohorts 2-6 Placebo Arm|
89429204|NCT02070939|Experimental|Japanese MAD cohort 7 Experimental arm|
89429205|NCT02070939|Placebo Comparator|Japanese MAD cohort 7 Placebo Arm|
89429206|NCT02805504|Experimental|Exparel|This arm will receive intraoperative local Liposomal Bupivacaine injection (Exparel) at the port placement site.
89429207|NCT02805504|Active Comparator|Marcaine|This group will receive will local bupivacaine HCl (Marcaine) injection at the port placement site.
89429208|NCT04450940|Experimental|PACV|The PACV arm received the PACV survey at baseline in order to assess the impact of administration on vaccine hesitancy. All participants received the PACV at 6-month follow up.
89429209|NCT04450940|Sham Comparator|Placebo|The placebo arm received a placebo survey on general childhood health topics at baseline. All participants received the PACV at 6-month follow up.
89429210|NCT02067507|No Intervention|Control|"LACDPH Site: CDC-developed small media in preferred language~AltaMed Health Services Corporation Site: Usual care - Standing order for the HPV vaccine; required web-based training module for medical assistants and nurses containing basic information on HPV, the HPV vaccine, and standing order implementation~Northeast Valley Health Corporation Site: Usual care"
89429211|NCT02067507|Experimental|Tailored education and referral|LACDPH Site: Tailored education and referral intervention administered at LACDPH Site
88909549|NCT05315232||Bleed diary|Daily bleed diary completion over 12 weeks
88909550|NCT05313555|Active Comparator|Ultraviolet lights (UV-B)|
89197466|NCT00855777|Active Comparator|Ibuprofen|Ibuprofen 1800 mg/day x 3 days
89197467|NCT04012294|Experimental|allopurinol|150 mg daily for a month then 300 mg daily for the rest of the study (5 months)
89197468|NCT00849459|Experimental|adenovirus-mediated human interleukin-12|starting dose of ADV-hIL12 - 1 x 10 to the 10th power vp (virus particles) per patient, escalating in half-log increments up to 1 x 10 to the 13th power vp per patient, after which dose escalation will be at lower increments of 2 x 10 to the 13th power vp, to a maximum of 3.0 x 10 to the 13th power vp per patient.
89429212|NCT02067507|Experimental|Staff training and patient reminders|Staff training and patient reminders administered at AltaMed Health Services Corporation Site
89429213|NCT02067507|Experimental|Clinic-level reminder systems|Clinic-level reminders administered at Northeast Valley Health Corporation Site
89429214|NCT03432338||idiopathic parkinson|Classical Parkinson´s disease, idiopathic
89429215|NCT03432338||secondary parkinsonism|parkinsonism due to other reasons than idiopathic
89429216|NCT03432338||controls|persona matched by age and gender, non parkinsonism
89429217|NCT02071251|Experimental|Prospective intervention|The skin and subcutaneous tissues were incised using a scalpel or cutting electrocautery. Use of coagulation current on the skin or subcutaneous tissues was not allowed, except focally to attain hemostasis. At the conclusion of surgery, a 7mm Jackson-Pratt drain was placed below Camper's fascia, which in turn was closed with 3-0 plain catgut suture. The skin was closed with staples. Dressings were retained for at least twenty-four hours. Staples were to be retained for at least two weeks.
89429218|NCT02281110||iFR/FFR assessment|Patients enrolled into this prospective registry will be derived from Stable Coronary Artery disease or Acute Coronary Syndrome (ACS) population undergoing cardiac catheterization. Patients with ACS may be evaluated by functional assessment in the non-culprit stenosis during the index PCI revascularization or in a staged procedure. The registry will enroll patients in whom physiological assessment (iFR/FFR) is particularly helpful in identifying haemodynamically significant stenosis: MVD patients defined by patients with lesions > 40% and <100% in 2 or more vessels.
89429219|NCT02783508|Active Comparator|IV Meperidine|Intravenous injection of meperidine 50mg given in 100cc NaCl 0.9% over 10 minutes. Repeated doses (if needed) will be given in intervals of 2 hours minimum until a maximum of 4 doses.
89536211|NCT04996485|Experimental|Experimental group №2 (Ustekinumab)|Ustekinumab - subcutaneous injections in the shoulder on schedule 0; 1 month, then every 2 months up to 52 weeks of therapy.
88909551|NCT05313555|Experimental|Ultraviolet lights (UV-C)|
88909552|NCT05309993|Active Comparator|Posterior Tibial Nerve Stimulation (PTNS)|Women randomized to the PTNS will be scheduled for sessions once weekly for 30 minutes, for 12 weeks total. The patient sits reclined with their legs elevated on a foot rest. After alcohol swab, a 34 gauge needle is inserted percutaneously 5 cm cephalad to the medial malleolus of the right or left ankle (patient's choice) at a 60 degree angle. A surface electrode is placed on the medial ipsilateral heel. The needle and electrode are connected to a low voltage (9V) electrical stimulator. Stimulation current with a fixed frequency of 20 Hz and a pulse width of 200 μsec is increased until flexion of the big toe or fanning of all toes visualized, or until the woman reports a tingling sensation across the heel or sole of the foot. The current is then set to the highest level of tolerable to the patient (0-10 mA) and then she undergoes therapy for 30 minutes.
89197469|NCT00698828|Experimental|Group 1|SUN11031 for injection, low dose, twice daily for 12 weeks
89197470|NCT00698828|Experimental|Group 2|SUN11031 for injection, higher dose, twice daily for 12 weeks
89197471|NCT00698828|Placebo Comparator|Group 3|Placebo injection, twice daily for 12 weeks
89197472|NCT00619515|Experimental|CyberKnife® stereotactic radiosurgery|
89197473|NCT03469843||Patients|patients with transposition of the great arteries long after repair with the arterial switch operation
89429220|NCT02783508|Active Comparator|Inhaled Nitrous Oxide|Nitrous oxide in a 50/50 mix with oxygen given via self-administered face mask. The parturient will be advised to place the mask tightly on her face and to breathe through it at the first sign of forthcoming uterine contraction. Between contractions, the parturient will be advised not to breath through the mask.
89429221|NCT03434288||Diabetic patients with foot osteomyelitis|Biological and MRI signs of foot osteomyelitis
89429222|NCT02071329|Experimental|Vaccine FP-01.1|Vaccine FP-01.1
89429223|NCT02071329|Placebo Comparator|Placebo|Placebo
89429224|NCT03439592||hyperglycemic patients|diabetic patients admitted for STEMI and with hyperglycemia at hospital admission.
88909553|NCT05309993|Experimental|Home transcutaneous electrical nerve stimulation (TENS)|"Women randomized to the TENS group will be asked to purchase a TENS 7000 device (estimated cost $30) and will administer self-treatment at home, daily for 20 minutes, for 12 weeks total.~TENS treatment will be performed as follows (adapted from the most common setting from a s systematic review of TENS for OAB):~- Surface electrodes, 2 x 2 in diameter, will be placed 5 cm cephalad to the medial malleolus of the right or left ankle (patient's choice). The second surface electrode is placed on the medial aspect of the ipsilateral calcaneus. The electrodes are connected to the TENS device with pre-set settings.~Women will complete 20-minute daily TENS treatment for 12 weeks total."
88909554|NCT05308862|Experimental|Intervention|Cluster randomization is going to take place via a computerized program prior to the workshops meaning that only those nurse aides, registered nurses and managers working in nursing homes allocated to the intervention group are going to develop an intervention together with the research group and then test it.
88909555|NCT05308862|No Intervention|Control|Continue with usual care.
88909556|NCT05307796|Experimental|Semantic Feature Analysis plus metacognitive strategy training|Participants attend three treatment sessions per week for eight weeks. Treatment sessions include: strategy education (participants learn about anomia, circumlocution, and circumlocution's purpose), Semantic Feature Analysis plus strategy application (participants build self-awareness and practice circumlocution), and strategy debriefing (participants reflect and receive feedback on their performance, and generate scenarios in which they could use the strategy in everyday life).
88909557|NCT05306340|Experimental|Giredestrant plus Everolimus|
88909558|NCT05306340|Active Comparator|Physician's Choice of Endocrine Therapy plus Everolimus|The physician's choice of endocrine therapy is defined as either exemestane, fulvestrant, or tamoxifen.
88909559|NCT05296798|Other|Induction Therapy: Phesgo plus Taxane-Based Chemotherapy|
88909560|NCT05296798|Active Comparator|Arm A, Maintenance Therapy: Phesgo|
88909561|NCT05296798|Experimental|Arm B, Maintenance Therapy: Giredestrant plus Phesgo|
88909562|NCT05289037|Experimental|Arm 01|mRNA-1273 administered through 0.2 mg/ml intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years) N=100
88909563|NCT05289037|Experimental|Arm 02|0.1 mg/ml of mRNA-1273.351 and 0.2 mg/ml of mRNA-1273.529 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years) N=100
88909564|NCT05289037|Experimental|Arm 03|0.1 mg/ml of mRNA-1273.351 and 0.2 mg/ml of mRNA-1273.529 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 and Day 57 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years) N=100
88909565|NCT05289037|Experimental|Arm 04|0.2 mg/ml of mRNA-1273.617.2 and 0.2 mg/ml of mRNA-1273.529 administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years) N=100
88909566|NCT05289037|Experimental|Arm 05|0.2 mg/ml of mRNA-1273.529 administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years) N=100
89429225|NCT03439592||normoglycemic patients|diabetic patients admitted for STEMI and with normoglycemia at hospital admission.
89429226|NCT02071407|Placebo Comparator|N1(traditional treatment group)|Patients in group N1 are treated with basic therapeutic measures which include reducing intracranial pressure with mannitol, hemostasis, acid inhibition, anti-infection, nutrition support and control of blood glucose, blood pressure and body temprature.
89429227|NCT02071407|Experimental|N2(midazolam group)|Patients in group N2 was treated with intravenous infusion of midazolam on the basis of basic treatment measures which include reducing intracranial pressure with mannitol, hemostasis, acid inhibition, anti-infection, nutrition support and control of blood glucose, blood pressure and body temprature.
89429228|NCT03432104|Experimental|Verum|This arm receives 1 x 450 mg-capsule of Oxxynea®, a blend of polyphenol-rich fruit and vegetable extracts
89429229|NCT03432104|Placebo Comparator|Placebo|This arms receives 1 x 450 mg-capsule of Placebo, containing maltodextrin only
89429230|NCT02071485||No treatment|Subjects in this study will receive no treatment and rather will only be trained in using the motor imagination-based BCI system
89429231|NCT03434210|Experimental|LAT-treated Community Model|The subjects in experimental group are on 'LAT-treated Community Model'. which means,beside care as usual, subjects will be treated by paliperidone palmitate, Psychiatrists will guide community mental health professinals about the treatment and management. Psychiatrists will give community mental health professinals and patients/ caregiver long acting injection related education information.
89429232|NCT03434210|Other|Care as usual|"The subjects in control group are on  cared as usual Which means Patients will be managed follow the request of National Continuing Management and Intervention Program for Psychoses. Patients will managed by community mental health professionals, get education information and rehablitation guidence from them."
88909567|NCT05289037|Experimental|Arm 06|0.2 mg/ml of mRNA-1273.529 and mRNA-1273 0.2 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years) N=100
88909568|NCT05289037|Experimental|Arm 07|500 mcg/mL of BNT162b2 (Wildtype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years) N=50
89197474|NCT00941746|Experimental|Lowest dose of PG110|single, slow intravenous infusion
89429233|NCT02281266|Experimental|treatment (T)|"The patients of treatment arm will be administered subcutaneously Thymalfasin at dose of 1.6mg twice a week for 12 months after curative resection, followed by 12 months observation.~Nucleoside analog plan to give to HBV DNA positive patients."
89429234|NCT02281266|Other|control (C)|"The patients of control arm will be followed up for 2 years periodically after curative resection, without the investigational product (Thymalfasin) therapy.~Nucleoside analog plan to give to HBV DNA positive patients."
89429235|NCT02065089|Experimental|playing the ipad quiz game|There will only be one arm--any patient who consents to participate in the intervention (playing the ipad quiz game)
89429236|NCT03432026||Non-smoker COPD patients|stable non-smoker COPD patients diagnosed by a previous spiromtery to have FEV1/FVC less than 70
89429237|NCT00625326|Experimental|75 µg/g COL-121 Ointment|75 µg/g COL-121 Ointment
89429238|NCT00625326|Experimental|150 µg/g COL-121 Ointment|150 µg/g COL-121 Ointment
89429239|NCT00625326|Experimental|300 µg/g COL-121 Ointment|300 µg/g COL-121 Ointment
89429240|NCT00625326|Active Comparator|50 µg/g Calcipotriene Ointment|50 µg/g Calcipotriene Ointment (active control)
89429241|NCT00625326|Placebo Comparator|Placebo Ointment|Placebo Ointment
89429242|NCT02065167|Experimental|Cultured autologous Mesenchymal Cells|"Cultured Mesenchymal Cells from bone marrow isolation, expanded under GMP protocol in associated facilities and introduced at the end of the appropriate forage up to the femoral head under fluoroscopic control.~20x106 cells per cc in a single administration of 7cc"
88909569|NCT05289037|Experimental|Arm 08|500 mcg/mL of BNT162b2 (Beta) and 500 mcg/mL of BNT162b2 (Omicron) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years) N=50
89429243|NCT03434054|Experimental|Losartan|single dose of 50mg losartan, tablet, over-encapsulated, to be taken orally
89429244|NCT03434054|Placebo Comparator|Placebo|single dose of placebo (main ingredient microcrystalline cellulose), tablet, over-encapsulated, to be taken orally
89429245|NCT02071563|Active Comparator|CSB14|Isocaloric amount and cost-effectiveness of CSB14 (with whey protein concentrate and enhanced micronutrient profile), prepared with fortified vegetable oil (FVO).
89429246|NCT02071563|Active Comparator|RUSF1|Isocaloric amount and cost-effectiveness of Ready-to Use Supplementary Food 1(RUSF1), USAID's Lipid-Based Nutrient Supplement (LNS) product
88909570|NCT05289037|Experimental|Arm 09|500 mcg/mL of BNT162b2 (Omicron) administered through intramuscular injection in the deltoid muscle on Day 1 and Day 57 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years) N=50
88909571|NCT05289037|Experimental|Arm 10|500 mcg/mL of BNT162b2 (Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years) N=50
88909572|NCT05289037|Experimental|Arm 11|500 mcg/mL of BNT162b2 (Beta) and 500 mcg/mL of BNT162b2 (Wildtype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years) N=50
88909573|NCT05289037|Experimental|Arm 12|500 mcg/mL of BNT162b2 (Omicron) and 500 mcg/mL of BNT162b2 (Wildtype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years) N=50
88909574|NCT05289037|Experimental|Arm 13|500 mcg/mL CoV2 preS dTM-AS03 [D614] (prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years) N=50
89429247|NCT02071563|Active Comparator|SC+|Isocaloric amount and cost-effectiveness of Supercereal Plus (SC+), the FBF used by WFP, which has an enhanced nutrient profile, dairy ingredient (non-fat dry milk), and oil already embedded into the flour
89429248|NCT02071563|No Intervention|CSB+|Isocaloric amount and cost-effectiveness of Supercereal/CSB+ prepared with FVO.
89429249|NCT04472988|Experimental|Eye Movement Desensitization and Reprocessing|"30 participants will be randomly allocated to the EMDR group. They will receive a 90 minutes session of EMDR each week for twelve weeks. The sessions will be conducted by clinicians or psychotherapists specialized in EMDR, and the participants will be randomly allocated to them.~EMDR is a structured, goal-oriented, short-term intervention organized around traumatic or stressful memories. This method was discovered in 1981 by F. Shapiro and represented an evidence-based treatment, one of the two first-line trauma treatment recommended for use with adults (NICE, 2005; World Health Organization, 2013). EMDR proved effective by hundreds of researches and has also been shown to be useful in alleviating physical symptoms such as pain or increased autonomic activity. But to our knowledge, research on EMDR efficacy in the treatment of autoimmune thyroiditis has not been previously reported."
89429250|NCT04472988|Placebo Comparator|Placebo|30 participants will be randomized to the placebo group. The placebo goup will receive an intervention that does not include working on past traumatic memories, it will be more focused on present and future.
89429251|NCT04472988|Active Comparator|Treatment as Usual|30 participants will be randomized to this group. They will continue only the medical treatment for Hashimoto their doctor prescribed to them.
89429252|NCT03433976|Other|Hyperbaric Bupivacaine|spinal anesthesia for planned cesarean sections control group
89429253|NCT03433976|Active Comparator|Hyperbaric Prilocaïne|spinal anesthesia for planned cesarean sections
88909575|NCT05289037|Experimental|Arm 14|500 mcg/mL CoV2 preS dTM-AS03 [B.1.351] (Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years) N=50
89197475|NCT00941746|Experimental|Second dose of PG110|single, slow intravenous infusion
89429254|NCT04473144|No Intervention|Control|Anesthesia induction and maintenance and postoperative recovery management were performed according to the standard anesthesia protocol for off pump coronary artery bypass surgery.
89429255|NCT04473144|Sham Comparator|Ulistin|"In the Ulistine administration group, 300,000 KIU was mixed with 100 mL physiological saline and administered over 15 minutes after induction of anesthesia.~Anesthesia induction and maintenance and postoperative recovery management were performed according to the standard anesthesia protocol for off pump coronary artery bypass surgery."
89429256|NCT04451564|Experimental|MORE Mindfulness oriented recovery enhancement group|MORE Mindfulness oriented recovery enhancement group
89429257|NCT04451564|No Intervention|Control|wait-list
89429258|NCT02605642||CT-P13|biosimilar infliximab
89429259|NCT02283450||the experimental group|The patients in experimental group received the relevant tests and inspections before the beginning of experiment，signed the informed consent. Then we get the venous blood centrifugalization and cryopreservation. The patients take the medicine qiliqiangxin three times per day，four tablets at a time. Afrer a month，we evaluated the symptoms，the function of heart，blood pressure，heart rate and keep blood specimens. Three and six month later，electrocardiogram and echocardiography were taken and the determination of the NT - proBNP was done.
89429260|NCT02283450||the placebo group|The placebo group was followed up in the same way.
89429261|NCT03128450|Experimental|h-NSC arm|"human neural stem cell: 100ul/vessel，2 vessel/one bag，≥2×10 6cells/vessel，produced by Shanghai Angecon Biotechology Cooperate.~One enrolled PD patient was given 2 vessels h-NSC througth nasal cavity weekly for 4 weeks。Total cell number will be over ≥4×10 6cells for one time."
89429262|NCT00624858|Experimental|NB32|Naltrexone SR 32 mg/Bupropion SR 360 mg/ day
89429263|NCT02071797|Active Comparator|Arm A - Blanketroll lll|Cutaneous Cooling Blanket, Blanketroll lll, applied to cool patient to 32C. Standard care
89429264|NCT02071797|Active Comparator|Arm B - RhinoChill|Intra nasal cooling system, RhinoChill, to cool patient to 32C - Standard care
89429265|NCT03128528|Placebo Comparator|Placebo Oral Tablet|Patients will be randomized to empagliflozin 10 mg orally once daily or one placebo tablet orally once daily.
89429266|NCT03128528|Active Comparator|Empagliflozin|Patients will be randomized to empagliflozin 10 mg orally once daily or one placebo tablet orally once daily.
89429267|NCT02071641|Experimental|Sunitinib|Patients will be treated in repeated 6-week cycles with 50 mg sunitinib orally daily for 4 weeks followed by 2 weeks off.
89429268|NCT02253810|Experimental|Tranexamic Acid|Patients randomized to this arm will receive standard dosing of tranexamic acid intraoperatively.
89429269|NCT02253810|Placebo Comparator|Placebo|Patients randomized to this arm will receive normal saline solution, instead of tranexamic acid, intraoperatively.
89197476|NCT00941746|Experimental|Third dose of PG110|single, slow intravenous infusion
89197477|NCT00941746|Experimental|Fourth dose of PG110|single, slow intravenous infusion
89197478|NCT00941746|Experimental|Fifth dose of PG110|single, slow intravenous infusion
89429270|NCT03128606|Experimental|GLPG3067 single dose|Single dose of GLPG3067 oral suspension at up to 6 dose levels in ascending order.
89429271|NCT03128606|Placebo Comparator|Placebo single dose|Single dose of Placebo oral suspension.
89429272|NCT03128606|Experimental|GLPG3067 oral suspension fed 1|Single dose 1 of GLPG3067 oral suspension after a standardized breakfast.
89429273|NCT03128606|Experimental|GLPG3067 oral tablet fed 1|Single dose 1 of GLPG3067 oral tablet after a standardized breakfast.
89429274|NCT03128606|Experimental|GLPG3067 oral tablet fasted 1|Single dose 1 of GLPG3067 oral tablet after an overnight fast.
89429275|NCT03128606|Experimental|GLPG3067 oral tablet fed 2|Single dose 2 of GLPG3067 oral tablet after a standardized breakfast.
89429276|NCT03128606|Experimental|GLPG3067 oral tablet fed 2 high-fat high-calorie|Single dose 2 of GLPG3067 oral tablet after a high-fat high-calorie breakfast
89429277|NCT03128606|Experimental|GLPG3067 multiple dose|Multiple doses of GLPG3067 oral suspension at up to 5 dose levels in ascending order.
89429278|NCT03128606|Placebo Comparator|Placebo multiple dose|Multiple doses of Placebo oral suspension.
89197479|NCT00941746|Experimental|Top dose of PG110|single, slow intravenous infusion
89197480|NCT00941746|Experimental|Placebo|single, slow intravenous infusion that matches PG110 in appearance
89197481|NCT00941746|Experimental|Seventh Dose of PG110|single, slow intravenous infusion
89197482|NCT00941746|Experimental|Eight Dose of PG110|single, slow intravenous infusion
89197483|NCT00852423|Experimental|DHAPQ|Three-day treatment with dihydroartemisinin-piperaquine
89197484|NCT00852423|Experimental|MQAS|Three-day treatment with mefloquine artesunate
89197485|NCT00852423|Active Comparator|AQAS|Three-day treatment with artesunate-amodiaquine
89197486|NCT00852423|Active Comparator|AL|Three day treatment with artemether-lumefantrine (Coartem(R)
89429279|NCT03128606|Experimental|GLPG3067/GLPG2222 multiple dose|Multiple doses of GLPG3067 oral suspension combined with GLPG2222 oral tablet up to 2 dose levels in ascending order.
89429280|NCT03128606|Placebo Comparator|GLPG3067/GLPG2222 Placebo multiple dose|Multiple doses of GLPG3067 matching placebo oral suspension combined with GLPG2222 matching placebo oral tablet.
89429281|NCT03128606|Experimental|GLPG3067/GLPG2222/GLPG2737 multiple dose|Multiple doses of GLPG3067 oral tablet combined with GLPG2222 oral tablet and GLPG2737 oral capsule at up to 2 dose levels in ascending order.
89429282|NCT03128606|Placebo Comparator|GLPG3067/GLPG2222/GLPG2737 Placebo multiple dose|Multiple doses of GLPG3067 matching placebo oral tablet combined with GLPG2222 matching placebo oral tablet and GLPG2737 matching placebo oral capsule.
89429283|NCT02071719||Sunitinib|
88909576|NCT05289037|Experimental|Arm 15|500 mcg/mL CoV2 preS dTM-AS03 [D614 + B.1.351] (prototype + Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years) N=50
88909577|NCT05289037|Experimental|Arm 16|100 mcg/mL BNT162b2 bivalent (wildtype and Omicron BA.1) + Wildtype (Prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 49 years; ( 45% in > / = 49 years) N=100
88909578|NCT05289037|Experimental|Arm 17|100 mcg/mL BNT162b2 bivalent (wildtype and Omicron BA.4/BA.5) + Wildtype (Prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 49 years; ( 45% in > / = 49 years) N=100
88909579|NCT05287906|Experimental|Normal Weight Group|The normal weight group incudes men and women with BMI 18.5 - 24.9 kg/m2, and will receive all interventions.
88909580|NCT05287906|Experimental|Overweight Group|The overweight group includes men and women with BMI 25.0 - 29.9 kg/m2, and will receive all interventions.
89197487|NCT00849537|Experimental|Triamcinolone|Injection of intravitreal Triamcinolone
89429284|NCT02071719||Sorafenib|
89429285|NCT02071719||Everolimus|
89429286|NCT02071719||Pazopanib|
89429287|NCT02071719||Axitinib|
89429288|NCT00624390|Experimental|Sepraspray|Sepraspray applied directly to both sides of the uterus, Fallopian tubes, and ovaries (or opposing sites if not possible to apply directly). Sepraspray was applied via a sterile cannula at a tissue concentration of approximately 5 mg/cm^2.
89429289|NCT00624390|No Intervention|Control|No anti-adhesion treatment was used.
89429290|NCT04411966|Experimental|18F-fluorothymidine PET|Patients receive fluorothymidine F-18 IV over 1 minute and undergo PET scan over 60 minutes at least 10 days prior to systemic chemotherapy, and at least 10 days after first and second cycles of systemic chemotherapy.
89429291|NCT00621894|Experimental|LGD4665|LGD-4665: Experimental Thrombopoietin mimetic
89429292|NCT00621894|Placebo Comparator|Placebo|Placebo
89536212|NCT04996485|Experimental|Experimental group №3 (Dupilumab)|"Dupilumab - subcutaneous injections in the shoulder:~for patients weighing from 15 to <30 kg: initial dose - 600 mg (2 injections of 300 mg), then 300 mg every 4 weeks; for patients weighing from 30 to <60 kg: initial dose - 400 mg (2 injections of 200 mg), then 200 mg every 2 weeks; for patients weighing 60 kg or more: the initial dose is 600 mg (2 injections of 300 mg), then 300 mg every 2 weeks."
89429293|NCT04806490||Chinese participants with Yin Deficiency Syndrome|"The participants with Yin Deficiency syndrome were included in this study. Chinese Medicine Experts evaluated the main symptoms of Yin Deficiency syndrome, diagnosed those participants.~And the participants were measured by the standard scale for syndrome differentiation of Yin Deficiency syndrome. The participants were followed up for 12 months to observe whether there were any manifestations of Yin Deficiency syndrome during the observation period."
89429294|NCT04806490||Chinese participants without Yin Deficiency Syndrome|"The participants without Yin Deficiency syndrome were included in this study. Chinese Medicine Experts evaluated the main symptoms of Yin Deficiency syndrome, diagnosed those participants.~And the participants were measured by the standard scale for syndrome differentiation of Yin Deficiency syndrome. The participants were followed up for 12 months to observe whether there were any manifestations of Yin Deficiency syndrome during the observation period."
89429295|NCT02065323|Active Comparator|ADT alone|Standard androgen deprivation therapy (LHRH analogue or orchiectomy)
89429296|NCT02065323|Experimental|ADT plus Dovitinib|"Standard androgen deprivation therapy (LHRH analogue or orchiectomy)~Dovitinib 500 mg/day given on a five-days-on-two-days-off schedule. One cycle equals 28 days. Cycles will repeat continuously until disease progression, or removal from study for other reasons."
89429297|NCT02521454|Experimental|MBRT|Mindfulness-Based Resilience Training
89429298|NCT02521454|No Intervention|WL Control|waitlist control group
89429299|NCT02283684|Active Comparator|Greenlight laser PVP|Greenlight (532-nm) laser Photoselective vaporization of the prostate using (XPS) 180W system
89429300|NCT02283684|Active Comparator|Bipolar TUVP|Bipolar transurethral vaporization of the prostate using bipolar system
89429301|NCT02071953|Experimental|Adhesive without acid pretreatment|Experimental adhesive w/out phosphoric acid in post. rest.
89429302|NCT02071953|Active Comparator|Adhesive with acid pretreatment|Experimental adhesive with phosphoric acid in post. rest.
89429303|NCT04806256|Experimental|CDSS group|Subjects' treatment regimens were influenced by the CDSS, which was the recommended system for Tradictional Chinese Medicine treatment of dry eye.
88909581|NCT05287906|Experimental|Type 2 Diabetes Mellitis Group|The T2DM group includes men and women with BMI 25.0 - 34.9 kg/m2, HbA1c <8%, and will receive all interventions.
88909582|NCT05286814|Experimental|1/ HAIP +M9241+FOLFOX or FOLFORI|M9241+HAIP FUDR and Dexamethasone chemotherapy in combination with FOLFOX or FOLFIRI
88909583|NCT05286814|Experimental|2/HAIP +M9241+GemOx|M9241+HAIP FUDR and Dexamethasone chemotherapy in combination with GemOx
88909584|NCT05285761|Experimental|paper brochure + smartphone application|Parents will receive the paper brochure (new communication support developed by Santé publique France (the French Public Health Agency)), which is the current official information on complementary feeding (CF) in France. They will also receive the new recommendations relating to complementary feeding through an educational device in the form of a smartphone application. This app will deliver information and very short videos illustrating various aspects of responsive feeding during CF and taking up the themes of the paper brochure. These 106 messages will be delivered regularly from the 3rd month until the 36th month of the child. Parents will also receive generic information (48 messages) contained in the health record and in connection with the general development.
88909585|NCT05285761|Active Comparator|paper brochure|Parents will receive the paper brochure (new communication support developed by Santé publique France (the French Public Health Agency)), which is the current official information on complementary feeding (CF) in France. Parents will also receive generic information (48 messages) contained in the health record and in connection with the general development.
89429304|NCT04806256|Active Comparator|non-CDSS group|The treatment of the subjects was routine and not affected by the CDSS for Tradictional Chinese Medicine.
89429305|NCT03431870|Other|Aorta dilated|Patients with aorta of 40mm or more who undergo a cardiac surgery. The intervention include: Trans-Esophageal Echocardiography
89429306|NCT00673062|Experimental|SCH 900538|
89429307|NCT00673062|Active Comparator|Encapsulated pseudoephedrine|Encapsulated pseudoephedrine (2X30 mg immediate release tablets)
89429308|NCT00673062|Placebo Comparator|Placebo Capsules|
89429309|NCT02260245|Other|Team training|All participating affiliates will undergo team training using the TeamSTEPPS model
89429310|NCT00504270|Placebo Comparator|Placebo|po daily
89429311|NCT00504270|Experimental|RG3421 120mg|120mg po daily
89429312|NCT00504270|Experimental|RG3421 20mg|20mg po daily
89429313|NCT04827082|Experimental|Diacutaneous fibrolysis group|Diacutaneous fibrolysis is a physiotherapeutic instrumental technique, used to treat musculoskeletal conditions causing pain and/or movement restriction. It is applied by means of metallic hooks, ending in a spatula with beveled edges. Regardless of its own dominance, diacutaneous fibrolysis will be applied to de following muscles and intermuscular septums: gluteus maximus, biceps femoris and semitendinosus to de lower experimental limb. A single session of 10 minutes will be applied.
88909586|NCT05282121|Experimental|Avenciguat (BI 685509) HBV treatment group|Hepatitis B Virus (HBV)
88909587|NCT05282121|Experimental|Avenciguat (BI 685509) HCV treatment group|Hepatitis C Virus (HCV)
89429314|NCT04827082|No Intervention|Control group|Participants will be used as their own controls, with one lower extremity randomly receiving intervention. The control extremity will not receive any intervention
89429315|NCT03559803|Experimental|Cisplatin|Weekly cisplatin (40 mg/m²) will be administered during radiotherapy. At least 3 cycles of cisplatin should be performed according to the hematological and renal functions but not mandatory.
89536213|NCT04996485|Active Comparator|Control group (Symptomatic therapy)|symptomatic therapy with emollients + systemic retinoids
89429316|NCT03439436|Experimental|xylo+dex nasal spray (0.1 mg+5 mg/dose)|Xylometazoline+Dexpanthenol metered nasal spray (0.1 mg+5 mg/dose) for nasal congestion. One spray into each nostril, 3 times daily for max 5 days.
89429317|NCT03439436|Active Comparator|Nasic|Xylometazoline+Dexpanthenol metered nasal spray (0.1 mg+5 mg/dose) for nasal congestion. One spray into each nostril, 3 times daily for max 5 days.
89429318|NCT00502710|Experimental|RO4876904 1|Escalating doses, at a starting dose of 12.5mg po daily. Patients receiving metformin before the study will continue on the same dose of metformin.
89429319|NCT00502710|Experimental|RO4876904 2|Escalating doses, at a starting dose of 12.5mg po daily. Patients receiving metformin before the study will continue on the same dose of metformin.
89429320|NCT00502710|Experimental|RO4876904 3|Escalating doses, at a starting dose of 12.5mg po daily. Patients receiving metformin before the study will continue on the same dose of metformin.
89429321|NCT00502710|Experimental|RO4876904 4|Escalating doses, at a starting dose of 12.5mg po daily. Patients receiving metformin before the study will continue on the same dose of metformin.
89429322|NCT00502710|Placebo Comparator|Placebo|Placebo po daily. Patients receiving metformin before the study will continue on the same dose of metformin.
89429323|NCT03439358|Experimental|Magnesium sulfate|Magnesium sulfate (MgSO4) infusion will be commenced prior to epidural top-up.
89429324|NCT03439358|Placebo Comparator|Normal saline|Normal saline infusion will be commenced prior to epidural top-up.
89429325|NCT02072031|Experimental|Anlotinib|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
89429326|NCT02072031|Active Comparator|Sunitinib maleate|Sunitinib 50 mg qd p.o., 4 weeks out of 6.The treatment continued until disease progression or intolerable toxicity happened or patients withdrawal of consent.
89429327|NCT04827160||COVID-19|Patients with COVID-19
89536214|NCT02447965|Active Comparator|Bupivacaine|Will have 20ml of bupivacaine injected into each rectus sheath.
89536215|NCT02447965|Placebo Comparator|Normal Saline|Will have 20ml of normal saline injected into each rectus sheath.
89429328|NCT03431792|Experimental|Long-Tail-FETO|"Fetus with severe CDH and o/e TFLV Ratio of < 25% or < 35% with liver herniation. The Long tail FETO will performed between 26 and 30 weeks of gestation.~The MRI control will be perfirmed ar 32-34 weeks of gestation. Long Tail FETO: fetal i.m. application of 0.1 mg/kg Pancuronium, 1 µg/kg Fentanyl® and 0.01 mg/kg atropine. (Long-Tail Goldbal 5, 2,5 ml, BALT Extrusion, Montmorency, France). The fetoscope (Karl Storz, Tuttlingen, Germany) with a diameter of 1.3 mm, will be percutaneously inserted through a sheath into the uterus and then into the fetal trachea. The fetoscope will be removed and the balloon will be inserted under 4-D ultrasound guidance into the fetal trachea. The position of the balloon and suture will be visualized using the fetoscopy.~The Long tail ballon will be removed by a second FETO after 34 weeks' gestation or bei the fetus itself with or without of the long tail balloon puncture with 22 gauge needle. The EXIT procedure is also possible."
88909588|NCT05282121|Experimental|Avenciguat (BI 685509) NASH treatment group|Non-Alcoholic Steatohepatitis (NASH)
88909589|NCT05282121|Experimental|Avenciguat (BI 685509) + empagliflozin NASH treatment group|
88909590|NCT05281471|Experimental|Olvi-Vec + Platinum-doublet & bevacizumab|"Olvi-Vec: A total of 2 consecutive days of intraperitoneal catheter infusions in Week 0~Platinum-doublet & bevacizumab (or biosimilar) administered beginning in Week 4 (preferred), but no later than Week 5"
88909591|NCT05281471|Active Comparator|Platinum-doublet & bevacizumab|Platinum-doublet & bevacizumab (or biosimilar) administered beginning in Week 0
88909592|NCT05275998|Experimental|Sentinel Group 1|10 HIV-1 infected subjects will receive one infusion of 2400 mg of each antibody, TMB-365 and TMB-380 and be followed for safety and pharmacokinetics. Oral suppressive cART will be continued throughout the course of the study participation.
88909593|NCT05275998|Experimental|Sentinel Group 2|10 HIV-1 infected subjects will receive one infusion of 3200 mg of each antibody, TMB-365 and TMB-380 and be followed for safety and pharmacokinetics. Oral suppressive cART will be continued throughout the course of the study participation.
88909594|NCT05275998|Experimental|Sentinel Group 3|10 HIV-1 infected subjects will receive one infusion of 4800 mg of each antibody, TMB-365 and TMB-380 and be followed for safety and pharmacokinetics. Oral suppressive cART will be continued throughout the course of the study participation.
88909595|NCT05275998|Experimental|Core Group 1|20 HIV-1 infected subjects will receive 4800 mg infusions of each antibody, TMB-365 and TMB-380 every 8 weeks and be followed for safety, pharmacokinetics, and ability to maintain antiviral activity. Oral suppressive cART will be discontinued for 24 weeks then resumed at week 24 with follow-up at week 52.
88909596|NCT05273450|Experimental|Quitline Information with Reinforcement|
89197488|NCT03167606|Experimental|Immediate Intervention|Study participants randomized to the immediate intervention arm will have access to the MyPEEPS Mobile from the baseline visit to 3-month follow-up visit. They will continue with follow-up visits at 6 months and 9 months, but will no longer have access to the MyPEEPS Mobile past the 3-month follow-up visit.
88909597|NCT05273450|No Intervention|Quitline Information Only|
88909598|NCT05268016|Experimental|ME3183 Dose 1, BID|Specified dose of ME3183 capsule for 16 weeks
88909599|NCT05268016|Experimental|ME3183 Dose 2, QD|Specified dose of ME3183 capsule for 16 weeks
88909600|NCT05268016|Experimental|ME3183 Dose 3, BID|Specified dose of ME3183 capsule for 16 weeks
88909601|NCT05268016|Experimental|ME3183 Dose 4, QD|Specified dose of ME3183 capsule for 16 weeks
88909602|NCT05268016|Placebo Comparator|Placebo|Placebo capsule of ME3183 for 16 weeks
88909603|NCT05268003|Experimental|Ponatinib|Participants will receive ponatinib (45mg daily) as a single agent for 3 days. These will be called Days -3, -2 and -1
88909604|NCT05268003|Experimental|Venetoclax|Patients will continue venetoclax 400mg daily on days 1-14 of each 28-day cycle.
88909605|NCT05268003|Experimental|Mini-hyper-CVD|Chemotherapy will be administered in the inpatient setting, starting on day 1 of each of the cycles 2-8.
88909606|NCT05266352|Experimental|Supervised exercise group|The group received the supervised exercise program
88909607|NCT05266352|Active Comparator|Home exercise group|The group received the home exercise program
89197489|NCT03167606|Experimental|Delayed Intervention|Study participants randomized to the delayed intervention arm will complete visits at baseline, 3 months, 6 months, 9 months, and 12 months. They will have access to the MyPEEPS Mobile from the 9-month follow-up visit until the 12-month follow-up visit.
89197490|NCT00951262|Experimental|life review|a life review program includes 3-session life review and formulation of a life review book as a gift for advanced cancer patients.
89197491|NCT00951262|No Intervention|controlled group|the subjects in the controlled group do not receive the life review program
89197492|NCT01049815|Experimental|Sevelamer hydrochloride|
89197493|NCT01049815|Active Comparator|Calcium carbonate|
89197494|NCT00849615|Experimental|FLOT|
89197495|NCT00688740|Experimental|TAC (Docetaxel)|docetaxel (75 mg/m^2) in combination with doxorubicin (50 mg/m^2) and cyclophosphamide (500 mg/m^2) on day 1 every 3 weeks for 6 cycles of treatment
89197496|NCT00688740|Active Comparator|FAC (5-fluorouracil)|5-fluorouracil (500 mg/m^2) in combination with doxorubicin (50 mg/m^2) and cyclophosphamide (500 mg/m^2) on day 1 every 3 weeks for 6 cycles of treatment
89197497|NCT01049893|Experimental|AC220|Dose finding study. Number of arms dependant upon dose limiting toxicities.
89197498|NCT00849771||1|Operative Treatment (Open Reduction Internal Fixation)
89197499|NCT00849771||2|Non-operative/Conservative Care
89197500|NCT00941902||Patients scheduled to bariatric surgery|
89197501|NCT04088942|Experimental|High-intensity group|"Will receive high-intensity intervention, which is a combination of pharmacological (varenicline) and behavioural support, described later."
88909608|NCT05266313|Experimental|Oncosexology program|Several workshops before and after the radical prostatectomy
88909609|NCT05266313|No Intervention|Usual care|Usual care of the urology department for patients with prostate cancer
88909610|NCT05265546|Experimental|Experimental|Psilocybin 0-14 mg, before fMRI measurement
88909611|NCT05265546|Other|Comparator|Psilocybin 0-14 mg, before fMRI measurement
88909612|NCT05263999|Experimental|Itolizumab (EQ001)|Itolizumab (EQ001) administered in a blinded fashion by intravenous infusion every 2 weeks for a total of 7 doses.
88909613|NCT05263999|Placebo Comparator|EQ001 Placebo|EQ001 Placebo administered in a blinded fashion by intravenous infusion every 2 weeks for a total of 7 doses
88922221|NCT05627856|Experimental|Study treatment|Participants receive GNC-038 as intravenous infusion for the first cycle (2 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
89008269|NCT04995263|No Intervention|Pre-intervention, control group|A basal measurement of primary and secondary outcomes of the target population, prior to the implementation the intervention. Estimated duration 3 months, n = 30.
89197502|NCT04088942|Active Comparator|Low-intensity group|Encouraged to quit smoking via own doctor and is prescribed varenicline.
89197503|NCT02545803|Other|study group|Adult patients (age ≥ 18 years) at the Intensive Care Unit (ICU) who become refractory to conventional mechanical ventilation and are switched to HFPV.
89197504|NCT02534857|Experimental|Intervention arm|Those allocated to the intervention arm, all the oocytes will be exposed to spermatozoa for 2 hours and gently wash through two organ dishes containing 1.5 ml of equilibrated medium, and then transferred to the corresponding microdroplet of equilibrated fresh medium. Surrounding cumulus cell will be retained, not removed from the ooctyes.
89197505|NCT02534857|Placebo Comparator|Control arm|Women who allocated to the control arm, all the oocytes will be exposed to spermatozoa for 20 hours, and checked for fertilization on day 1 (20 hours) after denuding
89197506|NCT00951340|Active Comparator|CBT with listening therapy|Participants will receive CBT with listening therapy.
89197507|NCT00951340|Experimental|CBT with emotional processing and interpersonal therapy|Participants will receive CBT with emotional processing and interpersonal therapy.
89197508|NCT00748332|Active Comparator|1|Standard oral nutritional supplement
89197509|NCT00748332|Experimental|2|Omega-3-enriched oral nutritional supplement
89536216|NCT05713175|Active Comparator|EVA plantar orthosis|Treatment consisting of a personalized plantar orthosis fabricated in 45º shore A hardness Ethyl Vinyl Acetate (EVA), which incorporates a 4mm heel rise and metatarsal dome placed proximal to the 2nd-3rd-4th metatarsal heads. No modifications applied to the patients' medial longitudinal arch.
88909614|NCT05263050|Experimental|Cabozantinib|Cabozantinib treatment will start at 40 mg of cabozantinib daily and dose escalate or de-escalate based on pre-specified criteria and at set dosing schedules to allow for smaller median dose changes between adjustments. The de-escalation would be fine-tuned and adjustments would be made in 10 mg average daily dosing increments by utilizing alternate day dosing schedules (e.g 60 mg/40 mg every other day) rather than decreasing by 20 mg. The maximum dose of cabozantinib is 60 mg daily. Cycles would be 28 days, with weekly follow-up for cycle 1 and bi-weekly follow-up for cycle 2 to allow for prompt dose adjustments, and then monthly. At each check-in, patients that have met the established protocol criteria and were not yet at the maximum dose of 60 mg daily would be eligible for dose-escalation. Patients would also be dose de-escalated as determined by the investigator. Patients who de-escalate may be allowed to re-escalate in the future.
88909615|NCT05263050|Experimental|Cabozantinib and nivolumab|Cabozantinib treatment will receive monthly fix-dosed nivolumab infusions, and start at 40 mg of cabozantinib daily and dose escalate or de-escalate based on pre-specified criteria and at set dosing schedules to allow for smaller median dose changes between adjustments. The de-escalation would be fine-tuned and adjustments would be made in 10 mg average daily dosing increments by utilizing alternate day dosing schedules (e.g 60 mg/40 mg every other day) rather than decreasing by 20 mg. The maximum dose of cabozantinib is 60 mg daily. Cycles would be 28 days, with weekly follow-up for cycle 1 and bi-weekly follow-up for cycle 2 to allow for prompt dose adjustments, and then monthly. At each check-in, patients that have met established protocol criteria and were not yet at the maximum dose of 60 mg daily would be eligible for dose-escalation. Patients would also be dose de-escalated as determined by the investigator. Patients who de-escalate may be allowed to re-escalate in the future.
88909616|NCT05261906|Experimental|LIBERATE Intervention|
88909617|NCT05258656|Experimental|Intervention|The intervention group will receive education about nutrition, resources, and specific instructions on promoting healthy development of their infant, including guidance regarding infant sleep, screen time, and building healthy relationships.
88909618|NCT05258656|Placebo Comparator|Control|The control group will receive specific instructions on promoting healthy development of their infant, including guidance regarding infant sleep, screen time, and building healthy relationships.
88909619|NCT05257408|Experimental|Nab-paclitaxel 80 mg/m^2 with Relacorilant 150 mg|Patients receive nab-paclitaxel 80 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle in combination with intermittent relacorilant (150 mg relacorilant once daily on the day before, the day of, and the day after nab-paclitaxel), administered orally under fed conditions. Relacorilant will not be administered on Cycle 1 Day -1.
88909620|NCT05257408|Active Comparator|Nab-paclitaxel 100 mg/m^2|Patients receive nab-paclitaxel 100 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle.
88909621|NCT05255718|Placebo Comparator|Control|The placebo supplement will have no polyphenol content and will consist of 100 mL of the following mixture: black cherry Koolaid, blue and red food coloring, sucrose and sorbitol. This placebo will match the sugar content of the chokeberry juice. Dose of 100 mL is consumed once daily for duration of 28-30 day supplementation period.
88909622|NCT05255718|Experimental|Aronia|100 mL of Aronia juice. Dose of 100 mL is consumed once daily for duration of 28-30 day supplementation period.
88909623|NCT05255068|Experimental|Staff|Start participants who enrolled in the study, received the OPTIMAL intervention, and were observed during data collection.
88909624|NCT05255068|Experimental|Resident|Resident participants who were cared in the study site, and received care from the staff participants before and after the OPTIMAL intervention was delivered to staff.
88909625|NCT05254002|Experimental|Finerenone and Empagliflozin|Participants will take Finerenone (10 or 20 mg once daily [OD]) and Empagliflozin (10 mg OD) for up to 180 days.
88909626|NCT05254002|Experimental|Finerenone and Empagliflozin placebo|Participants will take Finerenone (10 or 20 mg OD) and matching placebo to Empagliflozin (OD) for up to 180 days.
88909627|NCT05254002|Experimental|Empagliflozin and Finerenone placebo|Participants will take Empagliflozin (10 mg OD) and matching placebo to Finerenone (OD). for up to 180 days.
88909628|NCT05253651|Experimental|Tucatinib Arm|Tucatinib + trastuzumab + mFOLFOX6
88909629|NCT05253651|Active Comparator|Standard of Care Arm|mFOLFOX6 + (bevacizumab OR cetuximab). Either (1) mFOLFOX6, (2) mFOLFOX6 and bevacizumab, or (3) mFOLFOX6 and cetuximab
88909630|NCT05252351||Adults with congenital aortic stenosis|
88909631|NCT05243836|Active Comparator|MiSight®|MiSight® Contact Lens (Omafilcon A, 60% water)
88909632|NCT05243836|Experimental|S.T.O.P® F2|S.T.O.P® F2 Contact Lens (Ocufilcon D, 55% water)
88909633|NCT05243836|Experimental|S.T.O.P® DT|S.T.O.P® DT Contact Lens (Ocufilcon D, 55% water)
88909634|NCT05243342|Experimental|Dose escalation|Participants will receive escalating doses of XmAb24306 with daratumumab up to the maximum tolerated dose (MTD)
88909635|NCT05243342|Experimental|Dose expansion|Participants will receive XmAb24306 with daratumumab at the recommended phase 2 dose (RP2D)
88909636|NCT05241470|Active Comparator|Low Dose ST-100 Ophthalmic Solution|Low Dose ST100-001 Ophthalmic solution, 20mcg/ml
88909637|NCT05241470|Active Comparator|High Dose ST-100 Ophthalmic Solution|High Dose ST100-001 Ophthalmic Solution, 50mcg/ml
88909638|NCT05241470|Placebo Comparator|Placebo Ophthalmic Solution|Placebo Ophthalmic Solution (vehicle)
88909639|NCT05238285||Healthy adult population aged 18 to 80 years|Participants will be asked to produce vocal sounds of different nature according to the non-verbal parameters of interest for the given study.
88909640|NCT05237258|Experimental|Specialty Palliative Care|- Participants will complete baseline self-report assessments at the time of informed consent
88909641|NCT05237258|Experimental|Primary Palliative Care|- Participants will complete baseline self-report assessments at the time of informed consent
88909642|NCT05236296|Experimental|EASE-CG Intervention|"Participants will be offered one EASE-CG therapy session every week for up to 12 weeks. Each session will last for approximately 30-60 minutes, delivered by a trained therapist at our center. Frequency and/or length of sessions may vary to accommodate the needs and availability of each participant.~Outcomes will be assessed at baseline, 1, 3, 6, 9, and 12 months. Participants may be invited to brief, semi-structured interviews."
88909643|NCT05235815|Experimental|Sonoanatomy and retro SCTL compartment block|"During phase 1, ten healthy human volunteers will be involved. A bilateral ultrasound scan will be performed in the paravertebral region to describe the sonoanatomy of the retro SCTL compartment.~During phase 2, participants who are scheduled for video-assisted thoracoscopic surgery (VATS) will receive an ultrasound-guided multi-level (T3-4, T5-6 and T7-8) retro SCTL compartment block."
88909644|NCT05232032|Experimental|Participants with MDD or an anxiety disorder receiving the nociceptin receptor antagonist|After a diagnostic interview (determining the presence of MDD or an anxiety disorder) and collection of blood for Orphanin FQ/Nociceptin assays, participants will receive the nociceptin receptor antagonist. Participants will then complete an approach/avoidance task. Functional magnetic resonance imagining (fMRI) will begin 2 hours after the nociceptin receptor antagonist is administered.
88909645|NCT05232032|Placebo Comparator|Participants with MDD or an anxiety disorder receiving the placebo|After a diagnostic interview (determining the presence of MDD or an anxiety disorder) and collection of blood for Orphanin FQ/Nociceptin assays, participants will receive the placebo. Participants will then complete an approach/avoidance task. fMRI will begin 2 hours after the placebo is administered.
88909646|NCT05232032|Experimental|Healthy controls receiving the nociceptin receptor antagonist|After a diagnostic interview (determining healthy control status) and collection of blood for Orphanin FQ/Nociceptin assays, participants will receive a nociceptin receptor antagonist. Participants will then complete an approach/avoidance task. fMRI will begin 2 hours after the nociceptin receptor antagonist is administered.
88909647|NCT05232032|Placebo Comparator|Healthy controls receiving the placebo|After a diagnostic interview (determining healthy control status) and collection of blood for Orphanin FQ/Nociceptin assays, participants will receive the placebo. Participants will then complete an approach/avoidance task. fMRI will begin 2 hours after the placebo is administered.
88909648|NCT05231746|Experimental|hSTC810|6 escalating doses of hSTC810 will be administered to participants
88909649|NCT05230810|Experimental|Ib Safety Cohort /II Expansion Cohort|In phase Ib, the tolerability of tucatinib and alpelisib combination will be confirmed and maximum tolerated dose determined. Therapy will be administered in 28 day cycles of tucatinib 300 mg PO BID and alpelisib 250 mg PO daily (dose level 1). Treatment will continue until unacceptable toxicity, disease progression, withdrawal of consent, or study closure. Fulvestrant will also be administered in patients with HR+/HER2+ metastatic breast cancer. Once RP2D is determined, the study will be continued to phase II, and new patients will enroll at RP2D. All patients in phase IB part, who are remaining on study at the time of initiation of phase II, will be rolled over to phase II. At that time, their study drug doses will be modified as follows: (1) if a patient is on the drug doses lower than RP2D, doses will not be increased; (2) if a patient is on a higher doses compared to RP2D, doses of study drugs will be changed to RP2D.
88909650|NCT05229107|Active Comparator|Cereset Research|Intervention arm using 6 CR sessions
88909651|NCT05229107|No Intervention|Continued Current Care|Participants will continue their current care.
88909652|NCT05227703|Experimental|CVL-231 15 mg, once daily (QD)|Oral Dose
88909653|NCT05227703|Experimental|CVL-231 30 mg, once daily (QD)|Oral Dose
88909654|NCT05227703|Placebo Comparator|Placebo, once daily (QD)|Oral Dose
88909655|NCT05227690|Experimental|CVL-231 10 mg, once daily (QD)|Oral Dose
88909656|NCT05227690|Experimental|CVL-231 30 mg, once daily (QD)|Oral Dose
88909657|NCT05227690|Placebo Comparator|Placebo, once daily (QD)|Oral Dose
88909658|NCT05225792|Experimental|Injured Service Members|
88909659|NCT05225415|Active Comparator|CT1812 300 mg|CT1812 300 mg
88909660|NCT05225415|Active Comparator|CT1812 100 mg|CT1812 100 mg
88909661|NCT05225415|Placebo Comparator|Placebo|Placebo
88909662|NCT05224102|Experimental|Main Phase: Faricimab|Participants in the main study phase will receive 6-milligram (mg) faricimab intravitreal (IVT) injections once every 4 weeks (Q4W) up to Week 20, followed by 6-mg IVT faricimab injections once every 8 weeks (Q8W) up to Week 52. Participants will return for the Week 56 safety follow-up visit after ≥28 days following their last study treatment.
88909663|NCT05224102|Experimental|Long-Term Extension Phase: Faricimab|Eligible participants in the U.S. who opt to continue into the long-term extension (LTE) phase of this study will receive 6-mg faricimab IVT injections according to the personalized treatment interval (PTI) dosing algorithm. The minimum and maximum PTIs in the LTE are Q4W and once every 24 weeks (Q24W), respectively.
89197510|NCT02545569|Active Comparator|Hearing Device Type A|In the ear (ITE) hearing aid, 1-3 weeks wearing
89197511|NCT02545569|Experimental|Hearing Device Type B|In the ear (ITE) hearing aid, 1-3 weeks wearing
89197512|NCT05323058|Experimental|tulsi extract|4% tulsi extract as intervention
88909664|NCT05222932|Experimental|TILT-123 and avelumab|"Patients will receive multiple administrations of TILT-123 and avelumab.~Escalation to the next dose of TILT-123 level will occur when the safety data has been evaluated for all patients in the preceding dose level."
88909665|NCT05222373|No Intervention|Standard care|Standard care: will include the CHW curriculum focused on diabetes education and connecting individuals to appropriate resources in the community (materials in Spanish and English).
88909666|NCT05222373|Active Comparator|CBT-based lifestyle intervention group|CBT-based lifestyle intervention: standard care plus a theoretically-based, diet, activity, and mental health lifestyle intervention integrated within a culturally sensitive curriculum (materials in Spanish and English).
89429329|NCT05616442|Experimental|Group 1 as Vitamine E group|Vitamin E as standard therapy
88909667|NCT05216536||Long COVID|Adults who contracted COVID-19 and present at least one physical or cognitive long COVID-19 symptom for more than 12 weeks following the initial diagnosis.
89197513|NCT05323058|Active Comparator|benzydamine hydrochloride|0.15% benzydamine hydrochloride
89197514|NCT00849849||Postpartum GDM OGTT|200 women with prior GDM in their index pregnancies will undergo postpartum screening assessment. This program will follow these women who are at a high risk of developing DM2 after delivery for 1 year.
89197515|NCT00552760|Experimental|Ramelteon|8 mg
89197516|NCT00552760|Placebo Comparator|Placebo|
89197517|NCT01046773|Active Comparator|Children with Crohn's disease less than 35 kg|These are children ages 8 to 18 years inclusive, with mild to moderately active Crohn's disease.
89429330|NCT05616442|Experimental|Group two as Ketotifen group|Ketotifen as interventional
88909668|NCT05216536||Acute COVID|Adults who contracted COVID-19 but did not experience persistent symptoms for more than 4 weeks following the initial diagnosis.
88909669|NCT05216536||Control|Adults who did not contract COVID-19.
88909670|NCT05215717|Experimental|Self-Administered Hypnosis|Participants randomized to the self-administered hypnosis group will receive five audio-recordings of self-administered hypnosis, specifically targeting sleep improvement, which they will use for daily home practice.
88909671|NCT05215717|Active Comparator|White Noise Hypnosis Control|Participants randomized to the white noise hypnosis control will receive the same information and contact with the therapist but will be provided with audio recordings that contain white noise as a sham hypnosis condition. These recordings include instructions and the use of white noise as a hypnotic induction.
88909672|NCT05206513|Placebo Comparator|Placebo|Placebo dosed for 14 weeks followed by open-label valbenazine treatment for 32 weeks
89429331|NCT02072109||Bolus feeding|Preterm infants born in Meir Medical Center and being treated in the Neonatal Intensive Care Unit
88909673|NCT05206513|Experimental|Valbenazine|Valbenazine dosed for 14 weeks followed by open-label valbenazine treatment for 32 weeks
88909674|NCT05201066|Experimental|sabatolimab + azacitidine|Patients will take sabatolimab 800 mg i.v and azacitidine 75 mg/m2/d d1-7 s.c. or i.v./q4w or sabatolimab 400 mg i.v/q2w and azacitidine 75 mg/m2/d d1-7 s.c. or i.v./q4w.
88909675|NCT05201066|Experimental|sabatolimab + decitabine|Patients will take Sabatolimab 400 mg i.v/q2w and decitabine 20 mg/m2/d d1-5 i.v.
88909676|NCT05201066|Experimental|sabatolimab + venetoclax + azacitidine|Patients will take sabatolimab 200 mg i.v./q2w and venetoclax 400 mg p.o. d1-14/q4wk and azacitidine 75 mg/m2/d d1-7/q4w.
88909677|NCT05201066|Experimental|sabatolimab + spartalizumab + decitabine|Patients will take sabatolimab 400 mg i.v./q2w and decitabine 20 mg/m2/d d1-5 i.v. and spartalizumab 100 mg i.v/q2w.
88909678|NCT05201066|Experimental|sabatolimab + HMA|"Patients will take sabatolimab 800 mg and azacitidine 75 mg/m2/d d1-7 or decitabine 20 mg/m2/d d1-5/ all q4w~HMA means hypomethylating agents. Hypomethylating agents are azacitidine and decitabine."
88909679|NCT05201066|Experimental|sabatolimab|Patients will take sabatolimab 800 mg i.v q4w.
88909680|NCT05199311|Experimental|Starting Dose -1|"CC-220/Iberdomide: 1.1 mg [CC-220 dosing schedule: daily for 21 days of each 28-day cycle]~Carfilzomib: 20 mg/m2 C1D1 56 mg/m2 thereafter [Days 1, 8, 15 per 28-day cycle]~Dexamethasone: 40 mg (≤ 75 years) 20 mg (> 75 years) [Days 1, 8, 15, 22 per 28-day cycle]~Treatment will continue with carfilzomib, iberdomide, and dexamethasone for up to 4 cycles (28 days) at the physician's discretion followed by the Autologous Stem Cell Transplant. Patients will be followed every 3 months for up to 2 years, or until PD or the start of a new line of therapy."
89429332|NCT02072109||Continuous feeding|Preterm infants born in Meir Medical Center and being treated in the Neonatal Intensive Care Unit
89429333|NCT00498966|Experimental|Group A|Patients in group A will have previously failed a VEGF receptor inhibitor but not an mTOR inhibitor.Intervention: Perifosine.
89197518|NCT01046773|Active Comparator|Children with Crohn's disease 35 kg or greater|These are children ages 8 to 18 years inclusive, with mild to moderately active Crohn's disease.
89197519|NCT00745602|Experimental|1|Patients referred for elective direct current cardioversion (DCCV) of atrial fibrillation.
89197520|NCT00850005|Experimental|IVIG|Active treatment will be intravenous immunoglobulin G (Gamunex, immune globulin intravenous [human], 10%), at a dose of 2 g/kg divided over five days (0.4 g/kg/day).
89429334|NCT00498966|Experimental|Group B|Patients in group B will have failed both a VEGF receptor inhibitor and an mTOR inhibitor. Intervention: Perifosine.
89197521|NCT00850005|Placebo Comparator|Placebo|The placebo treatment will be intravenous normal saline and will be infused in a similar manner.
89197522|NCT04060706||Prostate Cancer|Adults suitable for radical image-guided radiotherapy for their Prostate cancer, approximately 170 patients Components from RTOG, LENT SOM(A), RMH symptom scale and UCLA PCI (prostate cancer index) questionnaires will be used.
89197523|NCT04060706||Head & Neck Cancer|Adults suitable for radical image-guided radiotherapy for their Head & Neck cancer, approximately 140 patients. Components from CTCAE v3, LENT SOM(A), EORTC QLQ H+N35 & Modified xerostomia questionnaires will be used.
89008270|NCT04995263|Experimental|Post-intervention, SUEÑA half bundle, active group 1|"Post-intervention, environmental and behavioral modifications in patient care interventions.~Implementation of components 1 through 4 of SUEÑA intervention in the entire PICU unit. All participants will be exposed to the intervention. Estimated duration: 3 months, n = 30."
89197524|NCT04060706||Central Nervous System Tumours|Adults suitable for radical image-guided radiotherapy for their CNS tumour, as many patients recruited as possible. Components from RTOG, LENT SOM(A), Folstein mini mental state examination & Generalised activites of daily living scale (G-ADL) questionnaires will be used.
89429335|NCT03439202|Other|No arm used|No drug use for this study. No arm used in this study. Subjects are exposed to hypoxic conditions (clinical study).
89429336|NCT04795570||Cases. Patients who develop urethral stricture|Patients who develop urethral stricture within 6 months after TUR P/B
89429337|NCT04795570||Controls. Patients who DO NOT develop urethral stricture|Patients who DO NOT develop urethral stricture within 6 months after TUR P/B
89197525|NCT04060706||Lung Cancer|Adults suitable for radical image-guided radiotherapy for their Lung cancer, as many patients recruited as possible. Components from RTOG & LENT SOM(A) questionnaires will be used.
89197526|NCT04012372|Experimental|ROSA water|Ad libitum hydration with ROSA oligomineral water
89197527|NCT04012372|Active Comparator|Control water|Ad libitum hydration with other waters
89429338|NCT02065401|Experimental|Deferitazole (disodium salt, granule)|
89429339|NCT02065401|Experimental|Deferitazole (disodium salt, tablet)|
89429340|NCT02065401|Experimental|Deferitazole (magnesium hydroxide salt)|
88909681|NCT05199311|Experimental|Dose Level 1|"CC-220/Iberdomide: 1.3 mg [CC-220 dosing schedule: daily for 21 days of each 28-day cycle]~Carfilzomib: 20 mg/m2 C1D1 56 mg/m2 thereafter [Days 1, 8, 15 per 28-day cycle]~CC-220 dose level 1 enrollment will occur following an independent safety review two months after the first 10 patients have completed at least 2 cycles of therapy at dose level -1.~Dexamethasone: 40 mg (≤ 75 years) 20 mg (> 75 years) [Days 1, 8, 15, 22 per 28-day cycle]~Treatment will continue with carfilzomib, iberdomide, and dexamethasone for up to 4 cycles (28 days) at the physician's discretion followed by the Autologous Stem Cell Transplant. Patients will be followed every 3 months for up to 2 years, or until PD or the start of a new line of therapy."
88909682|NCT05199311|Experimental|Dose Level 2|"CC-220/Iberdomide: 1.6 mg [CC-220 dosing schedule: daily for 21 days of each 28-day cycle]~Carfilzomib: 20 mg/m2 C1D1 56 mg/m2 thereafter [Days 1, 8, 15 per 28-day cycle]~CC-220 dose level 2 enrollment will occur following an independent safety review two months after the first 10 patients have completed at least 2 cycles of therapy at dose level 1.~Dexamethasone: 40 mg (≤ 75 years) 20 mg (> 75 years) [Days 1, 8, 15, 22 per 28-day cycle]~Treatment will continue with carfilzomib, iberdomide, and dexamethasone for up to 4 cycles (28 days) at the physician's discretion followed by the Autologous Stem Cell Transplant. Patients will be followed every 3 months for up to 2 years, or until PD or the start of a new line of therapy."
88909683|NCT05199311|Experimental|Dose Level -2|"CC-220/Iberdomide: 0.75 mg [CC-220 dosing schedule: daily for 21 days of each 28-day cycle]~Carfilzomib: 20 mg/m2 C1D1 56 mg/m2 thereafter [Days 1, 8, 15 per 28-day cycle]~Dexamethasone: 40 mg (≤ 75 years) 20 mg (> 75 years) [Days 1, 8, 15, 22 per 28-day cycle]~Treatment will continue with carfilzomib, iberdomide, and dexamethasone for up to 4 cycles (28 days) at the physician's discretion followed by the Autologous Stem Cell Transplant. Patients will be followed every 3 months for up to 2 years, or until PD or the start of a new line of therapy."
89429341|NCT00620256|Experimental|AL-37807|AL-37807 ophthalmic suspension, 0.1%, one drop in the study eye(s) at 8 AM, with latanoprost ophthalmic solution, one drop in the study eye(s) at 8 PM, for four weeks
89429342|NCT00620256|Active Comparator|Timolol|Timolol gel forming solution, 0.5%, one drop in the study eye(s) at 8 AM, with latanoprost ophthalmic solution, one drop in the study eye(s) at 8 PM, for four weeks
89429343|NCT00620256|Placebo Comparator|AL-37807 vehicle|AL-37807 ophthalmic solution vehicle, one drop in the study eye(s) at 8 AM, with latanoprost ophthalmic solution, one drop in the study eye(s) at 8 PM, for four weeks
89429344|NCT04450082||One anastomosis gastric bypass|One anastomosis gastric bypass in Sleeve Gastrectomy failure
89429345|NCT04795414||Vaccination Group|Participants vaccinated with inactivated SARS-CoV-2 vaccine are studied for safety and antibody response.
89429346|NCT02072187|Experimental|Active|"The vitamin D formula that will be used is Bio-D Mulsion 1000, produced by Biotics Research Corporation. This formula contains: Vitamin D (cholecalciferol), water and acacia gum and sesame oil.~Participants will be provided with a dose of vitamin D at each visit beginning at the Baseline visit. The weekly dose of vitamin D will be 28 000IU (the equivalent of 4000IU daily) for a period of eight weeks. If baseline or week 4 serum vitamin D levels are measured as >100nmol/L, the dose will be reduced to 14 000IU (the equivalent of 2000IU daily). The dose will be dispensed, using the bottle dropper, onto a disposable plastic spoon which the participant will insert into their mouth."
89429347|NCT02072187|Placebo Comparator|Placebo|"The placebo formula, also produced by Biotics Research Corporation, will contain all of the non-medicinal ingredients but no vitamin D. It will be identical in appearance and taste.~Participants will be provided with a dose of the placebo at each visit beginning at the Baseline visit. The weekly dose will be 28 drops or 14 drops if serum Vitamin D levels are >100nmol/L. The dose will be dispensed, using the bottle dropper, onto a disposable plastic spoon which the participant will insert into their mouth."
89429348|NCT00617526|Experimental|RDEA806 400 mg|Placebo or RDEA806 400 mg twice daily (BID) for 7 days and a single morning dose on Day 8.
89429349|NCT00617526|Experimental|RDEA806 600 mg|Placebo or RDEA806 600 mg once daily (QD) for 7 days with an additional dose on the morning of Day 8.
89429350|NCT00617526|Experimental|RDEA806 800 mg|Placebo or RDEA806 800 mg QD using enteric coated tablets for 7 days with an additional morning dose on Day 8.
89429351|NCT00617526|Experimental|RDEA806 1000 mg|Placebo or RDEA806 1000 mg QD using enteric coated tablets for 7 days with an additional dose on the morning of Day 8.
89429352|NCT04805710|No Intervention|clopidogrel combined with aspirin arm|Patients selected in the clopidogrel combined with aspirin arm will receive clopidogrel 75 mg once daily and aspirin 100 mg once daily.
89429353|NCT04805710|Experimental|clopidogrel combined with rivaroxaban arm|Patients selected in the clopidogrel combined with rivaroxaban arm will receive clopidogrel 75 mg once daily and rivaroxaban 10 mg once daily.
89429354|NCT02076477|Experimental|Arm A|"Patients receive concurrent chemoradiotherapy at first。Patients also receive chemotherapy every 3-4 weeks for two cycles after concurrent chemoradiotherapy.~chemotherapy：（1） squamous cell carcinoma：Docetaxel 60mg/m2 d1+Cisplatin 25mg/m2 d1-3.（2）non squamous cell carcinoma： pemetrexed 500mg/m2 d1+Cisplatin 25mg/m2 d1-3."
89429355|NCT02076477|Active Comparator|Arm B|"Patients receive neoadjuvant chemotherapy every 3-4 weeks for two cycles at first.Patients then receive concurrent chemoradiotherapy after neoadjuvant chemotherapy.~chemotherapy：（1） squamous cell carcinoma：Docetaxel 60mg/m2 d1+Cisplatin 25mg/m2 d1-3.（2）non squamous cell carcinoma： pemetrexed 500mg/m2 d1+Cisplatin 25mg/m2 d1-3."
89429356|NCT03433820|Experimental|randomized repeated biopsy|"The study will entail 1 cohort with a randomized repeated biopsy collection time. Three skin punch biopsies (3 mm) of the lower back will be taken from each volunteer on day 0. One biopsy sample taken on day 0 will serve as a baseline measurement for the repeated samples regarding the histology, immunohistochemistry, and RNA sequencing (RNA-seq) or real-time reverse transcription polymerase chain reaction (qRT-PCR) assessments.~Repeated biopsies of the same location as on day 0 will be taken on day 7, 14 or 21 (biopsy lesion and day randomized), and day 28, 42 or 56 (biopsy lesion and day randomized) for all subjects. The observation biopsy (biopsy lesion randomized) will serve as primary biopsy and followed for all measurements."
89429357|NCT04472832|Placebo Comparator|Treatment A|Participants will receive a single oral dose of mitapivat-matching placebo under fasted conditions on Day 1 of each of 4 periods.
89429358|NCT04472832|Experimental|Treatment B|Participants will receive a single oral dose of mitapivat 100 milligrams (mg) and placebo under fasted conditions on Day 1 of each of 4 periods.
89429359|NCT04472832|Experimental|Treatment C|Participants will receive a single oral dose of mitapivat 100 mg and placebo under high-fat meal conditions on Day 1 of each of 4 periods.
89429360|NCT04472832|Experimental|Treatment D|Participants will receive a single oral dose of mitapivat 300 mg under fasted conditions on Day 1 of each of 4 periods.
89429361|NCT02072265||Port-A implantation and chemotherapy|Patients scheduled for Port-A implantation and subsequent chemotherapy
89429362|NCT02072265||Port-A infection|Patients receiving Port-A removal due to infection
89429363|NCT03433664|Experimental|Treatment|Each treatment half of the scar received three standardised CO2 laser treatments using the DeepFX setting hand piece (Ultrapulse, Lumenis), performed under general anaesthetic at 4-6 week intervals. All treatments consisted of a single pass of 300Hz, 5% density and 50mJ energy with minimal overlapping. Post-operatively all laser treatment and control zones had emollient applied and silicone dressings which were removed at 48 hours. Further emollient was applied twice daily for 2 weeks to all areas of the scar. Standard care scar management (including silicone, massage and pressure garments) was directed by burn occupational therapists and was continued for all areas of scar.
89429364|NCT03433664|No Intervention|Control|Each control half of the scar received emollient applied twice daily for 2 weeks to all areas of the scar after each treatment. Standard care scar management (including silicone, massage and pressure garments) was directed by burn occupational therapists and was continued for all areas of scar.
89429365|NCT00615966|Experimental|1|
89429366|NCT00615966|Experimental|2|
89429367|NCT00615966|Placebo Comparator|3|
89429368|NCT02072343|Experimental|Mainstream capnometer|
88909684|NCT05198674|Experimental|Main Cohort: Renal Denervation|Renal angiography and Renal Denervation (Symplicity Spyral™ multi-electrode renal denervation system)
89429369|NCT02072343|Experimental|Microstream capnograph|
89429370|NCT03438968|Experimental|High-Intensity aerobic training|Individuals will exercise using a high-intensity interval exercise training protocol
89429371|NCT03438968|Active Comparator|Standard Moderate continuous training|Individuals will exercise using a standard moderate intensity continuous exercise training protocol
89429372|NCT02076555|Experimental|Education - Diabetes and Social Issues|"Patients randomized to this arm, will participate immediately in the education module Diabetes and Social Issues"
89429373|NCT02076555|No Intervention|Waiting-list control group|Patients in the control group will get the education with the education module after completion of the 6-month follow-up
89429374|NCT04879550||thrombotic event developing / not|Group I: Patients with no bleeding/thrombosis complications Group II: Patients with Thrombotic and/or thromboembolic complications Group III: Patients with bleeding complications
89429375|NCT02076633|Experimental|L19IL2 + L19TNF|One arm, intratumoral injections of 10 Mio IU of L19IL2 and 312 μg L19TNF. Weekly administration for all combined leasions
89429376|NCT00613002|Experimental|testosterone gel|1% testosterone transdermal gel
89429377|NCT00613002|Placebo Comparator|placebo gel|placebo transdermal gel
89429378|NCT02076711|Active Comparator|Active|Metoprololsuccinate
89429379|NCT02076711|Placebo Comparator|Placebo|Placebo
89429380|NCT02076789||ICD generator replacement|Patients with standard indications to ICD generator replacement
89429381|NCT00495222|Experimental|Tissue plication|The Endoscopic Suturing System (ESS) is used for tissue apposition and reduction of the size of a dilated GJ anastomosis in subjects who are regaining weight after successful weight loss following gastric bypass
89429382|NCT00492960|Experimental|Larazotide acetate 1 mg|larazotide acetate 1 mg capsules TID + 900 mg gluten capsules TID for 6 weeks
89429383|NCT00492960|Experimental|Larazotide acetate 4 mg|larazotide acetate 4 mg capsules TID + 900 mg gluten capsules TID for 6 weeks
88909685|NCT05195346||People Living with HIV (PLHIV)|Thai people living with HIV, aged 18 or above, who are on Antiretroviral Therapy (ART)
88909686|NCT05195346||HIV Healthcare Providers|Thai healthcare providers, including but not limited to doctors, nurses, counsellors, lay providers, pharmacists, lab technicians, etc., who take care of any persons living with HIV. All aged 18 or above
88909687|NCT05191745|Experimental|Intervention group|Patients will receive bilateral parasternal blocks at the end of cardiac surgery.
88909688|NCT05191745|Placebo Comparator|Control group|Patients will receive all standard care as per the hospital protocols.
88909689|NCT05189925|Experimental|IV infusion of gp91-Grans at dose K: 1e6 cells/kg|Adult CGD patients without systemic infection will participate in a dose-escalation trial to identify the most effective yet safe dose of study agent. Subjects enrolled will receive 1 administration of study agent at dose K, and safety of dose will be determined.
89429384|NCT00492960|Experimental|Larazotide acetate 8 mg|larazotide acetate 8 mg capsules TID + 900 mg gluten capsules TID for 6 weeks
89429385|NCT00492960|Placebo Comparator|Placebo|placebo capsules TID + 900 mg gluten capsules TID for 6 weeks
89429386|NCT02076945|Active Comparator|Healthy patients|Patients without diabetes and without peripheral neuropathy (based on the cross sectional area of the posterior tibial nerve 3 cm above the medial malleolus <19.01 mm2)
89429387|NCT02076945|Experimental|Diabetic patients without neuropathy|Patients with diabetes but without peripheral neuropathy (based on the cross sectional area of the posterior tibial nerve 3 cm above the medial malleolus <19.01 mm2)
89429388|NCT02076945|Experimental|Diabetic patients with neuropathy|Patients with diabetes and with peripheral neuropathy (based on the cross sectional area of the posterior tibial nerve 3 cm above the medial malleolus > 19.01 mm2)
89429389|NCT03438890|Experimental|Warm saline group|In subjects allocated to the warm saline group, a thermos flask, which was filled with heated sterile water, was used. A 1000 ml bottle of sterile water was heated to 60 ˚C in a stove for an hour at minimum. Just before introducing into the abdominal cavity, the laparoscope was placed into the thermos flask for 30 seconds at minimum . After each incidence of laparoscopic lens fogging (LLF), the scope was briefly inserted into the thermos flask about 10 seconds, and was then wrapped gauze around the lens before abdominal reinsertion.
89429390|NCT03438890|Experimental|anti-fog agent group|In the anti-fog agent group, Ultra-Stop TM (Sigmaphrarm, Vienna, Austria), which is a commercial anti-fogging solution containing alcohol, surfactant, and water for medical optical devices, was used. Wiping the lens with gauze soaked in Ultra-Stop TM and allowing the surfactant to act for 5 seconds, the laparoscope was introduced into the abdominal cavity. After each laparoscopic lens fogging (LLF), the scope was removed from the abdomen and cleaned using the same corresponding method.
89429391|NCT03438890|Experimental|chlorhexidine group|In the chlorhexidine group, the lens was wiped with gauze soaked in 4% chlorhexidine detergent solution (Firson, Cheonan, Korea) for 5 seconds before introducing into the abdominal cavity, and chlorhexidine was reapplied on the lens at the occurrence of laparoscopic lens fogging (LLF).
89429392|NCT03438890|No Intervention|control group|In the control group, the lens was not wiped gauze or applied any solution before use of the laparoscope. When occurred the event of each laparoscopic lens fogging (LLF) that splatter of irrigation fluid, blood, and body fluids affected visual clearance, the laparoscopic lens was manually rubbed with clean gauze by a scrub nurse.
89429393|NCT02077023||Asymptomatic Carotid Artery Disease, AF|
89429394|NCT03438812|Experimental|Poor ovarian responders with DHEA|Women who meet the Bologna criteria receive dehydroepiandrosterone (DHEA, 90 mg daily for two months at least) supplementation prior to the IVF cycle.
89429395|NCT03438812|No Intervention|Poor ovarian responders|Women who meet the Bologna criteria undergo the IVF cycle without pretreatment with DHEA
89429396|NCT03438812|No Intervention|Normal ovarian responders|Women who do not meet the Bologna criteria and have normal ovarian response to ovarian stimulation.
89429397|NCT02077101|Other|Quantitative study group|Patients complete questionnaires validated and published in the literature: Brief IPQ R and HIV PROQOL [28, 29]. The questionnaire RAVVIH therapeutic vaccine has been designed from the literature review and advice of the Scientific Council in particular Dr. Pierre Verger social scientist vaccination and experts on the perception of patients. It was tested on a sample of 15 PWLHA
89429398|NCT02077101|Other|Qualitative study group|"An interview guide was developed from the literature and expert community. Data will be collected through qualitative interviews with a psychologist trained to conduct interviews. Volunteers will be recruited according to the different categories of people representative of the HIV population in France.~These interviews will be conducted at the Foch Hospital. The physician investigator propose participation in the investigation and agree on a day appointment with the psychologist. Consent will be collected at that time after reading the prospectus . All interviews will be recorded orally with the agreement of the participants , and transcribed in full . They will be completely anonymous .~The average length of the interviews will be 45-60 minutes. Textual data from these interviews will be analysis."
89429399|NCT04189172||Neuro-Patch|Patients receiving Neuro-Patch® for duraplasty
89429400|NCT02077179|No Intervention|Standard of Care|Participants in this arm will receive care as per the usual standards from Kingston General Hospital and their primary care provider.
89429401|NCT02077179|Experimental|HIP Program|Participants in this arm will follow the HIP Program in addition to their usual care from Kingston General Hospital and their primary care provider.
89429402|NCT01109550||with biliary candidiasis|Patients with positive fungal cultures of bile samples.
89429403|NCT01109550||without biliary candidiasis|Patients with negative fungal cultures of bile samples.
89429404|NCT02077257|Other|Rosuvastatin 20mg|Rosuvastatin 20 mg/d
89429405|NCT02077257|Other|Rosuvastatin 10mg|Rosuvastatin 10 mg/d
89429406|NCT02732912|Active Comparator|Control|Patients in this arm will continue current standard management for sleep, which is largely reactive; if a patient requests night sedation or complains that they cannot sleep and that they want help, then zopiclone is prescribed, starting at 3.75 mg.
89429407|NCT02732912|Experimental|Eye mask and ear plugs|General management will be as for the control group. In addition, patients in this group will be given ear plugs and eye shades (masks) to use when trying to sleep. The patient will generally be responsible for using or not using the equipment, though ward nurses may remind patients if they notice that the patient has the equipment.
89429408|NCT02283918||Participants with education less than bachelor's degree|Participants are further divided into three sub-groups based on their age group Group 1: Participants aged between 25 to 34 years Group 2: Participants aged between 35 to 44 years Group 3: Participants aged between 45 to 58 years
89429409|NCT02283918||Participants with bachelor's degree or equivalent|Participants are further divided into three sub-groups based on their age group Group 1: Participants aged between 25 to 34 years Group 2: Participants aged between 35 to 44 years Group 3: Participants aged between 45 to 58 years
89429410|NCT04134494|Experimental|Intervention|Women with biopsy-proven lichen sclerosus will be treated with the ProFractional hand piece using the sapphire plate stand-off (Sciton, Inc. Palo, Alto, CA). The laser energy is delivered in a scanning fractional pattern to ablate microchannels in tissue to allow faster healing. Treatment will be delivered in 3 sessions scheduled 4 weeks (+/- 1 week) apart
89429411|NCT02792517|Experimental|Erenumab + Estrogen/Progestin Contraceptive|"Participants received a combination oral contraceptive for 3 28-day cycles during the study.~A single 140 mg dose of erenumab was administered subcutaneously to the abdomen on day 10 of cycle 3 by a healthcare provider."
89429412|NCT00488748|Experimental|MST|Magnetic Seizure Therapy (MST)
89429413|NCT00488748|Active Comparator|ECT|Electroconvulsive Therapy (ECT)
89536217|NCT05713175|Active Comparator|Polypropylene plantar orthosis|Treatment consisting of a personalized plantar orthosis fabricated in 4mm polypropylene, which incorporates a 4mm heel rise and metatarsal dome placed proximal to the 2nd-3rd-4th metatarsal heads. No modifications applied to the patients' medial longitudinal arch.Orthosis fabricated following the inverted orthotic technique.
88909690|NCT05189925|Experimental|IV infusion of gp91-Grans at dose K+1:1e7 cells/kg|Adult CGD patients without systemic infection will participate in a dose-escalation trial to identify the most effective yet safe dose of study agent. Subjects enrolled will receive 1 administration of study agent at dose K+1, and safety of dose will be determined.
88909691|NCT05189925|Experimental|IV infusion of gp91-Grans at dose K+2: 1-5e8 cells/kg|Adult CGD patients without systemic infection will participate in a dose-escalation trial to identify the most effective yet safe dose of study agent. Subjects enrolled will receive 1 administration of study agent at dose K+2, and safety of dose will be determined.
88909692|NCT05189210|Placebo Comparator|Placebo|Placebo SC injection administered once weekly for 4 weeks then every 2 weeks through Week 50
88909693|NCT05189210|Experimental|GV1001 0.56 mg|GV1001 0.56 mg SC injection administered once weekly for 4 weeks then every 2 weeks through Week 50
88909694|NCT05189210|Experimental|GV1001 1.12 mg|GV1001 1.12 mg SC injection administered once weekly for 4 weeks then every 2 weeks through Week 50
88909695|NCT05188222|Experimental|Intervention Group|Patients in the intervention group will receive an oral preparation of 50 grams of Maltodextrin solution mixed in 400 millilitres (mL) of water twice the night before surgery and within 2-3 hours before surgery. The entire drink is meant to be consumed within 15 minutes.
89429414|NCT03438734|Active Comparator|Low flow|"Anesthesia was maintained with desflurane inhalation with a flow of 2 L/min in 0.5 O2 oxygen-air mixture in both groups. While target minimum alveolar concentration (MAC) was 1-1.5 and the flow rate was adjusted to 0.75 L/min. Regional cerebral oxygen saturation is a useful clinical research tool for noninvasive and continuous monitoring of hemodynamic and brain oxygenation. Regional cerebral oxygen saturation (Near-infrared spectroscopy system, NIRS, Cerebral Oximeter) monitoring was performed to all patients.~The most effective method for depth of anesthesia and assessment of sedation is bispectral analysis of mean frequency of electroencephalography. The values of Bispectral Index (BIS, Bispectral Index, Monitoring System) decreases with the deepening of anesthesia."
89429415|NCT03438734|Sham Comparator|Normal flow|"Anesthesia was maintained with desflurane inhalation with a flow of 2 L/min in 0.5 O2 oxygen-air mixture in both groups. While target minimum alveolar concentration (MAC) was 1-1.5 and the flow rate was adjusted to 1.5 L/min.Regional cerebral oxygen saturation is a useful clinical research tool for noninvasive and continuous monitoring of hemodynamic and brain oxygenation. Regional cerebral oxygen saturation (Near-infrared spectroscopy system, NIRS, Cerebral Oximeter) monitoring was performed to all patients.~The most effective method for depth of anesthesia and assessment of sedation is bispectral analysis of mean frequency of electroencephalography. The values of Bispectral Index (BIS, Bispectral Index, Monitoring System) decreases with the deepening of anesthesia."
89429416|NCT00487656|Experimental|ART-123|6 mg/ml ampule solution for injection
89429417|NCT00487656|Placebo Comparator|Placebo|6 mg/mlampule of solution for injection
89429418|NCT03431714|Experimental|single arm|Artesunate amodiaquine tablets containing 25/67.5 mg, 50/135mg and 100/270 mg base of artesunate-amodiaquine were administered according to body weight Dihrdroartemisinin piperaquine tablets containing 160/20mg and 320/40mg base of piperaquine dihydroartemisinin were administered according to body weight
89429419|NCT02077413|Active Comparator|Healthy Muscle Group|Six subjects will be enrolled in this group. MRI measures will be performed at baseline and 48 hours post-exercise, when the largest amount of muscle damage is typically observed. They will be tested for maximum strength of the dorsiflexors and then undergo an eccentric exercise protocol for both lower legs on the Biodex with varying loads. Approximately two days after the exercise protocol, the participants will have another MRI of the lower legs to assess any change in T2 relaxation time as a construct of muscle edema/damage.
89429420|NCT02077413|Experimental|Stretch-Contract Pre-rehabilitation Group|"All subjects will be tested initially with an MRI, blood work for creatine kinase levels (CK), subjective report of pain, range of motion (ROM) of the lower leg/ankle, and maximum strength of the dorsiflexors. They will also receive the stretch-contract protocol on one leg consisting of the following: a 5 second passive stretch of the dorsiflexors, followed immediately by a 5 second active isometric contraction of the dorsiflexors, and a 5 second rest/relaxation period. This cycle will continue for a duration of ~5 minutes."
89429421|NCT02077413|Active Comparator|Stretch-Contract Control Group|All subjects will be tested initially with an MRI, blood work for creatine kinase levels (CK), subjective report of pain, range of motion (ROM) of the lower leg/ankle, and maximum strength of the dorsiflexors.
88909696|NCT05188222|Placebo Comparator|Placebo Group|Patients in the intervention group will receive a placebo in 400 millilitres (mL) of water twice the night before surgery and within 2-3 hours before surgery. The entire drink is meant to be consumed within 15 minutes.
88909697|NCT05184504||Patients with pathological diagnosis of renal cell carcinoma|Patients aged 18 years or older, who have been diagnosed with renal cell carcinoma (new case or recurrence) since January 2015 and during the study recruitment period.
88909698|NCT05184452|Experimental|PGDM1400LS 5 mg/kg IV|Participants will receive PGDM1400LS 5 mg/kg by intravenous (IV) infusion at Month 0
88909699|NCT05184452|Experimental|PGDM1400LS 20 mg/kg IV|Participants will receive PGDM1400LS 20 mg/kg by IV infusion at Month 0
88909700|NCT05184452|Experimental|PGDM1400LS 20 mg/kg SC|Participants will receive PGDM1400LS 20 mg/kg by subcutaneous (SC) infusion at Month 0
89429422|NCT02077413|Experimental|Muscle Atrophy|These subjects will undergo MRI and strength testing at baseline and will also be assessed for CK levels, pain report, and ROM. They will then receive an eccentric loading paradigm for the dorsiflexor muscles of the involved leg using an isokinetic dynamometer with varying loads. Approximately two days after the exercise protocol, follow-up assessment of MRI, CK levels, pain report, ROM, and strength will be done.
89429423|NCT03431636|Experimental|Immersion in cold water|"The athlete will remain submerged in a Cryo Control - Ice Bath Systems® bathtub, which allows filtration and maintenance of constant water temperature, and shoulder blade water (Getto and Golden, 2013) for 15 minutes in the 15 degrees Celsius (Machado et al, 2016)."
89429424|NCT03431636|Active Comparator|Ice pack|The athlete will remain for 20 minutes with plastic packets of 500 grams of ice each, in the region of the evaluated muscles.
89429425|NCT03431636|Sham Comparator|Control|Group in which the athlete will be instructed to remain seated in a comfortable position, at rest, for 20 minutes.
89429426|NCT02077491|Active Comparator|Intervention|High-protein diet and resistance training
89429427|NCT02077491|No Intervention|Control|The control group recieves standard care during the study.
89429428|NCT00484536|Experimental|CDP323 1000 mg/day|
89429429|NCT00484536|Experimental|CDP323 500 mg/day|
89429430|NCT00484536|Placebo Comparator|Placebo|
89429431|NCT03438422|Experimental|GROUP A|1 tablet a day of pollen A extract containing (140 mg aqueous extract and 8mg lipid purified pollen, aqueous extract pumpkin seed 300mg, 10mg Vitamin E)
89429432|NCT03438422|Active Comparator|GROUP B|1 tablet a day of pollen B extract containing (140 mg aqueous extract and lipid 8 mg of purified pollen)
89429433|NCT03438422|Active Comparator|GROUP C|1 tablet a day of pollen extract C containing (Pollen extract 160 mg, pumpkin seed extract, 300 mg and Vitamin E 10 mg)
89429434|NCT03438422|Placebo Comparator|PLACEBO|1 tablet a day of placebo
89429435|NCT02080065||liver transplantation|patients who underwent living donor liver transplantation during between 2007 and 2013
89429436|NCT03433586|Placebo Comparator|Placebo|Placebo pills that are visually identical to the Aspirin pills will be taken orally, daily for 10-14 days
89429437|NCT03433586|Active Comparator|Aspirin|Aspirin (81mg) will be taken orally daily for 10-14 days.
89429438|NCT02080143|Experimental|Air Activated Heat Patch|The experimental air activated heat patch will be worn by the subjects for 8 hours.
89429439|NCT02080143|Active Comparator|Marketed ThermaCare Air Activated Heat Patch|The marketed air activated heat patch will be worn by the subjects for 8 hours.
88909701|NCT05184452|Experimental|PGDM1400LS 40 mg/kg IV|Participants will receive PGDM1400LS 40 mg/kg by IV infusion at Month 0
89429440|NCT02273232|Active Comparator|Supervised Exercise Group|All PVD patients will get the standard advice regarding exercises but this group will have a constructed exercise program under supervision of Dr. Micheál Newell who is qualified Sports and Exercise Scientist with a Doctorate degree in Integrated Biology. This include six minute walk test, Chair Stand Test and symptoms free distance.
89429441|NCT02273232|Active Comparator|RIPC and supervised Exercise Group|This group will have structured intermitting periods of induced remote ischaemic preconditioning using standard blood pressure cuffs. The cuff will be applied for 5 minutes alternatively with 5 minutes rest to the total of 4 cycles, which needs 40 minutes per day. The RIPC group will receive an exercise program identical to the first group. The total number of days for each participant will be 28 days.
89429442|NCT02273232|Active Comparator|RIPC with Standard Care Group|The patients in this group will receive standard care advice regarding exercise in addition to RIPC as in the 2nd group.
89429443|NCT02273232|Sham Comparator|Control Group (Standard Care)|This group will get the standard advice regarding exercise for PVD patients and all the information available in Out patients clinic settings.
89429444|NCT03433508|Experimental|Liberal|2 PRBC /day to maintain the target of Hemoglobin 10 to 11 gm/dL. PRBC will be given intravenously at least for 28 days
89429445|NCT03433508|Active Comparator|Restrictive|To maintain the target Hemoglobin of 7 to 8 gm/dL.
89429446|NCT02072499|Experimental|KTP Green Light Prostatectomy|Device
89429447|NCT02072499|Active Comparator|Open prostatectomy|Surgical procedure
89429448|NCT03431558|Experimental|Group 1|"bLF (Bovine Lactoferrin plus Glucan D 99.4%) Dose: 150 mg Frequency: a single daily dose mixed with milk (preferentially breast milk otherwise formula milk).~Duration: 1 month"
89429449|NCT03431558|Experimental|Group 2|"bLF (Bovine Lactoferrin plus Glucan D 99.4%) Dose: 300mg Frequency: a single daily dose mixed with milk (preferentially breast milk otherwise formula milk).~Duration: 1 month"
89429450|NCT03431558|Placebo Comparator|Group 3|"Placebo: Only Glucan-D (99.4% glucoseDose: 150 mg Frequency: a single daily dose mixed with milk (preferentially breast milk otherwise formula milk).~Duration: 1 month"
89429451|NCT02273622|Experimental|hydroxytyrosol 5 mg|each participant will alternately by the three arms of the study (hydroxytyrosol 5 mg and 20 mg and placebo
89429452|NCT02273622|Experimental|hydroxytyrosol 20 mg|each participant will alternately by the three arms of the study (hydroxytyrosol 5 mg and 20 mg and placebo
89429453|NCT02273622|Placebo Comparator|placebo|each participant will alternately by the three arms of the study (hydroxytyrosol 5 mg and 20 mg and placebo
88909702|NCT05184452|Experimental|PGDM1400LS 40 mg/kg SC|Participants will receive PGDM1400LS 40 mg/kg by SC infusion at Month 0
88909703|NCT05184452|Experimental|PGDM1400LS 20mg/kg + VRC07-523LS 20mg/kg + PGT121.414.LS 20 mg/kg IV|Participants will receive PGDM1400LS 20mg/kg + VRC07-523LS 20mg/kg + PGT121.414.LS 20 mg/kg by IV infusion sequentially in this order at Month 0 and Month 4
89429454|NCT02077569|Experimental|AZD5363 480mg|STAGE 1 ONLY AZD5363 480mg Twice daily dosing for 4 and 1/2 days (9 doses) Oral Capsule
89429455|NCT02077569|Placebo Comparator|Placebo|STAGE 1 ONLY Twice daily dosing for 4 and 1/2 days (9 doses) Oral Capsule
88909704|NCT05184452|Experimental|PGDM1400LS 20mg/kg + VRC07-523LS 20mg/kg + PGT121.414.LS 20 mg/kg SC|Participants will receive PGDM1400LS 20mg/kg + VRC07-523LS 20mg/kg + PGT121.414.LS 20 mg/kg by SC infusion sequentially in this order at Month 0 and Month 4
88909705|NCT05184452|Experimental|PGDM1400LS 1.4gram + VRC07-523LS 1.4gram + PGT121.414.LS 1.4gram IV|Participants will receive PGDM1400LS 1.4gram + VRC07-523LS 1.4gram + PGT121.414.LS 1.4gram by IV infusion sequentially in this order at Month 0 and Month 4
88909706|NCT05184452|Experimental|PGDM1400LS 1.4gram + VRC07-523LS 1.4gram + PGT121.414.LS 1.4gram SC|Participants will receive PGDM1400LS 1.4gram + VRC07-523LS 1.4gram + PGT121.414.LS 1.4gram by SC infusion sequentially in this order at Month 0 and Month 4
88909707|NCT05184452|Experimental|PGDM1400LS 40mg/kg + VRC07-523LS 40mg/kg + PGT121.414.LS 40 mg/kg IV|Participants will receive PGDM1400LS 40mg/kg + VRC07-523LS 40mg/kg + PGT121.414.LS 40 mg/kg by IV infusion sequentially in this order at Month 0 and Month 4
89429456|NCT02077569|Experimental|AZD360mg|STAGE 2 AZD5363 360mg Twice daily dosing for 4 and 1/2 days (9 doses) Oral Capsule
89429457|NCT02077569|Experimental|AZD5363 240mg|STAGE 2 AZD5363 240mg Twice daily dosing for 4 and 1/2 days (9 doses) Oral Capsule
89429458|NCT02273934|Experimental|Reablement|Reablement is an intensive, multidisciplinary, client-centered, home-based type of rehabilitation, where ordinary activities of daily living are used for rehabilitative purposes. It is a rehabilitation alternative that may be offered to adults, and there is no lower age limit. An occupational therapist and physical therapist, or nurse, constitutes the key personal, while home helpers, assistants and others with lower education, are the ones who work rehabilitative with the person on a daily basis focusing on self-help.
89429459|NCT02273934|Active Comparator|Standard treatment|This arm consists of the standard treatment home-dwelling elderly persons receive when applying for home-based help. Some elderly may receive home-based nursing or home help services assisting them in daily activities, while others may receive occupational therapy or physical therapy measures for rehabilitative purposes.
89429460|NCT02077647||Conservative|Conservative treatment of osteoarthritis of the knee
89429461|NCT03431402|Other|Acute stroke receive hyperbaric oxygen|
89429462|NCT03431402|No Intervention|Acute stroke receive only conventional treatment|
89429463|NCT02072577|Experimental|Knowledge|Educational video.
88909708|NCT05180162|Experimental|Cohort 1: Liver Fibrosis|Patients with liver fibrosis will receive a single administration of 68Ga-FAP-2286 prior to PET imaging.
89429464|NCT00482664|Experimental|1 mg|
89429465|NCT00482664|Experimental|10 mg|
89429466|NCT00482664|Experimental|3 mg|
89429467|NCT00482664|Placebo Comparator|Placebo|
89429468|NCT02077803|Experimental|Treatment A|Each participant will receive a single dose of 1 tablet of canagliflozin (CANA), 100 mg, and 4 tablets of metformin extended release (MET XR), 500 mg, administered together under fed conditions.
89429469|NCT02077803|Experimental|Treatment B|Each participant will receive a single dose of 2 tablets of CANA/MET XR FDC, formulation 1, under fed conditions.
89429470|NCT02077803|Experimental|Treatment C|Each participant will receive a single dose of 2 tablets of CANA/MET XR FDC, formulation 2, under fed conditions.
89429471|NCT03431324|Experimental|Mating-EFT Intervention Effectiveness|"Study 1: 90 participants will attend an initial session, at which point they will provide demographic information as well as their relationship status. They will then be randomly assigned to complete either the Episodic Future Thinking about Mating Opportunities intervention, a general-EFT intervention, or an unrelated questionnaire (yoked control condition).~All participants will submit daily reports of the number of cigarettes smoked for a period of one week. Participants will then complete a series of questionnaires measuring individual differences in fundamental social motives (including mate-seeking motives), self-efficacy, and nicotine dependence."
89536218|NCT05713175|Active Comparator|Fixtoe device|Fixtoe device, simulating the metatarsophalangeal joint stabilization tape technique . Worn for one month, prior to definitive treatment.
89429472|NCT03431324|Experimental|Message Tailoring for Smoking Cessation|Study 2: A quasi-experimental design will be employed in order to determine whether targeting individuals who are single and highly motivated to seek a mate with a Targeted Mating-EFT Intervention is a more effective means of reducing cigarette consumption than presenting all individuals with a general-EFT intervention. A total of 180 smokers who intend to quit or reduce smoking will be recruited as participants. These individuals will be selected from a larger pool of participants based upon responses to screening questions. The screening questions will measure relationship status and mate seeking motivation.
89197528|NCT00852501||Non-functioning pituitary macroadenoma|The performance of surgery is the standard of care in the management of non-functioning pituitary macroadenomas. The tissue obtained during surgery is routinely sent for histopathological examination. A piece of the tissue will undergo receptor characterisation via RT-PCR.
89197529|NCT02562534|Other|Patients with conductive troubles|Patients with conductive troubles
89197530|NCT02562534|Other|Patients with rhythm troubles|Patients with rhythm troubles
89197531|NCT02562534|Other|Volunteers|Volunteers with normal ECG
88909709|NCT05180162|Experimental|Cohort 2: Pulmonary Fibrosis|Patients with pulmonary fibrosis will receive a single administration of 68Ga-FAP-2286 prior to PET imaging.
88909710|NCT05180162|Experimental|Cohort 3: Myocardial Fibrosis|Patients with myocardial fibrosis will receive a single administration of 68Ga-FAP-2286 prior to PET imaging.
88909711|NCT05179226|Experimental|Ferric Derisomaltose|"All subjects (a total of 200) will be treated with Ferric Derisomaltose. 12 subjects (half of the 24 subjects participating in the PK-part of the trial) will be treated with 10mg/kg while the remaining subjects will be treated with 20 mg/kg.~."
88909712|NCT05170971|Other|fecal microbiota transplantation|The fecal bacteria were transplanted once every 5 days for a total of 4 times.
88909713|NCT05169515|Experimental|Arm 1|Participants will receive subcutaneous (SC) mosunetuzumab + CC-220 or SC mosunetuzumab + CC-99282.
88909714|NCT05169515|Experimental|Arm 2|Participants will receive intravenous (IV) glofitamab + CC-99282.
88909715|NCT05167877||Control group|Participants without CLBP. Measurements include: bio-physiological, neurophysiological measurements at baseline. Remote monitoring of gait, physical activity for 7 days using inertial measurement unit (IMU) with wearable devices.
88909716|NCT05167877||Active group|Participants with CLBP. Measurements include: bio-physiological, neurophysiological measurements at baseline. Remote monitoring of gait, physical activity for 7 days using inertial measurement unit (IMU) with wearable devices. Self-reported measures of pain and type of activity for 7 days using electronic dairy.
88909717|NCT05167721|Active Comparator|Arm 1|25 million mesenchymal stem cells administered intrathecally every 3 months for 4 injections
88909718|NCT05167721|Active Comparator|Arm 2|25 million mesenchymal stem cells administered intrathecally every 6 months for 2 injections (placebo injections at 3 month and 9 month timepoints)
88909719|NCT05167721|Placebo Comparator|Arm 3|Placebo (lactated Ringer's) administered intrathecally every 3 months for 4 injections
88909720|NCT05167357|Experimental|COVID+ group|As the performance of the Richalet test is done by both arms, the intervention rather is the having undergone COVID19.
88909721|NCT05167357|No Intervention|Control group / COVID- group|Performance of the Richalet test is done by both arms, the control in this study here is the having stayed clear of COVID19.
88909722|NCT05166083||Trans man|"Trans man is assigned female at birth and identify as man"
89197532|NCT00852579|Experimental|1|Active treatment.
88909723|NCT05164705|Active Comparator|Intermittent Hypoxia|Participant will visit our center 2-4 times per week for three weeks to receive Acute Intermittent Hypoxia.
88909724|NCT05164705|Sham Comparator|Sham Intermittent Hypoxia|Participants will visit our center 2-4 times per week for three weeks to receive Sham Intermittent Hypoxia.
88909725|NCT05159284|Experimental|Intervention group|Softacort® Lephanet® Thealoz Duo® MGD Rx EyeBag®
88909726|NCT05159284|Other|Control group|Lephanet® Thealoz Duo® MGD Rx EyeBag®
88909727|NCT05155345|Experimental|Non-fractionated/Dose-finding|Participants will receive a single dose of mosunetuzumab.
89197533|NCT00852579|Placebo Comparator|2|Placebo control group.
89197534|NCT00942058||CA9 level|Serum and urinary CA9 level
88909728|NCT05155345|Experimental|Fractionated/Dose-escalation|Participants will receive a fractionated (divided) dose of mosunetuzumab on Days 1 and 8.
88909729|NCT05153239|Experimental|Lurbinectedin|Patients will consecutively receive lurbinectedin on Day 1 q3wk (every three weeks = one treatment cycle)
88909730|NCT05153239|Experimental|Lurbinectedin plus Irinotecan|"Patients will consecutively receive the following q3wk (every three weeks = one treatment cycle):~Irinotecan (Day 1 and Day 8)~Lurbinectedin (Day 1)"
88909731|NCT05153239|Active Comparator|Control arm|"Best Investigator's choice prior to randomization between:~Irinotecan on Day 1 q3wk~Topotecan on Days 1-5 q3wk"
88909732|NCT05150015|Experimental|Number of consented patients who complete the antibiotics through an elastomeric pump|Flucloxacillin, piperacillin/taozbactam and benzylpenicillin will be use
89429473|NCT00666900|Experimental|1|
89429474|NCT00666900|Experimental|2|
88909735|NCT05148195|Experimental|A: Solid tumor|Envofolimab（300mg，Q3W）+BD0801（2mg/kg，Q3W）
88909736|NCT05148195|Experimental|B: HCC|Envofolimab（300mg，Q3W）+BD0801（2mg/kg，Q3W）
88909737|NCT05148195|Experimental|D：NSCLC|Envofolimab（300mg，Q3W）+BD0801（2mg/kg，Q3W）+Docetaxel(75mg/m2，Q3W)
88909738|NCT05148195|Experimental|D：CRC|Envofolimab（200mg，Q2W）+BD0801（2mg/kg，Q2W）+FOLFIRI（Irinotecan 180 mg/m2，Leucovorin 400mg/m2，5-Fluorouridine 2400 mg/m2，Q2W）
88909739|NCT05147350|Experimental|Phase 1: RP-6306 in combination with FOLFIRI Dose Escalation|RP-6306 will be administered as oral capsules Multiple dose levels of RP-6306 (oral) and FOLFIRI (IV)
88909740|NCT05146375||MSF1|Each member of the MSF1 family who consents to participate to the study will be included.
88909741|NCT05144776||Chronic hepatitis B|300 patients diagnosed with chronic hepatitis B will be enrolled. A fingerstick HBV DNA test will be performed using the Xpert HBV Viral Load assay, and a dried blood spot sample will be collected which will be tested using a gold standard HBV DNA viral load assay. Both results will be compared against the HBV DNA viral load from standard of care venous blood using the gold standard HBV DNA viral load assy. Enrolment of HBV DNA undetectable participants will be capped at 100.
88909742|NCT05140499|Active Comparator|Single Shot Perineural Popliteal Nerve Block|Single shot perineural popliteal nerve block injection of 10cc 13.3% liposomal bupivacaine combined with 15cc 0.50% bupivacaine hydrochloride within one hour prior to surgery
88909743|NCT05140499|Active Comparator|Continuous perineural popliteal nerve block catheter|Placement of continuous perineural popliteal nerve block catheter with injection of 30cc 0.5% bupivacaine within one hour prior to surgery, followed by continuous infusion of 10cc 0.3% ropivacaine (current standard practice) for at least 72 hours following surgery. Saphenous single shot 20cc 0.2
88909744|NCT05136989||Professionals from the seven least coercive facilities|Volunteer professionals selected on the basis of their experience in reducing the use of coercion.
88909745|NCT05136989||Voluntary ex-patients|Voluntary ex-patients who were hospitalized in these establishments in the two years preceding the survey and whose condition is stabilized
88909746|NCT05133427|Experimental|Areas with de-novo or recurrent BCC|Areas with non-nodular de-novo or recurrent BCC area will be treated by high intensity focused ultrasound.
88909747|NCT05133323|Experimental|Lu AG09222 High Dose|Participants will receive a single high dose of Lu AG09222 by intravenous (IV) infusion.
88909748|NCT05133323|Experimental|Lu AG09222 Low Dose|Participants will receive a single low dose of Lu AG09222 by IV infusion.
88909749|NCT05133323|Placebo Comparator|Placebo|Participants will receive a single dose of placebo matching to Lu AG09222 by IV infusion.
88909750|NCT05131971|Experimental|Cohort 1: Participants receiving GSK3888130B at dose level 1|
88909751|NCT05131971|Placebo Comparator|Cohort 1: Participants receiving placebo|
89429475|NCT00666900|Placebo Comparator|3|
89429476|NCT03431246|Experimental|Gardasil and Gardasil-9|
89429477|NCT03559491||Macular Edema Patients|Patients affected by cystoid macular edema (CME) due to retinal vein occlusion of recent onset (less than three months) will be enrolled.
89429478|NCT04449848|Experimental|Sitting after intra tympanic injection|Patients with Sudden hearing loss sitting after intra tympanic injection of steroids
89429479|NCT02072655|No Intervention|without socio-asthetic care|
89429480|NCT02072655|Experimental|with socio-aesthetic cares|
89429481|NCT00664716|Placebo Comparator|Placebo|subcutaneous administration of placebo given for 12 weeks
89429482|NCT00664716|Experimental|One Dose|BG9924 - dosage level administered as per Biogen Idec protocol
89429483|NCT00664716|Experimental|Second Dose|BG9924 - dosage level administered as per Biogen Idec protocol
89429484|NCT00664716|Experimental|Third Dose|BG9924 - dosage level administered as per Biogen Idec protocol
89429485|NCT00664716|Experimental|Fourth Dose|BG9924 - dosage level administered as per Biogen Idec protocol
89429486|NCT00664716|Experimental|Fifth Dose|BG9924 - dosage level administered as per Biogen Idec protocol
89429487|NCT02072733|Other|geriatric assessment|"The intervention is individual and based on the Comprehensive Geriatric assessment (CGA) : collection of information on comorbidity, polypharmacy, physical, psychological and cognitive functions, nutrition as well as social status and support.~The results of the CGA, the eventual medical changes and recommendations regarding e.g. initiation of nutritional supplementation, home-care referral or referral to e.g. physiotherapist will be forwarded to the general practitioner and to the oncologist in charge of the treatment"
88909752|NCT05131971|Experimental|Cohort 2: Participants receiving GSK3888130B at dose level 2|
88909753|NCT05131971|Placebo Comparator|Cohort 2: Participants receiving placebo|
88909754|NCT05131971|Experimental|Cohort 3: Participants receiving GSK3888130B at dose level 3|
88909755|NCT05131971|Placebo Comparator|Cohort 3: Participants receiving placebo|
88909756|NCT05131971|Experimental|Cohort 4: Participants receiving GSK3888130B at dose level 4|
88909757|NCT05131971|Placebo Comparator|Cohort 4: Participants receiving placebo|
88909758|NCT05131971|Experimental|Cohort 5: Participants receiving GSK3888130B at dose level 5|
89429488|NCT03228069|Experimental|single visit 4-site ID vaccination|Blood would be drawn from those who received a single visit 4-site ID rabies booster vaccination in the previous trial.
89429489|NCT03228069|Active Comparator|Conventional IM vaccination|Blood would be drawn from those who received a conventional intramuscular rabies booster vaccination in the previous trial.
89429490|NCT05075096||COVID-19 ICU cohort|All patients admitted to a Swedish ICU with COVID-19 with at least one year of follow up. COVID-19 defined by the ICD-10 diagnosis U07.1 in the nationwide Swedish intensive care registry.
89429491|NCT05075096||COVID-19 hospital admission control cohort|Four random control patients per ICU patient matched on age legal gender and region. Controls selected from all patients admitted to a Swedish hospital with COVID-19 with at least one year of follow up. Not including patients in the COVID-19 ICU cohort. COVID-19 defined by the ICD-10 diagnosis U07.1 in the nationwide Swedish national patient registry.
89429492|NCT05075096||General population control cohort|Four general population controls per ICU patient, matched on age, legal gender and region drawn from the total population register of Sweden. Not including ICU and hospital admitted COVID-19 patients.
88909759|NCT05131971|Placebo Comparator|Cohort 5: Participants receiving placebo|
88909760|NCT05131971|Experimental|Cohort 6: Participants receiving GSK3888130B at dose level 6|
88909761|NCT05131971|Placebo Comparator|Cohort 6: Participants receiving placebo|
88909762|NCT05131971|Experimental|Cohort 7: Participants receiving GSK3888130B at dose level 7|
88909763|NCT05131971|Placebo Comparator|Cohort 7: Participants receiving placebo|
88909764|NCT05129397|Experimental|Treatment|The experimental arm of Virtual Mom Power is a manualized multi-family group intervention consisting of 10, 90-minute virtual group + 2 individual sessions led by two co-facilitators. The curriculum includes 5 core components: (1) Attachment-Focused Parenting Education; (2) Self-Care; (3) Parenting Practice; (4) Social Support; & (5) Connection to Resources. Individual sessions combine motivational interviewing with MP core components and focus on identifying goals and barriers. We will work with mothers in individual coaching to problem-solve childcare and privacy during group time. Weekly between-group phone/text check-ins are also a part of the curriculum, used to strengthen connection, build trust, ensure safety, and assess basic needs. Data regarding attendance will be recorded and total dosage examined in treatment effects.
88909765|NCT05129397|Active Comparator|Informational control|The control arm of this study consists of two individual sessions with mothers, along with 10 weeks of virtual informational mailings. The mailings will contain Mom Power curriculum about attachment-based parenting and self-care. The individual sessions will focus on individual goal-setting related to parenting and reflection on the parent-child relationship. The control group does not include the components of social support, affect regulation skills coaching, or guided parent-child interaction that are part of the experimental arm.
88909766|NCT05123144|Experimental|Behavioral Health Screener + ORCHID Intervention (BHS+ORCHID)|"At the clinic level, sites randomized to implement BHS+ORCHID will receive training, materials, and other support to administer behavioral health screening and refer their clients with elevated depression symptoms to ORCHID.~At the individual level, those clients who are eligible and choose to enroll in ORCHID will receive self-guided training on 8 positive affect skills through weekly online sessions and daily practice exercises."
89429493|NCT00472836|Experimental|Normal renal function|
88909767|NCT05123144|No Intervention|Standard of Care|usual care
89429494|NCT00472836|Experimental|Severe renal impairment|
89429495|NCT04472052||Appendectomy|Patients who required appendectomy for suspected acute appendicitis
89429496|NCT04472130||Early idiopathic Parkinson's Disease|200 patients with iPD based on Movement Disorder Society clinical diagnostic criteria for Parkinson's disease with disease onset less than 5 years
89429497|NCT04472130||Non-early idiopathic Parkinson's Disease|200 patients with iPD based on Movement Disorder Society clinical diagnostic criteria for Parkinson's disease with disease onset more than 5 years
89429498|NCT04472130||Multiple System Atrophy|100 patients with Multiple System Atrophy based on Second consensus statement on the diagnosis of MSA
89429499|NCT04472130||Progressive Supranuclear Palsy|100 patients with Progressive Supranuclear Palsy based on Clinical research criteria for diagnosis of PSP
89429500|NCT04472130||Alzheimer's Disease|100 patients with Alzheimer's Disease by Diagnostic and Statistical Manual of Mental disorder, Fifth edition (DSM-5) criteria
89429501|NCT04472130||Motor Neuron Disease|200 patients with Motor Neuron Diseases by revised El Escorial criteria or Awaji ALS criteria
88909768|NCT05121766|Experimental|Study arm - Omega 3 supplement|Omega-3 (EPA+DHA) - Dose is 2,100mg per day via 3 mini-capsules, 2x/day (a total of 6 mini-capsules per day). Each capsule has 252mg of EPA and 102mg of DHA.
88909769|NCT05121766|Placebo Comparator|Control arm - placebo|3 Soybean Oil Placebo capsules 2x/day (a total of 6 mini-capsules per day).
88909770|NCT05120830|Experimental|Phase 1 Study Arm|Participants assigned to 1 of 3 dose-escalation cohorts will receive a single dose of NTLA-2002 on Day 1 and will then be followed for 104 weeks. Primary observation period is 16 weeks.
89429502|NCT04472130||Small Vessel Disease|200 patients with cerebral Small Vessel Diseases
89429503|NCT04472130||Frontotemporal Dementia|100 patients with Frontotemporal Dementia by International consensus criteria for behavioral variant FTD (FTDC) or Primary Progressive Aphasia by Gorno-Tempini
89429504|NCT04472130||Healthy Control|200 age and sex matched healthy controls
89429505|NCT02072811|Other|Induction, DAC|"The first stage of treatment.~First DAC induction cycle is common to all patients (regardless of risk group). After completion of induction I occurs early assessment of bone marrow on the +14 day after the start of treatment (+7 day after completion of chemotherapy)."
89429506|NCT02072811|Other|II early induction, CLAG|"Patients with blasts in the bone marrow in D14> 10% receive early second induction (CLAG) which start form +16 day.~Patients with blasts in the bone marrow in D14 ≤ 10% do not receive early second induction and are qualified to assess the response times on +28 day or after full morphology recovery (if it occurs before the +28 day"
89429507|NCT02072811|Other|Consolidation, I HAM cycle|"I induction cycle starts after complete remission (CR).~- After I consolidation, patients from Intermediate I an Intermediate II group (ELN prognostic system):~If compatible donor is present - allogeneic HSCT qualification after I or II consolidation. If compatible donor for allogeneic HSCT is not present - attempt to CD34+ mobilization for autologous SCT after II consolidation~- After I consolidation, patients from Adverse risk group (ELN prognostic system):~If compatible donor is present - immediate qualification for allogeneic HSCT.~- Finding a donor should be initiated in all patients, at the latest after the end of I induction. In the first place, it should be checked whether the patient has a donor family, if not - searching start for an unrelated donor. For patients with no compatible donor for allogeneic HSCT - need to start searching for an alternative donor"
89197535|NCT02562456|Active Comparator|Conventional Treatment|Occlusal and occlusoproximal composite resin restorations in primary molars (rubber dam isolation + Adhesive system + composite resin Filtek z350)
89429508|NCT02072811|Other|II Consolidation HiDAraC|"Patients from all 5 risk group receive second after first consolidation [Ara-C] Patient from Very adverse risk receive Ara-C + CLA (Cladribine). If it is needed - more intensive consolidation treatment with 2-Cda.~Patients form Very adverse risk receive Maintenance treatment:~Decitabine 20 mg/m2 60 min infusion iv (Intravenous injection) for 5 days every 6 weeks.~Patients from Favorable, - Intermediate I an Intermediate II risk groups: CD34+ mobilization (HSCT qualification)."
89429509|NCT02072811|Other|Consolidation, III HiDAraC cycle|"Patients from Favorable, Intermediate I an Intermediate II risk groups receive III consolidation or autologous HSCT (depends on results of mobilization).~Patients from Adverse risk receive III Consolidation HiDAraC + Cladribina (CLA) If no CR: CLAG-M reinduction therapy and after CR - treatment according to protocol."
89429510|NCT02274324|Active Comparator|PD patients- Diet B first|Patients treated with Duodopa at least three months and are stable on medical therapy. The intervention cosists of Dietary Change. Patients that will be randomized to this group will start diet B and then crossover to diet C.
89429511|NCT02274324|Active Comparator|PD patients- Diet C first|Patients treated with Duodopa at least three months and are stable on medical therapy. The intervention cosists of Dietary Change. Patients that will be randomized to this group will start diet C and then crossover to diet B.
89429512|NCT04471896|Experimental|Treatment Arm|Participants will receive an infrared therapy device for use at home for 60 days. Participants will use the device every day for 10-20 minutes during the intervention period.
89429513|NCT02080299|Active Comparator|Remote ischemic preconditioning (RIPC)|RIPC-protocol before TAVI: after induction of conscious sedation/anesthesia, but prior to TAVI procedure, remote ischemic preconditioning (RIPC) protocol is performed, consisting of 3 cycles of 5 minutes left upper arm ischemia by inflation of a blood pressure cuff to 200 mmHg and 5 minutes of reperfusion, followed by a time interval between the end of the last deflation and local groin anaesthesia with subsequent skin puncture of 30 min.
88909771|NCT05120830|Experimental|Phase 2 Experimental Study Arm|Participants randomized to NTLA-2002 (2 dose levels), will receive a single dose of NTLA-2002 on Day 1 and will then be followed for 104 weeks. Primary observation period is 16 weeks.
88909772|NCT05120830|Placebo Comparator|Phase 2 Placebo Comparator Study Arm|Participants randomized to placebo will receive IV normal saline on Day 1 and will then be followed for up to 104 weeks. Primary observation period is 16 weeks.
88909773|NCT05119907|Experimental|Cohort A: Esophageal Squamous Cell Carcinoma (ESCC)|Participants will receive Sacituzumab Govitecan-hziy (SG) 8 or 10 mg/kg on Days 1 and 8 of a 21-day cycle. Participants will continue treatment until disease progression or intolerable toxicity or consent withdrawal for any reason.
88909774|NCT05119907|Experimental|Cohort B: Gastric or Gastroesophageal Junction Adenocarcinoma (G/GEJC)|Participants will receive SG 8 or 10 mg/kg on Days 1 and 8 of a 21-day cycle. Participants will continue treatment until disease progression or intolerable toxicity or consent withdrawal for any reason.
88909775|NCT05119907|Experimental|Cohort C: Cervical Cancer (CC)|Participants will receive SG 10 mg/kg on Days 1 and 8 of a 21-day cycle. Participants will continue treatment until disease progression or intolerable toxicity or consent withdrawal for any reason.
88909776|NCT05119907|Experimental|Cohort D: Biliary Tract Cancer (BTC)|Participants will receive SG 8 or 10 mg/kg on Days 1 and 8 of a 21-day cycle. Participants will continue treatment until disease progression or intolerable toxicity or consent withdrawal for any reason.
88909777|NCT05119907|Experimental|Cohort E: Lung Adenocarcinoma (LAC)|Participants will receive SG 10 mg/kg on Days 1 and 8 of a 21-day cycle. Participants will continue treatment until disease progression or intolerable toxicity or consent withdrawal for any reason.
88909778|NCT05119023|Experimental|Characterization of learning|All participants are assigned to complete behavioral (computer-based) learning tasks that measure their ability to learn observationally (observational learning ability) and via rules (rule-based learning ability).
88909779|NCT05117736|Experimental|Sacubitril/Valsartan|Treatment with Sacubitril/Valsartan
88909780|NCT05117736|Placebo Comparator|Placebo|Treatment with Placebo
88909781|NCT05116163|Experimental|Arm 1: Individuation Intervention plus implicit bias education|10 rheumatologists who will have 10 patient interactions each (100 patients total) recorded Rheumatologists will watch implicit bias training modules and then will be instructed to incorporate an individuation strategy into each of their clinical encounters.
88909782|NCT05116163|Active Comparator|Arm 2: Implicit bias education only|10 rheumatologists randomized and stratified by hospital and gender
88909783|NCT05116137|Experimental|Exercise Intervention|12-week circuit-based resistance exercise
89197536|NCT02562456|Experimental|ART using Fuji IX|Occlusal and occlusoproximal ART restorations in primary molars with GIC Fuji IX
88909784|NCT05116137|No Intervention|Wait-list Control|Standard of care wait-list control group
89197537|NCT00850083||Children in the ED|
89429514|NCT02080299|Placebo Comparator|Placebo|Placebo protocol before TAVI: After induction of conscious sedation/anesthesia and before TAVI, the cuff is left uninflated for 30 min, followed by a further time interval of 30 min until local groin anaesthesia with subsequent skin puncture.
89429515|NCT03428672|Experimental|osteoporotic fractures|patients with osteoporotic fractures, including femoral neck fracture and pertrochanteric fracture. Total hip arthroplasty or proximal femoral nails was needed.
89429516|NCT03428672|Sham Comparator|nonosteoporotic fractures|patients with nonosteoporotic fractures, including femoral neck fracture and pertrochanteric fracture. Total hip arthroplasty or proximal femoral nails was needed.
89429517|NCT02274636|No Intervention|Data collection|This first phase will involve having you report to the research coordinator through email the presence or absence of several symptoms associated with GERD that can occur during sleep. Phase 1 will occur over 14 days (and nights).
89429518|NCT02274636|Active Comparator|Intervention|In the second phase of the study, each subject will be given either a gel containing xylitol or discs containing xylitol to use for 14 days (the duration of the second phase of the study). If given the gel, a small amount (specified in the directions) is to be applied to the mouth lining just before bed. If given the discs, one will be placed on the gums beside a molar in each cheek each night just before bed (specified in the directions). Each subject will be asked to continue to provide daily email communication with the research coordinator detailing symptoms suggesting reflux experienced the prior night during product use as was provided during phase 1 of the study.
89429519|NCT02072889|Experimental|Neck Angle Measures|Subjects will position his/her neck in order to measure distance between the internal jugular and the carotid artery to determine if there is a maximal distance to target prior to cannulation
89429520|NCT02521220|Experimental|L-citrulline|Oral food-supplemental amino-acid L-citrulline. 2 times 3g per day.
88909785|NCT05110261|Experimental|Nirsevimab|Subjects will be randomized 2:1 to receive a single IM dose of nirsevimab or placebo.
88909786|NCT05110261|Placebo Comparator|Placebo|Subjects will be randomized 2:1 to receive a single IM dose of nirsevimab or placebo.
88909787|NCT05110157|Placebo Comparator|Placebo|Placebo once daily.
88909788|NCT05110157|Experimental|Vesicular monoamine transporter 2 (VMAT2) inhibitor|Valbenazine once daily
88909789|NCT05109065||Individuals with primary psychotic disorders|"Participants who have received any of the following diagnoses: schizophrenia, schizoaffective disorder, or schizophreniform disorder.~Participants will have urine toxicology screen, vitals recorded, and blood drawn in a single visit."
89429521|NCT02521220|Placebo Comparator|Maltodextrin|Maltodextrin as placebo. 2 times 3g per day
89429522|NCT02080377|Active Comparator|Current Standard Care|Insulin + Metformin
89429523|NCT02080377|Active Comparator|Treatment|Glibenclamide + Metformin
89429524|NCT00468000|Experimental|Ixmyelocel-T|The treatment arm of the study will receive injections of the study cellular product.
89429525|NCT00468000|Placebo Comparator|Placebo|The control arm of the study will receive placebo injections.
89429526|NCT02260479|Active Comparator|Preheated chlorhexidine|Preheated skin disinfection with 36ᵒC Chlorhexidine 5mg/ml in 70% alcohol.
89429527|NCT02260479|No Intervention|Room temperature chorhexidine|Room temperature skin disinfection with 20ᵒC Chlorhexidine 5mg/ml in 70% alcohol.
89429528|NCT03428594|Experimental|CKD-11101|The dose of investigational product (Darbepoetin alfa) is adjusted according to the principles reflecting the MFDS (Ministry of Food and Drug Safety) approval for NESP, but is determined by the investigator's judgment considering various factors of the subjects that may affect the treatment of anemia.
89008271|NCT04995263|Experimental|Post-intervention, randomization for SUEÑA half bundle plus, active group 2|"Randomization for full SUEÑA bundle: environmental and behavioral modifications in patient care interventions plus sleep informed treatment.~Participants will be randomized to receive SUEÑA components 1 through 5 Estimated duration: 6 months, n = 30"
89008272|NCT04995263|Experimental|Post-intervention, randomization for SUEÑA full bundle, active group 3|"Randomization for full SUEÑA bundle: environmental and behavioral modifications in patient care interventions plus sleep informed treatment and personalized psychoeducation.~. Participants will be randomized to receive SUEÑA components 1 through 6. Estimated duration: 6 months, n = 30"
89429529|NCT03428594|Active Comparator|NESP|The dose of investigational product (Darbepoetin alfa) is adjusted according to the principles reflecting the MFDS (Ministry of Food and Drug Safety) approval for NESP, but is determined by the investigator's judgment considering various factors of the subjects that may affect the treatment of anemia.
89429530|NCT02072967||Ribomustin and rituximab|
89429531|NCT03878810|Experimental|Exergaming, restless legs syndrome (+)|A video game-based physical activity training will be applied under a physiotherapist supervision for 2 days/week for 8 weeks.
89008273|NCT04598581|Active Comparator|Low Dose Radiation Therapy (LD-RT)|
89429532|NCT03878810|Experimental|Exergaming, restless legs syndrome (-)|A video game-based physical activity training will be applied under a physiotherapist supervision for 2 days/week for 8 weeks.
89429533|NCT03878810|No Intervention|Control, restless legs syndrome (+)|No specific intervention.
89429534|NCT03878810|No Intervention|Control, restless legs syndrome (-)|No specific intervention.
89429535|NCT02073045|Experimental|Supportive care (lymphedema education)|In an educational intervention, participants complete a five question lymphedema survey, designed by the Occupational Therapy staff, as an instrument to assess a patient's knowledge of lymphedema signs/symptoms before surgery. An OT, PT, and/or CLT provide written handouts to participants on the pathophysiology, signs, symptoms, and treatment of lymphedema. Participants repeat the survey at 3 months post-surgery. BUE circumferential measurements are also collected before surgery and at 3 months post-surgery.
89008274|NCT04598581|Sham Comparator|Sham irradiation|
89008275|NCT04598503||cases|All the babies admitted to the hospital with congenital anomalies during this period were included
89008276|NCT04598503||control|newborns without congenital anomalies
89008277|NCT04598191|Placebo Comparator|Control group|Participants in this group are administered inhaled normal saline.
89008278|NCT04598191|Experimental|iloprost group|Participants in this group are administered inhaled iloprost.
89008279|NCT04598113|Active Comparator|Effective Traction/Sham Traction|Group of patients treated firstly with Effective Traction then with Sham Traction
89008280|NCT04598113|Sham Comparator|Sham Traction/Effective Traction|Group of patients treated firstly with Sham Traction then with Effective Traction
89008281|NCT04598308||patients undergoing invasive assessment of the microcirculation|All patients are eligible for participation in this registry if they are undergoing coronary angiography with or without coronary intervention for any reason and if an indication for the foreseen intracoronary physiologic measurements is present according to the discretion of the investigating operator. There are no specific exclusion criteria other than contraindications for physiologic measurements in general.
89008282|NCT04598230|Active Comparator|Combination therapy (COMB)|Participants randomized to this arm will receive cognitive behavioral therapy and one of three study medications (fluoxetine, sertraline, or escitalopram).
89008283|NCT04598230|Active Comparator|Cognitive behavioral therapy (CBT)|Participants randomized to this arm will receive cognitive behavioral therapy (CBT) only
89008284|NCT04598347||Pregnant women diagnosed with SARS-CoV-2|Pregnant women diagnosed with SARS-CoV-2 infection(by PCR on nasopharyngeal aspirate or serology)that have an indication to perform an invasive technique(chorionic biopsy or amniocentesis) along thegestation.The sample size will depend on the duration of theSARS-CoV-2 pandemic.Initially we propose a study period of 18months in which we would have an approximate total of 225pregnant women with indication of invasive technique.It is planned to conduct a PCR study for SARS-CoV-2 in amniotic fluid or chorionic villi to thosepregnant women diagnosed with SARS-CoV-2 infection(approximately 5% of the total pregnant womenwith indication of invasive technique (11-12 pregnant women)).This determination is made as part of theroutine clinical practice in the context of the study of screening for perinatal infections
89008285|NCT04598464|Experimental|Exercise group|The home-based training program
89008286|NCT04598464|No Intervention|control group|All patients participated in a one-session educational program conducted by the investigators at each clinic.
89008287|NCT00565981|Experimental|Overall study|The FLUSALEM protocol combines 4 cycles of oral fludarabine phosphate (40mg/m² d1-3; q 29d) and an intensive dose schedule of alemtuzumab (30mg sc.3 times weekly for 16 weeks) in an outpatient setting
89008288|NCT04952519|Experimental|Amantadine|
89008289|NCT04952519|Placebo Comparator|Placebo|
89008290|NCT04598035||Primary Group|Patients with chronic low back pain that candidates them for surgical implant of a SCS device, and received a permanent SCS device.
89008291|NCT04598035||Control Group|Patients with chronic low back pain that are candidates for a surgical implant of a SCS device and do not receive a permanent SCS device after trial leads are placed.
89008292|NCT00414921|Active Comparator|1|clonidine
89008293|NCT00414921|Active Comparator|2|methylphenidate
89008294|NCT00414921|Active Comparator|3|methylphenidate and clonidine
89429536|NCT03877094|Active Comparator|Nature Virtual Reality Video|After signing the Informed Consent Form, the patient will receive a head-set dispositive to watch a nature virtual reality video during the whole procedure of breast biopsy. In the end of the procedure, the patient you will receive a Ipad (specific to the study and blocked for other functions) to respond a demographic questionnaire to characterize the sample and the likerts questionnaire to measure their pain, comfort, well-being, stress and anxiety during the procedure.
89429537|NCT03877094|No Intervention|Control group|This control group will not receive an intervention.
89429538|NCT02275260|Experimental|All patients|All patients undergo cerebral Diffusion-Weighted Magnetic Resonance Imaging (DW-MRI), Transesophageal (or Intracardial) Echocardiography and paperbased neurocognitive testing
89008295|NCT00414921|Placebo Comparator|4|
89008296|NCT04597762|Experimental|right eye: Ciclosporin, left eye: Ciclosporin + Hydrocortisone|Patients receive treatment with Ciclosporin eyedrops for the right eye and Ciclosporin eyedrops + Hydrocortisone eyedrops for the left eye
89008297|NCT04597762|Experimental|left eye: Ciclosporin, right eye: Ciclosporin + Hydrocortisone|Patients receive treatment with Ciclosporin eyedrops for the left eye and Ciclosporin eyedrops + Hydrocortisone eyedrops for the right eye
89429539|NCT02073201||High-functioning older adults|Participants with a SPPB score ≥ 11 will be categorized as high-functioning. The following test will be performed: Health and Quality of Life questionnaires, Mobility Assessments, Accelerometry, Body Composition (DEXA scan), Strength assessments, Neuromuscular stimulation, and Magnetic resonance imaging (MRI).
89429540|NCT02073201||Lower-functioning older adults|Participants with a SPPB score ≤ 8 will be categorized as lower-functioning. The following test will be performed: Health and Quality of Life questionnaires, Mobility Assessments, Accelerometry, Body Composition (DEXA scan), Strength assessments, Neuromuscular stimulation, and Magnetic resonance imaging (MRI).
89008298|NCT04597645|Experimental|Elastic band (EB)|EB group participants who are attending sheltered employment will received Elastic Thera band training program two times per week (once supervised and guided by a trained physical therapist and the other supervised by educational trainer) over 16 weeks for a total of 32 sessions.
89008299|NCT04597645|No Intervention|Control group (CG)|Control group participants will receive usual care.
89008300|NCT01580800||Breast cancer survivors|Patients who have undergone breast cancer treatment (e.g. surgery, node dissection, chemotherapy and/or radiation therapy), and what affect this has had on their arm health.
89008301|NCT04597957|Experimental|Fresh Rx Intervention group|The Fresh Rx intervention group will receive up to 8 visits to the community based farmers market with $10 incentive for fruits and vegetables at each visit.
89008302|NCT04597957|Active Comparator|Diabetic Standard of Care Control group|Diabetic standard of care control group will receive no incentive for the community based farmers market.
89008303|NCT04597723|Experimental|80% oxygen|80% oxygen given group
89008304|NCT04597723|Experimental|60% oxygen|60% oxygen given group
89008305|NCT04597723|No Intervention|routine hospital care|The patients in this group received routine hospital care.
89008306|NCT04597567|Active Comparator|Metal removal|
89008307|NCT04597567|No Intervention|Metal retention|
89008308|NCT04597216|Other|unique arm|there is only 1 arm in this study (all the participants will undergo the same diagnosis procedure)
89429541|NCT02073201||Young adults|Participants between the 20 - 30 years of age. The following test will be performed: Health and Quality of Life questionnaires, Mobility Assessments, Accelerometry, Body Composition (DEXA scan), Strength assessments, Neuromuscular stimulation, and Magnetic resonance imaging (MRI).
89429542|NCT02073357|Experimental|Light general anaesthesia (BIS = 50)|Light general anaesthesia
89429543|NCT02073357|Experimental|deep general anaesthesia (BIS = 35)|deep general anaesthesia
89429544|NCT02275494||shortening group|Shortening group where the operated leg was more than 5mm shorter compared with the contralateral side
89429545|NCT02275494||Restoration group|the restoration control group where the operated leg was within 5mm shortening and 9mm lengthening compared with the contralateral side
89429546|NCT02275494||Lengthening group|The lengthening group where the operated leg became more than 9mm longer compared with the contralateral side.
89429547|NCT03423446|Experimental|Severe Hepatic Impairment|Up to 8 subjects with severe hepatic impairment (Child-Pugh Class C, score of 10 to 15 points)
88909790|NCT05109065||Healthy Controls|"Healthy participants who do not have any exclusion criteria will undergo an assessment to confirm absence of psychiatric disorder.~Participants will have urine toxicology screen, vitals recorded, and blood drawn in a single visit."
88909791|NCT05103358|Experimental|Arm A: Pathogenic inactivating TSC1 alterations|Patients with pathogenic inactivating TSC1 alterations.
88909792|NCT05103358|Experimental|Arm B: Pathogenic inactivating TSC2 alterations|Patients with pathogenic inactivating TSC2 alterations.
88909793|NCT05100862|Experimental|Follicular Lymphoma Arm A: Zanubrutinib plus Obinutuzumab|Participants will receive zanubrutinib and Obinutuzumab. Following the completion of the combination treatment, participants will continue receiving zanubrutinib monotherapy until confirmed disease progression, unacceptable toxicity, withdrawal of consent, or study termination, whichever occurs first.
88909794|NCT05100862|Active Comparator|Follicular Lymphoma Arm B: Lenalidomide plus Rituximab|Participants will receive lenalidomide and rituximab.
89429548|NCT03423446|Experimental|Healthy Control|Up to 8 healthy control subjects with normal hepatic function
89429549|NCT02080533|Experimental|Single|Slow-paced respiration therapy
88909795|NCT05100862|Experimental|Marginal Zone Lymphoma Arm C: Zanubrutinib plus Rituximab|Participants will receive zanubrutinib and rituximab. Following the completion of the combination treatment, participants will continue receiving zanubrutinib monotherapy until confirmed disease progression, unacceptable toxicity, withdrawal of consent, or study termination, whichever occurs first.
88909796|NCT05100862|Active Comparator|Marginal Zone Lymphoma Arm D: Lenalidomide plus Rituximab|Participants will receive lenalidomide and rituximab.
88909797|NCT05099770|Sham Comparator|Cohort 1|Participants randomized to Cohort 1 will receive 2 sham injections of REACT. Second injection to occur 3 months (+30 days) after the first REACT injection. Sham procedures simulate real procedure. No tissue is taken during biopsy and nothing is injected into kidney for injection.
88909798|NCT05099770|Experimental|Cohort 2|Participants randomized to Cohort 2 will receive 2 injections of REACT. The second injection to occur 3 months (+30 days) after the first REACT injection.
88909799|NCT05099172|Experimental|Dose escalation|Doses of BAY2927088 will be increased in a stepwise fashion up to the MTD or MAD.
89429550|NCT03133962|Other|Patients applying for CAP or long-term central catheter|
89429551|NCT03430778|Experimental|High CO2 group|end tidal CO2 : 40-45 mmHg
89429552|NCT03430778|Placebo Comparator|Low CO2 group|end tidal CO2 : 30-35 mmHg
89429553|NCT02073513|Experimental|kinesiotape plus thenar pressure (PPTG)|"In the kinesiotape plus thenar pressure (PPTG). Kinesiotape was applied which controled the cortical thumb sign. In addition a piece of plastazote aiming to give thenar pressure was also applied.~The amount of pressure was regulated so that the child felt the pressure without being irritated and without restriction in grasping functions."
89429554|NCT02073513|Experimental|Taping Group (TG)|In the taping group (TG) kinesiotape was applied to control the cortical thumb sign.
89429555|NCT02073513|No Intervention|Control Group (CG)|No application.
89429556|NCT02281578|Experimental|Combination prevention|Community-based, combination HIV prevention intervention package
88909800|NCT05099172|Experimental|Backfill|Dose Escalation and Backfill run concurrently
88909801|NCT05099172|Experimental|Dose expansion|Dose Expansion is initiated after Dose Escalation and Backfill.
88909802|NCT05099172|Experimental|Extension part|The enrollment of the Extension part may be initiated once all ongoing participants from the corresponding Expansion cohort (participants within the same Group) have at least 12 weeks of treatment (corresponding to 2 post-baseline efficacy assessments) or discontinue treatment.
88909803|NCT05099003|Experimental|Treatment (selinexor and radiation therapy)|"CHEMORADIOTHERAPY: Patients receive standard of care radiation therapy 5 days per week for 5-7 weeks. Starting on day 4 or 5 of radiation therapy, patients receive selinexor PO on 1, 8, 15, 22, 29, 36, 43, and 50 in the absence of disease progression or unacceptable toxicity. After a 2-week rest period, patients proceed to Maintenance. Patients undergo a MRI and may undergo a biopsy during screening.~MAINTENANCE: Patients receive selinexor PO on days 1, 8, 15, and 22 of each cycle. Cycles repeat every 28 days for up to 24 cycles of maintenance therapy in the absence of disease progression or unacceptable toxicity. Patients undergo a MRI on study and during follow-up."
88909804|NCT05098873||Group gifted teens|
88909805|NCT05098873||Group no gifted teens|
88909806|NCT05097287|Experimental|Dupilumab|Dupilumab administered every 2 weeks (Q2W) after an initial loading dose (2 injections) on Day 1
89008309|NCT04597255|Experimental|Holographic optical coherence tomography|Healthy phakic participants
89429557|NCT02281578|Active Comparator|Standard of care|Locally run standard of care HIV prevention, treatment and care services
89429558|NCT03423368|Experimental|Libramed|Each patient will be admistered 6 tablets/day (3 tablets before lunch, 3 tablets before dinner) of Libramed for 30 days
89429559|NCT03423368|Placebo Comparator|Placebo|Each patient will be admistered 6 tablets/day (3 tablets before lunch, 3 tablets before dinner) of placebo for 30 days
89429560|NCT02073591||Ceradan Regimen|Ceradan Cream and Ceradan Wash
89429561|NCT02275650|Experimental|nbUVB|2 SED dose of nbUVB will be given every other week for this intervention group.
89429562|NCT02275650|No Intervention|control|No nbUVB illumination will be given for the control group.
89429563|NCT03423212|Experimental|Experimental Condition|Participants assigned to the experimental arm will be enrolled in the 2-session Just Do You intervention described elsewhere.
89429564|NCT03423212|No Intervention|Treatment as Usual Condition|Participants assigned to treatment as usual will receive the PROS program that is standard in the agencies without any additional intervention.
89429565|NCT03423212|Active Comparator|Active Control Condition|Participants assigned to the active control condition will receive the PROS program that is standard in the agencies, and a two-session curriculum on maintaining healthy relationships, which is an identified issue for the population.
88909807|NCT05097287|Placebo Comparator|Placebo|Matching placebo administered Q2W after an initial loading dose (2 injections) on Day 1
88909808|NCT05097222|Experimental|Active PBMT|Participants will receive 50minutes of PBMT, three times a week, for 8 weeks.
88909809|NCT05097222|Sham Comparator|Sham PBMT|Participants will receive 50minutes of Sham PBMT, three times a week, for 8 weeks. The Sham device will appear to function like the treatment device without providing any power intensity (0% power). At 0% power, no light is emitted from the LEDs.
88909810|NCT05096013|Experimental|individual nutrition therapy|Individualized nutrition therapy: Specialists in nutritional counseling determine the patient's individual energy and protein needs and create targeted individual measures to achieve them. Measures can include, for example, adjustments to the menu, food enrichment or supplementation. The measures are discussed with the patients on an ongoing basis and adjusted as necessary.
89429566|NCT02078037|Experimental|Arctic Sun cooling device|The Arctic Sun device pads will be placed on the patient as per manufacturer's instructions. Patients, who cannot tolerate placement of all the pads for any given reason, will still be included in the study if they can maintain normothermia (normal body temperature). The total normothermia time for the study is five days. After 5 days, the attending physician will make clinical decisions based on the patient needs.The temperature goal for this study is 36.5 degree Celsius, but normothermia for the purpose of this study will be defined as a temperature of 35.5 - 37.5 degree Celsius. A thermometer mounted urinary catheter will be used for temperature monitoring and feedback to the Arctic Sun.
89429567|NCT02078037|Active Comparator|Standard of Care|Patient will be given standard fever management (acetaminophen + cooling blanket at the discretion of the treating physician) initiated at a temperature of 38.5 degrees Celsius
88909811|NCT05096013|No Intervention|usual care|Usual care: Participants in the control group receive a standardized food fortification of the soups with fat and protein, as well as an energy- and protein-rich dessert. No additional advice or adjustments are made by the iNT.
88909812|NCT05092360|Experimental|Nemvaleukin and Pembrolizumab Combination|
89429568|NCT02275728|Experimental|Pelvic Floor Muscle Training(PFMT)|The conducted training by two groups, consisting of phasic contractions (3 sets of 10 repetitions of maximal contraction for two seconds to double or triple rest), endurance (two sets of six repetitions of sustained contractions of 6-10 seconds with the same rest time) and training effort, requesting the anticipated contraction of the abdominal pelvic floor coughing effort. We used the same protocol in the supine position, sitting and standing, as evolution of the patient. Both were treated 2 times per week, 20 minutes, totaling 8 sessions.
89429569|NCT02275728|Active Comparator|EMG Biofeedback treatment|In this group, the same protocol of the TMAP will be held, however, emg biofeedback is used during training for 20 minutes, 2 times a week, 8 sessions.
89429570|NCT02275728|No Intervention|no treatment|In this group, will be held only the initial assessment, you will not receive treatment for a month and will be reevaluated after being serviced this period.
89429571|NCT03423134|Experimental|Test of new adhesive strip|A new adhesive strip will be tested in this investigation
89429572|NCT02073669|Other|Second generation immigrants from high TB incidence countries|Answering the study Questionnaire and blood sampling for Interferon gamma release assay (IGRA).
89429573|NCT02073669|Other|Native Israelis|Answering the study Questionnaire and blood sampling for Interferon gamma release assay (IGRA).
89429574|NCT03428516|Experimental|Fixed CPAP|CPAP always deliver air with the same pressure
89429575|NCT03428516|Active Comparator|Auto-adjusting CPAP|Auto-CPAP changes the pressure delivered depending on events detected at any time (apnea, hypopnea …) and applies the lowest pressure required to eliminate events.
89429576|NCT02276742|No Intervention|Usual Care (UC)|Participants randomized to UC will receive baseline advice about the value of losing weight, becoming more physically active, and limiting intake of sodium and inorganic phosphates followed by 12 mos of UC. We have elected not to use a control group in which we provide equivalent attention to both study arms. Behaviors are difficult to change and there is no reason to believe that simply giving participants attention would create behavioral changes sufficient to result in weight loss, reduce sodium excretion, or reduce serum phosphorus. Numerous weight loss studies, including Look AHEAD, have used attention control groups that did not demonstrate weight loss.
89429577|NCT02276742|Active Comparator|Social Cognitive Theory (SCT)|Participants will be exposed to a group behavioral intervention that is based on SCT, which focuses on the role played by self-referent thought in the maintenance of behavior change. Self- efficacy is derived from four major sources of information: mastery experiences, social modeling, verbal persuasion, and physiological states. Mastery experiences will include emphasizing past successes; setting incremental, easily achievable goals; identifying modifiable barriers to healthy behavior; receiving positive feedback on goal achievement; and practicing problem solving skills around barriers to adherence.
88909813|NCT05092360|Experimental|Pembrolizumab|
88909814|NCT05092360|Experimental|Nemvaleukin|
88909815|NCT05092360|Active Comparator|Investigator's Choice|Options for protocol-specific Investigator's choice chemotherapy include one of the following: pegylated liposomal doxorubicin (PLD), paclitaxel, topotecan, or gemcitabine. The Investigator will pre-select the Investigator's choice treatment before the randomization of each patient.
88909816|NCT05091424|Experimental|Arm A|Participants with R/R CLL who have failed two prior lines of therapy and who have had prior exposure to BTKi and/or venetoclax will receive mosunetuzumab subcutaneous (SC) monotherapy
88909817|NCT05091424|Experimental|Arm B|Participants with R/R CLL who have failed two prior lines of therapy, who are currently progressing on BTKi therapy, and who require salvage therapy as assessed by their treating physician will receive mosunetuzumab SC with BTKi overlap therapy for the first two cycles of mosunetuzumab SC
88909818|NCT05091424|Experimental|Arm C|Participants with R/R CLL who have failed two prior lines of therapy and who have had prior exposure to BTKi and/or venetoclax will receive mosunetuzumab SC with venetoclax
88922222|NCT05623982|Experimental|Study treatment|Participants receive GNC-038 as intravenous infusion for the first cycle (2 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
88922223|NCT05619575|Experimental|CP1170 sound processor|Take home use of CP1170 Sound processor for 2 weeks followed by in booth testing of the investigational device.
89429578|NCT02276742|Active Comparator|Monitoring|Participants will be taught how to use a lifestyle self-monitoring program to reduce information processing requirements, make readily available the information required to make good self-management decisions, deliver automated, real-time feedback about achievement of behavioral goals, and permit individualized guidance from an interventionist who uses the MyNetDiary® electronic log to provide targeted education and advice. The Monitoring intervention reduces information processing demands by making relevant nutritional information readily available. Technology-based self-monitoring also can be used by interventionists to reduce information processing burden by using it for targeted counseling
89429579|NCT02276742|Active Comparator|Combined|Participants randomized to COMBINED will receive all aspects of the SCT and MONITORING intervention conditions. Social Cognitive Theory based behavioral intervention in complex patients is strengthened when technology is used to manage information complexity, and weakened in its absence. The Monitoring intervention reduces information processing demands by making relevant nutritional information readily available. Technology-based self-monitoring also can be used by interventionists to reduce information processing burden by using it for targeted counseling
89429580|NCT02073825|Experimental|Web Brief Intervention (WBI)|4-session WBI
89429581|NCT02073825|No Intervention|Delayed-WBI|4-session WBI after follow-up
89429582|NCT02281656|Experimental|Reverse End-to-side|"Surgery: a reverse end-to-side AIN to ulnar nerve transfer whereby the motor branch of the ulnar is left intact and the end of the AIN nerve is coapted to the side of the ulnar motor fascicle(5,6). The advantage of this technique is it preserves the continuity of the ulnar motor branch for axons if they do eventually reinnervate the intrinsic muscles while augmenting or babysitting these muscles during the time period until this occurs."
89429583|NCT02281656|Active Comparator|Surgery:standard care|Surgery: the anterior interosseous (AIN) to motor branch of the ulnar nerve transfer has been established as an effective means to reinnervate ulnar innervated intrinsic hand muscles (without loss of function from using the AIN) when nerve injury is too proximal for recovering axons to reach the hand by 18 months. . The procedure (surgery) is presently the standard of care
89429584|NCT03428438|Other|Study group SMS to home phone|A physical reminder by a physiotherapist, and a daily reminder of physical exercise by SMS on weekdays A through E.
89429585|NCT03428438|Other|Controlled group hospital based|Physical rehabilitation in the ward physiotherapist
89429586|NCT02078115||chronic kidney disease, hypertension|20 <= age < 75 years 15 <= estimated glomerular filtration rate (GFR) < 90
89429587|NCT02281812|Experimental|RFA group|A percutaneous (utlrasound-guided) radiofrequency ablation (RFA) of the tumor will be performed by the radiologist under general anesthesia. Immediately after, excision of the tumor with appropriate margin will be accomplished.
89429588|NCT02281812|No Intervention|Control group|Normal excision of the tumor according to the protocol
89536219|NCT03070275|Experimental|Group-A|In the experimental Group (Group-A), a two-stage implant will be placed in parallel with an overlying biocomplex (aBM-MSCs/fibrin glue/collagen fleece) that comprises autologous alveolar bone marrow mesenchymal stem cells free of animal derived reagents, produced in clean room facilities and seeded into collagen scaffolds enriched with autologous fibrin glue.
89429589|NCT03818438||Case subjects adult patients with chronic ankle instability|"Male or female subjects aged 18-45, presenting :~at least one acute lateral ankle sprain (i.e. initial ankle sprain more than 12 months before inclusion),~at least one residual symptom (giving way OR sensation of instability OR recurrent ankle sprain), confirmed by a score < 24 on the Chronic Ankle Instability Tool (CAIT)~Impact on activities of daily living and sport, score < 90% on Foot and Ankle Ability Measure (FAAM) and < 80% on FAAM-sport Case subjects are free of any other lower extremity pathologies or pain Subjects presenting bilateral chronic ankle instability are excluded"
88909819|NCT05091216|Experimental|Traditional Chinese Medicine Mouthwash Group|The subjects use traditional Chinese medicine mouthwash after three meals a day and before going to bed, four times a day for 7 consecutive days. After 7 days, record the PLI value and conduct a xerostomia questionnaire, and then retrieve the mouthwash bottle the remaining dose was checked to determine compliance. Those with significantly poor compliance were excluded from the experiment, and then the daily cleaning measures were resumed. The subjects still followed the way of mouthwash four times a day until the end of the 21st day after the xerostomia questionnaire.
88909820|NCT05091216|Active Comparator|Dilute 50 times of Traditional Chinese Medicine Mouthwash Group|The subjects use dilute 50 times traditional Chinese medicine mouthwash after three meals a day and before going to bed, four times a day for 7 consecutive days. After 7 days, record the PLI value and conduct a xerostomia questionnaire, and then retrieve the mouthwash bottle the remaining dose was checked to determine compliance. Those with significantly poor compliance were excluded from the experiment, and then the daily cleaning measures were resumed. The subjects still followed the way of mouthwash four times a day until the end of the 21st day after the xerostomia questionnaire.
88909821|NCT05090345||Biorepository trial of children and adolescents/young adults (AYA)|undergoing hematopoietic cell transplantation (HCT) to assess the impact of endotheliopathies in the HCT setting as a contributor of significant morbidity and mortality.
88909822|NCT05086432|Experimental|Sputum-guided management|During Weeks 0 to 16, participants randomized to the intervention arm will receive open-label sputum-guided management of airway inflammation (Table 1 in protocol) identified during screening (Figure 2 in protocol). Airway eosinophilia will be treated with regular inhaled corticosteroids based on the severity of eosinophilic inflammation. In participants with airway neutrophilia, as per the standard of care, sputum culture and sensitivity will be sent, and pathogenic organisms treated. Those participants with airway neutrophilia with negative cultures will be treated with thrice weekly Azithromycin (250mg). Combined eosinophilia and neutrophilia will receive treatment with both ICS and Azithromycin as per Table 2 in protocol.
88909823|NCT05086432|Active Comparator|Standard of Care|Participants in this arm will receive standard of care treatment as determined by their ILD specialist who will be blinded to the results of the sputum analysis.
89429590|NCT03818438||Healthy subjects|Male or female subjects aged 18-45 (matched with case Healthy subjects), without any lower extremity pathologies
89429591|NCT02073903||LEP inpatients and their providers|This is a feasibility project with the goal of improving communication between limited English proficiency (LEP )inpatients and their providers. Quantitative data will be obtained via two surveys: a patient survey to assess patients' feedback on the effectiveness of the communication during their hospital stay and their understanding of their medical care, and a provider survey to assess the handset's impact on the effectiveness of the communication. From this data we will be able to assess patient and provider communication effectiveness with both the current various practices at MSKCC and the new intervention.
89429592|NCT03428282|Experimental|VR Box|Inferior alveolar nerve block will be performed with the aid of VR box as a means of distracting patients' attention.
89429593|NCT03428282|Experimental|Tablet device|Inferior alveolar nerve block will be performed with the aid of a tablet device as a means of distracting patients' attention.
89429594|NCT03428282|Active Comparator|Anesthesia|Inferior alveolar nerve block will be performed in the normal manner without any specific intervention to distract patients' attention. Classic anesthesia will be applied.
89429595|NCT00463242|Experimental|Agomelatine|Dosing for each subject in this extension study began with the same dose (25 mg or 50 mg of agomelatine orally once daily) the subject was receiving at the end of Week 8, the week before this study began.
89429596|NCT00463242|Active Comparator|2|
89429597|NCT00463242|Placebo Comparator|3|
89429598|NCT02078271|Experimental|FBDG group|The group received Food Based Dietary Guidelines for feeding recommendation. Monthly-session with group of mothers involving interactive activities e.g. cooking session, cooking competition and games.
89429599|NCT02078271|Experimental|Stimulation group|The children received psychosocial stimulation from the mothers. Mothers were taught on psychosocial module which was developed using locally existing resources and was directed at improving four aspects of child development, namely gross motoric, fine motor, language and socio-emotional developments.
89429600|NCT02078271|Experimental|Combined (FBDG and Stimulation)|The group received both FBDG and psychosocial stimulation
89429601|NCT02078271|Other|Control|The group received standard health education messages from existing health care system.
89008310|NCT04597489||Angiography + FFR|Patients were stratified into the FFR group if a coronary angiography with adjunctive FFR measurement was performed during the index hospitalization.
89008311|NCT04597489||Angiography only|Patients were stratified into the angiography-only group if a coronary angiography without adjunctive FFR measurement was performed.
89429602|NCT02074137|Experimental|Cabazitaxel|Cabazitaxel 25 mg/m² intravenously every 3 weeks, in combination with oral prednisone or prednisolone 10 mg daily
89429603|NCT02078349|Experimental|Solid Tumors|"Patients will receive Selinexor once weekly (Schedule 1) or twice weekly (Schedule 2) or three times a week (Schedule 3) orally at a starting dose of 50 mg/m² (Schedule 1) and 40mg/m2 (Schedule 2) and 20mg/m2 (Schedule 3).~One cycle is 28 days for Schedule 1 and Schedule 3 and 21 days for Schedule 2. Treatment will continue until disease progression or the development of unacceptable toxicities."
89429604|NCT03795116|Experimental|LED-RL phototherapy|Thirty subjects will be randomly allocated to three treatment groups to receive LED-RL phototherapy or temperature-matched mock irradiation (control) to either periauricular incision site at fluences of 160 J/cm2, 320 J/cm2, or 480 J/cm2. Starting one week after surgery (postoperative days 4-8), treatments will be administered three times weekly for three consecutive weeks.
89429605|NCT03795116|Sham Comparator|Mock irradiation|Thirty subjects will be randomly allocated to three treatment groups to receive LED-RL phototherapy or temperature-matched mock irradiation (control) to either periauricular incision site at fluences of 160 J/cm2, 320 J/cm2, or 480 J/cm2. Starting one week after surgery (postoperative days 4-8), treatments will be administered three times weekly for three consecutive weeks.
89429606|NCT02277366||Fluorescence/Narrow Band Bronchoscopy|All patients in the group are examined by Fluorescence Bronchoscopy and Narrow Band Bronchoscopy to make a early detection of lung cancer.
89429607|NCT02277366||Routine Bronchoscopy|All patients in this group are examined by routine bronchoscopy to make a early detection of lung cancer.
89429608|NCT02080689|Other|Salvage setting|The clinical utility of Decipher will be evaluated for patients meeting the inclusion criteria in the salvage setting: post-RP with evidence of PSA rise or BCR (defined as PSA detectable and rising on 2 or more subsequent determinations)
89429609|NCT02080689|Other|Adjuvant setting|The clinical utility of Decipher will be evaluated for patients in the adjuvant setting: within 12 months after surgery (in the absence of detectable PSA rise of BCR)
89429610|NCT02281890||Proven sepsis|Children included in the INIS trial in whom pathogenic organisms (i.e. bacteria or fungi) were cultured from blood and/or cerebrospinal fluid during the sepsis period at the time of study inclusion
89429611|NCT02281890||Clinical sepsis|Children included in the INIS trial in whom no pathogenic organisms (i.e. bacteria or fungi) were cultured from blood or cerebrospinal fluid during the sepsis period at the time of study inclusion
89429612|NCT03127826|Active Comparator|Usual Care|"Managing Low Back Pain pamphlet from DoD/VA~No specific guidance regarding physical therapy (PT) or other referrals, thus decision to refer or not will be made by the primary care manager (PCM) according to their preference"
89429613|NCT03127826|Experimental|Risk Stratified Care|"Managing Low Back Pain pamphlet from DoD/VA~Self-management education and tools~2-item spinal manipulation screening/delivery if indicated~Low Risk:~Home Exercise Program as indicated~No referral for ongoing physical therapy~Medium Risk and High Risk~Referral to physical therapy for ongoing care at physical therapists discretion~Managed by a psychologically informed physical therapy trained physical therapist"
89429614|NCT00664482|Experimental|1|AGS-006
89429615|NCT03110666|Experimental|Autologous concentrated bone marrow aspirate|autologous concentrated bone marrow aspirate obtained from the BioCUE Concentration System
89429616|NCT00600288|Experimental|1|
89429617|NCT00600288|Placebo Comparator|2|
89429618|NCT03428204|Other|180 seconds balloon dilation|Percutaneous angioplasty with balloon dilation during 180 seconds for percutaneous treatment of femoropopliteal artery stenosis
89429619|NCT03428204|Other|300 seconds balloon dilation|Percutaneous angioplasty with balloon dilation during 300 seconds for percutaneous treatment of femoropopliteal artery stenosis
89536220|NCT03070275|Active Comparator|Control Group-B|In Group-B, a two-stage surgical implant placement on the alveolar crest is followed based on the manufacturer's guidelines with no use of adjunctive grafting materials.
89429620|NCT02284152|Experimental|Typical versus Infant-Led feeding|This is a within-subject study; all infants and mothers will be exposed to both conditions (typical feeding versus infant-led feeding conditions). Order of presentation will be counterbalanced across infant/mother dyads.
89429621|NCT03423056|Experimental|Preoperative exercise program|"The individualized aerobic training program will be developed according to Karvonem's equation . It will programmed in 3 sessions/week (not in row) during 4 weeks.~Each 50-minutes session will be organized in three phases: warm up, central and back to calm. The heart rate target will be prescribed as follows:~Week 1: heart rate target: 50% of maximum heart rate Week 2: heart rate target: 60% of maximum heart rate Week 3: heart rate target: 70% of maximum heart rate Week 4: heart rate target: 60% of maximum heart rate The aerobic exercise will be carried on a treadmill or in a stationary bicycle, according to the patient's preferences and will be supervised by a physical therapist."
89429622|NCT02278224|Experimental|Rumination Focused CBT|11 sessions of manualised group based Rumination Focused CBT for depression. 3 hours sessions are administered once during 11 weeks in groups of approximately 8 patients and two therapist.
89429623|NCT02278224|Active Comparator|Cognitive Behavioral Therapy|11 sessions of manualised group based CBT for depression. 3 hours sessions are administered once during 11 weeks in groups of approximately 8 patients and two therapist.
89429624|NCT03790436|Experimental|Betaquik|
89429625|NCT00594984|Active Comparator|Arm 1 - Phase 1|"Cetuximab + Irinotecan + Brivanib~OR~Cetuximab + Irinotecan + Brivanib Placebo"
89429626|NCT00594984|Placebo Comparator|Arm 2 - Phase 2|"Cetuximab + Irinotecan + Brivanib~OR~Cetuximab + Irinotecan + Brivanib Placebo"
89429627|NCT01369485|Active Comparator|Active Treatment group|VERV™ System
89429628|NCT01369485|Sham Comparator|Sham Treatment Group|Sham version of (VERV™ System)
89429629|NCT03422978|Sham Comparator|Saline bolus|10mL normal saline solution administered intravenously over 60 seconds starting after intubation.
89429630|NCT03422978|Experimental|Dexmedetomidine 0.25 mcg/kg|0.25 mcg/kg dexmedetomidine diluted with normal saline to a 10mL volume, administered intravenously over 60 seconds starting after intubation.
89429631|NCT03422978|Experimental|Dexmedetomidine 0.50 mcg/kg|0.50 mcg/kg dexmedetomidine diluted with normal saline to a 10mL volume, administered intravenously over 60 seconds starting after intubation.
89429632|NCT03422978|Experimental|Dexmedetomidine 1.00 mcg/kg|1.00 mcg/kg dexmedetomidine diluted with normal saline to a 10mL volume, administered intravenously over 60 seconds starting after intubation.
89429633|NCT02278692|Active Comparator|Vitamin K|Vitamin K1 (phytonadione) 10 mg orally three times a week after dialysis for 12 weeks
89429634|NCT02278692|Placebo Comparator|Placebo|Identical appearing placebo orally three times a week after dialysis for 12 weeks
89536221|NCT02450695|Experimental|Active rTMS|"In rTMS, a device called a stimulator provides energy to a magnetic coil. The coil is a handheld unit that delivers magnetic pulses. The coil is placed against the scalp on the top of your head. Sessions will occur once a day, 5 days/week, for 3 weeks."
89536222|NCT02450695|Sham Comparator|Sham rTMS|The coil in the sham rTMS phase will be positioned 90 degrees off the scalp, with one wind of the coil touching the scalp. This will ensure that the participant will not be affected by the machine during this time. All other factors will be similar to the active rTMS phase.
88909824|NCT05085977|Experimental|TARA-002|TARA-002 is a lyophilized biological preparation for instillation containing cells of Streptococcus pyogenes (Group A, type 3) Su strain treated with benzylpenicillin.
88909825|NCT05085002|Other|Lerociclib + letrozole or fulvestrant|
88909826|NCT05081453|Experimental|Pavlik harness treatment group|Application of a pavlik harness for 2 months in position seeking 90º of flexion of both knees and 45º of hip flexion with some abduction. An ultrasound control is performed at 2 and 6 months
88909827|NCT05081453|No Intervention|Control group without intervention|Control group without intervention. An ultrasound control is performed at 2 and 6 months
88909828|NCT05081180|Experimental|Avelumab + Lenvatinib|
88909829|NCT05077826|Experimental|Full Current tES|TES delivered with the anode over the right temple and cathode on the left arm, at an intensity of up to 4 milliamps, delivered for up to 40 minutes.
88909830|NCT05077826|Placebo Comparator|Partial Current tES|TES delivered with the anode over the right temple and cathode on the left arm, at an intensity of 0.1 milliamp, delivered for up to 40 minutes.
88909833|NCT05074030|Active Comparator|PNF|Participants in the PNF condition will receive normative feedback only on their alcohol use.
88909834|NCT05074030|Experimental|PFIcope+EMI|The 6-week PFIcope+EMI includes: 1) an in-person personalized feedback session to present feedback on problems with drinking to cope, discuss the individual's use of alcohol to cope, and generate coping skills messages to be used in the EMI intervention; 2) EMA to monitor affect, intention to drink, coping skills usage, alcohol use, drinking to cope post-discharge; 3) tailored text messages (EMI) based on EMA (individualized coping skills messages when NA and intention to drink are reported).
88909835|NCT05073718|Experimental|LDASA (n=200)|
88909836|NCT05073718|Placebo Comparator|Placebo (n=200)|
88922224|NCT05619575|Active Comparator|CP1150 sound processor|In booth testing of CP1150 sound processor.
88922225|NCT05617781||Control|
88922226|NCT05617781||Patient|
89429635|NCT03430622|Experimental|LTP Plus|LTP Plus group participants will receive intervention over the telephone for 3 months one session per week for 2 months and rest of the sessions fortnightly by trained graduates, expert in delivering LTP plus intervention.
89429636|NCT03430622|Active Comparator|Treatment as Usual (TAU)|TAU group will receive routine care and their follow up will be done after completion of the intervention and then at 6-month post randomization.
89429637|NCT02281968|Experimental|NSAID cohort|Patients who have had surgical management of ankle fracture will be given a standing regimen (scheduled doses) of 500 mg naproxen twice a day and will have received one intraoperative dose of ketorolac. Patients will have a prescription for opioids for breakthrough pain.
89008312|NCT04597489||Subgroup ACS|"Patients were stratified by index diagnoses, i.e. acute coronary syndrome (ACS) or chronic coronary syndrome (CCS) according to the index hospital admission diagnosis.~This subgroup consists of patients presenting with ACS."
89008313|NCT04597489||Subgroup CCS|"Patients were stratified by index diagnoses, i.e. acute coronary syndrome (ACS) or chronic coronary syndrome (CCS) according to the index hospital admission diagnosis.~This subgroup consists of patients presenting with CCS."
89008314|NCT04597489||Subgroup revascularization|"Patients were stratified by the type of treatment, i.e. percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG), or conservative management with optimal medical therapy (OMT) alone, based on the procedure codes during the index hospital stay.~This subgroup consists of patients undergoing revascularization after an angiography (with or without FFR) during the index hospital stay."
89008315|NCT04597489||Subgroup optimal medical therapy|"Patients were stratified by the type of treatment, i.e. percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG), or conservative management with optimal medical therapy (OMT) alone, based on the procedure codes during the index hospital stay.~This subgroup consists of patients undergoing optimal medical therapy after an angiography (with or without FFR) during the index hospital stay."
89008316|NCT02961660|Experimental|Cohort 1 (Severe Renal Impairment): Odalasvir|Participants will receive single oral dose of odalasvir 25 milligram (mg) under fed conditions (standard breakfast) on Day 1.
89008317|NCT02961660|Experimental|Cohort 2 (Normal Renal Function): Odalasvir|Participants will receive single oral dose of odalasvir 25 milligram (mg) under fed conditions (standard breakfast) on Day 1.
89429638|NCT02281968|Placebo Comparator|Placebo cohort|Patients who have had surgical management of ankle fracture will be given a standing regimen (scheduled doses) of placebo twice a day and will have received one intraoperative dose of saline solution. Patients will have a prescription for opioids for pain.
89429639|NCT03422900|Experimental|Specific Diabetes Formula|"Diabetes-Specific Enteral Formula:~Caloric density: 1,0 kcal/ml~Energy: 100 kcal~Carbohydrates: 10,1 g/100 ml;~Fat: 4,5 g/100 ml~Prot: 3,8 g/100 ml~Osmolarity: 345 mOsm/l~Fiber: 1,78 g/100 ml (80% soluble; 20% insoluble)."
89429640|NCT03422900|Active Comparator|Standard Formula|"Standard Enteral Formula:~Caloric density: 1,0 kcal/ml~Energy: 100 kcal~Carbohydrates: 13,8 g/100 ml;~Fat: 3,4 g/100 ml~Prot: 3,8 g/100 ml~Osmolarity: 220 mOsm/l~Fiber: 0 g/100 ml"
89429641|NCT02080845|Placebo Comparator|no caffeine & no theobromine|Drink 1
89429642|NCT02080845|Experimental|no caffeine & low theobromine|Drink 2
89429643|NCT02080845|Experimental|no caffeine & high theobromine|Drink 3
89429644|NCT02080845|Experimental|high caffeine & no theobromine|Drink 4
89429645|NCT02284230|Active Comparator|Liraglutide treatment|Subcutaneous, once daily injection of liraglutide, individually dosed up to 1.8 mg/day.
89429646|NCT02284230|Placebo Comparator|Placebo treatment|Subcutaneous, once daily injection of placebo, individually dosed up to 1.8 mg/day.
89429647|NCT00663936|Experimental|1|T-817MA once daily
89429648|NCT00663936|Placebo Comparator|2|Placebo once daily
89429649|NCT02074215|Experimental|Aerobic exercises|90-minute exercise sessions per week for 12 weeks
89429650|NCT02074215|Active Comparator|Stretch exercise|90-minute exercise sessions per week for 12 weeks
89429651|NCT02080923|Experimental|Brief Motivational Interview|Health-related counseling that takes place in as little as one hour or up to a few sessions.
89429652|NCT02080923|No Intervention|Standard Care|Participant will receive information about dating abuse in a handout and referrals to a national domestic violence hotline.
89429653|NCT02792088|Experimental|Besifovir|Besifovir 150 mg q.d.
89429654|NCT02792088|Active Comparator|Tenofovir|Tenofovir 300 mg q.d.
89429655|NCT02074293|Experimental|Splenius|"Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
89429656|NCT02074293|Experimental|Scalene|"Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
88814791|NCT03031418||Cohort 2|Enroll up to 500 patients to evaluate how the results of the urine test influences the decision process for determining whether to perform a prostate biopsy. The treating physician will collect a urine sample for testing and 2 weeks later discuss whether to perform a prostate biopsy with the subject knowing the results of the urine test and comparing them to the overall consensus report from Cohort 1 as well as other clinical factors the treating physician would otherwise use to determine whether they should have a prostate biopsy.
88814792|NCT03035084|Experimental|Group-2-D3|Subjects with total 25(OH)D more= 20 nmol/l and less= 40 nmol/l will receive vitamin D2 then randomly assigned to vitamin D3
88814793|NCT03035084|Placebo Comparator|Group-2-Placebo|Subjects with total 25(OH)D more= 20 nmol/l and less= 40 nmol/l will receive vitamin D2 then randomly assigned to placebo oral capsule.
89429657|NCT02074293|Experimental|Sterno-cleido-mastoid|"Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
89429658|NCT02074293|Experimental|Levator Scapulae|"Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
89429659|NCT02074293|Experimental|Semispinalis|"Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
89429660|NCT02074293|Experimental|Trapezius|"Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
89429661|NCT02074293|Experimental|Longissimus|"Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
89429662|NCT02074293|Experimental|Change from Baseline in Pain Frequency|Change from Baseline in Pain Frequency as Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12, Efficacy of Botox intramuscularly at Week 18, Efficacy of Botox intramuscularly at Week 24, and Efficacy of Botox intramuscularly at Week 30 vs.Efficacy of Botox subdermally at Week 6, Efficacy of Botox subdermally at Week 12, Efficacy of Botox subdermally at Week 18, Efficacy of Botox subdermally at Week 24, and Efficacy of Botox subdermally at Week 30.
89429663|NCT02074293|Experimental|Change from Baseline in Pain Intensity|Change from Baseline in Pain Intensity as Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12, Efficacy of Botox intramuscularly at Week 18, Efficacy of Botox intramuscularly at Week 24, and Efficacy of Botox intramuscularly at Week 30 vs.Efficacy of Botox subdermally at Week 6, Efficacy of Botox subdermally at Week 12, Efficacy of Botox subdermally at Week 18, Efficacy of Botox subdermally at Week 24, and Efficacy of Botox subdermally at Week 30. The severity on scales of 0(no pain) to 4(constant or extremely severe intensity).
89536223|NCT03070041|Experimental|Mothers and staff members|The mothers who will give birth at the study hospital and all the staff members taking care about mothers and/or infants
88814794|NCT03035084|Experimental|Group-1-D2|Subjects with 25(OH)D3 more= 40 nmol/l and total 25(OH)D less= 65 nmol/l will be randomly assigned to vitamin D2.
88814795|NCT03035084|Placebo Comparator|Group-1-Placebo|Subjects with 25(OH)D3 more= 40 nmol/l and total 25(OH)D less =65 nmol/l will be randomly assigned to placebo oral capsule.
88814796|NCT03034850||CRS/HIPEC|Patients with a confirmed histological diagnosis of peritoneal disease treated by cytoreductive surgery (CRS) with hyperthermic intraperitoneal peroperative chemotherapy (HIPEC).
88814797|NCT01663259|Experimental|Cetuximab|
88814798|NCT05711069|Active Comparator|Core Stability Exercise Program Group|23 Football players from Gönyeli Futbol Akademisi voluntarily will participate in the study. Subjects will include to study if they fulfil criteria. Athletes will involve 8 Weeks core stability exercise program. During this process they will continue to attend routine football training program. After 8. Weeks assessments will be repeated.
88814799|NCT05711069|Other|Routine Football Training Program Group|22 Football players from Gönyeli Futbol Akademisi voluntarily will participate in the study. Subjects will include to study if they fulfil criteria. Kicking velocity, run speed and agility performance will evaluate and athletes will continue to attend football training program. After 8 Weeks assessments will be repeated.
89429664|NCT02074293|Experimental|Change from Baseline in CDSS|Change from Baseline in CDSS as Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12, Efficacy of Botox intramuscularly at Week 18, Efficacy of Botox intramuscularly at Week 24, and Efficacy of Botox intramuscularly at Week 30 vs.Efficacy of Botox subdermally at Week 6, Efficacy of Botox subdermally at Week 12, Efficacy of Botox subdermally at Week 18, Efficacy of Botox subdermally at Week 24, and Efficacy of Botox subdermally at Week 30. The CDSS or Cervical Dystonia Severity Scale quantifies the severity of abnormal head positioning and was newly devised for this study. CDSS allots 1 point for each 5 degrees (or part thereof) of head deviation in each of the three planes of head movement (range of scores up to theoretical maximum of 54).
89429665|NCT02074293|Experimental|Percent of Patients with Improved PGAS|Percent of Patients with Improved PGAS as Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12, Efficacy of Botox intramuscularly at Week 18, Efficacy of Botox intramuscularly at Week 24, and Efficacy of Botox intramuscularly at Week 30 vs.Efficacy of Botox subdermally at Week 6, Efficacy of Botox subdermally at Week 12, Efficacy of Botox subdermally at Week 18, Efficacy of Botox subdermally at Week 24, and Efficacy of Botox subdermally at Week 30. The Physician Global Assessment Scale or PGAS is a 9 category scale scoring the physician's evaluation of the patients' status compared to baseline, ranging from -4 to +4 (very marked worsening to complete improvement), with 0 indicating no change from baseline and +1 slight improvement.
89429666|NCT02074293|Experimental|Adverse Reactions with Facial paresis|Facial paresis as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
89429667|NCT02074293|Experimental|Adverse Reactions with Eyelid ptosis|Eyelid ptosis as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
89429668|NCT02074293|Experimental|Adverse Reactions with Bronchitis|Bronchitis as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
89429669|NCT02074293|Experimental|Adverse Reactions with Neck pain|Neck pain as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
89429670|NCT02074293|Experimental|Adverse Reactions with Muscle stiffness|Musculoskeletal stiffness as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
89429671|NCT02074293|Experimental|Adverse Reactions with Muscular weakness|Muscular weakness as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
89429672|NCT02074293|Experimental|Adverse Reactions with Myalgia|Myalgia as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
89429673|NCT02074293|Experimental|Adverse Reactions with Muscle pain|Musculoskeletal pain as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
88909837|NCT05072626||high MCT formula nutritional support|Infants aged 0-3 months who underwent Kasai operation for congenital biliary atresia and were able to receive enteral nutrition through oral or tube feeding were administered a high MCT formula powder + breast milk (with the high MCT formula powder accounting for ≥50%) after the Kasai operation. If breast milk was insufficient, regular formula was used as a substitute. The recommended energy intake was set at 100-130% of DRIs.
88909838|NCT05070858|Experimental|Group 1|Placebo in DBTP; Re-randomized to Combination or Cemdisiran in ETP and OLTP
88909839|NCT05070858|Experimental|Group 2|Combination regimen throughout the study
88909840|NCT05070858|Experimental|Group 3|Cemdisiran throughout the study
88909841|NCT05070858|Experimental|Group 4|Pozelimab monotherapy in DBTP followed by combination in ETP and OLTP
88909842|NCT05067127|Experimental|Group 1: Pegcetacoplan administration|Subcutaneous infusion of 20mL (1080 mg), twice weekly (for adults or adolescents >50kg), and the three other weight-based doses either of 10mL (540mg), 12mL (648mg), or 15mL (810mg)
88909843|NCT05067127|Placebo Comparator|Group 2: Placebo administration|Subcutaneous infusion of either 10mL, 12mL, 15mL, or 20mL, twice weekly
88909844|NCT05067101|Experimental|Capsule Sparing Cystectomy|Patients undergoing transurethral resection and enucleation of the prostate before laparoscopic cystectomy
88909845|NCT05067101|Placebo Comparator|Conventional Radical Cystoprostatectomy|Patients undergoing conventional radical cystoprostatectomy
89429674|NCT02074293|Experimental|Adverse Reactions with Muscle spasms|Muscle spasms as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
89429675|NCT02074293|Experimental|Adverse Reactions Injection site pain|Injection site pain as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
89429676|NCT02074293|Experimental|Adverse Reactions with Hypertension|Hypertension as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
89429677|NCT00456378|Experimental|DIAM™ spinal stabilization system|Implantation of the DIAM Spinal Stabilization System
89429678|NCT00456378|Active Comparator|Conservative care|Conservative Care
89429679|NCT02282046||non-diabetic group|patients without diagnosed type 2 diabetes, having an HbA1c level below 6.0%
89429680|NCT02282046||type 2 diabetes group|patients diagnosed with type 2 diabetes of over 1 year duration.
89429681|NCT02282124|Experimental|Intervention|"The intensity of the intervention follows a defined algorithm during the first eight months after renal transplantation. Behaviours are classified in three groups:~Group 1: Patients with optimal behaviour in all three behaviours.~Group 2: Patients with slight deviation (defined) from optimal behaviour in one or more behaviours.~Group 3: Patients with larger deviation (defined) from optimal behaviour in one or more behaviours.~All patients (group 1-3) will receive an assessment, education and a monthly reassessment.~Patients from group 2 und 3 will receive additionally behavioral education and peer involvement. Patients from group 3 will receive additionally a consilium of specialized healthcare professionals such as a nutritionist, physiotherapist, or psychologist."
89429682|NCT02282124|Other|Control|
89429683|NCT03749252|Experimental|CNS Cohort 2-6 years|Pediatric patients aged 2-6 years undergoing CNS contrast-enhanced MRI
88909846|NCT05066178|Experimental|CAS Treatment for MV ASD|Participants will receive CAS treatment, modified for minimally verbal children with autism
88909847|NCT05063695||Epidural|Patients who underwent Nuss procedure under epidural protocol (between January and December of 2019)
88909848|NCT05063695||ESP|Patients who underwent Nuss procedure using ESP catheter protocol (June 2020 to April 2021)
88909849|NCT05063539|Experimental|LY3372689 High Dose|LY3372689 given orally
88909850|NCT05063539|Experimental|LY3372689 Low Dose|LY3372689 given orally
88909851|NCT05063539|Placebo Comparator|Placebo|Placebo given orally
88909852|NCT05062213|Experimental|Moisturizer Body Lotion|All participants will receive the product and use it at home.
88909853|NCT05061108|Experimental|Intervention|Randomized selection of recruited participants that will receive intervention
88909854|NCT05061108|No Intervention|Control|Randomized selection of recruited participants that will not receive intervention
88909855|NCT05055843|Experimental|Screening (3D MRI)|Patients undergo 3D MRI imaging over 15 minutes with standard of care MRI or at a separate time.
88909856|NCT05053139|Experimental|no PPX- no PPX - Mim8 PPXQW/QM|Participants not receiving prophylaxis will not enter the run-in period. In arm 1, participants will be randomised to continue no prophylaxis (on-demand treatment with their Standard of Care products) or Mim8 once-weekly or once-monthly prophylaxis in agreement with investigators in the main part of the study (26 weeks). After the main part, participants will continue in the extension part of the study (26 weeks) in agreement with the investigator, either weekly or monthly Mim8 prophylaxis regimen.
88909857|NCT05053139|Experimental|no PPX - Mim8 PPXQW - Mim8 PPXQW|Participants not receiving prophylaxis will not enter the run-in period. In arm 2a, participants will be randomised to Mim8 once-weekly prophylaxis in the main part of the study (26 weeks). After the main part, participants will continue in the extension part of the study (26 weeks) on once-weekly Mim8 prophylaxis regimen.
88909858|NCT05053139|Experimental|no PPX - Mim8 PPXQM - Mim8 PPXQM|Participants not receiving prophylaxis will not enter the run-in period. In arm 2b, participants will be randomised to Mim8 once-monthly prophylaxis in the main part of the study (26 weeks). After the main part, participants will continue in the extension part of the study (26 weeks) on once-monthy Mim8 prophylaxis regimen.
88909859|NCT05053139|Experimental|PPX - Mim8 PPXQW|Participants on coagulation factor prophylaxis prior to enrolment will preferably continue the same product type and dosing frequency in the run-in period for at least 26 weeks before they can be randomised into the main part of the study. These participants will only be allowed to receive coagulation factor prophylaxis. In arm 3, participants will be randomised to once-weekly Mim8 prophylaxis regimen in the main part of the study (26 weeks). After the main part, participants will continue in the extension part of the study (26 weeks) on once-weekly Mim8 prophylaxis regimen.
88909860|NCT05053139|Experimental|PPX- Mim8 PPXQM|Participants on coagulation factor prophylaxis prior to enrolment will preferably continue the same product type and dosing frequency in the run-in period for at least 26 weeks before they can be randomised into the main part of the study. These participants will only be allowed to receive coagulation factor prophylaxis. In arm 4, participants will be randomised to once-monthly Mim8 prophylaxis regimen in the main part of the study (26 weeks). After the main part, participants will continue in the extension part of the study (26 weeks) on once-monthly Mim8 prophylaxis regimen.
88909861|NCT05049759|Experimental|Feasibility testing|The feasibility trial, aims to assess the feasibility of the intervention, including assessment of acceptability and outcome measures. Twenty youths with anxiety and/or depressive symptoms will be recruited to the intervention. Physical activity will be measured using the Actigraph GT3X+ monitor at baseline and post-intervention. Outcome measures concerning symptom change will be assessed (anxiety and depression). Semi-structured qualitative interview with participants, caregivers and referring specialists will help identify possible contextual and practical factors associated with delivery of the intervention and explore acceptability of assessment procedures, the intervention, and perceived benefits and barriers to participation.
88909862|NCT05049174|Experimental|Intensive intervention|
89429684|NCT03749252|Experimental|CNS Cohort 7-11 years|Pediatric patients aged 7-11 years undergoing CNS contrast-enhanced MRI
89429685|NCT03749252|Experimental|CNS Cohort 12-17 years|Pediatric patients aged 12-17 years undergoing CNS contrast-enhanced MRI
89429686|NCT03749252|Experimental|Body Cohort 2-6 years|Pediatric patients aged 2-6 years undergoing contrast-enhanced MRI of other body organs (head and neck, thorax, abdomen, pelvis or musculoskeletal system)
89429687|NCT03749252|Experimental|Body Cohort 7-11 years|Pediatric patients aged 7-11 years undergoing contrast-enhanced MRI of other body organs (head and neck, thorax, abdomen, pelvis or musculoskeletal system)
88909863|NCT05049174|Active Comparator|Low-threshold intervention|
88909864|NCT05048823|Experimental|Intervention Protocol|Visceral techniques for the gastrointestinal system
88909865|NCT05048823|Sham Comparator|Placebo Protocol|simulated visceral techniques in the region of the gastrointestinal system, without therapeutic intent
88909866|NCT05048433|Experimental|implementation strategy for active learning to promote physical activity|
88909867|NCT05048433|Active Comparator|Usual Implementation support|
88909868|NCT05047926|Experimental|Cohort 1 (surveys, CT, blood samples)|Patients undergoing primary surgical intervention complete surveys, undergo CT, and undergo collection of blood samples at baseline.
88909869|NCT05047926|Experimental|Cohort 2 (exercise, supplement, Resilient Living)|Patients undergoing neoadjuvant chemotherapy complete physical activity for 30 minutes per day 3 times a week. Patients receive nutritional supplement drink up to 4.5 times daily, and complete Resilient Living program in-person or remotely over 60 minutes. Patients also undergo CT scans throughout the trial.
88909870|NCT05047926|Experimental|Cohort 3 (exercise, supplement, coaching, Resilient Living)|Patients undergoing neoadjuvant chemotherapy complete physical activity remotely for 30 minutes per day 3 times a week. Patients receive nutritional supplement drink up to 4.5 times daily. Patients also undergo health coaching remotely for 60 minutes weekly, complete Resilient Living program remotely over 60 minutes, and may wear a FitBit throughout the study.
89429688|NCT03749252|Experimental|Body Cohort 12-17 years|Pediatric patients aged 12-17 years undergoing contrast-enhanced MRI of other body organs (head and neck, thorax, abdomen, pelvis or musculoskeletal system)
89429689|NCT02078505|Experimental|PCOS after diet|Patients after 2 months of diet
89429690|NCT02078505|No Intervention|control|Ovulatory women
89429691|NCT00451152|Experimental|Anecortave Acetate Depot|
89429692|NCT00451152|Placebo Comparator|Anecortave Acetate Vehicle|
88909871|NCT05047809|Experimental|"Jingchuang Ointment(JCO) group"|"Ulcers were treated in this study using the four-step wound care guidelines, observation, rinsing, cleaning, and dressing, published by the Taiwan Food and Drug Administration. Besides, JCO was applied once a day on the wounds, last 3 months.~Jingchuang Ointment (JCO) is made by Chuang Song Zong Pharmaceutical Co., Ltd. (Taiwan)"
88909872|NCT05047809|Other|Regular treatment group|Ulcers were treated in this study using the four-step wound care guidelines, observation, rinsing, cleaning, and dressing, published by the Taiwan Food and Drug Administration.
89429693|NCT02279472|Other|laser peripheral iridotomy|Laser peripheral iridotomy (LPI) is widely regarded as the first-line intervention for either acute or chronic types of angle-closure glaucoma in early stage ,which relieves pupil block and thus flattening the iris contour and widening the drainage angle,performd by Nd.YAG LASER
88909873|NCT05047796|Experimental|Intervention Protocol|Visceral osteopathic techniques
88909874|NCT05047796|Sham Comparator|Sham Protocol|Simulated visceral osteopathic techniques
88909875|NCT05046860|Experimental|Dalbavancine + Rifampicine|
88909876|NCT05044039|Experimental|Dose Escalation Stage: Duvelisib|"Duvelisib is an oral medication taken on a once or twice daily basis on all dosing days. Doses being explored in this study are 15 mg BID (starting dose), 25 mg BID, and 15 mg QD. In the dose escalation stage, patients will receive duvelisib from Day -2 through Day 28.~CAR T-cells will be given per standard of care."
88909877|NCT05044039|Experimental|Cohort A Dose Expansion Stage: Duvelisib|"Patients in Cohort A will receive duvelisib from Day -2 to Day 28. The dose that will be given will be determined in the dose escalation stage (the maximum tolerated dose).~CAR T-cells will be given per standard of care."
88909878|NCT05044039|Experimental|Cohort B Dose Expansion Stage: Duvelisib|"Patients in Cohort B will receive duvelisib from Day -2 to Day 28 at the maximum tolerated dose (determined in dose expansion stage), followed by two weeks off therapy. This will be followed by 5 additional cycles of duvelisib for days 1-14 of 28 day cycles at the maximum tolerated dose.~CAR T-cells will be given per standard of care."
88909879|NCT05042115|Experimental|Education in pain neurosciences and clinical hypnosis|Pain neuroscience education and clinical hypnosis
88909880|NCT05042115|Active Comparator|Education in pain neurosciences and clinical hypnosis plus Osteopathic manipulative treatment|Pain neuroscience education and clinical hypnosis, associated with osteopathic manipulative treatment
88909881|NCT05041504|Experimental|Intervention|Participants assigned to the intervention arm will receive the True North Peer Navigation intervention.
88909882|NCT05041504|Other|Active Waitlist Control|Participants assigned to the control arm will receive usual care and access to an online health resource library. After completion of the study, they will receive the True North Peer Navigation intervention.
88909883|NCT05041309|Experimental|Axicabtagene Ciloleucel (KTE-C19 )|All participants who previously received axicabtagene ciloleucel (KTE-C19 ) in the parent study will be enrolled in this arm for long-term follow-up.
88909884|NCT05041309|Experimental|Brexucabtagene Autoleucel (KTE-X19)|All participants who previously received brexucabtagene autoleucel (KTE-X19) in the parent study will be enrolled in this arm for long-term follow-up.
89429694|NCT02078583|Experimental|Remifentanil，midazolam|Remifentanil 1µg/kg/hr intravenous pump and Midazolam loading dose 0.05mg/kg followed by 0.02~0.1mg/kg/h continuous intravenous pump for 7days or extubation
89429695|NCT02078583|Experimental|Fentanyl，midazolam|Fentanyl 1µg/kg/hr intravenous pump and Midazolam loading dose 0.05mg/kg followed by 0.02~0.1mg/kg/h continuous intravenous pump for 7days or extubation
88909885|NCT05041309|Experimental|KITE-585|All participants who previously received KITE-585 in the parent study will be enrolled in this arm for long-term follow-up.
88909886|NCT05041309|Experimental|KITE-718|All participants who previously received KITE-718 in the parent study will be enrolled in this arm for long-term follow-up.
88909887|NCT05041309|Experimental|KITE-439|All participants who previously received KITE-439 in the parent study will be enrolled in this arm for long-term follow-up.
88909888|NCT05041309|Experimental|KITE-222|All participants who previously received KITE-222 in the parent study will be enrolled in this arm for long-term follow-up.
88909889|NCT05041309|Experimental|KITE-363|All participants who previously received KITE-363 in the parent study will be enrolled in this arm for long-term follow-up.
88909890|NCT05040373||Patisiran|Pregnant women exposed to commercial patisiran-LNP (ONPATTRO) during the 12 weeks prior to their last menstrual period (LMP) or at any time during pregnancy.
88909891|NCT05038098|Experimental|Cohort I (preoperative injection)|Patients receive FerroTrace peritumorally within days 1-21. Patients then undergo gastrectomy and receive ICG peritumorally.
88909892|NCT05038098|Experimental|Cohort II (intraoperative)|Patients undergo gastrectomy and receive FerroTrace and ICG peritumorally during surgery.
88909893|NCT05037929|Experimental|Astegolimab Q2W|Participants will receive subcutaneous (SC) astegolimab every 2 weeks (Q2W).
88909894|NCT05037929|Experimental|Astegolimab Q4W|Participants will receive alternating SC astegolimab and placebo Q2W, thus receiving astegolimab every 4 weeks (Q4W).
88909895|NCT05037929|Placebo Comparator|Placebo|Participants will receive SC placebo Q2W.
88909896|NCT05035901|Experimental|visual-perception motor-coordination integration program|Visual-perception motor-coordination integration program (CCVPMCI) is a Chinese characteristic-based VMI-focused program involving the most Chinese-handwriting-related skills training. CCVPMCI mainly emphasizes the training role of visual-motor integration. The idea of CCVPMCI program will involve (1) visual motor integration training affiliated with visual perception and motor coordination as warm-up exercise, (2) more focus on visual spatial perception in connect with unique visual structure of Chinese characters, (3) the trace or component elements of Chinese characters as the interesting practice material and (4) appropriate challenge for learning.
88909897|NCT05035550|Experimental|Non-Deceptive Placebo|The NDP group was informed that the purpose of the study was to test a mind-body intervention that might help participants deal with the stress and anxiety that they are feeling during the pandemic. The intervention included two videos that introduced the effects of non-deceptive placebos, followed by a presentation on up-to-date non-deceptive placebo research. The participants then received instruction on how they would take their non-deceptive placebos for the next two weeks. Participants were asked to complete daily pill-taking adherence surveys (~5 min) and weekly at midpoint (1-week) and endpoint (2-week).
88909898|NCT05035550|No Intervention|No-Treatment Control|The Control group did not receive an intervention. Instead, participants were informed that the purpose of the study was to track individual psychological and physical health over longer time periods in the context of the pandemic. Participants were asked to complete weekly questionnaires at midpoint (1-week) and endpoint (2-week).
88909899|NCT05035225|Experimental|Specialty Pharmacy Patient|Patients who have been prescribed at least one selected specialty medication
88909900|NCT05030311|Experimental|Arm 1: LOU064 (blinded)|LOU064 (blinded) taken orally for 24 weeks, followed by LOU064 (open-label) taken orally open label for 28 weeks. Randomized in a 2:1 ratio (arm 1:arm 2).
88909901|NCT05030311|Placebo Comparator|Arm 2: LOU064 placebo (blinded)|LOU064 placebo (blinded) taken orally for 24 weeks, followed by LOU064 (open-label) taken orally for 28 weeks. Randomized in a 2:1 ratio (arm 1:arm 2).
88909902|NCT05027503|Active Comparator|Control Group|Home-based respiratory physiotherapy will be applied twice a day and every day of the week for 8 weeks
88909903|NCT05027503|Experimental|Training Group|In addition to home-based respiratory physiotherapy, 30 min exercises with the hippotherapy simulator will be done.
89429696|NCT02078583|Placebo Comparator|Normal saline|Normal saline1µg/kg/hr intravenous pump and Midazolam loading dose 0.05mg/kg followed by 0.02~0.1mg/kg/h continuous intravenous pump for 7days or extubation
89429697|NCT00449904|Experimental|Liprotamase|Liprotamase is a fixed combination of lipase (32,500 units), protease (25,000 units) and amylase (3,750 units) administered orally with each of three meals and two snacks daily for 12 months.
89429698|NCT02078661|Active Comparator|PG101 0.25%|Topical application of drug
89429699|NCT02078661|Active Comparator|PG101 1.0%|Topical application of drug
89429700|NCT02078661|Placebo Comparator|Placebo|Topical application of placebo
89429701|NCT02948660|Experimental|Patients with prolonged disorders of consciousness|"age ≥ 18 years;~presence of unresponsive wakefulness syndrome (UWS) or minimally conscious state (MCS) on admission;~time since onset > 4 weeks;~no history of neurodegenerative or psychiatric diseases.~All patients were administered 10 mg of zolpidem tartrate tablets via a feeding tube and received EEG-reactivity test."
88909904|NCT05025059|Experimental|Supportive care (coaching, exercise, questionnaire)|Patients participate in one-on-one coaching sessions with a health coach QW to discuss the content offered in the program, and challenges they are currently facing in achieving their exercise goals. Patients receive a copy of the WWE workbook, wear a fitness tracker and are encouraged to achieve 150 minutes of walking per week during chemotherapy and up to 1 month after chemotherapy. Patients also participate in the Growing Stronger Strength Training Program and receive instruction manuals. They perform the initial 2 exercises 2 days per week for 4 weeks, and subsequent 2 exercises 2 days per week for the remainder of the chemotherapy course. Patients maintain exercise logs and complete questionnaires over 30-45 minutes at baseline, end of chemotherapy and at 1 month after chemotherapy.
88909905|NCT05023005|Experimental|Piriformis Strain-Counterstrain|The treatment group will receive strain-counterstrain for the piriformis muscle.
88909906|NCT05023005|Sham Comparator|Hamstring Strain-Counterstrain|The sham group will receive strain-counterstrain treatment for the hamstring muscle.
88909907|NCT05021991|Experimental|Regimen 1|"Double-blind Part: Oral dosing, once daily in the morning with titration over 56 days to 100 mg PRAX-944: 7 days of 5 mg, 7 days of 10 mg, 7 days of 20 mg, 7 days of 40 mg, 7 days of 60 mg, 7 days of 80 mg, 14 days of 100 mg~Extension Part: Double-blind Lead-in: Oral dosing, once daily in the morning over 43 days: 100 mg PRAX-944~Extension Part: Open-label Flexible PRAX-944 Dosing: Oral dosing, once daily in the morning of 20 mg to 100 mg PRAX-944 for 469 days~Crossover Part: Following double-blind lead-in/open-label: 1:1 randomization to placebo or stable dose of PRAX-944 for 21 days followed by cross-over to either placebo or PRAX-944 oral dosing, once daily in the morning with titration over 7 days (3 days at 20 mg, 4 days at 40 mg) to 60 mg (14 days) before returning to open-label part."
88909908|NCT05021991|Experimental|Regimen 2|"Double-blind Part: Oral dosing, once daily in the morning with titration over 56 days to 60 mg PRAX-944: 7 days of 5 mg, 7 days of 10 mg, 7 days of 20 mg, 7 days of 40 mg, 28 days of 60 mg~Extension Part: Double-blind Lead-in: Oral dosing, once daily in the morning with titration over 43 days to 100 mg PRAX-944: 7 days of 80 mg, 36 days of 100 mg~Extension Part: Open-label Flexible PRAX-944 Dosing: Oral dosing, once daily in the morning of 20 mg to 100 mg PRAX-944 for 469 days~Crossover Part: Following double-blind lead-in/open-label: 1:1 randomization to placebo or stable dose of PRAX-944 for 21 days followed by cross-over to either placebo or PRAX-944 oral dosing, once daily in the morning with titration over 7 days (3 days at 20 mg, 4 days at 40 mg) to 60 mg (14 days) before returning to open-label part."
88909909|NCT05021991|Placebo Comparator|Regimen 3|"Double-blind Part: Oral dosing, once daily in the morning: 56 days of placebo~Extension Part: Double-blind Lead-in: Oral dosing, once daily in the morning with titration over 43 days to 100 mg PRAX-944: 7 days of 5 mg, 7 days of 10 mg, 7 days of 20 mg, 7 days of 40 mg, 7 days of 60 mg, 7 days of 80 mg, 14 days of 100 mg~Extension Part: Open-label Flexible PRAX-944 Dosing: Oral dosing, once daily in the morning of 20 mg to 100 mg PRAX-944 for 469 days~Crossover Part: Following double-blind lead-in/open-label: 1:1 randomization to placebo or stable dose of PRAX-944 for 21 days followed by cross-over to either placebo or PRAX-944 oral dosing, once daily in the morning with titration over 7 days (3 days at 20 mg, 4 days at 40 mg) to 60 mg (14 days) before returning to open-label part."
88909910|NCT05020236|Experimental|Part 1 Safety Lead-In Dose Escalation: Elranatamab + Daratumumab|
88909911|NCT05020236|Experimental|Part 2 Randomized Arm A: Elranatamab|
88909912|NCT05020236|Experimental|Part 2 Randomized Arm B: Elranatamab + Daratumumab|
88909913|NCT05020236|Active Comparator|Part 2 Randomized Arm C: Daratumumab + Pomalidomide + Dexamethasone|
88909914|NCT05017571|No Intervention|Adults no obesity, insulin resistance, or inflammation|Adults without obesity, insulin resistance or inflammation
88909915|NCT05017571|No Intervention|Adults with obesity, but no insulin resistance/inflammation|Adults with obesity, but without insulin resistance or inflammation
88909916|NCT05017571|Experimental|Colchicine - Adolescents|Adolescents given Colchicine 0.6 mg per day (1 capsule per day)
88909917|NCT05017571|Experimental|Colchicine - Adults|Adults given Colchicine 0.6 mg per day (1 capsule per day)
88909918|NCT05017571|Placebo Comparator|Placebo - Adolescents|Adolescents given Placebo (1 capsule per day)
88909919|NCT05017571|Placebo Comparator|Placebo - Adults|Adults given Placebo (1 capsule per day)
89429702|NCT02948660|Experimental|Healthy volunteers|Healthy volunteers without any history of autonomic or any other nervous system disorder were included in this study. They were administered 10 mg of zolpidem tartrate tablets orally.
89429703|NCT02078739|Experimental|Yoga Program|Yoga Program twice per week for 8 weeks
89429704|NCT02078739|Active Comparator|Education|Education once per week for 8 weeks
89429705|NCT00448890|Experimental|GSK729327|Dose escalation from 1.0mg to 6 mg.
89536224|NCT03209557|No Intervention|Control|25 pregnant women will be enrolled and provided with usual care through Healthy Beginnings or NFP but will not receive a smartwatch or the active intervention. Smoking behavior will be measured by self-report and sample testing for the duration of the trial. Self-reported smoking status will be collected weekly. Sample testing will occur weekly and will be identical to the intervention group. They will be compensated for sample collection and survey completion.
89429706|NCT00448890|Placebo Comparator|Placebo|
89429707|NCT02074605||Observation|Patients with melanoma who qualify for interferon treatment, but choose not to receive it.
89429708|NCT02074605||Interferon alpha|Patients who receive high dose interferon alpha for 4 weeks
89429709|NCT00448422|Experimental|1|Tablet
89429710|NCT00448422|Placebo Comparator|2|Tablet
89429711|NCT02081235||patients who underwent surgery for congenital heart disease|patients who underwent surgery for congenital heart disease during 2012 in Samsung Medical Center
89429712|NCT00583830|Active Comparator|A|Paclitaxel and carboplatin
89429713|NCT00583830|Experimental|B|Paclitaxel, carboplatin and Mapatumumab 10 mg/kg
89429714|NCT00583830|Experimental|C|Paclitaxel, carboplatin and Mapatumumab 30 mg/kg
89429715|NCT03422588|Experimental|Intracorporeal|Totally laparoscopic right colectomy with intracorporeal anastomosis
89429716|NCT03422588|Active Comparator|Extracorporeal|Laparoscopic assisted right colectomy with extracorporeal anastomosis
89429717|NCT02074683|Active Comparator|YEAR A PATHWAY|"Operative Procedure will occur after screening visit.~Fat grafting is a minimally invasive clinical procedure that has been widely used by plastic surgeons within reconstructive surgery for many years. In brief, fat tissue to be used for grafting is harvested (usually from abdomen or thighs) with a small liposuction cannula. The fat tissue is then sterilely centrifuged and allowed to decant before separating the fluid and oil layers from the fat tissue fraction. The aspirated fat is then loaded into 1cc syringes and injected into the plantar fat pad using specialized injection cannulas.~Follow-up visits:~Post op Visit 1 (2 weeks +/- 5 days)~Post op study visit 2 (1 month)~Post op study visit 3 (2 month)~Post op study visit 4 (6 month)~Post op study visit 5 (12 month) CROSSOVER to YEAR B PathWay~Post op study visit 6 (18 months)~Post op study visit 7 (24 months)"
89429718|NCT02074683|Active Comparator|Year B Pathway|"Observational visits at 6 and 12 months with fat grafting procedures during year 2.~Study visit 1 (month 6)~Study Visit 2 (month 12)~Collection of subject's medication profile, vital signs (Temp, HR, Resp, BP), and weight to calculate BMI,~Limited physical exam with a foot exam completed by the PI and /or the Coinvestigator~Adverse Event Reporting~Ultrasound~Pedobarograph~2D Photographs~Foot Pain Assessment Questionnaire~Medical chart review including review of records from SOC podiatrists~Operative Visit Followed by Post op study visits 2-5 as described in Year A Pathway"
89429719|NCT03430544|Placebo Comparator|Placebo|
89429720|NCT03430544|Experimental|1.5 mg/d cariprazine|
89429721|NCT03430544|Experimental|3.0 mg/d cariprazine|
89429722|NCT02081313|Active Comparator|Netherton syndrome|Patients with Netherton syndrome
89429723|NCT02081313|Active Comparator|Healthy controls|healthy controls
89429724|NCT00583674|Experimental|B|
89429725|NCT00583674|Experimental|A|
89429726|NCT00583674|Active Comparator|C|
89429727|NCT03422510|Experimental|Regimen 1 - CXA-10 75 mg|Subjects in regimen 1 will start at 75 mg and may stay at 75 mg or increase to 150 mg. This treatment arm stays at 75 mg.
89429728|NCT03422510|Experimental|Regimen 1 - CXA-10 150 mg|Subjects in regimen 1 will start at 75 mg and may stay at 75 mg or increase to 150 mg. This treatment arm increases to 150 mg.
89429729|NCT03422510|Experimental|Regimen 2 - CXA-10 150 mg|Subjects in regimen 2 will start at 150 mg and may stay at 150 mg or increase to 300 mg. This treatment arm stays at 150 mg.
89429730|NCT03422510|Experimental|Regimen 2 - CXA-10 300 mg|Subjects in regimen 2 will start at 150 mg and may stay at 150 mg or increase to 300 mg. This treatment arm increases to 300 mg.
89429731|NCT02074761||SImmetry Implant|Subjects who are indicated for the SImmetry device and meet the inclusion/exclusion criteria will receive a SImmetry implant.
89429732|NCT02930564|Experimental|a milk fat or gluten challenge|patients will regress to the first stage diet with either a milk fat /emulsifier or a gluten/emulsifier challenge over 7 days.
89429733|NCT03428048||Adults diagnosed with paroxysmal and persistent Afib|Adults diagnosed with paroxysmal and persistent Afib who are identified as candidates for an intervention either surgical (epicardial) known as the hybrid approach or an endocardial ablation with either laser, radio frequency or cryoablation energy source.
89429734|NCT00583128|Experimental|1|AST-120, 2 gram sachets
89429735|NCT00583128|Placebo Comparator|2|Celphere® CP-305, stained to match appearance of AST-120, in 2g sachets
89429736|NCT03430466|Experimental|Durvalmab&Tremelimumab&Fulvestrant|Durvalmab&Tremelimumab&Fulvestrant
89429737|NCT02280018|Experimental|JNJ-49122944, 5 milligram (mg)|Single dose of 5 mg JNJ-49122944, administered as a 22.2 milliliter (mL) intravenous (IV) infusion over 45 minutes in the morning following an overnight fast.
89429738|NCT02280018|Placebo Comparator|Placebo|Placebo matched to JNJ-49122944, administered as a 22.2 mL IV infusion over 45 minutes in the morning following an overnight fast.
89429739|NCT03422432|Experimental|Group 1|Patients are identified pre-operatively on radiological imaging. Prophylactic HIPEC will be delivered intra-operatively, immediately after the resection of the primary tumour, and only if the patient is deemed well enough to receive the HIPEC.
89429740|NCT03422432|Experimental|Group 2|Patients are identified post-operative based on histological findings. They will be counselled to receive prophylactic HIPEC only. If peritoneal nodules are found during surgery, these patients will be excluded from the study.
89429741|NCT03134274|Experimental|Pregnant women|Pregnant women above the age of 18 years, undergoing routine pre-natal care, who own and are familiar with use of a smartphone receive a Dip HBDA kit for home use.
89429742|NCT02280174|Experimental|Drug: linagliptin|linagliptin 5 mg/d for 12 weeks
89429743|NCT02280174|No Intervention|Drug: standard treatment|sulfonylurea treatment for 12 weeks
89429744|NCT03430388|Active Comparator|Rheumatic diseases patients|Vaccination against Yellow Fever, fractional dose (0,1mL) of 17D vaccine
88909930|NCT05011422|Experimental|ex vivo αβ-TCR/CD19 depleted haplo-hematopoietic stem cell infusion (HSCT)|"Patients will undergo standard of care conditioning regiment prior to HSCT~On Day 0, patients will undergo infusion of the ex vivo αβ-TCR/CD19 depleted haplo-HSCT from a stimulated peripheral stem cell source per institutional standard of care. Patients whose graft has a residual CD20+ count > 1.0 x 10^5 may receive a single infusion of rituximab on Day +1 at a dose of 375 mg/m^2 at provider's discretion."
88909931|NCT05010122|Experimental|Treatment (decitabine, cedazuridine, venetoclax, gilteritib)|"INDUCTION (CYCLE 1): Patients receive decitabine and cedazuridine PO QD on days 1-5, venetoclax PO QD on days 1-28, and gilteritinib PO QD on days 1-28 in the absence of disease progression or unacceptable toxicity~CONSOLIDATION (CYCLES 2-24): Patients receive decitabine and cedazuridine PO QD on days 1-5, gilteritinib PO QD on days 1-28, and venetoclax PO QD on days 1-21. Treatment repeats every 28 days for up to 23 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE (CYCLES 24+): Patients receive gilteritinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
89429745|NCT03430388|Active Comparator|Healthy controls|Vaccination against Yellow Fever, fractional dose (0,1mL) of 17D vaccine
88909933|NCT05005975|Experimental|Dersimelagon 200mg|
88909934|NCT05004974|Experimental|Sintilimab with Pemigatinib|Sintilimab combined with Pemigatinib every 3 weeks (Q3W): Sintilimab is administered every 3 weeks (200mg, IV), Pemigatinib 13.5 mg once daily (QD) orally, continuous administration.
88909935|NCT05001880|Experimental|Arm I (carboplatin, pemetrexed, bevacizumab, atezolizumab)|Patients receive atezolizumab IV over 60 minutes, bevacizumab IV over 30-90 minutes, carboplatin IV over 30 minutes, and pemetrexed IV over 10 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Within 4-8 weeks, patients undergo cytoreductive surgery and HIPEC. Patients not eligible for surgery may receive atezolizumab and bevacizumab in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan and PET scan on study. Patients also undergo blood and tissue sample collection on study.
88909936|NCT05001880|Active Comparator|Arm II (carboplatin, pemetrexed, bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes, carboplatin IV over 30 minutes, and pemetrexed IV over 10 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Within 4-8 weeks, patients undergo cytoreductive surgery and HIPEC. Patients not eligible for surgery may receive bevacizumab with or without atezolizumab at the discretion of the investigator in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan and PET scan on study. Patients also undergo blood and tissue sample collection on study.
89429746|NCT00579384|Experimental|001|
89429747|NCT03430232|Experimental|Part I (Panel 1): STR-324 or placebo|Subjects will receive STR-324 dose level 1, 3, 5, 7 or placebo as a short infusion according to randomization.
89429748|NCT03430232|Experimental|Part I (Panel 2): STR-324 or placebo|Subjects will receive STR-324 dose level 2, 4, 6, 8 or placebo as a short infusion according to randomization.
89429749|NCT03430232|Experimental|Part II (Panel 1): STR-324 or placebo|Subjects will receive STR-324 dose level A or placebo as a long infusion according to randomization.
89429750|NCT03430232|Experimental|Part II (Panel 2): STR-324 or placebo|Subjects will receive STR-324 dose level B or placebo as a long infusion according to randomization.
89429751|NCT03430232|Experimental|Part II (Panel 3): STR-324 or placebo|Subjects will receive STR-324 dose level C or placebo as a long infusion according to randomization.
89429752|NCT02284542||Patients with successful trial implant|Patients who have had a successful SCS trial and are indicated for permanent implantation will be approached to participate in this study prior to permanent implantation. Patients will be recruited and enrolled by physicians at any one of the involved sites. Each Investigator will only use one method (awake or non-awake) according to his/her typical practice. Patients will receive treatment from their enrolling physician.
89429753|NCT04470492|Experimental|Experiment|
89429754|NCT04470492|Other|Control|
89429755|NCT03422354|Active Comparator|Paravertebral block Group|Patients will receive single shot L1-L2 PVB before undergoing GA Full monitoring with ECG , NIBP , puls oximetry will be applied. The level between L1 and L2 will be identified using U/S as well as transverse processes depth. Insertion points will be marked 2.5 cm lateral to the superior aspect of corresponding spinous processes, A 22-gauge Tuohy needle will be advanced until it made contact with the transverse process. The needle will be withdrawn slightly and walked off caudally to an additional depth of 1 cm. Once this is reached, 20cc of bupivacaine 0.25% will be injected slowly To control intraoperative blood pressure, fentanyl will be used as well as hypotensive drugs ( propranolol and nitroglycerine and the total dose will be recorded.
89197538|NCT00942136|Experimental|Cohort 1, Sequence 1|Subjects in Cohort 1, Sequence 1 will receive a single dose of GSK134972 50 mg after a fast of 10 hours in Period 1. Following a 7 day washout, they will receive a single dose of GSK134972 50 mg after a high fat meal in Period 2. After the last PK sample is collected in Period 2, they will receive a single daily dose of omeprazole 40 mg for 5 days. On Day 5 they will receive a single dose of GSK134972 50 mg 2 hours after the omeprazole dose. Subjects will have a screening visit 30 days prior to the first dose and a follow-up visit 7-14 days after the last dose of medication.
89197539|NCT00942136|Experimental|Cohort 2|Subjects will receive a single dose of either GSK1349572 250 mg or placebo as a suspension. Subjects will have a screening visit within 30 days prior to the dose of study medication and a follow up visit 7-14 days after the dose of study medication.
88814800|NCT01664117||bDMARD Monotherapy|Patients with moderate to severe rheumatoid arthritis (RA) will be treated with bDMARD (biologic disease-modifying antirheumatic drug) monotherapy under routine clinical practice conditions at rheumatology clinics
88814801|NCT02980328|Experimental|LLLT group|Low-level light therapy (LLLT) was self-performed for 12 weeks, 3 times a day for 20 minutes each
88814802|NCT02980328|Placebo Comparator|Placebo-controlled group|Placebo low-level light therapy (LLLT) was self-performed for 12 weeks, 3 times a day for 20 minutes each. The placebo LLLT device was identical to the active device but did not radiate light as the hole was blocked.
88909937|NCT04992013|Experimental|Niraparib|Participants will receive niraparib 1x daily for each 28 day study treatment cycle up to 2 years or until disease worsens or unacceptable side effects occur.
88909938|NCT04989803|Experimental|KITE-363|"Phase 1a (Dose Escalation): Participants with r/r large B-cell lymphoma will receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single target starting dose of KITE-363 chimeric antigen receptor (CAR) transduced autologous T cells. Based on dose limiting toxicities (DLTs) observed in the first cohort, additional participants will be enrolled and administered escalating dose of KITE-363.~Phase 1b (Dose Expansion): After completion of dose escalation, additional participants with r/r B-cell lymphoma across different disease indications will receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single dose of KITE-363 at 1 or more dose-level deemed to be tolerable."
89429756|NCT03422354|Active Comparator|General anesthesia Group|"Patients will receive only GA All patients in the study will receive GA in the form of propofol 2mg/kg , atracurium 0.5ml/kg ,fentanyl 100 microgram in induction with ETT and mechanical ventilation , full monitoring with ECG , NIBP and puls oximetry will be applied.~To control intraoperative BP,fentanyl will be used as well as,hypotensive drugs ( propranolol and nitroglycerine and the total dose will be recorded.~To achieve post operative analgesia, intravenous paracetamol( 1gram ) and pethidine IV (50 mg ) will be added when needed"
89429757|NCT00658086|Active Comparator|1|ALN-RSV01
89429758|NCT00658086|Placebo Comparator|2|Normal saline
89429759|NCT03427970|Active Comparator|control group|Control subjects will receive observation for 6 months.
89429760|NCT03427970|Experimental|experimental group|Experimental group will perform three-dimensionally integrated exercise for scoliosis for a 60-min period for 1-2 times a week under the guidance of physical therapist in an outpatient clinic, and a 20-min period per day under the supervision of the parents at home.The treatment regimens lasted for 6 months.
89429761|NCT03128294||long-term survivors of ovarian cancer|long-term survivors of ovarian cancer
89429762|NCT03422120||Healthy Donors|Healthy patients, without a diagnosis of cancer and age>40. The Natural Killer Cell Activity Assay (NKA) will be measured with a blood test.
89429763|NCT03422120||Colorectal Cancer Surgery Patients|Patients >40 years of age with a histologically confirmed diagnosis of primary colorectal cancer and a planned surgical resection of the primary tumour. The Natural Killer Cell Activity Assay (NKA) will be measured at various perioperative time points with a blood test.
89429764|NCT00447954|Experimental|1 high dose NT-501 implant|
89429765|NCT00447954|Experimental|2 low dose NT-501 implant|
89429766|NCT00447954|Sham Comparator|3 sham procedure|No implant
89429767|NCT03128060|Experimental|Home-based Palliative Care|Home-based palliative care features home visits by an interdisciplinary PC team (physician, nurse, social worker, and chaplain) that provides pain and symptom management, psychosocial support, advance care planning, disease management education, spiritual and grief counseling, and other services as needed.
89429768|NCT03128060|Active Comparator|Enhanced Usual Care|Enhanced usual care refers to: 1) usual primary care provided by a primary care physician who has been offered special training in the core elements of palliative care; 2) case management services; and 3) provider support through palliative care consultation.
89429769|NCT00447564|Active Comparator|Group A|
89429770|NCT00447564|Placebo Comparator|Group B|
89429771|NCT03430154||Adults with hemophilia and obesity/overweight|Adults (any gender) aged ≥18 years with hemophilia (any severity, with or without inhibitors) self-identified with obesity or overweight
89429772|NCT03430154||Caregivers identified with obesity/overweight|Caregivers of children (any gender) currently aged <18 years with hemophilia (any severity, with or without inhibitors) caregiver-identified with obesity or overweight
89429773|NCT03430154||Spouses or partners self-identified with obesity/overweight|Spouses or partners of adults (any gender) aged ≥18 years with hemophilia (any severity, with or without inhibitors) self-identified with obesity or overweight
88909939|NCT04989803|Experimental|KITE-753|"Phase 1a (Dose Escalation): Participants with r/r large B-cell lymphoma will receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single target starting dose of KITE-753 chimeric antigen receptor (CAR) transduced autologous T cells. Based on dose limiting toxicities (DLTs) observed in the first cohort, additional participants will be enrolled and administered escalating dose of KITE-753.~Phase 1b (Dose Expansion): After completion of dose escalation, additional participants with r/r B-cell lymphoma across different disease indications will receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single dose of KITE-753 at 1 or more dose-level deemed to be tolerable."
88909940|NCT04989595||Women_Kyleena|
88909941|NCT04989595||Women_Jaydess|
88909942|NCT04989595||Women_Mirena|
88909943|NCT04984876|Experimental|ligelizumab 240 mg|ligelizumab 240 mg subcutaneous injection for 52 weeks
88909944|NCT04984876|Experimental|ligelizumab 120 mg|ligelizumab 120 mg subcutaneous injection for 52 weeks
88909945|NCT04984876|Experimental|Placebo 8 weeks and ligelizumab 120 mg|Placebo subcutaneous injection for first 8 weeks and ligelizumab 120 mg subcutaneous injection for 44 weeks
89197540|NCT00942136|Experimental|Cohort 1, Sequence 2|Subjects in Cohort 1, Sequence 2 will receive a single dose of GSK134972 50 mg after a a high fat meal in Period 1. Following a 7 day washout, they will receive a single dose of GSK134972 50 mg after fast of 10 hours in Period 2. After the last PK sample is collected in Period 2, they will receive a single daily dose of omeprazole 40 mg for 5 days. On Day 5 they will receive a single dose of GSK134972 50 mg 2 hours after the omeprazole dose. Subjects will have a screening visit 30 days prior to the first dose and a follow-up visit 7-14 days after the last dose of medication.
89197541|NCT00745680||A|A: AMI patient
89197542|NCT00748488|Experimental|A|Physical Therapy aimed to promote the level of physical activity
89197543|NCT00748488|Active Comparator|B|Physical Therapy aimed to move safely
89197544|NCT05300932|Experimental|Baricitinib 4mg|4mg of oral Baricitinib everyday for 48 weeks.
89197545|NCT05300932|Active Comparator|Cyclophosphamide|Subject received cyclophosphamide 400mg intravenous drip every 2 weeks combined with oral Prednisone 10-15 mg/d （standard of care）through the 24 weeks double blind period. Subsequently, subject were administered oral Baricitinib 4mg everyday through the 24-48 weeks open label period.
89197546|NCT02545491|Experimental|Care for Child Development group|Training of caregivers on the Care for Child Development (CCD) program, in addition to the training on Infant and Young Child feeding program by World Vision.
89197547|NCT02545491|Active Comparator|World Vision Lebanon training group|caregivers will receive training in Infant and Young Child Feeding (WV-IYCF) offered by World Vision.
89197548|NCT00850161|Experimental|Nasulin™|Intranasal insulin spray
89197549|NCT00850161|Active Comparator|aspart|Subcutaneous administration
89197550|NCT00951574|Placebo Comparator|saline solution|Pre-filled syringes of 0.4 ml, 1 subcutaneous injection/day (every 24 hours).
89197551|NCT00951574|Experimental|nadroparin calcium|Nadroparin calcium; Pre-filled syringes of 0.4 ml (3.800 anti-Xa IU), 1 subcutaneous injection/day (every 24 hours).
89197552|NCT00856011||1|Diabetic patients with carpal tunnel syndrome
89197553|NCT00856011||2|Non-diabetic patients with carpal tunnel syndrome
89197554|NCT00686790|Experimental|PegIntron|All participants received PegIntron (Peginterferon alfa-2b) weekly based on their body weight.
89197555|NCT00850239|Experimental|1|dutogliptin/PHX1149T
89197556|NCT00850239|Placebo Comparator|2|Plabeco
89197557|NCT00946426||Diagnostic|Hyperinsulinemic euglycemic clamp
89197558|NCT00942292|Active Comparator|Lipidem (fish oil)|Lipidem (TPN containing fish oil)
89197559|NCT00942292|Active Comparator|Lipofundin (TPN)|Control arm (no fish oil)
89197560|NCT02563392|Experimental|Uterine arteries occlusion|Laparoscopic myomectomy with preventive uterine arteries occlusion
89197561|NCT02563392|Active Comparator|No uterine arteries occlusion|Laparoscopic myomectomy without preventive uterine arteries occlusion
89429774|NCT03430154||Healthcare profs. managing hemophilia and obesity/overweight|Healthcare professional (pediatric or adult hematologist, nurse, nurse practitioner, physician assistant, physical therapist, social worker) actively working in a federally designated hemophilia-treatment center for at least 3 years and with experience managing patients with hemophilia and obesity or overweight.
88909946|NCT04984876|Experimental|Placebo 16 weeks and ligelizumab 120 mg/240 mg|Placebo subcutaneous injection for first 16 weeks and ligelizumab 120 mg OR 240 mg subcutaneous injection for 36 weeks
88909947|NCT04984876|Experimental|Placebo 8 weeks and ligelizumab 240 mg|Placebo subcutaneous injection for first 8 weeks and ligelizumab 240 mg subcutaneous injection for 44 weeks
88909948|NCT04983173|Experimental|Experimental: Clomiphene Citrate (CC) + rFSH|Ovarian Stimulation with CC+rFSH
88909949|NCT04983173|Active Comparator|rFSH|Ovarian Stimulation with rFSH
89197562|NCT00856089|Experimental|Retapamulin|
89197563|NCT00942370||accelerometric device|
89197564|NCT04041999|Experimental|Daily Cognition Training Program|"The intervention was administered by a qualified professional, in this case an occupational therapist. And it was always individually through specific activities or exercises.~Tasks are carried out in which the subject has to exercise different cognitive functions (praxies, attention, language, memory orientation, gnosias and executive functions; mainly working memory decision making, planning, reasoning and temporal estimation) during the development of AIVD For this, similar materials are used to those that the elderly could find in daily tasks or when solving day-to-day problems.~Specifically we focus on tasks related to taking medication and adherence to treatment."
89429775|NCT03427658|Experimental|Increase sweet food consumption|Participants are asked to increase their consumption of sweet foods throughout their diet. Participants will be supported through an individual dietary interview where sweet foods will be highlighted and additional sweet food consumption recommended.
89429776|NCT03427658|Active Comparator|Decrease sweet food consumption|Participants are asked to decrease their consumption of sweet foods throughout their diet. Participants will be supported through an individual dietary interview where sweet foods will be highlighted and substitutions for sweet food consumption will be recommended.
89429777|NCT03427580|Experimental|treatment group|
89429778|NCT03427580|Experimental|delayed treatment control group|
89429779|NCT02282202|Other|Off/on for 3 weeks followed by on/off for 3 weeks|Subjects are randomized to either Oscillating Positive Expiratory Pressure device (Aerobika ®) or no device for three weeks, then crossover for the following three weeks.
89429780|NCT02521610|Placebo Comparator|Placebo|Healthy volunteers will receive the placebo equivalent to RG7625 as oral capsules once or twice daily for 8 days. Each cohort will receive intradermal administration of 4 antigens (tetanus toxoid, tuberculin purified protein derivative [PPD], Candida albicans, and Trichophyton species) and a negative control at Screening and on Day 7 of treatment to assess for DTH.
89536880|NCT03312179||diabetics STEMI|Diabetics patients admitted for ST elevation myocardial infarction (STEMI) and associated with multi vessels (Mv) non obstructive coronary artery stenosis (NOCS). These patients received percutaneous coronary intervention (PCI), and primary stenting (DES) of culprit lesion. Then these patients received full medical STEMI therapy.
88909950|NCT04982393||Patients with PH1|Patients with a diagnosis of PH1 will be eligible for the study and will be managed and treated per routine clinical practice.
89197565|NCT04041999|Active Comparator|Traditional Cognitive Stimulation Program|"The intervention was administered by a qualified professional, in this case an occupational therapist. And it was always individually through specific activities or exercises.~Tasks are performed to work various cognitive functions."
88909952|NCT04975334|Experimental|kisspeptin, GnRH, naloxone|IV administration of kisspeptin 112-121; six boluses in up to a 26-hour period. IV administration of GnRH; two boluses in up to a 26-hour period. IV administration of naloxone; one bolus and an infusion over an up to 13-hour period.
88909953|NCT04968743|Experimental|Participants With Unilateral Stroke|"Participants with self-reported unilateral stroke will take part in two experimental sessions:~First, for assessment of stroke characteristics and MRI scan, and second, the main transcranial magnetic stimulation experiment. During the first experimental session, the unilateral stroke will be confirmed. In participants with stroke, TMS will be applied over the motor cortex on the affected and non-affected hemisphere at the intensity of up to 120% resting motor threshold."
88909954|NCT04968743|Experimental|Participants Without Unilateral Stroke|"Participants without self-reported unilateral stroke will take part in two experimental sessions:~First, for assessment of stroke characteristics, and second, the main transcranial magnetic stimulation experiment. During the first experimental session, the lack of unilateral stroke will be confirmed. In participants without stroke, TMS will be applied targeting at the intensity of up to 120% resting motor threshold both left and right hemisphere."
88909955|NCT04962087|Experimental|Health enSuite Insomnia|Health enSuite: Insomnia has been designed based on established cognitive behavioural treatments for insomnia and adapted to fit an automated interactive platform available via an internet enabled device. The program is divided into a series of treatment modules or levels that will be delivered over the course of 6-8 weeks. The content of these 6 levels includes the following components, a sleep diary, sleep restriction clock, sleep hygiene, relaxation techniques, sleep related thoughts and beliefs, and involving a support person.
88909956|NCT04962087|No Intervention|Psychoeducation Control|Participants allocated to the Control group will receive a version of the Health enSuite Insomnia app that contains a static psychoeducation module. It will contain information related to insomnia and its treatment. Topics covered will include a brief description of cognitive behavioural therapy for insomnia.
88909957|NCT04962087|Experimental|Health enSuite Insomnia - Deprescribing|All participants in Trial 2 will be initiating a gradual medication tapering schedule recommended to them by their physician. The module physicians use to refer their patients to the study includes a section where they fill out a brief drug history for sleep medications. This information is then used to generate a tapering schedule that the health care provider will review with their patient. Health care providers are responsible for providing appropriate medication counselling and follow-up care to supervise deprescribing. This study does not place any restriction on the usual care participants will receive.
88909958|NCT04962087|No Intervention|Psychoeducation Control - Deprescribing|Participants allocated to the Control group will receive a version of the Health enSuite Insomnia app that contains a static psychoeducation module. It will contain information related to insomnia and its treatment. Topics covered will include a brief description of cognitive behavioural therapy for insomnia and information about the benefits of medication de-prescribing for those in Trial 2.
88922227|NCT05616546|Experimental|Influenza Vaccine|"Healthy male and female individuals aged 18-64 years will be eligible to participate in this study.~Subjects will be offered the opportunity to participate in the study for up to 3 consecutive years, provided eligibility criteria are met each year. Subjects will be re-screened to verify continued eligibility and re-consented prior to subsequent participation and will receive new subject identifiers"
89197566|NCT00686712|Experimental|1 - Insulin glargine QHS|Insulin glargine injected subcutaneously once daily at bedtime
89429781|NCT02521610|Experimental|RG7625|Participants will undergo a series of Screening visits prior to treatment and 7- to 14-day follow-up. Healthy volunteers will be enrolled in up to 4 cohorts and will receive RG7625 as oral capsules once or twice daily for 8 days. The first cohort is planned to receive 100 milligrams (mg) on Day 1, followed by 100 mg twice daily on Days 3 to 9. Subsequent dose and frequency decisions will be based upon observations in previous cohort(s). Each cohort will receive intradermal administration of 4 antigens (tetanus toxoid, tuberculin PPD, Candida albicans, and Trichophyton species) and a negative control at Screening and on Day 7 of treatment to assess for DTH.
89429782|NCT00576342|Other|AL-3862+timolol, then COSOPT|AL-3862+timolol ophthalmic suspension, 1 drop in both eyes, followed by dorzolamide+timolol ophthalmic solution,1 drop in both eyes, 1 day later.
89429783|NCT00576342|Other|COSOPT, then AL-3862+timolol|Dorzolamide+timolol ophthalmic solution, 1 drop in both eyes, followed by AL-3862+timolol ophthalmic suspension, 1 drop in both eyes, 1 day later.
89429784|NCT00574860|Experimental|EN3285 (NAC ProGelz)|The EN3285 arm is the product under development
89429785|NCT00574860|Placebo Comparator|No active ingredients (placebo)|This will be an oral product that contains no active ingredient
89429786|NCT00574860|Other|Standard of Care|This arm will reflect the typical standard of care for the patient
89429787|NCT02282280||Study Group|All patients included in the study
89429788|NCT01591772||diagnosed with ovarian that recieved chemo|
89429789|NCT01591772||healthy controls|
89429790|NCT03429998|Placebo Comparator|LDL apheresis|LDL apheresis during at least one year
88909959|NCT04960046|Active Comparator|Infraclavicular nerve block using a costoclavicular approach|The costoclavicular approach, more recently described, proposes an insertion of the needle under the lower edge of the clavicle but in a lateral way to the axillary artery which makes it possible to reach the nerves at a place where the 3 main nerve bundles are still joined together. The clustering of nerve structures at the injection site may facilitate the spread of local anesthetics.
88909960|NCT04960046|Placebo Comparator|Infraclavicular nerve block using a paracoracoid approach|The paracoracoid approach involves inserting a needle under the lower rim of the clavicle below the coracoid process. This approach makes it possible to reach the 3 different nerve bundles, located around the axillary artery, which are involved in the sensitivity of the hand.
88909961|NCT04956848|No Intervention|Embryo selection supported by KIDScore™ D5|Each embryo reaching at least developmental stage of 3BB will annotated by an embryologist using the parameters required by the KIDScore™ D5. The embryo with the highest KIDScore™ will be selected proposed for transfer.
88909962|NCT04956848|Experimental|Embryo selection supported by iDAScore®|Images of all the embryos reaching at least developmental stage of 3BB will be analyzed by iDAScore®. The embryo with the highest iDAScore® will be proposed selected for transfer.
88909963|NCT04956796||Group A|At the beginning of Phase 1, participants from Group A will be exposed to the video airway library in addition to the conventional airway training. At the beginning of Phase 2, participants will continue with conventional airway training only. Each phase will last for 1 month.
89197567|NCT00686712|Experimental|2 - Insulin glargine QAM|Insulin glargine injected subcutaneously once daily in the morning
89429791|NCT03429998|Active Comparator|Evolocumab|140 mg evolocumab biweekly
89429792|NCT03429998|Active Comparator|LDL apheresis and evolocumab|LDL-apheresis monthly evolocumab 140 mg biweekly
89429793|NCT00658008|Experimental|PD 0332334 175 mg BID|
89429794|NCT00658008|Experimental|PD 0332334 225 mg BID|
89429795|NCT00658008|Experimental|PD 0332334 75 mg BID|
89429796|NCT00658008|Active Comparator|Paroxetine 20 mg QD|
89429797|NCT00658008|Placebo Comparator|Placebo BID|
89531157|NCT05043363||Observational cohort|"Patients with an established diagnosis of inflammatory bowel disease who have been identified as being 'at risk' by either their secondary care doctor or GP and now require endoscopic assessment for ongoing disease symptoms but are unable to access endoscopy services urgently.~Patients presenting directly to their GP practice with symptoms of anorectal disease (e.g. rectal bleeding or pain) or symptoms that would warrant referral to a hospital under a 2WW appointment according to NICE criteria~Recruited patients will undergo rectal examination in primary care with the LumenEye X1 with either contemporaneous or retrospective image review by a secondary care clinician. This will require a glycerine suppository to be administered. Patient feedback will be sought with a post-procedural questionnaire."
89197568|NCT00686712|Active Comparator|3 - NPH Insulin QHS|NPH insulin injected subcutaneously once daily at bedtime
89197569|NCT02545257|Active Comparator|Active comparator|In addition to normal, standard care, participants allocated to intervention group will receive a coordinated medication management model containing prescription review, drug-related problems (DRP) risk assessment and required action based on the DRP risk assessment.
89197570|NCT02545257|No Intervention|Control group (standard care)|Normal, standard care (control group)
89197571|NCT00748644|Experimental|1|Experimental drug = rituximab for maintenance
88909964|NCT04956796||Group B|At the beginning of Phase 1, participants from Group B will be exposed to the conventional airway training only. At the beginning of Phase 2, the participants in Group B will be exposed to the video airway library. Each phase will last for 1 month.
89197572|NCT00748644|Active Comparator|2|Comparator drug = azathioprine for maintenance
89197573|NCT04042779|Active Comparator|model-based WM training|In order to build the model-based WM training, existing tasks used to assess the different component of the Baddeley's model will be reviewed on their findings according to test-retest reliability and construct validity. For each component - phonological loop, visuospatial sketchpad, episodic buffer and central executive - the task with the highest reliability and validity will be chosen and then build the basis for the computerized training program. This procedure results in a model-based, adaptive, computerized training program for WM.
89197574|NCT04042779|Active Comparator|single-task WM training|"The basis for the single-task training administered to the second group will be the widely used dual-n-back training paradigm suggested by Jaeggi et al. (2008). A complex dual n-back task including a visual and an auditory WM task will be implemented for tablet devices."
89197575|NCT04042779|Active Comparator|multiple-task WM training|Verbal WM tasks - particularly letter span and digit span tasks - and a visuospatial WM task are most commonly used (e.g. Dahlin et al., 2008; Klingberg et al., 2005; Westerberg et al., 2007). Therefore, a multiple-task training including these tasks will be administered to the third group.
89197576|NCT04042779|Sham Comparator|sham intervention|Active control group that as well performs a training, however not based on WM. To exclude the involvement of WM, a motor training will be administered to the control group.
88922228|NCT05609409|Experimental|Digital Intervention|Eight 20-30 minute sessions of an online, multimedia application
89197577|NCT00748722||1|Female patients, age 18-60 years, suitable for breast reconstruction using the lower abdominal tissue.
89197578|NCT00745836|Experimental|atorvastatin 10 mg, 80 mg|
89197579|NCT00853203||Part 1|Interviews + Questionnaire + Electronically Activated Recorder (EAR)
89197580|NCT00853203||Part 2, Expressive Disclosure Group|Group Meetings + Written Materials
89429798|NCT03427502|Experimental|Study Group|"Experimental: Study Group At the end of surgery before nasal packing, scrub nurse will prepare 10 ml solution 0.5% bupivacaine with 1:2,00,000 adrenaline in a syringe and pass it over to the operating surgeon. The surgeon will block anterior ethmoidal nerve.~Injection technique: External nasal nerve will be blocked through an inter-cartilaginous injection into the dorsum of the nose.~Internal nasal nerve will be blocked in septum and lateral wall of nose. Septal block is done in upper anterior part of nasal septum. Three injections will be given on lateral nasal wall. First injection will be given just antero-superior to the attachment of middle turbinate (axilla). Second injection will be given at the anterior end of middle turbinate and third injection at the medial surface of middle turbinate. Withdrawal of injection will be done prior to deposition of solution every time to ensure that the solution is not deposited directly into a blood vessel."
89429799|NCT03427502|Placebo Comparator|Control Group|"At the end of surgery before nasal packing, scrub nurse will pass 10 ml of normal saline in a syringe to the surgeron.~Injection technique remains the same as in Study group."
89429800|NCT04449614||1|"Inclusion criteria: All consenting Infants and children who have had A Congenital Pulmonary Airway Malformation (CPAM) surgically removed by thoracoscopy over a 10 year period (2008-2017) in a regional centre.~Exclusion criteria: Non consenting participants"
89429801|NCT02280330|Active Comparator|MNP group|The MNP group will receive 60 sachets of MNP in a period of 6 months or 10 sachets per month equivalent to 3-4 sachets in a week.
89429802|NCT02280330|Placebo Comparator|Placebo group|The placebo group will receive 60 sachets of placebo (with same characteristics) as the MNP or 10 sachets per month equivalent to 3-4 sachets in a week.
89429803|NCT02284620|Experimental|CFNB group|Particiants in this group will receive a single injection for femoral nerve block intra-operatively combined continuous femoral nerve block post-operatively. This technique will be guided by ultrasound and nerve stimulator.The regimen is a loading dose of 0.8% ropivacaine 30 ml intra-operatively and 0.15% ropivacaine 300ml in the form of continuous femoral nerve block post-operatively.
89429804|NCT02284620|Active Comparator|LWI group|Particiants in this group will receive a peri-articular injection of suspension (48 ml of 0.8% ropivacaine with 2 ml of 40mg methylprednisolone) combined with intravenous patient controlled analgesia post-operatively (tramadol 800 mg and flurbiprofenaxetil 100 mg with saline added up to a volume of 80 ml )
89429805|NCT02886572|Experimental|Stereotactic Radiosurgery|All subjects will receive stereotactic radiosurgery(SRS) following the RTOG Stereotactic Radiotherapy Guidelines available at http://dx.doi.org/10.1016/j.prro.2011.06.014
89429806|NCT03422042|Active Comparator|Short duration of antibiotic|group A: will received intravenous antibiotic until the temperature is less than 37.8 c for 72 hours, then antibiotic is discontinued
89197581|NCT00853203||Part 2, Standard Care Control Group|Written Materials
89197582|NCT00748800|Experimental|1|
89197583|NCT00748800|Active Comparator|2|
89197584|NCT00856167|Active Comparator|TCM|Whole systems traditional Chinese medicine, including individually tailored herbal formulas, acupuncture, tuna (Chinese massage), lifestyle recommendations
89197585|NCT00856167|Active Comparator|Self-care|Self-care for TMD developed by Dworkin, LeResche et al.
89197586|NCT00686634|Experimental|1|Sitagliptin 100 mg once daily
89197587|NCT00856401|Experimental|PTH1-84 in parent study|In the RELAY, RACE, and HEXT study participants utilize PTH1-84. In the REPLACE Study participants utilize PTH1-84 or placebo of PTH1-84.
89197588|NCT00560404|Experimental|1|
89197589|NCT00560404|Active Comparator|2|
89197590|NCT00751920|Experimental|1|
89197591|NCT00850551|Active Comparator|Usual Care|Usual Care
89197592|NCT00850551|Other|Intervention|Twice weekly home spirometry and symptom assessment
89197593|NCT00850629|Placebo Comparator|placebo|Placebo
89197594|NCT00850629|Experimental|lifestyle intervention|After an initial weight loss, the weight regain will be measured during multimodal lifestyle intervention in children, adolescents and adults
89197595|NCT00850707||1|220 hemodialysis patients with Arterovenous fistula (AVF group)
89197596|NCT00850707||2|58 hemodialysis patients with Arterovenous graft (AVG group)
88909965|NCT04953884|Experimental|wilate treatment|PK: Single dose of 80 IU/kg body weight (BW). Prophylactic treatment: 30-50 IU/kg BW administered 2-3 times per week at the recommended dose of over 12 months. Minor haemorrhage: loading dose 30-50 IU/kg BW followed by a maintenance dose of 30-40 IU/kg BW every 12-24 hours to achieve von Willebrand factor activity (VWF:Ac) and FVIII:C trough levels of >30%. Major haemorrhage: loading dose 50-80 IU/kg BW followed by a maintenance dose of 30-50 IU/kg BW every 12-24 hours to achieve VWF:Ac and FVIII:C trough levels of >50%. Minor surgery: loading dose of 40-60 IU/kg BW followed by a maintenance dose of 20-30 IU/kg BW every 12- 24 hours for up to 3 days, to achieve VWF:Ac peak levels of 50% after loading dose and trough levels >30% during maintenance. Major surgery: loading dose of 60-80 IU/kg BW followed by a maintenance dose of 30-40 IU/kg BW every 12-24 hours for up to 6 days or longer, to achieve VWF:Ac peak levels of 100% after loading dose and trough levels >50% during maintenance
88909966|NCT04950192||Prospective Observational|Prospective observational subjects undergoing planned cardiac procedures utilizing image guidance
88909967|NCT04949646|Experimental|pIONM|"In the experimental group pIONM will be performed intraoperatively. For the implementation of pIONM, a special device, that allows simultaneous monitoring of sphincter signals and bladder manometry, will be introduced. This device will employ the placement of a bipolar electrode in the internal and external anal sphincter. Moreover, another electrode will be placed on the surrounding tissues. For bladder manometry, the catheter will be connected to the pressure sensor, and subsequently to the pIONM monitor. Intraoperatively, depending on the approach (open or laparoscopic), the respective bipolar stimulator will be used.~Prior to the initiation of pIONM, urinary bladder will be drained and filled with 200 ml R/L. The pIONM parameters will be the following: 1-25 milliampere current, 30 Hz frequency and 200 μs monophasic pulses."
88909968|NCT04949646|No Intervention|Control|In the control group pIONM will not be performed intraoperatively
88909969|NCT04949048|Experimental|Magneto PE Kit|Treatment with Magneto PE Kit
88909970|NCT04933266|Active Comparator|Low dose|After three injections of thoracic paravertebral block at T2, T4, T6 (a total of 21ml of 0.5% levobupivacaine with 1:200,000 adrenaline) under ultrasound guidance, patients will be put in supine position with ipsilateral arm and elbow flexed. Ultrasound scan will be performed below collarbone region, 5ml of 0.25% levobupivacaine will be injected in the first plane between pectoralis major and minor. Then under direct ultrasound visualization, the remaining 5ml of 0.25% levobupivacaine will be injected between the second plane of pectoralis minor and serratus anterior muscle (a total of 10ml will be given).
88909971|NCT04933266|Active Comparator|High dose|After three injections of thoracic paravertebral block at T2, T4, T6 (a total of 21ml of 0.5% levobupivacaine with 1:200,000 adrenaline) under ultrasound guidance, patients will be put in supine position with ipsilateral arm and elbow flexed. Ultrasound scan will be performed below collarbone region, 10ml of 0.25% levobupivacaine will be injected in the first plane between pectoralis major and minor. Then under direct ultrasound visualization, the remaining 10ml of 0.25% levobupivacaine will be injected between the second plane of pectoralis minor and serratus anterior muscle (a total of 20ml will be given).
88909972|NCT04933227|Experimental|Atezo + Tira + XELOX|Atezolizumab plus tiragolumab in combination with XELOX (oxaliplatin and capecitabine) will be administered during Cycles 1-4 (each cycle is 21 days). During Cycle 5 and beyond atezolizumab and tiragolumab will be administered on Day 1 of each 21-day cycle. Participants will receive study treatment until disease progression, unacceptable toxicity or loss of clinical benefit as determined by the investigator.
88909973|NCT04931615|Placebo Comparator|without ARTISS|Surgery performed without active comparative
88909974|NCT04931615|Active Comparator|with ARTISS|Surgery performed with active comparative
88909975|NCT04928599||Health Services Research (survey, interview, chart review)|Parents complete surveys over 15-30 minutes at the beginning of their child's induction chemotherapy, at the beginning of maintenance chemotherapy, and at the end of last chemotherapy. Parents may also participate in one-time individual interview over 30-45 minutes. Additionally, children's medical records are reviewed during the study
89429807|NCT03422042|Active Comparator|Standard treatment of antibiotic|group B: will received intravenous antibiotic for 7 days, and followed by oral antibiotic for 7 days, regardless of body temperature
89429808|NCT04449224||RA patients who start bDMARD|The efficacy and safety of targeted therapy will be evaluated in RA patients who are treated with a biologic disease modifying antirheumatic drug (bDMARD) including Adalimuab, Etanercept, Tocilizumab or Abatacept after shared-decision making.
89429809|NCT04449224||RA patients who start small molecule inhibitor|The efficacy and safety of targeted therapy will be evaluated in RA patients who are treated with a small molecular inhibitor including Tofacitinib or Baricitinib after shared-decision making.
89197597|NCT00850707||3|180 hemodialysis patients with Tunneled cuffed catheters (TCC group)
89197598|NCT00850707||4|60 healthy subjects as controls
89429810|NCT00437112|Experimental|1|"4 week pretreatment phase consists of continuation of usual OAM therapy~24 week treatment period with insulin glargine and OAM continuation followed by 24 week treatment period with HIIP and OAM continuation~8 week follow up period"
89429811|NCT00437112|Experimental|2|"4 week pretreatment phase consists of continuation of usual OAM therapy~24 week treatment period with HIIP and OAM continuation followed by 24 week treatment period with insulin glargine and OAM continuation~8 week follow up period"
89429812|NCT00434850|Experimental|Allogeneic Pancreatic Islet Cells|Participants in this study can receive up to three separate islet transplants. They will begin receiving antithymocyte globulin (ATG) and sirolimus 2 days prior to the first islet transplant. ATG will continue to be given until Day 2 post-transplant. Participants will continue taking sirolimus for the duration of the study. On the day of transplant, participants will receive DSG and etanercept, in addition to ATG and sirolimus. The DSG infusion will be administered over 3 hours and will immediately precede the islet transplant. Participants will continue receiving daily 3-hour infusions of DSG through Day 6 post-transplant. Etanercept will also be administered on Days 3, 7, and 10 post-transplant. Tacrolimus will be administered on Day 1 post-transplant and continued throughout the study.
89531158|NCT05043129||HIV infenction/AIDS|experimental group
89531159|NCT05043129||Healthy population|Control group
89197599|NCT00951730||Down syndrome|Adult and children with Down syndrome.
89197600|NCT02546037||SOLACEA 21H|single haemodiafiltration treatment using a SOLACEA 21H dialyzer (Nipro Corp, Osaka, Japan)
89429813|NCT04449302|Experimental|Immediate molar implant with customized healing abutment|Patients will receive an immediate mandibular molar implant with customized healing abutment
89429814|NCT04449302|Active Comparator|Immediate molar implant with submerged healing|Patients will receive an immediate mandibular molar implant with submerged healing
89429815|NCT04449380|Experimental|IFNβ 1a|
89429816|NCT04449380|Active Comparator|Standard care|
89429817|NCT03128216|Active Comparator|Blind Local Anesthetic Infiltration|
89429818|NCT03128216|Active Comparator|Transversals Fascia Block|
89429819|NCT03128216|Active Comparator|Spinal Anesthesia|
89429820|NCT00566202|Experimental|JNJ-18038683|
89429821|NCT00566202|Placebo Comparator|Placebo|
89429822|NCT00566202|Active Comparator|Escitalopram|
89429823|NCT04449068||Evaluation of patients with Tourette's Gilles Syndrome|Neurological and neuropsychological evaluations of patients with Tourette's Gilles syndrome treated with high frequency bilateral stimulation of the anterior part of the internal pallid globus
89197601|NCT02546037||FX100|single haemodiafiltration treatment using a FX100 dialyzer (Fresenius MC, Bad Homburg, Germany)
89429824|NCT02280486|Active Comparator|Saxagliptin|The treatment of saxagliptin will be initiated and maintained at 5mg every morning until the completion of the test.Meanwhile,subjects will be instructed to take stable doses of metformin (1500mg/d) through the whole trial.
89429825|NCT02280486|Active Comparator|Glimepiride|Glimepiride will be initially treated with 1 mg every morning to a dose of 6 mg/day.a.m. Every 4-week the subjects will be evaluated whether reach the target fasting plasma glucose (assayed by finger-stick ≦6.1 mmol/l ). If the fasting blood glucose not achieved the target at the maximum dose, maintain the maximum dose(6mg/d) until the completion of the test.Meanwhile,subjects will be instructed to take stable doses of metformin (1500mg/d) through the whole trial.
89429826|NCT00552474|Placebo Comparator|Group B|Implanted but no active stimulation
89429827|NCT00552474|Experimental|Group A|Active Stimulation
89429828|NCT00434226|Experimental|Bevacizumab + Carboplatin/Paclitaxel + Sunitinib|
89429829|NCT00434226|Placebo Comparator|Bevacizumab + Carboplatin/Paclitaxel|
89429830|NCT02741700|Experimental|Gout storytelling video|Participants view culturally relevant patient narrated storytelling in African-American Veterans' own voices about their experience with gout and its treatment and a patient narrated slide show of gout and its treatment.
89429831|NCT02741700|Active Comparator|Video about management of another chronic condition|Participants view a patient narrated slide show of roughly the same duration as the experimental arm, summarizing the management of stress, a non-gout chronic condition.
89429832|NCT00430950|Experimental|1|olmesartan medoximil (OM)/ hydrochlorothiazide (HCTZ) 40/25 mg + OM/HCTZ 20/25 mg matching placebo
88922229|NCT05607199|Experimental|AUR103, 25mg to 400mg|Currently planned dose levels in Part 1 are 25 mg BID, 50 mg BID, 100 mg BID, 200 mg BID and 400 mg BID
88922230|NCT05605119|Experimental|AUR105 50mg to 750mg|Currently planned dose levels in Part 1 are 50mg, 100mg, 200mg, 300mg, 450mg, 600mg and 740mg once daily
88922231|NCT05603832|Experimental|F14 + Multimodal Analgesia|
88922232|NCT05603832|Active Comparator|Multimodal Analgesia|
88922233|NCT05602038|Active Comparator|Group Q|QLB group will receive 30 ml 0.125% bupivacaine (Sunnypivacaine by Sunny Pharmaceuticals) for each side
88922234|NCT05602038|Active Comparator|Group M|Intrathecal morphine 100mcg will be added to bupivacaine 0.5% 15mg and fentanyl 20 µg
89429833|NCT00430950|Experimental|2|olmesartan medoximil (OM)/ hydrochlorothiazide (HCTZ)20/25 mg + OM/HCTZ 40/25 matching placebo
89429834|NCT00551148|Experimental|15 mg|
89429835|NCT00551148|Experimental|30 mg|
89429836|NCT00551148|Experimental|5 mg|
89429837|NCT00551148|Experimental|60 mg|
89429838|NCT00551148|Placebo Comparator|Placebo|
89429839|NCT02280564|No Intervention|Control|Standard diabetes care
88909979|NCT04927312|Experimental|PF-06947386 + Metronidazole|Multiple intravenous infusion of ceftazidime-avibactam followed by intravenous infusion of metronidazole, repeated every 8 hours for 5-14 days.
88909980|NCT04925024|Experimental|Lomecel B Group|Participants randomized to receive Lomecel-B injections during their Stage II palliation.
88909981|NCT04925024|No Intervention|No Study Intervention Control Group|Participants randomized to receive no study intervention during their Stage II palliation.
88909982|NCT04922957|Placebo Comparator|Placebo|Ringer's lactate solution
88909983|NCT04922957|Experimental|ALLOCETRA-OTS|Single IV dose of Allocetra-OTS containing 10x10^9 cells
88909984|NCT04921865||Patients treated with the DPS VA-LCP® Clavicle Plate 2.7 System or Hook Plate 2.7 System|Any patient undergoing surgical treatment for the fixation of clavicle bone fragments and acromioclavicular joint dislocations using the DPS VA-LCP® Clavicle Plate 2.7 System or DPS VA-LCP® Clavicle Clavicle Hook Plate 2.7 .
88909985|NCT04920864|Experimental|Active 10 Hz dlPFC rTMS|10 Hz dorsolateral prefrontal cortex stimulation for 10 sessions (2 sessions/day X 5 days)
88909986|NCT04920864|Sham Comparator|Sham dlPFC rTMS|inactive dorsolateral prefrontal cortex stimulation for 10 sessions (2 sessions/day X 5 days)
88909987|NCT04920864|Experimental|Active 1 Hz mPFC rTMS|1 Hz medial prefrontal cortex stimulation for 10 sessions (2 sessions/day X 5 days)
88909988|NCT04920864|Sham Comparator|Sham mPFC|inactive medial prefrontal cortex stimulation for 10 sessions (2 sessions/day X 5 days)
88909989|NCT04920071||Control|150 healthy control participants
88909990|NCT04920071||AMD Cohort high-contrast VA group i|Better than 0.4 logMAR
88909991|NCT04920071||AMD Cohort high-contrast VA group ii|0.4-0.6 logMAR
88909992|NCT04920071||AMD Cohort high-contrast VA group iii|0.6-0.8 logMAR
88909993|NCT04920071||AMD Cohort high-contrast VA group iv|0.8-1.0 logMAR
88909994|NCT04918654||Study Subjects|
88909995|NCT04918186|Experimental|Durvalumab + BA3011|
88909996|NCT04918186|Experimental|Durvalumab + BA3021|
88909997|NCT04918186|Experimental|Sub Study X (etc.)|
88909998|NCT04916795|Experimental|Vupanorsen 80 milligram (mg)|Participants will receive one, 0.8 milliliter (mL) subcutaneous injection with vupanorsen 100 mg/mL solution
89429840|NCT02280564|Experimental|Health coaching with technology support|Behavioral strategies including problem solving skills building, family communication counseling, technology support, motivational interviewing support.
89429841|NCT02081391|Experimental|Tapentadol immediate-release (IR)|"In the first 24 hours, tapentadol oral solution at a dose of 1.25 mg/kg body weight was given every 4 hours (±15 min) to participants aged 6 months to less than 18 years (maximum individual dose of tapentadol was 100 mg). Participants from 30 days to less than 6 months were dosed with 0.5 mg/kg body weight every 4 hours. Participants from birth to less than 30 days of age were dosed with 0.1 mg/kg body weight every 4 hours.~After 24 hours and up to 72 hours, the dose could be reduced based on the investigator's judgment."
89429842|NCT02081391|Placebo Comparator|Placebo|Matching placebo oral solution was administered every 4 hours (±15 min) up to 72 hours.
89429843|NCT00430092|Experimental|Difluprednate 0.05% BID|Difluprednate 0.05% 1 drop BID for 14 days
89429844|NCT00430092|Experimental|Difluprednate 0.05% QID|Difluprednate 0.05% 1 drop QID for 14 days
89429845|NCT00430092|Placebo Comparator|Placebo|Placebo for 14 days. Placebo was administered BID for 14 days and QID for 14 days. The outcomes of the 2 placebo groups were examined and were determined to be statistically indistinguishable so the placebo groups were pooled for comparison with the difluprednate groups.
88909999|NCT04916795|Experimental|Vupanorsen 160 milligram (mg)|Participants will receive two, 0.8 mL subcutaneous injections with vupanorsen 100 mg/mL solution
88910000|NCT04916600|Experimental|NET active|Active, non-invasive, alternating current transcutaneous stimulation through electrodes placed transcranially on the mastoid regions. Treatment is self-administered, with participant control of device output level and duration according to perceived benefit. Minimum treatment duration is one-hour, with self-administered extension not to exceed 7 days.
89429846|NCT02280642||Both doses on time|An on time dose 2 was defined as ≥ 30 days to ≤ 90 days after dose 1 and an on time dose 3 was defined as ≥ 60 days to ≤ 180 days after dose 2.
89008318|NCT04870151|Experimental|Anterolateral approach|"The minimally invasive anterolateral approach (Watson-Jones approach) is performed with the patient in supine position. An oblique incision is made from just dorsal to the anterior superior iliac spine, and extended distally to the greater trochanter. After the fascia is incised, deep dissection continues in the plane between the tensor fasciae latae and the gluteus medius muscles. The joint capsule is exposed and opened. The femoral head and neck are resected and the femoral canal is reamed according to the preoperative plan.~A femoral stem (Link Lubinus SPII) is fixed using bone cement (Heraeus Medical Palacos R+G pro) and connected to a bipolar femoral head (Zimmer Multipolar).~After implantation of the prosthesis, the fascia, subcutis and skin is closed in separate layers with sutures."
89008319|NCT04870151|Active Comparator|Direct lateral approach|"The direct lateral approach (Hardinge approach) is performed with the patient in a lateral decubitus position. A straight or curved longitudinal incision is made over the greater trochanter, and the fascia is incised longitudinally. The anterior aspect of the gluteus medius and minimus muscles are separated from the greater trochanter. The joint capsule is exposed and opened. The femoral head and neck are resected and the femoral canal is reamed according to the preoperative plan.~A femoral stem (Link Lubinus SPII) is fixed using bone cement (Heraeus Medical Palacos R+G pro) and connected to a bipolar femoral head (Zimmer Multipolar).~After implantation of the prosthesis, the gluteus medius and minimus muscles are reinserted using osteosutures. The fascia, subcutis and skin is closed in separate layers with sutures."
89008320|NCT04597177|Active Comparator|ST-IMRT|standard parotid sparing IMRT
89008321|NCT04597177|Experimental|SW-IMRT|swallowing sparing IMRT
89008322|NCT04596904|Experimental|Lavender oil group|Individuals, for 10 days, 3 drops of cotton drops of lavender oil, put on the shoulder parts, between 21:00 and 21:05 will smell every evening.
89429847|NCT02280642||Dose 2 delayed|A delayed dose 2 was defined as > 90 days after dose 1 and an on time dose 3 was defined as ≥ 60 days to ≤ 180 days after dose 2.
89429848|NCT02280642||Dose 3 delayed|An on time dose 2 was defined as ≥ 30 days to ≤ 90 days after dose 1 and a delayed dose 3 was defined as >180 days after dose 2.
89429849|NCT02280642||Both doses delayed|A delayed dose 2 was defined as > 90 days after dose 1 and a delayed dose 3 was defined as >180 days after dose 2.
89429850|NCT02074917|Experimental|AM anatomical ACL reconstruction|Femoral and tibial tunnels performed in anteromedial footprint of ACL reconstruction
89429851|NCT02074917|Experimental|CENTRAL anatomical ACL reconstruction|Femoral and tibial tunnels performed in the center of ACL footprint
89429852|NCT00427440|Experimental|AMG 102 at 10 mg/kg Dose Level|Up to 40 subjects will be treated at this dose level based upon investigator assessment of responses observed.
89429853|NCT00427440|Experimental|AMG 102 at 20 mg/kg Dose Level|Up to 40 subjects will be treated at this dose level based upon investigator assessment of responses observed.
89429854|NCT02081469|Other|Arm A:TDF for extend 24 weeks|Arm A:Continue TDF 300mg daily for extend 24 weeks after completion of chemotherapy
89429855|NCT02081469|Other|Arm B: TDF for extend 48 weeks|Arm B: Continue TDF 300mg daily for extend 48 weeks after completion of chemotherapy.
89429856|NCT02284698||Study Group|Study Group will have the field workers and active health education with referral mechanism
89429857|NCT02284698||Control Group|Control group will not have field workers and active health education. They will follow routine health care
89429858|NCT00425100|Experimental|Open Label-fesoterodine|Single treatment study arm.
89429859|NCT00546780|Active Comparator|Arm A|Tanespimycin + Bortezomib
89008323|NCT04596904|Placebo Comparator|Distilled water group|Individuals, for 10 days, 3 drops of cotton drops of distilled water, put on the shoulder parts, between 21:00 and 21:05 will smell every evening.
89197602|NCT00942526|No Intervention|1|no intervention with perioperative oral anti-infective agent or water for gargling
89197603|NCT00942526|Sham Comparator|2|perioperative gargling with water
89429860|NCT00546780|Active Comparator|Arm B|Bortezomib
89429861|NCT00545454|Experimental|SSR150106 QD|90 micro grams oral solution once daily (QD)
89429862|NCT00545454|Experimental|SSR150106 OEQD|90 micro grams oral solution once every other day (OEQD)
89429863|NCT00545454|Placebo Comparator|Placebo|oral solution QD or OEQD
89429864|NCT03134430|Placebo Comparator|Normal saline|equal volume of normal saline as treatment group
89429865|NCT03134430|Active Comparator|peripheral Nerve block|0.35% ropivacaine and 0.5% lidocaine in normal saline
89429866|NCT00420888|Experimental|Safety group|6-12 patients
89429867|NCT00420888|Experimental|1|
89429868|NCT00420888|Other|2|Standard treatment with IFN-alpha without add-on of ABR-217620/naptumomab estafenatox
89429869|NCT00420732|Experimental|Vaccine Group|
89429870|NCT03135132|Placebo Comparator|Control group|Usual dietary intake group
89429871|NCT03135132|Experimental|LCD group|Low calorie diet (LCD) group (300kcal/day intake reduction)
89429872|NCT00543582|Experimental|1|
89429873|NCT03134352|Experimental|ZL-3101(Fugan) bid group|Fugan AM + Fugan PM
89429874|NCT03134352|Experimental|ZL-3101(Fugan) qd group|Fugan AM + Placebo PM
89429875|NCT03134352|Placebo Comparator|placebo group|Placebo AM + Placebo PM
89429876|NCT00542724|Experimental|A|VIAject™
89429877|NCT00542724|Active Comparator|B|Regular Human Insulin
89429878|NCT02282436||COPD exacerbation|No specific intervention for this study
89429879|NCT02284776|No Intervention|Témoin|No treatment.
89429880|NCT02284776|Experimental|Action|People in hydrotherapeutic cure are following a program of Therapeutic Education. This program includes dietary advice, physical activities, behavior advice in order to change the lifestyle of the obese people.
89429881|NCT00384852|Experimental|A|1.0 mg/mL rhBMP-2/CPM + SOC
89429882|NCT00384852|Experimental|B|2.0 mg/mL rhBMP-2/CPM + SOC
89429883|NCT00384852|Active Comparator|C|Buffer/CPM + SOC
89429884|NCT00384852|Other|D|Standard of Care Alone (SOC)
89429885|NCT02284932||COPD patients|Group : COPD patients No specific intervention for this study
89429886|NCT02284932||Healthy controls|Group : healthy volunteers No specific intervention for this study
89429887|NCT00411528|Experimental|1: 8 mg/m2 study drug + prednisone|Patupilone 8 mg/m2 + prednisone 5 mg bid daily
89429888|NCT00411528|Experimental|2: study drug + prednisone days 1 -8|Patupilone 10 mg/m2 + prednisone days 1 -8 at 25 mg bid, day 9 at 20 mg bid, day 10 at 15 mg bid, day 11 at 10 mg bid, day 12 - 21 at 5 mg bid
89429889|NCT00411528|Experimental|3: Study drug + prednisone days 1 - 4|Patupilone 10 mg/m2 + prednisone days 1 - 4 at 5 mg bid, days 5 -12 at 25 mg bid, day 13 at 20 mg bid, day 14 at 15 mg bid, day 15 at 10 mg bid, day 16 - 21 at 5 mg bid
89429890|NCT00411528|Active Comparator|4: Docetaxel 75 mg/m2 + prednisone 5 mg bid daily|Docetaxel 75 mg/m2 once every 3 weeks + prednisone 5 mg bid daily
89197604|NCT00942526|Experimental|3|perioperative oral gargling with oral anti-infective agent for seven days
89429891|NCT00530166|Experimental|002|sham comparator 3(100 mg) tablets once daily for 12 weeks
89429892|NCT00530166|Experimental|001|JNJ-18054478 3(100 mg) tablets once daily for 12 weeks
89429893|NCT02286570|Active Comparator|face-to-face intubation of Glidescope|patients were intubated using glidescope by face-to-face approach
89429894|NCT02286570|Active Comparator|face-to-face intubation with Airtraq|patients were intubated using the Airtraq by face-to-face approach
89429895|NCT02286570|Active Comparator|face-to-face intubation with fastrach|patients were intubated using the Fastrach by face-to-face approach
89429896|NCT02282592||Cases|newly diagnosed (within 6 months) breast cancer patients, before adjuvant or neoadjuvant treatment.
89429897|NCT02282592||Controls|patients without any malignant disease, matched for age an menopausal status with cases.
89429898|NCT00408954|Placebo Comparator|Placebo|
89429899|NCT00408954|Active Comparator|UK-369,003|
89429900|NCT03133884|Experimental|Acupuncture|The needles will be inserted into the acupoints and the depths will be adjusted to the standard permissible layers, then even reinforcing-reducing technique will be performed on the needles until achieving deqi sensation.The needles will be retained for 30 minutes in each session and manipulated twice every 10 minutes with intermittent stimulation. Each manipulation will last for 20 seconds.
88910001|NCT04916600|Sham Comparator|NET sham|Sham, non-invasive, stimulation through electrodes placed transcranially on the mastoid regions. Treatment is self-administered, with participant control of device output level and duration according to perceived benefit. Minimum treatment duration is one-hour, with self-administered extension not to exceed 7 days.
88910002|NCT04914351|Experimental|Dose Escalation|"Cohort 1: 0.03 mg/kg Q2W HY-0102 ivgtt Duration: 26w DLT observation period: 28 days Accelerated dose escalation: One patient will be enrolled. Cohort 2: 0.3 mg/kg Q2W HY-0102 ivgtt Duration: 26w DLT observation period: 28 days Accelerated dose escalation: One patient will be enrolled. Cohort 3: 1 mg/kg Q2W HY-0102 ivgtt Duration: 26w DLT observation period: 28 days Standard 3+3 Dose escalation: Three patients will be enrolled for each dose cohort.~Cohort 4: 2 mg/kg Q2W HY-0102 ivgtt Duration: 26w DLT observation period: 28 days Standard 3+3 Dose escalation: Three patients will be enrolled for each dose cohort.~Cohort 5: 4 mg/kg Q2W HY-0102 ivgtt Duration: 26w DLT observation period: 28 days Standard 3+3 Dose escalation: Three patients will be enrolled for each dose cohort.~Cohort 6: 10 mg/kg Q2W HY-0102 ivgtt Duration: 26w DLT observation period: 28 days Standard 3+3 Dose escalation: Three patients will be enrolled for each dose cohort."
88910003|NCT04907253|Active Comparator|Quercetin|Patients receiving 500 mg quercetin twice daily
88910004|NCT04907253|Placebo Comparator|Placebo|Patients receiving placebo twice daily
88910005|NCT04907084|Experimental|Serine 200 mg/kg/day|Serine 200 mg/kg per day. To be taken once per day for 6 weeks. Exact dose dependent on participant's weight (in kg)).
88910006|NCT04907084|Experimental|Serine 400 mg/kg/day|Serine 400 mg/kg per day. To be taken once per day for 6 weeks. Exact dose dependent on participant's weight (in kg)).
88910007|NCT04907084|Experimental|Fenofibrate 160 mg/day|Fenofibrate 160 mg per day. To be taken once per day for 6 weeks.
88910008|NCT04907084|Experimental|Serine 200 mg/kg/day and Fenofibrate 160 mg/day|"Serine 200 mg/kg per day. To be taken once per day for 6 weeks. Exact dose dependent on participant's weight (in kg)).~Fenofibrate 160 mg per day. To be taken once per day for 6 weeks."
88910009|NCT04907084|Experimental|Serine 400 mg/kg/day and Fenofibrate 160 mg/day|"Serine 400 mg/kg per day. To be taken once per day for 6 weeks. Exact dose dependent on participant's weight (in kg)).~Fenofibrate 160 mg per day. To be taken once per day for 6 weeks."
88910010|NCT04907084|No Intervention|No treatment|Control group: no investigational product taken
88910011|NCT04906707|Experimental|EaseVRx Group|Participants will be asked to complete the 8-week program with assigned modules each week. Each week, participants will be asked to complete 7 modules, averaging 5 minutes in duration and ranging from 2 to 16 minutes in duration, for a total of 56 modules across the program. Participants will be instructed not to use the device while ambulating, and that they should use the headset a maximum of 3 times per 24-hour period (morning, noon, and evening) for not more than 30 minutes consecutively.
88910012|NCT04906707|Active Comparator|Active control Group|Participants in the control group will be asked to use the audio-only version of EaseVRx that excludes references to visual content. They will receive an electronic link to the audio recordings on SoundCloud (a music streaming platform) where they can choose to stream or download the audio recordings on their smartphone, laptop, or desktop computer. Each week, participants will be asked to complete 7 audio sessions.
88910013|NCT04905914|Experimental|50mg ATRN-119|Once daily oral administration.
88910014|NCT04905914|Experimental|100mg ATRN-119|Once daily oral administration.
88910015|NCT04905914|Experimental|200mg ATRN-119|Once daily oral administration.
88910016|NCT04905914|Experimental|350mg ATRN-119|Once daily oral administration.
88910017|NCT04905914|Experimental|550mg ATRN-119|Once daily oral administration.
88910018|NCT04905914|Experimental|800mg ATRN-119|Once daily oral administration.
88910019|NCT04904822|Experimental|Study group|Vaginal bisection of uterus
88910020|NCT04904822|Experimental|Control group|Abdominal bisection
88910021|NCT04904484|Experimental|With i-zephyr|using the hood
88910022|NCT04904484|No Intervention|Without i-zephyr|Not using the hood
88910023|NCT04903899|Experimental|177Lu-DOTATATE|A total of two doses of 177Lu-DOTATATE will be administered intravenously. The minimum time between treatments is 2 weeks.
88910024|NCT04903288|Experimental|Eladocagene Exuparvovec|Participants will receive eladocagene exuparvovec intraoperatively at 1.8×10^11 vector genomes (vg) via SmartFlow® MR Compatible Ventricular Cannula in a single operative session. Participants will receive standard of care for their AADC deficiency during the study.
88910025|NCT04902833||Cohort I|"Approximately 75 anemic (Hgb <11.0 g/dL) MDS Participants without overt clinical evidence of hemolysis.~- Single Blood Draw"
88910026|NCT04902833||Cohort 2|"25 Participants with clonal myeloid disorders of any type with evidence of non-immune, otherwise unexplained hemolytic anemia~-Single Blood Draw"
88910027|NCT04897100|Experimental|Needle tenotomy|Patient will receive an Achilles tendon tenotomy using a 22G needle when randomized into the needle group. Follow-up to measure dorsiflexion and register complications will be assured at 3 weeks and 3 months.
88910028|NCT04897100|Active Comparator|Blade tenotomy|Patient will receive an Achilles tendon tenotomy using a 11 blade when randomized into the needle group. Follow-up to measure dorsiflexion and register complications will be assured at 3 weeks and 3 months.
88910029|NCT04892446|Experimental|Safety Run-in Cohort (Magrolimab+Daratumumab)|"Participants with relapsed/refractory multiple myeloma who have had 3 or more prior therapies including an immunomodulatory drug (IMiD) and a proteasome inhibitor (PI) will receive magrolimab as per protocol and daratumumab 1800 mg subcutaneously (SC) or 16 milligrams per kilogram (mg/kg) intravenously (IV) on Days 8, 15, 22, 29 of Cycle 1, Days 1, 8, 15, 22 of Cycle 2 and Days 1 and 15 (every 2 weeks) until Cycle 6 (total of 8 doses) followed by Day 1 (every 4 weeks) for subsequent cycles. (Cycle 1=35 days, All other Cycles=28 days)~."
88910030|NCT04892446|Experimental|Safety Run-in Cohort (Magrolimab+Pomalidomide+Dexamethasone)|Participants with relapsed/refractory MM who have had 3 or more prior therapies including an IMiD and a PI will receive magrolimab as per protocol and pomalidomide 4 mg on Days 1 to 21 (daily) of Cycle 1, Days 1 to 21 (daily) of Cycle 2 and onward and dexamethasone 40 mg on Days 1, 8, 15, 22, 29 of Cycle 1, Days 1, 8, 15, 22 of Cycle 2 and onward. (Cycle 1=35 days, All other Cycles=28 days)
89197605|NCT00853281|Experimental|Hammocks with LLIN|Locally-made hammocks covered with long-lasting insecticidal net (LLIN)- Olyset(R), used in addition to the standard vector control measures
89429901|NCT03133884|Other|Superficial acupuncture|The selected acupoints will be punctured superficially by the depth of 1-3 mm, and the needles will be retained for 30 minutes without any manipulation.
89429902|NCT02286648|Experimental|Mineral Trioxide Aggregate|pulpotomy with MTA
89429903|NCT02286648|Active Comparator|Formocresol|pulpotomy with FC
89429904|NCT03133806|Experimental|Ultrasept LAA Closure System|Interventional percutaneous transcatheter device.
89429905|NCT02282670|Experimental|DA-5204|DA-5204 administered two times daily for two weeks
89429906|NCT02282670|Active Comparator|Stillen tab.|Stillen tab. administered three times daily for two weeks
89429907|NCT00406458|Experimental|SB-509|60 mg SB-509 injected IM into lower limbs every 2 months
89429908|NCT00406458|Placebo Comparator|Normal Saline|Normal saline injected IM into lower limbs every 2 months
89429909|NCT00379938|Experimental|1|25 micrograms + MF59 (n=26)
89429910|NCT00379938|Experimental|3|2.5 micrograms + MF59 (n=26)
89429911|NCT00379938|Placebo Comparator|4|saline (n=11)
89429912|NCT00379938|Experimental|2|25 micrograms alone (n=26)
89429913|NCT00406068|Experimental|Mycobacterial cell wall-DNA complex|Mycobacterial cell wall-DNA complex
88910031|NCT04892446|Experimental|Safety Run-in Cohort (Magrolimab+Carfilzomib+Dexamethasone)|Participants with relapsed/refractory multiple myeloma who have had 3 or more prior therapies including an IMiD and a PI will receive magrolimab as per protocol and carfilzomib 20 mg/m^2 on Days 8, 15, 22 of Cycle 1, Days 1, 8, 15 of Cycle 2 and onward (if the carfilzomib starting dose of 20 mg/m^2 is tolerated after Cycle 1, Day 8, the dose will be escalated to 70 mg/m^2 on Cycle 1, Day 15 and thereafter) and dexamethasone 40 mg on Days 1, 8, 15, 22, 29 of Cycle 1, Days 1, 8, 15, 22 of Cycles 2 to 9 and then Days 1, 8, 15 from Cycle 10 and onward. (Cycle 1=35 days, All other Cycles=28 days)
88910032|NCT04892446|Experimental|Safety Run-in Cohort (Magrolimab+Bortezomib+Dexamethasone)|"Bortezomib + Dexamethasone may be initiated based on the preliminary safety and efficacy of the Carfilzomib + Dexamethasone cohort.~Participants with relapsed/refractory multiple myeloma who have had 1 or more prior therapies including an IMiD and a PI will receive magrolimab as per protocol and carfilzomib 1.3 mg/m^2 on Days 8, 15, 22, 29 of Cycle 1, Days 1, 8, 15, 22 of Cycle 2 and onward (Maximum of 8 cycles in those who have previously received bortezomib) and dexamethasone 40 mg on Days 1, 8, 15, 22, 29 of Cycle 1, Days 1, 8, 15, 22 of Cycles 2 to 9 and then Days 1, 8, and 15 from Cycle 10 and onward. (Cycle 1=35 days, All other Cycles=28 days)"
88910033|NCT04892446|Experimental|Dose Expansion Cohort (Magrolimab+Daratumumab)|Participants with relapsed/refractory multiple myeloma who have had 3 or more prior therapies including an IMiD and a PI will receive magrolimab at the RP2D determined in the Safety Run-in Cohort and daratumumab 1800 mg SC or 16 mg/kg IV on Days 8, 15, 22, 29 of Cycle 1, Days 1, 8, 15, 22 of Cycle 2 and Days 1 and 15 (every 2 weeks) until Cycle 6 (total of 8 doses) followed by Day 1 (every 4 weeks) for subsequent cycles. (Cycle 1=35 days, All other Cycles=28 days)
88910034|NCT04892446|Experimental|Dose Expansion Cohort (Magrolimab+Pomalidomide+Dexamethasone)|Participants with relapsed/refractory MM who have had 3 or more prior therapies including an IMiD and a PI will receive magrolimab as per protocol and pomalidomide 4 mg on Days 1 to 21 (daily) of Cycle 1, Days 1 to 21 (daily) of Cycle 2 and onward and dexamethasone 40 mg on Days 1, 8, 15, 22, 29 of Cycle 1, Days 1, 8, 15, 22 of Cycle 2 and onward. (Cycle 1=35 days, All other Cycles=28 days)
88910035|NCT04892446|Experimental|Dose Expansion Cohort (Magrolimab+Carfilzomib+Dexamethasone)|Participants with relapsed/refractory multiple myeloma who have had 3 or more prior therapies including an IMiD and a PI will receive magrolimab at the RP2D determined in the Safety Run-in Cohort and carfilzomib 20 mg/m^2 on Days 8, 15, 22 of Cycle 1, Days 1, 8, 15 of Cycle 2 and onward (if the carfilzomib starting dose of 20 mg/m^2 is tolerated after Cycle 1, Day 8, the dose will be escalated to 70 mg/m^2 on Cycle 1, Day 15 and thereafter) and dexamethasone 40 mg on Days 1, 8, 15, 22, 29 of Cycle 1, Days 1, 8, 15, 22 of Cycles 2 to 9 and then Days 1, 8, 15 from Cycle 10 and onward. (Cycle 1=35 days, All other Cycles=28 days)
88922235|NCT05602038|Active Comparator|Group QM|Intrathecal morphine 100mcg will be added to bupivacaine 0.5% 15mg and fentanyl 20 µg combined by QLB of 30 ml 0.125%bupivacain
88922236|NCT05602038|Placebo Comparator|Group C|Control group with intrathecal bupivacaine 0.5% 15mg and fentanyl 20 µg.
89197606|NCT00853281|Active Comparator|ITN|Standard vector control measures (insectice-treated net or ITN)
89197607|NCT04042389|Experimental|WhatsApp|WhatsApp reminders
89429914|NCT02696031|Experimental|Secukinumab, 150 mg Load (Core phase)|Secukinumab 150 mg s.c., pre-filled syringe (PFS) at baseline, Weeks 1, 2, and 3, followed by administration every four weeks starting at Week 4, Load, Core phase
89429915|NCT02696031|Experimental|Secukinumab, 150 mg No Load (Core phase)|Secukinumab 150 mg s.c. PFS at baseline, placebo at Weeks 1, 2, and 3, followed by secukinumab 150 mg PFS administration every four weeks starting at Week 4, No Load, Core phase
89429916|NCT02696031|Placebo Comparator|Placebo (Core phase)|Placebo s.c., PFS at baseline, Weeks 1, 2, 3, followed by administration every four weeks starting at Week 4, Core phase
89429917|NCT02696031|Experimental|Core Phase Responder 150 mg (Extension phase)|Core Phase Responder 150 mg blinded: secukinumab 150 mg s.c. PFS and placebo (1 mL) s.c. PFS every four weeks, in the Extension phase
89429918|NCT02696031|Experimental|Core Phase Responder 300 mg (Extension phase)|Core Phase Responder 300 mg blinded: 2 injections with secukinumab 150 mg s.c. PFS every four weeks, in the Extension phase
89429919|NCT02696031|Experimental|Core Phase Non-Responder 300 mg (Extension phase)|Core Phase Non-Responder 300 mg: 2 injections with secukinumab 150 mg s.c. PFS every four weeks open-label, in the Extension phase
89429920|NCT00403416|Active Comparator|Mycophenolic Acid / tacrolimus|
89429921|NCT00403416|Experimental|AEB071 / tacrolimus arm 1|
89429922|NCT00403416|Experimental|AEB071 / tacrolimus arm 2|
89429923|NCT00401388|Experimental|Group A: chondrosarcoma|"Patients with sarcoma subtype: histologically or cytologically confirmed diagnosis of chondrosarcoma.~Supportive Care Guidelines for perifosine include antiemetic prophylaxis (antiemetics will be administered at the treating investigator's discretion), diarrhea management (loperamide), and hyperuricemia prophylaxis (allopurinol)."
89429924|NCT00401388|Experimental|Group B: alveolar soft part sarcoma|"Patients with sarcoma subtype: histologically or cytologically confirmed diagnosis of alveolar soft part sarcoma.~Supportive Care Guidelines for perifosine include antiemetic prophylaxis (antiemetics will be administered at the treating investigator's discretion), diarrhea management (loperamide), and hyperuricemia prophylaxis (allopurinol)."
88910036|NCT04892446|Experimental|Dose Expansion Cohort (Magrolimab+Bortezomib+Dexamethasone)|"Bortezomib + Dexamethasone may be initiated based on the preliminary safety and efficacy of the Carfilzomib + Dexamethasone cohort.~Participants with relapsed/refractory multiple myeloma who have had 1 or more prior therapies including an IMiD and a PI will receive magrolimab at the RP2D determined in the Safety Run-in Cohort and bortezomib 1.3 mg/m^2 on Days 8, 15, 22, 29 of Cycle 1, Days 1, 8, 15, 22 of Cycle 2 and onward (Maximum of 8 cycles in those who have previously received bortezomib) and dexamethasone 40 mg on Days 1, 8, 15, 22, 29 of Cycle 1, Days 1, 8, 15, 22 of Cycles 2 to 9 and then Days 1, 8, and 15 from Cycle 10 and onward. (Cycle 1=35 days, All other Cycles=28 days)"
88910037|NCT04889989|Other|Microwave Ablation of Lung Tumor|Adult patients with non-small cell lung cancer (NSCLC) or oligometastatic lung tumors who plan to receive percutaneous microwave ablation.
88910038|NCT04889638|Experimental|Cessation intervention|Participants will undergo pre-/post-comparisons of a personalized, remote smoking cessation intervention composed of two main elements: a) prescription and monitoring of nicotine (e.g., replacement therapy) and/or non-nicotine pharmacotherapies (e.g., varenicline) and b) cessation-centered motivational messaging.
88910039|NCT04886778|Experimental|Group A or Trial group|Group A was treated with a 12-week low-carbohydrate diet combined with probiotic compound preparations.
88910040|NCT04886778|Placebo Comparator|Group B or Placebo control group|Group B was treated as a control group with a 12-week low-carbohydrate diet combined with placebo treatment.
88910041|NCT04886154|Experimental|ABCWY low dose Group|Participants receive MenABCWY-2Gen low dose vaccine and are followed up until Day 211 in study Phase I.
88910042|NCT04886154|Placebo Comparator|Placebo low dose Group|Participants receive NaCl as a control for ABCWY low dose group and are followed up until Day 211 in study Phase I.
89197608|NCT04042389|Experimental|Email|Email reminders
89429925|NCT00401388|Experimental|Group C: extra-skeletal myxoid|"Patients with sarcoma subtype: histologically or cytologically confirmed diagnosis of extra-skeletal myxoid chondrosarcoma.~Supportive Care Guidelines for perifosine include antiemetic prophylaxis (antiemetics will be administered at the treating investigator's discretion), diarrhea management (loperamide), and hyperuricemia prophylaxis (allopurinol)."
88910043|NCT04886154|Experimental|ABCWY high dose Group|Participants receive MenABCWY-2Gen high dose vaccine and are followed up until Day 211 in study Phase I.
88910044|NCT04886154|Placebo Comparator|Placebo high dose Group|Participants receive NaCl as a control for ABCWY high dose group and are followed up until Day 211 in study Phase I.
88910045|NCT04886154|Experimental|ABCWY low dose_06 Group|Participants receive MenABCWY-2Gen low dose vaccine in a 0, 6 month schedule and 1 dose of NaCl and are followed up until Day 541 in study Phase II (Formulation and Schedule-finding).
89197609|NCT04042389|Other|Control|No reminder
89197610|NCT03967444|Other|Restylane Kysse|Hyaluronic acid
89197611|NCT03967444|Other|Restylane Kysse with other HA|Hyaluronic acid
88910046|NCT04886154|Experimental|ABCWY low dose_02 Group|Participants receive MenABCWY-2Gen low dose vaccine in a 0, 2 month schedule and 1 dose of NaCl and are followed up until Day 541 in study Phase II (Formulation and Schedule-finding).
88910047|NCT04886154|Experimental|ABCWY high dose_06 Group|Participants receive MenABCWY-2Gen high dose vaccine in a 0, 6 month schedule and 1 dose of NaCl and are followed up until Day 541 in study Phase II (Formulation and Schedule-finding).
88910048|NCT04886154|Experimental|ABCWY high dose_02 Group|Participants receive MenABCWY-2Gen high dose vaccine in a 0,2 month schedule and 1 dose of NaCl and are followed up until Day 541 in study Phase II (Formulation and Schedule-finding).
88910049|NCT04886154|Active Comparator|Control Group|Participants randomized to Control Group receive 2 doses of Bexsero (MenB) vaccine and 1 dose of Menveo (MenACWY), 1 dose of NaCl and are followed up until Day 541 in study Phase II (Formulation and Schedule-finding).
88910050|NCT04886154|Experimental|ABCWY low dose_01 Group|Participants receive MenABCWY-2Gen low dose vaccine in a 0,1 month schedule and are followed up until Day 211 in study Phase II (Sourcing).
88910051|NCT04886154|Experimental|ABCWY high dose_01 Group|Participants receive MenABCWY-2Gen high dose vaccine in a 0,1 month schedule and are followed up until Day 211 in study Phase II (Sourcing).
88910052|NCT04886154|Experimental|ABCWY low doseS_02 Group|Participants receive MenABCWY-2Gen low dose vaccine in a 0, 2 month schedule and are followed up until Day 241 in study Phase II (Sourcing).
88910053|NCT04886154|Experimental|ABCWY high doseS_02 Group|Participants receive MenABCWY-2Gen high dose vaccine in a 0, 2 month schedule and are followed up until Day 241 in study Phase II (Sourcing).
88910054|NCT04886154|Experimental|ABCWY low doseS_06 Group|Participants receive MenABCWY-2Gen low dose vaccine in a 0, 6 month schedule and are followed up until Day 361 in study Phase II (Sourcing).
88910055|NCT04886154|Experimental|ABCWY high doseS_06 Group|Participants receive MenABCWY-2Gen high dose vaccine in a 0, 6 month schedule and are followed up until Day 361 in study Phase II (Sourcing).
88910056|NCT04883905||Patients with AHP|Patients with a diagnosis of AHP will be eligible for the study and will be managed and treated per routine clinical practice.
88910057|NCT04880590||Sex Intercourse|women with a heterosexual sexual relationship after embryo transfer
88910058|NCT04880590||Non sex intercourse|women without a heterosexual sexual relationship after embryo transfer
88910059|NCT04880473|Experimental|PrevisEA device|The PrevisEA device is placed and activated on the patient's abdomen immediately post-op (within 1 hour of the completion of surgery) and maintained in position for at least 12 hours, counting the number of times MH4 is detected within a four-minute period at hourly intervals. The device determines the MH4 biomarker counts at each hourly collection point and the data are stored on the device. For this clinical trial, the display is obscured. Therefore, no value will be displayed for interpretation since this is a non-intervention trial and the device is not intended to affect or influence the standard of care for study participants.
88910060|NCT04877327|Experimental|Cross-over of ablation technique|Cross-over of cardiac ablation procedures (cryotherapy and radiofrequency; radiofrequency and cryotherapy)
89197612|NCT05300854|Active Comparator|Standard anesthesia in addition to serratus plane block|general anesthesia was given then ultrasound-guided serratus plane block
89197613|NCT05300854|Active Comparator|Standard anesthesia in addition to para-vertebral block|general anesthesia was given then ultrasound-guided para-vertebral block
89197614|NCT00946504|Experimental|1|Glipizide 10 mg Tablets (Geneva Pharmaceutical, Inc.)
89429926|NCT02282826|Experimental|Dose 1 IV|GZ402668 dose 1 intravenous, single administration. Acyclovir 200 mg twice daily for 28 days as prophylactic therapy
89429927|NCT02282826|Experimental|Dose 2 IV|GZ402668 dose 2 intravenous, single administration. Acyclovir 200 mg twice daily for 28 days as prophylactic therapy
89429928|NCT02282826|Experimental|Dose 3 IV|GZ402668 dose 3 intravenous, single administration. Acyclovir 200 mg twice daily for 28 days as prophylactic therapy
89429929|NCT02282826|Experimental|Dose 3 SC|GZ402668 dose 3 subcutaneous, single administration. Acyclovir 200 mg twice daily for 28 days as prophylactic therapy
89429930|NCT02282826|Experimental|Dose 4 SC|GZ402668 dose 4 subcutaneous, single administration. Acyclovir 200 mg twice daily for 28 days as prophylactic therapy
89429931|NCT02282826|Experimental|Dose 5 SC|GZ402668 dose 5 subcutaneous, single administration. Acyclovir 200 mg twice daily for 28 days as prophylactic therapy
89429932|NCT02282826|Placebo Comparator|Placebo SC|placebo subcutaneous, single administration. Acyclovir 200 mg twice daily for 28 days as prophylactic therapy
89429933|NCT02282826|Placebo Comparator|Placebo IV|placebo intravenous, single administration. Acyclovir 200 mg twice daily for 28 days as prophylactic therapy
89429934|NCT04471584|Active Comparator|Abbott Confirm Rx|All patients randomized to this group will be implanted Abbott Confirm RX
89429935|NCT04471584|Active Comparator|Medtronic Reveal LINQ|All patients randomized to this group will be implanted Medtronic Reveal LINQ
88910061|NCT04877327|No Intervention|Repetition of the same technique|Repeat the same procedure (cryotherapy and cryotherapy; radiofrequency and radiofrequency)
88910062|NCT04875702|Active Comparator|TTT-SU|The participants randomized to the Treat-to-Target-Serum Urate (TTT-SU) group will be counseled about gout, generalized lifestyle and dietary issues and will be provided with a three-month supply of allopurinol as well as a treatment to prophylax against attacks that might occur during the up-titration of urate lowering therapy. Allopurinol dose increases will occur until SU concentrations achieve a target level < 6.0 mg/dL.
88910063|NCT04875702|Active Comparator|TTASx|Subjects randomized to the treat-to-avoid-symptoms (TTASx) group will receive the same education as the TTT-SU group. In addition, they will receive anti-inflammatory treatments (naproxen, colchicine, and/or prednisone); enough to treat up to six flares over the ensuing three months.
88910064|NCT04874038|Experimental|Intervention|Intraoperative intravenous lidocaine/placebo infusion
88910065|NCT04874038|Placebo Comparator|Control|Intraoperative intravenous lidocaine/placebo infusion
89429936|NCT04471584|Active Comparator|Biotronik Biomonitor|All patients randomized to this group will be implanted Biotronik Biomonitor
89429937|NCT00374166|Experimental|SSR149415 - 250 mg|SSR149415 250 mg, twice daily for a maximum of 8 weeks
89429938|NCT00374166|Experimental|SSR149415 - 100 mg|SSR149415 100 mg and additional placebo capsules in order that all patients are being administered three capsules twice daily for a maximum of 8 weeks
89429939|NCT00374166|Active Comparator|Paroxetine|Paroxetine 20 mg and additional placebo capsules in order that all patients are being administered three capsules twice daily for a maximum of 8 weeks
89429940|NCT00374166|Placebo Comparator|Placebo|Placebo for a maximum of 9 weeks
89429941|NCT02081547||IPC status|presence of cancer cells.
89429942|NCT02285088|Experimental|GBT440|Subjects randomized 6:2 to receive daily oral dosing of GBT440 or placebo for 1 day (single dose) and up to 118 days (multiple dose)
89429943|NCT02285088|Placebo Comparator|Placebo|Subjects randomized 6:2 to receive daily oral dosing of GBT440 or placebo for 1 day (single dose) and up to 118 days (multiple dose)
89429944|NCT02081625|Experimental|NS-065/NCNP-01|
89429945|NCT02286882|Experimental|Cohort 1: PF-06409577 or placebo|Single ascending doses of PF-06409577 or placebo to investigate the safety, tolerability, and PK.
89429946|NCT02286882|Experimental|Cohort 2: PF-06409577 or placebo|Single ascending doses of PF-06409577 or placebo to investigate the safety, tolerability, and PK.
89429947|NCT02286882|Experimental|Cohort 3: PF-06409577 or placebo|Single ascending doses of PF-06409577 or placebo to investigate the safety, tolerability, and PK.
89429948|NCT02286882|Experimental|Cohort 4: PF-06409577 or placebo|Single ascending doses of PF-06409577 or placebo to investigate the safety, tolerability, and PK.
88910066|NCT04871282|Experimental|Part A Main Study 1.2 mg daily|AL102 1.2 mg
88910067|NCT04871282|Experimental|Part A Main Study 2 mg Intermittent|AL102 2 mg
88910068|NCT04871282|Experimental|Part A Main Study 4 mg Intermittent|AL102 4 mg
88910069|NCT04871282|Experimental|Part B AL102|AL102, recommended dose regimen from Part A, 1.2 mg daily
88910070|NCT04871282|Placebo Comparator|Part B Placebo|Placebo to match recommended dose regimen from Part A
88910071|NCT04871282|Experimental|Open Label Extension|AL102, recommended dose regimen from Part A, 1.2 mg daily
88910072|NCT04871048|Experimental|active tDCS stimulation|Transcranial direct current stimulation tDCS-Stimulation will be performed using a Neurocan DC-Stimulator Plus
89197615|NCT00946504|Active Comparator|2|Glucotrol 10 mg Tablets (Roerig Pharmaceutical, Inc.)
89429949|NCT02286882|Experimental|Cohort 5: PF-06409577 or placebo|Single ascending doses of PF-06409577 or placebo to investigate the safety, tolerability, and PK.
89429950|NCT02286882|Experimental|Cohort 6: PF-06409577 or placebo|Single ascending doses of PF-06409577 or placebo to investigate the safety, tolerability, and PK.
89429951|NCT02286882|Experimental|Cohort 7: PF-06409577 or placebo|Single ascending doses of PF-06409577 or placebo to investigate the safety, tolerability, and PK.
89429952|NCT02286882|Experimental|Cohort 8: PF-06409577 or placebo|Single ascending doses of PF-06409577 or placebo to investigate the safety, tolerability, and PK.
89429953|NCT02286882|Experimental|Cohort 9: PF-06409577 or placebo|Single ascending doses of PF-06409577 or placebo to investigate the safety, tolerability, and PK.
89429954|NCT02285244|Experimental|Treatment (sotrastaurin acetate)|Patients receive sotrastaurin acetate PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89429955|NCT02287116|No Intervention|nasal mask and nasal prongs|
89429956|NCT02078895|Experimental|Botox|The experimental group will include ureteral stent placement with three peri-ureteral injections of Botox A and fourteen site-specific intradetrusor injections of Botox A.
89429957|NCT02078895|No Intervention|Control|The control group will involve a ureteral stent placement with no injection.
88910073|NCT04871048|Sham Comparator|sham tDCS stimulation|Transcranial direct current stimulation tDCS-The control group will receive the sham stimulation following the same regimen, using the sham procedure .
88910074|NCT04870762|Experimental|Arm I (3D printed oral stent)|Patients wear 3D printed oral stent during standard of care radiotherapy.
88910075|NCT04870762|Active Comparator|Arm II (standard of care)|Patients receive standard of care during treatment.
88910076|NCT04867525||Colorectal Cancer Metastatic|
88910077|NCT04863924||Advanced NSCLC|Patients with radiologic evidence of advanced (unresectable stage III or IV) non-small cell lung cancer
88910078|NCT04857892|Experimental|Part 1 : Treatment sequence ABC|Participants will receive a single oral dose of GSK3640254 25 milligrams (mg) (2 x tablets), GSK3640254 100 mg (1 x tablet) and DTG 50 mg (1 x tablet) administered together under moderate fat and calorie conditions (reference) (Treatment A) in Period 1, followed by a single oral dose of GSK3640254/DTG, 150 mg/50 mg (1 x monolayer tablet) FDC administered under moderate fat and calorie conditions (Treatment B) in Period 2. In Period 3, participants will receive a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 x bilayer tablet) FDC administered under moderate fat and calorie conditions (Treatment C).
88910079|NCT04857892|Experimental|Part 1 : Treatment sequence BCA|Participants will receive a single oral dose of GSK3640254/DTG, 150 mg/50 mg (1 x monolayer tablet) FDC administered under moderate fat and calorie conditions (Treatment B) in Period 1, followed by a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 x bilayer tablet) FDC administered under moderate fat and calorie conditions (Treatment C) in Period 2. In Period 3 participants will receive a single oral dose of GSK3640254 25 mg (2 x tablets), GSK3640254 100 mg (1 x tablet) and DTG 50 mg (1 x tablet) administered together under moderate fat and calorie conditions (reference) (Treatment A).
88910080|NCT04857892|Experimental|Part 1 : Treatment sequence CAB|Participants will receive a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 x bilayer tablet) FDC administered under moderate fat and calorie conditions (Treatment C) in period 1, followed by a single oral dose of GSK3640254 25 mg (2 x tablets), GSK3640254 100 mg (1 x tablet) and DTG 50 mg (1 x tablet) administered together under moderate fat and calorie conditions (reference) (Treatment A) in Period 2. In Period 3 participants will receive a single oral dose of GSK3640254/DTG, 150 mg/50 mg (1 x monolayer tablet) FDC administered under moderate fat and calorie conditions (Treatment B).
88910081|NCT04857892|Experimental|Part 2 : Treatment sequence DE|Participants will receive a single oral dose of selected FDC from Part 1 of GSK3640254/DTG, 150 mg/50 mg administered under high fat and calorie conditions (Treatment D) in Period 1 followed by a single oral dose of selected FDC from Part 1 of GSK3640254/DTG, 150 mg/50 mg administered under fasted conditions (Treatment E) in Period 2.
88910082|NCT04857892|Experimental|Part 2 : Treatment sequence ED|Participants will receive a single oral dose of selected FDC from Part 1 of GSK3640254/DTG, 150 mg/50 mg administered under fasted conditions (Treatment E) in Period 1 followed by a single oral dose of selected FDC from Part 1 of GSK3640254/DTG, 150 mg/50 mg administered under high fat and calorie conditions (Treatment D) in Period 2.
88910083|NCT04857424||ERCP|Subjects with benign and malignant biliary obstruction who have or will undergo endoscopic retrograde cholangiopancreatography (ERCP)
88910084|NCT04857424||PTBD|Subjects with benign and malignant biliary obstruction who have or will undergo percutaneous trans-hepatic biliary drainage (PTBD).
88910085|NCT04854499|Experimental|Safety Run-in Cohort 1, Magrolimab + Pembrolizumab + 5-FU + Platinum|"Participants with untreated metastatic or unresectable, locally recurrent head and neck squamous cell carcinoma (HNSCC) regardless of programmed cell death ligand 1 (PD-L1) status will receive the following:~magrolimab~pembrolizumab 200 mg on Day 1 of each cycle~5-fluorouracil (5-FU) 1000 mg/m^2/day Days 1-4 of each cycle (for up to 6 cycles)~platinum chemotherapy (cisplatin 100 mg/m^2 or carboplatin area under the concentration versus time curve (AUC) 5 per investigator choice (for up to 6 cycles))~Participants will continue treatment until unacceptable toxicity or disease progression, whichever occurs first, and will not change their magrolimab dose level after the recommended Phase 2 dose (RP2D) is determined. Each cycle is 21 days."
88910086|NCT04854499|Experimental|Safety Run-in Cohort 2, Magrolimab + Docetaxel|"Participants with locally advanced/metastatic HNSCC regardless of PD-L1 status who were previously treated with at least 1 and no more than 2 lines of prior systemic therapy will receive the following:~magrolimab~docetaxel 75 mg/m^2 on Day 1 of each cycle~Participants will continue treatment until unacceptable toxicity or disease progression, whichever occurs first, and will not change their magrolimab dose level after the RP2D is determined. Each cycle is 21 days."
88910087|NCT04854499|Experimental|Pre-expansion Safety Run-in Cohort, Magrolimab + Pembrolizumab|"The pre-expansion safety run-in cohort may be conducted at the sponsor's discretion prior to the initiation of Phase 2 Cohort 2.~Participants with untreated metastatic or unresectable, locally recurrent HNSCC with a PD-L1 combined positive score (CPS) ≥ 1 will receive magrolimab and pembrolizumab 200 mg on Day 1 of each cycle. Each cycle is 21 days.~Participants will continue treatment until unacceptable toxicity or disease progression, whichever occurs first, and will not change their magrolimab dose level after the RP2D is determined. Each cycle is 21 days."
88922237|NCT05601154|Active Comparator|Crest Cavity Protection|Crest Cavity Protection toothpaste (1,100 ppm F) will be used to brush teeth, followed by a mouth rinse with tap water
89429958|NCT00399906|Active Comparator|A1|10 mg
89429959|NCT00399906|Active Comparator|A2|30 mg
89429960|NCT00399906|Active Comparator|A3|100 mg
89429961|NCT00399906|Placebo Comparator|P1|10 or 100 mg
89429962|NCT02078973|Active Comparator|15 mg tolvaptan|Oral administration of 15 mg tolvaptan on each examination day.
89429963|NCT02078973|Active Comparator|30 mg tolvaptan|Oral administration of 30 mg tolvaptan on each examination day.
89429964|NCT02078973|Active Comparator|45 mg tolvaptan|Oral administration of 45 mg tolvaptan on each examination day.
89429965|NCT02078973|Placebo Comparator|Placebo|Oral administration of a Unikalk tablet
88910088|NCT04854499|Experimental|Phase 2 Cohort 1, Magrolimab + Pembrolizumab + 5-FU + Platinum (Arm A)|"Participants with untreated metastatic or unresectable, locally recurrent HNSCC regardless of PD-L1 status will receive magrolimab at the recommended Phase 2 dose (RP2D) determined in the Safety run-in cohort 1, pembrolizumab 200 mg on Day 1 of each cycle, 5-FU 1000 mg/m^2/day Days 1-4 of each cycle, and platinum chemotherapy (cisplatin 100 mg/m^2 or carboplatin AUC 5 per investigator choice). Each cycle is 21 days.~Magrolimab will be continued until loss of clinical benefit, unacceptable toxicity, or death. Pembrolizumab therapy will be administered for up to 24 months or until loss of clinical benefit or unacceptable toxicity, whichever occurs first. 5-FU and platinum chemotherapy will be administered for up to 6 cycles or until loss of clinical benefit or unacceptable toxicity, whichever occurs first."
88910089|NCT04854499|Active Comparator|Phase 2 Cohort 1, Pembrolizumab + 5-FU + Platinum (Arm B)|"Participants with untreated metastatic or unresectable, locally recurrent HNSCC regardless of PD-L1 status will receive pembrolizumab 200 mg on Day 1 of each cycle, 5-FU 1000 mg/m^2/day Days 1-4 of each cycle, and platinum chemotherapy (cisplatin 100 mg/m^2 or carboplatin AUC 5 per investigator choice). Each cycle is 21 days.~Pembrolizumab therapy will be administered for up to 24 months or until loss of clinical benefit or unacceptable toxicity, whichever occurs first. 5-FU and platinum chemotherapy will be administered for up to 6 cycles or until loss of clinical benefit or unacceptable toxicity, whichever occurs first."
88910090|NCT04854499|Experimental|Phase 2 Cohort 1, Magrolimab + Zimberelimab + 5-FU + Platinum (Arm C)|"Participants with untreated metastatic or unresectable, locally recurrent HNSCC regardless of PD-L1 status will receive magrolimab at the recommended Phase 2 dose (RP2D) determined in the Safety run-in cohort 1, zimberelimab 360 mg on Day 1 of each cycle, 5-FU 1000 mg/m^2/day Days 1-4 of each cycle, and platinum chemotherapy (cisplatin 100 mg/m^2 or carboplatin AUC 5 per investigator choice). Each cycle is 21 days.~Magrolimab will be continued until loss of clinical benefit, unacceptable toxicity, or death. Zimberelimab therapy will be administered up to 24 months or until loss of clinical benefit or unacceptable toxicity, whichever occurs first. 5-FU and platinum chemotherapy will be administered for up to 6 cycles or until loss of clinical benefit or unacceptable toxicity, whichever occurs first."
88922238|NCT05601154|Active Comparator|Crest Cavity Protection followed by Act Mint Fluoride Rinse|Crest Cavity Protection toothpaste (1,100 ppm F) will be used to brush teeth, followed by a mouth rinse with Act Mint Fluoride Rinse (226 ppm)
88922239|NCT05601154|Active Comparator|Colgate PreviDent 5000+|Colgate PreviDent 5000+ (5,000 ppm F) will be used to brush teeth, followed by a mouth rinse with tap water
88922240|NCT05601154|Experimental|Colgate PreviDent 5000+ followed by Act Mint Fluoride Rinse|Colgate PreviDent 5000+ (5,000 ppm F) will be used to brush teeth, followed by a mouth rinse with Act Mint Fluoride Rinse (226 ppm)
88922241|NCT05599100|Experimental|STAR-VTF|Participants will receive the STAR-VTF intervention.
89008324|NCT04596787||Non-Obese Patients (Group NO: body mass index (BMI) <30)|Patients received bilateral single injection ultrasound (US)-guided bilateral thoracic paravertebral block (TPVB) at the level of T3-T4 with 20 mL bupivacaine 0.375% per injection/side.
89197616|NCT00619983|Active Comparator|Donepezil|Donepezil 5 mg once per day for 12 weeks. Gabapentin will be titrated in all groups beginning at week 8.
89197617|NCT00619983|Active Comparator|Duloxetine|Group 2: Will receive duloxetine 30 mg twice a day for 12 weeks. Gabapentin will be titrated in all groups beginning at week 8.
89429966|NCT00397254|Active Comparator|Clinical Limit|"Eligible patients were randomized to one of two treatment regimens in a 1:1 ratio. Those randomized to receive a clinical limit of study medication received Rizatriptan 10mg ODT: 27 tablets per month."
89429967|NCT00397254|Active Comparator|Formulary Limit|"Eligible patients were randomized to one of two treatment regimens in a 1:1 ratio. Those randomized to receive a formulary limit of study medication received Rizatriptan 10mg ODT: 9 tablets per month."
89429968|NCT01369641|Experimental|Experimental Ear - Sodium Thiosulfate (STS)|Subjects enrolled to study will have their ears randomized for treatment with STS. The experimental ear will receive STS treatments, while the comparator ear will receive a placebo.
89429969|NCT01369641|Placebo Comparator|Comparator Ear - Placebo|Subjects enrolled to study will have their ears randomized for treatment with STS. The experimental ear will receive STS treatments, while the comparator ear will receive a placebo.
89429970|NCT02283060|Experimental|Stribild switch arm|Patient to be taken off Atripla and switched to Stribild (co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) -one tablet taken daily with food
89429971|NCT02283060|Active Comparator|Atripla control arm|Patient to continue taking Atripla (co-formulated efavirenz/emtricitabine/ tenofovir disoproxil fumarate) - one tablet taken daily at bedtime on an empty stomach
89429972|NCT02079051|Experimental|High Intensity Weight Loss|High intensity medical weight loss
89429973|NCT02079051|Active Comparator|Moderate Intensity Weight Loss|Moderate intensity weight loss
89429974|NCT03559725|Experimental|VLN Menthol Cigarettes (A)|Subjects will smoke VLN menthol cigarettes
89429975|NCT03559725|Experimental|Usual Brand Menthol Cigarettes (B)|Subjects will smoke their usual brand menthol cigarettes
89429976|NCT03559725|Experimental|Nicotine Gum (C)|Subjects will chew nicotine gum
89429977|NCT00529152|Other|A|Ferriprox Oral Solution single treatment
89429978|NCT02287194||SpyGlass Direct Visualization System|Any patient who has undergone SpyGlass Choledochoscopy procedures for diagnosis and/or treatment of biliary tract diseases.
89429979|NCT02079207|Experimental|NBP606|Participants aged over 50 years are given a 0.5mL dose of 13-valent peumococcal conjugate vaccine administered on day 0.
89429980|NCT02079207|Active Comparator|Prodiax-23|Participants aged over 50 years are given a 0.5mL dose of 23-valent pneumococcal polysaccharide vaccine administered on day 0.
89197618|NCT00619983|Active Comparator|Donepezil + Duloxetine|Group 3: Will receive a combination of donepezil 2.5 mg and duloxetine 30mg for 12 weeks. Gabapentin will be titrated in all groups beginning at week 8.
88910091|NCT04854499|Experimental|Phase 2 Cohort 2, Magrolimab + Pembrolizumab|"Participants with untreated metastatic or unresectable, locally recurrent HNSCC with a PD-L1 combined positive score (CPS) ≥ 1 will receive magrolimab at the RP2D determined in the Safety run-in cohort 1 and pembrolizumab 200 mg on Day 1 of each cycle. Each cycle is 21 days.~Magrolimab will be continued until loss of clinical benefit, unacceptable toxicity, or death. Pembrolizumab therapy will be administered for up to 24 months or until loss of clinical benefit or unacceptable toxicity, whichever occurs first."
89197619|NCT00619983|Placebo Comparator|Placebo|Group 4:Will receive placebo pills. Gabapentin will be titrated in all groups beginning at week 8.
89429981|NCT03429920|Experimental|Q CAN PLUS POWDER|QCAN PLUS POWDER:2 pouches per day, each pouch contains(12-15gms of fermented soy powder)
88910092|NCT04854499|Experimental|Phase 2 Cohort 3, Magrolimab + Docetaxel|"Participants with locally advanced/metastatic HNSCC regardless of PD-L1 status who were previously treated with at least 1 and no more than 2 lines of prior systemic therapy will receive magrolimab at the RP2D determined in the Safety run-in cohort 2 and docetaxel 75 mg/m^2 on Day 1 of each cycle. Each cycle is 21 days.~Magrolimab and docetaxel will be continued until loss of clinical benefit, unacceptable toxicity, or death."
88910093|NCT04853394|Experimental|MASLIHAT peer education|A peer educator prevention intervention program consisting of five weekly 2-hour small group sessions.
88910094|NCT04853394|Sham Comparator|TANSIHAT health education|A health education program consisting of five weekly 2-hour sessions small group sessions.
89429982|NCT03429920|Placebo Comparator|placebo|Sprouted brown rice protein with flavor (provided by BESO Biological Research Inc.)
89429983|NCT00570336|Experimental|2.5 milligram (mg) CTS-1027|2.5 mg CTS-1027
89429984|NCT00570336|Experimental|5 mg CTS-1027|5 mg CTS-1027
89429985|NCT00570336|Experimental|10 mg CTS-1027|10 mg CTS-1027
89429986|NCT00570336|Experimental|30 mg CTS-1027|30 mg CTS-1027
88910095|NCT04850053||Alzheimer's disease|Criteria for AD according to the 2011 NIA-AA
88910096|NCT04850053||Non-AD dementia|Frontotemporal dementia (FTD); or Parkinson's disease dementia (PDD); or dementia with Lewy bodies (DLB); or vascular dementia (VaD); or corticobasal degeneration (CBD); or dementia not otherwise specified.
88910097|NCT04850053||Cognitively normal controls|Individuals with normal cognitive function
89197620|NCT00850863||A|20 healthy individuals not susceptible for COPD (age 18-40 years, 0 < pack years > 10, FEV1/FVC >70% , FEV1 >85% predicted)
89429987|NCT00570336|Placebo Comparator|Placebo|Placebo
88910098|NCT04849871|Experimental|Arm S_APBI (External Beam Accelerated Partial Breast Irradiation (APBI) 20 Gy-1 fraction)|-External Beam APBI 20 Gy to surgical bed surface (7 Gy to 1 cm from surgical bed in 1 fraction)
89197621|NCT00850863||B|30 healthy individuals susceptible for COPD (age 40-75years, pack years >20, FEV1/FVC > 70%, FEV1 > 85% predicted)
89197622|NCT00850863||C|20 healthy individuals very susceptible for COPD (age 18-40 year, 0 < pack years > 10, FEV1/FVC > 70%, FEV1 > 85% predicted)and high prevalance of COPD in smoking family members older than 45 years
89197623|NCT00850863||D1|30 COPD patients with GOLD stage I (age 40-75 years, Pack years > 10, FEV1/FVC ≤ 70%, FEV1 > 80% predicted)
89197624|NCT00850863||D2|30 COPD patients with GOLD stage II (age 40-75 years, Pack years > 10, FEV1/FVC ≤ 70%, FEV1 50-80 predicted)
89197625|NCT00850863||D3|30 COPD patients with GOLD stage III (age 40-75 years, Pack years > 10, FEV1/FVC ≤ 70%, FEV1 30-50% predicted)
89429988|NCT02075151|Other|Bronchial Thermoplasty|Bronchial thermoplasty
89429989|NCT00525330|Experimental|KRP-104 120 mg QD|
89429990|NCT00525330|Experimental|KRP-104 60 mg BID|
89429991|NCT00525330|Placebo Comparator|Placebo|
89429992|NCT02079285||EUS-FNA|Any patients who will undergo EUS-FNA for pancreas lesion during the study period
89429993|NCT00393120|Experimental|Treatment A - INCB009471 100mg IR|INCB009471, 100 mg IR orally once daily
89429994|NCT00393120|Experimental|Treatment B - INCB009471 300mg SR|INCB009471, 300 mg SR orally once daily
89429995|NCT00393120|Placebo Comparator|Treatment C - Placebo|Placebo matching INCB009471
89429996|NCT02079363||Patients with pancreatic adenocarcinoma|"Exclusion criteria:~No prior cancer. No anticoagulant treatment."
89429997|NCT02079363||Patients with chronic pancreatitis|"Exclusion criteria:~No prior cancer. No anticoagulant treatment."
89429998|NCT02079363||Patients with acute pancreatitis|"Exclusion criteria:~No prior cancer."
89429999|NCT02079363||Patients screened for but not having upper GI cancer|"Exclusion criteria:~No prior cancer."
89430000|NCT02287272|Active Comparator|Treatment period R|single inhaled dose of CHF 5993 pMDI (BDP/FF/GB fixed dose combination)
89430001|NCT02287272|Active Comparator|Treatment period T|Cimetidine plus CHF5993 pMDI: repeated doses of oral cimetidine for 6 days plus a single inhaled dose of CHF 5993 pMDI (BDP/FF/GB fixed dose combination)
89430002|NCT02079441||Infants, IBD mothers, anti TNF, pregnancy|Infants born to mother with IBD receiving ant- TNF medications during pregnancy
89197626|NCT00850863||D4|30 COPD patients with GOLD stage IV (age 40-75 years,Pack years > 10, FEV1/FVC ≤ 70%, FEV1 30% predicted)
89197627|NCT00850863||E|20 healthy individuels very susceptible for COPD ( Age 18-40 years,0 < Pack years > 10, FEV1/FVC >70%, FEV1 > 85% predicted, and one of the smoking family members has severe early onset COPD or mild COPD with very low smoke exposure
89430003|NCT02079441||infants, IBD mothers, pregnancy, medications|Infants born to mothers with IBD receiving non anti TNF medications during pregnancy
89430004|NCT00392574|Experimental|1|Prulifloxacin
89430005|NCT00392574|Placebo Comparator|2|Placebo
89430006|NCT02075229||Group A|45 participants with AzBio baseline sentence scores between 41 - 50%
89430007|NCT02075229||Group B|45 participants with AzBio baseline sentence scores between 51 - 60%.
89430008|NCT00391560|Experimental|Group 1 on Perifosine|"Patients with AML, MDS, CML-BP non-lymphoid, CMML, or Agnogenic Myeloid Metaplasia (AMM).~After a one-time loading dose of 600 mg (150 mg x 4 at least 4 hours apart) during the first cycle, perifosine will be given orally at 100 mg once a day continuously. Cycles are 28 days in length.~Intra-patient dose escalation for the maintenance dose to 150 mg daily will be done in the second cycle if no non-hematological toxicities beyond grade 0-1 occurred during the first cycle are observed."
89430009|NCT00391560|Experimental|Group 2 on Perifosine|"Patients with CLL, ALL, or CML-BP lymphoid. After a one-time loading dose of 600 mg (150 mg x 4 at least 4 hours apart) during the first cycle, perifosine will be given orally at 100 mg once a day continuously. Cycles are 28 days in length.~Intra-patient dose escalation for the maintenance dose to 150 mg daily will be done in the second cycle if no non-hematological toxicities beyond grade 0-1 occurred during the first cycle are observed."
89430010|NCT02081781||Probing, topical anesthesia|Nasolacrimal duct obstruction (NLDO) is a quite common condition among the infants. An imperforate membrane at the distal end of the nasolacrimal duct is the main cause of occlusion. Children with the signs of NLDO presenting with epiphora and/or mucous discharge were included in this study. Intervention with probing under topical anesthesia was performed on the same surgeon. And success rate was evaluated.
89430011|NCT04470414||Recovered COVID-19 patients|Patients recovered from COVID-19 infection within three months before the start of the study.
88910099|NCT04849871|Experimental|Arm F_APBI (External Beam Accelerated Partial Breast Irradiation (APBI) 30 Gy-5 fractions)|-External Beam APBI 30 Gy in 5 fractions over 5 days.
89008325|NCT04596787||Obese Patients (Group O: body mass index (BMI) ≥30)|Patients received bilateral single injection ultrasound (US)-guided bilateral thoracic paravertebral block (TPVB) at the level of T3-T4 with 20 mL bupivacaine 0.375% per injection/side.
89197628|NCT00850863||F|30 COPD patients who are highly susceptible (age > 53 years with Pack years > 10 , FEV1/FVC ≤ 70% and FEV1 < 40% predicted) or (age >18 years with 0 < pack years > 5, FEV1/FVC ≤ 70% and FEV1 < 80% predicted)
89430012|NCT02075307|Experimental|Blueberry Powder|The intervention group will receive the Blueberry freeze-dried powder equivalent to 1 cup of whole Blueberries twice a day for 8 weeks (i.e. 2 cups/day).
89430013|NCT02075307|Placebo Comparator|Placebo Powder|The placebo group will receive placebo powder in the same amounts for the same duration.
89430014|NCT00363636|Experimental|1|
89430015|NCT00363636|Active Comparator|2|
89430016|NCT02285322||BP control reached|Patients diagnosed with high blood pressure who lowered their blood pressure measurements during follow-up to <140/90mmHg if aged less than 60 years old, and <150/90mmHg for those of ≥60 years
89430017|NCT02285322||BP control not reached|Patients diagnosed with high blood pressure who did not lower their blood pressure measurement during follow-up (measurements were ≥140/90mmHg for individuals aged less than 60 years old, and ≥150/90mmHg for those of ≥60 years)
89430018|NCT02957253|Experimental|Intervention (CI)|Compensated intervention (CI). Nurse-led clinic one time per year. Focus on Life style and risk factors.
89430019|NCT02957253|No Intervention|Control (CC)|Compensated Control (CC)
89430020|NCT02957253|Experimental|Intervention (DI)|Decompensated intervention (DI). Nurse-led clinic two times every month to every third month. Focus on Lifestyle, risk factors, nutrition, selfcare and psychosocial needs
89430021|NCT02957253|No Intervention|Control (DC)|Decompensated Control (DC)
89430022|NCT02285400|Experimental|Moderate COPD patients|Patients are connected to the noninvasive ventilator and incremental CPAP level is performed.
89430023|NCT02285400|Experimental|Severe COPD patients|Patients are connected to the noninvasive ventilator and incremental CPAP level is performed.
89430024|NCT02605174|Experimental|Lasmiditan 50 milligram (mg)|Oral tablet. Lasmiditan 50 mg plus placebo (to match a lasmiditan dose). One dose for acute treatment of migraine. Second dose for rescue or recurrence of migraine allowed between 2 and 24 hours.
88910102|NCT04838756|Experimental|Intervention arm|AI-integrated mammography screening
89430025|NCT02605174|Experimental|Lasmiditan 100 mg|Oral tablet. Lasmiditan 100 mg plus placebo (to match a lasmiditan dose). One dose for acute treatment of migraine. Second dose for rescue or recurrence of migraine allowed between 2 and 24 hours.
88910103|NCT04838756|Experimental|Control arm|Conventional mammography screening (standard of care)
88910104|NCT04837638||Adults with HeFH|Adult men and women aged 18 to 65 years with genetically-defined HeFH.
88922242|NCT05597787|Active Comparator|HIV Connect|Participants randomized to this condition will complete HIV Connect, which is an online course developed by the Malaysian Society of HIV Medicine designed to educate primary care physicians in Malaysia about HIV. It consists of a series of modules featuring HIV infectious disease experts who instruct on topics including epidemiology and natural history of HIV, pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP), sexual history taking and STI testing, and others.
89430026|NCT02605174|Experimental|Lasmiditan 200 mg|Oral tablet. Lasmiditan 200 mg plus placebo (to match a lasmiditan dose). One dose for acute treatment of migraine. Second dose for rescue or recurrence of migraine allowed between 2 and 24 hours.
89430027|NCT02605174|Placebo Comparator|Placebo|Oral tablet. Placebo tablets match each of the lasmiditan doses (50 mg, 100 mg and 200 mg). One dose for acute treatment of migraine. Second dose for rescue or recurrence of migraine allowed between 2 and 24 hours.
89430028|NCT02285556|No Intervention|general information|use cross-sectional study to collect 1000 ATS abuse or dependence patients' general information and 5 ml blood,get their blood plasma and DNA sample in order to explore the possible addict mechanism.
89430029|NCT02285556|No Intervention|ATS diagnosis and evaluation for abusers|Use cohort study design to establish ATS abuse induced craving experiment.Do the initial and follow-up assessment from start smoking to stop smoking after 4 weeks, 12 weeks, 26 weeks, 52 weeks and 26 weeks of returning to the community . Thus compare with normal group to explore the possible psychological abuse mechanism.
89531160|NCT03340181|Experimental|RIPC|4 cycles of 5-min ischemia(using a blood pressure cuff inflated to 40mmHg over the patient's basic blood pressure) and 5-min repercussion are done on an upper limb.
89531161|NCT03340181|Sham Comparator|control|patient in control group using a blood pressure cuff on an upper limb without inflating
89008326|NCT04596748|Placebo Comparator|Placebo|Participants will be taking a placebo supplement that they will be taking by mouth once per day.
89008327|NCT04596748|Experimental|Probiotic|Participants will be taking a probiotic supplement that they will be taking by mouth once per day.
89008328|NCT00403013|Experimental|1|lateral, head-down position during axillary plexus block
89430030|NCT02285556|Active Comparator|psychological training intervention|The main content is self-awareness training, social and moral strengthening, impulse control training , problem solving training , situational awareness training , HIV prevention, social skills training under the family atmosphere , family social skills training , interpersonal skills training, community interaction skills training , psychiatric symptoms of self-monitoring skills training and so on.
89430031|NCT02285556|Active Comparator|brain stimulation intervention|Use randomized, prospective pseudo stimulus controlled clinical trial design, evaluation of repetitive transcranial magnetic stimulation of the left frontal lobe dorsal lateral effect on ATS dependent induced cognitive dysfunction and other symptoms.
89430032|NCT02285556|No Intervention|ATS diagnosis and evaluation for normal people|Do the same initial and follow-up assessment as ATS abusers who stop smoking after 4 weeks, 12 weeks, 26 weeks, 52 weeks and 26 weeks of returning to the community .
89430033|NCT02285556|Active Comparator|physical and neurological rehabilitation|The main content is drug rehabilitation exercise and functional physical training. Rehabilitation led by the discipline cadres , practice once a day, each lasting about 15 minutes .
89430034|NCT02285556|Placebo Comparator|fake brain stimulation intervention|fake transcranial magnetic stimulation of the left frontal lobe dorsal lateral effect on ATS dependent induced cognitive dysfunction and other symptoms.
89008329|NCT00403013|Active Comparator|2|standard position during axillary plexus block
89008330|NCT04597060|Experimental|Split Keloid - first side|
89008331|NCT04597060|Experimental|Split Keloid - second side|
89008332|NCT00566215|Experimental|1|Duodenal exclusion plus total omentectomy
89008333|NCT00566215|Active Comparator|2|Duodenal exclusion without omentectomy
89008334|NCT00566332|Active Comparator|1|Chlorambucil 8mg/m² (6 mg/m² if patient aged more than 75 years old) 10 days every 28 days during 12 months
89008335|NCT00566332|Active Comparator|2|Fludarabine
89008336|NCT00403052|Experimental|1|Low dose of 1018 ISS
89008337|NCT00403052|Experimental|2|Middle dose of 1018 ISS
89008338|NCT00403052|Experimental|3|High dose of 1018 ISS
89008339|NCT04596709|Active Comparator|Vitalose|dissolved in water
89430035|NCT02075385|Experimental|Speech pathology therapy|Pre, during and pos-treatment swallowing exercises.
89430036|NCT02075385|No Intervention|Control group|These patients will not receive speech pathology therapy.
89430037|NCT00522990|Experimental|1|Refractory Hematological Malignancies
89430038|NCT02079597||Healthy|Healthy individuals no infection
89008340|NCT04596709|Active Comparator|isomaltulose|dissolved in water
89008341|NCT04596709|Placebo Comparator|sucrose|dissolved in water
89008342|NCT04596709|Placebo Comparator|glucose|dissolved in water
89430039|NCT02079597||SIRS|SIRS patients no included in an interventional study no peroperative infection
89430040|NCT00522834|Active Comparator|1|Elesclomol (STA-4783) in Combination With Paclitaxel
89430041|NCT00522834|Other|2|Paclitaxel alone
89430042|NCT02075619|Experimental|Sequence 1|Four subjects (2 Chinese and 2 Caucasian) will receive one amlodipine 10mg tablet and one rosuvastatin 20mg tablet in Period 1; one GSK3074477 Fixed dose combination (FDC) formulation-1 tablet in Period 2 and one GSK3074477 FDC formulation-2 tablet in Period 3; all treatments will be administered orally in fasted state. The three treatment periods will be separated by a washout period of between 12-17 days.
89430043|NCT02075619|Experimental|Sequence 2|Four subjects (2 Chinese and 2 Caucasian) will receive one amlodipine 10mg tablet and one rosuvastatin 20mg tablet in Period 1; one GSK3074477 FDC formulation-2 tablet in Period 2 and one GSK3074477 FDC formulation-1 tablet in Period 3; all treatments will be administered orally in fasted state. The three treatment periods will be separated by a washout period of between 12-17 days.
89430044|NCT02075619|Experimental|Sequence 3|Four subjects (2 Chinese and 2 Caucasian) will receive one GSK3074477 FDC formulation-1 tablet in Period 1, one amlodipine 10mg tablet and one rosuvastatin 20mg tablet in Period 2; and one GSK3074477 FDC formulation-2 tablet in Period 3; all treatments will be administered orally in fasted state. The three treatment periods will be separated by a washout period of between 12-17 days.
89430045|NCT02075619|Experimental|Sequence 4|Four subjects (2 Chinese and 2 Caucasian) will receive one GSK3074477 FDC formulation-1 tablet in Period 1; one GSK3074477 FDC formulation-2 tablet in Period 2; and one amlodipine 10mg tablet and one rosuvastatin 20mg tablet in Period 3; all treatments will be administered orally in fasted state. The three treatment periods will be separated by a washout period of between 12-17 days.
89430046|NCT02075619|Experimental|Sequence 5|Four subjects (2 Chinese and 2 Caucasian) will receive one GSK3074477 FDC formulation-2 tablet in Period 1; one amlodipine 10mg tablet and one rosuvastatin 20mg tablet in Period 2; and one GSK3074477 FDC formulation-1 tablet in Period 3; all treatments will be administered orally in fasted state. The three treatment periods will be separated by a washout period of between 12-17 days.
89430047|NCT02075619|Experimental|Sequence 6|Four subjects (2 Chinese and 2 Caucasian) will receive one GSK3074477 FDC formulation-2 tablet in Period 1; one GSK3074477 FDC formulation-1 tablet in Period 2; and one amlodipine 10mg tablet and one rosuvastatin 20mg tablet in Period 3; all treatments will be administered orally in fasted state. The three treatment periods will be separated by a washout period of between 12-17 days.
89430048|NCT02079675|Experimental|SKI3246 Low Dose|Intervention: Drug: SKI3246 Low Dose
89430049|NCT02079675|Experimental|SKI3246 High Dose|Intervention: Drug: SKI3246 High Dose
89430050|NCT02079675|Placebo Comparator|Placebo|Intervention: Drug: Placebo
89430051|NCT02079753|Active Comparator|combined system|During the first visit, the technician installed a reservoir of liquid oxygen (Liberator 30, Caire) and a liquid Stroller oxygen pack (Caire) for patients using liquid oxygen, or a VisionAire5 (Airsep) stationary concentrator and an Inogen One G2 portable (Inogen) concentrator for patients using concentrators.
89430052|NCT02079753|Experimental|single system|Inogen One G2 portable concentrator (Inogen)
88910105|NCT04832984|Experimental|Intervention arm|Participants receiving the phone app together with a fitness tracker. All participants will receive the educational curriculum through the app over a period of 24 weeks. The mobile app allows secure patient monitoring through a participant dashboard that the coach can use to increase patient adherence and motivation to achieve goals. The participants can use the app to log their food intake, weight, steps, exercise, in addition to participating in the peer support via the chat function. Participants will also receive regular care and follow up in community pharmacies for support.
88910106|NCT04832984|Active Comparator|Usual care arm|"The control group will be a usual care condition in which participants are free to seek any assistance for their medical care during the study period. Participants will be given physical tracking sheets to record their food intake, weight, steps and exercises."
88922243|NCT05597787|Active Comparator|Project ECHO for HIV Prevention|Participants randomized to this condition will receive Project ECHO for HIV Prevention, without added evidence-based stigma reduction tools. Participants will meet with the Project ECHO Hub specialists and their learning community on a bi-weekly basis for 60 minutes over the course of 9 months. Each session will feature a didactic training incorporating standardized procedures for HIV testing, prevention, and/or linkage to care, and patient-case presentation and discussion.
89430053|NCT04795102|Experimental|L-PRF with ATBG around implant|L-PRF clots to cover ATBG around immediately placed dental implants in the extraction sockets
89430054|NCT04795102|Active Comparator|ATBG around implant|ATBG around immediately placed dental implants in the extraction sockets
89430055|NCT00517920|Experimental|ABT-869|
89430056|NCT02079831|Experimental|Higher protein and energy restriction|Participants in this arm will consume 30% of energy as protein with 25% energy restriction.
89430057|NCT02079831|Experimental|Lower protein and energy restriction|Participants in this arm will consume 15% of energy as protein with 25% energy restriction.
89430058|NCT04827004|Experimental|Anlotinib Hydrochloride Capsules|This is a multi-target receptor tyrosine kinase inhibitor.
89430059|NCT03559335||Patients after colorectal cancer surgery|
89430060|NCT02287506|Experimental|ODS from enrolment|Optimised Diagnostic Strategy used from enrolment to study
88910107|NCT04829617|Experimental|PP-MI Intervention|Participants will receive a 12-week, Positive Psychology-Motivational Interviewing (PP-MI) intervention. Each week, participants will complete a PP activity and work towards one or more health behavior goals, then complete a phone session with a study trainer. Each weekly session will include PP and goal setting portions. In the PP portion, a study trainer will (a) review the week's PP exercise, (b) discuss the rationale of the next week's PP exercise through a guided review of the PP-MI manual, and (c) assign the next week's PP exercise. Additionally for the goal-setting portion, the trainer will (a) review their goals and health behaviors from the prior week, (b) discuss techniques for improving health behavior adherence (e.g., monitoring physical activity, reading nutrition labels), and (c) set goals for the next week. Finally, participants will receive supplemental text messages throughout the 12 weeks of the intervention and during the initial follow-up period (Week 13-24).
88910108|NCT04829617|Active Comparator|MI-alone Intervention|This condition will mirror the MI component of the PP-MI intervention. During the first three sessions, participants will learn about the causes and types of HF, risk factors for cardiovascular disease, and methods for monitoring risk factors and symptoms. Then participants will complete nine sessions related to physical activity, a low sodium diet, and medication adherence. Weekly tasks (e.g., brainstorming barriers) will be assigned, completed between calls, and reviewed at the following call. Finally, participants will receive supplemental text messages throughout the 12 weeks of the intervention and during the initial follow-up period (Week 13-24).
89430061|NCT02287506|No Intervention|ODS at end of study|ODS fed back at the end of the participants involvement with the study
89430062|NCT02075853||Bovine Xenograft|Patients in this group received a bovine xenograft in their Evans calcaneal lengthening procedure. Up until April 2014, patients were randomized into receiving the bovine graft or allograft. However, the bovine xenograft will no longer be manufactured, so no future patients will receive the bovine xenograft during the procedure.
89430063|NCT02075853||Iliac Crest Allograft|Patients in this group received an iliac crest cadaver allograft (bicortical or tricortical) in their Evans calcaneal lengthening procedure. Up until April 2014, patients were randomized into receiving the bovine graft or allograft. However, the bovine xenograft will no longer be manufactured, so all future patients will receive the allograft during the procedure.
89430064|NCT04805476|Experimental|Non invasive mechanical ventilation|The subjects in the immediate intervention group (GI) will be extubated and placed in NIV the moment they enter the recovery room through a portable ventilator (Esprit ® or BiPAP Vision ®, Respironics) in face mask. The parameters will be adjusted as follows: FiO2 = 50%, positive expiratory pressure (EPAP, starting at 4-6 cmH2O and adjusting 1-2 cmH2O to avoid snoring, apnea, paradoxical breathing and desaturations) and adjusted inspiratory positive pressure (IPAP) to maintain a tidal volume of 400 to 500 ml, maintaining IPAP <15cmH2O17. Individuals will receive this ventilatory support for 1 hour. After this period the patients will be submitted to the same care of GP patients.
88910109|NCT04826003|Experimental|Part I: Dose-escalation of RO7122290|The dose-escalation of RO7122290 will use a QW dosing schedule of RO7122290 in combination with a Q3W dosing interval for cibisatamab with obinutuzumab pre-treatment. The starting dose for RO7122290 will be 35 mg, which represents the human equivalent dose for the minimal pharmacologically active dose (1 mg/kg) in mice.
88910110|NCT04826003|Experimental|Part II: Dose-expansion of RO7122290|Part II of this study will evaluate selected dose levels of RO7122290 from Part I (a QW RO712290 administration in combination with a Q3W cibisatamab administration with obinutuzumab pre-treatment) in a Q3W regimen in combination with a Q3W cibisatamab administration with obinutuzumab pre-treatment.
88910111|NCT04823624|Experimental|MG MBG453|Participants will be given MBG453 On Day 1 of each cycle 28 days (4 weeks) study cycle
89430065|NCT04805476|Active Comparator|Usual care|Subjects will receive oxygen therapy through a nasal cannula with 4 to 6 L / min of oxygen according to the team routine and patient need.
89430066|NCT02283216|Experimental|Acoustic, Body, Cortical|Acoustic corresponds to noise sound stimulation. Body corresponds to body electrical stimulation. Cortical corresponds to transcranial magnetic stimulation. Acoustic is presented together with body and cortical stimulation. Different body locations and timing among acoustic, body, and cortical stimulation are presented across testing sessions.
89430067|NCT02075931|Experimental|Physical Activity Feedback|The physical activity feedback intervention will involve real-time physical activity monitoring using a device to provide activity feedback directly to patients in combination with patient group meetings held monthly during the 12 week intervention for the purposes of mutual support in attaining physical activity goals.
89430068|NCT02075931|Active Comparator|Control|The control represents the current standard of care post total knee arthroplasty.
89430069|NCT04795180|No Intervention|Non-irrigations|No irrigations trough the efferent limb of loop ileostomy
88910112|NCT04823299|Active Comparator|Cryoballoon ablation|Cryoballoon Pulmonary Vein Isolation-Wide area circumferential ablation (WACA)
88910113|NCT04823299|Experimental|RF based WACA ± EP testing guided ablation of non-PV triggers of AF and low voltage area ablation|Radiofrequency wide area circumferential ablation (WACA) ± electrophysiological testing guided ablation of non-pulmonary vein triggers of AF and low voltage area ablation
89430070|NCT04795180|Experimental|Butyrate irrigations|Butyrate irrigations trough the efferent limb of loop ileostomy
89430071|NCT04795180|Sham Comparator|Saline irrigations|Saline irrigations trough the efferent limb of loop ileostomy
88910116|NCT04821284|Experimental|Arm I (sonazoid, ultrasound, chemotherapy)|Patients receive standard of care chemotherapy consisting of gemcitabine hydrochloride and nab-paclitaxel IV over 60 minutes on days 1, 8 and 15 OR FOLFIRINOX IV on days 1 and 2. Treatments repeat every 28 days for up to 3 cycles for gemcitabine and nab-paclitaxel, and every 14 days for up to 7 cycles for FOLFIRINOX in the absence of disease progression or unacceptable toxicity. Patients also receive sonazoid IV over 20 minutes and undergo CEUS. Patients undergo CT or PET/CT or MRI during screening and as clinically indicated on study.
89008343|NCT04596358||Healtcare workers|Women who work as nurses or doctors in public hospitals of which anthropometric and haematochemical data have been collected. Workers were given a questionnaire for the evaluation of the adherence to the Mediterranean diet.
89430072|NCT04471116|Active Comparator|Therapy group|Patients in the therapy group took 1 sachet of OMNi-BiOTiC® FLORA plus + (= 2 g) dissolved in 1/8 l of water once a day
89430073|NCT04471116|No Intervention|Control group|Patients in the control group received no additional medication.
89430074|NCT02076087||Normal Weight (BMI: 18.5-24.9 kg/m²)|Liposuction/lipectomy
89430075|NCT02076087||Overweight (BMI: 25.0-29.9 kg/m²)|Liposuction/lipectomy
89430076|NCT02076087||Obese (BMI: >30.0kg/m²)|Liposuction/lipectomy
89430077|NCT04471272|Experimental|RFA using gradual RF energy delivery mode|RFA therapy is performed on HCC less than 4 cm in size using an octopus electrode, a double-shift unipolar high-frequency transmission mode, and a gradual high-frequency energy loading mode.
89430078|NCT02081937|Experimental|Anti-CD19 CAR T cells|Patients receive anti-CD19-CAR retroviral vector-transduced autologous or donor-derived T cells on d1-5 in the absence of disease progression or unacceptable toxicity.
89430079|NCT04805242|Active Comparator|Dextrose prolotherapy groups|In the first group, dextrose prolotherapy injection will be applied.
89430080|NCT04805242|Sham Comparator|Saline groups|In the second group, physiological saline injection will be applied.
89430081|NCT02285712|No Intervention|Classical method of peripheral venous catheterization|Classical method will be applied only on arm and forearm.
89430082|NCT02285712|Experimental|Ultrasound guided peripheral venous catheterization|Nurse will use a vascular ultrasound system to orient the catheter toward the peripheral vein. Ultrasound method will be applied only on arm and forearm.
89430083|NCT02082015|Experimental|true coil|Use the true coil / Low frequency rTMS / Intensity: 100% of resting motor threshold; Location: Motor hotspot in primary motor cortex for the dominant hand; Frequency: 1Hz; Number of total stimuli: 1800; Coil orientation: tangential to scalp
89430084|NCT02082015|Sham Comparator|sham coil|Use the sham coil / Low frequency rTMS / Intensity: 100% of resting motor threshold; Location: Motor hotspot in primary motor cortex for the dominant hand; Frequency: 1Hz; Number of total stimuli: 1800; Coil orientation: vertical to scalp
89430085|NCT04805086|Experimental|MON002|Minimum of 1x10~7 cells to maximum of 2x10~6 cells/kg. Single infusion.
89430086|NCT02285790|Experimental|RCM-OSS procedure|The Vivascope 1500 will be used (CE certified, Lucid Technologies, Henrietta, NY, USA). Reflectance confocal microscopy (RCM) imaging will be performed for intended use only and interpreted on the Vivascope workstation by two investigators independently at both study locations. The investigators will be blinded to the results of the reference standard. After RCM imaging subjects will receive OSS surgical excision according to subtype. Clinically suspected primary BCCs that are not confirmed by RCM will also receive surgical treatment with a margin of 3mm.
89430087|NCT02285790|Active Comparator|Standard of care procedure|Clinical suspected primary BCCs, of all subtypes, will be diagnosed by conventional 3mm punch biopsy of the most elevated part of the lesion. Punch biopsies will be performed under local anesthetics using 1% xylocaine/adrenaline. HE stained sections of the punch biopsies will be evaluated by an experienced board certified pathologist. Subjects will receive surgical excision according to subtype within 6 weeks after punch biopsy has been performed. Clinically suspected new primary BCCs that are not confirmed by punch biopsy will also receive surgical treatment with a margin of 3mm.
89430088|NCT04804852||study population|Patient diagnosed with head & neck carcinoma at diagnosis
89430089|NCT02285868||Arm, Shoulder and Hand injuries|Pre- and post-treatment outcomes of care as measured by the DASH (Disabilities of the Arm, Shoulder and Hand) via physical therapy
89430090|NCT02285868||Lumbar spine injuries|Pre- and post-treatment outcomes of care as measured by the Modified Oswestry (lumbar spine) via physical therapy
89430091|NCT02285868||Knee injuries|Pre- and post-treatment outcomes of care as measured by the Knee Outcome Survey via physical therapy
89430092|NCT02285868||Foot and ankle injuries|Pre- and post-treatment outcomes of care as measured by the Foot & Ankle Ability Measure via physical therapy
89430093|NCT02285868||Hip and lower extremity injuries|Pre- and post-treatment outcomes of care as measured by the Lower Extremity Functional Scale via physical therapy
89430094|NCT02285868||Neck injuries|Pre- and post-treatment outcomes of care as measured by the Neck Disability Index Questionnaire via physical therapy
89430095|NCT02088021|Experimental|Portico Transcatheter Aortic Valve Implantation|Placement of the SJM Portico aortic valve with a ALC delivery system
89430096|NCT04826380|Other|Trapeziectomy|Simple trapeziectomy for treating CMC I arthritis
89430097|NCT04826380|No Intervention|Conservative|Conservative measures (e.g. splint, NSAID, activation modification) for treating CMC I arthritis
89430098|NCT02083341|Experimental|Muscle tension dysphonia - treatment|external vibration device. A prospective, randomized, placebo controlled, single blinded study design will be used to investigate the effects of an external vibration device on voice acoustic parameters and perceptual in MTD patients and singers. The external vibration device to be investigated is the Lelo® Siri vibrator. The external vibration therapy sessions, and pre and post acoustic recordings will be conducted by a SLP.
89430099|NCT02083341|Sham Comparator|Muscle tension dysphonia - Sham|external vibration device - sham. A prospective, randomized, placebo controlled, single blinded study design will be used to investigate the effects of an external vibration device on voice acoustic parameters and perceptual in MTD patients and singers. The external vibration device to be investigated is the Lelo® Siri vibrator. The external vibration therapy sessions, and pre and post acoustic recordings will be conducted by a SLP. Lelo® Siri vibrator with vibration component removed.
89430100|NCT02083341|Experimental|Classically trained singers|external vibration device. A prospective, randomized, placebo controlled, single blinded study design will be used to investigate the effects of an external vibration device on voice acoustic parameters and perceptual in MTD patients and singers. The external vibration device to be investigated is the Lelo® Siri vibrator. The external vibration therapy sessions, and pre and post acoustic recordings will be conducted by a SLP.
88910117|NCT04821284|Active Comparator|Arm II (chemotherapy)|Patients receive standard of care chemotherapy consisting of gemcitabine hydrochloride and nab-paclitaxel IV over 60 minutes on days 1, 8 and 15 OR FOLFIRINOX IV on days 1 and 2. Treatments repeat every 28 days for up to 3 cycles for gemcitabine and nab-paclitaxel, and every 14 days for up to 7 cycles for FOLFIRINOX in the absence of disease progression or unacceptable toxicity. Patients undergo CT or PET/CT or MRI during screening and as clinically indicated on study.
88910118|NCT04820933|Experimental|Doravirine plus emtricitabine and tenofovir alafenamide fumarate|PIFELTRO (doravirine) 100 mg tablet one daily for 3 months Descovy (200 mg emtricitabine + 10 mg tenofovir alafenamide fumarate) tablet one daily for 3 months
88910119|NCT04820855|Experimental|Treatment|This is an individual treatment program devised by a pelvic floor physical therapist including a daily yoga series and mindfulness via a Smartphone app.
88910120|NCT04820855|Active Comparator|Control|These are participants undergoing regular treatment for interstitial cystitis with their providers
88910121|NCT04813718|Active Comparator|Synbiotic|Omni-Biotic Pro Vi 5
88910122|NCT04813718|Placebo Comparator|Placebo|similar looking and tasting
88910123|NCT04809285|Experimental|Guardian™ Connect system, InPen™ Basal smart cap, and smart insulin pens|All subjects will wear the Guardian Connect system (real-time continuous glucose monitoring (CGM)) continuously and use smart insulin pens or insulin pens with smart caps for multiple daily injections and continue their standard therapy throughout the duration of the study.
88910124|NCT04808713|Experimental|Treatment condition|
88910125|NCT04808713|No Intervention|Waitlist condition|
89430101|NCT02083341|Sham Comparator|Classically trained singers - Sham|external vibration device - sham. A prospective, randomized, placebo controlled, single blinded study design will be used to investigate the effects of an external vibration device on voice acoustic parameters and perceptual in MTD patients and singers. The external vibration device to be investigated is the Lelo® Siri vibrator. The external vibration therapy sessions, and pre and post acoustic recordings will be conducted by a SLP. Lelo® Siri vibrator with vibration component removed.
89430102|NCT02083419||LVAD CRT|The following procedures will be performed: limited echocardiogram, an adjustment to the CRT device's programmed settings, follow-up in 30 days to adjust the CRT device's programmed settings. In addition, quality of life questionnaires will be filled out and a 6 minute walk test will be completed.
89430103|NCT00358878|Experimental|Satavaptan|
89430104|NCT00358878|Placebo Comparator|Placebo|
88910126|NCT04806373|Placebo Comparator|Talc Slurry Pleurodesis (TSP) plus placebo|Patients who sign informed consent may be randomized to receive TSP alone (talc, 5 gm in 50 ml NS) with placebo (50 ml Normal saline (NS)) through the chest pleural catheter.
88910127|NCT04806373|Experimental|Talc Slurry Pleurodesis (TSP) plus Cathflo Activase|Patients who sign informed consent may be randomized to receive TSP (Talc, 5mg in 50ml Normal saline (NS)) with cathflo activase (4 mg in 50 ml NS) through the chest pleural catheter
88910128|NCT04802759|Active Comparator|Cohort 1: Giredestrant Monotherapy|
88910129|NCT04802759|Experimental|Cohort 1: Giredestrant + Abemaciclib|
88910130|NCT04802759|Experimental|Cohort 1: Giredestrant + Ipatasertib|
89430105|NCT02082093|No Intervention|Traditional Care|
89430106|NCT02082093|Experimental|eNephro Application|"Telemedicine system which is a collaborative and expert system, consisting of:~A dynamic shared medical record for the collection of administrative , medical, biological and clinical data for each patient. All health professionals can access the folder and fill in the support. It is the same for patients treated at home.~A secure messaging for communication between health professionals and between patients and health professionals Expert systems analyzing data from each patient A management tool of therapeutic education~These patients have a chronic renal failure moderate to end up being treated by ambulatory dialysis or kidney transplantation. The patients of each population will be randomly assigned in group 1 ie traditional care or in group 2 ie traditional care added by telemedicine system"
88910131|NCT04802759|Experimental|Cohort 1: Giredestrant + Inavolisib|
88910132|NCT04802759|Experimental|Cohort 1: Giredestrant + Ribociclib|
88910133|NCT04802759|Experimental|Cohort 1: Giredestrant + Everolimus|
88910134|NCT04802759|Experimental|Cohort 1: Giredestrant + Samuraciclib|
88910135|NCT04802759|Experimental|Cohort 1: Giredestrant + Atezolizumab|
88910136|NCT04802759|Experimental|Cohort 1: Giredestrant + Abemaciclib + Atezolizumab|
88910137|NCT04802759|Active Comparator|Cohort 2: Giredestrant + PH FDC SC|
88910138|NCT04802759|Experimental|Cohort 2: Giredestrant + PH FDC SC + Abemaciclib|
88910139|NCT04802759|Experimental|Cohort 2: Giredestrant + PH FDC SC + Palbociclib|
88910140|NCT04802707|Experimental|dC/dT100-400 Arm|Children & Adult (0-60 Y), who takes the investigational product deoxynucleosides pyrimidine (mix of deoxycytidine and deoxythymidine), following the protocol.
88910141|NCT04797780|Experimental|Tamibarotene + Azacitidine|"Tamibarotene: 6 mg administered orally twice per day (BID) on Days 8 through 28 of each 28-day treatment cycle.~Azacitidine: 75 mg/m^2 administered intravenously or subcutaneously each day on Days 1 through 7 of each 28-day treatment cycle."
88910142|NCT04797780|Placebo Comparator|Tamibarotene Matched Placebo + Azacitidine|"Placebo: Tamibarotene-matching tablets administered orally BID on Days 8 through 28 of each 28-day treatment cycle.~Azacitidine: 75 mg/m^2 administered intravenously or subcutaneously each day on Days 1 through 7 of each 28-day treatment cycle."
89008344|NCT04596358||Non-Healthcare workers|Women who perform technical and managerial professions in a public administration body of which anthropometric and haematochemical data have been collected. Workers were given a questionnaire for the evaluation of the adherence to the Mediterranean diet.
89430107|NCT02082171|No Intervention|Control group|
89430108|NCT02082171|Experimental|Intervention group|Comprehensive geriatric assessment followed by multi-domain preventive intervention
89430109|NCT02283372|Experimental|nab-Paclitaxel + Gemcitabine + IMRT|"Prior to initiation of chemoradiation, patients will undergo 1 full cycle of gemcitabine and nab-paclitaxel on Days 1, 8, and 15 of a 28-day cycle.~Both gemcitabine and nab-paclitaxel will be given intravenously on an outpatient basis during the one-month lead-in period and during Weeks 1 and 2 (and, if enrolled to Dose Level or 2, Weeks 4 and 5) of radiotherapy. There may be up to 21 days between the last dose of lead-in chemotherapy (given on Day 15) and initiation of chemoradiation (inclusive of the week following Day 15, the fourth week of the lead-in cycle (an off-week), and an additional week following that).~Intensity modulated radiation (IMRT) - the prescribed dose will range from 40-67.5 Gy over 15 to 25 fractions."
89430110|NCT00507936|Experimental|A|ABT-894 1 mg BID
89430111|NCT00507936|Experimental|B|ABT-894 2 mg BID
89430112|NCT00507936|Experimental|C|ABT-894 4 mg BID
89430113|NCT00507936|Placebo Comparator|D|
89430114|NCT00507936|Active Comparator|E|Duloxetine 60 mg QD
89430115|NCT02083497|Experimental|No banding|The volunteers who make up this group, held 18 kicks, 9 with the dominant leg and 9 with the non-dominant lower limb, without the intervention of any kind of bandage.
89430116|NCT02083497|Experimental|Group with Rigid Bandage|Volunteers carry out the same protocol described above, however, using rigid bandage. The bandage will be used for tape, Cremer brand and will be applied ankle support member of the individual, in order to limit the movement of the joint inversion.
89430117|NCT02083497|Experimental|Group with elastic bands|The protocol will be maintained, however, a brand elastic bandage Kinesio Sport applied to the lower support member of the individual, also in order to limit the movement of the joint inversion is used.
89430118|NCT04427020|Experimental|Milk Protein + Probiotic|25 gram dose of milk protein concentrate with bacillus coagulans GBI-30, 6086
89430119|NCT04427020|Active Comparator|Milk Protein|25 gram dose of milk protein concentrate
88910143|NCT04794127|Experimental|Trabectedin in combination with Pioglitazone|Trabectedin administered at a dose of 1.5 mg/m2-1.3 mg/m2 (according to investigator's choice, with a top-dose of 2.6 total mg per cycle) as a 24-hour continuous infusion via a central venous access every 3 weeks and Pioglitazone given continuously at the daily dose of 45 mg by oral route. Since Trabectedin has no cumulative toxicities, and Pioglitazone as well, the combination will be administered until progressive disease, major toxicity, patient's intolerance or unwillingness to continue treatment, or medical decision by the responsible physician.
88910144|NCT04793399|Experimental|Bosutinib-Atezolizumab Combination|"Drugs to be administered:~Bosutinib 400 milligram (mg)/day Oral Tablet [Bosulif 100mg oral tablets] for 1 year Atezolizumab 1680 mg/28 days [Tecentriq 840 MG in 14 ML Injection] for 1 year"
88910145|NCT04784585|Experimental|Enhanced Education|Theory-driven intervention focused on providing information about dietary quality and goals
88910146|NCT04784585|Experimental|Self-efficacy|Theory-driven intervention focused on providing skills to increase self-efficacy for following dietary goals
88910147|NCT04784585|Experimental|Motivation|Theory-driven intervention focused on providing skills to increase motivation for following dietary goals
88910148|NCT04784585|Experimental|Self-regulation|Theory-driven intervention focused on providing skills to increase self-regulation
89430120|NCT02083575|Active Comparator|vitamin c|25 heavily iron-loaded thalassemia patients, receiving adjuvant vitamin c with iron chelator.
89430121|NCT02083575|Other|iron chelator|Included 25 heavily iron-loaded thalassemia patients, not receiving adjuvant vitamin c with iron chelator.
89430122|NCT04794946|Experimental|Liver Cirrhosis|Evidence of liver cirrhosis established during the clinical investigations and/or hospital stay, as evidenced by clinical, endoscopic, radiological and/or histological criteria.
89430123|NCT04794946|Active Comparator|Non Liver Cirrhosis (Healthy Control)|No major respiratory, cardiac comorbid illnesses or malignancy or immunosuppressed state
88910149|NCT04784585|Active Comparator|Generic Risk Alert|A notification to alert participant of lapse risk, no additional intervention provided
88910150|NCT04784585|Sham Comparator|No Intervention|No notification or intervention is delivered to the participant during lapse risk
89430124|NCT00358722|Experimental|Fermagate|
88910151|NCT04772300|Experimental|Sirolimus DCB group|Intervention with Sirolimus-coated balloon catheter
88910152|NCT04772300|Active Comparator|POBA group|Intervention with non-coated balloon catheter (POBA)
88910153|NCT04770025|Experimental|MI with tACS|Motivational interviewing with concurrent active stimulation
89430125|NCT02088099|Experimental|Complex clinical intervention|
89430126|NCT02088099|Active Comparator|Treatment as usual|
89430127|NCT04804462|Experimental|Virtual Reality Meditation for Fatigue|Participants will experience Virtual Reality Meditation in the comfort of their own home.
89430128|NCT03134040|Experimental|Incentives (Rebate)|On a weekly basis, participants receive a small monetary incentive to exercise each time they attend the YMCA.
89430129|NCT03134040|Experimental|Incentives (Donation)|On a weekly basis, a small monetary incentive to exercise is provided in the form of a donation to a charity of the participant's choice for attendance at the YMCA.
89430130|NCT03134040|Active Comparator|Control|Participants receive feedback on their exercise attendance on a weekly basis.
88910154|NCT04770025|Sham Comparator|MI with sham|Motivational interviewing with concurrent sham stimulation
88910155|NCT04770025|Active Comparator|MI-only|Motivational interviewing only, delayed treatment control
88910156|NCT04768972|Experimental|ION363|ION363 will be administered by lumbar intrathecal (IT) bolus injection with 1 dose every 4-12 weeks, after a loading dose at 4 weeks, over a 61-week double-blind treatment period in Part 1 and every 12 weeks for 85 weeks in the open-label extension treatment period, aside from a loading dose administered 4 weeks after the first dose in Part 2.
88910157|NCT04768972|Placebo Comparator|Placebo|Placebo will be administered by lumbar IT bolus injection with 1 dose every 4-12 weeks over a 61-week double-blind treatment period.
88910158|NCT04764305||Patients|Patients with Fontan circulation. No intervention planned (observational study)
88910159|NCT04764305||Controls|Healthy, biventricular controls. No intervention planned (observational study)
88910160|NCT04764266|Experimental|Normothermic Machine Perfusion|Blood sampling at 5 time points after transplantation Perfusate collection at 3 time points during normothermic machine perfusion prior to transplantation
88910161|NCT04761601|Experimental|Dose Finding as Monotherapy - Part 1|
88910162|NCT04761601|Experimental|Expansion as Monotherapy - Part 2|
89430131|NCT02082249|Experimental|ABT-SLV187|up to 6 years
88910163|NCT04761601|Experimental|Dose Finding in Combination - Part 3|
88910164|NCT04758988|Other|Group A|This group will receive access to the AI augmented digital online educational system and its two modules (Training Module and Clinical Feedback Module). They will receive continuous clinical feedback on their registered lesions.
88910165|NCT04758988|No Intervention|Group B|"This group is withheld their access to the AI augmented digital online educational system for 2 months.~After the 2 months delay, the subjects in the group are given the same access as the participants in Group A."
88910166|NCT04756037|Experimental|Relugolix/E2/NETA|Participants will receive relugolix combination therapy for 1 year (13 consecutive 28-day treatment cycles).
88910167|NCT04755764||Beta blockade|Beta blocker (labetalol or atenolol) will be given for a cardiac output >8 l/min.
88910168|NCT04755764||Nifedipine|Nifedipine will be given for a mean arterial pressure >100.
88910169|NCT04753788||Suspected Yaws Cases|Individuals with a lesion clinically suspected to be yaws and with evidence of positive treponemal and non-treponemal serology as assessed by point of care lateral flow tests (DPP Syphilis Screen and Confirm, Chembio)
88910170|NCT04752020|Experimental|Netarsudil use|Patients will receive Netarsudil eye drops to use 1 drop nightly in the operative eye after DWEK surgery until corneal clearance
88910171|NCT04751331|Experimental|LPS|Lipopolysaccharide (LPS) (0.8ng/kg of body weight; E. coli group O:113) administered as an intravenous bolus.
89430132|NCT02286258|Experimental|Inuline - Calcium EDTA|Calcium EDTA clearance for GFR measurement is compared to inuline clearance in healthy volunteers and CKD patients (stage 1 to 4).
88910172|NCT04751331|Placebo Comparator|Placebo|Placebo (same volume of 0.9% saline) administered as an intravenous bolus
88910173|NCT04751084|Active Comparator|treatment group|20mg Buscopan intravenous will be given 5 minutes prior to embryo transfer
88910174|NCT04751084|Placebo Comparator|control group|2ml Normal Saline intravenous will be given 5 minutes prior to embryo transfer
88910175|NCT04749628|Placebo Comparator|Ora-sweet SF|
88910176|NCT04749628|Experimental|400mg cannabidiol|
88910177|NCT04749628|Experimental|800mg cannabidiol|
88910178|NCT04748146|Other|Intervention and Control group|Each patient will receive electrical and sham stimulation, meaning that each patient will act as their own control.
88910179|NCT04746235|Experimental|Treatment (decitabine and cedazuridine, venetoclax)|Patients receive decitabine and cedazuridine PO daily on days 1-5 and venetoclax PO daily on days 1-28 of the first cycle and on days 1-21 of subsequent cycles. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
88910180|NCT04744831|Experimental|T-DXd 5.4 mg/kg Q3W|Participants will be randomized to receive intravenous T-DXd administered at a dose of 5.4 mg/kg every 3 weeks (Q3W).
89430133|NCT02286258|Experimental|Inuline - Gd-DOTA|Gd-DOTA clearance for GFR measurement is compared to inuline clearance in healthy volunteers and CKD patients (stage 1 to 4).
89430134|NCT04826146||CONOX|Patients are monitored with BIS and CONOX
88910181|NCT04744831|Experimental|T-DXd 6.4 mg/kg Q3W|Participants will be randomized to receive intravenous T-DXd administered at a dose of 6.4 mg/kg every 3 weeks (Q3W).
88910182|NCT04738071||Sex|Female and male patients
88910183|NCT04738071||Age >60 years of age|Patients younger or oder than 6o years of age
88910184|NCT04738071||World region|Patients from different world regions: North America, Europe, Asia, Latin America
88910185|NCT04738071||Stroke vs. TIA|Index event: stroke vs. TIA
88910186|NCT04738071||Neurocardiology Teams|Patients assessed by a neurocardiology team
88910187|NCT04733118|Experimental|Patient HER 2+ IHC 3+|Patients ≥18 years of age with previously untreated HER2-positive (HER2[+]) (Immunohistochemistry [IHC] 3+) invasive carcinoma according to the 2018 American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) criteria and tumor size between >5 to 25 mm by breast magnetic resonance imaging (MRI) and node-negative status by clinical exam, MRI, and ultrasound. Patients must have not been previously treated with chemotherapy, anti-HER2 therapy, radiation therapy, or endocrine therapy (ET) for invasive breast cancer. Patients with metastatic disease are not eligible. In patients with suspected axillary node involvement, a negative fine needle aspiration biopsy (FNAB) will be mandatory
88910188|NCT04731077|Other|Avenir Complete Femoral Stem|All enrolled subjects receive the study implant
88910189|NCT04719273|Experimental|Treatment (onapristone, anastrozole)|Patients receive onapristone PO BID and anastrozole PO QD on days 1-28. Treatment repeats every 28 days for up to 24 cycles (24 months) until November 30, 2023 or in the absence of disease progression or unacceptable toxicity.
88910190|NCT04717336|Placebo Comparator|PERIOD 1|Participant will be instructed to take 3 pills per day for a total of 3 grams. Participant will take Sodium Chloride or placebo for a two week period.
88910191|NCT04717336|Placebo Comparator|PERIOD 2|Participant will be instructed to take 3 pills per day for a total of 3 grams. Participant will take Sodium Chloride or placebo for a two week period.
88910192|NCT04717336|No Intervention|WASHOUT OUT PERIOD|Participant will have a wash-out period for three-weeks.
88910193|NCT04717193|Experimental|Rectus Sheath Block|Participants randomized to the experimental arm will receive a bilateral rectus sheath block which is additional to the standard of care (infiltration of 5mg (2mL) 0.25% bupivacaine with epinephrine around port site incisions). For rectus sheath block, use the formula Volume (ml) = 2mg/kg x weight (kg) divided by 2.5mg/ml - 6ml to a maximum of 14ml. Maximum total dose is 2mg/kg. Participants will be asked to rate their pain a total of 4 times for the study. Each occurrence is expected to take approximately 1-2 minutes to complete. There will be no additional follow-up required as part of the study. The 6 week follow-up visit is standard routine practice.
88910194|NCT04717193|Active Comparator|Local Anesthetic|Participants in the control arm will receive the standard care which is infiltration of 5mg (2mL) of 0.25% bupivacaine with epinephrine around port site incisions. Participants will be asked to rate their pain a total of 4 times for the study. Each occurrence is expected to take approximately 1-2 minutes to complete. There will be no additional follow-up required as part of the study. The 6 week follow-up visit is standard routine practice.
88910195|NCT04715685|Experimental|40 minute session, home practice e-health, phone call|This intervention arm consists of mind body skill introduction session that is 40 minutes in duration. The daily home practice component for headache management will utilize a migraine specific interactive web portal, Migraine e-health portal. This arm will also receive a follow up phone call 4 weeks after the introductory session to promote adherence to home practice.
88910196|NCT04715685|Experimental|40 minute session, home practice e-health, no phone call|This intervention arm consists of mind body skill introduction session that is 40 minutes in duration. The daily home practice component for headache management will utilize a migraine specific interactive web portal, Migraine e-health portal. This arm will not receive a follow up phone call 4 weeks after the introductory session to promote adherence to home practice.
89430135|NCT02088255|Active Comparator|Static surface|The subjects will do the walking training with partial body weight support on static surface. The will be submitted to three weekly training sessions of approximately 45 minutes each , for six weeks , totaling 18 sessions
89430136|NCT02088255|Active Comparator|dynamic surface|The subjects will do the walking training with partial body weight support on dynamic surface. The will be submitted to three weekly training sessions of approximately 45 minutes each , for six weeks , totaling 18 sessions
88910197|NCT04715685|Experimental|40 minute session, home practice handout, phone call|This intervention arm consists of mind body skill introduction session that is 40 minutes in duration. The daily home practice component for headache management will utilize a handout with explanations of mind body skills and a home practice plan. This arm will also receive a follow up phone call 4 weeks after the introductory session to promote adherence to home practice.
89430137|NCT04794556|Experimental|Group A|Participants were randomly assigned to groups A, B, and C to reduce learning effects according to the mask type
89430138|NCT04794556|Experimental|Group B|Participants were randomly assigned to groups A, B, and C to reduce learning effects according to the mask type
89430139|NCT04794556|Experimental|Group C|Participants were randomly assigned to groups A, B, and C to reduce learning effects according to the mask type
89430140|NCT03133728||Pre-Intervention Group|The Investigators will visit each of the selected 3 clusters (i.e. 6 primary health clinics) to construct a retrospective cohort of high-risk HIV-infected women who entered the national PMTCT program and received the SOC between June 1, 2017 and May 31, 2018. Using existing data through the electronic health record information (SmartCare and LIMS), the investigators will gather individual-level retrospective data on high-risk Mother-Infant Pairs (MIPs) from PMTCT enrolment through the child's ART enrolment, initiation, and retention rate at 3 months.
89531162|NCT03340103|Experimental|Experimental group A|Group A (18 newborns) will be treated with LUTEIN ofta 0,5 drops, (1 ml per Kg equal to 0,5 mg of lutein and 0,05 of zeaxantin) additionaly to the standard hospital treatment foreseen. The first dose will be given within 36 hours of life, the least to 30th day of life.
89531163|NCT03340103|Placebo Comparator|Control group B|Group B (18 newborns) treated with Placebo solution additionaly to the standard hospital treatment foreseen. The first dose will be given within 36 hours of life, the least to 30th day of life.
88910198|NCT04715685|Experimental|40 minute session, home practice handout, no phone call|This intervention arm consists of mind body skill introduction session that is 40 minutes in duration. The daily home practice component for headache management will utilize a handout with explanations of mind body skills and a home practice plan. This arm will not receive a follow up phone call 4 weeks after the introductory session to promote adherence to home practice.
88910199|NCT04715685|Experimental|20 minute session, home practice e-health, phone call|This intervention arm consists of mind body skill introduction session that is 20 minutes in duration. The daily home practice component for headache management will utilize a migraine specific interactive web portal, Migraine e-health portal. This arm will also receive a follow up phone call 4 weeks after the introductory session to promote adherence to home practice.
88910200|NCT04715685|Experimental|20 minute session, home practice e-health, no phone call|This intervention arm consists of mind body skill introduction session that is 20 minutes in duration. The daily home practice component for headache management will utilize a migraine specific interactive web portal, Migraine e-health portal. This arm will not receive a follow up phone call 4 weeks after the introductory session to promote adherence to home practice.
88910201|NCT04715685|Experimental|20 minute session, home practice handout, phone call|This intervention arm consists of mind body skill introduction session that is 20 minutes in duration. The daily home practice component for headache management will utilize a handout with explanations of mind body skills and a home practice plan. This arm will also receive a follow up phone call 4 weeks after the introductory session to promote adherence to home practice.
88910202|NCT04715685|Experimental|20 minute session, home practice handout, no phone call|This intervention arm consists of mind body skill introduction session that is 20 minutes in duration. The daily home practice component for headache management will utilize a handout with explanations of mind body skills and a home practice plan. This arm will not receive a follow up phone call 4 weeks after the introductory session to promote adherence to home practice.
88910203|NCT04708418|Experimental|Arm A (pembrolizumab)|"NEOADJUVANT PHASE: Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.~SURGERY: Patients undergo surgery 1-2 weeks after completion of neoadjuvant phase.~ADJUVANT PHASE: After recovery from surgery, patients receive pembrolizumab IV over 30 minutes on day 1 of every other cycle. Treatment repeats every 21 days for up to 16 cycles in the absence of disease progression or unacceptable toxicity.~Patients also undergo CT or PET/CT throughout the trial and may undergo optional biopsy at baseline and disease progression and optional collection of blood samples throughout the trial."
88910204|NCT04708418|Experimental|Arm B (CMP-001, pembrolizumab)|"NEOADJUVANT PHASE: Patients receive CMP-001 SC on day 1 of cycle 1 and then intratumorally on days 8 and 15 of cycle 1, days 1, 8, and 15 of cycle 2, and day 1 of cycle 3. Patients also receive pembrolizumab IV over 30 minutes on day 8 of each cycle. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.~SURGERY: Patients undergo surgery 1-2 weeks after completion of neoadjuvant phase.~ADJUVANT PHASE: After recovery from surgery, patients receive pembrolizumab IV over 30 minutes on day 1 of every other cycle. Treatment repeats every 21 days for up to 16 cycles in the absence of disease progression or unacceptable toxicity.~Patients also undergo CT or PET/CT throughout the trial and may undergo optional biopsy at baseline and disease progression and optional collection of blood samples throughout the trial."
88910205|NCT04707443||enteral nutrition|Infants, undergo enterostomy for various reasons within the age range of 0-6 months.The enteral nutrition can be administered orally or via enteral nutrition, including breast milk, preterm formula, infant formula, extensive hydrolyzed formula or amino acid formula et al .To observe and study the efficacy, safety and tolerance of enteral nutrition in infants after enterostomy.
88910206|NCT04706130|Other|Arm1: No primaquine|Enrolled patients will only received blood stage antimalarial (artesunate at 2 mg/kg per day every 24h for 7 days)
88910207|NCT04706130|Other|Arm2: Primaquine low dose|Enrolled patients will received blood stage antimalarial (artesunate at 2 mg/kg per day every 24h for 7 days) and primaquine at 0.25 mg/kg/day for 14 days (starting at day 7)
88910208|NCT04706130|Other|Arm3: Primaquine high dose|Enrolled patients will received blood stage antimalarial (artesunate at 2 mg/kg per day every 24h for 7 days) and primaquine at 0.50 mg/kg/day for 14 days (starting at day 7)
88910209|NCT04704167|Active Comparator|3D titanium mesh tray|3D titanium mesh tray as a method of fixation for double-barrel vascularized fibula
88910210|NCT04704167|Experimental|3D titanium miniplate|3D titanium miniplate as a method of fixation for double-barrel vascularized fibula
88910211|NCT04700371|Active Comparator|Interwoven stent|Use of an interwoven nitinol stent to treat patients with arteriosclerotic lesions of the distal portion of the superficial artery and/or the popliteal artery.
89531164|NCT05054283||Length of hospital Stay (normal)|The primary outcome was hospital length of stay (LOS), which was calculated according to the number of days of hospitalization. Patients were divided into two groups according to median value of LOS: ≤ 7 days as normal and > 7 days as prolonged LOS.
89531165|NCT05054283||Length of hospital Stay (prolonged)|The primary outcome was hospital length of stay (LOS), which was calculated according to the number of days of hospitalization. Patients were divided into two groups according to median value of LOS: ≤ 7 days as normal and > 7 days as prolonged LOS.
88910212|NCT04700371|Active Comparator|Laser-cut stent|Use of a laser-cut nitinol stent to treat patients with arteriosclerotic lesions of the distal portion of the superficial artery and/or the popliteal artery.
88910213|NCT04699799|Experimental|record brain activity while smelling odors|Record brain activity while smelling odors
89430141|NCT03133728||Post-Intervention Group|Study Research Assistants (RA) will review routine patient files and registers, augmented by existing electronic health record information, to identify a new cohort of high-risk Mother-Infant Pairs (MIPs) at each study site between the dates of June 1, 2019 and May 31, 2020. The outreach team will include, at a minimum, the study RA, a study peer, and an HIV counselor from the health facility, who will carry the Alere™ q HIV-1/2 Detect with them. When the outreach team contacts a high-risk MIP at community level, the team will approach the MIP for study screening, consent, and enrolment procedures. Study staff will ask the parent/guardian if the parent/guardian would like the IYC to be tested at their home, at a community health post, or other private space in the community. The IYC will be tested using both the Alere™ q HIV-1/2 Detect platform and a reflex DBS PCR test to evaluate performance of the POC platform in a mobile setting against the gold standard.
89430142|NCT02088411|Active Comparator|Diclofenac|Subjects assigned to receive 1 tablet of Diclofenac Sodium (50 mg) and two tablets of an indistinguishable placebo three times daily for a duration of 12 weeks.
89008345|NCT00566371|Experimental|1|Patients will then be randomized (at Visit 2) to receive either atomoxetine or placebo for 4 weeks (Treatment Period); study drug will be titrated individually according to tolerability and efficacy (measured by ADHD-RS and CGI-I) completed at Visits 3, 4, 5, and 6) at 7-10 day intervals to a maximum dose of 1.8 mg/kg.
89008346|NCT00566371|Placebo Comparator|2|Patients will then be randomized (at Visit 2) to receive either atomoxetine or placebo for 4 weeks (Treatment Period); study drug will be titrated individually according to tolerability and efficacy (measured by ADHD-RS and CGI-I) completed at Visits 3, 4, 5, and 6) at 7-10 day intervals to a maximum dose of 1.8 mg/kg.
89008347|NCT04825769|Experimental|Intervention|Red light irradiation was conducted at school from Monday to Friday and at home everyday in summer and winter holiday twice a day for 3 minutes per time, with an interval of 4 hours
89008348|NCT04825769|No Intervention|Control|No intervention
89008349|NCT04596397|Active Comparator|Induction of labour with oral misoprostol, inpatient setting|These women receive all treatment in the maternity unit.
89008350|NCT04596397|Experimental|Induction of labour with oral misoprostol, outpatient setting|These women will be observed 2 hours after they receive one dose of oral misoprostol before the can leave the maternity unit.
89008351|NCT00252915|Experimental|Verum|GM-CSF therapy
89008352|NCT04596280||Hinchey Classification|
89008353|NCT04596280||AAST classification|
89008354|NCT04596280||WSES classfication|
89008355|NCT04595929|Experimental|PIPAC group|"Staging laparoscopy + peritoneal lavage.~4 cycles of neoadjuvant chemotherapy: FLOT = Docetaxel 50 mg/m², Oxaliplatin 85 mg/m², Leucovorin 200 mg/m², 5-FU 2600 mg/m² every 2 weeks.~Radical gastrectomy with D2 - lymph node dissection.~Intraoperative Pressured Intraperitoneal Aerosol Chemotherapy (PIPAC) with cisplatin 7,5 mg/m², doxorubicin 1,5 mg/m².~Adjuvant chemotherapy according to indications."
89430143|NCT02088411|Active Comparator|Wobenzym|Subjects assigned to receive 2 tablets of Wobenzym(R) and 1 tablet of an indistinguishable placebo three times daily for a duration of 12 weeks.
89430144|NCT02088411|Placebo Comparator|Placebo|Subjects assigned to receive three tablets of an indistinguishable placebo three times daily for a duration of 12 weeks.
89430145|NCT04794712||Study group A|"Participants group: Group A : 20 participants with chronic venous insufficiency~3 months exercise pre surgery~Pre-surgery evaluation~Venous reflux assessment by ultrasound and PPG~Pain assessment by CHEPS,VAS QS MCGILL~3 months exercise post surgery~Post surgery evaluation by US, PPG, CHEPS and VAS QS MCGILL."
89430146|NCT04794712||Study group B|"Participants group: Group B : 20 participants with chronic venous insufficiency~Pre-surgery evaluation~Venous reflux assessment by ultrasound and PPG~Pain assessment by CHEPS,VAS QS MCGILL~Post surgery evaluation by US, PPG, CHEPS and VAS QS MCGILL."
89430147|NCT04794712||Study Group C|"Participants group: Control Group C : 40 participants with chronic venous insufficiency SUBGROUP 1: WITHOUT EXERCISE 20 PARTICIPANTS~VENOUS ASSESSMENT TOOLS( U/S, PPG )~PAIN ASSESSMENT TOOLS (CHEPS VAS, MCGILL)~SUBGROUP 2: 3 MONTHS EXERCISE 20 PARTICIPANTS~VENOUS ASSESSMENT TOOLS ( U/S, PPG )~PAIN ASSESSMENT TOOLS (CHEPS VAS, MCGILL)"
89430148|NCT02082327|Experimental|0.3 mg/kg|IV infusion of migalastat HCl or placebo
89430149|NCT02082327|Experimental|1 mg/kg|IV infusion of migalastat HCl or placebo
89430150|NCT02082327|Experimental|10 mg/kg|IV infusion of migalastat HCl or placebo
89430151|NCT02082327|Experimental|150 mg IV|150 mg single IV infusion
89430152|NCT02082327|Experimental|150 mg oral|150 mg single oral dose
89430153|NCT04469946|Experimental|Exploratory|Participants were fit with Oticon OPN™ behind-the-ear hearing aids with the OpenSound Navigator algorithm enabled. Pre-intervention measures were obtained within one week of the hearing aid fit and post-intervention measures were obtained after two months of daily hearing aid use.
89430154|NCT03559101|Active Comparator|Beverage 1 - Control|Distilled Water
89430155|NCT03559101|Experimental|Beverage 2|Medical Food 1 (8 amino acids, 60 mmol/L Na, 20 mmol/L K + citrate, Cl)
89430156|NCT03559101|Experimental|Beverage 3|Medical Food 2 (8 amino acids, 30 mmol/L Na, 10 mmol/L K + citrate, Cl)
89430157|NCT03559101|Experimental|Beverage 4|Pedialyte
89430158|NCT03559101|Experimental|Beverage 5|Gatorade
89430159|NCT04794244|Experimental|Experimental|group in which the experimental group training program is applied
89430160|NCT04794244|No Intervention|No Intervention|group without control group training program
89008356|NCT04595929|Active Comparator|Control group|"Staging laparoscopy + peritoneal lavage.~4 cycles of neoadjuvant chemotherapy: FLOT = Docetaxel 50 mg/m², Oxaliplatin 85 mg/m², Leucovorin 200 mg/m², 5-FU 2600 mg/m² every 2 weeks.~Radical gastrectomy with D2 - lymph node dissection.~Adjuvant chemotherapy according to indications."
89430161|NCT04470336|Active Comparator|Collagen Supplement|Three capsules post-breakfast Three capsules post-dinner
89430162|NCT04470336|Other|Glucosamine chondroitin|Three capsules post-breakfast Three capsules post-dinner
89430163|NCT04470336|Placebo Comparator|Placebo|Three capsules post-breakfast Three capsules post-dinner
89430164|NCT02083731|Experimental|MSCs|MSCs will be used to treat refractory CMV infection or CMV-associated diseases. MSCs will be intravenously infused at a dose of 1×10^6 cells/kg. If anticipates do not attain the complete remission standards within 14d, a second course of the same treatment will be given.
89008357|NCT04596085|Active Comparator|Investigational product|Experimental, Investigational Product Ingredient : ViraCide Dosage form softgels . Fequency: 3 soft gels, two times every day after breakfast and dinner . Duration: 14 days+ SOC Therapy
89008358|NCT04596085|Placebo Comparator|Placebo|Ingredient, Placebo Ingredient Starch softgels. Frequency: 3 soft gels, two times everyday after breakfast and dinner . Duration:14 days + SOC Therapy
89430165|NCT04441242|Placebo Comparator|Retrospective: Low lighting during screening colonoscopy|Screening colonoscopies performed with low lighting conditions.
89430166|NCT04441242|Active Comparator|Prospective: Ambient lighting during screening colonoscopy|Screening colonoscopies performed with ambient lighting conditions.
89430167|NCT02083887|Active Comparator|Group 1: ChAd63 ME-TRAP / MVA ME-TRAP at 16/24 weeks old|ChAd63 ME-TRAP / MVA ME-TRAP. 15 infants aged 16 weeks at time of first vaccination vaccinated with ChAd63 ME-TRAP 5 x 10^10 vp (virus particles) intramuscular (IM) at 16 weeks and MVA ME-TRAP 1 x 10^8 pfu (plaque forming units) IM at 24 weeks.
89008359|NCT04596007|Experimental|HEC83518 tablets|There will be a total of 7 dose cohorts: 5 mg,10 mg, 20 mg, 40 mg, 80 mg, and 140 mg,200 mg.
89008360|NCT04596007|Placebo Comparator|placebo tablets|There will be a total of 6 dose cohorts: 10 mg, 20 mg, 40 mg, 80 mg, and 140 mg,200 mg.
89430168|NCT02083887|Active Comparator|Group 2: ChAd63 ME-TRAP / MVA ME-TRAP at 8/16 weeks old|ChAd63 ME-TRAP / MVA ME-TRAP. 15 healthy infants aged 8 weeks at the time of first vaccination vaccinated with ChAd63 ME-TRAP 5 x 10^10 vp IM at 8 weeks and MVA ME-TRAP 1 x 10^8 pfu IM at 16 weeks
89430169|NCT02083887|Active Comparator|Group 3: ChAd63 ME-TRAP / MVA ME-TRAP at 1/8 weeks old|ChAd63 ME-TRAP / MVA ME-TRAP. 15 healthy infants aged 1 week will be vaccinated with ChAd63 ME-TRAP 5 x 10^10 vp IM at 1 week and MVA ME-TRAP 1 x 10^8 pfu IM at 8 weeks.
89430170|NCT02083887|No Intervention|Group 4: Control|20 healthy infants aged 16, 8 and 1 weeks will be enrolled into this group. (Five infants will be randomised to each of Groups 1 and 2 respectively while 10 infants aged 1 week will be randomised to Group 3). All twenty infants will receive EPI vaccinations only.
89430171|NCT02604550|Active Comparator|Femoral Nerve Block|Subjects undergoing anterior cruciate ligament (ACL) surgery will be randomized to receive 20 mL of ropivacaine 0.5% in the femoral nerve. Subjects will also receive standard of care Percocet 7.5/325 and naprosyn following surgery.
89430172|NCT02604550|Active Comparator|Adductor Canal Block|Subjects undergoing anterior cruciate ligament surgery will be randomized to receive 20 mL of ropivacaine 0.5% in the adductor canal. Subjects will also receive standard of care Percocet 7.5/325 and naprosyn following surgery.
88910214|NCT04695327|Experimental|Monotherapy|"Patients will receive multiple administrations of TILT-123.~Escalation to the next dose of TILT-123 level will occur when the safety data has been evaluated for all patients in the preceding dose level."
88910215|NCT04694781|Experimental|Monotherapy Dose Escalation|LVGN6051 monotherapy dose escalation
88910216|NCT04694781|Experimental|Monotherapy Dose Expansion|LVGN6051 dose expansion cohorts
89430173|NCT00388518|Active Comparator|Actos|
89430174|NCT00388518|Experimental|Aleglitazar 1|
89430175|NCT00388518|Experimental|Aleglitazar 2|
88910217|NCT04694781|Experimental|Combination therapy dose escalation|LVGN6051 in combination with anti-PD-1 antibody pembrolizumab dose escalation
88910218|NCT04694781|Experimental|Combination therapy dose expansion|LVGN6051 in combination with anti-PD-1 antibody pembrolizumab dose expansion cohorts
88910219|NCT04692493|Active Comparator|targeted synthetic DMARD class|Switching to a targeted synthetic DMARD (choice from targeted synthetic DMARDs; currently available are tofacitinib, baricitinib, upadacitinib) in people with active RA despite current treatment
88910220|NCT04692493|Active Comparator|non-TNFi-biologic class|Switching to a non-TNFi-biologic (choice from non-TNFi-biologics; currently available are rituximab, abatacept, tocilizumab, or sarilumab) in people with active RA despite current treatment,
88910221|NCT04687007|Experimental|SMART-ALD - Experimental group (EG)|Participants will receive 12 months of SMART-ALD intervention
88910222|NCT04687007|Other|Waiting List - Control group (CG)|Participants will receive 6 months of SMART-ALD after a 6-months waiting period
88910223|NCT04685200||Controls|90 controls to collect epidemiological data as well as blood samples, nasal swabs, salivary samples and stool samples from family members and cohabitants of subjects affected with PSC.
88910224|NCT04685200||PSC Pariticipants|40 patients with PSC diagnosed by standard clinical, biochemical, or imaging features (including up to 30 with a known diagnosis of IBD)
88910225|NCT04673032||Boston Scientific Radiofrequency Ablation Systems|Subjects with pain or other disorders treated with a commercially approved Boston Scientific RF system
88910226|NCT04671875|Experimental|MIL93|
88910227|NCT04669691|Experimental|Lowest dose, less adjuvant aH5N1 vaccine|Two consecutive intramuscular (IM) administrations (Day 1 and Day 22)
88910228|NCT04669691|Experimental|Low dose, less adjuvant aH5N1 vaccine|Two consecutive IM administrations (Day 1 and Day 22)
88910229|NCT04669691|Experimental|Mid dose, less adjuvant aH5N1 vaccine|Two consecutive IM administrations (Day 1 and Day 22)
88910230|NCT04669691|Experimental|Lowest dose, adjuvanted aH5N1 vaccine|Two consecutive IM administrations (Day 1 and Day 22)
88910231|NCT04669691|Experimental|Low dose, adjuvanted aH5N1 vaccine|Two consecutive IM administrations (Day 1 and Day 22)
88910232|NCT04669691|Experimental|Mid dose, adjuvanted aH5N1 vaccine|Two consecutive IM administrations (Day 1 and Day 22)
88910233|NCT04668781|Active Comparator|Epidural analgesia|
88910234|NCT04668781|Experimental|Wound catheter analgesia|
88910235|NCT04667520|Experimental|LPA+Fitbit|Participants in this group receive a Lifestyle Physical Activity intervention and are provided with a Fitbit to collect activity data
88910236|NCT04667520|Active Comparator|Fitbit Only|Participants in this group are provided with a Fitbit to collect activity data
88910237|NCT04667455|No Intervention|Control subjects|Infants and Children with no evidence of congenital heart disease based on echocardiography and standard ECG assessment
88910238|NCT04667455|Active Comparator|Congenital heart disease subjects|Infants and Children with evidence of predefined congenital heart disease lesions based on echocardiography and standard ECG assessment
88910239|NCT04663997|Experimental|177 Lu-PSMA-617|
88910240|NCT04663997|Active Comparator|Docetaxel|
88910241|NCT04663347|Experimental|Arm 1 - Epcoritamab + R-CHOP|In participants with previously untreated DLBCL.
88910242|NCT04663347|Experimental|Arm 2 - Epcoritamab + R2|In participants with R/R FL.
88910243|NCT04663347|Experimental|Arm 3 - Epcoritamab + BR|In participants with previously untreated FL.
88910244|NCT04663347|Experimental|Arm 4 - Epcoritamab + R-DHAX/C|In participants with R/R DLBCL eligible for ASCT.
88910245|NCT04663347|Experimental|Arm 5 - Epcoritamab + GemOx|In participants with R/R DLBCL ineligible ASCT.
88910246|NCT04663347|Experimental|Arm 6 - Epcoritamab + R2|In participants with previously untreated FL.
88910247|NCT04663347|Experimental|Arm 7 - Epcoritamab maintenance|In participants with FL who achieved a CR or PR after receiving SOC treatment in 1L or 2L.
88910248|NCT04663347|Experimental|Arm 8 - Epcoritamab + R mini-CHOP|In participants with previously untreated DLBCL who are ineligible to receive full-dose anthracycline.
88910249|NCT04663347|Experimental|Arm 9 - Epcoritamab + Lenalidomide|In participants with FL who progressed within 24 months of initiation of first-line anti-CD20-containing immunochemotherapy.
88910250|NCT04663347|Experimental|Arm 10 - Epcoritamab + R-ICE|In participants with R/R DLBCL eligible for ASCT.
88910251|NCT04662151|Experimental|Phase 1b open-label AT-100|Once daily AT-100 via intratracheal administration for up to 2 doses (initial Phase 1b dose-escalation portion) or 7 doses (latter Phase 1b highest tolerated & safety dose level tested portion).
88910252|NCT04662151|Sham Comparator|Phase 1b open-label air-sham|Once daily air-sham via intratracheal administration for up to 2 doses (initial Phase 1b dose-escalation portion) or 7 doses (latter Phase 1b highest tolerated & safety dose level tested portion).
89430176|NCT00388518|Experimental|Aleglitazar 3|
89430177|NCT00388518|Experimental|Aleglitazar 4|
89430178|NCT00388518|Placebo Comparator|Placebo|
89430179|NCT02084043|Experimental|Breath-actuated vibrating mesh nebulizer|500 mg/4 mL of Amikacin solution delivered with an experimental breath-actuated vibrating mesh nebulizer associated with a single limb circuit ventilator.
89430180|NCT02084043|Experimental|Conventional vibrating mesh nebulizer|500 mg/4 mL of Amikacin solution delivered with a conventional vibrating mesh nebulizer (in continuous mode) associated with a single limb circuit ventilator.
89430181|NCT02084199|Experimental|Part 1 - Severe renal impairment|Part 1 - Group 1: subjects with severe renal impairment or end-stage renal disease (ESRD), not on dialysis: Estimated glomerular filtration rate (eGFR) between 15-29 mL/min/1.73 m2 or <15 mL/min/1.73m² will be administered GLPG0634 100 mg once daily for 10 days
89430182|NCT02084199|Experimental|Part 1: Normal renal function|Part 1 - Group 2: subjects with normal renal function: eGFR ≥90 mL/min/1.73m² will be administered GLPG0634 100 mg once daily for 10 days
89430183|NCT02084199|Experimental|Part 2 - Mild renal impairment|Part 2 - Group 3: subjects with mild renal impairment: eGFR between 60-89 mL/min/1.73 m² will be administered GLPG0634 100 mg once daily for 10 days
89430184|NCT02084199|Experimental|Part 2 - Moderate renal impairment|Part 2 - Group 4:subjects with moderate renal impairment: eGFR between 30-59 mL/min/1.73 m² will be administered GLPG0634 100 mg once daily for 10 days
89430185|NCT02084199|Experimental|Part 2 - Normal renal function|Part 2 - Group 5: subjects with normal renal function: eGFR ≥90 mL/min/1.73 m² will be administered GLPG0634 100 mg once daily for 10 days
88910253|NCT04659629|Experimental|Part 1: NL-201 Monotherapy Dose Escalation|NL-201 given as monotherapy by intravenous administration testing ascending doses and two different schedules.
89430186|NCT04804150|Experimental|Medical Device active or inactive|The medical device will be active, or inactive. Randomization will define when and how long time the medical device will plugged and active, and when and how long time the medical device will be unplugged and inactive. The patient won't know if the medical device is active or not
89430187|NCT02286336|Experimental|middle aged group|brachial plexus block with ropivacaine 40ml, MEC90 for USG-SCB
89430188|NCT02286336|Active Comparator|young group|brachial plexus block with ropivacaine 40ml, MEC90 for USG-SCB
89430189|NCT04470258|Other|ELMO PROJECT AT COVID-19: PROOF OF CONCEPT AND USABILITY|A realistic simulation will be carried out, centered on the heuristic evaluation, by a multiprofessional team (N= 6), to evaluate the performance of the new equipment in the execution of the pre-defined skills. The prototype will be tested on a mannequin by the research team and on healthy volunteers by health professionals, where physiological parameters and interface comfort will be evaluated.
89430190|NCT04470258|Other|ELMO PROJECT AT COVID-19: STUDY IN HUMANS|The second phase will consist of a clinical trial, in the application of the non-invasive respiratory device in 10 patients with respiratory failure by COVID-19, to assess its clinical effectiveness, through the analysis of the physiological variables and patient comfort.
89430191|NCT02591290|Experimental|Menactra® Vaccine|Participants received 2-dose series of the study vaccine with 8-week interval.
89430192|NCT04470102|Other|isolated septal myectomy|Isolated extended septal myectomy
89430193|NCT04470102|Active Comparator|"Septal myectomy+ edge-to-edge"|advanced septal myectomy in combination with mitral valve repair using the edge-to-edge technique
88910254|NCT04659629|Experimental|Part 2: NL201 Monotherapy Expansion Cohorts|NL-201 given as monotherapy by intravenous administration in indication specific cohorts at a dose and schedule determined in Part 1.
88910255|NCT04659629|Experimental|Part 3: NL-201 in Combination with Pembrolizumab Dose Escalation|NL-201, in combination with a set Pembrolizumab dose, testing ascending doses and two different schedules
88910256|NCT04659629|Experimental|Part 4: NL-201 in Combination with Pembrolizumab Expansion Cohorts|NL-201 in combination with Pembrolizumab in indication specific cohorts at a dose and schedule determined in Part 3
88910257|NCT04655755|Experimental|Treatment (venetoclax, ASTX727)|Patients receive venetoclax orally PO QD on days 1-14. Patients also receive ASTX727 PO QD on days 1-5. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88910258|NCT04646213|Experimental|Therapy|psychotherapeutic intervention
88910259|NCT04643951||Dental students|Dental students in their two final years. No intervention.
88910260|NCT04643951||Dental professionals|Dental professionals aged 18-65, regularly working with children. No intervention.
88910261|NCT04635436||Pathologic group|At least 20 participants with various orthopaedic or neurologic conditions (for example, post-stroke hemiparesis, Parkinson's disease, multiple sclerosis, unilateral amputation, surgical orthopedic interventions) will be enrolled.
88910262|NCT04635098|Experimental|dexmedetomidine|0.5μg/kg bolus injection in 10 minutes followed by 0.1µg/kg/hr pump infusion from 22:00 pm to 6:00 am
88910263|NCT04635098|Placebo Comparator|saline|the same rate as dexmedetomidine
88910264|NCT04630353|Experimental|HB-201 Intravenously on Day 1|Patients with resectable stage I-III, HPV 16+ genotype squamous cell cancer of the oropharynx or unknown primary cancer site.
89430194|NCT02791893|Experimental|VNS device|Vagus Nerve Stimulation (VNS) hand held device - subjects to utilize the VNS hand held device for 20 weeks total, putting it on the skin overlying the vagus nerve in their neck and then turning it on for 120 second periods three times a day. The device is programmed to deliver only 6 bouts of stimulation per day - one to each side of the neck three times a day
89430195|NCT02791893|Placebo Comparator|Inactive device|Inactive hand held device - subjects to utilize the inactive device for 10 weeks and then will receive the VNS device for the next 10 weeks.
89430196|NCT04803682|Experimental|Prevention (ASPIRE, mentorship)|"Participants complete online ASPIRE course over 3.5-4 hours.~HIGH SCHOOL MENTORS: Eleventh grade high school students receive mentor training over 4-5 hours on how to mentor ninth grade students.~ALL STUDENTS: Mentors and mentees are paired up so that eleventh grade high school students mentor the ninth grade high school students over 30 minutes for 7 sessions about the different types of tobacco products (such as cigarettes, cigars, hookah, and so on) and the dangers of these products."
89430197|NCT03530670|Active Comparator|oral midazolam (demizolam)|"To prevent preoperative anxiety patient premedicated by 0.5 mg/kg oral midazolam.~In the preoperative holding area, in the operating room, while anesthesia induction by m-YPAS ( modified the Yale Preoperative Anxiety Scale) To make easier anesthesia induction While anesthesia induction by Mask Acceptance Scale"
89430198|NCT03530670|Active Comparator|http://www.animaturk.com/animasyon/suko-ameliyat-oluyor.|To prevent preoperative anxiety by watching a short movie ( at http://www.animaturk.com/animasyon/suko-ameliyat-oluyor.) In the preoperative holding area, in the operating room, while anesthesia induction by m-YPAS ( modified the Yale Preoperative Anxiety Scale) To make easier anesthesia induction While anesthesia induction by Mask Acceptance Scale
89430199|NCT03530670|Active Comparator|playing smartphone game|To prevent preoperative anxiety by playing smartphone game ( angry birds, subway surfers, snail Bob) In the preoperative holding area, in the operating room, while anesthesia induction by m-YPAS ( modified the Yale Preoperative Anxiety Scale) To make easier anesthesia induction While anesthesia induction by Mask Acceptance Scale
89430200|NCT04794400|Experimental|Intervention|An additional oxygen mask was applied for 30 minutes, in patients with ongoing HFNC treatment.
89430201|NCT00120042|No Intervention|1|No specific oxytocic to assist in placental delivery
89430202|NCT00120042|Active Comparator|2|Intramuscular oxytocin injection
88910265|NCT04630353|Experimental|HB-201 Intravenously 7 to 14 days before chemoradiation|Patients with newly diagnosed HPV 16+ genotype advanced cervical cancer, clinical stages IB to IVB with plan for initial treatment of definitive chemoradiation.
88910266|NCT04630171|Experimental|Group 1: VerTouch for labor epidural or spinal anesthesia procedure|VerTouch utilized for identification of site for labor epidural or spinal anesthesia procedure in women requesting labor analgesia.
88910267|NCT04630171|Active Comparator|Group 2: Ultrasound (US) for labor epidural or spinal anesthesia procedure|Ultrasound (US) utilized for identification of site for labor epidural or spinal anesthesia procedure in women requesting labor analgesia.
88910268|NCT04630171|Active Comparator|Group 3: Control group, palpation for labor epidural or spinal anesthesia procedure|Control group, palpation utilized for identification of site for labor epidural or spinal anesthesia procedure in women requesting labor analgesia.
88910269|NCT04630171|Experimental|Group 4: VerTouch for lumbar puncture procedure|VerTouch utilized for identification of site for lumbar puncture procedure in patients who require a therapeutic lumbar puncture.
88910270|NCT04630171|Active Comparator|Group 5: Ultrasound (US) for lumbar puncture procedure|Ultrasound (US) utilized for identification of site for lumbar puncture procedure in patients who require a therapeutic lumbar puncture.
89008361|NCT00252954|Placebo Comparator|1|
89430203|NCT00120042|Active Comparator|3|Oral misoprostol to assist in placental delivery
89430204|NCT04426942||Spontaneous pregnancy|
89008362|NCT04595812|Active Comparator|Misoprostol group|receive two tablets of 200µg misoprostol (Pfizer Limited, United Kingdom) administered into the posterior fornix of the vagina 1 hour before the onset of surgery
89430205|NCT04426942||Assisted reproduction pregnancy|
89430206|NCT02084277|Experimental|Self-ligating brackets|Several self-ligating brackets are currently FDA-approved but have not been rigorously studied in this malocclusion patient population or in comparison to traditional brackets methods. Unlike conventional brackets, Self-ligating brackets (SLB) are bracket systems, without the wire ligature or elastic ligature, that have a tube-like device build into the bracket to close off the edgewise slot.
89430207|NCT02084277|Placebo Comparator|Conventional brackets|"The conventional brackets (CB) (edgewise appliance) retain the basic principle design of a rectangular wire in a rectangular slot. Archwire are tied to the bracket once placed in the slot with either elastometric ligation ties (O-rings) or steel ligation."
89430208|NCT02084355|Experimental|opioid rotation|"Patients who are randomized to opioid rotation are treated with strong opioid other than currently used strong opioid (Reduce the dose by 25%-50% to allow for incomplete cross-tolerance between different opioids).~oral oxycodone : convert to oral hydromorphone or fentanyl patch~oral hydromorphone : convert to oral oxycodone or fentanyl patch~fentanyl patch : convert to oral oxycodone or oral hydromorphone"
89430209|NCT02084355|Active Comparator|opioid dose escalation|"Patients who are randomized to opioid dose escalation will be treated cancer pain by escalation dose of same strong opioid.~oral oxycodone : maintain oral oxycodone and titrate the dose~oral hydromorphone : maintain oral hydromorphone and titrate the dose~fentanyl patch : maintain fentanyl patch and titrate the dose"
89430210|NCT00353574|Experimental|Darusentan 50 mg|Darusentan 50 mg administered orally once daily
89430211|NCT00353574|Experimental|Darusentan 100 mg|Darusentan 100 mg administered orally once daily
89430212|NCT00353574|Experimental|Darusentan 300 mg|Darusentan 300 mg administered orally once daily
89430213|NCT02082405|Experimental|Treatment (bortezomib, cyclophosphamide, dexamethasone)|Patients receive bortezomib SC or IV over 3-5 seconds on days 1, 8, and 15; cyclophosphamide PO QD on days 1-21; and dexamethasone PO on days 1, 8, and 15. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
89430214|NCT05618548||Cohort A: Pregnant women vaccinated with a mRNA COVID-19 vaccine|Pregnant women who will be offered a mRNA COVID-19 vaccine (brand will depend on the vaccine available at the time of inclusion). Gestational age at vaccination will depend on the timing when the vaccine is offered to the specific participant, this being subject to the national recommendations for vaccination of priority groups.
89430215|NCT05618548||Cohort B: Pregnant women vaccinated with an adenoviral vector COVID-19 vaccine|Pregnant women who will be offered an adenoviral vector COVID-19 vaccine (Astra Zeneca). Gestational age at vaccination will depend on the timing when the vaccine is offered to the specific participant, this being subject to the national recommendations for vaccination of priority groups.
89430216|NCT05618548||Cohort C: Postpartum lactating women vaccinated with a mRNA COVID-19 vaccine|Non-pregnant women during lactation (postpartum) will be offered a mRNA COVID-19 vaccine (brand will depend on the vaccine available at the time of inclusion). Duration of lactation at vaccination will depend on the timing when the vaccine is offered to the specific participant, this being subject to the national recommendations for vaccination of priority groups.
89430217|NCT05618548||Cohort D: Postpartum lactating women vaccinated with an adenoviral vector COVID-19 vaccine (N=40)|Non-pregnant women during lactation (postpartum) will be offered an adenviral vector COVID-19 vaccine (brand will depend on the vaccine available at the time of inclusion). Duration of lactation at vaccination will depend on the timing when the vaccine is offered to the specific participant, this being subject to the national recommendations for vaccination of priority groups.
89430218|NCT02088489|Active Comparator|Atrial flutter, irrigated catheter|Patients with isthmus dependent atrial flutter, undergone to catheter ablation with Thermocool® (Biosense Webster, Diamond Bar, CA) irrigated catheter
89430219|NCT02088489|Experimental|Atrial flutter, porous tip catheter|Patients with isthmus dependent atrial flutter, undergone to catheter ablation with Thermocool® SF(Biosense Webster, Diamond Bar, CA) irrigated catheter
89430220|NCT03530592|Experimental|Seated Ankle Robot Training|
89430221|NCT04428268|Active Comparator|Chloroquine|Patients will receive chloroquine phosphate 450 mg every 12 hours orally
89430222|NCT04428268|Experimental|Chloroquine plus losartan|Patients will receive Chloroquine phosphate 450mg orally every 12hrs plus Losartan 25mg orally every 12hrs
89008363|NCT04595812|Active Comparator|Oxytocin group|After induction of general anaesthesia and immediately prior to the operation, an infusion of 30 IU oxytocin in 500 ml normal saline at a rate of 120 ml/h will be started during myomectomy.
89430223|NCT02082561|Experimental|Transdiagnostic Treatment (F-SET)|F-SET treatment consisted of five weekly individual sessions (approximately 50 minutes each). The F-SET protocol is consistent with current CBT protocols for anxiety disorders.
89430224|NCT02082561|No Intervention|Waitlist|The waitlist control condition was comprised of patients randomly assigned to the waitlist condition (WL). Individuals in this condition were reassessed after five weeks and were then offered treatment, but were no longer followed.
89430225|NCT02084433|Active Comparator|conventional anasthesia|para-apical maxillary and locoregional mandibular (Articaine 1/100000) anaesthesia
89430226|NCT02084433|Experimental|intraosseous anaesthesia|"intraosseous anaesthesia using a computerized system (Quicksleeper) 1 / Anesthesia of periosteum (Articaine 1/100000) 2 / penetration of the needle rotated to the apex 3 / osteocentral injection "
89430227|NCT04803760||mild disability|Those whose neck disability index value is 25 and below
89430228|NCT04803760||high disability|Those whose neck disability index value is 25 and above
89430229|NCT04427098|Active Comparator|a phase II single-arm interventional prospective study|"Patients included in the interventional study will receive subcutaneous enoxaparin in a single daily dose of:~60 mg once daily in case of body weight of 45 to 60 kg~80 mg per day in case of weight from 61 to 100 kg or~100 mg once daily in case of bodyweight >100 kg~Enoxaparin will be started on the first day of COVID19 diagnosis and continued for 14 days."
89430230|NCT04427098|Experimental|observational cohort study|Patients included in the observational cohort will will receive standard thrombo-prophylaxis with subcutaneous enoxaparin 40 mg/die
89008364|NCT04595812|Experimental|Carbetocin group|receive 100 μg IV Carbetocin (1ml) [Pabal, Ferring (UK)] in 5 ml saline over 1 minute just before skin incision
89430231|NCT00352560|Active Comparator|A|
89430232|NCT00352560|Placebo Comparator|B|
89008365|NCT04595812|Active Comparator|pericervical tourniquet group|pericervical tourniquet using a Foley catheter size 18, which will be firmly tied at the level of the cervico-isthmic junction of the uterus before the uterine incision.
89008366|NCT04596046|Active Comparator|Group S (systemic-peroral steroid)|Medication of oral methylprednisolonewas administered to the patients following the adjustment based on the severity of the lesion and regarding the clinic. The prednisolone dose was 0.5 mg/kg/day in patients with painful, small (<5.0 cm) unilateral lesions whereas in multiple, bilateral lesions with the diameter of ≥5 cm or for those who had significant cutaneous ulceration, the prednisolone dose was specified as 1 mg/kg/day
89008367|NCT04596046|Experimental|Group L (local-intralesional steroid)|Triamcinolone acetonidewas administered to the patients through injecting inside the lesion. The practice was based on the dose of TCA administered in acute and chronic inflammatory skin lesions. If the lesion is single-focused and small (<5.0 cm), 20mg / mL TCA was injected and if the lesion is multifocal or large (>5.0 cm) then 40mg / mL TCA was injected into the lesion with the guidance of ultrasonography
89008368|NCT04595500||GERD|
89008369|NCT04595500||Control|
89008370|NCT04595539|Experimental|Simultaneous interventions|In this condition, both interventions are proposed simultaneously. Condition 1 is spread over 5 weeks with 5 weekly laboratory sessions of 2-hours (one hour of BATD and one hour of ATT separated by a break). A 30-minutes ATT sessions at home were prescribed between sessions for a total of 5 laboratory ATT sessions and 5 at home ATT sessions.
89008371|NCT04595539|Experimental|Sequential interventions|In this condition, the interventions are introduced sequentially. Condition 2 is spread over 7 weeks with 8 weekly laboratory sessions, 7 sessions of 1-hour and one session of 2-hours (Sessions 4 with of one hour of ATT followed by one hour of BATD separated by a break). A six 30-minutes ATT sessions were prescribed between the first 4 sessions of ATT for a total of 4 laboratory ATT sessions and 6 at home ATT sessions.
89008372|NCT04595539|Experimental|Sequential interventions in reverse order|In this condition, the interventions are introduced sequentially in the reverse order than the condition 2. Condition 3 is spread over 7 weeks with 8 weekly laboratory sessions, 7 sessions of 1-hour and one session of 2-hours (Sessions 5 with of one hour of BATD followed by one hour of ATT separated by a break). A six 30-minutes ATT sessions were prescribed between the 4 last sessions for a total of 4 laboratory ATT sessions and 6 at home ATT sessions.
89008373|NCT00566566||1|ALL survivors 5 years after completion of treatment, during routine medical follow up
89008374|NCT04595695|Experimental|Transparent Mask|Surgeons will be provided a transparent mask for use during in-person clinic visits with a new patient. Otherwise, visits will be conducted as per usual and the patient will be surveyed immediately after the visit.
89008375|NCT04595695|Active Comparator|Covered Mask|Surgeons will be instructed to wear a typical, covered mask for the in-person clinic visit with a new patient. The visit will be conducted as it typically would, and the patient will be surveyed immediately after the visit.
89008376|NCT04595578|Active Comparator|Cerebellar rTMS + Physical therapy|rTMS was delivered on the scalp for over 2 cm under the inion, which is the scalp over the cerebellum area, using a double-cone coil connected to a Magstim Rapid2® stimulator with two Booster Modules (Magstim, Spring Gardens, Wales, UK) in accordance with safety recommendations. Stimulation was delivered to the cerebellum at 10 Hz with 90% of the mean resting motor threshold intensity for 5 seconds at 55 second intervals to deliver 1000 pulses in 20 minutes. Immediately after rTMS, the combination treatment group received balance and gait training by a physical therapist for 30 minutes/day and underwent aerobic exercise using a stationary bicycle at moderate intensity (12 to 14 rating of perceived exertion) for 30 minutes/day and 5 days/week for two weeks. In the control group, no participants received physical therapy or rTMS for two weeks.
89008377|NCT04595578|Sham Comparator|Sham stimulation + Physical therapy|Sham stimulation was delivered on the scalp for over 2 cm under the inion, which is the scalp over the cerebellum area, using a double-cone coil connected to a Magstim Rapid2® stimulator. Sham stimulation was delivered to the cerebellum for 5 seconds at 55 second intervals in 20 minutes. Immediately after rTMS, the combination treatment group received balance and gait training by a physical therapist for 30 minutes/day and underwent aerobic exercise using a stationary bicycle at moderate intensity (12 to 14 rating of perceived exertion) for 30 minutes/day and 5 days/week for two weeks. In the control group, no participants received physical therapy or rTMS for two weeks.
89008378|NCT00249366|Active Comparator|Fixed-schedule treatment|Fixed-schedule administration of lorazepam for alcohol withdrawal
89008379|NCT00249366|Active Comparator|Symptom-triggered treatment|Symptom-triggered administration of lorazepam per protocol using the Clinical Institute Withdrawal Assessment for Alcohol, revised version (CIWA-Ar)
89430233|NCT05616364|Experimental|Dexmedetomidine|Dexmedetomidine is a sedative, analgesic, anxiolytic, sympatholytic, and opioid-sparing alpha 2 adrenergic agonist with good selectivity and specificity.It has been shown to lower the threshold for shivering. Dexmedetomidine does not affect the locus ceruleus of the spinal cord, and it does not cause respiratory depression. [8] In postoperative patients, dexmedetomidine lowers cortisol and norepinephrine levels, as well as blood glucose, interleukin (IL)-6, tumour necrosis factor-a, and C-reactive protein, and raises interleukin-10. Moreover, because Dexmedetomidine does not affect upper airway reflexes, it is an excellent option.It was believed that the sedative impact of intravenous injection on newborn infants was very minimal and could be disregarded due to the delayed sedative effects
89430234|NCT05616364|Experimental|Tramadol|Tramadol, a centrally acting analgesic with -opioid agonist properties and little action on kappa and delta receptors, has been proven to be beneficial in preventing post-spinal shivering. The method of action is thought to be through a modulatory influence on central monoaminergic pathways, which inhibits noradrenaline and serotonin neuronal absorption in the spinal cord while boosting hydroxyltryptamine production, resetting the body temperature regulatory center. [3] However, it has many side effects, including nausea, vomiting, and dizziness, which add to the patient's pain. [5] Hence research into novel solutions with adequate safety and effectiveness is strongly advised. In this sense, despite taking into account the gold standard for post spinal shivering control is pethidine. it is contraindicated in breastfeeding which is both legally and ethically challenging for women.
89430235|NCT02082639|Experimental|HPV Group|Subjects will receive two doses of HPV vaccine intramuscularly
89430236|NCT02082639|Experimental|HAV Group|Subjects will receive two doses of HAV vaccine intramuscularly
89430237|NCT02082639|Experimental|HPV+HAV Group|Subjects will receive two doses of both HPV and HAV vaccines intramuscularly
89430238|NCT00345618|Experimental|Idrabiotaparinux|"Idrabiotaparinux sodium, 3.0 mg, once-weekly for 3 or 6 months depending on the stratum, after enoxaparin, 1.0 mg/kg, every 12 hours for at least 5 days.~Avidin, 100 mg, at the discretion of the investigator whenever deemed appropriate and possible (ie, life-threatening bleeding, emergency invasive procedure with the potential of uncontrolled bleeding, or over-dosage)."
89430239|NCT00345618|Active Comparator|Warfarin|"Warfarin, INR-adjusted dose, started 24 hours after the start of enoxaparin, 1.0 mg/kg, every 12 hours for at least 5 days, and continued for 3 or 6 months depending on the stratum.~Avidin, 100 mg, at the discretion of the investigator whenever deemed appropriate and possible (ie, life-threatening bleeding, emergency invasive procedure with the potential of uncontrolled bleeding, or over-dosage)."
89430240|NCT02476851|Other|POLFA (Experimental Needle Assembly) first, then Kawasumi (Control Needle Assembly)|"Ensure that whole blood passed through the POLFA needle assembly (the investigational needle assembly or INA) has a supernatant hemoglobin within the acceptable range of < 100mg/dL. Each subject receives the same intervention (Standard of Care blood draw) and blood is drawn into both the INA and CNA. The difference is the order in which the CNA or INA is applied."
89430241|NCT02476851|Other|Kawasumi (Control Needle Assembly) first, then POLFA (Experimental Needle Assembly)|"Ensure that whole blood passed through the POLFA needle assembly (the investigational needle assembly or INA) has a supernatant hemoglobin within the acceptable range of < 100mg/dL. Each subject receives the same intervention (Standard of Care blood draw) and blood is drawn into both the INA and CNA. The difference is the order in which the CNA or INA is applied."
89430242|NCT02595970|Experimental|Secukinumab|Weekly sub cutaneous injections of 300 mg during the first month and then Monthly until Week 52 plus extension until 03/11/2016.
89430243|NCT03530514|Experimental|Part A: Single dose cohort 1|Cohort 1 will receive a single IV dose of REGN4461 or matching placebo
89430244|NCT03530514|Experimental|Part A: Single dose cohort 2|Cohort 2 will receive a sequential ascending single IV dose of REGN4461 or matching placebo
89430245|NCT03530514|Experimental|Part A: Single dose cohort 3|Cohort 3 will receive a sequential ascending single IV dose of REGN4461 or matching placebo
89430246|NCT03530514|Experimental|Part A: Single dose cohort 4|Cohort 4 will receive a sequential ascending single SC dose of REGN4461 or matching placebo
89430247|NCT03530514|Experimental|Part A: Single dose cohort 5|Cohort 5 will receive a sequential ascending single IV dose of REGN4461 or matching placebo
89430248|NCT03530514|Experimental|Part A: Single dose cohort 6|Cohort 6 will receive a sequential ascending single SC dose of REGN4461 or matching placebo
88910271|NCT04630171|Active Comparator|Group 6: Control group, palpation for lumbar puncture procedure|Control group, palpation utilized for identification of site for lumbar puncture procedure in patients who require a therapeutic lumbar puncture.
89430249|NCT03530514|Experimental|Part A: Single dose cohort 7|Cohort 7 will receive a sequential ascending single IV dose of REGN4461 or matching placebo
89430250|NCT03530514|Experimental|Part A: Single dose cohort 8|Cohort 8 will receive a single IV dose of REGN4461 or matching placebo
89430251|NCT03530514|Experimental|Part A: Single dose cohort 9|Cohort 9 will receive a single IV dose of REGN4461 or matching placebo
89430252|NCT03530514|Experimental|Part B: Repeated dose cohort 10|Cohort 10 will receive repeated IV or SC doses of REGN4461 or matching placebo
89430253|NCT02287662|Experimental|Vancouver 3M Clinical Pathway|The Vancouver 3M Clinical Pathway utilizes objective anatomical and functional screening criteria as well as strict peri-procedural guidelines to determine if next day discharge home is appropriate.
89430254|NCT04793932|Active Comparator|PAXG Arm A|cisplatin 30 mg/m2 every 2 weeks, nab-paclitaxel 150 mg/m2 every 2 weeks, gemcitabine 800 mg/m2 every 2 weeks, capecitabine 1250 mg/m2/day (for 28 consecutive days) in 28-day cycles administered for 4 cycles (4 months).
89430255|NCT04793932|Active Comparator|mFOLFIRINOX Arm B|irinotecan 150 mg/m2 day 1, oxaliplatin 85 mg/m2 day 1, folinic acid at a fixed dose of 400 mg/m2, fluorouracil continuous IV infusion 2.4 g/m2 over 46 hours in 14-day cycles administered for 8 cycles (4 months).
89430256|NCT04793932|Active Comparator|short-course chemotherapy|Allocated by second randomization after 4 months of chemotherapy to receive immediate surgery followed by 2 further months of the same chemotherapy
88910272|NCT04626791|Experimental|Treatment (modified VR-CAP, acalabrutinib)|"CYCLES 1, 3, AND 5: Patients receive acalabrutinib PO BID on days 1-21. Patients also receive bortezomib SC on days 1, 8, and 15, rituximab (or rituximab and hyaluronidase human) IV, cyclophosphamide IV, and doxorubicin hydrochloride IV on day 1, and prednisone PO on days 1-5.~CYCLES 2, 4, AND 6: Patients receive acalabrutinib PO BID on days 1-21. Patients also receive rituximab (or rituximab and hyaluronidase human) IV on day 1 and cytarabine IV on days 1-2.~Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity."
88910273|NCT04625660|Experimental|Single Arm|The PQ Bypass system is used during a minimally invasive procedure to place stent grafts in the peripheral vasculature to improve blood flow.
89430257|NCT04793932|Active Comparator|long-course chemotherapy|Allocated by second randomization after 4 months of chemotherapy to receive 2 further months of the same chemotherapy followed by surgery
89430258|NCT04803838||Patiens|Patients With symptomatic or asymptomatic carotid stenosis (> 50%, NASCET criteria)
89430259|NCT04803838||Controls|For study 1: Healthy Controls, volunters (mostly blood donors) For study 2 and 3: Spouses/someone living in the same household as the patient.
89430260|NCT04793854||Case|Children with sickle cell anemia attending the centre of reference for sickle cell disease in Guadeloupe.
89430261|NCT04793854||Control|Control children without chronical disease
89430262|NCT04793542|No Intervention|Control|
89430263|NCT04793542|Sham Comparator|Lukewarm Water|
89430264|NCT04793542|Active Comparator|Hot Water|
89430265|NCT04803292||Second Affiliated Hospital, School of Medicine, Zhejiang University|a prospective cohort of patients of primary intracerebral hemorrhage in Second Affiliated Hospital, School of Medicine, Zhejiang University
89430266|NCT04803292||Second People's Hospital of Hangzhou City, Zhejiang Province|a prospective cohort of patients of primary intracerebral hemorrhage in Second People's Hospital of Hangzhou City, Zhejiang Province
89008380|NCT04595461|Placebo Comparator|Control|Standard of care patient education with verbal and written education
88910274|NCT04625270|Experimental|Part A|To determine the optimal regimen, either avutometinib(VS-6766) monotherapy or avutometinib (VS-6766) in combination with defactinib, for subsequent evaluation for efficacy in the Expansion Phase (Part B)
88910275|NCT04625270|Experimental|Part B|To determine the efficacy of the optimal regimen identified from Part A
88910276|NCT04625270|Experimental|Part C:|To evaluate additional efficacy parameters for the optimal regimen identified in Part A.
88910277|NCT04625270|Experimental|Part D|To evaluate additional efficacy parameters for a lower dose of avutometinib in combination with defactinib
88910278|NCT04624256|Experimental|Treatment (radiotherapy, genomic DNA testing)|Patients undergo SBRT per standard of care, then undergo collection of cheek swab and blood samples for the analysis of germline biomarkers. Afterwards, patients and their physicians engage in discussion about which form of radiotherapy to proceed with. Based on the decision, patients predicted to be at low risk of toxicity with SBRT continue to receive SBRT over 14 days while patients predicted to be at high risk of toxicity with SBRT will be counseled to undergo either conventionally fractionated radiotherapy over 63-70 days, moderate hypofractionated radiotherapy over 28-35 days, or may opt to still receive SBRT over 14 days per standard of care.
88910279|NCT04622943|Experimental|firearms safety|Children will spend two 45-minute sessions engaged on ShootSafe, an internet-based training program on firearms safety.
88910280|NCT04622943|Active Comparator|nutrition|Children will spend two 45-minute sessions engaged on nourishinteractive.com, an internet-based training program on nutrition and exercise.
88910281|NCT04614532|Other|patients with alzheimer's disease|
88910282|NCT04614532|Other|control subject|Matching by age (± 5 years), gender, and grade level
88910283|NCT04614454|Experimental|Experimental arm|Devices will be programmed by our study coordinator to provide a sham signal or the experimental signal. The location of the TENS electrodes will be determined by the location of the pain with the goal of placing the unit at the top of the dermatological level corresponding to the pain. The study coordinator will assist each subject to place the device appropriately. Treatment will be administered for 1 hour per day for 4 weeks.
88910284|NCT04614454|Sham Comparator|Sham arm|The sham unit looks identical to the experimental unit. There may be a sensation experienced by subjects with the sham device but it does not deliver an electric current as the experimental units. The study coordinator will assist each subject to place the device appropriately. Treatment will be administered for 1 hour per day for 4 weeks.
88910285|NCT04612725|Experimental|Benralizumab Arm 1|Benralizumab Dose A regimen A until Week 12, Dose B regimen A until Week 24, and Dose B regimen B during the extension period until Week 52 (n=30)
88910286|NCT04612725|Experimental|Benralizumab Arm 2|Benralizumab Dose A regimen A until Week 12, Dose B regimen A until Week 24,and Dose B regimen A during the extension period until Week 52 (n=30)
88910287|NCT04612725|Experimental|Benralizumab Arm 3|Benralizumab Dose B regimen A until Week 12, Dose B regimen A until Week 24, and Dose B regimen B during the extension period until Week 52 (n=30)
88910288|NCT04612725|Experimental|Benralizumab Arm 4|Benralizumab Dose B regimen A until Week 12, Dose B regimen A until Week 24, and Dose B regimen A during the extension period until Week 52 (n=30)
88910289|NCT04612725|Experimental|Placebo and Benralizumab|Placebo regimen A until Week 24, benralizumab Dose B regiment A until Week 36, and Dose B regimen B until Week 52 (n=40).
88910290|NCT04612413|Placebo Comparator|Cohort 1|Single IV dose of placebo solution
88910291|NCT04612413|Experimental|Cohort 2|Single IV dose of 5x10^9 Allocetra-OTS cells in suspension
88910292|NCT04612413|Experimental|Cohort 3|Single IV dose of 10x10^9 Allocetra-OTS cells in suspension
88910293|NCT04612413|Experimental|Cohort 4|Single or two doses of 10x10^9 Allocetra-OTS cells in suspension
88910294|NCT04610684|Experimental|Study Treatment Arm|4 cycles of induction treatment with Atezolizumab (1200 mg on Day 1) combined with carboplatin (5-6 AUC on Day 1) and etoposide (80-100 mg/m2 on Days 1-3). After 4 cycles of induction treatment, subjects will receive atezolizumab maintenance 1200 mg on Day 1 of each 3-week cycle.
88910295|NCT04609085||Participants with Rare Diseases|Participants with history of rare disease
88910296|NCT04608019|Experimental|Immediate Antibiotics|increased airway clearance plus early initiation of oral antibiotics
88910297|NCT04608019|Experimental|Tailored Therapy|increased airway clearance alone, with addition of antibiotics for worsening symptoms or failure to improve
88910298|NCT04606901|Active Comparator|Sugammadex|Patients in this arm of the study will receive Sugammadex as the drug used to reverse neuromuscular blockade.
88910299|NCT04606901|Active Comparator|Neostigmine/Glycopyrrolate|Patients in this arm of the study will receive Neostigmine/Glycopyrrolate as the drugs used to reverse neuromuscular blockade
88910300|NCT04602221|Experimental|Treatment sequence: T1-T2-R|"Treatments:~T1: Lamotrigine T2: BI 409306 T3: BI 425809 R: Placebo"
88910301|NCT04602221|Experimental|Treatment sequence: T1-R-T2|
88910302|NCT04602221|Experimental|Treatment sequence: T1-T3-R|
89430267|NCT04803292||4th Affiliated Hospital, School of Medicine at Zhejiang University|a prospective cohort of patients of primary intracerebral hemorrhage in 4th Affiliated Hospital, School of Medicine at Zhejiang University
89430268|NCT04786678|Experimental|All participants|All participants will have a baseline before all participants undergo intervention. The purpose is to pilot the intervention to establish possible effects, as well as to determine if there are any usability or other issues.
88910303|NCT04602221|Experimental|Treatment sequence: T1-R-T3|
88910304|NCT04602221|Experimental|Treatment sequence: T2-T1-R|
88910305|NCT04602221|Experimental|Treatment sequence: T2-R-T1|
88910306|NCT04602221|Experimental|Treatment sequence: T2-T3-R|
88910307|NCT04602221|Experimental|Treatment sequence: T2-R-T3|
88910308|NCT04602221|Experimental|Treatment sequence: T3-R-T1|
88910309|NCT04602221|Experimental|Treatment sequence: T3-T1-R|
88910310|NCT04602221|Experimental|Treatment sequence: T3-T2-R|
89531166|NCT04473183||General Healthy Population|Participants in this group are part of the general healthy population of adults 18 years-of-age and older, not known to be exposed to the virus as reported by potential participants and who have not sought medical help in the previous 4 months.
89531167|NCT04473183||Medical School Residents|Participants in this group are medical school residents.
89531168|NCT04473183||Individuals who are HIV positive|Participants in this group are HIV positive.
88910311|NCT04602221|Experimental|Treatment sequence: T3-R-T2|
88910312|NCT04602221|Experimental|Treatment sequence: R-T1-T2|
88910313|NCT04602221|Experimental|Treatment sequence: R-T2-T1|
88910314|NCT04602221|Experimental|Treatment sequence: R-T1-T3|
88910315|NCT04602221|Experimental|Treatment sequence: R-T3-T1|
88910316|NCT04602221|Experimental|Treatment sequence: R-T2-T3|
88910317|NCT04602221|Experimental|Treatment sequence: R-T3-T2|
88910318|NCT04589845|Experimental|Cohort A: ROS1 Fusion-positive tumors (excluding NSCLC)|Participants with metastatic or advanced solid tumors, with the exception of NSCLC will receive entrectinib once daily in repeated 28-day cycles at a dose of 600 milligram per day (mg/day) for adults and pediatric participants with a body surface area (BSA) >/= 1.51 squaremeter (m2). The total dose of daily entrectinib administration for pediatric participants with BSA<1.51 m2 will be lower.
88910319|NCT04589845|Experimental|Cohort B: NTRK1/2/3 fusion-positive tumors|Participants with metastatic or advanced solid tumors will receive entrectinib once daily in repeated 28-day cycles at a dose of 600 mg/day for adults and pediatric participants with a BSA >/= 1.51 m2. The total dose of daily entrectinib administration for pediatric participants with BSA<1.51 m2 will be lower.
88910320|NCT04589845|Experimental|Cohort C: ALK fusion-positive tumors (excluding NSCLC)|Participants with metastatic or advanced solid tumors, with the exception of NSCLC, will receive alectinib at a dosage of 600 mg orally twice a day (BID), taken with food, in repeated 28-day cycles.
88910321|NCT04589845|Experimental|Cohort D: TMB-high tumors|"Participants with metastatic or advanced solid tumors will receive atezolizumab intravenously (IV) at a fixed dose for participants aged >/= 18 years, and 15 mg/kg (maximum 1200 mg) for participants aged < 18 years on Day 1 of each 21-day cycle.~Note: Cohort D has been closed for enrollment"
88910322|NCT04589845|Experimental|Cohort E: AKT1/2/3 mutant-positive tumors|"Participants with metastatic or advanced solid tumors will receive ipatasertib orally once daily (QD) at the starting dose of 400 mg in repeated 28-day cycles until the participant experiences disease progression, intolerable toxicity, or withdraws consent. For participants 12-17 years of age, ipatasertib will be administered at the starting dose of 200 mg for participants <35 kg, 300 mg for participants >/= 35 and <45 kg, 400 mg for those >/=45 kg orally QD in repeated 28-day cycles until the participant experiences disease progression, intolerable toxicity, or withdraws consent.~Note: Cohort E has been closed for enrollment"
88910323|NCT04589845|Experimental|Cohort F: HER2 mutant-positive tumors|"Participants with metastatic or advanced solid tumors will receive trastuzumab emtansine IV at a dose of 3.6 mg/kg every 21 days.~Note: Cohort F has been closed for enrollment"
88910324|NCT04589845|Experimental|Cohort G: MDM2-amplified, TP53 wild-type tumors|"Participants with metastatic or advanced solid tumors will receive idasanutlin at a dose of 250 mg orally QD on Days 1-5 of each 28-day cycle.~Note: Cohort G has been closed for enrollment"
88910325|NCT04589845|Experimental|Cohort H: PIK3CA multiple mutant-positive tumors|"Participants with metastatic or advanced solid tumors will receive GDC-0077 QD at a starting dose of 9 mg by mouth (PO) in repeated 28-day cycles.~Note: Cohort H has been closed for enrollment"
88910326|NCT04589845|Experimental|Cohort I: BRAF class II mutant or fusion-positive tumors|"Participants with BRAF class II mutant/fusion-positive tumors (adults and adolescents ≥ 40 kg) will receive 400 mg belvarafenib by mouth (PO) BID (twice a day) with adequate water (more than 200 mL). One cycle consists of 28 days. Administration of belvarafenib should occur BID on every day of each 28-day cycle.~Note: Cohort I has been closed for enrollment"
89008381|NCT04595461|Experimental|Video Group|Patient education supplemented with four short youtube videos regarding chronic rhinosinusitis and endoscopic sinus surgery
88910327|NCT04589845|Experimental|Cohort J: BRAF class III mutant-positive tumors|"Participants with BRAF class III mutant-positive tumors(adults and adolescents ≥ 40 kg) will receive 400 mg belvarafenib by mouth (PO) BID (twice a day) with adequate water (more than 200 mL). One cycle consists of 28 days. Administration of belvarafenib should occur BID on every day of each 28-day cycle.~Note: Cohort J has been closed for enrollment"
88910328|NCT04589845|Experimental|Cohort K: RET fusion-positive tumors (excluding NSCLC)|"Participants with RET fusion-positive tumors will self-administer Pralsetinib orally at home (except on clinic days) on a continuous daily dosing regimen at a dose of 400 mg/day (four 100-mg capsules per day) for adult and pediatric patients ≥ 12 and < 18 years of age. A treatment cycle consists of 4 weeks (28 days).~Note: Cohort K has been closed for enrollment"
88910329|NCT04589845|Experimental|Cohort L: KRAS G12C-positive tumors (excluding NSCLC and CRC)|Participants with KRAS G12C-positive tumors will self-administer GDC-6036 orally at home (except on clinic days).
88910330|NCT04589845|Experimental|Cohort M: ATM Loss of Function tumors|Participants with ATM Loss of Function tumors will self-administer Camonsertib orally at home (except on clinic days).
88910331|NCT04589845|Experimental|Cohort N: SETD2 Loss of Function tumors|Participants with SETD2 Loss of Function tumors will self-administer Camonsertib orally at home (except on clinic days).
88910332|NCT04588077|Experimental|Cirrhosis, 3-dose regimen|Investigators will randomize the patient in the cirrhotic group to receive a 3-dose regimen of Heplisav-B.
88910333|NCT04588077|Active Comparator|Cirrhosis, 2-dose regimen|Investigators will randomize the patient in the cirrhotic group to receive a 2-dose regimen of Heplisav-B.
88910334|NCT04588077|Experimental|Non cirrhosis, 3-dose regimen|Investigators will randomize the patient in the noncirrhotic group to receive a 3-dose regimen of Heplisav-B.
88910335|NCT04588077|Active Comparator|Non cirrhosis, 2-dose regimen|Investigators will randomize the patient in the noncirrhotic group to receive a 2-dose regimen of Heplisav-B.
88910336|NCT04585295|Experimental|Betaine|"Aim 1: To evaluate the impact of preloaded betaine supplementation on fluid compartments in male athletes aged 18-45 years old.~Aim 2: To determine the degree to which preloading with betaine impacts heat tolerance relative to placebo in male athletes aged 18-45 years old.~Aim 3: To determine the degree to which preloading with betaine impacts exercise metabolism and performance in the heat relative to placebo in male athletes aged 18-45 years old."
88910337|NCT04585295|Experimental|Placebo|"Aim 1: To evaluate the impact of preloaded betaine supplementation on fluid compartments in male athletes aged 18-45 years old.~Aim 2: To determine the degree to which preloading with betaine impacts heat tolerance relative to placebo in male athletes aged 18-45 years old.~Aim 3: To determine the degree to which preloading with betaine impacts exercise metabolism and performance in the heat relative to placebo in male athletes aged 18-45 years old."
88910338|NCT04585295|Experimental|NOW Foods Big 6|"Aim 1: To evaluate the impact of preloaded betaine supplementation on fluid compartments in male athletes aged 18-45 years old.~Aim 2: To determine the degree to which preloading with betaine impacts heat tolerance relative to placebo in male athletes aged 18-45 years old.~Aim 3: To determine the degree to which preloading with betaine impacts exercise metabolism and performance in the heat relative to placebo in male athletes aged 18-45 years old."
88910339|NCT04580225|Active Comparator|Group A: Partial Wrist Arthrodesis without Triquetral Excision|Four-Corner Arthrodesis
88910340|NCT04580225|Active Comparator|Group B: Partial Wrist Arthrodesis with Triquetral Excision|Three-Corner or Capitolunate Arthrodesis with Triquetral Excision
88910341|NCT04579185|Experimental|Transcranial Photobiomodulation|Transcranial Photobiomodulation--a noninvasive intervention in which near-infrared light (850 nanometer) is applied to forebrain.
88910342|NCT04564222|Experimental|Micronutrient Enriched Crackers (MECs)|"Micronutrient Enriched Crackers (MECs) are a deep-fried snack product rich in iron, zinc, calcium, and vitamin A made from chicken liver and chicken eggshell powder.~Consume daily, 75 gram/day, during pregnancy (from 8-14 weeks gestation to delivery) and lactation (from delivery to 5 months post-partum)."
88910343|NCT04564222|Placebo Comparator|Placebo|"Placebo Crackers are a deep-fried snack product made from the basic cracker ingredients (mainly wheat flour) with the addition of Pangium edule seeds to provide a color similar to the intervention product (MECs).~Consume daily, 75 gram/day, during pregnancy (from 8-14 weeks gestation to delivery) and lactation (from delivery to 5 months post-partum)."
88910344|NCT04561518||Patients with ATTR amyloidosis|Patients with a diagnosis of ATTR amyloidosis, hereditary or wild type, will be eligible for the study and will follow routine clinical care.
88910345|NCT04561518||Pre-symptomatic Carriers|Pre-symptomatic carriers with a known disease-causing TTR mutation will be eligible for the study and will follow routine clinical care.
88910346|NCT04559230|Experimental|Sacituzumab govitecan|Dosing will be at 10 mg/kg on days 1 and 8 of a 21-day cycle
88910347|NCT04556136|Experimental|Standing Phototherapy Kiosk (SPK)|Volunteers assigned to this group were administered phototherapy treatments in a standing phototherapy kiosk once every other week, for 10 weeks. The treatment usually lasts no more than 10 minutes and is based on the Fitzpatrick skin type classification tool, which is self-reported via the computer touch screen in the kiosk.
88910348|NCT04556136|Active Comparator|Oral Supplement|Volunteers assigned to this group were provided with a 10-week supply (70 pills) of a vitamin D3 supplement. Consented subjects were instructed to take one 600 IU pill by mouth each day for ten weeks. They were instructed to take this with a meal. This dose is the RDA for adults between 18 and 70 years old according to the Institute of Medicine Committee to Review Dietary Reference Intakes for Vitamin D and Calcium.
88910349|NCT04555278|Experimental|Active rTMS + Motor control exercises|Active (real) repetitive transcranial magnetic stimulation (20 minutes), immediately followed by a session of motor control exercises taught and supervised by a physiotherapist (30 minutes).
88910350|NCT04555278|Sham Comparator|Sham rTMS + Motor control exercises|Sham repetitive transcranial magnetic stimulation (20 minutes), immediately followed by a session of motor control exercises taught and supervised by a physiotherapist (30 minutes).
88910351|NCT04555278|Experimental|Active rTMS|Active (real) repetitive transcranial magnetic stimulation (20 minutes).
88910352|NCT04555278|Sham Comparator|Sham rTMS|Sham repetitive transcranial magnetic stimulation (20 minutes).
89531169|NCT02497313|Placebo Comparator|Placebo+Placebo|Oral ingestion of metformin placebo combined with intravenous infusion of isotonic saline.
89430269|NCT04786834|Active Comparator|Traditional training group|Trainees in the Traditional trained group will be trained according to the traditional approach of 'See one, do one, teach one' principle. Trainees will have an e-learning didactic component (specifically on the anatomy & physiology of the procedure, clinical aspects of the procedure, published evidence etc) which they must complete before training by a procedure expert. On completion of the e-learning module they will complete a summative assessment of their knowledge. They will then be shown how and then trained to suture and tie knots using the robot. The VUA will be demonstrated initially by an expert and who will then proctor the trainees in the same technique for repeated training trials., i.e., repeated practice for a period of time matched to the PBP group.
89430270|NCT04786834|Experimental|Proficiency based progression (PBP) training group: a new training methodology|Participants in the PBP trained group will follow the exact same e-learning didactic course as the Traditional trained group but the PBP group will be required to pass a test of procedure knowledge before continuing to the surgical training. Their knowledge will be assessed in a formative and summative fashion. After their initial VUA assessment, procedure-specific and validated procedure metrics will be used to teach the students the steps of the procedure, as well as the correct (and incorrect) way to perform the procedure. The metrics will be used to give them performance feedback with specific advice on how they might improve their performance, i.e., deliberate practice.
89430271|NCT01866111|Placebo Comparator|Placebo|Placebo
89430272|NCT01866111|Experimental|YKP3089 Low Dose|YKP3089 Low Dose
89430273|NCT01866111|Experimental|YKP3089 Medium Dose|YKP3089 Medium Dose
88910353|NCT04551131|Experimental|Frontline Arm|"Safety Phase:~Patients with newly diagnosed HLH will receive ruxolitinib PO or NGT and dexamethasone, PO or IV. Etoposide IV will be added based on disease response.~Expansion Phase:~Patients with newly diagnosed HLH treatment will begin with ruxolitinib PO or NGT at the MTD dose. Dexamethasone will be administered PO or IV. Etoposide IV will be added based on disease response."
88910354|NCT04551131|Experimental|Salvage Arm|Patients with relapsed/refractory HLH will receive ruxolitinib PO or NGT and dexamethasone PO or IV. Etoposide IV will be added based on disease response.
88910355|NCT04550715|Experimental|Brief intervention (BI) then Portal|The BI will be delivered at intake and the portal will occur for 4 weeks starting at intake.
88910356|NCT04550715|Experimental|Brief intervention (BI) then Enhanced Usual Care (EUC)|The BI will be delivered at intake and EUC will be added 4 weeks later.
88910357|NCT04550715|Experimental|Enhanced Usual Care (EUC) then Portal|EUC will be delivered at intake and the portal will occur for 4 weeks starting at intake.
89430274|NCT01866111|Experimental|YKP3089 High Dose|YKP3089 High Dose
89430275|NCT04803136|Other|Bone SPECT/CT|Gamma Camera with computed tomography
89430276|NCT04803136|Other|Spine surgeries|spine stabilization and fusion surgeries
88910358|NCT04550715|Active Comparator|Enhanced Usual Care (EUC) then EUC|EUC will be delivered at intake and delivered again 4 weeks later.
88910359|NCT04550260|Experimental|Arm 1: Durvalumab + definitive CRT|Durvalumab + concurrent chemoradiation
88910360|NCT04550260|Placebo Comparator|Arm 2: Placebo + definitive CRT|Placebo + concurrent chemoradiation
88910361|NCT04549792|Experimental|Open Label|
89430277|NCT02084589|Active Comparator|PCEA of continuous background infusion with demand dose|PCEA with background infusion of 5 ml/h and demand dose of 5 ml with lockout 10 minutes, using ropivacaine 0,15% and fentanyl 2μg/ml.
89430278|NCT02084589|Active Comparator|PCEA with demand dose only|PCEA with demand dose of 5 ml with lockout 10 minutes, using ropivacaine 0,15% and fentanyl 2μg/ml.
88910364|NCT04544436|Experimental|Ocrelizumab Higher Dose|Participants will be randomized to receive a minimum of 5 higher treatment doses (1200 mg or 1800 mg) of ocrelizumab administered by intravenous (IV) infusion every 24 weeks in the double blind treatment (DBT) phase. During the optional open-label extension (OLE) phase, participants will continue with their assigned dose of ocrelizumab (either 1200 or 1800 mg) for approximately 96 weeks (4 doses in total). Mandatory methylprednisolone (or equivalent) and antihistaminic drug (e.g., diphenhydramine or equivalent) will be administered approximately 30-60 minutes prior to the start of each ocrelizumab infusion.
88910365|NCT04544436|Active Comparator|Ocrelizumab Approved Dose|Participants will be randomized to receive a minimum of 5 treatment doses of 600 mg ocrelizumab administered by intravenous (IV) infusion every 24 weeks in the DBT phase. During the optional OLE phase, participants will be offered a higher dose of ocrelizumab (either 1200 or 1800 mg), based on their body weight at OLE baseline, for approximately 96 weeks (4 doses in total). Mandatory methylprednisolone (or equivalent) and antihistaminic drug (e.g., diphenhydramine or equivalent) will be administered approximately 30-60 minutes prior to the start of each ocrelizumab infusion.
88910366|NCT04536805|Experimental|Metformin + SBRT at total dose of 30 Gray (Gy)|"Metformin: 850 mg per day (day -15 to day 0) 1700 mg per day (day 1 to day 75)~Stereotactic Body Radiation Therapy (SBRT): Dose escalation 5 x 6 Gy, (day 0 to day 10)"
88910367|NCT04536805|Experimental|Metformin + SBRT at total dose of 36 Gy|"Metformin: 850 mg per day (day -15 to day 0) 1700 mg per day (day 1 to day 75)~Stereotactic Body Radiation Therapy (SBRT): Dose escalation 6 x 6 Gy (day 0 to day 12)"
88910368|NCT04536805|Experimental|Metformin + SBRT at total dose of 25 Gy|"Metformin: 850 mg per day (day -15 to day 0) 1700 mg per day (day 1 to day 75)~Stereotactic Body Radiation Therapy (SBRT): Dose escalation 5 x 5 Gy (day 0 to day 10)"
88910369|NCT04531462|Experimental|Empagliflozin 10 mg|
89430279|NCT03557853||Golimumab injection|Patients with ankylosing spondylitis and coxitis being treated with Simponi (golimumab) according to local clinical practice and label.
88910370|NCT04531462|Placebo Comparator|Placebo|
89531170|NCT02497313|Active Comparator|Placebo+Cholecystokinin|Oral ingestion of metformin placebo combined with intravenous infusion of cholecystokinin.
89531171|NCT02497313|Active Comparator|Metformin+Placebo|Oral ingestion of metformin combined with intravenous infusion of isotonic saline.
89430280|NCT04786288|Experimental|Aromatherapy|"22 elderly participants received M technique hand massage that lasted for 10 minutes for both their hands and arms using 2% lavender essential oil diluted with odourless baby oil (12 drops of lavender essential oil mixed in 30 ml of carrier oil) was used to apply the hand massage.~Intervention: massage with lavender essential oil mixed in a carrier oil"
89430281|NCT04786288|Placebo Comparator|Placebo|"odourless baby oil was used for the application of the M technique hand massage on both hands and arms for 10 minutes for the 22 elderly participants.~Intervention: other: massage with no fragrance baby oil"
89430282|NCT04786288|No Intervention|Control|Participants in this group didn't receive any type of intervention from the researcher except the routine hospital management.
89430283|NCT02084823|Placebo Comparator|non-cancer stem cell vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
89430284|NCT02084823|Experimental|giving low dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
89430285|NCT02084823|Experimental|giving middle dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
89430286|NCT02084823|Experimental|giving high dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
89430287|NCT02084901|Experimental|Orsiro Arm|
89430288|NCT02084901|Active Comparator|BioMatrix or BioMatrix Flex Arm|
89430289|NCT03559023|Active Comparator|Ultrasound Only|Ultrasound assisted epidural placement
89008382|NCT04595227||Normal Subjects|Healthy eyes had intraocular pressure of less than 22 mmHg with no history of increased intraocular pressure and normal standard automated perimetry (SAP) results.
89008383|NCT04595227||Suspect Glaucoma|Eyes with suspect glaucoma were defined as those with suspicious neuroretinal rim thinning or retinal nerve fiber layer (RNFL) defects on masked stereophotographic assessment, without repeatable abnormal SAP results. Eyes with suspect glaucoma also included those with intraocular pressure (IOP) > 21 mm Hg but with healthy-appearing optic discs and without repeatable abnormal SAP results
89008384|NCT04595227||Primary Open Angle Glaucoma, early stage|Eyes were classified as glaucomatous if they had repeatable (≥2 consecutive) abnormal SAP(Humphrey) test results or progressive glaucomatous changes on masked grading of stereophotographs, with or without abnormal SAP results. Abnormal SAP results were defined by a pattern standard deviation outside the 95% confidence limits or glaucoma hemifield test results outside the reference range.( -0.01dB≤MD≤-6.00dB)
89008385|NCT04595227||Primary Open Angle Glaucoma, moderate stage|Eyes were classified as glaucomatous if they had repeatable (≥2 consecutive) abnormal SAP(Humphrey) test results or progressive glaucomatous changes on masked grading of stereophotographs, with or without abnormal SAP results. Abnormal SAP results were defined by a pattern standard deviation outside the 95% confidence limits or glaucoma hemifield test results outside the reference range.( -6.01≤MD≤-12.00dB)
89430290|NCT03559023|Active Comparator|Manometry Only|Manometry confirmation in epidural placement
89430291|NCT03559023|Active Comparator|Ultrasound Plus Manometry|Ultrasound Plus Manometry confirmation in epidural placement
89430292|NCT03559023|Sham Comparator|Usual Care/Management|Usual epidural technique placement
89430293|NCT02595502|Active Comparator|Sequence 1: Test Control Test|Test/control/test using the Johnson & Johnson Vision Care (JJVC) Marketed contact lens (test) and the Competitor Marketed contact lens (control). Lenses will be worn as daily wear, daily disposable on both eyes for approximately one week each in between lenses for total study duration of approximately three weeks per subject. Subjects are required to wear the lenses at least five days for at least eight hours per day worn.
89430294|NCT02595502|Active Comparator|Sequence 2: Control Test Control|Control/test/control using the JJVC Marketed contact lens (test) and the Competitor Marketed contact lens (control). Lenses will be worn as daily wear, daily disposable on both eyes for approximately one week each for total study duration of approximately three weeks per subject. Subjects are required to wear the lenses at least five days for at least eight hours per day worn.
89430295|NCT02082951|Experimental|Group 2: empathic behaviour by family.|Considered the empathic behaviour performed by family as a hospital visit with greater than 45 minutes duration, a person with whom the patient had a good relationship, he considered it to be important and welcome. It is emphasized that these families did not have any prior training and after the visit, patients were asked about how the visit had been seeking to detect the presence of any conversations that have been unpleasant for patients and, if present, the patients were excluded from the study.
89430296|NCT02082951|Experimental|Group 1: empathic behaviour by nurses.|The empathic behaviour in group 1 was performed by a trained nurse.
89430297|NCT04346290|No Intervention|Control|Standard anesthesia care for kidney donor
89430298|NCT04346290|Experimental|Dexmedetomidine|Standard anesthesia care and perioperative infusion of dexmedetomidine for kidney donor
89430299|NCT02084979|Experimental|Asynchronous telepsychiatry|Experimental Arm: Asynchronous telepsychiatry evaluation and consultation
89008386|NCT04595227||Primary Open Angle Glaucoma, advanced stage|Eyes were classified as glaucomatous if they had repeatable (≥2 consecutive) abnormal SAP(Humphrey) test results or progressive glaucomatous changes on masked grading of stereophotographs, with or without abnormal SAP results. Abnormal SAP results were defined by a pattern standard deviation outside the 95% confidence limits or glaucoma hemifield test results outside the reference range.( -12.00≤MD≤-20.00dB)
89008387|NCT04635683|Experimental|Treatment (lenalidomide, umbralisib, ublituximab)|Patients receive lenalidomide PO QD on days 1-21 and umbralisib PO QD on days 1-28. Beginning in cycle 2, patients also receive ublituximab IV over 90 minutes to 4 hours on day 1. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients who achieve a partial or complete response after cycle 6 continue treatment of lenalidomide PO QD and umbralisib PO QD for 12 additional cycles, and ublituximab IV on day 1 of subsequent even cycles (8, 10, 12, 14, 16, and 18). Patients with stable disease after cycle 6 may continue on treatment for an additional 12 cycles at the discretion of the investigator.
89008388|NCT04595383|No Intervention|Control|Usual care and usual communication with health professional
89008389|NCT04595383|Experimental|Intervention|They will be trained to use the ti.care platform and will be able to use it as a communication channel for any questions or clarification they require during the time elapsed between routine control visits. This platform will be a complement to the visits, but in no case will it replace them or be used as a diagnostic or therapeutic method. The platform does not have any treatment algorithm and only aims to facilitate communication between the patient at home and the health professional, both the doctor and the nurse educator. It will be used in a preventive and advisory manner for the patient for follow-up. In no case it will be used for emergencies. Daily during working hours from Monday to Friday, health professionals will review patient requests and respond to them.
89008390|NCT04595344|Active Comparator|Diagnostic cystoscopy , Binaural beat group|patients listened to binaural beats
89008391|NCT04595344|Active Comparator|Diagnostic cystoscopy, Classical music group|patients listened to classical music
89008392|NCT04595344|Placebo Comparator|Diagnostic cystoscopy , Placebo group|patients no audio only headphones
89008393|NCT04595344|Active Comparator|Ureteral stent removal, Binaural beat group|patients listened to binaural beats
89008394|NCT04595344|Active Comparator|Ureteral stent removal ,Classical music group|patients listened to classical music
89430300|NCT02084979|Active Comparator|Synchronous telepsychiatry|Control Arm: Synchronous telepsychiatry evaluation and consultation
89008395|NCT04595344|Placebo Comparator|Ureteral stent removal, Placebo group|patients no audio only headphones
89008396|NCT00403091|Experimental|Intervention|
89008397|NCT00403091|Active Comparator|Control|
89008398|NCT00566605|Active Comparator|Group 1|
89008399|NCT00566605|Active Comparator|Group 2|
89008400|NCT04594954|Experimental|Diet + Exercise + FMT|
89008401|NCT04594954|Active Comparator|Diet+Exercise|
89008402|NCT00253071|Active Comparator|A,2|Standard treatment: treatment as usual at a community psychiatric center, private psychiatrist or general practitioner.
89008403|NCT00253071|Experimental|A, 1|"Behavioral: Prophylactic combined medical and psychological treatment~Medical treatment is naturalistic and evidence based according to international recommendations.~Psychological treatment is either group psychoeducation or group cognitive behavioural therapy."
89430301|NCT04793386|Experimental|Carotid ultrasound|When stopping chest compressions to check manual palpation every 2 minutes, an ultrasound scan of the carotid artery is performed. Whether or not return of spontaneous circulation is determined based on the compressibility and pulsatility of the carotid artery, and the time taken from the start of the ultrasound scan to the determination is recorded.
89430302|NCT04803448|No Intervention|Control|No statement is provided before asking the health care question. Example: What is your weight in pounds?
89008404|NCT00249405|Experimental|1|citalopram
89008405|NCT00249405|Placebo Comparator|2|Placebo
89008406|NCT04594447|Other|Physica KR|Subject that receive Physica Kinematic Retaining total Knee replacement system
89008407|NCT04594447|Other|Physica CR|Subject that receive Physica Cruciate Retaining total Knee replacement system
89008408|NCT04594720||Thyroid cancers|Enrolled study population have papillary thyroid cancers and benign thyroid tumors
89008409|NCT04594330|Active Comparator|Group 1 - 30 COVID-19 patients aged ≥ 18 years old receiving the investigational drug|Group 1 - 30 COVID-19 patients receiving standard therapy and the investigational drug (Virgin Coconut Oil)
89008410|NCT04594330|Placebo Comparator|Group 2 - 30 COVID-19 patients aged ≥ 18 years old receiving placebo|Group 2 - 30 COVID-19 patients receiving standard therapy and placebo
89008411|NCT04618133|Experimental|Early time-restricted eating|Duration: 12 weeks
89008412|NCT04618133|Experimental|Late time-restricted eating|Duration: 12 weeks
89430303|NCT04803448|Experimental|Benefit Statement|A statement of benefit will be given (see intervention) after the health question.
89008413|NCT04618133|Active Comparator|Active control|Duration: 12 weeks
89008414|NCT04594057|Active Comparator|Early Start|Begin 6 weeks of gaze and postural stability training 10-14 days following surgery.
89008415|NCT04594057|Experimental|Delayed Start|Begin 6 weeks of gaze and postural stability training 6 weeks following surgery.
89008416|NCT04594135|Experimental|anti-CD5 CAR T cells|Experimental: anti-CD5 CAR T cells Dose escalation phase: anti-CD5 CAR T cells transduced with a lentiviral vector to express CD5 chimeric receptor domain on T cells with an escalation approach, 1e6 to 5e6 CAR-T cells/kg
89008417|NCT00253110|Active Comparator|risperidone|
89008418|NCT00253110|Active Comparator|haloperidol|
89430304|NCT04803448|Experimental|Risk Statement|A statement of risk will be given (see intervention) after the health question.
89430305|NCT04803448|Experimental|Privacy Statement|A statement of privacy will be given (see intervention) after the health question.
89430306|NCT04803448|Experimental|Benefit + Privacy statement|A statement of benefit and privacy will be given (see intervention) after the health question.
89008419|NCT04594252|Experimental|ALXN1840|Participants will be administered repeat doses of ALXN1840 30 milligrams (mg) for 15 days.
89008420|NCT04594174||Responders|
88910371|NCT04530565|Active Comparator|Arm A (steroid, TKI), Single Arm Pre-Induction|Patients receive prednisone PO QD on days 1-21 and ponatinib PO QD or dasatinib PO QD on days 1-21 based on investigator's choice.
88910372|NCT04530565|Experimental|Arm B (steroid, TKI, chemotherapy)|See Detailed Description.
88910373|NCT04530565|Experimental|Arm C (steroid, TKI, chemotherapy, immunotherapy)|"CYCLE 1: Patients receive ponatinib PO QD or dasatinib PO QD on days 1-28. Patients also receive dexamethasone PO or IV on day 1 and blinatumomab IV continuously on days 1-28, followed by methotrexate IT on day 28 or 29.~CYCLE 2: Patients receive ponatinib PO QD or dasatinib PO QD on days 1-28. Patients also receive dexamethasone PO or IV on day 1 and blinatumomab IV continuously on days 1-28.~Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity."
88910374|NCT04530565|Experimental|Arm D (steroid, TKI, chemotherapy, immunotherapy)|"Patients treated on Arm B who remain MRD positive at the end of induction therapy receive blinatumomab based re-induction identical to the regimen described for Arm C.~Patients whose molecular test remains MRD positive after re-induction proceed to follow-up at the discretion of the investigator or receive anti CD-19 CAR- T cell therapy, inotuzumab ozogamicin, intensive chemotherapy, or palliative care."
88910375|NCT04530565|Experimental|Arm E (steroid, TKI, chemotherapy)|"Patients treated on Arm C who remain MRD positive at the end of induction therapy receive chemotherapy based re-induction which is identical to regimen described for Arm B according to patient's age and the pre-specified chemotherapy arm.~Patients whose molecular test remains MRD positive after re-induction proceed to follow-up at the discretion of the investigator or receive anti CD-19 CAR- T cell therapy, inotuzumab ozogamicin, intensive chemotherapy, or palliative care."
88910376|NCT04529954|Experimental|Open-Label Safety|Participants roll-over from DA071976 or CLN100P.02
88910377|NCT04529161|Experimental|Group A|Diet followed by routine eating
88910378|NCT04529161|Experimental|Group B|Routine eating followed by diet
88910379|NCT04525547||Ofev treatment|Korean patients diagnosed with idiopathic pulmonary fibrosis, systemic sclerosis associated interstitial lung disease or chronic fibrosing interstitial lung diseases with a progressive phenotype receiving Ofev (nintedanib 150milligrams (mg)/100mg twice a day (BID))
88910380|NCT04524871|Active Comparator|Stage 1: Atezolizumab + Bevacizumab|Participants will receive atezolizumab plus bevacizumab until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
88910381|NCT04524871|Experimental|Stage 1: Atezolizumab + Bevacizumab + Tiragolumab|Participants will receive atezolizumab plus bevacizumab plus tiragolumab until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
88910382|NCT04524871|Experimental|Stage 1: Atezolizumab + Bevacizumab + Tocilizumab|Participants will receive atezolizumab plus bevacizumab plus tocilizumab until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
88910383|NCT04524871|Experimental|Stage 1: Atezolizumab + Bevacizumab + TPST-1120|Participants will receive atezolizumab plus bevacizumab plus TPST-1120 until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
88910384|NCT04524871|Experimental|Stage 1: RO7247669 2100 mg Q2W + Bevacizumab|Participants will receive RO7247669 plus bevacizumab until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
88910385|NCT04524871|Experimental|Stage 1: RO7247669 600 mg Q3W + Bevacizumab|Participants will receive RO7247669 plus bevacizumab until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
88910386|NCT04524871|Experimental|Stage 1: RO7247669 1200 mg Q3W + Bevacizumab|Participants will receive RO7247669 plus bevacizumab until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
88910387|NCT04524871|Experimental|Stage 1: Atezolizumab + Bevacizumab + ADG126|Participants will receive atezolizumab plus bevacizumab plus ADG126 until unacceptable toxicity or loss of clinical benefit as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
88910388|NCT04516876|Experimental|Camp-based bimanual intensive training(BIT)|
88910389|NCT04511819|Experimental|Losmapimod|COVID-19 patients with PCR confirmation will receive Losmapimod 15 mg twice daily given as two 7.5 mg tablets per dose by mouth; for a total of 4 pills or 30 mg daily for 14 days.
88910390|NCT04511819|Placebo Comparator|Placebo|COVID-19 patients with PCR confirmation will receive Placebo twice daily given as two tablets per dose by mouth; for a total of 4 tablets daily for 14 days.
88910391|NCT04504929|Sham Comparator|Sham tape|participants received sham taping during pitching, and removed after pitching
88910392|NCT04504929|Experimental|Dynamic tape|participants received dynamic taping during pitching, and removed after pitching
88910393|NCT04504812|Active Comparator|Phase 1: Best Practices + Duloxetine|Participants will receive Duloxetine and a prescription for guideline-recommended treatments for knee osteoarthritis, i.e., Best Practices. Best Practices can include topical or oral nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen; physical therapy that may include aquatherapy; integrative treatments such as acupuncture, yoga, or a structured exercise program; and other non-invasive treatments.
89008421|NCT04594174||Non responders|
89008422|NCT04598672|Experimental|Cognitive behavioral therapy for insomnia (CBTi)|
89008423|NCT00566683|Active Comparator|1|Diazemuls-Pethidine
89430307|NCT04803448|Experimental|Risk + privacy statement|A statement of risk and privacy will be given (see intervention) after the health question.
89531172|NCT02497313|Active Comparator|Metformin+Cholecystokinin|Oral ingestion of metformin combined with intravenous infusion of cholecystokinin.
89531173|NCT03095391||Cohort 1|GFR: ≥ 60 mL/min/1.73 m2 VFI dose: 47 mg/3 mL Number of doses: 1 Comparator: none Comparator dose: none
89531174|NCT03095391||Cohort 2|GFR: ≥ 60 mL/min/1.73 m2 VFI dose: 47 mg/3 mL Number of doses: 2 Comparator: Iohexol 5 mL Comparator dose: 1
89531175|NCT03095391||Cohort 3|GFR: ≥ 30 and < 60 mL/min/1.73 m2 VFI dose: 47 mg/3 mL Number of doses: 1 Comparator: Iohexol 5 mL Comparator dose: 1
89531176|NCT03095391||Cohort 4|GFR: ≥ 15 and < 30 mL/min/1.73 m2 VFI dose: 47 mg/3 mL Number of doses: 1 Comparator: Iohexol 5 mL Comparator dose: 1
89531177|NCT03339947||Travel medicine|All adult travellers who attended the consultation for travel medicine and international vaccination in Reims University Hospital.
88820593|NCT05947448||AZL-M + CCB drug group（Combined medication）|Nifedipine Controller-release Tablets，clinical maximum tolerated dose，tablet，QD，six months；and Levoamlodipine Maleate Table，clinical maximum tolerated dose，tablet，QD，six months； When the patient's upper pressure exceeds 160 Millimetre of mercury, the doctor will choose combination medication .CCB drug will be chosen either Nifedipine Controller-release Tablets or Levoamlodipine Maleate Table.
88820594|NCT05943938||ED Patients|All adult patients presenting to Emergency Departments (ED) in the Emory Healthcare system
88820595|NCT05938608|Experimental|Regimen 1 (Oral primaquine), 2(IV primaquine phosphate), 3(IV carboxyprimaquine)|"Regimen 1 (Oral primaquine): Primaquine 15 mg base orally once~Regimen 2 (IV primaquine phosphate): Primaquine 7.5 mg base in normal saline 500 mL infused over 30 minutes intravenously~Regimen 3 (IV carboxyprimaquine): Carboxyprimaquine 7.93 mg base in normal saline 500 mL infused over 30 minutes intravenously"
88820596|NCT05938036|Experimental|Part A : ALT-100 mAB (Dose Escalation)|"90 eligible participants will be randomized at a 2:1 ratio to receive a single dose of ALT-100 mAb.~Part A will assess 2 doses of ALT-100 mAb in sequentially enrolled cohorts of up to 9 participants in each cohort. (Randomised, Double-blind) Drug: ALT-100 mAb Dosage Form: Sterile liquid, pH 5.5, Dosage: 0.4 mg/kg (Cohort 1a) and 1.0 mg/kg (Cohort 2a) Dosage Form & Route of Admin: Solution for IV Infusion"
88820597|NCT05938036|Placebo Comparator|Part A Placebo|Part A participants with acute respiratory distress syndrome (ARDS) (Randomised, Double-blind) Dosage Form & Route of Admin: Normal Saline Solution for IV Infusion
88820598|NCT05938036|Experimental|Part B (Dose Expansion) ALT-100 mAb|Approximately 9 participants in each cohort in Part A, additional participants (up to 36 per dose cohort) may be enrolled into 2 dose expansion cohorts, the dose of which will be determined by the SRC. Drug: AT-02 Dosage: Will be decided by the SCR Route of Admin: Solution for IV Infusion
88820599|NCT05938010||Dailies Total1® contact lenses for astigmatism (T30fA)|Dailies Total1® contact lenses for astigmatism (T30fA)
88820600|NCT05935540|Experimental|ACP-Family|It is a ACP discussion intervention consisting of two sessions (45-60 mins) and to be delivered within one month in a face-to-face format as long as the patient is still in the hospital by a trained ACP facilitator.
88820601|NCT05935540|No Intervention|ACP-UC|Usual care that is available to all palliative care patients in the hospital.
88820602|NCT05934448|Experimental|PEMBROLIZUMAB|"Participants will undergo (leukapheresis) for manufacturing of commercial product as per standard of care (SOC) Cycle 1 Day -21or earlier~Pembrolizumab will be administered per protocol on cycle 1 day -20 and on day +1 following Chimeric Antigen Receptor (CAR) Therapy Infusion infusion, every 3 weeks for up to 2 years, unless there is confirmed progression of disease or unacceptable toxicity.~Upon the completion of successful manufacturing, patients will undergo lymphodepleting chemotherapy (fludarabine, cyclophosphamide) for chimeric antigen receptor (CAR) therapy infusion as per SOC.~Participants will receive Chimeric Antigen Receptor (CAR) Therapy Infusion (SOC) on day 0 in the hospital and will remain in the inpatient setting for observation for a minimum of 7 days or until CAR T-cell toxicities resolve to grade 1 or better. The choice of CAR-T product will be left to the discretion of the treating investigator."
88820603|NCT05930327|Experimental|High-Value Cash Transfer|Participants in the treatment group will receive four $325 payments. The first payment will be disbursed at the time of enrollment (between birth and 4 weeks of age), and second payment on the infant's one-month birthday, third payment on the infant's two-month birthday, and the fourth payment on the infant's three-month birthdays.
88820604|NCT05930327|Active Comparator|Low-Value Cash Transfer|Participants in the control group will receive four $25 payments. The first payment will be disbursed at the time of enrollment (between birth and 4 weeks of age), and second payment on the infant's one-month birthday, third payment on the infant's two-month birthday, and the fourth payment on the infant's three-month birthdays.
88820605|NCT05926804|Experimental|Cases|150-160 children with H. pylori-persistent infection, who will receive eradication therapy
88820606|NCT05926804|No Intervention|Controls|75-80 children with H. pylori-persistent infection, who will not receive eradication therapy
88820607|NCT05926804|No Intervention|Non infected Controls|60 adolescents with no H. pylori infection, they will not receive eradication therapy
88820608|NCT05912361|Experimental|Students using AI-platform for assessing the risk of pulp exposure receiving a training session|"Students will go through a one-hour hands-on training session before taking the test at the online platform. The session includes a theoretical session related to basic aspects of AI in radiology, CNN (Convolutional Neural Network) applications for cariology and endodontics, as well as basics of excavation therapy and pulp exposure. the theoretical part will be followed by a hands on session on which participants check 11 cases of teeth with deep caries and will find the closest line between caries and pulp.~Then, they will receive access to log in to the website on which pretreatment x-rays of cases undergoing caries excavation therapy is uploaded. The performance of students on will be assessed."
88820609|NCT05912361|No Intervention|Students using AI-platform for assessing the risk of pulp exposure without any training session|Students will not receive any training before starting the experiment. Only a 5-minute video will be played as the guide for answering the questions in the website. Then, they will receive access to log in to the website on which pretreatment x-rays of cases undergoing caries excavation therapy is uploaded. The performance of students on will be assessed.
88910394|NCT04504812|Active Comparator|Phase 1:Best Practices + Duloxetine + Pain coping skills|Participants will receive Duloxetine, pain coping skills training, and a prescription for guideline-recommended treatments for knee osteoarthritis, i.e., Best Practices. Best Practices can include topical or oral nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen; physical therapy that may include aquatherapy; integrative treatments such as acupuncture, yoga, or a structured exercise program; and other non-invasive treatments.
88910395|NCT04504812|Active Comparator|Phase 2: Intra-Articular Injection (HA+)|Participants will receive an intra-articular injection of hyaluronic acid mixed with steroid and bupivacaine.
88910396|NCT04504812|Active Comparator|Phase 2: Nerve Procedure: Long Acting Blocks|Participants will receive a nerve blocking procedure, long-acting local anesthetic, and steroid injection.
88910397|NCT04504812|Active Comparator|Phase 2: Nerve Procedure: Nerve Ablation|Participants will receive a nerve ablation procedure and steroid injection.
88910398|NCT04504812|Active Comparator|Phase 1: Best Practices|"Participants will receive a prescription for guideline-recommended treatments for knee osteoarthritis, i.e., Best Practices. Best Practices can include topical or oral nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen; physical therapy that may include aquatherapy; integrative treatments such as acupuncture, yoga, or a structured exercise program; and other non-invasive treatments.~Following the Phase 1 interim analysis in November 2023, the Data Safety and Monitoring Board and study sponsors approved formal closure of this arm per the pre-specified stopping rules."
88910399|NCT04475783|Experimental|Sirolomus DCB group|Intervention with Sirolimus-coated balloon catheter
88910400|NCT04475783|Active Comparator|Paclitaxel DCB group|Intervention with Paclitaxel-coated balloon catheter
88910401|NCT04468334|Experimental|LARIAT + PVI Treatment Group|"Percutaneously isolate and ligate the Left Atrial Appendage (LAA) from the left atrium (LA) with the LARIAT System prior to planned pulmonary vein isolation (PVI) catheter ablation~Subgroup 1: Radiofrequency (RF) PVI catheter ablation treatment (n<65) Subgroup 2: Cryoballoon PVI catheter ablation treatment (n<20)"
88910402|NCT04466891|Experimental|ZW25 (Zanidatamab) Monotherapy|
89430308|NCT04786132|Experimental|Dual Task (proprioception, balance and cognitive) training|"A DT training protocol of 8 weeks duration was carried out, during 2 days a week, with a duration of 30 minutes each session divided into: warm-up (mobility and warm-up 5 '), main part (20') and cool down (5 'dynamic stretching). The main part consisted of a choreography divided into five measures of thirty-two beats each, in turn divided into four parts of eight movements, which included proprioception and balance exercises such as: squats, imbalances, lateral movements, front, standing on one leg, twist, etc. The sessions evolved from individual exercises, in pairs, in trios and finally in groups. The sessions included music that was unknown to the subjects but at the same time easy to learn, so that while they performed the motor tasks, they would memorize the songs.~The sessions were carried out by the main researcher who controlled both the technique of the exercises and motivated them to sing and perform a cognitive exercise."
89430309|NCT04786132|Active Comparator|Proprioception and balance training|"The control group training protocol is the same as the experimental group, whit the same duration and the same sessions, the unique difference is that there was no music included in the sessions, and therefore cognitive ability was not worked.~The sessions were carried out by the main researcher who controlled the technique of the exercises and motivated the participant."
89430310|NCT04793308|Experimental|Group (1); (ProTaper Next, Rotary system).|Group I teeth were prepared with rotary instrumentation using ProTaper Next (Dentsply, Switzerland)
89430311|NCT04793308|Experimental|Group (2); K- files, Manual instruments.|Group II root canals were prepared by manual instrumentation using K type files Mani, Japan).
89430312|NCT04785742|Experimental|20 exon (20INS) mutation|
89430313|NCT04785742|Experimental|Rare mutations except for 20INS|
89430314|NCT04426552|Experimental|Dexmedetomidine|have a bolus of dexmedetomidine one μg/kg (Precedex; Hospira, Inc, Lake Forest, IL) administered for 10 minutes, followed by a continuous infusion at 0.7 μg • kg-1 • h-1 during FOI
89430315|NCT04426552|Active Comparator|Sevoflurane|(sevoflurane) will be preoxygenated using face mask with 100% oxygen for 3 min to increase oxygen reserve and then inhalational induction will be started with sevoflurane in 100% oxygen using Ayre's piece circuit/MapelsonD circuit according to age and weight of the patient while performing fiberoptic intubation
89430316|NCT04803370|Other|Control group|Standard treatment for COVID-19 (according to clinical guidelines for COVID-19).
89430317|NCT04803370|Experimental|Intervention group|Convalescent patient plasma 300 ml given in 2 consecutive days, plus standard treatment for COVID-19 (according to clinical guidelines).
89430318|NCT04793074|Experimental|Transforming nanoparticle dressing|Patients in the treatment group (n=30) had transforming nanoparticle dressing
89430319|NCT04793074|Active Comparator|Conventional compression dressing|The control group (n=30) received conventional compression dressing.
89430320|NCT04786054|Active Comparator|Group BED|Those who are diagnosed with having Binge Eating disorder. These individuals qualified after the questionnaire was administered.
89430321|NCT04786054|No Intervention|Group Non-BED|Those who are not diagnosed with having Binge Eating disorder
89430322|NCT04785664|Experimental|LLE- Long Live the Elderly!|"The group has been randomized among the Long Live the Elderly! (LLE) clients in two cities: Rome and Naples. The LLE central database includes all the participants to the program in Naples and Rome who have been administered the Functional Geriatric Evaluation (FGE) questionnaire."
89430323|NCT04785664|No Intervention|SoC- Standard of Care|No intervention will be carried out. The control group is selected by randomization from a pool of over-80s followed up by General Practitioners in the same cities who have been available to be involved in the study. Each GP provided a list of patients which 10 names have been selected from by randomization. The total pool consisted of approximately 8500 individuals. The sample was made up of 690 selected patients of which 83 (12.02%) refused to participate in the study.
89430324|NCT01369329|Placebo Comparator|001|Group 1: Placebo Form=solution for injection route=intravenous use in a single dose.
89430325|NCT01369329|Experimental|002|Group 2 ustekinumab 130 mg Type=exact unit=mg number=130 form=solution for injection route= intravenous use in a single dose.
89430326|NCT01369329|Experimental|003|Group 3: ustekinumab approximately 6 mg/kg Type=range unit=mg/kg number=6 form=solution for injection route= intravenous use in a single dose.weight-range based ustekinumab doses approximating ustekinumab 6 mg/kg: 260 mg (weight <= 55 kg) 390 mg (weight > 55 kg and <= 85 kg) and 520 mg (weight > 85 kg).
89430327|NCT04792996||Gilbert´s Syndrome|Subjects with mild hyperbilirubinaemia and a plasma level of unconjugated bilirubin of 17.1 µmol.
89430328|NCT04792996||Control group|Healthy controls with lower plasma level of unconjugated bilirubin of 17.1 µmol, aen and gender matched.
89430329|NCT04792762|Experimental|GIP(1-42)|
89430330|NCT04792762|Experimental|GIP(1-30)NH2|
89430331|NCT04792762|Placebo Comparator|Placebo|
89430332|NCT04802980|Experimental|HB002.1T + Oxaliplatin+ Capecitabine|21-24 patients with advanced gastric cancer administeredHB002.1T+ Oxaliplatin+ Capecitabine combination every 3 weeks in a 21-day cycle, total 18cycles
89008424|NCT00566683|Active Comparator|2|Propofol- Alfentanil
89430333|NCT04802980|Experimental|HB002.1T + Paclitaxel + Carboplatin|21-24 patients with advanced ovarian cancer, cervical cancer, head and neck cancer or lung cancer (not limited to the above tumor types) administered HB002.1T + Paclitaxel + Carboplatin combination every 3 weeks in a 21-day cycle, total 18cycles
89430334|NCT04802980|Experimental|HB002.1T + Gemcitabine + Cisplatin|21-24 patients with advanced biliary tract tumor, pancreatic cancer, bladder cancer or nasopharyngeal carcinoma (not limited to the above tumor types) administered HB002.1T + Gemcitabine + Cisplatin combination every 3 weeks in a 21-day cycle, total 18cycles
89430335|NCT02083029|Experimental|Syncopal Asthmatic|All subject undergo simulated dive reflex, with 30s facial immersion and continuous HR and BP monitoring with Nexfin over a period of 6 minutes.
89430336|NCT02083029|Experimental|Non Syncopal Asthmatic|All subject undergo simulated dive reflex, with 30s facial immersion and continuous HR and BP monitoring with Nexfin over a period of 6 minutes.
89430337|NCT02083029|Experimental|Normal Volunteers|All subject undergo simulated dive reflex, with 30s facial immersion and continuous HR and BP monitoring with Nexfin over a period of 6 minutes.
89430338|NCT04792606||"Natural History or watchful waiting"|
89430339|NCT04792606||Serial botulinum toxin injections|
89430340|NCT04792606||Adductor (+/- psoas) muscle releases alone|
88910403|NCT04461028|Other|GROUP 1 Liposomal Bupivacaine|Will receive a 20 ml mixture of 10 ml of Liposomal Bupivacaine 1.3% and 10 ml of Bupivacaine HCl 0.5%.
88910404|NCT04461028|Other|GROUP 2 Bupivacaine with dexamethasone|Will receive 20 ml of Bupivacaine HCl 0.5% with 4 mg of preservative-free dexamethasone.
88910405|NCT04457921|Experimental|Deep tissue massage|deep tissue massage applied group
88910406|NCT04457921|No Intervention|Standard of care|group without deep tissue massage
88910407|NCT04457284|Experimental|temozolomide, cisplatin and nivolumab|Subjects will receive oral TMZ at 150-200 mg/m2 day 1 to 5 every 4 weeks, cisplatin via IV infusion at 40 mg/m2 every two weeks (Q2W), and nivolumab via IV infusion at 480 mg every four weeks (Q4W).
88910408|NCT04456569|Experimental|GAE + Standard of Care|Participants in this arm will receive geniculate artery embolization and standard of care.
88910409|NCT04456569|No Intervention|Standard of Care|Participants in this arm will receive standard of care only.
89430341|NCT04792606||Hip reconstructive surgery|
89430342|NCT04792606||Salvage hip surgery|
89430343|NCT02085057||anorexia nervosa|Diagnosis of anorexia nervosa
89430344|NCT02085057||obsessive-compulsive disorder|Diagnosis of obsessive-compulsive disorder
89430345|NCT02085057||healthy control|No psychiatric diagnoses
89430346|NCT02085057||sisters|Sisters of those enrolled with a diagnosis of anorexia nervosa
89430347|NCT05616052|Active Comparator|standard arm|standard arm will start from 0.25mg per week for four weeks, then increase to 0.5mg per week for four weeks, and 1mg per week maintenance dose for 8 weeks..
89430348|NCT05616052|Active Comparator|titration arm|Titration arm dosage regime depends on the tolerance of the semaglutide from patients. The dosage will stabilize on the dose which patients could tolerate
89430349|NCT02088567|Experimental|dHACM|Total knee arthroplasty, per the usual practice of the physician with application of dHACM between the underlying fascia and the overlying skin layers to reduce scar formation
89430350|NCT02088567|Other|Control|Total knee arthroplasty, per the usual practice of the physician without application of dHACM.
88910410|NCT04451603||Surgical resection|
88910411|NCT04451603||Y-90 therapy|
88910412|NCT04451603||Systemic Therapy|
89430351|NCT04785430||Patients who underwent elective inguinal hernia surgery|Patients who have applied to the general surgery outpatient clinic of Bakırköy Dr Sadi Konuk Training and Research Hospital, diagnosed with inguinal hernia and underwent hernia repair surgery.
89430352|NCT04785430||Patients who underwent emergency inguinal hernia surgery|Patients who have applied to the emergency clinic of Bakırköy Dr Sadi Konuk Training and Research Hospital, diagnosed with incarcerated inguinal hernia and underwent hernia repair surgery.
89430353|NCT03558477|Experimental|Set 1(YYD601 1 & Nexium)|Set 1: YYD601 1 & Nexium
89430354|NCT03558477|Experimental|Set 2(YYD601 2 & Nexium)|Set 2: YYD601 2 & Nexium
89430355|NCT03558477|Experimental|Set 3(YYD601 3 & Nexium)|Set 3:YYD601 3 & Nexium
89430356|NCT02085213|Experimental|Glyceryl Trinitrate|"Nitrolingual Pump Spray [Coro-Nitro] A liquid within non-pressurised, red plastic-coated glass bottle fitted with a pump capable of delivering a metered dose containing 400μg of glyceryl trinitrate.~Excipients: The formulation contains fractionated coconut oil, absolute ethanol, medium chain partial glycerides and peppermint oil.~The treatment will be self administered (2 puffs) as a single intervention. No second intervention will be given."
89430357|NCT02085213|Placebo Comparator|Placebo|Matched placebo formulation (except for active ingredient of Glyceryl Trinitrate) with matched packaging and labelling.
89430358|NCT02088723|Experimental|head of bed elevation|Compare the apnea hypopnea index with the patient in standard polysomnography and in elevated polysomnography (head of bed elevation)
89430359|NCT02088801|Experimental|Airtraq, blade without channel for tracheal tube|intubation
89430360|NCT02088801|Experimental|KingVision , blade without channel for tracheal tube|intubation
89430361|NCT02088801|Experimental|A.P. Advance, blade without channel for tracheal tube|intubation
89430362|NCT02088801|Experimental|Macintosh|intubation
89430363|NCT04792294||Lung transplant recipients with chronic lung allograft dysfunction|Lung transplant recipients with chronic lung allograft dysfunction, who underwent extracorporeal photopheresis
89430364|NCT04792450||ED Patients|Patients presenting in Emergency Department
89430365|NCT04792450||ED Staff|Staff working within the Emergency Department
89430366|NCT02088879|Experimental|Group1|"first : chest compression with kneeling position~second : chst compression with standing position"
89430367|NCT02088879|Experimental|Group2|"first : chest compression with standing position~second : chst compression with kneeling position"
89430368|NCT04802278||Babies born to mothers convalescent from antenatal COVID-19|
89430369|NCT04802278||Babies born to healthy mothers|
89430370|NCT04802278||Vaccinated mothers|Lactating mothers who received COVID-19 vaccination
89430371|NCT02085291|Experimental|Resp-FL|Patients received 500 ml crystalloid for fluid challenge within 20 minutes, then a PLR test was performed to predict fluid responsiveness. If the patient was fluid responsive, more 500 ml crystalloids were given until fluid nonresponsive. If the MAP still not achieved the target value, NE was increased to achieve the target one. The target MAP was maintain MAP within 10% of the reference value.
89430372|NCT02085291|Experimental|Resp-NE|In Resp-NE group, norepinephrine was increased to enhance MAP within 10% of the reference value.
89430373|NCT02085291|Experimental|Nonresp-NE|In Nonresp-NE group, norepinephrine was increased to enhance MAP within 10% of the reference value.
89430374|NCT04792138||Men suspected of Prostate Cancer|
89430375|NCT05503641|Experimental|Experimental group|This group receives training in cognitive and psychomotricity stimulation activities.
89430376|NCT05503641|No Intervention|Control group|This group does not receive any treatment.
89430377|NCT04802122|Experimental|Sevoflurane group|Patients in this group will receive Sevoflurane 8% / O2 100% with the vital capacity breathing method (vital capacity induction, VCI) for induction to anesthesia and to facilitate endotracheal intubation (without the use of muscle relaxant) and thereafter Sevoflurane 1 MAC will be used for maintenance of anesthesia plus muscle relaxant until study completion.
89430378|NCT04802122|Active Comparator|Propofol group|Patients in this group will receive a standard anesthesia induction involving Propofol 1,5mg/Kg, supplemented by fentanyl 2mcg/Kg and rocuronium 0,5mg/Kg and O2 100% for induction to anesthesia and to facilitate endotracheal intubation and thereafter Sevoflurane 1 MAC will be used for maintenance of anesthesia.
88910415|NCT04442919|Experimental|Ticagrelor followed with methoxyflurane|patients who received ticagrelor followed with inhaled methoxyflurane due to unstable angina
88910416|NCT04442919|Active Comparator|Ticagrelor followed with morphine|patients who received ticagrelor followed with intravenous morphine due to unstable angina
88910417|NCT04442919|Active Comparator|Ticagrelor|patients who received ticagrelor without any analgesia due to unstable angina
89430379|NCT02089035|Experimental|MUFA-rich dairy products|"Subjects are asked to exchange habitual dairy products for modified MUFA-rich experimental dairy products for a 12 week period.~Participants will provided with standardised quantities of pasteurised UHT milk, cheese and butter that they will be asked to consume on a daily basis."
89430380|NCT02089035|Experimental|Conventional dairy products|"Subjects are asked to consume habitual non-modified dairy products for a period of 12 weeks.~Participants will provided with standardised quantities of pasteurised UHT milk, cheese and butter that they will be asked to consume on a daily basis."
89430381|NCT04784728|Experimental|Lidocaine topical system with swimming (Treatment A)|One topical system is applied to the mid- to upper-back for 12 hours. Subjects swim for 15 minutes in a heated pool 4 hours after topical system application.
89430382|NCT04784728|Experimental|Lidocaine topical system with showering (Treatment B)|One topical system is applied to the mid- to upper-back for 12 hours. Subjects take a 10-minute shower 8 hours after topical system application.
89430383|NCT04784728|Experimental|Lidocaine topical system under normal conditions (Treatment C)|One topical system is applied to the mid- to upper-back for 12 hours. Topical systems are not exposed to water during this period.
88820610|NCT05906940|Experimental|Health Participants|Participants in this group will be measured heart rate variability before and after transcutaneous vagus nerve stimulation.
88820611|NCT05904938|Experimental|Lenodiar Pediatric|Medical Device
88820612|NCT05904938|Placebo Comparator|Placebo|Placebo
88820613|NCT05899998|Experimental|Bright IDEAS|
88820614|NCT05899998|No Intervention|Standard of Care|
88820615|NCT05894395|Experimental|MMR Booster Vaccination Arm|Participants (adults 18+ having previously received 2 lifetime doses of MMR-containing vaccine) will receive a single MMR booster vaccination (3rd lifetime dose) as M-M-R-VaxPro.
88820616|NCT05894395|No Intervention|Observational Arm|Participants (adults 18+ having previously received 2 lifetime doses of MMR-containing vaccine) will be assessed at study enrollment and at a 1 year follow-up visit
88820617|NCT05893823||Cases|Patients that have symptomatic psoas impingement in a protruding acetabular cup documented by a Pelvis CT scan
88820618|NCT05893823||Controls|Asymptomatic patients with a protruding acetabular cup documented by a Pelvis CT scan
88820619|NCT05889988||HER2 Metastatic Group|HER2 Metastatic Setting (defined by breast cancer that has spread outside of the breast and the immediately draining lymph node regions; stage IV)
88820620|NCT05889988||HER2 Adjuvant Group|HER2 Adjuvant Setting (defined by breast cancer that is not known to have spread outside of the breast and the immediately draining lymph node regions; stages I-III). The Adjuvant Setting includes patients receiving neoadjuvant therapy.
88820621|NCT05886764|No Intervention|Arm 1 (No Intervention)|"Patient participants in this arm will receive no intervention but will be approached by their providers for participation in treatment clinical trials as per the usual methods.~Provider participants will receive information on available clinical trials for which their patient participant may be eligible from study staff per usual methods. Provider participants will be asked to complete surveys."
88820622|NCT05886764|Experimental|Arm 2 (Digital Intervention)|"Patient participants in this arm will receive digital messages (email, text, etc.) which include general educational information about clinical trials and available resources.~Provider participants will also receive digital messages with educational materials and will receive information on available clinical trials for which their patient participant may be eligible from study staff per usual methods. Provider participants will be asked to complete surveys."
89430384|NCT04791982|Experimental|Experimental group|
89008425|NCT04593706|Active Comparator|keloids|each patient will be injection by all 4 steroids for comparison patients with 4 or more keloids will be injection with each steroid for different keloid
89430385|NCT04791982|No Intervention|Control group|
89430386|NCT02085525|Other|Weekly NP Visits|100 HNC (Head and Neck Cancer) patients seen weekly in a Nurse Practitioner (NP) led symptom management clinic for supportive care.
89430387|NCT02085525|Other|Every Other Week NP Visits|100 HNC (Head and Neck Cancer) patients seen every other week in a Nurse Practitioner (NP) led symptom management clinic for supportive care.
89430388|NCT05615272|Experimental|Bio-PRF|This is a blood-derived platelet rich concentrate from the patient's whole blood sample. The patient typically donates two 9ml (1.5 tablespoons) vials of blood that is then spun in a centrifuge.
88910418|NCT04441593|Experimental|Intervention|Videoconferencing Intervention for Heavy Drinking and Chronic Pain
88910419|NCT04441593|Active Comparator|Control|Treatment as Usual
89008426|NCT04593706|Active Comparator|hypertrophic scars|each patient will be injection by all 4 steroids for comparison patients with a 11 cm hypertrophic scar will be injected by all 4 steroids along the scar with a 1 cm distance between each steroid
89430389|NCT05615272|Active Comparator|Alveogyl|Alveogyl is an intraalveolar sedative, obtundent dressing, which contains the active ingredient eugenol.
89430390|NCT02085603|Active Comparator|Saracatinib|Saracatinib at a dose of 125mg orally will be administered daily for four weeks.
89430391|NCT02085603|Placebo Comparator|Placebo|Placebo tablet to be orally administered daily for four weeks.
89430392|NCT02090829|Placebo Comparator|Placebo Group|"Placebo Comparator: Intranasal Placebo Intranasal placebo The placebo is identical to the oxytocin formulation with the exception of the active compound.~Route of administration: Intranasal Planned exposure: Each participant will receive one dose of intranasal placebo per day for 5 days.~One dose equals 6 spray puffs (3 puffs in each nostril)."
89430393|NCT02090829|Active Comparator|Experimental Group|"Intranasal oxytocin (Trade name: Syntocinon) Pharmacological class: The pharmacologic and clinical properties of Syntocinon are identical with the naturally occurring hormone oxytocin, which is released from the posterior pituitary.~Route of administration: Intranasal Planned exposure: Each participant will receive one dose of intranasal oxytocin (24 IU) per day for 5 days.~One dose of 24 IU equals 6 spray puffs (3 puffs in each nostril). Oxytocin will be imported from Victoria Pharmacy Zurich- Switzerland."
89430394|NCT04785040||1|
89430395|NCT02791659|Active Comparator|Left lateral decubitus|In this group, the position will be assigned to Left lateral decubitus during ERCP. The radiation from fluoroscopy will be adjusted by automatic beam adjustment function to obtain the image quality.
89008427|NCT04593667|Other|Full Inflation|100% TR Band inflation relative to recommended inflation with 15-18 cc air injected in TR band bladder
89008428|NCT04593667|Other|Mid Inflation|75% TR Band inflation relative to recommended inflation with 11-14 cc air injected in TR band bladder
89008429|NCT04593667|Other|Low Inflation|50% TR Band inflation relative to recommended inflation with 8-9 cc air injected in TR band bladder
89008430|NCT04593355||HCV|
89430396|NCT02791659|Experimental|Prone|In this group, the position will be assigned to Prone during ERCP. The radiation from fluoroscopy will be adjusted by automatic beam adjustment function to obtain the image quality.
89430397|NCT04784494|Experimental|Magnetic Seizure Therapy|MST treatments will be administered using the MagPro XP MST with Cool TwinCoil.
89430398|NCT02090907|Experimental|Levothyroxin|In the treatment group, daily doses of 100 mg of Levothyroxine will be administered every morning, half an hour before breakfast.
89430399|NCT02090907|Placebo Comparator|Placebo|In the placebo group treatment regimen and advices are identical to that of the treatment group, except for using a pharmacologically neutral agent, with complete resemblance to the real treatment.
89430400|NCT04801888|Experimental|Combined immunization group|The combined immunization group is randomly divided into two subgroups, 120 subjects in each group. The combined immunization subgroup Ⅰ receive SARS-CoV-2 inactivated vaccine (Vero cell)&Quadrivalent Influenza Vaccine on day0 and SARS-CoV-2 inactivated vaccine (Vero cell) (second dose) on day 28.The combined immunization subgroup Ⅱ receive SARS-CoV-2 inactivated vaccine (Vero cell) on day 0 and SARS-CoV-2 inactivated vaccine (Vero cell) (second dose) & Quadrivalent Influenza Vaccine on day 28.
89430401|NCT04801888|Experimental|Non combined immunization group|The non combined immunization group receive SARS-CoV-2 inactivated vaccine (Vero cell)(first dose) on day 0, Quadrivalent Influenza Vaccine on day 14 and SARS-CoV-2 inactivated vaccine (Vero cell)(second dose) on day 28.
89430402|NCT02089503||induction phase + intravitreal inj.|Group of patients who received Lucentis ® with induction phase
89430403|NCT02089503||intravitreal inj. without induction|Group of patients who received Lucentis ® without induction phase
89430404|NCT02089503||intravitreal inj. + monthly follow-up|group of patients who were monthly monitored (+/- 1 week)
89430405|NCT02089503||intravitreal inj. + follow-up :> 1 month|group of patients with Follow up visits intervals> 1 month (+/- 1 week)
89430406|NCT02089503||intravitreal inj +induction+ month. FU|Group of patients who received Lucentis with induction phase and who were monthly monitored (+/- 1 week)
89430407|NCT02089503||date Lucentis® 1st intravitreal Inj.|Group of patients selected in accordance with the date of Lucentis® treatment start.
89430408|NCT02090985|Experimental|Lipomodelling|Lipomodelling of peri-stomal skin contour abnormalities
89008431|NCT04593238|Experimental|Double antibiotic paste intra-canal medication group (n=25)|500 mg Metronidazole tablet+ 500 mg Ciprofloxacin tablet crushed into powder and mixed together with salline to form a creamy mix to be placed inside the root canal for 1 week.
89430409|NCT02594098|Experimental|Secukinumab|Secukinumab (300 mg) via subcutaneous injection using 2 prefilled syringes
89430410|NCT02594098|Placebo Comparator|Placebo|Placebo via subcutaneous injection using 2 prefilled syringes
89008432|NCT04593238|Active Comparator|Calcium hydroxide intra-canal medication group (n=25)|Calcium hydroxide paste (Metapaste) placed inside the root canal for 1 week
89008433|NCT04593316||Exertional heatstroke group|Patients presenting or having presented exertional heatstroke.
89008434|NCT04593316||Control group|Healthy people who never experienced exertional heatstroke.
89008435|NCT04593433|Experimental|Intervention|Group with the virtual museum guided tours
89430411|NCT02091063|Experimental|Phase Ib: Arm A: ACY-1215 QD|Phase Ib: ACY-1215 160mg PO QD
89430412|NCT02091063|Experimental|Phase Ib: Arm B: ACY-1215 BID|Phase Ib: ACY-1215 160mg PO BID
89430413|NCT02091063|Experimental|Phase II: ACY-1215|Phase I dosing schedule has been determined. 160 mg BID dosing will be administered for Phase II.
89430414|NCT02091219|Experimental|25(OH)D3|20 micrograms/day by mouth for 16 weeks
89430415|NCT02091219|Experimental|Vitamin D3|2,400 IU/day by mouth for 16 weeks
89430416|NCT02593864|Experimental|Variable-Stiffness Shoe|Subjects will wear a load-modifying variable-stiffness shoe for 6 months
89430417|NCT02091297|Active Comparator|TAP BLOCK|One unique regional technique for lower abdominal surgery, that has been shown effective for Cesarean Section in particular, is the transversus abdominis plane (TAP) block, which blocks T6-L1 sensory nerve branches and provides anesthesia to the anterior abdominal wall. The TAP block has been recommended and shown in case reports, but not clinically studied with trials, for patients on methadone or buprenorphine, to improve post-operative pain control. A long active local anesthetic, called ropivacaine, will be used to provide this anesthesia.
89430418|NCT02091297|Active Comparator|Common Care|Common care refers to the common way pain is treated after Cesarean Section: a long-acting spinal or epidural opioid such as morphine, plus oral and IV opioids and non-narcotic adjuncts such as non-steroidal anti-inflammatory drugs and acetaminophen. Due to the potential issues such as ineffectiveness and fear of respiratory depression, increasing the dosing of these opioids may not be ideal.
89430419|NCT02091297|Active Comparator|Patient Controlled Epidural Analgesia|For post-Cesarean analgesia, another regional technique that has been employed for superior pain control is continued epidural analgesia with local anesthesia and an opioid, either in addition or instead of long acting neuraxial opioids (Cohen). One study revealed equal analgesic efficiency, higher patient satisfaction scores, and less side effects with patient controlled epidural ropivacaine compared to epidural morphine (Chen). This is an especially attractive option for opioid dependent patients, but like the TAP block, has been not studied whether or not it lessens acute or chronic postoperative cesarean section, in the setting or in the absence of neuraxial opioids.
89430420|NCT02091453|Experimental|attention training acute|20 hours of attention training, APT training, or multiprofessional rehabilitation
89197629|NCT00942682|Experimental|Sorafenib and RAD001|"Since we are looking for the highest dose of the study drug that can be administered safely without severe or unmanageable side effects in participants that have neuroendocrine tumors, not everyone who participates in this research study will receive the same dose of the study drug. The dose the participant will be given will depend on the number of participants who have been enrolled in the study.~Each treatment cycle lasts 28 days. Participants will take RAD001 orally once a day in the morning. Participants will take sorafenib orally twice daily.~Participants will remain on this research study as long as they continue to benefit from the study medications."
89430421|NCT02091453|Experimental|attention training subacute|20 hours of attention training, APT training, or multiprofessional rehabilitation
89430422|NCT04760470|Experimental|Technological-assisted upper extremity rehabilitation|Technological-assisted upper extremity rehabilitation.
89008436|NCT04593511|Experimental|Formulation 1|a single dose of LY03009 F1
89008437|NCT04593511|Experimental|Formulation 2|a single dose of LY03009 F2
89008438|NCT04593511|Experimental|Formulation 3|a single dose of LY03009 F3
89008439|NCT04593511|Experimental|Formulation 4|a single dose of LY03009 F4
89008440|NCT00566839|Experimental|1|
89008441|NCT00566839|Active Comparator|2|
89008442|NCT04593160|Experimental|Diclofenac potassium- acetaminophen combination|Preoperative single dose of diclofenac potassium(50mg)- acetaminophen(1000mg) combination
89430423|NCT04760470|No Intervention|Wait list control|Continue their normal lives.
89430424|NCT02091609|Experimental|group : implants and oral hygiene|dental floss
89008443|NCT04593160|Experimental|Diclofenac potassium|Preoperative single dose of diclofenac potassium(50mg)
89008444|NCT04593160|Placebo Comparator|Placebo|Preoperative single dose of placebo
89008445|NCT04592965|Experimental|Clinical and neuropsychological examinations|Participants will be assessed by means of validated and lab-tailored clinical scales, alongside with semi-structured interviews, to assess the status of the disease (PD), amongst others, such as cognitive capabilities.
89008446|NCT04592965|Experimental|Robot induced PH, through sensorimotor stimulation|Participants will manipulate a patented robotic system designed to induce the PH and other accompanying bodily illusions. At the end, participants will report on various subjective experiences, by answering a structured questionnaire.
89008447|NCT04592965|Experimental|Resting-state fMRI acquistion|We will acquire resting-state data in the MRI scanner for all the participants. Respiration and heart beat rate data will also be acquired.
89430425|NCT02091609|Experimental|implants and oral hygiene|dental interproximal brush
89430426|NCT04784338|Experimental|Virtual shared teaching kitchen program|Participants will participate in virtual shared medical appointments that utilize the teaching kitchen
89430427|NCT03557073|Experimental|Phone Call|Subjects in this study arm receive a post-operative phone call by a physician.
89430428|NCT03557073|No Intervention|No Phone call|Subjects in this study arm do not receive an additional post-operative phone call by a physician.
89430429|NCT04791592|Active Comparator|Group PIFB|PIF block (20 ml, 0.25% bupivacaine + 1:400.000 adrenaline) + IV morphine-PCA
89430430|NCT04791592|Active Comparator|Group TTMPB|TTMP block (20 ml, 0.25% bupivacaine + 1:400.000 adrenaline) + IV morphine-PCA
89430431|NCT02091765|No Intervention|Minimal intervention control group|Women who are assigned to the control group will be contacted by telephone by a member of the study staff to inform them about this allocation. They will receive a booklet per mail that addresses 80 questions about sexuality and cancer. Six weeks later, they will receive an empathetic phone call from one of the sexologists, during which there is also time available to discuss further questions the participants may have concerning sexuality and cancer. The purpose of keeping in contact with the control group, as opposed to a pure waiting list control group, is creating the opportunity to provide some control for a possible attention placebo-effect. The final questionnaire will be completed twenty weeks post study entry, after which women will be given the opportunity to undergo the internet-based cognitive behavioral program.
89430432|NCT02091765|Experimental|Internet-based cognitive behavioral therapy|"Each woman who is allocated to the intervention group is assigned a personal sexologist (therapist) who guides her through the internet-based cognitive behavioral therapy (CBT) program and provides feedback on the homework assignments. The CBT program comprises a maximum of ten treatment modules that can be used in varying order. Each module contains three interventions and a personal evaluation form to report on the intervention. Each intervention comprises the following elements: 1) introduction, 2) psycho-education about symptoms, 3) homework assignments (e.g. relaxation techniques (pelvis); discuss intimacy with partner; sensate focus) and 4) reporting back to the therapist and receiving feedback on the homework assignments. Each week there are two practice sessions of 30 minutes each and one hour per week to report on/evaluate the intervention. The therapy has a mean duration of 20 weeks."
89430433|NCT04791202|Experimental|Dextrose Group|Injection for Group A: A 27-gauge needle to be inserted in the 1st CMC joint, at which time 0.5 ml of 15% dextrose mixed with 0.5 ml of 1% lidocaine solution is injected into intra and peri-articular area.
89430434|NCT04791202|Active Comparator|Methylprednisolone Acetate Group|Injection for Group B: A 27-gauge needle to be inserted in the 1st CMC joint, at which time 0.5 ml of 40mg methylprednisolone acetate mixed with 0.5 ml of 1% lidocaine solution is injected into intra and peri-articular area.
89430435|NCT02085681|Experimental|Tele-medicine|Tele-medicine aided retinal imaging and referral to eye hospital
89430436|NCT02085681|Other|Conventional Referral|Patients will be counselled on the importance of eye examination and will be referred to the eye hospital in the conventional manner.
89430437|NCT04801342|Experimental|Unilateral Hippocampal Avoidance WBRT with Memantine|Conformal whole brain radiotherapy with unilateral hippocampal avoidance and Concurrent use of Memantine HCL
89430438|NCT04801342|Active Comparator|Bilateral Hippocampal Avoidance WBRT with Memantine|Conformal whole brain radiotherapy with bilateral hippocampal avoidance and Concurrent use of Memantine HCL
89430439|NCT02085759||Normal BMI|Subjects with a BMI range of 18.5 to 24.9 which is defined by the CDC as within normal range.
89430440|NCT02085759||Overweight BMI|Subjects with a BMI of 25.0 to 29.9 are defined by the CDC as being overweight.
89430441|NCT02085759||Obese BMI|Subjects with a BMI of 30.0 and above are defined by the CDC as being obese.
89430442|NCT04801264|Experimental|68Ga-PSMA, PET/CT and 177Lu-EB-PSMA-617 therapy|All patients diagnosed with ACC underwent 68Ga-PSMA PET/CT scan. If the PET/CT showed high PSMA expression in tumor lesions of some patients, they would intravenously injected with the dose about 1.85GBq (50 mCi) of 177Lu-EB-PSMA-617 for therapy.
89430443|NCT02085837|Experimental|Healthy Transitions Group|"Additional nursing services will be provided to this group in addition to a usual care by Nephrologist.~Daily weight measurement and monitoring~Medication review~Universal dietary education~Focused advanced directive program~Countdown to fistula program"
89430444|NCT02085837|No Intervention|Usual Care Group|Usual care by nephrologist. No additional nursing support services will be provide to this group.
89430445|NCT02590588|Experimental|Idelalisib|Idelalisib 100 mg twice daily with possible escalation after 3 months to 150 mg twice daily at investigator discretion.
89430446|NCT02085915|Other|strip Peri Screen|
89430447|NCT02085993||single arm|single arm study
89430448|NCT02086071|Other|Re biopsies feasibility|the Interest of the study is to evaluate the feasibility of the re biopsy; the re biopsy is done if the patient agrees to perform it.
89430449|NCT03558399|Experimental|FET according to ERA|In preparation for frozen embryo transfer (FET), estradiol will be administered for approximately 10 to 14 days or until endometrial criteria are met. These endometrial criteria will be assessed with transvaginal ultrasound and serum estradiol levels. Women will then begin intramuscular progesterone injection and if assigned to the study arm, a single euploid embryo will be transferred at the time indicated by the ERA test results. Merely the timing of embryo transfer will distinguish the study from the control group.
89430450|NCT03558399|Active Comparator|FET according to standard protocol|In preparation for frozen embryo transfer (FET), estradiol will be administered for approximately 10 to 14 days or until endometrial criteria are met. These endometrial criteria will be assessed with transvaginal ultrasound and serum estradiol levels. Women will then begin intramuscular progesterone injection and if assigned to the control arm, a single euploid embryo will be transferred according to our standard FET protocol.
89430451|NCT02086149|Experimental|Exercise|12-week moderate-intensity behavioral exercise intervention (AE)
89430452|NCT02086149|Active Comparator|Health Education|12-week health education control
89430453|NCT02086227|Experimental|A Glucagon for Injection, Fresenius Kabi USA|The subjects will be administered the test (A) (Glucagon for Injection, Fresenius Kabi USA)or reference (B) product (GlucaGen® for Injection, Bedford Laboratories) according to a two treatments, four periods replicate crossover, randomized design with two sequences (BABA and ABAB, the Left-Right site of injection for each period and treatment will be randomized.
89430454|NCT02086227|Active Comparator|B GlucaGen® (Bedford Laboratories)|The subjects will be administered the test (A) Glucagon for Injection, Fresenius Kabi USA; or reference (B) product, GlucaGen® (Bedford Laboratories) according to a two treatments, four periods replicate crossover, randomized design with two sequences (BABA and ABAB, the Left-Right site of injection for each period and treatment will be randomized.
89197630|NCT00853515|Experimental|1|Goal-directed fluid resuscitation with lactated Ringer's solution
89197631|NCT00853515|Experimental|2|Goal-directed fluid resuscitation with normal saline
89430455|NCT03558321|Experimental|post menopausal bleeding|women with postmenopausal bleeding and endometrial thickness more than 5 mm
89430456|NCT02086305|Experimental|Usual Care + Transitional Care Model|Transitional Care, Evidence-based symptom management, Protocol-driven home visit and telephone follow-up, Trained nurse case manager and volunteer partnership
89430457|NCT02086305|Active Comparator|Usual Care|Usual care
89430458|NCT02086383||Patients with COPD|This is an observational study of patients with chronic obstructive pulmonary disease (COPD) who attend pulmonary rehabilitation, which is the routine standard of care in Guy's and St. Thomas' Hospital, London. It lasts for 14 sessions, twice a week and primarily consists of a supervised exercise program and educational sessions.
89430459|NCT02086461|Sham Comparator|15 mm Pyloric balloon dilatation.|During fluoroscopic control the pneumatic balloon is positioned of the pyloric sphincter and maintained there during the entire dilatation.
89430460|NCT02086461|Active Comparator|Pneumatic pyloric dilatation.|Endoscopy and 15 mm balloon dilatation is completed according to the same principle as active comparator arm.
89430461|NCT02086539|No Intervention|Normal Letter|This arm will receive the recruitment letter in a business sized envelope. The letter states the participant will receive a $25 check upon enrollment into the study.
88910420|NCT04440982|Experimental|Device Intervention: LUM Imaging System used during surgery|The LUM Imaging Device will be used to look inside the lumpectomy cavity to see if the dye indicates any areas that may contain residual tumor. If the imaging identifies that there may be cancer cells remaining in the lumpectomy cavity, the surgeon will remove an additional piece of tissue. This process will be continued until a negative reading from the device is obtained or a maximum of 2 shaves of additional tissue has been removed. Patients in this arm will receive the study drug, LUM015
88910421|NCT04440982|No Intervention|Standard of Care Arm|The LUM Imaging Device will not be used to guide additional tissue removal. Patients in this arm will receive the study drug, LUM015.
88910422|NCT04440358|Experimental|Exablate BBBD with carboplatin|Carboplatin will be administered via IV infusion about every 4 weeks for up to 6 cycles. The dosage will be calculated based on subject's creatinine level. On the day of planned carboplatin therapy, subjects will undergo Exablate procedure to open the blood-brain-barrier in the targeted cancerous brain areas prior to carboplatin administration.
88910423|NCT04430699|Experimental|Pembrolizumab, Cisplatin and Radiation Therapy|"Treatment period is 36 weeks with 21 day study cycles.~Participants will receive cisplatin at a predetermined dose 1x weekly, pembrolizumab at a predetermined dose every 3 weeks, concurrently with daily radiation therapy from week 1 up to week 8.~First 3 participants on the study, may skip 1 or 2 pembrolizumab dosages while receiving radiation therapy.~Following completion of daily radiation therapy with 1x weekly cisplatin and 1x every 3 weeks pembrolizumab, participants will continue at a pre-determined maintenance dose of pembrolizumab 1x every 3 weeks for a total of 12 cycles or 36 weeks."
88910424|NCT04430348|Experimental|PTX-35 Dose Level 1|Dose Level 1: PTX-35 0.01 mg/kg
88910425|NCT04430348|Experimental|PTX-35 Dose Level 2|Dose Level 2: PTX-35 0.03 mg/kg
88910426|NCT04430348|Experimental|PTX-35 Dose Level 3|Dose Level 3: PTX-35 0.10 mg/kg
88910427|NCT04430348|Experimental|PTX-35 Dose Level 4|Dose Level 4: PTX-35 0.30 mg/kg
88910428|NCT04430348|Experimental|PTX-35 Dose Level 5|Dose Level 5: PTX-35 1.0 mg/kg
88910429|NCT04430348|Experimental|PTX-35 Dose Level 6|Dose Level 6: PTX-35 3.0 mg/kg
88910430|NCT04427384||GammaTile|Patients who have received permanent implants of GammaTile radiation therapy immediately following brain tumor resection.
88910431|NCT04424979|Experimental|High power prisms|Various configurations of high power prisms will be developed for each individual and custom fit into spectacles lenses.
88910432|NCT04423211|Active Comparator|Arm A (EBRT, short-term androgen deprivation therapy [STAD])|"STEP 0: Patients undergo SOC PET/CT or PET/MR scan at baseline. Patients randomized to Arms C or D and receiving fluciclovine F18 IV undergo a repeat PET2 at time of PSA progression or clinical concerns for progression or 12 months after completion of enhanced systemic therapy, whichever occurs first. Patients in Arm C or D using another tracer for PET1 do not undergo PET2.~STEP 1: Patients who are PET negative for extera pelvic metastases undergo SOC EBRT for 6 months. Patients also receive goserelin acetate SC, leuprolide acetate IM, triptorelin IM, relugolix PO, or degarelix SC for 6 months starting up to 3 months prior to EBRT but no later than 7 days after start of EBRT. All treatment continues for 6 months in the absence of disease progression or unacceptable toxicity."
88922244|NCT05597787|Experimental|Project ECHO for HIV Prevention + Stigma Reduction|Participants randomized to this condition will receive the Project ECHO for HIV Prevention intervention with added evidence-based stigma reduction tools. Participants will meet with the Project ECHO Hub specialists and their learning community on a bi-weekly basis for 60 minutes over the course of 9 months. Each session will feature a didactic training incorporating standardized procedures for HIV testing, prevention, and/or linkage to care, and patient-case presentation and discussion.
88922245|NCT05593614|Experimental|ATX01 10%|A bottle of hydrogel formulation containing 10% amitriptyline hydrochloride w/w for topical use on the hands and/or feet, morning and night for 3 months.
89430462|NCT02086539|Experimental|Large Envelope|This arm will receive the recruitment letter in an 8.5 x 11 inch envelope. The letter states the participant will receive a $25 check upon enrollment into the study.
89430463|NCT02086539|Experimental|Priority Mail|Group 3 will receive a recruitment letter shipped via USPS priority mail. The letter states the participant will receive a $25 check upon enrollment into the study.
89430464|NCT02086539|Experimental|Amazon|This arm will receive a recruitment letter with the image of an Amazon gift card and told they will receive the $25 gift card if they enroll in the study.
89430465|NCT02086617|Other|ultrasound of aorta|
89430466|NCT02086695||Cancer Group|All subjects with cancer who will be treated with anyone of the following chemotherapy drugs; Pazopanib, Sutent or Bevacizumab
89430467|NCT02086773|Experimental|Low transfusion threshold|Patients receive red blood cell transfusions with a transfusion threshold of 7 g/dL hemoglobin (Hb). Transfusions will not be given on schedule but will be given whenever Hb dips below the threshold.
89531178|NCT05033691|Experimental|Early SRS treatment with SoC|Stereotactic surgery (SRS) to the brain metastases and continuation of Osimertinib, at 2 month (8 weeks) post Osimertinib start
88922246|NCT05593614|Experimental|ATX01 15%|A bottle of hydrogel formulation containing 15% amitriptyline hydrochloride w/w for topical use on the hands and/or feet, morning and night for 3 months.
89430468|NCT02086773|Active Comparator|High transfusion threshold|Patients receive red blood cell transfusions with a transfusion threshold of 8 g/dL hemoglobin (Hb). Transfusions will not be given on schedule but will be given whenever Hb dips below the threshold.
89430469|NCT02089581|Active Comparator|Drug|MR2XXX
89430470|NCT02089581|Experimental|MRXXX|MRXXX capsule 12 hourly
89430471|NCT02089581|Experimental|MR1XXX|MR1XXX capsule, 12 hourly
88910433|NCT04423211|Experimental|Arm B (EBRT, STAD, apalutamide)|"STEP 0: Patients undergo SOC PET/CT or PET/MR scan at baseline. Patients randomized to Arms C or D and receiving fluciclovine F18 IV undergo a repeat PET2 at time of PSA progression or clinical concerns for progression or 12 months after completion of enhanced systemic therapy, whichever occurs first. Patients in Arm C or D using another tracer for PET1 do not undergo PET2.~STEP 1: Patients who are PET negative for extra pelvic metastases undergo SOC EBRT and receive goserelin acetate SC, leuprolide acetate IM, triptorelin IM, relugolix PO, or degarelix SC as in Arm A. Patients also receive apalutamide PO QD for 6 months in the absence of disease progression or unacceptable toxicity."
88910434|NCT04423211|Experimental|Arm C (EBRT, STAD, apalutamide)|"STEP 0: Patients undergo SOC PET/CT or PET/MR scan at baseline. Patients randomized to Arms C or D and receiving fluciclovine F18 IV undergo a repeat PET2 at time of PSA progression or clinical concerns for progression or 12 months after completion of enhanced systemic therapy, whichever occurs first. Patients in Arm C or D using another tracer for PET1 do not undergo PET2.~STEP 1: Patients who are PET positive for extra pelvic metastases undergo SOC EBRT and receive goserelin acetate SC, leuprolide acetate IM, triptorelin IM, relugolix PO, or degarelix SC as in Arm A. Patients also receive apalutamide PO QD as in Arm B."
88910435|NCT04423211|Experimental|Arm D (EBRT, STAD, apalutamide, RT)|"STEP 0: Patients undergo SOC PET/CT or PET/MR scan at baseline. Patients randomized to Arms C or D and receiving fluciclovine F18 IV undergo a repeat PET2 at time of PSA progression or clinical concerns for progression or 12 months after completion of enhanced systemic therapy, whichever occurs first. Patients in Arm C or D using another tracer for PET1 do not undergo PET2.~STEP 1: Patients who are PET positive for extra pelvic metastases undergo SOC EBRT and receive goserelin acetate SC, leuprolide acetate IM, triptorelin IM, relugolix PO, or degarelix SC as in Arm A and apalutamide PO QD as in Arm B. Patients also undergo SBRT or 3D CRT, IMRT (including VMAT), and IMPT over 3-10 fractions in the absence of disease progression or unacceptable toxicity."
88910436|NCT04420676|Active Comparator|Probiotic|Group 1: receiving a probiotic mixture (Omni-Biotic® 10 AAD) twice a day
88910437|NCT04420676|Placebo Comparator|Placebo|Group 2: receiving a similar looking and tasting placebo without bacteria twice a day
88910438|NCT04420468||Possible COVID-19 infection and acute myocarditis|"Children presented with an acute myocarditis, fever and shock with a possible COVID-19 infection cared between April 2020 till the end of the main SARS-Cov-2 outbreak in 4 AP-HP Parisian hospitals :~Necker-Enfants Malades~Armand Trousseau~Robert Debré~Kremlin Bicêtre"
88910439|NCT04412083|Other|PPA Tele-Savvy Pilot Intervention|The Tele-Savvy program is comprised of weekly, two-hour interactive classes, over seven consecutive weeks, the same duration as the proposed intervention. Tele-Savvy consists of educational instruction, video and in-class exercises that engage participants on a functional level. Course material was designed to provide informal caregivers with the knowledge, skills, and attitude needed to carry out their role as a caregiver for a person living with dementia (PLWD). Course learning objectives include: 1) introduction to dementing disorder; 2) caregiver self-care; 3) the anchors of contented involvement; 4) levels of thinking and performance; 5) strengthening the family as a resource for caregiving; and 6) review and integration of the previous sections.
88910440|NCT04408638|Experimental|Glofit-GemOx|Participants will receive up to 8 cycles of glofitamab (Glofit) in combination with gemcitabine and oxaliplatin (GemOx), followed by up to 4 cycles of glofitamab monotherapy. A single dose of obinutuzumab will be administered 7 days prior to the first dose of glofitamab. Treatment is administered in 21-day cycles.
88910441|NCT04408638|Experimental|R-GemOx|Participants will receive rituxumab (R) in combination with gemcitabine and oxaliplatin (GemOx) for up to 8 cycles. Treatment is administered in 21-day cycles.
88910442|NCT04402996||Healthy|Individuals with Periodontally Healthy
88910443|NCT04402996||Gingivitis|Individuals with Gingival Inflammation
89430472|NCT02089581|Experimental|Experimental|Experimental Fed
89430473|NCT02086851|Experimental|Lifestyle Intervention plus Parent Motivational Interviewing|Lifestyle intervention + Parent MI
89430474|NCT02086851|Active Comparator|Lifestyle Intervention alone|lifestyle intervention alone
89430475|NCT02086929|Experimental|Trazodone|"300 mg/day for 8 weeks (including 1 week 150 mg/day of dose-titration). After 3 and 5 weeks of treatment, non responders will have dose increases (in increments of 75 mg/day) till to reach the maximum of 450 mg/day.~Dosage form: capsule."
89430476|NCT02086929|Active Comparator|Venlafaxine XR|"75 mg/die for 8 weeks. After 3 and 5 weeks of treatment, non responders will have dose increases (in increments of 75 mg/day) till to reach the maximum of 225 mg/day.~Dosage form: capsule."
89430477|NCT02248545||Non-celiac Wheat Sensitivity Patients|Consecutive adult patients with irritable bowel syndrome (IBS)-like clinical presentation, according to Rome II criteria, and a definitive diagnosis of NCWS.
89430478|NCT02248545||Celiac Disease Patients|Celiac disease adult patients, sex- and age-matched, diagnosed according to standard criteria, during the same study period, chosen at random and enrolled as first control group.
89430479|NCT02248545||Irritable Bowel Syndrome Patients|"Irritable Bowel Syndrome adult patients, sex- and age-matched, diagnosed according to Rome II criteria, and unrelated to NCWS or other food intolerance, during the same study period, chosen at random and enrolled as second control group."
89430480|NCT02249013|Experimental|HIPEC|Neoadjuvant Chemotherapy (NACT) followed by Cytoreductive Surgery (CRS) under a Fast-track recovery strategy plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and thus, Adjuvant Chemotherapy
89430481|NCT03557541|Experimental|Sardine group|
89430482|NCT03557541|Active Comparator|Control group|
89430483|NCT02249871|Experimental|Semaglutide|
89430484|NCT02249871|Experimental|Semaglutide + Omeprazole|
89430485|NCT02087007|Experimental|group 1|Cilostazol 50mg, Cilostzaol 100mg
89430486|NCT02087007|Placebo Comparator|group 2|placebo
89430487|NCT05500209|Experimental|Coping Self-Efficacy|Experimental condition enhancing coping self-efficacy
89430488|NCT05500209|No Intervention|Waitlist control|Waitlist control condition
89430489|NCT02089815|Experimental|Home based exercise|simple designed home based exercise program
89430490|NCT02089815|Active Comparator|fall prevention education and counseling|fall prevention education & counseling : home modification, vision screening, avoid sedative drugs use, proper shoes, report dizziness and fall to doctors
89430491|NCT02087319|Experimental|platelet-rich plasma|hair loss, baldness
89430492|NCT01434602|Experimental|1/Phase I|Daily everolimus (days 1- 28) in combination with sorafenib as per the Phase I dosing table. Maximum tolerated dose. Dose Escalation.
88910444|NCT04402996||Periodontitis|Individuals with Periodontitis
88910445|NCT04400994|Active Comparator|Rituximab only|"Rituximab infusion 375mg/m2 body surface area (BSA) weekly for 4 weeks from baseline (week 0, 1, 2, 3)~Rituximab infusion 375mg/m2 BSA weekly for 4 weeks at week 24 (week 24, 25, 26, 27)~Rituximab infusion 375mg/m2 BSA weekly for 2 weeks at week 52 (week 52, 53)~Rituximab infusion 375mg/m2 BSA weekly for 4 weeks at week 76 (week 76, 77)~A total of 12 doses of rituximab will be given in 55 weeks"
88910446|NCT04400994|Experimental|Rituximab and IVIG|"Rituximab (375 mg/m2 BSA) once a week for 4 weeks (week 1, 2, 3);~Week 4: Rituximab + IVIG 2g per kg~Week 5, 6, 7: Above treatment repeated for 2nd cycle, infusion of rituximab (375 mg/m2 BSA) once a week for 4 weeks (week 5, 6, 7);~Week 8: Rituximab + IVIG 2g/kg~In months 3, 4, 5, 6, patients received a single infusion of rituximab (375 mg/m2 BSA) plus infusion of 2g/kg IVIG~Thus in 6-month period patients received a total of 12 infusions of rituximab and 7 infusions of IVIG~If a patient was clinically free of disease at end of 6 months, additional infusions of IVIG will be given at week 30, 38, 48, 60 and 76~A total of 12 doses of rituximab and 12 cycles of IVIG will be given"
88910447|NCT04396860|Active Comparator|Arm I (radiation therapy, temozolomide)|Patients undergo radiation therapy for 5 days per week (Monday-Friday) for a total of 30 fractions over 6 weeks and simultaneously receive temozolomide PO daily for 6 weeks. After radiation, patients may wear the Optune device at the discretion of the patient and their treating physician. Beginning 1 month after radiation therapy, patients receive temozolomide on days 1-5. Treatment repeats every 28 days for up to 12 cycles at the discretion of the treating investigator in the absence of disease progression or unacceptable toxicity. Patients also undergo contrast-enhanced brain MRI throughout the trial.
88910448|NCT04396860|Experimental|Arm II (radiation therapy, ipilimumab, nivolumab)|Patients undergo radiation therapy for 5 days per week (Monday-Friday) for a total of 30 fractions over 6 weeks. Starting on the first day of radiation, patients also receive ipilimumab IV over 90 minutes Q4W for 4 doses and nivolumab IV over 30 minutes every 2 weeks until disease progression. Patients also undergo contrast-enhanced brain MRI throughout the trial.
88910449|NCT04396288|Experimental|Healthy volunteers|
88910450|NCT04390841|Experimental|Single Arm ( Qubic Stim Cardiac Stimulator )|There is only one Arm in this trial, the subjects who meet the inclusion and exclusion criteria will receive the intracardiac electrophysiological examination, during which the subjects will be subject to diagnostic electrical stimulation by the Qubic Stim Cardiac Stimulator. The subjects will also receive the clinical follow-up visit after cardiac electrical stimulation until they are discharged from the hospital.
88910451|NCT04377594|Experimental|Pulmonary vein isolation plus substrate modification|Pulmonary vein isolation plus ablation of low voltage areas in the left atrium
88910452|NCT04377594|Active Comparator|Pulmonary vein isolation|Pulmonary vein isolation
88910453|NCT04374630|Experimental|Arm 1|Arm 1 is afuresertib 125 mg PO QD + paclitaxel 80 mg/m2 intravenous (IV) infusion over 1 hour on Days 1, 8 and 15 of a 3 week cycle.
88910454|NCT04374630|Active Comparator|Arm 2|Arm 2 is paclitaxel 80 mg/m2 IV infusion over 1 hour on Days 1, 8, and 15 of a 3 week cycle
88910455|NCT04374305|Experimental|Sub-study A (brigatinib) - CLOSED TO ENROLLMENT|Subjects treated in this arm will receive brigatinib 90 mg by mouth daily for 7 days and then increased to 180 mg by mouth daily if the drug is tolerated.
88910456|NCT04374305|Experimental|Sub-study B (neratinib)|The first three participants treated in this arm will receive neratinib 200 mg mg by mouth daily. If these participants tolerate the medication well, subsequent participants will receive neratinib 240 mg by mouth daily.
88910457|NCT04368559|Experimental|Group 1: Rezafungin for Injection|Subjects in Rezafungin treatment group will receive a 400 mg loading dose in Week 1, followed by 200 mg once weekly, for a total of 13 weeks. Subjects will receive oral placebo for standard antimicrobial regimen (SAR) azole prophylaxis and oral placebo for SAR anti-Pneumocystis pneumonia (PCP) prophylaxis in accordance with the respective SAR dosing regimens for each. For subjects who are switched to a SAR IV regimen, oral placebo for SAR azole prophylaxis will be changed to IV placebo. There is no IV option for SAR anti-PCP prophylaxis.
88910458|NCT04368559|Active Comparator|Group 2: Oral Antifungal|Subjects in SAR treatment group will receive 400 mg oral fluconazole once daily for 13 weeks. Fluconazole may be switched, due to acute clinically significant graft versus-host disease (GVHD), to 300 mg oral posaconazole twice daily on the first day of the medication switch and 300 mg once daily, thereafter. However, subjects who are switched to posaconazole cannot be switched back to fluconazole. Azole-based antifungal therapy (fluconazole or posaconazole) can be switched from daily oral therapy to daily IV therapy at the discretion of the Investigator. In addition, subjects in the SAR group will receive anti-PCP prophylaxis with oral TMP/SMX (80 mg TMP/400 mg SMX) once daily. There is no IV option for SAR anti-PCP prophylaxis.
88910459|NCT04365374|Experimental|Surgical Resection and GammaTile Therapy|Surgical Resection and GammaTile Therapy
88910460|NCT04365374|Active Comparator|Surgical Resection and Stereotactic Radiation Therapy|Surgical Resection and Stereotactic Radiation Therapy
88910461|NCT04342975|Active Comparator|Basis|The investigational product, Basis™, contains a synthetic NR that is nature-identical to naturally-occurring NR, does not induce flushing or pruritus and has no effect on lipid levels. Also contains Pterostilbene (Ptero) that is a stilbenoid compound, characterized by two aromatic rings connected by a methylene bridge backbone, and it has two methoxy groups and one hydroxyl group extending from the aromatic rings.
88910462|NCT04342975|Placebo Comparator|Placebo|Correspondent placebo, a capsule not containing the active component.
88910463|NCT04341896||Caregivers|Prior obese living kidney donors who served as the primary caregiver for their recipient
88910464|NCT04341896||Non-caregivers|Prior obese living kidney donors who were not the primary caregiver for their recipient
88910467|NCT04334668|Active Comparator|Oral Sodium Chloride|Subject will be given 2 grams of oral sodium chloride three times daily with meals for approximately 4 days
89430493|NCT01434602|Experimental|2/Phase II|Combination of sorafenib and everolimus. Sorafenib 400mg twice daily will be taken for 7 days on, then 7 days off. Everolimus 5mg will be taken daily. Determined from dose escalation in phase I, maximum tolerated dose -1.
89430494|NCT02087397|Experimental|AD-SVF Cell Injection|
89430495|NCT02087475|Experimental|Neoadjuvant therapy arm|FOLFIRI * 6 cycles +/- radiotherapy -> surgery -> FOLFIRI * 6 cycles
89430496|NCT02087475|Active Comparator|Adjuvant therapy arm|Surgery -> FOLFIRI * 12 cycles +/- radiotherapy
89430497|NCT02087553||Transfused pediatric patients|Children who might receive packed red blood cell (PRBC) transfusion will be enrolled after obtaining consent from their parents/legal guardians and assent from the patient, if possible. Transfusion of red blood cells will be done according to standard of care.
89430498|NCT02087553||Saline/Albumin infusion|Children who might receive albumin or saline for volume resuscitation will be enrolled after obtaining consent from their parents/legal guardians and assent from the patient, if possible. Infusion will be done according to standard of care.
89430499|NCT03427190|Active Comparator|Control|Phone contact with patient will be made by a professional psychologist within 21 days of hospital discharge. If contact cannot be made after 9 attempts, post-cards will be sent monthly at M2, M3, M4 and M5, asking the participant to establish contact with the designated psychologist. The phone call will determine whether or not the participant is in a state of suicidal crisis. If yes, steps will be taken to attend the crisis within 24 hours.
89430500|NCT03427190|Other|APSOM|In complement to actions described in the control arm, the patient's general practitioner (GP) and the patient him/herself will be contacted within 21 days of hospital discharge in order to organize an appointment between them two; this consultation is expected to take place between day 22 and day 45 after hospital discharge. If the patient does not have a GP, a health-care professional (HCP) will be provided. .GP (or HCP) will also be contacted at 6 and 13 months.
89430501|NCT02092233||Blinded, Prospective Arm|The diagnostic accuracy for lesions from individuals suspected of having a herpes infection will be evaluated in prospectively collected, left-over de-identified, clinical specimens accrued between pre-defined dates.
89430502|NCT02092233||Blinded, Pre-selected Arm|For specimen types that are less common, banked, pre-selected, positive clinical specimens will be tested.
88910468|NCT04334668|Placebo Comparator|Placebo|Subject will be given a placebo orally three times daily with meals for approximately 4 days
88910469|NCT04325529||remitted MDD|Unmedicated Remitted Participants with Past History of MDD
88910470|NCT04325529||Control subjects|healthy control subjects
88910471|NCT04325308|Experimental|Protein-enriched human milk diet|Infants in this group will receive protein-enriched expressed human milk or donor human milk during the first 2 weeks after birth.
88910472|NCT04325308|Active Comparator|Usual human milk diet|Infants in this group will receive either expressed human milk or donor human milk during the first 2 weeks after birth.
89430503|NCT02089893||Healthy subjects|Healthy subjects
89430504|NCT02092545|Other|Ketogenic diet|Weight management on a male population of retired NFL athletes.
89430505|NCT03427034|Experimental|Cystoscopic surveillance|Patients with previous history of bladder cancer undergoing flexible cystoscopy will privide a urine sample to see if BladderLight system can exclude presence of bladder cancer
89430506|NCT03427034|Experimental|Haematuria group|Patients referred with haematuria to exclude bladder cancer will privide a urine sample to see if BladderLight system can exclude presence of bladder cancer
88910473|NCT04314193|Experimental|methotrexate|
88910474|NCT04314193|Active Comparator|prednisolone|
89430507|NCT03427034|No Intervention|Longitudinal group|Patient with Negative cystoscopy with a positive BladderLight® test will be followed for 12 months to see if they subsequently develop bladder cancer.
89430508|NCT05486949|Experimental|AZD4205 and carbamazepine|Subjects in arm 1 will receive AZD4205 single dose on Day 1, and the second dose of AZD4205 along with carbamazepine after the wash-out period.
89430509|NCT05486949|Experimental|AZD4205 and itraconazole|Subjects in arm 2 will receive AZD4205 single dose on Day 1, and the second dose of AZD4205 along with itraconazole after the wash-out period.
89430510|NCT03429764|Active Comparator|Control group (CG),CISS|continuous independent sling sutures (CISS) will be placed with minimum two intact contact points at the surgical site,
89430511|NCT03429764|Experimental|Test group (TG),VIMS|internal mattress suture (VIMS) will be placed with minimum two intact contact points at the surgical site,
89430512|NCT03429686|Experimental|DRT Intervention|Intervention: Individual digital reminiscence therapy programme.
88910475|NCT04311996|Experimental|Friend and Target Both|There are four conditions: (1) Friend and Target both undergo the stressor, (2) Friend provides support but does not undergo the stressor, (3) Unfamiliar Peer and Target undergo the stressor, and (4) Alone (no partner).
88910476|NCT04311996|Experimental|Friend Provides Support|There are four conditions: (1) Friend and Target both undergo the stressor, (2) Friend provides support but does not undergo the stressor, (3) Unfamiliar Peer and Target undergo the stressor, and (4) Alone (no partner).
88910477|NCT04311996|Experimental|Unfamiliar Peer and Target|There are four conditions: (1) Friend and Target both undergo the stressor, (2) Friend provides support but does not undergo the stressor, (3) Unfamiliar Peer and Target undergo the stressor, and (4) Alone (no partner).
89531179|NCT05033691|Active Comparator|SoC Tagrisso treatment only|continuation of osimertinib alone
89531180|NCT03339869|Experimental|blood sample group|Adult patient hospitalized in intensive care unit and treated for infection.
89531181|NCT02497157|Experimental|Treatment Arm|Patients receive FOLFOXIRI plus bevacizumab [oxaliplatin (L-OHP): 85 mg/sq.m., irinotecan hydrochloride hydrate (CPT-11): 165 mg/sq.m., continuous intravenous infusion of fluorouracil (CIV 5-FU): 3,200 mg/sq.m., Levofolinate calcium (l-LV): 200 mg/sq.m., bevacizumab: 5 mg/kg]. The treatment will be repeated every 2 weeks, for up to 12 cycles, unless the disease progression, unacceptable toxicity, tumor resection or consent withdrawal.
88910478|NCT04311996|Experimental|Alone|There are four conditions: (1) Friend and Target both undergo the stressor, (2) Friend provides support but does not undergo the stressor, (3) Unfamiliar Peer and Target undergo the stressor, and (4) Alone (no partner).
88910479|NCT04305808||Recurrent Urinary tract infection|Menopausal women, with two or more documented, culture-positive infections in the last six months or ≥3 infections in the last year
88910480|NCT04305808||Healthy controls|Menopausal women, without prior history of UTIs or other urologic abnormalities.
88910481|NCT04303260|Active Comparator|Interventional arm|"Patients in the interventional arm will be asked to complete 3 different videos repeatedly, as many days a week as possible. This repetition is to be maintained even if a patient missed one day of training.~The interventional exercise regimen will include specific exercises postulated to increase blood flow to the intestine and colon and thereby promote normal peristaltic s and decrease inflammation."
89430513|NCT03558243|Active Comparator|Patent Hemostasis Arm|The TR Band (Terumo medical) will be placed on the sheath entry site, the air bladder of the TR Band will be filled with 18 mL of air to achieve initial hemostasis. The sheath will be removed, air will be withdrawn slowly until a pulsatile bleeding is observed through the sheath's orifice, once this phenomenon occurs, 2 ml of air will be added to the air bladder and the absence of bleeding will be corroborated, immediately afterwards a pulse oximeter will be placed on the index finger of the patient and transient manual compression of the ipsilateral ulnar artery will be performed, patency of the radial artery will be corroborated by means of oxygen saturation and adequate pulse curve (Barbeau reverse test), if it is not possible to achieve patent hemostasis, it will be retried deflating 1-2 ml of the TR Band every 15 minutes until a positive reverse Barbeau test with absence of bleeding is achieved. TR Band removal will be attempted 2 hours after the procedure.
89430514|NCT03558243|Experimental|ULTRA Arm|The TR Band will be placed at the sheath entry site, the ipsilateral ulnar artery will be compressed at the Guyon's canal by placing a cylindrical composite made by wrapping 4 inch x 4 inch gauze around a 1-inch plastic needle cap, and compressing it using a circumferentially applied Hemoband. After occlusive compression of ulnar artery is confirmed by means of plethysmography, patent hemostasis protocol will be used for radial artery hemostasis as described at the patent hemostasis arm. The needle cap and hemoband that compresses the ulnar artery will be removed 1 hour after the procedure. TR Band removal will be attempted 2 hours after the procedure.
89430515|NCT03558243|Experimental|Hemostatic Disc Arm|The StatSeal hemostatic disc will be placed above sheath entry site, the TR Band will be placed above the disc, according to the manufacturer's specifications the air bladder will be filled with 8 ml of air, the sheath will be then removed, corroborating the absence of bleeding, 20 minutes later 3 ml of air will be removed, 20 minutes after that 5 ml of air will be removed, finally the investigators will try to remove the deflated TR Band 60 minutes after the procedure.
89430516|NCT03426956|Experimental|Glucose|
89430517|NCT03426956|Experimental|Glucose + Canagliflozin|
89430518|NCT03557229|Experimental|Melatonin|
89430519|NCT03557229|Experimental|Vitamin C|
89430520|NCT03557229|Experimental|Vitamin E|
89430521|NCT03557229|Experimental|N-acetylcysteine|
89430522|NCT03557229|No Intervention|Control|
89430523|NCT02521532|Experimental|Nitrate rich beetroot juice|Concentrated, beetroot juice is a rich source of dietary nitrate.
88910482|NCT04303260|Placebo Comparator|controled arm|"Patients in the controled arm will also be asked to practice generally recommended exercises in 3 different videos repeatedly, as many sets as possible..~The control arm will practice generally recommended exercises, without particular attention to the abdomen."
88910483|NCT04301089|Experimental|Experimental intervention|Experimental VR Intervention, Survey or Questionnaire Completion and Sample Submission
88910484|NCT04293562|Experimental|Arm A High Risk Group|Arm A High Risk Group: See Detailed Description.
88910485|NCT04293562|Experimental|Arm A Low Risk Group 1|Arm A Low Risk Group 1: See Detailed Description.
88910486|NCT04293562|Experimental|Arm A Low Risk Group 2|Arm A Low Risk Group 2: See Detailed Description.
88910487|NCT04293562|Experimental|Arm AC High Risk Group|Arm AC High Risk Group: See Detailed Description.
88910488|NCT04293562|Experimental|Arm AC Low Risk Group 2|Arm AC Low Risk Group 2: See Detailed Description.
88910489|NCT04293562|Experimental|Arm AD High Risk Group|Arm AD High Risk Group: See Detailed Description.
88910490|NCT04293562|Experimental|Arm AD Low Risk Group 2|Arm AD Low Risk Group 2: See Detailed Description.
88910491|NCT04293562|Experimental|Arm B High Risk Group|Arm B High Risk Group: See Detailed Description.
88910492|NCT04293562|Experimental|Arm B Low Risk Group 1|Arm B Low Risk Group 1: See Detailed Description.
88910493|NCT04293562|Experimental|Arm B Low Risk Group 2|Arm B Low Risk Group 2: See Detailed Description.
89430524|NCT02521532|Placebo Comparator|Nitrate depleted placebo beetroot juice|Placebo beetroot juice is identical to active beetroot juice in every way except nitrate content.
88910494|NCT04293562|Experimental|Arm BC High Risk Group|Arm BC High Risk Group: See Detailed Description.
88910495|NCT04293562|Experimental|Arm BC Low Risk Group 2|Arm BC Low Risk Group 2: See Detailed Description.
88910496|NCT04293562|Experimental|Arm BD High Risk Group|Arm BD High Risk Group: See Detailed Description.
88910497|NCT04293562|Experimental|Arm BD Low Risk Group 2|Arm BD Low Risk Group 2: See Detailed Description.
88910498|NCT04287049|Experimental|14 Day Azithromycin Monotherapy|For the first 14 days of therapy, participants will receive Azithromycin 250mg PO daily as monotherapy. Beyond day 14, all participants will receive guideline-based standard multi-drug therapy for Mycobacterium avium lung disease, as dictated by the physicians treating the participants.
88910499|NCT04278768|Experimental|Emavusertib (CA-4948) dose escalation|Patients receive emavusertib monotherapy BID daily. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88910500|NCT04278768|Experimental|Emavusertib dose escalation + Venetoclax|"The starting dose for emavusertib will be 200 mg BID for 21 days of a 28-day Cycle. Anticipated emavusertib doses will be 200 and 300 mg BID. Venetoclax will be administered at 100 mg orally (Day 1) per the product label at the same time each day with a ramp up over 3 days to 400 mg for 21days of a 28-day Cycle. Second and subsequent cycles start with target dose level.~This arm of the study has been closed to enrollment."
88910501|NCT04278768|Experimental|Emavusertib monotherapy dose expansion|The Expansion phase will begin once the RP2D from Phase 1 Dose Escalation phase has been identified. There will be 3 Cohorts and patients will be assigned to each Cohort based on baseline disease.
89430525|NCT02087631|Experimental|Quetiapine|Extended-release quetiapine fumarate up to 300mg once daily for 4 weeks
89430526|NCT03426800|Experimental|Migraine_acupuncture and training|Migraine acupuncture and training
89430527|NCT03426800|Experimental|Migraine training|Migraine training
89430528|NCT03426800|Experimental|Tension_acupuncture and training|Tension headache acupuncture and training
89430529|NCT03426800|Experimental|Tension headache training|Tension headache training
89430530|NCT03558165||Stage IV Lung Adenocarcinoma|
89430531|NCT00940940|Experimental|Live attenuated herpes zoster vaccine|
89430532|NCT00940940|Placebo Comparator|Placebo|
89430533|NCT02092623|Other|Transvaginal posterior mesh surgery|All study patients undergo transvaginal mesh operation.
89430534|NCT03557840|Experimental|Temocillin treatment|Patients treated with temocillin and sampled as per the protocol
89430535|NCT02092701|Experimental|cholecalciferol|
89430536|NCT02089971||Young Chinese adults|cross-sectional, observational study of community dwelling young Chinese adults
89430537|NCT03421262|Experimental|One-step:IADPSG Criteria|Gestational diabetes screening with fasting 2 hour 75g. Receive a fasting 2 hour 75 gr oral glucose tolerance test and diagnosed based on the IADPSG which is if one or more values exceed the following diagnostic threshold: Fasting 92, 1-hour 180, or 2-hour 153 mg/dL.
89430538|NCT03421262|Active Comparator|Two-step:NDDG Criteria|"Step 1: Perform a 1h 50-g glucose load test (nonfasting. If the plasma glucose level measured 1 h after the load is 140 mg/dL, proceed to a 100-g OGTT.~Step 2: 100-g OGTT. The diagnosis of GDM is made if at least two of the following four plasma glucose levels(measured fasting and 1 h, 2 h, 3 h after the OGTT) are met or exceeded: 105mg/dl, 190mg/dl, 165mg/dl and 145mg/dl respectively"
89430539|NCT02092779||Obese patients, no treatment|
89430540|NCT03421028|Active Comparator|Control group|Patients with masticatory muscle pain treated with occlusal splint, physiotherapy and counseling
88910502|NCT04278417|Experimental|Brolucizumab Arm|Intra-vitreal injection
88910503|NCT04278417|Active Comparator|Panretinal photocoagulation laser Arm|laser
88910504|NCT04276909|Experimental|Lum Imaging System|Single dose of LUM015 (1.0 mg/kg) will be administered by intravenous injection at the beginning of the surgery. All subjects will have intraoperative imaging using the LUM Imaging Device
88910505|NCT04272762|Active Comparator|Ablation|pulmonary vein isolation
88910506|NCT04272762|Placebo Comparator|Placebo|placebo procedure
88910507|NCT04266093||Cohort 1|Subjects who have received treatment on an NCI CIO or CIO gene therapy protocol.
88910508|NCT04260646|Active Comparator|Standard Urotherapy without enuresis alarm|Standard urotherapy inclunding normalized fluid intake and times voidings. The timed voiding regime of every 2 hours will be assisted by a timer Watch.
88910509|NCT04260646|Experimental|Standard Urotherapy with enuresis alarm|Standard urotherapy inclunding normalized fluid intake and times voidings. The timed voiding regime of every 2 hours will be assisted by a timer Watch. In addition an enuresis alarm will be provided and worn by the participants during the night.
89430541|NCT03421028|Experimental|Experimental group 1|Patients diagnosed with masticatory muscle pain treated with 4 meetings of EMG-biofeedback assisted training
89430542|NCT03421028|Experimental|Experimental group 2|Patients diagnosed with masticatory muscle pain treated with 8 meetings of EMG-biofeedback
89430543|NCT02087709|Experimental|Low-calorie diet|The subjects were prescribed a daily energy intake 500 kcal lower than the estimated energy requirement.
89430544|NCT03426722|Active Comparator|L-carnitine|L-carnitine 500mg three times daily (per oral)
89430545|NCT03426722|Placebo Comparator|Placebo|Placebo 500mg three times daily (per oral)
89430546|NCT02087787|No Intervention|Control|The control group will be provided the standard method, which is providing the Cancer Legal Line (CALL) brochure with a short explanation of the resource.
89430547|NCT02087787|Experimental|Intervention|The intervention group will be provided with a 2 hour consultation with an attorney in the BMT Legal Clinic with potential follow-up as needed.
89430548|NCT03426488||Västerbotten Intervention Programme|"The cohort is population-based and consists of blood and data from primarily 40, 50 and 60 year olds, taken every year in this age group in connection with the Västerbotten health surveys from 1985 - present.~The blood samples consist primarily of EDTA and heparin blood samples divided into plasma, erythrocyte concentrate and buffy coat and for a certain percentage, the DNA is extracted.~The database NSDD (Northern Sweden Diet Database) consists of survey data from VIP concerning nutritional factors.~A large part is fasting samples.~Individuals: 105,700 Individuals with repeated samples: 40,700 Sampling occasions: 156,300"
89008448|NCT04592965|Experimental|Robot induced PH, through sensorimotor stimulation (MRI)|All healthy participants, and all patients who are deemed capable of performing the robotic manipulation task in the MRI scanner, will take part on this arm. Participants will perform a robotic manipulation task, with a patented robotic system, capable of inducing the PH and other accompanying bodily illusions in the MRI scanner. At the end participants will report on the various subjective experiences, by answering a structured questionnaire.
89430549|NCT03426488||Mammography Screening Project|"Samples and data are collected in connection with mammography screenings 1995-2006. The blood samples consist primarily of EDTA and heparin blood samples divided into plasma, erythrocyte concentrate and buffy coat, and for a certain percentage, the DNA is also extracted. The cohort consists of women, 18-82 years old (95% between 48 and 70 years old).~Survey data can be linked to the blood samples.~Individuals: 28,800 Individuals with repeated samples: 14,600 Sampling occasions: 54,000"
89430550|NCT03426488||The Northern Swedish MONICA Project|"The MONICA study is a longitudinal population-based database for research in cardiovascular disease and diabetes. Since 1985, seven screenings has been performed (1986, 1990, 1994, 1999, 2004, 2009 and 2014) of a randomized selection of the population in the counties of Västerbotten and Norrbotten in Northern Sweden.~Individuals: 11,800 Individuals with repeated samples: 3,500 Sampling occasions: 15,300 (March 2015)"
89430551|NCT02090049|Experimental|Puravita Breakfast|Puravita Breakfast is a high protein and high fiber soft bread that contains 22% fruit (figs, apricots, raisins and prunes), a selection of cereals: wheat, oat and spelt and no added sugar.
89430552|NCT02090049|Placebo Comparator|Control breakfast|White bread (85g) with jam (10g) and margarine (2g) adjusted for energy, fat, and sugar levels and for energy density.
89430553|NCT03429608||patients with low thrombus burden|patients with the lower volume of aspirated thrombi, as measured using micro-CT
89430554|NCT03429608||patients with high thrombus burden|patients with the higher volume of aspirated thrombi, as measured using micro-CT
89430555|NCT03420872||Subset from PROGRESS cohort|Participants included children 4-6 years of age from mother-child pairs in the Programming Research in Obesity, Growth Environment and Social Stress (PROGRESS) prospective birth cohort in Mexico City
89430556|NCT01767129|Experimental|AVP-923-45|AVP-923-45 twice daily for 14 days
89430557|NCT01767129|Placebo Comparator|Placebo|Placebo twice a day for 14 days
89430558|NCT03420716|Experimental|functional yogurt|Participants are given the symbiotic yogurt daily (180 ml)
89430559|NCT03420716|Experimental|control yogurt|Participants are given the control yogurt daily (180 ml)
89008449|NCT04592926|Experimental|Accuro ultrasound|
89008450|NCT04592926|Sham Comparator|Control|
89430560|NCT04448912||Non-trauma damge control surgery|Patients with non-traumatic abdominal emergencies undergoing damage control surgery.
89430561|NCT04448912||Non-trauma conventional surgery|Patients with non-traumatic abdominal emergencies undergoing conventional surgery with primary abdominal closure.
89430562|NCT02095743|Experimental|PICC line|Use of a PICC line for chemo administration (PowerPICC SOLO²)
89430563|NCT02095743|Active Comparator|Implanted Port|Use of an implanted port for chemo administration
89430564|NCT04448522|Experimental|Reduced dosage IMRT group|3 cycles of gemcitabin and cisplatin induction chemotherapy plus concurrent cheomtherapy with IMRT dosage of 63.6 Gy
89008451|NCT00566917|Active Comparator|1|Anterior colporrhaphy (standardised)
89008452|NCT00566917|Experimental|2|Anterior PROLIFT
89008453|NCT00249483|Placebo Comparator|Placebo|Placebo
89008454|NCT00249483|Experimental|Venlafaxine|Venlafaxine 300mg daily
89430565|NCT04448522|Active Comparator|Conventional dosage IMRT group|3 cycles of gemcitabin and cisplatin induction chemotherapy plus concurrent cheomtherapy with IMRT dosage of 69.96 Gy
89430566|NCT02093013|Experimental|Integrated care program|
89430567|NCT02093013|No Intervention|Control group|This group kept receiving usual care from their health care professionals.
89430568|NCT03429374|Active Comparator|Liquiband Fix8 glue mesh fixation|
89430569|NCT03429374|Active Comparator|Mesh fixation with absorbable tacks|
89430570|NCT01309191|Experimental|Minoxidil|Patients received Minoxidil (same strength as sold over the counter) twice a day for 8 weeks.
89430571|NCT01309191|Placebo Comparator|Placebo|Placebo arm
89430572|NCT01094223|Experimental|Mindfulness|Mindfulness Based Relapse Prevention (MBRP). Meditation based therapy group incorporating relapse prevention skills training.
88910510|NCT04260529|Experimental|Arm A: CyPep-1 monotherapy|"Phase I of the trial, dose escalation, safety and tolerability will be documented and the MTD/RP2D will be determined. Cohorts of 3 subjects (in total 12 subjects) will receive IT injections with CyPep-1 by intratumoral injection at Day 1 of weeks 1, 3 and 5.~In Phase IIa of the trial, dose expansion, the safety and tolerability will be further evaluated in an expanded cohort of 9 subjects at the RP2D of CyPep-1, determined in Phase I. CyPep-1 administration is planned as Q2W injections"
88910511|NCT04260529|Experimental|Arm B: CyPep-1 in combination with pembrolizumab|The safety and tolerability of CyPep-1 in combination with pembrolizumab will be evaluated in a cohort of 15 subjects in total, using a staggered approach. CyPep-1 will be administered every 2 weeks (Q2W) and pembrolizumab will be administered following a Q6W schedule as per standard of care (SoC).
88910512|NCT04260529|Experimental|Arm C: CyPep-1 monotherapy liver lesions|The safety and tolerability of at least two dose levels of CyPep-1, the RP2D and the dose immediately below that, are planned to be evaluated when CyPep-1 is administered intratumorally to a metastatic lesion in the liver. CyPep-1 administration is planned as Q2W injections.
88910513|NCT04260529|Experimental|Arm D: CyPep-1 monotherapy melanoma|The safety and tolerability of CyPep-1 at RP2D will be further evaluated with focus on assessing efficacy signals of CyPep-1 monotherapy in subjects with melanoma. CyPep-1 administration is planned as QW injections until the second iRECIST/itRECIST assessment at week 16, followed by a Q2W dosing scheme.
88910514|NCT04259359||patients who will be treated with bee venom immunotherapy|
88910515|NCT04250714||Treatment patients|Subjects indicated for the treatment of AF with the cryoablation system according to current and future Guidelines and system indications for use
88910516|NCT04250545|Experimental|Treatment (CB-839 HCl, sapanisertib)|Patients receive glutaminase inhibitor CB-839 hydrochloride PO BID and sapanisertib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89197632|NCT00853515|No Intervention|3|Standard fluid resuscitation with lactated Ringer's solution
89430573|NCT01094223|Active Comparator|Health Education|Health education, psychoeducation group focused on various topics pertaining to physical health
89430574|NCT03420638|Experimental|Adjunct Exparel|After removal of the tonsils and before extubation, the principal investigator will infiltrate 0.5 mL of the standard of care medication-bupivacaine HCl 0.25% (2.5 mg/mL) with epinephrine (5 mcg/mL) i.m.-into the upper and lower poles of the anterior and posterior tonsillar pillars on the right and left side of the oropharynx for a volume of 2 mL of bupivacaine HCl on each side. Following the standard medication, the principal investigator will infiltrate 0.5 mL of adjunct Exparel (bupivacaine liposome suspension 1.3% [13.3 mg/mL], i.m.) into the upper and lower poles of the anterior and posterior tonsillar pillars on the right and left side of the oropharynx for a volume of 2 mL of bupivacaine liposome injectable suspension on each side.
89430575|NCT03420638|Other|Standard Care|After removal of the tonsils and before extubation, the principal investigator will infiltrate 0.5 mL of the standard of care medication-bupivacaine HCl 0.25% (2.5 mg/ mL) with epinephrine (5 mcg/mL) i.m.-into the upper and lower poles of the anterior and posterior tonsillar pillars on the right and left side of the oropharynx for a volume of 2 mL of bupivacaine HCl on each side.
89008455|NCT00566956|Experimental|1|For those assigned to Group 1, the hydrosalpinx will be aspirated after all the eggs have been collected, under GA. Under ultrasound-guidance, the aspiration (egg collection) needle will be inserted into the hydrosalpinx and suction applied until no more fluid is obtained. If there are bilateral hydrosalpinges, the process is repeated on the opposite side.
89430576|NCT02090205|Placebo Comparator|Non-ventilation during CPB|This group of patients will not be ventilated during the cardio-pulmonary bypass. They will be disconnected from the respirator.
89430577|NCT02090205|Experimental|Ventilation with CPAP|This group will receive a ventilation with CPAP (at least 5 cmH2O) and FiO2 50%-80%
89430578|NCT02090205|Experimental|Ventilation with 5 act/minute|This group will receive 5 respiratory acts/minute. Tidal volume = 2-3 ml/kg + PEEP = 3-5 cmH2O.
89430579|NCT03420560|Experimental|warmer temperature|To compare the incidence and intensity of pain on injection that is caused by propofol in warm temperature（27℃） versus normal temperature(23℃).
89430580|NCT03420560|Placebo Comparator|normal temperature|The purpose of this study is to compare the incidence and intensity of possible pain on injection as well as patient satisfaction caused by propofol in different room temperature(27 VS 23).
89008456|NCT00566956|No Intervention|2|Patients assigned to group 2 will not have the hydrosalpinx aspirated
89430581|NCT00715988|Experimental|Scheme 1|Patients who are feeding or not feeding and mechanically ventilated, >/=3 d of age and 29 0/7wks-48 6/7 wks PMA, treated with i.v. bolus doses or infusion of fentanyl, morphine or methadone for clinical indications, with arterial/venous line in place & expected treatment for at least 1-2 more days. Pk sampling = 0.5 ml blood samples x6/infant. ECG monitoring. Three patients will be enrolled in 5 PMA groups. Should apnea or hypotension occur, dosages for Treatment Scheme 2 will be reduced (50%); more patients will be studied in Treatment Scheme 1 to insure that the lower dose is well tolerated & effective.
89430582|NCT00715988|Experimental|Scheme 2|Patients defined in Scheme 1, tolerating feeds for >/= 3 days will be studied twice, after i.v. methadone and after enteral methadone after the end of sampling after the first dose. 4-5 samples will be obtained after dose 1 and after dose 2 depending on PMA and weight. Patients will be divided into groups based on PMA..
89430583|NCT02093091|Sham Comparator|Vitremer|Dental caries was removed from primary molars and was filled with the conventional filling material;Vitremer (n = 30). The right molars was always filled by Vitremer. A split-mouth design was used in the present clinical trial. Twenty nine children were involved in the present study and every one had one bilateral identical pair of carious molars except one child that had two identical pairs. This design was performed to enhance the accuracy of the present study.
89430584|NCT02093091|Active Comparator|Ketac Nano|Dental caries was removed from primary molars and was filled with the recent filling material; Ketac Nano (n=30). The left molars was always restored with Ketac Nano filling material.
89430585|NCT03429062||personal training|Individuals with a diagnosis of MS and any level of function will be recruited to participate in exercise two times per week with trained personal trainers. Exercise consists of strengthening, stretching, balance, endurance and gait when able. Equipment to be used include treadmill, stationary bike, weight equipment.
89430586|NCT03429062||Whole Body Platform|Individuals with a diagnosis of MS and able to walk with or without an assistive device will be recruited to participate in whole body platform training two times per week with a physical therapist. The exercise on the whole body platform includes strengthening, balance, stretching, and endurance for 30 second bouts. The whole body platform is on for 30 seconds then off. Each exercise will use the 30 seconds to complete.
89430587|NCT02093169|Experimental|Part A: Lu AF35700|
89197633|NCT00853515|No Intervention|4|Standard fluid resuscitation with normal saline
89430588|NCT02093169|Experimental|Part B: Lu AF35700|
89008457|NCT00567034|Active Comparator|1|taking naltrexone
89008458|NCT00567034|Placebo Comparator|2|taking placebo
89008459|NCT03454126|Experimental|Cohort 1: BIIB095 5 mg|Following an overnight fast from food of at least 8 hours, participants will receive a single dose of either BIIB095 5 mg or placebo orally, followed by a fast of at least 4 hours post dose.
89008460|NCT03454126|Experimental|Cohort 2: BIIB095 25 mg|Following an overnight fast from food of at least 8 hours, participants will receive a single dose of either BIIB095 25 mg or placebo orally, followed by a fast of at least 4 hours post dose.
89008461|NCT03454126|Experimental|Cohort 3: BIIB095 100 mg|Following an overnight fast from food of at least 8 hours, participants will receive a single dose of either BIIB095 100 mg or placebo orally, followed by a fast of at least 4 hours post dose.
89197634|NCT00576420|Experimental|FS VH S/D 500 s-apr - 60-Seconds|Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/ml thrombin and synthetic aprotinin (FS VH S/D 500 s-apr) will be applied to the study suture line, 60-second polymerization time
89430589|NCT03420326||Atria fibrillation (AF) group|"Detection of AF during 30 seconds ECG assessment~Once diagnosed with atrial fibrillation before~Undergo the frailty status assessment"
89430590|NCT03420326||Non-AF group|"No detection of AF during 30 seconds ECG assessment~Undergo the frailty status assessment"
89430591|NCT03556995||Bariatric surgery patients|All patients above 18 that underwent bariatric surgery
89430592|NCT03420248|Experimental|Non-spherical polyvinyl alcohol particle|For embolic material, non-spherical polyvinyl alcohol particle is used.
89430593|NCT03420248|Experimental|Tris-acryl gelatin microsphere|For embolic material, Tris-acryl gelatin microsphere is used.
89430594|NCT02791269|Experimental|HBeAg Negative Participants|HBeAg negative participants will receive peginterferon alfa-2a 180 micrograms (mcg) subcutaneous (SC) injection once weekly (QW) for 48 weeks followed by a 24 weeks treatment-free follow-up period.
89430595|NCT02791269|Experimental|HBeAg Positive Participants|HBeAg Positive participants will receive peginterferon alfa-2a 180 mcg SC injection QW for 48 weeks followed by a 24 weeks treatment-free follow-up period.
89430596|NCT02095821||Humoral rejection, TPE|
89430597|NCT03556449||Patients|High resolution ultrasound
89197635|NCT00576420|Experimental|FS VH S/D 500 s-apr - 120-Seconds|FS VH S/D 500 s-apr will be applied to the study suture line, 120-second polymerization time
89430598|NCT03556449||Healthy subjects|High resolution ultrasound
89008462|NCT03454126|Experimental|Cohort 4 (Fasted): BIIB095 200 mg|Following an overnight fast from food of at least 8 hours, participants will receive a single dose of either BIIB095 200 mg or placebo orally, followed by a fast of at least 4 hours post dose.
89430599|NCT02090361|Experimental|skin graft with dermal matrix|Epidermization of the defect by applying a thin layer of autologous epidermis with addition of a dermal matrix
89430600|NCT02090361|Placebo Comparator|skin graft - classic procedure|Epidermization of the defect by applying a thin layer of autologous epidermis
89008463|NCT03454126|Experimental|Cohort 4 (Fed): BIIB095 200 mg|After a minimum 2 week washout period, followed by an overnight fast of at least 8 hours, participants will consume a high fat breakfast. Participants will then receive a single dose of either BIIB095 200 mg or placebo orally within 30 minutes after starting the breakfast, followed by a fast from food for at least 4 hours post dose.
89430601|NCT03556917|Active Comparator|group 1|topical gel base + caffeine.
89430602|NCT03556917|Active Comparator|group 2|iontophoresis + caffeine
89430603|NCT03556917|Active Comparator|Group 3|iontophoresis
89430604|NCT02090439|Experimental|standard treatment with Silodosin|Silodosin
89430605|NCT02090439|No Intervention|standard treatment|
89430606|NCT02696564|Active Comparator|Losartan|At randomization participants will start with a dose of 50mg (one capsule) once a day for 2 weeks. If this dose is well tolerated and systolic BP is >90 mm Hg and diastolic BP is > 60 mm Hg, the dose will be increased to 100 mg (2 capsules) once a day for the remaining 46 weeks.
89430607|NCT02696564|Placebo Comparator|placebo|At randomization participants will start with a dose of one capsule (inactive) once a day for 2 weeks. After two weeks, if systolic BP is >90 mm Hg and diastolic BP is > 60 mm Hg, the dose will be increased to 2 capsules once a day for the remaining 46 weeks.
89430608|NCT03429530||Group1|20 patients with chronic HCV
89430609|NCT03429530||GroupII|20 patient with chronic HCV related liver cirrhosis
89430610|NCT03429530||GroupIII|40 patients with chronic HCV related liver cirrhosis complicated by hepatocellular cacinoma
89430611|NCT03429530||group IV|20 healthy blood donors will also be included as a control group
89430612|NCT02093325|Experimental|eltrombpag|Eligible patients will be enrolled randomly in 2:1 ratio to Investigational Drug (Eltrombopag) arm, 50 mg/day, or placebo arm for 7 days.
89008464|NCT03454126|Experimental|Cohort 5: BIIB095 400 mg|Following an overnight fast from food of at least 8 hours, participants will receive a single dose of either BIIB095 400 mg or placebo orally, followed by a fast of at least 4 hours post dose.
89430613|NCT02093325|Placebo Comparator|Eltrombopag/placebo|Eligible patients will be enrolled randomly in 2:1 ratio to Investigational Drug (Eltrombopag) arm, 50 mg/day, or placebo arm for 7 days
89430614|NCT02093403|Experimental|Treatment (decitabine and selinexor)|"INDUCTION: Patients receive decitabine IV over 1 hour on days 1-10 and selinexor PO on days 11, 13, 18, 20, 25 and 27. Treatment repeats every 31 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive decitabine IV over 1 hour on days 1-5 and selinexor PO on days 6, 8, 13, 15, 20 and 22. Courses repeat every 31 days in the absence of disease progression or unacceptable toxicity."
89430615|NCT03426176|Experimental|male oxytocin and ATD group|male subjects receiving oxytocin and ATD treatment
89430616|NCT03426176|Experimental|male oxytocin and placebo group|male subjects receiving oxytocin and ATD-placebo treatment
89430617|NCT03426176|Experimental|male placebo and ATD group|male subjects receiving oxytocin placebo and ATD treatment
89430618|NCT03426176|Placebo Comparator|male placebo group|male subjects receiving oxytocin placebo and ATD placebo treatment
89430619|NCT02095899|Experimental|Rufinamide|- oral Rufinamide administration as ad-on to Oxycodone
89430620|NCT02095899|Placebo Comparator|Manitol|- oral Placebo administration - as ad-on to Oxycodone
89430621|NCT03426098|Experimental|Treatment|After baseline evaluation, all subjects will undergo a series of 3 facial treatments with the Secret Micro-Needle Fractional RF System® at 4 week intervals.
89430622|NCT02095977|Other|participants|all subjects meeting inclusion and none of exclusion criteria
89430623|NCT03127670|Experimental|Solanum melongena peel extract 0.05%|25 Patients Solanum melongena peel extract 0.05% Twice daily applied topically for 12 weeks
89430624|NCT03428984|Experimental|EXPAREL 20 + 20|20 mL EXPAREL with 20 mL normal saline
89430625|NCT03428984|Experimental|EXPAREL 20 + 10|20 mL EXPAREL with 10 mL normal saline
89430626|NCT03426020|Active Comparator|Oral midazolam (Demizolam®)|To prevent emergence agitation patient premedicated by 0.5 mg oral midazolam At the end of sugery patients postoperatif emergence agitation evaluated by PAED(pediatric anesthesia emergence delirium scale).
89430627|NCT03426020|Active Comparator|Film http://www.animaturk.com/animasyon/suko-ameliyat-oluyor|To prevent emergence agitation patient premedicated by watching a short movie (at URL: http://www.animaturk.com/animasyon/suko-ameliyat-oluyor ) At the end of sugery patients postoperatif emergence agitation evaluated by PAED(pediatric anesthesia emergence delirium scale).
89430628|NCT03426020|Active Comparator|Play game (PC fishing game)|To prevent emergence agitation patient premedicated by playing a simple PC game (fishing game) At the end of sugery patients postoperatif emergence agitation evaluated PAED(pediatric anesthesia emergence delirium scale).
89430629|NCT03420170|Experimental|Graded Exercise Integrated Education|"The graded exercise (8 weeks)~Strengthening exercise~Aerobic Exercise~Educational session to increase exercise self-efficacy and physical activity level (16 weeks)"
89430630|NCT03420170|Active Comparator|Conventional physical therapy|Normal routine of physical therapy (8 weeks)
89430631|NCT03428906|Experimental|Oxytocin|Oxytocin (OXT), a neuropeptide produced in the hypothalamus, is a key modulator of complex socioaffective responses including affiliation, social approach and attachment, stress and anxiety. Subjects receiving an intranasal spray of OXT (8 IU or 13.44 mg; Syntocinon-spray; Novartis, Switzerland) .
89430632|NCT03428906|Placebo Comparator|Placebo|Placebo contains all ingredients except for the peptide in three puffs of 1.33 IU per 2.24mg nostril.
89430633|NCT02521298|Active Comparator|Strength Training + Placebo|"Strength Training: 2 weeks after the inclusion, the patients are instructed in heavy slow resistance exercise by a physiotherapist. Exercise is continued 3 times/week for the following 12 weeks, with supervised follow-up at week 4, 8 and 12. Exercise consists of wrist extension, flexion and supination/pronation. Starting at 3 x 15 repetition maximum, gradually increasing in weight to 3 x 6 repetition maximum from week 8.~Placebo: Ultrasound-guided subcutaneous injection of 2 ml isotonic saline over the proximal part of the common extensor tendon origin using a 0,8 mm needle. No-touch technique is used, and the patient is blinded with regards to the content of the syringe and the ultrasound-image."
89430634|NCT02521298|Experimental|Strength Training + Cortico-Steroid Inj.|"Strength Training: 2 weeks after the inclusion, the patients are instructed in heavy slow resistance exercise by a physiotherapist. Exercise is continued 3 times/week for the following 12 weeks, with supervised follow-up at week 4, 8 and 12. Exercise consists of wrist extension, flexion and supination/pronation. Starting at 3 x 15 repetition maximum, gradually increasing in weight to 3 x 6 repetition maximum from week 8.~Cortico-Steroid Injection: Ultrasound-guided injection of 1 ml depomedrol 40 mg/ml + 1 ml lidocaine 10 mg/ml deep to the proximal part of the common extensor tendon origin using a 0,8 mm needle. No-touch technique is used, and the patient is blinded with regards to the content of the syringe and the ultrasound-image."
89430635|NCT02521298|Experimental|Strength Training + Dry Needling|"Strength Training: 2 weeks after the inclusion, the patients are instructed in heavy slow resistance exercise by a physiotherapist. Exercise is continued 3 times/week for the following 12 weeks, with supervised follow-up at week 4, 8 and 12. Exercise consists of wrist extension, flexion and supination/pronation. Starting at 3 x 15 repetition maximum, gradually increasing in weight to 3 x 6 repetition maximum from week 8.~Dry Needling: Ultrasound-guided penetration of the proximal part of the common extensor tendon origin is repeated 10 times using a 0,8 mm needle, followed by subcutaneous injection of 2 ml isotonic saline superficial to the tendon. No-touch technique is used, and the patient is blinded with regards to the content of the syringe and the ultrasound-image."
89430636|NCT03127436||Acarovac Hausstaubmilbe|"This prospective open multi-centre non-interventional study was initiated to document the tolerability and the safety profile of the subcutaneous allergen-specific immunotherapy with Acarovac in house dust mite allergic patients (children and adults) in routine medical care.~During the up-dosing phase with Acarovac, patients will receive 4 injections in 1-2 week intervals with increasing allergen amount up to the individual maximum tolerable dose. After reaching the individual maximum tolerable dose patients will receive one maintenance dose in a 4 - 8 week interval.~Data on tolerability are documented by the physicians."
89430637|NCT03425942|Experimental|Internet CBT for insomnia|The intervention consists of Internet-based Cognitive Behavioral Therapy for insomnia (ICBT-i) (the main components are sleep restriction and stimulus control) for five consecutive weeks.
89430638|NCT03425942|Active Comparator|Internet ART for insomnia|The intervention consists of internet-based applied relaxation exercises/techniques (ART) (different and commonly used) for five consecutive weeks.The acronyme for this intervention is (IART-i).
89430639|NCT04449146|Experimental|shoulder localizer ultrasound|The localizer ultrasound of the shoulder is performed on an unclothed patient (at the shoulders) and comes to locate bony landmarks using the ultrasound probe as a Transcutaneous localizer. The Protocol plans to acquire different landmarks on the scapula: lower angle, coracoid, scapula spine and bilateral acromioclavicular joint (definition of the coronal plan). These acquisitions are carried out by the probe connected to a Tablet (Microsoft surface Pro 3) which allows to locate the probe and by extension of the probe the location of the points selected by ultrasound.
89430640|NCT02640950|Experimental|Open-Label TMS|Active Transcranial Magnetic Stimulation
89430641|NCT02559830|Experimental|transduced CD34+ hematopoietic stem cell|Transplantation of autologous CD34+ hematopoietic stem cells transduced with ARSA/ABCD1 encoding lentiviral vector. Dosage: 2x10^6/Kg （Minimum）to 20x10^6/Kg （Maximum） transduced CD34+ cells at bedside for infusion
88910517|NCT04249739|Experimental|CapeOx+Pembrolizumab(HER2 negative)|"<Cohort A>: HER2 negative patients CapeOx+Pembrolizumab therapy (N=78)~Cycle 1 CapeOX~Cycle 2 up to Cycle 8 CapeOX + pembrolizumab therapy~Cycle 9 up to Cycle 35 Capecitabine + pembrolizumab therapy~CapeOx + Pembrolizumab administered until disease progression, unacceptable toxicity or patient's refusal.~Cycle: Day 1 through Day 21)"
88910518|NCT04249739|Experimental|Cape/Cis+Trastuzumab+Pembrolizumab (HER2 positive )|"Cape/Cis+Trastuzumab+Pembrolizumab therapy (N=15)~Cycle 1 Capecitabine + cisplatin (Cape/Cis)~Cycle 2 up to Cycle 8 Cape/Cis + Trastuzumab + pembrolizumab therapy~Cycle 9 up to Cycle 35 Capecitabine + Trastuzumab + pembrolizumab therapy~Cape/Cis + Trastuzumab + Pembrolizumab administered until disease progression, unacceptable toxicity or patient's refusal.~Cycle: Day 1 through Day 21)"
88910519|NCT04243720||Immune Resistance Interrogation Study (IRIS)|Patients with a histological or cytological diagnosis of solid malignancies. Patients must have progressed on immunotherapy as their most recent line of therapy.
88910520|NCT04235686|Active Comparator|Mydayis - Active|"MYDAYIS®, Oral administration, dose regimen for Double blind phase and open label phase.~12.5 mg x 7 days. 25 mg x 7 days 37.5 mg x 14 days 50 mg daily x 28 days"
88910521|NCT04235686|Placebo Comparator|Placebo|"Matching placebo, Oral administration, dose regimen for Double blind phase and open label phase.~12.5 mg x 7 days. 25 mg x 7 days 37.5 mg x 14 days 50 mg daily x 28 days"
88910522|NCT04231708|Placebo Comparator|placebo stressor, sham rTMS|Placebo stressor (lactose) + sham (inactive) rTMS over the left dlPFC
88910523|NCT04231708|Experimental|placebo stressor, active rTMS|Placebo stressor (lactose) + active 10Hz rTMS over the left dlPFC
88910524|NCT04231708|Experimental|active stressor, sham rTMS|Stressor (yohimbine 54mg + hydrocortisone 20mg) + sham (inactive) rTMS over the left dlPFC
88910525|NCT04231708|Experimental|active stressor, active rTMS|Stressor (yohimbine 54mg + hydrocortisone 20mg) + active 10Hz rTMS over the left dlPFC
89430642|NCT03420092|Experimental|Treatment A|The participant will be administered with Form 1 of AZD5718 tablets with an overnight fast of at least 10 hours.
89430643|NCT03420092|Experimental|Treatment B|The participant will be administered with Form 2 of AZD5718 tablets with an overnight fast of at least 10 hours.
89430644|NCT03420092|Experimental|Treatment C|The participant will be administered with Form 3 of AZD5718 tablets with an overnight fast of at least 10 hours.
89430645|NCT03420092|Experimental|Treatment D|The participant will be administered with Form 4 of AZD5718 tablets with an overnight fast of at least 10 hours.
89430646|NCT03420092|Experimental|Treatment E|The participant will be administered with Form 5 of AZD5718 tablets with an overnight fast of at least 10 hours.
89430647|NCT03420092|Experimental|Treatment F|The participant will be administered with selected form (one of Form 2-5) of AZD5718 tablets 30 minutes after start of the meal.
89430648|NCT03419936||Helicobacter pylori(HP) positive|Participants who are diagnosed with gastric cancer and Helicobacter Pylori infection will be treated with subtotal gastrectomy.
89430649|NCT03419858|Experimental|Mindfulness Meditation Group|"Subjects participated in four sessions (20 min/session) of mindfulness training. Participants were taught that perceived sensory events are momentary and fleeting and require no further evaluation. They were asked to close their eyes, relax and to focus on the flow of their breathing and simply let go of discursive thoughts."
88910526|NCT04230278|Experimental|START-Play Intervention|Sitting Together And Reaching to Play is an intervention designed to work on motor-based problem-solving. Thus the activities keep thinking skills at the forefront while also working on advancing motor skills. When initially developed to work with children who were emerging sitters the motor tasks focused on sitting and reaching resulting in the name.
89430650|NCT03419858|Active Comparator|Placebo Meditation Group|The purpose of this intervention was to lead subjects to attend to one's breathing in a non-evaluative manner. Subjects were instructed to sit with a straight posture, closed eyes, and to take a deep, slow breaths every 2-3 minutes.
89430651|NCT03419858|Active Comparator|Slow-Breathing Group|A validated (Chalaye et al., 2009) slow breathing training regimen was employed, using fluctuating light, to teach individuals to independently lower their respective respiration rate. Subjects practiced lowering their respiration rates across four, 20 minute sessions.
89430652|NCT03417206|Experimental|SEVOFLURANE INHALATIONAL ANAESTHESIA|concentration of sevoflurane in the exhalation gas will be maintained to ensure target SE between 40, remifentanyl solution will be administered intravenously at a rate 0,25 mcg/kg of body weight/minute, intraoperatively PRD measurement every 15 minutes; when PRD>5% infusion speed of remifentanyl will be increased by 50% every 5 minutes until PRD decreases below 5%
89430653|NCT03417206|Experimental|DESFLURANE INHALATIONAL ANAESTHESIA|concentration of desflurane in the exhalation gas will be maintained to ensure target SE 40, remifentanyl solution will be administered intravenously at a rate 0,25 mcg/kg of body weight/minute, intraoperatively PRD measurement every 15 minutes; when PRD>5% infusion speed of remifentanyl will be increased by 50% every 5 minutes until PRD decreases below 5%
89430654|NCT03417206|Experimental|TIVA USING PROPOROL|Infusion of propofol will be adjusted at target of SE 40,remifentanyl solution will be administered intravenously at a rate 0,25 mcg/kg of body weight/minute, intraoperatively PRD measurement every 15 minutes; when PRD>5% infusion speed of remifentanyl will be increased by 50% every 5 minutes until PRD decreases below 5%
89430655|NCT02593786|Experimental|Nivolumab monotherapy|Nivolumab specified dose on specified days
89430656|NCT02593786|Experimental|Cohort Expansion|Nivolumab specified dose on specified days
89430657|NCT03425864|Other|immediate implant|patient will receive immediate implant alone.
89430658|NCT03425864|Active Comparator|immediate implant with connective tissue graft|patient will receive immediate implant and connective tissue gaft
89430659|NCT03425708|Active Comparator|Treatment group1|Febuxostat pill 20mg was used to treat CKD patients with hyperuricaemia.
89430660|NCT03425708|Active Comparator|Treatment group2|Febuxostat pill 40mg was used to treat CKD patients with hyperuricaemia.
89430661|NCT03425708|No Intervention|Control group|Treatment of CKD patients with hyperuricaemia with conventional methods.
89430662|NCT03417128|No Intervention|Control|Participants in the control group will receive a one-time personalised nutrition and lifestyle advised based from the Malaysian Dietary Guideline 2010. They will be assured to be followed up twice for the next six month.
89430663|NCT03417128|Experimental|Peer support|This group will receive a continuous three-months, peer-led nutrition and lifestyle behaviour intervention through a series of peer gathering.
88910527|NCT04230278|Active Comparator|Movement, Orientation, Repetition, and Exercise (MORE-PT) - Usual Care Physical Therapy|This intervention was based on the observations of usual care from a previous study. Key principles included the use of Movement, Orientation, Repetition, and Exercise thus the intervention name was changed to MORE-PT before enrollment started. This reduced bias as the therapists and families were not informed this was usual care which could have biased them.
88910528|NCT04225117|Experimental|Cohort 1: HR+/HER2- breast cancer|"Participants will receive enfortumab vedotin as an intravenous (IV) infusion on days 1, 8 and 15 of each 28-day cycle.~HR+/HER2- = Hormone receptor-positive/ human epidermal growth factor receptor 2-negative"
88910529|NCT04225117|Experimental|Cohort 2: Triple negative breast cancer (TNBC)|Participants will receive enfortumab vedotin as an intravenous (IV) infusion on days 1, 8 and 15 of each 28-day cycle.
88910530|NCT04225117|Experimental|Cohort 3: Squamous non-small cell lung cancer|Participants will receive enfortumab vedotin as an intravenous (IV) infusion on days 1, 8 and 15 of each 28-day cycle.
88910531|NCT04225117|Experimental|Cohort 4: Non-squamous non-small cell lung cancer|Participants will receive enfortumab vedotin as an intravenous (IV) infusion on days 1, 8 and 15 of each 28-day cycle.
88910532|NCT04225117|Experimental|Cohort 5: Head and neck cancer|Participants will receive enfortumab vedotin as an intravenous (IV) infusion on days 1, 8 and 15 of each 28-day cycle.
88910533|NCT04225117|Experimental|Cohort 6: Gastric or GEJ or esophageal cancer|"Participants enrolled into Cohort 6 will be reallocated based on disease type and histology into Cohorts 7 or 8.~GEJ= gastroesophageal junction"
88910534|NCT04225117|Experimental|Cohort 7: Gastric adenocarcinoma or esophageal adenocarcinoma (EAC) or GEJ adenocarcinoma|Participants will receive enfortumab vedotin as an intravenous (IV) infusion on days 1, 8 and 15 of each 28-day cycle.
89430664|NCT03417050||Randomized CABG patients|Patients which were randomized to undergo CABG.
89430665|NCT03417050||Randomized PCI patients|Patients which were randomized to undergo PCI.
89430666|NCT03417050||Registry CABG|Patients for whom only one treatment option was suitable were included into a parallel, nested registry: the CABG registry for PCI-ineligible patients.
89430667|NCT03417050||Registry PCI|Patients for whom only one treatment option was suitable were included into a parallel, nested registry: the PCI registry for CABG-ineligible patients.
88910535|NCT04225117|Experimental|Cohort 8: Esophageal squamous cell carcinoma (ESCC)|Participants will receive enfortumab vedotin as an intravenous (IV) infusion on days 1, 8 and 15 of each 28-day cycle.
88910536|NCT04225117|Experimental|Cohort 9: Head and neck squamous cell carcinoma (HNSCC)|Participants will receive enfortumab vedotin as an IV infusion on days 1 and 8 of each 21-day cycle. Pembrolizumab will be administered as an IV infusion on day 1 of each 21-day cycle.
88922247|NCT05593614|Placebo Comparator|ATX01 Placebo|A bottle of hydrogel formulation containing no active ingredient, for topical use on the hands and/or feet, morning and night for 3 months.
89430668|NCT05472922|Experimental|Banded Mini Gastric Bypass|Patients are treated for morbid obesity with a Mini gastric bypass (MGB-OAGB) with addition of the implantation of a MiniMizer Gastric Ring (Bariatric Solutions GmbH, Stein am Rhein Switzerland)
89430669|NCT05472922|Active Comparator|non-Banded Mini Gastric Bypass|Patients are treated for morbid obesity with a Mini gastric bypass (MGB-OAGB)
89430670|NCT05472610|Experimental|BZ019|The subjects are enrolled into single-dose(1～5x10^6/kg) of BZ019 ( non viral vector CD19-targeted Chimeric Antigen Receptor (CAR) T Cells Injection).
89430671|NCT03425630|Experimental|Argicolina (cross-over vs Normolip)|Argicolina is a dietary supplement containing monacolin (sachets)
89430672|NCT03425630|Active Comparator|Normolip (cross-over vs Argicolina)|Normolip is a dietary supplement containing monacolin (tablets)
89430673|NCT04791124||Typical Developing Subjects|EEG evaluation of typical developing subjects
88910537|NCT04224740|Experimental|Pembrolizumab plus standard of care chemotherapy|"-Pembrolizumab combined with standard of care therapy~Standard of care therapy: ciplastin 70mg/m² IV D1(or carboplatin AUC 5) plus 5-Fluouracil 1000mg/m²/day IV( continuous infusion on Days 1-4) Q3W for 6 cycles"
88910538|NCT04217473|Experimental|TILT-123|"Patients will receive administrations of TILT-123. Patients will also receive Tumor Infiltrating Lymphocytes (TILs) during the treatment phase.~Escalation to the next dose of TILT-123 level will occur when the safety data has been evaluated for all patients in the preceding dose level."
88910539|NCT04217252|Experimental|the experimental group|high throughput sequencing of infectious pathogens
89430674|NCT04791124||Down Syndrome Subjects|EEG evaluation of DS subjects
89430675|NCT03416972||Stage I-III NSCLC patients|Stage I/II NSCLC patients receiving standard stereotactic body radiation therapy and Stage III patients receiving Standard platinum-based chemoradiotherapy will receive PET/MRI, DCE-CT, ECG/EKG, and bloodwork before and six weeks post treatment.
89430676|NCT03425552|Experimental|Test treatment|Paliperidone palmitate extended-release injectable suspension for intramuscular use 156 mg (100 mg of Paliperiodne)
88910540|NCT04217252|No Intervention|the control group|no intervention
88910541|NCT04203576|Experimental|FIRE1 System|FIRE1 System
89430677|NCT03425552|Active Comparator|Reference treatment|Paliperidone palmitate 156 mg (equivalent to Paliperidone 100 mg) extended release injectable suspension
89430678|NCT04791046||By CDSS (MedicBK) Analysis|
89430679|NCT04791046||General practice|
89430680|NCT03425474|Experimental|Remimazolam Tosilate|Remimazolam Tosilate at 5mg for initial dose
89430681|NCT03425474|Active Comparator|Propofol|Propofol at 1.5mg/kg for initial dose
89430682|NCT05472454|Other|Ready-to-eat meals|Pre-Post
89430683|NCT03419624|Experimental|Dapagliflozin plus Exenatide|Dapagliflozin (10mg orally once daily) plus Exenatide (2mg subcutaneous once-weekly injection) as add-on to high-dose intensive insulin therapy
89430684|NCT03419624|Placebo Comparator|Placebo plus Placebo|Placebo (film-coated tablet once daily) plus Placebo (subcutaneous once-weekly injection) as add-on to high-dose intensive insulin therapy
89430685|NCT03419624|Active Comparator|Placebo plus Exenatide|Placebo (film-coated tablet once daily) plus Exenatide (2mg subcutaneous once- weekly injection) as add-on to high dose intensive insulin therapy
89430686|NCT05472376||3-month follow-up|
89430687|NCT05472376||6-month follow-up|
89430688|NCT05472376||12-month follow-up|
89430689|NCT05472376||24-month follow-up|
89430690|NCT05472376||36-month follow-up|
89430691|NCT05472298|Experimental|intervention arm|lifestyle modification, goal setting, coaching and peer support, problem-solving, and self-monitoring
89430692|NCT05472298|No Intervention|control arm|education leaflet
89430693|NCT03416660|Active Comparator|Low density|Fractional carbon dioxide laser: Lesion A or part A parameters: 20 W, 800-1000μs dwell time, 2 to 3 stacks according to scar thickness, 900µm spacing (7.4% density).
89430694|NCT03416660|Active Comparator|Medium density|Fractional carbon dioxide laser : Lesion B or part B parameters: 20 W, 800-1000μs dwell time, 2 to 3 stacks according to scar thickness, 600µm spacing (12.6% density).
89430695|NCT03416660|Active Comparator|High density|Fractional carbon dioxide laser : Lesion C or part C parameters: 20 W, 800-1000μs dwell time, 2 to 3 stacks according to scar thickness, 300 µm spacing (25.6% density).
89430696|NCT04800952|Other|To establish the appropriate dosing regimens of newly available antibiotics during CRRT|High dose (world standard dose) and low dose CRRT (Japan local) CRRT protocol Vascular access will be obtained by inserting a double-lumen dialysis catheter into the internal jugular or femoral veins. High dose CRRT in Australia, Blood flow through the extracorporeal circuit will be maintained at 150 ml/min. The CVVHF replacement volume will be set at 25ml/kg/hour and bicarbonate-buffered replacement fluids will be added in post-dilutional mode. Low dose CRRT in Japan, Blood flow through the extracorporeal circuit will be maintained at 80 ml/min. CVVHF replacement volume will be set at 15ml/kg/hour and bicarbonate-buffered replacement fluids will be added in the post-dilutional mode. Fluid balance, volume removal and the duration of CVVHF will be determined by the ICU physician based on the patient's individual clinical status.
89430697|NCT03419390|Other|Healthy subjects|One eye of each participant will be scanned with the investigational device (= combined Coaxial Optical Coherence Tomography (OCT) System)
89430698|NCT03419390|Other|Diseased groups|lf one eye is affected, this will be chosen. lf both eyes are be affected, the eye with the severest symptoms will be chosen. Scanning with the investigational device (= combined Coaxial Optical Coherence Tomography (OCT) System)
89430699|NCT03419390|Other|Diseased subgroups|"Every second subject will be allocated to the subgroup.~Scanning with the investigational device (= combined Coaxial Optical Coherence Tomography (OCT) System)~Thickness measurement with reference medical device."
89430700|NCT04800796||Intervention Group|Intervention Group with audiovisually blended learning concept
89430701|NCT04800796||Standard group|Standard Group receiving the Standard operating procedures via E-Mail and Confirmation when reading.
89430702|NCT03419312|Experimental|Study sequence A|"Proclaim™ Elite 5: Burst - Washout - Sham~14 days of burst stimulation.~7 days washout.~14 days of sham stimulation."
89430703|NCT03419312|Experimental|Study sequence B|"Proclaim™ Elite 5: Sham - Washout - Burst~14 days of sham stimulation.~7 days washout.~14 days of burst stimulation."
89430704|NCT04790500|Active Comparator|Group A|mobilization technique
89430705|NCT04790500|Experimental|Group B|muscle energy technique
89430706|NCT04790422|Experimental|Dietary fiber 1|
88910542|NCT04203173|Experimental|FINANCE-DM Intervention|The FINANCE-DM intervention is comprised of: 1) nurse education, 2) home telemonitoring, and 3) structured financial incentives.
89197636|NCT00576420|Active Comparator|Control Group- Manual compression with surgical gauze pads|Treatment of the study-suture line will be manual compression with surgical gauze pads.
89197637|NCT03846999||Long-term breast cancer survivors|"Analyze comorbidities and patterns of use of health services. Describe the specific use of health services in primary care vs. specialized care.~Analyze comorbidities and patterns of use of health services by tumor characteristics."
89197638|NCT03846999||Women without history of cancer|Analyze comorbidities and patterns of use of health services. Describe the specific use of health services in primary care vs. specialized care.
89197639|NCT00951964|Other|1|patients receive the treatment in first and placebo in second part of study
89197640|NCT00951964|Other|2|patients receive placebo in first and treatment in second part of study
89430707|NCT04790422|Experimental|Dietary fiber 2|
89430708|NCT04790422|Experimental|dietary fiber 3|
89430709|NCT04790422|Experimental|caseine protein hydrolisate|
89430710|NCT04790422|Placebo Comparator|Maltodextrine|
89430711|NCT03425240|Experimental|Nerve Stimulation|Acute placement of electrodes and electrostimulation of the pelvic plexus nerves during open radical prostatectomy.
89430712|NCT04790656|Active Comparator|Conventional Therapy|The control program will consist of progressive exercises according to each postoperative day. Two daily sessions with an average duration of 25 min will be performed. In addition to the physiotherapeutic program standardized by the hospital's team of physical therapists, the intervention group will perform physical exercise on a cycle ergometer with CPAP.
89430713|NCT04790656|Experimental|Cycle ergometer combine with CPAP|Physical exercise on a cycle ergometer combine with CPAP will be performed in a single daily session from the second to the fourth postoperative days
89430714|NCT03425162|Active Comparator|Group A|Group A:Ultrasound guided unilateral anterior Quadratus Lumborum block with 20 ml %0.25 bupivacaine+PCA (morphine)
89430715|NCT03425162|Sham Comparator|Group P|Group P:PCA (morphine)
89430716|NCT02096133|Experimental|Cholecalciferol|Patients receive 1dd 100ug vitamin D3 (drops) for 16 weeks
89430717|NCT02096133|Placebo Comparator|Placebo comparator|placebo drops during 16 weeks
89531182|NCT03339791|Active Comparator|Sleeve|Morbid obese patients, 65 years old or more, submitted to Sleeve Gastrectomy
89430718|NCT03416582|Experimental|SMENC Group|"The Symptom Management Education and Nurse Coaching (SMENC) intervention is a one hour in-person face-to-face education session followed by twice weekly telephone calls conducted all throughout the patient's chemoradiation treatment regimen.~During the telephone call, the patient will report the use of the Drinks Diary."
89430719|NCT02090517|Active Comparator|Pulsed Dye Laser|Subjects with multiple nose telangiectasias will be enrolled. One nose telangiectasia (of 5) will be treated with pulsed dye laser.
89430720|NCT02090517|Active Comparator|Long Pulsed Alexandrite Laser|Subjects with multiple nose telangiectasias will be enrolled. One nose telangiectasia (of 5) will be treated with long pulsed alexandrite laser.
89430721|NCT02090517|Active Comparator|Pulsed Dye Laser Plus Nd:YAG Laser|Subjects with multiple nose telangiectasias will be enrolled. One nose telangiectasia (of 5) will be treated with pulsed dye laser plus Nd:YAG laser.
89430722|NCT02090517|Active Comparator|Electrodesiccation|Subjects with multiple nose telangiectasias will be enrolled. One nose telangiectasia (of 5) will be treated with electrodesiccation.
89430723|NCT02090517|No Intervention|No Treatment|Subjects with multiple nose telangiectasias will be enrolled. One nose telangiectasia (of 5) will receive no treatment.
89430724|NCT03419156|Experimental|Text Message Arm|Patients in the Text Message Arm will receive a weekly set of text messages inquiring about the patients' symptoms instead of a weekly phone call from the nurse team (standard of care). Potentially harmful symptoms identified by the automated system will generate an alert that will be sent to the medical team. The alert will be immediately sent via email to the nursing team. The nurse will be able to contact the patient to decide the best further treatment. The nurses will check patient response rates daily. If a patient does not respond to their weekly message, then the patient will be called.
89430725|NCT02096289|Experimental|Thioridazine|Up to 3 dose levels of thioridazine will be assessed sequentially: 25 mg Q6H (Level I), 50 mg Q6H (Level II) and 100 mg Q6H (Level III). The duration of thioridazine therapy is for a total of 21 days (Days 1-22 on study). All patients will receive cytarabine 1 g/m2 administered as a 2 hour infusion for 5 consecutive days (Days 6-10 on study).
89430726|NCT04800640|No Intervention|No Electroanalgesia|The sample will consist of 132 individuals, of both sexes, where they will be randomly included in two groups: 1) Intervention group composed of 66 patients who will effectively receive the treatment through electroanalgesia through TENS; and 2) Control Group, which will also consist of 66 individuals; however, they will not be subjected to electroanalgesia
89430727|NCT04800640|Experimental|Electroanalgesia|The sample will consist of 132 individuals, of both sexes, where they will be randomly included in two groups: 1) Intervention group composed of 66 patients who will effectively receive the treatment through electroanalgesia through TENS; and 2) Control Group, which will also consist of 66 individuals; however, they will not be subjected to electroanalgesia
89430728|NCT03416504|Experimental|Gradual Exposure Group|The gradual exposure group received the Gradual Exposure (EXP-G) Intervention.
89430729|NCT03416504|Experimental|Variable Exposure Group|The variable exposure group received the Variable Exposure (EXP-V) Intervention.
89430730|NCT02090595|Experimental|MBCT-C|Mindfulness-Based Cognitive Therapy for Anxious Children (MBCT-C) is a 12-week manualized group therapy program for children with anxiety disorders. The program involves teaching children to pay attention to anxiety-related thoughts, emotions, and physical sensations with openness and non-judgment.
89430731|NCT02090595|Other|Waitlist Control|Education and Therapy
89430732|NCT02093481|Experimental|+ ind. CHO + prim|Test meal: ate intrinsic indigestible carbohydrates 3 days prior to measurements of variables (priming)
89430733|NCT02093481|Experimental|- ind. CHO + prim|Reference:ate no intrinsic indigestible carbohydrates 3 days prior to measurements of variables (priming)
89430734|NCT02093481|Experimental|+ ind. CHO - prim|Test meal: ate intrinsic indigestible carbohydrates 1 day prior to measurements of variables (no priming)
89430735|NCT02093481|Experimental|- ind. CHO - prim|Reference: ate no indigestible carbohydrates the day prior to measurements of variables (no priming).
89430736|NCT04775342||1 group|1 group will be assessed then will be given smartphone to use and assessed
89430737|NCT02090673||Group1:Type 2 diabetic patients treated with Exenatide therapy|Korean patients who are at least 18 years old, diagnosed with type 2 diabetes, and are treated with Exenatide in an ambulatory care setting according to the approved label
88910543|NCT04203173|Active Comparator|TIDES Intervention|Patients randomized to the active comparator group will be assigned the FORA 2-in-1 Telehealth System. A nurse educator will review the glucose and BP readings and use them to tailor and reinforce behavior change.
88910544|NCT04203147|Experimental|Home DM-BAT Intervention|A trained nurse educator will deliver the manualized Home DM-BAT intervention. Subjects will receive 8-weekly sessions of behavioral activation and monthly booster sessions from months 3-12 via telephone.
88910545|NCT04203147|Active Comparator|Control Group (GHE+ST)|Patients randomized to the control group will receive in-home 8-weekly sessions of combined general health education (GHE) and supportive therapy (ST) and monthly booster sessions from months 3-12 via telephone.
88910546|NCT04199026|Experimental|Device Feasibility (microdevice, surgery)|Patients undergo percutaneous implantation of up to 3 drug delivery microdevices up to 2 days before standard of care surgery. Patients receive doxorubicin hydrochloride, ifosfamide, vincristine, irinotecan, temozolomide, pazopanib, everolimus, polyethylene glycol, ganitumab, and temsirolimus via the microdevice in the absence of unacceptable toxicity. At the time of surgery 2 days later, patients have the drug delivery microdevice(s) removed.
88910547|NCT04191304|Experimental|Benralizumab arm|1x Benralizumab SC injection
89531183|NCT03339791|Active Comparator|Bypass|Morbid obese patients, 65 years old or more, submitted to Gastric Bypass
88910548|NCT04191304|Placebo Comparator|Placebo arm|1x Benralizumab matching placebo SC injection
89531184|NCT03095079|Experimental|EDP|Dacarbazine,DTIC： 250 mg/m2/d，IV, d1-5 Cisplatin PDD：75 mg/m2，IV Endostar ENDO：15 mg/m2/d，CIV,d1~14
89531185|NCT03120923|Experimental|Lidocaine 3 cc & Triamcinolone Acetonide|
89531186|NCT03120923|Active Comparator|Lidocaine 9cc & Triamcinolone Acetonide|
89531187|NCT03095157|Placebo Comparator|Placebo|
89531188|NCT03095157|Experimental|Treatment|
89197641|NCT00942760||Research MRI|High Grade Glioma patients who show progression based on MRI
89430738|NCT04758572|Experimental|Manual Therapy|"Mobilization. Axial decoaptation, talar mobilization, global and specific articulatory mobilization of the foot, mobilization of the fibular head, femorotibial mobilization, hip mobilization. In addition, lumbar joint mobilization is applied. The articulatory techniques last 15 minutes. Subsequently, Trigger Point Inhibition is applied. in the medial gastrocnemius, soleus, and square plantar muscles. The application of this technique lasted 15 minutes.~Plantar fascia massage. A deep friction technique was applied longitudinally and transversely to the plantar fascia and the triceps surae. It lasted 15 minutes.~Passive stretching. Stretches were applied to the plantar fascia, the gastrocnemius muscles and the soleus muscles in order to relax these muscles. The duration was 5/10 minutes."
89430739|NCT04758572|Sham Comparator|Placebo massage|Consist of gentle kneading and rubbing without intention to treat for 15 minutes.
89430740|NCT03419000|Experimental|Patient|Patients suffering from drug-resistant focal epilepsy or from drug-resistant generalized epilepsy according to ILAE classification and undergoing long-term video-EEG monitoring in Epilepsy unit of Lyon to record and characterize her/his seizure
89430741|NCT03419000|Active Comparator|healthy volunteers|Adult (≥ 18 years) Without history of neurological disorders and/or psychiatric disorders, and/or general medical disorders
89430742|NCT03556371|Experimental|N-acetylcysteine Treatment|Oral administration of two capsules, containing 600 milligrams (mg) of N-acetylcysteine each one, twice day (10.00 and 20.00 hours; Total = 2400 mg/day) for four weeks.
89430743|NCT03556371|Placebo Comparator|Placebo oral capsules|Oral administration of two capsules, containing 600 milligrams (mg) of Placebo each one, twice day (10.00 and 20.00 hours; Total = 2400 mg/day) for four weeks.
89430744|NCT04789798|Experimental|TeleDiab (Telemedicine)|"TeleDiab program components consist of:~Electronic transmission of capillary blood glucose measurement results~Electronic transmission of blood pressure measurements~Synchronized video-conferencing, secure messaging~Access to clinical data from patient files when necessary~Reminding of routine follow-up tests and examinations~Providing web-based educational materials to patients."
89430745|NCT04789798|Active Comparator|Usual Care|usual diabetes care, as provided by primary care providers in the hospital
89430746|NCT03416426||patients undergone PFO closure|patients with ischemic stroke and PFO documented by bubble contrast TEE with no other identifiable cause of the ischemic event who undergone PFO closure using Amplatzer® PFO occluder or Gore® Septal Occluder
89430747|NCT02090751||No Maculopathy|Aged 50 to 80 with no macular disease
89430748|NCT02090751||Early Maculopathy|Aged 50 to 80 with early AREDS defined 2,3 age related maculopathy
88910549|NCT04187703|Experimental|5AZA-alt-DEC|"Participants will be treated for a minimum of 24 weeks in the absence of clear evidence of progressive disease. Patients who have any response will be permitted to continue treatment until relapse or progression of disease that is not sensitive to protocol defined dose escalation.~Treatments will include:~5-azacytidine (50mg/m^2) Day 1 every week~Decitabine (5mg/m^2) Day 4 every week~Weeks 1-8 will be an induction phase, and weeks 9+ will be a long-term treatment phase"
89430749|NCT03906058|Experimental|Anlotinib|
89430750|NCT04799704||symptomatic patient|The first part of our study is to confirm the detectability of the SARS-nCoV-2 in the tear film of symptomatic patients.
89430751|NCT02096367|Experimental|Hemiplegia after vascular stroke|"Muscle vibration stimulation~Gait analysis with Gait Rite : quantitative and spatio-temporal gait parameters~Kinematic gait analysis in lower limb measured by optoelectronic system (Optitrack).~Analysis of static posture on force platform~Evaluation of the gait on treadmill during 2 minutes"
89430752|NCT04789876|Experimental|App Intervention Group (AIG)|Phosphate mobile app for 12 weeks.
88910550|NCT04184635|Experimental|Experimental ECMO + IABP Arm|"VA-ECMO will be instituted percutaneously under echo guidance via the femoral route as soon as possible.~An IABP will be systematically inserted in the contralateral femoral artery (unless technically not possible)."
88910551|NCT04184635|No Intervention|Control Conventional Treatment Arm|Standard management of cardiogenic shock due to myocardial infarction according to the current ESC guidelines. It is not recommended to use IABP support and no other TCS device (e.g., ECMO, Impella, Thoratec PHP, TandemHeart) will be permitted in the control group.
88910552|NCT04183595|Experimental|Arm A: NBMI (Study Medication)|600mg / day N1, N3-BIS- (2-MERCAPTOETHYL) ISOPHTHALAMIDE (NBMI) treatment for 14 days, administered as four capsules of 100 mg of NBMI every 24 hours.
88910553|NCT04183595|Placebo Comparator|Arm B: Placebo|(Excipients microcrystalline cellulose, silica and magnesium stearate) capsules will be administered every 24 hours for 14 days.
88910554|NCT04182204|Experimental|Pola-R-GemOx (Stage 1)|Participants will receive polatuzumab vedotin 1.8 milligrams per kilogram (mg/kg) for a maximum dose of 240 mg per cycle (mg/cycle) administered intravenously (IV) and rituximab 375 milligrams per square meter (mg/m^2) administered IV on Day 1. Participants will receive gemcitabine 1000 mg/m^2 administered IV and oxaliplatin 100 mg/m^2 administered IV on Day 2. Each cycle will consist of 21 days with up to 8 cycles of treatment administration.
88910555|NCT04182204|Experimental|Pola-R-GemOx (Stage 2)|Participants will receive polatuzumab vedotin 1.8 mg/kg for a maximum dose of 240 mg/cycle administered IV and rituximab 375 mg/m^2 administered IV on Day 1. Participants will receive gemcitabine 1000 mg/m^2 administered IV and oxaliplatin 100 mg/m^2 administered IV on Day 2. Each cycle will consist of 21 days with up to 8 cycles of treatment administration.
89430753|NCT04789876|Active Comparator|Dietitian Intervention Group (DIG)|One-off 45-minute dietary counselling delivered by a dietitian at the baseline of the study.
89430754|NCT02827526|Active Comparator|Ketamine|Patients in the ketamine arm will receive an intraoperative and postoperative infusion of ketamine
89430755|NCT02827526|Placebo Comparator|Control|Patients in the control arm will receive an intraoperative and postoperative infusion of dextrose
89430756|NCT04799314|Experimental|PD-1 Inhibitor maintenance|PD-1 Inhibitor Tislelizumab maintenance therapy dose 200mg frequency 1 time for 2 months duration 2 years
89430757|NCT04799314|No Intervention|No intervention|No intervention
89430758|NCT03425084|Experimental|Morphine|Intravenous morphine (0,15 mg/kg) will be given as a single dosis at the end of the surgery followed by morphine administrated by patient-controlled analgesia (PCA) as single boluses (0,04mg/kg)
89430759|NCT02096445|Experimental|Robot group|"Receive robot-assisted neurocognitive therapy instead of conventional neurocognitive therapy.~(4 x 45 min/week)"
89430760|NCT02096445|Active Comparator|Control group|Receive dose-matched conventional neurocognitive therapy
89430761|NCT03424928|Experimental|Pomalidomide 4 MG Oral Capsule|per os,capsule,4mg,1 capsule per period
89430762|NCT03424928|Experimental|Pomalidomide 4 MG Oral Capsule-Pomalyst|per os,capsule,4mg,1 capsule per period
89430763|NCT05449821||Periodontitis group|35 subjects had periodontitis. Periodontitis will be staged by including patients with a periodontal pocket (PD) measurement of 4 mm and above, accompanied by attachment loss and radiographic bone loss.
89430764|NCT05449821||Healthy group|30 subjects had healthy periodontal tissue.Healthy controls included volunteers with clinically healthy gingiva on an intact periodontium who had BOP < 10% and PD ≤ 3 mm, no sites with attachment loss, no radiographic sign of alveolar bone destruction, and no history of periodontitis.
89430765|NCT01878500|Experimental|Intraoperative stereotactic imaging|Surgeon will use intraoperative stereotactic imaging with VectorVision® Cranial Guided Image System by Brainlab Inc. to assist in bladder exstrophy closure.
89430766|NCT02093559|Experimental|Brief Counseling Intervention|The brief counseling intervention will utilize MI and skills-building techniques to modify personal overdose risk behaviors and develop skills as a peer responder for witnessed overdose. The counselor will draw upon themes of safer substance use to address HIV risk behaviors and determine readiness for change in substance use.
89430767|NCT02093559|No Intervention|Control Group|The control group will have access to brochures and be offered referral to services requested. SFDPH Community Behavioral Health Services (CBHS) provides immediate access to substance abuse treatment in San Francisco, including office- and clinic-based methadone and buprenorphine treatment. Given the pilot nature of this study, the control group will not be a full attention control; we will account for an attention effect due to assessment alone.
89430768|NCT04340284|Experimental|Patients with nonunion of long bones|A total of 11patients ( november 2012 to august 2018) with atrophic non-union of long bones already treated with percutaneous SVF implantation
89430769|NCT04448990|Experimental|tVNS|Stimulation will be applied using TENS device eco 2 (Schwa-Medico, Pierenkemper GmbH, Ehringshausen, Germany) bilaterally at the cymba conchae of the auricles for 20 minutes. Current intensity (1-max. 10 mA) will be individually adjusted for each ear separately until the maximal tVNS intensity, which is not uncomfortable or painful, will be achieved.
89430770|NCT04448990|Sham Comparator|Sham|Same stimulation will be applied using TENS device eco 2 (Schwa-Medico, Pierenkemper GmbH, Ehringshausen, Germany) to bilaterally to the earlobes for 20 minutes. Current intensity (1-max. 10 mA) will be individually adjusted for each ear separately until the maximal tVNS intensity, which is not uncomfortable or painful, will be achieved.
89430771|NCT02093637|Placebo Comparator|Placebo acupuncture|Placebo acupuncture up to 5 acupuncture needles* in each ear (up to 10 needles total) at points identified by point-finder to have no electrical conductance) plus usual operative and post-operative care (narcotic and non-narcotic pain medication).
89430772|NCT02093637|Experimental|Battlefield Acupuncture|Usual operative and post-operative care (narcotic and non-narcotic pain medication) plus Battlefield Acupuncture (up to 5 acupuncture needles* in each ear (up to 10 needles total), identified by a point-finder.
89430773|NCT02093637|No Intervention|standard therapy|standard therapy
89430774|NCT03424772||Patients with unexplained DD/ID|Whole genome sequencing will be performed on pediatric patients with unexplained developmental delay(DD)/intellectual disability(ID), multiple congenital abnormalities and other rare and undiagnosed diseases.
89430775|NCT02093715||RSV|Infant with acute bronchiolitis due to RSV
89430776|NCT02093715||Co- Infection|Infant with acute bronchiolitis due to RSV and other respiratory virus
89430777|NCT02093715||Other|Infant with acute bronchiolitis due to non-RSV respiratory virus
89197642|NCT02545179|Experimental|intervention|web-based daily care training 12 week interactive web based caring training education
89430778|NCT02093715||Unknown|Infant with acute bronchiolitis with negative PCR results for respiratory viruses
89430779|NCT02093715||Control|Healthy infants
89430780|NCT04799002|Active Comparator|Topotecan|Topotecan intraocular injection during chemotherapy
89430781|NCT04799002|Experimental|Melphalan|Melphalan intraocular injection during chemotherapy
89430782|NCT02250027|Experimental|experimental A (0.6g/day)|HL301 0.6g/day: 2 capsules at once, 3 times a day, for 7 days
89430783|NCT02250027|Experimental|experimental B (1.2g/day)|HL301 1.2g/day: 2 capsules at once, 3 times a day, for 7 days
89430784|NCT02250027|Experimental|experimental C (1.8g/day)|HL301 1.8g/day: 2 capsules at once, 3 times a day, for 7 days
89430785|NCT02250027|Placebo Comparator|Placebo|placebo: 2 capsules at once, 3 times a day, for 7 days
89430786|NCT03416192|Experimental|MCO-HD|Hemodialysis with Medium Cut-Off filter
89430787|NCT03416192|Active Comparator|High-flux HDF|Hemodiafiltration with standard high-flux filter
89430788|NCT04789642|Experimental|study group|A social group will be created on whatsapp for subjects of the intervention group and they will receive education about blood pressure measurement guidelines in 24 sessions, once per day in the form of text, image and video clips. In addition to British and Irish Hypertension Society (BIHS) blood pressure measurement auscultatory tutorials.
88910556|NCT04182204|Active Comparator|R-GemOx (Stage 2)|Participants will receive rituximab 375 mg/m^2 administered IV on Day 1. Participants will receive gemcitabine 1000 mg/m^2 administered IV and oxaliplatin 100 mg/m^2 administered IV on Day 2. Each cycle will consist of 21 days with up to 8 cycles of treatment administration.
88910557|NCT04181424|Active Comparator|Group 1- Diabetes Education Only|Individuals assigned to this group will receive diabetes education and skills training but will not receive food supplementation.
89430789|NCT04789642|No Intervention|control group|The control group will not receive any intervention only their routine education that is provided by the continuous staff development team of the hospital.
88910558|NCT04181424|Experimental|Group 2 - Diabetes Education Plus Monthly Food Vouchers|Individuals assigned to this group will receive diabetes education and skills training and monthly food vouchers for use at local Farmer's markets mailed to their home.
88910559|NCT04181424|Experimental|Group 3 - Diabetes Education Plus Monthly Stock Boxes|Individuals assigned to this group will receive diabetes education and skills training and monthly stock boxes with diabetes appropriate food items mailed to their home.
88910560|NCT04181424|Experimental|Group 4 -- Diabetes Education Plus Combination of Monthly Food|Individuals assigned to this group will receive diabetes education and skills training, monthly food vouchers for use at local Farmer's markets mailed to their home, and monthly stock boxes with diabetes appropriate food items mailed to their home.
88910561|NCT04177433|Experimental|Corticosteroid Injection|Pre-filled opaque syringe containing 40 mg (1cc) of depo-medrol combined with 0.5 cc of 1% lidocaine (or 1cc saline + 0.5 cc 1% lidocaine) will be injected in the symptomatic CMC joint using fluoroscopic imaging to ensure injection into the joint. If both CMC joints are symptomatic, the most symptomatic joint will be injected. If both CMC joints are equally symptomatic, the dominant hand will be injected.
89430790|NCT02096523|Experimental|platelet disease|patients with inherited platelet disorders
89430791|NCT02096523|Experimental|Healthy|Healthy family members of patients with inherited platelet disorders
89430792|NCT04788706|Active Comparator|Group I|LLLT over three weeks followed by an eight-week receiving Russian electrical stimulation
89430793|NCT04788706|Placebo Comparator|Group II|Placebo laser over three weeks followed by an eight-week receiving Russian electrical stimulation
89430794|NCT04788706|Active Comparator|Group III|LLLT over three weeks followed by an eight-week receiving LLLT application combined with Russian electrical stimulation
88910562|NCT04177433|Placebo Comparator|Saline|Pre-filled opaque syringe containing 0.5 cc of 1% lidocaine (or 1cc saline + 0.5 cc 1% lidocaine) will be injected in the symptomatic CMC joint using ultrasound imaging to ensure accuracy of injected location. If both CMC joints are symptomatic, the most symptomatic joint will be injected. If both CMC joints are equally symptomatic, the dominant hand will be injected.
88910563|NCT04175301|Experimental|Hydrogen|Five times per day for 6 weeks subjects will dissolve a hydrogen generating tablet into water and drink the effervescent water. Dissolving one tablet in 250 mL of water will achieve a saturating hydrogen concentration of approximately 1.6 ppm.
89197643|NCT02545179|No Intervention|control|Previous therapy
89430795|NCT04788706|Placebo Comparator|Group IV|Placebo laser over three weeks followed by an eight-week receiving Placebo laser application combined with Russian electrical stimulation
89430796|NCT05615740|Active Comparator|Healthy pediatric patients|Healthy pediatric patients will undergo optical coherence tomography.
89430797|NCT05615740|Active Comparator|Children with diabetes mellitus|Children with diabetes mellitus will undergo optical coherence tomography.
89430798|NCT02098785|Experimental|Caffeine citrate (Peyona) 400mg|Caffeine Citrate (Peyona) 400mg single dose (20ml oral solution)
89430799|NCT02098941||Topiramate|Subjects who newly visited to the investigator institution during January 1st 2006 to December 31st of 2010 and began their treatment with topiramate as mono or add-on therapy with conventional drugs.
89430800|NCT02098941||Levetiracetam|Subjects who newly visited to the investigator institution during January 1st 2006 to December 31st of 2010 and began their treatment with levetiracetam as mono or add-on therapy with conventional drugs.
89430801|NCT02098941||Oxcarbazepine|Subjects who newly visited to the investigator institution during January 1st 2006 to December 31st of 2010 and began their treatment with oxcarbazepine as mono or add-on therapy with conventional drugs.
89430802|NCT04798456||Patients with DoC|
89430803|NCT04798456||Caregivers/ legal guardian of patients with DoC|
89430804|NCT03556059|Active Comparator|RNYGB|The role of EOSS for the surgical intervention: Roux-en-Y gastric bypass for severe obesity
89430805|NCT03556059|Active Comparator|Sleeve|The role of EOSS for the surgical intervention: Sleeve Gastrectomy for severe obesity
89430806|NCT03556059|Active Comparator|MGB/OAGB|The role of EOSS for the surgical intervention: Mini/One anastomosis gastric bypass for severe obesity
89430807|NCT03424616|Experimental|Postoperative immediate Deep brain stimulation|The addicts undergone the deep brain stimulation while the stimulation (Suzhou Sceneray® DBS System) was turned on 1-2 weeks postoperatively.
89430808|NCT03424616|Sham Comparator|Postoperative delayed Deep brain stimulation|The addicts undergone the deep brain stimulation while the stimulation (Suzhou Sceneray® DBS System) was off until 25 months postoperatively, during which the following up was kept, then the the stimulation was turned on 25 months postoperatively.
89430809|NCT02096757|Placebo Comparator|Placebo|Pro-Omega Placebo soybean capsules; 4.4gm/day (Nordic Naturals, Watsonville, CA, USA) 2 weeks prior to surgery and continued for 4 weeks after.
88910564|NCT04175301|Placebo Comparator|Placebo|Five times per day for 6 weeks subjects will dissolve an placebo tablet into water and drink the effervescent water. The effervescent placebo tablet does not generate hydrogen-enriched water.
88910565|NCT04174924||Phakic intraocular lens (pIOL) explantation|Patients with pIOLs where a combined pIOL explantation and cataract surgery is needed.
88910566|NCT04174924||Cataract extraction|Healthy control group of patients scheduled for regular cataract surgery without comorbidities affecting an immune response.
88910567|NCT04172597|Experimental|Cohort 1|Patients with HER2-positive or HER2-negative BC with a HER2 activating mutation will receive poziotinib 8 milligrams (mg), orally, twice daily (BID) starting on Day 1 of each 28 day cycle for up to 24 months unless there is disease progression, death, intolerable AEs, or another protocol-specified reason for participant withdrawal. Loperamide may be prescribed for the treatment of diarrhea as needed.
88910568|NCT04172597|Experimental|Cohort 2|Patients with CRC with a HER2 activating mutation will receive poziotinib 8 mg, orally, BID starting on Day 1 of each 28 day cycle for up to 24 months unless there is disease progression, death, intolerable AEs, or another protocol-specified reason for participant withdrawal. Loperamide may be prescribed for the treatment of diarrhea as needed.
88910569|NCT04172597|Experimental|Cohort 3|Patients with CRC with a HER2 activating mutation will receive poziotinib 8 mg, orally, BID starting on Day 1 of each 28 day cycle for up to 24 months unless there is disease progression, death, intolerable AEs, or another protocol-specified reason for participant withdrawal. Loperamide may be prescribed for the treatment of diarrhea as needed.
88910570|NCT04172597|Experimental|Cohort 4|Patients with CRC with a HER2 activating mutation will receive poziotinib 8 mg, orally, BID starting on Day 1 of each 28 day cycle for up to 24 months unless there is disease progression, death, intolerable AEs, or another protocol-specified reason for participant withdrawal. Loperamide may be prescribed for the treatment of diarrhea as needed.
88910571|NCT04172597|Experimental|Cohort 5|Patients with CRC with a HER2 activating mutation will receive poziotinib 8 mg, orally, BID starting on Day 1 of each 28 day cycle for up to 24 months unless there is disease progression, death, intolerable AEs, or another protocol-specified reason for participant withdrawal. Loperamide may be prescribed for the treatment of diarrhea as needed.
88910572|NCT04166604|Experimental|trifluridine/tipiracil|35mg/m² BID (PER OS) (one cycle every 4 weeks)
88910573|NCT04163809|No Intervention|Control Group (no VR)|Patients will be randomly allocated to the control group, which receives no Virtual Reality (VR) during the regional anesthesia procedure.
88910574|NCT04163809|Experimental|Experimental Group (VR)|Patients will be randomly allocated to the the experimental group, which receives VR during the regional anesthesia procedure.
88910575|NCT04163419|Experimental|Arm A (treatment)|Tanezumab 10 mg SC administered on day 1 and Day 57 (± 4 days)
88910576|NCT04163419|Placebo Comparator|Arm B (placebo then treatment)|Placebo SC (to match tanezumab SC) administered on Day 1 and tanezumab 10 mg SC on Day 57 (± 4 days)
88910577|NCT04161248|Experimental|Venetoclax + R-GDP|
88910578|NCT04161248|Experimental|Glofitamab + R-GDP|
88910579|NCT04161248|Experimental|Tafasitamab + R-GDP|
89008465|NCT03454126|Experimental|Cohort 6: BIIB095 600 mg|Following an overnight fast from food of at least 8 hours, participants will receive a single dose of either BIIB095 600 mg or placebo orally, followed by a fast of at least 4 hours post dose.
89197644|NCT00749034|Experimental|1|VPM1002 in three dosages
89197645|NCT00749034|Active Comparator|2|BCG
89430810|NCT02096757|Experimental|Pro-Omega|High-dose, short-duration dietary omega-3 fatty acids supplementation; 325mg of EPA and 225mg of DHA per capsule. 4.4gm/day (Nordic Naturals, Watsonville, CA, USA) 2 weeks prior to surgery and continued for 4 weeks after.
89430811|NCT03418766||Normal|Normal healthy individual without migraine.
89430812|NCT03418766||Magraine|Clinical history of migraine diagnosed by a neurologist according to the International Classification of Headache Disorders.
89430813|NCT02093871|Experimental|ThermalCore Hyperthermia System|Patients will undergo 6 cycles of therapeutic hyperthermia with the ThermalCore Perfusion Induced Systemic Hyperthermia System every 28 days
89430814|NCT05430100|Experimental|Breast Milk Pacifiers Group|To determine the effectiveness of breast milk pacifier in reducing pain caused by Orogastric Tube (OGT) insertion in preterm newborns by monitoring behavioral and physiological changes in infants.
89430815|NCT05430100|Experimental|Sucrose Pacifiers Group|To determine the effectiveness of sucrose pacifier in reducing pain caused by Orogastric Tube (OGT) insertion in preterm newborns by monitoring behavioral and physiological changes in infants.
89430816|NCT05430100|Experimental|Pacifiers Group|To determine the effectiveness of pacifier in reducing pain caused by Orogastric Tube (OGT) insertion in preterm newborns by monitoring behavioral and physiological changes in infants.
88910580|NCT04159909|Experimental|VNS transcutaneous stimulation|"5 minutes of stimulation (VNS) twice a day for 4 days. Patients will receive transcutaneous stimulation (30 Hz, 300 msec.) on the auricular branch of the vagus nerve 5 minutes twice a day for 4 days. Due to the theoretical risk that right vagus nerve stimulation could affect the heart, and to ensure consistency of the intervention, all subjects randomized to receive transcutaneous vagus nerve stimulation will receive stimulation of the auricular branch of the left vagus nerve. The subject will be blinded to their treatment arm.~The device to be used will include a handheld electrical pulse generator and a pair of electrodes to be placed at the ear for stimulation. The specific target at the ear will be the auricular branch of the vagus nerve, which innervates the skin of a specific ear area termed Cymba Concha. Electrodes will be placed on this area to provide stimulation to the auricular branch of the afferent vagus nerve."
89430817|NCT05430100|No Intervention|Control Group|The camera recording will be started 5 minutes before the OGT insertion procedure and the routine OGT placement process will be performed. No pain-related procedures are performed during routine OGT in the NICU.
89430818|NCT03418688|Active Comparator|COR388|Increasing doses of COR388 will be administered for 10 days in cohorts 1-3 and for 28 days in cohort 4.
89430819|NCT03418688|Placebo Comparator|Placebo|Matching placebo capsules will be administered for 10 days in cohorts 1-3 and for 28 days in cohort 4.
89430820|NCT02521064||Exclusive Enteral Nutrition (EEN)|The patient will be admitted to hospital for placement of the nasogastric tube and commencement of exclusive enteral nutrition (EEN). Nutritional feeds will consist of a semi-elemental (whey-peptide based) formula that will make up all of the patient's daily caloric needs (120% of BMR). Feeds will slowly be titrated up to full volume and strength during the hospital stay. The patient will receive instructions how to decrease the number of hours of feeds once at home. The patient will be seen in clinic at two weeks and will receive a phone call from the dietician at 4 weeks to assess progress and symptom improvement. At 8 weeks, food will start to be reintroduced slowly, as per the dietician's instructions.
89430821|NCT02521064||Prednisone|Patients who receive the prednisone intervention will follow the Division of Pediatric Gastroenterology and Nutrition protocol for corticosteroid induction therapy, with 2 weeks of high dose IV/PO prednisone (maximum 40mg/day) followed by a 6 week wean (approximately decreasing 5mg/day per week). The patient will receive a phone call from the nurse practitioner at two weeks and will be seen in clinic at 4 weeks to assess progress and symptom improvement.
89430822|NCT02099097|Active Comparator|Standard Care|"usual care, which consists of four (face-to-face or telephone) counseling sessions with a trained nurse who has expertise in helping cancer patients quit smoking. This is the same as the treatment an MSK patient who enrolls in the MSK smoking cessation program would receive.~To collect further data to improve the game intervention, the investigators will conduct semi-structured telephone interviews with patients who were randomized to the treatment arm but did not play the game during the one month intervention period. The purpose of the interviews is to elicit qualitative feedback on any barriers that may have prevented participants from playing. At the completion of the intervention period, patients will be asked if they would like to participate in a telephone interview. Telephone interviews will take about twenty minutes and will be held at a time that is convenient for the patient."
89430823|NCT02099097|Experimental|Smoking Cues Coping Skills Game (SC+SCCS/Quit IT).|Smokers randomly assigned to SC+SCCS/Quit IT will receive all the components of Standard Care. The patient will be oriented and trained face-to-face (during their hospitalization) on use of the game by study staff using an iPad. The orientation and training session will comprise: 1) Overview of the game and its objectives; 2) discussion of the rules of the game; 3) watching a 10 minute tutorial given by the game narrator (avatar); 4) answering all patient questions; and 5) evaluation of the patient's comprehension of game play via a 17 question survey. Once patients have access to QuitIT, they will also receive a set of Coping Cards
89430824|NCT03424538|Experimental|MSt|The MSt group that received 5 weeks of intensive therapy.
89430825|NCT03424538|No Intervention|MSc|The MS controll group that did not receive treatment.
89430826|NCT03424538|Experimental|MStp|The MStp Group performs a traditional physiotherapy for 5 weeks.
89430827|NCT02096913|Active Comparator|Dolormin® extra (Ibuprofen) 4 weeks|
89430828|NCT02096913|Active Comparator|Dolormin® extra (Ibuprofen) 12 weeks|
89430829|NCT03418610|Other|Open Label Single Arm|Azelaic Acid Foam 15% applied twice daily
89430830|NCT03031197|Experimental|Tailored realtime triggered reminder pkg|The core intervention will utilize innovative wireless technology to provide patients with 1) real time, personalized wireless reminder messages when ART doses are not taken on time, and 2) 'feedback' on adherence behavior via monthly interactive counseling sessions informed by summaries of their previous month's behavior. The core intervention will be personalized by each intervention arm patient, who may choose features to suit their preferences.
89430831|NCT03031197|No Intervention|Control|Comparison subjects will receive usual care and an offer of counseling at monthly clinic visits.
89430832|NCT04604366|Active Comparator|vaginal mesoprostol|Vaginal dose---800 microgram 3 hourly two doses
89430833|NCT04604366|Experimental|sublingual mesoprostol|Sub lingual 600 microgram 3 hourly two doses
89430834|NCT02099253|Experimental|Youth Group|People in this group, aged 18~39,were accepted an initial dose of 1μg/kg, with dose adjustment intervals of 0.05μg/kg.
89197646|NCT00856713|Experimental|1 YM|Healthy young males
89197647|NCT00856713|Experimental|2 EM|Healthy elderly males
89197648|NCT00856713|Experimental|3 YF|Healthy young females
89197649|NCT00856713|Experimental|4 EF|Healthy elderly females
89430835|NCT02099253|Experimental|Middle-aged Group|People in this group, aged 40~64,were accepted an initial dose of 1μg/kg, with dose adjustment intervals of 0.05μg/kg.
89430836|NCT02099253|Experimental|Older Group|People in this group, aged 65~80,were accepted an initial dose of 0.7μg/kg, with dose adjustment intervals of 0.05μg/kg.
89430837|NCT05818449|Experimental|DigiNet group|The intervention group will receive the DigiNet intervention.
89430838|NCT05818449|No Intervention|Comparison group|The comparison group will receive usual care.
89430839|NCT05818436|Experimental|Experimental: Oral Functionalization Prosthesis repairment|Experimental: Oral Functionalization Prosthesis repairment: prosthetic reline and occlusal stabilization through repair of missing pieces and recovery of occlusal contacts and follow up with conventional prosthesis treatment
89430840|NCT05818436|Active Comparator|Active Comparator: control|Active Comparator: control conventional prosthetic treatment (new prosthesis)
89430841|NCT03419546||Bronchoscopic procedures|Bronchoscopies performed in different sites to evaluate the level of satisfaction of the operators with the device Ambu® aScope™ 4
89430842|NCT05818371|Other|Pathologic and non-pathologic intracranial pressure|Sonographic determination of Optic nerve sheath. Parallel recording of ICP
89430843|NCT05818306|Experimental|Cohort A Dose 1|Oral, daily administration of BL-001 Dose 1 or Placebo randomized 3:1 (BL-001: Placebo)
89430844|NCT05818306|Experimental|Cohort B Dose 2|Oral, daily administration of BL-001 Dose 2 or Placebo randomized 3:1 (BL-001: Placebo)
89430845|NCT05818306|Experimental|Cohort C Dose 3|Oral, daily administration of BL-001 Dose 3 or Placebo randomized 3:1 (BL-001: Placebo)
89430846|NCT05818306|Experimental|Cohort D Dose 4|Oral, daily administration of BL-001 Dose 4 or Placebo randomized 3:1 (BL-001: Placebo)
89430847|NCT05818241||Cast|Patients that are conservatively treated (in a cast, either without or with reduction)
89430848|NCT05818241||Surgery|Patients that undergo surgical treatment (regardless of method)
89430849|NCT05818215||All participants|Data from electronic medical records of all patients under 16 years of age with medical, surgical and traumatology emergencies attending the paediatric emergency departments during the study period
89430850|NCT05818202||Stroke patients|The stroke patients who can understand the questionnaires, have only a stroke history, and not have another neurological condition which affect the study.
89430851|NCT05818202||Physiotherapists|Physiotherapists graduated from a university with at least a bachelor degree of physiotherapy and rehabilitation and work in Denizli.
89430852|NCT05818163||with postoperative complications|Patients who experience postoperative complications after anesthesia, with symptoms such as pain, nausea and vomiting, delirium, and agitation.
89430853|NCT05818163||without postoperative complications|Patients who do not experience postoperative complications after anesthesia, free from symptoms such as pain, nausea and vomiting, delirium, and agitation.
89430854|NCT05818111|Experimental|low volume hydrodilatation|patient received ultrasound-guided low volume steroid hydrodilatation (4cc shincort + 4cc 2% xylocaine +2cc normal saline)
89430855|NCT05818111|Active Comparator|high volume hydrodilatation|patient received ultrasound-guided high volume steroid hydrodilatation (4cc shincort + 4cc 2% xylocaine +12cc normal saline)
89430856|NCT05818098|Experimental|Intravascular Lithotripsy System|Subjects in experimental group will be treated with the Intravascular Lithotripsy System manufactured by Shanghai Microport Rhythm Co. Ltd.
89430857|NCT05818059|Other|ARM 1: without computer-aided detection (CAD)|Diagnosis of tuberculosis without the aid of CAD
89430858|NCT05818059|Other|ARM 2: with computer-aided detection (CAD)|Diagnosis of tuberculosis with the aid of CAD
89430859|NCT05818007|Experimental|hyaluronic acid|The hyaluronic acid is a natural polysaccharide composed of D-glucuronic acid and N-acetyl-D-glucosamine and is synthesized as a linear polymer. The majority of the cells have a capacity to synthesize HA at a varying extent in the cell cycle.
89430860|NCT05818007|Active Comparator|sodium bicarbonate|
89197650|NCT00856713|Experimental|5 CTP-A|Patients with hepatic cirrhosis CTP-class A
89430861|NCT05817981||Adolescent and Young Adult Cancer Survivors|Adolescent and young adult cancer survivors who aged range from 15 to 39, having been diagnosed with cancer and completed cancer treatment for at least 6 months.
89430862|NCT05817981||Clinical oncology medical staff|Medical staff who routinely work in the oncology ward.
89430863|NCT05817955|Experimental|Azacitidine (AZA) with Ruxolitinib|"The treatment phase of each course of treatment is based on Azacitidine (AZA)+Ruxolitinib. Specific scheme: (1) Azacitidine+Ruxolitinib scheme: Azacitidine (AZA) 75mg · m-2 · D-1, D1 to D7, subcutaneous injection; Ruxolitinib, D1 to D28, orally, select Ruxolitinib initial dose according to platelet level: ① PLT> 100X10*9/L: 20mg BID orally; ② PLT (50-100) X10*9/L: 15mg BID orally; ③ PLT <50X10*9/L: 10mg Bid orally.~The above schemes are all 28 days of treatment. If the patient has serious adverse reactions (such as infection and bone marrow suppression), appropriately delay the next course of treatment or adjust the amount of RUXOLITINIB. Termination of the scheme treatment."
89430864|NCT05817916|Active Comparator|ESP Block|
89430865|NCT05817916|Active Comparator|LP block|
89197651|NCT00856713|Experimental|6 CTP-BC|Patients with hepatic cirrhosis CTP-class B and C
89430866|NCT05817864||Observational group|All participants included will be in one observational cohort.
89430867|NCT05817838|Other|Attention control: Academic Engagement|This intervention will be delivered using a similar format and schedule as the financial incentive+nutrition education, motivational interviewing and dietary norms intervention group (i.e., 11 community health worker led in-person group based sessions at the Center for Southeast Asians, 3 MI phone calls, and text messages). The content will focus on family-specific family engagement methods to improve children's academic outcomes.
89430868|NCT05817838|Experimental|Financial incentive only|Participants will receive weekly financial incentive coupons to purchase eligible foods at the partnering Southeast Asian grocery store. Research Assistants will explain the coupon procedures during the randomization phone call. Research Assistants will mail the adult a schedule of coupon disbursement dates. RAs will mail one month's worth of coupons (4, $15 coupons) to each adult's home. Coupons will be used at point-of-sale. Participants' will receive an automated weekly text message via Qualtrics directing them to upload their photos to the system if they used coupons during that week.
89430869|NCT05817838|Experimental|Financial incentive + nutrition education, motivational interviewing, dietary norms messages|The intervention consists of a) four $15 financial incentive coupons each month; b) twice-monthly group-based nutrition education at the Center for SEA; c) motivational interviewing (months 1, 3, 5); and d) weekly dietary norms text messages sent to adults and twice-monthly dietary norms infographics presented at nutrition education sessions for children. The research assistants will disburse one months' worth of the financial incentive coupon at the nutrition education sessions (or home mailings for absent participants). Families will attend 11 fortnightly, group-based nutrition education sessions lasting one hour. Southeast Asian community health workers will lead the sessions. Research assistants trained in motivational interviewing will call the adults. The calls will last 15-20 minutes. Adults will receive a series of weekly, interactive descriptive dietary norms text messages. Children will see descriptive dietary norms infographics at children's nutrition education sessions.
89430870|NCT05817799|Experimental|intervention|"L-Carnitine 500mg thrice daily~1g L-Carnitine IV three times a week"
89430871|NCT05817799|No Intervention|control|no intervention given
89430872|NCT05817760|Experimental|Z-scrotoplasty|Pediatric patients with congenital penoscrotal web who will be treated by Z-scrotoplasty
89430873|NCT05817760|Experimental|Heineke-Mikulicz scrotoplasty|Pediatric patients with congenital penoscrotal web who will be treated by Heineke-Mikulicz scrotoplasty
89430874|NCT05817747|Experimental|Surgery|Participants will after the dialogue support tool has been undergo surgery.
89430875|NCT05817747|Placebo Comparator|Non-surgery|Participants will after the dialogue support tool has been used not undergo surgery.
89430876|NCT05817682|Experimental|Intervention group|
89430877|NCT05817682|No Intervention|Control group|
89430878|NCT05817630||Group A|Group A: 3 months SO Tamponade
89430879|NCT05817630||Group B|Group B: 6 months SO Tamponade
89430880|NCT05817604||Localized Renal Cancer|Stereotatic Body Radiotherapy (SBRT) 13Gyx3 fraction-squeme for Medically Inoperable Localized Renal Cancer [Size <7cm (cT1b)] based on TC, MRI or PET Image Study.
89430881|NCT05817565||intervention group|"Patients underwent physical therapy program 3days/week for three months in the form of~Heat therapy by using infrared on the cervical region for relaxation of spasmed neck muscles, while the patient in sitting position.~While the patient is sitting, the ultrasound was applied on the para spinal muscles of cervical region for controlling pain.~Intermittent cervical traction (traction force equal 8% of body weight) was applied with the patient lying supine and the head in neutral position."
89430882|NCT05817513|Experimental|Control group|(Control group): will consist of 26 young females . They will receive traditional exercises for scoliosis.
89430883|NCT05817513|Experimental|(Study group)|(Study group): will consist of 26 young females. They will receive the same traditional scoliosis exercises in addition to myofascial release ( MFR ) .
89430884|NCT05817500||ICU patients with > 48h mechanical ventilation and/or > 5 days stay in ICU|
89430885|NCT05817487|Experimental|HIIT group|
89430886|NCT05817487|Experimental|COP group|
88910581|NCT04159909|Sham Comparator|Sham stimulation|"5 minutes of sham stimulation (no electrical stimulation) twice a day for 4 days Patients will receive sham stimulation on the auricular branch of the vagus nerve 5 minutes twice a day for 4 days.~The subject will be blinded to their treatment arm. The specific target at the ear will be the auricular branch of the vagus nerve, which innervates the skin of a specific ear area termed Cymba Concha. Electrodes will be placed on this area to provide sham stimulation (no electrical current) to the auricular branch of the afferent vagus nerve."
89430887|NCT05818176|Experimental|NAVIRFA® Navigation System|
89430888|NCT05818176|Active Comparator|ultrasound-guided|
89430889|NCT05817435|Experimental|Efgartigimod PH20 SC - prefilled syringe|efgartigimod PH20 SC administered by a prefilled syringe
89430890|NCT05817435|Active Comparator|Efgartigimod PH20 SC - vial + syringe|efgartigimod PH20 SC administered by a vial + syringe
89531189|NCT02497079|Experimental|Nested PCR for formalin-fixed tissues|In all patients, nested polymerase chain reaction for Mycobacterium tuberculosis is performed with formalin-fixed paraffin-embedded specimens obtained by endobronchial ultrasound-guided transbronchial needle aspiration.
89531190|NCT02497079|Experimental|Nested PCR for fresh tissues|In all patients, nested polymerase chain reaction for Mycobacterium tuberculosis is performed with specimens in sterile saline obtained by endobronchial ultrasound-guided transbronchial needle aspiration.
88910582|NCT04158934||Haemophilia A Group|Participants with haemophilia A in the study will receive ADYNOVI/ADYNOVATE prescribed prophylactically by physicians based on their standard clinical practice and in accordance with the national summary of product characteristics (SmPC).
88910583|NCT04153175|Active Comparator|CT-010 Active Therapy|Subjects in the active comparator arm will have been randomized to receive active therapy through the implanted drug delivery system through the 3-month blinded period.
89430891|NCT05817396|Experimental|Cooperative Planning for Promoting PAHCO|"Participatively developed intervention concept by means of cooperative planning (Rütten, 1997) to promote physical activity-related health competence (PAHCO): A separate cooperative planning process will take place in each of the four schools in this study arm from April to November 2023. Within the framework of these processes, suitable interventions tailored to the target group and the school will be developed for the implementation of the curriculum content PAHCO with the participation of actors from science and practice (e.g., teachers, nursing students of the schools). The developed interventions will be implemented from December 2023 under the responsibility of the actors in the schools."
89430892|NCT05817396|Experimental|Expert-Based Intervention for Promoting PAHCO Delivered by External Physical Activity Specialists|"Expert-based intervention concept with external physical activity specialists to promote physical activity-related health competence (PAHCO). We will develop a specific intervention concept for the implementation of the curriculum content PAHCO at nursing schools in Bavaria from April to November 2023. Currently (March 2022), it is planned that the intervention will comprise 12 sessions with a duration of 45 or 90 minutes. The entire intervention will be specified during the different steps of intervention mapping (i.e., needs assessment, goal formulation, screening evidence-based intervention content). Physical activity specialists (e.g. sports scientists, physiotherapists) will be trained to implement this expert-based intervention concept from December 2023 to March 2024."
89430893|NCT05817396|Experimental|Expert-Based Intervention for Promoting PAHCO Delivered by Teachers|"Expert-based intervention concept with teachers as multipliers to promote physical activity-related health competence (PAHCO). We will develop a specific intervention concept for the implementation of the curriculum content PAHCO at nursing schools in Bavaria from April to November 2023. Currently (March 2022), it is planned that the intervention will comprise 12 sessions with a duration of 45 or 90 minutes. The entire intervention will be specified during the different steps of intervention mapping (i.e., needs assessment, goal formulation, screening evidence-based intervention content). Teachers of the participating nursing schools of this study arm will be trained to implement this expert-based intervention concept in their school from December 2023 to March 2024."
89430894|NCT05817396|No Intervention|Regular Education and Health Promotion|"No systematic intervention concept: In the schools of this study arm, there is no systematic and scientifically supported intervention for the implementation of the curriculum content PAHCO."
89430895|NCT05817357|Experimental|Installation of air purifier (Rensair Ltd - Rensair Compact)|Rensair Compact air purifier unit will be installed in the homes of all children/young people participating in this study for a period of one-year.
89430896|NCT05817331||Patient|Patients with MDS
89430897|NCT05817331||Carer|Carers of patients with MDS
89430898|NCT05817331||Clinician|Clinicians who treat MDS
89430899|NCT05817305||Cardiac outpatients|Patients with stable cardiovascular disease who have been referred to the service by their general practitioner or cardiologist
89430900|NCT05817292||Probiotic|Assumption of commercially available supplements containing probiotics
89430901|NCT05817292||Control|No assumption of supplements containing probiotics
89430902|NCT05817253|Experimental|Early Letter + Portrait Arm|Early Letter + Portrait Arm received a Portrait + Therapeutics Letter with the initial mailing (September 23, 2021). At the delayed mailing (March 28, 2022), Early Letter + Portrait Arm received nothing.
89430903|NCT05817253|Experimental|Delayed Control Arm|Delayed Control Arm received nothing with the initial mailing (on September 23, 2021). At the delayed mailing (March 28, 2022), Delayed Control Arm received a Portrait +Therapeutics Letter.
89430904|NCT05817253|Experimental|Early Letter Arm|Early Letter Arm received a Therapeutics Letter only with the initial mailing (September 23, 2021). At the delayed mailing (March 28, 2022), Early Letter Arm received a Portrait + Therapeutics Letter
89430905|NCT05817214|Experimental|Treatment arm|This trial has a single treatment arm. All participants will receive small treatment including cadonilimab and anlotinib in this arm
88910584|NCT04153175|Placebo Comparator|Placebo|Subjects in the placebo comparator arm will have been randomized to receive placebo therapy through the implanted drug delivery system for the 3-month blinded period.
89430906|NCT05817201|Experimental|Toripalimab & Radiotherapy|Toripalimab, 240mg/d, radiotherapy D7, D28; Thoracic radiotherapy, 54Gy/25F, IMRT; Maintenance Toripalimab therapy after completed radiotherapy, 240mg/Q3W, until progression or 1 years or intolerant
89430907|NCT05817201|Active Comparator|Chemotherapy & Radiotherapy|Tegafur, 70mg/m2/d, radiotherapy D1-14, D29-42; Thoracic radiotherapy, 54Gy/25F, IMRT.
89430908|NCT05817149||Patients with melanoma|Patients with melanoma undergoing sentinel lymph node biopsy with perioperative blood samples.
89430909|NCT05817136||coronary HF aetiology|Patients with coronary HF
89430910|NCT05817136||non-coronary HF aetiology|Patients with non-coronary HF
89430911|NCT05817032|Experimental|Telerehabilitation group|Baseline measurement will be done in the rehabilitation center. Prescription for rehabilitation will be determined based on the result of baseline measurement. Participants will receive rehabilitation intervention that include telerehabilitation (video conference regular meeting, text message reminder, and mobile app). Participants will attend a regular check up at the center once a month. After 12 weeks post intervention measurement will be taken.
89430912|NCT05817032|Active Comparator|Control group|Baseline measurement will be done in the rehabilitation center. Prescription for rehabilitation will be determined based on the result of baseline measurement. Participants will be given instruction how to do proper exercise training at home. Participants will attend a regular check up at the center once a month. After 12 weeks post intervention measurement will be taken.
89430913|NCT05817019|Experimental|Sugammadex|sugammadex 2mg/kg
89430914|NCT05817019|Active Comparator|Neostigmine|neostigmine 50µg/kg + glycopyrollate 0.01mg/kg
89430915|NCT05817006|Experimental|Long-COVID-19|conducting laboratory tests, questionnaires, physical examination
89430916|NCT05816980|Other|Single|Re-irradiation consisting of hyperfractionated IMRT, 40.8 Gy in 1.2 fractions twice daily 5/7 days weekly, with oral capecitabine 825 mg/m2 BID on radiotherapy treatment days. Re-staging performed 4-6 weeks after the last dose, followed by surgery, when feasible.
88910585|NCT04145115|Experimental|Treatment (nivolumab, ipilimumab)|Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive nivolumab IV over 30 minutes on day 1. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Patients also undergo MRI throughout the study.
88910586|NCT04142866|Experimental|A-tDCS & speech-language therapy|Anodal transcranial direct current stimulation (2 milliamps [mA]) plus aphasia therapy for 16 sessions (20-minutes per each 60-minute treatment session) over the course of 8 weeks. The electrical current will be administered over ventral inferior frontal gyrus. The stimulation will be delivered at an intensity of 2 milliamps (mA) for a maximum of 20 minutes.
89197652|NCT04059510||Screening for GBS|Women will be recruited for screening for GBS in the UK and Uganda (250 at each site). At screening women will be consented for a vaginal and rectal swab to assess for GBS carriage and will also undergo an asymptomatic STI screen according to local usual practice. Anyone who meets the full inclusion criteria following screening will be invited to take part in the sampling study until the recruitment targets are reached. If any woman tests positive for any of the infections, she will be referred to a local centre for treatment and may still be included after completed treatment for the infection.
89430917|NCT05816967|Experimental|Intervention group|In the monocentric interventional part of the study, the effect of discharge counseling on the acceptance of pharmacotherapeutic recommendations will be evaluated 1 and 3 months after discharge.
89430918|NCT05816928||COVID19-associated ARDS (CARDS)|This group included COVID19 patients with acute respiratory distress syndrome. Patients were put under prone position while their pulmonary function was measured using EIT before and after proning.
89430919|NCT05816928||Non-COVID19-associated ARDS (non-CARDS)|This group included patients with acute respiratory distress syndrome from other etiologies. Patients were put under prone position while their pulmonary function was measured using EIT before and after proning.
89430920|NCT05816902||validation set 1|The validation set 1 was comprised of patients with CRC diagnosed and treated between January 1, 2016, and December 31, 2020, at the Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College.
89430921|NCT05816902||validation set 2|The validation set 2 was comprised of patients with CRC diagnosed and treated between January 1, 2016, and December 31, 2020, at the Second Affiliated Hospital of Harbin Medical University.
89430922|NCT05816876||Patients with primary ciliary dyskinesia|"Exercise capacity assessed using six minute walk test, physical activity using multi-sensor activity monitor, pulmonary function using spirometry, respiratory muscle strength using mouth pressure device, peripheral muscle strength using hand held dynamometer, respiratory muscle endurance using incremental threshold loading test, life quality using The Primary Ciliary Dyskinesia Quality of Life scale (Turkish version)."
89531191|NCT02497079|Experimental|Real-time PCR for fresh tissues|In all patients, real-time polymerase chain reaction for Mycobacterium tuberculosis is performed with specimens in sterile saline obtained by endobronchial ultrasound-guided transbronchial needle aspiration.
89531192|NCT02494271||Total intravenous anesthesia|Total intravenous anesthesia using propofol and remifentanil
89430923|NCT05816876||Patients with Kartagener Syndrome|"Exercise capacity assessed using six minute walk test, physical activity using multi-sensor activity monitor, pulmonary function using spirometry, respiratory muscle strength using mouth pressure device, peripheral muscle strength using hand held dynamometer, respiratory muscle endurance using incremental threshold loading test, life quality using The Primary Ciliary Dyskinesia Quality of Life scale (Turkish version)."
89430924|NCT05816876||Healthy controls|"Exercise capacity assessed using six minute walk test, physical activity using multi-sensor activity monitor, pulmonary function using spirometry, respiratory muscle strength using mouth pressure device, peripheral muscle strength using hand held dynamometer, respiratory muscle endurance using incremental threshold loading test, life quality using The Primary Ciliary Dyskinesia Quality of Life scale (Turkish version)."
89430925|NCT05816863||Experimental|pabolizumab
89430926|NCT05816772|Experimental|Endosequence Bio ceramic based Sealer|Sealer was introduced into the canal by coating the master gutta-percha point (Endosequence, Brasseler USA, Gutta Percha ) with sealer, followed by cold lateral compaction using a finger spreader # 30 and # 35 (Saybron Endo) with decreasing working length by 1-2 mm. A heated plugger was used to sear off GuttaPercha coronal to canal orifice.Recordings of postoperative pain was obtained at 24 hours, 48 hours, 72 hours and 7 days after obturation with aid of the Visual Analogue Scale.
89430927|NCT05816772|Active Comparator|Sealapex calcium hydroxide based sealer|Sealer was introduced into the canal by coating the master gutta-percha point (Dentsply Sirona, GuttaPercha Conform fit) with sealer, followed by cold lateral compaction using a finger spreader # 30 and # 35 (Saybron Endo) with decreasing working length by 1-2 mm. A heated plugger was used to sear off GuttaPercha coronal to canal orifice.Recordings of postoperative pain was obtained at 24 hours, 48 hours, 72 hours and 7 days after obturation with aid of the Visual Analogue Scale.
89430928|NCT05816720||Initial treatment|Patients who received initial treatment with lutetium-177 DOTATATE
89430929|NCT05816720||Re-treatment|Patients who received re-treatment with lutetium-177 DOTATATE
89430930|NCT05816720||Additional re-treatment|Patients who received additional re-treatment with lutetium-177 DOTATATE
89430931|NCT05816694|Active Comparator|CEP|Cisplatin was administered as 50 mg/m2 IV infusion on Day 1; Epirubicin was administered as 75 mg/m2 IV infusion on Day 1; Cyclophosphamide was administered as 500 mg/m2IV infusion on Day 1 of each 3-week cycle.Patients will receive maximum of 4 cycles if they do not meet the criteria for removal from the study.
89430932|NCT05816694|Experimental|NAB-Paclitaxel|NAB-Paclitaxel will be administered as 125 mg/m2 IV infusion on Day 1 、Day8 of each 3-week cycle. Cisplatin will be administered as 75 mg/m2 IV infusion on Day 1 of each 3-week cycle. Patients will receive maximum of 4 cycles if they do not meet the criteria for removal from the study.
89430933|NCT05816668|Experimental|Tranexamic Acid Group|Patients will receive an attack solution of 1,0 g of tranexamic acid 20 minutes before the surgery beginning, followed by a maintence dose of 1,0 mg/kg/h in pump surgery infusion
89430934|NCT05816668|Placebo Comparator|Placebo Group|Patients undergoinf to videolaparoscopic surgery will receive physcological saline as placebo under the same conditions of the tranexamic acid group.
89430935|NCT05816642|Active Comparator|Single targeted therapy|sunitinib or pazopanib
89430936|NCT05816642|Experimental|targeted therapy combined with immunotherapy|Programmed death-ligand 1 Inhibitor combined with axitinib
89430937|NCT05816577|Active Comparator|EcN|E Coli Nissle wildtype 10^11 once daily for 7 days
88910587|NCT04142866|Sham Comparator|Sham-tDCS & speech-language therapy|Sham transcranial direct current stimulation (2 milliamps [mA]) plus aphasia therapy for 16 sessions (20-minutes per each 60-minute treatment session) over the course of 8 weeks. Electrodes will be placed as in A-tDCS. Current will be ramped up for the first 30 seconds following which the intensity will drop to 0 milliamps (mA).
88910588|NCT04137978|Active Comparator|ADV7103|"Patients receive ADV7103 twice a day at optimal dose. Each dose of ADV7103 contains a fixed ratio of 1/3 of ADV7103-CK (potassium citrate) and 2/3 of ADV7103-BK (potassium bicarbonate) based on the mass of active substances.~Other Names:~• Potassium Citrate and Potassium Bicarbonate"
88910589|NCT04137978|Active Comparator|Standard of care comparator|Alkalinising treatment (SoC) taken at the usual dose and frequency
89430938|NCT05816577|Experimental|EcN colibactin-knockout|EcN colibactin-knockout 10^11 once daily for 7 days
89430939|NCT05816564|Experimental|Experimental Group|This is group that will receive the attention bias modification intervention that is programmed to train attention to positive stimuli 100% of the time. Both groups will receive the preceding 3-day brief mindfulness training.
88910590|NCT04136275|Experimental|CAR-37 T cells|"CAR-37 will be administered intravenously on day 0~Enrolled subjects will undergo a leukapheresis procedure processing approximately two times the subject's total blood volume.~Subjects will receive 3 days of lymphodepleting chemotherapy starting Day -5, before the infusion of CAR-37 T cells on Day 0"
88910591|NCT04136275|Experimental|CAR-37 T cells Dose Escalation|"CAR-37 will be administered intravenously on day 0~Enrolled subjects will undergo a leukapheresis procedure processing approximately two times the subject's total blood volume.~CAR-37 will undergo dose escalation"
89430940|NCT05816564|Placebo Comparator|Placebo/Control Group|"This is group that will receive the sham attention bias modification intervention that is programmed to train attention to positive stimuli 50% of the time. Both groups will receive the preceding 3-day brief mindfulness training."
88910592|NCT04132362||People living with dementia, their families and carers|The cohort consists of people living with dementia. Each of them will be accompanied, throughout the study, by a family member or friend. They will take part together in a one hour music listening session, to discover their personalised playlist. Where possible, a care home staff member will join in, in order to witness the benefits of the music to the dementia resident and learn how to provide the music, as part of their care in the care home.
88910593|NCT04128228|Other|Alcohol use disorder|Individuals with alcohol use disorder will receive an equivalent 8 week outpatient treatment.
89430941|NCT05816538|Active Comparator|Group 1 PVB|Group 1 will receive paravertebral block (PVB) as analgesia for breast surgery. PVB is a regional anesthetic technique applied at the thoracic (Th) level of Th2, Th3, and Th4 at a dose of 0.3ml/kg 0.5% levobupivacaine total, divided into levels. Block will be performed with ultrasound-guided in-plane technique and neurostimulation.
89430942|NCT05816538|Experimental|Group 2 PECS|Group 2 will receive Pectoralis and Serratus Plane Nerve blocks (PECS 2) as analgesia for breast surgery. PECS 2 block is a regional anesthetic technique applied in the space between the large and small pectoral muscles (10 ml of 0.5% levobupivacaine), and in the space between the small pectoralis muscle and the serratus anterior muscle (with 15 ml of 0.5% levobupivacaine). Block will be performed with ultrasound-guided in-plane technique and neurostimulation.
89430943|NCT05813990|Other|Pediatric patient with conductive hearing loss|All pediatric patients aged below 18 years old will subjected to reconstructive ear surgery (ossiculoplasty)
88910594|NCT04128228|No Intervention|Controls|Control participants will undergo a baseline assessment without receiving any outpatient treatment.
88910595|NCT04127578|Experimental|Dose Level 1|
88910596|NCT04127578|Experimental|Dose Level 2|
88910597|NCT04122313||Patients with Dupuytren's Contracture Disease|Patients with Dupuytren's Disease following the current treatment pathway
88910598|NCT04119843|Experimental|Mangoral|All participants will receive a single dose of Mangoral (equivalent to 800 mg Manganese (II) chloride tetrahydrate [MnCl2 4H2O]).
88910599|NCT04109716|Experimental|Interpersonal Psychotherapy-Adolescent Skills Training|Interpersonal Psychotherapy-Adolescent Skills Training (IPT-AST) is an indicated group depression prevention program. In IPT-AST, adolescents learn communication (e.g., using I statements, striking while the iron is cold) and interpersonal problem-solving strategies and apply these strategies to their relationships to decrease conflict, increase social support, and improve overall social functioning. IPT-AST consists of 1 or 2 individual pre-group sessions, 1 mid-group session, 8 weekly group sessions, and up to 6 individual booster sessions. Parents are invited to attend the mid-group session so the adolescents can apply the interpersonal strategies in a conversation with a parent. The purpose of the booster sessions is to monitor symptoms and apply the interpersonal strategies to current stressors. These sessions are designed to help solidify the interpersonal skills and address current problems before they result in a worsening of symptoms.
88910600|NCT04109716|Active Comparator|Services as Usual (SAU)|Investigators anticipate that counselors in SAU will see youth in the study for brief, periodic sessions and/or will refer youth for treatment in the community. Counselors will be permitted to see the adolescents as often as they would like throughout the course of the study (up to 15-months post-baseline). Investigators will ask counselors to complete a form each time they see a teen, noting the length of the session, whether the session was scheduled or not, and the topics discussed.
89430944|NCT05813444||Main Cohort|Dental students on the university hospital of Nice
89430945|NCT05809583||ozanimod|Patients with UC starting ozanimod therapy as part of their clinical care
89531193|NCT02494271||Inhalation|Balanced inhalation anesthesia using volatile anesthetics and remifentanil
89531194|NCT04135677|Active Comparator|DAPT group|asprin 100mg qd together clopidogrel 75mg for 24 weeks
89430946|NCT05806775|Experimental|Low-load resistance training with blood flow restriction|Exercises will target bilateral 1) knee extensor, 2) ankle plantarflexor, and 3) elbow extensor muscles. Exercises will be dosed based on 1RM and individualized for each participant from a standardized exercise set. Progression will be based on 1) body position (supine, seated, standing), and 2) degree of resistance. Dosing will be re-assessed every 2 weeks and progressed as tolerated. Resistance will be provided by the Shuttle Mini-Press (Shuttle Systems), a portable resistance trainer that allows for precise dosing but is also adaptable to people with mobility limitations.
89430947|NCT05805813|Experimental|Group A|group A carry on continuous ambulatory peritoneal dialysis (the original dialysis method) for 1 month, and then changed to intermittent peritoneal dialysis at night (using automatic peritoneal dialysis machine) for 1 month
89430948|NCT05805813|Experimental|Group B|Group B carry on intermittent peritoneal dialysis at night (using automatic peritoneal dialysis machine) for 1 month, and then change to continuous ambulatory peritoneal dialysis (original dialysis method) for 1 month.
89430949|NCT05803629|Experimental|68Ga-FAPI ,PET/CT|Inject 68Ga-FAPI and then perform PET/CT scan.
89430950|NCT05803434|Experimental|Cannabidiol treatment|
89430951|NCT05802576||Vitamin K|The vitamin K oral anticoagulant will be used on 25 patients.
89430952|NCT05802576||Apixaban|The apixaban oral anticoagulant will be used on 25 patients.
89430953|NCT05802576||Rivaroxaban|The rivaroxaban oral anticoagulant will be used on 25 patients.
89430954|NCT05802576||Dabigatran|The dabigatran oral anticoagulant will be used on 25 patients.
89430955|NCT05800184||Individuals with a shoulder injury|Individuals from a population based sample of 600 individuals aged 40 to 75 years that sustain a shoulder injury or a sudden onset of significant shoulder symptoms.
89430956|NCT05787873|Experimental|Sequence A|"Period 1: SIPS-2209-1 - A single oral dose of 1 tablet under fasting condition~Period 2: SIPS-2209-2, SIPS-2209-3 - A single oral dose of 2 tablets under fasting condition"
89430957|NCT05787873|Experimental|Sequence B|"Period 1: SIPS-2209-2, SIPS-2209-3 - A single oral dose of 2 tablets under fasting condition~Period 2: SIPS-2209-1 - A single oral dose of 1 tablet under fasting condition"
89430958|NCT05785676||Vena Cava Filter|Participants implanted with the vena cava filter OATF (ALN)
89430959|NCT05777226|Experimental|Epalrestat treatment group|Epalrestat;Tablet; 50mg; three times a day; 36 months
89008466|NCT03454126|Experimental|Cohort 7: BIIB095 50 mg BID|Participants will receive a single dose of either BIIB095 50 mg or placebo orally BID approximately 12 hours apart from Days 1 to 13, and once in the morning on Day 14. Morning doses will be preceded by an overnight fast from food of at least 8 hours and will be followed by a fast of at least 2 hours post dose. Evening doses will be preceded by a fast from food of at least 2 hours and will be followed by a fast of at least 2 hours post dose.
89008467|NCT03454126|Experimental|Cohort 8: BIIB095 100 mg BID|Participants will receive a single dose of either BIIB095 100 mg or placebo orally BID approximately 12 hours apart from Days 1 to 13, and once in the morning on Day 14. Morning doses will be preceded by an overnight fast from food of at least 8 hours and will be followed by a fast of at least 2 hours post dose. Evening doses will be preceded by a fast from food of at least 2 hours and will be followed by a fast of at least 2 hours post dose.
89430960|NCT05777226|No Intervention|control group|No Intervention
89430961|NCT05773209|Experimental|RLRL of 100% intensity|Participants will be treated with RLRL treatment (100% intensity) twice per day with an interval of at least 4 hours, each treatment last 3 minutes. Cross over arms after one month of use and one month of washout period.
89008468|NCT03454126|Experimental|Cohort 9: BIIB095 200 mg BID|Participants will receive a single dose of either BIIB095 200 mg or placebo orally BID approximately 12 hours apart from Days 1 to 13, and once in the morning on Day 14. Morning doses will be preceded by an overnight fast from food of at least 8 hours and will be followed by a fast of at least 2 hours post dose. Evening doses will be preceded by a fast from food of at least 2 hours and will be followed by a fast of at least 2 hours post dose.
89430962|NCT05773209|Sham Comparator|RLRL of 5% intensity|Participants will be treated with the sham device (5% intensity) twice per day with an interval of at least 4 hours, each treatment last 3 minutes. Cross over arms after one month of use and one month of washout period.
89430963|NCT05769920|Experimental|TTHX1114 Dose Level 1|TTHX1114(NM141) Ophthalmic Solution (DL1): 1 drop (gtt) to the Study Eye (SE) twice daily for a total of 7 days
89430964|NCT05769920|Experimental|TTHX1114 Dose Level 2|TTHX1114(NM141) Ophthalmic Solution (DL2): 1 drop (gtt) to the Study Eye (SE) twice daily for a total of 7 days
88910601|NCT04109235|Active Comparator|Population-Based Physical Activity (PA) Advice|This PA intervention will be primarily self-directed by the patients themselves. Each participant will receive a 1-page double-sided handout detailing their PA protocol. Participants in this arm will receive a CSEP handout (page 4&5 from: http://csep.ca/CMFiles/Guidelines/CSEP_PAGuidelines_0-65plus_en.pdf) detailing their PA recommendations.Participants will be instructed to follow their PA protocol, while noting down which days they completed the PA using a log booklet provided to them by Dr. Fernando (their family physician). Participants will be provided with the phone number for a research assistant who is a lifestyle coach and co-investigator on this trial. If participants have questions about their PA protocol, the research assistant will respond to these over the phone.
88910602|NCT04109235|Experimental|High-Intensity Interval Training Physical Activity (PA) Advice|This PA intervention will be primarily self-directed by the patients themselves. Each participant will receive a 1-page double-sided handout detailing their PA protocol. Participants in this arm will receive a High-Intensity-Interval-Training (HIIT) handout (developed based on research from Dr. Martin Gibala) detailing their PA recommendations. Participants will be instructed to follow their PA protocol, while noting down which days they completed the PA using a log booklet provided to them by Dr. Fernando (their family physician). Participants will be provided with the phone number for a research assistant who is a lifestyle coach and co-investigator on this trial. If participants have questions about their PA protocol, the research assistant will respond to these over the phone.
88910603|NCT04103307|No Intervention|Control: Standard of care|Participants in the control group will receive standard-of-care CRRT prescriptions, and have the returning venous blood warmed with an external blood warmer to a temperature of 37°C. The blood warmer temperature will be adjusted by the CRRT nurse as per usual practice to maintain normothermia.
89430965|NCT05769920|Experimental|TTHX1114 Dose Level 3|TTHX1114(NM141) Ophthalmic Solution (DL3): 1 drop (gtt) to the Study Eye (SE) twice daily for a total of 7 days
89430966|NCT05769920|Experimental|TTHX1114 Dose Level 4|TTHX1114(NM141) Ophthalmic Solution (DL4): 1 drop (gtt) to the Study Eye (SE) twice daily for a total of 7 days
89430967|NCT05766462||PLR group|The pacemaker lower rate of PLR group will be set as 75 bpm and might be adjusted according to physician diagnosis based on patients situation.
89430968|NCT05766462||control group|The pacemaker lower rate of control group will be set as 60 bpm.
89430969|NCT05757245|Experimental|GMCN-508A|GMCN-508A infusion
89430970|NCT05747963|Experimental|software-delivered CBT-I|Subjects in intervention group will receive a digital CBT-I for 6 weeks. The automated software incorporates all core elements of CBT-I, tailoring content based on each participant's reported baseline sleep function and sleep progress.
89430971|NCT05747963|Active Comparator|online PE|Subjects in control group will receive information about insomnia and sleep health education content.
89430972|NCT05738304|Experimental|External Ureteral Catheter group|After RIRS, an external ureteral catheter will be placed for one day.
89430973|NCT05738304|Active Comparator|Double J group|After RIRS, a double J internal ureteral stent will be placed for 2 weeks.
89430974|NCT05730842|Experimental|Part A - AME|Evaluation of absorption, metabolism, excretion and pharmacokinetics of a single oral dose of radiolabeled EDG-5506 in healthy male volunteers
89531195|NCT04135677|Experimental|Anticoagulation group|rivaroxaban 20mg qd for for 12 weeks and continued DAPT(asprin 100mg qd together clopidogrel 75mg) for 24 weeks
89430975|NCT05730842|Experimental|Part B - aBA|Evaluation of bioavailability of a single oral dose of EDG-5506 followed by a single intravenous dose of radiolabeled EDG-5506 in healthy male volunteers
89008469|NCT03454126|Experimental|Cohort 10: BIIB095 300 mg BID|Participants will receive a single dose of either BIIB095 300 mg or placebo orally BID approximately 12 hours apart from Days 1 to 13, and once in the morning on Day 14. Morning doses will be preceded by an overnight fast from food of at least 8 hours and will be followed by a fast of at least 2 hours post dose. Evening doses will be preceded by a fast from food of at least 2 hours and will be followed by a fast of at least 2 hours post dose.
89008470|NCT04592263||Group 1 - Qualitative phase|4 focus groups and 6 semi-structured interviews.
89008471|NCT04592263||Group 2 - Quantitative phase|Pilot study of the tools developed from phase 1.
89430976|NCT05720078|Experimental|Adaptive, two-phase RT|
89008472|NCT02961309|Experimental|Active THC|5.6% THC via smoked marijuana cigarette
89008473|NCT02961309|Experimental|Placebo|Placebo THC via smoked cigarette
89008474|NCT04592302||Smoking Cessation Group|participants are required to cease smoking for 4 weeks prior to and 2 weeks after TJA without any nicotine replacement (any other smoking cessation aids the patient chooses will be allowed)
89430977|NCT05716607|Experimental|Once-daily dual-release hydrocortisone|
89430978|NCT05716607|Active Comparator|Thrice-daily conventional immediate-release hydrocortisone|
89430979|NCT05713201||Index PCI|Patients with an aneurysmatic right coronary artery undergoing index PCI in the acute setting.
89430980|NCT05713201||Staged PCI|Patients with an aneurysmatic right coronary artery undergoing staged PCI in the acute setting.
89430981|NCT05709340|Experimental|study group|
89430982|NCT05709340|Active Comparator|control group|
89430983|NCT05699343|Experimental|Bone grafting with collagen membrane|This arm will receive surgical intervention involving placement of a bone xenograft subsitute (InterOss Collagen) into the peri-implant bone defect with a collagen membrane (InterCollagen Guide) placed over the bone graft.
89430984|NCT05699343|Active Comparator|Bone grafting without collagen membrane|This arm will receive surgical intervention involving placement of a bone xenograft subsitute (InterOss Collagen) into the peri-implant bone defect with no collagen membrane placed over the graft.
89430985|NCT05688579|Experimental|Mineralocorticoid Receptor Antagonists(MRAs)|Participants will treat with mineralocorticoid receptor antagonists(MRAs) (including spironolactone 20-60mg/ day, or eplerenone50-100mg/day, or finerenone 10-20mg/ day) in addition to the original antihypertensive drugs for 48 months.
89430986|NCT05688579|Placebo Comparator|Blank Control|Participants will be given the original antihypertensive drugs for 48 months.
89430987|NCT05688267|Experimental|Experimental group|The continuous mobility training adopted grading exercise level, which was evaluated and implemented by physical therapists, and focused on continuous mobility training courses with different levels. At each stage, the participants were instructed to perform spontaneous breathing exercise, which were confirmed by the physical therapists. The five stages are half-lying on the bed, sitting at the bedside, sitting on the chair, standing and marching on spot.
89531196|NCT02494193|Active Comparator|Regular Treatment|Partial caries removal; Provisional restoration - control; Total caries removal; Definitive restoration.
89531197|NCT02494193|Experimental|Alternative Treatment|Partial caries removal; Provisional restoration - experimental; Total caries removal; Definitive restoration.
89531198|NCT03339557|Active Comparator|PFC Total Knee Replacement|PFC, Conventional design Perioperative treatment will be carried out according to routine protocol of the hospital.
89430988|NCT05688267|Placebo Comparator|Control group|Participants of control group formed the routine care group, received the routine mechanical ventilation weaning plan and underwent hand bicycle training. The physicians assessed the participants and appropriately adjusted the settings of the mechanical ventilation modules to gradually reduce the participants' dependence on mechanical ventilation. Hand bicycle training was conducted by nurse practitioners once a day. The participants' bedhead was raised, and the participants held the cycle ergometer with both hands once they could tolerate upright positions for 15-20 minutes. Training intensity was targeted at the level of symptom limitation, on the basis of a modified Borg scale rating of 3-5. Intermittent and short-term periods of rest were allowed for participants to achieve the goal of a total of 15-20 minutes exercise session.
89430989|NCT05688072|Active Comparator|study group (A)|
89430990|NCT05688072|Active Comparator|Study group (B)|
89430991|NCT05675501|Experimental|Study Drug|Daily Encapsulated Benzoyl Peroxide (E-BPO) Cream, for 8 weeks (period 1). Subjects will then switch treatments to the vehicle cream for a period of 4 weeks (period 2),
89430992|NCT05675501|Placebo Comparator|Vehicle|Daily Vehicle Cream, for 8 weeks (period 1). Subjects will then switch treatments to the study drug encapsulated E-BPO for a period of 4 weeks (period 2),
89430993|NCT05673603|Experimental|Cohort 1 (Mild Impairment): Brensocatib|Participants with mild renal impairment will receive single oral dose of brensocatib on Day 1 under fasted conditions.
89430994|NCT05673603|Experimental|Cohort 2 (Moderate Impairment): Brensocatib|Participants with moderate renal impairment will receive single oral dose of brensocatib on Day 1 under fasted conditions.
89430995|NCT05673603|Experimental|Cohort 3 (Severe Impairment): Brensocatib|Participants with severe renal impairment will receive single oral dose of brensocatib on Day 1 under fasted conditions.
88910604|NCT04103307|Experimental|Intervention: Cooling|Participants in the intervention group will receive standard of care CRRT prescriptions and have the blood warmer set to 35.5°C, as long as the nasopharyngeal temperature remains above 35.5°C.
88910605|NCT04102436|Experimental|1/Sleeping Beauty|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + Sleeping Beauty Transposed PBL + high- or low-dose aldesleukin.
88910606|NCT04101565|Experimental|Text4Father|Receipt of twice-weekly texts that include resource links and instructions to support behavior change (e.g., videos, infographics) and start mid-pregnancy and continuing through 2 months of baby's age.
88910607|NCT04101565|No Intervention|Usual care|Usual care that is consistent with typical maternity care in involving expectant fathers.
88910608|NCT04097054|Experimental|Intervention|Patients in the interventional arm are operated after augmented planning of the procedure. The plan is prepared by the surgeon and made available to the study team a day prior to the procedure and on a screen in the OR during the procedure. The plan includes the current and next operative step, the used equipment and the approximate time used as well as the estimated time of when the procedure will end.
88910609|NCT04097054|No Intervention|Control|In the control cases no particular planning and distribution of operative plan is performed. The standard preparation only includes the distribution of information on the desired positioning of the patient, necessary special equipment and the overall estimated OR time.
88910610|NCT04094961|Experimental|ixazomib plus pomalidomide and dexamethasone|"The study drugs will be administered within a 21-day cycle~Phase I will follow a standard 3 +3 dose escalation design: Starting with the first cohort, 3 to 6 patients will be treated at this and each subsequent dose level.~The Phase II portion of the study will be a single-arm open-label enrollment with dosing based on the MTD determination in the Phase I portion of the study"
88910611|NCT04094610|Experimental|Repotrectinib (TPX-0005)|"Phase 1~Oral repotrectinib (TPX-0005):~Safety and tolerability at different dose levels~Phase 2~Oral repotrectinib (TPX-0005): 3 cohorts~Cohort 1: TKI-naive NTRK fusion Cohort 2: Prior TKI NTRK fusion Cohort 3: ROS1 gene fusions or other ROS1 aberrations"
88910612|NCT04091386||Hemophilia A patients|Patients with hemophilia A who are being treated with Damoctocog alfa pegol (Jivi, BAY94-9027) in routine medical practice and are enrolled in Bayer-sponsored study NCT03932201
88910613|NCT04090983|Active Comparator|Cognitive-behavioral therapy (Hesslinger protocol)|
89197653|NCT04059510||Sampling method optimisation|"If a woman is deemed to meet all inclusion criteria and no exclusion criteria following screening and is willing to take part in the sampling method optimisation study, she will be consented again for the further study including consent (optional) for participation in a focus group at the end of the study. 100 eligible women will be recruited on to this part of the study (50 colonised with GBS at baseline and 50 uncolonised with GBS at baseline) at each site (UK and Uganda).~The sampling study will last for 12 weeks and samples collected include:~A self-taken low vaginal swab~A self-taken rectal swab~Menstrual cup fluid~Serum sample~Urine pregnancy tests"
89430996|NCT05673603|Experimental|Cohort 4 (Normal): Brensocatib|Healthy participants with normal renal function will receive single oral dose of brensocatib on Day 1 under fasted conditions. Healthy participants will be matched within the protocol criteria to one or more participants with renal impairment.
89430997|NCT05662111|Active Comparator|Etidronate|Etidronate 20 mg/kg for two weeks on and ten weeks off during 12 months
89430998|NCT05662111|Placebo Comparator|Placebo|Placebo for two weeks on and ten weeks off during 12 months
89430999|NCT05659823|Active Comparator|Control group|Elective CS patients receiving current analgesia.
89431000|NCT05659823|Experimental|Intervention group|Elective CS patients receiving guideline recommended analgesia.
89431001|NCT05659823|Experimental|Emergency group|Emergency CS receiving current analgesia.
89431002|NCT05640453|Active Comparator|Pregabalin group|Patients will receive pregabalin capsules (75 mg) every 12 h for 24 hours by nasogastric tube.
89431003|NCT05640453|Active Comparator|Dexmedetomidine group|Patients will receive a bolus dose of 0.4 μg/kg dexmedetomidine (over a period of 10 to 20 min) followed by an infusion of 0.2 to 0.7 μg/h.
89431004|NCT05635851|Experimental|Glyceryl trinitrate sublingual spray|Glyceryl trinitrate (GTN) sublingual spray will be administered up to three times every fifteen minutes, each dose being 0.4mg.
89431005|NCT05635851|Placebo Comparator|Placebo sublingual spray|An approximate flavour-matched placebo sublingual spray will be administered up to three times every fifteen minutes.
89431006|NCT05633836|Experimental|Fluorescence guided surgery|During exploratory laparoscopy or at the end of macroscopically complete cytoreductive surgery, indocyanine green fluorescence-guided surgery is performed to identify peritoneal carcinoma lesions not visible in white light
89431007|NCT05611255|Experimental|Systematic Intermittent Catheterization (SIC)|A bladder catheter will be placed in the operating room, at the end of the operation, in a patient still under general anesthesia. Once the urine has been drained and quantified, the bladder catheter will be removed before the patient is discharged and extubated.
89431008|NCT05611255|Active Comparator|Bladder Scan Guided Catheterization (BSGC)|No systematic catheterization will be performed, the indication for catheterization will be guided by bladder-scan volume monitoring.
89431009|NCT05594134|Experimental|Automatic toothbrush with nylon bristles|
89431010|NCT05594134|Active Comparator|Automatic toothbrush with silicone bristles|
89431011|NCT05594134|Active Comparator|Manual toothbrush used for 2 minutes|
89431012|NCT05594134|Active Comparator|Manual toothbrush used for 45 seconds|
89431013|NCT05594134|No Intervention|No brushing|
89431014|NCT05591989|Experimental|Treatment|Subjects will undergo treatment with the NEUROMARK System
89431015|NCT05582018|Experimental|BioTrace|Use of the BioTraceIO 360 device for planning, monitoring and assessment of liver tissue ablations
89008475|NCT04592302||Smoker Group 2|participants who are allowed to continue smoking and using nicotine in any form at their own discretion during the perioperative period
89008476|NCT04592146|Active Comparator|Control group|Participants randomized into the intervention group will receive care according to the current organizational model in each pilot site (managed by community care). Frailty care will consist in a multicomponent intervention.
89008477|NCT04592146|Experimental|Intervention group|"Participants randomized into the intervention group will receive the same intervention as those allocated into the control group, but this intervention will be supported by the POSITIVE technology.Informal caregivers will also receive an app to follow the evolution of the cared person.~As in the control group, participants allocated into the intervention group will be managed by community care; these professionals will have access to the evolution of the older persons so they can take promote actions in case early deterioration is detected."
89431016|NCT05581901|Experimental|Methadone (Dose 1)|Methadone will be administered intravenously at the beginning of surgery, and will only be administered this one time. The gradual upward titration of Methadone will be managed using adaptive platform design. This way the number of patients in each group will be determined by the adaptive platform algorithm.
89431017|NCT05581901|Experimental|Methadone (Dose 2)|Methadone will be administered intravenously at the beginning of surgery, and will only be administered this one time. The gradual upward titration of Methadone will be managed using adaptive platform design. This way the number of patients in each group will be determined by the adaptive platform algorithm.
89431018|NCT05581901|Experimental|Methadone (Dose 3)|Methadone will be administered intravenously at the beginning of surgery, and will only be administered this one time. The gradual upward titration of Methadone will be managed using adaptive platform design. This way the number of patients in each group will be determined by the adaptive platform algorithm.
89431019|NCT05568316|Experimental|Experimental: Preoperative Immunonutrition (Group 1)|"Participants received oral IMN supplementation containing arginine, omega-3 fatty acids, and dietary nucleotides for only 5 days before surgery, in addition to their standard isocaloric diet.~Duration: 5 days (preoperative) Dietary therapy: Standard oral nutrition and IMN product for 5 days before operation.~The nutritional status of the patients was determined from the NRS 2002 screening tool. The biochemical parameters (albumin, prealbumin, CRP, FPG etc.), anthropometric measurements (body weight, BMI, MUAC), postoperative complications and hospital stay were recorded."
89431020|NCT05568316|Experimental|Experimental: Perioperative Immunonutrition (Group 2)|"Participants received oral IMN supplementation containing arginine, omega-3 fatty acids, and dietary nucleotides for 5 days before and after surgery, in addition to their standard isocaloric diet.~Duration: 5 days preoperative and 5 days postoperative Dietary therapy: Standard oral nutrition and IMN product for 5 days before and after operation (perioperative).~The nutritional status of the patients was determined from the NRS 2002 screening tool. The biochemical parameters (albumin, prealbumin, CRP, FPG etc.), anthropometric measurements (body weight, BMI, MUAC), postoperative complications and hospital stay were recorded."
89431021|NCT05566067||Anesthesiology residents|We plan to distribute a survey to the Stanford anesthesiology residents to investigate the factors that influence residents' decision to pursue a career as a critical care physician.
89431022|NCT05561426|Experimental|Fast UPF meals|Meals consisting of UPF with textures that are consumed fast
89431023|NCT05561426|Experimental|Slow UPF meals|Meals consisting of UPF with textures that are consumed slow
89431024|NCT05555186|Experimental|Experimental light: Sleep quality and well-being|Exposure to experimental systematic light exposure (BWL) in classroom where students are located every school day from 8:30 AM until the school finishes between 3 and 4 PM
89431025|NCT05555186|Sham Comparator|Comparison light: Sleep quality and well-being|Exposure to comparison systematic light exposure (DWL) in classroom where students are located every school day from 8:30 AM until the school finishes between 3 and 4 PM
89431026|NCT05555186|No Intervention|Unchanged lightning|Conventional lightning in classrooms where students are located every school day from 8:30 AM until the school finishes between 3 and 4 PM
89431027|NCT05549713||Blepharoplasty group|As a single arm study, all examinees will undergo upper blepharoplasty. Data regarding corneal topography, tear film quality and contrast sensitivity will be obtained before the surgery, seven days and one month postoperatively
89431028|NCT05520294||Chronic Cannabinoid Users|Ib or II Melanoma patients who are chronic cannabinoid users
89431029|NCT05520294||Non-users|Ib or II Melanoma patients non cannabinoid users
89431030|NCT05516927||Cancer Group|"Collect Subject Data~Collect Blood Specimen"
89431031|NCT05516927||Non-cancer Group|"Collect Subject Data~Collect Blood Specimen"
89431032|NCT05508061|Experimental|Lyumjev (insulin lispro)|Administration of Lyumjev for a 30-day study period (dosage and frequency is patient-dependent)
89431033|NCT05508061|Active Comparator|Humalog (insulin lispro)|Administration of standard used Humalog for a 30-day study period and 8-day wash-out period located between the two study periods (dosage and frequency is patient-dependent)
89431034|NCT05504642|Experimental|Study medication|"All eligible patients will receive study medication:~Pre-Chemo-radio-immunotherapy Treatment for two weeks before start of Chemo-radio-immunotherapy~Concurrent Chemo-radio-immunotherapy (week 1-7)~Maintenance Treatment (six months) after Chemo-radio-immunotherapy"
89431035|NCT05490953|Placebo Comparator|Group A with placebo|Patients with conventional treatment based on the OEPA/COPDAC, ABVD or BEACOPP scheme plus placebo, during the first two cycles of chemotherapy.
89431036|NCT05490953|Experimental|Group B with pentoxifylline|"Patients with conventional treatment based on the OEPA/COPDAC, ABVD or BEACOPP scheme plus pentoxifylline, during the first two cycles of chemotherapy.~Pentoxifylline dose of 20 mg/kg/day, maximum dose 1200 mg/day"
89431037|NCT05474729|Experimental|minocycline|minocycline capsule 100mg per day orally
89431038|NCT05474001|Active Comparator|Fentanyl group|"Patients will receive 10 mg hyperbaric Bupivacaine ( 2ml ) and 20 μg (0.5 mL) fentanyl IT.~1 mL IV normal saline immediately after the placement of the spinal."
89431039|NCT05474001|Active Comparator|Granisetron group|"Patients will receive 10 mg hyperbaric Bupivacaine ( 2ml ) and 0.5 mL normal saline IT.~1 mg (1 mL) IV granisetron after spinal placement."
89431040|NCT05474001|Placebo Comparator|Control group|"10 mg hyperbaric Bupivacaine ( 2ml ) IT and normal saline 0.5 ml~1 ml normal saline IV after spinal placement."
89431041|NCT05471232||Enrollees|These participants will be subject to whole genome sequencing to identify genetic changes and a EHR-Based network model to predict psychiatric outcomes in youth with IDDs.
89431042|NCT05471232||Historical Control Group|A historical control group from public databases will be used to compare against enrollees.
89431043|NCT05451199|Experimental|ICP-488|Single ascending doses of ICP-488 tablet; Multiple ascending doses of ICP-488 tablet; Part3 Patients with Psoriasis:ICP-488 tablet.
89431044|NCT05451199|Placebo Comparator|Placebo|Single ascending doses of placebo; Multiple ascending doses of placebo; Part3 Patients with Psoriasis of placebo.
89431045|NCT05446584|Active Comparator|Active left frontal HD-tDCS|Electrodes will be placed in a 4x1 ring configuration over the left frontal region in accordance with the International 10-10 EEG system. Stimulation will consist of a ramp up period in which the electrical current is gradually increased, 30 minutes of stimulation at 2 mA, and a ramp down period during which the electrical current is gradually removed. Stimulation will be applied back-to-back over three consecutive days.
89431046|NCT05446584|Active Comparator|Active left temporal HD-tDCS|Electrodes will be placed in a 4x1 ring configuration over the left temporal region in accordance with the International 10-10 EEG system. Stimulation will consist of a ramp up period in which the electrical current is gradually increased, 30 minutes of stimulation at 2 mA, and a ramp down period during which the electrical current is gradually removed. Stimulation will be applied back-to-back over three consecutive days.
89431047|NCT05446584|Sham Comparator|Sham HD=tDCS|Electrodes will be placed in the same 4x1 ring configuration over the left frontal region as the active left frontal condition to ensure a useful control condition. Stimulation will consist of a 30-second ramp up period until reaching 2 mA, followed immediately by a 30-second ramp down, and off for 29 minutes. The same ramp up and down process will be repeated in the final minute of the session to help preserve masking of conditions. Sham stimulation will be applied back-to-back over three consecutive days.
88910614|NCT04090983|Experimental|Cognitive-behavioral therapy (CADDI protocol)|
88910615|NCT04086329|Other|Affected MM Cases|Key eligibility criteria for MM cases includes physically-capable adults (male and females, ages 18 to 65 years, inclusive) with genetically-confirmed MM with predominant symptoms of myopathy as expressed by exercise intolerance and muscle weakness and fatigue.
89431048|NCT05445232|Experimental|LY3437943 + Drug Cocktail|"Midazolam in combination with warfarin and caffeine (drug cocktail) administered orally followed by LY3437943 administered subcutaneously (SC) in week 1.~At weeks 8, 12, & 16, the LY3437943 will be administered SC on Day 1 followed by midazolam in combination with warfarin and caffeine (drug cocktail) administered orally on Day 2."
89431049|NCT05439291|Active Comparator|Regular epilation regimen only|
89431050|NCT05439291|Active Comparator|Regular epilation regimen with surgical excision|
89431051|NCT05427344|Experimental|Water exercise group|Water exercise group where the Ai Chi technique was selected as the exercise method of choice. The activity will take place in a hydrotherapy pool approved by the Ministry of Health and will be led by a hydrotherapist who has been trained in Ai Chi
89431052|NCT05427344|Experimental|Land exercise group|Land exercise group who will perform the same Ai Chi movements on land in order to standardize the groups. The activity will take place in a hall and will be led by a physiotherapist who has been trained to teach Ai Chi on land
89431053|NCT05427344|Experimental|Control group|Control group who will not perform additional physical activity or receive any extra treatments
89431054|NCT05421715|Experimental|ALL ADOLESCENTS|For all adolescents, the proposed treatment consists, in addition to conventional care,an individual digital care and education(TELEDUC-DIAB)for 6 months using digital devices (myDiabby + Kidia).
89431055|NCT05420805|Active Comparator|Pre- and post-biotic (ALAC, inulin, FOS, and sodium butyrate)|The product (ALAC+butyrate+inulin+fructo oligosaccharides FOS) is a powder for oral suspension. Dosage is dependent on weight. For participants weighing <50 kg, a 4 g dose (i.e., one 4 g sachet) is intended to be administered orally once a day after dissolving in water. For participants weighing ≥50 kg, a 4 g dose (i.e., 4 g sachets) is intended to be administered orally twice a day (12h interval) after dissolving in water.
89531199|NCT03339557|Active Comparator|NexGen Total Knee Replacement|NexGen, Conventional design Perioperative treatment will be carried out according to routine protocol of the hospital.
89531200|NCT03339557|Active Comparator|Persona Total Knee Replacement|Persona, Novel design Perioperative treatment will be carried out according to routine protocol of the hospital.
88910616|NCT04086329|Other|Healthy Controls|Adult healthy volunteers will be individually matched with corresponding MM cases based on age, biological sex, and body mass index.
88910619|NCT04079621|Experimental|(P.f)|patients with falciparum malaria will receive artemether-lumefantrine (AL) twice daily over three days plus a low dose course of primaquine (PQ) (3.5mg/kg total dose) given 7 days during schizontocidal treatment
88910620|NCT04079621|Experimental|(P.v)|patients with vivax malaria will receive chloroquine (CQ) daily for three days plus a low dose course of PQ (3.5mg/kg total dose) given over 7 days during schizontocidal treatment.
88910621|NCT04079621|No Intervention|Standard care (P.f)|patients with falciparum malaria will receive artemether-lumefantrine (AL) twice daily over three days (plus a single dose PQ)
88910622|NCT04079621|No Intervention|Standard care (P.v)|patients with vivax malaria will receive chloroquine (CQ) daily for three days plus a low dose course of PQ (total dose 3.5mg/kg) over 14 days
88910623|NCT04075916|Experimental|Epclusa (sofosbuvir/velpatasvir)|Epclusa is taken by mouth for 12 weeks as per the FDA label.
88910624|NCT04074135|Experimental|1/ Arm 1|Study natural history of VHL pancreatic neuroendocrine tumors with yearly 68-Gallium DOTATATE PET/CT research scans.
88910625|NCT04074135|No Intervention|2/ Arm 2|Study natural history of VHL pancreatic neuroendocrine tumors without research scans.
88910626|NCT04067765|Experimental|Alcohol Cue|Alcohol cue exposure in scanner
88910627|NCT04067765|Active Comparator|Neutral Cue|Neutral cue exposure in scanner
88910628|NCT04062656|Experimental|B - Nivolumab|"Responders~6 preoperative cycles nivolumab (i.v., 240mg, q2w)~4 postoperative cycles nivolumab (i.v., 240mg, q2w)~followed by nivolumab monotherapy for up to one year (i.v., 480mg, q4w)~Non-responders~2 preoperative cycles nivolumab (i.v., 240mg, q2w)~4 additional cycles nivolumab (i.v., 240mg, q2w)+FLOT (i.v., 240mg, q2w) pre- and postoperative~followed by nivolumab monotherapy for up to one year (i.v., 480 mg, q4w)"
88910629|NCT04062656|Experimental|D - Nivolumab + relatlimab|"Responders~6 preoperative cycles nivolumab (i.v.,240 mg, q2w) and relatlimab (i.v.,80 mg, q2w)~4 postoperative cycles nivolumab (i.v.,240 mg, q2w) and relatlimab (i.v.,80 mg, q2w)~followed by nivolumab monotherapy for up to one year (i.v., 480mg, q4w)~Non-responders~2 preoperative cycles nivolumab (i.v.,240 mg, q2w) and relatlimab (i.v.,80 mg, q2w)~4 additional cycles nivolumab (i.v.,240 mg, q2w)+FLOT (i.v.,q2w) pre- and postoperative~followed by nivolumab monotherapy for up to one year (i.v., 480mg, q4w)"
88910630|NCT04060849|Experimental|Arm I (Nozin)|Beginning 7 days prior to transplant, patients receive Nozin via nasal single-use popswabs or single-use cotton tipped applicators and swab the inside of their nose BID up to 100 days after transplant.
88910631|NCT04060849|Active Comparator|Arm II (standard of care)|Patients receive standard of care.
89431056|NCT05420805|Active Comparator|Post-biotic (sodium butyrate and zinc oxide)|The product (sodium butyrate+ zinc oxide) is in the form of tablets. Dosage is dependent on weight. For participants weighing <25 kg, one 380 mg tablet is intended to be administered orally twice a day . For participants weighing 25 to 40 kg, three 380 mg tablet dose is intended to be administered orally according to the 2+1 tablets per day schedule (12h interval). For participants weighing ≥40 kg, four 380 mg tablet dose is intended to be administered orally according to the 2+2 tablets per day schedule (12h interval).
89431057|NCT05395533|Experimental|Recombinant CD20 monoclonal antibody-MMAE conjugte for injection (TRS005)|To evaluate the safety and tolerability of TRS005 in patients with recurrent or refractory CD20-positive B-cell non-Hodgkin's lymphoma with treatment at one or more times, and to recommend the dose for phase II clinical trials (RP2D).
89431058|NCT05395351||Group 1: IV rt-PA cohort with AIS patients aged >80 years|AIS patients aged >80 years who received IV rt-PA within 4.5 hours of symptom onset.
89431059|NCT05395351||Group 2: IV rt-PA cohort with AIS patients aged 18 to 80 years|AIS patients aged 18 to 80 years who received IV rt-PA within 4.5 hours of symptom onset.
89431060|NCT05395351||Group 3: Non-reperfusion cohort with AIS patients aged >80 years|AIS patients aged >80 years who arrived or were admitted to the hospital within 4.5 hours of symptom onset and did not receive thrombolysis treatment.
88910632|NCT04060394|Experimental|Phase I Cohort 1|LAE001 (capsules) 75mg Twice Daily (BID) + prednisone (tablet) 5mg BID +afuresertib (tablet) 100mg Once Daily (QD) will be administered in Cycles of 28 days.
88910633|NCT04060394|Experimental|Phase I Cohort 2|LAE001 (capsules) 100mg BID + prednisone (tablet) 5mg BID +afuresertib (tablet) 100mg QD will be administered in Cycles of 28 days.
88910634|NCT04060394|Experimental|Phase I Cohort 3|LAE001 (capsules) 100mg BID + prednisone (tablet) 5mg BID +afuresertib (tablet) 125mg QD will be administered in Cycles of 28 days.
88910635|NCT04060394|Experimental|Phase I Cohort 4|LAE001 (capsules) 100mg BID + prednisone (tablet) 5mg BID +afuresertib (tablet) 150mg QD will be administered in Cycles of 28 days.
88910636|NCT04060394|Experimental|Phase II Cohort 1|LAE001 (capsules) + prednisone (tablet) +afuresertib at the Recommended Phase II Dose (RP2D)
88910637|NCT04060394|Experimental|Phase II Cohort 2|Docetaxel/prednisone + afuresertib
89431061|NCT05395351||Group 4: Non-reperfusion cohort with AIS patients aged 18 to 80 years|AIS patients aged 18 to 80 years who arrived or were admitted to the hospital within 4.5 hours of symptom onset and did not receive thrombolysis treatment.
88910639|NCT04058431|Experimental|Osteopathic group|Treatment will be compromised of 8 weeks of standard care plus OMT. Each physician will maintain the same patient at recurring sessions. Osteopathic treatment is performed for 30 minutes and the techniques applied are highly individualized to the patient needs (i.e., techniques are selected based on structure/function, and techniques change over time based on treatment response). In an effort to standardize treatment, we will limit the study protocol to the following designated techniques: facilitated positional release treatment, high velocity low amplitude treatment, articulatory treatment, strain-counterstrain, muscle energy treatment, myofascial release treatment, soft tissue treatment.
88910640|NCT04052828|Experimental|FETO with GOLDBAL2|A balloon will be placed in the airway of the fetus during the FETO procedure.
89431062|NCT05387551|Experimental|CGM intervention|Continuous glucose monitoring with real-time glucose data using Dexcom G6.
88910643|NCT04032470||Essential Tremor|Subjects with Essential Tremor being implanted with Boston Scientific Deep Brain Stimulation Systems
89431063|NCT05378724|No Intervention|Control group|All subjects eligible for inclusion in this study will receive usual care physiotherapy treatment. The number of treatment sessions and content of physiotherapy treatment sessions will depend on the diagnosis and needs of the individual patient. This study will not interfere with the content of the usual care physiotherapy treatment. Usual care physiotherapy sessions wil take approximately 20-30 minutes per session. They receive no additional intervention and will not use Hospital Fit as part of their physiotherapy treatment. The patients in the control group will receive an activity monitor to collect data about their physical activity levels. However, patients and their healthcare professionals will not receive feedback on patients' physical activity levels.
89431064|NCT05378724|Experimental|Intervention group|Patients in the intervention group will receive usual care physiotherapy and us Hospital Fit additionally. At the end of the last physiotherapy treatment session before discharge, or after a maximum of nine days of study inclusion (whichever comes first), the physiotherapist will remove the activity monitor and data collection will end.
88910644|NCT04024488|Experimental|TI-CBT Intervention Arm|In the Randomized Trial, youth participants will be randomized in a 1:1 ratio with their caregivers to one of two study arms. One arm is the TI-CBT intervention arm consisting of: six 2-hour TI-CBT group sessions lead by Indigenous Youth Leaders (IYL) during weeks 1 - 6 and one 2-hour booster group session at 6-months. The caregivers (willing to participate with youth permission) for youth who are enrolled into the TI-CBT arm will be enrolled onto the same arm, and receive two 2-hour group sessions led by adult study staff during weeks 1-6 and one 2-hour booster group session at 6-months. The youth and caregiver sessions are held separately.
88910645|NCT04024488|Active Comparator|Discussion Control Arm|Arm two is the discussion control arm consisting of: six 2 hour discussion group sessions lead by IYL during weeks 1-6 and one 2-hour booster discussion group session at 6 months. The caregivers (willing to participate with youth permission) for youth randomized to the discussion control arm will have two 2-hour discussion group sessions led by adult study staff during weeks 1-6 and one 2-hour booster discussion group session at 6 months. The youth and caregiver sessions are held separately.
88910646|NCT04021355|Experimental|Early Sodium|Early sodium load: participants will consume a standardized diet providing 2.3 g of sodium per day for 7 days (run-in period), after which they will continue to consume the standardized diet for 9 days and in addition will take 2 g of sodium in the form of salt tablets with breakfast each day.
88910647|NCT04021355|Experimental|Late Sodium|Late sodium load: participants will consume a standardized diet providing 2.3 g of sodium per day for 7 days (run-in period), after which they will continue to consume the standardized diet for the next 9 days and in addition will take 2 g of sodium with dinner each day.
88910648|NCT04019353||cf-DNA Collection|All patients undergoing kidney allograft biopsy for suspicion of an acute rejection episode will be approached for consent into the study. Patients who consent to the study will have the cf-DNA test drawn at time of biopsy to determine levels of cf-DNA. All consented patients will be followed for biopsy outcomes. Those whose biopsy shows acute rejection leading to treatment will have cf-DNA determination at 2, 4, 6, and 8 weeks post biopsy. Recipients with persistent high cf-DNA levels will undergo repeat biopsy at ~6 weeks after end of treatment per standard of care (this is not performed for purpose of the study, but for clinical care).
88910649|NCT04014634|Placebo Comparator|Placebo|Injection of NaCl
88910650|NCT04014634|Experimental|Verum|
88910651|NCT04014361|Experimental|LY3154885 - Part A|15, 45, 100, 200, 300 or 375 milligrams (mg) LY3154885 administered orally in two of three study periods.
88910652|NCT04014361|Placebo Comparator|Placebo - Part A|Placebo administered orally in one of three study periods.
88910653|NCT04014361|Experimental|45 mg LY3154885 + Itraconazole - Part B|45 mg LY3154885 administered orally in period 1 followed by 200 mg Itraconazole administered orally on 10 consecutive days and then 45 mg LY3154885 co-administered with 200 mg itraconazole orally during period 2.
88910654|NCT04014361|Placebo Comparator|Placebo + Itraconazole - Part B|Placebo administered orally during period 1 followed by 200 mg Itraconazole administered orally on 10 consecutive days and then placebo co-administered with 200 mg itraconazole orally during period 2.
88910655|NCT04014361|Experimental|LY3154885 - Part C|Part C was not initiated.
88910656|NCT04014361|Placebo Comparator|Placebo - Part C|Part C was not initiated.
88910657|NCT04014361|Experimental|LY3154885 - Part D|Part D was not initiated.
88910658|NCT04012216||The study population|Patients consulting for persistant, moderate-to-severe rhinitis and meeting eligibility criteria.
88910659|NCT04007952|No Intervention|Intervention 1 (Control)|No anterior gastropexy will be performed.
89431065|NCT05375643|Experimental|Arm B (informational video)|"Participants will complete screening questionnaire via text or by phone to establish baseline awareness and interest in clinical trials and then randomized to the SURGE intervention where they will receive:~Informational Video"
89431066|NCT05375643|No Intervention|Arm A (standard of care)|"Participants will complete screening questionnaire via text or by phone to establish baseline awareness and interest in clinical trials and then randomized to Standard of Care (SOC) and receive:~Standard of Care"
89431067|NCT05375643|Experimental|Arm C (informational video and patient navigation)|"Participants will complete screening questionnaire via text or by phone to establish baseline awareness and interest in clinical trials and then randomized to the SURGE intervention where they will receive:~Informational Video and Patient Navigation"
89431068|NCT05355974|Experimental|Norepinephrine plus Isotonic Fluids|The treatment group will receive a continuous infusion of norepinephrine at 0.10 mcg/kg/min started 2-5 minutes prior to Rapid Sequence Intubation (assuming normal systolic blood pressure 90-140mmHg) in addition to a standard fluid bolus of Lactated Ringers or Normal Saline or Plasmalyte at 999 mL/hr.
89431069|NCT05355974|Active Comparator|Isotonic Fluids|The control group will receive an infusion of Lactated Ringers or Normal Saline or Plasma-Lyte with at least 500 mL at 999 ml/hr 2-5 minutes prior to Rapid Sequence Intubation.
89431070|NCT05348044|Experimental|Res-ET intervention|Res-ET will include a 6-week remote (Zoom) home-group-delivered IMST exercise intervention of approximately 20 minutes a session consisting of a warmup and 3 bouts of 5 sets x 6 inspiratory maneuvers using an IMST training device (POWERBreathe) and 1 min recovery between each set (inspiration to rest ratio taken from Craighead 2021). The intensity of the IMST maneuvers will begin at 40% of MIP during week one, 50% of MIP during week two, and 60% of MIP during weeks three through six. Participants will remotely perform Res-ET intervention 4 times per week in a group setting (Zoom). During the intervention multiple opportunities to engage in a group training session will be available and a recording of an IMST session will be available for viewing if the participant is unable to attend a live group session. Each week the CEP will record participation rates and accelerometry data in REDcap. Group conversations and motivation will be encouraged during live training sessions.
89431071|NCT05340413|Experimental|Cohort 1|"HER2-negative ABC with documented germline or somatic mutation in BRCA1, BRCA2, PALB2, RAD51C or RAD51D that is predicted to be deleterious or suspected deleterious (known or predicted to be detrimental/lead to loss of function). Patients with BRCA1, BRCA2, PALB2, RAD51C or RAD51D mutations that are considered to be non-detrimental (e.g., Variants of uncertain clinical significance or Variant of unknown significance or Variant, favor polymorphism or benign polymorphism, etc.) will not be eligible for this cohort."
89431072|NCT05340413|Active Comparator|Cohort 2|HER2-negative ABC with RAD51-foci low score in the most recent locally recurrence or biopsy from the metastatic context and without known or with negative germline or somatic mutations in BRCA1, BRCA2, PALB2, RAD51C or RAD51D predicted to be deleterious or suspected deleterious (known or predicted to be detrimental/lead to loss of function). Mutation status will be assessed in, at least, olaparib responding patients in this subgroup.
89431073|NCT05333796|Experimental|Healthy children (5 to 12 years old)|
89431074|NCT05328947|Experimental|Normal Controls|
89431075|NCT05316519|Experimental|Transcutaneous Vagus Nerve Stimulation|Transcutaneous vagus nerve stimulation paired with visuomotor task training
89431076|NCT05316519|Placebo Comparator|Transcutaneous Stimulation (Sham)|Transcutaneous stimulation paired with visuomotor task training
89431077|NCT05316051|Experimental|25° inverted angle foot orthoses|
89431078|NCT05316051|Experimental|15° inverted angle foot orthoses|
89431079|NCT05316051|No Intervention|Control|
89431080|NCT05309031|Experimental|Immersion|This group will receive the immersion intervention
89431081|NCT05296590||Positive Blood Culture/ Monocyte Distribution Width Normal|"No intervention Monocyte Distribution Width considered normal (MDW less than 20 IU) in Emergency Department patients with Positive Blood Cultures.~We will evaluate associated factors with this observation."
89431082|NCT05296590||Positive Blood Culture/ Monocyte Distribution Width Abnormal|"No intervention Monocyte Distribution Width considered abnormal (MDW equal or greater than 20 IU) in Emergency Department patients with Positive Blood Cultures.~We will evaluate associated factors with this observation."
89431083|NCT05296590||Negative Blood Culture/ Monocyte Distribution Width Normal|"No intervention Monocyte Distribution Width considered normal (MDW less than 20 IU) in Emergency Department patients with negative Blood Cultures.~We will evaluate associated factors with this observation."
89431084|NCT05296590||Negative Blood Culture/ Monocyte Distribution Width Abnormal|"No intervention Monocyte Distribution Width considered abnormal (MDW equal or greater than 20 IU) in Emergency Department patients with negative Blood Cultures.~We will evaluate associated factors with this observation."
89431085|NCT05293405|Experimental|Patients Group|
89431086|NCT05293405|Sham Comparator|Healthy Volunteers Group|
89431087|NCT05283811|Other|Epilepsy Monitoring Unit|Patient's behavioral and neural activity via computer tasks and questionnaires are monitored in the Epilepsy Monitoring Unit
89431088|NCT05283811|Other|Neuropace RNS Device|Patients are implanted with RNS device to treat their seizure activity
89431089|NCT05274152|Experimental|Patients IVR for Lower Limb and Knee Rehabilitation after surgery in children|"Patients will use the IVR during each physiotherapy session after surgery until their discharge from hospital, which is expected to comprise one 10 minute session per day for 3-5 days.~During each session, child participants will rate their anxiety, perceived pain and feedback any feelings about the experience."
88910660|NCT04007952|Experimental|Intervention 2 (Treatment)|Anterior gastropexy will be performed.
88910661|NCT03993912|Experimental|Arm 1: Experimental group|"Daratumumab SC 1800 mg~once every week for 8 weeks~then once every other week for 16 weeks~thereafter once every 4 weeks, until progression Lenalidomide PO (25mg): days 1 through 21 of each 28-day cycle, until progression Dexamethasone PO (20mg): days 1, 8, 15, 22 of a 28-day cycle, for the first 2 cycles, then discontinued"
88910662|NCT03993912|Sham Comparator|Arm 2: Control group|Lenalidomide PO (25mg): days 1 through 21 of each 28-day cycle, until progression Dexamethasone PO (20mg): days 1, 8, 15, 22 of each 28-day cycle, until progression
89431090|NCT05274152|Other|Occupational Therapist perceptions of the effectiveness of the IVR|"She recruited the patients, gave out devices, administered the outcome measures and provided us with feedback about their experience with the VR game.~At the end of the trial, an interview (10 minutes) with the OT was conducted by a research nurse."
89431091|NCT05269238|Other|control group patient|performing lumbar punctures by students with standard training
89431092|NCT05269238|Experimental|experimental group patient|performing lumbar punctures by students with standard training and an augmented reality simulator
89431093|NCT05269108|Experimental|Fluoroscopy-free RIRS|Patients will be treated by RIRS without fluoroscopy
89431094|NCT05269108|Active Comparator|Standard RIRS|Standard RIRS under fluoroscopy-guidance will be performed
89431095|NCT05258383||Lung Neoplasm patients|Lung Neoplasm patients (adults)
89431096|NCT05258383||Pelvic Neoplasm patients|Pelvic Neoplasm patients (adults)
89431097|NCT05258383||Breast Cancer patients|Breast Cancer patients(adults)
89431098|NCT05258383||Ear Nose and Throat (ENT) Cancer patients|Ear Nose and Throat (ENT) Cancer patients (adults)
89431099|NCT05258383||Pediatric Cancer patients|Pediatric cancer patients (under 18 years-old) : neurologic cancer , abdomen cancer, Thorax cancer, Ear Nose and Throat (ENT) Cancer
89431100|NCT05258370||incident patients with chronic respiratory failure|adult patients with untreated chronic respiratory failure
89431101|NCT05256134|Experimental|Gantenerumab|Gantenerumab will be administered as subcutaneous (SC) injection with gradual uptitration.
89431102|NCT05256134|Placebo Comparator|Placebo|Placebo will be administered as SC injection with gradual uptitration.
89431103|NCT05255250|Experimental|PLAYshop Intervention|Participants will receive a 60 minute virtual physical literacy workshop, an equipment goody-bag with basic play equipment and printed resources, and access to a digital app with an online toolkit and four bi-weekly boosters lessons.
89431104|NCT05255250|No Intervention|Control|Participants will receive the 60 minute virtual physical literacy workshop, equipment goody-bag, and access to the digital app after completing 2-month follow-up measures.
89431105|NCT05245656|Experimental|RB/RBAC alternating|"Every 4 weeks for 6 cycles~RB (1st, 3rd, and 5th cycles)~Rituximab + Bendamustine~RBAC (2nd, 4th, and 6th cycles)~Rituximab + Bendamustine + Cytarabine"
89431106|NCT05245656|Active Comparator|RB|"Every 4 weeks for 6 cycles~- Rituximab + Bendamustine"
89431107|NCT05243108|Experimental|NTs Intervention group|The subject of 1200mg has been given orally once a day for 4 months.
89431108|NCT05243108|Placebo Comparator|placebo control group|The ingredients, dosage, and usage are the same as experimental.
89431109|NCT05242744||Metastatic prostate cancer|Men at least 18 years of age with metastatic prostate cancer may be eligible for this study .Volunteers that meet the eligibility criteria will be considered for study participation regardless of race or ethnic background. Only individuals who can understand and give informed consent will be eligible to participate in this study.
89431110|NCT05231395|Experimental|Inspiratory Muscle Training Group|Patients in the training group will be performed inspiratory muscle training with the PowerBreathe® (inspiratory muscle training device) device at 50% of the maximal inspiratory pressure.
89431111|NCT05231395|Sham Comparator|Control Group|Control group will be given breathing exercises as a home program for 8 weeks.
89431112|NCT05229562|Experimental|Cohort 1: Low-Dose|Participants will receive Dose 1 of BIIB122, orally, once on Day 1.
89431113|NCT05229562|Experimental|Cohort 2: Mid-Dose|Participants will receive Dose 2 of BIIB122, orally, once on Day 1.
89431114|NCT05229562|Experimental|Cohort 3: High-Dose|Participants will receive Dose 3 of BIIB122, orally, once on Day 1.
89431115|NCT05229562|Experimental|Cohort 4: High-Multi-Dose|Participants will receive Dose 3 of BIIB122, orally, once daily (QD), for 10 days.
89431116|NCT05216887|Active Comparator|Aducanumab IV|Participants will receive a single weight-based dose of aducanumab via IV infusion on Day 1.
89431117|NCT05216887|Experimental|Aducanumab SC|Participants will receive 2 fixed doses of aducanumab via SC injection on Days 1 and 15.
89431118|NCT05182697|Experimental|SCI-210|Oral CBD oil plus pills of CannAmide (palmitoylethanolamide (PEA) 400 mg twice daily
89431119|NCT05182697|Active Comparator|CBD oil|CBD- active CBD oil with twice daily and CannAmide Placebo pills matched in appearance and taste to CannAmide active pill.
89431120|NCT05179200|Experimental|"Group 1: Frequent plasma donors"|Donors will donate 650 ml plasma (excluding anticoagulant) by plasmapheresis three times every 2 weeks for 16 weeks.
89431121|NCT05179200|Active Comparator|"Group 2: Regular plasma donors"|Donors will donate 650 ml plasma (excluding anticoagulant) by plasmapheresis once every 14 days for 16 weeks.
89431122|NCT05179200|Placebo Comparator|"Group 3: Regular whole blood donors"|Donors will donate 450 ml (405-495 ml) whole blood every 3 months for 16 weeks.
89431123|NCT05175599|No Intervention|Land Birth|Women in the land birth group will labor and give birth according to standard of care procedures.
89431124|NCT05175599|Experimental|Water Birth|Women in the water birth group will give birth in the water. During the first stage of labor, women may enter or leave the water at any point.
88910663|NCT03992417||Participants with AD|Adult and adolescent participants with AD initiating treatment with Dupixent® for AD according to the country-specific prescribing information, as part of their usual care as determined by their physician
89431125|NCT05164887||MIRACLe patients|"Patient affected by colorectal cancer submitted to laparoscopic resection with MBP + OA + perioperative Probiotics administration.~MBP = oral polyphosphate 500ml preoperative OA = Amoxicillin/Clavulanic acid 1g x 2 + metronidazole 250mg x 3 Probiotics = Streptococcus thermophilus; Bifidobacterium breve; Bifidobacterium longum; Bifidobacterium infantis; Lactobacillus acidophilus; Lactobacillus plantarum; Lactobacillus paracasei; Lactobacillus delbrueckii subsp. Bulgaricus 4,4g x 2"
89431126|NCT05148481|Experimental|BIIB104: Dose 1|Japanese and non-Japanese participants will receive BIIB104, Dose 1, oral capsule, BID, from Day 1 through Day 9 with an additional dose on Day 10.
89431127|NCT05148481|Experimental|BIIB104: Dose 2|Japanese and non-Japanese participants will receive BIIB104, Dose 2, oral capsule, BID, from Day 1 through Day 9 with an additional dose on Day 10.
89431128|NCT05148481|Placebo Comparator|Placebo|Japanese and non-Japanese participants will receive BIIB104-matching placebo, oral capsule, BID, from Day 1 through Day 9 with an additional dose on Day 10.
89431129|NCT05147545|Experimental|Subjects free of malignancy|Moderate intensity physical effort and meal (once)
89431130|NCT05147545|Experimental|Patients with colon cancer|Low intensity physical effort and meal (visit 1, day of cycle 1 chemotherapy) and low intensity physical effort (visit 2, day of cycle 2 chemotherapy)
89431131|NCT05147519||Step 1|Step 1 will enroll participants aged 15-55 years who are vulnerable to contracting HIV. They will be evaluated every 12 weeks for HIV and other sexually transmitted infections (STIs).
89431132|NCT05147519||Step 2|Participants who are diagnosed with HIV will proceed to Step 2, with evaluation of viral load and other HIV-related tests every four weeks for 12 weeks and then every 12 weeks for a total of 48 weeks.
89431133|NCT05147519||Step 3|Participants who achieve and maintain viral suppression in Step 2 will proceed to Step 3 for continued HIV monitoring every 24 weeks to document maintenance of viral suppression and maintain engagement with the study site for potential future recruitment into interventional studies, including clinical trials of novel strategies to achieve HIV remission.
89431134|NCT05143021||Pregnant Women with Sickle Cell Disease|Pregnant women with sickle cell disease from the 3 centers in Ghana
88910664|NCT03988569|Experimental|Intervention Group|Will view audiovisual decision aid (AVDA) and then have opportunity for questions with physician before signing consent forms
89431135|NCT05134103|Experimental|Mindbeacon TAI-CBT for Depression group|Participants randomized to this condition will receive immediate Therapist-Guided Internet-CBT for Depression for 12 weeks.
89431136|NCT05134103|Other|Waitlist Control Group|Participants randomized to this condition will remain on the waitlist for 12 weeks before crossing over and receiving Therapist-Guided Internet-CBT for Depression for 12 weeks.
89431137|NCT05128786|Experimental|CCT301-38|To determine the safety, tolerability, DLT and MTD of CCT301-38 cell therapy in patients with AXL-positive relapsed or refractory sarcomas.
89431138|NCT05120570|Experimental|PTCy/sirolimus plus VIC-1911|Patients enrolled and treated with PTCy/sirolimus plus VIC-1911
89431139|NCT05119868|Experimental|Group 1|Group 1 will receive standard obstetrical and gynecological follow-up and nutritional intervention based on Mediterranean Diet provided by certified dietitians
89431140|NCT05119868|No Intervention|Group 2|Group 2 will receive standard obstetrical and gynecological follow-up alone
89431141|NCT05112211|Experimental|doxycycline|patients administrated with doxycycline tablets 100mg orally per day
89431142|NCT05110040|Experimental|immunosuppressive agents|patients recruited will be treated with one or／and two immnuosuppressive agents
89431143|NCT05107427|Experimental|MRx0518 + Avelumab|Subjects will receive 1 capsule of MRx0518 BID throughout the treatment period and IV infusion of Avelumab every 2 weeks in 4-week cycles
89431144|NCT05099263|Experimental|Vivaer Procedure|"The Vivaer procedure will be performed in the study clinic using the Vivaer ARC Stylus and Aerin Console. The Vivaer ARC Stylus is a disposable handheld device capable of delivering bipolar radiofrequency energy to tissue when connected to the Aerin Console radiofrequency generating device. Participants will undergo bilateral treatment of the nasal airway in a single study procedure session. Each side of the nose will be treated as follows:~• Two (2) to six (6) nonoverlapping applications of RF energy are performed at the SSB per nostril.~The default treatment settings will be used for the study: temperature 60 C, power 4 watts, treatment time 18 seconds, and cooling time 12 seconds. No repeat (touch up) procedures will be permitted after the initial procedure through the end of the study (36 months)."
89431145|NCT05097352|Experimental|High Intensity Interval Training (HIIT)|High-intensity interval training will be performed three times a week for a total of six weeks.
89431146|NCT05097352|Sham Comparator|Waitlist Control|Waitlist participants were tested on the outcomes at the same time points as the treatment group (i.e., HIIT). Following completion of the waitlist treatment, participants will be eligible to receive a supervised exercise program (no data will be collected). The waitlist participants formed a no-treatment control group.
89431147|NCT05097131||All Participants|Participants who have been prescribed with aducanumab-avwa in the post-marketing setting according to standard care of practice will be enrolled.
89431148|NCT05091034|Experimental|CAMP Air|This is an e-health intervention consisting of 7 online modules. This behavioral intervention combines instruction, hands-on learning, interactive practice opportunities and tailored sessions. Teens learn about asthma, including treatment and triggers, the importance of seeing a medical provider and how they can overcome their specific barriers to seeing a medical provider, how they can talk to their parents about their asthma, and how they can care for their asthma, including managing stress and triggers. They also receive personalized feedback throughout the intervention and guidance on navigating the health care system.
88910665|NCT03988569|No Intervention|Control Group|Will undergo standard verbal informed consent with physician before signing consent forms
88910666|NCT03982992|Experimental|DLI-TARGET|"14d screening period: methotrexate, cytarabine, dexamethasone infusion i.th.~Cycle 1 (all patients): d1-28: blinatumomab continuous infusion i.v., d4: allogeneic donor lymphocyte single infusion i.v., d29: methotrexate, cytarabine, dexamethasone infusion i.th.~Cycle 2 (only patients with toxicity ≤ grade 2 CTCAE in cycle 1): d43-d70: blinatumomab continuous infusion i.v., d46: allogeneic donor lymphocyte single infusion i.v., d71: methotrexate, cytarabine, dexamethasone infusion i.th."
89431149|NCT05091034|Active Comparator|Attention Control Asthma Education Intervention|The control intervention consists of 7 online sessions delivered via PowerPoint slides with voice-over. Teens receive information on asthma and other related health conditions, such as stress and sleep, and will be given a list of relevant websites to learn more about these topics. They will learn how to monitor their health using checklists and will be referred to a medical provider for asthma and other conditions; if they do have a medical provider, they will be provided with a referral. The asthma education component for this group lacks the interactive and personalized elements of CAMP Air, differentiating it from the experimental arm.
89431150|NCT05080751|No Intervention|Control|In this modality of intervention, the focus will be on the development of skills through educational actions in health, using the pedagogy of transmission. The focus will be based on content related to food, nutrition and quality of life. Materials like videos, áudios (podcasts), booklets and short films will be available weekly, following a schedule of sessions.
89431151|NCT05080751|Experimental|Eating Behaviors|In the intervention group, the focus will be the development of skills through educational health actions that provide the development of autonomy and empowerment for behavior change, based on cognitive behavioral interventions, which involve eating behavior and impact on quality of life. Cognitive behavioral therapy (CBT) is based on ten principles that influence and / or determine treatment attitude and approach. Intervention group sessions will be based on principles.
89431152|NCT05073367||Participants with H. Pylori|Participants having evidence of H. pylori infection or having a positive result of H. pylori diagnostic testing recorded at inpatient or outpatient visits using pre-existing electronic medical record data in China will be observed retrospectively for 54 months.
88910667|NCT03981419|Experimental|GRF6021|Participants received 4 doses of GRF6021, 250 milliliters (mL), intravenous (IV) infusion. The first dose was administered on day before surgery, the next two doses on the day of surgery i.e., within 4 hours before start of surgery (first incision), and then upon arrival in the postoperative care unit (within 5 hours after the first incision) and the last dose was administered on the day after the surgery.
88910668|NCT03981419|Placebo Comparator|Placebo|Participants received 4 doses of GRF6021 matching placebo, 250 mL, IV infusion. The first dose was administered on day before surgery, the next two doses on the day of surgery i.e., within 4 hours before start of surgery (first incision), and then upon arrival in the postoperative care unit (within 5 hours after the first incision) and the last dose was administered on the day after the surgery.
88910669|NCT03975907|Experimental|CAR-BCMA T Cells|Phase I: The subjects are enrolled into 2 dose level cohorts in sequence. Phase II: Single arm
88910670|NCT03974347||Acute kidney injury, no acute kidney injury|Acute kidney injury after cardiac surgery will be defined by KDIGO criteria, Creatinine rise from baseline and or urine production.
88910671|NCT03974347||No Acute Kidney Injury|No Acute kidney Injury after Cardiac surgery, according to KDIGO AKI definition
89431153|NCT05061095||Pilot Testing: Aggressive Lymphoma|20 patients diagnosed with aggressive lymphomas (e.g. diffuse large B-cell, advanced Hodgkin's) participating in the questionnaire portion of the study.
89431154|NCT05061095||Pilot Testing: Acute Leukemia|20 patients diagnosed with acute leukemias participating in the questionnaire portion of the study.
89431155|NCT05061095||Pilot Testing: Myeloma/CLL/CML|10 patients diagnosed with either myelomas, chronic lymphocytic leukemia, or chronic myeloid leukemia that are participating in the questionnaire portion of the study.
89431156|NCT05061095||Qualitative Interviews: Living Longer|"10 participants (subset of the three pilot testing cohorts) that designate in their questionnaires that living longer is the most important outcome for them."
89431157|NCT05061095||Qualitative Interviews: Other|"10 participants (subset of the three pilot testing cohorts) that designate in their questionnaires that any other outcome besides living longer is the most important."
89431158|NCT05058846||Group I: No strong family history of pancreatic cancer|Participants in Group 1 consist of BRCA, ATM and PALB2 mutation carriers without a strong family history of pancreatic cancer and can choose to undergo annual magnetic resonance imaging (MRI)/Magnetic resonance cholangiopancreatography (MRCP) screening, or they may opt out of annual MRI screening. Participants also have the opportunity to co-enroll in the University of California, San Francisco (UCSF) BRCA Center Biorepository for biospecimen/biomarker collection and will complete surveys, including the optional eGene questionnaire, which involves co-enrollment in the eGene Study.
89431159|NCT05058846||Group II: Strong family history of pancreatic cancer|Participants in Group 2 consist of BRCA, ATM and PALB2 mutation carriers with a strong family history of pancreatic cancer. Participants may undergo annual MRI/MRCP screening and may also elect to get an endoscopic ultrasound (EUS) every other year. Participants also have the opportunity to co-enroll in the UCSF BRCA Center Biorepository for biospecimen/biomarker collection and will complete surveys, including the optional eGene questionnaire, which involves co-enrollment in the eGene Study.
89431160|NCT05058729||Cohort 1|Participants with multiple sclerosis (MS) or clinically isolated syndrome (CIS) who are enrolled in MS PATHS under Study 888MS001 and have completed at least one COVID-19 questionnaire administered by a participating healthcare institution.
89431161|NCT05057039||hypertensive group|SBP >=140mmHg, DBP >=90mmHg, or use of antihypertensive drug
89431162|NCT05057039||normotensive group|SBP <=140mmHg and DBP <=90mmHg without use of antihypertensive drug
89431163|NCT05055661|No Intervention|The control group|Patients randomized to the control group will receive health education, audiovisual educational meterial regarding the use of inhalers and inhalators spacers and be contacted throughout the six months to collect the study variables, by telephone contact.
89431164|NCT05055661|Experimental|The intervention group|Patients randomized to the intervention grop will receive the same health education as the control group at the reference Basic Health Unit and also will be carried, once a month, the pharmaceutical teleconsultation during six months, by video call. The study variables will be collected in the same periods as the control group patients, by telephone contact.
89431165|NCT05053451|Experimental|dlPFC/TPJ Stimulation + Rest|20 minutes of 2 mA direct current stimulation during rest.
89431166|NCT05035745|Experimental|Patients with refractory solid tumors|Phase I will be carried out in a modified 3+3 dose escalation design, with a projected enrolment of patients with refractory solid tumors to determine the RP2D.
88910672|NCT03972527|Active Comparator|Active Device Treatment Cohort - Chemoradiation therapy|The MuReva Phototherapy System consists of Light Control Unit and two Mouthpiece Cable Assemblies. Subjects will begin device treatment photobiomodulation sessions on the first day of radiotherapy (RT) treatment. They will receive once-daily investigative device photobiomodulation treatments prior to radiation therapy (RT) with their assigned Mouthpiece for 5 days per week for the duration of their CRT treatment. Each device treatment session will last up to 5 minutes, not including up to 5 additional minutes for treatment breaks. All subjects will visit the study site once during the Screening period (Days -28 to 1) and an anticipated 30 to 40 times during the treatment period. Each patient will be assigned their own Mouthpiece Cable Assembly set.
88910673|NCT03972527|Sham Comparator|Sham Device Treatment Cohort- Chemoradiation therapy|The MuReva Phototherapy System (or sham control) is a Light Control Unit and a set of Mouthpiece Cable Assemblies. The sham control Mouthpiece Cable Assemblies will appear identical to the active Mouthpiece Cable Assembly, and will be used in the same manner as the active cohort. However, the sham control device will be configured where the mouthpiece will not emit any light at any time during the study. The same Light Control Unit will be used with sham and active Mouthpiece Cable Assemblies. Each patient will be assigned their own Mouthpiece Cable Assembly set.
88910674|NCT03972527|Active Comparator|Active Device Treatment Cohort - Radiation therapy only|The MuReva Phototherapy System consists of Light Control Unit and two Mouthpiece Cable Assemblies. Subjects will begin device treatment photobiomodulation sessions on the first day of radiotherapy (RT) treatment. They will receive once-daily investigative device photobiomodulation treatments prior to radiation therapy (RT) with their assigned Mouthpiece for 5 days per week for the duration of their CRT treatment. Each device treatment session will last up to 5 minutes, not including up to 5 additional minutes for treatment breaks. All subjects will visit the study site once during the Screening period (Days -28 to 1) and an anticipated 30 to 40 times during the treatment period. Each patient will be assigned their own Mouthpiece Cable Assembly set.
89431167|NCT05033964|Experimental|DESyne BDS Plus Arm|DESyne BDS Plus Drug Eluting Coronary Stent System (DESyne BDS Plus DECSS; DESyne BDS Plus) is loaded with Sirolimus, Rivaroxaban and Argatroban
89431168|NCT05033964|Active Comparator|DESyne X2 Arm|The DESyne X2 Novolimus Eluting Coronary Stent System (DESyne X2 NECSS; DESyne X2) is loaded with Novolimus
89431169|NCT05030454|Experimental|CT-guided stereotactic adaptive radiotherapy|-Radiotherapy will consist of stereotactic body therapy, to be given over five fractions, delivered once daily or once every other day for a period of one to two weeks, for a total of five treatments.
89431170|NCT05024708|Experimental|ARVC patients|
89431171|NCT05024708|Active Comparator|Endurance athletes with a dilated RV|
89431172|NCT05024708|Active Comparator|Endurance athletes with normal RV|
89431173|NCT05024708|Experimental|Untrained subject with normal RV|
89431174|NCT05023655|Experimental|Tazemetostat|tazemetostat 800 mg po twice daily in continuous 28- day cycles
89431175|NCT05011552|Experimental|The intervention group|
89431176|NCT05011552|Placebo Comparator|The control group|
89431177|NCT05005897|Experimental|Screening - treatment|From 6 weeks of age, infants will be screened for elevated plasma total homocysteine concentrations. Those who have a concentration above the defined cut-off will be treated with cobalamin (vitamin B12).
88910675|NCT03972527|Sham Comparator|Sham Device Treatment Cohort- Radiation therapy only|The MuReva Phototherapy System (or sham control) is a Light Control Unit and a set of Mouthpiece Cable Assemblies. The sham control Mouthpiece Cable Assemblies will appear identical to the active Mouthpiece Cable Assembly, and will be used in the same manner as the active cohort. However, the sham control device will be configured where the mouthpiece will not emit any light at any time during the study. The same Light Control Unit will be used with sham and active Mouthpiece Cable Assemblies. Each patient will be assigned their own Mouthpiece Cable Assembly set.
88910676|NCT03969901|Experimental|IMI/REL|Participants with cIAI or cUTI will receive imipenem/cilastatin/relebactam (IMI/REL) via IV infusion, once every 6 hours, for a minimum of 5 days (with optional oral switch after 3 days) up to a maximum of 14 days. Participants with HABP/VABP will receive IMI/REL via IV infusion, once every 6 hours, for a minimum of 7 days up to a maximum of 14 days. All oral switch medications will be chosen from a list of acceptable approved agents and will be administered per authorized Package Insert (PI), Summary of Product Characteristics (SPC), or international treatment guidelines.
88910677|NCT03969901|Active Comparator|Active Control|Participants with cIAI or cUTI will receive active control via IV infusion for a minimum of 5 days (with optional oral switch after 3 days) up to a maximum of 14 days. Participants with HABP/VABP will receive active control via IV infusion for a minimum of 7 days up to a maximum of 14 days. All active control and oral switch medications will be administered per authorized PI, SPC, or international treatment guidelines. All active control and oral switch medications will be chosen from a list of acceptable approved agents.
88910678|NCT03966872|Experimental|Integrated Illness Management and Recovery (I-IMR):|Participants assigned to I-IMR will receive 2 individual sessions to discuss principles of recovery and set personally meaningful goals, with the remainder of the 14 I-IMR sessions delivered in groups of 8-10 (to enable individual tailoring)
89431178|NCT05005897|No Intervention|Control|The control-group sample will be stored and analyzed when the child is 12 months old. Those with elevated tHcy will contribute to the control group.
89431179|NCT04994977|Experimental|Intra-arterial Chemotherapy|Subjects are pre-treated with heparin, and then given single doses of Melphalan, Carboplatin, and Topotecan consecutively via intra-arterial infusion. Multiple arteries may be used, with the total dose of the drugs remaining the same.
89431180|NCT04963465||Before rupture of membranes|Vaginal swab collection prior to iatrogenic rupture of membranes
89431181|NCT04963465||After rupture of membranes|Vaginal swab collection after iatrogenic rupture of membranes
89431182|NCT04942613|Experimental|Multicomponent Telehealth Intervention (Group1)|This group will be randomized to receive the 12-week multicomponent intervention first. They will receive individual physical therapy sessions, group physical therapy sessions, and biobehavioral interventions emphasizing program engagement and increased daily physical activity. Most interventions will be provided synchronously through videoconferencing. Each participant will receive an individualized home exercise program.
89431183|NCT04942613|Other|Education (Group2)|This group will be randomized to 12-week waitlist control condition. They will receive a one-hour education session every 2 weeks (6 sessions total) on general health topics (e.g., basic nutrition, stress reduction, sleep hygiene). At the end of 12 weeks, they will transition to the 12-week multicomponent intervention
89008478|NCT04592380|Experimental|Stage 1: Clevidipine (double-blinded)|Clevidipine (0.5 mg/mL in 20% lipid emulsion) will be administered in a double-blinded fashion intravenously to all patients randomized to the clevidipine arm in Stage 1. Clevidipine will be initiated at an initial rate of 2 mg/h for the first 1.5 minutes (90 seconds) and titrated thereafter per the Food and Drug Administration (FDA) approved clevidipine label, to achieve the target SBP +/- 5 mmHg. If the target SBP is achieved at any of the titration doses, that rate may be continued for up to 24 hours. If the desired BP lowering effect is not attained within 30 minutes or not maintained thereafter, any alternative antihypertensive agent may be used per institutional treatment practice, with or without stopping the study drug infusion.
89431184|NCT04942613|Other|Research Participants|Participants will be asked to complete up to 2 semi-structured interviews following completion of the 12-week multicomponent intervention. The first interview will occur within 3 weeks of program completion (by week 15 for Group 1 and by week 27 for Group 2). The second interview will occur between 3 to 6 months after the first interview.
89008479|NCT04592380|Placebo Comparator|Stage 1: Placebo (double-blinded)|Placebo will be administered in a double-blinded fashion intravenously to all patients randomized to the clevidipine arm in Stage 1. Placebo will be initiated at an initial rate of 2 mg/h for the first 1.5 minutes (90 seconds) and titrated thereafter according to the same dosing instructions as for clevidipine to achieve the target SBP +/- 5 mmHg. If the target SBP is achieved at any of the titration doses, that rate may be continued for up to 24 hours. If the desired BP lowering effect is not attained within 30 minutes or not maintained thereafter, any alternative antihypertensive agent may be used per institutional treatment practice, with or without stopping the study drug infusion.
89431185|NCT04924153||EIMFS and EOEE (Up to 2 years)|Participants who have been diagnosed with epilepsy of infancy with migrating focal seizures (EIMFS) and early-onset epileptic encephalopathy (EOEE) with duration of symptoms for up to 2 years will be enrolled.
89008480|NCT04592380|Experimental|Stage 2: Clevidipine (open-label)|Clevidipine (0.5 mg/mL in 20% lipid emulsion) will be administered in an open-label fashion intravenously to all patients randomized to the clevidipine arm in Stage 2, following the same dosing instructions as in the clevidipine arm in Stage 1. If the desired BP lowering effect is not attained within 30 minutes or not maintained thereafter, any alternative antihypertensive agent may be used per institutional treatment practice, with or without stopping the study drug infusion.
89431186|NCT04924153||EIMFS and EOEE (More than 2 years)|Participants who have been diagnosed with EIMFS and EOEE with duration of symptoms for more than 2 years will be enrolled.
89431187|NCT04924153||SHE (Up to 2 years)|Participants who have been diagnosed with sleep-related hypermotor epilepsy (SHE) with duration of symptoms for up to 2 years will be enrolled.
89431188|NCT04924153||SHE (More than 2 years)|Participants who have been diagnosed with SHE with duration of symptoms for more than 2 years will be enrolled.
89431189|NCT04915300|Active Comparator|Apabetalone|100mg BID, 24-week (168±3 days) Treatment Period.
89431190|NCT04915300|Placebo Comparator|Placebo|24-week (168±3 days) period.
89431191|NCT04910997|Experimental|HRV Group|Heart rate variability training group
89431192|NCT04910997|Active Comparator|Traditional Exercise Group|Traditional (e.g. standard) exercise training
89431193|NCT04910997|No Intervention|Control Group|Usual care
89431194|NCT04909710|Experimental|Autism Case Group|Autistic participants will receive mobile game system for 12 weeks and be asked to play a minimum of ten 90-second game sessions per week per child over 12 weeks. Research team will further require that at least three of these 10 weekly sessions with each child be with game decks displaying emotion.
89431195|NCT04909710|Other|Neurotypical Sibling Control Group|Neurotypical control participants will receive the same mobile game system for 12 weeks and be asked to play a minimum of ten 90-second game sessions per week per child over 12 weeks. Research team will further require that at least three of these 10 weekly sessions with each child be with game decks displaying emotion.
89431196|NCT04909203|Experimental|iKinnect2.0|Parent-Youth dyads assigned to the iKinnect2.0 condition will be given access to the iKinnect2.0 app that has been developed for this study. Parent and youth will be asked to download the app to their phone during the baseline assessment process and asked to use it as often as they would like throughout the duration of the 16 week trial. The app is designed to be used several times throughout each day.
89431197|NCT04909203|Placebo Comparator|Attention-Control Placebo App & Supporting Materials|Parent-Youth dyads assigned to the control condition will be asked to download the free Life360 app to their phone during the baseline assessment process and will also be given access to an online suicide resources brochure. Participants will be asked to use the control-condition app and associated materials as often as they would like throughout the duration of the 16 week trial.
89431198|NCT04888481|Experimental|68Ga-HA-DOTATATE PET/CT scan|2.64 MBq/kg (minimum 37 MBq, maximum 250 MBq) 68Ga-HA-DOTATATE intravenous single-dose administration for PET/CT imaging
89431199|NCT04879745|Experimental|Decision Aid Users|Patients with a rheumatic disease who are given access to the MyVoice:Rheum decision aid
89431200|NCT04879745|Active Comparator|Pamphlet Users|Patients with a rheumatic disease who are given access to a widely-accessible pamphlet about family planning
89431201|NCT04879745|Experimental|Rheumatologists|Rheumatologists who interact with patients who have used the MyVoice: Rheum decision aid
89431202|NCT04878367|Experimental|COPD_E|COPD patients with intervention
89431203|NCT04878367|No Intervention|COPD_C|COPD patients without intervention
89431204|NCT04866069|Experimental|Low-Dose Group (Group A)|20 participants will receive 10 µg-3M inactivated virus + 1 mg Al(OH)3 + 300 µg CpGODN adjuvanted vaccine
89431205|NCT04866069|Experimental|High-Dose Group (Group B)|20 participants will receive 20 µg-6M inactivated virus + 1 mg Al(OH)3 + 300 µg CpGODN adjuvanted vaccine
89431206|NCT04866069|Placebo Comparator|Placebo Group|10 participants will receive 1 ml of 0.9% sodium chloride (NaCl)
89431207|NCT04846478|Experimental|Dose Escalation Talazoparib + Tazemetostat|"Standard 3+3 dose escalation will be followed, participants will initially receive talazoparib and tazemetostat at a dose of 75% of the starting dose for their FDA-approved indications.~During each 28 day study treatment cycle participants will take:~Talazoparib once daily.~Tazemetostat twice daily."
89431208|NCT04846478|Experimental|Dose Expansion Talazoparib + Tazemetostat|"Participants will receive talazoparib and tazemetostat at the safe dose identified in the first part (dose escalation) of the study.~During each 28 day study treatment cycle participants will take:~Talazoparib once daily.~Tazemetostat twice daily."
89431209|NCT04835844||Mapping with CARTO|CARTO (Biosense Webster) in conjunction with CONFIDENSE mapping module and PENTARRAY catheter
88910679|NCT03966872|Experimental|Stanford Chronic Disease Self-Management Program (CDSMP):|Participants randomly assigned get a 6-session group-based educational program co-delivered by two peers (lay people who have successfully managed a chronic illness) or a peer and a professional
89431210|NCT04835844||Mapping with RHYTHMIA|RHYTHMIA (Boston Scientific) in conjunction with the 64-electrodes ORION mini-basket catheter.
89431211|NCT04834973|Experimental|Single arm open label|Single or multiple Intratumoural treatment of tigilanol tiglate at escalating doses of 0.6 mg/m2, 1.2 mg/m2 and 2.4 mg/m2 given every 28 days (+1 to 14days) in combination with three weekly 200 mg intravenous doses of pembrolizumab.
89431212|NCT04829331|Experimental|Restrata with a split-thickness skin graft|
89431213|NCT04829331|No Intervention|Split-thickness skin graft alone|
89431214|NCT04800809||Children and young adults with SCD and stroke|"Participants with SCD confirmed with hemoglobin electrophoresis or high pressure liquid chromatography (HPLC)~Age 5 to 26 years old~Present within three months of stroke event that is diagnosed as a stroke by the local health care provider~Medical records are available for review for the stroke event that occurred within 3 months"
89431215|NCT04800809||The participants in SPIN and SPRING and SPRINT Trials|The participants enrolled in our previous primary and secondary stroke prevention trials in northern Nigeria; SPIN and SPRING (children with SCD with normal and abnormal TCD measurements; NCT02560935 and NCT01801423), SPRINT (children with SCD and strokes; NCT02675790) Trials for ascertainment of incidences rates of strokes in children and young adults receiving standard care after completion of primary stroke prevention trials. For this purpose, we will enroll these participants to follow their progress after completion of the trials. No intervention is planned, only to follow the participants with and without abnormal TCD measurements and with and without strokes.
88910680|NCT03964233|Experimental|Dose Escalation - BI 907828 + ezabenlimab|All neoplasms
88910681|NCT03964233|Experimental|Dose Expansion - Cohort 1 BI 907828 + ezabenlimab|
88910682|NCT03964233|Experimental|Dose Expansion - Cohort 2 - BI 907828 + ezabenlimab|
88910683|NCT03964233|Experimental|Dose Escalation - BI 907828 + ezabenlimab + BI 754111|All neoplasms
88910684|NCT03960476|Experimental|Access to Web-Based Intervention|All study participants will be given access to the web-based study intervention, PlanYourLifespan.org.
88910685|NCT03957603|Experimental|TPF-DM Combined with Medical Nutrition Therapy Intervention|Participants in the experimental group will be provided with an individualized dietary, nutrition recommendation and the additional Enteral Nutrition Suspension (TFP-DM, Diason 0.75 kcal/ml). Participants are required to schedule the first follow-up visit one week after receiving the individualized recommendations. Afterward, the regularly scheduled follow-up visit will be scheduled every two to four weeks.
88910686|NCT03957603|Active Comparator|Medical Nutrition Therapy Intervention|Based on the standard care, Participants will receive an individualized dietary, nutrition recommendations with the application of food exchange porting. Participants are required to schedule the first follow-up visit one week after receiving the individualized recommendations. Afterward, the regularly scheduled follow-up visit will be scheduled every two to four weeks.
88910687|NCT03954210|Experimental|Six-Week CBT-I Program|"CBT-I, six sessions, forty-five to sixty minutes in duration.~Session 1: set up sleep restriction and stimulus control, discuss strategies for how to stay awake to a prescribed hour and what to do with wake after onset sleep time, provide sleep hygiene education.~Session 2: determine if upward titration of total sleep time is warranted, review sleep hygiene.~Session 3: continue upward titration of total sleep time, cognitive therapy for negative sleep beliefs if indicated.~Session 4: continue upward titration of total sleep time, follow-up regarding negative sleep beliefs.~Session 5: continue upward titration of total sleep time, discuss relapse prevention.~Session 6: assess global treatment gains, discuss questions regarding relapse prevention."
88910688|NCT03954210|Active Comparator|Six-Week Sleep and Lifestyle Education Program|"Sleep and Lifestyle Education, six sessions, forty-five to sixty minutes in duration.~Session 1: Sleep education, Instruction/demonstration on stretching exercises.~Session 2: Education on environmental factors & sleeping positions that impact sleep.~Session 3: Education on lifestyle factors that impact sleep.~Session 4: Education on diet and sleep.~Session 5: Education on exercises and sleep.~Session 6: Discus maintaining achievements & preventing relapses."
88910689|NCT03952559|Experimental|Baricitinib Open Label High Dose (PK Lead-in)|"Participants 10 to < 18 years received Baricitinib high dose (4 mg) administered orally in tablet form QD.~Participants 2 to < 10 years received Baricitinib high dose (2 mg) administered as oral suspension (1 mL) QD."
88910690|NCT03952559|Experimental|Baricitinib High Dose|"Participants 10 to < 18 years received Baricitinib high dose (4 mg) and placebo to maintain the blind, administered orally in tablet form QD.~Participants 2 to < 10 years received Baricitinib high dose (2 mg) administered as oral suspension QD or placebo oral suspension QD to maintain the blind."
88910691|NCT03952559|Experimental|Baricitinib Medium Dose|"Participants 10 to < 18 years received Baricitinib low dose (1 mg) and placebo to maintain the blind, administered orally in tablet form QD.~Participants 2 to < 10 years received Baricitinib low dose (0.5 mg) administered as oral suspension QD or placebo oral suspension QD to maintain the blind."
88910692|NCT03952559|Experimental|Baricitinib Low Dose|"Participants 10 to < 18 years received Baricitinib low dose (1 mg) and placebo to maintain the blind, administered orally in tablet form QD.~Participants 2 to < 10 years received Baricitinib low dose (0.5 mg) administered as oral suspension QD or placebo oral suspension QD to maintain the blind."
88910693|NCT03952559|Placebo Comparator|Placebo|Participants 10 to < 18 years received placebo tablets. Participants 2 to < 10 years received placebo as oral suspension.
88910694|NCT03946670|Experimental|MBG453 + hypomethylating agents|Patients are taking MBG453 plus hypomethylating agents
88910695|NCT03946670|Placebo Comparator|Placebo + hypomethylating agents|Patients are taking placebo plus hypomethylating agents
88910696|NCT03939897|Experimental|Phase I Part A (copanlisib, abemaciclib, fulvestrant)|Patients receive copanlisib hydrochloride IV over 1 hour on days 1, 8, and 15 or days 1 and 15 (depending on dose level) and abemaciclib PO BID on days 2-28 of cycle 1 and on days 1-28 of subsequent cycles. Patients also receive fulvestrant IM on days 2 and 16 of cycle 1, and on day 1 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo an ECHO or MUGA scan during screening. Patients also undergo blood sample collection pre-treatment, cycle 1 days 1, 8, 15, and 22, cycle 2 day 1, cycle 4 day 1, cycle 7 day 1, and then every 3 cycles thereafter and at time of progression. Patients undergo tissue biopsy pre-treatment and optionally on cycle 1 day 15 and at the time of progression. Patients also undergo imaging at screening and at the completion of cycle 3, then every 3 cycles thereafter.
88922248|NCT05593523||Aim 1: Partial Thickness Burn Wounds|"Participants with 1-30% total body surface area (TBSA) partial thickness burn wounds admitted to the University of Wisconsin (UW) Burn Center within 24 hours of burn injury and expected to be admitted for 3 days.~Indocyanine green angiography (ICGA) fluorescence imaging immediately after administration of 7mg of ICG, and second window indocyanine green (SWIG) fluorescence imaging ~24 hours after administration of up to 5 mg/kg ICG of human burn wounds. ICGA within 72 hours of admission with the OnLume Clinical Imaging System (CIS). SWIG fluorescence imaging will also be performed perioperatively if applicable."
88910697|NCT03939897|Experimental|Phase I Part B (copanlisib, abemaciclib, fulvestrant)|Patients receive copanlisib hydrochloride IV over 1 hour on days 1, 8, and 15 or days 1 and 15 (depending on dose level) and abemaciclib PO twice daily BID for 5 days each week (2 days off). Patients also receive fulvestrant IM on days 2 and 16 of cycle 1, and on day 1 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo an ECHO or MUGA scan during screening. Patients also undergo blood sample collection pre-treatment, cycle 1 days 1, 8, 15, and 22, cycle 2 day 1, cycle 4 day 1, cycle 7 day 1, and then every 3 cycles thereafter and at time of progression. Patients undergo tissue biopsy pre-treatment and optionally on cycle 1 day 15 and at the time of progression. Patients also undergo imaging at screening and at the completion of cycle 3, then every 3 cycles thereafter.
88910698|NCT03939897|Experimental|Phase II, Arm I (FAC) (copanlisib, abemaciclib, fulvestrant)|Patients receive copanlisib hydrochloride as in phase I. Patients also receive abemaciclib PO BID on days 1-28 and fulvestrant IM on days 1 and 15 of cycle 1 and day 1 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo an ECHO or MUGA scan during screening. Patients also undergo blood sample collection pre-treatment, cycle 1 days 1, 8, 15, and 22, cycle 2 day 1, cycle 4 day 1, cycle 7 day 1, and then every 3 cycles thereafter and at time of progression. Patients undergo tissue biopsy pre-treatment and optionally on cycle 1 day 15 and at the time of progression. Patients also undergo imaging at screening and at the completion of cycle 3, then every 3 cycles thereafter.
88910699|NCT03939897|Active Comparator|Phase II, Arm II (FA) (abemaciclib, fulvestrant)|Patients receive abemaciclib PO BID on days 1-28 and fulvestrant IM on days 1 and 15 of cycle 1 and day 1 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo an ECHO or MUGA scan during screening and ECG during screening and as clinically indicated. Patients undergo an ECHO or MUGA scan during screening. Patients also undergo blood sample collection pre-treatment, cycle 1 days 1, 8, 15, and 22, cycle 2 day 1, cycle 4 day 1, cycle 7 day 1, and then every 3 cycles thereafter and at time of progression. Patients undergo tissue biopsy pre-treatment and optionally on cycle 1 day 15 and at the time of progression. Patients also undergo imaging at screening and at the completion of cycle 3, then every 3 cycles thereafter.
88910700|NCT03937804||asthmatics|persons with asthma
88910701|NCT03937804||control|persons without asthma
88910702|NCT03936478|Experimental|8.2 Gy Radiation Therapy|Accelerated partial breast irradiation using 3 x 8.2 Gy to the lumpectomy cavity with a 3mm PTV margin. Treatment duration will be 5-6 days and treatments will be on alternative weekdays, with a minimum interval of 40 hours between subsequent fractions.
88910703|NCT03935997|Experimental|Intervention|Within the intervention arm 9 long-term care homes will receive the SPA-LTC program:3 in Ontario; 3 in Saskatchewan and 3 in Manitoba.
88910704|NCT03935997|No Intervention|Control|Within the control arm 9 long-term care homes will receive the standard of care: 3 in Ontario; 3 in Saskatchewan and 3 in Manitoba.
88910705|NCT03934203|Experimental|H/L/P/P/M treatment sequence|In this randomized, placebo-controlled, 5-period crossover trial participants were randomized to one of 15 possible treatment sequences based on a balanced, Prescott triple Latin square design. Treatments administered were 50 mg BI 409306 administered orally as a single dose (1 film-coated tablet plus 4 film-coated placebo tablets), 250 mg BI 409306 administered orally as a single dose (5 film-coated tablets), 400 mg moxifloxacin administered orally as a single dose (1 film-coated tablet), Placebo 1 and Placebo 2 both administered orally as a single dose (5 film-coated tablets). In all treatment periods tablets were taken with 240 milliliter of water after an overnight fast of at least 10 hours on day 1 of the treatment period. The trial was double-blind for placebo and BI 409306, but open-label for moxifloxacin. A washout period of least 6 days was adhered to between drug administrations. L=50 mg BI 409306, H=250 mg BI 409306, M= 400 mg moxifloxacin, P=Placebo 1/Placebo 2.
88910706|NCT03934203|Experimental|H/M/P/P/L treatment sequence|In this randomized, placebo-controlled, 5-period crossover trial participants were randomized to one of 15 possible treatment sequences based on a balanced, Prescott triple Latin square design. Treatments administered were 50 mg BI 409306 administered orally as a single dose (1 film-coated tablet plus 4 film-coated placebo tablets), 250 mg BI 409306 administered orally as a single dose (5 film-coated tablets), 400 mg moxifloxacin administered orally as a single dose (1 film-coated tablet), Placebo 1 and Placebo 2 both administered orally as a single dose (5 film-coated tablets). In all treatment periods tablets were taken with 240 milliliter of water after an overnight fast of at least 10 hours on day 1 of the treatment period. The trial was double-blind for placebo and BI 409306, but open-label for moxifloxacin. A washout period of least 6 days was adhered to between drug administrations. L=50 mg BI 409306, H=250 mg BI 409306, M= 400 mg moxifloxacin, P=Placebo 1/Placebo 2.
88910707|NCT03934203|Experimental|H/P/P/M/L treatment sequence|In this randomized, placebo-controlled, 5-period crossover trial participants were randomized to one of 15 possible treatment sequences based on a balanced, Prescott triple Latin square design. Treatments administered were 50 mg BI 409306 administered orally as a single dose (1 film-coated tablet plus 4 film-coated placebo tablets), 250 mg BI 409306 administered orally as a single dose (5 film-coated tablets), 400 mg moxifloxacin administered orally as a single dose (1 film-coated tablet), Placebo 1 and Placebo 2 both administered orally as a single dose (5 film-coated tablets). In all treatment periods tablets were taken with 240 milliliter of water after an overnight fast of at least 10 hours on day 1 of the treatment period. The trial was double-blind for placebo and BI 409306, but open-label for moxifloxacin. A washout period of least 6 days was adhered to between drug administrations. L=50 mg BI 409306, H=250 mg BI 409306, M= 400 mg moxifloxacin, P=Placebo 1/Placebo 2.
88910708|NCT03934203|Experimental|L/M/H/P/P treatment sequence|In this randomized, placebo-controlled, 5-period crossover trial participants were randomized to one of 15 possible treatment sequences based on a balanced, Prescott triple Latin square design. Treatments administered were 50 mg BI 409306 administered orally as a single dose (1 film-coated tablet plus 4 film-coated placebo tablets), 250 mg BI 409306 administered orally as a single dose (5 film-coated tablets), 400 mg moxifloxacin administered orally as a single dose (1 film-coated tablet), Placebo 1 and Placebo 2 both administered orally as a single dose (5 film-coated tablets). In all treatment periods tablets were taken with 240 milliliter of water after an overnight fast of at least 10 hours on day 1 of the treatment period. The trial was double-blind for placebo and BI 409306, but open-label for moxifloxacin. A washout period of least 6 days was adhered to between drug administrations. L=50 mg BI 409306, H=250 mg BI 409306, M= 400 mg moxifloxacin, P=Placebo 1/Placebo 2.
89431216|NCT04797520|Other|Treatment|All participants will have placement of ETT confirmed using both Core stethoscope and point-of-care ultrasound
88910709|NCT03934203|Experimental|L/P/H/M/P treatment sequence|In this randomized, placebo-controlled, 5-period crossover trial participants were randomized to one of 15 possible treatment sequences based on a balanced, Prescott triple Latin square design. Treatments administered were 50 mg BI 409306 administered orally as a single dose (1 film-coated tablet plus 4 film-coated placebo tablets), 250 mg BI 409306 administered orally as a single dose (5 film-coated tablets), 400 mg moxifloxacin administered orally as a single dose (1 film-coated tablet), Placebo 1 and Placebo 2 both administered orally as a single dose (5 film-coated tablets). In all treatment periods tablets were taken with 240 milliliter of water after an overnight fast of at least 10 hours on day 1 of the treatment period. The trial was double-blind for placebo and BI 409306, but open-label for moxifloxacin. A washout period of least 6 days was adhered to between drug administrations. L=50 mg BI 409306, H=250 mg BI 409306, M= 400 mg moxifloxacin, P=Placebo 1/Placebo 2.
88910710|NCT03934203|Experimental|L/P/M/H/P treatment sequence|In this randomized, placebo-controlled, 5-period crossover trial participants were randomized to one of 15 possible treatment sequences based on a balanced, Prescott triple Latin square design. Treatments administered were 50 mg BI 409306 administered orally as a single dose (1 film-coated tablet plus 4 film-coated placebo tablets), 250 mg BI 409306 administered orally as a single dose (5 film-coated tablets), 400 mg moxifloxacin administered orally as a single dose (1 film-coated tablet), Placebo 1 and Placebo 2 both administered orally as a single dose (5 film-coated tablets). In all treatment periods tablets were taken with 240 milliliter of water after an overnight fast of at least 10 hours on day 1 of the treatment period. The trial was double-blind for placebo and BI 409306, but open-label for moxifloxacin. A washout period of least 6 days was adhered to between drug administrations. L=50 mg BI 409306, H=250 mg BI 409306, M= 400 mg moxifloxacin, P=Placebo 1/Placebo 2.
88910711|NCT03934203|Experimental|M/H/P/L/P treatment sequence|In this randomized, placebo-controlled, 5-period crossover trial participants were randomized to one of 15 possible treatment sequences based on a balanced, Prescott triple Latin square design. Treatments administered were 50 mg BI 409306 administered orally as a single dose (1 film-coated tablet plus 4 film-coated placebo tablets), 250 mg BI 409306 administered orally as a single dose (5 film-coated tablets), 400 mg moxifloxacin administered orally as a single dose (1 film-coated tablet), Placebo 1 and Placebo 2 both administered orally as a single dose (5 film-coated tablets). In all treatment periods tablets were taken with 240 milliliter of water after an overnight fast of at least 10 hours on day 1 of the treatment period. The trial was double-blind for placebo and BI 409306, but open-label for moxifloxacin. A washout period of least 6 days was adhered to between drug administrations. L=50 mg BI 409306, H=250 mg BI 409306, M= 400 mg moxifloxacin, P=Placebo 1/Placebo 2.
88910712|NCT03934203|Experimental|M/L/P/H/P treatment sequence|In this randomized, placebo-controlled, 5-period crossover trial participants were randomized to one of 15 possible treatment sequences based on a balanced, Prescott triple Latin square design. Treatments administered were 50 mg BI 409306 administered orally as a single dose (1 film-coated tablet plus 4 film-coated placebo tablets), 250 mg BI 409306 administered orally as a single dose (5 film-coated tablets), 400 mg moxifloxacin administered orally as a single dose (1 film-coated tablet), Placebo 1 and Placebo 2 both administered orally as a single dose (5 film-coated tablets). In all treatment periods tablets were taken with 240 milliliter of water after an overnight fast of at least 10 hours on day 1 of the treatment period. The trial was double-blind for placebo and BI 409306, but open-label for moxifloxacin. A washout period of least 6 days was adhered to between drug administrations. L=50 mg BI 409306, H=250 mg BI 409306, M= 400 mg moxifloxacin, P=Placebo 1/Placebo 2.
88910713|NCT03934203|Experimental|M/P/H/P/L treatment sequence|In this randomized, placebo-controlled, 5-period crossover trial participants were randomized to one of 15 possible treatment sequences based on a balanced, Prescott triple Latin square design. Treatments administered were 50 mg BI 409306 administered orally as a single dose (1 film-coated tablet plus 4 film-coated placebo tablets), 250 mg BI 409306 administered orally as a single dose (5 film-coated tablets), 400 mg moxifloxacin administered orally as a single dose (1 film-coated tablet), Placebo 1 and Placebo 2 both administered orally as a single dose (5 film-coated tablets). In all treatment periods tablets were taken with 240 milliliter of water after an overnight fast of at least 10 hours on day 1 of the treatment period. The trial was double-blind for placebo and BI 409306, but open-label for moxifloxacin. A washout period of least 6 days was adhered to between drug administrations. L=50 mg BI 409306, H=250 mg BI 409306, M= 400 mg moxifloxacin, P=Placebo 1/Placebo 2.
88910714|NCT03934203|Experimental|P/H/L/M/P treatment sequence|In this randomized, placebo-controlled, 5-period crossover trial participants were randomized to one of 15 possible treatment sequences based on a balanced, Prescott triple Latin square design. Treatments administered were 50 mg BI 409306 administered orally as a single dose (1 film-coated tablet plus 4 film-coated placebo tablets), 250 mg BI 409306 administered orally as a single dose (5 film-coated tablets), 400 mg moxifloxacin administered orally as a single dose (1 film-coated tablet), Placebo 1 and Placebo 2 both administered orally as a single dose (5 film-coated tablets). In all treatment periods tablets were taken with 240 milliliter of water after an overnight fast of at least 10 hours on day 1 of the treatment period. The trial was double-blind for placebo and BI 409306, but open-label for moxifloxacin. A washout period of least 6 days was adhered to between drug administrations. L=50 mg BI 409306, H=250 mg BI 409306, M= 400 mg moxifloxacin, P=Placebo 1/Placebo 2.
88922249|NCT05593523||Aim 2: Deep Partial or Full Thickness Burn Wounds|"Participants with 1-30% total body surface area (TBSA) deep partial or full thickness burn wounds that will likely require surgery.~ICGA fluorescence imaging immediately after administration of 7mg of ICG, and second window indocyanine green (SWIG) fluorescence imaging ~24 hours after administration of up to 5 mg/kg ICG of human burn wounds. Imaging will occur with the OnLume Clinical Imaging System (CIS)."
88922250|NCT05592015|Experimental|Treatment (ruxolitinib)|Patients receive ruxolitinib PO BID on days 1-28. Cycles repeat every 28 days for 12 months in the absence of disease progression or unacceptable toxicity. Patients who achieve a response (CR or PR) may receive an additional 12 months of ruxolitinib, for a maximum of 24 months.
89431217|NCT04782193|Experimental|prime CAR- T cells|Patients will be be treated with CD19 and CD22 prime CAR- T cells
89431218|NCT04781634|Experimental|prime CAR- T cells|Patients will be be treated with CD19 and CD22 prime CAR- T cells
89431219|NCT04776330|Experimental|BCMA targeted prime CAR-T cells treat|Patients will be be treated with BCMA targeted prime CAR-T cells
89431220|NCT04764825|Experimental|Methadone, induction|"Patients receive methadone 0.15-0.2 mg/kg ideal bodyweight 10 minutes prior to surgery start (Syringe A).~45 minutes before expected extubation patients will receive saline (syringe B)."
89431221|NCT04764825|Experimental|Methadone, end of surgery|Patients receive saline 10 minutes prior to surgery start (Syringe A). 45 minutes before expected extubation patients will receive methadone 0.15-0.2 mg/kg ideal bodyweight (syringe B).
89008481|NCT04592380|Active Comparator|Stage 2: Standard of Care (open-label)|For patients randomized to SOC, the infusion must be continuous, administered per the institution's treatment practice, and dose titration must be performed to a maximum allowed or maximum tolerated dose to achieve target SBP. If treatment with an alternative IV anti-hypertensive agent is required, the patient will be transitioned to an alternative IV antihypertensive agent according to the institutional standard of care.
89008482|NCT04471220|Active Comparator|Low FIO2 and low flow rate under HFNC|In this condition, patients have undergone 6MWT under the HFNC (FIO2 value that the minimum SpO2 value in a 6MWT is 86-88%, and a flow of 10 L/min).
89008483|NCT04471220|Active Comparator|Low FIO2 and high flow rate under HFNC|In this condition, patients have undergone 6MWT under the HFNC (FIO2 value that the minimum SpO2 value in a 6MWT is 86-88%, and a flow of 40-50 L/min).
89008484|NCT04471220|Active Comparator|High FIO2 and low flow rate under HFNC|In this condition, patients have undergone 6MWT under the HFNC (FIO2 value that the minimum SpO2 value in a 6MWT is 92-94%, and a flow of 10 L/min).
89008485|NCT04471220|Active Comparator|High FIO2 and high flow rate under HFNC|In this condition, patients have undergone 6MWT under the HFNC (FIO2 value that the minimum SpO2 value in a 6MWT is 92-94%, and a flow of 40-50 L/min).
89008486|NCT04592497|Experimental|QDOT|will undergo the AF ablation procedure with assistance THERMOCOOL SMARTTOUCH SF-5D QDOT system
89008487|NCT04592497|Active Comparator|standard|will undergo the AF ablation procedure with assistance standard Thermocool Smartouch SF system
89008488|NCT04592068||Retinal multi-diseases diagnosed by DL algorithm|
89008489|NCT04592068||Retinal multi-diseases diagnosed by expert panel|
89008490|NCT04595071|No Intervention|Standard Control|Use of standard two-site myoelectric control of multi-articulating hand.
89431222|NCT04764825|Active Comparator|Morphine|Patients receive saline 10 minutes prior to surgery start (Syringe A). 45 minutes before expected extubation patients will receive morphine 0.15-0.2 mg/kg ideal bodyweight (syringe B).
89431223|NCT04760743|Experimental|low dose level cohort|2 dose of NBP2001 adjuvanted with alum (Receptor Binding domain (RBD) 30μg/dose), 1 dose each on Day 0 and 28
89008491|NCT04595071|Experimental|Voice Recognition Control|Use of voice recognition control in addition to standard two-site myoelectric control of a multi-articulating hand.
89008492|NCT00249561|Experimental|Recovery by Choice|A modified Therapeutic Community program.
89431224|NCT04760743|Experimental|high dose level cohort|2 dose of NBP2001 adjuvanted with alum (Receptor Binding domain (RBD) 50μg/dose), 1 dose each on Day 0 and 28
89431225|NCT04760743|Placebo Comparator|Placebo group|2 doses of Placebo Saline, 1 dose each on Days 0 and 28.
89431226|NCT04756700|Experimental|Healthy Participants|Healthy participants matched with PwMS will have their cognitive and motor functions assessed using the DigiCog (BCCAMS app) tablet once in clinic and Konectom smartphone-based application for 2 days in clinic and at least 15 days at home.
89431227|NCT04756700|Experimental|PwMS: Participants with MS|Participants with MS will have their cognitive and motor functions assessed using the DigiCog (BCCAMS app) tablet once in clinic and Konectom smartphone-based application for 2 days in clinic and at least 15 days at home.
89431228|NCT04742738|Experimental|Test group 1 - Stage 1 Low dose-level Cohort|2 doses of GBP510 adjuvanted with Alum (Receptor Binding Domain (RBD) 10μg/dose), 1 dose each on Days 0 and 28.
89431229|NCT04742738|Placebo Comparator|Placebo group - Stage 1 Low dose-level Cohort|2 doses of Placebo Saline, 1 dose each on Days 0 and 28.
89431230|NCT04742738|Experimental|Test group 2 - Stage 1 High dose-level Cohort|2 doses of GBP510 adjuvanted with Alum (RBD 25μg/dose), 1 dose each on Days 0 and 28.
89431231|NCT04742738|Placebo Comparator|Placebo group - Stage 1 High dose-level Cohort|2 doses of Placebo Saline, 1 dose each on Days 0 and 28.
89008493|NCT00249561|Active Comparator|Intensive Outpatient Program|Designed to address substance abuse and criminality, with a focus on prevention of relapse and recidivism.
89008494|NCT04591756|Active Comparator|N95 Filtering Facepiece Respirator|Subjects will wear the model of filtering facepiece respirator that they are currently approved to wear
89008495|NCT04591756|Active Comparator|Elastomeric Half-Mask Respirator with P100 filters|Subjects will wear the model of elastomeric half mask respirator that they are currently approved to wear.
89008496|NCT04591795|Experimental|100 mg SHT extract|Drug: Sahastara remedy alcoholic extract comparison with diclofenac
89008497|NCT04591795|Experimental|25 mg dicolfenac|Drug: diclofenac comparison with diclofenac
89008498|NCT04591639|Other|Patients with heart failure without type 2 diabetes|60 patients with heart failure without type 2 diabetes will be recruited and will either be randomised to placebo or Dapagliflozin after their baseline cardiac MRIs. They will have 2 cardiac MRIs (gadolinium and manganese enhanced) at baseline and further manganese enhanced cardiac MRI at 1 month post randomisation + gadolinium and manganese enhanced cardiac MRI at 6 months post randomisation.
89431232|NCT04742738|Experimental|Test group 1 - Stage 2|2 doses of GBP510 adjuvanted with Alum (RBD 10μg/dose), 1 dose each on Days 0 and 28.
89431233|NCT04742738|Experimental|Test group 2 - Stage 2|2 doses of GBP510 adjuvanted with Alum (RBD 25μg/dose), 1 dose each on Days 0 and 28.
89431234|NCT04742738|Placebo Comparator|Placebo group - Stage 2|2 doses of Placebo Saline, 1 dose each on Days 0 and 28.
89431235|NCT04775784||Adult neurosurgical patients|Adult, both sex, neurosurgical patients candidate for intracranial surgery, able to sign informed consent.
89431236|NCT04725435|Experimental|Kangaroo care|"No Intervention: Standard care The control group will be followed by infants using nesting in the incubator. It will be followed for 60 minutes without any action or application.~Experimental: Kangaroo care The mother kangaroo will care for at least 60 minutes."
89431237|NCT04725435|Experimental|Facilitated tucking position|"No Intervention: Standard care In the Control Group, the heel stick procedure will be performed in the infants own bed as in the clinical routine.~Experimental 1: Manual Facilitated Tucking Position, infants will be given a manual facilitated tucking position during the heel stick procedure.~Experimental 2: Facilitated Tucking Position, with the Nesting Bed (Tortoise Neo Bed), the facilitated tucking position will be given by the clinic nurse with the nesting bed during the heel stick collection procedure."
89431238|NCT04706910|Experimental|18F-DOPA injection|All enrolled participants will receive an intravenous injection of the investigational 18F-DOPA radiopharmaceutical
89431239|NCT04705805||Case|Patient presenting an olfactory dysfunction of any acquired aetiology that has been evolving for at least 3 months without total recovery.
88910715|NCT03934203|Experimental|P/H/L/P/M treatment sequence|In this randomized, placebo-controlled, 5-period crossover trial participants were randomized to one of 15 possible treatment sequences based on a balanced, Prescott triple Latin square design. Treatments administered were 50 mg BI 409306 administered orally as a single dose (1 film-coated tablet plus 4 film-coated placebo tablets), 250 mg BI 409306 administered orally as a single dose (5 film-coated tablets), 400 mg moxifloxacin administered orally as a single dose (1 film-coated tablet), Placebo 1 and Placebo 2 both administered orally as a single dose (5 film-coated tablets). In all treatment periods tablets were taken with 240 milliliter of water after an overnight fast of at least 10 hours on day 1 of the treatment period. The trial was double-blind for placebo and BI 409306, but open-label for moxifloxacin. A washout period of least 6 days was adhered to between drug administrations. L=50 mg BI 409306, H=250 mg BI 409306, M= 400 mg moxifloxacin, P=Placebo 1/Placebo 2.
89431240|NCT04705805||Control|Patient with no sense of smell problems followed up in ENT for another pathology that does not affect the sense of smell
89431241|NCT04704271|Active Comparator|Delta-9-Tetrahydrocannabinol (THC)|4 mg vaporized THC will be administered.
89431242|NCT04704271|Placebo Comparator|Placebo|Inhaled placebo (no active cannabinoids)
88910716|NCT03934203|Experimental|P/L/M/P/H treatment sequence|In this randomized, placebo-controlled, 5-period crossover trial participants were randomized to one of 15 possible treatment sequences based on a balanced, Prescott triple Latin square design. Treatments administered were 50 mg BI 409306 administered orally as a single dose (1 film-coated tablet plus 4 film-coated placebo tablets), 250 mg BI 409306 administered orally as a single dose (5 film-coated tablets), 400 mg moxifloxacin administered orally as a single dose (1 film-coated tablet), Placebo 1 and Placebo 2 both administered orally as a single dose (5 film-coated tablets). In all treatment periods tablets were taken with 240 milliliter of water after an overnight fast of at least 10 hours on day 1 of the treatment period. The trial was double-blind for placebo and BI 409306, but open-label for moxifloxacin. A washout period of least 6 days was adhered to between drug administrations. L=50 mg BI 409306, H=250 mg BI 409306, M= 400 mg moxifloxacin, P=Placebo 1/Placebo 2.
88910717|NCT03934203|Experimental|P/M/P/L/H treatment sequence|In this randomized, placebo-controlled, 5-period crossover trial participants were randomized to one of 15 possible treatment sequences based on a balanced, Prescott triple Latin square design. Treatments administered were 50 mg BI 409306 administered orally as a single dose (1 film-coated tablet plus 4 film-coated placebo tablets), 250 mg BI 409306 administered orally as a single dose (5 film-coated tablets), 400 mg moxifloxacin administered orally as a single dose (1 film-coated tablet), Placebo 1 and Placebo 2 both administered orally as a single dose (5 film-coated tablets). In all treatment periods tablets were taken with 240 milliliter of water after an overnight fast of at least 10 hours on day 1 of the treatment period. The trial was double-blind for placebo and BI 409306, but open-label for moxifloxacin. A washout period of least 6 days was adhered to between drug administrations. L=50 mg BI 409306, H=250 mg BI 409306, M= 400 mg moxifloxacin, P=Placebo 1/Placebo 2.
88910718|NCT03934203|Experimental|P/P/L/H/M treatment sequence|In this randomized, placebo-controlled, 5-period crossover trial participants were randomized to one of 15 possible treatment sequences based on a balanced, Prescott triple Latin square design. Treatments administered were 50 mg BI 409306 administered orally as a single dose (1 film-coated tablet plus 4 film-coated placebo tablets), 250 mg BI 409306 administered orally as a single dose (5 film-coated tablets), 400 mg moxifloxacin administered orally as a single dose (1 film-coated tablet), Placebo 1 and Placebo 2 both administered orally as a single dose (5 film-coated tablets). In all treatment periods tablets were taken with 240 milliliter of water after an overnight fast of at least 10 hours on day 1 of the treatment period. The trial was double-blind for placebo and BI 409306, but open-label for moxifloxacin. A washout period of least 6 days was adhered to between drug administrations. L=50 mg BI 409306, H=250 mg BI 409306, M= 400 mg moxifloxacin, P=Placebo 1/Placebo 2.
88910719|NCT03934203|Experimental|P/P/M/L/H treatment sequence|In this randomized, placebo-controlled, 5-period crossover trial participants were randomized to one of 15 possible treatment sequences based on a balanced, Prescott triple Latin square design. Treatments administered were 50 mg BI 409306 administered orally as a single dose (1 film-coated tablet plus 4 film-coated placebo tablets), 250 mg BI 409306 administered orally as a single dose (5 film-coated tablets), 400 mg moxifloxacin administered orally as a single dose (1 film-coated tablet), Placebo 1 and Placebo 2 both administered orally as a single dose (5 film-coated tablets). In all treatment periods tablets were taken with 240 milliliter of water after an overnight fast of at least 10 hours on day 1 of the treatment period. The trial was double-blind for placebo and BI 409306, but open-label for moxifloxacin. A washout period of least 6 days was adhered to between drug administrations. L=50 mg BI 409306, H=250 mg BI 409306, M= 400 mg moxifloxacin, P=Placebo 1/Placebo 2.
88910720|NCT03933306|Placebo Comparator|Placebo+routine blood pressure management|Placebo (normal saline) is administered during anesthesia. Blood pressure is managed according to routine practice.
88910721|NCT03933306|Experimental|Dexmedetomidine+routine blood pressure management|Dexmedetomidine is administered during anesthesia (0.6 mcg/kg for 10 min, then 0.5 mcg/kg/h). Blood pressure is managed according to routine practice.
88910722|NCT03933306|Experimental|Placebo+goal-directed blood pressure management|Placebo (normal saline) is administered during anesthesia. Blood pressure is maintained within ±10% of baseline with noradrenaline infusion and fluid management.
89431243|NCT04680286|Placebo Comparator|Placebo|A 5 ml syringe with saline will be prepared and study drug will be administered as intravenous bolus dose (0.1 mg/kg). The study drug will be administered at induction of anesthesia.
89431244|NCT04680286|Experimental|Methadone|A 5 ml syringe with 1 mg/ml of methadone will be prepared and study drug will be administered as intravenous bolus dose (0.1 mg/kg). The study drug will be administered at induction of anesthesia.
89431245|NCT04678284|Experimental|D-Homes intervention|Behavioral treatments by a diabetes wellness coach as defined below.
89431246|NCT04675762|Experimental|fingolimod with standard therapy|Patients will be treated with standard alteplase bridging and mechanical thrombectomy with fingolimod.
89431247|NCT04675762|Placebo Comparator|Placebo with standard therapy|Patients will be treated with standard alteplase bridging and mechanical thrombectomy with placebo.
89431248|NCT04674722|Experimental|Injection of 99mTc-NM-02|All breast cancer patients recruited to the study will be administered 3-12 MBq/kg of 99mTc-NM-02 (99mTc labeled anti-HER2 sdAb) in a single dose injection.
89431249|NCT04674722|Experimental|Injection of 188Re-NM-02|Ten breast cancer patients recruited to the study will be administered 66 MBq/kg of 188Re-NM-02 (188Re labeled anti-HER2 sdAb) in a single dose injection.
89431250|NCT04672018|Experimental|Test group (Houtou Jianeweiling tablet )|Houtou Jianweiling tablet (0.38 g), 4 tablets taken orally at a time, 3 times a day and Omeprazole Enteric-coated placebo tablet, taken 1 tablet orally once a day before breakfast.
89431251|NCT04672018|Active Comparator|Control group (Omeprazole enteric-coated tablet)|Omeprazole Enteric-coated tablet (20 mg), 1 tablet taken orally once a day before breakfast and Houtou Jianweiling placebo tablets, taken orally, 4 tablets at a time, 3 times a day.
89431252|NCT04649983|Experimental|Arm 1|Patients will be be treated with CD19 and CD22 CAR-T cells
89431253|NCT04648475|Experimental|Arm 1|CD19 and CD22 targeted CAR-T cells treat
89431254|NCT04638881|Experimental|Magnesium sulfate 50 mg/kg bolus + 25 mg/kg/hr infusion|Bolus to be administered at start of mucosal incision, followed by infusion. Infusion to be terminated at extubation.
89431255|NCT04638881|Placebo Comparator|Normal saline 0.9% 50 mg/kg bolus + 25 mg/kg/hr infusion|Bolus to be administered at start of mucosal incision, followed by infusion. Infusion to be terminated at extubation.
89431256|NCT04631198|No Intervention|No Intervention: GROUP CONTROL|Patients selected for the control group (conventional physiotherapy) will be exposed to respiratory physiotherapy techniques such as vibrocompression, manual passive expiratory therapy, expiratory flow acceleration, fractional inspiration in times, diaphragmatic breaths and aspiration when required
89431257|NCT04631198|Experimental|Active Comparator: INTERVENTION GROUP|The patients selected for the intervention group will be submitted to the handling of thoracoabdominal rebalancing as abdominal supports and / or in the ileo-costal space, inspiratory help, scapular waist release, thoracic swing, pectoralis major muscle release and deltoid together with aspiration if necessary.
89431258|NCT04630795||3D printed insole|Intervention insole will be produced as 3D printed insole with the Turf-Like patches incorporated in the areas of interest, while the Control Insole will be a standard 3D printed flat insole with NO Turf-like patches.
89431259|NCT04627753|Experimental|Lenalidomide and Rituximab therapy|"The clinical trial drug is administered in one cycle for 28 days and is administered as follows.~Drug : Rituximab It will be administered 375 mg/m² IV infusion Day 1. (Rituximab: up to 6 cycles)~Drug : Lenalidomide It will be administred 20 mg PO day 1 -21.~The medication is taken for up to 2 years, and if there is no recurrence, it is stopped after 2 years~, Or stop when disease progression is confirmed during the administration period."
88910723|NCT03933306|Experimental|Dexmedetomidine+goal-directed blood pressure management|Dexmedetomidine is administered during anesthesia (0.6 mcg/kg for 10 min, then 0.5 mcg/kg/h). Blood pressure is maintained within ±10% of baseline with noradrenaline infusion and fluid management.
89431260|NCT04623853|Experimental|Aim 2|Participants will carry out a protocol comprised of treadmill walking in a laboratory setting while wearing the Dynamic AFO device.
89431261|NCT04623853|Experimental|Aim 3|"Participants will be asked to take the Dynamic AFO home and wear the device for up to 4 weeks. The device will be set in either an adjustment-capable mode, or a locked mode that functions similar to their own orthotic--the order in which they are tested will be randomized."
89431262|NCT04617951|Experimental|Ishige Okamurae extracts group|This group takes Ishige Okamurae extracts for 12 weeks.
89431263|NCT04617951|Placebo Comparator|Placebo group|This group takes placebo for 12 weeks.
89431264|NCT04605718|Experimental|Part 1 (SAD)|Due to mandatory sentinel dosing, participants will be divided into two groups: 2 participants will be dosed on one day (sentinel group with 1 on active treatment and 1 on placebo) and remaining participants of the dose cohort (randomized as 5 on active treatment and 1 on placebo) at the earliest 24 hours after the first dosing occasion.
88910724|NCT03932279||Stage IA-IIA cutaneous T cell lymphoma|
88910725|NCT03932279||Stage IIB and above cutaneous T cell lymphoma|
88910726|NCT03932279||CD30+ lymphoproliferative disorders|
88910727|NCT03932279||Plaque psoriasis with BSA>5% on routine phototherapy|
88910728|NCT03932279||Moderate to severe atopic dermatitis on routine bleach bath|
88910729|NCT03932279||Healthy controls|
88910730|NCT03921801|Active Comparator|Gait retraining|8-week intervention. Intervention includes weekly gait retraining sessions with real-time electromyography biofeedback.
88910731|NCT03921801|Experimental|Gait retraining + strength training|8-week intervention. Intervention includes weekly gait retraining sessions with real-time electromyography biofeedback and home-based strength training session for plantarflexor muscles three times per week.
88910732|NCT03919513|Experimental|respiratory muscle weakness|Patients with respiratory muscle weakness are performing the inspiratory pressure threshold device, combined CPAP and inspiratory pressure threshold device and continue oxygen therapy randomly.
88910733|NCT03919513|Experimental|normal respiratory muscle|Patients with normal respiratory muscle are performing the inspiratory pressure threshold device, combined CPAP and inspiratory pressure threshold device and continue oxygen therapy randomly.
89431265|NCT04605718|Experimental|Part 2 (MAD)|In each dose cohort, a minimum of 4 participants and a maximum of 12 participants will receive either multiple IV doses of RO72232809 or placebo once-daily for 10 days (3:1 ratio of active:placebo treatment).
89431266|NCT04605718|Experimental|Part 3 (Elderly)|In this cohort, a minimum of 4 participants and a maximum of 12 participants will receive a single IV dose of RO7223280 or placebo (3:1 ratio of active:placebo treatment).
89431267|NCT04602546|Active Comparator|Sevoflurane alone|"Sevoflurane will be administered in steps to achieve a loss of consciousness via a tight-face mask by increasing the end-tidal concentration of Sevoflurane (ETSEVO). Targeted concentration for ETSEVO are 0.25, 0.5, 0.75, 1, 3, 4, 5% or higher until MOAA/S scales at values less than 2 is reached.~The equilibration time for each targeted concentration will be approximately 12 minutes to maintain a constant ETSEVO. The BIS™ value, MOAA/S score and picture recall test will be assessed when the patient is awake and at the different ETSEVO concentrations.~ETSEVO is decreased by the same steps until consciousness is regained."
89431268|NCT04602546|Active Comparator|Sevoflurane with Remifentanil Group|"Two (2) minutes before starting sevoflurane, to attain an effect-site targeted concentration of remifentanil of 4 ng/ml, an initial IV bolus of remifentanil will be given followed by the start of an infusion. Approximately within 7 minutes, the infusion rate of remifentanil may be adjusted to maintain the effect-site concentration of remifentanil of 4 ng/ml.~Sevoflurane will be administered via a tight-face mask in steps to achieve a loss of consciousness by increasing the end-tidal concentration of Sevoflurane (ETSEVO). Targeted concentration for ETSEVO are 0.25, 0.5, 0.75, 1, 3, 4, 5% or higher until an MOAA/S score of less than 2 is reached.~ETSEVO is decreased by the same steps until consciousness is regained."
89431269|NCT04602546|Active Comparator|Sevoflurane with Fentanyl Group|"Two (2) minutes before starting sevoflurane, to attain an effect-site targeted concentration of fentanyl of 2 ng/mL, an initial IV bolus of fentanyl will be given followed by the start of an infusion. Approximately within 10 minutes, the infusion rate of fentanyl may be adjusted to maintain the effect-site concentration of fentanyl of 2 ng/ml.~Sevoflurane will be administered via a tight-face mask in steps to achieve a loss of consciousness by increasing the end-tidal concentration of Sevoflurane (ETSEVO). Targeted concentration for ETSEVO are 0.25, 0.5, 0.75, 1, 3, 4, 5% or higher until an MOAA/S score of equal to or less than 2 is reached.~ETSEVO is decreased by the same steps until consciousness is regained."
89431270|NCT04602546|Active Comparator|Desflurane Group|"Due to desflurane being a volatile agent and not well tolerated as an induction agent, an initial IV bolus of 1% propofol provided at 2mg/kg, with supplemental boluses given at the investigators discretion in order to achieve laryngeal mask (LMA) insertion, will be administered 15-20 minutes prior to desflurane. Once correct LMA placement has been confirmed, there will be an equilibrium time of approximately 15-20 minutes to allow the effect site concentration of propofol to reach a level consistent with a pharmacodynamic effect of consciousness as measured by a MOAA/S score of 2 or 3. Desflurane will then be administered via a tight-face mask at the targeted end-tidal concentration (ETDES) of 2, 5, 7, 8, 9, 10 %, or higher until an MOAA/S score of less than 2 is reached.~The BIS™ value will be correlated with desflurane ETDES concentration. ETDES is decreased by the same steps until consciousness is regained."
88910735|NCT03918278|Experimental|Part 1: MK-0482 Monotherapy|Participants receive escalating doses of MK-0482 via intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W) for up to 35 administrations (up to approximately 2 years).
88910736|NCT03918278|Experimental|Part 1: MK-0482 + Pembrolizumab Combination Therapy|Participants receive escalating doses of MK-0482 via IV infusion + pembrolizumab 200 mg via IV infusion on Day 1 of each 21-day cycle (Q3W) for up to 35 administrations (up to approximately 2 years).
88910737|NCT03918278|Experimental|Part 2: Cohort A|Participants with metastatic triple negative breast cancer (TNBC) first line treatment (1L) receive MK-0482 via IV infusion plus pembrolizumab 200 mg via IV infusion on Day 1 of each 21-day cycle (Q3W) up to 35 administrations (up to approximately 2 years) and paclitaxel 90 mg/m^2 via IV infusion until PD or discontinuation.
88910738|NCT03918278|Experimental|Part 2: Cohort B|Participants with recurrent non-operable glioblastoma (GBM) current treatment of second line (2L) receive MK-0482 via IV infusion plus pembrolizumab 200 mg via IV infusion on Day 1 of each 21-day cycle (Q3W) up to 35 administrations (up to approximately 2 years).
88910739|NCT03918278|Experimental|Part 2: Cohort C|Participants with metastatic pancreatic ductal adenocarcinoma (PDAC) (1L) receive MK-0482 via IV infusion plus pembrolizumab 200 mg via IV infusion on Day 1 of each 21-day cycle (Q3W) up to 35 administrations (up to approximately 2 years), Nab-Paclitaxel 125 mg/m^2 via IV infusion and gemcitabine 1000 mg/m^2 via IV infusion until PD or unacceptable toxicity that requires discontinuation.
88910740|NCT03918278|Experimental|Part 2: Cohort D|Participants with metastatic soft tissue sarcoma (STS) (2L) receive MK-0482 via IV infusion plus pembrolizumab 200 mg via IV infusion on Day 1 of each 21-day cycle (Q3W) up to 35 administrations (up to approximately 2 years).
88922251|NCT05587322|Experimental|BLI5100 Low Dose|During the Treatment Period, patients will take BLI5100 low dose once daily, orally, for 8 weeks. During the Extension Period, patients will continue to take BLI5100 low dose once daily, orally, for 20 weeks.
88922252|NCT05587322|Experimental|BLI5100 High Dose|During the Treatment Period, patients will take BLI5100 high dose once daily, orally, for 8 weeks. During the Extension Period, patients will continue to take BLI5100 high dose once daily, orally, for 20 weeks.
89431271|NCT04602546|Active Comparator|Isoflurane Group|"Due to isoflurane being a volatile agent and not well tolerated as an induction agent, an initial IV bolus of 1% propofol provided at 2mg/kg, with supplemental boluses given at the investigators discretion in order to achieve LMA insertion, will be administered 15-20 minutes prior to isoflurane.Isoflurane will be administered via a tight-face mask in steps to achieve a loss of consciousness (MOAA/S of 0,1) by increasing the end-tidal concentration of Isoflurane (ETISO). Targeted concentration for ETISO are 0.25, 0.5, 0.75, 1, 1.5% or higher until MOAA/S scales at values less than 2 is reached.~The BIS™ value will be correlated with desflurane ETISO concentration. ETISO is decreased by the same steps until consciousness is regained."
89431272|NCT04591366|Active Comparator|Control|Standard skin prep prior to procedure will be performed and an adhesive iodine-infused barrier dressing will be applied post procedure but prior to taking the culture swab and closing the incision.
89431273|NCT04591366|Experimental|Intervention|Standard skin prep prior to procedure plus an adhesive iodine-infused barrier dressing prior to incision, post procedure a culture swab will be taken and the incision closed.
89431274|NCT04577209|Experimental|Pediatric Patients|Participants undergoing anesthesia-related aerosol generating medical procedures (AGMPs) and pediatric otolaryngologic surgeries will have a local exhaust ventilation system to the exposure seen by the medical providers during the AGMPs and surgeries.
89431275|NCT04571424|Experimental|Cohort 1: BIIB133 Dose 1|Participants will receive single IV infusion of BIIB133 Dose 1.
89431276|NCT04571424|Experimental|Cohort 2: BIIB133 Dose 2|Participants will receive single IV infusion of BIIB133 Dose 2.
89431277|NCT04571424|Placebo Comparator|Cohort 1-2: Placebo|Participants will receive single IV infusion of matching placebo to BIIB133.
89431278|NCT04569864|Experimental|Mild hypothermia (30-32°C)|During aortic hemiarch replacement, mild hypothermia (30-32°C) will be used during circulatory arrest.
89431279|NCT04569864|Active Comparator|Moderate hypothermia (26-28°C)|During aortic hemiarch replacement, moderate hypothermia (26-28°C) will be used during circulatory arrest.
89431280|NCT04564612|Experimental|Part 1|Participants will receive single oral dose of BIIB091 on Day 1 of each study period, in fasted state, for up to 5 periods. There will be a minimum 7-day washout between Day 1 of each study period.
89431281|NCT04564612|Experimental|Part 1B|Participants will be randomized to receive single oral or 2 oral doses for divided daily doses of BIIB091 on Day 1 of Period 1, in fasted state or single oral dose of BIIB091 on Day 1 of Period 1, in fed state. Participants will receive single oral dose of BIIB091 on Day 1 of Period 2, in fasted state. Participants will receive single or two divided oral dose(s) of BIIB091 on Day 1 of Periods 3 and 4, in fasted or fed state. There will be a minimum 7-day washout between Day 1 of each study period.
89431282|NCT04564612|Experimental|Part 2|Participants will receive single oral dose of BIIB091 on Day (D) 1 of Period (P) 1 in fasted/fed state; then itraconazole 100 milligram (mg) capsules (cap), orally, twice daily (BID) for 1 day (D -4) of P2, in fed state; then itraconazole 100 mg cap, orally, once daily (QD) for 2 days (D -3, -2) of P2, in fed state; then itraconazole 100 mg cap, orally, QD for 1 day (D -1) of P2, in fasted/fed state; then combination of itraconazole 100 mg cap, orally and BIIB091, orally on 5th day (D 1) of P2, in fasted/fed state; then itraconazole 100 mg cap, orally on 6th day (D 2) of P2, in fed state; then rabeprazole 20 mg tablets (tab), orally, BID for 3 days (D -3, -2, and -1) of P3 in fed state; then combination of rabeprazole 20 mg tab, orally and BIIB091, orally, on 4th day (D 1) of P3 in fasted/fed state. Minimum 7-day washout between dose of BIIB091 in P1 and 1st dose of itraconazole in P2; minimum 10-day washout between final dose of itraconazole in P2 and 1st dose of rabeprazole in P3.
89431283|NCT04564612|Experimental|Part 3|Participants will receive BIIB091, orally, QD or BID for at least 7 days in fasted or fed state.
88910741|NCT03918278|Experimental|Part 2: Cohort E|Participants with metastatic non-squamous non-small cell lung carcinoma (NSCLC) (1L) receive MK-0482 via IV infusion plus pembrolizumab 200 mg via IV infusion plus Pemetrexed 500 mg/m^2 via IV infusion on Day 1 of each 21-day cycle (Q3W) up to 35 administrations (up to approximately 2 years) plus carboplatin with desired dose of area under the curve (AUC) 5 and pemetrexed 500 mg/m^2, both administered via IV infusion, followed by maintenance therapy with pemetrexed 500 mg/m^2 via IV infusion for up to a total of 35 administrations (up to approximately 2 years).
88910742|NCT03916185|Experimental|RSV ΔNS2/Δ1313/I1314L Vaccine|Participants will receive a single dose of the RSV ΔNS2/Δ1313/I1314L vaccine at study entry (Day 0).
88910743|NCT03916185|Experimental|RSV 6120/ΔNS2/1030s Vaccine|Participants will receive a single dose of the RSV 6120/ΔNS2/1030s vaccine at study entry (Day 0).
89008499|NCT04591639|Other|Patients with heart failure with type 2 diabetes|60 patients with heart failure with type 2 diabetes will be recruited and will either be randomised to placebo or Dapagliflozin after their baseline cardiac MRIs. They will have 2 cardiac MRIs (gadolinium and manganese enhanced) at baseline and further manganese enhanced cardiac MRI at 1 month post randomisation + gadolinium and manganese enhanced cardiac MRI at 6 months post randomisation.
89431284|NCT04539470|Experimental|Cohort A: Efmarodocokin Alfa Dosage Level 1|Participants undergoing allogeneic hematopoietic stem cell transplantation will receive Efmarodocokin Alfa dosage level 1 in combination with standard of care prophylaxis treatment for acute graft versus-host disease (aGVHD), consisting of tacrolimus plus methotrexate per institutional practices.
89431285|NCT04539470|Experimental|Cohort B: Efmarodocokin Alfa Dosage Level 2|Participants undergoing allogeneic hematopoietic stem cell transplantation will receive Efmarodocokin Alfa dosage level 2 in combination with standard of care prophylaxis treatment for acute graft versus-host disease (aGVHD), consisting of tacrolimus plus methotrexate per institutional practices.
89431286|NCT04539470|Experimental|Cohort C: Efmarodocokin Alfa Dosage Level 3|Participants undergoing allogeneic hematopoietic stem cell transplantation will receive Efmarodocokin Alfa dosage level 3 in combination with standard of care prophylaxis treatment for acute graft versus-host disease (aGVHD), consisting of tacrolimus plus methotrexate per institutional practices.
89431287|NCT04534907|Active Comparator|VR(ERP）|The combination of exposure and response prevention (ERP) and VR will be applied twice a week for the fist two weeks. For the next four weeks, this treatment will be applied once a week. 8 times in total
89431288|NCT04534907|Active Comparator|traditional ERP|The traditional ERP will be applied twice a week for the fist two weeks. For the next four weeks, this treatment will be applied once a week. 8 times in total
89431289|NCT04524637||Traumatic brain injury|Patients who are delivered within 24 hours after head trauma and sustain isolated traumatic brain injury are included in this study.
89431290|NCT04521062|Other|Dilapan S|Placement of dilators
89431291|NCT04518319|Experimental|omega-3 polyunsaturated fatty acids|Patients randomized to the omega-3 polyunsaturated fatty acids will receive treatment with 1200mg per day plus on-going olanzapine.
89431292|NCT04518319|Experimental|Xbox aerobic exercise|Patients randomized to the Xbox aerobic exercise will do Xbox aerobic exercise 30min per day plus on-going olanzapine.
89431293|NCT04518319|Experimental|transcranial direct current stimulation|Patients randomized to the transcranial direct current stimulation will be applied for transcranial direct current stimulation 5 session/week at 2mA, 20min plus on-going olanzapine. The anodal electrode will be placed over the left dorsolateral prefrontal cortex.
89431294|NCT04518319|Experimental|olanzapine|Patients randomized to the olanzapine will receive conventional treatment-olanzapine.
89431295|NCT04516226|Experimental|Vaginal cleansing|This group includes patients diagnosed with PPROM that are randomized to undergo vaginal cleansing with chlorhexidine gluconate within 24 hours of PPROM diagnosis.
89431296|NCT04516226|No Intervention|No vaginal cleansing|This group includes patients diagnosed with PPROM that are randomized to not undergo vaginal cleansing.
89431297|NCT04511871|Experimental|CCT303-406|"To determine the safety, tolerability, dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) of CCT303-406 cell therapy in patients with HER2-positive (IHC 3+ in ≥50% tumor cells) relapsed or refractory solid tumors.~Dose cohorts:~Dose 1: 3x10^5 CCT303-406 CAR-positive T cells/kg body weight, intravenous infusion~Dose 2: 1x10^6 CCT303-406 CAR-positive T cells/kg body weight, intravenous infusion~Dose 3: 1x10^7 CCT303-406 CAR-positive T cells/kg body weight, intravenous infusion"
89431298|NCT04503941|Experimental|Active Comparator|Acupuncture treatment will be the Traditional Chinese Medicine type. Acupuncture 3 times per week, 4 weeks is one treatment period. Every patient will be given 3 treatment period.
89431299|NCT04503941|Placebo Comparator|The control group|False Needle treatment will be the Traditional Chinese Medicine type. Acupuncture 3 times per week, 4 weeks is one treatment period. Every patient will be given 3 treatment period.
89431300|NCT04495868|Experimental|Bacteriostatic Normal Saline then 1% Lidocaine|Participants undergoing a lumbar medial branch block who are randomized to receive an intradermal administration of bacteriostatic normal saline followed by an intradermal administration of 1% lidocaine.
89431301|NCT04495868|Active Comparator|1% Lidocaine then Bacteriostatic Normal Saline|Participants undergoing a lumbar medial branch block who are randomized to receive an intradermal administration of 1% lidocaine followed by an intradermal administration of bacteriostatic normal saline.
89431302|NCT04483544|Experimental|Treatment|PD-1 inhibitor pembrolizumab, in combination with the PARP inhibitor olaparib
89431303|NCT04475029|Experimental|Methadone|A 10 ml syringe with 2 mg/ml of methadone will be prepared and and study drug will be administered as intravenous bolus dose (0.15 mg/kg treatment weight (height (cm) - 100)). The study drug will be administered 1 hour prior to expected extubation.
89431304|NCT04475029|Active Comparator|Morphine|A 10 ml syringe with 2 mg/ml of morphine will be prepared and and study drug will be administered as intravenous bolus dose (0.15 mg/kg treatment weight (height (cm) - 100)). The study drug will be administered 1 hour prior to expected extubation.
89431305|NCT04466735|Experimental|Active group|Participants will be on the active intervention for 6 months
89431306|NCT04466735|Placebo Comparator|Placebo Group|Participants will be on the placebo intervention for 6 months
89431307|NCT04466735|Active Comparator|Open phase on active product|At the end of the 6-month randomized controlled phase, participants will be unblinded and invited to continue on the active product for an additional 3 months.
89431308|NCT04456881|Experimental|anatomical reconstruction group of Patellofemoral ligament|
89431309|NCT04441047|Experimental|Vaccination|ID injection AlloStim Days 0, 3/4, 7, 10/11 and 14
89431310|NCT04417205|Active Comparator|Carbohydrate rich breakfast|Participants will be provided with 28-days worth of pre-weighed carbohydrate rich breakfast materials to consume before 1000h daily.
89431311|NCT04417205|Experimental|Whey protein enriched breakfast|Participants will be provided with 28-days worth of pre-weighed whey protein enriched rich breakfast materials to consume before 1000h daily.
89431312|NCT04417205|No Intervention|Extended morning fast|Participants will be asked to remain fasted (i.e. to not consume breakfast) until 1200h daily for 28-days.
88910744|NCT03916185|Experimental|RSV 276 Vaccine|Participants will receive a single dose of the RSV 276 vaccine at study entry (Day 0).
88910745|NCT03916185|Placebo Comparator|Placebo|Participants will receive a single dose of placebo at study entry (Day 0).
88910746|NCT03914625|Active Comparator|Arm A (SR-Avg control)|Arm A: See detailed description.
88910747|NCT03914625|Experimental|Arm B (SR-Avg experimental)|Arm B: See detailed description.
88910748|NCT03914625|Active Comparator|Arm C (SR-High Control)|Arm C: See detailed description.
88910749|NCT03914625|Experimental|Arm D (SR-High experimental)|Arm D See detailed description.
88910750|NCT03914625|Experimental|B-LLy|See detailed description.
88910751|NCT03914625|Experimental|DS B-ALL|See detailed description.
88910752|NCT03914625|Experimental|NCI SR or HR DS B-ALL|See detailed description.
88910753|NCT03913442|Placebo Comparator|Placebo|Placebo in capsule identical to study drug
89431313|NCT04404101|Active Comparator|1). EUS-FNA plus MFB|A 19-G needle plus micro-forceps will be used for FNA plus MFB.
89431314|NCT04404101|Active Comparator|2). EUS-FNA Alone|A 19-G needle will be used for FNA alone.
89431315|NCT04364958|Experimental|Intervention group|Patients who agree participant and will sign the informed consent, will complete the baseline assessment. Then, those allocated to the intervention group will review the web-based PtDA (shown on the computer), with the help of a researcher if necessary, and then will fill the questionnaires assessing the outcome measures in the same web interface.
89431316|NCT04364958|Active Comparator|Control group|Patients allocated to the control group will receive a web-based fact sheet (one page shown on the computer) with general information on mental health as a part of usual care, and they will also complete the same questionnaires.
89431317|NCT04348643|Experimental|CEA+ CAR-T|CAR-T cell reinfusion is carried out in 1~3 times
89431318|NCT04340661|Experimental|Bionocol arm|
89431319|NCT04340661|Placebo Comparator|Placebo arm|
89431320|NCT04324268|Placebo Comparator|Placebo|Placebo
88910754|NCT03913442|Experimental|Colchicine|"0.6 or 0.8 mg orally once daily.~Because recent studies suggest that a dose of 0.6mg may be sufficient for chronic inflammatory suppression and may reduce the already low risk of toxicity of 0.8mg, for the remainder (second half) of the study the dosage will be switched from 0.8mg to a 0.6mg dose to allow comparison of the two doses."
88910755|NCT03904940|Experimental|Total Contact Insole Group|Ethyl vinyl acetate insole shaped in the cast of the patient's foot, every 6 months.
88910756|NCT03904940|Sham Comparator|Flat Insole group|Flat insole made the same material ethyl vinyl acetate, every 6 months.
88910757|NCT03902782|Experimental|ESP block|patients will receive an ultrasound guided ESP block (technique as described by Forero et al) under strict sterile conditions in the operating room area. After identifying the T5 transverse process (TP) and after infiltration of lidocaine 2% subcutaneously. A 22g 100mm block needle will be advanced under vision, in a cephalad to caudad direction, until the tip contacts the T5 TP. 20 ml of 0.25% bupivacaine with 5 mcg/ml of epinephrine and 10 mg dexamethasone will be injected under the erector spinae muscle. A visible separation of the erector spinae muscle from the TP will be the sign of a successful block. A 20 ml syringe of Normal Saline will be given to the surgeon (unaware of the content) at the end of the surgery, for the intercostal nerve block as per standard present technique.
88910758|NCT03902782|Sham Comparator|ESP sham block|patients will receive an ultrasound guided sham ESP block under strict sterile conditions in the operating room area as described above. 20 ml of Normal Saline will be injected under the erector spinae muscle. A 20 ml syringe of 0.25% bupivacaine with 5 mcg/ml of epinephrine and 10 mg dexamethasone will be given to the surgeon (blinded to the content) at the end of the surgery for the intercostal nerve block.
89431321|NCT04324268|Experimental|SC 0.3 mg/kg of lirentelimab (AK002)|Subjects in this arm will receive a single dose of 0.3 mg/kg of lirentelimab (AK002) administered subcutaneously.
89431322|NCT04324268|Experimental|SC 1 mg/kg of lirentelimab (AK002)|Subjects in this arm will receive a single dose of 1 mg/kg of lirentelimab (AK002) administered subcutaneously.
89431323|NCT04324268|Experimental|SC 3 mg/kg of lirentelimab (AK002)|Subjects in this arm will receive a single dose of 3 mg/kg of lirentelimab (AK002) administered subcutaneously.
89431324|NCT04324268|Experimental|SC 5 mg/kg of lirentelimab (AK002)|Subjects in this arm will receive a single dose of 5 mg/kg of lirentelimab (AK002) administered subcutaneously.
89431325|NCT04324268|Experimental|IV 1 mg/kg of lirentelimab (AK002)|Subjects in this arm will receive a single dose of 1 mg/kg of lirentelimab (AK002) administered intravenously.
89431326|NCT04324268|Experimental|IV 3 mg/kg of lirentelimab (AK002)|Subjects in this arm will receive a single dose of 3 mg/kg of lirentelimab (AK002) administered intravenously.
89431327|NCT04324268|Experimental|IV 3 mg/kg of lirentelimab (AK002) (Priming)|Subjects in this arm will receive a single dose of 3 mg/kg of lirentelimab (AK002) administered intravenously from an IV bag prepared with extra volume for priming IV set.
89431328|NCT04324268|Experimental|SC 300 mg of lirentelimab (AK002)|Subjects in this arm will receive a single dose of 300 mg of lirentelimab (AK002) administered subcutaneously.
89431329|NCT04324268|Experimental|SC 450 mg of lirentelimab (AK002)|Subjects in this arm will receive a total of 450 mg of lirentelimab (AK002), administered as two separate subcutaneous injections.
89431330|NCT04300153|Experimental|ESP Group|At the end of the skin closure, patients will be positioned in lateral decubitis and unilateral ESP block will be performed with single injection of 30 ml 0.25% bupivacaine at the level of T12 transverse process. All patients will receive intravenous (iv) paracetamol 1000 mg at the arrival to the recovery room. The dosage will be repeated at every 8-hours interval.
89431331|NCT04300153|Sham Comparator|Control Group|At the end of the skin closure, patients will be positioned in lateral decubitis and unilateral ESP block will be performed with single injection of 30 ml normal saline at the level of T12 transverse process. All patients will receive intravenous (iv) paracetamol 1000 mg at the arrival to the recovery room. The dosage will be repeated at every 8-hours interval.
89431332|NCT04298216|Active Comparator|Assessment of Inferior Vena Cavae with Subcostal View|Patients will have a novel operator attempt to visualize their Inferior Vena Cavae with the probe placed in the subcostal region.
89431333|NCT04298216|Experimental|Assessment of Inferior Vena Cavae with Transhepatic View|Patients will have a novel operator attempt to visualize their Inferior Vena Cavae with the probe placed in the transhepatic region.
89431334|NCT04283097|Experimental|Single arm|KPG-818 dose escalation
89431335|NCT04279574|Other|CAD/CAM Onlays|Lithium disilicate chairside CAD/CAM onlays (IPS emaxCAD/Ivoclar) will be adhesively bonded using a selective enamel etch technique with an adhesive (3M) and cement (3M).
89431336|NCT04279574|Other|CAD/CAM Crowns|Full contour zirconia crowns (3M Chairside Zirconia/3M) will be cemented using a self-adhesive cement (3M).
89431337|NCT04278157|Experimental|SCBT-SB|A culturally centered CBT treatment protocol called Socio-Cognitive Behavioral Therapy for Suicidal Behavior (SCBT-SB)
89431338|NCT04278157|Active Comparator|Treatment as Usual|Treatment as usual is base on the standard care for teens and their parents under a community mental health center.
89431339|NCT04272151|Experimental|BCMA CAR-T cells treat|Patients will be be treated with BCMA CAR-T cells
89431340|NCT04272125|Experimental|CD123 CAR-T cells treat|Patients will be be treated with CD123 CAR-T cells
89431341|NCT04271800|Experimental|CD19 CAR-T cells treat|Patients will be be treated with CD19 CAR-T cells
89431342|NCT04271644|Experimental|BCMA CAR-T cells treat|Patients will be be treated with BCMA CAR-T cells
89431343|NCT04271410|Experimental|CD19 CAR-T cells treat|Patients will be be treated with CD19 CAR-T cells
89431344|NCT04265963|Experimental|CD123 CAR-T cells treat|Patients will be be treated with CD123 CAR-T cells
89431345|NCT04254705|Other|Subjects with CF and R334W mutation|Subjects with CF and R334W mutation
89431346|NCT04253561|Experimental|Ipatasertib + Trastuzumab + Pertuzumab|"Ipatasertib will be given from Day 1 to Day 21 in every 28-day cycles. The starting dose is 400 mg orally (PO) QD and may be decreased to 300 mg QD and further to 200 mg QD (dose levels 1, - 1 and -2, respectively).~Pertuzumab will be given IV every 21 days at the dose of 420 mg.~Trastuzumab will be given SC every 21 days at the dose of 600mg. Intravenous (IV) Trastuzumab"
89431347|NCT04240171||dapagliflozin|Group 1(n=30): are the patients who are prescribed dapagliflozin to control their blood sugar level.
89431348|NCT04240171||glimepiride|Group 2 (n=30): are the patients who are prescribed glimepiride
89431349|NCT04221958||Electrocardiogram (ECG) Mapping|Participants will have 10 superficial electrode-patches placed on their chest in two vertical columns of 5 electrode-patches. The channels V1-V5 will be connected to one of the columns. The channel V6 will be connected to each of the electrode-patches in the second column ad recordings will be taken for approximately 2 minutes on each electrode-patch. ECG readings will be recorded.
89431350|NCT04212091|Experimental|Part A (Group 1): PGT121.414.LS (3 mg/kg)|Participants will receive 3 mg/kg of PGT121.414.LS by intravenous (IV) infusion at Month 0.
89431351|NCT04212091|Experimental|Part A (Group 2): PGT121.414.LS (10 mg/kg)|Participants will receive 10 mg/kg of PGT121.414.LS by IV infusion at Month 0.
89431352|NCT04212091|Experimental|Part A (Group 3): PGT121.414.LS (30 mg/kg)|Participants will receive 30 mg/kg of PGT121.414.LS by IV infusion at Month 0.
89431353|NCT04212091|Experimental|Part A (Group 4): PGT121.414.LS (5 mg/kg)|Participants will receive 5 mg/kg of PGT121.414.LS by subcutaneous (SC) infusion at Month 0.
89431354|NCT04212091|Experimental|Part B (Group 5): PGT121.414.LS + VRC07-523LS (20 mg/kg)|Participants will receive 20 mg/kg of PGT121.414.LS and 20 mg/kg of VRC07-523LS by IV infusion sequentially in this order at Months 0, 4, and 8.
89431355|NCT04212091|Experimental|Part B (Group 6): PGT121.414.LS + VRC07-523LS (5 mg/kg)|Participants will receive 5 mg/kg of PGT121.414.LS and 5 mg/kg of VRC07-523LS by SC infusion sequentially in this order at Months 0, 4, and 8.
89431356|NCT04207333|Experimental|Prolonged Sitting + Mental Stress, Then Brief Sitting + Mental Stress|Participants will sit for 120 min prior to being exposed to mental stress Following 10 minutes of supine rest, participants will switch to an upright sitting position and remain seated for 120 minutes while watching a documentary. Following the 10 minutes quiet rest the participants will be subjected to a 5 minute mental arithmetic test. Following a 2-5 day wash-out period, participants will be exposed to the other condition (brief sitting, followed by mental stress). For this condition participants will rest in the supine position for 10 minutes, then will be switched to an upright seated position. Following the 10 minutes quiet rest in the seated position, participants will be subjected to a 5 minute mental arithmetic test.
89431357|NCT04207333|Experimental|Brief Sitting + Mental Stress, Then Prolonged Sitting + Mental Stress|Following 10 minutes of supine rest, participants will switch to an upright sitting position and remain seated for 10 minutes. Following the 10 minutes quiet rest the participants will be subjected to a 5 minute mental arithmetic test. Following a 2-5 day wash-out period, participants will be exposed to the other condition (prolonged sitting, followed by mental stress). For this condition participants will rest in the supine position for 10 minutes, then will be switched to an upright seated position. Participants will sit quietly for 120 min while watching a documentary, following which the participants will be subjected to a 5 minute mental arithmetic test.
89431358|NCT04191512||Upper airway stimulation|
89431359|NCT04191512||Continuous positive airway pressure|
89431360|NCT04170738|Experimental|Adderall|dosage = start at 0.25-0.50mg/kg, adjusted as necessary pills by mouth
88910759|NCT03900494|Active Comparator|Children treated with VHC 1|In this group children are receiving salbutamol with valved holding chamber number 1. Otherwise the children in both groups are treated exactly the same way. The only difference is the device used to deliver the bronchodilator. Children in both arms have the same condition and the same inclusion and exclusion criteria. We only compare the efficacy of the two VHC devices.
88910760|NCT03900494|Active Comparator|Children treated with VHC 2|In this group children are receiving salbutamol with valved holding chamber number 2. Otherwise the children in both groups are treated exactly the same way. The only difference is the device used to deliver the bronchodilator. Children in both arms have the same condition and the same inclusion and exclusion criteria. In this group children are receiving salbutamol with valved holding chamber number 1. Otherwise the children in both groups are treated exactly the same way. The only difference is the device used to deliver the bronchodilator. Children in both arms have the same condition and the same inclusion and exclusion criteria.
88922253|NCT05587322|Placebo Comparator|Placebo|During the Treatment Period, patients will take placebo once daily, orally, for 8 weeks. In the Extension Phase, patients who received placebo in the Treatment Phase will be re-randomized to receive either BLI5100 low dose or BLI5100 high dose to take once daily, orally, for 20 weeks.
88922254|NCT05587309|Experimental|Healing Phase - BLI5100|During the Healing Phase, patients will take BLI5100 once daily, orally, for up to 8 weeks.
89431361|NCT04158817|Experimental|Experimental Arm|All Prostate cancer patients recruited to the study will be administered 2.11 MBq/kg of 68Ga-THP-PSMA in a single dose injection.
89431362|NCT04158375|Experimental|Insulin Resistant Exercise Group|Resistance (RE) training will be performed 4 days per week using a combination of upper and lower body exercises at 8-12 repetitions per set. Resistance training will be performed using a combination of upper and lower body exercises using machine and free weights. Upper body exercises are chest press, incline press, seated row, lat pull down, triceps extension, biceps curl and lateral raises. Major muscle groups for upper body exercises will include chest (pectoralis major and minor), arm (biceps and triceps), shoulder (deltoids) and back (latissimus dorsi and rhomboids). Lower body exercises are leg press, lunge (with body weight progressing to dumbbells), seated leg extension, seated leg curl, calf raises and abdominal crunches. Major muscle groups for the lower body exercises will be thighs (quadriceps and hamstrings), calves (gastrocnemius and soleus) and core (rectus abdominus and obliques).
89431363|NCT04158375|No Intervention|Insulin Resistant Control Group|Participants in this group will perform no exercise for the 3 month study period.
89431364|NCT04158375|No Intervention|Insulin Sensitive Lean Group|Participants in this group will have a baseline study for comparison to the insulin resistant groups.
88922255|NCT05587309|Active Comparator|Healing Phase - PPI Control|During the Healing Phase, patients will take a PPI control once daily, orally, for up to 8 weeks.
88922256|NCT05587309|Experimental|Maintenance Phase - BLI5100 Low Dose|During the Maintenance Phase, patients will take BLI5100 low dose once daily, orally, for 24 weeks.
88922257|NCT05587309|Experimental|Maintenance Phase - BLI5100 High Dose|During the Maintenance Phase, patients will take BLI5100 high dose once daily, orally, for 24 weeks.
89431365|NCT04150991|Experimental|Fiber intervention|The investigator's targeted supplemental fiber mixture (35 g total) will be composed of 6g of fiber from oligofructose + 10g from resistant maltodextrin + 12g from acacia gum + 4g from whole foods + 3g from RS2; and will be split into three meals each day.
89431366|NCT04150991|Placebo Comparator|Placebo treatment|Maltodextrin will be used as a placebo control, as it is digested in the small intestine and thus does not exert local effects in the colon.
89431367|NCT04135261|Experimental|Part 1: Dose escalation|"QW - up to 4 (28 day) cycles of treatment (treatment administered 1x weekly) or Q3W - up to 6 (21 day) cycles of treatment (treatment administered 1x q3w)~Dose for cohorts to be confirmed following consultation and approval by Safety Review Committee."
88910761|NCT03896464|Active Comparator|Soft-tissue hamstring|All patients in the study will undergo arthroscopic-assisted, single-bundle, complete transphyseal, anatomic primary ACL reconstruction at the discretion of the surgeon, considering the individual patient's age, physeal status, and anticipated years of growth remaining to skeletal maturity. Patients in this arm will undergo soft-tissue autograft reconstruction using hamstrings (i.e. semitendinosus and/or gracilis) grafts. Grafts will be secured on the femur and tibia according to surgeon preference, given literature demonstrating no clear superior method for graft fixation.
88910762|NCT03896464|Active Comparator|Quadriceps tendon|Patients in this arm will undergo soft-tissue autograft reconstruction using all-soft-tissue quadriceps (i.e. full or partial thickness) grafts. Grafts will be secured on the femur and tibia according to surgeon preference, given literature demonstrating no clear superior method for graft fixation.
88910763|NCT03895541|Other|Stratification|All patient will have the same intervention. They will be stratified regarding their degree of heart failure gravity.
88910764|NCT03892291||Civilian mTBI|Civilians with persistent symptoms from mTBI
88910765|NCT03892291||Civilian Control|Civilian healthy controls
88910766|NCT03892291||Active Duty Control|Active duty service member healthy controls
88910767|NCT03892291||Active Duty mTBI|Active duty service members with persistent symptoms from mTBI who are referred for physical therapy due to their symptoms
88910768|NCT03891199|No Intervention|Control|Traditional THA.
88910769|NCT03891199|Active Comparator|Intervention|Robotic-arm assisted THA.
88910770|NCT03887715|Active Comparator|Active|Group will have VNS activated 2 weeks post implant.
88910771|NCT03887715|Sham Comparator|Control|Group will be implanted with VNS but device is not activated for the first 12 months. After 12 months, this group can receive stimulation.
88910772|NCT03887052|Experimental|Study Arm|Adult cardiac patients at risk for sudden cardiac arrest otherwise protected with an Implantable Cardioverter Defibrillator (ICD)
88910773|NCT03874663||Oral HIV Self-testing|Evaluate the acceptability and performance of a directly assisted oral HIV self-testing (HIVST) in a youth population aged 14-24 in Nigeria
88910774|NCT03869372|Experimental|Study subjects|"At the baseline session, measures of autonomic activity (electrogastrogram - EGG, electrocardiogram - ECG, cardiac impedance - CI) will be monitored from about 15 minutes before up to 1 hour after consumption of a test meal, water or a nutrient drink. In addition, motor-evoked potentials (MEPs) elicited with paired pulse transcranial magnetic stimulation (ppTMS) will be assessed before and after the meal or drink.~In subsequent sessions, repetitive transcranial magnetic stimulation (rTMS) is applied before the meal or drink. Based on responses to symptom surveys (IBS-SSS and PAGI-SYM), study subjects will be characterized as healthy or as having functional dyspepsia and/or IBS."
88910775|NCT03867604|Sham Comparator|Sham injection|Subcutaneous injection at upper trapezium muscle level
88910776|NCT03867604|Experimental|Fascia injection|Fascia injection, below upper trapezium muscle
88910777|NCT03863132|Active Comparator|TAVR Group|Patients will be treated by transcatheter aortic valve repair (TAVR).
88910778|NCT03863132|No Intervention|Medical Treatment Group|Patients will receive optimal medical treatment alone.
88910779|NCT03858985|Active Comparator|Transcutaneous Vagus Nerve Stimulation|Cervical Transcutaneous vagus nerve stimulation. Participants will undergo once daily cervical transcutaneous vagus nerve stimulation.
88910780|NCT03858985|Sham Comparator|Sham Vagus Nerve Stimulation|Sham Cervical Transcutaneous Vagus Nerve Stimulation. Participants will undergo once daily sham cervical transcutaneous vagus nerve stimulation.
88910781|NCT03858244||IS with SDB|Idiopathic scoliosis with untreated and treated sleep-disordered breathing
88910782|NCT03858244||IS without SDB, controls|Idiopathic scoliosis without sleep-disordered breathing, control group
88910783|NCT03858049|Experimental|Crinone|Participants received Crinone 8% (90 milligrams [mg] an intravaginal progesterone gel contained in a single use, one piece applicator) once daily in morning from the day of endometrial transformation (Day -5) until ongoing pregnancy was confirmed up to Day 63.
88910784|NCT03858049|Experimental|Crinone plus Duphaston|Participants received Crinone 8% (90 mg an intravaginal progesterone gel contained in a single use, one piece applicator) once daily in morning followed by 10 mg of Duphaston tablet orally twice a day from the day of endometrial transformation (Day -5) until ongoing pregnancy was confirmed up to Day 63.
88910785|NCT03856216|Experimental|Group I (inotuzumab ozogamicin, chemotherapy, transplant)|See Detailed Description.
88910786|NCT03856216|Experimental|Group II (inotuzumab ozogamicin, chemotherapy, transplant)|See Detailed Description.
88910787|NCT03853031|Active Comparator|LVEDA guided intraoperative fluid therapy|Patients in TEE group will be given crystalloid fluids during surgery guided by LVEDA cm2 to be maintained between 10 -18 cm2 , if LVEDA < 10 cm2 then 200ml colloid bolus will be given and increase in LVEDA noted.
88910788|NCT03853031|Active Comparator|CVP guided intraoperative fluid therapy|Patients in CVP group will be given crystalloid fluids during surgery guided by CVP values to be maintained between 10 -16 cms of water H2O ,if CVP value < 10 cms H2O then 200 ml colloid bolus will be given and increase in CVP value noted.
88910789|NCT03851627|Active Comparator|Testosterone undecanoate|intramuscular Testosterone undecanoate 1000mg/4ml
89431368|NCT04135261|Experimental|Part 2: Dose expansion|Treatment administered at Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) established in Part 1, in specific tumor cohorts - Melanoma, HCC and RCC.
89431369|NCT04105660|Experimental|Intervention arm|EEG monitoring in addition to standard monitoring (clinical parameters and BIS index)
89431370|NCT04105660|Active Comparator|Control arm|Standard monitoring including clinical parameters and BIS index
89536881|NCT03312179||non diabetics STEMI|Non diabetics patients admitted for ST elevation myocardial infarction (STEMI) and associated with multi vessels coronary artery stenosis(Mv) non obstructive coronary artery stenosis (NOCS). These patients received percutaneous coronary intervention (PCI), and primary stenting (DES) of culprit lesion. Then these patients received full medical STEMI therapy.
89431371|NCT04094142|Experimental|Treatment arm|"Acalabrutinib is provided as hard gelatin capsules for oral administration. Acalabrutinib 100 mg will be administered approximately every 12 hours from day 1 to day 28 Rituximab is provided as single-use vials for intravenous administration only. Rituximab 375 mg/m2 will be administered on day 1.~Lenalidomide is provided as opaque hard capsules for oral administration. Lenalidomide 20 mg will be administered once daily from day 1 to day 21"
89431372|NCT04089514||Adalimumab Therapy|Adult participants diagnosed with immune-mediated inflammatory disease will receive adalimumab as a prescribed therapy
89431373|NCT04088409|Experimental|Baricitinib|Baricitinib given orally.
89431374|NCT04088409|Active Comparator|Adalimumab|Adalimumab given subcutaneously (SC).
88910790|NCT03851627|Placebo Comparator|Testosterone like Placebo|intramuscular Testosterone undecanoate like Placebo
89431375|NCT04074109|Experimental|Teleyoga|group will receive instruction via computer tablet
89431376|NCT04074109|Active Comparator|In-person yoga|group will receive instruction in-person
88910791|NCT03848663|Experimental|Patients with scotoma|No remapping (control condition), traditional remapping, personalized remapping
88910792|NCT03848663|Active Comparator|Normally sighted with artificial scotoma|No remapping (control condition), traditional remapping, personalized remapping
88910793|NCT03847714|Active Comparator|Probiotic|Bifidobacterium bifidum W23, B. lactis W51, B. lactis W52, Lactobacillus acidophilus W22, L. casei W56, L. paracasei W20, L. plantarum W62, L. salivarius W24, Lactococcus lactis W19, 7.5 × 109 Colony Forming Units/g twice daily dissolved in water
88910794|NCT03847714|Placebo Comparator|Placebo|3g of a similar looking and tasting powder, twice daily
88910795|NCT03841747|Experimental|Pembrolizumab + Paclitaxel|200 mg Pembrolizumab IV Q3W plus 80 mg/m2 paclitaxel IV on Days 1,8, and 15 of each 28 day cycle.
88910796|NCT03841747|Active Comparator|Paclitaxel|80 mg/m2 paclitaxel IV on Days 1,8, and 15 of each 28 day cycle.
88910797|NCT03841123|Experimental|Intervention|At the maternity wards mothers will receive dietary counseling and leaflets as a reminder to prevent the early introduction of added sugar and ultra-processed foods.
88910798|NCT03841123|No Intervention|Control|At the maternity wards mothers assigned to control groups will have all the health assistance related to the maternity routine without any interference from the study protocol.
88910799|NCT03838562|Experimental|Virtual Reality Arm|
88910800|NCT03838562|Active Comparator|Control Arm|
88910801|NCT03836443|Active Comparator|NAFL patients (group 1)|"A western diet meal (high saturated fat, high refined sugar, high fructose) will be administered in each group (800 kcal/meal)."
88910802|NCT03836443|Active Comparator|NASH patients (group 2)|"A western diet meal (high saturated fat, high refined sugar, high fructose) will be administered in each group (800 kcal/meal)."
88910803|NCT03836261|Experimental|Acalabrutinib, Venetoclax|Acalabrutinib in combination with Venetoclax
88910804|NCT03836261|Experimental|Acalabrutinib, Venetoclax, Obinutuzumab|Acalabrutinib in combination with Venetoclax with Obinutuzumab
89431377|NCT04057820|Active Comparator|Usual care, Finnegan Neonatal Abstinence Scoring Tool|Usual institutional care for infants with NOWS with the Finnegan Neonatal Abstinence Scoring Tool (FNAST)
89431378|NCT04057820|Active Comparator|Eat, Sleep, Console care tool|New treatment implemented at the site for infants with NOWS using the Eat, Sleep, Console (ESC) care tool
89431379|NCT04056689|Experimental|DNL151 Low Dose|
89431380|NCT04056689|Experimental|DNL151 Mid Dose|
89431381|NCT04056689|Experimental|DNL151 High Dose|
88910805|NCT03836261|Active Comparator|Chemoimmunotherapy|"Chemoimmunotherapy~FCR: Fludarabine, Cyclophosphamide and Rituximab~BR: Bendamustine and Rituximab"
88910806|NCT03831152|Experimental|Experimental ADV7103|All patients receive ADV7103 at their individualized dose
89431382|NCT04056689|Placebo Comparator|Placebo|
89431383|NCT04045353|No Intervention|Standard of care|Subjects will receive standard counseling on obesity as part of routine postpartum care.
88910809|NCT03816228||Experimental Flortaucipir|Participants will receive a single intravenous bolus injection of flortaucipir along with PET imaging.
88910810|NCT03811535|Experimental|Somapacitan weekly|Participants will receive somapacitan weekly for 52 weeks (main trial period). Participants completing the main trial period in both the treatment arms ('Somapacitan weekly' and 'Norditropin® daily') will receive somapacitan weekly for 3 years (extension trial period).
88910811|NCT03811535|Active Comparator|Norditropin® daily|Participants will receive Norditropin® daily for 52 weeks (main trial period).
89431384|NCT04045353|Active Comparator|Low carbohydrate diet education|Subjects will receive educational materials regarding a low carbohydrate diet in addition to the standard counseling on obesity as part of routine postpartum care.
89431385|NCT04045353|Active Comparator|Low carbohydrate diet education with behavioral component|Subjects will receive in person instruction regarding a low carbohydrate diet as part of a 12 week course, in addition to receiving educational materials regarding a low carbohydrate diet and the standard counseling on obesity as part of routine postpartum care.
89431386|NCT04028700|Experimental|G6PD Deficient Red Blood Cell Transfusion, then Non-G6PD deficient Red Blood Cell Transfusion|Transfusion of a red blood cell unit that has been identified by local laboratory procedures to be deficient in G6PD enzyme activity followed after 4 months by transfusion of a red blood cell unit that has been identified by local laboratory procedures to not be deficient in G6PD enzyme activity.
88910812|NCT03811236|Experimental|Cold exposure|
88910813|NCT03811236|No Intervention|Room temperature|
88910814|NCT03810911|Active Comparator|Early start|Participants given study drug immediately at randomization
88910815|NCT03810911|No Intervention|Delayed start|Participants given study drugs 12 weeks after randomization
89431387|NCT04028700|Active Comparator|Non-G6PD deficient Red Blood Cell Transfusion, then G6PD Deficient Red Blood Cell Transfusion,|Transfusion of a red blood cell unit that has been identified by local laboratory procedures to not be deficient in G6PD enzyme activity followed after 4 months by transfusion of a red blood cell unit that has been identified by local laboratory procedures to be deficient in G6PD enzyme activity
88910816|NCT03810573|Experimental|NB1-1.5|NB1 low dose
88910817|NCT03810573|Experimental|NB1-2.0|NB1 high dose
88910818|NCT03810573|No Intervention|Autograft|Autograft
88910819|NCT03806881||Treatment group|Patients treated with a Glenius Glenoid Reconstruction System
88910820|NCT03796884|Experimental|Arm I (linaclotide)|Patients receive linaclotide PO daily on days 1-7 and undergo standard of care colonoscopy or surgery on day 7.
89431388|NCT04008901|Active Comparator|Treatment group|The randomly assigned target was given a Lonicera Flos extract (BST104) 175 mg/day for eight weeks.
88910821|NCT03796884|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD on days 1-7 and undergo standard of care colonoscopy or surgery on day 7.
88910822|NCT03791216||Psoriasis patients to be treated only topically|
88910823|NCT03791216||Psoriasis patients with moderate-to-severe psoriasis who begin|
88910824|NCT03791216||Age-, sex- and BMI percentile-matched controls|
88910825|NCT03791216||Patients being treated with isotretinoin for acne|
89431389|NCT04008901|Placebo Comparator|Placebo group|The randomly assigned target was given a placebo for eight weeks.
89431390|NCT04004988|Experimental|Tirzepatide Test|Participants received single dose of 5 milligram (mg) Tirzepatide by subcutaneous injection (SC) via an autoinjector (AI) in one of two study periods.
89431391|NCT04004988|Experimental|Tirzepatide Reference|Participants received single dose of 5mg Tirzepatide by subcutaneous injection (SC) via a prefilled syringe (PFS) in one of two study periods.
89431392|NCT03979482||PAH patients|Male and female subjects, aged between 20 and 60 years old. Absence of obesity/diabètes. PAH patients presenting with metabolic syndrome (MS).
89431393|NCT03979482||Sedentary healthy patients|Male and female subjects, aged between 20 and 60 years old. Absence of obesity/diabètes. Healthy but sedentary subjects.
89431394|NCT03971513|No Intervention|usual practice|Control group (usual practice): patients receiving a general anaesthesia with propofol, sufentanyl and cisatracurium for the induction, and sevoflurane, sufentanyl and cisatracurium for the maintenance. Patients receiving a multimodal intravenous analgesia, with acetaminophen, ketoprophen, nefopam and morphine. if necessary. Antimicrobial prophylaxis is performed according to recommendations
88910829|NCT03749044|Experimental|Patient Educational Tool|At the baseline visit, after having responded to the questionnaire, participants in the education arm will be given the patient educational tool.
88910830|NCT03749044|No Intervention|Standard of Care|Subjects in the standard of care arm will not receive the patient educational tool. If participants ask specific questions on pregnancy complications and/or preeclampsia, the clinicians will provide relevant information as they judge appropriate, but without handing out the patient educational tool.
88910831|NCT03739814|Experimental|Cohort 1 (inotuzumab ozogamicin, blinatumomab)|See Detailed Description
88910832|NCT03739814|Experimental|Cohort 2 (inotuzumab ozogamicin, blinatumomab)|See Detailed Description.
88910833|NCT03735238||Lupus Patients|All lupus patients, regardless of if they are having an active flare
88910834|NCT03733093||1|HIV Positive
88910835|NCT03732898|Experimental|New Programming Paradigm|This arm will include patients receiving stimulation with a new programming paradigm
89431395|NCT03971513|Experimental|TAP block|In addition of usual practice, patients receiving a TAP block at the beginning of the surgery
89431396|NCT03966092|No Intervention|Usual practice|Patients receiving a general anaesthesia with propofol, sufentanyl and cisatracurium for the induction, and sevoflurane, sufentanyl and cisatracurium for the maintenance. Patients receiving a multimodal intravenous analgesia, with acetaminophen, ketoprophen and morphine. Antimicrobial prophylaxis is performed according to recommendations
89431397|NCT03966092|Experimental|QLB block|"Patients receiving a general anaesthesia with propofol, sufentanyl and cisatracurium for the induction, and sevoflurane, sufentanyl and cisatracurium for the maintenance. Patients receiving a multimodal intravenous analgesia, with acetaminophen, ketoprophen and morphine. Antimicrobial prophylaxis is performed according to recommendations.~In addition, patients receiving a bilateral QLB at the end of the surgery"
89431398|NCT03961347|Active Comparator|Probiotic Group|The probiotic group will receive a daily capsule with Lactobacillus johnsonii N6.2 1x109 CFUs. Participants will consume one capsule (treatment or placebo) daily for 24 weeks.
89431399|NCT03961347|Placebo Comparator|Placebo Group|The placebo group will receive a capsule daily with dried skim milk (vehicle of the probiotic). Participants will consume one capsule (treatment or placebo) daily for 24 weeks.
89431400|NCT03958890|Experimental|HLX10|
89431401|NCT03958890|Placebo Comparator|placebo|
89431402|NCT03935568|Experimental|Single Dose Placebo|Patients randomized to receive Placebo
89431403|NCT03935568|Experimental|Single Dose Active (PU-AD)|Patients randomized to receive Active (PU-AD)
89431404|NCT03935568|Experimental|Multiple Dose (Placebo)|Patients randomized to receive Placebo
89431405|NCT03935568|Experimental|Multiple Dose Active (PU-AD)|Patients randomized to receive Active (PU-AD)
89431406|NCT03934840|Experimental|Carboplatin, Cabazitaxel and Abiraterone|
89431407|NCT03913715|Active Comparator|Ostomy Self-Management Training|Ostomy Self-management Training group in which subject will learn using pouches and equipment, skincare, ostomy complications, nutritional needs, Impact on feelings, clothing changes, social relationships, being prepared for emergencies, Intimacy and sexuality, communication skills, tips for traveling and physical activity recommendations
89431408|NCT03913715|Placebo Comparator|Usual care|Usual care in peri-operative and long-term settings is not standardized for ostomy patients. Usual care does not provide any formal, reproducible training for patients or their caregivers. It typically consists of an Ostomy Care Nurse who works with patients and caregivers concerning technical issues (fitting, emptying, supplies, surrounding skin care, etc.) while the new ostomate is still an inpatient.
89431409|NCT03898700|Other|coaching in context|10, 1 hour sessions of face to face strength based coaching sessions provided face to face or over the phone.
89431410|NCT03897036|Experimental|CX-4945 28 Day Dose Duration|CX-4945 capsules at 1000mg BID, on Days 1 through 28 of each treatment cycle
89431411|NCT03897036|Experimental|CX-4945 21 Day Dose Duration|CX-4945 capsules at 1000mg BID, on Days 1 through 21 of each treatment cycle
89431412|NCT03897036|Experimental|Expansion CX-4945 Locally Advanced BCC|CX-4945 capsules at 1000mg BID, on the dosing schedule identified during the Phase I treatment duration increment part of the study
89431413|NCT03897036|Experimental|Expansion CX-4945 Metastatic BCC|CX-4945 capsules at 1000mg BID, on the dosing schedule identified during the Phase I treatment duration increment part of the study
89431414|NCT03881046||lung cancer|
89431415|NCT03881046||healthy control group|
89431416|NCT03867006|No Intervention|control group|Patients will be randomized in the control group. They will have test MNA (Mini Nutritional Assessment), frailty screening tool (questionnaire FiND), clinical examination, blood sample, blood sample with heparin, white blood cells, urine sample, stool sample, maximal voluntary contraction of quadriceps, walking test, get up-and-go test, Hand Grip test, physical activity questionnaire, bioelectrical impedance analysis and Dual Energy X-ray Absorptiometry (DEXA).
89431417|NCT03867006|Experimental|protein group|Patients will be randomized in the protein group. They will have test MNA (Mini Nutritional Assessment), frailty screening tool (questionnaire FiND), clinical examination, blood sample, blood sample with heparin, white blood cells, urine sample, stool sample, maximal voluntary contraction of quadriceps, walking test, get up-and-go test, Hand Grip test, physical activity questionnaire, bioelectrical impedance analysis, Dual Energy X-ray Absorptiometry (DEXA) and protein.
89431418|NCT03867006|Experimental|protein and carbohydrates group|Patients will be randomized in the protein and carbohydrates group. They will have test MNA (Mini Nutritional Assessment), frailty screening tool (questionnaire FiND), clinical examination, blood sample, blood sample with heparin, white blood cells, urine sample, stool sample, maximal voluntary contraction of quadriceps, walking test, get up-and-go test, Hand Grip test, physical activity questionnaire, bioelectrical impedance analysis, Dual Energy X-ray Absorptiometry (DEXA) and protein and carbohydrates.
89431419|NCT03863457|Experimental|UPTAKE OF [18F]F-GLN BY PET/CT IN BREAST CANCER|Pilot data will be collected to evaluate image quality and collect preliminary information on the uptake of [18F]F-Gln in breast cancer. Uptake measures will be compared to tumor markers of glutamine metabolism, when tissue is available. The safety of [18F]F-Gln will also be evaluated in all subjects.
89008500|NCT04719585|Experimental|Experimental: Duloxetine group|Prior to discharge, the drug is prescribed for a total of 6 weeks by dividing the duloxetine-administered group and the opioid-administering group, respectively. The administration period of duloxetine is 6 weeks. The follow-up periods for out-patient clinic are 2 weeks, 6 weeks, 3 months, 6 months, and 1 year after the TKA surgery. During the follow-up period, NSAIDs will be prescribed the same in both groups. As an additional rescue medication, 650 mg of acetaminophen will be allowed to use up to 2g per day.
89008501|NCT04719585|Active Comparator|Active comparator: Opioid group|Prior to discharge, the drug is prescribed for a total of 6 weeks by dividing the duloxetine-administered group and the opioid-administering group, respectively. The administration period of opioid is 6 weeks. The follow-up periods for out-patient clinic are 2 weeks, 6 weeks, 3 months, 6 months, and 1 year after the TKA surgery. During the follow-up period, NSAIDs will be prescribed the same in both groups. As an additional rescue medication, 650 mg of acetaminophen will be allowed to use up to 2g per day.
89008502|NCT04592029|Experimental|TACE-Sin-Bev|TACE combined with sintilimab and bevacizumab.
89008503|NCT04591678||SMA nusinersen adult cohort|"The nusinersen treatment will be given as standard of care. The treatment (which is NOT research, but the standard care) will be given by an injection into the cerebrospinal fluid (fluid in your spine) through a needle inserted into your lower back. Participants will receive a 12 mg (5 mL) dose during each administration/injection, which will occur on the following days: 1 (baseline), 15, 29, and 60. Following the 60 day treatment, participants will receive treatment every 4 months (6, 10, 14 etc.).~After the 60 day, 6 month, 10 month, 14 month, 18 month and 22 month treatments the study team will see each participant afterwards to collect information to evaluate your general health, function and response to the treatment for the study."
89008504|NCT04591444|Active Comparator|ClinproTM White Varnish|"Application of ClinproTM White Varnish containing sodium fluoride (5%) and Tricalcium phosphate (TCP).~A technology that allows calcium and phosphate ions to coexist with fluoride ions separately, forming a more resistant mineral on the tooth surface (3M ESPE Clinpro White Varnish; 3M ESPE Clinpro 5000)."
89008505|NCT04591444|Active Comparator|ClinproTM XT Varnish|"Application of ClinproTM XT Varnish, a resin-modified glass ionomer sealant.~Creates a protective layer on exposed dentin, which is durable and has the ability to release fluoride, calcium and phosphate into the surroundings. (3M ESPE Clinpro XT Varnish)."
89008506|NCT04591444|Placebo Comparator|Placebo Group|Participants who were part of the placebo group continuously used only the conventional toothpaste provided in the oral hygiene kit during the initial four weeks of the research and received a simulated treatment.
89008507|NCT04404335||Healthy (control group)|"This group will include a total of 30 patients free of periodontitis Samples of crevicular fluid to quantity levels of antimicrobial peptide LL-37 will be taken at baseline~ELISA analysis of all samples will be performed by using a specific ELISA kit commercially available for human LL-37 and also IL-4, IL-6 and IL-10"
89008508|NCT04404335||Periodontitis (test group)|"30 Periodontal patients (subdivided in 2 groups of 15, depending of the severity of their disease):~15 patients with Stage I-II periodontitis (mild/moderate)~15 patients with Stage III-IV periodontitis (severe).~Two sets of samples of crevicular fluid will be obtained before and after receiving a course of routine basic periodontal treatment (root scaling and planing).~A reevaluation visit to re-assess clinical periodontal parameters will take place at 4-6 weeks after treatment. New samples of crevicular fluid will then be taken at this stage to compare the level of LL-37 before and after the treatment.~ELISA analysis of all samples will be performed by using a specific ELISA kit commercially available for human LL-37 (HyCult Biotechnology, Uden, the Netherlands)."
89008509|NCT04591522|Experimental|FMT group|Patients were carried by fecal microbiota transplantation which described in detail that fecal bacteria are extracted from the faeces of healthy people and poured into the intestines of patients.
89008510|NCT04591522|No Intervention|control group|
89008511|NCT03453970|Experimental|Therapeutic Education Program|"The program is based on adapted interventions and will consist of the following phases:~Phase I: Identification of self-care needs in Diabetes Mellitus through the EBADE questionnaire. This instrument will identify the needs grouped by constructs of the theory of planned behavior (behavioral beliefs, subjective norm, behaviors of perceived control and behavioral intention).~Phase II: Application of interventions adapted according to the behavioral mediator who encounters barriers. The interventions will be applied both in the face-to-face and telephone modality, using the Nursing Intervention Classification and their respective activities.~Phase III: measurement of the clinical variables and reported by the patients described in the objectives."
89008512|NCT03453970|No Intervention|Usual Care|The conventional intervention consists of the usual care that is followed in the nursing consultations in primary care to patients with type 2 DM, based on the recommendations of the Clinical Practice Guide of the National Health System
89008513|NCT04591327||general anesthesia|
89008514|NCT04591327||spinal anesthesia|
89008515|NCT04591132|Experimental|kinematic analysis|each patient with a diagnosis of parkinsonism, ataxia, chorea, dystonia or tremor will be asked to perform some motor tasks routinely used in clinical evaluation wearing inertial sensors.
89008516|NCT00253266|Experimental|Verum|Quetiapine augmentation
89008517|NCT00253266|Placebo Comparator|Placebo|"Placebo augmentation"
89008518|NCT04591288|Experimental|FES + Treadmill|Functional Electrical stimulation walking group.
89008519|NCT04591288|Active Comparator|Treadmill only|Treadmill walking group (no electrical stimulation).
89008520|NCT04591288|No Intervention|Control|"Control group.~After control period of 12 weeks, they are randomized into FES + Treadmill or Treadmill group."
89431420|NCT03861858|Experimental|DBT-A|The standard treatment to be delivered to all participants is DBT-A, which is a treatment model adapted from DBT. DBT-A is an adaptation for adolescents with emotion dysregulation and BPD features (Miller, Rathus, & Linehan, 2007; Rathus & Miller, 2015). DBT-A involves weekly individual therapy with the adolescent, weekly multifamily skills group in which adolescents and family members participate, as needed phone coaching, and weekly consultation team for the therapists.
89431421|NCT03838289||Individuals with absent filling of CVs|Individuals with absent filling of following CVs: superficial middle cerebral vein, vein of Labbe, vein of Trolard, Sphenoid sinus, thalamostriate vein, Internal cerebral vein, Rosenthal's vein
89431422|NCT03838289||individuals without any absent filling of CVs|Individuals without any absent filling of following CVs: superficial middle cerebral vein, vein of Labbe, vein of Trolard, Sphenoid sinus, thalamostriate vein, Internal cerebral vein, Rosenthal's vein
89431423|NCT03781765|Active Comparator|Methylphenidate|0.5 mg/kg for 1 week and 1 mg/kg for 2 weeks
89431424|NCT03781765|Active Comparator|Atomoxetine|0.5 mg/kg for 1 week and 1 mg/kg for 2 weeks
89431425|NCT03781752|Experimental|Methylphenidate|Youth with ADHD
89431426|NCT03765892||Adult Case Group|Adults with type 1 narcolepsy according to the ICSD3
88910836|NCT03728361|Experimental|Treatment (nivolumab, temozolomide)|Patients receive nivolumab IV on day 1 of a 28 day cycle. Patients also receive temozolomide PO on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88910837|NCT03727165|Active Comparator|Continuous infusion|Patients with continuous infusion enteral nutrition in the intensive care unit at San Ignacio University Hospital
88910838|NCT03727165|Experimental|Cyclic infusion|Patients formulated with cyclic enteral nutrition infusion, administrated at night hours, from 4pm until 7am.
88910839|NCT03720262|Experimental|Mesh reinforcement|Retro muscular mesh at the stoma site.
88910840|NCT03720262|Placebo Comparator|No reinforcement|Standard closure of the abdominal wall
88910841|NCT03712605|Experimental|Arm A (pembrolizumab, radiation therapy)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 17 cycles in the absence of disease progression or unacceptable toxicity. Patients may also undergo standard of care radiation therapy within 14 days of day 1, cycle 1. Patients undergo PET-CT, CT, or MRI throughout the trial. Patients may also undergo blood sample collection as clinically indicated at the discretion of the treating investigator.
88910842|NCT03712605|Active Comparator|Arm B (standard of care observation, radiation therapy)|Patients receive standard of care observation every 3 months for 1 year, and then every 6 months for 5 years. Patients may also undergo standard of care radiation therapy within 14 days of day 1, cycle 1. Patients undergo PET-CT, CT, or MRI throughout the trial. Patients may also undergo blood sample collection as clinically indicated at the discretion of the treating investigator.
88910843|NCT03712566||MASST|Patients with a histological or cytological confirmed diagnosis of Squamous Cell Cancer of the Head & Neck, Esophagus or Anal Canal who have radiologically confirmed recurrent or metastatic disease and are commencing on a new treatment or either first-line platinum based chemotherapy or any line immunotherapy.
88910844|NCT03708328|Experimental|Dose Escalation Part A: Once Every 2 Weeks (Q2W)|Lomvastomig will be administered in treatment cycles once every 2 weeks (Q2W). Dose escalation will be carried out according to a modified continual reassessment method (mCRM) with escalation with overdose control (EWOC) design.
88910845|NCT03708328|Experimental|Expansion Part B1: Metastatic Melanoma Cohort|This cohort will comprise participants with checkpoint inhibitor (CPI) experienced, second line and beyond metastatic melanoma. The starting dose of lomvastomig for Expansion will be derived from the maximum tolerated dose (MTD)/recommended dose for expansion (RDE) and the best dosing schedule determined during Dose Escalation.
89431427|NCT03765892||Adult Control Group|Parents, cousins and / or friends of included narcoleptic adult patients, at least 18 years old and not suffering from narcolepsy.
89431428|NCT03765892||Children Case Group|Children with type 1 narcolepsy according to the OCSD3
89431429|NCT03765892||Children Control Group|Close friends and cousins of included narcoleptic children, minor and not suffering from narcolepsy.
89431430|NCT03714958|Experimental|combination HDM201 - Trametinib|"HDM201: Therapeutic class HDM2 inhibitor, given Per Os every D1 and D8 over a 28 day cycle. Four dose-levels possible in dose escalation part: 40 mg, 80mg, 100 mg, 120mg.~Trametinib: Therapeutic class Protein kinase inhibitor of MEK1 and MEK2 activation and kinase activity. Administrated daily, countinous dosing , twodose-level possible in dose escalation: 1.5 mg and 2mg"
89431431|NCT03708315|Active Comparator|Order 1|Subjects will be given a sublingual formulation of BXCL501 (dexmedetomidine)
89431432|NCT03708315|Placebo Comparator|Order 2|Subjects will be given a sublingual film of placebo.
89431433|NCT03682575||Infants WITH diagnosis of bronchopulmonary dysplasia (BPD)|Preterm infants who were on oxygen at 28 days of life.
89431434|NCT03682575||Infants WITHOUT diagnosis of bronchopulmonary dysplasia (BPD|Preterm infants who were not on oxygen at 28 days of life.
89431435|NCT03636386|Experimental|Percutaneous microelectrolysis group (MEP)|Group exposed to direct current application using an acupuncture needle with intensities in microamps (μA) in MTrP of upper trapezius muscle. Acupuncture needle correspond to negative electrode or cathode. This group was also be treated with conventional ultrasound (US) before MEP application. US treatments parameters will include; 1MHz, 1.5W/cm2, 5cm2 ERA, 100% duty cycle and 15 minutes treatment time.
89431436|NCT03636386|Active Comparator|Ultrasound therapy|Group treated with conventional ultrasound (US) on MTrP with 1MHz, 1.5W/cm2, 5cm2 ERA, 100% duty cycle and 15 minutes treatment time.
89431437|NCT03612583|Experimental|Lower PEEP|Lung- and Diaphragm-Protective Ventilation - PEEP will be set at 8 cm H2O
89431438|NCT03612583|Experimental|Higher PEEP|Lung- and Diaphragm-Protective Ventilation - PEEP will be titrated to achieve end-expiratory PL = 2-3 cm H20 and at least 5 cm H2O greater than the level applied in the lower PEEP arm
89431439|NCT03586973|Experimental|Cohort A: Cabozantinib 60 mg|Participants who have received first/second line anticancer therapy with sorafenib were assigned to Cohort A and received cabozantinib 60 milligrams (mg), tablet, orally, once daily in the fasted state, up to approximately 2 years.
88910846|NCT03708328|Experimental|Expansion Part B2: NSCLC Cohort 1|This cohort will comprise participants with CPI and platinum experienced, second or third line PD-L1 positive non-small cell lung cancer (NSCLC). The starting dose of lomvastomig for Expansion will be derived from the MTD/RDE and the best dosing schedule determined during Dose Escalation.
88910847|NCT03708328|Experimental|Expansion Part B3: NSCLC Cohort 2|This cohort will comprise participants with PD-L1 high, cancer immunotherapy (CIT) naïve first line NSCLC. The starting dose of lomvastomig for Expansion will be derived from the MTD/RDE and the best dosing schedule determined during Dose Escalation.
89431440|NCT03586973|Experimental|Cohort B: Cabozantinib 60 mg|Participants who did not receive first/second line anticancer therapy with sorafenib were assigned to Cohort B and received cabozantinib 60 mg, tablet orally, once daily in the fasted state, up to approximately 2 years.
89431441|NCT03579966|Experimental|amifampridine phosphate|tablets equivalent to 10mg amifampridine, 3 to 4 times per day
89431442|NCT03578380|Experimental|Surgery|Lymphovenous anastomosis
89431443|NCT03578380|Active Comparator|Compression|Conservative treatment with physiotherapy and compression
89431444|NCT03533985|Experimental|Song of Kin|Voice (with or without guitar)- lullaby/ Holding meter
89431445|NCT03533985|Experimental|Gato box|Simple rhythms using Remo Gato box will be played by the MT-BC using a 3rd to comfort, engage or sedate
89431446|NCT03533985|Experimental|Ocean disc|Creating a consistent womb-like sound soundscape to comfort, engage or sedate
89431447|NCT03533985|Experimental|Contingent singing|"Provision of communicative vocalization-parantese to engage with infants, prosodic responses to infant cues (eye contact, body position)"
89431448|NCT03533985|Experimental|Tonal Vocal holding|Providing a 'blanket of tone' to comfort, engage or sedate
89431449|NCT03533985|Experimental|Muted shaker|If infant is awake, the muted shaker will be used to entrain to the infant's vital signs-to comfort, soothe or sedate
89431450|NCT03533764|Experimental|Asthma Self-Management for Adolescents|Asthma Self-Management for Adolescents (ASMA) consists of three complementary components: (1) an 8- week intervention for students; (2) caregiver education; and (3) education for students' medical providers.
89431451|NCT03533764|No Intervention|Attention Control|In 3 group sessions and 5 one-on-one sessions, held at school during the school day, students will receive information about asthma and other health topics relevant to adolescents (e.g., nutrition, safety). They will learn to monitor their health by using diaries to record behaviors, such as what they eat, and/or their sleep patterns. Students will be referred to their medical providers for asthma and other health concerns; if they do not have a provider, they are given referrals in their community.
89431452|NCT03520374|Other|Healthy adult volunteers|Novice ultrasonographers will be taught to assess gastric contents with a short and simple educational program. Each novice will assess the gastric contents of 3 healthy adult volunteers using the clinical algorithm for gastric ultrasound and aspiration risk assessment - giving an antral grade for each subject (a score of 0-2). Each novice ultrasound assessment will be video recorded. In the weeks following this evaluation, expert ultrasonographers will observe each video and give their own scores for each subject using the antral grading system.
89431453|NCT03520374|Other|Pediatric patients|Novice ultrasonographers will be taught to assess gastric contents with a short and simple educational program. Each novice will assess the gastric contents of 3 pediatric patients undergoing surgery in the preoperative area or the in-patient unit using the clinical algorithm for gastric ultrasound and aspiration risk assessment - giving an antral grade for each subject (a score of 0-2). Each novice ultrasound assessment will be video recorded. In the weeks following this evaluation, expert ultrasonographers will observe each video and give their own scores for each subject using the antral grading system.
89431454|NCT03508869|Active Comparator|Mirvaso® (brimonidine) topical gel, 0.33%|Mirvaso® (brimonidine) topical gel, 0.33% is an alpha adrenergic agonist indicated for the topical treatment of persistent facial erythema of rosacea in adults 18 years of age or older.
89431455|NCT03508869|Active Comparator|Dysport®|Dysport® is an acetylcholine release inhibitor and a neuromuscular blocking agent.
88910848|NCT03708328|Experimental|Expansion Part B4: SCLC Cohort|This cohort will comprise participants with CPI naïve small cell lung cancer (SCLC) with prior failure of, progression on, or intolerance to, standard therapy. The starting dose of lomvastomig for Expansion will be derived from the MTD/RDE and the best dosing schedule determined during Dose Escalation.
88910849|NCT03708328|Experimental|Expansion Part B5: ESCC Cohort|This cohort will comprise participants with CPI-naïve esophageal squamous cell carcinoma (ESCC). The starting dose of lomvastomig for Expansion will be derived from the MTD/RDE and the best dosing schedule determined during Dose Escalation.
88910851|NCT03691376|Experimental|Treatment (autologous NY-ESO-1 engineered T and HSC)|Patients receive melphalan IV over 30 minutes on day -1. Patients then receive autologous NY-ESO-1 CD4-TCR CD34+ HSC IV on day 0 and autologous NY-ESO-1-specific CD8-positive T lymphocytes IV between days 7 and 21. Patients also receive aldesleukin SC BID for 14 days on the following day after the T cell infusion (between days 8 and 22).
89431456|NCT03508869|Active Comparator|Dysport® in conjunction with Mirvaso|Dysport® in conjunction with Mirvaso
89431457|NCT03507699|Experimental|Immunotherapy alone|Nivolumab will be administered at a dose of 3mg/kg every 2 weeks. Ipilimumab will be administered at a dose of 1mg/kg every 6 weeks. CMP-001 will be administered both into the liver metastasis (once), and also injected subcutaneously (four times, over six weeks) at a dose of 5-10 mg.
89431458|NCT03507699|Experimental|Combined radiotherapy and immunotherapy|"Liver radiation therapy: three treatments to one liver metastasis, administered on alternate days.~Nivolumab will be administered at a dose of 3mg/kg every 2 weeks. Ipilimumab will be administered at a dose of 1mg/kg every 6 weeks. CMP-001 will be administered both into the liver metastasis (once), and also injected subcutaneously (four times, over six weeks) at a dose of 5-10 mg."
89431459|NCT03507647|Experimental|Mindfulness Based Cognitive Therapy added to usual care|Patients in the MBCT arm will be invited to participate in MBCT added to their usual care.
88910852|NCT03690115|Experimental|Experimental|Administration of ponatinib after allo-SCT transplant in FLT3-ITD AML patient
88910853|NCT03678883|Experimental|9-ING-41|Drug: 9-ING-41
88910854|NCT03678883|Experimental|9-ING-41 plus Gemcitabine|Drugs: Gemcitabine - 21 day cycle. 9-ING-41
88910855|NCT03678883|Experimental|9-ING-41 plus Doxorubicin|Drugs: Doxorubicin. 9-ING-41
88910856|NCT03678883|Experimental|9-ING-41 plus Lomustine|Drugs: Lomustine. 9-ING-41.
88910857|NCT03678883|Experimental|9-ING-41 plus Carboplatin|Drugs: Carboplatin. 9-ING-41.
88910858|NCT03678883|Experimental|9-ING-41 plus nab paclitaxel Gemcitabine|Drugs: Nab-paclitaxel. Gemcitabine - 28 day cycle. 9-ING-41.
88910859|NCT03678883|Experimental|9-ING-41 plus Paclitaxel/Carboplatin|Drugs: Paclitaxel. Carboplatin. 9-ING-41.
88910860|NCT03678883|Experimental|9-ING-41 plus Irinotecan|Drugs: Irinotecan. 9-ING-41.
89431460|NCT03507647|Active Comparator|Usual Care|Usual care will typically consist of pharmacotherapy, psycho-education and self-management interventions (usually with a psychiatric nurse).
89431461|NCT03497923|Active Comparator|Neostigmine|Patients are anesthesized with Propofol and receive 0.6mg-1 of rocuronium for tracheal intubation. Neuromuscular monitoring will be done on the ulnar nerve by train-of-four (TOF) using a TOF-Watch-SX® acceleromyograph (Organon [Ireland] Ltd). After spontaneous recovery of 2 twitches at the train-of-four monitor (TOF), patients receive neostigmine 50 μg kg-1.
89431462|NCT03497923|Experimental|Sugammadex|Patients are anesthesized with Propofol and receive 0.6mg-1 of rocuronium for tracheal intubation. Neuromuscular monitoring will be done on the ulnar nerve by train-of-four (TOF) using a TOF-Watch-SX® acceleromyograph (Organon [Ireland] Ltd). After spontaneous recovery of 2 twitches at the train-of-four monitor (TOF), patients receive sugammadex (Bridion®) 2 mg kg-1.
89431463|NCT03494478|Experimental|Cohort group|All participants will have evaluations at inclusion and 12 months. Neuropsychological testing Actimetry Selfquestionnaires on emotional topics
89431464|NCT03457935||Non-IPF ILD|non-IPF ILD diagnosis
89431465|NCT03457935||IPF|Naive patients with no IPF treatment
89431466|NCT03457935||Control|no lung diseases
89431467|NCT03429205|Experimental|No heating - Study group|Patient will undergo bariatric surgery without utilization of external heating device.
89431468|NCT03429205|Other|Heating - Control group|Patient will undergo bariatric surgery with utilization of external heating device.
89431469|NCT03377387|Experimental|capecitabine 7/7 with neratinib|"In the phase I portion of the study, a 3+3 design will be used. Once the MTD is reached, the phase II portion will enroll up to 24 patients. Capecitabine will be taken orally in AM and PM (at the assigned dose per cohort) 7 days on and 7 days off. Neratinib is given as 240 mg daily continuously without stopping. A cycle is 28 days. Patients will be seen on Day 1 of each cycle (+/- 3 days).~The MD has been determined as 240mg of neratinib and 1000mg BID of capecitabine."
89431470|NCT03372837|Experimental|SyB L-0501|"The administration of SyB L-0501 at 120 mg/m^2/day by intravenous infusion on Day 2 and Day 3 of each 21-day cycle with up to 6 cycles. Dose modifications are permitted from 2nd cycle according to dose reduction schedule.~SyB L-0501 60 mg/m^2, 90 mg/m^2 or 120 mg/m^2/day on Day 2 and Day 3 will be followed by 18 days of observation."
89431471|NCT03371420|Experimental|124I-PU-AD|A single dose of 124I-PU-AD will be administered by intravenous (IV) injection
89431472|NCT03349502|Experimental|MG4101|"MG4101 administration (Not yet commercialized)~Dosage Bwt<50 : 2.0 x109 cells (2 bags) 50≤Bwt<70 : 3.0 x109 cells (3 bags) 70≤Bwt<100 : 4.0 x109 cells (4 bags) Bwt≥100 : 5.0 x109 cells (5 bags)~Duration and frequency~Intravenous over 1 hour~Day 4, Day 11, Day 18 of each cycle"
88910861|NCT03677830|Active Comparator|Intravenous Acetaminophen|Infants randomized to the intervention arm will receive scheduled IV acetaminophen per LexiComp dosing guideline (28 0/7-32 6/7 weeks 10 mg/kg/dose every 12 hours; 33 0/7-38 6/7 weeks 10 mg/kg/dose every 8 hours; >39 0/7 weeks 10 mg/kg/dose every 6 hours). N-PASS scores will guide administration of IV morphine. Continuous infusion of morphine will be started if an infant requires 3 doses of morphine within a 6-hour period and titrated as needed per N-PASS scores.
89431473|NCT03324191|Placebo Comparator|Placebo|"Participants will consume 567 ml of plain water at least 1 hour before testing the trial.~Information on dietary compliance will be collected. Participants will then be cannulated in an arm vein and a baseline fasting blood sample will be taken. Participants will be asked to consume a standard study meal challenge (providing 40 g dietary fat and less than 2 g carbohydrate or 1.2 g protein) and placebo drink within 15 min. Serial blood samples will be collected at baseline, 30, 60, 90, 120 and 180 min. The intervention will end once the 180 min sample is collected.~For the tracer test subpopulation (n=15) the test meal will also contain 300 mg [1,1,1-13C3] tripalmitin to trace the incorporation of dietary lipid into plasma fatty acids."
89431474|NCT03324191|Experimental|Tea beverage|"Participants will consume 567 ml of plain water at least 1 hour before testing the trial.~Information on dietary compliance will be collected. Participants will then be cannulated in an arm vein and a baseline fasting blood sample will be taken. Participants will be asked to consume a standard study meal challenge (providing 40 g dietary fat and less than 2 g carbohydrate or 1.2 g protein) and tea within 15 min. Serial blood samples will be collected at baseline, 30, 60, 90, 120 and 180 min. The intervention will end once the 180 min sample is collected.~For the tracer test subpopulation (n=15) the test meal will also contain 300 mg [1,1,1-13C3] tripalmitin to trace the incorporation of dietary lipid into plasma fatty acids."
88922258|NCT05587309|Active Comparator|Maintenance Phase - PPI Control|During the Maintenance Phase, patients will take a PPI control once daily, orally, for 24 weeks.
88922259|NCT05585749|Experimental|Virtual Reality Based Relaxation Program|Virtual Reality Based Relaxation Program
88922260|NCT05585749|No Intervention|Control group|Routine maintenance will be applied.
88922261|NCT05582304|Experimental|TEST/CONTROL/Photopic CSF|Eligible subjects who are habitual wearers of silicone hydrogel contact lenses will be randomized to the photopic condition and randomized contralaterally to the TEST/CONTROL lenses.
89431475|NCT03324191|Experimental|Tea extract (medium concentration)|"Participants will consume 567 ml of plain water at least 1 hour before testing the trial.~Information on dietary compliance will be collected. Participants will then be cannulated in an arm vein and a baseline fasting blood sample will be taken. Participants will be asked to consume a standard study meal challenge (providing 40 g dietary fat and less than 2 g carbohydrate or 1.2 g protein) and concentrated tea extract at a medium concentration within 15 min. Serial blood samples will be collected at baseline, 30, 60, 90, 120 and 180 min. The intervention will end once the 180 min sample is collected.~For the tracer test subpopulation (n=15) the test meal will also contain 300 mg [1,1,1-13C3] tripalmitin to trace the incorporation of dietary lipid into plasma fatty acids."
89431476|NCT03324191|Experimental|Tea extract (high concentration)|"Participants will consume 567 ml of plain water at least 1 hour before testing the trial.~Information on dietary compliance will be collected. Participants will then be cannulated in an arm vein and a baseline fasting blood sample will be taken. Participants will be asked to consume a standard study meal challenge (providing 40 g dietary fat and less than 2 g carbohydrate or 1.2 g protein) and concentrated tea extract at a high concentration within 15 min. Serial blood samples will be collected at baseline, 30, 60, 90, 120 and 180 min. The intervention will end once the 180 min sample is collected.~For the tracer test subpopulation (n=15) the test meal will also contain 300 mg [1,1,1-13C3] tripalmitin to trace the incorporation of dietary lipid into plasma fatty acids."
89431477|NCT03314974|Experimental|TBI Regimen|
89431478|NCT03314974|Experimental|Non-TBI Regimen|
88910862|NCT03677830|Placebo Comparator|Intravenous Placebo|Infants randomized to the control arm will receive normal saline placebo IV at the appropriate volume and times for the gestational age. IV acetaminophen is concentrated at 10 mg/ml; corresponding saline volumes will be 1 ml to 5 ml, approximately, based on subject weight. Control infants will also have N-PASS scores assessed using the same protocol following the surgical procedure for 72 hours. Dosing of IV morphine will be the same as the dosing for the intervention arm.
88910863|NCT03672279||Mild neurocognitive disorder|
88910864|NCT03672279||Major neurocognitive disorder|
89431479|NCT03261284|Experimental|DIAMOND group|D-dimer and anti-Xa are mornitored. If D-dimer levels continue to rise (>1.5 times previous result ), increase the dose of heparin to reach the upper limit of the treatment target; If the D-dimer levels is stable (<1.5 times previous result ) or is decreasing, the anticoagulation dose is maintained at current level (no active bleeding) or decreased (active bleeding).
89431480|NCT03261284|Active Comparator|Control group|Heparin dose adjusted according to anti-Xa activity or activated partial thromboplastin time (aPTT). The target range is aPTT 1.5 to 2.5 times the upper limit of normal or therapeutic anti-Xa levels (0.3 U/ml to 0.7 U/ml) for unfractionated heparin.
89431481|NCT03221244|Experimental|VR Treatment|"The VR distractor condition is an adaptive training, experimental treatment. Participants will wear a headset VR system programmed to simulate a virtual classroom. They will be asked to perform computer tests of math, attention, or working memory in the virtual reality context. Distractors will be presented intermittently throughout the test session. During training sessions, distractor saliency and frequency will increase or decrease based on performance on the tests.~25 sessions should be completed in approximately 5-7 weeks. In-home VR training sessions will each be about 20-30 minutes in length.~The investigators expect a decrease in distraction after adaptive distractor exposure in the VR classroom."
88910865|NCT03670368|Experimental|Intervention (Mentor/Mentee)|Youth in the intervention group will participate in one-on-one mentoring sessions (between mentors and mentees) once per week after school. Mentoring sessions will focus on social relationships, coping behaviors, and healthy lifestyles.
88910866|NCT03670368|Active Comparator|Comparison group - written materials|Youth in the comparator group will receive written versions of all materials covered in the mentoring sessions.
88910867|NCT03664765|Active Comparator|Intervention exercise arm|daily oropharyngeal and respiratory muscle exercises
88910868|NCT03664765|Sham Comparator|Control arm|Daily sham exercises
88910869|NCT03664609||Parkinson's Disease|Subjects with Parkinson's disease, implanted with a Boston Scientific Deep Brain Stimulation System
88910870|NCT03664609||Essential Tremor|Subjects with Essential Tremor, implanted with a Boston Scientific Deep Brain Stimulation System
88910871|NCT03664609||Dystonia|Subjects with dystonia, implanted with a Boston Scientific Deep Brain Stimulation System
88910872|NCT03663881|Experimental|P2Et extract|P2Et extract daily doses. Dosage scaling will be performed according to the 3 + 3 standard design.
89008521|NCT04591600|Experimental|Ivermectin-Doxycycline|Ivermectin 200ug/kg PO per day for two days, and in some patients who needed more time to recover, a third dose 200ug/kg PO per day was given 7 days after the first dose. Doxycycline 100mg capsule PO every 12h per day was given for 5-10 days, based on the clinical improvement of patients. In addition, standard of care was given to the patients of Ivermectin-Doxycycline group based on the clinical condition of each patient.
89008522|NCT04591600|Active Comparator|Control|Control group: The patients in this group received only standard care which included all or some of the following, according to the clinical condition of each patient.
89008523|NCT04590742|Placebo Comparator|Group 1|Placebo Tablet
89008524|NCT04590742|Active Comparator|Group 2|Melatonin (6mg)
89008525|NCT04590859||Penile block|Patients undergoing procedure with penile block
89008526|NCT04590859||caudal block|Patients undergoing procedure with caudal block
89008527|NCT00567346|Active Comparator|grass pollen extract twice weekly|Current standard dose regimen of grass pollen immunotherapy (9,500 BU), given twice weekly. Note: patients in twice weekly dosing regimen will also receive placebo on days no active treatment is given.
89008528|NCT00567346|Active Comparator|Grass pollen extract, daily|Grass pollen immunotherapy, 9,500 BU, given daily
89008529|NCT00567346|Active Comparator|Increased dose of grass pollen extract|Increased dose of grass pollen immunotherapy, 19,000 BU, given daily
89008530|NCT00567346|Placebo Comparator|Placebo control|Patients randomized to placebo will receive placebo daily.
89008531|NCT00253383|Experimental|ENABLE (concurrent palliative care)|telephone based ENABLE educational intervention
89008532|NCT00253383|Active Comparator|Usual Care|Supportive and palliative usual care services at DHMC, Behavioral
89008533|NCT00567463|Placebo Comparator|Placebo|Placebo inhalator will be used by subjects in the placebo group(same course as patients in the treated group)
89008534|NCT04590625|Experimental|Group1|"Neoadjuvant therapy:~Apatinib:apatinib one course will last 21 days.Oral administration at a dose of 250 mg, qd; Abraxane:abraxane one course will last 21 days.Intravenously guttae at a dose of 260 mg/m2,d1; Cis-platinum or Carboplatin:cis-platinum or carboplatin one course will last 21 days.cis-platinum introperitoneal injection at a dose of 75-100 mg/m2,d1;carboplatin intravenous injection at a dose of AUC=5-6,d1.~Neoadjuvant therapy is 3-4 cycles.After Neoadjuvant therapy will received interval cytoreductive surgery.~Adjuvant therapy:~After interval cytoreductive surgery,patients will received adjuvant therapy same as neoadjuvant therapy.~Adjuvant therapy is 3 cycles~maintenance treatment: After above treatment finished,patients will received aptinib for 2 years."
89008535|NCT04590625|Experimental|Group2|"1.Adjuvant therapy:~After primary cytoreductive surgery,patients will received adjuvant therapy:~Apatinib:apatinib one course will last 21 days.Oral administration at a dose of 250 mg, qd; Abraxane:abraxane one course will last 21 days.Intravenously guttae at a dose of 260 mg/m2,d1; Cis-platinum or Carboplatin:cis-platinum or carboplatin one course will last 21 days.cis-platinum introperitoneal injection at a dose of 75-100 mg/m2,d1;carboplatin intravenous injection at a dose of AUC=5-6,d1.~Adjuvant therapy is 3 cycles 3.maintenance treatment: After above treatment finished,patients will received aptinib for 2 years."
89008536|NCT04590469|Experimental|WHELD training/virtual coaching programme supported with digital resources|WHELD training/virtual coaching programme supported with digital resources
89008537|NCT04590469|No Intervention|Treatment as Usual|Usual Best practice
89008538|NCT04590352||Index case and household contacts|"nasophryngeal and throat swab at day 0.~collection of mucosal lining fluid: day 0, 7, 14, 28 for index case and day 0, 3, 6, 28 for household contacts.~fingerprick at day 28 (optional).~daily record of symptoms from day 0-28."
89008539|NCT04590391|Other|Visual and Auditory Breathing-swallowing Coordinated Training device|
89008540|NCT04590157|Experimental|study group|received pelvic floor muscle training in addition to laser acupuncture on neurogenic acupoints
89431482|NCT03221244|Active Comparator|VR Active Control|"The VR classroom with no distractors presented is an active control group. This group will undergo the same training regimen, only their virtual classroom environment will not contain adaptive distractors. Participants will wear a headset VR system programmed to simulate a virtual classroom. They will be asked to perform computer tests of math, attention, or working memory in the virtual reality context.~25 sessions should be completed in approximately 5-7 weeks. In-home VR training sessions will each be about 20-30 minutes in length.~The investigators expect no change in response to distraction in the ADHD group after control exposure to the VR classroom."
89008541|NCT04590157|Experimental|control group|received pelvic floor muscle training
89431483|NCT03219450|Experimental|NeoVax|"NeoVax will be administered in a priming and booster phase.~The priming shots will comprise days 1, 4, 8, 15, and 22.~Booster shots will be given on days 78 and 134."
89431484|NCT03219450|Experimental|Neovax + Low-dose cyclophosphamide|"NeoVax will be administered in a priming and booster phase.~The priming shots will comprise days 1, 4, 8, 15, and 22.~Booster shots will be given on days 78 and 134.~Low dose cyclophosphamide is administered twice daily on weeks -2, 1, 3, 5"
89431485|NCT03219450|Experimental|Neovax + Low-dose cyclophosphamide + Pembrolizumab|"NeoVax will be administered in a priming and booster phase.~The priming shots will comprise days 1, 4, 8, 15, and 22.~Booster shots will be given on days 78 and 134.~Low dose cyclophosphamide is administered twice daily on weeks -2, 1, 3, 5~Pembrolizumab will be administered starting on Week 12 Day 78 and for up to 17 cycles (approximately 1 year)."
89431486|NCT03199196|Experimental|Group 1 - Intervention|"Participants given an activity tracker at the given an accelerometer at each visit. Participants instructed in use of a smartphone application at the baseline visit.~Participant emailed electronic newsletters to read that may help participant be more physically active.~Research staff provides telephone counseling to participant and partner biweekly during weeks 1-8 (weeks 1, 3, 5, and 7), and monthly during weeks 9-16 (weeks 11 and 15).~Study visits performed 2 times (1 time at the beginning of the study, and 1 time 16 weeks after beginning the study).~Participants complete questionnaires 1 time at the beginning of the study, 8 weeks after joining the study, and 16 weeks after beginning the study.~Participants invited to take part in a final focus group sometime after the 16-week visit."
89008542|NCT00567658|Placebo Comparator|A 1|Arm I: placebo group receives BID placebo
89008543|NCT00567658|Experimental|A2|subjects receive active drug, esomeprazole 40 mg BID
89008544|NCT04589806|Experimental|2-stage ridge splitting with simultaneous implant placement|
89008545|NCT00567697|Active Comparator|A|0.5 ml 10mg/ml (0.5 mg) ranibizumab for intravitreal injection
89008546|NCT00567697|Sham Comparator|B|
89008547|NCT04589416|Active Comparator|Single Bond 2|Single Bond 2 is a traditional etch and rinse adhesive system. It is used to bond the composite resin to the dental tissues. It was applied to the cavities opened in accordance with the manufacturer's instructions.
89008548|NCT04589416|Active Comparator|Clearfil SE Bond|Clearfil SE bond is traditional two step self-etch adhesive system. It is used to bond the composite resin to the dental tissues. It was applied to the cavities opened in accordance with the manufacturer's instructions.
89008549|NCT04589416|Active Comparator|Tri-S Bond|Tri-S bond is traditional one step self-etch adhesive system. It is used to bond the composite resin to the dental tissues. It was applied to the cavities opened in accordance with the manufacturer's instructions.
89008550|NCT04589455|Experimental|hennep extract|A hennep extract administered in soft gel capsules in a fasted state
89008551|NCT04589455|Experimental|hennep extract + high fat meal|A hennep extract administered in soft gel capsules in a fed state
89008552|NCT04589494|Active Comparator|tramadol group|tramadol hydrochloride 100 mg three times daily
89008553|NCT04589494|Active Comparator|morphine group|morphine 30 mg twise times daily
89008554|NCT04589299|Active Comparator|Patients treated with immunoglobulin intravenously (IVIG)|Immunoglobulin (PRIVIGEN) intravenously 2 g/kg/4week for 26 weeks. After this 60 weeks of reduction every 12 weeks (90%, 75%, 50%, 25% and 0%).
89008555|NCT04589299|Active Comparator|Patients treated with immunoglobulin subcutaneously (SCIG)|Immunoglobulin (HIZENTRA) subcutaneously 0.54 g/kg/week for 26 weeks. After this 60 weeks of reduction every 12 weeks (90%, 75%, 50%, 25% and 0%).
89008556|NCT00253500|Experimental|Epirubicin|
89008557|NCT04589026|Active Comparator|Active Arm: Candin + Consentyx|Participants will receive a single dose of Candin injection intradermally along with a saline solution of 0.9% sodium chloride (NaCl), and a single dose of Cosentyx injection subcutaneously.
89008558|NCT04589026|No Intervention|Control Arm: Candin|All participants will receive a single dose of Candin injection intradermally along with a saline solution of 0.9% NaCl, and no Cosentyx.
89008559|NCT04589182|Experimental|Verum|Patients will receive all-night auditory stimulation during sleep over 3 nights using a portable, safe, in-home device (MSHL-SleepBand). This device records biosignals (EEG) and precisely plays tones (between 45-65 dB, maximum 80 dB) targetted to the up-phase of sleep slow waves.
89008560|NCT04589182|Sham Comparator|Sham|Patients will receive all-night sham stimulation over 3 nights, i.e. the wearable stimulation device will be applied (EEG will be recorded), but no tones will be played.
89008561|NCT04588987|Experimental|Neoadjuvant group|Patients need to treat with PD-1 and apatinib before surgery. Sequential therapy with PD-1 and apatinib when patients accepted surgery.
89008562|NCT04588987|Experimental|Adjuvant group|Before surgery, patients no need to treat with PD-1 and apatinib. Sequential therapy with PD-1 and apatinib when patients accepted surgery.
89008563|NCT04589104|Experimental|Expressive writing|"The expressive writing intervention consists of a 6-week, virtually-delivered writing program. Each week, participants meet for 90 minutes via Zoom and will be guided through writing prompts designed to encourage emotional expression and enhance personal resilience. The progression of writing exercises flows as follows:~Week 1: Writing to expressive difficult emotions~Week 2: Writing to release & integrate difficult emotions~Week 3: Writing to nurture gratitude~Week 4: Writing to enhance strengths & resources~Week 5: Writing to cultivate positive meaning & savor goodness~Week 6: Writing to invite insight, perspective, & growth"
89008564|NCT04588558|Experimental|Flywheel exercise|The term isoinertial is derived from the words iso (same) and inertial (resistance), which define the primary concept of the isoinertial system in a terminology or that expresses both the concentric and eccentric phases of the same muscle contraction. Isoinertial refers to resistance used in exercise training, maintaining a constant inertia throughout the range of motion, a constant resistance in all respects, and facilitating maximum muscle strength. All participants received home exercise for 8 weeks.
89008565|NCT04588558|Active Comparator|Electrotherapy modality|"Electrotherapy modalities especially transcutaneous electrical nerve stimulation (TENS) and ultrasound is used to treat OA.~All participants received home exercise for 8 weeks."
89008566|NCT04588558|Active Comparator|Home exercise|All participants received home exercise three times a week for 8 weeks. Home exercises are structured with squats. The exercise program includes stretching exercises and strengthening (isometric and isotonic) exercises.
89008567|NCT04588831|Experimental|Pre-fabricated|
89008568|NCT04588831|Experimental|Mouth-formed|
89431487|NCT03199196|Other|Group 2 - Control|"Participants sent electronic newsletters throughout the study that may help participant be more physically active.~Study visits performed 2 times (1 time at the beginning of the study, and 1 time 16 weeks after beginning the study).~Participants complete questionnaires 1 time at the beginning of the study, 8 weeks after joining the study, and 16 weeks after beginning the study.~Participants invited to take part in a final focus group sometime after the 16-week visit."
89431488|NCT03172689|Other|CardioQ|CardioQ will be used as CO monitor simultaneously with the standard of care PiCCO CO monitor
89431489|NCT03127267|Experimental|Masitinib (4.5) & Riluzole|Participants receive masitinib (3.0 mg/kg/day), given orally twice daily, with a dose escalation to 4.5 mg/kg/day after 4 weeks of treatment. Each ascending dose titration is subjected to a safety control. Masitinib will be administered as an add-on to riluzole at 50 mg b.i.d
89431490|NCT03127267|Experimental|Masitinib (6.0) & Riluzole|Participants receive masitinib (3.0 mg/kg/day), given orally twice daily, with a dose escalation to 4.5 mg/kg/day after 4 weeks of treatment, followed by dose escalation to 6.0 mg/kg/day after 4 weeks of treatment. Each ascending dose titration is subjected to a safety control. Masitinib will be administered as an add-on to riluzole at 50 mg b.i.d.
89431491|NCT03127267|Placebo Comparator|Placebo & Riluzole|Participants receive a matched dose placebo, given orally twice daily, in combination with riluzole at 50 mg b.i.d.
89008569|NCT04588831|Experimental|Custom-fitted|
89431492|NCT03123198|Experimental|Dialectical Behavior Therapy|All participants receive six months of standard DBT which includes individual therapy, skills training, and as-needed phone consultation.
89431493|NCT03092466|Active Comparator|femoral group|Group 1: placement of a femoral nerve catheter plus femoral block with 15 ml of a Ropivacaine 0,75% solution through the femoral catheter
89431494|NCT03092466|Placebo Comparator|control group|Group 2: placement of a femoral nerve catheter plus the administration of an equivalent volume (15 ml) of a saline solution through the femoral catheter
89431495|NCT03089463||Observation group|The entire participants in this study will be included in this group.
89431496|NCT03038568||Cohort 1|-15 second time gap between routine abdominal CT and add on CT, Noise Index of 12
89431497|NCT03038568||Cohort 2|-15 second time gap between routine abdominal CT and add on CT, Noise Index of 14
89431498|NCT03038568||Cohort 3|-15 second time gap between routine abdominal CT and add on CT, Noise Index of 16
89431499|NCT03038568||Cohort 4|-10 second time gap between routine abdominal CT and add on CT, Noise index 12
89431500|NCT03038568||Cohort 5|-10 second time gap between routine abdominal CT and add on CT, Noise index 14
89431501|NCT03038568||Cohort 6|-10 second time gap between routine abdominal CT and add on CT, Noise index 16
89431502|NCT03038568||Cohort 7|- 5 second time gap between routine abdominal CT and add on CT, Noise index 12
89431503|NCT03038568||Cohort 8|- 5 second time gap between routine abdominal CT and add on CT, Noise index 14
89431504|NCT03038568||Cohort 9|- 5 second time gap between routine abdominal CT and add on CT, Noise index 16
89431505|NCT03038568||Cohort 10|+ 5 second time gap between routine abdominal CT and add on CT, Noise index 12
89431506|NCT03038568||Cohort 11|+ 5 second time gap between routine abdominal CT and add on CT, Noise index 14
89431507|NCT03038568||Cohort 12|+ 5 second time gap between routine abdominal CT and add on CT, Noise index 16
89431508|NCT03038568||Cohort 13|+ 10 second time gap between routine abdominal CT and add on CT, Noise index 12
89431509|NCT03038568||Cohort 14|+ 10 second time gap between routine abdominal CT and add on CT, Noise index 14
89431510|NCT03038568||Cohort 15|+ 10 second time gap between routine abdominal CT and add on CT, Noise index 16
88910873|NCT03660930|Experimental|Treatment (ABI-009, pazopanib)|Participants receive nab-sirolimus intravenously (IV) on days 1 and 8 or day 1 only and pazopanib hydrochloride orally (PO) daily on days 1-21. Cycles repeat every 21 days until unequivocal clinical disease progression, unacceptable toxicity, or until in the opinion of the investigator the patient is no longer benefiting from therapy, or at the patient's discretion.
88910874|NCT03649880|Experimental|Diagnostic (FMISO, PET/MRI or PET/CT)|Participants receive FMISO intravenously (IV). Participants also undergo dynamic PET/computed tomography (CT) or PET/MRI over 120 minutes beginning 1 minute prior to FMISO injection, and static PET/CT or PET/MRI over 20-40 minutes approximately 90 minutes after FMISO injection. Participants then undergo a retest examination within 7 days. Participants may undergo 2 more PET/MRI or PET/CT scans no sooner than every 4 weeks. Supplemental oxygen may be administered to effect MRI signal.
88910875|NCT03646877|Experimental|Ozone (O3)|The O3 level during the exposures will be 200 ppb, which has previously been used in human exposure studies without short or long term, untoward side effects (and comparable to peak levels attained during the summer in the Raleigh-Durham area of North Carolina) (REF - Bromberg review).
88910876|NCT03646877|Placebo Comparator|Filtered Air (FA)|Control will be treadmill walk with filtered room air in chamber.
88910877|NCT03640793|Experimental|Single center, prospective, non-randomized, non-blinded study|Implantation of 6 PPIS implants in each patient
89431511|NCT03038568||Cohort 16|+ 15 second time gap between routine abdominal CT and add on CT, Noise 12
88910879|NCT03629977||early RRT|A patient where initiation of RRT is started without the absolute indications
88910880|NCT03629977||late RRT|"CRRT based on absolute indications.~Absolute indications:~hyperkalemia (serum potassium≥6 mEq/L),~severe acidosis (pH≤7.15),~plasma urea>36 mmol/L (equals BUN=100.8 mg/dl),~oliguria or anuria (urine output<0.3 ml/kg per hour for ≥24 hours or anuria for ≥12 hours), and~fluid overload with pulmonary edema as defined by the presence of all the following factors: (a) >10% fluid accumulation (cumulative fluid balance/baseline weight>10%), (b) oliguria (urine output<0.5 ml/kg per hour for ≥12 hours), and (c) severely impaired oxygenation (PaO2/FiO2<200 indicated by respiratory Sequential Organ Failure Assessment [SOFA] score≥3)"
89431512|NCT03038568||Cohort 17|+ 15 second time gap between routine abdominal CT and add on CT, Noise 14
89431513|NCT03038568||Cohort 18|+ 15 second time gap between routine abdominal CT and add on CT, Noise 16
89431514|NCT03017872|Active Comparator|Standard of Care (SoC) arm|2 x NRTIs + darunavir/ritonavir 800mg/100mg po od
89431515|NCT03017872|Experimental|Dolutegravir arm|Dolutegravir 50mg + darunavir/ritonavir 800mg/100mg po od
89431516|NCT03017872|Experimental|Dolutegravir 2NRTI arm (D2N)|Dolutegravir 50mg + 2 x NRTIs (tenofovir plus emtricitabine or lamivudine)
89431517|NCT03000205|Experimental|hypertonic dextrose water|20% hypertonic dextrose water injection for chronic shoulder spin
89431518|NCT03000205|Placebo Comparator|Normal Saline|normal saline and Lidocaine as placebo for sham group
89431519|NCT02982876|No Intervention|Medical Management Group|The patients assigned to the medical management group will be placed on a scheduled institution protocol using mucolytic and expectorant therapy (nebulizer treatments using mucolytic (N-acetylcysteine) for 15 minutes BID, Guafenesin (Mucinex®) 1200 mg BID, codeine as needed and Flutter valve BID.
89431520|NCT02982876|Active Comparator|Treatment group|The patients assigned to treatment group will undergo flexible bronchoscopy with dynamic maneuvers, rigid bronchoscope , tracheobronchial wash and airway stent placement
88910881|NCT03629977||never RRT|RRT is never started, matched against early RRT group.
88910882|NCT03615105|Experimental|Radiation, Thiotepa & Cyclophosphamide|
89431521|NCT02956902|No Intervention|Waiting list control|
89431522|NCT02956902|Experimental|Intervention|Clinician-supported smartphone application intervention
89431523|NCT02942095|Experimental|Dose Escalation Group - Ixazomib + Erlotinib|"Dose Escalation Phase: Participants take Ixazomib capsules by mouth on Days 1, 8, and 15 of each 28 day cycle starting with Dose Level 1.~Participants take Erlotinib tablets by mouth on Days 1 - 28 of each 28 day cycle."
89431524|NCT02942095|Experimental|Dose Expansion Group - Non Small Cell Lung Cancer|"Dose Expansion Phase : Participants take Ixazomib capsules by mouth on Days 1, 8, and 15 of each 28 day cycle at the maximum tolerated dose from Dose Escalation Phase.~Participants take Erlotinib tablets by mouth on Days 1 - 28 of each 28 day cycle."
89431525|NCT02942095|Experimental|Dose Expansion Group - Pancreatic Ductal Adenocarcinoma|"Dose Expansion Phase : Participants take Ixazomib capsules by mouth on Days 1, 8, and 15 of each 28 day cycle at the maximum tolerated dose from Dose Escalation Phase.~Participants take Erlotinib tablets by mouth on Days 1 - 28 of each 28 day cycle."
88910883|NCT03615105|Experimental|Busulfan, Fludarabine & Melphalan|
88910884|NCT03615105|Experimental|Clofarabine, Thiotepa & Melphalan|
88910885|NCT03611530|Experimental|CoQun®|Patients in Arm A will be randomized to receive Prostaglandin analogue (PGA) monotherapy + CoQun®. CoQun® ophthalmic solution will be administered two times daily. CoQun® will be administered in addition to hypotensive therapy. Dose modifications for CoQun® are not permitted.
88910886|NCT03611530|Placebo Comparator|Placebo|Patients in Arm B will be randomized to receive Prostaglandin analogue (PGA) monotherapy +Placebo. Placebo ophthalmic solution will be administered two times daily. Placebo will be administered in addition to hypotensive therapy. Dose modifications for Placebo are not permitted.
88910887|NCT03604991|Experimental|Arm A (carboplatin, paclitaxel, radiation therapy)|Patients receive carboplatin IV and paclitaxel IV once weekly and undergo radiation therapy QD (Monday-Friday) beginning on day 1 of each cycle. Cycles repeat every week for up to 5 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo a CT or PET scan during screening and follow-up and undergo collection of blood samples throughout the trial.
88910888|NCT03604991|Experimental|Arm B (carboplatin, paclitaxel, radiation therapy, nivolumab)|Patients receive carboplatin, paclitaxel, and radiation therapy as in Arm A. Patients also receive nivolumab IV over 30 minutes on days 1 and 15 of each cycle. Cycles repeat every week for up to 5 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo a CT or PET scan during screening and follow-up and undergo collection of blood samples throughout the trial.
88910889|NCT03604991|Experimental|Arm C (nivolumab)|Patients receive nivolumab IV over 30 minutes on day 1 of each cycle. Treatment repeats every 4 weeks for up to 13 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan and collection of blood samples throughout the trial.
88910890|NCT03604991|Experimental|Arm D (nivolumab, ipilimumab)|Patients receive nivolumab as in Arm C and receive ipilimumab IV over 90 minutes on day 1 of cycles 1 and 4 and day 15 of cycles 2 and 5. Treatment repeats every 4 weeks for up to 13 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan and collection of blood samples throughout the trial.
88910891|NCT03600155|Experimental|Arm A (nivolumab)|Beginning at least 6 weeks post-stem cell transplant, patients receive nivolumab IV over 60 minutes on days 1 and 15. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
88910892|NCT03600155|Experimental|Arm B (ipilimumab)|Beginning at least 6 weeks post-stem cell transplant, patients receive ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
88910893|NCT03600155|Experimental|Arm C (nivolumab and ipilimumab)|Beginning at least 6 weeks post-stem cell transplant, patients receive nivolumab IV over 60 minutes on days 1, 14, and 28, and ipilimumab IV over 90 minutes on day 1. Treatment repeats every 6 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
88922262|NCT05582304|Experimental|TEST/CONTROL/Mesopic CSF|Eligible subjects who are habitual wearers of silicone hydrogel contact lenses will be randomized to the mesopic condition and randomized contralaterally to the TEST/CONTROL lenses.
89008570|NCT00567736|Active Comparator|1|Disci/Rhus toxicodendron comp.®
89008571|NCT00567736|Placebo Comparator|2|placebo solution
89431526|NCT02879708|No Intervention|Control|40 (of 120) randomly selected villages receive no intervention
89431527|NCT02879708|Other|Information Only|"40 randomly selected villages are assigned to the information only arm where households will receive information regarding their rights and entitlements pertaining to healthcare, certain health outcomes specific to their village, as well as health-related activities happening in their village."
89431528|NCT02879708|Other|Information and Facilitation|The remaining 40 villages will receive similar information as the villages in the Information Only Arm, but will also have facilitators present that ensure the existence of the VHSNC at the village level as well as the occurrence of VHSNC monthly meetings.
89008572|NCT00567736|No Intervention|3|waiting list group
89008573|NCT00253539|Experimental|Arm I|Participants receive oral tamoxifen once daily for 6 months in the absence of disease progression or unacceptable toxicity. After the completion of 6 months of treatment, participants are offered the opportunity to continue treatment for an additional 6 months.
89008574|NCT00253539|Experimental|Arm II|Participants receive oral arzoxifene once daily for 6 months in the absence of disease progression or unacceptable toxicity. After the completion of 6 months of treatment, participants are offered the opportunity to continue treatment for an additional 6 months.
89008575|NCT00253539|Placebo Comparator|Arm III|Participants receive an oral placebo once daily once daily for 6 months in the absence of disease progression or unacceptable toxicity. After the completion of 6 months of treatment, participants are offered treatment with arzoxifene for an additional 6 months.
89008576|NCT04180163|Experimental|Lanadelumab 300 mg q2w or q4w|Lanadelumab 300 mg solution, subcutaneously (SC), once every 2 weeks (q2w) for 26 weeks in Treatment Period A. This was followed by Treatment Period B (additional 26 weeks, total of 52 weeks including Treatment Period A) during which participants remained on Treatment Period A regimen or received 300 mg lanadelumab solution once every 4 weeks (q4w) for 26 weeks if well-controlled (attack-free) for 26 consecutive weeks with lanadelumab treatment. The dose frequency change was based on the Investigator's discretion and approval by the Sponsor's Medical Monitor.
89008577|NCT04588636|Active Comparator|Behavioral and self-care therapy control group|Subjects received verbal and written information on the etiology and prognosis of TMDs. In addition, advice on habits and behavior changes, relaxation techniques, sleep hygiene, diet modification, thermotherapy, encouragement to practice social and aerobic activities, and how to prevent risk factors and bad habits.
89008578|NCT04588636|Active Comparator|Rigid occlusal splint group|Subjects in this group received behavioral and self-care therapy, in combination with a rigid occlusal splint
89008579|NCT04588636|Active Comparator|Soft occlusal splint group|Subjects in this group received behavioral and self-care therapy, in combination with a soft occlusal splint
89008580|NCT04588636|Placebo Comparator|Non-occlusive splint group|Subjects in this group received behavioral and self-care therapy, in combination with a non-occlusive splint
89008581|NCT04720365|Experimental|play-based rehabilitation|"Patients randomized in the play-based rehabilitation group will perform 2 to 3 gambling rehabilitation sessions at home using the Kinect® system linked to the Curapy.com platform for 12 months."
89008582|NCT04720365|No Intervention|routine care|"Patients randomized in the usual care group will have their usual rehabilitation care provided by their physiotherapist."
89008583|NCT00567814|Active Comparator|1|Lower dose combination of metyrapone with oxazepam
89008584|NCT00567814|Active Comparator|2|Higher dose combination of metyrapone with oxazepam
89008585|NCT00567814|Placebo Comparator|3|
89008586|NCT04588753|Active Comparator|Active Isolated Stretch|active isolated stretching, strengthening exercises
89008587|NCT04588753|Active Comparator|Post Facilitation Stretch|Post Facilitation Stretching, strengthening exercises
89008588|NCT04588090|Experimental|Experimental group|The concurrent 3 weeks treatment group（external radiation plus intraluminal after-loading irradiation+concurrent platinum-containing 3 weeks chemotherapy）
89008589|NCT04588090|Placebo Comparator|Standard chemoradiation group|Standard chemoradiation（external radiation plus intraluminal after-loading irradiation+concurrent platinum-containing weekly chemotherapy）
89008590|NCT00253578|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89536225|NCT03209557|Experimental|SmokeBeat Intervention|"25 pregnant women will be enrolled and provided with a smartwatch. The smartwatch SmokeBeat application will be active. Smoking behavior will be measured by the smartwatch for the duration of the trial. Self-reported smoking status will be collected weekly. Sample testing will occur weekly.~A second phase of the trial was initiated to evaluate a new watch. The smoking habits of participants who are receiving financial incentives to wear the watch are being compared to participants who are being given financial incentives for every day they go without smoking.~A third phase of the trial was initiated to evaluate efficacy of larger financial incentives. All participants are incentivized to wear the watch, with the experimental arm also incentivized to abstain from smoking."
89536226|NCT02482103||Patients treated with renal denervation|Patients treated with RD in the Netherlands. The decision to perform RD was made by the treating physician in the participating hospitals.
89431529|NCT02872467|Experimental|Syntocinon treatment|Syntocinon spray, 24 IU twice daily (A single dose will be delivered consisting of 6 intranasal insufflations (3 in each nostril) which is equivalent to a total of 24 international units (IU) of oxytocin twice daily).
89431530|NCT02872467|Placebo Comparator|Placebo|Placebo nasal spray vials will contain the same ingredients in the nasal preparation, but without oxytocin.
89431531|NCT02800122||Patients with acute dyspnea|"Patients with acute dyspnea treated by a medical team of emergencies of CHRU of Nancy.~All patients admitted to the emergencies in the last 5 years matching the inclusion criteria will be evaluated. About 4,000 patients will be affected, including more than 800 patients with acute heart failure. (Figures based on export of ICD X codes (R06.0: Dyspnea) of patients cared in extra-hospital for acute dyspnea (diagnosis Dyspnea + Heart Failure) over the last 5 years)."
88910896|NCT03594630|Active Comparator|Group I (surgical resection)|Participants who have achieved clinical complete response undergo standard surgical resection.
88910897|NCT03594630|Experimental|Group II (active surveillance)|Participants who have achieved clinical complete response receive active surveillance and consolidated chemotherapy for up to 4 months in the absence of disease progression or unacceptable toxicity. Participants with incomplete response or regrowth of tumor, undergo surgical resection as in Group I.
88910898|NCT03588104|Experimental|POWER2DM support group|Participants in this group will receive access to the POWER2DM system as an adjunct to usual care. The participants have three intervention visits in which they will use the Shared Decision Making Dashboard to set self-management goals and will use the Self-Management Support system for trying to reach those goals in the periods after the intervention visits.
88910899|NCT03588104|Active Comparator|Usual care group|Participants in this group will follow their usual diabetes care with their own diabetes care team.
88910900|NCT03574571|Experimental|Docetaxel|Docetaxel 75 mg/m2 will be administered IV every three weeks for 10 doses. Prednisone will be given at a dose of 5mg orally twice daily.
88910901|NCT03574571|Experimental|Docetaxel with Radium-223|Docetaxel 60 mg/m2 will be administered IV every 3 weeks for 10 doses. Radium-223 will be administered at 55 kBq/kg, 6 injections at 6 weeks intervals.
88910902|NCT03572153|Experimental|Self-Administered Hypnosis|Self-administered hypnosis will be practiced daily using different audio recordings using the researcher's voice. Participants will practice hypnosis at home after completing the two study sessions.
88910903|NCT03572153|Active Comparator|Self-Administered White Noise Hypnosis|Self-administered white noise hypnosis will be practiced daily using a white noise recording. Participants will practice hypnosis at home after completing the two consent and education sessions.
88910904|NCT03565783|Experimental|Treatment (cemiplimab)|Patients receive cemiplimab IV over 30 minutes every 3 weeks. Cycles repeat every 3 weeks for up to 6 weeks with or without radiation therapy at the discretion of the treating physician in the absence of disease progression or unacceptable toxicity.
88910905|NCT03565445|Experimental|ASP1948 70 mg Monotherapy Dose Escalation|Participants have received ASP1948 70 mg intravenously, on day 1 of every 2-week (Q2W) cycle for a period of up to 24 cycles or until a discontinuation criterion is met during treatment period. Qualifying participants have entered a re-treatment period and have received treatment for an additional 24 cycles or until a discontinuation criteria is met.
88910906|NCT03565445|Experimental|ASP1948 200 mg Monotherapy Dose Escalation|Participants have received ASP1948 200 mg intravenously, on day 1 of Q2W cycle for a period of up to 24 cycles or until a discontinuation criterion is met during treatment period. Qualifying participants have entered a re-treatment period and have received treatment for an additional 24 cycles or until a discontinuation criteria is met.
89431532|NCT02781519|Active Comparator|THC|Active THC (0.015mg/kg) administered intravenously over 10 minutes.
89431533|NCT02781519|Placebo Comparator|Placebo|Control: small amount of alcohol intravenously (quarter teaspoon), with no THC over 10 minutes.
89431534|NCT02691637||H. pylori eradication group|Patients who have had H. pylori infection. After diagnosis of H. pylori infection, the patients who subsequently received successful H. pylori eradication treatment according to appropriate indication.
89431535|NCT02691637||Control Group|Patients who still have H. pylori infection. The patients of control group do not have successful H. pylori eradication result or do not received eradication treatment for any reason.
89431536|NCT02669212|Other|Healthy Volunteer Participants|Healthy volunteer participants
89431537|NCT02669212|Other|ME/CFS Participants|Participants with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
88910907|NCT03565445|Experimental|ASP1948 700 mg Monotherapy Dose Escalation|Participants have received ASP1948 700 mg intravenously, on day 1 of every 2 week cycle for a period of up to 24 cycles or until a discontinuation criterion is met during treatment period. Qualifying participants have entered a re-treatment period and have received treatment for an additional 24 cycles or until a discontinuation criteria is met.
88910908|NCT03565445|Experimental|ASP1948 1200 mg Monotherapy Dose Expansion|Participants have received ASP1948 1200 mg intravenously, on day 1 of every 2 week cycle for a period of up to 24 cycles or until a discontinuation criterion is met during treatment period. Qualifying participants have entered a re-treatment period and have received treatment for an additional 24 cycles or until a discontinuation criteria is met.
88910909|NCT03565445|Experimental|ASP1948 2000 mg Monotherapy Dose Escalation|Participants have received ASP1948 2000 mg intravenously, on day 1 of every 2 week cycle for a period of up to 24 cycles or until a discontinuation criterion is met during treatment period. Qualifying participants have entered a re-treatment period and have received treatment for an additional 24 cycles or until a discontinuation criteria is met.
88910910|NCT03565445|Experimental|ASP1948 3000 mg Monotherapy Dose Escalation|Participants have received ASP1948 3000 mg intravenously, on day 1 of every 3-week (Q3W) cycle for a period of up to 16 cycles or until a discontinuation criterion is met during treatment period. Qualifying participants have entered a re-treatment period and have received treatment for an additional 16 cycles or until a discontinuation criteria is met.
88910911|NCT03565445|Experimental|ASP1948 2000 mg Monotherapy Dose Expansion|Participants have received ASP1948 2000 mg intravenously, on day 1 of Q2W cycle for a period of up to 24 cycles or until a discontinuation criterion is met during treatment period. Qualifying participants have entered a re-treatment period and have received treatment for an additional 24 cycles or until a discontinuation criteria is met.
88910912|NCT03565445|Experimental|ASP1948 1200 mg + Nivolumab 240 mg CT Dose Escalation|Participants have received ASP1948 1200 mg intravenously in combination with nivolumab 240 mg administered as a 30 minute intravenous infusion, on day 1 of Q2W cycle for a period of up to 24 cycles or until a discontinuation criterion is met. Qualifying participants have entered a re-treatment period and have received combination treatment for an additional 24 cycles or until a discontinuation criteria is met.
88910913|NCT03565445|Experimental|ASP1948 2000 mg+ Nivolumab 240 mg CT Dose Escalation|Participants have received ASP1948 2000 mg intravenously in combination with nivolumab 240 mg administered as a 30 minute intravenous infusion, on day 1 of Q2W cycle for a period of up to 24 cycles or until a discontinuation criterion is met. Qualifying participants have entered a re-treatment period and have received combination treatment for an additional 24 cycles or until a discontinuation criteria is met.
88910914|NCT03565445|Experimental|ASP1948 2000 mg + Nivolumab 240 mg CT Dose Expansion|Participants have received ASP1948 2000 mg intravenously in combination with nivolumab 240 mg administered as a 30 minute intravenous infusion, on day 1 of every 2 week cycle for a period of up to 24 cycles or until a discontinuation criterion is met. Qualifying participants have entered a re-treatment period and have received combination treatment for an additional 24 cycles or until a discontinuation criteria is met.
88922263|NCT05582304|Experimental|CONTROL/TEST/Photopic CSF|Eligible subjects who are habitual wearers of silicone hydrogel contact lenses will be randomized to the photopic condition and randomized contralaterally to the CONTROL/TEST lenses.
88910915|NCT03565445|Experimental|ASP1948 2000 mg + Pembrolizumab 400 mg CT Dose Escalation|Participants have received ASP1948 2000 mg intravenously on day 1 of Q2W cycle in combination with pembrolizumab 400 mg administered as a 30 minute intravenous infusion, on day 1, once every 6 weeks (Q6W) for a period of up to 24 cycles or until a discontinuation criterion is met. Qualifying participants have entered a re-treatment period and have received combination treatment for an additional 24 cycles or until a discontinuation criteria is met. Participants who completed 24 cycles of treatment and have entered the follow-up period with PR or SD are allowed to continue on pembrolizumab alone for a period of up to an additional 10 doses of pembrolizumab. If the participant is eligible for a re-treatment period during follow up, administration of pembrolizumab alone is discontinued and combination therapy with ASP1948 is resumed per the protocol.
89531201|NCT02496923|Experimental|High flow nasal oxygen therapy (Optiflow™)|In patients randomised to receive high flow nasal oxygen therapy (HFNO) the gas flow through the HFNO will be calculated for each patient, based on their body characteristics, and comfort level. The standard starting flow rate will be 30 L/min, and this will be adjusted up or down between a range of 20-50 L/min with the aim of achieving both patient comfort and a respiratory rate of less than 16 breaths per minute.
88910916|NCT03565445|Experimental|ASP1948 3000 mg + Pembrolizumab 200 mg CT Dose Escalation|Participants have received ASP1948 3000 mg intravenously in combination with pembrolizumab 200 mg administered as a 30 minute intravenous infusion, on day 1 of Q3W cycle for a period of up to 16 cycles or until a discontinuation criterion is met during treatment period. Qualifying participants have entered a re-treatment period and have received combination treatment for an additional 16 cycles or until a discontinuation criteria is met. Participants who completed 16 cycles of treatment and have entered the follow-up period with PR or SD were allowed to continue on pembrolizumab alone for a period of up to an additional 19 cycles. If the participant is eligible for a re-treatment period during follow up, administration of pembrolizumab alone is discontinued and combination therapy with ASP1948 is resumed per the protocol.
88910917|NCT03565445|Experimental|ASP1948 3000 mg + Pembrolizumab 200 mg CT Dose Expansion|Participants have received ASP1948 3000 mg intravenously in combination with pembrolizumab 200 mg administered as a 30 minute intravenous infusion, on day 1 of Q3W cycle for a period of up to 16 cycles or until a discontinuation criterion is met during treatment period. Qualifying participants have entered a re-treatment period and have received combination treatment for an additional 16 cycles or until a discontinuation criteria is met. Participants who completed 16 cycles of treatment and have entered the follow-up period with PR or SD were allowed to continue on pembrolizumab alone for a period of up to an additional 19 cycles. If the participant is eligible for a re-treatment period during follow up, administration of pembrolizumab alone is discontinued and combination therapy with ASP1948 is resumed per the protocol.
88910918|NCT03556904|Active Comparator|Standard of Care|Standard of care therapy will be up to the treating medical oncologist and is not the study intervention. Current systemic therapy is most commonly a second generation androgen pathway inhibitor, including enzalutamide or abiraterone, although other standard agents (e.g. docetaxel, cabazitaxel) are allowed. Patients should begin systemic treatment within 3 weeks of randomization. Standard of care systemic therapy may continue in the absence of toxicities or other specific criteria per protocol.
88910919|NCT03556904|Experimental|Standard of Care + Ablative Radiation|Standard of care systemic therapy plus radiation. Radiation will start within 8 weeks of randomization and complete by day 84. Standard of care systemic therapy may continue in the absence of toxicities or other specific criteria per protocol.
88910920|NCT03555097|Experimental|COPD Group|incremental pressure support
88910921|NCT03550391|Experimental|Hippocampal-avoidant (HA-WBRT) plus Memantine|WBRT 30Gy in 10 fractions + memantine
88910922|NCT03550391|Experimental|Stereotactic Radiosurgery (SRS)|SRS 18-20 or 22Gy in single fraction
88910923|NCT03547739|Active Comparator|Home visits|Participants randomized to intervention arm receive 5 home visits conducted by one female and one male lay health worker.
88910924|NCT03547739|Active Comparator|HIV Self-testing|Women in this study group will receive HIV self-test kits for themselves and their male partner at up to 4 time points.
88910925|NCT03547739|No Intervention|Standard Care|Participants will receive current standard clinic-based services including the option for women and partners to return to the clinic for male partner HIV testing or Couples HIV Counseling and Testing (CHCT).
88910926|NCT03540433||Study group|Surgical patients aged ≥70 years
88910927|NCT03540433||Control group|Healthy subjects, aged ≥70 years, American Society of Anesthesiologists (ASA) I+II+III, no surgery
88922264|NCT05582304|Experimental|CONTROL/TEST/Mesopic CSF|Eligible subjects who are habitual wearers of silicone hydrogel contact lenses will be randomized to the mesopic condition and randomized contralaterally to the CONTROL/TEST lenses.
89536227|NCT03070977|Experimental|Interprofessional study unit|In 2015, Psychiatry in Slagelse established an interprofessional clinical training unit. The aim was to create a new environment for learning, where students could learn from each other and develop competence in interprofessional collaboration. In the training unit there are more students than in the other standard psychiatric wards and several professions are included.
89536228|NCT03070977|No Intervention|Standard unit|Students in the control group receive training in standard psychiatric wards.
89431538|NCT02616094|Experimental|Treatment Seeking Alcohol Dependent Adults|Group consists of 100 treatment seeking alcohol dependent (AD) men and women (ages 18-60). AD subjects will complete either 8 weeks of outpatient treatment at the Yale Stress Center, or the first 4 weeks as inpatient treatment at the CNRU, followed by 4 weeks of outpatient treatment at the Yale Stress Center. While in outpatient treatment, AD subjects may be admitted to the CNRU or HRU for the 1-5 days prior to one or both of their scans, to ensure abstinence for their scans.
88910928|NCT03535363|Experimental|Maximum Tolerated Dose of Osimertinib with standard of care|For patients with 1-10 brain metastases, begin daily Osimeritinib 0-7 days prior to stereotactic radiosurgery (SRS), provide daily Osimeritinib concurrently with radiotherapy, followed by maintenance Osimeritinib until disease progression, withdrawal, or unacceptable toxicity. Dose Level 1: 80mg daily. Dose Level -1: 40mg daily
88910929|NCT03533946|Experimental|Rucaparib, all participants|Single Arm study, all participants will get rucaparib
89431539|NCT02616094|Active Comparator|Social Drinking Controls|Group consists of demographically and handedness matched 50 socially drinking controls. Healthy controls will be moderate and binge/heavy social drinkers who will participate in a single MRI session after baseline assessments. Healthy controls may be admitted to the HRU overnight prior to their scan.
89008591|NCT04588324|Experimental|Phase 1 Dose-Escalation|With a standard 3+3 dose escalation design, the enrollment will proceed until the MTD has been defined or the highest dose level has been reached.
89431540|NCT02616094|Active Comparator|Prazosin/Placebo Group|This is a separate group of 60 treatment seeking AD subjects in a NIAAA-funded RCT of Prazosin vs placebo for alcohol dependence ( PI: Sinha, Hic protocol 0705002691, NCT00585780) to assess target primary and secondary predictors of alcohol treatment outcomes in the context of a currently ongoing RCT. AD subjects enrolled in the PZ/PL RCT will NOT be given drugs as part of this study. That study and intervention is listed elsewhere (NCT00585780). Subjects will participate in a baseline scan and a second scan between weeks 10-12 of the 12-week RCT with follow-ups. PZ/PL is only given to subjects enrolled in 0705002691, not the current protocol.
89431541|NCT02610959|Experimental|Intervention group|Intervention with cod 200 grams two times the week for four months.
88910930|NCT03532243|Experimental|respiratory muscle weakness|Patients with respiratory muscle weakness are performing the threshold loading device with incremental inspiratory load.
88910931|NCT03532243|Experimental|normal respiratory muscle|Patients with normal respiratory muscle are performing the threshold loading device with incremental inspiratory load.
88910932|NCT03530397|Experimental|Arm A: MEDI5752|MEDI5752
88910933|NCT03530397|Experimental|Arm B: MEDI5752 and chemotherapy|MEDI5752, pemetrexed, carboplatin and paclitaxel.
88910934|NCT03530397|Active Comparator|Arm C: Pembrolizumab and chemotherapy|pembrolizumab, pemetrexed, and carboplatin
88910935|NCT03528369|Experimental|CGS-200-1|CGS-200-1 (1% Capsaicin content), a topical analgesic liquid. A single dose will be topically applied to both knees for 60 minutes on Visit 2 on Day 1, Day 2, Day 3, and Day 4.
88910936|NCT03528369|Experimental|CGS-200-5|CGS-200-5 (5% Capsaicin content), a topical analgesic liquid. A single dose will be topically applied to both knees for 60 minutes on Visit 2 on Day 1, Day 2, Day 3, and Day 4.
88910937|NCT03528369|Sham Comparator|CGS-200 Vehicle|CGS-200 Vehicle (no Capsaicin), a topical liquid. A single dose will be topically applied to both knees for 60 minutes on Visit 2 on Day 1, Day 2, Day 3, and Day 4.
88910938|NCT03523546|Experimental|Cancer Episode Payment Model|Oncologists in this arm will be paid for each member's episode of care. The episode of care is 6 months in duration. Oncologists will have the opportunity to receive performance-based payments based upon a set of 6 quality metrics.
88910939|NCT03523546|No Intervention|Fee for Service|Oncologists in this arm will not receive the intervention and will continue to be paid through fee-for-service.
88910940|NCT03521622|Experimental|brief counseling interventions|"For smoking patients the brief intervention is 5 As model for motivated patients and 5Rs for not motivated patients.~For risky alcohol drinkers the brief intervention is simple advise for motivated patients and brief intervention for not motivated patients."
88910941|NCT03521622|Placebo Comparator|Control group|written informative material about healthy lifestyles
88910942|NCT03519295|Experimental|ARM A - mDCF + Atezolizumab|"MPDL3280A (atezolizumab) will be administered every 2 weeks at 800 mg for 12 months.~Patients will receive 8 cycles of mDCF (docetaxel 40 mg/m2 day 1, cisplatin 40 mg/m2 day 1 and 5FU at 1200 mg/m2/day for 2 days) every 2 weeks"
88910943|NCT03519295|Active Comparator|ARM B - mDCF|Patients will receive 8 cycles of mDCF (docetaxel 40 mg/m2 day 1, cisplatin 40 mg/m2 day 1 and 5FU at 1200 mg/m2/day for 2 days) every 2 weeks.
88910944|NCT03504397|Experimental|Arm A (zolbetuximab plus mFOLFOX6)|Participants will receive a loading dose of zolbetuximab at Cycle 1 Day 1 followed by a lower dose in subsequent cycles every 3 weeks. Additionally, participants will receive up to 12 treatments of mFOLFOX6 (or components of mFOLFOX6 if some components are discontinued due to toxicity) over 4 or more cycles (each cycle is approximately 42 days) in which mFOLFOX6 is administered on Days 1, 15 and 29. After 12 mFOLFOX6 treatments, participants may continue to receive fluorouracil (5-FU) and folinic acid at the investigator's discretion until the subject meets study treatment discontinuation criteria.
88910945|NCT03504397|Placebo Comparator|Arm B (Placebo plus mFOLFOX6)|Participants will receive placebo starting at Cycle 1 Day 1 and every 3 weeks thereafter. Additionally, participants will receive up to 12 treatments of mFOLFOX6 (or components of mFOLFOX6 if some components are discontinued due to toxicity) over 4 or more cycles (each cycle is approximately 42 days) in which mFOLFOX6 is administered on Days 1, 15 and 29. After 12 mFOLFOX6 treatments, participants may continue to receive fluorouracil (5-FU) and folinic acid at the investigator's discretion until the subject meets study treatment discontinuation criteria.
88910946|NCT03500042|Experimental|respiratory muscle weakness|Patients with respiratory muscle weakness are performing the inspiratory pressure threshold device, expiratory pressure threshold device and concurrent inspiratory and expiratory muscle device for one minute randomly.
88910947|NCT03500042|Experimental|normal respiratory muscle|Patients with respiratory muscle weakness are performing the inspiratory pressure threshold device, expiratory pressure threshold device and concurrent inspiratory and expiratory muscle device for one minute randomly.
88910948|NCT03496883|Active Comparator|Recombinant Activated Factor VII (rFVIIa)|rFVIIa given as IV injection over 2 minutes within 120 minutes of stroke onset
88910949|NCT03496883|Placebo Comparator|Placebo|Matching placebo given as IV injection over 2 minutes within 120 minutes of stroke onset
88910950|NCT03478878|Experimental|Participants|Participants with reticular pseudodrusen
88910951|NCT03472573|Experimental|Treatment (palbociclib, dexamethasone)|"INDUCTION: Participants receive palbociclib PO daily and dexamethasone PO daily for 28 days in the absence of disease progression or unacceptable toxicity. Participants with disease response (M0, M1, or M2) continue to Maintenance. Patients without a disease response discontinue treatment.~MAINTENANCE: Participants receive dexamethasone with a taper PO daily on days 1-7. Participants also receive palbociclib daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
88922265|NCT05579249|Experimental|Semaglutide|Participants will receive semaglutide 2.4 milligrams (mg) subcutaneous (s.c.) injection once weekly for 52 weeks as adjuncts to a reduced-calorie diet and increased physical activity for chronic weight management.
89008592|NCT04588324|Experimental|Phase 2 Dose-Expansion|SHR2150 RP2D will be combined with chemotherapy plus PD-1 or CD47 antibody in 3-week treatment cycles.
89431542|NCT02610959|Experimental|Control group|Control group which will continue to eat their habitual diet.
89431543|NCT02600910||Manual Wheelchair User Cohort|"Physical Exam. Screening exam performed by a licensed physical therapist to confirm inclusion/exclusion criteria.~Assessment of Shoulder Function in Everyday Life. Shoulder motion & hand loading data will be collected over a few days, twice per yr for 3-5 yrs in home & community environment.~Magnetic Resonance Imaging (MRI) of Shoulders. Imaging will use standard clinical protocol once per yr for 3-5 yrs.~Shoulder Strength Testing. Once per yr for 3-5 yrs. Additional Variables. Updated demographic info will be collected yearly including but not limited to weight, chair type, health status, and job type."
89431544|NCT02600910||Matched Able-bodied Cohort|"Physical Exam. Screening exam performed by a licensed physical therapist to confirm inclusion/exclusion criteria.~Assessment of Shoulder Function in Everyday Life. Shoulder motion & hand loading data will be collected over a few days, twice per yr for 3-5 yrs in home & community environment.~Magnetic Resonance Imaging (MRI) of Shoulders. Imaging will use standard clinical protocol once per yr for 3-5 yrs.~Shoulder Strength Testing. Once per yr for 3-5 yrs. Additional Variables. Updated demographic info will be collected yearly including but not limited to weight, health status, and job type."
89431545|NCT02580201|Experimental|Oral Polio Vaccine|"Opvero™ (oral) is a trivalent, live attenuated poliomyelitis virus vaccine containing at least 6.0 log 50% cell culture infective dose (CCID50) of LS c2ab strain of live attenuated polio virus type 1, 5.0 log CCID50 of P712, Ch, 2ab strain of live attenuated polio virus type 2, 5.8 log CCID50 Leon I2aIb strain of polio virus type 3. Excipients: human albumin, HEPES buffer solution, magnesium chloride solution (containing polysorbate 80 and phenol red), hydrochloric acid or sodium hydroxide for pH adjustment.~The vaccine is presented as a suspension for oral administration. One dose of vaccine (0.1 ml) is contained in two drops which are delivered from the dropper supplied with the multidose container."
89431546|NCT02536664||First-line Stratum|Participants who were untreated and decided by the treating physician to be treated with Rituximab for the CD 20-positive follicular lymphoma condition.
89431547|NCT02536664||Relapsed/Refractory Stratum|Participants who relapsed after treatment with chemotherapeutic regimens with or without Rituximab and were decided by the treating physician to be treated with Rituximab for the CD 20-positive follicular lymphoma condition.
89431548|NCT02483988|Experimental|NUsurface Meniscus Implant|All eligible patients will receive the NUsurface® Meniscus Implant.
89008593|NCT04587895|Experimental|MI Intervention|The VITAAL exergame intervention for MI includes 36 training sessions with three sessions per week, each lasting around 45 minutes (30 minutes real training time) resulting in 12 weeks of training (two weeks of break/holiday allowed). A training session includes an individually calculated amount of strength, cognitive-motor and balance training, which remains the same over the 12 week intervention period.
89008594|NCT04587895|Active Comparator|MI Control|"Participants of the MI control group are instructed to do a non-individualized conventional training including 15 minutes walking exercise (in nature or on treadmill) and additional 15 minutes of strength, balance, and cognitive-motor exercises (at the therapy centre or at home). The exercises are based on recommendations from the Beratungsstelle für Unfallverhütung (bfu). The participants will receive a training booklet with the exercises. In total there are three different training programs which are divided according to their level of difficulty. Participants are instructed to start with the first level for four weeks and then go on to the next level for another 4 weeks. The control group training in this study includes 36 training session with three sessions per week, each lasting around 45 minutes resulting in 12 weeks of training (two weeks of break/holiday allowed)."
89431549|NCT02438111||age related macular degeneration|metagenome AMD
89431550|NCT02438111||controls|metagenome controls
89431551|NCT02426892|Experimental|ISA101 + Nivolumab|"HPV-16 vaccination (ISA 101) administered subcutaneously at 100 mcg for a total of 3 doses at 3 to 4 weeks intervals starting on Day 1.~Nivolumab administered intravenously at 3 mg/kg every 2 weeks beginning on day 8 after the first vaccine dose.~There are 3 weeks in Cycle 1 and 2 weeks in Cycles 2 and beyond."
89431552|NCT02312687|Experimental|KRN23|KRN23 subcutaneous (SC) injections every 4 weeks. Starting doses will be based on the subject's last dose in study KRN23-INT-001 (NCT02312687) or KRN23-INT-002 (NCT01571596). Doses may be titrated to achieve the target peak serum phosphorus range.
89008595|NCT04587895|Experimental|UI Intervention|For the incontinent women in this study, the VITAAL exergame intervention will last over 12 weeks and consists of three parts 1) VITAAL exergame (2 sessions/week) lasting 45 minutes each (30 minutes real training time) at the physio centre, 2) PFM exercises according to a training booklet (3 sessions/week) lasting 10 minutes each at home and 3) education related to UI at home.
89008596|NCT04587895|Active Comparator|UI Control|The control group training will last over 12 weeks. The training sessions will be divided in three parts 1) 30 minutes of brisk walking (2 sessions/week, 2) PFM exercises according to a training booklet (3 sessions/week) lasting 10 minutes each at home and 3) education related to UI at home. The PFM training booklet will be based on two studies that showed a reduction of incontinence in older adults while performing group pelvic floor muscle training (PFMT) and mobility exercises. The PFMT program will consist of 4 PFM exercises and will be divided into three phases allowing for the gradual progression in treatment (from first to third month), with gradual increase in difficult exercises in terms of duration, repetition and position. Each phase will last four weeks.
89008597|NCT04588168|Experimental|Experimental: Chemotherapy + mpMRI + surgery|"Baseline mpMRI /Neoadjuvant chemotherapy /Immediate mpMRI /Cystectomy and Lymphadenectomy / Postoperative pathology~Drug: Chemotherapy Procedure: Immediate Multiparametric MRI Procedure: Cystectomy and Lymphadenectomy"
89008598|NCT04588168|Experimental|Experimental: Chemotherapy + surgery|"Baseline mpMRI /Neoadjuvant chemotherapy /Cystectomy and Lymphadenectomy / Postoperative pathology~Drug: Chemotherapy Procedure: Cystectomy and Lymphadenectomy"
89008599|NCT04587817||Camrelizumab+Hypofractionated radiation therapy|"Camrelizumab: 200mg every 2 weeks until disease progression (as determined by RECIST 1.1), intolerance, or patient/physician decision to stop treatment.~Hypofractionated Radiotherapy(SABR): tumor center dose of 24-32Gy/8Gy/3-4f and surrounding important organs at risk ≤3.0Gy will be performed when one week following completion of the first immunotherapy. And the routine radiotherapy will be started with reaching a radical cure dose for the tumor margin. Generally, the radiotherapy will end before the fourth immunotherapy."
89431553|NCT02304367|Experimental|Burosumab|Participants received burosumab at a starting dose of 0.3 mg/kg administered subcutaneously (SC) every 4 weeks (Q4W). Doses may have been titrated up to a maximum of 2.0 mg/kg every 2 weeks (Q2W) in order to achieve fasting peak serum phosphorus levels within the target range of 2.5 to 4.0 mg/dL.
89431554|NCT02094625|Experimental|N-Acetylcysteine Intervention|"This is a dose-finding study using a traditional 3+3 dose escalation scheme. Up to 18 subjects (3 dose levels as per below) will be enrolled to determine the maximum tolerated dose (MTD). The MTD is defined as per traditional 3+3 criteria of less than or equal to one dose-limiting toxicity at the dose level. Once the MTD is determined, subjects will be equally distributed at the safe dose levels (less than or equal to the MTD) to determine the optimum dose to achieve NAC levels in the blood necessary for hearing protection.~As of August 2018: The dose-escalation phase was completed and dose-level three was selected for expansion in 9 subjects."
89431555|NCT02094625|No Intervention|Observation only|"Subjects who are ineligible to receive the study drug NAC will have the option to enroll for study assessments only including laboratory testing and hearing assessments identical to the experimental intervention arm. This is a cohort of convenience for which we anticipate up to 36 children will be enrolled over the course of the study."
89431556|NCT02054520|Experimental|Arm 1A HyperAcute®-Melanoma (HAM) + Ipilimumab|Arm 1A will receive ipilimumab at 3 mg/kg given every 3 weeks for 4 weeks and 300 Million HyperAcute®-Melanoma (HAM) Immunotherapy cells per each immunization, given every week for 4 weeks, every 2 weeks for 5 months, every month for 6 months, and every 3 months for one year.
89431557|NCT02054520|Active Comparator|Arm 2A Ipilimumab Alone|Arm 2A will receive ipilimumab alone at 3 mg/kg every 3 weeks for a total of four doses.
89431558|NCT02054520|Experimental|Arm 1B HyperAcute®-Melanoma (HAM) + nivolumab|Arm 1B will receive nivolumab alone at 3 mg/kg given every 2 weeks and 300 Million HyperAcute®-Melanoma (HAM) Immunotherapy cells per each immunization, given every week for 4 weeks, every 2 weeks for 5 months, every month for 6 months, and every 3 months for one year.
89431559|NCT02054520|Active Comparator|Arm 2B Nivolumab alone|Arm 2B will receive nivolumab alone at 3 mg/kg given every 2 weeks
89431560|NCT02054520|Experimental|Arm 1C HyperAcute®-Melanoma (HAM) + pembrolizumab|Arm 1C will receive pembrolizumab at 2 mg/kg given every 3 weeks and 300 Million HyperAcute®-Melanoma (HAM) Immunotherapy cells per each immunization, given every week for 4 weeks, every 2 weeks for 5 months, every month for 6 months, and every 3 months for one year.
89431561|NCT02054520|Active Comparator|Arm 2C Pembrolizumab alone|Arm 2C will receive pembrolizumab at 2 mg/kg given every 3 weeks
89008602|NCT04587505|Active Comparator|Epidural anesthesia and analgesia|Epidural catheter insertion: Th 12- L 1 or Th 11 - Th 12 using the midline approach. Safety of the epidural catheter was confirmed with lidocaine 60 mg. Epidural loading dose was given according to our classification (3,4,5 or 6 ml). Postoperative period in urology high care unit. Epidural analgesia ropivacaine/morphine was administered by a urologist according to our classification (2x2 ml, 2x3 ml and 3x3 ml).
89008603|NCT04587505|Active Comparator|Balanced general anesthesia and tramadol analgesia|Postoperative period in urology high care unit.
89431562|NCT02049827|Experimental|Renal transplant|
89431563|NCT01931904||Trabeculectomy or Tube Shunt Patients|46 glaucoma patients undergoing trabeculectomy or tube shunt surgery to lower IOP
89431564|NCT01922921|Active Comparator|Arm I (placebo)|Patients receive HER2 ICD peptide-based vaccine ID once monthly for 3 months, trastuzumab (or trastuzumab and pertuzumab) per standard of care, and placebo PO BID for 4 months.
89431565|NCT01922921|Experimental|Arm II (polysaccharide-K)|Patients receive HER2 ICD peptide-based vaccine ID and trastuzumab (or trastuzumab and pertuzumab) as in Arm I and polysaccharide-K PO BID for 4 months.
89431566|NCT01807715||Study group|Women seeking first trimester surgical abortion
89431567|NCT01778777|Experimental|UniverseReverse|Cohort get an universe reverse prosthesis
89431568|NCT01682980|Experimental|Strength training|The strength group include progressive strength training and neuromuscular exercises. The inclusion will be performed 2-3 times a week for 12 weeks.
89431569|NCT01682980|Experimental|Aerobic exercise|The aerobic exercise group will cycle on an ergometer bicycle 2-3 times a week for 12 weeks on moderate loading. The loading will be controlled by a heart rate monitor and is defined as 75% of maximal heart rate (calculated with formula for maximal heart rate reserve).
89431570|NCT01682980|No Intervention|Control group|The control group will do as usual.
88910952|NCT03471143|Experimental|IV adrabetadex (VTS-270) for NPC1 infants|"Phase 1: Dosing frequency will be twice a week administered via a peripherally inserted central catheter (PICC) for six weeks for a total of 12 administrations. Doses 3-12 will occur as an outpatient.~Doses to be studied are 500, and 1000 mg/kg. Six subjects will be studied at each dose level. Cohort 1: Subjects 1-6 will receive 500 mg/kg Cohort 2: Subjects 7-12 will receive 1000 mg/kg Subjects who demonstrate significant reduction either in the glycine-conjugated trihydroxycholanic acid biomarker or serum bilirubin (direct bilirubin or direct bilirubin:total bilirubin ratio) will be allowed to crossover into the second phase of the study, an open-label phase of six months duration. In the this phase of the study, dosing frequency will be monthly with IV VTS-270 administered via peripheral IV access for six months for a total of six administrations."
88910953|NCT03452137|Active Comparator|Atezolizumab|Participants will receive Atezolizumab for 16 cycles, or up to 1 year (whichever occurs first)
88910954|NCT03452137|Experimental|Placebo|Participants will receive Placebo for 16 cycles, or up to 1 year (whichever occurs first).
88910955|NCT03449069|Experimental|MSC-AFP|This is a single treatment group study. All patients will receive treatment of a stem cell coated fistula plug.
88910956|NCT03436745|Active Comparator|Female|Single 5 mg oral dose of zolpidem
88910957|NCT03436745|Experimental|Zolpidem pre and post castration|5 mg oral dose of zolpidem prior to undergoing ADT followed by 5 mg oral dose of zolpidem after ADT and testosterone reaches castrate levels
88910958|NCT03432065|Experimental|Buspirone|Buspirone tablets will be administered twice daily, and will be titrated to a maximum daily dose of 60mg for 8 weeks.
88910959|NCT03428152||Hypo|The participants with a superior hypogastric block
88910960|NCT03428152||NoHypo|The participants without a superior hypogastric block; the patients with an epidural catheter, who receive a different block technique (ie: TAP block), or who are unsuitable for SHP block (ie: if retro-peritoneum is opened intraoperatively by the surgeon)
88910961|NCT03424005|Active Comparator|Atezolizumab + Nab-Paclitaxel|"1L PD-L1-positive participants will receive doublet combination treatment with atezolizumab + nab-paclitaxel until unacceptable toxicity or loss of clinical benefit as determined by the investigator.~Enrollment is closed."
88910962|NCT03424005|Experimental|Atezolizumab + Nab-Paclitaxel + Tocilizumab|"1L PD-L1-positive participants will receive combination treatment with atezolizumab plus nab-paclitaxel and tocilizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.~Enrollment is closed."
88910963|NCT03424005|Experimental|Atezolizumab + Sacituzumab Govitecan|"1L PD-L1-positive participants will receive doublet combination treatment with atezolizumab plus sacituzumab govitecan until unacceptable toxicity or loss of clinical benefit as determined by the investigator.~Enrollment is closed."
88910964|NCT03424005|Active Comparator|Capecitabine|"2L CIT-naive participants will receive capecitabine until unacceptable toxicity or disease progression per Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1).~Participants who progressed on treatment may have the option of receiving atezolizumab + chemo, provided they meet the eligibility criteria.~Enrollment is closed."
88910965|NCT03424005|Experimental|Atezolizumab + Ipatasertib|"2L CIT-naive participants will receive doublet combination treatment with atezolizumab + ipatasertib until unacceptable toxicity or loss of clinical benefit as determined by the investigator.~Participants who progressed on treatment may have the option of receiving atezolizumab + chemo, provided they meet the eligibility criteria.~Enrollment is closed."
88910966|NCT03424005|Experimental|Atezolizumab + SGN-LIV1A|"2L CIT-naive participants will receive doublet combination treatment with atezolizumab plus SGNLIV1A until unacceptable toxicity or loss of clinical benefit as determined by the investigator.~Participants who progressed on treatment may have the option of receiving atezolizumab + chemo, provided they meet the eligibility criteria.~Enrollment is closed."
88910967|NCT03424005|Experimental|Atezolizumab + Selicrelumab + Bevacizumab|"2L-CIT-naive participants will receive doublet combination treatment with atezolizumab plus selicrelumab and bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.~Participants who progressed on treatment may have the option of receiving atezolizumab + chemo, provided they meet the eligibility criteria.~Enrollment is closed."
88910968|NCT03424005|Experimental|Atezolizumab + Chemo (Gemcitabine + Carboplatin or Eribulin)|"2L CIT-naive participants enrolled in the active comparator arm who experience disease progression per RECIST v1.1 and 2L CIT-naive participants enrolled in an experimental arm who experience loss of clinical benefit as determined by the investigator may receive doublet combination treatment with atezolizumab plus chemotherapy (gemcitabine + carboplatin or eribulin) until unacceptable toxicity or loss of clinical benefit as determined by the investigator.~Enrollment is closed."
88910969|NCT03424005|Experimental|Inavolisib + Abemaciclib + Fulvestrant|Hormone receptor-positive (HR+) participants will receive treatment with inavolisib plus abemaciclib plus fulvestrant until unacceptable toxicity or disease progression per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1).
88910970|NCT03424005|Experimental|Inavolisib + Ribociclib + Fulvestrant|Hormone receptor-positive (HR+) participants will receive treatment with inavolisib plus ribociclib plus fulvestrant until unacceptable toxicity or disease progression per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1).
89431571|NCT01565447||Children with ALL or LL|Children diagnosed with ALL or LL will be recruited for this study
89431572|NCT01546987|Active Comparator|ADT + RT|Standard androgen deprivation therapy (ADT) beginning two months prior to radiation therapy (RT). ADT comprised of anti-androgen continuing for two years and GnRH agonist stopping at end of RT.
89431573|NCT01546987|Experimental|TAK-700 + ADT + RT|TAK-700 and standard androgen deprivation therapy (ADT) beginning two months prior to radiation therapy (RT). ADT comprised of anti-androgen continuing for two years and GnRH agonist stopping at end of RT. TAK-700 continues for two years.
89431574|NCT01494324|Experimental|CT guided percutaneous ablation|The selected patients will undergo CT guided percutaneous ablation. The use of multi-tined electrode is encouraged, unless tumor location requires the use of an internally cooled needle electrode to eliminate injury to an adjacent vital structure or the operator prefers to use an internally cooled electrode for a specific reason.
89431575|NCT01957267||Glaucoma Group|Patients with clinically confirmed glaucomatous ONH or NFL defects, with or without VF abnormalities
89431576|NCT01957267||Normal Group|Volunteers with healthy eyes
89431577|NCT01221480||Beta Blocker Use|
89431578|NCT01221480||No beta blocker use|
89431579|NCT01018654|Experimental|Culturally Adapted Cognitive-Behavioral Treatment|Culturally Adapted CBT for Substance Abuse
89431580|NCT01018654|Active Comparator|Standard Cognitive-Behavioral Treatment|Standard Cognitive-Behavioral Treatment for Substance Abuse
89431581|NCT00809991|Experimental|Hypofractionated radiation therapy in prostate adenocarcinoma|Participants with histologically confirmed, locally confined adenocarcinoma of the prostate receive 3.6 Gy per day to a total dose of 57.6 Gy (16 fractions).
89431582|NCT00788307|Experimental|Experimental Arm|
89431583|NCT00708760||2|web based learning group
89431584|NCT00708760||1|paper based learning group
89431585|NCT00614211|Active Comparator|1|Total Abdominal Radical Hysterectomy
89431586|NCT00614211|Experimental|2|Total Laparoscopic or Robotic Radical Hysterectomy
89431587|NCT00268476|Active Comparator|Arm A: Standard of Care|Androgen Deprivation Therapy [ADT] (plus Radiotherapy for newly-diagnosed non-metastatic disease, plus or minus Docetaxel, plus or minus Abiraterone)[Control]
89431588|NCT00268476|Experimental|Arm B: Zoledronic Acid|(ADT + zoledronic acid) NO LONGER RECRUITING
89431589|NCT00268476|Experimental|Arm C: Docetaxel|(ADT + docetaxel + prednisolone) NO LONGER RECRUITING
89431590|NCT00268476|Experimental|Arm D: Celecoxib|(ADT + celecoxib) NO LONGER RECRUITING
89431591|NCT00268476|Experimental|Arm E: Zoledronic Acid & Docetaxel|(ADT + zoledronic acid + docetaxel + prednisolone) NO LONGER RECRUITING
89431592|NCT00268476|Experimental|Arm F: Zoledronic Acid & Celecoxib|(ADT + zoledronic acid + celecoxib) NO LONGER RECRUITING
89431593|NCT00268476|Experimental|Arm G: Abiraterone|(ADT + abiraterone acetate + prednisolone) NO LONGER RECRUITING
89431594|NCT00268476|Experimental|Arm H: M1 RT|(ADT + radiotherapy to the prostate) NO LONGER RECRUITING
89431595|NCT00268476|Experimental|Arm J: Abiraterone * Enzalutamide|(ADT + abiraterone + enzalutamide + Prednisolone) NO LONGER RECRUITING
89431596|NCT00268476|Experimental|Arm K: Metformin|(ADT + Metformin) RECRUITING IN SELECTED SITES
89431597|NCT00268476|Experimental|Arm L: tE2|(Transdermal oestradiol) RECRUITING
89431598|NCT00261443|Placebo Comparator|A1|/Active Comparator
89431599|NCT00261443|Experimental|A2|
89431600|NCT00093379|Experimental|Capecitabine + Oxaliplatin + XRT|Capecitabine (825 mg/m^2 twice a day, Monday-Friday during weeks 1, 2, 4, and 5) and Oxaliplatin (50 mg/m^2, Days 1, 8, 22, 29) during the duration of radiation therapy only. Radiotherapy once daily on days 1-3, 6-10, 13-17, 20-24, 27-31, 34-38, and 41-42. Participants with T3-4 lesions undergo radiotherapy once daily on days 43 and 44. The final dose of radiation therapy determined by the T stage of the primary tumor. Radiotherapy = XRT.
88910971|NCT03424005|Experimental|Inavolisib (6 mg) + Trastuzumab Deruxtecan|HER2+/HER2-low participants will receive inavolisib (6 mg) + trastuzumab deruxtecan until unacceptable toxicity or disease progression as determined by the investigator according to RECIST v1.1.
88910972|NCT03424005|Experimental|Inavolisib (9 mg) + Trastuzumab Deruxtecan|HER2+/HER2-low participants will receive inavolisib (9 mg) + trastuzumab deruxtecan until unacceptable toxicity or disease progression as determined by the investigator according to RECIST v1.1.
88910973|NCT03417856||Control|Healthy subjects with no history of ichthyosis from 1 year to 60 years of age.
88910974|NCT03417856||Ichthyosis|Subjects with a diagnosis of Netherton syndrome or ichthyosis from 1 year to 60 years of age.
88910975|NCT03417115||Advanced breast cancer - Her2 positive|Patients with HER2-positive advanced breast cancer
88910976|NCT03417115||Advanced breast cancer - triple negative|Patients with triple negative advanced breast cancer
88910977|NCT03417115||Advanced breast cancer - HR positive, Her2 negative|Patients with HR positive, Her2 negative advanced breast cancer
88910978|NCT03417115||Early breast cancer - HER2 positive|Patients with HER2 positive early breast cancer
88910979|NCT03417115||Early breast cancer - triple negative|Patients with triple negative early breast cancer
88910980|NCT03417115||Early breast cancer - HR positive, HER2 negative|Patients with HR positive, HER2 negative early breast cancer
88910981|NCT03412162|Experimental|Ethnic and Racial Identity Promotion|Students will participate in 8, 1 hour and 15 minute classroom based intervention sessions at their local high school, during which a facilitator will lead them through a series of lectures, group activities, and individual homework activities designed to promote a positive ethnic and racial identity (positive feelings about ones' ethnic and racial heritage and ethnic and racial group membership).
88910982|NCT03412162|Active Comparator|Academic Skills Promotion|Students in this active comparison group will participate in an 8-week, 1 hour and 15 minute classroom based intervention, during which a facilitator will lead them through a series of lectures, group activities, and individual homework activities designed to provide information regarding college and career planning, and promote college and career planning as well as study skills and strategies. This condition receives the same amount of facilitator time and attention as the Experimental condition.
88910983|NCT03392454||T+LRTI Patients|Patients who received Trapeziectomy with Ligament Reconstruction and Tendon Interposition.
88910984|NCT03392454||PT+TI Patients|Patients who received the Partial Trapeziectomy and Tendon Interposition
88910985|NCT03386578|Experimental|Pharmacokinetics Component: Group 1|Participants will be enrolled during singleton pregnancy at 14-24 weeks' gestation. Participants will receive a fixed-dose combination of emtricitabine and tenofovir disoproxil fumarate (FTC/TDF) once daily under direct observation from Day 0 through Week 12.
88910986|NCT03386578|Experimental|Pharmacokinetics Component: Group 2|Participants will be enrolled postpartum within 6-12 weeks after delivery. Participants will receive a fixed-dose combination of FTC/TDF once daily under direct observation from Day 0 through Week 12.
88910987|NCT03386578|Experimental|PrEP Comparison Component: Cohort 1|Participants will receive daily oral PrEP (FTC/TDF) from Day 0 through Week 26. Participants will also receive behavioral HIV risk reduction package, including cohort-appropriate SMS messages, from Day 0 through Week 26.
88910988|NCT03386578|Active Comparator|PrEP Comparison Component: Cohort 2|Participants will receive a behavioral HIV risk reduction package, including cohort-appropriate SMS messages, from Day 0 through Week 26.
88910989|NCT03381261|Experimental|Botulinum toxin type A injection arm|All patients will be injected with Botulinum toxin on one side of the back of the head.
88910990|NCT03376477|Experimental|Lenalidomide plus GM-CSF Vaccine plus Prevnar13|"Patients will continue on a standard dose of lenalidomide as a single agent until progression, or treatment limiting toxicity, following enrollment.~Patients assigned to vaccine therapy will receive injections on day 14 (+/-3 days) of cycles 1, 2, 3 and 6 from enrollment, and then annually thereafter. Prevnar vaccine will be administered with the GM-CSF vaccine administration."
88910991|NCT03376477|Placebo Comparator|Lenalidomide Only|Patients will continue on a standard dose of lenalidomide as a single agent until progression, or treatment limiting toxicity, following enrollment. Patients will also get placebo GM-CSF vaccine and placebo prevnar13. Placebo will be saline.
88910992|NCT03376477|Placebo Comparator|Lenalidomide plus GM-CSF Vaccine|"Patients will continue on a standard dose of lenalidomide as a single agent until progression, or treatment limiting toxicity, following enrollment.~Patients assigned to vaccine therapy will receive injections on day 14 (+/-3 days) of cycles 1, 2, 3 and 6 from enrollment, and then annually thereafter. Patients will also be administered a placebo prevnar13 vaccination. Placebo will be saline."
88910993|NCT03375489|Experimental|Telehealth|"Patients will meet with the PC clinician in person within four weeks of enrollment~Subsequent visits with the PC clinician will be conducted with the patients in their home or other location using video at least every four weeks~Patients may be scheduled to meet with the PC clinician in the clinic if requested by the patient or a clinician"
88910994|NCT03375489|Active Comparator|In Person PC|"Patients will be scheduled for their first In-person PC visit within four weeks of enrollment and then at least every four weeks thereafter until the patient is no longer coming into the clinic~PC visits will be scheduled on the same day as an oncology visit if possible"
88910995|NCT03374215||Adult AA with primary aldosteronism|Adult individuals (age 18 or older) with HTN and discrete adrenal masses or bilateral hyperplasia of the adrenal glands, with outpatient positive ARR or string clinical suspicion for PA
88910996|NCT03374215||Family members age >= 7 of participants|DNA from relatives of patients (age 7 or older)
88910997|NCT03366155|Experimental|1/ Arm 1|HAIP chemotherapy + Systemic chemotherapy
89431601|NCT02593318|Experimental|Part 1 - Oxaloacetate (OAA) 1 gram/day|Participants take 1 gram of OAA per day for period of 4 weeks
89431602|NCT02593318|Experimental|Part 2 - Oxaloacetate (OAA)2 gram/day|Participants take 2 grams of OAA per day for period of 4 weeks
89536229|NCT03209635|Placebo Comparator|Placebo|4 capsules (300 mg/capsule) containing 52% crystalline cellulose and 46% lactose in identical-looking with test product
89536230|NCT03209635|Experimental|Probiotic|4 capsules (300 mg/capsule) containing each capsule 1.0 x 10^10 colony-forming units (cfu) of Weissella cibaria JW15, twice a day
89431603|NCT04583852|Experimental|brightening micro-needle patch|apply brightening micro-needle patch to one of the two assigned spots on the face according to the instructions on the package
89431604|NCT04583852|Placebo Comparator|Placebo|apply placebo micro-needle patch to another one of the two assigned spots on the face according to the instructions on the package
89431605|NCT02094027|Experimental|Guided Self Help|Guided Self Help intervention to reduce binge eating
89431606|NCT02094027|Placebo Comparator|Treatment As Usual|No intervention for binge eating (treatment as usual in the form of bariatric surgery)
88910998|NCT03346343|Experimental|Non-invasive forced airway oscillometry|"Analyze lung function using forced airway oscillometry in preterm infants and term infants with and without lung disease with both cross-sectional and longitudinal comparisons.~Aim 1: Lung function in term and preterm infants without lung disease (anticipated n=264) Aim 2: Lung function in preterm infants with respiratory distress syndrome (RDS) who develop bronchopulmonary dysplasia (BPD) and preterm infants with RDS who do not develop BPD (anticipated n=264) Aim 3: Lung function measurements in infants with common neonatal lung diseases (including RDS, BPD, meconium aspiration syndrome, and transient tachypnea of the newborn) and controls without lung disease (anticipated n=570) Aim 4: Lung function in infants with lung disease before and after common therapeutic interventions"
88910999|NCT03343574|Experimental|Abdominal Strengthening Exercise|All participants in this arm shall perform exercises for the strengthening of abdominal muscles for a period of three months in addition to the routine care provided to them for the management of Parkinson's Disease. The exercises are structured and need to be performed on a routine basis.
88911000|NCT03343574|No Intervention|Routine Care|All participants in this group shall continue to obtain routine care for the management of Parkinson's Disease.
88911001|NCT03337698|Active Comparator|Stage 1: Cohort 1: Atezolizumab|"Participants in the Atezolizumab arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.~Participants who progressed on treatment, may have the option of receiving Atezolizumab + Pemetrexed + Carboplatin or Atezolizumab + Gemcitabine + Carboplatin treatment, provided they meet the eligibility criteria."
88911002|NCT03337698|Experimental|Stage 1: Cohort 1: Atezolizumab + Cobimetinib|"Participants in the Atezolizumab + Cobimetinib arm will receive treatment (cycle length 28 days) until unacceptable toxicity or loss of clinical benefit.~Participants who progressed on 1L treatment, may have the option of receiving Atezolizumab + Pemetrexed + Carboplatin or Atezolizumab + Gemcitabine + Carboplatin treatment, provided they meet the eligibility criteria.~Participants who progressed on 2L/3L treatment, may have the option of receiving Atezolizumab + RO6958688, Atezolizumab + Docetaxel or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria."
88911003|NCT03337698|Experimental|Stage 1: Cohort 1: Atezolizumab + RO6958688|"Participants in the Atezolizumab + RO6958688 arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.~Participants who progressed on 1L treatment, may have the option of receiving Atezolizumab + Pemetrexed + Carboplatin or Atezolizumab + Gemcitabine + Carboplatin treatment, provided they meet the eligibility criteria.~Participants who progressed on 2L/3L treatment, may have the option of receiving Atezolizumab + Docetaxel treatment or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria."
88911004|NCT03337698|Active Comparator|Stage 1: Cohort 2: Docetaxel|"Participants in the Docetaxel arm will receive treatment (cycle length 21 days) until unacceptable toxicity or disease progression.~Participants who progressed on treatment may have the option of receiving Atezolizumab + RO6958688 or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria."
88911005|NCT03337698|Experimental|Stage 1: Cohort 2: Atezolizumab + Cobimetinib|"Participants in the Atezolizumab + Cobimetinib arm will receive treatment (cycle length 28 days) until unacceptable toxicity or loss of clinical benefit.~Participants who progressed on treatment, may have the option of receiving Atezolizumab + Pemetrexed + Carboplatin, Atezolizumab + Gemcitabine + Carboplatin, Atezolizumab + RO6958688, Atezolizumab + Docetaxel or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria."
88911006|NCT03337698|Experimental|Stage 1: Cohort 2: Atezolizumab + CPI-444|"Participants in the Atezolizumab + CPI-444 arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.~Participants who progressed on treatment, may have the option of receiving Atezolizumab + RO6958688, Atezolizumab + Docetaxel or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria."
88911007|NCT03337698|Experimental|Stage 1: Cohort 2: Atezolizumab + RO6958688|"Participants in the Atezolizumab + RO6958688 arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.~Participants who progressed on treatment, may have the option of receiving Atezolizumab + Pemetrexed + Carboplatin, Atezolizumab + Gemcitabine + Carboplatin, Atezolizumab + Docetaxel or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria."
89431607|NCT02099331|Experimental|Melatonin|The investigators will administer melatonin at 40mg by mouth (two 20 mg tablets), nightly prior to sleep. The administration will start 2 days prior to the scheduled surgery date and will continue until post-operative day 3.
89008604|NCT04587544|Experimental|Cold Water Immersion|The participants maintained their daily activities during the intervention. When daily activity ended, the intervention was begun. CWI therapy by immersed the whole part of inflamed target joints in the water at 20-30C for 20 minutes/day. The intervention was continued for four weeks. The researchers work together with the nurses of community health services to give the intervention.
89008605|NCT04587544|No Intervention|No Intervention|The participants would not receive Cold Water Intervention. However, they are allowed to received the usual care
89008606|NCT00249756|Experimental|Re-entry Modified Therapeutic Community (Re-entry MTC)|
89008607|NCT00249756|Active Comparator|Parole Supervision and Case Management|
89008608|NCT04587349|Active Comparator|Exercise+FU 2/week|Post stroke group that received 2 years of intensive therapy. (2/week)
89431608|NCT02099331|Placebo Comparator|Placebo|The investigators will administer matching Placebo by mouth (two tablets to match Melatonin), nightly prior to sleep. The administration will start 2 days prior to the scheduled surgery date and will continue until post-operative day 3.
89431609|NCT02250105|Active Comparator|ARI-3037MO|ARI-3037MO 3g bid orally for 12 weeks
89431610|NCT02250105|Placebo Comparator|Placebo|Matching placebo 3g bid orally for 12 weeks
89431611|NCT02099409|Experimental|Starting with FLORENCED2 followed by open loop|Start 2 Overnight periods with closed loop through FLORENCED2 Device , followed by 2 overnight periods with open loop.
89431612|NCT02099409|Experimental|Start open loop followed by FLORENCED2|Start with 2 overnight periods with open loop , followed by 2 overnight with closed loop FLORENCED2
89431613|NCT03418454||Oral Squamous Cell Carcinoma|Buccal mucosa samples for Extraction of BACTERIAL DNA
89008609|NCT04587349|Active Comparator|Exercise+FU 3/week|Post stroke group that received 2 years of intensive therapy. (3/week)
89008610|NCT04587349|Active Comparator|physiotherapy|Post stroke group that received 2 years of traditional physiotherapy. (3/week)
89008611|NCT04587349|No Intervention|Exercise+FU - controll|He did not receive treatment after 4 weeks of intensive care. it functions only as a control group.
89008612|NCT04586998|Experimental|"Exhaled drug monitor Edmon"|Comparison between propofol in exhaled breath and blood plasma
89431614|NCT03418454||Oral Epithelial Dysplasia|Buccal mucosa samples for Extraction of BACTERIAL DNA
89431615|NCT03418454||Control: Healthy age matched patients|Buccal mucosa samples for Extraction of BACTERIAL DNA
89431616|NCT03418454||Osteonecrosis of the Jaw|Buccal mucosa samples for Extraction of BACTERIAL DNA
89431617|NCT03418454||Underlying disease, no necrosis of the jaw|Buccal mucosa samples for Extraction of BACTERIAL DNA
89431618|NCT05328388|Experimental|Lycomato|Lycomato soft gel
89008613|NCT00253734|Active Comparator|4|31 subjects to receive 15 mcg of TIV administered intramuscularly.
89008614|NCT00253734|Experimental|2|31 subjects to receive 6 mcg of TIV administered intradermally.
89008615|NCT00253734|Experimental|1|31 subjects to receive 9 mcg of TIV administered intradermally.
89008616|NCT00253734|Experimental|3|31 subjects to receive 3 mcg of TIV administered intradermally.
89008617|NCT00253734|Active Comparator|5|31 subjects to receive 9 mcg of TIV administered intramuscularly.
89008618|NCT00253734|Active Comparator|7|31 subjects to receive 3 mcg of TIV administered intramuscularly.
89008619|NCT00253734|Active Comparator|6|31 subjects to receive 6 mcg of TIV administered intramuscularly.
89008620|NCT04587115|Placebo Comparator|Oxycodone|This arm will be considered the control arm, containing oxycodone as the placebo.
89008621|NCT04587115|Experimental|Oxycodone and Risperidone|Administration of oxycodone plus risperidone in a single capsule
89008622|NCT04587115|Experimental|Oxycodone and Ziprasidone|Administration of oxycodone and risperidone in a single capsule
89008623|NCT00403247|Experimental|A|vitamin capsule
89008624|NCT00403247|Placebo Comparator|B|placebo capsule
89008625|NCT04587037|Experimental|Fascia lata group|
89008626|NCT04587037|Experimental|Dermal allograft group|
89008627|NCT04586725|Active Comparator|Encouragement every minute|Patients will be randomised to six tests at one week apart
89008628|NCT04586725|Active Comparator|Encouragement every two minutes|Patients will be randomised to six tests at one week apart
89008629|NCT00403286|Experimental|C 10/1|
89008630|NCT00403286|Experimental|C 5/2|
89008631|NCT00403286|Experimental|C 5/1|
89008632|NCT00403286|Experimental|FP 1000|
89008633|NCT00403286|Experimental|FF 20|
89008634|NCT00403286|Active Comparator|AD 250/50|
89008635|NCT00403286|Placebo Comparator|Plc|
89008636|NCT00403286|Experimental|C 10/2|
89431619|NCT02099487|Experimental|Radiation|To evaluate safety and feasibility of hypofractionated Intensity Modulated Radiotherapy
89431620|NCT03424382||Phase I|Participants will complete an intake form and assessment tool survey on an electronic device provided by research staff in their hospital room. If an individual is unable to complete the instrument, he or she may have another individual enter his or her answers on the electronic device.
89431621|NCT03424382||Phase II|Participants will complete an intake form and assessment tool survey on an electronic device provided by research staff in their hospital room. If an individual is unable to complete the instrument, he or she may have another individual enter his or her answers on the electronic device.
89431622|NCT02096991|Active Comparator|Glass|consume beverage in glass first and cross over to other interventions
89431623|NCT02096991|Experimental|Can 1|consume one canned beverage and a glass bottled beverage first and cross over to other interventions
89431624|NCT02096991|Experimental|Can 2|Consume two canned beverage first and cross over to other interventions
89431625|NCT04788160|Experimental|Cervical SNAGs along with conventional therapy|patient will receive Cervical SNAGs along with conventional therapy (Group A)
89431626|NCT04788160|Other|Conventional Therapy|patient will receive only conventional therapy (Group B)
89431627|NCT02097069|Other|Subgroup A|folic acid 400 mcg/day
89431628|NCT02097069|Experimental|Subgroup B|myo-inositol 2000 mg twice a day
89431629|NCT02097069|Experimental|Subgroup C|D-chiro-inositol 250 mg twice a day
89431630|NCT02097069|Experimental|Subgroup D|Myo-inositol plus D-chiro inositol 550mg/13,8 mg twice a day
89536231|NCT05713097||ATD withdrawal|"ATD treatment was decided to be stopped at the discretion of the attending physician. Then, patients were followed after ATD withdrawal to determine who would have relapse of GD.~Finally, patients were divided into 2 groups: Relapse and No relapse"
88911008|NCT03337698|Experimental|Stage 1: Cohort 2: Atezolizumab + Ipatasertib|"Participants in the Atezolizumab + Ipatasertib arm will receive treatment (cycle length 28 days) until unacceptable toxicity or loss of clinical benefit.~Participants who progressed on treatment, may have the option of receiving Atezolizumab + Docetaxel treatment or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria."
88911009|NCT03337698|Experimental|Stage 1: Cohort 2: Atezolizumab + Docetaxel|"Participants in Atezolizumab + Docetaxel arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.~Participants who progressed on treatment, may have the option of receiving Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria."
88911010|NCT03337698|Experimental|Stage 1: Cohort 2: Atezolizumab + Bevacizumab|"Participants in Atezolizumab + Bevacizumab arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.~Participants who progressed on treatment, may have the option of receiving Atezolizumab + Docetaxel or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria."
88911011|NCT03337698|Experimental|Stage 2: Cohort 1: Atezolizumab + Pemetrexed + Carboplatin|Participants in the Atezolizumab + Pemetrexed + Carboplatin arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
88911012|NCT03337698|Experimental|Stage 2: Cohort 1: Atezolizumab + Gemcitabine + Carboplatin|Participants in the Atezolizumab + Gemcitabine + Carboplatin arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
88911013|NCT03337698|Experimental|Stage 2: Cohort 2: Atezolizumab + RO6958688|Participants in the Atezolizumab + RO6958688 arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
88911014|NCT03337698|Experimental|Stage 2: Cohort 2: Atezolizumab + Docetaxel|"Participants in the Atezolizumab + Docetaxel arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.~Participants who have received treatment with Atezolizumab + Docetaxel in Stage 1 will not receive this treatment in Stage 2."
88911015|NCT03337698|Experimental|Stage 2: Cohort 2: Atezolizumab + Linagliptin|Participants in the Atezolizumab + Linagliptin arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
88911016|NCT03337698|Experimental|Stage 1: Cohort 2: Atezolizumab + Sacituzumab Govitecan|Participants in the Atezolizumab + Sacituzumab Govitecan arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
88911017|NCT03337698|Experimental|Stage 1: Cohort 2: Atezolizumab + Bevacizumab + Radiotherapy|Participants in the Atezolizumab + Bevacizumab + Radioatherapy arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
88911018|NCT03337698|Experimental|Stage 1: Cohort 2: Atezolizumab + Evolocumab|Participants in the Atezolizumab + Evolocumab arm will receive treatment (cycle length 28 days) until unacceptable toxicity or loss of clinical benefit.
88911019|NCT03337698|Active Comparator|Stage 1: Cohort 1: Atezolizumab + Tiragolumab|Participants in the Atezolizumab + Tiragolumab arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
88911020|NCT03337698|Experimental|Stage 1: Cohort 1: Atezolizumab + Tiragolumab + XL092 (Zanzalintinib)|Participants in the Atezolizumab + Tiragolumab + XL092 arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
88911021|NCT03337698|Experimental|Stage 1: Cohort 2: Atezolizumab + Camonsertib|Participants in the Atezolizumab + Camonsertib arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
88911022|NCT03337698|Experimental|Stage 1: Cohort 2: Atezolizumab + Bevacizumab + Camonsertib|Participants in the Atezolizumab + Bevacizumab + Comonsertib arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
88911023|NCT03337698|Experimental|Stage 1: Cohort 2: Atezolizumab + Bevacizumab + Tiragolumab|Participants in the Atezolizumab + Bevacizumab + Tiragolumab arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
88911024|NCT03332797|Experimental|Dose Escalation: GDC-9545|During dose escalation, postmenopausal participants will be assigned sequentially to escalating doses of GDC-9545, up to the maximum tolerated dose (MTD) or maximum administered dose (MAD).
88911025|NCT03332797|Experimental|Dose Escalation: Cohort B0: GDC-9545 + Palbociclib|GDC-9545 will be administered to postmenopausal participants, at a dose lower than the MTD or MAD determined in single-agent dose escalation, in combination with the label-recommended dose of palbociclib.
89536232|NCT05713097||No ATD withdrawal|Patients treated with ATD still the end of the study
89536233|NCT03198481|Active Comparator|Patient-Centered Counseling Video Group|MUS video utilizing a patient mentor.
88911026|NCT03332797|Experimental|Dose Expansion: Cohort A1: GDC-9545 Dose 1|GDC-9545 will be administered to postmenopausal participants as a single-agent at a dose that is less than or equal to the MTD/MAD (Dose 1).
88911027|NCT03332797|Experimental|Dose Expansion: Cohort A2: GDC-9545 Dose 1 + LHRH|GDC-9545 will be administered to pre- or perimenopausal participants at a dose that is less than or equal to the MTD/MAD (Dose 1) in combination with an approved LHRH agonist.
88911028|NCT03332797|Experimental|Dose Expansion: Cohort A3: GDC-9545 Dose 2|GDC-9545 will be administered to postmenopausal participants as a single-agent at a dose that is less than or equal to the MTD/MAD (Dose 2).
88911029|NCT03332797|Experimental|Dose Expansion: Cohort A4: GDC-9545 Dose 2 + LHRH|GDC-9545 will be administered to pre- or perimenopausal participants at a dose that is less than or equal to the MTD/MAD (Dose 2) in combination with an LHRH agonist.
88911030|NCT03332797|Experimental|Dose Expansion: Cohort A5: GDC-9545 Dose 3|GDC-9545 will be administered to postmenopausal participants as a single-agent at a dose that is less than or equal to the MTD/MAD (Dose 3).
88911031|NCT03332797|Experimental|Dose Expansion: Cohort B1: GDC-9545 + Palbociclib|GDC-9545 will be administered to postmenopausal participants, at a dose that is less than or equal to the MTD/MAD, in combination with the label-recommended dose of palbociclib.
89536234|NCT03198481|Active Comparator|Physician Counseling Video Group|MUS video by a physician.
89536235|NCT05713019|Placebo Comparator|Effect of saline|Saline will be inhaled from a nebuliser
89008637|NCT04586803|Experimental|A|Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.
89536236|NCT05713019|Active Comparator|Effect of ATP|ATP solution will be inhaled from a nebuliser
89536237|NCT04990089||VIVO|Patients in which VIVO is used.
89536238|NCT03198403|Experimental|Popliteal plexus block|Patients with an FTB, reporting postoperative pain (NRS > 3) will have a popliteal plexus block
89008638|NCT04586803|Experimental|B|Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.
89008639|NCT04586803|Experimental|C|Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.
89008640|NCT04586803|Experimental|D|Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.
89008641|NCT04586803|Experimental|E|Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.
89008642|NCT04586803|Experimental|F|Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.
89008643|NCT04586608|Active Comparator|active comparator|
89008644|NCT04586608|Other|soybean oil-based IVFE|soybean oil-based IVFE
89008645|NCT04586491|Experimental|Study group/ Oral care protocol with saline solution|All patients took oral care protocol in the unit with saline solution
89008646|NCT04586491|Experimental|Control group/ Oral care protocol with sodium bicarbonate solution|All patients took oral care protocol in the unit with sodium bicarbonate solution
89008647|NCT04719429|Experimental|Cricket-derived protein beverage|Ingestion of a cricket-derived protein beverage
89008648|NCT04719429|Experimental|Beef-derived protein beverage|Ingestion of a beef-derived protein beverage
89008649|NCT04586218|Active Comparator|Manual control of vasopressor infusion|"Vasopressor will be manually titrated by intensive care unit nurses in charge of the patients to maintain mean arterial pressure > 65 mmHg.~Fluid administration consists in optimization of stroke volume (assisted fluid management) during the postoperative period"
89008650|NCT04586218|Experimental|Computer guided vasopressor infusion|"Vasopressor will be titrated automatically by the closed-loop system to maintain mean arterial pressure > 65 mmHg.~Fluid administration consists in optimization of stroke volume (assisted fluid management) during the postoperative period"
89536239|NCT03198403|No Intervention|No intervention|Patients with postoperative pain NRS < or = 3
89008651|NCT04586374||Control Group|Transported patients with full monitoring (including an arterial line), without inotropic/vasoactive support.
89008652|NCT04586374||Study Group|Transported patients with full monitoring and vasoactive/inotropic support being delivered by a syringe driver.
89008653|NCT04585867|Active Comparator|Liposomal bupivacaine|Exparel (266mg) given by surgeon just prior to sternal closure
89008654|NCT04585867|Active Comparator|Bupivacaine|40ml of 0.125% bupivacaine given by surgeon just prior to sternal closure
89008655|NCT04585828|Experimental|Bili Cocoon|The infants will be treated with phototherapy using a double sided fiber optic pad called Bili Cocoon with an irradiance of 30 uW/cm2/nm from both sides.
89008656|NCT04585828|Active Comparator|Conventional blue light|The infants will be treated with blue light from above at 30 Uw/cm2/nm which is the standard treatment.
89008657|NCT04585672|Other|Healthy and Cirrhosis|Ammonia infusion with and without ammonia targeting
89008658|NCT04585555||Accuryn Monitoring System|Observational only (no intervention). Patients undergoing cardiovascular surgical intervention(s) monitored with the Accuryn Monitoring System (per standard of care) during their hospital stay.
89008659|NCT04585282|Experimental|intervention group|The study group was treated with intensive cognitive behavioral therapy for insomnia.
89008660|NCT04585282|Active Comparator|control group|The control group was treated with traditional cognitive behavioral therapy for insomnia.
89008661|NCT00249912|Experimental|Lapaquistat Acetate 50 mg QD + Rosuvastatin|
89008662|NCT00249912|Experimental|Lapaquistat Acetate 100 mg QD + Rosuvastatin|
89008663|NCT00249912|Active Comparator|Rosuvastatin|
89536240|NCT03314441|Experimental|Yoga|Patients receiving Yoga lessons for 3 months
89008664|NCT04585438|Experimental|Single trans-mucosal bio-adhesive disc containing Diclofenac Potassium|Premedication 1 hour before starting endodontic treatment.
89536241|NCT03198793|Experimental|QGC001|Capsules of QGC001 250 mg
89536242|NCT04990245||patients with ulcerative colitis|patients with ulcerative colitis and planned endoscopy as part of routine care
89536243|NCT03198949|Experimental|everolimus first arm|All subjects will receive everolimus during Core phase I and placebo during Core phase II.
89431631|NCT05294770|Experimental|Very Low Calorie Diet (VLCD)|Patients randomized to this group will receive a VLCD, which consists of a replacement diet based on a liquid enteral formula (46% carbohydrates, 19% fat and 32% protein; 654 Kcal/day): OPTISOURCE® PLUS, taken as 3 shakes a day. In addition, participants may consume 2 pieces of fruit/day (about 250 g/day) and up to 300 g/day of non-starchy vegetables according to the list of foods that will be provided to patients; this will constitute a total daily energy intake of about 800 Kcal. In addition, protein intake (0.8 to 1.3 g/kg/day of adjusted weight) will be adjusted by adding Resource® Instant Protein individually, depending on the anthropometry and the renal function of the patients (to preserve fat free mass, whose loss has been correlated with subsequent weight recovery)
89431632|NCT05294770|Active Comparator|Hypocaloric Mediterranean diet|Randomized participants in this group will be recommended to follow a Mediterranean Diet, based on the use of olive oil as the main source of visible fat and regular consumption of vegetables (≥2 servings/day), fruits (≥3 servings/day), legumes (≥3 servings/week) and fish (≥3 times a week), reducing the consumption of red meat or sausages (<2 times a week) and eliminating the consumption of sugary drinks, pastries or industrial pastries. In this Mediterranean Diet, an energy restriction of 30% of the estimated energy needs (Harris-Benedict equation) will be established.
89431633|NCT03424226|Experimental|day of acetazolamide|acetazolamide 125mg twice a day, started morning of ascent
89431634|NCT03424226|Active Comparator|night before acetazolamide|acetazolamide 125mg twice a day, started evening before ascent
88911032|NCT03332797|Experimental|Dose Expansion: Cohort B2: GDC-9545 + Palbociclib + LHRH|GDC-9545 will be administered to pre- or perimenopausal participants, at a dose that is less than or equal to the MTD/MAD, in combination with the label-recommended dose of palbociclib and an approved LHRH agonist.
89431635|NCT03555513||living kidney transplanted patients|Any patients over 18 who received kidney transplantation from living donor
89431636|NCT04353856||twin pregnancy|Women followed for a twin pregnancy
89431637|NCT03416036|Experimental|Arm 1: TV003 + rDEN2Δ30-7169|Participants will receive a single dose of TV003 at study entry (Day 0) and rDEN2Δ30-7169 on Day 28.
89431638|NCT03416036|Experimental|Arm 2: TV003 + rDEN3Δ30|Participants will receive a single dose of TV003 at study entry (Day 0) and rDEN3Δ30 on Day 28.
89431639|NCT03416036|Placebo Comparator|Arm 3: Placebo + rDEN2Δ30-7169|Participants will receive placebo at study entry (Day 0) and rDEN2Δ30-7169 on Day 28.
89431640|NCT03416036|Placebo Comparator|Arm 4: Placebo + rDEN3Δ30|Participants will receive placebo at study entry (Day 0) and rDEN3Δ30 on Day 28.
89431641|NCT02250729|Experimental|cases with NMBA anaphylaxis|Patients who experienced NMBA anaphylaxis during anesthesia
89431642|NCT02250729|Other|controls|Patients who underwent anesthesia with NMBA injection but did not experience anaphylaxis
88911033|NCT03332797|Experimental|Dose Expansion: Cohort C1: GDC-9545 Dose 2 +/- Palbociclib|GDC-9545 will be administered to postmenopausal participants at a pre-defined dose level (Dose 2) as a single agent for 14 days, followed by treatment with either GDC-9545 (Dose 2) plus palbociclib or GDC-9545 (Dose 2) alone for the duration of the study, as determined by the investigator.
88911034|NCT03332797|Experimental|Dose Expansion: Cohort C2: GDC-9545 Dose 2 + Palbociclib|GDC-9545 will be administered to postmenopausal participants at a pre-defined dose level (Dose 2), in combination with the label-recommended dose of palbociclib.
89431643|NCT04788472|Experimental|CAR-T therapy|Administration of CD19 and CD22 CAR T-cells
89431644|NCT04788082|No Intervention|Control|Standard of care (not involving 3D printing)
88911035|NCT03332797|Experimental|Dose Expansion: Cohort X: GDC-9545 Dose 3|GDC-9545 will be administered at a pre-defined dose level (Dose 3) to postmenopausal participants currently receiving clinical benefit with GDC-0927 or GDC-0810 on Studies GO29656 (NCT02316509) or GO29642 (NCT01823835), respectively, upon completion of their studies.
89431645|NCT04788082|Experimental|3D Model|3D printed models (at least one rigid blood volume model and one flexible shell model) will be used for surgical planning.
89431646|NCT02099565||OPTIMA study patients|The study population will consist of OPTIMA study patients who have not been lost for follow-up and have given a written informed consent.
89431647|NCT03424070|Active Comparator|Laryngoscopy view with a shoulder roll|The primary outcome is the difference in the height of the lateral canthus of the eyelid of the laryngoscopist above the OR table during laryngoscopy with and then without the shoulder roll. These two positions will be compared using photos of the best glottic view taken during laryngoscopy with a shoulder roll in place. Then a photo of the best glottic view will be taken during laryngoscopy without the shoulder roll in place. These two views will be compared by a blinded anesthesiologist using the POGO scale.
89536244|NCT03198949|Placebo Comparator|placebo first arm|All subjects will receive placebo during Core phase I and everolimus during Core phase II.
89536245|NCT04990011|Experimental|BioXclude amnion chorion membrane|
89536246|NCT02447809|Experimental|Regular DAPT(IPA≤60%)|ASA and Clopidogrel
89536247|NCT02447809|Active Comparator|Regular DAPT(IPA>60%)|ASA and Clopidogrel
89536248|NCT04989933|Active Comparator|ESP 20 ml|Ultrasound-Guided erector spinae plane block with 20 ml of 0.25% bupivacaine
89536249|NCT04989933|Active Comparator|ESP 30 ml|Ultrasound-Guided erector spinae plane block with 30 ml of 0.25% bupivacaine
88911036|NCT03329365||ESUS/ETUS|Patients with embolic ischemic stroke or transient ischemic attack of undetermined source
89536250|NCT04989855|Experimental|Fruquintinib plus Tislelizumab|Fruquintinib 5mg QD d1-d14, Q3W; Tislelizumab 200mg IV Q3W d1
89431648|NCT03424070|Placebo Comparator|Laryngoscopy without a shoulder roll|The primary outcome is the difference in the height of the lateral canthus of the eyelid of the laryngoscopist above the OR table during laryngoscopy without and then with the shoulder roll. These two positions will be compared using photos of the best glottic view taken during laryngoscopy with a shoulder roll in place. Then a photo of the best glottic view will be taken during laryngoscopy without the shoulder roll in place. These two views will be compared by a blinded anesthesiologist using the POGO scale.
89431649|NCT02097147|Experimental|Vilazodone 20 mg|Vilazodone 10 mg once daily for 7 days, followed by vilazodone 20 mg once daily for 28 days.
89431650|NCT02097147|Experimental|Vilazodone 40 mg|Vilazodone 10 mg once daily for 7 days, followed by vilazodone 20 mg once daily for 7 days, followed by vilazodone 40 mg once daily for 21 days
89431651|NCT02097147|Active Comparator|Paroxetine 20 mg|Paroxetine 10 mg once daily for 7 days, followed by paroxetine 20 mg for 28 days
89431652|NCT02097147|Placebo Comparator|Placebo|Placebo once daily for 35 days
89431653|NCT03415958||Open reduction internal fixation|Patients with displaced midshaft clavicle fractures will be offered operative treatment which involves open reduction and internal fixation.
89431654|NCT03415958||Conservative care|Patients will be treated in a sling for the acute phase of two weeks with progressive physiotherapy.
89431655|NCT02094105|Experimental|screening|endoscopy examination with iodine staining
89431656|NCT02094105|No Intervention|control|1/10 sampling questionnaire interview for control group.
89431657|NCT03423992|Experimental|Biological: Chimeric antigen receptor T cells|
89431658|NCT03423914|Experimental|Writing Intervention Group|Expressive writing The participant will write four days about her deepest thoughts and feelings in relation to the experience of hospitalization of the premature newborn and how this experience is related to your current life and to your future.
89431659|NCT03423914|Active Comparator|Control Group|Only Writing The participants will write about situations not related to the subjective human experience of their preterm birth, but about general aspects.
89431660|NCT05425095|Experimental|Buteyko Breathing Technique|Group A
89431661|NCT05425095|Experimental|Corpse-Pose Technique|Group B
89431662|NCT03418298|Experimental|Prehabilitation group|Subjects will carry out a preoperative internet-based program including aerobic and resistance training three sessions per week
89431663|NCT03418220|Other|AMD early / intermediate|A blood and aqueous humor sample will be taken during cataract surgery in patients with AMD early / intermediate
89536251|NCT04987125|Experimental|Dyspnea Neuroscience education|
89431664|NCT03418220|Other|AMD exudative|A blood and aqueous humor sample will be taken during cataract surgery in patients with AMD exudative
89431665|NCT03418220|Other|AMD atrophic|A blood and aqueous humor sample will be taken during cataract surgery in patients with AMD atrophic
89431666|NCT03418220|Other|control group|A blood and aqueous humor sample will be taken during cataract surgery in patients with cataract (control group)
89431667|NCT02633150|Experimental|Polyphenol|red grapes polyphenol supplementation on metabolic parameters in obese insulinoresistant subjects
89431668|NCT02633150|Placebo Comparator|Placebo|Placebo supplementation on metabolic parameters in obese insulinoresistant subjects
89431669|NCT03415802|Experimental|Nab-paclitaxel Plus S-1|Nab-paclitaxel 120 mg/m2 (D1, D8, q3w) S-1 (40mg BID for body surface area<1.25 m2; 50mg BID for body surface area of 1.25-1.5m2; and 60mg BID for body surface area>1.5 m2; D1-14, q3w)
89431670|NCT02094183|Experimental|GLP-1|GLP-1 and low calorie diet
89431671|NCT02094183|Experimental|Control|low calorie diet
89431672|NCT03127202|Experimental|Cardiac Resynchronization Therapy-Defibrillator|Eligible patients were implanted with a Cardiac Resynchronization Therapy -Defibrillator
89431673|NCT02099877||Nulliparous requesting epidural|"Nulliparous parturients ≥ 37 weeks gestation, with ASA I or II, with an uncomplicated course of singleton vertex pregnancy requesting epidural analgesia for pain relief will be included.~When the patient requests analgesia, cervical dilatation will be verified by the obstetric resident/attending. Then epidural analgesia will be initiated with a test dose of 3mL of 2% lidocaine and epinephrine 15 µg and a dose of fentanyl 100 µg diluted to a total volume of 10 mL with preservative- free normal saline. Before placement of the epidural, venous blood (2 mL) will be drawn into special tubes. Genotyping of OPRM1: p.118A/G will be also performed."
89431674|NCT02097381|Other|naïve for cART that met the criteria to start treatment|"patients naïve for antiretroviral treatment that met the criteria to start cART according to International Guidelines.~These patients will be studied for primary and secondary outcomes after a short term antiretroviral therapy."
89431675|NCT03418142|Experimental|Priovi|Priovi is an Internet-administered intervention for people with BPD.
89536252|NCT04987125|Active Comparator|Usual care|
89431676|NCT03418142|Active Comparator|Care-as-Usual (CAU) / wait list|Additionaly, they will be informed about helpful and free available online self-help-proposals for BPD patients immediately after randomization.
89431677|NCT03127280|No Intervention|Conventional Foley Care|Following surgery, the patient's Foley catheter is removed on the morning of post-operative day one.
89431678|NCT03127280|Experimental|Fast Tract Foley care|Following surgery, the patient's Foley catheter is removed on post-operative day zero, four hours after the completion of surgery.
89431679|NCT02099955|No Intervention|Screening Study|To determine the prevalence and severity of vitamin D deficiency and glucose tolerance in persons with chronic SCI.
89431680|NCT02099955|Experimental|Pulmonary Arm|"Vitamin D3 Supplementation and Pulmonary Function:~To determine the relationship between levels of vitamin D and overall pulmonary function, as measured by PFTs (spirometry and body plethysmography).~To determine effects of vitamin D supplementations on overall pulmonary function and selected biomarkers of inflammation (FeNO, pH, 8- isoprostane levels)."
89431681|NCT02099955|Experimental|Endocrine Arm|"Vitamin D3 Supplementation and Endocrine Function:~To determine the effect of vitamin D replacement therapy on carbohydrate metabolism and insulin resistance in persons with vitamin D deficiency (<20ng/ml) and IGT, mild DM (e.g. fasting serum glucose <140 mg/dL) and/or IR."
89431682|NCT02097459|Experimental|Failed group|Patients who have recurrence of menstruation after changing endocrine therapy to anastrozole and then go back to the original SERMs therapy.
89431683|NCT02097459|Experimental|Succeeded group|Patients who have no recurrence of menstruation after changing endocrine therapy and then go on with anastrozole therapy.
89431684|NCT02097459|Active Comparator|No chang group|Patients who don't change the endocrine therapy and go on with the original tamoxifen or toremifene therapy.
89431685|NCT02343302|Other|Soft Pancreatic Gland|This arm will be patients with glands felt to have a soft texture during surgery. This arm will receive either a suction drain or a gravity drain based on the note inside the sealed envelope.
88911037|NCT03329365||SSS-CVTUS|Patients with superior sagittal sinus cerebral venous thrombosis of undetermined source
88911040|NCT03320733|Experimental|Surgical|"Includes patients who will undergo surgery for their pancreatic cysts.~In addition to the routine pre-operative CT abdomen performed for surgical planning purposes, these patients will receive Dual Energy CT scan with subtraction imaging before surgery."
88911041|NCT03320733|Experimental|Surveillance|"Includes patients who are undergoing surveillance for their pancreatic cysts.~Dual Energy CT scan with subtraction imaging will be performed in addition to the standard-of-care surveillance method of MRI scans."
88911042|NCT03312751|Experimental|Emapalumab|
88911043|NCT03311828|Experimental|Diagnostic (Copper 64Cu-DOTA-daratumumab, PET)|Patients receive daratumumab IV over 10-45 minutes, and within 6 hours, patients receive copper 64Cu-DOTA-daratumumab IV on day 0. Patients undergo PET on days 1 and 2.
88911044|NCT03307304||Family members|Unaffected family members of individuals diagnosed with CLN3-Batten
88911045|NCT03307304||Proband/Affected Individuals|Individuals diagnosed with CLN3-Batten
88911046|NCT03304054|Experimental|amifamapridine phosphate tablets|
88911047|NCT03304054|Placebo Comparator|placebo tablets|
88911048|NCT03297112|Experimental|contrast-enhanced subharmonic ultrasound imaging|Patients receive perflutren lipid microspheres IV. After 15 minutes, patients receive perflutren lipid microspheres IV again over 5 minutes and undergo contrast-enhanced subharmonic ultrasound imaging over 60 minutes.
88911049|NCT03295175||Congenital Megaprepuce|Congenital Megaprepuce Hematoxylin-eosin and smooth muscle actin markers
88911050|NCT03295175||Hypospadias|Hypospadias Hematoxylin-eosin and smooth muscle actin markers
88911051|NCT03295175||Control|Circumcision for non-medical reasons. Hematoxylin-eosin and smooth muscle actin markers
88911052|NCT03280563|Active Comparator|Stage 1: Fulvestrant|Participants will receive fulvestrant until unacceptable toxicity or disease progression according to RECIST v1.1.
89008665|NCT04585438|Placebo Comparator|Placebo Control|Premedication 1 hour before starting endodontic treatment. Identically-appearing trans-mucosal bio-adhesive disc (Does not contain medication)
89008666|NCT00567853|Other|MEMO 3D ring|All patients in the study will be implanted with the MEMO 3D ring
89008667|NCT00567931|Experimental|Treatment (Immunomodulating therapy)|Patients receive oral 1-methyl-d-tryptophan (1-MT) once or twice daily on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
89008668|NCT04585516||Patient with suspected colorectal cancer|All patients that were admitted to the department of surgery with suspected colorectal cancer between January 2016 and December 2018 (n=459).
89008669|NCT04585516||Patients admitted according to the standardized course of care for colorectal cancer|All patients that were admitted to the endoscopy department according to the standardized course of care for colorectal cancer between September 2016 and December 2018 (n=1271).
89431686|NCT02343302|Other|Hard Pancreatic Gland|This arm will include patients felt to have a hard gland tecture at the time of surgery. This arm will receive either a suction drain or a gravity drain based on the note inside the sealed envelope.
89008670|NCT04585516||Patients < 50 years that were admitted for gastroscopy|All patients younger than 50 years that were admitted to the endoscopy department for a gastroscopy between jan 2018 and April 2019 (n= 1915)
89008671|NCT04585516||Patients >80 years that were admitted for colonoscopy|All patients older than 80 years that were admitted to the endoscopy department for a colonoscopy between Sept 2016 and Jan 2019 (n= 981)
89008672|NCT04585321|Other|T-R|"Part 1 (QD) and part 2 (BID):~Period 1: Test drug (T): Diclofenac Sodium 140mg Medicated Plaster EQI7, topical plaster.~Period 2: Reference drug (R): Flector® topical plaster containing 180 mg of diclofenac hydroxyethylpyrrolidine equivalent to 140 mg of sodium diclofenac."
89431687|NCT02097615|Experimental|chlorhexidine gluconate|application every 24 hours, six weeks
89431688|NCT02097615|Other|Other: deionized water|application every 24 hours, six weeks
89008673|NCT04585321|Other|R-T|"Part 1 (QD) and part 2 (BID):~Period 1: Reference drug (R): Flector® topical plaster containing 180 mg of diclofenac hydroxyethylpyrrolidine equivalent to 140 mg of sodium diclofenac.~Period 2: Test drug (T): Diclofenac Sodium 140mg Medicated Plaster EQI7, topical plaster."
89008674|NCT04585360||Patient with Behcet disease|adult patient with Behcet's disease followed regularly in the internal medicine department of Bicetre
89008675|NCT00412997|Experimental|LBH589|
89008676|NCT04585048|No Intervention|waiting list|waiting list
89431689|NCT03423836||High Risk Infants|Motor infants born prior to 35 weeks gestational age, or, infants small (<10th percentile) for gestational age.
89431690|NCT03423836||Low Risk Infants|Motor infants born after the completion of the 37th week of gestation and appropriate for gestational age.
89536253|NCT04492163|Experimental|Experimental: TTFields|Patients receive continuous TTFields treatment using the Optune® System with high intensity transducer arrays.
89008677|NCT04585048|Experimental|treatment|treatment with the Integrated Behavioral Therapy fo Selective Mutism
89008678|NCT04584931|Experimental|Treatment of gingival recession with colored composite|Composite restoration will be applied to the gingival recession defect
89008679|NCT04584931|Active Comparator|Treatment of gingival recession with coronally advanced flap|coronally advanced flap at the gingival defect
89008680|NCT04585126|No Intervention|General anesthesia without intermediate cervical block|General anesthesia performed by the anesthesiologist
89008681|NCT04585126|Active Comparator|General anesthesia with intermediate cervical block|General anesthesia performed by the anesthesiologist associated with an echoguided intermediate cervical block (bilateral in total thyroidectomy, unilateral in partial thyroidectomy) : 10 to 30cc of ropivacaine (2 to 3,75 %)
89008682|NCT00568048|Experimental|Combination Therapy Temozolomide & Bevacizumab|"Combination therapy~Temozolomide 150 mg/m2 p.o., days 1-7, repeated every 14 days~Bevacizumab 10 mg/kg i.v., day 1, repeated every 14 days"
89008683|NCT04584775|Experimental|Traditional Chinese Medicine plus Standard Care|Participants in this group will receive standard Palliative Care and will additionally see a practitioner of Traditional Chinese Medicine. No strict protocol for the actual intervention exists (pragmatic approach). The participants will at least receive acupuncture and/or chinese herbal medicine. The standard care will include any established medical intervention according to currently available guidelines in palliative care.
89008684|NCT04584775|Other|Standard Care|The standard care will include any established medical intervention according to currently available guidelines in palliative care.
89008685|NCT00568165|Experimental|1|Mobile Team
89008686|NCT00568165|Active Comparator|2|Standard care
89008687|NCT04584580|Active Comparator|Therapeutic dose low-molecular-weight heparin (LMWH)|Therapeutic dose low-molecular-weight heparin from admission until the end of hospital stay Enoxaparin 1 mg/kg subcutaneous every 12 hours
89008688|NCT04584580|Experimental|D-dimer levels and weight adjusted low-molecular-weight heparin (LMWH)therapy|"from admission until the end of hospital stay. Patients will be stratified according to their body weight and D-dimer level and receive LMWH~D-Dimer level Body Weight LMWH dose~<1 mg/dl <100kg Enoxaparin 40mg OD 100-150kg Enoxaparin 40mg BD >150kg Enoxaparin 60mg BD~1-3 mg/ dl <100kg Enoxaparin 40mg BD 100-150kg Enoxaparin 80mg BD >150kg Enoxaparin 120mg BD~>3 mg/ dl Enoxaparin 80mg BD"
89008689|NCT04584697|Experimental|COVI-AMG|A single injection of 40 mg, 100 mg, or 200 mg of COVI-AMG will be given on Study Day 1. Standard of care will be maintained for all subjects throughout the study.
89008690|NCT04584697|Placebo Comparator|Placebo|A single injection of placebo will be given on Study Day 1. Standard of care will be maintained for all subjects throughout the study.
89008691|NCT04584736|Experimental|Livalo 2mg, Ezetrol 10mg|Pitavastatin 2mg, Ezetimibe 10mg
89008692|NCT04584736|Active Comparator|Livalo 2mg|Pitavastatin 2mg
89008693|NCT04584736|Experimental|Livalo 4mg, Ezetrol 10mg|Pitavastatin 4mg, Ezetimibe 10mg
89008694|NCT04584736|Active Comparator|Livalo 4mg|Pitavastatin 4mg
89008695|NCT04584268|Experimental|mindfulness|3 30 minute in person interventions as well as promotion and involvement of self-guided meditations on the Insight Timer smart phone application
89008696|NCT04584268|Active Comparator|control|standard medical resident education
89008697|NCT04584307|Experimental|Elotuzumab + Pomalidomide|Elotuzumab, 10 mg/kg IV, Days 1,8,15,22 for cycles 1 and 2 Elotuzumab, 20 mg/kg IV, Day 1 for cycles 3 + Pomalidomide 2mg PO, Day 1-21 for all cycles
89008698|NCT04720521|Experimental|OE+white light|Using white light firstly to observe from esophagus to duodenum and then switch OE mode to observe from antrum to esophagus.
89008699|NCT04720521|No Intervention|White light|Using White light to observe from esophagus to duodenum.
89008700|NCT04584034|Active Comparator|Salbutamol|Salbutamol inhalation 4x200ug daily for 7 days, delivered using a Babyhaler
89008701|NCT04584034|Placebo Comparator|Placebo|Placebo 4 x 2 inhalations daily for 7 days, delivered using a Babyhaler
89008702|NCT04584229||question not suitable for study|question not suitable for study
89008703|NCT04584073|Active Comparator|Adenoidectomy|Adenoidectomy
89008704|NCT04584073|Active Comparator|Adenoidectomy and Myringotomy|Adenoidectomy and Myringotomy
89008705|NCT04584073|Active Comparator|Adenoidectomy,Myringotomy and Tympanostomy tube application|Adenoidectomy and Myringotomy and Tympanostomy tube application
89008706|NCT04583722|Other|AX oleoresin|Raw AX oleoresin, 15 mg AX (in 4 pululan capsules)
89008707|NCT04583722|Experimental|AX-olive oil-PP emulsion|Microencapsulated AX (1%:2%:3% (AXO:OO:PP, %w/v ratio) + 0.15% maltodextrin). 15 mg AX (in 4 pululan capsules)
89008708|NCT04583683|Active Comparator|Intensive lifestyle modification: Very low calorie diet|Patients will undergo a very low calorie diet
89008709|NCT04583683|Active Comparator|Metabolic Surgery|Patients will undergo metabolic surgery
89008710|NCT04583605||PREVENA|A vacuum wound closure therapy like PREVENA is applied after axillary or inguinal lymph node dissection in the management of metastatic skin tumors
89008711|NCT04583605||NON PREVENA|A conventional wound closure is applied after axillary or inguinal lymph node dissection in the management of metastatic skin tumors
89008712|NCT04583566||COVID-19 Severe Symptoms|Patients with severe symptoms need oxygen and ventilation.
89431691|NCT02590432|Experimental|LINZESS® 145 μg (CIC, Open Label)|LINZESS® (linaclotide) 145 μg capsules, orally, once daily for up to 52 weeks for participants with CIC. If an intolerable AE occurred participants could be randomized to the Double-blind Treatment Period.
89431692|NCT02590432|Experimental|LINZESS® 290 μg (IBS-C, Open Label)|LINZESS® 290 μg capsules, orally, once daily for up to 52 weeks for participants with IBS-C. If an intolerable AE occurred participants could be randomized to the Double-blind Treatment Period.
89431693|NCT02590432|Experimental|LINZESS® 290 μg (IBS-C, Double Blind)|Following participation in the Open Label Treatment Period, LINZESS® 290 μg capsules, orally, once daily from double-blind randomization up to Week 52 for participants with IBS-C. If an intolerable AE occurred, dose was reduced to Open Label 72 μg, if applicable.
89431694|NCT02590432|Experimental|LINZESS® 145 μg (IBS-C, Double Blind)|Following participation in the Open Label Treatment Period, LINZESS® 145 μg capsules, orally, once daily from double-blind randomization up to Week 52 for participants with IBS-C. If an intolerable AE occurred, dose was reduced to Open Label 72 μg, if applicable.
89431695|NCT02590432|Experimental|LINZESS® 72 μg (IBS-C, Double Blind)|Following participation in the Open Label Treatment Period, LINZESS® 72 μg capsules, orally, once daily from double-blind randomization up to Week 52 for participants with IBS-C. If an intolerable AE occurred, dose was maintained at Open Label 72 μg, if applicable.
89431696|NCT02590432|Experimental|LINZESS® 145 μg (CIC, Double Blind)|Following participation in the Open Label Treatment Period, LINZESS® 145 μg capsules, orally, once daily from double-blind randomization up to Week 52 for participants with CIC. If an intolerable AE occurred, dose was reduced to 72 μg, if applicable.
89431697|NCT02590432|Experimental|LINZESS® 72 μg (CIC, Double Blind)|Following participation in the Open Label Treatment Period, LINZESS® 72 μg capsules, orally, once daily from double-blind randomization up to Week 52 for participants with CIC. If an intolerable AE occurred, dose was maintained at Open Label 72 μg, if applicable.
89008713|NCT04583566||COVID-19 Mild Symptoms|Patients with moderate symptoms, like normal flu symptoms. They do not need oxygen or ventilation
89431698|NCT02590432|Experimental|LINZESS® 72 μg (CIC, Dose-reduced Open Label)|Following participation in the Double-blind Treatment Period, if an intolerable AE occurred, LINZESS® 72 μg capsules, orally, once daily up to Week 52 for participants with CIC.
89431699|NCT02590432|Experimental|LINZESS® 72 μg (IBS-C, Dose-reduced Open Label)|Following participation in the Double-blind Treatment Period, if an intolerable AE occurred, LINZESS® 72 μg capsules, orally, once daily up to Week 52 for participants with IBS-C.
89431700|NCT02094339|Experimental|Local analgesic|This group uses local analgesia infusion pump of 0.2% ropivacaine 360ml through periarticular infiltration for postoperative analgesia.
89431701|NCT02094339|Active Comparator|Nerve Block|People in this group will receive a postoperative pain management by continuous lumbar plexus block with 0.2% ropivacaine.
88911053|NCT03280563|Experimental|Stage 1: Atezolizumab + Entinostat|Participants will receive doublet combination treatment with atezolizumab plus entinostat until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
88911054|NCT03280563|Experimental|Stage 1: Atezolizumab + Fulvestrant|Participants will receive doublet combination treatment with atezolizumab plus fulvestrant until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
88911055|NCT03280563|Experimental|Stage 1: Atezolizumab + Ipatasertib|Participants will receive doublet combination treatment with atezolizumab plus ipatasertib until unacceptable toxicity or loss of clinical benefit as determined by the investigator. Prior to enrollment into this arm, the first 6 participants in the study will complete a safety run-in with atezolizumab plus ipatasertib.
88911056|NCT03280563|Experimental|Stage 1: Atezolizumab + Ipatasertib + Fulvestrant|Participants will receive triplet combination treatment with atezolizumab plus ipatasertib plus fulvestrant until unacceptable toxicity or loss of clinical benefit as determined by the investigator. Prior to enrollment into this arm, the first 6 participants in the study will complete a safety run-in with atezolizumab plus ipatasertib.
88911057|NCT03280563|Experimental|Stage 2: Atezolizumab + Bevacizumab + Endocrine Therapy|Those who progress or experience unacceptable toxicity during treatment in Stage 1 may be eligible to enter Stage 2. Participants will receive triplet combination therapy with atezolizumab plus bevacizumab plus one of three endocrine therapies (fulvestrant, exemestane, or tamoxifen) selected by the physician. Treatment in Stage 2 will continue until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
88911058|NCT03280563|Experimental|Stage 1: Mandatory On-Treatment Biopsy|For experimental combination arms that demonstrate clinical activity during the preliminary phase, the Sponsor may open enrollment into a separate mandatory on-treatment biopsy cohort for that combination.
88911059|NCT03280563|Experimental|Stage 1: Atezolizumab + Abemaciclib + Fulvestrant|Participants will receive triplet combination treatment with atezolizumab plus abemaciclib plus fulvestrant until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
88911060|NCT03259763|Active Comparator|EUS-guided gastroenterostomy (EUS-GE)|In this technique, the gastric wall and its adjacent small intestine are punctured by a needle to make a connection between the stomach and small intestine. Then a lumen-apposing metal stent is deployed at the puncture site to keep the stomach-small intestine connection open.
89431702|NCT02094339|Active Comparator|Intravenous analgesic|This group is treated with intravenous electronic analgesia pump infusion of flurbiprofen axetil 250mg,palonosetron 0.5mg,pentazocine 240mg.dezocine 30mg.
89431703|NCT03415724|Active Comparator|1.8 ml Lignocaine plus adrenaline|The study subjects will receive conventional inferior alveolar nerve block with 1.8 ml of 2% inj lignocaine with adrenaline 1:80000.
89431704|NCT03415724|Active Comparator|3.6 ml Lignocaine plus adrenaline|The study subjects will receive conventional inferior alveolar nerve block with 3.6 ml of 2% inj lignocaine with adrenaline 1:80000.
89431705|NCT03415724|Active Comparator|1.8 ml Lignocaine plus dexmedetomidine|conventional inferior alveolar nerve block with1.8 ml of injection lignocaine plus injection dexmedetomidiene 1micromol/ ml.
89008714|NCT04583566||Control Healthy|Healthy group with out any infection or symptoms.
89008715|NCT04583410|Experimental|Nicotine patch|
89008716|NCT04583410|Placebo Comparator|Placebo patch|
89008717|NCT04583371|No Intervention|GROUP CONTROL|"For basal aspiration, the patient will be placed in the supine position with the head elevated at 30º, will be submitted to a single aspiration with a size 12 probe (Mark Med), with a vacuum adjusted to -40cmH2O of pressure, with basic asepsis care being maintained for performing the technique.~In the control group, patients will be ventilated for 1 minute with 100% inspired oxygen (FiO2), followed by three aspirations for 15 seconds and with an interval of 30 seconds."
89008718|NCT04583371|Active Comparator|INTERVENTION GROUP|"For basal aspiration, the patient will be placed in the supine position with the head elevated at 30º, will be submitted to a single aspiration with a size 12 probe (Mark Med), with a vacuum adjusted to -40cmH2O of pressure, with basic asepsis care being maintained for performing the technique.~In the participants of the intervention group, the calculation of the ideal tidal volume of each patient will be performed, after which they will be positioned in the supine position, the headboard elevated to 30º in assisted pressure-controlled ventilatory mode, increasing 10 cmH2O in inspiratory pressure and in assisted ventilation mode. -controlled by volume, we will increase 50% of the tidal volume for a period of 10 minutes, with Ppeak not exceeding 40 cmH2O and drive pressure not exceeding 15 cmH2O in both ventilation modes, and then a new aspiration in the same way as the control group."
89008719|NCT04583332|Other|Rhymes, Individual Items in Rhymes, Objects|Existing method Post intervention
89008720|NCT04583137|Experimental|Buffered lidocaine|Each participant receives a single intranasal application of atomized 1 mL lidocaine 5% solution combined with bicarbonate 8.4% in a 1:10 ratio.
89008721|NCT04583137|Experimental|Plain lidocaine|Each participant receives a single intranasal application of atomized 1 mL lidocaine 5% solution.
89008722|NCT00223691|Experimental|1: active intervention|atomoxetine, pyridostigmine bromide, yohimbine, midodrine hcl, modafinil, octreotide, water intake, ranitidine hcl, diphenhydramine hydrochloride, tranylcypromine, ergotamine/ caffeine, celecoxib, pseudoephedrine, methylphenidate, indomethacin, ibuprofen, Oxymetazoline 0.05% nasal solution, acarbose, Rivastigmine tartrate, acetazolamide, carbidopa/levodopa, inflatable abdominal binder or bovril
89008723|NCT00223691|Placebo Comparator|2: Placebo or sham device|placebo pill or inflatable abdominal binder (sham)
89008724|NCT04583020|Experimental|Neoadjuvant PD-1 inhibitor|Neoadjuvant PD-1 inhibitor Camrelizumab will be administered to patients with newly diagnosed glioblastomas, followed by surgical resection, standard radiochemotherapy, and further PD-1 inhibitor treatment.
89008725|NCT04583059|Experimental|Taping Group|A hard-preventive Zinc oxide tape was used in this study. Taping procedure consists of three separate steps: First step involved application of the anchor tape, which achieved by applying the tape circumferentially just above the malleolar level at the lower end of the shank. Second step involved application of the stirrup. During this step, the foot was held in neutral, and the tape applied to pass from the medial side of the ankle, under the foot just over the heel area (posterior one-third of the foot) and up along the lateral side of the ankle. The second step was repeated to apply the second stirrup. Both ends of the stirrups were firmly attached to the anchor tape applied during the first step and this attachment was reinforced with a locking tape during the third and final step by once again applying the tape circumferentially just above the malleolar level at the lower end of the shank. Taping was applied by a physical therapist according to the health association requirements
89008726|NCT04583059|Experimental|Bandaging Group|Standard 10 cm width elastic bandage was used. The elastic bandage was wrapped around the ankle joint to form an 8-figure shape starting from the forefoot. Then, the bandage was taken diagonally upwards, steeply enough to go well above the heel. Then, the bandage was taken around the lower calf area to form an anchor. Then its diagonally taken down across the midfoot. Again the bandage was wrapped around the forefoot and going diagonally up to finish off around the lower calf, leaving the heel open. During the bandage application process, the therapiest didn't stretch the bandage, because bandage does note need to be stretched during the application, as the bandage becomes naturally tight when its layers wraped over each others. the participant was asked to wear his/her sport shoes over the bandage during the measurement procedures.
89008727|NCT04582552||Ovarian cancer patients treated with PARP inhibitors|PARP inhibitors therapy until disease progression
89008728|NCT00568204|Experimental|1|Mexyn-A
89008729|NCT04582747||Major abdominal Surgery patients|Major Abdominal Surgery Patients
89008730|NCT00223730|Experimental|citrulline|Patients randomized to receive oral citrulline at 3.8 gm/m2 in split BID dosing
89008731|NCT00223730|Placebo Comparator|Placebo|Patients randomized to receive oral diluent for citrulline in BID dosing
89008732|NCT04582630||Omega 3 fatty acid|Participants will take 0.1-0.2 g/kg/day of omega 3 fatty acids for 7 days.
89008733|NCT04582630||Control (standart)|Standart medical nutrition therapy
89008734|NCT04582786|Active Comparator|Standard group|Standard treatment (morphine) administered according to usual practice
89431706|NCT03415724|Active Comparator|3.6 ml Lignocaine plus dexmedetomidine|conventional inferior alveolar nerve block with3.6 ml of injection lignocaine plus injection dexmedetomidiene 1micromol/ ml.
89008735|NCT04582786|Experimental|Test group: Infusion with bolus|STR-324 or morphine HCl infusion started with a initial bolus
89431707|NCT04447664|Experimental|Telemedicine arm|
89431708|NCT04447664|No Intervention|Control arm|
89431709|NCT03775941||Cross-Sectional Lifespan Connectomics Study|
88911061|NCT03259763|Active Comparator|Enteral Stenting (ES)|In this technique, under endoscopic visualization, a guidewire will be advanced through the obstructed part of the stomach. Then an enteral self-expandable metal stent will be deployed under direct endoscopic visualization and fluoroscopic guidance.
89431710|NCT04447586|Active Comparator|Patients following Command A and B|This group of patients followed the Commands A and B with this specific order, and performed 3 exhalation attempts for each command.
89431711|NCT04447586|Active Comparator|Patients following Command B and A|This group of patients followed the Commands B and A with this specific order, and performed 3 exhalation attempts for each command.
89431712|NCT04447586|Active Comparator|intervention group|"Intervention group was requested to exhale as indicated by the right command, performing 3 sets of 10 repetitions."
89431713|NCT04447586|No Intervention|control group|"Did not perform exhalation attempts by the right command."
89431714|NCT02097693||dyston-dyskinetic cerebral palsy|Young patients with dyston-dyskinetic cerebral palsy who receive DBS in the GPi
89431715|NCT02100033|Experimental|acupuncture|acupuncture manipulation
89431716|NCT03415646|Active Comparator|Block Group|Erector Spinae Plane Block administered group
89431717|NCT03415646|Sham Comparator|Control Group|Control group
89431718|NCT05615116||Before ileocecal resection|Patients diagnosed with Crohn's disease after comprehensive evaluation of clinical symptoms, endoscopic features, radiological manifestations and histological features were recruited，and the patients were admitted for right hemicolectomy
89431719|NCT05615116||After ileocecal resection|Patients diagnosed with Crohn's disease after comprehensive evaluation of clinical symptoms, endoscopic features, radiological manifestations and histological features were recruited，and the patients underwent reversal of ileostoma after right hemicolectomy
88911062|NCT03251027|Experimental|Treatment (IM-SRT)|Patients undergo intensity-modulated (IM)-stereotactic radiotherapy (SRT) daily over 6 weeks.
88911063|NCT03243539|Experimental|Lung Protective Ventilation|Subjects with acute brain injury (traumatic brain injury and non-traumatic brain injury) will receive neuro lung protective ventilation which targets a normal arterial partial pressure of carbon dioxide with the lowest tidal volume possible (6 to 8 ml/kg predicted body weight). Protocols for oxygenation and weaning from the ventilator will also be followed.
89431720|NCT02097771|Active Comparator|LMA SupremeTM|
89431721|NCT02097771|Sham Comparator|Ambu AuraOnce|
88911066|NCT03225131||0|participants without AMD meaning no large drusen (= 125 microns) or advanced AMD in either eye
88911067|NCT03225131||1|participants with large drusen (= 125 microns) in the study eye and no large drusen or advanced AMD (choroidal neovascularization (CNV) or geographic atrophy (GA)) in the fellow eye
88911068|NCT03225131||2|participants with bilateral large drusen (= 125 microns) with or without retinal pigment epithelial hypo/hyperpigmentary changes
88911069|NCT03225131||3|participants with large drusen (= 125 microns) in the study eye and advanced AMD (CNV or GA) in the fellow eye
88911070|NCT03225131||4|participants with findings of reticular pseudodrusen (RPD) in the study eye, without advanced AMD in the study eye, and any level of AMD in the fellow eye
88911071|NCT03224000|Experimental|MRI Guided Intensity Modulated Radiotherapy (IMRT)|"Modified barium swallow (MBS) performed at baseline and at 6 months, 2 years, and 5 years after finishing radiation therapy.~Swallowing questionnaire completed at baseline, every week while receiving radiation therapy, and at 6 months, 2 years, and 5 years after finishing radiation therapy.~Symptom questionnaire completed at baseline, every week while receiving radiation therapy, and at 6 months, 2 years, and 5 years after finishing radiation therapy.~Video-strobe procedure performed at baseline, at week 3 during radiation therapy, and at 6 months, 2 years, and 5 years after finishing radiation therapy.~IMRT planned with MRI guidance. Participants receive an individualized prescription of up to 70 Gy in 33 fractions with radiation therapy (RT) given once daily, 5 days a week, over 6 weeks and 3 days."
88911072|NCT03224000|Active Comparator|Standard-of-Care Intensity Modulated Radiotherapy (IMRT)|"Modified barium swallow (MBS) performed at baseline and at 6 months, 2 years, and 5 years after finishing radiation therapy.~Swallowing questionnaire completed at baseline, every week while receiving radiation therapy, and at 6 months, 2 years, and 5 years after finishing radiation therapy.~Symptom questionnaire completed at baseline, every week while receiving radiation therapy, and at 6 months, 2 years, and 5 years after finishing radiation therapy.~Video-strobe procedure performed at baseline, at week 3 during radiation therapy, and at 6 months, 2 years, and 5 years after finishing radiation therapy.~IMRT planned by standard-of-care. Participants receive an individualized prescription of up to 70 Gy in 33 fractions with radiation therapy (RT) given once daily, 5 days a week, over 6 weeks and 3 days."
88911073|NCT03214796||Albumin infusion|Patients with decompensated cirrhosis and an indication for routine human albumin infusion
89008736|NCT04582786|Experimental|Test group: Infusion without bolus|STR-324 or morphine HCl infusion started without a initial bolus
89431722|NCT05170100|Experimental|NUIG OAB App|Digital behaviour change intervention. Software-delivered intervention including best-practice behavioural therapy, and evidence-based dietetics, physiotherapy and psychology treatments to reduce the symptoms of overactive bladder.
89431723|NCT04787770||diabetes without complications|diabetes without complications
89431724|NCT04787770||diabetes with Peripheral Arterial Disease|diabetes with Peripheral Arterial Disease
89431725|NCT04787770||diabetic foot group|diabetic foot group
89431726|NCT02250495|Experimental|Sympara Therapeutic System|All subjects will wear for the Sympara device for 30 days
89431727|NCT03417908|Active Comparator|COPD - PNF|COPD - PNF
89431728|NCT03417908|Sham Comparator|COPD - sham|COPD - sham
89431729|NCT03417908|Active Comparator|Individuals Without COPD - PNF|Individuals Without COPD - PNF
89431730|NCT03417908|Sham Comparator|Individuals Without COPD - sham|Individuals Without COPD - sham
89431731|NCT02250573|Experimental|Replenine®-VF|
89431732|NCT03415568|Placebo Comparator|LCT consumption|Muffin that contains 15g of long-chain triglyceride (LCT) oils were provided to conduct 6-h meal tolerance test.
89431733|NCT03415568|Experimental|MCDG consumption|Muffin that contains 15g of the mixture of medium-chain triglyceride and diacylglycerol (MCDG) oils were provided to conduct 6-h meal tolerance test.
89431734|NCT02250261|Experimental|KÄPY group|Workplaces, which are supported to promote employees' ACW.
89431735|NCT02250261|No Intervention|Comparison group|Workplaces, which are not supported to promote employees' ACW but will be offered support to do so after the study.
89431736|NCT03417596|Experimental|Vestibular Rehabilitation|"Adaptation Exercises The exercises were performed in horizontal and vertical planes, for a period of one minute each, three times a day.~Substitution Exercises Standing dynamic balance exercises: The patient stands and moves without walking. The patient might march in place, step forward or backward, step to the side, step up or down, or turn around.~Habituation exercises: These exercises that cause mild to moderate difficulty in daily life was given as an exercise to the patient. These exercises involved movements and positions sufficient to cause mild-to-moderate symptoms during the patient's daily activities Ambulation exercises: Exercises that include walking with head moving towards different sides.~The exercise program consisted of one session per week for a period of eight weeks. Each session lasted approximately 30-45 minutes and was conducted in the rehabilitation unit."
89431737|NCT03417596|Experimental|Vestibular Rehabilitation+Pharmacological Therapy|"Same exercises that were applied in first group were also applied to this group.~For pharmacological therapy, patients were assessed by a neurologist and appropriate drug options were applied based on patients' needs and features. Propranolol was selected primarily and other prophylactic drugs were used in the case of its' being contraindicated."
89431738|NCT03417596|Other|Pharmacological Therapy only|Patients were assessed by a neurologist and appropriate drug options were applied based on patients' needs and features. Propranolol was selected primarily and other prophylactic drugs were used in the case of its' being contraindicated.
89431739|NCT02100111||Participants with advanced or metastatic BCC|Participants with BCC who received any treatment including surgeries, radiation, photodynamic therapy, chemotherapy, supportive/palliative care, or other therapies, will be included as a part of study.
89431740|NCT02590354|Experimental|Treatment interruption|The ART treatment in patients with a very low viral reservoir will be interrupted.
89431741|NCT03417518|Active Comparator|Desflurane Inhalant Product Group|general anesthesia with desflurane
89431742|NCT03417518|Experimental|Propofol Group|general anesthesia with propofol
89431743|NCT03415490|Active Comparator|Classic technique of self-adherent wrap|"over 16 years old~free of any symptoms in the eyes~classic technique of self-adherent wrap after surgery"
89431744|NCT03415490|Experimental|Folded technique of self-adherent wrap|"over 16 years old~free of any symptoms in the eyes~folded technique of self-adherent wrap after surgery"
89431745|NCT03417362|Other|Animation|Animation describing process of early medical abortion, what to expect, how to take medicines. This is prior to consultation.
89431746|NCT03417362|No Intervention|Standard|Standard of Care - no animation ,standard consultation only.
89431747|NCT03555903||Endometriosis cohort|The aim of the study is to advance the scientific knowledge of deep infiltrating endometriosis (DIE) and to evaluate the impact of surgery on the quality of life and the fertility of affected women.
89431748|NCT04787458|Experimental|Experimental group|In subjects allocated to the abdominal binder group, the abdomen binder with a standard height of 22 cm (Sejung Korea, Seoul, Republic of Korea) was applied before leaving the operating room. Subjects were carefully instructed to use the abdominal binder during at least the first 2 consecutive days and night, and to reposition the abdominal binder correctly when needed.
89431749|NCT04787458|No Intervention|Control group|subjects allocated in the control group, subjects were not given any opportunity to ware an abdominal binder.
89431750|NCT05169632|Active Comparator|Program 1|Computerized Gaming Rehabilitation Program 1
89431751|NCT05169632|Experimental|Program 2|Computerized Gaming Rehabilitation Program 2
89431752|NCT03555747|Other|Canine distalization by 75 g force|Canine was distalized using a continuous force of 75 g with nickel-titanium closed coil springs.
89431753|NCT03555747|Other|Canine distalization by 150 g force|Canine was distalized using a continuous force of 150 g with nickel-titanium closed coil springs.
89431754|NCT05151562|Experimental|Virtual Music Therapy|Participants will attend two 30 minutes long virtual music therapy sessions per week for 8 weeks using Zoom.
88911075|NCT03207958|Experimental|Belimumab|"Subjects meeting eligibility criteria will start treatment between Day +3- and Day +60 after alloHCT~Belimumab will be administered intravenously every 2 weeks for 3 cycles and then every 4 weeks for a total of 7 cycles (6 months)"
88911076|NCT03198650|Experimental|Part 1 / Part 2|Acalabrutinib
88911077|NCT03198650|Experimental|Part 3|Acalabrutinib in combination with Obinutuzumab
88911078|NCT03193307|Experimental|Microgynon® 30 +BI 409306 then BI 409306 alone|Run in period: Microgynon alone Treatment period: Microgynon® 30 +BI 409306 then BI 409306 alone
88911079|NCT03191149|Experimental|Treatment (osimertinib)|Patients receive osimertinib PO QD on days 1-21 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo MRI or CT with contrast and collection of blood samples throughout the trial.
88911080|NCT03186066|Active Comparator|Standard Therapy|Buried Bumper Syndrome is treated by endoscopically dissecting the overgrown tissue with an endoscopic submucosal dissection knife.
88911081|NCT03186066|Experimental|Flamingo Device|The Flamingo device is used for treatment of Buried Bumper Syndrome.
88911082|NCT03151057|Experimental|Idelalisib 100mg|"Idelalisib is an orally-administered, selective inhibitor of Phosphoinositide 3 kinase (PI3K)-delta which has been shown to be extremely effective in inducing partial to complete responses in many B-cell derived malignancies.~intervention: 100mg Idelalisib twice daily beginning +90(+/- 10) days after allo HSCT and continued through Day 270 post transplant"
88911083|NCT03151057|Placebo Comparator|Placebo oral tablet|Placebo to be taken twice daily beginning +90(+/- 10) days after allo HSCT and continued through Day 270 post transplant
88911084|NCT03144323|Experimental|Study group|This group will receive 4 daily electronic reminders via the Calendar app on their mobile phones, reminding them to wear their elastics.
88911085|NCT03144323|No Intervention|Control group|This group will receive their orthodontic treatment and elastics instructions as normal, without reminders.
88911086|NCT03128385|Experimental|Intensive CIT Model Program|"In day camp model, the therapist will monitor and modify the activities to fit each child's ability and need (e.g. implementing task analysis, grading the challenge for each individual with varying capabilities) to make sure the intervention quality is equivalence to the individualized treatment.The day camp model will be arranged as Adventure Camp that decorating the treatment place as the adventure world and the participants take role as a warrior. This novel design is mean to enhance and motivate the engagement of participation."
89008737|NCT04582513||Pre-checklist implementation group|Patients undergoing major elective surgery where intraoperative handover occurs. This handover is performed according to current hospital standard without a standardized checklist.
89431755|NCT02097927|Experimental|High energy, low sensory|Mango-flavour beverage
89431756|NCT02097927|Experimental|Low energy, high sensory|Mango-flavour beverage
89431757|NCT02097927|Experimental|High energy, high sensory beverage|Mango-flavour beverage
89431758|NCT02098005|Active Comparator|Usual care|usual care evidence-based physiotherapy
89431759|NCT02098005|Experimental|modern neuroscience approach|modern neuroscience approach
89431760|NCT04058860|Other|Study Patients|Patients undergoing open heart surgery with minimal invasive extracorporeal circulation (MiECC) according to accepted indications
89431761|NCT03415334|Other|behavioral change|two approaches for behavior changes : social marketing and behavioral development
89431762|NCT02094495||breast cancer group|Taking tamoxifen
89431763|NCT02094651|Experimental|divalproex sodium|divalproex sodium will be administered in sprinkle capsule formulation, target dose of 30mg/kg, drug will be administered for 12 weeks
89431764|NCT02094651|Placebo Comparator|Placebo|Blue and white capsules with equivalent amount of lactose spheres/beads inside Placebo will be formulated to look identical to the active medication
89431765|NCT03411200|Experimental|Intervention group (n=50)|Participants in the intervention group will receive usual care and the multimodal and exercise-based intervention.
89008738|NCT04582513||Post-checklist implementation group|Patients undergoing major elective surgery where intraoperative handover occurs. This handover is performed after implementation of the AnCHor-CHecklist, a standardized checklist based on the SBAR concept.
89008739|NCT04583449|Experimental|Outcome imagery|Outcome imagery condition participants will be asked to visualize themselves successfully wearing a face covering in all required public places/situations over coming week, and to imagine how they would feel. The importance of imagining distinctive relevant visual imagery linked to having successfully routinely worn face covering will be underscored in this passage. Outcome imagery participants will then be asked to write in a free-text box how they would feel having successfully worn a face covering in required public places/situations over the week ahead.
89008740|NCT04583449|Experimental|Process imagery|Process imagery condition participants will be asked to visualize the kinds of strategies involved in successfully wearing a face covering in all required public places/situations over the coming week. The importance of imagining distinctive relevant visual imagery linked to having effective strategies involved in successfully wearing a face covering in required public places/situations over the week ahead will be underscored in this passage. Process imagery participants will then be asked to write in a free-text box about the kinds of strategies that would be involved in successfully wearing a face covering in all required public places/situations over the coming week.
89008741|NCT04583449|Experimental|Combined imagery (outcome imagery and process imagery)|A third experimental condition will receive both outcome and process imagery exercises to read and complete in sequential order.
89008742|NCT04583449|No Intervention|Public health message|A fourth condition will involve viewing a UK Government public health message (HM Government, 2020) circulated on social media as an image concerning the importance of wearing face covering while in public places.
89008743|NCT04582474|Experimental|Dengue module and rapid diagnostic tests|
89008744|NCT04582123|Other|comparison of two cross pin fixation methods|Fixation of supracondylar humerus fractures with 2 crossed pins and 3 crossed pins are compared in terms of Flynn's criteria
89008745|NCT04582084||Autoimmune Arthritis|Patients with autoimmune arthritis, including rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis, receiving biosimilar etanercept in real-world settings
89008746|NCT00254046|Placebo Comparator|002|Placebo 2 tablets b.i.d.96 weeks
89008747|NCT00254046|Active Comparator|001|TMC125 2 X100 mg tablets b.i.d.96 weeks
89008748|NCT00223847|Other|1|
89431766|NCT03411200|No Intervention|Control group (n=50)|Participants in the control group will receive usual care.
89431767|NCT03411122|Experimental|Single-sequence 3-period|Period 1: napabucasin 240 mg BID on days 1-2 Period 2: cytochrome P450 probe drugs during days 1-4 Period 3: napabucasin 240 mg BID on days 1-11, cytochrome P450 probe drugs during days 6-9
89431768|NCT04787224||infected sockets|Signs of infection were periapical radiolucency only in 3 sites (2 patients), fistula in 2 sites (2 patients), sinus in 11 sites (7 patients) and finally swelling in 3 sites (2 patients)
89431769|NCT04787224||Non infected sockets|This is ensured by the absence of any clinical signs and symptoms of infection in addition to negative radiographic findings
89008749|NCT04582162|Experimental|Unsplinted implants|
89008750|NCT04582162|Active Comparator|Splinted implants|
89008751|NCT04582396|Experimental|Stellate Ganglion Block + Psychoeducation|For the active SGB arm, 7 to 8 mL of ropivacaine, 0.5%, will be injected around and into the site of the ganglion once before the hospital discharge. They will also receive a 30 minutes session of psychoeducation by a health professional with experience working with CA patients.
89008752|NCT04582396|Placebo Comparator|Normal saline injection + Psychoeducation|For the sham procedure, 1 to 2 mL of preservative-free normal saline will be injected into deep musculature in the neck. They will also receive a 30 minutes session of psychoeducation by a health professional with experience working with CA patients.
89008753|NCT04581772|Experimental|Cohort A|
89431770|NCT02094807|Other|Conservative management|Not operated. Thoracic epidural anesthesia will be used togeteher with paracetamol. If not sufficient opioids and NSAID will be added.
89008754|NCT04581772|Experimental|Cohort B|
89008755|NCT04581772|Experimental|Cohort C|
89008756|NCT00223925|Placebo Comparator|Placebo|
89431771|NCT02094807|Active Comparator|Operative management|Operative fixation of rib fractures. Thoracic epidural anesthesia will be used togeteher with paracetamol. If not sufficient opioids and NSAID will be added.
89431772|NCT05139472|Experimental|Treatment Arm|This arm of the study will take 10 mg empagliflozin daily for 12 weeks
88911087|NCT03128385|Experimental|Distributed CIT Model Program|All treatment activities will be focused on the training of the more affected upper limbs with contextual restraint. Investigators choose this child-friendly way to restraint children's non or less impaired hand without any devices. Investigators will provide a unilateral activities and verbal cues to restraint participants' non or less affected side. All tailored activities will be designed as fun and age-appropriated based on the child's preference and parents' concerns. In order to help children to generalize the therapeutic gains to the real world environment, the intervention will take place in the natural environment such as home or school where it may be easier to identify real practical problems and makes the family or caregivers involved more closely and directly.
88911088|NCT03128047|Experimental|Recurrent high grade gliomas and ependymomas|"Recurrent high-grade glioma and ependamoma patients will receive treatment with the Optune NovoTTF-200A system as monotherapy.~Interventions: Device: Optune NovoTTF-200A System Optune NovoTTF-200A System receive treatment with 200kHz for a minimum of 18 hours per day in 28 day cycles combined with Temozolomide and Bevacizumab."
88911089|NCT03124407|Active Comparator|Once daily-Active|40 subjects receiving once daily application of complete drug product (contains 0.25% capsaicin) to the knee
88911090|NCT03124407|Placebo Comparator|Once daily-Vehicle|20 subjects receiving once daily application of drug product vehicle (i.e., with no capsaicin) to the knee
88911091|NCT03124407|Active Comparator|Twice daily-Active|40 subjects receiving twice daily application of complete drug product (contains 0.25% capsaicin) to the knee
88911092|NCT03124407|Placebo Comparator|Twice daily-Vehicle|20 subjects receiving twice daily application of drug product vehicle (i.e., with no capsaicin) to the knee
88911093|NCT03111485|Experimental|A (drug-placebo)|Sinemet CR (Long-acting levodopa: levodopa 200mg/ carbidopa 50mg) followed by a washout period and placebo oral capsule, each taken at bedtime for 2 weeks
88911094|NCT03111485|Experimental|B (placebo-drug)|Placebo oral capsule followed by a washout period and Sinemet CR (Long-acting levodopa: levodopa 200mg/ carbidopa 50mg), taken at bedtime for 2 weeks
88911095|NCT03104504|No Intervention|No Intervention|Baseline Retrospective Chart Reviews that are conducted on subjects for the one year period prior to the implementation of the study will serve as the control.
88911096|NCT03104504|Other|Intervention|"The intervention targets will be the following suicide-related clinician behaviors.~suicide risk screening~safety planning~means restriction counseling~Post-acute care follow-up calls A Lean Implementation Strategy: The Implementation of the intervention targets guided by Lean; is expected to increase suicide-related clinician behaviors"
88911097|NCT03104257||Cannabis Dependent Subjects|Subjects who are frequent cannabis users
88911098|NCT03104257||Healthy Controls|Subjects with no current cannabis use
88911099|NCT03096743|Experimental|Patients with increased intracranial hypertension|Patients will receive the MR elastography, MRI structural brain imaging, Optical Coherence Tomography (OCT) imaging, Optic nerve B-scan ultrasound and Lumbar puncture.
88911100|NCT03096743|Experimental|Patient without raised intracranial hypertension|Patients will receive the MR elastography, MRI structural brain imaging, Optical Coherence Tomography (OCT) imaging, and Optic nerve B-scan ultrasound. Some patients will receive lumbar punctures.
88911101|NCT03092518|Experimental|1/Arm 1|HIPEC with gastrectomy
88911102|NCT03092492||Participants with bilateral early AMD|Participants with bilateral early AMD
88911103|NCT03092492||Participants with large RPD|Participants with large RPD
89008757|NCT00223925|Experimental|Maribavir (100 mg twice daily)|
89431773|NCT04757090|Experimental|89Zr-trastuzumab PET/CT imaging|"Enrolled subjects will be asked to undergo 18F-FDG PET/CT imaging (if not performed within the previous 90 days) and 89Zr-trastuzumab PET/CT imaging at baseline prior to the start of monotherapy MT-5111 treatment. Standard of care 18F-FDG PET/CT examinations performed within 90 days of 89Zr-trastuzumab administration can be used in place of a study specific 18F-FDG PET/CT scan. Baseline 89Zr-trastuzumab imaging should be completed no more than 30 days prior to initiating treatment with MT-5111.~Cold trastuzumab and 89Zr-trastuzumab will be administered at Visit 1 and the 89Zr-trastuzumab PET/CT (Visit 2) will take place 4 days (+/-1 day) after administration of 89Zr-trastuzumab."
89431774|NCT03397862|Experimental|Corplex Donepezil TDS 5 mg/day|Subjects will receive Corplex Donepezil TDS 5 mg/day during Induction, Challenge, and Re-Challenge phase.
89431775|NCT03397862|Placebo Comparator|Vehicle TDS|Subjects will receive Vehicle TDS during Induction, Challenge, and Re-Challenge phase.
89431776|NCT02100267|Experimental|Asthma patients|
89431777|NCT02100267|Experimental|Healthy volunteers|
89431778|NCT05614726|Placebo Comparator|Placebo|Consists of 575 mg rice oligodextrin
89431779|NCT05614726|Active Comparator|Active|Consists of 575mg [30 billion colony forming units probiotic blend of Bifidobacterium breve 19bx, Lactobacillus acidophilus 16axg, Lacticaseibacillus rhamnosus 18fx, Saccharomyces boulardii 16mxg, and alpha amylase
89431780|NCT03397784||fluid responders|Patients whose stroke volume index increase by ≥15% in response to a 500-ml fluid bolus was defined as fluid responders.
89431781|NCT03397784||fluid non-responders|Patients whose stroke volume index increase by <15% in response to a 500-ml fluid bolus was defined as fluid non-responders.
89431782|NCT02094963|Experimental|Ticagrelor|
88911104|NCT03092492||Participants with small or medium-sized drusen|Participants with small or medium-sized reticular pseudodrusen (RPD)
88911105|NCT03092492||Unaffected Age-matched controls|Healthy age-matched controls
88911106|NCT03091374|Experimental|Growth Hormone|
88911107|NCT03085043|Experimental|Diagnostic (bone scan, CT, MRI, magnetic resonance WB-DWI)|Participants undergo standard of care bone scan, CT of the abdomen and pelvis, and pelvic MRI. Participants also undergo magnetic resonance WB-DWI over 20-30 minutes.
88911108|NCT03082924|Experimental|Control group|Neither cycle training nor inspiratory muscle training.
88911109|NCT03082924|Experimental|Cycle training group|A calibrated cycle ergometer is used to do 30-minute cycling training session 3 days a week.
88911110|NCT03082924|Experimental|Inspiratory training group|A threshold loading device is used to perform 21-minute inspiratory muscle training 3 days a week.
88911111|NCT03082924|Experimental|Combined group|Calibrated cycle ergometer and threshold loading device are applied.A 30-minute cycle training is performed using calibrated cycle ergometer and a 21-minute inspiratory muscle training using threshold loading device 3 days a week.
88911112|NCT03070535|Experimental|HIGH meal|The HIGH meal is a 700 calorie breakfast style meal, with 50% total fat (25% saturated fat), 30% carbohydrates with a glycemic index of >70, and 20% protein.
88911113|NCT03070535|Experimental|LOW meal|The LOW meal is a 700 calorie breakfast style meal, with 25% of those calories coming from fat (5% saturated fat), 55% carbohydrate (with a glycemic index of <55), and 20% protein.
88911114|NCT03064490|Other|Single arm interventional study|Single arm, non randomized, open label study. Subjects will receive three doses of neoadjuvant pembrolizumab (200 mg administered as an intravenous infusion over 30 minutes every 3 weeks). Pembrolizumab will be administered with weekly standard of care Carboplatin/Paclitaxel concurrent chemo-radiation therapy in the neo-adjuvant setting. Postoperatively, three additional cycles of pembrolizumab (200 mg every 3 weeks) will be administered as adjuvant therapy.
88911115|NCT03048084|Active Comparator|Levetiracetam|Patients in this treatment arm will receive levetiracetam monotherapy. The dosage depends on the specific treatment step, as indicated in the protocol. In step 1, patients will receive 2x500 mg/d levetiracetam in the form of tablets. In step 2, dosage is increased to 1x250 plus 1x500 mg/d and in step 3 to 2x1000 mg/d levetiracetam. In step 4, levetiracetam is increased to 2x1500mg/d. In the fifth treatment step, patients will receive 2x1500 mg/d levetiracetam, and another AED will be added. The type and dosage of this add-on AED is according to the physician's preference, but in line with current clinical practice in the Netherlands.
88911116|NCT03048084|Active Comparator|Valproic acid|Patients in this treatment arm will receive valproic acid monotherapy. The dosage depends on the specific treatment step, as indicated in the protocol. In step 1, patients will receive 2x500 mg/d valproic acid in the form of tablets. In step 2, dosage is increased to 1x250 plus 1x500 mg/d and in step 3 to 2x1000 mg/d valproic acid. In step 4, valproic acid dosage is increased to a maximum of 2x1250mg/d. In the fifth treatment step, patients will receive 2x1250mg valproic acid, and another AED will be added. The type and dosage of this add-on AED is according to the physician's preference, but in line with current clinical practice in the Netherlands.
88911117|NCT03034096|Experimental|Propofol infusion|Maintenance of general anesthesia with propofol infusion
88911118|NCT03034096|Experimental|Volatile agent|Maintenance of general anesthesia with volatile agent (sevoflurane, desflurane, or isoflurane)
88911119|NCT03031665||Current MDD|Subjects experiencing a current episode of Major Depressive Disorder.
88911120|NCT03031665||Remitted MDD|Subjects who have a history of Major Depressive Disorder, but have not had a depressive episode for at least two months.
88911121|NCT03031665||Control Subjects|Subjects who have no history of clinical depression or other psychological disorder.
89008758|NCT00223925|Experimental|Maribavir (400 mg twice daily)|
89431783|NCT02094963|Active Comparator|Clopidogrel|
89431784|NCT03985696|Experimental|patients with DLBCL|
89431785|NCT03985696|Active Comparator|Healthy volunteers|
89536254|NCT03209245|Active Comparator|Active AIT group|"Injection immunotherapy with Purethal Mites were administered as perennial therapy using the following regimen of injections: 1 dose- 0.1 ml, 2 doses - 0.2 ml, 3 doses - 0.5 ml every week, and 0.5 ml every four weeks during 24 months.~monitoring of allergen specific IgE monitoring of allergen specific IgG4"
89197654|NCT04059510||Focus groups|"In the UK investigators will recruit up to 20 women from the sampling study to take part in focus groups about their experiences with self-sampling methods and the acceptability of controlled human infection models. Consent to participate in focus group discussions will be included as part of the consent to take part in the sampling study but will be optional.~Women may opt out of the focus groups at any time but remain in the sampling study if they choose.~In Uganda, the investigator will recruit more widely to our focus groups, including representation from midwives and the participant's partners and community leaders.The investigator will explore potential issues around maternal vaccination, and traditional and contemporary views on taking vaginal swabs and blood samples."
89431786|NCT03415256|Experimental|passive vibration group|The passive vibration group patients will receive passive vibration (50 Hz, one cycle= 60 seconds working time with 2 seconds rest time) on their calf in supine position for ten minutes. The total number of sessions will be nine. Passive vibration will be given to the treatment group twice a week for four weeks (eight sessions) and the ninth session will be the follow up. At every session, the skin blood flow will be measured before, immediately, and 15 minutes after passive vibration.
89536255|NCT03209245|Placebo Comparator|non-active, placebo treatment|symptomatic treatment with concomitant use of placebo injection monitoring of allergen specific IgE monitoring of allergen specific IgG4
88911123|NCT03014271|Experimental|Sources of Strength Suicide (SOS)|Receive Sources of Strength Suicide (SOS) Prevention Program
88911124|NCT03014271|Active Comparator|SOS Waitlist Control|Delayed implementation of Sources of Strength Suicide Prevention Program after 16 months.
88911125|NCT03012399|Experimental|Group I (hypnosedation)|Patients undergo hypnosedation performed by a mind-body specialist before surgery begins and continuing until after surgery is complete.
89197655|NCT00856869|Experimental|1 YM|Healthy young males
88911126|NCT03012399|Active Comparator|Group II (verbal support)|Patients speak to a mind-body specialist before surgery and prior to receiving general anesthesia.
88911127|NCT02978911|Experimental|Skull base tumors|Patients who presented a skull base tumor that requires a surgical removal
88911128|NCT02967458|Experimental|Prostate Biopsy Patients|Fifty patients who are scheduled for a clinically indicated prostate biopsy, and who are able to undergo contrast enhanced transrectal ultrasound will be included in this single arm study. Each of the study subjects will receive in intravenous infusion of a microbubble contrast agent known as Definity™, (Perflutren Lipid Microsphere, Lantheus Medical Imaging, Inc; N. Billerica, MA). Based upon our previous experience, two vials of Perflutren Lipid Microsphere will be mixed and diluted in 50 ml of normal saline, yielding a concentration of 49.4 μl/ml. For the purpose of contrast-enhanced imaging, Perflutren Lipid Microsphere will be infused over approximately 10-12 minutes, during which time ultrasound imaging and biopsy will be performed.
88911129|NCT02965326|Other|Cystic fibrosis, treated|Cystic fibrosis patients treated either by Ivacaftor or by the association Ivacaftor-Lumacaftor
88911130|NCT02965326|Other|Cystic fibrosis, non treated|Cystic fibrosis patients, non treated by a CFTR modulator
88911131|NCT02965326|Other|Non-Cystic fibrosis|Patients in whom cystic fibrosis diagnosis has been suspected, but excluded by physiological and genetic investigations
88911132|NCT02960022|Experimental|enzalutamide|Subjects will receive enzalutamide orally once daily at the same time each day
88911133|NCT02960022|Experimental|enzalutamide plus abiraterone acetate and prednisone|Subjects enrolling from study 9785-CL-0011 or MDV3100-10 (PLATO) study may receive abiraterone acetate once daily and prednisone twice daily, in addition to enzalutamide once daily
88911134|NCT02950883|Experimental|Active Treatment Group|7% Hypertonic Saline administered via inhalation twice daily for 48 weeks
88911135|NCT02950883|Active Comparator|Control Group|0.9% Isotonic Saline administered via inhalation twice daily for 48 weeks
88911136|NCT02940171||Early surgery|Early Excision of full thickness burn First excision surgery of full -thickness burn performed within 48 hours from burn injury
88911137|NCT02940171||Late surgery|Late Excision of full thickness burn First excision surgery of full -thickness burn performed after 48 hours from burn injury
88911138|NCT02933801|Experimental|Arm A: ODM-201|600mg ODM-201 BID (twice daily) and Best Supportive Care until progression
88911139|NCT02933801|Placebo Comparator|Arm B: Placebo|Placebo BID (twice daily) and Best Supportive Care until progression
88911140|NCT02923739|Active Comparator|Arm I (paclitaxel, bevacizumab)|Patients receive paclitaxel IV over 60 minutes on days 1, 8, 15, and 22 and bevacizumab IV over 90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88911141|NCT02923739|Experimental|Arm II (paclitaxel, bevacizumab, emactuzumab)|Patients receive paclitaxel and bevacizumab as in Arm I. Patients also receive emactuzumab IV over 30 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89197656|NCT00856869|Experimental|2 EM|Healthy elderly males
89008759|NCT00223925|Experimental|Maribavir (400 mg once daily)|
89008760|NCT04582006||LSG|Patients undergoing laparoscopic sleeve gastrectomy.
89197657|NCT00856869|Experimental|3 YF|Healthy young females
89197658|NCT00856869|Experimental|4 EF|Healthy elderly females
89197659|NCT00856869|Experimental|5 NASH|Patients with presumed NASH
89197660|NCT00856869|Experimental|6 CTP-A|Patients with hepatic cirrhosis CTP-class A
89197661|NCT00856869|Experimental|7 CTP-BC|Patients with hepatic cirrhosis CTP-class B and C
89197662|NCT00755742|Experimental|Group 1 - Viremic / Non-cirrhotic|13 obese and insulin resistant, non-cirrhotic, non-diabetic (by fasting glucose), non-genotype 3 patients with chronic hepatitis C (HCV RNA positive) will undergo 24 week lifestyle intervention comprising diet, physical activity (monitored by pedometers) in combination with behavior modification counseling. This arm includes patients who are naive to antiviral therapy, relapsed or not responded to antiviral therapy.
89431787|NCT03415256|Active Comparator|no passive vibration group|The control group will not receive any treatment and continue their usual lifestyle. Balance, sensory measurement and skin blood flow will be taken at the beginning of the study, prior to the 5th treatment, and 1 week after the last intervention .
89431788|NCT03982810||Surgical Site Infections|Patients equal or greater than 18 years of age undergoing non-emergent non-cardiac surgical procedures involving a skin incision will be included in the study.
89197663|NCT00755742|Active Comparator|Group 2 - Non-viremic / Non-cirrhotic|13 obese and insulin resistant, non-cirrhotic, non-diabetic (by fasting glucose), non-genotype 3 patients with cured chronic hepatitis C (HCV RNA negative) will undergo 24 week lifestyle intervention comprising diet, physical activity (monitored by pedometers) in combination with behavior modification counseling. This arm includes patients who have cleared hepatitis C virus with previous antiviral therapy.
89197664|NCT00755742|Experimental|Group 3 - Viremic / Cirrhotic|13 obese and insulin resistant, cirrhotic, non-diabetic (by fasting glucose), non-genotype 3 patients with chronic hepatitis C (HCV RNA positive) will undergo 24 week lifestyle intervention comprising diet, physical activity (monitored by pedometers) in combination with behavior modification counseling. This arm includes patients who are naive to antiviral therapy, relapsed or not responded to antiviral therapy.
89197665|NCT00755742|Active Comparator|Group 4 - Non-viremic / Cirrhotic|13 obese and insulin resistant, cirrhotic, non-diabetic (by fasting glucose), non-genotype 3 patients with cured chronic hepatitis C (HCV RNA negative) will undergo 24 week lifestyle intervention comprising diet, physical activity (monitored by pedometers) in combination with behavior modification counseling. This arm includes patients who have cleared hepatitis C virus with previous antiviral therapy
89197666|NCT00857025|Experimental|Treatment (beta-glucan MM-10-001)|Patients receive oral beta-glucan MM-10-001 once or twice daily. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89197667|NCT04041765|Experimental|Treatment Group|IgM-enriched IVIG given with dose of 0.25g/kg over 3 hours for 3 days in addition to Antibiotics
89197668|NCT04041765|Placebo Comparator|Placebo Group|Antibiotics only
89197669|NCT00752076|Experimental|1|We collected malignant pleural effusion for NSCLC cell lines with different EGFR mutations development and then we can compare the difference responses and signal pathways in these cell lines. We can also explore the detailed mechanism of TKI responsive cancer cell and try to develop other agent to enhance the pathways.
89197670|NCT00942916||Patients with confirmed diagnosis of NTM pulmonary disease|Those with sputum mycobacterial culture yielded the same NTM species for at least two sets within one year.
89197671|NCT00942916||Patients with not definite NTM pulmonary disease|Those who had sputum culture yielded NTM but did not satisfy the criteria for diagnosis with NTM pulmonary disease.
89197672|NCT02546271|Experimental|Treatment Group|GPS program - an 8-week, peer-led group counselling program using motivational interviewing techniques.
89197673|NCT04057014|Active Comparator|Extraction Only|Immediate extraction of infected tooth without antibiotic prescription.
89197674|NCT04057014|Experimental|Average Dose Antibiotic|Average dose antibiotic therapy(25 mg/kg/day in divided doses every 12 hours (maximum 875 mg/dose)) for 10 days and receive tooth extraction on day 10 (25 patients). (*given the average weight of a 12 year old is 45 kilos, we do not expect that we will reach the maximum dose in this group)
89197675|NCT04057014|Experimental|High Dose Antibiotic|High dose antibiotic therapy (45 mg/kg/day in divided doses every 12 hours (maximum 875 mg/dose)) for 5 days and receive tooth extraction on day 10 (25 patients)
89431789|NCT02098239|Active Comparator|Group A|Jaundiced patients with bilirubin value >80 μmol/L. Received G17DT immediately prior to biliary stenting.
89431790|NCT02098239|Active Comparator|Group B|Patients to be treated following biliary decompression or for immediate treatment if non-jaundiced. Received G17DT 2 weeks after biliary stenting when bilirubin was <40 μmol/L.
89431791|NCT02098317|Experimental|TREATED GROUP|this group will treated with pearls containing DHA plus Vitamin D3 (500 mg and 800 IU, respectively) given orally in association with lifestyle intervention [hypocaloric diet (25-30 Kcal/kg/day) or isocaloric (40-45 Kcal/kg/day) and physical activity] for 24 weeks
89008761|NCT04582006||LRYGB|Patients undergoing laparoscopic Roux-en-Y gastric bypass.
89008762|NCT04581577||Adult patients with neuromuscular or neurological disorders|Telephone questionnaires administered directly to patients over 16 years of age with neuromuscular or neurological disorders
89008763|NCT04581577||Parents of paediatric patients with neuromuscular or neurological disorders|Telephone questionnaires administered to the parents of patients over 16 years of age with neuromuscular or neurological disorders
89008764|NCT00223964|Experimental|dose level 1|1.5 mg/kg
89431792|NCT02098317|Placebo Comparator|PLACEBO GROUP|this group will treated with identical placebo pearls given orally in association with lifestyle intervention [hypocaloric diet (25-30 Kcal/kg/day) or isocaloric (40-45 Kcal/kg/day) and physical activity] for 24 weeks
89008765|NCT00223964|Experimental|dose level 2|3 mg/kg
89008766|NCT04581694|Experimental|TAVI without contrast|
89008767|NCT00224081|Experimental|Ferric gluconate|
89008768|NCT00224081|No Intervention|standard of care|
89008769|NCT04581265|Experimental|nab-PTX, ifosfamide and cisplatin|albumin-bound paclitaxel (nab-PTX), ifosfamide and cisplatin in the treatment of pediatric advanced, recurrent or refractory extracranial germ cell tumor.
89197676|NCT00946738|Active Comparator|physical therapy|
89197677|NCT00946738|No Intervention|control|
89197678|NCT00857103|No Intervention|1|Standard care
89197679|NCT00857103|Experimental|2|Use of Choice intervention to support consultations
89197680|NCT00364351|Active Comparator|1|Erlotinib
89197681|NCT00364351|Experimental|2|Vandetanib
88911142|NCT02909777|Experimental|CUDC-907|"CUDC-907 orally administered~CUDC-907 once daily for 5 consecutive days per week followed by two days without dosing~Dose level assigned at registration~Pre-dose pharmacokinetic blood sample will be collected~Dose escalation will follow a standard 3+3 design"
89431793|NCT03410966|Experimental|Intervention group|All patients affected by paroxysmal symptomatic atrial fibrillation, and anti-arrhythmic drug refractory atrial fibrillation will receive a trans catheter ablation therapy (intervention).
89431794|NCT03410888|Experimental|popliteal approach|Blockade of the sciatic nerve at the level of the popliteal fossa.
89431795|NCT03410888|Active Comparator|infragluteal approach|Blocking the sciatic nerve at the subgluteal level.
89431796|NCT02100423|Experimental|Treatment (curcumin, cholecalciferol)|Patients receive curcumin PO daily on days 1-28 and cholecalciferol PO daily on days 8-28 of course 1 and days 1-28 of subsequent courses. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients achieving partial response or better may receive treatment for a total of 2 years.
88911143|NCT02908048||Hepatocellular Carcinoma|Blood samples will be collected at entry into the study and at varying intervals over a two to three year period.
88911144|NCT02908048||Biliary Tract Cancer|Blood samples will be collected at entry into the system and at varying intervals over a two to three year period.
89431797|NCT04787146||Patients|"From Monday to Friday, the study will be offered to patients selected consecutively and who have fallen within the previous 24 hours (between 7.55 a.m. the day before and 7.55 a.m. the next day).~After delivery of the written information note to the patient, the investigating physician answers the patient's questions and accepts his non-objection. The patient should be given sufficient time to think things through to make the decision to participate in the study.~Its non-opposition will be traced in the computerized medical file created on the day of its inclusion in the protocol. Each patient participating in the study retains the possibility of participating simultaneously in another research. No exclusion period is provided for in the protocol."
89431798|NCT03415100|Experimental|CAR-NK cells targeting NKG2D ligands|
89431799|NCT02098551||Four (4)|"Group 1: Birch pollen-related atopic dermatitis (AD) (n=15) Group 2: Birch pollen allergic patients without AD (n=5) Group 3: Allergic individuals without birch pollen allergy (n=5) Group 4: Non-allergic individuals (n=5)~Patients will be tested by SPT and APT:~SPT: Histamine, buffer, commercial birch pollen extract, rBet v 1, rBet v 1 fragment 1, rBet v 1 fragment 2, and equimolar rBet v 1 fragment mix (20 and 40 μg/ml) in duplets.~APT: birch pollen extract, rBet v 1, rBet v 1 fragment 1, rBet v 1 fragment 2, equimolar mix of rBet v 1 fragments (160 μg/application); negative control with vaseline"
89431800|NCT03410732|Experimental|Radical surgery plus activated DCs|In 21 days after a radical surgery, activated DCs are iv infused
89431801|NCT03410732|Active Comparator|Radical surgery only|Radical surgery only group as a control group
89431802|NCT03556605|Other|Intervention Arm|A target of 100 subjects will be enrolled in the Intervention arm using the OneTouch Reveal® Mobile APP system
88911145|NCT02908048||Cirrhosis|Blood samples will be collected during regular intervals over a three year period.
89431803|NCT03556605|Other|Control Arm.|A target of 50 subjects will be enrolled in the Control intervention arm. Subjects continue to use their current Blood Glucose Monitor without connection to mobile diabetes apps.
89431804|NCT02520830|Active Comparator|Blueberry Group|Dietary Supplement: 22 gram freeze-dried blueberry powder per day
89431805|NCT02520830|Placebo Comparator|Placebo Group|blueberry polyphenol deprived powder 22 gram per day
89431806|NCT04787068|Experimental|Treatment group|Intervention is occupational therapy support
89431807|NCT04787068|No Intervention|Control group|No intervention was provided, only educational material was given.
89431808|NCT02095041||Healthy Term infants|
89431809|NCT02094729|Experimental|BAN2401 2.5 mg/kg|Cohorts 1: Intravenous infusions of 2.5 mg/kg BAN2401
89431810|NCT02094729|Experimental|BAN2401 5 mg/kg|Cohorts 2: Intravenous infusions of 5 mg/kg BAN2401
89431811|NCT02094729|Experimental|BAN2401 10 mg/kg|Cohorts 3: Intravenous infusions of 10 mg/kg BAN2401
88911146|NCT02908048||Chronic Liver Disease without Cirrhosis|A single blood sample will be collected at entry into the study
89431812|NCT02094729|Placebo Comparator|Placebo|Intravenous infusions of placebo for 60 +/- 10 minutes.
89431813|NCT02520752|Experimental|INC280|
89431814|NCT05199922|Active Comparator|Group M = M-TAPA group|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by a pain nurse blinded to the procedure. 100 mg tramadol will be performed for rescue analgesia.
89536256|NCT04915287|Experimental|Avatrombopag|Oral administration of Avatrombopag Maleate Tablets to the thrombocytopenic patients with chronic liver disease undergoing an elective procedure whose mean baseline platelet count is less than 50 × 10^9/L. RhuTPO, rhIL-11, Romiplostim, Eltrombopag, or Lusutrombopag, etc., are prohibited during the trial.
88911147|NCT02908022|Experimental|Interaction|"Phase 1:~Prior to the MRI sessions, the clinician will be introduced to the patient and do a general intake of physical examination.~During the MRI sessions, the patient will receive experimental pressure pain via the Hokanson Rapid Cuff Inflator and electroacupuncture analgesia to the leg for pain relief."
88911148|NCT02908022|Experimental|No Interaction|"Phase 1:~The clinician and the patient will first be introduced at the MRI sessions.~During the MRI sessions, the patient will receive experimental pressure pain via the Hokanson Rapid Cuff Inflator and electroacupuncture analgesia to the leg for pain relief."
88911149|NCT02908022|Experimental|Longitudinal|"Phase 2:~Prior to first MRI session, both clinician and patient will go through a training visit.~During the first MRI session, the patient will receive experimental pressure pain to the left leg via Hokanson Rapid Cuff Inflator and electroacupuncture to the same leg for pain relief.~Following the first MRI session, the patient will attend biweekly acupuncture treatment sessions with the clinician (6 treatments total). During the first session the clinician will be introduced to the patient and do a general intake in addition to the acupuncture treatment.~The final MRI session will be identical to the first. The patient will receive experimental pressure pain via Hokanson Rapid Cuff Inflator and electroacupuncture to the same leg for pain relief."
88911150|NCT02896335|Experimental|Palbociclib|"Description Patients who fulfill eligibility criteria will be entered into the trial to receive Palbociclib~After the screening procedures confirm participation in the research study:~Palbociclib- Fixed Dose, daily for 21 days per cycle.~The participant will be requested to maintain a medication diary of each dose of medication. The medication diary will be returned to clinic staff at the end of each cycle."
88911151|NCT02890342||Affected Patients with Propionic Acidemia|Patients with Propionic Acidemia, standard adult, parental permission
88911152|NCT02890342||Healthy Volunteers|Healthy Volunteers, standard adult, parental permission
88911153|NCT02890342||Unaffected Family Members|Unaffected family members
88911154|NCT02886585|Experimental|Previously Untreated Brain Metastases-Cohort A|"- Previously Untreated Brain Metastases~Baseline Brain MRI and PET CT~For all cohorts, pembrolizumab will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle. Treatment will be administered on an outpatient basis.~Brain MRI and PET/CT"
88911155|NCT02886585|Experimental|Progressive Brain Metastases-Cohort B|"- Progressive Brain Metastases~Baseline Brain MRI and PET CT~For all cohorts, pembrolizumab will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle. Treatment will be administered on an outpatient basis.~Brain MRI and PET/CT"
88911156|NCT02886585|Experimental|Neoplastic Meningitis-Cohort C|"Neoplastic Meningitis~Histologically confirmed solid malignancy~Positive Cytology~Baseline Brain MRI~For all cohorts, pembrolizumab will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle. Treatment will be administered on an outpatient basis.~Brain MRI and PET/CT"
88911157|NCT02886585|Experimental|1-4 Brain Metastases from Melanoma Cohort D|"1-4 Brain Metastases from Melanoma~Clinical indication for stereostatic radiosurgery~Evaluable extracranial focus~For all cohorts, pembrolizumab will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle. In Cohort D, cycle 1 and 2 of pembrolizumab will be administered 3 weeks apart and stereotactic radiosurgery will be administered between cycles. Treatment will be administered on an outpatient basis.~Brain MRI and PET CT"
88911158|NCT02879318|Active Comparator|Gemcitabine plus Nab-Paclitaxel|Gemcitabine 1000 mg/m2 IV & Nab-Paclitaxel 125 mg/m2 until unequivocal progression or unacceptable toxicity. Days 1, 8, 15 Q28 days.
88911159|NCT02879318|Experimental|Gemcitabine + Nab-Paclitaxel + Durvalumab + Tremelimumab|"Gemcitabine 1000 mg/m2 IV & Nab-Paclitaxel 125 mg/m2 until unequivocal progression or unacceptable toxicity. Day 1, 8, 15 Q28 days.~plus Durvalumab 1500mg IV day 1 only Q28 days; and Tremelimumab 75 mg IV Days 1 cycles 1, 2, 3 and 4 only until unequivocal progression or unacceptable toxicity."
88911160|NCT02849223|Experimental|Transcranial Direct Current Stimulation|Participants will receive 24 sessions (3 times a week) of anodal transcranial direct current stimulation concurrent with working memory training. Stimulation will be administered at 2 milliamps (mA) for 20 minutes over the left dorsal lateral prefrontal cortex.
88911161|NCT02849223|Sham Comparator|Sham|Participants will receive 24 sessions of working memory training. The experience of transcranial direct current stimulation will be simulated by administering 30 seconds of stimulation at the beginning of the session.
88911164|NCT02830308||Adults with known or suspected endocrine or metabolic dissorde|Adults with known or suspected endocrine or metabolic dissorders
88911165|NCT02829268|Experimental|Pediatric|Pediatric patients treated with dantrolene sodium
88911166|NCT02829268|Experimental|Adult|Adult patients treated with dantrolene sodium
88911167|NCT02808156|Experimental|unilateral upper limbs intensive training|The unimanual intensive training group focuses on the training of the more affected arm and restraint the less affected arm.
88911168|NCT02808156|Experimental|bilateral upper limbs intensive training|The bimanual intensive training focuses activities that required the use of both hands.
88911169|NCT02802618|Experimental|Interactive 3D visualization technique|"The pulmonary rehabilitation consists of exercise training during 10 weeks and a theoretic part presented with 3D technique.~Patients randomized into education by 3D technique."
88911170|NCT02802618|No Intervention|Conventional technique|The pulmonary rehabilitation consists of exercise training during 10 weeks and a theoretic part presented with conventional technique. Patients randomized into education by conventional technique.
88911171|NCT02797899|Active Comparator|Palatal donor site received PRF|Following profound anesthesia and harvesting free gingival graft from the palate, the graft was positioned to the recipient area. The donor area were cleaned with sterile saline and received platelet rich fibrin and periodontal pack as assigned randomly by a flip of coin during the screening visits.
89536257|NCT04915287|Experimental|Conventional treatment|Conventional treatment (platelet transfusion if needed or rhuTPO, rhIL-11, Romiplostim, Eltrombopag, or Lusutrombopag, etc.) to the thrombocytopenic patients with chronic liver disease undergoing an elective procedure whoes mean baseline platelet count is less than 50 × 10^9/L.
89008770|NCT04580875|Active Comparator|Minimally invasive surgery (laparoscopy, laparoscopic-assisted procedures)|This study will be conducted out at 3 pediatric surgery tertiary centers (Al-Azhar University hospitals in Cairo, Prince Mohammed bin Abdulaziz Hospital in Riyadh and Maternity & Children's Hospital in Bisha) on patients aged from 1-14 years presenting to the ER by stable penetrating abdominal trauma with significant clinical/radiologic findings, in the period from April 2017 to March 2022. Responders to initial resuscitation will be managed by minimally invasive surgery (laparoscopy and laparoscopic-assisted procedures). All patients enrolled in the study will give a written informed consent even for possible conversion to laparotomy if necessary.
89008771|NCT04580875|Active Comparator|Conservative management|patients aged from 1-14 years presenting to the ER by penetrating abdominal trauma with imsignificant findings will be managed conservatively.
89008772|NCT04581109|Experimental|Patients with metastatic prostate cancer|
89008773|NCT02962466|Experimental|CC-Test diagnosis and Day 3 transfer|Patients undergo the standard ART treatment, as prescribed by the treating physician, with standard morphology based scoring of the embryos + the extra cumulus cell based diagnosis and transfer of the best embryo based on morphology and CC diagnosis on day 3 of embryo growth (cleavage stage embryo).
89008774|NCT02962466|No Intervention|D3 transfer control group|Patients undergo the standard ART treatment, as prescribed by the treating physician, with standard morphology based scoring of the embryos and transfer of the best embryo based on day 3 of embryo growth (cleavage stage embryo).
89008775|NCT02962466|No Intervention|D5 transfer control group|Patients undergo the standard ART treatment, as prescribed by the treating physician, with standard morphology based scoring of the embryos and transfer of the best embryo based on day 5 of embryo growth (blastocyst stage embryo).
89008776|NCT04580797|Experimental|PF-06700841: IR, MR1, MR2, MR1_fed|Participants receive single doses of immediate release (IR) followed by modified release (MR) MR1 and MR2, all in fasted condition followed by MR1 in fed condition in Periods 1-4
89008777|NCT04580797|Experimental|PF-06700841: MR1, MR2, IR, MR1_fed|Participants receive single doses of MR1 followed by MR2 and IR, all in fasted condition followed by MR1 in fed condition in Periods 1-4
89008778|NCT04580797|Experimental|PF-06700841: MR2, IR, MR1, MR1_fed|Participants receive single doses of MR2 followed by IR and MR1, all in fasted condition followed by MR1 in fed condition in Periods 1-4
89008779|NCT04580797|Experimental|PF-06700841: IR, MR1, MR2, MR2_fed|Participants receive single doses of IR followed by MR1 and MR1, all in fasted condition followed by MR2 in fed condition in Periods 1-4
89008780|NCT04580797|Experimental|PF-06700841: MR1, MR2, IR, MR2_fed|Participants receive single doses of MR1 followed by MR2 and IR, all in fasted condition followed by MR2 in fed condition in Periods 1-4
89008781|NCT04580797|Experimental|PF-06700841: MR2, IR, MR1, MR2_fed|Participants receive single doses of MR2 followed by IR and MR1, all in fasted condition followed by MR2 in fed condition in Periods 1-4
89008782|NCT04580797|Experimental|PF-06700841 MR3 (Dose A) or matching placebo|Participants receive dosing regimen 1 of MR3 (Dose A) or matching placebo for 7 days under fasted condition
89008783|NCT04580797|Experimental|PF-06700841 MR3 (Dose B) or matching placebo|Participants receive dosing regimen 1 of MR3 (Dose B) or matching placebo for 7 days under fasted condition
89008784|NCT04580797|Experimental|PF-06700841 MR3 (Dose C) or matching placebo|Participants receive dosing regimen 1 of MR3 (Dose C) or matching placebo for 7 days under fasted condition
89008785|NCT00415038|Experimental|Rostafuroxin 50 micrograms capsules|5 weeks, once a day capsule treatment of active drug or placebo, followed by a 5 weeks, once a day capsule treatment of placebo or active drug according to a cross-over design
89431815|NCT05199922|No Intervention|Group C = Control group|"Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by a pain nurse blinded to the procedure.~Wound local anesthetic infiltration will be applied to the patients in the control group. 100 mg tramadol will be performed for rescue analgesia."
89431816|NCT03410576||Carotid artery stenting|Patients undergo carotid artery stenting.
89008786|NCT00415038|Experimental|Rostafuroxin 150 micrograms capsules|5 weeks, once a day capsule treatment of active drug or placebo, followed by a 5 weeks, once a day capsule treatment of placebo or active drug according to a cross-over design
89008787|NCT00415038|Experimental|Rostafuroxin 500 micrograms capsules|5 weeks, once a day capsule treatment of active drug or placebo, followed by a 5 weeks, once a day capsule treatment of placebo or active drug according to a cross-over design
89008788|NCT00415038|Experimental|Rostafuroxin 1.5 mg capsules|5 weeks, once a day capsule treatment of active drug or placebo, followed by a 5 weeks, once a day capsule treatment of placebo or active drug according to a cross-over design
89008789|NCT00415038|Experimental|Rostafuroxin 5 mg capsule|5 weeks, once a day capsule treatment of active drug or placebo, followed by a 5 weeks, once a day capsule treatment of placebo or active drug according to a cross-over design
89008790|NCT00568477|Experimental|Arm 1|Treatment with rituximab
89008791|NCT00568477|No Intervention|Arm 2|Treatment without rituximab
89008792|NCT04580836|Experimental|Treatment (MRI-guided SBRT)|Patients undergo an MRI scan to check the status and location of the disease, including the motion of the tumor during breathing. Two weeks after MRI, patients undergo SBRT over 1-2 hours on 3 non-consecutive weekdays in the absence of disease progression or unacceptable toxicity.
89008793|NCT00415077|Active Comparator|2|LASEK- laser-assisted subepithelial keratectomy
89008794|NCT00415077|Active Comparator|3|Mitomycin C PRK
89008795|NCT00415077|Active Comparator|1|PRK- Photorefractive keratectomy
89008796|NCT00568516|Experimental|1.Low dose group|
89431817|NCT03410576||Carotid endarterectomy|Patients receive elective carotid endarterectomy.
89431818|NCT02100501||Atkins diet group|pediatric patients diagnosed with intractable epilepsy. Their ages ranged between 1 to 18 years amd indicated to dietary therapy. the targeting number of patients was 53. enrolled patients are assigned to randomly in one of KD group or Atkins group.
89431819|NCT02100501||Ketogenic diet group|pediatric patients diagnosed with intractable epilepsy. Their ages ranged between 1 to 18 years amd indicated to dietary therapy. the targeting number of patients was 51. enrolled patients are assigned to randomly in one of KD group or Atkins group.
89431820|NCT02100735|Experimental|Sedation protocol|Sedation protocol is a document that will be used to guide the adjustment of sedation in the ICU.
89431821|NCT02100735|Active Comparator|Standard of care|Current practices
89431822|NCT02095275||Acute kidney injury|ICU patients with Acute kidney injury
89431823|NCT03738202|Experimental|Intervention|Multifaceted intervention package will be implemented at textile mills in the intervention arm.
89431824|NCT03738202|No Intervention|Control|No intervention will be provided to mills in the control arm.
89431825|NCT05168852|Experimental|Permanent Resin 1 week|1st week control
89431826|NCT05168852|Experimental|Permanent Resin 6 mouth|6th month control
89431827|NCT01667224|Experimental|Actiponin|Actiponin(extract of Gynostema pentaphyllum, 450mg/day) for 12weeks
89431828|NCT01667224|Placebo Comparator|Placebo|Placebo(450mg/day) for 12weeks
89431829|NCT04709354||rheumatoid arthritis patient|Skin and fingernail examination of newly diagnosed (diagnosed before 1 year) rheumatoid arthritis patients will be done. A detailed dermoscopic examination will be performed on the nails of these patients.
89431830|NCT04709354||patients with spondylopathy|Skin and fingernail examination of newly diagnosed (diagnosed before 1 year) patient with spondylopathy will be done. A detailed dermoscopic examination will be performed on the nails of these patients.
89431831|NCT04709354||psoriatic arthritis|Skin and fingernail examination of patient with psoriatic arthritis will be done. A detailed dermoscopic examination will be performed on the nails of these patients. PASI and NAPSI scores of all patients will be calculated.
89431832|NCT04709354||psoriasis patients without joint involvement|Skin and fingernail examination of patient with psoriasis patients without joint involvement will be done. A detailed dermoscopic examination will be performed on the nails of these patients. PASI and NAPSI scores of all patients will be calculated.
89431833|NCT02095431||with AKI and without AKI|development of AKI by sCr and by novel biomarkers
89431834|NCT02098629|Active Comparator|Milrinone+Esmolol|"Approximately 5 minutes before stent deployment, the patients in the milrinone+esmolol group start to receive continuous intravenous drug infusion for 10 minutes. Milrinone and esmolol (each in 10 ml volume) will be placed in two separate syringes being connected to their respective venous catheters.~Dosage of study drugs: Syringe #1 Milrinone 5 ug/kg/min Syringe #2 Esmolol 10 ug/kg/min"
89008797|NCT00568516|Experimental|2.High dose group|
89431835|NCT02098629|Placebo Comparator|Saline infusion|Approximately 5 minutes before stent deployment, the patients in the placebo group start to receive continuous intravenous saline infusion for 10 minutes. Two syringes containing saline (10 ml volume in each) will be connected to two separate venous catheters during the infusion.
89431836|NCT03397472|Experimental|treatment group|use the sleep pillow with the magnetic field modulation treatment
89431837|NCT03397472|Placebo Comparator|placebo group|use the sleep pillow without magnetic field modulation treatment
89431838|NCT05176912|Experimental|Experimental Exercise Group|Reformer Pilates exercises will given for 8 weeks, 3 days in a week.
89008798|NCT00224198||Lung Disease|All study individuals will be males or females that are 18 years or older and are able to provide informed consent and have been diagnosed with lung disease.
89008799|NCT00568711|Active Comparator|1|a 5-day course of daily 200-mg doses of doxycycline
89008800|NCT00568711|Active Comparator|2|a 5-day course of daily 600-mg doses of rifampin
89008801|NCT04580758|Active Comparator|Fractional laser with PRP fluid|Fractional CO2 laser then the PRP is injected afterwards
89008802|NCT04580758|Active Comparator|Fractional laser with PRP gel|Fractional CO2 laser then the PRP gel is injected afterwards
89008803|NCT04580641||Subjects with migraine|No medical intervention. All included subjects will filled in the questionnaire concerning migraine characteristics and associated symptoms.
89008804|NCT00568750|Experimental|Dasatinib|
89008805|NCT00224237||A|Participants will be self-identified, adult Latino men and women from the community setting. The sample will comprise of a convenience sample from community-based organizations, including persons of Mexican, Puerto Rican, Cuban, Dominican, Central American, South American, or other Spanish-speaking culture.
89008806|NCT00568789|Experimental|Ramelteon 8 mg, zolpidem 10 mg and placebo|
89008807|NCT00568945|Experimental|Arm 1|
89008808|NCT00569023|Experimental|A,1,I|
89008809|NCT00569101|Experimental|single|single arm study (tacrolimus trial group)
89008810|NCT00569179|Experimental|Alloreactive NK cell infusion|Escalating doses of alloreactive NK cells.
89431839|NCT05176912|No Intervention|Control Group|Nothing given to the control group, will be told to continue their normal life for 8 weeks.
89431840|NCT03397316|No Intervention|Marginal bone loss without grafting.|immediate implant placement in upper esthetic zone.
89431841|NCT03397316|Active Comparator|marginal bone loss with xenograft.|xenograft placement (Geistlich Bio-Oss) in immediate implant placement in upper esthetic zone between the residual labial bone and implant surface.
89431842|NCT03555357|Active Comparator|PRP|Platelet Rich Plasma (PRP) injections into one half of the scar will be preformed. PRP is already considered an effective treatment for scar therapy.This will be randomly assigned by the clinical research coordinator .
89431843|NCT03555357|Experimental|PRF|Platelet Rich Fibrin (PRF) injections will be preformed the other half of the scar that is not treated with PRP. PRF has not been established as an effective scar treatment. The PRF will be considered experimental as this study seeks to evaluate if it is more effective than PRP.
89431844|NCT03397160|No Intervention|Usual care|Participants assigned to the control arm will receive usual care, including whatever information materials are provided to them by their urologist.
89431845|NCT03397160|Active Comparator|Decision Support Intervention (DSI)|"Participants assigned to the intervention will receive Decision Support Intervention in the form of a decision aid plus health coaching. The decision aid (delivered by internet and as a Portable Document Format (PDF) document) provides participants with a report on options and outcomes as described in the literature; along with more tailored risk information. The tailored risk information will include their estimated risk of harboring more aggressive prostate cancer based on their clinical/pathologic features (i.e., My Clinical Risk). The DSI was developed and piloted at UCSF according to the International Patient Decision Aid Standards (see http://ipdas.ohri.ca/) (IRS# 14-13332), and incorporates tailored risk models developed and validated."
89431846|NCT02098707||30 Parkinson disease patients|30 patients (12 M, 18 F, mean age 66,8 ± 8,7) diagnosed with PD in stage 3 of Hoen&Yahr (mean Unified Parkinson Disease Rating Scale [UPDRS] III 18.8±10.5) will undergo a balance training using a stabilometric platform.
89431847|NCT04649918||mild to moderate COVID 19|patients post-acute mild to moderate COVID 19
89431848|NCT04649918||severe to critical COVID 19|patients post-acute severe to critical COVID 19
89431849|NCT05053672|No Intervention|Conventional therapy back pain treatment|Participants randomized to сonventional therapy group will receive complex rehabilitation program including physical exercise, phonophoresis with hydrocortisone, lumbar region massage, acupuncture within 2 weeks.
89431850|NCT05053672|Active Comparator|Conventional physiotherapy therapy back pain treatment + ReOxy-therapy|Participants randomized to Active Comparator group will receive complex rehabilitation program and 10 ReOxy-therapy sessions within 2 weeks (5 sessions per week).
89008811|NCT00569296|Experimental|T-cells|EGFRBi-armed autologous activated T cells
89431851|NCT05053672|Placebo Comparator|Conventional physiotherapy therapy + Sham ReOxy-therapy|Participants randomized to Placebo Comparator group will receive complex rehabilitation program and 10 sham ReOxy-therapy sessions within 2 weeks (5 sessions per week).
89431852|NCT02095509|Active Comparator|Subcutaneous Enoxaparin|Subcutaneous enoxaparin 40 mg every 24 hours for three days
89431853|NCT02095509|Active Comparator|Intravenous Enoxaparin|40 mg enoxaparin daily as continuous intravenous infusion for three days (72 hours)
89431854|NCT03397082|Experimental|Lidocaine + Paracervical blockade|5 minutes previous to endouterine manual aspiration, 5mL of lidocaine gel was applied plus standard paracervical blockade.
89008812|NCT00569335|Experimental|1|S-1, Irinotecan, Bevacizumab
89431855|NCT03397082|Placebo Comparator|Placebo + paracervical blockade|5 minutes previous to endouterine manual aspiration, standard paracervical blockade was applied plus placebo gel (KY).
89431856|NCT05164276|Active Comparator|Sniffing group|Before intubation, the patient's shoulder is supported by a 5cm pillow to make neck flexion with extension of atlanto-occipital joint, confirming that the external auditory meatus and sternal notch plane are horizontal and aligned. Then, nasotracheal intubation is performed with a reinforced tube (Mallinckrodt Medical, Dublin, Ireland) using video-laryngoscope (AceScope, AceMedical, Seoul, Korea).
89431857|NCT05164276|Experimental|Neutral group|Before intubation, the patient's head is placed without a pillow on the bed. Then, nasotracheal intubation is performed with a reinforced tube (Mallinckrodt Medical, Dublin, Ireland) using video-laryngoscope (AceScope, AceMedical, Seoul, Korea).
89431858|NCT05164276|Experimental|Flexed group|Before intubation, the patient's neck is flexed with pads until the chin touches the chest. Then, nasotracheal intubation is performed with a reinforced tube (Mallinckrodt Medical, Dublin, Ireland) using video-laryngoscope (AceScope, AceMedical, Seoul, Korea).
89008813|NCT00569413||1|Healthy control subjects (n=20) age 21-65 who do not suffer from a psychiatric diagnosis or neurological damage, are under age, or are pregnant women
89008814|NCT00569413||2|20 patients who suffer from sexual disorder (reduced sexual desire or sexual function) from a sexual disorder clinic, age 21-65, without any other psychiatric disorder, neurological damage, are not under age or pregnant women.
89431859|NCT02101047|Experimental|phenylephrine 50mcg bolus|Phenylephrine 50 mcg bolus dosing with continuous placebo infusion
89431860|NCT02101047|Experimental|Phenylephrine 100 mcg bolus|Phenylephrine 100 mcg bolus dosing wtih continuous placebo infusion.
89431861|NCT02101047|Experimental|Phenylephrine continuous infusion 100mcg/min|Continuous phenylephrine infusion of 100 mcg/min with placebo bolus dosing.
89008815|NCT00569452|Experimental|A|
89008816|NCT00569452|Experimental|B|
89008817|NCT00569569|Experimental|1|Patients treated with Retaane
89431862|NCT03396848|Experimental|SHAReClinic|All participants will have access to the online clinic
89431863|NCT02095587|Experimental|Mild Hepatic Impairment|
89431864|NCT02095587|Experimental|Moderate Hepatic Impairment|
89431865|NCT02095587|Experimental|Healthy Subjects|
89431866|NCT02095587|Experimental|Severe Hepatic Impairment|Optional arm based on results from Arms 1, 2, and 3
89431867|NCT03396536||Group 1|Group 1 will be implants with keratinized mucosa (KM).
89008818|NCT00569608|Experimental|EDA|Neonates submitted to the protocol of early discharge.
89008819|NCT00569608|No Intervention|SDP|Discharge following the standard protocol of the neonatal intensive care unit.
89431868|NCT03396536||Group 2|Group 2 implants without keratinized mucosa (KM). Alveolar mucosa (AM) directly present around the implant.
89431869|NCT02095665|Active Comparator|Narcotic analegesic only|"Drug:~Tylenol #3 1 tablet every six hours as necessary"
89431870|NCT02095665|Active Comparator|Mirabegron and narcotic analgesia|"Drug :~Mirabegron 50 mg oral daily~Drug:~Tylenol #3 1 tablet every six hours as necessary"
89431871|NCT02095665|Active Comparator|Tamsulosin and narcotic analgesia|"Drug:~Tamsulosin 0.4mg oral daily Drug: Tylenol #3 1 tablet every six hours as necessary"
89431872|NCT02095665|Experimental|Mirabegron, Tamsulosin and narcotic|"Drug:~Mirabegron 50 mg oral daily~Drug:~Tamsulosin 0.4mg oral daily~Drug:~Tylenol #3 1 tablet every six hours as necessary"
89431873|NCT03414944|Experimental|SMART-Brain|selective brain radiotherapy based on SIB and hippocampus, inner ear avoidance.
89431874|NCT02101125|Experimental|BMS-986020 + Rosuvastatin (Treatment A, B and C)|"Cohort 1: Rosuvastatin Tablet Single dose and BMS- 986020 orally on specific days~Cohort 2 (Administered 4 hrs, after the morning dose of BMS-986020): Rosuvastatin Tablet Single dose and BMS- 986020 orally on specific days"
89431875|NCT04602182|Experimental|music therapy gruop (experimental group)|Experimental group: Patients will receive a daily music therapy intervention from the beginning until the end of the weaning from mechical ventilation.
89431876|NCT04602182|Active Comparator|control group|Control group: Patient will follow the usual clinical practice for the weaning from mecanichal ventilation to the end of the weaning.
89431877|NCT02101203|Experimental|Placebo|40 subjects administered placebo
88911172|NCT02797899|Active Comparator|Palatal donor site NOT receiving PRF|Following profound anesthesia and harvesting free gingival graft from the palate, the graft was positioned to the recipient area. The donor area were cleaned with sterile saline and sutured followed by periodontal pack application.
88911173|NCT02789774|Experimental|Surgical treatment|Stabilization of odontoid fracture with posterior fusion C1-C2
88911174|NCT02789774|Active Comparator|Conservative treatment|External stabilization of odontoid fracture with a rigid cervical collar for 3 months.
88911175|NCT02753972|Experimental|Mindful Eating and Living|The goal of the Mindful Eating and Living (MEAL) intervention was to apply mindfulness to apply mindfulness to eating behavior. The content for the MEAL sessions included group discussion, mindfulness meditation, and group eating exercises. The course, based on the work of Kristeller, Baer, & Quillian-Wolever (31), emphasized brief daily meditation and pairing meditation with eating, but was more streamlined in terms of didactic content and course length. Participants examined hunger and satiety cues, the qualities of foods they crave, and emotional and cognitive states associated with eating. Each session included an eating exercise with a variety of foods. The monthly refresher sessions included a brief meditation, a brief eating exercise, and group discussion. (The MEAL curriculum is available from the authors.)
88911176|NCT02753972|Active Comparator|Active Control|The Active Control (CONT) group matched the MEAL group regarding schedule. The agenda for the CONT sessions involved giving each participant the opportunity to discuss issues such as food choices, activity levels, and caloric goals. The sessions began by having the participants check-in about their experiences with eating. Next, the clinical psychology graduate student led the participants in goal setting and finally there was a question and answer period when the registered dietician answered questions about food selection. The monthly refresher sessions had the same agenda as the initial weekly sessions.
89431878|NCT02101203|Experimental|Testosterone + Buspirone|40 subjects administered 0.5 mg Testosterone + 10 mg Buspirone hydrochloride
89431879|NCT04583384|Other|Assigned Intervention|"Addition to the cervical angio-MRI, of a sequence of 1H-SRM 3T (SUCCESS) centered on the lesion studied, performed according to the following parameters: PRESS asymmetric monovoxel PROBE, TE 144 ms, TR 2500 ms, 768 or 1024 medium."
89431880|NCT03414866||Acute thoracic aortic syndrome|60 patients, standard of care (non-interventional) EQ-5D-5L QOL Questionnaire
89431881|NCT03414866||Subacute/chronic dissection of the aorta|60 patients, standard of care (non-interventional) EQ-5D-5L QOL Questionnaire
89431882|NCT03414866||Aortic aneurysm|60 patients, standard of care (non-interventional) EQ-5D-5L QOL Questionnaire
89431883|NCT05110846|Placebo Comparator|Placebo|Placebo
89431884|NCT05110846|Experimental|CT-868 Low Dose|CT-868
89431885|NCT05110846|Experimental|CT-868 Maximum Tolerated Dose|CT-868
89431886|NCT02101593|Experimental|ADI-PEG 20|
89431887|NCT04523246|Experimental|Shingrix|Shingrix Dosage: two .5 ml injections into the deltoid muscle, administered 3 months apart (Day 0 and Day 90).
89431888|NCT04523246|Placebo Comparator|Normal Saline|Sterile Normal Saline Solution, two .5 ml injections into the deltoid muscle, administered 3 months apart (Day 0 and Day 90)
89431889|NCT02102607||age|subjects stratified according to age: 20-30 years (Group 1), 31-40 years (Group 2), 41-50 years (Group 3), 51-60 years (Group 4), 61-70 years (Group 5), and 71-80 years (Group 6).
89431890|NCT03414788|Experimental|Treatment Arm - PF 06687234 and [124I]IB PF 06687234|PF 06687234 and [124I]IB PF 06687234
89536258|NCT05709353|Experimental|COPE + MDMA|"4x COPE sessions~Dose 1:~2x MDMA capsules (80mg) + 1x niacin-matched placebo capsule~Optional supplementary dispense:~1x MDMA capsule (40mg)~4x COPE sessions~Dose 2:~2x MDMA capsules (80mg) + 1x niacin-matched placebo capsule~Optional supplementary dispense:~1x OR 2x white MDMA capsule (40 or 80mg)~4x COPE sessions"
89536259|NCT05709353|Other|COPE + Niacin (Control)|"4x COPE sessions~Dose 1:~2x MDMA-matched placebo capsules + 1x niacin capsule (250mg)~Optional supplementary dispense:~1x MDMA-matched placebo capsule~4x COPE sessions~Dose 2:~2x MDMA-matched placebo capsules + 1x niacin capsule (250mg)~Optional supplementary dispense:~1x OR 2x MDMA-matched placebo capsule~4x COPE sessions"
88911181|NCT02747004|Experimental|Abemaciclib + Tamoxifen|Abemaciclib given orally every 12 hours (Q12H) in combination with tamoxifen given orally every day. Participants may continue to receive treatment until discontinuation criteria are met.
88911182|NCT02747004|Experimental|Abemaciclib|Abemaciclib given orally Q12H. Participants may continue to receive treatment until discontinuation criteria are met.
88911183|NCT02747004|Experimental|Abemaciclib + Prophylactic Loperamide|Abemaciclib given orally Q12H in combination with prophylactic loperamide given orally. Participants may continue to receive treatment until discontinuation criteria are met.
88911184|NCT02725463|Experimental|vestibular implant|Up to 30 participants will undergo implantation, activation and deactivation of a Labyrinth Devices MVI™ Multichannel Vestibular Implant System
88911185|NCT02724488||Part 1|Patients with a histological or cytological diagnosis of advanced solid tumors who are currently on immune checkpoint inhibitors will have archival tumor specimens requested and used for whole exome sequencing (WES) of tumor DNA. 3 tubes of blood at a single time point will be collected for ctDNA analysis and germ line DNA analysis (to study normal variants) using next generation sequencing.
88911186|NCT02724488||Part 2|Patients with a histological or cytological diagnosis of advanced solid tumors who are candidates for a phase I, II, or III clinical trial testing immune checkpoint inhibitors (ICIs) or planning to have treatment with ICIs or other immunological therapy as standard of care will have image-guided fresh tumor core needle biopsy at a maximum of 3 time points: 1) prior to commencement of immune checkpoint inhibitors, 2) when disease response to therapy is confirmed using radiology RECIST 1.1 criteria and/or immune related response criteria, and 3) when radiological disease progression is confirmed by using RECIST 1.1. Blood samples for ctDNA analysis will be collected at the commencement of immunotherapy and every 6-12 weeks thereafter until radiological disease progression is confirmed.
88911187|NCT02720094|Experimental|Arm A|In Step 1, participants will receive daily oral CAB and daily oral TDF/FTC placebo for 5 weeks. In Step 2, participants will receive CAB LA and daily oral TDF/FTC placebo to Week 153. In Step 3, participants will receive daily oral TDF/FTC starting at Week 153 and for 48 weeks.
88911188|NCT02720094|Experimental|Arm B|In Step 1, participants will receive daily oral TDF/FTC and daily oral CAB placebo for 5 weeks. In Step 2, participants will receive daily oral TDF/FTC and placebo for CAB LA to Week 153. In Step 3, participants will receive daily oral TDF/FTC starting at Week 153 and for 48 weeks.
89536260|NCT03195673|Experimental|TZ group|"Treatment:Patients in this group received standard medical therapy and Terazosin (TZ) treatment.~Drug: TZ 0.5mg once a day for 3-7 days before carotid artery stenting to 30 days later.~Procedure: Carotid Artery Stenting"
89536261|NCT03195673|Other|control group|Treatment: Patients in this group received standard medical therapy alone. Procedure: Carotid Artery Stenting
89536262|NCT02481791|Experimental|Remifentanil|"Induction Phase: A dose of remifentanil 1mcg/kg by slow bolus, will be given to facilitate endotracheal intubation. Further doses of either remifentanil (0.5 mcg/kg) or propofol (1-2mg/kg) may be given to ensure an anaesthetised patient.~Settling Period: An infusion of the test dose of remifentanil will be commenced from an infusion prepared prior to the patient being anaesthetised. 1mg of Remifentanil (one vial) will be diluted to a volume of 50mls in normal saline 0.9% in a 50ml syringe. Maintenance dose of propofol 130 mcg/Kg/min for the first 5 minutes reduced to 100 mcg/kg/min thereafter. 40mls of propofol 1% (10mg/ml) will be drawn undiluted into a 50ml syringe. During the settling period further doses of either remifentanil (0.5 mcg/kg) or propofol (1-2mg/kg) may be given.~Equilibrium Period: During this period propofol will be infused at a constant rate of 100mcg/kg/min."
89536263|NCT02447731||Sonic Gas Exchange|"Gas exchange rates in the lungs of subjects breathing through a mouthpiece will be compared with their gas exchange rates after addition of sound pressure vibrations into the supplied gas. 'Induction of sound waves in lungs by sonic oscillator' can be as loud as a human screaming or singing very loudly (about 95 dB). The effects of these pressure oscillations on gas exchange will be assessed using 3 tests as explained in the section under detailed description."
89536264|NCT03314285|Other|Neck Pain|Patients with chronic mechanical neck pain will be evaluated for sleep quality by the Pittsburgh Sleep Quality Scale.
89536265|NCT03314285|Other|Healthy volunteers|Healthy volunteers without any disease will be evaluated for sleep quality by the Pittsburgh Sleep Quality Scale.
89536266|NCT04484467|Experimental|Food supplement Standart Zdorovya GASTRO|"In the intervention group (Group 1), the supplement Standart Zdorovya GASTRO (1 capsule, 730 mg, once a day) was added to the standard treatment regimen for 30 days."
89536267|NCT04484467|Placebo Comparator|Placebo|In the control group (Group 2), placebo (1 capsule, 730 mg, once a day) was added to the standard treatment regimen for 30 days.
89536268|NCT03209167||DIEAP group|Patients who had undergone DIEAP flap breast reconstruction
89536269|NCT03209167||AP group|Patients who had undergone conventional abdominoplasty
89008820|NCT00569647|Experimental|v|Use of VRH headset
89008821|NCT00569647|Placebo Comparator|c|
89008822|NCT00569686|Active Comparator|1|treatment with lovaza
89008823|NCT00569686|Placebo Comparator|2|
89197682|NCT00854139|Experimental|Bone marrow and renal transplant|Cyclophosphamide, anti-thymocyte globulin, thymic irradiation conditioning and kidney transplant and bone marrow transplant from a related donor for patients with multiple myeloma and end stage renal disease with cyclosporine for graft versus host disease prophylaxis
89197683|NCT00755820||EXP-DCS/Exposure-D-cycloserine|Exposure Therapy + D-Cycloserine
89008824|NCT00569764||observational|patients with schizophrenia who want to change an antipsychotics due to metabolic side effect
89008825|NCT00569842||observational|
89197684|NCT00755820||EXP-PBO|Exposure Therapy + Placebo
89197685|NCT00755820||SP|Supportive psychotherapy
89197686|NCT00952042|Experimental|Heavy slow resistance training|12 wks of heavy slow resistance training. training three times per week. each session: 3 heel-raise exercises. 12-6RM. Slow contractions.
89197687|NCT00952042|Active Comparator|Eccentric resistance training|12 wks of eccentric resistance training. 3 x 15 Eccentric heel-raises performed twice daily.
89197688|NCT00854217|Placebo Comparator|placebo, hemodilution|
89431891|NCT03410264|Experimental|CR-EXP|Cognitive restructuring before exposure with response prevention (45 minute intervention).
89431892|NCT03410264|Experimental|EXP-CR|Exposure with response prevention before cognitive restructuring (45 minute intervention).
89431893|NCT03410264|Active Comparator|Stress Management|Stress management skills.
89431894|NCT02102685|Active Comparator|VAC Therapy|active comparator: 14 patients within the first three days the VAC therapy was placed , proceeding as follows : organize the material , bandage removal , cleaning of the wound with irrigation solution , cut the sponge and placement on the wound , use of polyvinyl alcohol and / or silver foam, insertion of the tube seal and connection to the containing recipient.
89431895|NCT02102685|Placebo Comparator|Traditional Therapy|14 patients: after surgical drainage, a culture was taken, photographs every three days (during hospital stay ) and secretion culture; daily cleaning stipulated by the service was perform. The control of the patients were made until wound closure (presence of epithelialization tissue) .
89431896|NCT05083078|Experimental|Part 1: Healthy Participants-Coadministration|Healthy participants will receive a single co-administered dose of risankizumab and guselkumab subcutaneously (SC) on Day 1.
89431897|NCT05083078|Experimental|Part 2: Psoriatic Arthritis (PsA) Participants-Coadministration|Participants with PsA will receive a single co-administered dose of risankizumab and guselkumab SC on Day 1 and Day 29.
89431898|NCT05083078|Experimental|Part 3: PsA Participants-Separate Administration|Participants with PsA will receive a single dose of either risankizumab or guselkumab SC on Day 1 and Day 29.
89431899|NCT02520674|Other|Glaucoma and Ocular Hypertension|Patients to be examined with both smartphone ophthalmoscopy and slit-lamp biomicroscopy.
89431900|NCT05068024|Experimental|Treatment of NSCLC patients with EGFR or HER2 genetic alterations|
89431901|NCT03414710|Experimental|Intervention group|"Health education booklet plus video plus brief counseling~In addition to the educational booklet received by the control group, the intervention group will receive the following health promotion:~Watch a 10-minute video promoting VMMC~Receive a brief counseling promoting VMMC If the participants are willing to take up VMMC, the counselors will facilitate them to make an appointment for check-up and surgery."
89431902|NCT03414710|Active Comparator|Control group|"Health education booklet only After randomization took place, the control group will receive an education booklet introducing voluntary medical male circumcision.~If the participants are willing to take up VMMC, the counselors will facilitate them to make an appointment for check-up and surgery."
89008826|NCT00569881||1|Corneal epithelial wound healing with moxifloxacin
89431903|NCT03555201|Experimental|Manual therapy|Protocol of soft tissue techniques
89431904|NCT03555201|Active Comparator|Regular treatment control.|Regular treatment control.
89431905|NCT03396458||Hepatitis B group|Hepatitis B serology and questionnaire
89431906|NCT04940884|Experimental|Supervised exercise training|Pre- and Post- exercise training effects. Part of the participants were randomly assigned to underwent additional 24 sessions of supervised exercise training (SET) and the remaining participants follow the above instruction without additional supervised exercise training. After the 24 sessions of SET, they were then followed a 16-week of follow-up of their daily activities without additional exercise training.
89431907|NCT04940884|Active Comparator|home exercise training|All included subjects were instructed to walk>=8000 steps per day (stp/d), which was recorded by wrist-worm smart watches
89431908|NCT02102841|Experimental|Skin biopsy|5mm skin punch biopsy on forearm
89431909|NCT02102841|Experimental|Skin suction blister|Skin suction blister induced on forearm
89431910|NCT02102841|Experimental|Mantoux, skin biopsy, suction blister|0.1ml tuberculin purified protein derivative (PPD) is injected intradermally into an area of non-lesional skin on the volar aspect of each of the patient's forearms. This is followed by a skin biopsy on one arm and induction of a skin suction blister on the other arm.
89431911|NCT05613634|Experimental|Study group|The study group received rTMS in addition to the vestibular physical therapy exercises
89536270|NCT02478203|Placebo Comparator|normal|intubation of a normal airway pediatric manikin with direct laryngoscopy, airtraq , glidescope
88911207|NCT02707978|Experimental|Experimental F 18 T807|
89431912|NCT05613634|Experimental|Control group|Patients in control group received the vestibular physical therapy exercises, three sessions a week for four weeks
89431913|NCT03396380|Active Comparator|vitamin D|93 women who will receive clomiphene citrate for induction of ovulation with vitamin D and calcium supplement
89431914|NCT03396380|Placebo Comparator|placebo|93 women who will receive clomiphene citrate for induction of ovulation with placebo and calcium supplement
88911208|NCT02703493|Experimental|Cohort 1|Patients will receive 6 weeks of Intensity-Modulated Radiation Therapy (IMRT) (standard of care) followed by the dose escalated stereotactic radiosurgery (SRS Boost). Cohort 1 will receive 8 Gy in a single fraction, cohort 2 will receive 10 Gy in a single fraction and cohort 3 will receive 10 Gy split into two fractions.
88911209|NCT02701712|Experimental|Magnetic resonance - guided radiation therapy (MRgRT)|Magnetic resonance (MR) - guided radiation therapy
88911210|NCT02678884|Experimental|HNSCC Patients receiving RT|
88911211|NCT02670837|Experimental|Graft from HCT donor|Cells are harvested from a donor using Cellutome, then transferred via Adaptic dressing to the recipient's wound with up to 3 donor harvest sites/treated wound sites on day 0.
88911212|NCT02670837|Experimental|Self donor from intact skin patch|Cells are harvested from the subject using Cellutome, then transferred via Adaptic dressing to that subject's wound with up to 3 harvest sites/treated wound sites on day 0.
88911213|NCT02656381||Anterior Uveitis|Participants with AU at entry
88911214|NCT02656381||Intermediate Uveitis|Participants with IU at entry
88911215|NCT02656381||Other|Participants not fitting above criteria
88911216|NCT02656381||Posterior/Pan Uveitis|Participants with non-infectious posterior or pan-uveitis
88911217|NCT02653300|Experimental|Oral Insulin|treatment
89431915|NCT02102919|Experimental|Intervention group|T0 - intervention over 4 weeks with stochastic resonance whole-body vibration (SR-WBV) (start with 3 up to 6 Hz, noise 4) T1 - intervention 4 weeks (SR-WBV (start with 3 up to 6Hz, noise 4 & virtual games) - T2
88911218|NCT02645266|Experimental|Aflibercept Injection [Eylea] group|Intervention: Subjects will be receiving a (2mg/ml) dose of VEGF-Trap, injected intravitreally at the start of every month, for the 4 months duration of the trial.
88911219|NCT02636322|Experimental|RLI WITH EPOCH|"SMART START: Patients receive rituximab IV over 4-6 hours on day 1, lenalidomide PO QD on days 1-10, and ibrutinib PO QD on days 1-21. Treatment repeats every 21 days for 2 cycles in the absence of disease progression or unacceptable toxicity.~After SMART START therapy, patients receive rituximab IV over 4-6 hours on day 1, lenalidomide PO QD on days 1-10, and ibrutinib PO QD on days 1-21. Patients also receive etoposide IV over 24 hours on days 1-4, prednisone PO QD on days 1-5, vincristine sulfate IV over 24 hours on days 1-4, doxorubicin hydrochloride IV over 24 hours on days 1-4, and cyclophosphamide IV over 1 hour on day 5. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity."
88911220|NCT02636322|Experimental|RLI WITH R-CHOP|"SMART START: Patients receive rituximab IV over 4-6 hours on day 1, lenalidomide PO QD on days 1-10, and ibrutinib PO QD on days 1-21. Treatment repeats every 21 days for 2 cycles in the absence of disease progression or unacceptable toxicity.~After SMART START therapy, patients receive rituximab IV over 4-6 hours on day 1, lenalidomide PO QD on days 1-10, and ibrutinib PO QD on days 1-21. Patients also receive prednisone PO QD on days 1-5, vincristine sulfate IV over 1 hour on day 1, doxorubicin hydrochloride IV over 1 hour on day 1, and cyclophosphamide IV over 1 hour on day 1. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity."
88911221|NCT02610465||1|Computed Tomography (CT) images
89008827|NCT00569881||2|Corneal epithelial wound healing with gatifloxacin
89431916|NCT02102919|Sham Comparator|Sham Comparator|T0 - intervention 4 weeks (SR-WBV 1 Hz, noise 1) - T1 - intervention 4 weeks (SR-WBV 1 Hz, noise 1 & Aktiv Tramp) - T2
89431917|NCT03464110|No Intervention|Standard of Care|Investigator will compare patients randomized into the intervention group to those who receive standard of care.
89431918|NCT03464110|Experimental|Communication Intervention|The intervention will contain elements of Motivational Interviewing coaching but also will teach providers how to address patient emotion and increase the efficiency of their visits. Clinicians randomized to the intervention will receive a tailored communication coaching intervention that includes didactic elements, audio recording encounters and providing feedback, and role-playing.
89197689|NCT00943228|Experimental|mycophenolate mofetil|mycophenolate mofetil 2000mg BID (4g/day) for 14 days, followed by mycophenolate 1000mg BID (2g/day) thereafter
88911222|NCT02597426||Patient|Nasopharyngeal carcinoma (NPC) patients who are disease free more than four years after definitive management with radiotherapy +/- chemotherapy who were treated with Intensity-Modulated Radiotherapy (IMRT), study will involve Collection of demographic data, endocrine assessment (Pituitary and Thyroid), Patient reported outcomes (Quality of Life Questionnaire), neurocognitive assessment (Behavioral rating scale) and audiology assessment (Assessment of hearing)
88911223|NCT02597426||Caregiver/Family member|Caregivers for patients who consent to participate. Study will involve Frontal Systems Behavior Scale- FrSBe (behavioral rating scale)
88911224|NCT02591134|Experimental|Non Nutritive Sweetened Beverages|Non-nutritive sweeteners (NNS) beverages will be provided to participants using a home delivery system and they are expected to consume at least two portions (330ml) per day.
88911225|NCT02591134|Placebo Comparator|Control Water Beverages|Water beverages will be used as a comparator to NNS beverages during the trial. These beverages will encompass a range of water-based drinks that contain no NNS. Including water as a comparator is vital to understand whether NNS beverages are equally as effective as water during phases of weight loss and weight maintenance.
88911226|NCT02590783|Experimental|experimental intervention surgery|screw osteosynthesis of the sacrum and in certain cases additional plate osteosynthesis of dislocated pubic rami fractures, postoperative analgesia, physiotherapy, work-up for osteoporosis, geriatric rehabilitation if necessary
88911227|NCT02590783|Active Comparator|control intervention conservative|analgesia, physiotherapy, work-up for osteoporosis, geriatric rehabilitation if necessary
88911228|NCT02584647|Experimental|Phase 1: PLX3397 and Sirolimus|Cohort 1 (Phase 1): Subjects with unresectable or metastatic sarcoma will take orally PLX3397 (600 - 1000mg) in combination with Sirolimus (2-6mg) daily .
88911229|NCT02584647|Experimental|Phase 2: PLX3397 and Sirolimus|Cohort 2 (Phase 2): Subjects with unresectable or metastatic Malignant Peripheral Nerve Sheath Tumors (MPNSTs) will take PLX3397 and Sirolimus at the recommended Phase 2 dose (RP2D).
88911230|NCT02574910|Experimental|Abiraterone acetate 1 mg/kg/d|Abiraterone acetate will be administered orally at a daily dose of 1 mg/kg for 7 days in addition to the standard of care treatment of hydrocortisone and fludrocortisone.
89008828|NCT00224471|Experimental|Group A|
89536271|NCT02478203|Active Comparator|tongue edema|intubation of a tongue edema simulated pediatric manikin with diract laryngoscopy, glidescope and airtraq
89431919|NCT04449926|Experimental|BCG Vaccinated|"Experimental: BCG Group FDA-approved BCG Tice strain, procured from Merck, will be used. The vaccine will be reconstituted according to the package insert. In brief, a vial containing ~1x10^8 CFU of lyophilized BCG will be reconstituted in 50 mL of saline. A single dose will consist of 0.1 mL (~2x10^5 CFU) will be administered by slow intradermal injection using a 25 gauge/ 0.5 mm syringe in the deltoid area. A follow up booster dose will be given one month after the initial dose."
89431920|NCT03414632|Other|SPECT/CT|99mTc-PYP single-photon positive emission computed tomography with computed tomography
89431921|NCT02103075|Experimental|The SCA|
89431922|NCT02103075|Experimental|The age-matched control|
89008829|NCT00224471|Experimental|Group B|
89008830|NCT00224471|Experimental|Group C|
89008831|NCT00569920|Placebo Comparator|1|Placebo
89008832|NCT00569920|Active Comparator|2|"dexamethasone low-dose"
89008833|NCT00569920|Active Comparator|3|"Dexamethasone high-dose"
89008834|NCT00569959|Other|Fasting|
89008835|NCT00569959|Other|Non-fasting|
89008836|NCT00570115||A|The subjects for this group are matched for age, gender, body mass index. The presence of obstructive sleep apnea will divide the cohort in 02 subgroups: non-Obstructive Sleep Apnea and Obstructive Sleep Apnea
89008837|NCT00570193|Experimental|I|Combined treatment with verteporfin (Visudyne) and ranibizumab (Lucentis)
89008838|NCT00570193|Experimental|II|Treatment with ranibizumab (Lucentis)
89008839|NCT00570271|Experimental|1|
89431923|NCT02103075|Experimental|The young control|
89431924|NCT04921618||Index patients|"People aged 18 or more diagnosed with >= 1 STI in testing centers.~[STI = bacterial STIs and/or HIV and/or acute hepatitis C virus (HCV)]"
89431925|NCT04921618||Notified partners|"People aged 18 or more getting STI testing in testing centers after being notified by a sexual partner.~[STI = bacterial STIs and/or HIV and/or acute HCV]"
89431926|NCT03414554||HCV patients receiving DAAs|Patients with HCV-related liver cirrhosis (eligible for treatment) who will recieve DAAs therapy with one year follow up.markers: miR121, miR122, miR124will be assessed in both groups before and after DAAs
89431927|NCT03554577|Active Comparator|Hearing Aid without NR|Hearing Aid without Noise Reduction (NR) serves as reference condition.
89431928|NCT03554577|Experimental|Hearing Aid with NR_A|NR_A: Noise Reduction principle A
89431929|NCT03554577|Experimental|Hearing Aid with NR_B|NR_B: Noise Reduction principle B.
89431930|NCT03554577|Experimental|Hearing Aid with NR_C|NR_C: Noise Reduction principle C.
89431931|NCT03396302|Experimental|Experimental|The experimental group will receive access to the web-based lifestyle intervention (exercise and nutritional education).
89008840|NCT00570271|Experimental|2|
89008841|NCT00570271|Experimental|3|
89008842|NCT00570271|Experimental|4|
89008843|NCT00570271|No Intervention|5|
89008844|NCT00570271|No Intervention|6|
89008845|NCT00570388|Active Comparator|2|Subjects in the active Prometa group will receive flumazenil, gabapentin, and hydroxyzine per the Prometa Protocol.
89008846|NCT00570388|Placebo Comparator|1|"Subjects in the placebo group will receive placebo flumazenil, gabapentin, and hydroxyzine"
89008847|NCT00570427|Experimental|1.|All participants
89008848|NCT04580719||Patiente|Patients aged 18 to 50, presenting menstrual cycles, consulting in the obstetrics and gynecology department of the University Hospital of Reims whatever the reason for consultation can participate in the study after signing the consent of no opposition. Participation in the study will not change the patient's medical management.
89431932|NCT03396302|No Intervention|Control|The control group will receive Hospital treatment as usual.
89431933|NCT04972630|Active Comparator|Control|"Control group participants will be recruited from the cancer patients in need of palliative care at Tata Medical Center (TMC), Kolkata, India. Participants will be recruited and consented by TMC researchers. There will be random allocation to the control or Pal-Care group. The control group (n=45) will receive usual care palliative services in which the patient or caregiver (by proxy) must visit the Tata Medical Center (TMC) cancer center for care. TMC services include consultation with a multi-disciplinary team (oncologist, nurse, psychologist), a 21-day morphine supply at reduced cost (as morphine is regulated in use),basic training on medication usage, catheter and wound care, other topics as relevant,and psychological counseling. Patients (or their proxy) must return to the cancer center as needed for follow up care and they are provided a 24/7 hotline to call in case of emergency."
89008849|NCT00570466|Experimental|Video games|Two interactive, computer-based video games (9 sessions each) played in sequence to increase fruit, vegetable and water intake, physical activity and decrease TV viewing.
89008850|NCT00570466|Placebo Comparator|Web and DVD knowledge|Parallel web and DVD based knowledge games on fruit, vegetable, water, physical activity and physical inactivity.
89008851|NCT00570544||1|patients with moderate to severe copd with varying extent of emphysema
89008852|NCT04580329|Experimental|NMES group|
89008853|NCT04580329|Experimental|control group|
89008854|NCT00254436|Experimental|Epoetin Alfa|
89008855|NCT00570583||Depressed|Older individuals with major depression
89008856|NCT00570583||Non-depressed|Older individuals without psychiatric disorder
89431934|NCT04972630|Experimental|Pal-Care|Intervention group participants will be recruited from cancer patients in need of palliative care at Tata Medical Center (TMC), Kolkata, India. Pal-Care will be delivered over a 6-month period. At baseline visit, the patient and their caregiver will meet with their community health worker (CHW) and clinical team and an individualized care plan will be created. Patients will be assigned to the CHW living nearest to their home. The CHW will make home visits to patients 1+ times weekly, depending on patient need. At each visit, the CHW will use resources from the WHO Palliative Care Toolkit to: 1)monitor patient condition, 2) provide basic palliative care (medication administration, wound care, catheter care), 3) deliver prescribed morphine, 4) teach caregivers to deliver care,5) monitor pain and symptom control, and 6) assist patients to access their oncologists and other resources. Timely communication between CHW and clinical team will be maintained using a tele-health platform.
89531202|NCT02496923|Active Comparator|Standard oxygen therapy (Hudson face mask or nasal prongs)|Patients randomised to receive standard oxygen therapy will be fitted with a soft face mask or nasal prongs, and the oxygen flow titrated to provide pulse oxygen saturation of at least 95% (93% for those at risk of hypercapnic respiratory failure such as confirmed COPD patients and morbidly obese patients). The standard oxygen therapy group will have their oxygen gas flow reduced to the minimum level which provides saturations of at least 95% (93% for those at risk of hypercapnic respiratory failure such as patients with confirmed COPD and morbidly obese patients).
89531203|NCT02496845|Experimental|Group A|Topical treatment and PK. Administration of VL#FIA3-30 (dual administration of MH30-01 & IS045-01)
89197690|NCT00850941||Questionnaire|Prognostic factors and outcome for patients treated with radiation with curative intent for rising Prostate Specific Antigen (PSA) post-prostatectomy.
89197691|NCT00952198|Experimental|ARRY-403|
89197692|NCT00952198|Placebo Comparator|Placebo|
89197693|NCT00851019|Experimental|DDR|"Dance Dance Revolution (DDR) Exergaming"
89197694|NCT00851019|Active Comparator|Treadmill|Treadmill exercise
89197695|NCT00946816|Active Comparator|Anorexia Nervosa|
89197696|NCT00946816|Active Comparator|Obesity|
89431935|NCT04972630|No Intervention|Post-Intervention Interviews|Semi-structured interviews of stakeholder groups will be conducted by MUSC researchers who are well-trained and speak the local language, to evaluate the Pal-Care intervention. We will conduct 20 key informant interviews/KIIs (or until saturation is reached), representing Pal-Care clinical team members, CHWs and patients/caregivers, who participated in the intervention at TMC, India. Clinicians will include social workers, oncology nurses, cancer center administrators, counselors, and palliative care oncologists. Patients/ caregivers will be purposefully selected to represent experiences across different cancers, clinical problems and assigned CHWs. Interviews will be performed in-person or over a telehealth platform, as needed. Interviews will query barriers, facilitators, optimal strategies, experiences, needs and expectations for palliative care delivery. Interviews will be digitally recorded, transcribed and analyzed.
88911231|NCT02574910|Experimental|Abiraterone acetate 2 mg/kg/d|If the 1 mg/kg/d dosing does not result in androstenedione level normalization, abiraterone acetate will be administered orally at a daily dose of 2 mg/kg for 7 days in addition to the standard of care treatment of hydrocortisone and fludrocortisone.
88911232|NCT02574910|Experimental|Abiraterone acetate 4 mg/kg/d|If the 2 mg/kg/d dosing does not result in androstenedione level normalization, abiraterone acetate will be administered orally at a daily dose of 4 mg/kg for 7 days in addition to the standard of care treatment of hydrocortisone and fludrocortisone.
88911235|NCT02545309||SSC-CIP|Patients with secondary sclerosing cholangitis in critically ill patients
88911236|NCT02545309||control|Patients with similar degree of critical illness who do not develop secondary sclerosing cholangitis in critically ill patients
89431936|NCT02106273||Bronchial blocker|Pilot study to enroll ASA class I-III patients age between 18-70 years who undergoes thoracic surgery which require one-lung ventilation.
89431937|NCT03414476|Experimental|ET group|Sampling : Hair follicles sampling on the scalp in women with Telogene Effluvium
89431938|NCT03414476|Experimental|Control group|Sampling: Hair follicles sampling on the scalp in women without Telogene Effluvium
89431939|NCT03414398||Experimental|Qualitative interview
89431940|NCT04893616|Experimental|Intervention Arm|These facilities will be those selected to have the intervention carried out.
88911237|NCT02543983|Experimental|1|Ketamine Hydrochloride infusion
89431941|NCT03396146|Experimental|Type1diabetes with exocrine pancreatic function insufficiency|12 ml total blood tubes volume Fecal sample
89431942|NCT03396146|Experimental|Type1diabetes without exocrine pancreatic function insuficienc|12 ml total blood tubes volume Fecal sample
89008857|NCT00570622|Active Comparator|1|Patients receive 60mg of pioglitazone once a day orally for 9 days
88911239|NCT02530073|Experimental|Fetoscopic Endoluminal Tracheal Occlusion (FETO)|An un-blinded non-randomized single arm pilot study of FETO in fetuses with congenital diaphragmatic hernia (CDH)
89197697|NCT00946816|Active Comparator|Healthy volunteers|
89197698|NCT00755976|Experimental|Epirubicin hydrochloride (75mg/m2 i.v.) Sulindac: 600mg|
89197699|NCT00857181||Liver Cirrhosis|Single cohort of patients with liver cirrhosis to be investigated in the study. Two-monthly measurements of serum cytokines.
89197700|NCT04012060|Active Comparator|Conventional group|All patients undergoing aortic valve replacement through full sternotomy.
89197701|NCT04012060|Experimental|Limited access group|All patients undergoing aortic valve replacement through partial upper hemisternotomy.
89431943|NCT03396146|Active Comparator|Type 3c diabetes|12 ml total blood tubes volume Fecal sample
89431944|NCT03414320|Experimental|Study Arm|We will gather data from this group of patients.
89431945|NCT05614414|Experimental|VL Group|Patients who were intubated by videolaryngoscope.
89431946|NCT05614414|Active Comparator|LD Group|Patients who were intubated by direct laryngoscope
89431947|NCT04866862|Experimental|Combination of Fruquintinib and Camrelizumab|Fruquintinib 5mg d1-21+ Camrelizumab 200mg d1; Repeated every 4 weeks
88911240|NCT02518269|Active Comparator|G7 MoP (Arcom XL) + Echo BiMetric|Eligible patients will be enrolled and planned for Hip Arthroplasty and operated with the Echo BiMetric femoral stem and G7 Acetabular cup. This group will receive an Arcom Xl liner and a metal head
88911241|NCT02518269|Active Comparator|G7 MoP (E1) + Echo BiMetric|Eligible patients will be enrolled and planned for Hip Arthroplasty and will be operated with the Echo BiMetric femoral stem and G7 Acetabular cup. This group will receive an E1 liner and a metal head.
88911242|NCT02518269|Active Comparator|G7 CoC + Echo BiMetric|Eligible patients will be enrolled and planned for Hip Arthroplasty and operated with the Echo BiMetric femoral stem and G7 Acetabular cup. This group will receive a ceramic liner and a ceramic head
88911243|NCT02499328|Experimental|Part A1: AZD9150 / MEDI4736|Patients allocated in cohort of arm A1 (AZD9150/MEDI4736 will be evaluated for DLT until an MTD is achieved.
88911244|NCT02499328|Experimental|Part A2: AZD5069 / MEDI4736|Patients allocated in cohort of arm A2 (AZD5069/MEDI4736 will be evaluated for DLT until an MTD is achieved.
88911245|NCT02499328|Experimental|Part B1:AZD9150+MEDI4736:PDL1 pretreated|Patients in arm B1 will be evaluated for efficacy until disease progression and then followed-up for safety and survival.
88911246|NCT02499328|Experimental|Part B2:AZD5069+MEDI4736:PDL1 pretreated|Patients in arm B2 will be evaluated for efficacy until disease progression and then followed-up for safety and survival.
88911247|NCT02499328|Experimental|Part B3: AZD9150+MED4736:naiive 2L|Patients in arm B3 will be evaluated for efficacy until disease progression and then followed-up for safety and survival.
88911248|NCT02499328|Experimental|Part B4:AZD5069+MEDI4736:naiive patients|Patients in arm B4 will be evaluated for efficacy until disease progression and then followed-up for safety and survival.
88911249|NCT02499328|Experimental|Part B5: AZD9150 in naiive patients|Patients in arm B5 will be evaluated for efficacy until disease progression and then allowed to receive additional MEDI4736 and followed for safety and survival
88911250|NCT02499328|Experimental|Part B6:AZD5069 in naiive patients|Patients in arm B6 will be evaluated for efficacy until disease progression and then allowed to receive additional MEDI4736 and followed for safety and survival
88911251|NCT02499328|Experimental|Part A3: AZD5069/MEDI4736|Patients allocated in cohort of arm A3 (AZD5069/MEDI4736) will be evaluated for DLT and viability as alternate dosing option for Phase 2 studies
88911252|NCT02499328|Experimental|Part A4: AZD9150/Treme/MEDI4736|Patients allocated in cohort of arm A4 (AZD9150/treme/MEDI4736) will be evaluated for DLT and MTD
88911253|NCT02499328|Experimental|Part A5: AZD5069/Treme/MEDI4736|Patients allocated in cohort of arm A5 (AZD5069/treme/MEDI4736) will be evaluated for DLT and MTD.
88911254|NCT02499328|Experimental|Part A6: AZD9150/MEDI4736|Patients allocated in cohort of arm A6 (AZD9150/MEDI4736) will be evaluated for safety, PK and PD.
88911255|NCT02499328|Experimental|Part A7: AZD5069/MEDI4736|Patients allocated in cohort of arm A7 (AZD5069/MEDI4736) will be evaluated for safety, PK and PD.
89008858|NCT00570622|Placebo Comparator|2|Patients receive Placebo orally once a day for 9 days
89431948|NCT04855942|Experimental|Focused Extracorporeal Shock Wave Therapy (ESWT)|2000 impulses of 5 Hz and 0.32 mJ/mm2 , twice per week for 3 weeks
89431949|NCT04855942|Active Comparator|Physiotherapy|therapeutic ultrasound, 12 times in 3 weeks
89431950|NCT03414164|Experimental|procyanidine group|
89431951|NCT03414164|No Intervention|control group|
89431952|NCT05613478|Experimental|Experimental group|Preoperative TACE treatment → preoperative camrelizumab combined with apatinib mesylate (q2w, 2 cycles) → radical surgery → postoperative TACE treatment → sequential camrelizumab and apatinib mesylate (q3w, at least 6 cycles) (Note: Surgery at least 1 week after the last administration of neoadjuvant therapy, postoperative TACE treatment within 4~8 weeks after surgery, camrelizumab combined with apatinib mesylate at 1 week after TACE treatment)
89431953|NCT05613478|Active Comparator|Radical surgery|Radical surgery→postoperative TACE treatment
89008859|NCT00570817|Other|1|"The child will receive prehydration at the methotrexate infusions in the following order:~At the 1st methotrexate infusion the child will receive 4 hours prehydration. At the 2nd methotrexate infusion the child will receive 12 hours prehydration. At the 3rd methotrexate infusion the child will receive 4 hours prehydration. At the 4th methotrexate infusion the child will receive 12 hours prehydration. At the 5th methotrexate infusion the child will receive 4 hours prehydration. At the 6th methotrexate infusion the child will receive 12 hours prehydration. At the 7th methotrexate infusion the child will receive 4 hours prehydration. At the 8th methotrexate infusion the child will receive 12 hours prehydration."
89008860|NCT00570817|Other|2|"The child will receive prehydration at the methotrexate infusions in the following order:~At the 1st methotrexate infusion the child will receive 12 hours prehydration. At the 2nd methotrexate infusion the child will receive 4 hours prehydration. At the 3rd methotrexate infusion the child will receive 12 hours prehydration. At the 4th methotrexate infusion the child will receive 4 hours prehydration. At the 5th methotrexate infusion the child will receive 12 hours prehydration. At the 6th methotrexate infusion the child will receive 4 hours prehydration. At the 7th methotrexate infusion the child will receive 12 hours prehydration. At the 8th methotrexate infusion the child will receive 4 hours prehydration."
89008861|NCT00570856|Experimental|1|Folic acid supplementation
89008862|NCT00570856|Placebo Comparator|2|
89008863|NCT00570895|Active Comparator|A|Subjects in Arm A will receive the juice without ascorbic acid in addition to the muffin with ferrous fumarate.
89008864|NCT00570895|Active Comparator|B|Subjects in Arm A will receive the juice with 25mg ascorbic acid in addition to the muffin with ferrous fumarate
89008865|NCT00570934|Experimental|Placebo|order of interventions placebo,calcium, cholecalciferol, calcium plus cholecalciferol
89008866|NCT00570934|Experimental|Calcium|order of treatment calcium, placebo, calcium plus cholecalciferol, cholecalciferol
89008867|NCT00570934|Experimental|Cholecalciferol|order of treatments cholecalciferol, calcium and Cholecalciferol, placebo, and calcium
89008868|NCT00570934|Experimental|Calcium and cholecalciferol|order of treatment calcium and cholecalciferol, cholecalciferol, calcium, placebo
89008869|NCT00570973|Active Comparator|1|Endoscopic Band ligation combined with medical therapy (orally, daily administered propranolol and mononitrate)
89008870|NCT00570973|Active Comparator|2|Transjugular intrahepatic portosystemic stent shunt with PTFE-covered stent
89008871|NCT00571012||Only one group- A|Healthy young subjects aged 18-45.
89008872|NCT00571051|Experimental|1|MBSR 8 week course
89197702|NCT04012060|Other|Registry group|"All patients unwilling or unable to participate in the randomized part of the trial.~All patients will undergo aortic valve replacement through median full sternotomy."
89197703|NCT03850353||OSAS|Patients with Obstructive Sleep Apnea (AHI>15 in a sleep study)
89431954|NCT04412018|No Intervention|Usual Care|Participants in this arm will continue with usual care
89008873|NCT00571051|No Intervention|2|8 weeks of natural history
89008874|NCT00571090||Thyroid nodule|Subjects who present with thyroid nodules will be enrolled into the study. Euthyroid and hypothyroid subjects with a solitary thyroid nodule or multinodular goiter will be enrolled. For subjects with a suppressed TSH, a thyroid scan will be performed. Subjects with a hypoactive nodule in the thyroid scan and a low TSH will be enrolled.
89008875|NCT00254553|Active Comparator|Arm 1|Testim 1% (testosterone gel)
89008876|NCT00254553|Placebo Comparator|Arm 2|Placebo
89008877|NCT00571129|Active Comparator|with tubes or mitomycin|After DCR bicanalicular tubes were inserted After re-DCR mitomycin in cottonpads were placed into rhinostoma for 5 minutes
89008878|NCT00571129|Active Comparator|without tubes or mitomycin|After DCR no tubes were inserted After re-DCR no mitomycin was used
89008879|NCT00571168|Experimental|A|Aprepitant plus standard therapy (Kevatril + Dexamethason) on day 1-4
89008880|NCT00571168|Placebo Comparator|B|Placebo plus standard therapy (Kevatril + Dexamethason) on day 1-4
89008881|NCT00571207||I|Drivers suspected of driving under the influence of drugs
89008882|NCT00571207||II|Drivers not suspected of driving under the influence of drugs
89008883|NCT00571246|Experimental|Topiramate|Participants will be randomized to topiramate (250mg)
89008884|NCT00571246|Experimental|Lamotrigine|Participants will be randomized to lamotrigine (250mg)
89008885|NCT00571246|Placebo Comparator|Placebo|Participants will be randomized placebo
89008886|NCT00254631|Active Comparator|study group|pre operative medication with 20 mg oxycontine PO
88911256|NCT02499328|Experimental|Part B7: AZD9150+MEDI4736: naiive 1L|Patients in Arm B7 will be evaluated for efficacy until disease progression and then followed up for safety and survival
88911257|NCT02499328|Experimental|Part B8: AZD9150 (every other week)+MEDI4736: naive 1L|Patients in Arm B8 will be evaluated for efficacy until disease progression and then followed up for safety and survival
88911258|NCT02474160||Ancillary-correlative (tissue and blood procurement)|Tumor tissue and blood samples are procured during procedures that are required for the patients' clinical management and stored via xenograft (transplant to another species) models or in vitro cell culture for future analysis.
88911259|NCT02472665|Experimental|plasma-derived FVIII/VWF concentrate|Pharmacokinetic single dose study with Fanhdi (high-purity Von Willebrand containing FVIII concentrate)
88911260|NCT02465060|Experimental|Subprotocol A (EGFR activating mutation)|Patients with EGFR activating mutation receive afatinib orally (PO) once daily (QD) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88911261|NCT02465060|Experimental|Subprotocol B (HER2 activating mutation)|Patients with HER2 activating mutation receive afatinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88911262|NCT02465060|Experimental|Subprotocol C1 (MET amplification)|Patients with MET amplification receive crizotinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88911263|NCT02465060|Experimental|Subprotocol C2 (MET exon 14 deletion/mutation)|Patients with MET exon 14 deletion or other mutations that disrupt exon 14 receive crizotinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88911264|NCT02465060|Experimental|Subprotocol E (EGFR T790M or rare activating mutation)|Patients with EGFR T790M or rare activating mutation receive osimertinib (AZD9291) PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo radiologic evaluation throughout the trial, ECHO or MUGA during screening, and biopsy and collection of blood samples on trial and at end of treatment.
88911265|NCT02465060|Experimental|Subprotocol F (ALK translocation)|Patients with ALK translocation receive crizotinib PO twice daily (BID) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88911266|NCT02465060|Experimental|Subprotocol G (ROS1 translocation or inversion)|Patients with ROS1 translocation or inversion receive crizotinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88911267|NCT02465060|Experimental|Subprotocol H (BRAF V600E/R/K/D mutation)|Patients with BRAF V600E/R/K/D mutation receive dabrafenib PO BID and trametinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88911268|NCT02465060|Experimental|Subprotocol I (PIK3CA mutation)|Patients with PIK3CA mutation without RAS mutation or PTEN loss receive taselisib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88911269|NCT02465060|Experimental|Subprotocol J (HER2 amplification >= 7 copy numbers)|Patients receive pertuzumab IV over 30-60 minutes and trastuzumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients also undergo radiologic evaluation throughout the trial, ECHO at screening and end of treatment, and biopsy and collection of blood samples on trial and at end of treatment.
88911270|NCT02465060|Experimental|Subprotocol K1 (FGFR amplification)|Patients with FGFR amplification receive erdafitinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and MRI throughout study. Patients may also undergo blood sample collection and tumor biopsy throughout the trial.
88911271|NCT02465060|Experimental|Subprotocol K2 (FGFR mutation or fusion)|Patients with FGFR mutation or fusion receive erdafitinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88911272|NCT02465060|Experimental|Subprotocol L (mTOR mutation)|Patients with mTOR mutation receive sapanisertib PO daily on days 1-28. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
88911273|NCT02465060|Experimental|Subprotocol M (TSC1 or TSC2 mutation)|Patients with TSC1 or TSC2 mutation receive sapanisertib PO daily on days 1-28. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
89008887|NCT00254631|Placebo Comparator|placebo group|pre operative medication with placebo tablet PO
89431955|NCT04412018|Experimental|Icosapent Ethyl|Participants in this arm will take icosapent ethyl (4 g BID for 3 days, then 2 g BID for the subsequent 11 days)
89431956|NCT04426474|Experimental|LY3502970|LY3502970 administered orally.
89431957|NCT04426474|Placebo Comparator|Placebo|Placebo administered orally.
89008888|NCT00571285|Placebo Comparator|Placebo|Placebo capsule once a week and 600 IU vitamin D daily for 26 weeks
89431958|NCT03406988|Experimental|Autologous fat grafting|Implantation of 0.5-1 ml of autologous AT at the base of the finger with DU.
89431959|NCT03406988|Placebo Comparator|Sham procedure|False liposuction followed by the injection of 0.5-1 ml of 0.9% saline solution at the base of the affected finger.
88911274|NCT02465060|Experimental|Subprotocol N (PTEN mutation or deletion and PTEN expression)|Patients with PTEN mutation or deletion and PTEN expression receive PI3K-beta inhibitor GSK2636771 PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88911275|NCT02465060|Experimental|Subprotocol P (PTEN loss)|Patients with PTEN loss receive PI3K-beta inhibitor GSK2636771 PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88911276|NCT02465060|Experimental|Subprotocol Q (HER2 amplification)|Patients with HER2 amplification receive trastuzumab emtansine intravenously (IV) over 30-90 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
88911277|NCT02465060|Experimental|Subprotocol R (BRAF fusion or BRAF non-V600 mutation)|Patients with BRAF fusion or BRAF non-V600 mutation receive trametinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88911278|NCT02465060|Experimental|Subprotocol S1 (NF1 mutation)|Patients with NF1 mutation receive trametinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88911279|NCT02465060|Experimental|Subprotocol S2 (GNAQ or GNA11 mutation)|Patients with GNAQ or GNA11 mutation receive trametinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88911280|NCT02465060|Experimental|Subprotocol T (SMO or PTCH1 mutation)|Patients with SMO or PTCH1 mutation receive vismodegib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88911281|NCT02465060|Experimental|Subprotocol U (NF2 inactivating mutation)|Patients with NF2 inactivating mutation receive defactinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88911282|NCT02465060|Experimental|Subprotocol V (cKIT exon 9, 11, 13, or 14 mutation)|Patients with cKIT exon 9, 11, 13, or 14 mutation receive sunitinib malate PO QD for 4 weeks. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
88911283|NCT02465060|Experimental|Subprotocol W (FGFR pathway aberrations)|Patients with FGFR1-3 mutation or translocation receive FGFR Inhibitor AZD4547 PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88911284|NCT02465060|Experimental|Subprotocol X (DDR2 S768R, I638F, or L239R mutation)|Patients with DDR2 S768R, I638F, or L239R mutation receive dasatinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88911285|NCT02465060|Experimental|Subprotocol Y (Akt mutation)|Patients with Akt mutation receive capivasertib PO BID on days 1-4, 8-11, 15-18, and 22-25. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88911286|NCT02465060|Experimental|Subprotocol Z1A (NRAS mutation in codon 12, 13, or 61)|Patients with NRAS mutation in codon 12, 13, or 61 receive binimetinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88911287|NCT02465060|Experimental|Subprotocol Z1B (CCND1, 2, or 3 amplification with Rb by IHC)|Patients with CCND1, 2, or 3 amplification that have tumor Rb expression by IHC receive palbociclib PO QD for 21 days. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88911288|NCT02465060|Experimental|Subprotocol Z1C (CDK4 or CDK6 amplification and Rb protein)|Patients with CDK4 or CDK6 amplification and tumor Rb protein receive palbociclib PO QD on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88911289|NCT02465060|Experimental|Subprotocol Z1D (Loss of MLH1 or MSH2 by IHC)|Patients with mismatch repair deficiency (loss of MLH1 or MSH2 by IHC) receive nivolumab IV over 30 minutes on days 1 and 15 for 4 cycles and then on day 1 every 28 days. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88911290|NCT02465060|Experimental|Subprotocol Z1E (NTRK1, NTRK2 or NTRK3 gene fusion)|Patients with NTRK1, NTRK2, or NTRK3 gene fusion receive larotrectinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89008889|NCT00571285|Experimental|Vitamin D|50K IU vitamin D3 (high dose) weekly plus 600 IU Vitamin D3 capsule daily for 26 weeks
89008890|NCT00571363|Active Comparator|standard surgery|basal cell carcinomas were excised with 4 mm margins
89536272|NCT02478203|Active Comparator|face-to-face intubation|intubation of an entrapped pediatric manikin with diract laryngoscopy, glidescope and airtraq
89431960|NCT03297424|Experimental|PLX2853|"Phase 1b (Dose Escalation): Approximately 45 subjects with advanced malignancies to establish the MTD/RP2D. Up to 6 additional subjects may be enrolled at the MTD/RP2D as a dose confirmation.~Phase 2a (Dose Expansion): There will be 5 total expansion cohorts. Either 10 or 29 subjects per cohort in each of 4 expansion cohorts: advanced SCLC, uveal melanoma, OCCC, and any other advanced malignancy with a known ARID1A mutation (between 40 to 116 subjects total for the solid tumor expansion phase). For the 5th expansion cohort, up to 20 subjects may be enrolled for NHL."
89431961|NCT03406832|Experimental|Nitroprusside group|After coronary target vessel blood flow recovery by thrombus aspiration or/and balloon angioplasty (diameter ≤ 2.0mm), intracoronary infusion of Nitroprusside Sodium via guide-catheter was performed. Then repeated administration of Nitroprusside Sodium was done prior to coronary stent implantation or post dilatation.
89431962|NCT03406832|Experimental|Tirofiban group|After coronary target vessel blood flow recovery by thrombus aspiration or/and balloon angioplasty (diameter ≤ 2.0mm), intracoronary infusion of Tirofiban Hydrochloride via guide-catheter was performed.
89008891|NCT00571363|Active Comparator|Mohs|Basal cell carcinoma were removed via Mohs Micrographic surgery
89197704|NCT03850353||Dizziness|Patients with Dizziness (defined as a non-spinning sensation, without illusion of movement)
89431963|NCT03406832|Placebo Comparator|Control group|After coronary target vessel blood flow recovery by thrombus aspiration or/and balloon angioplasty (diameter ≤ 2.0mm), intracoronary infusion of heparinized saline via guide-catheter was performed.
89431964|NCT04836442|Experimental|Alcohol-PTSD-PFI (AP-PFI)|Hazardous drinkers with at least subclinical PTSD and elevated AS (N=100) recruited from the community will be randomly assigned to receive Alcohol-PTSD-PFI (AP-PFI) or an active comparison control condition (C-PFI).
89431965|NCT04836442|Other|Active Comparison Condition (C-PFI)|Participants in the time-matched comparison condition will receive personalized feedback on alcohol use but will not receive PTSD or AS-related personalized feedback. C-PFI will include alcohol-focused components identical to those provided in AP-PFI (e.g., alcohol profiles, normative feedback). Therefore, it will be possible to isolate the impact of personalized PTSD and AS feedback versus personalized alcohol feedback.
89431966|NCT03414008|Experimental|Active Drug Group|Single dose
89431967|NCT03414008|Placebo Comparator|Placebo Group|
89431968|NCT04960306|Active Comparator|Fecal filtrate transplantation|Patients randomized to the fecal filtrate transplantation group
89431969|NCT04960306|Active Comparator|Conventional fecal microbiota transplantation|Patients randomized to the conventional fecal microbiota transplantation group
89431970|NCT03406442|Other|patients|The patient who have lesions affecting pterygopalatine fossa, lateral recess of the sphenoid sinus, petrous apex, Meckel's cave, cavernous sinus, infratemporal fossa and lateral nasopharynx and can be treated by endonasal endoscopic transptergoid approaches
89431971|NCT03406052|Experimental|Smartphone-Assisted MB-CBT|Online intervention accessed through smartphone or online accessed computer comprised of Mindfulness-Based Cognitive Behaviour content
89431972|NCT03406052|No Intervention|Control|Standard psychiatric care
89431973|NCT03405974|Experimental|Aspirin|"Aspirin 100 mg~1 tablet/ day for 2 years"
89431974|NCT03405974|Placebo Comparator|Placebo|"Placebo~1 tablet/ day for 2 years"
89431975|NCT04802668||Circulatory failure patients|Circulatory failure patients requiring fluid responsiveness evaluation
89431976|NCT03404882|Experimental|text messaging plus peer support arm|Patients will be assigned a peer support worker who will visit them during the last week of their inpatient stay to introduce themselves and build rapport before patients are discharged into the community. The peer support workers will visit the participants up to eight times over a six month period. The peer support workers will offer the opportunity for interactive text message support for six months. In addition to peer support, participants in this arm of the study will receive daily supportive text messages from an automated online application and reminder text messages for their community clinic/program appointments.
89008892|NCT00571402|Experimental|FFT|Family-focused therapy (FFT) and pharmacotherapy for adolescents, a 21 session family psychoeducational interventio0n administered with best practice medication treatment
89431977|NCT03404882|Active Comparator|supportive/reminder text message only arm|Patients in the supportive/reminder text message only arm of the study will receive daily supportive text messages from the automated online application and reminder text messages for their community clinic/program appointments.
89431978|NCT03404882|No Intervention|Control arm|Patients in the control arm of the study will receive the usual follow-up appointment offered to all patients who are discharged from acute care. However, they will not receive peer support or supportive/reminder text messages.
89531204|NCT02496845|Experimental|Groups B, C, D|Dual topical biweekly administration and intraurethral. Triple topical weekly administration. Multiple topical administration. Administration of VL#FIA3-30 (dual administration of MH30-01 & IS045-01)
88911291|NCT02465060|Experimental|Subprotocol Z1F (PIK3CA mutation)|Patients receive copanlisib IV over 1 hour on days 1, 8, and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo tumor biopsies at screening and end of treatment as well as CT or MRI at baseline and repeated every 2 cycles for the first 26 cycles then every 3 cycles thereafter until progressive disease or start of another MATCH treatment step.
88911292|NCT02465060|Experimental|Subprotocol Z1G (PTEN loss)|Patients with PTEN loss receive copanlisib IV over 1 hour on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88911293|NCT02465060|Experimental|Subprotocol Z1H (PTEN mutation)|Patients with PTEN mutation receive copanlisib IV over 1 hour on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88911294|NCT02465060|Experimental|Subprotocol Z1I (BRCA1 or BRCA2 gene mutation)|Patients with BRCA1 or BRCA2 gene mutation receive adavosertib PO QD for 5 days for 2 weeks. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
88911295|NCT02465060|Experimental|Subprotocol Z1K (AKT mutation)|Patients receive ipatasertib PO QD. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88911296|NCT02465060|Experimental|Subprotocol Z1L (BRAF fusion, aberration or non-V600 mutation)|Patients with a BRAF non-V600 mutation or BRAF fusion, or another BRAF aberration receive ulixertinib (BVD-523FB) PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88911297|NCT02465060|Experimental|Subprotocol Z1M (LAG-3 expression >= 1%)|Patients receive nivolumab IV over 30 minutes and relatlimab IV over 30 minutes on day 1.Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88911298|NCT02451943|Experimental|Doxorubicin + Olaratumab|75 milligrams per meter squared (mg/m^2) doxorubicin administered intravenously (IV) on day 1 of each 21-day cycle for 8 cycles plus 20 milligrams per kilogram (mg/kg) dose of olaratumab administered IV on day 1 and day 8 of cycle 1 and 15 mg/kg olaratumab administered IV on day 1 and day 8 of cycles 2-8. Beginning with cycle 9, 15 mg/kg olaratumab administered IV on day 1 and day 8 of each subsequent 21-day cycle until documented progressive disease (PD) or discontinuation for any other reason.
88911299|NCT02451943|Placebo Comparator|Doxorubicin + Placebo|75 mg/m^2 doxorubicin administered IV on day 1 of each 21-day cycle for 8 cycles plus placebo (equivalent volume) administered IV on day 1 and day 8 for 8 cycles. Beginning with cycle 9, placebo (equivalent volume) administered on days 1 and 8 of each subsequent 21-day cycle until PD or discontinuation for any other reason.
88911300|NCT02451111|Active Comparator|Rituximab/Ibrutinib|Ibrutinib capsules for 24 months (104 weeks) daily (always at the same time) in a dose of 560 mg (4 x 140 mg capsules)
88911301|NCT02451111|Placebo Comparator|Rituximab/Placebo|Placebo as comparator for 24 months (4 capsules daily always at the same time)
88911302|NCT02436707|Active Comparator|R-GDP|"Rituximab - 375 mg/m2 IV, 1.5 - 6 hours D1 (prior to cisplatin);~Gemcitabine - 1000 mg/m2, IV 30 min D1, D8;~Dexamethasone - 40 mg daily PO D1 - D4;~Cisplatin - 75 mg/m2 IV, 1 hour D1;"
88911303|NCT02436707|Experimental|Ibrutinib plus R-GDP (ACCRUAL COMPLETE)|"Ibrutinib 560 mg PO -- D1 - D21~Rituximab 375 mg/m2 IV 1.5 - 6 hours D1 (prior to cisplatin)~Gemcitabine 1000 mg/m2 IV 30 min D1, D8~Dexamethasone 40 mg daily PO -- D1 - D4~Cisplatin 75 mg/m2 IV 1 hour D1"
89008893|NCT00571402|Active Comparator|Echanced Care|Enhanced care (EC) and pharmacotherapy for adolescents
89008894|NCT00571441||Primary|All subjects are included in this group, non-randomized observational study.
89008895|NCT00571480|Experimental|1 true acupuncture|acupuncture needles are inserted into three preselected ear acupuncture points which are thought to be specific for low back pain
89008896|NCT00571480|Sham Comparator|2|three acupuncture needles are inserted to three ear acupuncture points which are not specific for low back pain during pregnancy
89008897|NCT00571480|Other|3|standard of care
89531205|NCT02639247|Experimental|SOF/VEL/VOX|SOF/VEL/VOX for 12 weeks
89431979|NCT03404882|Active Comparator|peer support only arm|Patients will be assigned a peer support worker who will visit them during the last week of their inpatient stay to introduce themselves and build rapport before patients are discharged into the community. The peer support workers will visit the participants up to eight times over a six month period. The peer support workers will offer the opportunity for interactive text message support for six months. Patients will not receive daily supportive/reminder text messages
89431980|NCT03116074|No Intervention|Study 1: Pre-intervention 1|"Usual care.~Patients/caregivers do not have access to patient portal. Providers have access to safety dashboard without discharge preparation indicator. Providers do not have access to secure patient-provider messaging tools."
89431981|NCT03116074|Experimental|Study 1: Post-intervention|"Patient-Centered Discharge Toolkit: patient portal and provider safety dashboard PLUS patient pre-discharge checklist, provider discharge preparation indicator, secure patient-provider messaging~Patients/caregivers have access to patient portal with discharge module (pre-discharge preparation checklist) and secure patient-provider messaging tools activated. Providers have access to discharge preparation indicator on safety dashboard and secure patient-provider messaging tools."
89431982|NCT03116074|No Intervention|Study 1: Pre-intervention 2|"Usual care PLUS patient portal and provider safety dashboard.~Patients/caregivers have access to patient portal but not discharge module or secure patient-provider messaging tools. Providers have access to safety dashboard without discharge preparation indicator. Providers do not have access to secure patient-provider messaging tools."
89431983|NCT03116074|No Intervention|Study 2: Pre-intervention|"Usual care on three general medicine units.~Patients/caregivers do not have access to the discharge preparation checklist. Providers do not have access to the safety dashboard."
89008898|NCT00571558|Experimental|Treatment (aminolevulinin acid and photodynamic therapy)|Patients receive aminolevulinic acid PO 3-4 hours before undergoing photodynamic therapy using pulsed dye laser on day 1.
89008899|NCT02961231|Active Comparator|PCV 2p+1|PCV 2p+1 schedule: WHO recommended 2 primary at 2, 4 months and a booster dose at 12 month
88911304|NCT02436707|Experimental|R-DICEP|"Rituximab 375 mg/m2 IV 1.5-6hrs Day 1 and Day 5 prior to Cisplatin~Mesna 1.75 g/m2 IV 24 hour Cycle 1, Day 2, Day 3 and Day 4~Cyclophosphamide, 1.75 g/m2 IV 2 hours, Day 2, Day 3 and Day 4~Etoposide 350 mg/m2 IV 2 hours, Day 2, Day 3 and Day 4~Cisplatin 35 mg/m2 IV, 2 hours, Day 2, Day 3 and Day 4~G-CSF 300 mcg (<60kg); 480 mcg (60-90kg); 600 mcg (>90kg); SC, Daily, starting Day 15 until apheresis completed."
88911305|NCT02436707|Experimental|Selinexor + R-GDP|"Selinexor - 40mg PO, D1, D3, D8~Rituximab - 375 mg/m2 IV, 1.5 - 6 hours D1 (prior to cisplatin);~Gemcitabine - 1000 mg/m2, IV 30 min D1, D8;~Dexamethasone - 40 mg daily PO D1 - D4;~Cisplatin - 75 mg/m2 IV, 1 hour D1;"
88911306|NCT02428140|Experimental|Implanted Loop Recorder|long-term implantable ECG (Medtronic Reveal LINQ) coupled with remote monitoring (MyCareLink) for 12 months
88911307|NCT02428140|Experimental|External Loop Recorder|external event-triggered ECG loop recorder (Sorin Spiderflash-t) for 30 days
89197705|NCT03850353||No OSAS No Dizziness|Patients without dizziness and no evidence for OSAS (subjects referred for the ENT or the Sleep clinic with no dizziness and no evidence of OSAS )
88911309|NCT02389374|Other|chloroquine primaquine 14days|P.vivax malaria patients receiving chloroquine and primaquine 14days as per guidelines
88911310|NCT02389374|Other|artemether-lumefantrine primaquine 1day|P.falciparum malaria patients receiving artemether-lumefantrine combination and primaquine 1day as per guidelines
88911311|NCT02389374|Other|artemether-lumefantrine primaquine 14days|mixed malaria infection receiving artemether-lumefantrine combination and primaquine 14days as per guidelines
88911312|NCT02386800|Experimental|Ruxolitinib monotherapy or ruxolitinib plus panobinostat in combination|All participants will receive either ruxolitinib monotherapy or ruxolitinib in combination with panobinostat, at the same dose/schedule that they were taking in the parent study.
88911313|NCT02359565|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for 34 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo standard MRI, DCE permeability MRI, DTI, DSC perfusion MRI, MR diffusion imaging and may undergo MR spectroscopy as well as CSF and blood sample collection during screening and on study.
88911314|NCT02358811||Eldery SAOS+|Patients with severe obstructive sleep apnea (AHI>30) 70 years old and more
88911315|NCT02358811||Eldery SAOS-|People without obstructive sleep apnea (AHI<10) 70 years old and more
88911316|NCT02358811||Adult SAOS+|Patients with severe obstructive sleep apnea (AHI>30) 18 < Age < 55 years old
88911317|NCT02358811||Adult SAOS-|People without obstructive sleep apnea (AHI<10) 18 < Age < 55 years old
88911318|NCT02299141|Experimental|Nintedanib|-Nintedanib will be administered orally at a dose of 200 mg twice daily during each 28 day cycle. Starting with cycle 64, cycles will last 12 weeks.
88911319|NCT02260466|Other|elderly patients with Aortic steNosis valvular replacement|
88911320|NCT02230930|Active Comparator|Massage with a spiky ball|Subjects are instructed to massage the apomorphine-induced skin reactions with a spiky ball 3 times a day for 2 minutes for 14 days.
88911321|NCT02230930|Active Comparator|Hydrocortisone cream 1%|Subjects are instructed to apply hydrocortisone cream 1% once daily for 14 days.
88911322|NCT02230930|Active Comparator|Subcutaneous hydrocortisone 10mg|Subjects are instructed to administer subcutaneous hydrocortisone (Solu-Cortef 10mg) prior to apomorphine via the subcutaneous infusion line which is used for administration of apomorphine, for 14 days.
88911323|NCT02230930|Active Comparator|Apomorphine 0.25% (2.5mg/ml)|Subjects are instructed to dilute apomorphine 0.5% (5mg/ml) with the same volume of physiologic saline (NaCl 0.9%) to 0.25% (2.5mg/ml). Apomorphine will be infused subcutaneously for 14 days.
88911324|NCT02209363|Experimental|Positive airway pressure (PAP)|Auto-adjusting positive airway pressure
88911325|NCT02209363|Sham Comparator|nasal dilator strips|Sham treatment
88911326|NCT02166541|Experimental|INRS with BCSK|"Intensive Neurophysiological Rehabilitation System (INRS) including the Biomechanical correction of the spine according to Kozyavkin (BCSK).~The daily treatment for about 2 hours are in general equal for all children except for the type of spinal manipulation. Duration of all treatment will be noted in a Treatment Diary."
89431984|NCT03116074|Experimental|Study 2: Post-intervention|Patients/caregivers have access to the discharge preparation checklist. Providers have access to safety dashboard.
89431985|NCT03035422|Other|Patients with primary refractory acute myeloid leukemia|Patients with primary refractory acute myeloid leukemia
89431986|NCT04337060|Active Comparator|Group LB|Ultrasound-guided bilateral erector spinae plane block (10 ml 1% lidocaine + 10 ml 0.5% bupivacaine) + intravenous morphine patient-controlled analgesia.
89431987|NCT04337060|Sham Comparator|Group S|Ultrasound-guided bilateral erector spinae plane block. block (20 ml Normal Saline) + intravenous morphine patient-controlled analgesia.
89431988|NCT05611996|Other|Peer support|Peer mentors who have experienced depression provide social support through video chats and texting for 8 weeks.
89431989|NCT03413930|Experimental|TaTME|Patients with mid or low rectal cancer undergo transanal total mesorectal excision.（assisted by laparoscopy to control the IMA）
89431990|NCT03413930|Active Comparator|LaTME|Patients with mid or low rectal cancer undergo laparoscopic total mesorectal excision.
89531206|NCT02639247|Experimental|SOF/VEL|SOF/VEL for 12 weeks
88911327|NCT02166541|Sham Comparator|INRS with traditional spinal manipulation|"Intensive Neurophysiological Rehabilitation System (INRS) including spinal manipulation by the traditional technique.~The daily treatment for about 2 hours are in general equal for all children except for the type of spinal manipulation. Duration of all treatment will be noted in a Treatment Diary."
88911328|NCT02166541|Experimental|Total population|All participants (i.e., both arms described above INRS with BCSK or traditional spinal manipulation)
88911329|NCT02159404||Allergic Rhinoconjunctivitis|Patients with diagnosed Allergic Rhinoconjunctivitis
88911330|NCT02159404||Healthy controls|
88911331|NCT02155699|Experimental|Exercise 1|65% of V02 Max, 3x per week, 3 months
88911332|NCT02155699|Experimental|Exercise 2|85% of VO2 Max, 2x per week, 3 months
88911333|NCT02155699|No Intervention|Waitlist|Waitlist (three months)
89431991|NCT02992600||study group|300 male and female patients undergoing non-cardiac surgery are enrolled at the Affiliated Hospital of Xuzhou Medical University [Jiangsu China]. Patients will be divided into POCD and non-POCD groups according to the scores of neuropsychological tests.
89431992|NCT02992600||control group|30 healthy volunteers are enrolled for calculating the Z-scores of study group.
89431993|NCT05614336|Other|Cystic Fibrosis patients|Patients with cystic fibrosis, regardless of age, genetic profile, transplant status and disease severity will be eligible to participate in the study.
89431994|NCT04267640|Experimental|AMG0001 4mg|AMG0001 4mg + standard wound care
89431995|NCT04267640|Experimental|AMG0001 8mg|AMG0001 8mg + standard wound care
89431996|NCT04267640|Placebo Comparator|Placebo|Placebo + standard wound care
88911334|NCT02155647|Experimental|Part A: Avelumab|Participants with metastatic Merkel cell carcinoma (MCC) after failing first-line chemotherapy received Avelumab at a dose of 10 milligram per kilogram (mg/kg) as 1-hour intravenous infusion once every 2 weeks until therapeutic failure, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the trial or investigational medicinal product occurs.
88911335|NCT02155647|Experimental|Part B: Avelumab|Participants received Avelumab as first-line treatment for metastatic or distally recurrent MCC at a dose of 10 mg/kg as 1-hour intravenous infusion once every 2 weeks until therapeutic failure, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the trial or investigational medicinal product occurs.
88911336|NCT02136134|Experimental|Daratumumab+VELCADE+dexamethasone|Daratumumab, VELCADE and dexamethasone
88911337|NCT02136134|Active Comparator|VELCADE+dexamethasone|VELCADE and dexamethasone.
88911338|NCT02107703|Experimental|Abemaciclib + Fulvestrant|Abemaciclib 150 milligram (mg) administered orally every 12 hours on Days 1 to 28 of a 28-day cycle in combination with fulvestrant 500mg administered intramuscularly (IM) on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond. Participants received treatment until discontinuation were met.
88911339|NCT02107703|Placebo Comparator|Placebo + Fulvestrant|Placebo administered orally every 12 hours on Days 1 to 28 of a 28-day cycle in combination with fulvestrant 500mg administered IM on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond. Participants received treatment until discontinuation were met.
88911340|NCT02096588|Experimental|Simvastatin|Simvastatin will be administered on an outpatient basis orally at a dose of 40 mg once daily. Treatment will start 7 days prior to the planned doxorubicin/cyclophosphamide chemotherapy initiation and will continue for a total of 25 weeks.
88911341|NCT02096588|Active Comparator|No drug|Participant not randomized to simvastatin will participate in all aspects of the study, including planned doxorubicin/cyclophosphamide chemotherapy, with the exception of simvastatin administration.
88911342|NCT02079740|Experimental|Treatment (trametinib, navitoclax)|Patients receive trametinib PO QD and navitoclax PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. If unacceptable toxicity is observed, patients may receive trametinib PO QD on days 1-14.
88911343|NCT02071134||Parkinson's disease|Subjects with Parkinson's disease who will receive Vercise DBS for deep brain stimulation.
89431997|NCT04447274|Experimental|Camrelizumab and Apatinib|Drugs should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
89531207|NCT03339479|Experimental|dielectric property test|The patient with lung nodules/mass is firstly arranged to be tested for dielectric property after the nodules/mass resection and cutting open.
89531208|NCT03339479|Placebo Comparator|frozen pathological examination|The resected lung nodules/mass will be sent for frozen pathological examination after dielectric property test.
89531209|NCT03339479|Other|final pathological examination|The resected lung nodules/mass will undergo the final pathological examination for final diagnosis after dielectric property test and frozen pathological examination.
88911344|NCT02044458|Active Comparator|Stylette|Stylette: a thin wire inserted into a catheter to maintain rigidity, used to guide the insertion of the Foley catheter.
88911345|NCT02044458|No Intervention|No Stylette|No Stylette: 22 French Foley catheter placed without stylette or guide.
89531210|NCT03339323|No Intervention|Control|Standard rehabilitation procedure
89431998|NCT02977156|Experimental|Combination PexaVec + Ipilimumab|"PEXA-VEC (Pexastimogene devacirepvec): Oncolytic live replicating virus, Recombinant vaccinia virus GM-GCF of Classe 1, administered by Intra-tumoral injection with fixed-dosage regimen of 1x109 pfu (9.0 Log pfu)/ injection. Up to 5 IT injections, at Week 1 Day 1, Week 3 Day 1, Week 5 Day 1 and Week 9 Day 1, and one additional IT treatment allowed in case of disease progression following a documented objective response at W12. Provided by Transgene.~IPILIMUMAB: Anti-CTLA-4 monoclonal antibody (IgG1k) produced in CHO cells by recombinant DNA technology, administered by Intra-tumoral injection. Up to 4 IT injections at Week 3 Day 1, Week 5 Day 1 and Week 9 Day 1, and one additional IT treatment allowed In case of disease progression following a documented objective response at W12. Four dose levels of ipilimumab will be tested in dose escalation step: 2.5mg, 5mg, 7.5mg, 10mg, 20mg or 40 mg."
88911346|NCT02042430|Experimental|Treatment (IDO1 inhibitor INCB024360)|Patients receive IDO1 inhibitor INCB024360 PO BID on days 1-14 and undergo surgery on day 15. Treatment continues in the absence of disease progression or unacceptable toxicity. In circumstances where there are medical or administrative reasons for delaying surgery, treatment with IDO1 inhibitor INCB024360 may continue for up to 3 weeks.
88911347|NCT02008721|Active Comparator|EGCG as putative neuroprotective agent|Treatment with 800 mg - 1200 mg EGCG as putative neuroprotective agent
88911348|NCT02008721|Placebo Comparator|Placebo|Placebo
88911349|NCT01950572||1/Eligible cancer diagnosis|Subjects with mesothelioma, thymic carcinoma, pancreatic or biliary adenocarcinoma or lung, gastric or ovarian cancers
88911350|NCT01927783||Group 1|Healthy Volunteer
88911351|NCT01927783||Group 2|Focus Group- Neighborhood and Physical Activity
88911352|NCT01927783||Group 3|Focus Group
88911353|NCT01927783||Group 4|Focus Group- Mobile App
88911354|NCT01927783||Group 5|Consent for Cooking Survey Focus Group
88911355|NCT01927783||Group 6|Community Organization Survey focus Group
88911356|NCT01925196||C9ORF72|Participants with C9ORF72 mutation
88911357|NCT01910610|Experimental|STRATEGY A|FOLFIRI-cetuximab, followed by oxaliplatin-based chemotherapy with bevacizumab
88911358|NCT01910610|Experimental|STRATEGY B|OPTIMOX-bevacizumab, followed by irinotecan-based chemotherapy with bevacizumab, followed by anti-EGFR mab with or without irinotecan
88911359|NCT01904162|Experimental|healthy young adult males|healthy young adult males receiving 400 mg finafloxacin single dose
88911360|NCT01904162|Experimental|healthy young adult females|healthy young adult females receiving 400 mg finafloxacin single dose
88911361|NCT01904162|Experimental|healthy elderly adult males|healthy elderly adult males receiving 400 mg finafloxacin single dose
88911362|NCT01904162|Experimental|healthy elderly adult females|healthy elderly adult females receiving 400 mg finafloxacin single dose
88911363|NCT01892722|Experimental|Fingolimod|Fingolimod was administered orally once daily at a dose of either 0.5 mg or 0.25 mg (depending on patient's body weight) with the aim to achieve systemic exposure in range of that in adults at the licensed 0.5 mg dose. Participants in this arm during core continued into extension and received open-label treatment
88911364|NCT01892722|Active Comparator|Interferon beta-1a|An intramuscular (IM) injection of Interferon beta-1a was administered once weekly during core phase. Participants switched to receive open-label fingolimod in extension phase
88911365|NCT01892722|Experimental|Fingolimod-Younger Cohort|The 'younger cohort' refers to the new pediatric patients to be recruited in the extension phase who fulfill any single one or a combination of the following criteria: being ≤12 years of age, or weighing ≤40 kg, or being prepubertal (i.e. pubertal status of Tanner stage <2)
88911366|NCT01885949|Experimental|Experimental Treatment Arm|Tivozanib, taken daily for 21 days followed by a 7 day break Enzalutamide taken daily for 28 days
88911367|NCT01875601|Experimental|A|NK cell infusion (dose escalation)
88911368|NCT01875601|Experimental|B|NK cell infusion + escalating doses of rhIL15
88911369|NCT01869114|Experimental|High risk Myleodysplastic Syndrome (MDS)|Patients receive sirolimus PO on days 1-10 or 1-12 and azacitidine IV on days 4-8, 11, and 12 or days 4-10. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
88911370|NCT01869114|Experimental|Acute Myeloid Leukemia (AML)|Patients receive sirolimus PO on days 1-10 or 1-12 and azacitidine IV on days 4-8, 11, and 12 or days 4-10. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
88911371|NCT01869114|Experimental|MDS or AML with prior Azacitadine therapy|Patients receive sirolimus PO on days 1-10 or 1-12 and azacitidine IV on days 4-8, 11, and 12 or days 4-10. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
88922266|NCT05579249|Active Comparator|Other anti-obesity medication|Participants will receive one of 4 commercially available anti-obesity medication chosen by the study doctor for 52 weeks as adjuncts to a reduced-calorie diet and increased physical activity for chronic weight management. The 4 anti-obesity medications are orlistat per os [by mouth] (p.o.), phentermine/topiramate extended release p.o., naltrexone/bupropion extended release p.o. or liraglutide 3.0 mg s.c injection.
89008900|NCT02961231|Active Comparator|PCV 3p+0|PCV 3p+0 schedule: WHO recommended 3 primary doses at 2, 3 and 4 months
88911372|NCT01861314|Experimental|Treatment (bortezomib, sorafenib tosylate, decitabine)|"STEP A: Patients receive bortezomib SC on days 1 and 4, sorafenib tosylate PO BID on days 1-14, and decitabine IV over 1 hour on days 5-14.~STEP B: Patients receive bortezomib SC on days 1, 4, and 8 or 1, 4, 8 and 11, sorafenib tosylate PO BID on days 1-14, and decitabine IV over 1 hour on days 9-18 or 12-21.~STEP C: Patients receive bortezomib SC on days 1, 4, and 8 or 1, 4, 8 and 11, sorafenib tosylate PO BID on days 1-14, and decitabine IV over 1 hour on days 5-14.~Treatment repeats every 28 days for up to 4 courses in the absence of unacceptable toxicity. Patients achieving CR or CRi receive maintenance therapy comprising decitabine IV on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
88911375|NCT01851395||1/Thoracic|Patients with histologically or cytologically confirmed metastatic NSCLC, SCLC, EPCC, pNET, thymic epithelial tumor (thymoma, thymic carcinoma) or mesothelioma
88911376|NCT01851395||2/Genitourinary|Patients with genitourinary malignancies
88911377|NCT01851395||3/ACT|Patients treated with an adoptive cellular therapy
88911378|NCT01851395||4/Ovarian|Patients with ovarian cancer
88911379|NCT01851395||5/Epithelial|Patients with breast, colorectal, pancreatic, stomach or biliary cancer.
88911382|NCT01827904|Experimental|Transcranial ExAblate|Transcranial ExAblate
88911383|NCT01827904|Sham Comparator|Sham Transcranial ExAblate|Sham Treatment with Transcranial ExAblate
88911384|NCT01819233|Experimental|Behavioral dietary intervention|Beginning 2-4 weeks after completion of lumpectomy, patients receive food diaries to complete for 7-10 days. Dietary counselors then give patients guidelines for dietary modifications to reduce caloric intake by 25% of their normal diet. Patients follow caloric restricted diet for 10 weeks (2 weeks prior to radiation therapy, during 6 weeks of radiation therapy, and at least 2 weeks after radiation therapy). Patients undergo radiation therapy QD 5 days a week for 6 weeks.
89431999|NCT03413774||Abortion group|910 women attended Fayoum University hospital outpatient gynecology clinic with recent first trimesteric spontaneous miscarriage
89432000|NCT03413774||Control group|940 women attended Fayoum University hospitalpresented for any other gynecological complaint
88911387|NCT01798004|Experimental|Treatment (induction therapy, consolidation therapy, ASCT)|"INDUCTION THERAPY:~COURSES 1-2: Patients receive cyclophosphamide IV over 15-30 minutes and topotecan hydrochloride IV over 30 minutes on days 1-5. Treatment repeats every 3 weeks for 2 courses.~COURSES 3 AND 5: Patients receive cisplatin IV over 1 hour on days 1-4 and etoposide IV over 1-2 hours on days 1-3. Treatment repeats every 3 weeks for 2 courses.~COURSE 4: Patients receive cyclophosphamide IV over 1-6 hours on days 1-2, vincristine sulfate IV over 1 minute on days 1-3, and doxorubicin hydrochloride IV over 24 hours on days 1-3. Treatment repeats every 3 weeks for 1 course.~Treatment continues in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION THERAPY: Beginning 4-8 weeks following the 5th course of induction therapy, patients receive busulfan IV over 3 hours on days -6 to -3 and melphalan IV on day -1. Patients undergo ASCT on day 0.~Some patients also undergo EBRT after induction and consolidation."
88911388|NCT01794403|Experimental|Extended Hypofractionation Radiotherapy (EHRT) Group|Participants in this group will receive the EHRT intervention over a period of 6 weeks.
88911389|NCT01794403|Experimental|Accelerated Hypofractionation Radiotherapy (AHRT) Group|Participants in this group will receive the AHRT intervention over a period of 2 weeks.
88911390|NCT01782703||Control|Healthy subjects with no history of atopy (atopic dermatitis, asthma, or allergic rhinitis) from 0 months to 17 years of age that are age and sex matched to our atopic dermatitis subjects.
88911391|NCT01782703||Atopic Dermatitis|Children with atopic dermatitis from 0 months to 17 years of age.
88911392|NCT01782703||Control with Atopy history|Healthy subjects from 0 months to 17 years of age with history of asthma, food allergies, or allergic rhinitis, but no atopic dermatitis or with positive family history of atopy
89432001|NCT03413696||Not referred for HCV therapy|
89432002|NCT03413696||Referred for HCV therapy,did not show up|
89432003|NCT03413696||Referred,attended HCV therapy evaluation|
89432004|NCT05168072|Experimental|m-Health|participants receive conventional outpatient obesity management assisted with m-Health APP
89432005|NCT05168072|Active Comparator|conventional|participants receive conventional outpatient obesity management
89432006|NCT02419846|Experimental|Men over 40: Screening with intervention|Participants over the age of 40 complete an educational intervention comprising a 10-20 minute PowerPoint presentation given by an experienced healthcare professional that discusses prostate cancer facts, screening guidelines, risks, benefits, and consequences. Participants may undergo a screening exam comprising a prostate specific antigen level and digital rectal exam.
89432007|NCT02419846|Experimental|Men 18-39: Educational intervention|Participants between 18 and 39 complete an educational intervention comprising a 10-20 minute PowerPoint presentation given by an experienced healthcare professional that discusses prostate cancer facts, screening guidelines, risks, benefits, and consequences.
88911396|NCT01719055||Boston Scientific SCS Systems|Subjects permanently implanted with a Boston Scientific neurostimulation systems
88911397|NCT01702922||1/Active Cancer Parents|Must have been in a partnership at the time child was diagnosed with cancer &amp; must have been diagnosed at least 3 months prior to enrollment on this study &amp; be currently receiving treatment
88911398|NCT01702922||2/Complete Cancer Parents|Must have been in a partnership at the time the child was diagnosed with cancer and the child has completed treatment at age 21 or younger (without evidence of disease) within the previous 3 years
88911399|NCT01702922||3/NF1 Parents|Must have been in a partnership at the time the child was diagnosed with NF1 and the child must have been diagnosed with NF1 at least 3 months prior to enrollment on this study.
88911400|NCT01686334|Experimental|DC vaccine|Vaccination with autologous WT1 mRNA-electroporated DCs plus follow-up care. Patients receiving low-intensity chemotherapy are allowed to continue this treatment in combination with DC vaccination.
88911401|NCT01686334|No Intervention|Control arm|Follow-up care. Patients receiving low-intensity chemotherapy are allowed to continue this treatment during the follow-up care
88911402|NCT01679054||EOX|Epirubicin + Oxaliplatin + Capecitabine (EOX) Epirubicin 50 mg/m2 iv bolus d1 q3w x 8 cycles Oxaliplatin (Eloxatin) 130 mg/m2 iv over 2 hours d1 q3w x 8 cycles Capecitabine (Xeloda) 625 mg/m2 po bid x 6 months
88911403|NCT01679054||FOLFOX4|FOLFOX4 Leucovorin 200 mg/m2 iv over 2 hrs before 5-FU, d1 and 2 5-FU 400 mg/m2 iv bolus and then 600 mg/m2 iv over 22 hrs, d 1 and d2 Oxaliplatin (Eloxatin) 85 mg/m2 iv d1 Q2w x 12 cycles
88911404|NCT01660984||Parents/caregivers|Parents or caregivers of study patients to assess their psychosocial experiences and needs.
88911405|NCT01660984||Patients|Children and adults with MTC and MEN2B, other non-tumor manifestations of MEN2, and patients with MEN2 who do not demonstrate MTC. Characterize the biology and manifestations of their disease.
88911406|NCT01660971|Experimental|Treatment (gemcitabine, dasatinib, erlotinib)|Patients receive gemcitabine hydrochloride IV over 30-60 minutes on days 1, 8, and 15, and dasatinib PO QD and erlotinib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89008901|NCT02961231|Experimental|PCV 1p+1|PCV 1p+1 schedule: one primary dose at 2 month and a booster at 12 month
89008902|NCT02961231|Experimental|PCV 0p+1|PCV 0p+1 schedule: no primary dose, only a booster at 12 month
89008903|NCT00571636|Active Comparator|fentanyl|Patients assigned to this arm will receive continuous infusion of fentanyl + open label boluses of Fentanyl if necessary.
89008904|NCT00571636|Placebo Comparator|placebo|Patients assigned to this arm will receive continuous infusion of placebo+ open label boluses of Fentanyl if necessary.
89008905|NCT00224744|Active Comparator|Classical surgical Inguinal curage|Classical Inguinal curage
89432008|NCT04114292|Experimental|TUDCA|1.75-2 grams daily in divided dosing
89432009|NCT02413138|Experimental|Phase 2: Somavaratan (VRS-317)|Active treatment arm
89432010|NCT02413138|Experimental|Phase 3: Somavaratan (VRS-317)|Somavaratan long acting recombinant human growth hormone administered subcutaneously twice-monthly
89432011|NCT05167994|Experimental|Anlotinib arm|Pre-operative IMRT with concurrent and sequential Anlotinib
89432012|NCT04690426|Placebo Comparator|Cohort 1, Low Dose, Placebo|Low dose of placebo by intramuscular injection, 3 doses at 4-week intervals
89432013|NCT04690426|Experimental|Cohort 1, Low Dose, PRV-101|Low dose of PRV-101 by intramuscular injection, 3 doses at 4-week intervals
89432014|NCT04690426|Placebo Comparator|Cohort 2, High Dose, Placebo|High dose of placebo by intramuscular injection, 3 doses at 4-week intervals
89432015|NCT04690426|Experimental|Cohort 2, High Dose, PRV-101|High dose of PRV-101 by intramuscular injection, 3 doses at 4-week intervals
89432016|NCT04667338||Cohort A: NT1 Participants|Participants with confirmed diagnosis of narcolepsy type 1 (NT1) defined by the International Classification of Sleep Disorders, Third Edition (ICDS-3) will be observed for up to 24 months.
89432017|NCT04667338||Cohort B: NT2 Participants|Participants with confirmed diagnosis of narcolepsy type 2 (NT2) defined by the ICDS-3 will be observed for up to 24 months.
89432018|NCT05167916|Experimental|T1 Bladder cancer patients|
89432019|NCT01896778|Experimental|Arm I (B-WARM for 30 minutes)|Patients undergo B-WARM at 39 degrees C for 30 minutes.
89432020|NCT01896778|Experimental|Arm II (B-WARM for 2 hours)|Patients undergo B-WARM at 39 degrees C for 2 hours.
89432021|NCT03413540|Experimental|Group 1|10-cm step, 10 reps
89432022|NCT03413540|Experimental|Group 2|10-cm step, 50 reps
89432023|NCT03413540|Experimental|Group 3|10-cm step, 100 reps
89432024|NCT03413540|Experimental|Group 4|20-cm step, 10 reps
89432025|NCT03413540|Experimental|Group 5|20-cm step, 50 reps
88911407|NCT01659749|Other|Metabolic Camp|Metabolic Camp is an educational and social support program for females age 11 through adult with phenylketonuria (PKU) and maple syrup urine disease (MSUD), two inherited metabolic disorders (IMD). Camp provides a supportive environment for adolescent girls and women to learn about the importance of nutrition and diet self-management, with the intention of arresting the disease process and minimizing the instances of miscarriages and severe birth defects, which are high in this population. After 20+ years, Metabolic Camp is established as a unique, national program allowing up to 35 campers to live and learn during a week of nutritional support and productive activities, while simultaneously providing researchers an opportunity to gather important data.
88911408|NCT01582984|Active Comparator|iMedConsentTM and customized written handout group|iMedConsentTM and a customized written handout
88911409|NCT01582984|Experimental|iMedConsentTM, handout, and standard video g|iMedConsentTM, handout, and standard AAOS video
88911410|NCT01582984|Experimental|iMedConsentTM, handout, video, and formal education|iMedConsentTM, the handout, the video, and a formal education session
88911411|NCT01581580|Other|treatment arm|patients with Parkinson's Disease, dysonia, and essential tremor
89008906|NCT00224744|Experimental|Ultracision surgical Inguinal curage|
89008907|NCT00571675|Experimental|1|AT-101, prednisone and docetaxel
89432026|NCT03413540|Experimental|Group 6|20-cm step, 100 reps
89432027|NCT03413540|Experimental|Group 7|30-cm step, 10 reps
89432028|NCT03413540|Experimental|Group 8|30-cm step, 50 reps
89432029|NCT03413540|Experimental|Group 9|30-cm step, 100 reps
89432030|NCT03413540|No Intervention|Group 10|Control
89432031|NCT01648894|Experimental|11 weeks|The cancer surgery is practice 11 weeks after neoadjuvant radio-chemotherapy
89432032|NCT01648894|Other|7 weeks|The cancer surgery is practice 7 weeks after neoadjuvant radio-chemotherapy
89432033|NCT04014920|Active Comparator|Oxygen Group|Patient will receive standard oxygenotherapy
89432034|NCT04014920|Experimental|NIV Group|Patient will receive non invasive ventilation
89432035|NCT05167604||MRD-positive Cohort|ctDNA positivity in pretreatment and posttreatment plasma samples was defined by accessing the presence of one or more mutations identified in match tumor samples. A mutation was considered present when at least one consensus read contained the mutation and passed the local polishing pipeline. The MRD positive cohort was randomly divided into two groups, one group for interventional treatment and the other group for observation.
89432036|NCT05167604||MRD-negative Cohort|ctDNA negative in pretreatment and posttreatment plasma samples was defined by accessing the presence of no mutation identified in match tumor samples. According to the clinical prognostic characteristics of the MRD negative group, the clinician decides to observe or treat.
89432037|NCT05611684|Experimental|Polyethylene Glycol Losenatide|Trearment for 12 weeks
89432038|NCT03413462|Active Comparator|HS-25|20mg, QD, 12 weeks
89432039|NCT03413462|Placebo Comparator|Placebo of HS-25|20mg, QD, 12 weeks
89432040|NCT01058512|Experimental|Single|single-arm study
89432041|NCT05167214|Experimental|Star tape|Group 1 ( n=35) was applied with the star technique. Visual Analogue Scale (VAS) to evaluate pain before taping, immediately after taping and 4 days after taping, Oswestry low back pain disability scale (OLBPDS) to assess disability level, Lumbar Flexion Repeat Speed Test, Sit-and-Stand Test to evaluate functional performance in both groups. Biering Sorenson Test was applied to evaluate the forward bending test with weight and trunk endurance. Individuals in both groups were told to continue with their daily lives while on the tapes. It was stated that the bands should stay on the applied area for 4 days, that they can have a bath while the bands are on, and that if the bands are uncomfortable or excessive itching on the skin, the individuals can remove the bandage with an oily solution. No itching, redness, or allergic reactions was observed in either group.
89432042|NCT05167214|Placebo Comparator|I Tape|Group 2 (n=35) was applied in the form of I tape. Visual Analogue Scale (VAS) to evaluate pain before taping, immediately after taping and 4 days after taping, Oswestry low back pain disability scale (OLBPDS) to assess disability level, Lumbar Flexion Repeat Speed Test, Sit-and-Stand Test to evaluate functional performance in both groups. Biering Sorenson Test was applied to evaluate the forward bending test with weight and trunk endurance. Individuals in both groups were told to continue with their daily lives while on the tapes. It was stated that the bands should stay on the applied area for 4 days, that they can have a bath while the bands are on, and that if the bands are uncomfortable or excessive itching on the skin, the individuals can remove the bandage with an oily solution. No itching, redness, or allergic reactions was observed in either group.
89432043|NCT01014598|Experimental|Treatment (cisplatin)|Patients receive cisplatin intra-arterially via isolated lung suffusion over 2 hours. Beginning approximately 2 weeks later (6-8 weeks if indicated for patients with sarcoma undergoing surgery after cisplatin), patients receive standard chemotherapy regimen.
89432044|NCT03413306|Experimental|Eltrombopag + IST (ATG + CsA)|
89432045|NCT03413306|Active Comparator|IST (ATG + CsA)|
89432046|NCT03404804|Experimental|Oral Challenge|Patients getting amoxicillin
89432047|NCT05611450|Placebo Comparator|routine care|
89432048|NCT05611450|Experimental|lung cancer self-management|
89432049|NCT03403946|Experimental|Intervention|"All patients received the same treatment.~Laryngscopy with C-MAC PM + Macintosh blade~Laryngscopy with C-MAC PM + D-Blade~Intubation with C-MAC PM + D-Blade"
89432050|NCT04523584||Hepatic Steatosis|<5% liver fat fraction by MRI PDFF
89432051|NCT04523584||No Hepatic Steatosis|>5% liver fat fraction by MRI PDFF
88911416|NCT01562782|Experimental|South Asians|Participants in this group have only South Asian heritage. The intervention is Fructose + Glucose Beverage.
88911417|NCT01562782|Active Comparator|Caucasians|Participants in this group have only Caucasian heritage. The intervention is Fructose + Glucose Beverage.
88911418|NCT01552356|Experimental|Treatment (pazopanib hydrochloride)|Patients receive pazopanib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Course length can be extended to 56 days at the discretion of the treating physician after 12 courses (1 year) of treatment on study.
88911419|NCT01550575||Patients eligible for SCS, RF or other treatment approaches|Patients who have previously been implanted with, or are eligible for implantation with a spinal cord stimulation system or various other treatment approaches such as RF, IDS, etc.
88911420|NCT01550575||Patients Eligible for treatment options with prior treatment|Patients who have previously been implanted with a spinal cord stimulation system or other various treatments, and have thereafter received a different form of chronic pain treatment such as a different SCS system, RF, IDS etc.
88911421|NCT01543698|Experimental|dual combination|LGX818 QD and MEK162 BID
88911422|NCT01543698|Experimental|triple combination|LGX818 QD and MEK162 BID and LEE011 QD 3 weeks on, 1 week off.
89432052|NCT03403244|Experimental|US-MR image fusion-guided PTED|US-MR image fusion-guided PTED: the puncture procedure during PTED was performed under the guidance of ultrasound-MR fusion technique.
89432053|NCT03403244|Active Comparator|fluoroscopy-guided PTED|fluoroscopy-guided PTED: the puncture procedure during PTED was performed under the guidance of fluoroscopy.
89432054|NCT05611372|Experimental|Early Intervention|0-52 week: rasagiline 1 mg/day
89432055|NCT05611372|Active Comparator|Delayed Intervention|0-26 week: palcebo 1mg/day 27-52 week: rasagiline 1mg/day
88911423|NCT01480154|Experimental|Treatment (Akt inhibitor MK2206, hydroxychloroquine)|Patients receive Akt inhibitor MK2206 PO on days 1, 8, and 15. Beginning on cycle 2, patients also receive hydroxychloroquine PO BID on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
88911424|NCT01461837|Experimental|Haplo Stem Cell Transplantation|CD34 selected T-cell depleted allogeneic SCT
88911425|NCT01375829|Experimental|Treatment (ixabepilone, temsirolimus)|Patients receive ixabepilone IV over 3 hours on day 1 and temsirolimus IV over 30-60 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
88911426|NCT01374984||Subjects treated with VIGIV.|"Subjects treated with VIGIV deployed from the US Strategic National Stockpile for any of the following conditions:~Eczema vaccinatum.~Progressive vaccinia.~Severe generalized vaccinia.~Vaccinia infections in individuals who have skin conditions.~Aberrant infections induced by vaccinia virus (except in cases of isolated keratitis)."
88911427|NCT01364051|Experimental|Treatment (cediranib maleate, selumetinib)|Patients receive cediranib maleate PO QD and selumetinib sulfate PO QD or BID on days 1-28 (days 8-28 of cycle 1). Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Cycles may be extended to 12 weeks after 1 year of study treatment.
88911428|NCT01362803|Experimental|Arm 1|Phase 1: AZD6244 PO BID x 28 DAYS
88911429|NCT01362803|Experimental|Arm 2|Phase 2: AZD6244 PO BID x 28 DAYS
88911430|NCT01352975||Group 0|participants without AMD (no large drusen or advanced AMD in either eye)
88911431|NCT01352975||Group 1|participants with large drusen in study eye and no large drusen or advanced AMD or GA in fellow eye
89432056|NCT03923738|Experimental|TCZ IV Q4W|Participants will receive up to 6 doses of Dose 1 of TCZ IV Q4W followed by up to 6 doses of Dose 2 of TCZ IV Q4W.
89432057|NCT05475184|Experimental|JPI-547|
89432058|NCT05611294|Active Comparator|Topography-Guided LASIK|Subjects receive Topography-Guided LASIK surgery on one eye.
89432059|NCT05611294|Active Comparator|Small Incision Lenticule Extraction|Subjects receive Small Incision Lenticule Extraction surgery on one eye.
89432060|NCT04447508|Experimental|Exercise class and motivational interviewing|Patients receiving the intervention will be enrolled in an online instructor led group exercise class and five online one on one motivational interviewing sessions.
89432061|NCT04447508|No Intervention|Usual care|Participants in the control group will receive an exercise booklet and educated on the benefits of exercise for low back pain. They will be advised to exercise for the duration of the study
89432062|NCT04447196||CCHS|20 patients presenting with central hypoventilation syndrome during spontaneous breathing and with Non Invasive Ventilation
89432063|NCT05171426||incidental cancer|familial adenomatous polyposis with incidental cancer
89432064|NCT03395834|Experimental|O3 monitor|tissue oxygenation comparison of O3 & INVOS
89432065|NCT04448288|Experimental|Hamstring Group|Pretest-posttest experimental design. Subjects participated in three experimental trials on three different days. On day-I for static-stretching for 2 minutes (SS2), day-II for 4 minutes (SS4), and day-III for 8 minutes (SS8). Testing was conducted before (pre), immediately after (post), and at 10 and 20 min post stretching. MVCF was measured using strain gauze as main outcome measure. The SS trials involved varied repetitions of 30-s static-stretches and 20-s relax period. MVC force was assessed.
89432066|NCT03395756|Active Comparator|12-14 mm follicle size group|Once the participant's leading follicle reaches 12-14mm, she will receive an IM administration of 150 mg Depot-Medroxyprogesterone Acetate. Prior to administration, she will have blood drawn for baseline progesterone, estradiol, and LH levels. One hour after receiving the injection, she will have blood drawn for medroxyprogesterone acetate levels. The next day, she will undergo a transvaginal ultrasound to assess the leading follicle and will have blood drawn for progesterone, estradiol, LH, and medroxyprogesterone acetate levels. For the next 4 consecutive days, she will have daily transvaginal ultrasounds to assess for signs of follicular rupture, and blood draws for hormonal assays. After, she will return twice weekly for two weeks for blood draw for progesterone levels.
89008908|NCT00571675|Placebo Comparator|2|Placebo, prednisone and docetaxel
89432067|NCT03395756|Active Comparator|15-17 mm follicle size group|Once the participant's leading follicle reaches 15-17mm, she will receive an IM administration of 150 mg Depot-Medroxyprogesterone Acetate. Prior to administration, she will have blood drawn for baseline progesterone, estradiol, and LH levels. One hour after receiving the injection, she will have blood drawn for medroxyprogesterone acetate levels. The next day, she will undergo a transvaginal ultrasound to assess the leading follicle and will have blood drawn for progesterone, estradiol, LH, and medroxyprogesterone acetate levels. For the next 4 consecutive days, she will have daily transvaginal ultrasounds to assess for signs of follicular rupture, and blood draws for hormonal assays. After, she will return twice weekly for two weeks for blood draw for progesterone levels.
89432068|NCT03395756|Active Comparator|18 mm or greater follicle size group|Once the participant's leading follicle reaches 18mm or greater, she will receive an IM administration of 150 mg Depot-Medroxyprogesterone Acetate. Prior to administration, she will have blood drawn for baseline progesterone, estradiol, and LH levels. One hour after receiving the injection, she will have blood drawn for medroxyprogesterone acetate levels. The next day, she will undergo a transvaginal ultrasound to assess the leading follicle and will have blood drawn for progesterone, estradiol, LH, and medroxyprogesterone acetate levels. For the next 4 consecutive days, she will have daily transvaginal ultrasounds to assess for signs of follicular rupture, and blood draws for hormonal assays. After, she will return twice weekly for two weeks for blood draw for progesterone levels.
89432069|NCT05558254|Active Comparator|ROBERT|The intervention group will receive usual practice. As add-on, the intervention leg will receive 3-4 sets of 15-20 repetitions (30 seconds rest between each set) of muscle strength training for hip flexion with ROBERT® three times a week.
89432070|NCT05558254|No Intervention|Control|Usual practice in the control group consist of 3-5 times physiotherapy a week for 8 weeks. A session last 45 minutes. The sessions are individually adapted and can contain exercise therapy, functional training, assistive devices, electrical stimulation, hydrotherapy and tread mill training.
89432071|NCT03395678|Experimental|Microneedling|Participants in this arm will receive 5 treatments of microneedling.
89432072|NCT03395678|Active Comparator|Fractional non-ablative 1,540nm laser|Participants in this arm will receive 5 treatments of fractional non-ablative1,540nm laser.
88911432|NCT01352975||Group 2|participants with bilateral large drusen with or without retinal pigment epithelial hypo/hyperpigmentary changes
88911433|NCT01352975||Group 3|participants with large drusen in study eye and advanced AMD (CNV and GA) in fellow eye
88911434|NCT01352975||Group 4|participants with findings of RPD
89008909|NCT02961270|Experimental|icotinib|patients will be administered study drug (icotinib) until disease progression or unacceptable toxicity
89008910|NCT00571753|Experimental|Test|Isoniazid dose adapted according to NAT2 status i.e. appr. 2.5 mg/kg, 5 mg/kg and 7.5 mg/kg for slow, intermediate and rapid acetylators, respectively
89008911|NCT00571753|Active Comparator|Control|Treatment with standard isoniazid dose (appr. 5 mg/kg b.w.)
89008912|NCT00224783|Active Comparator|CAIV-T|CAIV-T contains 3 cold-adapted influenza virus strains (A/H1N1, A/H3N2, B) concentrated and refined by centrifugal separation from the chorioallantoic membrane of specific pathogen-free (SPF) eggs, containing SPG (sucrose-phosphate-glutamate), arginine, and acid hydrolyzed pig gelatin as stabilizers. Subjects were inoculated once with about 0.1 mL of investigational vaccine in each nasal cavity (a total of 0.2 mL) using a nebulizer.
89008913|NCT00224783|Placebo Comparator|Placebo|Placebo contained 0.01 mol/L potassium phosphate buffer containing 0.85% sodium chloride (pH 7.2). Subjects received about 0.1 mL (a total 0.2 mL) of the control drug using a nebulizer.
89008914|NCT04580173||SYNTAX score = 0|Patients with nonobstructive CAD (≤50 % diameter stenosis)
89008915|NCT04580173||0 < SYNTAX score <=22|Low SYNTAX group
89008916|NCT04580173||23<=SYNTAX score<=32|Intermediate SYNTAX group
89008917|NCT04580173||SYNTAX score>=33|High SYNTAX group
89008918|NCT00571831|No Intervention|letter|a blue-filtering IOL an UV-filtering IOL
89008919|NCT00571870|Active Comparator|A|Stimulated as conventional protocol
89008920|NCT00571870|Experimental|B|GnRH antagonist stopped one day earlier than conventional protocol
89008921|NCT00254748|Placebo Comparator|1|Placebo
89008922|NCT00254748|Experimental|2|Flexible doses of 200 mg/day to 600 mg/day quetiapine fumarate
89432073|NCT04448132|Experimental|IPV-Al AJV|One dose of 0.5 mL of IPV-Al AJV injected intramuscularly perpendicular to the skin in the RIGHT deltoid muscle.
89432074|NCT05475028||HFpEF|We will recruit HFpEF (LVEF > 50%)
89432075|NCT05475028||HFrEF|We will recruit HFrEF (LVEF < 40%)
89008923|NCT00571909|Experimental|video thoracoscopic splanchnicectomy (VSPL)|
89008924|NCT00572026|Experimental|1|Daytrana
89008925|NCT00572026|No Intervention|2|No treatment for ADHD
89008926|NCT00572065|Experimental|All Patients|Arsenic trioxide [TrisenoxTM Injection], will be administered at a dose of 0.25 mg/kg on days 1-5 and days 8-12.
89008927|NCT00572104|Experimental|resistance exercise|12 month resistance exercise training
89008928|NCT00572104|Experimental|plyometric exercise|12 month plyometric exercise training
89008929|NCT00572143|Active Comparator|1|Postoperative follow-up of ca coli patients at the surgical outpatient dpt
89008930|NCT00572143|Active Comparator|2|Postoperative follow-up of ca coli patients by GP's
89008931|NCT00572221|Other|CQI Program Only|The main intervention is a facility-wide Continuing Quality Improvement and Quality Assurance system, with problem recognition and ongoing evaluation. (The SAVE+ intervention, the CQI system with facility responsible for identifying or designing care protocols for the identified problem condition.)
89008932|NCT00572221|Other|CQI Program and Best-Practice Care Protocols|A facility-wide Continuing Quality Improvement and Quality Assurance system, with problem recognition and ongoing evaluation. Research clinical staff will also provide best-practice care protocols designed by our research team to address targeted problem conditions. (The SAVE+ intervention, a CQI system plus best-practice protocols designed by study team to address identified problem condition.)
89008933|NCT00572299||glucocorticoids|patients receiving glucocorticoid treatment
89008934|NCT00572299||glucocorticoids and bisphosphonates|patients receiving both glucocorticoids and bisphosphonates
89008935|NCT00572338||patients with myeloma/related diseases|
89008936|NCT00572377|Active Comparator|FemLife Gel|
89008937|NCT00572377|Placebo Comparator|Placebo|
89008938|NCT00413075|Experimental|oral belinostat|
89008939|NCT00572494|Experimental|1|Stenting with AMS
89008940|NCT00572494|Active Comparator|2|PTA alone
89008941|NCT00572611|Experimental|I|Single oral dose of 20 mg [14C]-bilastine
89008942|NCT00572650|Active Comparator|1|
89432076|NCT05475028||Healthy controls|We will recruit volunteer blood donors
88911435|NCT01352962|Experimental|Arm 1|Standard of Care plus escalating doses of Lenalidomide
88911436|NCT01352962|Experimental|Arm 2|Lenalidomide Lead for 14 days + standard of care + lenalidomide MTD
88911437|NCT01352949||Healthy Volunteers|Healthy volunteers without scoliosis or obesity
88911438|NCT01352949||Obesity|Healthy volunteers with obesity
88911439|NCT01352949||Scoliosis|Healthy volunteers with scoliosis but no obesity
88911440|NCT01351909|Experimental|Treatment (veliparib, cyclophosphamide)|Patients receive veliparib orally PO QD and cyclophosphamide PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
88911441|NCT01350648||HBV and HCV Co-infection|HBV and HCV Co-infection
88911442|NCT01350648||Hepatitis B|Hepatitis B alone
88911443|NCT01350648||Hepatitis C|Hepatitis C alone
88911444|NCT01350648||HIV and HBV and HCV Tri-Infection|HIV and HBV and HCV Tri-Infection
88911445|NCT01350648||HIV and HBV Co-infection|HIV and HBV Co-infection
88911446|NCT01350648||HIV/HCV Co-Infection|HIV and HCV Co-infection
89432077|NCT04448444|Experimental|Motor Program Activating Therapy (MPAT)|The MPAT was chosen for our clinical experience - it was developed and verified by our team. In this therapy, patients are corrected into a postural position where the joints are functionally centred. Then somatosensory (manual and verbal) stimuli are applied to activate motor programs in the brain, which then lead to the co-contraction of the patient's whole body when the patient is lying, sitting, standing up or moving forward. Activated programs are repeated under various conditions and in different situations and environments to teach the patients to use the acquired motor skills automatically in daily life.
88911447|NCT01343706|Experimental|BI 409306 0.5 mg PiB [EM]|Extensive metaboliser [EM] subjects administered one single dose of 0.5 milligram (mg) BI 409306 powder in bottle (PiB) reconstituted for oral solution (0.5 mg /milliliter (mL)) in a volume of 80 mL of the solvent containing aqueous 0.5% tartaric acid solution orally with 240 mL water (160 mL containing the respective diluted volume of reconstituted solution and 80 mL drinking water) after an overnight fast of at least 10 hours.
88911448|NCT01343706|Experimental|BI 409306 2 mg PiB [EM]|EM subjects administered one single dose of 2 mg BI 409306 PiB reconstituted for oral solution (0.5 mg/mL) in a volume of 80 mL of the solvent containing aqueous 0.5% tartaric acid solution orally with 240 mL water (160 mL containing the respective diluted volume of reconstituted solution and 80 milliliter drinking water) after an overnight fast of at least 10 hours.
89531211|NCT03339323|Experimental|Exercise|Aerobic exercise combined with resistance training; Concentric resistance training; Eccentric resistance training
88911449|NCT01343706|Experimental|BI 409306 5 mg PiB followed by BI 409306 5 mg Tablet [EM]|EM subjects administered one single dose of 5 mg BI 409306 powder in bottle (PiB) reconstituted for oral solution (0.5 mg/ mL) in a volume of 80 mL of the solvent containing aqueous 0.5% tartaric acid solution orally with 240 mL water (160 mL containing the respective diluted volume of reconstituted solution and 80 mL drinking water) after an overnight fast of at least 10 hours in period 1; followed by a washout period of 5 days; followed by one single dose of 5 mg BI 409306 immediate release tablet administered orally with 240 mL water after an overnight fast of at least 10 hours in period 2.
88911450|NCT01343706|Experimental|BI 409306 10 mg Tablet [EM]|EM subjects administered 2 immediate release tablets of 5 mg BI 409306 as a single dose (total dosage: 10 mg) orally with 240 mL water after an overnight fast of at least 10 hours.
88911451|NCT01343706|Experimental|BI 409306 25 mg Tablet [EM]|EM subjects administered 5 immediate release tablets of 5 mg BI 409306 as a single dose (total dosage: 25 mg) orally with 240 mL water after an overnight fast of at least 10 hours.
88911452|NCT01343706|Experimental|BI 409306 50 mg Tablet followed by BI 409306 50mg PiB [EM]|EM subjects administered one single dose of 50 mg BI 409306 immediate release tablet orally with 240 mL water in period 1; followed by a washout period of 5 days; followed by one single dose of 50 mg BI 409306 powder in bottle (PiB) reconstituted for oral solution (0.5 mg/mL) in a volume of 80 mL of the solvent containing aqueous 0.5% tartaric acid solution administered orally with 240 mL water (160 mL containing the respective diluted volume of reconstituted solution and 80 mL drinking water) after an overnight fast of at least 10 hours in period 2.
88911453|NCT01343706|Experimental|BI 409306 100 mg Tablet [EM]|EM subjects administered 2 immediate release tablets of 50 mg BI 409306 as single dose (total dosage: 100 mg) orally with 240 mL water after an overnight fast of at least 10 hours.
88911454|NCT01343706|Experimental|BI 409306 200 mg Tablet [EM]|EM subjects administered 1 immediate release tablet of 150 mg and 1 immediate release tablet of 50 mg of BI 409306 together as single dose (total dosage: 200 mg) orally with 240 mL water after an overnight fast of at least 10 hours.
88911455|NCT01343706|Experimental|BI 409306 350 mg Tablet [EM]|EM subjects administered 2 immediate release tablet of 150 mg and 1 immediate release tablet of 50 mg of BI 409306 together as single dose (total dosage: 350 mg) orally with 240 mL water after an overnight fast of at least 10 hours.
88911456|NCT01343706|Experimental|BI 409306 10 mg Tablet followed by BI 409306 100mg Tablet [PM]|Poor metaboliser [PM] subjects administered 2 immediate release tablets of 5 mg BI 409306 as single dose (total dosage: 10 mg) orally with 240 mL water after an overnight fast of at least 10 hours in period 1; followed by washout period of 5 days; followed by 2 immediate release tablets of 50 mg BI 409306 administered as single dose (total dosage: 100 mg) orally with 240 mL water after an overnight fast of at least 10 hours in period 2.
88911457|NCT01343706|Placebo Comparator|Placebo matching to BI 409306 PiB|Subjects administered one single dose of placebo matching to BI 409306 powder in bottle (PiB) after an overnight fast of at least 10 hours.
88911458|NCT01343706|Placebo Comparator|Placebo matching to BI 409306 film-coated tablet|Subjects administered one single dose of placebo matching to the BI 409306 film-coated tablet (5 milligrams (mg), 50 mg, and 150 mg) orally with 240 mL water after an overnight fast of at least 10 hours.
88911459|NCT01186367|Experimental|Linear Aerobic Training|The ultimate goal is for participants to complete approximately 130-180 minutes/week of aerobic training, at 60% to 75 % of the individually determined exercise capacity (VO2peak), for 16 weeks. VO2peak will be determined by the second CPET performed at baseline.
88911460|NCT01186367|Experimental|Nonlinear Aerobic Training|The ultimate goal is for participants to complete approximately 130-180 minutes/week of aerobic training at 55% to 100% of the individually determined exercise capacity (VO2peak), for 16 weeks. VO2peak will be determined by the second CPET performed at Baseline and as well as the CPET performed at Midpoint.
88911461|NCT01186367|Experimental|Progressive Stretching Group (Attention control)|The ultimate goal for the progressive stretching program is 3 to 4 individual stretching sessions/week for 10 to 50 minutes per session (+/- 10 minutes).
88911464|NCT01143480||ABCA1|SNP or allele of interest
88911465|NCT01143480||APOE|SNP or allele of interest
88911466|NCT01143480||APOL1|SNP or allele of interest
88911467|NCT01143480||CD14|SNP or allele of interest
88911468|NCT01143480||CD44|SNP or allele of interest
88911469|NCT01143480||IRGM|SNP or allele of interest
88911470|NCT01143480||ITIH3|SNP or allele of interest
88911471|NCT01143480||ITIH4|SNP or allele of interest
89531212|NCT05033457||unilateral biportal endoscopy technique group|Treatment of lumbar intervertebral disc herniation with unilateral biportal endoscopy technique in unilateral biportal endoscopy technique group
88911472|NCT01143480||MyD88|SNP or allele of interest
88911473|NCT01143480||TIRAP|SNP or allele of interest
88911474|NCT01143480||TLR4|SNP or allele of interest
88911475|NCT01143480||TLR5|SNP or allele of interest
88911476|NCT01143480||TNFa|SNP or allele of interest
88911477|NCT01132885||Adults with WS or genetic abnormalities|Adults with Williams syndrome or genetic abnormalities in chromosome 7q11.23
89531213|NCT05033457||percutaneous endoscopic transforaminal discectomy group|Treatment of lumbar intervertebral disc herniation with percutaneous endoscopic transforaminal discectomy in percutaneous endoscopic transforaminal discectomy group
88911478|NCT01132885||Children with WS or genetic abnormalities|children ages 5-17 with Williams Syndrome or genetic abnormalities in chromosome 7q11.23
88911479|NCT01132885||Parents|Parents of children with 7q11.23 CNV will undergo blood draws
88911480|NCT01132885||Unaffected Siblings|Siblings of children with 7q11.23 CNV
88911481|NCT01132885||Unrelated children|Typically developing children ages ages 5-17
88911484|NCT01081405|Experimental|TOTAL LYMPHOID IRRADIATION|Allogeneic Hematopoietic Cell Transplantation Using a Non-myeloablative Preparative Regimen of Total Lymphoid Irradiation and Anti-Thymocyte Globulin for Patients with Hematologic Malignancies
88911485|NCT01013649|Active Comparator|Arm I (gemcitabine hydrochloride or combination chemotherapy)|Patients receive either gemcitabine hydrochloride or allowable combination chemotherapy per standard of care for 5 months. Patients undergo CT, MRI, and/or x-ray imaging throughout the trial. Patients also undergo blood sample collection during screening and follow-up and undergo tissue sample collection at baseline.
88911486|NCT01013649|Experimental|Arm II (gemcitabine hydrochloride, erlotinib hydrochloride)|Patients receive gemcitabine hydrochloride IV over 30 minutes once a week for 3 weeks then off 1 week and erlotinib hydrochloride PO once daily on days 1-28. Treatment repeats every 28 days for up to 5 courses in the absence of disease progression or unacceptable toxicity. Patients undergo CT, MRI, and/or x-ray imaging throughout the trial. Patients also undergo blood sample collection during screening and follow-up and undergo tissue sample collection at baseline. (closed to accrual 4/2/14)
88911487|NCT01013649|Experimental|Arm III (chemotherapy)|Patients receive the same treatment as in arm I for 1 month. Patients undergo CT, MRI, and/or x-ray imaging throughout the trial. Patients also undergo blood sample collection during screening and follow-up and undergo tissue sample collection at baseline.
88911488|NCT01013649|Experimental|Arm IV (chemotherapy, chemoradiotherapy)|Patients receive the same treatment as in arm I for 1 month. Beginning within 7-21 days after completion of chemotherapy, patients undergo radiotherapy (3-dimensional conformal radiotherapy or intensity-modulated radiotherapy) 5 days per week for 5.5 weeks (28 fractions). During radiotherapy, patients receive either capecitabine PO BID 5 days per week or fluorouracil IV continuously for 5.5 weeks or until radiotherapy is completed. Patients undergo CT, MRI, and/or x-ray imaging throughout the trial. Patients also undergo blood sample collection during screening and follow-up and undergo tissue sample collection at baseline.
88911489|NCT00900198||1/Standard|Standard
88911490|NCT00900198||2/Standard and Preclinical Models|Standard and Preclinical Models
88911491|NCT00900198||3/Preclinical Models|Preclinical Models
88911492|NCT00900198||4/Preclinical Models, Pediatric|Preclinical Models, Pediatric
88911493|NCT00878163|Experimental|Treatment (vismodegib, erlotinib hydrochloride, gemcitabine)|Patients receive Hedgehog antagonist GDC-0449 PO QD and erlotinib hydrochloride PO QD on days 1-28. Some patients also receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88911494|NCT00797719|Experimental|All|This is a single arm study. All patients enrolled will be in this arm.
88911495|NCT00773773|Experimental|Patients undergoing prostatic biopsy|This study will enroll two groups of 250 patients who are to undergo prostatic biopsy as part of their routine medical care because of suspicion of prostate cancer (elevated PSA between 2 and 10 ng/ml, abnormal rectal examination, or both). The first group will contain 250 patients of African-American descent and the second will contain 250 Caucasian men.
88911496|NCT00767312||Patients|HIV-infected patients who are 18 years of age or older, have been enrolled in another NIH protocol.
88911497|NCT00719719||Drug Anaphylaxis|Drug Anaphylaxis
88911498|NCT00719719||Food Anaphylaxis|Food Anaphylaxis
88911499|NCT00719719||Idiopathic Anaphylaxis|Idiopathic Anaphylaxis
88911500|NCT00719719||Venom Anaphylaxis|Venom Anaphylaxis
88911501|NCT00668187||Gangliosidosis Diseases Study Population|This study observes one cohort: 42 infantile or juvenile Tay-Sachs disease, Sandhoff disease, or GM1 gangliosidosis affected subjects; and 10 late-onset gangliosidosis disease affected subjects.
88911502|NCT00616304|Active Comparator|A|L-arginine infusion
88911503|NCT00616304|Placebo Comparator|S|Normal saline infusion
88911504|NCT00589680||2|Patients treated for DKA under DKA protocol implemented by hospital
88911505|NCT00589680||1|To establish a baseline on how patients are being treating with DKA in general and without a standardized DKA protocol
88911506|NCT00588991|Experimental|Treatment (veliparib, topotecan hydrochloride, carboplatin)|Patients receive veliparib orally twice daily on days 1-8, 1-14, or 1-21 and topotecan hydrochloride with or without carboplatin IV continuously over 120 hours on days 3-7. Treatment repeats every 28-63 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
88911507|NCT00572481|Other|Sentinel Lymph Node Biopsy Only|Axillary Reverse Mapping
88911508|NCT00572481|Other|Full Axillary Lymph Node Dissection|Axillary Reverse Mapping
88911509|NCT00537914|Experimental|Omnitrope|All enrolled patients received Omnitrope. The median daily dose varied between 0.0340 and 0.0351 mg/kg/day and the maximum range was 0.000 to 0.040 mg/kg/day over all visits.
88911510|NCT00409435|Active Comparator|pyridostigmine|Active study drug
88911511|NCT00409435|Placebo Comparator|Placebo|Control
88911515|NCT00368446||1|Normal
88911516|NCT00368446||2|patients with Genetic Disorders of Mucociliary Clearance
88911517|NCT00342589||Healthy Volunteers|Individuals exposed to environmental or person-to-person sources of organisms, including healthy volunteers, health care professionals, patient families, or other patients in health care facilities
88911518|NCT00342589||Patients|Patients immunosuppressed with acute pneumonia and are undergoing or have undergone a clinically indicated procedure to obtain a respiratory sample for diagnostic purposes.
88911519|NCT00340028||Women in Early Pregnancy|Women enrolled in the University of North Carolina's Right from the Start study are followed while trying to become pregnant and through 9 weeks of pregnancy
89432078|NCT04448444|Experimental|Vojta Reflex Locomotion (VRL)|VRL was developed by prof. Vojta and is standardly used in the Czech Republic. In this therapy, patients should be set up into the precisely given initial position with defined angular setting of extremities. In each position (supine, prone, lying on the side, and low kneeling position), activation points (zones) are stimulated with precise localization and pressure direction. Such stimulation activates one of the global movement patterns (reflex turning and reflex creeping) corresponding to the initial position. In addition to motor involuntarily reaction, also sensory and autonomic response is activated.
89432079|NCT04448444|No Intervention|healthy controls|sex and age matched healthy controls
89432080|NCT03413228||Influenza-like illness group|
89432081|NCT05613166|Experimental|everolimus 1h|The study participants will orally receive everolimus within 1 hour and placebo at 8-9 hours after each seizure event, but with intervals longer than 24 hours.
89432082|NCT05613166|Experimental|everolimus 8-9h|The study participants will orally receive placebo within 1 hour and everolimus at 8-9 hours after each seizure event, but with intervals longer than 24 hours.
89432083|NCT05613166|Placebo Comparator|placebo|The study participants will orally receive placebo both within 1 hour and at 8-9 hours after each seizure event, but with intervals longer than 24 hours.
89432084|NCT05166668|Active Comparator|standard GnRH antagonist protocol|Gonadotropins (300-450 IU) IM start on cycle day 2 then the dose modulated according to response
89432085|NCT05166668|Active Comparator|Aromatase inhibitor/flexible antagonist protocol|letrozole orally in a dose of 2.5 mg daily, on day 2 of cycle for 5 days and gonadotropins (300-450 IU) IM start on cycle day 3. then the dose modulated according to response
88911520|NCT00336063|Experimental|Treatment (azacitidine, vorinostat)|Patients receive azacitidine SC on days 1-10 and vorinostat PO BID on days 1-14. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.
88911521|NCT00331331||Patients|Participants with appropriate ocular disorders who were previously enrolled as part of the MUST study and patients who participate in other intramural NIH studies
88911522|NCT00233272||Healthy Volunteers|Healthy volunteers over a wide age-range
88911523|NCT00128973||Healthy Volunteers|Healthy adult M/F 18-85 y/o.Hgb>=11.Wt>110 lbs. No heart,lung,kidney,bleeding disorders. No hep BorC since age 11. No IV drug use. No exposure to the AIDS virus. Not pregnant.
88911524|NCT00128973||Patients|Patients with abnormalities of immune function
88911525|NCT00128973||Relatives of Patient:|Relatives may be mother, father, siblings, children, grandparents, aunts, uncles, and first cousins to a patient.
88911527|NCT00114647||1|Healthy Volunteers
88911528|NCT00114647||2|HIV
88911529|NCT00107289|Experimental|Radiation|
88911530|NCT00081523||Patients|Individuals with known or suspected sickle cell disease
89432086|NCT05558176|Active Comparator|Sildenafil citrate arm|"The same brand of sildenafil citrate (VIAGRA, manufactured by Fareva Amboise Zone Industrielle, 29 route des Industries, 37530 Poce Sur Cisse, France, under authority of Pfizer Inc, NewYork, NAFDAC Reg NO: 04 - 1509, Batch No: 477209; Exp date: 11 - 2024) will be used in the course of the study.~Women will receive the first dose of trial medication after transfer to the birth suite once diagnosed to be in labour with cervical dilatation < 8 cm. Sildenafil citrate will be given orally as a 50-mg dose 6 hourly to a maximum of 3 doses (150mg). Blood pressure will be monitored 15-30 minutes after each dose. Labour will be monitored with the aid of partograph, appropriate analgesic given in labour. Foetal heart rate monitoring will be performed in all cases by cardiotocograph or intermittent auscultation every fifteen minutes"
89432087|NCT05558176|Placebo Comparator|Placebo|The placebo will be a vitamin C of the same size, colour and shape with sildenafil (Viagra).
89432088|NCT04748224|Active Comparator|group A (bupivacaine only)|Group A will be injected with 20 ml of 0. 25% bupivacaine in each side
89432089|NCT04748224|Active Comparator|group B (bupivacaine plus dexmedetomidine)|Group B will be injected with 20 ml of 0. 25% bupivacaine in each side added to it dexmedetomidine 0.5 μg/kg; (Precedex 100 μg/ml (Hospira, inc, lake forest, USA).
89432090|NCT03399968|Experimental|ESWT|Application of shockwaves non-invasively at the level of injury
89432091|NCT03399968|Placebo Comparator|Placebo ESWT|Positioning of the therapy head at the injury level without application of shockwaves
89432092|NCT03395600|Active Comparator|0.1%bupivacaine+10µg sufentanyl|Epidural labour analgesia was initiated with 10µg sufentanyl along with 5 ml bupivacaine 0.1% as the test dose. After 3 min, 10 ml of 0.1% bupivacaine epidural was injected
89432093|NCT03395600|Active Comparator|0.125%bupivacaine+5µg sufentanyl|Epidural labour analgesia was initiated with 5µg sufentanyl along with 5 ml bupivacaine 0.125% as the test dose. After 3 min, 10 ml of 0.125% bupivacaine epidural was injected
89432094|NCT03395600|Active Comparator|0.1%bupivacaine+5µg sufentanyl|Epidural labour analgesia was initiated with 5µg sufentanyl along with 5 ml bupivacaine 0.1% as the test dose. After 3 min, 10 ml of 0.1% bupivacaine epidural was injected
88911535|NCT00029965||Glycoprotein Disorders|Glycoprotein Disorders
88911536|NCT00029965||Lysosomal Storage Diseases|Lysosomal Storage Diseases
88911537|NCT00025935||Children/adolescents with ADHD|Children/adolescents with ADHD
88911538|NCT00025935||Children/Adolescents with DMDD or subthreshold DMDD|Children/Adolescents with DMDD or subthreshold DMDD
88911539|NCT00025935||Children/adolescents with MDD|Children/adolescents with MDD
88911540|NCT00025935||Healthy volunteer adults|Healthy volunteer adults
88911541|NCT00025935||Healthy volunteer children/adolescents|Healthy volunteer children/adolescents
88911542|NCT00025935||Parents of children/adolescents with DMDD or subthreshold DMDD|Parents of children/adolescents with DMDD or subthresdhold DMDD
88911545|NCT00012545||Healthy Pregnant Volunteers|Pregnant women whose babies are at risk for sickle cell anemia will be identified and referred to the NIH Research Coordinator for evaluation and entry into the study
89008943|NCT00572689|Experimental|A|Subject receives injection of 10 micrograms of Exenatide sub-cutaneously the given mixed meal test and blood samples will be drawn for laboratory testing.
89008944|NCT00572689|No Intervention|B|Patients given mixed meal test and blood samples drawn for laboratory testing
89008945|NCT00572767|Experimental|1|
89008946|NCT00572767|Placebo Comparator|2|
89008947|NCT00572845|Experimental|1|Weaning of Spasticity Medication over a three day period while measuring Modified Ashworth Scale and Penn Spasm Frequency Score. Then titration of medication back to previous dose over a three day period.
89432095|NCT04736758|Experimental|GP681 tablet 40mg|Patients in the GP681 tablet 40mg group is treated with GP681 tablet 40mg orally once with 240mL water.
88911548|NCT00001975||Group 1|Patients will be those already diagnosed with TSC (definite or possible)
88911549|NCT00001846||research donors|healthy volunteers (age 18 years or greater) who donate blood for in vitro research purposes
88911550|NCT00001813||1|Subjects with clinical and/or laboratory documentation of typical features or suggestiveclinical features of XP, CS, TTD, or overlap syndromes
88911551|NCT00001813||2|Family members of patients with XP, CS, TTD, or overlap syndromes
88911552|NCT00001813||3|Healthy volunteers
88911553|NCT00001595||Patients with pituitary tumors or hypothalmic defects|Patients with pituitary tumors or hypothalmic defects
88911554|NCT00001456||HPS|HPS patients of any gender and ethnicity age 1-80 years
88911555|NCT00001456||HPS Symptom Questionnaire|Includes both patients and family members or caregivers.
89432096|NCT04736758|Experimental|GP681 tablet 20mg|Patients in the GP681 tablet 40mg group is treated with GP681 tablet 20mg orally once with 240mL water.
89432097|NCT04736758|Placebo Comparator|Placebo group|Patients in the Placebo group is treated with GP681 Simulant orally once with 240mL water.
89432098|NCT03413150||severely ill patients receiving amiodarone for ATs|cohort study was conducted from January 2007 to April 2012 in the 18-bed medical ICU of a tertiary teaching hospital.Data were extracted from the files of 80 consecutive critically ill patients who had received at least one dose of amiodarone to treat or prevent atrial tachycardia during their hospitalization in the ICU.
89432099|NCT04447976||Patients undergoing ERCP by formally trained Endoscopists|No intervention has been used and this is an observational study of evaluation of a TIP duodenoscope performance overall.
89432100|NCT03395444|Active Comparator|Study Group|Pulsed shortwave therapy device used as an adjunct therapy immediately on the completion of the operation
89432101|NCT03395444|Sham Comparator|Control Group|Sham pulsed shortwave therapy device used as an adjunct therapy immediately on the completion of the operation
89432102|NCT03399890||Group S|Group S: Group sugammadex Patients in this group received sugammadex at the end of the surgery, as neuromuscular reversal agent. Neurological physical exam time was recorded.
89432103|NCT03399890||Group N|"Group N: Group Neostigmine~Patients in this group received neostigmine at the end of the surgeryas neuromuscular reversal agent. Neurological physical exam time was recorded."
88911564|NCT00001372||1|Longitudinal cohort study with affected SLE patients
88911565|NCT00001372||2|Patient relatives
88911566|NCT00001372||3|Unrelated healthy volunteers
88911567|NCT00001230||1|Patients that have, or are suspected of having, one of the filarial infections affecting humans
88911569|NCT00001160||thyroid cancer|Patients with thyroid cancer
88911570|NCT00001160||thyroid nodules|Patients with thyroid nodules
88911571|NCT01570179|Experimental|deep block ideal body weight|
88911572|NCT01570179|Active Comparator|deep block real body weight|
88911573|NCT01570179|Experimental|moderate block ideal body weight|
88911574|NCT01570179|Active Comparator|moderate block real body weight|
88911575|NCT01570205|Experimental|XG-102 10 µg/kg|
88911576|NCT01570205|Experimental|XG-102 40 µg/kg|
88911577|NCT01570205|Experimental|XG-102 80 µg/kg|
88911578|NCT01570205|Placebo Comparator|placebo|
88911579|NCT01570218|Experimental|Music therapy|Music therapy arm: Intervention with 10 sections of music therapy will be performed, twice a week, during 45 days.
88911580|NCT01570218|No Intervention|Control|
88911581|NCT01570231|Experimental|bilateral limb ischemic preconditioning (BLIPC)|5 minutes bilateral limb ischemic preconditioning treatment with an inflating tourniquets to 200 mmHg
88911582|NCT01570231|No Intervention|Control group|underwent equivalent medical treatments only
88911583|NCT01570257|No Intervention|control group|These patients receive a shunt with the valve preset and fixed at a Performance level of 1.0, corresponding to an opening/closing pressure of 35-55 mm H2O.
88911584|NCT01570257|Experimental|Intervention group|These patients receive a shunt with the valve preset at a Performance level (PL) of 2.5, corresponding to an opening/closing pressure of 135-155 mm H2O. The PL is allowed to be lowered until clinical improvement occurs.
88911585|NCT01570270|Experimental|regular cheese|This study was a 3-week, randomized, single blind, controlled, cross over clinical trial. The subjects were randomly assigned to eat 90g/d of the control or enriched cheese for 3 weeks, with a cross over after 3 weeks of washout. The study included 5 visits: 2 screening/baseline visits at weeks -1 and 0, 1 end of intake of 90 g/d of cheese visit at week 3, 1 end of the first wash out visit at week 6, and 1 end of treatment after crossing over visit at week 9. T
88911586|NCT01570374|Experimental|iCBT|Receives treatment.
88911587|NCT01570374|No Intervention|Waiting list control group|The waiting list control group initially receives no treatment, but do weekly screenings. After 9 weeks, the control group receives the same treatment as the other study arm.
88911588|NCT01570400|Experimental|CBM training program variant 1 + iCBT|Cognitive bias modification training program variant 1 combined with iCBT
88911589|NCT01570400|Experimental|CBM training program variant 2 + iCBT|Cognitive bias modification training program variant 2 combined with iCBT
88911590|NCT01570413|Active Comparator|Pelvic Exam|Subjects receive pelvic exam
89432104|NCT03399812|Experimental|Whey protein isolate|
88911591|NCT01570413|Experimental|No Pelvic Exam|Subjects do not receive pelvic exam
88911592|NCT01570426||Bipolar Disorder|Children, 7- 17 years-old, who meet diagnostic criteria for bipolar disorder, Type 1
88911593|NCT01570426||ADHD/ADD|Children, 7-17 years-old, who meet diagnostic criteria for attention deficit/hyperactivity disorder (ADHD) OR attention deficit disorder (without hyperactivity)
89432105|NCT03399812|Active Comparator|Pea protein isolate|
89432106|NCT05474716|Experimental|Topical Brimonidine 0.2% bid ophthalmic solution|Topical Brimonidine tartrate 0.2% ophthalmic solution used twice daily. It is a selective alpha 2 adrenergic agonist that is used as an ocular hypotensive in glaucoma and ocular hypertension patients and has proposed neuroprotective effect.
89432107|NCT03399734|Experimental|Treatment A|4 milligrams (mg) perampanel tablet
89432108|NCT03399734|Experimental|Treatment B|4 mg perampanel fine granules
89432109|NCT03126578|Experimental|All subjects|"Part I - Maximum Tolerated Dose: All subjects will receive oral doses of LEO 32731 up-titrated from 10 mg bid on Days 1-3, 20 mg bid on Days 4-6 and 40 mg bid on Days 7-12.~Part II - Drug-Drug Interaction: All subjects will receive oral doses of LEO 32731 in dose schedule decided upon data from Part I. Subjects will receive a single oral dose of 2.5 mg midazolam on Day -1 prior to the first dose of LEO 32731 and on Days 4, 7 and 17 of multiple dosing with LEO 32731."
89432110|NCT03412994|Experimental|Apatinib group|"Apatinib combined with second-line chemotherapy (5-Fu combined with irinotecan or oxaliplatin standard regimen ) Apatinib tablets: 500 mg po qd . Continuous medication, the cycle is consistent with the chemotherapy cycle.~Oxaliplatin: Day 1, 130mg/m2, IV infusion. Capecitabine: Day 1-14, 1000mg/m2 Twice Daily, po. A total of 6 cycles, 3 weeks apart of chemotherapy.（Take CAPEOX for example）"
89432111|NCT03412994|Placebo Comparator|Control group|Oxaliplatin: Day 1, 130mg/m2, IV infusion. Capecitabine: Day 1-14, 1000mg/m2 Twice Daily, po. A total of 6 cycles, 3 weeks apart of chemotherapy.（Take CAPEOX for example）
89432112|NCT03412916|Experimental|GetActive|The GetActive program uses a multimodal approach to introduce and reinforce new skills, including didactics, in-session activities, discussions, and weekly practice assignments (homework). The GetActive sessions reflect a purposeful integration of the three treatment approaches (relaxation methods, stress appraisal & coping, and growth enhancement). The format is a 10-week program with weekly meetings and a focus on relaxation response strategies, cognitive behavioral training, positive psychology and mind-body interactions.
89432113|NCT03412916|Experimental|GetActive with Fitbit|The GetActive with Fitbit is identical to that of the p3RP with the addition of a digital monitoring device (i.e., Fitbit) for recording of physical activity.
89432114|NCT02588248|Experimental|Peppermint Oil|"Solution A) Peppermint oil solution (1.6% peppermint oil, which is 0.8% L-menthol)~Ingredients:~16mL of peppermint oil (provided by the NowFoods® company)~0.4mL of Tween® 80 (i.e. Polysorbate 80) - this is a commonly used food additive that acts as a surfactant to bring the peppermint oil into solution~1L prepackage sterile water~2.6mL of undyed simethicone"
89432115|NCT02588248|Placebo Comparator|Placebo|"Solution B) Placebo solution~Ingredients:~0.4mL of Tween® 80 (i.e. Polysorbate 80) - this is a commonly used food additive that acts as a surfactant to bring the peppermint oil into solution~1L prepackage sterile water~2.6mL of undyed simethicone~Instructions to prepare:~Add tween and simethicone to sterile water. Then, shake vigorously.~Once solution has settled, and patient has been randomized, draw 20mL of solution into a plastic syringe"
89432116|NCT03412838|Active Comparator|Cortico-Cancellous|Graft surgery with cortico-cancellous block, freeze dried bone allograft (FDBA) for treatment the atrophic maxilla prior implant placement
89432117|NCT03412838|Active Comparator|Cancellous|Graft surgery with cancellous block, freeze dried bone allograft (FDBA) for treatment the atrophic maxilla prior implant placement
89432118|NCT05239442|Other|Patients|"Hospital Patients:~- Person hospitalized in one of the following departments: endocrinology-diabetology, geriatric medicine, pulmonology, rheumatology, dermatology, infectious diseases, internal medicine, cardiology, as well as in the rehabilitation department"
89432119|NCT05239442|Other|Institutional staff|Person working in the establishment where the taste commissions have been in place for at least 3 months
89432120|NCT05239442|Other|Residents|Patients residing in nursing home
89432121|NCT05557318|Experimental|Bacterial infections|"The subject is infected with at least one of the following pathogens:~Bacterial vaginosis (BV) / Escherichia coli / Trichomonas / Group B streptococcus / Chlamydia trachomatis / Neisseria gonorrhoeae"
89432122|NCT05557318|Experimental|Fungal infection :|The subject is infected with Candida albicans only.
89432123|NCT05557318|Experimental|Mixed infection|Bacterial and fungal infections coexist.
89432124|NCT05557318|Experimental|No infection|Healthy participant
89008948|NCT00572923||1|"Inclusion criteria~Histological or cytological proven SCLC~UICC stage I-III, limited disease~Performance status 0-2~FeV1 and DLCO at least 30% of age-predicted value~Exclusion criteria:~Not SCLC or mixed SCLC and other histologies (e.g. non-small cell carcinoma)~stage IV~performance status 3 or more~FeV 1 or DLCO< 30% of the age-predicted value"
89008949|NCT00573001|Experimental|1|
89432125|NCT03412682|Experimental|Budesonide (6 mg)|
89432126|NCT03412682|Experimental|Budesonide (9 mg)|
89432127|NCT03412682|Active Comparator|Mesalazine (3,600 mg)|
89008950|NCT00573001|Experimental|2|
89008951|NCT00573001|Experimental|3|
89008952|NCT00573001|Active Comparator|4|
89008953|NCT03453853|Experimental|Mitral Loop Cerclage|Intervention: Device: Mitral Loop Cerclage Annuloplasty with CSTV Protective Device
89008954|NCT03453775|Active Comparator|Ultrasound guided infiltration|"Ultrasound guided periradicular lumbar infiltration. Prone position. Lumbar spine level located in a median sagittal plane (spinous processes). High resolution curved 5MHz ultrasound probe. Probe is then rotated 90° for a median transverse image. Transverse plane translation towards desired side to have in the same plane: spinous process, vertebral blade, zygapophysial articulation, lateral facet, transverse process. Needle passes skin at 45° angle, directed in plane to the foramen. Fluoroscopy then performed to check needle's correct position. Poorly positioned needles will be replaced to obtain an intra-foraminal/epidural periradicular diffusion of the contrast medium. Once position is confirmed, Depomedrol 40mg + lidocaine 2% (1ml) is injected."
89008955|NCT03453775|Active Comparator|Fluoroscopy guided infiltration|"Fluoroscopy guided periradicular lumbar infiltration. Prone position. Anatomical identification by radioscopy: antero-posterior and sagittal planes. Needle placement in an anteroposterior view, needle is then advanced in an inclined plane of 20° with respect to the initial axis, tunnel vision type image. Foramen is then reached in a sagittal view (not to progress too far in the intra-foraminal level). Needle progression is secured by neurostimulation (territory concerned by the root, intensity 0.2 milliampere to be at a distance of 1mm from the nerve root). Once needle is in place, fluoroscopy is performed to verify correct positioning (Omnipaque 300mg/ml of Iohexol, 0.2 to 0.5ml). Once position confirmed, mixture Depomedrol 40mg + lidocaine 2% (1ml) is injected."
89008956|NCT03453736||Robotic procedures|Experiences and practices in Robotic theatres will be studied via semi-structured interviews with staff as well as team observations during real time robotic surgery. As the study is a qualitative one, data collection will continue till we reach saturation of theoretical categories. We expect 20 interviews and 10 observations to suffice.
89008957|NCT03453736||Non-Robotic procedures|"Staff involved in robotic surgery will have almost definitely worked in non-robotic theatres ie major abdominal and laparoscopic. Staff interviews will explore differences in experiences and practices between these different theatre setups.~In addition, we aim to observe further 5 non-robotic procedures to evaluate staff teamwork and communication within the more regular theatre setup."
89008958|NCT00254826|Other|YF-VAX® plus saline|Drug: YF-VAX® plus saline
89008959|NCT00254826|Experimental|17D YF Vaccine plus Ig|Drug: 17D YF Vaccine plus Ig; one vaccine on day 0
89008960|NCT03453697|Experimental|acute intermittent hypoxia|Adjust the proportion of nitrogen and oxygen, through increasing the suction nitrogen concentration, the subject's blood oxygen saturation could decrease to 80%~90% within 30 seconds and also lasts 30 seconds; then quickly reduce the concentration of nitrogen gas suction to make the subject's blood oxygen saturation gradually return to normal level (consistent with the air inhalation), and then continue breathing air about 60 seconds to enter the next round of hypoxic state.Through adjusting the inhaled nitrogen concentration in patients, the patients could be simulated as the OSA patients who had intermittent hypoxic state due to upper airway collapse at night. This process is equivalent to acute intermittent hypoxia 25-30 times/h, which is clinically intermediate to severe OSA.
89008961|NCT00573040||1|"Inclusion criteria~Histological or cytological proven NSCLC~UICC stage I-III~Performance status 0-2~FeV1 and DLCO at least 30% of age-predicted value~Exclusion criteria:~Not NSCLC or mixed NSCLC and other histologies (e.g. small cell carcinoma)~Stage IV~Performance status 3 or more~FeV 1 or DLCO < 30% of the age-predicted value"
89008962|NCT00573079||Observation|Premature infants in the NICU; 500-1500g birthweight, >=25 weeks gestation
89008963|NCT00225173|Experimental|Treatment|"Doxorubicin 25 mg/m2 IV w 1,3,5,7,9,11~Vinblastine 6 mg/m2 IV w 1,3,5,7,9,11~Cyclophosphamide 750 mg/m2 IV w 1, 5, 9~Etoposide2 60 mg/mg2 x 2 IV w 3, 7,11~Vincristine1 1.4 mg/m2 IV w 2,4,6,8,10,12 (cap @ 2mg)~Bleomycin 5 u/m2 IV w 2,4,6,8,10,12~Gemcitabine 1250 mg/m2 IV w 13,15,17,19~Vinorelbine 25 mg/m2 IV w 13,15,17,19~Prednisone 40 mg/m2 PO qod w 1-10, taper"
89008964|NCT00234975|Active Comparator|HCV +|
89008965|NCT00234975|Active Comparator|HCV -|
89008966|NCT00573118||1|The study group included 49 patients with a previous history of one or more of the following pregnancy complications: preeclampsia (n = 17), severe IUGR (n = 13), IUFD (n = 14) or placental abruption (n = 5).
89008967|NCT00573118||2|The control group included 49 healthy women who delivered during the study period, who did not smoke during pregnancy and in whom pregnancy and delivery were uneventful
89008968|NCT00573196|Experimental|1|
89432128|NCT05166434|Active Comparator|bone formation around implant at 2mm membrane elevation crestal sinus lifting|
89432129|NCT05166434|Active Comparator|bone formation around implant at 4mm membrane elevation crestal sinus lifting|
89432130|NCT05166434|Active Comparator|bone formation around implant at 6mm membrane elevation crestal sinus lifting|
89432131|NCT03412526|Experimental|ACT TIL|"Reduced Intensity, non-myeloablative, lymphodepleting induction regimen using Fludarabine (25 mg/m2 for 3 days) followed by Total Body Radiation (TBR) (2 Gray as a single treatment) for 1 day~Preparation and administration of unselected or 4-1BB enriched TIL~Bolus high-dose (720,000 IU/kg) IL-2 will be administered to each patient every 8 hours, to tolerance. A maximum of 10 doses will be administered per patient."
89432132|NCT05130710||case|26 patients with gastric cancer wo were referred to our center between February 25th to December 25th of 2020.
89432133|NCT05130710||control|54 patients with gastric cancer wo were referred to our center between February 25th to December 25th of 2019.
89432134|NCT04447430|Experimental|bright light group|treat patients with bright light (10000 lux)
89432135|NCT04447430|Placebo Comparator|dim red light group|treat patients with dim red light (100 lux)
88911594|NCT01570426||Generalized Anxiety Disorder (GAD)|Children, 7-17 years-old, who meet diagnostic criteria for Generalized Anxiety Disorder (GAD)
88911595|NCT01570426||Health Controls|Children, ages 7-17 years-old, without a history of psychiatric diagnosis
88911596|NCT01570452||healthy volunteers|healthy subjects not affected by benign or malignant colonic disease
88911597|NCT01570452||benign colonic tumor patients|patients affected by benign colonic tumor such as adenoma
88911598|NCT01570452||cancer patient I-II stage|Patients affected by colonic cancer in I-II stage
88911599|NCT01570452||cancer patients III-IV stage|Patients affected by colonic cancer in III-IV stage
88911600|NCT01570478|Experimental|Foster® NEXThaler®|Foster® NEXThaler® (beclomethasone dipropionate 100 µg plus formoterol 6 µg per actuation), 2 inhalations b.i.d. (daily dose of BDP 400 µg plus FF 24 µg)
88911601|NCT01570478|Active Comparator|Seretide® Accuhaler®|Seretide® Accuhaler® (fluticasone propionate 250 μg plus salmeterol xinafoate 50 μg per actuation), 1 inhalation b.i.d. (daily dose of fluticasone 500 μg plus salmeterol 100 μg)
88911602|NCT01570504|Experimental|ivermectin multiple doses|A dose of 200 mcg/kg of ivermectin given on days 1,2, 15 and 16
88911603|NCT01570504|Active Comparator|1 dose ivermectin|A single 200 mcg/kg dose of ivermectin
88911604|NCT01570517|Experimental|Device implantation|Subjects are implanted with the study device.
88911605|NCT01570530|Active Comparator|Atorvastatin|Patients treated with atorvastatin
88911606|NCT01570530|Other|Without Atorvastatin|Patients treated without atorvastatin
88911607|NCT01570543||orthopedic implants, no treatment|
88911608|NCT01570556|Active Comparator|Patients with positive culture, treatment group|These asymptomatic patients with positive urinary culture, seven days of antibiotics will be given according to the bacteriogram sensitivity.
88911609|NCT01570556|No Intervention|Patients with positive culture, observation only|These asymptomatic patients with positive urine culture, will be observed only during the study period.
88911610|NCT01570569|Active Comparator|Omeprazole|
88911611|NCT01570569|Active Comparator|Losartan|
88911612|NCT01570569|Active Comparator|Dextromethorphan|
89432136|NCT05117684||Novel|Balloon- Occlusion thrombolysis was done in adjunct to thrombus maceration, balloon sweeping and thrombosuction.
89432137|NCT05117684||Conventional|Continuous catheter directed thrombolysis (Continuous urokinase infusion) was done along with thrombus maceration, balloon sweeping and thrombosuction.
89432138|NCT05238818|Experimental|GT202 in Metastatic or Recurrent Gynecological Tumor patients|Autologous Tumor Infiltrating Lymphocyte Injection (GT202) will be infused at 1.0×10^8 cells, 5.0×10^8 cells and 2.0×10^9 cells in metastatic or recurrent gynecological tumor patients.
88911613|NCT01570569|Active Comparator|Caffeine|
88911614|NCT01570569|Active Comparator|Midazolam|
88911615|NCT01570582|Experimental|drug effect|"Subjects assigned to Arm I Neople taksoljuwa Latin week the first day of the week based outpatient / inpatient treatment receive it. The subjects first received taksoljureul given over 3 hours followed by 30 minutes will be administered Neople Latin week.~Subjects assigned to Arm II Gemcitabine and Latin Neople every week based on the first day of the outpatient / inpatient treatment receive it. The subjects first received Gemcitabine given over 30 minutes followed by 30 minutes will be administered Neople Latin week.~Gemcitabine and eighth day of the foreign / hospitalization are given over 30 minutes.~Regimen of the progression of the disease, the subject can not continue to deny or toxic dose every 3 weeks until at least 6 cycles should be administered to. Subjects completed six cycles of medication which responds subjects, the researchers believe it is necessary to sustain if the regimen is"
88911616|NCT01570595|Experimental|Web-Based Intervention|This group will be asked to participate in the online quit smoking program. At their first visit, they will be given an ID number to log in to the quit smoking program, and they will complete their first log in with the research assistant. The online program is made up of 8 separate online sessions that are supposed to be completed approximately once per week. Each sessions is written to take an average reader 15-30 minutes to complete. The entire program is meant to be completed in 7 weeks. At the first visit, participants are asked to provide an email address and/or cell phone number so reminders can be sent, by email or text message, to complete the sessions. If participants are late completing a session, they may receive call from clinic staff as a reminder.
88911617|NCT01570595|Active Comparator|Standard Care|"This group will receive standard care for their smoking, including advice to quit, a quit-smoking brochure, and an offer of three months of nicotine replacement therapy (nicotine patches)."
88911618|NCT01570608|Active Comparator|monotherapy arm|patients receiving 3 initial Ranibizumab injections, thereafter as needed
88911619|NCT01570608|Active Comparator|combined treatment arm|
88911620|NCT01570647||Healthy controls|
88911621|NCT01570647||Chronic low back pain|
88911622|NCT01570647||restricted hamstrings|
88911623|NCT01570647||systemic scleroderma|
88911624|NCT01570647||joint hyperlaxity|
88911625|NCT01570660|No Intervention|control group|parallel group without intervention
89432139|NCT05238662|Active Comparator|Group A|pedicle screw fixation on one side and intervertebral cage on the other sided
88911626|NCT01570673|Experimental|Group Urotherapy|Children in this arm wil receive group urotherapy in small groups with other children.
89432140|NCT05238662|Active Comparator|Group B|pedicle screw fixation and interbody cage on the same side
89432141|NCT05238428|No Intervention|Control sender + control content|"Participants will read the following text in an online survey:~You are invited to book your COVID-19 booster vaccination. Click here to book an appointment: accurx.thirdparty.nhs.uk/r/aafwaczmd5"
89432142|NCT05238428|Experimental|Control sender + Low trust boost content|"Participants will read the following text in an online survey:~You are invited to book your COVID-19 booster vaccination. The vaccine reduces your chance of becoming infected and protects you against severe forms of the illness. It also protects your loved ones by reducing the risk that you infect others. COVID can be severe, don't risk it.~Click here to book an appointment: accurx.thirdparty.nhs.uk/r/aafwaczmd5"
89432143|NCT05238428|Experimental|Control sender + Medium trust boost content|"Participants will read the following text in an online survey:~You are invited to book your COVID-19 booster vaccination. The vaccine reduces your chance of becoming infected and protects you against severe forms of the illness. It also protects your loved ones by reducing the risk that you infect others. COVID can be severe, don't risk it.~Vaccines may cause side effects, but the benefits outweigh the risks. The most common side effects are very mild (e.g., sore arm, fever) and severe side effects are very rare (e.g., allergic reaction).~Click here to book an appointment: accurx.thirdparty.nhs.uk/r/aafwaczmd5"
89432144|NCT05238428|Experimental|Control sender+ high trust boost content|"Participants will read the following text in an online survey:~You are invited to book your COVID-19 booster vaccination. The vaccine reduces your chance of becoming infected and protects you against severe forms of the illness. It also protects your loved ones by reducing the risk that you infect others. COVID can be severe, don't risk it.~This vaccination is especially important for people who are at higher risk from COVID such as older individuals or those from ethnic minorities.~Vaccines may cause side effects, but the benefits outweigh the risks. The most common side effects are very mild (e.g., sore arm, a fever) and severe side effects are very rare (e.g., allergic reaction).~Click here to book an appointment: accurx.thirdparty.nhs.uk/r/aafwaczmd5"
89432145|NCT05238428|Experimental|Low trust boost Sender + control content|"Participants will read the following text in an online survey:~As your local GP, I would like to invite you to book your COVID-19 booster vaccination.~Click here to book an appointment: accurx.thirdparty.nhs.uk/r/aafwaczmd5"
89432146|NCT05238428|Experimental|Low trust boost Sender + low trust boost content|"Participants will read the following text in an online survey:~As your local GP, I would like to invite you to book your COVID-19 booster vaccination.~The vaccine reduces your chance of becoming infected and protects you against severe forms of the illness. It also protects your loved ones by reducing the risk that you infect others. COVID can be severe, don't risk it.~Click here to book an appointment: accurx.thirdparty.nhs.uk/r/aafwaczmd5"
89432147|NCT05238428|Experimental|Low trust boost Sender + medium trust boost content|"Participants will read the following text in an online survey:~As your local GP, I would like to invite you to book your COVID-19 booster vaccination.~The vaccine reduces your chance of becoming infected and protects you against severe forms of the illness. It also protects your loved ones by reducing the risk that you infect others. COVID can be severe, don't risk it.~Vaccines may cause side effects, but the benefits outweigh the risks. The most common side effects are very mild (e.g., sore arm, fever) and severe side effects are very rare (e.g., allergic reaction).~Click here to book an appointment: accurx.thirdparty.nhs.uk/r/aafwaczmd5"
89432148|NCT05238428|Experimental|Low trust boost sender + high trust boost content|"Participants will read the following text in an online survey:~As your local GP, I would like to invite you to book your COVID-19 booster vaccination.~The vaccine reduces your chance of becoming infected and protects you against severe forms of the illness. It also protects your loved ones by reducing the risk that you infect others. COVID can be severe, don't risk it.~This vaccination is especially important for people who are at higher risk from COVID such as older individuals or those from ethnic minorities.~Vaccines may cause side effects, but the benefits outweigh the risks. The most common side effects are very mild (e.g., sore arm, a fever) and severe side effects are very rare (e.g., allergic reaction).~Click here to book an appointment: accurx.thirdparty.nhs.uk/r/aafwaczmd5"
89432149|NCT05238428|Experimental|Medium trust boost Sender + control content|"Participants will read the following text in an online survey:~As your local GP and a health expert who cares for the local community, I would like to invite you to book your COVID-19 booster vaccination.~Click here to book an appointment: accurx.thirdparty.nhs.uk/r/aafwaczmd5"
89432150|NCT05238428|Experimental|Medium trust boost sender + low trust boost content|"Participants will read the following text in an online survey:~As your local GP and a health expert who cares for the local community, I would like to invite you to book your COVID-19 booster vaccination.~The vaccine reduces your chance of becoming infected and protects you against severe forms of the illness. It also protects your loved ones by reducing the risk that you infect others. COVID can be severe, don't risk it.~Click here to book an appointment: accurx.thirdparty.nhs.uk/r/aafwaczmd5"
89531214|NCT03120455|Experimental|Almond group (AG)|Obese or overweight female adults will be randomly allocated to have have almond as afternoon snack while they have a hypoenergetic diet.
89531215|NCT03120455|Active Comparator|Pistachio group (PG)|Obese or overweight female adults will be randomly allocated to have have Pistachio as afternoon snack while they have a hypoenergetic diet.
89008969|NCT00573274||1|Elective cesarean section patients
89008970|NCT00235014|Active Comparator|A-1, B-1|A-1 pertains to Phase 1; B-1 pertains to Phase 2
89008971|NCT00235014|Active Comparator|A-2, B-2|A2 pertains to Phase 1; B-2 pertains to Phase 2
89008972|NCT00235014|Placebo Comparator|A-3|
89008973|NCT00235014|Active Comparator|A-4|
89008974|NCT00573352|Other|1|Far infrared radiation
89432151|NCT05238428|Experimental|Medium trust boost sender + Medium trust boost content|"Participants will read the following text in an online survey:~As your local GP and a health expert who cares for the local community, I would like to invite you to book your COVID-19 booster vaccination.~The vaccine reduces your chance of becoming infected and protects you against severe forms of the illness. It also protects your loved ones by reducing the risk that you infect others. COVID can be severe, don't risk it.~Vaccines may cause side effects, but the benefits outweigh the risks. The most common side effects are very mild (e.g., sore arm, fever) and severe side effects are very rare (e.g., allergic reaction).~Click here to book an appointment: accurx.thirdparty.nhs.uk/r/aafwaczmd5"
88911627|NCT01570673|Active Comparator|Individual urotherapy|Children will receive standard individual urotherapy in regular pediatric urology clinic.
89531216|NCT03120455|Placebo Comparator|Nut Free (NFG, CG)|Obese or overweight female adults are asked to avoid all nuts, seeds, and nut products while they have a hypoenergetic diet. , as the control group.
89531217|NCT05033535|Experimental|S086|
88911628|NCT01570699||2: patients included in METHADOSE study|includes opiate-dependent patients substituted by methadone
88911629|NCT01570699||1: opiate-non dependent patients|Will be included in the COM ON study subjects who have consumed illicit opiates (heroin, methadone, buprenorphine or morphine) more than 10 times in their life, without ever having the DSM-IV criteria for opiate dependence or abuse
88911630|NCT01570712|Experimental|Housing First Program|
88911631|NCT01570712|Active Comparator|traditional French services|
88911632|NCT01570725|Experimental|1|Virtual reality exposure to a relaxing virtual environment. The virtual experience will be provided using immersive equipment.
89531218|NCT05033535|Placebo Comparator|Olmesartan medoxomil|S086 PLCEBO
89531219|NCT03339167|Experimental|metabolic availability of lysine in millet|"Participants will be seen initially for pre-study assessment (2 hour). They will then be studied at 8 levels of lysine intake.~Subjects will visit SickKid's Clinical Research Center a total of 9 times, with each visit being at least one week before the next. All 9 visits must be made within 6 months. Each set of experiment consists of a 3 day period. During the first 2 days (Adaptation Days) you will be expected to consume 4 meals per day consisting of a protein liquid drink and protein free-cookies and/or cooked millet with or without lentils, which will all be provided by the investigators."
89531220|NCT04434495|Experimental|PRP group|mock embryo transfer and PRP injection
88911633|NCT01570725|Experimental|2|Exposure to relaxing music. The music will be selected between classical music tunes.
88911634|NCT01570764|Experimental|Cyclophosphamide|Prednisone 15 mg/d + monthly pulse cyclophosphamide 700 mg/m ² diminished to 600 mg/m ² in patients over 65 years or having a creatinine clearance lower than 30 ml/min for 12 months.
88911635|NCT01570764|Placebo Comparator|Placebo|Prednisone 15 mg/d + monthly pulse of placebo of cyclophosphamide. The posology and the methods of administration of the placebo of cyclophosphamide (NaCl) will be the same as those used for cyclophosphamide
88911636|NCT01570777|Experimental|Renal denervation|
88911637|NCT01570777|Other|optimized medication regimen|optimized medication regimen
88911638|NCT01570790|Experimental|Cohort 1|
88911639|NCT01570790|Experimental|Cohort 2|
88911640|NCT01570790|Experimental|Cohort 3|
88911641|NCT01570803|Experimental|Complete SE Stent|study design is 2x2 randomization design. First, before randomization, stratification will be performed according to lesion length 15cm criteria at web-based computerized program. Patients will be randomized in a 1:1 manner according to different two (SMART versus Complete-SE) stents. And then, patients received aspirin and clopidogrel during one month. After one month from index procedure, patients were randomized to receive either clopidogrel group (clopidogrel will not be changed but continue) or cilostazol group (clopidogrel will be changed into cilostazol) in separate groups of SMART group and Complete SE group. Randomization procedure will be performed using a web-based program
88911642|NCT01570803|Active Comparator|SMART CONTROL Stent|same to Complete SE
88911643|NCT01570816|Experimental|Experimental|Volunteers are evaluated for appropriateness for inclusion in the study on an intent-to-treat basis. Qualifying candidates all receive the implanted neuroprosthesis and participate in post-operative training and follow-up procedures
88911644|NCT01570842|Other|Anthropometric Measurements; Tissue Samples|All participants will have their waist circumference and waist to hip ratio taken as a measurement of central obesity. Participants undergoing clinically indicated upper endoscopy and who consent to providing tissue samples will have 8 tissue samples taken for future research purposes.
88911645|NCT01570881||Delirium,Nondelirium|those with delirium and those without delirium
88911646|NCT01570920|Experimental|walking|a cohort of stroke patients trained during 3 month, based on walking
88911647|NCT01570933|Experimental|NAVAfirst|Starting crossover by NIVnava mode
88911648|NCT01570933|Active Comparator|Cpap first|Start crossover by Cpap on nasal canula
88911649|NCT01570946|Experimental|Lifestyle modification|The mobile phone based intervention will use short messaging service (SMS or text messaging) to deliver education, treatment targets, advice, support and motivation.
88911650|NCT01570946|No Intervention|Standard Care|Baseline 30-minute interview delivering personalised diet and exercise advice supplemented with educational material on diabetes.
88911651|NCT01570972|Other|MFG and GCBT|There is a single arm for this study. All participants will be able to participate in MFG and GCBT
89531221|NCT04434495|No Intervention|control group|only mock embryo transfer
88911652|NCT01570985|Active Comparator|Steroid injection Without distension|Group 1 consists of patients receiving Triamcinolone acetonide 20 mg intraarticular injection with Lidocaine 10mg/ml 3 ml and a total of 4 ml solution.
88911653|NCT01570985|Active Comparator|Steroid with distension|Patients in group 2 will receive intraarticular Triamcinolone Acetonide 20 mg, 3 ml Lidocaine and physiological natrium chloride 9 mg/ml, comprising a total volume from 8 ml and upwards up to 20 ml
88911654|NCT01570985|No Intervention|Control|Group 3 will serve as control group and patients in this group could receive any other treatment other than corticosteroid injections or per oral corticosteroid medication. The control group will remain without treatment with corticosteroids, in injection or tablet form till 61 days, which is also the last day of the outcome measurements.
88911655|NCT01571011|Experimental|CURB Intervention|The intervention is made up of 14 internet modules based on behavioral activation, cognitive behavioral therapy, and interpersonal psychotherapy as well as motivational interviews in the primary care setting (to enhance behavior change). It is suggested that an adolescent navigates through 2 modules a week. The motivational interviews with the physicians occur directly before and after the adolescent is exposed to the website (at baseline and 3 months) in the providers office. The parents of the enrolled adolescents are also invited to navigate through their own, 3 module, parent internet program.
88911656|NCT01571011|Experimental|CURB Intervention (Wait List)|Same as the CURB Intervention arm, however, individuals assigned to this arm wait 3 months before receiving the intervention.
89432152|NCT05238428|Experimental|Medium trust boost Sender+ high trust boost content|"Participants will read the following text in an online survey:~As your local GP and a health expert who cares for the local community, I would like to invite you to book your COVID-19 booster vaccination.~The vaccine reduces your chance of becoming infected and protects you against severe forms of the illness. It also protects your loved ones by reducing the risk that you infect others. COVID can be severe, don't risk it.~This vaccination is especially important for people who are at higher risk from COVID such as older individuals or those from ethnic minorities.~Vaccines may cause side effects, but the benefits outweigh the risks. The most common side effects are very mild (e.g., sore arm, a fever) and severe side effects are very rare (e.g., allergic reaction).~Click here to book an appointment: accurx.thirdparty.nhs.uk/r/aafwaczmd5"
89432153|NCT05238428|Experimental|High trust boost sender + control content|"Participants will read the following text in an online survey:~As your local GP and a health expert who cares for the local community, I would like to invite you to book your COVID-19 booster vaccination.~Click here to book an appointment: accurx.thirdparty.nhs.uk/r/aafwaczmd5~Dr Sanjay Kumar"
89432154|NCT05238428|Experimental|High trust boost sender + low trust boost content|"Participants will read the following text in an online survey:~As your local GP and a health expert who cares for the local community, I would like to invite you to book your COVID-19 booster vaccination.~The vaccine reduces your chance of becoming infected and protects you against severe forms of the illness. It also protects your loved ones by reducing the risk that you infect others. COVID can be severe, don't risk it.~Click here to book an appointment: accurx.thirdparty.nhs.uk/r/aafwaczmd5~Dr Sanjay Kumar"
89432155|NCT05238428|Experimental|High trust boost Sender + medium trust boost content|"Participants will read the following text in an online survey:~As your local GP and a health expert who cares for the local community, I would like to invite you to book your COVID-19 booster vaccination.~The vaccine reduces your chance of becoming infected and protects you against severe forms of the illness. It also protects your loved ones by reducing the risk that you infect others. COVID can be severe, don't risk it.~Vaccines may cause side effects, but the benefits outweigh the risks. The most common side effects are very mild (e.g., sore arm, fever) and severe side effects are very rare (e.g., allergic reaction).~Click here to book an appointment: accurx.thirdparty.nhs.uk/r/aafwaczmd5~Dr Sanjay Kumar"
89432156|NCT05238428|Experimental|High trust boost sender + high trust boost content|"Participants will read the following text in an online survey:~As your local GP and a health expert who cares for the local community, I would like to invite you to book your COVID-19 booster vaccination.~The vaccine reduces your chance of becoming infected and protects you against severe forms of the illness. It also protects your loved ones by reducing the risk that you infect others. COVID can be severe, don't risk it.~This vaccination is especially important for people who are at higher risk from COVID such as older individuals or those from ethnic minorities.~Vaccines may cause side effects, but the benefits outweigh the risks. The most common side effects are very mild (e.g., sore arm, a fever) and severe side effects are very rare (e.g., allergic reaction).~Click here to book an appointment: accurx.thirdparty.nhs.uk/r/aafwaczmd5~Dr Sanjay Kumar"
89432157|NCT05238272|Experimental|tRNS-augmented unilateral MT|"A battery driven multi-channel electrical stimulator will deliver alternating electrical current over the scalp through sailine-soaked sponge electrodes (surface area = 25 cm2). The stimulation electrodes were directly positioned on an adult sized cap that will be worn by the participants, and labeled according to the 10-20 EEG system of electrode positioning. The stimulation intensity will be ramp up to 1.5 to 2 mA.~For the unilateral MT, the participants will practice movements using only the unaffected arm while the affected arm will remain relaxed behind the mirror during MT training. The training therapists will instruct the participants to look at the mirror reflection of the unaffected arm and imagine that it is the affected arm performing the task."
89432158|NCT05238272|Experimental|tRNS-augmented bilateral MT|"A battery driven multi-channel electrical stimulator will deliver alternating electrical current over the scalp through sailine-soaked sponge electrodes (surface area = 25 cm2). The stimulation electrodes were directly positioned on an adult sized cap that will be worn by the participants, and labeled according to the 10-20 EEG system of electrode positioning. The stimulation intensity will be ramp up to 1.5 to 2 mA.~For the bilateral MT, the participants will be encouraged to move the affected arm as symmetrically and simultaneously as the unaffected hand during MT training. At the same time, participants will also be instructed to look at the mirror reflection of the unaffected arm and imagine that it is the affected arm performing the task."
89432159|NCT05238272|Sham Comparator|sham tRNS with unilateral MT|"For the sham tRNS condition, the electrode placement will be the same as the real stimulation conditions. The current will first turn up for 30 seconds and subsequently turn off in the next 30 seconds .~For the unilateral MT, the participants will practice movements using only the unaffected arm while the affected arm will remain relaxed behind the mirror during MT training. The training therapists will instruct the participants to look at the mirror reflection of the unaffected arm and imagine that it is the affected arm performing the task."
88911657|NCT01571024|Experimental|BKM120 + mFOLFOX6|BKM120 + mFOLFOX6 in patients with advanced solid tumors including metastatic pancreatic cancer.
88911658|NCT01571050|Experimental|Fresh NaF/SiO2 toothpaste|
88911659|NCT01571050|Placebo Comparator|Purified water|
88911660|NCT01571050|Experimental|Aged NaF/SiO2 toothpaste|
89432160|NCT05238272|Sham Comparator|sham tRNS with bilateral MT|"For the sham tRNS condition, the electrode placement will be the same as the real stimulation conditions. The current will first turn up for 30 seconds and subsequently turn off in the next 30 seconds .~For the bilateral MT, the participants will be encouraged to move the affected arm as symmetrically and simultaneously as the unaffected hand during MT training. At the same time, participants will also be instructed to look at the mirror reflection of the unaffected arm and imagine that it is the affected arm performing the task."
89432161|NCT03126422|Experimental|Dexmedetomidine 0 μg/kg/min|
89432162|NCT03126422|Experimental|Dexmedetomidine 0.03 μg/kg/min|
89432163|NCT03126422|Experimental|Dexmedetomidine 0.06 μg/kg/min|
89432164|NCT03126422|Experimental|Dexmedetomidine 0.09 μg/kg/min|
89432165|NCT03399422|Experimental|i-PRF assisted upper canine retraction|I-PRF assisted upper canine retraction will be performed in one side of patients with Class II Division 1 malocclusion patients requiring therapeutic extraction of the maxillary first premolars
89432166|NCT03399422|Experimental|conventional upper canine retraction|Conventional upper canine retraction will be performed in the other side of patients with Class II Division 1 malocclusion patients requiring therapeutic extraction of the maxillary first premolars
89432167|NCT03399344|Other|DW-MRI|Patients with undergo an additional diffusion-weighted MRI in addition to the standard diagnostic work-up
89432168|NCT03412370||Observational (questionnaires, cognitive assessment)|Patients complete questionnaires and cognitive assessments over 45-60 minutes within 3 weeks following mammography and at about 3 months in patients for whom biopsy is not required, before biopsy and at about 3 months in patients for whom biopsy is required, and at 4-6 weeks after first chemotherapy infusion in patients receiving chemotherapy.
89432169|NCT03399266|Experimental|Double balloon catheter for induction of labor|in this group a trans-cervical double balloon catheter will be inserted. Following device insertion, 20 minutes of external monitoring is performed. The patient will be transferred to the Ob/Gyn ward for hospitalization. 12 hours after insertion of the device the balloons are deflated and the device removed. At this stage the patient is assessed for a second Bishop score and expectant management is resuming.
89432170|NCT03399266|No Intervention|Expectant management|Women in the expectant management group will be transferred to the Ob/Gyn ward for hospitalization and conservative management until spontaneous labor ensues.
88911661|NCT01571050|Experimental|Fresh MFP/CaCO3 toothpaste|
88911662|NCT01571050|Experimental|Aged MFP/CaCO3 toothpaste|
88911663|NCT01571063|Experimental|Vitamin D3|
88911664|NCT01571063|Placebo Comparator|Placebo|
88911665|NCT01571076|Experimental|Group B - Severe Male Factor|PGS of day three biopsies and consequent embryo transfer on on Day 5 (blastocyst)
88911666|NCT01571076|Experimental|Group B - Advanced Age|PGS of day three biopsies and consequent embryo transfer on on Day 5 (blastocyst)
88911667|NCT01571076|Active Comparator|Group A - Advanced Age|Prolonged culture, no PGS, for Day 5 (blastocyst) embryo transfer for the Advanced Age group
88911668|NCT01571076|Active Comparator|Group A - Severe Male Factor|Prolonged culture, no PGS, for Day 5 (blastocyst) embryo transfer for the Severe Male Factor group.
88911669|NCT01571089|Experimental|DBT-inspired exposure treatment|DBT-inspired exposure treatment.
88911670|NCT01571115|Active Comparator|Insomnia Stretching Exercise|This group will realize stretching exercise
88911671|NCT01571115|No Intervention|Control|This group will not realize any type of intervention.
88911672|NCT01571115|Active Comparator|Insomnia Physical Exercise|This group will realize resistance physical exercise
88911673|NCT01571141|Experimental|Monogin|
88911674|NCT01571141|No Intervention|No intervention|
88911675|NCT01571167|Placebo Comparator|Placebo|
88911676|NCT01571167|Active Comparator|Varenicline 2 mg|
88911677|NCT01571167|Active Comparator|Varenicline 1 mg|
88911678|NCT01571180||Gastric Bypass|Obese patients who have scheduled a gastric bypass
88911679|NCT01571206|Active Comparator|CT-P13|infliximab
88911680|NCT01571219|Experimental|CT-P13|
88911681|NCT01571245||Veterans with PTSD|Operation Enduring Freedom/Operation Iraqi Freedom/Operation New Dawn (OEF/OIF/OND) veterans who are ages 18 to 60 and currently in or about to start treatment for deployment-related Post-Traumatic Stress Disorder (PTSD) at the Central Arkansas Veterans Healthcare System Mental Health Clinics.
88911682|NCT01571258|No Intervention|Control|
88911683|NCT01571258|Experimental|Text Messaging|Participants in the intervention group will receive on average 4 texts per day consisting of weight related behavioral recommendations, knowledge based questions, and prompts to promote physical activity and weight monitoring. Texts are interactive and personally relevant based upon a baseline questionnaire.
88911684|NCT01571271|Experimental|Electrohydraulic lithotripsy|Electrohydraulic lithotripsy: Lithotripsy will be performed using electrohydraulic method
88911685|NCT01571271|Experimental|Laser Lithotripsy|Laser Lithotripsy: Lithotripsy will be performed using laser method
88911686|NCT01571310|Experimental|Omitted Breakfast|Experimental: The patients in Omitted Breakfast day will omit the breakfast and will continue the fast until noon. Thereafter will eat Lunch at 13;30 and Dinner at 19:00
88911687|NCT01571310|Active Comparator|Breakfast|The patients in Breakfast day will consume breakfast at 8:00 and then lunch at 13;30 and dinner at 19:00
88911688|NCT01571323|Active Comparator|Misoprostol|
88911689|NCT01571323|Active Comparator|Oxytocin|
88911690|NCT01571323|Active Comparator|Oxytocin and Misoprostol|
88911691|NCT01571349||chronic ITP group|ITP patients with elevated level of vWF, ITP patients with preserved MA of thromboelastography
89432171|NCT03395132|Experimental|Fucicort® Lipid cream|Fucicort® Lipid cream is a combination of the antibiotic fusidic acid (20 mg/g) and the corticosteroid betamethasone (1 mg/g (as 17-valerate)). Twice daily for two weeks.
89432172|NCT03395132|Active Comparator|Fucidin cream +betamethasone cream|The combination treatment with Fucidin® cream followed by betamethasone (Lianbang Beisong®) cream. Twice daily for two weeks.
89432173|NCT03395132|Placebo Comparator|Vehicle cream|The vehicle cream, also named as Fucicort® Lipid cream vehicle, is the identical cream of Fucicort Lipid cream but without the active ingredient. Twice daily for two weeks.
89432174|NCT03395054|Other|the stabilization group|the stabilization group performed cervical stabilization exercises in lying, sitting, standing and on a swisball 3times a week during 8 weeks.
89432175|NCT03395054|Other|the control group|the control group performed conventional exercises including neck isometric, isotonic and posture exercises 3 times a week during 8 weeks.
89432176|NCT03127124|Experimental|NANT-008 in combination with other agents|NANT-008 will be administered in combination with 5-fluorouracil, bevacizumab, leucovorin, and oxaliplatin in patients with metastatic pancreatic adenocarcinoma.
89432177|NCT03399188|Experimental|FMT group|Group who received fecal microbiome transplantation
89432178|NCT03127046|Experimental|Group 1|Aceclofenac → Esomeprazole → Concomitant of Aceclofenac and esomeprazole
89432179|NCT03127046|Experimental|Group 2|Concomitant of Aceclofenac and esomeprazole→Aceclofenac→ Esomeprazole
89432180|NCT03127046|Experimental|Group 3|Esomeprazole →Concomitant of Aceclofenac and esomeprazole→ Aceclofenac
89432181|NCT03127046|Experimental|Group 4|Concomitant of Aceclofenac and esomeprazole→Esomeprazole→Aceclofenac
89432182|NCT03127046|Experimental|Group 5|Esomeprazole→Aceclofenac→ Concomitant of Aceclofenac and esomeprazole
89432183|NCT03127046|Experimental|Group 6|Aceclofenac→Concomitant of Aceclofenac and esomeprazole→Esomeprazole
89432184|NCT05105672|Experimental|chemoradiotherapy + Sintilimab|Participants will be given intravenous administration of sintilimab (200mg, q3w), cisplatin(75 mg/m², q3w) and Radiotherapy. After completing 2 cycles of concurrent chemoradiation, the Participants will continue to use 4 cycles of sintilimab (200mg, q3w) and cisplatin(75 mg/m², q3w) as maintenance therapy.
89432185|NCT03394820|Active Comparator|dexamethasone 1 hour prior to block|The patient will receive dexamethasone through IV one hour prior to receiving their block. During the patient's block, 1 hour after and 2 hours after the block the patient will receive infusions of normal saline to maintain the blind.
89432186|NCT03394820|Experimental|dexamethasone during the block|The patient will receive dexamethasone through IV at the same time the patient has the SCB done. One hour prior to the block, one hour after the block and 2 hours after the block the patient will receive infusions of normal saline to maintain the blind.
89432187|NCT03394820|Active Comparator|dexamethasone 1 hour after block|The patient will receive dexamethasone through IV one hour after the block has been administered. One hour prior to block, during the block and two hours after the block the patient will receive normal saline to maintain the blind.
89432188|NCT03394820|Active Comparator|dexamethasone 2 hours after block|The patient will receive dexamethasone 2 hours after the block has been administered. One hour prior to the block, during the block and one hour after the block the patient will receive normal saline to maintain the blind.
89432189|NCT01328054|Experimental|lapatinib/placebo|This is a crossover study where subjects will receive placebo that mimics lapatinib for 2 days and lapatinib for 2 days. Subjects will not know when they are receiving placebo vs. lapatinib.
89432190|NCT03394742|Experimental|Intervention group|Peer support group received, in addition to usual care, peer support via telephone 1-5 times according to their own preference. Peer support was started at the time between diagnosis and the beginning of treatments.
89432191|NCT03394742|No Intervention|Control group|The control group received usual care only. For ethical reasons, participants in the control group were not discouraged from seeking peer support by themselves if they felt a need for it.
89432192|NCT05067920||Asymptomatic patients|60 patients without COVID-19 symptoms related at the time of diagnosis.
89432193|NCT05067920||Symptomatic patients|60 patients with COVID-19 symptoms related at the time of diagnosis.
89432194|NCT05171036|Experimental|Institutionalized elderly people undergoing adapted physical activity|2h/week for 3 months (i.e. 24 sessions), after 3 months of no-APA for gait and balance baseline recordings, with the rehabilitation team in place in the establishments, around the 4 specific programmes
89432195|NCT05018780|Experimental|Muscle Energy Technique|"Post isometric relaxation: Patient will perform isometrics on piriformis, iliopsoas and erector spinae muscles one by one. Each isometric contraction will be held for 10 seconds and than participants will be asked to relax the contraction with an exhalation. This will be repeated five times in one session.~- Routine physical therapy including TENS, Hot pack and strengthening exercises will also be delivered along with Muscle Energy Technique."
89432196|NCT05018780|Experimental|Sacral Manipulation|"To manipulate an iliac anterior rotation displacement sacroiliac joint dysfunction and to restore posterior rotation of the ilium, participant will be positioned in side lying. Therapist will place one hand at Anterior superior iliac supine (ASIS) and the other at Ischial tuberosity. A quick thrust will be applied and ASIS will be pushed posteriorly while Ischial tberosity anteriorly. This will be maintained for 10 to 30 seconds.~To manipulate an iliac posterior rotation displacement sacroiliac joint dysfunction and to restore anterior rotation of the ilium, participant will be in prone position. One hand of therapist will be at Posterior superior iliac supine (PSIS) and the other one at pubic rami. A quick thrust will be delivered and PSIS will be moved anteriorly while pubic rami posteriorly. This will be maintained for 10 to 30 seconds.~Routine physical therapy including TENS, Hot pack and strengthening exercises will also be delivered along with Sacral Manipulation."
89432197|NCT05002244|Experimental|Arm A|CTL0801 (Azilsartan) QD, 4days → CTL0801 (Azilsartan) + CTL0802 (Rosuvasatin) QD, 7days
89432198|NCT05002244|Experimental|Arm B|CTL0802 (Rosuvasatin) QD, 7days → CTL0801 (Azilsartan) + CTL0802 (Rosuvasatin) QD, 7days
89432199|NCT05170880|Experimental|Treatment Group|After fulfilling the eligibility criteria, patients will be informed about the study and written consent to participate in the study will be acquired from each patient after explaining risks, benefits and alternative treatments.The endodontic treatment for all patients will be performed by a single operator (S.A) following a standardized protocol.
89432200|NCT05170880|No Intervention|Control Group|The control group will receive no endodontic treatment during the study period. After completion of the study, these patients will be given primary non-surgical endodontic treatment.
89432201|NCT03412136|Experimental|Control|
89432202|NCT03412136|Experimental|Glucose|
89432203|NCT03412136|Experimental|Protein|
89432204|NCT04446884|Experimental|mesenchymal stem cells|Patients with Stress urinary incontinence receiving standard treatment plus adipose-derived mesenchymal stem cells
89432205|NCT04446884|Active Comparator|control|Patients with Stress urinary incontinence receiving standard treatment
89432206|NCT04446494|Experimental|Axillary dissection with DEPART technique|In the experimental group, 1 ml (2.5 mg) indocyanine green (ICG) and methylene blue (MB) was intradermally injected into the internal bicipital sulcus of ipsilateral arm. During axillary dissection, the identified arm sentinel nodes were carefully injected with 0.1 ml methylene blue (MB) using a 1-cc syringe with a 32-gauge needle. MB could then flow from the nodes along several lymphatic channels toward the infraclavicular nodes. Subsequent-echelon nodes and lymphatics were identified. Sentinel lymph nodes (SLNs) were removed after the identification of the arm sentinel nodes and the procedure of MB injection. When patients harbored positive SLNs, axillary lymph node dissection (ALND) was performed subsequently. All discernible arm lymphatics and lymph nodes were preserved, except that gross arm lymph nodes (major axis larger than 10 mm or node firm on palpation) were sent for immediate partial frozen section (pFS) to determine their resection during ALND.
89432207|NCT04446494|No Intervention|Standard axillary dissection|In the control group (no intervention), ALND was performed with complete resection of at least Berg's levels I and II. Resection of level III was performed only in cases with gross disease in level II and/or III
89432208|NCT03398876|Experimental|Part 1; Treatment Sequence ABDC|Participants will receive Treatment A (one spray of oromucosal nicotine spray [ONS]) at Visit 1, then Treatment B (2 consecutive sprays of ONS at Visit 2, then Treatment D (1 cigarette [10 puffs]) at Visit 3, followed by Treatment C (nicotine gum) at Visit 4. The visits will be separated by a period of at least 7 calendar days.
88911692|NCT01571349||acute ITP group|ITP patients with normal level of vWF, ITP patients with decreased MA of thromboelastography
88911693|NCT01571375||FinnHEMS10|Patients Treated by Helsinki HEMS.
89432209|NCT03398876|Experimental|Part 1; Treatment Sequence BCAD|Participants will receive Treatment B at Visit 1, then Treatment C at Visit 2, then Treatment A at Visit 3 followed by Treatment D at Visit 4. The visits will be separated by a period of at least 7 calendar days.
89432210|NCT03398876|Experimental|Part 1; Treatment Sequence CDBA|Participants will receive Treatment C at Visit 1, then Treatment D at Visit 2, then Treatment B at Visit 3 followed by Treatment A at Visit 4. The visits will be separated by a period of at least 7 calendar days. The visits will be separated by a period of at least 7 calendar days.
89432211|NCT03398876|Experimental|Part 1; Treatment Sequence DACB|Participants will receive Treatment D at Visit 1, then Treatment A at Visit 2, then Treatment C at Visit 3 followed by Treatment B at Visit 4. The visits will be separated by a period of at least 7 calendar days.
88911694|NCT01571375||FinnHEMS30|PAtients Treated by Tampere HEMS.
88911695|NCT01571388|Experimental|Group 1|Healthy Subjects to receive dacomitinib
88911696|NCT01571388|Experimental|Group 2|Subjects with mildly impaired hepatic function to receive dacomitinib
88911697|NCT01571388|Experimental|Group 3|Subjects with moderately impaired hepatic function to receive dacomitinib
88911698|NCT01571401|Experimental|Supervised PA plus Exercise Counselling|Participants will be provided with six individual supervised exercise sessions with a physical activity specialist that will taper to an unsupervised program by the end of the intervention. Over the 4-week period, this group will be required to attend two sessions per week for weeks 1-2, and one session per week for weeks 3-4 at fitness centre. In order to achieve the physical activity guidelines established by the current public health recommendations, additional unsupervised sessions will be prescribed. In addition to the supervised sessions, traditional exercise counselling will be provided to teach proper technique, how to monitor intensity, and to progress PA safely and effectively to achieve the public health physical activity guidelines
88911699|NCT01571401|Experimental|Supervised PA plus behavioural counselling|"In addition to the same supervised PA sessions as the SPA group, participants in this group will receive six individual face-to-face behavioural counselling sessions with a physical activity specialist. These counselling sessions will be combined with the supervised PA sessions, and will be provided directly following the supervised PA session. Counselling strategies will be based on the TPB and will target the unique benefits of PA for kidney cancer survivors, strategies for making PA enjoyable, for overcoming barriers, for including social support from family and friends, time management, self-monitoring, goal setting, and planning."
88911700|NCT01571414|Experimental|Arm 1A-EFV and PA-824|Participants will receive PA-824 on Days 1 to 7, no study medication on Days 8 to 21, EFV on Days 22 to 35, and EFV plus PA-824 on Days 36 to 42. Inpatient study visits will occur at Days 7, 34, and 41 to 42.
88911701|NCT01571414|Experimental|Arm 1B-EFV and PA-824|Participants will receive EFV on Days 1 to 14, EFV plus PA-824 on Days 15 to 21, no study medication on Days 22 to 35, and PA-824 on Days 36 to 42. Inpatient study visits will occur at Days 13, 20 to 21, and 42.
89432212|NCT03398876|Experimental|Part 2; Treatment Sequence EF|Participants who complete Part 1 will be selected for Part 2 based on the results of genetic polymorphism test and other examinations. Selected participants will receive Treatment E (two consecutive sprays of ONS once every 30 minutes until 11.5 hours) at Visit 5, followed by Treatment F (two consecutive sprays of ONS once every 1 hour until 11 hours) at Visit 6. The visits will be separated by a period of at least 7 calendar days.
89432213|NCT03398876|Experimental|Part 2; Treatment Sequence FE|Participants who complete Part 1 will be selected for Part 2 based on the results of genetic polymorphism test and other examinations. Selected participants will receive Treatment F at Visit 5 followed by Treatment E at Visit 6. The visits will be separated by a period of at least 7 calendar days.
89008975|NCT00573586|Other|HIFU|"Completely destroy prostate cancer tissue, without causing damage to the intervening tissue, with a drop in PSA levels to <0.5ng/ml.~Result in negative biopsies for evidence of viable malignant cells after the treatment (12 months if Nadir is not reached or PSA rises from Nadir)~Safely treat localized prostate cancer patients, with minimal and acceptable adverse effects"
89432214|NCT03411980|Experimental|Subjects with moderately decreased renal function|Subjects with moderate renal impairment with an estimated glomerular filtration rate (eGFR) of 30 to 59 mL/min/1.73 m*2 according to the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula.
89432215|NCT03411980|Experimental|Subjects with severely decreased renal function|Subjects with severe renal impairment not on dialysis with an eGFR <30 mL/min/1.73 m*2 (CKD-EPI formula).
89432216|NCT03411980|Experimental|Control subjects with normal renal function|Subjects with an eGFR ≥90 mL/min/1.73 m*2 (CKD-EPI formula) who are matched based on sex, age, race and weight.
89432217|NCT03398720|Experimental|Cohort 1|One participant will receive HTI-1066 at the starting dose.
89432218|NCT03398720|Experimental|Cohort 2|Participants will receive HTI-1066 at dose level 2.
89432219|NCT03398720|Experimental|Cohort 3|Participants will receive HTI-1066 at dose level 3.
89432220|NCT03398720|Experimental|Cohort 4|Participants will receive HTI-1066 at dose level 4.
89432221|NCT04971668|Experimental|Aromatherapy|Designated blend aromatherapy (ginger & lavender) and patient will be asked to inhale deeply and simulate like chewing gum for 5 minutes.
89432222|NCT04971668|Experimental|Gum Chewing|Patients will chew gum (sugar free) and inhale deeply with inert gauze for 5 minutes.
89432223|NCT04971668|Other|Placebo|Patient will simulate like chewing gum and inhale deeply with inert gauze for 5 minutes.
89432224|NCT03398642|Experimental|French Lifestyle Redesign|16 older adults, 10 without and 6 with disabilities, participated to weekly 2-hour group sessions, including outings, and monthly 1-hour individual sessions led by a occupational therapist over 6-month period and promoting healthy lifestyle and involvement in meaningful activities.
89432225|NCT03394664|Experimental|Very-Low Carbohydrate Diet|Feeding study. Dietary composition (approximately): 75% fat
89432226|NCT03394664|Experimental|High-Carbohydrate Low-Sugar Diet|Feeding study. Dietary composition (approximately): 25% fat 0% added sugars.
89432227|NCT03394664|Experimental|High-Carbohydrate High-Sugar Diet|Feeding study. Dietary composition (approximately): 25% fat, 20% added sugars.
89432228|NCT03394586||UC patients with golimumab|We will retrospectively analyze all ulcerative colitis patients from the Swiss IBD cohort study treated with golimumab.
89432229|NCT03394430|Placebo Comparator|Group A|
89432230|NCT03394430|Experimental|Group B|
89432231|NCT03394430|Experimental|Group C|
89432232|NCT04951310|No Intervention|Control|No Intervention: Control participants (residents of Bucks County, Montgomery County, Delaware County, and Allegheny County, PA) are not eligible for the sweepstakes.
89008976|NCT00573664|Active Comparator|1|Gabapentin
89008977|NCT00573664|Placebo Comparator|2|Placebo
89008978|NCT00573703|Active Comparator|Group A|
89008979|NCT00573703|Experimental|Group B|
89432233|NCT04951310|Experimental|Selected Zip Code Treatment|Selected Zip Code Treatment participants will have a significantly greater chance to win a prize in the sweepstakes than all other Philadelphia residents. Half of all prizes in every drawing will go to Philadelphia residents in the selected zip code.
89432234|NCT04951310|Experimental|All other Philadelphia Residents Treatment|All other Philadelphia Residents Treatment participants will be eligible for the sweepstakes. Half of all prizes in every drawing will go to Philadelphia residents outside of the selected zip code.
89432235|NCT03411668|Experimental|EBP Educational Programme|The educational EBP programme will include 12 hours of classroom lessons regarding EBP more 6 hours of mentorship made to a small groups of students (2 or 3 students per group).
89432236|NCT03411668|No Intervention|Usual Educational Programme|Without intervention. The participants in this group will be maintain usual educational programme.
89432237|NCT03398564|Placebo Comparator|Group I (Control)|ultrasound guided Bilateral Erector Spinae Plan Block using isotonic saline
89432238|NCT03398564|Active Comparator|Group II (ESP)|ultrasound guided Bilateral Erector Spinae Plan Block with bupivacaine 0.25%
89432239|NCT03398564|Active Comparator|Group III(OSTAP)|Ultrasound-guided bilateral oblique subcostal TAP block
89432240|NCT03398486|Experimental|Kinesiotaping|Original kinesiotaping active tapes Duration: 2 times Application maintenance 5 days with a break for the weekend Muscle application on the masseter muscle area, using a tape (5 cm wide) dissected into 2 parts called tails, which included the treatment site without their tension.
89432241|NCT03398486|Experimental|inactivation of trigger points (TrP)|Duration: 10-20 minutes of surgery; 2 inactivation treatments Between the treatments 5 days break
89432242|NCT03398408|Experimental|Intervention|"Patients in both groups will complete paper-pencil TMT A and B and the CWMST, the computer-based TMT A and B and Color Match, and NCPT tests upon enrollment into the study.~Participants in the intervention group will then be provided with the Lumosity cognitive flexibility training module and complete daily training for a total of five weeks. 1-3 days after completion of their training, all patients will be invited to complete the computerized versions of the TMT A and B, Color Match, and NCPT tests again on their personal computers."
89008980|NCT00573781|Experimental|A|Diet with increased intake of rye bread, berries and fish
89008981|NCT00573781|Experimental|B|Increased intake of whole grain and rye bread
89008982|NCT00573781|Active Comparator|C|Control diet with decreased intake of rye bread, berries and fish
89008983|NCT00573820|Other|1|
89432243|NCT03398408|No Intervention|Control|"Patients in both groups will complete paper-pencil TMT A and B and the CWMST, the computer-based TMT A and B and Color Match, and NCPT tests upon enrollment into the study.~Patients in the control group will complete all tests upon enrollment and approximately five weeks after their initial testing, but will not participate in training."
89432244|NCT03394352|Experimental|Activity on Board|Blinded CGM data will be collected prior to the Experimental Admission to determine the insulin bolus that will be determined by the activity on board calculator. Subjects will wear a continuous glucose monitor during the study admission.
89008984|NCT04579822||Pregnant women vaccinated with a QIV|Women aged 20-44 years who had received a QIV during their pregnancy between September 22, 2020, and April 30, 2021, under the national immunization program in South Korea.
89432245|NCT03394352|Placebo Comparator|Usual Diabetes Care|Subjects will use their usual diabetes care, including basal rate, correction factor and carbohydrate-insulin ratio. Subjects will determine their own insulin usage during the Control Admission. Subjects will wear a continuous glucose monitor during the study admission.
89432246|NCT03411590|Other|200ml|Toddlers will be allocated to the 200 ml group
89432247|NCT03411590|Other|400ml|Toddlers will be allocated to the 400 ml group
89432248|NCT03411590|Other|600ml|Toddlers will be allocated to the 600 ml
89432249|NCT03411512||CHD|Newborns with structural congenital heart defects. The exclusion criteria were pulmonary or neurological disease, perinatal asphyxia, acute illness, prematurity and congenital abnormality other than CHD.
89432250|NCT03411512||Healthy controls|The control group comprised of healthy matched newborns without a diagnosed CHD.
89432251|NCT03394274||Transfusion|Patients (n:892) were enrolled who underwent elective major surgery between the 01/01/2016-31/12/2016, and over the age of 18 years. They separated subgroups as restrictive and liberal blood transfusion groups
89432252|NCT02520440||GIF and/or MOF patients|Development during the ICU stay of gastro-intestinal failure and/or multiple organ failure. Investigators performed in each patient monitoring of plasmatic levels of Citrulline, monitoring of plasmatic levels of Arginine and Glutamine, and intra-abdominal pressure monitoring.
89432253|NCT02520440||Controls|patients admitted to ICU without gastrointestinal failure and/or multiple organ failure during the intensive care unit stay. Investigators performed in each patient monitoring of plasmatic levels of Citrulline, monitoring of plasmatic levels of Arginine and Glutamine, and intra-abdominal pressure monitoring.
89432254|NCT03394196|Experimental|No HIV-2 resistance|
89432255|NCT03394196|Experimental|HIV-2 NRTI resistance only|
89008985|NCT04579822||Pregnant women unvaccinated with a QIV|Women aged 20-44 years who had not received a QIV during their pregnancy between September 22, 2020, and April 30, 2021, under the national immunization program in South Korea.
89432256|NCT03394196|Experimental|HIV-2 NRTI and PI resistance|
89432257|NCT03398174|Experimental|Motor Control Exercise Plus Patient Education|"Participants will receive a total of 12 sessions (2 sessions per week) of exercise program consisting of motor control training and group patient education session once a week (6 sessions) all over 6-weeks.~The motor control training will be aiming at improving function of specific muscles of the lumbopelvic region and the control of posture and movement.~The patient education program will be aiming to provide non-threatening information to enable patients to better understand their pain, change any unhelpful beliefs about LBP, and integrate self-management and active coping strategies that deals with fear avoidance behavior and catastrophic thought.~In addition, participants will also perform stretching exercises and instructed to perform continuous overground walk."
89432258|NCT03398174|Experimental|Motor Control Exercise|"Participants will receive the same motor control exercise program described in the patient education and motor control exercise group.~In addition, participants will also perform stretching exercises and instructed to perform continuous overground walk."
89432259|NCT03398174|Experimental|Patient Education|"Participants will receive the same patient education program described in the motor control exercise plus patient education group.~In addition, participants will also perform stretching exercises and instructed to perform continuous overground walk."
89432260|NCT03398096|Experimental|Cardiac shock wave therapy (CSWT) group|The CWST group were performed with a CSWT equipment (Storz Medical, Switzerland) followed the recommended protocol developed by Tohoku University of Japan with respect to the shockwave output and the number of shots implemented to each spot and the protocol developed by the University of Essen, Germany.
89432261|NCT03398096|No Intervention|Control group|No CWST treatment.
89432262|NCT03398018|Experimental|Treatment|Treated with repository corticotropin injection
89432263|NCT03411434|Experimental|ADHD patients|90 patients will be enrolled and assessed (i.e., neurocognitive and oculomotor tests) at baseline ; after a single low dose of methylphenidate (10 mg orally); and after 6 months of adequate dose of methylphenidate oral tablet
89432264|NCT03411278|Experimental|Deep Oscillation (DO) self treatment|"DO self treatment with the device mobile (Physiomed, Laipersdorf, Germany; U.S. patent 7,343,203 B2). The device produces an alternating electrostatic field, which results in a low-frequency vibration penetrating the tissue. The Field is pulsed at a frequency of 90 Hz. For self-treatment, each volunteer is given an apparatus to take home. An applicator with a diameter of 9 cm is used. The treatment will be carried out in the morning and evening for 15 minutes each in supine position on a sofa. In accordance with the technique of classical manual lymphatic drainage, stroking and circular movements in the upper and lower leg and the inguinal area take place in a fixed order."
89432265|NCT03411278|No Intervention|No intervention, control|No intervention
89432266|NCT03126656|Experimental|Hypogonadic with chronic heart failure|patients suffering from mild to moderate heart failure (LVEF ≥ 40%, NYHA I-II), and hypogonadism (plasma testosterone levels <11.4 nmol / L);
89432267|NCT03126656|Experimental|Hypogonadic|patients just with hypogonadism (testosterone <11.4 nmol / L) in the absence of documented cardiovascular disease
89432268|NCT03126656|No Intervention|chronic heart failure|patients suffering from mild to moderate heart failure (LVEF ≥ 40%, NYHA I-II) with normal testosterone levels(plasma testosterone levels > 11.4 nmol / L), in optimized standard therapy for heart failure
89432269|NCT03126734|Experimental|Experimental Group|The parents of this group will receive 5 sessions of infant massage course (1 per week) between two measurements of the variables
89432270|NCT03126734|No Intervention|Control Group|The parents of this group will not receive infant massage course (1 per week) between two measurements of the variables. They will receive it after two measurements.
89432271|NCT03126500||Malnourished|malnourished, geriatrics patients at hospital discharge
89432272|NCT03385382||Dexamethasone group|Patients with diabetic macular edema receiving dexamethasone
89008986|NCT04579861||High human development|Countries classified as very high and high human development as per the United Nations development programme.
89008987|NCT04579861||Low and medium human development|Countries classified as low and medium human development as per the United Nations development programme.
89008988|NCT04579978||Subjects with advanced solid tumors starting immunotherapy|Subjects with advanced solid tumors planned to initiate standard of care immune checkpoint inhibitors
89432273|NCT03385382||ranibizumab|Patients with diabetic macular edema receiving ranibizumab
89432274|NCT03394118|Experimental|Group_TAGRISSO|Each subject will continue the study drug(Osimertinib) until disease progression or manifestation of unacceptable toxicity during the study period.
89432275|NCT03394040||1|The study seeks individuals of all ages experiencing diarrhea from the Washington Metropolitan area
89432276|NCT03389672||spinal anesthesia|The anesthesia technique were applied with modified approach and conventional approach
89432277|NCT03389672||epidural anesthesia|The anesthesia technique were applied with modified approach and conventional approach
89432278|NCT03389672||combined spinal-epidural anesthesia|The anesthesia technique were applied with modified approach and conventional approach
89432279|NCT01941446|Experimental|pre-generated treatment scheme|Treatment A: Eravacycline (TP-434) 1.5 mg/kg administered intravenously over 60 minutes and one placebo oral tablet
89432280|NCT01941446|Placebo Comparator|Pre-generated tratment scheme|Treatment B: Placebo (0.9% sodium chloride) administered intravenously over 60 minutes and one moxifloxacin 400 mg oral tablet
89432281|NCT01941446|Placebo Comparator|Moxifloxacin|Treatment C: Placebo (0.9% sodium chloride) administered intravenously over 60 minutes and one placebo oral tablet
89432282|NCT03393962|Experimental|OC-EIEs|Autologous ovarian cancer antigen-specific cytotoxic lymphocytes
89432283|NCT01907360|Experimental|HLD200 (methylphenidate hydrochloride) in Adolescents|HLD200 (B formulation, 54 mg, oral capsules) administered as a single treatment in the evening to children aged 13-17 years.
89432284|NCT01907360|Experimental|HLD200 (methylphenidate hydrochloride) in Children|HLD200 (B formulation, 54 mg, oral capsules) administered as a single treatment in the evening to children aged 6-12 years.
89432285|NCT03126032||Patients with suspected sepsis|"Patients presenting in the Emergency Room (ER) with the clinical suspicion of infection/sepsis.~Evaluation of the glycocalyx damage with the use of GlycoCheck™-System, as well as blood sample at presentation, day 1 and day 7 of their hospital stay."
88911702|NCT01571414|Experimental|Arm 2A-LPV/r and PA-824|Participants will receive PA-824 on Days 1 to 7, no study medication on Days 8 to 21, LPV/r on Days 22 to 35, and LPV/r plus PA-824 on Days 36 to 42. Inpatient study visits will occur at Days 7, 35, and 42.
89432286|NCT03126032||Non-Sepsis Patients|"Patients presenting in the Emergency Room with other conditions apart from infection/sepsis.~Evaluation of their sublingual glycocalyx and blood sample for further microbiologic and laboratory analysis at presentation."
88911703|NCT01571414|Experimental|Arm 2B-LPV/r and PA-824|Participants will receive LPV/r on Days 1 to 14, LPV/r plus PA-824 on Days 15 to 21, no study medication on Days 22 to 35, and PA-824 on Days 36 to 42. Inpatient study visits will occur at Days 14, 21, and 42.
88911704|NCT01571414|Experimental|Arm 3-RIF and PA-824|Participants will receive PA-824 on Days 1 to 7, RIF on Days 8 to 14, and RIF plus PA-824 on Days 15 to 21. Inpatient study visits will occur at Days 7 and 21.
88911705|NCT01571440|Placebo Comparator|No Soluble Corn Fiber|Each teen will receive a package of fruit snacks containing 0 g soluble corn fiber two times daily.
88911706|NCT01571440|Active Comparator|12 g Soluble Corn Fiber|Each teen will receive a package of fruit snacks containing 6 g soluble corn fiber two times daily
89432287|NCT03126032||Healthy Individuals|Evaluation of their sublingual glycocalyx and blood sample for further microbiologic and laboratory analysis at presentation.
89432288|NCT03126188||Sertraline group|Mild and Moderate depressive episode without somatic syndrome who are treated with Sertraline. Tab. Sertraline 50 mg/day, which will be optimized to 75mg/day after 2 weeks if required, and maintained on the same dose for a minimum period of 6 weeks.
89432289|NCT03126188||Dosulepin group|Mild and Moderate depressive episode with somatic syndrome who were treated with Dosulepin. Tab. Dosulepin 25mg/day, which will be gradually hiked up to 75mg/day over 2 weeks
89432290|NCT03126188||Venlafaxine group|Severe depressive episode without psychotic symptoms who were treated with Venlafaxine. Tab. Venlafaxine 75mg/day, which will be hiked to 112.5 mg/day after 2 weeks, and the patients will be continued on the same dose for a minimum period of 6 weeks.
89432291|NCT03389594|No Intervention|Surgical guide designed from voxel size 0.2mm|Surgical guide will be designed based on CBCT voxel size 0.2mm
89432292|NCT03389594|Active Comparator|Surgical guide designed from voxel size 0.4m|Surgical guide will be designed based on CBCT voxel size 0.4 mm
89432293|NCT03389516|Active Comparator|Polymem breast pads|
89432294|NCT03389516|Active Comparator|Lanolin|
89432295|NCT01860092||Argus II Retinal Prosthesis|Patients implanted with the Argus II Retinal Prosthesis
89432296|NCT01849250|Experimental|Arm I (Docosahexaenoic Acid)|Docosahexaenoic Acid orally twice a day (PO BID) for 12 weeks.
89432297|NCT01849250|Placebo Comparator|Arm II (placebo)|Placebo orally twice a day (PO BID) for 12 weeks.
89432298|NCT03385148|Experimental|colorectal patients|the colorectal patients undergo 68Ga-Sgc8 PET/CT
88911707|NCT01571466|Experimental|Vaccine group|Modified Pox virus, strain MVA clade -B (expressing HIV-1 Bx08gp120 and IIIB gagpolnef) (MVA HIV-B)
88911708|NCT01571466|Placebo Comparator|Placebo|
89432299|NCT04446338||Healthcare Worker|Staff of the Department of Ophthalmology, University Tuebingen, Germany
89432300|NCT03389204|Active Comparator|Breast surgery and exercise|Patient that underwent breast surgery only without other intervention with exercise of the upper limb and instruction to continue after discharge.
89432301|NCT03389204|Active Comparator|Breast surgery and no exercise|Patient after breast surgery alone are discharged without exercise and instructions.
89432302|NCT03389204|Active Comparator|Breast, axilar surgery with exercise|Patients that underwent surgery of the breast and axilar lymph node surgery with exercise of the upper limb and instruction to continue after discharge.
89432303|NCT03389204|Active Comparator|Breast, axillar surgery without exercise|The patients that underwent surgery of the breast and axilar nodes samples or dissection are discharged without exercise and instructions.
89432304|NCT02520206||Arthritis|subjects with arthritis
89432305|NCT02520206||Health control subjects|Health control
89432306|NCT03393728|Experimental|Intervention|72-hour propanolol before specific treatment of hyperthyroidism
89432307|NCT03393650|Active Comparator|Exercise + Placebo group|50 subjects will receive a placebo supplementation with an exercise intervention (EX group)
89432308|NCT03393650|Active Comparator|Exercise + Protein group|50 subjects will receive a protein supplementation combined with an exercise intervention (PROTEX group)
89432309|NCT03393572|Active Comparator|Group BM|bupivacaine 0.25% plus magnesium sulphate.
89432310|NCT03393572|Active Comparator|Group BN|bupivacaine 0.25% plus nalbuphine
89432311|NCT03393416|Experimental|MASCT-I or MASCT-I +PD1 antibody|"This study is divided into three stages:~The first, second stage is the stage of the dose climbing, and the third stage is the dose expansion stage. The first stage is MASCT-I, using 3+3 design. The second stage is divided into two groups: MASCT-I+PD1 antibody in low dose group and MASCT-I+PD1 antibody in high dose group, using 3+3 design. The third stage is the dose expansion stage , 10 patients in the low or high dose group were treated with the corresponding dose group."
89432312|NCT05172674||spontaneous pregnancies|
88911709|NCT01571479|No Intervention|2-mm mini-instrument (M-LC)|M-LC is three-port laparoscopic cholecystectomy using a 2-mm mini-instrument.
89432313|NCT05172674||pregnancies arising through IVF (homologus + hetereologus)|
89432314|NCT04445948|Active Comparator|Triple Therapy|Received triple therapy in the form of esomeprazole 40 milligrams tablets once daily 30 minutes before breakfast plus amoxicillin 1 gram tablets twice daily and clarithromycin 500 milligrams tablets twice daily after meal for 14 days.
89432315|NCT04445948|Active Comparator|Sequential Therapy|Received the sequential therapy in the form of esomeprazole 40 milligrams tablets once daily 30 minutes before breakfast plus amoxicillin 1 g tablets twice daily for 5 days, then esomeprazole 40 milligrams tablets once daily 30 minutes before breakfast plus metronidazole 500 milligrams tablets twice daily plus clarithromycin 500 milligrams tablets twice daily after meal for another 10 days.
89432316|NCT04445948|Active Comparator|Triple Therapy plus Lactoferrin|Received triple therapy in the form of esomeprazole 40 milligrams tablets once daily 30 minutes before breakfast plus amoxicillin 1 gram tablets twice daily and clarithromycin 500 milligrams tablets twice daily after meal for 14 days. in addition to 200 milligrams of bovine lactoferrin sachets twice daily 30 minutes after breakfast and dinner for 14 days.
89432317|NCT04445948|Active Comparator|Sequential Therapy plus Lactoferrin|Received the sequential therapy in the form of esomeprazole 40 milligrams once daily 30 minutes before breakfast plus amoxicillin 1 gram twice daily for 5 days, then esomeprazole 40 mg once daily 30 minutes before breakfast plus metronidazole 500 milligrams twice daily plus clarithromycin 500 milligrams twice daily after meal for another 10 days in addition to 200 milligrams of bovine lactoferrin sachets twice daily 30 minutes after breakfast and dinner throughout the 15 days.
89432318|NCT02479646|Experimental|Treatment A|MYL-1401H: single subcutaneous injection (2mg)
89432319|NCT02479646|Active Comparator|Treatment B|EU-Neulasta: single subcutaneous injection (2mg)
89432320|NCT02479646|Active Comparator|Treatment C|US-Neulasta: single subcutaneous injection (2mg)
89432321|NCT02467868|Experimental|MYL-1401H|MYL-1401H
89432322|NCT02467868|Active Comparator|Neulasta|Neulasta
89432323|NCT02791191|Experimental|Dose 1 LY3202626|3 mg LY3202626 given orally once daily for 52 weeks.
88911710|NCT01571479|No Intervention|conventional instrument(C-LC)|C-LC is conventional three port laparoscopic cholecystectomy
88911711|NCT01571492|Experimental|L2 Paravertebral peripheral nerve block|L2 paravertebral peripheral nerve block catheter will be placed.
88911712|NCT01571492|Active Comparator|Continuous Lumbar plexus peripheral nerve block|Continuous unilateral lumbar plexus peripheral nerve block catheter will be placed.
89432324|NCT02791191|Experimental|Dose 2 LY3202626|12 mg LY3202626 given orally once daily for 52 weeks.
89432325|NCT02791191|Experimental|Placebo|Placebo given orally once daily for 52 weeks.
89432326|NCT02101671||trendelemburg positioning|Patients undergone laparoscopic surgery in trendelemburg position
89432327|NCT02101671||Not trendelemburg positioning|Patients undergone laparoscopic surgery not in trendelemburg position
89432328|NCT02106429||PAD and CLI patients|Subjects undergoing non emergent lower extremity revascularization
89432329|NCT02103231||Full Term Birth|History of full term birth (>37 weeks gestation) including sub-group with diagnosis of hypertension
89432330|NCT02103231||Preterm Birth|History of preterm birth (<37 weeks gestation) including subgroup with diagnosis of hypertension
88911713|NCT01571505|Experimental|IPV vaccination|Randomized IPV vaccination to children at the age of 39 weeks.
88911714|NCT01571505|Placebo Comparator|OPV vaccination|Randomized OPV vaccination to children at the age of 39 weeks.
88911715|NCT01571518|Experimental|early injection|injection of G-CSF (leukostim)5㎍/kg from day 2 of TAC chemotherapy
88911716|NCT01571518|Sham Comparator|late injection|injection of G-CSF (leukostim)5㎍/kg from day 5 of TAC chemotherapy
88911717|NCT01571544|Experimental|Thermal suit|Randomly selected half of the patients will use thermal suit prior to anesthesia, during the surgery and post anesthesia care unit.
88911718|NCT01571544|Active Comparator|Conventional clothing|Randomly selected half of the patients will use conventional clothing prior to anesthesia, during the surgery and post anesthesia care unit.
88911719|NCT01571570|Experimental|Treatment A|Panel 1: single oral dose of 150 mg TMC435 150 mg capsule, fed
88911720|NCT01571570|Experimental|Treatment B|Panel 1: single oral dose of 150 mg TMC435 oral suspension (20 mg/mL), fasted
88911721|NCT01571570|Experimental|Treatment C|Panel 1: single oral dose of 150 mg TMC435 oral suspension (20 mg/mL), fed
89432331|NCT02101749|Active Comparator|trivalent inactivated influenza (INTANZA)|Intradermal injection
89432332|NCT02101749|Active Comparator|trivalent inactivated influenza (VAXIGRIP)|Intramuscle injection
89432333|NCT02106585|Experimental|Dose 1 JTT-251 or Placebo|Tablets, single dose in fed condition
89432334|NCT02106585|Experimental|Dose 2 JTT-251 or Placebo|Tablets, single dose in fed condition
89432335|NCT02106585|Experimental|Dose 3 JTT-251 or Placebo|Tablets, single dose in fed condition
89432336|NCT02106585|Experimental|Dose 4 JTT-251 or Placebo|Tablets, single dose in fed condition
89432337|NCT02106585|Experimental|Dose 5 JTT-251 or Placebo|Tablets, single dose in fed condition
89432338|NCT02106585|Experimental|Dose 6 JTT-251 or Placebo|Tablets, single dose in fed condition
89432339|NCT02106585|Experimental|Dose 7 JTT-251 or Placebo|Tablets, single dose in fed condition
88911722|NCT01571570|Experimental|Treatment D|Panel 2: single oral dose of 150 mg TMC435 150 mg capsule, fed
88911723|NCT01571570|Experimental|Treatment E|Panel 2: single oral dose of 150 mg TMC435 oral solution (10 mg/mL), fasted
88911724|NCT01571570|Experimental|Treatment F|Panel 2: single oral dose of 150 mg TMC435 oral solution (10 mg/mL), fed
89432340|NCT02106585|Experimental|Dose 8 JTT-251 or Placebo|Tablets, single dose in fed condition
89432341|NCT02106585|Experimental|Dose 9 JTT-251 or Placebo|Tablets, single dose in fasted or fed condition followed by a single dose in the alternate fed or fasted condition
89432342|NCT02101827||Hysteroscopic surgery|Women who received hysteroscopic surgeries or examinations
88911725|NCT01571570|Experimental|Treatment G|Panel 3: single oral dose of 150 mg TMC435 150 mg capsule, fed
88911726|NCT01571570|Experimental|Treatment H|Panel 3: single oral dose of 150 mg TMC435 capsule concept K, fed
88911727|NCT01571570|Experimental|Treatment I|Panel 3: single oral dose of 150 mg TMC435 capsule concept L, fed
88911728|NCT01571583|Experimental|Telaprevir+Peg-IFN-alfa-2a+Ribavirin|Patients will be treated for 12 weeks with telaprevir in combination with Pegylated interferon alfa-2a (Peg-IFN-alfa-2a) and ribavirin followed by 36 weeks of treatment with Peg-IFN-alfa-2a and ribavirin alone.
88911729|NCT01571609|Experimental|Carriers|
88911730|NCT01571609|Experimental|Non-carriers|
89432343|NCT02103387|Experimental|Cognitive Behavioral Training|Cognitive Behavioral Training 5 weekly 1.5-hour sessions of group-based cognitive behavioral training
88911731|NCT01571622|Placebo Comparator|Water before breakfast|Each patient will consume a high-GI breakfast (white bread). Each subject will be pretreated 30 min before breakfast with 250 ml of water
88911732|NCT01571622|Experimental|Whey before breakfast|Each patient will consume a high-GI breakfast (white bread). Each subject will be pretreated 30 min before breakfast with Whey Protein Concentrate (WPC 80 %) 45 gr dissolved in 250 ml of water\
88911733|NCT01571648|Experimental|Oral azacitidine|
88911734|NCT01571661|Experimental|Part A Treatment 1|GSK189075A 20mg
88911735|NCT01571661|Experimental|Part A Treatment 2|GSK189075A 50mg
88911736|NCT01571661|Experimental|Part A Treatment 3|GSK189075A 150mg
88911737|NCT01571661|Experimental|Part A Treatment 4|GSK189075A 500mg
88911738|NCT01571661|Experimental|Part A Treatment 5|GSK189075A 1000mg
88911739|NCT01571661|Placebo Comparator|Placebo|Placebo
88911740|NCT01571661|Experimental|Part B Low dose|low dose chosen from Part A
88911741|NCT01571661|Experimental|Part B High Dose|high dose chosen from Part A
88911742|NCT01571674|Experimental|Manipulation + Exercise Group|The treatment received by the manipulation+exercise group will differ from the exercise group for the first week only (two treatment sessions). During the first two sessions, patients in the manipulation+exercise group will receive cervicothoracic spine manipulations and range of motion (ROM) exercises only. Beginning on the third session these patients will receive the same exercise program as the exercise group.
88911743|NCT01571674|Active Comparator|Exercise Group|The exercise group will be treated with a stretching and strengthening program.
88911744|NCT01571687|Active Comparator|antioxidant supplements|800 I.E. Vitamin E, 1000mg Vitamin C, 200000 I.E. Vitamin A, 600mg Acetylcystein.
88911745|NCT01571687|Placebo Comparator|Placebo|identically appearing placebo
88911746|NCT01571700||Study|Patients with pulmonary hypertension.
88911747|NCT01571700||Control|ASD patients or patients with normal hearts
88911748|NCT01571713||Study|Pediatric patients with pulmonary hypertension
89008989|NCT04579978||Subjects with advanced solid tumors receiving ICIs|Subjects with advanced solid tumors already receiving standard of care immune checkpoint inhibitors
89432344|NCT02103387|Experimental|Relaxation Training|Relaxation Training 5 weekly 1.5-hour sessions of group-based relaxation training
89432345|NCT02103387|Active Comparator|Health Education Control|Health Education Control 5 weekly 1.5 sessions of group-based health education training
89432346|NCT02102061|Experimental|multidisciplinary intervention|
89432347|NCT02102061|No Intervention|control|
89432348|NCT02103465|Experimental|Rotigotine|80 patients with late onset PD are randomized in 2 parallel groups, ratio 1:1.
89432349|NCT02103465|Placebo Comparator|Placebo|80 patients with late onset PD are randomized in 2 parallel groups, ratio 1:1.
89432350|NCT02106663|Active Comparator|Circumferential Pulmonary Vein Ablation|Contiguous ablation lesions will be performed to encircle the two left and right pulmonary veins (PVs), guided by 3D electroanatomic mapping (Carto, Biosense Webster, Inc. or ESI NavX, St. Jude, Inc.) with a 3D LA geometry created either by using the roving mapping catheter or by importing a pre-recorded 3D CT image of the left atrium. After completion of the circumferential ablation, PV isolation will be confirmed by the mapping catheter, and further focal ablation performed as required until electrical PV isolation is confirmed (entrance block at a minimum).
89432351|NCT02106663|Active Comparator|Segmental Pulmonary Vein Isolation|Electrical potentials recorded in the pulmonary vein (PV) ostium using a circular mapping catheter, representing myocardial connections between the left atrium and PVs will be ablated at or just proximal to the PV ostium in the PV antrum. Ablation will be performed segmentally at multiple sites guided by the mapping catheter around the PV ostium or antrum, until mapping demonstrates elimination of all PV potentials (entrance block at a minimum).
89432352|NCT02106741|Experimental|Relaxation acupressure|
89432353|NCT02106741|Active Comparator|Stimulating acupressure|
89432354|NCT02106741|No Intervention|Wait-list control|
89432355|NCT02102139|Experimental|DXM + Propofol|"DXM (1 µg kg -1) was loaded intravenously for 10 min before anaesthesia induction.During DXM loading, the depth of anaesthesia was monitored using a bispectral index (BIS) monitor. Electrocardiogram, heart rate, pulse oximetry, and non-invasive arterial blood pressure were monitored at 2-min intervals.~Anaesthesia was induced with propofol 3.5 μg mL 1 and remifentanil 5 ng mL 1 at an effect site concentration using a target-controlled infusion (TCI) device. Anaesthesia was maintained with propofol and remifentanil continuous infusions.~During surgery except the study period, propofol and remifentanil doses were adjusted to maintain BIS value of 40-60 and systolic blood pressure (SBP) within ±20% from baseline respectively."
89432356|NCT02102139|Placebo Comparator|Saline + Propofol|"Saline (1 µg kg -1) was loaded intravenously for 10 min before anaesthesia induction.During saline loading, the depth of anaesthesia was monitored using a bispectral index (BIS) monitor. Electrocardiogram, heart rate, pulse oximetry, and non-invasive arterial blood pressure were monitored at 2-min intervals.~Anaesthesia was induced with propofol 3.5 μg mL 1 and remifentanil 5 ng mL 1 at an effect site concentration using a target-controlled infusion (TCI) device. Anaesthesia was maintained with propofol and remifentanil continuous infusions.~During surgery except the study period, propofol and remifentanil doses were adjusted to maintain BIS value of 40-60 and systolic blood pressure (SBP) within ±20% from baseline respectively."
89432357|NCT02106819||Cerebellar Ataxia subjects|40 individuals with either hereditary or sporadic ataxia will have testing of emotional communication ability and may have magnetic resonance imaging (MRI) of the brain.
89432358|NCT02106819||Healthy Control subjects|40 age matched controls will have testing of emotional communication ability and may have magnetic resonance imaging (MRI) of the brain.
89432359|NCT02103543|Active Comparator|Physical Therapy first|patients will undergo physical therapy 3-4 sessions followed by lumbar interlaminar epidural steroid injection
89432360|NCT02103543|Active Comparator|lumbar epidural steroid first|lumbar interlaminar epidural steroid injection followed by patients will undergo physical therapy 3-4 sessions
89432361|NCT02102217|Experimental|Precious arm|Postoperative controls according to the PRECious protocol, which entails standardized measurement of CRP levels on postoperative day three, four and five. If CRP levels exceed 140 mg/l additional CT-scan imaging will be conducted.
89432362|NCT02102217|No Intervention|Control|Standard postoperative controls. Additional testing will only be conducted on demand.
89008990|NCT04580056||Incision Group|Women following IVF treatment with donor oocytes who underwent during hysteroscopy fundus endometrial scratching by incision, before embryo transfer.
89008991|NCT04580056||No incision Group|Women following IVF treatment with donor oocytes who underwent office hysteroscopy without fundus endometrial scratching by incision, before embryo transfer.
89008992|NCT04719468|Experimental|Intervention|
89008993|NCT04719468|No Intervention|Usual Treatment|usual treatment with the addition of joining 'Tea and Biscuit' sessions remotely
89008994|NCT00574015|Active Comparator|oral|administration of oral analgesia
89008995|NCT00574015|Experimental|Dental Block|Administration of supraperiosteal nerve block to effected tooth
89008996|NCT00574054|Other|1|
89432363|NCT02103621|Experimental|Unifed Protocol (UP) for Discontinuation|Unified Protocol (UP) for Discontinuation is delivered in 14 weekly individual sessions of 45-60 minutes followed by 3 booster sessions scheduled at two, four and eight weeks thereafter. The UP is a cognitive behavioral treatment that focuses on increasing emotional awareness and cognitive flexibility, preventing behavioral and emotional avoidance, and situational and interoceptive emotion-focused exposure. Participants will also receive 7 biweekly medication management sessions over 14 weeks with a study psychiatrist to facilitate gradual taper of SRI medication.
89008997|NCT00255021|Experimental|1|
89432364|NCT02103621|Active Comparator|Taper and Monitoring (TAP-M)|Taper and Monitoring (TAP-M) is delivered in biweekly individual sessions over 14 weeks, with booster sessions at two, four, and eight weeks thereafter. TAP-M consists of assessment and monitoring. Participants will also receive 7 biweekly medication management sessions over 14 weeks with a study psychiatrist to facilitate gradual taper of SRI medication.
89008998|NCT00574093|Experimental|A|A: This will be a single arm study. Patients will be administered Lucentis™ on Day 1,at Months 1 and 2, and then as needed at intervals of at least 30 days through Month 11 based on the retreatment criteria algorithm. These patients will also be administered Visudyne® only on Day 3.
89432365|NCT03555123|Experimental|SIMDAX|Levosimendan2.5mg/mL
89432366|NCT03555123|Placebo Comparator|SIMDAX Placebo|Water for injection
89432367|NCT03554499|Experimental|Hydrodissection|Bichectomy with hydrodissection = infiltration of 15ml per side of a special solution (250ml of saline 0.9% + 1mg of epinephrine + 20ml of 2% Lidocaine, equivalent to 0.0555mg of epinephrine and 22.2mg of Lidocaine per side), prior to the incision with the following distribution: 1ml in the form of a wheal in the oral mucosa with a 22G needle 1cm behind the Stenon canal opening that corresponds to the incision site and 14 ml on the virtual space where the buccal fat pad is located.
89432368|NCT03554499|Active Comparator|Control|Bichectomy without hydrodissection = infiltration with 3ml per side of 2% Lidocaine with 1: 200,000 epinephrine ( equivalent to 0.015mg of epinephrine and 60mg of Lidocaine per side) at the operative site.
89432369|NCT02102295|Active Comparator|Experimental toothpaste|L-ascorbic acid 2-phosphate magnesium salt / fluoride
89432370|NCT02102295|Placebo Comparator|Control toothpaste|fluoride
89432371|NCT02102373|Active Comparator|low-fiber diet|Patients received low-fiber diet for 24 hours before colonoscopy
89432372|NCT02102373|Active Comparator|clear liquid diet|Patients received clear liquid diet for 24 hours before colonoscopy
89432373|NCT03555045|Active Comparator|conducting the slanted recession technique|conducting the slanted recession technique on the superior and inferior poles of the muscle based on far and near deviations.
89432374|NCT03555045|Active Comparator|conducting the augmented recession technique on the muscle|conducting the augmented recession technique on the muscle for 1 to 1.50 mm more compared with the standard method.
89432375|NCT02110017|Other|Patients with schizophrenia|"Twenty patients suffering from schizophrenia (DSM-IV-R), with medication and medical care. No recent relapse of the psychotic disease, nor change in medications.~No neurological comorbidity.~After anatomic scans, each subject will go through the fMRI social cognition task."
89432376|NCT02110017|Other|Healthy subjects|"Twenty healthy subjects (no mental or neurological disease)~After anatomic scans, each subject will go through the fMRI social cognition task."
89008999|NCT00574210|Experimental|1|Bilastine oral 20 mg once per day (1 x 20 mg bilastine tablet plus 1 placebo tablet)
89009000|NCT00574210|Experimental|2|Bilastine oral 20 mg twice per day (2 x 20 mg bilastine tablets)
89009001|NCT00574210|Experimental|3|Bilastine oral 10 mg once per day (1 x 10 mg bilastine tablet plus 1 placebo tablet)
89009002|NCT00574210|Experimental|4|Bilastine oral 10 mg twice per day (2 x 10 mg bilastine tablets)
89009003|NCT00574210|Placebo Comparator|5|Placebo oral twice per day (2 placebo tablets)
89009004|NCT00574366|Experimental|Erlotinib/RAD001 Ph I|"Tarceva (OSI-774; erlotinib) Everolimus (RAD001)~Study did not progress to Phase II:~Experimental: Erlotinib/RAD001 Phase II Maximum tolerated dose of erlotinib (Tarceva,OSI-774) and RAD001 (Everolimus)"
89009005|NCT00574444|Experimental|Procedure|Procedure/Surgery: transvaginal diagnostic peritoneoscopy For patients with pelvic pain, a transvaginal procedure can be done to explore the abdomen. Entering through the vagina, will hopefully decrease the number of ports in the abdomen and decrease pain and healing time.
89009006|NCT00574483|Experimental|1|Unblinded treatment arm
89009007|NCT00574522|Other|1|Infrared Radiation, wavelength between 5 and 20 microns
89009008|NCT00225563|Active Comparator|e-prescribing|Providers who used electronic prescriptions. electronic health records were used as opposed to paper based prescriptions
89009009|NCT00225563|No Intervention|Paper-based prescriptions|providers who used paper based prescriptions
89009010|NCT00574600|Experimental|Vaccine|SAAVI DNA-C2 administered as 1 ml intramuscularly in either deltoid at study entry and Months 1 and 2; SAAVI MVA-C administered as 0.5 ml intramuscularly in either deltoid at Months 4 and 5
89009011|NCT00574600|Placebo Comparator|Placebo|Placebo administered at Months 0, 1, 2, 4 and 5
89432377|NCT02103699||Hepatitis C virus infected patients receiving simeprevir|
89432378|NCT02103777|Active Comparator|High dose caffeine|High dose (loading 40 mg/kg/day equivalent to 20 mg /kg/day of caffeine base and maintenance of 20 mg/kg/day equivalent to 10 mg /kg/day of caffeine base)
89432379|NCT02103777|Active Comparator|Low dose caffeine|Low dose (loading 20 mg/kg/day equivalent to 10 mg /kg/day of caffeine base and maintenance of 10 mg/kg/day equivalent to 5 mg /kg/day of caffeine base) caffeine.
89432380|NCT02104011|Experimental|Patient|
89432381|NCT02104089||Endovascular treatment|Zenith® t-Branch™ Thoracoabdominal Endovascular Graft
89432382|NCT03554889|Experimental|Experimental Group|Peripheral blood lymphocytes will be collected. The NK cell will be selected and expanded ex vivo, then adaptive transfer back into patients. A total of 5.0 x 10^8/L NK cells will be infused in one cycle.To avoid allergic reactions, 50 mg hydrocortisone was intramuscularly injected into patient 30 min before cells infusion every time. Best supportive care was also provided for patients. Nimotuzumab will be used 24 hours before infusion. Patients continued receiving treatment unless they had unacceptable adverse effects, or progressive disease confirmed by CT and PET-CT or they withdrew consent.
88911749|NCT01571765|Experimental|MNCH programming|protocols and training for data collection, referrals, and management for health district. Training in obstetrics, newborn care and management of sick children for health workers, Increased community health promotion such as training of CHWs, health centre management teams and bednet distribution
89432383|NCT03554421|Experimental|Posterior tibial nerve stimulation|Percutaneous tibial nerve stimulation. Stimulation av posterior tibial nerve via neuromodulator for 30 minutes. 10 sessions
89432384|NCT02250963||DSE|Patients, who underwent Dobutamine Stress Echocardiography (DSE)
89432385|NCT02250963||CTCA|Computed tomography coronary angiography is going to perform with a 64-slice system (Brilliance 64, Philips Healthcare, Best, the Netherlands).
88911750|NCT01571765|No Intervention|no added MNCH activities|
88911751|NCT01571791|Placebo Comparator|group SF|either saline infusion and intravenous fentanyl boluses
88911752|NCT01571791|Active Comparator|group KL|ketorolac-lidocaine infusion and intravenous saline boluses
88911753|NCT01571804|Active Comparator|pregabalin 150 mg group|one capsule of pregabalin 150 mg and one placebo capsule
89432386|NCT02251041|Active Comparator|cases|the group receives a combination of drugs
89432387|NCT02251041|Placebo Comparator|controles|the group do not receive a combination of drugs, but a placebo (sodium chloride solution)
89432388|NCT02106897|Experimental|Part 1, Cohort 1: BIIB059 0.05 mg/kg IV|BIIB059 0.05 mg/kg IV dose, Once on Day 1
89432389|NCT02106897|Experimental|Part 1, Cohort 2: BIIB059 0.3 mg/kg IV|BIIB059 0.3 mg/kg IV dose, Once on Day 1
88911754|NCT01571804|Active Comparator|pregabalin 300 mg group|two capsules of pregabalin 150 mg
88911755|NCT01571804|Placebo Comparator|placebo group|to receive two identical placebo capsules
88911756|NCT01571817|Experimental|Study intervention|endoscopically-guided intestinal submucosal transplantation of Isolated Human Pancreatic Islets in a type 1 diabetic patient
88911757|NCT01571843|Experimental|PHPT/ Walking + Forearm exercise|Ten participants with PHPT will be randomized to the intervention of 52 weeks of the forearm exercise program plus walking.
89432390|NCT02106897|Experimental|Part 1, Cohort 3: BIIB059 1 mg/kg IV|BIIB059 1 mg/kg IV dose, Once on Day 1
89432391|NCT02106897|Experimental|Part 1, Cohort 4: BIIB059 3 mg/kg IV|BIIB059 3 mg/kg IV dose, Once on Day 1
89432392|NCT02106897|Experimental|Part 1, Cohort 5: BIIB059 10 mg/kg IV|BIIB059 10 mg/kg IV dose, Once on Day 1
89432393|NCT02106897|Experimental|Part 1, Cohort 6: BIIB059 20 mg/kg IV|BIIB059 20 mg/kg IV dose, Once on Day 1
89432394|NCT02106897|Experimental|Part 1, Cohort 7: BIIB059 50 mg SC|BIIB059 50 mg SC dose, Once on Day 1
89432395|NCT02106897|Placebo Comparator|Part 1, Cohort 1-6: Placebo IV|Matching placebo IV dose, Once on Day 1
89432396|NCT02106897|Placebo Comparator|Part 1, Cohort 7: Placebo SC|Matching placebo SC dose, Once on Day 1
89432397|NCT02106897|Experimental|Part 2, Cohort 8: BIIB059 20 mg/kg IV|BIIB059 20 mg/kg IV dose, Once on Day 1
89432398|NCT02106897|Placebo Comparator|Part 2, Cohort 8: Placebo IV|Matching placebo IV dose, Once on Day 1
89432399|NCT02106897|Experimental|Part 3a, Cohort 9: BIIB059 20 mg SC|BIIB059 20 mg SC dose, Every 4 weeks for 2 doses
89432400|NCT02106897|Experimental|Part 3a, Cohort 10: BIIB059 50 mg SC|BIIB059 50 mg SC dose, Every 4 weeks for 2 doses
89432401|NCT02106897|Experimental|Part 3a, Cohort 11: BIIB059 150 mg SC|BIIB059 150 mg SC dose, Every 4 weeks for 2 doses
89432402|NCT02106897|Experimental|Part 3a, Cohort 12: BIIB059 300 mg or less SC|BIIB059 300 mg or less SC dose, Every 2 weeks for 3 doses
89432403|NCT02106897|Placebo Comparator|Part 3a, Cohort 9-12: Placebo SC|Matching placebo SC dose, Every 4 weeks for 2 doses or every 2 weeks for 3 doses
89432404|NCT02106897|Experimental|Part 3b, Cohort 13: BIIB059 50 mg SC|BIIB059 50 mg SC dose, Every 4 weeks for 2 doses
88911758|NCT01571843|Placebo Comparator|PHPT/ Walking alone|Ten participants with PHPT will be randomized to the intervention of 52 weeks of the walking program alone. Walking will consist of 30 minutes at a moderate pace every other day for 52 weeks.
89432405|NCT02106897|Experimental|Part 3b, Cohort 14: BIIB059 300 mg or less SC|BIIB059 300 mg or less SC dose, Every 2 weeks for 3 doses
89432406|NCT02106897|Placebo Comparator|Part 3b, Cohort 13-14: Placebo SC|Matching placebo SC dose, Every 4 weeks for 2 doses or every 2 weeks for 3 doses
88911759|NCT01571843|Active Comparator|Osteopenia/ Walking + Forearm exercise|Ten healthy, postmenopausal women with osteopenia will be randomized to the intervention of 52 weeks of the forearm exercise program plus walking.
88911760|NCT01571843|Placebo Comparator|Osteopenia/ Walking alone|Ten healthy, postmenopausal women with osteopenia will be randomized to the intervention of 52 weeks of the walking program alone. Walking will consist of 30 minutes at a moderate pace every other day for 52 weeks.
88911761|NCT01571856|Active Comparator|zinc sulfate|zinc sulphate solution.
88911762|NCT01571856|Placebo Comparator|cornstarch solution|cornstarch powder diluted in distilled water
88911763|NCT01571869|Experimental|1 = Tested product|
88911764|NCT01571869|Placebo Comparator|2 = Control product|
89432407|NCT02107053|Experimental|IV iron + PJ|Each patient will serve as a self control
89432408|NCT02107053|Experimental|No IV iron + PJ|Each patient will serve as a self control
89432409|NCT02107053|Experimental|IV iron no PJ|Each patient will serve as a self control
89432410|NCT02110251|Experimental|Supervised exercise therapy|Adequacy of initial therapy, Investigation degree of confusion and dementia, Preoperative preparation, Life-style coaching, Supervised Exercise therapy.
89432411|NCT02110251|No Intervention|Walking advice|Standard care and a oral walking advice.
89432412|NCT02107209|Experimental|Bronchoscopic Lung volume reduction using Autologous blood.|Injection of 30 ml autologous blood plus 3ml calcium chloride plus 3 ml tranexamic acid per segment via fiber-optic bronchoscope
89432413|NCT02107209|Active Comparator|Bronchoscopic Lung volume reduction using Fibrin glue|injection of 30 ml locally prepared fibrin glue per segment via triple lumen balloon catheter passing through fiberoptic bronchoscopy
89432414|NCT02104323|Experimental|Endostatin，treatment effect evaluation|Patients receive continuous intravenous Endostatin drug pumping during the course of treatment. The drug dosage is 7.5mg/m2/d. Every course of treatment lasts three months. Patients are designed to receive total three courses of treatment if there is no disease progression. The interval between two courses is one month.
89432415|NCT02104401|Experimental|tDCS|tDCS will be applied with a Soterix CT tDCS Device with a HD-tDCS 4x1 Multi-Channel Stimulation Interface. During stimulation, a low level of constant DC electrical current (1-2 mA) will be applied via the electrodes. Current will be ramped up over 10-60 seconds, and typically causes very mild tingling and itching sensations. The current will be applied for no more than 20 minutes per session, at which time the current is ramped down over 10-60 seconds. Subjects will be seated in a chair throughout tDCS administration. Subjects will receive tDCS 5 days/week for 4 weeks.
89432416|NCT02104479||Immunocompromised Patients|Immunocompromised patients with suspected IPA who have Pleural effusions act as the observed study population
89432417|NCT02104479||Control Group|Patients without Immunosuppression with pleural effusions
89432418|NCT02107287|Experimental|IMRT Hypofractionated|Neo-adjuvant hormone therapy for three months followed by IMRT combined with a 24-month hormonal therapy.
89432419|NCT02110329|No Intervention|stage II-III colon cancer treated with surgery|stage II-III colon cancer treated with surgery
88911765|NCT01571882|Experimental|1 = Tested product 1|
88911766|NCT01571882|Experimental|2 = tested product 2|
88911767|NCT01571882|Active Comparator|3 = Active control product|
88911768|NCT01571921|Experimental|Gamma-Delta Tocotrienol|
88911769|NCT01571921|Active Comparator|TRF|
88911770|NCT01571934||Mild or moderate hemophilia A|Subjects with mild or moderate hemophilia A (fVIII activity 1-40%) who are scheduled to undergo surgery for which at least 5 consecutive days of fVIII replacement therapy is required.
89432420|NCT02107365|Experimental|Asunaprevir, Daclatasvir, Ribavirin, Peg-Interferon alpha-2a|Quadritherapy from Day 0 to Week 24
89432421|NCT02110407|Sham Comparator|training + sham stimulation|Combination of intensive training of visual-spatial abilities (LOCATO task) with sham stimulation
89432422|NCT02110407|Experimental|training + tDCS|Combination of intensive training of visual-spatial abilities (LOCATO task) with transcranial direct current stimulation (tDCS)
89432423|NCT03554343||All newborn from Southern Belgium|All newborns except newborns for which parents refuse newborn screening will be tested for exon 7 deletion in survival motor neuron 1 (SMN1)
89432424|NCT02104635|No Intervention|Control group|The control group receives standard of care from Jacaranda clinic and does not receive any additional post-partum check-in from a community health worker.
89432425|NCT02104635|Experimental|CHW-Visit|The CHW-Visit group will receive a visit at their home from a community health worker (CHW) three days after delivery. The CHW will administer a checklist designed to identify maternal and newborn complications and will provide information about positive maternal health and care behaviors. The CHW will encourage women to return to the clinic at 7 days to receive a well-baby check.
89432426|NCT02104635|Experimental|CHW-Phone|The CHW-Visit group will receive a phone call from a community health worker (CHW) three days after delivery. The CHW will administer a checklist designed to identify maternal and newborn complications and will provide information about positive maternal health and care behaviors. The CHW will encourage women to return to the clinic at 7 days to receive a well-baby check.
89432427|NCT02104713|Experimental|Allogeneic (MSC's) Application to the Burn Wounds|"Allogeneic (MSC's) Application to the Burn Wounds. The 1st group of 5 will be started on the lowest dose. If there are no adverse reactions, the 2nd group of 5 will receive a higher dose. This will be repeated for the 3rd and 4th groups with each receiving a higher dose.~Up to 2 administrations of cells per dose level to be given over a period of no more than 8 weeks. Each administration of cells will be no less than ten days apart and no more than 6 weeks apart."
89432428|NCT02110563|Experimental|DCR-MYC|Patient groups (cohorts) will receive a single dose level of DCR-MYC; the dose level of DCR-MYC will be increased in subsequent cohorts
89432429|NCT02104791||procalcitonin in blood|-Group 1: Healthy preterm Group: will include 50 pregnant females all at 24-34 weeks of gestational age .
89432430|NCT02104791||plasma of blood|-Group 2: Preterm premature rupture of membrane Group include 50 pregnant women
89432431|NCT02104791||procalcitonin,prematureruptureofmembrane in blood|"Complete history including (special habits like smoking and alcohol taking, menstrual history especially LMP, medical diseases, past obstetric history including duration, mode of delivery for each pregnancy, and if there were fetal or maternal complications).~Physical examination including (general condition, height, weight, vital signs).-Ultrasound to execlude multiple pregnancies, IUFD and to confirm oligohydraminos in group2.~The venous blood samples will be taken for measuring of -Procalcitonin in mothors -CRP and WBCs in mothers to detect infection -CRP in neonates of mothers of group 2.~They will be asked for their permission and consent."
89432432|NCT02104869|Active Comparator|Recommended dose (kidney transplant)|"Intervention: trivalent influenza vaccine (inactivated and fragmented).~Dosage form: each 0.5 mL dose of the vaccine contains Myxovirus influenzae strains propagated in embryonated chicken eggs, equivalent to: A/California/7/2009 (H1N1) pdm09 (15 mcg of hemagglutinin); A/Texas/50/2012 (H3N2) (15 mcg of hemagglutinin); B/Massachusetts/2/2012 (15 mcg of hemagglutinin); Thimerosal (2 mcg).~Dose: single 0.5 mL dose."
89432433|NCT02104869|Active Comparator|Healthy adults|"Intervention: trivalent influenza vaccine (inactivated and fragmented).~Dosage form: each 0.5 mL dose of the vaccine contains Myxovirus influenzae strains propagated in embryonated chicken eggs, equivalent to: A/California/7/2009 (H1N1) pdm09 (15 mcg of hemagglutinin); A/Texas/50/2012 (H3N2) (15 mcg of hemagglutinin); B/Massachusetts/2/2012 (15 mcg of hemagglutinin); Thimerosal (2 mcg).~Dose: single 0.5 mL dose."
89432434|NCT02104869|Experimental|Single double dose (kidney transplant)|"Intervention: trivalent influenza vaccine (inactivated and fragmented).~Dosage form: each 0.5 mL dose of the vaccine contains Myxovirus influenzae strains propagated in embryonated chicken eggs, equivalent to: A/California/7/2009 (H1N1) pdm09 (15 mcg of hemagglutinin); A/Texas/50/2012 (H3N2) (15 mcg of hemagglutinin); B/Massachusetts/2/2012 (15 mcg of hemagglutinin); Thimerosal (2 mcg).~Dose: single 1.0 mL dose."
89536273|NCT03198247|Active Comparator|Control Group: Usual Care|"Procedure: Usual care The biomedical education session will be imparted 2 weeks before surgery by the preoperative nurse and a physiotherapist. It will have a duration of 2 hours and it is designed for a group of 5 subjects.~The hospital rehabilitation starts 6 hours after surgery, and it is based in early wandering stimulation, articular mobility exercises and isometric exercises."
88911771|NCT01571947|Active Comparator|SFA|
88911772|NCT01571947|Active Comparator|MUFA|
88911773|NCT01571947|Active Comparator|PUFA|
88911774|NCT01571947|Active Comparator|CARB|
88911775|NCT01571960|Experimental|Group 1: study vaccine|Participants in this arm will receive a 0.3-mg dose injection of GEO-D03 DNA vaccine at Days 0 and 56, followed by injections of MVA62B vaccine at Days 112, 168, and 224.
88911776|NCT01571960|Placebo Comparator|Group 1: placebo vaccine|Participants in this arm will receive injections of placebo for GEO-D03 DNA vaccine at Days 0 and 56, followed by injections of placebo for MVA62B vaccine at Days 112, 168, and 224.
88911777|NCT01571960|Experimental|Group 2: study vaccine|Participants in this arm will receive a 3-mg dose injection of GEO-D03 DNA vaccine at Days 0 and 56, followed by injections of MVA62B vaccine at Days 112, 168, and 303.
88911778|NCT01571960|Placebo Comparator|Group 2: placebo vaccine|Participants in this arm will receive injections of placebo for GEO-D03 DNA vaccine at Days 0 and 56, followed by injections of placebo for MVA62B vaccine at Days 112, 168, and 303.
88911779|NCT01571960|Experimental|Group 3: study vaccine|Participants in this arm will receive a 3-mg dose injection of GEO-D03 DNA vaccine at Days 0 and 56, followed by injections of MVA62B vaccine at Days 112 and 224.
88911780|NCT01571960|Placebo Comparator|Group 3: placebo vaccine|Participants in this arm will receive injections of placebo for GEO-D03 DNA vaccine at Days 0 and 56, followed by injections of placebo for MVA62B vaccine at Days 112 and 224.
88911781|NCT01571973|No Intervention|control group|outpatients receiving usual care
88911782|NCT01571973|Experimental|intervention group|outpatients receiving pharmaceutical care or pharmacotherapeutic follow-up by 6 months
88911783|NCT01571999|Experimental|Severe renally impaired subjects|Approximately 9 subjects will complete each treatment arm
88911784|NCT01571999|Experimental|Matched healthy volunteers|Matched to the severe renal impairment subjects based on gender, ethnicity, body mass index (±15%) and age (±5 years). Approximately 9 subjects will complete each treatment arm
88911785|NCT01572012|Experimental|Subcutaneous Administration|Ondansetron + Hylenex administered subcutaneously
88911786|NCT01572012|Experimental|Oral Administration|Ondansetron administered orally
89432435|NCT02104869|Experimental|Two sequential doses (kidney transplant)|"Intervention: trivalent influenza vaccine (inactivated and fragmented).~Dosage form: each 0.5 mL dose of the vaccine contains Myxovirus influenzae strains propagated in embryonated chicken eggs, equivalent to: A/California/7/2009 (H1N1) pdm09 (15 mcg of hemagglutinin); A/Texas/50/2012 (H3N2) (15 mcg of hemagglutinin); B/Massachusetts/2/2012 (15 mcg of hemagglutinin); Thimerosal (2 mcg).~Dose: two 0.5 mL doses 21 days apart."
89432436|NCT02107521|Active Comparator|ICSI group|In this group, sperm selected for injection will be morphologically evaluated under 400x magnification
89432437|NCT02107521|Experimental|IMSI group|In this group, sperm selected for injection will be morphologically evaluated under 6600x magnification
89432438|NCT02250885|Experimental|Selinexor (KPT-330)|Selinexor will be taken orally at a starting dose of 50mg/m2 twice weekly on weeks 1, 2, and 3 of each 4 week cycle.
89432439|NCT02110719|Active Comparator|Standard|"Patients will be given the following:~no preoperative medications~intraoperative medications per anesthesia~postoperatively, patients will receive ibuprofen, tylenol and narcotics as needed"
89432440|NCT02110719|Active Comparator|Multimodal|"Patients in the multimodal arm will receive the following:~preoperative celebrex and gabapentin~intraoperative IV acetaminophen, dexamethasone, zofran~postoperative scheduled IV acetaminophen, PO celebrex and gabapentin, and as needed PO narcotics~patient will be discharged on scheduled ibuprofen and acetaminophen for 3 days followed by as needed use as well as as needed narcotics"
88911787|NCT01572012|Experimental|Intramuscular Administration|Ondansetron administered intramuscularly
88911788|NCT01572012|Experimental|Intravenous Administration|Ondansetron administered intravenously
88911789|NCT01572025|Experimental|DHEA supplementation|
88911790|NCT01572025|Placebo Comparator|Control|
88911791|NCT01572051|Experimental|Group 1A (3month plus phone)|This group will attend to two courses with a 3 month interval between them This group will receive phone calls This group will receive printed material This group will be reassessed in 6 months
88911792|NCT01572051|Experimental|Group 1B (3month no phone)|This group will attend to two courses with a 3 month interval between them This group will NOT receive phone calls This group will receive printed material This group will be reassessed in 6 months
88911793|NCT01572051|Experimental|Group 2A (2month plus phone)|This group will attend to two courses with a 2 month interval between them This group will receive phone calls This group will receive printed material This group will be reassessed in 6 months
88911794|NCT01572051|Experimental|Group 2B (2month no phone)|This group will attend to two courses with a 2 month interval between them This group will NOT receive phone calls This group will receive printed material This group will be reassessed in 6 months
88911795|NCT01572051|Experimental|Group 3A (1month plus phone)|This group will attend to two courses with a 1 month interval between them This group will receive phone calls This group will receive printed material This group will be reassessed in 6 months
89432441|NCT02105103|Other|Accu-Chek® Insight Insulin Pump|
89432442|NCT02110797|Other|RETT patients|
89432443|NCT02110875||CONTROLS|Age- and Gender-Matched Controls
89432444|NCT03012165|Experimental|ADX-102 Ophthalmic Drops (0.5%)|ADX-102 Ophthalmic Drops (0.5%) administered twice in two weeks.
89432445|NCT03012165|Experimental|ADX-102 Ophthalmic Drops (0.1%)|ADX-102 Ophthalmic Drops (0.1%) administered twice in two weeks.
89432446|NCT03012165|Placebo Comparator|Vehicle of ADX-102 Ophthalmic Drops|Vehicle of ADX-102 Ophthalmic Drops
89432447|NCT02107755|Experimental|Treatment (ipilimumab, stereotactic radiosurgery)|Patients receive ipilimumab IV over 90 minutes on day 1 in weeks 1, 4, 7, and 10. Treatment repeats every 3 weeks for up to 4 total doses in the absence of disease progression or unacceptable toxicity. At approximately 5-6 weeks, patients undergo stereotactic radiosurgery over 2-3 days per week. Patients with stable disease or confirmed partial or complete response after completion of ipilimumab therapy at week 12 may receive re-induction ipilimumab at the discretion of the treating physician.
89432448|NCT02110953|Experimental|Treatment (irinotecan-eluting beads)|Patients receive irinotecan-eluting beads via hepatic artery embolization every 3 weeks for a total of 2 treatments in the absence of disease progression or unacceptable toxicity. Patients with bi-lobular disease and no evidence of progression in the treated lobe may repeat treatment at the discretion of the treating physician.
88911796|NCT01572051|Experimental|Group 3B (1month no phone)|This group will attend to two courses with a 1 month interval between them This group will NOT receive phone calls This group will receive printed material This group will be reassessed in 6 months
88911797|NCT01572051|Experimental|Group 4A (no course plus phone)|This group will NOT attend to any courses This group will receive phone calls This group will receive printed material This group will be reassessed in 6 months
89432449|NCT03554109|Experimental|Group A|"NANT Neoadjuvant Triple Negative Breast Cancer Vaccine~A combination of agents will be administered to subjects in this study:~cyclophosphamide, 5-fluorouracil, leucovorin, nab-paclitaxel, avelumab, aldoxorubicin HCl, ALT-803, haNK, GI-4000, GI-6207, GI-6301, ETBX-011, ETBX-051 and ETBX-061"
89432450|NCT03554109|Active Comparator|Group B|Standard treatment with a combination of doxorubicin, cyclophosphamide and paclitaxel.
89432451|NCT02107833|Experimental|2 mg|OPRX-106 2 mg oral once daily for 5 days
89432452|NCT02107833|Experimental|8 mg|OPRX-106 8 mg oral once daily for 5 days
89432453|NCT02107833|Experimental|16 mg|OPRX-106 16 mg oral once daily for 5 days
89432454|NCT02105181|Other|Fully covered metal stent (FCMS)|There is one arm in the study : the intervention consists on placing a device which is a fully covered metal stent in the biliary tract of all patients
89432455|NCT02111031||Case|Patients with documented (histologically/pathologically confirmed) mBC diagnosis, at lease 65 years of age at documented mBC diagnosis, and actively treated by a physician at a participating cancer center who routinely (i.e., test at lease every quarter) use CTC testing (excluding patients who sought consults or second opinions).
89432456|NCT03554031|Experimental|rhGH injection/Jintropin AQ|Drug: Recombinant Human Growth Hormone Injection /Jintropin AQ, 30IU/10 mg/3ml/kit, 0.5 mg/m2/d for the first 4 weeks, then 1.0 mg/m2/d for subsequent 48 weeks; by subcutaneous injection, once per day for total 52 weeks.No control.
88911798|NCT01572051|Experimental|Group 4B (no course no phone)|This group will NOT attend to any courses This group will NOT receive phone calls This group will only receive printed material This group will be reassessed in 6 months
88911799|NCT01572077|Experimental|FTHA/GDF PET imaging|"This study plans to enrol 60 subjects with Type I pulmonary arterial hypertension (PAH) and 20 healthy, age and sex individuals to serve as normal controls. These subjects will have no known cardiac or pulmonary disease.~Both groups will undergo FTHA/FDG PET imaging."
88911800|NCT01572090|Active Comparator|Conventional weight loss: CONV-NG|"Obese normoglycemic (NG) patients evidenced by a body fat ≥ 35% in women and ≥ 25% in men and a 2-h oral glucose tolerance test.~Conventional weight loss will be achieved by Lifestyle changes including advice on increasing physical activity and prescription of a hypocaloric diet providing a daily energy deficit of 500-1000 kcal/d as calculated from the determination of the resting energy expenditure through indirect calorimetry (Vmax29, SensorMedics Corporation, Yorba Linda, CA) and multiplication by the physical activity level factor to obtain the individual's total energy expenditure. Regular visits with the dietitian will be scheduled as in the surgical groups."
88911801|NCT01572090|Active Comparator|Conventional weight loss: CONV-T2D|"Obese type 2 diabetic (T2D) patients evidenced by a body fat >35% in women and ≥ 25% in men and proven documentation of T2D diagnosis, history and treatment in accordance with good clinical practice.~Conventional weight loss will be achieved by Lifestyle changes including advice on increasing physical activity and prescription of a hypocaloric diet providing a daily energy deficit of 500-1000 kcal/d as calculated from the determination of the resting energy expenditure through indirect calorimetry (Vmax29, SensorMedics Corporation, Yorba Linda, CA) and multiplication by the physical activity level factor to obtain the individual's total energy expenditure. Regular visits with the dietitian will be scheduled as in the surgical groups."
89432457|NCT02111109||Traumatic injury|
88911802|NCT01572090|Active Comparator|Laparoscopic Sleeve gastrectomy: SG-NG|The intervention in this arm comprises obese (BMI ≥ 40 kg/m2 or ≥ 35 kg/m2 with comorbidities) normoglycemic (NG) patients (evidenced by a 2-h OGTT) undergoing a sleeve gastrectomy (SG). The Sleeve gastrectomy SG-NG involves the removal of the mayor curvature of the stomach. Via a laparoscopic approach. In addition to the surgery, patients will have regular follow-up with a dietitian and endocrinologist for appropriate counselling on lifestyle changes (diet, physical activity and vitamin/mineral supplementation counselling) following bariatric surgery.
89432458|NCT02111265|Experimental|Propofol|Target controlled infusion propofol, the effect compartment concentration is 3-4μg/ ml for induction and maintenance of anesthesia.
89432459|NCT02111265|Experimental|Etomidate|Target controlled infusion etomidate, the effect compartment concentration is 0.5-1.0μg/ ml for induction and maintenance of anesthesia.
88911803|NCT01572090|Active Comparator|Laparoscopic Sleeve gastrectomy: SG-T2D|The intervention in this arm comprises obese (BMI ≥ 40 kg/m2 or ≥ 35 kg/m2 with comorbidities) type 2 diabetic (T2D) patients with proven documentation of T2D diagnosis, history and treatment in accordance with good clinical practice undergoing a sleeve gastrectomy (SG). In addition to the surgery, patients will have regular follow-up with a dietitian and endocrinologist for appropriate counselling on lifestyle changes (diet, physical activity and vitamin/mineral supplementation counselling) following bariatric surgery as well for adjustment of antidiabetic medication. Adjustment of oral antidiabetics/insulin therapy consisting in continuation, adjustment or discontinuation of medical antidiabetic therapy if needed in accordance with good clinical practice.
88911804|NCT01572090|Active Comparator|Laparoscopic R-Y gastric bypass: RYGB-NG|The intervention in this arm comprises obese (BMI ≥ 40 kg/m2 or ≥ 35 kg/m2 with comorbidities) normoglycemic (NG) patients (evidenced by a 2-h OGTT) undergoing laparoscopic Roux-en-Y gastric bypass (RYGB). In addition to the surgery, patients will have regular follow-up with a dietitian and endocrinologist for appropriate counselling on lifestyle changes (diet, physical activity and vitamin/mineral supplementation counselling) following bariatric surgery.
88911805|NCT01572090|Active Comparator|Laparoscopic R-Y gastric bypss: RYGB-T2D|The intervention in this arm comprises obese (BMI ≥ 40 kg/m2 or ≥ 35 kg/m2 with comorbidities) type 2 diabetic (T2D) patients with proven documentation of T2D diagnosis, history and treatment in accordance with good clinical practice undergoing laparoscopic Roux-en-Y gastric bypass (RYGB). In addition to the surgery, patients will have regular follow-up with a dietitian and endocrinologist for appropriate counselling on lifestyle changes (diet, physical activity and vitamin/mineral supplementation counselling) following bariatric surgery as well for adjustment of antidiabetic medication. Adjustment of oral antidiabetics/insulin therapy consisting in continuation, adjustment or discontinuation of medical antidiabetic therapy if needed in accordance with good clinical practice.
88911806|NCT01571908|Experimental|Magnesium perfusion - Rocuronium|60 mg/kg of magnesium perfusion over 15 minutes before Anaesthesia. After Anaesthesia induction 0.6 mg/kg of Rocuronium intravenously
88911807|NCT01571908|Active Comparator|Placebo perfusion - Succinylcholine|1ml/kg of saline (placebo) over 15 minutes before Anaesthesia. After Anaesthesia induction 1 mg/kg of Succinylcholine intravenously
88911808|NCT01572103|Experimental|Administration of coffee|Administration of 4 cups of coffee/day for 1 month
88911809|NCT01572103|No Intervention|Coffee abstinence|Total coffee and caffeine containing beverages abstinence
88911810|NCT01572116|Placebo Comparator|Lidocaine with Epinephrine+ Normal saline|
88911811|NCT01572116|Active Comparator|Lidocaine with Epinephrine + sufentanil|
88911812|NCT01572129|Experimental|Reload|600 mg of clopidogrel loading dose 6-8 h before coronary angiogram, in addition to the chronic daily dose of 75 mg
88911813|NCT01572129|Placebo Comparator|Placebo|Placebo arm in addition to the chronic daily dose of 75 mg
88911814|NCT01572142||Parkinson disease group|Subjects with Parkinson disease
88911815|NCT01572155|No Intervention|Sham stimulation|No stimulation of nervus vagus
88911816|NCT01572155|Active Comparator|Vagus stimulation 1|2 times 2 minutes (beginning and end of surgery) stimulation at 5 Hz, 500 micro s, 2.5 mA
89432460|NCT02251119|Experimental|TPV|"Administration of LOP on days 1, 9 and 22~Administration of TPV on days 4-9~Administration of TPV/RTV on days 12-22"
88911817|NCT01572155|Active Comparator|Vagus stimulation 2|2 times 2 minutes (beginning and end of surgery) stimulation at 20 Hz, 500 micro s, 2.5 mA
88911818|NCT01572168|Experimental|Acupuncture|Eight sessions of weekly acupuncture
88911819|NCT01572181|Experimental|Drugs|Fludarabine IV- Busulfan IV (Busilvex®) - Anti-thymocyte globulines (Thymoglobuline®)
88911820|NCT01572220|Other|stress echocardiography|Comparative effectiveness
88911821|NCT01572220|Other|Myocardial SPECT|CER
88911822|NCT01572233|Experimental|Patient with HCV Infection|Personalized Physical Activity and Psycho-Education (PPAPE) Program will be tested on this group.
88911823|NCT01572233|No Intervention|usual care|waiting list group with usual care
88911824|NCT01572246||Non-cardiac above-the-waist surgery|Subjects with an implanted ICD who present for a non-cardiac above-the-waist surgical procedure involving monopolar electrocautery
88911825|NCT01572246||Cardiac surgery|Subjects with an implanted ICD who present for a cardiac surgical procedure involving monopolar electrocautery
88911826|NCT01572246||Below-the-waist surgery|Subjects with an implanted ICD who present for a below-the-waist surgical procedure involving monopolar electrocautery
88911827|NCT01572259|Experimental|interruption of the growth hormone treatment.|
88911828|NCT01572259|Experimental|Patients traited by grouth hormone|
89009012|NCT00574639|Experimental|Arm 1|Day 1 study two hyperinsulinemic (high Insulin dose) euglycemic (normal glucose level) clamps x 2. Day 2 exercise for 90 minutes on recumbent bike. Patient randomized to placebo or Xanax (Alprazolam) drug on Day 1 to receive 1 mg orally prior to each clamp.
89009013|NCT00574639|Experimental|Arm 2|Day 1 study two hyperinsulinemic (high Insulin dose) euglycemic (normal glucose level) clamps x 2. Day 2 exercise for 90 minutes on recumbent bike. Patient randomized to placebo or Xanax (Alprazolam) drug on Day 1 to receive 1 mg orally prior to each clamp.
89009014|NCT00574639|Experimental|Arm 3|Day 1 study two hyperinsulinemic (high Insulin dose) hypoglycemic (low glucose level) clamps x 2. Day 2 exercise for 90 minutes on recumbent bike. Patient randomized to placebo or Xanax (Alprazolam) drug on Day 1 to receive 1 mg orally prior to each clamp.
89009015|NCT00574639|Experimental|Arm 4|Day 1 study two hyperinsulinemic (high Insulin dose) hypoglycemic (low glucose level) clamps x 2. Day 2 exercise for 90 minutes on recumbent bike. Patient randomized to placebo or Xanax (Alprazolam) drug on Day 1 to receive 1 mg orally prior to each clamp.
89009016|NCT00574678|No Intervention|1|
89009017|NCT00574717|Experimental|A|Infants will receive spectacle under-correction of their hyperopia.
89432461|NCT02251119|Experimental|RTV|"Administration of LOP on days 1, 9 and 22~Administration of RTV on days 4-9~Administration of TPV/RTV on days 12-22"
89432462|NCT02105337||tegaderm placement|all pts will have tegaderm placed prior to goggles for VEP
89432463|NCT02105493|Active Comparator|500 microgram of Nitroglycerin|500 mcg nitroglycerin was given intra-arterially through the sheath at the end of a transradial procedure
89432464|NCT02105493|Placebo Comparator|Saline 5 mL|0,9% Saline 5 mL was given intra-arterially through the sheath at the end of a transradial procedure
89432465|NCT02105571|Experimental|Intervention|Intervention activities take place over a 6-month period for each participant, and include a weight loss competition with self-monitoring and feedback; computer-based training units on healthy weight loss, healthy eating, exercise, and sleep; and up to four motivational interviews with a health coach by cell phone.
89432466|NCT02105571|No Intervention|Control|"Continued work conditions and Usual Practices in that workplace"
89432467|NCT02105649|Experimental|calf muscle strengthenig group|"experimental group~will receive the same selected physical therapy program in addition to manual and mechanical strengthening exercises and electrical stimulation program for calf muscles of both lower limbs."
89432468|NCT02105649|Other|No calf muscle strengthening group|"control group~will receive only the selected physical therapy program"
89432469|NCT02111343|Experimental|Computer-based auditory training (CBAT)|The CBAT programmes in the current study were specifically designed to improve speech-in-noise and dichotic listening skills of children diagnosed with CAPD. All the training programmes were designed to be installed on home-user's computer, and they were visually attractive and appealing to children. The development of the software (non commercial) for the speech-in-noise and dichotic listening training was done by two different teams in the United Kingdom and Singapore, respectively.
89432470|NCT02111343|No Intervention|Control|No intervention other than participants' regular school activities
89432471|NCT02105727|Experimental|Salt reduction|Community-based salt reduction
89432472|NCT02105805|Experimental|low energy diet|low energy diet treatment
89432473|NCT02105805|Active Comparator|Nordic recommendation|Nordic recommendation, no restrictions on energy
89009018|NCT00574756|Other|1|Active drug for 2 weeks, then washout period for 2 weeks, then placebo for 2 weeks
89009019|NCT00574756|Other|2|Placebo for 2 weeks, then washout for 2 weeks, then ranolazine for 2 weeks
89009020|NCT03453658|Active Comparator|Manual instrumentation|Manual instrumentation: Endodontic treatment will be performed with the use of conventional endodontic manual files.
89009021|NCT03453658|Experimental|Reciprocating instrumentation|Mechanized instrumentation: Endodontic treatment will be performed with the use of reciprocating mechanized files. The files are activated by an engine that produces reciprocating movements.
89432474|NCT02105883|No Intervention|Scenario C (control)|no badge
89432475|NCT02105883|Active Comparator|Scenario B (badge)|Use of Identification badge during scenarios (roles and places)
89432476|NCT02107911||men who have sex with men|MSM who seek voluntary HIV counseling and testing service at the Anonymous Clinic, TRC-ARC, including those who describe risky sexual exposure to HIV within the preceding 72 hours and meet nPEP criteria.
89432477|NCT02111421|Experimental|parturients|Parturients after the umbilical cord was clapped in cesarean section were accepted an initial dose of 1.0 μg/kg dexmedetomidine, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last four turning points.
89432478|NCT02111421|Experimental|nonpregnant women|Nonpregnant women were accepted an initial dose of 1.0 μg/kg dexmedetomidine, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last four turning points.
89432479|NCT02106039|Experimental|intensive monitoring|more intensive monitoring strategy of blood glucose and clinical review
89432480|NCT02106039|No Intervention|standard monitoring|glucose monitoring followed the prevailing practice at each site
89432481|NCT02111499|Experimental|formulation 1|topical treatment, once daily for 4 weeks
89432482|NCT02111499|Experimental|formulation 2|topical treatment, once daily for 4 weeks
89432483|NCT02111499|Experimental|formulation 3|topical treatment, once daily for 4 weeks
89432484|NCT02111499|Experimental|formulation 4|topical treatment,once daily for 4 weeks
89432485|NCT02111499|Placebo Comparator|formulation 5|topical treatment, once daily for 4 weeks
89009022|NCT03453424|Active Comparator|TEA+DEX group|"Intra operative thoracic epidural injection of (bupivacaine 0.125% +fentanyl 2 mic/ ml) , initial bolus dose of 8 ml before skin incision followed by fixed rate infusion of 6 ml/h till end of abdominal layer closure.~Postoperative, thoracic epidural injection of (bupivacaine 0.0625%+fentanyl 2 mic /ml + dexmedetomidine 0.5 mic/ ml) at infusion rate 6 ml /h and bolus dose of 3 ml with lockout time 10 min"
89432486|NCT02111499|Active Comparator|formulation 6|topical treatment, once daily for 4 weeks
89432487|NCT02106117||neutropenic patients|Patients receiving treatment for hematological malignancies expected to result in prolonged neutropenia (neutrophil counts <0.5 x 10 ^9/L for more than seven days).
88911829|NCT01572272||Open|Open group: Data derived from the Capnostream20p and displayed to the medical team. It will allow the treating physician and the nursing team to review the real time data and make clinical decisions based upon it if felt necessary.
88911830|NCT01572272||Masked|Data derived from the Capnostream20p will be recorded; however the medical staff will be masked from it and hence will not use it.
88911831|NCT01572285|Sham Comparator|Sham|Sham arm received a simulation of transforaminal injection using a non-penetrating needle
88911832|NCT01572285|Experimental|Transforaminal|Subjects received TF with infiltration of lidocaine 1% 0.5mL and 1.5mL of Dexamethasone 10mg/ml
88911833|NCT01572311|Experimental|Exercise Intervention Group|For 26 weeks, attend Canadian Centre for Activity and Aging combined classes (75-minute or 60-minute classes, 2 to 3 days/week) and also complete 45 minutes of dual-task gait training (15 minutes for 3 days/week or 22.5 minutes for 2 days/week)
88911834|NCT01572311|Active Comparator|Exercise Control group|For 26 weeks, attend Canadian Centre for Activity and Aging combined classes (75-minute or 60-minute classes, 2 to 3 days/week) and also complete 45 minutes of gait training (15 minutes for 3 days/week or 22.5 minutes for 2 days/week). Note: no dual-task challenges during gait training
88911835|NCT01572324|Experimental|Arterial infusion|
88911836|NCT01572350|Active Comparator|Grid laser|It's a reference standard as the treatment which is currently accepted for NTDDME
88911837|NCT01572350|Experimental|Triamcinolone 4 mg|
88911838|NCT01572350|Experimental|Bevacizumab|
88911839|NCT01572363|Experimental|Sildenafil|All patients will be given Sildenafil 50 mg with evaluation of pulmonary vascular resistance and systemic ventricular function at rest and during exercise after 30 minutes.
88911840|NCT01572376|Experimental|Bone marrow stem cells|Bone marrow was obtained by posterosuperior iliac crest aspiration under topical anesthesia. Mononuclear cells were isolated by Ficoll density gradient and will be resuspended in heparinized isotonic saline for infusion into the wound.
88911841|NCT01572402|Experimental|Patients with type 2 diabetes|Study group: 40 individuals with type 2 diabetes treated by diet and/or oral hypogylycemic agents, diabetes duration at least 1 year, both men and women, age 30-65 years, BMI 27-50 kg/m². The subjects will be explained aims, methods and risks of the study and they will sign informed consent
88911842|NCT01572402|Active Comparator|Healthy subjects|Mean and women, age 30-70 years, no diabetes, no metabolic syndrome
88911843|NCT01572441||12-14 year olds|No intervention administered. This is a longitudinal observational study including observation of behaviors and physiological responses.
88911844|NCT01572454|Experimental|Dexmedetomidine group|Dexmedetomidine infusion 0.2 mcg/kg/hr during anesthetic induction 0.3 - 0.7 mcg/kg/hr during the surgery
88911845|NCT01572454|Active Comparator|Remifentanil group|Remifentanil infusion 0.05 - 0.3 mcg/kg/min during the anesthetic induction and surgery
88911846|NCT01572519|Experimental|JNJ-40346527|
88911847|NCT01572545|Experimental|Denosumab|
88911848|NCT01572545|Experimental|Zoledronic Acid|
88911849|NCT01572558|Active Comparator|Appendectomy|Standard surgical treatment, appendectomy
88911850|NCT01572558|Experimental|Conservative, non-surgical treatment|Non-operative treatment with intravenous and oral antibiotics
88911851|NCT01572597|Experimental|Acetylcystein|10-day triple therapy plus N-acetyl-cystein to remove the biofilm.
88911852|NCT01572597|Active Comparator|Metronidazole|10-day triple therapy plus metronidazole (concomitant therapy) as active comparator
88911853|NCT01572610|Experimental|RTA 402|
88911854|NCT01572623|Active Comparator|Antiplatelet before carotid artery stenting|Clopidogrel 600 mg after carotid artery stenting
88911855|NCT01572623|Active Comparator|Statin therapy before carotid artery stenting|Reloading dose of Atorvastatin (80 mg at 12 hours and 40 mg at 6-8 hours before carotid artery stenting) versus no reload.
88911856|NCT01572636||Laronidase use in Hurler Syndrome|Laronidase receiving prior and post transplant
88911857|NCT01572649|Placebo Comparator|Placebo|1 single administration (volume matched to the dose lixisenatide: 50 µL or 100µL) once a day subcutaneously
88911858|NCT01572649|Experimental|Dose 1|1 single administration of 5 µg lixisenatide (50 µL) once a day subcutaneously
88911859|NCT01572649|Experimental|Dose 2|1 single administration of 10 µg lixisenatide (100 µL) once a day subcutaneously
88911860|NCT01572688|Experimental|autologous stem cell transplant|
88911861|NCT01572701|Experimental|20 (±3) mCi of study drug|
88911862|NCT01572753|Experimental|Post-dose fasting 120 mins/50 ml water|
88911863|NCT01572753|Experimental|Post-dose fasting 60 mins/50 ml water|
88911864|NCT01572753|Experimental|Post-dose fasting 30 mins/50 ml water|
88911865|NCT01572753|Experimental|Post-dose fasting 15 mins/50 ml water|
88911866|NCT01572753|Experimental|Post-dose fasting 120 mins/120 ml water|
88911867|NCT01572753|Experimental|Post-dose fasting 60 mins/120 ml water|
88911868|NCT01572753|Experimental|Post-dose fasting 30 mins/120 ml water|
88911869|NCT01572753|Experimental|Post-dose fasting 15 mins/120 ml water|
88911870|NCT01572766|Active Comparator|FRAX Assessment|FRAX Assessment Tool administered by a pharmacist. This group also receives a heel ultrasound and pharmacist counseling.
88911871|NCT01572766|No Intervention|Control group|Control group receives heel ultrasound and pharmacist counseling
88911872|NCT01572779|Experimental|Intervention|BSM device with bio-feedback
88911873|NCT01572779|Placebo Comparator|Control|The BSM device without feed-back
88911874|NCT01572805|Active Comparator|melatonin 3mg|
88911875|NCT01572805|Active Comparator|melatonin 6mg|
88911876|NCT01572805|Placebo Comparator|placebo|
88911877|NCT01572818|Experimental|Phlebotomy|phlebotomy associated with dietary and lifestyle counseling
88911878|NCT01572818|Active Comparator|Lifestyle counseling|dietary and lifestyle counseling
88911879|NCT01572831|No Intervention|standard care|Abx will be determined by the managing physician
88911880|NCT01572831|Experimental|experimental arm|Abx determined by normalization of PCT and basic clinical parameters
88911881|NCT01572857||first phase|"This first phase aims to study the variations in urinary excretion of FLC immunoglobulin during the day and night to determine the appropriate time of day for collection of urine.~20 patients hospitalized."
89432488|NCT03554811|Experimental|Functional electrical stimulation assisted supine cycling|Patients will start functional electrical stimulation assisted supine cycling (FESC) within 48 hours of ICU admission and will undergo up to 1 hour of supine cycling daily, 5 days per week for 28 days, or until discharge from ICU.
89432489|NCT03554811|Active Comparator|Conventional early exercise and mobility interventions|Patients will undergo standard ICU exercise and mobility interventions.
88911882|NCT01572857||Second phase|"Determination of creatinine in 24 hours by measuring the creatinine of 24 hours 3 days in a row. This value will check the quality of urine collection for 24 hours during the study.~30 patients hospitalized."
88911883|NCT01572870||No ABPA nor Aspergillus infection|CF patients who had neither ABPA nor Aspergillus infection in the past (the control group)
88911884|NCT01572870||persistent Aspergillus infection, without ABPA|CF patients with persistent Aspergillus infection, without ABPA.
88911885|NCT01572870||Current or past ABPA infection|CF patients with current or past ABPA
88911886|NCT01572896|Experimental|Taking Charge Experimental Group|
88911887|NCT01572896|Active Comparator|Control Group|
88911888|NCT01572961|Active Comparator|Aspirin|Aspirin
88911889|NCT01572961|Placebo Comparator|Placebo|Placebo
88911890|NCT01572974||No Barrett's esophagus|Subject without columnar lined esophagus
88911891|NCT01572974||Nondysplastic BE|Subject with columnar lined esophagus and absence of dysplasia
88911892|NCT01572974||Low grade dysplastic BE|subject with columnar lined esophagus and presence of low grade dysplasia
88911893|NCT01572974||High grade dysplastic BE|subject with columnar lined esophagus and presence of high grade dysplasia
88911894|NCT01572987|Active Comparator|RFA arm|Under this arm, study patients will undergo radiofrequency ablation.
89432490|NCT03554733|Experimental|Treatment|Re-Inventing Yourself after SCI protocol - 6-week educational sessions
89432491|NCT03554733|No Intervention|Control|No intervention during course of study; participants offered the option of receiving the study intervention after completion of study.
88911895|NCT01572987|Active Comparator|EMR arm|Under this arm, the individuals will undergo endoscopic mucosal resection.
88911896|NCT01573013|Active Comparator|NaFeEDTA treatment, biscuit|Group receives 10 mg of Fe in form of NaFeEDTA per day. wheat flour based biscuit
88911897|NCT01573013|Active Comparator|EDTA treatment, biscuit|Group receives Na2EDTA enriched biscuit
88911898|NCT01573013|Active Comparator|FeSO4 treatment, biscuit|Group receives 10 mg of iron as FeSo4 per day for 8 months
88911899|NCT01573013|Placebo Comparator|control treatment, biscuit|group receives a biscuit without additional iron
88911900|NCT01573065|Experimental|Single arm|
88911901|NCT01573078||Crohn's disease patient|Outpatients who carry a diagnosis of Crohn's disease made by a gastroenterologist.
89432492|NCT03553953||Patients with recording from BIS device|One hundred screened adult patients and no more than 60 valid cases who undergo elective surgery under general anesthesia with recording from the BIS device at the same time and comply with the inclusions criteria
88911902|NCT01573091||Heart failure patients|Patients with a CRT device according to current guidelines
88911903|NCT01573104|Experimental|Biomarker group|Patients undergoing CPB having proteomic assays, blood sampling and biomarker assays performed on D0, D1, D2 and D3
88911904|NCT01573117|Active Comparator|Cold infusions|Infusion of 2L cold crystalloid solution (4°C) over 30 minutes
88911905|NCT01573117|Active Comparator|RhinoChill|Nasopharyngeal cooling with the RhinoChill device (BeneChill, USA)
88911906|NCT01573130|Experimental|Initial treatment group|Group receives treatment.
88911907|NCT01573130|No Intervention|Waiting list control group|The waiting list control group receives treatment after 9 weeks, before which they do weekly ratings.
88911908|NCT01573143|Placebo Comparator|Sugar pill|Placebo
88911909|NCT01573143|Experimental|Rosuvastatin|Rosuvastatin (20 mg od)
88911910|NCT01573156|Experimental|VTP treatment to small renal mass|
88911911|NCT01573182|Experimental|Donor|VZV seropositive donors 50 years and over will receive vaccination with a live attenuated herpes zoster vaccine (Zostavax) by the intramuscular (IM) route 4 to 6 weeks prior to stem cell harvesting..
89432493|NCT02111655|Other|Clasical Surveillance of AVF|"Classical evaluation of AVF includes:~Vital sings and predialysis physical examination of AVF every dialysis session.~Effective blood flow, venous pressure, arterial pressure, at the beginning and at the end of the dialysis session.~Weekly ktv test using biosensors or monthly if using monocompartimental Daugirdas equation.~Quarterly recirculation with urea method.~Following Spanish Nephrology VA guidelines will be consider as alarm criteria:~1.25% Increased venous pressure. 2.25% Decreased pump blood flow. 3.0,2 ktv decreased compared with previous measurement. 4.> 10% recirculation using urea method. 5.Prolonged coagulation time or cannulation difficulties in 3 consecutive dialysis sessions.~6.Pathologic physical examination with any other criteria."
89432494|NCT02111655|Experimental|Second generation surveillance of AVF|"In addition to the classical surveillance and monitoring methods, in the experimental group Doppler ultrasound and transonic dilution method will be performed on a quarterly basis.~In addition to the classical alarm criteria and derived from the results in Doppler ultrasound an transonic dilution method the following alarm criteria would also be considered in the experimental group:~25% or higher decreased in QA compared with previous measurement.~QA lower than 500 ml/min.~Stenotic area with a higher than 50% reduction of blood vessel lumen would be considered as alarm criteria only if it comes with a haemodynamic repercussion criteria defined as Peak systolic velocity (PSV) higher than 400 cm/sc, aliasing, or PSV ratio stenosis/pre-stenosis higher than 3."
89432495|NCT02108145|Active Comparator|unilateral metal stent insertion|unilateral metal stent insertion was performed either left or right hepatic lobe as can be drainage more liver volume
88911912|NCT01573195||All prescribing MDs at UWHC|Observational for accept, reject, or accept with modification of Best Practice Alers
88911913|NCT01573221||stroke|
88911914|NCT01573234|Experimental|MySkin patch|Hydrogel and polyurethane film
88911915|NCT01573234|Active Comparator|Traditional Dressing|
88911916|NCT01573247|Experimental|AKN-028|
88911917|NCT01573286|Experimental|Intestinal Failure in children (>1 year)|Children requiring parenteral nutrition for >30% of calories more than 1 year (365) days post surgery will be eligible for treatment with Glucagon-like peptide 2 (20 ug/kg/day) for 6 weeks
88911918|NCT01573286|Experimental|GLP-2 in Infants (<1 year of age)|Infants under one year of age with congenital anomalies, or intestinal resection, leaving them with anatomic short bowel syndrome (total remaining small intestine less than 40 % of predicted for gestational age) or with intestinal resection or repaired gastroschisis who have demonstrated dependence on parenteral nutrition at 45 days post operation with the requirement for >50% of calories by PN (independent of the length of remnant small intestine) will be eligible for treatment with Glucagon-like peptide 2, at a dose of 5, 10 or 20 ug/kg/day.
88911919|NCT01573299|Active Comparator|Early vertical positioning|
88911920|NCT01573299|Active Comparator|Progressively vertical positioning|
89432496|NCT02108145|Experimental|bilateral metal stent insertion|percutaneous transhepatic biliary drainage plus bilateral metal stent.The bare stents were used for PTBS
89432497|NCT02113683||MMS test|therapy monitoring of patients with colo-rectal or stomach disease or with melanoma
89432498|NCT02111733|Experimental|Hs-TnT|Hs-TNT dosage
88911921|NCT01573312|Experimental|Inactivated monovalent influenza A/H5N1 with ASO3 adjuvant|Ten subjects will be vaccinated with 3.75 micrograms(mcg) of H5N1 hemagglutinin plus AS03 given intramuscularly in two doses 28 days apart.
88911922|NCT01573312|Experimental|Inactivated monovalent influenza A/H5N1 without ASO3 adjuvant|Ten subjects will be vaccinated with 3.75 mcg of H5N1 hemagglutinin alone, given intramuscularly, in two doses 28 days apart.
88911923|NCT01573338|Experimental|Arm 1|BAY1000394 will be administered in combination with chemotherapy (etoposide and cisplatin or carboplatin) for up to 6 cycles. BAY1000394 will continue beyond Cycle 6 of chemotherapy. Type of chemotherapy for each patient will be decided by the investigator case by case.
89432499|NCT02108301|Experimental|tacrolimus-cyclosporine A|conversion of immunosuppression from tacrolimus to cyclosporine A in hepatitis C-positive renal transplant recipients
89432500|NCT02111889|Experimental|one|
89432501|NCT02113839|Active Comparator|No frequent exacerbators|"Patients without exacerbations: 0 or 1 that did not required hospitalization in the previous year.~Interventions:~Spirometry~Emogas analysis~Modified Borg Dyspnea Scale~CO Exhaled breath~P01~FeNO"
89432502|NCT02113839|Active Comparator|Frequent exacerbators|"Patients with frequent exacerbations: ≥2 or ≥1 if it required hospitalization in the previous year.~Interventions:~Spirometry~Emogas analysis~Modified Borg Dyspnea Scale~CO Exhaled breath~P01~FeNO"
89432503|NCT02111967||Diabetes mellitus type 2, Metformin|The case group consists of patients with diagnosed diabetes mellitus type 2 treated with Metformin.
89432504|NCT02111967||Diabetes mellitus type 2|The control group consists of patients with diagnosed diabetes mellitus type 2 which do not have metformin treatment
89432505|NCT02113995|Active Comparator|ACERTO|"Patients received 400 ml of a beverage containing water and 50 g of maltodextrin 6 hours before the operation. They received orally extra 200 ml of this beverage containing water and 25 g of maltodextrin 3 hours before the operation. Regarding the intravenous fluids, they received 1 to 1.5 liter of crystalloid fluids (ringer lactate) in the intraoperative. In the immediate postoperative they were programmed to receive 2 liters of crystalloid fluids (ringer lactate) and 1 to 2 liters in the first day of the postoperative period. The venous hydration was suspended as soon as they started to drink liquids.~Prophylaxis of nausea and vomiting with dexamethasone 8 mg at the beginning of the anesthesia and ondansetron 4-8 mg after the surgery. In the postoperative period we utilized analgesics such as dipyrone and ketorolac and, if necessary, low doses of morphine and antiemetics like ondansetron."
89197706|NCT00943462||Glioblastoma Multiforme (GBM)|We will conduct a prospective study on 20 consecutive patients who are seen at the Hôpital Notre-Dame neuro-oncology clinic for a diagnosis of GBM and who meet our inclusion criteria. We will meet with the eligible patients in order to provide them with a detailed description of the study procedures as well as to have them sign a consent form.
89197707|NCT02560974|Experimental|Capecitabine + Oxaliplatin|Patients will receive oral capecitabine (1000 mg/m^2 BID on Days 1 to 15 ) plus IV oxaliplatin (130 mg/m^2 on Day 1) during each 3-week cycle for up to 8 cycles (6 months).
89197708|NCT02560974|No Intervention|Observation|Participants will not receive any treatment but will be seen regularly by a physician.
89197709|NCT00861159||1|
89197710|NCT00946894|Experimental|Total thyroidectomy|Patients who underwent total thyroidectomy
89197711|NCT00946894|Experimental|Dunhill operation|Patients who underwent unilateral total thyroid lobectomy and contralateral subtotal thyroid lobectomy
89197712|NCT00946894|Active Comparator|Bilateral subtotal thyroidectomy|Patients who underwent bilateral subtotal thyroidectomy
89197713|NCT00854451|Active Comparator|1 omeprazole plus amoxicillin|omeprazole 20mg bid 2wk + amoxicillin 500mg qid 2wk
89197714|NCT00854451|Active Comparator|2 omeprazole plus amoxicillin|omeprazole 20mg bid 2wk + amoxicillin 250mg qid 2wk
89197715|NCT00854451|Active Comparator|3 omeprazole plus amoxicillin|omeprazole 20mg qd 2wk + amoxicillin 500mg qid 2wk
89197716|NCT00854451|Active Comparator|4 omeprazole plus amoxicillin|omeprazole 20mg qd 2wk + amoxicillin 250mg qid 2wk
89197717|NCT00854529|Experimental|1|20 patients who had an uneventful trabeculectomy with usage of mitomycin C, will receive subconjunctival bevacizumab 1 week after the surgery
89197718|NCT00854529|Active Comparator|2|20 patients who had an uneventful trabeculectomy with usage of mitomycin C, will receive subconjunctival bevacizumab 2 weeks after the surgery
89197719|NCT00854529|No Intervention|3|20 patients after an uneventful trabeculectomy with usage of mitomycin C, will not receive any bevacizumab injection.
89197720|NCT00947050|Active Comparator|rest first|rest first, cfi, exercise, cfi
89197721|NCT00947050|Active Comparator|exercise first|ex first
89009023|NCT03453424|Active Comparator|TEA group|"Intraoperative,thoracic epidural injection of bupivacaine (0.125%+fentanyl 5 mic/ml ) ,initial bolus dose of 8 ml before skin incision followed by fixed rate infusion of 6 ml/h till start of abdominal layer closure.~Postoperative, thoracic epidural injection of (bupivacaine 0.0625%+fentanyl 2 mic /ml) at infusion rate 6 ml /h and bolus dose of 3 ml with lockout time 10 min"
89009024|NCT00225641|Active Comparator|1 frequent control|Follow-up 6, 12, 18, 24 and 36 months after surgery
89009025|NCT00225641|Other|2 less frequent control|Follow-up 12 and 36 months after surgery
89009026|NCT00235131|Experimental|1|Cordis S.M.A.R.T.™ CONTROL™ Nitinol Stent System
89009027|NCT00235131|Active Comparator|2|Bard® Luminexx™ 6F Vascular Stent
89432506|NCT02113995|Active Comparator|Traditional care|"The analgesia in the postoperative period of the group control was performed with dipyrone, tramadol hydrochloride, and morphine. The prophylaxis of nausea and vomiting with dexamethasone 8 mg in the beginning of the anesthesia and the metoclopramide at the end of the surgery. During the anesthetic induction antibiotic prophylaxis (cefazolin 3 grams/day for 2 days) was administrated.~The control group were submitted to the protocol of traditional fasting with at least 8 hours. Patients in this group received 1 to 2 liters of crystalloid fluid (ringer lactate) in the intraoperative, and they received 3 to 4 liters of crystalloid fluids (ringer lactate, saline 0.9% and/or dextrose 5%). In the immediate postoperative, 2 to 3 liters in the first day of postoperative and, finally, 1 to 2 liters in the second day of the postoperative."
89432507|NCT02108379|Experimental|Rhinix Nasal Filters|All included will receive rhinix nasal filters
89432508|NCT02112123|Placebo Comparator|Placebo|Matching placebo given for 5 days (qd po)
89432509|NCT02112123|Active Comparator|Icariin - 100 mg/day|Icariin given at 100 mg/day (qd po) for 5 days
89432510|NCT02112123|Active Comparator|Icariin - 200 mg/day|Icariin given at 200 mg/day (qd po) for 5 days
89432511|NCT02112123|Active Comparator|Icariin - 400 mg/day|Icariin given at 400 mg/day (qd po) for 5 days
89432512|NCT02112123|Active Comparator|Icariin - 840 mg/day|Icariin given at 840 mg/day (qd po) for 5 days
89432513|NCT02112123|Active Comparator|Icariin - 1680 mg/day|Icariin given at 1680 mg/day (qd po) for 5 days
89432514|NCT02108535|Experimental|Nanocrystalline silver|Flexible polyester low-grip coated nanocrystalline silver dressing. The dressing was applied to the lesion after being soaked in sterile distilled water. About this compresses to bandage movements will have been added and comes to avoid tourniquet bandage on-site maintenance, temperature of the affected area, cushioning and absorption of wound exudate when present. Is finished with the application of crepe bandages in the form of flakes containment curative and maintenance of pressure. This procedure aids in the bloodstream, and avoids the increased edema. The bandage is started from the periphery to the central region, avoiding tourniquet. The exchanges were performed every three days.
89432515|NCT02108535|Active Comparator|Silver sulfadiazine|Ranges for rayon containing cream 1% silver sulfadiazine were used. Involving this layer, bandages for dressings were added in movements back and forth to avoid the tourniquet, providing maintenance of the temperature of the affected area, cushioning and absorption of wound exudate when present. This application was completed with crepe bandages to contain the dressing and maintain pressure. This procedure aids in the bloodstream, and avoids the increased edema. The bandage is started from the periphery to the central region, scales, avoiding the tourniquet. Dressing changes were performed daily.
89432516|NCT02108613|Experimental|Intervention|The intervention arm will receive sexual health counselling, exercise sessions, nutrition education, and will be assigned a peer support volunteer.
89009028|NCT03453346|Experimental|Noncirrhotic and cirrhotic GT-2|Generic sofosbuvir tablet 400 mg once daily plus weight-adjusted ribavirin tablet (1000 mg for <75 kg, and 1200 mg for >=75 kg) twice daily with meal, orally given, for 12 successive weeks
89009029|NCT00575068|Experimental|1|
89009030|NCT00575107|Experimental|VSC-VLC|velocity-controlled variable resistance, lengthening contraction
89009031|NCT00575107|Active Comparator|SC|Constant weight shortening contraction
89009032|NCT00575224|Other|A|Pegylated interferon and ribavirin for 24 weeks
89009033|NCT00575224|Other|B|Pegylated interferon and ribavirin for 48 weeks
89009034|NCT00235170|Experimental|1|Cypher Sirolimus-eluting Coronary stent
89432517|NCT02108613|No Intervention|Control|The control group will receive sexual health counseling.
89432518|NCT02114073|Experimental|Cyclosporine|In the first postoperative day following a standard, fornix-based trabeculectomy, ophthalmic emulsion of Cyclosporine A, 2%, every 4 hours for the first postoperative week and every 6 hours for the next 3 weeks will be prescribed for the patients.
89432519|NCT02114073|Active Comparator|Betamethasone|In the first postoperative day following a standard, fornix-based trabeculectomy, betamethasone eye drop, every 4 hours for the first postoperative week and every 6 hours for the next 3 weeks will be prescribed for the patients.
89432520|NCT03553407|Experimental|Low Level Laser - Pulse|In this group the patient will receive the following laser protocol: 880nm, 30mW, 3.6 J / cm², 25 Hz
89432521|NCT03553407|Experimental|Low Level Laser - continuous|In this group the patient will receive the following laser protocol: 880nm, 30mW, 3.6 J / cm²
89432522|NCT03553407|Placebo Comparator|Low Level Laser - Placebo|In this group the patient will receive the protocol with the equipment turned off.
89432523|NCT02114463|Experimental|Local analgesic|This group uses local analgesia infusion pump of 0.2% ropivacaine 360ml through periarticular infiltration for postoperative analgesia.
89009035|NCT00575263||Normal Teeth|Normal molar teeth
89009036|NCT00575263||painful teeth|Painful molar teeth
89009037|NCT03453307||Group-1|NSCLC patients receiving chemotherapy or target therapy treatment.
89009038|NCT00590941|No Intervention|R-CHOP|Patients receiving R-CHOP via standard of care which consists of cyclophosphamide 750 mg/m2 IV day 1 of each 21 day cycle, doxorubicin 50 mg/m2 IV day 1 of each 21 day cycle, vincristine 1.4 mg/m2 IV day 1 of each 21 day cycle, prednisone 100 mg PO days 1-5 of each 21 day cycle, and rituximab 375 mg/m2 IV day 1 of each 21 day cycle.
89009039|NCT00591058|Experimental|Cohort 1|0.04 mg/kg TM-601 dose per administration
89009040|NCT00591058|Experimental|Cohort 2|0.08 mg/kg TM-601 dose per administration
89009041|NCT00591058|Experimental|Cohort 3|0.16 mg/kg TM-601 dose per administration
89432524|NCT02114463|Active Comparator|Intravenous analgesic|This group is treated with intravenous electronic analgesia pump infusion of flurbiprofen axetil 250mg,palonosetron 0.5mg,pentazocine 240mg.dezocine 30mg.
89432525|NCT02112201|Experimental|Integrated intervention for parents and adolescent girls|Twelve session parent education and support group; twelve session one-on-one adolescent skills training intervention
89432526|NCT02112201|No Intervention|Treatment as usual|Treatment as usual
89432527|NCT02114619|Active Comparator|Low dose of I-131|Patients with Graves' disease who will be treated with I-131, using 100 microcurie per gram (uCi/gr) of thyroid weight
89432528|NCT02114619|Active Comparator|Intermediate dose|Patients with Graves' disease who will be treated with 150 microcurie (uCi) of I-131 per gram of thyroid weight.
89432529|NCT02114619|Active Comparator|High dose|Patients with Graves' disease who will be treated with I-131 using 200 uCi/gr of thyroid weight.
89432530|NCT02112279|Experimental|Microbiota Transplant|Close relative or purchased donor microbiota transplant will be administered via colonoscopy; Donor microbiota applied via colonoscopy
89432531|NCT02114697|Active Comparator|Lifestyle modification|Lifestyle modification is tailored to each participant and includes a recommended exercise regimen, a healthy diet and decreasing alcohol intake.
89432532|NCT02114697|Experimental|Statin therapy|Participants will receive statin medication along with instruction about regular exercise.
89432533|NCT02251197|Experimental|BIII 890 CL|escalating doses
89432534|NCT02251197|Placebo Comparator|Placebo|
89432535|NCT02112357||Targeted genetic sequencing of tumour specimen|
89432536|NCT02112435|Active Comparator|Narval ORM ® or SomnoDent ®|Mandibular advancement splint (Narval ORM ® or SomnoDent ®)
88911924|NCT01573377|Experimental|metformin|425mg bid for morning and evening after meals, one week after treatment, increase the dosage to 850 mg bid. If the patients have side effects such as nausea, diarrhea and other gastrointestinal symptoms, the dose would be reduced to 425mg bid for 1 week, and try the dosage to 425mg tid again, until the maximum tolerated dose.
88911925|NCT01573377|Experimental|Ethinylestradiol and Cyproterone Acetate|From the first day of the menstruation, oral administration of one pill daily for 21 days consecutively, then discontinue using the pill for seven days, and on the eighth day, restart taking the pill.
89432537|NCT02112435|Experimental|Somnyx ®|Active mandibular advancement splint (Somnyx ®)
89432538|NCT02108769|Experimental|Yogic Breathing|"Chanting Om~Sharp deep inhalation through nostrils~Slow exhalation through mouth while chanting Om. At this step the subjects will perform a slow and complete exhalation.~Repeat for 10 min. During the whole period of chanting, the subjects keep their eyes closed.~Yogic Breathing:~Check which of the two nostrils exhibit free flow of air. For the explanation purpose the nostril with free flow of air is treated as Nostril 1 and the other one as Nostril 2.~Close Nostril 2 and inhale a sharp deep breath through Nostril 1 and then close both the nostrils so no inhaled air escapes. Air should not escape through mouth either. This inhalation step should take about 4 seconds.~Hold breath in this position for about 16 seconds.~Open Nostril 2 and exhale for about 8 seconds. Complete exhalation is required. Abdomen will slowly curve-in as the subject exhales. This is normal and encouraged. No air should leak through the Nostril 1 or mouth.~Go to step a)."
89432539|NCT02108769|Active Comparator|Attention Control|The participants will read a text of their choice for 20 minutes.
89432540|NCT02114775|Active Comparator|Recombinant Growth Hormone|Double blind placebo/Genotropin cross over design for 6 months with cross over at 3 months. Then open label Genotropin from month 6 - 12.
89432541|NCT02114775|Active Comparator|Sildenafil|Double blinded placebo/Sildenafil crossover design for 6 months with crossover at month 3. Then open label Sildenafil from months 6-12.
89432542|NCT02108847|Experimental|Fascia Iliaca Block - Ropivacaine|Ultrasound guided fascia iliaca block performed preoperatively with 40 mL of 0.2% ropivacaine.
89432543|NCT02108847|Sham Comparator|Fascia Iliaca Block - Saline|Ultrasound guided fascia iliaca block performed preoperatively with 40 mL of Saline.
89432544|NCT02251353||lung and/or hepatic metastasis|intervention to metastasis (resection and/or radiofrequency ablation (RFA), transcatheter arterial chemoembolization (TACE), cyberKnife stereotactic radio surgery) vs no intervention (only systemic treatment)
89432545|NCT02108925|Experimental|Supplementary oxygen|Study subjects receive, in randomized order, either supplementary 30% oxygen or air (21% Oxygen) from a gas tight bag
89432546|NCT02109003|Experimental|Continuous control of Pcuff followed by manual control|Patients receive continuous control of cuff pressure with Pressure easy® device for 24h, followed by discontinuous control (every 4 hours) with a manual manometer for 24 h.
89432547|NCT02109003|Active Comparator|Manual control of Pcuff followed by continuous control.|Patients receive the reverse sequence (manual control followed by continuous control of Pcuff)
88911926|NCT01573403|Experimental|Treatment 1|one dose of DLBS2411 @250 mg
88911927|NCT01573403|Experimental|Treatment II|two doses of DLBS2411 @250 mg
88911928|NCT01573403|Placebo Comparator|Treatment III|
88911929|NCT01573416|Placebo Comparator|Control group|
88911930|NCT01573416|Active Comparator|Intervention group|
88911931|NCT01573468|Experimental|Capecitabine-tesetaxel|21-day cycle; tesetaxel 27 mg/m2 orally once on Day 1; capecitabine 1750 mg/m2/day orally in 2 equally divided doses on Days 1-14
88911932|NCT01573468|Active Comparator|Capecitabine-placebo|21-day cycle; placebo orally once on Day 1; capecitabine 1750 mg/m2/day orally in 2 equally divided doses on Days 1-14
88911933|NCT01573481|Active Comparator|Pressure support ventilation|"Patients in this group are ventilated during the night (10 PM to 9 AM) with pressure support ventilation mode. The level of the pressure support is the same as the previous day.~During the day (9 AM to 10 PM), patients are ventilated with pressure support ventilation (the level of pressure support is progressively decreased)."
88911934|NCT01573481|Active Comparator|Pressure controlled ventilation|Patients in this group are ventilated during the night (10 PM to 9 AM) with pressure controlled ventilation mode. The level of inspiratory pressure is set to 20 cm H2O and the respiratory rate is adjusted to avoid any spontaneous breathing (respiratory rate > or equal to 12 breath per min). During the day (9 AM to 10 PM), patients are ventilated with pressure support ventilation (the level of pressure support is progressively decreased).
89432548|NCT02112513||salivary estriol measurement|Serum Estriol measurement via different assays is complex, expensive, labor intensive, time consuming, and generally performed at specific reference labs. Salivary Estriol level is an ideal potential surrogate for serum Estriol. It is convenient, non-invasive, and expedient. It may not, however, be as sensitive as serum estriol concentrations at detecting the association with glucocorticoid response. This study will collect both samples to determine which one is better suited for clinical use in this condition.
89432549|NCT02112513||serum estriol measure|we will determine if changes in maternal serum estriol represent a biomarker of response to antenatal corticosteroids as evidenced by neonatal development of RDS
89432550|NCT02112513||Betamethasone pharmacokinetic|we will determine if pharmacokinetic parameters and neonatal outcomes after antenatal corticosteroid use are associated with genetic polymorphisms in drug metabolizing enzymes, transporters, and steroid pathway genes
89432551|NCT02112513||betamethasone concentration and genetics|we will determine if maternal betamethasone concentrations and genetics are associated with maternal estriol changes or RDS development
89432552|NCT02112591|Active Comparator|Transobturator suburethral tape (TOT)|transobturator approaches for the placement in mid-urethral position of polypropylene tape that is 1.5cm wide
89432553|NCT02112591|Experimental|S-TOT|transobturator subtrigonal tape: S-TOT
88911935|NCT01573494|Experimental|Metastatic melanoma patients|Sampling of blood before and after chemotherapy
89432554|NCT02115087|Experimental|ultrasound guided rectus sheath block|Ultrasound guided rectus sheath block
89432555|NCT02115087|Active Comparator|iv morphine|0.1 mg.kg-1 loading dose of morphine by intravenous route in intraoperative period
89432556|NCT02115165|Experimental|Cabazitaxel|
88911936|NCT01573507|Experimental|sodium lactate infusion|Continuous i.v. infusion of Sodium Lactate (2'400 mOsmol/L) over 3 hours
88911937|NCT01573520|No Intervention|usual care|
88911938|NCT01573520|Active Comparator|adherence intervention arm|Monitoring drug adherence to guide treatment
88911939|NCT01573546|Experimental|Aerobic Exercise|
88911940|NCT01573546|Experimental|DASH diet|
88911941|NCT01573546|Experimental|Combined aerobic exercise and DASH diet|
89432557|NCT02115243|Other|Ipi/ILI|Patients will receive ipilimumab followed by ILI.
89432558|NCT02109237|Experimental|Bronchiolitis Obliterans 2 & 3|Assessment of sleep disorders and treatment if required
89432559|NCT02109237|Active Comparator|Bronchiolitis Obliterans 0|Assessment of sleep disorders and treatment if required
89432560|NCT03004053||Volunteers will be identified by the Head and Neck Service|25 volunteers (Part I - 8 volunteers. Part II - 17 volunteers). during the course of 12 months. The volunteers will be imaged with the endoscope, and the images will be evaluated visually and with qualitative (descriptive) statistics.
89432561|NCT02109315|Experimental|Liraglutide endovenous 6 mg|Liraglutide endovenous de 0.6 mg. one time a day
88911942|NCT01573546|Active Comparator|Health education control|
88911943|NCT01573559||ClearView/Predicate|
88911944|NCT01573585|Active Comparator|Usual care|The usual care will consist of strength training, endurance, range of motion, patient education, weight shifting in standing and gait re-training.
88911945|NCT01573585|Experimental|FAST protocol|The Fast muscle activation and stepping training will be the Experimental arm of this trial. This program will be exercises emphasizing speed of movement.
89432562|NCT02109315|Experimental|Vitamine C|C Vitamine endovenous 1000 mg/5 ml. Infusion dose: 30 mgr/min
88911946|NCT01573598|Placebo Comparator|Placebo|Dose-matched placebo capsules, oral administration
88911947|NCT01573598|Experimental|Vilazodone 20mg|Vilazodone tablets, 20 mg per day, oral administration
88911948|NCT01573598|Experimental|Vilazodone 40mg|Vilazodone tablets, 40 mg per day, oral administration
88911949|NCT01573611|Experimental|Grape Powder|
88911950|NCT01573611|Placebo Comparator|Placebo Powder|
88911951|NCT01573637|Experimental|Raloxifene hydrochloride 60 mg|"Patients fulfilling inclusion criteria and those giving the general informed consent for the study will be randomly allocated to one of the two groups in the trial (placebo or raloxifene) in a 1:1 proportion and in blocks of 4 patients, using the random number tables designed for this purpose.~The dose of raloxifene hydrochloride administered will be 60 mg/day. Both placebo and the raloxifene will be administered over 6 months. Patients will take one single daily dose administered in the morning. Both drugs will be given orally in capsule form. The medication of each of the treatment groups (lactose as placebo, raloxifene) will be introduced into dark green gelatin capsules to guarantee the blinding."
88911952|NCT01573637|Placebo Comparator|Lactosa (placebo)|"Patients fulfilling inclusion criteria and those giving the general informed consent for the study will be randomly allocated to one of the two groups in the trial (placebo or raloxifene) in a 1:1 proportion and in blocks of 4 patients, using the random number tables designed for this purpose.~The dose of raloxifene hydrochloride administered will be 60 mg/day. Both placebo and the raloxifene will be administered over 6 months. Patients will take one single daily dose administered in the morning. Both drugs will be given orally in capsule form. The medication of each of the treatment groups (lactose as placebo, raloxifene) will be introduced into dark green gelatin capsules to guarantee the blinding."
88911953|NCT01573663|Experimental|Ambroxol and Levodropropizine|
88911954|NCT01573663|Active Comparator|Ambroxol|
88911955|NCT01573663|Active Comparator|Levodropropizine|
88911956|NCT01573676||Bariatric surgery patients|Candidates for bariatric surgery.
88911957|NCT01573715|Active Comparator|severe ARDS patients|
88911958|NCT01573715|Active Comparator|control group|
88911959|NCT01573715|Experimental|moderate SDRA patients|
88911960|NCT01573728|Active Comparator|Low Exercise Arm|Low dose exercise (50 Minutes)
88911961|NCT01573728|Experimental|Public Health Exercise|Public Health dose exercise (150 minutes)
88911962|NCT01573741|Experimental|ketamine,four hours monitoring hydrochloride injection|a single infusion of ketamine hydrochloride (0.5 mg/kg) infused over 40 minutes
88911963|NCT01573793|Active Comparator|Intervention|Will receive parenting educational materials hypothesized to enhance emotional and cognitive development
88911964|NCT01573793|Sham Comparator|Control|Will receive safety and dental hygiene materials that have no bearing on emotional and cognitive development
88911965|NCT01573806|Active Comparator|Exenatide|Subjects dosed with exenatide in Phase 2
88911966|NCT01573806|Placebo Comparator|Exenatide vehicle|Subjects dosed with exenatide vehicle in Phase 2
89432563|NCT02112669|Experimental|AV fistula with VasQ|Implant VasQ over AV fistula
89432564|NCT02112669|No Intervention|AV fistula|AV fistula without any adjunct device
89432565|NCT02115399||ADStaph-|Atopic Dermatitis without a history of Eczema Herpeticum and without S. aureus skin colonization. A minimum of 45 participants will be enrolled in this group.
89432566|NCT02115399||ADStaph+|Atopic Dermatitis without a history of Eczema Herpeticum and with S. aureus skin colonization. A minimum of 45 participants will be enrolled in this group.
88911967|NCT01573819|Experimental|Cohort 1|A dose of 2mg per day for 10 days
88911968|NCT01573819|Experimental|Cohort 2|A dose of Xmg for 14 days. the dose will be determined from Cohort 1 not to exceed 14 mg
88911969|NCT01573819|Experimental|Cohort 3|a single dose of Ymg with a wash out of 7 days followed by 28 days of repeat dosing. The dose (Ymg) will be determined from cohort 1 and 2 not to exceed 14 mg.
88911970|NCT01573832|Experimental|Diabetic Foot Ulcer Intervention|
88911971|NCT01573832|No Intervention|Diabetic Foot Ulcer Usual Care|
88911972|NCT01573832|Experimental|Pionidal Sinus Ulcer Intervention|
88911973|NCT01573832|No Intervention|Pionidal Sinus Ulcer Usual Care|
88911974|NCT01573845|Experimental|Healthy Eating + Eco-Friendly Campaign|
88911975|NCT01573845|Active Comparator|Healthy Eating Campaign|
88911976|NCT01573845|No Intervention|Control/Delayed Intervention|
88911977|NCT01573858|Experimental|Acupuncture treatment 1 plus CC|
88911978|NCT01573858|Active Comparator|Acupuncture treatment 2 plus CC|
88911979|NCT01573858|Active Comparator|Acupuncture treatment 1 plus CC placebo|
88911980|NCT01573858|Active Comparator|Acupucture treatment 2 and CC placebo.|
88911981|NCT01573871|Experimental|Hydrolyzed infant formula|Hydrolyzed infant formula to be fed ad libitum
88911982|NCT01573897||Foot-wound without SAS|patients with diabetic foot wound(or at risk of diabetic foot wound) without sleep apnea syndrome
88911983|NCT01573897||Foot-wound with SAS|patients with diabetic foot wound(or at risk of diabetic foot wound) with sleep apnea syndrome
88911984|NCT01573923|Sham Comparator|Conventional therapy|only apply for conventional medical therapy without any cell therapy
88911985|NCT01573923|Active Comparator|mesenchymal stem cells|combination of conventional therapy with umbilical mesenchymal stem cells intravenous injection, (4x107/40ml, once per three months, four times in one year)
88911986|NCT01573936|Experimental|rehabilitation program|Rehabilitation program from January 2008 through July 2010, which consists of 40-minutes of many therapies for 1-2 days a week
88911987|NCT01573975|Experimental|Seq-Metronidazole|10-day sequential therapy with metronidazole
88911988|NCT01573975|Experimental|Seq-Tetracycline|10-day sequential therapy with tetracycline.
88911989|NCT01573975|Active Comparator|Control|10-day standard triple therapy.
88911990|NCT01573988|Other|non-obese volunteers|Volunteers with a BMI (Body Mass Index) between 20 and 25 kg/m2.
88911991|NCT01573988|Other|Obese volunteers|Volunteers with a BMI (Body Mass Index) between 30 and 35 kg/m2.
89009042|NCT00591058|Experimental|Cohort 4|0.3 mg/kg TM-601 dose per administration
89009043|NCT00591058|Experimental|Cohort 5|0.6 mg/kg TM-601 dose per administration
88911992|NCT01574001|Experimental|Antismoking intervention with minimal early follow-up|"an intervention according to the 5A's model with one follow-up visit within one week after discharge from the hospital; follow-up assessment will include two visits: 3 and 12 months after stroke"
88911993|NCT01574001|Active Comparator|Antismoking intervention with no early follow-up|"an anti-smoking intervention in line with the 5A's method without early follow-up; follow-up assessment will be limited to two visits: 3 and 12 months after stroke"
88911994|NCT01574001|Experimental|Antismoking intervention with intensive early follow-up|"an anti-smoking intervention in line with the 5A's method will be given, including four follow-up visits within 6 weeks after discharge from the hospital (week 1, week 2, week 4, week 6 after stroke); follow-up assessment will include two visits: 3 and 12 months after stroke"
88911995|NCT01574014|Active Comparator|1: CBGT & Hydrocortisone|
88911996|NCT01574014|Placebo Comparator|2: CBGT & Placebo|
88911997|NCT01574027|Placebo Comparator|Placebo|Some participants were given a placebo pill to take daily for the length of the study. The placebo patients were used as a control group to compare against those taking the Vitamin D supplement.
88911998|NCT01574027|Experimental|Vitamin D3 (cholecalciferol)|Other participants were administered Vitamin D3 (cholecalciferol) for the six month study duration to determine if it would decrease the number of aberrant crypt foci in the colon as compared to the baseline number.
88911999|NCT01574040|Experimental|Staff (and visitors) of the University Medical Centre Utrecht|This is a dynamic study population
88912000|NCT01574066|Experimental|Chest CT-scan|Patients with a suspicion of acquired pneumonia visiting the emergency department will do a chest CT-scan
88912001|NCT01574092|Experimental|Irinotecan plus Cisplatin combination|This is a open-label study with only one treatment experimental arm. The patients will be treated, in a weekly basis, with 30 mg/m2 of cisplatino plus 65 mg/m2 of irinotecán (one cycle), until a total of 16 cycles.
88912002|NCT01574131|Placebo Comparator|Sugar pill|pill
88912003|NCT01574131|Active Comparator|Fenofibrate|ppar-alpha agonist
88912004|NCT01574196||Young adult survivors of childhood cancer|Young adult survivors of childhood cancer diagnosed between 1987 and 1992 in the Rhône-Alpes and Auvergne regions of France.
88912005|NCT01574209||Celiac Disease|Patients suffering from coeliac diseases confirmed by small intestinal biopsy
88912006|NCT01574209||IBS patients|Patients suffering from irritable bowel syndrome (IBS) according to Rome III criteria
88912007|NCT01574209||Healthy subjects|Healthy subjects as control group
88912008|NCT01574222|Experimental|Arm 1|Eligible patients will be assigned to a cohort and will receive intratumoral injections of Ad-CCL21-DC in conjunction with tumor sampling
88912009|NCT01574235||Curative or prophylactic Nivestim® treatment for FN|
88912010|NCT01574261|Active Comparator|Inositol|Patients will be randomized to receive Inositol 4 g/die per os for four months of treatment
88912011|NCT01574261|Placebo Comparator|Placebo|Patients will be randomized to receive placebo for four months
88912012|NCT01574300||Biospecimens and biofluids|"This is a multi-cohort parallel study in which tumor, plasma and serum samples will be collected prior to the start of any therapeutic intervention for stage IV lung cancer. These biospecimens will be correlated with treatment and clinical data and distributed for peer reviewed research purposes to academic and community centers in the U.S. and Europe.~The biospecimens collected in CASTLE will be analyzed for a panel of biomarkers, currently including:~tumor: epidermal growth factor receptor (EGFR), KRAS (Kirsten RAt Sarcoma) gene and EML4-ALK (echinoderm microtubule-associated protein-like 4 - anaplastic lymphoma kinase) translocations, and EGFR, TS (thymidylate synthase), ERCC1 (excision repair cross-complementing 1) and RRM1 (Ribonucleotide Reductase, M1 Subunit) gene expressions~serum: proteomics predictive for EGFR-TKI (tyrosine kinase inhibotors)response"
88912013|NCT01574313|Experimental|Stellate ganglion block|treated with SGB
88912014|NCT01574313|Active Comparator|Oral medication|treated with oral medications: 0.25mg of erispan@ (fludiazine) , 25mg cephadol@ (diphenidol), and 200mg kentons@ (tocopherol nicotinate).
88912015|NCT01574339|Experimental|Treatment Arm|
88912016|NCT01574365|Experimental|RTA402|
88912017|NCT01574365|Experimental|RTA402 Low|
88912018|NCT01574365|Experimental|RTA402 Medium-low|
88912019|NCT01574365|Experimental|RTA402 Medium-high|
88912020|NCT01574378|Active Comparator|Control arm|Control arm- conventional method of wound closure
88912021|NCT01574378|Experimental|V-Loc group|V-Loc 90 barbed sutures
88912022|NCT01574391|Active Comparator|EPIDRUM|EPIDRUM DEVICE IS USED TO SITE THE EPIDURALS IN THE PATIENTS RANDOMISED TO THIS ARM
88912023|NCT01574391|No Intervention|Control|This arm is the control where normal technique is used
88912024|NCT01574404|Experimental|Polar Body Biopsy with PGS|Polar Body Biopsy with Pre implantation genetic screening
88912025|NCT01574417|Experimental|Plant stanol-enriched margarine|
88912026|NCT01574417|Placebo Comparator|control margarine|
88912027|NCT01574430|Active Comparator|50% dose PDT|patients in this group was given 50% verteporfin dose PDT
88912028|NCT01574430|Experimental|30% dose PDT|patients in this group was given 30% verteporfin dose PDT
88912029|NCT01574443||epilepsy resection patients|Patients undergoing resection for refractory epilepsy
88912030|NCT01574456||7 patients diagnosed with dementia of the Alzheimer's type|
88912031|NCT01574456||13 patients with mild cognitive impairment|
88912032|NCT01574456||19 healthy controls|
88912033|NCT01574469|Active Comparator|1 = Tested product|
88912034|NCT01574469|Placebo Comparator|2 = Control product|
88912035|NCT01574482|Experimental|1 = Tested product|
88912036|NCT01574482|Placebo Comparator|2 = Control product|
88912037|NCT01574495|Experimental|Error Augmentation-Control|
88912038|NCT01574495|Experimental|Control-Error Augmentation|
88912039|NCT01574508|Experimental|Continuous Subcutaneous Insulin Infusion|CSII
88912040|NCT01574508|Active Comparator|Multiple Daily Insulin Injections|MDI
88912041|NCT01574521||Only father carrier|fetuses whose fathers were HBV carriers whereas mothers negatively.
88912042|NCT01574521||only mother carrier|fetuses whose mothers were HBV carriers whereas fathers negatively.
88912043|NCT01574521||both parents carriers|fetuses whose both parents were HBV carriers
88912044|NCT01574534|Experimental|Drug eluting balloon|paclitaxel-eluting SeQuent® Please balloon, B.Braun Melsungen AG, Berlin, Germany
88912045|NCT01574534|Active Comparator|Drug eluting stent|paclitaxel-eluting Taxus Element® stent, Boston Scientific Corp, Natick MA or everolimus-eluting Xience® stent Abbott Vascular, Santa Clara, California, USA
88912046|NCT01574547||Cat Scratch Colon|Patients with mucosal tears during colonoscopy
88912047|NCT01574547||Control group|Patients without mucosal tears during the colonoscopy
88912048|NCT01574560|Active Comparator|Control Group - Health Education|This group is provided with information regarding secondhand smoke and creating a healthy home environment.
88912049|NCT01574560|Active Comparator|Treatment Group - Counseling|This group is provided with biomarker feedback on child exposure to secondhand smoke. Active participants receive 5 counseling sessions from a trained research counselor; 3 sessions in the home and 2 by phone. The counseling sessions focus on changing smoking behaviors and/or other behaviors that impact smoking.
88912050|NCT01574573|Experimental|Obese individuals with weight loss|Self support, group sessions
88912051|NCT01574573|Experimental|Obese individuals without weight loss|self support, group sessions
88912052|NCT01574586|Active Comparator|2-link stent Nobori|Bifurcation stenting
88912053|NCT01574586|Active Comparator|3-link stent Xience|Bifurcation stenting
88912054|NCT01574599|Experimental|Repetitive Facilitative Exercise|Occupational therapy program - Repetitive facilitative exercise therapy protocol including 40 min of RFE and 20 minutes of task-specific activity. 3 treatment sessions weekly for a total of 4 weeks.
88912055|NCT01574599|No Intervention|Conventional Therapy Program|Typical therapy excluding robotics, RFE
88912056|NCT01574625||Mosaic prosthetic heart valve|All patients who were enrolled and implanted with a Mosaic bioprosthesis in the Albertinen-Krankenhaus (Hamburg, Germany) during the previous Mosaic PMA study and who agree to participate in this long-term follow-up study by informed consent.
88912057|NCT01574638|Experimental|Arm 1B|Participants in Arm 1B will receive RPT based on weight at entry, at a dose of 20 mg/kg once daily with a low-fat breakfast, on Days 1 to 14. Participants will not receive RPT on Days 15 to 42 and will resume receipt of RPT on Days 43 to 56, at a dose of 10 mg/kg twice daily with low-fat meals.
89009044|NCT00591058|Experimental|Cohort 6|1.2 mg/kg TM-601 dose per administration
89009045|NCT00591097||pediatric|
89009046|NCT00591136|Experimental|Single Arm|
89432567|NCT02115399||NAStaph-|Non-atopic healthy participants without S. aureus skin colonization. A minimum of 45 participants will be enrolled in this group
89432568|NCT02115399||NAStaph+|Non-atopic healthy participants with S. aureus skin colonization. As the NAStaph+ phenotype is expected to be rare, as many participants as possible will be enrolled in this group; however, we do not expect to enroll 45 participants in this group.
89432569|NCT02112747|No Intervention|Arm 1: website access only|There is no intervention with this arm. Completion of the website is part of enrollment.
89432570|NCT02112747|Experimental|Arm 2: patient navigator|"The intervention consists of participants receiving the services of a patient navigator to address individual barriers to adhering to the personal prescription for colon and rectal cancer screening."
89432571|NCT02112747|No Intervention|Arm 3: genetic counseling|There is no intervention in this arm. Patients diagnosed as positive for Lynch Syndrome use genetic counseling to discuss medical and family history and genetic risk of CRC, including genetic factors such as DNA mismatch repair genes, autosomal dominant inheritance, cancer risks associated with LS, screening recommendations, and genetic testing. There is no intervention. This is standard care.
89432572|NCT02112747|Experimental|Arm 4:Gen. counselor & patient navigator|Participants diagnosed positive for Lynch syndrome use genetic counseling as in Arm 3 and in addition receive the services of a patient navigator to address individual barriers to adhering to the CRC screening recommendations.
89432573|NCT02115477||Group with lymphadenectomy|The group of women with high risk endometrial cancer who undergoes pelvic and/or paraaortic lymphadenectomy at primary surgery
89432574|NCT02115477||Group without lymphadenectomy|The group of women with low risk endometrial cancer who do not have lymphadenectomy at primary surgery
89432575|NCT02112825|Experimental|Exercise|12 weeks of blended supervised-home based exercise 3-4 times per week for 30-45 minutes
88912058|NCT01574638|Experimental|Arm 1A|Participants in Arm 1A will receive RPT based on weight at entry, at a dose of 10 mg/kg twice daily with low-fat meals, on Days 1 to 14. Participants will not receive RPT on Days 15 to 42 and will resume receipt of RPT on Days 43 to 56, at a dose of 20 mg/kg once daily with a low-fat breakfast.
88912059|NCT01574638|Experimental|Arm 2A|Participants in Arm 2A will receive RPT based on weight at entry, at a dose of 15 mg/kg once daily with a boiled egg, on Days 1 to 14. Participants will not receive RPT on Days 15 to 42 and will resume receipt of RPT on Days 43 to 70, at a dose of 15 mg/kg once daily with a low-fat breakfast.
89197722|NCT00861237|Placebo Comparator|Placebo globules group|Patients receive Placebo globules made out of sugar and looking similar to active drug sublingually before surgery.
89432576|NCT02112825|No Intervention|control|Control group asked to continue usual activities
89432577|NCT02115555|Experimental|HIT-aided approach|Adolescents and their parents randomized to this arm will be oriented on a HIT system. The system transmits self monitoring blood glucose self monitoring blood glucose data to a secure web portal. The subject will receive messages from the HIT system on the meter based upon the Self Monitored Blood glucose tests.
89432578|NCT02115555|Experimental|Contracted conflict management system|Adolescent-parent pairs will meet with a health educator to establish a behavioral contract that will set patient-centered self-management goals for the adolescent.
89009047|NCT00591292|Experimental|Single Arm|
89432579|NCT02115555|Experimental|HIT plus contracted conflict management|Adolescents and their parents randomized to this arm will be oriented on a HIT system. The system transmits self monitoring blood glucose data to a secure web portal. The subject will receive messages from the HIT system on the meter based upon the tests. In addition, adolescent-parent pairs will meet with a health educator to establish a behavioral contract that will set patient-centered self-management goals for the adolescent. This arm combines arms 1 and 2.
89432580|NCT02112903|Experimental|Encapsulated vortioxetine IR tablet, 20 mg|Single oral dose
89432581|NCT02112903|Experimental|Vortioxetine MR capsule 20 mg (pH 5.5)|Single oral dose
89432582|NCT02112903|Experimental|Vortioxetine MR capsule 20 mg (pH 6.0)|Single oral dose
89432583|NCT02112903|Experimental|Vortioxetine MR capsule 20 mg (pH 7.0)|Single oral dose
89432584|NCT02115711|Experimental|Community health worker|Home visits by community health worker to deliver the multi-component behavioural intervention targeted at the individual's hypertension, diabetes or smoking.
89432585|NCT02115711|No Intervention|Usual care|Patients will receive usual care in the community
89432586|NCT02109393|Experimental|MIRT group|"This group underwent a 4-weeks MIRT exploiting the use of a treadmill-plus (treadmill associated with visual cues and auditory feedbacks).~Inclusion criteria: a) diagnosis of idiopathic PSP in accordance to the NINDS-SPSP International Criteria (Litvan et al., 1996), b) age between 55 and 85 c) ability to walk unassisted for at least 6 meters, d) stable dopaminergic drugs dosage in the month preceding the admission to the study. Exclusion criteria: a) any others significant neurological or orthopedic disorders, b) osteoarthritis, osteoporosis, cutaneous lesions and/or other pressure wounds, c) body weight exceeding 135 kg (the weight limit for the use of Lokomat®), respiratory and cardiovascular diseases."
89432587|NCT02109393|Experimental|MIRT+Lokomat group|"This group underwent a 4-weeks MIRT involving the use of Lokomat® for 5 days per week in spite of treadmill-plus.~Inclusion criteria: a) diagnosis of idiopathic PSP in accordance to the NINDS-SPSP International Criteria (Litvan et al., 1996), b) age between 55 and 85 c) ability to walk unassisted for at least 6 meters, d) stable dopaminergic drugs dosage in the month preceding the admission to the study. Exclusion criteria: a) any others significant neurological or orthopedic disorders, b) osteoarthritis, osteoporosis, cutaneous lesions and/or other pressure wounds, c) body weight exceeding 135 kg (the weight limit for the use of Lokomat®), respiratory and cardiovascular diseases."
89432588|NCT02112981|Experimental|Sirolimus Eluting Coronary Stent|BioMime Sirolimus Eluting Stent of Meril Life Sciences
89432589|NCT02112981|Active Comparator|Everolimus-eluting Coronary stent|XIENCE family (V, Xpedition or Prime) of Everolimus-eluting stent system of Abbott Vascular Inc.
88912060|NCT01574638|Experimental|Arm 2B|Participants in Arm 2B will receive RPT based on weight at entry, at a dose of 15 mg/kg once daily with a low-fat breakfast, on Days 1 to 14. Participants will not receive RPT on Days 15 to 42 and will resume receipt of RPT on Days 43 to 56, at a dose of 15 mg/kg once daily with a boiled egg.
88912061|NCT01574664||Subjects scheduled to undergo lumpectomy|
88912062|NCT01574677||Screening FIT positive|Patients aged 49-80, with a positive screening FIT, who are referred to colonoscopy, and who meet inclusion criteria.
88912063|NCT01574690||Heart failure patients|50 subjects (both male and female) Heart failure patients already receiving RHC as part of their usual care
88912064|NCT01574729|Active Comparator|Surgery plus post-surgery chemotherapy|Surgery plus post-surgery chemotherapy
88912065|NCT01574729|Experimental|Surgery combined with rAd-p53 gene therapy|Surgery combined with the surgery wound surface injection of rAd-p53 plus post-surgery chemotherapy
88912066|NCT01574742|Experimental|Minocycline|Minocycline 200 mg/day (2X100 mg) from day 1 to day 3 and Minocycline 400 mg/day (2X200mg) form day 4 until termination visit (day 35)
89432590|NCT02109549||Diabetes and metformin|Patients with diabetes mellitus treated with metformin only.
89432591|NCT02109549||Insulin-diabetes without metformin|Patients with insulin-dependent diabetes mellitus not treated with metformin
89432592|NCT02109549||Controlgroup|The remaining patients serve as control group.
89432593|NCT02115789||Survey Group|Adult male or female volunteers.
89432594|NCT02115867|Active Comparator|Probiotic|"Probiotic arm Liquid broth~1 mL/kg every morning for 90 days"
89432595|NCT02115867|Placebo Comparator|Placebo|"Placebo arm Liquid broth~1 mL/kg each morning for 90 days"
89432596|NCT03553485|Experimental|taVNS|Treatment will be carried out twice a day (once before the RT session and 8h later) during 7 weeks. Each treatment takes 30 minutes.
89432597|NCT03553485|Sham Comparator|Control|Treatment will be carried out twice a day (once before the RT session and 8h later) during 7 weeks. Each treatment takes 30 minutes.
89432598|NCT02113059||Liver resection|Patients undergoing a hemihepatectomy.
89009048|NCT00591331|Experimental|1|NatrOVA Creme Rinse - 1%
89009049|NCT00591331|Experimental|2|NatrOVA Creme Rinse Vehicle Only
89009050|NCT00591331|Placebo Comparator|3|Blank patch
89009051|NCT00591448|Experimental|Virtual Reality|Patients with burns participate in VR during occupational therapy (OT) or physical therapy (PT) sessions ranging from 2 to 9 min in length
89009052|NCT00591487|Active Comparator|I|Infiltration with 0.9% saline+1:1,000,000 epinephrine+0.06% Lidocaine
89009053|NCT00591487|Placebo Comparator|II|Infiltration with 0.9% saline+1:1,000,000 epinephrine
89009054|NCT03452215|Experimental|Study|
89009055|NCT03452215|Sham Comparator|Control|
89009056|NCT03452059|Experimental|AiLegs/AiWalker|use of lower extremity rehabilitation training robot assisted walking (including AiLegs, AiWalker)
89009057|NCT03452059|Active Comparator|HKAFO/RGO|use hip and knee ankle foot orthosis (HKAFO) assisted walking
89009058|NCT03452020|Other|Tyto Thermometer, SoC Thermometer, Predicate IR Th|"All the study participants undergo temperature measurements with:~Tyto Thermometer~Standard of Care thermometer~Predicate IR thermometer"
89009059|NCT03451981|Sham Comparator|Chlorhexidine|mechanical debridement and chemical decontamination: Inflammatory tissue, excess cement or plaque deposits will be removed using hand instruments and the implant surface will be cleaned by copious irrigation with Chlorhexidine.
89009060|NCT03451981|Experimental|Er:YAG laser|Er:YAG laser treatment will be provided on the implant surface.
89009061|NCT03451981|Active Comparator|Air Powder|an Air-Powder treatment will be provided on the implant surface.
89009062|NCT03451942|Experimental|surgery group after FLOT regimen chemotherapy|After received 4 cycles FLOT regimen chemotherapy , D2 gastric resection and imaging metastases resection was performed. Then continue 4 cycles of FLOT regimen chemotherapy (Chemotherapy begins within 4-6 weeks after surgery)
89009063|NCT03451942|Placebo Comparator|FLOT regimen chemotherapy|Continue 4 cycles of the FLOT regimen chemotherapy and evaluate the efficacy every 8 weeks.
89009064|NCT00255372|Experimental|1|
89009065|NCT00255372|Active Comparator|2|
89009066|NCT00225914|Experimental|1|Subjects enter into a six-week, double blind phase, randomized in a 1:1 ratio to paroxetine CR 12.5 mg/day; dosing may be adjusted up to 25 mg/day after two weeks, based on treatment response and tolerability.
89197723|NCT00861237|Active Comparator|Nux vomica group|Patients receive Nux vomica globules made out of sugar sublingually before surgery.
89009067|NCT00225914|Placebo Comparator|2|Subjects then enter into a six-week, double blind phase, randomized in a 1:1 ratio to paroxetine CR 12.5 mg/day or matching placebo pill
89009068|NCT03451903||Mechanical thrombectomy group|Patients with acute stroke treated by mechanical thrombectomy.
89009069|NCT03451903||Combined procedure group|Patients with acute stroke treated by intravenous thrombolysis (with actilyse) and mechanical thrombectomy.
89009070|NCT03451864||Deficient Vit D|Mothers with serum 25(OH) D levels less than 20 ng/dl
89009071|NCT03451864||Normal vit D|Mothers with serum 25(OH) D levels more than 20 ng/dl
89009072|NCT03451747||postmenopausal hypertensive women|
89009073|NCT03451747||mached hypertensive men|
89009074|NCT03451669||Shunt suspected to be functioning|
89009075|NCT03451669||Shunt suspected to not be functioning|
89009076|NCT00235248|Experimental|Clopidogrel-aspirin|Clopidogrel-aspirin
89009077|NCT00235248|Active Comparator|Warfarin|Warfarin
89009078|NCT04574323|Experimental|Paleolithic lifestyle group|The Paleolithic lifestyle (PL) intervention during radiotherapy consists of daily outdoor walks or bike rides of at least 30 min duration, preferably done at noon to maximize vitamin D production, and the adoption of a Paleolithic diet. For the outdoor activity, patients were told to not use sun screen. The Paleolithic diet prescription emphasized the consumption of fatty meats and organ meats from humanely raised animals, wild-caught fish, eggs, nuts and seeds, algae, spices, vegetables and fruits. Excluded were processed foods, grains of all types, legumes, vegetable oils except for native coconut and olive oil and dairy products except for ghee. No dietary supplements were allowed. Patients were supposed to start the PL intervention at least two days prior to the first irradiation and to protocol their food consumption on two days during the first week on the diet. They were also asked about their compliance to the PL intervention at each weekly measurement appointment.
89009079|NCT04574323|Other|Standard diet group|This group is on a standard diet while receiving radiotherapy.
89009080|NCT03451435|No Intervention|Control|No intervention will be administered in this group as it serves as a control group.
89009081|NCT03451435|Experimental|NAC Treatment|N-Acetyl Cysteine treatment during root canal revascularization
89009082|NCT04574596||3GCR ceftriaxone-resistant-E. coli|Positive blood culture for above resistant e coli. Observational there will be no intervention
89009083|NCT04574596||3GCS ceftriaxone-susceptible-E. coli|Positive blood culture for above susceptible e coli. Observational there will be no intervention
89009084|NCT04575064|Other|Standard of Care (SoC)|This arm will receive standard supportive care according to guidelines for COVID-19. This is expected to vary regionally and may change throughout the trial based on new and emerging data on best care guidelines for patients.
89009085|NCT04575064|Experimental|Remdesivir + SoC|Remdesivir 200 mg IV on day 1, followed by 100 mg IV daily infusion for 9 days plus optimized supportive care
88912067|NCT01574781||Women with abnormal fetus|Women carrying fetus that is identified as chromosomally abnormal by CVS/Amniocentesis
88912068|NCT01574781||Women experiencing miscarriage|Women identified as miscarrying, prior to any D&C or D&E procedure
88912069|NCT01574781||Born children|The children born from women participating in other cohorts of the study.
88912070|NCT01574781||Male relatives|The male partners (and presumed biological father of any fetuses/children) of women participating in other cohorts of the study or the biological father's brother and/or father.
88912071|NCT01574781||Non-pregnant women|Healthy women who are not pregnant
88912072|NCT01574781||Pregnant women|
88912073|NCT01574794|Experimental|Strengthening Exercises|Recreational older runners recruited from local community
88912074|NCT01574794|Experimental|Stretching Exercises|Recreational older runners recruited from local community
88912075|NCT01574794|No Intervention|Control Group|Recreational older runners recruited from local community
88912076|NCT01574820|Placebo Comparator|placebo|
88912077|NCT01574820|Experimental|rosiglitazone (4 mg)/day|
88912078|NCT01574833|Active Comparator|PEMF|arm that receive PEMF treatment
88912079|NCT01574833|Sham Comparator|Sham|arm that receive sham treatment
88912080|NCT01574846||Vantas|
88912081|NCT01574859||hypopituitarism|group of patients with hypopituitarism
88912082|NCT01574872|Experimental|Aerosal|This arm include all patients treated with Aerosal®
88912083|NCT01574872|Placebo Comparator|Placebo|This arm include all patients treated with placebo
88912084|NCT01574885|Experimental|Aerosal|This arm include all patients treated with Aerosal®
88912085|NCT01574885|Placebo Comparator|Placebo|This arm include all patients treated with placebo
88912086|NCT01574898|Active Comparator|Niquitin® Fresh Mint 4 mg|
88912087|NCT01574898|Active Comparator|V0118 - B mg|
88912088|NCT01574898|Experimental|V0474 - C mg|
88912089|NCT01574898|Experimental|V0474 - B mg|
88912090|NCT01574898|Experimental|V0474 - A mg|
88912091|NCT01574911||healthy adults|The objective of this project is the validation of real time reconstruction and calculation of limb volume using a 3 D laser scanner In each subject limb volume will be measured once by water - displacement and twice by 3D laser scanning
89197724|NCT00952354||research group|60 children aged from 3 to 10 years, both genders, observed in a symbolic play situation with their language therapists
88912092|NCT01574911||Adults Chronic venous insufficiency|The objective of this project is the validation of real time reconstruction and calculation of limb volume using a 3 D laser scanner In each subject limb volume will be measured once by water - displacement and twice by 3D laser scanning
88912093|NCT01574911||patients primary lymphedema|The objective of this project is the validation of real time reconstruction and calculation of limb volume using a 3 D laser scanner In each subject limb volume will be measured once by water - displacement and twice by 3D
88912094|NCT01574924||Medical residents|
88912095|NCT01574937|Experimental|Treatment Arm|Cabozantinib and abiraterone
88912096|NCT01574963||CAD Patients|Patients suffering from CAD requiring coronary artery bypass grafting
88912097|NCT01574963||Control Patients|Patients without CAD
88912098|NCT01574976|Active Comparator|control, no feeback|subjects without ADHD, probabilistic choices without feedback
88912099|NCT01574976|Active Comparator|control, feedback|subjects without ADHD, probabilistic choices with feedback
88912100|NCT01574976|Experimental|ADHD, no feedback|subjects with ADHD, probabilistic choices without feedback
88912101|NCT01574976|Experimental|adhd, feedback|subjects with ADHD, probabilistic choices with feedback
88912102|NCT01574989|Experimental|Active low-frequency rTMS/sham tDCS|Subjects will have both the rTMS and tDCS on their scalp during the session, however only one will be active. For this arm, the rTMS will be active, low-frequency, and the tDCS will be sham. They will undergo only one session of this condition, and it will last 20 minutes.
88912103|NCT01574989|Experimental|Active high-frequency rTMS/sham tDCS|Subjects will have both the rTMS and tDCS on their scalp during the session, however only one will be active. For this arm, the rTMS will be active, high-frequency, and the tDCS will be sham. They will undergo only one session of this condition, and it will last 20 minutes.
88912104|NCT01574989|Experimental|Sham rTMS/active anodal tDCS|Subjects will have both the rTMS and tDCS on their scalp during the session, however only one will be active. For this arm, the tDCS will be active, anodal, and the TMS will be sham. They will undergo only one session of this condition, and it will last 20 minutes.
88912105|NCT01574989|Experimental|Sham rTMS/active cathodal tDCS|Subjects will have both the rTMS and tDCS on their scalp during the session, however only one will be active. For this arm, the tDCS will be active, cathodal, and the TMS will be sham. They will undergo only one session of this condition, and it will last 20 minutes.
88912106|NCT01574989|Sham Comparator|Sham rTMS/Sham tDCS|Subjects will have both the rTMS and tDCS on their scalp during the session, and both interventions will be sham. They will undergo only one session of this condition, and it will last 20 minutes.
88912107|NCT01575002|Experimental|Active tDCS|Subjects will undergo 20 minutes of active tDCS stimulation.
88912108|NCT01575002|Sham Comparator|Sham tDCS|Subjects will undergo 20 minutes of sham tDCS stimulation.
88912109|NCT01575015|Active Comparator|Standard intraoperative support (no CRRT)|
88912110|NCT01575015|Experimental|Intraoperative renal support (CRRT)|
88912111|NCT01575041|Active Comparator|Sodium|For 4 weeks subjects will consume 3 grams of sodium by the intake of capsules on top of a low-sodium (2 grams of sodium), low-potassium (2 grams of potassium) diet
88912112|NCT01575041|Active Comparator|Potassium|For 4 weeks subjects will consume 3 grams of potassium by the intake of capsules on top of a low-sodium (2 grams of sodium), low-potassium (2 grams of potassium) diet.
88912113|NCT01575041|Placebo Comparator|Placebo|For 4 weeks subjects will consume placebo capsules (content: cellulose) on top of a low-sodium low-potassium diet
88912114|NCT01575067||blood pressure monitor|Cuff circumference:22cm-42cm
88912115|NCT01575067||stethoscopy|Cuff circumference: 22cm-42cm
89009086|NCT03451318|Active Comparator|drug therapy|Nasonex(mometasone furoate),1 spray,QD (Quaque Die in Latin),for 3 months.
89009087|NCT03451318|Active Comparator|tonsillar adenoidectomy|tonsillar adenoidectomy
89009088|NCT03451318|Active Comparator|orthodontic treatment|Apply Twin-block appliance combined with maxillary expander
89009089|NCT03451318|Active Comparator|tonsillar adenoidectomy plus orthodontic treatment|Apply Twin-block appliance combined with maxillary expander one month after tonsillar adenoidectomy .
89009090|NCT03451240|Experimental|Intervention|
89009091|NCT04573894||Positives blood cultures|Collection of clinical and biological data of patients with blood cultures positives for potential contaminants, as well as PCT levels measurements, from January 2016 to May 2019 at the Nancy CHRU
89009092|NCT04574284|Experimental|TQB2450 + Anlotinib|TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle ,Anlotinib capsules 12 mg given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
89009093|NCT04574284|Experimental|TQB2450|TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle.
89009094|NCT04574284|Experimental|Anlotinib|Anlotinib capsules 12 mg given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
89009095|NCT04574128|Experimental|Retransfusion of cardiotomy blood or not|Intervention group does not get cardiotomy blood retransfusion via heart-and lung machine while control does.
89009096|NCT04574128|No Intervention|No retransfusion of cardiotomy blood|
89009097|NCT00226031|Active Comparator|1|Usual care.
89009098|NCT00226031|Experimental|2|Mailed reminder with a summary of osteoporosis screening and treatment guidelines sent to the family physician and a letter and educational package for the women.
89009099|NCT04573855|Experimental|Anti-SARS-CoV-2 immunoglobulin|Treatment with Anti-SARS-CoV-2 immunoglobulin
89009100|NCT04573855|No Intervention|Control|
89009101|NCT04574206|Experimental|Elaborative Reminiscence (ER)|ER is a communication strategy used between a caregiver and child to support children's cognitive and emotional development. ER involves a caregiver and child jointly reminiscing about a past event that they personally experienced, to co-create a coherent narrative that describes the event from both their perspectives. ER consists of two crucial elements, the use of elaborative language (e.g. open ended questions, contributing new information to the conversation) and specific talk focused on recollections of the past as opposed to observations of the present.
89009102|NCT04574206|Sham Comparator|Present Tense Talk (PTT)|PTT is an active control intervention, designed to ensure that caregivers/ guardians in this group spend a similar amount of time engaging in conversation with their children but do not use elaborative reminiscing language. The focus will be on describing activities as they are happening in real time; PTT caregivers will be asked to avoid reference future or past events .
89009103|NCT04574011|Experimental|Fluid challenge responder|If the ratio of the stroke volume change after passive leg raising is the same or larger than 10%, the patient is assigned to RESPONDER group.
89009104|NCT04574011|Experimental|Fluid challenge non-responder|If the ratio of the stroke volume change after passive leg raising is less than 10%, the patient is assigned to RESPONDER group.
89009105|NCT04721379|Experimental|Heartfulness Meditation Group|Participants will be guided through relaxation and meditation session with a Heartfulness trainer with EEG and EKG recording. After finishing the session, they fill out meditation depth questionnaire.
89009106|NCT04721379|Active Comparator|Control Group with Self Meditation|Participants will be self-guided through relaxation and meditation session without a trainer with EEG and EKG recording. After finishing the session, they fill out meditation depth questionnaire.
89009107|NCT00226109|Active Comparator|A|
89009108|NCT04573426||Overweight/Obese+Drug+Stigma|40 participants with overweight or obesity will consume 1,000mg of acetaminophen in a liquid vehicle briefly following the start of the appointment. After one hour, they will read a short vignette meant to induce weight stigma.
89009109|NCT04573426||Overweight/Obese+Drug+Control|40 participants with overweight or obesity will consume 1,000mg of acetaminophen in a liquid vehicle briefly following the start of the appointment. After one hour, they will read a short control vignette meant to have no impact on their emotional state.
89432599|NCT02115945|Experimental|epidural block|Visual anlogue score vas used to evaluate pain. The anxiety/depression scale (HAD) was used to assess anxiety and depression. The SF 12 test (SHORT FORM 12) was used to evaluate quality of life. The DN4 test was used to evaluate neuropathic pain.
89432600|NCT02115945|Active Comparator|femoral block|Visual anlogue score vas used to evaluate pain. The anxiety/depression scale (HAD) was used to assess anxiety and depression. The SF 12 test (SHORT FORM 12) was used to evaluate quality of life. The DN4 test was used to evaluate neuropathic pain.
89432601|NCT02113137|Experimental|group 1: drug|Drug: group 1: drug: chlorine dioxide 12ml chlorine dioxide (ClO2) mouthwash two times per day, for three consecutive weeks
89432602|NCT02113137|Experimental|group 2: device:|group 2: device: small tooth brush for tongue cleaning small tooth brush for tongue cleaning
89432603|NCT02116023|Experimental|Orange flavored beverage - Test1|240ml processed whole orange low dose
89432604|NCT02116023|Experimental|Orange flavored beverage - Test2|240ml processed whole orange high dose
89432605|NCT02116023|Placebo Comparator|Orange flavored beverage - Placebo|240ml orange beverage
89432606|NCT02113215||Young Males|Males, age 18-35 years. 9-hour Stable isotope infusion
89432607|NCT02113215||Young Females|Females, age 18-35 years. 9-hour Stable isotope infusion
89432608|NCT02113215||Older Males|Males, age 60-75. 9-hour Stable isotope infusion
88912116|NCT01575119|Experimental|In-patient surgery|Decision Aid tool is presented by respiratory therapist, prompting a discussion with the provider (physician or physician assistant)about smoking around time of surgery
88912117|NCT01575119|Active Comparator|In-patient|Standard of care information, including distributing patient education brochure, to provide information regarding perioperative smoking
88912118|NCT01575119|Experimental|Out-patient surgery|Decision Aid tool is presented by respiratory therapist, prompting a discussion with the provider (physician or physician assistant)about smoking around time of surgery
88912119|NCT01575119|Active Comparator|Out-patient|Standard of care information, including distributing a patient education brochure, to provide information regarding perioperative smoking
88912120|NCT01575132||Parkinson's Disease, DBS, 10-14 years|
88912121|NCT01575145|Experimental|Quitline facilitation intervention|brief quitline facilitation intervention given
88912122|NCT01575145|Active Comparator|Stop-smoking intervention|brief review of tips to maintain smoking abstinence, using brochure
88912123|NCT01575158|Experimental|citalopram|citalopram
88912124|NCT01575158|Active Comparator|clomipramnine|clomipramine
88912125|NCT01575158|Placebo Comparator|placebo|placebo
88912126|NCT01575171||"Intervention/Nudge"|"Individuals will be analyzed according to their assigned intervention group, to compare the effectiveness of an opt-out EHR decision support system to enhance the prescription of statins to those patients with an elevated LDL-C and to subsequently titrate the medication dose until LDL-C control is obtained. Physicians randomized to the automated clinical decision support nudge will see the new optout prescribing procedure as part of their EHR interface. This will include initially prescribing the guideline-based medication, simvastatin 20mg. Nearly six months after this visit, physicians will receive a reminder via EHR to schedule a follow-up fasting lipid profile as recommended by ATP III guidelines."
89432609|NCT02113215||Older Females|Females, age 60-75. 9-hour Stable isotope infusion
89432610|NCT02116101|Active Comparator|Bright Momchilovtsi yogurt|Bright Momchilovtsi yogurt Contains 1×106cfu/g prebiotics including Lactobacillus bulgaricus and Streptococcus thermophilus
89432611|NCT02116101|Placebo Comparator|Bright Dairy Beverage|Dairy beverage product without prebiotics
88912127|NCT01575184|Experimental|Shoulder traction|The ultrasonographic measurements with shoulder traction
88912128|NCT01575184|Active Comparator|No traction|The ultrasonographic measurements without shoulder traction
88912129|NCT01575210|Experimental|Group A_ washing procedure 1|This group will apply washing technique 1.
88912130|NCT01575210|Experimental|Group B_washing procedure 2|This group will apply washing technique 2.
88912131|NCT01575223|Active Comparator|High volume saline irrigation|Patients in this group will receive high volume saline irrigation (NeilMed sinus rinse)
89432612|NCT02113293|Experimental|CyclASol®|CyclASol®
89432613|NCT02113293|Placebo Comparator|Placebo|Placebo (vehicle)
89432614|NCT02116179|Experimental|DVD Intervention|DVD Intervention presented at one 90 minute group session
89432615|NCT02116179|No Intervention|Wait list Control Group|Group will get no intervention until after 90 day follow up
89432616|NCT02116257|Experimental|Propacetamol|
89432617|NCT02116257|Placebo Comparator|PCA regimen|routine PCA drug
89009110|NCT04573426||Overweight/Obese+Placebo+Stigma|40 participants with overweight or obesity will consume a placebo solution briefly following the start of the appointment. After one hour, they will read a short vignette meant to induce weight stigma.
89432618|NCT02109627|Experimental|Ficlatuzumab, Cytarabine|"Ficlatuzumab 5-20 mg/kg; intravenous; Days 0, 14, 28, 42; Number of cycles: until progression or unacceptable toxicity develops.~Cytarabine 2 g/m2; intravenous; Days 2-7; Number of cycles: until progression or unacceptable toxicity develops."
89432619|NCT02113371|Experimental|Intervention|The intervention consists of monthly scripted, peer-led social support sessions covering health and safety topics.
89432620|NCT02113371|No Intervention|Control|Usual practices with regard to health and work conditions.
89432621|NCT02116413||The study population|"The study population consists of patients admitted to intensive care, sedated and under controlled ventilatory support with septic shock criteria defined by severe sepsis associated with hypotension despite fluid resuscitation of 20-40 ml / kg and requiring vascular filling according to the following criteria:~oliguria <0.5 ml / kg / h for at least 2h skin mottling Arterial Lactate > 2 mmol / l SvcO2 <70% or SvO2 <65% Patient on noradrenaline.~Severe sepsis is defined as a systemic inflammatory response associated with a suspected or proven infection and hypotension before filling, a lactate> 4 mmol / l or organ dysfunction.~Intervention: Fluid challenge Intervention: Cardiac ultrasound"
89009111|NCT04573426||Overweight/Obese+Placebo+Control|40 participants with overweight or obesity will consume a placebo solution briefly following the start of the appointment. After one hour, they will read a short control vignette meant to have no impact on their emotional state.
89009112|NCT04573426||Normal Weight+Placebo+Stigma|40 participants with normal weight will consume a placebo solution briefly following the start of the appointment. After one hour, they will read a short vignette meant to induce weight stigma.
89432622|NCT02113527||Epigastric pain syndrome (EPS)|Patients suffering from functional dyspepsia characterized by epigastric pain syndrome according to Rome III criteria
89432623|NCT02113527||Postprandial distress syndrome (PDS)|Patients suffering from functional dyspepsia characterized by postprandial distress syndrome according to Rome III criteria
89432624|NCT02113527||Healthy subjects|Healthy subjects as control group
89432625|NCT02116491|No Intervention|Closed suction system|All ES procedures were performed on indication by RICU nurses and according to protocol, according to which Cloesd suction system was performed which the patient remained connected to the ventilator. The catheter was inserted into the endotracheal tube until resistance was met and withdrawn 0.5 cm. A negative pressure of maximum 150mmHg was set, and the catheter was withdrawn while gently rotating. The procedure lasted for a total of 10 seconds. Nonsterile gloves were to be used during all procedures.
88912132|NCT01575223|Placebo Comparator|Placebo|Patients in this group will receive low volume saline irrigation (Salinex)
88912133|NCT01575236|Experimental|Guardian|Guardian Laryngeal Mask
88912134|NCT01575236|Experimental|Supreme|Supreme Laryngeal Mask Airway
88912135|NCT01575249||Asymptomatic group|one hundred patients with a negative exercise stress echo for symptoms/ECG/wall motion abnormalities (WMA), negative spirometry test for pulmonary disease, without known CAD or other valvular diseases, in sinus rhythm and with a LVEF>55%
88912136|NCT01575249||Symptomatic group|one hundred patients with symptomatic AS (negative pulmonary tests but positive stress echo or prior CAD or other valvular diseases and a LVEF>55%
88912137|NCT01575262|Experimental|Incentive|Participants use their PAL card to self-monitor physical activity levels (intrinsic motivation) and minutes of physical activity were converted to points (1 minute of physical activity = 1 point; capped at 30 points per day) over the 12-week intervention period. Points are redeemed for rewards (extrinsic motivation) at week 6 and week 12.
88912138|NCT01575262|Active Comparator|No Incentive|Participants used their PAL card to self-monitor their physical activity levels (intrinsic motivation) over the 12-week intervention period but do not collect points or earn rewards.
88912139|NCT01575288|Placebo Comparator|Maltose|
88912140|NCT01575288|Experimental|High-dose trehalose|
88912141|NCT01575314|Experimental|stapling device|stapling device refer to patients who were randomized to use stapler for dividing lung parenchyma.
88912142|NCT01575314|No Intervention|hand sewn|hand sewn refer to patients who were randomized to use hand suturing for dividing lung parenchyma.
88912143|NCT01575327|Active Comparator|Fixed oxygen flow delivery|Oxygen flow delivery is adjusted by respiratory therapists. Standard medical treatment.
88912144|NCT01575327|Experimental|FreeO2 system|FreeO2 is a new system that automatically adjusts the oxygen flow delivered to patients in a closed-loop based on the SpO2 signal. This system is intended to maintain SpO2 in a predefined target and to adapt oxygen flow to patient's needs.
88912145|NCT01575340|Experimental|fish oil encapsuled|will receive the supplementation of 2 g / day of fish oil encapsulated for 9 weeks
88912146|NCT01575340|No Intervention|without supplementation|not will receive supplementation or encapsulated fish oil or placebo
88912147|NCT01575353|Active Comparator|Venturi mask|After extubation, patients will receive oxygen therapy through the standard Venturi mask (control)
88912148|NCT01575353|Active Comparator|Nasal high-flow|After extubation, patients will receive oxygen therapy through the nasal high-flow (intervention)
88912149|NCT01575366|Experimental|Slow tracking training|
88912150|NCT01575366|Experimental|Fast tracking training|
88912151|NCT01575392||Patients coming for creatinine clearance|For this single group study, all patients presenting at the laboratory facility for a 24-hour creatinine clearance and patients in the dialysis population of the Isala Clinics who came for their periodical KT/V control, were informed about the study and asked to participate. Moreover, 20 'healthy' volunteers (including the investigators of this study and staff working at the clinical chemistry department of the Isala clinics) participated in this study.
88912152|NCT01575405|Experimental|Rectal-specific formulation (RF) stage|During this stage, participants will receive seven rectally-administered doses of the rectal-specific formulation (RF), with the first and last dose administered in clinic and five doses in between self-administered by a participant at home. Various specimens will be collected after administration of the last dose, including blood, vaginal and rectal fluids, and endoscopic biopsies. Blood and fluids will be additionally collected at 2hr, 4hr, and 24hr post-last-dose administration.
89432626|NCT02116491|Experimental|Visual Sputum Suctioning System|All ES procedures were performed on indication by RICU nurses and according to protocol, according to which Closed suction system was performed which the patient remained connected to the ventilator. The double-lumen catheter of the Visual Sputum Suctioning System integrated with a 0.9-mm micro-imaging fiber was inserted into the endotracheal tube until resistance was met and withdrawn 0.5 cm. A negative pressure of maximum 150mmHg was set, and the catheter was withdrawn while gently rotating. The procedure lasted for a total of 10 seconds. Nonsterile gloves were to be used during all procedures.
88912153|NCT01575405|Active Comparator|Vaginal formulation (VF) stage|"During this stage, only one exposure to the vaginal formulation (VF) will be administered (as the seventh dose in the stage), but it will be coupled with six preceding exposures to the Universal HEC Placebo Gel to balance it out against the other three stages in the study.~First and last doses will be administered in clinic, and after the administration of the last dose, various specimens will be collected, including blood, vaginal and rectal fluid, and endoscopic biopsies. Additional blood and fluids will be collected at 2, 4, and 24 hours post seventh dose administration."
88912154|NCT01575405|Active Comparator|Reduced Glycerin Vaginal Formulation (RGVF) stage|During this stage, participants will receive seven rectally-administered doses of the reduced glycerin vaginal formulation (RGVF), with the first and last dose administered in clinic and five doses in between self-administered by a participant at home. Various specimens will be collected after administration of the last dose, including blood, vaginal and rectal fluids, and endoscopic biopsies. Blood and fluids will be additionally collected at 2hr, 4hr, and 24hr post-last-dose administration.
88912155|NCT01575418|Experimental|Rectal specific formulation (RF) stage|Each participant will receive two inpatient doses of each radiolabeled study product. The first inpatient dose of each product will be administered without coital dynamics simulation (CDS), while the second inpatient dose will be followed by a CDS procedure at 1-hour post dose with instillation of radiolabeled autologous semen. There will be a washout period of at least 11 days between each dose.
89009113|NCT00235287|Active Comparator|A,AIIA|24 weeks of treatment with Candesartan, where Enalapril is added in the last 8 weeks.
89432627|NCT02116569|Experimental|Daratumumab 8 milligram per kilogram (mg/kg)|Participants will be administered intravenously with daratumumab at a dose of 8 mg/kg up to 8 weeks (total 7 infusions). After 8 weeks, participants will receive daratumumab intravenously two times in every 2 weeks until Week 24 followed by one time in 4 weeks until study discontinuation.
89432628|NCT02116569|Experimental|Daratumumab 16 mg/kg|Participants will be administered intravenously with daratumumab at a dose of 16 mg/kg up to 8 weeks (total 7 infusions). After 8 weeks, participants will receive daratumumab intravenously at a same dose, two times in every 2 weeks until Week 24 followed by one time in 4 weeks until study discontinuation.
89432629|NCT02116647|Experimental|Psychoanalytic therapy|manualized psychoanalytic psychotherapy
89432630|NCT02116647|No Intervention|Control Group|Standard care
89432631|NCT02109783|Active Comparator|Caffeine 4 mg|To compare exercise performance of 2 or 4 mg of caffeine per kilogram of body weight to placebo within subjects. Subjects will perform 4 exercise tests.
89432632|NCT02109783|Active Comparator|Caffeine 2 mg|To compare exercise performance of 2 or 4 mg of caffeine per kilogram of body weight to placebo within subjects. Subjects will perform 4 exercise tests.
89009114|NCT00235287|Active Comparator|A, ACE-I|24 weeks of treatment with Enalapril, where Candesartan is added in the last 8 weeks.
89009115|NCT00235287|Active Comparator|C, AIIA|8 weeks of treatment with Candesartan, followed by 8 weeks of treatment with Enalapril. The treatment in the last 8 out of the 24 weeks is a combination of Candesartan and Enalapril.
89432633|NCT02109783|Placebo Comparator|Caffeine 0 mg|To compare exercise performance of 2 or 4 mg of caffeine per kilogram of body weight to placebo within subjects. Subjects will perform 4 exercise tests.
89432634|NCT02109861|Experimental|Melphalan|A microdose of 2 mg/m2 iv Melphalan (1% of standard dose) is given two hours prior to planned standard dose Melphalan
89432635|NCT02109861|Experimental|Bortezomib|A microdose of 0.013 mg/m2 iv Bortezomib (1% of standard dose) is given two hours prior to planned standard dose Bortezomib
89432636|NCT02109861|Experimental|Dexamethasone|A microdose of 0.4 mg iv Dexamethasone (1% of standard dose) is given two hours prior to planned standard dose of Dexamethasone
89432637|NCT02113605|Experimental|Cognitive behavior therapy|All included children are treated with a face-to-face exposure-based cognitive behaviour therapy for 10 weeks. There will be no comparison arm.
89009116|NCT00235287|Active Comparator|C, ACE|8 weeks of treatment with Enalapril in incremental doses (5,10,20 mg) , followed by 8 weeks of treatment with Candesartan in incremental doses (4,8,16 mg) . The treatment in the last 8 out of the 24 weeks is a combination of Candesartan 16 mg and Enalapril in incremental doses (5,10,20 mg)
89009117|NCT04573348||Groups 1-4|no intervention will be performed in this study, only blood drawn
89432638|NCT02118753|No Intervention|ischemic preconditioning|"After baseline recordings of contractile function, the investigators will assign 2 trabeculae of each patient to either a stimulus for (1) ischemic preconditioning (IP) or (2) no IP. Subsequently, the trabeculae will be exposed to 90 min of ischemia, followed by 120 minutes of recovery. The investigators will measure the recovery of contractile function in both trabeculae.~This experiment serves as a positive control, to ensure that our model is still working properly."
89432639|NCT02118753|Experimental|eplerenone|In the next patients, a similar ischemia-reperfusion experiment will be performed, but now the 2 trabeculae will be randomized to pretreatment with eplerenone or DMSO. The percentage recovery (compared to baseline) of contractile force of the trabeculae at the end of reperfusion will serve as the primary endpoint.
89432640|NCT02118909|Experimental|Part 1 (Pracinostat + Itraconazole)|Single-dose pracinostat and itraconazole dosing every day for 8 days
89432641|NCT02118909|Experimental|Part 2 (Pracinostat + Ciprofloxacin)|Single dose pracinostat and ciprofloxacin 2 times a day for 7 days
89432642|NCT02116725|Experimental|Shower gel with zinc|Zinc gel is applied daily (50 µl/cm2) to wound and surrounding noninjured skin.
88912156|NCT01575418|Active Comparator|Vaginal formulation (VF) stage|Each participant will receive two inpatient doses of each radiolabeled study product. The first inpatient dose of each product will be administered without coital dynamics simulation (CDS), while the second inpatient dose will be followed by a CDS procedure at 1-hour post dose with instillation of radiolabeled autologous semen. There will be a washout period of at least 11 days between each dose.
88912157|NCT01575418|Active Comparator|Reduced glycerin vaginal formulation (RGVF) stage|Each participant will receive two inpatient doses of each radiolabeled study product. The first inpatient dose of each product will be administered without coital dynamics simulation (CDS), while the second inpatient dose will be followed by a CDS procedure at 1-hour post dose with instillation of radiolabeled autologous semen. There will be a washout period of at least 11 days between each dose.
88912158|NCT01575431||Stable angina|Patients who undergo an elective and successful single or multivessel percutaneous coronary intervention can be considered for the study.
89432643|NCT02116725|Placebo Comparator|Plain shower gel|Plain shower gel is applied daily (50 µl/cm2) to wound and surrounding noninjured skin.
89432644|NCT02116725|Sham Comparator|Distilled water|Distilled Water is applied daily (50 µl/cm2) to wound and surrounding noninjured skin.
89432645|NCT02118987|Experimental|Omalizumab|300mg of omalizumab under the skin every four weeks at three separate visits representing a treatment period of 12 weeks. During this treatment period, patients will continue receiving their regularly scheduled chemotherapy desensitizations per the prescribed treatment schedule from the patient's oncologist.
89432646|NCT02119143|Active Comparator|Vitamines and minerals|41 middel aged subjects receive vitamin and mineral supplementation
89432647|NCT02119143|Placebo Comparator|cellulose|41 middle aged subjects get the placebo
89432648|NCT02116881||Open colorectal surgery|Patients scheduled to undergo open colorectal surgery from Department of Colorectal Surgery at Cleveland Clinic
88912159|NCT01575444||Home Based Vaginal Collection|Somali women who are randomized for Home based Vaginal Collection will be given a kit to perform the vaginal sample collection for HPV analysis, with detailed written instructions.
88912160|NCT01575444||Clinic Based Pap Test Collection|30 Somali women who are randomized for Standard Clinic Pap Group will be given a list of clinics that they can attend for cervical cancer screening using pap test. Follow-up will be done on test completion with the clinic at 3 months after enrollment.
88912161|NCT01575457|Experimental|Intervention|The Healthy Futures Program is an interactive, multi-session training program. The intervention participants will participate in College/vocational school, Job, and Career Planning activities with a career coach.
89432649|NCT02116881||Laparoscopic colorectal surgery|Patients scheduled to undergo laparoscopic colorectal surgery from Department of Colorectal Surgery at Cleveland Clinic
89432650|NCT02122965|Experimental|Pharmacist-led medication review|Pharmacist-led medication review in the ED
89432651|NCT02122965|No Intervention|Usual care|Usual care includes nurse-led medication reconciliation.
89432652|NCT02119221|Experimental|[14C]Copanlisib|
89432653|NCT02116959|Experimental|Cohort 1|"Patients will receive alternating treatments beginning with systemic chemotherapy then followed by intra-arterial (IA) therapy.~Bilateral retinoblastoma patients will be in Cohort 1.~For bilateral Bilateral retinoblastoma patients where one eye is stage A or B and the other eye is C, D, or E, only the higher stage eye (C, D, E) will be treated with IA chemotherapy unless the stage A or B eye is not amenable or has failed local therapy."
89432654|NCT02116959|Experimental|Cohort 2|Patients will receive only intra-arterial (IA) therapy for more limited disease.
89432655|NCT02123043|No Intervention|Control|The control group will not experience any wheelchair training or 'practice' with a manual wheelchair.
89432656|NCT02123043|Experimental|Motor learning-based training|The motor learning-based training, like the 'practice' condition, will consist of six visits over three weeks. Each visit will involve two 5-minute wheeling trials with 10-minutes of rest between trials. The motor learning-based training will focus on variable practice and sporadic feedback.
88912162|NCT01575457|Other|Comparison|The Healthy Futures Program is an interactive, multi-session training program. The comparison group participants will receive newsletters and be invited to participate in college and career planning workshops.
89432657|NCT02123043|Active Comparator|Practice wheeling|To provide a comparable amount of exposure to wheelchair propulsion, the practice group will participate in the same number of visits and wheeling time as the motor-learning based training group. This will allow us to determine whether the motor-learning based training is superior to exposure through practice. The practice group will come to the lab six times over three weeks and wheel for two 5-minute trials with a 10-minute rest break in between. Participants randomized to this group will receive no feedback.
88912163|NCT01575483||Patients with T2DM|Patients with diagnosis of type 2 diabetes mellitus (T2DM) initiating Onglyza® treatment within the approved indications will be enrolled
88912164|NCT01575496|Active Comparator|Active tDCS|Subjects will receive 20 minutes of active tDCS.
88912165|NCT01575496|Sham Comparator|Sham tDCS|Subjects will receive 20 minutes of sham tDCS.
88912166|NCT01575574|Other|GADOXETIC ACID|Is a non comparative study. a magnetic resonance will be done using gadoxetic acid : 0.025mmol/Kg
88912167|NCT01575587|Experimental|Treatment A|
89432658|NCT02119377||Transgender and Transsexual People|Transgender and transsexual (trans) people aged 18 years or older living in Australia were invited to complete a questionnaire assessing a range of mental and physical health domains.
88912168|NCT01575587|Experimental|Treatment B|
88912169|NCT01575587|Experimental|Treatment C|
88912170|NCT01575587|Experimental|Treatment D|
88912171|NCT01575600|Active Comparator|10 mL/kg/h lactated Ringer's solution|Group 1, 10 mL/kg/h lactated Ringer's solution
88912172|NCT01575600|Experimental|30 mL/kg/h lactated Ringer's solution|Group 2, 30 mL/kg/h lactated Ringer's solution
88912173|NCT01575613|Experimental|Hotspot Targeting|Four hotspot-targeted interventions will be superimposed on ongoing control measures: hotspots will be targeted with a combination of IRS, long-lasting insecticide treated nets (LLINs), larviciding and a focal screening and treatment (FSAT)campaign.
88912174|NCT01575613|No Intervention|Control|Standard of care as determined by the Division of Malaria Control of the Kenyan Ministry of Health
88912175|NCT01575626|Active Comparator|first sevoflurane concentration|patients will be given 3 different end-tidal sevoflurane concentrations in the following order: 0%, 7%, 4%
88912176|NCT01575626|Active Comparator|second sevoflurane concentration|patients will be given 3 different end-tidal sevoflurane concentrations in the following order: 4%, 7%, 0%
88912177|NCT01575626|Active Comparator|third sevoflurane concentration|patients will be given 3 different end-tidal sevoflurane concentrations in the following order: 7%, 4%, 0%
88912178|NCT01575626|Active Comparator|Propofol|General anesthesia will be induced using propofol (5 mcg/ml) administered by target controlled infusion (TCI - Schnider model).Following tracheal intubation, concentration of propofol will be decreased till 0.
88912179|NCT01575639|Experimental|High dose|Oral Prednisolone will be given at dose of 4 mg/kg/day for 14 days
88912180|NCT01575639|Active Comparator|Usual dose|Oral prednisolone will be given at dose of 2 mg/kg/day for 14 days
88912181|NCT01575652|Active Comparator|ACE-I|Group using ACEIs
88912182|NCT01575652|No Intervention|ACE-I, 2|group not using ace-i
89009118|NCT04573621|Active Comparator|Pelvic drain|Placement of a pelvic drain
89432659|NCT03553173|Active Comparator|Control|"Subjects undergoing usual psycho-pharmacological treatment for smoking cessation.~Prescribed treatments:~Bupropion pills + Psychological advice~Varenicline pills + Psychological advice"
89432660|NCT03553173|Experimental|Intervention|"Subjects undergoing usual psycho-pharmacological treatment for smoking cessation plus a smart phone App.~Prescribed treatments:~Bupropion pills + Psychological advice + So-Lo-Mo~Varenicline pills + Psychological advice + So-Lo-Mo"
89432661|NCT02117037|Other|study of PEC markers and chemokines/ chemokine recep|blood sample for dosage and study of PEC markers and chemokines/ chemokine receptors
89432662|NCT01330017|Experimental|PE 10 mg|
89432663|NCT01330017|Experimental|PE 20 mg|
89432664|NCT01330017|Experimental|PE 30 mg|
89432665|NCT01330017|Experimental|PE 40 mg|
89432666|NCT01330017|Placebo Comparator|Placebo|
89432667|NCT02117115|Experimental|CT scan with contrast|
89432668|NCT02123199||Indacaterol/QAB149|Patients treated with Indacaterol for COPD prior to enrollment in study
89432669|NCT02123277|Experimental|concept proof|Balloon catheter for the Eustachian tube
89432670|NCT02251899|Experimental|Disease-Management intervention|Behavioral: Disease-Management intervention The participants in the intervention group receive a nurse-managed disease-management intervention that is regularly delivered by telephone or, when necessary, in person
88912183|NCT01575665|Experimental|Partial Rebreathing Mask|A novel membrane breathing mask which facilitates a partial rebreathing of expired gas (thereby raising systemic CO2), while allowing a diffusion of oxygen from the atmosphere to the user, through the membranes.
88912184|NCT01575678|Active Comparator|Melatonin|
88912185|NCT01575678|Placebo Comparator|Lactose|
88912186|NCT01575704|Experimental|Sport|
88912187|NCT01575704|Other|Control|
88912188|NCT01575717|Experimental|Vitamin D 4000|Subjects taking 4000 IU of vitamin D
88912189|NCT01575717|Experimental|Vitamin D 2000|Subjects taking 2000IU of vitamin D
88912190|NCT01575717|No Intervention|No Intervention|
88912191|NCT01575743|Experimental|Aerobic Exercise|
88912192|NCT01575743|Other|healthy controls|
89432671|NCT02251899|No Intervention|No Intervention: Control arm|Control group not receiving any in
89432672|NCT02117271|Placebo Comparator|nasal dilator strip|Breathe Right ® nasal dilator strip used during sleep
89432673|NCT02117271|Experimental|continuous positive airway pressure|nasal continuous positive airway pressure used during sleep
89432674|NCT02119845|Experimental|Endovascular AVF (EndoAVF)|The FLEX System will be used to endovascularly create a fistula in CKD patients who require hemodialysis vascular access.
89432675|NCT02117505|Experimental|Group 1 (Formulation 2 Then Formulation 1)|Single-dose of JNJ-54781532 formulation 2 will be administered as 150 milligram (mg) oral tablet in first treatment period; followed by JNJ-54781532 formulation 1 as 150 mg orally (5*30 mg tablet=150 mg) in second treatment period. A washout period of at least 7 days will be maintained between each treatment period.
89432676|NCT02117505|Experimental|Group 2 (Formulation 1 Then Formulation 2)|Single-dose of JNJ-54781532 formulation 1 will be administered as 150 mg oral tablet (5*30 mg tablet=150 mg) in first treatment period; followed by JNJ-54781532 formulation 2 as 150 mg oral tablet in second treatment period. A washout period of at least 7 days will be maintained between each treatment period.
89432677|NCT02117583|Experimental|Treatment A|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
89432678|NCT02117583|Experimental|Treatment B|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
89432679|NCT02117583|Experimental|Treatment C|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
89432680|NCT02117583|Experimental|Treatment D|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
88912193|NCT01575782|Experimental|Chloroquine|
88912194|NCT01575795|Active Comparator|Ticagrelor 180mg loading dose|Ticagrelor 180mg loading dose
88912195|NCT01575795|Experimental|Ticagrelor 360mg loading dose|Ticagrelor 360mg loading dose
88912196|NCT01575821|Experimental|Eucalyptus honey ,|75 children
89432681|NCT02117661|Experimental|L-carnitine capsules|2000 mg daily (2x 500 mg capsules twice a day - BID) for six months
89432682|NCT02117661|Placebo Comparator|Cellulose capsules|2x capsules twice a day - BID (4 total per day) for six months
89432683|NCT02117739|Experimental|All Participants|Dapsone gel and dapsone gel vehicle applied to the skin by separate occlusive patches twice a week for 21 days followed by a 10 to 17 day rest period then another application of dapsone gel and dapsone gel vehicle by patch.
89432684|NCT05293587|Experimental|Physical Activity|Physical activity sessions at public parks led by a Serenity Behavioral Health Certified Peer Specialist
89432685|NCT05293587|No Intervention|Waitlist|Participants will continue their usual care in the PEERS program. They will be offered the intervention after they have completed posttest measures.
89432686|NCT02251509|Experimental|Carvedilol|carvedilol BID for 2 weeks
89432687|NCT02251509|Experimental|Metoprolol tartrate|Metoprolol tartrate BID for 2 weeks
89432688|NCT03553017||Participants with eye disease|A maximum of 200 participants with various eye diseases will be recruited from appropriate eye clinics at Moorfields Eye Hospital. Eye conditions will include both anterior segment disease such as corneal disease and ocular inflammatory disease, retinal vascular and macular diseases, and optic nerve disease such as glaucoma.
89432689|NCT02119923|Experimental|Working memory training|
89432690|NCT02119923|Placebo Comparator|Placebo training|
89432691|NCT02117895|Experimental|Pancreatectomy & celiac plexus resection|Left celiac plexus resection will be performed besides standard distal pancreatectomy. Celiac plexus at the left side of aorta, between celiac trunk and superior mesenteric artery will be resected.
89432692|NCT02117895|Active Comparator|Pancreatectomy|Standard distal pancreatectomy includes distal pancreatectomy, splenectomy, and regional lymph nodes resection for pancreatic cancer at the body and tail. Regional lymph nodes includes group 8, 10, 11, 18, 7, 9, 14, 15, according to the 2003 edition of lymph nodes group system defined by Japan Pancreas Society (JPS).
89432693|NCT02117973|Active Comparator|Conventional Technique using Persona prosthesis|The surgeon will realize the implantation of the Persona prosthesis according to the surgical technique. Potential variables such as methodology for determining tibial rotation, measuring of bone cuts, and any intra-operative adjustments will be captured on the operative case report form.
89432694|NCT02117973|Experimental|iAssist Technique using Persona prosthesis|iAssist is an electronic displacement sensor based instrumentation system that provides intra-operative verification at each surgical step (bone cuts alignment and resection level); in order to help reduce bone cuts errors. iAssist features simple and intuitive instrumentation that is based on conventional total knee arthroplasty instrumentation. iAssist should take less than 2-3 minutes (on average) to setup
89432695|NCT02118051|Experimental|CFA , hMG,Ganirelix,choriogonadotropin alfa,progesterone.|"Corifollitropin Alfa (CFA) 150 ug from the 2nd day of the cycle for 7 days. hMG 300 IU/24h, if required from the 8th day of the Controlled Ovarian Stimulation , until the day human chorionic gonadotropin ( hCG.) Ganirelix 0.25 mg,Dose: 250μg/24h since the day observe a follicle> 14mm. Recombinant choriogonadotropin alfa,Dose: 6,500 IU, pods, when follicles> 17 mm are observed.~Micronized natural progesterone. Route of administration: vaginal. Dose: 400mg/24, from embryo transfer until the day of b-hCG."
89432696|NCT02118051|Active Comparator|hMG ,Ganirelix,choriogonadotropin alfa,progesterone|"Human Menopausal Gonadotropin (hMG). Dose: 300 IU/24h from the 2nd day of the cycle throughout the stimulation.~Ganirelix 0.25 mg,Dose: 250μg/24h since the day observe a follicle> 14mm. Recombinant choriogonadotropin alfa,Dose: 6,500 IU, pods, when follicles> 17 mm are observed.~Micronized natural progesterone. Route of administration: vaginal. Dose: 400mg/24, from embryo transfer until the day of b-hCG."
89432697|NCT02118129|Experimental|Behavioural intervention|Behavioural intervention consisting of an educational video component and use of a handheld mobile app to track vitamin D intake.
89432698|NCT02118129|Placebo Comparator|Control group|Wait-list control group
89432699|NCT02123355|Experimental|Dexmedetomidine|Dexmedetomidine is given at 0.5μg/kg/h by continuous infusion and is stopped to given 30 minutes before the surgery is over.
89432700|NCT02123355|Sham Comparator|Normal saline|Normal saline is given at 0.5μg/kg/h by continuous infusion and is stopped to given 30 minutes before the surgery is over.
89432701|NCT02123433|Experimental|13-valent vaccine|
89432702|NCT02120313|Active Comparator|inpatient rehabilitation|After discharge, patients participate in daily physical therapy for 3 weeks in a rehabilitation hospital.
89432703|NCT02120313|Experimental|outpatient rehabilitation|After discharge, patients participate in daily physical therapy for 3 weeks in an outpatient rehabilitation center.
89432704|NCT02120391|Sham Comparator|Control (Arm A)|"Patients randomized to Arm A(control group) will receive an iPhone application without any of the adherence intervention turned on. The control phone application will allow patients to record their medications and how many refills they have remaining. The application will also provide patients with links about their medication.~No adherence intervention will be done to these patients."
89432705|NCT02120391|Experimental|Cases (Arm B)|"Patients randomized to Arm B will receive an iPhone application with the adherence intervention turned on. The study coordinator will help with the installation of the iPhone application.~Participants in this group will not need to pay for the iPhone application."
89432706|NCT02123589|Experimental|Deep sedation|Injection of 0.05~0.1mg/kg midazolam and 1~2μg/kg fentanyl,then continuous intravenous infusion 0.05mg/kg.h midazolam and1~2μg/kg.h fentanyl to maintain sedation until attaining the target level of sedation,RASS score between -5 and -3
89432707|NCT02123589|Experimental|Deep and daily interruption of sedation|Injection of 0.05~0.1mg/kg midazolam and 1~2μg/kg fentanyl,then continuous intravenous infusion 0.05mg/kg.h midazolam and1~2μg/kg.h fentanyl to maintain sedation until attaining the target level of sedation,RASS score between -5 and -3.and from the second day after subject was admitted in ICU, daily interruption of sedation will be taken .
89432708|NCT02123589|Experimental|Light sedation|Injection of 0.05~0.1mg/kg midazolam and 1~2μg/kg fentanyl,then continuous intravenous infusion 0.05mg/kg.h midazolam and1~2μg/kg.h fentanyl to maintain sedation until attaining the target level of sedation,RASS score between -2 and +1.
89432709|NCT02120547|Experimental|Cenicriviroc in mild liver impaired|Subjects with mild liver impaired will receive cenicriviroc, 1 tablet once daily, for 14 days. Matching healthy subjects will receive Cenicriviroc, 1 tablet once daily, for 14 days.
89432710|NCT02120547|Experimental|Cenicriviroc in moderate liver impaired|Subjects with moderate liver impaired will receive cenicriviroc, 1 tablet once daily, for 14 days. Matching healthy subjects will receive Cenicriviroc, 1 tablet once daily, for 14 days.
89432711|NCT02118207|Experimental|Control dives 1st|Subjects in this group complete the first 3 dives as control dives and the second 3 dives preceded by aerobic exercise
89432712|NCT02118207|Experimental|Predive exercise 1st|Subjects complete the first 3 dives preceded by the intervention of aerobic exercise and the second 3 with no exercise as control dives
89432713|NCT03552861|Active Comparator|left and right DLPFC active treatment|Intervention: repetitive transcranial stimulation (rTMS) Each patient will be given 5 treatment sessions per week for 2 weeks (a total of 10 sessions).In each rTMS conditioning session,1200 pulses of stimuli at an intensity of 100% rest motor threshold (RMT) will give over the left and rigt DLPFC.Each session is 45 minutes long and will be consisted of 10Hz stimulation trains (active) over the left DLPFC and 1Hz over the right DLPFC，Interval of 5 minutes each side.During rTMS blocks, the coil will be oriented tangential to the surface.
89531222|NCT03339011|Experimental|SMS text message|"The content of the text messages is developed based on recommendation and advice from the Danish Health Authority about the importance of regular daily physical activity.~For 6 weeks, the text messages will be send three times per week, twice during the week days and once in the weekend, based on previous experience with SMS as motivation for chronic pain patients."
88912197|NCT01575821|Experimental|Labiatae honey|75 children allocated
88912198|NCT01575821|Experimental|Silan date extract (placebo)|75 children allocated
88912199|NCT01575821|Experimental|Citrus honey|75 children allocated
89009119|NCT04573621|Experimental|No pelvic drain|No pelvic drain placed
89009120|NCT04573465|Experimental|Phone Coaching Condition|Participants will receive weekly, 10-15 minute phone coaching from a trained peer-support coach throughout the 10 weeks that they use ACT Guide, an online program for general mental health. Coaches will adhere to an ACT-based protocol that includes reinforcing adherence, identifying and problem solving non-adherence, strengthening and generalizing ACT skills, and using ACT skills to increase commitment to ongoing program adherence.
89009121|NCT04573465|Experimental|Text Message Coaching Condition|Participants assigned to the text messaging condition will receive weekly text messages from their peer-support coach throughout the 10 weeks that they use ACT Guide, an online program for general mental health. These text messages will reflect content delivered in the phone coaching group, but through a briefer protocol that accounts for the abbreviated, asynchronous nature of texting. Text messages will similarly focus on reinforcing adherence, problem solving non-adherence, strengthening ACT skills, and using ACT to increase program adherence. However, these areas will be covered in short messages and with limited exchanges between participants and coaches due to the asynchronous nature of texting.
89009122|NCT04573465|Active Comparator|No Coaching Condition|Participants will be asked to use ACT Guide, an online program for general mental health, over the course of 10 weeks while receiving no coaching.
89009123|NCT04573153|Experimental|Treatment Arm|Subjects in ambulatory-at home-treatment will receive hydroxychloroquine (standard therapy) + dietary supplement consisting of serine, L-carnitine tartrate, N-acetylcysteine and nicotinamide riboside.
89009124|NCT04573153|Placebo Comparator|Placebo Arm|Subjects will take hydroxychloroquine (standard therapy) + dietary supplement placebo.
89009125|NCT02277418|Experimental|Child ETI withoutchest compressions|Endotracheal intubation of pediatric mannikin during resuscitation without chest compressions.
89009126|NCT02277418|Experimental|Child ETI with chest compressions|Endotracheal intubation of mannikin during resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
89009127|NCT02277418|Experimental|Infant ETI with chest compressions|endotracheal intubation (ETI) during infant mannikin resuscitation with uninterrupted chest compressions.
89009128|NCT02277418|Experimental|Infant ETI without chest compressions|Endotracheal intubation of infant mannikin during resuscitation without chest compressions.
89432714|NCT03552861|Active Comparator|left DLPFC active and right DLPFC sham treatment group|Each patient will be given 5 treatment sessions per week for 2 weeks (a total of 10 sessions).In each rTMS conditioning session,1200 pulses of stimuli at an intensity of 100% rest motor threshold (RMT) will give over the left and rigt DLPFC.Each session is 45 minutes long and will be consisted of 10Hz stimulation trains (active) over the left DLPFC and 1Hz over the right DLPFC，Interval of 5 minutes each side.During rTMS blocks, the coil will be oriented tangential to the surface. For sham control rTMS blocks, the coil will be oriented 90◦ away from the scalp so that no pulses perturbed underlying neural tissue.
89432715|NCT03552861|Active Comparator|left DLPFC sham and right DLPFC active treatment group|Each patient will be given 5 treatment sessions per week for 2 weeks (a total of 10 sessions).In each rTMS conditioning session,1200 pulses of stimuli at an intensity of 100% rest motor threshold (RMT) will give over the left and rigt DLPFC.Each session is 45 minutes long and will be consisted of 10Hz stimulation trains (active) over the left DLPFC and 1Hz over the right DLPFC，Interval of 5 minutes each side.During rTMS blocks, the coil will be oriented tangential to the surface. For sham control rTMS blocks, the coil will be oriented 90◦ away from the scalp so that no pulses perturbed underlying neural tissue.
89009129|NCT04573270|Experimental|COVID-19 Patients Experimental|13 COVID-19 infected subjects (Patients admitted to hospital suffering complications from COVID-19) will be randomized and equally distributed between placebo and experimental intervention.
89009130|NCT04573270|Placebo Comparator|COVID-19 Patients Placebo|13 COVID-19 infected subjects (Patients admitted to hospital suffering complications from COVID-19) will be randomized and equally distributed between placebo and experimental intervention.
89009131|NCT04573270|Experimental|Healthcare Providers Experimental|7 healthy subjects (healthcare providers following patients admitted to hospital suffering complications from COVID-19) will be randomized and equally distributed between placebo and experimental intervention.
89009132|NCT04573270|Placebo Comparator|Healthcare Providers Placebo|7 healthy subjects (healthcare providers following patients admitted to hospital suffering complications from COVID-19) will be randomized and equally distributed between placebo and experimental intervention.
89009133|NCT04572919|Active Comparator|group A|Patients were randomly assigned to undergo lateral advancement flap
89009134|NCT04572919|Active Comparator|group B|Patients were randomly assigned to undergo classic Limberg flap
89009135|NCT04572685|Experimental|LY03010 Process 1|"Drug Product of Process 1 ( P1): 156 mg/vial; Single Injection on Day 1 during the entire 120 Day's study.~LY03010 P1 using a non-sterile Active Pharmaceutical Ingredients (API) with an absolute ethanol recrystallization was manufactured by an optimized production process"
89432716|NCT03552861|Sham Comparator|left DLPFC sham and right DLPFC sham treatment group|Each patient will be given 5 treatment sessions per week for 2 weeks (a total of 10 sessions).In each rTMS conditioning session,1200 pulses of stimuli at an intensity of 100% rest motor threshold (RMT) will give over the left and rigt DLPFC.Each session is 45 minutes long and will be consisted of 10Hz stimulation trains (active) over the left DLPFC and 1Hz over the right DLPFC，Interval of 5 minutes each side.During rTMS blocks,the coil will be oriented 90◦ away from the scalp so that no pulses perturbed underlying neural tissue.
89432717|NCT02120703|Active Comparator|gabapentin|
89432718|NCT02120703|Active Comparator|Pregabalin|
89432719|NCT02118285|Experimental|Treatment|Haploidentical donor NK cells and IL-2 are infused intraperitoneally (IP) after a non-myeloablative preparative regimen of cyclophosphamide and fludarabine. INCB024360, at the assigned dose, begins 2 days before the NK cell infusion and continues twice daily for 90 days.
89432720|NCT02251587|Active Comparator|Standard Weight Management Program|Participants will be given information on diet and exercise. Participants will attend meetings to discuss barriers to exercise and nutrition and ways to solve these problems. Participants will be given healthy snack ideas and planning tools.
89531223|NCT03339011|No Intervention|No intervention|No attention from the study
89009136|NCT04572685|Experimental|LY03010 Process 2|"Drug Product of Process 2 (P2): 156 mg/vial; Single Injection on Day 1 during the entire 120 Day's study.~LY03010 P2 using a sterile Active Pharmaceutical Ingredients (API) with an isopropanol recrystallization was manufactured by the same optimized production process as that used in P1."
89432721|NCT02251587|Experimental|$ensible Weigh Program|Participants will be given information on diet and exercise with an emphasis on food security. Participants will be provided with additional information on community resources such as those for food, transportation, and safe places to exercise. A weekly cooking demonstration will be provided using inexpensive ingredients and common food pantry items.
89432722|NCT02118519|Active Comparator|mesenchymal stem cells|Autologous Mesenchymal Stem Cells primed prior to intra articular injection into knees of patients with advanced articular cartilage injury
89009137|NCT04572685|Experimental|INVEGA SUSTENNA|INVEGA SUSTENNA 156 mg/vial; Single Injection on Day 1 during the entire 120 Day's study
89432723|NCT02118519|Active Comparator|mesenchymal cells&platelet lysate|Autologous Mesenchymal Stem Cells primed prior to intra articular injection with platelet lysate into knees of patients with advanced articular cartilage injury
89432724|NCT02118675||Age 5-17 years|Participants age 5 - 17 will complete the following Body Measurements Body Composition and Circumference Measurements Whole Body DXA Scan Bioelectrical Impedance Analysis (BIA) BodPod Circumferences Ultrasound
89432725|NCT02118675||Age 18-80 years|Participants age 18-80 will complete the following Body Measurements Body Composition and Circumference Measurements Whole Body DXA Scan Bioelectrical Impedance Analysis (BIA) BodPod Circumferences Ultrasound
89432726|NCT02126709|Experimental|Treatment Arm|"Name: Repigel Active ingredient: Povidone iodine Dosage form: Liposomal hydrogel Administration route: Topical Strength: 3%~Application of study cream twice a day during the 8 week study period~It will be applied once in the morning and once in the night~We recommend the application to occur after the face is washed~One Finger Tip Unit is required per application to the entire face~The gel should be left on and not washed of for at least15 -30 minutes"
89432727|NCT02126709|Placebo Comparator|Placebo Arm|"Name: Neutrogena hydroboost gel Active ingredient: NA Strength: NA Dosage form: Water gel Administration route: Topical~Application of placebo cream twice a day during the 8 week study period~It will be applied once in the morning and once in the night~We recommend the application to occur after the face is washed~One Finger Tip Unit is required per application to the entire face~The gel should be left on and not washed of for at least15 -30 minutes"
89432728|NCT02126787|Experimental|Intensive Group Analytic Psychotherapy|Intensive Group Analytic Psychotherapy in a day clinic setting
89432729|NCT02126787|Experimental|Intensive GCBT|Intensive transdiagnostic cognitive-behavioral group therapy in a day clinic setting
89432730|NCT02126787|No Intervention|Wait-list control group|
89432731|NCT02123667||Asthmatic patients|asthmatic patients 18 to 65
89009138|NCT04572724|Experimental|Sacubitril/Valsartan treatment group|"Sacubitril/Valsartan will be administered step by step with a titrated dose. When patients switching to Sacubitril/Valsartan from RAS inhibitor, a washout period of at least 36 hours is required to decrease the risk of angioedema.~All subjects can have a beta-blocker, CCB, and/or alpha-blockers to control BP. Dialysis treatment: patients normally complete hemodialysis or peritoneal dialysis, need to ensure adequate dialysis requirements, no obvious overload, patients achieve dry weight after dialysis."
89432732|NCT02123667||Healthy volunteers|Volunteers 18 to 65
89432733|NCT03551925|Experimental|Treatment as Usual Plus Occupational Therapy|The occupational therapy intervention will be guided by the Integrative Medication Self-Management Intervention (IMedS).The IMedS process guides the occupational therapist and client through an initial evaluation process and a three-step intervention plan to improve medication management.
89432734|NCT03551925|Active Comparator|Treatment as Usual (TAU)|Participants will receive only the TAU intervention which is provided by a clinical pharmacist and is the protocol at Jordan Valley Community Health Center. The intervention seeks to improve medication adherence in individuals with hypertension.
89432735|NCT02123901|Experimental|Walking meditation & Walking|
89432736|NCT02123901|Active Comparator|Walking meditation & No exercise|
89432737|NCT02123979|Placebo Comparator|placebo patch|Neupro® transdermal patch/placebo randomly allocated like a flip of a coin applied to your skin at the dose of 8 mg/day or a matching placebo patch after the oral surgery procedure is completed.
89432738|NCT02123979|Experimental|Neupro® transdermal patch|Neupro® transdermal patch/placebo randomly allocated like a flip of a coin applied to your skin at the dose of 8 mg/day or a matching placebo patch after the oral surgery procedure is completed.
89432739|NCT03552315|Active Comparator|Water with amino acids and chromium|The carbonated water with a proprietary blend of five amino acids and chromium picolinate is consumed with a standardized test meal to study its effects on glucose and insulin responses.
89432740|NCT03552315|Placebo Comparator|Carbonated water|The placebo carbonated water is consumed with a standardized test meal to study its effects on glucose and insulin responses.
89432741|NCT02120859|Experimental|FFR - guided DEB angioplasty|DEB-only angioplasty is attempted in all patients. At baseline, quantitative coronary angiography (QCA) and fractional flow reserve (FFR) using an intracoronary standard bolus of adenosine are performed. If FFR at baseline is greater than 0.8, PCI is deferred, otherwise predilation with a non-coated balloon is performed. In case of severe recoil (> 50% residual stenosis) or flow-limiting dissection the procedure is deemed not suitable for DEB-only angioplasty and stent implantation is performed at the discretion of the operator. In all other cases, the lesion is treated using a Sequent Please® paclitaxel-eluting balloon (DEB). QCA and FFR measurements are repeated and the result is considered satisfactory if there is no flow-limiting dissection, residual stenosis < 40% and FFR > 0.8.
89432742|NCT02120859|Other|DEB angioplasty with provisional bare metal stenting|In case of suboptimal results after the FFR-guided DEB angioplasty described above, a bare metal stent is implanted inside the segment previously treated by DEB.
89432743|NCT02126865|Experimental|BI 1060469 Healthy|Multiple rising dose qd for 15 days
88912200|NCT01575847||Part I|"Part 1 will be a feasibility study conducted in the Emergency Department at UAMS and ACH. This Part will test the research use dipsticks and dipstick testing kit in subjects that are having APAP levels obtained as part of their medical evaluation.~Part 1 20 subjects~Part I~Inclusion Criteria:~Subject is 12-18 years of age. Subject has an APAP level ordered as part of clinical management.~Exclusion Criteria:~Previous recent history of APAP overdose in the previous 30 days."
88912201|NCT01575847||Part 2|"Part 2~Part 2 will be a non-intervention study in adults presenting to hepatology centers participating in the Acute Liver Failure Study Group (ALFSG). The dipstick will be tested in these subjects and the results will be compared to the HPLC-EC measurement of APAP protein adducts. The results of the dipstick testing will not be used for diagnosis or clinical decision-making.~Part 2 100 subjects~Part 2~Inclusion Criteria:~Subject is 18 years of age or older. Subject is enrolled in the ALFSG registry.~Exclusion Criteria:~None."
88912202|NCT01575938|Experimental|HIV group-based prevention intervention|The HIV prevention intervention is a 6-session group-based and manualized intervention. Participants will also receive HIV and STI testing and counseling prior to the start of the intervention.
88912203|NCT01575938|Active Comparator|Diet and nutrition|The comparison condition is a 6-session group-based and manualized health promotion intervention. Participants will also receive HIV and STI testing and counseling prior to the start of the intervention.
88912204|NCT01575938|No Intervention|Standard-of-care|This arm will receive HIV and STI testing and counseling only.
88912205|NCT01575951|Experimental|All patients|All participants enrolled.
88912206|NCT01576029|Active Comparator|Docetaxel|75 mg/m2, administered as a 1-hour intravenous infusion, every 3 weeks
89432744|NCT02126865|Placebo Comparator|Placebo to BI 1060469|Matching placebo as tablet for 15 days
89432745|NCT02126865|Experimental|BI 1060469 asthmatics|Multiple rising dose qd for 29 days
88912207|NCT01576029|Experimental|Cabazitaxel|25 mg/m2, administered as a 1-hour intravenous infusion, every 3 weeks
88912208|NCT01576068|Other|High Risk Customers|Pharmacy customers with GOLD COPD Criteria of high-risk subjects.
88912209|NCT01576081|Experimental|Unilateral orthotic intervention|The HEPHAISTOS orthotic was worn unilaterally for 56days by 11 healthy male subjects.
88912210|NCT01576094|Active Comparator|Milrinone|Milrinone (MR) lactate 1 mg/ml: dose 1, starting immediately after central lines were placed and maintained for the duration of the surgical procedure; dose 2, on NICU admission; dose 3, after 2 hours of stability with dose 2, and maintained up to 48 hours. Accordingly, patients randomised to MR received 0.5 , 0.75 and 1 microg/kg per min
88912211|NCT01576094|Active Comparator|Levosimendan|
89432746|NCT02126865|Placebo Comparator|Placebo to BI 1060469 asthmatics|Matching placebo as tablet for 29 days
89432747|NCT02120937|Experimental|MBCT-C Therapy|Mindfulness Based Cognitive Therapy for Children is a manualized psychotherapeutic intervention that combines mindfulness techniques with certain features of cognitive behavioral therapy. This particular protocol for youth includes weekly group sessions, regular home practice, and the core curriculum of formal mindfulness practices (e.g., body scan, sitting, movement, and walking meditations).
88912212|NCT01576107|Experimental|Physical activity|Exercise counseling (behavior change techniques)
88912213|NCT01576107|Experimental|Stress-management|Stress-management training
88912214|NCT01576133|Experimental|CAPABLE|Experimental group participants received up to 10 sessions; up to 6 with an OT, and up to 4 sessions with an RN, and ≤ $1200 of safety and functional modifications from a licensed handyman. These sessions happened in coordinated fashion over the course of 4 months.
88912215|NCT01576133|Active Comparator|Attention visits|Participants in the attention visit arm received 10 visits of one hour length spaced across 16 weeks. These visits included sedentary activities of their choice based on their goals and interests.
89432748|NCT06284395||Control Group|Thalidomide 100mg-200mg PO daily alone or in combination with dexamethasone 40mg PO every 24 hours on days 1-4, 8-11 of each cycle.
89432749|NCT06284395||Bortezomib Group|Bortezomib 1.3mg/m2 SC on days 1,4, 8,11 to the TD scheme for a total of 6 treatment cycles (VTD).
89432750|NCT06284382|Other|Presence of early trauma|"In the presence of early trauma arm, 15 participants are recruited based on a high Childhood Trauma Questionnaire total score."
89432751|NCT06284382|Other|Absence of early trauma|"In the absence of early trauma arm, 15 participants are recruited based on a low Childhood Trauma Questionnaire total score."
89432752|NCT06284343||Patients affected by Gynecologic Cancer undergoing systemic antineoplastic treatment|Study population will consist of subsequent patients prospectively enrolled at the time of prescription of a new line of systemic antineoplastic treatment for a gynecologic oncological disease, defined as ovarian, tubal, uterine, cervical, vaginal, or vulvar neoplasm
89432753|NCT06284330|No Intervention|Standard of care cascade testing|Standard of care cascade genetic testing
89432754|NCT06284330|Experimental|Choice architecture cascade testing|Direct mailed genetic testing kit to probands' relatives.
88912216|NCT01576185||Observational (xenograft models)|Human acute myeloid leukemia cells are injected into NSG mice. Mice are then treated with sorafenib or quizartinib via gavage once daily for 28 days. Peripheral blood and tissue samples are collected biweekly or weekly and analyzed for the presence of human CD45+ and CD33+ cells by quantitative flow cytometry.
89432755|NCT06284304|Experimental|Experimental radiotherapy treatment|SBRT 5x30Gy of whole prostate and isotoxic 45 Gy GTV plus intra-prostatic margin
89432756|NCT06284291|Experimental|Genetic epilepsy|Patients with epilepsies of genetic etiology
89432757|NCT06284291|Experimental|Patients with primary headache|Patients with primary headache with non-migraine features
89432758|NCT06284278|Experimental|Diaphragmatic breathing exercise group|Diaphragmatic breathing exercise through telehealth
89432759|NCT06284278|Active Comparator|Pelvic stabilization exercise group|Pelvic stabilization exercise through telehealth
89432760|NCT06284265|Experimental|Raphamin|"Take orally, do not take with meals. Keep the tablets in the mouth until completely dissolved.~On the first day of treatment, 8 tablets are taken according to the following scheme: 1 tablet every 30 minutes in the first 2 hours (a total of 5 tablets in 2 hours), then during the same day another 1 tablet is taken 3 times at regular intervals. On the 2nd day and then take 1 tablet 3 times a day. The duration of treatment is 10 days."
89432761|NCT06284265|Placebo Comparator|Placebo|Take orally, do not take with meals. Keep the tablets in the mouth until completely dissolved. Placebo is administered according to the Raphamin regimen for 10 days.
88912217|NCT01576224|Experimental|Immediate mobilization|Patients start exercises immediately after osteosynthesis.
88912218|NCT01576224|Active Comparator|Later mobilization|Patients are allowed exercises after 14 days.
88912219|NCT01576237||healthy apheresis donors|healthy blood donors for blood cell aphereses
88912220|NCT01576250|Experimental|unilateral lower limb suspension|This is an intervention study, where each subject will undergo 12 days of unilateral lower limb suspension. Randomly, the dominant or the non-dominant leg of the subject will be suspended by attachment of a sling to a non-rigid ankle brace and to a harness on the upper body and unloaded from all weight bearing. The knee will be slightly flexed at an angle of 130°. Hip, knee and ankle will be fully mobile. The sling will be used during all locomotory activity, and the subjects will use crutches for walking.
88912221|NCT01576263||Total knee arthroplasty|25 consecutive patients diagnosed for total knee arthroplasty.
88912222|NCT01576263||Total hip arthroplasty|27 patients diagnosed for total hip arthroplasty.
88912223|NCT01576289||Patients undergoing uppper endoscopy|Consecutive patients with and without symptoms of reflux disease who routinely undergo upper endoscopy from November 2011 through May 2012.
89432762|NCT06284252|No Intervention|Control group|This is the group that takes theoretical lessons and does not play virtual games. Students will receive physical examination training and participate in laboratory practices. Pre-test and post-test skill evaluation will be made.
89432763|NCT06284252|Experimental|Initiative group|Students will participate in theoretical training and laboratory practice. Students will play three different virtual game simulations. Students will participate in pre-test and post-test skill practice.
89432764|NCT06284226|Experimental|A group|
88912224|NCT01576302|Experimental|Diaphragmatic breathing|Training in diaphragmatic breathing as response incompatible with rumination.
88912225|NCT01576302|Active Comparator|Muscle relaxation|Patients in this arm of study will be taught muscle relaxation as intervention for rumination, instructed in habit-reversal paradigm to use after eating food or if urge to ruminate
88912226|NCT01576328|Experimental|Cohort 1|MPC dose 1 or Placebo
88912227|NCT01576328|Experimental|Cohort 2|MPC dose 2 or Placebo
88912228|NCT01576328|Experimental|Cohort 3|MPC dose 3 or Placebo
89432765|NCT06284213||Normal Cognition (NC) with at least 1 vascular risk factor|"NC is defined as:~No diagnosis of SCD, MCI, or dementia; AND~CDR: Sum of Boxes = 0 AND neuropsychological testing in normal range.~Participants must have at least 1 of the following criteria prior to enrollment:~Diabetes (at least 1):~Fasting (8-hour) blood sugar ≥126 mg/dL~Random or Post-prandial blood sugar ≥200 mg/dL~HbA1C ≥6.5%~Treatment with anti-diabetic medicine~Hypertension plus (at least 2):~Use of anti-hypertensive medications for lowering blood pressure for ≥10 years~Current use of 2 or more anti-hypertensive meds for lowering blood pressure~Blood pressure in a research or clinical setting in the last 2 years with SBP ≥140 or DBP ≥90~Second blood pressure reading in a research or clinical setting in the last 2 years (different date) with SBP ≥140 or DBP ≥90~Evidence of likely HTN end organ damage~MRI factors (at least 1):~Peri-Ventricular Fazekas Extent Grade or Deep Fazekas Extent Grade ≥2~≥1 microbleeds~≥1 lacunar infarcts"
88912229|NCT01576354|Active Comparator|Prolonged-release Fampridine|
88912230|NCT01576354|Placebo Comparator|Placebo|
88912231|NCT01576380|Experimental|TKI258|TKI258 is dosed on a flat scale of 500 mg, to be administered orally on a 5 days on / 2 days off dosing schedule which will be repeated every week.
88912232|NCT01576393|Experimental|Home-Based family therapy|12 home-based family therapy sessions
88912233|NCT01576393|Active Comparator|Office-based family therapy|12 office-based family therapy sessions
88912234|NCT01576393|Placebo Comparator|Women's Health Education|12 womens's health education sessions
89432766|NCT06284213||Subjective Cognitive Decline (SCD)|"Subjective cognitive decline is defined as:~Cognitive concerns based on a Short eCog-12 score ≥ 3 (based on administration to participant), AND~Normal cognition (neuropsychological testing within normal range)."
89432767|NCT06284213||Mild Cognitive Impairment (MCI)|"Mild cognitive impairment is defined as:~There is a cognitive concern, i.e., the subject, the co-participant, or a clinician is concerned about a change in cognition compared to the subject's previous level.~There is impairment in one or more cognitive domains (memory, language, executive function, attention, and visuospatial skills) that is greater than would be expected for the patient's age and educational background.~There is largely preserved independence in functional abilities (no change from prior level of functioning or requires only extra effort and minimal aids or assistance).~There is no evidence of dementia (cognitive changes are mild and there is no evidence of a significant impairment in social or occupational functioning)."
89432768|NCT06284213||Mild Dementia|"Mild dementia is defined as:~The subject has cognitive or behavioral (neuropsychiatric) symptoms that meet all of the following criteria:~Interfere with ability to function as before at work or at usual activities?~Represent a decline from previous levels of functioning?~Are not explained by delirium or major psychiatric disorder? AND~Impairment in one* or more of the following domains.~Impaired ability to acquire and remember new information.~Impaired reasoning and handling of complex tasks, poor judgment.~Impaired visuospatial abilities.~Impaired language functions.~Changes in personality, behavior, or comportment * In the event of single-domain impairment (e.g., language in PPA, behavior in bvFTD, posterior cortical atrophy), the subject must not fulfill criteria for MCI.~AND~CDR: Global Score = 0.5 or 1"
89432769|NCT06284174|Placebo Comparator|control group|Before wound closure, patients will undergo 0.9% normal saline irrigation solutions for soaking the wound for three minutes followed by rinsing with copious saline.
89432770|NCT06284174|Experimental|povidone-iodine group|Before wound closure, patients will undergo 3.5% povidone-iodine solutions for soaking the wound for three minutes followed by rinsing with copious saline.
88912235|NCT01576419|Experimental|PG201 tablet|
88912236|NCT01576419|Active Comparator|Celecoxib capsule|
88912237|NCT01576432|Experimental|Breastfeeding + skin-to-skin contact|In group 1 (BF+SSC), neonates dressed with a diaper were held in prone, in SSC with the mother; breastfeeding (BF) was started at least 5 minutes before heel lance and maintained during sampling
88912238|NCT01576432|Experimental|Sucrose + skin-to-skin contact|In group 2 (sucrose + SSC), neonates were held in prone between the mothers' breast at least 5 minutes before sampling and 2 ml 24% sucrose was given with a sterile syringe in the mouth 2 minutes before heel lance.
88912239|NCT01576432|Experimental|Skin-to-skin contact|In group 3 (SSC), neonates were held between the mother's breast as in group 2, but no sucrose was given.
88912240|NCT01576432|Active Comparator|Sucrose|In group 4 (Sucrose), 2 ml 24% sucrose was administered through a sterile syringe in the mouth 2 minutes before heel lance to neonates laid on supine on a cot; the procedure was done in the presence of the mother
88912241|NCT01576445|Experimental|Mid-vastus approach|
88912242|NCT01576445|Experimental|medial parapatellar approach|
88912243|NCT01576458|Active Comparator|ursodeoxycholic acid|10 pregant women with intrahepatic cholestasis of pregnancy
88912244|NCT01576458|Active Comparator|placebo|10 pregnant women with intrahepatic cholestasis of pregnancy
88912245|NCT01576497|Active Comparator|EUS-FNA with suction|EUS-FNA with suction/10, 15, 20 to-and-fro motion vs. EUS-FNA with suction/10, 15, 20 to-and-fro motion Visual assessment as stoping rule: 20 to-and-fro motion at different site will be performed when EUS-FNA sampling with 10, 15, 20 to-and-fro motion is unsatisfactory.
88912246|NCT01576497|Active Comparator|EUS-FNA without suction|EUS-FNA with suction/10, 15, 20 to-and-fro motion vs. EUS-FNA without suction/10, 15, 20 to-and-fro motion Visual assessment as stoping rule: 20 to-and-fro motion at different site will be performed when EUS-FNA sampling with 10, 15, 20 to-and-fro motion is unsatisfactory.
88912247|NCT01576510|Experimental|Prolonged Exposure (PE) treatment.|
88912248|NCT01576510|No Intervention|Trauma exposed healthy controls|Clinical assessments at baseline, 7 and 10 weeks. fMRI assessments at baseline and 10 weeks.
89432771|NCT06284174|Experimental|CHG group|Before wound closure, patients will undergo 0.05% chlorhexidine gluconate (CHG) solution for soaking the wound for three minutes followed by rinsing with copious saline.
88912249|NCT01576562||Study Group - Control Group|VAD implantation (study group) or other cardiothoracic surgery (control group)
88912250|NCT01576601||Hopkins|Pediatric patients (0-18 yo) who are scheduled for craniotomy surgery under general anesthesia. This will include patients undergoing brain surgery for cancer, epilepsy, vascular malformations, and craniofacial reconstructive surgery. Patients will receive routine postoperative management and treated for pain based on institutional routine. We will follow patients for the first 5 post-operative days or until discharge, whichever comes first.
88912251|NCT01576601||Childrens Hospital of Philadelphia|Pediatric patients (0-18 yo) who are scheduled for craniotomy surgery under general anesthesia. This will include patients undergoing brain surgery for cancer, epilepsy, vascular malformations, and craniofacial reconstructive surgery. Patients will receive routine postoperative management and treated for pain based on institutional routine. We will follow patients for the first 5 post-operative days or until discharge, whichever comes first.
89432772|NCT06284161|Other|Quadriceps Combined Test|
88912252|NCT01576601||Childrens Hospital Boston|Pediatric patients (0-18 yo) who are scheduled for craniotomy surgery under general anesthesia. This will include patients undergoing brain surgery for cancer, epilepsy, vascular malformations, and craniofacial reconstructive surgery. Patients will receive routine postoperative management and treated for pain based on institutional routine. We will follow patients for the first 5 post-operative days or until discharge, whichever comes first.
88912253|NCT01576614||Nurse-Physician Rounding by Phone|"The SICU's practice involves daily morning team rounding at the bedside. The team includes the critical care attending physician (AP), surgical resident physician, and critical care nurse. The AP is physically present in the SICU during these rounds and for the hours between approximately 7am and 7pm. During off-shift hours (7pm-7am), the AP is available by phone as the on-call attending physician. In addition to this on-call availability, the standard of practice in SICU for years has been that the on-call physician proactively places a telephone call to the SICU at least once every evening to perform telephone rounds with the resident physician aeach SICU patient."
88912254|NCT01576614||Nurse-Physican rounding by R T P|"Remote Telepresence Robotics (RTP) is a form of telemedicine that enables a fast and direct face-to-face response by a physician, located remotely, and may sometime utilize a mobile robot.~RTP provides the physician the ability to teleconference with patients and other healthcare providers using two way audio visual technology. The sophistication of these devices varies and can range from simple video conferencing to remote robotic control devices with audio visual conferencing capabilities. The robotic capabilities refer to ability of the physician to remotely direct or drive the device from one location to another.~The technology allows clinical experts to provide the right care at the right time and has become an accepted standard of care when used under appropriate circumstances."
88912255|NCT01576627|Experimental|zinc citrate|
88912256|NCT01576627|Active Comparator|zinc gluconate|
88912257|NCT01576627|Active Comparator|zinc oxide|
88912258|NCT01576640|Other|Replapse Prevention Therapy|
88912259|NCT01576653|Active Comparator|No IFI|Bronchoscopy will be performed routinely in most patients with clinical suspicion of IFI. IFIs in patients will be retrospectively graded in possible, probable, proven and no IFI according to revised EORTC/MSG criteria. Patients that do not fulfill EORTC/MSG IFI criteria will serve as negative controls.
88912260|NCT01576653|Active Comparator|IFI|Bronchoscopy will be performed routinely in most patients with clinical suspicion of IFI. IFIs in patients will be retrospectively graded in possible, probable, proven and no IFI according to revised EORTC/MSG criteria. Patients that do fulfill EORTC/MSG criteria of possible/probable/proven IFI will serve as study group.
88912261|NCT01576666|Experimental|LDE225 and BKM120 in combination|LDE225 and BKM120 in combination
89432773|NCT06284148|Other|Sequence 1|"5 clinics. In stepped wedge design study, this was the sequence with shortest control (run-in) period.~All sequences have a run-in period and intervention period. In control period participants were screened using existing nurse-led oral screening, in intervention period both - nurse-led and our new confidential screen were used at the same time."
89432774|NCT06284148|Other|Sequence 2|5 clinics.
89432775|NCT06284148|Other|Sequence 3|5 clinics. This was the sequence with longest control (run-in) period.
89432776|NCT06284135|Experimental|Michl-stitch|
89432777|NCT06284135|No Intervention|control|
89432778|NCT06284083|No Intervention|Polysomnographic (PSG) diagnosis and scoring.Oxygen saturation mesurment (SpO2)|The participants were put to sleep with polysomnography (PSG) in the sleep laboratory for 1 night and were divided into 3 groups according to their disease severity. (mild, moderate, severe).The apnea/hypopnea index (AHI) was defined as the sum of the apnea and hypopnea number per hour of sleep. The mean SpO2 percentages of the PSG device were measured from the fingertip with a system-defined pulse oximeter.
89432779|NCT06284083|Experimental|Agmatine, Telomerase and Trace element levels measurment|With the permission of the participants, 7 ml of venous, fasting blood was taken after the night's sleep.In the blood serum of the participants, agmatine, telomerase, and trace element levels were measured with a commercial ELISA kit.
88912262|NCT01576679|Experimental|tPA|tissue Plasminogen Activator
88912263|NCT01576679|Placebo Comparator|Placebo|Saline
88912264|NCT01576692|Experimental|Treatment|"Participants receive humanized anti-GD2 antibody, chemotherapy, cytokines, and natural killer cells.~Cells for infusion are prepared using the CliniMACS System."
88912265|NCT01576731|Active Comparator|Tenofovir + emtricitabine + lopinavir/r|Standard postexposure prophylaxis combination
88912266|NCT01576731|Experimental|Tenofovir + Emtricitabine + Raltegravir|new postexposure prophylaxis combination
88912267|NCT01576757||Heart failure|Patients with heart failure from any cause will be considered as potential participants given their clinical background meets eligibility criteria.
88912268|NCT01576770|Active Comparator|ethyl chloride vapocoolant spray|"Half of the patients will randomly be assigned to receive Gebauer's ethyl choride topical anesthetic vapo-coolant spray immediately prior to placing a 22 gauge intravenous catheter.~Pain in this group will be evaluated at the time of IV placement by an independent observer (unblinded) and the patient on a 0-10 scale. Pain will again be evaluated when propofol is injected at anesthesia induction by a blinded observer and the staff anesthesiologist (also blinded) on a scale of 1-4.~Blinding will occur following IV placement by draping and securing the hand and IV site with Coban self-adherent elastic wrap to cover any skin changes due to the ethyl chloride or the patch."
88912269|NCT01576770|Experimental|Synera Patch|"The other half of the patients will randomly be assigned to receive Synera Patches, to be applied to the dorsum of both hands, at least 30 minutes before placing a 22 gauge intravenous catheter.~Pain in this group will be evaluated at the time of IV placement by an independent observer (unblinded) and the patient on a 0-10 scale. Pain will again be evaluated when propofol is injected at anesthesia induction by a blinded observer and the staff anesthesiologist (also blinded) on a scale of 1-4.~Blinding will occur following IV placement by draping and securing the hand and IV site with Coban self-adherent elastic wrap to cover any skin changes due to the patch or ethyl chloride."
89432780|NCT06284031|Experimental|3 fractions|
89009139|NCT04572724|Active Comparator|RAS inhibitor treatment group|RAS inhibitor group allows the use of a monodose of any ACEi or ARB. All subjects can have a beta-blocker, CCB, and/or alpha-blockers to control BP. Dialysis treatment: patients normally complete hemodialysis or peritoneal dialysis, need to ensure adequate dialysis requirements, no obvious overload, patients achieve dry weight after dialysis.
89009140|NCT00255567|Active Comparator|1|Sodium Stibogluconate (30 days)
89432781|NCT06284005|Experimental|prosthetic group|prosthetic group performs the entire protocol with the prosthesis prototype.
89432782|NCT06283953|Active Comparator|Active Comparator Caregivers|TrachMeHome program delivered in the hospital including education, skills training and case management for caregivers
89432783|NCT06283953|Experimental|Intervention Caregivers|Trach Me Home and Trach@Home with additional education, outpatient care team communication and social support for caregivers.
89432784|NCT06283953|Active Comparator|Active Comparator Physicians|Primary care physicians' of the enrolled participant's child receiving discharge communication
89432785|NCT06283953|Experimental|Intervention Physicians|Primary care physicians' of the enrolled participant's child receiving outpatient care team communication prior to discharge
89432786|NCT06283940|Experimental|Physiotherapist-led exercise based cardiac rehabilitation (PT-X)|PT-X consists of centralcirculatory aerobic exercise and muscular endurance training in an existing PT-X group at Alingsas Hospital in Sweden. The patients will follow an individually tailored exercise program, twice a week for 60 minutes each session over 12 weeks. The physiotherapist guides and progresses the program based on the patient's exercise capacity throughout the intervention. Additionally, two sessions of home-based exercise will be added and recorded in an exercise diary. The exercise programs are prescribed after the patient's individual exercise capacity, with perceived exertion graded 13-17 on Borg's 6-20 scale.
89432787|NCT06283940|No Intervention|Control group|The patient will continue with their usual activities during the control period
89432788|NCT06283927||Re-resection|Resection of the recurrent tumor
89432789|NCT06283927||Best oncological treatment|Best oncological treatment consisting of re-challenge temozolomide, re-irradiation, experimental therapy, or best supportive care
89432790|NCT06283875||Surgical treatment queue (N=40)|Cervical cancer patients who meet the inclusion criteria and are eligible for radical surgical resection. Collect surgical tumor tissue samples from the screening stage of patients in this queue, as well as peripheral blood samples (20 ml/time) from baseline, postoperative, postoperative radiotherapy and chemotherapy end nodes, consolidation treatment end nodes (some patients with this treatment), and multiple nodes during the 6-month follow-up stage. Perform ctDNA MRD testing in a timely manner separately
89432791|NCT06283875||Radical radiotherapy and chemotherapy treatment cohort (N=40)|Cervical cancer patients who meet the inclusion criteria and are eligible for radical radiotherapy and chemotherapy. Collect baseline tumor tissue samples from patients during the screening phase, as well as peripheral blood samples (20 ml/time) from multiple nodes at baseline, mid-term of curative radiotherapy and chemotherapy, after curative radiotherapy and chemotherapy, after consolidation therapy (if any), and at 6 months/time during the follow-up phase. Perform ctDNA MRD testing in a timely manner separately
89432792|NCT06283862|Experimental|Immediate Education|Education sessions starting ~ week 4 of trial
89432793|NCT06283862|Other|Waitlist Control - delayed education|Education sessions starting ~ week 12 of trial
88912270|NCT01576822|Active Comparator|Low Dose|Participants randomized to this group will undergo a protocol consisting of 1 hour of sauna therapy per day, for a minimum of 3 days per week, completed in 3 weeks or less (21 days). (9 total sessions, 9 hours of sauna). Participants will be able to schedule visits on any of 7 days per week. Maximum flexibility in hours of operation as well as flexibility in which days are attended will be utilized to increase likelihood of retention. Participants will be able to attend 9 consecutive sessions, should they wish.
88912271|NCT01576822|Active Comparator|High Dose|Participants randomized to this group will undergo a protocol consisting of 2 hours of sauna therapy per day, for a minimum of 5 days per week, completed in 3 weeks or less (21 days). (15 total sessions, 30 hours of sauna). Participants will be able to schedule visits on any of 7 days per week. Maximum flexibility in hours of operation as well as flexibility in which days are attended will be utilized to increase likelihood of retention. A participant may attend visits for 15 consecutive days, should they wish.
88912272|NCT01576848|Experimental|GROUP 1 (OLD-PRO)|test drink contains intrinsically labeled protein alone
88912273|NCT01576848|Experimental|GROUP 2 (OLD-PRO/CARB)|test drink contains intrinsically labeled protein and carbohydrate
88912274|NCT01576848|Experimental|GROUP 3 (YOUNG-PRO)|test drink contains intrinsically labeled protein alone
88912275|NCT01576848|Experimental|GROUP 4 (YOUNG-PRO/CARB)|test drink contains intrinsically labeled protein and carbohydrate
88912276|NCT01576861|Experimental|GH replacement|Patients will receive 48 months of substitutive somatotropin (growth hormone) therapy at a dose of 0,012 mg/kg every second day, added to their background optimized CHF therapy
88912277|NCT01576861|No Intervention|Control CHF patients under optimized CHF therapy|
88912278|NCT01576900||Desmopressin monotherapy|Control group: Desmopressin (Minirin Tablet 0.1-0.4mg/day) + simple instruction
88912279|NCT01576900||Combination group|"Study group: Desmopressin (Minirin Tablet 0.1-0.4mg/day) + SyBeMeP~* Patients will be randomized and assigned to each group at the ratio of 1:1."
88912280|NCT01576913|Active Comparator|Music pacing|Exercise testing with music pacing
88912281|NCT01576913|No Intervention|No music pacing|Exercise testing without music pacing
89432794|NCT06283849|Experimental|Experimental group|Black adults aged 55 and older with T2D
88912282|NCT01576926||surgery|patients with obstructive sleep apnea
88912283|NCT01576965|Experimental|Mechanical Bowel Prep Group|Half of the subjects will be randomized to a group that does mechanical bowel preparation with sodium phosphate enema. Those assigned to the mechanical bowel prep group will be asked to administer a single sodium phosphate enema rectally before going to bed the night before surgery. If stool is not clear in the morning, mechanical bowel prep subjects will administer one additional enema the morning of surgery. All subjects will be instructed to restrict their diet to clear liquids the day prior to their surgery and to continue this diet after midnight, save a small sip of water for medications in the morning.
89009141|NCT00255567|Experimental|2|Paromomycin Sulphate (21 days)
89009142|NCT00255567|Experimental|3|Sodium Stibogluconate + Paromomycin Sulphate (17 days)
89009143|NCT04572607|No Intervention|Control group 1|
89009144|NCT04572607|No Intervention|Control group 2|
89432795|NCT06283836|Active Comparator|Group D|Continuous infusion of dexmedetomidine during intervention ( 1ug/kg over 15 minutes then 0.4 ug/kg/hour)
89009145|NCT04572607|No Intervention|Control group 3|
89009146|NCT04572607|No Intervention|Control group 4|
89009147|NCT04572607|No Intervention|Control group 5|
89009148|NCT04572607|No Intervention|Control group 6|
89009149|NCT04572607|No Intervention|Control group 7|
88912284|NCT01576965|No Intervention|No Bowel Prep Group|Participants randomly assigned to this group will not have the bowel prep treatment before the surgery. All subjects will be instructed to restrict their diet to clear liquids the day prior to their surgery and to continue this diet after midnight, save a small sip of water for medications in the morning.
89432796|NCT06283836|Active Comparator|Group R|Target-controlled infusion of remifentanil ( 2ng//ml- plasma concentration)
89432797|NCT06283797|Experimental|Automated insulin delivery|Participants will use an automated insulin delivery system with study CGM
89432798|NCT06283797|Active Comparator|Conventional insulin therapy|Participants will use multiple insulin daily insulin injections or insulin pump with study CGM
88912285|NCT01576978|Active Comparator|postural orientations|The group of postural orientations receive a pamphlet containing information about the sitting, standing and lying postures to be performed at home for 10 weeks.The marking of the note pain will be before and after 10 weeks.
88912286|NCT01576978|Active Comparator|hatha yoga exercises|The allocates women will participate in the Hatha yoga class for 10 weeks. At first in class, the women will make a note of pain according to VAS. Class Moments: heating ten minutes, forty minutes postures of stretching and strengthening exercises and breathing exercises, ten minutes of relaxation and meditation. Marking note of pain after practice.
88912287|NCT01576991||Oocyte collection|This is an observational study; there are no cohorts or groups
88912288|NCT01577004|Experimental|Omega-3 fatty acid supplement|Data obtained after the intervention was compared to baseline data
88912289|NCT01577017|Experimental|Letrozole|Group L will be assigned with Letrozole 5 mg on night on day 5 to day 9 of the cycle
88912290|NCT01577030|Experimental|Dairy|Add 4 daily servings of non-fat dairy to diet for a period of 4 weeks
88912291|NCT01577030|Active Comparator|Fruit|Add 4 daily servings of fruit to diet, remove all dairy from diet for a period of 4 weeks
88912292|NCT01577043|Active Comparator|Racecadotril|intestinal antisecretory
89432799|NCT06283745|Active Comparator|Platelet Rich Plasma (PRP)|Participants receive PRP intranasal injection into the olfactory cleft three times, separated by two weeks each. Blood is drawn from the patient. This is placed in a centrifuge and using a specialized PRP kit (Emcyte), the sequential spinning process isolates the platelet-rich plasma portion of the blood and we inject that back into the patient within the nasal cavity.
88912293|NCT01577043|Placebo Comparator|cornstach solution|Cornstarch powder diluted in distilled water
89432800|NCT06283745|Active Comparator|Saline|Participants receive saline injections into the olfactory cleft three times, separated by two weeks each. (Sham/placebo injections).
89432801|NCT06283732|Experimental|Dietary Supplement: Greens powder|Participants are to consume one scoop (8.5 g) of the greens powder mixed in 8-10 oz of water every morning before breakfast for two weeks.
89432802|NCT06283719|Experimental|Dose Escalation|A total of six dose escalations were preset: 0.1 mg, 0.3 mg, 1 mg, 3 mg, 10 mg, and 30 mg.
89432803|NCT06283719|Experimental|Dose Expansion|Participants will receive the RP2D identified in Dose exploration of the study.
88912294|NCT01577056|Active Comparator|Fish oil|
88912295|NCT01577056|Placebo Comparator|Placebo|FH subjects with standard treatment (statin treatment)
88912296|NCT01577082|Experimental|CHF 1535 200/6µg|
88912297|NCT01577082|Active Comparator|BDP 100µg|
88912298|NCT01577121|Placebo Comparator|placebo|
88912299|NCT01577121|Experimental|indomethacin|50 mg/ 6 hours of indomethacin oral use
88912300|NCT01577134|Experimental|Intervention to enhance physical activity|Participants in this arm have high motivation to be regularly physically active. Face-to-face group intervention includes behavior change techniques to enhance physical activity.
88912301|NCT01577134|Active Comparator|Active control intervention|Face-to-face group intervention includes behavior change techniques to enhance volunteering and improve attitudes towards volunteering.
88912302|NCT01577134|Other|Passive control intervention|Waiting-list control group, who receives all information (that the active groups got) via mail after completion of 8.5 months follow-up.
88912303|NCT01577095|Experimental|EA + Rosiglitazone|
88912304|NCT01577095|Placebo Comparator|Rosiglitazone|
88912305|NCT01577147|Other|sample collection|Ovulation prediction products provided to aid conception
88912306|NCT01577199|Active Comparator|High dose gonadotropins|High dose gonadotropins protocol compared to Low-dose Clomiphene
88912307|NCT01577199|Experimental|Low-dose Clomiphene|clomid-based, low dose gonadotropin protocol compared to High dose gonadotropins
88912308|NCT01577212|Experimental|Individualized dose escalation|Individualized dose escalation on the basis of the dose to the organs at risk.
88912309|NCT01577225|Experimental|OPSITE Post-Op Visible|Subject is randomized to OPSITE Post-Op Visible group or Tape&Gauze group. Dressing should be used right after surgery and changed as needed.
88912310|NCT01577225|Active Comparator|Tape&Gauze|Subject is randomized to OPSITE Post-Op Visible group or Tape&Gauze group. Tape and Gauze should be used right after surgery and changed as per routin practice.
88912311|NCT01577264||Cimzia treatment|
88912312|NCT01577290|Experimental|Mindfulness training|Group receives mindfulness training.
88912313|NCT01577290|Active Comparator|Discussion group|Group has access to a discussion group.
88912314|NCT01577303|Experimental|CBM training program variant 1|Attention training towards positive cues using words as stimuli
88912315|NCT01577303|Experimental|CBM training program variant 2|Attention training towards positive cues using words and faces as stimuli
89009150|NCT04572607|Experimental|Honey group 1|
88912316|NCT01577303|Experimental|CBM training program variant 3|Attention training towards negative using words as stimuli
88912317|NCT01577303|Experimental|CBM training program variant 4|Attention training towards negative using words and faces
88912318|NCT01577303|Experimental|Control training variant 1|Control training condition using words as stimuli
88912319|NCT01577303|Experimental|Control training variant 2|Control training condition using words and faces as stimuli
88912320|NCT01577316|Experimental|Pregnant Woman|Pregnant Woman
89009151|NCT04572607|Experimental|Honey group 2|
89432804|NCT06283693|Experimental|Experimantal group:|Intervention Group : The women in this group will receive a 4-week Mindfulness-Based Stress Reduction program in addition to routine outpatient clinic follow-up at the relevant institution. Before the implementation of the Mindfulness-Based Stress Reduction program, the women in the intervention group will be administered the Informed Voluntary Consent Form, Descriptive Characteristics Information Form, Perceived Stress Scale, DASS-21 and salivary cortisol measurements for pre-test measurements. After the mindfulness program, follow-up tests will be conducted in the 4th week. In the 8th week, the post-test will be conducted. In the post-test and follow-up test; Perceived Stress Scale, DASS-21 and salivary cortisol measurements will be applied.
89432805|NCT06283693|No Intervention|Control group:|The women in this group will not be subjected to any intervention and will be followed up in the routine outpatient clinic of the relevant institution. Informed Voluntary Consent Form, Descriptive Characteristics Information Form, Perceived Stress Scale, DASS-21 and salivary cortisol measurements will be applied for the pre-test measurements of the control group women. In the study, post-test measurements will be made 4 weeks after the pre-test measurements of the control group and follow-up measurements will be made 8 weeks later. Perceived Stress Scale, DASS-21 and salivary cortisol measurements will be applied to the women in the control group for pre-test, post-test and follow-up measurements.
89432806|NCT06283680||Group 1|Ex patients on the lung transplant waiting list
89432807|NCT06283680||Group 2|Tansplant patients
89432808|NCT06283680||Group 3|Patients waiting on the current list
89432809|NCT06283667||Wegovy®|Patients with obesity treated with Wegovy® (semaglutide) once weekly under real-world clinical practice conditions in Japan.
89432810|NCT06283654||1-lead ECG group|Patients after PVI that received a 1-lead ECG
89432811|NCT06283654||standard care group|standard care group
89432812|NCT06283641||Saxenda®|Patients with obesity treated with Saxenda® for weight management in routine clinical practice in Taiwan
89432813|NCT06283628|Active Comparator|Subjects with traditional approach on the right side and parasagittal approach on the left side.|Patients will undergo bilateral RFA; the right side will be done following the traditional approach, and the left side will be done following the parasagittal approach. Traditional approach is done by placing the electrode at a 20 degrees' ipsilateral oblique angle to the sagittal plane toward the junction of the superior articular process and transverse process of the vertebral body to target the traversing medial branch nerve. The reason for the proposed angle is to avoid the mamillo-accessory ligament that may be ossified in up to 10% of the normal spine and potentially prevent proper coagulation of the medial branch nerve during the RFA procedure. Parasagittal (new) approach: is performed by placing the RF cannula parasagittally and more dorsally. To achieve maximum nerve coagulation, the electrode should be placed as parallel to the nerve as possible, and placing it parasagittally helps achieve this goal. The remainder of the procedure does not differ from the traditional method.
89432814|NCT06283628|Active Comparator|Subjects with traditional approach on the left side and parasagittal approach on the right side.|Patients will undergo bilateral RFA; the left side will be done following the traditional approach, and the right side will be done following the parasagittal approach. Traditional approach is done by placing the electrode at a 20 degrees' ipsilateral oblique angle to the sagittal plane toward the junction of the superior articular process and transverse process of the vertebral body to target the traversing medial branch nerve. The reason for the proposed angle is to avoid the mamillo-accessory ligament that may be ossified in up to 10% of the normal spine and potentially prevent proper coagulation of the medial branch nerve during the RFA procedure. Parasagittal (new) approach: is performed by placing the RF cannula parasagittally and more dorsally. To achieve maximum nerve coagulation, the electrode should be placed as parallel to the nerve as possible, and placing it parasagittally helps achieve this goal. The remainder of the procedure does not differ from the traditional method.
89432815|NCT06283602|Other|Kahramanmaraş Sütçü İmam University|Patient who apply to our clinic for routine paediatric treatment for the included in the study
89432816|NCT06283589|Experimental|INZ-701|The study consists of a 26-day treatment period where the dose of INZ-701 will be 1.8 mg/kg once weekly. INZ-701 will be administered as a subcutaneous injection once weekly for 4 weeks on Days 3, 10, 17, and 24. The study participant's post-hemodialysis body weight on Day 1 will be used to calculate the dose to be administered.
89432817|NCT06283576||Pancreatic cancer, early|Early pancreatic cancer, T1/T2 NoM0
89432818|NCT06283576||IPMN|
89432819|NCT06283576||Pancreatic cancer, advanced|Advance pancreatic cancer T1-4, Nx, Mx
88912321|NCT01577316|Experimental|Nonpregnant women|2011-2012 Seasonal Influenza Vaccine (include A/California/7/2009 (H1N1)-like, A/Perth/16/2009 (H3N2)-like, and B/Brisbane/60/2008-like antigens) administered to 15ug without adjuvant, via intramuscular in pregnant and nonpregnant women.
89432820|NCT06283576||Healthy controls|
88912322|NCT01577342|Active Comparator|Moxifloxacin 0.5%|1 drop four times daily for 3 days in affected eye post intravitreal injection
88912323|NCT01577342|No Intervention|No antibiotic use|
89009152|NCT04572607|Experimental|Honey group 3|
89432821|NCT06283563|Experimental|Experimental group|Participants will receive reminders regarding physical activity promotion via the social media group created.
89432822|NCT06283563|Active Comparator|Control group|Participants will be encouraged to continue their routine lives.
88912324|NCT01577355|Experimental|[C14]-LY2784544|Single 30 mg oral dose containing 100 micro curies of LY2784544
88912325|NCT01577368|Experimental|Piperacillin continuous infusion|Piperacillin-Tazobactam 2gr (Loading dose DAY 1) plus Piperacillin-Tazobactam continuous infusion 8gr every 24 hours
88912326|NCT01577368|Active Comparator|Piperacillin intermittent infusion|Piperacillin-Tazobactam 4gr intermittent infusion 4gr every 8 hours
88912327|NCT01577394|Experimental|Early stage of dementia|oculomotor measurements
88912328|NCT01577407|Experimental|Nefopam|
88912329|NCT01577407|Placebo Comparator|placebo|
88912330|NCT01577420|Experimental|Group A|Reflexology Sessions: One session per week performed by certified reflexologist for four consecutive weeks.
88912331|NCT01577420|Placebo Comparator|Group B|Placebo Sessions: One session per week performed by research aide for four consecutive weeks.
88912332|NCT01577420|No Intervention|Group C|Control; no foot sessions
88912333|NCT01577433||Control Group|Historical control HeartMate II BTT and DT data
89009153|NCT04572607|Experimental|Honey group 4|
88912334|NCT01577433||Prospective and Retrospectively identified SSI|Prospectively and Retrospectively identified HeartMate II patients where the full length of the velour coated portion of the driveline is tunneled under the skin
88912335|NCT01577446|Experimental|CRT|The CRT group undergoes implantation of a CRT defibrillator
88912336|NCT01577446|No Intervention|no-CRT|The no-CRT group receives a dual-chamber defibrillator
88912337|NCT01577459|Experimental|TR-701 FA with PSE|TR-701 FA 200 mg oral with PSE
89197725|NCT02544867|Experimental|Reduction in sitting time|Those randomized to this condition focused on reducing their overall sitting time by two hours per day (a goal achieved in similar studies [17,18] that represented approximately a 25% reduction in daily sitting time). Participants were encouraged to reach this goal by standing in bouts of roughly 10 minutes per hour. The purpose of this arm was to investigate whether we could replicate improvements in sitting time achieved in other worksite studies in our cohort of older adults, which included both workers and non-workers.
89197726|NCT02544867|Experimental|Increase in sit-to-stand transitions|Those randomized to the sit-to-stand condition focused on increasing the number of sit-to-stand transitions they performed throughout the day with a goal of adding 30 additional transitions per day. Previous studies have not succeeded in increasing the number of sit-to-stand transitions in older adults, possibly because they focused on reducing overall sitting time, encouraged longer standing breaks and did not provide a specific goal for sit-to-stand transitions [26-28]. An increase in sit-to-stand transitions would not be expected with an increase standing intervention alone, as prolonged standing reduces the opportunity for sit-to-stand transitions.
89197727|NCT00952432|Active Comparator|ACUPUNCTURE|ACUPUNCTURE
89197728|NCT00952432|Active Comparator|MEDICATION|Carbamazepine
89197729|NCT00861315|Experimental|Nebulized amikacin|Patients receive nebulized amikacin once a day during three days. Placebo is administered intravenousely
89197730|NCT00861315|Active Comparator|Intravenous amikacin|
89197731|NCT00952510||Whiplash patients|The cohort is based on 100 whiplash patients which underwent the measure procedure to obtain cervical range of motion.
89197732|NCT00388297|Experimental|Levothyroxine for Subclinical Hypothyroidism|100 µg of Levothryoxine for participants with subclinical hypothyroidism
89197733|NCT00388297|Placebo Comparator|Placebo for Levothyroxine - Subclinincal Hypothyroidism|Placebo for Levothyroxine for participants with subclinical hypothyroidism
89197734|NCT00388297|Experimental|Levothyroxine for Hypothyroxinemia - Hypothyroxinemia|50 µg of Levothyroxine for participants with hypothyroxinemia
89197735|NCT00388297|Placebo Comparator|Placebo for Levothyroxine|Placebo for Levothyroxine for participants with hypothyroxinemia
89197736|NCT00943540|Experimental|Raltegravir BID-QD|"Week 1-4~600 mg of atazanavir to be taken once daily~400 mg of raltegravir to be taken twice daily~300 mg of lamivudine (or 200 mg of emtricitabine) to be taken once daily~Week 5-8~600 mg of atazanavir to be taken once daily~800 mg of raltegravir to be taken once daily~300 mg of lamivudine (or 200 mg of emtricitabine) to be taken once daily"
89197737|NCT00861393|Other|CBT|
89197738|NCT00861393|Other|Waitlist|
89197739|NCT00854685|Experimental|1|
89197740|NCT00854685|Experimental|2|
89197741|NCT00854685|Experimental|3|
89197742|NCT00854685|Experimental|4|
88912338|NCT01577459|Placebo Comparator|TR-701 FA Placebo with PSE|TR-701 FA Placebo 200 mg oral with PSE
88912339|NCT01577472|Active Comparator|High Dose Clomiphencitrat|450 IU Merional® plus 100mg Serophene®
88912340|NCT01577472|Active Comparator|Low Dose Clomiphencitrat|150 IU Merional® plus 100mg Serophene®
88912341|NCT01577472|Placebo Comparator|High Dose Placebo|450 IU Merional® plus Placebo
88912342|NCT01577472|Placebo Comparator|Low Dose Placebo|150 IU Merional® plus Placebo
88912343|NCT01577485|Experimental|Probiotic pastille|Test group
89197743|NCT00854685|Placebo Comparator|5|
89197744|NCT00854685|Placebo Comparator|6|
89197745|NCT01864720|Active Comparator|Professionally Administered CBT-I (Standard Care)|Patients (n = 59) assigned to this group will receive 6 weekly sessions of cognitive-behavioral therapy for insomnia (CBT-I) of approximately 50 minutes, offered individually by a licensed psychologist with significant experience (at least 2 years) in the administration of CBT-I with cancer patients.
89197746|NCT01864720|Experimental|Stepped Care CBT-I|Patients having an ISI score > 7 but < 15 (n = 65), will all receive first a web-based CBT-I for six weeks. Each week, the patients will first have to read written information on the website, and then watch a video capsule (duration between 5 and 20 min each). Patients with an ISI score > 14 (n = 53) will receive six weekly sessions of CBT-I administered individually by a professional.
89197747|NCT00857571|Experimental|Suspension|PF-02413873 suspension
88912344|NCT01577485|Active Comparator|Control pastille|Control group
89197748|NCT00857571|Experimental|Tablet|PF-02413873 Phase 2 Tablets
89432823|NCT06283537|Experimental|Online episiotomy group|30 students will be assigned to the online education group with a random sampling model. To this group; Online episiotomy simulation training will be provided.
89432824|NCT06283537|Experimental|Face to face training group|30 students will be assigned to the face-to-face education group with a random sampling model. This group will be given face-to-face episiotomy simulation training in the school environment, which is traditionally applied to the face-to-face training group..
89432825|NCT06283524||Single cohort of MS patients with EDSS 1.0-8.0|Confirmed diagnosis of MS with an EDSS score ranging from 1.0 and 8.0.
89432826|NCT06283485||Male|"Phase 1: Creating artificial intelligence from ultrasound scans of 150 healthy volunteers Sonoanatomical PENG and Suprainguinal Fascia Iliaca Block pictures are taken as follows.~1) PENG (Pericapsular Nerve Group Block): Linear and convex probes will be used to collect images. No invasive procedures will be conducted on healthy subjects for sonoanatomical data. 150 healthy volunteers (75 women-75 males) will be ultrasounded.~1.2) Suprainguinal Fascia Iliaca Block: Linear probe images. No invasive procedures will be conducted on healthy subjects for sonoanatomical data. 150 healthy individuals (75 female-75 male) will be ultrasounded.~Phase 2: Smart Alfa Teknoloji San. and Tic. Inc. will use Nerveblox, an artificial intelligence system built using data from the first stage, in the second part of the study. First-stage artificial intelligence technology validation and accuracy study. The accuracy study will involve 40 healthy volunteers. 20 men and 20 women will be studied."
88912345|NCT01577511||30 Patients|"Patients with operable, stage III or IV, adenocarcino-type colorectal cancer treated at the Nîmes University Hospital.~Intervention: Samples and follow up"
88912346|NCT01577524|Active Comparator|Diluted Povidone Iodine Solution|
89197749|NCT00943774||All subjects|All subject participants
89432827|NCT06283485||Female|"Phase 1: Creating artificial intelligence from ultrasound scans of 150 healthy volunteers Sonoanatomical PENG and Suprainguinal Fascia Iliaca Block pictures are taken as follows.~1) PENG (Pericapsular Nerve Group Block): Linear and convex probes will be used to collect images. No invasive procedures will be conducted on healthy subjects for sonoanatomical data. 150 healthy volunteers (75 women-75 males) will be ultrasounded.~1.2) Suprainguinal Fascia Iliaca Block: Linear probe images. No invasive procedures will be conducted on healthy subjects for sonoanatomical data. 150 healthy individuals (75 female-75 male) will be ultrasounded."
89432828|NCT06283446|Experimental|High-Intensity|Participants will receive high-intensity episodic future-thinking cue images, and high-intensity episodic recent-thinking cue images during an MRI decision-making task.
89432829|NCT06283446|Active Comparator|Low-Intensity (Control)|Participants will receive low-intensity episodic future-thinking cue images, and low-intensity episodic recent-thinking cue images during an MRI decision-making task.
89432830|NCT06283433|Active Comparator|Control Group (venipuncture)|Conventional blood sampling via venipuncture method by a skilled drawing facility
89432831|NCT06283433|Experimental|Intervention Group (DBS)|Blood sampling via dried blood spotting (DBS) method at patient's home
89432832|NCT06283420||HF patients iniciated with SGLT2 inhibitor|HF patients with medical indication to iniciation of SGLT2 inhibitors
89432833|NCT06283420||HF patients iniciated with sGC stimulator|HF patients with medical indication to iniciation of sGC stimulator
89432834|NCT06283420||HF patients iniciated with ARNI|HF patients with medical indication to iniciation of ARNI
89432835|NCT06283420||HF patients without change of their chronic medication|these HF patients (without ARNI, sGCs or SGLT2i) will serve as internal controls during oservational part of the study (3 mo)
89432836|NCT06283381|Experimental|Arm A: experimental group|no administration of Esomeprazole or any other proton pump inhibitor after the Endoscopic Sleeve Gastroplasty
89432837|NCT06283381|Active Comparator|Arm B: standard of care group|administration of Esomeprazole 40 mg twice a day for 4 weeks and 40 mg once a day for another 4 weeks after the Endoscopic Sleeve Gastroplasty
89432838|NCT06283355|Experimental|Single NMT|Swab parent nares then insert swab directly into neonate nares once.
89432839|NCT06283355|Experimental|Repeat NMT|Swab parents nares then insert swab directly into neonate nares multiple times.
89432840|NCT06283355|Placebo Comparator|Placebo|Insert a sterile swab into neonate nares.
89432841|NCT06283342||Iron deficiency group|Patients with a ferritin level below 12 mg/L were considered to have Iron deficiency group.
89432842|NCT06283342||Not iron deficiency group|Patients with a ferritin level above 12 mg/L were considered to have not iron deficiency group.
89432843|NCT06283342||Iron deficiency anemia group|Patients with ferritin level below 12 mg/L and hemoglobin (Hb) value below 11 g/dL were considered to have IDA.
88912347|NCT01577524|Placebo Comparator|Normal Saline Wash|
88912348|NCT01577550|Experimental|i.v. BI 655066|A subject to receive a single i.v. dose of BI 655066
88912349|NCT01577550|Placebo Comparator|i.v. placebo|A subject to receive a single i.v. dose of placebo
88912350|NCT01577550|Experimental|s.c. BI 655066|A subject to receive a single s.c. dose of BI 655066
88912351|NCT01577550|Placebo Comparator|s.c. placebo|A subject to receive a single s.c. dose of placebo
88912352|NCT01577576||Upper-body athletes|This group includes swimmers, rowers or kayakers with a history of at least 10 years of intense training, and performance in regional competitions for the past five years.
88912353|NCT01577576||Lower-body athletes|This group includes runners (marathon or trail) and cyclists with a history of at least 10 years of intense training, and performance in regional competitions for the past five years.
88912354|NCT01577576||Sedentary volunteers|This group of healthy volunteers does not participate in athletic activity for more than two hours per week. They are matched by age and sex with the athletic groups.
89432844|NCT06283342||Not iron deficiency anemia group|Patients with ferritin level below 12 mg/L and hemoglobin (Hb) value above 11 g/dL were considered to have Not iron deficiency anemia group.
89432845|NCT06283329||Group A|a group of patients receiving systematic decurarization using neostigmine , a unique dose of 40 µg/kg associated with atropine 20 µg/kg
89432846|NCT06283329||Group B|a group of patients extubated through clinical criteria without use of neostigmine
89432847|NCT06283277||Singleton pregnant women at gestational age between 37-42 weeks|estimated fetal weight measured by ultrasound using Hadlock IV formula and Youssef's formula compared with the sensitivity of fetal clavicular measurement.
88912355|NCT01577589|Experimental|A|600 mg ceftaroline fosamil in 50 ml infusion volume
88912356|NCT01577589|Placebo Comparator|B|Placebo in 50 ml infusion volume
88912357|NCT01577589|Experimental|C|600 ceftaroline fosamil in 250 ml infusion volume
88912358|NCT01577589|Placebo Comparator|D|Placebo in 250 ml infusion volume
88912359|NCT01577589|Experimental|E|600 mg ceftaroline in 100 ml infusion volume
88912360|NCT01577589|Placebo Comparator|F|Placebo in 100 ml infusion volume
88912361|NCT01577602|No Intervention|Standard practice|
88912362|NCT01577602|Experimental|Printed list intervention|Providing patients a list of their current medications before they see medical assistant and begin their visit.
89432848|NCT06283251|Experimental|PediRISE Program Group|"Participants will be randomized in a 1:1 fashion and will be stratified by site. Participant parents will complete:~Baseline survey in-person, by telephone, or virtually.~PediRISE program orientation with study team member, in-person or virtual.~Optional meeting with certified benefits counselor.~Receive fixed funds twice a month for 6 months.~Standard supportive care from social worker and/or resource specialist to identify and discuss available resources.~End of study survey."
89432849|NCT06283251|No Intervention|Usual Care Group|"Participants will be randomized in a 1:1 fashion and will be stratified by site. Participant parents will complete:~Baseline survey in-person, by telephone, or virtually, and orientation with study team member.~Standard supportive care from social worker and/or resource specialist to identify and discuss available resources.~End of study survey."
88912363|NCT01577602|Experimental|Open ended question intervention|"Medical assistants begin the medication review with a scripted, open ended question (i.e., tell me about your medications)"
89432850|NCT06283238||Cohort A|Participating subjects will be enrolled prior to initiating treatment with a regimen that includes an immune checkpoint inhibitor or chemotherapy alone in the case of the immunotherapy ineligible cohort. Archived formalin fixed paraffin embedded (FFPE) tumor tissue will be collected for all subjects if available. Patients will have an optional fresh research only biopsy if there is a lesion amenable to safe biopsy which will be frozen for further studies.
89432851|NCT06283238||Cohort B (Melanoma Cohort)|Melanoma samples were previously collected and analyzed under Pro00059349, NCT02694965. Data will continue to be collected from participant's electronic medical records.
89432852|NCT06283238||Cohort C|Retrospective portion that will allow for collection of data and archived tissue The Duke Enterprise Data Unified Content Explorer (DEDUCE) software tool will be utilized to identify patients with gastroesophageal adenocarcinoma or squamous cell or melanoma initiated on anti-PD-1 antibody immunotherapy at Duke University Medical Center and the Duke Cancer Institute between January 1, 2011 and August 31, 2023, and patients ineligible for immunotherapy that received chemotherapy during the same time period.
89432853|NCT06283186|Experimental|Lower limb cycle ergometer|The participants in the lower limb cycle ergometer group will undergo a 30-minute aerobic exercise intervention comprising a 5-minute warm-up, 20 minutes of training at 70-80% of the heart rate reserve, and a 5-minute cool-down.
89432854|NCT06283186|Experimental|Upper limb cycle ergometer|The participants in the upper limb cycle ergometer group will undergo a 30-minute aerobic exercise intervention comprising a 5-minute warm-up, 20 minutes of training at 70-80% of the heart rate reserve, and a 5-minute cool-down.
89432855|NCT06283186|No Intervention|Control|Participants in the control group will remain seated for the entire 30-minute duration of the experiment without receiving any form of distraction.
89432856|NCT06283173|Experimental|Collagen wound dressing with positive and negative controls|Application of test dressing, 0.5% sodium lauryl sulfate in distilled water, and distilled water on areas of the back or upper arm.
89432857|NCT06283095|Experimental|study group|we will do expansion palatoplasty
88912364|NCT01577602|Experimental|Combined intervention|
88912365|NCT01577615|Experimental|Patterned Experience Group|Infants in the patterned experience group will receive a patterned feeding experience with all feedings through discharge. They will receive a touch intervention at each gavage feeding. Once oral feedings are initiated, they will be offered an oral feeding at every scheduled feeding. They will be held for feedings. They will be observed twice a week utilizing the computer data acquisition system. Follow up visits will occur at 2,6 amd 24 months corrected age.
88912366|NCT01577615|No Intervention|Usual Care Group|In the usual care group infants usually are not held or contained during gavage feeding. Infants in the usual care group are orally fed at the discretion of the nurses or medical team. Once oral feedings are initiated, infants will be observed twice a week using the computer data acquisition system. Follow up visits will occur at 2,6 and 24 months corrected age.
88912367|NCT01577667|No Intervention|Conventional ventilation|Usual ventilation is administered according to the protocols implemented in the unit
88912368|NCT01577667|Experimental|Intellivent|"Intellivent is a ventilatory mode included in ventilator S1, Hamilton Medical. Intervention: the patient is ventilated with the same ventilator than in the conventionnal group; but the ASV-Intellivent ventilation has to be activated via a dedicated key on the ventilator screen.~IntelliVent® activation requires selecting the kind of patient: ARDS, COPD and whether hemodynamic instability exists.~The initial settings are IntelliVent® by default settings (% MV: 110%, PEEP: 5 cm H2O, FiO2: 60% - 100% in case of ARDS).~Therefore modification of these various parameters is automatic. FiO2 and PEP are modified according to SpO2; %MV according to EtCO2."
88912369|NCT01577680|Experimental|Moderate Hepatic Impairment|Approximately 9 subjects will complete each of these treatment arms
88912370|NCT01577680|Experimental|Matched Healthy Volunteers|Matched to the moderate hepatic impairment subjects based on gender, ethnicity, body mass index (+/-15%) and age (+/-5 years) Approximately 9 subjects will complete each of these treatment arms
88912371|NCT01577693|Experimental|0.5 mg novel dose form (test)|0.5 mg novel dose form (test)
88912372|NCT01577693|Other|0.5 mg Soft Gel Capsule|0.5 mg Soft Gel Capsule (reference)
88912373|NCT01577719|Active Comparator|Multimedia Lifestyle Improvement|Multimedia lifestyle intervention
88912374|NCT01577719|Placebo Comparator|Usual Care|usual care
88912375|NCT01577771|Active Comparator|Child|1 dose of Prevnar13 at 2 to 4 years of age
89432858|NCT06283082|Experimental|Asymptomatic subjects with an AGXT heterozygous mutation|
89432859|NCT06283082|Active Comparator|Symptomatic subjects with an AGXT heterozygous mutation|
88912376|NCT01577771|Experimental|Toddler 1 dose|Single dose of Prevnar13 at 12-15 months of age
88912377|NCT01577771|Active Comparator|Toddler 2 dose|2 doses of Prevnar13 2 months apart beginning at 12-15 months of age
89009154|NCT04572607|Experimental|Honey group 5|
89009155|NCT04572607|Experimental|Honey group 6|
89197750|NCT00943930||Marijuana-dependent volunteers|
89197751|NCT00854763||Hypertension|
89432860|NCT06283056|Experimental|Device Treatment|Eligible subjects will undergo two treatments with the Morpheus8 device using the 3, 5 7 mm depths or sequential (Burst) mode, based on the treating physician's discretion.
89432861|NCT06283043||experimental group|Parkinson's patients will be included and the evaluations specified in the method section will be applied.
89009156|NCT03450967|Experimental|Durvalumab Plus Tremelimumab|Durvalumab 1500mg plus tremelimumab 75mg via IV infusion Q4W, starting on Week 0, for up to a maximum of 4 doses/cycles followed by durvalumab monotherapy 1500mg via IV infusion Q4W, starting 4 weeks after the last infusion of the combination until progression.).
89432862|NCT06283043||control group|The healthy group will be included and the evaluations specified in the method section will be applied.
89432863|NCT06283004|Active Comparator|Level walking|It will walk at a 0-degree slope (0) throughout the research.
89432864|NCT06283004|Experimental|Downhill walking|It will walk at a 10-degree downhill slope (-10) throughout the research.
89432865|NCT06283004|Experimental|Uphill walking|It will walk at a 10-degree uphill slope (+10) throughout the research.
89432866|NCT06282991||Lorlatinib|Patients received lorlatinib treatment under EAP
89432867|NCT06282965|Experimental|Ang 1-7 100 mcg/kg/day|Angiotensin I/II (1-7) acetate will be delivered as a subcutaneous injection at a dose of 100 micrograms per kilogram per day for 21 days.
89432868|NCT06282965|Experimental|Ang 1-7 200 mcg/kg/day|Angiotensin I/II (1-7) acetate will be delivered as a subcutaneous injection at a dose of 200 micrograms per kilogram per day for 21 days.
89432869|NCT06282965|Placebo Comparator|Placebo|Sterile saline (NaCl) will be delivered as a subcutaneous injection for 21 days.
88912378|NCT01577771|Experimental|Infants 2+1|Infants receiving Prevnar13 at 6 weeks, 14 weeks and 9 months. Note: This infant immunization schedule is used in many European countries and in South Africa and has been shown to be immunogenic and effective. However, few head-to-head comparisons of the 2+1 and 3+0 schedules have been conducted.
88912379|NCT01577771|Active Comparator|Infants 3+0|Infants receiving Prevnar13 at 6, 10 and 14 weeks
88912380|NCT01577784|Experimental|Pazopanib|800 mg / day of pazopanib in monotherapy
88912381|NCT01577797|Experimental|CBT-based text messages - Week 1 or 3|One week CBT-based text messages followed by a 1-week washout period (Week 2)
88912382|NCT01577797|Placebo Comparator|Placebo text messages - Week 3 or 1|
88912383|NCT01577823|No Intervention|No foley catheter|
88912384|NCT01577823|Active Comparator|Foley Catheter|
88912385|NCT01577849|Active Comparator|Vitamin D3|
88912386|NCT01577849|Experimental|DP-R206|
88912387|NCT01577862|Active Comparator|Colistin|Colistin alone, 2 million units every 8 hours intravenously or according to renal function
88912388|NCT01577862|Experimental|Colistin plus Rifampicin|Colistin, 2 million units every 8 hours intravenously or according to renal function, plus Rifampicin, 600 mg every 12 hours intravenously
88912389|NCT01577875|No Intervention|control group|histologic prediction only with the narrow band imaging (without magnification)
88912390|NCT01577875|Other|test group|histologic prediction with narrow band imaging plus magnification
88912391|NCT01577888|Experimental|Lithotripsy Treatment|Shockwave System Treatment -Lithotripsy-enhanced, low-pressure balloon dilation of calcified, stenotic peripheral arteries.
88912392|NCT01577914|Experimental|Carvedilol Tablets USP 12.5 mg|Carvedilol Tablets USP 12.5 mg of M/s Ipca Laboratories Limited, India
88912393|NCT01577914|Active Comparator|Coreg®|Coreg® (Carvedilol Tablets) 12.5 mg of M/s GlaxoSmithKline
88912394|NCT01577927|Active Comparator|Usual home care|No assistance or care by PT.
88912395|NCT01577927|Experimental|PT-assisted home rehabilitation|Assisted home care is supported by a PT at least 2 times/month. Few brief educational lessons preceeded the training activity that the patient performs by himself at home.
88912396|NCT01577940|Experimental|Infusion of local anesthetic|TAP block with 20 ml of ropivacaine 0,5%, catheter with infusion of ropivacaine 0,2% 5 ml/h 24 hours.
89432870|NCT06282952|Experimental|Fecal microbiota transplant from biobank|The newborns receive fecal microbiota transplant from their own mother (50 newborns).
89432871|NCT06282952|Active Comparator|Fecal microbiota transplant from own mother|Newborns receive fecal microbiota transplant from normal weight, healthy female donor from the Microbiome Biobank (50 newborns).
89432872|NCT06282952|No Intervention|The observational cohort|"If mother has Group B streptococcus (GBS) colonization or other infectious, and microbiota transplant cannot be given or if mother will have non-elective-CS and the microbiome transplant is not available, the mother is included in the observational cohort, which is open (not blinded)."
89432873|NCT06282926||Group 1|Healthy adult volunteers
89432874|NCT06282926||Group 2|ACHD patients with repaired Tetralogy of Fallot and known moderate or severe pulmonary regurgitation
89432875|NCT06282913|Experimental|Mindfulness Meditation Group|During the first meeting, before the planned training, data will be collected face to face using the personal information form, Compassion Fatigue Brief Scale, Maslach Burnout Scale, Psychological Well-Being Scale. Physicians and nurses in the intervention group were given group counseling sessions by the researcher, in groups of 10-15 people, for 20 minutes once a week for 8 weeks. An online meditation practice will be provided for a long time. At the end of the mindfulness meditation application (in the 8th week) and four weeks after the end of the application (in the 12th week) for follow-up purposes, data will be collected through an online survey for physicians and nurses using Compassion Fatigue Brief Scale, Maslach Burnout Scale, Psychological Well-Being Scale.
89432876|NCT06282913|No Intervention|Control Group|During the first meeting, data will be collected face to face using the personal information form, MY-KÖ, MTÖ and PİÖÖ. In the 8th and 12th weeks of the research, the data will be re-administered to the physicians and nurses in the control group via an online survey using Compassion Fatigue Brief Scale, Maslach Burnout Scale, Psychological Well-Being Scale. After the implementation process of the research is completed, mindfulness meditation application will be applied online once to the physicians and nurses in the control group.
89432877|NCT06282887|Experimental|Music Therapy Group|Participants in the Music Therapy Group will receive standard care and approximately 15 minutes of music therapy before the MRI scan and will have music played through their headphones during the scanning process.
89432878|NCT06282887|No Intervention|Control Group|Participants in the Control Group will receive standard care throughout the awaiting period and the scanning process.
88912397|NCT01577940|Placebo Comparator|Infusion of saline|TAP block with 20 ml of ropivacaine 0,5%, catheter with infusion of saline 5 ml/h 24 hours.
88912398|NCT01577953|Experimental|SB010|The drug SB010 is administered in phosphate-buffered saline solution, inhaled via a controlled breathing system over a 5 to 10 min.
88912399|NCT01577953|Placebo Comparator|Placebo|The placebo (phosphate-buffered saline) is administered as a solution inhaled via a controlled breathing system over a 5 to 10 min.
88912400|NCT01577979|Experimental|Reminder/Recall Strategy|The experimental group will consist of patients randomly selected from participating clinics. Patients from private practices and the safety net provider may be exposed to a reminder/recall strategy involving text messaging. Text messages will be used to notify parents that their child is due for an immunization or well-care visit. Parents will be able to reply with one of three response options. Patients presenting to the randomly selected experimental managed care clinics for the first HPV vaccination dose will be offered the ability to provide the clinic with their preferred contact method. The preferred method of contact will be used for the second and third HPV dose reminder/recalls.
88912401|NCT01577979|No Intervention|Usual Care|The patients in the usual care group will receive the clinic's usual care in terms of immunization and well-care reminder/recall.
88912402|NCT01577992|Experimental|Group 1: MSA disease|determination of objective and subjective pain threshold before and after levodopa intake
88912403|NCT01577992|Experimental|Group 2: Parkinson disease|determination of objective and subjective pain threshold before and after levodopa intake
88912404|NCT01577992|Other|Group 3: healthy volunteers.|one determination of objective and subjective pain threshold without treatment
88912405|NCT01578018|Other|Lung Cancer|Diagnostic
88912406|NCT01578018|Other|Lung Disease|Diagnostic
88912407|NCT01578057|Experimental|tasimelteon + placebo ethanol|
88912408|NCT01578057|Experimental|ethanol + placebo tasimelteon|
88912409|NCT01578057|Experimental|tasimelteon + ethanol|
88912410|NCT01578057|Experimental|placebo tasimelteon + placebo ethanol|
88912411|NCT01578070|Experimental|ViscoGel® and 0.2μg Act-HIB®|
88912412|NCT01578070|Experimental|0.2μg Act-HIB®|
88912413|NCT01578070|Experimental|ViscoGel® and 2μg Act-HIB®|
88912414|NCT01578070|Experimental|2μg Act-HIB®|
88912415|NCT01578070|Active Comparator|10μg Act-HIB®|
88912416|NCT01578083||Cognitive Impairment|With self-report cognitive impairment.
88912417|NCT01578083||No Cognitive Impairment|Without self-report cognitive impairment.
88912418|NCT01578096|No Intervention|Diabetes education|Group-based diabetes education delivered to participants through community health workers
88912419|NCT01578096|Experimental|Diabetes education plus stress management|Group-based diabetes education plus stress management delivered to participants through community health workers
89197752|NCT00952666|Experimental|Device|Both the Robot-Assisted Laparoscopic Radical Prostatectomy (RALRP) and the Transrectal Ultrasound (TRUS) are common performed procedures, but are normally performed separately. In this proposed feasibility study, the procedures will be combined.
88912421|NCT01578122|Experimental|25mmHg ECS|Thigh-length graduated elastic compression stockings applying 25mmhg of targeted pressure at the ankle worn daily for two years
88912422|NCT01578122|Active Comparator|35mmHg ECS|Thigh-length graduated elastic compression stockings applying 35 mmhg of targeted pressure at the ankle worn daily for two years
88912423|NCT01578148|Experimental|Noxipoint Therapy|
88912424|NCT01578148|Active Comparator|Physical Therapy|
88912425|NCT01578161|Experimental|Dexmedetomidine0.25|dexmedetomidine 0.25 microg.kg(-1),(Group D0.25) ivs. for 10min.
88912426|NCT01578161|Experimental|Dexmedetomidine0.5|dexmedetomidine 0.5 microg.kg(-1),(group D0.5) ivs. for 10min.
88912427|NCT01578161|Experimental|Dexmedetomidine1.0|dexmedetomidine 1 microg.kg(-1) ivs. for 10min.
89197753|NCT00944008|Experimental|Depocyte|
89009157|NCT03450928|Active Comparator|Short POEM|Patients in the Short POEM-group will undergo a Peroral Endoscopic Myotomy (POEM) extended for a total of 7 cm (including 4 cm above the esophago-gastric junction and 3cm on the stomach).
89432879|NCT06282874|Experimental|BM/LM cohort|Fifty eligible subjects will be divided into a BM cohort (brain parenchymal metastasis only) and an LM cohort (leptomeningeal metastasis ± brain parenchymal metastasis)
89432880|NCT06282861|Experimental|Trelegy|Trelegy commercial product. 1 inhalation daily for 12 months
89432881|NCT06282861|Active Comparator|LABA-LAMA|Any LABA-LAMA combination approved in Spain is accepted. To be used according to product specifications for 12 months.
89432882|NCT06282835||Eravacyline combination|
89432883|NCT06282796||Anthracycline-Based Breast Cancer Chemotherapy Group|Age ≥18 years, histologically or cytopathologically confirmed stage I-III HER2+ breast cancer, scheduled to receive consecutive anthracycline chemotherapy or subsequent sequential trastuzumab targeted therapy, with a prechemotherapy LVEF≥53%.
89009158|NCT03450928|Active Comparator|Long POEM|Patients in the Long POEM-group will receive a 12cm-long Peroral Endoscopic Myotomy (POEM), including 9 cm on the esophagus and 3cm on the gastric wall
89009159|NCT00235365|Experimental|meta-cognitive therapy|meta-cognitive therapy
89432884|NCT06282783|Experimental|Men|Sex assigned at birth, male Single dose of 400mg topiramate
89009160|NCT00235365|Active Comparator|waiting list|waiting list control
89432885|NCT06282783|Experimental|Women|Sex assigned at birth, female Single dose of 400mg topiramate
89432886|NCT06282770|Experimental|Brace With Electrical Diodes|The patient will be given a laser diode brace to wear for 1 year. At the defined time points following surgery (2, 4, 6, 8, 12, 24, 36 and 48 weeks), subjects will be asked to complete pain and ability-to-function questionnaires and submit scar/wound images to determine their status at each time interval.
89432887|NCT06282770|Sham Comparator|Sham Brace Without Electrical Diodes|The patient will be given a sham/placebo laser diode brace to wear for 1 year. At the defined time points following surgery (2, 4, 6, 8, 12, 24, 36 and 48 weeks), subjects will be asked to complete pain and ability-to-function questionnaires and submit scar/wound images to determine their status at each time interval.
89432888|NCT06282731|Other|urine growth factor|"Previous studies have showed that overactive bladder syndrome (urge, frequency, nocturia or urinary incontinence) has been considered as an important factor to predict successful treatment.~Urine nerve growth factor level, brain-derived neurotrophic factor and endothelium vascular growth factor have been proved as a simple and noninvasive biomarker for diagnosing overactive bladder."
89009161|NCT03450889||Intervention arm|This study uses only one arm. All patients in this intervention arm will be surveyed using the aforementioned study protocol, which means patients will undergo a colonoscopy (or sigmoidoscopy in patients with previous subtotal colectomy) with surveillance intervals of either 1 or 2 years, depending on the amount and type of polyps resected during previous surveillance.
89009162|NCT03450616|Experimental|Negative Pressure Wound Therapy|Subjects will have one venous stasis ulcer treated with the PICO Negative Pressure Wound Therapy Device
89432889|NCT06282718||POS-ARI-PC|"POS-ARI-PC AUDIT:~Anonymous registration of patients of any age presenting at the participating primary care facility with ARI.~POS-ARI-PC CORE:~Patients of any age presenting at the participating primary care facility with ARI.~POS-ARI-PC-001:~Patients 60 and over presenting at the participating primary care facility with ARI."
89432890|NCT06282705|Experimental|0 cm Diagonal drop jump|Participants will complete 4 unsupervised home drop jump sessions per week ( minimum 24 hours between each session) for the duration of the study (e.g., Mon, Wed, Fri, Sun) from a height of 0 cm (floor). They will perform 20 diagonal drop jumps on each side (20 x dropping left and 20 x dropping right) with 30 seconds between each jump. The routine will be demonstrated in full on the first laboratory session. The intervention will last 16 weeks.
89432891|NCT06282705|Experimental|40 cm diagonal drop jump|Participants will complete 4 unsupervised home drop jump sessions per week ( minimum 24 hours between each session) for the duration of the study (e.g., Mon, Wed, Fri, Sun) from a height of 40 cm (plyometric box). They will perform 20 diagonal drop jumps on each side (20 x dropping left and 20 x dropping right) with 30 seconds between each jump. The routine will be demonstrated in full on the first laboratory session. The intervention will last 16 weeks.
88912428|NCT01578161|Placebo Comparator|NormalSaline|Normal saline 10ml ivs. for 10min.
88912429|NCT01578174|Placebo Comparator|Control|
88912430|NCT01578174|Active Comparator|Dexmedetomidine|
88912431|NCT01578200|Experimental|Lanthanum carbonate|Patients are given Lanthanum Carbonate oral administration after meals three times per day in total daily dose of 750-2250mg.
88912432|NCT01578200|Active Comparator|Calcium Carbonate|Patients are given Calcium carbonate oral administration after meals three times per day in total daily dose of 3.0g.
88912433|NCT01578213|Experimental|Imatinib|
88912434|NCT01578226||Decompensated cirrhotic patients|Cirrhotic patients presenting with clinically detectable ascites (Grade 2 o Grade 3)
88912435|NCT01578252|Experimental|Ondansetron Tablets USP 8 mg|Ondansetron Tablets USP 8 mg of M/s Ipca Laboratories Limited, India
88912436|NCT01578252|Active Comparator|Zofran®|Zofran® (Ondansetron Hydrochloride) Tablets 8 mg of M/s GlaxoSmithKline
88912437|NCT01578265|Experimental|Ondansetron Tablets USP 8 mg|Ondansetron Tablets USP 8 mg of M/s Ipca Laboratories Limited, India
88912438|NCT01578265|Active Comparator|Zofran®|Zofran® (Ondansetron Hydrochloride) Tablets 8 mg of M/s GlaxoSmithKline
88912439|NCT01578291|No Intervention|No intervention|Parents given routine information by the medical staff.
88912440|NCT01578291|Active Comparator|Parental information|Parents are provided with an educational brochure of the study and the expectations of the discomfort.
88912441|NCT01578291|Active Comparator|Play Therapy|Child and the parents will spend time in the office with the child life therapist undergoing play therapy.
88912442|NCT01578304|Experimental|Imidafenacin|
88912443|NCT01578304|Active Comparator|Fesoterodine|
88912444|NCT01578343|Experimental|Vorinostat-FND|Vorinostat-fludarabine, mitoxantrone, dexamethasone Induction treatment (Total 4 cycles) FND D1-3 Fludarabine 25mg/m2 + NS 100mL iv over 30 min D1 Mitoxantrone 10mg/m2 + NS 100mL iv over 30 min D1-5 Dexamethasone 20mg IV or PO every 4 weeks Vorinostat D1-10 Vorinostat 200mg once daily PO (When vorinostat is concurrently administered with FND regimen, vorinostat will be administered 3 hours before chemotherapy)
88912445|NCT01578369|Experimental|Exercise group|Supervised exercise classes which included pelvic floor muscle training. 3 sessions per week. 55-60 min per session, with 10 minutes of pelvic floor muscle training. At least during 22 weeks.
88912446|NCT01578369|No Intervention|Control|Usual care
88912447|NCT01578382||Hypertensive ischemic leg ulcer|"Twenty consecutive patients with Martorell HYTILU as defined in:~Arch Dermatol 2010;146:961-968"
88912448|NCT01578382||Calciphylaxis|"Ten subjects with calciphylaxis (calcific uremic arteriolopathy) as described in:~Vasa 1998;27:137-143"
88912449|NCT01578382||Venous ulcer (controls)|"Twenty subjects with venous ulcers (CEAP C4-6) as described in:~J Vasc Surg. 2004 Dec;40(6):1248-52"
88912450|NCT01578395|Experimental|N-acetylcysteine|This arm consists of 30 patients who will receive 1200mg n-acetylcysteine dissolved in 50ml NaCl 0.9% iv before either low-dose (10 patients) or high-dose (10 patients) radiation exposure, or no radiation exposure (10 patients)
88912451|NCT01578395|Experimental|Ascorbic acid|This arm consists of 30 patients who will receive 3000 mg ascorbic acid dissolved in 50 ml NaCl 0.9% iv before either low-dose (10 patients) or high-dose (10 patients) radiation exposure, or no radiation exposure (10 patients)
88912452|NCT01578395|Placebo Comparator|Sodium Chloride (NaCl)|This arm consists of 30 patients who will receive 50 ml NaCl 0.9% iv before either low-dose (10 patients) or high-dose (10 patients) radiation exposure, or no radiation exposure (10 patients)
89432892|NCT06282705|Experimental|60 cm diagonal drop jump|Participants will complete 4 unsupervised home drop jump sessions per week ( minimum 24 hours between each session) for the duration of the study (e.g., Mon, Wed, Fri, Sun) from a height of 60 cm (plyometric box). They will perform 20 diagonal drop jumps on each side (20 x dropping left and 20 x dropping right) with 30 seconds between each jump. The routine will be demonstrated in full on the first laboratory session. The intervention will last 16 weeks.
89432893|NCT06282705|No Intervention|Control|No exercise intervention performed.
89432894|NCT06282692|Experimental|Experimental:|"INAVAC (Vaksin Merah Putih - UA-SARS CoV-2 (Vero Cell Inactivated) 5 µg~Study product are provided in the form of liquid in vial single dose (0.5 ml). The vaccine will be given 1 dose (0.5 ml) twice."
89432895|NCT06282679|Experimental|left cheek and right cheek|"First, apply an appropriate amount of lidocaine cream to your face and wait (30-45 minutes) for the anesthetic to take effect;~Second step, after cleaning, mark the injection site on your face, about 25-30 points on one cheek, 1 cm apart, using a randomized half face control trial, Use of botulinum toxin type A for injection (Botox) (Allergan Pharmaceticals Ireland Limited, Import Drug Registration No. : S20171003), 0.5U botulinum toxin type A (Botox) was injected per point on one cheek and 1U on the other. The total amount of botulinum toxin type A was between 15 and 30U on each side."
89432896|NCT06282666|Experimental|Epidural|"Combined spinal and epidural anesthesia will be performed before the surgery in the patient's lateral position with the operated hip down. The Espocan set will be used (B.Braun). After identification of the epidural space on the level of L3/L4, 0.5% bupivacaine (Marcaine Heavy Spinal) with fentanyl (5 mcg/mL) will be injected through the 27 G pencil point spinal needle. Then, the epidural catheter will be placed and a test dose of 2% lidocaine (2 mL) will be administered. At the end of the surgery, the patient will receive 5 mL of a mixture containing 0.1% bupivacaine with fentanyl (2 mcg/mL). Moreover, we will administer 5 mg of oxycodone i.v.~the mixture of bupivacaine and fentanyl will be administered in a constant flow of 5 mL/h for a day."
89432897|NCT06282666|Experimental|ESPB|"Spinal anesthesia will be performed in the patient's lateral position with the operated hip down. 0.5% bupivacaine (Marcaine Heavy Spinal) with fentanyl (5 mcg/mL) will be used and a 25-27 G pencil point spinal needle.~The lumbar ESPB will be performed under ultrasound control at the L3 level on the ipsilateral site of the surgery. After dissection with 0.9 NaCl, a catheter will be left in the ESP. Then, we will administer 0.25% bupivacaine with epinephrine (5mcg/mL), 0.4 mL per kg, up to 40 mL. Moreover, 5 mg of oxycodone i.v. will be administered A mixture of 0.1% bupivacaine with fentanyl (2 mcg/mL) will be given in a constant flow of 5 mL/h for a day."
89432898|NCT06282653||Group 1|1st Year Students
88912453|NCT01578408|Active Comparator|Uncemented HA Coated Corail stem|Surgery with an inversed hybrid arthroplasty with an uncemented hydroxyapatite coated Corail stem and a cemented Marathon cup (DePuy).
88912454|NCT01578408|Active Comparator|Cemented Lubinus SPII stem (control arm)|Surgery with a totally cemented option with a Lubinus SPII stem and a IP cup (Link).
88912455|NCT01578421|Other|FX 100 dialyzer|
88912456|NCT01578421|Other|Polyflux 210 H dialyzer|
88912457|NCT01578421|Other|FXCorDiax 100 dialyzer|
88912458|NCT01578434|Active Comparator|Calcium Carbonate|Calcium: 75 mg/kg calcium daily for 3 months
88912459|NCT01578434|Active Comparator|Vitamin D|Vitamin D: 6 lakh IU single im dose
88912460|NCT01578434|Active Comparator|Vitamin D and Calcium|vitamin D and Calcium: combination of above two
88912461|NCT01578447|Other|Depo-SubQ Provera 104 in Uniject|
88912462|NCT01578447|Other|Intramuscular DMPA|
88912463|NCT01578460|Active Comparator|Control Group|Participants will self-select which group they wish to participate in at time of consent. The control group will use standard glucose meter testing to monitor their glucose levels.
88912464|NCT01578460|Experimental|Continuous Glucose Monitor (CGM) Group|Participants will self-select which group they wish to participate in at time of consent. The CGM group will utilize the iPro2 CGM to monitor their glucose levels during their 28, 32, and 36 week of gestation.
89432899|NCT06282653||Group 2|2nd year students
89432900|NCT06282640|Experimental|Vitamin D in Carpal Tunnel Syndrome|
89432901|NCT06282627||Non-hospitalised individuals|No intervention. Observational study
89432902|NCT06282614|Experimental|Mucogyne treatment|"2 planned visits for each eligible patient :~Screening/Baseline visit : V1 at Day 0. Patient receive Mucogyne Ovule.~End-of-study visit : V2 at Day 35 ± 3"
88912465|NCT01578473|Active Comparator|Vitamin D and E|Oral Vitamin D and E alone in men with penile curvature due to PD.
89432903|NCT06282601|Experimental|Presbyacusis patients|
89432904|NCT06282588|Experimental|Phase 2 Open Label|Darolutamide for up to 96 weeks (24 months) and primary SOC RT
89432905|NCT06282588|Experimental|Phase 3 Blinded Experimental|Darolutamide + LHRHA for up to 96 weeks (24 months) and primary SOC RT
89432906|NCT06282588|Placebo Comparator|Phase 3 Blinded Comparator|Darolutamide matched placebo + LHRHA for up to 96 weeks (24 months) and primary SOC RT
89432907|NCT06282575|Experimental|Zanidatamab with Standard-of-care Therapy Arm|Zanidatamab plus standard of care treatment of CisGem with or without a PD-1/L1 inhibitor. PD-1/L1 inhibitor will be physician's choice of either Durvalumab or Pembrolizumab, where approved under local regulations.
89432908|NCT06282575|Active Comparator|Standard-of-care Therapy Arm|Standard of care treatment of CisGem with or without a PD-1/L1 inhibitor. PD-1/L1 inhibitor will be physician's choice of either Durvalumab or Pembrolizumab, where approved under local regulations.
89432909|NCT06282536|Experimental|Neoadjuvant Therapy With Iruplinalkib|In this arm, 20 patients with III-IVA stage, potentially resectable ALK Positive non-small cell lung cancer will receive 4 circles of neoadjuvant Iruplinalkib. And the patients who are resectable after neoadjuvant therapy will be treated with surgery. Postoperative patients receive adjuvant Iruplinalkib therapy up to 2 years/until the disease progressed.
89432910|NCT06282510|Active Comparator|Intranasal Povidone Iodine|Nasal iodophor applied twice daily for five days.
89432911|NCT06282510|No Intervention|Control|Routine care.
89432912|NCT06282497|Experimental|Study Group|optimised neck CTV delineation
89197754|NCT00854919|Experimental|CBT|All subjects received cognitive-behavioral therapy (CBT) during the study period.
89432913|NCT06282497|Active Comparator|Control Group|standard neck CTV delineation
89432914|NCT06282484||chronic gastritis|patients with chronic non-atrophic gastritis and chronic atrophic gastritis according to histopathological results
89432915|NCT06282484||precancerous lesion|patients with gastric intestinal metaplasia and intraepithelial neoplasia according to histopathological results
89432916|NCT06282484||gastric cancer|patients with gastric cancer according to histopathological results
89531224|NCT05053893|Experimental|New treatment group(Roxadustat combined with Sacubitril Valsartan Sodium Tablets)|Roxadustat(FibroGen, China), 100mg (45-60kg) or 120mg (≥ 60kg) each time, three times a week, orally on an empty stomach in the morning. The initial dose of Sacubitril Valsartan Sodium Tablets(Novartis, China) is 50mg, once a day, taken on an empty stomach in the morning, and gradually titrated from the minimum dose to the maximum tolerated dose.
89432917|NCT06282445|Experimental|Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebrelimab|"The enrolled patients with microsatellite stable (MSS) initially unresectable metastatic colorectal cancer will receive a chemotherapy with XELOX and Bevacizumab in combination with Adebrelimab in first-line treatment.~XELOX: Oxaliplatin 130 mg/m2, day 1, q3w; Capecitabine 1000 mg/m2, bid, d1-d14, q3w; Bevacizumab: 7.5mg/kg, intravenous infusion, day 1. q3w. Adebrelimab: intravenously guttae, 1200mg, day 1, q3w. 4 cycles.~Imaging assessment of tumor remission was performed every 8 weeks. Patients who received 4-6 months of treatment and achieved disease control entered the maintenance treatment stage, receiving maintenance treatment:~Bevacizumab: 7.5mg/kg, intravenous infusion, d1, Q3W; Capecitabine: 1250mg/ m2, orally, bid, Q3W; Adebrelimab: 1200mg, intravenous infusion, day 1, Q3W."
89432918|NCT06282432||Subjects that received RP-L201 on the RP-L201-0318 Parent Study|Subjects that received RP-L201 on the RP-L201-0318 Parent Study and either completed the study or discontinued early.
89432919|NCT06282406|Experimental|Paired, Sub-Threshold Stim|Sub-threshold stimulation paired with successful task repetitions
89432920|NCT06282406|Experimental|Paired, Supra-Threshold Stim|Supra-threshold stimulation paired with successful task repetition
89432921|NCT06282406|Experimental|Unpaired, Sub-Threshold Stim|Sub-threshold stimulation after successful task repetition
89432922|NCT06282406|Experimental|Unpaired, Supra-Threshold Stim|Supra-threshold stimulation after successful task repetition
89432923|NCT06282406|Sham Comparator|Sham|No stimulation
89432924|NCT06282393|Other|FibriCheck recordings|
89432925|NCT06282380|Other|FibriCheck Mobile Application measurements|Participants will perform one measurement using the FibriCheck Mobile Application and the result will be compared with the ground truth.
89432926|NCT06282367||Bowel preparation for colonoscopy using Polyethylene glycol|
89432927|NCT06282367||Bowel preparation for colonoscopy using oral Lactulose|
89432928|NCT06282354||Face-to-face appointment|Patients allocated in face-to-face appointment after urooncologic surgical procedures
89432929|NCT06282354||Telemedicine appointment|Patients allocated in telemedicine appointment after urooncologic surgical procedures
89432930|NCT06282341|Active Comparator|MARASIM|During visit 2, road runners will take part in a simulated marathon race on a treadmill.
89432931|NCT06282341|Active Comparator|TRAILSIM|During visit 2, trail runners will take part in a simulated trail race on a treadmill.
89432932|NCT06282341|Active Comparator|TRAILNAT|During visit 2, trail runners will take part in a real trail race in the nature.
89432933|NCT06282315|Experimental|Fixed Dose Combination (FDC) albendazole and Ivermectin (ALB/IVM )|"Single dose of a tablet of FDC 400 mg/18 mg IVM or 400 mg ALB/9 mg IVM, administered according to the following age criteria:~For children from 5-14 years old (included) at the time of screening visit: 1 tablet of FDC 400 mg ALB/9 mg IVM~For children from 15-17 years old (included) at the time of screening visit: 1 tablet of FDC 400 mg ALB/18 mg IVM"
89432934|NCT06282315|Active Comparator|Albendazole (ALB)|Single dose of a tablet of ALB 400 mg (active control arm).
89432935|NCT06282302|Experimental|Group control|The control session will consist of keeping the volunteer sitting in a calm, air-conditioned environment for 40 minutes.
89432936|NCT06282302|Experimental|Isometric Exercise|The intervention with isometric exercise for the lower limbs, the volunteers will start in a vertical position, with shoulders and hips in contact with the wall, feet parallel and shoulder-width apart and hands at the sides of the body. Then (second phase), the volunteers, maintaining contact with the wall, squatted and advanced their feet in the desired position until the knee joint angle reached the previously determined value. The third phase referred directly to the isometric effort of the isometric exercise session. For the isometric wall squat exercise session, volunteers will be asked to perform 4 repetitions of 2 minutes, with a 2-minute rest interval in a seated position for adequate rest between each repetition.
89432937|NCT06282302|Experimental|Aerobic Exercise|Volunteers will perform 50 minutes of horizontal exercise cycling (brand: pro-user), continuously and at moderate intensity (50% to 60% of HR reserve).
89432938|NCT06282263|Experimental|Intervention Group|"Awareness Development Program on Suicide Prevention for Oncology Nurses was applied to the nurses in the experimental group."
89432939|NCT06282263|No Intervention|Control Group|No programme was applied to the control group.
89531225|NCT05053893|Experimental|Traditional treatment group(EPO combined with ACEI or ARB )|Recombinant human erythropoietin (SEBOR, 10000 units / Branch) was injected subcutaneously once a week; Perindopril tablets (Servier, China), taken on an empty stomach, gradually titrated from the minimum dose to the maximum tolerated dose.
89531226|NCT03096327|Experimental|Intervention (Montelukast)|Aireez contains Montelukast which is a potent and selective blocker of the CysLT1 receptor. For treatment of chronic asthma, montelukast is administered once daily to adults as a 10-mg film-coated tablet, to children aged 6-14 years as a 5-mg chewable tablet, and to children aged 2-5 years as a 4-mg chewable tablet form.
88912466|NCT01578473|Active Comparator|Testosterone Pellets and Vitamin D and E|Testosterone in combination with oral Vitamin D an E supplementation in men with penile curvature due to PD.
88912467|NCT01578512|Experimental|Face-to-Face|8 sessions of weekly group behavioral weight loss treatment
88912468|NCT01578512|Experimental|Web-based|Participants receive one group face-to-face session followed by 7 web-based lessons, reporting of key behaviors, and feedback on progress.
88912469|NCT01578512|Active Comparator|Single Session|Single session behavioral weight loss
88912470|NCT01578525|No Intervention|standard care|Standard care (by German definition), traditional care by physician and nurse on the ward
88912471|NCT01578525|Other|Intensified standard care|Intensified standard care: traditional care by physician and nurse, additional pharmaceutical care by a pharmacist during hospitalization
88912472|NCT01578538|Active Comparator|mesh used repair|mesh used hernia repair will be perform
88912473|NCT01578538|Active Comparator|nonmesh|nonmesh hernia repair techniques will be used
88912474|NCT01578564|Experimental|SOR-C13|
88912475|NCT01578590|Experimental|Subjects will consume lean minced meat|Subjects will perform resistance exercise and consume a piece of meat (135 grams, 35 g of protein)
88912476|NCT01578590|Active Comparator|Subjects will consume a milk beverage|Subjects will perform resistance exercise and consume a milk protein beverage
89432940|NCT06282250|Other|Psycho-education and Imagery Focused Cognitive Therapy (in addition to Bright Light Therapy)|"Treatment will be personalized in accordance to one of three options:~1. In case of depressive symptoms.~Bright Light Therapy (BLT) will be administered for 30 minutes on five consecutive days (duration: 1-3 weeks).~1 PE session focused on lifestyle and physical activity will take place. 6 sessions of ImCT will take place. This includes in-depth identification of images, constructing a micro-formulation along the lines of regular Cognitive Behavioural Therapy.~2. In case of hyperactivity symptoms.~The same PE and ImCT will be administered. The exception is that in this case, BLT is replaced by wearing blue-light blocking glasses for 1-3 weeks, 1 hour prior to bedtime.~3. In case of at risk mental state, but no clear depressive or hyperactive symptoms.~The same PE and ImCT will be administered. There will be no light intervention."
89432941|NCT06282224|Experimental|surgery with AR-integrated endoscope|Performing endoscopic transnasal skull base surgery with AR-integrated endoscope
89432942|NCT06282211|Experimental|Ondansetron Oral Soluble Pellicles|nausea and vomiting prophylaxis with Ondansetron Oral Soluble Pellicles, 8 mg tid for 5-7 days after chemotherapy
89432943|NCT06282211|Sham Comparator|no antiemetic drugs or drugs with antiemetic active ingredients|no antiemetic drugs or drugs with antiemetic active ingredients for 5-7 days after chemotherapy
89432944|NCT06282198||Cases|Patients with Distal Femoral megaprosthesis
89432945|NCT06282198||Control|Healthy subjects
89432946|NCT06282185|Experimental|intervention|supervised training program for twelve weeks + usual care + advice about exercise
89432947|NCT06282185|No Intervention|usual care|usual care + advice about exercise
88912477|NCT01578603|Experimental|sugar substituted chewing gum A|
88912478|NCT01578603|Experimental|Sugar substituted chewing gum B|
88912479|NCT01578616||3 / non-CAD, ACS with or without TCFA|ACS patients with thin cap fibroatheroma. ACS patients without thin cap fibroatheroma. Age-, gender-, and rate of hypertension or diabetes mellitus-matched patients who have never been diagnosed or treated for CAD are also enrolled as non-CAD patients
88912480|NCT01578616||non-CAD, ACS without TCFA, ACS with TCFA|Acute coronary syndrome (ACS) patients with thin cap fibroatheroma. ACS patients without thin cap fibroatheroma. Age-, gender-, and rate of hypertension or diabetes mellitus-matched patients who have never been diagnosed or treated for CAD are also enrolled as non-CAD patients
88912481|NCT01578629|Active Comparator|Healthy Volunteers|Healthy participants randomized into one of 6 groups that will take 4 capsules, twice a day of vitamin E tocotrienol (TCT) capsules ; Low Dose Aspirin or placebo capsule for 7 months.
88912482|NCT01578629|Active Comparator|Hyperlipidemic|hyperlipidemic patients randomized into one of 6 groups that will take 4 capsules, twice a day of Vitamin E Tocotrienol (TCT) capsules; Low Dose Aspirin or placebo vehicle control capsule for 7 months.
88912483|NCT01578642|Other|Single Arm open label|EndoStim LES Stimulation System
88912484|NCT01578668|Experimental|Erlotinib, pemetrexed, cisplatin|
88912485|NCT01578668|Experimental|erlotinib|
88912486|NCT01578681|Active Comparator|Airway clearance, bronchiectasis|"The patient would be selected randomly to one of the two groups (intervention or placebo). And follow up for one year with regular visits with the physician and the respiratory therapist.~Each patient will be visited 7 times. At each visit all the variable will be registered. Patient will have also a personal registration diary."
88912487|NCT01578681|Placebo Comparator|bronchiectasis, stretching|"The patient would be selected randomly to one of the two groups (intervention or placebo). And follow up for one year with regular visits with the physician and the respiratory therapist.~Each patient will be visited 7 times. At each visit all the variable will be registered. Patient will have also a personal registration diary."
89432948|NCT06282172|Experimental|Treatment with BTL-785-7|Active treatment with BTL-785-7
88912488|NCT01578694|Other|Patient Group|The patient group has been diagnosed by the surgeon as having femoro-acetabular impingement (FAI) of the hip and will undergo a magnetic resonance imaging (MRI) test, more specifically, T1-rho to examine articular cartilage.
88912489|NCT01578694|Other|Control healthy volunteers|The control group has not been diagnosed with any hip problems, but will undergo a magnetic resonance imaging (MRI) test, more specifically, T1-rho to examine articular cartilage.
88912490|NCT01578720|Other|IVT injection once every 8 weeks after 3 initial monthly doses|"Intravitreal aflibercept injection 2.0mg dosed every 4 weeks (monthly)for the first 3 months followed by 2.0 mg (0.05mL) via intravitreal injection every eight weeks (2 months).~Dosing at monthly intervals is allowed if needed in the opinion of the investigator based on presence of fluid on OCT and/or a decrease in visual acuity of greater than or equal to 5 letters from the previous visit."
88912491|NCT01578733|Experimental|protein intake|different levels of protein intake
88912492|NCT01578746|Active Comparator|Direct lateral approach|Patient operated using direct lateral approach.
88912493|NCT01578746|Active Comparator|Anterior approach|Patient operated using anterior approach.
89432949|NCT06282172|No Intervention|Control|No active treatment
89432950|NCT06282159|Placebo Comparator|Placebo|
89432951|NCT06282159|Active Comparator|DNTH103 low dose Q2W|
89432952|NCT06282159|Active Comparator|DNTH103 high dose Q2W|
89432953|NCT06282146|Experimental|Open-label aiTBS to posterior parietal cortex|10 iTBS treatment sessions per day (18,000 pulses/day) for 5 consecutive days (90,000 pulses total). In the unlikely event that a participant is late for an hourly treatment, then the treatment will be delayed accordingly. The minimum gap between treatments will be 25 minutes. Each iTBS treatment will consist of 60 cycles of 10 bursts of three pulses at 50 Hz delivered in 2-second trains (5 Hz) with an 8-second intertrain interval. Stimulation will be delivered at 90% resting motor threshold (rMT), adjusted for depth of the identified functional connectivity target.
89432954|NCT06282133|Experimental|Behavioural Experiments (CBT)|"Behavioural experiments involve selecting a specific thought to test (for example, uncertainty makes me incapable of acting) and designing a detailed experiment to challenge this thought."
89432955|NCT06282120||Study Arms|Drug: Irinotecan Hydrochloride Liposome Injection The recommended dose and regimen of Irinotecan Hydrochloride Liposome Injection is 70 mg/m2 intravenously over 90 minutes, followed by dl-LV 400mg/m2 or l-LV 200mg/m2 intravenously over 30 minutes, followed by 5-FU 2400 mg/m2 intravenously over 46 hours, administered every 3 weeks.It can be combined or partially combined immunotherapy.
89531227|NCT03096327|Placebo Comparator|Placebo|Patients in placebo group will receive identical looking drug (placebo) produced by same manufactured.
89432956|NCT06282107|Experimental|Bilateral superselective adrenal arterial embolization|Selectively injects 1.5-2.5 mL ethanol into bilateral adrenal artery to ablate part of the adrenal gland; irbesartanhydrochlorothiazide 162.5 mg/d, amlodipine 5 mg/d
89432957|NCT06282107|Active Comparator|traditional triple antihypertensive treatment|irbesartanhydrochlorothiazide 162.5 mg/d, amlodipine 5 mg/d
89432958|NCT06282055||Women with T1D|Women living with T1D who are willing to share their diabetes management and menstrual cycle data.
89432959|NCT06282042|Experimental|TEER + OMT|Early transcatheter edge-to-edge mitral valve repair (TEER) plus optimal medical treatment
89432960|NCT06282042|Other|OMT|Optimal medical treatment
89432961|NCT06282029|Experimental|Intervention arm|Group therapy
89432962|NCT06282003|Active Comparator|Conventional ventilation procedure|
89432963|NCT06282003|Experimental|The protective lung ventilation procedure|In the PV group, laung protective ventilation also included the procedure of opening the alveoli (recruitment maneuver, RM). RM was performed twice. The first instance occurred following the administration of anesthesia, with a FiO2 value of 50% (0.5). The second instance took place shortly before extubation. RM consisted of maintaining an airway pressure of 40-45 kPa for 40 s, which keeps the collapsed alveoli open and corresponds to maximum spontaneous inhalation. The specified pressure of PEEP during RM refers to conditions where hemodynamic stability. PEEP was set at 7 kPa, but just before the extubation and awakening, patients were switched to spontaneous breathing the PEEP was set to 10 kPa. There was no additive effect of positive pressure, just an addition of 3 kPa positive airway pressure was applied to keep current alveoli open continuously and possibly recruit some new ones in that short period, which corresponds to the stochastic model of respiration.
89432964|NCT06281990|No Intervention|Control group|The control group received standard care.
89432965|NCT06281990|Experimental|Intervention group|1:Patients who were planned to undergo sleeve gastrectomy surgery were informed about the perioperative period when they came to the outpatient clinic2-4weeks before surgery and were educated about the exercises to be performed before and after surgery. The content of this education included pain management, breathing exercises,foot rotation, and leg exercises. In addition, the education book prepared by the researchers was given to the patients to make the education and information permanent until the day of surgery.
89432966|NCT06281977|Active Comparator|Dexmedetomidine|Participants randomized to receive dexmedetomidine will be started at a dose of 0.3 mcg/kg/hr and titrated to a target dose of 1.0 mcg/kg/hr. Once the participant reaches their maximum tolerated dose (as decided by the blinded treating physician), they will continue treatment for 48 ± 6 hours. This will be followed by a weaning phase that will similarly be at the discretion of the treating physician.
89432967|NCT06281977|Placebo Comparator|Placebo|Participants randomized to receive placebo will be started on normal saline. In similar fashion to the active comparator, participants will be titrated to their maximal tolerated dose, continue treatment for 48 ± 6 hours, and be weaned at the discretion of the blinded treating physician.
89432968|NCT06281964|Experimental|PLB1004|PLB1004 given alone as monotherapy
89432969|NCT06281964|Active Comparator|platinum-based chemotherapy with or without Sintilimab|platinum-based chemotherapy with or without Sintilimab
89432970|NCT06281925|Experimental|Cryotherapy|Patients receiving oxaliplatin who are randomized to the Interventional (Cryotherapy) Arm will wear a pair of gloves that has removable ice packs throughout their treatment, starting 15 minutes before and ending 15 minutes after completion of oxaliplatin. These ice packs will be replaced every 30 minutes. The total wearing time of the cryotherapy will be approximately 2 hours.
88912494|NCT01578759|Experimental|Salpingectomy group|Participants in this group will have their fallopian tubes removed.
88912495|NCT01578759|No Intervention|No Salpingectomy Group|Participants in this group will not have their fallopian tubes removed.
88912496|NCT01578811|Placebo Comparator|Placebo|
88912497|NCT01578811|Experimental|SK-MS10 160mg t.i.d|
88912498|NCT01578811|Experimental|SK-MS10 320mg t.i.d|
88912499|NCT01578824|Active Comparator|Healthy Control|
88912500|NCT01578824|Active Comparator|Vitamin D resistant Rickets|Vitamin D resistant Rickets patients
88912501|NCT01578837|Experimental|Ginseng|Combined Rg3-enriched Korean Red Ginseng and American Ginseng capsule
88912502|NCT01578837|Placebo Comparator|Wheat Bran|100 % Natural Wheat Bran capsule
89432971|NCT06281925|No Intervention|Control|Patients receiving oxaliplatin who are randomized to the Control Arm will not receive the gloves with removable ice packs throughout their treatment.
88912503|NCT01578863|Active Comparator|Intervention program|6 months intervention program to lose weight in obese children. Behavioral, emotional, physical, familial and demographic questioners will be fulfilled at the beginning and at the end of the program.
88912504|NCT01578863|No Intervention|Untreated obese children|Behavioral, emotional, physical, familial and demographic questioners will be fulfilled twice in a 6 month program.
89432972|NCT06281912||adolescent/childhood|patients <20 years old with with stage III and IV melanoma diagnosis
89432973|NCT06281912||young adult|patients < 30 years with stage III and IV melanoma diagnosis
89432974|NCT06281899|Experimental|Intervention|Patients will receive a plant-based low protein diet (0.6 g proteins/kg ideal body weight per day) associated with Dapagliflozin 10 mg per day
89432975|NCT06281899|Active Comparator|Control|Patients will receive Dapagliflozin 10 mg per day
89432976|NCT06281886|Experimental|The study group|Patients are planned to receive 2 cycles of induction immuno-chemotherapy plus apatinib, followed by concurrent chemoradiotherapy plus apatinib.
89432977|NCT06281886|Active Comparator|The control group|Patients are planned to receive 2 cycles of induction immuno-chemotherapy, followed by concurrent chemoradiotherapy.
89432978|NCT06281873|Experimental|closure of the OAF with PRF application|This study was conducted on 9 patients. application of PRF membrane
89432979|NCT06281860|Experimental|Cohorte 1 _ 7.5 mg/m2|cohorte 1: 7.5 mg/m2 of cisplatin (once)
89432980|NCT06281860|Experimental|Cohorte 2 _ 12.5 mg/m2|cohorte 2: 12.5 mg/m2 of cisplatin (once)
89432981|NCT06281860|Experimental|cohorte 3: 35 mg/m2 of cisplatin|cohorte 3: 35 mg/m2 of cisplatin (once)
89432982|NCT06281860|Experimental|cohorte 4: 70 mg/m2 of cisplatin|cohorte 4: 70 mg/m2 of cisplatin (once)
89432983|NCT06281847|Experimental|Open Label CCTx-001 infusion|CCTx-001 infusion 2 to 7 days after completion of LDC
89432984|NCT06281834|Experimental|Dolutegravir PK during weekly rifapentine/isoniazid for TB prevention|This is a single arm study: all patients are started on standard HIV treatment, with LTBI/TB prevention treatment varying according to age cohorts. Children 2-11 years receive standard weekly rifapentine/isoniazid (3HP) for TB prevention; those <2 years received a single-dose of extrapolated weekly RPT/INH, followed by standard INH prophylaxis.
89432985|NCT06281821|Experimental|Mobile App Intervention|Mobile health intervention delivered through an app
89432986|NCT06281821|No Intervention|Control|Assessment Only Control condition
89432987|NCT06281808|Experimental|Photon Counting Detector CT|PCD CT
89432988|NCT06281795|Active Comparator|Active tVNS|Active stimulation will be carried out using the tVNS device with an ear clip attached to the left earlobe at a frequency of 20 Hz, 200 μs at a current slightly below the discomfort threshold. The device's operating mode is active therapeutic.
89432989|NCT06281795|Sham Comparator|Sham tVNS|Fictitious stimulation will be carried out using the tVNS device with an ear clip attached to the left earlobe at a frequency of 20 Hz, 200 μs at a current slightly below the discomfort threshold. The device's operating mode is research mode.
89432990|NCT06281782|Active Comparator|topical retinoid and platelet-rich plasma (PRP) group|
89432991|NCT06281782|Active Comparator|topical retinoid group|
89432992|NCT06281730|Experimental|Karl Storz fetoscopes|Participants will receive In utero surgery using the new generation Karl Storz fetoscopes (11508AAK and 11506AAK) for fetal conditions amenable to treatment with fetoscopy.
89432993|NCT06281717|Experimental|Fetal Endotracheal Occlusion (FETO)|Participants with severe congenital diaphragmatic hernia will undergo the FETO therapy.
89432994|NCT06281704|Experimental|Part 1 : AK101 IV|Subjects will be enrolled in sequential cohorts treated with successively higher doses of AK101 via intravenous injection on Day1.
89432995|NCT06281704|Experimental|Part 1 : AK101 SC|Subjects will be enrolled in sequential cohorts treated with successively higher doses of AK101 via subcutaneous injection on Day1.
88912505|NCT01578863|No Intervention|Normal weight children|Behavioral, emotional, physical, familial and demographic questioners will fulfill twice in the 6 month period.
88912506|NCT01578876|Experimental|CSWT for 3 month|A group
89432996|NCT06281704|Placebo Comparator|Part 1 :Placebo|Subjects will be received matching placebo intravenously or subcutaneously on Day1.
88912507|NCT01578876|Experimental|CSWT for 1 month|B group
88912508|NCT01578876|No Intervention|Control group|C group
88912509|NCT01578889|Experimental|Group 1: Vaccine|At study entry and Months 1 and 3, participants will receive HIV-MAG vaccine administered as 0.5 mL by intramuscular (IM) injection in both the left and right deltoids using the Ichor Medical Systems TriGrid™ Delivery System (TDS) electroporation (EP) device. At Month 6, they will receive the VSV HIV gag vaccine by IM injection in both the left and right deltoids.
88912510|NCT01578889|Placebo Comparator|Group 1: Placebo|At study entry and Months 1 and 3, participants will receive placebo administered as 0.5 mL by IM injection in both the left and right deltoids using the Ichor Medical Systems TDS EP device. At Month 6, they will receive placebo by IM injection in both the left and right deltoids.
88912511|NCT01578889|Experimental|Group 2: Vaccine|At study entry and Months 1 and 3, participants will receive HIV-MAG vaccine admixed with 250 mcg IL-12 pDNA adjuvant, and divided into two 0.55 mL IM injections administered in both the left and right deltoids using the Ichor Medical Systems TDS EP device. At Month 6, they will receive the VSV HIV gag vaccine by IM injection in both the left and right deltoids.
88912512|NCT01578889|Placebo Comparator|Group 2: Placebo|At study entry and Months 1 and 3, participants will receive placebo administered as 0.55 mL by IM injection in both the left and right deltoids using the Ichor Medical Systems TDS EP device. At Month 6, they will receive placebo by IM injection in both the left and right deltoids.
88912513|NCT01578889|Experimental|Group 3: Vaccine|At study entry and Months 1 and 3, participants will receive HIV-MAG vaccine admixed with 1,000 mcg of the IL-12 pDNA adjuvant and divided into two 0.75 mL IM injections administered in both the left and right deltoids using the Ichor Medical Systems TDS EP device. At Month 6, they will receive the VSV HIV gag vaccine by IM injection in both the left and right deltoids.
88912514|NCT01578889|Placebo Comparator|Group 3: Placebo|At study entry and Months 1 and 3, participants will receive placebo administered as 0.75 mL by IM injection in both the left and right deltoids using the Ichor Medical Systems TDS EP device. At Month 6, they will receive placebo by IM injection in both the left and right deltoids.
88912515|NCT01578889|Experimental|Group 4: Vaccine|At study entry and Months 1 and 3, participants will receive HIV-MAG vaccine admixed with 1500 mcg of the IL-12 pDNA adjuvant divided into two 0.9 mL IM injections administered in both the left and right deltoids using the Ichor Medical Systems TDS EP device. At Month 6, they will receive the VSV HIV gag vaccine by IM injection in both the left and right deltoids.
88912516|NCT01578889|Placebo Comparator|Group 4: Placebo|At study entry and Months 1 and 3, participants will receive placebo administered as 0.9 mL by IM injection in both the left and right deltoids using the Ichor Medical Systems TDS EP device. At Month 6, they will receive placebo by IM injection in both the left and right deltoids.
89432997|NCT06281704|Experimental|Part 2:AK101-AK101 low-dose SC every 8 weeks|Subjects received single IV infusion of AK101 on Day1 will be randomized to receive low-dose AK101 subcutaneously every 8 weeks along with matching placebo subcutaneously (to maintain the blind).
89432998|NCT06281704|Experimental|Part 2: AK101-AK101 high-dose SC every 8 weeks|Subjects received single IV infusion of AK101 on Day1 will be randomized at Week8 to receive high-dose AK101 subcutaneously every 8 weeks.
88912517|NCT01578915||Cases|Women with 4 or more sexual partners during the past year
88912518|NCT01578915||Controls|Women with only one sexual partner during the past year
89432999|NCT06281704|Experimental|Part 2: Placebo-AK101 low-dose SC every 8 weeks|Subjects received placebo on Day1 will receive a single IV infusion of AK101 at Week8 along with matching subcutaneous placebo (to maintain the blind). And subjects will be randomized at Week8 to receive low-dose AK101 subcutaneously every 8 weeks along with matching placebo subcutaneously (to maintain the blind).
89433000|NCT06281704|Experimental|Part 2:Placebo-AK101 high-dose SC every 8 weeks|Subjects received placebo on Day1 will receive a single IV infusion of AK101 at Week8 along with matching subcutaneous placebo (to maintain the blind). And subjects will be randomized at Week8 to receive high-dose AK101 subcutaneously every 8 weeks.
89433001|NCT06281691||Greenlandic citizens aged 18 years and above, referred for cystoscopy|Patients who have been referred for a cystoscopy will be invited to participate in the study. During their cystoscopy appointment, they will be asked to provide a urine sample for the Xpert bladder cancer detection test.
89433002|NCT06281678|Experimental|IBI363|IBI363 will be administered as an intravenous (IV) infusion every 2 weeks or every 3 weeks.
89433003|NCT06281665|Placebo Comparator|Placebo Group|Similar appearing placebo pill daily for 6 months will be given to subjects.
89433004|NCT06281665|Experimental|Intervention Group|Low-dose [81 mg] aspirin pill daily for 6 months will be given to subjects
89433005|NCT06281639||study group|Caregivers who have a child with a scheduled Pediatric congenital ultrasound (PCU) the day of recruitment
89433006|NCT06281626||Young adults|people aged 18 to 25 years.
89433007|NCT06281587||Group 1 - low-risk (LR) keratoplasty|if the patient was diagnosed with keratoconus and there were no concomitant complicating diagnoses (n = 42)
89433008|NCT06281587||Group 2 - high-risk (HR) keratoplasty|in the presence of corneal dystrophy (pseudophakic bullous keratopathy, primary dystrophy), corneal inflammatory pathology (erosions, corneal ulcers, corneal fistulas,leucoma), complicated keratoconus, CGR or rekeratoplasty (n = 51)
89433009|NCT06281535|Experimental|Early loading group|The surgical treatment protocol entails atraumatic tooth extraction, fixture insertion and placement of the final restoration 2 months following implant placement.
89433010|NCT06281535|Active Comparator|Conventional loading group|The surgical treatment protocol entails atraumatic tooth extraction, fixture insertion and placement of the final restoration 3 months following implant placement.
89433011|NCT06281483|Active Comparator|PRP / Group A|12 patient
89433012|NCT06281483|Active Comparator|PRF / Group B|12 patient
89433013|NCT06281483|Active Comparator|Group C (the control group)|12 patient
89433014|NCT06281470|Experimental|Single Ascending Dose(SAD) Treatment 1|WS016 single dose（6g）
89433015|NCT06281470|Experimental|SAD Treatment 2|WS016 single dose（12g）
88912519|NCT01578928|Experimental|SOM230|subjects with varying degrees of renal impairment along with subjects without renal impairment
89433016|NCT06281470|Experimental|SAD Treatment 3|WS016 single dose（24g）
89433017|NCT06281470|Experimental|SAD Treatment 4|WS016 single dose（36g）
89433018|NCT06281470|Experimental|SAD Treatment 5|WS016 single dose（48g）
89433019|NCT06281470|Placebo Comparator|SAD matching placebo|SAD Matching placebo
89433020|NCT06281470|Experimental|Multiple Ascending Dose(MAD) Treatment 1|WS016 multiple dose(MAD Low Dose)
89433021|NCT06281470|Experimental|MAD Treatment 2|WS016 multiple dose(MAD Medium Dose)
89433022|NCT06281470|Experimental|MAD Treatment 3|WS016 multiple dose(MAD High Dose)
89433023|NCT06281470|Placebo Comparator|MAD matching placebo|MAD matching placebo
89433024|NCT06281457|Experimental|Manipulations of task demands (Expt 2.1)|Participants will view a single stimulus containing dots moving in one of two directions (clock-wise or counterclockwise) and drawn in one of two colors (orange and cyan). To complete the correct task for a trial, a cue at fixation will be manipulated.
89433025|NCT06281444|Active Comparator|ESWT group|The participants in this group will be applied with ESWT plus a home-based exercise program.
88912520|NCT01578941|Placebo Comparator|Placebo|
88912521|NCT01578941|Active Comparator|Treximet|
88912522|NCT01579019|Active Comparator|1000 mg 24 weeks|
88912523|NCT01579019|Active Comparator|1000 mg 26 weeks|
88912524|NCT01579019|Experimental|1500 mg 24 weeks|
88912525|NCT01579019|Experimental|1500 mg 26 weeks|
88912526|NCT01579032||CKD patients|
88912527|NCT01579058|Active Comparator|bisoprolol|bisoprolol 5mg qd
89433026|NCT06281444|Sham Comparator|Sham-ESWT group|The participants in this group will be applied with sham-ESWT plus a home-based exercise program.
89433027|NCT06281431|Experimental|Echogenic nerve block needle|Using a echogenic nerve block needle.
89433028|NCT06281431|Other|Non-echogenic nerve block needle|Using a common nerve block needle.
89433029|NCT06281405|Experimental|Immunochemotherapy group|The patients will receive 6 cycles of CAPOX and PD-1 antibody. TME surgery is scheduled after TNT while a W&W option can be applied to patients achieving cCR.
89433030|NCT06281405|Experimental|Radiation plus immunochemotherapy group|The patients will receive short-course radiotherapy (25Gy/5Fx), followed by 6 cycles of CAPOX and PD-1 antibody. TME surgery is scheduled after TNT while a W&W option can be applied to patients achieving cCR.
89433031|NCT06281392|Experimental|Colonoscopy assisted by CADe|
89433032|NCT06281392|Active Comparator|Virtual Colonoscopy with NBI|
89433033|NCT06281379|Experimental|Group 1|Total gastrectomy+mesogastrectomy
89433034|NCT06281379|Other|Group 2|Total gastrectomy with concentional D2 lymphadenectomy
89433035|NCT06281353|Experimental|Capsules with active ingredient /Nanocurcumin|Participants received a dosage of 200mg capsules with active ingredient /Nanocurcumin per day after breakfast, for 8 weeks.
89433036|NCT06281353|Placebo Comparator|Placebo|Participants received a dosage of 200mg capsules without Nanocurcumin per day after breakfast, for 8 weeks
89433037|NCT06281340|Experimental|Experimental group|The patients included in the experimental group will receive a session of manual physiotherapy using joint gliding techniques, myofascial and manipulative techniques of the tobioperoneoastotalar and subtalar joints. The intervention will be performed on both ankles.
89531228|NCT03338777|Experimental|Suicide plus immunogene therapy|Intra and peritumoral infiltrates with multiple injections of lipoplexes carrying the HSVtk suicide gene co-administered with GCV and subcutaneous vaccine produced with formolized allogeneic tumor extracts and lipoplexes carrying hIL-2 and hGM-CSF genes.
89433038|NCT06281340|Placebo Comparator|Control group|Patients included in the control group will receive a placebo manual physical therapy session, simulating joint sliding techniques, myofascial and manipulative techniques of the tobioperoneoastotalar and subtalar joints, without any stimulus other than the pressure exerted by the physical therapist with his hands when mobilizing the foot. The placebo intervention will be performed on both ankles.
89433039|NCT06281327|Experimental|Treatment group: Avatrombopag|Sixty subjects will be enrolled with the indicated treatment dose of avatrombopag
89433040|NCT06281301|Other|no additional information|
88912528|NCT01579058|Placebo Comparator|placebo|placebo
88912529|NCT01579071|Experimental|CO2 sufflation group|
89433041|NCT06281301|Experimental|education tool|
88912530|NCT01579071|Experimental|Room air sufflation group|
88912531|NCT01579097|Active Comparator|compounded ternary parenteral nutrition|compounded ternary Parenteral Nutrition admixture
88912532|NCT01579097|Experimental|Oliclinomel N4 formulation|Oliclinomel N4 is a ready-to-use PN product presented as a triple chamber bag
88912533|NCT01579110|Experimental|prednisolone + levamisole|
88912534|NCT01579110|Active Comparator|Prednisone|
88912535|NCT01579123|Active Comparator|Laser atherectomy|
88912536|NCT01579123|Active Comparator|Angioplasty|
88912537|NCT01579136|No Intervention|Control group|This group will not get a home blood pressure monitor.
88912538|NCT01579136|Experimental|Home monitors|This group will be given a home blood pressure monitor to use.
88912539|NCT01579149|Experimental|plerixafor|Single subcutaneous (SC) dose of plerixafor (160 μg/kg, 240 μg/kg, or 400 μg/kg)
88912540|NCT01579149|Placebo Comparator|Placebo|
88912541|NCT01579175|No Intervention|Standard postoperative care|
88912542|NCT01579175|Experimental|Chewing gum arm|Sugar free (extra, spearment) chewing gum given to the patient to chew during waking hours every four hours for 15 minutes
89433042|NCT06281236|Experimental|prednisolone + SPI-62|Participants will receive prednisolone throughout the trial and SPI-62 on days 3-16.
89433043|NCT06281210|Experimental|Omission of surgical treatment|Omission of surgical treatment in patients with complete pathological response after neoadjuvant chemotherapy and negative VABB biopsy
88912543|NCT01579188|Experimental|GV1001|The adjuvant GM-CSF is administered first as an intradermal injection followed in 10-15 minutes by the GV1001 peptide injected into the same site.
89433044|NCT06281197|Experimental|Conventional Group|In conventional group, Le Fort I osteotomy was made using a piezosurgical saw after nasal mucosa elevation as usual Le Fort I technique.
89433045|NCT06281197|Active Comparator|Subspinal Group|In Subspinal group, No dissection was performed between the nasal mucosa and the ANS of the patients. Osteotomy was performed in the subspinal Le Fort I group that is described by Mommaerts . A triangular osteotomy line was created between the maxilla and the ANS with a piezosurgery.
89433046|NCT06281184||MTX -- MTX|MERINO trial: randomized to methotrexate (MTX) MERINO:2 study: continues with MTX
89433047|NCT06281184||MTX -- No treatment|MERINO trial: randomized to methotrexate (MTX) MERINO:2 study: continues without MTX
89433048|NCT06281184||Placebo -- MTX|MERINO trial: randomized to placebo MERINO:2 study: continues with MTX
88912544|NCT01579188|Placebo Comparator|Placebo|Placebo
89009163|NCT03450616|Active Comparator|Compression Dressing- Standard of Care|Subjects will have one venous stasis ulcer treated with the standard of care compression dressing.
89433049|NCT06281184||Placebo -- No treatment|MERINO trial: randomized to placebo MERINO:2 study: continues without MTX
89433050|NCT06281171|Experimental|Video Library Group|This arm will receive the intervention. This intervention is access to the SkillTalk for AYA Microskills video library, about 60 minutes in duration. The library includes a curriculum covering skills such as setting boundaries, resolving conflict, and emotional regulation.
89433051|NCT06281171|Active Comparator|Flyer Library Group|During the intervention period, arm 2 will receive flyers with information on relationship skills. This arm will receive the intervention upon completion of follow-up study activities.
89433052|NCT06281145|Experimental|Standard of care + HRV biofeedback intervention|"Experimental: Heart-rate variability (HRV) biofeedback intervention + standard of care Deep paced breathing with the HRV monitoring performed three times a day for seven minutes during three months with standard of care.~Cohort A- breast cancer, Cohort B- colon cancer"
89433053|NCT06281145|No Intervention|Standard of care|Cohort A- neoadjuvant chemotherapy +/- targeted therapy +/- immunotherapy defined standard of care in current European Society For Medical Oncology (ESMO) guideline in the defined disease subtype Cohort B- adjuvant chemotherapy +/- targeted therapy +/- immunotherapy defined standard of care in current ESMO guideline in the defined disease subtype
89433054|NCT06281132|Experimental|Sequence 1|"Period 1: D956~Period 2: CKD-341~Period 3: D956~Period 4: CKD-341"
88912545|NCT01579201|Experimental|Carbetocin|
88912546|NCT01579227||1-TOP group 1|TOP group 1 will have biopsy #2 collected 3 days after 1st biopsy collected.
88912547|NCT01579227||TOP group 2|TOP group 2 will have biopsy #2 collected 30 days after 1st biopsy collected.
88912548|NCT01579227||OTOP group-1|OTOP will use topical cream (either topical tocotrienol (TCT) or placebo cream) as well as oral supplementation (either oral Tocotrienol capsules (TCT) or placebo capsules). OTOP group 1 will have biopsy #2 collected 3 days after 1st biopsy collected.
89433055|NCT06281132|Experimental|Sequence 2|"Period 1: CKD-341~Period 2: D956~Period 3: CKD-341~Period 4: D956"
89433056|NCT06281119|Experimental|Cervavac administered as three doses|Recombinant Quadrivalent Human Papillomavirus (Types 6,11 16, 18) Vaccine manufactured by Serum Institute of India Pvt Ltd administered as three doses at day 0, 60 and 180.
89433057|NCT06281119|Experimental|Cervavac administered as two doses|Recombinant Quadrivalent Human Papillomavirus (Types 6,11 16, 18) Vaccine manufactured by Serum Institute of India Pvt Ltd administered as two doses at day 0 and 180.
89433058|NCT06281119|Active Comparator|Gardasil administered as three doses|Recombinant Quadrivalent Human Papillomavirus (Types 6,11 16, 18) Vaccine manufactured by MSD administered as three doses at day 0, 60 and 180.
89433059|NCT06281106|Active Comparator|'Deucravacitinib'|Deucravacitinib 6mg oral intake once daily for 4 weeks
88912549|NCT01579227||OTOP group-2|OTOP will use topical cream (either topical tocotrienol (TCT) or placebo cream) as well as oral supplementation (either oral Tocotrienol capsules (TCT) or placebo capsules). OTOP group 2 will have biopsy #2 collected 30 days after 1st biopsy collected.
88912550|NCT01579227||TAM Group 1|TAM group 1 will have #2 biopsy collected 21 days after 1st biopsy collected. Tamoxifen cream and placebo cream will be applied where biopsies are collected from 1 week prior to having the biopsy procedure until the second biopsy is collected (21 days later).
89197755|NCT00854919|Experimental|1|Drug; Paroxetine (30-50mg/D)or Fluvoxamine (150-250mg/D), 1-year administration
89433060|NCT06281106|Placebo Comparator|'Placebo'|Matching Placebo oral intake once daily for 4 weeks
89433061|NCT06281080|Experimental|Treatment arm|Patients underwent En-Bloc Resection of Bladder Tumours using Agilis Robotic System.
89433062|NCT06281067|Experimental|"full-physiology approach arm"|"In the full-physiology approach arm, patients will be, during CA, simultaneously subjected to a full interventional diagnostic procedure, including:~resting distal coronary pressure to aortic pressure ratio (Pd/Pa);~fractional flow reserve (FFR) after intravenous adenosine administration;~Resting Ful-Cycle Ratio (RFR);~coronary flow reserve (CFR) and index of microvascular resistance (IMR);~assessment of FFR, CFR and IMR after inotropic stimulation with dobutamine (respectively FFR-d, CFR-d and IMR-d);~acetylcholine (ACH) provocative test."
88912551|NCT01579227||Normal Skin|Placebo group will apply placebo and TCT cream that will be applied daily to a specified area on the subjects legs (normal skin) for 5 weeks. One leg will be applied with placebo and the other will be applied with TCT cream. Subjects will return weekly for 5 weeks, where non-invasive measurements using Laser Speckle imaging, will be completed at each study visit
88912552|NCT01579240|Experimental|program visits|visits to intervention program
88912553|NCT01579279|Experimental|ABT-652 6 mg|ABT-652 capsules - twice daily
88912554|NCT01579279|Experimental|ABT-652 12 mg|ABT-652 capsules twice daily
88912555|NCT01579279|Experimental|ABT-652 12 mg - 18 mg|ABT-652 capsules twice daily
88912556|NCT01579279|Placebo Comparator|Placebo|Placebo capsules twice daily
88912557|NCT01579279|Active Comparator|Duloxetine|Duloxetine capsules once daily
88912558|NCT01579292|Experimental|Physical Activity and Diet Intervention|5-month physical activity and diet intervention which includes 6 in-person sessions, mobile app, and pedometer
88912559|NCT01579292|Active Comparator|Pedometer only|Pedometer only
88912560|NCT01579331|Experimental|Dynamic Contour Tonometry|All recruited volunteers in present study, that underwent diurnal GAT tonometry (3 measures) and 5 DCT measurements.
88912561|NCT01579344|Active Comparator|Thyroid carcinoma, Radioactive iodine therapy|50 patients (100 eyes) diagnosed with differentiated thyroid carcinoma undergoing radioactive iodine therapy
88912562|NCT01579344|No Intervention|Thyroid carcinoma, without radioactive iodine therapy|50 patients (100 eyes) diagnosed with differentiated thyroid carcinoma not undergone radioactive iodine therapy
89433063|NCT06281067|Other|"standard approach arm"|"In the standard approach arm, patients will undergo only an angiographic evaluation, without any invasive intracoronary assessment."
88912563|NCT01579357|Other|A|Capecitabine in week 1,2,4,5,7 and 8 Cetuximab in week 3 to 9 Oxaliplatin in week 7
88912564|NCT01579357|Other|B|Capecitabine in weeks 1,2,4,5,7, and 8 Cetuximab in weeks 1,8 and 9 Oxaliplatin in week 7
88912565|NCT01579370|Active Comparator|Quaternary ammonium|Rooms will be terminally cleaned using quaternary ammonium-containing compounds, the reference standard for hospital cleaning in US hospitals.
88912566|NCT01579370|Experimental|Bleach|Rooms will be terminally cleaned using bleach-containing products.
88912567|NCT01579370|Experimental|Quaternary ammonium and UV-C light|Rooms will be terminally cleaned with quaternary ammonium-containing solutions followed by irradiation by a UV-C light emitting device.
88912568|NCT01579370|Experimental|Bleach and UV-C light|Rooms will be terminally cleaned with bleach-containing solutions followed by irradiation by a UV-C light emitting device.
88912569|NCT01579383|Experimental|Part A, Cohorts A - H|ALD403/Placebo
88912570|NCT01579383|Experimental|Part A, Cohort I|ALD403/Placebo
88912571|NCT01579383|Experimental|Part B|ALD403/Placebo/Sumatriptan
88912572|NCT01579396|Experimental|septeX|septeX CVVH for 12h after cardiac surgery
88912573|NCT01579396|Other|standard therapy|standard therapy according to local practice
88912574|NCT01579409|Other|1-25th percentile of the PNNS score|
88912575|NCT01579409|Other|75-100th percentile of the PNNS score|
88912576|NCT01579422|Experimental|social cognitive training|
88912577|NCT01579435|Experimental|Therapeutic tDCS|6 patients with essential tremor
88912578|NCT01579435|Experimental|Physiopathological tDCS|6 patients with essential tremor
88912579|NCT01579448|Experimental|Vaccine to past vaccinated participants|The first arm includes subjects, who were immunized with two Shanchol™ doses, five years prior. In this study, arm one will receive one Shanchol™ booster dose at baseline and one booster dose on day fourteen.
88912580|NCT01579448|Active Comparator|Vaccine to past placebo recipients|The second arm includes subjects, who received two placebo doses, five years prior. Arm two will receive a primary immunization series consisting of one Shanchol™ dose at baseline and one at day fourteen
88912581|NCT01579448|Placebo Comparator|No intervention to past placebo recipients|The third arm includes subjects, who received two placebo doses, five years prior. This third arm will not receive any intervention and will serve to represent a baseline immune response by vaccine naïve individuals exposed to natural exposure.
88912582|NCT01579461|Experimental|mild hepatic impairment|
88912583|NCT01579461|Experimental|moderate hepatic impairment|
88912584|NCT01579461|Experimental|healthy volunteers (matched with mild hepatic)|
88912585|NCT01579461|Experimental|healthy volunteers (matched with moderate hepatic)|
88912586|NCT01579500|Active Comparator|botulinum toxin A|
88912587|NCT01579500|Placebo Comparator|normal saline|
88912588|NCT01579526|Experimental|FP01 Dose 1|Drug
88912589|NCT01579526|Experimental|FP01 Dose 2|Drug
88912590|NCT01579526|Experimental|FP01 Dose 3|Drug
88912591|NCT01579526|Active Comparator|Comparator|Drug
88912592|NCT01579539|Experimental|Patients|Patients with moderate to severe thyroid-associated ophthalmopathy
88912593|NCT01579591|Experimental|VSL#3 PROBIOTIC PREPARATION|
88912594|NCT01579591|Placebo Comparator|Placebo|
88912595|NCT01579604|Experimental|Surgical arm|"Nerve reconstruction:~Early nerve transfer (around 6-9 months post cervical spine injury) will be performed in this group of patients."
88912596|NCT01579604|No Intervention|Non-surgical (or observed)|Patients in this group will receive standard of care and be observed for up to two years post injury.
88912597|NCT01579617|Experimental|BUtiful|Intervention arm, 'BUtiful. Be yoU! Talented, Informed, Fearless, Uncompromised, Loved', has 8 website sessions focused on pregnancy and STI prevention
88912598|NCT01579617|Other|DIVAS|Attention control arm, 'DIVAS. Diversity, Individuality, Vitality, Activity and Strong', has 8 website sessions focused on general health and nutrition
88912599|NCT01579630|Experimental|Pemetrexed 500mg/m2 iv|
88912600|NCT01579630|Experimental|Pemetrexed 500 mg/m2 i.v. and Gefitinib 250 mg|
88912601|NCT01579643|Experimental|LALAK|
89433064|NCT06281054||Revascularized Group|Cancer patients with diagnosis of acute myocardial infarction that was treated with PCI or CABG
89433065|NCT06281054||Medical Group|Cancer patients with diagnosis of acute myocardial infarction that was treated with medical treatment only
89433066|NCT06281041||Antiplatelet agents|Among patients with intermediate coronary artery stenosis (50-70% diameter stenosis by quantitative coronary angiography) but who did not undergo PCI based on negative FFR, those who were taking antiplatelet agents (aspirin or clopidogrel) are classified into this group.
89433067|NCT06281041||No antiplatelet agents|Among patients with intermediate coronary artery stenosis (50-70% diameter stenosis by quantitative coronary angiography) but who did not undergo PCI based on negative FFR, those who were not taking antiplatelet agents (aspirin or clopidogrel) are classified into this group.
89433068|NCT06281028|Other|A : SOLACEA-H/HYDROLINK-NVU|"The dialysis sessions will take place in the following order :~Wash - SOLACEA-H dialysis - Wash - HYDROLINK-NVU dialysis"
89433069|NCT06281028|Other|B : HYDROLINK-NVU/SOLACEA-H|"The dialysis sessions will take place in the following order :~Wash - HYDROLINK-NVU dialysis - Wash - SOLACEA-H dialysis"
89433070|NCT06280963|Experimental|muscle energy technique arm|this arm will receive muscle energy technique
89433071|NCT06280963|Experimental|posterior innominate mobilization arm|this arm will receive posterior innominate mobilization
88912602|NCT01579643|Active Comparator|Penetrating Keratoplasty (KP)|
88912603|NCT01579656|Experimental|Salba|25g of ground Salba baked into a bran muffin
88912604|NCT01579656|Experimental|Poppy|25g of ground poppy seeds baked into a bran muffin
88912605|NCT01579656|Experimental|Flaxseed|25g of ground flaxseed baked into a bran muffin
88912606|NCT01579656|Experimental|Sesame|25g of ground sesame seeds baked into a bran muffin
88912607|NCT01579656|Placebo Comparator|Wheat Bran|Bran muffin matched for total available carbohydrates, total dietary fibre and calories
88912608|NCT01579682|Experimental|Psychotherapy|Family-Based Therapy (12 sessions)
88912609|NCT01579682|Experimental|Family-Based Therapy with Intensive Family-Focused Treatment|The patient will receive 4 sessions of Family-Based therapy, and if the participant does not make adequate weight gain within this time period, will be assigned to Intensive Family-Focused Therapy (IFT).
88912610|NCT01579695||Exposed Group will receive Tesamorelin|
88912611|NCT01579695||Control Group will not receive Tesamorelin|
88912612|NCT01579708|Experimental|Program SI! educational intervention|
88912613|NCT01579708|No Intervention|Control|
89433072|NCT06280963|Placebo Comparator|control arm|this arm will receive conventional treatment
89433073|NCT06280950|Experimental|Interventional Group 1|Participants in this group will slowly reduce their dose of tacrolimus and continue everolimus as their only immunosuppression medication.
88912614|NCT01579721|Experimental|SILS-group|20 patients undergoing Single Incision Laparoscopic Surgery
88912615|NCT01579721|No Intervention|CLS-group|20 patients undergoing Conventional Laparoscopic Surgery for rectal cancer
88912616|NCT01579760|Experimental|aflibercept every 2 months|
88912617|NCT01579760|Experimental|aflibercept monthly|
88912618|NCT01579786|No Intervention|Acetaminophen|A group All patients will be treated only with drugs used for this type during the operation and post operative pain controlled with usual acetaminophen drug administration (maximum 3 g/day)
88912619|NCT01579786|Experimental|Acetaminophen and acupuncture|B group patients. All patients will receive the standard pharmacological treatment for the operation. Acetaminophen (maximum 3g/day) during all seven days after surgery and patients will be treated with acupuncture the first day after surgery and thirty minutes before the surgical procedure
88912620|NCT01579799|Active Comparator|Dose 0.5|
88912621|NCT01579799|Active Comparator|Dose 7.5|
88912622|NCT01579799|Active Comparator|Dose 3|
88912623|NCT01579799|Active Comparator|Dose 1.2|
88912624|NCT01579825|Experimental|Buffer|
88912625|NCT01579825|No Intervention|Control|
88912626|NCT01579838|Experimental|Eculizumab|Eculizumab will be administrated according to known protocols.
88912627|NCT01579864|Active Comparator|succinylcholine|Succinylcholine 1 mg/kg and a second dose if necessary.
89433074|NCT06280950|Experimental|Interventional Group 2|Participants in this group will continue to take reduced Tacrolimus and Everolimus IS regimen.
89433075|NCT06280950|No Intervention|Observational Group|"Participants in this group could not tolerate the addition of everolimus. These participants will not be randomized.~Participants in this group will stop taking everolimus.~Participants in this group will resume taking their tacrolimus +/- mycophenolate compound and prednisone immunosuppression regimen."
89433076|NCT06280937|No Intervention|Control Group|In this group, participants will go on their daily activities. No additional intervention will be applied to the participants in this group.
89433077|NCT06280937|Experimental|Study Group|In this group, participants will wear a tie during one office working day
89531229|NCT03098121|Experimental|Genotype 1 HCV and HIV co-infection|Patients with chronic Genotype 1 HCV and HIV co-infection, with or without resistance-associated substitution (RAS) of NS5A, received grazoprevir and elbasvir in a fixed-dose combination tablet once daily with ribavirin for 16 weeks, and patients with chronic genotype 1b received grazoprevir and elbasvir once daily for 12 weeks.
89433078|NCT06280924|Active Comparator|Standard Care|Participants in this group will receive exercise counseling as per standard care for 10-weeks. This will include: (1) counseling on remaining active during chemotherapy; (2) handouts on the benefits of exercise during chemotherapy, exercise behavior change strategies, and how to exercise safely. Participants will be encouraged to remain as physical active as possible. As per American College of Sports Medicine 2019 guidelines, participants will be advised to take part in moderate intensity exercise for a total of 90 minutes per week.
89433079|NCT06280924|Experimental|Supported Exercise Group|Participants assigned to the exercise group will take part in a 10-week exercise program delivered in-person and through the HEAL-ME app. The program comprises (1) a minimum of one supervised session (in-person or virtual through a Zoom platform embedded in HEAL-ME), (2) a minimum of one independent exercise workout within the HEAL-ME app, and (3) exercise specific education content as per standard care.
89433080|NCT06280885|Experimental|FIERCE Programme|"The FIERCE programme will consist of an aerobic and resistance exercise program delivered for the duration of chemotherapy.~Exercise will be prescribed with the aim of achieving an overall exercise volume over the course of a chemotherapy cycle. The total volume of exercise prescribed in each cycle will be targeted towards achieving the exercise guidelines for cancer survivors which recommends 90 minutes of aerobic activity per week, in addition to resistance exercise at least two times per week.~Exercise intensity will be autoregulated by participants based on how they are feeling on a given day. Participants will be given a choice of exercising at low, moderate, or higher intensity based on how BORG rating of perceived exertion (RPE) scale.~Weekly check ins will be made to each participant over the phone by an exercise physiologist for goal setting. Participants will also be given a pedometer to monitor daily physical activity levels."
89433081|NCT06280885|Active Comparator|Pedometer programme|Participants randomized to the pedometer programme will receive individualised advice about exercising during chemotherapy and will also receive a pedometer to encourage daily activity. Participant in both groups will receive a personal exercise consultation to identify their individual needs and understand their exercise preferences.
89531230|NCT03342209|Experimental|HFNC therapy|Fisher&Paykel AIRVO™ 2 High Flow Nasal Cannula Therapy will be implemented to CO-poisoned patients. Oxygen flow rate will be started 60 L/min and be decreased as the patient has requested.
88912628|NCT01579864|Experimental|Rocuronium|rocuronium 0,9 mg/kg with additional boluses of 0,3 mg/kg f necessary
88912629|NCT01579877|Experimental|Yukmijihwang-tang|Yukmijihwang-tang: Real herbal extract granule
88912630|NCT01579877|Placebo Comparator|Yukmijihwang-tang_Placebo|Yukmijihwang-tang_Placebo: Placebo herbal extract granule
88912631|NCT01579903|Experimental|Sequence 1|Subjects randomized to receive Treatment A during Period 1, then Treatment B during Period 2.
88912632|NCT01579903|Experimental|Sequence 2|Subjects randomized to receive Treatment B during Period 1, then Treatment B during Period 2.
88912633|NCT01579929|Experimental|LDE225, Etoposide and Cisplatin|This is a single institution phase I trial of LDE225 combined with etoposide and cisplatin in patients with untreated, newly diagnosed extensive stage small cell lung cancer (ES-SCLC). LDE225 is an oral drug, which will be taken daily by patients. Patient self-reporting via STAR will be used in an evaluation of the extent to which patient-reported toxicity influences dose finding in phase I clinical trials. Specifically, STAR reports will be presented to clinicians in real-time at clinic visits, & clinicians will have an opportunity to either agree or modify the patient self-assessments & use this information in their grading & attribution of toxicities.
88912634|NCT01579942||Patients with Major Depressive Disorder|Patients who have Major Depressive Disorder and are taking a Selective Serotonin Re-uptake Inhibitor (SSRI) as part of another study at our clinic.
88912635|NCT01579942||Healthy Controls|Patient with no history of significant mental health problems.
88912636|NCT01579955||eptacog alpha users|
88912637|NCT01579968||eptacog alpha users|
88912638|NCT01579994|Experimental|Ganetespib (STA-9090) and crizotinib|This protocol is a phase I single arm, open label, single institution study of crizotinib and ganetespib (STA-9090) in patients with ALK+ advanced NSCLC who are crizotinib naïve.
88912639|NCT01580124|Active Comparator|PVI alone|Pulmonary vein isolation alone in persistent atrial fibrillation
88912640|NCT01580124|Active Comparator|PVI + Defragmentation + linear lesions|AF ablation continuation aiming for AF termination
88912641|NCT01580150|Experimental|Berry meal|Carbohydrate meals with berries
88912642|NCT01580150|Active Comparator|Reference meal|Carbohydrate meals without berries
88912643|NCT01580228|Experimental|Dinaciclib|
88912644|NCT01580228|Active Comparator|Ofatumumab|
88912645|NCT01580280|Experimental|Thrust manipulation|
88912646|NCT01580280|Active Comparator|Non-thrust mobilization and exercise|
88912647|NCT01580475|Experimental|Lifestyle (exercise training)|Training, detraining and retraining
88912648|NCT01580579||locally advanced lung cancer|Patients with locally advanced lung cancer who are candidates to chemoradiation
88912649|NCT01580735|Experimental|ARQ 197|
88912650|NCT01580787|Experimental|Virtual Reality Training|The virtual reality training was done by experimental group with ten games of Nintendo Wii Fit.
88912651|NCT01580787|Active Comparator|Physical Therapy|The Control Group was trained by conventional Physical Therapy exercises.
88912652|NCT01581034|Active Comparator|Padma|
88912653|NCT01581034|Placebo Comparator|Placebo|
88912654|NCT01581333|Experimental|Experimental Arm|Empirical antimicrobial treatment discontinuation
88912655|NCT01581333|Active Comparator|Control Arm|Standard empirical antimicrobial treatment discontinuation
88912656|NCT01581359|Active Comparator|GnRHa|Triptorelin acetate 3,75 mg subcutaneous injection administered on days 1, 28 and 56 after menstrual cycle.
88912657|NCT01581359|Placebo Comparator|Physiological serum|physiological serum subcutaneous injection with same delivery device and same volume that active comparator ) administered on days 1, 28 and 56 after menstrual cycle.
88912658|NCT01581476|Active Comparator|Statin|Participants receive active statin and placebo ACE Inhibitor
88912659|NCT01581476|Active Comparator|Angiotensin-converting enzyme inhibitor|Participants receive active ACE Inhibitor and placebo statin
89433082|NCT06280872|Experimental|Physiological Based Cord Clamping (PBCC)|In the intervention group, newborns will receive PBCC. The resuscitation table will be placed as close as possible to the mother's pelvis. Stabilization will start as soon as the infant is placed on the platform. The nurse will place the oximeter sensor on the right wrist, electrocardiogram electrodes on the chest of the newborn. Local resuscitation guidelines will be in respect of the Newborn Life support European Resuscitation Council 2021 guidelines. Stabilization of the newborn will be performed while the cord is intact and the cord will be clamped after respiratory stabilization will be achieved, de ﬁned as the establishment of regular spontaneous breathing, a heart rate above 100 bpm and oxygen saturation by pulse oximetry above 85% while using supplemental oxygen less than 0,4. If the infant does not reach the criteria for being stable, the maximum clamping time will be 10 min. After clamping, the platform will be withdrawn and placed next to the bed of the mother.
89536274|NCT03198247|Experimental|Experimental: Usual Care + PNE and CST|"Procedure: Usual care + PNE and CST. The PNE and CST program will be divided in 3 individual sessions. This program is mainly based in Explain Pain concept, used in multiple rehabilitation programs. Its aim is to change the subject's pain understanding, teaching them the biological processes underneath the pain construct, as a mechanism to reduce itself and its related maladaptative thoughts and behaviours"
88912660|NCT01581476|Placebo Comparator|Placebo|Participants receive placebo ACE Inhibitor and placebo statin
88912661|NCT01581476|Other|Combination therapy|Participants receive both active ACE Inhibitor and active Statin
89536275|NCT03198169|Experimental|Active AWC + Active ABFD|Active Antimicrobial Wound Cleanser + Active Antimicrobial Barrier Film Dressing + SOC
88912662|NCT01581502||NVAF, acute ischemic stroke/TIA|Consecutive acute ischemic stroke/TIA patients with nonvalvular atrial fibrillation; most of these patients begin to receive anticoagulant therapy after index stroke/TIA for secondary prevention
88912663|NCT01581749|Other|36.25Gy to prostate in 5 fractions|36.25Gy to be delivered to the prostate in 5 fractions. There is only 1 arm in this study.
88912664|NCT01581762|Sham Comparator|Conventional 22G Needle|Device: EUS-FNA with conventional 22G Needle
88912665|NCT01581762|Active Comparator|22G Procore Needle|Device: EUS-FNA with 22G Procore Needle which has a reverse bevel at the tip of the needle to enhance tissue collection
89433083|NCT06280872|Active Comparator|Differed Cord Clamping (DCC)|In the control group, newborns will receive standard DCC defined as time based and performed at 60 seconds after birth, depending on the clinical condition of the infant, in accordance with the ERC guidelines 2021.Then infants will be transferred to a standard resuscitation table located in a stabilization room next to the operating room. Further treatment and intervention required for cardiopulmonary stabilization will be provided on the standard resuscitation table. Stabilization will start as soon as the infant is placed on the resuscitation table. The nurse will place the oximeter sensor on the right wrist, ECG electrodes on the chest and temperature probe on the right hypochondrium of the newborn. Local resuscitation guidelines will be in respect of the Newborn Life support European Resuscitation Council 2021 guidelines. The time to reach the stabilisation described above (a HR above 100 bpm and SpO 2 above 85% while using supplemental oxygen less than 0,4) is recorded.
89433084|NCT06280794|Experimental|Laser acupuncture Group|"Steroids. Patients in the laser acupuncture group (LA group) received 12 sessions of laser acupuncture (3 times per week). Laser aucpuncture used a class IV Multiwave Locked System (MLS) laser (Mphi laser, ASA Srl, Vicenza, Italy).~In LA group, we choose 5 acupoints on the affected side. It includes ST2(Si Bai), ST4(Di Cang), ST6(Jia Che), GB14(Yang Bai), GB20(Feng chi). We choose 6 acupoints, including LI4 (He Gu), LI11(Qu Chi), ST36 (Zu San Li), SP6 (San Yin Jiao), KI3 (Tai Xi), LR3 (Tai Chong).~Laser acupuncture used have wavelength of 808 nm and 905nm, 1.2 W power (808nm is 1 W, 905 nm is 200 mW), continuous mode emission (808 nm) and pulsed mode emission (905 nm), 500 Hz, 50% power level, 50% duty cycle, 8.35 J/cm2 dosimetry, 26.22 J for each point, administered for 3 times per week in the first 2 weeks, and 1500 Hz, 50% power level, 50% duty cycle, 8.35 J/cm2 dosimetry, 26.22 J for each point, in the last 2 weeks, 12 times total treatment."
89433085|NCT06280794|Sham Comparator|Sham laser acupuncture Group|"Steroids. Patients in the laser acupuncture group (LA group) received 12 sessions of laser acupuncture (3 times per week). Laser aucpuncture used a class IV Multiwave Locked System (MLS) laser (Mphi laser, ASA Srl, Vicenza, Italy).~In LA group, we choose 5 acupoints on the affected side. It includes ST2(Si Bai), ST4(Di Cang), ST6(Jia Che), GB14(Yang Bai), GB20(Feng chi). We choose 6 acupoints, including LI4 (He Gu), LI11(Qu Chi), ST36 (Zu San Li), SP6 (San Yin Jiao), KI3 (Tai Xi), LR3 (Tai Chong).~The Sham LA group received the same laser device and the same acupoints. The device showed the same red light but did not emit a laser, administered for 3 times per week in the 4 weeks."
89433086|NCT06280794|Other|Control group|Steroids.
89536276|NCT03198169|Experimental|Active AWC + Placebo ABFD|Active Antimicrobial Wound Cleanser + Placebo Antimicrobial Barrier Film Dressing + SOC
89536277|NCT03198169|Experimental|Placebo AWC + Active ABFD|Placebo Antimicrobial Wound Cleanser + Active Antimicrobial Barrier Film Dressing + SOC
88912666|NCT01581892|Experimental|Bone marrow stem cells|Bone marrow is obtained by posterosuperior iliac crest aspiration under topical anesthesia. Mononuclear cells were isolated by Ficoll density gradient and will be resuspended in heparinized isotonic saline for mixing with osteogenic matrix.
89433087|NCT06280781|No Intervention|Standard care (Control) Arm|PSA 3 monthly in year 1 and then 6 monthly with rectal exam annually. MRI will be carried out at 12 months (if not had one at diagnosis). If a diagnostic MRI was carried out, a 12 month MRI scan will not be required. A biopsy will be required if indicated due to changes in rectal exam or PSA. Follow-up for 5 years.
89536278|NCT03198169|Experimental|Placebo AWC + Placebo ABFD|Placebo Antimicrobial Wound Cleanser + Placebo Antimicrobial Barrier Film Dressing + SOC
89433088|NCT06280781|Experimental|Intervention Arm|Patients with a visible lesion or medium risk cancer will have PSA 6 monthly and MRI scans annually. As per international PIRADS committee guidance the surveillance MRIs will be biparametric MRI scans which last approximately 15 minutes and exclude gadolinium contrast injection. All other patients will undergo PSA 6 monthly and MRI in years 1, 3 and 5. In all patients, a targeted biopsy will be carried out if the MRI PRECISE score is >/=4.
89433089|NCT06280768|Experimental|SHR-2004 injection|
89433090|NCT06280755||Data from real-world clinical practice|Retrospective, real-world clinical data obtained via the 6 participating clinical centers in the study.
88912667|NCT01581905|Active Comparator|LH Group|The LH Group includes individuals undergoing conventional laparoscopic hysterectomy, total or supracervical.
88912668|NCT01581905|Active Comparator|RH Group|The RH Group includes individuals undergoing Robot-Assisted laparoscopic hysterectomy, total or supracervical.
88912669|NCT01581957|Active Comparator|Specific Enteral formulation|
88912670|NCT01581957|Placebo Comparator|Standard enteral formulation|
88912671|NCT01582321|Experimental|Part 1 Male|16 healthy male volunteers will be recruited. Primary and secondary outcome measures will be made on day 1, 3 and 4. At 24 and 72 hours prior to outcome measures on day 3 a cantharidin-soaked 1cm2 filter paper disc will be applied to participants forearm or back on leg for blister formation. Blister fluids will be harvested on day 3.
88912672|NCT01582321|Experimental|Part 1 Female|16 healthy female volunteers will be recruited. Primary and secondary outcome measures will be made on day 1, 3 and 4. At 24 and 72 hours prior to outcome measures on day 3 a cantharidin-soaked 1cm2 filter paper disc will be applied to participants forearm or back on leg for blister formation. Blister fluids will be harvested on day 3.
88912673|NCT01582321|Experimental|Part 2 Male|12 healthy male volunteers will be recruited. Primary and secondary outcome measures will be made on day 0, 1 and 2. At 8 hours prior to outcome measures on day 1 intra-muscular typhoid vaccine will be administered.
88912674|NCT01582321|Experimental|Part 2 Female|12 healthy female volunteers will be recruited. Primary and secondary outcome measures will be made on day 0, 1 and 2. At 8 hours prior to outcome measures on day 1 intra-muscular typhoid vaccine will be administered.
88912675|NCT01582711|Active Comparator|3HP Directly Observed Therapy (DOT)|900mg of isoniazid plus 900mg of rifapentine given weekly for 3 months (12 weeks, 12 doses) under Directly Observed Therapy (DOT)
88912676|NCT01582711|Experimental|3HP Self Administered Therapy (SAT)|900mg of isoniazid plus 900mg of rifapentine given weekly for 3 months (12 weeks, 12 doses) as patient Self Administered Therapy (SAT)
88912677|NCT01582711|Experimental|3HP SAT with SMS Reminders|900mg of isoniazid plus 900mg of rifapentine given weekly for 3 months (12 weeks, 12 doses) as patient Self Administered Therapy (SAT). In addition, patient receives phone Short Message Service (SMS) reminders weekly.
88912678|NCT01583062|Active Comparator|1|Both groups receive amoxicillin/clavulanic acid 1.2 g intravenously every eight hours from admission up to 24 hours postoperatively. Group 1 then receives amoxicillin/clavulanic acid 625 mg orally every eight hours for four days.
89433091|NCT06280755||Data from the control arms of relevant clinical trials|Data from the control arms of relevant clinical trials obtained via the 4 participating pharmaceutical partners in the study.
89433092|NCT06280742|Experimental|Patients|MRI with added injection of gadolinium
89433093|NCT06280742|Active Comparator|Healthy Volunteers|
89433094|NCT06280729||T1DM cohort|A. T1DM label attached in the EHR OR B. patients with at least a record of Glycated Hemoglobin level of >6.5% (48 mmol/mol) AND < 45 years old AND no use of oral antidiabetic drug AND positivity of ≥2 anti-islet antibodies
89433095|NCT06280729||T2DM cohort:|A. T2DM label attached in the EHR OR B. patients with at least a record of Glycated Hemoglobin level of >6.5% (48 mmol/mol) AND Medication history of antidiabetic drug comprising insulin or not
88912679|NCT01583062|Placebo Comparator|2|Both groups receive amoxicillin/clavulanic acid 1.2 g intravenously every eight hours from admission up to 24 hours postoperatively. Group 2 receives oral placebo using the same schedule for the same duration as group 1.
88912680|NCT01583075|Other|Circumferential ablation|
88912681|NCT01583075|Experimental|Single ring ablation|
88912682|NCT01583088|Experimental|phenic nerve stimulation|effective phenic nerve stimulation NeurX™ (Synapse Biomedical)
88912683|NCT01583088|Sham Comparator|sham|sham phenic nerve stimulation
88912684|NCT01583309|No Intervention|low-flux hemodialysis|
88912685|NCT01583309|Experimental|online pre-dilution hemofiltration|
88912686|NCT01583309|Experimental|online pre-dilution hemodiafiltration|
88912687|NCT01583335|Experimental|Improved lifestyle|
88912688|NCT01583335|No Intervention|Control group|The control group was seen at baseline and follow-up, but not in between.
88912689|NCT01583335|No Intervention|Shadow group|The shadow group was followed in registers exclusively
88912690|NCT01583400|Active Comparator|RESPECT-D|The RESPECT-D Model: Collaborative Care depression treatment within primary care including care manager
88912691|NCT01583400|Experimental|RESPECT-D-E|RESPECT-D-E: Collaborative Care depression treatment within primary care including care manager plus on-line coaching, education and symptom, side effect and, medication adherence tracking with the digital health coaching program for depressive symptoms.
88912692|NCT01583426|Experimental|nab-Paclitaxel|nab-Paclitaxel (125 mg/m² weekly, infusion) is applicated for 12 weeks, followed by epirubicin and cyclophosphamide, applicated 4 cycles 3-weekly . In case of HER2-positive tumor patients receive tarstuzumab and pertuzumab 3-weekly during all cycles.
88912693|NCT01583426|Active Comparator|Paclitaxel|Paclitaxel (80 mg/m² weekly, infusion) is applicated for 12 weeks, followed by epirubicin and cyclophosphamide, applicated 4 cycles 3-weekly . In case of HER2-positive tumor patients receive tarstuzumab and pertuzumab 3-weekly during all cycles.
88912694|NCT01583517|Active Comparator|Biliary sphincterotomy|Cutting of the biliary sphincter muscle alone
88912695|NCT01583517|Active Comparator|Dual sphincterotomy|Cutting of both the biliary and pancreatic sphincter muscles.
88912696|NCT01583517|Sham Comparator|Sham|Among patients with normal sphincter of Oddi manometry, patients will undergo no sphincterotomy (sham therapy).
88912697|NCT01583517|Active Comparator|Biliary sphincterotomy - Normal SOM|Among patients with normal SOM, patients may be randomized to empiric biliary sphincterotomy alone.
88912698|NCT01583712|Experimental|Endomicroscopy|All patients included in the study will undergo endomicroscopy of the upper GI-tract including the reachable parts of the small bowel.
88912699|NCT01583972|Experimental|Vitamin A|50,000 IU vitamin A in edible oil
88912700|NCT01583972|Placebo Comparator|Placebo|edible oil used as diluent for vitamin A
88912701|NCT01584336|Experimental|LATG group|It means the patients who will be enrolled in our study.
88912702|NCT01584362|Experimental|oxfendazole 0.3|administration of a single oral 0.3mg/kg dose of oxfendazole
88912703|NCT01584362|Placebo Comparator|placebo comparator|administration of a single oral dose of placebo
88912704|NCT01584362|Experimental|oxfendazole 1.0|administration of a single oral 1.0 mg/kg dose of oxfendazole
88912705|NCT01584362|Experimental|oxfendazole 3.0|administration of a single oral 3 mg/kg dose of oxfendazole
88912706|NCT01584362|Experimental|oxfendazole 10|administration of a single oral 10 mg/kg dose of oxfendazole
88912707|NCT01584362|Experimental|oxfendazole 20|administration of a single oral 20 mg/kg dose of oxfendazole
88912708|NCT01584362|Experimental|oxfendazole 30|administration of a single oral 30 mg/kg dose of oxfendazole
88912709|NCT01579851|Active Comparator|Propofol-Remifentanil|Anesthesia is maintained with Propofol and Remifentanil; myorelaxation is obtained with rocuronium
88912710|NCT01579851|Active Comparator|Sevoflurane-Remifentanil|Anesthesia is maintained with Sevoflurane and Remifentanil; myorelaxation is obtained with rocuronium
88912711|NCT01584453|Experimental|Sodium Nitrite|
88912712|NCT01584453|Placebo Comparator|Placebo|
88912713|NCT01584713|Experimental|Adipose derived Stem Cells|
88912714|NCT01584921|Placebo Comparator|Placebo|1 ml of saline (Sodium Chloride 9 mg/ml) is given subcutaneously before 10 O-clock a.m. on day 1,2,3,5,7,9,11 and 13. On day 1,2 and 3 six ml in total is given in six syringes in order to maintain the double blinding.
88912715|NCT01584921|Active Comparator|Low dose Erythropoietin|
88912716|NCT01584921|Active Comparator|High dose Eryhropoietin|
88912717|NCT01585493|Active Comparator|Treatment as usual|Treatment as usual
88912718|NCT01585493|Active Comparator|Care coordinator|
88912719|NCT01585493|Experimental|CHANGE|
88912720|NCT01585662|Experimental|Naso-pancreatic tube|The patients enrolled in this group will be treated with modified naso-pancreatic tube drainage method.
88912721|NCT01585662|Experimental|Stents|The patients enrolled this group will be treated by placing the stents (at least 2 stents) between gastric and pancreatic pseudocyst.
88912722|NCT01586013|Experimental|propofol infusion|Healthy adults scheduled for elective surgery will receive a computer controlled infusion until obtain the loss of counsiousness (BIS <50). After stoping the infusion we observe the emergency of anesthesia and the correspondant BIS curve. Using the complete loss and recovery curve of BIS we can describe the course of the effect of the drug. Venous sample will be taken during the study to evaluate the pharmacokinetic performance of the model.
88912723|NCT01586221|Other|Music & Physical Therapy|Subjects will received Music and Physical Therapy in a group setting.
89197756|NCT00854919|Active Comparator|2|Either risperidone (1-5mg/D), olanzapine (1-5mg/D) or quetiapine (25-100mg/D) was added to ongoing SSRI, the combination trial was continued at least for half a year.
88912724|NCT01586273|Experimental|MR-HIFU treatment|Subjects undergo a MR-HIFU treatment for pain palliation of bone metastases on their most painful metastasis.
88912725|NCT01586377||CRPS Type 1|Patients with CRPS 1 affecting a single upper limb
88912726|NCT01586377||Healthy volunteers|Volunteers without the diagnosis of CRPS Type 1
88912727|NCT01586676|Experimental|MIA: STEP|Motivational Interviewing Assessment: Supervisory Tools for Enhancing Proficiency (MIA: STEP)
88912728|NCT01586676|Active Comparator|Supervision-as-usual|Supervision-as-usual consists of the typical clinical supervision services provided to clinicians by their supervisors in their community programs.
88912729|NCT01586689|Experimental|Safe Haven|participants assigned to the Safe haven condition and agree to move into the A Safe Haven residential treatment facility
88912730|NCT01586689|Experimental|Usual aftercare|participants assigned to the control condition, and may or may not seek treatment on their own
89197757|NCT00861783|Experimental|Group A - irinotecan|"Note: As of Amendment 2 (March 2009), treatment in the irinotecan arm of the study (Group A) is closed to enrollment.~Treatment with escalating doses of ON 01910.Na in combination with irinotecan."
89197758|NCT00861783|Experimental|Group B - oxaliplatin|Treatment with escalating doses of ON 01910.Na in combination with oxaliplatin.
89197759|NCT00947128|Experimental|1|Ondansetron HCl 24 mg Tablets (Sandoz, Inc.)
89197760|NCT00947128|Active Comparator|2|Zofran (Ondansetron HCl) 24 mg Tablets (GlaxoSmithKline)
89433096|NCT06280716|Experimental|Lebrikizumab every 2 weeks (Q2W)|"Induction Period (Baseline-Week 16):~Two subcutaneous (SC) injections of lebrikizumab as a loading dose at Baseline and Week 2 followed by a single injection every 2 weeks (Q2W) from Week 4 until Week 14. Induction period includes mono cohort with only lebrikizumab and combo cohort where lebrikizumab is in combination with TCS treatment."
88912731|NCT01586689|Experimental|Oxford House|participants who were assigned to the Oxford House condition and agree to move into an Oxford House
89197761|NCT00947206|Experimental|LHWO about CRC|The intervention group participants will be exposed to 2 LHWO sessions and 2 telephone calls aimed at increasing their CRC screening receipt.
89433097|NCT06280716|Experimental|Lebrikizumab every 4 weeks (Q4W)|"Maintenance Period (Week 16-Week 52):~Treatment from Week 16 to Week 52 is based on re-randomization of responders (from lebrikizumab Q2W arm) in the Induction Period. Participants re-randomized to the Lebrikizumab Q4W arm receive one lebrikizumab injection Q4W from Week 16 until Week 48."
88912732|NCT01586702|No Intervention|Regular care|Consisting of structured information given at hospital discharge regarding stroke etiology and recommended secondary prevention plus regular outpatient care by general practitioners or family doctors.
88912733|NCT01586702|Active Comparator|Support program|In addition to regular care: Up to 8 appointments in outpatient clinics. Results of risk factor measurements and assessed adherence to medical recommendations are shared with the patients. In case that a patients fails to meet target values, preventive measures will be modified directly or via recommendation to GPs / family doctors. Patients are also offered assistance in finding appropriate physical activities or smoking cessation programs.
88912734|NCT01586715|Experimental|Autologous Stem Cells|
88912735|NCT01586780|Experimental|Reference meal|
88912736|NCT01586780|Experimental|Whey protein|
88912737|NCT01586780|Experimental|Whey + 5 amino acids|
88912738|NCT01586780|Experimental|Whey + 6 amino acids|
88912739|NCT01586780|Experimental|Soy protein drink|
88912740|NCT01586780|Experimental|Soy + 5 amino acids|
89197762|NCT00947206|Active Comparator|Nutrition education + CRC brochure|The comparison group will receive a bilingual CRC brochure as well as a lecture on healthy nutrition for cardiovascular health and a post-intervention LHWO session on CRC screening.
89536279|NCT03195361|Experimental|Single-arm|Subjects suffering from anterior POP-Q grade 2 (point Aa and Ba≥ -1) and above, who are scheduled for POP surgery, will be transplanted with the SRS device
89433098|NCT06280716|Experimental|Lebrikizumab every 8 weeks (Q8W)|"Maintenance Period (Week 16-Week 52):~Treatment from Week 16 to Week 52 is based on re-randomization of responders (from lebrikizumab Q2W arm) in the Induction Period. Participants re-randomized to Lebrikizumab Q8W arm receive one lebrikizumab injection Q8W, with one placebo injection 4 weeks after each lebikizumab injection from Week 16 until Week 48."
89433099|NCT06280716|Experimental|Escape Arm (Lebrikizumab Q2W)|"Maintenance Period (Week 16-Week 50):~Participants who require rescue treatment for atopic dermatitis (AD) during the Induction Period, or are non-responders at Week 16, will be eligible for treatment in an Escape Arm where participants will receive open label lebrikizumab Q2W from Week 16 through Week 50. In addition, participants who do not maintain an acceptable response during the Maintenance Period (have an EASI score <50% of baseline), will be eligible for the Escape Arm."
89433100|NCT06280716|Placebo Comparator|Placebo|"Induction Period (Baseline-Week 16):~Two subcutaneous (SC) injections of Placebo as a loading dose at Baseline and Week 2 followed by a single injection every 2 weeks (Q2W) from Week 4 until Week 14. Induction period includes mono cohort with only Placebo and combo cohort where Placebo is given in combination with topical corticosteroid (TCS) treatment.~Maintenance Period (Week 16-Week 52):~Participants of responders at Week 16 will receive single injection of placebo every 4 weeks (Q4W) from Week 16 until Week 48."
89433101|NCT06280677||GnRH Antagonist & hr-FSH|Patients stimulated with GnRH Antagonist & hr-FSH with GnRH Agonist trigger
89433102|NCT06280677||Progesterone & hr-FSH|Patients stimulated with Progesterone & hr-FSH with GnRH Agonist trigger
89433103|NCT06280638|Experimental|Virtual stenting-guided incremental optimization strategy (VIOS)|"Virtual Stenting analysis is conducted based on pre-PCI CCTA angiograms by Imaging-Heart Team to determine simulated optimal treatment strategy according VIOS protocol. If the patient is assigned to the VIOS, the result of virtual stenting and recommended treatment strategy will be disclosed to the operator. The operator will then follow the recommended strategy to attempt to obtain the target optimal post-PCI FFR result. Blinded FFR must be obtained after PCI."
89433104|NCT06280638|Sham Comparator|Standard angiographic strategy|"Virtual Stenting analysis is conducted based on pre-PCI CCTA angiograms by Imaging-Heart Team to determine simulated optimal treatment strategy according VIOS protocol. If the patient is assigned to the standard angiographic strategy, the result of virtual stenting and recommended treatment strategy will be blinded to the operator. The operator will then perform PCI based on international guidelines, local protocols and practice. Blinded FFR must be obtained after PCI."
89433105|NCT06280625|Experimental|Bread|Bread will be prepared with 100 % of wheat flour and with some replacements by different % of soy flour (at three concentrations)
89433106|NCT06280625|Experimental|Tortilla|Bread will be prepared with 100 % of wheat flour and with some replacements by different % of soy flour (at three concentrations)
89433107|NCT06280625|Experimental|Arepa|Arepa will be prepared with 100 % of wheat flour and with some replacements by different % of soy flour (at three concentrations)
89433108|NCT06280599|Experimental|Transitional care model|In-hospital assessments, video-based stroke education, home visits, and weekly telephone follow-up
89433109|NCT06280599|No Intervention|Post-stroke usual care|Treatment as usual after discharged home
89433110|NCT06280586|No Intervention|Control|Usual clinical practice
89433111|NCT06280586|Experimental|Intervention|"bimonthly personalized follow-up with the appropriate specialists (5 in a year) i~a program of group activities (6 sessions in a year) with a monitor with the aim of reinforcing adherence to the study intervention and adapting it to the circumstances and the physical, personal and social reality around each participant. The sessions will last approximately one hour and will cover:~General dietary and hydration recommendations and dietary recommendations for people at risk of malnutrition~Dietary and physical exercise recommendations in obese elderly~General physical exercise recommendations in the elderly and physical exercise recommendations in the elderly with sarcopenia~Physical exercise recommendations for the elderly at risk of falls.~Medication management and social resources for the elderly in Mataró."
89433112|NCT06280560||Natural Cycle (NC)|No hormonal stimulation
89433113|NCT06280560||Controlled Ovarian Stimulation (COS) + Luteal Phase Support (LPS)|Hormonal fresh transfer protocol
89433114|NCT06280560||HRT programmed artificial cycle|Delayed hormonal transfer protocol
89433115|NCT06280560||Endometrial receptivity reference group|No hormonal stimulation
89433116|NCT06280547||School children aged 6-15 years old|"School children aged (6 to15) years old. Children with or without previous dental experience. Children who agree to participate in the study along with a parent/guardian consent.~Children without any mental or physical disabilities."
89433117|NCT06280534|Experimental|Single dose group|Single doses of 12.5mg (Group 1), 25mg (Group 2), 37.5mg (Group 3), 62.5mg (Group 4, Group A), 125mg (Group 5), 250mg (Group 6), alternative groups (Groups 7-10, 400-800mg).
89433118|NCT06280534|Experimental|Multiple dosing group|Multiple administrations of 125mg, 250mg (groups 11, 12) Select one or both groups.
89433119|NCT06280534|Experimental|Food Impact Group|62.5 mg (i.e., single dose Group 4)
89433120|NCT06280521|Other|Women with autistic spectrum disorder|
89433121|NCT06280521|Other|Men with autistic spectrum disorder|
89433122|NCT06280521|Other|Women without autistic spectrum disorder|
89433123|NCT06280521|Other|Men without autistic spectrum disorder|
89009164|NCT04572334|Other|visual acuity and refractive outcome for Tecnis Eyhance|Evaluation the comparability and reproducibility of different refraction methods in patients implanted with Eyhance lens
89433124|NCT06280508|Experimental|treatment arm|
89433125|NCT06280482|Experimental|Treatment|
89433126|NCT06280469|Experimental|pilot group|endoscope and overtube equipped with a balloon are operated by one endoscopist.
89433127|NCT06280469|Experimental|control group|endoscope is operated by one endoscopist and overtube equipped with a balloon is operated by one assistant
89433128|NCT06280456|Experimental|Tranexamic Acid 4-hour group|10 mL of TXA (100 mg/mL) was injected into the joint at the end of the index operation and the drain was clamped for 4 hours.
89433129|NCT06280456|Experimental|Tranexamic Acid 8-hour group|10 mL of TXA (100 mg/mL) was injected into the joint at the end of the index operation and the drain was clamped for 8 hours.
89197763|NCT00854997||1|AMI with OSA
88912741|NCT01586780|Experimental|Soy + 6 amino acids|
88912742|NCT01586793|Experimental|High Frequency rTMS|10 Hz in 75 trains of 4-seconds duration, with 26-seconds intertrain intervals (3,000 pulses per session) at 120% of the rMT.
88912743|NCT01586793|Experimental|Low Frequency rTMS|1 Hz in 1 train of 20-minute duration (1,200 pulses per session) at 120% of the rMT.
88912744|NCT01586845|Experimental|Voclosporin|Voclosporin
89433130|NCT06280430||Patients with behcet disease|
88912745|NCT01586845|Active Comparator|Tacrolimus|Tacrolimus
88912746|NCT01586884|Experimental|Intervention|"Ten patients undergoing LV lead placement for either initial CRT device implant or revision of an existing system at Lancaster General Hospital who meet the inclusion and exclusion criteria will be screened and approached for enrollment in this safety and feasibility study. Study participants may have ischemic or non-ischemic cardiomyopathy; results for ischemic and non-ischemic patients will be analyzed separately. Any device system from any manufacturer may be used; the choice of device and leads will be at the implanting physician's discretion.~Post implant procedures will be the same as those for any CRT implant. Outpatient follow-up other than the 1-month follow-up will be per the implanting physician's usual practice."
88912747|NCT01586949|Experimental|Treatment|Intervention: Daily Challenge
88912748|NCT01586949|No Intervention|Control|Weekly Well-being, an email-based health information delivery service.
88912749|NCT01586988|Experimental|IMAGE Intervention|mothers are provided the IMAGE Parenting and Self-Care intervention
88912750|NCT01586988|No Intervention|Control|Standard care.
88912751|NCT01587248|Active Comparator|Electrocautery|Raising of the flaps with electrocautery
88912752|NCT01587248|Experimental|Harmonic|Dissection with harmonic scalpel in modified radical mastectomy
88912753|NCT01587339||Drug-resistant (or refractory) partial epilepsy of all types|Drug-resistant (or refractory) partial epilepsy of all types
88912754|NCT01587378|Experimental|metformin|
88912755|NCT01587378|Placebo Comparator|placebo|
88912756|NCT01587417|Experimental|BI 187004 CL|1 single dose per subject as oral solution
88912757|NCT01587417|Placebo Comparator|Placebo to BI 187004 CL|1 single dose per subject as oral solution
88912758|NCT01587482||drug eluting balloon|"In this observationnal study, the intervention of interest is the use of drug eluting balloon in stent restenosis.~Only the treated patients were included in this cohort."
88912759|NCT01587625|Experimental|High dose of oxytocin infusion|Oxytocin: High dose infusion
88912760|NCT01587625|Active Comparator|Low dose of oxytocin infusion|Oxytocin: Low dose infusion
88912761|NCT01587820|Experimental|Intra-arterial cisplatin and radiation|150 mg/m2 cisplatin given intra-arterially combined with sodium thiosulfate infusion given on days 1, 8, 15, for a total of 4 cycles, each cycle totaling 7 days and Radiotherapy: Primary tumor and upper neck will be treated with 2 Gy/fraction, once a day, five days a week to a total dose of 70 Gy/35 fractions/7 weeks
88912762|NCT01587820|Active Comparator|Intravenous cisplatin and radiation|100 mg/m2 cisplatin given intravenously once every 21 days (3 week cycle) for 3 cycles and Radiotherapy: Primary tumor and upper neck will be treated with 2 Gy/fraction, once a day, five days a week to a total dose of 70 Gy/35 fractions/7 weeks
88912763|NCT01587846|Experimental|Probiotic/abdominal pain|Children with functional abdominal pain that will receive probiotic.
88912764|NCT01587846|Experimental|Placebo/abdominal pain|Children with functional abdominal pain that will receive placebo.
88912765|NCT01587846|Experimental|Probiotic/constipation|Children with chronic constipation tha will receive probiotic plus lactulose
88912766|NCT01587846|Experimental|Placebo/chronic constipation|Children with chronic constipation that will receive placebo plus lactulose
88912767|NCT01587937|Experimental|Antibiotic stewardship intervention|Audit-and-feedback intervention to prescribers of patients receiving 3rd or 10th day of targeted broadspectrum antimicrobial
88912768|NCT01587937|No Intervention|Control|The pre-intervention period will serve as the control period on each medical and surgical service. The cross-over is uni-directional from control to intervention; all services receive the intervention by the end of the study. This is a stepped wedge design. The order of roll-out is randomized.
88912769|NCT01588132|Experimental|Single dose gourp 1|Anfibatide injection at the concentration of 0.33μg/60kg in healthy volunteers
88912770|NCT01588132|Experimental|Single dose group 2|Anfibatide injection at the concentration of 0.66μg/60kg in healthy volunteers
88912771|NCT01588132|Experimental|Single dose groups 3|Anfibatide injection at the concentration of1.0μg/60kg in healthy volunteers
88912772|NCT01588132|Experimental|Single dose group 4|Anfibatide injection at the concentration of 1.5μg/60kg in healthy volunteers
89433131|NCT06280430||Healthy control group|
89433132|NCT06280378|Experimental|KL003 Cell Injection Drug Product|Transplant of auto-HSC transduced with lentiviral vector encoding βA-T87Q-globin gene
89433133|NCT06280365|Experimental|MWM group|Participants in group 2 will receive MWM technique treatment 3 times a week for 4 weeks. The patient should lie face down with a pillow over the knee and the physiotherapist should stand on the contralateral side for the application. The physiotherapist passes the belt around the waist to the patient's tibia edge. The knee is stabilized with one hand while the leg is supported with the other hand. The knee is moved medially without applying too much force through the belt and the patient is asked to stretch. If there is no pain, the movement is indicated. If pain occurs during the movement, the same procedure is performed for the lateral side by changing the position. It is important that the arch remains horizontal and does not cause rotation of the hip. The movement will be repeated 3 times at the point where there is no pain.
89433134|NCT06280365|No Intervention|Control Group|"Participants in group 1 will receive conservative treatment 3 times a week for 4 weeks. Conservative treatment includes hot packs and traditional transcutaneous electrical nerve stimulation (TENS), an electrotherapy.~All participants in the study will receive 20 minutes of hot pack application to the knee area each session by a physiotherapist. All participants in the study will receive TENS for 20 minutes each session from the physiotherapist, who will place personalized electrodes around the knee joint and adjust the current to the level the person can tolerate."
89433135|NCT06280339|Experimental|Avoidance group|Avoidance Strategy: This strategy focuses on teaching individuals how to modify their immediate environments to make it easier to control food cravings. Examples include redesigning your home to remove tempting foods or limiting access to craved foods. It also covers tips on making grocery lists and communicating health goals within your social circle. Additionally, it includes a toolkit for situations where controlling the immediate environment may be challenging, such as at parties or social gatherings Both strategies include educational materials explaining the definition of food cravings, factors that contribute to food cravings, and the distinction between hunger and cravings.
89433136|NCT06280339|Experimental|Inclusion group|"Inclusion Strategy: This strategy teaches individuals how to modify their eating habits by paying attention to the portion size of craved foods and incorporating them into well-balanced meals, avoiding eating between meals. It also includes a toolkit for situations where individuals may struggle to include craved foods in their balanced meals.~Both strategies include educational materials explaining the definition of food cravings, factors that contribute to food cravings, and the distinction between hunger and cravings."
89433137|NCT06280326|Experimental|Sunflower Oil Group|In the experimental group, patch removal will be performed using sunflower oil instead of silicone-based spray remover, which is the routine of the clinic. In children in the experimental group, the patch that has stuck to the baby's skin and needs to be changed is planned to be removed by applying sunflower oil on the patch.
88912773|NCT01588132|Experimental|Single dose group 5|Anfibatide injection at the concentration of 2.0μg/60kg in healthy volunteers
88912774|NCT01588132|Experimental|Single dose group 6|Anfibatide injection at the concentration of 3.0μg/60kg in healthy volunteers
88912775|NCT01588132|Experimental|Single dose group 7|Anfibatide injection at the concentration of 4.0μg/60kg in healthy volunteers
88912776|NCT01588132|Experimental|Single dose group 8|Anfibatide injection at the concentration of 5.0μg/60kg in healthy volunteers
88912777|NCT01588132|Experimental|Multiple dose group 9|Give intravenous injection of 3μg as the first dose and after 1.5 hours, infusion of the study product 0.12μg/h for 24 hours
88912778|NCT01588132|Experimental|Multiple dose group 10|Give intravenous injection of 3μg as the first dose and immediately infusion of the study product 0.12μg/h for 24 hours.
89009165|NCT04572334|Other|visual acuity and refractive outcome for Tecnis ZCB00|Evaluation the comparability and reproducibility of different refraction methods in patients implanted with ZCB00 lens
89197764|NCT00854997||2|AMI without OSA
89433138|NCT06280326|Active Comparator|Control group|"In the clinic, the orogastric catheter is fixed above the lip (mustache area) with a hypoallergenic patch. In cases where the oral gastric catheter needs to be replaced or the adhesive patch needs to be renewed, hypoallergenic patches attached to the skin may cause tape abrasions and scratches on the newborn's skin when removed.Silicone-based spray removers are used to avoid causing injuries.~In the control group in the study, a silicone-based spray remover was used, which is the routine of the clinic, during the removal of hypoallergenic patches attached to the lip (moustache area) to fix the oragastric catheter."
89433139|NCT06280300|Active Comparator|Standard of Care|
89433140|NCT06280300|Experimental|Multidisciplinary Care|
89433141|NCT06280287||Carotid stenosis|Patients with carotid stenosis and suitable for carotid endarterectomy
89433142|NCT06280287||Coronary artery disease|Patients with stable ischemic heart disease or acute coronary syndrome
89433143|NCT06280248|Other|Endoscopic ultrasound guided cystogastrostomy of symptomatic pancreatic pseudocyst|
89433144|NCT06280235|Experimental|BI 1569912 low dose group|
89433145|NCT06280235|Experimental|BI 1569912 medium dose group|
89433146|NCT06280235|Experimental|BI 1569912 high dose group|
89433147|NCT06280235|Placebo Comparator|Placebo group|
88912779|NCT01588132|Experimental|Multiple dose group 11|Give intravenous injection of 5μg as the first dose and immediately infusion of the study product 0.12μg/h for 24 hours
88912780|NCT01588171|Active Comparator|Bemiparin|A new second generation Low Molecular Weight Heparin
88912781|NCT01588171|Active Comparator|Enoxaparin|A well known Low Molecular Weight Heparin
88912782|NCT01588171|No Intervention|control group|Risky group patients for VTE, but they will not receive any thromboprophylactic drug.
88912783|NCT01588210|Experimental|Glass Ionomer Cement group|a high-viscosity glass-ionomer cement (KETAC™ MOLAR APLICAP 3M Espe, Germany)
88912784|NCT01588210|Experimental|Resin Based Fluoride Group|white photopolymerizable Resin-Based sealant containing fluoride (Helioseal F®, Ivoclar Vivadent AG, Fürstentum Liechtenstein)
88912785|NCT01588210|Placebo Comparator|Resin Based sealant|white photopolymerizable Resin-Based sealant (Concise 1930TM 3M Espe, Germany)
88912786|NCT01588730|Experimental|Dynasplint|Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. This unit is worn at night while sleeping (6-8 hours).
89433148|NCT06280222|No Intervention|Routine management|Usual care of patients prior to a surgical procedure : oocyte retrieval
89433149|NCT06280222|Experimental|Virtual reality management|20 minutes of scenery VR movies prior to the surgical procedure (oocyte retrieval)
89433150|NCT06280209|Experimental|Cohort 1A|Cohort 1A will consist of both a single ascending dose (SAD) part and a multiple ascending dose (MAD). BMN 351 will be administered once every 2 weeks during the SAD portion of the study for up to 8 weeks and once weekly during the MAD portion for up to 56 weeks.
89433151|NCT06280209|Experimental|Cohort 1B|BMN 351 low dose will be administered once weekly for up to 48 weeks
89433152|NCT06280209|Experimental|Cohort 2|BMN 351 medium dose will be administered once weekly for up to 48 weeks
89433153|NCT06280209|Experimental|Cohort 3|BMN 351 high dose will be administered once weekly for up to 48 weeks
89197765|NCT00857805|Active Comparator|Transarterial Chemoembolization|Transarterial Chemoembolization
89433154|NCT06280183|Active Comparator|Aerobic and Resistive Exercise Training|"The exercise program will start with a 5-10 minute warm-up and end with a 5-10 minute cool down. Aerobic exercise is planned at 60-85% of Maximum Heart Rate on the bike for 30-40 minutes.~Resistive exercise program, covering all major major muscle groups; The upper body (pectoralis, latissimus dorsi, rotator cuff muscles, deltoid, biceps, triceps), abdominal muscles and lower extremities (quadriceps, hamstring, gastrosoleus) will be exercised to strengthen. For upper body muscles, abdominal muscles and lower extremity muscles, 1-3 sets of 10-15 repetitions will be planned as 40-70% of 1 maximum repetition (1RM)."
89433155|NCT06280183|Experimental|Functional Inspiratory Muscle Training Group in obese individuals:|Inspiratory muscle training will be applied simultaneously with aerobic exercise. This program will create the functional IMT. The exercise program will start with a 5-10 minute warm-up and cool down. Aerobic exercise is planned at 60-85% of MHR on the bike for 30-40 minutes, progress will be achieved. Participants will first work with bicycle ergometry and then continue with IMT in the same session for the first three weeks. The intensity of IMT exercise will be set at 40-60% of MIP. After 10 consecutive breathing cycles, participants will be asked to perform 3-4 breath checks. Resistive exercise program, covering all major muscle groups; The upper body (pectoralis, latissimus dorsi, rotator cuff muscles, deltoid, biceps, triceps), abdominal muscles and lower extremities (quadriceps, hamstring, gastrosoleus) will be exercised to strengthen. For upper body muscles, abdominal muscles and lower extremity muscles, 1-3 sets of 10-15 repetitions will be planned as 40-70% of 1RM.
89433156|NCT06280183|No Intervention|Control Group:|Patient education will be given and no intervention will be made.
89197766|NCT00857805|Active Comparator|Proton Beam Radiotherapy|Proton Beam Radiotherapy
89197767|NCT00947362|Experimental|ETC + DAC N-055|
89197768|NCT00947362|Active Comparator|ETC + physiological saline|
89197769|NCT00861861|Active Comparator|1|pitavastatin group
89197770|NCT00861861|Active Comparator|2|atorvastatin group
89197771|NCT01529866|Experimental|New abutment connection implant|Implant with new abutment connection
89197772|NCT01529866|Active Comparator|Nanotite Certain Tapered implant|Nanotite Certain Tapered (standard abutment connection) implant
89433157|NCT06280170|No Intervention|Services-as-usual (SAU)|During the services-as-usual (SAU) phase of this study, providers will deliver the routine case management services offered by Centerstone and report these services in the usual way they do.
89433158|NCT06280170|Experimental|Artificial Intelligence (AI)|Once randomized to start using the AI-based platform for documenting their services, providers will have access to the Eleos Health platform, a secure and HIPAA-compliant tool specifically designed for documenting behavioral health encounters. This AI-powered platform enables providers to complete progress notes more quickly. Providers will complete the progress notes on their phones, and these notes will be integrated into the client's electronic health records.
89433159|NCT06280157||One dose of GBS-NN/NN2|Participants who participated in study MVX003 and had received one dose of GBS-NN/NN2 prior to this study.
89433160|NCT06280157||Two doses of GBS-NN/NN2|Participants who participated in study MVX002 and had received two doses of GBS-NN/NN2 prior to this study.
89433161|NCT06280157||Three doses of GBS-NN/NN2|Participants who participated in study MVX002 and MVX003 and had received three doses of GBS-NN/NN2 prior to this study.
89433162|NCT06280144|Experimental|Experimental group|Influenza Vaccine, Live, Nasal, Freeze-dried
89433163|NCT06280144|Placebo Comparator|Placebo group|Sterile water for inhalation
89433164|NCT06280118|No Intervention|Pre-test (Control group)|
89433165|NCT06280118|No Intervention|Post test (Control group)|
89433166|NCT06280118|No Intervention|Pre test (experimental group)|
89009166|NCT00255606|Experimental|Arm I|Patients receive docetaxel IV over 1 hour on days 1 and 15 and oral prednisone once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89433167|NCT06280118|Experimental|Post test (experimental group)|
89433168|NCT06280105|Experimental|cadonilimab+regorafenib|
89433169|NCT06280092|Experimental|AMSCs|A single dose of 5x10^6 AMSCs will be resuspended in 1ml of LRS and infused via intraparenchymal at the time of DBS surgery
89433170|NCT06280053|Experimental|HealiAid group|The patients' wound conditions were divided into three types: venous ulcers, bedsores and burn wounds.
89433171|NCT06280027||group1|patients (laypeople) of the university clinic. The inclusion criteria were age ≥18 and ≤70 years.
89433172|NCT06280027||group2|restorative dentists and prosthodontists with similar levels of clinical experience (at least 3 years of academic training). The inclusion criteria were age ≥18 and ≤70 years.
89009167|NCT00255606|Experimental|Arm II|Patients receive docetaxel IV over 1 hour on day 1 and prednisone once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89009168|NCT03450577||PCI of bifurcation lesions|Patients who have undergone bifurcation coronary artery stenting.
89009169|NCT03450499|Experimental|analgesic effects of ketamine|the experimental group will receive ketamine intravenously at 0.25 mg per kg before skin incision.
89433173|NCT06280014|Experimental|Mefenamic acid was used to see post operative effects after extraction of 3rd molar in study group|In this study of 30 patients, 22 females and 8 males, 60 fully impacted lower wisdom teeth were extracted bilaterally and in the same position. One of the bilaretal teeth of the patients was randomly selected and mefenamic acid was used as a drug to see post operative effects after extraction of impacted 3rd molars in the study group.
89433174|NCT06280014|Placebo Comparator|Dexketoprofen was used to see post operative effects after extraction of 3rd molar in control group|Bilateral impacted wisdom teeth of the patients were randomly selected. After the tooth in the experimental group was extracted, the other impacted wisdom tooth was selected as the control group and dexketoprofen was used as a drug to see post operative effects.
89433175|NCT06279962|Experimental|Experimental: V1: Woman with Major Depressive Disorder|Depicting a young woman with symptomatic major depressive disorder
89009170|NCT03450499|Placebo Comparator|placebo|they will receive same volume of 0.9% normal saline as calculated for experimental group before skin incision.
89009171|NCT03450460|Experimental|1/week peer support|These individuals with acquired brain injury will receive the Ontario Brain Injury Association Peer Support program once per week.
89009172|NCT03450460|No Intervention|wait list control group|These individuals with acquired brain injury will receive the Ontario Brain Injury Association Peer Support once the trial period is complete.
89009173|NCT03450421|Experimental|Actamax™Adhesion Barrier|Following Myomectomy, subjects randomized to the Actamax™Adhesion Barrier Arm will have up to 30mL of product applied to all sites of surgery (area of treatment/trauma).
89009174|NCT03450421|No Intervention|Surgical Control|Myomectomy will be performed with no adhesion barrier application.
89009175|NCT00235404|Experimental|Intermediate community hospital|
89009176|NCT00235404|Active Comparator|Usual care|
89433176|NCT06279962|Experimental|Experimental: V2: Man with Major Depressive Disorder|Depicting a young man with symptomatic major depressive disorder
89433177|NCT06279962|Experimental|Experimental: V3: Man with Generalized Anxiety Disorder|Depicting a young man with symptomatic generalized anxiety disorder
89433178|NCT06279962|Experimental|Experimental: V4: Woman with Generalized Anxiety Disorder|Depicting a young woman with symptomatic generalized anxiety disorder
89009177|NCT01580839|Experimental|intravenous tissue plasminogen activator|
89009178|NCT01580839|Placebo Comparator|Placebo|
89433179|NCT06279962|Experimental|Experimental: V5: Woman with Schizophrenia|Depicting a young woman with symptomatic schizophrenia
89433180|NCT06279962|Experimental|Experimental: V6: Man with Schizophrenia|Depicting a young man with symptomatic schizophrenia
89433181|NCT06279962|Experimental|Experimental: V7: Woman with Alcohol Use Disorder|Depicting a young woman with symptomatic alcohol use disorder
89433182|NCT06279962|Experimental|Experimental: V8: Man with Alcohol Use Disorder|Depicting a young man with symptomatic alcohol use disorder
89433183|NCT06279949|No Intervention|No provider training or clinic protocols|This clinic will not receive training on state-specific laws regulating minors' access to confidential HIV testing or implementation of new protocols to support confidential care provision.
89009179|NCT03450382|Experimental|Hans Kai Participant|Participants receiving Hans Kai intervention
89009180|NCT03450382|No Intervention|Control|Participants not enrolled in Hans Kai
89009181|NCT03450265|Experimental|Hemopatch|Patients undergo elective pulmonary resection. Following resection, primary stapling and suturing will be done and air leakage will be assessed. If a specific grade-level of air leakage is present, patients will be randomized and either Hemopatch or TachoSil applied.
89009182|NCT03450265|Active Comparator|TachoSil|Patients undergo elective pulmonary resection. Following resection, primary stapling and suturing will be done and air leakage will be assessed. If a specific grade-level of air leakage is present, patients will be randomized and either Hemopatch or TachoSil applied.
89009183|NCT03450226|Experimental|treatment|patients will receive a stellate ganglion block with 10 ml of 0.25 % bupivacaine
89009184|NCT03450226|No Intervention|control|patients will be controlled
89009185|NCT04572373||SMOFlipid group|"TPN and SMOFlipid support were indicated for patients who received NPO for more than 3 days, such as those with repeated laparotomy, staged biliary reconstruction, massive nasogastric (NG) drainage (>500 mL/day), ileus, diarrhoea, poor digestion (NG extraction >50 mL/time), and chylous ascites.~Furthermore, SMOFlipid was discontinued when the platelet count decreased to 40,000/μL or less. In all cases, heparinisation was prescribed to maintain the aPTT level between 1.5 and 2 times the normal controlled level at least for 10-14 days, with daily blood examination conducted. Oral administration of dipyridamole (75 mg, QID) for 3 months was indicated for stimulation of antiplatelet activity when the platelet count increased to 40,000/μL or more."
89009186|NCT04572373||non SMOFlipid group|On the basis of our experience in patient management at this institute, we allocated patients with a pretransplant platelet count less than 40,000/μL and those with a count more than 40,000/μL to the non-SMOFlipid group and the SMOFlipid group , respectively. Patients with well-tolerated oral intake and those in whom the TPN supplement was discontinued within 10 days were excluded from this study.
89009187|NCT03450148|Experimental|Pavlok wristband with electric stimulus|Participants in intervention group will wear wristband and will get a slight electric stimulus when they press the device
89009188|NCT03450148|Placebo Comparator|Pavlok wristband without electric stimulus|Participants in control group will wear wristband and will not get a slight electric stimulus when they press the device
89009189|NCT03450109|Experimental|LY01005|One LY01005 3.6 mg gluteal IM injection.
89009190|NCT03450109|Active Comparator|Zoladex|One Zoladex 3.6 mg subcutaneous injection into the anterior abdominal wall
89009191|NCT03450031|Experimental|NAC (no drug/no device) and NFP|NAC with mixed grass pollen will be conducted. Nasal mucosal inflammatory mediators will be collected via nasal filter paper (NFP)
89433184|NCT06279949|Active Comparator|Clinic protocols|This clinic will receive training on navigating new protocols to support confidential care provision.
89433185|NCT06279949|Active Comparator|Provider training|This clinic will receive training on state-specific laws regulating minors' access to confidential HIV testing.
89433186|NCT06279949|Active Comparator|Provider training and clinic protocols|This clinic will receive training on state-specific laws regulating minors' access to confidential HIV testing and navigating new protocols to support confidential care provision.
88912787|NCT01588730|Active Comparator|Static Splint|The control group will be treated with a static splint for a minimum of 6 4 hours each night while sleeping with the end goal of 6-8 hours.
88912788|NCT01588873|Active Comparator|Oral contraceptive pill|
88912789|NCT01588873|Active Comparator|Contraceptive ring|
88912790|NCT01588886||with PPI|CKD with PPI use, follow up at least 5 years began PPI use
88912791|NCT01588886||with or without Pneumonia outcome|Patients were eligible for inclusion if they received any PPIs treatment between January 1, 1998 and December 31, 2002 and had been diagnosed with pneumonia between January 1, 1998 and December 31, 2008 in an inpatient setting.
88912792|NCT01589367|Experimental|Arm1_ Metformin|Letrozole with concurrent metformin
88912793|NCT01589367|Placebo Comparator|Arm 2_ Letrole alone|Letrozole with placebo
88912794|NCT01589432|Experimental|ABT-639|
88912795|NCT01589432|Placebo Comparator|Placebo|
88912796|NCT01589432|Active Comparator|Lidocaine|
88912797|NCT01589458|Placebo Comparator|Non-fluoride toothpaste|
88912798|NCT01589458|Experimental|NaF/SiO2 toothpaste|
88912799|NCT01589458|Experimental|MFP/CaCO3 toothpaste|
88912800|NCT01589614|Experimental|PH-797804 6 mg|Subjects will receive a single 6 mg dose in the fed state
88912801|NCT01589614|Experimental|PH-797804 6 mg + erythromycin 800 mg|Subjects will receive multiple 800 mg doses of erythromycin and a single 6 mg dose of PH-797804 in the fed state
88912802|NCT01589718|Experimental|0.3mg Pegaptanib Sodium, Macugen|will receive Macugen intravitreal injection prior to surgery
88912803|NCT01589718|Sham Comparator|Sham injection|will receive a sham injection
88912804|NCT01589757|Placebo Comparator|Standard Care|Standard care dietary advice to emphasize high fiber foods with a moderate to high GI
88912805|NCT01589757|Experimental|Low GI Diet|Low GI dietary advice in addition to standard care
88912806|NCT01589796|Active Comparator|classic TAP|classic US-guided TAP block in a space between iliac crest and the costal margin in the region of the anterior axillary line
88912807|NCT01589796|Active Comparator|Medial TAP|US-guided TAP block in a space between iliac crest and the costal margin within 1 inch lateral to transversus abdominis muscle origination
88912808|NCT01589861|Experimental|BKM120+Lapatinib|"BKM120 40, 60 or 80 mg/day per os for 28 days cycle~+ Lapatinib 750, 1000 or 1250 mg/day per os for 28 days cycle"
88912809|NCT01589913|Experimental|Treatment as usual plus remote care|"The same treatment as described under treatment as usual plus participation in the intervention ICD-Forum."
88912810|NCT01589913|No Intervention|Treatment as usual|Standard information provided by hospitals on ICD-technology as well as consequences of ICD-implantation plus medical aftercare including cardiology appointments at 1, 3, and 6 months, and one year after ICD-implantation.
88912811|NCT01589965|Experimental|Treatment group: T5|Small Lottery reward
88912812|NCT01589965|No Intervention|Control group|
88912813|NCT01589965|Experimental|Treatment group T1|High Lottery reward
88912814|NCT01589991|Placebo Comparator|Non-fluoride toothpaste|
88912815|NCT01589991|Experimental|Toothpaste 550 µg F/g (NaF/SiO2)|
88912816|NCT01589991|Experimental|Toothpaste 1100 µg F/g (NaF/SiO2)|
88912817|NCT01589991|Experimental|Toothpaste 1450 µg F/g (MFP/CaCO3)|
88912818|NCT01590030|Experimental|Laparoscopic mesial incision|
89433187|NCT06279936||Long Covid patients|Long Covid patients with (neuro)psychological complaints
89433188|NCT06279936||Covid controls (Ca)|COVID-19 survivors without persistent complaints
89433189|NCT06279936||Non-Covid controls (Cb)|healthy uninfected controls
88912819|NCT01590030|Active Comparator|Laparoscopic antimesial incision|
88912820|NCT01590043||Control|Healthy 3-18 years old participants
88912821|NCT01590043||Inflammatory bowel disease|3-18 years old patients identified with inflammatory bowel disease
88912822|NCT01590043||Abdominal pain|3-18 years old patients suffering from abdominal pain not related to Inflammatory bowel disease
88912823|NCT01590056||PD patients|PD patients that are treated or are candidates for treatment with STN DBS
88912824|NCT01590108|Experimental|Apelin|Subject will perform cardiopulmonary exercise testing and receive (Pyr1)apelin-13 intravenously.
88912825|NCT01590108|Placebo Comparator|Control|Subject will take cardiopulmonary exercise testing with receive placebo
88912826|NCT01590121||Pateints with hereditary haemorrhagic telangiectasia|
88912827|NCT01590134|No Intervention|Control|"Following randomisation,to no active intervention, blood and urine samples will be collected at 6 stated intervals over a 48 hour period~Total number of participants in arm = 6"
88912828|NCT01590134|Active Comparator|Iron control|"Following randomisation, on each of two consecutive mornings, the participant will receive a single dose of ferrous sulphate 200mg. Blood and urine samples will be collected pre first dose, and at 5 further stated intervals over a 48 hour period.~Total number of participants in arm = 6"
88912829|NCT01590134|Experimental|Dietary supplement|"Following randomisation, on each of two consecutive mornings, the participant will receive the experimental dietary iron supplement. Blood and urine samples will be collected pre first dose, and at 5 further stated intervals over a 48 hour period.~Toal participants in arm = 6"
88912830|NCT01590147|Experimental|Arm 1 (YST)|Patients participate in three 15-minute YST sessions, comprising awareness meditation practice, movement practice, and breathing practice and relaxation. Patients also receive a CD recording of a 15-minute YST session and are instructed to practice the YST at home 4 times weekly.
88912831|NCT01590147|Active Comparator|Arm 2 (CE)|Patients participate in three 15-minute CE sessions, comprising empathic attention with an interventionist who allows patients to direct the flow of conversation and provides supportive comments according to standardized procedures. Patients also receive CDs with recorded information related to coping with colorectal cancer similar in length to the suggested practice time in Arm I.
88912832|NCT01590160|Experimental|Cisplatin/Pemetrexed|Cisplatin 75mg/m2, Day 1 every 21 days Pemetrexed 500mg/m2, Day 1 every 21 days
89433190|NCT06279923|Experimental|Administration of CD19-BAFF Targeted CAR T-cells|Dose escalation follows the standard 3+3 dose escalation design. A total of 3 dose levels are set for subjects.
89433191|NCT06279910||Patients treated with calcifediol|Patients admitted to the GAI Hospital Complex of Albacete, due to COVID-19 (respiratory infection confirmed by radiographic pattern of viral pneumonia and positive PCR/antigen for SARS-CoV-2) treated with calcifediol
89433192|NCT06279910||Patients not treated with calcifediol|Patients admitted to the GAI Hospital Complex of Albacete, due to COVID-19 (respiratory infection confirmed by radiographic pattern of viral pneumonia and positive PCR/antigen for SARS-CoV-2) not treated with calcifediol
89433193|NCT06279897|Experimental|Skin Temperature Control During Simulated Blood Loss After Exercise Cold Stress|After exercise in the cold and participants skin will remain cold (~82°F), be returned to normal (~90°F), be slightly warmed (~93°F) or heated (~95°F) sixty seconds after the onset of LBNP.
89433194|NCT06279871|Experimental|Group 1a (ARCT-2303/Influenza vaccine)|Participants will receive one 0.5-mL IM (intramuscular) dose of ARCT-2303 and one 0.5-mL IM dose of influenza vaccine on Day 1 followed by a 0.5-mL IM dose of placebo on Day 29.
89433195|NCT06279871|Experimental|Group 2a (ARCT-2303)|Participants will receive one 0.5-mL IM dose of ARCT-2303 and one 0.5-mL IM dose of placebo on Day 1 followed by a 0.5-mL IM dose of influenza vaccine on Day 29.
89433196|NCT06279871|Active Comparator|Group 3a (Influenza vaccine)|Participants will receive one 0.5-mL IM dose of influenza vaccine and one 0.5-mL IM dose of placebo on Day 1 followed by a 0.5-mL IM dose of ARCT-2303 on Day 29.
89433197|NCT06279871|Experimental|Group 1b (ARCT-2303/ Influenza vaccine)|Participants will receive one 0.5-mL IM dose of ARCT-2303 and one 0.5-mL IM dose of influenza vaccine on Day 1 followed by a 0.5-mL IM dose of placebo on Day 29.
89433198|NCT06279871|Experimental|Group 2b (ARCT-2303)|Participants will receive one 0.5-mL IM dose of ARCT-2303 and one 0.5-mL IM dose of placebo on Day 1 followed by a 0.5-mL IM dose of influenza vaccine on Day 29.
89433199|NCT06279871|Active Comparator|Group 3b (Influenza vaccine)|Participants will receive one 0.5-mL IM dose of influenza vaccine and one 0.5-mL IM dose of placebo on Day 1 followed by a 0.5-mL IM dose of ARCT-2303 on Day 29.
89536280|NCT02726399|Experimental|Ramucirumab With Trastuzumab and Capecitabine/Cisplatin|This will be a single arm study of ramucirumab 8mg/kg administered intravenously on days 1 and 8 + trastuzumab (8 mg/kg loading dose; 6 mg/kg maintenance) administered intravenously every 21 days. On subsequent cycles for all patients capecitabine 850mg/m2 will be added, taken orally twice a day for fourteen days (days 1 through 14) followed by a 7 day rest period, in addition to cisplatin 80mg/m2 administered as an IV infusion every 21 days. Each cycle consists of 21 days.
88912833|NCT01590160|Experimental|Carboplatin/Pemetrexed|Carboplatin AUC5, Day 1 every 21 days Pemetrexed 500mg/m2, Day 1 every 21 days
88912834|NCT01590173|Experimental|Prednisolone and Heparin during COH for IVF|
88912835|NCT01590173|Active Comparator|COH for IVF|
88912836|NCT01590199|Experimental|RAD001 + SOM230|
88912837|NCT01590225|Experimental|Part A: boceprevir + peginterferon alpha-2b + ribavirin|
88912838|NCT01590225|Experimental|Part B: boceprevir + peginterferon alpha-2b + ribavirin|
88912839|NCT01590251|Experimental|Yoga|Gentle yoga for chronic pain and opioid dependence
88912840|NCT01590251|Active Comparator|Educational Counseling|Educational counseling is a didactic, lecture-discussion format to supplement the information and advice provided in opioid agonist maintenance treatment.
88912841|NCT01590290|Active Comparator|pay for performance|
88912842|NCT01590290|No Intervention|no pay for performance|
88912843|NCT01590303|Experimental|Vitamin C|Intravenous Vitamin C will be administered (1 gram) every 8 hours for 28 days or discharge from intensive care unit
88912844|NCT01590303|Placebo Comparator|placebo|placebo vehicle administered in same fashion as active treatment
88912845|NCT01590316|Experimental|Cerebral NIRS oximetry + treatment guideline based on reading|
88912846|NCT01590316|No Intervention|Blinded cerebral NIRS oximetry|
88912847|NCT01590329|Experimental|Micrografting|
88912848|NCT01590342|Active Comparator|Diclofenac|
88912849|NCT01590342|Placebo Comparator|Placebo|
88912850|NCT01590368|Other|Marketed electrode|The currently marketed electrodes using the current CE marked adhesive
88912851|NCT01590368|Active Comparator|Modified hydrogel|"Electrodes with the new modified adhesive - the test electrodes"
88912852|NCT01590381||personnel in medical training - COURSE 1|
88912853|NCT01590381||personnel in medical training - COURSE 2|
88912854|NCT01590381||personnel in medical training - COURSE 3|
88912855|NCT01590381||personnel in medical training - COURSE 4|
88912856|NCT01590381||personnel in medical training - COURSE 5|
88912857|NCT01590381||personnel in medical training - COURSE 6|
88912858|NCT01590381||personnel in medical training - COURSE 7|
88912859|NCT01590381||personnel in medical training - COURSE 8|
88912860|NCT01590381||personnel in medical training - COURSE 9|
88912861|NCT01590381||personnel in medical training - COURSE 10|
88912862|NCT01590407|Experimental|ALS-002200|
88912863|NCT01590407|Placebo Comparator|Placebo|
88912864|NCT01590420|Experimental|CPAP treatment|1000 patients with 3-years CPAP treatment after a PSG titration
89433200|NCT06279858|Experimental|Probiotics|Each participant receives probiotic for 3 months (12 weeks). Participants act as their own controls by measuring the microbiome and other parameters before and after taking the probiotics. This was chosen because individual's microbiome is highly personalized. The unique composition of an individual's microbiome can have implications for the effectiveness of probiotics. All participants will receive probiotic mixture which contains: (i) Lactobacillus casei BL 2401 (40%), (ii) Lactobacillus salivarius BL 2201 (40%) (iii) Bifidobacterium breve BL 3406 (20%). Total amount is 5 x109 CFU in one HPMC capsule, at the end of the shelf life. These strains are registered and preserved in the French National Collection of Cultures of Microorganisms (CNCM, Collection Nationale de Cultures de Microorganismes). They are on EFSA's QPS (Qualified and Presumption of Safety) list and are considered safe for use in food and dietary products
89197773|NCT00857883|Placebo Comparator|Part A|Part A: This part of the study will start with a very low dose of study drug, which will then be gradually increased in subsequent doses. This is known as dose-rising and is the way to assess safety and tolerability (i.e. possible presence of any side effects that make taking the drug unpleasant) of increasing doses of the study drug. Effects will be compared to those seen when a placebo is taken. Up to 4 groups of 6-9 healthy male or female volunteers will be enrolled.
88912865|NCT01590446|Placebo Comparator|Placebo|
88912866|NCT01590446|Active Comparator|BMN 111|
89433201|NCT06279832|Experimental|Transcriptomic analyses|
89433202|NCT06279819|Experimental|intervention group|The intervention group will receive the gut microbiota-targeted dietary intervention thrice weekly for 3 months, accompanied by bi-weekly health education videos for the same duration. The intervention will span three months, followed by a three-month follow-up period.
89433203|NCT06279819|No Intervention|control group|The control group will continue routine follow-up and health education practices.
89433204|NCT06279806|Experimental|İntervention Group|Mobile health application use
89433205|NCT06279806|Experimental|Control Group|Information of the breast cancer survivor period booklet
89433206|NCT06279793|Experimental|Omegaven|Omegaven infusion will be given at 0.20 grams/kg IBW/day plus standard of care.
89433207|NCT06279793|Placebo Comparator|Control|Intravenous 0.9% Sodium Chloride in dose 0.20 grams/kg IBW/day plus standard of care.
88912867|NCT01590472||Mesothelioma|Individuals who have been diagnosed with mesothelioma
88912868|NCT01590485|Placebo Comparator|Starch capsule|starch with dose of 100 mg in each capsule every 6 hours up to 48 hours (400 mg/day)
88912869|NCT01590485|Active Comparator|Saffron capsule|saffron with dose of 100 mg in each capsule every 6 hours up to 48 hours (400 mg/day)
88912870|NCT01590498||Salvage radiotherapy|local radiation to the prostate and metastasis following biochemical or clinical recurrence
88912871|NCT01590498||observation|did not receive salvage following biochemical or clinical recurrence
88912872|NCT01590511||The study population|Patients in the emergency room or intensive care in acute circulatory failure without ventilatory support.
88912873|NCT01590524|Experimental|CAM group|Subjects receiving the interventions and standard psychological care
89433208|NCT06279780|Experimental|Very low-calorie diet Intervention|
89433209|NCT06279767|Experimental|Treatment with a combination of 6-mercaptopurine and temozolomide|
88912874|NCT01590524|No Intervention|No-CAM group|Parents receiving only standard psychological care
88912875|NCT01590537||Group 1|
88912876|NCT01590537||Group 2|
88912877|NCT01590576||lower urinary tract symptoms and pelvic organ prolapse|
89197774|NCT00857883|Active Comparator|Part B|Part B: A dose selected from Part A that was well tolerated will be used to check if there is a difference in the pharmacokinetics (blood levels) of the study drug when taken without food in liquid form, or as a capsule, or as a capsule together with a high fat meal to assess the effect of food. One group of 12 healthy male or female volunteers will be enrolled.
89197775|NCT00857883|Placebo Comparator|Part C|Part C: A well tolerated dose selected from Parts A & B will be used to test whether the drug has an effect on individual preferences for sugary and high fat food, when compared to placebo. Up to 32 healthy overweight male volunteers will be enrolled.
89433210|NCT06279754|Experimental|recombinant human endostatin Group|Recombinant human endostatin and enrolizumab injection combined with Synchronal Radiochemotherapy
89536281|NCT03198091|Experimental|Dun Ye Guan Xin Ning mono-therapy|
88912878|NCT01590589||REGISTRY participants|"Individuals~with manifest HD~unaffected but known to carry the HD mutation~unaffected but at risk of carrying the HD mutation~from HD families known not to carry the HD mutation~from outside HD families acting as control research participants (e.g., spouses)"
88912879|NCT01590602||JHD cases|All ages included, but must have an HD age of onset 25 or below
88912880|NCT01590615||Participants with chronic HBV infection|Participants with decompensated liver disease due to chronic HBV infection, who are receiving or anticipated to receive anti-HBV nucleoside/nucleotide therapy, will be included in the study.
88912881|NCT01590641|Experimental|0.3mg GS-9620|
88912882|NCT01590641|Experimental|1mg GS-9620|
88912883|NCT01590641|Experimental|2mg GS-9620|
88912884|NCT01590641|Experimental|4mg GS-9620|
88912885|NCT01590641|Experimental|0.3mg GS-9620 QW x 2 doses|
88912886|NCT01590641|Experimental|1mg GS-9620 QW x 2 doses|
88912887|NCT01590641|Experimental|2mg GS-9620 QW x 2 doses|
88912888|NCT01590641|Experimental|4mg GS-9620 QW x 2 doses|
88912889|NCT01590654|Experimental|0.3mg GS-9620|
88912890|NCT01590654|Experimental|1mg GS-9620|
88912891|NCT01590654|Experimental|2mg GS-9620|
88912892|NCT01590654|Experimental|4mg GS-9620|
88912893|NCT01590654|Experimental|0.3mg GS-9620 QW x 2 doses|
88912894|NCT01590654|Experimental|1mg GS-9620 QW x 2 doses|
88912895|NCT01590654|Experimental|2mg GS-9620 QW x 2 doses|
88912896|NCT01590654|Experimental|4mg GS-9620 QW x 2 doses|
88912897|NCT01590667|Active Comparator|Litramine|2 tablets 3 times daily (oral consumption, 30 minutes after meal)
88912898|NCT01590667|Placebo Comparator|Placebo|2 tablets 3 times daily (oral consumption, 30 minutes after meal)
89197776|NCT00952900|Experimental|Early Biobehavioral Intervention|This intervention involves the use of non-invasive treatment modalities such as relaxation/biofeedback, stress management, and cognitive coping skills. It is based upon previous clinical research studies demonstrating the efficacy of this intervention in allowing acute TMD patients to better cope with stress and lifestyle issues that produce the TMD pain/discomfort.
89197777|NCT00952900|Active Comparator|Attention Control Group|This intervention involves the presentation of helpful information to patients that explains etiology and potential treatment modalities used to modify/reduce TMD pain/discomfort.
89197778|NCT00952900|No Intervention|No Active Treatment Comparison Group|Unlike the other two treatment groups, that involve high-risk acute TMD patients, this group includes low-risk acute TMD patients. Past studies have shown that these low risk patients do not need any early intervention in order to prevent chronicity.
89197779|NCT02545413|Experimental|Probiotic|Probiotic VSL#3 will be given at a dose of one capsule thrice daily for 8 weeks, amounting to a total of 337.5 billion CFU/day. Each capsule contains 112.5 billion viable lyophilized bacteria of four strains of Lactobacillus (L. acidophilus DSM 24735, L. plantarum DSM 24730, L. paracasei DSM 24733, L. delbrueckii subsp. bulgaricus DSM 24734), three strains of Bifidobacterium (B. longum DSM 24736, B. breve DSM 24732, B. infantis DSM 24737) and one strain of Streptococcus (S. thermophilus DSM 24731) and excipients.
89433211|NCT06279741|Experimental|EXOB-001 (Phase 1)|EXOB-001 will be administered via the endotracheal route in an already intubated newborn. EXOB-001 will be administered in three dose levels (low dose, medium dose and high dose) with one or three administrations.
89433212|NCT06279741|Experimental|Active group 1 EXOB-001 (Phase 2)|In phase 2, active group 1 consists of administering the first (out of two) of the safest selected dose/regimen of EXOB-001 based on phase 1 interim results.
89433213|NCT06279741|Experimental|Active group 2 EXOB-001 (Phase 2)|In phase 2, active group 2 consists of administering the second (out of two) of the safest selected dose/regimen of EXOB-001 based on phase 1 interim results.
89433214|NCT06279741|Placebo Comparator|Placebo (Phase 2)|In phase 2, the saline solution for infusion is used as a placebo.
88912899|NCT01590693|Experimental|Group 2|Children treated with four weeks of below knee walking casts and botulinum toxin A injections
88912900|NCT01590693|Active Comparator|Group 1|Children treated with four weeks of below knee walking casts.
88912901|NCT01590732|Experimental|Treatment (romidepsin, ifosfamide, carboplatin, etoposide)|Participants receive romidepsin IV over 4 hours on days 1 and 4, ifosfamide IV over 24 hours on day 1, carboplatin IV over 1 hour on day 1, and etoposide IV over 2 hours on day 1-3. Treatment repeats every 14 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
88912902|NCT01590745|Placebo Comparator|Sham Ultrasound regimen|A switch in the transducer circuit allows mock ionisation as a result no ultrasound emitted.
88912903|NCT01590745|Active Comparator|Real Ultrasound therapy|Pulsed mode ultrasound therapy
88912904|NCT01590823|Other|Dabigatran etexilate 110 mg|Single dose of Dabigatran etexilate 110 mg po
88912905|NCT01590836|Experimental|IDeg-->IDegAsp|
88912906|NCT01590849|No Intervention|No hormonal contraception|
88912907|NCT01590849|Active Comparator|Hormonal Contraceptive|healthy women, users of COC containing 20 mcg EE and 3 mg DRSP (Yaz®), 24 days of active pills, 4 days of pill-free interval (n=40).
88912908|NCT01590901|Other|probucol in healthy male subjects|multiple oral doses of probucol in single group of healthy male subjects
88912909|NCT01590914|Experimental|Roux-En Y Gastric Bypass|40 subjects who plan to undergo Roux-En-Y Gastric Bypass bariatric surgery. BOLD fMRI responses to food cues will be collected in the Fed Condition and Fasted Condition Pre-Surgery and 3 months post Surgery.
88912910|NCT01590914|Experimental|Gastric Banding|40 Subjects who plan to undergo Gastric Banding bariatric Surgery. BOLD fMRI responses to food cues will be collected in the Fed Condition and Fasted Condition Pre-Surgery and 3 months post Surgery.
88912911|NCT01590914|Experimental|Formula Diet Weight-Loss|40 subjects will undertake a 12-week liquid formula weight loss plan. BOLD fMRI responses to food cues will be collected in the Fed Condition and Fasted Condition pre-weight loss and 3 months after a 12-week weight loss plan.
88912912|NCT01590914|Experimental|No Treatment|40 subjects who do not undergo any treatment for weight loss. BOLD fMRI responses to food cues will be collected in the Fed Condition and Fasted Condition at baseline and after 3 months.
88912913|NCT01590927||20 healthy women|
88912914|NCT01590940||Parietex mesh|Enrolled patients who met criteria for inclusion would have undergone open inguinal hernia repair using the Parietex plug and patch hernia system
88912915|NCT01590966|Experimental|Patients with an active inflammatory joint disease|In total there will be 20 patients included: 5 patients with active rheumatoid arthritis, 5 patients with active early axial spondyloarthritis, 5 patients with active early peripheral spondyloarthritis and 5 patients with active ankylosing spondylitis.
88912916|NCT01590992|Experimental|Exposure-based Psychotherapy for Somatic Symptoms|First: 1-2 months waiting period; followed by: exposure-based psychotherapy
88912917|NCT01590992|Active Comparator|Relaxation Therapy|First: 1-2 months waiting period; followed by: relaxation therapy
88912918|NCT01591031|Active Comparator|sevoflurane|anesthesia induction with propofol, remifentanil and sevoflurane
88912919|NCT01591031|Active Comparator|rocuronium|anesthesia induction with propofol, remifentanil and rocuronium
88912920|NCT01591057|Experimental|2 Portions|
88912921|NCT01591057|Experimental|5 portions|
88912922|NCT01591057|Experimental|8 portions|
88912923|NCT01591070|No Intervention|vehicle twice weekly|
88912924|NCT01591070|Experimental|tacrolimus once weekly|
88912925|NCT01591070|Experimental|tacrolimus twice weekly|
89433215|NCT06279702|Experimental|simulation group|"Students will be asked to perform first aid in the First Aid Training for Injuries Serious Game Simulation Scenario without any first aid training and to fill in the data collection tools integrated into the game. Correct approach training to the injured will be given through First Aid in Injuries Training Serious Game Simulation Scenario CORRECT PRACTICES TRAINING integrated into the serious game. Upon completion of the training, the next step will be free work time. Students will be able to play as many games as they want."
89197780|NCT02545413|Placebo Comparator|Placebo|Placebo capsules will be given at a dose of one capsule thrice daily for 8 weeks; Placebo capsules contain all excipients as present in capsules (without the 8 strains of bacteria as mentioned above).
88912926|NCT01591083|Active Comparator|Double oral dose|Each enrolled patient receives an 80 mg loading dose of intravenous esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden) immediately after hemostasis was achieved spontaneously or by gastroscopy. Patients then received a 3-day continuous high dose (8 mg per hour) of esomeprazole infusion. Then, patients receive 40 mg oral esomeprazole twice daily for 11 days and followed by 40 mg once daily for 14 days.
88912927|NCT01591083|Active Comparator|Regular oral dose|Each enrolled patient receives an 80 mg loading dose of intravenous esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden) immediately after hemostasis was achieved spontaneously or by gastroscopy. Patients then received a 3-day continuous high dose (8 mg per hour) of esomeprazole infusion. Then, patients receive 40 mg oral esomeprazole once daily for 25 days.
89197781|NCT00944086||Recruitment Manoeuvre ,Laparoscopy|
89197782|NCT00855075||Cerebral State Monitor|A cerebral state monitor will provide a cerebral state index for mechanically ventilated intensive care patients. Recorded cerebral state indexes will be correlated with clinical assessments of sedation using the Richmond Agitation-Sedation Scale.
89433216|NCT06279702|Experimental|Comic Group|Students will be given First Aid Training in Injuries, prepared in the form of a comic book.
89433217|NCT06279702|No Intervention|other|Training will not be provided within the scope of serious games and with comic books.
88912928|NCT01591083|Active Comparator|Control group|Each enrolled patient receives an 80 mg loading dose of intravenous esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden) immediately after hemostasis was achieved spontaneously or by gastroscopy. Patients then received a 3-day continuous high dose (8 mg per hour) of esomeprazole infusion. Then, patients receive 40 mg oral esomeprazole once daily for 25 days.
88912929|NCT01591109||Bevacizumab including chemotherapy|Patients treated with bevacizumab including chemotherapy for metastatic liver tumor derived from colorectal cancer before metastasectomy.
88912930|NCT01591109||no adjuvant chemotherapy|Patients with no adjuvant chemotherapy including bevacizumab
88912931|NCT01591122|Experimental|Abiraterone acetate and prednisone|
88912932|NCT01591122|Active Comparator|Placebo and prednisone|
88912933|NCT01591135|Active Comparator|Cisplatin|Chemoradiotherapy with cisplatin and 5-fluorouracil for 2 cycles followed by adjuvant chemotherapy for 2 cycles.
88912934|NCT01591135|Experimental|Paclitaxel|Patients randomized in Arm B will receive chemoradiation with weekly paclitaxel and 5-fluorouracil for 5 weeks followed by adjuvant chemotherapy with paclitaxel and 5-fluorouracil for 2 cycles.
88912935|NCT01591148|Experimental|Morbidly obese subjects|Morbidly obese subjects (body mass index greater than 40) will be given propofol for induction of general anesthesia. Plasma samples will be taken to ascertain drug concentration over time.
88912936|NCT01591148|Active Comparator|Control subjects (body mass index 20-25)|Normal weight subjects (body mass index 20-25) will be given propofol during induction of general anesthesia. Plasma samples will be collected over time to ascertain propofol plasma concentration.
88912937|NCT01591174||Functional Dyspepsia with PDS|Study participants 8-17 years of age will be recruited for this arm after an evaluation at Children's Mercy Hospital and Clinics in the Abdominal Pain Clinic (APC)or in the Section of Gastroenterology, general, and diagnosed with FD, fail to respond to acid suppression therapy and have Postprandial Distress Syndrome (PDS).
88912938|NCT01591174||Functional Dyspepsia without PDS|Study participants 8-17 years of age will be recruited for this arm after an evaluation at Children's Mercy Hospital and clinics (CMH) Abdominal Pain Clinic (APC)or the Section of Gastroenterology, general, and diagnosed with FD, fail to respond to acid suppression therapy and do not have Postprandial Distress Syndrome (PDS).
88912939|NCT01591174||Control Group|Healthy participants 8-17 years of age recruited from internal advertising within Children's Mercy Hospital and Clinics.
88912940|NCT01591187||Cancer|Participants with a diagnosis of cancer.
88912941|NCT01591187||Sickle Cell Disease|"Participants with a diagnosis of sickle cell disease.~Interventions: Text messaging, Questionnaire, Interviews"
88912942|NCT01591200|No Intervention|Control|This arm will receive standard protocol of care alone
88912943|NCT01591200|Experimental|Stem cells high dose|This arm will receive high dose of Allogeneic Mesenchymal Stem Cells
89197783|NCT00944164|Experimental|Healthy eating/physical activity|
89197784|NCT00944164|Active Comparator|Safety/Injury prevention|
89536882|NCT03312179||diabetics incretin-users STEMI|Diabetics patients admitted for ST elevation myocardial infarction (STEMI) and associated with multi vessels coronary artery stenosis (Mv) non obstructive coronary artery stenosis (NOCS). These patients received percutaneous coronary intervention (PCI), and primary stenting (DES) of culprit lesion. Then these patients received full medical STEMI therapy. These patients were treated by incretin therapy at last 6 months before study enrollment.
88912944|NCT01591200|Experimental|Stem cells intermediate dose|This arm will receive intermediate dose of Allogeneic Mesenchymal Stem Cells
88912945|NCT01591200|Experimental|Stem cells low dose|This arm will receive low dose of Allogeneic Mesenchymal Stem Cells
88912946|NCT01591213||Healthy Volunteers|Fourth grade students enrolled in Memphis-area schools.
88912947|NCT01591226|Active Comparator|Caffeine|6mg per kg bodyweight ingested 60min before test
88912948|NCT01591226|Placebo Comparator|Placebo|Sodium chloride and mannitol as placebo are ingested by the athlete
88912949|NCT01591226|Active Comparator|Sodium Citrate|sodium citrate diluted in 7dl water, ingestion 120 to 90min prior test
88912950|NCT01591226|Active Comparator|Caffeine and Sodium Citrate|sodium citrate 120-90min prior test capsules:60min prior test
88912951|NCT01591265|Active Comparator|Compensatory Extraction|Patients allocated to this group, both the upper FPM and lower FPM teeth will be extracted.
88912952|NCT01591265|Active Comparator|No Compensatory Extraction|Patients allocated to this group, only the lower FPM tooth will be extracted.
88912953|NCT01591278|Experimental|Pulp dressing agent|
88912954|NCT01591278|Active Comparator|Pulp dressing|MTA
88912955|NCT01591304|Active Comparator|Group A|Ulthera System Treatment provided using 1.5mm and 1.0mm transducers at 0.25J and 0.20J energy settings, respectively.
88912956|NCT01591304|Active Comparator|Group B|Ulthera System Treatment provided using 1.5mm and 1.0mm transducers, at 0.18J and 0.15J energy settings, respectively.
88912957|NCT01591343|Experimental|Depigoid® (500 DPP/ml)|Patients will receive either Depigoid® Dermatophagoides pteronyssinus or 50% Dermatophagoides pteronyssinus / 50% Dermatophagoides farinae (500 DPP/ml), depending on their sensitization to one or both mites (Dermatophagoides pteronyssinus and Dermatophagoides farinae).
88912958|NCT01591395|Active Comparator|Multiport TEP|Adult inguinal hernia patients who randomized to receive multiport endoscopic TEP repair
88912959|NCT01591395|Active Comparator|LESS TEP|Adult inguinal hernia patients who randomized to receive laparoendoscopic single-site TEP repair
88912960|NCT01591434|Active Comparator|AQUACEL®|A sterile non-woven sheet of sodium carboxymethylcellulose (NaCMC).
88912961|NCT01591434|Active Comparator|AQUACEL® Extra™|A sandwiched construction of two layers of optimally textiled non-woven fabric, stitch-bonded together using Lyocel (Tencel™ regenerated cellulose) yarns.
88912962|NCT01591486||Hp-negative cohort|"Hp-negative cohort~The second cohort consists of ASA users with ulcer bleeding but no current or past Hp infection, as evidenced by:~negative rapid urease test~negative histology for Hp infection on both initial and follow-up endoscopy~negative serology test~absence of intestinal metaplasia and atrophy on 4 random biopsies of the antrum and corpus~After ulcer healing, the Hp-negative cohort will receive enteric-coated ASA (<160 mg daily) without regular co-prescription of anti-ulcer drugs."
89433218|NCT06279689|Experimental|Healthy subjects : Adult and pediatric populations|"Only ultrasound procedures will be performed using an investigational ultrasound system.~All subjects will be asked to undergo 1 on site visit (Study Visit) during which the eligibility assessment and the ultrasound scans will be performed is to evaluate the anatomical characteristics of both anterolateral thighs, one shoulder (deltoid) and one upper arm (biceps and triceps) before and while applying a force similar to the ZENEO® triggering force."
88912963|NCT01591486||Hp-eradicated cohort|Hp-eradicated cohort This cohort consists of ASA users with ulcer bleeding and Hp infection who have healed ulcers and successful eradication of Hp on follow-up endoscopy. They will receive plain ASA (<160 mg daily) without co-prescription of anti-ulcer drugs.
88912964|NCT01591486||Average-risk cohort|Average-risk cohort The third cohort consists of ASA-naive patients without a history of ulcer who attend the general outpatient clinic. They require long-term ASA for established cardiothrombotic diseases. They receive plain ASA (<160 mg daily) without co-prescription of anti-ulcer drugs. Hp status will not be determined in this cohort because Hp testing is not justified in average-risk asymptomatic patients.
88912965|NCT01591525||Uncontrolled Diabetic|Individuals who were previously diagnosed with Type II Diabetes, but have a HgA1C greater than 7.0%
88912966|NCT01591525||Newly diagnosed Type II Diabetic|Individuals who have never been diagnosed with Type II Diabetes, but have an HgA1c greater than 7.0%
88912967|NCT01591525||Newly diagnosised pre-diabetics|Individuals who have never been diagnosed with Type II Diabetes, but have a HgA1C of 6.0%-6.9%
88912968|NCT01591525||Controlled|Diabetic or non-diabetic individuals with RPCG of less than 130 mg/dl.
88912969|NCT01591538||lifestyle condition|
88912970|NCT01591551|Other|Natalizumab (Tysabri) naive|Patients who are newly prescribed Natalizumab (TYSABRI®), but have not received their first infusion, will be invited to participate.
88912971|NCT01591564|Other|therapy|All participants will receive the intervention.
88912972|NCT01591590|Experimental|All Patients|This is an Interventional, Non Therapeutic arm
88912973|NCT01591603|Experimental|Group 1|
88912974|NCT01591603|Experimental|Group 2|
88912975|NCT01591668|Experimental|0.3mg GS-9620|
88912976|NCT01591668|Experimental|1mg GS-9620|
88912977|NCT01591668|Experimental|2mg GS-9620|
88912978|NCT01591668|Experimental|4mg GS-9620|
88912979|NCT01591668|Experimental|0.3mg GS-9620 QW x 2 doses|
88912980|NCT01591668|Experimental|1mg GS-9620 QW x 2 doses|
88912981|NCT01591668|Experimental|2mg GS-9620 QW x 2 doses|
88912982|NCT01591668|Experimental|4mg GS-9620 QW x 2 doses|
88912983|NCT01591694||FamilyLive|Families with a history of intergenerational trauma (maltreatment, violence exposure, domestic violence, substance abuse, etc.)
88912984|NCT01591694||Yoga Based Psychotherapy|Children with a history of maltreatment and/or violence exposure
88912985|NCT01591694||Biofeedback|Children with a history of maltreatment and violence exposure and their caregivers
88912986|NCT01591694||TST-SA|Trauma Systems Therapy for Adolescent Substance Abuse
89433219|NCT06279650|Experimental|Self-hypnosis|
89433220|NCT06279650|Active Comparator|Psyco-education and cognitive behavioral therapy|
88912987|NCT01591720|Experimental|Tailored Internet-delivered CBT|The intervention is delivered within a primary care clinic.
88912988|NCT01591759|Experimental|Citicoline|8-week treatment of 2,000mg/day of citicoline
88912989|NCT01591759|Placebo Comparator|Placebo|
88912990|NCT01591798|Experimental|Robotic surgery|Proctectomy using robot
88912991|NCT01591798|Active Comparator|Laparoscopic surgery|Conventional laparoscopic rectal resection
88912992|NCT01591811|Experimental|Arm 1 Daily Boost of Radiation Therapy|Arm 1 of treatment, you will be receiving 15 daily radiation fractions of 2.7 Gy (measure of radiation dose) daily for three weeks to the entire breast with a daily concomitant boost of 0.5 Gy
88912993|NCT01591811|Experimental|Arm 2 Weekly Boost of Radiation Therapy|Arm 2 Weekly Boost will receive 15 daily radiation fractions of 2.7 Gy for three weeks to the entire breast with a weekly boost of 2.0 GY.
88912994|NCT01591824|Experimental|POLD TREATMENT|Patients who applies the treatment of resonant oscillation according to the Pold Concept
88912995|NCT01591824|Active Comparator|CONVENCIONAL: column exercise group|Patients who applied the conventional treatment of hospital
88912996|NCT01591850|Experimental|1 Ketoconazole DDI|
88912997|NCT01591850|Experimental|2 Rifampicin DDI|
88912998|NCT01591850|Experimental|3 ATZ/r DDI|
88912999|NCT01591876|Sham Comparator|Progressive muscle relaxation|As well as usual care participants in the control arm will receive instruction in progressive muscle relaxation.
88913000|NCT01591876|Active Comparator|Aerobic exercise|Intervention -moderate intensity aerobic exercise.
88913001|NCT01591889|Active Comparator|tindamax|500 mg tablet
88913002|NCT01591889|Active Comparator|tinidazole|500 mg tablet
88913003|NCT01591902|Experimental|EGRIFTA Treatment Grop|Sterile, lyophilized, nonpyrogenic powder containing tesamorelin acetate with mannitol as excipient
88913004|NCT01591902|Placebo Comparator|Placebo|Placebo-controlled
88913005|NCT01591915|Experimental|MBSR self care program including weekly sessions|Participants will participate in an 8 week course of MBSR practice of homework assignments consisting of 20 minutes sessions, 6 days/week. Participants will partake in a structured group-formatted 8 week course that patients attend once a week for an average of 2 hours.
88913006|NCT01591915|Experimental|MBSR self care program|Participants will participate in an 8 week course of MBSR practice of homework assignments consisting of 20 minutes sessions, 6 days/week.
88913007|NCT01591915|No Intervention|Standard care|
88913008|NCT01591928||Infants with heterotaxy syndrome|
88913009|NCT01591941|Active Comparator|CON group|Control Group underwent a standard soccer warm-up
88913010|NCT01591941|Experimental|Core-PAC|Experimental took part in the Core position and control movement strategy (Core-PAC) warm-up
88913011|NCT01591967|No Intervention|Control|Control -- no intervention
88913012|NCT01591967|No Intervention|Placebo w/ sham|"Sham intervention with the adjusting tool turned off"
88913013|NCT01591967|Experimental|Activator treatment|Treatment with Activator
88913014|NCT01591980|Experimental|Pregabalin 100 mg|
88913015|NCT01591980|Experimental|pregabalin 150 mg|
88913016|NCT01591980|Sham Comparator|Placebo|
88913017|NCT01591993|Experimental|Test subject|To each subject, the investigators will randomly apply 10% lactic acid on one nasolabial fold, once.
88913018|NCT01591993|Placebo Comparator|Placebo|To each subject, the investigators will apply placebo (0.9% saline solution) on the contralateral nasolabial fold to the lactic acid, simultaneously.
89009192|NCT03450031|Experimental|NAC (no drug/no device) and NFP AND NLF|NAC with mixed grass pollen will be conducted. Nasal filter paper (NFP)sampling will be conducted from one nostril per time point. Subjects in Cohort B will also undergo nasal lavage (NLF) pre-NAC and at serial time points thereafter up to 8 hours
88913019|NCT01592019|Experimental|Reference, Patch location thigh, batch 1|Reference, Patch location thigh, batch 1: A single dose of the patch will be applied. In addition, the Microdialysis probe consisting of three probes will be inserted to test for the amount of the drug diclofenace. This will determine whether the site of application affects the availability of the drug.
88913020|NCT01592019|Experimental|Test, Patch location thigh, batch 2|Test, Patch location thigh, batch 2: A single dose of the patch will be applied. In addition, the Microdialysis probe consisting of three probes will be inserted to test for the amount of the drug diclofenace. This will determine whether the site of application affects the availability of the drug.
88913021|NCT01592019|Experimental|Reference, Patch location abdomen, batch 1|Reference, Patch location abdomen, batch 1: A single dose of the patch will be applied. In addition, the Microdialysis probe consisting of three probes will be inserted to test for the amount of the drug diclofenace. This will determine whether the site of application affects the availability of the drug.
88913022|NCT01592019|Experimental|Test, Patch location abdomen, batch 2|Test, Patch location abdomen, batch 2: A single dose of the patch will be applied. In addition, the Microdialysis probe consisting of three probes will be inserted to test for the amount of the drug diclofenace. This will determine whether the site of application affects the availability of the drug.
88913023|NCT01592032|Experimental|Vancomycin antimicrobial-lock|Vancomycin antimicrobial-lock solution. Dosage: 2 mg/mL. Dosage form: liquid in syringe. Frequency: 1. Duration: from 1 to 10 days according to HPLC corrected by urea gradient.
88913024|NCT01592032|Experimental|Teicoplanin antimicrobial-lock|Teicoplanin antimicrobial-lock solution. Dosage: 10 mg/mL. Dosage form: liquid in syringe. Frequency: 1. Duration: from 1 to 10 days according to HPLC corrected by urea gradient.
88913025|NCT01592032|Experimental|Linezolid antimicrobial-lock|Linezolid antimicrobial-lock solution. Dosage: 1.8 mg/mL. Dosage form: liquid in syringe. Frequency: 1. Duration: from 1 to 10 days according to HPLC corrected by urea gradient.
88913026|NCT01592032|Experimental|Daptomycin antimicrobial-lock|Daptomycin antimicrobial-lock solution. Dosage: 5 mg/mL. Dosage form: liquid in syringe. Frequency: 1. Duration: from 1 to 10 days according to HPLC corrected by urea gradient.
88913027|NCT01592032|Experimental|Tigecycline antimicrobial-lock|Tigecycline antimicrobial-lock solution. Dosage: 4.5 mg/mL. Dosage form: liquid in syringe. Frequency: 1. Duration: from 1 to 10 days according to HPLC corrected by urea gradient.
88913028|NCT01592084||lipid lowering therapy|those with lipid lowering therapy those without lipid lowering therapy
88913029|NCT01592123||The participants with septal deviation|
88913030|NCT01592149||Group 1|
88913031|NCT01592162|Active Comparator|propofol 1% (Astra-Zeneca) - remi 0|propofol 1% (Astra-Zeneca)plus remifentanil 0 ng/ml
88913032|NCT01592162|Active Comparator|propofol 1% (Astra-Zeneca) - remi 2|propofol 1% (Astra-Zeneca)plus remifentanil 2 ng/ml
88913033|NCT01592162|Active Comparator|propofol 1% (Astra-Zeneca) - remi 4|propofol 1% (Astra-Zeneca)plus remifentanil 4 ng/ml
88913034|NCT01592162|Active Comparator|propofol 1% (Fresenius) - remi 0|propofol 1% (Fresenius) plus remifentanil 0 ng/ml
88913035|NCT01592162|Active Comparator|propofol 1% (Fresenius) - remi 2|propofol 1% (Fresenius) plus remifentanil 2 ng/ml
88913036|NCT01592162|Active Comparator|propofol 1% (Fresenius) - remi 4|propofol 1% (Fresenius) plus remifentanil 4 ng/ml
89433221|NCT06279637|Experimental|Joint Home-DM-BAT Intervention|A trained health educator will deliver the manualized Joint Home-DM-BAT intervention. Participants will receive 8-weekly sessions of diabetes education, problem solving around social needs, and behavioral activation via telephone; and 3 monthly booster sessions.
89433222|NCT06279637|Active Comparator|Usual Care|Patients randomized to the usual care arm will receive weekly mailings of diabetes education modules for 8 weeks and monthly mailings for 3 months to match the weekly and monthly booster sessions.
89433223|NCT06279611|Experimental|LY007|The CAR T cell preparation to be evaluated in this study is LY007, developed and produced by Shanghai Longyao Biotechnology Co., LTD Cell injection. LY007 cell injection is a chimeric antigen receptor targeting CD20 genetically modified using lentiviral vectors (CAR) Autologous T cells are CD20 CAR-T independently developed by Shanghai Longyao Biotechnology Co., LTD., in the CAR facility The independent co-stimulatory signal receptor OX40 was introduced to increase the proliferation and killing function of CAR-T cells. Table of CAR gene The frame comprises the following elements: (1) MSCVEF1α fusion promoter; (2) Single-chain antibody CD20 scFv targeting CD20; (3) CD8 junction and transmembrane region; (4) Intracellular region of 4-1BB; (5) CD3ζ intracellular region; (6) P2A self-shearing peptide; (7) Co-stimulated receptor OX40
88913037|NCT01592162|Active Comparator|propofol 1% (B-Braun) - remi 0|propofol 1% (B-Braun) plus remifentanil 0 ng/ml
88913038|NCT01592162|Active Comparator|propofol 1% (B-Braun) - remi 2|propofol 1% (B-Braun) plus remifentanil 2 ng/ml
88913039|NCT01592162|Active Comparator|propofol 1% (B-Braun) - remi 4|propofol 1% (B-Braun) plus remifentanil 4 ng/ml
88913040|NCT01592188|Active Comparator|MT|Mindfulness training. Participants will be provided with once per week training in mindfulness meditation.
88913041|NCT01592188|Experimental|CBCT|Cognitively-based compassion training. Participants in this arm will be provided with once weekly training on the cognitively-based compassion training program.
88913042|NCT01592201|Experimental|Paliperidone ER|Immediate initiation of Paliperidone ER for a total of 12 weeks
88913043|NCT01592201|Experimental|Antipsychotics and paliperidone ER|Delayed initiation included previous atypical antipsychotics for 8 weeks and then be initiated on paliperidone ER at Day 56 for 4 weeks. The atypical antipsychotics includes aripiprazole, olanzapine and risperidone. These antipsychotics belongs to the class of second generation bipolar atypical antipsychotics.
89433224|NCT06279598|Active Comparator|Prolonged Exposure|Intervention: Prolonged Exposure therapy, 14 sessions of 60 minutes in 8 weeks.
89433225|NCT06279598|Active Comparator|Eye Movement Desensitization Reprocessing|Intervention: Eye Movement Desensitization Reprocessing (EMDR), 14 sessions of 60 minutes in 8 weeks.
88913044|NCT01592214|Experimental|Part 1 #2-XF-73 in 2% Klucel® gel, concentration 2.0 mg/g|4 subjects: 2.0 mg/g concentrations of a modified 2% Klucel® gel formulation of XF-73 intranasally to both nares twice in a single day in a volume of 0.3 mL/naris/dose and total daily dose of 2.4 mg.
88913045|NCT01592214|Placebo Comparator|Part 2 #4-Placebo in 4% Klucel® gel, concentration 0 mg/g|12 subjects: a placebo in 4% Klucel® gel intranasally to both nares in a volume of 0.3 mL/naris/dose,3 doses 8 hours apart on Day 1 and 2 doses, 12 hours apart on Days 2 to 5. Total daily volume of 1.8 ml on Day 1 and 1.2 ml on Days 2 to 5.
89433226|NCT06279598|Experimental|Interpersonal Psychotherapy|Intervention: Interpersonal Psychotherapy (IPT), 14 sessions of 60 minutes in 8 weeks. In phase 2 of the study for treatment non-responders, IPT is studied as an alternative switching option compared to the switch of the aforementioned trauma-focused forms of psychotherapy.
89433227|NCT06279585|Experimental|Experimental group|Participants from both groups will undergo the three assessments and receive standard medical care.The patients in the experimental group will participate, at Time T1 (week 1 to 12), in a 12-week physiotherapy treatment program consisting of a total of 38 sessions: 2 health education sessions, 24 supervised combined exercise sessions, and 12 self-administered complementary exercise sessions.
89433228|NCT06279585|No Intervention|Control group|"Participants from both groups will undergo the three assessments and receive standard medical care.~The Control Group (GC), externally to the trial itself, for ethical reasons, considering potential benefits without risks, and as a strategy for blinding the study itself, will carry out the physiotherapy treatment program following the final assessment of the study, becoming a hybrid program under the same protocol."
88913046|NCT01592214|Active Comparator|Part 2 # 3-XF-73 in 4% Klucel® gel, concentration 0.5 mg/g:|12 subjects: a modified 4% Klucel® gel formulation of XF-73 intranasally to both nares in a concentration of 0.5 mg/g and volume of 0.3 mL/naris/dose in, 3 doses 8 hours apart on Day 1 and 2 doses, 12 hours apart on Days 2 to 5. Total daily volume of 1.8 ml on Day 1 and 1.2 ml on Days 2 to 5; and total daily dose of 0.9 mg on Day 1 and 0.6 mg on Days 2 to 5.
88913047|NCT01592214|Experimental|Part 2 #2- XF-73 in 2% Klucel® gel, concentration 2.0 mg/g|12 subjects; a modified 2% Klucel® gel formulation of XF-73 intranasally to both nares in a concentration of 2.0 mg/g and volume of 0.3 mL/naris/dose,3 doses 8 hours apart on Day 1 and 2 doses, 12 hours apart on Days 2 to 5. Total daily volume of 1.8 ml on Day 1 and 1.2 ml on Days 2 to 5; and total daily dose of 3.6 mg on Day 1 and 2.4 mg on Days 2 to 5.
88913048|NCT01592214|Experimental|Part 2 #1- XF-73 in 2 % Klucel® gel, concentration 0.5 mg/g|12 subjects: a modified 2% Klucel® gel formulation of XF-73 intranasally to both nares in a concentration of 0.5 mg/g and volume of 0.3 mL/naris/dose, 3 doses 8 hours apart on Day 1 and 2 doses, 12 hours apart on Days 2 to 5. Total daily volume of 1.8 ml on Day 1 and 1.2 ml on Days 2 to 5; and total daily dose of 0.9 mg on Day 1 and 0.6 mg on Days 2 to 5.
88913049|NCT01592214|Experimental|Part 1 #1-XF-73 in 2% Klucel® gel, concentration 0.5 mg/g:|4 subjects: 0.5 mg/g concentration of a modified 2% Klucel® gel formulation of XF-73 intranasally to both nares twice in a single day in a volume of 0.3 mL/naris/dose and total daily dose of 0.6 mg.
88913050|NCT01592227|Active Comparator|Marketed paracetamol|Marketed paracetamol
88913051|NCT01592227|Experimental|Experimental paracetamol formulation|Experimental formulations
88913052|NCT01592266||AML|patients with AML prior and after treatment
88913053|NCT01592279|Experimental|liraglutide|
88913054|NCT01592279|Active Comparator|Insulin injections|
88913055|NCT01592305|Experimental|S1 P1 TDF + DNV/r|
88913056|NCT01592305|Experimental|S1/S2 P2 DNV/r + ATZ|
88913057|NCT01592305|Experimental|S2 P1 ATZ/r|
88913058|NCT01592318|Active Comparator|DNV + r reference|
88913059|NCT01592318|Experimental|DNV/r fixed dose combination|
89433229|NCT06279572||Observational (blood collection, bone marrow aspirate)|Patients undergo blood sample collection and bone marrow aspirate on study. Patients' medical records are reviewed.
88913060|NCT01592331|Placebo Comparator|Placebo|
88913061|NCT01592331|Experimental|RO5508887|
88913062|NCT01592357|Experimental|Tai Chi|
88913063|NCT01592357|Sham Comparator|Sham Exercise|
89433230|NCT06279559|Experimental|clinical experimental group|pregnant women with the risk of preterm birth who will undergo music therapy intervention
88913064|NCT01592422|Experimental|Immunotherapy|Subjects receive autologous cytokine-induced killer cell infusion every month
88913065|NCT01592422|Active Comparator|Best Supportive Care|Best Supportive Care
88913066|NCT01592448||Usual Care|"Participants will be shown standard (defined as currently commercially available) over-the-counter and prescription medicine bottles and asked questions regarding safety and use. Participants will also be shown additional standard over-the-counter bottles and asked whether these comparison bottles could safely be taken in addition to the primary products shown."
89009193|NCT03459781|Experimental|Cognitively-Based Compassion Training|Cancer survivors and their informal caregivers (family and close friends), one of whom has at least mild depression and/or anxiety features (determined by PROMIS Depression 4a and PROMIS Anxiety 4a, respectively) who are randomized to CBCT®.
89433231|NCT06279559|No Intervention|clinical control group and non-clinical control group|pregnant women with the risk of preterm birth who will receive the usual ward care and pregnant women with pregnancy with a physiological course
89433232|NCT06279546||AI-based model|AIWorks-EUS Convolutional Neural Network version 2 (CNNv2) (mdconsgroup, Guayaquil, Ecuador) applied on pre-recorded videos for the detection of normal anatomical structures.
89433233|NCT06279546||Expert endoscopists|Endoscopists with >190 EUS procedures per year, including 75 pancreatobiliary and mucosal cancer staging procedures each, 40 subepithelial cases; and 50 cases of EUS-fine needle aspiration (FNA) (25 of them being pancreatic cases); following the American Society for Gastrointestinal Endoscopy (ASGE) recommendations.
88913067|NCT01592448||Written Orientation|"Participants will be exposed to over-the-counter and prescription bottles enhanced with an icon pertaining to active ingredient and asked questions regarding safety and use. Participants will be exposed to a flier describing the safe use of acetaminophen and orienting the participant towards the icon that is used to indicate the presence of acetaminophen in a product. This flier will be passively hanging within sight of the participant in the room, but no verbal explanation of the flier will be given to the participant. (This is designed to represent a passive education campaign such as posters in drug stores that may be used should these icons be adopted by manufacturers.)"
88913068|NCT01592448||Written + Verbal Orientation|"Participants will be exposed to over-the-counter and prescription bottles enhanced with an icon pertaining to active ingredient and asked questions regarding safety and use. Participants will be exposed to a flier describing the safe use of acetaminophen and orienting the participant towards the icon that is used to indicate the presence of acetaminophen in a product. Research personnel will also verbally go through the flier with the participant and answer any questions in a standardized fashion. (This is designed to represent an active education campaign such as pharmacist counseling that may be used should these icons be adopted by manufacturers.)"
88913069|NCT01592487||Lean BMI|BMI in the 25th - 75th percentile
88913070|NCT01592487||Overweight BMI|BMI in the 85th - 95th percentile
88913071|NCT01592513|No Intervention|Control|
88913072|NCT01592513|Experimental|BIS monitor|"Patients in this group will be monitored by BIS (placement of an electrode over the forehead before sedation).~Patients in this group will receive propofol (boluses of 10-20 mg) to reach a BIS target value of 80-90."
88913073|NCT01592526|Experimental|Untrained, healthy volunteers A|(Endotoxin) before (Endotoxin + Nicotine)
88913074|NCT01592526|Experimental|Well-trained healthy volunteers A|(Endotoxin) before (Endotoxin + Nicotine)
88913075|NCT01592526|Experimental|Untrained, healthy volunteers B|(Endotoxin + Nicotine) before (Endotoxin)
88913076|NCT01592526|Experimental|Well-trained healthy volunteers B|(Endotoxin + Nicotine) before (Endotoxin)
88913077|NCT01592539||Case|Patients with Type 1 Diabetes Mellitus
88913078|NCT01592539||Control|Age and sex matched healthy controls.
88913079|NCT01592578|Active Comparator|Ligation and Cyanoacrylate Group|
88913080|NCT01592578|Experimental|Ligation plus Sclerotherapy and Cyanoacrylate Group|
88913081|NCT01592604|Experimental|Treatment A|Patients receive supportive compressive bandage for 4 weeks
88913082|NCT01592604|Experimental|Treatment B|Below knee walking plaster cast for 4 weeks
88913083|NCT01592630|Experimental|Ropivacaine|Subjects with TAP catheters attached to the On-Q pump with 0.2% ropivacaine
89433234|NCT06279546||Non-expert endoscopists|Endoscopists with <190 EUS procedures per year, including 75 pancreatobiliary and mucosal cancer staging procedures each, 40 subepithelial cases; and 50 cases of EUS-FNA (25 of them being pancreatic cases); following the American Society for Gastrointestinal Endoscopy (ASGE) recommendations.
88913084|NCT01592630|Placebo Comparator|Saline|Subjects with TAP catheters attached to the On-Q pump with saline
88913085|NCT01592656|Active Comparator|Non-invasive ventilation (NIV)|30 patients will receive NIV during 6 months = group 1
88913086|NCT01592656|Placebo Comparator|Control group|10 patients will act as control group, they will not be treated with NIV = group 2
88913087|NCT01592669|Experimental|passive leg group|bilateral PLR was achieved by raising the patient's legs to a 45 angle.
88913088|NCT01592669|No Intervention|control|supine baseline position
88913089|NCT01592682|No Intervention|Usual care|Household pairs that are assessment only and receive usual care of local in-language smoking cessation resource referral including quitline.
88913090|NCT01592682|Experimental|Smokefree counseling|Household pairs assigned to smokefree counseling intervention, consisting of group education sessions, tobacco exposure lab report, individual follow-up phone calls.
88913091|NCT01592734|Experimental|PEG-only|Polyethylene glycol 4000 only (PEG-only).
88913092|NCT01592734|Active Comparator|PEG-EL|Polyethylene glycol 3350 with electrolytes (PEG-EL).
88913093|NCT01592812|Experimental|electrical stimulation|Evaluation of the effect of calf stimulation on flow and tissue oxygenation
88913094|NCT01592838||Hospitalized Group|Data collection for changes in hospital pattern pre- versus post-rotavirus vaccination, in children ≤15 years old hospitalised for any reason between June 2004 and May 2010.
88913095|NCT01592890|Experimental|[14C]-labeled RO4917523|
88913096|NCT01592903||Patients with symptomatic uterine fibroids.|Samples of human leiomyomas are obtained from patients undergoing laparoscopic myomectomy for symptomatic uterine fibroids. These leiomyomas are isolated and cultured for stem cells.
88913097|NCT01592916||Fibromyalgia|Women with fibromyalgia, aged 20-50 years
88913098|NCT01592916||Healthy controls|Women without severe disease, aged 20-50 years
88913099|NCT01592942|Experimental|glue fixation|Optilene™ mesh 60 g/m2 (B. Braun), fixation Histoacryl™ cyanoacrylate glue (price 14+37 euros)
88913100|NCT01592942|Active Comparator|self-gripping|ProGrip™ mesh 60 g/m2 (Covidien, USA) (price 113 euros)
88913101|NCT01592942|Active Comparator|suture fixation|Ultrapro™ mesh 28 g/m2 (Ethicon, USA) (price 45 euros) fixated by non-absorbable sutures
88913102|NCT01592955|Experimental|EYEOP1 device|cyclocoagulation HIFU
88913103|NCT01592981|Experimental|bortezomib, cyclophosphamide, rituximab|"Bortezomib:1.6 mg/m2 s.c; days 1, 8, 15 of each cycle. Cyclophosphamide:250 mg/m2 oral; days 1, 8, 15 of each cycle. Rituximab: 375 mg/m2 i.v. infusion; days 1, 8, 15 and 22 of cycles 2 and 5 only.~Cycle repeated every 28 days. After 3 cycles of treatment, patients are reassessed and those with evidence of progression stop trial treatment. All other patients continue with further 3 cycles (to a total of 6) unless a clear clinical contradiction to further treatment exist."
89009194|NCT03459781|Active Comparator|CHE (Cancer Health Education)|Cancer survivors and their informal caregivers (family and close friends), one of whom has at least mild depression and/or anxiety features (determined by PROMIS Depression 4a and PROMIS Anxiety 4a, respectively) who are randomized to CHE.
89009195|NCT03458767|Experimental|Intervention group|Eight weekly 90-minute group educational sessions attended via a computer, tablet, or smart phone using a web-based video conference platform.
89009196|NCT03458767|No Intervention|Control group|Enhanced usual care control group will receive an illustrated instructional booklet on Physical Activity for persons with MS developed by the National Center on Health, Physical Activity and Disability (NCHPAD).
89009197|NCT03457519|Active Comparator|Intervention Group A|"CHWs trained in ChARM and using ChARM as a self-monitoring tool for 8 months while counting respiratory rate of children under 5 visually using a timer.~Intervention: The Children's Respiration Monitor (also known as ChARM) device is routinely used to diagnose Pneumonia cases but in this study it will be used as a self-monitoring and teaching aide for strengthening CHWs skills."
89009198|NCT03457519|Active Comparator|Intervention Group B|"CHWs trained in ChARM and using ChARM as a self-monitoring tool for 4 months while counting respiratory rate of children under 5 visually using a time; then discontinue using ChARM and continue to monitor the respiratory rate visually using a timer only for the remaining 4 months.~Intervention: The Children's Respiration Monitor (also known as ChARM) device is routinely used to diagnose Pneumonia cases but in this study it will be used as a self-monitoring and teaching aide for strengthening CHWs skills."
89009199|NCT03457519|No Intervention|Control Group C|CHWs who did not receive the ChARM training and will be monitoring the respiratory rate of children under 5 visually using a timer only, as per the MoH traditional training.
89433235|NCT06279533|Experimental|PK characteristics of multiple ascending doses study|There are 24 subjects devided into 3 dose groups (15mg, 25mg and 40mg).8 subjects will be enrolled in each dose group and the ratio of investigational product to placebo is 3:1. LV232/Placebo is administered sequentially from low-dose to high-dose and each subject can only orally receive one dose level. Investigational product is orally administrated QD for day1, day3~day9. When 7th day visit after last dose (D15) is completed for previous dose group, investigator and sponsor will evaluate the safety and determine whether the next dose group can be started or adjusted.
89009200|NCT03451552|No Intervention|Control (211 services)|Patients allocated to the control arm will be directed to the Ontario 211 navigation service, which is already available to the general public free of charge. After consenting to participate in the study and completing the telephone survey, the research assistant will inform these patients that they can use existing navigation services provided by Ontario 211 to help them access the CR referred to them by their PHCP. The research assistant will instruct patients to dial 2-1-1 to obtain additional information on the nature of this service.
89009201|NCT03451552|Experimental|Intervention (Patient Navigator)|Patients allocated to the intervention arm will be offered the services of the ARC Patient Navigator. After consenting to participate in the study and completing the telephone survey, the research assistant will inform these patients that they can use the services offered by the ARC patient navigator to help them access the CR referred to them by their PHCP. Following a brief description of the services provided by the navigator (e.g., arrange transportation, make appointments, fill out forms, etc.), patients will be offered to be contacted by the navigator by telephone or to meet with the navigator in person on a day and time that is most convenient for them.
89531231|NCT03342131||STEMI group|The study population consists of 150 patients with ST-elevated acute myocardial infarction (STEMI) who are admitted within 24 hours after chest pain attack. They will all undergo coronary angiography. The diagnosis is made according to American Heart Association (AHA, 2014 and 2015) guidelines. Patients who had autoimmune diseases, malignancies, chronic or acute infections, asthma, severe heart failure (NYHA class 3 and 4) and advanced liver or renal diseases are excluded. Blood (150 each group) is obtained into ethylenediaminetetraacetic acid（EDTA） tubes from all subjects via antecubital venepuncture to explore circulating wnt 2 and wnt 4 concentration by ELISA at 0 , 7days and 12 months after admission.
89536282|NCT03209323|Experimental|sevoflurane - increasing concentrations|The patient was breathing spontaneously via the face mask and the sevoflurane concentration in the inhaled gas was doubled every 10 breaths starting from 0.3 vol. % in a sequence 0.3-0.6-1.2-2.4-4.8-8 vol. % until a minimal alveolar concentration (MAC) of 2 was obtained in the exhalation gas. Electroencephalography (EEG), bispectral index (BIS), response and state entropy (RE and SE), middle latency auditory evoked potentials (MLAEP) were monitored.
89009202|NCT00413387|Experimental|1|chf1535
89009203|NCT00413387|Active Comparator|2|Symbicort
89009204|NCT04572490||Narrow platform implant|All measurements will be obtained after dental implant functional loading. Periodontal index will be recorded and alveolar bone loss measurements will be made on periapical radiographs.
89009205|NCT04572490||Regular platform implants|All measurements will be obtained after dental implant functional loading. Periodontal index will be recorded and alveolar bone loss measurements will be made on periapical radiographs.
89009206|NCT03458845||Group 1|This group consists of cirrhotic patients with any abdominal hernia
89009207|NCT03458845||Group 2|This group consists of cirrhotic patients without any hernias
89009208|NCT00255762|Experimental|Treatment (carboplatin, paclitaxel, bevacizumab)|Patients receive carboplatin IV over 30 minutes on day 1, paclitaxel IV over 1 hour on days 1, 8, and 15, and bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89009209|NCT03456583||Brevera Breast Biopsy System|The Brevera Breast Biopsy System with CorLumina imaging technology is a vacuum-assisted biopsy device, which is used to remove breast tissue in a minimally invasive manner using stereotactic or tomosynthesis imaging. A breast biopsy is a test that removes tissue or sometimes fluid from the suspicious area. The removed cells are examined under a microscope and further tested to check for the presence of breast cancer. A biopsy is a diagnostic procedure that can definitely determine if the suspicious area is cancerous.
89009210|NCT03455998||post surgery|Patienst consultation Questionnaires
89009211|NCT03455998||pre and post surgery|Patient consultation Questionnaires
89433236|NCT06279533|Experimental|FE study|24 healthy subjects divided into 2 group (25mg and 40mg) will be enrolled once all eligibility criteria are met after screening within 14 days prior to investigation product administration. Informed consent should be obtained before any protocol defined procedures can be started.Investigational product administration plan given below: 12 healthy subjects in each group will be randomized to 3 sub-groups, i.e., Group A, Group B, Group C, with 4 subjects in each sub-group. For group A, investigation product will be given after fasting for Period 1, after standard diet for Period 2, and after high-fat diet for Period 3; For group B, investigation product will be given after high-fat diet for Period 1, after fasting for Period 2, and after standard diet for Period 3; For group C, investigation product will be given after standard diet for Period 1, after high-fat diet for Period 2, and after fasting for Period 3. Wash-out period is 5 days.
89009212|NCT02277457|Experimental|EGFR Mutation|Patients with an identified EGFR mutation will receive PET (Positron Emission Tomography) - Adaptive RT (Radiation Therapy) plus concurrent Erlotinib followed by 1 year total of Erlotinib Treatment.
89009213|NCT02277457|Experimental|ALK Rearrangement|Patients with an identified EGFR mutation will receive PET (Positron Emission Tomography) - Adaptive RT (Radiation Therapy) plus concurrent Crizotinib followed by 1 year total ofCrizotinib Treatment.
89009214|NCT00199888|Experimental|124I-cG250|Patients who were scheduled for surgical resection of renal masses received a single intravenous (IV) dose of 10 mg of 5 milliCurie (mCi) /10 mg 124I-cG250. Patients underwent Positron-Emission Tomography/Computed Tomography (PET/CT) imaging of the whole body on at least 2 occasions: once following injection and once immediately prior to surgical resection. Patients were scheduled for surgical resection of their renal masses on day 8.
89009215|NCT04721223|Experimental|JAB-3068+PD1 inhibitor Part1|JAB-3068+JS001 dose escalation
89009216|NCT04721223|Experimental|JAB-3068+PD1 inhibitor Part2|JAB-3068+JS001 dose expansion
89433237|NCT06279520|Other|Adult drivers|Individuals over the age of 19 who are currently driving
89433238|NCT06279507|Active Comparator|Hyaluronic acid|Hyaluronic acid, Ostenil Plus, 2 mL (40 mg) will be injected once afer 2-4 week of glucocorticoid injection
89433239|NCT06279507|Placebo Comparator|Normal saline|Two-millilitres of normal saline will be injected once after 2-4 weeks of glucocorticoid injection
89433240|NCT06279481|Experimental|Virtual Reality|The virtual reality hardware includes a headset (OLED display mode), a headset cable, a High-Definition Multimedia (HDM) cable, a processor unit, an Alternating Current (AC) power converter, a six-axis dynamic sensing system (three-axis gyroscope, three-axis accelerator sensor), a cinema AC screen, and a camera. The software that patients would be engaged in is highly interactive and requires total attention for about 15 minutes. The device would be tried out by the patients prior to the operation.
89433241|NCT06279481|No Intervention|Control|Patients undergo traditional colonoscopy procedures.
89433242|NCT06279468|Experimental|IDR group|A group designated as the IDR group will undergo subsequent intervertebral disc release following Ponte osteotomy on the predetermined vertebral levels.
89433243|NCT06279468|Active Comparator|PO group|The PO group will solely undergo Ponte osteotomy.
89433244|NCT06279455|No Intervention|Control Group|"Pregnant women in the control group were not trained and routine follow-up was performed in the outpatient clinic.~Female Sexual Function Index (FSFI) and International Consultation on Incontinence Questionnaire-Female Lower Urinary Tract Symptoms Long Form (ICIQ-FLUTS LF) at 18-20 weeks of gestation, Mid-term Evaluation Form at 26 weeks of gestation and FSFI and ICIQ-FLUTS LF at 32 weeks of gestation were applied to pregnant women in the control group participating in the study. Data on the birth process were collected within the first seven days after birth with the Birth Process Follow-up Form."
89009217|NCT00255918|Experimental|Dimethoxybenzylidene anabaseine 75 mg|Participants will take active experimental medication (Dimethoxybenzylidene anabaseine (DMXB-A) 75 mg)
89009218|NCT00255918|Placebo Comparator|Placebo|Participants will take placebo.
89009219|NCT00255918|Experimental|Dimethoxybenzylidene anabaseine 150 mg|Participants will take active experimental medication (Dimethoxybenzylidene anabaseine (DMXB-A) 150 mg)
89009220|NCT00199849|Experimental|Cohort 1|"4 µg NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine~NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine was administered by particle-mediated epidermal delivery (PMED) at a pressure of 500 psi using the XR-1 Powderject® delivery device. The 4 µg dosage of NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine was administered as 4 X 1 µg PMEDs in close proximity.~The vaccine was administered in weeks 1, 5, and 9 of Cycle 1. In the absence of > Grade 3 toxicity and in the absence of progressive disease requiring other treatment or the presence of NY-ESO-1 immunity, patients could receive an additional cycle of vaccinations of NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine."
89009221|NCT00199849|Experimental|Cohort 2|"8 µg NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine~NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine was administered by particle-mediated epidermal delivery (PMED) at a pressure of 500 psi using the XR-1 Powderject® delivery device.~The 8 µg dosage of NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine was administered as 8 X 1 µg PMEDs.~The vaccine was administered in weeks 1, 5, and 9 of Cycle 1. In the absence of > Grade 3 toxicity and in the absence of progressive disease requiring other treatment or the presence of NY-ESO-1 immunity, patients could receive an additional cycle of vaccinations of NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine."
89433245|NCT06279455|Experimental|Experimental Group|"Two sessions of training were given using the Pelvic Floor Health & Sexual Life in Pregnancy Training Booklet and the pelvic floor muscle exercise training video developed by the researcher between 18-20 weeks of pregnancy. Before the training, the FSFI and the ICIQ-FLUTS LF were administered to the pregnant women. Pregnant women were asked to perform pelvic floor muscle exercises, 3 sets a day, 3 days a week, for 12 weeks, starting from the 20th week of pregnancy, and record them in the Pelvic Floor Muscle Exercise Follow-up Form created by the researcher. By scanning the literature, 1 set of exercise was determined as 8-12 slow contractions (6-8 seconds) followed by 3-4 fast contractions (1 second)."
89433246|NCT06279403|Experimental|Experimental|Experimental arm
89009222|NCT00199849|Experimental|Cohort 3|"8 µg NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine~NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine was administered by particle-mediated epidermal delivery (PMED) at a pressure of 500 psi using the XR-1 Powderject® delivery device.~The 8 µg dosage of NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine was administered as a cluster dosage of 4 doses (day 1, 3, 5, 8) as 2 X 1 µg PMEDs per day.~The vaccine was administered in weeks 1, 5, and 9 of Cycle 1. In the absence of > grade 3 toxicity and in the absence of progressive disease requiring other treatment or the presence of NY-ESO-1 immunity, patients could receive an additional cycle of vaccinations of NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine."
89009223|NCT00226694|Active Comparator|Citalopram Group|Subjects receive provocative tests with citalopram, dexamethasone/corticotropin-releasing hormone and placebo on 3 separate, counterbalanced occasions at monthly intervals.
89009224|NCT00226694|Placebo Comparator|Placebo Group|Subjects receive provocative tests with citalopram, dexamethasone/corticotropin-releasing hormone and placebo on 3 separate, counterbalanced occasions at monthly intervals.
89009225|NCT00226733|Experimental|A|Interval exercise training with high intensity
89433247|NCT06279377|Experimental|Stabilization Exercise Group|"In the stabilization exercise group, in addition to those performed in the standard exercise group, training of deep neck flexor muscles with stabilizers and dynamic stabilization exercises will be applied.~Stabilizer Pressure Biofeedback unite, elastic resistance bands and elastic balls will be used in the stabilization exercise program.~Exercises performed with an elastic resistance band will be started in the 4th week, and exercises performed with an elastic ball will be started in the 6th week, depending on the suitability of the patient."
89433248|NCT06279377|Active Comparator|Standard Exercise Group|"On the day they will be discharged from the hospital, cervical normal joint movement, patient and posture training will be given.~Then the exercise program will begin and the first session will be held. Patients will be given a 5-minute warm-up program before starting the exercise and a 5-minute cool-down program at the end of the exercise.~Cervical flexion, extension, lateral flexion and rotation movements will be performed within the scope of the warm-up and cool-down program. Then, posture exercises and neck exercises with elastic resistance band will be performed."
89433249|NCT06279364|Experimental|SKB264|Participants will receive SKB264 on Day 1 and Day 15 of each 4-week cycle
89433250|NCT06279364|Active Comparator|Investigator's choice chemotherapy|"If no prior taxane, or prior taxane in the (neo)adjuvant setting and disease-free interval (DFI) >12 months: paclitaxel or nab-paclitaxel.~If prior taxane and DFI ≤ 12 months: capecitabine, eribulin. If known BRCA1/2 mutation: carboplatin"
89433251|NCT06279351|Experimental|Test group|Thalidomide+cetuximab+FOLFOX/FOLFIRI
89433252|NCT06279351|No Intervention|control group|cetuximab+FOLFOX/FOLFIRI
89433253|NCT06279338|Experimental|Azacitidine|Combining azacitidine with classic BUCY2 regimen as conditioning regimen
89433254|NCT06279325|Experimental|Cognitive Stimulation program|
89433255|NCT06279325|Active Comparator|Control Group|
89433256|NCT06279299|Experimental|Lateral Pelvic lymph node dissection|After performing TME surgery, further conduct lateral pelvic lymph nodes dissection.
89433257|NCT06279286|Experimental|HS-10506, 10 milligram (mg) and placebo|Phase Ib part: Participants will receive either 10mg of HS-10506 or matching placebo at night on Day 1 up to Day 5. Phase II part: Participants will receive either 10mg of HS-10506 or matching placebo at night on Day 1 up to Day 28.
89009226|NCT00226733|Active Comparator|B|Exercise training with moderate intensity
89009227|NCT00415155|Experimental|A|
89009228|NCT04710225|Active Comparator|Group 1 (General anesthesia group)|"Upper limb fracture surgery will be performed with the aid of pneumatic tourniquet. General anesthesia will be induced with intravenous (IV) thiopental sodium and fentanyl.~Rocuronium will be used as the neuromuscular blocking agent. Endotracheal tube will be placed and anesthesia will be maintained with sevoflurane and IV fentanyl while the lungs were ventilated with O2-N2O (50-50%) to achieve an EtCO2 at 30-35 mm Hg."
89433258|NCT06279286|Experimental|HS-10506, 20 milligram (mg) and placebo|Phase Ib part: Participants will receive either 20mg of HS-10506 or matching placebo at night on Day 1 up to Day 5. Phase II part: Participants will receive either 20mg of HS-10506 or matching placebo at night on Day 1 up to Day 28.
89433259|NCT06279286|Experimental|HS-10506, 40 milligram (mg) and placebo|Phase Ib part: Participants will receive either 40mg of HS-10506 or matching placebo at night on Day 1 up to Day 5. Phase II part: Participants will receive either 40mg of HS-10506 or matching placebo at night on Day 1 up to Day 28.
89433260|NCT06279286|Experimental|HS-10506, 80 milligram (mg) and placebo|Phase Ib part: Participants will receive either 80mg of HS-10506 or matching placebo at night on Day 1 up to Day 5. Phase II part: Participants will receive either 80mg of HS-10506 or matching placebo at night on Day 1 up to Day 28.
89433261|NCT06279273|Active Comparator|real tDCS|
89433262|NCT06279273|Sham Comparator|sham tDCS|
89433263|NCT06279221||Japanese participants with alopecia areata|Japanese participants with alopecia areata
89009229|NCT04710225|Active Comparator|Group 2 (Multiple injection axillary block group)|Multiple injection axillary block will be performed with the aid of a nerve stimulator. When the slight twitching of the motor response from the relevant muscles is achieved (at 0.4 mA, 2Hz, 0.1 ms) % 18-20 ml of Bupivacaine 0.5 (90-100 mg) will be injected.
89009230|NCT04709913|Active Comparator|Active Treatment: HU6 Planned doses of HU6; N = 32|Drug = HU6 HU6 is designed to reduce the steatosis, inflammation, fibrosis and hepatocyte injury in Noncirrhotic Nonalcoholic Steatohepatitis (NASH)
89009231|NCT04709913|Placebo Comparator|Placebo Comparator Non-active study drug N = 8|Placebo Comparator, non-active study drug.
89009232|NCT00199381|Experimental|Single Arm|Treatment with oral istradefylline (KW-6002) 20 or 40 mg once daily.
89009233|NCT00227006|Experimental|Taste-Based Goal Setting|6-month intervention (14 lifestyle counseling classes)
89009234|NCT00227006|Active Comparator|Smart Consumers|6-month intervention (14 lifestyle counseling classes)
89009235|NCT00227006|Active Comparator|Community Access|Can enroll in behavioral treatment programs available in the community that do not include medication or very-low calorie diets
89009236|NCT04710069|No Intervention|Control/Usual Care|standard treatment of postoperative pain, which involves automatic prescription of a narcotic pain medication regimen after surgery,
89009237|NCT04710069|Experimental|Opt-in/POINT|An opt-in program (POINT), which requires the patient to consent to receiving a prescription for narcotics
89009238|NCT04709991||Procedures with EndoNaut|
89009239|NCT04709991||Procedures without Endonaut|
89009240|NCT04709952|Active Comparator|High real stimulation group|2mA tDCS stimulation daily (42 times) for 6 weeks
89433264|NCT06279195|Experimental|Idiopathic Pelvic Pain|Participants with Idiopathic Pelvic Pain must: 1. Self-report an average non-menstrual pelvic pain rating of ≥ 4/10 (on a 0 to 10 Numeric Rating Scale) over the past 6 months. 2. Not have received a prior diagnosis attributed to a secondary cause (e.g., leiomyoma, endometriosis). Participants will be instructed to start taking Relugolix-combination therapy (40 mg of relugolix, 1 mg of estradiol, and 0.5 mg of norethindrone acetate) within 7 days of their period starting, at the same time every day for the next 6 months.
89433265|NCT06279195|Experimental|Endometriosis:|Participants with Endometriosis: 1. Must self-report an average non-menstrual pelvic pain rating of ≥ 4/10 (on a 0 to 10 Numeric Rating Scale) over the past 6 months. 2. Have a previously confirmed surgical diagnosis of stage III-IV endometriosis, indicating potential remission. Participants will be instructed to start taking Relugolix-combination therapy (40 mg of relugolix, 1 mg of estradiol, and 0.5 mg of norethindrone acetate) within 7 days of their period starting, at the same time every day for the next 6 months.
89433266|NCT06279052|Experimental|Phone interview|"Patients will then be contacted by the investigator to arrange a telephone appointment date.~On the day of the telephone appointment, the psychiatry intern will call the patient to conduct the interview which will last between 30 and 60 minutes.~At the end of the telephone interview, the patient's participation in the research will end."
89433267|NCT06279013|Active Comparator|Arm I - Interactive Voice Response (IVR) Monitoring|Patients receive IVR symptom monitoring calls once a week for 12 weeks, and a summary symptom report is sent to their provider. Call duration is approximately 15 minutes.
89433268|NCT06279013|Experimental|Arm II - Automated Telephone Symptom Management (ATSM), TIPC|Patients receive the Symptom Management and Survivorship handbook and receive IVR symptom monitoring calls for 12 weeks, with summary symptom reports sent to their provider. Call duration is approximately 20 minutes. Patients who report anxious, discouraged, or sad mood items on their monitoring calls for two consecutive weeks between weeks 1 and 4 also receive Telephone Interpersonal Counseling (TIPC) calls for up to 8 weeks. TIPC call duration is approximately 30 minutes.
89433269|NCT06279000|Experimental|Colchicine|The first dose of the IMP is administered in the evening prior to the surgical procedure. Administrations of the study drug follow a 1-0-1 schedule (colchicine 0.5 mg per intake). Thus, half a tablet is taken in the morning and half a tablet in the evening on the day of surgery and so on. The last study drug is administered in the evening of the third postoperative day.
89433270|NCT06279000|Placebo Comparator|Control (Placebo)|"Patients in the control group will receive the same perioperative anaesthetic, surgical and medical treatment as patients in the experimental group, the sole difference being that patients will be given a placebo instead of the IMP colchicine.~The first dose of the placebo is administered in the evening prior to the surgical procedure. Administrations of the placebo follow a 1-0-1 schedule. Thus, half a tablet is also taken in the morning and half a tablet in the evening on the day of surgery and so on. The last placebo is administered in the evening of the third postoperative day."
89009241|NCT04709952|Active Comparator|Low real stimulation group|1mA tDCS stimulation daily (42 times) for 6 weeks
89009242|NCT04709952|Sham Comparator|Sham stimulation group|sham stimulation daily (42 times) for 6 weeks
89009243|NCT00227123|Active Comparator|1|Quetiapine versus Risperidone
89009244|NCT00256035|Other|Unstable coronary artery disease|Patients with unstable coronary artery disease will have daily IL6 levels
89009245|NCT00256035|Other|Coronary Angioplasty Patients|Patients having coronary angioplasty will have levels taken before and immediately after the proceedure and 24 hours post.
89009246|NCT00256035|Other|Coronary bypass grafts patients|Patients will have levels collected immediately after and 24 hours post procedure
89009247|NCT00256035|Other|Stable coronary Artery Diseaese Patients|Once the patients are commenced on treatment with statins and or angiotensin converting enzyme they will have twice weekly levels taken
89009248|NCT00227162|Active Comparator|Group 1|Positive affect
89009249|NCT00227162|Active Comparator|Group 2|Self-Affirmation
89009250|NCT00227162|Active Comparator|Group 3|Positive Affect and self-affirmation
89009251|NCT00227162|No Intervention|Group 4|Control group
89009252|NCT00256074|Other|Standard Therapy Group|Standard therapy group. Will receive high carbohydrate, low fat enteral feeding, (16.7% protein, 30% fat and 53.3% carbohydrate). The target rate is determined by the treating physician and dietician, for a minimum of 5 days following randomisation.
89009253|NCT00256074|Other|Alternative Therapy Group|2.Alternative therapy group will receive high-fat, low carbohydrate enteral feeding, (16.7% protein, 55.2% fat and 28.1% carbohydrates. At a target rate determined by the treating physician and dietician, for a maximum of 5 days following randomisation.
89009254|NCT00227279|Experimental|1|
89009255|NCT00227279|Placebo Comparator|2|
89009256|NCT00227357||Buprenorphine|Study patients receiving buprenorphine treatment
89009257|NCT00227357||Comparison|Study patients receiving methadone or no agonist treatment
89009258|NCT00198133|Experimental|Pemetrexed|Pemetrexed infusion once every 21 days (one cycle).
89433271|NCT06278428||early onset developmental epileptic encephalopathy|"Select one that meets all 5 of the following criteria:~Diagnosed with EIDEE or EIMFS or ISS or SMEI or EMAS (according to ILAE's diagnostic criteria 2022)~Diagnosed with drug-resistant epilepsy according to ILAE 2010 criteria (according to ILAE's diagnostic criteria 2010)~Age at the start of participating in the study ranged from 0 to 23 months old~Relatives agree to participate in the research~There is no medical history of any diagnosis of hypoxic encephalopathy or inflammatory encephalopathy or traumatic encephalopathy or cerebral infarction or cerebral hemorrhage."
89433272|NCT06278415|Experimental|Physiological based cord clamping (PBCC)|In the intervention group, newborns will receive PBCC. The resuscitation table will place in the operating room as close as possible to the mother's pelvis. After the infant is born, the obstetrician holds the infant. Stabilization will start as soon as the infant is placed on the platform. The nurse places the oximeter sensor on the right wrist and ECG electrodes on the chest of the newborn. Local resuscitation guidelines will be in respect of the NLS-ERC 2021 guidelines. Stabilization of the newborn will be performed while the cord is intact and the cord will be clamped after respiratory stabilization will be achieved, deﬁned as the establishment of regular spontaneous breathing, a HR above 100 bpm SpO 2 above 85% while using supplemental oxygen less than 0,3.
89433273|NCT06278415|Active Comparator|Differed cord clamping (DCC)|In the control group, newborns will receive standard DCC defined as time based and performed at 60 seconds after birth. Then infants will be transferred to a standard resuscitation table located in a stabilization room next to the operating room. Further treatment and intervention required for cardiopulmonary stabilization will be provided on the standard resuscitation table. Stabilization will start as soon as the infant is placed on the resuscitation table. The nurse will place the oximeter sensor on the right wrist and ECG electrodes on the chest of the newborn. Local resuscitation guidelines will be in respect of the NLS-ERC 2021 guidelines. The time to reach the stabilisation described above (a HR above 100 bpm and SpO 2 above 85% while using supplemental oxygen less than 0,3) is recorded. Then, the infant will be placed on the mother's chest or partner's chest, or alternatively, be prepared and transferred to the transport incubator if further neonatal care is needed.
89433274|NCT06278116|Active Comparator|Water|
89433275|NCT06278116|Active Comparator|Dish soap|
89433276|NCT06278116|Active Comparator|Polident Antibacterial Denture Cleaner®|
89433277|NCT06278116|Active Comparator|Invisalign Cleaning Crystals®|
89433278|NCT06278116|Active Comparator|Geldis®|
89433279|NCT06278090||Patients treated with Ursodeoxycholic acid|Patients that recieved prescription for Ursodeoxycholic acid, 10-15 mg/kg for at least 6 months.
88913104|NCT01592981|Active Comparator|fludarabine, cyclophosphamide, rituximab|"Fludarabine:40 mg/sq m, oral, days 1,2 and 3 of each cycle. Cyclophosphamide:250 mg/sq m; oral, days 1, 2 and 3 of each cycle. Rituximab: 375 mg/sq m i.v. infusion days 1, 8, 15 and 22 of cycles 2 and 5 only.~Cycle repeated every 28 days.After 3 cycles of treatment, patients are reassessed and those with evidence of progression stop trial treatment. All other patients continue with further 3 cycles (to a total of 6) unless a clear clinical contradiction to further treatment exist."
89433280|NCT06278090||Patients not treated with Ursodeoxycholic acid|Patients without prescription of Ursodeoxycholic acid
89433281|NCT06277934|Experimental|RGT001-075 Group|Patients will receive once daily dose of study drug for a total of 12 weeks
88913105|NCT01592994|No Intervention|control|control participants received basic messages on the utility of condoms in protecting from HIV and other STIs, and they were informed about local HIV/STI counseling and testing services.
89433282|NCT06277934|Placebo Comparator|Placebo Group|Patients will receive once daily dose of matching placebo for a total of 12 weeks
89536283|NCT03209323|Experimental|sevoflurane - vital capacity|The anaesthetic circuit was prefilled with 8% sevoflurane. The patients were asked to exhale to the residual volume. Then the patients were explained to perform a vital-capacity breath with a face mask applied tightly to their faces. Then the patients were encouraged to hold their breaths as long as possible. Thereafter, the patients were asked to breathe spontaneously. Electroencephalography (EEG), bispectral index (BIS), response and state entropy (RE and SE), middle latency auditory evoked potentials (MLAEP) were monitored.
88913106|NCT01592994|Experimental|RHANI Wives Intervention|The RHANI Wives intervention included four household individual sessions and two small group community sessions delivered over 6-9 weeks. The intervention was based on Social Cognitive Theory (SCT) and the Theory of Gender and Power (TGP). SCT application supported focus on HIV/STI knowledge and condom skills building, as well as safer sex social norms and motivation. TGP guided the intervention focus on problem solving and skills building toward marital communication; embedded in this was gender equity counseling and support. The TGP approach allowed women to take a more active and assertive stance with husbands. Group sessions reinforced individual session knowledge and skills building and provided local social support.
88913107|NCT01592617|Experimental|S-488410|
88913108|NCT01593007|Experimental|Inspiratory Muscle Training|Inspiratory Muscle Training
89433283|NCT06277739|Experimental|Group1 (Spinal Manipulation Therapy)|The participant was placed in a side-lying position facing the clinician with the more painful side facing upward. The clinician passively flexed the participant's hips and knees to induce lumbar spine flexion until they felt the spinous process of the affected lumbar vertebrae begin to move. Next, the clinician passively rotated the participant's torso opposite to the side they were lying on until they felt rotation in the vertebra above the suspected lesion. The clinician applied a rapid thrust to the shoulder (anterior to posterior force) and pelvis (posterior to anterior force) resulting in a rotation force couple on the hypomobile segment.
89433284|NCT06277739|Placebo Comparator|Group2 Sham Laser Treatment)|The laser manufacturer (MedX Health Corp) provided a MedX 1100 system that did not deliver any significant amount of light energy or heat but otherwise appeared operational to participants and clinicians. The sham laser was delivered over the painful region with the study participant positioned as described for spinal manipulation and spinal mobilization treatments.
89433285|NCT06277739|No Intervention|Group3 (healthy controls)|
89433286|NCT06277648|No Intervention|Control|All patients received standard spinal anaesthesia procedures with multimodal pain protocol postoperatively.
89433287|NCT06277648|Experimental|PENG block|All patients received standard spinal anaesthesia procedures with PENG block postoperatively.
89433288|NCT06277648|Experimental|SIFI block|All patients received standard spinal anaesthesia procedures with SIFIB postoperatively.
89433289|NCT06277466|Experimental|Comparison of T2DM susceptibility gene expression between newly diagnosed T2DM patients and controls|To determine the effect of gene mutations on the susceptibility of T2DM by comparing the expression levels of T2DM susceptibility genes in newly diagnosed T2DM patients and controls.
89433290|NCT06277388||Impedance cardiography(ICG)|The ICG during 6MWT was performed before induction chemo-immunotherapy, before CCRT, and before consolidative immunotherapy for patients with locally advanced NSCLC.
89433291|NCT06277115|Other|Single arm (therapy initiation followed by therapy withdrawal)|Continuous positive airway pressure (CPAP)
89433292|NCT06276608||Pediatric cardiac surgery patients|All patients who underwent pediatric cardiac surgery in our institution between January 1, 2019 and december 31, 2023
89433293|NCT06276569|Experimental|experimental|sivelestat was dissolved in 0.9% sodium chloride injection and diluted with 50ml of the same solution to achieve a dose of 4.8mg/kg/day; this mixture was then placed in a sealed package and administered intravenously at a rate of 0.2 mg/kg/h for seven consecutive days.
89433294|NCT06276569|Placebo Comparator|placebo comparator|received an equivalent volume (50ml) of saline continuously administered intravenously at a rate of 0.2 mg/kg/hour.
89536284|NCT03209323|Experimental|propofol - intravenous induction|the patients were preoxygenated with 100% oxygen following which propofol was intravenously administered at a single dose of 2.5 mg/kg of body weight, after which it was infused with an infusion speed of 4 mg/kg body weight/h. Electroencephalography (EEG), bispectral index (BIS), response and state entropy (RE and SE), middle latency auditory evoked potentials (MLAEP) were monitored.
89536285|NCT02477969|Experimental|PEX168(100µg)|PEX168,100µg,Subcutaneous injection,once a week. Metformin,0.5mg, tid,oral.
88913109|NCT01593007|Placebo Comparator|Control group|Patients from the control group were also assessed weekly to ensure homogenization of the learning effect for the manometer maneuver.
88913110|NCT01593033|Experimental|Fish oil and Micronutrient Supplementation|
88913111|NCT01593033|Experimental|Micronutrient Supplementation|
88913112|NCT01593033|Placebo Comparator|Placebo|
88913113|NCT01593046|Experimental|Run-in Period|Oral GSK1265744 30mg once daily for 14 days
88913114|NCT01593046|Experimental|Cohort 1|GSK1265744 LAP injection given subcutaneously once a month for 4 months
88913115|NCT01593046|Experimental|Cohort 2|GSK1265744 LAP injection given intramuscularly once a month for 4 months. TMC278 LA + GSK1265744 given in Month 3 and 4.
88913116|NCT01593046|Experimental|Cohort 3|GSK1265744 LAP injection given intramuscularly once a month for 4 months. TMC278 LA + GSK1265744 given in Month 3 and 4.
88913117|NCT01593046|Experimental|Cohort 4|GSK1265744 LAP injection given intramuscularly once every 12 weeks.
88913118|NCT01593059||Orsiro DES|
88913119|NCT01593072|Active Comparator|AVI-7537|AVI-7537
88913120|NCT01593072|Other|Placebo|Normal Saline Solution (NSS)
88913121|NCT01593085||patients in palliative cares|patients with cancer in palliative cares An interview and will be offered to this patient during his hospitalization to be held (with the collection of personal and family psychiatric history of the patient, family and social context, the assessment of chronic pain and fatigue and quality of life,assessment of anxiety, Evaluation of symptoms of depression,asessment of suicide risk)
88913122|NCT01593098||Exposed siblings|Siblings (age >40 and <70) of individuals diagnosed with advanced neoplasm on screening colonoscopy. Advanced neoplasm is defined as adenomas≥10mm size, >25% villous features, severe dysplasia or carcinoma-in-situ
88913123|NCT01593098||unexposed siblings|Siblings (age >40 and <70) of individuals diagnosed with no polyp on screening colonoscopy who is age and sex matched to case.
89433295|NCT06276400|Experimental|Duration difference estimation|Participants will view emotional sequences composed of four emotional images. They will be asked to indicate whether the total duration of positive or negative emotional events was longer, by responding with a button press to a contextual cue defining the relevant action (Left vs Right button). The amount of temporal evidence in favor of one valence in a 12-s sequence is varied orthogonally with respect to the (predominant) emotional valence by varying individual picture presentation times. Participants will undergo one fMRI session and 3 TMS+fMRI sessions (2 of the TMS sessions target prefrontal (PFC) sites, and 1 targets a non-PFC control site).
89433296|NCT06276179|Experimental|Oxycodone (study group)|Patient will receive a bolus dose of 0.15 mg/kg plus 20 ml bupivacaine 0.25% followed by an infusion 0.03 mg/kg/h oxycodone plus 0.1 mL/Kg/h bupivacaine 0.125%.
89433297|NCT06276179|Active Comparator|Bupivacaine (control group)|Patient will receive a bolus 20 ml bupivacaine 0.25% followed by an infusion 0.1 mL/Kg/h bupivacaine 0.125%.
88913124|NCT01593124|Active Comparator|Imiquimod, 2 doses, vaginally|Participants first have sampling in the follicular and luteal phases of the menstrual cycle. Then participants receive 4 doses of HEC placebo gel in the luteal phase. Finally, participants are randomized to the order of IMiquimod, 2 doses vaginally, in the luteal phase and nonoxynol-9, 4%, 4 doses vaginally in the luteal phase.
88913125|NCT01593124|Placebo Comparator|Placebo|Participants first have sampling in the follicular and luteal phases of the menstrual cycle. Then participants receive 4 doses of HEC placebo gel in the luteal phase. Finally, participants are randomized to the order of IMiquimod, 2 doses vaginally, in the luteal phase and nonoxynol-9, 4%, 4 doses vaginally in the luteal phase.
89009259|NCT00197236|Active Comparator|Havrix Group|Subjects received one dose of Havrix at Day 0 followed by a second dose of Havrix at Month 6-9.
89536286|NCT02477969|Experimental|PEX168(200µg)|PEX168,200µg,Subcutaneous injection,once a week. Metformin,0.5mg, tid,oral.
89433298|NCT06276153||Gallbladder cancer|"Diagnostic criteria:~Patients with gallbladder cancer diagnosed by pathology, and combined with clinical manifestations and imaging results, the first diagnosis and discharge were diagnosed as patients with gallbladder cancer."
89433299|NCT06276140||Iron deficiency anaemia|Defined as: decreased serum iron concentration and TSAT, increased TIBC, UIBC, as well as decreased haemoglobin concentration (HGB)
89433300|NCT06276140||Iron deficiency in the latent phase|Defined as: decreased serum iron concentration and TSAT, increased TIBC, UIBC, as well as normal HGB
89433301|NCT06276140||Control group|Defined as: normal serum iron concentration, TSAT, TIBC, UIBC and HGB
88913126|NCT01593124|Active Comparator|Nonoxynol-9|Participants first have sampling in the follicular and luteal phases of the menstrual cycle. Then participants receive 4 doses of HEC placebo gel in the luteal phase. Finally, participants are randomized to the order of IMiquimod, 2 doses vaginally, in the luteal phase and nonoxynol-9, 4%, 4 doses vaginally in the luteal phase.
88913127|NCT01593137|Experimental|Liraglutide + metformin|
88913128|NCT01593137|Active Comparator|glimepiride + metformin|
88913129|NCT01593150|Experimental|Conventional|Conventional treatment Pradaxa prior to DC cardioversion
88913130|NCT01593150|Experimental|TEE|Transesophageal echo prior to DC cardioversion (early DC)
88913131|NCT01593150|Active Comparator|Early versus Late DC cardioversion|Comparing early versus late DC cardioversion. Patients randomized to either early or late DC cardioversion, follow-up time after intervention 12 month.
88913132|NCT01593163|Experimental|EchoG|Infants in the experimental group (echoG treatment) received additional doses of ibuprofen only if PDA was still ≥ 1.5 mm at the time of the corresponding ibuprofen dose.
88913133|NCT01593163|Other|ST (standard treatment)|Infants received 3 doses of ibuprofen at 24-hour intervals, independently of ductal size, as long as additional doses were not contraindicated.
88913134|NCT01593176||Distal Femur Fracture, LISS Plate|Patients presenting with a distal femur fracture requiring surgical fixation with a Less Invasive Stabilization System (LISS) plate will have placement of RSA beads for analysis.
88913135|NCT01593189|Experimental|KITS Program|The KITS intervention consists of: (a) child school readiness play groups to facilitate the development of self-regulatory, social, and early literacy skills (2 times per week in summer, 1 times per week in the fall); and (b) a bi-monthly psychoeducational support group to promote parent involvement in the child's early literacy and schooling and the use of effective parenting techniques
88913136|NCT01593189|No Intervention|Services as usual|Families continued to receive any services that they had been receiving in the community.
88913137|NCT01593267|Active Comparator|Endovascular|Subjects randomized to endovascular coil embolization will be treated by one of two neurosurgeons expert in such treatment. All endovascular coil embolization treatments will be accomplished using accepted techniques.
88913138|NCT01593267|Active Comparator|Surgical|Subjects randomized to surgical clip occlusion repair will receive treatment from one of two neurosurgeons expert in clip occlusion surgery for ruptured aneurysms.
88913139|NCT01593280|Active Comparator|TAP catheter|Indwelling TAP catheter placed at the end of c-section. It will be dosed with 20ml of Ropivacaine 0.5% at that time. Double lumen OnQ C-block pump containing 700 ml of the Ropivacaine 0.2% will be attached to the TAP catheters in the recovery room. The catheters will run at 7cc/hr/side for 50 hrs.
88913140|NCT01593280|Active Comparator|intrathecal morphine|0.3 mg of intrathecal morphine
89433302|NCT06276062|Experimental|pediatric distal radial fractures.|Pediatric traumatized patients aged between 4 to 16 years old who presented by distal radial fractures and need to go under operative management.
89433303|NCT06275776|Active Comparator|Monocryl Smooth Suture|Study arm consisting of participants receiving Monocryl Smooth Suture for closure of the superficial skin. Monofilament suture, placed subcutaneously to approximate the wound edges. Currently used in standard care.
89433304|NCT06275776|Active Comparator|Vicryl Rapide + Indermil|Study arm consisting of participants receiving Vicryl Rapide Braided Suture in combination with Indermil Topical Skin Adhesive for closure of the superficial skin. Multifilament suture, placed subcutaneously to approximate the wound edges. Skin glue is applied after the application of the suture to further seal the wound from the external environment. Currently used in standard care.
88913141|NCT01593293|Active Comparator|PemCarbo|Pemetrexed/Carboplatin arm
88913142|NCT01593293|Active Comparator|Pem only|Pemetrexed arm
88913143|NCT01593306|Experimental|cisplatin and paclitaxel with concurrent radiotherapy|weekly cisplatin at 30mg/m2 and paclitaxel at 50mg/m2 are given with concurrent radiotherapy at 2Gy per fraction at 5 fractions per week for 5 weeks followed by either low dose rate (LDR) Intracavitary (I/C) Brachytherapy or supplement Chemoradiotherapy (CRT); if not fit for I/C Brachytherapy
89536287|NCT02477969|Placebo Comparator|Placebo|Placebo,0.5ml,Subcutaneous injection,once a week. Metformin,0.5mg, tid,oral.
89536288|NCT03195205|Other|High-Risk Patients|OraQuick HCV screening for HCV-Infected Individuals on Opioid Substitution Therapy and High-Risk Populations
88913144|NCT01593306|Active Comparator|cisplatin with concurrent radiotherapy|weekly cisplatin @ 40mg/m2 is given along with concurrent radiotherapy at 2Gy per fraction with 5 fractions per week for 5 weeks followed by LDR I/C brachytherapy or supplement CRT; if not fit for I/C Brachytherapy
88913145|NCT01593319|Active Comparator|ropivacaine|
88913146|NCT01593319|Placebo Comparator|Natrium chloride|
88913147|NCT01593332|Active Comparator|Rituximab|
89009260|NCT00197236|Experimental|Infanrix + ActHIB→Havrix Group|Subjects received Infanrix co-administered with ActHIB at Day 0, followed by one dose of Havix at Day 30 and a second dose of Havrix at Month 7-10.
89009261|NCT00197236|Active Comparator|Havrix + Infanrix + ActHIB Group|Subjects received one dose of Havrix co-administered with Infanrix and ActHIB vaccines at Day 0 followed by a second dose of Havrix at Month 6-9.
89433305|NCT06275776|Experimental|Dermabond Prineo|Study arm consisting of participants receiving Dermabond Prineo Skin Closure System for closure of the superficial skin. Relatively novel skin closure system consisting of a self-adhesive transparent mesh, over which skin glue is applied as well. This system approximates the wound edges, shields the wound from the external environment, enables healthcare professionals to still be able to see the wound and surrounding tissue, and eliminates the invasive aspect of conventional sutures. Currently not used in standard care at the RHOC, but elsewhere it is being used.
89433306|NCT06275776|Experimental|Stryker Zip|Study arm consisting of participants receiving Stryker Zip Skin Closure System for closure of the superficial skin. Relatively novel skin closure system consisting of two self-adhesive strips placed parallel to either side of the wound. Zip tie/Cable tie-like structures running perpendicular to the adhesive strips can be tightened to approximate the wound edges and thusly close the wound. This system enables healthcare professionals to still see the wound and surrounding tissue, and eliminates the invasive aspect of conventional sutures. Currently not used in standard care at the RHOC, but elsewhere it is being used.
89009262|NCT00256152|No Intervention|AF Suppression OFF|
89009263|NCT00256152|Experimental|AF Suppression ON|
89433307|NCT06275451||Semi-structured interview|Semi-structured interview
89433308|NCT06275165|Experimental|acupressure|Participants received routine care and acupressure.
89433309|NCT06275165|No Intervention|no intervision|received routine care
89433310|NCT06274684|Experimental|Virtual Reality assistance group|Patient receiving VR headset during prostate biopsies
89433311|NCT06274684|No Intervention|Control group|
89433312|NCT06274320|Active Comparator|Group A: holistic approach|adult subjects having AK (grade I or II) lesions on the scalp and meeting specific inclusion/exclusion criteria including a Tolak® treatment planned before study start
89433313|NCT06274320|Active Comparator|Group B: Tolak® Standard of use|adult subjects having AK (grade I or II) lesions on the scalp and meeting specific inclusion/exclusion criteria including a Tolak® treatment planned before study start
89433314|NCT06270953||Obervational group|Patients admitted in the SNF facility during the study period
89433315|NCT06270953||Control group|Historical control with patients admitted in the SNF before the study period
89433316|NCT06270355|Experimental|Experimental arm|Women randomised to the experimental arm / individualised screening will have their 2-year breast cancer risk assessed upfront. This is done via an AI (artificial intelligence) derived analyses of the mammograms. Women scored with the highest 2-year risk will be offered a contrast enhanced mammography and an additional mammography at 12 months.
89433317|NCT06270355|Active Comparator|No intervention arm|The 35,000 women randomised to the no intervention arm will continue in the Swedish National Breast Cancer Screening Program. This means that they are invited for the next mammography screening after 24 months.
89433318|NCT06269601|Other|adolescent male basketball players|14-16 years adolescent male basketball players
89433319|NCT06269328|Active Comparator|TIVA group|Patients will be anesthetized with total ıntravenous anesthesia by propofol and remifentanyl infusion. End of the procedure all patients will be extubated and awakened in the operating room. İntravenous morphine patient-controlled analgesia will be used in the postoperative period.
89433320|NCT06269328|Active Comparator|İnhalation group|Patients will be anesthetized with induction of propofol and sevoflurane (inhalational agent) will be used for maintenance. End of the procedure all patients will be extubated and awakened in the operating room. İntravenous morphine patient-controlled analgesia will be used in the postoperative period.
89433321|NCT06268002|Experimental|Vernonia cinerea group|1 lozenges 3 times per day
89433322|NCT06268002|Placebo Comparator|Placebo group|1 placebo lozenges 3 times per day
89433323|NCT06267859|No Intervention|First stage|"Study of children from the group of frequently ill children, and with congenital diseases, collection of anamnesis, their examination, clinical and laboratory examination. Purpose: to identify the most frequently encountered group of diseases among children."
89433324|NCT06267859|No Intervention|Second stage|Study the effectiveness of treatment according to approved treatment standards
89009264|NCT00227513|Experimental|Arm I|"Patients receive oral vorinostat (SAHA) twice daily on days 1-14 in step A. Patients receive oral vorinostat (SAHA) twice daily on days 1-4 and 8-11 in Step B and bortezomib IV over 3-5 seconds on days 2, 5, 9, and 12 during the first course and on days 1, 4, 8, and 11 during subsequent courses in both steps A and B. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 1-6 patients receive escalating doses of bortezomib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Up to 6 additional patients receive bortezomib at the MTD. Subsequent cohorts of 3-6 patients receive escalating doses of SAHA until the MTD of that drug is determined."
89009265|NCT04709445|Experimental|ICG-NIRF Imaging and objective perfusion rate|Intraoperatively, ICG-NIRF imaging is used to visualize the blood supply and the rate of tissue perfusion in the area of the anastomotic site. Postoperatively, an additional ingress and egress analysis at specific regions of interest is performed.
89009266|NCT00256230|Experimental|Disulfiram|
89009267|NCT00227669|Active Comparator|Arm I: Gemcitabine|"Gemcitabine at Day 1, Day 8 and Day 15. No treatment at Day 22.~1 cycle = 28 days.~Treatment duration: 8 months"
89009268|NCT00227669|Experimental|Arm II: Gemcitabine + Docetaxel|"Gemcitabine at Day 1 and Day 8. No treatment at Day 15. Docetaxel at Day 8.~1 cycle = 21 days.~Treatment duration: 6 months"
89009269|NCT00256269|Experimental|Oxaliplatin plus Irinotecan|Drug: Oxaliplatin-40 mg/m2 IV over 60 minutes Every 21 days. Drug: Irinotecan-60 mg/m2 IV over 60 minutes, immediately following oxaliplatin Every 21 days.
89009270|NCT00197002|Active Comparator|Havrix Group|Healthy male or female subjects, 15 months of age, who received Havrix® vaccine administered intramuscularly in the right anterolateral thigh, at Day 0 and at Month 6-9.
89009271|NCT00197002|Experimental|Havrix+Prevnar Group|Healthy male or female subjects, 15 months of age, who received Havrix® and Prevnar™ vaccines co-administered intramuscularly in the right and left anterolateral thighs, respectively, at Day 0 and Havrix® vaccine administered intramuscularly in the right anterolateral thigh, at Month 6-9.
89433325|NCT06267859|No Intervention|third stage|Based on the research results, develop your treatment tactics. It is approved by the Ethics Committee for working with patients.
89009272|NCT00197002|Active Comparator|Prevnar Havrix Group|Healthy male or female subjects, 15 months of age, who received Prevnar™ vaccine administered intramuscularly in the left anterolateral thigh, at Day 0 and Havrix® vaccine, administered intramuscularly in the right anterolateral thigh, at Day 30 and at Month 7-10.
89009273|NCT00196105|Experimental|6 mm Zilver|6 mm Nitinol Zilver Stent
89009274|NCT00196105|Experimental|10 mm Zilver|10 mm Nitinol Zilver Stent
89009275|NCT00196105|Active Comparator|10 mm Wallstent|10 mm Stainless Steel Wallstent
89009276|NCT04722068|Experimental|Volunteers with known HoFH and particpated in R1500-CL-1331 clinical trial|
89433326|NCT06267859|Experimental|fourth stage|Use your treatment tactics among a group of patients. Study the effectiveness of the proposed therapy and rehabilitation methods.
89433327|NCT06267859|No Intervention|fifth stage|Based on the research data, clinical recommendations for doctors will be developed.
89433328|NCT06267716|Active Comparator|PENG block|Immediately after the insurance of general anaesthesia and LFCN block application, PENG block was performed by the primary investigator (B.C) following proper skin disinfection with the patient in the supine position. Under the guidance of a low-frequency curvilinear ultrasound probe, the iliopubic eminence and the psoas tendon were identified, and local anaesthetic (20 ml 0,375% bupivacaine) was injected between the periosteum and psoas tendon following negative aspiration.
89009277|NCT00227747|Experimental|Radiothérapie + Xelox|
89009278|NCT00227747|Active Comparator|Radiothérapie + Capécitabine|
89009279|NCT02962089|Placebo Comparator|Placebo|Isocaloric isonitrogenous placebo for 4 months (7g, twice daily)
89009280|NCT02962089|Active Comparator|Branched chain amino acids (BCAA)|BCAA mixture for 4 months (7g, twice daily)
89009281|NCT00227864|Placebo Comparator|Treatment as Usual|Participants are administered assessments at baseline, 1, 3 and 6 months
89009282|NCT00227864|Experimental|Intervention|Participants complete assessments at baseline, 1, 3 and 6 months, and receive a 2-session behavioral intervention at the baseline and 1-month study appointments.
89009283|NCT04721990|Experimental|Automatic Sound Management 3.0|Current SONNETEAS listeners, who meet the eligibility criteria, will be tested with their current listening configuration and also fit with a SONNET2EAS, programmed with Automatic Sound Management 3.0 (under the Investigational Device Exemption).
89009284|NCT00227942|Experimental|1|Participants will receive estrogen replacement therapy
89009285|NCT00227942|Experimental|2|Participants will receive treatment with zolpidem
89009286|NCT00227942|Placebo Comparator|3|Participants will receive treatment with placebo
89009287|NCT00256503|Experimental|Insomnia|Insomnia subjects who receive 8 session cognitive behavioral therapy for insomnia.
89009288|NCT00256503|No Intervention|Good Sleeper|Good sleeper controls who receive no intervention
89009289|NCT00228020|Experimental|Basiliximab|Patients will be on a regimen of Basiliximab, MMF, cyclosporine and steroids
89009290|NCT00228020|Active Comparator|Basiliximab-free|Patients will be on a regimen of MMF, cyclosporine and steroids.
89009291|NCT00413543|Experimental|interventional, rehabilitation|'early pulmonary lung rehabilitation'
89009292|NCT00413543|No Intervention|control|"standard care"
89009293|NCT00228215|No Intervention|Usual care|
89009294|NCT00228215|Experimental|TIPS Intervention|
89009295|NCT00195676|Other|Adalimumab|
89009296|NCT00194077|Active Comparator|Aripiprazole|Phase I and Phase III are open label Abilify phases where all subjects receive active Abilify
89009297|NCT00194077|Placebo Comparator|Placebo|in Phase 2 subjects are randomized to either placebo or abilify for up to 72 weeks
89009298|NCT00228371|Other|1|The stimulator is switch ON during the first phase of the cross-over and switch OFF during the second phase
89009299|NCT00228371|Other|2|The stimulator is switch OFF during the first phase of the cross-over and switch ON during the second phase
89009300|NCT00193609|Experimental|Oxaliplatin/Capecitabine|All patients received treatment with oxaliplatin 130mg/m2, given intravenously on day 1 of each 21 day cycle. Capecitabine 1000mg/m2 by mouth twice daily was administered on days 1-14 of each cycle.
89433329|NCT06267716|Experimental|IPP block|After ensuring aseptic conditions, the low-frequency curvilinear ultrasound probe was transversely placed caudad to the anterior superior iliac spine, then rotated anticlockwise and slid along the inguinal ligament to detect the head of the femur, as described by Nielsen et al. The primary investigator (B.C.) directed the needle tip into the iliopsoas plane between the iliopsoas muscle and iliofemoral ligament through an in-plane approach, and 10 ml of 0,375% bupivacaine was injected.
89433330|NCT06267300|Experimental|Hyperbaric Oxygen therapy|40 sessions of HBOT at 2.4 ATM
89433331|NCT06267300|No Intervention|Standard care|
89433332|NCT06267092|Other|Part A|Participants will not get any medicine during this study.
89433333|NCT06267092|Experimental|Part B|Participants will receive CagriSema or placebo (Dose 1,2,3,4) for 16-weeks dose-escalation period followed by 37-weeks intervention period on CagriSema or placebo (Dose 5) that includes a 12-day standardised energy intake period.
89433334|NCT06266455|Active Comparator|Standardized Fortification|"All study participants will undergo feed advancement and fortification with liquid, bovine-based human milk fortifier (HMF) to an assumed human milk content of 24kcal/oz per the Children's National Hospital NICU standardized clinical feeding protocol. The same milk fortification recipes are utilized for mother's own milk (MOM) and donor human milk (DHM). Each infant's growth trajectory is monitored (weight, length, and head circumference) with dietary modifications performed as needed based on growth parameters.~Growth failure is defined as a decline in weight-for-age z-score by greater than 1 standard deviation (>1 SD) beginning 1 week after reaching goal fortified feeds. For infants who demonstrate growth failure, Step 1 will be to add medium chain triglyceride (MCT) oil. If growth remains sub-optimal, Step 2 will be to add liquid protein."
89536289|NCT02481401|No Intervention|Control Arm|Will not receive any structured program except for the health promotion education program that the children will receive for 4 months. Complementary to the Si! Program. This is essentially healthy habits related information and activities to be performed with their kids through family newsletters. All participants (including controls) have access to the study website for health related information.
88913148|NCT01593332|Active Comparator|Methotrexate|
88913149|NCT01593345|Experimental|Mentor|
88913150|NCT01593345|Active Comparator|Guidebook|
88913151|NCT01593371|Active Comparator|Metformin|patients receiving fixed dose metformin 1000 mg daily
88913152|NCT01593371|Active Comparator|Pioglitazone|patients receiving fixed dose pioglitazone 30 mg daily
88913153|NCT01593397|Experimental|Propofol and Fentanyl administration|Propofol and Fentanyl will be administered to all subjects. All subjects will have blood drawn to determine pharmacokinetic variables. Processed EEG will be used to determine pharmacodynamics. Plasma samples will be used to ascertain adiponectin levels and for DNA sampling for analysis of adiponectin single nucleotide polymorphisms.
88913154|NCT01593410|Experimental|Lenalidomide and dexamethasone|Cycle 1: 25 mg oral lenalidomide once daily on Days 1-21 every 28 Days and 40 mg oral dexamethasone on Days 8, 15, and 22. Cycle 2 and beyond: 25 oral lenalidomide once daily on Days 1-21 every 28 days and 40 mg oral dexamethasone once daily on Days 1, 8, 15, and 22.
88913155|NCT01593436|Active Comparator|mindfulness training|mindfulness training for patients with insomnia
88913156|NCT01593436|No Intervention|polysomnography and actigraphy|The intention is to assess the sleep architecture of meditators and non meditators women without menopausal insomnia by polysomnographic , actigraphy, and questionnaires to assess sleep quality and emotional state
88913157|NCT01593449|Active Comparator|American Heart Association|Participants will receive handouts on increasing physical activity derived from the American Heart Association materials on increasing physical activity.
88913158|NCT01593449|Experimental|Dog Walking|The 6-month dog walking intervention involves 5 components to address the individual, interpersonal and community levels of the socio-ecological model: newsletters, pedometers, social networking website, neighborhood dog walks, and invitations to community events.
88913159|NCT01593462|Experimental|Pediatric Small Bowel Crohn's Disease|MRE (magnetic resonance enterography) performed 4 weeks after SBCD treatment begins, or ends or treatment changes, or at 6 months whichever comes first. One research MRE will be performed and one MRE may or may not be performed as part of your routine care.
88913160|NCT01593475|Experimental|Induction chemotherapy followed by CCRT|"In one cycle (4-weeks), gemcitabine 1,000 mg/m2 will be given by 30-minute intravenous infusion on days 1, 8, and 15, and 1 hour infusion of CDDP was administered at a dose of 25 mg/m2 weekly diluted in 500 mL of normal saline to ensure adequate hydration 1 hour before the administration of gemcitabine. Gemcitabine 300mg/m2 will be given by 30-minute intravenous infusion weekly during RT and CRT will be started within 3 weeks after completion of 2 cycles of induction chemotherapy.~Radiotherapy~- Total dose of PGTV and PCTV were 55 Gy, 22 fractions and 44 Gy, 22 fractions, respectively."
88913161|NCT01593501|Active Comparator|High dose vitamin D|50,000 IU vitamin D3 every 15 days, with a loading dose of 50,000 IU per day for the first 15 days of an approximate 365-day treatment.
88913162|NCT01593501|Active Comparator|Low dose vitamin D|800 IU vitamin D3 every day of an approximate 365-day treatment.
88913163|NCT01593501|Placebo Comparator|Placebo|A pill that looks like the low/high dose vitamin D pills, but contains no vitamin D. Given to preserve the double-blind nature of the study.
88913164|NCT01593514|Active Comparator|Group 1 Conjugate-conjugate|Group I will receive 2 doses of the MenACWY-CRM conjugate vaccine (Novartis Vaccines) given 1 month apart. All vaccine doses are 0.5ml and will be administered intramuscularly into the deltoid.
88913165|NCT01593514|Experimental|Group 2 Polysaccharide-conjugate|"Group II will receive one full dose of MenACWY-PS polysaccharide vaccine meningococcal vaccine, followed by one dose of MenACWY-CRM conjugate vaccine given 1 month later.~0.5 mL of MenACWY-PS vaccine will be administered subcutaneously and 0.5 mL of the MenACWY-CRM vaccine will be administered intramuscularly into the deltoid."
88913166|NCT01593514|Experimental|Group 3 Polysaccharide (subcutaneously)-conjugate|Group III will receive a full dose of MenACWY-PS polysaccharide vaccine meningococcal vaccine subcutaneously, followed by one dose of MenACWY-CRM conjugate vaccine given 1 month later.
89009301|NCT00228449|Experimental|Cohort 1|Conversion from epoetin alfa to peginesatide with a conversion factor (CF) of 0.033: peginesatide dose administered intravenously once every 4 weeks (Q4W) for a total of up to 6 doses. No transition period between epoetin treatment and start of peginesatide treatment.
89009302|NCT00228449|Experimental|Cohort 2|Conversion from epoetin alfa to peginesatide with a CF of 0.041: peginesatide dose administered intravenously Q4W for a total of 6 doses. No transition period between epoetin treatment and start of peginesatide treatment.
89433335|NCT06266455|Experimental|Adjustable|"Adjustable fortification will begin 1 week after tolerating goal feeds of standardized fortification. Blood urea nitrogen (BUN) level as a marker of protein metabolism will be measured weekly, and supplementation with liquid protein will be adjusted as necessary to maintain a goal BUN level between 9-14mmol/dL, up to a maximum assumed protein intake of 4.5 g/kg/day. Liquid protein supplementation will be modified as follows:~BUN Level <9 mmol/dL: Increase by 0.5g/kg/day~BUN Level 9-14 mmol/dL: No change~BUN Level >14 mmol/dL: Decrease by 0.25g/kg/day~BUN Level >20 mmol/dL: Hold for 1 week and re-assess~Growth failure is defined as a decline in weight-for-age z-score by >1 SD beginning 1 week after achieving BUN within goal range from adjustable fortification. For infants who demonstrate growth failure, MCT oil will be added and increased weekly as needed."
89433336|NCT06266455|Experimental|Targeted|"Targeted fortification will begin 1 week after tolerating goal feeds of standardized fortification. Additional supplementation with liquid protein and/or MCT oil will be provided based on twice weekly milk analysis using a mid-infrared human milk analyzer in order to meet macronutrient (carbohydrate, protein, lipid) and energy intake goals per pediatric nutrition guidelines (protein 4-4.5g/kg/day, fat 6-8g/kg/day, energy 120-130kcal/kg/day).~Growth failure is defined as a decline in weight-for-age z-score by >1 SD beginning 1 week after receiving macronutrient and energy intake within goal range from targeted fortification. For infants with growth failure, total energy intake will be increased with additional protein and/or MCT oil supplementation. Energy intake may be increased weekly as needed."
89009303|NCT00228449|Experimental|Cohort 3|Conversion from epoetin alfa to peginesatide with a CF of 0.050: peginesatide dose administered intravenously Q4W for a total of 6 doses. No transition period between epoetin treatment and start of peginesatide treatment.
89009304|NCT00228449|Experimental|Cohorts 4 and 9|Conversion from epoetin alfa to peginesatide with a CF of 0.050: peginesatide dose administered intravenously Q4W for a total of 6 doses. With transition period between epoetin treatment and start of peginesatide treatment.
89433337|NCT06264921|Experimental|Dose Escalation|Dose escalation will assess the safety, efficacy, and PK/PD data of oral dosing NKT3447 at increasing dosage levels to determine the MTD and/or preliminary RDEs.
89009305|NCT00228449|Experimental|Cohort 5|Conversion from epoetin alfa to peginesatide with a CF of 0.066: peginesatide dose administered intravenously Q4W for a total of 6 doses. With transition period between epoetin treatment and start of peginesatide treatment.
89009306|NCT00228449|Experimental|Cohort 6|Conversion from epoetin alfa to peginesatide with tiered peginesatide starting doses of 0.05, 0.075, 0.1 or 0.15 mg/kg based on total weekly doses of epoetin alfa . Doses were administered intravenously Q4W for a total of 6 doses. With transition period between epoetin treatment and start of peginesatide treatment.
89009307|NCT00228449|Experimental|Cohorts 7 and 8|Conversion from epoetin alfa to peginesatide with tiered peginesatide starting doses of 0.05, 0.075, 0.1 or 0.15 mg/kg based on total weekly doses of epoetin alfa dose. Doses were administered intravenously Q4W for a total of 6 doses. No transition period between epoetin treatment and start of peginesatide treatment.
89009308|NCT00228449|Experimental|Cohorts 10 and 11|Conversion from epoetin alfa to peginesatide with fixed peginesatide starting doses of 4, 6, 12 or 16 mg based on total weekly doses of epoetin alfa. Doses were administered intravenously Q4W for a total of 6 doses. No transition period between epoetin treatment and start of peginesatide treatment.
89009309|NCT00193180|Experimental|Intervention|All patients in this study received docetaxel 30 mg/m2 weekly for 3 consecutive weeks of each 28-day cycle, along with continuous imatinib mesylate. Initially, imatinib mesylate was given at a dose of 600 mg orally daily, beginning concurrently with the first dose of docetaxel; however, after the first 15 patients were treated it became evident that this imatinib dose was not tolerable, and subsequent patients received imatinib mesylate 400 mg orally daily.
89009310|NCT00193063|Experimental|Intervention|All patients entering this trial received treatment with a combination of gemcitabine and trastuzumab. Gemcitabine 1000 mg/m2 was administered intravenously on days 1, 8,and 15 of a 28-day cycle. Trastuzumab was administered as a 4 mg/kg intravenous loading dose on day 1 and subsequently at a dose of 2 mg/kg on a weekly basis.
89009311|NCT00191854|Experimental|Gemcitabine + Paclitaxel|"gemcitabine: 2500 milligrams per square meter (mg/m2), intravenous (IV), every 14 days x 8 cycles.~paclitaxel: 150 mg/m2, IV, every 14 days x 8 cycles."
89009312|NCT00191854|Experimental|Gemcitabine + Carboplatin|"gemcitabine: 2500 milligrams per square meter (mg/m2), intravenous (IV), every 14 days x 8 cycles.~carboplatin: Area Under the Curve (AUC) 2.5, IV, every 14 days x 8 cycles."
89009313|NCT00191854|Experimental|Gemcitabine + Cisplatin|"gemcitabine: 2500 milligrams per square meter (mg/m2), intravenous (IV), every 14 days x 8 cycles.~cisplatin: 50 mg/m2, IV, every 14 days x 8 cycles"
89009314|NCT00191815|Experimental|Gemcitabine + Cisplatin|
89009315|NCT00191386|Experimental|Atomoxetine|0.5 milligrams per kilogram (mg/kg) twice daily (BID), orally (PO) titrated to 1.2 mg/kg BID, PO over 2 weeks then 1.2 to 1.8 mg/kg BID, PO for 6 months and up to 4 years
89433338|NCT06264921|Experimental|Dose Expansion|Dose expansion will include 2 RDEs selected to determine the preliminary antitumor activity and the RP2D.
89433339|NCT06264336|Experimental|High-intensity interval treadmill training|Walking with high intensity intervals interspersed.
89433340|NCT06264336|Active Comparator|Moderate-intensity continuous treadmill training|Continuous walking at a moderate intensity
89433341|NCT06263946|Other|Essilor® Stellest® spectacle lenses|patients will be asked to wear Essilor® Stellest® spectacle lenses for a full time wear (>12 hours daily) for 24 months
89433342|NCT06263907|Experimental|Stellate gangalion block group (Group S)|Patients will receive ipsilateral stellate gangalion block (4ml) bupivacaine 0.25 %+( 4ml) normal saline + (8mg) dexamethasone in a total 10 ml
89433343|NCT06263907|No Intervention|Control group (Group C)|Patients will not receive stellate gangalion block
89433344|NCT06263634|Experimental|Home exercises group|The intervention group will perform 30-45 minutes of home exercises consisting of stretching, mobility and strengthening, 4 days a week for 8 weeks, and the patients' compliance with the exercise will be monitored by phone call once a week.
89433345|NCT06263634|No Intervention|Control group|Patients in the control group will be on the waiting list and will be taught hand exercises when the program ends.
89009316|NCT00191308|Experimental|Pemetrexed + Cisplatin|"Pemetrexed: 500 milligrams per square meter (mg/m^2) intravenous (IV) every 21 days (q 21 days) for 3 cycles unless disease progression occurs~Cisplatin: 75 mg/m^2 IV q 21 days for 3 cycles unless disease progression occurs"
89009317|NCT00191269|Experimental|A|Dose Level 1 - 1000 mg/m2
89009318|NCT00191269|Experimental|B|Dose Level 2 - 1250 mg/m2
89009319|NCT00228878|Experimental|Effects of Pulsatile IV insulin on QoL|Effects of Pulsatile IV insulin on Diabetic Quality of Life
89009320|NCT00413946|Experimental|Erythropoietin|Three doses of rErythropoietin (3000 U/kg body weight) intravenously at 3, 12-18 and 36-42 hours after birth.
89009321|NCT00413946|Placebo Comparator|saline|Three doses of placebo (0.9% saline 1 ml/kg body weight) intravenously at 3, 12-18 and 36-42 hours after birth
89009322|NCT00191191|Experimental|Pemetrexed 500 mg/m2|Pemetrexed 500 mg/m2
89009323|NCT00191191|Experimental|Pemetrexed 1000 mg/m2|Pemetrexed 1000 mg/m2
89433346|NCT06263101||Biomarker-group|We considered for the study all patients diagnosed with colorectal cancer through preoperative colonoscopy, aged 18-80, underwent laparoscopic radical resection with confirmed pathology, without prior radiotherapy, chemotherapy, or immunotherapy, and voluntarily participated in and signed informed consent for the study, collected indicators of inflammation in the peripheral blood and post-operative drainage fluid of enrolled patients on post-operative days 1 and 3.
89433347|NCT06261853|Experimental|3D-CBCT Scan|The surgeons will only utilise the 3D-CBCT scan of their patient during wisdom tooth surgery. The patient should observe no difference in their care in this arm of the trial on the day of surgery as they wouldn't typically be aware of which image was being viewed
89009324|NCT00229151|Experimental|Sleep deprivation|Sleep deprivation and sleep phase advancement
89009325|NCT00229151|Active Comparator|usual treatment|
89433348|NCT06261853|Active Comparator|2D-OPG X-ray|The surgeons will only utilise the 2D-OPG X-ray of their patient during wisdom tooth surgery. The patient should observe no difference in their care in this arm of the trial on the day of surgery as they wouldn't typically be aware of which image was being viewed
89009326|NCT00229229|Other|1|Low glycemic load diet
89009327|NCT00229229|Other|2|Canada Food Guide Diet
89433349|NCT06261749||Healthy individuals|"Inclusion criteria:~18-30 age Physical activity level should be at least 5 according to Tegner activity scale"
89433350|NCT06261398|Experimental|BETTER Intervention|Patients in the intervention group will receive one motivational interviewing session immediately after randomization and biweekly text messages until delivery to encourage them to connect to resources to address their social needs.
89009328|NCT00229229|Other|3|Low glycemic index diet
89009329|NCT00229229|Other|4|Low carbohydrate diet
89009330|NCT00414102|Experimental|Ramelteon 8 mg QD|
89009331|NCT00414102|Placebo Comparator|Placebo QD|
89009332|NCT00229307|Active Comparator|1|
89009333|NCT00229307|Active Comparator|2|
89009334|NCT00229385|Active Comparator|1|
89009335|NCT00229385|Active Comparator|2|
89009336|NCT00236223|Experimental|1|
89009337|NCT00236223|Placebo Comparator|2|
89009338|NCT00229424|Experimental|1|Lafutidine group
89009339|NCT00229424|Active Comparator|2|Famotidine group
89009340|NCT00229424|Placebo Comparator|3|Placebo group
89009341|NCT00256932|Placebo Comparator|Placebo|
89009342|NCT00256932|Experimental|Alvimopan 0.5 mg once daily|
89009343|NCT00256932|Experimental|alvimopan 0.5 mg twice daily|
89009344|NCT00229502||1|Subjects receiving Avonex
89433351|NCT06261398|Active Comparator|Standard of care|No motivational interviewing or text messages will be provided.
89433352|NCT06259292||HHT patients|Those diagnosed with HHT based on the Curacao diagnostic criteria or genetic testing
89433353|NCT06258291|Experimental|Treatment arm|The REBOOT Hemosystem will be tested in the treatment arm for a maximum of 5 treatments, the treatment will be applied in addition to standard of care alone.
89433354|NCT06258291|No Intervention|Standard of care|Best standard of care will be applied to these patients.
89433355|NCT06256575|Active Comparator|Active|diosmin xxx mg, plus diosmetin xxx mg, one (1) capsule, two (2) times per day for eight (8) weeks
89009345|NCT00229502||2|Subjects receiving Rebif
89009346|NCT00229502||3|Subjects receiving Copaxone
89009347|NCT00229502||4|Healthy controls
89009348|NCT00229541|Experimental|IG|intervention group, receives counselling on medical inpatient rehabilitation by statutory health insurance, is intended to apply for a 3-wek medical inpatient rehabilitation at the co-operating clinic (Bad Bramstedt)
89433356|NCT06256575|Placebo Comparator|Placebo|cornstarch, xxx mg, one (1) capsule, two (2) times per day for eight (8)
89009349|NCT00229541|No Intervention|KG|control group, receives usual care
89009350|NCT00191152|Experimental|Gemcitabine + Docetaxel|
89009351|NCT00191152|Active Comparator|Capecitabine + Docetaxel|
89009352|NCT00229580|Experimental|1|Motivational feedback
89433357|NCT06254677||Acute tubular injury (ATI) only|Kidney biopsy with features of acute tubular injury only, no other pathology detected
89433358|NCT06254677||Concurrent diagnosis of acute tubular injury with any other pathology|Kidney biopsy with features of acute tubular injury AND other pathology. Non-ATI pathology includes but not limited to diagnosis of any type of glomerulonephritis, vasculitis, hereditary nephritis, thrombotic microangiopathy, kidney transplant rejection, podocytopathy, diabetic or hypertensive nephropathy, interstitial nephritis, pyelonephritis, amyloidosis, malignancy or paraneoplastic related kidney disease.
89009353|NCT00229580|Active Comparator|2|treatment as usual
89009354|NCT01059188|Experimental|Cetuximab, Cisplatin, Docetaxel, Radiotherapy and Surgery|
89009355|NCT00236301|Active Comparator|1|17 Beta-estradiol (2mg/day)and (1mg/day)
89009356|NCT00236301|Active Comparator|2|CLIMASTON
89009357|NCT00236301|Placebo Comparator|3|placebo
89009358|NCT00229697|Experimental|1|ZD1839 + Nolvadex
89009359|NCT00229697|Other|2|Nolvadex + placebo
89009360|NCT00236379|Experimental|001|Risperidone Target oral dose of 6 milligrams per day for for 6 months
89009361|NCT00236379|Experimental|002|Olanzapine Target oral dose of 20 milligrams per day for 6 months
89009362|NCT00229736|Experimental|AAV-hAADC-2 (9x10^10 vector genomes)|
89009363|NCT00229736|Experimental|AAV-hAADC-2 (3x10^11 vector genomes)|
89009364|NCT00257127|Experimental|1|Patients will receive PCV, HBV, and MMR at study entry
89009365|NCT00257127|Experimental|2|Patients will receive PPV, HBV, and MMR at study entry
89009366|NCT00190684|Experimental|Atomoxetine|Atomoxetine-naive patients will have an acute titration to a stable dose, atomoxetine experienced patients whose therapy has been interrupted with be rapidly titrated to their previously established stable dose, and atomoxetine patients on a known stable dose may continue treatment at that dose.
89009367|NCT04721834|Active Comparator|Low-intensity ESWT|Patient would be positioned in a supine position. Shockwaves would be delivered to the stretched penis at proximal, mid and distal penile shaft and bilateral crura of penis. (Energy: 0.1-0.25 mJ/mm2; 3000pulses per session; Frequency 3Hz) Treatment consists of 6 sessions over 5 weeks in total. It would be a twice-weekly treatment with one-week interval of resting period. Patient would be discharged home after each treatment session.
89009368|NCT04721834|Sham Comparator|Sham ESWT|Sham therapy would be given with a modified probe which no shockwave would be emitted. A working noise would still be generated which mimicked active treatment.
89433359|NCT06254677||Biopsies with no acute tubular injury (neg control)|Kidney biopsy with any diagnosis other than (no features of) acute tubular injury
89433360|NCT06254105|Experimental|Intervention group|Receive the HANDY programme
89433361|NCT06252402|Experimental|Dose Level -1|EGFR+ T Cell Dose (Day 0) 5 x 10^6 cells
89009369|NCT00193219|Experimental|Intervention|"Bevacizumab 5 mg/kg IV~Cetuximab 400 mg/m2 (first cycle only) IV on day 1 and 250 mg/m2 IV on day 8 with all subsequent cycles 250 mg/m2 IV on days 1 and 8~5-Fluorouracil 400 mg/m2 bolus IV bolus followed by 2400 mg/m2 administered as continuous IV infusion over 46 hours via pump (outpatient)~Leucovorin 350 mg IV~Oxaliplatin 85 mg/m2 IV"
89009370|NCT00196339|Experimental|Cyproterone acetate 5 mg ( DR-2031)|1 tablet daily
89009371|NCT00196339|Experimental|Cyproterone acetate 15 mg ( DR-2031)|1 tablet daily
89009372|NCT00196339|Experimental|Cyproterone acetate 25 mg ( DR-2031)|1 tablet daily
89009373|NCT00196339|Placebo Comparator|Placebo|1 tablet daily
89009374|NCT00179959|Active Comparator|Treatment|Intranasal mupirocin ointment and sodium hypochlorite (bleach) baths
89009375|NCT00179959|Placebo Comparator|Placebo|Intranasal petrolatum ointment treatment and plain water baths
89009376|NCT02961933|Experimental|Apneic oxygenation|
89009377|NCT02961933|Active Comparator|non-apneic oxygenation|
89009378|NCT00257400|Experimental|Interpersonal Psychotherapy (IPT)|Interpersonal Psychotherapy
89433362|NCT06252402|Experimental|Dose Level +1|EGFR+ T Cell Dose (Day 0) 25 x 10^6 cells
89009379|NCT00257400|Active Comparator|Individual Psychotherapy|Individual Psychotherapy
89009380|NCT00257439||CKD|Elevated se-creatinine + proteinuria
89009381|NCT00257439||Healthy controls|Healthy controls, normal se-creatinine, no proteinuria
89009382|NCT02961972|Placebo Comparator|control group|Oral ingestion of placebo pills (maltodextrin) during three weeks
89009383|NCT02961972|Experimental|creatine supplementation|Oral supplementation with 5 g of monohydrate and micronized creatine during three weeks
89009384|NCT00199550|Active Comparator|2|Bipolar Electrosurgical Unit
89009385|NCT00199550|Active Comparator|1|Monopolar Electrosurgical Unit
89009386|NCT04721340||Test Group|people with multiple sclerosis
89009387|NCT04721340||Control Group|healthy volunteers
89433363|NCT06252402|Experimental|Dose Level +2|EGFR+ T Cell Dose (Day 0) 50 x 10^6 cells
89433364|NCT06251713|Experimental|VeXUS score guided fluid management|"Fluid management:~Restrictive intake~Diuretic-induced fluid removal aiming for a diuresis of 2-4mL/Kg/h if VeXUS score > 1~During 24 to 48 hours"
89433365|NCT06251713|Other|Usual care|"Fluid management:~Usual care~at the discretion of the attending physician"
89433366|NCT06251011|No Intervention|Control group|Receive an advice and a leaflet for cardiopulmonary rehabilitation.
89433367|NCT06251011|Experimental|Physiotherapy group|Receive the physical therapy training via video call (Pulmonary training, Calisthenic exercise, Upper and lower limbs strengthening exercise, Core stabilizer exercise, Aerobic exercise) at day 3, 6, 9, 12, 16, and 21 after positive in COVID-19 testing and also receive advise and a leaflet for cardiopulmonary rehabilitation.
89433368|NCT06250166|Experimental|Intervention group|Receive iPLANT diet plan and diet counselling by a qualified dietitian in oncology setting.
89433369|NCT06250166|Active Comparator|Control group|Receive usual diet counselling only
89433370|NCT06248320|Experimental|Sigh ventilation|"Sigh breaths consisting of increasing positive end-expiratory pressure (PEEP) that produces a plateau pressure of 35 cmH2O (or 40 cmH2O in patients with BMIs > 35). The sigh breaths will be delivered once every 6 minutes, as part of usual invasive mechanical ventilation, from intubation to extubation.~No sigh ventilation during thoracotomy~Lung protective ventilation from intubation to extubation, consisted of low tidal volume (6-8ml/kg/pbw) and positive end-expiratory pressure setting according to ARDS low PEEP-FiO2 table"
89009388|NCT04709172|Experimental|Cefditoren pivoxil 400mg|Cefditoren pivoxil 400mg bid for 7 days
89009389|NCT00415311|Other|0 mg/kg|
89009390|NCT00415311|Other|0.5 mg/kg|
89009391|NCT00415311|Other|1.0 mg/kg|
89009392|NCT02961114|Experimental|Microcannula Harvest Adipose|Acquisition of AD-tSVF via closed syringe microcannula harvest from subdermal fat deposits
89009393|NCT02961114|Experimental|Centricyte 1000|Autologous AD-tSVF via enzymatic isolation/concentration via Centricyte 1000 closed system to create AD-cSVF
89009394|NCT02961114|Experimental|IV Sterile Normal Saline|Re-suspension of AD-cSVF pellet in Normal Saline for deployment via IV
89009395|NCT00257673|Experimental|A|Active 30 mg MEM 1003
89009396|NCT00257673|Experimental|B|90 mg MEM 1003
89009397|NCT00257673|Placebo Comparator|C|Placebo for MEM 1003
89009398|NCT00410306||Group 1|
89009399|NCT00257712|Experimental|1|
89009400|NCT00257712|Placebo Comparator|2|
89009401|NCT00179647|Other|Lenalidomide 5-25 mg, w/wo dexamethasone|single-arm, open-label, lenalidomide, 5-25 mg, 21/28 days, with/without dexamethasone
89009402|NCT00200096|Active Comparator|1|Acupuncture and questionnaires
89009403|NCT00200096|Sham Comparator|2|placebo acupuncture and questionnaires
89009404|NCT00179413|Active Comparator|PEG-Intron|PEG-Intron 0.5mcg/kg once a week SC
89009405|NCT00179413|Active Comparator|Colchicine|0.6mg twice a day
89009406|NCT00200135||1|Treated and released from ED (minor injuries)
89009407|NCT00200135||2|Trauma, admitted to the hospital (injured)
89009408|NCT00200135||3|Fatalities reported by the coroner (deaths)
89009409|NCT00200135||4|Reported by the police (No medical treatment)
89009410|NCT00178633||Bariatric Surgery|Procedures were not part of the trial. Patients already undergoing these clinical procedures agreed to analysis and follow-up for research purposes. All patients had one of two different types of procedures, but outcome analyses did not distinguish between the two procedures.
89009411|NCT04571866|Experimental|Beta-glucan bread|Participants will receive a standardised meal consisting of beta-glucan-enriched bread (in an amount corresponding to 25 g of available dietary carbohydrates) and water (250 ml). The bread is produced by NOFIMA AS, one of the collaborating parties. The participants will be asked to spend approximately 10 minutes consuming the standardised meal.
89009412|NCT04571866|Sham Comparator|Control bread|Participants will receive a standardised meal consisting of a wheat bread with no additives (in an amount corresponding to 25 g of available dietary carbohydrates) and water (250 ml). The bread is produced by NOFIMA AS, one of the collaborating parties. The participant will be asked to spend approximately 10 minutes consuming the standardised meal.
89009413|NCT00178399|Experimental|Stereotactic body radiation therapy|
89009414|NCT00178126|Active Comparator|Segmented Foam Cushion|Receive seating assessment, wheelchair and seat cushion representing the standard of care in nursing homes
89009415|NCT00178126|Experimental|Skin Protection Cushion|Receive seating assessment, wheelchair and cushion meeting CMS code for Skin Protection Wheelchair Cushion
89009416|NCT00200252|Active Comparator|group B|women in group B will receive 10 uts oxytocin IM
89009417|NCT00200252|Active Comparator|group C|women in group C will receive oxytocin 5 uts IV
89009418|NCT00200252|Active Comparator|group A|women in group A will receive oxytocin 5 uts IM
89009419|NCT00177307|Experimental|Oxaliplatin, Capecitabine, and Bevacizumab|
89009420|NCT00200291|Experimental|1|Behavioral: hypocaloric low-fat diet
89009421|NCT00200291|Placebo Comparator|2|Behavioral: hypocaloric, low-fat diet
89433371|NCT06248320|No Intervention|Conventional ventilation|- Lung protective ventilation from intubation to extubation, consisted of low tidal volume (6-8ml/kg/pbw) and positive end-expiratory pressure setting according to ARDS low PEEP-FiO2 table
89433372|NCT06247839|Experimental|Psilocybin|25mg Psilocybin
88913167|NCT01593514|Experimental|Group 4: 1/5th dose Polysaccharide:conjugate|"Group IV will receive one fifth dose of MenACWY-PS polysaccharide vaccine meningococcal vaccine, followed by one dose of MenACWY-CRM conjugate vaccine given 1 month later.~0.1 mL of MenACWY-PS vaccine will be administered IM and 0.5 mL of the MenACWY-CRM vaccine will be administered intramuscularly into the deltoid."
88913168|NCT01593527|Experimental|Arm 1|Canakinumab 150 mg s.c.
89433373|NCT06246396|Experimental|Minocycline Hydrochloride|Minocycline hydrochloride 100 mg, administered twice daily for 3 months
88913169|NCT01593527|Experimental|Arm 2|Triamcinelone acetonide 40 mg i.m.
88913170|NCT01593540|Experimental|metal-free interdental brushes.|
88913171|NCT01593540|Active Comparator|metal-core interdental brushes|
88913172|NCT01593553|Experimental|ECG screening|Twice daily screening using intermittent ECG recorder (Zenicor) for two weeks
88913173|NCT01593553|No Intervention|Control group|Standard of care
88913174|NCT01593566|Active Comparator|0.25% bupivacaine|femoral nerve block using 0.25% bupivacaine versus 0.5% bupivacaine
88913175|NCT01593566|Active Comparator|0.5% bupivacaine|femoral nerve block using 0.25% bupivacaine versus 0.5% bupivacaine
89433374|NCT06246396|Placebo Comparator|Placebo|Placebo administered twice daily for 3 months
89433375|NCT06246019||Early Blood-based biomarkers Arm|The results of the blood-based biomarkers will be communicated to the managing neurologist at visit 1 (at 3 months from baseline visit).
89433376|NCT06246019||Late Blood-based biomarkers Arm|The results of the blood-based biomarkers will be communicated to the managing neurologist at visit 2 (at 9 months from baseline visit).
89433377|NCT06244537|Experimental|MR-linac|Patients enrolled will be treated with MR-Linac with short course radiotherapy (25Gy/5F), followed by 4 cycles of mFOLFOX6 or 3 cycles of XELOX chemotherapy, then radical surgical resection, and then postoperatively with 8 cycles of mFOLFOX6 or 5 cycles of XELOX chemotherapy.
89433378|NCT06244238||Emergency Nurse|"Employed in an urgent care unit.~Holds a nursing or registered nurse license.~Currently engaged in nursing duties.~Has a minimum of three months of nursing service in this hospital."
88913176|NCT01593579||Patients with Melanoma|Patients with Melanoma that are enrolled in a clinical trial at the Vanderbilt Ingram Cancer Center (VICC) including an arm with an oral Akt inhibitor
89433379|NCT06243289||Healthy participants|Volunteers with no kidney disease, autoimmune disease or major cardiovascular comorbidities
89009422|NCT00237003|Active Comparator|1) assessment plus motivational interview|Participants are assigned, in this 6 month study, to an assessment-only condition or an assessment plus motivational interview condition. Two motivational interview sessions are conducted during the first month of study participation.
89433380|NCT06243289||Participants with kidney disease|Includes patient with chronic kidney disease, dialysis or functioning transplant
89433381|NCT06241326||retrospective cohort|The patients in the retrospective cohort are hepatocellular carcinoma patients who have been previously treated with immunotherapy-based combination regimens. It is anticipated that approximately 10,000 cases will be included.
89433382|NCT06241326||prospective cohort|The patients included in the prospective cohort are hepatocellular carcinoma patients who are being evaluated by researchers to determine the potential benefits of undergoing immunotherapy-based combination treatment regimens. It is anticipated that approximately 1,000 cases will be enrolled.
89433383|NCT06238960|Experimental|Telerehabilitation|"the patients who will be randomized and subjected to the experimental treatment will undergo a physiotherapy treatment with a biweekly frequency which will be started at the same times as the standard group.~After the sixth session, the process will continue through telerehabilitation until the end of outpatient treatment."
89433384|NCT06238960|Active Comparator|traditional physiotherapy|Patients who will be randomized and subjected to standard treatment (usual care at our clinic) will undergo physiotherapy treatment on a bi-weekly basis in person.
89433385|NCT06238869|Experimental|Computerized Cognitive Behavioral Therapy (CCBT)|The experimental group received a 4-week CCBT intervention, which consisted of completing 3 modules every week, each taking roughly 20 minutes.
89009423|NCT02277535|Experimental|E-mail intervention|"ICU clinicians caring for patients who have not yet been initiated on nutrition 48 hours after ICU admission will receive a reminder email.~ICU clinicians caring for patients who accumulate a caloric deficit greater than 4000 calories or 150 g protein deficit will receive a feedback email"
89009424|NCT02277535|No Intervention|No E-mail intervention|Nutrition status of patients will be assessed but no reminder or feedback emails will be sent
89009425|NCT02484664|Experimental|celecoxib|Celecoxib 200mg PO QD for 6 months
89009426|NCT00176605|Experimental|Arm 1 (Etoposide + Cyclophosphamide)|Therapy will be divided into 4 cycles. Each cycle will be composed of 6 weeks of therapy. Total duration of therapy is 24 weeks. Administration of etoposide (50 mg po qd) and cyclophosphamide (50 mg po qd) will alternate in 21 day intervals. Starting with etoposide, patients will receive 21 days of therapy, upon completion of etoposide therapy patients will then receive 21 days of cyclophosphamide therapy. Therapy will continue in this alternating manner for 24 weeks. Week 1 of each cycle, begins with etoposide; Week 4 of each cycle, begins with cyclophosphamide.
89009427|NCT00176488|Experimental|Sequential epirubicin/vinorelbine|For patients with stage IIB (T3N0), IIIA, or IIIB breast cancer, epirubicin and vinorelbine will be administered for up to 5 cycles. For patients with stage IV breast cancer, epirubicin and vinorelbine will be administered as long as there is evidence of continued response or stable disease and no evidence of cardiac or other serious toxicities.
89009428|NCT00200408||smokers|college students who smoke
89009429|NCT00200408||non smokers|college students who don't smoke
89433386|NCT06238869|Experimental|Music Therapy(MT)|All the participants of Music Therapy will be treated with 12 sessions (3 sessions per week),15 minutes each time, and conducted for 4 weeks.
89433387|NCT06238869|Experimental|Health education|The health education group will conduct a series of mental health lectures through the WeChat Mini Program on a weekly basis, with each session lasting for 30 minutes, spanning over a duration of four weeks.
89433388|NCT06238869|No Intervention|Blank Control Group|All the participants in this group receive no intervention and undergo only psychological health screenings at designated time points.
89009430|NCT00175825|Placebo Comparator|Placebo|Matching Placebo tablets administered twice a day
89433389|NCT06237816|Experimental|Patient Education Intervention|"A multimedia educational series is designed to provide patient education on cancer clinical trials.~The following topics are addressed:~What is a clinical trial?~Types of clinical trials.~Phases of clinical trials.~Benefits and drawbacks.~Costs.~FAQs. This section covers common myths and clarifies these myths using a Q&A format.~How to join a clinical trial. Information about eligibility and informed consent.~Clinical trial stories. Testimonies from oncology providers and patients. Each module is approximately 2-5 minutes, and they can be reviewed in the order/schedule preferred by the patient.~The overall program is 30 minutes to view including the videos. The tablet provided to patients provides additional benefits for participation."
89009431|NCT00175825|Experimental|Brivaracetam 5 mg/day|Brivaracetam 5 mg/day, 2.5 mg administered twice a day
89009432|NCT00175825|Experimental|Brivaracetam 20 mg/day|Brivaracetam 20 mg/day, 10 mg administered twice a day
89009433|NCT00175825|Experimental|Brivaracetam 50 mg/day|Brivaracetam 50 mg/day, 25 mg administered twice a day
89009434|NCT04710329||C Vit|The patients who were admitted to the intensive care unit and received a high dose intravenous vitamin C protocol constituted the treatment group
89433390|NCT06237816|Experimental|Provider Education Intervention|"The provider education intervention will consist of 3 provider informational sessions conducted individually. These individual provider sessions will be conducted by teleconference by the research team and scheduled according to provider's availability.~Provider workshops are designed to provide both a background on clinical trial infrastructure in Hawaii and resources for additional information. The content of these sessions includes:~An overview of clinical trials infrastructure in Hawaii.~Available trials in Hawaii. At each informational session, the research team will review available trials and any new/upcoming trials with the provider.~An overview of how to get involved in clinical trials. As experience and background re: clinical trials may vary across providers, the content of these informational sessions will be tailored to each provider. Following the initial session, 2 additional meetings will be scheduled in 4-6 months as follow-up sessions."
89433391|NCT06236516|Experimental|One Fraction SBRT|Consenting and eligible patients will receive a prescription dose of 25-34 Gy in one fraction with adaptation based on daily anatomic changes as per clinical standard of care.
89433392|NCT06233877|Experimental|G-GLIP plus Mitomycin C|G-FLIP: Gemcitabine, Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin every 2 weeks plus Mitomycin C every 4 weeks
89433393|NCT06230471|Experimental|Pembrolizumab,Lenvatinib and Gemox Chemotherapy（Gemcitabine and Oxaliplatin）|Drug：Pembrolizumab Pembrolizumab 200 mg will be administered intravenously once every three weeks, with intravenous infusion on Day 1 of each cycle. Drug: Lenvatinib Oral Product The dose of lenvatinib is 12mg/day for patients with a body weight of ≥60 kg, and 8mg/day for patients with a body weight of <60 kg, taken once daily. Drug: Chemotherapy GEMOX regimen: Gemcitabine 1000mg/m2 will be administered intravenously over 30 minutes on Day 1 and Day 8; Oxaliplatin 100mg/m2 will be administered intravenously over 2 hours on Day 1, and the cycle will be repeated every 3 weeks
89536290|NCT02481401|Experimental|Intensive Individual Intervention Program|A combination of one-on-one personalized lifestyle counseling (8 months with 4 complimentary sessions for a total of 12 months) and a wearable physical activity monitor such as the Garmin Vivofit.
88913177|NCT01593605|Active Comparator|Dietary Supplement/insulin sensitivity|The first study supplement contains resveratrol that may improve insulin sensitivity and Leucine.Resveratrol 50mg with leucine 1.11 g. - one tablet taken twice a day by mouth
88913178|NCT01593605|Placebo Comparator|Sugar Pill|Neutral treatment Placebo - one tablet taken twice a day by mouth
88913179|NCT01593605|Active Comparator|Dietary Supplement 2|2nd study supplement contains resveratrol and HMB which may stimulate protein building.
88913180|NCT01593618|Experimental|Web-Based Intervention|UMFollowUp - web-based internet resource for information about their diagnostic histories, recommendations for follow-up care, and tips to enhance their treatment, psychosocial and physical well-being.
88913181|NCT01593618|Active Comparator|Standard of Care|Patients will receive information regarding their diagnosis, treatments, and ongoing health needs from their provider, but will not be provided access to the website.
88913182|NCT01593631|Active Comparator|2 billion lyoph. yoghurt bacteria|
88913183|NCT01593631|Active Comparator|3300 FCC acid lactase|
88913184|NCT01593631|Active Comparator|9000 FCC acid lactase|
88913185|NCT01593631|Active Comparator|Combination of Substances of arm 1 and 2|
88913186|NCT01593631|Placebo Comparator|Placebo|
88913187|NCT01593644|Experimental|adenosine + dypiridamole|
88913188|NCT01593657|Experimental|Mindful Movement and Breathing program|Mindful Movement and Breathing program implemented in a hospital room or clinic room three times by a yoga instructor: prior to surgery, one day and two days after surgery.
88913189|NCT01593683|Experimental|Psychological education program|Patients receive the psychological education program upon study enrollment.
88913190|NCT01593683|No Intervention|Waitlist|Participants are assigned to a 16-week wait-list period upon enrollment. Participants are invited to receive the psychological education program following the waitlist period.
88913191|NCT01593709||Cohort 1|Healthy adults; age 18 or older
88913192|NCT01593735|Experimental|Panel A: GT1, low dose|Participants with genotype 1 (GT1) Hepatitis C Virus (HCV) will receive low dose MK-2748 daily for 7 days.
88913193|NCT01593735|Experimental|Panel B: GT1, lower dose|Participants with GT1 HCV will receive lower dose MK-2748 daily for 7 days.
88913194|NCT01593735|Experimental|Panel C: GT1, dose based on Panels A+B|Participants with GT1 HCV will be dosed with MK-2748 daily for 7 days based on the safety, pharmacokinetic, and/or pharmacodynamic data from Panels A (low dose) and B (lower dose).
89009435|NCT04710329||non-C Vit|The patients who were admitted to the intensive care unit but did not receive the vitamin C protocol constituted the control group
89433394|NCT06230471|Experimental|Pembrolizumab and Lenvatinib|Drug：Pembrolizumab Pembrolizumab 200 mg will be administered intravenously once every three weeks, with intravenous infusion on Day 1 of each cycle. Drug: Lenvatinib Oral Product The dose of lenvatinib is 12mg/day for patients with a body weight of ≥60 kg, and 8mg/day for patients with a body weight of <60 kg, taken once daily.
89009436|NCT00174967|Placebo Comparator|Placebo QD|
89009437|NCT00174967|Experimental|Febuxostat 40 mg QD|
89009438|NCT00174967|Experimental|Febuxostat 80 mg QD|
89009439|NCT00174967|Experimental|Febuxostat 120 mg QD|
89009440|NCT00174265|Experimental|asenapine|
89009441|NCT00174265|Active Comparator|olanzapine|
89009442|NCT00200720|Experimental|Atkins Diet|Participants randomized to this arm will consume a low carbohydrate diet as described by Dr. Robert Atkins in his book: Dr. Atkins' New Diet Revolution New York: Avon Books, 2002.
89009443|NCT00200720|Active Comparator|DASH Diet|Participants randomized to this arm will consume the Dietary Approaches to Stop Hypertension (DASH) diet as described here: http://www.nhlbi.nih.gov/health/public/heart/hbp/dash/new_dash.pdf
89009444|NCT00265356|Experimental|1|PET diagnostic imaging
89009445|NCT00265356|No Intervention|2|No PET
89009446|NCT00200876|Active Comparator|pain challenge|
89009447|NCT00200876|Sham Comparator|non-painful control|
89009448|NCT00200954|Placebo Comparator|placebo|placebo group
89009449|NCT00200954|Active Comparator|2|Probiotic bacteria group
89009450|NCT00265434|Active Comparator|Dornase alfa|DBPC-cross over trial
89009451|NCT00265434|Placebo Comparator|isotonic saline|
89009452|NCT00172042|Experimental|Zoledronic acid|Zoledronic acid 4 mg intravenous infusion over at least 15 minutes every 3 to 4 weeks for 24 months. Dosage was adjusted for participants with mild or moderate renal impairment.
89009453|NCT00172042|Other|Control|No investigational treatment. If a participant developed bone metastases, treatment was started with Zoledronic acid 4 mg intravenous infusion over at least 15 minutes every 3 to 4 weeks until 24 months from the date of study entry had elapsed.
89009454|NCT00201071||South Bronx, Harlem, Lower East Side|
89009455|NCT00201110|Experimental|1|Intensive Intervention: CVD Risk Education (1 session) + Intensive Health Problem-Solving Training (8 sessions)
89009456|NCT00201110|Active Comparator|2|Brief Intervention: CVD Risk Education (1 session) + Brief Health Problem-Solving Training (1 session)
89009457|NCT00201149|Experimental|1|In one team of clinicians we will implement only the patient-centered counseling program.
89009458|NCT00201149|No Intervention|3|The control group will provide usual care
89009459|NCT00201149|Experimental|2|In a subset of those clinicians receiving the patient-centered counseling program intervention, we will augment it with cultural competency training.
89009460|NCT00201188|Experimental|1|Participants will receive feedback and peak flow monitoring reports from their doctors.
89009461|NCT00201188|No Intervention|2|Participants will receive usual care.
89536291|NCT02481401|Active Comparator|Peer-To-Peer Program Intervention|Monthly meetings for 60-90 minutes in groups of about up to 20 supporting each other in self-control of CV risk factors, for a total of 12 months.
89009462|NCT00171925|Experimental|Zoledronic acid (ZOL446)|Participants received intravenous infusion of Zoledronic acid every 4 weeks for 48 weeks, and calcium and Vitamin D daily.
89009463|NCT00171925|No Intervention|Control|No treatment with study medication.
89009464|NCT00201227|Experimental|Practice Change|Enhancement of primary care practice performance and practice guideline adherence
89009465|NCT00201227|No Intervention|Control|Usual care
89009466|NCT00201266||Exacerbation resistant asthma|Control group
89009467|NCT00201266||Exacerbation prone asthma|Cases
89009468|NCT00265629|Experimental|1|RF ablation
89009469|NCT00201422|Experimental|Omeprazole, Amoxicillin, Clarithromycin|Anti-H. pylori Therapy (Triple therapy)
89009470|NCT00201461|Active Comparator|1|Best medical therapy
89009471|NCT00201461|Experimental|2|STARFlex arm
89009472|NCT00201500||preeclampsia|women with preeclampsia
89009473|NCT00201500||controls|healthy pregnant women
89009474|NCT00201539|Active Comparator|double dose once|double dose immediate-release oral morphine at bedtime in cancer patients, placebo after 4 hours
89009475|NCT00201539|Experimental|single dose twice|single dose immediate-release oral morphine at bedtime in cancer patients, second single dose after 4 hrs
89009476|NCT04709055|Experimental|Co-management arm (geriatric and surgical)|
89009477|NCT04709055|Active Comparator|Usual care|
89009478|NCT00201617||1|normal hearing sensitivity
89009479|NCT00201617||2|Unilateral deafness who are implanted with a Bone Anchored Hearing Aid
89009480|NCT04709328|Experimental|SCTA01 low dose +SOC|SCTA01, a recombinant anti-SARS-CoV-2 spike protein monoclonal antibody
89009481|NCT04709328|Experimental|SCTA01 middle dose+SOC|SCTA01, a recombinant anti-SARS-CoV-2 spike protein monoclonal antibody
89009482|NCT04709328|Experimental|SCTA01 High dose +SOC|SCTA01, a recombinant anti-SARS-CoV-2 spike protein monoclonal antibody
89009483|NCT04709328|Placebo Comparator|Placebo+SOC|SCTA01, a recombinant anti-SARS-CoV-2 spike protein monoclonal antibody
89009484|NCT02962778||treatment-resistant hypertension|patients with Treatment-resistant arterial hypertension receiving standard antihypertensive treatment with at least 3 antihypertensive agents including one diuretic
89009485|NCT00258687|Experimental|Treatment Arm A|GVAX for Sarcoma / Renal Cell Patients
89009486|NCT00258687|Experimental|Treatment Arm B|GVAX for Pediatric Melanoma Patients
89009487|NCT00201656|Active Comparator|1 Retention of Cerclage|Group one = Subject whose Cerclage is retained after randomization.
89009488|NCT00201656|Active Comparator|2 - Removal of Cerclage|Group 2 = Subjects who will have cerclage removed after randomization
89433395|NCT06230471|Active Comparator|Pembrolizumab and Gemox Chemotherapy（Gemcitabine and Oxaliplatin）|Drug：Pembrolizumab Pembrolizumab 200 mg will be administered intravenously once every three weeks, with intravenous infusion on Day 1 of each cycle. Drug: GEMOX Chemotherapy GEMOX regimen: Gemcitabine 1000mg/m2 will be administered intravenously over 30 minutes on Day 1 and Day 8; Oxaliplatin 100mg/m2 will be administered intravenously over 2 hours on Day 1, and the cycle will be repeated every 3 weeks
89433396|NCT06230003|Active Comparator|Intervention group|Ultrasound guided bilateral ESP block either with local anesthetic
89009489|NCT00265824|Active Comparator|bevacizumab alone|
89009490|NCT00265824|Experimental|Bevacizumab + erlotinib|
89433397|NCT06230003|Placebo Comparator|Control group|Ultrasound guided bilateral ESP block either with normal saline
89009491|NCT00410345|Experimental|Pitocin|Treatment with Pitocin after mifegine
89009492|NCT00410345|Active Comparator|Cytotec|Treatment with cytotec after mifegine
89009493|NCT00265863|Experimental|Patients with Malignant Ascites|Patients meeting protocol criteria enrolled with malignant ascites.
89009494|NCT00258765|Experimental|Zoledronic Acid|
89009495|NCT00258765|Active Comparator|Docetaxel|
89433398|NCT06229860||Adult patients with CML in chronic phase (CML-CP)|
89433399|NCT06228937||Group A|patients affected by limb lymphedema with recurrent soft tissue infections
89433400|NCT06228937||Group B|patients affected by limb lymphedema without recurrent soft tissue infections
89433401|NCT06223334||GTCS (generalized Tonic Clonic Seizures)|
89433402|NCT06223334||Tonic Seizures|
89433403|NCT06223334||Clonic Seizures|
89433404|NCT06223334||Myoclonic Seizures|
89433405|NCT06223334||Absence Seizures|
89433406|NCT06223334||Focal Seizures|
89433407|NCT06222749|Experimental|NC follicular|Naturally cycling, healthy women in the follicular menstrual cycle phase.
89433408|NCT06222749|Experimental|NC luteal|Naturally cycling, healthy women in the luteal menstrual cycle phase.
89433409|NCT06222749|Experimental|OC combined|Healthy women taking combined oral hormonal contraceptives.
89433410|NCT06222749|Experimental|OC progestogen-only|Healthy women taking progestogen-only oral hormonal contraceptives.
89433411|NCT06222684|Experimental|Intervention Group|Women in the intervention group applying for mammography screening will listen to music for 5 minutes before, during and after the procedure.
89433412|NCT06222684|No Intervention|Control Group|Women in the control group applying for mammography screening will not receive any intervention other than routine mammography screening.
89433413|NCT06221969|Experimental|CagriSema|Participants will receive cagrilintide dose 1 and semaglutide dose 2 subcutaneously once-weekly (dose escalation period of 16 weeks) for up to 68 weeks.
89009496|NCT00258843|Experimental|Group 1|Children at 18 months of age
89009497|NCT00258843|Experimental|Group 2|Infants at 2 months of age
89009498|NCT00201890|Experimental|1|Standard of Care plus Lymphatic massage (Decongestive Lymphatic Therapy)
89009499|NCT00201890|No Intervention|2|Standard of Care
89009500|NCT04709094|Experimental|Part 1: Danicopan and Warfarin|"Period 1: Participants received a single dose of warfarin.~Period 2: Participants received danicopan three times daily, in addition to coadministration with a single dose of warfarin.~Scheduled pharmacokinetics (PK) and pharmacodynamics samples were collected, with a washout period of at least 14 days between the dose of warfarin in Period 1 and the first dose of danicopan in Period 2."
89009501|NCT04709094|Experimental|Part 2: Danicopan and Bupropion|"Period 1: Participants received a single dose of bupropion.~Period 2: Participants received danicopan three times daily, in addition to coadministration with a single dose of bupropion.~Scheduled PK samples were collected, with a washout period of at least 7 days between the dose of bupropion in Period 1 and the first dose of danicopan in Period 2."
89009502|NCT04709094|Experimental|Part 3: Danicopan and EE/NET|"Period 1: Participants received a single dose of EE/NET.~Period 2: Participants received danicopan three times daily, in addition to coadministration with a single dose of EE/NET.~Scheduled PK samples were collected, with a washout period of at least 7 days between the dose of EE/NET in Period 1 and the first dose of danicopan in Period 2."
89009503|NCT00171340|Experimental|Upfront Zoledronic Acid|Zolendronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months for 5 years beginning on Day 1. All participants took Letrozole tablets 2.5 mg/day for 5 years beginning on Day 1.
89009504|NCT00171340|Experimental|Delayed Zoledronic Acid|Zolendronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months beginning when one of the following occurred: BMD T-score <= -2.0 SD at either the lumbar spine or total hip, any clinical fracture unrelated to trauma or an asymptomatic fracture discovered at the Month 36 visit. All participants took Letrozole tablets 2.5 mg/day for 5 years beginning on Day 1.
89433414|NCT06221969|Active Comparator|Tirzepatide|Participants will receive tirzepatide dose 1 subcutaneously once-weekly (dose escalation period of 20 weeks) for up to 68 weeks.
89433415|NCT06221189|Experimental|ACT-CSP|Three sessions of acceptance and commitment therapy.
89433416|NCT06221189|No Intervention|Usual Care|Usual treatment provided at the participating site.
89536292|NCT03209011|Experimental|experimental group|patients who were untreated ever in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly till 48 weeks.
88913195|NCT01593735|Experimental|Panel G: GT1, dose based on Panels A+B+C|Participants with GT1 HCV will be dosed with MK-2748 daily for 7 days based on the safety, pharmacokinetic, and/or pharmacodynamic data from Panels A (low dose), B (lower dose), and C.
88913196|NCT01593735|Experimental|Panel H: GT1, dose based on Panels A+B+C+G|Participants with GT1 HCV will be dosed with MK-2748 daily for 7 days based on the safety, pharmacokinetic, and/or pharmacodynamic data from Panels A (low dose), B (lower dose), C, and G.
88913197|NCT01593735|Experimental|Panel D: GT3, low dose (Omitted)|Participants with genotype 3 (GT3) HCV were to receive low dose MK-2748 daily for 7 days. Panel D was omitted from the study design and participants were not enrolled in this panel.
88913198|NCT01593735|Experimental|Panel E: GT3, high dose|Participants with genotype 3 (GT3) HCV will receive high dose MK-2748 daily for 7 days.
88913199|NCT01593735|Experimental|Panel F: GT3, dose based on Panel E|Participants with GT3 HCV will be dosed with MK-2748 daily for 7 days based on the safety, pharmacokinetic, and/or pharmacodynamic data from Panel E (high dose).
88913200|NCT01593735|Experimental|Panel I: GT3, dose based on Panels E+F|Participants with GT3 HCV will be dosed with MK-2748 daily for 7 days based on the safety, pharmacokinetic, and/or pharmacodynamic data from Panels E (high dose) and F.
88913201|NCT01593735|Experimental|Panel J: GT3, dose based on Panels E+F+I|Participants with GT3 HCV will be dosed with MK-2748 daily for 7 days based on the safety, pharmacokinetic, and/or pharmacodynamic data from Panels E (high dose), F, and I.
88913202|NCT01593774|Experimental|Melatonin|Tablet melatonin 3 mg/day at 9 pm as intervention group for eight week
88913203|NCT01593774|Placebo Comparator|Placebo|Placebo (with the same shape and taste as melatonin) at 9 pm as control group
88913204|NCT01593800|Experimental|open label probiotics|Bio-25 is an innovative formula containing 11 different strains of unique probiotic bacteria and over 25 billion active bacteria in each capsule. All participants will receive either Probiotics (Bio-25,will be provided by SupHerb) or placebo pills blindly for six months. One day prior to each visit, subjects will be asked to consume lactose, fructose and sorbitol free foods, in order to avoid high base line of hydrogen from the presence of unabsorbed carbohydrates. Subjects will also be asked not to smoke 24 hours prior to each visit.
88913205|NCT01593826|Active Comparator|Charcoal and Symbicort Turbuhaler|
88913206|NCT01593826|Active Comparator|Symbicort Turbuhaler|
88913207|NCT01593826|Experimental|Charcoal and Budesonide/formoterol Easyhaler|
88913208|NCT01593826|Experimental|Budesonide/formoterol Easyhaler|
88913209|NCT01593865||BIMA Grafting Group|Group consists of patients who received bilateral internal mammary artery grafting for treatment of severe coronary disease since June 2012.
88913210|NCT01593865||Control Group|This Group consists of historical control patients who received conventional coronary artery bypass grafting (left mammary artery graft only plus great saphenous vein grafts) in the 2010-2012 period, and who are propensity-matched to the BIMA Group patients.
88913211|NCT01593878|Experimental|TV|Test taken with TV on
88913212|NCT01593878|No Intervention|Control|test taken in quiet
88913213|NCT01593930|Experimental|1 Articaine(Infiltration)|Buccal infiltration of one 4% Articaine cartridge with 1/100000 epinephrine
88913214|NCT01593930|Experimental|2 Articaine(Infiltration)|Buccal infiltration of two 4% Articaine cartridges with 1/100000 epinephrine
88913215|NCT01593930|Experimental|Lidocaine(IANB)+1Articaine(Infiltration)|Inferior alveolar nerve block using one 2% Lidocaine cartridge with 1/80000 epinephrine + Buccal infiltration of one 4% Articaine cartridge with 1/100000 epinephrine
88913216|NCT01593930|Experimental|Lidocaine(IANB)|Inferior alveolar nerve block using one 2% Lidocaine cartridge with 1/80000 epinephrine
88913217|NCT01593943|No Intervention|Control Condition|
88913218|NCT01593943|Experimental|CHARM Intervention|CHARM will be conducted via three 30-minute counseling sessions delivered in a rural setting, with the first session being required and the subsequent sessions being optional. The first two CHARM sessions will be for men only to build family planning (FP) and gender equity (GE) awareness and investment, and the third session will be for the couple with an emphasis on FP services, shared decision-making and marital communication. The three sessions can occur anytime within a 3 month timeframe but with a minimum of 1 week between sessions. All sessions and FP services (pill, condom, EC) will be provided at no cost to patients.
88913219|NCT01593956|Other|Concussed athletes|
88913220|NCT01593956|Other|Healthy controls|
88913221|NCT01593969|Active Comparator|Standard RUTF|Standard RUTF given according to National Guidelines
88913222|NCT01593969|Experimental|RUTF/Flax Oil|RUTF/Flax Oil is reformulated RUTF to increase n3 content
88913223|NCT01593969|Experimental|RUTF/Flax Oil plus additional Fish Oil|RUTF/Flax Oil plus additional Fish Oil is RUTF reformulated to increase n3. Fish oil to provide long chain n3
88913224|NCT01593982|Placebo Comparator|Sham rTMS|Drug-free patients, receiving 20 sessions (1 session daily) of Sham (placebo) rTMS delivered to the left dorsolateral prefrontal cortex.
88913225|NCT01593982|Active Comparator|Active rTMS|Drug-free patients, receiving 20 sessions (1 session daily) of Active rTMS delivered to the left dorsolateral prefrontal cortex.
89536293|NCT03209011|No Intervention|control group|patients who were untreated ever in immune-active phase took Nucleoside Analogues for maintenance treatment.
89536294|NCT02481323|Active Comparator|Group 1|Isosorbide mononitrate 25mg bd
89536295|NCT02481323|Active Comparator|Group 2|Cilostazol 100mg bd
88913226|NCT01593995|Experimental|EGF ointment|
88913227|NCT01594021|Experimental|High pre-emptive volume loading|
88913228|NCT01594021|Active Comparator|Low pre-emptive volume loading|
88913229|NCT01594034||no treatment|
88913230|NCT01594060|Active Comparator|sliding scale|
88913231|NCT01594060|Active Comparator|basal bolus|
88913232|NCT01594086|Experimental|green tea powder|Natural green tea powder
89433417|NCT06221137|Active Comparator|conventional circumferential supracrestal fiberotomy|"The amount of tooth that need to be extruded will be measured Bonding brackets slot 0,022x0.028 Roth prescription on piggyback for the tooth with (0.016. x 0.022 ) stainless steel main arch wire and 0.0014 nickel titanium auxiliary.~• Fiberotomy After 2 days of bonding, local anaesthetic solution will be administrated. The depth of the fibrotomy should be equal to the amount of tooth that need to be extruded.~supracrustal fibrotomy will be performed using 15 c blade (Carvalho, Bauer et al. 2006)"
89536296|NCT02481323|Active Comparator|Group 3|Isosorbide mononitrate 25mg bd and cilostazol 100mg bd start immediately
89536297|NCT02481323|Other|Group 4|Isosorbide mononitrate 25mg bd and cilostazol 100mg bd delayed start
89536298|NCT03197779|Experimental|BMS-962212 Two Hour Administration|Intravenous administered over 2 hours of BMS-962212
89536299|NCT03197779|Experimental|BMS-962212 5 Day Administration|Intravenous administered over 5 days of BMS-962212
88913233|NCT01594099|Active Comparator|Radiotherapy alone|
88913234|NCT01594099|Experimental|Radiotherapy plus cisplatin|
89197785|NCT00686166|Experimental|Chemo + Chemo and radiation + Surgery|"Chemotherapy Cycle 1 (1 cycle is 35 days):~Oxaliplatin, 50 mg/m^2, IV, Days 1,8,15,22,29~Cetuximab, 400 mg/m^2, IV, Day 1~Cetuximab, 250 mg/m^2, IV, Days 8,15,22,29~Capecitabine, 1650 mg/m^2/day, PO, Monday-Friday (Day 1-35)~Chemotherapy+ Radiation Cycle 2:~Oxaliplatin, 50 mg/m^2, IV, Days 50,57,71,78~Cetuximab, 250 mg/m^2, IV, Days 50,57,64,71,78~Capecitabine, 1650 mg/m^1, PO, Monday-Friday (Day 50-84)~Radiation therapy: Planning target value 1: 4500 cGy (centigray) in 25 fractions; Planning target value 2 (stage T3 patients): Boost of 540 cGy in 3 fractions; Planning target value 2 (stage T4 patients): Boost of 900 cGy in 5 fractions.~Therapeutic Surgical procedure: Resection"
89433418|NCT06221137|Active Comparator|laser circumferential supracrestal fiberotomy|"The amount of tooth that need to be extruded will be measured~Bonding brackets slot 0,022x0.028 Roth prescription~piggyback for the tooth with (0.016. x 0.022 ) stainless steel main arch wire and 0.0014 nickel titanium auxiliary.~• Fiberotomy~After 2 days of bonding, local anaesthetic solution will be administrated.~The depth of the fibrotomy should be equal to the amount of tooth that need to be extruded.~A diode laser of 980 nm wavelength will be used The laser tip will be inserted, and incision will be extended around tooth circumference with the system configured to a continuous wave with the movement of the laser tip in an up and down stroking movement The laser tip will be moved in a circumferential manner taking care that all the fibers are lysed."
88913235|NCT01594099|Experimental|Radiotherapy plus liposome paclitaxel|
89009505|NCT00201968|Other|FES training|Arm 1 receives functional electrical stimulation while walking on body weight suspension training.
89197786|NCT04280536|Experimental|Cohort A|Patients with prior exposure to fluoropyrimidines
89197787|NCT04280536|Experimental|Cohort B|Patients without prior exposure to fluoropyrimidines
89009506|NCT00201968|Other|Control Group training|Aerobic and resistance training program
89433419|NCT06220422||Standard Department procedure for managing direct-acting oral anticoagulants|Standard Department procedure for managing direct-acting oral anticoagulants (NACO < 50 ng/mL) in the management of fractures before September 2021
89433420|NCT06220422||New Department procedure for managing direct-acting oral anticoagulants|Intervention Description New Department procedure for managing direct-acting oral anticoagulants (NACO < 100 ng/mL) in the management of fractures after September 2021
89433421|NCT06217185|Experimental|Experimental arm|"Pyrotinib, Trastuzumab Combined With Taxanes~*When taxane drugs are discontinued (after completing 6-8 cycles of treatment or due to intolerance), the therapy can be continued with the combination of metronomic capecitabine and trastuzumab, along with pyrotinib."
89433422|NCT06216145|Experimental|Experimental group|"Before the skills exam, the 'Self-Efficacy Survey in the Most Commonly Used Skill-Requiring Practices in Nursing' will be administered. Apart from the end-of-term skill exam, students will be given a different skill exam than the control group, in which they will not receive any grades. For applications requiring invasive interventions, a skill test will be administered in the laboratory.~For applications that do not require invasive intervention, a skill test will be administered in the clinical environment. At the end of the semester, students will be asked to fill out the 'Self-Efficacy Survey in Practices Requiring the Most Commonly Used Skills in Nursing'. At the end of the semester, students will be evaluated with 2 skill applications and skill exam scores to be selected by written exam and lottery method."
89433423|NCT06216145|Placebo Comparator|conrol group|At the end of the fall semester midterm exam, the 'Self-Efficacy Survey in Practices Requiring the Most Commonly Used Skills in Nursing' will be administered. At the end of the semester, students will be asked to fill out the 'Self-Efficacy Survey in Practices Requiring the Most Commonly Used Skills in Nursing'. This scale will measure self-efficacy. At the end of the semester, students will be evaluated with 2 skill applications and skill exam scores to be selected by written exam and lottery method. With these exams, skills and theoretical knowledge will be measured.
89433424|NCT06215183|Experimental|Intervention Group|Women in the intervention group applying for IUD application will listen to music for 5 minutes before, during and after the procedure.
89433425|NCT06215183|No Intervention|Control Group|Women in the control group applying for IUD application will not be subjected to any intervention other than routine IUD insertion procedures.
89433426|NCT06212479||MRI Scan Arm|Whole Body MRI Scan
89433427|NCT06212011|Experimental|Superimposed Neuromuscular Electrical Stimulation Group|Superimposed NMES involves stimulating the lumbar multifidus muscle while the individual performs a sit-to-stand activity.
89433428|NCT06212011|Experimental|Conventional Neuromuscular Electrical Stimulation Group|Conventional NMES intervention involves only stimulating the lumbar multifidus muscle while the individual is in the prone position, and the individual will not reveal any voluntary contraction during stimulation.
89433429|NCT06211660|Experimental|AI-based AR training system|The AI-empowered AR training system will be used.
89433430|NCT06211660|Experimental|Hand scanner and Video training|Both hand scanner results and a training video will be provided.
89009507|NCT00171301|Experimental|Deferasirox|Deferasirox was given orally once daily (10 to 20 mg/kg) to participants 2 years and older based on participant's body weight.
89009508|NCT00202046||Patients with lymphedema|Identification of risk factors for lymphedema in women who have had axillary surgery for breast cancer.
89009509|NCT00202046||Control patients without lymphedema|Controls matched on type of axillary surgery and surgery date for comparison in quality of life (QOL) ratings from women who have lymphedema.
89009510|NCT00266058|Active Comparator|Lopinavir/ritonavir, artemethr/lumefantrine|Determination of the antimalarial drug levels artemether/lumefantrine in the absence and in the presence of co-administered antiretrovirals lopinavir and ritonavir.
89009511|NCT00266058|Active Comparator|efavirenz, artemether, lumefantrine|Determination of the antimalarial drug levels artemether/lumefantrine in the absence and in the presence of co-administered antiretroviral efavirenz.
89433431|NCT06210113|Experimental|Mindfulness|8-week mindfulness-based stress reduction training
89197788|NCT00363649|Experimental|Arm A|Patients will receive injections of interferon alfa and sargramostim once a day for 6 months. Some patients may receive treatment for up to 1 year. After 1 year, some patients may receive treatment as in arm II.
89197789|NCT00363649|Experimental|Arm B|Patients will receive an injection of GM-K562 cell vaccine every 3 weeks for at least 6 months. Some patients may receive treatment for up to 1 year. After 1 year, some patients may receive treatment as in arm I. NOTE: Study Arm B is not available to newly accrued and enrolled subjects based on the interim analysis directing all new subjects to the combination of Interferon + sargramostim (Arm A).
89009512|NCT00171223|Experimental|All Participants With Chronic Myeloid Leukemia|Participants received STI571, capsules or tablets, orally, once a day at a dose of 400 mg. During the Core Phase of the study, participants received STI571 daily for up to 12 months. Participants completing 12 months of therapy were eligible to continue treatment in the Extension Phase of the study, and they continued STI571 for as long as the therapy was beneficial or until death, intolerable toxicity or the decision to discontinue by the investigator, whichever came first. (Maximum duration on study was approximately 14 years).
89197790|NCT00855153|Experimental|treatment|Subjects receive 50mg DCS prior to 90 min session with graded VRE treatment
89197791|NCT00947440|Active Comparator|Tablet 1 vs. Capsule|Single dose of 2 x 50 mg tablets (Tablet 1) vs. 100 mg ABT-072 (contents of capsules) suspended in liquid.
89197792|NCT00947440|Active Comparator|Tablet 2 vs. Capsule|Single dose of 2 x 50 mg tablets (Tablet 2) vs. 100 mg ABT-072 (contents from capsules) suspended in liquid.
89197793|NCT02545023||Observational (Supportive care, health-related QOL)|Participants complete the demographic questionnaire, SCNS-34, SF-36, and the Lifestyle Needs Survey. Within 1 year of completing questionnaires, some participants may complete a one-hour in-person one-on-one interview comprising questions about the challenges and experiences of cancer survivorship, their health and well-being, and supportive care needs.
89197794|NCT00952978|Experimental|10 mg ilaprazole|
89433432|NCT06210113|No Intervention|Placebo|received usual care
89433433|NCT06209983|Experimental|Arm E|"Preoperative preparation: shorten the fasting time, take a small amount of sugar water two hours before the surgery, and reduce excessive bowel preparation.~Intraoperative care: multi-model analgesia (mainly epidural analgesia), sleep depth monitoring, warm air blanket to avoid hypothermia.~Postoperative care: focus on pain relief methods (such as oral analgesics, patient-controlled epidural analgesia), early postoperative feeding (try drinking water on the first day after surgery, liquid diet on the second day, and soft diet on the third day), early removal of invasive tubes such as nasogastric tubes, intravenous catheters, and urinary catheters, and medication to prevent postoperative nausea and vomiting."
89536300|NCT03197779|Experimental|BMS-962212 and Aspirin|BMS-962212 intravenous administration, followed by aspirin oral administration, then combination administration of BMS-962212 and aspirin
89536301|NCT03197779|Placebo Comparator|Placebo and Aspirin|Placebo intravenous administration, followed by aspirin, then combination administration of placebo and aspirin
89197795|NCT00952978|Active Comparator|20 mg omeprazole|
89197796|NCT01046851|Active Comparator|Nopan|
89197797|NCT01046851|Placebo Comparator|Placebo|
89197798|NCT00861939|Experimental|1|Bupropion HCl 300mg Extended Release Tablet
89197799|NCT00861939|Active Comparator|2|WELLBUTRIN XL 300mg Tablets
89197800|NCT01046929|Experimental|limonene|
89197801|NCT00953134|Experimental|1|IFA - Iron and Folic Acid (60 mg of ferrous fumarate and 400 mcg folic acid)
89197802|NCT00953134|Active Comparator|2|FA - Folic Acid (400 mcg folic acid)
89197803|NCT02544945|Active Comparator|Standard Bolus|The radiotherapy treatment days when the standard bolus is used
89009513|NCT04571905|Other|Syntellix Treatment Arm|General anaesthesia, open fracture reduction, insertion of the appropriate screw with x-ray control and documentation intraoperatively, cast immobilisation Use of bioresorbable Magnezix CS or CBS Screws, if intraoperatively suitable bioresorbable screws not available, use of conventional ostesynthesis screws
89009514|NCT00266097|Experimental|Part I|Oxaliplatin + Gemcitabine + Radiation
89009515|NCT00266097|Experimental|Part II|Erlotinib + Oxaliplatin + Gemcitabine + Radiation
89009516|NCT00470236|Active Comparator|Arm 1 (Standard WB Fractionation)|Whole Breast RT alone - Standard fractionation schedule (50GY/25 Fractions/35days)
89009517|NCT00470236|Experimental|Arm 2 (Shorter WB Fractionation)|Whole Breast RT alone - Shorter fractionation schedule (42.5 Gy/16 fractions/22 days)
89009518|NCT00470236|Active Comparator|Arm 3 (Standard WB fractionation+Boost)|Whole Breast RT + tumor bed boost - Standard fractionation schedule (50 Gy/25 fractions/35 days; Boost 16 Gy/8 fractions/10 days)
89009519|NCT00470236|Experimental|Arm 4 (Shorter WB fractionation + Boost)|Whole breast RT + tumour bed boost - Shorter fractionation schedule (42.5 Gy/16 fractions/22 days; Boost 16 Gy/8 fractions/10 days)
89009520|NCT00476554|Experimental|Arm A: High dose|High-dose (Arm A): 200 mg b.i.d. x 3 consecutive days per week for 2 weeks followed by 1-week rest
89009521|NCT00476554|Experimental|Arm B: High dose|Low-dose (Arm B): 100 mg b.i.d. x 3 consecutive days per week for 2 weeks followed by 1-week rest
89197804|NCT02544945|Experimental|3D printed bolus|the radiotherapy treatment days when the 3D bolus is used
89433434|NCT06209983|Placebo Comparator|Arm H|"Preoperative preparation: overnight fasting preparation, bowel preparation.~Intraoperative care: traditional pain care (intravenous analgesics), sleep depth monitoring, warm air blanket, central venous pressure and body water monitoring indicators, traditional muscle tension relaxation treatment and the use of health insurance antagonist drugs (Neostigmine).~Postoperative care: patient-controlled intravenous drip for postoperative pain relief, oral feeing (rice porridge) on the postoperative day 5, and according to the progression of patient condition, step by step to removal of invasive tubes such as nasogastric tubes, intravenous catheters, and urinary catheters."
89531232|NCT03342131||NST-ACS group|The study population consists of 150 patients with non-ST elevated acute myocardial infarction (NST-ACS) including unstable angina pectoris (UAP),who are admitted within 24 hours after chest pain attack. They will all undergo coronary angiography. The diagnosis is made according to American Heart Association (AHA, 2014 and 2015) guidelines. Patients who had autoimmune diseases, malignancies, chronic or acute infections, asthma, severe heart failure (NYHA class 3 and 4) and advanced liver or renal diseases are excluded.Blood (150 each group) is obtained into ethylenediaminetetraacetic acid（EDTA） tubes from all subjects via antecubital venepuncture to explore circulating wnt 2 and wnt 4 concentration by ELISA at 0 , 7days and 12 months after admission.
89197805|NCT00944398|Experimental|Zinc fortified group|Daily consumption of zinc-fortified complementary food
89197806|NCT00944398|Placebo Comparator|Non-fortified group|Daily consumption of non-fortified complementary food and placebo supplement.
89197807|NCT00944398|Experimental|Zinc supplement group|Daily consumption of zinc supplement and non-fortified complementary food.
89197808|NCT00862017|Experimental|MSG|Subjects receive a 6-d supplementation of MSG and are studied on the 7th day in the postprandial period following a standard meal ingestion with 2g MSG
89197809|NCT00862017|Placebo Comparator|Control|
89009522|NCT04709289|Experimental|Conventional Photodynamic Therapy(C-PDT) group|The conventional photodynamic therapy(C-PDT) group underwent narrow-band light-emitting diode (LED) irradiation (630 nm; 140 J/cm2) after applying 5% 5-aminolevulinic acid cream for 3h.A repeat treatment was administered once every two weeks for 3 times.
89009523|NCT00259038|Experimental|Experimental Drug|
89009524|NCT00259038|Placebo Comparator|Placebo|
89009525|NCT00230594|Active Comparator|1|desmopressin
89009526|NCT00230594|Placebo Comparator|2|placebo
89009527|NCT00479674|Experimental|Abraxane, Carboplatin, Bevacizumab|Abraxane 100 mg/m2 IV over 30 min days 1,8,15.; Carboplatin AUC=2 IV over 15 min days 1,8,15., Bevacizumab 10 mg/kg IV days 1,15
89009528|NCT02962310|Experimental|Test|Torrent Pharmaceutical Ltd's Rosuvastatin Calcium Tablets 40 mg
89009529|NCT02962310|Active Comparator|Reference|Crestor 40 mg Tablets of AstraZeneca Pharmaceuticals LP, USA
89531233|NCT03342131||Control group|150 age and body mass index matched healthy subjects with neither coronary artery disease nor any of the components of the metabolic syndrome are studied as Control group. Circulation wnt2 and wnt4 concentration in Control group will be measured only once with 24h after admission.
89536302|NCT03197779|Placebo Comparator|Placebo|Placebo intravenous administration
88913236|NCT01594112||Patient with at least one ID|Patient with ICD who received at least one inappropriate diagnosis (with or without therapy) during the 15 months follow-up.
88913237|NCT01594138||Suicidal Subjects|Suicidal Subjects
88913238|NCT01594138||Non-Suicidal Control Subjects|Non-Suicidal Control Subjects
88913239|NCT01594177|Experimental|Treatment arm|Afatinib-Trastuzumab (6 weeks) followed by Afatinib*-Paclitaxel-Trastuzumab (12 weeks) followed by Epirubicin-Cyclophosphamide-Trastuzumab (12 weeks). *only 11 weeks.
88913240|NCT01594190|Active Comparator|Low Dose Training|15 minutes/day on a weight-bearing treadmill
88913241|NCT01594190|Active Comparator|High Dose Training|2x 30 minutes/day on a weight-bearing treadmill
88913242|NCT01594203||Advanced Soft Tissue Sarcoma|patients with advanced Soft Tissue Sarcoma
88913243|NCT01594229|Experimental|Arm 1|Non-Hodgkin's Lymphoma (NHL)
88913244|NCT01594242|Experimental|Autophagy Induction After Bortezomib|"Subjects will undergo a baseline bone marrow aspirate and biopsy (under sedation if preferred by the subject) and have baseline blood samples (and urine samples if clinically indicated for measurement of their myeloma).~The following week, subjects will undergo a second bone marrow aspirate and biopsy and have additional blood samples taken for research assays prior to starting therapy on treatment day 1 with bortezomib at the standard dose of 1.3 mg/m2. Subjects will receive a second dose of bortezomib on treatment day 4, followed by a third bone marrow aspirate and biopsy on treatment day 4 or 5, along with serial blood samples on treatment days 4 and 5. After completion of the week of study treatment, subjects may continue treatment with the bortezomib-containing regimen planned by their treating oncologist. Active study participation will end after the completion of the week of study treatment."
88913245|NCT01594255|Experimental|AEB071 300 mg|
88913246|NCT01594255|Experimental|AEB071 900 mg|
88913247|NCT01594255|Placebo Comparator|Placebo to AEB071|
88913248|NCT01594255|Active Comparator|Moxifloxacin|
88913249|NCT01594268|Other|Kidney transplantation patient|Kidney transplantation patient; single arm
88913250|NCT01594307||blood pressure monitor|Cuff circumference:13.5cm-22cm
88913251|NCT01594307||stethoscopy|Cuff circumference: 13.5cm-22cm
88913252|NCT01594320|Experimental|Group A|
88913253|NCT01594320|Experimental|Group B|
88913254|NCT01594320|Experimental|Group C|
88913255|NCT01594320|Experimental|Group D|
88913256|NCT01594320|Experimental|Group E|
88913257|NCT01594320|Experimental|Group F|
88913258|NCT01594346|Placebo Comparator|Sugar Pill|
88913259|NCT01594346|Active Comparator|Alpha-Tocopherol|
88913260|NCT01594359|Active Comparator|High iron bean|High-iron bean
88913261|NCT01594359|Placebo Comparator|Low iron bean|Low-iron bean
88913262|NCT01594437|Experimental|TCN-202|
88913263|NCT01594437|Placebo Comparator|Placebo|
88913264|NCT01594450|Experimental|biological mesh|patients will undergo the implantation of a biological mesh (after debridement and treatment of the infection) at the same time as the primary operation, or within one month of randomization.
88913265|NCT01594450|Active Comparator|without biological mesh|patients undergo traditional wound care (debridement and treatment of infection), without placement of a biological mesh. For arm B, the common wound care used follows the normal practice of the treating surgeon, except the placement of the biological mesh, which must not be performed within 6 months of randomization.
88913266|NCT01594463|Experimental|late ultrasound examination|late examination between 34+1 weeks to 35+6 weeks.
88913267|NCT01594463|Experimental|early ultrasound examination|early examination between 30+1 weeks to 31+6 weeks
88913268|NCT01594489|Experimental|Aminophylline|Additional Aminophylline therapy to hydration (sodium bicarbonate) and N-acetilcysteine
88913269|NCT01594489|Active Comparator|Control group|Control group treated with hydration (sodium bicarbonate) and N-acetilcysteine
88913270|NCT01594502||Dutasteride Year 2 PCa|Subject assigned to dutasteride, prostate cancer found on Year 2 biopsy.
88913271|NCT01594502||Placebo Year 2 no PCa, Year 4 PCa|Subject assigned to placebo, no prostate cancer found on Year 2 biopsy, but prostate cancer found on Year 4 biopsy.
89009530|NCT00230711|Experimental|Exercise Counseling|
89009531|NCT00230711|Placebo Comparator|Contact Control|
89433435|NCT06202482|Experimental|Experimental group|Participants in the intervention group will participate in a 6-week Connect Active Program (CAP). Young participants will be the pioneers and take the initiative to change their inactive and sedentary lifestyles by including exercise into their daily routines about once a week, at least 45 minutes each time. For instance, they could organize family field trips to waterfront parks or involve their older family members in their favorite sports. All walking activities included in the study should be done with the Nike Run Club App for record and outcome measures. For other activities in CAP, participants will use other apps following that week's topic. For instance, they will use Google Maps to search for the best routes to their destinations; transportation apps such as Kowloon Motor Bus, Long Win Bus, and Mass Transit Railway apps to search for stops and exits.
89433436|NCT06202482|No Intervention|Control group|Participants in the control group will be provided with a leaflet as usual care. The pamphlet contains information about the benefits and some instructions for walking exercises for older adults.
89433437|NCT06199141||VV-ECMO patients|Patients requiring VV-ECMO for acute respiratory distress syndrome (ARDS)
89433438|NCT06198556|Experimental|HRS-1167 with rifampicin|
89433439|NCT06198023|Experimental|Educational|
89433440|NCT06198023|Experimental|Interactive|
89531234|NCT03095001|Experimental|Intraperitoneal bevacizumab+ carboplatin|"Intraperitoneal administration: intraperitoneal bevacizumab plus carboplatin every 3 weeks for 4-6 cycles~Systemic chemotherapy: paclitaxel, iv. every 3 weeks for 4-6 cycles"
89531235|NCT03095001|Active Comparator|Intraperitoneal carboplatin|"Intraperitoneal administration: intraperitoneal carboplatin every 3 weeks~Systemic chemotherapy: paclitaxel, iv. every 3 weeks for 4-6 cycles"
89531236|NCT03338699|Experimental|ShangRing|Topical anesthesia based, no-flip ShangRing circumcision.
89531237|NCT03338699|Active Comparator|Mogen clamp|Mogen clamp circumcision.
89197810|NCT00944476||Pts/volunteers getting regular MRI exam|Fat-free MRI images utilizing standard magnetization transfer imaging will be acquired on 10 patients known or suspected sarcoma of the of the extremity or trunk, in addition to their traditional clinical MRI. In addition, we will perform the same scans on 4 volunteers who have no history of sarcoma.
88913272|NCT01594502||Dutasteride Year 2 no PCa, Year 4 PCa|Subject assigned to dutasteride, no prostate cancer found on Year 2 biopsy, but prostate cancer found on Year 4 biopsy.
89197811|NCT00858039||Her-2 positive ESBC|
89197812|NCT00953368|Active Comparator|Remote ischemic preconditioning|Remote ischemic preconditioning will be induced by four 5-min cycles of upper limb ischemia and 5-min reperfusion with a blood-pressure cuff inflated to 200 mmHg and be performed before and after the coronary anastomosis
89433441|NCT06195176|Experimental|SHOULDER EXERCISES|Patients randomized to the exercise routine group will be instructed, upon recovery, about the exercise routine. The routine consists of lifting the shoulders as high as possible towards the ears, holding for 3 seconds, and then resting. This should be repeated 10 times at the beginning of each hour during the immediate postoperative period while on the hospital ward. The routine will be suspended at night. The procedure will be standardized, as the principal investigators will personally explain and demonstrate it to all involved individuals who are responsible for explaining it to the patients. In-person reminders will be made, and pain in the shoulders, incisions, and abdomen will be recorded at 6 hours and 24 hours postoperatively, as well as during the follow-up consultations on day post-surgery
89531238|NCT05042271||Meropenem: Patients who underwent TPE (Phase 1)|In phase 1, each patient received a 1 hour infusion of a single dose of 1 g of meropenem diluted in 100 ml of normal saline solution, at the same time as the start of the first therapeutic plasma exchange (TPE) and meropenem PK studies were carried out after the administration of meropenem. Blood samples (3 ml) were obtained by direct venipuncture at the following times: shortly before (time zero) and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6 and 8 hours after the start of the meropenem administration.
88913273|NCT01594502||Placebo, Year 2 and 4 no PCa|Subject assigned to placebo, no prostate cancer found on Year 2 or Year 4 biopsy.
88913274|NCT01594502||Dutasteride, Year 2 and 4 no PCa|Subject assigned to dutasteride, no prostate cancer found on Year 2 or Year 4 biopsy.
88913275|NCT01594502||Placebo, Year 2 PCa|Subject assigned to placebo, prostate cancer found on Year 2 biopsy.
88913276|NCT01594541||Patients Treated with CerefolinNAC®|
88913277|NCT01594541||Patients Not Treated with CerefolinNAC®|
88913278|NCT01594554||HCV Patients|A sample of 600 Han ethnic Chinese male or female who are ≥ 18 years old enrolled and completed in the study of AI452-009 (i.e., CCgenos cross sectional phase, ClinicalTrials.gov Identifier: NCT01293279).
88913279|NCT01594593|Experimental|Acceptance and Commitment Therapy|Group-based behavioral workshop to address cancer-related distress
88913280|NCT01594593|No Intervention|treatment as usual|
88913281|NCT01594606|Experimental|Animal-assisted|This group receives the dog training program in which they will be teaching a dog basic obedience skills.
88913282|NCT01594606|Active Comparator|Dog Walking|This group will walk a different dog each week but will not engage in dog training.
88913283|NCT01594619|Experimental|A|Single dose naloxegol 25mg
88913284|NCT01594619|Active Comparator|B|Diltiazem 240mg once daily day 4-6
88913285|NCT01594619|Active Comparator|C|Diltiazem 240mg once daily day 7 and 8. Single dose naloxegol 25mg day 7
88913286|NCT01594632|Experimental|Jadelle|Contraception using Jadelle implant
88913287|NCT01594632|Active Comparator|Sino-implant (II)|levonorgestrel containing subdermal contraceptive implant [Zarin, Femplant, Trust or Simplant]
88913288|NCT01594645|Experimental|Spermatozoa election using a polscope|AR+ spermatozoa are selected for ICSI using a polscope
88913289|NCT01594645|Active Comparator|Control|Spermatozoa for ICSI are selected based on morphology and motion under conventional light microscopy
88913290|NCT01594658||Foam sclerotherapy|This arm corresponds to ultrasound-guided foam sclerotherapy of superficial venous reflux plus conservative management
88913291|NCT01594658||Conservative|This arm only has medical standard handling (healings performed by the nurse group)
88913292|NCT01594671|Experimental|Tranexamic acid|"Intravenous Tranexamic Acid Two dosage Tranexamic acid during the surgical intervention: the first dosage 15-30' before the leg ischemia and the second dosage at 60 -90' after the first dosage.~Each dosage: 2 ampoules of 500mg/5 mL/ampoule Other Name: Amchafibrin"
88913293|NCT01594671|Active Comparator|Habitual haemostasia|The surgical habitual haemostasia.
88913294|NCT01594671|Experimental|Topical Tranexamic acid|Topical Tranexamic acid one dose before the closure of the knee joint: a solution containing 1g of tranexamic acid in 50 ml of normal saline (0.9% sodium chloride) applied with a syringe diffuser.
88913295|NCT01594684|Active Comparator|drug eluting balloon|treatment with drug eltuing balloon
88913296|NCT01594684|Placebo Comparator|uncoated balloon|treatment with uncoated balloon
88913297|NCT01594684|Active Comparator|double drug eluting balloon|if treatment fails 30 days or later
88913298|NCT01594697|Experimental|metformin|
88913299|NCT01594710||Apparently Health People|
88913300|NCT01594736|Active Comparator|ORSIRO|
88913301|NCT01594736|Active Comparator|XIENCE PRIME DES|
88913302|NCT01594775|Active Comparator|nasal spray|
88913303|NCT01594775|Placebo Comparator|Placebo|
88913304|NCT01594801|No Intervention|Control|Subject continue their routine therapy
88913305|NCT01594801|Experimental|Test|Subjects using the InsuPad device
88913306|NCT01594814||RFA of AVNRT of AVRT|
89433442|NCT06195176|Sham Comparator|HAND EXERCISES|Patients randomized to the exercise routine group will be instructed, upon recovery, about the exercise routine. The sham routine consists of tightly opening and closing the hands, holding for 3 seconds, and then resting. This should be repeated 10 times at the beginning of each hour during the immediate postoperative period while on the hospital ward. The routine will be suspended at night. The procedure will be standardized, as the principal investigator will personally explain and demonstrate it to all individuals responsible for instructing the patients. In-person reminders will be issued, and pain in the shoulders, incisions, and abdomen will be recorded at 6 hours and 24 hours postoperatively, as well as during the follow-up consultations on the 7th day after surgery.
89433443|NCT06194591|Active Comparator|Stage A - Active treatment|The medical device NephrospecTM is used to administer 6 treatments of Low-intensity extracorporeal shockwave therapy (Li-ESWT) to the kidneys during 3 weeks.
89433444|NCT06194591|Sham Comparator|Stage A - Sham treatment|The sham group will undergo the same treatment schedule, but with an applicator with an internal barrier to prevent shockwaves to pass through to the patient.
89433445|NCT06194591|Active Comparator|Stage B - Open label active treatment|Patients that were in the placebo group of stage A and do not exhibit a significant improvement in one of the main parameters will be eligible to enter stage B where they are treated with the active device in an open-label fashion.
89433446|NCT06193408|Experimental|VR-AD-1005|
89433447|NCT06193408|Placebo Comparator|Placebo|
89433448|NCT06193356|No Intervention|Pre learning tool|Assessment of endoscopic images prior to a learning tool about scars and recurrence
89433449|NCT06193356|Experimental|post learning tool|Assessment of endoscopic images after a learning tool about scars and recurrence
89433450|NCT06188715|Experimental|Arm A: MOX 4/8 mg|Combination therapy of moxidectin (4 mg or 8 mg, i.e. 2 or 4 tablets of 2 mg) and albendazole (Zentel®, 1 tablet of 400 mg) administered orally at day 0
89433451|NCT06188715|Active Comparator|Arm B: ALB|Placebo for moxidectin (2 or 4 tablets) and albendazole (Zentel®, 1 tablet of 400 mg) administered orally at day 0
89433452|NCT06188715|Placebo Comparator|Arm C: Placebo|Placebo for moxidectin (2 or 4 tablets) and placebo for albendazole (Zentel®, 1 tablet of 400 mg) administered orally at day 0
89433453|NCT06188364|Other|Standard of Care|Transition Supports and Services (USS) that prepare care partners of persons with TBI for post-rehabilitation discharge
89433454|NCT06188364|Experimental|Experimental|USS supplemented with community health services delivered by a certified CHW (CHW+USS) for care partners
89433455|NCT06187831||Before the change of the departmental pre-procedural platelet transfusion trigger for CVC placement|Patients ≥18 years of age admitted to a hematological ward at the current department, with an indication for CVC placement will be eligible for inclusion in the study
89433456|NCT06187831||After the change of the departmental pre-procedural platelet transfusion trigger for CVC placement|Patients ≥18 years of age admitted to a hematological ward at the current department, with an indication for CVC placement will be eligible for inclusion in the study
89433457|NCT06187181|Placebo Comparator|G. I : Completely edentulous patients|videofluroscopy for completely edentulous patients
89433458|NCT06187181|Active Comparator|G.II: patients with complete dentures|complete denture construction for edentulous patient and videofluroscopy evaluation
89433459|NCT06187181|Active Comparator|G.III: patients with implant overdentures|construction of implant overdenture and videofluroscopy evaluation
89531239|NCT05042271||Meropenem: after TPE (Phase 2)|was similar to phase 1 except that the meropenem administration and PK studies were conducted >6 hours apart from the next TPE
88913307|NCT01594840|Experimental|Changing chat|Diapers will have tips on them
89536303|NCT03197623|Experimental|LLP2A-ALENDRONATE|50, 150, 400, 750 or 1200 μg/kg or placebo given as a one time intravenous administration over 120 minutes.
88913308|NCT01594840|Active Comparator|Control|Normal diapers
88913309|NCT01594866|Placebo Comparator|Escitalopram, 20mg, placebo|escitalopram 20mg + placebo (same taste, appearance, texture of escitalopram 10mg)
88913310|NCT01594866|Experimental|Escitalopram 20mg, escitalopram 10mg|Escitalopram 20mg + Escitalopram 10mg
88913311|NCT01594879|Experimental|Endometrial cancer, LNG-IUS with MPA|
88913312|NCT01594892|Experimental|Dose intensified SBRT|Depending on the modified Mizumoto Score (0-4 points or 5-9 points) patients will be treated with 10 fractions of 4.85Gy in involved parts of the vertebra and 3Gy in not-involved parts using a simultaneous integrated boost or with 5 fractions of 7Gy in involved parts of the vertebra and 4Gy in not-involved parts using a simultaneous integrated boost, respectively.
88913313|NCT01594905|Experimental|Entecavir 1.0mg + Tenofovir 300mg|All subjects will orally take investigational drugs once daily for 48 weeks.
88913314|NCT01594918|Experimental|Cabazitaxel, Mitoxantrone, Prednisone|
88913315|NCT01594957|Experimental|LCQ908 (mild hepatic impairment plus healthy volunteers)|Healthy subjects will be matched pair-wise by, sex, race, age (±10 years) and weight (±20%) to subjects with mild hepatic impairment and will receive a single dose of LCQ908.
88913316|NCT01594957|Experimental|LCQ908 (moderate hepatic impairment plus healthy volunteers)|Healthy subjects will be matched pair-wise by, sex, race, age (±10 years) and weight (±20%) to subjects with moderate hepatic impairment and will receive a single dose of LCQ908.
89531240|NCT03094767|Experimental|Control Group|Patients will be submitted only to the initial protocol of rehabilitation, i. e., they will have only one session on the initial day and one session on the final day, after 12 weeks.
89531241|NCT03094767|Experimental|Interventional Group|Patients will participate in the cardiovascular rehabilitation program during 12 weeks.
89009532|NCT00230750|Experimental|2|100 subjects to receive 90 mcg of inactivated influenza A/H5N1 vaccine on days 0, 28, and 6 months following the 1st vaccination.
89009533|NCT00230750|Placebo Comparator|3|40 subjects to receive saline placebo on days 0, 28, and 6 months following the 1st vaccination.
89009534|NCT00230750|Experimental|1|100 subjects to receive 45 mcg of inactivated influenza A/H5N1 vaccine on days 0, 28, and 6 months following the 1st vaccination.
89009535|NCT00479401|Experimental|Pramipexole Extended Release (PPX ER)|
89009536|NCT00479401|Experimental|Pramipexole Immediate Release (PPX IR)|
89433460|NCT06186128|No Intervention|Control|All participants will receive the following: 1) a ClinCard and instructions for completing a weekly financial journal to record participants' spending patterns and social needs during the first 6 months of the study; 2) materials about financial literacy and community-based resources that provide support to low-income individuals; 3) description and instructions for follow-up assessments and check-ins; 4) a copy of signed medical release, consent, and HIPAA forms; 5) respondent-driven sampling referral cards; 6) 3 study referral cards, and 7) information about voter registration services provided through the Pulaski County Circuit and County Clerk's Office (https://www.pulaskiclerk.com/voter-registration/). Participants will be provided information about the importance of voting, restoration of voting rights, and the process of voting and sealing records.
89531242|NCT03338543|Experimental|percutaneous stimulation|PENS in 2/100 hertz (HZ), 30 min for each time, twice a day, for 3 days. With conventional analgesic medication if necessary.
89531243|NCT03338543|Experimental|transcutaneous stimulation|TENS in 2/100 HZ, 30 min for each time, twice a day, for 3 days. With conventional analgesic medication if necessary.
89009537|NCT00479401|Placebo Comparator|Placebo|
89009538|NCT00415818|Experimental|Arm 1|MVA-MUC1-IL2 in combination with 1st line Chemotherapy
89009539|NCT00415818|Active Comparator|Arm 2|1st line Chemotherapy without a MVA-MUC1-IL2 combination
89009540|NCT02962544|Active Comparator|Visumax device for FS-SMILE group|(FS-SMILE )femtosecond small incision lenticule extraction procedure using Visumax laser device as a surgical intervention for correction of myopia and myopic astigmatism will be done for 30 eyes of patients with myopia or myopic astigmatism.
89009541|NCT02962544|Active Comparator|FS 200 device for FS-LASIK group|(FS-LASIK)femtosecond assisted LASIK procedure using Fs200 laser device as a surgical intervention for correction of myopia and myopic astigmatism will be done for 30 eyes of patients with myopia or myopic astigmatism.
89009542|NCT00478777|Experimental|lenalidomide plus dexamethasone|Lenalidomide administered orally, 25 mg daily (QD) for the first 21 days of each 28-day cycle. Pulse dexamethasone administered orally, 40 mg daily on Days 1-4, 9-12, and 17-20 for each 28-day cycle during Cycles 1 to 4 (approximately months 1-4). Beginning with Cycle 5 (approximately month 5), dexamethasone was to be reduced to 40 mg QD for Days 1-4 of each 28 day-cycle.
89009543|NCT00477607|Experimental|Arm 1|Receiving alpha-lipoic acid during cisplatin treatment.
89009544|NCT00477607|Placebo Comparator|Arm 2|Receiving placebo during cisplatin treatment
89009545|NCT00259194|Active Comparator|Alternative Observation|Moving in bed during observation after coronary angiography
89009546|NCT00259194|Experimental|Standard Observation|No moving in bed during observation after coronary angiography
89009547|NCT00266214|Experimental|Lidocaine Patch 5%|1 patch applied topically to the volar aspect of each affected wrist daily, 2-4 hours before bedtime.
89009548|NCT00266214|Placebo Comparator|Placebo|1 patch applied topically to the volar aspect of each affected wrist daily, 2-4 hours before bedtime.
89009549|NCT00230945|Experimental|1|Patient-oriented education and support intervention
89009550|NCT00230945|Experimental|2|Couple-oriented education and support intervention
89009551|NCT00266253|Experimental|1|
89009552|NCT00266253|Experimental|2|
89009553|NCT00266253|Experimental|3|
89009554|NCT00266253|Experimental|4|
89009555|NCT00266253|Experimental|5|
89009556|NCT00266253|Active Comparator|6|
89009557|NCT04721678|Experimental|Interpersonal psychotherapy (IPT)|10 weeks of internet-administered interpersonal psychotherapy with therapist support.
89009558|NCT04721678|No Intervention|Wait-list control group|The participants in the control group will receive access to the treatment after the post-treatment assessment has been conducted.
89009559|NCT00415350|Active Comparator|Azithromycin treatment 1|
89009560|NCT00415350|Placebo Comparator|Placebo 2|
89009561|NCT00266331|Active Comparator|Group A, RayGel Topical Cream|RayGel Topical Cream applied in thin layer to the area exposed to radiation 60-90 minutes prior to radiotherapy, standard skin care between treatments.
89009562|NCT00266331|Placebo Comparator|Arm B Placebo Topical Cream|Placebo Topical Cream applied in thin layer to the area exposed to radiation 60-90 minutes prior to radiotherapy, standard skin care between treatments.
89009563|NCT00415389|Active Comparator|1|interactive educational program
89009564|NCT00415389|Active Comparator|2|usual medical care
89009565|NCT02961192|No Intervention|Control|Participants will receive a wireless weight scale and a wearable activity tracker to monitor their weight and step counts.
89009566|NCT02961192|Experimental|Supportive|Participants will receive a wireless weight scale and a wearable activity tracker to monitor their weight and step counts. Additionally, participants will play a game designed with insights from behavioral economics. The game will involve points and levels. In addition to playing the game, participants will identify a family member or friend to receive updates and support them in their progress.
89009567|NCT02961192|Experimental|Competitive|Participants will receive a wireless weight scale and a wearable activity tracker to monitor their weight and step counts. Additionally, participants will play a game designed with insights from behavioral economics. The game will involve points and levels. In this arm, participants will be placed into competitive groups with one or two other participants to play the game.
89009568|NCT02961192|Experimental|Collaborative|Participants will receive a wireless weight scale and a wearable activity tracker to monitor their weight and step counts. Additionally, participants will play a game designed with insights from behavioral economics. The game will involve points and levels. In this arm, participants will be placed into collaborative groups with one or two other participants to play the game.
89009569|NCT00231296|Active Comparator|Treatment with CryoCor Cryoablation System|Intervention includes ablation therapy with the CryoCor catheter for the treatment of symptomatic PAF.
89009570|NCT00231296|Active Comparator|Treatment with standard medical therapy|Intervention includes treatment with ant-arrhythmic medications alone.
89009571|NCT00415428||1.|
89009572|NCT00415467|Experimental|GliaSite Radiation Therapy System (RTS)|Surgical removal of brain tumor followed by GliaSite RTS targeted brachytherapy to the specific brain tumor site
89433461|NCT06186128|Experimental|Intervention|Participants in Arm 2 will receive a monthly UBI stipend of $500 for 6 months. Study staff will explain that UBI payments will continue for 6 months and that the UBI payments will be suspended if an individual is reincarcerated (e.g. the participant will not receive UBI payments to their ClinCard during months of incarceration and will not receive additional months post-release from incarceration). Participants will receive their monthly UBI payment, along with all study-related compensation for completing baseline and follow-up assessments, through a ClinCard, which is a loadable debit card with an ID number unique to the participant. The UBI will be loaded to the participant's ClinCard on the first day of each month.
89433462|NCT06185660||Chronic Kidney Disease patients not on dialysis|Chronic Kidney Disease patients not on dialysis
89433463|NCT06185660||Chronic Disease Patients on dialysis|Chronic Disease Patients on dialysis
89433464|NCT06185660||Heart Failure patients|Heart Failure patients receiving Renin angiotensin aldosterone inhibitors/Mineralocorticoid receptor antagonists (Raas i/Mras)
89433465|NCT06184399|Placebo Comparator|Arm A: IVM ODT Placebo|Placebo for ivermectin (oro-dispersible tablets) and albendazole (Zentel®, 1 tablet of 400 mg) administered orally at day 0
89433466|NCT06184399|Experimental|Arm B: IVM ODT 100 µg/kg|Combination therapy of ivermectin (100 µg/kg using oro-dispersible tablets of 1.5 mg) and albendazole (Zentel®, 1 tablet of 400 mg) administered orally at day 0
89433467|NCT06184399|Experimental|Arm C: IVM ODT 200 µg/kg|Combination therapy of ivermectin (200 µg/kg using oro-dispersible tablets of 1.5 mg) and albendazole (Zentel®, 1 tablet of 400 mg) administered orally at day 0
89433468|NCT06184399|Experimental|Arm D: IVM ODT 300 µg/kg|Combination therapy of ivermectin (300 µg/kg using oro-dispersible tablets of 1.5 mg) and albendazole (Zentel®, 1 tablet of 400 mg) administered orally at day 0
89433469|NCT06184399|Experimental|Arm E: IVM ODT 400 µg/kg|Combination therapy of ivermectin (400 µg/kg using oro-dispersible tablets of 1.5 mg) and albendazole (Zentel®, 1 tablet of 400 mg) administered orally at day 0
89433470|NCT06184399|Active Comparator|Arm F: IVM standard tablets|Combination therapy of ivermectin (Stromectol®, 200 µg/kg using tablets of 3 mg) and albendazole (Zentel®, 1 tablet of 400 mg) administered orally at day 0
89433471|NCT06183034|Other|Very Low Calorie Diet|Very Low Calorie Diet - caloric intake restricted to approximately 800 kcal/day
89433472|NCT06182150|Experimental|PAUSE-Cardio Moderate-Intensity Exercise Arm|Arm receiving moderate-intensity indoor cycling exercise once weekly for 4 weeks.
89433473|NCT06181253|Experimental|Prehabilitation group|Watch a video created by the investigators, discussing exercise prior to surgery, receive text message reminders to begin exercise before surgery, and take walking tests before and after surgery.
89433474|NCT06181253|No Intervention|Control group|Receive the usual preoperative and post operative care and they will be provided a pedometer.
89009573|NCT00231452|Experimental|Late exposure group|Participants received monthly Sulfadoxine-Pyrimethamine (SP) plus Artesunate (AS) from 2.5-4.5 months of age and monthly placebo from 5.5-9.5 months of age.
89009574|NCT00231452|Experimental|Early exposure group|Participants received monthly placebo from 2.5-4.5 months of age and monthly SP+AS from 5.5-9.5 months of age.
89433475|NCT06181032|Experimental|Single arm|Neoadjuvant treatment with adebrelimab in combination with apatinib gemcitabine and cisplatin
89433476|NCT06180486|Other|Waitlist control: Receive MMI After 90 days|The waitlist control group will allow for comparison of those who had access to the mindfulness meditation intervention (MMI) prior to surgery to those who did not. This group will be given the mindfulness meditation intervention 90 days after their surgery when all study questionnaires are complete. Up until 90-days, they will be asked the same questionnaires as the intervention group aside from the MMI practice survey and the exit survey. They will then be given the exit survey 2 weeks after receiving the MMI. This is done to ensure that both groups receive the potential benefit of the teachings and to deter patient dropout for those interested in the study because of wanting to receive the mindfulness training.
89531244|NCT03338543|No Intervention|Control|Conventional analgesic medication is offered.
89009575|NCT00231452|Placebo Comparator|Control group|Participants received monthly placebo from 2.5 to 9.5 months of age.
89009576|NCT00477490|Placebo Comparator|Placebo|Participants took a placebo 'melt' for 28 days to complete part 1 of the study. In part 2, placebo patients were randomized to one of the other 4 treatment arms based on assignments predetermined at the initial randomization, to receive active desmopressin melt for between 1 and 6 months (until the database for part 1 was locked and treatment was unblinded).
89009577|NCT00477490|Experimental|desmopressin melt 10 μg|Participants took desmopressin melt 10 μg for 28 days to complete part 1 of the study. Participants continued on this dose in part 2 of the study for between 1 and 6 months (until the database for part 1 was locked and treatment was unblinded).
89009578|NCT00477490|Experimental|desmopressin melt 25 μg|Participants took desmopressin melt 25 μg for 28 days to complete part 1 of the study. Participants continued on this dose in part 2 of the study for between 1 and 6 months (until the database for part 1 was locked and treatment was unblinded).
89197813|NCT00953368|Placebo Comparator|control|sham placement of a blood-pressure cuff around the upper limb without inflation
89197814|NCT00855387||Costs|Patients collected consecutively for undergoing major surgical procedures(liver, bile duct, pancreas, small bowel, colo-rectal, gastric bypass resections).
89197815|NCT00947596|Experimental|Atropine Dry Powder Inhaler|
89197816|NCT00947596|Active Comparator|Atropen Autoinjector|
89197817|NCT00865059|Experimental|A|Gabapentin 800 mg Tablets, single dose
89433477|NCT06180486|Experimental|Intervention: Receive MMI before their day of surgery|The intervention group will be given the mindfulness meditation intervention (MMI) 1 week prior to their day of surgery. Up until 90-days, they will be asked the same questionnaires as the waitlist control group, with the addition of the MMI practice survey and the exit survey.
89433478|NCT06178614|Experimental|JNJ-87890387|In Part 1 (Dose escalation) participants will receive JNJ-87890387. The dose will be escalated sequentially until the recommended phase 2 dose (RP2D) regimen(s) have been identified. In Part 2 (Dose expansion), participants will receive JNJ-87890387 at the RP2D regimen(s) determined in Part 1.
89433479|NCT06177132|Experimental|VIS-REHAB Protocol|The VIS-REHAB protocol entails 30-minute sessions conducted twice a week over a span of 9 weeks. These sessions are structured with 20 minutes dedicated to enhancing postural stability and 10 minutes focused on improving gaze stability. In greater detail, a minimum of 5 minutes time is reserved for counselling and providing background information on the exercises, focused on the vestibular issue. Apart from the counselling part, each session consist of 3 different exercise categories ((static postural stability, dynamic postural stability, general gross motor training (focus on PS), oculomotor function, gaze stability, or general gross motor training (focus on GS)), each carried out for 5 to 10 minutes.
89433480|NCT06177132|No Intervention|CTRL Protocol|In the control (CTRL) protocol, all forms of physical therapy in the context of motor development are ceased. Occupational therapy, speech-language therapy and physical therapy for other purposes are not covered by this commitment. Additionally, the child and parents are asked to not do any home exercises on their own. However, sports activities and other recreational hobbies will not be asked to be temporary halted, since they will be continued in the active rehabilitation programme as well.
89433481|NCT06177041|Experimental|M108 plus CAPOX|
89433482|NCT06177041|Placebo Comparator|placebo plus CAPOX|
89433483|NCT06176768|Experimental|LY3972406 Dose 1|Participants will receive an oral dose of LY3972406
89433484|NCT06176768|Experimental|LY3972406 Dose 2|Participants will receive an oral dose of LY3972406
89433485|NCT06176768|Placebo Comparator|Placebo|Participants will receive placebo.
89433486|NCT06175338|Experimental|Rituximab (manufactured by Mabscale, LLC)|Eligible subjects (104 patients) will receive Rituximab 1000 mg in 150 ml 0,9 % NaCl (total volume of infusion 250 ml) twice: on Visit 1 and 5. The following visits are the visits of safety and PK, PD and immunogenicity and also preliminary effectiveness). Patients will also receive background treatment Methotrexate+ Folic acid.
89433487|NCT06175338|Active Comparator|MabThera®|Eligible subjects (104 patients) will receive MabThera® 1000 mg in 150 ml 0,9 % NaCl (total volume of infusion 250 ml) twice: on Visit 1 and 5. The following visits are the visits of safety and PK, PD and immunogenicity and also preliminary effectiveness). Patients will also receive background treatment Methotrexate+ Folic acid.
89433488|NCT06174987|Experimental|T-DXd|"Participants who choose to continue treatment with T-DXd may be enrolled. Participants who were on the comparator arm in the parent study will be provided the option to access the drug through standard of care (SoC) or other available options.~Participants will remain on their current dosage regimen of T-DXd as the last dose administered in the parent study, unless they experience an AE that requires dose reduction at the EOT of the parent study, in which case the starting dose in this study will be the next lower dose-level."
89433489|NCT06173973|Active Comparator|Ketone Supplement|Ketone Supplement drink with 10 g ketones three times daily for five days.
89433490|NCT06173973|Placebo Comparator|Placebo Beverage|Matching Placebo drink three times daily for five days
89433491|NCT06173401|Experimental|Single-fraction spine SRS|Single-fraction spine SRS (22 Gy x 1)
89433492|NCT06173401|Experimental|Multi-fraction spine SRS|Multi-fraction spine SRS (14 Gy x 2)
89531245|NCT05054049|Experimental|Abbott i-stat Allinity|Randomised patients to this arm receive the application of the point of care testing device to provide further diagnostic information to assist clinical decision making.
89531246|NCT05054049|Placebo Comparator|Usual Care|Randomised patients to this arm receive usual care.
89531247|NCT03338465|Active Comparator|Group A|3 weekly sessions of focused extracorporeal shockwave treatment (2.000 impulses at 0.20 millijoules/mm2 per session)
89531248|NCT03338465|Active Comparator|Group B|3 weekly sessions of focused extracorporeal shockwave treatment (2.000 impulses at 0.01 millijoules/mm2 per session)
88913317|NCT01594957|Experimental|LCQ908 (severe hepatic impairment plus healthy volunteers)|Healthy subjects will be matched pair-wise by, sex, race, age (±10 years) and weight (±20%) to subjects with severe hepatic impairment and will receive a single dose of LCQ908.
89197818|NCT00865059|Active Comparator|B|NEURONTIN® 800 mg Tablets, single dose
88913318|NCT01594996||Seroquel XR group|
88913319|NCT01595009|Experimental|Everolimus (RAD001)|Participants received Everolimus 10 mg orally once daily until documented tumor progression, unacceptable toxicity or any other reason.
88913320|NCT01595022|Placebo Comparator|Flexi ring FR01|
89197819|NCT00956410|Experimental|CAD106|
89197820|NCT00865137|Experimental|1 FK506E|
89197821|NCT00756132||Bloods Only (B)|Women aged 18-65 years with a newly diagnosed locally advanced or high risk operable breast cancer
89197822|NCT00756132||A-Cog|Women aged 18-65 years newly diagnosed with LABC/high risk who are willing and able to complete cognitive testing.
89197823|NCT00756132||Control (C)|Healthy women aged 18-65 years who are willing and able to complete cognitive testing.
89197824|NCT00756132||A1-Cog|Women newly diagnosed locally advanced or high risk breast cancer that qualify for cognitive testing but have a condition related to elevated serum levels of cytokines or other inflammatory markers.
89197825|NCT00947674|Experimental|Cellsorba EX|
89197826|NCT00947674|Sham Comparator|Sham treatment|
89197827|NCT00862095|Placebo Comparator|Placebo|Placebo group
89433493|NCT06172452|Experimental|Project Body Neutrality SSI|Project Body Neutrality is a digital, self-guided SSI that teaches adolescents about body neutrality. It contains self-reflection exercises, vignettes from fictional peers, and psychoeducation that support users in understanding why body positivity may be a difficult mindset for some individuals to obtain; additional self-reflection exercises and vignettes that present body neutrality as a well-rounded alternative to body positivity; exercises that culminate in a user-generated list of activities that their body allows them to enjoy as well as statements they can use to counter negative thoughts about their body; writing prompts where users provide advice based on body neutrality principles to fictional peers struggling with their body image; and an opportunity to contribute their advice or reflections anonymously to a lab-run social media campaign as a form of body neutrality advocacy. See all materials for this intervention here: https://osf.io/7qtuj.
89433494|NCT06172452|Placebo Comparator|Supportive Therapy SSI|The Sharing Feelings SSI is a digital, self-guided SSI that is structurally similar to Project Body Neutrality, but it is designed to mimic supportive therapy (ST). The goals of the ST intervention are to encourage participants to identify and express feelings to close others; the intervention does not teach or emphasize specific skills or beliefs. The ST-SSI is designed to control for nonspecific aspects of intervention, including engagement in a computer program, reading and writing exercises, and vignettes from fictional peers. See all materials for this intervention here: https://osf.io/u4axs/.
89433495|NCT06171867|Experimental|Feasibility of the PNEUMACRIT belt|Neonates will be monitored with a PNEUMACRIT electrode belt for 6 to 24 hours. After the study period, patient parents and nurses will give feedback.
89433496|NCT06171386|Active Comparator|microneedling|microneedling is a form of collagen induction therapy, often used in conjunction with platelet-rich plasma or hyaluronic acid - Patients will receive two treatments, once at 6-8 weeks following facial surgery, and the second at 12-16 weeks following facial surgery
89433497|NCT06171386|Active Comparator|dermabrasion|dermabrasion is a technique that improves the skin structure, quality, and appearance of scars through collagen remodeling and reepithelization - Patients will receive the standard of care treatment 6-10 weeks following facial surgery
89433498|NCT06168006|Experimental|Exercise intervention|The subjects randomized to this group will perform three app-based training sessions per week for 12 weeks, each session lasting a maximum of 40 minutes.
89433499|NCT06168006|Sham Comparator|Control intervention|This group will receive a booklet with exercise instructions, and will be recommended the same frequency and duration of exercise as the experimental group
89433500|NCT06167681|Experimental|NouvNeu001|
89433501|NCT06163742|Active Comparator|Standard-of-Care|
89433502|NCT06163742|Experimental|Product X|
88913321|NCT01595022|Placebo Comparator|Flexi ring FR20|
88913322|NCT01595022|Placebo Comparator|Ultra low dose LCS|
89197828|NCT00862095|Experimental|Propranolol|Propranolol (target dose 80 mg a day)
88913323|NCT01595035|Experimental|counselling|Patients who receive the Pain booklet and support by telephone
88913324|NCT01595035|No Intervention|Control|Standard care
88913325|NCT01595074||Ancillary-Correlative (laboratory biomarkre analysis)|Archived RNA and DNA samples are analyzed for gene expression, mutations, and variations by RT-qPCR, MassARRAY, molecular inversion probe assay, and microarray assays. Results are then compared with patients' clinical outcomes.
88913326|NCT01595087|Experimental|Osteodex, infusion|Osteodex
88913327|NCT01595126||Patients with Central Nervous System Tumors|
88913328|NCT01595139||NF-1 without evidence of glioma|
88913329|NCT01595139||NF-1 with evidence of glioma|
88913330|NCT01595152|Active Comparator|solifenacin succinate (10 mg OD)|
88913331|NCT01595152|Active Comparator|fesoterodine (8mg OD)|
88913332|NCT01595165|Placebo Comparator|Control|Control group receiving saline instead of ropivacaine
89197829|NCT00862095|Experimental|Topiramate|Topiramate (target dose 100 mg a day)
89197830|NCT00862095|Experimental|Amitriptyline|Amitriptyline (target dose 50 mg a day)
89197831|NCT04054128|Experimental|Sodium bicarbonate catheter lock group (SBCL)|Chronic hemodialysis patients with a catheter as a vascular access, will be lock with sodium bicarbonate 7.5% Injection.
89197832|NCT04054128|Active Comparator|Heparin catheter lock group (HCL)|Chronic hemodialysis patients with a catheter as a vascular access, will be lock with heparin, 1000 Units/mL injectable solution
88913333|NCT01595165|Experimental|TAP|TAP group receiving ropivacaine total of 150 mg at TAP under US
88913334|NCT01595191|Active Comparator|Music by Mozart|"The sequence by which Bach, Mozart, or no music were administered (over 3 consecutive days) was determined by randomization using random numbers. Infants listened to Bach or Mozart using the compact discs entitled Baby Bach and Baby Mozart (Baby smart, Nir Zvi, Israel). The music was played using a music player at a volume of 65-70 dB with attached speakers which were placed at a distance of 30 cm from the infant's ears. According to the American Academy of Pediatrics recommendations (5): the volume did not exceed 75dB and the background noise near the infant's ears was maintained below 45 dB. Music (Mozart or Bach) was initiated 10 minutes prior to the beginning of the metabolic measurements and continued for 30 minutes while energy expenditure (EE) was recorded. In the same manner EE was recorded for each infant with no music therapy."
88913335|NCT01595191|Active Comparator|Bach Music|"The sequence by which Bach, Mozart, or no music were administered (over 3 consecutive days) was determined by randomization using random numbers. Infants listened to Bach or Mozart using the compact discs entitled Baby Bach and Baby Mozart (Baby smart, Nir Zvi, Israel). The music was played using a music player at a volume of 65-70 dB with attached speakers which were placed at a distance of 30 cm from the infant's ears. According to the American Academy of Pediatrics recommendations (5): the volume did not exceed 75dB and the background noise near the infant's ears was maintained below 45 dB. Music (Mozart or Bach) was initiated 10 minutes prior to the beginning of the metabolic measurements and continued for 30 minutes while energy expenditure (EE) was recorded. In the same manner EE was recorded for each infant with no music therapy."
88913336|NCT01595204|Experimental|Diagnostic Laparoscopy|Laparoscopy will be performed in each case of clinical/radiological suspicious primary advanced ovarian/peritoneal cancer.
88913337|NCT01595217|Experimental|MRCP and DWI using 3T MRI|MRCP and DWI using Magnetic resonance imaging（GE Signa,3.0 T )
88913338|NCT01595217|Experimental|MRCP only using 3T MRI|MRCP only using Magnetic resonance imaging（GE Signa,3.0 T )
88913339|NCT01595230|Experimental|Inertervention group_Clips to avoid internal herniation|LRYGB with closure of the defects with simple hernia stapler clips. Aim of this study is to evaluate the benefits and disadvantages of closing the mesenteric defects during gastric bypass in order to avoid internal herniation.
88913340|NCT01595230|No Intervention|Control group|conventional LRYGB without closure of the mesenteric defects
88913341|NCT01595243|No Intervention|control|patient with liver cancer in non-surgical treatment after discharge receive usual care
88913342|NCT01595243|Experimental|patient in experiment|patient in the experimental group will receive seven instances of telephone follow-up or face to face education
88913343|NCT01595256|Experimental|walking group|
88913344|NCT01595256|No Intervention|usual care|
88913345|NCT01595269|Placebo Comparator|Education mode 1 (control)|Education mode 1 (control) is comprised of participants educated using CHR's current traditional face-to-face delivery method, with printed materials and written log journals. These participants will be trained to use the University's web portal if they elect to access internet-based diabetes information. This allows for the tracking of the type and amounts of diabetes information accessed by participants.
88913346|NCT01595269|Active Comparator|Education mode 2 (static interface)|Education mode 2 (static interface) participants will be educated using digitized forms of the traditional materials provided by CHR as well as an electronic log journal (e-journal) where participants will record their diabetes-related outcomes and behavioural information. Education mode 2 will be assessed and approved by CHR.
89009579|NCT00477490|Experimental|desmopressin melt 50 μg|Participants took desmopressin melt 50 μg for 28 days to complete part 1 of the study. Participants continued on this dose in part 2 of the study for between 1 and 6 months (until the database for part 1 was locked and treatment was unblinded).
89009580|NCT00477490|Experimental|desmopressin melt 100 μg|Participants will take desmopressin melt 100 μg for 28 days to complete part 1 of the study. Participants will continue on this dose in part 2 of the study for between 1-6 months (until the database for part 1 is locked and treatment is unblinded).
89009581|NCT00415545|Experimental|1|Fluid Watchers LITE program
89009582|NCT00415545|Experimental|2|Fluid Watchers PLUS program
89433503|NCT06163079||Single women applying for sperm donation|"Inclusion of all single women consulting the Reproductive Medicine Service for a parenthood project by sperm donation between January 2021 and June 2023.~Exclusion :~Minors~Person under guardianship"
88913347|NCT01595269|Active Comparator|Education mode 3 (dynamic interface)|Education mode 3 (dynamic interface) participants will be educated using the digitized traditional materials from education mode 2 as well as an enhanced dynamic e-journal (visualization of blood glucose and alerts). In addition, this mode will provide informative disease-related internet sites and diabetes news and articles vetted by the medical team. Participants and health professionals will then be able to electronically discuss the content and quality of this information (discussion board). New sites and articles will be added on an ongoing basis. Participants will also have access to a chat room that will encourage information sharing with other education mode 3 participants and health professionals at CHR. Education mode 3 will be assessed and approved by CHR.
88913348|NCT01595295||Hypomethylating Agents|Patients treated with hypomethylating agents
88913349|NCT01595308|Experimental|Pomegranate juice|Pomegranate juice
89009583|NCT00415545|No Intervention|3|Usual care control group
89009584|NCT00231569|Experimental|Cohort A|Loading doses followed by weekly maintenance doses
89009585|NCT00231569|Experimental|Cohort B|Loading doses followed by weekly maintenance doses
89433504|NCT06163079||women in relationship with a women applying for sperm donation|"Inclusion of all women in relationship with a women consulting the Reproductive Medicine Service for a parenthood project by sperm donation between January 2021 and June 2023.~Exclusion :~Minors~Person under guardianship"
89433505|NCT06161896||DLBCL cohort|"Interventions for the DLBCL cohort are:~Fecal samples~Blood samples~Bioelectrical impedance analyses~Filling in questionnaires~All other procedures will be in accordance with local and national guidelines corresponding to clinical standard care."
89433506|NCT06161896||Healthy control cohort|"The control group applied in the current study is based on the Danish General Suburban Population Study (GESUS). The control subjects are selected from the GESUS cohort and matched according to age and gender.~Serial stool samples are planned in a subset of the control cohort with sampling time points corresponding to the DLBCL cohort. The sample material is handled and stored the same way as for the DLBCL cohort."
89433507|NCT06156930|Experimental|Intervention group Lavander|The group will receive aromatherapy massage with a 5% mixture prepared with sesame oil and lavender oil for 10 minutes on both lower leg areas, three times a week for four weeks.
88913350|NCT01595334|Active Comparator|Study subjects desiring pregnancy|"Study subjects to be treated with rFSH, rLH throughout controlled ovarian hyperstimulation (COH) in appropriate dosages,considering age, body mass index (BMI), ovarian reserve, etc. and GnRH antagonist, cetrorelix in 0.25 mg/d when needed till the desired follicular maturity and the minimum required number of follicles are achieved.~INTRVENTIONS - Monitoring at regular intervals by transvaginal ultrasound and hormonal studies.Once pregnancy established by beta-human chorionic gonadotropin (hCG) and ultrasound will be supported by intervention of adequate luteal support by estrogen (E) + progesterone (P) for 12 weeks of gestation."
88913351|NCT01595334|Other|Control subjects desiring pregnancy|"Control subjects selected in randomized way,desiring pregnancy will be treated with gonadotrophins, rFSH and rLH in appropriate dosages considering age, BMI, ovarian reserve, etc. after standard downregulation with GnRH agonist, Leuprolide acetate, 1 mg/d under established 'Long Luteal Suppression Protocol' from the previous cycle.~INTERVENTIONS - Monitoring of response to treatment by hormonal study and sonography evaluation at regular intervals during COH till adequate number of mature follicles of minimum 18 mm mean diameter is achieved, to be followed by hCG trigger and ovum pick-up (OPU) and embryo transfer (ET). Chemical pregnancy by beta-hCG would be confirmed 14 days post-ET. Clinical pregnancy would be confirmed by sonography 6 weeks after ET (visibility of yolk sac and fetal heart-beat). Pregnancy support by E+P for 12 weeks would be provided."
88913352|NCT01595347|Active Comparator|Hyper-oxigenated fatty acid|Hyper-oxigenated fatty acid,Equisetum arvense, Hypericum perforatum
88913353|NCT01595347|Experimental|Olive oil's Cream|Cream with 60% extra virgin olive oil.
88913354|NCT01595360|Placebo Comparator|Placebo|Placebo
88913355|NCT01595360|Experimental|TT-173|TT-173
88913356|NCT01595373|Active Comparator|Ghrelin|Ghrelin
88913357|NCT01595373|Placebo Comparator|Placebo|Ringer acetate is used for placebo.
89433508|NCT06156930|Placebo Comparator|Placebo group sesame|The group will receive a massage with sesame oil on both lower leg areas for 10 minutes on each leg, three times a week for four weeks.
89433509|NCT06156930|No Intervention|Control group|Group of individuals receiving HD treatment who do not receive any treatment other than standard treatment
89433510|NCT06156514|Experimental|A (Gemcitanine)|To receive concomitant chemotherapy based on gemcitabine at 300 mg / m2 weekly
88913358|NCT01595399|Active Comparator|Atropine, fentanyl and succinylcholine|20 mcg/kg atropine IV, 3 mcg/kg fentanyl slowly IV and 2 mg/kg succinylcholine IV.
88913359|NCT01595399|Placebo Comparator|placebo, fentanyl and succinylcholine|an equivalent volume of normal saline to atropine IV, 3 mcg/kg fentanyl slowly IV and 2 mg/kg succinylcholine IV.
88913360|NCT01595412|Active Comparator|Cohort 2|Cohort 2 (two) will consist of 120 patients with an external rectal prolapse (Oxford Grade V)treated by Laparoscopic Resection Rectopexy (LRR). These patients will be included in the US centers involved in this study and treated by LRR.
88913361|NCT01595412|Active Comparator|Cohort 1|Cohort one will consist of 120 patients with an external rectal prolapse (Oxford Grade V) which will be treated with Laparoscopic Ventral Rectopexy. As this is the standard treatment in the European centers involved in this study these patients will be selected in the participating centers in the Netherlands, Belgium and England.
89433511|NCT06156514|Active Comparator|B (Cisplatin)|To receive concomitant chemotherapy based on cisplatin 40 mg / m2 weekly
88913362|NCT01595425|Experimental|D961H Sachet 20 mg|2 way crossover
89433512|NCT06155396|Experimental|Disitamab Vedotin + Zimberelimab|Disitamab Vedotin（RC48-ADC）with Zimberelimab arm
89433513|NCT06152809|Experimental|Cohort 1: Dose Level 0|"A maximum tolerated dose (MTD) will be established, and dosage will start at dose level 0. 5-10 participants at dose level 0 will complete:~Baseline visit.~Bone marrow biopsies: at screening visit #2, end of treatment, and at discretion of PI.~Days -6 through -2: predetermined doses of standard-of-care lymphodepleting chemotherapy.~Day 0: Predetermined dose of CIML NK cells 1x daily. Hospitalization for up to 3 to 4 weeks for CIML NK infusion.~Days 0 through 12: Predetermined dose of IL-2 1x daily every other day for up to 7 doses.~Day 7 through Day 21: Predetermined dose of Venetoclax 1 x daily.~If ≤1 dose-limiting toxicities (DLTs) are observed, this dose will be the MTD, and 5 additional participants will be enrolled.~Follow-up visits: Days 42, 60, 100 and months 6, 9, and 12."
89433514|NCT06152809|Experimental|Cohort 1: Dose Level -1|"De-escalation to dose level -1 will be conducted per protocol if DLTs occur in Cohort 1 dose Level 0. Participants will complete:~Baseline visit.~Bone marrow biopsies: at screening visit #2, end of treatment, and at discretion of PI.~Days -6 through -2: predetermined doses of standard-of-care lymphodepleting chemotherapy.~Day 0: Predetermined dose of CIML NK cells 1x daily. Hospitalization for up to 3 to 4 weeks for CIML NK infusion.~Days 0 through 12: Predetermined dose of IL-2 1x daily every other day for up to 7 doses.~Day 7 through Day 21: Predetermined dose of Venetoclax 1 x daily.~Follow-up visits: Days 42, 60, 100 and months 6, 9, and 12."
89197833|NCT00956566|Active Comparator|low fat hypocaloric diet|
89197834|NCT00956566|Active Comparator|Low carbohydrate hypocaloric diet|
89197835|NCT00865215|Experimental|A|Propranolol Hydrochloride Extended Release Capsules 160 mg, single dose
89197836|NCT00865215|Active Comparator|B|INDERAL® LA 160 mg Capsules, single dose
89197837|NCT00865293||Obesity|Subjects with obesity, defined as BMI > 30, aged 25-60
89197838|NCT00865293||Control|Subjects with a BMI 18,5-25, aged 25-60
89197839|NCT00684060|Experimental|1|Participants will receive active stem cell infusion 2 to 3 weeks after a percutaneous coronary intervention (PCI).
89197840|NCT00684060|Placebo Comparator|2|Participants will receive placebo infusion (5% human serum albumin [HSA]) 2 to 3 weeks after a PCI.
89009586|NCT00231569|Experimental|Cohort C|Loading doses followed by weekly maintenance doses
89009587|NCT00231569|Experimental|Cohort D|Loading doses followed by weekly maintenance doses
89197841|NCT00865371|Experimental|A|Abrika Bupropion 150 mg Extended-Released Tablet, single dose
89197842|NCT00865371|Active Comparator|B|Wellbutrin SR® 150 mg Extended-Release Tablet, single dose
89433515|NCT06151847|Experimental|Treatment (Lifileucel)|Lifileucel (LN-144) is an autologous Tumor Infiltrating Lymphocytes (TIL) cell therapy. A tumor sample is resected from each patient for lifileucel manufacturing. Patients then receive the lifileucel regimen which consists of a reduced dose non-myeloablative lymphodepletion, lifileucel infusion followed by interleukin-2.
89433516|NCT06147414||pregnant women undergoing invasive PND in a context of family history of SGD|SGD-NIPD will be proposed by CPDPN recruitment centres to pregnant women undergoing invasive PND in a context of family history of SGD because of parental pathogenic mutation.s in one of the following gene: HBB, CFTR, FMR1, SMN1, DMPK, DMD, NF1, HTT, F8, F9, GCK, L1CAM, PKHD1 or ATP7A
89197843|NCT00865449|Active Comparator|1|Peritoneal Dialysis patients on aldactone for 6 months
89433517|NCT06147414||pregnant women undergoing prenatal counselling in a context of maternal history of diabetes MODY-GCK|
89433518|NCT06147076|No Intervention|Usual Pre-Transplant Counseling Intervention|Participants in control arm will undergo usual pre-transplant counseling as per the standard of care.
89433519|NCT06147076|Experimental|Social Support Network Counseling Intervention|Participants in the intervention arm will undergo an additional pretransplant counseling session along with members of their social support networks after their initial transplant evaluation and counseling.
89433520|NCT06146790|Experimental|Endovascular treatment+ standard medical management|For the subjects randomized to endovascular treatment (EVT), treatment initiation is defined as the date and time of arterial puncture. Ideally, femoral artery puncture will occur within 30 minutes of randomization and no longer than 60 minutes after the completion of the qualifying imaging. Treatment initiation (arterial puncture) must occur before 12 hours since the subject was last known well. Date and time of arterial puncture, revascularization, and procedure end will be recorded. It is expected that the interventional procedure will be completed within two (2) hours of arterial access. If an appropriate thrombus or residual stenosis is identified, the choice of EVT strategy will be made by the treating neurointerventionalist. All mechanical thrombectomy devices for EVT, which are approved by CFDA for this purpose, are allowed in the trial.
89433521|NCT06146790|Active Comparator|Standard medical management|Standard medical management
89433522|NCT06146348||CVC confirmed by DRAUP|new mode of CVC confirmation for correct location and excluding pneumothorax
89433523|NCT06146348||CVC confirmed by CXR|traditional mode of CVC confirmation for correct location and excluding pneumothorax
89433524|NCT06145321|Experimental|Experimental Group|G-CSF at a dose of 5 mcg/kg/day intravenously infused for 4 hours
89433525|NCT06145321|Other|Control Group|G-CSF at a dose of 5 mcg/kg/day intravenously bolus
89433526|NCT06143046|Experimental|mRNA-1345 Dose A|Participants will be vaccinated in the period from 28 weeks to 36 weeks of gestation with a single intramuscular (IM) injection of mRNA-1345 Dose A.
89433527|NCT06143046|Experimental|mRNA-1345 Dose B|Participants will be vaccinated in the period from 28 weeks to 36 weeks of gestation with a single IM injection of mRNA-1345 Dose B.
89433528|NCT06143046|Experimental|mRNA-1345 Dose C|Participants will be vaccinated in the period from 28 weeks to 36 weeks of gestation with a single IM injection of mRNA-1345 Dose C.
89433529|NCT06143046|Placebo Comparator|Placebo|Participants will receive single IM injection of mRNA-1345 vaccine matching placebo in the period from 28 weeks to 36 weeks of gestation.
89531249|NCT02138955|Experimental|Liposomeal curcumin ascending dose phase 1b|
89009588|NCT00231569|Experimental|Cohort E|Loading doses followed by weekly maintenance doses
89009589|NCT00231569|Experimental|Cohort F|Loading doses followed by extended weekly maintenance doses
89197844|NCT00865449|Placebo Comparator|2|Peritoneal dialysis Patients on the placebo arm for 6 months
89197845|NCT00865527|Active Comparator|Fecal Occult Blood Test|fecal occult blood test
89197846|NCT00865527|Active Comparator|Virtual Colonoscopy|virtual colonoscopy
89197847|NCT00865527|Active Comparator|Optical Colonoscopy|optical (conventional / endoscopic) colonoscopy
89009590|NCT00231569|Experimental|Cohort G|Loading doses followed by extended weekly maintenance doses
89009591|NCT00477334|Experimental|1|Famciclovir 1000 mg; twice a day for one day.
89009592|NCT00477334|Placebo Comparator|2|Placebo; twice a day for one day.
89197848|NCT00858195|Experimental|1|Indomethacin 75mg ER Capsules
89197849|NCT00858195|Active Comparator|2|Indocin 75mg SR Capsules
89197850|NCT00750516||Lacid|Hypotensive, non pregnant by history, non comfort care Emergency Department patients.
89197851|NCT00750594||1|
89197852|NCT00750594||2|
89197853|NCT00858351|Experimental|Thermal Biofeedback Assisted Relaxation|
89197854|NCT00858351|Active Comparator|Discussion|
89197855|NCT03131648|Experimental|Initial treatment period - Tralokinumab Q2W|"Week 0 to Week 16:~Two subcutaneous (SC) injections of tralokinumab as a loading dose on Day 0, followed by a SC injection of tralokinumab Q2W regimen for 16 weeks."
88913363|NCT01595425|Experimental|D961HHPMC Capsule 20 mg|2 way crossover
88913364|NCT01595451|Active Comparator|Traditional Acupuncture|Acupuncture will be delivered to 12 points traditionally used to treat chronic low back pain.
88913365|NCT01595451|Placebo Comparator|Non-traditional Acupuncture|You will receive non-traditional acupuncture at 12 points for chronic low back pain.
88913366|NCT01595464|Experimental|Mind-Body Skills Groups|
88913367|NCT01595464|No Intervention|Control Group|
88913368|NCT01595477|Experimental|Mind-Body Skills Groups|
88913369|NCT01595477|No Intervention|Control Group|
88913370|NCT01595490|Experimental|Mind-Body Skills Groups|
88913371|NCT01595490|No Intervention|Control Group|
88913372|NCT01595542|Experimental|Intervention|Parents served by experimental school sites received intervention packets including modified vaccine consent form
88913373|NCT01595542|No Intervention|Control|Did not receive intervention materials
88913374|NCT01595568|Experimental|Learning to cope with your impulsivity|Cognitive-behavioural intervention targeting impulsive personality
88913375|NCT01595568|Experimental|Learning to cope with your sensation seeking|Cognitive behavioural intervention designed to help sensation seeking youth manage their need for stimulation and excitement.
88913376|NCT01595568|Experimental|Learning to cope with your anxiety sensitivity|Cognitive behavioural intervention teaching anxiety sensitive youth to manager their sensitivity to threat and anxiety.
88913377|NCT01595568|Experimental|Learning to manage your negative thinking|Cognitive behavioural intervention targeting pessimistic and negative thinking in hopeless youth
88913378|NCT01595594|Active Comparator|Systemic Doxycycline|
88913379|NCT01595594|Experimental|aPDT+ Placebo|
88913380|NCT01595607|Active Comparator|Typical American Diet|Participants will receive a typical American diet for 6 weeks.
88913381|NCT01595607|Experimental|Avocado Diet|Participants will receive a modified typical American diet in which avocado is substituted for foods that contain moderate and high amounts of saturated fat to allow the inclusion of avocado.
88913382|NCT01595633|Active Comparator|Adefovir, nucleoside analogues|Nucleoside analogues (Lamivudine 100mg, Telbivudine 600mg, Entecavir 1mg, or Clevudine 30mg) + Adefovir 10mg
88913383|NCT01595633|Experimental|Tenofovir, nucleoside analogues|Nucleoside analogues (Lamivudine 100mg, Telbivudine 600mg, Entecavir 1mg, or Clevudine 30mg) + Tenofovir 300mg
88913384|NCT01595659|Placebo Comparator|no alcohol and passenger|Blood alcohol concentration (BAC) = 0.00% and risk accepting or averse passenger
88913385|NCT01595659|Experimental|low alcohol dose and passenger|BAC = 0.02% and risk accepting or averse passenger
88913386|NCT01595659|Experimental|moderate alcohol dose and passenger|BAC = 0.05% and risk accepting or averse passenger
88913387|NCT01595672|Active Comparator|EHVCVVH group|Patients receive conventional treatments recommended by guidelines with adjunctive early high-volume continuous veno-venous hemofiltration (EHVCVVH).
88913388|NCT01595672|Active Comparator|Control group|Patients receive conventional treatments recommended by guidelines only.
88913389|NCT01595685|Experimental|Telbivudine|Telbivudine 600 mg Daily Oral
88913390|NCT01595685|Active Comparator|Entecavir|Entecavir 0.5 mg Daily Oral
88913391|NCT01595698|Sham Comparator|Control|
88913392|NCT01595698|Experimental|Physical Exercise|
88913393|NCT01595711||Thoracotomized patients|
88913394|NCT01595724||Group 1|
88913395|NCT01595737|Experimental|Levosimendan|
88913396|NCT01595737|Placebo Comparator|Placebo|
88913397|NCT01595750|Placebo Comparator|Placebo|
88913398|NCT01595750|Active Comparator|Roflumilast|Roflumilast 500 mcg
88913399|NCT01595763||Deep Vein Thromobosis signs or symptoms|
88913400|NCT01595776|Experimental|single arm: autologous EPCs|
88913401|NCT01595789|Placebo Comparator|Placebo + metformin|
88913402|NCT01595789|Active Comparator|Liraglutide + metformin|
88913403|NCT01595815|Active Comparator|Conventional ICSI|The couple showed complete fertilization failure after ICSI.
88913404|NCT01595815|Active Comparator|Convention ICSI|The couple showed a low fertilization rates after ICSI.
88913405|NCT01595828|Experimental|Pitavastatin 4mg daily|4 mg tablets of pitavastatin by oral route for a period of 6 months
88913406|NCT01595867|Placebo Comparator|Treatment A|Placebo
88913407|NCT01595867|Experimental|Treatment B|EMBEDA 30 mg crushed
88913408|NCT01595867|Active Comparator|Treatment C|Morphine Sulfate Controlled Release 30 mg crushed
88913409|NCT01595880|Experimental|G+M|Coadministration of gemigliptin 50mg and metformin HCl extended release 500mg
88913410|NCT01595880|Experimental|C|Combination of gemigliptin50mg/metformin HCl extended release 500mg
88913411|NCT01595893|Experimental|Vitamin D3|
88913412|NCT01595893|Placebo Comparator|Placebo|
88913413|NCT01595906|Experimental|The experiment subjects|"The subjects will undergo:~6 acclimatization days carried out by a standard protocol including a daily 2 hour effort performed in a climatic chamber, during which the subjects walk on a treadmill at 5km/h on a 2% incline under heat conditions (40 deg. centigrade & 40% RH). Core (rectal) and skin temperatures and heart rate will be monitored continuously.~Three consecutive days including 3 scenarios:~Without a helmet b.With a helmet c.With a ventilated helmet During the experiment days the subjects will be exposed to the following protocol : A 5 minute sitting, performing cognitive tests on a computer for 15 min, 120 min walking on a treadmill at 5km/h on a 2% incline, at the end of the effort the same cognitive tests will be repeated for extra 15 min, 155 min in total."
88913414|NCT01595919|Experimental|1% Milk|
88913415|NCT01595919|Experimental|Regular Cola|
88913416|NCT01595919|Experimental|Diet cola|
88913417|NCT01595919|Experimental|Orange juice|
88913418|NCT01595919|Placebo Comparator|Water|
88913419|NCT01595932|Placebo Comparator|placebo|
88913420|NCT01595932|Experimental|α-galactosidase|
88913421|NCT01595945|Other|Gastric bypass|Subjects with planned gastric bypass surgery are followed-up in regard of resting metabolic rate.
88913422|NCT01595945|Other|Caloric restriction|Caloric restriction calculated by an online weight management program (based on subject's starting weight, start BMI, age, target weight and time span). Subjects are followed-up in regard to resting metabolic rate.
88913423|NCT01595958|Experimental|Cyclosporine A|Single intravenous bolus of cyclosporine A (2.5 mg/kg) at the onset of resuscitation
88913424|NCT01595958|Active Comparator|Control|usual care of cardiac arrest
88913425|NCT01595971|Experimental|continuing education|RESPIRANET is a multifaceted intervention directed at professionals of the Family Health Teams in the inner cities.Includes telemedicine, reminders, video conferences, educational materials for patients and consultants.
88913426|NCT01595971|Placebo Comparator|Usual Care|usual care
88913427|NCT01595984|Active Comparator|Cyclosporin + Mycophenolate mofetil|
88913428|NCT01595984|Experimental|Everolimus + mycophenolate mofetil|
88913429|NCT01595997|Placebo Comparator|Placebo|
88913430|NCT01595997|Experimental|DLX105|
88913431|NCT01596010|Experimental|New formulation|
88913432|NCT01596010|Active Comparator|Old formulation|
88913433|NCT01596023|Experimental|NIOV Ventilator|Breathe NIOV Ventilator under various volume augmentation settings
88913434|NCT01596036|Experimental|Early Appointment|Patients will receive an early appointment (within 10 days) from the time of their anticipated hospital discharge
88913435|NCT01596036|Placebo Comparator|Standard Referral|Patients will receive an appointment to cardiac rehabilitation at 5 weeks from the date of their anticipated hospital discharge. A routine referral to cardiac rehabilitation will also occur in parallel. Consequently, it is possible that some patients will attend cardiac rehabilitation earlier than their assigned 5 week appointment.
88913436|NCT01596049||Self-fixating Mesh|patients attributed to that arm, undergoing surgery of open inguinal unilateral hernia repair, using Self-fixating Mesh which is acceptable in the literature.
88913437|NCT01596075|Experimental|Oral Cannabidiol|Patients undergoing allogeneic SCT will receive standard GVHD prophylaxis consisting of a calcineurin inhibitor and methotrexate or mycophenolate mofetil. Patients developing grade I/II acute GVHD will be treated by IV or oral methylprednisolone 1-2 mg/kg/day and oral cannabidiol at a starting dose of 10 mg twice daily. Doses of cannabidiol can be escalated every day according to clinical response to a maximal dose of 600 mg/day,if no significant drug related side effects present (CTCAE3 grade>2). Cannabidiol will be given up to 90 days.
88913438|NCT01596101||acute burns|
88913439|NCT01596101||rehab patients|
88913440|NCT01596114|Experimental|Stop treatment|TKI treatment will be stopped in CML patients with very deep molecular responses for at least one year and at least 3 years TKI treatment
88913441|NCT01596140|Experimental|Vemurafenib + Oral Everolimus|Vemurafenib starting dose 720 mg orally twice day (morning/evening) for 28-day cycle plus Oral Everolimus starting dose 5 mg daily.
89009593|NCT00266565|Experimental|Anti-IL5 (Mepolizumab)|The purpose of the study is to assess the toxicity of anti-IL-5 (Mepolizumab), and to see whether it lowers eosinophils in peripheral blood and/or tissue and whether it has a steroid and/or interferon sparing effect.
89009594|NCT02211859|Experimental|BI 2536|single escalating dose, followed by repeated administration in patients with clinical benefit
89009595|NCT04560985|Experimental|Hydrophilic sealant|UltraSeal XT hydro™ sealant ®
89009596|NCT04560985|Active Comparator|Hydrophobic sealant|Helioseal-F Sealant ®
89009597|NCT04721483|Active Comparator|T3-T4 sympathicotomy|In this group, patients underwent a classical T3 and T4 sympathicotomy to treat primary palmar hyperhidrosis
89009598|NCT04721483|Experimental|T3-T4 ramicotomy|In this group, patients underwent a selective T3 and T4 gray ramicotomy
89009599|NCT04560946|Experimental|PACT|Personalized Augmented Cognitive Training (PACT)
89009600|NCT04560946|Active Comparator|ETAU|Enhanced Treatment As Usual (ETAU)
89009601|NCT04561024||RT-PCR Positive Patients|RT-PCR confirmed patients positive for SARS-CoV-2
89009602|NCT04561024||Negative patients|RT-PCR confirmed patients negative for SARS-CoV-2 or patients with CXR performed before the emergence of COVID-19 pandemic
89009603|NCT04561336|Experimental|avelumab plus cetuximab|avelumab at a dose of 10 mg/kg once every 2 weeks plus cetuximab at a starting dose of 400 mg/m2 by i.v.infusion over 120 minutes at first dose and at the dose of 250 mg/ m2 by i.v.infusion over 60 minutes for subsequent infusions every week.
89009604|NCT00259428|Experimental|Dronedarone 400mg bid|dronedarone 400mg tablets
89009605|NCT00259428|Placebo Comparator|Placebo|matching placebo tablets
89536304|NCT03197623|Placebo Comparator|Placebo|Placebo given as a one time intravenous administration over 120 minutes.
89009606|NCT04560907|Experimental|Aquablation|
89009607|NCT04560907|Active Comparator|HoLEP|
89009608|NCT02211898|Experimental|BNS003|
89009609|NCT04560751||Lenvatinib and TACE|Patients in Lenvatinib + TACE group will take oral lenvatinib within ten days after TACE.
89009610|NCT04560478|Active Comparator|Pro Seal Sealant|ProSeal Sealant was applied to the facial surfaces of the maxillary anterior teeth (canine to canine)
89009611|NCT04560478|Active Comparator|MI Varnish|MI Fluoride Varnish was applied to the maxillary anterior teeth (canine to canine)
89009612|NCT04560244|Experimental|SHR 1701+radiotherapy|SHR-1701 Simultaneously Combined with High Fractionation and Low-dose Radiotherapy
89009613|NCT04559854|Experimental|Mindful After Cancer|Participants will be asked to attend 8 weekly sessions via videoconference, and to complete home activities and mindfulness practice between sessions.
89009614|NCT04560205|Experimental|Group intervene with Tocilizumab|"Review effect of Tocilizumab as clinical trial among hospitalized patients with COVID-19 infection.~Participants with severe disease will receive an intravenous (IV) injection of 8 mg/kg (not to exceed 800 mg) tocilizumab. Specifically, we will test whether tocilizumab is associated with a reduction in multi-organ dysfunction among hospitalized COVID-19 adult patients with elevated inflammatory biomarkers."
89009615|NCT04559971|Experimental|1.0mg/kg|Drug: SLN124
89009616|NCT04559971|Placebo Comparator|Placebo|
89009617|NCT04559971|Experimental|3.0mg/kg|Drug: SLN124
89009618|NCT04559971|Experimental|Optional Cohort|An additional dose level may be explored
89009619|NCT04560049|Experimental|Phenolisation|Surgical pit excision and phenolisation of sinus tract
89009620|NCT04560049|Active Comparator|Silver Nitrate Irrigation|Surgical pit excision and silver nitrate irrigation of sinus tract
89009621|NCT04559425||Prospective observational cohort 1|Complete AVB (3rd degree) diagnosed ≤ 32+0 weeks with or without hydrops
89009622|NCT04559425||Prospective observational cohort 2|Incomplete AVB (2nd; 2:1; 2nd-3rd degree) diagnosed ≤ 32+0 weeks with or without hydrops
89009623|NCT04559503|Experimental|İntervention Group|Progressive relaxation exercises were applied once a day for four weeks in the intervention group in addition to the standard treatments. The patients were called 3 times each week on the telephone, and it was monitored whether they continued to do the exercises.
89009624|NCT04559503|No Intervention|Control group|The control group received standard treatment.
89536305|NCT03195595||mitral valve replacement|patients whom underwent Mitral valve replacement through minimal invasive incision
89536306|NCT03195595||conventional mitral valve replacement|patients whom underwent Mitral valve replacement through conventional sternotomy
89009625|NCT04559776|Experimental|typically developing toddlers|toddlers with a typical development and with less than 3 years old and less than 6 months of independent walking
89433530|NCT06142552|Experimental|Prevention and Treatment Group (PPX group)|"Subjects received single and multiple doses of 50 IU/kg FRSW117 at first administration of V1 (D1), V4 (18w), and V7 (50w), and PK samples were collected until 168 h post-administration, respectively.~During prophylaxis, FRSW117 is used for breakthrough therapy if the subject has a breakthrough bleeding event (i.e., a bleeding event during prophylaxis) that requires treatment."
89197856|NCT03131648|Placebo Comparator|Initial treatment period - Placebo Q2W|"Week 0 to Week 16:~Two subcutaneous (SC) injections of placebo as a loading dose on Day 0 followed by a SC injection of placebo Q2W regimen for 16 weeks."
89433531|NCT06142552|Experimental|On Demand/Preventive Treatment Group (On Demand /PPX Group)|The appropriate dose and frequency of administration of FRSW117 is recommended until bleeding events are controlled or returned to pre-bleeding activity.
89433532|NCT06142552|Experimental|Perioperative management|Patients in the PPX and on demand /PPX groups will be allowed to undergo surgery (both major and minor) during the main trial period (prior to 50w), while FRSW117 will be administered perioperatively
89009626|NCT04559776|Experimental|unilateral cerebral palsy toddlers|toddlers with a unilateral cerebral plasy and with less than 3 years old and less than 6 months of independent walking
89009627|NCT04559308|Experimental|metformin arm|4 cycles (Doxorubicin+Cyclophosphamide) followed by 12 cycles Paclitaxel+ Metformin (1000 mg twice daily) followed by surgery.
89009628|NCT04559308|Active Comparator|control arm|4 cycles (Doxorubicin+Cyclophosphamide) followed by 12 cycles Paclitaxel followed by surgery.
89009629|NCT04559191|No Intervention|HbA1c-guided group|Glycemic control is controlled by guideline-recommended HbA1c control.
89009630|NCT04559191|Active Comparator|CGM-guided group|Glycemic control is controlled by CGM-guided control.
89009631|NCT00231803|Experimental|Multifactorial intervention|Nurse led clinic involving a nephrologist administering protocol driven interventions aimed at preservation of kidney function, and cardiovascular risk reduction. Blood pressure targets were specified. No specific drugs were specified. Drug classes such as primarily statins for achieving LDL targets, use of an ACE inhibitor or ARB if possible, treatment of acidosis, anemia, hyperphosphatemia, advice on smoking cessation
89009632|NCT00231803|Active Comparator|Usual care|Usual care includes any intervention thought appropriate by the treating family doctor and or specialists involved in the case
89009633|NCT04559113|Experimental|Group intervene with Methylprednisolone|"Review effect of Methylprednisolone as clinical trial among hospitalized patients with COVID-19 infection.~Anyone of the following Corticosteroids dose will be given to moderate disease patients of COVID-19~0.5mg to 1mg/Kg methylprednisolone or equivalent dexamethasone dose (to a maximum of 20mg) given daily x 5 to 7-days or~Methylprednisolone 1 mg/kg daily IV for 5 days followed by 40 mg daily x 3 days, followed by 10 mg daily x 2 day. *Note: in Diabetic patients' dose of methyl prednisolone should be divided in doses preferably 40mg BD."
89009634|NCT02211937|Active Comparator|Treatment A|BI 44847 suspension high dose, fasted
89009635|NCT02211937|Experimental|Treatment B|BI 44847 tablet high dose, fasted
89009636|NCT02211937|Experimental|Treatment C|BI 44847 tablet high dose, fed
89009637|NCT02211937|Active Comparator|Treatment D|BI 44847 solution low dose, fasted
89009638|NCT02211937|Experimental|Treatment E|BI 44847 tablet low dose, fasted
89009639|NCT04559269||Cohort 1|Cohort of 98 patients suffering from sleep disorders hospitalized between September 2017 and January 2019 in the Sleep Medicine Center of the Croix Rousse Hospital (Lyon) for objective sleepiness evaluation with polysomnography and MWT.
89009640|NCT04559152|Experimental|Zinc Supplementation Group|Zinc capsule (20mg) was taken in the morning after meals once daily for 12 weeks. All subjects in this arm were also given iron and folic acid tablets in accordance with the Indonesian government program.
89009641|NCT04559152|Placebo Comparator|Placebo Group|Placebo (sugar tablet) was taken in the morning after meals once daily for 12 weeks. All subjects were also given iron and folic acid tablets in accordance with the Indonesian government program. Each placebo tablet was inserted into a capsule of the same shape and color with zinc capsule
89197857|NCT03131648|Experimental|Maintenance treatment period - Tralokinumab Q2W|"Week 16 to Week 52:~Tralokinumab responders from the initial treatment period re-randomised at Week 16 and administered tralokinumab maintenance subcutaneous injection regimen Q2W for 36 weeks."
89197858|NCT03131648|Experimental|Maintenance treatment period - Tralokinumab Q4W|"Week 16 to Week 52:~Tralokinumab responders from the initial treatment period re-randomised at Week 16 and administered tralokinumab maintenance subcutaneous injection regimen Q4W for 36 weeks.~Subjects in this group receive alternating doses of tralokinumab SC injection and placebo SC injection every 2 weeks."
89433533|NCT06140888|Experimental|The ginkgo biloba extract group|Ginkgo biloba extract 8 pills three times per day is administrated.
89433534|NCT06140888|No Intervention|The control group|Standard medical therapy
89433535|NCT06139861|Experimental|TranS-C|
89009642|NCT04558996||OBS COVID 3|"Objective/s The purpose of this study was to test if pregnant patients with COVID-19 have more obstetrical morbidity than those non-infected.~Determine the variables that are associated with more maternal and neonatal morbidity.~Quantify the risk of adverse pregnancy outcomes (e.g., miscarriage, stillbirth, growth restriction) and neonatal outcomes (e.g., NICU, prematurity, death, birth defects).~Design Longitudinal cohort case study to quantify the obstetrical and perinatal morbi-mortality throughout all hospitals in Spain with a universal, consecutive PCR based screening program.~Recruitment: 1st March 2020 to 30 September 2020. Spanish sites collected in Appendix 1."
89197859|NCT03131648|Placebo Comparator|Maintenance treatment period - Placebo Q2W|"Week 16 to Week 52:~Tralokinumab responders from initial treatment period randomised at Week 16 and administered placebo subcutaneous maintenance injection for 36 weeks."
89433536|NCT06139861|Active Comparator|Psychoeducation|
89009643|NCT04558996||OBS COVID 4|Substudy 4. Epidemiological prevalence study Objective/s Determine the prevalence of SARS_COV2 infection in Spanish pregnant women Design Cross-sectional study. The nQuery Advisor Release 7.0 software was used to calculate the sample size, based on the available data. As we do not have data on the prevalence of COVID-19, we set an expected percentage of 50% (a situation that maximizes the sample size) of asymptomatic women during delivery. We determined the sample size for a COVID-19 delivery prevalence study with an expected prevalence of 50%, a 95% confidence level and 5% accuracy, resulting in a sample size of 1056 pregnant women.
89009644|NCT04559542||Female material art athletes|Females practicing material art during recruitment time, in Oslo-area in Norway
89009645|NCT02211976|Experimental|Bisacodyl|
89009646|NCT02211976|Experimental|Simeticone|
89009647|NCT02211976|Experimental|Bisacodyl and simeticone|
89009648|NCT04558606|Experimental|Sonic toothbrush|"All patients receive full periodontal charting, a session of professional oral hygiene and OHI (oral hygiene instruction).~Each patient is instructed by the hygienist in the correct use of the sonic toothbrush"
89009649|NCT04558606|Active Comparator|Manual toothbrush|"All patients receive full periodontal charting, a session of professional oral hygiene and OHI (oral hygiene instruction).~Each patient is instructed by the hygienist in the correct use of the manual toothbrush"
89009650|NCT04558645||Patients with type 1 diabetes mellitus|Patients with Type 1 diabetes mellitus willing to participate in the study
89009651|NCT04558645||Healthy controls|Healthy controls without chronic disease willing to participate in the study
89009652|NCT04558684|Experimental|radiotherapy, chemotherapy and PD1 inhibitor|Treatment will comprise 5 daily fractions of radiotherapy at 5 Gy per fraction followed by chemotherapy and immunotherapy. Those who achieve a clinical complete response will be considered for organ preservation approach. All other patients will receive standard surgery.
89009653|NCT00231959|Placebo Comparator|Sugar pill|Placebo
89009654|NCT00231959|Experimental|Pramipexole|
89009655|NCT04558762||Women who had a MUS inserted.|Women who underwent surgery with insertion of a MUS due to SUI 2006-2010 in Sweden with the MUS coming out retropubic (TVT) or through foramen obturatorium (TOT).
89009656|NCT04558762||Controls|Women who have not had a MUS inserted due to stress urinary incontinence. Matched in age.
89009657|NCT02278393|Active Comparator|1-Fermented Dairy Product with Phytosterols (test)|one arm active = 3 bottles of test product/day with 1,6g of phytosterols each
89009658|NCT02278393|Placebo Comparator|2-Fermented dairy Product with No Phytosterols (control)|one arm control product= 3 bottles test productl/day with no Phytosterols
89009659|NCT04558411|No Intervention|Control Group (assessment only)|This group will receive assessments only.
89009660|NCT04558411|Experimental|Assessment + Intervention Group|This group will receive assessments and the 14 brief intervention videos.
89009661|NCT00231998|Experimental|1|
89009662|NCT04558333||LTx (lung transplant) patients|identification of possible biomarkers
89009663|NCT02212054|Experimental|conservative & operative treatment|anal dilation; colon lavage; probiotics
89009664|NCT02212054|Active Comparator|operative treatment|one stage pull- through radical colectomy
89009665|NCT00266838|Placebo Comparator|Lacrystat|Lacrystat
89009666|NCT00266838|Active Comparator|Maxidex|Applying Maxidex
89009667|NCT02212093||pneumonia and mechanical ventilation|The data are collected retrospectively from this one group.
89009668|NCT02212132||Patient|Neuropsychological evaluation, psychopathological assessment and fatigue
89009669|NCT02212132||Control group|Neuropsychological evaluation, psychopathological assessment and fatigue
89009670|NCT02212171|Experimental|TRIAP intervention|
89009671|NCT02212171|No Intervention|Usual care|Usual care: Patients in the control group will be treated according to Osakidetza recommendations.
89009672|NCT02212210|Active Comparator|Methylprednisolone|1cc of 80mg methylprednisolone to be diluted with 1cc preservative free normal saline
89009673|NCT02212210|Placebo Comparator|Normal saline|2cc preservative free normal saline
89009674|NCT04558060|Experimental|Virtual Standardized Patient|Training for 45 minutes at each training time point with a computer program that presented a virtual human patient and two simulated patient encounters. The virtual standardized patient involves a branching story line. Participants select 1 of 3 computer-generated response options at each conversational pause: 1) a response that is consistent with the principles and skills of MI, 2) an MI inconsistent response, or 3) a response that is mixed - partly consistent and partly inconsistent with MI.
89009675|NCT04558060|Active Comparator|Academic Study|Study of a summary handout of motivational interviewing concepts and techniques for 45-minutes.
89009676|NCT00232115|Experimental|1|Pimecrolimus
89009677|NCT00232115|Placebo Comparator|2|Vehicle
89009678|NCT02212249|Active Comparator|Systemic sclerosis|patients with systemic sclerosis
89009679|NCT02212249|Sham Comparator|primary raynaud disease|patients with primary raynaud disease
89433537|NCT06138860|Experimental|strain counter strain technique|the patients will receive strain counter strain technique plus physical therapy exercises three times a week for four weeks
89433538|NCT06138860|Active Comparator|physical therapy exercises|the patients will receive physical therapy exercise three times a week for four week
89433539|NCT06138587|Experimental|Phase 1/1b: CIML NK Cells + Interleukin-2|"5 eligible participants will be enrolled to determine the maximum tolerated dose (MTD) of CIML NK at starting dose level 0.~Screening and baseline visit with assessments and bone marrow aspirate and biopsy.~Day 0: Standard-of-care conditioning chemotherapy and stem cell infusion.~Day 7: Predetermined dose of CIML NK cells 1x daily.~Days 9, 11, 13, 15, 17, 19: Predetermined dose of Interleukin-2 1x daily every other day (7 doses total).~Dose limiting toxicity period for 6 weeks after infusion of CIML NK cells~If 0 or 1 dose limiting toxicity is observed at the dose level, then this dose will be the MTD and study will proceed to Phase 1b.~De-escalation to dose level -1 per protocol if ≥2 DLTs occur with dose Level 0.~In phase Ib, 10 additional participants will be enrolled at the maximum tolerated dose."
89433540|NCT06137300|Experimental|Urinary Kallidinogenase group|Patients are treated with urinary kallidinogenase and guideline-prescribed basic medical therapy.
89433541|NCT06137300|Other|Control group|Patients are only treated with guideline-prescribed basic medical therapy.
89531250|NCT05032911||Asymptomatic participants|Asymptomatic subjects should not present any pain in the cervical region during the last 3 months and no previous treatment for neck pain in order to be included in the study.
88913442|NCT01596140|Experimental|Vemurafenib + Intravenous Temsirolimus|Vemurafenib starting dose 720 mg orally twice day (morning/evening) for 28-day cycle plus Intravenous Temsirolimus starting dose 15 mg daily on Days 1, 8, 15, and 22 of each cycle.
88913443|NCT01596153|Placebo Comparator|Placebo|BID
88913444|NCT01596153|Active Comparator|Go Live Rx Probiotic|BID
88913445|NCT01596166|Experimental|Metoclopramide, Ketorolac|"10 mL/kg IV 0.9% sodium chloride~Metoclopramide 0.2 mg/kg (max 10 mg) IV~Ketorolac 0.5 mg/kg (max 30 mg) IV"
88913446|NCT01596166|Placebo Comparator|Metoclopramide, Placebo|"10 mL/kg IV 0.9% sodium chloride~Metoclopramide 0.2 mg/kg (max 10 mg) IV~Placebo (normal saline)"
88913447|NCT01596179|Experimental|Interactive navigational support|Patients on the intervention arm are provided with a netbook computer and internet access with ongoing interaction with a nurse and a social worker navigators for a one year period.
88913448|NCT01596179|Active Comparator|control arm|Patients on the control arm are provided with a netbook computer, internet access and general website information but no interactive navigational support for a one year period.
88913449|NCT01596192||Patients with acute GVHD|Patients after allogeneic hematopoietic cell transplantation who have developed acute GVHD
88913450|NCT01596205|Experimental|Robot intervention|Participants were given baseline assessments and randomly assigned into 3 groups; 24 with robot assisted cognitive training group (Robot intervention group), 24 with experienced behavioral therapist group (Conventional intervention group), and 37 without cognitive training (Control group).It was explained that there was a waiting list, therefore, participants in control group had an opportunity to participate in cognitive training program after a delay of 12 weeks for the intervention.
88913451|NCT01596205|Active Comparator|Conventional intervention|conventional cognitive training group - pen and pencil with experienced behavioral therapists
88913452|NCT01596205|No Intervention|Control group|
88913453|NCT01596218|Experimental|Treatment Arm|Treatment Arm for all participants - Brentuximab vedotin
88913454|NCT01596244|Experimental|Microclinics training|Diabetic, pre-diabetic, or those with family members who are diabetic/pre-diabetic who participated in a 4 month long intervention with a focus on disease management, health behavior change, and social network supports in order to improve chronic disease risk factors.
88913455|NCT01596270|Experimental|Once daily dosing|escalating doses, once daily dosing every day, no eating for 2 hours prior and 1 hour after dose
89433542|NCT06137261|Experimental|Participants randomized to HF screening|"Active screening on HF and its risk factors, using anamnesis, physical examination, an ECG, blood tests and an echocardiogram.~After 1 year follow-up, both participants randomized to standard care and to screening for HF will be approached. Participants will be asked whether they have had an unplanned hospital admission for HF. Also, in all participants an echocardiogram will be acquired. Finally, participants will be asked to fill-out the HR-QoL with the EQ-5D-5L questionnaire."
89433543|NCT06137261|No Intervention|Participants randomized to standard care|"Participants randomized to standard care will not undergo any tests related to the study at baseline.~After 1 year follow-up, both participants randomized to standard care and to screening for HF will be approached. Participants will be asked whether they have had an unplanned hospital admission for HF. Also, in all participants an echocardiogram will be acquired. Finally, participants will be asked to fill-out the HR-QoL with the EQ-5D-5L questionnaire."
88913456|NCT01596270|Experimental|Twice daily dosing|escalating doses, twice daily dosing every day, no eating for 2 hours prior and 1 hour after dose
88913457|NCT01596296|Active Comparator|Transcervical foley catheter|
88913458|NCT01596296|Active Comparator|Dinoprostone|
88913459|NCT01596309|Placebo Comparator|control group, placebo|This period will consist on a structured personalised hypocaloric diet containing ready prepared meals without extract added
88913460|NCT01596309|Experimental|Intervention group, cocoa extract|This period will consist on a structured personalised hypocaloric diet containing ready prepared meals with cocoa extract added. Final cocoa extract daily intake will be of 1.4 g.
88913461|NCT01596322||UARTO|
88913462|NCT01596348||RA patients|Patients with Rheumatoid Arthritis
88913463|NCT01596387|Experimental|Propofol|20 obese patients(IMC>35 kg m-2) scheduled for laparoscopic bariatric surgery.
88913464|NCT01596400|Experimental|Sancuso Arm|
88913465|NCT01596400|Active Comparator|IV Granisetron Arm|IV
88913466|NCT01596413|Experimental|Sancuso Arm|Transdermal Patch 34.3mg graniestron per patch, size 52cm2 Dose: 3.1mg/24 hrs
88913467|NCT01596413|Active Comparator|IV Granisetron|"Aqueous solution for IV administration~1 mg/mL ampoules Dose: 0.01mg/kg (maximum 1 mg)"
88913468|NCT01596426|Experimental|Sancuso Arm|patch
88913469|NCT01596426|Active Comparator|IV granisetron|IV
89009680|NCT04558372|Experimental|Group 1- 43 COVID-19 patients|COVID-19 patients breath normally via disposable non-rebreathing mask
89009681|NCT04558372|Experimental|Group 2- 40 non COVID-19 patients|Non COVID-19 patients breath normally via disposable non-rebreathing mask
89009682|NCT04558372|Experimental|Group 3- suspected COVID-19 patients|The participants breath normally using a mask for 2 times then they are asked to inhale and exhale in a forced expiratory volume through an e-nose tube connected to the Hepa-filter at the inlet.
89009683|NCT04558021|Experimental|Intervention Arm-I|Niclosamide 200 mg/10 mL Suspension will be administered to patients 3 times a day for 5 days along with the treatment regimen selected according to the official guidance for COVID-19 Adult Treatment Algorithm established by Republic of Turkey Ministry of Health
89009684|NCT04558021|Placebo Comparator|Intervention Arm-II|10 mL placebo will be administered to patients 3 times a day for 5 days along with the treatment regimen selected according to the official guidance for COVID-19 Adult Treatment Algorithm established by Republic of Turkey Ministry of Health
89009685|NCT02212288||PKU patients|Adult PKU patients;Blood samples;Urine sample only at inclusion
89009686|NCT02212288||Healthy controls|Adult Healthy controls;Blood samples;Urine samples only at inclusion
89009687|NCT04557826|Experimental|RD19 Experimental Device|RD19 Experimental Device used twice/day for 3 minutes each use at least 4 hours, and preferably 8-12 hours, apart
89009688|NCT00232193||IFNβ+DS group|IFNβ+DS group received lyophilized Avonex 30mcg IM weekly plus dexamethasone 160 mg IV every 4 weeks for 52 weeks and was treated with Avonex 30mcg IM weekly from week 53 to 104
89009689|NCT00232193||IFNβ group|IFNβ group received lyophilized Avonex 30mcg IM weekly for 104 weeks
89009690|NCT02212327||PD subjects|
89009691|NCT02212327||Controls|
89009692|NCT04557943|Active Comparator|Sodium Hyaluronate|Hyaluronate sodium injection is performed intra-articularly using 2 mL of Adant® Disposable. The treatment will be given five times, on day 1st, 8th, 15th, 22nd, and 29th
89009693|NCT04557943|Experimental|Prolotherapy|"Prolotherapy injection is performed intra-articularly and extra-articularly by a physician. Intra-articular injection with 25% dextrose will be carried out with the following details: 5 mL of 40% dextrose, 2 mL of lidocaine, and 1 mL of aqua dest are inserted into the 10-mL syringe, then 5 mL are injected with the superolateral approach. An extra-articular injection with 15% dextrose will be carried out with the following details:~in the 10-mL syringe 4 mL of 40% dextrose, 2 mL lidocaine, and 4 mL of distilled water are injected, to make a total of 30-40 mL injections. Treatment will be carried out on day 1st, 29th, and 57th."
89009694|NCT04709133|Experimental|multi-ligament knee injures|A chart review will be performed to identify patients who underwent surgical treatment for multiligamentous knee injuries at Assiut University Hospital performed by one of sports medicine orthopaedic surgeons at Assiut arthroscopy and sport unit.
89433544|NCT06134089||Perceived Shareablility Prompt First|
89009695|NCT00232232|No Intervention|Control|No fish oil
89433545|NCT06134089||Perceived Effectiveness Prompt First|
89009696|NCT00232232|Experimental|Fish oil|Patients prescribed 6g/day of fish oil containing 1.8g EPA+DHA in a 1.5:1 ratio
89433546|NCT06133881|Experimental|prilocaine|
89433547|NCT06133881|Active Comparator|bupivacaine|
89433548|NCT06133621||cases|Patients treated at HCL who have had an increased dRVVT ratio during pregnancy, investigated in the context of the development of VDP during pregnancy
89433549|NCT06133621||Controls|Patients with normal pregnancies followed at the Croix Rousse maternity hospital
89433550|NCT06132854|Experimental|VR|"Participants in the VR group are immersed in a unique 360° VR experience specifically designed for this study.~The custom made VR experience consists of two parts. In the first part, children find themselves in a simulated MRI room which resembles to the one they will be scanned.~The second half of the VR experience introduces a mindfulness-ACT based meditation segment within the context of a space travel."
89433551|NCT06132854|Active Comparator|Booklet|Children in the booklet condition will be prepared by using an educational booklet containing colorful illustrations of the MRI examination room and about the procedure. This serves as a resource to familiarize them with the MRI procedure, address common concerns, and provide information about what to expect during the exam. The role of the booklet condition is to serve as an active control for our experimental condition. This condition also contains an interaction with the experimenter and increases familiarity through explanation and illustrations. However, it does not involve the immersive effect of the VR.
89433552|NCT06132854|No Intervention|Usual care|In the usual care condition children are prepared by the healthcare staff through explanations, reframing, playing as per personal preference which is currently the standard of care in our departments.
88913470|NCT01596465|Active Comparator|Control|Control arm
88913471|NCT01596465|Active Comparator|Intervention|Intervention arm
88913472|NCT01596478|Active Comparator|Treatment As Usual|The standard treatment usually provided at the clinic.
88913473|NCT01596478|Active Comparator|Cognitive Motivational Behavior Therapy|An approach that addresses motivation to change gambling and behavioral patterns related to gambling.
88913474|NCT01596478|Active Comparator|12-week wait list|Participant will start treatment 12 weeks from day of consent.
88913475|NCT01596491||patients with peripheral nerve injury|10 patients with neuropathic pain, because of peripheral nerve injury will obtain a baseline-QST and after capsaicin-application a QST 2, 4, 6, 8 and every 2 weeks until re-occurrence of pain and/or recovery of the capsaicin-induced sensory deficits
88913476|NCT01596491||patients with postherpetic neuralgia|10 patients with neuropathic pain, because of postherpetic neuralgia will obtain a baseline-QST and after capsaicin-application a QST 2, 4, 6, 8 and every 2 weeks until re-occurrence of pain and/or recovery of the capsaicin-induced sensory deficits
88913477|NCT01596517|Experimental|Korean CHC|Two CHC patient groups. One is CHC patients who are treated with combination of peginterferon alfa-2a and ribavirin in a prospective, multicenter, industry-sponsored, open-label, uncontrolled, community-based clinical trial (Pegasys Expanded Access Program) conducted at 6 tertiary referral centers in Korea between 2003 and 2004. Another is a cohort of hepatitis C patients who were treated in a single tertiary referral hospital (Asan Medical Center, Seoul, Korea) between 2004 and 2008.
88913478|NCT01596530|Active Comparator|AZD8931|AZD8931
89536307|NCT05679323||Early discharge|Patients who will be discharged 24 hours after cesarean section
89536308|NCT05679323||Traditional discharge|Patients who will be discharged 48 hours after cesarean section
89536309|NCT02449603|Experimental|Exenatide|Exenatide (Colorless transparent liquid, comes in a prefilled pen.5ug/10ug, AstraZeneca) should be initiated, 60 minutes pre-breakfast and pre-supper, at 5ug twice a day for 4 weeks and then titrated up at 10ug twice a day until the completion of the study.
88913479|NCT01596530|Placebo Comparator|Placebo|Placebo
88913480|NCT01596543|Experimental|sleep deprivation|The research contains only one arm. The subjects will be tested with no sleep deprivation (which will be used as a control measurement) and with partial and complete sleep deprivation.
88913481|NCT01596556|Experimental|smokers|This arm consists of smokers.
88913482|NCT01596556|Active Comparator|non-smokers|non-smoking participants in the study
89433553|NCT06131775|Other|Immunotherapy|"Patients with locally advanced/metastatic disease who are due to receive as a first attempt an immune checkpoint inhibitors immunotherapy-based treatment.~Blood sample collection : One blood draw of 10 mL will be realized before the initiation of immunotherapy. Any adverse event related to the blood draw will be recorded. A follow-up will be performed at 6 months to record the immune-related adverse events, a statement of the disease and any other cancer treatments received. A 24 months long term follow up will be performed to record patient vital status and any date of disease progression."
89433554|NCT06131775|Other|Curative surgery|"Patients newly diagnosed and naive of any anticancer treatment who are due to receive a curative surgery of their primitive tumor.~Blood samples collection : Three blood draws of 10 mL will be realized : one before the surgery, one after 3 months and one after 6 months. Any adverse event related to the blood draw will be recorded. A follow-up will be performed at 6 months to record the statement of the disease and any other cancer treatments received. A 24 months long term follow up will be performed to record patient vital status and any date of disease relapse."
89433555|NCT06129435|Experimental|Visuospatial Task (VST)|
89433556|NCT06129435|Sham Comparator|Word Association Task (WAT)|
89433557|NCT06129435|No Intervention|No Game Play (NT-CTRL)|
89433558|NCT06128954|Experimental|Once Daily Dose Formulation (Treatment A)|1 x 900mg TETA 4HCl, new once daily formulation (3x300mg trientine base tablets as a single AM dose)
89433559|NCT06128954|Active Comparator|Cuprior® comparator (Treatment B)|2 x 450mg TETA 4HCl, Marketed Cuprior® formulation (6 x150mg trientine base tablets in two equally divided doses (450mg doses 8 hours apart)
89433560|NCT06126445|Active Comparator|Battery operated toothbrush|battery operated toothbrush
89433561|NCT06126445|Active Comparator|Manual toothbrush|Manual toothbrush
89433562|NCT06124209|Experimental|Tachosil® used in Vena Cava Inferior anastomosis|Tachosil® used in Vena Cava Inferior anastomosis.
89433563|NCT06124209|No Intervention|Control|Standard haemostatic treatment in HPB surgery.
89433564|NCT06123689|Experimental|AMT-Regenera activa|All the patients of the group will be treated with one unique articular injection of autologous micrografts obtained through the Rigenera® Technology
89433565|NCT06123689|Active Comparator|Hyalubrix|All the patients of the group will be treated with one unique articular injection of Sodium Hyaluronate (Hyalubrix 60 -1,5%-2ml vial)
89433566|NCT06122896|Experimental|Pancreatic Cancer High-Risk Participants|"Study procedures will be conducted as follows:~Baseline visit with questionnaires, blood tests, and pancreas screening procedure (EUS or MRI/MRCP).~Pancreas screening procedures (Endoscopic ultrasound (EUS), or Magnetic Resonance (MRI)/Magnetic Resonance Cholangiopancreatography (MRCP), and collection of blood, stool, and saliva samples) every 12 months.~Blood tests and questionnaires every 6 months.~Follow up visits."
89433567|NCT06122883|Experimental|Distraction in the reception area.|
89433568|NCT06122883|Experimental|Distraction in the treatment area.|
89433569|NCT06122883|Experimental|Distraction in both treatment and reception area.|
89433570|NCT06122883|Other|Basic behavior guidance techniques without using any type of distraction aids.|
89433571|NCT06121505|Experimental|Radiotherapy combined with sintilimab and chemotherapy|Subjects received radiotherapy (SBRT+LDRT). Sintilimab combined with standard platinum-containing double-drug chemotherapy was performed within 1 week after the end of radiotherapy.
89433572|NCT06121505|Active Comparator|Sintilimab+Chemotherapy|Subjects received sintilimab combined with standard platinum-based doublet chemotherapy for a total of 4 cycles.
89433573|NCT06119581|Experimental|Dose Optimization: LY3537982 Dose Level 1 plus Pembrolizumab|LY3537982 Dose level 1 administered orally in combination with pembrolizumab administered intravenously (IV) in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met.
88913483|NCT01596569|Active Comparator|Active TMS and Cognitive Intervention|"Active TMS and Cognitive Intervention:~Repetitive Transcranial Magnetic Stimulation (rTMS) and Cognitive intervention designed specifically to address the most common cognitive deficits (executive function and memory)."
89009697|NCT04557904|Experimental|Group A: Craniocervical flexion exercises|Exercise protocol were performed over a 4 week duration under the command of a supervisor. Subjects were asked not to obtain any other particular intervention for cervical ache. Command the subject to be in crook lying position. Lock their finger to place their finger below the skull and retract the lower jaw and retract chin as far as possible.
89009698|NCT04557904|Experimental|Group B: Scapular stabilization exercises|Group B performed scapular stabilization workout for 30 minutes per session, three days a week for four weeks. The scapular stabilization exercises were made up of four stages
89009699|NCT04557475|Experimental|ASA Group|Receives standard of care and intervention.
89009700|NCT04557475|No Intervention|SOC Group|Receives standard of care (SOC), only
89009701|NCT00232271|Active Comparator|clexane|patients received clexane
89009702|NCT00232271|No Intervention|non clexane|no clexane given
89009703|NCT04557397|Other|Part A|Subjects will receive fruquintinib, alone and with itraconazole.
89197860|NCT03131648|Placebo Comparator|Maintenance treatment period - Placebo|"Week 16 to Week 52:~Placebo responders from the initial treatment period re-assigned at Week 16 and administered placebo maintenance subcutaneous injection regimen Q2W for 36 weeks."
89009704|NCT04557397|Other|Part B|Subjects will receive fruquintinib, alone and with rifampin.
89009705|NCT04557241|Experimental|Brief Intervention arm|The primary intervention in this study will be an infographic that is designed to build trust in the scientific process (as described in the Intervention section). This arm will introduce the intervention and then instruct the participant to review it carefully (including a mandated pause on the infographic screen) before continuing to the remaining data collection.
89009706|NCT04557241|Placebo Comparator|Placebo Control arm|"The comparator in this study will be a control (placebo) infographic that is completely unrelated to science (As described in the Placebo Control section). This arm will introduce the control infographic and then instruct the participant to review it carefully (including a mandated pause on the infographic screen) before continuing to the remaining data collection."
89009707|NCT04557319|Experimental|GNR-038, 25 МЕ/kg|Recombinant C1-esterase (25 ME/kg) inhibitor intravenous infusion
89009708|NCT04557319|Experimental|GNR-038, 50 МЕ/kg|Recombinant C1-esterase (50 ME/kg) inhibitor intravenous infusion
89009709|NCT04557319|Experimental|GNR-038, 100 МЕ/kg|Recombinant C1-esterase (100 ME/kg) inhibitor intravenous infusion
89009710|NCT04557514|Active Comparator|platelet rich plasma injection in post burn facial scar|"prp in subgroup allocation 1:1 Obtain WB by venipuncture in acid citrate dextrose (ACD) tubes~Do not chill the blood at any time before or during platelet separation.~Centrifuge the blood using a 'soft' spin.~Transfer the supernatant plasma containing platelets into another sterile tube (without anticoagulant).~Centrifuge tube at a higher speed (a hard spin) to obtain a platelet concentrate.~The lower 1/3rd is PRP and upper 2/3rd is platelet-poor plasma (PPP). At the bottom of the tube, platelet pellets are formed.~Remove PPP and suspend the platelet pellets in a minimum quantity of plasma (2-4 mL) by gently shaking the tube."
89009711|NCT04557514|Active Comparator|fat injection in post burn facial scar|After aspiration of the fatty tissue, it is important that nonviable components of the aspirate, such as oil, blood, and local anesthetics are removed and, at the same time, the quality, integrity, and viability of the adipocytes and the inherent mesenchymal stem cells in the aspirate be maintained. Processing techniques are sedimentation , filtering and washing There is no consensus as to the optimal method of fat graft preparation.
89009712|NCT02212366|Experimental|Active TDCS|2-week course of daily (5 days/week) active bilateral anodal TDCS, duration 30 minute each session. Current 2 mA.
89433574|NCT06119581|Experimental|Dose Optimization: LY3537982 Dose Level 2 plus Pembrolizumab|LY3537982 Dose level 2 administered orally in combination with pembrolizumab administered IV in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met.
89433575|NCT06119581|Experimental|Safety Lead In: LY3537982 plus Pembrolizumab, Pemetrexed and Platinum|LY3537982 administered orally in combination with pembrolizumab, pemetrexed, and platinum (cisplatin or carboplatin) administered IV in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met.
89009713|NCT02212366|Sham Comparator|Sham TDCS|2-week course of daily (5 days/week) Sham bilateral tDCS. Duration 30 minute each session.
89009714|NCT04557202|Active Comparator|Group A|Group A had 58 patients who underwent non-stented ureteroscopy using Ho-YAG laser for stone disintegration and received alpha1-blockers for one week preoperatively and another two weeks postoperatively
89009715|NCT04557202|Placebo Comparator|Group B|62 patients who underwent non-stented ureteroscopy and laser and received placebo.
89009716|NCT00232349|Experimental|Intervention group|All subjects enrolled in study are in the intervention group.
89009717|NCT02212405|Sham Comparator|rTMS Sham + PET|An advanced sham coil will be used that mimicks the sound and sensation of real repetitive Transcranial Magnetic Stimulation. The repetitive Transcranial Magnetic Stimulation sham intervention is followed by radiotracer and PET.
89009718|NCT02212405|Experimental|rTMS 1Hz + PET|Deep repetitive Transcranial Magnetic Stimulation will be applied to the insula for 30 minutes. This will consist of 20 trains each comprising of 50 pulses at 1Hz. The inter-train interval is 15 seconds. The intervention is followed by radiotracer and PET.
89197861|NCT03131648|Experimental|Open-label treatment - Tralokinumab + optional TCS|"Week 16 to Week 52:~Subjects receiving initial treatment with tralokinumab Q2W or placebo Q2W assigned to open-label treatment at Week 16 and administered Tralokinumab subcutaneous (SC) injection + optional TCS* regimen Q2W.~OR~Subjects receiving maintenance treatment with tralokinumab Q2W/Q4W or placebo assigned to open-label treatment after Week 16 and administered tralokinumab SC injection + optional TCS* regimen Q2W.~*TCS = topical corticosteroids."
88913484|NCT01596569|Sham Comparator|Sham TMS and Cognitive Intervention:|"Sham TMS and Cognitive Intervention:~Repetitive Transcranial Magnetic Stimulation (rTMS) and Cognitive intervention designed specifically to address the most common cognitive deficits (executive function and memory)."
88913485|NCT01596608|Experimental|Magnetic Seizure Therapy|
88913486|NCT01596634|Experimental|Supportive care (bovine lactoferrin)|Patients receive bovine lactoferrin PO (rinse or tablet) TID for 1 month. Treatment continues in the absence of unacceptable toxicity.
88913487|NCT01596647|Experimental|TKI258 (dovitinib)|dovitinib, 5 days on / 2 days off dose schedule
88913488|NCT01596660|Experimental|Bupivacaina|20 cc of bupivacaine 0.5% in 20 cc de saline solution and it is infiltrated 20 cc each side.
88913489|NCT01596660|Placebo Comparator|saline solution|20 cc of saline solution 0.9% to infiltrate each side.
88913490|NCT01596673|Experimental|BCAD Treatment Group|"Subjects in this group will receive study drug in the following sequence:~Treatment B - 1 intact placebo tablet, hydrocodone bitartrate powder at a dose strength of 45 mg reconstituted in 60 mL of a noncarbonated flavored beverage, and 1 crushed placebo tablet.~Treatment C - 1 intact 45-mg hydrocodone bitartrate extended-release tablet, 60 mL of a noncarbonated flavored beverage, and 1 crushed placebo tablet.~Treatment A - 1 intact placebo tablet, 60 mL of a noncarbonated flavored beverage, 1 crushed 45-mg hydrocodone bitartrate extended-release tablet.~Treatment D - 1 intact placebo tablet, 60 mL of a noncarbonated flavored beverage, and 1 crushed placebo tablet(matching the 45-mg hydrocodone bitartrate extended-release tablet)."
88913491|NCT01596673|Experimental|CDBA Treatment Group|"Subjects in this group will receive study drug in the following sequence:~Treatment C - 1 intact 45-mg hydrocodone bitartrate extended-release tablet, 60 mL of a noncarbonated flavored beverage, and 1 crushed placebo tablet.~Treatment D - 1 intact placebo tablet, 60 mL of a noncarbonated flavored beverage, and 1 crushed placebo tablet (matching the 45-mg hydrocodone bitartrate extended-release tablet).~Treatment B - 1 intact placebo tablet, hydrocodone bitartrate powder at a dose strength of 45 mg reconstituted in 60 mL of a noncarbonated flavored beverage, and 1 crushed placebo tablet.~Treatment A - 1 intact placebo tablet, 60 mL of a noncarbonated flavored beverage, 1 crushed 45-mg hydrocodone bitartrate extended-release tablet."
88913492|NCT01596673|Experimental|DACB Treatment Group|"Subjects in this group will receive study drug in the following sequence:~Treatment D - 1 intact placebo tablet, 60 mL of a noncarbonated flavored beverage, and 1 crushed placebo tablet(matching the 45-mg hydrocodone bitartrate extended-release tablet).~Treatment A - 1 intact placebo tablet, 60 mL of a noncarbonated flavored beverage, 1 crushed 45-mg hydrocodone bitartrate extended-release tablet.~Treatment C - 1 intact 45-mg hydrocodone bitartrate extended-release tablet, 60 mL of a noncarbonated flavored beverage, and 1 crushed placebo tablet.~Treatment B - 1 intact placebo tablet, hydrocodone bitartrate powder at a dose strength of 45 mg reconstituted in 60 mL of a noncarbonated flavored beverage, and 1 crushed placebo tablet."
88913493|NCT01596673|Experimental|ABDC Treatment Group|"Subjects in this group will receive study drug in the following sequence:~Treatment A - 1 intact placebo tablet, 60 mL of a noncarbonated flavored beverage, 1 crushed 45-mg hydrocodone bitartrate extended-release tablet.~Treatment B - 1 intact placebo tablet, hydrocodone bitartrate powder at a dose strength of 45 mg reconstituted in 60 mL of a noncarbonated flavored beverage, and 1 crushed placebo tablet.~Treatment D - 1 intact placebo tablet, 60 mL of a noncarbonated flavored beverage, and 1 crushed placebo tablet(matching the 45-mg hydrocodone bitartrate extended-release tablet).~Treatment C - 1 intact 45-mg hydrocodone bitartrate extended-release tablet, 60 mL of a noncarbonated flavored beverage, and 1 crushed placebo tablet."
89197862|NCT03131648|Experimental|Open-label short-term- Tralokinumab + optional TCS|"Week 52 to Week 68 [Short term extension (Japan only)] :~Japanese subjects who were transferred to the open-label tralokinumab Q2W arm at Week 16 continued an additional 16 weeks (Week 52 to Week 66) of open-label treatment to receive 52 weeks of active therapy."
89197863|NCT00618813|Experimental|Treatment (combination chemotherapy)|See Detailed Description
89197864|NCT00685698|Other|Nemonoxacin|Nemonoxacin 750 mg,oral administration, single-arm, once daily 7±1 and 14±1 days.
88913494|NCT01596686|Active Comparator|sodium picosulphate and magnesium citrate (Picoprep)|
88913495|NCT01596686|Active Comparator|polyethylene glycol (Fortrans)|
88913496|NCT01596712|Experimental|QGE031 Dose 1|QGE031 Dose 1: subcutaneous injection, single dose
88913497|NCT01596712|Experimental|QGE031 Dose 2|QGE031 Dose 2: subcutaneous injection, single dose
88913498|NCT01596712|Experimental|QGE031 Dose 3|QGE031 Dose 3: subcutaneous injection, single dose
88913499|NCT01596712|Placebo Comparator|Placebo|Placebo to QGE031 : subcutaneous injection, single dose
88913500|NCT01596725|Experimental|Group A|
88913501|NCT01596725|Experimental|Group B|
88913502|NCT01596725|Experimental|Group C|
88913503|NCT01596725|Experimental|Group D|
89433576|NCT06119581|Experimental|Part A: LY3537982 plus Pembrolizumab|LY3537982 administered orally in combination with pembrolizumab administered IV in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met.
88913504|NCT01596725|Experimental|Group E|
88913505|NCT01596725|Experimental|Group F|
88913506|NCT01596738|Experimental|Tranexamic Acid group|"Tranexamic acid 50mg/ml, 15 mg/kg intravenous after anesthetic induction~Tranexamic acid 50mg/ml, 15 mg/kg intravenous after neutralization"
88913507|NCT01596738|Placebo Comparator|Placebo group|"Equivalent volume of saline, equal to that of 50mg/ml tranexamic acid at the dosage of 15mg/kg, intravenous after anesthetic induction~Equivalent volume of saline, equal to that of 50mg/ml tranexamic acid at the dosage of 15mg/kg, intravenous after neutralization"
88913508|NCT01596764|Placebo Comparator|Treatment A|Administration of LOP Placebo (0 h, 12 h, 24 h, 36 h, 48 h), Colon Transit (0 h, 12 h, 24 h, 36 h, 48 h), Placebo (0 h, 12 h, 24 h, 36 h, 48 h) and SSP (48 h). To assess WGT, OCT and CTT under placebo condition.
88913509|NCT01596764|Placebo Comparator|Treatment B|Administration of LOP (0 h, 12 h, 24 h, 36 h, 48 h), Colon Transit (0 h, 12 h, 24 h, 36 h, 48 h), Placebo (0 h, 12 h, 24 h, 36 h, 48 h) and SSP (48 h). To assess WGT, OCT and CTT under loperamide-induced obstipation condition.
88913510|NCT01596764|Active Comparator|Treatment C|Administration of LOP (0 h, 12 h, 24 h, 36 h, 48 h), Colon Transit (0 h, 12 h, 24 h, 36 h, 48 h), NLX-ER (0 h, 12 h, 24 h, 36 h, 48 h) and SSP (48 h). To describe the effects of repeated-dose naloxone in preventing loperamide-induced delay of WGT, OCT and CTT and measure pharmacokinetics of naloxone.
88913511|NCT01596764|Active Comparator|Treatment D|Administration of LOP (0 h, 12 h, 24 h, 36 h, 48 h), Colon Transit (0 h, 12 h, 24 h, 36 h, 48 h), MNTX-ER (0 h, 12 h, 24 h, 36 h, 48 h) and SSP (48 h). To describe the effects of repeated-dose methylnaltrexone in preventing loperamide-induced delay of WGT, OCT and CTT and measure pharmacokinetics of methylnaltrexone.
88913512|NCT01596777|Placebo Comparator|Treatment A|Administration of LOP placebo (-24 h, -12 h, -1 h, 12 h), Colon Transit (-24 h, -12 h, -1 h), SSP (+ 2 h) and MNTX placebo (0 h). To asses the oro-cecal and whole-gut transit time under placebo condition.
88913513|NCT01596777|Placebo Comparator|Treatment B|Administration of LOP 4 mg (-24 h, -12 h, -1 h, 12 h), Colon Transit (-24 h, -12 h, -1 h), SSP (+ 2 h) and MNTX placebo (0 h). To asses the oro-cecal and whole-gut transit time under loperamide-induced obstipation condition.
88913514|NCT01596777|Active Comparator|Treatment C|Administration of LOP 4 mg (-24 h, -12 h, -1 h, 12 h), Colon Transit (-24 h, -12 h, -1 h), SSP (+ 2 h) and MNTX 12 mg sc. (0 h). To assess the effects of methylnaltrexone in preventing loperamide-induced delay of the oro-cecal and whole-gut transit time and to measure pharmacokinetics of methylnaltrexone after subcutaneous administration.
88913515|NCT01596777|Active Comparator|Treatment D|Administration of LOP 4 mg (-24 h, -12 h, -1 h, 12 h), Colon Transit (-24 h, -12 h, -1 h), SSP (+ 2 h) and MNTX IR (0 h). To assess the effects of methylnaltrexone in preventing loperamide-induced delay of the oro-cecal and whole-gut transit time and to measure pharmacokinetics of methylnaltrexone after oral administration of immediate release capsule.
88913516|NCT01596777|Active Comparator|Treatment E|Administration of LOP 4 mg (-24 h, -12 h, -1 h, 12 h), Colon Transit (-24 h, -12 h, -1 h), SSP (+ 2 h) and MNTX ER (0 h). To assess the effects of methylnaltrexone in preventing loperamide-induced delay of the oro-cecal and whole-gut transit time and to measure pharmacokinetics of methylnaltrexone after oral administration of extended release capsule.
88913517|NCT01596790|Other|CTC assay|Detection & characterization of viable CTC in the peripheral blood.
88913518|NCT01596803|Active Comparator|vitamins minerals|VitE 400/d, vitC 500mg/d, Se 200µg/d (selenomethionine), Zn 25 mg/d gluconate Venous blood samples( analysis oxidative stress inflammatory markers) Needle biopsy of the vastus lateralis muscle (analysis oxidative stress inflammatory markers)
88913519|NCT01596803|Placebo Comparator|Placebo|Supplementation 17 weeks placebo venous blood samples (analysis of oxidative stress inflammatory markers) needle biopsy of the vastus lateralis muscle
88913520|NCT01596816|Experimental|Boost by CyberKnife|
88913521|NCT01596816|Experimental|Boost by linear accelerator|
88913522|NCT01596829|Active Comparator|Probiotic|Probiotic consumption during and after course of antibiotic
88913523|NCT01596829|Placebo Comparator|Placebo|Placebo consumed during and after course of antibiotic
88913524|NCT01596855|Experimental|FG-4592|Active Drug
88913525|NCT01596855|Active Comparator|Epoetin alfa|Standard of care
88913526|NCT01596868|Active Comparator|Gemcitabine and Cisplatin|Drug: gemcitabine and cisplatin The GP regimen consists of gemcitabine at a dose of 1,000 mg/m2 by intravenous (i.v.) infusion over 30 min on day 1 and day 8, and cisplatin 80 mg/m2 by i.v. infusion for 4 h on day 1-3, The regime will be repeated every 3 weeks up to a total of 2-3 courses. Concurrent chemoradiotherapy is administrated with 3 cycles of weekly Cisplatin 80 mg/m2 starting on the first day of IMRT..
89197865|NCT00858429|Experimental|Cohort 1 (capecitabine, Y90)|2,000mg/m2 capecitabine +110 Y90
89197866|NCT00858429|Experimental|Cohort 2 (capecitabine , Y90)|2,000mg/m2 capecitabine + 130 Y90
89197867|NCT00858429|Experimental|Cohort 3 (capecitabine, Y90)|2,000mg/m2 Capecitabine + 150 Y90
89197868|NCT00858429|Experimental|Cohort 4 (capecitabine, Y90)|2,000 mg/m2 capecitabine = 170 Y90
89197869|NCT00862173||Patients with NSCLC with CNS Metastasis|Patients who developed CNS metastasis of NSCLC during the treatment.
89197870|NCT00862173||Patients with NSCLC without CNS Metastasis|Patients with NSCLC that does not develop CNS metastasis during the treatment.
89197871|NCT00756366|Active Comparator|1|Heart Failure-OSA Group, randomized to early CPAP
89197872|NCT00756366|Active Comparator|2|Heart Failure-OSA Group, randomized to late CPAP
88913527|NCT01596868|Active Comparator|docetaxel and cisplatin|Drug: Docetaxel and cisplatin TP regimen consists of docetaxel at a dose of 75 mg/m2/day on day 1, and cisplatin 80 mg/m2 by i.v. infusion for 4 h on day 1-3. The regime will be repeated every 3 weeks up to a total of 2-3 courses. Concurrent chemoradiotherapy is administrated with 3 cycles of weekly Cisplatin 80 mg/m2 starting on the first day of IMRT.
88913528|NCT01596881||Multiple Sclerosis Patients|Physician-confirmed diagnosis of multiple sclerosis. Any subtype is acceptable. For example, relapsing-remitting, secondary progressive, primary progressive
88913529|NCT01596881||Healthy Normal Subjects|Volunteers with healthy eyes.
88913530|NCT01596894|Experimental|Azithromycin + Metronidazole|Oral Azithromycin 7.5 mg/kg once daily (maximum 500mg) 5 consecutive days a week for the first 4 weeks and 3 consecutive days a week for the last 4 weeks +metronidazole 10mg/kg X2/day (maximum 1000mg) for 8 weeks.
88913531|NCT01596894|Active Comparator|Metronidazole|Oral metronidazole 10mg/kg X2/day (maximum 1000mg) for 8 weeks.
88913532|NCT01596907|Active Comparator|Ephedrine and caffiene|"Drug treatment:~ephedrine sulfate 25-mg with caffeine 200-mg per capsule to be given three times per day 4 hours apart for 6 months after gastric bypass surgery. Weight loss rate, resting energy expenditure, fat free mass will be measured during the treatment."
88913533|NCT01596907|Placebo Comparator|placebo|one placebo capsule will be taken three times per day 4 hours apart, identical to the instructions for the active drug for approximately 6 months following gastric bypass surgery. Weight loss rate, resting energy expenditure and fat free mass will be measured during the treatment.
88913534|NCT01596920|Active Comparator|Grafix®|
88913535|NCT01596920|Placebo Comparator|Control (non-adherent dressing)|
88913536|NCT01596933|Experimental|omega-3 fatty acid supplementation|omega-3 fatty acid supplementation (echium oil)
88913537|NCT01596933|Placebo Comparator|standard nutritional support|sunflower oil supplementation
88913538|NCT01596946|Active Comparator|Contact tracing mode test at clinic|Conventional mode of contact tracing where the partners were asked by either the index patient or demanded by the counsellor to attend a clinic for C. trachomatis testing. The date of testing for chlamydia of the study subject i e a sexual partner to a chlamydia infected index patient was noted. Those partners being C trachomatis positive were referred to the STD-clinic for contact tracing and following the same study arm a the index patient.
88913539|NCT01596946|Experimental|Self-sampling at home|The intervention: Self-sampling of sexual partners to infected index patient for chlamydia by urine test or vaginal sampling at home. They sent the kit tube to a microbiological laboratorium for analysis. The test kit was sent by post by the counsellor at the STD-clinic or distributed via the index patient. The partner in this arm was informed about the test result from the STD-clinic and those tested C trachomatis positive were given an appointment for treating and contact tracing as soon as possible. Their partners were not randomised but following the same mode. The days from the counselling conversation with the index patient to the date of testing was measured and compared with partners tested following arm 1 mode.
88913540|NCT01596959|Active Comparator|ECI CONTACT-ACTIVE|Irrigated Radiofrequency ablation performed using the ECI contact data
88913541|NCT01596959|Placebo Comparator|ECI CONTACT-INACTIVE|irrigated RF ablation performed to the right atrium without the use of ECI contact data
88922267|NCT05577221|Experimental|Experimental group|installation of the high-flow humidified nasal oxygen therapy device and variation of the inspiratory flow rate (0 L/min, 30 L/min, 50 L/min and 70 L/min) then performance of the weaning test. of the weaning test. During each step of the protocol (= each variation of the inspiratory flow), the intensity of the dyspnea will be collected, the esophageal pressure will be measured, the respiratory control will be measured, the EMG of the respiratory muscles will be measured and the comfort will be measured. Each step lasts about 15 minutes with 5 minutes of wash-out before the next step. Once the 4 conditions are tested, the weaning test is performed (without wash-out), for a duration of one hour. The whole test lasts 2h15.
89433577|NCT06119581|Placebo Comparator|Part A: Placebo plus Pembrolizumab|Placebo administered orally in combination with pembrolizumab administered IV in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met.
89433578|NCT06119581|Experimental|Part B: LY3537982 plus Pembrolizumab, Pemetrexed, and Platinum|LY3537982 administered orally in combination with pembrolizumab, pemetrexed, and platinum (cisplatin or carboplatin) administered IV in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met.
89433579|NCT06119581|Placebo Comparator|Part B: Placebo plus Pembrolizumab, Pemetrexed, and Platinum|Placebo administered orally in combination with pembrolizumab, pemetrexed, and platinum (cisplatin or carboplatin) administered IV in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met.
89433580|NCT06118684|Experimental|Part A - EP395 as a 'victim' of DDIs|Part A will investigate EP395 as a 'victim' of DDIs. The impact of CYP3A4 and P-glycoprotein (Pgp) inhibition on the pharmacokinetics (PK) of EP395 will be assessed. Verapamil has been selected as a moderate inhibitor of CYP3A4 and an inhibitor of Pgp.
89433581|NCT06118684|Experimental|Part B - EP395 as a 'perpetrator' of DDIs|Part B will investigate EP395 as a 'perpetrator' of DDIs. The impact of EP395 on the PK of a CYP3A4 substrate and a Pgp substrate will be assessed. Midazolam has been selected as the CYP3A4 substrate and digoxin as the Pgp substrate.
89433582|NCT06116929|Other|Patients with Hodgkin's disease|
89433583|NCT06116929|Other|Controls without Hodgkin's disease|
88913542|NCT01596985|Experimental|Ablation using the PlasmaJet system|"Origin of cyst invagination is identified after lysis of adhesions between ovary and adjacent broad ligament, leading to characteristic chocolate fluid evacuation. Surgeon then attempts to turn cyst completely inside out via original invagination site of diameter averaging 1 to 2cm. Ablation of cyst's inner surface is performed using the PlasmaJet system in coagulation mode set at 40, at distance averaging 5mm from tip of handpiece, and with exposure time limited to 1 to 2s on each site. Care is taken not to leave any untreated sites and to ablate the edges of the invagination site and corresponding peritoneal implants on adjacent broad ligament. When cyst reversion is not feasible, surgeon progressively exposes cyst interior to guide plasma beam at an angle perpendicular to the inner surface."
88913543|NCT01596985|Active Comparator|Cystectomy|"Surgical excision of an ovarian endometrioma by cystectomy involves three distinct areas, each requiring a different excision procedure. Area A from where cyst invagination originates, measures 1 cm² on average and is revealed by lysing adhesions between the ovary and the adjacent broad ligament, leading to the characteristic chocolate fluid evacuation. The excision by scissors of area A allows the surgeon to identify a cleavage plane close to the cyst wall, which can be followed without significant bleeding (area B). Should adhesions appear in the cleavage plane, they are coagulated and cut, so as not to strip the ovarian cortex. Close to the ovarian hilus, for complete cyst removal, adhesions require coagulation using bipolar current and section by scissors (area C)."
89433584|NCT06115889|Experimental|Smart Taiko Drumming Group|Smart Taiko Drumming
89433585|NCT06115889|No Intervention|Usual Care Waitlist Control Group|Usual care
89433586|NCT06113861||Presumptive pediatric TB cases-- Test population|"Inclusion criteria: Children ages 2 months to 14 years with symptomatic disease and suspicion of TB (based on Bolivian Ministry of Health guidelines).~Exclusion criteria (prior treatment for TB in 12 mo, current treatment for TB, weight < 2.5 kg., instability, positive COVID-19 test) Study subgroups are determined in part based on the results of diagnostic tests and on clinical response.~A. Confirmed TB~Symptomatic by case definition from the 2015 NIH Expert Panel~Positive culture or positive Xpert MTB/RIF from at least one sample.~B. Unconfirmed TB-~Symptomatic and clinical/radiographic evaluation consistent with TB, by case definition from the 2015 NIH Expert Panel~Negative M. tuberculosis culture and negative Xpert MTB/RIF from all samples.~C. Unlikely TB---~Symptomatic BUT clinical/radiographic eval does NOT meet criteria for Unconfirmed TB, per clinical definition-2015 Expert Panel~Negative culture and negative Xpert MTB/RIF from all specimens."
89433587|NCT06113861||Control group--Test population|"Well Children Control Group-One for each child in groups A-C above, age matched for paired case.~Well children presenting for reasons other than respiratory diseases, and not symptomatic for TB.~Clinical and radiographic evaluation (if performed) NOT suggestive of TB, and NOT diagnosed or treated for TB during the follow-up period (minimum 8 weeks).~Divided into 2 subgroups based on presence or absence of LTBI (by Quantiferon Gold assay)."
88913544|NCT01596998|Active Comparator|Levobupivacaine without epinephrine|
88913545|NCT01596998|Experimental|Levobupivacaine with epinephrine|
88913546|NCT01597011||Fibrin sealant group|Patients who have undergone laparoscopic inguinal hernia repair with fibrin sealant for mesh fixation
88913547|NCT01597011||Tissue-penetrating fixation group|Patients who have undergone laparoscopic inguinal hernia repair with the use of tacks, staples or sutures for mesh fixation
88913548|NCT01597024|Experimental|Phase 1: Breakfast Study|
88913549|NCT01597024|Experimental|Phase 2: fMRI Study|
88913550|NCT01597037|Active Comparator|High complexity, high feedback|Scripts are one grade level higher than the typical script that would be provided for the severity of aphasia; there is an opportunity for the participant to listen to his/her production and assess performance.
88913551|NCT01597037|Active Comparator|High complexity, low feedback|Scripts are one grade level higher than the typical script that would be provided for the severity of aphasia; there is no opportunity for the participant to listen to his/her production and assess performance.
88913552|NCT01597037|Active Comparator|Low complexity, high feedback|Scripts are one grade level lower than the typical script that would be provided for the severity of aphasia; there is an opportunity for the participant to listen to his/her production and assess performance.
88913553|NCT01597037|Active Comparator|Low complexity, low feedback|Scripts are one grade level lower than the typical script that would be provided for the severity of aphasia; there is no opportunity for the participant to listen to his/her production and assess performance.
88913554|NCT01597063||low risk pregnancies|
88913555|NCT01597076|Experimental|60-240 mL/day|60 -240 mL/day dose group
88913556|NCT01597102||Liver transplantation|Patients with liver failure and liver transplantation
88913557|NCT01597115|Active Comparator|Duplex|Patients in this group will be examed by duplex ultrasonography at 2 and 4 weeks after surgery
88913558|NCT01597115|No Intervention|physical exam|According to the K/DOQI guideline, patients will be examed by vascular access surgeon at 2 and 4 weeks after surgery
88913559|NCT01597154|Experimental|Lifestyle counselling|Exercise, nutrition and self-efficacy based lifestyle training in a peer mentoring setting
88913560|NCT01597154|No Intervention|Control|Youth randomized to the control group will receive standard care for the first 16 weeks followed by 16 weeks of intervention
88913561|NCT01597167|Experimental|Magnesium sulfate crossover|IV infusion of magnesium sulfate followed by 5-day washout period and crossover to 5% dextrose (placebo)
89197873|NCT00756366|Other|3|Heart Failure- no OSA, no CPAP therapy, observational group
89531251|NCT05032911||Neck pain patients|Patients with neck pain should have an intensity of pain of at least 3 points out of 10 on a Visual Analog Scale and a neck pain duration of at least 3 months of evolution. Neck pain could be from nonspecific mechanical origin, associated with whiplash or with a previous medical diagnosis of degenerative or inflammatory alterations of the cervical spine, associated or not with headache and pain in the shoulder region or the upper limb.
88913562|NCT01597167|Placebo Comparator|Placebo crossover|IV infusion of 5% dextrose with 5 day washout and crossover to magnesium sulfate
88913563|NCT01597206|Experimental|Removable partial denture Group|Patients with a reduced posterior dental arch will be randomized into one of 2 Groups Group A will receive a removable partial denture prosthesis
88913564|NCT01597206|Active Comparator|Reduced Posterior Dental Arch Group|Patients with a reduced posterior dental arch and not receiving any Intervention will be compared to the removable partial denture group
88913565|NCT01597219|Experimental|Reduced intensity haploidentical transplant|Fludarabine 30mg/m2 IV days -6 to -2 Cyclophosphamide 14.5 mg/kg IV days -6 and -5 Total body irradiation 2Gy day -1 Stem cell transplant: day 0 Cyclophosphamide 50mg/kg days +3 & +4
88913566|NCT01597219|Experimental|Myeloablative haploidentical stem cell transplant|Total body irradiation 12Gy in 8 fractions days -9 to -6 Donor lymphocyte infusion day -6 Cyclophosphamide 60mg/kg IV days -3 & -2 Stem cell transplant day 0
88913567|NCT01597232|Experimental|Transfusion trigger based on WCPTS|Determination of whether a patient need red blood cells transfusion or which hemoglobin level should be maintained is based on WCPTS.
88913568|NCT01597232|Active Comparator|Hemoglobin level 10g/dL|The patient's hemoglobin level is maintained more than 10g/dL perioperatively.
88913569|NCT01597232|Active Comparator|Transfusion trigger based on experience|Determination of whether a patient need red blood cell transfusion or which hemoglobin level should be maintained is base on the physician's experience.
88913570|NCT01597297|Experimental|Fampridine-PR|Prolonged-Release Fampridine (Fampridine-PR) 10 mg twice daily (every 12 hours) for up to 24 weeks.
88913571|NCT01597297|Placebo Comparator|Placebo|Matched placebo twice daily (every 12 hours) for up to 24 weeks.
88913572|NCT01597310|Experimental|Warfarin|25 mg Warfarin, Treatment Period 1 & Treatment Period 2
88913573|NCT01597310|Experimental|Dexpramipexole|150 mg BID Treatment Period 2
88913574|NCT01597323||Treatment Group|Healthy Male of Female between ages 35 and 60 with presence of mild to moderate facial photodamage (sun damage) and presence of mild to moderate facial wrinkling
88913575|NCT01597336|Active Comparator|Saline only flush of abscess|Saline alone used to flush abscess
88913576|NCT01597336|Experimental|Saline plus tPA flush of abscess|Saline plus tPA used for abscess flush
88913577|NCT01597362|Other|Veress needle technique|
88913578|NCT01597362|Other|Direct trocar technique|
88913579|NCT01597362|Other|Open technique|
88913580|NCT01597401|Experimental|Aes-103 300 mg to 1000 mg (Group A)|Group A will consist of six subjects receiving a single dose of either a low dose of Aes-103 (300 mg) or placebo without food. After a minimum of a 1- to 2-week washout period and evaluation of blinded safety data, subjects initially randomized to Aes-103 will receive a second, higher dose of Aes-103 (1,000 mg), and subjects initially randomized to placebo will receive a second dose of placebo without food.
88913581|NCT01597401|Experimental|Aes-103 2000 mg to 4000 mg (Group B)|Group B will consist of six subjects receiving an initial dose of either Aes 103 (2,000 mg) or placebo without food. After a minimum of a 1- to 2-week washout period and evaluation of blinded safety data, subjects initially randomized to Aes-103 will receive a second, higher dose of Aes-103 (4,000 mg), and subjects initially randomized to placebo will receive a second dose of placebo without food.
88913582|NCT01597401|Experimental|Top Dose Expansion (Group C)|Once the top dose (i.e., highest tolerated) of Aes-103 has been determined, the size of this group will be expanded with an additional six subjects (Group C) for a total of 12 at that dose, distributed so that six subjects receiving hydroxyurea (HU) and six subjects not receiving HU (for the past 6 months) will receive study drug (five receiving Aes-103 and one receiving placebo in each of the HU and non-HU treated cohorts). This total of 12 subjects includes the initial six subjects who received the highest dose in the study plus six Group C subjects. These subjects will receive a single dose of the top dose of Aes-103 or placebo without food. After a minimum of a 1- to 2-week washout period and evaluation of blinded safety data, subjects initially randomized to Aes-103 will receive a second dose of the top dose of Aes-103 and subjects initially randomized to placebo will receive a second dose of placebo; all subjects will be administered a pre-dose, high fat, high protein meal.
88913583|NCT01597427|Sham Comparator|Clonidine|Administration of 2 μg/kg of intravenous clonidine.
88913584|NCT01597427|Placebo Comparator|Placebo|Injection of placebo solution.
88913585|NCT01597453|Other|Lifestyle counseling|There are no different arms, NOR-SYS is an observational study
88913586|NCT01597466|Experimental|Epidrum|Epidrum (Exmoor Innovations, Lisieux Way, Taunton, Somerset TA1 2LB, U.K.)
88913587|NCT01597466|Active Comparator|Loss of resistance technique|
88913588|NCT01597518|Experimental|Riluzole|
88913589|NCT01597518|Placebo Comparator|Placebo|
88913590|NCT01597531|Active Comparator|Liraglutide only|
88913591|NCT01597531|Active Comparator|Orlistat only|
88913592|NCT01597531|Active Comparator|Liraglutide + Orlistat|
88913593|NCT01597544|No Intervention|CISC instruction post-operatively|For those patients that are randomized to CISC instruction before surgery, instruction will begin on post-operative day one. One of the nurses from the hospital gynecology unit will teach and supervise the patients until they feel comfortable with the technique or until catheterization is no longer required (e.g. when the patient passes her voiding trial on two separate occasions). This is the protocol currently in use at our institution.
88913594|NCT01597544|Active Comparator|CISC instruction pre-operatively|Patients allocated to the pre-operative CISC teaching group will be taught how to perform CISC by one of urogynecology nurses working at the Women's Health Care Centre. Patients will be allowed to practice until they feel comfortable with the technique. This should take approximately 30 minutes. The session will take place on the day of their pre-operative medical appointment (PAF), which normally occurs less than a month before the surgery. If a patient is not seen in PAF or is seen more than a month before her surgery, a separate appointment for CISC teaching during the month preceding the surgery will be organized. Post-operatively, a nurse from the hospital gynecology unit will review the technique to make sure the patient is still comfortable with performing CISC.
88913595|NCT01597570|Experimental|FASTSEAL® Bioabsorbable VCD|Fastseal® Bioabsorbable Vascular Access Closure System
88913596|NCT01597570|Active Comparator|Perclose® ProGlide SMC System|Perclose® ProGlide Suture-Mediated Closure System
88913597|NCT01597609|Experimental|Cohort A|- 600 Kcal deficit, Sibutramine placebo
88913598|NCT01597609|Experimental|Cohort B|- 600 Kcal deficit, Sibutramine 10 mg once daily
88913599|NCT01597609|Experimental|Cohort C|- 600 Kcal deficit, Moderate exercise (The energy expenditure will be equivalent to 30 minutes of brisk walking/5 times week i.e. ~1,000 Kcal/week) /sibutramine placebo
88913600|NCT01597648|Experimental|Sequence 1|Treatment A: 1 tablet of GSK2838510 (maraviroc 300 mg, lamivudine 150 mg, and zidovudine 300 mg as a combined formulation) after an overnight fast Washout Treatment B: 1 tablet of maraviroc 300 mg + 1 tablet of Combivir taken concurrently after an overnight fast.
88913601|NCT01597648|Experimental|Sequence 2|"Treatment B: 1 tablet of maraviroc 300 mg + 1 tablet of Combivir taken concurrently after an overnight fast.~Washout Treatment A: 1 tablet of GSK2838510 (maraviroc 300 mg, lamivudine 150 mg, and zidovudine 300 mg as a combined formulation) after an overnight fast"
88913602|NCT01597661||Malformed and population-based sample of non-malformed infants|Infants with any of a wide range of malformations are identified at tertiary care and birth hospitals in four study centers (Boston, Philadelphia, Toronto, San Diego) using approaches that include reviewing lists of discharge diagnoses available in medical records; contacting newborn nursery and/or labor and delivery rooms; reviewing admission/discharge lists; and reviewing clinic and surgical logs. A population-based random sample of non-malformed newborns in Massachusetts is also included. Information gathered on each subject includes name, address, telephone number, diagnostic information, and date of birth.
88913603|NCT01597700|Experimental|Acotral® ezetimibe 10mg|Subjects will be fasted overnight and receive one tablet by mouth in accordance with a randomisation list and venous blood samples will be taken at specified intervals over the ensuing 3 day.
88913604|NCT01597700|Active Comparator|Zetia® ezetimibe 10mg|Subjects will be fasted overnight and receive one tablet by mouth in accordance with a randomisation list and venous blood samples will be taken at specified intervals over the ensuing 3 days.
88913605|NCT01597713|Experimental|Part 1, level 1-7 escalating doses|
88913606|NCT01597713|Experimental|Part 2, cross-over|
88913607|NCT01597726|Active Comparator|Misoprostol|
88913608|NCT01597726|Experimental|Laminaria|
88913609|NCT01597739|Experimental|JNJ-40346527|
88913610|NCT01597739|Placebo Comparator|Placebo|
88913611|NCT01597752|Experimental|1|"Blomia tropicalis allergen extract (four concentrations: 5, 0.5, 0.05, 0.005 mg/ml)~Positive control~Negative control"
88913612|NCT01597765|Experimental|Curcuminoids|The administrate curcuminoids is intervention for 30 patients
89009719|NCT02212405|Experimental|rTMS 10Hz + PET.|Deep repetitive Transcranial Magnetic Stimulation will be applied to the insula for 30 minutes. This will consist of 34 trains each comprising of 30 pulses at 10Hz. The inter-train interval is 3 seconds. The intervention is followed by radiotracer and PET.
89009720|NCT00267033|Experimental|1|injection of orthopaedic cement into vertebral bodies
89433588|NCT06113861||Presumptive pediatric TB cases-- Validation population|"Inclusion criteria: Children ages 2 months to 14 years with symptomatic disease and suspicion of TB (based on Bolivian Ministry of Health guidelines).~Exclusion criteria (prior treatment for TB in 12 mo, current treatment for TB, weight < 2.5 kg., instability, positive COVID-19 test) Study subgroups are determined in part based on the results of diagnostic tests and on clinical response.~A. Confirmed TB~Symptomatic by case definition from the 2015 NIH Expert Panel~Positive culture or positive Xpert MTB/RIF from at least one sample.~B. Unconfirmed TB-~Symptomatic and clinical/radiographic evaluation consistent with TB, by case definition from the 2015 NIH Expert Panel~Negative M. tuberculosis culture and negative Xpert MTB/RIF from all samples.~C. Unlikely TB---~Symptomatic BUT clinical/radiographic eval does NOT meet criteria for Unconfirmed TB, per clinical definition-2015 Expert Panel~Negative culture and negative Xpert MTB/RIF from all specimens."
89433589|NCT06113861||Control group--Validation population|"Well Children Control Group-One for each child in groups A-C above, age matched for paired case.~Well children presenting for reasons other than respiratory diseases, and not symptomatic for TB.~Clinical and radiographic evaluation (if performed) NOT suggestive of TB, and NOT diagnosed or treated for TB during the follow-up period (minimum 8 weeks).~Divided into 2 subgroups based on presence or absence of LTBI (by Quantiferon Gold assay)."
89433590|NCT06113640|Active Comparator|control group|Control group (Levo-dopa group, n =30) who received levodopa/carbidopa (250/25 mg) three times daily for 3 months
89433591|NCT06113640|Active Comparator|Montelukast group|who received levodopa/carbidopa (250/25 mg) three times daily plus Montelukast 10 mg once daily for 3 months
89009721|NCT04566055||Prospective observational cohort|
89433592|NCT06112743|Experimental|Mavacamten|
89433593|NCT06112743|Placebo Comparator|Placebo|
89009722|NCT04566211|Experimental|(panto+amox+clar+metr)+(panto+amox)|a 7-day quadruple regimen with pantoprazole 40 mg twice daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily, followed by a 3-day dual regimen with pantoprazole 40 mg twice daily and amoxicillin 1 g twice daily
89009723|NCT04566211|Active Comparator|pantoprazole+bismuth+amox+clar|pantoprazole 40 mg twice daily, bismuth subcitrate 240 mg twice daily, and amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily for 10 days
89009724|NCT04565587|Other|Videofluoroscopy|All participants will undergo a Videofluoroscopy when swallowing different viscosity levels of the thickener Tsururinko Quickly (japanese thickener)
89433594|NCT06112704|Experimental|Phase IIa: Cohort 1|Participants with advanced esophageal squamous cell carcinoma will be administered HS-20093.
89433595|NCT06112704|Experimental|Phase IIa: Cohort 2|Participants with advanced esophageal adenocarcinoma and gastroesophageal junction adenocarcinoma will be administered HS-20093.
89433596|NCT06112704|Experimental|Phase IIa: Cohort 3|Participants with other advanced solid tumor will be administered HS-20093.
89433597|NCT06112704|Experimental|Phase IIb|Participants with advanced esophageal squamous cell carcinoma will be administered HS-20093.
89433598|NCT06110117|Experimental|Nasal Spray|1 to 2 sprays per nostril of Sterimar Stop & Protect Irritation & Dryness for a minimum of 2 times (morning and evening) and, as needed, up to a maximum of 6 times per day (i.e. maximum 12 sprays per nostril each day) for seven days.
89433599|NCT06109337||ADHD children|Take peripheral blood 5ml; IQ and cognitive function test; Head MRI scan
89433600|NCT06109337||typically developing controls|Take peripheral blood 5ml; IQ and cognitive function test; Head MRI scan
89433601|NCT06109025|Experimental|EXPERIMENTAL GROUP|The sample will be composed mainly, but not exclusively, of adults of legal age, belonging to the group of university students.
89009725|NCT02210923||Resistant hypertensive patients with Rheos system|"We will program 6 electrical device activation setting twice in a random order to see what happens with the aforementioned respiratory and cardiovascular variables. The following electrical settings will be programmed for 4 minutes each setting:~20 Hz, 3 Volts, 480 microseconds~20 Hz, 6 Volts, 480 microseconds~50 Hz, 3 Volts, 480 microseconds~50 Hz, 6 Volts, 480 microseconds~90 Hz, 3 Volts, 480 microseconds~90 Hz, 6 Volts, 480 microseconds"
89009726|NCT00232466|No Intervention|2|conservative therapy (no intervention)
89009727|NCT00232466|Active Comparator|1|Vertebroplasty
89009728|NCT02211040|Experimental|No general practitioner involvement|The selection and motivation of adults will be conducted by a researcher in the waiting room. There is no extra motivation of the general practitioner.
89009729|NCT02211040|Experimental|General practitioner involvement|An intervention group in which general practitioners select and motivate adults to be more physical active and eat more fruit and vegetables.
88913613|NCT01597765|Experimental|Vitamin E|The vitamin E is intervention for 30 patients
88913614|NCT01597804|Experimental|"Supportive care (Bathing Bundle)"|"Patients undergo preoperative preparation with the Bathing Bundle comprising CHG 4% skin prep solution and disposable wash cloths to bathe or shower with the night before and morning of surgery."
88913615|NCT01597817|Active Comparator|chitosan coated textile|Chitosan coated cotton long sleeved t-shirts and pants.
88913616|NCT01597817|Placebo Comparator|chitosan free cotton textile|Chitosan free cotton long sleeved t-shirts and pants.
88913617|NCT01597830|Experimental|active shoe|
88913618|NCT01597830|Sham Comparator|Control|
88913619|NCT01597882||Case managed patients|Patients aged 65 years and over receiving community case management.
88913620|NCT01597895|Active Comparator|Maraviroc|
88913621|NCT01597895|Experimental|Maraviroc + Boceprevir|
88913622|NCT01597895|Experimental|Maraviroc + Telaprevir|
89433602|NCT06109025|Active Comparator|CONTROL GROUP|The sample will be composed mainly, but not exclusively, of adults of legal age, belonging to the group of university students.
89433603|NCT06107595|Experimental|Efficacy of conditioned open label placebo pill|"On postoperative day 0, participant will self-administer one OLP with all opioid analgesics (whether administered intravenously or orally). This pairing will be done from postoperative day 0 to postoperative day 17.~Starting on postoperative day 2, participants take 3 scheduled placebo doses (pills or inhalation) every day, at 3 convenient times. In parallel, the OLP pairing to standard and rescue doses of opioids will continue.~The patients are told to continue taking both scheduled standalone COLP and paired COLP (if needed) until postoperative day 17."
89433604|NCT06107595|Experimental|Efficacy of conditioned open label placebo odor|"1 drops of clove oil (i.e. eugenol) will be disposed on a cotton and inserted into a stick. The patients will be asked to actively smell them by sniffing using a stick of inhalation. On postoperative day 0, participant will self-administer one OLP with all opioid analgesics (whether administered intravenously or orally). This pairing will be done from postoperative day 0 to postoperative day 17.~On postoperative day 2, participants take 3 scheduled placebo doses (pills or inhalation) every day, at 3 convenient times. In parallel, the OLP pairing to standard and rescue doses of opioids will continue.~The patients are told to continue taking both scheduled standalone COLP and paired COLP (if needed) until postoperative day 17"
89433605|NCT06107595|Active Comparator|Standard of care|Usual postoperative pain management, relying mainly on opioids
89433606|NCT06106555||Individuals with BPD|Individuals with BPD, as defined by the DSM-V, and a recent history (past 12 months) of self-harming behaviour.
89433607|NCT06106490|Active Comparator|Suprasacapular nerve block|Patients will receive ultrasound guided intra articular Gleno-humeral steroid injection of Diprofos® (betamethasone 14 mg/ 2ml) and ultrasound guided suprascapular nerve block US SSN with 10mL of 0.25% preservative-free bupivacaine
89433608|NCT06106490|Active Comparator|Pulsed Radiofrequency group|Patients will receive ultrasound guided intra articular Gleno-humeral steroid injection of Diprofos® (betamethasone 14 mg/ 2ml) and ultrasound guided suprascapular nerve block US SSN with 10mL of 0.25% preservative-free bupivacaine with application of pulse PRF at 42 Celsius of suprascapular nerve for 480 seconds.
89433609|NCT06104436|Experimental|Individualized music playlist|Composed of preferred music genres sequenced according to the ISO-Principle in addition to usual care.
89433610|NCT06104436|Active Comparator|Preferred music|Preferred music genres played in random sequence in addition to usual care.
89433611|NCT06104436|Sham Comparator|Treatment as usual|Usual care for agitation management.
89433612|NCT06104124|Experimental|Dazodalibep Dose 1|Participants will be administered dose 1 of dazodalibep by intravenous (IV) infusion.
89433613|NCT06104124|Experimental|Dazodalibep Dose 2|Participants will be administered dose 2 of dazodalibep by IV infusion.
89433614|NCT06104124|Placebo Comparator|Placebo|Participants will be administered placebo by IV infusion.
89433615|NCT06102590|Experimental|Individualized RBCT|Requires daily assessment of hemoglobin (Hb) levels. Prescription of RCBT is restricted to patients who present Hb ≤ 9.0 g/dL and O2ER ≥ 30%. If O2ER < 30%, transfusion will take place only when Hb falls below 7.0 g/dL. Further O2ER measurements during the day in this group are allowed, and the clinician should not be blinded of the results. To tolerate Hb levels below 7.0 g/dL with O2ER < 30% remains a clinical decision, documented in the CRF. Transfusion with Hb below 6.0 g/dL is mandatory
89531252|NCT02493881|Active Comparator|Group 1|The RLNs having motor function on the anterior branch assessed by intraoperative neuromonitoring.
89531253|NCT02493881|Active Comparator|Group 2|RLNs having motor function on anterior and posterior branch assessed by intraoperative neuromonitoring.
88913623|NCT01597921||Breast cancer patient receiving RT|Total dose:2Gy/Fx
88913624|NCT01597934|Active Comparator|Group A:|Maintaining LAM/LdT+ADV combination Lamivudine 100mg / Telbivudine 600mg +Adefovir 10mg
88913625|NCT01597934|Experimental|Group B|Switching to ETV plus TDF combination Entecavir 1.0mg + Tenofovir 300mg
88913626|NCT01597947|Experimental|Arm A|
88913627|NCT01597947|Placebo Comparator|Arm B|
88913628|NCT01597960|Active Comparator|Yoga 12 week programme|Usual care (standard cardiac rehabilitation programme) plus yoga intervention.
88913629|NCT01597960|No Intervention|Usual care|Usual care (standard cardiac rehabilitation programme) only.
88913630|NCT01597986|Experimental|Isavuconazole and oral contraceptive|Arm description(as needed): Subjects receive single dose of oral contraceptive consisting of ethinyl estradiol and norethindrone on Days 1 and 13 and oral doses of isavuconazole every 8 hours on Days 9 and 10 followed by a once a day dose in the mornings on Days 11 through 16.
88913631|NCT01597999|Other|No treatment|Accuracy of magnetic resonance imaging (MRI) in predicting aggressiveness of early breast cancer according to molecular subtypes identified by ER PR and HER-2 status ( Additional benefits of magnetic resonance imaging (MRI) with Gadovist in early breast cancer with poor prognostic features )
88913632|NCT01598012|Experimental|Ayurved Siriraj Prasaplai|
88913633|NCT01598012|Placebo Comparator|placebo|
89433616|NCT06102590|Active Comparator|Control group|Requires daily assessment of hemoglobin levels. Prescription of RCBT is restricted to patients who present Hb ≤ 7.0 g/dL, despite of O2ER values. Indeed, O2ER calculation takes place at least once daily in this group but does not interfere with clinical decision to prescribe RBCT. A liberal transfusion threshold (i.e. 9.0 g/dL) is still possible in critically ill adults with acute coronary syndromes, as indicated by the European current guidelines
89433617|NCT06101537||Brain temperature-pressure monitoring group|From a neurointensive care unit with intracranial pressure monitoring during treatment, which allows continuous recording of brain temperature-pressure data, in patients with moderate and severe acute brain injury due to subarachnoid hemorrhage, cerebral hemorrhage, and craniocerebral trauma.
88913634|NCT01598038|No Intervention|Afinitor|"The recommended dose of Afinitor is 10 mg everolimus once daily, at fixed hour.Treatment should continue as long as clinical benefit is observed or until unacceptable toxicity occurs.~In case of frail patients, treatment could be initiated at a lower daily-dose (5mg/d for example) and then increase if tolerance is acceptable."
88913635|NCT01598051||Group 1|Patients treated with Xarelto under practical manner for SPAF.
88913636|NCT01598077|Experimental|Dose escalation and dose expansion|
88913637|NCT01598142|Other|experienced assistant group|experienced endoscopist with an experienced assistant.
88913638|NCT01598142|Other|new trained assistant group|same experienced endoscopist with a new trained assistant
88913639|NCT01598155|Experimental|Supragingival biofilm control|
88913640|NCT01598155|Experimental|Supra- and subgingival biofilm control|
88913641|NCT01598168|Experimental|Rivaroxaban|Rivaroxaban 15 mg bid until HIT excluded by local laboratory assay or platelets recovered. If HIT positive and platelets have recovered, patients will receive rivaroxaban 20 mg od until Day 30.
88913642|NCT01598181|Experimental|active tDCS|
88913643|NCT01598181|Sham Comparator|sham tDCS|tDCS fades out after 20 sec. administered double blind by coded program.
88913644|NCT01598220|Experimental|Computer-assisted cognitive remediation therapy|
88913645|NCT01598220|Placebo Comparator|attentional task|
88913646|NCT01598233|Experimental|Intragastric balloon|Patients submitted to six-month intragastric balloon
88913647|NCT01598246||Extubation Success|Patients who do not require re-intubation, upto 72 hours after a planned extubation in the pediatric intensive care unit.
88913648|NCT01598246||Extubation failure|Patients who required re-intubation within 72 hours after a planned extubation in pediatric intensive care unit. To be further classified as early <12 hour and late 12-72 hour, extubation failures.
88913649|NCT01598259|Experimental|melatonin|Subjects will receive melatonin
88913650|NCT01598259|Placebo Comparator|placebo|
88913651|NCT01598272|Experimental|Vitality product AM + Vitality product PM|"Dietary Supplement:~Proprietary blend of ginseng, cordyceps, and pomegranate + proprietary blend of broccoli seed, red orange, and grape seed taken twice a day for 8 weeks."
88913652|NCT01598272|Placebo Comparator|Placebo|Dietary Supplement: Placebo Placebo taken twice a day for 8 weeks
88913653|NCT01598324||escitalopram responders no augmentation|Participants who show a clinical response following 8 weeks on an SSRI will have a final magnetic resonance scan at the end of 8 weeks and will complete the study at that time.
88913654|NCT01598324||Ziprasidone augmentation|Participants who do not respond to escitalopram and are randomized to ziprasidone augmentation will have a final magnetic resonance scan following 8 weeks on ziprasidone.
88913655|NCT01598324||Placebo augmentation|Participants who do not respond to escitalopram and are randomized to placebo augmentation will have a final magnetic resonance scan following 8 weeks on placebo.
88913656|NCT01598337|Active Comparator|Aspirin alone|
88913657|NCT01598337|Experimental|Tirofoban|Patient assigned to this arm will receive tirofiban infusion starting approximately six hours post bypass surgery once hemomstasis established and no evidence of bleeding
88913658|NCT01598337|Experimental|Clopidogrel|Patients receive oral clopidogrel 75 mg 6-8 hours before coronary bypass surgery and continue daily mentenance dose as per instruction by investigators
89433618|NCT06099301|No Intervention|Waitlist control (WC)|The WC group will not receive treatment from the research team during the assessment period. But they will be notified their evaluation results (mild to moderate depression) after they complete the baseline assessment. They will receive the information about mental health hotline services for general public (e.g. Social Welfare Department: 2343 2255; Caritas Family Crisis Support Centre: 18288; Joyful Mental Health Foundation: 2301 2303). The intervention group will receive the hotline information as well. If they want to consult a family doctor, information about the primary care provider/directory for mental health care and counselling services will be provided in their preferred district. Their treatment or help-seeking of the formal mental health services will not be intervened. The mobile app list will be provided to the WC group after the assessment period. The instruction session will be delivered to the WC group and provide necessary assistance.
89433619|NCT06099301|Experimental|Brief advice of a list of mobile apps|In the instruction session, the participants will be introduced with the concept of self-care, a list of three mobile apps with high quality and suitability, and the main functions of these apps. Participants will be instructed to use at least one of the apps for 10 min each day for 30 days. They have freedom to choose which one app to use, or a mix of two or three apps. For each app they choose, they will create user accounts by themselves but be reminded to protect privacy. Two reminders will be sent to the participants at the 2nd and 3rd week. The message will include reminders to use the suggested mobile apps, self-care concept, and tips of using the provided apps. If they have not accessed to any of the mobile apps, the project coordinator will discuss the reasons and work together with the participants to overcome the problems.
89433620|NCT06098508|Experimental|Osteopathic Manual Treatment|
89433621|NCT06098508|Sham Comparator|Sham Treatment Arm|
89433622|NCT06097026|No Intervention|Standard treatment (CONT)|The patient will be managed according to the routine clinical protocol, homogenizing the interventions in both participating centers.
89433623|NCT06097026|Experimental|iNO 20-40 ppm|In this arm, inhaled nitric oxide therapy will be initiated at 20 ppm immediately after randomization and after initial data collection. The dose will be reassessed after the first 30 min and may be increased to a maximum of 40 ppm depending on the response observed in ventricular function.
89433624|NCT06097026|Experimental|iNO 20 - 40 ppm + Lung recruitment (iNO-RM)|After 30 min after initiation of nitric oxide therapy following randomization, once patient stability has been confirmed, a brief recruitment maneuver will be performed and the subsequent PEEP level will be individualized according to the best lung compliance. Ventilation will then continue with the standard baseline ventilator settings, but with the PEEP level individually optimized.
89433625|NCT06094803|Experimental|Receiving Mindfulness-based Zentangle Interventions|"Participants in the intervention group will receive two 2-hour weekly sessions, focusing on two main themes, which are Self-awareness and self-kindness as well as Acceptance and non-judgmental attitude. Each session with one hour duration and have five different contents separately."
89433626|NCT06094803|No Intervention|Waitlist Control Group|The waitlist control group will not receive any training before all the assessments have been done by both groups. Yet, they will receive the same mindfulness-based Zenatngle training after the assessment period (3 months after baseline). They will be notified that their level of depressive and/or anxiety symptoms when the baseline assessment has been finished. Respondents with Patient Health Questionnaire (PHQ-9) or General Anxiety Disorder (GAD-7) score higher than 14 will be advised to consult a doctor, same as the intervention group.
89433627|NCT06089603|Experimental|CPAP treatment|Diet and conventional pharmacological treatment plus continuous positive airway pressure (CPAP)
89433628|NCT06089603|Active Comparator|Control treatment|Diet and conventional pharmacological treatment
89433629|NCT06087861|Experimental|External beam radiotherapy|Patients will receive treatment with external beam radiotherapy at a total of 30 Gy delivered over five fractions delivered daily.
89433630|NCT06087588|Active Comparator|sham PENG block|PENG block - 20ml 0,9% normal saline
89433631|NCT06087588|Active Comparator|PENG neurolysis|PENG neurolysis with 5ml 95% ethanol
89433632|NCT06087549|Active Comparator|Control group|regional anesthesia: spinal anesthesia - 0,1ml/kg 0,5% ropivacaine
89433633|NCT06087549|Active Comparator|Pericapsular nerve group block (PENG) group|regional anesthesia: spinal anesthesia - 0,1ml/kg 0,5% ropivacaine + PENG block - 0.5mL/kg 0.2% ropivacaine, max. 20mL
89433634|NCT06087549|Active Comparator|Erector Spinae Plane Block (ESPB) group|regional anesthesia: spinal anesthesia - 0,1ml/kg 0,5% ropivacaine + ESP block - 0.5mL/kg 0.2% ropivacaine, max. 20mL
89433635|NCT06085690|No Intervention|Existing central venous catheters in the hospital or ICU maintain routine care procedures|According to the hospital or ICU catheterization, maintenance and removal of central venous catheter routine care
89433636|NCT06085690|Experimental|evidence-based intervention Plan for the Prevention of CRBSI in ICU patients|"On the basis of routine nursing, the evidence-based intervention Plan for the Prevention of CRBSI in ICU patients was implemented for intervention."
89433637|NCT06081101|Active Comparator|Corticosteroid|Patients will receive ultrasound guided corticosteroid injection to see pain relief after injection
89433638|NCT06081101|Active Comparator|Ketorolac|Patients will receive ultrasound guided ketorolac injection to see pain relief after injection
89009730|NCT02211079|Experimental|JNJ-54861911 + Caffeine + Midazolam +Tolbutamide|JNJ-54861911, 50 milligram (mg) (2*25 mg tablets) orally once daily from Day 2 to Day 9 along with caffeine 100 mg (2*50 mg tablets), midazolam 2 mg (1 milliliter [mL], 2 mg/mL solution), and tolbutamide 500 mg tablet, orally on Day 1, 2, and 9.
89009731|NCT04565860|Active Comparator|X-tra fil (bulk-filling) (X-traB)|X-tra fil composite placed as bulk-filling
89009732|NCT04565860|Active Comparator|X-tra fil (incremental) (X-traI)|X-tra fil composite placed as incremental
89009733|NCT04565860|Active Comparator|Filtek Bulk (bulk-filling) (FBB)|Filtek Bulk composite placed as bulk-filling
89433639|NCT06080061|Experimental|Hypofractionated accelerated radiation therapy (HART)|Patients will either be treated with 60-66 Gy in 30, 25, or 20 fractions based on ability to meet constraints to key organs at risk
89433640|NCT06079372|Experimental|ALXN1850|Starting at Day 1 of the Randomized Evaluation Period participants will receive ALXN1850 for a total of 24 weeks. Participants will receive bodyweight dependent doses of either 20mg, 35mg or 50mg of ALXN1850 once q2w via SC injection. During Part A of the OLE Period, participants will have frequent visits over the first 24 weeks; Part B of the OLE Period participants will have visits every 9 months for up to approximately 108 weeks.
89433641|NCT06079372|Experimental|asfotase alfa|Starting at Day 1 of the Randomized Evaluation Period, participants will receive asfotase alfa for a total of 24 weeks. Participants will receive 6 mg/kg/week of asfotase alfa via SC injection as either 2 mg/kg 3 times per week or 1 mg/kg 6 times per week. Part A of the OLE Period participants will have frequent visits over the first 24 weeks; Part B will have visits every 9 months for up to approximately 108 weeks.
89433642|NCT06079359|Experimental|ALXN1850|Starting at Day 1 of the Randomized Evaluation Period, the ALXN1850 group will receive bodyweight dependent doses of either 20mg, 35mg or 50mg of ALXN1850 once every 2 weeks (q2w) via SC injection, for 24 weeks. Participants will enter the OLE Period and continue q2w dosing with ALXN1850 for up to 132 weeks.
89433643|NCT06079359|Placebo Comparator|Placebo|Starting at Day 1 during the Randomized Evaluation Period, participants will receive placebo q2w for a total of 24 weeks. Participants will enter the OLE Period and continue q2w dosing with ALXN1850 for up to 132 weeks.
89433644|NCT06078709|Experimental|Treatment (Radiation and FOLFOX)|Patients receive oxaliplatin IV over 2-6 hours on day 1, leucovorin calcium IV over 10-120 minutes on day 1, and and fluorouracil IV over 46-48 hours on days 1 and 2. Treatment repeats every 2 weeks for a total of 3 cycles in the absence of disease progression or unacceptable toxicity. Starting at cycle 2, patients undergo radiation therapy daily on Monday through Friday for a total of 15 treatments. Patients undergo EGD and/or EUS during screening and undergo CT/PET scan and CT scan as well as blood sample collection throughout the study.
89433645|NCT06077812|Active Comparator|In-Person Migraine Self-Management|
89433646|NCT06077812|Active Comparator|Remote Migraine Self-Management|
89433647|NCT06077513|Experimental|CAD-CAM Ti-Mesh frame|Participants randomized into this arm will have their tooth loss treated with CAD-CAM designed and preprinted Ti-MESH during surgery.
89433648|NCT06077513|Active Comparator|Conventional Ti-Mesh frame|Participants randomized into this arm will have their tooth loss treated with conventional chairside fabrication of Ti-MESH during surgery.
89433649|NCT06077240|Experimental|E-cigarettes|Adults who smoke cigarettes will be randomized to receive e-cigarettes for a duration of 4 weeks and to 1 of 4 possible regulatory scenarios within products where flavor availability is either menthol and tobacco/unflavored available or tobacco/unflavored only available, and nicotine concentration is either higher (5% e-cig) or lower (2.4% e-cig). Participants will return for bi-weekly research visits (in person or remote videocall) to complete measures for study aims. They will complete a final follow-up at Week 6 to assess maintenance of cigarette reduction and willingness to continue using products once they are no longer provided.
89433650|NCT06077240|Experimental|Nicotine Pouches|Adults who smoke cigarettes will be randomized to receive nicotine pouches for a duration of 4 weeks and to 1 of 4 possible regulatory scenarios within products where flavor availability is either menthol and tobacco/unflavored available or tobacco/unflavored only available, and nicotine concentration is either higher (6mg pouch) or lower (3mg pouch). Participants will return for bi-weekly research visits (in person or remote videocall) to complete measures for study aims. They will complete a final follow-up at Week 6 to assess maintenance of cigarette reduction and willingness to continue using products once they are no longer provided.
89531254|NCT05032989|Experimental|Extraction of distoangular and vertically positioned 3rd molar using cowhorn forcep|Extraction with new technique
89531255|NCT05032989|Active Comparator|Extraction of distoangular and vertically positioned 3rd molar via conventional method|Extraction with the conventional technique
89433651|NCT06076421|Experimental|Evidence-based fact box on COVID-19 or influenza (intervention)|"Health educators (HE) will receive a flyer with a brief description of the study, a Quick Response-code (QR-code) and a link to an online survey, including either a fact box as tabular format or a visualization on the reverse side about COVID-19 or the flu vaccine to distribute to potential study participants. HE are free to decide if and how to use the fact boxes: whether during, before or after vaccination education, and who to target.~Participants who receive the flyer from their HE can decide on their own to participate in the study by using the QR-code or link on the flyer."
89433652|NCT06076421|No Intervention|Usual education/care|Study participants whose HE will be randomised to the control will receive the same flyer but without a fact box on the reverse side.
89433653|NCT06076317|No Intervention|Standard arm|Patients will have the usual care
89433654|NCT06076317|Experimental|Interventional arm|Patients will have telemedicine session
89433655|NCT06075537|Experimental|Cohort A2|Participants with nMPS II, aged ≥5 to ≤10 years
89433656|NCT06075537|Experimental|Cohort B2|Participants with nMPS II or nnMPS II, aged ≥1 to ≤18 years
89433657|NCT06075537|Experimental|Cohort C2|Participants with nMPS II, aged <4 years
89433658|NCT06075537|Experimental|Cohort D2|Participants with nMPS II or nnMPS II, aged ≤18 years with preexisting hepatomegaly who have never taken standard-of-care ERT
89433659|NCT06075537|Experimental|Cohort E2|Participants with nMPS II, aged ≥6 years; participants with nnMPS II, aged <6 or ≥17 years; or participants with nMPS II, aged ≥1 to ≤18 years, with a history of prior HSCT or gene therapy and have completed at least 48 weeks in Study DNLI-E-0001
89433660|NCT06075537|Experimental|Cohort A7|Participants with nMPS II, aged ≥2 to <6 years
89433661|NCT06075537|Experimental|Cohort B7|Participants with nnMPS II, aged ≥6 to <17 years
89433662|NCT06071728|Active Comparator|Endocalyx Pro|Subjects will receive 6 capsules per day (3,712mg) of Endocalyx Pro (Microvascular Health Solutions, US Patent Number: 9943572), a commercially available supplement that includes a proprietary blend of glycocalyx precursors and antioxidants
89433663|NCT06071728|Placebo Comparator|Placebo|Subjects will ingest placebo pills
89433664|NCT06071624|Experimental|Treatment|"Redirected autologous T cells transduced with the anti-CD4 lentiviral vector (referred to as CD4CAR cells)"
89433665|NCT06068179|Experimental|intervention group|Mycophenolate Mofetil 0.5 twice daily for 12 months added to methimazole standard therapy.
89433666|NCT06068179|Active Comparator|control group|Methimazole 15-30mg daily initially, then titrate to maintenance dose. Beta-blocker used when necessary.
89433667|NCT06066983|Experimental|Treatment|Parent-child dyads will receive DINOSAUR, a group-based cognitive-behavioral therapy (CBT) intervention, adapted for young children and delivered via telehealth. This 14 week intervention teaches parents and children strategies to reduce anxiety and intolerance of uncertainty, an underlying construct of anxiety.
89433668|NCT06066983|Active Comparator|Active Control|Parents in the active control condition will participate in three psychoeducational groups focused on presenting information regarding anxiety prevalence, differentiating anxiety from autism, and anxiety triggers. These groups will be delivered via telehealth across a 14-week period.
89433669|NCT06063499|Experimental|6 weeks of sessions|Participants will be asked to attend 6 2-hour weekly in-person sessions
89009734|NCT04565860|Active Comparator|Filtek Bulk (incremental) (FBI)|Filtek Bulk composite placed as incremental
89433670|NCT06057324|Experimental|Multi-component intervention groups|"Multi-component intervention with non-invasive approaches:~-Digital interactive tools (AI-based Apps): They will consist of a combination of two Artificial Intelligence (AI) Apps that will be used by parents to empower them in their daily dietary choices for children's dietary plan.~- Educational materials (Mediterranean-based diet toolkit) and activities: The toolkit will include a set of specific games and activities for kids designed to facilitate the ''learning through playing'' approach improving their understanding of different nutrition themes. The educational activities will be co-designed and carried out by adolescents outside of school hours.~- Healthy plant-based snacks: They will be adapted to children's nutritional requirements and to be consumed in-between time on a daily basis. Based on local and traditional products for each country including vegetables, fruits, legumes, seeds and nuts as main ingredients."
89433671|NCT06057324|No Intervention|Control group|Families which will not follow any intervention; they will receive basic Mediterranean guidelines for parents and their children.
89433672|NCT06057142|Experimental|Fun activities for reciting Tang poems|The students will participate in three weekly sessions of Tang poem classes and one session of performance show. Each session lasts for 1.5 hours. Parents can sit in the class. A total of six poems will be taught by two experienced Chinese teachers.
89433673|NCT06056635|Experimental|Karl Storz Curved or Straight Scope|A Karl Storz Curved (11508AAK) or Straight (11506AAK) Fetoscope will be used to provide visualization during in-utero (in the womb) diagnostic and interventional procedures. The curved scope will be used in patients with a placenta that sits at the front of their uterus. The straight scope will be used in patients with a placenta that sits at the back of their uterus.
89433674|NCT06055504|Other|Control Strategy|
89433675|NCT06055504|Experimental|Personalized precision ICD implantation Strategy based in genetic findings and CMR results|
88913659|NCT01598337|Experimental|Prasugrel|Patients started on prasugrel 6 hours post surgery 10 mg then continue on daily 10mg as per instruction by investigators
88913660|NCT01598376|Active Comparator|5/0 gauge vicryl suture|Patients randomly assigned to 5/0 gauge test everting suture
88913661|NCT01598376|Active Comparator|7/0 gauge vicryl suture|Patients randomly assigned to 7/0 gauge test everting suture
88913662|NCT01598389|Experimental|Low energy-dense preload|
88913663|NCT01598389|Experimental|High energy-dense preload|
88913664|NCT01598389|Experimental|No preload|
88913665|NCT01598402|No Intervention|No prophylactic treatment|When a lower airway infection is suspected cultures will be taken and a chest radiography will be made; after that the standard care will be given (in most patients admission to hospital and start of intravenous antibiotics).
88913666|NCT01598402|Experimental|prophylactic treatment|Administration of prophylactic amoxicillin/clavulanic acid suspension, 625 mg tid, start day 29 after the start of CRT until 14 days after the end of CRT. If a lower airway infection is suspected cultures will be taken and a chest radiography will be made; after that the standard care will be given (in most patients admission to hospital and start of intravenous antibiotics)
88913667|NCT01598415|Experimental|SAR113945|TDU11685 selected dose
88913668|NCT01598415|Placebo Comparator|Placebo|
88913669|NCT01598441|Experimental|iloprost|Iloprost nebuliser solution 500 ng/kg inhaled
88913670|NCT01598441|Placebo Comparator|distilled water|aerosolized distilled water 1-2 ml
89433676|NCT06054802||ACL surgery|Pediatric subjects undergoing surgery for ACL repair.
88913671|NCT01598454|Experimental|Racotumomab|
88913672|NCT01598467|Other|Women with pelvic organ prolapse|Women with pelvic organ prolapse (simplified POP-Q > stage 1)
88913673|NCT01598480|Active Comparator|Control|Flamazine is applied on the wound in the control group instead and then covered with sterile gauze.
88913674|NCT01598480|Experimental|BCT Antimicrobial Dressing|The wound in the experimental group is first cleansed with normal saline and then applied with BCT Antimicrobial Dressing and covered by sterile gauze, and dressings will be changed every 3 days.
88913675|NCT01598493|Active Comparator|Control|Flamazine is applied on the wound in the control group instead and then covered with sterile gauze
88913676|NCT01598493|Experimental|BCT Antimicrobial Dressing|The wound in the experimental group is first cleansed with normal saline and then applied with BCT Antimicrobial Dressing and covered by sterile gauze, and dressings will be changed every 3 days.
88913677|NCT01598519|Experimental|study group|1500 students are randomized to receive a universal suicide intervention apart from usual school psychology classes. Furthermore, high risk of suicidal students screened in study group will receive an indicated suicide intervention in addition to usual school psychology classes.
88913678|NCT01598519|No Intervention|control group|1500 students are randomized to receive usual school psychology classes. High risk of suicidal students screened in control group will receive usual psychology classes.
89009735|NCT00232622|Active Comparator|Standard infusion of streptokinase|Standard infusion of streptokinase
89009736|NCT00232622|Experimental|Accelerated infusion of streptokinase|Accelerated infusion of streptokinase
89009737|NCT04565938|Experimental|one-step self-etch adhesive with enamel etching|Non carious cervical lesions which will receive composite-resin restorations, with one-step self-etch adhesive with enamel etching
89531256|NCT02493803|Experimental|Receive detailed dietary advice|Half of the participants will be randomly allocated to receive detailed dietary advice
89009738|NCT04565938|Experimental|one-step self-etch adhesive without enamel etching|Non carious cervical lesions which will receive composite-resin restorations, with one-step self-etch adhesive without enamel etching
89433677|NCT06052150||Cirrhosis|"Outpatients with cirrhosis with the following criteria~Inclusion criteria A. Age>18 years B. Cirrhosis confirmed (liver biopsy, signs of current or prior decompensation, varices in patients with chronic liver disease, nodular liver on imaging, AST>ALT and platelet count >150K in patients with chronic liver disease, ultrasound, or MR elastography suggestive of cirrhosis).~C. Willing and able to give consent Exclusion criteria A. Unclear diagnosis of cirrhosis B. Unable or unwilling to consent C. Edentulous D. Prior organ transplant E. On anticoagulant therapy"
89433678|NCT06051331|Experimental|Experimental group|Simulation-based breast health education
89433679|NCT06051331|No Intervention|Control group|The control group will not take part the simulation-based breast health education
89433680|NCT06051006||Patients|Minor patients from 8 years with cochlear implants for at least 1 year and followed at Hôpital Necker-Enfants malades.
89433681|NCT06049836|Experimental|Group A|Group A analyses 15 patient cases 3D Hologram models (first stage) and after the washout period the same 15 patients cases (anonymised, renamed and shuffled) in liver 3D models on computer monitor visualisation (PDF) (second stage)
89433682|NCT06049836|Experimental|Group B|Group B analyses 15 patient cases liver 3D models on computer monitor visualisation (PDF) (first stage) and after the washout period the same 15 patients cases (anonymised, renamed and shuffled) on 3D Hologram models (second stage)
89433683|NCT06048484|Experimental|Arm A: Safety run-in|Prior to resection: SBRT 40 Gy over 5 fractions, zimberelimab (AB122) 240 mg intravenously (IV) every 2 weeks for 7 weeks (4 doses), quemliclustat (AB680) 100 mg IV every 2 weeks for 7 weeks (4 doses) and etrumadenant (AB928) 150 mg PO daily for 7 weeks. After resection: mFOLFIRINOX (4 cycles)
89433684|NCT06048484|Active Comparator|Arm B: SBRT with Zimberelimab (AB122) Alone (Control Arm)|Prior to resection: SBRT 40 Gy over 5 fractions, 240 mg IV zimberelimab (AB122) every 2 weeks for 7 weeks (4 doses) prior to surgery. After resection: mFOLFIRINOX (4 cycles)
89433685|NCT06048484|Experimental|Arm C: SBRT, Zimberelimab with quemliclustat (AB680)|Prior to resection: SBRT 40 Gy over 5 fractions, 240 mg IV zimberelimab (AB122) every 2 weeks for 7 weeks (4 doses) prior to surgery in combination with quemliclustat IV at the recommended therapeutic dose (RTD)every 2 weeks for 7 weeks (4 doses) prior to surgery. After resection: mFOLFIRINOX (4 cycles)
89433686|NCT06048484|Experimental|Arm D: SBRT, Zimberelimab with AB680 and Etrumadenant (AB928)|Prior to resection: SBRT 40 Gy over 5 fractions, 240 mg IV zimberelimab (AB122) every 2 weeks for 7 weeks (4 doses) prior to surgery in combination with quemliclustat IV at the RTD every 2 weeks for 7 weeks (4 doses) and etrumadenant (AB928) PO at the RTD daily for 7 weeks prior to surgery. After resection: mFOLFIRINOX (4 cycles)
89433687|NCT06048419|Experimental|Go Move Home Program|Goal driven home program
89433688|NCT06047236||Observational Arm|Initial diagnosis of primary salivary gland carcinoma in the head and neck region
88913679|NCT01598558|Experimental|64Cu-DOTA|Subjects will be injected with less than 14 mCi of 64Cu-DOTA-Rituximab. This is a slow infusion, done over 20 minutes.
88913680|NCT01598571|Experimental|Fostamatinib 50 mg tablet|
88913681|NCT01598571|Experimental|Fostamatinib 100 μg [14C] R406 intravenous micro tracer dose|
88913682|NCT01598584|Placebo Comparator|placebo plus gemcitabine|we design placebo plus gemcitabine as control arm
88913683|NCT01598584|Experimental|Mirtazapine plus gemcitabine|We design Mirtazapine plus gemcitabine as experimental arm
88913684|NCT01598597||Cohort|
88913685|NCT01598623|Experimental|Oxytocin+ Non Specific Counselling|
88913686|NCT01598623|Experimental|Oxytocin + Social Skills training|
88913687|NCT01598623|Placebo Comparator|Placebo + Non Specific Counselling|
88913688|NCT01598623|Experimental|Placebo + Social Skills Training|
88913689|NCT01598649|Experimental|Lupin protein|Lupin protein isolate (cultivar: Lupinus angustifolius Boregine; incorporated in study products) and placebo capsules with mannitol
88913690|NCT01598649|Active Comparator|Milk protein|Milk Protein Isolate (75% sodium caseinate (EM7; DMV international) and 25% whey protein (Megglosat HP; Meggle), incorporated in study products) and Placebo capsules
88913691|NCT01598649|Active Comparator|Milk protein and arginine|Milk Protein Isoalte (75% sodium caseinate (EM7; DMV international) and 25% whey protein (Megglosat HP; Meggle), incorporated in study products) and 1,6 g Arginin in four caspules per day
88913692|NCT01598675|Active Comparator|Control|Symmetric Gait. Dual-belted treadmill belts moving at the same belt speeds during training
88913693|NCT01598675|Experimental|Gait Asymmetry|Error Augmentation. Belts of a dual-belted treadmill may move at different belt speeds to amplify spatiotemporal gait asymmetry during training
88913694|NCT01598675|Experimental|Gait Symmetry|Error Minimization. Belts of a dual-belted treadmill may move at different belt speeds to encourage spatiotemporal gait symmetry during training
88913695|NCT01598688|Active Comparator|Blood collection immediately after interrupting the drug|Blood samples were collected from the peripheral venous access, from the catheter line used to infuse the drug and from the line not used for infusion immediately after interrupting the drug infusion.
88913696|NCT01598688|Experimental|Blood collection five minutes after interrupting the drug|Blood samples were collected from the peripheral venous access, from the catheter line used to infuse the drug and from the line not used for infusion five minutes after interrupting the drug infusion.
88913697|NCT01598714|Other|Darco shoe|Darco walking shoe provided
88913698|NCT01598714|Other|Podalux Shoe|Podalus shoe
88913699|NCT01598714|Other|Standard dressing shoe|Standard dressing shoe
88913700|NCT01598727|Experimental|Fluobeam(TM) Imaging System (Fluoptics)|Single arm observational pilot study
88913701|NCT01598766|Experimental|Diagnostic Coil|This coil is a lightweight, flexible coil which can be used for many pediatric MRI exams
88913702|NCT01598805|Experimental|roll out of eAlerts|Roll out of eAlerts providing evidence-based guidelines on prophylaxis against venous thromboembolism. An eAlert is displayed in the electronic patient chart if no prophylaxis has been ordered within 6 h after admission or transfer.
88913703|NCT01598844||High risk patients with aortic stenosis|Transapical aortic valve implantation using a transcatheter heart valve for aortic stenosis.
88913704|NCT01598844||High risk patients with AI|Transapical aortic valve implantation using a transcatheter heart valve for aortic regurgitation.
89433689|NCT06047236||Control Group 1|Initial diagnosis of a benign salivary gland tumor in the head and neck region
89531257|NCT02493803|No Intervention|Receive standard of care dietary advice|These patients will receive dietary advice which is the current standard of care
89433690|NCT06047236||Control Group 2|Healthy control group. Functional diseases of the nose or ear (patients with the indication for functional ear surgery and rhinoplasty) without salivary gland tumor.
89433691|NCT06047106|Experimental|Living kidney donor|Patient eligible for living kidney donation with eGFR > 60 ml/min/1.73m²
89433692|NCT06047106|Experimental|Recipient of kidney transplant from living donor|Patient with end-stage chronic kidney failure awaiting kidney transplant from living donor
89433693|NCT06045156|Active Comparator|Tirofiban group|Tirofiban infused with 0.4μg/kg/min for 30min and 0.1μg/kg/min until 24h after IVT
89433694|NCT06045156|Placebo Comparator|Tirofiban simulant group|Tirofiban simulant infused with 0.4μg/kg/min for 30min and 0.1μg/kg/min until 24h after IVT
89433695|NCT06045039||Stent-balloon-stent (SBS) technique|Patients with coronary bifurcation lesions underwent stent-balloon-stent (SBS) technique. The procedure of this technique is to implant the stent into the side branch at the 1~2mm, which is away from the opening of the branch, and then implant the stent into the main vessel. The guide wire enters the side branch from the mesh at the distal end of the main vascular stent, and the drug balloon is used to dilate the opening of the side branch, so that the opening area of the side branch is more than 5mm².
89433696|NCT06044285|Experimental|Self-Guided Low UP Food Diet|Participants asked to eat a low UP food diet according to study provided nutritional guidance.
89433697|NCT06044285|Experimental|Meals Provided Low UP Food Diet|.Participants asked to eat a low UP food diet provided by the study team.
89433698|NCT06044285|Active Comparator|Control|Participants asked to eat as they usually do.
89433699|NCT06043362|Experimental|0 mg + Smooth flavor|Participants are provided with zero strength (0 mg) nicotine pouches with smooth flavor.
88913705|NCT01598857|Experimental|Blisibimod|
88913706|NCT01598857|Placebo Comparator|Placebo|
88913707|NCT01598870||Patients with cirrhosis and ascites|Patients requiring diagnostic and/or therapeutic paracentesis.
89433700|NCT06043362|Experimental|3 mg + Smooth flavor|Participants are provided with medium strength (3 mg) nicotine pouches with smooth flavor.
89433701|NCT06043362|Experimental|6 mg + Smooth flavor|Participants are provided with high strength (6 mg) nicotine pouches with smooth flavor.
89433702|NCT06043362|Experimental|0 mg + Wintergreen flavor|Participants are provided with zero strength (0 mg) nicotine pouches with wintergreen flavor.
89433703|NCT06043362|Experimental|3 mg + Wintergreen flavor|Participants are provided with medium strength (3 mg) nicotine pouches with wintergreen flavor.
89433704|NCT06043362|Experimental|6 mg + Wintergreen flavor|Participants are provided with high strength (6 mg) nicotine pouches with wintergreen flavor.
89433705|NCT06042452|Experimental|Genetic|Participants will have their DNA tested and this data alongside lifestyle data will personalize the information they receive
89433706|NCT06041425|Experimental|Oxycodone|The patients were given 0.1mg/kg oxycodone 15 minutes before transcatheter arterial chemoembolization (TACE).
89433707|NCT06041425|Active Comparator|Sufentanil|The patients were given 0.1μg/kg sufentanil 15 minutes before transcatheter arterial chemoembolization (TACE).
89433708|NCT06040957|Experimental|single intra-articular injection of BMAC|Patients randomized in this group will undergo single knee intra-articular injection of bone marrow aspirate concentrate (BMAC)
89433709|NCT06040957|Experimental|single intra-articular injection of MM-AT|Patients randomized in this group will undergo single knee intra-articular injection of minimally manipulated adipose tissue (MM-AT)
89433710|NCT06040125|Experimental|Exercise Group|Participants will partake in a 16-week supervised exercise program.
89433711|NCT06040125|Experimental|Attention Control Group|Participants will continue with their normal daily activities.
89433712|NCT06038695|Experimental|Xenogeneic Volume-Stable Collagen (VCMX) graft with growth factor-BB|Subjects in this arm will have a xenogeneic volume-stable collagen matrix in combination with recombinant human platelet-derived growth factor-BB at the time of immediate implant placement.
89433713|NCT06037694|Active Comparator|Free Gingival Graft|A mucogingival surgery where a conventional free gingival graft harvested from the palate is placed on a recipient site prepared to increase the width of KM at implant sites.
89433714|NCT06037694|Experimental|Meshed Free Gingival Graft|A mucogingival surgery where a meshed free gingival graft harvested from the palate is placed on a recipient site prepared to increase the width of KM at implant sites.
89433715|NCT06037460|Experimental|Gradual discontinuation of TCZ|
89433716|NCT06037460|Active Comparator|Immediate discontinuation of TCZ|
88913708|NCT01598883|Other|ACT after initial heparin bolus less than 450|If a patients activated clotting time (ACT) is less than 450 after the bolus dose of heparin (350U/kg) they will be randomized to one of two interventions.
89433717|NCT06037109||Apparently Healthy Adults|Apparently healthy adults (age ≥ 21 years); who have provided written informed consent for sample use in this study
89433718|NCT06037109||Adults with Chronic, Stable Morbidities|Adults (age ≥ 21 years);with one or more of the following chronic, stable morbid conditions.
89433719|NCT06036758||Persons with Stage 2 to Stage 3 AKI|Persons with Stage 2 to Stage 3 AKI who are in the ICU.
89433720|NCT06036667|Experimental|Study group|All patients undergone Uniportal-VATS upper lobectomy with 28Fr Smart Coaxial drain placed at the end of surgery
89433721|NCT06036667|No Intervention|Study group 1|All patients undergone Uniportal-VATS upper lobectomy with standard 28Fr chest drain placed at the end of surgery
88913709|NCT01598883|Active Comparator|ACT after first intervention less than 450|
88913710|NCT01598909|Active Comparator|Arnica ointment|
88913711|NCT01598909|Placebo Comparator|Placebo ointment|
88913712|NCT01598909|No Intervention|Control|
88913713|NCT01598948|Experimental|Mipomersen|Patients randomized to this arm will receive mipomersen 200 mg weekly
88913714|NCT01598948|No Intervention|Control|patients randomized to this arm will receive no additional drug
88913715|NCT01598961|Active Comparator|TOF count-guided group|Using partial neuromuscular blockade to maintain train-of-four response of two, TOF response measured by the neuromuscular transmission module (NMT module)
88913716|NCT01598961|Active Comparator|T1/Tc amplitude group|Using partial neuromuscular blockade to maintain T1/Tc amplitude of 50%, T1/Tc amplitude measured by the neuromuscular transmission module (NMT)
88913717|NCT01598961|Experimental|No neuromuscular blockade group|to maintain no neuromuscular blockade during LSR monitoring except the intubation dose during anesthetic induction
88913718|NCT01598974|Experimental|Traditional Acupuncture|Participants will receive acupuncture over 6 30-minute sessions.
88913719|NCT01598974|Experimental|Laser Acupuncture|Participants will receive laser acupuncture over 6 30-minute sessions.
89433722|NCT06036667|Experimental|Study group 2|All patients undergone Biportal-VATS upper lobectomy with 28Fr Smart Coaxial drain placed at the end of surgery
89433723|NCT06035809|Experimental|Active SMART|Participants in the active SMART condition will complete 8 individual, 1-hour, weekly sessions of SMART with a therapist, as well as pre-treatment, post-treatment and 3-month follow-up assessments.
89009739|NCT04565938|Experimental|two-step etch-and-rinse adhesive|Non carious cervical lesions which will receive composite-resin restorations, with a two step etch-and-rinse adhesive
89009740|NCT04565548|Experimental|Intervention|Participants will receive the newly developed theory-guided program for 12 weeks.
89009741|NCT04565548|Active Comparator|Control|Participants will receive the usual care and non-hypertension related text messaging for 12 weeks.
89433724|NCT06035809|No Intervention|Wait List|Participants in the Wait List condition will receive no treatment for approximately 8 weeks, and they will be asked to complete pre-wait list, post-wait list and 3-month follow-up assessments. After all assessments have been completed, this group will be offered the same 8 individual, 1-hour, weekly sessions of SMART (no further assessments needed).
89433725|NCT06035692|Experimental|Brachial plexus block group（BPB）|All patients received receive Ultrasound-guided BPB with 0.15% ropivacaine 20ml 30min before surgery
89433726|NCT06035692|No Intervention|Control group （Control）|All patients received receive Ultrasound-guided BPB with normal saline 20ml 30min before surgery
89433727|NCT06035679|Experimental|Pyrotinib Combined With Trastuzumab and Chemotherapy|T1cN0M0 HER2+ breast cancer Patients received 2 cycles (pyrotinib + trastuzumab + taxoid) regimen and were evaluated to continue with the original regimen if PR, and 4 cycles (pyrotinib + trastuzumab + taxoid + carboplatin) regimen if SD/PD. Phase II-III HER2+ breast cancer Patients received 6 cycles of treatment (pyrotinib + trastuzumab + taxoid + carboplatin)
89433728|NCT06035276|Other|Healthy subjects|
89433729|NCT06035276|Other|COPD patients|
89433730|NCT06032910|Experimental|Study group|Patients who receive prophylactic mesh during the surgery.
89433731|NCT06032377|Experimental|online cognitive behavioral therapy for insomnia, anxiety and depression|10 self-directed modules of cognitive behavioral therapy for insomnia, anxiety and depression, delivered online, once a week
89433732|NCT06032377|Active Comparator|online intervention on nutrition and communication in older age|10 self-directed modules on healthy nutrition habits and communication strategies, delivered online, once a week
89433733|NCT06031493|Experimental|Multimodal Intervention Group|Multimodal Intervention on sexual dysfunction and quality-of-life after treatment for cervical cancer: application of topical vaginal estrogens, systematic evaluation of the need of systemic hormone replacement therapy (and treatment if needed), application of hormone-free vaginal-vulvar moisturizing cream containing hyaluronic acid, use of a vaginal vibrator twice a week for 5 to 10 minutes each time with the help of intimate lubricant, access to online informational content about sexuality, access to online informational content about nutrition, access to online informational content about sports, access to online informational content about lifestyle habits
89433734|NCT06031493|No Intervention|Standard Care Group|Standard follow-up in Gynecological Oncology Units of participating centers after treatment for cervical cancer
89433735|NCT06030947|Active Comparator|Connective Tissue Graft|A mucogingival surgery where a conventional connective tissue graft harvested from the palate is placed on a recipient site prepared for modified coronally advanced tunnel and sutured to cover multiple adjacent gingival recession defects.
89433736|NCT06030947|Experimental|Meshed Connective Tissue Graft|A mucogingival surgery where a meshed connective tissue graft harvested from the palate is placed on a recipient site prepared for modified coronally advanced tunnel and sutured to cover multiple adjacent gingival recession defects.
89433737|NCT06030440|Active Comparator|Control Arm|postoperative radiotherapy of the head and neck region according to current standard including elective nodal irradiation
89433738|NCT06030440|Experimental|Investigational Arm|postoperative radiotherapy of the head and neck region without elective nodal irradiation
89433739|NCT06028152|Experimental|Game participants|"All participants will engage in playing the end-of-life conversation game called Hello, which involves answering open-ended questions about medical decision making and end-of-life issues."
89433740|NCT06025032|Experimental|HG205|Method of Administration: Once Unilateral intracochlear injection/subject; The duration of the study for each subject includes a screening period, enrollment visit, treatment visit, a 26-week follow-up period, and a 5-year long-term safety follow-up after the injection
88913720|NCT01598974|No Intervention|Wait-List|Subjects will be put on a 6 week wait-list and receive vouchers for acupuncture at a local clinic.
88913721|NCT01599000|Active Comparator|Efficacy arm|Supervised administration of six doses of fixed-dose artemether-lumefantrine (Coartem, Novartis)
88913722|NCT01599000|Experimental|Effectiveness arm|Un-supervised administration of six doses of fixed-dose artemether-lumefantrine (Coartem, Novartis)
88913723|NCT01599013|Other|Vinflunine plus Gemcitabine|
88913724|NCT01599013|Other|Vinflunine plus Carboplatin|
88913725|NCT01599039||breast cancer patients with SN|1. Breast cancer patients with sentinel node biopsy (n=25)
88913726|NCT01599039||breast cancer patients with AD|2. Breast cancer patients with axillary dissection (n=25)
88913727|NCT01599039||colo-rectal patients|3. Colo-rectal patients as control group (n=25)
88913728|NCT01599052||Brain Tumour Patients|Newly diagnosed brain tumour patients aged between 5 and 13 years
88913729|NCT01599052||Cystic Fibrosis patients|Patients diagnosed with Cystic Fibrosis aged between 5 and 13 years
88913730|NCT01599052||Healthy control group|Healthy children aged between 5 and 13 years
88913731|NCT01599065||Magnet|group treated by disabling ICD during procedure
88913732|NCT01599065||Off-On|Group having ICD turned off during the procedure
88913733|NCT01599078|Placebo Comparator|Placebo|
88913734|NCT01599078|Active Comparator|Paclitaxel|
88913735|NCT01599091||Fibroblast's donors|Patients undergoing tooth extraction will be asked permission to use the anyway extracted teeth and gingiva in order to harvest fibroblasts for further basic research.
88913736|NCT01599117|Placebo Comparator|Placebo arm|Capsule that is identically appearing with udenafil will be administered to patients in placebo group. For the first 4 weeks, patients will receive 50 mg of placebo drug two times a day, and then the dosage will be doubled to 100 mg two times a day for next 8 weeks.
88913737|NCT01599117|Active Comparator|Udenafil|Patients will receive 50 mg of udenafil two times a day, and then the dosage will be doubled to 100 mg two times a day for next 8 weeks.
88913738|NCT01599130|Active Comparator|entecavir|patients continue to use entecavir
88913739|NCT01599130|Experimental|peg-interferon|patients switch to sequential peg-interferon α-2a
89433741|NCT06024993|Experimental|FCV-VCV|After titration of ventilation in baseline VCV (all arms), participants will first receive 30 min of baseline-matched FCV and subsequently 30 min of baseline-matched VCV.
88913740|NCT01599143|Experimental|Mindfulness-based Stress Reduction group|All eligible participants attend a 3-hour weekly session, for 8 consecutive weeks, to learn meditation and simple Hatha Yoga techniques, and incorporate them into their daily lives.
88913741|NCT01599156|Experimental|Reflexology|reflexology treatment, x2-3/week for 12 weeks
88913742|NCT01599169|Experimental|B-Back® verum|
88913743|NCT01599169|Placebo Comparator|B-Back® placebo|
88913744|NCT01599182||High-Risk Prostate Cancer|
88913745|NCT01599182||Intermediate-Risk Prostate Cancer|
88913746|NCT01599195||adults|adults audiodoc use to evaluate for carotid or femoral bruit
88913747|NCT01599208|Experimental|Single-pulse online stimulation|Online single-pulse online stimulation at 120% of motor threshold to either the right or left MTL, in comparison to sham condition, in either -400/0/400/800 ms relatively to stimulus in either the study or test phases of a recognition test.
88913748|NCT01599208|Experimental|Repetitive online stim., 400ms, 10Hz|Repetitive online stimulation for 400ms at 10Hz at 120% of motor threshold to either the right or left MTL, in comparison to sham condition, in either -400/0/400/800 ms relatively to stimulus in either the study or test phases of a recognition test.
89433742|NCT06024993|Experimental|VCV-FCV|After titration of ventilation in baseline VCV (all arms), participants will first receive 30 min of baseline-matched VCV and subsequently 30 min of baseline-matched FCV.
89009742|NCT04565314|Experimental|Plumpy'Mum|Mother/child dyads will be enrolled at child age 0-3 months and mothers will immediately begin consuming a packet of Plumpy'Mum (or similar protein food product) daily. Plumpy'Mum will be provided by the study team to the mother, who will consume this however she desires (i.e., alone or with other food). Intervention will continue for 3 months. The rational is that Plumpy'Mum consumption will improve the quality of the breast milk the child is consuming, contributing to improved growth over time. Growth will be compared to historical controls from prior studies in the area.
89009743|NCT04565002|Experimental|EG|The TEDS protocol will consist of the following parameters: a) frequency of 30 Hz; b) pulse width of 0.4 ms; c) respiratory rate of 15 irpm; d) holding time of 1 s; e) rise time of 1 s; f) 2 s descent time; and g) 2 s non-stimulus time. Phrenics equipment (Dualpex 961, Quark®) will be used. The positioning of the electrodes will be performed according to a study by Cancelliero et al. (2012), who proposed the placement of two electrodes in the right and left paraxiphoid regions, and two others in the direction of the axillary midline, over the seventh intercostal space, also on the right and left sides.
89009744|NCT04565002|No Intervention|CG|The control group will undergo the same assessments as the experimental group, but the TEDS will not be applied.
89009745|NCT04565197|Experimental|Group intervene with convalescent plasma|"Review effect of Plasma therapy as clinical trial among hospitalized patients with COVID-19 infection.~Transfuse 2 aliquots of plasma (200 mL x 2) per patient.~Transfuse first aliquot for 2-3 hours (~1.4 to 2 mL/min)~Transfuse second aliquot at same rate 2 hours after completion of first aliquot"
89009746|NCT04564924||MRI & DXA patients|No intervention
89009747|NCT04564924||MRI & DXA volunteers|No intervention
89009748|NCT04564729|Experimental|Decision Aid|The shared decision aid (SDA) includes factual information about the World Health Organization pain ladder, the 0-10 numeric rating score pain scale, pharmacologic pain management options, opioid medication benefits and risks and predicted post-discharge opioid requirements based on previous modeling in total knee arthroplasty patients. Subjects in the decision aid group will view the decision aid and have the opportunity to participate in shared decision-making for their discharge opioid prescriptions.
89009749|NCT04564729|No Intervention|Control|Subjects in the control group will undergo standard care and discharge practices. Baseline pain and psychosocial factors will be documented as well as postoperative pain and analgesic consumption.
89009750|NCT04564651|Experimental|platelet transfusion treatment|
89433743|NCT06022159|Experimental|Neo-adjuvant Cohort|
89433744|NCT06022159|Experimental|Adjuvant Cohort|
89433745|NCT06020703|Experimental|Fermented Foods Diet|Subjects will incorporate fermented food into their diet.
89433746|NCT06020703|No Intervention|Normal Diet|Subjects will continue their regular diet.
89433747|NCT06020157|Experimental|Simple Suture Group|
89433748|NCT06020157|Experimental|Continuous Suture Group|
89433749|NCT06019949|Active Comparator|Training (RT) group|80 scTS sessions will be administered using the Neostim/Biostim (Cosyma Inc., Denver CO) device applying up to five conductive electrodes placed on the skin at the midline over the thoracic levels as cathodes between T1 to T8, and up to four self-adhesive electrodes located symmetrically on the skin over the iliac crests and shoulders as anodes. During the intervention, optimally configured scTS will be delivered based on the measures assessed during mapping sessions. The scTS with 5 mA-sub-motor threshold intensity with optimal frequency and pulse width will be delivered using 5 min on and 5 min off stimulation periods during interventional bouts. Every research participant will be slowly acclimated to stimulation. Blood pressure, heart rate, and respiratory rate will be closely monitored throughout stimulation sessions in the Lab by using beat-to-beat blood pressure, and respiratory kinematics monitoring.
89531258|NCT05032287|Active Comparator|tamsulosin|tamsulosin 0.4 mg once daily
89531259|NCT05032287|Placebo Comparator|Placeb|Placebo once daily
89531260|NCT02493959|Experimental|PYY infusion|IV infusion on 4 separate days of PYY or saline in Healthy, normal-weight men, age 18-50 years
88913749|NCT01599208|Experimental|Repetitive online stim., 400ms, 20Hz|Repetitive online stimulation for 400ms at 20Hz at 120% of motor threshold to either the right or left MTL, in comparison to sham condition, in either -400/0/400/800 ms relatively to stimulus in either the study or test phases of a recognition test.
88913750|NCT01599208|Experimental|Repetitive offline stimulation at 10Hz|Repetitive offline stimulation at 10Hz for 4 min before study or for 8 min before test (in accordance with the phase length), comprising 2-second stimulation trains and 20-second breaks. Stimulation will be given at 120% of motor threshold to either the right or the left MTL in comparison to sham condition.
89009751|NCT04564651|No Intervention|standard medical treatment|
89009752|NCT04564690|Experimental|QUARTET®|Consumption of three QUARTET® (n-3 PUFA, selenium, vitamin E, lutein enriched) hen eggs per day for three weeks
89433750|NCT06019949|Active Comparator|Spinal Cord Transcutaneous Stimulation (scTS) group|Participants will undergo 80 RT sessions using standard threshold Positive Expiratory Pressure Device (PEP, Respironics Inc., Cedar Grove, NJ) and standard threshold Inspiratory Muscle Trainer (IMT, Respironics Inc., Cedar Grove, NJ) assembled together using a T-shaped connector with a flanged mouthpiece (Airlife 001504). Participants will be trained at the Frazier Rehab Institute and remotely to complete eighty 45-minute sessions during 16 weeks. The participants will be instructed to perform inspiratory and expiratory efforts against a pressure threshold load. The training will be initiated with a load equal to 20% of their individual Maximum Inspiratory Pressure (PImax) and Maximum Expiratory Pressure (PEmax) values with progressive increases as tolerated up to 60% of their baseline PImax and PEmax measures. The goal will be to reach the 60% load of PImax and PEmax during the last week of each month of the training.
89433751|NCT06019949|Experimental|Spinal Cord Transcutaneous Stimulation and Respiratory Training (scTS+RT) group|Participants will undergo 80 scTS combined with the RT while seated in their own wheelchairs with an approximately 45° head-up tilt. The scTS will be administered using the Neostim/Biostim (Cosyma Inc., Denver CO) and Standard threshold Positive Expiratory Pressure Device (PEP, Respironics Inc., Cedar Grove, NJ) and standard threshold Inspiratory Muscle Trainer (IMT, Respironics Inc., Cedar Grove, NJ) assembled together using a T-shaped connector with a flanged mouthpiece (Airlife 001504) will be used for the RT as described for the Arms 1 and 2.
89433752|NCT06018727|Experimental|Hydrocortisone + Yohimbine|Participants will ingest hydrocortisone and yohimbine during Session 2 approximately 10 minutes into the session.
89433753|NCT06018727|Placebo Comparator|Placebo + Placebo|Participants will orally ingest two placebos during Session 2 approximately 10 minutes into the session.
89433754|NCT06017050|Experimental|BullyDown intervention|
89433755|NCT06017050|Placebo Comparator|Healthy lifestyle control|
89433756|NCT06014463||Patients with Primary Immune Deficiency|Patients between the ages of 18-65 years who have been diagnosed with primary immunodeficiency
89433757|NCT06014463||Healthy Controls|Age and sex matched healthy controls between the ages of 18-65 years
89009753|NCT04564690|Experimental|Control|Consumption of three regular hen eggs per day for three weeks
89009754|NCT04564456|Experimental|Test Product|Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals
89433758|NCT06014242|Experimental|Peripheral vascular flow reserve measurement|Post-procedure peripheral vascular flow reserve by thermodilution will be measured by the pressure wire.
89433759|NCT06012279|Experimental|Dapagliflozin group|This group will receive oral Dapagliflozin 10 mg once daily within 24 hours from hospital admission, in addition to the standard treatment for acute heart failure.
89433760|NCT06012279|No Intervention|Standard group|This group will only receive the standard treatment for acute heart failure.
89433761|NCT06009926|Experimental|Group I (BSSE-placebo)|Participants receive BSSE PO QD for 7-10 days then undergo the first flashover training between day 7-10 of agent intervention. Participants then receive placebo PO QD for 7-10 days then undergo second flashover training after a washout period of 2 weeks to 3 months. Participants also undergo urine sample collection throughout the study.
89009755|NCT04564456|Active Comparator|Reference Product|ADVAIR DISKUS® 500/50
89009756|NCT04564144|Experimental|Volunteers receiving the prepared orodispersible tablets|6 human volunteers will receive the prepared orodispersible tablets plus a commercial one all containing Meclizine HCl in a parallel manner.
89009757|NCT04563949||PLA-|PLA- initially and repeat testing 1-2 years later
89009758|NCT04563949||PLA+|Not eligible for the study
89009759|NCT04563910||less than 2 episodes|Patients were classified into 3 groups according to number of episodes (1-2 episodes, 3-5 episodes, more than 5 episodes)
89009760|NCT04563910||2-5 episodes|Patients were classified into 3 groups according to number of episodes (1-2 episodes, 3-5 episodes, more than 5 episodes)
89009761|NCT04563910||more than 5 episodes|Patients were classified into 3 groups according to number of episodes (1-2 episodes, 3-5 episodes, more than 5 episodes)
89009762|NCT04675021|Experimental|AZD6094 (Savolitinib) D5084C00010|All volunteers will receive either a single dose or two doses of AZD6094 (Savolitinib) D5084C00010
89009763|NCT04564066|Experimental|efgartigimod IV|intravenous infusions of efgartigimod
89009764|NCT04564066|Experimental|efgartigimod PH20 SC|subcutaneous injections of efgartigimod PH20 SC
89009765|NCT00232817|Experimental|1|Propofol anesthetic with and without nicotine
89009766|NCT00232817|Experimental|2|isoflurane anesthetic with and without nicotine
89009767|NCT04674865|Active Comparator|Conventional treatment protocol group|Standardized treatment protocol including chest physical therapy as well as limb physical therapy and functional mobility was addressed.
89009768|NCT04674865|Experimental|ANB group|2 sessions per day was added to the standardized treatment protocol
89009769|NCT04674943|No Intervention|Control group|No physical therapy intervention was given. Only pharmacological treatment was provided.
89009770|NCT04674943|Experimental|Breathing exercise group|1. Pursed lip breathing 15 reps x 3 sets) 2: Diaphragmatic breathing (15 reps x 3 sets) 3:Lateral costal breathing 15 reps x 3 sets)
89009771|NCT04674904|Experimental|Group A|Dry Needling
89009772|NCT04674904|Active Comparator|Group B|Hot pack , TENS , Stretching
89009773|NCT04675060|Experimental|Cohort 1|TQ-B3139 capsules administered single dose of 600 mg under fasted conditions in day 1 followed by single dose of 600 mg with a high-fat meal in day 5, then TQ-B3139 capsules administered 600mg orally, twice daily.
89009774|NCT04675060|Experimental|Cohort 2|TQ-B3139 capsules administered single dose of 600 mg with a high-fat meal in day 1 followed by single dose of 600 mg under fasted conditions in day 5, then TQ-B3139 capsules administered 600mg orally, twice daily.
89433762|NCT06009926|Experimental|Group II (placebo-BSSE)|Participants receive placebo PO QD for 7-10 days then undergo the first flashover training between day 7-10 of agent intervention. Participants then receive BSSE for 7-10 days then undergo second flashover training after a washout period of 2 weeks to 3 months. Participants also undergo urine sample collection throughout the study.
89433763|NCT06007729|Experimental|HS-20093 (phase 2a and Phase 2b)|Participants in all subjects will receive HS-20093 at 10mg/kg
89433764|NCT06006676|Experimental|Near Apnoeic Ventilation|Near Apnoeic ventilation (with a respiratory rate of 2 breaths per minute, plateau pressure of 30cmH20 and PEEP set according to the mean airway pressure being delivered during mechanical ventilation prior to randomisation) for a 72 hour period following randomisation
89433765|NCT06006676|Active Comparator|Standard Care|Standard care for patient on ECMO as per consultant with respiratory rate of 15-30, PEEP of 10cmH20 or more and Plateau pressure of 25cmH20 or less for a 72 hour period following randomisation
89433766|NCT06003036|Experimental|iTBS, then Sham|
89433767|NCT06003036|Experimental|Sham, then iTBS|
89433768|NCT06001788|Experimental|Phase 1a|"Oral ziftomenib; sequential cohorts of escalating dose levels of ziftomenib to identify the safety and tolerability of the combination regimens. Participants will be enrolled in 1 of 5 dose escalation cohorts:~A-1: Participants with a NPM1 mutation: ziftomenib plus FLAG-IDA~A-2: Participants with a NPM1 mutation: ziftomenib plus low-dose cytarabine (LDAC)~A-3: Participants with a NPM1 mutation: ziftomenib plus gilteritinib~B-1: Participants with a KMT2A rearrangement: ziftomenib plus FLAG-IDA~B-2: Participants with a KMT2A rearrangement: ziftomenib plus low-dose cytarabine (LDAC)"
89433769|NCT06001788|Experimental|Phase 1b|"Oral ziftomenib; Following the determination of the maximum tolerated dose in Phase 1a, participants will be enrolled in 1 of 5 dose validation/expansion cohorts:~A-1: Participants with a NPM1 mutation: ziftomenib plus FLAG-IDA~A-2: Participants with a NPM1 mutation: ziftomenib plus low-dose cytarabine (LDAC)~A-3: Participants with a NPM1 mutation: ziftomenib plus gilteritinib~B-1: Participants with a KMT2A rearrangement: ziftomenib plus FLAG-IDA~B-2: Participants with a KMT2A rearrangement: ziftomenib plus low-dose cytarabine (LDAC)"
89433770|NCT05999903||Observational Kinematic Driving Data|Longitudinal kinematic driving data paired with neurocognitive assessments at 3- and 6-months
89433771|NCT05995405|Experimental|GTX-104|GTX-104 is a sterile concentrate of 10 mg nimodipine/5 mL (2 mg/mL), to be diluted in normal saline to obtain a dosing solution composed of dispersed micelles containing nimodipine for IV infusion. It will be administered as a continuous IV infusion of 0.15 mg/hour and a 30-minute IV bolus of 4 mg every 4 hours for up to 21 days
89433772|NCT05995405|Active Comparator|Oral nimodipine|Oral nimodipine is a soft gelatin capsule. The dose is 60 mg (two 30 mg capsules) every 4 hours for up to 21 consecutive days.
89433773|NCT05993429||EUS-FNA/B group; ERCP with or without POCS-TB group|EUS-FNA/B group: Patients with suspected hilar cholangiocarcinoma who were considered suitable for obtaining histopathological diagnosis by EUS-FNA/B by experts
89433774|NCT05993429||ERCP with or without POCS-TB group|ERCP with or without POCS-TB group: Patients with suspected hilar cholangiocarcinoma who were considered suitable for obtaining histopathological diagnosis by ERCP with or without POCS-TB by experts
89531261|NCT02496377|Active Comparator|Group 1: Per Os Tardyferon|EPO associated with Iron per os tardyferon before surgery. The oral group received 160 mg ferrous glycine sulfate daily during the month prior surgery, associated with 3 epoetin alpha (EPO) injections (40 000 IU subcutaneous on day - 21, day - 14 and day-7).
88913751|NCT01599208|Experimental|Repetitive offline stimulation at 20Hz|Repetitive offline stimulation at 20Hz for 4 min before study or for 8 min before test (in accordance with the phase length), comprising 2-second stimulation trains and 20-second breaks. Stimulation will be given at 120% of motor threshold to either the right or the left MTL in comparison to sham condition.
88913752|NCT01599208|Experimental|Repetitive offline stimulation with iTBS|Repetitive offline stimulation with Intermittent Theta Burst Stimulation (iTBS) comprising 3 pulses at 50Hz, repeated at 5Hz for 2-second stimulation trains with 8-second breaks for 192 seconds. Stimulation will be given at 90% of motor threshold to either the right or the left MTL in comparison to sham condition.
88913753|NCT01599221||Subjects with EBA2|Subjects who have undergone surgery with EBA2 medical device for lateral proximal femoral fractures
88913754|NCT01599247||Suicidal ideation/behavior|
89536310|NCT02449603|Active Comparator|Biphasic insulin Aspart 30|Biphasic insulin Aspart 30 (Colorless transparent liquid, 100u/mL, 3ml each, Novo Nordisk), subcutaneous injection, starting at a dose of 0.2-0.4 IU/kg, or 10～12 IU/d assigned in pre-breakfast and pre-supper in a 1:1 ratio. The adjustment of insulin dose is instructed to achieve an optimal balance between glycaemic control and risk of hypoglycaemia as dictated by best clinical practice, titrated to glucose targets of fasting plasma glucose (FPG) and pre-supper <7 mmol/L.
88913755|NCT01599260|Experimental|Resistance Exercise|Subjects will participate in a 16 week long resistance exercise program which will consist of 2 30-minute individually supervised sessions per week.
88913756|NCT01599273|Experimental|Triam inj|
88913757|NCT01599273|No Intervention|observation group|
88913758|NCT01599299||Ultrasound, internal jugular vein|All patients who will need a central venous access (into the right jugular vein) preoperative are included.
88913759|NCT01599312|Other|Classic Macintosh laryngoscope|Classic Macintosh laryngoscope (Karl Storz, Tuttlingen, Germany)
88913760|NCT01599312|Other|McGrath®|McGrath® (Aircraft Medical Ltd, Edinburgh, UK)
88913761|NCT01599312|Other|C-MAC®|C-MAC® (Karl Storz, Tuttlingen, Germany)
88913762|NCT01599312|Other|GlideScope® Cobalt|GlideScope® Cobalt (Verathon Medical, Bothell, WA, USA)
88913763|NCT01599338|Experimental|Liraglutide|Single Arm study. T2DM patients are studied before and after 3 months of Liraglutide treatment (1.2 mg/day).
88913764|NCT01599351|Active Comparator|Prone|Patients were in prone position along the ERCP procedure.
88913765|NCT01599351|Active Comparator|Left lateral decubitus|Patients were in left lateral decubitus along the ERCP procedure.
88913766|NCT01599364|Experimental|Switch|Switch to Atazanavir 300 mg with ritonavir 100 mg plus lamivudine 300 mg
88913767|NCT01599364|No Intervention|continue|Continue Atazanavir 300 mg with ritonavir 100 mg with the same NRTI backbone
88913768|NCT01599377|Experimental|Cohort 1|
88913769|NCT01599377|Experimental|Cohort 2|
88913770|NCT01599390||Influenza Group|
89536311|NCT02481479|Other|Single group -Paired comparison|Saxagliptin 2.5mg or 5mg od
89536312|NCT03208777||control group|taking blood samples from apparently healthy people
88913771|NCT01599403|Active Comparator|Paravertebral Block|Patients will receive 1 or 2 paravertebral catheters for ongoing infusion of local anesthestic
88913772|NCT01599403|No Intervention|Patient Controlled Anesthesia|Standard usual care
88913773|NCT01599403|Experimental|Epidural Block|"Intervention:~Patients will have epidural catheters placed for the infusion of local anesthetic solution to control pain (if qualified for this approach and randomized here)"
88913774|NCT01599403|Active Comparator|Intercostal Nerve Block|Patients will receive intercostal catheters for the infusion of local anesthetic solution to control pain(if qualified for this arm and randomized here)
88913775|NCT01599416|Active Comparator|U-relax Group|Day 1-5: take two capsuals of oral U-relax everyday before sleep Day 6-360: take one capsual of oral U-relax everyday before sleep
88913776|NCT01599416|Placebo Comparator|Placebo Group|Day 1-5: take two capsuals of oral placebo everyday before sleep Day 6-360: take one capsual of oral placebo everyday before sleep
88913777|NCT05691153|Experimental|Dose Level 1|ThisCART19A，2×10^6 cells/kg（Single dose of Allogeneic Anti-CD19 CAR T cells will be infused）
88913778|NCT05691153|Experimental|Dose Level 2|ThisCART19A，3×10^6 cells/kg（Single dose of Allogeneic Anti-CD19 CAR T cells will be infused）
88913779|NCT05691088|Experimental|Group A|Paracetamol injection
88913780|NCT05691088|No Intervention|Group B|Equivalent physiological saline
88913781|NCT05691049|Experimental|Profhilo® Structura treatment group|"Treatment of acne scars of the face by using a subcision+injection technique: the needle (25 G) or cannula (25 G) (wider areas are treated with the cannula) is inserted into the skin and made to move with a back-and-forth motion in order to detach scar collagen bundles. Then 1 syringe (2 ml) of Profhilo® Structura is injected.~Day 0: Information and consent form provided, Clinical assessment, Digital clinical pictures, Instrumental assessment, Profilometry measurement.~First treatment of Profhilo® Structura (refer to study protocol).~Day 30 (1 month after day 0): Clinical assessment, Digital clinical pictures, Instrumental assessment, Profilometry measurement.~Second treatment of Profhilo® Structura (refer to study protocol).~Day 120 (4 months after day 0): Clinical assessment, Digital clinical pictures, Instrumental assessment, Profilometry measurement.~NO treatment, Self-evaluation questionnaire."
89536313|NCT03208777||benign colorectal|taking blood samples from patients
89536314|NCT03208777||malignant colorectal|taking blood samples from patients
89433775|NCT05992519||People suspected with asthma|"Patients will receive an in invitation letter at the time of BPT scheduling. In the week proceeding the test, the clinical inhalation therapist will discuss the project and schedule the study visit on the day of the BPT. The study visit will be done prior to BPT whenever possible.~Baseline visit:~Medical history~5-item Asthma Control Questionnaire (ACQ-5)~FeNO measurement (NIOX VERO device)~Nasosorption for nasal epithelial lining fluid (NELF) biobanking~blood tests (complete blood count with differential, C-reactive protein, total and specific serum immunoglobulin E, biobank), capillary blood eosinophils (Sight OLO),~urine sample (biobank)"
89433776|NCT05990686||paracetamol plus tramadol|randomized selection of 66 adult patients
89009775|NCT04674982|Experimental|Vibration Group|In the vibration group, a vibrating device (Mini vibrator, 8.5 cm, 92-100 Hz) was applied to the middle/side area through which the sural nerve passes immediately below the knee of the extremity from which heel blood was to be collected approximately 30 seconds prior to commencement of the heel lance procedure. The vibration was continued throughout the heel lance procedure unless there was redness, swelling, bruising or a change in the skin integrity in the area to which the vibration was applied, and the vibration was stopped once the procedure was over.
89009776|NCT04674982|No Intervention|Control Group|No interventions were made on the newborns in the control group during the heel lance procedure.
89009777|NCT00259935|Experimental|All treated subjects|Subjects were randomized to receive 4 mg of a new formulation and current formulation of oral topotecan on Days 1 and 8 of Course 1.
89009778|NCT04674709|Placebo Comparator|Safety of Oleander 4X HPUS|: To evaluate the clinical safety of OLEANDER 4X HPUS in healthy volunteers relative to the control arm (placebo group).
89009779|NCT04674709|Experimental|Pharmacokinetics evaluation of Oleander 4X HPUS|To evaluate the pharmacokinetics of OLEANDER 4X HPUS versus placebo.
89433777|NCT05990686||fentanyl|randomized selection of 66 adult patients
89433778|NCT05989685||Study group|Adolescents between the ages of 14-21 who meet diagnostic criteria for an autism spectrum disorder.
89009780|NCT00555841|Experimental|ALC|I g three times daily
89009781|NCT00555841|Placebo Comparator|Placebo|1 g three times daily
89009782|NCT00232856|Other|1|Cypher™ sirolimus-eluting stent
89433779|NCT05989685||Control group|Adolescents aged 14-21 years without a lifetime psychiatric diagnosis.
89009783|NCT00259974|Experimental|1|Rituximab
89009784|NCT00555919|Experimental|Arm 1|
89009785|NCT00555919|Experimental|Arm 2|
89009786|NCT00555958|Experimental|A|All study subjects will be implanted with the Maestro System, and all will receive VBLOC therapy.
89433780|NCT05986240|Experimental|Danvatirsen Monotherapy|"Patients will be enrolled in cohorts of 3 for the Danvatirsen dose escalation substudy. Based on the DLT of the first cohort of participants, subsequent cohorts will either be administered doses at the next higher dose level, de-escalated to the next lower dose level, or remain the same. Dose escalation discontinuations and MTD will be determined as described in the 'Detailed Study Description.' The total duration of 1 cycle is approximately 4 weeks (28 days). Proposed dose levels and treatment schedule are as follows:~Dose Level 1 (DL1): Danvatirsen Day 1 - Day 28 (1mg/kg loading dose on Cycle 1/Day 1 (C1D1), Cycle 1/Day 3 (C1D3); and Cycle 1/Day 5 (C1D5) followed by weekly 1mg/kg infusion for 3 weeks) Dose Level 2 (DL2): Danvatirsen Day 1 - Day 28 (2mg/kg loading dose on C1D1, C1D3, and C1D5 followed by weekly 2mg/kg infusion for 3 weeks) Dose Level 3 (DL3): Danvatirsen Day 1 - Day 28 (3mg/kg loading dose on C1D1, C1D3, and C1D5 followed by weekly 3mg/kg infusion for 3 weeks)"
89531262|NCT02496377|Experimental|Group 2: IV Ferinject|EPO associated with Iron per IV Ferinject before surgery. The IV group received ferric carboxymaltose 1000 mg IV in 15 minutes one month before surgery, associated with 3 EPO injections.
89009787|NCT04673968|Active Comparator|prehabilitation (P)|inhospital exercise training 5 times/week, 5~6 weeks during nCRT (neoadjuvant chemoraiotherapy); home exercise 5 times/week, 5~6 weeks, between completion of nCRT and before surgery
89009788|NCT04673968|No Intervention|control group (C)|no prehabilitation
89009789|NCT04674046|Experimental|Nonoperative treatment if deltoid ligament is intact|AirCast Air-stirrup (DJO Global) functional orthosis for 6 weeks.
89009790|NCT04674046|Experimental|Operative treatment if deltoid ligament is ruptured|Open reduction, internal fixation of the fibular fracture using plate and screws.
89009791|NCT04673929||patients with HNC recurrence treated with TORS|Report of disease-free survival at 2 years for patients with HNC recurrence treated with TORS
89009792|NCT04673812|Active Comparator|Bupivacaine-Fentanyl Spinal Anaesthesia|
89009793|NCT04673812|Active Comparator|Bupivacaine-Fentanyl-Naloxone Spinal Anaesthesia|
89009794|NCT04673500|Experimental|Propofol-lidocaine through large vein|Eighty patients randomly assigned in this arm received a 20 gauge intravenous catheter at the antecubital fossa and a mixture of 2% lidocaine 1 ml and 1% propofol 2mg/kg was given for induction of general anesthesia.
89009795|NCT04673500|Placebo Comparator|Propofol-lidocaine through small vein|Another eighty patients randomly assigned in this arm received a 20 gauge intravenous catheter at the dorsum of hand and a mixture of 2% lidocaine 1 ml and 1% propofol 2mg/kg was given for induction of general anesthesia.
89009796|NCT04673695|Experimental|Group A|"Period 1: Reference drug(Lixiana 60 mg)~Period 2: Test drug(CKD-344 60 mg)"
89009797|NCT04673695|Experimental|Group B|"Period 1: Test drug(CKD-344 60 mg)~Period 2: Reference drug(Lixiana 60 mg)"
89009798|NCT04673305|Experimental|Arm 1|patients ≥ 70 years, whith haematological malignancy, who need to start a treatment within 3 months
89009799|NCT04673344|No Intervention|Partial Rotator Cuff Repair|Routine partial rotator cuff repair
89531263|NCT03096171|No Intervention|Control App|Initially this control group will have access to a Control App and after 8 weeks this goup will receive the intervention (Flourishing App Program).
89531264|NCT03096171|Experimental|Flourishing App Program|This group will receive the intervention Flourishing App Program for 16 weeks.
89531265|NCT03094689|No Intervention|Control group|
89536315|NCT02481167||group1|This study was consisted of patients with older than 40 years of age who complained with dry eye.
88913782|NCT05691036||Pregnant women with ICP|Case: Pregnant women with consistent pruritus or on medication for pruritus associated with an elevated level of serum transaminase alanine transaminase(ALT)>40 IU/L or aspartate transaminase(AST)>37 IU) and raised serum bile acids ≥10µmol/L will be eligible for the inclusion in the study.
89531266|NCT03094689|Experimental|Immersion group|They will be immersed in a barrel of 200 liters of water (without ice) at room temperature, according to local conditions of temperature and humidity (Natal county - RN). They will be immersed to the height of the iliac crests for 10 minutes.
88913783|NCT05691036||Pregnant women without ICP|Controls: Healthy pregnant women of the same gestational age with routine physical examinations will be enrolled as a control group.
88913784|NCT05691023||Vivistim|All subjects will be commercially implanted with the Vivistim System® after an ischemic stroke prior to Study treatment.
88913785|NCT05690945|Experimental|QL1706+chemotherapy|Participants with locally advanced or metastatic NSCLC patients who are PD-L1 negative will receive QL1706, paclitaxel/pemetrexed and carboplatin by intravenous (IV) injection on Day 1 of each 21-day cycle for 4 cycles in the induction treatment. In the maintenance phase, participants will be treated with QL1706 or QL1706 combined with pemetrexed.
88913786|NCT05690945|Active Comparator|Tiselizumab+chemotherapy|Participants with locally advanced or metastatic NSCLC patients who are PD-L1 negative will receive tiselizumab, paclitaxel/pemetrexed and carboplatin by intravenous (IV) injection on Day 1 of each 21-day cycle for 4 cycles in the induction treatment. In the maintenance phase, participants will be treated with tiselizumab or tiselizumab combined with pemetrexed.
88913787|NCT05690867|Other|Group 1|group 1 starts with volume controlled ventilation
88913788|NCT05690867|Other|Group 2|group 2 starts with pressure controlled ventilation
88913789|NCT05690802|Experimental|Palonosetron hydrochloride capsules|The recommended dose for adults is 0.5mg (1 capsule) for a single oral dose about 1 hour before chemotherapy.
88913790|NCT05690711|Experimental|HRS8179|
89531267|NCT03094689|Experimental|Cold water immersion group|They will be immersed in a barrel of 200 liters of ice water at an average temperature of 10 ° C for 10 minutes. They will be immersed to the height of the iliac crests.
88913791|NCT05690711|Placebo Comparator|Placebo|
88913792|NCT05690620|Experimental|Laughter Yoga|In a systematic review study, it was determined that it was appropriate to practice laughter yoga for at least 4 weeks. Therefore, the laughter yoga program; It was planned as a face-to-face group session, for four (4) weeks, twice a week, for a total of eight (8) sessions and 20-25 minutes.
88913793|NCT05690620|Active Comparator|Control|"No intervention will be applied to the students in the control group. Students will be followed for four weeks. Before the study, data collection tools will be applied to the students. Again, after the study starts and the study ends, all other data collection tools except the Student Information Form will be applied."
89531268|NCT02496299|Active Comparator|dexametasone (BD),|BD ,a mixture of 0.2mg/kg dexamethasone in 1ml/kg bupivacaine
89531269|NCT02496299|Active Comparator|Bupivacaine,B|B ,1ml/kg bupivacaine:
88913794|NCT05690607||HIV: Phase 1|People (over 18 years) living with HIV-1 attending London Mortimer Market Centre for routine blood tests as part of their HIV care.
88913795|NCT05690607||HIV: Phase 2|Subset of HIV participants sent TINIES test kit to use in home environment
88913796|NCT05690607||HBV: Phase 1|People (over 18 years) living with HBV patients attending London Mortimer Market Centre for routine blood tests as part of their HBV care.
89531270|NCT03096015|Experimental|Intensive Treatment for Aphasia|
89433781|NCT05986240|Experimental|Danvatirsen + Venetoclax Combination Therapy|"Patients will be enrolled in cohorts of 3 for the Danvatirsen + Venetoclax dose escalation substudy. Dose escalation administration will be as described in the Danvatirsen monotherapy substudy arm and dose escalation discontinuations and MTD will be determined as described in the 'Detailed Study Description.'~Up to 2 dose levels of Danvatirsen will be evaluated based on data from the Danvatirsen monotherapy arm. Dose 1 will be one level lower than the dose with expected target activity.~Venetoclax: 400 mg (or equivalent) administered as fixed dose daily (except for specific dose modifications described in the protocol) orally for 28 days per cycle. To mitigate risk of tumor lysis syndrome, during Cycle 1 Venetoclax will be dose escalated daily to the goal dose of 400mg daily (100mg on Day 1, 200mg on Day 2 and 400mg on Day 3, and onwards, or adjusted dose ramp-up per Venetoclax label if on concomitant azoles).~The three cycles are approximately 28 days each in duration."
89433782|NCT05985330||Patients|Patients with metastatic non-small-cell lung cancer
89433783|NCT05984823|Experimental|Intervention group|Body weight exercise with blood flow restriction
89433784|NCT05984823|Active Comparator|Exercise only group|Body weight exercise only
89433785|NCT05983198|Experimental|Group-1 (post-177Lu)|"Dose Escalation: All eligible participants with mCRPC heavily pre-treated and refractory to 177Lu-labelled PSMA-targeting RLT will receive the starting dose of 7 Megabecquerel (MBq) of 225Ac-PSMA-R2 to determine the Maximum Tolerated Dose/Recommended Dose for Expansion (MTD/RDE) of Group 1.~Dose Expansion: Once RDE is determined for Group-1, participants being non/partial responders to 177Lu-labelled PSMA-targeted RLT or requiring re-treatment/re-challenge after 177Lu-labelled PSMA-targeted RLT treatment will be enrolled in Group 1 dose expansion."
89531271|NCT03338153||controlled diabetes|diabetic patients with HbA1C level below 7.0%
89531272|NCT03338153||uncontrolled diabetes|diabetic patients with hbA1C level above 7%
89531273|NCT03338153||non-diabetic|patients who does not have diabetes at the time of PCI
89531274|NCT02493725|Active Comparator|Eculizumab|Eculizumab, 900 mg intravenously once a week
88913797|NCT05690607||HBV: Phase 2|Subset of participants sent TINIES test kit to use in home environment
88913798|NCT05690568|Other|Pre-intervention and post-intervention FMS scores|multimodal chiropractic care with FMS scores assessed pre- and post-intervention
88913799|NCT05690542||patients from intensive care units|patients with hemostasis disorders (coagulation and/or platelets), antiplatelet and/or anticoagulant treatment
88913800|NCT05690542||controls|healthy people
88913801|NCT05690529||No recurrence|No recurrence of AF
88913802|NCT05690529||Recurrence|Recurrence of AF
88913803|NCT05690490|Experimental|endoscopic mucosal resection with circumferential incision|The endoscope will be passed into the intestine to the site of the tumor. Then, using an endoscopic needle, a solution will be injected into the submucosa to remove the neoplasm. Using an endoscopic knife (insulated tip knife, Olympus or Water Jet, Erbe), a circular incision will be made around the lesion. Then there will be a one-stage electro excision of the neoplasm using an endoscopic loop.
89433786|NCT05983198|Experimental|Group-2 (pre-177Lu)|"Dose Escalation: All eligible participants with mCRPC who have received previous treatment with Androgen Receptor Pathway Inhibitors (ARPI) or Computed Tomography (CT) but have never been treated with 177Lu-labelled PSMA-targeted RLT (177Lu-labelled PSMA-targeted RLT treatment naïve) will receive one level higher than the RDE of Group 1 as the starting dose of 225Ac-PSMA-R2 in order to determine the MTD/RDE of Group 2.~Dose Expansion: Once RDE is determined for Group 2, participants naïve to 177Lu-labelled PSMA-targeted RLT with high volume soft tissue and visceral disease and in participants with diffuse bone metastasis will be enrolled in Group 2 dose expansion.~Alternatively, if the RDE1 is not determined, Group 2 will begin the evaluation for the dose escalation at the dose of 7 MBq of 225Ac-PSMA-R2 upon Novartis decision. The early starting of Group 2 will be supported by emerging safety and preliminary efficacy data from Group 1 dose escalation."
89433787|NCT05983029||Study Group|Each patient will be requested to adopt a standardised upright position. First, two of the investigators will use a spirit level ruler and ink pen to agree upon and visibly mark the horizontal intercristal line on the back of the patient. Second, investigator B will leave the room, and investigator A will make a vertical mark with an ultraviolet pen denoting the intersection of the inferior aspect of the intergluteal cleft and the horizontal intercristal line. Third, investigator A will then leave the room, and investigator B will return to the room to make a vertical mark with an ink pen representing the intersection of the neuraxial midline, as established with the transverse spinous process view on ultrasound, and the horizontal intercristal line. After these two vertical marks have been made at the level of the intercristal line, the horizontal distance between them will be measured in mm by these same two investigators
89433788|NCT05977114|Experimental|4Rs Group|
88913804|NCT05690490|Active Comparator|endoscopic submucosal dissection|The endoscope will be passed into the intestine to the site of the tumor. Then, using an endoscopic needle, a solution will be injected into the submucosa to remove the neoplasm. Using an endoscopic knife (Insulated Tip Knife, Olympus or Water Jet, Erbe), the lesion will be resected through the submucosal plane using the eb-block principle, after which the patient will be monitored.
88913805|NCT05690321|Active Comparator|Active treatment|Administration of opium tincture (Dropizol)
88913806|NCT05690321|Placebo Comparator|Placebo treatment|Administration of placebo (identical to opium tincture in taste and appearance)
88913807|NCT05690217||COPD group|There are 40 chronic obstructive pulmonary disease (COPD) patients in the COPD group.
88913808|NCT05690217||Healthy control group|There are 40 age-matched healthy participants in the healthy control group.
88913809|NCT05690191||Chidamide in combination with rituximab and lenalidomide|Chidamide tablets: 20mg orally, twice a week (at least 3 days between doses); Rituximab injection: 375mg/m2 intravenously, once every 4 weeks (Q4w), on the first day of each cycle; Lenalidomide capsule: 25mg orally, once before going to bed every night, from day 1 to day 21 of each cycle
88913811|NCT05690139||Obese patients|Obese patients received LSG surgery approval
88913812|NCT05690022|No Intervention|Before sleeve gastrectomy|Gastroesophageal Reflux Disease (GERD) will be evaluated before surgery. EndoFlip, gastroscopy, pH-study and GERD-Health-Related Quality of Life Questionnaire will be realized for all patients.
88913813|NCT05690022|Experimental|Sleeve gastrectomy|After the surgical intervention, new onset or worsening of GERD will be evaluated.
88913814|NCT05689996|Experimental|Infective keratitis|"Preparation of nanostructure lipid carriers (NLCs):~The emulsification-solvent evaporation technique was used to prepare the NLCs. The method was followed by ultrasonication as reported [1]. In brief, the lipid phase was composed of stearic acid (solid lipid, 300 mg and oleic acid (liquid lipid, 300 mg) dissolved in ethanol (2 mL, 1:1, v/v) at 70oC. In total, 20 mL of the distilled water containing 2% of the Tween® 80 were heated at 70 oC to prepare the aqueous phase. Then, both phases, aqueous and lipid phases, were mixed at the same temperature using 2000 rpm stirring for 15 min. The resulting pre-emulsion obtained from the mixture of the aqueous and lipid phases was sonicated by a probe-type sonicator (Cole-Parmer, Vernon Hills, IL, USA) for 10 min at pulse-ON for 3 s and pulse-OFF for 5 s (40 W). The obtained dispersion was allowed to cool to RT under continuous stirring for 60 min at 1000 rpm for 1 h to obtain the NLCs dispersions."
88913815|NCT05689983|Active Comparator|As needed inhaled corticosteroid and long-acting beta-agonist|Symptom-driven ICS/LABA treatment strategy
88913816|NCT05689983|Placebo Comparator|Standard therapy: maintenance inhaled corticosteroid and as needed short-acting beta-agonist|Continue maintenance ICS and SABA therapy
88913817|NCT05689957|Experimental|deep neuromuscular block group|Group 1 (Induction with Rocuronium 0.6mg/kg + maintenance with intravenous Rocuronium rocuronium 8-12mcg/kg/minute (0.48-0.72 mg/kg/hour maintain PTC 0-1(deep block). (Study Group) intraoperatively
88913818|NCT05689957|Active Comparator|moderate neuromuscular block group|Group 2 (Induction with intravenous Rocuronium 0.6mg/kg + maintenance with intermittent intravenous Rocuronium 0.2mg/kg bolus. maintain PTC >1, TOF 0-2). Moderate block. (Control Group) intraoperatively
88913819|NCT05689931||Asthma patients initiating Mepolizumab treatment|Patients will be selected on the standard criteria used to select eligible asthma patients for mepolizumab treatment (i.e. patients with eosinophilic asthma that are not controlled by conventional high dose ICS and LABA etc). All eligible asthma patients may be included. Exclusion criteria: any infection
89009800|NCT04673344|Active Comparator|Partial Rotator Cuff Repair with Regeneten Scaffold|Routine partial rotator cuff repair with the addition of the Regeneten scaffolding patch
89433789|NCT05977114|Active Comparator|4As Group|
89433790|NCT05976347|Experimental|Selective serotonin reuptake inhibitors (SSRI)|Fluoxetine, 20mg once daily
88913820|NCT05689931||Asthma patients already on Mepolizumab treatment|Patients that have been selected and given Mepolizumab treatment for > 4 months according to standard eligible and treatment regimen criteria (i.e. patients with eosinophilic asthma that are not controlled by conventional high dose ICS and LABA etc). All eligible asthma patients that have been on Mepolizumab treatment for > 4 weeks will be included. Exclusion criteria: any infections
88913821|NCT05689931||Asthma patients without Mepolizumab treatment|Inclusion: Asthma patients without any biological (antibody-based) treatment but on routine ICS and LABA treatment as part of their normal care. Exclusion criteria are any infections
88913822|NCT05689931||Healthy non-asthmatic control subjects|Exclusion criteria: previous history of lung disease, chronic inflammatory condition, or atopy, or cardiovascular disease. Diagnosed or perceived infection within 3 weeks prior to blood sampling
88913823|NCT05689801|Experimental|Patient on conventional hemodialysis then on optimized hemodialysis|
88913824|NCT05689775||Patients|Patients over 18 years of age operated for locally advanced anal or rectal cancer with robot-assisted abdomino-perinal resection and robot-assisted reconstruction of pelvic floor and/or vagina with vertical rectus abdomínis muscle flap.
88913825|NCT05689723|Experimental|Manipulation|Left and right sidelyiing gaping high velocity low amplitude thrust mobilization
88913826|NCT05689723|Sham Comparator|Sham Manipulation|The experimenter holds both knees with one arm while placing their opposite hand on the participant's lumbar spine. The experimenter performs 1 min of ﬂexion and extension PROM without reaching physiological end range in either direction of movement. This is repeated with the subject in left sidelying.
88913827|NCT05689697|Placebo Comparator|Placebo group|Patients will recieve matched by taste and color shot of 25 ml liquid in ampules
88913828|NCT05689697|Experimental|Active treatment group|Patients will recieve shot of PanTrek 25 ml in anpules
88913829|NCT05689632|Placebo Comparator|Placebo|Placebo - Medium-chain triglyceride
88913830|NCT05689632|Active Comparator|Vitamin D3|Vitamin D3 - 7000 IU daily
88913831|NCT05689632|Experimental|Vitamin D3 + K2-MK7|Vitamin D3 - 7000 IU + Vitamin K2-MK7 180mcg combined, daily
88913832|NCT05689606|Experimental|Exercise group|The exercise group performs acute high-intensity interval training.
88913833|NCT05689606|No Intervention|Control group|The Control group includes the same participants. In this session, they do not exercise, and they watch a nature documentary.
88913834|NCT05689580|Experimental|Patients received ketogenic diet then Balanced diet|subjects will be educated by dietitian and receive two months of ketogenic diet. Then, followed by three months of washout period. Finally, they will receive dietary education and follow balanced diet for two months.
88913835|NCT05689580|Experimental|Patients received Balanced diet then ketogenic diet|subjects will receive dietary education and follow balanced diet for two months first, then followed by three months of washout period. At last, they will receive dietary education of ketogenic diet and need to follow the ketogenic diet for two months.
88913836|NCT05689554|Experimental|Intervention|Educational intervention
88913837|NCT05689554|No Intervention|Usual Care|Usual care
88913838|NCT05689489|Experimental|Puzzle|
89433791|NCT05976347|Experimental|serotonin and norepinephrine reuptake inhibitors (SNRI)|Duloxetine, 30mg once daily
88913839|NCT05689489|Active Comparator|control group|
88913840|NCT05689437||ILD Silent Mode|The ILD model will be run on patients undergoing routine treatment planning imaging where the notification is sent to the study team for a period of one month to ensure the pipeline is operating as intended.
88913841|NCT05689437||ILD Prospective Mode|Following successful silent mode, the ILD model will be run on patients undergoing routine treatment planning imaging and the notifications will be sent to the treating physician to incorporate into their workflow.
88913842|NCT05689437||SGR Silent Mode|The SGR model will be run on patients undergoing routine treatment planning imaging where the notification is sent to the study team for a period of one month to ensure the pipeline is operating as intended.
88913843|NCT05689437||SGR Prospective Mode|Following successful silent mode, the SGR model will be run on patients undergoing routine treatment planning imaging and the notifications will be sent to the treating physician to incorporate into their workflow.
88913844|NCT05689437||CBCT Silent Mode|The CBCT model will be run on patients receiving routine on-treatment imaging where the notification is sent to the study team for a period of one month to ensure the pipeline is operating as intended.
88913845|NCT05689437||CBCT Prospective Mode|Following successful silent mode, The CBCT model will be run on patients receiving routine on-treatment imaging and the notifications will be sent to the treating physician to incorporate into their workflow.
88913846|NCT05689320|Experimental|Intervention|The intervention group will first receive 3 times EMA per day for 21 consecutive days. This assessment length was designed to capture participants' exposure to alcohol marketing for a long period of time. The EMA will include questions about self-reported exposure to and /or responses to alcohol marketing. The intervention group participants should complete at least two EMA surveys in a day and need to comply with the intervention at least 85% of the time.
88913847|NCT05689320|No Intervention|Control|The control group will first receive 3 times EMA per day for 21 consecutive days. This assessment length was designed to capture participants' exposure to alcohol marketing for a long period of time. The EMA will include questions about self-reported exposure to and /or responses to alcohol marketing. The conrol group participants should complete at least two EMA surveys in a day and No intervention will be provided after completing the 21 consecutive days EMA documentation.
88913848|NCT05689242|Experimental|Group I|Receive initial loading dose of (Dexmedetomidine 1 μg/kg I.V) diluted up to 10 ml with normal saline infused over 10 min, followed by a continuous infusion of 0.2-0.8 μg/kg/h through a 50 ml syringe and an electronic infusion pump
88913849|NCT05689242|Experimental|Group II|Receive (Nalbuphine 0.1 to 0.2 mg/kg I.V) diluted up to 10 ml with normal saline infused slowly over 10 min.
88913850|NCT05689229|Active Comparator|Colistin IV|
88913851|NCT05689229|Active Comparator|Colistin Aerosolized|
88913852|NCT05689229|No Intervention|Control|
89433792|NCT05976347|Other|Observational|Referral to behavioral health per standard practice and provision of resources for strategices to address depressive symptoms.
89009801|NCT04673110||Anastomotic leakage group|9 patients developed anastomotic leakage (8%) in a median of 8 days (range: 5-9) median CRP level postoperative day 4:164mg/dL
89009802|NCT04673110||no Anastomotic leakage group|117 patients (92%) median CRP level postoperative day 4: 64mg/dL
89009803|NCT04672954|Placebo Comparator|Placebo|Placebo matching to 10 mg BI 474121 administered as uncoated tablets with 240 milliliter of water after subjects fasted overnight for at least 10 hours. This arm was part of Part 1: randomised, placebo-controlled, single-blind.
89009804|NCT04672954|Experimental|2.5 milligram (mg) BI 474121|2.5 mg BI 474121 administered as uncoated tablets (1 x 2.5 mg) with 240 milliliter of water after subjects fasted overnight for at least 10 hours. This arm was part of Part 3 of the study: randomised, open-label.
89433793|NCT05973045|Active Comparator|24 Centigrade Degree|Operative hysteroscopy will be performed at room temperature distention medium.
89433794|NCT05973045|Active Comparator|37 Centigrade Degree|Operative hysteroscopy will be performed using a heated distention medium.
89009805|NCT04672954|Experimental|10 milligram (mg) BI 474121|10 mg BI 474121 administered as uncoated tablets (1 x 10 mg) with 240 milliliter of water after subjects fasted overnight for at least 10 hours. This arm was part of Part 3 of the study: randomised, open-label.
89433795|NCT05970666|Experimental|Single arm|
89531275|NCT02493725|Placebo Comparator|Placebo|Matched placebo, intravenously once a week
88913853|NCT05689216|Experimental|Awake timed prone and repositioning group|Patients' cumulative prone and repositioning time is encouraged to reach 8-10 hours per day for 4 days following a timed prone and repositioning strategy.
88913854|NCT05689216|No Intervention|Standard care group|Patients can change their positions freely according to their own needs. Health providers do not take the initiative to give guidance on prone and repositioning.
88913855|NCT05689203|Experimental|QLS1128|QLS1128 will be administered orally for 5 days.
88913856|NCT05689203|Placebo Comparator|Placebo|Placebo matching to QLS1128 will be administered orally for 5 days.
88913857|NCT05688046||IA group|Immune checkpoint inhibitors plus angiogenesis inhibitors group
88913858|NCT05688046||NIA group|Immune checkpoint inhibitors without angiogenesis inhibitors group
88913859|NCT05687812|Experimental|Diabetic group|After 10-12 h fasting, an OGTT test with 75 g glucose was performed on the participants, showing no glucose metabolism disorder. Another independent day was chosen as the test day, and the participants were asked to no-restrict carbohydrates and not make any changes in their diet in the days before the test. Volunteers were fed 100g of white bread containing only 250 ml of water and 50g of carbohydrate (CH) for breakfast (after 12 hours of fasting). After 1 week, the same participants were fed 250 ml of water and 100g of test bread (consisting of 0.2% Cephalaria Syriaca flour bread) containing 50g of carbohydrates (KH). During the test, venous and capillary blood samples were taken at 0, 30, 60, 90, and 120 minutes.
88913860|NCT05687812|Experimental|Non-diabetic obese group|After 10-12 h fasting, an OGTT test with 75 g glucose was performed on the participants, showing no glucose metabolism disorder. Another independent day was chosen as the test day, and the participants were asked to no-restrict carbohydrates and not make any changes in their diet in the days before the test. Volunteers were fed 100g of white bread containing only 250 ml of water and 50g of carbohydrate (CH) for breakfast (after 12 hours of fasting). After 1 week, the same participants were fed 250 ml of water and 100g of test bread (consisting of 0.2% Cephalaria Syriaca flour bread) containing 50g of carbohydrates (KH). During the test, venous and capillary blood samples were taken at 0, 30, 60, 90, and 120 minutes.
88913861|NCT05687812|Experimental|Non-diabetic and non-obese healthy group|After 10-12 h fasting, an OGTT test with 75 g glucose was performed on the participants, showing no glucose metabolism disorder. Another independent day was chosen as the test day, and the participants were asked to no-restrict carbohydrates and not make any changes in their diet in the days before the test. Volunteers were fed 100g of white bread containing only 250 ml of water and 50g of carbohydrate (CH) for breakfast (after 12 hours of fasting). After 1 week, the same participants were fed 250 ml of water and 100g of test bread (consisting of 0.2% Cephalaria Syriaca flour bread) containing 50g of carbohydrates (KH). During the test, venous and capillary blood samples were taken at 0, 30, 60, 90, and 120 minutes.
88913862|NCT05686252|Active Comparator|30 degrees|Baby is held at 30 degrees during kangaroo mother care in the NICU
88913863|NCT05686252|Active Comparator|60 degrees|Baby is held at 60 degrees during kangaroo mother care in the NICU
88913864|NCT05684471|Active Comparator|Ultrasound Guided Suprainguinal Fascia iliaca Block|Patients randomized to receive suprainguinal fascia iliaca block
88913865|NCT05684471|Active Comparator|Ultrasound Guided Anterior quadratus lumborum block|Patients randomized to receive anterior quadratus lumborum block
88913866|NCT05680246||DHOPE-PRO|Outcomes of recipients who underwent liver transplantation of donor organs that were perfused with prolonged (>4 hours) DHOPE.
88913867|NCT05678166||NTM-LD|Diagnosis is made on the basis of the guidelines produced by the American Thoracic Society . Briefly, Patients have pulmonary symptoms with identified chest image and fit with the microbiology criteria.
88913868|NCT05678166||NTM pulmonary colonizers and others|Those without fulfilling the diagnostic criteria but having at least one set of positive sputum for MAC or patients infected with NTM other than MAC species.
88913869|NCT05678166||Pulmonary tuberculosis (TB)|Those with respiratory specimen culture positive for Mycobacterium tuberculosis or typical TB pulmonary pathology.
88913870|NCT05678166||Healthy control|Healthy control
88913871|NCT05678140|Experimental|soft tissue mobilization+conventional physical therapy|Hot-pack to warm the superficial tissue, TENS for pain relief, ultrasound (US) to warm the joint structures before mobilization techniques, ROM, stretching, and isometric strengthening exercises to restore joint mobility and function of the shoulder area soft tissue mobilization; For the shoulder area, the application will take between 3-5 minutes. Instrumental Soft tissue mobilization will be performed while the participant is sitting in a supported chair, parallel to the shoulder and scapular muscle fibers and at an angle of 45 degrees to the vertical. Patients will be told that there may be small red spots called petechiae in the treated area. The application will be made using Graston iron rods.
88913872|NCT05678140|Placebo Comparator|conventional physical therapy|Hot-pack to warm the superficial tissue, TENS for pain relief, ultrasound to warm the joint structures before mobilization techniques, ROM, stretching, and isometric strengthening exercises to restore joint mobility and function of the shoulder area.
88913873|NCT05634109|Experimental|Whole Blood|Leukoreduced whole blood with a platelet-sparing filter. Participants will be transfused with 3 whole blood units. If the participant requires, an additional transfusion pack composite by 3 whole blood units will be administered.
88913874|NCT05634109|Active Comparator|Blood Components Therapy|1:1:1 ratio of red blood cells unit, plasma unit, and platelets unit. Participants will be transfused with 3 red blood cell units, 3 fresh frozen plasma units, and 3 platelets units. A second intervention with the same ratio can be transfused to participants if they require it.
88913875|NCT05632237|Experimental|Family strengthening program|
88913876|NCT05632237|No Intervention|Care as usual|These participants have already been receiving case management from the Child Reintegration Centre prior to the study, and they will continue to receive care as usual, which is to receive normal case management visits without this added Family Strengthening Program component. Case management consists of a social work staff alternating between visiting children at home or at school each month to provide supervision, coaching, counseling, assessments, and identification of additional support needs.
88913877|NCT05618132|Experimental|Vasospastic angina|Interventional diagnostic protocol
88913878|NCT05596422||Cohort 1: Participants With Biologics Discontinuation|Participants with IBD (UC or CD) who had received biologic treatments for at least 6 months after the initial confirmed diagnosis of IBD, and with at least 3 months follow-up period after biologics discontinuation will be observed retrospectively.
88913879|NCT05596422||Cohort 2: Participants Treated With Biologics|Participants with IBD (UC or CD) who had any dose of biologic for IBD treatment after the initial confirmed diagnosis of IBD will be observed retrospectively.
89433796|NCT05970653|Active Comparator|RIC Group|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mm Hg. RIC will be conducted twice daily for 7 consecutive days or from enrollment to discharge.
88913881|NCT05553808|Active Comparator|Docetaxel|
88913882|NCT05553808|Experimental|Feladilimab plus Docetaxel|
88913883|NCT05549388|No Intervention|No label|In this arm, participants will view images of packaged food or beverage products without a front-of-pack label and respond to questions about the products.
88913884|NCT05549388|Experimental|Multiple Traffic Light (MTL)|In this arm, participants will view images of packaged food or beverage products which have multiple traffic light labels displayed on the front-of-pack and respond to questions about the products.
89009806|NCT04672954|Experimental|20 milligram (mg) BI 474121|20 mg BI 474121 administered as uncoated tablets (2 x 10 mg) with 240 milliliter of water after subjects fasted overnight for at least 10 hours. This arm was part of Part 1 of the study: randomised, placebo-controlled, single-blind.
89009807|NCT04672954|Experimental|40 milligram (mg) BI 474121|40 mg BI 474121 administered as uncoated tablets (4 x 10 mg) with 240 milliliter of water after subjects fasted overnight for at least 10 hours. This arm was part of Part 2 of the study: non-randomised, open-label.
89433797|NCT05970653|Placebo Comparator|Sham-RIC Group|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mm Hg. RIC will be conducted twice daily for 7 consecutive days or from enrollment to discharge.
89536316|NCT03195829|Experimental|Computerized cognitive stimulation|Computerized Cognitive Stimulation was administered to intervention group (IG).
89536317|NCT03195829|Active Comparator|Multimedia-based internet activities|Multimedia-based internet activities was administered to active control group (ACG).
89536318|NCT03195049|Experimental|blood group|blood is collected for maternal and infant blood group,complete blood count,before, during and after the procedure of exchange transfusion .
89536319|NCT03195049|Experimental|serum bilirubin estimation|estimation of serum bilirubin before, during and after the procedure of exchange transfusion .
89536320|NCT03195439|Experimental|patients in ICU|
89536321|NCT02481089||training group|
89536322|NCT03195283||Traditional meal service|TMS consists of three meals served by nutritional assistants throughout the day. Preference for dinner can be indicated in the morning by the individual patient from a menu list with predefined choices for meat, potatoes/rice/pasta and vegetables with various portion sizes.
89536323|NCT03195283||FoodforCare|FfC consists of a 6-meals per day service. At bedside, patients are offered one or more small protein-rich dishes from a choice of 3. Nutritional assistants play a key role in recommending and delivering these protein-rich meals and assist patient in choosing the most optimal dish, based on the patient's nutrition order in the electronic patient record.
89536324|NCT05667155|Experimental|CB dualCAR-NK19/70|All subjects were intravenously administrated with CB dualCAR-NK19/70
89536325|NCT02449759|Experimental|ACT Intervention Group|This group will receive an ACT self-help manual to be completed over the course of 6 weeks. They will also receive two brief telephone calls during the reading of the manual by a member of the research team.
89536326|NCT02449759|No Intervention|Control Group|This group will receive no intervention
89536327|NCT03198013|Experimental|Module A|Single Ascending Dose
89536328|NCT03198013|Experimental|Module B|Multiple Ascending Dose
89536329|NCT05651399|Active Comparator|Remimazolam|A maintenance dose of remimazolam is administered for sedation
89536330|NCT05651399|Active Comparator|Propofol|A maintenance dose of propofol is administered for sedation
89536331|NCT03197545||Stress fracture group|110 recruits diagnosed (clinicaly and/or by imaging) with at least one stress fracture, during basic and advanced infantry trainig.
89536332|NCT03197545||Traumatic fracture group|110 infantry recruits with medical history of having at least one traumatic fracture, during their life (from birth up to date).
89536333|NCT03197545||Control group|220 healthy infantry recruits never diagnosed with stress fracture or traumatic fractures
89536334|NCT02447263|Experimental|HepaSphere|liver cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
89536335|NCT02447263|No Intervention|control|liver cancer patients did not receive any interventional therapy
89536336|NCT03208543|Experimental|HECT-CL|HECT-CL heat pack will be applied on CL lesions (50-52 degrees Celsius for 3 minutes on 7 consecutive days)
89536337|NCT02477813|Experimental|Temozolomide|oral Temozolomide 200 mg/m2/die for 5 consecutive days, every 28 days.Treatment will be continued until tumor progression, intolerable toxicity or patient refusal
89536338|NCT03119311|Experimental|VOG group|Video-oculography
89536339|NCT03119311|Active Comparator|APCT group|alternative prism cover test
89536340|NCT02481011||users|patients on antithrombotic drugs admitted to a Norwegian hospital for intracranial hemorrhage (ICH)
89536341|NCT02481011||non-users|patients not on antithrombotic drugs admitted to a Norwegian hospital for intracranial hemorrhage (ICH)
89536342|NCT02447341||In patients|
89536343|NCT02447341||Out patients|
89536344|NCT02480855|Other|Questionnaire and feedback|Patients that will see a doctor randomized to the intervention group will fill in the Work Stress Questionnaire prior to the visit. The doctor gets the results from the questionnaire and then gives consultation to the patient based on the results.
89536345|NCT02480855|No Intervention|Control group|Patients that will see a doctor randomized to the control group get the usual treatment/consultation and after the visit fill in the Work Stress Questionnaire.
89536346|NCT02450617|Experimental|Stabilizing group treatment for PTSD|Group treatment, 20 sessions psychoeducation and skills-training. In combination with conventional individual treatment.
89536347|NCT02450617|Active Comparator|Conventional Individual treatment - PTSD|Conventional individual treatment.
89536348|NCT02450617|Experimental|Stabilizing group treatment for Dissociative disorders|Group treatment, 20 sessions psychoeducation and skills-training. In combination with conventional individual treatment.
89536349|NCT02450617|Active Comparator|Conventional Individual treatment - Dissociative disorders|Conventional individual treatment.
89536350|NCT02480933|Experimental|female cadavers|female cadavers above 40 years without known breast cancer Bilateral mastectomy Biopsy
89536351|NCT02480933|Experimental|Male cadavers|male cadavers above 40 years without known breast cancer Bilateral mastectomy Biopsy
89536352|NCT03197857|Experimental|Control|"Physical condition will be evaluated in obese patients before surgery and 1, 4, 6, 12, 18 and 24 months after surgery.~Between 1 and 4 months after surgery, participants will be assigned to one of the postoperative care groups:~Control~Control + protein supplementation~Training in aquabike~Training in aquabike + protein supplementation~Bicycle training~Bicycle training + protein supplementation"
89009808|NCT04673227||Contact with active TB/ LTBI|After a close contact with bacteriologically confirmed TB suspicion for LTBI with an evidence of previous BCG vaccination status TB confirmed with TST (TST ≥ 5 mm or BCG unvaccinated or TST ≥ 15 mm for BCG vaccinated) 20 children and adolescents 20 adults
89009809|NCT04673227||Active TB group|Active TB group with positive microbial culture and pathological chest radiography or chest CT 20 children and adolescents 20 adults
89009810|NCT04673227||Contact with active TB/ negative|After a close contact with bacteriologically confirmed TB no evidence of TB in TST or IGRA test for 3 months 20 children and adolescents 20 adults
89009811|NCT00260091|Active Comparator|I.|Conventional infertility therapy
89009812|NCT00260091|Active Comparator|II.|Fast track to in vitro fertilization therapy
89009813|NCT04673071|Active Comparator|Thread Embedding Acupuncture (TEA)|TEA once a month for 4 months + AEDs
89009814|NCT04673071|Sham Comparator|Sham-TEA (STEA)|STEA once a month for 4 months + AEDs
89009815|NCT04672642|Experimental|SpyGlass DS after endoscopic treatment|
89009816|NCT00233129|Active Comparator|Standard Treatment|cognitive rehabilitation day treatment program
89009817|NCT00233129|Experimental|Top-Down|"cognitive rehabilitation day treatment program that incorporates systematic top down treatment of executive function deficits (problem solving and emotional regulation training), systematic treatment of attention deficits, and modular, contextual and embedded approaches to treatment."
89009818|NCT00260130|Active Comparator|1|Consuming fruit and vegetable juice
89009819|NCT00260130|Active Comparator|2|Consuming whole fruits and vegetables
89536353|NCT03197857|Experimental|Control + protein supplementation|"Physical condition will be evaluated in obese patients before surgery and 1, 4, 6, 12, 18 and 24 months after surgery.~Between 1 and 4 months after surgery, participants will be assigned to one of the postoperative care groups:~Control~Control + protein supplementation~Training in aquabike~Training in aquabike + protein supplementation~Bicycle training~Bicycle training + protein supplementation"
89009820|NCT00556036||1|lean healthy women, age 18-45
89009821|NCT00556036||2|overweight healthy women, age 18-45
89009822|NCT00556036||3|women with hypothalamic amenorrhea (have not had a period in three months), age 18-45
89009823|NCT00556036||4|women with anorexia nervosa, age 18-45
89009824|NCT03454906||L Hemoglobin|L Hemoglobin: consistently low all 6 months with low hemoglobin levels
89536354|NCT03197857|Experimental|Training in aquabike|"Physical condition will be evaluated in obese patients before surgery and 1, 4, 6, 12, 18 and 24 months after surgery.~Between 1 and 4 months after surgery, participants will be assigned to one of the postoperative care groups:~Control~Control + protein supplementation~Training in aquabike~Training in aquabike + protein supplementation~Bicycle training~Bicycle training + protein supplementation"
89009825|NCT03454906||T Hemoglobin|T Hemoglobin; consistently within the target range all 6 months with target-range hemoglobin levels
89009826|NCT03454906||H Hemoglobin|H Hemoglobin: consistently high all 6 months with high hemoglobin levels
89009827|NCT03454906||LAL Hemoglobin|LAL Hemoglobin: low amplitude fluctuation with low hemoglobin; all 6 months with low or target range hemoglobin levels
89009828|NCT03454906||LAH Hemoglobin|LAH Hemoglobin: low-amplitude fluctuation with high hemoglobin levels 6 months with target-range or high hemoglobin levels)
89009829|NCT03454906||HA Hemoglobin|HA Hemoglobin ; high-amplitude fluctuation low, target-range, and high hemoglobin levels within the 6 month period
89009830|NCT04672603|Experimental|Complete Preservation of Denonvilliers Fascia|Complete preservation of Denonvilliers fascia in Laparoscopy-assisted pelvic autonomic nerve preservation surgery with TME for mid-low rectal cancer patients.
89009831|NCT04672603|No Intervention|Partial Preservation of Denonvilliers Fascia|Partial preservation of Denonvilliers fascia in Laparoscopy-assisted pelvic autonomic nerve preservation surgery with TME for mid-low rectal cancer patients.
89009832|NCT00233168|Experimental|1|Peer medication adherence counseling
89009833|NCT00233168|Active Comparator|2|Peer life skills counseling
89009834|NCT04672837|Experimental|Manual Therapy Group|"10 sessions of Pediatric Manual Therapy, once a week. Soft cervical mobilisation, myofascial induction and cranial techniques will be administered. Educational physiotherapy consists in tummy time stimulation, visual and kinaesthetic stimulation on the non preferential head position and counter position will be also administered."
89009835|NCT04672837|Active Comparator|Stretching Group|"A protocol of Stretching at home. 3-5 sessions twice a day. Each stretch will be maintain10 to 30 seconds. Each session 15 will take no less than 15 minutes. 7 days a week.~Educational Physical Therapy consists in tummy time stimulation, visual and kinaesthetic stimulation on the non preferential head position and counter position will be administered."
89009836|NCT00267579|Experimental|Treatment|50% randomized to receive Strongest Families (formerly Family Help Program): Behaviour treatment
89009837|NCT00267579|Active Comparator|Control|50% randomized to control group: standard/usual care for behaviour disorder
89009838|NCT04672759||Cohort 1|Cohort 1 will include patients with unresectable stage III non-small cell lung cancer. Patients receive durvalumab as an intravenous infusion over 60 minutes on day 1. Courses repeat every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity.
89009839|NCT04672759||Cohort 2|Cohort 2 will enroll patients with histologically or cytologically confirmed NSCLC or SCLC who will or have received chemotherapy/radiotherapy at the physician's discretion.
89009840|NCT04672408|Active Comparator|His bundle pacing|Pacing programmed from the His bundle lead
89009841|NCT04672408|Placebo Comparator|Right ventricular pacing|Pacing programmed from the right ventricular lead
89009842|NCT04672096|Experimental|Neuronoff BASMATI Injectrode|Subjects will be provided with the placement of an Injectrode insert. The maximal placement duration will be 28 days.
89009843|NCT00260169|Experimental|1|Participants will receive collaborative care
89009844|NCT00260169|Active Comparator|2|Participants will receive enhanced usual care
89009845|NCT04672057|Active Comparator|Right hemiparetics|right-sided affected hemiparetic individuals
89009846|NCT04672057|Active Comparator|Left hemiparetics|left-sided affected hemiparetic individuals
89009847|NCT04672057|Active Comparator|Control|healthy individuals
89009848|NCT04671745||Expérimental|patient receiving care with interactive music
89009849|NCT04671745||Control|patient receiving care without interactive music
89009850|NCT04671589|Experimental|Meropenem|Meropenem 1 gram intravenous every 8 hours
89009851|NCT04671589|Placebo Comparator|Placebo|Placebo intravenous every 8 hours
89009852|NCT04671277|Experimental|Chewing of breads|"6 samples (2x3 full factorial design with 2 white sandwich bread types (a regular gluten-containing (GC) and a gluten-free version (GF)) and 3 spread conditions (no spread, butter and mayonnaise)) were evaluated in two sessions of 30 min each. The first session was designed for video recording and the second session for the evaluation of texture attributes and collection of food bolus.~Bread samples were served as two stacked cylinders resembling the consumption of a sandwich (diameter: 3.5 cm, approximate total height: 2.4 cm) (Figure 1). Due to differences in bread density, the average weight of two stacked cylinders was 5.1 ± 0.2 and 5.7 ± 0.4 for GC and GF breads, respectively. Butter and mayonnaise were added to breads at approximately 12% w/w."
89009853|NCT04671160||1|Group treated with CVVHDF and receiving enoxaparin as anticoagulant prophylaxis.
89009854|NCT04671160||2|Group treated with CVVHDF and receiving fondaparinux as anticoagulant prophylaxis.
89009855|NCT04671160||3|Group not treated with CVVHDF and receiving enoxaparin as anticoagulant prophylaxis.
89009856|NCT04671160||4|Group not treated with CVVHDF and receiving fondaparinux as anticoagulant prophylaxis.
89009857|NCT04671394|Experimental|Test (FMUD + DLIG)|Periodontal pockets are treated by ultrasonic debridement and, after 7 and 28 days, by irrigation with indocyanine green solution and diode laser irradiation.
89009858|NCT04671394|Sham Comparator|Control (FMUD + ST)|Periodontal pockets are treated by ultrasonic debridement and, after 7 and 28 days, by sham therapy.
89009859|NCT00267618|Experimental|Treatment|50% randomized to receive FHP Pain intervention
89009860|NCT00267618|No Intervention|control|50% randomized to receive standard/usual care for recurrent headache/abdominal pain
89009861|NCT04670926|Experimental|TruGraf - Group 1:|Patients randomized to Group 1 will receive serial TruGraf testing at months 3, 4, 5, 6, 7, 8, 9, and 12. Results will be available in real-time and used by the physician to guide management of immunosuppression.
89009862|NCT04670926|Active Comparator|CPMC Standard of Care - Group 2:|Patients randomized to Group 2 or CPMC Standard of Care Group patients will have current standard of care laboratory assessments.
89009863|NCT04670887|Active Comparator|Immediate surgery|Patients undergo excision of a renal mass by partial or radical nephrectomy and will be followed by UISS risk classification.
89009864|NCT04670887|Active Comparator|Active surveillance|Patients enter active surveillance protocol. Delayed surgery on active surveillance will be recommended if progression from Bosniak 3 to 4 or a solid mass is noted on imaging by radiologist
89009865|NCT04671121|Active Comparator|Grup LP (n = 31)|CO2 insufflation pressure was kept at 8 mmHg throughout the surgery.
89009866|NCT04671121|Active Comparator|Grup SP (n = 31)|CO2 insufflation pressure was kept at 14 mmHg throughout the surgery.
88913885|NCT05549388|Experimental|Nutri-Score|In this arm, participants will view images of packaged food or beverage products which have a Nutriscore front-of-pack label and respond to questions about the products.
88913886|NCT05549388|Experimental|Warning Label|In this arm, participants will view packaged food or beverage products which have front-of-pack warning labels if the product is high in one or more nutrients of concern and respond to questions about the products.
88913887|NCT05544890|Active Comparator|Therapeutic exercise Group (ET)|The ET group is going to follow a program of core stabilization through specific therapeutic exercise. Two weekly sessions will be programmed for 12 weeks, making a total of 24 sessions. Each session will have a duration of 60 minutes. All patients will start learning how to activate the transversus abdominal muscle in the first training session. The exercises will be made in 1 to 3 series of among 8 and 15 repetitions and the isometric contractions for 5 to 10 seconds. The rest between series will be of 30 seconds, and between exercise of 2-3 minutes.
88913888|NCT05544890|Active Comparator|Manual Therapy group (ETmanualtherapy)|Prior the core exercise previously exposed in group ET, group ETmanualtherapy will lay on the stretcher, where the physiotherapist will work on a manual therapy thrust. The participant will receive a high velocity and low range impulse technique in lateral position on both sides.
88913889|NCT05544890|Active Comparator|Kinesiotape Group (ETkinesiotape)|"The ETkinesiotape will go previously through physiotherapy, where a kinesiotape band will be applied (Kinesiotape Nondolens 5cmx5cm black color), in Y technique, by applying the kinesiotape base in neutral position of the lumbar spine without any tension on the tape. The participants realize the same exercise program than the other groups plus the kinesiotape applied."
88913890|NCT05540184|Experimental|Hydration plus Trimetazidine|Hydration plus Trimetazidine 35mg twice daily will be given to patients before the procedure and 24 hours after the procedure
88913891|NCT05540184|Experimental|Hydration ,Trimetazidine & allopurinol|Hydration plus Trimetazidine 35mg once daily will be given to patients before the procedure and up to 24 hours after the procedure and allopurinol 300 mg once daily 5 hours before the procedure and next day of the procedure
88913892|NCT05540184|Placebo Comparator|Hydration|Hydration only will be given to the patients normal saline at the rate of 1 mL/kg per hour (3 to 4 hrs before the procedure and up to 24 hours post-procedure, maximum 100 ml/hr)
88913893|NCT05533268|Experimental|Mental Training|mindfulness meditation for 6-weeks.
88913894|NCT05533268|Experimental|Physical Training|Continuous moderate-intensity training for 6-weeks.
88913895|NCT05533268|Experimental|Mental and Physical Training|Combination of mindfulness meditation and continuous moderate-intensity training for 6 weeks.
88913896|NCT05533268|Active Comparator|DASH Diet Plan|Dietary Approaches to Stop Hypertension for 6-weeks.
88913897|NCT05523271|No Intervention|Patients undergoing White Light Endoscopy (standard of care)|All subjects in Experimental Arm A will undergo SOC (white-light endoscopy).
88913898|NCT05523271|Experimental|Patients undergoing CAD EYE endoscopy|All subjects in Experimental Arm B will undergo CADEYE endoscopy.
88913899|NCT05522777|Experimental|Test product consumption group|Drink one bottle of Yakult a day
88913900|NCT05512884|Experimental|Speeded anomia therapy|21h of anomia therapy
88913901|NCT05512884|No Intervention|Standard care|Participants' typical daily routine
88913902|NCT05506852|Experimental|Strategy Training|Participants will play the Breakfast Game with training strategy.
88913903|NCT05506852|Active Comparator|Regular Approach|Participants will play the Breakfast Game without training strategy.
88913904|NCT05488769||Clareon Vivity extended depth of focus (EDOF) intraocular lens|Implantation with the Clareon Vivity extended depth of focus (EDOF) intraocular lens
89536355|NCT03197857|Experimental|- Training in aquabike + protein supplementation|"Physical condition will be evaluated in obese patients before surgery and 1, 4, 6, 12, 18 and 24 months after surgery.~Between 1 and 4 months after surgery, participants will be assigned to one of the postoperative care groups:~Control~Control + protein supplementation~Training in aquabike~Training in aquabike + protein supplementation~Bicycle training~Bicycle training + protein supplementation"
89009867|NCT04671316|Experimental|T1T2R|"Period I: T1, DA-5209 60mg without water Period II: T2, DA-5209 60mg with 150mL water Period III: R, Lixiana 60mg with 150mL water"
88913905|NCT05473195|Experimental|Arm 1|BVL-GSK098 9 mg once daily (OD) plus ethionamide 250 mg OD (b9Eto250)
88913906|NCT05473195|Active Comparator|Arm 2|Isoniazid 300 mg po OD (INH)
88913907|NCT05473195|Experimental|Arm 3|BVL-GSK098 27 mg OD plus ethionamide 125 mg po OD (b27Eto125)
88913908|NCT05473195|Experimental|Arm 4|BVL-GSK098 27 mg OD plus ethionamide 250 mg po OD (b27Eto250)
88913909|NCT05473195|Experimental|Arm 5|BVL-GSK098 27 mg OD plus ethionamide 500 mg po OD (b27Eto500)
88913910|NCT05473195|Experimental|Arm 6|Ethionamide 250 mg po OD (Eto250)
88913911|NCT05473195|Experimental|Arm 7|Ethionamide 750 mg po given in a single or divided dose daily (Eto750)
88913912|NCT05458817|Experimental|1. Digital diary|75 participants in the group
88913913|NCT05458817|Active Comparator|2. Paper diary|75 participants in the group
88913914|NCT05458817|Experimental|3. Digital: diary and headache nurse|75 participants in the group
88913915|NCT05458817|Active Comparator|4. Paper diary and conventional headache nurse|75 participants in the group
88913916|NCT05458817|Experimental|5. Digital: diary, headache nurse and clinal psychologist|75 participants in the group
88913917|NCT05458817|Active Comparator|6. Paper diary, conventional headache nurse and conventional clinical psychologist|75 participants in the group
88913918|NCT05458817|Experimental|7. Digital: diary, headache nurse, clinal psychologist and physiotherapist|75 participants in the group
88913919|NCT05458817|Active Comparator|8. Paper diary, conventional: headache nurse, clinal psychologist and physiotherapist|75 participants in the group
88913920|NCT05450952|Active Comparator|Active|Dietary Supplement (Theanine Formulation)
88913921|NCT05450952|Placebo Comparator|Placebo|Placebo Tablet
88913922|NCT05433103|Experimental|Low-Load Exercise with Blood Flow Restriction|The BFR intervention will combine low-load resistance training with between 60%-80% blood flow occlusion under the supervision of a licensed physical therapist.
88913923|NCT05433103|Active Comparator|Low-Load Exercise Control|The control group with consist only of low-load resistance training under the supervision of a licensed physical therapist.
88913924|NCT05422053|Experimental|t:slim X2 insulin pump with Control-IQ technology|Adults with type 1 diabetes will use the t:slim X2 insulin pump with Control-IQ technology 1.5 for 3-months of outpatient use. Meal and exercise challenges will be performed.
88913925|NCT05418127|Placebo Comparator|30 Participants receiving Placebo product.|Solution of filtered water, Calcium Carbonate powder, and coconut extract.
88913926|NCT05418127|Active Comparator|30 Participants receiving Active product.|Traditionally-fermented coconut milk kefir.
88913927|NCT05349760|Experimental|AMB-05X|AMB-05X will be administered every 4 weeks for 24 weeks (for 6 treatments in total).
88913928|NCT05349760|Placebo Comparator|Placebo|Placebo will be administered every 4 weeks for 24 weeks (for 6 treatments in total).
88913929|NCT05344911|Active Comparator|remifentanil|Anesthesia maintenance：target-controlled infusion of propofol combined with remifentanil）
88913930|NCT05344911|Experimental|alfentanil|Anesthesia maintenance：target-controlled infusion of propofol combined with afentanil
88913931|NCT05338021|Experimental|Intrawound Administration of Vancomycin|After closure of the arthrotomy, 1 g of vancomycin powder suspended in 30ml of normal saline was injected directly into the joint with an 18-gauge needle. Then 20ml of normal saline was injected directly into the joint.
88913932|NCT05338021|Experimental|Intrawound Administration of Vancomycin combined with epsilon-aminocaproic acid (EACA)|After closure of the arthrotomy, 1 g of vancomycin powder suspended in 30ml of normal saline was injected directly into the joint with an 18-gauge needle. Then 4g (20ml) of epsilon-aminocaproic acid (EACA) was injected directly into the joint.
88913933|NCT05338008|Experimental|Intrawound Administration of Vancomycin|After closure of the arthrotomy, 1 g of vancomycin powder suspended in 30ml of normal saline was injected directly into the joint with an 18-gauge needle. Then 20ml of normal saline was injected directly into the joint.
88913934|NCT05338008|Experimental|Intrawound Administration of Vancomycin combined with epsilon-aminocaproic acid (EACA)|After closure of the arthrotomy, 1 g of vancomycin powder suspended in 30ml of normal saline was injected directly into the joint with an 18-gauge needle. Then 4g (20ml) of epsilon-aminocaproic acid (EACA) was injected directly into the joint.
88913935|NCT05334680||COVID-19|Individuals experiencing COVID-19 like symptoms.
88913936|NCT05334680||Healthy Controls|Individuals without any known significant health problems
88913937|NCT05325112||FFR-CT Group|Sites who have CCTA and FFR-CT analysis incorporated into their standard evaluation of chest pain in the ED/observation unit.
88913938|NCT05325112||Control Group|Sites who have CCTA but not FFR-CT incorporated into the ED/observation unit.
88913939|NCT05322590|Experimental|BXQ-350|BXQ-350 will be administered by IV infusion
88913940|NCT05322590|Placebo Comparator|Placebo|Placebo (0.9% normal saline) will be administered by IV infusion (Stage 2 only)
88913941|NCT05314023|Experimental|9 to 19 Years Old: Day 1, Months 2 and 6|Chinese males 9 to 19 years old will receive a 0.5 mL intramuscular (IM) injection of 9-valent HPV (9vHPV) vaccine on Day 1, Month 2 and Month 6
88913942|NCT05314023|Experimental|9 to 14 Years Old: Day 1, and Month 6|Chinese males 9 to 14 years old will receive a 0.5 mL IM injection of 9vHPV vaccine on Day 1 and Month 6
88913943|NCT05314023|Experimental|9 to 14 Years Old: Day 1 and Month 12|Chinese males 9 to 14 years old will receive a 0.5 mL IM injection of 9vHPV vaccine on Day 1 and Month 12
88913944|NCT05308797|Active Comparator|Erector Spinae Plane Block|An erector spinae plane block will be performed at the level of the 5th thoracic vertebrae with 30 mL of 0.25% bupivacaine solution under ultrasound guidance before the operation.
88913945|NCT05308797|Active Comparator|Combine Serratus Anterior Plane Block|Combine Serratus Anterior Plane block will be performed at the level of 5th costa with 30 mL of 0.25% bupivacaine (15 mL superficial serratus plane block and 15 mL deep serratus plane block) solution under ultrasound guidance before the operation.
88913946|NCT05305638|Experimental|Experimental Group|
88913947|NCT05305638|Experimental|Control Group|
88913948|NCT05303545||All subjects with poliomyelitis sequelae|
88913949|NCT05282992|Experimental|Native type II collagen|Native type II collagen
88913950|NCT05282992|Placebo Comparator|Placebo|Placebo
88913951|NCT05251376|Experimental|LYN-014 Extended-Release Levomethadone HCl|Extended-release levomethadone HCl 187 mg administered orally once on Day 8 of the study.
88913952|NCT05249257||No Treatment - previously treated in parent study|Participants who completed the parent study EN3835-224 (NCT04580303) will be eligible for this study.
89433798|NCT05970523|Experimental|Exercise Group|Intervention includes core stabilization exercises for 45 minutes 3 times a week. Participants do exercise face to face under supervision of a physiotherapist and via an online application under the supervision of a physiotherapist once a week. Also participants do home exercise once a week. Exercise group walk for an hour in other two days.
88913953|NCT05248555||People at risk of HCV acquisition|Clinic staff will offer HCV point-of-care testing to participants as they access services. Testing will be performed using point-of-care HCV RNA testing.
88913954|NCT05219097||Cell Based Assay (CBA)|Use AChR/MuSK Ab CBA Kit (Tianjin New Terrain Biological Technology Co., Ltd, China) to detect AChR and MuSK Ab of myasthenia gravis
88913955|NCT05219097||RIPA Assay|Use AChR and MuSK Ab radioimmunoassay kit (RSR Limited, UK) to detect AChR and MuSK Ab of myasthenia gravis
88913956|NCT05219097||ELISA Assay|Use AChR Ab ELISA Kit (RSR Limited, UK) and MuSK ELISA kit (IBL Limited, Germany) to detect AChR and MuSK Ab of myasthenia gravis
89433799|NCT05970523|No Intervention|Control Group|There is no exercise or intervention for control group.
89433800|NCT05963503||Cystic Fibrosis|"Inclusion Criteria:~have a confirmed diagnosis of CF stable clinical condition 18-65 ages volunteering to participate~Exclusion Criteria:~having a serious comorbidity that limits mobilization or participation in physical activity being illiterate having cognitive problems being pregnant incomplete answers to surveys"
88913957|NCT05196906||Modified Broström operation group|Patients who accept a modified Broström operation
88913958|NCT05196906||Anatomic reconstruction operation group|Patients who accept an anatomic reconstruction
88913959|NCT05164354|Experimental|Aromatherapy|Aromatherapy will be done in the form of a 20-minute application period for three days.
88913960|NCT05164354|Experimental|music concert|"Music concert will be performed in the form of a 20 minute daily practice period for three days."
88913961|NCT05163613|Experimental|Patients with COVID - 19, who we were treated with magnetic stimulation.|"The study group included patients hospitalized due to PCR-confirmed SARS-Cov-2 infection, who were treated with magnetic stimulation in addition to a standard therapy.~Standard therapy used in all patients consisted of the use of pharmacological agents necessary to treat the viral infection (antiviral drugs, antibiotics, dexamethasone) and the inclusion of proper care, education, occupational therapy, self-service learning, breathing exercises and motor mobilization."
88913962|NCT05163613|Experimental|Patients with COVID - 19, who we were treated without magnetic stimulation.|The control group included patients receiving a comprehensive treatment without magnetic stimulation. The patients were in a moderately severe condition.
89433801|NCT05963503||Controls|"Inclusion Criteria:~18-65 ages volunteering to participate~Exclusion Criteria:~having any cardiopulmonary disease having cognitive problems being illiterate"
89433802|NCT05963438|Other|Two-step retraction group (control group)|In this group, immediately after placement of mini-implant and extractions of upper first premolars, heavy ligation will be done from mini-implant to maxillary second premolar and first molar. Canine will be retracted by sliding mechanics and the four anterior teeth will be retracted by loop mechanics. Loops will be activated every three weeks by 1 mm.
89433803|NCT05963438|Experimental|En-masse retraction group(experimental group)|After placement of mini-implants and extraction of maxillary first premolar, rectangular stainless steel arch wire with anterior 8mm height crimpable hooks distal to the lateral incisors will be inserted and force will be applied using elastic chains attached between the mini-implant and the hooks for conducting en-masse retraction. Elastic chains will replace after every three weeks
89433804|NCT05959707|Experimental|VRC01.23LS 5 mg/kg|VRC01.23LS 5 mg/kg to be administered via intravenous (IV) infusion at Month 0
89009868|NCT04671316|Experimental|T1RT2|"Period I: T1, DA-5209 60mg without water Period II: R, Lixiana 60mg with 150mL water Period III: T2, DA-5209 60mg with 150mL water"
89433805|NCT05959707|Experimental|VRC01.23LS 20 mg/kg|VRC01.23LS 20 mg/kg to be administered via IV infusion at Month 0
89433806|NCT05959707|Experimental|VRC01.23LS 40 mg/kg|VRC01.23LS 40 mg/kg to be administered via IV infusion at Month 0
89433807|NCT05959707|Experimental|VRC01.23LS 5 mg/kg + PGT121.414.LS 5 mg/kg + PGDM1400LS 5 mg/kg|VRC01.23LS 5 mg/kg + PGT121.414.LS 5 mg/kg + PGDM1400LS 5 mg/kg to be administered via IV infusion sequentially in this order at Month 0 and Month 6
89433808|NCT05959707|Experimental|VRC01.23LS 20 mg/kg + PGT121.414.LS 5 mg/kg + PGDM1400LS 5 mg/kg|VRC01.23LS 20 mg/kg + PGT121.414.LS 5 mg/kg + PGDM1400LS 5 mg/kg to be administered via IV infusion sequentially in this order at Month 0 and Month 6
89433809|NCT05959707|Experimental|VRC01.23LS 20 mg/kg + PGT121.414.LS 20 mg/kg+ PGDM1400LS 20 mg/kg|VRC01.23LS 20 mg/kg + PGT121.414.LS 20 mg/kg+ PGDM1400LS 20 mg/kg to be administered via IV infusion sequentially in this order at Month 0 and Month 6
89433810|NCT05959707|Experimental|VRC01.23LS 40 mg/kg + PGT121.414.LS 5 mg/kg + PGDM1400LS 5 mg/kg|VRC01.23LS 40 mg/kg + PGT121.414.LS 5 mg/kg + PGDM1400LS 5 mg/kg to be administered via IV infusion sequentially in this order at Month 0 and Month 6
89433811|NCT05959707|Experimental|VRC01.23LS 40 mg/kg + PGT121.414.LS 40 mg/kg + PGDM1400LS 40mg/kg|VRC01.23LS 40 mg/kg + PGT121.414.LS 40 mg/kg + PGDM1400LS 40mg/kg to be administered via IV infusion sequentially in this order at Month 0 and Month 6
89433812|NCT05958537|Experimental|Intervention|In the intervention group, 50 L/min with 0.6 FiO2 will be administered through a high-flow nasal cannula.
89433813|NCT05958537|No Intervention|Control|In the control group, oxygen therapy will also be administered in all cases, using the usual procedure: oxygen therapy through a conventional nasal cannula and at a flow of 5 L/min
89009869|NCT04671316|Experimental|RT1T2|"Period I: R, Lixiana 60mg with 150mL water Period II: T1, DA-5209 60mg without water Period III: T2, DA-5209 60mg with 150mL water"
89009870|NCT04671316|Experimental|RT2T1|"Period I: R, Lixiana 60mg with 150mL water Period II: T2, DA-5209 60mg with 150mL water Period III: T1, DA-5209 60mg without water"
89009871|NCT04671316|Experimental|T2RT1|"Period I: T2, DA-5209 60mg with 150mL water Period II: R, Lixiana 60mg with 150mL water Period III: T1, DA-5209 60mg without water"
89433814|NCT05958407|Experimental|Tralokinumab|Tralokinumab is administered for 32 weeks (16 weeks double-blinded period + 16 weeks open-label period)
89433815|NCT05958407|Placebo Comparator|Placebo + tralokinumab|Placebo is administered for 16 weeks (double-blinded period) prior to roll-over to a 16 weeks open-label period where tralokinumab is administered
89433816|NCT05957978|Experimental|LXE408|LXE408 orally once daily for 14 days
89433817|NCT05957978|Active Comparator|Standard of care|Standard of care sodium stibogluconate 20 mg/kg/day intravenous/intramuscular (IV/IM) q.d. and paromomycin 15 mg/kg/day IM q.d. for 17 days
89433818|NCT05953194|Active Comparator|Control (neutral) messages|Participants will view control messages approximately matched to the intervention messages on length, but discussing a neutral topic unrelated to sugary drinks (safe driving). Participants will view a total of 4 messages developed for this arm.
89433819|NCT05953194|Experimental|Traditional health messages|Participants will view traditional health messages focused on the health consequences of sugar-sweetened beverage consumption, using text adapted from prior sugary drink campaigns. Participants will view a total of 4 messages developed for this arm.
89433820|NCT05953194|Experimental|Counter-marketing messages|Participants will view counter-marketing messages about sugary drinks that incorporate principles of effective counter-marketing campaigns, including describing industry manipulation of consumers, appealing to emotions (especially anger), describing health consequences, and criticizing the industry for demographic targeting. Messages include text adapted from prior counter-marketing campaigns. Participants will view a total of 4 messages developed for this arm.
89433821|NCT05953116|Active Comparator|Intervention Group|A protein product (combination of whey protein and plant-derived protein) in powdered form with flavoring. Product will be added to 180-200 mL of warm water prior to consumption.
89433822|NCT05953116|Placebo Comparator|Placebo Group|An isocaloric product (made with maltodextrin) in powdered form with flavoring. Product will be added to 180-200 mL of warm water prior to consumption.
89433823|NCT05952648|Experimental|Film-array Pneumonia Panel Plus group|Patients with suspected HAP or VAP in which lower tract respiratory samples are analyzed with new multiplex PCR assay (Film-array Pneumonia Panel Plus)
89433824|NCT05952648|Active Comparator|Standard culture group (control group)|Patients with suspected HAP or VAP in which lower tract respiratory samples are analyzed with standard culture
89433825|NCT05949814||HIV-negative men who have sex with men (MSM) and transgender persons|
89433826|NCT05948943|Experimental|Adult participants, alpelisib dose 1 (Stage 1)|Adult participants (≥18 years of age) who will receive dose 1 of alpelisib an open-label fashion for at least 24 weeks unless they discontinue earlier (Stage 1)
89009872|NCT04671316|Experimental|T2T1R|"Period I: T2, DA-5209 60mg with 150mL water Period II: T1, DA-5209 60mg without water Period III: R, Lixiana 60mg with 150mL water"
89009873|NCT04670614|Other|Nerve Block Procedure|Supra-orbital and Infra-orbital peripheral nerve blocks with 0.5% ropivicaine
89009874|NCT04670614|Sham Comparator|Placebo sham control|sham control 0.9% Normal Saline
89433827|NCT05948943|Experimental|Adult participants, alpelisib dose 2 (Stage 1)|Adult participants (≥18 years of age) who will receive dose 2 of alpelisib in an open-label fashion for at least 24 weeks unless they discontinue earlier (Stage 1).
88913963|NCT05147246|Experimental|Intervention Schools - School Staff|
89433828|NCT05948943|Experimental|Pediatric participants (6-17 years of age), alpelisib dose 2 (Stage 1)|Pediatric participants 6-17 years of age who will receive dose 2 of alpelisib in an open-label fashion for at least 24 weeks unless they discontinue earlier (Stage 1)
89433829|NCT05948943|Experimental|Pediatric participants (6-17 years of age), alpelisib dose 3 (Stage 1)|Pediatric participants 6-17 years of age who will receive dose 3 of alpelisib in an open-label fashion for at least 24 weeks unless they discontinue earlier (Stage 1).
89433830|NCT05948943|Experimental|Adult participants, alpelisib (Stage 2)|Adult participants (≥18 years of age) who will receive alpelisib at the dose selected for confirmatory phase in adult participants (Stage 2)
89433831|NCT05948943|Placebo Comparator|Adult participants, placebo (Stage 2)|Adult participants (≥18 years of age) who will receive matching placebo
89433832|NCT05948943|Experimental|Pediatric participants (6-17 years of age), alpelisib (Stage 2)|Pediatric participants (6-17 years of age) who will receive alpelisib at the dose selected for confirmatory phase in pediatric participants (Stage 2)
89536356|NCT03197857|Experimental|Bicycle training|"Physical condition will be evaluated in obese patients before surgery and 1, 4, 6, 12, 18 and 24 months after surgery.~Between 1 and 4 months after surgery, participants will be assigned to one of the postoperative care groups:~Control~Control + protein supplementation~Training in aquabike~Training in aquabike + protein supplementation~Bicycle training~Bicycle training + protein supplementation"
89536357|NCT03197857|Experimental|- Bicycle training + protein supplementation|"Physical condition will be evaluated in obese patients before surgery and 1, 4, 6, 12, 18 and 24 months after surgery.~Between 1 and 4 months after surgery, participants will be assigned to one of the postoperative care groups:~Control~Control + protein supplementation~Training in aquabike~Training in aquabike + protein supplementation~Bicycle training~Bicycle training + protein supplementation"
89536358|NCT03197311|Experimental|Mobile app group|In addition to receiving standard of care which includes prescription of postoperative narcotic and NSAID analgesics and usual postoperative instructions a customized mobile app will be downloaded to the participant's smartphone to application to monitor postoperative analgesic consumption, disposal and pain control and patient satisfaction for one week after surgery.
89536359|NCT03197311|No Intervention|Control group|The control group will receive the standard of care which includes prescription of postoperative narcotic and NSAID analgesics and usual postoperative instructions and a case report form will be used to gather data from the medical record and from a post op telephone survey a week after surgery..
89536360|NCT02480543|Active Comparator|PO Misoprostol|Cervical preparation with per-os (PO) Misoprostol 400 mcg 2-4 hours prior to curettage
89536361|NCT02480543|Active Comparator|PV Misoprostol|Cervical preparation with per-vagina (PV) Misoprostol 400 mcg 2-4 hours prior to curettage
89536362|NCT02480543|Active Comparator|Buccal Misoprostol|Cervical preparation with buccal Misoprostol 400 mcg 2-4 hours prior to curettage
89536363|NCT02447185|Experimental|Ranibizumab|"A week before 25-gauge vitrectomy, all subjects in Ranibizumab group will receive Ranibizumab 0.5mg/0.05 ml intravitreal injection.~During operation all subjects in this group will be injected Triamcinolone Acetonide 4 mg/0.1ml.~All subjects in this group will get Ranibizumab 0.2 mg/0.02 ml intravitreal injection just after the operation."
89536364|NCT02447185|Active Comparator|Triamcinolone Acetonide|"A week before 25-gauge vitrectomy, all subjects in Triamcinolone Acetonide group will receive Triamcinolone Acetonide 4mg/0.1 ml intravitreal injection.~During operation all subjects in this group will be injected Triamcinolone Acetonide 4 mg/0.1ml.~All subjects in this group will get Triamcinolone Acetonide 1mg/0.025 ml intravitreal injection just after the operation."
89536365|NCT05714813|Experimental|High-Speed Circuit Resistance Training Group|Participants in this group will receive high-speed circuit resistance training 3 times a week for 24 consecutive weeks for a total of 72 training sessions.
89536366|NCT05714813|Other|Control Group|Participants in this arm will receive two lectures on fitness, diet, or cognition each month for 24 weeks for a total of 12 lectures.
89536367|NCT05714735||Whole-brain venography|Cerevbral venography
89536368|NCT05714657|Experimental|Radiotherapy|"The volume treated to the regional lymphatics will be according to the characteristics of the primary site and involved lymph nodes. The dose of radiotherapy delivered will be 30 Gy, over the course of 10 treatments (5 daily treatments/week).~Treatment of the primary tumor bed will be omitted in appropriate patients, as per the initial TORS de-intensification protocol.1 In patients requiring treatment of the primary site, reduced dose (30 Gy) will be delivered."
89536369|NCT03118219|Experimental|Positive adjustment coping intervention|All persons allocated to the intervention group will receive daily text messages (SMS) to their smartphones with sentences for positive adjustment over two weeks starting from the day of the egg-cell punctuation.
89536370|NCT03118219|Other|Brainteaser|All persons allocated to the comparison intervention group will receive daily text messages (SMS) to their smartphones with brainteasers over two weeks starting from the day of the egg-cell punctuation.
89536371|NCT05714579|Experimental|severe aortic stenosis with complete right bundle branch block|patients with aortic stenosis undergoing a Transcatheter Aortic Valve Implantation procedure
89536372|NCT02449447|Experimental|Blended treatment|10 weeks of four face-to-face Cognitive behavioral therapy sessions and internet-based CBT as a complement and support to the four sessions.
89536373|NCT02449447|Active Comparator|Treatment as usual|Usual course of antidepressants and management in primary care (e.g medication and supportive counselling).
89536374|NCT03196921|Experimental|Symptomatic Cryptococcal Meningitis|CAMB (Encochleated Amphotericin B)
89536375|NCT03196921|Experimental|Asymptomatic Cryptococcal Antigenemia|CAMB (Encochleated Amphotericin B)
89536376|NCT02477735||Study group|Infants with COME who will be referred for TTI will undergo actigraphy for 7 consecutive nights prior to TTI and for 7 consecutive nights 4-6 weeks following TTI.
89536377|NCT02477735||Healthy infants|Healthy infants that were recruited from the community well-baby clinics.
89536378|NCT03208621||Observational group|The diagnostic tests to be investigated in this study is the use of PET and DLS in addition to the initial staging with gastroscopy and CT of patients with an advanced tumor (cT3-4)
89536379|NCT02480465|Experimental|Lobelitazone 0.5mg|Lobelitazone 0.5mg
89433833|NCT05948943|Placebo Comparator|Pediatric participants (6-17 years of age), placebo (Stage 2)|Pediatric participants (6-17 years of age) who will receive matching placebo
89433834|NCT05948943|Experimental|Pediatric participants (2-5 years of age), alpelisib (Stage 2)|Pediatric participants of 2-5 years who will dose 3 of alpelisib in an open-label fashion for at least 24 weeks unless they discontinue earlier
88913964|NCT05147246|Experimental|Intervention Schools - Parent-Child Pairs|
89197874|NCT02566928|Experimental|Decolonization and Decontamination|Index Patients will receive: 1) guidelines-directed care, which may consist of incision, drainage, oral antibiotics, and antibiogram-based antibiotic prescribing, and 2) a home-based intervention implemented by Community Health Workers/Promotoras that includes index patient and household member education and instructions to complete a decolonization and decontamination regimen, along with printed materials describing a standard hygiene protocol for reducing household contamination. Index patients and consenting household members will complete a decolonization regimen consisting of twice-daily application of 2% mupirocin ointment to the anterior nares with a clean cotton applicator for five days, as well as daily bathing with chlorhexidine wash for five days. The household decontamination hygiene protocol includes the use of hand-washing, surface disinfection, and laundering.
89433835|NCT05948930|Experimental|Aerobic Exercise|Progressive aerobic exercise 3x/week for 12 weeks.
89433836|NCT05948930|Experimental|Cognitive Training|Adaptive cognitive training on Cogmed 5x/week for a total of 25 sessions in 5-8 weeks.
88913965|NCT05147246|No Intervention|Wait-List Control Schools - School Staff|
88913966|NCT05147246|No Intervention|Wait-List Control Schools - Parent-Child Pairs|
88913967|NCT05145036|Active Comparator|Tai Chi exercise|In addition to standard of care participants will be asked to apply Tai Chi. There are 8 movements. Each session consisted of 10 minutes of warm-up, 40 minutes of Tai Chi, and 10 minutes of cool down. The 8 movements are: Ward-off, Rollback, Push, Press, Grab, Split, Elbow strike, and shoulder strike.
88913968|NCT05145036|Active Comparator|Comprehensive training|In addition to standard of care participants will be asked to apply Comprehensive training. There are 3 exercises. Each session consisted of 10 minutes of warm-up, 40 minutes of Tai Chi, and 10 minutes of cool down. The 8 movements are: stretch exercise, strengthening exercise, and balance exercise.
88913969|NCT05127954|Experimental|Ubrogepant Dose A (12 to 17 Years Old)|Participants will receive oral tablets of ubrogepant Dose A for qualifying migraine attack. Participants have the option to take a second dose of ubrogepant or rescue medication, 2 to 24 hours after initial dose for headache of any intensity.
88913970|NCT05127954|Experimental|Ubrogepant Dose B (6 to 11 Years Old)|Participants will receive the highest dose of oral tablets of ubrogepant tested in Study 3110-305-002 for qualifying migraine attack. Participants have the option to take a second dose of ubrogepant or rescue medication, 2 to 24 hours after initial dose for headache of any intensity.
88913971|NCT05111964|Experimental|HIFU Treatment of STS or Intra-abdominal Desmoid Tumour|All participants receive HIFU to their target tumour, hence this is a single arm study with 4 recruitment pathways.
88913972|NCT05082831|Active Comparator|microfracture surgery + HST003|This is an Intervention Model where all patients who are identified/confirmed candidates for microfracture surgery will be enrolled to receive the microfracture surgery (standard of care). Ten (10) patients will be randomized to receive the study intervention (HST003). HST003 will be injected into the microfracture defects (interstices) and fill the remainder of the defect to the cartilage margin following surgery.
88913973|NCT05082831|No Intervention|microfracture surgery only|This is an Intervention Model where all patients who are identified/confirmed candidates for microfracture surgery will be enrolled to receive the microfracture surgery (standard of care). Ten (10) patients will be randomized to receive the microfracture surgery (standard of care).
88913974|NCT05071820|Experimental|Mobile application program|
88913975|NCT05071820|Active Comparator|Traditional program|
88913976|NCT05062265|Active Comparator|Tight Rope Fixation|
88913977|NCT05062265|Active Comparator|tight rope fixation w/ AITFL repair augmentation with an internal brace|
89433837|NCT05948930|Experimental|Combined Cognitive and Aerobic Exercise|Combined progressive aerobic exercise 3x/week for 12 weeks and adaptive cognitive training on Cogmed 5x/week for a total of 25 sessions in 5-8 weeks simultaneously.
89433838|NCT05948865|Experimental|Part A, Dose Escalation|Participants receive escalating doses of CPO301 of 0.6 mg/kg, 1.8mg/kg, 3.6 mg/kg, 4.8 mg/kg, 6.4 mg/kg and 8 mg/kg administered by IVI every 3 weeks (Q3W), with 21 days as a treatment cycle.
89433839|NCT05948865|Experimental|Part B, Dose Expansion|Participants receive CPO301 at the recommended phase 2 dose (RP2D) determined in Part A, administered by IVI every 3 weeks (Q3W), with 21 days as a treatment cycle.
89433840|NCT05948605|Active Comparator|Active Treatment|The Active Treatment will use a functional Stimulator system.
89433841|NCT05948605|Sham Comparator|Sham Treatment|The Sham Treatment (Placebo) will use a functional Stimulator system, but will provide a treatment in a location that is believed to have no benefit or harm to the subject.
89433842|NCT05947305|Placebo Comparator|Surgical Blade|A surgical blade will be used to de-epithelialize gum tissue during the subject's regularly scheduled dental surgery.
89433843|NCT05947305|Experimental|Mucotome|A mucotome will be used to de-epithelialize gum tissue during the subject's regularly scheduled dental surgery.
89433844|NCT05947305|Experimental|Diamond Bur|A diamond bur will be used to de-epithelialize gum tissue during the subject's regularly scheduled dental surgery.
89433845|NCT05947305|Experimental|Er:YAG Laser|A dental laser will be used to de-epithelialize gum tissue during the subject's regularly scheduled dental surgery.
89433846|NCT05947084|Experimental|Study Formula 1_365 Day Grass-Fed Cow's Milk Infant Formula|Infant formula meets all nutrient requirements of the FDA.
89433847|NCT05947084|Experimental|Study Formula 2_Goat Milk Infant Formula|Infant Formula meets all nutrient requirements of the FDA.
89433848|NCT05947084|Experimental|Study Formula 3_Cow's Milk Infant Formula void of A1-BetaCasein|Infant Formula meets all nutrient requirements of the FDA.
89433849|NCT05947084|Active Comparator|Study Formula 4_USDA Organic iron fortified infant formula|Infant Formula meets all nutrient requirements of the FDA.
89433850|NCT05946044|No Intervention|Attention Control|This comparison group provides attention, social interaction, and healthy lifestyle classes. There will be 4, 1-hour face-to-face group meetings per year featuring community health professionals, quarterly newsletters, and quarterly text messages.
89433851|NCT05946044|Experimental|Diet and Exercise|The dietary component of the weight loss intervention is characterized by the frequency of contacts, methods to induce dietary restriction, and behavioral therapy strategies. The first 6 months of the diet program is an energy-restricted diet with the option of using partial meal replacements and nutritious snacks (Rapid Nutrition, PLC). The weight loss goal for the diet and exercise group is a minimum of 10% of baseline body weight by the end of year 1. The weight loss phase is followed by 3 years of a weight-loss maintenance program, with the goal of sustaining the achieved weight loss. The exercise component includes 60-minute sessions 2 days per week for 48 months.
89433852|NCT05945355|Experimental|Active Low Dose inspiratory muscle rehabilitation (IMR) group|Each participant will be provided a PrO2™ device and trained on its use as well as its accompanying PrO2 Fit™ app. Participants will be instructed to inspire forcefully through PrO2™ until the device signals that the user has achieved the target resistance (via audible alarm and visible light signal). The research team will implement biofeedback signals at a specific inspiratory resistance to provide precise and individualized training target. Successful IMR repetitions will require that subjects achieve a pressure target that is 40% of their MIP (maximum inspiratory pressure).
88913978|NCT05017337||BASILICA-A|"Breast implant associated anaplastic large cell lymphoma (BIA-ALCL) patients recruited both retrospectively and prospectively.~Pre- and post-operative (3m and 12m) blood samples taken from prospectively recruited patients. Patients undergoing surgery + neo-adjuvant chemotherapy will be invited to donate an additional blood sample following the end of their neo-adjuvant chemotherapy.~Diagnostic pathology: Where possible fresh seroma aspirate / capsular tissue will be obtained, if not possible the FFPE embedded seroma or tissue block will be requested.~Post-operative pathological FFPE tissue samples obtained from all recruited patients."
88913979|NCT05017337||BASILICA-C|"Patients undergoing capsule related surgery (any-grade of capsular contracture, irradiated and unirradiated capsules) recruited prospectively.~Pre- and post-operative (3m) blood samples taken from all patients. Intra-operative tissue sampling (capsular washings, 2 samples of ADM and 2 samples of non-ADM capsule) from all patients."
88913980|NCT05017337||BASILICA-N|"Implant naive patients undergoing implant insertion surgery recruited prospectively.~Pre- and post-operative (3m and 12 m) blood samples taken from all patients."
88913981|NCT05012904|Experimental|Parent involvement Group|A parent was involved in the procedure. The parent held the children in their arms and holding the extremity from which the blood was drawn, holding the hands of children and communicating with their children in the child's room, and in this way the parent was involved in the procedure.
88913982|NCT05012904|No Intervention|Control Group|Routine venipuncture procedure was applied to the control group. The parent was present in the child's room but did not participate in the procedure.
88913983|NCT04997395|Experimental|MediCabilis Cannabis sativa 50|"The medicinal cannabis used for this study is MediCabilis Cannabis sativa 50, a full spectrum CBD dominant plant based medicinal cannabis containing 50 mg/ml CBD and 2 mg/ml THC.~On commencing the oral medication, it will be titrated over a 2 week period to a dose of 1 ml twice a day (total dose 2 ml = 100 mg CBD and 4 mg THC). Participants will be given a written titration schedule at the initial clinic visit. There will be the potential for a further dose increase to a total dose of 3 ml per day (150 mg CBD and 6 mg THC) at the 1-month follow-up visit."
88913984|NCT04997161|Experimental|SZC arm with enhanced dietary advice|Participants will continue taking Sodium Zirconium Cyclosilicate (SZC), which can be titrated up or down to maintain S-K+ in the range 3.5-5.5 mmol/L; participants will also receive enhanced nutritional advice to consume fruit and vegetables. Advice will be provided by dietitians at study visits and by Noom app between visits.
88913985|NCT04997161|Other|SoC arm with standard dietary advice|SZC will be withdrawn and participants will receive SoC as per site practice, including dietary K+ restriction. Dietary advice will be given by dietitians at study visits and by Noom app between study visits.
89536380|NCT02480465|Active Comparator|Sitagliptin 100mg|Sitagliptin 100mg
88913990|NCT04956016|Active Comparator|classic rTMS treatment|Arm A: classic rTMS treatment (use of the 8-shaped coil) and standard therapy
88913991|NCT04956016|Active Comparator|treatment with deep rTMS|Arm B: treatment with deep rTMS (use of the H1-shaped coil (helmet)) and standard therapies
88913992|NCT04938609|Experimental|Pembrolizumab + SBRT + Surgery|Pembrolizumab administration (3 dose) every 3 weeks and 1 dose before radiation (5 days) therapy followed by an additional administration of Pembrolizumab (2 doses) prior to restaging and surgical resection followed by risk-adapted adjuvant therapy, per standard of care. Patient will then be treated with adjuvant pembrolizumab every 3 weeks for 14 additional doses (17 doses total)
88913993|NCT04935411||nAMD patients|patients diagnosed with Neovascular Age-Related Macular Degeneration
88913994|NCT04934007|Experimental|Active stimulation|Active rTMS stimulation , 2 session per day during 10 days.
89433853|NCT05945355|Experimental|Active High Dose inspiratory muscle rehabilitation (IMR) group|Each participant will be provided a PrO2™ device and trained on its use as well as its accompanying PrO2 Fit™ app. Participants will be instructed to inspire forcefully through PrO2™ until the device signals that the user has achieved the target resistance (via audible alarm and visible light signal). The research team will implement biofeedback signals at a specific inspiratory resistance to provide precise and individualized training target. Successful IMR repetitions will require that subjects achieve a pressure target that is 75% of their MIP (maximum inspiratory pressure).
88913995|NCT04934007|Sham Comparator|Sham Stimulation|Sham rTMS stimulation , 2 session per day during 10 days.
88913996|NCT04917419|Experimental|Luminotherapy and Psychoeducation Program|
88913997|NCT04917419|Active Comparator|Psychoeducation Program|
88913998|NCT04898062|Active Comparator|CRP-apheresis|Patients randomized to this group will undergo apheresis treatments with treatments every 24 ± 12 h each lasting 4-7 hours, until the CRP value does not rise to ≥ 30 mg/l within 96 h after the last treatment
88913999|NCT04898062|No Intervention|Control|Patients randomized to this group will not undergo a apheresis treatments. They will be treated according to the current conventional treatment concept for covid-19 disease
88914000|NCT04891354|Experimental|Part I: single ascending dose (SAD)|In Part I, each subject will receive a 30 minute i.v. infusion of placebo followed by a 1-hour i.v. infusion of PDNO in parallel with a carrier sodium bicarbonate buffer, the infusion of which will start 5 minutes prior to start of placebo infusion and continue until 15 minutes after end of PDNO infusion. Between the end of placebo infusion and prior to the start of PDNO infusion, there will be a 20-minute stabilisation period with infusion of sodium bicarbonate buffer only.
88914001|NCT04891354|Experimental|Part II: ascending doses of PDNO|In Part II, each subject will receive a 30 minute i.v. infusion of placebo followed by 2 x 30 minute infusions of PDNO at 2 ascending dose levels and one 3-hour infusion of PDNO at a third dose level.
89536381|NCT02446951||ED Jaundice Patients|Patients presenting to the ED in either the implementation period or pre-implementation period.
89197875|NCT02566928|No Intervention|Usual Care|Index Patients will receive: 1) guidelines-directed care, which may consist of incision, drainage, and oral antibiotics, as well as antibiogram-based antibiotic prescribing, and 2) printed materials describing a standard hygiene protocol for reducing household contamination.
89433854|NCT05945355|Active Comparator|SHAM|Each participant will be provided a PrO2™ device and trained on its use as well as its accompanying PrO2 Fit™ app. Participants will be instructed to inspire forcefully through PrO2™ until the device signals that the user has achieved the target resistance (via audible alarm and visible light signal). The research team will implement biofeedback signals at a specific inspiratory resistance to provide precise and individualized training target. Successful IMR repetitions will require that subjects achieve a pressure target that is 15% of their MIP (maximum inspiratory pressure).
89009875|NCT04670692|Experimental|5G-MCE examination|There will be 20 volunteers assigned to the 5G-MCE system group. These patients will accept the magnetically controlled capsule examination in Yinchuan. After an overnight fasting and drinking 800-1000 mL water and simethicone for gastric dilatation and preparation, the subjects put on the data recorder with the help of the assistant in Yinchuan. Then, the assistant activated the capsule with the capsule locator. The patient is instructed to swallow the capsule with a small amount of water to effectively observe the esophagus and dentate line. After the capsule entering into the stomach, the examination will be performed through the 5G-MCE system by the endoscopist (W.Z.), with experience of more than 1000 cases of MCE operation, in Shanghai.
89536382|NCT03208465|Experimental|Patients with Empagliflozin|
89009876|NCT04670692|Active Comparator|MCE examination|There will be 20 volunteers assigned to the MCE system group as comparator group. After an overnight fasting and drinking 800-1000 mL water and simethicone for gastric dilatation and preparation, the subjects put on the data recorder with the help of the endoscopist. Then, the endoscopist activated the capsule with the capsule locator. The patient is instructed to assume the left lateral decubitus position and to swallow the capsule with a small amount of water to effectively observe the esophagus and dentate line. Then, under the guidance of the endoscopist (W.Z.) face to face, subject continue the examination of stomach and duodenum.
89009877|NCT04670809|Experimental|Clevidipine Butyrate Injection|
89009878|NCT04670809|Active Comparator|Ncardipine Hydrochloride Injection|
89009879|NCT04670575||Vivity|Patients implanted with Vivity or Vivity Toric intraocular lens at the time of cataract surgery.
89009880|NCT04670341|Experimental|chewing tapioca pearls in the bubble tea drinks|In the first week, the subjects drink as much as 100 ml of bubble tea over a span of 5 minutes once a day for 3 days
89009881|NCT04670341|Placebo Comparator|drink tea without chewing tapioca pearls|In the second week, the subjects drink tea without tapioca pearls as much as 100 ml for 5 minutes per day for 3 days.
89009882|NCT00267735|No Intervention|Module 1 Only|
89009883|NCT00267735|Experimental|Modules 1, 2, and 3|
89009884|NCT00233714|Active Comparator|1|Single-dose Sirolimus-Eluting Coronary stent
89009885|NCT00233714|Active Comparator|2|Double-dose Sirolimus-Eluting Coronary stent
89009886|NCT04670497|Active Comparator|ultrasound guided lumbar plexus block|patients were recieved lumbar plexus block ultrasound guided by shamrock technique using 0.5% bupavacaine in a dose 0.3ml/kg
89009887|NCT04670497|Active Comparator|ultrasound guided Fascia iliaca block|patients were received fascia iliaca block ultrasound guided using 0.5% bupoavacaine in a dose 0.3ml\kg
89197876|NCT00865605|Experimental|A|Halobetasol Propionate 0.05% Ointment, single exposure
89197877|NCT00865605|Active Comparator|B|Ultravate® 0.05% ointment, single exposure
89197878|NCT00756756|Experimental|1|post MI post PCI and G-CSF infusion
89197879|NCT00756756|Placebo Comparator|2|post MI and post PCI only placebo infused
89433855|NCT05945199|Experimental|tDCS active|
89433856|NCT05945199|Placebo Comparator|Sham tDCS|
89433857|NCT05945043||Symptomatic pleural effuion|Patients with symptomatic unilateral pleural effusion of any cause who will be undergoing pleural fluid removal via thoracocentesis, chest drain insertion or IPC drainage for relief of their breathlessness.
89433858|NCT05942794|Experimental|Screening examination|All patients will undergo a screening examination (with or without GOCCLES ® glasses) by all three operators.
89433859|NCT05942274|Experimental|Screen group|This is a single-center, non-randomized open study with a single-patient clinical trial design (i.e., the patients serve as their own control).
89433860|NCT05941793|Experimental|Cohort 1|low dosage of IP
89433861|NCT05941793|Experimental|Cohort 2|high dosage of IP
89433862|NCT05941793|Placebo Comparator|Cohort 3|Placebo
89433863|NCT05941767|Active Comparator|Dexmedetomidine nebulization|The patient will receive nebulized dexmedetomidine via face mask nebulizer (1mcg/kg) 20 minutes before induction.
89433864|NCT05941767|Active Comparator|Lidocaine Nebulization|The patient will receive nebulized lidocaine 4% (3 mg /kg) added to 2 ml normal saline 0.9% 10 minutes before induction of general anesthesia.
89197880|NCT02565056|Active Comparator|Self-help|Self-help book completed over 6 weeks with up to 30 minutes of telephone support per week.
89197881|NCT02565056|No Intervention|Treatment as usual|Treatment as usual.
89197882|NCT00865683|Active Comparator|1|Participants will receive DHA supplements.
89197883|NCT00865683|Placebo Comparator|2|Participants will receive placebo capsules of corn oil.
88914002|NCT04885491|Experimental|Treatment with PDNO|"Placebo treatment administered during the 120-minute observation period, followed by PDNO infusion. PDNO administered as an i.v. infusion of 5-15 minutes, respectively, for the increased planned dose titration steps: 3, 10 and thereafter steps of max 10 nmol/kg/min until the target effect on the mean pulmonary arterial pressure/pulmonary vascular resistance (MPAP/PVR) or a maximal dose of 120 nmol/kg/min is reached.~After 4 patients have been treated, the internal safety review committee (iSRC) will decide if the start dose will be increased. The new start dose could be in the interval 1 to 5 nmol/kg/min."
89197884|NCT00953446|Experimental|Arterial Spin Labeling Blood Flow Magnetic Resonance Imaging|"ASL MRI~Performed at baseline, 2 weeks upon initiation of therapy, after cycle 2 and/or cycle 4 of therapy, and at the end of treatment"
89536383|NCT03208465|Active Comparator|Patients with Sitagliptin|
89197885|NCT02560818|Active Comparator|Control population : Healthy Volunteers|"20 Healthy Volunteers will be recruited:~10 women to recover breast tissue (from surgical waste) : populations A and C~10 women to recover ovarian tissue (from surgical waste) : population B"
89197886|NCT02560818|Experimental|Patients|blood samples of 50 patients will be used (use of blood collection in study EXSAL N°ID-RCB 2009-A00833-54)
89197887|NCT03058250|No Intervention|Control|Standard of care, no intervention
89197888|NCT03058250|Active Comparator|Transesophageal echocardiography|Patients will have intraoperative transesophageal echocardiography along with standard of care for management.
88914003|NCT04873557|Experimental|Copper Intervention|Intervention with copper-based surfaces plus copper-enriched linen
88914004|NCT04873557|No Intervention|Control Group|Control group without copper intervention
89536384|NCT03196999|Active Comparator|Personalized Attention Bias Training|Personalized version of ABM Training.
88914005|NCT04866511|Experimental|NET intervention|This study will follow a single case design and will involve delivering and evaluating the child-friendly protocol of NET. Therefore, there will only be one arm (NET intervention) and no comparators.
88914006|NCT04830995|Experimental|diet program|moderate restricted diet (1800-2000 kcal/day) for four weeks, 3 sessions weekly
88914007|NCT04830995|Experimental|high intensity interval training|high intensity interval training for four weeks, 3 sessions weekly
88914008|NCT04812457|Experimental|Physiological cures using pure hyaluronic acid (Hialucic®)|After the intervention of unilateral onychocryptosis, the partial matricectomy technique with phenol / alcohol,next to an ointment with hyaluronic acid (hyalucic ®) will be used together with a non-stick dressing and a semi-compression bandage to prevent bleeding
88914009|NCT04812457|Active Comparator|Control group using traditional cure (Betadine Gel).|After the intervention of unilateral onychocryptosis, the partial matricectomy technique with phenol / alcohol,next to Povidone Iodine Gel (Betadine Gel®) will be applied following the same procedure.
89197889|NCT00956644|Experimental|irbesartan/amlodipine|Before randomisation : amlodipine 5 mg for 7 to 10 days (common to 2 arms) then After randomisation : irbesartan/amlodipine 150/5 mg fixed combination for 5 weeks followed by irbesartan/amlodipine 150/10 mg fixed combination for 5 additional weeks
89197890|NCT00956644|Active Comparator|amlodipine|Before randomisation : amlodipine 5 mg for 7 to 10 days (common to 2 arms) then After randomisation : amlodipine 5 mg for 5 weeks followed by amlodipine 10 mg for 5 additional weeks
89197891|NCT00756834||Mammography Image Collection|Acquired images
89197892|NCT00756834||CAD Radiologist Reader|Retrospective reader study
89197893|NCT00858663|Experimental|Chemoradiation|"IMRT, 1 fraction/day, over approximately 33 treatment days~RAD001 per oral or PEG, per dose escalation scheme (Days 1 - 42)~Cisplatin IV weekly, per dose escalation scheme (Days 1, 8, 15, 22, 29, 36)"
89197894|NCT02544789|Experimental|clofarabine|Clofarabine (Betta Pharmaceuticals Co., Ltd, Zhejiang, China) was administered intravenously at 52 mg/m2 over 2 hours daily for 5 consecutive days. During the first two induction cycles, patients who did not achieve an objective response were taken off the study, and responsive patients continued to receive consolidation for a maximum 11 cycles if non-hematological toxicity was grade 2 or less.
89197895|NCT00956722|Experimental|Treatment|Active treatment with Bovine colostrum
88914010|NCT04789616|Experimental|Maraviroc (Celsentri)|Maraviroc (Celsentri) will be administered to this group. Participants will be administered a dose of 300mg to be taken twice per day for the duration of the exercise intervention (8 weeks).
89197896|NCT00858741|Experimental|8 Gy arm|8.0 Gy in 1 fraction to 8.0 Gy total dose.
89197897|NCT00858741|Active Comparator|30 Gy arm|3.0 Gy x 10 fractions to 30.0 Gy total dose in two weeks.
89197898|NCT04985864|Experimental|Robot gait training with brain stimulation|Lokomat robot training and anodal transcranial direct current stimulation (tDCS) on the leg motor areas
89197899|NCT04985864|Active Comparator|Gait training with sham brain stimulation|Treadmill gait training and anodal sham transcranial direct current stimulation (tDCS) on the leg motor areas
89536385|NCT03196999|Placebo Comparator|Neutral Attention Training Condition|Non-active version of ABM training.
89536386|NCT03196999|Active Comparator|Non-Personalized Attention Bias Training|Non-personalized version of ABM training.
89536387|NCT05714423|Active Comparator|Mini-PCNL Group|In this group kidney stones will be treated with Mini-PCNL Surgery
89536388|NCT05714423|Active Comparator|RIRS Group|In this group kidney stones will be treated with Retrograde Intrarenal Surgery.
89433865|NCT05941767|Active Comparator|Dexmedetomidine IV|The patient will receive an intravenous infusion of dexmedetomidine (1 ml= 4 mcg) via a syringe pump and will be started at a dose of 1 mcg/kg 20 minutes before induction of general anesthesia.
88914011|NCT04789616|Placebo Comparator|Placebo|"An over-encapsulated placebo, or sugar pill (so it appears identical to the trial drug) will be administered to this group. Participants will be administered the placebo identical to the 300mg maraviroc tablet for the duration of the exercise intervention (8 weeks)."
89433866|NCT05941767|Active Comparator|Lidocaine IV|The patient will receive 1.5mg/kg intravenous lidocaine 2% completed to 10 ml with normal saline 0.9% intravenous 90 seconds before induction of general anesthesia.
89433867|NCT05940090||Comparison of outlier analysis with dermatologist made biopsy decisions|Skin lesions recommended for skin biopsy by the dermatologist will be compared to lesions highlighted by the application outlier analysis.
89433868|NCT05938946|Experimental|L608 Liposomal inhalation solution|Eight subjects will be enrolled in each cohort and be randomized to receive assigned dose of L608 or placebo (6:2).
89197900|NCT00858819||AS|Patients with AS attending three different rheumatology clinics in Western Sweden have been invited to participate.
89197901|NCT00956800|Experimental|telemedicine/study group|
89197902|NCT00956800|Active Comparator|control group|
89197903|NCT02565836||fixed-dose aPCC|Patients receiving fixed-dose activated prothrombin complex concentrate (FEIBA VH) for reversal of warfarin-associated major hemorrhage.
89197904|NCT02565836||variable-dose PCC|Patients receiving vairable-dose inactivated prothrombin complex concentrate (Kcentra) for reversal of warfarin-associated major hemorrhage.
88914012|NCT04765280||Patients with chronic musculoskeletal pain|Patients with any musculoskeletal pain for at least 3 months
89197905|NCT00865761|Experimental|A|Alprazolam 3 mg Extended Release Tablets, single dose
88914013|NCT04753216|Experimental|Treatment (bevacizumab, irinotecan sucrosofate)|Patients receive bevacizumab IV and irinotecan sucrosofate IV over 90 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88914014|NCT04714619|Experimental|CB-103 + NSAI therapy|Hormone Receptor (HR)-positive and HER2-negative advanced breast cancer, including metastatic (ABC).Approximately 80 patients
88914015|NCT04689945||Morphine|30 patients who received intravenous morphine intraoperatively, without regional block application
88914016|NCT04689945||Erector Spinae Block|30 patients who had preoperative esp block but did not use morphine during or after surgery
88914017|NCT04689945||Control|30 patients who received multimodal analgesia methods other than ESP block or IV morphine
88914018|NCT04643366|Experimental|Concurrent Chemotherapy/ Radiation Therapy|5-Fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) four 14-day cycles will be given before CRT starts. Pelvic Intensity-modulated radiation therapy (IMRT): 25 Gy in 5 fractions over 5 days + Continuous infusion 5-fluorouracil (5-FU) for 4 days (96 hours) followed by four 14-day cycles of (mFOLFOX6) to be given after CRT ends.
88914019|NCT04642625||wound infiltration analgesia|25 patients who underwent wound infiltration analgesia
88914020|NCT04642625||ultrasound-guided bilateral erector spina plan block analgesia|25 patients who underwent ultrasound-guided bilateral erector spina plan block analgesia
88914021|NCT04642625||wound infiltration and ultrasound-guided bilateral erector spina plan block analgesia both together|25 patients who underwent wound infiltration and ultrasound-guided bilateral erector spina plan block analgesia
88914022|NCT04600154|Experimental|MS-20|4ml, twice, daily
88914023|NCT04600154|Placebo Comparator|Placebo|4ml, twice, daily
89197906|NCT00865761|Active Comparator|B|XANAX XR® 3 mg tablets, single dose
89197907|NCT00953758|Experimental|1|
89197908|NCT00947908|Experimental|A|Patients are treated with hymenoptera (bee or wasp) venom using subcutaneous injections. The initiation of immune therapy consists of a 52-hour-period in which patients are treated with increasing doses of hymenoptera venom. Afterwards, patients are treated with monthly subcutaneous injections with a fixed dose of hymenoptera venom. Blood will be collected directly before and 1 hour after initiation of immune therapy and after 12 months of immune therapy (directly before the next subcutaneous injection of hymenoptera venom).
89197909|NCT00865839|Experimental|A|Metformin HCl 500 mg tablets, single dose
89433869|NCT05938946|Experimental|Placebo|Eight subjects will be enrolled in each cohort and be randomized to receive assigned dose of L608 or placebo (6:2).
89197910|NCT00865839|Active Comparator|B|CLUCOPHAGE® XR 500 mg tablets, single dose
89433870|NCT05936138|Experimental|LY3502970 (Control)|LY3502970 administered orally to participants with normal renal function
89433871|NCT05936138|Experimental|LY3502970 (Severe Renal Impairment)|LY3502970 administered orally to participants with severe renal impairment
89433872|NCT05936138|Experimental|LY3502970 (End-Stage Renal Disease)|LY3502970 administered orally to participants with end-stage renal disease (ESRD)
88914024|NCT04584827||complication positive (up to 30 days after surgery)|"Complications:~Moderate to severe intracerebral hemorrhage confirmed in a brain CT scan (Midline shift in brain imaging ≥ 3 mm),~İntracranial hypertension requiring post op surgical drainage,~Status epilepticus or seizures,~The need for tracheal intubation or use of mechanical ventilation after surgery,~Decrease in GKS,~Unmanageable agitation that requires restriction or sedation,~Need for respiratory failure and oxygen therapy,~Unexpected serious motor deficit~Died"
88914025|NCT04584827||complication negative (up to 30 days after surgery)|No complications are seen within 30 days and the patient is healthy
88914026|NCT04582045||low risk, silver impregnated|low risk, silver impregnated
88914027|NCT04582045||low risk, border bandage|low risk, border bandage
88914028|NCT04582045||high-risk, silver impregnated|high-risk, silver impregnated
88914029|NCT04582045||high-risk, wound vacuum|high-risk, wound vacuum
88914030|NCT04563494|Active Comparator|IV Dexmethsone and oral placebo|
88914031|NCT04563494|Active Comparator|Oral dexamethasone and IV placebo|
88914032|NCT04542343|Experimental|Risk Reduction of COVID-19 Among African American Parishioners|"This arm will implement one group pretest-posttest design to improve COVID associated health outcomes of AA older parishioners in collaboration with trained young church-based health educators."
88914033|NCT04539795|Placebo Comparator|Placebo oral tablet|placebo
88914034|NCT04539795|Active Comparator|Alvelestat oral tablet - dose 1|MPH966
88914035|NCT04539795|Active Comparator|Alvelestat oral tablet - dose 2|MPH966
88914036|NCT04539795|Active Comparator|Alvelestat oral tablet - dose 3|MPH966
88914037|NCT04530747|Experimental|Metformin + PAP|"Subjects randomized to this arm will be orally given 2000 mg metformin daily. Metformin dosage will be slowly increased to improve tolerance.~Subjects will also be provided PAP (positive airway pressure) device for standard management of obstructive sleep apnea."
88914038|NCT04530747|Placebo Comparator|Placebo oral capsule + PAP|Subjects randomized to this arm will receive placebo matching study drug. Subjects will also be provided PAP (positive airway pressure) device for standard management of obstructive sleep apnea.
88914039|NCT04483440|Experimental|4D-110 Dose 1|4D-110 IVT injection
88914040|NCT04483440|Experimental|4D-110 Dose 2|4D-110 IVT injection
88914041|NCT04456296|Active Comparator|AVEED (Testosterone Undecanoate Injection)|Fixed dosage level of 750 milligrams (mg)/3 milliliters (mL) administered by intramuscular injections.
88914042|NCT04456296|Active Comparator|FORTESTA (Testosterone Gel)|40 mg once daily topical gel administration.
88914043|NCT04456296|Active Comparator|TESTIM (Testosterone Gel)|50 mg once daily topical gel administration.
89433873|NCT05929898|Experimental|Intentional Versus Cue-Evoked Midbrain Activation|Participants meeting study inclusion will be scheduled for two sessions: one baseline behavioral visit and an fMRI session to assess the ability to self-stimulate VTA activation. Session one will include a battery of cognitive assessments and a demonstration of the reward-based learning task in session two. The experimental imaging task session will be done within one week of session one. Participants will been randomly split into two group: group one will complete a reward-based learning task before the VTA activation task and group two will complete reward task after VTA activation. During the VTA activation task, participants will be instructed to achieve a heightened state of motivation using personally relevant thoughts and imagery.
88914044|NCT04429165||ACL reconstruction|ACL reconstruction using an autologous hamstring tendon
89433874|NCT05929898|Experimental|Intentional Midbrain Activation Effects on Effort-Based Decision Making|Participants will be randomly assigned to an MRI group or a behavioral control group. All participants will complete an effort-based learning task and a series of questionnaires in session one. Session two may include an MRI based on group assignment. Participants in the MRI group will complete the VTA activation task. Following, they will complete the effort task and questionnaires a second time. The behavioral control group will complete a second session consisting of the effort task and questionnaires.
89433875|NCT05929898|Experimental|Intentional Midbrain Activation Effects on Motivated Memory|Participants will take part in four sessions: visit 1-baseline + memory encoding, visit 2-memory retrieval, visit 3-memory encoding, visit 4-memory retrieval). Encoding and retrieval of the memoranda will occur 24 hours apart. Study visits will take place no more than 7 days apart. One group of participants will complete all sessions at the Center for Cognitive Neuroscience. The remainder of participants will complete the encoding sessions in the MRI machine, .
88914045|NCT04429165||control group|knee-healthy, age-matched subjects as a control group
88914046|NCT04412837|Experimental|CBD Patch|Topical CBD patch to be worn for 24 hours and changed daily for the course of 4 weeks.
88914047|NCT04412837|Placebo Comparator|Control Patch|Control placebo patch to be worn for 24 hours and changed daily for the course of 4 weeks.
89433876|NCT05929196|Experimental|Blood sample donator|The participant donates approximately 5 ml of blood sample.
89433877|NCT05928728|Experimental|Colchicine|
88914048|NCT04403321|Placebo Comparator|Eltrombopag|Eltrombopag and the placebo would be applied. Eltrombopag will be started at 25 mg/day and increased by 25 mg/day every 2 weeks according to the platelet count up to 150 mg/day, or the best response was achieved.
88914049|NCT04403321|Experimental|Eltrombopag + Tacrolimus|Eltrombopag and tacrolimus would be applied. Eltrombopag will be started at 25 mg/day and increased by 25 mg/day every 2 weeks according to the platelet count up to 150 mg/day, or the best response was achieved. Tacrolimus will be given at 1mg bid with the target trough concentration of 4-10 ng/mL throughout the study.
88914050|NCT04300400||Delphi panel|Urologists of the Belgian Working group of Functional Urology willing to participate on the Delphi project.
88914051|NCT04265755|Experimental|Single arm|Erenumab packed in a SureClick® Autoinjector Pen (AI)
88914052|NCT04260984|Active Comparator|palpation-guided injection|Injectate: a mixture of 10mg triamcinolone acetonide (10mg/1ml) and 0.3ml 1% lidocaine. For palpation-guided injection, a 2.5cm 25-gauge needle will be inserted almost horizontally between APL and EPB tendons, just distal to the radial styloid, at the site of maximum tenderness. Then the mixture of triamcinolone and lidocaine will be pushed into the common tendon sheath.
89433878|NCT05928728|Placebo Comparator|Placebo|
89433879|NCT05926557|Experimental|Spermidine Group|Mechanical therapy (NSMD) will be performed by means of an ultrasonic scaler with a plastic tip. Finally, the spermidine-based gel will be applied in the peri-implant sulcus using a blunt-tipped needle.
89009888|NCT04670302|Active Comparator|Control group (Tendon repair)|The control group will undergo tendon repair procedure only (without augmentation)
89009889|NCT04670302|Experimental|Experimental group (Tendon repair augmented with AAdMSC-HAM composite)|The experimental group will undergo tendon repair procedure augmented with AAdMSC-HAM composite
88914053|NCT04260984|Active Comparator|US-guided injection|For US-guided injection, a 22 MHZ linear array probe (Esaote MyLab™ClassC, Italy) will be used for guidance of injection via a transverse scan, in-plane approach. After sterilization, the probe will be placed at the radial styloid with maximal swelling or tenderness. Then a 2.5 cm 25-gauge needle will be placed into the tendon sheath via transverse scan, in-the-plane approach, and the injectate will be pushed into the tendon sheath. Care will be taken avoiding injury of vessels and the superficial branch of radial nerve during the injection.
88914054|NCT04246320|Experimental|Intervention|Patients monitored and receiving a standard anesthesia plan in addition of a goal directed therapy (GDT) hemodynamic management (MAP > 60 mmHg) and processed EEG-guided anesthesia (PSI targeted between 30-50).
88914055|NCT04231981|Experimental|Interventional arm|Patients will receive INCMGA00012 500 mg by intravenous infusion on Day1 of each cycle.
88914056|NCT04230512|Experimental|Locked|The prototype mechanical system is locked from compressing
88914057|NCT04230512|Experimental|Unlocked|The prototype mechanical system is free to compress normally
88914058|NCT04229771|Experimental|Participants who received proparacaine hydrochloride solution in left eye and placebo in right eye|Participants receiving a drop of Proparacaine Hydrocholoride 0.5% ophthalmic solution in left eye and a drop of basic salt solution (BSS, placebo) in the right eye prior to probing and irrigation.
88914059|NCT04229771|Experimental|Participants who received proparacaine hydrochloride solution in right eye and placebo in left eye|Participants receiving a drop of Proparacaine Hydrocholoride 0.5% ophthalmic solution in right eye and a drop of basic salt solution (BSS, placebo) in the left prior to probing and irrigation.
88914060|NCT04192409|Experimental|Intervention-Smartphone Application|Patients will install a smartphone application that custom-developed for the study and learn to use it with the help of researchers. The application will have the following functions: 1) providing health education information about glycemic control, postoperative management and important of drug compliance; 2) providing alert & record service on patients' DM and CAD medication treatment; 3) aiding patients to conduct self-evaluate by providing questionnaire about patients' recent basic health parameters on times. The information will be interpreted automatically by application and brief feedback will be provided to patients; 4) recording patients' fasting plasma glucose value that input by patients and generate a recent glycemic control report.
88914061|NCT04192409|No Intervention|Control|Patients will receive no additional intervention from researchers except the usual care provided by hospital.
88914062|NCT04169295|Experimental|Intervention group|At the time of their fresh embryo transfer couples will receive a document with the following feedback: a photo of their transferred embryo, the number of cryopreserved embryos, the quality rating of the transferred embryo's, and couple's personalized IVF-prognosis
88914063|NCT04169295|Sham Comparator|Control group|At the time of their fresh embryo transfer couples will receive a document with a photo of their transferred embryo(s) and the number of cryopreserved embryos.
89433880|NCT05926557|Active Comparator|NSMD Group|Control group will be treated only through a non-surgical mechanical therapy with curettes or scaler peek tips.
89433881|NCT05926505|Placebo Comparator|Placebo|Placebo is injected subcutaneously once daily for 4 weeks.
88914064|NCT04167540|Experimental|Earlier stage PD|
88914065|NCT04167540|Experimental|Later stage PD|
88914066|NCT04146441|Experimental|SonoVue|SonoVue + chemotherapy
88914067|NCT04146441|Active Comparator|control|chemotherapy
88914068|NCT04142788|No Intervention|Standard dose MRA|Participants in this arm will have titration to guideline-recommended doses of MRA attempted.
88914069|NCT04142788|Experimental|Patiromer and high dose MRA|Participants assigned to patiromer may be titrated to 200mg/day spironolactone or the highest licensed dose of eplerenone (50mg/day).
89433882|NCT05926505|Experimental|Anakinra|Anakinra is injected subcutaneously as 100 mg once daily for 4 weeks.
89433883|NCT05926297|Experimental|NaOCl + HA Group|A NaOCl-based gel will initially be applied in the peri-implant sulcus for 30 seconds, without the need for flushing. Furthermore, mechanical therapy (NSMD) will be performed by means of an ultrasonic scaler with a plastic tip. Finally, the HA-based gel will be applied in the peri-implant sulcus by means of a blunt-tipped needle.
89433884|NCT05926297|Active Comparator|NSMD Group|Control group will be treated only through a non-surgical mechanical therapy with curettes or scaler tips.
89433885|NCT05925088||Focus group 1|
89433886|NCT05925088||Focus group 2|
88914075|NCT04123444|Experimental|Iloprost|Patients randomized to active treatment (n=190 patients) will receive continuous infusion of iloprost for 72 hours after inclusion or until discharge to ward or death, whichever comes first.
88914076|NCT04123444|Placebo Comparator|Placebo|Patients randomized to placebo treatment (n=190 patients) will receive continuous infusion of placebo for 72 hours after inclusion or until discharge to ward or death, whichever comes first.
89433887|NCT05922761|Experimental|Cohort A: Belumosudil + Standard of Care Medications|"30 participants with bronchiolitis obliterans syndrome (BOS) will complete study procedures as follows:~Drug diary~CT scans at Cycles 3 and 7 and at End of Treatment.~Cycle 1~Day 1 - 28 of 28-day cycle: Predetermined dose of Belumosudil 1x daily.~Predetermined doses of Fluticasone, Montelukast, and Prednisone 1x daily.~Predetermined dose of azithromycin 3 days per treatment week.~Cycle 2 - 3~Day 1 - 28 of 28-day cycle: Predetermined dose of Belumosudil 1x daily.~Predetermined doses of Fluticasone Montelukast 1x daily. Predetermined doses of Prednisone 1x daily at treating physician's discretion.~Predetermined dose of azithromycin 3 days per treatment week.~Cycle 4 - 12~Day 1 - 28 of 28-day cycle: Predetermined dose of Belumosudil 1x daily.~Predetermined doses of Fluticasone and Montelukast 1x daily.~Predetermined dose of azithromycin 3 days per treatment week."
89433888|NCT05922761|Experimental|Cohort B: Belumosudil|"15 participants with signs concerning developing BOS will complete study procedure as follows:~Drug diary~CT scans at Cycles 3 and 7 and at End of Treatment.~Cycle 1 - 12 - Day 1 - 28 of 28-day cycle: Predetermined dose of Belumosudil 1x daily."
89433889|NCT05919459|Experimental|Parents with ACT intervention|5-week online synchronous ACT intervention plus asynchronous online AIS education
89433890|NCT05919459|Other|Parents without ACT intervention|5-week interactive online AIS education
89433891|NCT05919446|Experimental|Older people with ACT intervention|4 week ACT plus back exercise group
88914077|NCT04120025|No Intervention|Control Group|Subject will continue standard of care for GERD symptoms
88914078|NCT04120025|Experimental|Treatment Group|Subjects will continue with usual care but will also receive diaphragm training (belly breathing) instructions using verbal, visual and tactile cues for proper contraction of the diaphragm as a home program
88914079|NCT04072926|Experimental|PDT+/BIOROOT|Photodynamic therapy will bi conducted with diode laser (660nm, 100mW, 60 seconds) with toluidine at the end of chemomechanical preparation. Final root canal filling will be with BioRoot in combination with guttapercha points.
88914080|NCT04072926|Experimental|PUI/BIOROOT|This arm will only get PUI (passive ultrasound irrigation) with 2,5ml of 2,5% sodium hypochlorite, then 2ml of 15% EDTA which will be activated for 60seconds (EndoUltra MicroMega, France) and finally 2,5ml of 2,5% of sodium hypochlorite will be also activated for 30 seconds. Root canal filling in combination with BioRoot and guttapercha points.
88914081|NCT04072926|Active Comparator|PDT+/AH+|Photodynamic therapy will bi conducted with diode laser (660nm, 100mW, 60 seconds) with toluidine at the end of chemomechanical preparation. Final root canal filling will be with AH+ epoxy based cement in combination with guttapercha points.
88914082|NCT04072926|Active Comparator|PUI/AH+|This arm will only get PUI (passive ultrasound irrigation) in combination with AH+ epoxy based cement and guttapercha points.
88914083|NCT04041375|Experimental|iNSPiRED|Peer coaching intervention
88914084|NCT04041375|Active Comparator|Usual Care|Directory of resources and encouragement to follow-up with Primary Care Physician
88914085|NCT04040751|Experimental|CARE-CITE Carepartner|This study arm consists of carepartners receiving the CARE-CITE intervention. The CARE-CITE intervention will occur over 4 weeks in the dyad's home. The research interventionist will conduct two in-home visits (at orientation and during week 4), two phone call visits (at weeks 2 and 3), and one telephone follow up at week 8.
88914086|NCT04040751|Active Comparator|Control Carepartners|"Carepartners in this study arm receive customary care outpatient rehabilitation therapy but no CARE-CITE intervention. The carepartner will receive the same number of structured weekly phone calls and the booster call to answer any questions, assess helpfulness of the information and ascertain if there was any use of the web resources or social support groups."
88914087|NCT04040751|Experimental|CARE-CITE Stroke Survivor|This study arm consists of stroke survivors of carepartners receiving the CARE-CITE intervention. The CARE-CITE intervention will occur over 4 weeks in the dyad's home. The research interventionist will conduct two in-home visits (at orientation and during week 4), two phone call visits (at weeks 2 and 3), and one telephone follow up at week 8.
88914088|NCT04040751|Active Comparator|Control Stroke Survivors|"Stroke survivors in this study arm receive customary care outpatient rehabilitation therapy but no CARE-CITE intervention. Carepartners of the stroke survivors will receive the same number of structured weekly phone calls and the booster call to answer any questions, assess helpfulness of the information and ascertain if there was any use of the web resources or social support groups."
88914089|NCT03998748|Experimental|Experimental|This group of participants will receive the feedback that they have a genetic vulnerability to depression.
88914090|NCT03998748|Active Comparator|Control|This group of participants will receive the feedback that they do not have a genetic vulnerability to depression.
89009890|NCT04670107|Experimental|combination group|
89197911|NCT00549328|Experimental|Pazopanib Open-label|Single-arm, non-randomised, single-stage pazopanib monotherapy.
89433892|NCT05919446|Other|Older people without ACT intervention|4-week back exercise control group
89531276|NCT03095859|Active Comparator|Control|Standard care (once daily physical rehabilitation, approx. 30 minutes). Standard care will consist of physical exercise, such as early mobility, endurance training, upper limb, lower limb and trunk activity. This will involve non-physical interventions including respiratory therapy, airway clearance and patient and carer education.
89531277|NCT03095859|Experimental|Experimental|Early intensive physical rehabilitation, which will consist of standard care plus one additional treatment per day. The additional early intensive physical rehabilitation session provided to the experimental group will allow for progression of aerobic, strength and flexibility exercise and / or completion of a more comprehensive physical rehabilitation program.
89433893|NCT05919225|Experimental|INTERVENTION|Once AHF has been diagnosed at ED, and before decision-making about hospitalize/discharge home is taken, physicians will objectively measure the severity of decompensation, based on risk of 30-day death using MEESSI scale. As result, patient can be allocated to low, intermediate, high or very-high risk. For patients classified as low-risk, the propocol recommendation will be discharge patient to home. For patients classified as increased risk (i.e., intermediate, high or very-high risk categories), the protocol recommendation will be to hospitalize patient. Nonetheless, final decission will be left to emergency physician, and overruling (disposition against recommendation) will be allowed. For discharged patients, there is no follow up intervention planned, and it will be based on current centre protocols.For hospitalized patients, department of admission will be based on current centre protocols, with no intervention at this level.
89433894|NCT05919225|No Intervention|USUAL CARE|Once AHF has been diagnosed at ED, emergency physicians will decide patient disposition according to their usual strategies of care, that currently do not include risk stratification. For discharged patients, there is no follow up intervention planned, and it will be based on current centre protocols. For hospitalized patients, department of admission will be based on current centre protocols, with no intervention at this level.
89433895|NCT05918354||Allergy|Adults aged 18 years or above, consulting the outpatient clinic for an allergy diagnosis to aeroallergens with skin prick automated test device.
89433896|NCT05915832|Active Comparator|RIC|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mm Hg. RIC will be conducted twice daily for 7 consecutive days.
89433897|NCT05915832|Placebo Comparator|Sham RIC|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mm Hg. RIC will be conducted twice daily for 7 consecutive days.
89433898|NCT05915702|Experimental|Gadoquatrane - Approved Macrocyclic GBCA|Participants will receive one intravenous injection of gadoquatrane before or during MRI in Period 1, followed by one intravenous injection of any approved macrocyclic GBCA before or during MRI in Period 2.
89433899|NCT05915702|Experimental|Approved Macrocyclic GBCA - Gadoquatrane|Participants will receive one intravenous injection of any approved macrocyclic GBCA before or during MRI in Period 1, followed by one intravenous injection of gadoquatrane before or during MRI in Period 2.
89197912|NCT00865917|Active Comparator|1|beta-blocker
89433900|NCT05915234|Experimental|Order number 1: Ice-Peas-Control|Each subject will receive all interventions and the control and they will randomly assigned to a sequence order. In this arm the sequence order is: crushed ice - frozen peas - control.
89433901|NCT05915234|Experimental|Order number 2: Ice-Control-Peas|Each subject will receive all interventions and the control and they will randomly assigned to a sequence order. In this arm the sequence order is: crushed ice - control - frozen peas.
88914091|NCT03997916|Other|Participant|All patients scheduled for attended overnight in-lab polysomnography (PSG), also known as sleep study, in our 2 sleep labs will undergo PSG testing. On the same night of the PSG testing, these same patients will also wear the Belun Ring device. After the study, we will compare results of the Belun Ring device vis-à-vis with the results of the PSG on the same patient. There will be no separate arm to test a different device.
88914092|NCT03987503|Experimental|at Point-of-Diagnosis HCV treatment|At the point of HCV infection diagnosis, (HCV RNA positive and anti-HCV positive) individuals who meet eligibility criteria and elect to start HCV treatment at the same visit and monitored at two-week intervals at the community-site.
88914093|NCT03987503|Active Comparator|Passive observation|Participants who test positive for HCV chronic infection (HCV RNA positive, and anti-HCV positive) but elect to not enroll in the intervention arm. Electronic medical record data will be reviewed for up to 2 years for HCV related care information (e.g., HCV treatment start date, end date, SVR-12).
89433902|NCT05915234|Experimental|Order number 3: Peas-Ice-Control|Each subject will receive all interventions and the control and they will randomly assigned to a sequence order. In this arm the sequence order is: frozen peas - crushed ice - control.
89433903|NCT05915234|Experimental|Order number 4: Peas-Control-Ice|Each subject will receive all interventions and the control and they will randomly assigned to a sequence order. In this arm the sequence order is: frozen peas - control - crushed ice.
88914094|NCT03977181|Experimental|Health Club|A group-based community health club akin to an ART adherence club
89197913|NCT00865917|Experimental|2|I(f)-blocker
88914095|NCT03977181|Experimental|One-on-one|One-on-one adherence counselling and support
88914096|NCT03977181|No Intervention|Medication pick-up|Community-based medication dispensary
89197914|NCT00865917|Placebo Comparator|3|Placebo
89197915|NCT00696410|Experimental|CHF patients Given Zinc Acetate|Patients with CHF received zinc acetate 50 mg po TID. This is a pre-post study
89433904|NCT05915234|Experimental|Order number 5: Control-Ice-Peas|Each subject will receive all interventions and the control and they will randomly assigned to a sequence order. In this arm the sequence order is: control - crushed ice - frozen peas.
89009891|NCT04557007||Treatment-naive NSCLC patients|Treatment-naive NSCLC patients receiving immunotherapy (pembrolizumab) alone or in combination With chemotherapy divided in groups based on treatment administered. Clinical information will be gathered at start of treatment and at evaluations every 3rd month.
89009892|NCT04670458||CA group|Patients with In-Hospital Cardiac Arrest
89433905|NCT05915234|Experimental|Order number 6: Control-Peas-Ice|Each subject will receive all interventions and the control and they will randomly assigned to a sequence order. In this arm the sequence order is: control - frozen peas - crushed ice.
89433906|NCT05913674|Experimental|mEPIC|Adults (male and female) with a diagnosis of appendicular or colorectal cancer with peritoneal carcinomatosis will undergo mEPIC on post-operative days 1 and 2 following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
89433907|NCT05913050|Experimental|Therapeutic exercise plus education|The treatment will consist of a progressive resistance exercise program along with education.
89009893|NCT04670458||CONTROL group|Patients without In-Hospital Cardiac Arrest
89009894|NCT00233792|Other|1|sirolimus coated Bx VELOCITY stent - fast release
89009895|NCT00233792|Other|2|sirolimus coated Bx VELOCITY stent - slow release
89433908|NCT05912517|Experimental|Nipocalimab|Participants will receive nipocalimab intravenously (IV) once weekly (qw) from randomization through gestational age (GA) Week 35.
89433909|NCT05912517|Placebo Comparator|Placebo|Participants will receive matching placebo IV qw from randomization through GA Week 35.
89009896|NCT04556812|Experimental|Study group|"underwent four-in-one surgical technique centered on tibial tuberosity osteotomy and proximal displacement"
89009897|NCT04556812|Placebo Comparator|Control group|traditional soft tissue surgery
89009898|NCT00556153||Phase I|Children, ages 5-15 years with brain tumors
89009899|NCT00556192|Active Comparator|1|Rituximab
89009900|NCT00556192|Active Comparator|2|Rituximab + Cyclophosphamide
89009901|NCT00556192|Active Comparator|3|Cyclophosphamide
89009902|NCT00260442|Placebo Comparator|Placebo|< 200 mg/day dietary cholesterol, resistance training, sedentary
89433910|NCT05911308|Experimental|Neoadjuvant therapy|Subjects with operable Non-Small Cell Lung Cancer received neoadjuvant durvalumab plus platinum doublet chemotherapy and neoadjuvant durvalumab plus platinum doublet chemotherapy in combination with abequolixron (RGX-104), an LXR/ApoE agonist.
89433911|NCT05910242|Active Comparator|RIC group|Patients are treated with remote ischemic conditioning (RIC).
89009903|NCT00260442|Experimental|Average intake|400 mg/day dietary cholesterol, resistance training, sedentary
89009904|NCT00260442|Experimental|High intake|800 mg/day dietary cholesterol, resistance training, sedentary
89009905|NCT00556231||1|Children with congenital heart lesions - males/females, ages 6-20, scheduled for a regular stress test
89009906|NCT00556231||2|Children without congenital heart lesions - males/females, ages 6-20, scheduled for a regular stress test
89009907|NCT00556231||3|
89009908|NCT00556231||4|
89009909|NCT00556231||5|
89009910|NCT00556231||6|
89009911|NCT00556270||Matrix II|
89009912|NCT00260481|Placebo Comparator|Control Group|During the Infusion periods, participants in the placebo condition will receive pre-treatment with hydroxyzine (50mg) followed by placebo medications administered both orally and through infusion, as well as a second dose of hydroxyzine (50mg), delivered at the same rate and delivery system to match the active condition. All participants may receive daily multivitamins as determined appropriate by the study physician. Multivitamins are not considered active medications for the PROMETA pharmacotherapy, but may be provided to participants in both conditions at the same rates and delivery methods for the duration of the study. Because participants are treatment-seeking and use of a placebo condition is warranted, all participants will be provided with once weekly, manual-guided cognitive behavioral therapy sessions during all outpatient periods of the study.
89433912|NCT05910242|Sham Comparator|Sham RIC group|Patients are treated with sham remote ischemic conditioning (sham-RIC).
89433913|NCT05909930|Experimental|Therapeutic exercise and education|The treatment will consist of a progressive resistance exercise program along with education.
89433914|NCT05909865|Experimental|Therapeutic exercise plus education|The treatment will consist of a progressive resistance exercise program along with education.
89009913|NCT00260481|Active Comparator|Prometa|During the infusion periods, participants assigned to the PROMETA pharmacotherapy condition will receive pre-treatment with hydroxyzine (50mg) followed by intravenous flumazenil (2mg) over a 2-hour period. Before bedtime, patients will again take 50mg of hydroxyzine orally, as well as 300mg of oral gabapentin (participants will titrate up their dosage of gabapentin each day - 300mg on day 0, 600mg on day 1, 900mg on day 2). All participants may receive daily multivitamins as determined appropriate by the study physician. Multivitamins are not considered active medications for the PROMETA pharmacotherapy, but may be provided to participants in both conditions at the same rates and delivery methods for the duration of the study. Because participants are treatment-seeking and use of a placebo condition is warranted, all participants will be provided with once weekly, manual-guided cognitive behavioral therapy sessions during all outpatient periods of the study.
89009914|NCT00267852||1.0|As per routinary clinical practice
89009915|NCT00234143|Active Comparator|Aranesp and Neupogen|solution for subcutaneous injection , syringe 500 mcg and 300 mcg respectively
89009916|NCT00234143|Active Comparator|Aranesp|solution for subcutaneous injection, 500 mcg
89009917|NCT00234143|No Intervention|Best supportive care|Red cell transfusion support
89009918|NCT04670419||HEV gt 3 clade abchijklm|patients infected with HEV gt 3 clade abchijklm
89009919|NCT04670419||HEV gt 3 clade efg|patients infected with HEV gt 3 clade efg
89009920|NCT04670185|Experimental|Internet-based parent training|Five weeks of therapist-guided online delivered parents training
89009921|NCT04670185|No Intervention|Waitlist|Five weeks of waitlist
89009922|NCT04669873|Active Comparator|Active Comparator: Standard|Whole breast Radiotherapy, 40 Gray (40Gy) fractions
89009923|NCT04669873|Experimental|Experimental 1: Hypofractionated radiotherapy|Whole breast Radiotherapy, 26 Gray (26Gy) in 5 fractions
89009924|NCT04669873|Experimental|Experimental 2: Accelerated Partial Breast Irradiation|Partial Breast Irradiation 26 Gray (26Gy) to the tumor bed in 5 fractions.
89009925|NCT04669756|Experimental|A|ovariopexy for 2 days
89009926|NCT04669756|Experimental|B|ovariopexy for 4 days
89009927|NCT04669756|Experimental|C|ovariopexy for 6 days
89009928|NCT04669756|Placebo Comparator|D|Placebo Operation for 2 days
89009929|NCT04669795|Placebo Comparator|Group 1|Placebo was given to ten patients during consolidation period ( 2 capsule daily for 6 months during consolidation period)
89009930|NCT04669795|Experimental|Group 2|Cissus quadrangularis in form of capsules given to ten patients ( 2 capsule daily for 6 months during consolidation period)
89009931|NCT04670029|No Intervention|Standard|
89197916|NCT00696410|No Intervention|Healthy controls|Health controls; no zinc acetate administered.
89197917|NCT00865995||1|patients undergoing elective procedures with intubation and no known respiratory pathology
89433915|NCT05909137||study group|CTV-omitted IMRT+adjuvant immunotherapy
89433916|NCT05909137||control group|CTV-delineated IMRT+adjuvant immunotherapy
88914097|NCT03967197|Experimental|Lidocaine|Patients randomized to the lidocaine intervention will receive 2 sprays of lidocaine hydrochloride 10% in each nostril 3-5 minutes before their test.
88914098|NCT03967197|Placebo Comparator|Placebo (Saline)|Patients randomized to placebo will receive 2 sprays of physiological saline in each nostril 3-5 minutes before their test.
88914099|NCT03935646|Experimental|Stimulant Medication|Participants will be administered a stimulant medication (Adderall IR 10mg). The ordering of experimental vs. placebo appointments will be counterbalanced. Participants will complete computer-based tests of sustained attention and working memory during all appointments.
88914100|NCT03831009|Active Comparator|Weight-bearing stable/Gravity stable|Ankles that are considered stable using weight-bearing radiographs AND gravity stress test will be assigned to conservative treatment
88914101|NCT03831009|Active Comparator|Weight-bearing stable/Gravity unstable|Ankles that are considered stable using weight-bearing radiographs but unstable using gravity stress test will be assigned to conservative treatment
88914102|NCT03831009|Active Comparator|Weight-bearing unstable/Gravity unstable|Ankles that are considered unstable using weight-bearing radiographs AND gravity stress test will be assigned to open reduction internal fixation (ORIF)
88914103|NCT03831009|Active Comparator|Weight-bearing unstable/Gravity stable|Ankles that are considered unstable using weight-bearing radiographs but stable using gravity stress test will be assigned to open reduction internal fixation (ORIF)
88914104|NCT03788616|Active Comparator|Group I|Group I : will consist of 30 teeth that will be restored by high-viscosity glass ionomer (Fuji IX Extra) with ART approach
88914105|NCT03788616|Active Comparator|Group II|Group II : will consist of 30 teeth that will be restored by bioactive restorative material (ACTIVA KIDS bioactive restorative material) with ART approach.
89197918|NCT00865995||2|patients with tracheostomy
89197919|NCT00865995||3|patients with chronic lung disease or respiratory symptoms undergoing bronchoscopy
89197920|NCT00956878||Cancer Pain Patients|
89197921|NCT00921362||1|Schizophrenia patients under Seroquel treatment
89197922|NCT00683904|Active Comparator|Ixabepilone, 32 mg/m^2 + Carboplatin, 5 mg/min/mL|
89197923|NCT00683904|Active Comparator|Ixabepilone, 32 mg/m^2 + Carboplatin, 6 mg/min/mL|
89197924|NCT00947986|Experimental|Johnson's Baby Shampoo|1% diluted solution
89197925|NCT00862329|Experimental|Casein|
89197926|NCT00862329|Experimental|MSP|
89197927|NCT00862329|Experimental|Casein/MSP|
89197928|NCT00862329|Experimental|Soy protein|
89197929|NCT00956956|Experimental|PF-04455242 treatment|
89197930|NCT00956956|Placebo Comparator|Placebo|
89197931|NCT00866073|Experimental|A|Decitabine 15 mg/m2 i.v. - single arm
89197932|NCT00957112|Experimental|Arm I|Patients undergo a 20-minute acupuncture session once a week for 6 weeks. Patients also receive written information about fatigue and its possible management.
89197933|NCT00957112|No Intervention|Arm II|Patients receive standard care. They also receive written information about fatigue as in arm I.
89433917|NCT05907473|Experimental|Conventional Rehabilitation Group|In the conventional rehabilitation program, bed exercises, mat activities, balance exercises inside or outside the parallel bar and walking training will be given to the patients every weekday.
89197934|NCT00957112|Experimental|Arm A|Patients receive treatment as in arm I for 4 more weeks.
89197935|NCT00957112|No Intervention|Arm B|Patients receive standard care as in arm II for 4 more weeks.
89433918|NCT05907473|Experimental|Virtual Reality Therapy Group|The patients in this group will be able to play balance-based games with the Virtual Reality System for 20 minutes, 3 days a week, together with the conventional rehabilitation program.
89433919|NCT05907369|Experimental|aEC/ stDCS|Participants in this group receive active EC training but sham tDCS.
89433920|NCT05907369|Active Comparator|sEC/atDCS|Participants in this group receive active tDCS training but sham EC training.
89433921|NCT05907369|Experimental|aEC/atDCS|Participants in this group receive both active EC training and active tDCS.
89433922|NCT05907369|Sham Comparator|sEC/stDCS|Participants in this group receive the sham EC training and also sham tDCS.
89433923|NCT05906082|Experimental|Intervention (E-cigarette cessation text-messaging intervention)|
89433924|NCT05906082|Active Comparator|Standard care (Standard care control using standard national resources)|This standard care group will receive standard care resources from smokefree.gov.
89433925|NCT05905991|Experimental|ESRT Intervention|Five 1-hour weekly ESRT sessions
89433926|NCT05905991|Other|Waitlist Control|The control group will receive ESRT after the intervention group finishes the 5-week ESRT program.
89433927|NCT05905887|Experimental|rivoceranib plus paclitaxel|
89433928|NCT05899439||Subjects with diabetes age 0 to 100 years|People who have not been diagnosed with type 1 diabetes
88914106|NCT03769493|Experimental|Mobile After-Care Support (MACS) app|All participants will download the MACS app to their mobile phone (or a study provided phone, as needed). The app runs through the third-party platform, mEMA, designed by Ilumivu. It is designed to prompt engagement through questions and tailored responses at multiple times throughout the day and provide brief interventions.
88914107|NCT03732768|Experimental|Radspherin|
88914108|NCT03713619|Active Comparator|secukinumab 1|Secukinumab 300mg every 2 weeks
89433929|NCT05899439||Subjects with type 1 diabetes age 0 to 100 years|People who have been diagnosed with type 1 diabetes
89433930|NCT05898854|Experimental|Gastric or gastro-esophageal junctioncancer|Patients with biopsy verified gastric or gastro-esophageal junction cancer undergo FAPI PET/CT in addition to conventional imaging
89433931|NCT05898581|Experimental|PENG Block|Participants will receive ultrasound-guided PENG block (PENG group) with local anesthetics (20 ml of 0.5% ropivacaine) before administration of spinal anesthesia.
89433932|NCT05898581|Sham Comparator|Control Group|Participants will receive a sham PENG block performed with 20ml of normal saline solution before spinal anesthesia. After, patients will receive ILAI (performed by the operating surgeon) with a plain solution of ropivacaine 0.25% 60ml.
89433933|NCT05897658|Experimental|Seizure Prophylaxis (Levetiracetam)|Levetiracetam 1 g taken orally twice a day for 7 days
89433934|NCT05897658|Placebo Comparator|Placebo|Placebo taken orally twice a day for 7 days
89433935|NCT05897398||Patients already receiving WEGOVY® treatment included in the ATUc/AP2|Data collected at initiation, 6 months and 12 months of WEGOVY® treatment will be retrospectively extracted from the WEGOVY® ATU/AP2 eCRF.
89433936|NCT05897398||New WEGOVY® patients included in the AP2,|"At initiation, 6 months and 12 months of WEGOVY® treatment, the following procedures will be performed (in addition to the data collection already provided for in the ATU/AP2):~Blood sampling for routine care (max 15mL) and constitution of a plasma bank (28 mL)~Completion of questionnaires for the entire cohort:~To assess hyperphagia and eating behaviour: BES, DEBQ and Hunger Score questionnaire~To assess physical activity: short IPAQ~To assess sleep behaviour: MCTQ~To assess quality of life: EQ5D5L~To assess digestive system disorders: GIQLI~To assess anxiety and depression: HAD~Collection of clinical and biological data from the WEGOVY® ATU/AP eCRF"
89433937|NCT05896943||Ulcerative colitis patients treated with ustekinumab|Patients with Ulcerative Colitis treated with ustekinumab
89433938|NCT05896878|Experimental|Daily Supplement Treatment|Following study recruitment and obtaining consent, participants will complete a baseline urine test. The FPI is a simple urine test from Ethos Laboratories that screens for 11 biomarkers that are more likely to contribute to symptoms of pain.
89433939|NCT05895175||DONATED GAMETE GROUP|couples who got pregnant through egg donation (with their own semen)
89433940|NCT05895175||OWN GAMETE GROUP|couples who got pregnant through standard IVF treatment, with their own gametes
89433941|NCT05893017|Experimental|Virtual Reality Exercises|Virtual Reality Exercises will be applied
89433942|NCT05893017|Experimental|Virtual Reality Exercises and Kinesiotaping|Virtual Reality Exercises and Kinesio taping for quadriceps and hamstring muscles will be applied
89433943|NCT05893017|Experimental|Virtual Reality Exercises and Valgus Orthoses|Virtual Reality Exercises and Valgus Orthoses will be applied.
89433944|NCT05891249|Experimental|Luspatercept|
89433945|NCT05888480|Experimental|Intervention group (IG)|The IG will receive the end-of-life CST between the two measurement points
89197936|NCT00957112|Experimental|Arm C|Patients learn to self-acupuncture and do so weekly for 4 more weeks.
89197937|NCT02544711|Experimental|Prospective group :Innovation|Surgical treatment using a patient specific instrument (PSI)
89433946|NCT05888480|Other|Control group (CG)|The CG will be a waitlist group and receive the training after the end of data collection.
89433947|NCT05887765|Active Comparator|placebo injection|5ml of 0,9% sodium chloride - before the popliteal nerve block
89433948|NCT05887765|Active Comparator|0,1mg/kg Dexamethasone|0,1mg/kg dexamethasone sodium phosphate - before the popliteal nerve block
89433949|NCT05887765|Active Comparator|0,2mg/kg Dexamethasone|0,2mg/kg dexamethasone sodium phosphate - before the popliteal nerve block
89433950|NCT05884294|Experimental|PowerGlide Pro Midline catheter.|The Intervention Group will be represented by hospitalized adult clinical patients who have been identified with difficult intravenous access. These patients will receive an ultrasound-guided insertion of the PowerGlide ProTM Midline 20G (10 cm).
89433951|NCT05884294|No Intervention|Introcan Safety Deep Access long peripheral venous catheter.|The control group will be subjected to the same selection criteria as the patients in the intervention group; however, they will receive an ultrasound-guided insertion of a long peripheral venous catheter Introcan Safety Deep Access 20G (6.4 cm).
89433952|NCT05882812|Experimental|SAM Ultrasound Device and Diclofenac Patch|Patients receive treatment from the wired SAM Ultrasonic Diathermy Device for 4 hours at least 5 days a week for 8 weeks combined with 2.5% diclofenac patch. The SAM Device emits continuous ultrasound at 3 megahertz(MHz) frequency and 0.132 watts/cm^2 intensity.
89433953|NCT05882812|Active Comparator|SAM Ultrasound Device and SAM Patch|Patients receive treatment from the wired SAM Ultrasonic Diathermy Device for 4 hours at least 5 days a week for 8 weeks combined with SAM patch(0% diclofenac).
89433954|NCT05882812|Active Comparator|Diclofenac Patch|Patients wear 2.5% diclofenac patch for 4 hours at least 5 days a week for 8 weeks combined.
89433955|NCT05882695|Experimental|Experimental Part 1: Active SPG302 to be administered to healthy volunteers (SAD)|8 participants will be randomized in a 3:1 ratio to active or placebo. Study intervention will be administered orally once. Randomization to each SAD cohort will be done in a staggered manner; initially 2 sentinel participants (1 active and 1 placebo) will be randomized and dosed and after a safety evaluation period after the dose without clinically significant adverse events (AEs) and investigator approval, then, 6 additional participants will be randomized and dosed (5 active and 1 placebo) at the discretion of the Investigator according to the randomization schedule
89433956|NCT05882695|Placebo Comparator|Placebo Comparator Part 1: Placebo comparator to be administered to healthy volunteers (SAD)|8 participants will be randomized in a 3:1 ratio to active or placebo. Study intervention will be administered orally once. Randomization to each SAD cohort will be done in a staggered manner; initially 2 sentinel participants (1 active and 1 placebo) will be randomized and dosed and after a safety evaluation period after the dose without clinically significant adverse events (AEs) and investigator approval, then, 6 additional participants will be randomized and dosed (5 active and 1 placebo) at the discretion of the Investigator according to the randomization schedule
89433957|NCT05882695|Experimental|Experimental Part 2: Active SPG302 to be administered to healthy volunteers (MAD)|8 participants will be randomized in a 3:1 ratio to active or placebo. Participants will receive study intervention QD over 5 days and will be discharged on Day 6. A follow-up safety visit will be conducted on Day 12 (±3 days).
89433958|NCT05882695|Placebo Comparator|Placebo Comparator Part 2: Placebo comparator to be administered to healthy volunteers (MAD)|8 participants will be randomized in a 3:1 ratio to active or placebo. Participants will receive study intervention QD over 5 days and will be discharged on Day 6. A follow-up safety visit will be conducted on Day 12 (±3 days).
89433959|NCT05882695|Experimental|Experimental Part 3: Active SPG302 to be administered to participants with ALS|Participants with ALS will be randomized to receive SPG302 or placebo at a 3:1 ratio. Study intervention will be administered QD over 28 days. A follow-up safety visit will be conducted 30 days after last dose (±7 days). Participants who complete Part 3 may be offered to participate in an open-label extension.
89433960|NCT05882695|Placebo Comparator|Placebo Comparator Part 3: Placebo comparator to be administered to participants with ALS|Participants with ALS will be randomized to receive SPG302 or placebo at a 3:1 ratio. Study intervention will be administered QD over 28 days. A follow-up safety visit will be conducted 30 days after last dose (±7 days). Participants who complete Part 3 may be offered to participate in an open-label extension.
88914109|NCT03713619|Active Comparator|secukinumab 2|Secukinumab 300mg every 4 weeks
89197938|NCT02544711|Other|Retrospective group: Reference|Conventional surgical treatment without PSI, using 2D imaging planification
88914110|NCT03713619|Placebo Comparator|placebo 1|Placebo group to secukinumab 300mg every 2 weeks
88914111|NCT03713619|Placebo Comparator|placebo 2|Placebo group to secukinumab 300mg every 4 weeks
89197939|NCT04982588|Experimental|Medtronic CoreValve™ Evolut™ PRO System|"The system comprised of the following three components:~CoreValve™ Evolut™ PRO Transcatheter Aortic Valve (TAV)~EnVeo™ PRO Delivery Catheter System (DCS)~EnVeo™ PRO Loading System (LS)"
89197940|NCT00957190|Experimental|Cosopt|Cosopt ('Dorzolamide 20 mg and Timolol 5 mg) bid And Xalatan hs Vs Xalatan hs Alone
89197941|NCT00866151||1|"Previously enrolled subjects in the Benefits and Risks of Alternative Weight Loss Strategies - a Clinical Trial, which was run at Stanford 2003-2005. (A to Z Study)"
89197942|NCT04051398|Experimental|Intervention Arm (BI)|The BI participants will initially undergo simple spirometry and a 6-minute walk test and Borg scale application upon admission to the thoracic surgery department. Immediately after the exams, they will undergo a TENS application session over the acupuncture points: Feishu, Zhongfu, Taiyuan and Dingchuan using a frequency of 200Hz and a pulse time of 80 seconds of sufficient intensity to cause a slight sensation of local numbness without muscle fasciculations. The TENS application time will be 30 minutes. Immediately after the TENS application, the participants will be submitted to a new spirometry, a new 6-minute walk test and again to the Borg scale.
89197943|NCT04051398|Placebo Comparator|Control Arm (BC)|The BC participants will undergo the same steps as BI, however when applying TENS to these participants investigators will place the electrodes over the points without turning on the device in order to obtain the effect of a placebo.
89197944|NCT00953914|Experimental|Pyridostigmine|
89197945|NCT00953914|Placebo Comparator|Placebo|If a subject is randomized to placebo, he will receive placebo pills 3 times daily for 1 day.
89197946|NCT00858975|Experimental|Cryotherapy|The patients who receive cryotherapy for their renal tumors
89197947|NCT00756912|Experimental|1|
89197948|NCT00948220|Experimental|Treatment|Chronic hepatitis C patients on standard antiviral therapy with peginterferon alfa-2a and ribavirin
89197949|NCT00948220|No Intervention|Control|Chronic hepatitis C patients without standard antiviral therapy
89197950|NCT00756990|Experimental|Single group|Depot Naltrexone
88914112|NCT03670693|Experimental|Fatigued Crohn's Disease|Crohns disease patients in remission(Harvey Bradshaw index <4 and CRP<5mg/dl and faecal calprotectin <50ug/g) suffering from fatigue (General fatigue and physical fatigue score on the Multiple Fatigue Inventory-20 >14, and a score of >4 in the Fatigue questionnaire.)
88914113|NCT03670693|Experimental|Non-Fatigued Crohn's Disease|Crohns disease patients in remission(Harvey Bradshaw index <4 and CRP<5mg/dl and faecal calprotectin <50ug/g) without fatigue (General fatigue and physical fatigue score on the Multiple Fatigue Inventory-20 <14, and a score of <4 in the Fatigue questionnaire.)
88914114|NCT03670693|Experimental|Healthy Volunteers|Age,gender,muscle mass, and physical activity-matched healthy controls.
88914115|NCT03666416|Experimental|Sprint Interval Training|Participants will be scheduled for two in-lab experimental appointments: sprint interval training (SIT) and Non-SIT. During the SIT appointment, the researcher will lead the participant through a set of stretches and three minutes of low-intensity cycling on a Schwinn AD2 Airdyne leg-cycling and arm-cranking ergometer to warm up and increase blood flow to active muscles. Participants will then complete 16 minutes of SIT, consisting of eight bouts of 20 seconds of cycling followed by 100 seconds of rest. Participants will complete computer-based tests of sustained attention and working memory during both the SIT (15 minutes following the exercise) and Non-SIT appointments.
88914116|NCT03615937|Experimental|Comprehensive Intervention|"This is a holistic package of interventions, including:~Child interactive intervention (dialogic reading and play intervention)~Family Empowerment (positive parenting and grandparenting)~Access to Community Hub and its services~Enhancement to the kindergartens~Health education, screening, and support"
88914117|NCT03615937|Active Comparator|Health Support|"This is a control arm with only health components.~1. Health education, screening, and support"
88914118|NCT03596177|Experimental|MEDI0382|Participants will receive subcutaneous (SC) injection of placebo for 16 days in the single-blind treatment period, and then SC injection of MEDI0382 titrated up to 300 μg for 42 days (100 μg for 4 days, followed by 200 μg for 4 days, and finally 300 μg for 34 days) in double-blind treatment period.
88914119|NCT03596177|Placebo Comparator|Placebo|Participants will receive SC injection of placebo for 16 days in the single-blind treatment period, and then SC injection of placebo matched to MEDI0382 for 42 days in double-blind treatment period.
89197951|NCT05301244|Experimental|laughter yoga practice|Laughter yoga practiced by a researcher with a laughter yoga practitioner certificate
88914120|NCT03585517|Experimental|IM23 CART|All patients will be treated with fludarabine and cyclophosphamide for 3 days,then,CAR-T cells expressing CD123 CAR will be infused 24-96 hours later.
88914121|NCT03579459|Active Comparator|Clostridium difficile vaccine Lot 1|
88914122|NCT03579459|Active Comparator|Clostridium difficile vaccine Lot 2|
88914123|NCT03579459|Active Comparator|Clostridium difficile vaccine Lot 3|
88914124|NCT03579459|Placebo Comparator|Placebo|Normal saline solution (0.9% sodium chloride)
89197952|NCT05301244|Experimental|Laughter yoga session parts-1|Deep breathing exercises (5 minutes)
89197953|NCT05301244|Experimental|Laughter yoga session parts-2|Warm-up exercises (10 minutes)
89197954|NCT05301244|Experimental|Laughter yoga session parts-3|Childish games (10 minutes)
89197955|NCT05301244|Experimental|Laughter yoga session parts-4|Laughter exercises (15 minutes)
89197956|NCT02561286|Experimental|HIV risk reduction|BRO HIV Risk Reduction Intervention
89197957|NCT02561286|Active Comparator|Health promotion control|Health Promotion Intervention
89197958|NCT00757068|Active Comparator|SBT|Women assigned to SBT (blue) will receive a six month program that offers to help them stay quit after having a baby.
88914125|NCT03547999|Active Comparator|Arm A - Control|mFOLFOX6 and Nivolumab every 2 weeks for 4 cycles. After neoadjuvant therapy, patients will be re-evaluated for surgical resection. Patients still considered resectable will undergo surgical resection with the goal of completely treating all of their disease by either resection and/or ablation. Patients with bilobar disease must have all of their disease treated in a single operation. Once patients in the post-operative period are deemed ready to begin therapy, patients in the control arm will then undergo another 8 cycles of mFOLFOX6 in addition to Nivolumab. After this, Nivolumab will be given every 4 weeks completing therapy at week 110.
88914126|NCT03547999|Experimental|Arm B - Experimental|Two doses of Nivolumab and MVA-BN-CV301 each given 2 weeks apart (Days -28, -14), followed by four doses of Nivolumab plus FPV-CV301 given 2 weeks apart concurrently with mFOLFOX6, which will again be administered every 2 weeks for 4 cycles (Nivolumab, FPV-CV301 and mFOLFOX6). After neoadjuvant therapy, patients will be re-evaluated for surgical resection. Patients still considered resectable will undergo surgical resection with the goal of completely treating all of their disease by either resection and/or ablation. Patients with bilobar disease must have all of their disease treated in a single operation. Patients in the experimental arm will receive 8 cycles of mFOLFOX6 in addition to Nivolumab and FVP-CV301 boosters with the first two given on Day 0 and 14 and then every 4 weeks. FVP-CV301 will then be administered every twelve weeks completing therapy at week 110.
89197959|NCT00757068|Experimental|CBT|Women assigned to CBT (pink) will receive a six month treatment designed to provide support and address the concerns of women who have just had a baby and do not want to resume smoking.
89197960|NCT00957346|Experimental|Mifepristone + Misoprostol|200 mg mifepristone followed by 400 mcg buccal misoprostol repeated every 3 hours until complete abortion or maximum of 5 doses.
89197961|NCT00957346|Placebo Comparator|Misoprostol|Placebo resembling 200mcg mifepristone followed by 400 mcg buccal misoprostol repeated every 3 hours until complete abortion or maximum of 5 doses
89197962|NCT04061096|Active Comparator|MIH-effected carious first permanent molar teeth|MIH-effected carious permanent first molar teeth were well-demarcated white/yellow or brown/yellow enamel opacities which is a sign for hypomineralization and asymptomatic which meant to be without any spontaneous pain or pain during eating or drinking, percussion or palpation tenderness, formation of abcess or fistula.
89197963|NCT04061096|Active Comparator|not MIH-effected carious first permanent molar teeth|The carious not MIH-effected teeth were only carious without any hypomineralize areas and asymptomatic which meant to be without any spontaneous pain or pain during eating or drinking, percussion or palpation tenderness, formation of abcess or fistula.
89197964|NCT04061096|Placebo Comparator|MIH-effected non-carious first permanent molar teeth|MIH-effected teeth were carious permanent first molar teeth with well-demarcated white/yellow or brown/yellow enamel opacities which is a sign for hypomineralization and did not have any sign of caries.
89197965|NCT04061096|Placebo Comparator|not MIH-effected non-carious first permanent molar teeth|not any signs of being caries or hypomineralization.
89197966|NCT00750984|Experimental|1|This arm utilizes the anterolateral approach using the ReCap® Total Hip Resurfacing System.
89197967|NCT00750984|Active Comparator|2|This arm utilizes the posterior approach using the ReCap® Total Hip Resurfacing System.
89433961|NCT05882695|Experimental|Experimental Part 3: Open Label Extension - Active SPG302 administered to participants with ALS|Participants with ALS will be randomized to receive SPG302 or placebo at a 3:1 ratio. Study intervention will be administered QD over 28 days for up to 12 cycles. A follow-up safety visit will be conducted 30 days after last dose (±7 days).
89433962|NCT05882448|Active Comparator|Laparotomy|Exploratory and therapeutic laparotomy if necessary, in case of necrotic intestine requiring resection with anastomosis or stoma-type bowel diversion
89433963|NCT05882448|Experimental|Laparotomy and laparoscopy|Exploratory and therapeutic laparotomy if necessary preceded by laparoscopy with insufflation of CO2 (placement of a 3mm trocar in the left hypochondrium and insufflation of a pneumoperitoneum (carbon dioxide, pressure: 6 mmHg, flow rate: 1.5 Liter/minute) for a duration of at least 5 minutes.
89433964|NCT05881915|Active Comparator|phenylephrine|
89433965|NCT05881915|Active Comparator|epinephrine|
89433966|NCT05873192|Experimental|ADT plus Enzalutamide plus Talazoparib|Participant will recive ADT plus Enzalutamide for a total of 8 weeks. After about 8 weeks of ADT and Enzalutamide treatment, participant will begin taking Talazoparib
89433967|NCT05870553|Experimental|CTP0301-A|Subjects who are randomized into this group will take CTP0301-A from the evening before colonoscopy to the morning of colonoscopy.
89197968|NCT00954070||Case (subjects with NERD)|The investigators cases are subjects with confirmed NERD and include male or female patients aged between 21 and 65 years, who present with typical clinical manifestations of gastroesophageal reflux and have no esophageal mucosal breaks upon conventional white-light endoscopy examination but show evidence of pathologic gastroesophageal reflux on 24-hr pH monitoring.
89433968|NCT05870553|Experimental|CTP0301-B|Subjects who are randomized into this group will take CTP0301-B before the morning of colonoscopy.
89433969|NCT05870553|Active Comparator|Cool prep|Subjects who are randomized into this group will take Cool prep from the evening before colonoscopy to the morning of colonoscopy.
89433970|NCT05869877|No Intervention|Control|Proficient RN who works in IV Therapy Department - PIVC inserted without using ultrasound; non-bordered transparent dressing; 1-1.25 inch catheter; microbore extension set with neutral needleless connector; transpore tape. Standard of care
89197969|NCT00954070||Control|Healthy individuals aged between 21 and 65 years who are asymptomatic for GERD and other digestive diseases
89197970|NCT00957502|Experimental|One year aged staples|Subjects implanted with sterile staples aged to approximately one year.
89197971|NCT00957502|Experimental|18 month aged staples|Subjects implanted with sterile staples aged to approximately 18 months.
89197972|NCT00751062|Active Comparator|Timolol|
89197973|NCT00751062|Experimental|PhXA41|
88914127|NCT03536728|Experimental|Part 1|Dose escalation of AMXT1501 with a fixed low dose of DFMO will follow a 3 + 3 dose escalation design. The AMXT 1501 starting dose administered in the first cohort will be 80 mg (2 capsules); each capsule contains 40 mg of active drug. The dose will be given orally, once daily, fasted state alone for 14 days, and starting on Day 15 AMXT 1501 80 mg given in combination with fixed low-dose oral DFMO at 250mg 2x per day (BID), for an additional 14 days; for a total 28 days of treatment per cycle. Cycle 2 includes AMXT1501 + DFMO that will be administered for 28 days. The patient can be treated for additional 28 day treatment cycles as deemed appropriate by their study investigator. Dose escalation of AMXT1501 alone will increase per Part 1 cohort.
88914128|NCT03536728|Experimental|Part 2|"Dose escalation of DFMO with the Part 1 AMXT1501 RP2D fixed dose will follow a 3 + 3 dose escalation design.~The AMXT 1501 starting dose administered in the first cohort will be one level below the AMXT 1501 Part 1 RP2D with 500 mg DFMO BID. The morning dose will be given orally of both AMXT1501 and DFMO, in a fasted state. The evening dose of DFMO alone will be given prior to bed-time for 28 days per cycle. The patient can be treated for additional 28 day treatment cycles as deemed appropriate by their study investigator. Dose escalation of DFMO alone will increase per Part 2 cohort."
88914129|NCT03536728|Experimental|Expansion|The expansion cohort will include up to 14 evaluable patients at a proposed RP2D level of AMXT1501 and DFMO defined by Part 2 to further characterize safety at proposed RP2D dose level with repeat dosing, and characterize early anti-tumor activity.
89197974|NCT04031456|Experimental|Participants receiving PRP treatment|Women presenting with POI, 25-39 years of age, treated with autologous PRP intra ovarian infusion
89197975|NCT04031456|Placebo Comparator|Participants receiving Platelet Free Plasma (PFP) treatment|Women presenting with POI, 25-39 years of age, treated with autologous PFP intra ovarian infusion
89197976|NCT00948376||Patients|All ages
89197977|NCT00948376||Fetuses|
89197978|NCT00752700|No Intervention|1|Control group
89197979|NCT00752700|Active Comparator|2|Conventional resistance training program (CRT)
89197980|NCT00752700|Experimental|3|Whole body vibration resistance training (WBV) on the FITVIBE-platform
89197981|NCT00948454||Light smokers|2 blood draws, 3 urine collections and a test called an FMD which tests the circulation in your arm via ultrasound will be performed on the study day. Subjects will bring their own cigarettes on that day and smoke their regular amount. Female subjects will also have a pregnancy test done on the test day.
88914130|NCT03477305|Experimental|BerryCare Participants|Subjects will be recruited to participate in a community gardening program where they will learn the benefits of both physical active gardening and consuming homegrown foods through blackberry consumption.
88914131|NCT03477019|Experimental|Breast cancer target lesion|This arm will receive experimental treatment of focused ultrasound. In addition this arm will receive treatment with microbubbles intravenously and conventional chemotherapy for breast cancer.
88914132|NCT03477019|Other|Breast cancer control lesion|This arm will only receive treatment with conventional chemotherapy for breastcancer and microbubbles intravenously.
88914133|NCT03477019|Experimental|Colorectal cancer target lesion|This arm will receive experimental treatment of focused ultrasound. In addition this arm will receive treatment with microbubbles intravenously and conventional chemotherapy for colorectal cancer.
88914134|NCT03477019|Other|Colorectal cancer control lesion|This arm will only receive treatment with conventional chemotherapy for colorectal cancer and microbubbles intravenously.
88914135|NCT03462251|Experimental|Arm A|Combination of ribociclib and aromatase inhibitor or fulvestrant
88914136|NCT03462251|Active Comparator|Arm B|Capecitabine + bevacizumab OR Paclitaxel +/- bevacizumab
88914137|NCT03434132|Active Comparator|Open Radical Cystectomy|Open Radical Cystectomy, pelvic lymph node dissection, urinary diversion (neobladder or ileal conduit)
88914138|NCT03434132|Experimental|Robot assisted radical cystectomy|Robot assisted radical cystectomy, pelvic lymph node dissection, intracorporeal urinary diversion (neobladder or ileal conduit)
88914139|NCT03430479|Experimental|Cohort A|
88914140|NCT03430479|Experimental|Cohort B|
88914141|NCT03404089|Experimental|pharmacokinetic device|MON4STRAT system
88914142|NCT03327857|Experimental|Neihulizumab (ALTB-168)|Intravenous doses of Neihulizumab (ALTB-168)
88914143|NCT03272685|Experimental|Very Low Nicotine Content Cigarettes|Very low nicotine content cigarettes (0.4 mg/g nicotine; 9 mg of tar)
88914144|NCT03272685|Active Comparator|Normal Nicotine Content Cigarettes|Normal (Conventional) Nicotine Content (15.8 mg/g nicotine; 9 mg of tar)
88914145|NCT03272334|Experimental|Schedule #1|At approximately 4 weeks following leukapheresis, 8 infusions of HER2 BATs are given twice weekly in weeks #1, #2, #5, and #6 plus 1 infusion of Pembrolizumab in week #7. No interventions within weeks #3 and 4.
88914146|NCT03272334|Experimental|Schedule #2|At approximately 4 weeks following leukapheresis, 8 infusions of HER2 BATs are given twice weekly in weeks #1, #2, #5, and #6 plus 2 infusions of Pembrolizumab; the first given within weeks #3 - 4 and the second in week #7.
88914147|NCT03272334|Experimental|Schedule #3|At approximately 4 weeks following leukapheresis, 8 infusions of HER2 BATs are given twice weekly in weeks #1, #2, #5, and #6 plus 3 infusions of pembrolizumab; the first given one week prior to first BATs infusion, the second is given within weeks #3 - 4, and the third at week #7.
88914148|NCT03258281|Active Comparator|evolocumab 420mg|75 subjects on optimal statin therapy undergoing elective PCI will receive evolocumab 420mg.
88914149|NCT03258281|Placebo Comparator|placebo|75 subjects on optimal statin therapy undergoing elective PCI will receive placebo
88914150|NCT03231787|Experimental|Experimental group|"In this group the platelet aggregability will be evaluated and if it is normal, the surgery will be performed within 24-48 hours.~If it is not normal, the evaluation of platelet aggregability will be repeated daily until the third day or until it is normalized if it is earlier.~If at the third day is not normalized, it will proceed as with the control group, which will take into account the safety time of the drug."
88914151|NCT03231787|No Intervention|Control group|The control group will wait for the safety time of the drug according to the usual practice of the center.
88914152|NCT03230981|Experimental|Healthy subjects|Optical imaging of the cornea in healthy subjects
89433971|NCT05869877|Experimental|Bundled|Proficient RN who works in IV Therapy Department - 6 cm catheter inserted with or without ultrasound; chlorhexidine embedded transparent bordered dressing; transpore tape; microbore extension set with antireflux needleless connector
89433972|NCT05869526|Active Comparator|Fish oil|Fish oil 4 g/day
89433973|NCT05869526|Active Comparator|Krill oil|Krill oil 4g/day
89433974|NCT05869526|Placebo Comparator|Placebo|Vegetable oil 4g/day
89433975|NCT05866926|Experimental|Open Label|Drug: FAB122 Daily dose 100 mg
89433976|NCT05863234|Experimental|Treatment with PPMX-T003|
88914153|NCT05705388|Active Comparator|POSE2.0 Procedure|The POSE2.0 is a per-oral endoscopic gastroplasty procedure performed by the USGI Medical Incisionless Operating Platform (USGI Medical, San Clemente, CA) to deploy preloaded snowshoe suture anchors, and cinch create gastric endoscopic plications. In the POSE2.0 procedure a series of 15-20 pairs of snowshoes anchors are deployed along the greater curvature of the stomach from the proximal antrum to the proximal gastric body along narrowing the anteroposterior diameter of the stomach and decreasing its vertical length to improve satiety and satiation for weight loss. This device is registered and approved for obesity management in the United Arab Emirates, where the study is performed.
88914154|NCT05705388|Active Comparator|Liraglutide|Liraglutide is a GLP-1 agonists approved for the management of obesity. In the study, it will be Initiated at 0.6 mg subcutaneously daily for 1 week; increase by 0.6 mg/day in weekly intervals until a dose of 3 mg/day achieved. If patients do not tolerate an increased dose during dose escalation, dose escalation will be delayed for an additional week. The patient will continue at the maximal tolerated does up to 3mg per day. If the patient has not lost at least 4% of baseline body weight at 16 weeks from medication initiation, the medication will be discontinued.
88914155|NCT05705362|Experimental|Simple crossover arm|This arm will receive the main vessel stenting only (with proximal optimization technique).
88914156|NCT05705362|Active Comparator|Side branch opening arm|This arm will receive a side branch opening procedure after the main vessel stenting.
88914157|NCT05705336|Active Comparator|1. Tranexamic Acid Oral Product (n=30 cases)|Single dose of 1950 mg (3 tablets of 650 mg) was administered orally 2 hours before the surgical incision. The dose was administered by the nurse on duty who provided 100ml of water to swallow the pills.
88914158|NCT05705336|Placebo Comparator|2. Placebo (30 cases)|Nursery team would provide 100ml of water, and 3 tablets of placebo pills administered 2 hours prior to surgery.
88914159|NCT05705310|Experimental|Intervention Group|
88914160|NCT05705310|No Intervention|Control Group|Individuals in the control group will receive usual care
88914161|NCT05705284|Experimental|Patients participating in structured multidisciplinary medication review|Patients participating in structured multidisciplinary medication review
88914162|NCT05705245||recruitment|Patients who received alveolar recruitment manouever during bariatric surgery
88914163|NCT05705245||non recruitment|patients who did not receive alveolar recruitment manoeuver during bariatric surgery
88914164|NCT05705180||A Retrospective samples|"Retrospective (samples already stored, CoVaKo study cohort): Retrospective samples were consecutively collected during March 2020 and March 2022 (n=420).~Group 1A: RZV 1-12 months before COVID-19 -mRNA vaccination Group 1B: no RZV (control arm)"
88914165|NCT05705180||B Prospective samples|"Prospective (samples to be recruited, CoVaKo study cohort): Prospective samples will be collected April 2022 to July 2022 (n=180).~Group 2A: RZV 1-12 months before COVID-19 -mRNA vaccination Group 2B: no RZV (control arm)"
88914166|NCT05705141||Combined metabolic syndrome|HBeAg-positive CHB patients with metabolic syndrome
88914167|NCT05705141||Uncombined with metabolic syndrome|HBeAg-positive CHB patients without combined MS
89433977|NCT05861973|Experimental|Adaptive SMARTer intervention (|Smartphone application, diet and activity goals, online lessons, brief remote sessions with a Health Promotionist. Will have physical measures taken at baseline, 3 months, 6 months, 9 months, and 12 months.
89433978|NCT05861973|Experimental|Diabetes Prevention Program Participants (DPP)|Participant program manual, diet and activity logs, hour long remote sessions with a Health Promotionist. Will have physical measures taken at baseline, 3 months, 6 months, 9 months, and 12 months.
89433979|NCT05861973|No Intervention|Assessments-Only (Control)|Resources educating on leading a healthier lifestyle, including information on wellness and physical activity. Will have physical measures taken or extracted from the medical record at baseline, 3 months, 6 months, 9 months, and 12 months.
89433980|NCT05859620||Before implementation|Patients included before implementation of the PMI-screening
89433981|NCT05859620||After implementation|Patients included after implementation of the PMI-screening
89433982|NCT05855330|Active Comparator|L-arginine loading dose + standard dose|L-arginine loading dose (200 mg/kg IV) + standard dose (100 mg/kg IV TID).
89433983|NCT05855330|Active Comparator|Standard dose|Standard dose (100mg/kg IV TID).
88914168|NCT05705076|Placebo Comparator|Placebo without anticoagulation|Without any anticoagulation
88914169|NCT05705076|Active Comparator|Low Dose Direct Oral Anticoagulation|Apixaban 2.5 mg twice Rivaroxaban 10 mg plus placebo
89433984|NCT05855330|Active Comparator|Low dose|Low dose (25mg/kg IV TID).
89433985|NCT05854238|Experimental|TIRA-VoM|treated with transcatheter RF ablation system (TIRA catheter with its supplemental devices)
89433986|NCT05853458|Experimental|Hydroxyurea (HU)|Participants will be treated with HU capsules, orally taken, for a maximum duration of 15 months.
88914170|NCT05705063|Experimental|Bipolar Patients|Patients follow ketogenic diet for 16 weeks, with monitoring of physical and psychological health and coaching support
88914171|NCT05705037|Sham Comparator|Group A (CPP-ACPF mousse + sham light therapy)|CPP-ACPF mousse (MI Paste®) was applied with a microbrush on the cervical buccal surface of each tooth for 5 minutes and it was subsequently distributed for 20 seconds with a rubber cup coupled to a low speed handpiece. Right after, a sham therapy was performed, using RAFFAELLO 980 BIO - Dental Medical Technologies - DMT S.r.l. Although the device was switched on, the hand piece did not work and the sound was emitted by a mobile phone. The tip of the laser device was positioned on two areas for each dental element, located one in the center of the cervical region and the other in the middle third of the crown.
88914172|NCT05705037|Placebo Comparator|Group B (placebo mousse + PBMT)|A placebo mousse (Elmex Junior®) was applied with a microbrush on the cervical buccal surface of each tooth for 5 minutes and it was subsequently distributed for 20 seconds with a rubber cup coupled to a low speed handpiece. Right after, a PBMT was performed, using RAFFAELLO 980 BIO - Dental Medical Technologies - DMT S.r.l. The tip of the laser device was positioned on two areas for each dental element, located one in the center of the cervical region and the other in the middle third of the crown. The parameters used were: wavelength 980 nm, power 4 W, irradiation area1 cm2, application time 15 sec per 1 cm2, energy density 60 J/cm2
88914173|NCT05705037|Experimental|Group C (CPP-ACPF + PBMT)|CPP-ACPF mousse (MI Paste®) was applied with a microbrush on the cervical buccal surface of each tooth for 5 minutes and it was subsequently distributed for 20 seconds with a rubber cup coupled to a low speed handpiece. Right after, a PBMT was performed, using RAFFAELLO 980 BIO - Dental Medical Technologies - DMT S.r.l. The tip of the laser device was positioned on two areas for each dental element, located one in the center of the cervical region and the other in the middle third of the crown. The parameters used were: wavelength 980 nm, power 4 W, irradiation area1 cm2, application time 15 sec per 1 cm2, energy density 60 J/cm2
88914174|NCT05704998|Experimental|Posterior Edentulous Group|Posture exercises, manual therapy and kinesio taping were applied twice a week for six weeks.
88914175|NCT05704998|Experimental|Fully Toothed Group|Posture exercises, manual therapy and kinesio taping were applied twice a week for six weeks.
88914176|NCT05704972||Operation Room Nurses|
88914177|NCT05704959|Other|Measurement|
88914178|NCT05704894|Experimental|Intervention group|"Administration of Erythropoietin 150UI/Kg/week divided into 3 doses, IV, for a period of 12 weeks, in patients with hemoglobin between <12g/dL.~Every week (1 to 12), the study medication will be administered 3 times, according to the proposed treatment, for those allocated in the intervention group. All assessments, procedures and notes must be recorded in a source document and in a CRF."
88914179|NCT05704894|No Intervention|Control Group|For the control group, the procedures will be performed according to the institution's standard treatment (Vitamin B12 and folic acid). The use of Iron, Vitamin B12 and folic acid will be allowed both in the intervention arm and in the control arm. Doses should be prescribed at the physician's discretion.
88914180|NCT05704881||Patient admitted for acute Exacerbation of Chronic Obstructive Pulmonary Disease|Patient admitted for acute Exacerbation of COPD. The measurement of EtCO2 will be performed at the emergency department
88914181|NCT05704842|Other|Exercise|Intervention: Subject will be assessed by a Physical Therapist. Based on the assessment, the Physical Therapist will provide the patient with a home-based exercise program including core exercises as follows: Core Stabilization, core extension, leg extensions, squats with and without weights, shoulder and arm exercises. Patients will be asked to complete a symptom survey weekly via a web-based platform for tracking cancer and treatment-related symptoms and fatigue.
88914182|NCT05704842|No Intervention|Control|Subject will not be provided an exercise program but will be asked to complete the symptom survey weekly via a web-based platform for tracking cancer and treatment-related symptoms and fatigue.
88914183|NCT05704816||Quincke (Q)-25 Gauge|
88914184|NCT05704816||Quincke (Q)-26Gauge|
88914185|NCT05704816||Quincke (Q)-27 Gauge|
88914186|NCT05704816||Pencil-point (P)-25Gauge|
88914187|NCT05704816||Pencil-point (P)-26Gauge|
88914188|NCT05704816||Pencil-point (P)-27Gauge|
88914189|NCT05704777|Experimental|exercise|The intervention (endurance + resistance training) group will perform 48 training sessions (24 weeks, twice per week). In each session, they will perform the leg and arm cycling exercises during the first half of the session (15 minutes of leg cycling and 15 minutes of arm cycling) and resistance training exercises involving the lower-body (e.g., squat) and upper-body (e.g., a variety exercises performed against the resistance imposed by elastic bands) during the second half of the session.
88914190|NCT05704777|No Intervention|control|The control group will not perform any supervised training program, and will follow standard care.
88914191|NCT05704699|Experimental|eTRE|participants allocated to this group are required to consume food during 0800h and 1600h.
88914192|NCT05704699|Active Comparator|eTRE with BISC|participants allocated to this group are required to consume food during 0800h and 1600h as well as complete 3 sessions of BISC per week.
88914193|NCT05704660|Experimental|Adjusted and modified Cognitive-Biased Modification Task|The intervention is based on a Go/No-Go task.
88914194|NCT05704660|Placebo Comparator|Normal Cognitve-Biased modification Task|The Sham-intervention is based on a Go/No-Go task.
88914195|NCT05704608|Experimental|Experimental Group|Aerobic training program was performed by participants.
88914196|NCT05704608|No Intervention|Control group|No intervention was performed by the participants.
88914197|NCT05704413||digestive cancer or IBD|Patient with digestive cancer or IBD having surgery with intestinal resection planned in the Visceral Surgery Department of St Antoine Hospital
88914198|NCT05704348|Active Comparator|No gastropexy|Sleeve gastrectomy without gastropexy.
88914199|NCT05704348|Experimental|Gastropexy|Sleeve gastrectomy with gastropexy
89433987|NCT05851898|Experimental|Duloxetine 30mg|Duloxetine 30mg daily 90 day supply and 3 refills
88914200|NCT05704270|Experimental|Adaptive cognitive training|This arm is the intervention arm. Participants randomized to this arm will use a tablet to receive the multi-domain adaptive cognitive training, which will be delivered 30 minutes at least 5 times a week for 12 weeks.
88914201|NCT05704270|Active Comparator|Active control|This arm is the control arm. Participants randomized to this arm will use the same tablet to receive the cognitive training of low difficulty level with no adaptive change. The intervention dosage will be the same, which is 30 minutes each time, at least 5 times a week for 12 weeks.
88914202|NCT05704231|Experimental|Experimental: Intervention Group|Motivational Interviewing with WhatsApp video call The individuals in the intervention group will be given a smoking cessation education and motivational interview with a WhatsApp video call for 3 months. The motivational interview will be applied every two weeks, 6 times in total. Self-efficacy scale and smoking behavior scale will be administered again at 3, 6 and 12 months after the intervention. tumor recurrence and progression will be checked by cystoscopy at 3rd and 12th months
88914203|NCT05704231|No Intervention|No Intervention: Control Group|the control group received the routine care/education provided in the hospital. Self-efficacy scale and smoking behavior scale will be administered again at 3, 6 and 12 months after the routin hospital care. Both intervention and control groups' tumor recurrence and progression will be checked by cystoscopy at the 3rd and 12th months
88914204|NCT05704218|Other|domestic HP|"All the patients will be in the same arm until obtention of the final diagnosis.~The final diagnosis will be used to compare data of serology to determine thresholds"
88914205|NCT05704140||catheter based dialysis|All patients receiving catheter based dialysis in Vienna as of November 2022
88914206|NCT05704127|Experimental|Intelligent Moxibustion Robot|The intelligent moxibustion robot holds the thunder fire moxibustion stick and conducts suspension moxibustion treatment on the points BL23, BL25, DU3 and pain points for 10 minutes in each group, a total of 40 minutes. BL23 and BL25 have one acupuncture point on each side of the spine, and the straight line reciprocating moxibustion technique is adopted. DU3, a single point, adopts the whirling moxibustion technique. Pain points,according to the number of pain points, choose straight reciprocating moxibustion or rotary moxibustion.
88914207|NCT05704127|Experimental|Artificial moxibustion|The people hold the thunder fire moxibustion stick and conducts suspension moxibustion treatment on the points BL23, BL25, DU3 and pain points for 10 minutes in each group, a total of 40 minutes. BL23 and BL25 have one acupuncture point on each side of the spine, and the straight line reciprocating moxibustion technique is adopted. DU3, a single point, adopts the whirling moxibustion technique. Pain points,according to the number of pain points, choose straight reciprocating moxibustion or rotary moxibustion.
88914208|NCT05704114|Experimental|Treatment Arm|This is a single arm study. All participants are receiving the treatment.
88914209|NCT05704088|Active Comparator|study group|Study group: will receive SGLT2i as add on drug or replace another drug according to the patient clinical situation, Dapagliflozin 10 mg will be used once daily with or without food for one year.
88914210|NCT05704088|Placebo Comparator|control group|Control group: will receive placebo as add on drug once daily with or without food for one year.
88914211|NCT05704075|Other|Control Group|Conventional Treatment: Dressing + Negative Pressure Wound Therapy
89433988|NCT05851196||Patients with non-specific low back pain|Individuals with chronic non-specific ow back pain
89433989|NCT05851196||Healthy controls|Healthy, age- and sex-matched individuals without low back pain
88914212|NCT05704075|Experimental|TTT Group|Dressing + Negative Pressure Wound Therapy + Transverse Tibial Transport
88914213|NCT05704023|Experimental|Mobile app (WIapp) group|"Standard physical therapy program: 2x10 sessions, 5 times a week, 3-week break in between;~Mobile app with instructions on exercise at home and daily reminder to exercixse"
88914214|NCT05704023|No Intervention|Control group|Standard physical therapy program: 2x10 sessions, 5 times a week, 3-week break in between, written instructions on exercises at home
88914215|NCT05703997|Experimental|Maintenance treatment with cyclic, 5-day calorie restriction plus atezolizumab|"The experimental maintenance treatment will consist of:~triweekly cycles of 5-day calorie restriction (on days -2 through 2 of each cycle) in combination with~atezolizumab (at a dose of 1200 mg, administered intravenously on day 0 of each cycle)~The experimental maintenance treatment will be administered until the occurrence of unacceptable toxic effects, disease progression, consent withdrawal or patient death.~Patients interrupting cyclic calorie restriction for any reason other than disease progression may continue the maintenance treatment with atezolizumab alone, if clinically indicated."
88914216|NCT05703984|Experimental|GC2129A + Reference drugs|Period 1: GC2129A Period 2: Individual Components
88914217|NCT05703984|Experimental|Reference drugs + GC2129A|Period 1: Individual Components Period 2: GC2129A
89433990|NCT05848661|Experimental|AUDISSEE-verbal, AUDISSE-non-verbal, Placebo, Placebo|"In this arm, the group will perform first the AUDISSEE therapy starting with the verbal sub-training then the non-verbal sub-training. Then it will perform the placebo training for 10 weeks.~The AUDISSEE therapy takes place over 10 weeks with 3 sessions of 20 minutes per week. It is divided into two parts (5 weeks for each part):~verbal training exercises in noise that are specifically aimed at improving patients' intelligibility in noise~non-verbal training exercises using environmental sounds and musical sounds, which are specifically aimed at improving non-verbal auditory perception"
88914218|NCT05703932|No Intervention|Group One|AS patients diagnosed according to ASAS criteria under pharmacological treatment using NSAID ,anti-tnf and DMARD
89197982|NCT00948454||Heavy Smokers|2 blood draws, 3 urine collections and a test called an FMD which tests the circulation in your arm via ultrasound will be performed on the study day. Subjects will bring their own cigarettes on that day and smoke their regular amount. Female subjects will also have a pregnancy test done on the test day.
89197983|NCT00948454||Non Smokers|2 blood draws, 3 urine collections and a test called an FMD which tests the circulation in your arm via ultrasound will be performed on the study day. Female subjects will also have a pregnancy test done on the test day.
89197984|NCT00957736||Allogeneic stem cell transplant|Stem cells from a genetically non-identical donor transplanted into a patient.
89433991|NCT05848661|Experimental|AUDISSE-non-verbal, AUDISSEE-verbal, Placebo, Placebo|In this arm, the group will perform first the AUDISSEE therapy starting with the non-verbal sub-training then the verbal sub-training. Then it will perform the placebo training for 10 weeks.
89197985|NCT00751374|Other|group A|Topical gentamicin cream
89433992|NCT05848661|Placebo Comparator|Placebo, Placebo, AUDISSEE-verbal, AUDISSE-non-verbal|"In this arm, the group will perform first placebo training for 10 weeks. Then, it will perform the AUDISSEE therapy starting with the verbal sub-training then the non-verbal sub-training.~At each session of the placebo therapy, the patient will listen to an excerpt from an audio-book or podcast of similar length to the duration of the training exercises (20 min).~This therapy engages the patient in a similar manner than the AUDISSEE therapy in terms of time spent (same session frequency, same session duration), but does not specifically train auditory perception networks."
89433993|NCT05848661|Placebo Comparator|Placebo, Placebo, AUDISSE-non-verbal, AUDISSEE-verbal|In this arm, the group will perform first placebo training for 10 weeks. Then, it will perform the AUDISSEE therapy starting with the non-verbal sub-training then the verbal sub-training.
88914219|NCT05703932|Active Comparator|Group Two|AS patients diagnosed according to ASAS criteria under pharmacological treatment using NSAID ,anti-tnf and DMARD ;and will take exercise program including; joint range of motion and stretching exercises for cervical, thoracic and lumbar spine, stretching for erector spina, hamstring and shoulder muscles, chest expansion, abdominal and diaphragmatic breathing exercises . Exercises will be performed at submaximal level, paying attention to blood pressure, arterial (TA) and heart rate.For the patients in the exercise group, it was planned to perform the exercise program 5 days a week in 1 set with 10 repetitions, 40 minutes/day.
89433994|NCT05848596|Active Comparator|Hand hygiene training|Hand hygiene theoretical training and simulation application
89433995|NCT05848596|Placebo Comparator|Observation group|Hand hygiene theoretical training was given.
89433996|NCT05847686|Experimental|Treatment (psilocybin, therapy)|Patients receive psilocybin PO and participate in group and individual therapy sessions on trial.
89433997|NCT05842902|Experimental|mPRISM|The Experimental (mPRISM) arm will receive mPRISM upon completion of their baseline study surveys.
89433998|NCT05842902|Other|Waitlist control|Usual Care (UC) available to both study arms consists of standard non-directed supportive care provided for all patients including an assigned social worker throughout cancer treatment. In a waitlist design, the UC arm will receive mPRISM upon completion of 3-month follow-up surveys.
89433999|NCT05841485||Stable angina patients with a history of severe COVID-19 infection requiring mechanical ventilation|Patients with a history of severe COVID-19 infection (confirmed by a polymerase chain reaction test) requiring mechanical ventilation. This group includes patients who have been recently diagnosed with stable angina and have previously experienced a severe COVID-19 infection that necessitated mechanical ventilation support during their illness.
89434000|NCT05841485||Patients with stable angina without a history of COVID-19 (Group B)|Patients without a history of COVID-19. This group consists of patients who have been diagnosed with stable angina but have no history of COVID-19 infection. This group serves as a comparison group to assess the potential impact of severe COVID-19 infection on coronary microvascular dysfunction in patients with stable angina.
89434001|NCT05840211|Experimental|Sacituzumab Govitecan-hziy (SG)|Participants will receive SG at a dose of 10 mg/kg infusion on Days 1 and 8 of a 21-day cycle.
89434002|NCT05840211|Active Comparator|Treatment of Physician's Choice (TPC)|"Participants will receive TPC determined prior to randomization to 1 of the 3 allowed regimens:~paclitaxel 80 mg/m^2 over 1 hour (± 10 minutes) on Days 1, 8, and 15 of a 28-day cycle.~nab-Paclitaxel 100 mg/m^2 over 30 minutes (± 10 minutes) on Days 1, 8, and 15 of a 28-day cycle.~capecitabine at 1000-1250 mg/m^2 twice daily for 2 weeks followed by a 1-week rest period of a 21-day cycle."
88914220|NCT05703906|Experimental|Telerehabilitation|"All patients will receive a kit home-based consisting of a tablet home, an exercise equipment and access to a daily individualized training program based on their needs (i.e., motor, language and/or cognitive training programs).~The exercise program and patients' sessions will be remotely supervised by therapists."
88914221|NCT05703802||Sepsis|Withdrawal of 3 blood collection tubes for ELISA-measurements at a single time during hyperprocalcitoninemia.
89197986|NCT00751374|Active Comparator|Group B|topical gentamicin cream alternates with mupirocin cream at monthly basis
89434003|NCT05836623|Experimental|Part A - Optimisation Phase|Following administration of 89Zr-CB307, patients will undergo PET scans The timing of the scans and CB307 dose administration will be determined by the Optimisation Review Committee (ORC)
88914222|NCT05703802||SIRS|Withdrawal of 3 blood collection tubes for ELISA-measurements at a single time during hyperprocalcitoninemia.
88914223|NCT05703802||Adiposity|Withdrawal of 3 blood collection tubes for ELISA-measurements at a single time during hyperprocalcitoninemia.
88914224|NCT05703802||Granulomatosis with polyangiitis / microscopic polyangiitis|Withdrawal of 3 blood collection tubes for ELISA-measurements at a single time during hyperprocalcitoninemia.
88914225|NCT05703802||Pre-eclampsia|Withdrawal of 3 blood collection tubes for ELISA-measurements at a single time during hyperprocalcitoninemia.
88914226|NCT05703802||Healthy controls|Withdrawal of 3 blood collection tubes for ELISA-measurements at a single time during hyperprocalcitoninemia.
89434004|NCT05836623|Experimental|Part B - Expansion phase|89Zr-CB307 PET scanning will be performed based on the optimal dosing and timing determined in Part A by the Optimisation Review Committee (ORC)
88914227|NCT05703789|Experimental|Oral rehabilitation|Name Oral rehabilitation. Patients receiving dental treatment will be allocated to one of two different treatment groups based on individual treatment need and proven experience. Patients in group 1 will be treated with minimal invasive treatment, with restorative composite fillings. Patients in group 2 will be treated with prosthetic rehabilitation, dental crowns.
88914228|NCT05703789|Other|Waiting list|Name: Waiting list. Patients in waiting list will receive no treatment. After four months they will be offered to be included in the oral rehabilitation arm.
89434005|NCT05833945||Pre-hospital and in-hospital patients|Patients recruited at the ambulance (ARM A) and at the hospital (ARM B).
89434006|NCT05832645|Experimental|A novel mindfulness approach|
89434007|NCT05832645|Other|Breathing meditation|
89434008|NCT05832606|Experimental|High Fiber diet|During the first 12 weeks of immune checkpoint inhibitor therapy, patients will receive weekly boxes containing 30 different plants (vegetables, fruits, nuts, grains) according to seasonal availability following the Flemish Superior Health Council guidelines. Recipes will be added to inspire processing of the box. Boxes will be ordered at an online supermarket, who will deliver the boxes at patients' homes. Weekly follow-up will ensure a minimum daily intake of 20 g of fiber, progressively increasing over the first 4 weeks.
89434009|NCT05831176|Experimental|Part A: Phase 2|Randomized 1:1
89434010|NCT05831176|Experimental|Part B: Phase 3|Randomized 1:1:1
89434011|NCT05831176|Experimental|Part C: Extended Active Treatment Period|Eligible participants from Part A and Part B will enter Part C. Part A participants will get Dose 1. Part B participants who received Dose 1 or Dose 2 will remain on Dose 1 or Dose 2. Part B placebo participants will be randomized 1:1 to receive Dose 1 or Dose 2.
89434012|NCT05827965|Experimental|patients with secondary adrenal insufficiency|education and treatment adjustment
89434013|NCT05827614|Experimental|Single Agent Dose Escalation|Single agent BBI-355, administered orally in 28-day cycles
89434014|NCT05827614|Experimental|Single Agent Dose Expansion|Single agent BBI-355, administered orally in 28-day cycles
89434015|NCT05827614|Experimental|Dose Escalation in Combination with EGFR Inhibitor|Combination therapy of BBI-355 and EGFR inhibitor erlotinib, administered orally in 28-day cycles.
89434016|NCT05827614|Experimental|Dose Escalation in Combination with FGFR Inhibitor|Combination therapy of BBI-355 and FGFR1-4 inhibitor futibatinib, administered orally in 28-day cycles.
89434017|NCT05827016|Experimental|Arm A1: Iberdomide Dose 1|
89434018|NCT05827016|Experimental|Arm A2: Iberdomide Dose 2|
89434019|NCT05827016|Experimental|Arm A3: Iberdomide Dose 3|
89009932|NCT04670029|Experimental|APA|"During the first 3 cures, 3 APA sessions will be offered per week:~2 sessions of anaerobic type of 1 hour with muscle strengthening, stretching, flexibility and balance, supervised in the room,~1 aerobic type exercise session of 1.5 hours (Nordic walking: outdoors) or a 3rd indoor session if not possible,~+ home exercise book if the patient so wishes with record the time in minutes per session and the intensity felt and the modalities of the exercises carried out.~During the 5 remaining cycles, 3 APA sessions will be offered per week:~1 session of 1 hour in an anaerobic exercise room (muscle strengthening, stretching, flexibility, balance) supervised,~1 session of anaerobic exercise per week in autonomy at home (with exercise book),~1 or more session per week of one hour of walking or cycling independently at home (aerobic effort) with declaration in the logbook of the intensity of exertion felt and the time in minutes per session."
89009933|NCT04669951|Experimental|uPAR expression|Immunohistochemistry
89434020|NCT05827016|Active Comparator|Arm B: Lenalidomide|
89434021|NCT05826561|No Intervention|Control Clinicians - post test only|N=25 control pediatric clinicians, who will receive the post test only. Each clinician will be presented with 10 randomly selected vignettes of 10 children [5 with and 5 without asthma] and asked to provide a prediction of a child's asthma risk at 6-10 years.
89009934|NCT00234221|Active Comparator|Strengths Based Case Management Model (SBCM)|The Strengths Based Case Management Model (SBCM) consists of 5 case-management sessions designed to promote linkage and engagement in assessment and treatment services, while assisting with the patient's perceived needs, as well as personal strengths and barriers to linkage and engagement.
89197987|NCT02566694||Failed implants|All patients undergoing revision of an orthopaedic implant (previously this was limited to metal hips but this has now expanded to other orthopaedic implants)
89197988|NCT02566694||Controls with different failure modes|We will compare findings with different types of orthopaedic implants and categories of failure mode.
89197989|NCT00954148|Active Comparator|PET/CT follow-up|PET/CT with history and physical exams at 3,9,18,36,60 months only
89197990|NCT00954148|Other|conventional follow-up|NCCN recommendations
89434022|NCT05826561|Experimental|PDM Intervention Clinicians - post test only|N=25 intervention pediatric clinicians, who will receive the post test only. Using the PDM, each clinician will be presented with 10 randomly selected vignettes of 10 children [5 with and 5 without asthma] and asked to provide a prediction of a child's asthma risk at 6-10 years.
89434023|NCT05826561|No Intervention|Control Clinicians - pre and post test|N=25 control pediatric clinicians, who will receive the pre and post test. Each clinician will be presented with 10 randomly selected vignettes of 10 children [5 with and 5 without asthma] and asked to provide a prediction of a child's asthma risk at 6-10 years.
89434024|NCT05826561|Active Comparator|PDM Intervention Clinicians - pre and post test|N=25 intervention pediatric clinicians, who will receive the pre and post test. Using the PDM, each clinician will be presented with 10 randomly selected vignettes of 10 children [5 with and 5 without asthma] and asked to provide a prediction of a child's asthma risk at 6-10 years.
89434025|NCT05825781|Experimental|Pertuzumab (manufactured by Mabscale, LLC)|Eligible subjects (57 healthy men) will receive once Pertuzumab 420 mg/14 ml in 250 ml 0,9 % NaCl intravenous on the Visit 2. The following visits are the visits of safety and pharmacokinetics visits.
89434026|NCT05825781|Active Comparator|Perjeta®|Eligible subjects (57 healthy men) will receive once Perjeta® 420 mg/14 ml in 250 ml 0,9% NaCl intravenous on the Visit 2. The following visits are the visits of safety and pharmacokinetics visits.
89434027|NCT05818644||Conservative treatment|
89434028|NCT05818644||Surgical revascularization|
89434029|NCT05818644||Endovascular revascularization|
89434030|NCT05818644||Re-transplantation|
89434031|NCT05815797|Experimental|SDD Formula|Subjects will receive SDD Formula granules (37g twice daily) for 12 weeks.
89434032|NCT05815797|Placebo Comparator|Placebo|Subjects will receive placebo granules (37g twice daily) for 12 weeks.
89434033|NCT05814679|Experimental|Intervention Group|The patient will relax with virtual reality in the hemodialysis center with the researcher.
89434034|NCT05814679|Placebo Comparator|Control Group|The patients in the control group will be given a training on the functions of the kidneys.
89434035|NCT05809557|Placebo Comparator|Usual Care|
89434036|NCT05809557|Experimental|Chemotherapy Toxicity Tool|
89434037|NCT05807906|Experimental|Intervention Group|virtual reality will be applied in the fistula puncture procedure in patients receiving hemodialysis treatment.
89434038|NCT05807906|No Intervention|Control Group|Routine nursing care and diet compliance narration
89434039|NCT05807399|Experimental|Arm 1 (Stage 1)|Rifampicin 2,100mg, isoniazid 300mg, pyrazinamide 1,600mg moxifloxacin 600mg; given once daily for 17 weeks (R2100HZM600)
89434040|NCT05807399|Experimental|Arm 2 (Stage 1)|Rifampicin 2,100mg, isoniazid 300mg, pyrazinamide 2,000mg/2,400mg, moxifloxacin 600mg; given once daily for 12 weeks (R2100HZoptM600)
89434041|NCT05807399|Active Comparator|Arm 3|Stage 1: control arm (2HRZE-4RH) Stage 2: continuation of control-arm from STAGE 1 (2HRZE-4RH)
88914229|NCT05703776|Experimental|Nordic Walking|2 weekly sessions of supervised Nordic Walking in a city park with trees, grass, and ponds. Exercise intensity was set at 65%-75% of age-predicted maximal heart rate. The length of training was consecutive 10 weeks
88914230|NCT05703776|No Intervention|control|no intervention
88914231|NCT05703698|Experimental|Cognitive Behavioural Therapy for psychosis|CBTp will be delivered according to an established manual that the PI has previously used successfully for in-person treatment. Treatment will consist of individual sessions with a psychologist employed by the University of Toronto for 1-hour per week for 6-months, or by one of the listed clinical graduate students under his supervision. All treatment will be delivered in-person. This treatment will be delivered in addition to usual care and no changes to usual care will be required.
88914232|NCT05703620|Experimental|Chronic Kidney Disease|Renal Denervation
88914233|NCT05703620|Experimental|Heart Failure|Renal Denervation
89434042|NCT05807399|Experimental|Arm 4 (Stage 2)|Rifampicin, Isoniazid, and Pyrazinamide in weight-banded standard dosages with BTZ-043 1,000mg; given once daily for 17 weeks (RHZT), then rifampicin and isoniazid in weight-banded dosages; given once daily for 9 weeks (RH)
88914234|NCT05703620|Experimental|End stage renal disease|Renal Denervation
88914235|NCT05703594|Other|Dokuz Eylul University|Dokuz Eylul University Clinic
88914236|NCT05703581||PD(TRIANGLE)|"Patients with pancreatic head cancer or periampullary cancer underwent Heidelberg Triangle dissection (TRIANGLE operation) combined with Pancreatoduodenectomy and standard lymphadenectomy"
88914237|NCT05703581||PD(non-TRIANGLE)|Patients with pancreatic head cancer or periampullary cancer underwent pancreatoduodenectomy with standard lymphadenectomy
88914238|NCT05703581||DP(TRIANGLE)|"Patients with carcinoma of the body and tail of the pancreas underwent Heidelberg Triangle dissection (TRIANGLE operation) combined with distal pancreatectomy and standard lymphadenectomy"
89434043|NCT05805566||Post-Covid Syndrome Patients|
89434044|NCT05802277|Experimental|Menstrual cycle group|Women who are not currently taking any form of hormonal contraception and who present a regular menstrual cycle.
89434045|NCT05802277|Active Comparator|Oral contraceptive group|Women taking a second-generation oral contraceptive estrogen-progestogen pill.
89434046|NCT05797662|Experimental|Propranolol|Propranolol Twice Daily (BID) x 12 weeks Dosage: For ages ≤ 12 years: 3mg/kg/day divided BID; for ages > 12 years, 120 mg BID.
89434047|NCT05797506|Experimental|Sulforaphane (Avmacol Extra Strength)|Four tablets of Sulforaphane (Avmacol Extra Strength) per day. The tablets will be provided by Nutramax.
89434048|NCT05797506|Placebo Comparator|Placebo|Nutramax will provide the matched placebo tablets.
89434049|NCT05796427|Experimental|START Intervention|Participants in the experimental group will be part of a 6-module weekly intervention where they will learn more about ADHD and its treatment.
89434050|NCT05796427|No Intervention|Educational Brochure|Participants in the control group will receive an educational brochure by Children and Adults with Attention-Deficit/Hyperactivity Disorder (CHADD).
88914239|NCT05703581||DP(non-TRIANGLE)|Patients with carcinoma of the body and tail of the pancreas underwent distal pancreatectomy with standard lymphadenectomy
88914240|NCT05703529|Experimental|Positive Psychotherapy group|
89434051|NCT05794763|Experimental|Body Project: In Person Delivery|In the in-person peer-led group intervention, participants voluntarily engage in verbal, written, and behavioral exercises in which they critique and discuss the costs of pursuing the thin-ideal ideal. The intervention is 4 sessions long (1-hr each) and is administered by trained peer facilitators who use an intervention script. Participants will be asked to complete weekly home exercises throughout the course of the intervention.
88914241|NCT05703529|Other|Control group|Usual Care means treating as usual, including a regular home visit.
88914242|NCT05703308|Experimental|MenSCs group|Study group, treated with autologous intra-ovarian MenSCs injection and monitored for spontaneous pregnancy for 3 months after intervention. ICSI was used in cases where the pregnancy did not occur naturally.
88914243|NCT05703308|No Intervention|ICSI group|Control group, monitored for spontaneous pregnancy for 3 months after their last ovarian stimulation for ICSI or IVF. ICSI was used in cases where the pregnancy did not occur naturally.
88914244|NCT05702320|Experimental|Reference Group|Patients in this group will be warmed for 15 minutes with a full-body blanket belonging to the air-blown heater device before surgery. The heating will be Decelerated until he is taken to the operating table, and after the preparations are completed, the lower extremities will continue to be heated with a half-body blanket belonging to the heating device. After the patient is taken to the post-anesthesia care unit, the soaked blankets will be removed and the whole body will continue to be warmed with a blanket as in the preoperative period. When the patient's body temperature rises above 36 °C, the heating process will be terminated and when he meets the criteria for being transferred to the clinic, his transfer to the clinic will be provided in accordance with the institution's policy.
89434052|NCT05794763|Experimental|Body Project: Virtual Delivery|In the virtual peer-led group intervention held over Zoom, participants voluntarily engage in verbal, written, and behavioral exercises in which they critique and discuss the costs of pursuing the thin-ideal ideal. The intervention is 4 sessions long (1-hr each) and is administered by trained peer facilitators who use an intervention script. Participants will be asked to complete weekly home exercises throughout the course of the intervention.
88914245|NCT05702320|Experimental|intervention group|The patients in this group will be wrapped with a reflective blanket from the neck to the whole body with the reflective side facing the patient for 15 minutes before the operation, so that only the surgical gown is on the patients in this group. After a layer of operating room cover is placed on the patient's lower extremities on the operating table in accordance with the hospital procedure, a reflective blanket will be wrapped on it with the reflective side facing the patient. After the patient is taken to the post-anesthesia care unit, the soaked covers will be removed and the entire body of the patient will be wrapped with a reflective blanket, as in the preoperative period. When the patient's body temperature rises above 36 °C and he meets the criteria for being transferred to the clinic, his transfer to the clinic will be provided in accordance with the institution's policy.
88914246|NCT05702320|No Intervention|control group|No heating procedure will be performed by the researcher in this group of patients during the perioperative period, only the number of covers provided for heating in the post-anesthesia care unit will be recorded. The duration of stay in the post-anesthesia care unit, the transfer of the patient to the clinic and the follow-up in the clinic will be carried out according to the hospital procedure.
88914247|NCT05702190|Active Comparator|Opium tincture|Administration of opium tincture (Dropizol)
89434053|NCT05792774|Experimental|Phrenic nerve anesthetics infiltration|The experimental intervention will consist of ultrasound-guided anesthetic blockade of the phrenic nerve at the laterocervical supraclavicular level with 1 ml of lidocaine without vasoconstrictor 2% to infiltrate the skin and 3ml of bupivacaine without vasoconstrictor 0.25% for neural blockade, making the local anesthetic surround the nerve between the anterior scalene muscle and the sternocleidomastoid muscle.
89434054|NCT05792774|Placebo Comparator|Physiological serum infiltration|The placebo intervention will be similar in relation to 2% lidocaine without vasoconstrictor for the skin, but an ultrasound-guided puncture will be performed at the level of the subcutaneous cellular tissue by injecting 3 ml of physiological saline.
89434055|NCT05788666|Experimental|Geriatric Assessments using GeriKit App|Participants will receive comprehensive geriatric assessment via GeriKit app at baseline. All participants will complete a follow-up assessment via phone at 6 months. 20 of the 150 enrolled participants will continue onto a qualitative questionnaire after the completion of the 6-month follow up call.
89434056|NCT05788497|Experimental|Hemorrane® Plus|Daily application of Hemorrane Plus (Hemorrane® + benzocaine) 10 mg/g rectal ointment + 30 mg/g benzocaine for 7 days.
89197991|NCT03951194|Experimental|Participants receiving PRP treatment|Perimenopausal women, 40-50 years of age, treated with autologous PRP intra ovarian infusion.
88914248|NCT05702190|Placebo Comparator|Placebo|Administration of placebo (identical to opium tincture in taste and appearance)
88914249|NCT05701124|Active Comparator|Aggressive ROP|Intravitreal injection (IVI) was performed under topical anesthesia in standard ophthalmic operating room. 5% povidone-iodine disinfection and topical antibiotic were instilled. Ranibizumab (0.25 mg/0.025 mL) was injected into the vitreous cavity with a 31-gauge needle, aiming the needle directly toward the optic nerve in direction of visual axis 1.0 mm posterior to the corneoscleral junction at the inferotemporal quadrant.
89197992|NCT03951194|Placebo Comparator|Participants receiving Platelet Free Plasma (PFP)|Perimenopausal women, 40-50 years of age, treated with autologous PRP intra ovarian infusion.
89197993|NCT00957814|Experimental|Control|Usual care with medical and nursing staff
89197994|NCT00957814|Experimental|Intervention|Usual care with medical and nursing staff and additional nutritional guidance about diet and its relationship with disease, sources of nutrients, and reduction of dietary sodium and fats. Enforcement of the nutritional guidance was performed after 4 weeks.
89197995|NCT00757224|No Intervention|non-smoking|
89197996|NCT00757224|No Intervention|smoking parents A|
89197997|NCT00757224|Experimental|smoking parents B|Parents will be educated on the hazards of passive smoke exposure and ways to reduce it
89197998|NCT00954304|Experimental|1mg group|Administration of HM30181AK 1mg on day 4 and Loperamide 16mg (Loperamide 2mg x 8cap) on day 1,4,8,11,15
89197999|NCT00954304|Experimental|5mg group|Administration of HM30181AK 5mg on day 4 and Loperamide 16mg(Loperamide 2mg x 8cap) on day 1,4,8,11,15
89434057|NCT05788497|Active Comparator|Hemorrane®|Daily application of Hemorrane 10 mg/g rectal ointment for 7 days.
89434058|NCT05788497|Placebo Comparator|Placebo|Daily application of placebo for 7 days.
89434059|NCT05785507||Cases|Women with PCOS according to the Rotterdam criteria.
89434060|NCT05785507||Controls|Women with PCOS.
89434061|NCT05783687||A - Newly diagnosed|Newly diagnosed (DPA/Trientine/Zinc for < 28 days)
89434062|NCT05783687||B - D-penicillamine|D-penicillamine
89434063|NCT05783687||C - Zinc|Zinc
89434064|NCT05783687||D - Trientine (2HCl or 4HCl)|Trientine (2HCl or 4HCl)
89434065|NCT05781750|Experimental|zetomipzomib 30 mg + standard-of-care|Initial 30 mg dose of zetomipzomib, followed by weekly doses of 30 mg zetomipzomib through 52 weeks of the treatment period.
89434066|NCT05781750|Experimental|zetomipzomib 60 mg + standard-of-care|Initial 30 mg dose of zetomipzomib, followed by weekly doses of 60 mg zetomipzomib through 52 weeks of the treatment period.
89434067|NCT05781750|Placebo Comparator|placebo + standard-of-care|Initial 30 mg dose of placebo, followed by weekly doses (30 mg or 60 mg) of placebo through 52 weeks of the treatment period.
89434068|NCT05781438|Experimental|In-home standing and walking intervention|Infants will participate in the in-home standing and walking intervention for 16 weeks. In addition, infants will continue with any intervention in the community recommended by their health care team.
88914250|NCT05701124|Active Comparator|Type 1 prethreshold ROP|Intravitreal injection (IVI) was performed under topical anesthesia in standard ophthalmic operating room. 5% povidone-iodine disinfection and topical antibiotic were instilled. Ranibizumab (0.25 mg/0.025 mL) was injected into the vitreous cavity with a 31-gauge needle, aiming the needle directly toward the optic nerve in direction of visual axis 1.0 mm posterior to the corneoscleral junction at the inferotemporal quadrant.
88914251|NCT05700071|Experimental|MRI examination|
88914252|NCT05699980||Patient aged 60 or over presenting to their general practitioner|Patient aged 60 or over presenting to his general practitioner (among the 20 general practitioners recruited in Lorraine (eastern France))
88914253|NCT05699889||Patients in intensive care for SARS-CoV 2 infection with severe respiratory impairment.|
88914254|NCT05699889||Patients in intensive care without SARS-CoV 2 infection with severe respiratory impairment.|
88914255|NCT05696015|Active Comparator|Standard education|Standard education group will be carried out at discharge, discharge orientation of the patient with diabetes and application of the Diabetes Self-Care Activity Questionnaire (QAD). For this group, a new contact will be made within 30 days after discharge, where the QAD will be applied again.
88914256|NCT05696015|Experimental|Amplied education|Amplied education group will be performed at the time of discharge, guidance for discharge of patients with diabetes. This group will receive 3 contacts, the first will be carried out within 72 hours after discharge, the second contact within 10 days after the first contact and the third within 30 days after discharge, where diabetes education guidelines will be given to the patient in all contacts. At the time of discharge, and in the third contact, 30 days, the QAD will also be applied.
88914257|NCT05692037|Experimental|Yttrium-90 carbon microspheres|Single dose of yttrium-90 carbon microspheres injection. Patients will be assessed by SPECT-CT imaging within 24 hours for yttrium-90 distribution in the chest and upper abdomen, including extrahepatic shunts, intrahepatic distribution, and target lesion distribution as expected.Ten Patients will be tested for the radioactivity of yttrium-90 in blood, urine, and feces (if available).
88914258|NCT05673291||Active working group|For the study group, dentists who have completed at least 1 year in the profession, actively working in their professional life, and 4th and 5th-year of intern dentistry students
88914259|NCT05673291||Control group|In the study, 3rd-grade dentistry students who have not yet started the clinical education process will be selected as the control group.
88914260|NCT05610254|Active Comparator|Cold-Warm|Trial day 1: Participants receive Ringer's lactate cold (15°C, 59°F), Trial day 2: Participants receive Ringer's lactate at body temperature (37°C, 98.6°F)
88914261|NCT05610254|Active Comparator|Warm-Cold|Trial day 1: Participants receive Ringer's lactate at body temperature (37°C, 98.6°F) Trial day 2: Participants receive Ringer's lactate cold (15°C, 59°F),
88914262|NCT05593107|Experimental|[68Ga]N188|Subjects with suspected or confirmed malignancy will receive an intravenous injection of 68Ga-N188 followed by PET imaging. The subjects will also receive a whole-body 18F-FDG PET/CT scan within a one-week period.
88914263|NCT05584709|Experimental|STI-6129 infusion|Intravenous infusion to be given with prophylaxis for infusion reactions if necessary.
88914264|NCT05576441|Experimental|test group: VCMX|Volume stable collagen matrix will be placed at recipient site and suturing will be done with a 5-0 vicryl suture.
89198000|NCT00954304|Experimental|10mg group|Administration of HM30181AK 10mg(HM30181AK 5mg x 2tab)on day 4 and Loperamide 16mg (Loperamide 2mg x 8cap) on day 1,4,8,11,15
89198001|NCT00954304|Experimental|15mg group|Administration of HM30181AK 15mg on day 4 and Loperamide 16mg (Loperamide 2mg x 8cap) on day 1,4,8,11,15
88914265|NCT05576441|Experimental|Control group:SCTG|SCTG will be harvested from donor site as per the requirement and will be placed at the recipient and suturing will be done with 5-0 vicryl suture.
88914266|NCT05568030|Experimental|Mindfulness|
88914267|NCT05568030|Active Comparator|Psycho-education|
88914268|NCT05506098||Healthy|Subjects without periodontitis
88914269|NCT05506098||Periodontitis|Subjects with periodontitis
88914270|NCT05504486|Experimental|Arm 1|Brexpiprazole
88914271|NCT05502835|Experimental|conventional fluid management group|patients will do elective open colonic mass resection and anastomosis will receive Infusion of 6 ml/kg/hr. Ringer's solution.
88914272|NCT05502835|Active Comparator|ppv group|patients will do elective open colonic mass resection and anastomosis. Infusion of 2 ml/kg/hr. Ringer's solution guided by pulse pressure variation.
88914273|NCT05479630|Experimental|Adolescents and their parent of the intervention group|Adolescents and their parent who are participating in TWAH
88914274|NCT05479630|No Intervention|Adolescents and their parent of the control group|Adolescents and their parent who are not participating in TWAH
88914275|NCT05465057|Active Comparator|HIIT + lifestyle intervention|Allocation of HIIT training in conjuction with lifestyle intervention (TCOCT protocol) through computerbased randomization proces.
88914276|NCT05465057|Active Comparator|Lifestyle intervention|Allocation of lifestyle intervention (TCOCT protocol) through computerbased randomization proces.
89434069|NCT05780125|Experimental|FibCLOT|Patients randomized to the FibCLOT arm will receive 30 mg/kg, approximated to the closest between 2 and 3 grams, of FibCLOT (LFB, Puteaux, France).
89198002|NCT00954304|Experimental|60mg group|Administration of HM30181AK 60mg on day 4 and Loperamide 16mg (Loperamide 2mg x 8cap) on day 1,4,8,11,15
89198003|NCT00363415|Experimental|A|
89198004|NCT00363415|Active Comparator|B|
89198005|NCT00757302|Experimental|I|For the first 10 patients, only a pre-operative procedure will be performed.
89198006|NCT00757302|Experimental|II|The last 100 patients will receive the complete procedure.
88914277|NCT05458232||5mg tadalafil once daily for 14 days|
88914278|NCT05447598|Experimental|Intervention|Remote monitoring program
88914279|NCT05447598|Active Comparator|Usual care|Current clinical pratice at the participating hospitals
88914280|NCT05412693|Experimental|Functional orthosis|Use of a functional orthosis device (AirCast Air-Stirrup) for 6 weeks. Weightbearing as tolerated will be allowed in both groups immediately after application of the cast or orthosis.
88914281|NCT05412693|Active Comparator|Cast immobilization|Use of a below-the-knee cast circular cast (3M scotch cast) for 6 weeks.
88914282|NCT05404594|Experimental|Very preterm infant|Preterm infant below 33 weeks of GA
88914283|NCT05404594|Active Comparator|Full term neonate|Term neonate from a gestational age of 37 weeks.
88914284|NCT05389124||Experimental gingivitis|Group will wear a splint during oral hygiene to cover one quadrant of their dentition. They will develop gingivitis over 3 weeks. They will practise normal oral hygiene in the rest of their mouth (with minor restrictions, e.g. no mouthwash) and one other quadrant will act as an internal control for the gingivitis. After 3 weeks, normal oral hygiene will be restored throughout the mouth and subjects will continue to be monitored for a further 3 weeks.
88914285|NCT05383274|Experimental|Optilume Urethral DCB|The Optilume Drug Coated Balloon (DCB) is a guidewire compatible catheter with a tapered atraumatic tip. The distal end of the catheter has an inflatable balloon coated with a proprietary coating containing the drug paclitaxel that facilitates the drug's transfer to the urethral wall upon inflation.
89198007|NCT00757380|Active Comparator|Group 1|Trypan Blue
89198008|NCT00757380|Active Comparator|Group 2|Brillant Blue
89198009|NCT00957970|Active Comparator|Stemless femoral component|Stemless PROXIMA femoral component
88914286|NCT05382702|Other|High Fat Yogurt - Low Fat Yogurt|Participants will eat yogurt described as 'high fat' at Study Visit 2 and yogurt described as 'low fat' at Study Visit 3.
88914287|NCT05382702|Other|Low Fat Yogurt - High Fat Yogurt|Participants will eat yogurt described as 'low fat' at Study Visit 2 and yogurt described as 'high fat' at Study Visit 3.
88914288|NCT05364840|Experimental|STI-1558|Subjects will receive in each part either a single ascending dose (SAD): 300 mg, 600 mg, 1200 mg, 2000 mg on Day1 or as part of the multiple ascending dose (MAD): 300 mg, 600 mg, and 800 mg twice a day for 7.5 days
88914289|NCT05364840|Placebo Comparator|Placebo|Subjects will receive placebo orally following either the SAD or MAD dosing schedule
88914290|NCT05341622|Experimental|Arm 1: Box + Text + Reminder|Box + Text + Reminder
88914291|NCT05341622|Experimental|Arm 2: Box + Text + No Reminder|Box + Text + No Reminder
88914292|NCT05341622|Experimental|Arm 3: Box + No Text + Reminder|Box + No Text + Reminder
88914293|NCT05341622|Experimental|Arm 4: Box + No Text + No Reminder|Box + No Text + No Reminder
88914294|NCT05341622|Experimental|Arm 5: Standard Mail + Text + Reminder|Standard Mail + Text + Reminder
88914295|NCT05341622|Experimental|Arm 6: Standard Mail + Text + No Reminder|Standard Mail + Text + No Reminder
88914296|NCT05341622|Experimental|Arm 7: Standard Mail + No Text + Reminder|
88914297|NCT05341622|Experimental|Arm 8: Standard Mail + No Text + No Reminder|Standard Mail + No Text + No Reminder
88914298|NCT05324709|Experimental|Experimental|The program will be carried out one day a week for four weeks. Yin yoga practices will be applied in the program. Each session will last a total of 40 minutes. The first 20 minutes of yin yoga sessions. Participants will be given training on stress management, breathing and yin yoga. Afterwards, each session of Yin yoga exercises will be started with pranayama (breathing) exercises for 2 minutes, followed by Suryanamaskar-A (Sun Salute-A) for warming up and Yin yoga exercises will be done. The program will be completed by applying the focus on Moment in the last 5 minute. In addition, the participants will be given homework related to the subject of each week. The training booklet will be distributed to the participants before the program. Stress management sessions of the Adolescent Health Promotion-Physical Activity, Nutrition, Stress Management (COPE HEALTH- TEEN ) program will be used in the stress management training to be explained in the program.
88914299|NCT05324709|No Intervention|No Intervention|"The control group will be given 60 minutes of in the moment and stress management training."
88914303|NCT05288413||Goldstandard DVT diagnostic through specialist sonographer|Patients with DVT symptomatic of lower limb which present at the DVT Clinic the Bays at St. Mary's Hospital will receive Goldstandard Scan through specialist.
88914304|NCT05288413||DVT diagnostic with Ultrasound probe with AutoDVT Software|Above patients will receive a second Ultrasound scan by a non-specialist with AutoDVT device.
88914305|NCT05288413||Retrospective data evaluation|result of AutoDVT is equivalent to diagnosis of specialist sonographer. Results specifically highlighted in patients with adipositas or malignant disease.
88914306|NCT05273879|Other|decompression group|minimally invasive decompression without fusion
88914307|NCT05273879|Other|fusion group|minimally invasive decompression with trans-foraminal interbody fusion
88914308|NCT05271799|Experimental|Participants receiving gepotidacin powder for oral suspension followed by tablet|
89434070|NCT05780125|Active Comparator|RiaSTAP|Patients randomized to the RiaSTAP arm will receive 30 mg/kg, approximated to the closest between 2 and 3 grams, of RiaSTAP (King of Prussia, PA, USA).
88914309|NCT05271799|Experimental|Participants receiving gepotidacin tablet followed by powder for oral suspension|
88914310|NCT05261841||TYPE 2 DIABETES|Patients affected by type 2 diabetes
88914311|NCT05253417|Experimental|50 mg CBD|50 mg CBD to be administered as a single oral dose. Each capsule contains 25 mg CBD. Two capsules to be taken (plus two placebo capsules)
88914312|NCT05253417|Experimental|100 mg CBD|100 mg CBD to be administered as a single oral dose. Each capsule contains 25 mg CBD. Four capsules to be taken.
88914313|NCT05253417|Placebo Comparator|Placebo|Placebo capsules contain no CBD. Four capsules to be taken as a single oral dose.
88914314|NCT05250570|Experimental|Distress Tolerance - Benzodiazepine Discontinuation (DT-BD)|This psychosocial treatment intervention uses a combination of interoceptive exposure therapy and elements of acceptance and commitment therapy (ACT) and psychoeducation about benzodiazepine use in OAT.
88914315|NCT05250570|Active Comparator|Relaxation Therapy|The relaxation therapy control condition involves psychoeducation about benzodiazepine use in OAT and progressive muscle-relaxation training.
88914316|NCT05204030|Experimental|Narrative|The intervention condition will present narrative-focused messages about HPV and the HPV vaccine that includes important parent focused exemplar language and cultural norms on Twitter told through stories and characters (i.e., pseudo-parents).
88914317|NCT05204030|Active Comparator|Non-Narrative|The non-narrative condition will present scientific-focused messages about HPV and the HPV vaccine that includes important information relayed with numbers and facts.
88914318|NCT05200416|Experimental|Test Product - Heylo|The arm includes the test product Heylo
88914319|NCT05200416|Active Comparator|Standard of Care|The arm includes Standard of Care
88914320|NCT05114629||Active|Individuals in the active group will meet or exceed the American College of Sports Medicine's Guidelines for Physical Activity in Adults with Chronic Health Conditions and Disabilities. ACMS recommends individuals participate in at least 150 to 300 minutes of moderate-intensity aerobic exercise, 75 to 150 minutes of vigorous-intensity activity.(health.gov/ PAGuidelines)
89434071|NCT05778578|No Intervention|Control|All participants will receive the following: 1) a ClinCard and instructions for completing a weekly financial journal to record participants' spending patterns and social needs during the first 6 months of the study; 2) materials about financial literacy and community-based resources that provide support to low-income individuals; 3) description and instructions for follow-up assessments and check-ins; 4) a copy of signed medical release, consent, and HIPAA forms; 5) respondent-driven sampling referral cards; 6) 3 study referral cards, and 7) information about voter registration services provided through the Pulaski County Circuit and County Clerk's Office (https://www.pulaskiclerk.com/voter-registration/). Participants will be provided information about the importance of voting, restoration of voting rights, and the process of voting and sealing records.
89434072|NCT05778578|Experimental|Intervention|Participants in Arm 2 will receive a monthly UBI stipend of $500 for 6 months. Study staff will explain that UBI payments will continue for 6 months and that the UBI payments will be suspended if an individual is reincarcerated (e.g. the participant will not receive UBI payments to their ClinCard during months of incarceration and will not receive additional months post-release from incarceration). Participants will receive their monthly UBI payment, along with all study-related compensation for completing baseline and follow-up assessments, through a ClinCard, which is a loadable debit card with an ID number unique to the participant. The UBI will be loaded to the participant's ClinCard on the first day of each month.
89434073|NCT05776953|Active Comparator|15mg IV Ketorolac|Patients will be randomized to 15mg IV ketorolac
89434074|NCT05776953|Active Comparator|30mg IV Ketorolac|Patients will be randomized to 30mg IV ketorolac
89198010|NCT00957970|Active Comparator|Stemmed femoral component|IPS, proximal anatomical fit stemmed femoral component
89198011|NCT00751452||1|
88914321|NCT05114629||Inactive|Individuals in the inactive group are those who do not meet the American College of Sports Medicine's Guidelines for Physical Activity in Adults with Chronic Health Conditions and Disabilities. ACMS recommends individuals participate in at least 150 to 300 minutes of moderate-intensity aerobic exercise, 75 to 150 minutes of vigorous-intensity activity.(health.gov/ PAGuidelines)
89434075|NCT05774717|Experimental|Tranexamic Acid|Patients receive 1 gram IV tranexamic acid in the operating room prior to surgical incision.
89434076|NCT05774717|No Intervention|Control|Routine care, no tranexamic acid given.
89434077|NCT05774665|Experimental|Omega-3|Omega-3 fatty acid (ProEPA Xtra) capsules containing a total of 4 g/day of eicosapentaenoic acid (EPA), administered for 12 weeks.
89198012|NCT00751452||2|
89198013|NCT00954382||IQ trend|all subjects
89198014|NCT00752934|Experimental|group a|Baclofen followed by Placebo
89198015|NCT00752934|Experimental|group b|Placebo followed by Baclofen
89434078|NCT05774665|Placebo Comparator|Placebo|Placebo capsules containing soybean oil (about 54% omega-6 and 6% omega-3, but no EPA or docosahexaenoic acid (DHA)), and matched to the ProEPA Xtra capsules in terms of appearance, odor, and taste.
89434079|NCT05770011|Active Comparator|Conventional impression|Impression will be taken conventionally using rubber base open tray
89434080|NCT05770011|Experimental|digital impression without splinting the scan bodies|Impression will be taken by intraoral scaner
88914322|NCT05085470|Experimental|Reinfection group|Participants will be exposed three times to 20 male Schistosoma mansoni cercariae (weeks 0, 9, and 18)
88914323|NCT05085470|Active Comparator|Infection control group|12 participants who will undergo a placebo mock infection with water twice (weeks 0 and 9) and will be exposed once to 20 male Schistosoma mansoni cercariae (week 18)
88914324|NCT05071846|Experimental|MVX-ONCO-2|
88914325|NCT05037188|Experimental|COVID-19 vaccine candidate (BCD-250) low dose|The participants will receive the low dose of BCD-250
88914326|NCT05037188|Experimental|COVID-19 vaccine candidate (BCD-250) high dose|The participants will receive the high dose of BCD-250
88914327|NCT05037188|Experimental|Cohort 1/COVID-19 vaccine candidate (BCD-250)|The participants will receive the selected dose of BCD-250
88914328|NCT05037188|Placebo Comparator|Cohort 1/Placebo|The participants will receive placebo
88914329|NCT05037188|Experimental|Cohort 2/COVID-19 vaccine candidate (BCD-250)|The participants will receive the selected dose of BCD-250
88914330|NCT05037188|Placebo Comparator|Cohort 2/Placebo|The participants will receive placebo
88914331|NCT05032365|Experimental|Close-loop FiO2 Controller|Two hours period where the fraction of inspired oxygen (FiO2) delivered will be automatically titrated based on SpO2 values obtained from the patient.
88914332|NCT05032365|Active Comparator|Conventional|Two hours period where the FiO2 delivered will be conventionally adjusted by the healthcare personnel based on SpO2 values obtained from the patient.
88914333|NCT05030506|Experimental|Belzutifan + Lenvatinib|Participants will receive a daily oral dose of 120 mg of belzutifan monotherapy for 3 weeks, followed by a combination of a daily oral dose of 120 mg of belzutifan with a daily oral dose of 20 mg of lenvatinib until progressive disease or discontinuation.
88914334|NCT05030506|Experimental|Belzutifan + Lenvatinib + Pembrolizumab|Participants will receive an intravenous dose of 400 mg of pembrolizumab once every six weeks for up to 18 infusions (up to 2 years) in combination with a daily oral dose of 120 mg of belzutifan and a daily oral dose of 20 mg of lenvatinib until progressive disease or discontinuation.
88914335|NCT05008328|Experimental|Music Therapy plus Standard Care|Music therapy intervention in addition to standard hospital care during an SBT.
88914336|NCT05008328|Active Comparator|Standard Care|Standard hospital care during an SBT.
88914337|NCT04955379|Other|Measurements|Subjects will be tested with the Autorefractor and the EQ103 device
88914338|NCT04911621|Experimental|Stratum A (newly diagnosed)|Dendritic cell vaccination plus temozolomide-based chemoradiotherapy
88914339|NCT04911621|Experimental|Stratum B (prior treatment)|Dendritic cell vaccination plus optional conventional anti-glioma treatment (in line with standard-of-care practice, at the investigator's discretion)
88914340|NCT04900428|Experimental|COVI-DROPS|10 mg or 20 mg of COVI-DROPS administered intranasally
88914341|NCT04900428|Placebo Comparator|Placebo|1 mL administered intranasally
88914342|NCT04873492|Other|Retrospective Aggressive MS patients|Patients from who the clinical outcome is already known and classified as poor based on study definition detailed in inclusion criteria (retrospective arm). Blood sample collected after first event is available and used to characterize OMIC profile of T and B cells involve in MS.
88914343|NCT04873492|Other|Retrospective Non Aggressive MS patient|Patient from who the clinical outcome is already known and classified as non-aggressive based on study definition detailed in inclusion criteria (retrospective arm). Blood sample collected after first event is available and used to characterize OMIC profile of T and B cells involve in MS.
88914344|NCT04873492|Other|Healthy volunteers|Prospective arm use as comparator.
88914345|NCT04873492|Other|Prospective MS patients|MS patients from who the clinical outcome will be established at the end of the follow up. Blood sample will be collected after the first event to validate molecules of interest from OMIC results by using FACS a different technology and classify MS patient.
88914346|NCT04852172|Active Comparator|Arm 1 (L-citrulline)|25 mg/kg bolus + 9 mg/kg/hr continuous infusion of L-citrulline for up to 7 hours
88914347|NCT04852172|Active Comparator|Arm 2 (L-citrulline)|50 mg/kg bolus + 9 mg/kg/hr continuous infusion of L-citrulline for up to 7 hours
88914348|NCT04852172|Active Comparator|Arm 3 (L-citrulline)|100 mg/kg bolus + 9 mg/kg/hr continuous infusion of L-citrulline for up to 7 hours
89434081|NCT05770011|Experimental|digital impression with splinting the scan bodies|Impression will be taken by intraoral scaner
89434082|NCT05769621||PA Participants|Participants with PA who meet all eligibility criteria for medical record abstraction.
89434083|NCT05766345|Experimental|BCG vaccine|BCG-Vaccine SSI [Statens Serum Institut]) Danish strain 1331 0.1ml (=0.0075mg) One-time vaccination intradermally
89434084|NCT05766345|Placebo Comparator|Placebo vaccine|0.9% NaCl placebo 0.1ml One-time vaccination intradermally
89434085|NCT05764733|Experimental|Resistance Training (RT) + Bisphosphonate (BIS)|"Progressive Resistance Training (RT) and Bone-Loading Exercise~+ 70 mg/weekly dose alendronate"
89434086|NCT05764733|Experimental|No RT + BIS|"No Resistance Training~+ 70 mg/weekly dose alendronate"
89009935|NCT00234221|Active Comparator|Motivational Enhancement Therapy (MET)|The MET therapist will conduct 2 motivational enhancement sessions to work through the content of an educational workbook targeting the participant's alcohol use/abuse with the goal of negotiating a 'contract' to: 1) link to services, with the eventual goal of seeking and receiving specialized alcohol treatment; or 2) provide a strategy to self-monitor alcohol use, consider consequences, and later seek assessment.
89009936|NCT00234221|Active Comparator|Brief Informational Feedback (BIF) session|Subjects will receive brief informational feedback on the results of their alcohol screening and assessment and encouragement to seek treatment.
89009937|NCT00267930|Placebo Comparator|1|Tier 1: 1 placebo capsule b.i.d Tier 2: 2 placebo capsules b.i.d
89009938|NCT00267930|Experimental|2|Tier 1: Vernakalant (oral) 1 x 300 mg capsule b.i.d
89009939|NCT00267930|Experimental|3|Tier 2: Vernakalant (oral) 2 x 300 mg (600 mg) b.i.d
89009940|NCT04669405|Active Comparator|HILT group|Patients with hemiplegic shoulder pain with partial thickness rotator cuff receiving high intensity laser therapy.
89009941|NCT04669405|Other|Control group|Patients with hemiplegic shoulder pain with partial thickness rotator cuff receiving exercise.
89009942|NCT02962271||Psoriatic Arthritis|Musculoskeletal ultrasound (MSUS) of the lower limbs' entheses were performed
89198016|NCT00696020|Experimental|BI 1744 CL low dose/tiotropium bromide|BI 1744 CL low dose plus tiotropium bromide fixed dose combination; Solution for inhalation via Respimat® Inhaler (A5); Oral inhalation
89198017|NCT00696020|Experimental|BI1744CL medium dose/tiotropium bromide|BI 1744 CL medium dose plus tiotropium bromide fixed dose combination; Solution for inhalation via Respimat® Inhaler (A5); Oral inhalation
89434087|NCT05764733|Active Comparator|No RT + Placebo (PL)|No Resistance Training + Weekly Placebo
89434088|NCT05764733|Active Comparator|RT + PL|Progressive RT and Bone-Loading Exercise + Weekly Placebo
89434089|NCT05763355|Other|Transrectal biopsy using KOELIS fusion system|Transrectal procedure will be performed with the patient in the left lateral position with a completely free-hand technique utilising the KOELIS fusion system.
89434090|NCT05763355|Other|Transperineal biopsy using KOELIS perine grid|"Transperineal biopsy will be performed in the lithotomy position. KOELIS Perine Grid needle guidance device and Steady Pro free-hand probe arm will be utilised (free-hand assisted technique)."
89434091|NCT05762068||Airway management experts|The Steering Committee selected Experts from across the globe based on pre-defined criteria and will conduct iterative Delphi rounds to generate consensus among the experts.
89009943|NCT02962271||Psoriasis|Musculoskeletal ultrasound (MSUS) of the lower limbs' entheses were performed
89009944|NCT00556348|Experimental|1|
89009945|NCT04556539|Experimental|SC10914 group|
89009946|NCT00556387|Placebo Comparator|1|Placebo Group receiving Saline Infusion.
89009947|NCT00556387|Experimental|2|Case Group receiving Ketamine infusion.
89009948|NCT04556422|Active Comparator|Sauna alone|Sauna exposure for 30 minutes
89009949|NCT04556422|Experimental|Exercise and Sauna|Cycling exercise for 15 minutes followed by sauna for 15 minutes
89009950|NCT04669483||Intervention group (post-interruption)|Patients receive evidence-based informed consent forms for total knee arthroplasty and related anaesthesia procedures
89009951|NCT04669483||Control group (pre-interruption)|Patients receive standard consent forms (of the study centre) for total knee arthroplasty and related anaesthesia procedures
89009952|NCT04552093|Experimental|Colorectal liver metastases|Patients with potentially resectable colorectal liver metastases will undergo hepatic artery infusion pump placement. Subsequent hepatic artery infusion of floxuridine via the HAIP as well as standard of care Dutch systemic chemotherapy (FOLFOX or FOLRIRI) will be administered in a combined chemotherapy schedule.
89009953|NCT00260676|Other|conventional ventilation, protective ventilation|
89009954|NCT04556110|Experimental|Perindopril tert-Butylamine tablets （ Produced by Haisco）|The trial was divided into four cycles, between of each cycle with a 14-day wash-out period.In the first cycle，subjects in experimental group took the test preparation Perindopril tert-butylamine after meal, and subjects in control group took the reference preparation ACERTIL® after meal; In the second cycle subjects in experimental group took the reference preparation ACERTIL® after meal , the trial preparation perindopril tert-butylamine was taken orally after meals for the subjects in control group ; the order of taking the medicines for the subjects in the third cycle was the same as that in the first cycle, and the taking order of the subjects in the fourth cycle was the same as that in the second cycle. A single oral administration was used for the four cycles, and the dose was 4 mg.
89198018|NCT00696020|Experimental|BI 1744 CL high dose/tiotropium bromide|BI 1744 CL high dose plus tiotropium bromide fixed dose combination; Solution for inhalation via Respimat® Inhaler (A5); Oral inhalation
89198019|NCT00696020|Experimental|tiotropium bromide|tiotropium bromide; Solution for inhalation via Respimat® Inhaler (A5); Oral inhalation
88914349|NCT04852172|Active Comparator|Arm 4 (L-citrulline)|100 mg/kg bolus + 11 mg/kg/hr continuous infusion of L-citrulline for up to 7 hours
88914350|NCT04852172|Active Comparator|Part 2 Arm 1 (L-citrulline)|Subjects will be randomized to 2 of the doses selected from Part 1 and placebo in a 1:1:1 ratio. L-citrulline will be administered to the active arm.
88914351|NCT04852172|Placebo Comparator|Part 2 Arm 2 D5 1/2NS|Subjects will be randomized to 2 of the doses selected from Part 1 and placebo in a 1:1:1 ratio.
88914352|NCT04818580|Experimental|Right-Sided Progressive Tension Sutures|
89434092|NCT05761899|Experimental|Gene-Corrected Macrophages|Autologous bone marrow CD34+ cell-derived, CSF2RA lentiviral vector-transduced macrophages (CSF2RA gene-corrected macrophages) by bronchoscopic instillation into individual lung segments.
88914353|NCT04818580|Active Comparator|Left-Sided Progressive Tension Sutures|
88914354|NCT04804215|Experimental|The experimental group in Intraductal transanastomotic stent|"Inclusion criteria~19 years old or older ~ under 70 years old~Patients eligible for liver transplantation ③ Patients who have consented to written consent~Intraductal transanastomotic stent was used during biliary reconstruction"
88914355|NCT04804215|Experimental|The controled group in non-Intraductal transanastomotic stent|"Inclusion criteria~19 years old or older ~ under 70 years old~Patients eligible for liver transplantation ③ Patients who have consented to written consent~No stent was used during biliary reconstruction"
88914356|NCT04781127|Experimental|Active tDCS|Active Transcranial Direct Current Stimulation (tDCS), Soterix Medical mini-CT tDCS stimulator
88914357|NCT04764643|Active Comparator|sodium thiosulfate solution arm|20ml of 5% sodium thiosulfate solution were prepared with 1g sodium thiosulfate crystal dissolved in normal saline in a 20 ml syringe
88914358|NCT04764643|Experimental|N-acetylcysteine solution arm|20ml of 3% N-acetylcysteine solution were prepared with one piece of N-acetylcysteine effervescent tablet （ net weight 0.6g ）dissolved in normal saline in a 20 ml syringe
88914359|NCT04657705|Experimental|High power ablation|High power ablation parameters (50-55 W)
88914360|NCT04657705|Active Comparator|Standard ablation power|Standard ablation power parameters (40-45 W)
88914361|NCT04610047|Experimental|Norketotifen|Norketotifen oral capsules, twice daily for 7 days
88914362|NCT04610047|Placebo Comparator|Placebo|Placebo oral capsules, twice daily for 7 days
88914363|NCT04563234|Experimental|COFLEX training|Neurocognitive training, delivered via a mobile device app
88914364|NCT04563234|Active Comparator|Crossword group|Access to crossword puzzles via a mobile device app
88914365|NCT04558892|Experimental|Nephrotic syndrome - fixed dose (NS-FD)|Drug: Enoxaparin; Dose: 40 mg; Administration: once daily subcutaneously.
88914366|NCT04558892|Experimental|Nephrotic syndrome - adjusted dose (NS-AD)|Drug: Enoxaparin; Dose: 1 mg/kg of ideal body weight; Administration: once daily subcutaneously.
88914367|NCT04558892|Active Comparator|Control - fixed dose (C-FD)|Drug: Enoxaparin; Dose: 40 mg; Administration: once daily subcutaneously.
88914368|NCT04558476|Experimental|Convalescent Plasma|2 units of plasma ( 400-500ml) from 2 different donnors duration of treatment =2 h
88914369|NCT04558476|Other|Standard of care|Standard of care according the last gold standards
88914370|NCT04506359|No Intervention|control group|Control Group: Usual care +case manager care, UC group or Control group
88914371|NCT04506359|Experimental|experimental group|The experimental group is COPSCCP+ UC+ case manager care. In this group, a 6-month intervention providing for each time while subject visit their chest surgeon(s) in the OPD (from the first time before hospital discharge/T1) - usually patients visited hospital in 2 weeks, 1 month, 2 months, 3 months and 6 months (T2-6) after surgery. Patients will receive (a) nurse-guided touch-screen computer screening (assessment) for their psychological and physical distress and care needs during current week; (b) the screening /assessment results will immediately show as the outcome (we are developing a calculation system to sum those scores).
88914372|NCT04449276|Experimental|Dose Escalation CVnCoV|"Participants will be vaccinated with CVnCoV at escalating dose levels on Day 1 and Day 29. Safety data will inform the decision to continue enrolling at the current dose level, or to proceed to dose escalation. Initially, dose levels of 2, 4 and 8 μg will be evaluated.~Dose levels of 2, 4, 6, 8 and 12µg will be evaluated with potential increase to dose levels up to 20 μg."
88914373|NCT04449276|Placebo Comparator|Dose Escalation Placebo|Participants will be given placebo on Day 1 and Day 29.
89198020|NCT00751608|Experimental|1|
89198021|NCT00751608|Active Comparator|2|
88914374|NCT04391894|Experimental|ECF843 0.45 mg/mL TID or vehicle (Part 1)|ECF843 0.45 mg/mL TID or vehicle (Part 1)
88914375|NCT04391894|Experimental|ECF843 0.15 mg/mL TID or vehicle (Part 1)|ECF843 0.15 mg/mL TID or vehicle (Part 1)
88914376|NCT04391894|Placebo Comparator|ECF843 vehicle TID (Part 1)|ECF843 vehicle TID (Part 1)
88914377|NCT04391894|Experimental|ECF843 0.15 mg/mL BID or vehicle (Part 1)|ECF843 0.15 mg/mL BID or vehicle (Part 1)
88914378|NCT04391894|Placebo Comparator|ECF843 vehicle BID (Part 1)|ECF843 vehicle BID (Part 1)
88914379|NCT04288830|Experimental|TCMMMRT First|Participants will perform an instructor-led mind-body exercise regimen 1 day per week during this arm of the study for a total of 8 weeks. Home practice will be logged. At the completion of the TCMMMRT Condition, participants will perform an instructor-led low impact aerobic exercise regimen 1 day per week for a total of 8 weeks. Home exercise will be logged.
89198022|NCT00751608|Placebo Comparator|3|
89198023|NCT00958048|Experimental|2|ALS with non-invasive ventilation
89198024|NCT00958048|No Intervention|1|ALS without non-invasive ventilation
89198025|NCT00751686||RV GE Group|
89434093|NCT05761574|Experimental|Acetaminophen/Naproxen Sodium Fixed Combination|Participants will receive a single oral dose of two Acetaminophen/Naproxen Sodium Fixed Combination tablets.
89434094|NCT05761574|Active Comparator|Naproxen Sodium|Participants will receive a single oral dose of one Naproxen Sodium tablet with one Placebo capsule.
89434095|NCT05761574|Active Comparator|Acetaminophen|Participants will receive a single oral dose of two Acetaminophen tablets.
88914380|NCT04288830|Active Comparator|Aerobic Exercise First|Participants will perform an instructor-led low impact aerobic exercise regimen 1 day per week during this arm of the study for a total of 8 weeks. Home exercise will be logged. At the completion of the aerobic exercise condition, participants will perform an instructor-led mind-body exercise regimen 1 day per week for a total of 8 weeks. Home practice will be logged.
88914381|NCT04260282||Neutrophilic asthma|Patients with asthma diagnosed according to guidelines, with eosinophils <300/mm3 in blood and <3% in induced sputum
88914382|NCT04260282||Eosinophilic asthma|Patients with asthma diagnosed according to guidelines, with eosinophils >300/mm3 in blood and/or >3% in induced sputum
88914383|NCT04233788||Sequence optimization (Healthy Control Group 1 (10 Persons))|"The MEGA-based editing sequences as well as the SLOW-EPSI sequence will be applied to this group using a 3T Prisma and a 7T Terra scanner. Data will be used for optimization of the pulse sequences.~Aim: find those sequence parameters to obtain best spectral quality data (SNR, spatial resolution versus measurement time)."
88914384|NCT04233788||Healthy Control Group 2 (15 Persons)|"The best performing sequence which will be applied to this group using a 7T Terra scanner. Data will be used normative data for glutamate/glutamine and GABA levels in healthy controls.~Aim: normal reference data for future studies."
88914385|NCT04233788||Patient Group 1: Comparison of 5 different spectral editing sequences (30 Patients)|Two editing pulse sequence types will be applied to this group at a 3T Prisma and a 7T Terra scanner. The sequences being compared are MEGA-semiLASER-SVS, MEGA-semiLASER based MRSI (on both 3T and 7T) and SLOW-EPSI (on 7T only).
88914386|NCT04233788||Patient Group 1: Comparison of 4 different CEST sequences (30 Patients)|"Two different CEST sequence types will be applied to this group at a 3T Prisma and a 7T Terra scanner. The CEST performance will be compared between 3T and 7T, as well which of the two types in the best on each scanner.~Aim: which of the four sequence predicts the IDH-mutation status best."
88914387|NCT04225533|Experimental|SP16|Patients will receive a single dose of SP16 0.2 mg/kg by subcutaneous injection
88914388|NCT04202705|Experimental|SYD1875|5T4-targeting Antibody-Drug Conjugate
88914389|NCT04077515|Active Comparator|high blood concentration group|The blood concentration is maintained at 10-15ng/ml (not including 10ng/ml).
88914390|NCT04077515|Experimental|low blood concentration group|The blood concentration is maintained at 7-10ng/ml (including 10ng/ml).
88914391|NCT04026711|Active Comparator|MitoQ|MitoQ 40 mg per day for 12 weeks
88914392|NCT04026711|Placebo Comparator|Placebo|placebo daily for 12 weeks
88914393|NCT04021589|Experimental|WLS-intervention group|chemotherapy + WLS
88914394|NCT04021589|Active Comparator|the control group|chemotherapy
88914395|NCT03959982|Experimental|HHHFA Randomized Group|Subjects will be randomized to use the HHHFA device during bedtime for at least 4 hours. Subjects will complete MRC, SGRQ, CAT, CASA-Q and PSQI questionnaires. They will do spirometry, 6-minute walk, and CT scan. These interventions will be done at baseline and at the completion of their study (6 weeks). Spirehealth Device will be worn by subject daily for 12 weeks.
88914396|NCT03959982|Active Comparator|Control Group|Subjects will complete MRC, SGRQ, CAT, and PSQI questionnaires. They will do spirometry, 6-minute walk, and CT scan. These interventions will be done at baseline and at the completion of their study (6 weeks). Spirehealth Device will be worn by subject daily for 12 weeks.
88914397|NCT03958461|Other|Calculus removement|Anti-infective treatment of teeth
88914398|NCT03928808|Experimental|FMT for SE-AN|Inpatients at the UNC-Chapel Hill Center of Excellence for Eating Disorders (CEED) and will receive weekly fecal microbiota transplantations for four weeks. This will be in addition to standard care at CEED.
88914399|NCT03926637||Study Participants|Participants with MS, including CIS will complete the MSPT at their standard of care visits.
88914400|NCT03922217|Experimental|Mindfulness|This group will be given the Mindfulness mobile intervention, Mindful My Way (MMW)
89434096|NCT05761574|Placebo Comparator|Placebo|Participants will receive a single oral dose of two Placebo capsules.
89434097|NCT05761444|Experimental|Eze/Ato: Ezetimibe/Atorvastatin|Participants will receive ezetimibe/atorvastatin 10/40 mg QD from Visit 2 (Day 1) to Visit 3 (Week 6). If the LDL-C target is reached (LDL-C < 55 mg/dL) at Visit 3, maintain the dose to Visit 4 (Week 12). If the LDL-C target level is not reached at Visit 3, dose is increased to ezetimibe/atorvastatin 10/80 mg QD from Visit 3 to Visit 4.
89434098|NCT05761444|Active Comparator|Ato: Atorvastatin|Participants will receive atorvastatin 40 mg QD from Visit 2 (Day 1) to Visit 3 (Week 6). If the LDL-C target is reached (LDL-C < 55 mg/dL) at Visit 3, maintain the dose to Visit 4 (Week 12). If the LDL-C target is not reached at Visit 3, dose is increased to atorvastatin 80 mg QD from Visit 3 to Visit 4.
89434099|NCT05757791|Experimental|Participants with Major Depressive Disorder (MDD)|Patients will receive empagliflozin 10mg daily for two weeks and then empagliflozin 25mg for four weeks, for a total treatment duration of 6 weeks. Patients will be instructed to take the medication each morning, daily, with or without food. The number of doses given may be increased to a small degree to allow for flexibility in the scheduling of follow-up visits.
89434100|NCT05755074|Experimental|Ablation through upper extremity|Ablation through arm
89434101|NCT05755074|Active Comparator|Ablation through femoral vein|Ablation through vein
88914401|NCT03851705|Experimental|Part 1 - Inclisiran|Participants who received a dose of 300 milligram (mg) inclisiran sodium for injection administered by SC injection on Day 1 and Day 90.
88914402|NCT03851705|Placebo Comparator|Part 1 - Placebo|Participants who received a dose of placebos administered by SC injection on Day 1 and Day 90.
88914403|NCT03851705|Experimental|Part 2 - Inclisiran|Participants who received a dose of 300 mg inclisiran sodium for injection administered by SC injection on Day 270, Day 450 and Day 630. In addition, participants who were assigned to the placebo arm in Part 1 will receive a dose of 300 mg inclisiran sodium administered by SC injection on Day 180 after completion of Part 1.
88914404|NCT03841110|Experimental|FT500 Monotherapy|FT500 administered once weekly for 3 weeks as a monotherapy
88914405|NCT03841110|Experimental|FT500 in Combination with Immune Checkpoint Inhibitor|FT500 administered once weekly for 3 weeks in combination with one of the following immune checkpoint inhibitors: nivolumab, pembrolizumab or atezolizumab.
88914406|NCT03841110|Experimental|FT500 +IL-2 in Combination with Immune Checkpoint Inhibitor|FT500 + IL-2 administered once weekly for 3 weeks in combination with one of the following immune checkpoint inhibitors: nivolumab, pembrolizumab or atezolizumab.
88914407|NCT03824366|Experimental|Volumetric MR imaging planning|"All patients will undergo volumetric MR imaging on treatment days in positioning appropriate for the specific treatment site.~Patients will receive standard of care palliative radiation therapy"
89434102|NCT05753592|Experimental|Part 1; LOU064 (Remibrutinib)|Mild and Moderate HI participants and matching healthy participants
89434103|NCT05753592|Experimental|Part 2; LOU064 (Remibrutinib)|Severe HI participants and matching healthy participants
89434104|NCT05753345|Experimental|Intervention: aquatic occupational therapy (AquOTic-NM)|aquatic occupational therapy 30 minutes, self care training 15 minutes
89434105|NCT05752721||Food Pantry Scheduled to Transition to Online Ordering|Low-income adults who have visited the food pantry that is scheduled to transition to online ordering at least once. Participants will complete an in-person survey and a research assistant will record the food items they received in the relevant visit to the pantry. After the transition to online ordering at the intervention food pantry, participants will again complete the survey. Food selections for participants in the this arm will be accessible through the online ordering platform.
89434106|NCT05752721||Food Pantry NOT Scheduled to Transition to Online Ordering|Low-income adults who have visited the food pantry that is NOT scheduled to transition to online ordering at least once. Participants will complete an in-person survey and a research assistant will record the food items they received in the relevant visit to the pantry. After the transition to online ordering at the intervention food pantry, participants will again complete the survey. Participants in this arm will record their food selections and send them to the study team.
88914408|NCT03810313|Experimental|Brolucizumab 6 mg|1 intravitreal injection every 4 weeks for a total of 6 injections, followed by 48 weeks of individual flexible treatment (IFT)
88914409|NCT03810313|Active Comparator|Aflibercept 2 mg|1 intravitreal injection every 4 weeks for a total of 6 injections, followed by 48 weeks of individual flexible treatment (IFT)
88914410|NCT03808389|Experimental|Treatment group: Donor FMT|Fecal microbiota transplantation using fecal matter from a healthy donor selected through strict inclusion criteria assessing the presence of any infectious diseases.
88914411|NCT03808389|Sham Comparator|Control group: Autologous FMT|Fecal microbiota transplantation using the patient's own fecal matter.
88914412|NCT03802630|Experimental|Brolucizumab 6 mg|1 intravitreal injection every 4 weeks for a total of 6 injections, followed by 48 weeks of individualized flexible treatment (IFT)
88914413|NCT03802630|Active Comparator|Aflibercept 2 mg|1 intravitreal injection every 4 weeks for a total of 6 injections, followed by 48 weeks of individualized flexible treatment (IFT)
89434107|NCT05752149|Experimental|0.05 mg/kg cRGD-ZW800-1|n=3. Injection of 0.05 mg/kg cRGD-ZW800-1, within 2 hours before imaging/surgery
88914414|NCT03785691|Experimental|Mirtazapine|"Mirtazapine 15 mg oral tablet (incapsulated in gelatine to provide blinding) will be administered once daily (bedtime) for 7 days. Placebo (empty gelatine capsule) will be administered once daily (morning).~On Day 7 dosage increase is optional. If desired, mirtazapine 30 mg oral tablet (incapsulated in gelatine) will be administered once daily (bedtime) for 7 days. Placebo (empty gelatine capsule) will be administered three times daily (morning, noon and late afternoon). In case dosage increase is not desired, the subject will continue the initial treatment for an additional 7 days."
89198026|NCT01047085|Active Comparator|Control group|Control group: Impedance pH measurements of healthy controls are performed to compare the results with the study group.
89198027|NCT01047085|Experimental|Study group|Study group: Pre-operative and post-operative impedance pH measurements are performed to patients in which elective cholecystectomy is planned.
88914415|NCT03785691|Experimental|Ondansetron|"Ondansetron 8 mg oral tablet (incapsulated in gelatine) will be administered twice daily (morning and bedtime) for 7 days.~On Day 7 dosage increase is optional. If desired, ondansetron 8 mg oral tablet (incapsulated in gelatine) will be administered four times daily (morning, noon, late afternoon and bedtime) for 7 days. In case dosage increase is not desired, the subject will continue the initial treatment for an additional 7 days."
88914416|NCT03785691|Placebo Comparator|Placebo|"Placebo oral tablet (empty gelatine capsule) will be administered twice daily (morning and bedtime) for 7 days.~On Day 7 dosage increase is optional. If desired, placebo oral tablet (empty gelatine capsule) will be administered four times daily (morning, noon, late afternoon and bedtime) for 7 days. In case dosage increase is not desired, the subject will continue the initial treatment for an additional 7 days."
88914417|NCT03775213|Experimental|Standard Treatment Options + Active Monitoring|Participants explore decision support tool that includes current standard treatment options for DCIS, as well as active monitoring.
88914418|NCT03775213|Active Comparator|Standard Treatment Options|Participants explore decision support tool that includes current standard treatment options for DCIS.
88914419|NCT03739450|Experimental|Problem Solving Training + Education|Participants in this arm will receive the TBI-specific education intervention and the Problem Solving Training (PST) intervention.
88914420|NCT03739450|Active Comparator|Education|Participants in this arm will only receive the TBI-specific education intervention.
88914421|NCT03710564|Experimental|Brolucizumab|Brolucizumab 6 mg dosed every 4 weeks was administered via intravitreal injection for 100 weeks.
88914422|NCT03710564|Active Comparator|Aflibercept|Aflibercept 2 mg dosed every 4 weeks was administered via intravitreal injection for 100 weeks.
88914423|NCT03624127|Experimental|BMS-986165|
88914424|NCT03624127|Placebo Comparator|Placebo|
88914425|NCT03624127|Active Comparator|Apremilast|
88914426|NCT03616912|Placebo Comparator|Placebo|Participants received two placebo tablets: one matching baricitinib 4 milligram (mg) and one matching baricitinib 2 mg administered orally every day (QD) for 52 weeks.
88914427|NCT03616912|Experimental|2 mg Baricitinib|Participants received one Baricitinib 2 mg tablet and one placebo tablet matching Baricitinib 4 mg administered QD for 52 weeks.
88914428|NCT03616912|Experimental|4 mg Baricitinib|Participants received one Baricitinib 4 mg tablet and one placebo tablet matching baricitinib 2 mg administered orally every day (QD) for 52 weeks.
88914429|NCT03616912|Placebo Comparator|Placebo Maximum Extended Enrollment (MEE)|Participants received two placebo tablets: one matching baricitinib 4 mg and one matching baricitinib 2 mg administered orally QD for 52 weeks.
88914430|NCT03616912|Experimental|2 mg Baricitinib (MEE)|Participants received one Baricitinib 2 mg tablet and 1 placebo tablet matching Baricitinib 4 mg administered QD for 52 weeks.
88914431|NCT03616912|Experimental|4 mg Baricitinib (MEE)|Participants received one Baricitinib 4 mg tablet and one placebo tablet matching baricitinib 2 mg administered orally every day (QD) for 52 weeks.
88914432|NCT03594253|Experimental|RFP-C|Regulation Focused Psychotherapy for Children (RFP-C; Hoffman & Rice with Prout, 2015) is a novel, manualized, time-limited psychodynamic treatment approach for children who manifest disruptive behaviors and emotional dysregulation. Throughout the 16 sessions of play therapy and four parent meetings, the clinician works with the parents and the child to increase understanding that all behavior, even disruptive behavior, has meaning in the service of emotional and behavioral regulation. This insight leads to a decreased need and reliance to act on the distressing emotions (e.g. less need for disruptive behaviors) and an increased ability to tolerate, work through, and talk about the feelings that previously needed to be warded off.
88914433|NCT03594253|No Intervention|Wait List control|Participants assigned to this condition will receive no intervention. They may continue on current medication regimens (no major changes) but may not be enrolled in psychological treatments. They will be evaluated weekly via phone call with primary caregiver. At the conclusion of this 10-week wait list period all participants assigned to this condition will receive RFP-C treatment.
88914434|NCT03499899|Experimental|LAG525 + PDR001|Participants received LAG525 and PDR001 administered as infusion once every 3 weeks
88914435|NCT03499899|Experimental|LAG525 + PDR001 + carboplatin|Participants received LAG525, PDR001 and carboplatin administered as infusion once every 3 weeks.
88914436|NCT03499899|Experimental|LAG525 + carboplatin|Participants received LAG525 and carboplatin administered as infusion once every 3 weeks
88914437|NCT03481634|Experimental|Brolucizumab 3 mg|"Brolucizumab 3 mg/0.05 mL, 5 loading doses, with subsequent doses per protocol-specified maintenance schedule.~To fulfil the double-masking requirement, each investigational site had masked and unmasked staff. The investigator who performed the injection was unmasked to the treatments as were any other site personnel who had been delegated responsibility for working with the Investigational Product (IP)."
88914438|NCT03481634|Experimental|Brolucizumab 6 mg|"Brolucizumab 6 mg/0.05 mL, 5 loading doses, with subsequent doses per protocol-specified maintenance schedule.~To fulfil the double-masking requirement, each investigational site had masked and unmasked staff. The investigator who performed the injection was unmasked to the treatments as were any other site personnel who had been delegated responsibility for working with the Investigational Product (IP)."
89198028|NCT00576576|Experimental|A|All patients in this arm are given atorvastatin therapy.
89198029|NCT01049971|Active Comparator|no wound protector|instead of wound protector, a woven drape is applied
89434108|NCT05752149|Experimental|0.025 mg/kg cRGD-ZW800-1|n=3. Injection of 0.025 mg/kg cRGD-ZW800-1, within 2 hours before imaging/surgery
89434109|NCT05752149|Experimental|0.01 mg/kg cRGD-ZW800-1|n=3. Injection of 0.01 mg/kg cRGD-ZW800-1, within 2 hours before imaging/surgery.
89434110|NCT05752149|Experimental|Expansion Cohort|n=18: expansion cohort will be added to the group of patients that had received the selected dose in WP-I.
88914439|NCT03481634|Active Comparator|Aflibercept 2 mg|"Aflibercept 2 mg/0.05 mL, as labeled, 5 loading doses, with subsequent doses every 8 weeks.~To fulfil the double-masking requirement, each investigational site had masked and unmasked staff. The investigator who performed the injection was unmasked to the treatments as were any other site personnel who had been delegated responsibility for working with the Investigational Product (IP)."
88914440|NCT03430700|Experimental|Treatment|All patient will receive Pembrolizumab (100 mg/ 4mL) every 3 weeks for a maximum of 2 years. Pembrolizumab 200mg will be administered as a 30 minute IV infusion every 3 weeks.
88914441|NCT03373461|Placebo Comparator|Placebo|Placebo identical to LNP023 twice a day
88914442|NCT03373461|Experimental|LNP023 10 mg BID|10 mg taken twice a day.
88914443|NCT03373461|Experimental|LNP023 50 mg BID|50 mg taken twice a day.
88914444|NCT03373461|Experimental|LNP023 100 mg BID - Part 2|100 mg taken twice a day.
88914445|NCT03373461|Experimental|LNP023 200 mg BID|200 mg taken twice a day.
88914446|NCT03364751|Active Comparator|IQOS arm|~86 patients, switching from cigarette smoking to IQOS use.
88914447|NCT03364751|Active Comparator|Cigarette arm|~86 patients, continuing cigarette smoking.
88914448|NCT03364127|Active Comparator|Experimental: Active Acupuncture|Active Acupuncture two times per week for 5 weeks
88914449|NCT03364127|Placebo Comparator|Placebo Acupuncture|Placebo Acupuncture two times per week for 5 weeks
88914450|NCT03251508|Experimental|Peanut OIT/dietary peanut|Single arm study with all subjects receiving peanut OIT study drug for the initial 6 months. This is followed by daily ingestion of common dietary foods containing approximately 300 mg of peanut protein for an additional 6 months.
88914451|NCT03106454|Active Comparator|Combination oral contraceptive pill|Ethinyl Estradiol 10mcg/Norethindrone acetate 1mg/ferrous fumarate 75mg Taken cyclically as 24 tablets containing EE 10mcg/NET acetate 1mg 2 tablets of EE 10mcg only 2 tablets of ferrous fumarate 75mg
88914452|NCT03106454|Experimental|Progestin only pill|Norethindrone 0.35mg Marketed use for 1 tablet per day. For study dosing, patients will take 3 tablets daily for a total of 1.05mg daily.
88914453|NCT03074617|Experimental|LTE field|
88914454|NCT03074617|Sham Comparator|sham field|
88914455|NCT03045913||Genoss DES|Subject implanted Genoss DES for coronary artery disease
88914456|NCT02990806|Experimental|Stages 1, 2 and 3: NI-071 Group|Participants received intravenous (IV) infusion of NI-071 at a dose of 3 milligrams/kilograms (mg/kg) at Weeks 0, 2, 6, 14 during stage 1 and at Weeks 22, 30, 38, 46, and 54 during stage 2. Participants were followed up to Week 62 (Stage 3).
88914457|NCT02990806|Experimental|Stage 1: Remicade-US Group|Participants received IV infusion of Remicade-US (infliximab) at a dose of 3 mg/kg at Weeks 0, 2, 6, 14 during stage 1.
89198030|NCT01049971|Experimental|wound protector|after minilaparotomy, wound protector is applied
89434111|NCT05744401|Experimental|AL002 Dose 1|AL002 every 4 weeks
89434112|NCT05744401|Experimental|AL002 Dose 2|AL002 every 4 weeks
89434113|NCT05744401|Experimental|AL002 Dose 3|AL002 every 4 weeks
89434114|NCT05739552|Experimental|Telerehabilitation|
89434115|NCT05739539|Active Comparator|pars plana vitrectomy with ILM peeling|Diabetic patients who fulfill the inclusion critera and will undergo pars plana vitrectomy and ILM peeling
89434116|NCT05739539|Active Comparator|pars plana vitrectomy without ILM peeling|Diabetic patients who fulfill the inclusion critera and will undergo pars plana vitrectomy without ILM peeling
89434117|NCT05736406|Experimental|200 J/cm^2|Patient will undergo intraoperative Photodynamic therapy at 200 J/cm^2
89434118|NCT05736406|Experimental|400 J/cm^2|Patient will undergo intraoperative Photodynamic therapy at 400 J/cm^2
88914458|NCT02990806|Experimental|Stage 2 and Stage 3: Remicade US to Remicade-US Group|Participants who received Remicade US during stage 1; were re-randomized during stage 2 to continue Remicade-US dose 3 mg/kg from Week 22 through Week 54 with every 8 weeks dosing intervals. Participants were followed up to Week 62 (Stage 3).
89434119|NCT05734781||1|Interviewees: terminally ill patients, families and healthcare providers of such patients
89434120|NCT05731492|Experimental|Open-label Core Treatment Period: Macitentan|Participants will receive macitentan as a monotherapy or add-on to an existing therapy daily for 24 weeks during core treatment period. Optional treatment extension period of up to 1 year for those participants who completed the core treatment period.
89434121|NCT05729932|Experimental|Intranasal Opioid Agonist|Participants will receive non-therapeutic, experimental doses of an opioid agonist or placebo. Active opioid agonist/placebo will be administered once per session and will be administered intransally (snorting).
89434122|NCT05729932|Experimental|Vaporized cannabis|Participants will receive non-therapeutic, experimental doses of active or placebo vaporized cannabis. Active cannabis/placebo will be administered once per session and will be administered via a vaporizer.
89434123|NCT05726578|Experimental|Lung recruitment|preterm infants with moderate to severe respiratory distress
89434124|NCT05726097|Active Comparator|Standard preparation regimen|4 L polyethylene glycol as laxative 30 + 15 mL sodium phosphate as a booster
89434125|NCT05726097|Experimental|Optimized preparation regimen|1 L polyethylene glycol + ascorbic acid as laxative and gastrografin and magnesiumoxid + sodium picosulfate as a booster
89434126|NCT05726097|Experimental|Optimized preparation regimen with prucalopride|1 L polyethylene glycol + ascorbic acid as laxative and gastrografin and magnesiumoxid + sodium picosulfate as a booster + 2 mg of prucalopride
89434127|NCT05725902|Experimental|Etavopivat|Single-arm, open-label
89434128|NCT05724420|Experimental|STRIVE Group|"STRIVE is comprised of a 4-hour formal education session where participants are provided knowledge, skills, and resources specific to self-assessment for mental wellness and effective mindfulness strategies.~High-fidelity simulation sessions are utilised to reinforce and apply mindfulness techniques learned in the formal session. Clinical scenarios are designed to be challenging and stressful."
89434129|NCT05724420|No Intervention|Control|Residents randomized to the control group will receive information regarding resilience development as per the usual standard of communication. All new residents will receive contact details of physician wellness services available at Schulich School of Medicine & Dentistry.
89434130|NCT05724121||Cohort A|includes all patients prior to starting therapy with a BTKi
89434131|NCT05724121||Cohort B|includes all patients already on therapy with a BTKi
89434132|NCT05724121||Cohort C|includes all patients prior to starting therapy with venetoclax
89434133|NCT05722522|Experimental|Secukinumab|"Name and Strength: 2 X Secukinumab 150 mg / 1 mL~Pharmaceutical Dosage Form: Solution for subcutaneous (s.c.) injection~Randomized in a 1:1 ratio"
89434134|NCT05722522|Placebo Comparator|Placebo|"Name and Strength: 2 X Placebo / 1 mL~Pharmaceutical Dosage Form: Solution for subcutaneous (s.c.) injection~Randomized in a 1:1 ratio"
89434135|NCT05722015|Experimental|Arm 1 (MK-3475A + Platinum Doublet Chemotherapy)|Participants with treatment-naïve metastatic NSCLC will receive MK 3475A SC in combination with platinum doublet chemotherapy.
89434136|NCT05722015|Active Comparator|Arm 2 (Pembrolizumab + Platinum Doublet Chemotherapy)|Participants with treatment-naïve metastatic NSCLC will receive Pembrolizumab IV in combination with platinum doublet chemotherapy.
88914459|NCT02990806|Experimental|Stage 2 and Stage 3: Remicade US to Switch Group|Participants who received Remicade US during stage 1; were re-randomized during stage 2 and received IV infusion of NI-071 at Week 22 followed by Remicade-US at Week 30, followed by NI-071 at Weeks 38, 46, and 54. Participants were followed up to week 62 (Stage 3).
88914460|NCT02947048|Experimental|100 mg open|open-label lead-in 100 mg L1-79 t.i.d.
89434137|NCT05720741|Experimental|Project THINK|Project THINK is a 30-minute self-guided digital intervention designed to teach children and adolescents how to change the way that they think. Specifically, Project THINK is based on the principles of cognitive restructuring, a core component of cognitive behavioral therapy, a gold standard treatment for internalizing disorders. Project THINK uses vignettes, interactive activities, and engaging graphics to teach youth a systematic strategy for assessing the presence of unhelpful thoughts and replacing them with more helpful ones. Although not yet formally tested in a randomized trial, Project Think has been used by hundreds of students, and feedback has been very positive.
89434138|NCT05720741|Placebo Comparator|Project SHARE|Intervention delivered in a web browser that focuses on encouraging feelings disclosure to trusted others using facts about the brain, testimonials from peers, and writing exercises (also referred to as Sharing Feelings Intervention; Schleider et al., 2021).
88914461|NCT02947048|Experimental|100 mg blinded|blinded and randomized 100 mg L1-79 t.i.d.
88914462|NCT02947048|Experimental|200 mg open|open-label lead-in 200 mg L1-79 t.i.d.
88914463|NCT02947048|Experimental|200 mg blinded|blinded and randomized 200 mg L1-79 t.i.d.
88914464|NCT02947048|Placebo Comparator|Placebo|placebo t.i.d.
88914465|NCT02866721|Experimental|Human Allogeneic Mesenchymal Stem Cells|"One time intravenous (IV) Infusion of up to 5 x 10^6 allogeneic human mesenchymal stem cells per kilogram of body weight (hMSCs/kg). A dose escalation using the 3+3 design will be employed. The three doses are 1 x 10^6, 3 x 10^6, and 5 x 10^6 hMSCs/kg. There is no placebo group. All study participants will receive stem cells."
88914466|NCT02814227|Experimental|Zansors® sleep screening device|Zansors device compared to overnight polysomnography
89434139|NCT05717712|Experimental|Experimental Group|Multiple intratumoral injections of Ad-TD-nsIL12.
89434140|NCT05717699|Experimental|Experimental Group|Multiple intratumoral injections of Ad-TD-nsIL12.
89434141|NCT05714930|Experimental|Treat-to-target|T2T will be implemented based on shared decision-making (SDM), tight control and remission as a validated treatment target (disease activity score clinical SLEDAI-2k = 0 & glucocorticoids (GC) ≤ 5 mg prednisolone equivalent & physician global assessment (PGA 0-3) < 0.5 ± immunomodulatory therapy); All intervention centers will receive T2T/SDM trainings. Patients not meeting their target criterion at study entry or at any time during the trial will be included in a tight control T2T loop of 24 weeks with assessments every 6 weeks to reach the target by adjustments of their immunomodulatory treatments. Patients in target will be assessed every 12 weeks as it is standard in clinical routine care.
89434142|NCT05714930|No Intervention|Standard of Care|In the standard of care (SoC) arm, patients receive 3-to 6-monthly controls and treatment adjustments according to their physician's discretion.
89434143|NCT05711901|No Intervention|No Intervention: Baseline therapy|Basic therapy - the routine practice of an institution for the treatment of patients with maternal sepsis
89434144|NCT05711901|Experimental|Experimental: Basic therapy + Efferon LPS|Basic therapy is a routine practice of the institution for the treatment of patients with maternal sepsis plus extracorporeal hemoperfusion therapy (Efferon LPS)
89434145|NCT05707741|Placebo Comparator|Group A|normal saline infusion rate 0.4uq/kg /hour
89434146|NCT05707741|Active Comparator|Group B|dexmetomedine 0.2 µg/kg/hr
89434147|NCT05707741|Active Comparator|Group C|dexmetomedine 0.4 µg/kg/hr
89434148|NCT05707702|Experimental|Probiotic lozenges|Participants in this arm will be be instructed to take a lozenge daily for 6 weeks. They will also receive oral dysplasia standard of care.
89434149|NCT05707702|Active Comparator|Standard of care for oral dysplasia|Participants in this arm will receive oral dysplasia standard of care.
89434150|NCT05707494|Experimental|Basic therapy + Efferon LPS NEO|Study group: Basic therapy + Efferon LPS NEO - 80 patients, prospective enrollment.
89434151|NCT05707494|No Intervention|Baseline therapy|Control group: Basic therapy - 160 patients, retrospective enrollment. Basic therapy is the routine practice of the institution for the treatment of patients with sepsis (conservative anti-infective therapy). Antibacterial therapy regimens, antibiotic dosage adjustment regimens for AKI and prolonged RRT procedures are not specifically prescribed in the CT Plan.
89434152|NCT05706168|No Intervention|Control group|The participants in this category will not undergo any structured exercise training for the duration of the study.
89434153|NCT05706168|Experimental|Treadmill Group|The targeted treadmill exercise dosage will consist of 1.)a session duration=30mins, 2.) frequency=3times/wk and 3.) Intensity= (60-84% heart rate reserve (HHR).4.) overall program duration=3months.
89434154|NCT05706168|Experimental|Cycle ergometer Group|The targeted cycling exercise dosage will consist of 1.) a session duration=30mins, 2.) frequency=3times/wk and 3.) Intensity= (60-84% heart rate reserve (HHR).4.) overall program duration=3months.
89434155|NCT05706129|Experimental|Part A: [68Ga]Ga-DPI-4452|Participants will receive [68Ga]Ga-DPI-4452, a single dose on Day 1.
89434156|NCT05706129|Experimental|Part B: [177Lu]Lu-DPI-4452|Participants will receive a single dose of [68Ga]Ga-DPI-4452, at screening then escalating doses of [177Lu]Lu-DPI-4452, on Day 1 of each 28-cycle and RP2D will be determined.
88914467|NCT02557438||Roux-en-Y Gastric Bypass|Males and females aged 13-25 undergoing Roux-en-Y gastric bypass (RYGB) surgery
88914468|NCT02557438||Vertical Sleeve Gastrectomy|Males and females aged 13-25 undergoing vertical sleeve gastrectomy (VSG) surgery
89434157|NCT05706129|Experimental|Part C: [177Lu]Lu-DPI-4452|Participants will receive a single dose of [68Ga]Ga-DPI-4452, at screening and RP2D dose of [177Lu]Lu-DPI-4452, on Day 1 of each 28-day cycle during the treatment period.
88914469|NCT02557438||Non-surgical Obese Controls|Males and females aged 13-25 who are obese and not undergoing weight loss surgery
88914470|NCT02503254|Experimental|CHTP 1.0|Ad libitum use of the Carbon Heated Tobacco Product 1.0 (CHTP 1.0) for 5 days in confinement
88914471|NCT02503254|Active Comparator|Conventional cigarette (CC)|Ad libitum use of subject's own preferred brand of CC for 5 days in confinement
88914472|NCT02489539|Experimental|Short Neck Substudy|Subjects with abdominal aortic aneurysms having infrarenal aortic neck angulation ≤ 60˚ and infrarenal aortic neck length ≥10 mm treated with the GORE® EXCLUDER® Conformable AAA Endoprosthesis.
88914473|NCT02489539|Experimental|High Neck Angulation Substudy|Subjects with abdominal aortic aneurysms having infrarenal aortic neck angulation > 60˚ and ≤ 90˚ and infrarenal aortic neck length ≥10 mm treated with the GORE® EXCLUDER® Conformable AAA Endoprosthesis.
88914474|NCT02438436|Experimental|simo decoction|Patients will receive simo decoction (10 mL/piece,three times per day) and bilateral tsusanli acupoint injections with vitamin B1 two times per day, starting in the first day after resection until flatus.
88914475|NCT02438436|Active Comparator|gum chewing|Patients will receive gum chewing (three times per day) in the first day after resection until flatus.
88914476|NCT02438436|No Intervention|empty control|
88914477|NCT02432729||Study population|"Adult smokers who are willing to quit smoking within the next 30 days at the Screening Visit will be asked to continuously quit smoking for 1 year.~Smokers who are not continuously abstinent from smoking or any nicotine/tobacco containing product from the actual quit date will be discontinued from the study."
88914478|NCT02420821|Experimental|Atezolizumab + Bevacizumab|Participants will receive both atezolizumab and bevacizumab until loss of clinical benefit, unacceptable toxicity or symptomatic deterioration attributed to disease progression, withdrawal of consent, or death, whichever occurs first.
88914479|NCT02420821|Active Comparator|Sunitinib|Participants will receive sunitinib until loss of clinical benefit, unacceptable toxicity or symptomatic deterioration attributed to disease progression, withdrawal of consent, or death, whichever occurs first.
88914480|NCT02811263|Active Comparator|Erythropoietin|Erythropoietin 1000 U/kg IV, at about 1, 2, 3, 4, and 7 days of age (i.e., 5 doses)
88914481|NCT02811263|Placebo Comparator|Placebo|Normal saline IV (equal volume), at about 1, 2, 3, 4, and 7 days of age
88914482|NCT02188121|Experimental|Statin and/or Angiotensin Receptor Blocker|Simvastatin 20mg PO daily and/or Losartan 25mg PO daily
89198031|NCT04056156|No Intervention|Control|Standard of care (no specific intervention)
89434158|NCT05705271|Experimental|Finerenone|Participants will receive study treatment for 18 months ± 7 days.
89434159|NCT05704153|Sham Comparator|Sham|Control group to be subjected to sham stimulation.
89434160|NCT05704153|Experimental|30 hertz (Hz) Stimulation|Group of patients treated via 30Hz transcutaneous electrical nerve stimulation
89434161|NCT05704153|Experimental|1Hz Stimulation|Group of patients treated via 1Hz transcutaneous electrical nerve stimulation
89434162|NCT05703555|Experimental|Tusamitamab ravtansine 100mg/m2|Tusamitamab ravtansine 100 mg/m2 IV Q2W
89531278|NCT02493647|Experimental|Love, Sex, & Choices|Love, Sex, and Choices (LSC) is an engaging 12-episode video series to reduce HIV risk in young, adult predominately Black women. A peer video guide was added to the end of LSC episodes to provoke viewers to question their own sex scripts and consider their own need for change. Investigators propose to conduct a two-arm clinical trial of guide enhanced LSC impact on reducing unprotected sex with high risk partners and increasing HIV testing in Black women in high HIV prevalence neighborhoods.
89434163|NCT05702840|Experimental|Resistance exercise training + weight loss group (RT+WL)|Participants (WL-RT) will be provided with a resistance exercise booklet containing instructions for exercises and links to demonstration videos. A demonstration and explanation of the exercises will be given at the beginning of the intervention, alongside a discussion of the principles of the programme such as starting level and progression. We will ask participants to perform the resistance exercises for 12-week period. Participants will be asked to perform exercises 3 times a week (3 sets reaching the RPE scale between 8 - 10 out of 10 (4-6 out of 10 in the first week)) for the intervention period. The exercises will include press-ups, band lateral raises, band seated low row, squat, lunge and calf raise.
89434164|NCT05702840|Experimental|Weight loss only group (WL)|All participants (WL and WL-RT) will be provided with vouchers to access the weight watchers weight loss programme for a 12-week period. Weight Watchers is a commercially available programme and participants will set an initial goal to lose 5kg of body mass. If 5kg weight loss is achieved then the participant can chose further weight loss goals, as long as it would result in a body mass in the weight watchers healthy weight range (https://www.weightwatchers.com/uk/weight-loss/programme/tools/healthy-weight-chart).This plan works on the basis of an individualised points plan that can then be used by the participant to select foods/meals to consume throughout the day.
89434165|NCT05701995|Experimental|Deucravacitinib|
89434166|NCT05701995|Placebo Comparator|Placebo then Deucravacitinib|
89434167|NCT05701098|Experimental|Break Wave™ Procedure|The subject will undergo the Break Wave procedure.
89434168|NCT05700357|Active Comparator|Thoracic Paravertebral Block 20 ml|In patients who are planned to have a thoracic paravertebral block, the needle will be advanced to the paravertebral area with ultrasound-guided in-plane technique. 20 ml of 0.25% bupivacaine will be injected into this area.
88914483|NCT02188121|No Intervention|Usual treatment|"We will compare the initial treatment intervention with usual treatment (control arm), with both arms superimposed on a system of regular monitoring base. The investigators will make no effort to alter or influence treatment or use of that treatment for subjects in the control arm. Note that our goal in the Control arm is to characterize usual treatment. We will not intervene in this care except in emergencies. Some patients who need care for metabolic syndrome may not be receiving it - just as they would if not in our trial."
88914484|NCT02177162|Other|Intervention= education peer review group|For this controlled trial a group of physiotherapists will recieve specific education about optimal exercise therapy for patioents with knee OA in early stage
88914485|NCT02085486|Experimental|Ultrasound-assisted puncture|Ultrasound-assisted puncture by the nursing staff of patients with difficult AV-shunts.
88914486|NCT02085486|Other|Standard|Classical method wtih inspection and palpation
88914487|NCT02039063|Experimental|1|E6011 2 mg/kg
88914488|NCT02039063|Experimental|2|E6011 5 mg/kg
88914489|NCT02039063|Experimental|3|E6011 10 mg/kg
88914490|NCT02039063|Experimental|4|E6011 15 mg/kg
88914491|NCT01970410|Experimental|Teriflunomide|Teriflunomide 14 mg oral teriflunomide daily
88914492|NCT01746173|Experimental|CHOEP + High Dose Therapy + Auto SCT|Patients received 6 cycles of induction chemotherapy: Cyclophosphamide, Doxorubicin, Vincristine, Etoposide and Prednisone (CHOEP) (5 if previously received 1 cycle of CHOP). CHOP was given at standard doses, with a dose of etoposide of 100 mg/m2 intravenously (IV) or 200 mg/m2 orally added on days 1-3 of each cycle. Patients who did not achieve a partial (PR) or complete (CR) remission at restaging after either 3 or 6 cycles were taken off study. Responders after 6 cycles had stem cell (SC) mobilization using filgrastim and plerixafor (if necessary) within 4 weeks of the end of induction. SC mobilization, harvesting, and reinfusion were performed per standard institutional protocol. A minimum collection of 2x106 CD34+ cells/kg was required to proceed to autologous stem cell transplant. Conditioning was comprised of gemcitabine 2700 mg/m2 on days -8 and -3, IV busulfan 105 mg/m2 days -8 to -5, and melphalan 60 mg/m2 given daily on days -3 and -2 (per MD Andersen protocol).
88914493|NCT01694004|Experimental|Benzocaine Infusion into Duodenum|The investigator will conduct a study in 20 lean (BMI = 19-27 kg/m2) subjects involving intravenous (IV) and intraduodenal (ID) infusions of glucose tracers or amino acid traces and measurement of tracer rate of appearance in the plasma. An ID infusion of LCFA will allow the investigators to determine if LCFA can alter nutrient absorption and glucose and amino acid metabolism. Benzocaine will be added to the ID infusion of LCFA to inhibit nerve terminals in the duodenum thereby preventing gut-brain communication. Plasma levels of glucose and amino acid tracers, glucose oxidation (13CO2 breath test), gut hormones (CCK, GIP, PYY, GLP-1, ghrelin), and bioactive lipids (N-acyl phosphatidylethanolamines, NAPEs) will be measured during all infusion periods.
88914494|NCT01679275||measuring cerebral oxygenation|NIRS: Measurement of cerebral oxygenation using Near Infrared Spectroscopy (NIRS) during the pre-operative phase in neonates with congenital heart disease.
88914495|NCT01545843|Active Comparator|No sleep deprivation|Sleep scheduling plus fluoxetine. 8 hours time in bed for two weeks plus fluoxetine for 8 weeks
88914496|NCT01545843|Experimental|Late bedtime sleep deprivation|Sleep scheduling plus fluoxetine. 6 hours time in bed for two weeks plus fluoxetine for 8 weeks. Bedtime delayed by 2 hours.
89536389|NCT02447107||Outpatients|Outpatients enrolled in this study are required to complete study assessments on mobile applications and through questionnaires. A daily electronic diary will be completed through the Ohmage app. The Mobility app will be used to track the patients' movement and activity. Patients will be administered a questionnaire at the 1 and 2 week endpoints.
88914497|NCT01545843|Experimental|Early risetime sleep deprivation|Sleep scheduling plus fluoxetine. 6 hours time in bed for two weeks plus fluoxetine for 8 weeks. Risetime advanced by 2 hours.
88914498|NCT00843791|Placebo Comparator|Placebo|Treatment with placebo for 3 months before spectroscopy, hyperinsulinemic-euglycemic clamp, control diet, blood sampling.
88914499|NCT00843791|Active Comparator|pioglitizone|Treatment with pioglitazone for 3 months before hyperinsulinemic-euglycemic clamp, control diet with blood sampling and spectroscopy.
88914500|NCT03187769|Experimental|ALKS 3831|Coated bilayer tablet
88914501|NCT03187769|Active Comparator|Olanzapine|Coated bilayer tablet
88914502|NCT03158402|Sham Comparator|sham IMT|Preoperative Inspiratory muscle training at low intensity (15% Pimax) which is considered as a no effect training.
88914503|NCT03158402|Experimental|Hi Intensity IMT|High intensity muscle training in the preoperative period at 80% of the maximal inspiratory muscle pressure.
88914504|NCT03136731||Healthy family members of celiac disease|Celiac disease screening, no intervention.
88914505|NCT03136731||Celiac disease index cases|Assessment of disease related factors, no intervention.
88914506|NCT03092297||ICU patients with anaemia|At admission to the ICU all patients, or their legal representatives, expected to stay at the ICU for longer than 24 hours will be asked to participate in the study and will be asked informed consent. ICU patients with anaemia in whom a central venous catheter is already in place and in whom a red cell transfusion is planned, will be included in the study.
88914507|NCT03092245|Active Comparator|OctaplasLG|OctaplasLG® is an industrial donor plasma product pooled from 630 -1520 single donor units. It possesses unique features when compared to standard FFP, such as having a standardized concentration of natural pro- and anti-coagulation factors, a standardized volume as well as being pathogen-free.12 Most importantly, the manufacturing method of OctaplasLG® removes immune complexes and cells in several steps of microfiltration. The manufacturing process also inactivates viral, bacterial and prion pathogen by immune neutralization, solvent-detergent treatment and a prion specific ligand affinity chromatography step.
88914508|NCT03092245|Placebo Comparator|Ringer-Acetate|standard of care resuscitation fluid Ringer-acetate is a mixture of electrolytes in water to a slightly hypotonic solution.
88914509|NCT03008642|Experimental|CO-Rebreathing|The intervention consists in one red cell mass determination using the CO-Rebreathing technique at diagnosis of polycythemia, in addition to the regular tests performed in this indication, including RCM isotopic measurement.
88914510|NCT02995733|Active Comparator|PARTICS|addition of PARTICS strategy - Patient Activated Reliever-Triggered Inhaled CorticoSteroid (PARTICS) using QVAR . Patient will use inhaled corticosteroid at time of rescue inhaler use
88914511|NCT02995733|No Intervention|Usual Care|Provider-enhanced usual care arm; no change in asthma management
88914512|NCT02994043|Active Comparator|MBRP|
88914513|NCT02994043|Active Comparator|RP|
88914514|NCT02956382|Experimental|Phase I - Dose Level 0|"Ibrutinib (capsule) - 420mg Venetoclax (tablet) - 400mg~Each medication is taken daily. Treatment cycles are 28 days long."
88914515|NCT02956382|Experimental|Phase I - Dose Level 1|"Ibrutinib (capsule) - 560mg Venetoclax (tablet) - 400mg~Each medication is taken daily. Treatment cycles are 28 days long."
88914516|NCT02956382|Experimental|Phase I - Dose Level 2|"Ibrutinib (capsule) - 560mg Venetoclax (tablet) - 600mg~Each medication is taken daily. Treatment cycles are 28 days long."
88914517|NCT02956382|Experimental|Phase I - Dose Level 3|"Ibrutinib (capsule) - 560mg Venetoclax (tablet) - 800mg~Each medication is taken daily. Treatment cycles are 28 days long."
88914518|NCT02956382|Experimental|Phase II Dose|The Phase II dose will be the maximum tolerated dose as determined in the Phase I portion.
88914519|NCT02855229||Phase 1 Participants [No Study Drug]|Phase 1 participants are not being assigned to any study drug.
88914520|NCT02855229||Phase 2 Participants [Placebo]|Phase 2 participants that are randomly assigned to the placebo.
88914521|NCT02855229||Phase 2 Participants [Methylphenidate]|Phase 2 participants that are randomly assigned to take methylphenidate.
88914522|NCT02855229||Phase 2 Participants [Modafinil]|Phase 2 participants that are randomly assigned to take modafinil.
88914523|NCT02833883|Experimental|Enzalutamide plus CC-115|The first several study participants will receive the lowest dose. If the drug does not cause serious side effects, it will be given to other study participants at a higher dose. The doses will continue to increase for every group of study participants until the maximum tolerated dose is identified. Participants at each site will participate in the dose escalation phase of the study. During the dose escalation phase, study participants will be assigned sequentially to three dose levels in groups (cohorts) of 3 to 6 subjects per dose level: Cohort 1: CC-115 at 5 mg dose twice a day & enzalutamide at 160 mg once a day. Cohort 2: CC-115 at 10 mg dose twice a day & enzalutamide at 160 mg once a day. The protocol has been amended to accrue an additional in the expansion phase treated at 7.5 mg BID. Amended to treat expansion group with 5mg BID of CC-115.
88914524|NCT02829931|Experimental|Combination Therapy|"Safety Cohort: The first 6 participants will receive Hypofractionated Stereotactic Irradiation (HFSRT) followed by Ipilimumab + Nivolumab + Bevacizumab.~Dose Expansion Cohort: All 26 participants will be treated with Hypofractionated Stereotactic Irradiation (HFSRT), followed by Ipilimumab + Nivolumab +Bevacizumab"
88914525|NCT02815566|Experimental|Immediate switch|Open label tenofovir-alafenamide (25/10mg)-emtricitabine (200mg) tablet once daily by mouth for 96 weeks
88914526|NCT02815566|Active Comparator|delayed switch|Open-label tenofovir (300mg)-emtricitabine (200mg) tablet once daily by mouth for 48 weeks followed by open label tenofovir-alafenamide (25/10mg)-emtricitabine (200mg) tablet once daily by mouth for an additional 48 weeks
88914527|NCT02702492|Experimental|KPT-9274|"Part A: [CLOSED TO ENROLLMENT]~Oral KPT-9274 three times a week every other day (Days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26) during each 28 day cycle."
89536390|NCT05408819||Coplanar Template group|Paticipant will undergo coplanar template assisted CT-guided abdominal tumor biopsy or fiducial markers implantation and the prospective accuracy and safety data will record.
89434169|NCT05700357|Active Comparator|Thoracic Paravertebral Block 25 ml|In patients who are planned to have a thoracic paravertebral block, the needle will be advanced to the paravertebral area with ultrasound-guided in-plane technique. 25 ml of 0.25% bupivacaine will be injected into this area.
89434170|NCT05700357|Active Comparator|Thoracic Paravertebral Block 30 ml|In patients who are planned to have a thoracic paravertebral block, the needle will be advanced to the paravertebral area with ultrasound-guided in-plane technique. 30 ml of 0.25% bupivacaine will be injected into this area.
89434171|NCT05698056||Women undergoing breast cancer screening with MRI|No interventions are administered. Data is retrospectively collected in an anonymized way after ethical approval at each site.
89434172|NCT05697172|Experimental|Active Low Intensity Focused Ultrasound (LIFU)|An 80-second train of 20-millisecond bursts of ultrasound (0.5 MHz), repeated every 200 milliseconds (400 bursts). Acoustic simulations will be performed with the k-Wave Matlab Toolbox to individually confirm the estimated total energy delivered during sonication and verify tissue temperature increases are <1°C, decreasing actual Power/Channel values if necessary. We estimate a 75% tissue attenuation of energy when the ultrasound wave reaches its target, therefore we will set the free-field Intensity Spatial-Peak Pulse-Average (ISPPA) at 9.04 Watt /cm2 or 518 kPascal (to achieve 2.26 Watt/cm2 derated ISPPA).
89434173|NCT05697172|Sham Comparator|Sham LIFU|Identical parameters of sonication and positioning procedures as those in the Active LIFU arm will be employed, but a Sorbothane(R) film will be interposed between the transducer and the subject's scalp.
89434174|NCT05696821|Other|Cluster 1|"Participants are randomised into clusters. Each cluster includes 20 participants. All clusters receive the same educational intervention but at different time-points. Each cluster contributes with both exposed and unexposed outcomes and as such acts as its own control.~Cluster one contributes with 3 months unexposed and 18 months exposed outcomes."
88914528|NCT02702492|Experimental|KPT-9274 & Niacin Extended Release (ER)|"Part B:[CLOSED TO ENROLLMENT]~500 mg niacin ER co-administered with each dose of oral KPT-9274 three times a week every other day (Days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26) during each 28 day cycle."
88914529|NCT02702492|Experimental|KPT-9274 + Nivolumab|"Part C:~Oral KPT-9274 three times a week every other day (Days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26) during each 28 day cycle.~Nivolumab 480 mg IV administered Day 1 during each 28 day cycle."
88914530|NCT02652455|Experimental|PD-1, CD137 and Adoptive Cell Therapy|"Combination Therapy and Immunotherapy as described in intervention descriptions.~Nivolumab Treatment: The first 6 participants will not have pre-treatment with nivolumab and instead will be scheduled for the removal of their tumor sample for tumor Infiltrating lymphocytes (TIL) growth in the lab. The second 6 participants will receive treatment with nivolumab prior to removal of tumor sample for TIL growth; about 2 weeks after their tumor sample has been taken, these participants may receive additional infusions of nivolumab.~Surgery to remove tumor for growth of TIL followed by: TIL growth process; lymphodepleting chemotherapy with cyclophosphamide and fludarabine; TIL infusion; Interleukin-2 treatment."
89434175|NCT05696821|Other|Cluster 2|"Participants are randomised into clusters. Each cluster includes 20 participants. All clusters receive the same educational intervention but at different time-points. Each cluster contributes with both exposed and unexposed outcomes and as such acts as its own control.~Cluster one contributes with 4 months unexposed and 17 months exposed outcomes."
89434176|NCT05696821|Other|Cluster 3|"Participants are randomised into clusters. Each cluster includes 20 participants. All clusters receive the same educational intervention but at different time-points. Each cluster contributes with both exposed and unexposed outcomes and as such acts as its own control.~Cluster one contributes with 5 months unexposed and 16 months exposed outcomes."
89434177|NCT05696821|Other|Cluster 4|"Participants are randomised into clusters. Each cluster includes 20 participants. All clusters receive the same educational intervention but at different time-points. Each cluster contributes with both exposed and unexposed outcomes and as such acts as its own control.~Cluster one contributes with 6 months unexposed and 15 months exposed outcomes."
89536391|NCT02446873|No Intervention|Control|Control group
88914531|NCT02590289|Experimental|BBI-5000 Dose 1|Low dose of BBI-5000
88914532|NCT02590289|Experimental|BBI-5000 Dose 2|Middle dose of BBI-5000
89009955|NCT04556110|Active Comparator|Perindopril tert-Butylamine tablets（ACERTIL®）|The trial was divided into four cycles, between of each cycle with a 14-day wash-out period.In the first cycle，subjects in experimental group took the test preparation Perindopril tert-butylamine after meal, and subjects in control group took the reference preparation ACERTIL® after meal; In the second cycle subjects in experimental group took the reference preparation ACERTIL® after meal , the trial preparation perindopril tert-butylamine was taken orally after meals for the subjects in control group ; the order of taking the medicines for the subjects in the third cycle was the same as that in the first cycle, and the taking order of the subjects in the fourth cycle was the same as that in the second cycle. A single oral administration was used for the four cycles, and the dose was 4 mg.
89434178|NCT05696821|Other|Cluster 5|"Participants are randomised into clusters. Each cluster includes 20 participants. All clusters receive the same educational intervention but at different time-points. Each cluster contributes with both exposed and unexposed outcomes and as such acts as its own control.~Cluster one contributes with 8 months unexposed and 13 months exposed outcomes."
89434179|NCT05696821|Other|Cluster 6|"Participants are randomised into clusters. Each cluster includes 20 participants. All clusters receive the same educational intervention but at different time-points. Each cluster contributes with both exposed and unexposed outcomes and as such acts as its own control.~Cluster one contributes with 10 months unexposed and 11 months exposed outcomes."
89434180|NCT05696821|Other|Cluster 7|"Participants are randomised into clusters. Each cluster includes 20 participants. All clusters receive the same educational intervention but at different time-points. Each cluster contributes with both exposed and unexposed outcomes and as such acts as its own control.~Cluster one contributes with 12 months unexposed and 9 months exposed outcomes."
89434181|NCT05696821|Other|Cluster 8|"Participants are randomised into clusters. Each cluster includes 20 participants. All clusters receive the same educational intervention but at different time-points. Each cluster contributes with both exposed and unexposed outcomes and as such acts as its own control.~Cluster one contributes with 13 months unexposed and 8 months exposed outcomes."
89434182|NCT05696821|Other|Cluster 9|"Participants are randomised into clusters. Each cluster includes 20 participants. All clusters receive the same educational intervention but at different time-points. Each cluster contributes with both exposed and unexposed outcomes and as such acts as its own control.~Cluster one contributes with 14 months unexposed and 7 months exposed outcomes."
89434183|NCT05696821|Other|Cluster 10|"Participants are randomised into clusters. Each cluster includes 20 participants. All clusters receive the same educational intervention but at different time-points. Each cluster contributes with both exposed and unexposed outcomes and as such acts as its own control.~Cluster one contributes with 15 months unexposed and 6 months exposed outcomes."
89434184|NCT05696080|Experimental|V116|Participants will receive a single intramuscular (IM) dose of V116 on Day 1, and single IM dose of placebo for PCV15 + PPSV23 on Week 8
89434185|NCT05696080|Active Comparator|PCV15 + PPSV23|Participants will receive a single IM dose of PCV15 on Day 1, and a single IM dose of PPSV23 on Week 8.
88914533|NCT02590289|Experimental|BBI-5000 Dose 3|High dose of BBI-5000
88914534|NCT02590289|Experimental|BBI-5000 Dose 4|High dose of BBI-5000
88914535|NCT02572284|Experimental|Dose Escalation of SBRT|Stereotactic Body Radiation Therapy (SBRT) followed by prostatectomy and Quality of Life questionnaires. The radiation will be given for only 5 days. Conventional radiation to the prostate is given over 7-8 weeks.
88914536|NCT02525783|Experimental|Hemi Shoulder Arthroplasty|Hemi Shoulder Arthroplasty using the Aequalis Pyrocarbon Humeral Head
88914537|NCT02491983|Active Comparator|Arm A|Combination of Palbociclib and Letrozole
88914538|NCT02491983|Experimental|Arm B|Combination of Palbociclib and Fulvestrant
88914539|NCT02467478|Placebo Comparator|Placebo|Matching placebo 1 pill daily for 12 weeks
88914540|NCT02467478|Active Comparator|Linagliptin|Linagliptin 5mg once daily for 12 weeks
88914541|NCT02466243|Experimental|JBT-101|"Part A: JBT-101 20 mg capsule once a day on Days 1-28, then 20 mg capsule twice a day on Days 29-84.~Part B: JBT-101 20 mg twice daily on Days 1 - 365 of the OLE."
89434186|NCT05690633|Experimental|Oropharyngeal oximetry|The use of a pulse oximeter in the oropharynx on either an oral airway or a tongue blade.
88914542|NCT02466243|Placebo Comparator|Placebo|"Part A: Placebo capsule once a day on Days 1-28, then placebo capsule twice a day on Days 29-84.~Part B: Placebo twice daily on Days 1 - 365 of the OLE."
88914543|NCT02321098|Experimental|Investigator blinded Loceryl NL+ Cosmetic varnish|Loceryl NL+ Cosmetic varnish once/week for 12 weeks on right or left foot toenails
88914544|NCT02321098|Experimental|Investigator blinded Loceryl NL alone|Loceryl NL once/week for 12 weeks on right or left foot toenails
88914545|NCT02250339||LAKU family program|Time-limited (12 or 24 months) intervention program for children (aged 5-12) with neuropsychiatric/psychiatric disorder(s). LAKU family program (12 month program) includes 35 family-based meetings. Families are also given an opportunity to attend two separate family weekends. In addition to this, parent group format may include 10 meetings at maximum. A 24-month-program will include 15 additional family-based meetings.
88914546|NCT02250339||Etä-LAKU family program|Time-limited (18 or 24 months) intervention program for children (aged 5-12) with neuropsychiatric/psychiatric disorder(s). Etä-LAKU family program (18 months) includes 35 family-based meetings and two separate family weekends. A 24-month-program will include 10 additional family-based meetings.
88914547|NCT02250339||Family therapy|Time-limited (12 or 24 months) family therapeutic intervention for children (aged 5-12) with neuropsychiatric/psychiatric disorder(s). Family therapy intervention includes 15 (1-year program) or 30 (2-year program) family meetings.
88914548|NCT02211794||1 cohort|subject requires primary total knee arthroplasty with the Journey II BCS Total Knee System, including patella resurfacing due to degenerative joint disease (primary osteoarthritis, post-traumatic arthritis, avascular necrosis, rheumatoid arthritis)
88914549|NCT02185417|Active Comparator|Hydrochlorothiazide|Hydrochlorothiazide daily dose of 50 mg or 25 mg for duration of study
88914550|NCT02185417|Active Comparator|Chlorthalidone|Chlorthalidone daily dose of 25 mg or 12.5 mg for duration of study
88914551|NCT02158234|Experimental|Dose Escalation: SBRT and Cisplatin|Stereotactic Body Radiation Therapy (SBRT) and Cisplatin. Starting Dose: 6 Gy/ Fraction 5/ Total 30 Gy/ Cisplatin 15 mg/m^2
89009956|NCT00234299|Active Comparator|Group A|Enteric coated aspirin 325mg, one tablet orally every day for six months prior to prostate biopsy.
89198032|NCT04056156|Experimental|Level 1: Online dissemination of the HIV screening advice|General practitioners included at the first level receive the HIV-testing advice through a personal electronic mail by their local GP-organization coordinator containing an information message with the printer-friendly screening advice attached. The message also provides a link to the website of the Flemish umbrella organization for GPs (https://domusmedica.be), where the tool is available for download for all Flemish GPs. A reminder is sent out to all participants after 13 months.
89434187|NCT05687604|Active Comparator|STELLAR Program|STELLAR arm participants will receive goals related to their physical activity, smoking, and/or obesity, and will be asked to meet those goals weekly/daily. Participants will also be asked to record their weight, activity, and/or cigarette smoking daily, and will complete 16 telehealth sessions with study staff across the 12 months of the study. Will have physical measures taken or extracted from the medical record at baseline, 3 months, 6 months, and 12 months.
89009957|NCT00234299|Placebo Comparator|Group B|Enteric coated placebo, one tablet orally every day for six months prior to prostate biopsy.
89536392|NCT02446873|Experimental|Treatment|Egg supplementation
89198033|NCT04056156|Experimental|Level 2: additional group-level training session|At the second intervention level, GPs first receive intervention condition 1 and additionally the face-to-face group-level training session. These sessions are organized as part of regular 'continuous medical education' provided by the GP organizations ('quality circles') at their usual venues and are organized a few months after receiving intervention level 1. A reminder of the advice is sent out 13 months after the initiation of intervention level 1.
89434188|NCT05687604|No Intervention|Enhanced Usual Care|Patients in the EUC group will receive informational packets about their risk behaviors - obesity, physical inactivity, and/or smoking. Will have physical measures taken or extracted from the medical record at baseline, 3 months, 6 months, and 12 months
89434189|NCT05686304|Experimental|Money management group|Participants in the money management condition start the 4-week money management program immediately after randomization and complete the post-intervention assessment right after they finish the treatment. They will be invited to participate in an interview after completing the post-intervention assessment.
89434190|NCT05686304|No Intervention|Waitlist control group|Participants in the waitlist control group will wait for 4 weeks without the money management program and then complete the post-intervention assessment. The waitlist control participants will start a money management program (equivalent to that of the money management group) immediately after completing the post-intervention assessment.
88914552|NCT01859026|Experimental|Phase I - Dose Escalation|"For the Phase I portion, patients will start MEK162 by mouth (p.o.) on cycle 1, day 1 and erlotinib on cycle 1, day 2. The MEK162 will be dosed once daily (QD) or twice (b.i.d.), and erlotinib will be dosed daily (QD) on a 28-day cycle.~Phase I will be followed by an expansion Phase Ib."
88914553|NCT01859026|Experimental|Arm A: Dose Expansion|"Phase Ib Arm A: EGFR Mutant Tumor Status. In the phase IB expansion cohort study there are 2 arms based on the presence of the EGFR (Arm A) or KRAS (Arm B) mutation.~The treatments for each arm are the same: MEK162 (2 time a day) and erlotinib (once) daily on 28 day cycles."
88914554|NCT01859026|Experimental|Arm B: Dose Expansion|"Phase Ib Arm B: KRAS Mutant Tumor Status. In the phase IB expansion cohort study there are 2 arms based on the presence of the EGFR (Arm A) or KRAS (Arm B) mutation.~The treatments for each arm are the same: MEK162 (2 time a day) and erlotinib (once) daily on 28 day cycles."
88914555|NCT01753089|Other|WDVAX|Treatment
89434191|NCT05686291|Experimental|Treatment group|Participants in the treatment condition start the online volunteer training immediately after randomization and completed the online module within 2-week. Then they are invited to attend the face-to-face training within 1-week. They will complete the post-intervention assessment right after they finish the face-to-face training, and be invited to participate in an interview.
89434192|NCT05686291|No Intervention|Wait-list control group|Participants in the waitlist control group will wait for 4 weeks without the training and then complete the post-intervention assessment. The waitlist control participants will start training (equivalent to that of the treatment group) immediately after completing the post-intervention assessment.
89434193|NCT05684133||Patients with Sepsis|Adult patients (18 years or older) meeting Sepsis-3 criteria within 6 hours of emergency department admission. Patients will be excluded with the following conditions: traumatic injury, cardiac arrest, stroke, comfort measures only.
88914556|NCT01705067|Other|Journey II BCS TKA|Subjects having TKA with Journey II BCS Total Knee System
89009958|NCT04556227|Experimental|Simultaneous Cycle/Cognitive Training|After discharge from the hospital the group will engage in recumbent cycling with simultaneous cognitive training on a tablet.
89009959|NCT04556227|No Intervention|Usual Care|After discharge from the hospital the group will complete baseline activies.
89434194|NCT05683574|Experimental|etoricoxib 90 mg + cyclobenzaprine 15 mg|Investigational group: FDC of etoricoxib 90 mg + cyclobenzaprine 15 mg from Eurofarma Laboratórios SA
89009960|NCT04556032|Experimental|L-Ergothioneine 10 mg/d|Participants will receive L-Ergothioneine 10 mg capsule orally once daily for 16 weeks.
89198034|NCT00751764|Experimental|1|
89198035|NCT00757458|Active Comparator|1|TCI with EDTA
89198036|NCT00757458|Active Comparator|2|Re-filling of propofol syringe (Diprivan®-Astra Zeneca) with propofol containing EDTA
89198037|NCT00757458|Active Comparator|3|Re-filling of propofol syringe (Diprivan®-Astra Zeneca) with propofol without EDTA
89198038|NCT00757458|Active Comparator|4|Target controlled infusion of propofol without EDTA
89009961|NCT04556032|Experimental|L-Ergothioneine 25 mg/d|Participants will receive L-Ergothioneine 25 mg capsule orally once daily for 16 weeks.
89009962|NCT04556032|Placebo Comparator|Placebo|Participants will receive placebo orally once daily for 16 weeks.
89009963|NCT04556149||Case|Inpatients with confirmed COVID-19 with pulmonary symptoms
89009964|NCT04556149||Matched Control|Inpatients without COVID-19 with non-pulmonary diagnoses or symptoms
89009965|NCT04556071|Experimental|Niraparib-bevacizumab combination|Niraparib-bevacizumab combination therapy until disease progression
89009966|NCT02211118|Experimental|IN-DEX|Subjects will be administered 1 mcg/kg or 1.5 mcg/kg intranasal dexemdetomidine (IN-DEX) and monitored for up to 5 hours.
89009967|NCT02211157|Experimental|BIBR 796 BS, fasted|dose escalation
89009968|NCT02211157|Experimental|BIBR 796 BS, fed|50 mg BIRB 796 BS (food effect)
89009969|NCT02211157|Placebo Comparator|Placebo|
89009970|NCT02211196|Experimental|Health Services Research (smoking cessation intervention)|Participants complete a survey over approximately 10-15 minutes related to their provider's cessation advice and assistance with quitting.
89009971|NCT04563364|Experimental|Hospital-Home|This group will receive an interdisciplinary intervention of education to parents for get better outcomes of motor development.
89009972|NCT04563364|Active Comparator|Control Intervention|Control group will receive a conventional treatment given by the institutions
89009973|NCT04562857|Active Comparator|obstructive sleep apnea|interval exercises (intervention) on bicycle for patients with AF and OSA for 10 weeks, 3 times/week for duration of 30-45 min/ session.
89009974|NCT04562857|Active Comparator|Central sleep apnea|interval exercises (intervention) on bicycle for patients with AF and CSA for 10 weeks, 3 times/week for duration of 30-45 min/ session.
89009975|NCT04563052|Experimental|Education|Air pollution educational module exposure.
89009976|NCT00234455|Other|1|stent in the main branch with balloon angioplasty by a kissing balloon technique in the side branch (stent/PTCA group)
89009977|NCT00234455|Other|2|stents in both the main and side branches (stent/stent group)
89009978|NCT04563169|Experimental|Video consultation|Patients in the video consultation group will receive video consultations.
89009979|NCT04563169|No Intervention|Face-to-Face consultation|Patients in the usual care group will receive face-to-face consultations.
89009980|NCT04563091|Experimental|Interventional group|"The study population will consist of 6 evaluable, outpatient patients with chronic kidney failure who need to perform hemodialysis thrice weekly for their survival.~In the case of drop out of a patient will be enrolled another patient to arrive at 6 patients evaluable both at the end of Period A and at the end of Period B of the study"
89009981|NCT04562818||Daunorrubicin|Patient treated with daunorrubicin
89009982|NCT04562818||Idarrubicin|Patient treated with idarrubicin
89434195|NCT05683574|Active Comparator|etoricoxib 90 mg|Comparator group: etoricoxib 90 mg (Arcoxia®)
89434196|NCT05683574|Active Comparator|cyclobenzaprine hydrochloride 15 mg|Comparator group: cyclobenzaprine hydrochloride 15 mg (XL - Mitrul®)
89434197|NCT05682300||Patient under regional anesthesia|patients who recieve peripheral nerve blocks as analgesic technique
89434198|NCT05682248|Experimental|Real rTMS group|True rTMS stimulation: 10Hz, intensity: 90% RMT, duration: 10s, interval: 30s, stimulation cycle: 1 time/day, treatment duration: 10 days;
89434199|NCT05682248|Placebo Comparator|Sham rTMS group|sham stimulation group : intensity :0; other parameters are the same as true rTMS stimulation
89434200|NCT05682157|Experimental|Paula Method|12 weeks of the Paula Method of muscle exercises with standard care
89434201|NCT05682157|No Intervention|Standard Care|standard care
89434202|NCT05679700|Experimental|Chronic stroke patients with knee hyperextension|
89009983|NCT04562506|Active Comparator|Real rTMS stimulation|real deep excitatory, high frequency rTMS with H-coil stimulation
89009984|NCT04562506|Sham Comparator|Sham rTMS stimulation|sham high frequency H-coil stimulation
89009985|NCT04562545|Active Comparator|Maximum Bite Advancement|
89434203|NCT05678556|Experimental|Experimental Arm|all2GETHER is an HIV prevention and relationship education program designed for young MSM. all2GEHTER consists of 3 online didactic skills modules and 2 videoconference-based skills coaching sessions The 3 online modules focus on developmental skills related to sexual health and relationship functioning, including HIV prevention in couples, communication skills, coping skills, problem-solving and acceptance. Individualized couple sessions focus on implementation of skills specific to the needs of each couple.
89434204|NCT05678556|No Intervention|Control Arm|Participants will receive no intervention, but have access to HIV prevention resources from the CDC website and national databases. We will also assess exposure to other interventions that may be naturally occurring in participants' local context, which can be used to describe the sample and as a covariate (as necessary).
89434205|NCT05677425|Experimental|Temperature measurement group|Temperature measurement in the renal pelvis during ureteroscopic laser stone disintegration. Temperature measurement will be performed using different laser power settings.
89009986|NCT04562545|Experimental|Incremental Bite Advancement|
89009987|NCT02211274|Experimental|Study Group|Individuals who want to leave the CLC will be allowed to participate in the study, there will be no assignment to groups. Individuals who want to leave the CLC will undergo transition care planning using the investigators' standardized toolkit. The investigators will compare outcomes to administrative data from other similar VA nursing homes.
89009988|NCT02211352|Active Comparator|Active(Korean Red Ginseng) first group:|Korean Red Ginseng Capsules 2g,daily, 8 week and than crossover to placebo capsules(2g), daily 8week
89009989|NCT02211352|Placebo Comparator|Placebo capsules|placebo Capsules(2g),daily, 8 week and than crossover to Korean Red Ginseng capsules(2g), daily 8week
89009990|NCT02211391|Experimental|Casein Protein|Casein protein (30g) will be consumed as the last food/caloric beverage and within 30 minute of sleep
89009991|NCT02211391|Placebo Comparator|Non-caloric Placebo|The non-caloric placebo beverage will will be consumed as the last food/caloric beverage and within 30 minute of sleep
89009992|NCT02211469|Experimental|Panel 1: BMS-986104 or Placebo|BMS-986104 or Placebo single dose by mouth as specified
89009993|NCT02211469|Experimental|Panel 2: BMS-986104 or Placebo|BMS-986104 or Placebo single dose by mouth as specified
89198039|NCT02919098|Experimental|Intervention|Two schools (all students grades 9-12) will serve as the intervention group.Participants will complete a baseline survey that will take no longer than 30 minutes. Afterwards, a trained facilitator will delivery a game-based bystander intervention program aimed at teaching students the knowledge and skills to prevent or intervene in instances in sexual harassment and violence among peers. This will last for 4 class periods (approximately 45 minutes each period, 180 minutes total). Afterwards, participants will complete an immediate post-program survey lasting no more than 30 minutes. Three months later, students will fill out an a follow up survey lasting no more than 30 minutes. School staff and administrators will be interviewed to gather their insights on the program's feasibility and acceptability.
89198040|NCT02919098|Placebo Comparator|Delayed Control|"One school (all students grades 9-12) will serve as a delayed control group. Participants will complete a baseline survey that will take no longer than 30 minutes. Afterwards, a trained facilitator will delivery a game-based health program unrelated to sexual health, sexual violence, sexual harassment, and bystander behaviors. This will last for 4 class periods (approximately 45 minutes each period, 180 minutes total). Afterwards, participants will complete an immediate post-program survey lasting no more than 30 minutes. Three months later, students will fill out an a follow up survey lasting no more than 30 minutes.~After completing the follow-up survey, this group will follow the same procedures to deliver the bystander program and capture data outlined for the intervention group."
88914557|NCT01657591|Experimental|Dose Escalation|The treatment period will include dosing (taking a certain amount on a regular schedule) with vemurafenib along with the study drug, XL888. Everyone in the study will receive both drugs, but the XL888 will be given at different doses (different amounts). Everyone in this study will be given vemurafenib at the standard dose (the amount of the drug that is given as standard treatment) of 960 milligrams (mg) twice per day, unless the first people in the study have severe side effects when taking the lowest dose of XL888 along with vemurafenib. If that happens, the next people in the study may be given a lower dose of vemurafenib (720 mg twice per day) along with the lowest dose of XL888.
88914558|NCT01558544|Other|Use of high dose chemotherapy|Use of chemotherapy without removal of the disease ovary.
89198041|NCT00923247|Experimental|Phase 1 - vandetanib and bortezomib|Patients will be treated with vandetanib and bortezomib to find the maximally tolerated dose
89198042|NCT00923247|Active Comparator|Phase 2 B - vandetanib alone|Patients will be treated with vandetanib alone.
89198043|NCT00923247|Active Comparator|Phase 2 A - vandetanib and bortezomib at the MTD|Patients will be treated with vandetanib and bortezomib at the maximally tolerated dose (MTD) of the Phase I study
89434206|NCT05677139||Prospective Cohort|Participants with severe uncontrolled asthma will receive tezepelumab. Relevant demographics, baseline clinical data, and asthma control questionnaire-6 (ACQ-6) will be retrospectively collected. All patient reported outcomes (PROs) will be prospectively collected. Other outcomes of interest (tezepelumab patterns of utilization, lung function, asthma exacerbations, medication use, and healthcare resource utilization [HRU]) will be collected at baseline (retrospective collection for 52-week pre-index period during enrolment) and prospectively collected during enrolment for participants who enroll into the study before the first dose of tezepelumab, and for a period of up to 52 weeks (at Weeks 4, 12, 24, and 52) after the index date. The index date is defined as the date when participants receive the first dose of tezepelumab.
88914559|NCT01028144|Experimental|ACT Program|Motivational and Behavioral Skills Physical activity after-school program
89198044|NCT00757536|Active Comparator|Group 1|
89198045|NCT00757536|Active Comparator|Group 2|
89198046|NCT00757692|Experimental|A|Vandetanib at 300 mg in combination with Bicalutamide at 50 mg will be administered orally, daily and continuously
89434207|NCT05677048|No Intervention|Group 1 (Standard of Care Group)|"Participants (probands, those with a hereditary cancer syndrome) are sent a family letter to share with relatives. The letter contains information about hereditary cancer syndromes and encourages relatives to participate in the study and to get genetic testing.~Relatives of probands randomized to the usual care arm will have access to the family letter if probands decide to share it with them, and will receive study surveys. The letter contains information about hereditary cancer syndromes and encourages relatives to participate in the study and to get genetic testing"
89536393|NCT02477033|Active Comparator|Butyricicoccus pullicaecorum|Lyophilized Butyricicoccus pullicaecorum 25-3T bacteria, encapsulated with a pH-resistent coating.
88914560|NCT01028144|Active Comparator|General Health|General health education after-school program
88914561|NCT01025726|Experimental|Full Intervention|Police Patrolled Walking Program plus Social Marketing Intervention
88914562|NCT01025726|Experimental|Walking Only|Police Patrolled Walking Only Intervention
88914563|NCT01025726|Active Comparator|General Health|General Health Education Intervention
88914564|NCT01599455||Inpatient|Youths admitted for inpatient rehabilitation training
88914565|NCT01599455||Outpatient|Youths visiting outpatient clinics
88914566|NCT01599455||Urodynamic study|Youths who undergo scheduled urodynamic study
88914567|NCT01599468|Experimental|tranexamic acid, post partum hemorrhage|
88914568|NCT01599468|Placebo Comparator|placebo|
88914569|NCT01599481|Experimental|Intervention|Standard Care (IAPT Therapy) + Individual Career Management (ICM)
88914570|NCT01599481|Active Comparator|Control|Standard Care (IAPT Therapy)
88914571|NCT01599507|Experimental|FG-4592|Active Drug
88914572|NCT01599507|Placebo Comparator|Placebo|
88914573|NCT01599533|Other|abdominal aortic aneurysms|
88914574|NCT01599546||Full Term children|born >36 weeks, currently age 6 +/- 6 months
88914575|NCT01599546||Preterm children|born <35 weeks, age 6 +/- 6 months at the beginning of the study.
88914576|NCT01599572|Experimental|30mg/day zinc supplementation|30mg/day of zinc supplement provided for 3 months to zinc deficient elderly
88914577|NCT01599598|Active Comparator|Progressive Muscle Relaxation|A stress intervention where subjects will learn to regulate stress based on the tensing and releasing of the major muscle groups in the body, accompanied with relaxed breathing techniques.
88914578|NCT01599598|Active Comparator|Coherence Advantage|A stress intervention where subjects will learn to regulate stress by focusing on breathing and mindfulness techniques while recognizing physiological coherence by way of a portable biofeedback device.
89434208|NCT05677048|Experimental|Group 2 (Free genetic testing and counseling group)|Enrolled relatives will receive a letter and baseline survey with information to contact the tele-genetics company to arrange free genetic counseling and testing. This letter will be given to the relatives directly by the study
88914579|NCT01599611||Exposed group|Children age 5-10 years old who had a total serum bilirubin > 450 umol/L in the neonatal period
88914580|NCT01599611||Non-exposed group|Matched 1:1 to the exposed group on gender, age, gestational age and municipality of residence
88914581|NCT01599624|Experimental|iPad-based SRTS|
88914582|NCT01599624|Experimental|iPad-based PMR program|
88914583|NCT01599663|Experimental|Intervention units|"A time period before the clinicians will be educated, trained and guided in the pain management algorithm, pre-test data will be collected in four ICU units.~The clinicians in three of the ICU units will be educated, trained and guided in the pain management algorithm. The algorithm will then be used to assess and treat pain in all consecutive ICU patients. Post-test data will be collected a time period after the intervention is implemented."
89009994|NCT02211469|Experimental|Panel 3: BMS-986104 or Placebo|BMS-986104 or Placebo single dose by mouth as specified
89434209|NCT05677048|Experimental|Group 3 (IGNITE-TX Group)|"Relatives of probands randomized to the IGNITE-TX intervention will receive a family letter after enrollment and baseline survey with their personal access codes (not to be shared) to the IGNITE-TX Hub (access online educational material through a platform). Relatives will have also access services of a family genetic navigator. Study investigators and navigators will not directly provide genetic counseling and/or testing in this arm"
89434210|NCT05677048|Experimental|Group 4 (IGNITE-TX and free genetic testing and counseling group)|"Relatives randomized to this arm will receive a family letter after enrollment and baseline survey with their personal access codes (not to be shared) to the IGNITE-TX Hub (access online educational material through a platform) and information to contact the tele genetics company. This arm will receive both the IGNITE-TX Intervention and access to free genetic testing and counseling services, as well as access to assistance from family genetic navigator"
89009995|NCT02211469|Experimental|Panel 4: BMS-986104 or Placebo|BMS-986104 or Placebo single dose by mouth as specified
88914584|NCT01599663|No Intervention|Control unit|The clinicians in the fourth ICU (control unit) will not be educated, trained and guided in the pain management algorithm. They will continue to assess and treat pain in all consecutive ICU patients as before. The unit, which will be used as a comparison unit, will collect the same post-test data at the same time as data in intervention ICUs were collected.
89434211|NCT05676515|Active Comparator|culture media of fabricant A|use of culture media of fabricant A
89434212|NCT05676515|Active Comparator|culture media of fabricant B|use of culture media of fabricant B
89434213|NCT05676515|Active Comparator|culture media of fabricant C|use of culture media of fabricant C
89434214|NCT05676281|Other|Healthy Together (includes Streetwyze) (Control/Standardized Care)|Control - standardized Healthy Together program: The Healthy Together Program is not standard of care at Family Health Centers (FHC). Instead, it was originally developed by FHC clinicians interested in addressing childhood obesity and has been implemented by a limited number of clinicians at FHC. UCSD has been working in partnership with FHC to create standardized protocols and to incorporate additional research-oriented tools into this standardized protocol, which will be used as our experimental control.
89434215|NCT05676281|Active Comparator|Healthy Together + Promotora support|In addition to the basic program described above, those randomized to this intervention will receive Promotora support. Families assigned to a promotora will receive 30-60 minutes of phone-based support weekly, with more frequent interactions that will taper starting at month 3 of the intervention. Promotoras may also provide home-visit support up to 4 times during the 6 months, based on family interest and needs. The wellness coach will try to minimize in-person meetings with FHC professionals each week and space out visits to reduce burden on families. For families in this condition, they will be asked to engage in at least 30 minutes of additional sessions per week with the promotora beyond the 1- hour allotted time working with FHC professionals.
88914585|NCT01599676|Sham Comparator|Not essential amino acid|"Non essential amino acid:~The subjects will have a regimen of high-intensity progressive resistance training of the knee extensors 3 days per week for 12 weeks. The subjects will receive 1 unit of an equivalent quantity of nonessential amino acids (alanine, aspartate, glycine, serine, histidine and proline in equimolar quantity) isonitrogenous to 10 g of citrulline, once in the morning for 12 weeks."
88914586|NCT01599676|Experimental|Citrulline|The subjects will have a regimen of high-intensity progressive resistance training of the knee extensors 3 days per week for 12 weeks. The subjects will receive citrulline 10 g/day orally in the morning for 12 weeks.
88914587|NCT01599689|Experimental|Mirrors Intervention|Patients allocated to Mirrors will receive a structured, protocol-driven bedside mirrors intervention as part of their postsurgical ICU care. This intervention will commence as soon as all anaesthetic agents have been switched off and the patient is awake following surgery unless considered clinically inappropriate.
88914588|NCT01599689|No Intervention|Standard Care|Patients allocated to Standard Care will receive the usual postsurgical ICU care that does not include the use of mirrors.
88914589|NCT01599702|Experimental|Group A Monofer|Depending on the body weight, subjects in Treatment Group A will receive a total dose of 1,500 mg or 2,000 mg IV iron isomaltoside 1000 where 1,500 mg is administered as a single infusion and 2,000 mg is divided into 2 administrations: 1 administration of 1,500 mg at baseline and 1 administration of 500 mg 1 week later. All doses will be diluted in 100 ml normal saline (0.9 % sodium chloride) and administered by infusion over approximately 15 minutes.
88914590|NCT01599702|Experimental|Group B Monofer|Depending on the body weight, Subjects in Treatment Group B will receive a total dose of 2,500 mg or 3,000 mg IV iron isomaltoside 1000 divided into 2 administrations; 1 administration of 1,500 mg and 8 weeks later a second administration of 1,000 mg or 1,500 mg.. All doses will be diluted in 100 ml normal saline (0.9 % sodium chloride) and administered by infusion over approximately 15 minutes.
88914591|NCT01599715|Other|Instructional DVD Intervention|Participants randomized to this arm watched an eighteen minute bladder health instructional DVD at the conclusion of a successful baseline screening visit. This intervention occurred only once
88914592|NCT01599715|Other|Bladder Health Class Intervention|Participants randomized to this arm attended a two-hour bladder health instruction session that reviewed 3 primary self-care techniques that have been proven to prevent or lessen the severity of urinary incontinence. This session occurred only once 1-3 weeks subsequent to a successful baseline screening visit.
88914593|NCT01599728|Other|Patients with heart failure|Assessing the response to infusion of intra-arterial Urocortin 2, 3 and Substance P in patients with heart failure
88914594|NCT01599728|Other|Healthy controls|Assessing response to intra-arterial infusions of Urocortin 2, 3 and Substance P in age and sex-matched healthy volunteers as controls.
89434216|NCT05676281|Active Comparator|Healthy Together + Parenting training|In addition to the basic program described above, those randomized to this intervention will attend Parenting Training sessions with the mental health provider at FHC. Families assigned to parenting training will receive 10-12 sessions. Sessions will focus on topics like strategies to support the child's physical, social, and emotional growth. The wellness coach will try to minimize in-person meetings with FHC professionals each week and space out visits to reduce burden on families.
89536394|NCT02477033|Placebo Comparator|Placebo (maltodextrin)|Lyophilized maltodextrin, encapsulated with a pH-resistent coating.
88914595|NCT01599767|Experimental|Active tDCS|Subjects will undergo 20 minutes active tDCS.
88914596|NCT01599767|Sham Comparator|Sham tDCS|Subjects will undergo 20 minutes of sham stimulation.
89198047|NCT00757692|Active Comparator|B|Bicalutamide at 50 mg will be administered orally, daily and continuously.
88914597|NCT01599780||Full-Term Children|≥37 weeks gestation; 18 months old at the start of the study
88914598|NCT01599780||Preterm Children|<33 weeks gestation; 18 months old at the start of the study
88914599|NCT01599819|Experimental|Cohort 1|Low dose of ADVATE followed by low dose of BAX 855
88914600|NCT01599819|Experimental|Cohort 2|High dose of ADVATE followed by high dose of BAX 855
88914601|NCT01599845||Nanoparticle exposed|
88914602|NCT01599871|Experimental|Intervention|Inhaled corticosteroids and long-acting beta agonist + theophylline (Slophylline capsules 100 mg/Theo-dur Retard 100 mg b.i.d.)
88914603|NCT01599871|Placebo Comparator|Control|inhaled corticosteroids and long-acting beta agonist + Placebo
89198048|NCT04041141||Oral Cancer|Patients receiving curative radiation treatment for an oral cancer.
89198049|NCT00757770|Experimental|Group HRV Lot A|
89198050|NCT00757770|Experimental|Group HRV Lot B|
89198051|NCT00757770|Experimental|Group HRV Lot C|
89198052|NCT00757770|Active Comparator|Group Placebo|
89434217|NCT05676281|Active Comparator|Healthy Togethers + Parenting Training + Promotora support|Those randomized to this intervention will receive all components described above including the Healthy Together Program, Parenting Training and Promotora support. The wellness coach will try to minimize in-person meetings with FHC professionals each week and space out visits to reduce burden on families.. Families in this group will also be asked to engage in at least 30-60 minutes of additional sessions per week including up to 4 home visits.
89434218|NCT05674708|Active Comparator|Butter|Butter based meal
89434219|NCT05674708|Active Comparator|Coconut|Coconut based meal
89434220|NCT05674708|Active Comparator|Corn oil|Corn oil based meal
89434221|NCT05674708|Active Comparator|Flax seed oil|Flax seed oil based meal
89434222|NCT05673811|Active Comparator|Arm 1-SoC|Nab-paclitaxel and gemcitabine as SoC.
89434223|NCT05673811|Experimental|Arm 2 -VCN-01 + SoC|A maximum of two (2) doses of VCN-01 administrated as a single IV infusion in combination with nab-paclitaxel and gemcitabine as SoC.
89434224|NCT05672576|Experimental|Cenerimod 4 mg|Participants will receive cenerimod once daily in addition to background SLE therapy.
89434225|NCT05672576|Placebo Comparator|Placebo|Participants will receive matching placebo once daily in addition to background SLE therapy.
89434226|NCT05666609|Active Comparator|Group 4weeks|Duration of placed seton 4 weeks
89434227|NCT05666609|Active Comparator|Group 12weeks|Duration of placed seton 12 weeks
89434228|NCT05664737|Experimental|Transfusion Dependent (TD): Luspatercept + Best supportive care (BSC)|
89434229|NCT05664737|Placebo Comparator|Adult TD Cohort: Placebo + BSC|
89434230|NCT05664737|Experimental|Non-transfusion Dependent (NTD): Luspatercept + BSC|
89434231|NCT05664737|Placebo Comparator|Adult NTD Cohort: Placebo + BSC|
89434232|NCT05662982|Experimental|Intervention Group|Participants will be assessed for 12 weeks in their usual ischial containment socket before receiving a subischial socket to be worn and assessed for 24 weeks.
89434233|NCT05662982|No Intervention|Reference Group|Participants will be assessed for 40 weeks in their usual ischial containment socket. No intervention will be provided.
89434234|NCT05662852|Experimental|Tdap for Plasma Donors|Dose: 0.5 mL; Route: Intramuscular (IM) in the deltoid muscle; Frequency: Every 90 days; Duration: 5 doses over 1 year.
89434235|NCT05660421|Experimental|Treatment (itacitinib)|Patients receive itacitinib PO and corticosteroids PO or IV. Patients may undergo endoscopy and skin biopsy throughout the study. Patients also undergo blood collection throughout the study.
89434236|NCT05656911|Experimental|Zabedosertib|Participants will receive zabedosertib for up to 12 weeks (84 days).
89434237|NCT05656911|Placebo Comparator|Matching placebo to zabedosertib|Participants will receive placebo to zabedosertib for up to 12 weeks (84 days).
89434238|NCT05655403|Experimental|Step training group|The participants assigned to the ST condition will receive a 40-minute ST session twice a week for 12 weeks. The sessions will be delivered at community centers for older adults by an instructor with at least 5 years of experience in dementia care. Each session will consist of a 5-minute flexibility exercise warm-up, a 30-minute stepping exercise, and a 5-minute cool-down. A non-slip plastic mat marked with two standing panels and a number of removable stepping panels that can be secured to the plastic mat using hook-and-loop fasteners will be used as the exercise device. While standing on the standing panels, the participants will receive verbal instructions to (1) use one of their feet to step on a specific stepping panel and (2) return the stepping foot to the standing panel multiple times throughout every session.
89434239|NCT05655403|Active Comparator|Wait-list control group|The participants assigned to the WC condition will then receive usual care for 12 weeks. After completing the 12-week assessment, they will complete the ST program.
89434240|NCT05654467|Experimental|Group 1: Young Children, nOPV3 10^5.5 CCID50|48 young children aged 1 to <5 years will receive 2 doses of nOPV3 at a dose level of 10^5.5 CCID50 on Day 1 and Day 29
89434241|NCT05654467|Experimental|Group 3: Young Children, nOPV3 10^6.0 CCID50|48 young children aged 1 to <5 years will receive 2 doses of nOPV3 at a dose level of 10^6.0 CCID50 on Day 1 and Day 29
88914604|NCT01599884|Active Comparator|N-acetylcysteine|N-acetylcysteine, 1800 mg twice daily
88914605|NCT01599884|Placebo Comparator|Sugar pill|Identical to active drug
88914606|NCT01599897|Experimental|2 µg ID93 + 2 µg GLA-SE|Low dose and antigen and low dose of adjuvant.
88914607|NCT01599897|Experimental|10 µg ID93 + 2 µg GLA-SE|High dose of antigen and low dose of adjuvant.
88914608|NCT01599897|Experimental|2 µg ID93 + 5 µg GLA-SE|Low dose of antigen and high dose of adjuvant.
88914609|NCT01599897|Experimental|10 µg ID93 + 5 µg GLA-SE|High dose of antigen and high dose of adjuvant.
88914610|NCT01599897|Active Comparator|2 µg ID93 alone|Low dose of antigen alone.
88914611|NCT01599897|Active Comparator|10 µg ID93 alone|High dose of antigen alone.
88914612|NCT01599923|Experimental|Alacramyn|
88914613|NCT01599936|Experimental|Anascorp|Three vials of Anascorp® will be administered in a total volume of 50 mL, intravenous over not less than 10 minutes or as permitted by IV access
88914614|NCT01599949|Experimental|Ibrutinib|
88914615|NCT01599962|Experimental|Cinacalcet|
88914616|NCT01599962|Placebo Comparator|Sugar pill|
88914617|NCT01599975|Active Comparator|Group A: 2 tabs of 18 mg Concerta daily|20 subjects to receive active study drug in a blinded fashion x 2 weeks, then washout x 2 weeks, then cross over to receive matched placebo x 2 weeks.
88914618|NCT01599975|Placebo Comparator|Group B: Matched placebo, 2 tabs daily|Group B to receive matched placebo x 2 weeks, then washout x 2 weeks, then cross over to receive active drug in a blinded fashion x 2 weeks.
88914619|NCT01599988|Active Comparator|Milk protein isolate|The test meal is a vanilla flavoured enteral drink, containing 1.5kcal/ml, 21% CHO, 6% protein and 5% fat. The 6% protein in this test meal is Milk Protein Isolate.
88914620|NCT01599988|Active Comparator|Caseinate|The test meal is a vanilla flavoured enteral drink, containing 1.5kcal/ml, 21% CHO, 6% protein and 5% fat. The 6% protein in this test meal is Caseinate.
88914621|NCT01600157|Experimental|Laparoscopic Nephrectomy|
88914622|NCT01600391|Active Comparator|Usual Care|A task specific-based intervention that does not include use of visual cues to influence quality or adaptability of gait.
88914623|NCT01600391|Experimental|Overground visual cue training|Overground visual cue training will involve stepping to targets which are positioned to improve gait symmetry and speed. Training will include turning practice and the avoidance of obstacles for adaptability during straight walking.
88914624|NCT01600391|Experimental|Treadmill visual cue training|Treadmill training with visual cues will be delivered using a force-instrumented treadmill (CMill, Forcelink, NL). Walking training will involve stepping to targets which are positioned to improve gait symmetry and speed. Training will include turning practice and the avoidance of obstacles for adaptability during straight walking.
88914625|NCT01600430|Active Comparator|Oral Vitamin D--200 IU/day|Cholecalciferol 200 IU given orally once per day
88914626|NCT01600430|Placebo Comparator|Placebo|Identical-appearing treatment that does not contain the test drug given orally four times per day.
88914627|NCT01600430|Active Comparator|Oral Vitamin D--800 IU/day|Cholecalciferol 800 IU given orally once per day
89434242|NCT05654467|Experimental|Group 5: Young Children, nOPV3 10^6.5 CCID50|48 young children aged 1 to <5 years will receive 2 doses of nOPV3 at a dose level of 10^6.5 CCID50 on Day 1 and Day 29
88914628|NCT01600508|Active Comparator|Traditional stoma care|Being discharged from a hospital with a stoma is a challenge to the patient's quality of life in many aspects. Optimal stoma function and care is essential to keep quality of life best possible. Videoconference can be a useful tool to help patients cope with stoma problems without travelling long distances to a surgical outpatient clinic.
88914629|NCT01600508|Experimental|Videoconference Stoma Consultations|Videoconference Stoma Consultations
88914630|NCT01600599|Active Comparator|IV & topical TA|patients in this group will receive both intravenous & topical tranexamic acid
88914631|NCT01600599|Placebo Comparator|IV tranexamic acid & Topical Saline|
88914632|NCT01600898||Asymptomatic BMPR2 mutation carriers|Asymptomatic BMPR2 mutation carriers
88914633|NCT01600937|No Intervention|Control|Standard care including physician recommendations for daily PA
88914634|NCT01600937|Experimental|Exercise|Theoretical & practical exercise counseling including 2 sessions/ per wk for 1 month of supervised exercise training
88914635|NCT01600976|Experimental|Group 1|10 patients with moderate hepatic impairment (CPB [Child-Pugh score 7 to 9])
88914636|NCT01600976|Experimental|Group 2|10 healthy control patients with normal hepatic function. Each healthy control patient is matched to a patient in Group 1 with respect to sex, age (± 5 years) and body mass index (BMI) (± 15%)
88914637|NCT01600976|Experimental|Group 3|up to 4 patients with severe hepatic impairment (CPC [limited to Child Pugh score 10 to 12])
88914638|NCT01601028|Active Comparator|Hydroxychloroquine|Hydroxychloroquine 300 mg once daily p.o.
88914639|NCT01601028|Placebo Comparator|Placebo|Placebo
88914640|NCT01601223||Surgical mechanically-ventilated|Surgical patients undergoing invasive mechanical ventilation for general anesthesia
88914641|NCT01601301|Experimental|PRECICE System|
88914642|NCT01601457|Experimental|Activated recombinant human factor VII|
88914643|NCT01601457|Placebo Comparator|Placebo|
88914644|NCT01601587|No Intervention|Treatment as usual|Patients will receive treatment as usual
88914645|NCT01601587|Other|Introduction Seminar|Psychoeducational group
88914646|NCT01601639|Active Comparator|Argon Plasma Coagulation|Patients with GAVE and/or chronic anemia, active GI bleeding, blood transfusion requirements
88914647|NCT01601639|Active Comparator|Endoscopic Band Ligation|Patients with GAVE and/or chronic anemia, active GI bleeding, blood transfusion requirements
89434243|NCT05654467|Active Comparator|Groups 2, 4 and 6: Young Children, mOPV3|48 young children aged 1 to <5 years will receive 2 doses of mOPV3 at a dose level of ≥ 10^5.8 CCID50 on Day 1 and Day 29
89434244|NCT05654467|Experimental|Group 7: Infants, nOPV3 10^5.5 CCID50|240 infants aged 6 weeks (+6 days) will receive 1 dose of IPV on Day 1, then 2 doses of nOPV3 at a dose level of 10^5.5 CCID50 on Day 29 and Day 57, and a challenge dose of mOPV on Day 113.
89434245|NCT05654467|Experimental|Group 9: Infants, nOPV3 10^5.5 CCID50|240 infants aged 6 weeks (+6 days) will receive 1 dose of IPV on Day 1, then 2 doses of nOPV3 at a dose level of 10^6.0 CCID50 on Day 29 and Day 57, and a challenge dose of mOPV on Day 113.
89434246|NCT05654467|Experimental|Group 11: Infants, nOPV3 10^6.5 CCID50|140 infants aged 6 weeks (+6 days) will receive 1 dose of IPV on Day 1, then 2 doses of nOPV3 at a dose level of 10^6.5 CCID50 on Day 29 and Day 57, and a challenge dose of mOPV on Day 113.
89434247|NCT05654467|Active Comparator|Groups 8, 10 and 12: Infants, mOPV3|240 infants aged 6 weeks (+6 days) will receive 1 dose of IPV on Day 1, then 2 doses of mOPV3 at a dose level of ≥ 10^5.8 CCID50 on Day 29 and Day 57, and a challenge dose of mOPV on Day 113.
89434248|NCT05654467|Experimental|Group 13: Neonates, nOPV3 10^5.5 CCID50|120 neonates (day of birth + 3 days) will receive 2 doses of nOPV3 at a dose level of 10^5.5 CCID50 on Day 1 and Day 29.
89434249|NCT05654467|Experimental|Group 15: Neonates, nOPV3 10^6.0 CCID50|120 neonates (day of birth + 3 days) will receive 2 doses of nOPV3 at a dose level of 10^6.0 CCID50 on Day 1 and Day 29.
89434250|NCT05654467|Experimental|Group 17: Neonates, nOPV3 10^6.5 CCID50|120 neonates (day of birth + 3 days) will receive 2 doses of nOPV3 at a dose level of 10^6.5 CCID50 on Day 1 and Day 29.
88914648|NCT01601834|Experimental|Cohort 1: Experimental intervention: PF-06273340 or placebo|Subjects in Cohort 1 will receive single ascending doses of PF-06273340 or placebo to investigate the safety/tolerability and PK of PF-06273340. The effect of food on PK may also be investigated.
88914649|NCT01601834|Experimental|Cohort 2: Experimental intervention: PF-06273340 or placebo|Subjects in Cohort 2 will receive single ascending doses of PF-06273340 or placebo to investigate the safety/tolerability and PK of PF-06273340. The effect of food on PK may also be investigated.
88914650|NCT01602029|Active Comparator|Ondansetron|ondansetron added to TAU Ondansetron will be administered in 8mg once daily dose
88914651|NCT01602029|Active Comparator|Simvastatin|Simvastatin added to TAU Simvastatin 20mg taken as once daily dose
88914652|NCT01602029|Placebo Comparator|Placebo|Placebo added to TAU
88914653|NCT01602029|Active Comparator|Odansetron Plus Simvastatin|Ondansetron will be administered in 8mg once daily dose and Simvastatin 20mg taken as once daily dose
88914654|NCT01602237||Bakery workers|
88914655|NCT01602705|Placebo Comparator|Usual care|
88914656|NCT01602705|Active Comparator|Usual care + feedback of practice performance|
88914657|NCT01602705|Active Comparator|Usual care + feedback + health psychology intervention|
88914658|NCT01602718|No Intervention|Physical Function/Activity|"cross-sectional comparison study of physical function/activity, frailty and inflammation measures in prevalent home Dx and prevalent in-center hemodialysis patients.~Subjects: Forty-five prevalent home dialysis patients will be recruited and tested once for all outcome measures. Forty-five prevalent in-center hemodialysis patients will be identified from prevalent patients in the University of Utah in-center dialysis system who are matched for gender, age, comorbidities and time on dialysis as the home dialysis patients who have been tested. Consenting patients will be tested for all outcome measures once and compared to the home dialysis group."
88914659|NCT01602718|No Intervention|Incident Patients|"Study 2: is a longitudinal cohort study of incident patients starting either home dialysis or in-center hemodialysis.~Consenting patients will be tested upon initiation of dialysis therapy and every 6 months for 18 months to track physical functioning /activity, frailty and inflammation over time."
88914660|NCT01602718|Other|Independent Home Exercise|pilot study of independent home exercise training in home dialysis (PD only) patients. Consenting patients will be tested at baseline, then randomized into exercise training or usual care (no prescribed change in activity levels) and retested after 3 months.
88914661|NCT01602796|Experimental|School-based intervention|
88914662|NCT01602796|No Intervention|Control|
88914663|NCT01602848|Experimental|Intervention enrollee|HIgh risk fee for service Medicaid recipients identified as eligible by the New York State Dept of Health and enrolled in the intensive care management and coordination intervention
88914664|NCT01602848|No Intervention|Eligible, not enrolled|Medicaid fee-for-service patients who are identified as eligible for the intervention but are not enrolled. These patients receive usual services provided by Medicaid.
88914665|NCT01602874|Experimental|A. Tigecycline|
88914666|NCT01602874|Active Comparator|B. Ceftriaxone regimen|
88914667|NCT01602887|Active Comparator|Reference|This is the reference formulation
88914668|NCT01602887|Experimental|NF1|This is a test formulation
88914669|NCT01602887|Experimental|NF2|This is a test formulation
88914670|NCT01602887|Experimental|SOL|This is a test formulation
89434251|NCT05654467|Active Comparator|Groups 14, 16 and 18: Neonates, mOPV|120 neonates (day of birth + 3 days) will receive 2 doses of mOPV3 at a dose level of ≥ 10^5.8 CCID50 on Day 1 and Day 29
89434252|NCT05653674|Experimental|Experiment|The experimental group will consist of 40 students in total, 4 groups of 10 students each, and the students will receive face-to-face psychoeducation for 6 weeks, each session for 60 minutes.
89434253|NCT05653674|No Intervention|Control|The control group will not receive any intervention during the application period and will be put on waitlist.
89434254|NCT05653271|Experimental|Treatment Group A (ACE1831)|ACE1831 dose escalation, monotherapy. Lymphodepleting regimen followed by escalating doses of ACE1831.
89434255|NCT05653271|Experimental|Treatment Group B (ACE1831 and obinutuzumab)|ACE1831 dose escalation, in combination with obinutuzumab. Lymphodepleting regimen followed by escalating doses of ACE1831, given in combination with obinutuzumab.
89434256|NCT05653037|Experimental|RBD4059 SAD experimental group|Subjects in SAD experimental groups will receive a single subcutaneous injection of RBD4059 on Day 1.
89434257|NCT05653037|Placebo Comparator|Placebo SAD group|Subjects in SAD placebo groups will receive a single subcutaneous injection of placebo on Day 1.
89434258|NCT05651906||Donors|
89434259|NCT05651906||Recipients|
89009996|NCT00415974|Other|Enhanced Usual Care|"Enhanced Usual Care Arm: This group will receive 2 face-to-face sessions with a health educator for dietary and health counseling in addition to an initial physician-patient visit. Educational materials that a patient might receive at his/her physician's office will also be provided at the initial health educator visit and monthly thereafter. This condition is called Enhanced Standard Care because it is, in fact, more than most obese adolescents currently receive in primary care offices in San Diego."
89198053|NCT04847648|Active Comparator|Control - Mechanical instrumentation of implant surface|The control group will be subjected to non-surgical decontamination including the use of hand instruments and polishing cups aiming at the removal of all supra-mucosal soft and hard deposits from the implant surfaces.
89434260|NCT05651841|Experimental|Placebo / Tezepelumab|"After 6-months of treatment, patients initially receiving placebo will switch to Tezepelumab for an additional 6 months.~For 6 months of treatment, six subcutaneous (injections in accessorized pre-filled syringes (APFS)) are performed every 4 weeks. Each subcutaneous injection corresponds to 210 mg of Tezepelumab or analogous placebo."
89434261|NCT05651841|Experimental|Tezepelumab / Tezepelumab|After 6-months of treatment, patients receiving Tezepelumab will continue Tezepelumab for an additional 6 months. For 6 months of treatment, six subcutaneous (injections in accessorized pre-filled syringes (APFS)) are performed every 4 weeks.Each subcutaneous injection corresponds to 210 mg of Tezepelumab.
89434262|NCT05651841|Experimental|Tezepelumab / Placebo|"After 6-months of treatment, patients receiving Tezepelumab will be switched to a placebo for an additional 6 months.~For 6 months of treatment, six subcutaneous (injections in accessorized pre-filled syringes (APFS)) are performed every 4 weeks. Each subcutaneous injection corresponds to 210 mg of Tezepelumab or analogous placebo."
89434263|NCT05650697|Experimental|CBD oil + Silicone|These participants will treat the one half of their forehead scar with a combination of silicone ointment and cannabidiol (CBD) oil + silicone ointment . They will attend clinic visits over the course of 7 months, have pictures taken of the scar's healing progress and complete a questionnaire at each visit.
89434264|NCT05650697|Experimental|Silicone Only|These participants will treat the one half of their forehead scar with silicone ointment only. They will attend clinic visits over the course of 7 months, have pictures taken of the scar's healing progress and complete a questionnaire at each visit.
89434265|NCT05648825|Experimental|Experimental: Apical Hypertrophic Cardiomyopathy|Transapical beating-heart myectomy for the treatment of apical hypertrophic cardiomyopathy
89434266|NCT05648500|Experimental|Cenerimod 4 mg|Participants will receive cenerimod once daily in addition to background SLE therapy.
89434267|NCT05648500|Placebo Comparator|Matching placebo|Participants will receive matching placebo once daily in addition to background SLE therapy.
89434268|NCT05648253|Experimental|Hyivy Device|Participants will receive a Hyivy device with both verbal and written instructions. Recommended use is three times per week for 12 weeks and consists of: 10 minutes of heat (37-42ºC) per session and 10 minutes of dilation per session
89434269|NCT05647577||Inflammatory arthritis patients|Patients with an confirmed diagnosis of rheumatoid arthritis or axial spondyloarthritis.
89434270|NCT05647577||Participants from the general population|Patients with inflammatory arthritis will be compared to community-dwelling individuals from the 4th and 5th examination round from the Copenhagen City Heart Study (ClinicalTrials.gov identifier NCT02993172, I-Suite no. 03741, National Committee on Health Research Ethics approval HEH-2015-045).
89434271|NCT05643573|Experimental|Asundexian|Participants will receive asundexian and apixaban matching placebo.
89434272|NCT05643573|Active Comparator|Apixaban|Participants will receive apixaban and asundexian matching placebo.
89434273|NCT05643131|Experimental|Hyivy Device|Participants will receive a Hyivy device with both verbal and written instructions. Recommended use is three times per week for 12 weeks and consists of: 10 minutes of heat (37-42ºC) per session and 10 minutes of dilation per session
89434274|NCT05637775|Experimental|EXP - BCI|(EEG-)BCI- assisted MI training delivered as add-on regimen (Standard physiotherapy-3 h/day, 5 day/week).
89434275|NCT05637775|Active Comparator|CTRL - MI|MI training delivered as add-on regimen (Standard physiotherapy-3 h/day, 5 day/week).
89434276|NCT05636982|Experimental|Telecare-based intervention program|This group of participants will receive a 3-month telecare-based intervention program which includes three main components: 1) online nurse case management supported by a health-social partnership team, 2) individual-specific video messages covering caregiving skills via WhatsApp, and 3) online information center and discussion forum via a password-protected, newly-developed caregiver website.
89434277|NCT05636982|No Intervention|Control|The control group will receive conventional community services. The caregiver will attend five educational sessions that covers caregiving skills in the community centers on a fixed schedule.
89434278|NCT05636969||Prehabilitation|Patients in this cohort will undergo baseline and post-NAT pulmonary function test (spirometry, diffusion capacity of carbon monoxide) and cardiorespiratory fitness assessment (CPET). In addition, they will attend a multimodal prehabilitation programme consisted of 1) twice weekly, supervised exercise training at the hospital gym for approximately 12 weeks; 2) nutritional consultation and optimization if needed; 3) individual or group-based psychological support.
89434279|NCT05636969||Control|Patients in the control cohort would undergo baseline and post-NAT pulmonary function test and cardiorespiratory fitness assessment (CPET).
89434280|NCT05636293|Active Comparator|Ritlecitinib|10g gluten + 200mg of Ritlecitinib
89434281|NCT05636293|Placebo Comparator|Placebo|10g gluten + placebo
89434282|NCT05635708|Experimental|Sub-study 1: Experimental Arm 1A|Tislelizumab + BGB-A445
89434283|NCT05635708|Experimental|Sub-study 1: Experimental Arm 2A|Tislelizumab + LBL-007
89434284|NCT05635708|Experimental|Sub-study 1: Experimental Arm 3A|Tislelizumab + BGB-15025
89434285|NCT05635708|Experimental|Sub-study 1: Reference Arm Tislelizumab alone|Tislelizumab alone
89434286|NCT05635708|Experimental|Sub-study 2: Experimental Arm 1B|Tislelizumab + investigator's choice of histology-appropriate chemotherapy + BGB-A445
89434287|NCT05635708|Experimental|Sub-study 2: Experimental Arm 2B|Tislelizumab + investigator's choice of histology-appropriate chemotherapy + LBL-007
89198054|NCT04847648|Experimental|Test - Mechanical instrumentation and air-polishing of implant surface|In the test group the mechanical instrumentation will be supplemented by the use of an air-polishing device during non-surgical therapy.
89434288|NCT05635708|Experimental|Sub-study 2: Experimental Arm 3B|Tislelizumab + investigator's choice of histology-appropriate chemotherapy + BGB-15025
89434289|NCT05635708|Active Comparator|Sub-study 2: Reference Arm|Tislelizumab + investigator's choice of histology-appropriate chemotherapy
89434290|NCT05631184|Experimental|Self-administered acupressure group|The participants in the self-administered acupressure group will attend an acupressure training course (2 sessions, 2 h each) to learn self-administered acupressure from an acupuncturist in a classroom at the School Nursing, the Hong Kong Polytechnic University. Each class will be conducted in a small group of 4 to 7 participants to enhance interaction and ensure the quality of teaching. Participants will then practice two times a day for 8 weeks.
89434291|NCT05631184|Active Comparator|Mental health education group|The participants in the comparison group will receive mental health education group from a registered nurse with the same frequency as those in the treatment group (2 sessions, 2 h each) in a classroom at the School Nursing, the Hong Kong Polytechnic University, and will be reminded to follow the mental health practice daily for 8 weeks.
89434292|NCT05630937|Experimental|NMS-01940153E|"Phase I: Patients will be allocated to sequential cohorts of progressively higher dose levels of NMS-01940153E based on the presence of Dose Limiting Toxicities (DLT).~Phase II: Patients will be treated at the recommended Phase II dose (RP2D) defined in the Phase I portion."
89434293|NCT05627752|Experimental|Group of Combination|Docetaxel plus Enzalutamide
89434294|NCT05627752|Placebo Comparator|Group of Docetaxel|Docetaxel plus placebo
89434295|NCT05625828|Experimental|SILVER XIII EQUILIBRE|Cognitive-motor 10 weeks program
89434296|NCT05625828|Active Comparator|VIVIFRAIL|Multifactorial 10 weeks program
89434297|NCT05625646||Course participants|Participants will be enrolled in a quality assurance program with an online multiple-choice quiz including still-pictures and video sequences of 10 application specific POCUS examinations. Through 15-20 questions, the quiz tests participants (1) knowledge about indications for performing POCUS examinations, (2) applied knowledge of ultrasound equipment, (3) ability to optimize images, (4) ability to recognize and present structures, (5) ability to interpret images, (6) ability to describe and document findings and (7) medical decision-making. Following the quiz, the participants are offered guidance to improve their performance.
89434298|NCT05623059|Other|50mg dose|This arm will start with a one-time dose and progress to twice daily dosing for 3 days, every 12 hours. Study cohort will be 9 subjects with severe asthma and serum DHEA-S <90 μg/dL in men and <45 μg/dL in women. DHEA dose will be 50 mg via slow release capsules. Endpoints will be serum DHEA and DHEA-S levels at 10, 20, 30, 60 min & 2, 4, 6, 8, 12h after administration. After a one-week washout period, the protocol will be repeated using 100 mg of SR-DHEA.
89434299|NCT05623059|Other|100mg dose|This arm will start with a one-time 100mg dose and progress to twice daily dosing for 3 days, every 12 hours. Study cohort will be same 9 subjects with severe asthma and serum DHEA-S <90 μg/dL in men and <45 μg/dL in women. DHEA dose will be 100mg via slow release capsules. Endpoints will be serum DHEA and DHEA-S levels at 10, 20, 30, 60 min & 2, 4, 6, 8, 12h after administration.
88914671|NCT01602926|Experimental|conventional surgery arm|The conventional surgical technique is a Chevron-type distal metatarsal osteotomy, which is performed through a dorsomedial incision approximately 7 cm long. And osteotomy of the distal portion of the first metatarsal is made. The capital or distal fragment of the metatarsal is mobilized and displaced laterally an adequate amount to correct the hallux valgus deformity. The capital or distal fragment is stabilized in corrected position with screws.
88914672|NCT01602926|Experimental|minimally invasive technique|The minimally invasive surgical technique is a transverse subcapital distal metatarsal osteotomy, which is performed through a direct medial incision approximately 1 cm long. The osteotomy of the distal portion of the first metatarsal is made using fluoroscopic image guidance. The capital or distal fragment of the metatarsal is mobilized and displaced laterally an adequate amount to correct the hallux valgus deformity. A 2.0 mm Kirschner wire is placed percutaneously in a position medial to the proximal phalanx, and advanced proximally using fluoroscopic guidance until the proximal end of the wire is located in a stable position within the medullary cavity of the first metatarsal
88914673|NCT01603147|Placebo Comparator|Saline|A total of 10 subjects will receive placebo
89434300|NCT05622708|Experimental|Treatment Period 1|Open-label Secukinumab PFS (prefilled syringe) labeled as AIN457 150mg/1mL
89434301|NCT05622708|Experimental|Treatment Period 2|Double-blind Secukinumab and Placebo PFS labeled as AIN457 150mg/1mL/Placebo
89434302|NCT05621616|Experimental|mirabegron|Participants will receive mirabegron prolonged-release microgranula-based oral suspension.
89434303|NCT05621109|Experimental|Intervention|Rapid moderate weight loss (approximately 10% of body weight at baseline over 8-10 weeks or BMI 23 kg/m^2 is achieved) by very low-calorie diet (VLCD), reintroduction (4 weeks), weight loss maintenance until pregnancy (up to 12 months), and a high protein, high fiber diet during pregnancy (n=120 females/couples).
89434304|NCT05621109|No Intervention|Standard of care|The control group will not receive any dietary advice prior to pregnancy. During pregnancy control subjects will receive dietary advice similar to the intervention group, i.e. a high protein, high fiber diet (n=120 females/couples).
89434305|NCT05620407|Experimental|Arm 1: Deucravacitinib|
89434306|NCT05620407|Placebo Comparator|Arm 2: Placebo|
89434307|NCT05614011|Experimental|Subjects 18+ years of age|"A healthcare professional will take a sample per subject for the comparator test, following the manufacturer's (IFU) in one nostril. Mid-turbinate swab samples will be taken from the opposite nostril using Copan FLOQ Swabs and placed into MSwab buffer (Q14-116-P02), for the candidate test. In instances where opposite nostrils cannot be swabbed for both the comparator and the test under investigation, a 15-minute wait period to allow for viral reloading must occur between collecting both the comparator and the test samples on the same nostril.~Comparator RT-PCR samples will be shipped overnight with ice packs and processed for testing within 48 hours of collection. Candidate test samples will tested as soon as possible following collection, however if time is required between specimen collection and testing, the samples must be stored at 2-8 °C for up to 24 hours. Test samples must also be stored at 2-8 °C whilst the Q-POC test is running."
89434308|NCT05612828|Experimental|Conventional training|Combat Life Savers trained by conventional combat medicine approach.
89434309|NCT05612828|Experimental|Simulation manikin training|Training based on principles of simulation medicine.
89434310|NCT05612347|Active Comparator|FIT|FIT (annual)
89434311|NCT05612347|Active Comparator|Colonoscopy|Surveillance colonoscopy (one time)
89434312|NCT05611671|Experimental|Group 1|MORF-057 Dosing Regimen One for Induction and Maintenance Periods
89434313|NCT05611671|Experimental|Group 2|MORF-057 Dosing Regimen Two for Induction and Maintenance Periods
89434314|NCT05611671|Experimental|Group 3|MORF-057 Dosing Regimen Three for Induction and Maintenance Periods
89434315|NCT05611671|Placebo Comparator|Group 4|Matching Placebo Dosing Regimen for Induction and MORF-057 Dosing Regimen Four for Maintenance
89434316|NCT05607095|Experimental|Participants with Metastatic Uveal Melanoma|Participants have metastatic uveal melanoma who will undergo surgical excision to generate LN-144
89434317|NCT05603481||CGM|
89434318|NCT05603260|Other|Meta-cognitive imagery rescripting techniques (M-Int)|"These techniques are developed to reduce the power of an image by changing how the client responds to an image by shifting attention away from it, or by doing something that reinforces that it is just an image and not real."
89434319|NCT05603260|Other|Imagery rescripting techniques (ImRs)|These techniques are developed to update imagery appraisals, by for example adding a helpful other to the image or by imagining the scene from another perspective.
89434320|NCT05603260|Other|Promoting positive imagery de novo|These involve creating a new stand-alone positive imagery to help a client to increase his ability to self-soothe and reduce fear.
89434321|NCT05603260|Other|Visuospatial working memory tasks|These tasks are also known as imagery competing tasks (such as Tetris) and are used to directly target imagery using a tax visuospatial working memory task to reduce the frequency of intrusive imagery.
89434322|NCT05602363|Experimental|Dose Escalation|"Dose escalation (3+3 design) and determination of MTD and DLTs~CLL/SLL or B-cell NHL patients previously treated with ≥2 lines of systemic therapy will self-administer AS-1763 oral tablet at multiple dose levels twice daily for 24 cycles (1 cycle = 28 days)."
89434323|NCT05602363|Experimental|Dose Expansion Cohort 1|CLL/SLL patients previously treated with ≥2 lines of systemic therapy will self-administer AS-1763 oral tablet for 24 cycles (1 cycle = 28 days). Dose levels will be determined based on the result of dose escalation part.
89009997|NCT00415974|Experimental|Stepped Care|"PACE-PC is a 1-year stepped-care intervention (subdivided into three 4-month blocks) utilizing multiple modalities including clinician and tailored health educator counseling, phone counseling, mailed content for overweight adolescents and their family to promote improved diet and physical activity behaviors aimed at weight loss and weight loss maintenance.~PACE-PC is designed to be based in the primary care setting and promotes involvement, management, and decision-making by the primary care provider about the level of PACE-PC step for each enrolled patient~Participants randomized to the PACE-PC condition will be enrolled in Step 1 (the most intensive) for the first 4 months. Depending upon response at the end of Step 1, for the next 4 months adolescents will be triaged to Step 2 (less intensive) or will repeat Step 1. At 8 months, again based upon treatment response, triage will occur to either Step 3 (least intensive) or repetition of the previous step."
89434324|NCT05602363|Experimental|Dose Expansion Cohort 2|B-cell NHL patients previously treated with ≥2 lines of systemic therapy will self-administer AS-1763 oral tablet for 24 cycles (1 cycle = 28 days). Dose levels will be determined based on the result of dose escalation part.
89434325|NCT05598671|Experimental|without reverse insertion of a ureteral catheter|Percutaneous nephrolithotomy without reverse insertion of a ureteral catheter
89009998|NCT04562584|Experimental|MyHomeDoc|Comparison of MyHomeDoc pulse oximetry readings with arterial blood saturation laboratory analysis in the same subject
89434326|NCT05598671|No Intervention|Conventional|Percutaneous nephrolithotomy with reverse insertion of a ureteral catheter
89009999|NCT04562350|Experimental|Intervention group|A sample of students aged 12 to 16 years from middle school and high school in the sanitary region of Anoia in the course of 2020-21.
89434327|NCT05597839|Experimental|Monotherapy DF9001 Dose Escalation|Dose escalation cohorts of DF9001 in sequential ascending order.
89434328|NCT05597839|Experimental|Monotherapy DF9001 PK/PD Expansion|Expansion cohorts of monotherapy DF9001 in multiple dose levels after evaluation for safety in Monotherapy Dose Escalation arm. Additional pharmacokinetic (PK) and pharmacodynamic (PD) samples included in this arm.
89434329|NCT05597839|Experimental|Monotherapy DF9001 Expansion in Head and Neck Squamous Cell Carcinoma|Monotherapy expansion cohort enrolling up to 40 patients with head and neck squamous cell carcinoma (HNSCC) using the recommended phase 2 dose (RP2D) identified in the Monotherapy Dose Escalation arm.
89434330|NCT05597839|Experimental|Monotherapy DF9001 Expansion in Colorectal Cancer|Monotherapy expansion cohort enrolling up to 40 patients with colorectal cancer (CRC) using the recommended phase 2 dose (RP2D) identified in the Monotherapy Dose Escalation arm.
89434331|NCT05597839|Experimental|Monotherapy DF9001 Expansion in Non-small Cell Lung Cancer|Monotherapy expansion cohort enrolling up to 40 patients with Non-small cell lung cancer (NSCLC) using the recommended phase 2 dose (RP2D) identified in the Monotherapy Dose Escalation arm.
89434332|NCT05597839|Experimental|Combination Escalation with DF9001 and nivolumab|Combination dose escalation of DF9001 in combination with a PD-1 checkpoint inhibitor in patients with select solid tumors.
89434333|NCT05597839|Experimental|Combination PK/PD Expansion with DF9001 and nivolumab|Expansion cohorts of DF9001 in combination with a PD-1 checkpoint inhibitor in multiple dose levels after evaluation for safety in Monotherapy Dose Escalation arm. Additional pharmacokinetic (PK) and pharmacodynamic (PD) samples included in this arm.
89434334|NCT05597839|Experimental|Combination Expansion of DF9001 and nivolumab in Head and Neck Squamous Cell Carcinoma|Combination expansion cohort using DF9001 and a PD-1 checkpoint inhibitor enrolling up to 40 patients with head and neck squamous cell carcinoma (HNSCC) using the recommended phase 2 dose (RP2D) identified in the Monotherapy Dose Escalation arm.
89434335|NCT05597839|Experimental|Combination Expansion of DF9001 and nivolumab in Colorectal Cancer|Combination expansion cohort using DF9001 and a PD-1 checkpoint inhibitor enrolling up to 40 patients with colorectal cancer (CRC) using the recommended phase 2 dose (RP2D) identified in the Monotherapy Dose Escalation arm.
89010000|NCT04562350|No Intervention|Control group|A sample of students aged 12 to 16 years from middle school and high school in the sanitary region of Osona in the course of 2020-21.
89010001|NCT04562311|Experimental|Chidamide with Immunotherapy|Chidamide: 30mg orally BIW. Immunotherapy: tislelizumab,the fixed dose of 200 mg IV. Treatment cycles are repeated every 3 weeks.
89010002|NCT02211547|No Intervention|Control|No treatment to be rendered following separator placement.
89010003|NCT02211547|Placebo Comparator|Placebo|Single blind lack of laser treatment (the laser will be positioned and operated as if applying the treatment, but the energy transfer will not take place).
89434336|NCT05597839|Experimental|Combination Expansion of DF9001 and nivolumab in Non-Small Cell Lung Cancer|Combination expansion cohort using DF9001 and a PD-1 checkpoint inhibitor enrolling up to 40 patients with non-small cell lung cancer (NSCLC) using the recommended phase 2 dose (RP2D) identified in the Monotherapy Dose Escalation arm.
89434337|NCT05593159|Active Comparator|Dentin Conditioning & RM-GIC|"Dentin Conditioning:~After washing and drying -but not desiccating- Dentin Conditioner 20% (GC, Japan) will be applied using a cotton pellet for 20 seconds then rinsed thoroughly and gently dried.~RM-GIC:~RM-GIC (Fuji II LC) will be applied in <2mm incremental layers afterward light-cured for 10 sec (1,000 mW/cm2) per increment to fill the cavity."
89434338|NCT05593159|Experimental|1-step adhesive & Cention N|"1-step adhesive: A universal adhesive system (Tetric® N-Bond Universal) will be applied on both enamel and dentin and gently scraped for 20 sec, then dispersed with oil-free gentle air stream, then light-cured for 10 sec (1,000 mW/cm2).~Cention N:~The cavity will be restored using cention N followed by light curing for 10sec (1,000 mW/cm2)"
89434339|NCT05593159|Experimental|Dentin roughness & Gingival retentive groove preparation & Cention N|"Dentin roughness:~Using a round carbide bur size 14/16, (H1SEM.204.014 VPE5 or H1SEM.204.016 VPE 5, Komet Dental, Lemgo, Germany) on a low-speed handpiece. (No bevel preparation will be made)~Gingival retentive groove preparation:~Using size-010 round carbide bur (H1SEM.205.010 VPE 5, Komet Dental, Lemgo, Germany) on a low-speed handpiece.~Cention N:~The cavity will be restored using cention N followed by light curing for 10sec (1,000 mW/cm2)"
89434340|NCT05592184||Dual task|Exercise (elastic resistance) with dual task The dual task will be self-regulated and will consist of subtracting 3 by 3 from 100, and performing the maximum number of repetitions possible.
89434341|NCT05592184||Single task|exercise (elastic resistance) without dual task
89434342|NCT05591209||Alive and Dead|Following ICU admission patients are followed until discharge with the outcome of alive or dead
89434343|NCT05588011|Active Comparator|LivaNova Inspire|A high pressure oxygenator (LivaNova) will be used during cardiopulmonary bypass.
89434344|NCT05588011|Active Comparator|Terumo|A low pressure oxygenator (Terumo) will be used during cardiopulmonary bypass.
89434345|NCT05587361|Placebo Comparator|Placebo Patch/Placebo Propranolol|Placebo Nicotine Patch Placebo Propranolol
89434346|NCT05587361|Experimental|Placebo Patch/Active Propranolol|Placebo Nicotine Patch Active Propranolol (40 mg, immediate release)
89434347|NCT05587361|Experimental|Active Patch/Placebo Propranolol|Active Nicotine Patch (14 mg) Placebo Propranolol
89434348|NCT05587361|Experimental|Active Patch/Active Propranolol|Active Nicotine Patch (14 mg) Active Propranolol (40 mg, immediate release)
89434349|NCT05585541||Ataxic multiple sclerosis|In the study, those aged between 18-50 years, diagnosed with MS by a neurologist, Expanded Disability Status Scale (EDSS) score between 3-5, EDSS pyramidal system score ≤ 3 and cerebellar functional system score ≥ 1, patients who have been clinically stable for the last 3 months and have agreed to participate in the study will be included.
89434350|NCT05580432|Experimental|Immediate behavioral intervention|Participants will receive the intervention immediately
89434351|NCT05580432|Active Comparator|Delayed behavioral intervention|Participant will receive the intervention after a 12 month delay
89434352|NCT05575648|Other|Duchenne Muscular Dystrophy|Children who have been diagnosed with Duchenne Muscular Dystrophy.
89434353|NCT05575648|Active Comparator|Healthy Subjects|Children who have a normal motor and cognitive development.
89434354|NCT05575128|Experimental|Behavioral activation and medication optimization|"Behavioral activation (BA) will begin perioperatively and will span across 3 months postoperatively, with sessions approximately weekly or biweekly, depending on patient preference & health condition.~Medications will be reviewed by a team of interventionists to minimize brain-toxic medications and optimize doses of antidepressants and other mental health medications. In-hospital and after discharge, the interventionists' role will include coordinating with the care teams to ensure that medication changes that were introduced preoperatively are maintained."
89434355|NCT05575128|Other|Control (treatment as usual)|Participants in control arm will continue care as usual. They will receive printed resources for supporting sleep hygiene, stress reduction, cognitive and mental health exercises, as well as community resources for older adults.
89434356|NCT05575037|Experimental|Dupilumab|Subjects will receive dupilumab (300mg every-other-week for 8 weeks).
89434357|NCT05573997||Heart failure with reduced ejection fraction|Left Ventricular Ejection Fraction of ≤40%
89434358|NCT05573997||Heart failure with mid-range ejection fraction|Left Ventricular Ejection Fraction of 41-49%
89434359|NCT05573997||Heart failure with preserved ejection fraction|Left Ventricular Ejection Fraction of ≥50%
89434360|NCT05572684|Experimental|NC410 and pembrolizumab|All participants will receive NC410 (IV) and pembrolizumab (IV) according to the treatment schedule until a reason for treatment discontinuation is reached.
89434361|NCT05571137||Cohort 1: Resistant, Refractory, or Intolerant (RRI) to Anti-CMV treatment|Participants who had a HSCT after January 1, 2016, and developed post-transplant CMV infection were subsequently characterized as RRI to currently available anti-CMV treatment for at least 12 months before being enrolled, will be observed in this retrospective study for 24 months.
89434362|NCT05571137||Cohort 2: Pre-emptive CMV Treatment|Participants who had a HSCT after January 1, 2019, were preemptively treated for CMV for at least 12 months before being enrolled, will be observed in this retrospective study for 24 months.
89434363|NCT05568537|Experimental|Treatment MRIs and Pylarify PSMA PET/CTs|2 MRIs and 2 Pylarify PSMA PET/CTs, occurring at mid-treatment and when testosterone level is 75% recovered or 12 months after androgen deprivation therapy (ADT), whichever comes first
89434364|NCT05568043|Experimental|In-person intervention delivery with virtual mentoring|The implemented interventions will be in-person and will include virtual mentoring. The mentored implementation model (MIM) is an evidence-based strategy to promote the success and sustainability of hospital-based quality improvement (QI) initiatives. After completing the contextual assessments and pre-implementation planning in Aim 1, the investigators will collaborate with the SHM to harness their expertise with the MIM to implement the COPD Program over a one-year period during Aim 2 (implementation). Virtual Mentored Implementation involves implementing their assigned care transition program intervention delivery method using an innovative virtual mentored implementation approach using tele-conferencing technology (i.e., video-conferences) for two-way visualization of individuals in different locations for educational purposes. Monthly mentoring sessions will occur to maximize mentors' input.
89434365|NCT05568043|Experimental|In-person intervention delivery with virtual mentoring and co-design|The implemented interventions will be in-person and will include virtual mentoring and co-design support with our study partner, Onda Collective. The mentored implementation model (MIM) is an evidence-based strategy to promote the success and sustainability of hospital-based quality improvement (QI) initiatives. After completing the contextual assessments and pre-implementation planning in Aim 1, the investigators will collaborate with the SHM to harness their expertise with the MIM to implement the COPD Program over a one-year period during Aim 2 (implementation). Virtual Mentored Implementation involves implementing their assigned care transition program intervention delivery method using an innovative virtual mentored implementation approach using tele-conferencing technology (i.e., video-conferences) for two-way visualization of individuals in different locations for educational purposes. Monthly mentoring sessions will occur to maximize mentors' input.
89434366|NCT05568043|Experimental|Virtual intervention delivery with virtual mentoring|The implemented interventions will be virtual and will include virtual mentoring. The mentored implementation model (MIM) is an evidence-based strategy to promote the success and sustainability of hospital-based quality improvement (QI) initiatives. After completing the contextual assessments and pre-implementation planning in Aim 1, the investigators will collaborate with the SHM to harness their expertise with the MIM to implement the COPD Program over a one-year period during Aim 2 (implementation). Virtual Mentored Implementation involves implementing their assigned care transition program intervention delivery method using an innovative virtual mentored implementation approach using tele-conferencing technology (i.e., video-conferences) for two-way visualization of individuals in different locations for educational purposes. Monthly mentoring sessions will occur to maximize mentors' input.
89536395|NCT03118453|Experimental|Active implementation clinics|Patients recruited by physical therapists who underwent an implementation period with active implementations strategies, such as supervision, web lectures, peer learning in groups consisting of colleagues. A behavioral medicine approach in physical therapy for patients with musculoskeletal pain was encouraged with these active implementation strategies.
88914674|NCT01603147|Experimental|ch-mAb7F9|The single doses to be administered in each cohort are 0.2, 0.6, 2, 6, and 20 mg/kg, respectively.
88914675|NCT01603264|Experimental|A|PF-05280014
88914676|NCT01603264|Active Comparator|B|Trastuzumab-EU
88914677|NCT01603264|Active Comparator|C|Trastuzumab-US
88914678|NCT01603485|Experimental|Lersivirine|
88914679|NCT01603524|Active Comparator|OMSC Group|"The OMSC Group will receive a multi-component intervention which includes:~Coaching and Outreach Facilitation Visits: Each practice will receive on-site support to implement the intervention components.~Practice tools and real time prompts: Practices will be provided with 4 tools to support the integration of evidence-based cessation practices into brief clinical encounters as part of a practice-level strategy.~Provider Training in Smoking Cessation Interventions: All clinic providers will be invited to a 3 hour training workshop on smoking cessation(CME).~Telephone follow-up support program: Clinics will be able to refer smokers embarking upon a quit attempt to the smoker's telephone follow-up counseling program."
89434367|NCT05568043|Experimental|Virtual intervention delivery with virtual mentoring with co-design|The implemented interventions will be virtual and will include virtual mentoring and co-design support with our study partner, Onda Collective. The mentored implementation model (MIM) is an evidence-based strategy to promote the success and sustainability of hospital-based quality improvement (QI) initiatives. After completing the contextual assessments and pre-implementation planning in Aim 1, the investigators will collaborate with the SHM to harness their expertise with the MIM to implement the COPD Program over a one-year period during Aim 2 (implementation). Virtual Mentored Implementation involves implementing their assigned care transition program intervention delivery method using an innovative virtual mentored implementation approach using tele-conferencing technology (i.e., video-conferences) for two-way visualization of individuals in different locations for educational purposes. Monthly mentoring sessions will occur to maximize mentors' input.
88914680|NCT01603524|Experimental|OMSC + Performance Feedback Group|The OMSC + Provider Performance Feedback Group will receive the same intervention program as the OMSC group. In addition, clinicians will complete a one-hour audit and feedback session prior to the implementation of the OMSC program at their clinic.
89434368|NCT05567185|Experimental|Dose Escalation: Erdafinitib Intravesical Delivery System|Participants with bladder cancer and fibroblast growth factor receptor (FGFR) mutations or fusions will receive erdafitinib intravesical delivery system and study will evaluate 2 dose levels of erdafitinib. Participants with a complete response (CR) may continue to receive treatment up to a duration of 1 year as long as there is no disease recurrence or progression, intolerable toxicity or withdrawal of consent.
89434369|NCT05565664|Active Comparator|Ketamine group|"After preoperative assessment, participants will receive IM midazolam (0.1 mg/kg) and atropine (0.02 mg/kg) 30 min. before surgery as premedication.~Inhalation induction of GA will be done using 8% sevoflurane in 100% oxygen. After insertion of a peripheral IV cannula, IV fentanyl 1 mcg/kg and atracurium 0.5 mg/kg will be given. Direct laryngoscopy will be attempted to insert an age-appropriate cuffed ETT.~Patients will be maintained on controlled mechanical ventilation with a mixture of isoflurane in 60% oxygen in air, using a tidal volume of 8cc/kg and a frequency of 16-20 cycle/min. to maintain an ETCO2 35-40 mmHg and to keep an ET isoflurane concentration of 1.5-2%. All patients will receive 10 ml/kg of IV Ringer's solution in the operating room. A single dose of paracetamol 15 mg/kg IV drip will be administered for all patients once they arrive at the PACU.~Patients will receive IV ketamine hydrochloride in a dose of 0.5 mg/kg."
88914681|NCT01603537||PHTLS|The exposure is defined from the dichotomization of the probability in each event/accident that at least one of the caring ambulance crew members was PHTLS certified.
88914682|NCT01603537||No PHTLS|Not exposed to PHTLS
88914683|NCT01603589|Active Comparator|MiECC group|Patients operated for elective coronary artery bypass grafting with the use of minimal invasive extracorporeal circulation (MiECC).
88914684|NCT01603589|Active Comparator|CECC group|Patients operated for elective coronary artery bypass grafting under conventional extracorporeal circulation (CECC).
88914685|NCT01603680|Other|Circumferential (C)|"Circumferential(C) spread group will be defined as mepivacaine injectate visualized by ultrasonography all around the median and ulnar nerves imaged in short axis."
88914686|NCT01603680|Other|Non circumferential (NC)|Local anesthetic spread will be asymmetrical around the median and ulnar nerves, the mepivacaine will be partially in contact with the nerve
88914687|NCT01603706|Active Comparator|Echo guided implantation group|Echo guided implantation group Patients undergoing speckle tracking based LV lead implantation.
88914688|NCT01603706|No Intervention|Conventional implantation group|Patients undergoing conventional LV lead implantation
88914689|NCT01603914|Experimental|scheduled wire-guided every six days|scheduled wire-guided every six days and a replacement of the catheter in a different place after 12 days from randomization.
88914690|NCT01603914|Experimental|Scheduled replacement every six days|Scheduled replacement every six days in a different location
88914691|NCT01603914|Experimental|replacement guided by clinical criteria|re change of catheter strategy guided by clinical suspicious of catheter-related bacteremia and replacement of the catheter in a different location.
88914692|NCT01603927||Colonoscopy with Narrow band imaging (NBI)|All patients attending for routine colonoscopies performed for the diagnosis of symptoms or asymptomatic screening.
88914693|NCT01604213|Experimental|Vildagliptin+metformin|Oral Vildagliptin+metformin combination
88914694|NCT01604213|Active Comparator|Metformin only|Oral metformin only
88914695|NCT01604538||patients with acute pulmonary embolism|
88914696|NCT01604798||Colorectal Cancer Patients|Patients with histologically confirmed colorectal cancer
88914697|NCT01604798||Healthy Controls|Healthy volunteers
88914698|NCT01605214||Bilateral Lung Transplant|All patients undergoing bilateral lung transplant for any indication will be considered for enrollment in the study. The characteristics of measurements of extravascular lung water will be compared following surgery in those who develop primary graft dysfunction compared to those who do not.
88914699|NCT01605240|Active Comparator|Acetaminophen and Codeine|After their fracture is reduced, these patients will receive acetaminophen (15mg/kg) and codeine (1mg/kg) at regular dosing intervals.
89434370|NCT05565664|Active Comparator|Magnesium group|"After preoperative assessment, participants will receive IM midazolam (0.1 mg/kg) and atropine (0.02 mg/kg) 30 min. before surgery as premedication.~Inhalation induction of GA will be done using 8% sevoflurane in 100% oxygen. After insertion of a peripheral IV cannula, IV fentanyl 1 mcg/kg and atracurium 0.5 mg/kg will be given. Direct laryngoscopy will be attempted to insert an age-appropriate cuffed ETT.~Patients will be maintained on controlled mechanical ventilation with a mixture of isoflurane in 60% oxygen in air, using a tidal volume of 8cc/kg and a frequency of 16-20 cycle/min. to maintain an ETCO2 35-40 mmHg and to keep an ET isoflurane concentration of 1.5-2%. All patients will receive 10 ml/kg of IV Ringer's solution in the operating room. A single dose of paracetamol 15 mg/kg IV drip will be administered for all patients once they arrive at the PACU.~Patients will receive IV magnesium sulphate in a dose of 40 mg/kg."
89434371|NCT05565534|Experimental|Nurse-practitioner led intervention group|A nurse practitioner (NP) who is trained in diabetes on the oncology team will help manage diabetes for breast cancer patients undergoing cancer treatments
89434372|NCT05565534|No Intervention|Non-intervention (control) group|Patient will not have access to the nurse practitioner led intervention.
89434373|NCT05561322||Spinal fusion patients|Patients who have undergone spinal fusion surgery and have had at least 3 years of follow-up.
89434374|NCT05561322||Lumbar arthroplasty patients|Patients who have undergone lumbar arthroplasty with disc replacement and have had at least 3 years of follow-up.
89434375|NCT05559801|Experimental|Children with OI receiving Bone marrow-derived MSCs infusion|Intravenously-infused allogeneic, bone marrow-derived mesenchymal stromal cells (MSCs) in children with Osteogenesis Imperfecta Type III that will be infused at 0 months, 4 months, 8 months, 12 months, 16 months, and 20 months, after enrollment.
89434376|NCT05559320|Experimental|Single Joystick Ride-on-car Navigation Training|Participants will first participate in a 6-week control phase followed by a 6-week intervention phase. During the intervention phase, they will receive the ride-on-toy navigation training program. The training will be provided by the researchers twice a week, 30-45 minutes/session for 6 weeks. Caregivers will be asked to provide 2 additional sessions/week during the intervention phase. In this study design, the participants will serve as their own controls.
89434377|NCT05559112|Experimental|Mushrooms|Participants will consume their usual, unrestricted, self-selected diet plus 84 g of vitamin D-enriched mushrooms twice daily for 12 weeks.
89434378|NCT05559112|Placebo Comparator|No Mushrooms|This is a behavioral control where no change in Vitamin D status is expected to occur. Participants will consume their usual, unrestricted, self-selected diet plus 1 tsp of dried study powder twice daily for 12 weeks.
89434379|NCT05558189|Experimental|Vibrotactile Coordinated Reset (vCR)|Vibrotactile Coordinated Reset delivers vibratory stimulation to the fingertips of each hand. A specific pattern of vibration to each fingertip is delivered which theoretically disrupts abnormal synchrony in the brain.
89434380|NCT05551806|Experimental|CBT-I group|Participants in the CBT-I condition start the 6-week CBT-I immediately after randomization, complete the post-intervention assessment right after they finish the treatment, and complete the follow-up assessment 4 weeks after the post-intervention assessment. They will be invited to participate in an interview after completing the post-intervention assessment.
89434381|NCT05551806|No Intervention|Waitlist control group|Participants in the waitlist control group will wait for 6 weeks without the CBT-I intervention and then complete the post-intervention assessment; while waiting for 4 more weeks and then completing the follow-up assessment. The waitlist control participants will start CBT-I (equivalent to that of the CBT-I group) immediately after completing the follow-up assessment.
88914700|NCT01605240|Active Comparator|Acetaminophen and Ibuprofen|Following reduction of their fracture, these patients will receive acetaminophen (15mg/ml) and ibuprofen (10mg/ml) at regular dosing intervals.
88914701|NCT01605279|Experimental|Dobutamine|Patients with low SVCF in the first 12 hours of life will be randomised to receive dobutamine or placebo.
88914702|NCT01605279|Placebo Comparator|Placebo|Patients with low SVCF in the first 12 hours of life will be randomised to receive Dobutamine or Placebo.
88914703|NCT01606072|Experimental|Desmopressin|
88914704|NCT01606657|Active Comparator|Irrigation|THE PATIENT IS TO HAVE IRRIGATION OF THE ABSCESS WITH NORMAL SALINE AS PART OF THE I&D PROCEDURE
88914705|NCT01606657|Placebo Comparator|No Irrigation|THE PATIENT IS NOT TO HAVE IRRIGATION OF THE ABSCESS AS PART OF THE I&D PROCEDURE
88914706|NCT01606722||Darunavir-ritonavir monotherapy|HIV-infected patients with undetectable viral load for at least for 6 months on stable therapy and no darunavir related mutations in the HIV-protease gene
88914707|NCT01606904|Experimental|Weight loss counseling|Cognitive behavioral therapy - based weight loss program
88914708|NCT01606904|Other|Control|Short term weight loss counseling, control group
88914709|NCT01607060|Experimental|Lactulone|Patients receiving lactulone
88914710|NCT01607060|Active Comparator|Control|Observational group. Compare to lactulone group.
88914711|NCT01607242||patients|patients undergoing total thyroidectomy
88914712|NCT01607281||anesthesiologists, experience|There is one arm. All participating anesthesiologists wıll fulfill the questionary survey and show the imaginary puncture site by USG bilaterally.
88914713|NCT01607489|Other|pulmonary vascular disease|Dual-energy computed tomography investigation
88914714|NCT01607749|Experimental|Educational Program|"Students in the intervention schools learn the educational program Asthma, Sport and Health in three sessions during a period of 6 weeks. The content of the educational program has been published elsewhere."
88914715|NCT01607749|No Intervention|Asthma information for teachers|Information about asthma the Ministry of Education to all schools in the community.
88914716|NCT01607983|Experimental|inhaled nitric oxide|
88914717|NCT01608217|Active Comparator|Namisol|Namisol is a tablet containing delta-9-tetrahydrocannabinol, the main cannabinoid from Cannabis sativa L. Namisol is added to a standardized treatment with acetaminophen.
88914718|NCT01608217|Placebo Comparator|Placebo|The control product is placebo, consisting of a tablet with similar appearance and taste of the test product. Placebo is added to a standardized treatment with acetaminophen.
88914719|NCT01608425|No Intervention|Control|Control group. Regular treatment.
88914720|NCT01608425|Experimental|Diabetes ulcer monitoring|Receives a telemedicine intervention: Diabetes ulcer monitoring.
88914721|NCT01608594|Experimental|Ipilimumab 10 mg/kg + HDI|Ipilimumab 10 mg/kg + standard dose IFN alpha
88914722|NCT01608594|Experimental|Ipilimumab 3mg/kg + HDI|Ipilimumab 3mg/kg + standard dose IFN alpha
88914723|NCT01608854||24 Hour Antibiotics|Patients were randomized to receive 24 hours of postoperative antibiotics following spine surgery
88914724|NCT01608854||Duration Antibiotics|Patients were randomized to receive antibiotics for the duration of time a spinal drain was in place following spinal surgery
88914725|NCT01608880|Placebo Comparator|Polysporin Control|Patients in control group will receive polysporin ointment application. Polysporin ointment will be made to look like Nitroglycerin ointment.
88914726|NCT01608880|Active Comparator|Nitroglycerin|Patients in treatment group will receive nitroglycerin ointment application
88914727|NCT01608958|Active Comparator|IV infusion|Oxytocin 10 IU will be administered IV infusion according to randomization assignment as soon as possible after delivery of the baby.
88914728|NCT01608958|Active Comparator|IM Injection|Oxytocin 10 IU will be administered IM according to randomization assignment as soon as possible after delivery of the baby.
88914729|NCT01609140|Experimental|A|
88914730|NCT01609140|Experimental|B|
88914731|NCT01609140|Experimental|C|
88914732|NCT01609140|Experimental|D|
88914733|NCT01609140|Experimental|E|
88914734|NCT01609140|Placebo Comparator|F|
88914735|NCT01609153|Active Comparator|Olanzapine or Placebo|
88914736|NCT01609153|Active Comparator|Amisulpride or Placebo|
88914737|NCT01609153|Active Comparator|Olanzapine and Amisulpride|
88914738|NCT01609309|Experimental|Laparoscopic gastrectomy|Laparoscopic distal subtotal gastrectomy with D2 lymphadenectomy will be performed for the treatment of patients assigned to this group.
88914739|NCT01609309|Active Comparator|Open gastrectomy|Open distal subtotal gastrectomy with D2 lymphadenectomy will be performed for the treatment of patients assigned to this group.
88914740|NCT01609530|Active Comparator|Liquid Nitrogen Cryotherapy|Every two weeks for a total of 5 treatments or until the patient clears, patients in the cryotherapy arm will be treated with 5-7 seconds of freeze time maintaining a 1mm freeze halo around the wart.
88914741|NCT01609530|Experimental|Pulsed 1064nm Nd:YAG|Every 2 weeks for a total of five treatments or until the wart clears, patients in the laser arm will be treated with the Nd:YAG. The settings will be 180J, 20ms pulse width and 5mm spot size. For warts 3mm or less, a 3mm spot size will be used, 180J and 15ms. If the patient reports no response after treatment, including crusting or blistering, the energy will be increased by 10 J until 200J has been reached.
88914742|NCT01609608|Experimental|vibration|
89434382|NCT05549661|Experimental|Treatment (onvansertib)|Patients receive onvansertib PO QD on study. Patients also undergo bone marrow aspiration and biopsy, collection of blood samples, and ultrasound imaging during screening and throughout the trial.
89434383|NCT05548582|Other|Post-operative opioid prescription|"Ibuprofen 600mg every 6 hours x 48 hours then as needed (total 30 tablets). If allergy or contraindication to ibuprofen, then will receive Meloxicam 15mg daily x 48 hours then as needed~Acetaminophen 500mg every 6 hours x 48 hours then as needed (total 30 tablets)~Oxycodone 5mg every 4 hours as needed (total 12 tablets)"
89434384|NCT05548582|Active Comparator|No Opioid prescription|"Ibuprofen 600mg every 6 hours x 48 hours then as needed (total 30 tablets). If allergy or contraindication to ibuprofen, will receive Meloxicam 15mg daily x 48 hours then as needed~Acetaminophen 500mg every 6 hours x 48 hours then as needed (total 30 tablets)"
89434385|NCT05545826|Experimental|Vibrotactile Coordinated Reset (vCR)|Vibrotactile Coordinated Reset delivers vibratory stimulation to the fingertips of each hand. A specific pattern of vibration to each fingertip is delivered which theoretically disrupts abnormal synchrony in the brain.
88914743|NCT01609608|Placebo Comparator|placebo|
88914744|NCT01609725|Experimental|Comprehensive treatment|Test treatment group
88914745|NCT01609725|Other|Community treatment|Control treatment group
88914746|NCT01609751|Experimental|Yakult 62 ml daily|
88914747|NCT01609894|Experimental|Individualized fortification of breast milk|"Macronutrient content (for protein, carbohydrate and fat content) will be analyzed of native breast milk batches which had been prepared for 24 hr feeding.~Routine fortifier will be added to breast milk batches.~Modular products for individual adjustment of protein and/or carbohydrate and/or fat will be given in order to achieve target macronutrient level."
88914748|NCT01609894|Active Comparator|Routine fortification of breast milk|"Macronutrient content (for protein, carbohydrate and fat content) will be analyzed of native breast milk batches which had been prepared for 24 hr feeding.~Routine fortifier will be added to breast milk batches."
88914749|NCT01610024|Active Comparator|Beetroot|
88914750|NCT01610050|Experimental|LFA102|
88914751|NCT01610089|Experimental|stable isotope infusion|Infusion of isotopes [15N2-ureido] arginine, [5-13C,4, 4, 5, 5-D4] citrulline, [15N]citrulline, 15N sodium nitrate and [15N][18O3] potassium nitrate,[18O][13C]urea.
88914752|NCT01610128||chronic urticaria patients|all patients suffering from chronic types of urticaria (chronic spontaneous urticaria as well as chronic inducible forms such as cold contact urticaria)
88914753|NCT01610141|Experimental|Genotype-guided warfarin dosing|A pharmacogenetic dosing algorithm including clinical factors and genotype information (VKORC1, CYP2C9 and CYP4F2) will be used to determine warfarin doses.
88914754|NCT01610141|Active Comparator|Non-genotype guided warfarin dosing|A fixed warfarin dose of 3 mg/day was given to the patients for at least 3 days. Following doses were adjusted according to the INR measurement.
88914755|NCT01610180|Other|Eltrombopag Olamine|Eltrombopag Olamine Initial dose 50 mg/day for 14 days. Then adjusted according to platelet count
89434386|NCT05542836||Expedited postoperative activity instructions|Ad lib postoperative activity and return to work recommendations
89434387|NCT05542836||Standard postoperative activity restrictions|Standard conservative postoperative activity and return to work recommendations
89434388|NCT05538910|Placebo Comparator|Arm 1: Placebo|Placebo patch + Placebo Pill
89434389|NCT05538910|Experimental|Arm 2: Nicotine Patch|Nicotine Patch + Placebo Pill
89434390|NCT05537025|Experimental|ARO-MMP7|single or multiple doses of ARO-MMP7 by inhalation of nebulized solution
89434391|NCT05537025|Placebo Comparator|Placebo|single or multiple doses of placebo by inhalation of nebulized solution
88914756|NCT01610193||Right sided abdominal pain|Patients that present at the Emergency Department with abdominal pain and a clinical suspicion of appendicitis.
88914757|NCT01610219|Active Comparator|Lifestyle Modification for Diabetes Prevention|Family based intervention utilizing Traffic Light Diet, self monitoring, parent behavioral skill training and tool kit of items promoting physical activity.
88914758|NCT01610219|Other|Nutrition and Physical Activity|Family based intervention providing education on healthy eating and physical activity but no behavioral skills training, goal setting, self monitoring or physical activity toolkit.
88914759|NCT01610232|Experimental|LED Group|Phototherapy associated with treadmill training
88914760|NCT01610232|Active Comparator|Exercise Group|Treadmill training
88914761|NCT01610232|No Intervention|Sedentary Group|Neither physical training nor phototherapy
88914762|NCT01610310|Experimental|peginterferon beta-1a PFS/autoinjector|A single dose of peginterferon beta-1a 125 mcg administered by prefilled syringe (PFS) on Day 1, then by a single dose of peginterferon beta-1a 125 mcg by autoinjector on Day 22.
89434392|NCT05535166|Experimental|Stratum S-2|"Patients with Sonic Hedgehog subgroup 2 (SHH-2), 0-2.99 years, or M0 and 3-4.99 years, will receive systemic high-dose methotrexate (HD-MTX) and conventional chemotherapy.~Interventions: Surgery, Methotrexate, Cisplatin, Vincristine, Cyclophosphamide, Carboplatin, Topotecan, Pegfilgrastim, Filgrastim"
89434393|NCT05535166|Experimental|Stratum S-1|"Patients with SHH-1, SHH-3, SHH-4, or SHH-Not otherwise specified (NOS), 0-2.99 years, will receive intraventricular methotrexate (IVT-MTX) in parallel with systemic HD-MTX and conventional chemotherapy.~Interventions: Surgery, Methotrexate, Cisplatin, Vincristine, Cyclophosphamide, Carboplatin, Topotecan, Pegfilgrastim, Filgrastim"
89434394|NCT05535166|Experimental|Stratum N|"Patients with Medulloblastoma (MB) group 3 or group 4 (G3/G4) or MB [including Non-WNT non-SHH medulloblastoma (NWNS) NOS or otherwise indeterminate cases] (0-2.99 years) will receive systemic HD-MTX and conventional chemotherapy only for radiation delaying purposes. At 3 years of age, these patients will receive risk-stratified craniospinal irradiation (CSI).~Interventions: Surgery, Methotrexate, Cisplatin, Vincristine, Cyclophosphamide, Carboplatin, Topotecan, Etoposide, Pegfilgrastim, Filgrastim, Radiation"
89434395|NCT05535166|Experimental|Cognitive Study Group I (educational video and games)|Educational video and games
89434396|NCT05535166|Active Comparator|Cognitive Study Group II (standard-of-care control)|Standard-of-care (SOC) followed by educational video and games
89434397|NCT05534061|Experimental|Connect2Test Intervention + Contingency Management|$10 financial incentive for vaccination and $10 financial incentive for testing plus a brief feedback-based motivational enhancement intervention.
89434398|NCT05534061|Active Comparator|Contingency Management Alone|$10 financial incentive for vaccination and $10 financial incentive for testing.
89434399|NCT05531864|Experimental|Continuous serratus anterior plane block|Ultrasound-guided continuous serratus anterior plane block.
89434400|NCT05531864|Active Comparator|Single serratus anterior plane block combined with rectus sheath nerve block|Ultrasound-guided single serratus anterior plane block combined with rectus sheath nerve block.
89434401|NCT05530655|No Intervention|Control group|Patients who receive radiation but no intervention
89434402|NCT05530655|Experimental|Intervention group|
89434403|NCT05527184|Experimental|IMGN151 Open Label|IMGN151 is administered via intravenous (IV) infusion on Day 1 of Cycle 1 and every subsequent 21-day cycle thereafter, at the assigned dose for each cohort during dose escalation, and at the RP2D for expansion. Infusion duration will vary depending on dose and participant tolerability.
89434404|NCT05523414|Experimental|SKY|In-person SKY sessions will be 3 hours long on each of 3 consecutive days, and participants must be willing to attend all 3 sessions. Each session comprises a combination of breathwork, emotional resilience training, yoga, and leadership skills. The SKY technique includes a unique set of standardized breathing techniques to rapidly reduce neuroendocrine stress responses and the autonomic imbalance due to sympathetic overdrive. 8 weeks of online and/or in-person sessions will be delivered to participants in the follow-up period after the initial in-person intervention. They will receive intermittent reminders about their daily practice during the 8-week follow-up period. The participants will be asked to engage in daily 30 minute SKY sessions remotely, that is led by an instructor. Each participant will be required to log in the number of times a week they practice. In addition, weekly 60-minute reinforcement sessions will be conducted, in-person.
89434405|NCT05523414|No Intervention|Control|Waitlist control participants will not be provided any intervention. However, they will have the same schedule for data and biological specimen collection as the SKY intervention participants. They will be provided an opportunity to take the SKY retreat free of charge at the end of the follow up period.
89434406|NCT05522803|Other|Sequence 1|TMS followed by sham TMS
89434407|NCT05522803|Other|Sequence 2|Sham TMS followed by TMS
88914763|NCT01610310|Experimental|peginterferon beta-1a autoinjector / PFS|A single dose of peginterferon beta-1a 125 mcg administered by autoinjector on Day 1, then by a single dose of peginterferon beta-1a 125 mcg by prefilled syringe (PFS) on Day 22.
88914764|NCT01610323|Experimental|Exercise group|Exercise intervention
88914765|NCT01610323|Other|Control group|Standard care
88914766|NCT01610362|Active Comparator|5-dose IM rabies vaccines, HRIG 20 IU/kg|Rabies exposed victims, 5-dose IM rabies vaccine, HRIG 20 IU/kg
88914767|NCT01610362|Experimental|5-dose IM rabies vaccines, HRIG 40 IU/kg|Healthy volunteers, 5-dose IM rabies vaccine, HRIG 40 IU/kg
88914768|NCT01610375|Other|Telephone Follow-up|Women previously treated for endometrial cancer will be recruited into one study group and continue to be followed per the current routine clinic follow-up. However, an additional program (telephone follow-up) will be offered in parallel to the current clinic follow-up. Outcomes obtained from the telephone follow-up will be compared with the current clinical assessment.
88914769|NCT01610388|Experimental|Cohort A1|Single dose 60 minute infusion of 500mg IV GSK1322322/placebo followed by BID for 4 days
88914770|NCT01610388|Experimental|Cohort A2|Single dose 30 minute infusion of 500mg IV GSK1322322/placebo followed by BID for 4 days
88914771|NCT01610388|Experimental|Cohort B|Initial single 1000mg oral GSK1322322/placebo dose, initial single dose 1000mg IV GSK1322322/placebo followed by BID for 4 days
88914772|NCT01610388|Experimental|Cohort C|Initial single 1500mg oral GSK1322322/placebo dose, initial single dose 1500mg IV GSK1322322/placebo followed by BID for 4 days
88914773|NCT01610388|Experimental|Cohort D|Single dose 2000mg IV GSK1322322J/placebo
88914774|NCT01610388|Experimental|Cohort E|Single dose 3000mg IV GSK1322322J/placebo
89434408|NCT05521854|Sham Comparator|Control|Participants in this group will have access to the DynamiCare app; however, no behavioral incentives will be provided to this group.
88914775|NCT01610388|Experimental|Cohort F|1000mg IV GSK1322322J/placebo followed by BID for 4 days
88914776|NCT01610401|Active Comparator|Pretreatment with metformin|Pretreatment with metformin 500 mg three times a day for 3 days.
88914777|NCT01610401|No Intervention|No pretreatment.|no intervention
88914778|NCT01610401|Active Comparator|Pretreatment with Metformin/caffeine|to study whether caffeine (4 mg/kg intravenously over 10 minutes) attenuates the protective effect of metformin (500 mg three times a day for 3 days) on FMD after ischemia/reperfusion
89010004|NCT02211547|Experimental|Treatment|Single blind laser treatment (the laser will be positioned and operated, and energy transfer will take place).
89434409|NCT05521854|Experimental|Escalating Low|"Participants will have access to the DynamiCare app. Through the app, participants will receive incentive amounts for drug negative saliva tests. Incentive amounts increase with every negative drug test up to a ceiling and reset to the lowest amount when a test is positive or missed. The Low group will receive lower incentive amounts than the High group."
89434410|NCT05521854|Experimental|Escalating High|"Participants will have access to the DynamiCare app. Through the app, participants will receive incentive amounts for drug negative saliva tests. Incentive amounts increase with every negative drug test up to a ceiling and reset to the lowest amount when a test is positive or missed. The High group will receive higher incentive amounts than the Low group."
88914779|NCT01610401|Other|No metformin, only pretreatment with caffeine|No pretreatment with metformin, FMD measurement after forearm ischemia/reperfusion and infusion of caffeine (4 mg/kg intravenously over 10 minutes).
88914780|NCT01610440|Experimental|Intervention Group|Participants will be given rehabilitation therapy plus human umbilical cord mesenchymal stem cells transplantation with one year follow-up
88914781|NCT01610466|Experimental|Curriculum training group|Surgical residents in the curriculum training group will complete the entire curriculum. They will participate in a cognitive component, which will consist of self-directed readings and a faculty-led seminar. Participants will also train to proficiency in laparoscopic jejunojejunostomy and gastrojejunostomy using a laparoscopic box trainer with cadaveric porcine bowels. Finally, for the non-technical skills component participants will participate in an introductory lecture on non-technical skills in surgery, as well as a practice crisis scenario with a debriefing session.
88914782|NCT01610466|No Intervention|Conventional training group|Participants in the conventional training group will proceed through surgical residency training in the usual fashion.
88914783|NCT01610479|Experimental|TAS-114/S-1|TAS-114 plus S-1
88914784|NCT01610518|Experimental|250 mL medium viscosity|250 mL beverage containing 4g low molecular weight oat beta-glucan and 50g glucose
88914785|NCT01610518|Experimental|600 mL low viscosity|600 mL beverage containing 4g low molecular weight oat beta-glucan and 50g glucose
88914786|NCT01610518|Experimental|250 mL high viscosity|250 mL beverage containing 4g high molecular weight oat beta-glucan and 50g glucose
88914787|NCT01610518|Experimental|600 mL medium viscosity|600 mL beverage containing 4g high molecular weight oat beta-glucan and 50g glucose
88914788|NCT01610518|Placebo Comparator|250mL control|250 mL beverage containing 50g glucose
88914789|NCT01610518|Placebo Comparator|600mL control|600mL beverage containing 50g glucose
88914790|NCT01610609|Experimental|Population Health Management Intervention|Participants randomized to this arm will receive the population health management intervention.
88914791|NCT01610609|No Intervention|Usual Care Control Group|Participants randomized to this arm will receive usual care.
89434411|NCT05521854|Experimental|De-Escalating Low|"Participants will have access to the DynamiCare app. Through the app, participants will receive incentive amounts for drug negative saliva tests. Incentive amounts increase with every positive drug tests (up to a ceiling), and decrease by the same increment with every negative drug test (down to a floor). The Low group will receive lower incentive amounts than the High group."
88914792|NCT01610635|Experimental|Male - 8 weeks|Male donors assigned to an 8 week donation interval frequency
88914793|NCT01610635|Experimental|Male - 10 weeks|Male donors assigned to 10 week donation interval frequency
88914794|NCT01610635|No Intervention|Male - 12 weeks|Male donors assigned to 12 week donation interval frequency
88914795|NCT01610635|Experimental|Female - 12 weeks|Female donors assigned to 12 week donation interval frequency
88914796|NCT01610635|Experimental|Female - 14 weeks|Female donors assigned to 14 week donation interval frequency
88914797|NCT01610635|No Intervention|Female - 16 weeks|Female donors assigned to 16 week donation interval frequency
88914798|NCT01610648||Patients presenting for a diagnostic sleep study|Patients presenting to the TMC sleep center for sleep study
88914799|NCT01610661|Other|Unrefined-carbohydrate|unrefined carbohydrate diet
88914800|NCT01610661|Other|Refined-carbohydrate|refined carbohydrate diet
88914801|NCT01610661|Other|Simple-carbohydrate|simple carbohydrate diet
88914802|NCT01610674|Experimental|Tailored improvement strategy|In 3 hospitals a tailored strategy to improve perioperative diabetes care is performed
88914803|NCT01610674|No Intervention|Usual perioperative diabetes care|Three hospitals that provide usual perioperative diabetes care serve as control hospitals
88914804|NCT01610726|Active Comparator|enhanced recovery|
88914805|NCT01610726|No Intervention|conventional recovery|
88914806|NCT01610739|Other|Median nerve perfusion|Injection of indigocyanine green dye to evaluate perfusion of the median nerve with the SPY scope before and after carpal tunnel release
88914807|NCT01610765|Active Comparator|Novel Antiviral Drug|Subjects will be randomized to receive one of 3 oral doses of a Novel Antiviral Drug: 0.50 mg/kg/dose, 1.0 mg/kg/dose or 2.0 mg/kg/dose twice a week for up to 3 weeks during the time in which the 21 day administration of parenteral acyclovir is being administered
88914808|NCT01610765|Placebo Comparator|Placebo|Subjects will be randomized to receive one of 3 oral doses of placebo matched in volume to active drug: 0.50 mg/kg/dose, 1.0 mg/kg/dose or 2.0 mg/kg/dose twice a week for up to 3 weeks during the time in which the 21 day administration of parenteral acyclovir is being administered
88914809|NCT01610778|Placebo Comparator|Placebo|
88914810|NCT01610778|Experimental|Supplement|
88914811|NCT01610804||CSCR-Patients|Patients suffering from Central Serous Chorioretinopathy
88914812|NCT01610804||Healthy Subjects|Healthy subjects with (assumed) normal choroidal thickness
88914813|NCT01610817||Patients with the InPAct intervention|The InPAct intervention will be presented to the last patients recruited by each general practitioner
88914814|NCT01610817||Patients without the InPAct intervention|The InPAct intervention will not be presented to the first patients recruited by each general practitioner
89010005|NCT04562272|Active Comparator|Mechanical unloading|Mechanical unloading by Impella-CP for 36-48 hours, on top of the standard treatment
89010006|NCT04562272|No Intervention|Standard care|Standard treatment of AMI after PCI according to guidelines.
89434412|NCT05521854|Experimental|De-Escalating High|"Participants will have access to the DynamiCare app. Through the app, participants will receive incentive amounts for drug negative saliva tests. Incentive amounts increase with every positive drug tests (up to a ceiling), and decrease by the same increment with every negative drug test (down to a floor). The High group will receive higher incentive amounts than the Low group."
88914815|NCT01610830||Group A|have skin involvement +/- an extra renal disease (arthritis, digestive and/or HSP without renal disease. The absence of renal disease is defined by the absence of hypertension (BP <95th percentile for height in children, BP <140/90 mmHg in adults with no known history of hypertension), the absence of hematuria (<5 RBCs per mm3), the absence of proteinuria (proteinuria <0.1 g/24h) and the absence of renal dysfunction (MDRD> 80 ml / min).
89434413|NCT05521854|Experimental|Constant High|"In the Constant groups, incentive amounts will remain unchanged across time. The High group will receive higher incentive amounts than the Low group."
89434414|NCT05521854|Experimental|Constant Low|"In the Constant groups, incentive amounts will remain unchanged across time. The Low group will receive lower incentive amounts than the High group."
89434415|NCT05521776|Experimental|With first trimester preeclampsia screening|Risk assessment of developing preeclampsia between 11 and 14 WG based on maternal parameters, blood pressure measurement, Doppler measurements of the uterine arteries and maternal PlGF concentration. Patients at high risk of preeclampsia are treated with aspirin.
88914816|NCT01610830||group B|"HSP with renal impairment, defined by the presence of renal dysfunction (calculated clearance <60 ml/min) and/or proteinuria (daily proteinuria greater than 0.3 g) and/or hematuria (more than 5000 RBC per ml or 5 RBC per mm3). We distinguish:~Group B1 patients with moderate renal disease if renal biopsy was not indicated or no evidence of histologic severity in renal biopsy (histological classification class 1 or 25)~Group B2 patients with severe renal impairment, with signs of histological severity in renal biopsy (class 3, 4 or 5)."
89198055|NCT02544555|Experimental|Intentional intraluminal approach|Intentional intraluminal approach is the way that the passage of guidewire in chronic total occlusive femoro-popliteal arterial lesion is performed via intraluminal route using various intraluminal devices. in an intraluminal approach, the response to the balloon is more favorable, but the outcome depends on the experience of the surgeon, and the approach requires more time and is more costly.
89434416|NCT05521776|No Intervention|Without first trimester preeclampsia screening|Usual prenatal care
88914817|NCT01610856|Experimental|PEG - 4 L|4 Litres PEG bowel preparation given the day prior to colonoscopy with a clear fluid diet
88914818|NCT01610856|Active Comparator|Split Dose PEG|4 Litres of Colyte given as two split doses of 2L each either the day before colonoscopy 8 hours apart in the case of an AM colonoscopy or in the case of an afternoon colonoscopy given 5PM the day before and 6:00AM the day of the colonoscopy
88914819|NCT01610869|Experimental|Cyclophosphamide and BIBF-1120|Patients will receive oral BIBF 1120 (200mg bd) and cyclophosphamide (100mg) on a daily basis until disease progression or unacceptable toxicity.
88914820|NCT01610869|Placebo Comparator|Cyclophosphamide and placebo|Patients will receive oral BIBF 1120 (200mg bd) and placebo capsules on a daily basis until disease progression or unacceptable toxicity.
88914821|NCT01610882|Other|Panda first|Panda evaluation of post-operative pain first, followed by manual method of pain assessment.
88914822|NCT01610882|Other|Manual first|Manual evaluation of post-operative pain first followed by Panda pain assessment.
88914823|NCT01610895|Active Comparator|Split-dose PEG Based Lavage (2L + 2L) + Low-fiber Diet|Patients randomized to this arm will have a split-dose Polyethylene Glycol Based lavage (2L + 2L), have a low-fibre diet 4 days prior to Colonoscopy and the day before Colonoscopy, have a low-fibre breakfast, a low-fibre lunch by 2PM and then drink only clear fluids until after the procedure is completed.
88914824|NCT01610895|Placebo Comparator|Split-dose PEG Based Lavage (2L + 2L) + Clear fluid diet|Patients randomized to this arm will have a split-dose Polyethylene Glycol Based lavage (2L + 2L), have a low-fibre diet 4 days prior to Colonoscopy and the day before Colonoscopy, have a low-fibre breakfast and then drink only clear fluids until after the procedure is completed.
88914825|NCT01610921|Experimental|bronchial provocationtest|Provocation tests with adenosine dry powder and nebulized AMP (adenosine-5'monophosphate). The AMP provocation test is a standard test and consists of 14 doubling concentrations in a range of 0.04mg/ml to 320mg/ml. The aerosols will be inhaled during tidal breathing for 2 minutes. The dry powder adenosine also consists of 14 doubling steps with doses in a range of 0.01mg to 20mg.
88914826|NCT01610934|Experimental|liraglutide|
88914827|NCT01610934|Active Comparator|glimepiride|
88914828|NCT01610947|Active Comparator|Maintain|Continuation of usual treatment with fixed intervals according to standard recommendations
88914829|NCT01610947|Active Comparator|Spacing|Progressive spacing of injections according to disease activity observed during follow-up and predefined protocol.
88914830|NCT01610960|Active Comparator|HELMET|The HELMET and HELMET NEXT modes will be tested by each patient.
88914831|NCT01610960|Sham Comparator|Facemask|The facemask will be used by each patient.
89198056|NCT02544555|Active Comparator|Intentional subintimal approach|Intentional subintimal approach is the method that recanalization is performed via subintimal route with a 0.035-inch looped guidewire and a supporting catheter at the occlusion site. Due to its simplicity and low cost, this approach has been used for many patients with femoropopliteal occlusion.
89434417|NCT05514470|Experimental|Patients|Patients with mutations in genes encoding cytosolic aminoacyl-tRNA synthetases and cared at Necker Hospital.
89434418|NCT05514132|Experimental|Ceralasertib in Combination with Durvalumab|This is a sequential group treatment/dose-escalation study with 2 cohorts with no masking.
89434419|NCT05513781||Chronic stroke patients with knee hyperextension|
89434420|NCT05511207|Experimental|RECOM - hBCI training|Patients in the RECOM group will receive treatment in add-on to standard rehabilitation as follows. The RECOM device is a h-BCI system that controls FES of upper limb muscles: the patient is asked to attempt simple upper limb movements (eg extension of fingers); the device recognizes (in correct trials) close-to-normal EEG-EMG activation and initiates FES of extensor muscles in the forearm. RECOM training consists in a set of trial repetition for a total duration per session of approximately 20-30 minutes (excluding set up time and calibration). FES parameters will be set specifically for each patients according to standard guidelines to achieve full movement and so as to avoid any kind of discomfort for the patients. The intervention regimen will be 2-3 times per week for 4 consecutive weeks.
89434421|NCT05511207|Active Comparator|CTRL - upper limb training with FES|Patients in the CTRL group will receive treatment in add-on to standard rehabilitation as follows. An expert physiotherapist will define a set of active exercises focused on upper limb function; the exercises will be combined with FES of forearm muscles. FES parameters will be set specifically for each patients according to standard guidelines to achieve the full required movement and so as to avoid any kind of discomfort for the patients. Session duration will be approximately 20-30 minutes (excluding FES calibration time). The intervention regimen will be 2-3 times per week for 4 consecutive weeks.
89434422|NCT05509881|Experimental|Continuous glucose monitoring (CGM) arm|"During the intervention period, patients in the CGM arm will undergo continuous real-time unblinded CGM using Dexcom CGM devices."
89434423|NCT05509881|Active Comparator|Usual care arm|During the intervention period, patients in the usual care arm will conduct self-monitored blood glucose (SMBG) at least 4 times/day. At Weeks 6 and 12 of the intervention period, usual care arm patients will also undergo 10-days of blinded CGM data collection.
89434424|NCT05509738|Experimental|Group 1: Diaries - SMS|"Group 1 will be asked to complete a 2-day bladder diary + food diary during the first two weeks of the study, then will receive SMS Text reminders during the last 2 weeks of the study.~Both groups will complete a pre-survey at the beginning of the study and a post-survey after each phase of the study (total 2 post-surveys)."
89434425|NCT05509738|Experimental|Group 2: SMS - Diaries|"Group 2 will receive SMS Text reminders during the first 2 weeks of the study, and then will be asked to complete a 2-day bladder diary + food diary during the last two weeks of the study.~Both groups will complete a pre-survey at the beginning of the study and a post-survey after each phase of the study (total 2 post-surveys)."
89434426|NCT05508282|Experimental|Intervention|"These parents will have a new mobile app (Reading Bees) installed onto their smartphone during a baseline clinic visit between 0 and 2-months old. They will also receive a specially designed children's book modeling the SHARE/STEP approach to reading with infants.~At 6-months, these parents will also receive guidance regarding limiting digital media use (screen time) using content in the app and a specially designed children's book.~They will also receive usual guidance during clinic visits via the Reach Out and Read program"
89434427|NCT05508282|No Intervention|Control|These parents will receive usual reading and screen time guidance during pediatric clinic visits, including via the Reach Out and Read program.
89434428|NCT05507879||Ancillary-Correlative (biospecimen collection)|Patients undergo collection of blood samples at time of therapy initiation. Patients who develop cardiac toxicity may undergo additional collection of blood samples. Patients' medical records are also reviewed.
89434429|NCT05506215|Experimental|NovoSorb SynPath|Arm receives application on NovoSorb SynPath Dermal Matrix and appropriate Off-loading
89434430|NCT05506215|Active Comparator|Standard of Care|Arm receives application of wound dressing composed of 90% Collagen and 10% Alginate plus appropriate Off-loading
89434431|NCT05505357|Experimental|Patients with pCR predicted by MRI and vacuum-assisted biopsy (VAB) after neoadjuvant chemotherapy|When there is no residual tumor cells on the vacuum-assisted biopsy specimen, breast surgery will be omitted. In the case of clinical N0 AND MRI size ≤ 0.5cm AND lesion-to-background signal enhancement ratio ≤1.6, sentinel lymph node biopsy will be omitted. Otherwise, sentinel lymph node biopsy will be performed. If necessary, axillary lymph node dissection will be performed.
89434432|NCT05504902|Experimental|Vibrotactile Coordinated Reset (vCR)|Vibrotactile Coordinated Reset delivers vibratory stimulation to the fingertips of each hand. A specific pattern of vibration to each fingertip is delivered which theoretically disrupts abnormal synchrony in the brain.
89434433|NCT05503719|Experimental|Absorbable Suture|Surgical wounds of this arm will be closed with an absorbable suture.
89434434|NCT05503719|Active Comparator|Non-absorbable suture|Surgical wounds of this arm will be closed with a non-absorbable suture.
89434435|NCT05497765|Experimental|Compound silymarin|Dietary supplement: 4 tablets of compound silymarin twice a day for 12 weeks The active ingredient in each tablet: 81.6 mg of silibinin, mixed power of pueraria, schisandra and salvia miltiorrhiza
89434436|NCT05497765|Active Comparator|Silymarin|Dietary supplement: 4 tablets of silymarin twice a day for 12 weeks The active ingredient in each tablet: 81.6 mg of silibinin
89434437|NCT05497765|Placebo Comparator|Placebo|Dietary supplement: 4 tablet of placebo twice a day for 12 weeks Placebo Composition: corn dextrin
89434438|NCT05495750|Active Comparator|Maxillary block group|"The ultrasound probe will be placed in the infra zygomatic area, with an inclination of 45 degrees in the transverse plane. A 27-gauge 38-mm needle will be used for the injection. The needle will be inserted perpendicular to the skin at the frontozygomatic angle and advanced to the greater wing of the sphenoid. The needle will be then redirected and advanced to the pterygopalatine fossa.~Loss of resistance after passing through the temporalis muscle will assist in determining the puncture depth, and real-time ultrasound guidance will allow seeing the spread of local anesthetic in the pterygopalatine fossa."
89434439|NCT05495750|No Intervention|Control group|Patients will receive only general anesthesia with regulated doses of IV opioids.
89434440|NCT05492877|Placebo Comparator|Placebo|Approximately 203 participants will be randomised to receive placebo.
89434441|NCT05492877|Experimental|Mitiperstat (AZD4831)|Approximately 203 participants will be randomised to receive mitiperstat (AZD4831).
89434442|NCT05491369|Active Comparator|Application users|Participants will use application for self-management.
89434443|NCT05491369|No Intervention|Control group|Participants will be in the waiting list which don't use the app.
89434444|NCT05490589|Experimental|EQUIPE Program|
88914832|NCT01610973|Experimental|Manual preparation|Manual preparation of the graft
88914833|NCT01610973|Active Comparator|Automatized preparation|Automatized preparation of the graft with microkeratoma
88914834|NCT01610986|Experimental|Glucose-fructose|Participants will take glucose-fructose drinks during training sessions
88914835|NCT01610986|Experimental|Water|Participants will take only water during training sessions
88914836|NCT01610999|Experimental|Cohort A|0.24 mg/kg plerixafor on day 1
88914837|NCT01610999|Experimental|Cohort B|0.24 mg/kg plerixafor daily on days 1 & 2
88914838|NCT01610999|No Intervention|Cohort C|"Six control subjects will have research bloods drawn but receive no plerixafor."
88914839|NCT01611038|Placebo Comparator|Placebo|Placebo given daily
89434445|NCT05490576|Experimental|[18F] PI-2620 PET Tau Ligand Active Agent|Participants receive dose of active agent [18F] PI-2620 PET Tau Ligand during dynamic PET scan acquisition
89434446|NCT05490277|Active Comparator|Active Vibrotactile Coordinated Reset (vCR)|Vibrotactile Coordinated Reset delivers vibratory stimulation to the fingertips of each hand. A specific pattern of vibration to each fingertip is delivered which theoretically disrupts abnormal synchrony in the brain.
89434447|NCT05490277|Sham Comparator|Sham Vibrotactile Coordinated Reset (vCR)|Vibrotactile Coordinated Reset delivers vibratory stimulation to the fingertips of each hand. An inactive pattern of vibration to each fingertip is delivered which theoretically will not have the effects of active vCR.
89434448|NCT05489705||Mavacamten|Participants will receive mavacamten as prescribed by a physician according to standard of care for symptomatic oHCM
88914840|NCT01611038|Experimental|Methylselenocysteine|Methylselenocysteine given daily
88914841|NCT01611051|Experimental|Pegylated rhG-CSF: 100µg/kg|Chemtherapy naive patients receiving chemotherapy and Pegylated rhG-CSF 100µg/kg
88914842|NCT01611051|Experimental|Pegylated rhG-CSF: 6mg|Chemtherapy naive patients receiving chemotherapy and Pegylated rhG-CSF 6mg
88914843|NCT01611051|Active Comparator|rhG-CSF 5ug/kg/day|Chemtherapy naive patients receiving chemotherapy and rhG-CSF 5ug/kg/day
88914844|NCT01611064|Active Comparator|Oxygen|Volunteer receives oxygen at a rate of 10litres/minute by mask
88914845|NCT01611064|Placebo Comparator|Air|Volunteer receives normal air at a rate of 10litres/minute by mask
88914846|NCT01611077|Other|Single Arm|Candesartan 16 mg tablets p. o. once daily for 14 days, 32 mg tablets once daily for 28 days, then olmesartan 40 mg tablets once daily for 42 days, then olmesartan/amlodipine 40/5 mg tablets once daily for 14 days, then olmesartan/amlodipine 40/10 mg tablets once daily for 28 days
88914847|NCT01611103|Sham Comparator|Sham Stimulation|transcranial direct current stimulation that is ramped up and ramped down providing the sensation of tDCS without delivering the full amount of tDCS
88914848|NCT01611103|Experimental|Anodal Stimulation|transcranial direct current stimulation using Anodal stimulation over the area of interest
88914849|NCT01611129|Active Comparator|reading about hearing loss and its management|General self-reading reading about hearing loss and its management This would run for 30 days and the participants have to manage their own time.
88914850|NCT01611129|Experimental|Internet-based counseling|This would involve 4 stages of designated internet sessions and additional tasks which the patients can complete in their own time. This programme should be completed within 30 days.
88914851|NCT01611142|Experimental|KW-0761|
88914852|NCT01611181|Active Comparator|Hemoboost (iron supplementation)|A registered natural product containing specially haemolysed haemoglobin and iron dextran.
88914853|NCT01611181|Active Comparator|Kräuterblut (iron supplementation)|A registered natural product made from a number of herbs with ferrous gluconate as the active substance.
88914854|NCT01611181|Active Comparator|Ferrofumerat (iron supplementation)|Ferrous sulphate
88914855|NCT01611207|Experimental|Negative Pressure Wound Therapy|Used therapy systems
88914856|NCT01611207|Active Comparator|Standard Conventional Wound Therapy|Standard conventional wound therapy according to current evidence-based guideline (basic and advanced methods of wound treatment)
88914857|NCT01611220|No Intervention|Control|Standard cognitive behavior inpatient treatment
88914858|NCT01611220|Experimental|RePAN|Standard cognitive behavior inpatient treatment plus 8 dissonance relapse prevention groups
89434449|NCT05489705||Beta-blocker (BB) / non-dihydropyridine (non-DHP) calcium channel blocker (CCB) / disopyramide|Participants will receive BB/non-DHP CCB/disopyramide as prescribed by a physician according to standard of care for symptomatic oHCM
89434450|NCT05489211|Experimental|Substudy-1A|Dato-DXd will be evaluated as monotherapy
88914859|NCT01611233||DePuy ASR THA|Adults having received a Depuy ASR metal on metal hip system which is subject to a voluntary recall.
88914860|NCT01611246||Anesthetization|Anesthetization
88914861|NCT01611272||1|Unstable angina, Non ST-segment Elevation Myocardial Infarction or ST-segment elevation myocardial infarction including patients managed medically, and those who are managed with percutaneous coronary intervention or coronary artery by-pass grafting
88914862|NCT01611285||Robotic Sacrocolpopexy patients|Patients who underwent Robotic Sacrocolpopexy to treat pelvic organ prolapse between 2009 and 2010
88914863|NCT01611285||UPHOLD patients|Patients who underwent the UPHOLD procedure to treat pelvic organ prolapse from 2009-2010.
88914864|NCT01611324|Experimental|Alkalinised anesthetic solution|
88914865|NCT01611324|Active Comparator|Non alkalinised anesthetic solution|
88914866|NCT01611337|Other|insight evaluation|insight evaluation using the Q8 scale
88914867|NCT01611350|Experimental|Health Marketing Message|Marketing message focused on health effects of cooking with wood on a three stone fire.
89434451|NCT05489211|Experimental|Substudy-1B|Dato-Dxd in combination with Durvalumab will be evaluated
89434452|NCT05489211|Experimental|Substudy-1C|Dato-Dxd in combination with Saruparib (AZD5305) will be evaluated
88914868|NCT01611350|Experimental|Savings Marketing Message|Marketing message focused on savings (both time and money) related to using an energy efficient cookstove.
88914869|NCT01611350|Experimental|Savings and Health Marketing Messages Combined|One group will receive both the savings and health marketing messages.
88914870|NCT01611350|Experimental|Novel Sales Offer|This group will receive a free trial and time payments when purchasing an energy efficient cookstove.
88914871|NCT01611350|Experimental|Early vs. Late Buyers|Of those who accept the Novel Sales Offer, half the buyers will randomly be selected to start their free trial within a few weeks of the sales meeting, while the other half- the late buyers- will start their free trial a within 2 months of the sales meeting.
88914872|NCT01611363|Experimental|Part A|Ipragliflozin (low dose) & Placebo
88914873|NCT01611363|Experimental|Part B|Ipragliflozin (high dose)
88914874|NCT01611389|Experimental|Long AV delay.|
88914875|NCT01611389|Active Comparator|Short AV delay.|
88914876|NCT01611415|Experimental|ipragliflozin|
88914877|NCT01611415|Experimental|furosemide|
88914878|NCT01611415|Experimental|ipragliflozin & furosemide|
88914879|NCT01611428|Experimental|Ipragliflozin - oral|open label
88914880|NCT01611428|Experimental|Ipragliflozin - i.v.|open label
89434453|NCT05489211|Experimental|Substudy-1D|Dato-Dxd in combination with Durvalumab + Saruparib (AZD5305) will be evaluated
89434454|NCT05489211|Experimental|Substudy-2A|Dato-DXd in combination with capecitabine will be evaluated
89434455|NCT05489211|Experimental|Substudy-2B|Dato-DXd in combination with 5-FU will be evaluated
89434456|NCT05489211|Experimental|Substudy-2C|Dato-DXd in combination with chemotherapy (capecitabine or 5-FU) + volrustomig (MEDI5752) will be evaluated
89434457|NCT05489211|Experimental|Substudy-3A|Dato-DXd will be evaluated as monotherapy
89434458|NCT05489211|Experimental|Substudy-3B|Dato-DXd in combination with Saruparib (AZD5305) will be evaluated
89434459|NCT05489211|Experimental|Substudy-3C|Dato-DXd will be evaluated in combination with prednisone/prednisolone
89434460|NCT05489211|Experimental|Substudy-4A|Dato DXd will be evaluated as monotherapy
89434461|NCT05489211|Experimental|Substudy-4B|Dato-DXd in combination with carboplatin followed by Dato-DXd + Saruparib (AZD5305) will be evaluated
89434462|NCT05489211|Experimental|Substudy-5A|Dato-DXd will be evaluated as monotherapy
89434463|NCT05489211|Experimental|Substudy-5B|Dato-DXd + 5-FU + LV + bevacizumab OR Dato-DXd + capecitabine + bevacizumab will be evaluated
89434464|NCT05489211|Experimental|Substudy- 6A|Dato-DXd in combination with volrustomig (MEDI5752) will be evaluated
89434465|NCT05489211|Experimental|Substudy-6B|Data-DXd in combination with rilvegostomig (AZD2936) will be evaluated
89434466|NCT05489211|Experimental|Substudy- 7A|Dato-DXd will be evaluated as monotherapy
89434467|NCT05488314|Experimental|Phase 1 (Combination Dose Selection)|Participants will receive capmatinib 400 milligrams (mg) orally twice daily from Cycle 1 Day 1, in combination with amivantamab 700 mg intravenous (IV) infusion (for body weight less than 80 kilograms [kg]) or 1050 mg IV infusion (for body weight greater than or equal to 80 kg) once weekly from Cycle 1 Day 1 for 4 weeks and then every 2 weeks from Week 5 (Cycle 2; each cycle of 28 days). Doses will be escalated or de-escalated based on the dose limiting toxicities (DLTs) and the recommended Phase 2 combination dose (RP2CD) will be determined by the study evaluation team (SET).
89434468|NCT05488314|Experimental|Phase 2 (Dose Expansion)|Participants with mesenchymal-epithelial transition (MET) exon 14 skipping mutation who are treatment naïve (Cohort 1A), who have received prior therapy (Cohort 1B), or participants with MET amplification who have received prior therapy (Cohort 1C) will receive capmatinib in combination with amivantamab at the RP2CD determined by the SET in Phase 1.
89434469|NCT05486962||Remote Patient Monitoring|Patients undergoing elective abdominal surgery will be asked to use a wearable activity tracker, vivosmart®HR by Garmin, pre and post-operatively to help remotely monitor health metrics. Data collected through the Garmin device will be reviewed to assess compliance and improvement in activity. Aggregate data will be analyzed to assess feasibility and effectiveness of this device in improving patient recovery.
88914881|NCT01611441||Patients with osteoarthritis of the knee|Patients with osteoarthritis of the knee undergoing total knee replacement surgery.
88914882|NCT01611467|Experimental|20 mg oral CC-223 with microtracer|A single 20-mg oral dose of CC-223 capsule containing a microtracer of [14C]-CC-223 solution
89434470|NCT05484973|Experimental|All patients will use AMMA|Device: AMMA Portalbe Scalp Cooling System AMMA is indicated for use in chemotherapy infusion centers, during transit from the infusion center andat home and is intended for use by patients who are undergoing chemotherapy treatment and who want to reduce the likelihood of chemotherapy-induced alopecia.
89434471|NCT05481749||Neuropsico-Ger|People aged 80 or more years, non-institutionalized, and without pathologies potentially affecting cognitive status.
89434472|NCT05481164||Screen for Spinal Muscular atrophy for newborns|Babies with an SMA screen-positive result
89434473|NCT05475769||Nummular headache patients|Patients that fulfill the International Classification of Headache Disorders, 3rd edition, for Nummular Headache.
89434474|NCT05474378|Experimental|Dose escalation|Participants will follow a standard 3+3 dose escalation design up to four dose levels, repeated every 28 days up to 6 doses.
89434475|NCT05474378|Experimental|Dose Expansion|After maximum tolerated dose and/or recommended phase 2 dose (MTD/RP2D) is established, subjects will be enrolled at the RP2D to further explore safety and conduct a preliminary assessment of benefit.
89434476|NCT05469360|Experimental|NIO752 - Dose A - Cohort 1|A single intrathecal injection of Dose A
89434477|NCT05469360|Placebo Comparator|Matching placebo - Cohort 1|A single intrathecal injection of artificial cerebrospinal fluid (CSF)
89434478|NCT05469360|Experimental|NIO752 Dose B - Cohort 2|A single intrathecal injection of Dose B
88914883|NCT01611467|Experimental|20 mg oral CC-223 fasting|A single 20-mg oral dose of CC-223 tablet under fasting conditions
88914884|NCT01611467|Experimental|20 mg oral CC-223 fed|A single 20-mg oral dose of CC-223 tablet under fed conditions
88914885|NCT01611493|Experimental|Osseotite Prevail Implant|The Osseotite Prevail will be placed in sites with native bone, with at least three months of healing since tooth extraction or four months from bone augmentation grafting procedure.
88914886|NCT01611493|Active Comparator|Osseotite Non Prevail Implant|Osseotite Non Prevail Implant will be placed in sites with native bone, with at least three months of healing since tooth extraction or four months from bone augmentation grafting procedure
88922268|NCT05573373|Experimental|Pamilarib in combination with Chemotherapy Drugs|The specific chemotherapy regimen was formulated by the investigator. The dosage of chemotherapy drugs is selected according to the drug use guidelines. Combination medication, the initial dose is 40mg each time (2 capsules), 2 times a day, the total daily dose is 80mg. Can be taken with a meal or on an empty stomach. If the patient misses a dose, no additional dose should be taken, and the next prescribed dose should be taken normally at the planned time. Continue the treatment until the disease progresses or unacceptable adverse reactions occur, and the dose is adjusted.
89198057|NCT00753168|Experimental|1|OT-730 ophthalmic solution
89198058|NCT00753168|Active Comparator|2|timolol maleate ophthalmic solution
89434479|NCT05469360|Placebo Comparator|Matching placebo - Cohort 2|A single intrathecal injection of artificial cerebrospinal fluid (CSF)
89434480|NCT05469360|Experimental|NIO752 OLE|Multiple intrathecal injections of Dose A
89434481|NCT05466123|Experimental|Virtual reality intervention in palliative care patients|Palliative care patients with a limited life expectancy will participate in a virtual reality experience for 10-30 minutes
88914887|NCT01611506|Experimental|Cetuximab, capecitabine, cisplatin based chemoradiation|"Induction chemotherapy:~3 cycles (of 3 weeks) with capecitabine, cisplatin and weekly cetuximab: Cetuximab 400mg/m2 (loading dose)on day 1 and 250mg/m2 weekly thereafter, Cisplatin 80mg/m2 on day 1 every three weeks, Capecitabine 1000mg/m2 twice daily from the evening of day 1 to the morning of day 15 within each 3 weeks cycle.~Followed by:~Radio-chemo-immunotherapy:~Cetuximab 250mg/m2 weekly on day 1, Cisplatin 30mg/m2 weekly on day 1, Radiotherapy (dose escalation levels) 36/39.6/45 Gy(according to dose level) in 5 fractions of 1.8 Gy per week~Surgery:~Will be performed 4-6 weeks after neoadjuvant radiochemotherapy~Postoperative treatment:~3 cycles of Chemo-immunotherapy with cetuximab, cisplatin and capecitabine -as described above- will be administered postoperatively if the patient has recovered adequately from surgery and the treatment is considered as feasible by the investigator."
88914888|NCT01611519||Early (within 48 hours of surgery)|Patients will have their urinary catheter removed within 48 hours of surgery
88914889|NCT01611519||Late (6 hours after epidural removal)|Patients will have their urinary catheter removed 6 hours after their epidural is removed
88914890|NCT01611532||Acute pancreatitis|All adult patients (>18y.o.) requiring admission for acute pancreatitis (amylase >3 times the upper limit of normal and typical symptoms of abdominal pain and vomiting)
88914891|NCT01611545||Clopidogrel|Patients taking or prescribed clopidogrel or under consideration Utilizing pharmacogenomics to determine the most effective treatment
88914892|NCT01611584|Experimental|ALA|No arms for the trial. Participants will have proven or presumed lung cancer and will be assessed for participant by a research team member.
88914893|NCT01611610|Other|Ambulant SMA|
89198059|NCT00753168|Placebo Comparator|3|placebo eye drops
89198060|NCT02565602|Other|Ca-41 & Sr-84 (isotope tracers) & vit D|Dosages: 3.7 kBq (100 nCi) Ca-41, 5 mg of Sr-84 and 400IU of vitamin D (daily)
89198061|NCT00866463|Active Comparator|Conventional Oral Tablet With Water|
89198062|NCT00866463|Experimental|Experimental Tablet With Water|
89198063|NCT00866463|Experimental|Experimental Tablet Without Water|
89198064|NCT04051164|Experimental|Progressive Muscle Relaxation Technique|Progressive muscle relaxation technique
89198065|NCT04051164|Active Comparator|Conventional treatment|Conventional Treatment: (Strengthening exercises of residual limb, Gait training, Deep Breathing exercise)
89198066|NCT03823118|Experimental|S1/Anlotinib|Anlotinib 12mg qd, day 1 to day 14 followed by 7 days off treatment in a 21-day cycle until maximum 6 cycles； S1 60mg bid, day 1 to day 14 followed by 7 days off treatment in a 21-day cycle until it can not tolerate, or disease progression.
89198067|NCT00866541|Experimental|volunteers|artificial increased respiratory resistance
89198068|NCT00695864|Placebo Comparator|Placebo - sugar pill|Placebo - sugar pill
89198069|NCT00695864|Experimental|Ondansetron|Ondansetron
89198070|NCT00684996|Active Comparator|Phase II Arm I|Patients receive bevacizumab (10mg/kg) IV over 30-90 minutes on days 1 and 15.
89198071|NCT00684996|Active Comparator|Phase II Arm II|Patients receive bevacizumab IV as in arm I at the RPTD determined in phase I, and humanized monoclonal antibody MEDI-522 (8mg/kg) IV over 30 minutes on days 1, 8, 15, and 22.
89198072|NCT00862485||StudyGroup|
89198073|NCT04841408|Experimental|Vaginal self-sampling|Vaginal self-sampling performed by the patient at the follow-up visit at 3 weeks and remote follow-up at 9 weeks.
88914894|NCT01611610|Other|Non-ambulant SMA|
88914895|NCT01611623|Experimental|SNX-5422|Open label administration of SNX-5422 tablets every other day for 21 days on a 28 day cycle. Dose escalation based on safety outcomes
88914896|NCT01611649|Experimental|Dairy lipids and plant oils|
88914897|NCT01611649|Experimental|Plant oils|
89198074|NCT00751842|Active Comparator|A|This arm will receive 2 subcutaneous injections with 20 µg Diamyd on days 1 and 30, i.e., 1 prime and 1 booster dose, followed by 2 additional single doses with Diamyd 20 µg on days 90 and 270.
89198075|NCT00751842|Active Comparator|B|This arm will receive 2 subcutaneous injections with 20 µg Diamyd on days 1 and 30, i.e., 1 prime and 1 booster dose, followed by 2 additional single doses with placebo on days 90 and 270.
89198076|NCT00751842|Placebo Comparator|C|This arm will receive 4 injections of placebo, 1 each on days 1, 30, 90 and 270.
89198077|NCT05325008|Experimental|Immunosuppression reduction/modification + Intravenous Immunoglobulin|Receives Immunosuppression reduction/modification + Intravenous Immunoglobulin
89198078|NCT05325008|Other|Immunosuppression reduction/modification|Receives Immunosuppression reduction/modification as part of standard of care.
89198079|NCT00684762|Experimental|Cilostazol|A single dose of cilostazol (1 x 100 mg tablet) administered after an overnight fast of at least 10 hours.
89198080|NCT00684762|Experimental|Pletal® (cilostazol)|A single dose of cilostazol (Pletal® 1 x 100 mg tablet) administered after an overnight fast of at least 10 hours.
89434482|NCT05463419|Experimental|PIKA COVID-19 vaccine|One dose of the experimental vaccine should be administered on Study Day 0 in the deltoid muscle.
89198081|NCT00753246|Placebo Comparator|Arm B|adults with TMZ, RT
89198082|NCT00753246|Experimental|Arm A|adults with TMZ, RT, nimotuzumab
89198083|NCT00695786|Experimental|Schedule A (lenalidomide, rituximab)|Participants receive lenalidomide PO on days 1-21 and rituximab IV over 4-8 hours on day 1 of courses 1-12. Courses repeat every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity
89198084|NCT00695786|Experimental|Schedule B (lenalidomide, rituximab)|Participants receive lenalidomide PO on days 2-22 and rituximab IV over 4-8 hours on days 1, 8, 15, and 22 of course 1 and on day 1 of all subsequent courses. Courses repeat every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
89198085|NCT02561676|Experimental|Web-Based Education Program Type 1|The education program involves ten weeks of web-based classes (1.5 hours per class) given once per week with daily homework assignments of approximately 30 minutes per day.
89434483|NCT05463419|Active Comparator|Inactivated Covid-19 vaccine|One dose of the control vaccine should be administered on Study Day 0 in the deltoid muscle.
89434484|NCT05462236|Experimental|Module 1: Arm A: Multiple dose finding cohorts|Monotherapy with Tinodasertib administered orally QOD
89434485|NCT05462236|Experimental|Module1: Arm B/C: Multiple cohorts of Tinodasertib with fixed dose of pembrolizumab or irinotecan|Combination doses with Tinodasertib administered orally QOD with intravenous pembrolizumab at 200mg Q3W or Irinotecan at 350mg/m2 Q3W
89434486|NCT05462236|Experimental|Module 2: Arm B' and C': Dose Expansion|Combination therapy with Tinodasertib administered orally QOD at RP2D (as determined in Module 1) and either pembrolizumab at 200mg IV Q3W (arm B') or irinotecan 350mg/m2 IV Q3W (arm C')
89434487|NCT05460078|Experimental|Virtual program|Seen at a location where the virtual program is being offered
89434488|NCT05460078|No Intervention|Standard care|Seen at a location where standard care is offered
89434489|NCT05459896|Experimental|Experimental Group|Participants in the experimental group will be triaged to receive different types of interventions at Level 2, namely physical activity training, mindfulness coping strategies and energy conservation techniques, based on participants' screening and outcome assessment results at Level 1. These interventions will be taught in the 8-week regular supervision phase and self-practice during the 16-week self-help phase. The features in the Health Apps for Post-Pandemic Years (HAPPY) will be introduced to the participants in the first two sessions. In the other six sessions participants will be provided guidance in practicing the assigned intervention. Participants will self-practice the assigned intervention at home during 16-week self-help phase. At Level 3 Self-management, participants will be encouraged to work through a total of six thematic modules which aim to enhance participants' favourable appraisals of the current stress factors, to reduce stress levels and improve coping.
89434490|NCT05459896|No Intervention|Waitlist Control Group|Participants in the waitlist control group will receive materials on the promotion of physical and psychological health during the waiting period. Participants will then receive the same 24-week intervention as the experimental group in Week 25 after completing the baseline assessment.
89434491|NCT05458609|Active Comparator|Lemborexant plus Naltrexone|10 milligrams of Lemborexant will be given daily at nighttime and 50 milligrams of Naltrexone will be given daily for a total of 4 weeks
89434492|NCT05458609|Placebo Comparator|Placebo plus Naltrexone|10 milligrams of placebo will be given daily at nighttime and 50 milligrams of Naltrexone will be given daily for a total of 4 weeks
89434493|NCT05457725|Experimental|rtfMRI-guided Neurofeedback Training|Real-time functional magnetic resonance imaging guided neurofeedback
89434494|NCT05457725|Sham Comparator|Sham control|non-contingent-sham neurofeedback
89434495|NCT05453201|Experimental|Long COVID Coping and Recovery (LCCR) Intervention|Veterans will participate in a LCCR (1x/week for a total of 16 sessions) via the HIPAA-compliant telehealth platform VA Video Connect (VVC) and/or VA WebEx with two co-therapists.
89434496|NCT05452577|Experimental|Chinese medicine group|"Participants received Suanzaoren Decoction and Huanglian Wendan Decoction orally twice daily for 4 weeks.~Subjects who had previously taken Western medicine hypnotics continued to take them, and those who did not take them did not add Western medicine hypnotics."
89434497|NCT05452577|Active Comparator|Western medicine group|Participants received Estazolam 1mg tablet orally once daily for 4 weeks.
89434498|NCT05451264|Experimental|Hydrocortisone|During the PREMILOC trial, patients received hydrocortisone (0.5mg/kg/12h for 7 days and 0.5mg/kg/24h for 3 days).
89434499|NCT05451264|Placebo Comparator|Placebo|During the PREMILOC trial, patients received placebo (0.5mg/kg/12h for 7 days and 0.5mg/kg/24h for 3 days).
89434500|NCT05449132|Experimental|RTX-GRT7039|Participants will receive a single intra-articular injection of RTX-GRT7039 during the 52-week double-blind treatment period.
89434501|NCT05449132|Placebo Comparator|Placebo|Participants will receive a single intra-articular injection of placebo matching RTX-GRT7039 during the 52-week double-blind treatment period.
89434502|NCT05447156|Other|Aim 2: Tailored App (pilot run of Aim 3)|All participants will use the tailored QuitGuide app, a smoking cessation app, downloaded to their personal phone.
89434503|NCT05447156|Experimental|Aim 3:Tailored App|Randomized subset of participants will use the tailored QuitGuide app, a smoking cessation app, downloaded to their personal phone.
89434504|NCT05447156|Placebo Comparator|Aim 3: Standard App|Randomized subset of participants will use the standard QuitGuide app, a smoking cessation app available to the public, downloaded to their personal phone.
89434505|NCT05445843|Experimental|Cohort A- PD-L1<1%|Participants whose tumors harbor a KRAS G12C mutation and a PD-L1 expression <1%, regardless of STK11 mutation status.
88914898|NCT01611649|Experimental|Dairy lipids and plant oils, DHA+ARA|DHA: docosahexaenoic acid, ARA: arachidonic acid
88914899|NCT01611649|No Intervention|Human milk|
88914900|NCT01611675|Experimental|Treatment Arm|Leflunomide + Vemurafenib
88914901|NCT01611688|Experimental|Active|
88914902|NCT01611688|Placebo Comparator|Placebo|
88914903|NCT01611701|Active Comparator|Cryoballoon group|
88914904|NCT01611701|Active Comparator|RF group|
89434506|NCT05445843|Experimental|Cohort B- PD-L1≥ 1% and STK11 mutation|Participants whose tumors harbor a KRAS G12C mutation, a PD-L1 expression ≥ 1% and an STK11 co-mutation.
88914905|NCT01611714|Experimental|Audit-feedback|Arm 1: Audit-feedback only
88914906|NCT01611714|Experimental|CDS message|Arm 2: CDS message only
88914907|NCT01611714|Experimental|Both Interventions|Arm 3: Audit-feedback and CDS message
88914908|NCT01611714|No Intervention|Control|Arm 4: Control
88914909|NCT01611727|Experimental|Cisplatin|
88914910|NCT01611740||Preterm infants|Telemonitoring system prototype developed by INSERM U-642
88914911|NCT01611753|Active Comparator|liberal group|Patients in the liberal group received transfusions immediately, as the objective was to maintain hemoglobin levels above 9.0 g/dL.
88914912|NCT01611753|Active Comparator|restrictive group|Patients in the liberal group received transfusions immediately, as the objective was to maintain hemoglobin levels above 7.0 g/dL.
88914913|NCT01611766|Experimental|secondary cytoreductive surgery|SCR followed by chemotherapy
88914914|NCT01611766|Active Comparator|Salvage Chemotherapy|platinum-based chemotherapy
88914915|NCT01611805|Experimental|GSK1605786 250mg|Opaque Swedish orange body and cap.
88914916|NCT01611805|Placebo Comparator|Placebo|Opaque Swedish orange body and cap.
88914917|NCT01611805|Experimental|GSK1605786 500mg|Opaque Swedish orange body and cap.
88914918|NCT01611805|Experimental|GSK1605786 1000mg|Opaque Swedish orange body and cap.
88914919|NCT01611805|Experimental|GSK1605786 500mg in fed|Opaque Swedish orange body and cap.
88914920|NCT01611818|Other|Low intensity Internet-delivered psychotherapy|Low intensity Internet-delivered psychotherapy + improved treatment as usual by GP.
88914921|NCT01611818|Other|Self-guided Internet-delivered psychotherapy|Self-guided Internet-delivered psychotherapy + improved treatment as usual
88914922|NCT01611818|Other|Improved treatment as usual by GP|
88914923|NCT01611831|Experimental|ACT in group|Patients assigned to this arm will receive Acceptation and Commitment Therapy (ACT) in groups of 8-12 patients. Intervention has been protocolized. Therapy will be administered by two experienced therapists (psychologists).
88914924|NCT01611831|Active Comparator|Improved Treatment as usual by General practitioner|Patients assigned to this arm will receive treatment as usual by their General Practitioner in the Primary Care center. To enhance treatment, investigators participating in the trial will receive the Guidelines for fibromyalgia treatment in Primary Care handed by Health Service in Aragón.
88914925|NCT01611844|Experimental|Medical device : micro-needle BD 1.5 mm 30G|
88914926|NCT01611844|Active Comparator|Manthoux method: lance 26G X 16mm|
88914927|NCT01611896|Active Comparator|Selenium|
88914928|NCT01611896|Placebo Comparator|Placebo|
88914929|NCT01611909|Experimental|2% PMDO|
89434507|NCT05441527|Experimental|MI Paste, then, Biotene Dry Mouth Gel|Subjects in this arm will use 1 milliliter of MI Paste daily for 7 days. Then, the subjects in this arm will use 1 milliliter of Biotene Dry Mouth gel daily for 7 days. There will be no wash-out period between the two products.
88914930|NCT01611909|Experimental|5% PMDO|
88914931|NCT01611909|Active Comparator|Mupirocin|
88914932|NCT01611922||Symptomatic Lens Wearers|Contact lens wearers reporting a habitual wear time of less than eight hours and a noticeable reduction in comfort over a wearing day
89434508|NCT05441527|Experimental|Biotene Dry Mouth Gel, then, MI Paste|Subjects in this arm will use 1 milliliter of Biotene Dry Mouth gel for 7 days. Then, the subjects in this arm will use 1 milliliter of MI Paste for 7 days. There will be no wash-out period between the two products.
89434509|NCT05440786|Experimental|Abemaciclib + Irinotecan +Temozolomide|Abemaciclib given orally in combination with irinotecan given IV and temozolomide given orally.
88914933|NCT01611922||Non-Symptomatic Contact Lens Wearers|Contact lens wearers reporting a comfortable wear time of more than 10 hours and minimal reduction in comfort over a wearing day
88914934|NCT01611922||Asymptomatic Non-Contact Lens Wearers|Non-contact lens wearers reporting a minimal reduction in ocular comfort over the course of a day
88914935|NCT01611961|Experimental|DT-LM|Docetaxel Lipid Microsphere (DT-LM)
88914936|NCT01611961|Active Comparator|Taxotere|Commerical Product
88914937|NCT01611987|Experimental|MSTEP|The MSTEP program is a 6 day tailored exercise program. It includes flexibility, aerobic, peripheral strengthening, core and balance training, power and speed training and push days.
88914938|NCT01611987|Active Comparator|General guideline approach|The general Guideline approach is the general guidelines that are recommended for people with MS by the Canadian Society Exercise Physiology.
89434510|NCT05440786|Experimental|Irinotecan +Temozolomide|Irinotecan given IV and temozolomide orally.
88914939|NCT01612013|Active Comparator|Intravenous NAC plus saline|Acetylcysteine was given via intravenous bolus at a rate of 150 mg/kg over 60 min immediately before contrast exposure and followed by 50 mg/kg during and for 6 hours after the procedure. Saline (0.9 percent) was given intravenous at a rate of 1 ml/Kg/h over 60 min prior and followed at the same rate during and for the next 6 hours the procedure.
88914940|NCT01612013|Active Comparator|Sodium bicarbonate plus saline|Sodium bicarbonate solution (Sodium bicarbonate 8.4%, Equiplex, Brazil) was given by adding fifteen ampoules of sodium bicarbonate (150 mEq of sodium) to 1 L of 5% dextrose. Infusion in bolus began 60 min prior to the start of contrast administration at 3.5 ml/Kg/h, decreased to 1.18 ml/Kg/h during the contrast exposure and for the next 6 hours after the procedure. Saline (0.9 percent) was given IV at a rate of 1 ml/Kg/h over 60 min prior to the start of contrast administration and followed at the same rate during and for the next 6 hours after the procedure.
88914941|NCT01612013|Active Comparator|NAC plus sodium bicarbonate plus saline|Acetylcysteine was given intravenous at a rate of 150 mg/kg over 60 min before contrast exposure and followed by 50 mg/kg during and for 6 hours after the procedure. Sodium bicarbonate solution (150 mEq/L of sodium) was given in bolus began 60 min before contrast administration at 3.5 ml/Kg/h, decreased to 1.18 ml/Kg/h during and for the next 6 hours of the procedure. Saline was given intravenous at a rate of 1 ml/Kg/h over 60 min prior to the start of contrast administration and followed at the same rate during and for the next 6 hours after the procedure.
88914942|NCT01612013|Placebo Comparator|Saline|Saline (0.9 percent) was given IV at a rate of 1 ml/Kg/h over 60 min prior to the start of contrast administration and followed at the same rate during and for the next 6 hours after the procedure.
88914943|NCT01612026||Ultrasound|
88914944|NCT01612026||Fluoroscopy|
88914945|NCT01612052|Active Comparator|Cefazolin plus Daptomycin|
88914946|NCT01612052|Active Comparator|Cefazolin plus Vancomycin|
89198086|NCT02561676|Experimental|Web-Based Education Program Type 2|The education program involves ten weeks of web-based classes (1.5 hours per class) given once per week with daily homework assignments of approximately 30 minutes per day.
89434511|NCT05440708|Experimental|Cohort A: TTI-101 as a Single Agent|"Cohort A Phase 1b: Participants will receive up to 3 dose levels of TTI-101 as a single agent to determine the RP2D.~Cohort A Phase 2: Enrollment in Phase 2 may commence with approval from the safety review committee. Participants will be enrolled and treated at the RP2D of TTI-101 as a single agent."
88914947|NCT01612065|Active Comparator|Misoprostol vaginally, 200 ug|200 ug misoprostol in the posterior vaginal fornix
88914948|NCT01612065|Active Comparator|Misoprostol vaginally, 400ug|Misoprostol in the posterior vaginal fornix
88914949|NCT01612078|Experimental|Droxidopa, antihypotensive drug, tablet|
88914950|NCT01612078|Placebo Comparator|placebo, tablet|
89434512|NCT05440708|Experimental|Cohort B: TTI-101 in Combination with Pembrolizumab|"Cohort B Phase 1b: Participants will receive up to 3 dose levels of TTI-101 in combination with pembrolizumab to determine the RP2D.~Cohort B Phase 2: Enrollment in Phase 2 may commence with approval from the safety review committee. Participants will be enrolled and treated at the RP2D of TTI-101 in combination with pembrolizumab."
89531279|NCT02493647|No Intervention|Attention-Time Control|The Control is a 12-episode popular web miniseries with a storyline that promotes respectful relationships. time and frequency are matched to the active intervention.
88914951|NCT01612091|Experimental|Monitoring Messenger|
88914952|NCT01612091|Active Comparator|Control|Traditional tools (monitors, paper records)
89198087|NCT02560740|Experimental|PerOx Arm|PerOx Quench arm 4g/sachet each time by water, q6h
89198088|NCT02560740|Placebo Comparator|Comparative Arm|PerOx Quench placebo 4g/sachet each time by water, q6h
89010007|NCT04561843||case group|Women complaining of any of the pelvic floor disorder symptoms such as: Pelvic organ prolapse (POP), Stress urinary incontinence (SUI), urgency symptoms of obstructed defecation, fecal incontinence (FI), pelvic pain, and/or sexual problems.
89010008|NCT04561843||control group|Women not complaining of any of the pelvic floor disorder symptoms
89010009|NCT04561960|Active Comparator|Control|"Participants will be trained to perform oral hygiene using the modified bass technique.~The participants will be asked to brush their teeth twice daily using a manual tooth brush and fluoridated toothpaste containing 1450ppm of fluoride"
89010010|NCT04561960|Experimental|Miswak|Participants will be trained to chew and condition a miswak stick Participants will be asked to use the miswak stick twice daily
89198089|NCT04049838|Active Comparator|lateral transversus abdominis block|patients will take lateral transversus abdominis plan block. The block will be done unilaterally on the same side of proposed surery with 0.25% bupivacaine at a volume of 1 ml·kg-1
89010011|NCT04561960|Experimental|Miswak Paste|"Participants will be trained to perform oral hygiene using the modified bass technique.~The participants will be asked to brush their teeth twice daily using a manual tooth brush a non-fluoridated toothpaste containing miswak extract"
89198090|NCT04049838|Active Comparator|posterior tansversus abodominis plane block|patients will take posterior transversus abdominis plane block. The block will be done unilaterally on the same side of proposed surery with 0.25% bupivacaine at a volume of 1 ml·kg-1
89198091|NCT04049838|Active Comparator|convential analgesia|conventional analgesia in form of 1 micrograms. Kg-1 fentanyl and paracetamol 15 mg. Kg-1 suppositories
89198092|NCT00753324|Experimental|Routine three-drug antiretroviral prophyalxis|Cohort of 160 HIV-infected women, approached at > 28 weeks gestation and initiated on routine HAART for the purposes of PMTCT.
89198093|NCT00753324|No Intervention|Control arm|A cohort of 160 women will be enrolled from the control clinics, from 28 weeks gestation onward. At these sites, the antenatal zidovudine will be offered, with provision of single-dose nevirapine for self-administration in labor. This practice is in accordance with the current standard of care recommended by the Zambian National Guidelines for PMTCT.
89198094|NCT00757926|Experimental|1|
89198095|NCT00757926|Placebo Comparator|2|
89198096|NCT02561520|Experimental|PRP and PPP|PRP eye drops and PPP eye drops will be prepared from patient's own blood by Magellan technology. Patients will receive eye drops in sterile amber glass droppers. Patients will be instructed to keep refrigerated each bottle after opening for 7 days and keep frozen the unopened bottles up to 30 days.
89198097|NCT00387127|Experimental|Lapatinib|1500mg lapatinib orally daily
89198098|NCT00387127|Placebo Comparator|Placebo|orally daily
89198099|NCT00683592|Experimental|1|vilazodone
89198100|NCT00683592|Placebo Comparator|2|
89198101|NCT00695396|Experimental|001|Epoetin alfa 40 000 IU subcutaneously once every week (1 mL dose) for 48 weeks
89198102|NCT00695396|Experimental|002|Epoetin alfa 80 000 IU subcutaneously once every week (2 mL dose) for 48 weeks
89198103|NCT00695396|Placebo Comparator|003|Placebo Matching volume 1 mL for 48 weeks
89198104|NCT00695396|Placebo Comparator|004|Placebo Matching volume 2 mLfor 48 weeks
89198105|NCT00753402|Placebo Comparator|A|IV Endotoxin plus saline vehicle (placebo)
89198106|NCT00753402|Active Comparator|B|IV Endotoxin plus IV epinephrine
89198107|NCT05434884|Experimental|OV group|Patients will receive occlusal veneer restorations
89198108|NCT05434884|Experimental|EN group|Patients will receive endocrown restorations
89198109|NCT00758004|Other|Reference|Commercial 80 mg atorvastatin tablet
89198110|NCT00758004|Other|Test|Pediatric appropriate atorvastatin 40mg formulation
89198111|NCT02656706|Experimental|Adjuvant treatment|Ipilumumab:1mg/kg q6weeks (1 dose per cycle, 4 planned treatments over 6 months total) Nivolumab:3mg/kg q2weeks (3 doses per cycle, 12 planned treatments over 6 months total)
89198112|NCT00758082|Active Comparator|1|Patients will have face to face visits at 3 months and no PDA-phone. Patients will record glycemia on paper support
89198113|NCT00758082|Experimental|2|PDA-phone + phone consultations + standard visit at 3 months
89198114|NCT04049916|Active Comparator|Pyronaridine-artesunate (PA)|Subjects will receive pyronaridine-artesunate (PA) once daily for 3 days.
89198115|NCT04049916|Experimental|PA with single low dose primaquine (PQ)|Subjects will receive pyronaridine-artesunate (PA) once daily for 3 days, and a low dose of primaquine (PQ) on the first dat of treatment. PQ dose is at the World Health Organization (WHO) recommended dose of 0.25 mg/kg.
89198116|NCT04049916|Active Comparator|Dihydroartemisinin-piperaquine (DP)|Subjects will receive dihydroartemisinin-piperaquine (DP) once daily for 3 days.
89198117|NCT04049916|Active Comparator|DP with single low dose primaquine (PQ)|Subjects will receive dihydroartemisinin-piperaquine (DP) once daily for 3 days., and a low dose of primaquine (PQ) on the first dat of treatment. PQ dose is at the World Health Organization (WHO) recommended dose of 0.25 mg/kg.
89198118|NCT00753558|Placebo Comparator|2|Oral solution of 0.45% saline and oral solution of H2O & saccharine. Oral gel composed of mineral oil, gelatine powder, pectin, sodium carboxymethylcellulose, polyethylene
89198119|NCT00753558|Active Comparator|1|Oral solution and buccal gel of gentamicin and polymyxin E
89198120|NCT02561208|Active Comparator|mHealth Intervention Group|Women with HPV self-collected tests will receive a mixed intervention which includes counseling through an interactive Apps and SMS text messages.
89198121|NCT02561208|No Intervention|Usual Care Group|Women with HPV self-collected tests receive usual care.
89198122|NCT02559960||Breviscapine Powder-Injection|Breviscapine Powder-Injection will be given to the patients, and the investigators will record all the information including ADR, application of Breviscapine Powder-Injection and the combined medications, etc.
89198123|NCT00921596|Other|Totally endoscopic cardiac operation|Patients with cardiac diseases undergo cardiac operations with totally endoscopic and cardiopulmonary bypass
89198124|NCT03625544|Experimental|MagnetOs™ Granules|MagnetOs™ Granules
89198125|NCT03625544|Active Comparator|Autograft|Autologous bone graft
89198126|NCT00575328|Experimental|Maca Root|Subjects in this arm will be given 3g/day of Maca Root.
89198127|NCT00575328|Placebo Comparator|Placebo|Subjects in this arm will receive inactive placebo.
89198128|NCT00753792|Active Comparator|1|methylprednisolone 1.000 mg/day intravenous administration during three days + placebo of methylprednisolone orally administered
89198129|NCT00753792|Experimental|2|methylprednisolone 1.250 mg/day orally administered during three days + placebo of methylprednisolone intravenous administered
89434513|NCT05440708|Experimental|Cohort C: TTI-101 in Combination with Atezolizumab and Bevacizumab|"Cohort C Phase 1b: Participants will receive up to 3 dose levels of TTI-101 in combination with atezolizumab and bevacizumab to determine the RP2D.~Cohort C Phase 2: Enrollment in Phase 2 may commence with approval from the safety review committee. Participants will be enrolled and treated at the RP2D of TTI-101 in combination with atezolizumab and bevacizumab."
89434514|NCT05439616|Experimental|Cariprazine|Participants will receive age-and weight dependent flexible doses of cariprazine once daily for 8-weeks.
88914953|NCT01612104|Experimental|Psychological First Aid|Psychological material developed for children and adolescents, based on cognitive behavioral theory, used to structure therapeutic conversations and/or for self-help.
88914954|NCT01612117||consecutive, PCP patients|All patients requiring percutaneous coronary procedures, such as coronary angiography or intervention
88914955|NCT01612130|Experimental|Valeriana officinalis L (100mg)|100 mg of Valeriana officinalis L. (Valerian)
88914956|NCT01612130|Placebo Comparator|Placebo (100 mg)|Placebo 100mg
89198130|NCT05434494|Active Comparator|remifentanil group|"Start the continuous infusion of 25cc of remifantanil (labeled as a test drug) by TCI mode ( the target effect site concentration is 2.0).~While slowly injecting the prescribed dose of remimazolam over 30 seconds, observe whether it responds to the investigator's oral commands and the disappearance of the eyelash reflex for 3 minutes after administering the drug. Success in inducing loss of consciousness during anesthesia is defined as the loss of both verbal command response and eyelash reflex within 3 minutes after infusion, otherwise it is considered a failure.~The dose of remimazolam is initially 0.15 mg/kg and the next experimental dose is determined according to the biased coin design up-and-down sequential method. The standard deviation of this study is 0.05 mg."
89198131|NCT05434494|Placebo Comparator|control group|"Start the continuous infusion of 25cc of normal saline (labeled as a test drug).~While slowly injecting the prescribed dose of remimazolam over 30 seconds, observe whether it responds to the investigator's oral commands and the disappearance of the eyelash reflex for 3 minutes after administering the drug. Success in inducing loss of consciousness during anesthesia is defined as the loss of both verbal command response and eyelash reflex within 3 minutes after infusion, otherwise it is considered a failure.~The dose of remimazolam is initially 0.15 mg/kg and the next experimental dose is determined according to the biased coin design up-and-down sequential method. The standard deviation of this study is 0.05 mg."
89198132|NCT05433792|Experimental|Myolens CN|Subjects' will be allocated to Myolens CN study arm in a 1:1:1 ratio.
89198133|NCT05433792|Experimental|Myolens CF|Subjects' will be allocated to Myolens CF study arm in a 1:1:1 ratio.
89198134|NCT05433792|Active Comparator|MiSight®|Subjects' will be allocated to MiSight® study arm in a 1:1:1 ratio.
89198135|NCT00753870|Experimental|A|Otherwise healthy smokers
89198136|NCT00553696|Experimental|A|
89198137|NCT00553540|No Intervention|Control Group|Patients in this group will receive physical therapy and posture education for low back pain
89198138|NCT00553540|Active Comparator|Test Group|Patients in this group will receive spinal / back supports in addition to physical therapy and posture education for low back pain
89198139|NCT02559804||patients NB with SCI|Survival and late effects. Diagnosis of peripheral neuroblastic tumour - peripheral neuroblastic tumour (neuroblastoma, ganglioneuroblastoma, ganglioneuroma) presenting with SCI, symptomatic or asymptomatic, independent of disease extension (stage), and clinical course (first diagnosis or relapse/progression).
89198140|NCT00958204|Experimental|1|Light treatment using a fluorescent light box (30 minutes daily) plus a placebo pill every day
89198141|NCT00958204|Experimental|2|Negative ion generator (30 minutes daily) plus 20 mg of fluoxetine per day
89198142|NCT00958204|Active Comparator|3|Light treatment using a fluorescent light box (30 minutes daily) plus 20 mg of fluoxetine per day
89198143|NCT00958204|Placebo Comparator|4|Negative ion generator (30 minutes daily) plus placebo pill every day
89198144|NCT00754026|Active Comparator|1|
89198145|NCT00754026|Active Comparator|2|
89198146|NCT00617409|Active Comparator|Standard of Care|Arm A - Active Comparator: Observation (Standard of Care) + Second Line Chemotherapy
89198147|NCT00617409|Experimental|Ad.p53-DC Vaccines|Arm B - Experimental: Ad.p53-DC vaccines + Second Line Chemotherapy
89198148|NCT00617409|Experimental|Ad.p53-DC Vaccines + ATRA|Arm C - Experimental: Ad.p53-DC vaccines + All -trans Retinoic Acid (ATRA) + Second Line Chemotherapy
89198149|NCT00695318|Experimental|A, 2, I 0.2 µg/Day + Sham|0.2 µg/Day
89198150|NCT00695318|Experimental|A, 2, II 0.5 µg/Day + Sham|0.5 µg/Day
89198151|NCT00754104|Experimental|A|
89198152|NCT00386425|Experimental|Standard therapy|24 microgram/kilogram/hour (mcg/kg/hr) for 24 hours, followed by 24 mcg/kg/hr for an additional 72 hours
89198153|NCT00386425|Experimental|Alternative therapy:moderate protein C deficiency|24 mcg/kg/hr for 24 hours, followed by 24 mcg/kg/hr for an additional 48 to 144 hours (original protocol) or an additional 72 to 144 hours (amended protocol)
89198154|NCT00386425|Experimental|Alternative therapy:severe protein C deficiency|24 mcg/kg/hr for 24 hours, followed by 30 or 36 mcg/kg/hr for 48 to 144 hours (original protocol) or an additional 72 to 144 hours (amended protocol)
89198155|NCT05300230||Patients with Zti Opticon Cochlear Implant|Patients that are users of Neuro Zti and Neuro 2 processor with a minimum of 6 months of habituation after the implementation.
89198156|NCT00758238|Experimental|myBP intervention|participants will receive access to hypertension self-management tools and support via a personal patient electronic health record
89198157|NCT00758238|No Intervention|usual care|participants allocated to usual care may still opt to use the personal patient electronic health record, but will not have access to the hypertension self-management tools until after the intervention period. The usual care group will be given a web-link for patient hypertension management resources
88914957|NCT01612143|Active Comparator|A: STV capsule (after high fat meal)|
88914958|NCT01612143|Active Comparator|B: STV capsule (fasted state)|
88914959|NCT01612143|Experimental|C: STV tablet (after high fat meal)|
88914960|NCT01612143|Experimental|D: STV tablet (fasted state)|
89010012|NCT04561804||LISESTYLE INTERVENTION|LOW CARB LOW GLYCEMIC LOAS DIET
89010013|NCT04561804||WEGHT LOSS SURGERY|SLEEVE OR MINBYPASS SURGERY
89198158|NCT05352412|Active Comparator|Baseline Counseling As Usual|Patients randomized to the baseline counseling as usual arm will receive provision of one of 3 MAT options, prescription and referral to community providers; overdose prevention education and access to naloxone kits; harm reduction counseling (e.g safe injection practices, referral to PrEP); lab testing for HIV, HBV, HCV infection, and routine vaccinations (e.g. Hepatitis A). That includes wrap-around services modeled on the Ryan White Program, with access to social worker, case manager, and mental health counselor who follow up with patients, enroll them in insurance as eligible, and provide ongoing support. This will be a 10-minute tablet- or web-based intervention administered by one of our wraparound care service team members in-person or via telehealth (or possibly in person depending on pandemic procedures). IT will be a 10-minute procedure with summary of decision considerations and patient value assessment.
89010014|NCT04561921|Experimental|megnesium sulphate|Injection of 1.8 mL of an anaesthetic solution containing 1% magnesium sulphate , and 1.8% mepivacaine HCL with .06mg Levonordefrin HCl during inferior alveolar nerve block.
89198159|NCT05352412|Active Comparator|Shared Decision Making Aid|Patients randomized to the decision aid arm will receive all of the above as well as a shared decision making aid. This will be a 10-minute tablet- or web-based intervention administered by one of our wraparound care service team members in-person or via telehealth (or possibly in person depending on pandemic procedures). IT will be a 10-minute procedure with summary of decision considerations and patient value assessment.The provider will have access to then have access to this summary in making final care decisions with the patient.
89198160|NCT00859365|Experimental|Acupuncture|Real Acupuncture
89198161|NCT00859365|Placebo Comparator|2 Placebo acupuncture|
89536396|NCT03118453|Active Comparator|Passive implementation clinics|Patients recruited by physical therapists who underwent an implementation period with passive implementations strategies, such as written material and a short web lecture. A behavioral medicine approach in physical therapy for patients with musculoskeletal pain was encouraged with these passive implementation strategies
89536397|NCT02477579|Experimental|NovaCross|NovaCross microcatheter will be used.
89536398|NCT04484779|Experimental|IIM System|The IIM system is comprised of an insulin lispro pen and/or an insulin glargine pen (both U-100), an investigational mobile medical application (MMA) that transmits data to cloud storage, an investigational Bluetooth Low Energy® (BLE)-paired insulin data transmission (IDT) module and a compatible commercially available BLE-paired blood glucose meter (BGM).
89198162|NCT00859365|No Intervention|3 No treatment|No treatment performed
89198163|NCT02544477|Experimental|High-flow nasal cannula oxygen (HFNCO)|Patients will receive HFNCO treatment with a gas flow level = 50 L/min and a FiO2 set to maintain peripheral oxygen saturation (SpO2) of 92% - 98%.
89198164|NCT02544477|Active Comparator|standard oxygen therapy|Patients will receive oxygen treatment by means of a conventional face mask, with a level of fraction of inspired oxygen (FiO2) set to maintain peripheral oxygen saturation (SpO2) of 92% - 98%.
89198165|NCT00949000|Other|ICD Implant|Implantation of a commercially available AnalyST or AnalyST Accel ICD
89198166|NCT03993145|Experimental|Web-based lifestyle intervention|participants will be provided access to web-based lifestyle intervention program with personalized coaching from a clinical dietician
89198167|NCT00859599|Active Comparator|1|"At the study start, the patient will be given a subject number according to a fixed randomisation list. The investigator/study nurse will be instructed to log in at the Biolight® website to get the patient-number and treatment code, with the information which treatment model (i.e. marked A & B, E & F, X & Y) the randomised patient shall receive.~Up to 44 monochromatic Phototherapy treatment sessions (Biolight® or placebo) will be given, additional to standard care treatment. The treatment session schedule compromise of three times weekly during the first four weeks and twice weekly during the following weeks or until the ulcer is completely healed."
89198168|NCT00859599|Placebo Comparator|2|"At the study start, the patient will be given a subject number according to a fixed randomisation list. The investigator/study nurse will be instructed to log in at the Biolight® website to get the patient-number and treatment code, with the information which treatment model (i.e. marked A & B, E & F, X & Y) the randomised patient shall receive.~Up to 44 monochromatic Phototherapy treatment sessions (Biolight® or placebo) will be given, additional to standard care treatment. The treatment session schedule compromise of three times weekly during the first four weeks and twice weekly during the following weeks or until the ulcer is completely healed."
89198169|NCT00694304|Experimental|Vortioxetine|
89198170|NCT05352334|Experimental|High Intensity Interval Training|
89198171|NCT05352334|Experimental|Aerobic Exercise|
89198172|NCT00371839|Active Comparator|Mild Hearing Loss|Audiological Evaluation will show average hearing threshold at 500, 1000, 2000, and 4000 Hz of 20-39 decibels hearing level (dBHL)
89198173|NCT00371839|Active Comparator|Moderate Hearing Loss|Audiological Evaluation will show average hearing threshold at 500, 1000, 2000, and 4000 Hz of 40-49 decibels hearing level (dBHL)
89434515|NCT05439616|Placebo Comparator|Placebo|Participants will receive placebo once daily for 8-weeks.
89434516|NCT05433454|Experimental|Outreach via Postcard|40 percent of the sample
89198174|NCT00371839|Active Comparator|Moderate-Severe Hearing Loss|Audiological Evaluation will show average hearing threshold at 500, 1000, 2000, and 4000 Hz greater than 50 decibels hearing level (dBHL)
89198175|NCT05386836|Experimental|Healthy adult volunteers|All subjects within this single arm of the study will undergo the validation experiment as described in the description
89434517|NCT05433454|Experimental|Outreach via Postcard + Outbound Call|Outreach via postcard, plus placed an outbound phone call from navigators (20% of sample)
89434518|NCT05433454|Experimental|Outreach via Text Message Encouraging Call to Hotline|Outreach via text message encouraging a call to a hotline for assistance (15% of sample)
88914961|NCT01612169|No Intervention|Treatment as Usual (TAU) Group|"Participants assigned to the TAU group will receive the standard treatment provided at each hospital for linking patients to HIV and substance use care.~During the formal site selection process, a thorough assessment will be conducted of each site's standard practice for linkage to HIV care and substance use treatment. Throughout the course of the trial, hospital sites will be monitored for any potential changes that might occur in standard practice around linkage to HIV care and substance use treatment."
89434519|NCT05433454|Experimental|Outreach via Text Message Encouraging Call to Hotline + Outbound Call|Outreach via text message encouraging a call to a hotline for assistance, plus outbound phone call from navigators (7.5% of sample)
89434520|NCT05433454|Experimental|Outreach via Text Message Encouraging Text Reply To Connect with Navigators|Outreach via text message encouraging a text reply to connect with navigators via chatbot (15% of sample)
89434521|NCT05433454|Experimental|Outreach via Text Message Encouraging Text Reply To Connect with Navigators + Outbound Call|Outreach via text message encouraging a text reply to connect with navigators via chatbot, plus an outbound phone call from navigators (7.5% of sample)
89434522|NCT05433454|Experimental|Outreach via Text Message Encouraging a Call to a Hotline for Assistance + a Reminder Message|Outreach via text message encouraging a call to a hotline for assistance plus a similar reminder message two weeks later (15% of sample)
89434523|NCT05433454|Experimental|Outreach Text Message Encouraging Call a Hotline for Assistance + Reminder Message|Outreach via text message encouraging a call to a hotline for assistance plus a similar reminder message two weeks later + outbound call (7.5% of sample)
89434524|NCT05433454|Experimental|Outreach via Text Message Encouraging Text Reply To Connect with Navigators+ a Reminder Message|Outreach via text message encouraging a text reply to connect with navigators via chatbot plus a similar reminder message two weeks later (15% of sample)
88914962|NCT01612169|Experimental|Patient Navigation (PN) Group|"The patient navigator approach includes five functions: 1) establishing an effective working relationship; 2) encouraging identification and use of strengths, abilities and assets; 3) supporting client control over goal setting and the search for needed resources; 4) viewing the community as a resource and identifying informal sources of support; and 5) conducting case management as an active community based activity.~After the initial four meetings, patient navigators will meet with PN group participants ideally twice monthly during months 2 and 3 and once monthly during months 4 - 6."
88914963|NCT01612169|Experimental|Patient Navigator Plus Contingency Management (PN+CM) Group|"Study participants randomized to this group will receive the patient navigation (PN) intervention as outlined above combined with contingency management (CM). Using the principles of contingency management, this combined intervention will incorporate viral load suppression as a target of reinforcement as well as several other behaviors (HIV clinical care, medication adherence, cessation or reduction of substance use) that are hypothesized to be moderators or mediators of the primary outcome.~For participants randomly assigned to the PN+CM study group, patient navigators will: 1) effectively communicate the incentive plan to the participant, 2) track each of the seven target behaviors that may earn participant incentives, 3) verify occurrence of the target behaviors, 4) deliver incentives according to the protocol, and 5) maintain a record of incentives delivered. PNs will use a computer-based tracking program to facilitate this work."
88914964|NCT01612182||ESBL(+) Klebsiella pneumonia|All the patient who's the culture result showed ESBL(+) Klebsiella pneumonia in any site during hospitalization
89434525|NCT05433454|Experimental|Outreach via Text Message Encouraging Reply To Connect with Navigators + Reminder Message|Outreach via text message encouraging a text reply to connect with navigators via chatbot plus a similar reminder message two weeks later + outbound call (7.5% of sample)
88914965|NCT01612182||ESBL(-) Klebsiella pneumonia|All the patient who's the culture result showed ESBL(-) Klebsiella pneumonia in any site during hospitalization
88914966|NCT01612195|Experimental|Anal fistula plug|
88914967|NCT01612208||Distal femur fractures|(AO/OTA types 33-A and 33-C)
88914968|NCT01612234|Experimental|High palmitate or high oleate diet.|This is a solid food diet in which vegetable oils are used to create a dietary fat composition similar to the average American/Western diet in which palmitic and oleic acid are ingested in approximately equal amounts (high palmitate diet) or a composition similar to the Mediterranean Diet (low palmitate, high oleate, using hazelnut oil as the source of fat). There are no interventions other than the diet itself.
88914969|NCT01612234|Experimental|high palmitate or high oleate diet|This is a solid food diet in which vegetable oils are used to create a dietary fat composition similar to the average American/Western diet in which palmitic and oleic acid are ingested in approximately equal amounts (high palmitate diet) or a composition similar to the Mediterranean Diet (low palmitate, high oleate, using hazelnut oil as the source of fat). There are no interventions other than the diet itself.
88914970|NCT01612260|Experimental|Shensong Yangxin capsule|Shensong Yangxin capsule 4 granules t.i.d. po for 12weeks
88914971|NCT01612260|Placebo Comparator|placebo Capsule|placebo Capsule 4 granules t.i.d. po for 12weeks
88914972|NCT01612273|Experimental|Disgren|Dose: 300mg bid, Mode of administration: oral, Duration: from randomization to 6 week, crossover-design.
88914973|NCT01612273|Experimental|Aspirin|Dose: 150mg bid, Mode of administration: oral, from randomization to 6weeks, crossover-design.
88914974|NCT01612286|Experimental|endostatin|chemotherapy concurrently with endostatin
88914975|NCT01612299|Active Comparator|Standard Immunosuppression|Tacrolimus + Myfortic®/Cellcept + Corticosteroids
88914976|NCT01612299|Experimental|Zortress®|Tacrolimus + Zortress® + Corticosteroids
88914977|NCT01612312|Active Comparator|Thrombectomy|
88914978|NCT01612312|Other|Standard percutaneous coronary intervention|In the standard percutaneous coronary intervention (PCI) group, patients will be treated by conventional PCI according to local practice without thrombectomy.
88914979|NCT01612325|Experimental|Holmium-166 MS radioembolization|Single radioembolization met Holmium-166 polylactic microspheres administered
88914980|NCT01612338|Experimental|Targeted|Targeted letter and booklet
88914981|NCT01612338|Experimental|Tailored|Tailored letter and booklet, enhanced family communication and support brochure
88914982|NCT01612364|Experimental|thoracic sympathetic block|Sympathetic block of upper limb via thoracic vertebra T3
89434526|NCT05431387|Placebo Comparator|Placebo + Behavioral Support|one placebo tablet orally (PO) three times daily (TID) plus behavioral support for 12 weeks
89434527|NCT05431387|Experimental|Cytisinicline + Behavioral Support|one cytisinicline tablet PO TID plus behavioral support for 12 weeks
89434528|NCT05425667|Experimental|Experimental|sensory integration training exercise for improving balance and walking ability of patients with lumbar stenosis and neurological claudication.
89434529|NCT05418491||Partially hydrolyzed protein Infant formula|Originating from A.R.T. cohort.
89434530|NCT05418491||Standard infant formula|Originating from A.R.T. cohort.
89434531|NCT05418491||Exclusively breastfed infants|Originating from A.R.T. cohort.
89434532|NCT05416476|Experimental|Anisodine Hydrobromide|Participants in this group took oral Anisodine Hydrobromide tablets 1 mg bid for 12 consecutive weeks and were followed up for 12 weeks.
89434533|NCT05416476|Placebo Comparator|Anisodine Hydrobromide Placebo|Participants in this group took oral Anisodine Hydrobromide placebo tablets 1 mg bid for 12 consecutive weeks and were followed up for 12 weeks.
89434534|NCT05413304|Experimental|1/Abemaciclib and microdialysis monitoring|Abemaciclib orally BID for 4.5 days followed by resection or biopsy and microdialysis catheter placement with continuous monitoring for 48 hours post-operative and genomic sampling of tissue/blood; followed by abemaciclib+temozolomide maintenance therapy
88914983|NCT01612364|Active Comparator|control block|Same medication used in experimental group, but in dorsal subcutaneous
88914984|NCT01612377|Experimental|prednisolone-dipyridamole|
88914985|NCT01612377|Active Comparator|prednisone 5mg|
88914986|NCT01612377|Active Comparator|prednisone 7.5mg|
88914987|NCT01612390||group 1|receive 400 Mg sublingual misoprostol.
88914988|NCT01612390||group 2|receive 600 Mg sublingual misoprostol.
88914989|NCT01612390||group 3|receive 5IU of intravenous oxytocin.
88914990|NCT01612403||Single group|Single group: all participants receive same intervention throughout study (Non-randomised)
88914991|NCT01612416|Sham Comparator|Normal subjects|
88914992|NCT01612416|Active Comparator|Primary open angle glaucoma|
88914993|NCT01612416|Active Comparator|Normal tension glaucoma|
88914994|NCT01612429|Experimental|Amino acid supplementation|Up to 500 mL of 5.4% amino acid solution (NephrAmine) by intravenous infusion 3 x weekly for 6 weeks.
88914995|NCT01612442|Experimental|Integrated education|
88914996|NCT01612442|No Intervention|Control|
88914997|NCT01612442|Experimental|Nutrition education|
88914998|NCT01612455|No Intervention|Standard of Care|Control participants will receive the narcology hospital's standard of care. With regard to linkage to HIV medical care, patients will be given printed information about where to obtain HIV medical care - the outpatient clinic that is involved in the intervention. Control patients will be referred to outpatient narcology care as part of standard of care. If control participants are newly diagnosed with HIV infection at the addiction hospital, they will receive HIV post test counseling consistent with CDC recommendations (this represents an enhancement of the current standard of care in Russia).
88914999|NCT01612455|Experimental|LINC Case Management (Intervention)|LINC Case Management (study Intervention) - see Intervention description
88915000|NCT01612468|Experimental|Liraglutide|
88915001|NCT01612468|Placebo Comparator|Placebo|
88915002|NCT01612481|Active Comparator|chest radiography|clinical exam + chest radiography every 3 months during 2 years and every 6 months during 1 year
88915003|NCT01612481|Active Comparator|chest CT|clinical exam + Chest CT every 3 months during 2 years and every 6 months during 1 year
88915004|NCT01612507|Experimental|A|600 mg Ceftaroline fosamil 1 h infusion
88915005|NCT01612507|Experimental|B|Placebo 1 h infusion
88915006|NCT01612507|Experimental|C|600 mg Ceftaroline fosamil 2 h infusion
88915007|NCT01612507|Experimental|D|Placebo 2 h infusion
88915008|NCT01612520|Active Comparator|telecoaching|
89434535|NCT05412368||Children and young people (CYP)|Children and young people who have been referred to CAMHS
89434536|NCT05412368||Parents/carers|Parents/carers of CYP who have been referred to CAMHS
89434537|NCT05412368||Key referrers|Key referrers (e.g. Teachers, GPs, SENCOs, Social Workers) who have referred CYP to CAMHS
89434538|NCT05412368||CAMHS Professionals|CAMHS Professionals who have received referrals to CAMHS
88915009|NCT01612520|No Intervention|control|
88915010|NCT01612598|Experimental|Supportive Care (PCI)|"PCI PART I: Patients undergo comprehensive PC assessment based on baseline data and complete goals of care discussion.~PCI PART II: Following the first dose of phase I investigational treatment, patients meet with the IDT, where PC recommendations are made. This is followed by two patient educational sessions that will cover QOL-related domains, including physical, social, emotional, and spiritual well-being. Supportive care referrals are made based on IDT recommendations."
88915011|NCT01612611||a cohort using Shenmai injection|
88915012|NCT01612637|Experimental|Group 1|Group 1 will be individually examined and instructed in pelvic floor muscle training before the intervention starts by specialized physiotherapists. The examination includes a vaginal or an anal examination. The women attend six group sessions within 12 weeks containing structured information about POP and the possible affection of POP on quality of life, exercising and sexual relationship. The lifestyle advice contains information about life style changes that could improve POP symptoms, such as bladder and bowel habits, coughing, heavy lifting, eating habits and weight loss. The women will perform pelvic floor muscle training in the group and they will perform pelvic floor muscle training at home. The training will be individually planned according to the findings of the pelvic floor physiotherapist. The women in the intervention group fill in an exercise diary and also describe on a Visual Analog Scale if the training causes any bother.
88915013|NCT01612637|Active Comparator|Group 2|Group 2 attend six group sessions within 12 weeks containing structured information about POP and the possible affection of POP on quality of life, exercising and sexual relationship. The lifestyle advice contains information about life style changes that could improve POP symptoms, such as bladder and bowel habits, coughing, heavy lifting, eating habits and weight loss
88915014|NCT01612650|Active Comparator|breast cancer histologically proven|Patient with breast cancer histologically proven, addressed to Oscar Lambret Center for treatment
88915015|NCT01612650|Active Comparator|surveillance of a treated breast cancer|surveillance of patient already treated for breast cancer must have annual mammography
88915016|NCT01612650|Active Comparator|diagnosis of a detected anomaly|patient addressed for diagnosis of a detected anomaly
88915017|NCT01612689|Experimental|Physiologic Data Collection|
89434539|NCT05406791|Experimental|Sensor-enabled digital mental health intervention (DMHI)|"Patients randomized to sensor-enabled DMHI condition will use Ksana Health's Vira mobile therapy platform with support from a study coach"
89434540|NCT05406791|Experimental|Experimental: Control Treatment (CT)|Participants randomized to the CT condition will use a Mood Education App designed by researchers at the University of Virginia to deliver psychoeducational content to help people self-manage symptoms of depression, anxiety, and stress.
89434541|NCT05403320|Experimental|AnapnoGuard group|Patients intubated with AnapnoGuard endotracheal tube (polyvinylchloride tube with ellipsoidal shape, thin wall polyurethane cuff with dual suction lines and an extra venting line) which is connected to AnapnoGuard 100 System
89434542|NCT05403320|Active Comparator|Control group|Patients intubated with TaperGuard Evac endotracheal tube (polyvinylchloride conic cuff with additional lumen for subglottic secretion suctioning)
89434543|NCT05401851|Other|Body surface mapping|With the Insite Vest, activation of the epicardium will be performed.
89434544|NCT05401643|Experimental|mHealth intervention|Installation of the mHealth application Xemio in the participant's smartphones. Voluntary use of the application for 12 months. Outcome measures collected every 3 months.
89434545|NCT05401643|No Intervention|Control|No application installed. Outcome measures collected every 3 months.
89434546|NCT05399667||Early stimulation|Skin-to skin care by mother, kangaroo care, breastfeeding policy plus massage therapy are made by the mothers until hospital discharge. After discharge, they receive standard follow up care plus orientation for a continuous global simulation at home (total of 10 home visits independently of the standard evaluation and care that will be performed; visits promoting guidance and supervision sessions).
89434547|NCT05399667||Conventional care|Standard care according to the routine care of the Neonatal Intensive Care Unit (NICU) (skin-to skin care by mother, kangaroo care, and breast feeding policy) and their needs in the follow up program (motor, and cognition evaluations and interventions).
89434548|NCT05399667||Control group|Term born children to obtain reference values for the variables evaluated in the present study.
89434549|NCT05398783||Healthy Volunteers|Male and female volunteers aged 10+ years in good general health as evidenced by medical history
89434550|NCT05398783||Patients|Male and female patients aged 10+ years diagnosed with diseases thought to alter metabolism or body composition and/or taking medication thought to alter metabolism or body composition
89434551|NCT05396079|Experimental|Tahini and bread|"After an overnight fast (10-12 h), participants will come tο the lab and, after a 10-min resting period in the supine position in a quiet room with temperature a constant 20-25 °C, assessment of blood pressure, pulse rate, hemodynamic parameters, and endothelial function will be performed.~Then, an intravenous cannula will be inserted into a forearm vein and a baseline blood sample will be collected (time 0) as well as urine sample will be also collected. Afterward, each patient will consume 2 slices of white bread with 50 g of tahini and collection of the blood and urine sample will be repeated 1,2, 3 and 4 h postprandially. Assessment of blood pressure, pulse rate, hemodynamic parameters, and endothelial function will be also repeated at the end of the trial. During the trial, patients will not be allowed to eat or drink anything apart from water."
89434552|NCT05396079|Experimental|Margarine, cheese and bread|"After an overnight fast (10-12 h), participants will come tο the lab and, after a 10-min resting period in the supine position in a quiet room with temperature a constant 20-25 °C, assessment of blood pressure, pulse rate, hemodynamic parameters, and endothelial function will be performed.~Then, an intravenous cannula will be inserted into a forearm vein and a baseline blood sample will be collected (time 0) as well as urine sample will be also collected. Afterward, each patient will consume 2 slices of white bread with 46 g of margarine and 38 g of lowfat cheese and collection of the blood and urine sample will be repeated 1,2, 3 and 4 h postprandially. Assessment of blood pressure, pulse rate, hemodynamic parameters, and endothelial function will be also repeated at the end of the trial. During the trial, patients will not be allowed to eat or drink anything apart from water."
89434553|NCT05394025||Veterans who tested positive for COVID-19 (case)|"The investigators will organize the sampling of cases (and later of comparators) around the waves of the epidemic, as defined by their nadirs between national death rates-each approximately 3-4 months long. The investigators will initiate surveys of Veterans who have survived their initial SARS-CoV-2 infection. The viral infection index date will be defined as date of each patient's first positive test."
89010015|NCT04561921|Active Comparator|mepivacaine HCl|Injection of 1.8 mL of a local anaesthetic solution containing 1.8% mepivacaine HCL with .06mg Levonordefrin HCL during inferior alveolar nerve block
89010016|NCT04561882|Experimental|Transcatheter exclusion of atrial septal aneurysm|Transcatheter reconstruction of atrial septum might be achieved with PFO occluder through transseptal perforation in patients with ASA.
89434554|NCT05394025||Veterans who did not test positive for COVID-19 (comparator)|To support causal inference, the investigators will also sample Veterans without COVID who are matched to participants with COVID-19. In general, cases will be compared to comparators matched on risk of developing COVID infection during a given wave.
89434555|NCT05392010||ventilated critically ill patients|All consecutive adult patients (≥ 18 years old) who are admitted to the ICU and require invasive mechanical ventilation (endotracheal tube or tracheostomy) longer than 12 hours. 2. Adult patients admitted to the ICU and require advanced respiratory support (high flow oxygen nasal cannula [HFONC], or noninvasive ventilation [NIV] BIPAP or CPAP with oronasal, nasal, helmet or facial mask) with acute respiratory failure defined as PaO2/ fraction of inspired oxygen (FiO2), [PaO2/FiO2] ratio <300, or the pulse oximetric saturation (SpO2/FiO2 ) ratio < 315 for more than 1 hour.
89434556|NCT05391750|Experimental|Treatment (venetoclax, tocilizumab)|Patients receive tocilizumab IV on day -7 of cycle 1, and on day 1 of subsequent cycles. Patients also receive venetoclax PO on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89434557|NCT05390307|Experimental|GLP1RA alone|Participants in the GLP1RA will be prescribed either Liraglutide 3.0mg or Semaglutide 1.0mg, whichever is licensed and available locally. The dose and titration will follow the usual clinical practice. The treatment will continue for 6 months.
89434558|NCT05390307|Experimental|SGLT2i alone|Participants in the SGLT2i group will be prescribed dapagliflozin 5-10mg once daily for 6 months.
89434559|NCT05390307|Experimental|GLP1RA/SGLT2i combination|Participants in the combination GLP1RA and SGLT2i group will be prescribed liraglutide 3mg once daily or semaglutide1mg once weekly subcutaneous injection plus dapagliflozin 5-10mg for 6 months.
88915018|NCT01612715||Study Population|Mild asthma, cat-allergic, 18-65 years old, males and females will be recruited for the study.
89010017|NCT04561999||Patients with Superficial Lymphadenopathy|
89434560|NCT05390307|Experimental|GLP1RA/SGLT2i combination with intensive lifestyle changes|Participants in the combination GLP1RA and SGLT2i and intensive weight loss groupwill be prescribed liraglutide 3mg once daily or semaglutide 1mg once weekly subcutaneous injection plus dapagliflozin 5-10mg together with an intensive dietary and lifestyle approach for 6 months. This typically involves dietary advice to reduce energy intake (and may includea period of partial or total meal replacement), accompanied -if available -by a physical activity programme, both supported by behavioural change techniqueswith regular professional contacts.
89434561|NCT05390307|Experimental|Usual Care|Participants in the usual care arm will follow the best medical care by following the international guidelines for 6 months. This usually involves diet and exercise advice.
89434562|NCT05389540||members of selected households at the time of survey|371 households will be randomly selected from each site in Bangladesh, Cambodia, Myanmar, and Thailand. Assuming each household has an average of 4.5 members and all members will be sampled, 1500 participants will be recruited per site.
89434563|NCT05386082||Study participants|Study participants
89434564|NCT05383495|Experimental|Intranasal dexmedetomidine|IN dexmedetomidine 3 mcg/kg [100 mcg/mL (max 200 mcg or 2 mL)]
89434565|NCT05383495|Experimental|Intranasal midazolam|IN midazolam 0.4 mg/kg [5 mg/mL (max 10 mg or 2 mL)]
89434566|NCT05383495|Experimental|Inhaled nitrous oxide|50% N2O in 50% oxygen by face mask or on-demand system
89434567|NCT05382754|Experimental|HSAT first|Participants will be randomized to undergo HSAT before receiving their clinical, in-lab polysomnography
89434568|NCT05382754|Active Comparator|PSG first|Participants will be randomized to undergo HSAT after receiving their clinical, in-lab polysomnography.
89434569|NCT05381116|Active Comparator|Experimental Arm|Avation System
89434570|NCT05381116|Sham Comparator|Control Arm|Sham Avation System
89434571|NCT05378204|Other|Patients with breast cancer|Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer.
89434572|NCT05375851|Experimental|Digital Intervention|"The digital interventions will consist of two parts:~A) Psychoeducation videos: Five psychoeducation videos on mental health and GAD will be produced especially for the research to be watched by the patient between consultations. These videos will last approximately 3 minutes, will use animations and educational content. They will be available on +PSI app. The topics of the videos will be as follows: Normal Anxiety versus Pathological Anxiety; Sleep Hygiene; Healthy Eating and Mental Health; Physical Exercise and Mental Health; Excessive Consumption of Alcohol and Drugs.~B) GAD-7 Scale: The patient will be instructed to respond to the GAD-7 self-administered scale the day before their next scheduled appointment. This instrument will also be available free of charge on +PSI mobile app and will be used to guide clinical management.~The above digital interventions will be added to the usual GAD treatment."
89434573|NCT05375851|Active Comparator|Control|"The usual treatment will be standardized as follows:~Biweekly online consultations (via WhatsApp or Google Meet) previously scheduled, 20/30 minutes-long, with a trained psychiatrist.~The patient will receive only clinical, not psychotherapeutic treatment. The psychiatrist will be instructed to perform an assessment of symptoms, general guidelines on the pathology, use of medication when necessary.~The medication of choice, when necessary, will be fluoxetine, as it is the medication for the treatment of GAD available free of charge in our health system in Brazil."
89434574|NCT05375838|Experimental|mRNA-1273 Plus Placebo|Participants will receive 2 intramuscular (IM) injections, one in each arm, of mRNA-1273 plus placebo at the specified dose level on Day 1.
89434575|NCT05375838|Experimental|mRNA-1010 Plus Placebo|Participants will receive 2 IM injections, one in each arm, of mRNA-1010 plus placebo at the specified dose level on Day 1.
88915019|NCT01612728|Experimental|Women with Arthralgia|Women who develop joint pain on Aromatase Inhibitor therapy will be placed on the clinical algorithm, as specified in the protocol.
88915020|NCT01612728|Other|Women without Arthralgia|Women who do not develop arthralgia will continue to have their joint pain and strength measured, as well as their medication compliance. However, they will not be placed on the clinical algorithm which is meant for alleviation of joint pains.
88915021|NCT01612741||Group 1|
88915022|NCT01612754|No Intervention|Reference group - cloaked noise meters|"Reference group or phase 1~Theatre equipped with multiple sound meters disguised as CO2 meter for sound probing in the absence of a research clerk with personnel completely unaware of sound measurements."
88915023|NCT01612754|Sham Comparator|Control Noise AND Stress measurements|"Control Group - Phase 2~No intervention but research clerk is present in theatre to protocoll the operation and test for stress by collecting saliva cortisol and probing electrodermal activity"
88915024|NCT01612754|Experimental|Noise Reduction Intervention Group|"Intervention Group - Phase 3~A panel of noise reduction measures (staff workplace rules, technical devices as optical noise warners, optical telephones) is put into effect. Surgeons are monitored by biometry, psychometry and the outcome."
88915025|NCT01612806|Experimental|PriMatrix|PriMatrix Dermal Repair Scaffold
89434576|NCT05375838|Experimental|mRNA-1010 Plus mRNA-1273|Participants will receive 2 IM injections, one in each arm, of mRNA-1010 plus mRNA-1273 at the specified dose level on Day 1.
88915026|NCT01612806|Experimental|PriMatrix Ag|PriMatrix Ag Antimicrobial Dermal Repair Scaffold
88915027|NCT01612806|Active Comparator|Standard of Care|Standard of Care Moist Wound Therapy
88915028|NCT01612832|Experimental|Lyrica|Patients in one group will receive 150 mg of PGL at 20:00 h the night before surgery and at 1.5 h before surgery, and will undergo surgery under general anesthesia (GA).
88915029|NCT01612832|Active Comparator|Control|no liryca treatment
89434577|NCT05375838|Experimental|Dose A: mRNA-1073 Plus Placebo|Participants will receive 2 IM injections, one in each arm, of mRNA-1073 plus placebo at the specified dose level on Day 1.
89434578|NCT05375838|Experimental|Dose B: mRNA-1073 Plus Placebo|Participants will receive 2 IM injections, one in each arm, of mRNA-1073 plus placebo at the specified dose level on Day 1.
89434579|NCT05375838|Experimental|Dose C: mRNA-1073 Plus Placebo|Participants will receive 2 IM injections, one in each arm, of mRNA-1073 plus placebo at the specified dose level on Day 1.
89434580|NCT05375513|Active Comparator|SYNERGIC 2|"Personalized multidomain coached 1-to-1 interventions at home (PMI@Home) including:~Physical Exercise~Cognitive Training~Diet~Sleep~Vascular Risk Factors Control"
88915030|NCT01612845|Experimental|PRF|the group in which the PRF was administered
88915031|NCT01612845|Active Comparator|Control|repair without PRF
88915032|NCT01612871|Experimental|hormone therapy treatment|Tamoxifen 20 mg/day, Letrozole 2.5 mg/day, Anastrozole 1 mg/day, Exemestane 25mg/day
88915033|NCT01612897|Experimental|Computer based reminders to MD|Children in this arm attend a clinic that is randomly assigned to receive physician alerts to screen appropriate children for autism.
88915034|NCT01612897|No Intervention|Usual care arm|Children in this are receive usual care from a clinic randomly chosen to serve as a control.
88915035|NCT01612910|Experimental|microencapsulated diindolylmethane, lab. biomarker analysis|Patients receive oral microencapsulated diindolylmethane orally (PO) twice a day (BID) for 1 year in the absence of disease progression or unacceptable toxicity
88915036|NCT01612923|Experimental|midwife|Gynecological exam and ultrasound performed by midwife, medical abortion service provided by midwife,contraceptive advice provided by midwife. Follow-up visit provided by midwife
89198176|NCT00949156||Retrospective cohort|The 198 cases of CP with primary surgery in our hospital (since July, 1997 until now) were divided into three topographical groups based on the pre-operative MRI, intraoperative findings and the tumor-membrane relationship. The presurgical manifestation, the different surgical approach, intraoperative techniques, and postoperative complication were described and analyzed to establish a normalized surgical treatment of individual CP patient, which has the highest rate of the totally tumoral resection and the lowest rate of the hypothalamic injury.
89198177|NCT00949156||Prospective cohort|The anticipated 40 cases of CP were surgical treated by our standard procedure, which is recruited in the prospective cohort. With the long-term follow up, QOL including the cognition, circadian rhythm, endocrine, Water-Electrolyte, and body weight et al were evaluated to assess the rationality of the treatment. Then according to the results, the surgical treatment was modified, and the endocrinic substitution therapy was also been developed.
89198178|NCT02544399||Subject practicing golf and accept bone measure|Each patient will have 1 blood sample and 1 measure of bone by 3D micro-tomography
88915037|NCT01612923|No Intervention|Physician|Gynecological exam and ultrasound and contraceptive advice provided by physician. Medical abortion service and follow-up visit provided by midwife
88915038|NCT01612936|Experimental|Allergic asthmatic, allergic nonasthmatic|Adults who are allergic asthmatics or allergic non-asthmatics will receive segmental allergen challenge to the lung
88915039|NCT01612962||bony debridement or amputation|In this study, the investigators will perform a retrospective chart analysis of patients that underwent a bony debridement or amputation in the operating room at Georgetown University Hospital during 2009-2010 under Drs. Steinberg and Attinger
88915040|NCT01612975|Placebo Comparator|Placebo|This study arm will encompass the administration of a placebo (physically identical to Naproxen) orally to participants. Naproxen is a painkiller with intrinsic anti-inflammatory properties, while the placebo has no pharmacological properties associated with it. Participants will also be taking Pantoprazole to negate the gastrointestinal consequences of Naproxen (or the placebo). Participants will not know which arm of the study they belong to. In addition, they will attend scheduled check-ups where their vitals will be recorded, as well as laboratory indicators of gastrointestinal complications (creatinine levels, etc) for their safety.
89198179|NCT02544399||Subject practicing foot walk and accept bone measure|Each patient will have 1 blood sample and 1 measure of bone by 3D micro-tomography
89198180|NCT02544399||Subject sedentary and accept bone measure|Each patient will have 1 blood sample and 1 measure of bone by 3D micro-tomography
88915041|NCT01612975|Experimental|Naproxen|Intervention arm involves administering 500mg Naproxen twice a day to participants and 40mg of Pantoprazole once a day in tandem. Pantoprazole will negate gastrointestinal consequences of Naproxen and reduce the likelihood of a complication occurring. Participants will take Naproxen at the above dosage from the time of surgery to four weeks following surgery. They will attend scheduled check-ups where their vitals will be recorded, as well as laboratory indicators of gastrointestinal complications (creatinine levels, etc) for their safety. This experiment is double-blinded so neither investigators nor participants will know which arm of the study they belong to.
88915042|NCT01612988|Experimental|Chemotherapy BOMP|Bendamustine, Ofatumumab and Methylprednisolone prephase and a maximum of 6 cycles every 4 weeks
88915043|NCT01613001||DoD Beneficiaries|"Exclusion: Active Duty Air Force members with the following conditions will be excluded from the study:~Documented preexisting musculoskeletal injury/disease before onset of obesity~Hypothyroidism/Hyperthyroidism~Hyperparathyroidism~Osteopenia/Osteoporosis~Nicotine dependence~Alcohol dependence~Eating disorders (anorexia nervosa, bulimia nervosa)~Cancer requiring chemotherapy or radiation therapy~Status-post gastrectomy~Status-post bilateral oophorectomy~Crohn's Disease~Ulcerative Colitis~Celiac Disease~Cushing's Disease~Prior to or during the study period, more than 6 months of taking proton pump inhibitors, medroxyprogesterone acetate, bisphosphonates, methotrexate, selective serotonin reuptake inhibitors, or inhaled/intranasal corticosteroids~Prior to or during the study period, more than 1 month of taking fluoroquinolones, oral or intramuscular corticosteroids, oral or intramuscular testosterone, or leuprolide"
88915044|NCT01613040|Experimental|Treatment A|
88915045|NCT01613040|Experimental|Treatment B|
89010018|NCT04561687|Active Comparator|Azelastine and Nasal Budesonide|Spray nasal Azelastine 1puff daily for 6-12years old patients and 2puff for older
89010019|NCT04561687|Active Comparator|Montelukast and Nasal budesonide|Montelukast 5mg 6-14years old and 10mg for older
89010020|NCT04561687|Placebo Comparator|Nasal Budesonide and Placebo|Placebo once daily
89198181|NCT01044511|Experimental|Home visit|After SEMS placement, 2 home visits and a phonecall are made by a specialist nurse
89198182|NCT01044511|Active Comparator|Standard|Standard contact via Hotline and traditional referring methods
89434581|NCT05375513|Placebo Comparator|Brain Health PRO (BHPro)|"Brain Health PRO (BHPROBHPRO) is an independent, educational program with content also related to:~Physical Exercise~Cognitive Training~Diet~Sleep~Vascular Risk Factors~Social engagement"
88915046|NCT01613040|Placebo Comparator|Treatment C|
88915047|NCT01613040|Placebo Comparator|Treatment D|
88915048|NCT01613066|Experimental|Treatment|Patients with high risk haematological malignancies
88915049|NCT01613079|Placebo Comparator|Methotrexate|Patients were treated with methotrexate alone.
88915050|NCT01613079|Experimental|T2|Patients were treated with oral T2 (chloroform/methanol extract of Tripterygium wilfordii Hook F).
89434582|NCT05373615|Experimental|Cefiderocol|Participants will receive four to six doses of Cefiderocol as per current prescribing information based on effluent rate
89434583|NCT05372354|Experimental|Part 1 Arm A: Dose Finding|
88915051|NCT01613079|Experimental|MTX+T2|The patients were treated with methotrexate and T2.
88915052|NCT01613092|Experimental|Conventional|Preoperative Antibiotics
88915053|NCT01613092|Active Comparator|Aggressive (Incremental)|Preoperative antibiotics, antibiotic wash and post operative antibiotics
88915054|NCT01613105||Group 1|
88915055|NCT01613170|Experimental|Toviaz and Premarin Vaginal Cream|Toviaz 4 mg PO q day and premarin cream 1 g per vagina 2 times a week.
88915056|NCT01613170|Placebo Comparator|Toviaz , Placebo Premarin Vaginal Cream|Toviaz 4 mg PO q day and placebo cream 1 g per vagina 2 times a week.
88915057|NCT01613183|Experimental|Chinese Medicine group|Chinese Medicine prescription of one of three prestigious Chinese medicine clinicians
88915058|NCT01613183|Placebo Comparator|placebo group|
88915059|NCT01613196|Experimental|Positron Emission Tomography|Positron Emission Tomography
88915060|NCT01613209|Experimental|Olmesartan/Amlodipin fixed combination|
88915061|NCT01613235|No Intervention|No intervention|No induced hypertension (reference group)
88915062|NCT01613235|Active Comparator|Induced hypertension|Patients who are randomised to this arm will have their blood pressure raised with vasopressors and fluids. Blood pressure will be raised in order to improve cerebral blood flow (CBF). In case of a low cardiac output, inotropics will be added. Induced hypertension will be continued for at least 48 hours when patients show some improvement within the first 24 hours. After 48 hours, the dose of vasopressor will be tapered daily, and resumed in case of clinical deterioration. In patients who do not show any improvement within 24 hours, induced hypertension will not be continued.
88915063|NCT01613261|Experimental|TAK-733 and alisertib|
88915064|NCT01613274|Experimental|Gum chewing|Chewing mint flavored sugarless gum for 10-20 minutes three times a day following colon resection.
88915065|NCT01613274|Placebo Comparator|no gum chewing|no gum chewing
88915066|NCT01613287|Experimental|Immunoadsorption|Patients are treated with the TheraSorb® Ig flex adsorber used exclusively with the LIFE 18® apheresis system for extracorporeal application for IA therapy (5 treatments) performed over 5 to 8 consecutive days
88915067|NCT01613300|Experimental|Ofatumumab|Ofatumumab as part of the reduced intensity conditioning regimen (RIC)
89434584|NCT05372354|Experimental|Part 1 Arm B: Dose Finding|
89434585|NCT05372354|Experimental|Part 1 Arm C: Dose Finding|
89434586|NCT05372354|Active Comparator|Part 2 Arm D: Dose Expansion|
89434587|NCT05372354|Experimental|Part 2 Arm E: Dose Expansion|
89434588|NCT05372354|Experimental|Part 2 Arm F: Dose Expansion|
88915068|NCT01613352|Experimental|Day surgery group|Patients who underwent breast conserving surgery and sentinel node biopsy only and were randomized to ambulatory surgery group.
89434589|NCT05372354|Experimental|Part 2 Arm G: Dose Expansion|
89434590|NCT05371093|Experimental|Axicabtagene Ciloleucel|Participants will receive cyclophosphamide 500 mg/m^2/day intravenously (IV) and fludarabine 30 mg/m^2/day IV lymphodepleting chemotherapy for 3 days followed by axicabtagene ciloleucel administered as a single IV infusion at a target dose of 2 x 10^6 anti-cluster of differentiation (CD)19 chimeric antigen receptor (CAR) transduced autologous T cells/kg on Day 0. For participants weighing ≥ 100 kg, a maximum flat dose of axicabtagene ciloleucel at 2 x 10^8 anti-CD19 CAR T cells will be administered.
89434591|NCT05371093|Active Comparator|Standard of Care Therapy|"Participants will receive the investigator's choice of one of the following therapies/dosing schedules:~Rituximab plus lenalidomide (R^2) for 12 cycles (28-day cycle)~Cycle 1: lenalidomide 20 mg/day on Day 1 through Day 21; rituximab 375 mg/m^2 on Day 1, Day 8, Day 15, and Day 22~Cycle 2 through Cycle 5: lenalidomide 20 mg/day on Day 1 through Day 21; Rituximab 375 mg/m2 on Day 1~Cycle 6 through Cycle 12: lenalidomide 20 mg/day on Day 1 through Day 21~Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for 6 cycles (21-day cycle)~rituximab 375 mg/m^2 on Day 1~cyclophosphamide 750 mg/m^2 on Day 1~doxorubicin 50 mg/m^2 on Day 1~vincristine 1.4 mg/m^2 (maximum 2 mg) on Day 1~prednisone 40 mg/m^2 on Day 1 through Day 5~Rituximab plus bendamustine (BR) for 6 cycles (28-day cycle)~rituximab 375 mg/m^2 on Day 1~bendamustine 90 mg/m^2 on Day 1 and Day 2"
89434592|NCT05369559|Active Comparator|Mini Bolus 50|"receiving a mini-bolus A:50 ml of crystalloid solution, regularly infused over 30 seconds"
89434593|NCT05369559|Active Comparator|Mini Bolus 100|"receiving a mini-bolus B:100 ml of crystalloid solution, regularly infused over 30 seconds"
88915069|NCT01613352|Active Comparator|In-Patient group|Patients who underwent breast conserving surgery and sentinel node biopsy only and were randomized to in-patient group.
88915070|NCT01613365|Experimental|chlorhexidine gluconate|
89434594|NCT05364944|Experimental|Cohort A: Participants With Acromegaly|Participants will receive Sandostatin Long-acting repeatable (LAR) or Somatuline Autogel (ATG) (or equivalent formulations of octreotide/lanreotide) in Run-in Period and further will receive Debio 4126 in this group.
89434595|NCT05364944|Experimental|Cohort B: Participants With GEP-NET|Participants will receive Sandostatin LAR or Somatuline ATG (or equivalent formulations of octreotide/lanreotide) in Run-in Period and further will receive Debio 4126 in this group.
89434596|NCT05358522|No Intervention|Standard Feedback|No feedback about opioid prescribing behaviors.
89434597|NCT05358522|Experimental|Opioid Prescribing Report Cards|Procedure and prescribing providers will be randomized to when they will begin receiving individual reports on their opioid prescribing.
89434598|NCT05357612|Experimental|Pimavanserin|
89434599|NCT05355779||Interviewees|Paediatric cancer survivors, their parent/caregiver and health care professionals will be invited to express their views and perspectives in an interview with the researcher
89434600|NCT05355766|Experimental|CN128 Group|"All subjects will be given the lower (10 mg/kg bw, bid) to higher dose (30 mg/kg bw, bid) for 52 weeks, according to the administration plan.~The dosage form is tablets."
89434601|NCT05354531|Experimental|INFIX group|Those group of cases will be managed by INFIX for their pelvic ring disruption
89434602|NCT05353530|Experimental|8R-70CAR T cells|Cohort 1 will receive 1 x 10^6 cells/kg. Cohort 2 will receive 1 x 10^7 cells/kg. Cohort 3 will receive 1 x 10^8 cells/kg. Cohort 4 will receive Cy/Flu + CAR T cells at established maximum tolerated dose.
89434603|NCT05344456|Experimental|PVC response ''Off''|
89434604|NCT05338723|No Intervention|control-group|This group will include 25 patients who will receive doxorubicin for 4 cycles (3 months) followed by trastuzumab adjuvant therapy.
89434605|NCT05338723|Active Comparator|rosuvastatin-group|This group will include 25 patients who will receive doxorubicin for 4 cycles (3 months) followed by trastuzumab adjuvant therapy in addition to 20 mg of oral rosuvastatin 24 hours prior to the first cycle of chemotherapy and once daily for the rest of the follow-up period (6 months).
89434606|NCT05333432|Other|Men at high genetic risk of prostate cancer|Cohort of unaffected men from 40 to 70 years olds with high risk of prostate cancer (PC) defined as being a member from a family that meets hereditary PC criteria or by carrying a mutation of a DNA repair gene or a gene specific to PC.
89434607|NCT05332392|Experimental|INVSENSOR00040|All subjects who are enrolled into the test group and participate in data collection receive the noninvasive INVSENSOR00040 device.
88915071|NCT01613365|Experimental|placebo|
88915072|NCT01613391||RYGBP|Patients underwent Roux-en-Y Gastric Bypass for morbid obesity.
88915073|NCT01613391||LAGB|Patients underwent Laparoscopic Adjustable Gastric Banding for morbid obesity.
88915074|NCT01613404||Patients with nurse case manager|Patients will receive a dedicated nurse case manager (intervention group) in this group.
88915075|NCT01613404||Patients with no nurse case manager|Patients will not receive nurse case manager (control group) in this group.
89434608|NCT05331053|Experimental|Atorvastatin|"Oral atorvastatin (Lipitor) therapy (10mg/day) for seven days.~Atorvastatin acts as a systemic LOX inhibitor."
89434609|NCT05330702|Experimental|Tuberosity Connective Tissue Graft (CTG)|Subjects in this arm will have a tuberosity connective tissue graft at the time of immediate implant placement.
88915076|NCT01613430|Active Comparator|Printed Educational Material (PEM) only|Participants and their coaches will be provided with educational brochures about cancer screening for colorectal, breast and cervical cancers at the completion of the baseline survey.
88915077|NCT01613430|Experimental|Coach Training (COACH)|The COACH intervention consists of the Printed Educational Materials (PEM) plus the addition of cancer-related training for participant-designated coaches.
88915078|NCT01613456|Placebo Comparator|Placebo|Dicalcium phosphate, Maltodextrin and Magnesium stearate.
88915079|NCT01613456|Experimental|Saccharomyces cerevisiae CNCM I-3856|
88915080|NCT01613469|Other|5FU/Leucovorin- post distal rectal srgy|Assess complete clinical response rate following neoadjuvant chemoradiation in patients with distal rectal cancer
88915081|NCT01613482|Active Comparator|Arm A|Without cerebral prophylactic radiation
88915082|NCT01613482|Experimental|Arm B|With cerebral prophylactic radiation
89010021|NCT04561414|Other|LED light source system for endoscope|The prospective, multi-center, single-blind, parallel, randomized controlled superiority trial design is adopted to evaluate the safety and effectiveness of the LED light source system for endoscope during ureter transillumination. The trial will be carried out in 5 centers, with the competitive grouping mode adopted. This trial will be carried out in the General Surgery Department and the Gynecology Department. Totally 120 subjects with rectal cancer, endometriosis, cervical cancer, adenomyosis and pelvic adhesion requiring operation (60 subjects for each of the test group and control group) are involved. The test group use LED light source system for endoscope
89434610|NCT05330702|Experimental|Xenogeneic Volume-Stable Collagen Matrix (VCMX) graft|Subjects in this arm will have Xenogeneic Volume-Stable Collagen Matrix (VCMX) graft at the time of immediate implant placement.
89434611|NCT05330702|No Intervention|No Soft Tissue Augmentation|Subjects in this arm will have no soft tissue augmentation at the time of immediate implant placement.
89434612|NCT05330221|Experimental|Intervention Group|"PAL2 Intervention~Drug Therapy"
89434613|NCT05330221|No Intervention|Usual Care Group|Participants that are randomized into usual care will be assisted with arrangement of follow-up, either with existing primary care provider (PCP) or a Wayne Health provider. All subsequent medical treatment will be at the discretion of the PCP.
89434614|NCT05326594|Experimental|Physical Therapy|
89434615|NCT05326282|Experimental|Multi-parametric and micro ultrasound|Transrectal ultrasound imaging in men with suspected or known low grade prostate cancer using both standard and micro-ultrasound technology
89434616|NCT05325944|Experimental|Self-guided digital intervention for NSSI|The self-guided digital intervention for NSSI will consist of 8 weekly modules containing psychoeducation and skill-based practice, and daily ecological momentary assessments. All content is delivered by a highly interactive conversational agent that guides users through the app content via a text-like interface.
89434617|NCT05325944|Experimental|Digital intervention for NSSI with coaching|The self-guided digital intervention for NSSI will consist of 8 weekly modules containing psychoeducation and skill-based practice, and daily ecological momentary assessments. All content is delivered by a highly interactive conversational agent that guides users through the app content via a text-like interface. This arm will additionally receive lightweight coaching which consists of a one 20-30 minute engagement call at the beginning of treatment. Thereafter, coaches will check in with participants via medium of participants choice twice per week and respond to patient texts, calls, or emails.
88915083|NCT01613508|Active Comparator|Direct Anterior Approach|An oblique incision is made over the anterior margin of the tensor muscle. The fascia of the tensor muscle is identified and incised. The muscle is swept digitally laterally and a retractor is placed over the superior aspect of the femoral neck. The hip capsule is then incised and retracted.
89434618|NCT05325944|Active Comparator|Active control|The active control arm will receive 8 weekly modules with psychoeducational components only, without the interaction features or EMA for personalization.
89434619|NCT05325580|Placebo Comparator|Placebo Group|1g paracetamol + 20 min infusion of 150ml of saline serum
89434620|NCT05325580|Experimental|magnesium group|1g paracetamol + 20 min infusion of 2g magnesium in 150 ml of serum saline
89434621|NCT05317754|Experimental|Mindful breathing|
89434622|NCT05317754|Experimental|Prostrations, according to Tibetan Buddhist tradition|
89434623|NCT05317754|Experimental|The Koan Mu, according to Zen Buddhist tradition|
89434624|NCT05317754|Experimental|The mirror exercise, according to Toltec tradition|
89434625|NCT05315908|Active Comparator|Automated call|Patients receive up to two automated phone calls in English or Spanish depending the patients' language indicated in their electronic health record (EHR), between the hours of 10:00am and 9:00pm Monday through Friday.
89434626|NCT05315908|Active Comparator|Text messaging|Patients receive up to two text messages in English or Spanish depending the patients' language indicated in their electronic health record (EHR), between the hours of 10:00am and 9:00pm Monday through Friday.
89434627|NCT05315804|Experimental|Amelogenin Group (A)|Amelogenins in gel will be applied in intraosseous periodontal defects, after Minimally Invasive Non Surgical Debridement (MINSD)
89198183|NCT04011904|Experimental|Traditional Inuit Diet|This will be a traditional Inuit diet (TID) rich in marine mammals (such as walrus, seal, and whale), fish, caribou and musk ox, with low intake of grains, fast food and other imported foods. The TID diet will be high in fat (>40 of the energy (E%)) and low in carbohydrate (<30 E%).
89198184|NCT04011904|Placebo Comparator|Westernized Diet|This will be a Westernized diet will be consisting of high amounts of grains, potatoes, rice and imported meats from livestock animals (beef, pork and chicken). The Westernized diet will be high in carbohydrate (55-65 E%) and lower in fat (30-35 E%).
89434628|NCT05315804|Active Comparator|No-amelogenin Group (B)|Only Minimally Invasive Non Surgical Debridement (MINSD) will be performed
89434629|NCT05312736||Vision Cohort 1|"Criteria that must be met in the better eye* at the Screening Visit:~visual acuity ETDRS letter score of 54 or more (approximate Snellen equivalent 20/80 or better) and visual field** diameter 10 degrees or more in every meridian of the central field~The better eye is defined as the eye with the better Screening Visit ETDRS visual acuity. However, if both eyes have the same visual acuity, which is defined as the same Snellen equivalent, then the determination will be made at investigator discretion. In this scenario, the investigator will consider the eye with better fixation or clearer ocular media to permit highest quality retinal imaging.~The visual field (VF) is defined as the clinically determined kinetic VF III4e performed within the last 18 months prior to the Screening Visit or performed on the day of the Screening Visit."
89434630|NCT05312736||Vision Cohort 2|"Criteria that must be met in the better eye* at the Screening Visit:~visual acuity ETDRS letter score of 19-53 (approximate Snellen equivalent 20/100 - 20/400) OR visual acuity ETDRS letter score of 54 or more (approximate Snellen equivalent 20/80 or better) and visual field** diameter less than 10 degrees in any meridian of the central field.~The better eye is defined as the eye with the better Screening Visit ETDRS visual acuity. However, if both eyes have the same visual acuity, which is defined as the same Snellen equivalent, then the determination will be made at investigator discretion. In this scenario, the investigator will consider the eye with better fixation or clearer ocular media to permit highest quality retinal imaging.~The visual field (VF) is defined as the clinically determined kinetic VF III4e performed within the last 18 months prior to the Screening Visit or performed on the day of the Screening Visit."
89434631|NCT05312736||Vision Cohort 3|"Criteria that must be met in the better eye* at the Screening Visit:~visual acuity ETDRS letter score of 18 or less (approximate Snellen equivalent 20/500 or worse).~The better eye is defined as the eye with the better Screening Visit ETDRS visual acuity. However, if both eyes have the same visual acuity, which is defined as the same Snellen equivalent, then the determination will be made at investigator discretion. In this scenario, the investigator will consider the eye with better fixation or clearer ocular media to permit highest quality retinal imaging.~The visual field (VF) is defined as the clinically determined kinetic VF III4e performed within the last 18 months prior to the Screening Visit or performed on the day of the Screening Visit."
89434632|NCT05308914||Resilience Study Cohort|Observational, descriptive longitudinal cohort design. See inclusion and exclusion criteria for more information
89434633|NCT05306015|Experimental|test group|Patients undergoing brain-computer interface-based mindfulness meditation training during the perioperative period of radiofrequency ablation.
89434634|NCT05306015|Active Comparator|control group|Patients receiving routine care for radiofrequency ablation.
89198185|NCT00682890|Placebo Comparator|1|Placebo tablet and birth control pill daily
89198186|NCT00682890|Active Comparator|2|metformin 2000 mg and birth control pill daily
89198187|NCT02565368|Experimental|RT group|R: Reference drug(Duvie Tab. 0.5mg, Glucophage XR Tab. 1000mg) 1T T: Test drug(CKD-395 0.5/1000mg) 1T
89198188|NCT02565368|Experimental|TR group|T: Test drug(CKD-395 0.5/1000mg) 1T R: Reference drug(Duvie Tab. 0.5mg, Glucophage XR Tab. 1000mg) 1T
89198189|NCT01047163||Statin|Men aged 65-75yr on Simvastatin therapy presenting with muscle soreness
89198190|NCT01047163||Control|Men, aged 65-75yr not on Statin therapy
89434635|NCT05305508|Placebo Comparator|placebo|The comparator (placebo, Mannitol 500 mg) will be administered orally twice a day for 7 days.
89198191|NCT00949390||Phase I and CAM Survey|Complementary and alternative medicine (CAM) in patients with advanced malignancies currently treated on University of Texas MD Anderson Cancer Center Phase I clinical trials.
89198192|NCT04040595|Experimental|Adipocyte measurement|Abdominal fat biopsy
89198193|NCT03889574||combination of aspirin, P2Y12 Inhibitor with a NOAC|As this is a retrospective study with limited patients available for the cohort, all patients meeting inclusion criteria from April 1, 2017 - April 1, 2018 will be included to obtain the largest sample size possible
89198194|NCT03889574||combination of aspirin, P2Y12 Inhibitor with warfarin|As this is a retrospective study with limited patients available for the cohort, all patients meeting inclusion criteria from April 1, 2017 - April 1, 2018 will be included to obtain the largest sample size possible
89198195|NCT03992365|Experimental|Quiklean®|Quiklean® (32 tablets)
89434636|NCT05305508|Experimental|Calcium Dobesilate|The CaD (Calcium Dobesilate 500 mg) will be administered orally twice a day for 7 days.
89434637|NCT05305430||Prospective|All patients for whom the decision has been made to have the Synergy Disc implanted at participating investigative centers and give informed consent to participate in the prospective segment of this protocol, per country-specific requirements, will be enrolled in the prospective portion of this protocol.
89434638|NCT05305430||Retrospective|Patients who have previously had a Synergy Spine Solutions Synergy Disc implanted will be eligible for inclusion in the retrospective data collection; a waiver of consent, or informed consent, for retrospective data collection from the medical records of the implanting surgeon will be sought per country-specific regulations as applicable.
89434639|NCT05301270||Transtibial Amputees|Individuals aged 18-45 years, with unilateral transtibial amputation, traumatic amputation cause, using prosthesis for at least 1 year, no skin lesions-open wound on the stump, no phantom sensation or pain, no musculoskeletal problems that may affect balance other than amputation will be included.
89434640|NCT05301270||Transfemoral Amputees|Individuals aged 18-45 years, with unilateral transfemoral amputation, traumatic amputation cause, using prosthesis for at least 1 year, no skin lesions-open wound on the stump, no phantom sensation or pain, no musculoskeletal problems that may affect balance other than amputation will be included.
89434641|NCT05301270||Healthy Subjects|Healthy individuals between the ages of 18-45 will be included.
89434642|NCT05297071|Other|Dental Loupes|The surgeon will use dental loupes with a head lamp during the subject's tooth extraction and socket grafting.
89434643|NCT05297071|Other|Surgical microscope|The surgeon will use a surgical microscope (with built-in lighting) during the subject's tooth extraction and socket grafting.
89434644|NCT05296382|Experimental|Crushed Tebipenem Tablet with Tube feeds|Crushed tebipenem tablets will be administered by syringe through the nasogastric tube and flushed with water to ensure all drug is passed through. Subjects will also receive concurrent enteral tube feeds (feeds run for 2h before dose and 4h post-dose).
89434645|NCT05296382|Experimental|Whole Tebipenem Tablet|Tebipenem tablet will be swallowed whole without crushing.
89434646|NCT05296382|Experimental|Crushed Tebipenem Tablet without Tube feeds|Crushed tebipenem tablets will be administered by syringe through the nasogastric tube and flushed with water to ensure all drug is passed through.
89434647|NCT05290714|Experimental|Mentalization Based Treatment for Children (MBT-C)|Mentalization Based Therapy for Children (MBT-C) is a transdiagnostic time-limited (12 weekly sessions) and manualized treatment for children aged between 5 to 12 years old with the main aim of increasing mentalization and restoring epistemic trust. Parallel parental work takes place to increase parental mentalization.
89434648|NCT05290714|Active Comparator|Parenting and Social Skills Group|"Parenting groups will run for 12 weeks with 10 parents per group. They will involve activities to help parents develop effective parenting skills via working on a family genogram, providing information on child development, developing acceptance and empathy, setting boundaries and anger regulation.~The social skills groups will run for 12 weeks and will be conducted with 10 children per group. They will involve activities on self-presentation, peer communication, play skills, empathy and anger management."
89434649|NCT05284760|Experimental|Part A, Sequence 1: Treatment A + Treatment B + Treatment C|Soticlestat T4 tablets 300 mg, orally, once on Day 1 of Period 1 under fasted condition as Treatment A, followed by soticlestat T3 mini-tablets 300 mg, orally, once on Day 1 of Period 2 under fasted condition as Treatment B, and followed by soticlestat T3 commercial tablets 300 mg, orally, once on Day 1 of Period 3 under fasted condition as Treatment C. A washout interval of exactly 4 days will be maintained between each Treatment Period.
89198196|NCT03992365|Active Comparator|GroKlean-Prep with Dulcolax®|2 sachets of Klean-Prep with 1 tablet of Dulcolax®
89434650|NCT05284760|Experimental|Part A, Sequence 2: Treatment A + Treatment C + Treatment B|Soticlestat T4 tablets 300 mg, orally, once on Day 1 of Period 1 under fasted condition as Treatment A, followed by soticlestat T3 commercial tablets 300 mg, orally, once on Day 1 of Period 2 under fasted condition as Treatment C, and followed by soticlestat T3 mini-tablets 300 mg, orally, once on Day 1 of Period 3 under fasted condition as Treatment B. A washout interval of exactly 4 days will be maintained between each Treatment Period.
89434651|NCT05284760|Experimental|Part A, Sequence 3: Treatment B + Treatment A + Treatment C|Soticlestat T3 mini-tablets 300 milligram (mg), orally, once on Day 1 of Period 1 under fasted condition as Treatment B, followed by soticlestat T4 300 mg, tablets, orally, once on Day 1 of Period 2 under fasted condition as Treatment A, and followed by soticlestat T3 commercial tablets 300 mg, orally, once on Day 1 of Period 3 under fasted condition as Treatment C. A washout interval of exactly 4 days will be maintained between each Treatment Period.
89434652|NCT05284760|Experimental|Part A, Sequence 4: Treatment B + Treatment C + Treatment A|Soticlestat T3 mini-tablets 300 mg, orally, once on Day 1 of Period 1 under fasted condition as Treatment B, followed by soticlestat T3 commercial tablets 300 mg, orally, once on Day 1 of Period 2 under fasted condition as Treatment C, and followed by soticlestat T4 300 mg, tablets, orally, once on Day 1 of Period 3 under fasted condition as Treatment A. A washout interval of exactly 4 days will be maintained between each Treatment Period.
89434653|NCT05284760|Experimental|Part A, Sequence 5: Treatment C + Treatment A + Treatment B|Soticlestat T3 commercial tablets 300 mg, orally, once on Day 1 of Period 1 under fasted condition as Treatment C, followed by soticlestat T4 300 mg, tablets, orally, once on Day 1 of Period 2 under fasted condition as Treatment A, and followed by soticlestat T3 mini-tablets 300 mg, orally, once on Day 1 of Period 3 under fasted condition as Treatment B. A washout interval of exactly 4 days will be maintained between each Treatment Period.
89434654|NCT05284760|Experimental|Part A, Sequence 6: Treatment C + Treatment B + Treatment A|Soticlestat T3 commercial tablets 300 mg, orally, once on Day 1 of Period 1 under fasted condition as Treatment C, followed by soticlestat T3 mini-tablets 300 mg, tablets, orally, once on Day 1 of Period 2 under fasted condition as Treatment B, and followed by soticlestat T4 tablets 300 mg, orally, once on Day 1 of Period 3 under fasted condition as Treatment A. A washout interval of exactly 4 days will be maintained between each Treatment Period.
89434655|NCT05284760|Experimental|Part B, Sequence 1: Treatment D + Treatment E + Treatment F|Soticlestat T4 300 mg, tablets, orally, once on Day 1 of Period 1 under fasted condition as Treatment D, followed by soticlestat T4 300 mg, tablets, orally, once on Day 1 of Period 2 under fed condition as Treatment E, and followed by soticlestat T4 300 mg tablets crushed and mixed with applesauce, orally, once on Day 1 of Period 3 under fasted condition as Treatment F. A washout interval of exactly 4 days will be maintained between each Treatment Period.
89434656|NCT05284760|Experimental|Part B, Sequence 2: Treatment D + Treatment F + Treatment E|Soticlestat T4 300 mg, tablets, orally, once on Day 1 of Period 1 under fasted condition as Treatment D, followed by soticlestat T4 300 mg, tablets crushed and mixed with applesauce, orally, once on Day 1 of Period 2 under fasted condition as Treatment F, and followed by soticlestat T4 300 mg, orally, once on Day 1 of Period 3 under fed condition as Treatment E. A washout interval of exactly 4 days will be maintained between each Treatment Period.
88915084|NCT01613508|Active Comparator|Mini-Posterior Approach|The surgical approach involved a 7 to 9.5 cm incision along the posterior aspect of the femur starting at the tip of the greater trochanter and proceeding distally. The fascia of the gluteus maximus was split, and blunt dissection revealed the underlying abductor and external rotator musculature. The external rotators an the hip capsule were incised and preserved as one layer, with an attempt being made to preserve the insertion of the quadratus femoris on the femur. The hip was dislocated posteriorly and the femoral neck was cut in accordance with the preoperative plan.
88915085|NCT01613521|Experimental|DCE-MRI and 18F-FMISO PET|Each patient will undergo three DCE-MRI (dynamic contrast-enhanced MRI) studies: a baseline DCE-MRI within two weeks before chemoradiation; a second DCE-MRI after the second week of treatment (within a week); and a third DCE-MRI three months after treatment. As a pilot study in 10 patients, we will perform 18F-FMISO PET/CT on the same day of a baseline DCE-MRI before chemoradiation. Treatment decisions will not be based on DCE-MRI and 18F-FMISO PET/CT studies.
88915086|NCT01613534|Experimental|APC plus oral sucralfate|Argon plasma coagulation treatment followed by oral sucralfate (6 grams b.i.d.) administration for four weeks.
88915087|NCT01613534|Placebo Comparator|APC plus placebo|Argon plasma coagulation treatment followed by placebo administration for four weeks.
88915088|NCT01613547|Active Comparator|Routine antibiotic prescription|Routine antibiotic prescription with amoxicillin (80 mg/kg/day for 7 days)
88915089|NCT01613547|Placebo Comparator|No routine antibiotic prescription|
88915090|NCT01613586|Experimental|Low dose ASP3652 twice daily|50 mg twice daily for 12 weeks
88915091|NCT01613586|Experimental|Medium dose ASP3652 twice daily|150 mg twice daily for 12 weeks
88915092|NCT01613586|Experimental|High dose ASP3652 twice daily|300 mg twice daily for 12 weeks
88915093|NCT01613586|Placebo Comparator|Placebo|Matching placebo twice daily for 12 weeks
88915094|NCT01613612|Sham Comparator|control group:core decompression|single core decompression
88915095|NCT01613612|Active Comparator|Treatment group: BMCs+core decompression|Enriched bone marrow cells combined with core decompression
88915096|NCT01613625|Experimental|Elastography|
89434657|NCT05284760|Experimental|Part B, Sequence 3: Treatment E + Treatment D + Treatment F|Soticlestat T4 300 mg, tablets, orally, once on Day 1 of Period 1 under fed condition as Treatment E, followed by soticlestat T4 300 mg, tablets, orally, once on Day 1 of Period 2 under fasted condition as Treatment D, and followed by soticlestat T4 300 mg, tablets crushed and mixed with applesauce, orally, once on Day 1 of Period 3 under fasted condition as Treatment F. A washout interval of exactly 4 days will be maintained between each Treatment Period.
89434658|NCT05284760|Experimental|Part B, Sequence 4: Treatment E + Treatment F + Treatment D|Soticlestat T4 300 mg, tablets, orally, once on Day 1 of Period 1 under fed condition as Treatment E, followed by soticlestat T4 300 mg tablets crushed and mixed with applesauce, orally, once on Day 1 of Period 2 under fasted condition as Treatment F, and followed by soticlestat T4 300 mg, tablets, orally, once on Day 1 of Period 3 under fasted condition as Treatment D. A washout interval of exactly 4 days will be maintained between each Treatment Period.
89434659|NCT05284760|Experimental|Part B, Sequence 5: Treatment F + Treatment D + Treatment E|Soticlestat T4 300 mg tablets crushed and mixed with applesauce, orally, once on Day 1 of Period 1 under fasted condition as Treatment F, followed by soticlestat T4 300 mg, tablets, orally, once on Day 1 of Period 2 under fasted condition as Treatment D, and followed by soticlestat T4 300 mg, tablets, orally, once on Day 1 of Period 3 under fed condition as Treatment E. A washout interval of exactly 4 days will be maintained between each Treatment Period.
89434660|NCT05284760|Experimental|Part B, Sequence 3: Treatment F + Treatment E + Treatment D|Soticlestat T4 300 mg tablets, crushed and mixed with applesauce, orally, once on Day 1 of Period 1 under fasted condition as Treatment F, followed by soticlestat T4 300 mg, tablets, orally, once on Day 1 of Period 2 under fed condition as Treatment E, and followed by soticlestat T4 300 mg tablets, orally, once on Day 1 of Period 3 under fasted condition as Treatment D. A washout interval of exactly 4 days will be maintained between each Treatment Period.
89434661|NCT05284045|No Intervention|Usual information|Subjects allocated to this arm will receive the usual information about OSA and CPAP treatment given in clinical practise
89434662|NCT05284045|Active Comparator|Detailed information|Subjects allocated to this arm will also receive the usual information about OSA and CPAP treatment and they will also receive information related to the possible adverse side effects of CPAP treatment. The healthcare professional will enumerate the possible side effects and indicate which are more and less common.
89434663|NCT05276804|Experimental|Sugammadex|Prospective cohort of patients undergoing laparoscopic inguinal hernia repair will receive Sugammadex. Sugammadex will be used for reversal of their neuromuscular blockade. The dosing for Sugammadex is 4mg/kg for a deep reversal and a 2mg/kg for a standard reversal, which will be more common for this study. Sugammadex comes in 200mg/2mL and 500mg/5mL vials. Because of the variability in weight of the patients and the type of reversal needed (deep vs standard), 140 5mL vials will be required.
89434664|NCT05276804|No Intervention|Retrospective cohort|Retrospective cohort of patients who did not receive Sugammadex
88915097|NCT01613651|Experimental|Arm I (RALP)|Patients undergo RALP.
88915098|NCT01613651|Experimental|Arm II (RALP and placement of pelvic drain)|Patients undergo RALP and placement of pelvic drain.
88915099|NCT01613664|Experimental|tisseel|tisseel will be applied during the surgery
88915100|NCT01613664|Placebo Comparator|no tisseel|no tisseel will be applied during the surgery
88915101|NCT01613677|Experimental|BKM120|
88915102|NCT01613690|Experimental|Healthy volunteers|control group receiving 100 μg NVA237
88915103|NCT01613690|Experimental|Mild renal impairment|(eGFR 50-80 mL/min/1.73m2) receiving 100 μg NVA237
88915104|NCT01613690|Experimental|Moderate renal impairment|(eGFR 30-49 mL/min/1.73m2) receiving 100 μg NVA237
88915105|NCT01613690|Experimental|Severe renal impairment|(eGFR <30 mL/min1.73m2) receiving 100 μg NVA237
88915106|NCT01613690|Experimental|End-stage subjects requiring dialysis (ESRD)|receiving 100 μg NVA237
88915107|NCT01613703|Experimental|Experimental|
88915108|NCT01613755|Active Comparator|Metformin therapy with concomitant use of dipyridamole|Metformin 500 mg twice daily for four days in combination with dipyridamole 200 mg twice daily for four days
88915109|NCT01613755|Active Comparator|Metformin therapy|Metformin 500 mg twice daily for four days
88915110|NCT01613781|Active Comparator|T1/Tc amplitude-guided group|Using partial neuromuscular blockade to maintain T1/Tc amplitude of 50%, T1/Tc amplitude measured by the neuromuscular transmission module (NMT)
88915111|NCT01613781|Active Comparator|TOF count-guided group|Using partial neuromuscular blockade to maintain train-of-four response of two, TOF response measured by the neuromuscular transmission module (NMT module)
88915112|NCT01613794|No Intervention|No intervention|
88915113|NCT01613794|Experimental|Rosuvastatin|
88915114|NCT01613807|Experimental|Mix 50/50|Insulin LISPRO: 3 doses of Humalog® Mix50/50™ at mealtime.
88915115|NCT01613807|Active Comparator|Usual insulin regimen|Usual insulin regimen of insulin, Long-Acting and Insulin: 3 injections of Humalog(r) daily with meals; 3 injections of Humulin N (r) daily on rising, mid-afternoon, and at bedtime
88915116|NCT01613820|Experimental|Ketamine plus placebo|Subjects assigned to this paradigm will receive a 15 minute infusion of normal saline (placebo) followed by IV ketamine at 0.25mg/kg over 45 minutes twice a week for 3 weeks.
89434665|NCT05270083|Active Comparator|Athletes with mild to moderate traumatic brain injury (mTBI) and good outcome|Young athletes who have sustained one or more concussions without persistent cognitive complaints at least one year post-injury
89434666|NCT05270083|Active Comparator|Athletes with persistent cognitive deficits due to mild to moderate traumatic brain injury (mTBI)|Young athletes who have sustained one or more concussions with persistent cognitive complaints at least one year post-injury in spite of medical and cognitive treatment intervention.
89434667|NCT05267444|Experimental|Intervention group|Individualized motion-based interactive game program
89434668|NCT05267444|No Intervention|Control group|The control group participants will receive usual care, that is, service that provided by community elderly center
89434669|NCT05265273|Experimental|Nipocalimab|Participants aged 2 to less than [<] 18 years of age will receive nipocalimab once every two weeks for 24 weeks. After Week 24, all participants will have the option to enroll in long term extension (LTE).
89434670|NCT05258773|Experimental|A, Treatment arm|Arm A: Participants scheduled for cochlear implantation and treated with oral 43.5 mg SENS-401 (R-Azasetron Besylate) twice daily for up to 49 days.
89434671|NCT05258773|No Intervention|B, Control arm|Arm B: Participants scheduled for cochlear implants and not treated with SENS-401 (R-Azasetron Besylate).
89434672|NCT05257356|Experimental|Chronic Pain Patients|"All participants perform 1 psychophysical task to assess sensory-discriminative and emotional-motivational pain responses simultaneously. The performance of chronic pain patients will be compared to healthy volunteers to characterize possible alterations in patients. Associative learning by monetary reinforcement will be implemented to diminish the aversiveness of pain, which is assumed to be already increased in patients.~Primary objectives: Show that emotional-motivational components are increased relative to sensory-discriminative components in chronic pain, and that enhanced emotional-motivational pain responses in chronic pain can be decreased by counterconditioning, leading to a normalization of pain perception relative to healthy individuals.~Secondary objective: Assess whether chosen personality traits assessed by questionnaires can explain variations in sensory-discriminative and emotional-motivational pain responses."
89434673|NCT05257356|Experimental|Healthy Controls|"Substudy 1(b): Participants perform 1 psychophysical task to assess sensory-discriminative and emotional-motivational pain responses simultaneously. Associative learning by monetary reinforcement is implemented to diminish the pain aversiveness. Substudy2: Participants perform the same task combined with MRI assessing the counterconditioning effects on frontostriatal circuits.~Primary objective: Show that emotional-motivational components are increased relative to sensory-discriminative components in chronic pain (Substudy 1(b)). Assess the neural correlates of the counterconditioning effects on emotional-motivational pain responses, specifically alterations in functional connectivity in frontostriatal networks compared to the unchanged natural state (Substudy 2).~Secondary objective: To assess whether chosen personality traits assessed by questionnaires can explain variations in sensory-discriminative and emotional-motivational pain responses (Substudy1(b)+2)."
89434674|NCT05256706|Experimental|SomaSignal Informed Medical Management SSCVD|Blood draw for SSCVD test at baseline and 6 months (±50 days). SomaSignal Cardiovascular Risk (SSCVD) results will be sent to the providers and participants approximately 2-4 weeks after testing.
89434675|NCT05256706|Active Comparator|Standard of Care (Uninformed Arm)|Blood draw for SSCVD test at baseline and 6 months (±50 days). SomaSignal Cardiovascular Risk (SSCVD) results will not be provided to the provider or participant until the 6-month visit.
89434676|NCT05255601|Experimental|Relatlimab + Nivolumab|
89434677|NCT05252390|Experimental|Phase 1 Monotherapy|NUV-868 will be administered at escalating dose levels until the maximum tolerated dose (MTD) is reached or a recommended Phase 2 dose (RP2D) is determined.
89434678|NCT05252390|Experimental|Phase 1b Combination: NUV-868 + Olaparib|"NUV-868 will be administered at escalating dose levels in combination with olaparib until the recommended Phase 2 combination dose (RP2cD) is determined.~300 mg olaparib will be administered orally twice daily throughout the 28-day cycles of NUV-868."
89434679|NCT05252390|Experimental|Phase 1b Combination: NUV-868 + Enzalutamide|"NUV-868 will be administered daily at escalating dose levels in combination with enzalutamide until the RP2cD is determined.~160 mg enzalutamide will be administered orally daily throughout the 28-day cycles of NUV-868."
89434680|NCT05252390|Experimental|Phase 2 Combination: NUV-868 + Olaparib|"NUV-868 will be administered at the RP2cD.~Olaparib will be administered at the RP2cD."
89434681|NCT05252390|Experimental|Phase 2 Combination: NUV-868 + Enzalutamide|"NUV-868 will be administered at the RP2cD.~Enzalutamide will be administered at the RP2cD."
89434682|NCT05252390|Experimental|Phase 2: NUV-868 Monotherapy|NUV-868 will be administered at the RP2D in one arm of a randomized Phase 2 combination (NUV-868 + enzalutamide) cohort.
89434683|NCT05252390|Active Comparator|Phase 2: Enzalutamide Monotherapy|160 mg enzalutamide will be administered orally daily in one arm of a randomized Phase 2 combination (NUV-868 + enzalutamide) cohort.
88915117|NCT01613820|Experimental|Scopolamine plus placebo|Subjects will receive a 15 minute infusion of IV scopolamine 2ug/kg followed by a 45 minute infusion of normal saline (placebo).
89434684|NCT05248386|Experimental|RTX-GRT7039|Participants will receive 2 intra-articular injections of RTX-GRT7039 during the 52-week double-blind treatment period.
89434685|NCT05248386|Placebo Comparator|Placebo|Participants will receive 2 intra-articular injections of placebo matching to RTX-GRT7039 during the 52-week double-blind treatment period.
89434686|NCT05247060||Hypertensive Patients Hospitalized in Internal Medicine|Clinical data will be collected from all consecutive patients diagnosed with arterial hypertension hospitalized in Internal Medicine and able to assume the erect station
88915118|NCT01613820|Experimental|Ketamine plus scopolamine|Subject will receive an IV scopolamine infusion at a dose of 2ug/kg over 15 minutes, followed by an IV infusion of ketamine at a dose of 0.25mg/kg over 45 minutes.
88915119|NCT01613833||Primary OA Group|Subjects who are to undergo primary total knee arthroplasty due to primary OA which may include but is not limited to bilateral or peripheral involvement with no significant history of overuse or trauma to the joint.
89434687|NCT05246657||intervention|EUS-guided Entero-biliary Anastomosis
89434688|NCT05246644|Experimental|Intravenous Acetaminophen|subjects will receive IV acetaminophen and a placebo oral acetaminophen starting immediately after surgery and for 8 doses
89434689|NCT05246644|Active Comparator|Oral acetaminophen|subjects will receive a placebo for IV acetaminophen and active oral acetaminophen starting immediately after surgery and for 8 doses
89434690|NCT05245682|Experimental|Treatment (tolinapant, radiation therapy)|Patients undergo standard of care radiation therapy for a total of 35 fractions over 7 weeks and receive tolinapant PO daily for 7 days during weeks 1, 3, 5, and 7 of radiation therapy in the absence of disease progression or unacceptable toxicity.
89434691|NCT05239988||COVID-19 patients treated with Remdesivir|Patients suffering from SARS-CoV-2 and treated with Remdesivir admitted to Internal Medicine Unit
89434692|NCT05238389|Experimental|Robotic group|In the robotic group, patients will undergo a 30-session upper limb robotic rehabilitation using the device MOTORE.
88915120|NCT01613833||Secondary/Post-traumatic OA Group|Subjects who are to undergo primary total knee arthroplasty due to osteoarthritis of the knee that is secondary to injury or overuse of the joint.
89434693|NCT05233930|Experimental|TKR with augmented reality-based navigation system.|This technology offers the orthopedic surgeon intraoperative assistance in positioning the implants with the help of a pair of augmented reality glasses. The cutting planes are oriented with respect to the mechanical axes calculated according to anatomical landmarks acquired with a pointer. The connected glasses calculate precisely the 3D coordinates of the instruments thanks to the analysis of their specific markers (QR-Code), filmed by the integrated camera. The navigation information is displayed in the surgeon's field of vision, who interacts with the application thanks to the glasses' accelerometers.
88915121|NCT01613846|Experimental|Sorafenib followed by pazopanib|"Sorafenib 400 mg bid orally until progression or intolerable toxicity, followed by pazopanib 800 mg once daily orally until progression or intolerable toxicity.~During first- and second-line, treatment visits are scheduled in weeks 0,2,4,8,12, and every 4 weeks thereafter, with tumor assessments and electrocardiogram after every second cycle (every 8 weeks)."
88915122|NCT01613846|Experimental|Pazopanib followed by Sorafenib|"Pazopanib 800 mg once daily orally until progression or intolerable toxicity, followed by Sorafenib 400 mg bid orally until progression or intolerable toxicity:~During first- and second-line, treatment visits are scheduled in weeks, 0,2,4,8,12, and every 4 weeks thereafter, with tumor assessments and electrocardiogram after every second cycle (every 8 weeks)."
88915123|NCT01613872|No Intervention|Control|Wait List Control
88915124|NCT01613872|Experimental|Mindfulness Based Stress Reduction|An 8 week standardized protocol of stress reduction using gentle yoga and meditation
88915125|NCT01613885||Twins|Twins that are ages 0 to 80 years, with or without allergy disease.
88915126|NCT01613898||CTX Group|
88915127|NCT01613911||Epileptics having invasive monitoring|People between 10 and 65 years of age with epilepsy and who are coming in to have invasive electrophysiological monitoring.
88915128|NCT01613924|Placebo Comparator|Heat based treatment/no treatment|Split face treatment with handheld acne heat based device and no treatment
88915129|NCT01613924|Active Comparator|Heat based treatment/benzoyl peroxide|Split face treatment with handheld acne heat based device and benzoyl peroxide 4%
88915130|NCT01613937|Experimental|Lifestyle|12 once weekly Lifestyle training program
88915131|NCT01613950|Experimental|BYL719 + AUY922|Dose finding study to estimate the maximum tolerated dose(s) (MTD) and/or recommended dose(s) for safety expansion (RDE) followed by an expansion phase to further assess the safety and preliminary activity of the combination. BYL719 tablets will be administered orally on a daily schedule (q.d.). a b.i.d. regimen may be explored. AUY922 will be administered by IV infusion once per week.
88915132|NCT01613963||Patients with ocular inflammation|Patients with ocular inflammation
88915133|NCT01613976|Experimental|Panobinostat and Azacitidine|combination regimen
88915134|NCT01614002||carcinoma, Doce onkovis (Docetaxel)|treatment in mono- or combination therapy with Docetaxel of breast cancer, non-small cell lung cancer, prostata carcinoma, adenocarcinoma of the stomach and advanced squamous cell carcinoma of the head/neck region.
88915135|NCT01614015|Experimental|Supervision as Usual|Supervision as Usual
88915136|NCT01614015|Experimental|Observation Based Supervision|Behavioral
88915137|NCT01614028|Active Comparator|Total Hip Arthroplasty using Fitmore femoral stem|
88915138|NCT01614028|Active Comparator|Total Hip Arthroplasty using M/L Taper Femoral stem|
88915139|NCT01614041|Active Comparator|Control Group|Patient randomized to control group is administrated with usual dose of tandospirone treatment, 30 mg/day
88915140|NCT01614041|Experimental|Study Group|Comparative high dose of tandospirone treatment, 60 mg/day
88915141|NCT01614054|Experimental|Survey Group|Patients will receive a survey along with their meal tray, provided by Food and Nutrition Services. The survey will consist of questions related to smoking habits, desire for NRT and desire for assistance with smoking cessation. The results of these surveys will be collected by allied health professionals and forwarded to the CTU team. The CTU team will then be encouraged to use that information to engage in a discussion with the patient regarding prescription of NRT. It will then be left to the discretion of the HCP whether or not to prescribe NRT taking into account patient preference, absence of contraindications and clinical benefit. All those participating in the survey will be offered referral to a smoking cessation clinic upon discharge.
88915142|NCT01614054|No Intervention|Standard of Care|In the control arm, surveys will also be given out to all patients along with their meal trays. However, these surveys will include only questions related to smoking habits in order to get a baseline number of smokers. The surveys will then be collected by the allied health and nursing staff and forwarded only to the research team. The HCP taking care of the patients will still provide standard of care treatment with NRT and smoking cessation referral as clinically indicated.
88915143|NCT01614080||High sc-tPA/tc-tPA ratio group|A threshold value of the sc-tPA/tc-tPA ratio will be defined as the median value found in the population. The High sc-tPA/tc-tPA ratio group will be defined as the group of patients with a sc-tPA/tc-tPA ratio higher than the median
89198197|NCT04011514||Baseline period|Usual care. Stroke patients admitted to the ED during the 3-month baseline inclusion period.
89434694|NCT05233930|Active Comparator|TKR with traditional mechanically aligned technique.|TKR with traditional mechanically aligned technique will be performed according to local practice and standard guidelines.
89434695|NCT05232981|Experimental|Study group|Conservative management of PAS with Ligation of the bilateral internal iliac arteries
89434696|NCT05232981|Active Comparator|Control group|Conservative treatment with Shehata's technique and no internal iliac ligation
89434697|NCT05232630|Experimental|- Group 1A.|Patients with genetic testing showing a pathogenic or likely pathogenic variant in main synaptopathy genes (SYNGAP1 and STXBP1)
89434698|NCT05232630|Experimental|Group 1B.|Patients with genetic testing showing a pathogenic or likely pathogenic inverted duplication of chromosome 15 [inv-dup (15)].
89434699|NCT05232630|Experimental|Group 1C.|Patients with neuroimaging showing multifocal or bilateral malformations of cortical development.
89434700|NCT05232630|Experimental|Group 2.|Electroclinical diagnosis of Continuous Spikes and Waves during Sleep (CSWS) syndrome, with baseline video-EEG monitoring showing epileptiform activity occupying at least 50% of slow sleep tracing, after failing at least 3 antiseizure medications
89434701|NCT05226559|Active Comparator|Multimodal Physical therapy approach plus usual care|HVLA spinal manipulation, mobilization, soft tissue treatment, therapeutic exercise, education, plus standard pharmacological treatment.
89434702|NCT05226559|No Intervention|Usual care|Standard pharmacological treatment alone
89434703|NCT05226507|Experimental|Part A: Dose Escalation|Escalating doses of NXP800.
89434704|NCT05226507|Experimental|Part B: Expansion in Ovarian Cancers Cohort 1|Subjects will be treated with NXP800 at 50 mg/day.
89434705|NCT05226507|Experimental|Part B: Expansion in Ovarian Cancers Cohort 2|Subjects will be treated with NXP800 at 75 mg/day.
89434706|NCT05226169|Experimental|Active treatment arm : IV FCM|Intravenous ferric carboxymaltose
89434707|NCT05226169|Active Comparator|Control treatment arm: Conservative management|"Conservative management~Absolute IDA: oral ferrous sulfate~Functional IDA: no treatment or oral ferrous sulfate according to the physician's choice~Other IV iron or PRC transfusion or ESA therapy is not allowed"
89434708|NCT05225298|Active Comparator|Static frequency|Test based screening for SARS-CoV-2 every two weeks
89434709|NCT05225298|Active Comparator|Dynamic frequency|Test based screening for SARS-CoV-2 ranging from once a week to once every four weeks anchored to county COVID-19 case rates
89434710|NCT05223751|Experimental|HRV4 + Breathing and Humming Training|On a biweekly basis, and with the other members of their subgroup within the cohort, participants will meet with the Meo Health breathing coach on Zoom for approximately 30 minutes. These sessions will encourage participants to complete their daily exercises and provide additional respiratory training.
89434711|NCT05223751|No Intervention|HRV4 Only|Control participants will complete the daily heart rate variability (HRV) reading using the HRV4Training application.
89434712|NCT05223608|Other|ImmuCCo Cohort|"Blood sampling at initiation of immunotherapy, at the first tumor assessment, in case of severe toxicity.~Urine collection at initiation of immunotherapy."
89434713|NCT05220709|Other|Bio impedance spectroscopy in children scheduled for elective surgery under general anesthesia|All subjects receive bio impedance monitor measurements pre operatively and post operatively.
89434714|NCT05219331|Other|Disorder of consciousness|Ventriculo peritoneal shunt
89434715|NCT05214911|Experimental|Experimental drug (Desloratadine 0.5 mg/mL/Prednisolone 4 mg/mL)|ADF Group 1 - Eurofarma drug association of Desloratadine 0.5 mg/mL / Prednisolone 4 mg/mL
88915144|NCT01614080||Low sc-tPA/tc-tPA ratio|A threshold value of the sc-tPA/tc-tPA ratio will be defined as the median value found in the population. The Low sc-tPA/tc-tPA ratio group will be defined as the group of patients with a sc-tPA/tc-tPA ratio lower than the median
88915145|NCT01614119|Experimental|Sportsmen|One single group of active healthy subjects was investigated
88915146|NCT01614132|Experimental|Vincristin, CCNU, cis-platin|"radiotherapy and concomitant chemotherapy (7 cycles of 7 days):~2 mg/m2 vincristin i.v.~55,0 Gy Posterior cranial fossa (M0)~55,0 Gy Posterior cranial fossa / cerebral metastases + 49,6 Gy spinal metastases (M1-M3)~maintenance chemotherapy (8 cycles of 42 days):~once at day 1 at each cycle: 70 mg/m2 cis-platin i.v. 75 mg/m2 CCNU oral 2 mg/m2 vincristin i.v.~once at day 8 and 15 at each cycle: 2 mg/m2 vincristin i.v."
88915147|NCT01614145||Proven/probable CNS IA|Immunocompromised patients with proven/probable invasive CNS Aspergillosis based on modified criteria by the EORTC/MSG
88915148|NCT01614145||Possible/No CNS IA|Immunocompromised patients with possible/NoIA invasive CNS Aspergillosis based on modified criteria by the EORTC/MSG
88915149|NCT01614158||acute N-AION (< 7 d)|"physical, intellectual and linguistic abilities, in order to understand the test requirements~willingness to comply with the protocol (4 visits)~45 - 80 years, informed consent~acute N-AION (< 7 d)~D-BCVA > 0.1 (2/20)~RAPD ≥ 0.3 logE steps (neutral density filters)"
88915150|NCT01614184|Experimental|All patients|All patients enrolled in study.
88915151|NCT01614223|Active Comparator|ACP treatment|
88915152|NCT01614223|Active Comparator|Corticosteroid treatment|
88915153|NCT01614236|Active Comparator|control|patients will be randomized similarly but will undergo surgery under epidural analgesia
88915154|NCT01614236|Active Comparator|Lyrica|Patients will received 150 mg of PGL or placebo at 20:00 the evening before surgery and 1.5 h before surgery and will undergo surgery under GA
88915155|NCT01614262|Experimental|Continuous Glucose Monitoring|The Continuous Glucose Monitoring (CGM) arm will receive care based upon results from there CGM data; treatment decisions are based on algorithm and CGM data
88915156|NCT01614262|Active Comparator|Self Monitoring Blood Glucose|Subjects in the Self Monitoring Blood Glucose group will have treatment decisions based on self monitored blood glucose values and not CGM values, per current standard of care.
88915157|NCT01614275|Experimental|Technology-enhanced Parent Training|The investigators will demonstrate that web-based instructional technologies provides an efficient and effective mechanism for training military parents of children with autism, regardless of their geographic location, to implement effective behavior management and teaching strategies with high procedural integrity (90% accuracy).
88915158|NCT01614275|Experimental|Technology-enhanced Tutor Training|The investigators will demonstrate that web-based instructional technologies provides an efficient and effective mechanism for training tutors to implement early intervention services that are commonly used with children diagnosed with autism with high procedural integrity (above 80%).
88915159|NCT01614275|Experimental|Technology-enhanced Early Intensive Behavioral Intervention|The investigators will demonstrate that technology-enhanced service delivery will provide remote access to efficient and effective EIBI services to military families affected by autism.
89198198|NCT04011514||Intervention period|Intervention: 2 month implementation period of specialized stroke nurses allocated to ED for nurse specific treatment of stroke patients specific observations and care
89198199|NCT00867243||Group 1: HCV Positive|50 patients whom are HCV positive
89434716|NCT05214911|Active Comparator|Active Comparator: Desalex® (Desloratadine 0.5 mg/mL)|Desalex® Group 2 - Eurofarma drug Desloratadine 0.5 mg/mL
89434717|NCT05202327|Placebo Comparator|Placebo|Two placebo capsules thrice daily for 56 days (8 weeks).
89198200|NCT00867243||Group 2: HCV Negative|50 patients whom are HCV negative.
89434718|NCT05202327|Experimental|Low-dose|One placebo capsule and 1 PDC-1421 Capsule, thrice daily for 56 days (8 weeks).
89434719|NCT05202327|Experimental|High-dose|Two PDC-1421 Capsules thrice daily for 56 days (8 weeks).
89434720|NCT05201235|Experimental|MAEVAD - DeCaLigne|The experimental group will first receive MAEVAD then the control therapy
89434721|NCT05201235|Placebo Comparator|DeCaLigne - MAEVAD|The control group will first receive the control therapy then MAEVAD
89434722|NCT05191485||Patients of decision making need assessment|"We will conduct semi-structured interviews with target patients and patients' representatives to assess their decisional needs. Decisional needs including difficult decision type /timing, unreceptive decisional stage, decisional conflict (uncertainty), inadequate knowledge & unrealistic expectations, unclear values, inadequate support & resources, and Personal & clinical needs. All interviews will be conducted one-to-one or one-to-many (including families) and be audio-recorded for further analysis. Written informed consent will be obtained prior to each interview.~Nonrandom purposive sampling will be used to select key respondents to conduct in depth interview. Snowball sampling, where potential participants are asked to identify others who may be willing to participate, as well as convenience sampling, will be utilized. For patients, aiming for diversity regarding age, sex, education level and annual household income. All participants should be Chinese-speaking."
89531280|NCT04467879|Experimental|"Zona Plus - Active - Normal Grip"|Using the Zona Plus Device, the patient will perform a twelve-minute isometric handgrip therapy session at approximately the same time each day . After an initial handgrip strength assessment (the session calibration), a two-minute isometric routine is performed four times, two sessions per hand, with a one-minute non-grip, or rest session between each isometric routine.
89198201|NCT00921804|Experimental|1|AZD8529 40 mg
89198202|NCT00921804|Placebo Comparator|2|Placebo
89198203|NCT00921804|Other|3|Risperidone 4 mg (2mg on Day 1)
89198204|NCT00949468||Keratitis group|37 patients with keratitis
89198205|NCT00949468||Control Study Group|37 control volunteers
88915160|NCT01614275|Placebo Comparator|Wait-list No-intervention Control Group|Tutors and families will be assigned to treatment and control groups using the process of minimization, which has been recommended for small clinical trials because it minimizes differences between the groups on relevant covariables while guarding against bias in ways comparable to simple randomization. The control group will not receive intervention services.
88915161|NCT01614288|Active Comparator|Knee Arthroscopy + HTO|
88915162|NCT01614288|Active Comparator|HTO Alone|
88915163|NCT01614301|Experimental|Experimental Arm|Temsirolimus: 15 or 25 mg iv weekly , week 1+.In the phase I part of the study the finally used dosis will be determined. Pioglitazone (Actos) 60 mg p.o. daily, day 1+. Etoricoxib (Arcoxia) 60 mg p.o. daily, day 1+ Trofosfamide (Ixoten) 50 mg p.o. thrice daily as metronomic angiostatically and immunomodulatory acting therapy, day 1+. Treatment until disease progression or toxicity
88915164|NCT01614301|Other|Controll Arm|Dacarbazine (DTIC) 1000 mg/m2 day 1, every 3 weeks. The total number of DTIC cycles should not exceed 6 cycles due to cumulative toxicity.
88915165|NCT01614314|Active Comparator|Auto-instructional guide|The subjects performed the procedure on a manikin simulator, with the aid of an auto-instructional guide, lasting one hour.
88915166|NCT01614314|Experimental|Preceptorship|The subjects performed the procedure on a manikin simulator, with the aid of a nurse preceptorship, lasting one hour.
88915167|NCT01614327||Retinal Screening; Diabetes 1 and 2|Patients diagnosed as either having Pre-Diabetes, Diabetes 1 or Diabetes 2
88915168|NCT01614340|Other|Usual Care|Usual Physical Therapy Plan of Care
88915169|NCT01614340|Other|Usual Care Plus Pain Management Program|Behavioral: Cognitive-Behavioral Pain Self-management Program.
88915170|NCT01614353||Study Cohort|All participants (N=30) will be asked to identify perceptions and behaviors surrounding the medication-taking process using technology-assisted prompts and recordings. Half (n=15) of the participants will participate in two hermeneutic interviews using an interpretive phenomenological approach to generate an interpretation of the meaning of medication taking.
88915171|NCT01614366|Active Comparator|AM 5 + DM 0|Amlodipine 5 mg + DMTA07 0mg, once daily
88915172|NCT01614366|Experimental|AM 5 + DM 2.5|Amlodipine 5 mg + DMTA07 2.5mg, once daily
88915173|NCT01614366|Experimental|AM 5 + DM 7.5|Amlodipine 5 mg + DMTA07 7.5mg, once daily
89198206|NCT02534779|Experimental|Placebo Vaginal Insert|Placebo insert
89198207|NCT00867399|Active Comparator|20mg of ABT-126 QD|20 mg of ABT-126 QD for 10 days
89198208|NCT00867399|Active Comparator|30mg and 45mg ABT-126 QD|30 mg and 45mg of ABT-126 QD for 21 days
89198209|NCT00758316|Active Comparator|1|Thoracoscopy with pleurodesis Patients will then undergo standard medical thoracoscopy in the endoscopy center including the use of moderate sedation, prophylactic antibiotics for 1 week and 20F chest tube insertion at the end of the procedure.
89198210|NCT00758316|Experimental|2|Combined thoracoscopy with pleurodesis and pleurx catheter. In the combined procedure group, a PleurxTM tunnelled catheter will be inserted under ultrasound guidance. As this procedure will be done concurrently with thoracoscopy, there is no estimated increase in endoscopy time.
89198211|NCT00859755|Experimental|ARRY-403|
89198212|NCT00859755|Placebo Comparator|Placebo|
89198213|NCT00754182|Experimental|A|Patients underwent thyroidectomy, emithyroidectomy, parathyroidectomy sutured with synthetic glue
89198214|NCT00754182|Active Comparator|B|Patients underwent thyroidectomy, emithyroidectomy, parathyroidectomy sutured with subcuticular suture
89198215|NCT00859911|Active Comparator|2|Thiamine Mononitrate 5mg, Riboflavin 2 mg, Niacin amide 20 mg, Pyridoxine hydrochloride 2 mg
89198216|NCT00859911|Experimental|1|Vitamin A 1500 µg, Vitamin D 15 µg, Thiamine Mononitrate 1.22 mg, Riboflavin 1.7 mg, Ascorbic Acid 60 mg, Niacin amide 20 mg, Pyridoxine hydrochloride 2 mg, Folic Acid 400 µg, Calcium pantothenate 10.8 mg, Cyanocobalamin 6 µg, Vitamin E 18 IU, ferrous sulphate 19 mg, potassium iodide 145 µg, Potassium sulphate 11 mg, Manganese sulphate 0.38 mg, copper sulphate 0.509 mg, zinc sulphate 15 mg
89198217|NCT00954694|Experimental|introductory exercise regimen|sedentary adults will be introduced to an introductory fitness regimen using the NuStep
89198218|NCT00385723|Experimental|1|1.25 g/d
89198219|NCT00385723|Experimental|2|2.496 g/d
89198220|NCT00385723|Placebo Comparator|3|
89198221|NCT00698516|Experimental|Open label, Single arm|Oral topotecan + IV Bevacizumab
89198222|NCT00679302|Placebo Comparator|placebo group|Maalox and bitter mixture
89198223|NCT00679302|Active Comparator|antibiotic group|Trimethoprim-sulfamethoxazole suspension
89198224|NCT04011124|Experimental|Rifampicin + Fluzoparib|
88915174|NCT01614366|Experimental|AM 5 + DM 30|Amlodipine 5 mg + DMTA07 30mg, once daily
88915175|NCT01614379||Healthy control subject|10 healthy control subjects for statistical comparison
88915176|NCT01614379||Type 1 diabetic patient|40 type 1 diabetic patients with diabetic foot ulcers.
88915177|NCT01614405|Placebo Comparator|Placebo|6 months therapy with blinded placebo followed by 6 months open label therapy with Kaletra and Truvada. Then there is an option for an 18 month follow-up study.
88915178|NCT01614405|Active Comparator|Truvada and Kaletra|Patients will be take Truvada and Kaletra for 6 months with the option of open label for additional 18 months.
88915179|NCT01614418|Experimental|Endoscopic radiofrequency ablation|Endoscopic radiofrequency ablation using BARRX HALO90 catheter
89198225|NCT00862797||endotracheal tube|Patients intubated with cuffed endotracheal tubes
89198226|NCT00954772||Staged Bilateral STN DBS|
89198227|NCT00954772||Simultaneous Bilateral STN DBS|
89198228|NCT01047397|Experimental|Group 1|Active Drug
89198229|NCT01047397|Placebo Comparator|Group 2|Placebo
89198230|NCT02564822||Migraneurs - Visual stimulation|Patients will be recruited via advertisements on the university. Patients should have migraine diagnosis according to the International Classification of Headache Disorders (ICHD-III) criteria and clinical diagnosis by a neurologist.
89198231|NCT02564822||Control - Visual stimulation|Healthy volunteers will be recruited via advertisements on the university. For control subjects the individuals should not have migraine diagnosis assessed according to IHCD-III criteria.
89198232|NCT00754416||S.E.S prosthesis|Consecutive series of patients with a S.E.S prosthesis.
89198233|NCT00954850||Severe asthmatics|Main study group
89198234|NCT00954850||Mild-moderate asthmatics|Control group
89198235|NCT00862875|Experimental|1:Insulin detemir|Insulin detemir (Levemir® - Novolin® 4 pen)
89198236|NCT00862875|Active Comparator|2:Insulin Glargin|Insulin glargine (Lantus® - Solostar®)
89198237|NCT02566616|Experimental|Intervention|"Cubital Tunnel Release with stimulator for nerve location~1 hour of Ulnar nerve stimulation"
89198238|NCT02566616|Active Comparator|Non-Intervention|Cubital Tunnel Release with stimulator for nerve location NO prolonged ulnar nerve stimulation
89198239|NCT00867477|Experimental|Cohort 1: Esophagus Cancer|Breathing Test + Respiratory Symptoms Questionnaire
89198240|NCT00867477|Experimental|Cohort 2: Lung Cancer|Breathing Test + Respiratory Symptoms Questionnaire
89198241|NCT00954928||Anticoagulated patients|Those patients taking Coumadin, Plavix, Aspirin, Lovenox.
89198242|NCT00954928||Control patients|Those patients having hand or wrist surgery who do not take any anticoagulant medication.
89198243|NCT00867555|Experimental|EGCG|"Double blind randomized, placebo-controlled cross-over design with two arms:~the green tea extract TEAVIGO, high in EGCG and~placebo"
89198244|NCT00867555|Placebo Comparator|placebo|
89198245|NCT00955006|Experimental|Group 1|Participants will receive three injections of VRC-HIVDNA-016-00-VP at Months, 0, 1, and 2 and one injection of VRCHIVADV014-00-VP at Month 6.
89198246|NCT02544165|Experimental|Caffeine intake|100mg of Caffeine intake
89198247|NCT02544165|Experimental|Cigarette smoking|smoking of one cigarette
89198248|NCT02544165|Experimental|Caffeine intake and Cigarette smoking|100mg of Caffeine intake and smoking of one cigarette
89198249|NCT02544165|No Intervention|Control group|no intervention group
89198250|NCT05343156|Experimental|DexNP Eye Drop|The study eye received 1 DexNP eye drop 3 times a day (every 8 hours) for 12 weeks.
89198251|NCT05343156|Placebo Comparator|Vehicle Eye Drop|The study eye received 1 vehicle eye drop 3 times a day (every 8 hours) for 12 weeks.
89198252|NCT00955162|Active Comparator|Subutex|
89198253|NCT00955162|Experimental|Suboxone|
89198254|NCT00867633||Urothelial carcinoma|The DNA samples extracted from the urothelial carcinoma tissue
89198255|NCT00867633||RCC|the DNA sample extracted from RCC
89198256|NCT00867633||Non-cancer|The DNA sample extracted from the non-cancerous kidney tissue
89198257|NCT00742664|Experimental|1|Will receive 12 sessions of twice weekly psychotherapy targeting obsessive-compulsive symptoms.
89198258|NCT00742664|Placebo Comparator|2|
89198259|NCT00862953|Active Comparator|Normal protein normal carbohydrate|Normal protein normal carbohydrate calory restricted nutrition
88915180|NCT01614431|Experimental|N acetyl cysteine|NAC will be given to cystinosis patients and we will observe the renal function status and a marker of oxidative stress (TBARS)
88915181|NCT01614444|Active Comparator|Acupressure Treatment|
88915182|NCT01614444|Placebo Comparator|Placebo Acupressure Treatment|
88915183|NCT01614522|Experimental|HER-2 Amplified|
88915184|NCT01614522|Experimental|HER-1 & HER-2 Co-expression|
88915185|NCT01614535|Experimental|Female group|Female gender patients undergoing thyroidectomy
88915186|NCT01614535|Active Comparator|Male group|Male gender patients undergoing thyroidectomy
89198260|NCT00862953|Experimental|Normal protein low carbohydrates|Normal protein low carbohydrate energy-restricted diet
89198261|NCT00862953|Experimental|High protein normal carbohydrates|High protein normal carbohydrates
89198262|NCT00862953|Experimental|High protein low carbohydrate|High protein low carbohydrate nutrition
89198263|NCT00949546||placebo controlled|A randomized, double-blind trial of 3 months duration comparing etanercept 50 mg sc twice weekly to placebo in 20 patients with HS. Patients will be randomized with equal allocation to the two treatment groups.
89198264|NCT00742742|Experimental|A|Nutrition advice (accroding to AHA recommendation) + 30 grams/day supplement of walnuts,walnuts were incorpatated into bread that provided to the participants
89198265|NCT00742742|Sham Comparator|B|Registed dietians give the advice for health lyfestyle
89198266|NCT00949624|Experimental|Cohort 1|60 mg BID/ 75 mg/m2
89434723|NCT05191485||Other stakeholders of decision making need assessment|"We will conduct semi-structured interviews with other stakeholders to assess their decisional needs. All interviews will be conducted one-to-one and be audio-recorded for further analysis. Written informed consent will be obtained prior to each interview.~Nonrandom purposive sampling will be used to select key respondents to conduct in depth interview. Snowball sampling, where potential participants are asked to identify others who may be willing to participate, as well as convenience sampling, will be utilized. For other stakeholders (including thoracic surgeons, nurses, psychoanalyst, hospital administrators, molecular testing company staffs and insurance company staffs), region, seniority, position, and attitude toward both molecular testing and SDM are considered. All participants should be Chinese-speaking."
89434724|NCT05191485||Participants of cognitive debriefing/alpha tests|The purpose of Alpha test is to test the understandability of Decision Aid for Lung Cancer Molecular Testing version 1.0 (DA_LCMT 1.0). All debriefing interviews will be conducted one-on-one with structured probing questions. Participants will be encouraged to comment on DA_LCMT 1.0 and give recommendations to replace any unclear wording. At the start, the interviewer will explain the aim of the study and the procedures of the cognitive debriefing to participants. Then a paper-based DA_LCMT 1.0 will be given to participants, and sufficient time will be guaranteed to allow them to read DA_LCMT 1.0. The cognitive debriefing interview will start afterwards, and participants will answer questions probing questions asked by interviewers about DA_LCMT 1.0. Each cognitive debriefing interview will last for about 20 minutes. DA_LCMT 2.0 will be generated after the completion of the cognitive debriefing (Alpha test).
89434725|NCT05191485||Patients of Field testing /β tests|"Then the investigators will conduct the field testing (Beta test) with patient and clinician facing the decision in real time. The purpose of Beta test is to test the usability of DA_LCMT 2.0 in real-world setting. Clinician and patients will use the DA_LCMT 2.0 for real-time decision making. The conversation of decision progress will be audio-recorded. After the decision is made by patients, structured interview will be conducted and audio-recorded separately between clinician and patients. All the field testing interviews will conducted one-on-one and written informed consent will be obtained prior to each interview. Each field testing interview will last for about 20 minutes."
89434726|NCT05191485||Clinician of Field testing /β tests|"Then the investigators will conduct the field testing (Beta test) with patient and clinician facing the decision in real time. The purpose of Beta test is to test the usability of DA_LCMT 2.0 in real-world setting. Clinician and patients will use the DA_LCMT 2.0 for real-time decision making. The conversation of decision progress will be audio-recorded. After the decision is made by patients, structured interview will be conducted and audio-recorded separately between clinician and patients. All the field testing interviews will conducted one-on-one and written informed consent will be obtained prior to each interview. Each field testing interview will last for about 20 minutes."
89434727|NCT05189834|Other|Treatment sequence A|"Patients will follow the following treatment sequence:~Treatment with Gelsectan® (30 days)~Washout period (15 days)~Treatment with placebo (30 days)"
89434728|NCT05189834|Other|Treatment sequence B|"Patients will follow the following treatment sequence:~Treatment with placebo (30 days)~Washout period (15 days)~Treatment with Gelsectan® (30 days)"
89434729|NCT05188898|Experimental|Hyaluronic acid Group|Hyaluronic acid gel will be applied in intraosseous periodontal defects, after Minimally Invasive Non Surgical Debridement (MINSD)
89434730|NCT05188898|Active Comparator|No-hyaluronic acid Group|Only Minimally Invasive Non Surgical Debridement (MINSD) will be performed
89434731|NCT05186909|Experimental|CM310 300mg Q2W|CM310 is injected subcutaneously (SC) with a loading dose of 600 mg at the first dose, and then 300 mg each time, once every 2 weeks (Q2W) for a total of 12 doses.
89434732|NCT05186909|Experimental|CM310 150mg Q2W|CM310 is injected subcutaneously (SC) with a loading dose of 300 mg at the first dose, and then 150 mg each time, once every 2 weeks (Q2W) for a total of 12 doses.
89434733|NCT05186909|Placebo Comparator|Placebo|Subcutaneous injection (SC), once every 2 weeks (Q2W) for a total of 12 doses.
89434734|NCT05185661|Experimental|Intervention Group|"Two surveys: Demographic, lifestyle, hygiene-related (1) & knowledge, attitude, and practice (2) regarding anemia at baseline and end line of study.~Investigations and physical examination will perform for CBC blood test except ESR, urine R/E, stool R/E, Height, weight for BMI, waist circumference, hip circumference, hip - waist ratio, and mid-upper arm circumference (MUAC) at baseline, mid-line, and end-line of study."
89536399|NCT02476643||Integrative Therapy|"This group receives and integrative therapy at the Department of Internal and Integrative Medicine, i.e. a combination of conventional diagnostic and therapeutic interventions with specific naturopathic, and complementary medicine approaches, and physical therapy.~Patients are admitted to the hospital ward for 14 days."
89198267|NCT00949624|Experimental|Cohort 2|100 mg BID/75 mg/m2
89198268|NCT00949624|Experimental|Cohort 3|100 mg BID/100 mg/m2
89198269|NCT00949624|Experimental|Cohort 4b|CP-868,596 + AG-013736 + TXT 75
89198270|NCT02560272|Experimental|Minhai-HIB|Participants at age 1 to 5 years of enrollment will receive one dose on Hib vaccine. Participants at age 6 to 11 months of enrollment will receive 2 doses on Hib vaccine at one months apart. Participants at age 2 to 5 months of enrollment will receive 3 doses on Hib vaccine at one months apart.
89010022|NCT04561414|Other|Ureteral stent (Cook Ireland Ltd.)|The prospective, multi-center, single-blind, parallel, randomized controlled superiority trial design is adopted to evaluate the safety and effectiveness of the LED light source system for endoscope during ureter transillumination. The trial will be carried out in 5 centers, with the competitive grouping mode adopted. This trial will be carried out in the General Surgery Department and the Gynecology Department. Totally 120 subjects with rectal cancer, endometriosis, cervical cancer, adenomyosis and pelvic adhesion requiring operation (60 subjects for each of the test group and control group) are involved. The control group use Ureteral stent (Cook Ireland Ltd.)
89010023|NCT04561726|Experimental|Study Group|"All of the 20 participants in the study group were asked to do the given 11 home exercises (balance, stretching and strengthening exercises) twice a week for 6 weeks. The exercises were progressed day by day. All of the exercises were taught in the first assessment day, after the all measurements collected. All participants were controlled every week by social media and face-to-face conversations.~Additionally, CTM was applied to the volunteers in study group for 6 weeks, 2 sessions in a week.CTM applied to lumbosacral area (basic region), lower toracal, scapular, interscapular and cervical regions, respectively."
89010024|NCT04561726|Active Comparator|Exercise Group|All of the 20 participants in the exercise group were asked to do the given 11 home exercises (balance, stretching and strengthening exercises) twice a week for 6 weeks. The exercises were progressed day by day. All of the exercises were taught in the first assessment day, after the all measurements collected. All participants were controlled every week by social media and face-to-face conversations.
89010025|NCT04561531|Experimental|Intermittent bolus|In intermittent bolus of 3%NaCl group ,patients will receive intermittent bolus of 3%NaCl 150 ml in 30 minutes and then follow plasma sodium,observe glasglow coma scale and level of consciousness until improvement of consciousness and achieve target plasma sodium which is 5 mmol/L in 6 hours and should not be overcorrected which defined that plasma sodium change should not be more than 12 mmol/L in 24 hours and 18 mmol/L in 48 hours.
89010026|NCT04561531|Experimental|Traditional continuous drip|In traditional continuous drip of 3%NaCl group ,patients will receive 3%NaCl adjust rate start from 1 ml/kg/hr and follow plasma sodium every 1 hour,observe glasglow coma scale and level of consciousness until improvement of consciousness and achieve target plasma sodium which is 5 mmol/L in 6 hours and should not be overcorrected which defined that plasma sodium change should not be more than 12 mmol/L in 24 hours and 18 mmol/L in 48 hours.
89010027|NCT00234806|Experimental|Telemedicine intervention group|
89010028|NCT00234806|Placebo Comparator|Control group|
89010029|NCT04561219|Experimental|Nitazoxanide|Patients received nitazoxanide 500mg 8/8hours, for 5 days.
89010030|NCT04561219|Placebo Comparator|Placebo|Patients received placebo 500mg 8/8hours, for 5 days
89010031|NCT04561609|Active Comparator|CO2 treated|Patients receiving treatment with transcutaneous application of gaseous CO2 on lower limbs
89010032|NCT04561609|Placebo Comparator|control|Patients receiving placebo treatment with air on lower limbs
89010033|NCT00424866|Placebo Comparator|Placebo|The dosing groups correspond to total doses of 0 µg/kg of FGF-1.
89010034|NCT00424866|Active Comparator|Human FGF-1|The dosing groups correspond to total doses of either 3, 10 or 30 µg/kg of FGF-1.
89010035|NCT02211625|Experimental|TRV734 125 mg|Part A, open-label will evaluate the the safety, PK and PD profile of a 125mg dose of TRV734 in which subjects are fasted, fed a standard meal, or fed a high-fat meal. Part A will also inform the dosing paradigm for Part B.
89010036|NCT02211625|Active Comparator|Multiple ascending dose study, active and placebo comparators|Part B will assess the safety, tolerability, PD and PK of TRV734. Subjects will be randomized in a ratio of 3:1:1 to receive either multiple doses of TRV734, oxycodone IR 10mg or placebo.
89010037|NCT02211664|Experimental|Passeo-18-Lux & Pulsar-18|"The interventional procedure sequence consists of the following steps:~pre-dilation of the lesion with a Passeo-18 balloon (mandatory)~dilation of the lesion with a Passeo-18 Lux drug releasing balloon (mandatory); a maximum of 2 Passeo-18 Lux balloons can be used per lesion (drug load cannot exceed 12µg)~stenting of the lesion with a Pulsar-18 stent (mandatory)~post-dilation of the lesion with a Passeo-18 balloon (not mandatory)"
89010038|NCT02211703||Observation|This is an epidemiology study in which all the data from the subjects enrolled will be collected and analysis to investigate the current patient warming condition and actual perioperative hyperthermia rate in the elective operation with general anesthesia. During the whole procedure none intervention is administered.
89010039|NCT00234923|Active Comparator|1|Kaletra Monotherapy: lopinavir/ritonavir
89010040|NCT00234923|Active Comparator|2|Kaletra based triple therapy: lopinavir/ritonavir + lamivudine/zidovudine
89010041|NCT04551937|Placebo Comparator|Control|4-5 week period where participant will consume control beverage
89010042|NCT04551937|Experimental|Prebiotic|4-5 week period where participant will consume the intervention beverage
89010043|NCT04552054|Active Comparator|CT guided localization|Computerized Tomography(CT)-guided percutaneous lung puncture staining marker localization
89010044|NCT04552054|Experimental|MR+3D guided localization|Mixed reality(MR)+3D printing-guided percutaneous lung puncture staining marker localization
89198271|NCT02560272|Active Comparator|Act-HIB®|Participants at age 1 to 5 years of enrollment will receive one dose on Hib vaccine. Participants at age 6 to 11 months of enrollment will receive 2 doses on Hib vaccine at one months apart. Participants at age 2 to 5 months of enrollment will receive 3 doses on Hib vaccine at one months apart.
89198272|NCT04019379|Experimental|Sequence A|Low Ca/High Phos crossover to Low Ca/Low Phos
89198273|NCT04019379|Experimental|Sequence B|Low Ca/Low Phos crossover to Low Ca/High Phos
89198274|NCT00690482|Experimental|AZD1981|AZD1981 Oral tablet, twice daily
89198275|NCT00690482|Placebo Comparator|Placebo|Placebo Oral tablet, twice daily
88915187|NCT01614548||all patients|We selected 9 cities (Zhengzhou, Luoyang, Kaifeng, Anyang, Xinyang, Zhoukou, Shangqiu, Nanyang, Zhumadian) by probability proportional to size sampling from geographical regions in central China. All cases with complete follow-up data of histological-proven prostate cancer treated in 2003 and 2008 at 14 department of urology in the 9 cities were retrospectively collected. Only patients with newly diagnosed prostate cancer were included in the study. Those with a history of prostate cancer who were treated for another disease were excluded from study.
88915188|NCT01614587||Cases|"Early, unexplained recurrence (within six months of procedure) after Sacrocolpopexy~The recurrence required treatment (surgery or pessary)"
88915189|NCT01614587||Controls|"Sacrocolpopexy during the same period~No recurrence, no reoperation, no retreatment to date (minimum of 12 months from surgery)"
88915190|NCT01614639|Experimental|Traditional Acupuncture|Traditional Acupuncture given at 2 visits.
88915191|NCT01614639|Experimental|Electroacupuncture|Electro-acupuncture given at 2 visits.
88915192|NCT01614652|Experimental|Parachute Implant and All Appropriate Medical Therapy (AAMT)|
88915193|NCT01614652|No Intervention|All Appropriate Medical Therapy (AAMT)|
88915194|NCT01614678|Other|AIR OPTIX® COLORS Auto, then AIR OPTIX® COLORS Semi-auto|Lotrafilcon B contact lens with color, automated, worn first, with Lotrafilcon B contact lens with color, semi-automated, worn second. Each product worn on a daily wear basis approximately 8 hours a day, 5 days a week, for 2 weeks.
89198276|NCT00385255|Experimental|BOOSTRIX+FLUARIX GROUP|Healthy male or female adults, aged between 19 to 64 years of age inclusive and 65 years or older, who received Boostrix® vaccine co-administered with Fluarix® vaccine at Day 0, injected intramuscularly in the left and right upper deltoid regions, respectively.
89198277|NCT00385255|Experimental|FLUARIX BOOSTRIX GROUP|Healthy male or female adults, aged between 19 to 64 years of age inclusive and 65 years or older, who received Fluarix® vaccine at Day 0 and Boostrix® vaccine at Month 1, both injected intramuscularly in the upper left deltoid region.
89198278|NCT05299996|Experimental|all patients having stones in the upper tract of anomalous kidney|"patients having stones in abnormal anatomy , example horse-shoe kidney ,malrotation, crossed fusion , duplex collecting system. The stone size is 1 cm to 2.5 cm or 3.5 cm with variable density , located in calyx or the pelvis , single or multiple.~the patient complain may be abdominal pain , loin pain, uremic symptoms .ct-kub non contrast , full lab & fitness before the operation."
89198279|NCT02560506|Experimental|Elastic assisted treadmill walking|Participants will participate in treadmill training with a low cost pulley system device made of rubber bands (Theraband(R)), which will assist therapists in advancing limbs while gait training.
89198280|NCT04005339|Experimental|Single Arm|Nanoliposomal irinotecan 70 mg/ IV over 90 minutes, every 14 days. Leucovorin 400 mg/ IV over 30 minutes, every 14 days. Fluorouracil 2,400 mg/m IV over 46 hours.
89198281|NCT00949780|Active Comparator|chloral hydrate , sedative|
89198282|NCT02544243|Experimental|A|Vinorelbine 25 mg/m2 d1, 8; Gemcitabine 1000 mg/m2 d1, 8 q 3 weeks
89198283|NCT02544243|Experimental|B|Vinorelbine 25 mg/m2 d1, 8; Cisplatin 25 mg/m2 d1,2,3 q 3 weeks
89198284|NCT04061408|Experimental|FSRT|3 to 5 fractions and 8Gy per fraction will be used for breast cancer patients with 1-10 brain metastases based on the lesion number and volume.
89198285|NCT04011670|Active Comparator|Caffeine group|Participants will receive a caffeine tablet and all electrical stimulations in a random order (tACS 140 Hz at 1 mA and sham tACS). Participant's vigilance status will be monitor based on active vigilance condition or passive vigilance condition.
89198286|NCT04011670|Placebo Comparator|Placebo group|Participants will receive a placebo tablet and all electrical stimulations in a random order (tACS 140 Hz at 1 mA and sham tACS). Participant's vigilance status will be monitor based on active vigilance condition or passive vigilance condition.
89198287|NCT01581073|Experimental|High Hb group|Darbepoetin alfa is given to the patients. Target Hb level is 12.0g/dL and it should be maintained greater than or equal to 11.0g/dL and less than 13.0g/dL. If the patients do not have medical history of myocardial infarction, stroke, pulmonary embolism, unstable angina, or peripheral artery disease, the target Hb level will be greater than or equal to 12.0g/dL and less than 13.0g/dL. Maximum dose of darbepoetin alfa is 240 microgram per 4 weeks.
88915195|NCT01614678|Other|AIR OPTIX® COLORS Semi-auto, then AIR OPTIX® COLORS Auto|Lotrafilcon B contact lens with color, semi-automated, worn first, with Lotrafilcon B contact lens with color, automated, worn second. Each product worn on a daily wear basis approximately 8 hours a day, 5 days a week, for 2 weeks.
88915196|NCT01614691|Experimental|SPARC1203 low dose|
89434735|NCT05185661|No Intervention|Control Group|"Two surveys: Demographic, lifestyle, hygiene-related (1) & knowledge, attitude, and practice (2) regarding anemia at baseline and end line of study.~Investigations and physical examination will perform for CBC blood test except ESR, urine R/E, stool R/E, Height, weight for BMI, waist circumference, hip circumference, hip - waist ratio, and mid-upper arm circumference (MUAC) at baseline, mid-line, and end-line of study."
89434736|NCT05184803|Experimental|treatment|treatment arm(docetaxel, oxaliplatin, S-1)
89434737|NCT05178056|Active Comparator|Respiratory Training|Research subjects with no implanted stimulator undergoing RT intervention.
88915197|NCT01614691|Experimental|SPARC1203 mid dose|
88915198|NCT01614691|Experimental|SPARC1203 high dose|
89434738|NCT05178056|Active Comparator|Spinal Cord Stimulation|Research subjects with implanted stimulator undergoing stimulation intervention.
88915199|NCT01614691|Placebo Comparator|Placebo|
89434739|NCT05178056|Experimental|Spinal Cord Stimulation and Respiratory Training|Research subjects with implanted stimulator undergoing stimulation intervention in combination with respiratory training.
89434740|NCT05176587||Integrated group (SPOC)|
89434741|NCT05176587||Control group|
89434742|NCT05176379|Experimental|fluconazole|fluconazole tablet/pill 150 mg, single acute dose
89434743|NCT05176379|Placebo Comparator|Placebo|250 mg pill microcrystalline Cellulose, single acute dose
89434744|NCT05170451|Active Comparator|Active Comparator: Start with CBD|The study design with be a double-blind, randomized controlled trial with crossover. Treatment will be blinded to the subjects and investigators. Patients will be randomly assigned 2 weeks of the CBD and then crossover to the other condition (Shea butter only) for 2 additional weeks. Patients will apply the topical cream to the affected body region or joint two times daily for 1 hour. Subjects will be advised to observe for physiologic changes, skin changes, or other adverse effects.
89434745|NCT05170451|Active Comparator|Active Comparator: Start with control (Shea butter)|The study design with be a double-blind, randomized controlled trial with crossover. Treatment will be blinded to the subjects and investigators. Patients will be randomly assigned 2 weeks of Shea butter and then crossover to the other condition (CBD) for 2 additional weeks. Patients will apply the topical cream to the affected body region or joint two times daily for 1 hour. Subjects will be advised to observe for physiologic changes, skin changes, or other adverse effects.
89434746|NCT05170126||Ozanimod-exposed|Pregnant women with a diagnosis of Multiple sclerosis (MS) who are exposed to ozanimod at any time during pregnancy
89434747|NCT05170126||Unexposed comparator cohort with MS|Pregnant women with a diagnosis of MS who are not exposed to ozanimod at any time during pregnancy
89434748|NCT05170126||Unexposed comparator cohort without MS|Pregnant women without a diagnosis of MS who are not exposed to ozanimod at any time during pregnancy
89198288|NCT01581073|Active Comparator|Low Hb group|Darbepoetin alfa is given to the patients. Target Hb level is 10.0g/dL and it should be maintained greater than or equal to 9.0g/dL and less than 11.0g/dL. If the Hb level exceeds 10.0g/dL in patients, reduce the dose amount or stop giving dose.
89198289|NCT00742820|Experimental|1|Calcium Acetate Oral Solution 667 mg per 5 mL
89198290|NCT00742820|Active Comparator|2|Calcium Acetate 667 mg Gelcaps
89434749|NCT05170048|Active Comparator|Control Arm: AREDS2 supplements (SOC)|All patients assigned to this Control Group will receive standard of care to include AREDS2 supplements daily throughout the study.
89434750|NCT05170048|Experimental|Experomental Arm: AREDS2 supplements (SOC) plus EG-301|Patients assigned to the Experimental Group will receive a standard of care equivalent to that of the Control Group plus EG-DPMP-01 (150 mg daily, given at bedtime with a light snack).
89434751|NCT05169814|Placebo Comparator|Acute Wounds - Control|This arm will include patients with acute wounds and will receive standard of care: irrigation with normal saline.
89434752|NCT05169814|Experimental|Acute Wounds - Experimental|This arm will include patients with acute wounds and will receive experimental treatment: irrigation with micro/nanobubbles (MNB's) in normal saline.
89434753|NCT05169814|Placebo Comparator|Chronic Wounds - Control|This arm will include patients with chronic wounds and will receive standard of care: negative pressure wound therapy with instillation (NPWTi) using normal saline.
89434754|NCT05169814|Experimental|Chronic Wounds - Experimental|This arm will include patients with chronic wounds and will receive experimental treatment: negative pressure wound therapy with instillation (NPWTi) using micro/nanobubbles (MNB's) in normal saline.
89434755|NCT05165368|Experimental|Intraneural Facilitation® Therapy (INF® Therapy) + Dietary Education|The INF® Therapy+ group will receive dietary education with weekly follow-up by a physical therapist either in person, or via email or text message. The INF® Therapy+ group will additionally receive meal preparation ideas and sample menus promoting a gluten-free diet.
89536400|NCT02477501|Active Comparator|Ephedrine|A continuous Ephedrine infusion at 10 mcg/kg/min
89010045|NCT02213887|Experimental|Start Pantoprazole|"Participants have been diagnosed with gastroesophageal reflux disease but have not started pharmacological treatment.~Intervention: Days 2-8"
89010046|NCT02213887|Experimental|Stop Pantoprazole|"Participants have been taking pantoprazole for more than 8 weeks and are asymptomatic for gastroesophageal reflux disease.~Intervention: Days 2-8"
89198291|NCT00742820|Other|3|Calcium Citrate 950 mg Caplets
89198292|NCT00860145|Experimental|radiosurgery|Radiosurgical treatment of the medial temporal lobe
89536401|NCT02477501|Active Comparator|Norepinephrine|A continuous Norepinephrine infusion at 0.1 mcg/kg/min
89536402|NCT02446795|Experimental|Experimental Arm|Phase I Sunitinib: 50mg once daily orally schedule treatment according to Investigator's choice Isoquercetin: 225mg twice a day (at 08 a.m. and at 4 p.m). Phase II Sunitinib: 50mg once daily orally schedule treatment according to Investigator's choice Isoquercetin: 450 mg twice a day (at 08 a.m. and at 4 p.m).
89434756|NCT05165368|Active Comparator|Intraneural Facilitation® Therapy (INF® Therapy)|"INF® Therapy is a manual therapy technique that consists of three components. The first is the pressurization or facilitation hold which biases circulation more consistently in the nerves, which is thought to pressurize the entire system The secondary hold attempts to stretch the innervated structure, pulling apart the tough dividing membrane and allowing the pressurized blood flow to transport from the outside holding chamber to the endoneurium and push open the closed capillary beds next to the nerve axons. Once capillaries surrounding the nerves are pressurized, the circulation needs to be induced up the neural connective tissue. A separate set of pressure points or holds are performed distal to the secondary holds to ensure the circulation is drawn up the inflamed capillary beds using the Bernoulli principle."
89434757|NCT05161312|Experimental|iACT-BC: Oncovox experimental|A guided internet-delivered ACT intervention to improve psychosocial outcomes in BCP diagnosed in the past two years.
89434758|NCT05161312|No Intervention|Wait list control group|Wait list, treatment as usual
89434759|NCT05161195|Other|Ribociclib|All participants will receive ribociclib in combination with other drugs at the same dose/schedule as in the parent study.
89434760|NCT05157724||PLASMA|This technique consists of an endoscopic intervention, through the natural route (urethra).
89010047|NCT04551859|Other|Sacrospinofixation|After accepting the surgeon's proposal to perform a sacrospinofixation to treat the pelvic organ prolapse, participation in this study will be proposed to the patient. It will not change the management or the course of the surgery
89010048|NCT00424905|Experimental|1|Enterogermina® vials containing 2×109 spores of polyantibiotic resistant Bacillus clausii (test drug)
89010049|NCT00424905|No Intervention|2|No treatment (reference group)
89434761|NCT05157724||HOLEP|"This is a recent and difficult technique of endoscopic prostate enucleation, requiring a greater learning curve for the operators compared to PLASMA. The principle remains the same technically as the PLASMA procedure, the energy used is not electrical energy, but a laser.~Once the adenoma has been enucleated, it can only be removed by a morcellator (additional material) which can lead to complications such as bladder perforation. This is a blade that rotates in a tube that has to cut the adenoma once it has been freed from the prostate when it is in the bladder and it can happen that this blade catches on the bladder wall and causes a bladder wound or even a perforation."
89010050|NCT04551703|Experimental|Adrenaline saline irrigation|Adrenaline saline irrigation will be prepared by adding one ampule of 0.1 percent adrenaline in one liter bag of normal saline, which made the adrenaline concentration in the solution 1:100 000
89010051|NCT04551703|No Intervention|Normal saline irrigation|Normal saline bag will be used for irrigation during the procedure
89010052|NCT04551976|Experimental|Mindful Video Game Then Laundry Group|Receive mindfulness prompt and play their video game first and fold laundry second.
89010053|NCT04551976|Experimental|Mindful Laundry Then Video Game Group|Receive mindfulness prompt and fold laundry first, play their video game second.
89010054|NCT04551976|No Intervention|Control Video Game Then Laundry Group|Control condition that receives no mindfulness prompt and is asked to complete activities like they normally would. They will play their video game first and fold laundry second.
89010055|NCT04551976|No Intervention|Control Laundry Then Video Game Group|Control condition that receives no mindfulness prompt and is asked to complete activities like they normally would. They will fold laundry first and will play their video game second.
89010056|NCT00235001|Experimental|1|
89010057|NCT04551781|Experimental|steroid|20 mg prednisolone for 14 days
89010058|NCT04551781|Placebo Comparator|control|controll
89010059|NCT00424944|Experimental|I, GMZ2 vaccine arm|20 volunteers will receive GMZ2 vaccine on days 0, 28, and 56
89010060|NCT00424944|Active Comparator|II, Rabies vaccine arm|20 volunteers will receive standard vaccine against rabies on the similar schedule on days 0, 28, and 56
89010061|NCT02214004|Experimental|Trastuzumab and Letrozole|- Concurrently initiate two drugs on Day 1 of Cycle 1
89010062|NCT04551274|Experimental|Music Therapy|Participants in the music therapy group will complete a 4 week music therapy program, with a minimum of 2 sessions per week.
89010063|NCT04551274|No Intervention|Control|Control group participants will not experience any intervention
89010064|NCT04551118|Experimental|tACS group|Participants receive 20 min sessions of 1.5 mA alternating current delivered over the dorsolateral prefrontal cortex, for 7 consecutive days.
89010065|NCT04551118|Experimental|tDCS group|Participants receive 20 min sessions of 1.5 mA direct current delivered over the dorsolateral prefrontal cortex, for 7 consecutive days.
89198293|NCT00860145|Active Comparator|temporal lobectomy|Resection of medial temporal lobe
89198294|NCT00754728|Experimental|I|
89434762|NCT05154253|Experimental|Device resisted gait training (treatment)|We will conduct a randomized controlled trial (treatment vs. control) to compare functional outcomes following bilateral targeted ankle resistance training (2 visits/week for 12 weeks) vs. dose-matched standard functional gait training.
89010066|NCT04551118|Sham Comparator|Sham group|Participants receive sham stimulation that administered similarly, but with current continued less than 30s.
89198295|NCT05301166|Experimental|Interventional Group|"The intervention group of the RCT consisted of 42 randomly selected students with a Body Mass Index (BMI) score of 25 and above, who were evaluated by inclusion and exclusion criteria.~Students in the intervention group will participate in the Technology-Based Motivation Education Program. This program will last 4 months.~Students in the intervention group will conduct semi-structured individual motivational interviews, consisting of 6 sessions in total, prepared according to the components of the Health Belief Model.~Students in the intervention group will access the web-based education and motivation program that supports motivational interviews by logging into the website prepared for the study."
89434763|NCT05154253|Experimental|Standard gait training (control)|We will conduct a randomized controlled trial (treatment vs. control) to compare functional outcomes following bilateral targeted ankle resistance training (2 visits/week for 12 weeks) vs. dose-matched standard functional gait training.
89198296|NCT05301166|Other|Control Group|"The intervention group of the RCT consisted of 42 randomly selected students with a Body Mass Index (BMI) score of 25 and above, who were evaluated by inclusion and exclusion criteria.~Students in the control group will only participate in the web-based education of the Technology-Based Motivation Education Program prepared according to the Health Belief Model for obesity.~Students in the control group will be given face-to-face or online interviews once a month for 4 months, lasting 10-15 minutes, in accordance with the web-based education content."
89434764|NCT05154253|Experimental|Comparison to Standard PT (within subjects control)|We will use a within-subject repeated measures design to compare both gait training groups to matched standard physical therapy.
89010067|NCT04551079|Experimental|TAK-994 Dose A+ Placebo + TAK-994 Dose B|TAK-994 Dose A tablets, orally, on Days 1 and 2 of Treatment Period 1, followed by TAK-994 placebo-matching tablets, orally, on Days 1 and 2 of Treatment Period 2, further followed by TAK-994 Dose B tablets, orally, on Days 1 and 2 of Treatment Period 3. A Washout Period of at least 7 days will be maintained between each treatment period.
89434765|NCT05154253|Experimental|Device assisted ambulation|We will compare task capacity and performance with adaptive ankle assistance vs. standard ankle foot orthoses and vs. shod (no ankle aid).
89434766|NCT05154253|Experimental|Passive brace assisted ambulation|We will compare task capacity and performance with adaptive ankle assistance vs. standard ankle foot orthoses and vs. shod (no ankle aid).
88915200|NCT01614704||Adjuvant treatment|Patients in this group will be offered the option of ovarien cryopreservation as well as the follow up of the follicule stock during chemotherapy.
88915201|NCT01614704||Neo adjuvant treatment|patients in this group will only have the follow up of the follicule stock.
88915202|NCT01614717|Active Comparator|Treatment Group|CRT-P Implant. Patients randomized in Treatment Group will have the device programmed to optimized DDD pacing
88915203|NCT01614717|Placebo Comparator|Control Group|CRT-P Implant. Patients randomized in the control Group will have the device programmed to back-up pacing AAI
89434767|NCT05154253|Experimental|No ankle aid ambulation|We will compare task capacity and performance with adaptive ankle assistance vs. standard ankle foot orthoses and vs. shod (no ankle aid).
89434768|NCT05152966|Experimental|FARAPULSE™ Endocardial Cardiac Ablation|Ablation using FARAPULSE™ Cardiac Ablation System Plus
89434769|NCT05150977||Idiopathic hypersomnia|Observation
89434770|NCT05150197|Experimental|Patient (pathology) group|This group will perform both the standard of care Humphrey Visual Field (HVF) and the VisuALL Virtual Reality Visual Field.
88915204|NCT01614730|Sham Comparator|Modified Neurotech Vital Device|Checking to see no contraction is stimulated during treatment with the Modified Neurotech Device
88915205|NCT01614730|Active Comparator|Neurotech Vital Device|Checking to see a contraction is stimulated during treatment of the Neurotech Vital Device
88915206|NCT01614756|Experimental|Dose Escalation-BMS-981164 (0.1 mg/kg) or Placebo|"Part 1~Single dose of BMS-981164 0.1 mg/kg solution subcutaneously~OR~Single dose of Placebo matching with BMS-981164 0 mg/kg solution subcutaneously"
88915207|NCT01614756|Experimental|Dose Escalation-BMS-981164 (0.01 mg/kg) or Placebo|"Part 1~Single dose of BMS-981164 0.01 mg/kg solution subcutaneously~OR~Single dose of Placebo matching with BMS-981164 0 mg/kg solution subcutaneously"
88915208|NCT01614756|Experimental|Dose Escalation-BMS-981164 (0.03 mg/kg) or Placebo|"Part 1~Single dose of BMS-981164 0.03 mg/kg solution subcutaneously~OR~Single dose of Placebo matching with BMS-981164 0 mg/kg solution subcutaneously"
88915209|NCT01614756|Experimental|Dose Escalation-BMS-981164 (0.06 mg/kg) or Placebo|"Part 1~Single dose of BMS-981164 0.06 mg/kg solution subcutaneously~OR~Single dose of Placebo matching with BMS-981164 0 mg/kg solution subcutaneously"
88915210|NCT01614756|Experimental|Dose Escalation- BMS-981164 (0.1 mg/kg) or Placebo|"Part 1~Single dose of BMS-981164 0.1 mg/kg solution subcutaneously~OR~Single dose of Placebo matching with BMS-981164 0 mg/kg solution subcutaneously"
88915211|NCT01614756|Experimental|Dose Escalation-BMS-981164 (0.3 mg/kg) or Placebo|"Part 1~Single dose of BMS-981164 0.3 mg/kg solution subcutaneously~OR~Single dose of Placebo matching with BMS-981164 0 mg/kg solution subcutaneously"
88915212|NCT01614756|Experimental|Dose Escalation-BMS-981164 (1 mg/kg SC) or Placebo|"Part 1~Single dose of BMS-981164 1 mg/kg solution subcutaneously~OR~Single dose of Placebo matching with BMS-981164 0 mg/kg solution subcutaneously"
88915213|NCT01614756|Experimental|Dose Escalation-BMS-981164 (1 mg/kg IV) or Placebo|"Part 1~Single dose of BMS-981164 1 mg/kg solution intravenously~OR~Single dose of Placebo matching with BMS-981164 0 mg/kg solution intravenously"
89198297|NCT00742898|Experimental|1|Non-targeted opt-out rapid HIV screening fully integrated into an urban, inner-city ED.
89434771|NCT05150197|Other|Control group|This group will only perform the VisuALL Virtual Reality Visual Field.
89434772|NCT05149378|Experimental|Venetclax combined with azacitidine|Relapsed or refractroy acute lymphoblastic leukemia patients reveive venetclax combined with azacitidine regimen treatment.
89434773|NCT05147844|Experimental|Toripalimab +Radiotherapy|
89434774|NCT05144516|Experimental|Patient Caregiver Dyad|Participants who are 65 years or older with cancer and mild cognitive impairment with their caregiver.
89434775|NCT05143957|Experimental|Sapablursen Dose Level 1|Sapablursen will be administered by SC injection every 4 weeks.
89434776|NCT05143957|Experimental|Sapablursen Dose Level 2|Sapablursen will be administered by SC injection every 4 weeks
89434777|NCT05137834|Experimental|"Exercise with a peanut ball."|"The rehabilitation program consists of mobility- and functional training exercises with a peanut ball."
89198298|NCT00742898|Active Comparator|2|Diagnostic rapid HIV testing fully integrated into an urban, inner-city ED.
89434778|NCT05137834|Active Comparator|"Exercise without peanut ball"|"The rehabilitation program consists of standard mobility- and functional training exercises without a peanut ball."
89434779|NCT05136287||Diabetes mellitus 2 patients with obesity|Patients that meet criteria to start treatment with GLP-1 receptor agonists (dulaglutide; exenatide; liraglutide; lixisenatide )
89434780|NCT05135975|Experimental|Cabozantinib|Enrolled patients will be treated with cabozantinib maleate, tablet formulation, using the recommended Phase 2 dose of 40 mg/m2/day, to a maximum of 420 mg/week. Treatment will be administered in 28- day cycles.
89434781|NCT05132075|Experimental|JDQ443|Participants will be treated with JDQ443
88915214|NCT01614756|Experimental|Dose Escalation-BMS-981164 (3 mg/kg IV) or Placebo|"Part 1~Single dose of BMS-981164 3 mg/kg solution intravenously~OR~Single dose of Placebo matching with BMS-981164 0 mg/kg solution intravenously"
88915215|NCT01614756|Experimental|Dose Escalation-BMS-981164 (10 mg/kg IV) or Placebo|"Part 1~Single dose of BMS-981164 10.0 mg/kg solution intravenously~OR~Single dose of Placebo matching with BMS-981164 0 mg/kg solution intravenously"
88915216|NCT01614756|Experimental|Dose Escalation- BMS-981164 or Placebo (dose group 1)|"Part 2~BMS-981164: Solution, Depending on dose level selected could be subcutaneous or IV, 3 mg/kg, once, single dose~OR~Placebo matching with BMS-981164: Solution, Depending on dose level selected could be subcutaneous or IV, 0 mg, once, single dose"
88915217|NCT01614756|Experimental|Dose Escalation- BMS-981164 or Placebo (dose group 2)|"Part 2~BMS-981164: Solution, Depending on dose level selected could be subcutaneous, 0.1 mg/kg, once, single dose~OR~Placebo matching with BMS-981164: Solution, Depending on dose level selected could be subcutaneous, 0 mg, once, single dose"
89434782|NCT05132075|Active Comparator|Docetaxel|Participant will be treated with docetaxel following local guidelines as per standard of care and product labels
89434783|NCT05130567|Experimental|Single-dose Experimental Group|LP-128 capsule will be adminstrated one time at doses up to 240mg
88915218|NCT01614756|Experimental|Dose Escalation- BMS-981164 or Placebo (dose group 3)|"Part 2~BMS-981164: Solution, Depending on dose level selected could be subcutaneous, ≤ 0.1 mg/kg, once, single dose~OR~Placebo matching with BMS-981164: Solution, Depending on dose level selected could be subcutaneous, 0 mg, once, single dose"
89434784|NCT05130567|Placebo Comparator|Single-dose Control Group|Placebo capsule will be adminstrated one time at doses up to 240mg
89434785|NCT05130567|Experimental|Multi-dose Experimental Group|LP-128 capsule will be adminstrated once daily, for up to 14 days
89434786|NCT05130567|Placebo Comparator|Multi-dose Control Group|Placebo capsule will be adminstrated once daily, for up to 14 days
89434787|NCT05130528|No Intervention|Usual Care|Infants randomly assigned to this arm will not receive any study intervention but will continue with any intervention in the community recommended by their health care team.
89434788|NCT05130528|Experimental|Sensorimotor Intervention|Infants randomly assigned to this arm will participate in the sensorimotor intervention starting in the hospital and lasting for 6 months. This intervention includes 10 visits with a physical or occupational therapist and parent working together to advance an intervention program and 6 months of parent daily intervention. In addition, this arm will continue with any intervention in the community recommended by their health care team.
89434789|NCT05130437|Experimental|mRNA-3927|Participants will receive the applicable dose identified during Study mRNA-3927-P101 (NCT04159103) on Day 1. The dose can be adjusted based on Sponsor recommendation.
89434790|NCT05125952|Experimental|Acute Respiratory Failure|Patients with acute respiratory failure managed with pressure-support ventilation.
89434791|NCT05120284|Active Comparator|Pre-Surgical Dichloroacetate (DCA)|Study medication begins in subjects randomized to preoperative DCA. All subjects will be given the 12.5 mg/kg/12 hour DCA for pre-surgical dosing. Post-surgery the GSTZ1 haplotype will be utilized to dose all patients.
89434792|NCT05120284|Active Comparator|No Pre-Surgical Dichloroacetate (DCA)|Subject randomized to start DCA after surgery will do so 12-24 hours postoperatively, depending on their ability to safely receive medication.
89434793|NCT05117671||revision total hip or knee arthroplasties|THA/TKA patients that underwent revision surgery between 01.01.2013 until 31.12.2018
89434794|NCT05116917|Experimental|Experimental Arm|SBRT of 15 Gy will be given on day 1 of the first cycle. Nivolumab 3 mg/kg (up to 240 mg maximum) will be given on day 1 (± 3 days) of each 14-day treatment cycle until the progression of disease or maximum of 48 weeks, discontinuation due to toxicity, withdrawal of consent. Ipilimumab 1 mg/kg will be given on day 1 cycle 1 (± 3 days) and once more after 6 weeks. Nivolumab will be administered as an IV infusion over 60 (± 5) minutes and then, after a 30 minutes rest period, ipilimumab will be administered as an IV infusion over 30 (± 5) minutes. Seasonal influenza vaccine is given IM or via PharmaJet Stratis Needle-Free Injection System, 0.5 mL per dose as a single on day 1 cycle 1 (± 3 days).
88915219|NCT01614756|Experimental|Dose Escalation- BMS-981164 or Placebo (dose group 4)|"Part 2~BMS-981164: Solution, Depending on dose level selected could be subcutaneous, ≤ 3.0 mg/kg and >1.0mg/kg, once, single dose~OR~Placebo matching with BMS-981164: Solution, Depending on dose level selected could be subcutaneous, 0 mg, once, single dose"
88915220|NCT01614782|Experimental|0.35 mg MK-5823 - Healthy Participants|
88915221|NCT01614782|Experimental|0.7 mg MK-5823 - Healthy Participants|
88915222|NCT01614782|Experimental|1.4 mg MK-5823 - Healthy Participants|
88915223|NCT01614782|Experimental|2.8 mg MK-5823 - Healthy Participants|
88915224|NCT01614782|Experimental|1.4 mg MK-5823 - Participants with T2DM|
88915225|NCT01614782|Experimental|2.8 mg MK-5823 - Participants with T2DM|
88915226|NCT01614808||Observational|Archived urine samples are analyzed for specific metabolite patterns by nuclear magnetic resonance (NMR) spectroscopy and principal component analysis (PCA). Tumor tissue may also be examined by NMR and PCA.
89434795|NCT05116540|Experimental|Treatment|Adipose derived Mesenchymal stem cells (Autologous)
89434796|NCT05116540|Placebo Comparator|Placebo|Normal Saline
89434797|NCT05113199|Experimental|Virtual Dignity Therapy|
89434798|NCT05109975|Experimental|Part 1: Dose Escalation|Participants will receive Debio 0123 orally in escalating dose cohorts during each 21-day treatment cycle until progression of disease, unacceptable toxicity, participant's withdrawal, or Investigator's decision, whichever occurs first.
89434799|NCT05109975|Experimental|Part 2: Expansion|Debio 0123 at the RP2D established in Part 1 participants with uterine serous carcinoma (USC) (arm A), recurrent or progressive, high-grade epithelial ovarian cancer (EOC) with cyclin E1-driven selection (arm B), and solid tumor with biomarker-driven selection (arm C).
88915227|NCT01614834||chronic urticaria patients|all patients suffering from chronic forms of urticaria (chronic spontaneous urticaria as well as chronic inducible forms such as cold contact urticaria)
88915228|NCT01614873|Active Comparator|Pressure Support Ventilator|"Gold standard partial ventilator support: Pressure Support Ventilation performed with Servo-i® ventilator (MAQUET,Critical Care, Sweden).~During pressure support the inspiratory muscles are assisted by a constant inspiratory pressure adjusted by the prescriptor and applied to the airway by either an invasive or a non invasive interface. Then the subject initiate the inspiratory effort and a constant pressure is delivered to the airway in order to assist inspiration. Three levels of pressure will be tested (5 cmH2O, 8 cmH2O and 12 cmH2O)"
89010068|NCT04551079|Experimental|TAK-994 Dose B + TAK-994 Dose A + Placebo|TAK-994 Dose B tablets, orally, on Days 1 and 2 of Treatment Period 1, followed by TAK-994 Dose A tablets, orally, on Days 1 and 2 of Treatment Period 2, further followed by TAK-994 placebo-matching tablets, orally, on Days 1 and 2 of Treatment Period 3. A Washout Period of at least 7 days will be maintained between each treatment period.
89434800|NCT05107544|Experimental|High Intensity Interval Training|The entire group is going to be undergo the intervention
89434801|NCT05106127|Experimental|EG-007 1000mg + Len + Pem|3 to 6 patients will receive EG-007 1000 mg once weekly starting on the day of injection of Pembrolizimab starting the next 21-day cycle of treatment.
89434802|NCT05106127|Experimental|EG-007 1000mg Loading + Len + Pem|6 to 10 patients will receive EG-007 loading dose of 5000 mg given as 1000 mg daily over 5 consecutive days starting 4 days before the first dose of Pembrolizumab under this protocol.
89434803|NCT05106127|Experimental|EG-007 1000mg D-4 Loading + Len + Pem|6 to 12 patients initiating new regimens of Len+Pem will receive EG-007 loading dose of 5000 mg given as 1000 mg daily over 5 consecutive days starting 4 days before the first dose of Pembrolizumab.
89434804|NCT05104554|Experimental|Weekly IFA|Receive weekly IFA
89434805|NCT05104554|Experimental|Daily MMS|Receive daily MMS (including iron and folic acid as components)
89434806|NCT05104554|No Intervention|Control|
88915229|NCT01614873|Experimental|NAVA|Spontaneous Breathing using Neurally Adjusted Ventilatory Assist with trigger adjusted on diaphragmatic electromyogram. Electrical activity of the diaphragm will be obtained through a naso-gastric tube with multiple array of electrodes placed at its distal end (Eadi catheter® , Maquet Critical Care, Sweden). During NAVA the inspiratory muscles are assisted by a pressure which is proportional to this electrical activity. Then the subject initiate the inspiratory effort and a pressure proportional to the integrated EMG activity is delivered to the airway in order to assist inspiration. The adjustment of the level of NAVA (expressed in cmH2O/microvolt) will be adjusted in order to obtain a peak pressure similar to pressure support (5 cmH2O, 8 cmH2O and 12 cmH2O)
88915230|NCT01614938|Active Comparator|cisplatin-radiotherapy (CRT)|The arm receiving docetaxel-cisplatin neoadjuvant chemotherapy followed by concurrent weekly cisplatin and radiotherapy
88915231|NCT01614938|Experimental|cetuximab-radiotherapy (ERT)|The arm receiving docetaxel-cisplatin neoadjuvant chemotherapy followed by concurrent cetuximab and radiotherapy
88915232|NCT01614951|Experimental|Pulmonary perfusion|
88915233|NCT01614951|Experimental|Pulmoplegia|
88915234|NCT01614951|Other|Control group|
88915235|NCT01614964|Experimental|AQ-13|Adult Malian males 18 years of age or older with uncomplicated P. falciparum malaria who agree to participate and provide their informed consent will be randomized to receive treatment with either AQ-13 or Coartem. Intervention 'AQ-13 Treatment' Participants randomized to the AQ-13 arm will be treated with two (350 mg) capsules on days 1 and 2 and one (350 mg) AQ-13 capsule on day 3 for a total oral dose of 1750 mg of AQ-13 (5 capsules containing 350 mg apiece) over 3 days.
88915236|NCT01614964|Active Comparator|Coartem Treatment|Adult Malian males 18 years of age or older with uncomplicated P. falciparum malaria who agree to participate and provide their informed consent will be randomized to receive treatment with either AQ-13 or Coartem. Intervention: Active Comparator: Coartem. Participants randomized to the Coartem arm will be treated with 80 mg artemether and 480 mg lumefantrine at the time of diagnosis and 8 hours later on day 1, the same doses (80 mg artemether and 480 mg lumefantrine) twice on day 2 (24 and 36 hours after diagnosis) and twice more on day 3 (48 and 60 hours after diagnosis) for total oral doses of 480 mg artemether and 2880 mg lumefantrine over 3 days.
88915237|NCT01613729|Active Comparator|Rosuvastation 5 Initiator Arm|These patients will start the study with Rosuvastatin 5 mg and then after 12 weks they will be switched to Rosuvastatin 10 mg.
88915238|NCT01613729|Active Comparator|Rosuvastatin 10 initiator arm|These patients will continue with Rosuvastatin 10 mg and after 12 weeks they will be switched to Rosuvastatin 5 mg
88915239|NCT01614977|Experimental|Methylprednisolone|"Clarithromycin 15mg/Kg/day divided into 2 doses for 28 days.~Rifambutin 20mg/Kg/day divided into 2 doses for 28 days.~Methylprednisolone (Danalone) 1mg/Kg/dose twice daily for 14 days followed by 1mg/Kg/dose in the morning once daily for 14 days."
88915240|NCT01614977|No Intervention|Placebo|"Clarithromycin 15mg/Kg/day divided into 2 doses for 28 days.~Rifambutin 20mg/Kg/day divided into 2 doses for 28 days.~placebo pills with an identical outward appearance and volume prescribed according to the same schedule."
88915241|NCT01615003|Experimental|Xuesaitong soft capsule group|Patients who confirmed by coronary angiography and diagnosed blood stasis syndrome of coronary heart disease are given conventional Western medicine treatment and Xuesaitong soft capsule.
88915242|NCT01615003|Placebo Comparator|control group|Patients who confirmed by coronary angiography and diagnosed blood stasis syndrome of coronary heart disease are given conventional Western medicine treatment and placebo.
88915243|NCT01615016|Experimental|MISurf|Minimally Surfactant application via small tube inserted into the trachea under CPAP therapy without formal intubation and without mechanical ventilation
89434807|NCT05104385||Hacettepe University Health Cohort- Students of Health Sciences|"Students of medical school (grades 4,5, and 6) in 2021 Spring Students of dental school (grades 4 and 5) in 2021 Spring New comers of grade 4 in both medical and dental school will be recruited early in October 2021.~There is no intervention. Vaccinations for COVID-19 have been provided by the Turkish Ministry of Health, in a pre-planned schedule. The study will follow students after vaccination, regardless of the type and dose administered."
89434808|NCT05100810||Angelman syndrome patients|This study will comprehensively evaluate the natural clinical progression of the disease using scales and questionnaires for the assessment of motor function and global development, movement monitoring devices (ActiMyo), and by collecting sleep and seizure diaries. In addition, proteomic analysis and electroencephalography (EEG) recordings will be collected to identify biomarkers that will indicate improvements in disease outcome following treatment.
89434809|NCT05100095|Experimental|Radiation therapy|Patients receive radiation therapy in 10 daily fractions (M-F) over 2 weeks.
89434810|NCT05095597|Other|Umbilical cord PRP donors|"Women who are going to give birth to a healthy live newborn at the Hospital Universitario y Politécnico La Fe.~Donors will donate their umbilical cord blood to obtain the hUC-PRP. A total of 30±15 donors will be recruited."
89434811|NCT05095597|Experimental|Group B- Asherman with PRP treatment and estrogen therapy|Women with thin endometrium/endometrial atrophy and/or Asherman's syndrome with fertility problems and reproductive desires, desires that could be achieved by their participation in the present study. A total of 15 patients will be included; all of them will receive the investigational treatment as well as estrogen therapy.
89434812|NCT05095597|Other|Group A1- POI with PRP treatment and estrogen therapy|Women with premature ovarian failure (POI). A total of 10 patients will be included. All of them will receive the investigational treatment as well as estrogen therapy.
89434813|NCT05095597|Other|Group A2- POI with estrogen therapy|Women with premature ovarian failure (POI). A total of 10 patients will be included. All of them will receive the estrogen therapy.
89434814|NCT05095597|Other|Group A3- POI without PRP treatment nor estrogen therapy|Women with premature ovarian failure (POI). A total of 10 patients will be included. None of them will receive either the investigational treatment nor estrogen therapy.
89010069|NCT04551079|Experimental|Placebo + TAK-994 Dose B+ TAK-994 Dose A|TAK-994 placebo-matching tablets, orally, on Days 1 and 2 of Treatment Period 1, followed by TAK-994 Dose B tablets orally, on Days 1 and 2 of Treatment Period 2, further followed by TAK-994 Dose A tablets, orally, on Days 1 and 2 of Treatment Period 3. A Washout Period of at least 7 days will be maintained between each treatment period.
89010070|NCT00235040|Other|1|Intervention
89010071|NCT00235040|No Intervention|2|Control
89010072|NCT02214043||Group 2|
89434815|NCT05083351|Experimental|MightySat|All subjects who are enrolled into the test group and participate in data collection have the noninvasive MightySat pulse oximeter applied on their finger(s).
89434816|NCT05082545|Experimental|Dose escalation:SHR-2002+SHR-1316|SHR-2002 +SHR-1316 C1D1 SHR-2002,C1D22 SHR-2002+SHR-1316, C2 SHR-2002+SHR-1316
89434817|NCT05082545|Experimental|Dose expansion stage: SHR-2002+SHR-1316|Dose expansion of SHR-2002 will be decided after finishing few cohorts in Dose escalation part.
89434818|NCT05082545|Experimental|Indication expansion stage：SHR-2002+SHR-1316|Indication expansion of SHR-2002 will be decided after finishing few cohorts in Dose expansion part.
89434819|NCT05080491|Experimental|Determination of thyroid profile and neuropsychological assessment|
89434820|NCT05075993|Experimental|Regimen A: LVGN3616 + LVGN6051 + Nab-Paclitaxel|given in combination with other drugs to patients with cancers that are advanced, relapsed (have come back), refractory (have not responded to treatment), or metastatic (have spread).
89434821|NCT05075993|Experimental|Regimen B: LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide|given in combination with other drugs to patients with cancers that are advanced, relapsed (have come back), refractory (have not responded to treatment), or metastatic (have spread).
89434822|NCT05075993|Experimental|Regimen C: LVGN3616 + LVGN6051 + LVGN7409 + Nab-Paclitaxel|given in combination with other drugs to patients with cancers that are advanced, relapsed (have come back), refractory (have not responded to treatment), or metastatic (have spread).
89434823|NCT05075993|Experimental|Regimen D: LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide|given in combination with other drugs to patients with cancers that are advanced, relapsed (have come back), refractory (have not responded to treatment), or metastatic (have spread).
89434824|NCT05073575|Experimental|Hyaluronic acid Group|Hyaluronic acid gel will be applied to exposed dental roots surfaces, after scaling and root planing therapy
89434825|NCT05073575|Active Comparator|No-hyaluronic acid Group|Only scaling and root planning will be performed on the exposed dental roots surfaces
89010073|NCT02214043||group 1|
89010074|NCT02214082|No Intervention|Next day discharge|this group will be discharged as is the standard practice at our facility; i.e. the day after the PCI procedure
89434826|NCT05061693|Experimental|INCB054707 Dose A|Participants will receive INCB054707 Dose A for 16 weeks (Period 1), followed by INCB054707 Dose B (responders) or by INCB054707 Dose C (partial or nonresponders) for 24 weeks (Period 2).
89434827|NCT05061693|Experimental|INCB054707 Dose B|Participants will receive INCB054707 Dose B for 16 weeks (Period 1), followed by INCB054707 Dose B (responders) or by INCB054707 Dose C (partial or nonresponders) for 24 weeks (Period 2).
89434828|NCT05061693|Experimental|INCB054707 Dose C|Participants will receive INCB054707 Dose C for 16 weeks (Period 1), followed by INCB054707 Dose B (responders) or by INCB054707 Dose C (partial or nonresponders) for 24 weeks (Period 2).
89434829|NCT05061693|Placebo Comparator|Placebo followed by INCB054707 Dose B or C|Participants will receive placebo for 16 weeks (Period 1), followed by INCB054707 Dose B (responders) or by INCB054707 Dose C (partial or nonresponders) for 24 weeks (Period 2).
89434830|NCT05060601|Experimental|Gracey micro-curettes|Subgingival mechanical debridement will be performed using an ultrasonic scaler with specific thin tips and Gracey micro-curette.
89434831|NCT05060601|Active Comparator|Standard Gracey curettes|Subgingival mechanical debridement will be performed using a conventional ultrasonic scaler and standard Gracey curettes.
89434832|NCT06294717|Experimental|Experimental Group|Progressive relaxation exercises will be explained and taught to the puerperant after cesarean section. Experimental Group (in the group where progressive relaxation exercises were applied); The first application will be made at the 8th postoperative hour. Before the application, the Puerperal Identification Form, Beck Anxiety Scale, Visual Analogue Scale (VAS) and Physiological Parameters forms will be filled out. Starting from the 8th post-op hour, the first, second and third applications will be made eight hours apart within a 48-hour period. On the second day, progressive relaxation exercises will be performed once, twice and three times at eight-hour intervals. At the end of the second day, the Postpartum Definition Form, Beck Anxiety Scale, Visual Analogue Scale (VAS) and Physiological Parameters forms will be filled in again.
89010075|NCT02214082|Experimental|Same Day Discharge|Patients in this arm will be discharged on the same day as their angioplasty.
89010076|NCT04550806||GDM|
89010077|NCT04550806||non-GDM|
89010078|NCT00235079|Experimental|Colchicine|Colchicine 0.5mg BID (>70Kg) or 0.5 once daily for 6 months
89010079|NCT00235079|Placebo Comparator|Placebo|Placebo 0.5mg BID (>70Kg) or 0.5 once daily for 6 months
89010080|NCT04550767||local infections|local infections
89010081|NCT04550767||systemic infections|systemic infections
89010082|NCT00260988|Active Comparator|Dalteparin|Dalteparin 200 IU/kg/day for three days prior to surgery and dalteparin 5000IU daily for 3-5 days post-surgery
89010083|NCT00260988|Active Comparator|Tinzaparin|Tinzaparin 175 IU/kg/day for three days prior to surgery and Tinzaparin 4500 IU for 3-5 days post surgery
89434833|NCT06294717|No Intervention|Control Group|"No application will be made with participants in the control group. At the 8th postoperative hour, the Puerperal Identification Form, Beck Anxiety Scale, Visual Analogue Scale (VAS) and Physiological Parameters forms will be filled out. These participants will be asked not to engage in regular physical activity or sports for 2 days and not to make any changes in their living habits.~During the interview two days later, the Postpartum Identification Form, Beck Anxiety Scale, Visual Analogue Scale (VAS) and Physiological Parameters forms will be filled out again by the postpartum women."
89434834|NCT06294691|Active Comparator|the early infused group|infused stem cell within 11:30 am and 12:30 am
89198299|NCT05435430||women with previously SARS-COV2 infection.|"2 group from 2 IVF CENTER with egual criteria :~INCLUSION CRITERIA:~Women 24-43 years of age~Previous history of COVID-19 infection~INFERTILITY DIAGNOSIS~ESCLUSION CRITERIA:~women with current symptoms of COVID-19 infection~Positive for HIV or the presence of active viral hepatitis~Previosuly ovarian cancer, removal of ovaries or gonadotoxic treatments"
89434835|NCT06294691|Sham Comparator|the late infused group|infused stem cell within 5:30 pm and 6:30 pm
89434836|NCT06294678|Active Comparator|the early infused group|infused stem cell within 11:30 am and 12:30 am
89434837|NCT06294678|Sham Comparator|the late infused group|infused stem cell within 5:30 pm and 6:30 pm
89434838|NCT06294665|Active Comparator|Group A : ( Bupivacaine + Dexmedetomidine )|Group A : will receive bupivacaine 0.25% + dexmedetomidine 1 mic/kg, total volume (20 ml)
89198300|NCT02566460|Experimental|lactate clearance group|Refer to lactate clearance rate to perform resuscitation therapy
88915244|NCT01615016|Active Comparator|InSurE|Surfactant application via Intubation - Surfactant Application - Extubation sequence
88915245|NCT01615042|Experimental|Dose Escalation/High Dose Lenalidomide|Subjects are given a single dose of the drug while they are observed and tested for a period of time. If they do not exhibit any adverse side effects the dose is escalated, and a new group of subjects is then given a higher dose.
88915246|NCT01615055|Experimental|Fluoxetine tablets|
89198301|NCT02566460|Sham Comparator|SCVO2 group|Refer to SCVO2 to perform resuscitation therapy
89198302|NCT00863031|Experimental|problem-solving therapy|Three sessions of brief problem-solving counselling at week 1, 3 and 5 by a family doctor.
89198303|NCT00863031|Placebo Comparator|viewing video|Three sessions of health education viewing video in groups of 3 to 5 people
89198304|NCT00742976|Active Comparator|1|8 weeks of insulin Detemir, then cross over to 8 Weeks of Insulatard, then cross over to 1 week of Detemir
89434839|NCT06294665|Active Comparator|Group B: ( Bupivacaine + Dexamethasone )|Group B : will receive bupivacaine 0.25% +dexamethasone (8 mg), total volume(20 ml).
89434840|NCT06294639|Experimental|esketamine|esketamine will be given intravenously
89434841|NCT06294626||Examination of neuromotor development of cases diagnosed with scaphocephaly|21 cases with scaphocephaly were included. Neuromotor development was evaluated with the Denver-II Developmental Screening Test and Alberta Infant Motor Scale.
89434842|NCT06294587|Experimental|FGG before GBR|Free Gingival Graft(FGG) before the guided bone regeneration(GBR)
89434843|NCT06294587|Experimental|FGG after GBR|Free Gingival Graft(FGG) after the guided bone regeneration(GBR)
89434844|NCT06294574|Experimental|Hydromark plus clip placement|Patients with a previously placed HydroMARK T3 coil clip or a clip made by another manufacturer and will have a HydroMARK Plus clip placed during the scout localization procedure for this study. Breast surgeons will perform retrieval and then complete a satisfaction survey to compare the two clips.
89434845|NCT06294496||CEA group|The patient with carotid stenosis underwent CEA surgery.
89198305|NCT00742976|Active Comparator|2|8 weeks of Insulin Insulatard, then cross over to 8 weeks of insulin Detemir, then crossover to 1 week of Insulin Insulatard
89198306|NCT01050049||Before guidelines implemented|
89434846|NCT06294496||CAS group|The patient with carotid stenosis underwent CAS treatment.
89434847|NCT06294483||early onset SLE|group of patients diagnosed as SLE before age of fifty years old
89434848|NCT06294483||late onset SLE|Patients were diagnosed as SLE at age of fifty years old or more
88915247|NCT01615055|Placebo Comparator|Placebo tablets|
88915248|NCT01615068||Cohort|
89198307|NCT01050049||After guidelines implemented|
89198308|NCT04040985|Other|Legion Primary|Legion Primary TKA
89198309|NCT02566382|Experimental|shoulder arthroscopy arthrodesis|The shoulder surgery will be realized under arthroscopy only.
89198310|NCT05261100|Placebo Comparator|Active group|Conventional Physical therapy
89198311|NCT05261100|Experimental|Experimental group|Conventional Physical therapy with Core stability
89198312|NCT00867867|Active Comparator|1|Ferrous Fumarate with Ferrous Sulphate
89198313|NCT00867867|Active Comparator|2|Ferric pyrophosphate with ferrous sulphate
89198314|NCT00867867|Placebo Comparator|3|Ferrous sulphate
89198315|NCT00955318|Experimental|KW-6500|
89198316|NCT01044667|Other|Patients taking Myfortic|Lung transplant patients converted from MMF to Myfortic as part of standard of care treatment will have GI and Quality of Life assessments done at the time of conversion to Myfortic and at 60 days, 90 days and 180 days.
89434849|NCT06294470|Experimental|Experimental|Altomare Score score ≥3pts and Agachan Wexner Score ≥12pts
89434850|NCT06294470|Active Comparator|Control|Altomare Score score <3pts and Agachan Wexner Score <12pts
89434851|NCT06294457|Experimental|Intervention|"The total number of sessions to be conducted for each patient will be 10 sessions, spread over 5 weeks, which means a frequency of twice a week.~Each NESA microcurrent session will last 60 minutes. A maximum time of 15 minutes will be allowed for connecting the patient at the beginning and for removing the device at the end.~The directing electrode will be located throughout the treatment between the spinous processes of C6 and C7 to act generally on the individual, and in later sessions, the electrode will be placed d at T12-S3 to influence the sacral plexus.~The intensity will be set to Low (3 volts) in all sessions,. The other device parameters range between 100-900 microamperes and between 1.14 and 14.29 hertz, and are preset by each program."
89434852|NCT06294457|Placebo Comparator|Placebo|Non-active Non-Invasive Neuromodulation NESA
89434853|NCT06294444|Experimental|Constraint induced Movement Therapy|Group of 15 members will be given constraint induced movement therapy for 6 weeks.
89434854|NCT06294444|Experimental|Mirror therapy group|Group of 15 members will be given modified constraint induced movement therapy with mirror theray for 6 weeks.
89434855|NCT06294431|Placebo Comparator|Placebo Control 1|Clarity Product Form 1 - control
89434856|NCT06294431|Experimental|Active Product 1.1|Clarity Product Form 1 - active product 1
89434857|NCT06294418|Experimental|Low grade glioma|Patients with postoperative low grade glioma will undergo one FCI scan.
89434858|NCT06294392|Experimental|KEEP-CK|Participants who are randomly assigned to the KEEP-CK condition will participate in 16 weekly group sessions with 8-12 other informal kinship caregivers, and receive manualized content related to positive parenting skills, and peer-to-peer supports and recommendations for services.
89434859|NCT06294392|No Intervention|"Services as usual (SAU) waitlist control"|"Participants who are randomly assigned to the services as usual (SAU) waitlist control condition will be eligible to receive SAU that are available to all informal kinship caregivers in Oregon. Participants who ask about receiving supports will be referred to the Oregon Kinship Navigator, which is a statewide kinship navigator program that is available to all informal kinship caregivers in Oregon regardless of their participation in this study. Participants in the SAU waitlist control condition will be offered the opportunity to participate in a KEEP-CK group after 10 months, with these participants only contribute data to the SAU control condition for the impact analyses."
89434860|NCT06294366|Active Comparator|Bipolar enucleation|Bipolar enucleation of the prostate larger than 60 gm
89434861|NCT06294366|Active Comparator|Bipolar TURP|Bipolar transurethral resection of the prostate larger than 60 gm
89434862|NCT06294340||Participants with normal body weight|The effects of noise exposure on blood pressure, cardiovascular and hemodynamic parameters, stress hormones, and markers of oxidative stress and inflammation in individuals with normal body weight.
89434863|NCT06294340||Overweight / obese participants|The effects of noise exposure on blood pressure, cardiovascular and hemodynamic parameters, stress hormones, and markers of oxidative stress and inflammation in individuals with overweight/obesity.
89434864|NCT06294314||Treatment|These patients receive the surgery and are followed for two years for outcomes.
89434865|NCT06294314||Control|These patients do not need and don't receive surgery and are followed for two years to compare to the surgery treatment group
89434866|NCT06294301|Experimental|Cohort 1: LP-005 Dose 1 (Single)|
89434867|NCT06294301|Experimental|Cohort 2: LP-005 Dose 2 (Single)|
89434868|NCT06294301|Experimental|Cohort 3: LP-005 Dose 3 (Single)|
89434869|NCT06294301|Experimental|Cohort 4: LP-005 Dose 4 (Single)|
89434870|NCT06294301|Experimental|Cohort 5: LP-005 Dose 5 (Single)|
89434871|NCT06294301|Experimental|Cohort 6: LP-005 Dose 6 (Single)|
89434872|NCT06294301|Placebo Comparator|Cohort 7: Placebo (Single)|
89434873|NCT06294301|Experimental|Cohort 8: LP-005 Dose 7 (Multiple)|
88915249|NCT01615081|Active Comparator|Sucrose solution|75 g sucrose (75 g carbohydrate) desolved in 750 ml water
88915250|NCT01615081|Experimental|Malt extract solution|183 g malt extract (corresponding to 75 g carbohydrate and 103 ml water) desolved in 647 ml water
88915251|NCT01615094||High-risk Stage B Heart Failure Patients|American College of Cardiology/American Heart Association (ACC/AHA) asymptomatic Stage B patients with B-Type natriuretic peptide (BNP) ≥ 65pg/ml
88915252|NCT01615107|Experimental|GROUP 1: Oxytocin infusion alone|GROUP 1: Oxytocin infusion alone
88915253|NCT01615107|Experimental|double balloonand oxytocin|insertion of the double balloon and oxytocin
88915254|NCT01615146|Experimental|Therapeutic Platelet Transfusion Arm|Patients allocated to the therapeutic platelet transfusion group will not receive routine prophylactic platelet transfusions.
88915255|NCT01615146|Active Comparator|Prophylactic Platelet Transfusion Group|Patients allocated to the prophylactic platelet transfusions will receive a platelet transfusion (a single dose of random donor platelets (4 unit pool or random donor platelets or one apheresis unit) when the measured platelet count is < 10 x 109/L.
88915256|NCT01615172|Active Comparator|Aortic cannulation|routine placement of aortic cannula
88915257|NCT01615172|Active Comparator|axilaris cannulation|new type of cannulation
88915258|NCT01615185|Experimental|sulpiride plus amisulpride|sulpiride 800mg/d + amisulpride 400mg/d
88915259|NCT01615185|Active Comparator|full-dose amisulpride|amisulpride 800mg/d
89434874|NCT06294301|Experimental|Cohort 9: LP-005 Dose 8 (Multiple)|
89434875|NCT06294301|Experimental|Cohort 10: LP-005 Dose 9 (Multiple)|
89434876|NCT06294301|Placebo Comparator|Cohort 11: Placebo (Multiple)|
89434877|NCT06294288|Experimental|Cohort 1: LP-003 Dose 1 (Single)|
89434878|NCT06294288|Experimental|Cohort 2: LP-003 Dose 2 (Single)|
89434879|NCT06294288|Experimental|Cohort 3: LP-003 Dose 3 (Single)|
89434880|NCT06294288|Experimental|Cohort 4: LP-003 Dose 4 (Single)|
89434881|NCT06294288|Experimental|Cohort 5: LP-003 Dose 5 (Single)|
89434882|NCT06294288|Placebo Comparator|Cohort 6: Placebo (Single)|
89434883|NCT06294288|Experimental|Cohort 7: LP-003 Dose 6 (Multiple)|
89434884|NCT06294288|Experimental|Cohort 8: LP-003 Dose 7 (Multiple)|
89434885|NCT06294288|Experimental|Cohort 9: LP-003 Dose 8 (Multiple)|
89434886|NCT06294288|Placebo Comparator|Cohort 10: Placebo (Multiple)|
89434887|NCT06294275|Experimental|Cohort 1: LP-001 Dose 1 (Single)|Single dose administration of LP-001 with dose 1
89434888|NCT06294275|Experimental|Cohort 2: LP-001 Dose 2 (Single)|Single dose administration of LP-001 with dose 2
89434889|NCT06294275|Experimental|Cohort 3: LP-001 Dose 3 (Single)|Single dose administration of LP-001 with dose 3
89434890|NCT06294275|Experimental|Cohort 4: LP-001 Dose 4 (Single)|Single dose administration of LP-001 with dose 4
89434891|NCT06294275|Experimental|Cohort 5: LP-001 Dose 5 (Single)|Single dose administration of LP-001 with dose 5
89434892|NCT06294275|Experimental|Cohort 6: LP-001 Dose 6 (Single)|Single dose administration of LP-001 with dose 6
89434893|NCT06294275|Placebo Comparator|Cohort 7: Placebo (Single)|Single dose administration of placebo drug
89434894|NCT06294275|Experimental|Cohort 8: LP-001 Dose 7 (Multiple)|LP-001 with dose 7 was administered 4 times in total
89434895|NCT06294275|Experimental|Cohort 9: LP-001 Dose 8 (Multiple)|LP-001 with dose 8 was administered 4 times in total
89434896|NCT06294275|Placebo Comparator|Cohort 10: Placebo (Multiple)|Placebo drug was administered 4 times in total
89434897|NCT06294262|Active Comparator|VaxigripTetra in healthy adults aged 18-50 years|A single, 0.5 mL intramuscular injection of VaxigripTetra without adjuvant in healthy adults aged 18-50 years (N = 12)
89434898|NCT06294262|Experimental|VaxigripTetra with 0.5 mg of LiteVax Adjuvant in healthy adults aged 18-50 years|A single, 0.55 mL intramuscular injection of VaxigripTetra with 0.5 mg of LiteVax Adjuvant in healthy adults aged 18-50 years (N = 12)
89434899|NCT06294262|Experimental|VaxigripTetra with 1 mg of LiteVax Adjuvant in healthy adults aged 18-50 years|A single, 0.55 mL intramuscular injection of VaxigripTetra with 1 mg of LiteVax Adjuvant in healthy adults aged 18-50 years (N = 12)
89434900|NCT06294262|Active Comparator|VaxigripTetra in healthy adults aged 60 years or older|A single, 0.5 mL intramuscular injection of VaxigripTetra without adjuvant in healthy adults aged 60 years or older (N = 16)
89434901|NCT06294262|Experimental|VaxigripTetra with 0.5 mg of LiteVax Adjuvant in healthy adults aged 60 years or older|A single, 0.55 mL intramuscular injection of VaxigripTetra with 0.5 mg of LiteVax Adjuvant in healthy adults aged 60 years or older (N = 16)
89434902|NCT06294262|Experimental|VaxigripTetra with 1 mg of LiteVax Adjuvant in healthy adults aged 60 years or older|A single, 0.55 mL intramuscular injection of VaxigripTetra with 1 mg of LiteVax Adjuvant in healthy adults aged 60 years or older (N = 16)
89434903|NCT06294210|Experimental|Mobile app and wearable heart rate variability monitoring|A mobile app was developed based on students feedback about their wellbeing needs gathered in a previous study through focus groups, surveys and design activities. This app includes features for students to track wellbeing habits, enter goals, access evidence-based resources related to their wellbeing topics of interest, and see heart rate variability summary metrics. These metrics will stream via bluetooth from the wrist-worn wearable device that has been developed at the Royal College of Surgeons in Ireland. This device includes a PPG sensor, charging port, and light indicator. There is no screen, so all data will be displayed through the mobile app.
89434904|NCT06294197|Experimental|Pelvic Floor Exercises|In the intervention types, women are given training on pelvic floor exercises, that they can perform in the form of home exercises for 12 weeks. Before starting pelvic floor exercises therapy, a physiotherapist who specializes in pelvic floor compatibility will provide information about the location of the pelvic floor muscles through anatomical models and their effect on healthy, vaginal and sexual function. The effects of pelvic floor exercises on this system will be explained on an individual basis, and normal palpation is required to demonstrate their correct execution of contraction of the pelvic floor muscles. Participants will be taught how to contract and contract different muscles, such as the abdominal muscles, hip muscles, and gluteal muscles, or how to avoid pelvic tilt during contraction, and how to perform both rapid and sustained contractions.
89434905|NCT06294197|No Intervention|Control|No intervention will be made in the control unit.
89434906|NCT06294184|Experimental|lDLPFC tdcs stimulation group|The current is 2mA, duration is 1200s, fade in 30s, fade out 30s, anode is on the F3, cathode is on the FP2.
89434907|NCT06294184|Experimental|rVLPFC tdcs stimulation group|The current is 2mA, duration is 1200s, fade in 30s, fade out 30s, anode is on the F6, cathode is on the FP1.
89434908|NCT06294184|Sham Comparator|Sham group|The current only persist in the fisrt 30s, duration is 1200s, fade in 30s, fade out 30s, anode is on the F3/F6, cathode is on the FP2/1.
89531281|NCT04467879|Sham Comparator|"Control Device - Sham - Weaker Grip"|Using the Zona Sham Control Device the patient will perform a twelve-minute isometric handgrip therapy session at approximately the same time each day. After an initial handgrip strength assessment (the calibration), a two-minute isometric routine is performed four times, two sessions per hand, with a one-minute non-grip, or rest session between each isometric routine.
88915260|NCT01615211|No Intervention|Standard treatment|patients will receive standard treatment with 200mg Mifepristone and after 36-48 hours 800 mcg of misoprostol vaginally
88915261|NCT01615211|Active Comparator|trilostane|patients will receive Day 1: Mifepristone 200 mg and Trilostane 120mg 1 tablet twice and Day 2 Trilostane 240mg twice. On Day 3 800 mcg misoprostol will be given vaginally.
88915262|NCT01615211|Active Comparator|Letrozole|Patients will receive on Day 1 Mifepristone 200mg and Letrozole 2,5mg 3 tablets and on Day 2 Letrozole 2,5mg 3 tablets. On day 3 800mcg of misoprostol will be given vaginally
88915263|NCT01615224|No Intervention|single dose|Patients receive the standard treatment with 800mcg of vaginal misoprostol
88915264|NCT01615224|Experimental|repeated doses|patients receive 800mcg of vaginal misoprostol. In addition to this they receive repeated doses of 400mcg oral misoprostol after 3 and 5 hours. Women of more than 9 weeks pregnancy according to last menstrual period will be given a choice of vacuum aspiration or further medical treatment with 2 additional doses of misoprostol given after 7 and 9 hours after the initial vaginal treatment.
88915265|NCT01615237|Active Comparator|CBP + PF|Field sites randomly assigned to Arm 2 will receive as an intervention current best practices and quarterly audits and performance feedback reports (PF) on provider delivery of cessation services using chart audit procedures that we have used successfully in prior work. Depending on what is used at the site, paper or Electronic Dental Record, we will work with the site to create a registry of patients who are tobacco users.
88915266|NCT01615237|Active Comparator|CBP + PF + P4P|Field sites randomly assigned to this implementation condition (Arm 3) will receive current best practices (CBP), quarterly audit and performance feedback reports (PF), and financial incentives (pay for performance, P4P) for every documented (documentation in patient chart of counseling, prescription, or referral to the quit-line) delivery of adherence to clinical practice guidelines.
88915267|NCT01615237|Active Comparator|Current Best Practices (CBP)|All dental field sites will receive current best practices (CBP) for training and technical assistance in promoting adoption of clinical practice guidelines for treating tobacco dependence.
88915268|NCT01615250|No Intervention|Standard therapy|Treatment with standard therapy. Cardiospec shock-wave therapy
88915269|NCT01615250|Active Comparator|Stem cells|Group of of intramyocardial implantation of peripheral mononuclear cells with CD34+ stem cells in patient with ischemic cardiomyopathy after preparatory course of shock - wave therapy.
88915270|NCT01615276|Placebo Comparator|Protein ingestion|Protein ingestion directly after the contralateral leg received NMES
89434909|NCT06294171|Other|measurement of alveolar ridge width|the surgical procedure started with envelop flap reflection. A mucoperiosteal elevator was used to reflect the buccal and palatal flaps that were enough to expose the crestal part of alveolar ridge with clear visibility and accessibility. Measuring the width of the alveolar ridge 1 mm below the crest using bone caliber. Using piezoelectric surgery unit (Piezosurgery Ultrasonic® mectron, Italy), a horizontal crestal cut was produced along the crest of the bone. The cut depth extended into the same depth of the final dental implant to be inserted and then Versah Drills will be used in a successive manner and under copious irrigation with chilled sterile normal saline.We will measure the rate of ridge expansion by bone caliber to determine the efficacy of combining Versah drills with piezo surgery in expanding narrow alveolar bone.
89434910|NCT06294158||Observation Cohort|Adult patients (age ≥ 18 years) admitted to to participating Intensive Care Units with an expected (further) stay in participating Intensive Care Unit ≥ 48 hours who are not (currently) deeply sedated (RASS ≥ -3) and are not already in delirium (CAM-ICU positive), do not require environmental modification due to treatment necessities (e.g., burns care), and do not have advanced directives or treatment limitation orders in place, in whom environmental light and noise are measured.
89434911|NCT06294145|Experimental|Savoring intervention|7 sessions of psychotherapy designed to augment reward anticipation, reward attainment, and reward learning.
89010084|NCT04550416|Experimental|ProMark Information and Results|Participants in the intervention arm will receive information (both print and webinar format) about ProMark in between Round 1 and Round 2 data collection, as well as appropriate ProMark test results for each of the vignette-based simulated patients that they care for in the second round of data collection.
89010085|NCT04550416|No Intervention|Standard Practice|Physicians will care for online virtual patients as they normally would in practice.
89010086|NCT00235157|Experimental|1|Sirolimus-eluting Palmaz Genesis peripheral stent
89010087|NCT04550338|Experimental|Tranexamic Acid Treatment|
89010088|NCT04550338|Placebo Comparator|Placebo Treatment|
89010089|NCT02214199|Active Comparator|Exercise Therapy|Home exercises for 30 minutes (2/weeks) with muscle stretching and strengthening the shoulder girdle.
89198317|NCT01766492||male (age > 18 y/o) with prostate cancer|Men received Stereotactic Body Radiation Therapy (SBRT) for clinically localized prostate cancer
89198318|NCT00860223|Experimental|1|Digoxin alone
89434912|NCT06294119|Other|Cardiac surgery|An experimental setup will be devised for the simultaneous monitoring and recording of EEG, ECG, AP, and R together with CBF in patients scheduled for major cardiac surgery. Recording sessions will take place 1 day before (PRE) and within 7 days after (POST) surgery. The experimental protocol including physiological data recordings includes three sessions lasting 10 minutes each: a session at resting state in supine position, a session during autonomic challenge obtained via active standing evoking reflex sympathetic activation, and a session of emotional elicitation via the administration of videos. The overall duration of the experiment is therefore 30 minutes in PRE and POST. A total of 40 short video clips of the duration of 15 seconds each will be presented to a total of 80 voluteers will be recruited for the MANCAVA study.
89434913|NCT06294106|Experimental|eTMS|The active side of a TMS coil will be used to administer eTMS application.
89434914|NCT06294106|Sham Comparator|eTMS sham|The sham side of a TMS coil will be used to administer a sham dosage of eTMS application.
89531282|NCT03337061|Experimental|Experimental (Mindfulness)|This arm will receive mindfulness-based interventions through a mobile application
89531283|NCT03337061|No Intervention|Control (Sleep Advice)|This is the control arm that will receive usual care
89434915|NCT06294080|Experimental|Dance|Participants will be provided with three dance genre options to choose from, ballroom dance, street dance/Hip-pop and ballet, and the most-voted genre will be delivered. Dance sessions are instructed twice a week for eight weeks. Every session lasts 45-60 minutes, containing 5-10 minutes of warm-up and 35-55 minutes of learning or practicing. In the first four weeks, a short dance sequence will be taught and in the following four weeks, participants will mainly practicing the learnt sequence along with music.
89434916|NCT06294080|Experimental|Tai Chi|The Tai Chi Group will be given the essential 18-form of Chen's style Tai Chi Chuan. Each session lasts 45-60 minutes, twice a week for 8 weeks. Every session contains 5-10 minutes of warm-up, 5 minutes of standing exercise (站桩) with calming music, and 30-45 minutes of learning or practicing. In the first 8 sessions, 15 forms will be taught in total, averagely two forms are taught every session. In the next 8 sessions, participants will practise the complete 18-form repeatedly following the lead of an instructor with background music. Each repetition takes approximately 2 minutes 20 seconds. Apart from movements, the Taoism philosophy as the origin of Tai Chi will also be embedded during the intervention
89434917|NCT06294080|No Intervention|Control|Participants will be told to maintain their usual lifestyle and only attend for physical assessments
89434918|NCT06294041|Other|Sleep Restriction Therapy (SRT)|
89434919|NCT06294041|Other|Sleep Hygiene Education|
89434920|NCT06294028|Active Comparator|Implantation of an automatic defibrillator|Implantation of an automatic defibrillator
89434921|NCT06294028|Experimental|Percutaneous catheter ablation|Percutaneous catheter ablation
89434922|NCT06294015|Experimental|20% Autologous serum eye drops + Artificial tear drops|
89434923|NCT06294015|Placebo Comparator|0.9% NS eye drops + Artificial tear drops|
89434924|NCT06293989|Experimental|diazepam 5 mg|Medications will be diluted with 5 mL of normal saline solution slowly intravenously injected (over 5 minutes). The associate clinical research coordinator was responsible for preparation and dispensing the study drug.
89434925|NCT06293989|Experimental|diazepam 10 mg|Medications will be diluted with 5 mL of normal saline solution slowly intravenously injected (over 5 minutes). The associate clinical research coordinator was responsible for preparation and dispensing the study drug.
89434926|NCT06293989|Experimental|placebo|Medications will be diluted with 5 mL of normal saline solution slowly intravenously injected (over 5 minutes). The associate clinical research coordinator was responsible for preparation and dispensing the study drug.
89434927|NCT06293976|Experimental|Patients under mechanical ventilation|Patients intubated for more than 12 hours, on assist-control ventilation, not triggering the ventilator with or without reverse triggering, exposed to sedation for at least 6 hours, with a sedation-agitation score ≤ 4.
89434928|NCT06293950|Experimental|WJMSC|- Patients receive three intravenous doses of MSCs (1 million/kg) every two weeks as treatment.
89198319|NCT00860223|Experimental|2|Digoxin plus neratinib
89198320|NCT05223504||Observed patients|Adult patients (≥18 years) admitted with an acute medical disease and who are scheduled for discharge to their own homes within five days from inclusion.
89198321|NCT01044823||Adult RA|
89198322|NCT01044823||pediatric JRA|
89198323|NCT02564276|Experimental|Indocyanine Green on the right side|Indocyanine Green will be injected on the right side of the cervix and Methylene blue on the left side of the cervix.
89198324|NCT02564276|Experimental|Methylene Blue on the right side|Methylene blue will be injected on the right side of the cervix and Indocyanine Green on the left side of the cervix.
89198325|NCT00860301|Experimental|Acupuncture group|
89198326|NCT00860301|No Intervention|Control group|Infants come to the clinic six times, are left alone for five minutes with the acupuncture nurse who hold its hand and talks to it.
89434929|NCT06293924||Pericarditis patients|Patients with acute idiopathic or post-cardiac injury pericarditis who require diagnostic or therapeutic pericardiocentesis. Four ml of pericardial fluid should be collected: 2 ml for biochemical analysis in lithium heparin or serum-gel separator-associated tubes, and 2 ml for cellular analysis in K3 ethylenediaminetetraacetic acid (K3-EDTA) tubes.
89434930|NCT06293924||Pericardial effusion patients without inflammation|Subjects with non-inflammatory pericardial effusion who require diagnostic or therapeutic pericardiocentesis. Four ml of pericardial fluid should be collected: 2 ml for biochemical analysis in lithium heparin or serum-gel separator-associated tubes, and 2 ml for cellular analysis in K3 EDTA tubes.
89434931|NCT06293924||Cardiac surgery pericardial effusion|Patients who undergo cardiac surgery that involves a pericardiotomy. During cardiac surgery, 4 ml of pericardial fluid is collected and analyzed upon opening the pericardial sac. Four ml of pericardial fluid should be collected: 2 ml for biochemical analysis in lithium heparin or serum-gel separator-associated tubes, and 2 ml for cellular analysis in K3 EDTA tubes.
89434932|NCT06293911|Experimental|Postbiotic group|
89434933|NCT06293911|Active Comparator|Placebo group|
89434934|NCT06293898|Experimental|BL-M07D1 administered Day 1 of a 21-day cycle|
89434935|NCT06293885|Experimental|D50|A solution of 50% glucose will be injected into the pleural space on the first and possibly the second day after surgery. The injection will be administered through the chest tube, which is already in place.
89434936|NCT06293885|Active Comparator|Standard of care|monitor air leak, if the air leak continues on post-operative day #5, a talc pleurodesis may be given.
89434937|NCT06293872|Experimental|12*2 mm length miniscrew|"The self-drilling screw is directed at 90° to the occlusal plane at this point. After the initial notch in the bone is created after couple of turns to the driver, the bone screw driver direction is changed by 55°-70° toward the tooth, downward, which aid in bypassing the roots of the teeth and directing the screw to the infra-zygomatic area of the maxilla. The bone screw is screwed until only the head of the screw is visible outside the alveolar mucosa.~Follow-up: C.B.C.T will be performed after surgery to verify the implant position relative to the adjacent roots."
89434938|NCT06293872|Active Comparator|14*2 mm length miniscrew|"The self-drilling screw is directed at 90° to the occlusal plane at this point. After the initial notch in the bone is created after couple of turns to the driver, the bone screw driver direction is changed by 55°-70° toward the tooth, downward, which aid in bypassing the roots of the teeth and directing the screw to the infra-zygomatic area of the maxilla. The bone screw is screwed until only the head of the screw is visible outside the alveolar mucosa.~Follow-up: C.B.C.T will be performed after surgery to verify the implant position relative to the adjacent roots."
89434939|NCT06293859|Placebo Comparator|Conventional oat flakes-placebo|
89434940|NCT06293859|Experimental|Probiotic oat flakes|
88915271|NCT01615276|Experimental|Protein ingestion after NMES|Ingestion of intrinsically labeled protein, directly after one hour of Neuromuscular electrical stimulation (NMES)
88915272|NCT01615289|Active Comparator|Green tea extract, 250 ml|Single intragastric instillation of 250 ml green tea extract
88915273|NCT01615289|Active Comparator|Green tea extract, 500 ml|Intragastric instillation of 500 ml green tea extract solution
89434941|NCT06293833|Experimental|High-risk (ex-) smokers|Prevention and early detection of lung cancer are considered the cornerstones to increase the chances of successful treatment and improved outcomes. There is strong scientific evidence that screening for lung cancer through an annual low-dose CT scan (LDCT) in a high-risk population of (ex-)smokers significantly reduces lung cancer mortality and is cost-effective. This implementation study will investigate the participation rate of eligible high risk (ex-)smokers in the First Line Zone (ELZ) South East Region of Antwerp (ZORA) in a LDCT screening program, combined with smoking cessation.
89434942|NCT06293820|Active Comparator|TL-925 Arm|Subjects will be dosed in clinic and at home.
89434943|NCT06293820|Placebo Comparator|Placebo Arm|Subjects will be dosed in clinic and at home.
89434944|NCT06293794|Experimental|Traditional Clinical Decision Support (CDS)|
88915274|NCT01615289|Placebo Comparator|Control solution, 250 ml|Intragastric instillation of 250 ml control solution
88915275|NCT01615289|Placebo Comparator|Control solution, 500 ml|Single intragastric instillation of 500 ml control solution
88915276|NCT01615302|Active Comparator|Mucosa advancement flap|
88915277|NCT01615302|Experimental|Mucosa advancement flap + PRP|Platelet rich plasma added to the mucosa advancement flap
88915278|NCT01615354|Placebo Comparator|Placebo|
88915279|NCT01615354|Experimental|Treatment|
89198327|NCT01047631|Experimental|Functional circuit training and lifestyle counseling|
89198328|NCT01047631|Active Comparator|Health education and independent walking|
89434945|NCT06293794|Experimental|Personalized Clinical Decision Support (CDS)|
89434946|NCT06293781|Experimental|ACT|Web-based ACT with treatment as usual
89434947|NCT06293781|Active Comparator|Controls|Waitlist being on the treatment as usual
89434948|NCT06293768|Experimental|Group A continuous monitoring|Group A includes patients admitted to the acute ward who are considered transferable to the ward for subacute by the seventh day of hospitalization. These patients receive continuous telemonitoring of the patient's clinical condition for 5 days after transfer to the subacute ward
89531284|NCT02493569||Epidemiology breast cancer patients|Observe the features of clinical diagnosis and treatment for female breast cancer patients
89434949|NCT06293768|No Intervention|Group A standard monitoring|Group A includes patients admitted to the acute ward who are considered transferable to the ward for subacute by the seventh day of hospitalization. These patients receive standard telemonitoring of the patient's clinical condition for 5 days after transfer to the subacute ward
89434950|NCT06293768|Experimental|Group B continuous monitoring|Group B includes patients admitted to the acute ward who are considered dismissible by the seventh day of hospitalization. These patients receive continuous telemonitoring of the patient's clinical condition for 5 days after discharge to the home
89434951|NCT06293768|No Intervention|Group B standard monitoring|Group B includes patients admitted to the acute ward who are considered dismissible by the seventh day of hospitalization. These patients receive standard telemonitoring of the patient's clinical condition for 5 days after discharge to the home
89434952|NCT06293755|Experimental|Microneedle patch with Botulinum toxin|Participants recieve microneedle path with 20 units Botulinum toxin at nose and cheek one side.
89434953|NCT06293755|Active Comparator|Intradermal Botulinum toxin injection|Participants recieve intradermal 20 units Botulinum toxin injection at nose and cheek in other side.
89434954|NCT06293742|Experimental|Digoxin, Rosuvastatin, ECC5004 (Part A)|Part A consists of 2 treatment periods. Participants will receive Digoxin and Rosuvastatin administered alone in treatment period 1 and in combination with ECC5004 in treatment period 2.
89434955|NCT06293742|Experimental|Midazolam, Atorvastatin, ECC5004 (Part B)|Part B consists of 5 treatment periods. In treatment period 1, participants will receive Midazolam administered alone followed by treatment period 2 in which participants will receive Atorvastatin administered alone. In treatment period 3, participants will receive ECC5004 alone. In treatment period 4, participants will receive ECC5004 in combination with Midazolam. In treatment period 5, ECC5004 will be administered alone and co-administered with Atorvastatin.
89434956|NCT06293742|Experimental|Digoxin, Rosuvastatin, ECC5004 (optional Part C)|Optional Part C consists of 2 treatment periods. Participants will receive Digoxin and Rosuvastatin administered alone in treatment period 1 and in combination with ECC5004 in treatment period 2.
89434957|NCT06293742|Experimental|Midazolam, Atorvastatin, ECC5004 (optional Part D)|Optional Part D consists of 5 treatment periods. In treatment period 1, participants will receive Midazolam administered alone followed by treatment period 2 in which participants will receive Atorvastatin administered alone. In treatment period 3, participants will receive ECC5004 alone. In treatment period 4, participants will receive ECC5004 in combination with Midazolam. In treatment period 5, ECC5004 will be administered alone and co-administered with Atorvastatin.
89434958|NCT06293729|Experimental|NGGT006|3 doses of NGGT006 will be administered according to the principle of dose escalation
89434959|NCT06293716|Experimental|part1:treatment group|Patients were given CVL237 tablets, 100 mg/ day, QD, for 4 weeks (28 days), and safety assessment was performed on day 28 of the first cycle. If there was no safety risk, patients could take CVL237 tablets, 200 mg/ day, QD, for 4 weeks (28 days).
89434960|NCT06293716|Experimental|part2:treatment group|Patients were randomly assigned to the trial and placebo groups in a ratio of 2:1 to take an oral CVL237 tablet once daily.
89434961|NCT06293716|Placebo Comparator|part 2:placebo group|Patients were randomly assigned to the trial and placebo groups in a ratio of 2:1 to take a placebo CVL237 simulant once daily.
88915280|NCT01615380|Active Comparator|CBT+ Contact|In addition to the smoking cessation program, those in the CBT + CONTACT condition will enroll in a Wellness Program and will receive weekly wellness materials to read as well as receiving 4 sessions with a health educator in weeks 1, 4, 8 and 12 to discuss the wellness materials.
89434962|NCT06293703|Experimental|aRYGB|BP and roux limb lengths measuring 30% and 15% respectively of patient's total small bowel length.
88915281|NCT01615380|Experimental|CBT+ Exercise|Participants will receive an identical 12-week cognitive behavioral smoking cessation program delivered by YMCA staff and monitored by members of the research team to ensure fidelity of treatment delivery. In addition to the smoking cessation program, those in the CBT + EXERCISE condition will enroll in the 12-week YMCA Personal Fitness Program (PFP) where they will receive 4 sessions with a personal trainer in weeks 1, 4, 8 and 12 and will engage in aerobic exercise at least 3 times per week either in the PFP facilities or in other programs offered at the YMCA, such as aerobics classes.
88915282|NCT01615393|Active Comparator|Ribavirin capsule arm|
88915283|NCT01615393|Experimental|Ribavirin tablet arm|
88915284|NCT01615406|Experimental|Drug: 99mTc-MIP-1404|20 ±3 mCi intravenous (IV) injection of 99mTc MIP 1404
88915285|NCT01615419||Cohort|
88915286|NCT01615445|Active Comparator|Resveratrol|Group A Participants will received resveratrol 500 mg twice daily for 1 week then 1000 mg twice daily for 3 weeks, according to tolerance. They will discontinue medication for 2 weeks. The will receive placebo for 4 weeks.
88915287|NCT01615445|Placebo Comparator|Placebo|Group B (n=6) Will receive placebo for 4 weeks, they will discontinue medication for two weeks. Then receive resveratrol for 4 weeks
88915288|NCT01615458|Active Comparator|Usual Care|Patients will receive their usual care from providers at the clinic.
88915289|NCT01615471|Active Comparator|Large Group|In person group sessions in large group format (up to 125 others)
88915290|NCT01615471|Active Comparator|Small group|Small group in person sessions (up to 25 other participants)
88915291|NCT01615497|Active Comparator|Standard Treatment as Usual (TAU)|Treatment that would normally be received at the clinic typically consisting of individual or group counseling sessions focusing on alcohol and substance abuse.
88915292|NCT01615497|Experimental|Web-based CBT4CBT for alcohol plus TAU|A computerized program that teaches skills for stopping drug and alcohol use by increasing coping skills such as how to understand patterns of drug use, coping with cravings, etc. plus standard treatment as usual.
88915293|NCT01615497|Active Comparator|Web-based CBT with minimal clinical contact|A computerized program that teaches skills for stopping drug and alcohol use by increasing coping skills such as how to understand patterns of drug and alcohol use, coping with cravings, etc. plus 10 minute check in with clinician.
88915294|NCT01615523||Children/adolescents born preterm|
88915295|NCT01615523||Control children and adolescents|
88915296|NCT01615536|Experimental|Canine fossa trephine group (CFT)|
88915297|NCT01615536|Active Comparator|Non Canine fossa trephine group (NonCFT)|
89434963|NCT06293703|Active Comparator|sRYGB|Standard fixed-length RYGB
89434964|NCT06293677|Active Comparator|Control Group 1c|Group 1c includes patients with augmented renal clearance (ARC) who have been randomized to receive a standard dosage of antibiotic (méropenem or piperacilline-tazobactam)
88915298|NCT01615549|Active Comparator|Free training|
88915299|NCT01615549|Experimental|Proficiency-based training|
88915300|NCT01615562||PCOS adolescents|Post-menarchal females ages 14-17 with and without PCOS (15 each group for a total of 30 subjects).
88915301|NCT01615562||PCOS women|Women ages 18-40 with and without PCOS (15 each group for a total of 30 subjects).
88915302|NCT01615575|Active Comparator|Haemorrhoidal dearterialisation|Closure of the arterial blood flow to the haemorrhoidal plexus, using a dedicated proctoscope with a Doppler probe, and addiction of rectal mucopexy.
88915303|NCT01615575|Active Comparator|Stapler haemorrhoidopexy|Haemorrhoidopexy was performed with a single dedicated circular stapling device (PPH 03, Ethicon Endo-Surgery, Ohio, USA.)
88915304|NCT01615588|Experimental|honey|Manuka honey
88915305|NCT01615601||darunavir (PREZISTA)|PREZISTA co-administered with 100 mg ritonavir as per Canadian Product Monograph. (Observational Study)
88915306|NCT01615601||etravirine (INTELENCE)|INTELENCE co-administered with other antiretroviral medicinal products as per Canadian Product Monograph (Observational Study)
88915307|NCT01615614|Experimental|Treatment A|Rilpivirine 25 mg once daily will be administered for 11 days
88915308|NCT01615614|Experimental|Treatment B|Rilpivirine 50 mg once daily will be administered for 11 days and rifabutin 300 mg once daily will be administered for 17 days
88915309|NCT01615614|Experimental|Treatment C|Rilpivirine (in a regimen to be determined based on an interim pharmacokinetic analysis of treatment A and B) will be administered for 11 days and rifabutin 300 mg once daily will be administered for 17 days.
88915310|NCT01615627|Experimental|Hypotonic Treprostinil Solution|Hypotonic Treprostinil Solution
88915311|NCT01615627|Active Comparator|Eutonic Treprostinil Solution|Eutonic Treprostinil Solution
88915312|NCT01615640||Osteosarcoma patients|Patients with an histologically proven osteosarcoma will be entered into the study.
88915313|NCT01615653|Active Comparator|EUS 1|
88915314|NCT01615653|Active Comparator|EUS 2|
88915315|NCT01615666||Healthy volunteers|Healthy volunteers who will undergo functional MRI (fMRI) to obtain fMRI index
88915316|NCT01615666||Alzheimer's disease|Individuals with Alzheimer's disease who will undergo functional MRI (fMRI) to obtain fMRI index
88915317|NCT01615666||Non-Alzheimer's dementia|Individuals with Non-Alzheimer's dementia who will undergo functional MRI (fMRI) to obtain fMRI index
88915318|NCT01615666||Amnestic mild cognitive impairment|Individuals with Amnestic mild cognitive impairment who will undergo functional MRI (fMRI) to obtain fMRI index
88915319|NCT01615666||Nonamnestic mild cognitive impairment|Individuals with Nonamnestic mild cognitive impairment who will undergo functional MRI (fMRI) to obtain fMRI index
88915320|NCT01615692||36-mth follow up visit|The cohort will consist of original subjects of the SOX Trial who consent to participate in the extension to follow up sub study.
88915321|NCT01615705||Blood Draw|"SOX Subjects:~The cohort consists of original subjects from the SOX Trial who consented to participate in the sub study."
88915322|NCT01615718|Experimental|Active Electrical Stim/Active Ultrasound|Subjects will undergo active low-intensity transcranial electrical stimulation in conjunction with active transcranial ultrasound for 20 minutes.
88915323|NCT01615718|Sham Comparator|Sham Electrical Stim/Sham Ultrasound|Subjects will undergo sham (placebo) low-intensity transcranial electrical stimulation in conjunction with sham transcranial ultrasound for 20 minutes.
88915324|NCT01615718|Active Comparator|Active Electrical Stim/Sham Ultrasound|Subjects will undergo active low-intensity transcranial electrical stimulation in conjunction with sham (placebo) transcranial ultrasound for 20 minutes.
88915325|NCT01615718|Active Comparator|Sham Electrical Stim/Active Ultrasound|Subjects will undergo sham (placebo) low-intensity transcranial electrical stimulation in conjunction with active transcranial ultrasound for 20 minutes.
88915326|NCT01615744||Surgical ORIF calcaneal fx|
88915327|NCT01615744||Conservative treatment calcaneal fx|
88915328|NCT01615757|Experimental|Arm B, Ara-c - 12 gm/m2|Arm B will receive HIDAC at 12 gm/m2/cycle for 3 cycles , i.e. 2 gm/m2 BD , Day 1,3,5
88915329|NCT01615757|Active Comparator|Arm A. Ara-c 18 gm/m2|Arm A will receive HIDAC at 18 gm/m2/cycle for 3 cycles , i.e. 3 gm/m2 BD , Day 1,3,5
89198329|NCT04018287||HPP-Group|"genetical verified hypophosphatasia~age >18 years~written informed consent~complete serological and radiological examinations"
89434965|NCT06293677|Experimental|Intervention DAR-ARC Group 1i|Group 1i (DAR-ARC) includes patients with ARC who have been randomized to receive an experimental dosage of antibiotic (méropenem or piperacilline-tazobactam)
89434966|NCT06293677|Active Comparator|Control Group 2|Control Group 2 includes patients with normal or decreased renal function who will receive standard dosage of antibiotic (méropenem or piperacilline-tazobactam)
89434967|NCT06293664|Experimental|α-MSH infusion|Pharmaceutical grade α-MSH will be dissolved in 0.9% saline containing 0.5% human albumin.
89434968|NCT06293664|Placebo Comparator|Saline infusion|Saline infusion: Pharmaceutical GMP-grade sterile 0.5% human albumin dissolved in saline.
89434969|NCT06293651|Experimental|Monotherapy|Phase 1a: Dose escalation Phase 1b: Dose expansion Phase 2a: Pharmacodynamic Biomarkers
89010090|NCT02214199|Experimental|Manipulative Therapy Techniques|Lift Technique for mid-thoracic spine. Mobilization by low cervical spine on the upper lateral thoracic translation. Technical Dog flexion for high thoracic spine (T1-T4). Technical Dog flexion for mid-thoracic spine (T5-T8). Technical Dog flexed to low thoracic spine (T9-T12). Direct drive technology prone to mid-thoracic spine.
89010091|NCT04550611|Experimental|Mini-pool Intravenous Immunoglobulin (MP-IVIG)|will receive blood group -specific MP-IVIG in a regimen of 2 g/kg bodyweight, usually as 0.4 g/kg bodyweight per day for five consecutive days within two weak of onset of symptoms.
89434970|NCT06293651|Experimental|Combination with Pembrolizumab|Phase 1a: Dose escalation Phase 1b: Dose expansion Phase 2a: Proof of concept Phase 2a: Pharmacodynamic Biomarkers
89434971|NCT06293638||Essential Tremor with DBS|"40-80 years of age~Diagnosis of ET~Previously implanted with a DBS system for disease management per standard of care"
89434972|NCT06293638||Essential Tremor without DBS|"40-80 years of age~Diagnosis of ET~Has not been previously implanted with a DBS system for disease management per standard of care"
89434973|NCT06293638||No Known Neurological Disease or Disorder|"40-80 years of age~No known neurological disease or disorder"
89434974|NCT06293625|Experimental|NeoAdjuvant Chemotherapy arm|
89434975|NCT06293625|Active Comparator|Current standard of care|
89434976|NCT06293612||Training cohort|The patients were randomized into a training cohort (n ＝ 211) to train the model. The patients' clinicopathological data were reviewed, including age, sex, obesity, serum carcinoembryonic antigen and cancer antigen 19-9 levels, T- and N-stages evaluated by MRI, yp-T and yp-N stages evaluated by histopathology. The MR-T/N stages of the tumors were assessed by radiologists. The tumor region of interest was manually delineated on high-resolution oblique axial T2WI and generated the VOI using ITK-SNAP. Overall, 1229 features were extracted from each VOI. Biopsy specimens from colonoscopy were sectioned into 5 μm slices and stained with H&E. Areas with both stromal and tumor cells presented on all four sides were selected to evaluate tumor stroma ratio using an automated scoring method with the highest proportion of stromal components in all measured areas recorded.
89010092|NCT04550611|Experimental|plasmapheresis|plasma exchange (plasmapheresis ) in a regimen of removing of 1.3 plasma volumes in each cycle for total of five cycle for five consecutive days within four weeks of onset of symptoms.
89434977|NCT06293612||Validation cohort|The patients were randomized into a validation cohort (n ＝91) to verify the model. The patients' clinicopathological data were reviewed, including age, sex, obesity, serum carcinoembryonic antigen and cancer antigen 19-9 levels, T- and N-stages evaluated by MRI, yp-T and yp-N stages evaluated by histopathology. The MR-T/N stages of the tumors were assessed by radiologists. The tumor region of interest was manually delineated on high-resolution oblique axial T2WI and generated the VOI using ITK-SNAP. Overall, 1229 features were extracted from each VOI. Biopsy specimens from colonoscopy were sectioned into 5 μm slices and stained with H&E. Areas with both stromal and tumor cells presented on all four sides were selected to evaluate tumor stroma ratio using an automated scoring method with the highest proportion of stromal components in all measured areas recorded.
89434978|NCT06293599|Experimental|scapular stabilization exercise|thirty patients with scapular dyskinesia will receive scapular stabilization exercise and regular routine three times a week for eight weeks
89434979|NCT06293599|Experimental|virtual reality exercise|thirty patients with scapular dyskinesia will receive virtual reality exercise and regular routine three times a week for eight weeks
89434980|NCT06293599|Active Comparator|Regular routine exercise|thirty patients with scapular dyskinesia will receive regular routine exercises three times a week for eight weeks
89434981|NCT06293586|Experimental|Peribulbar group (Group P)|The peribulbar group (P group _ 40) received a peribulbar block with 0.25 mL/kg of a 1:1 local anesthetic mixture (LAM) of 0.5% bupivacaine and 2% lignocaine. Peribulbar block using a two-injection technique was performed by a second anesthetist under sterile conditions and before the application of surgical drapes. LAM was injected both infratemporal and superonasally using a 26-G needle, in contrast to the single infratemporal injection approach.
89434982|NCT06293586|Experimental|sub-tenon group (group S)|Children in the sub-Tenon group (sub-Tenon group (S), n _ 40) received a sub-Tenon block. Sub-Tenon's anesthesia was performed with 0.5% bupivacaine (0.08 ml/kg), bearing in mind not to exceed the maximum dose. Under sterile conditions, a 19- gauge curved blunt metallic cannula (25 mm) was inserted into sub-Tenon's space and the local anesthetic was injected by the ophthalmologist after the application of surgical drapes.
89434983|NCT06293586|Active Comparator|paracetamol (group C)|Children in the paracetamol group received IV paracetamol (15 mg/kg) after induction of anesthesia before any surgical intervention.
89434984|NCT06293573|Experimental|whole body vibration group|Group A (Study group): Will receive whole body vibration exercises with conventional progressive resistance exercises and diet modification life style
89434985|NCT06293573|Experimental|aerobic exercise group|Group B (Study group): Will receive aerobic exercises training with conventional progressive resistance exercises and diet modification life style.
89434986|NCT06293573|Active Comparator|conventional resistance exercise group|Group C (Control Group): will receive conventional progressive resistance exercises and diet modification life style
89010093|NCT04550026|Experimental|Inhalation of HTP|Inhalation of HTP for 30 minutes
89010094|NCT04550026|Active Comparator|Sham inhalation of HTP|Sham usage of HTP for 30 minutes
89010095|NCT04550299|Active Comparator|Group A|single bundle technique with the use of bioabsorbable implants
89010096|NCT04550299|Active Comparator|Group B|single bundle technique with the use of Bio-Intrafix
89010097|NCT04550299|Active Comparator|Group C|double bundle technique with the use of bioabsorbable implants
89010098|NCT04550299|Active Comparator|Group D|double bundle technique with the use of Bio-Intrafix
89010099|NCT00235235||A|Doxorubicin 60 mg/m2 + Cyclophosphamide 600 mg/m2 day 2 of every 21-day cycle
89010100|NCT00235235||B|Capecitabine 1000mg/m2 bid days 1-14 of every 21-day cycle
89010101|NCT00235235||C|Vinorelbine 25 mg/m2 days 1, 8, 15 of every 28-day cycle
89010102|NCT00235235||D|Gemcitabine 1000mg/m2 days 1, 8, 15 of every 28-day cycle
89434987|NCT06293547|Experimental|Single arm|Following a standard dental examination, which may have included intraoral radiographs as needed, the application of 38% SDF (Riva Star, SDI Australia) was conducted on carious lesions identified in primary teeth. The application procedure of SDF adhered to the protocol recommended in the literature and the instructions provided by the manufacturer. One and experienced researcher applied SDF to each patient. Initially, the affected teeth were isolated and dried using gauze and cotton rolls. Subsequently, the SDF solution was applied directly to the lesions using a microbrush, with an absorption time ranging from a minimum of 30 seconds to a maximum of 120 seconds, depending on the child's behavior (30-60-90-120 seconds). Any excess solution was carefully removed using gauze. Parents were instructed to ensure that the child refrained from eating or drinking for at least one hour following the application of SDF.
89434988|NCT06293534||Patients with major psychiatric disorders|Patients diagnosed with major psychiatric disorders according to the Diagnostic Statistical Manual version 5 (DSM 5-TR), admitted to the psychiatry department in Assiut University Hospital.
89434989|NCT06293521|Experimental|MTA Pulpotomy|Intervention group
89434990|NCT06293521|Active Comparator|Zinc Oxide Eugenol Partial Pulpectomy|Control group
89434991|NCT06293508|No Intervention|Control Arm|Participants do not receive any message throughout the study period.
89434992|NCT06293508|Experimental|Experimental Arm 1|Participants in this group will receive a message on a weekly basis throughout the intervention period, which is 6 months, via WhatsApp.
89434993|NCT06293508|Experimental|Experimental Arm 2|Participants in this group will receive a message on a weekly basis throughout the intervention period, which is 6 months, via WhatsApp.
89434994|NCT06293495|Active Comparator|Single Cephalic Screw System|A Gamma 3 nail (single cephalic screw system) will be used for osteosynthesis of the fracture.
89434995|NCT06293495|Experimental|Double Cephalic Screw System|A Chimaera nail (system with double cephalic screw) will be used for osteosynthesis of the fracture.
89434996|NCT06293482|Experimental|Cochlear™ Nucleus® System|Participants will be implanted with a commercially approved Cochlear™ Nucleus® implant.
89434997|NCT06293456|Experimental|Dignity Therapy|The DT intervention is a 45-75-minute virtual interview, which is recorded and transcribed within 72-96 hours of the interview.
89434998|NCT06293443|Other|Lower extremity unilateral amputee|Unilateral transtibial and unilateral transfemoral amputees were evaluated in the study. Criteria for autees to participate in the study; Being a unilateral lower extremity amputee, using a prosthesis, being literate, being between the ages of 18-65, having a healthy stump, and using their current prosthesis in daily life activities. Individuals who had knee disarticulation amputation and individuals who had hip disarticulation amputation were not included in the study.
89434999|NCT06293404|Active Comparator|Group F|the lateral decubitus position, Group F will keep the spinal cord flexed for 10 minutes,
89435000|NCT06293404|Other|Group N|the lateral decubitus position, Group N will keep the natural position of the spinal cord in lateral decubitus for 10 minutes,
89435001|NCT06293391||ODM measurements of patients undergoing open surgery in supine and trendelenburg position|After intubation, serial ODM measurements were performed in the supine and trendelenburg position of the patient and CO: Cardiac output, FTc: Flow time corrected, PV: Peak velocity, SD: Stroke distance values were recorded.
89010103|NCT04549714|Experimental|High AI in paroxysmal atrial fibrillation|In this group,patients with paroxysmal AF will receive pulmonary vein vestibule ablation with high AI value, the AI target value for the front wall and the top wall is 550, and the rear wall and the lower wall are 400.
89198330|NCT04018287||Control-Group|"healthy men and women without any history of musculoskeletal diseases~Alkaline phosphatase (AP) in reference range~written informed consent~complete serological and radiological examinations"
89435002|NCT06293391||ODM measurements of patients undergoing laparoscopic surgery in supine and trendelenburg position|After intubation, serial ODM measurements were performed in the supine and trendelenburg position of the patient and CO: Cardiac output, FTc: Flow time corrected, PV: Peak velocity, SD: Stroke distance values were recorded.
89435003|NCT06293378|Experimental|Cohort A：Patients with PBC were treated with sulfasalazine|Sulfasalazine enteric-coated tablets, 0.25 g/tablet, 2 tablets (0.5 g) each time, three times each time, were taken orally for 12 months.
88915330|NCT01615770|No Intervention|Open Label CBT and Pharmacotherapy|All study participants received 8 weeks of cognitive and behavioral cessation and relapse prevention skills training (CBT) and nicotine patch therapy combined with 9 weeks of bupropion SR therapy. Following open-label, this group received general supportive therapy delivered via four telephone calls made to participants over a 12-week period.
88915331|NCT01615770|Experimental|Behavioral: cognitive behavior therapy|All study participants received 8 weeks of cognitive and behavioral cessation and relapse prevention skills training (CBT) and nicotine patch therapy combined with 9 weeks of bupropion SR therapy. Following open-label treatment, half the participants received an additional 12 weeks of CBT that combined clinic-based skills training sessions, voicemail monitoring and telephone counseling
88915332|NCT01615783||Medicaid beneficiaries|Medicaid beneficiaries with at least one medical or pharmacy claim during each year in the identification period (2004-2006)
88915333|NCT01615796|Experimental|Cohort A1|GSK2140944 200mg single dose
89435004|NCT06293378|Experimental|Cohort B：Patients with HBV were treated with sulfasalazine|Sulfasalazine enteric-coated tablets, 0.25 g/tablet, 2 tablets (0.5 g) each time, three times each time, were taken orally for 12 months.
89435005|NCT06293378|Experimental|Cohort C：Patients with HCV were treated with sulfasalazine|Sulfasalazine enteric-coated tablets, 0.25 g/tablet, 2 tablets (0.5 g) each time, three times each time, were taken orally for 12 months.
88915334|NCT01615796|Experimental|Cohort A2|GSK2140944 600mg single dose
88915335|NCT01615796|Experimental|Cohort A3|GSK2140944 1200mg single dose
88915336|NCT01615796|Experimental|Cohort A4|GSK2140944 1800mg single dose
88915337|NCT01615796|Experimental|Cohort A5|GSK2140944 1800mg single dose
88915338|NCT01615796|Experimental|Cohort A6|GSK2140944 dose to be determined, single dose
88915339|NCT01615796|Experimental|Cohort B1|GSK2140944 400 mg repeat dose BID up to 7 days
88915340|NCT01615796|Experimental|Cohort B2|GSK2140944 750 mg repeat dose BID up to 7 days
88915341|NCT01615796|Experimental|Cohort B3|GSK2140944 1000 mg repeat dose BID up to 7 days
88915342|NCT01615796|Experimental|Cohort B4|GSK2140944 to be determined repeat dose BID up to 7 days
88915343|NCT01615796|Experimental|Cohort B5|GSK2140944 to be determined repeat dose TID up to 14 days
88915344|NCT01615796|Experimental|Cohort B6|GSK2140944 to be determined repeat dose TID up to 14 days
88915345|NCT01615848|Experimental|mediterranean diet restricted calorie|1500 k/calories 47-51% carbohydrate 14-17% protein 33-36% fat: 7-7.6% saturated fat 22-30% monounsaturated & polyunsaturated fat
88915346|NCT01615848|Experimental|high protein diet, restricted calorie|1500 k/calories 40 % carbohydrate 30% protein 30% fat
88915347|NCT01615861|Experimental|IOL implantation|Hydrophilic acrylic lens implantation through a micro-incision phacoemulsification and cataract surgery (MICS)
88915348|NCT01615900|Other|Teleconsultation|
88915349|NCT01615900|Other|Standard consultation|
88915350|NCT01615913|Experimental|3% terbinafine patch|A 10-cm2 patch containing 3 mg terbinafine and 2 mg ketoconazole
88915351|NCT01615913|Experimental|6% terbinafine patch|A 10-cm2 patch containing 6 mg terbinafine and 2 mg ketoconazole
88915352|NCT01615913|Experimental|8% terbinafine patch|A 10-cm2 patch containing 8 mg terbinafine and 2 mg ketoconazole
89198331|NCT00698204|Experimental|I- Celecoxib|
89198332|NCT00698204|Placebo Comparator|II|
89435006|NCT06293378|Experimental|Cohort D：Patients with alcoholic liver fibrosis/cirrhosis were treated with sulfasalazine|Sulfasalazine enteric-coated tablets, 0.25 g/tablet, 2 tablets (0.5 g) each time, three times each time, were taken orally for 12 months.
89435007|NCT06293365|Experimental|Cohort 1: Sequence 1 + Thigh|"Patients randomized to receive injection (2 x 1 mL) PFS in TP1 in Thigh (1 X 2 mL) AI in TP2 in Thigh~(1 x 2 mL) AI in ETP in Thigh/ Abdomen"
89435008|NCT06293365|Experimental|Cohort 1: Sequence 1 + Abdomen|"Patients randomized to receive injection~X 2 mL) AI in TP1 in Abdomen~x 1 mL) PFS in TP2 in Abdomen~(1 x 2 mL) AI in ETP in Thigh/ Abdomen"
89435009|NCT06293365|Experimental|Cohort 1: Sequence 2 + Thigh|"Patients randomized to receive injection (2 x 1 mL) PFS in TP1 in Thigh (1 X 2 mL) AI in TP2 in Thigh~(1 x 2 mL) AI in ETP in Thigh/ Abdomen"
89435010|NCT06293365|Experimental|Cohort 1: Sequence 2 + Abdomen|"Patients randomized to receive injection~X 2 mL) AI in TP1 in Abdomen~x 1 mL) PFS in TP2 in Abdomen~(1 x 2 mL) AI in ETP in Thigh/ Abdomen"
89435011|NCT06293365|Experimental|Cohort 2: Sequence 1 + Thigh|"Patients randomized to receive injection (2 x 1 mL) PFS in TP1 in Thigh (1 X 2 mL) PFS in TP2 in Thigh~(1 x 2 mL) PFS in ETP in Thigh/ Abdomen/ Upper Arm"
89435012|NCT06293365|Experimental|Cohort 2: Sequence 1 + Abdomen|"Patients randomized to receive injection~X 2 mL) PFS in TP1 in Abdomen~x 1 mL) PFS in TP2 in Abdomen~(1 x 2 mL) PFS in ETP in Thigh/ Abdomen/ Upper Arm"
89435013|NCT06293365|Experimental|Cohort 2: Sequence 1 + Upper Arm|"Patients randomized to receive injection (2 x 1 mL) PFS in TP1 in Upper Arm (1 X 2 mL) PFS in TP2 in Upper Arm~(1 x 2 mL) PFS in ETP in Thigh/ Abdomen/ Upper Arm"
89435014|NCT06293365|Experimental|Cohort 2: Sequence 2 + Thigh|"Patients randomized to receive injection~X 2 mL) PFS in TP1 in Thigh~x 1 mL) PFS in TP2 in Thigh~(1 x 2 mL) PFS in ETP in Thigh/ Abdomen/ Upper Arm"
89435015|NCT06293365|Experimental|Cohort 2: Sequence 2 + Abdomen|"Patients randomized to receive injection (2 x 1 mL) PFS in TP1 in Abdomen (1 X 2 mL) PFS in TP2 in Abdomen~(1 x 2 mL) PFS in ETP in Thigh/ Abdomen/ Upper Arm"
88915353|NCT01615952||Sitting Position (head of bed 90 degrees)|"Ultrasound measurements will be performed. A= skin to the pleura at the level lateral to the subclavian artery, B= skin to center of the subclavian artery, C= skin to first rib, D= skin to corner pocket"
89435016|NCT06293365|Experimental|Cohort 2: Sequence 2 + Upper Arm|"Patients randomized to receive injection~X 2 mL) PFS in TP1 in Upper Arm~x 1 mL) PFS in TP2 in Upper Arm~(1 x 2 mL) PFS in ETP in Thigh/ Abdomen/ Upper Arm"
89435017|NCT06293352|Active Comparator|All-cement articulating spacer|An articulating spacer with a tibial and femoral component made of cement using molds, that are cemented in place; use of highdose antibiotic cement (at least 2g/batch, including vancomycin and tobramycin); use of dowels at discretion of surgeon; 6 weeks IV antibiotics; intent to reimplant definitive prosthesis if infection eradicated.
89435018|NCT06293352|Active Comparator|Durable, real-component articulating spacer|Uses metal (or ceramicized metal) on plastic for bearing surface; use of high-dose antibiotic cement (at least 2g/batch, including vancomycin and tobramycin); no cones/sleeves, no pressurized cement in canal; use of stems/dowels/augments and level of constraint at discretion of surgeon; 6 weeks IV antibiotics; intent to leave in situ indefinitely/until clinical failure.
89435019|NCT06293352|Other|Observation|Patients who do not wish to be randomized or who meet the randomization-specific exclusion criteria will be offered enrolment into the non-randomized, prospective observational arm of the study. The participant and their surgeon will collaboratively decide which of the 2 treatments the participant will receive.
89435020|NCT06293339|Experimental|Rechallenge group|Previous CoGA phase 1 study participants who were immunised with GA2 and who did not develop blood-stage malaria during CHMI (protected)
89435021|NCT06293339|Placebo Comparator|Infection control group|Malaria-naïve participants who have not been previously vaccinated with GA2
89435022|NCT06293313|Experimental|Mindfulness group|Students who agree to participate in the research will be met with students in a quiet room of the school by making an appointment. Individuals will be pre-tested. Mindfulness will be applied within the first 3 days of the menstrual period. After continuing the training for 8 weeks, an interim test will be applied. After 3 months, the final test will be applied
88915354|NCT01615952||Semi-sitting position (45 degrees)|"Ultrasound measurements will be performed. A= skin to the pleura at the level lateral to the subclavian artery, B= skin to center of the subclavian artery, C= skin to first rib, D= skin to corner pocket"
88915355|NCT01615952||Supine position|"Ultrasound measurements will be performed. A= skin to the pleura at the level lateral to the subclavian artery, B= skin to center of the subclavian artery, C= skin to first rib, D= skin to corner pocket"
88915356|NCT01615965|Experimental|micrometastases|Molecular biologic detection of micrometastases in lymph nodes of patients with localized prostate cancer treated with radical prostatectomy and lymphadenectomy.
88915357|NCT01615978|Experimental|Fixed dose: 5 mcg/kg|
88915358|NCT01615978|Experimental|Escalated dose: 10 mcg/kg|
88915359|NCT01615991|Other|radiosynoviorthesis with yttrium-90 or rhenium -186|Patients suffering from arthritis or chronic inflammatory joint disease.
88915360|NCT01616004|Experimental|N2O|N20 70% inhalation 5 minutes O2 100 % inhalation for 5 minutes
88915361|NCT01616004|Sham Comparator|Air|
88915362|NCT01616030|Experimental|Strength training, fractured limb|"Knee-extension strength training of the fractured limb:~Daily knee-extension strength training with 3 x 10 repetitions using an intensity of 10 Repetition Maximum (RM) for the hip fractured limb started as soon as possible after surgery."
88915363|NCT01616043|Experimental|Glyaderm + STSG|All included patients in this arm will undergo full thickness removal of the burned skin or adequate debridement of all necrotic tissue. The wounds of the patients will be covered with glycerol preserved allografts for wound bed preparation. At the second operation, 5-7 days after the first operation, the allografts are removed. If the wound bed is not suitable for grafting, additional wound bed preparation with allografts is required until the wound bed is satisfactory. If the wound bed is suitable for grafting, the wounds of the patients are covered with Glyaderm®. After 6-8 days the wounds are finally covered with a thin STSG.
89010104|NCT04549714|Experimental|Middle AI in paroxysmal atrial fibrillation|In this group,patients with paroxysmal AF will receive pulmonary vein vestibule ablation with middle AI value, the AI target value for the front wall and the top wall is 500, and the rear wall and the lower wall are 350.
89198333|NCT00867945||1. Pregnant Women|
89198334|NCT00867945||2. Non-Pregnant Controls|
89198335|NCT00867945||3. IVF controls|
89435023|NCT06293313|Sham Comparator|Control Group|Students in the control group will not be given any application. A pre-test will be administered before starting the study, an interim test will be applied 8 weeks after the pre-test, and a post-test will be applied 3 months after the interim test. After the study is over, mindfulness will be applied to the students in the control group.
89435024|NCT06293300|Experimental|BoNT-A Group|Participants will receive BoNT-A intervention for up to 6 months.
89010105|NCT04549714|Experimental|Low AI in paroxysmal atrial fibrillation|In this group,patients with paroxysmal AF will receive pulmonary vein vestibule ablation with low AI value, the AI target value for the front wall and the top wall is 450, and the rear wall and the lower wall are 300.
89010106|NCT04549909||preimplantation genetic testing for aneuploidy (PGT-A) Group|Patients who have undergone preimplantation genetic testing for aneuploidy (PGT-A) (transfer of own frozen embryo)
89010107|NCT04549909||endometrial receptivity array (ERA) Group|Patients who have undergone frozen embryo transfer (FET) with endometrial receptivity array (ERA) test (embryos from own or donated oocytes)
89010108|NCT04549909||CONTROL OWN (CO) Group|Control group of FET from own oocytes (without ERA or PGT-A)
89435025|NCT06293261||Rosuampin 5/5mg (Rosuvastatin 5mg + Amlodipine 5mg)|
89435026|NCT06293261||Rosuampin 10/5mg (Rosuvastatin 10mg + Amlodipine 5mg)|
89435027|NCT06293261||Rosuampin 20/5mg (Rosuvastatin 20mg + Amlodipine 5mg)|
89435028|NCT06293261||Rosuampin 10/10mg (Rosuvastatin|
89435029|NCT06293235||Subfertile couples|Couples who are not able to conceive for at least 12 months with female partners without infertility diagnosis.
89435030|NCT06293235||Fertile couples|Couples with attempted time to conceive within 12 months to achieve this pregnancy or with unplanned pregnancy, with female partners who are currently pregnant with viable intrauterine pregnancy.
89435031|NCT06293209|Placebo Comparator|The control group (non-cryotherapy group)|Routine preoperative protocol ankle fracture on short leg slab compression with bandage
89435032|NCT06293209|Active Comparator|The cold pack group|The cold pack group consists of patients with ankle fractures who receive cold therapy using ice packs sized 20x20 centimeters. The ice packs are placed in the freezer compartment for 30 seconds after they have solidified, then applied to the injured ankle for 10 minutes, followed by a 10-minute break. This process is repeated every 2 hours for a total of 6 times (from 8:00 AM to 6:00 PM).
89435033|NCT06293209|Active Comparator|The cold spray|The cold spray group consists of patients with ankle fractures who receive cold therapy using Perskindol cold spray containing Levomenthol. The spray is applied to the injured ankle 5-6 times, followed by a 10-minute break. This process is repeated every 2 hours for a total of 6 times (from 8:00 AM to 6:00 PM).
89435034|NCT06293196|Experimental|standard Chinese acupoint eye exercise group|The volunteers performed a set of standard Chinese acupoint eye health exercises.
89435035|NCT06293196|Experimental|fake acupoint eye exercise group|Volunteers performed a group of fake acupoint eye health exercises, the acupoint design in the place without acupoints.
89435036|NCT06293196|No Intervention|simple eye closure group|The volunteers only closed their eyes and did not perform acupressure.
89435037|NCT06293196|No Intervention|simple distance observation group|The volunteers only looked far without acupressure.
89435038|NCT06293183|Experimental|Intervention group|After the purpose and method of the research are explained, a written informed consent form will be obtained and the Patient Introduction Form will be filled out. Mobile phone usage skills of patients undergoing hemodialysis treatment will be evaluated using the Digital Literacy Scale. Individuals in the initiative group will be given individual training on how to use the application through the application demo. Individuals in the initiative group will be given consultancy by the researcher while downloading the application and logging in with their username. Questionnaires and scale forms will be applied to the patients in the control group on the 0th day, the 14th day, and at the 1st, 2nd and 3rd months. Laboratory values and intradialytic weight information will be obtained from patient files.
89435039|NCT06293183|No Intervention|Control group|After the purpose and method of the research are explained, a written informed consent form will be obtained and the Patient Introduction Form will be filled out. No intervention will be made to the participants in this group. Questionnaires and scale forms will be applied to the patients in the control group on the 0th day, 14th day, 1st, 2nd and 3rd months. Laboratory values and intradialytic weight information will be obtained from patient files.
89435040|NCT06293170|Other|Control|Conventional care alone
89435041|NCT06293170|Experimental|DETECT|DETECT in addition to conventional care will be initiated according to randomization plan
89010109|NCT04549909||CONTROL DONATED(CD) Group|Control group of FET from donated oocytes (without ERA or PGT-A)
89010110|NCT04549675|Experimental|Arm 1 Sun Safe Partners Online Intervention|Web-based intervention called Sun Safe Partners Online. Website developed by the study team. Participants received individual username and password to login.
89435042|NCT06293157|Experimental|Transpedicular spinal stabilization using carbon system + SBRT|Transpedicular spinal stabilization using a radiolucent composite system made of carbon fibers and PEEK followed by stereotactic radiotherapy of the spine at a dose of 5x5 Gy (25 Gy in the total dose)
89435043|NCT06293157|Active Comparator|Transpedicular spinal stabilization using titanium system + SBRT|Transpedicular spinal stabilization using a titanium system followed by stereotactic radiotherapy of the spine at a dose of 5x5 Gy (25 Gy in the total dose)
89435044|NCT06293157|Sham Comparator|SBRT + Transpedicular spinal stabilization using titanium system|Transpedicular spinal stabilization using a titanium system preceded with stereotactic spine radiotherapy at a dose of 5x5 Gy (25 Gy in the total dose) as the first stage of treatment
89435045|NCT06293144|Experimental|ciprofol-assisted sedation 1|Adjusting the dose of ciprofol-assisted sedation in knee arthroplasty on a case-by-case basis
89435046|NCT06293131|Experimental|ciprofol-assisted sedation 1|Adjusting the dose of ciprofol-assisted sedation in knee arthroplasty on a case-by-case basis
89435047|NCT06293118|Experimental|Ischemic conditioning group|Therapy will be performed bilaterally on the upper limbs. The ischemic conditioning group will perform 4 times, 8 cycles with 30 seconds of ischemia (80 - 200 mmHg) with 5 seconds of reperfusion in each cycle. Ischemia cycles are controlled by a device (KAATSU C3 - KAATSU GLOBAL / USA) In the first cycle, participants will be subjected to pressures of 80 to 150 mmHg. In the 3 subsequent cycles, pressures from 130 to 200 mmHg will be applied.
89010111|NCT04549675|Active Comparator|Generic Online Sun Safety Information intervention|Publicly online available skin cancer and sun protection information emailed to participants in 4 seperate email links.
89010112|NCT04549948|Experimental|0.017X0.025 Stainless Steel Archwire|Leveling of COS using 0.017X0.025 Stainless Steel (SS) Archwire A reverse COS using 0.017X0.025 SS was used to correct the excessive COS in the lower arch.
89435048|NCT06293118|Sham Comparator|Sham group|Participants in the control group (Sham) will perform 4 cycles of 5 minutes of ischemia (30 mmHg) with 4 subsequent cycles of reperfusion (rest) bilaterally in the arms with a sphygmomanometer (Welch Allyn DS44-11BR Durashock).
88915364|NCT01616043|Other|STSG alone|All included patients in this arm will undergo full thickness removal of the burned skin or adequate debridement of all necrotic tissue. The wounds of the patients will be covered with glycerol preserved allografts for wound bed preparation. At the second operation, 5-7 days after the first operation, the allografts are removed. If the wound bed is not suitable for grafting, additional wound bed preparation with allografts is required until the wound bed is satisfactory. If the wound bed is suitable for grafting, the wounds are immediately covered with a thin STSG.
89435049|NCT06293105||People who are homeless|People who are currently homeless, as per UK Government definition, or have experience of homelessness.
89435050|NCT06293105||Stakeholders|People with work or other experience relating to homelessness in London
89435051|NCT06293092|Experimental|control group C|receive hemodialysis sessions
89198336|NCT02560194|Active Comparator|Flexible Sigmoidoscopy|People randomized to this arm are offered flexible sigmoidoscopy in addition to FOBT at the age of 60.
89435052|NCT06293092|Experimental|study group A aerobic exercise|receive hemodialysis sessions and intradialytic aerobic exercise
89435053|NCT06293092|Experimental|study group B resistive exercise|receive hemodialysis sessions and intradialytic resistive exercise
89435054|NCT06293079|Active Comparator|Telerehabilitation Group|An eight-week rehabilitation program will be implemented synchronously with the physiotherapist two days a week via video conferencing system.
89435055|NCT06293079|Experimental|Hybrid Telerehabilitation Group|The first two weeks of the eight-week program will be applied face to face in the clinic, and the six weeks will be applied synchronously with the physiotherapist via video conferencing system.
89435056|NCT06293079|Active Comparator|Clinic Group|An eight-week rehabilitation program will be implemented face to face in the clinic.
89435057|NCT06293053|Experimental|Dupilumab|Administered subcutaneously (SC) based on weight and age
89435058|NCT06293040|Placebo Comparator|Placebo cannabis + placebo alcohol|Participants administer vaporized cannabis containing 0mg THC in combination with a placebo alcohol drink.
88915365|NCT01616069|Active Comparator|epinephrine|Assessment of systolic and diastolic heart function during CABAG with CPB with levosimendan using TEE.
88915366|NCT01616069|Active Comparator|levosimendan|Assessment of systolic and diastolic heart function during CABAG with CPB with epinephrine using TEE.
88915367|NCT01616095||Adults with Growth Hormone Deficiency|if multiple hormonal deficiences exist, long term adequate supplementation is provided and tightly monitored.
88915368|NCT01616095||Healthy Controls|matched for BMI, age, and gender
89198337|NCT02560194|Placebo Comparator|FOBT only|People in this are offered fecal occult blood testing only.
89198338|NCT00549718|Experimental|Lurasidone 40mg|
89198339|NCT00549718|Experimental|Lurasidone 80mg|
89198340|NCT00549718|Experimental|Lurasidone 120mg|
89198341|NCT00549718|Placebo Comparator|Sugar Pill|
89198342|NCT00863187|Experimental|rituximab|b cell depletion drug
89198343|NCT00743132||1|Postoperative no renal dysfunction
89198344|NCT00743132||2|Postoperative renal dysfunction
89198345|NCT00754884|Experimental|A|200 U.I. of intranasal salmon calcitonin
89198346|NCT00754884|Placebo Comparator|B|intranasal saline solution and glycerol
89435059|NCT06293040|Experimental|Low dose cannabis with placebo alcohol|Participants administer vaporized cannabis containing 5mg THC in combination with a placebo alcohol drink.
89435060|NCT06293040|Experimental|High dose cannabis with placebo alcohol|Participants administer vaporized cannabis containing 25mg THC in combination with a placebo alcohol drink.
89435061|NCT06293040|Experimental|Low dose cannabis with low dose alcohol|Participants administer vaporized cannabis containing 5mg THC in combination with an alcohol drink (0.05 percent BAC).
89435062|NCT06293040|Experimental|High dose cannabis with low dose alcohol|Participants administer vaporized cannabis containing 25mg THC in combination with an alcohol drink (0.05 percent BAC).
89435063|NCT06293040|Experimental|Placebo cannabis + low dose alcohol|Participants administer vaporized cannabis containing 0mg THC in combination with an alcohol drink (0.05 percent BAC).
89435064|NCT06293040|Experimental|Placebo cannabis + high dose alcohol|Participants administer vaporized cannabis containing 0mg THC in combination with an alcohol drink (0.08 percent BAC).
88915369|NCT01616108|Experimental|Bupivacaine Injection|Differences in concentration from 0.75% to 3.0% are compared. Differences in volume for 1.0 mL to 3.0 mL are compared. Differences in compounding with addition of epinephrine will be used and compared to plain bupivacaine.
88915370|NCT01616121|Active Comparator|Conventional Treatment Heart Failure|Conventional Treatment
88915371|NCT01616121|Experimental|Lung Impedance-Guided Therapy|Lung Impedance-Guided Therapy
88915372|NCT01616134|Active Comparator|Korea Red Ginseng|Intervention group were administered with 4 capsules (2 g) each of powdered red ginseng (6-year old , rootlets) 40 minutes before breakfast, lunch and dinner, totaling 12 capsules (6 g) per day, for 12 weeks.
88915373|NCT01616134|Placebo Comparator|placebo contating constarch|
89198347|NCT00743210|Experimental|1|Oral L-citrulline, 3 grams once per day for 3 weeks.
89435065|NCT06293027||FXS affected individuals|Individuals with genetic diagnosis of FXS.
89435066|NCT06293027||Neurotypical controls|Healthy volunteers without known health or medical issues.
89435067|NCT06293014|Experimental|second-line maintenance treatment group|TAS-102 combined with bevacizumab
89435068|NCT06293014|Active Comparator|second-line continuous treatment group|Standard chemotherapy (FOLFOX，FOLFIRI or CAPEOX) combined with bevacizumab
89435069|NCT06293001||Patients with shoulder pain|Patients with shoulder pain, pain for at least three months and aged between 18 and 64 years, and for the re-test only participants with unchanged health status were included in the study. Patients with rheumatological, neurological or musculoskeletal diseases, invasive intervention in the last 3 months, active infection, history of cancer, post-traumatic condition requiring surgery were excluded.
89435070|NCT06292962|Experimental|Group VTG|Group VTG will receive active non-invasive transcutaneous vagal nerve stimulation (tVNS)
89435071|NCT06292962|Sham Comparator|Group STG|Group STG will receive Inactive sham stimulation
89435072|NCT06292949|Experimental|Resistant starch intervention group|or the recruited patients with functional constipation, stool samples were collected and 2 packets of resistant starch were taken every day, each packet of 10g. The resistant starch was brewed with 200ml warm water for 14 days, and the fecal samples of volunteers were collected on the 0th, 7th and 14th day. Patients filled out questionnaires on days 0 and 14 to evaluate the improvement of constipation symptoms.
89531285|NCT03120689|Active Comparator|Live Surgery with VITOM|Learner will not assist during the surgery, but watch the live surgery that is projected on a screen via the VITOM camera followed by a short questionnaire.
89531286|NCT03120689|Active Comparator|Live Surgery without VITOM|Learner will assist in the traditional manner without the use of the VITOM camera followed by a short questionnaire.
89198348|NCT00743210|Placebo Comparator|2|Placebo, 3 grams once per day for 3 weeks.
89531287|NCT03120689|Active Comparator|Video viewing with VITOM|Learner will watch a video taped using the VITOM camera followed by a short questionnaire.
88915374|NCT01616147|Experimental|Intensive Lifestyle Intervention (ILI)|Women in the ILI arm will receive intensive counseling during pregnancy and group counseling after delivery regarding behavior, nutrition, and physical activity change. Visits to counselors will occur twice monthly with additional weekly telephone and internet contacts.
88915375|NCT01616147|Active Comparator|Usual Care|Women in the usual care group will be offered group support classes approximately every 2 months during pregnancy and 3 months after pregnancy.
88915376|NCT01616186|Experimental|Everolimus/Sorafenib|Patients will be stratified by current smoking status (smoker: yes or no0, for each smoking stratum patients will be randomized in a 2:1 ratio
88915377|NCT01616186|Active Comparator|Sunitinib|"Sunitinib is the concurrent control group~Patients will be stratified by current smoking status (smoker: yes or no), for each smoking stratum patients will be randomized in a 2:1 ratio"
88915378|NCT01616212|Experimental|TX1|Motivational Enhancement Therapy for adolescents, Parenting Wisely for parents
88915379|NCT01616212|Experimental|TX 2|Motivational Enhancement Therapy for adolescents
88915380|NCT01616212|Experimental|TX3|Drug Education for adolescents, Parenting Wisely for parents
88915381|NCT01616212|Experimental|TX4|Drug Education for adolescents
88915382|NCT01616225|Active Comparator|No Growth Hormone Supplementation|
88915383|NCT01616225|Experimental|Luteal Growth Hormone Start|Growth hormone starting in the luteal phase of the previous menstrual cycle.
88915384|NCT01616225|Experimental|Follicular Growth Hormone Start|Starting growth hormone during the follicular phase of the prior menstrual cycle.
88915385|NCT01616238|Experimental|Philadelphia Positive Patients|All patients with Philadelphia positive ALL will be treated in this group and will receive a standard imatinib-containing chemotherapy regimen
88915386|NCT01616238|Experimental|Philadelphia -ve Patients- Intensive|Patients with Philadelphia negative ALL who are fit for intensive treatment will be allocated into this group.
88915387|NCT01616238|Experimental|Philadelphia -ve Patients- Intensive +|Patients with Philadelphia negative disease and who are fit for intensive treatment will be entered into this group
88915388|NCT01616238|Experimental|Philadelphia -ve Patients- Non Intensive|Patients with Philadelphia negative disease who are not fit for intensive chemotherapy will be entered into this group
88915389|NCT01616238|No Intervention|Registration only|Patients with either Philadelphia positive or negative ALL who do not wish to enter the study will be allocated to this group for data collection purposes only.
88915390|NCT01616251|Experimental|Vegetable protein meal|Vegetable protein meal based on legumes (3.6 MJ, 19E% protein, 28 g dietary fibers)
88915391|NCT01616251|Experimental|Egg protein meal + fibers|Protein meal based on eggs and added pea dietary fibers (3.6 MJ, 19E% protein, 28 g dietary fibers)
88915392|NCT01616251|Experimental|Egg protein meal|Protein meal based on egg without added dietary fibers (3.6 MJ, 19E% protein, 6 g dietary fibers)
88915393|NCT01616251|Experimental|Meat protein meal + fibers|Protein meal based on meat and added pea dietary fibers (3.6 MJ, 19E% protein, 29 g dietary fibers)
88915394|NCT01616316|Experimental|subfascial flap|
88915395|NCT01616316|Experimental|Subplatysmal flap|
88915396|NCT01616342|Active Comparator|Comprehensive Medical Management|Comprehensive Medical Management will include analgesic management in accordance with guidelines and practices at the site.
88915397|NCT01616342|Active Comparator|Spinal Cord Stimulation (SCS)|Subjects assigned to Arm A, CMM + SCS, will be treated with electrical pulses from a surgically implanted Precision Plus® SCS System (Boston Scientific Corporation).
88915398|NCT01616368|Experimental|MEAL|Participation in an 8-week mindful eating course
88915399|NCT01616381|Active Comparator|Sildenafil|Sildenafil tablets 40 mg x 3 daily
88915400|NCT01616381|Placebo Comparator|Placebo|Placebo tablet x 3 daily
88915401|NCT01616394||children with congenital heart disease|
88915402|NCT01616407|Experimental|MDMA, methylphenidate, placebo|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but three treatment conditions in the same subject.
88915403|NCT01616420|No Intervention|Delayed aPS|
88915404|NCT01616420|Experimental|Immediate aPS|
88915405|NCT01616433|Active Comparator|Arthritis Foundation Exercise Program|
88915406|NCT01616433|Experimental|AFEP + 10 Keys to Healthy Aging|"Arthritis Foundation Exercise Program integrated with the 10 Keys to Healthy Aging"
88915407|NCT01616446||remission|Nephrotic patients in remission
88915408|NCT01616446||relapse|Nephrotic patients in recidive
88915409|NCT01616472||Incident diabetes cases|Individuals with newly diagnosed SLE selected from the Hopkins Lupus Cohort (1987-2011) who are newly diagnosed with diabetes during follow-up, subsequent to SLE diagnosis.
88915410|NCT01616472||Incident diabetes controls|Individuals with newly diagnosed SLE selected from the Hopkins Lupus Cohort (1987-2011) who have no record of diabetes during follow-up time (years) since SLE diagnosis that is equivalent to length of case at-risk time. Controls are matched to cases on decade of SLE diagnosis: 1987-1989, 1990-1999, 2000-2009, 2010+
88915411|NCT01616472||Incident hypertension cases|Individuals with newly diagnosed SLE selected from the Hopkins Lupus Cohort (1987-2011) who are newly diagnosed with hypertension during follow-up, subsequent to SLE diagnosis.
89010113|NCT04549948|Experimental|0.019X0.025 Stainless Steel Archwire|A reverse COS using 0.019X0.025 SS was used to correct the excessive COS in the lower arch.
89198349|NCT00371761|Experimental|PegIntron|PegIntron, 1.5 micrograms/kg weekly, for up to 24 weeks followed by a 48-week observation phase
89198350|NCT00371761|Active Comparator|Adefovir|Adefovir, 10 mg daily, for up to 48 weeks followed by a 24-week observation phase
89531288|NCT03120689|Active Comparator|Video viewing with standard camera|Learner will watch a video taped using the standard hand-held high definition camera followed by a short questionnaire.
89531289|NCT03094923|Experimental|Inspiratory muscle training|Inspiratory muscle training with threshold device and workloud 30% of the peak inpiratory preassure, during two weeks prior to surgery, seven days a week, twice a day, three sets of ten repetitions with supervision.
89531290|NCT03094923|No Intervention|Control group|Control group will receive a supportive educational component in the preoperative period.
89435073|NCT06292936|Experimental|Acceptance-Based Behavioral Intervention|Participants assigned to ABTi will receive a remotely delivered intervention consisting of 20 modules over 6 months. Based on theory derived from acceptance and mindfulness approaches, the intervention provides psychological strategies to facilitate engagement in weight control behaviors. Each module includes a video presentation of material synchronized with a slideshow illustrating session material, interactive features, quizzes that will ensure participants have mastered the material, and directed assignments to be completed throughout the week. Participants will be assigned to view each module, self-monitor their daily food intake, and weigh themselves weekly. At the completion of each module, a brief call with a coach will be scheduled to discuss and clarify the content of the session, review homework, and provide feedback on food records and weekly weights.
89435074|NCT06292936|No Intervention|Control|Participants assigned to the Control condition will receive telephone contacts from the coaches on the same schedule as those who receive ABTi. The content will focus on the (re) delivery of the dietary and behavioral instruction that patients received prior to bariatric surgery. For example, participants will be reminded to consume reduced portion sizes, avoid foods higher in sugar and fat, and eat discrete meals throughout the day. They will receive a Wi-Fi scale and will be asked to weigh themselves weekly, similar to those receiving ABTi.
89435075|NCT06292897||obese individuals [Body Mass Index (BMI) > 30 affected by prostate cancer|
89435076|NCT06292897||normal-weight individuals [18 < BMI < 25] affected by prostate cancer|
89435077|NCT06292884||CTD affected individuals|Individuals with genetic diagnosis of CTD.
89435078|NCT06292884||GAMT-D affected individuals|Individuals with genetic diagnosis of GAMT-D.
89435079|NCT06292884||Neurotypical controls|Healthy volunteers without known health or medical issues.
89435080|NCT06292871|Experimental|Intervention Group|Pregnant women with GDM receiving additional support via social media platform continuously for 1 month, in addition to the usual care management.
89435081|NCT06292871|Active Comparator|Control Group|Pregnant women with GDM under usual care management.
89435082|NCT06292858|Experimental|Experimental|"Part A: Dose escalation phase~Six dose levels of IMB071703 injection are planned in Part A, 1 subject in the first dose level (accelerated titration design), 3 subjects in the 2nd through 6th dose levels separately (conventional Fibonacci 3+3 design). 19 to 33 subjects are expected to enroll.~Part B: Dose/cohort expansion phase~1 to 2 dose levels of subjects with 1 to 2 tumor types are tentatively planned; a total of up to 15 subjects are included in each dose level for each tumor type, 15 to 60 subjects are expected to enroll."
89435083|NCT06292845|Experimental|Topical application of a fluorescent imaging agent|In this arm the investigators use the freshly resected human solid tumor specimens to assess the performance of topically applied fluorescent imaging agents for the detection of tumor tissue and close / tumor-positive resection margins ex vivo.
89435084|NCT06292832|Active Comparator|Obese Spinae Plane Block|Spinae Plane Block for pain control
89435085|NCT06292832|Active Comparator|Obese Transversus Abdominis Plane Block|Transversus Abdominis Plane Block for pain control.
89435086|NCT06292832|Active Comparator|Morbidly Obese Spinae Plane Block|Spinae Plane Block for pain control
89435087|NCT06292832|Active Comparator|Morbidly Obese Transversus Abdominis Plane Block|Transversus Abdominis Plane Block for pain control.
88915412|NCT01616472||Incident hypertension controls|Individuals with newly diagnosed SLE selected from the Hopkins Lupus Cohort (1987-2011) who have no record of hypertension during follow-up time (years) since SLE diagnosis that is equivalent to length of case at-risk time. Controls are matched to cases on decade of SLE diagnosis: 1987-1989, 1990-1999, 2000-2009, 2010+
88915413|NCT01616472||Incident cataract cases|Individuals with newly diagnosed SLE selected from the Hopkins Lupus Cohort (1987-2011) who are newly diagnosed with cataract during follow-up, subsequent to SLE diagnosis.
88915414|NCT01616472||Incident cataract controls|Individuals with newly diagnosed SLE selected from the Hopkins Lupus Cohort (1987-2011) who have no record of cataract during follow-up time (years) since SLE diagnosis that is equivalent to length of case at-risk time. Controls are matched to cases on decade of SLE diagnosis: 1987-1989, 1990-1999, 2000-2009, 2010+
88915415|NCT01616472||Incident osteoporosis cases|Individuals with newly diagnosed SLE selected from the Hopkins Lupus Cohort (1987-2011) who are newly diagnosed with osteoporosis during follow-up, subsequent to SLE diagnosis.
88915416|NCT01616472||Incident osteoporosis controls|Individuals with newly diagnosed SLE selected from the Hopkins Lupus Cohort (1987-2011) who have no record of osteoporosis during follow-up time (years) since SLE diagnosis that is equivalent to length of case at-risk time. Controls are matched to cases on decade of SLE diagnosis: 1987-1989, 1990-1999, 2000-2009, 2010+
88915417|NCT01616472||Incident avascular necrosis cases|Individuals with newly diagnosed SLE selected from the Hopkins Lupus Cohort (1987-2011) who are newly diagnosed with avascular necrosis during follow-up, subsequent to SLE diagnosis
88915418|NCT01616472||Incident avascular necrosis controls|Individuals with newly diagnosed SLE selected from the Hopkins Lupus Cohort (1987-2011) who have no record of avascular necrosis during follow-up time (years) since SLE diagnosis that is equivalent to length of case at-risk time. Controls are matched to cases on decade of SLE diagnosis: 1987-1989, 1990-1999, 2000-2009, 2010+
88915419|NCT01616485|Experimental|Treatment A|TA-1790 + glyceryl trinitrate
88915420|NCT01616485|Active Comparator|Treatment B|sildenafil citrate + glyceryl trinitrate
88915421|NCT01616485|Placebo Comparator|Treatment C|placebo + glyceryl trinitrate
88915422|NCT01616498||Lean|Comparison data from this lean cohort will be compared to the obese older adults are already being collected in an R01-funded study (Improving Muscle for Functional Independence Trial; IRB00009098; NCT01049698)
88915423|NCT01616511||Pathway CH-1 Subjects|
88915424|NCT01616550||Patients undergoing thoracic surgery|Assessment of postoperative pain management in patients undergoing elective thoracoscopy or thoracotomy in a teaching hospital
89010114|NCT04549948|Experimental|0.021X0.025 TMA archwire|A reverse COS using 0.021X0.025 TMA archwire was used to correct the excessive COS in the lower arch.
89435088|NCT06292819|Active Comparator|Bright light|
89435089|NCT06292819|Active Comparator|Near-infrared light|
89435090|NCT06292819|Active Comparator|Bright light+ near-infrared light|
89435091|NCT06292793|Active Comparator|Pain Coping Information|
89435092|NCT06292793|Experimental|Cyclical Sighing|
88915425|NCT01616589||Fragile X full mutation (affected)|Individual whose previous blood specimen was tested at Esoterix Genetic Laboratories and molecular analysis for fragile X revealed >200 CGG repeats with abnormal methylation pattern; interpretation is full mutation for fragile X syndrome
88915426|NCT01616589||Fragile X premutation (carriers)|Individual whose previous blood specimen was tested at Esoterix Genetic Laboratories and molecular analysis for fragile X revealed 55-200 CGG repeats with normal methylation pattern; interpretation is premutation carrier of fragile X syndrome
88915427|NCT01616589||Fragile X intermediate|Individual whose previous blood specimen was tested at Esoterix Genetic Laboratories and fragile X molecular analysis revealed 45-54 CGG repeats; interpretation is intermediate, not a carrier of a fragile X expansion mutation
88915428|NCT01616602|Placebo Comparator|Left-sided Position|
88915429|NCT01616602|Experimental|Prone Position|
88915430|NCT01616615|Experimental|ASPIRIN|150 mg milligram(s)/ day oral use
88915431|NCT01616615|Placebo Comparator|PLACEBO|
88915432|NCT01616277|Placebo Comparator|1|
88915433|NCT01616277|Placebo Comparator|2|
88915434|NCT01616277|Placebo Comparator|3|
88915435|NCT01616277|Placebo Comparator|4|
88915436|NCT01616277|Placebo Comparator|5|Repeat dose of PF-06252616, IV infusion, single dose - 10.0 miligram per kilogram
88915437|NCT01616277|Placebo Comparator|6|
88915438|NCT01616277|Placebo Comparator|7|
88915439|NCT01616628|No Intervention|Wait listed control|Participants grocery shop without the intervention for extended baseline and have delayed entrance into the intervention period.
88915440|NCT01616628|Experimental|Rewards for purchases & topic education|Participants earn reward points at 50% the rate of how much they spend on fruit and vegetables.
88915441|NCT01616641||rheumatoid arthritis group|75 patients with rheumatoid arthritis
88915442|NCT01616641||control group|75 healthy women
88915443|NCT01616667|Active Comparator|Modified direct lateral approach|The patients included is operated with a total hip arthroplasty using a modified direct lateral approach
88915444|NCT01616667|Active Comparator|Posterior approach|The patients included is operated with a total hip arthroplasty using posterior approach
89435093|NCT06292780|Experimental|Phase 1: Cohort 1: Low Dose|Dose Escalation: Non-Randomized
89435094|NCT06292780|Experimental|Phase 1: Cohort 2: High Dose|Dose Escalation: Non-Randomized
89435095|NCT06292780|Experimental|Phase 2: Low Dose|Dose Expansion: Participants will be randomized in a 1:1 ratio
89435096|NCT06292780|Experimental|Phase 2: High Dose|Dose Expansion: Participants will be randomized in a 1:1 ratio
88915445|NCT01616680|Experimental|Supportive care (brentuximab vedotin)|Patients receive brentuximab vedotin IV over 30 minutes on days 1, 8, and 15.
88915446|NCT01616719|Other|DTRAX graft|
88915447|NCT01616732|Active Comparator|testosterone|against placebo
88915448|NCT01616732|Placebo Comparator|placebo|
88915449|NCT01616784|Active Comparator|Multiple daily injections plus DAFNE|Optimised MDI therapy using rapid and twice daily (Detemir/Levemir) long-acting insulin analogues
88915450|NCT01616784|Experimental|CSII (Insulin Pump) plus DAFNE|Medtronic MiniMed Paradigm Veo Insulin pumps (X54)
88915451|NCT01616797|Experimental|Computerized intervention|Participants will be asked to visit a customized website and engage in computerized exercises. Cognitive and emotion training games.
88915452|NCT01616797|Sham Comparator|Control|Participants will be asked to visit a customized website and engage in computerized games.
88915453|NCT01616810||observation|Healthy participants
88915454|NCT01616823||HIV Positive Women|HIV positive women in two downtown Toronto, Ontario academic-affiliated hospitals
88915455|NCT01616836|Active Comparator|continuous FNB|Bolus femoral nerve block (ropivacaine 0.5% 20 mL), continuous infusion 48 hours (ropivacaine 0.2%, 5 mL/h), placebo local infiltration
88915456|NCT01616836|Active Comparator|single FNB|femoral nerve block (ropivacaine 0.5% 20 mL), placebo femoral nerve block infusion, placebo local infiltration
88915457|NCT01616836|Active Comparator|LIA|placebo fascia iliac block, placebo fascia iliaca infusion, local infiltration analgesia
89435097|NCT06292767||Not ventilated|Non-ventilated patient group.Patients will be placed in the cardiac bypass mode of the anesthesia machine. Only 150 ml of free air flow will be provided and mechanical ventilation will be turned off.
88915458|NCT01616849|Experimental|PF+ Nimotuzumab|Patients treated with cisplatin and 5-Fu combined with nimotuzumab
88915459|NCT01616862||Parents of PA positive CF children|parents of children with cystic fibrosis who are positive for Pseudomonas aeruginosa
88915460|NCT01616862||parents of Pa negative CF children|parents of children with cystic fibrosis who are negative for pseudomonas aeruginosa
88915461|NCT01616875|Experimental|Cabazitaxel + Cisplatin chemotherapy|Cabazitaxel 15mg/m2 Intravenous (IV)followed by Cisplatin 70mg/m2 IV on day 1 of each 21 day cycle for 4 cycles
88915462|NCT01616888|Active Comparator|Treatment arm|SFA angioplasty with In.Pact Admiral drug eluting balloon
88915463|NCT01616901|Experimental|Spontaneous breathing trial|
88915464|NCT01616914||delirium group|patients with delirium during ICU stay
88915465|NCT01616914||non-delirium group|patients without delirium during ICU stay
88915466|NCT01616927|No Intervention|standard care|Subjects in this arm will receive standard care
88915467|NCT01616927|Experimental|Lanreotide|
88915468|NCT01616940|No Intervention|Standard-of-care|Standard-of-care at 3 demonstration sites includes: HIV medical care, medical case management, and referral to substance abuse, mental health, and housing services.
88915469|NCT01616940|Experimental|Enhanced Peer Intervention|Provides emotional, informational, and instrumental peer support, in addition to Standard-of-Care.
89435098|NCT06292767||Ventilated|Patients will continue to be ventilated at Fraction of inspired oxygen(FiO2): 40%, Tidal volume(TV): 3 ml/kg, frequency 12 breaths/min, Positive end expiratory pressure (Peep): 5 cm/H2O.
88915470|NCT01616966|Active Comparator|Sevoflurane|Anesthesia was maintained with sevoflurane during surgery.
88915471|NCT01616966|Active Comparator|Anesthesia with propofol|Anesthesia was maintained with propofol during surgery.
88915472|NCT01616979||OPCAB surgery|Fifteen elective OPCAB surgery patients who undergo grafting in the left circumflex artery territory due to three-vessel disease
88915473|NCT01616992||Interstitial Cystitis|
88915474|NCT01616992||Myofascial Pelvic Pain|
88915475|NCT01616992||Healthy|
88915476|NCT01616992||First Degree Relative|
88915477|NCT01617018||Exposed group|Biotherapy
88915478|NCT01617018||Non-exposed group|Major conventional systemic therapy (methotrexate or cyclosporine)
88915479|NCT01617031||Diabetic patients with coronary artery disease|Type 2 diabetic patients with previous coronary artery disease. All patients are routinely treated with aspirin in secondary prevention of cardiovascular disease. Coronary artery disease is defined as a previous coronary angiography with at least 1 coronary artery stenosis >50%. Type 2 diabetes is defined as patients with diabetes discovered after 30 years old and insulin was not the first treatment except in case of acute coronary syndrome.
88915480|NCT01617044|Experimental|Treatment|"iron 3 mg/kg/day elemental iron FeSO4 up to 45 mg (dose to be determined by PI)~+ vitamin C-250 mg chewable tab~+ probiotics lactobacillus plantarum 299 (1x10x8 colony forming units)"
88915481|NCT01617044|Placebo Comparator|Control|"iron 3 mg/kg/day elemental iron FeSO4 to 45 mg~+ vitamin C-250 mg chewable tab~+ placebo (identical capsule)"
88915482|NCT01617057|Experimental|Skelid|tiludronic acid
88915483|NCT01617057|Placebo Comparator|Control|Placebo
88915484|NCT01617109|Placebo Comparator|Placebo|
88915485|NCT01617109|Experimental|Ca/Vit D|
88915486|NCT01617122|Experimental|Bacteriophage|Subjects receive bacteriophage vaccinations and blood draws
89435099|NCT06292754|Experimental|Intervention group|The intervention groups receives treated using magnesium pin in additional to the suture anchor used routinely in clinical practice.
89435100|NCT06292754|Active Comparator|Control group|The control group receives routine suture anchor for the treatment-as-usual (TAU).
88915487|NCT01617135|Experimental|CVT-301 Low Dose|CVT-Low; levodopa inhalation powder (LIP)
88915488|NCT01617135|Experimental|CVT-301 High Dose|CVT-High; levodopa inhalation powder (LIP)
88915489|NCT01617135|Placebo Comparator|Inhaled Placebo|Inhaled placebo powder
88915490|NCT01617135|Active Comparator|Oral Sinemet (carbidopa/levodopa)|Open-label oral carbidopa/levodopa (CD/LD)
88915491|NCT01617174||assessments completed by patients|"A single-arm observational study will be conducted at three institutions in the Prostate Cancer Clinical Trials Consortium (PCCTC): Memorial Sloan-Kettering Cancer Center; Johns Hopkins; and Oregon Health & Science University. MSKCC is the coordinating center. The target enrollment is 400 patients, with at least 250 experiencing moderate or worse pain intensity at baseline, defined as a score of ≥4, the preferred regulatory cutoff."
88915492|NCT01617200|Experimental|Asenapine 2.5 mg BID|
88915493|NCT01617200|Experimental|Asenapine 5 mg BID|
88915494|NCT01617200|Active Comparator|Olanzapine 15 mg QD|
88915495|NCT01617200|Experimental|Placebo switched to Asenapine 2.5 mg BID|
88915496|NCT01617213|Experimental|Maintenance Lenalidomide After Melphalan|
88915497|NCT01617226|Active Comparator|azacitidine|azacitidine (75mg/m2) by SC injection on 7 consecutive days (excluding weekends), starting day 1 of 28-day cycles for up to 6 cycles. This should be delivered in a 5-2-2 schedule
88915498|NCT01617226|Active Comparator|azacitidine and vorinostat|Patients will receive (75mg/m2) azacitidine by SC injection on 7 consecutive days (excluding weekends), starting day 1 of 28-day cycles for up to 6 cycles. Azacitidine should be delivered in a 5-2-2 schedule. Vorinostat (300mg bid) will be taken orally for 7 consecutive days starting on day 3 of each cycle in 28-day cycles for up to 6 cycles. (Day 3 is defined as the 3rd day of azacitidine administration).
88915499|NCT01617239|Experimental|Group 1|1 x standard dose (0.5 mL) on Day 1, Day 29, and Day 57
88915500|NCT01617239|Experimental|Group 2|1 x double standard dose (1.0 mL) on Day 1 and 1 x standard dose (0.5 mL) on Day 57.
88915501|NCT01617239|Experimental|Group 3|1 x triple standard dose (1.5 mL) on Day 1
88915502|NCT01617252|Experimental|Optiflow|
88915503|NCT01617252|Experimental|Facial mask|
88915504|NCT01617265|Experimental|Prevention of oversedation group|In this arm sedation and analgesia will be administered according to a bundle of measures aimed at limiting oversedation, including repeated assessment of patients needs and graduate therapeutic response to control pain, discomfort, poor synchrony with the ventilator and agitation. The therapeutic options include non hypnotic anxiolytics, repeated intravenous (IV) hypnotics boluses, short-duration (6 hours) IV hypnotics infusion and round the clock IV hypnotics infusion.
88915505|NCT01617265|Active Comparator|Conventional sedation group|In this arm, sedation will be administered according to the usual practices in each participating center.
88915506|NCT01617278|Experimental|I-Scan 1|I-Scan 1 modality will be used by the endoscopist for the entire procedure
88915507|NCT01617278|Experimental|HD Colon|High definition white light modality will be used by the endoscopist for the entire procedure
88915508|NCT01617278|Experimental|I-scan 2|I-Scan 2 modality will be used by th endoscopist through out the procedure
88915509|NCT01617304|Experimental|low AGE, glucose|Food prepared by boiling/steaming and 20 g of glucose 3 times a day in a water solution
88915510|NCT01617304|Experimental|low AGE, fructose|Food prepared by boiling/steaming and 20 g of fructose 3 times a day in a water solution
88915511|NCT01617304|Experimental|high AGE, fructose|Food prepared by frying/baking and 20 g of fructose 3 times a day in a water solution
88915512|NCT01617304|Experimental|high AGE, glucose|Food prepared by frying/baking and 20 g of glucose 3 times a day in a water solution
88915513|NCT01617317|Active Comparator|Intravenous immunoglobulin|Single intravenous infusion of 0.4g/kg of simple IVIG which contain no H1N1 2009 antibody (manufactured before 2009).
88915514|NCT01617317|Experimental|Hyperimmune intravenous immunoglobulin|Single intravenous infusion of 0.4g/kg of H1N1 2009 H-IVIG fractionated from convalescent plasma (H1N1 2009 antibody titer was 1:320 by hemagglutination inhibition and neutralizing antibody assays)
88915515|NCT01617330|Experimental|Diesel exhaust|2 hour exposure to diesel exhaust at 100 microgram per cubic meter during intermittent exercise
88915516|NCT01617330|Experimental|Filtered air exposure|2 hour exposure to filtered air during intermittent exercise
88915517|NCT01617343|No Intervention|Usual care|Patients in this control group will receive usual care following stroke including standard physiotherapy and occupational therapy.
88915518|NCT01617343|Experimental|HEP-OKS|
88915519|NCT01617356|Active Comparator|Dextrose Injection|
88915520|NCT01617356|Active Comparator|Sterile Water Injection|
88915521|NCT01617473|Experimental|procedure/surgery|transplant with G-CSF mobilized PBSCs
88915522|NCT01617473|No Intervention|other|no intervention after transplant with mobilized BMPB
88915523|NCT01617486|Experimental|BALANCE|
88915524|NCT01617499||University employees|Participants will include employees of Washington University in St. Louis. Recruitment will be directed to staff employees of the Central Fiscal Unit (CFU) on the Danforth campus.
88915525|NCT01617525|Experimental|Korean Recommended Diet|A dietary pattern that follows the recommendations by the Korean Rural Development Administration.
88915526|NCT01617525|Active Comparator|US Recommended Diet|Diet based on recipes and menus developed by the USDA Dietary Guidelines for Americans intramural team.
88915527|NCT01617525|Active Comparator|Typical American Diet|Diet based on data from the NHANES surveys, as summarized in the USDA report What We Eat in America.
88915528|NCT01617538|Experimental|Atorvastatin|30 patients who had MCA infarction within 6 months prior to screening, and has not received any statins treatment before stroke.in this study ,we will give them atorvastatin 40mg treatment for 24 weeks and monitor and evaluate the change of intracranial hemodynamics after treatment.
88915529|NCT01617538|No Intervention|compare|30 patients who had MCA infarction within 6 months prior to screening, and has not received any statins treatment.we will monitor and evaluate the intracranial hemodynamics as a baseline.
88915530|NCT01617551|Experimental|Renal denervation|Patient group randomized to renal denervation
88915531|NCT01617551|Sham Comparator|Sham|Patients randomized to sham procedure
88915532|NCT01617564|Active Comparator|Bupivacain|
88915533|NCT01617564|Sham Comparator|Sodium Chloride|
88915534|NCT01617590|Experimental|leflunomide|Leflunomide 10-20 mg/d
89435101|NCT06292741|Experimental|cognitive decline|comparison of autonomic parameters among subjects with different forms of cognitive decline
88915535|NCT01617590|Active Comparator|methotrexate|MTX 7.5-15 mg/week
88915536|NCT01617616||Normal tilt test|Patients with normal tilt table testing (they may have symptoms which precipitated the tilt, but in the end did not qualify as POTS, NMH, ETC.)
88915537|NCT01617616||confirmed POTS diagnosis|after review of tilt table results, this group will be the confirmed postural orthostatic tachycardic syndrome group patient
88915538|NCT01617616||Neurocardiogenic syncope on tilt|This group is comprised of patients with confirmed diagnosis of neurocardiogenic syncope on tilt
88915539|NCT01617616||Neurally-mediated hypotension|Patients with confirmed diagnosis neurally mediated hypotension
88915540|NCT01617694|Experimental|group R|continuation of remifentanil target controlled infusion (TCI) at effect-site concentration of 2 ng/ml during anesthetic recovery until extubation.
88915541|NCT01617694|Active Comparator|group D|remifentanil TCI discontinuation and dexmedetomidine 0.5 mg/kg intravenous injection before 10 min of the end of surgery
88915542|NCT01617707|Active Comparator|conventional sedation group|midazolam
88915543|NCT01617707|Experimental|BPS group|midazolam plus propofol
88915544|NCT01617733|Experimental|Pasireotide|4 Weeks pasireotide 0.6mg s/c injections twice daily followed by 24 weeks treatment with pasireotide LAR 60mg every 28 days with dose reductions if poor tolerability is encountered
88915545|NCT01617746|Experimental|Ambrisentan|5mg od ambrisentan
88915546|NCT01617746|Experimental|Bosentan|62.5mg bosentan
88915547|NCT01617746|Placebo Comparator|Placebo|
88915548|NCT01617772|Experimental|Atorvastatin|20mg atorvastatin daily
88915549|NCT01617772|Experimental|Carnitine|1000mg L-carnitine daily
88915550|NCT01617772|Experimental|Atoral|1000mg L-carnitine and 20mg atorvastatin
88915551|NCT01617772|Placebo Comparator|Placebo|Identically looking placebo
88915552|NCT01617785||CABG group|Three-vessel disease patients undergoing CABG at index hospitalization
88915553|NCT01617785||PCI group|Three-vessel disease patients undergoing PCI at index hospitalization
88915554|NCT01617785||OMT group|Three-vessel disease patients undergoing no revascularization at index hospitalization
88915555|NCT01617798|Placebo Comparator|Control-- furosemide (lasix) only|"Control arm receives standard of care diuresis with furosemide(lasix)only. The treatment team will decide the dosing of furosemide (lasix).~No actual placebo is administered."
88915556|NCT01617798|Active Comparator|Study Arm|Study arm receives evolving standard of care diuresis with furosemide and metolazone.
88915557|NCT01617824|Experimental|Linagliptin|Linagliptin 5 mg tablets daily for 4 days
88915558|NCT01617824|Placebo Comparator|Placebo|Placebo tablets 1 daily for 4 days
88915559|NCT01617837|Active Comparator|P6 acupressure group|"In the end of the operation Sea-Band®, a single-sized elastic acupressure band with a plastic button, was placed unilaterally at the place of P6 (the P6 Neiguan acupoint, located about 3 cm proximal to the distal wrist, between the tendons of the flexor carpi radialis and the palmaris longus)to apply acupressure."
89435102|NCT06292728|Experimental|Treatment|
89435103|NCT06292715|Experimental|microwave ablation of the spleen combined with splenic artery occlusion|The ablation puncture needle is percutaneously punctured into the spleen under ultrasound guidance, and the ablation method of one needle and multi-point method and needle insertion and pulling is mostly used
88915560|NCT01617837|Placebo Comparator|Placebo group|In the end of the operation an identical Sea-Band® with no button and thereby no acupressure was placed unilaterally at the place of P6.
88915561|NCT01617850|Experimental|optimized physical exercise training|Intervention: Supervised physical exercise training x3 weekly for 12 weeks
88915562|NCT01617850|Active Comparator|conventional group|Intervention: Supervised physical exercise training x2 weekly for 8 weeks
88915563|NCT01617889|Active Comparator|Powdered milk-based formula, standard fat blend|
88915564|NCT01617889|Experimental|Powder milk-based formula, alternate fat blend|
88915565|NCT01617928|Experimental|veliparib (ABT-888)|
89435104|NCT06292702|Experimental|Traditional laparoscopic Burch procedure|Patients who were randomized to receive classic laparoscopic Burch colposuspension.
89435105|NCT06292702|Experimental|Modified laparoscopic Burch procedure:|Patients who were randomized to receive modified laparoscopic Burch colposuspension by applying lateral tension for the anterior vaginal wall before performing traditional anterior vaginal wall suspension toward Cooper's ligament.
88915566|NCT01617941|Experimental|BGG492|At Baseline 60 patients will be randomized to receive BGG492 for the upcoming 12 weeks (dose: 75 mg BID administered in approx. 12 hours +/- 2 hours intervals).
89435106|NCT06292689|Experimental|Treatment|"1.Not systematically treated: 20 patients with recurrent or metastatic vulvar and vaginal cancers enrolled without systemic treatment (platinum-based doublet chemotherapy) will be treated with cardunolizumab + platinum-based doublet chemotherapy ± bevacizumab.~2.Previous systematic treatment: Twenty patients with recurrent or metastatic vulvar and vaginal cancers previously treated with systemic therapy (platinum-based doublet chemotherapy) will be enrolled as subjects receiving cardunolizumab ± investigator&amp;#39;s choice of chemotherapy ± bevacizumab."
89435107|NCT06292650|Experimental|group 1|IVT administration of a single low dose ZM-02 injection
89435108|NCT06292650|Experimental|group 2|IVT administration of a single high dose ZM-02 injection
89435109|NCT06292650|Sham Comparator|group 3|Sham IVT injection
89435110|NCT06292611|Active Comparator|Battery operated toothbrush|Battery operated toothbrush
89435111|NCT06292611|Active Comparator|Manual toothbrush|Manual toothbrush
88915567|NCT01617941|Placebo Comparator|Placebo|At Baseline 30 patients will be randomized to receive Placebo for the upcoming 12 weeks (matching a dose of 75 mg BID BGG492 administered in approx. 12 hours +/- 2 hours intervals).
88915568|NCT01617954||Subjects with MammaPrint Result|
88915569|NCT01617980|Other|Multimodal hypoxia imaging|Patients with inoperable, stage III non-small cell lung cancer receive serial 18F-FMISO dPET-CT and functional MRI investigations prior, during and post radiation treatment
88915570|NCT01617993||Women undergoing IVF treatment|Women undergoing IVF treatment
88915571|NCT01618006|Active Comparator|Aspirin 81mg daily|Patients will receive 81mg daily during the postoperative period.
88915572|NCT01618006|Active Comparator|Aspirin 325mg daily|Patients will receive 325mg daily during the postoperative period, until day 7 postop or the end of hospitalization.
88915573|NCT01618006|Experimental|Aspirin 81mg four times daily|Patients will receive ASA 81mg four times daily until postoperative day 7 or end of hospitalization
88915574|NCT01618032|Experimental|HVLA|High velocity and low amplitude traction manipulation on the ankle joint
88915575|NCT01618032|Experimental|MWM|Mobilization with movement on ankle joint as Mulligan
88915576|NCT01618032|Sham Comparator|placebo|Contact without therapeutic effect
88915577|NCT01618045||Fermented Papaya Preparation (FPP)|This a is single arm study - all participants will receive and take fermented papaya preparation (FPP) for a total of 6 weeks. Participants will take 3 grams of FPP three times per day (a total of 9 grams per day).
88915578|NCT01618058||ARV-Treated Participants|Those participants who received dapivirine during HIV seroconversion
88915579|NCT01618058||ARV-Naive Participants|Those participants who received placebo during HIV seroconversion
88915580|NCT01618071|Active Comparator|Oleic acid|75 g high oleic acid sunflower oil.
88915581|NCT01618071|Active Comparator|Linoleic acid|75 g high linoleic acid sunflower oil.
88915582|NCT01618071|Experimental|Eicosapentaenoic acid and docosahexaenoic acid|5 g EPA and DHA derived from fish oil, made up to a total of 75 g with high oleic sunflower oil.
88915583|NCT01618071|Experimental|Docosahexaenoic acid|5 g DHA derived from algal oil, made up to a total of 75 g with high oleic sunflower oil.
89435112|NCT06292598||Patients with untreated NT1|
88915584|NCT01618084|Experimental|Tritanium cup|
88915585|NCT01618084|Active Comparator|Trident HA cup|
88915586|NCT01618097|Experimental|DVD Decision Aid|Patient assigned to watch DVD decision aid.
88915587|NCT01618097|Experimental|Internet Based Decision Aid|Patient assigned to watch OA specific internet based decision aid.
88915588|NCT01618110|Active Comparator|Treatment Group|
88915589|NCT01618110|Sham Comparator|Sham group|Sham TMS coil (same noise, minimal magnetic field)
88915590|NCT01618149||severe knee OA who are indicated for total knee arthroplasty|the woman who are indicated for TKR and are post menopausal will be recruited in this study. We will excluded the patients who had immune disease ,previous fracture of femur and end stage of renal disease
88915591|NCT01618175|Experimental|Home oxygen therapy|Infants with acute bronchiolitis of low to moderate severity will be discharged home with supplemental oxygen and monitored by phone calls and home visits.
88915592|NCT01618201||50 subjects with migraine without aura|Inflammation Migraine Headache
88915593|NCT01618201||50 subjects with migraine with aura|Inflammation Migraine Headache
88915594|NCT01618201||50 subjects with tension headache and cluster headache|Inflammation Migraine Headache
88915595|NCT01618201||50 healthy subjects|Inflammation Migraine Headache
88915596|NCT01618253|Experimental|Radiation therapy with concurrent sorafenib|
88915597|NCT01618292||Robotic-assisted sacrocolpopexy patients|Patients who underwent robotic-assisted laparoscopic sacrocolpopexy between January 2007 and August 2011.
88915598|NCT01618318||General asthma population|People with asthma, aged 18 years and over, non smoker, all severities of disease, regardless of treatment, broad inclusion and few exclusion criteria.
88915599|NCT01618331|Active Comparator|Protein supplementation|Patients consume a drink after each exercise session. The drink consist of whey protein, maltodextrin, and flavors mixed in water.
88915600|NCT01618331|Placebo Comparator|Placebo supplement|Patients consume a drink after each exercise session. The drink consist of flavors mixed in water.
88915601|NCT01618331|No Intervention|Control|Patients will be tested before and after a none-intervention period of 12 weeks.
88915602|NCT01618370|Experimental|Radium-223 dichloride|
89435113|NCT06292598||Matched controls|Controls matched on sex, age (+/- 2 years) and BMI class (BMI < 25: normal; 25 ≤ BMI ≤ 30: overweight; BMI > 30: obesity)
89435114|NCT06292585|Experimental|Intervention group|MMA embolization
89435115|NCT06292585|Active Comparator|Control group|Conservative treatment
89435116|NCT06292572||Initial Retinal Detachment|First of both eyes of the same patient that underwent retinal detachment repair
89435117|NCT06292572||Subsequent Retinal Detachment|Subsequent eye undergoing retinal detachment repair
88915603|NCT01618383|Other|Colonic biopsies|Colonic biopsies obtained during the course of colonoscopy or rectosigmoidoscopy
88915604|NCT01618409|Experimental|PictureRx cards|Illustrated format of medication instructions that includes pictures of pills and icons to show their purpose
88915605|NCT01618409|No Intervention|Control|Usual care
88915606|NCT01618188|Experimental|Formulation A|
88915607|NCT01618188|Experimental|Formulation B|
88915608|NCT01618188|Active Comparator|Insulin Aspart|
88915609|NCT01618435|Active Comparator|Fusion, allograft|Allograft used for fusion in the operation site
88915610|NCT01618435|Experimental|Fusion, i-FACTOR|i-FACTOR used for fusion in the operation site
88915611|NCT01618448|Experimental|Placebo|Placebo once daily
88915612|NCT01618448|Experimental|Tolvaptan|Tolvaptan 15mg once daily
88915613|NCT01618461|No Intervention|Text instructions|Medication instructions displayed in text format
88915614|NCT01618461|Experimental|Drug indication icons|Icons illustrate the purpose of each medication
88915615|NCT01618461|Experimental|Structured instructions|Graphical format shows what time(s) of day each medication should be taken
88915616|NCT01618461|Experimental|Icons + Structured instructions|Icons illustrate the purpose of each medication, and a graphical format shows what time(s) of day each medication should be taken
88915617|NCT01618474|Experimental|DX|DX: Docetaxel 60mg/m2, intravenous infusion, day 1; Capecitabine 1000mg/m2, oral administration, twice a day, day1-14; 3 weeks a cycle for 8 consecutive cycles.
88915618|NCT01618474|Active Comparator|XELOX|XELOX: oxaliplatin 130mg/m2, intravenous infusion, day 1; Capecitabine 1000mg/m2, oral administration, twice a day, day 1-14, 3 weeks a cycle for 8 consecutive cycles
88915619|NCT01618487|Active Comparator|Arthroscopic tenotomy|Patients who are in this group will have arthroscopic tenotomy. A scope is used to see the tendon and release it.
88915620|NCT01618487|Active Comparator|Open tenotomy|Patients in this group will undergo open tenotomy. This involves opening the skin to expose the muscle and tendon, and then the tendon is released.
88915621|NCT01618487|Active Comparator|Debridement and repair|The patients in this group will undergo an arthroscopic technique (scope and small incision) to go in and remove any tissue that is diseased/does not belong and repair the tear(s) in the tendon.
88915622|NCT01618500||INPH-patients|"Inclusion criteria~Older than 60 years of age Probable INPH according to the NIH guidelines Planned shunt surgery based on a diagnosis of INPH.~Exclusion criteria~Known cause for hydrocephalus (i.e., secondary NPH). Medical condition preventing cognitive testing (e.g. deafness, blindness).~Patients not considered for shunt operation."
88915623|NCT01618513|Experimental|SA monitored by GH|
88915624|NCT01618513|Experimental|SA monitored by IGF-I|
88915625|NCT01618513|No Intervention|Control|Control, patients who have achieved sufficient disease control by surgery alone.
88915626|NCT01618526|Active Comparator|Healthy Carbohydrate Diet|4 weeks of intervention with a diet rich in Arabinoxylans and Resistent Starch
88915627|NCT01618526|Placebo Comparator|Western Style Diet|4 weeks of intervention with a diet with low content of Resistent Starch and Arabinoxylans.
88915628|NCT01618552|Experimental|SEE IT training (interviewing skills)|Intervention to train primary care physicians in the use of self-efficacy enhancing interviewing techniques (SEE IT) with patients who have coexisting depression and diabetes
88915629|NCT01618552|Active Comparator|Control (knowledge enhancement)|Brief video clip designed to increase primary care physician awareness of new medication treatments for patients with diabetes
88915630|NCT01618578||Patients with CRPS|24 patients with CRPS of the upper limb type 1 were included into the study.
88915631|NCT01618578||Patients with unilateral upper limb pain|21 patients with unilateral upper limb pain served as controls.
88915632|NCT01618578||healthy subjects|24 healthy subjects were age- and sex matched to patients with CRPS.
88915633|NCT01618591|Experimental|Acute Watery Diarrhea|
88915634|NCT01618591|Experimental|Acute Dysentery/Febrile|
88915635|NCT01618604||Healthy|26 healthy voluntary probands
88915636|NCT01618617|Experimental|Probiotic, high dose|High dose Multistrain probiotic, 100 billion cfu/day
89435118|NCT06292559|Placebo Comparator|Bilateral STN deep brain stimulation|Patients with Meige syndrome accepted STN DBS
89435119|NCT06292559|Experimental|Bilateral GPi deep brain stimulation|Patients with Meige syndrome accepted GPi DBS
89435120|NCT06292533|Experimental|Intervention Group|Ultrapulse treatment will be delivered by trained beautician for 6 sessions with 2 weeks interval. After the last session, participants will then follow up every 2 weeks for 1 month.
88915637|NCT01618617|Experimental|Probiotic, low dose|Low dose Multistrain probiotic, 15 billion cfu/day
88915638|NCT01618617|Placebo Comparator|Placebo|Placebo
88915639|NCT01618630|Experimental|EAA Supplementation + Exercise Training|Drink an amino acid supplementation during exercise training.
88915640|NCT01618630|Placebo Comparator|Placebo + Exercise Training|Drink a placebo supplementation during exercise training.
88915641|NCT01618643||Acetic acid chromoendoscopy|"Patients with known Barrett's metaplasia under surveillance~Patients with Barrett's metaplasia who had undergone endoscopic treatment for neoplasia previously and were under surveillance for metachronous neoplasia~Patients suspected of neoplasia referred for endoscopic mucosal resection or other targeted endoscopic treatment of the lesion"
88915642|NCT01618682||Hand Transplant Patients|These will be subjects who have undergone a hand transplant.
88915643|NCT01618682||Hand Replant Patients|These will be patients who have undergone a hand replant procedure.
88915644|NCT01618734||Romiplostim and eltrombopag in ITP|ITP patients who received alternatively romiplostim or eltrombopag with at least two months of follow-up for each period.
88915645|NCT01618747||Cohort|
88915646|NCT01618760|Experimental|Risperidone Tablet 1 mg|Risperidone Tablet 1 mg of M/s Ipca Laboratories Limited, India
88915647|NCT01618760|Active Comparator|Risperdal®|Risperdal® (Risperidone) Tablet 1 mg of Janssen Pharmaceutica Products, USA
88915648|NCT01618799|Active Comparator|LAMICTAL®|Lamictal® (Lamotrigine) Tablets 25 mg of GlaxoSmithkline, USA
88915649|NCT01618799|Experimental|Lamotrigine Tablets 25 mg|Lamotrigine Tablets 25 mg of M/s Ipca Laboratories Limited, India
88915650|NCT01618812||Pes plano valgus|Children with painful flatfeet
88915651|NCT01618825|Active Comparator|LAMICTAL®|Lamictal® (Lamotrigine) Tablets 25 mg of GlaxoSmithkline, USA
88915652|NCT01618825|Experimental|Lamotrigine Tablets 25 mg|Lamotrigine Tablets 25 mg of M/s Ipca Laboratories Limited, India
88915653|NCT01618877|Experimental|Levetiracetam iv infusion|Levetiracetam intravenous (iv) infusion.
88915654|NCT01618877|Placebo Comparator|Placebo infusion|
88915655|NCT01618890|Experimental|HVPG-propranolol arm|"A baseline hepatic venous pressure gradient measurement (HVPG measurement) is performed in day-care setting. After this procedure propranolol is started at 20 mg BID. with dose escalation as described in the propranolol arm.~A second HVPG measurement is performed at 4 weeks after adequate propranolol therapy. In patients who reach target HVPG reduction (responders), propranolol is continued at the same dose without routine control endoscopy. In patients who do not reach target HVPG reduction (nonresponders), endoscopic band ligation is performed in day-care setting with intervals of 2-4 weeks until complete obliteration of varices. Follow-up endoscopy with 6 months interval is performed to detect and treat recurrent large varices."
88915656|NCT01618890|No Intervention|Propranolol arm|Propranolol start 20 mg BID. orally with dose escalation based on heart frequency (HF) with 3-days interval to the maximum tolerated dose. No routine control endoscopy is required.
88915657|NCT01618903|Experimental|Levetiracetam iv infusion|Levetiracetam intravenous (iv) 45 min infusion administered as one single dose.
88915658|NCT01618903|Experimental|Levetiracetam oral tablet|Levetiracetam oral tablet administered as one single dose.
88915659|NCT01618929|Active Comparator|asthma with food allergy|The study will be performed in 2 groups of patients (Patients with and without food allergy) parallel to each other at the same time and within each group the patients will take montelukast and placebo (one after another in a double-blind design).
88915660|NCT01618929|Active Comparator|asthma without food allergy|The study will be performed in 2 groups of patients (Patients with and without food allergy) parallel to each other at the same time and within each group the patients will take montelukast and placebo (one after another in a double-blind design)
88915661|NCT01618981|Experimental|first active|
88915662|NCT01618981|Experimental|first inactive|
88915663|NCT01618994||Expert Surgeons|Gynecologic robotic surgeons, each averaging >75 robotic cases per year
88915664|NCT01618994||Study Surgeons|Gynecologic surgeons who are completely naive to robotics
88915665|NCT01618994||Control Surgeons|Gynecologic surgeons with full robotic privileges but were not averaging more than 2 cases a month and had never used the simulator
88915666|NCT01619007||Group 1|
88915667|NCT01619007||Group 2|
88915668|NCT01619020|Active Comparator|Flaxseed Lignans|Capsules
88915669|NCT01619020|Placebo Comparator|Placebo|Capsules
88915670|NCT01619033|Experimental|impaired renal function subjects|impaired renal function subjects
88915671|NCT01619033|Other|Healthy volunteers|matched with impaired renal function subjects on ethnic group, sex, age (+/- 5 years), and BMI (+/- 20%)
88915672|NCT01619046|Active Comparator|PK substudy|A cohort of 13-18 subjects will be included in the pharmacokinetic (PK) evaluation of GreenGene™ F and an approved recombinant Factor VIII product (Refacto AF); a minimum of 13 of these subjects will be re-evaluated at study end (50 exposure day).
88915673|NCT01619046|Experimental|Prophylaxis safety and efficacy substudy|Hemostatic efficacy of GreenGene™ F will be assessed by its effectiveness in controlling spontaneous or traumatic bleeding episodes and by the rate of breakthrough bleeding during prophylaxis over ≥ 50 exposure days.
88915674|NCT01619046|Experimental|On-demand safety and efficacy substudy|Hemostatic efficacy of GreenGene™ F will be assessed by its effectiveness in controlling spontaneous or traumatic bleeding episodes and by the rate of breakthrough bleeding in a minimum of 10 on demand treated subjects during 50 exposure days.
88915675|NCT01619046|Experimental|Surgical substudy|Peri-operative hemostatic control of GreenGene™ F in surgery or invasive procedures will be assessed in at least 10 surgeries, some of them major, in at least five subjects
88915676|NCT01619072|Active Comparator|Misoprostol|800 mcg sublingual misoprostol + referral to higher level care
88915677|NCT01619072|Placebo Comparator|Placebo|Placebo + referral to higher level care
89435121|NCT06292533|No Intervention|Control-waitlist Group|Participants in control-waitlist group will receive homecare treatment that does not interfere with hair growth for 6 sessions with 2 weeks interval, follow up every 2 weeks for 1 month after last session and receive Ultrapulse treatment after the research end.
88915678|NCT01617291|Experimental|Induced Hypothermia|Induced hypothermia after the return of spontaneous circulation by the application of ice packs to the axilla and groin with cold IV fluids
88915679|NCT01617291|No Intervention|Regular Care|Treatment of the return of spontaneous circulation under standing paramedic protocol without the addition of induced therapeutic hypothermia
88915680|NCT01619098|Experimental|Patient Navigator|Hospital-based Patient Navigator (a bilingual community health worker) engaged in discharge planning and made outreach phone calls to patients for 30 days after discharge and assisted patints with follow-up appointments, obtaining and taking medications, transportation, financial barriers, and linkages to community resources
88915681|NCT01619098|No Intervention|Usual Care|Home care plan at discharge, outreach phone call from RN at patient's primary care clinic
88915682|NCT01619137|Active Comparator|Povidone-iodine And normal salin|40 patients with complaint of ununion wound of laparatomy or episiotomy coming to Gynecologist's office or hospital enrolled to this study randomly recieve Povidone-iodine And normal salin treatment.
88915683|NCT01619137|Active Comparator|water and soap|40 patients coming to Gynecologist's offices or hospital with complaint of ununion wound of laparatomy or episiotomy in Bandarabbas enrolled to this study and randomly recieve water and soap to irrigation of the wound (it's not require to be at hospital), washing is for each 6-8 hours per day. and if not difference seen after 4 day, treatment change to Povidone-iodine And normal salin.
88915684|NCT01619150|Other|Etoricoxib, followed by placebo|4 weeks of treatment with etoricoxib, followed by a wash out period of at least 6 days, followed by another 4 weeks of treatment with placebo.
88915685|NCT01619150|Other|Placebo, followed by etoricoxib|4 weeks of treatment with placebo, followed by a wash out period of at least 6 days, followed by another 4 weeks of treatment with etoricoxib.
88915686|NCT01619163|Experimental|prednisolone|
88915687|NCT01619163|Placebo Comparator|Placebo|
88915688|NCT01619189|Experimental|Tranplantation of cultured LSC in stage 3 limbal deficiency|Transplantation of Allogeneic or Autologous Limbal Epithelial Stem Cells Cultured on Human Amniotic Membrane with no Feeders in stage 3 unilateral or bilateral limbal stem cell deficiency.
88915689|NCT01619202|Experimental|Risk Anticipation-Perception Training|Complete the Risk Anticipation-Perception Training (RAPT) program
88915690|NCT01619202|No Intervention|No training program|Does not complete the Risk Anticipation-Perception Training (RAPT) program
89435122|NCT06292520|Experimental|ABLLS-R protocol|The study will evaluate the ABLLS-R (Assessment of Basic Language and Learning Skills test) and compare their effectiveness in developing the Receptive.
89435123|NCT06292520|Experimental|Portage Guide Protocol|The study will evaluate Portage guidance and compare their effectiveness in developing the Receptive Language Skills in children with Autism Spectrum Disorder.
89435124|NCT06292507|Experimental|EFFECTS OF MYOFASCIAL STRETCH|This group will receive Myofascial stretch Group.
88915691|NCT01619215||Bariatric Surgery|As the number of patients dropping out during follow-up, we had difficulty achieving our secondary outcomes, and so the team decided to continue the recruitment until all our outcomes are reached. Main part of the primary outcomes is finalised and published The effects of bariatric surgeries on nonalcoholic fatty liver disease. Aldoheyan T, Hassanain M, Al-Mulhim A, Al-Sabhan A, Al-Amro S, Bamehriz F, Al-Khalidi H. Surg Endosc. 2016 Jul 12
88915692|NCT01619228||Premature Infants|Infants born at < 37 weeks gestational age
88915693|NCT01619228||Full Term Infants|Infants born at equal to or greater than 37 weeks gestational age
88915694|NCT01619228||Adults|Adults are parents of infants enrolled in the study
88915695|NCT01619241||advanced non-small cell lung cancer|
88915696|NCT01619254|Experimental|Hand hygiene|Hand washing with soap measures will be carried out as an intervention activity
88915697|NCT01619254|Experimental|Hand finger nail hygiene|Hand finger nail clipping activities
88915698|NCT01619254|Experimental|Hand and finger nails hygiene|Both hand washing with soap and hand finger nail clipping activities will be implemented
88915699|NCT01619254|Placebo Comparator|Customary practice|No hand washing with soap and nail clipping activities. House holds and children assigned to the control group will not have the interventions (hand washing with soap and nail clipping activities)
88915700|NCT01619267||device associated infection|patients with proven device associated infection
88915701|NCT01619267||control group|patients without device associated infection
88915702|NCT01619280|Experimental|Nebulized sodium nitroprusside|
88915703|NCT01619293||Epidural H.|patients with hematoma epidurale
88915704|NCT01619293||Subdural H.|patients with hematoma subdurale
88915705|NCT01619293||Subarachnoidal H.|patients with hematoma subarachnoidale
88915706|NCT01619293||Intracerebral H.|patients with hematoma intracerebrale
88915707|NCT01619293||E. cerebri|patients with edema cerebri
88915708|NCT01619293||Concussion|patients with concussion
88915709|NCT01619345|Experimental|Period 1: NN9924 with 50 mL water|
88915710|NCT01619345|Experimental|Period 2: NN9924 with 240 mL water|
88915711|NCT01619371||Lactating women|Lactating women willing to use a breast pump.
88915712|NCT01619384|No Intervention|Treatment as Usual|Usual VA care
88915713|NCT01619384|Experimental|MBSR|participation in an 8-week stress reduction course (mindfulness-based stress reduction)
88915714|NCT01619397|Other|Condom|Test condom with new Xanthan gum condom coating
88915715|NCT01619436|Active Comparator|clonidine|clonidine 2 mg/kg IV
88915716|NCT01619436|Placebo Comparator|ringer lactato 1 ml|Ringer lactato 1 ml IV as Placebo
89435125|NCT06292507|Experimental|CONTRACT-RELAX TECHNIQUE ON TONE|This group will receive Contract-Relax technique Group
89435126|NCT06292494|Experimental|FUS-treated epilepsy|
89010115|NCT04549987|Experimental|Without changing working archwire|Extraction space closed using the same working archwire throughout 3 visits after insertion
89010116|NCT04549987|Experimental|With changing working archwire|The extraction space closed having the working archwire changed monthly.
89010117|NCT04549636||healthy COVID-19+|Individuals who recently recovered from COVID-19 and who have no history of lung disease
89010118|NCT04549636||asthmatic COVID-19+|Individuals who recently recovered from COVID-19 and who have asthma
89435127|NCT06292481|Experimental|Brunnstorm Movement therapy|this group received Brunnstorm Movement therapy for 3 to 5 sessions per week, each lasting approximately 30 to 60 minutes for 6 weeks
89010119|NCT04549636||healthy COVID-19-|Individuals who have not been diagnosed with COVID-19 and who have no history of lung disease
89010120|NCT04549636||asthmatic COVID-19-|Individuals who have not been diagnosed with COVID-19 and who have asthma
89435128|NCT06292481|Experimental|Combined Brunnstorm Movement therapy and low level laser therapy|this group received Combined Brunnstorm Movement therapy and low level laser therapy for 3 to 5 sessions per week, each lasting approximately 30 to 60 minutes for 6 weeks
89435129|NCT06292468|Active Comparator|Traditional physical therapy|This group received conventional physical therapy protocol along with foot care guidelines.
89435130|NCT06292468|Experimental|Plantar cutaneous sensory stimulation.|This group received plantar cutaneous sensory stimulation along with conventional physical therapy protocol and foot care guidelines.
89435131|NCT06292455|Experimental|Elastic resistance training|elastic resistance training of upper limb
89435132|NCT06292455|Other|Conventional resistance training|players follow their routine exercise protocol
89435133|NCT06292442|Active Comparator|Traditional physical therapy|This group received conventional physical therapy treatment including Range of Motion (ROM) exercises for the affected hip, knee, and ankle joints, as well as stretching exercises for tight lower limb muscles, administered 3 times per week for 4 weeks, with each session lasting approximately 20-30 minutes.
88915717|NCT01619449|Experimental|Renal replacement therapy|Liver transplant recipients who receive continuous renal replacement therapy intra-operatively.
88915718|NCT01619449|Active Comparator|No CRRT|This arm consists of standard of care without CRRT in the OR for OLT
88915719|NCT01619462|Other|Synflorix or PCV10|130 children will receive Synflorix at 1-2-3 months
88915720|NCT01619462|Other|Prevenar 13|130 children will receive Prevenar 13 at 1-2-3 months
88915721|NCT01619475||Prospective|Individuals approved as liver donors and recipients shortly Pre-donation/Pre-transplant at the study sites.
88915722|NCT01619475||Long-Term Follow-up|"Donors and recipients enrolled in the original A2ALL Cohort study.~Donors and LDLT recipients whose donation/transplant occurred during the period of time that began with the end of enrollment into the original Cohort study (Aug. 31, 2009) and ended with the opening of the enrollment in the current core protocol; this is referred to as the Gap Era.~LDLT recipients and donors who were not in the original Cohort study or from the Gap Era will enter the study at time proximate to time of living donation."
88915723|NCT01619475||HCV-Infected Liver Transplant Recipients|Male and female HCV-infected adult liver transplant recipients from those enrolled in the A2ALL-1 Cohort study and from those concurrently transplanted at the new A2ALL-2 centers (University of Toronto, University of Pittsburgh, Lahey Clinic).
88915724|NCT01619527|Experimental|Treatment A|Single-dose co-administration of 800 mg darunavir and 150 mg cobicistat as single agents (under fasted condition)
88915725|NCT01619527|Experimental|Treatment B|Single-dose co-administration of the fixed dose combination darunavir/cobicistat (800/150-mg) (under fasted condition).
88915726|NCT01619527|Experimental|Treatment C|Single-dose co-administration of 800 mg darunavir and 150 mg cobicistat as single agents (under fed condition - standardized breakfast).
88915727|NCT01619527|Experimental|Treatment D|Single-dose co-administration of the fixed dose combination darunavir/cobicistat (800/150-mg) (under fed condition - standardized breakfast).
88915728|NCT01619527|Experimental|Treatment E|Single-dose co-administration of the fixed dose combination darunavir/cobicistat 800/150-mg (under fasted condition).
88915729|NCT01619527|Experimental|Treatment F|Single-dose co-administration of the fixed dose combination darunavir/cobicistat (800/150-mg) (under fed condition - high-fat breakfast).
88915730|NCT01619540|Other|acute heart failure|control arm
88915731|NCT01619540|Experimental|COPD exacerbation|COPD exacerbation
88915732|NCT01619566|No Intervention|Control|Control subjects undergo a skin biopsy.
88915733|NCT01619566|Experimental|Treatment|Subjects in the treatment arm also undergo a skin biopsy, followed by 8 week treatment with Duloxetine.
88915734|NCT01619592|Active Comparator|Intervention group|webbased education (telemonitoring)
88915735|NCT01619592|No Intervention|control group|standard care
88915736|NCT01619605|Experimental|Shrim|
89435134|NCT06292442|Experimental|High intensity interval training|This group received high-intensity interval training along with conventional treatment for the lower limb muscles
89435135|NCT06292429|Experimental|Complex Training|
89435136|NCT06292429|Active Comparator|Conventional Training|
89435137|NCT06292429|Other|Control Group|
88915737|NCT01619631|Experimental|12-week Tai Chi intervention|
88915738|NCT01619631|Active Comparator|Education control group|After 24 weeks, and upon completion of the study, each participant will be offered twelve weeks of Tai Chi twice weekly.
89435138|NCT06292416|Experimental|Mirror therapy with sensory motor training.|"Visual perception activities~Body awareness~Tactile perception.~Visual-motor coordination training~The child will be seated on a chair and a 30*30 cm mirror will set up on a table in front of them. The affected hand will be placed behind the mirror so that the image of a healthy hand can be seen clearly"
89435139|NCT06292416|Experimental|Mirror Therapy with motor training.|supination-pronation, wrist flexion-extension, finger flexion-extension, abduction, adduction, opposition
89435140|NCT06292416|Other|Motor Training|"Holding objects~Stabilize objects~manipulate objects"
89435141|NCT06292403|Active Comparator|Strength Training|Non-hemiplegic lower limb stepping forward training Non-hemiplegic upper limb pulling elastic belt in standing position repeatedly Hemiplegic lower limb stepped over an obstacle or climbed a platform The patients will stretch their arms to touch distant objects in a standing position repeatedly.
89435142|NCT06292403|Experimental|Mirror Therapy and strength Training Group|Participants in the (trial group) mirror and strength training group observed the reflection of the exercising arm and leg in the mirror. Participants in the (control group) strength training only group will exercise without a mirror entirely.
88915739|NCT01619631|No Intervention|Waitlist control group|The waitlist control will not receive any intervention during the duration of the study. After 24 weeks, and upon completion of the study, each participant will be offered twelve weeks of Tai Chi twice weekly.
88915740|NCT01619644|Experimental|Sodium Valproate|Group of 40 patients receiving one year of sodium valproate
88915741|NCT01619644|Placebo Comparator|Placebo|Group of 20 patients receiving one year of placebo
88915742|NCT01619657|Experimental|Hypertonic Saline|Inhalation with 6% Hypertonic Saline twice daily over 1 year
88915743|NCT01619657|Active Comparator|Isotonic Saline|Inhalation with 0.9% Isotonic Saline twice daily over 1 year
88915744|NCT01619670|No Intervention|no intervention|standard wound care
88915745|NCT01619670|Active Comparator|Apligraf|non adhesive layer with apligraf
88915746|NCT01619683|Experimental|Androxal|
88915747|NCT01619683|Placebo Comparator|Placebo|
88915748|NCT01619696|Experimental|Intervention|
88915749|NCT01619709|Other|lobar hemorrhage group|PET AV-45 in patients with cortical or corticosubcortical hemorrhage (involving predominantly the cortex and underlying white matter)
88915750|NCT01619709|Other|deep hemorrhage group|PET AV-45patients with subcortical hemorrhage (involving predominately the basal ganglia, periventricular white matter, or internal capsule).
89435143|NCT06292377|Experimental|Stroke patients|Patients, hospitalized at the Stroke Unit of CHU Brugmann and UZ Brussel, after the clinical diagnosis of a first-ever ischemic stroke.
89435144|NCT06292364|Other|control group|beggs wrap around Retainer will be given to the patients immediately [Just after debonding].
89435145|NCT06292364|Active Comparator|experimental group|beggs wrap around Retainer will be delivered to the patients 7 days post debonding.
89435146|NCT06292312|Experimental|Treatment group|Patients in this grop are the group to which craniosacral therapy and convensional physiotherapy will be applied.
89435147|NCT06292312|Active Comparator|Control group|Patients in this group are the group to which conventional physiotherapy will be applied.
89531291|NCT03120611|Experimental|Virtural reality exercise|Virtual reality exercise performed during the hemodialysis session, using the Kinect, specially adapted for patients undertaking hemodialysis
88915751|NCT01619735||Fragments basketed|"Active extraction is whereby the ureteroscope is passed back and forth into the kidney to remove all visible stone fragments."
88915752|NCT01619735||Fragments dusted|"Dusting is whereby the stones are broken into tiny fragments or dust with the intention that achieving such a small stone size will allow the stones to pass spontaneously."
88915753|NCT01619748||Untreated OSA patients|Patients with obstructive sleep apnoea who are untreated
89435148|NCT06292299||Patient attending for overnight cardiorespiratory polysomnography sleep study|Any patient attending the Royal Hospital for Children, Glasgow sleep laboratory for overnight cardiorespiratory polysomnography for evaluation of sleep disordered breathing. Pneumowave device will collect data from patients alongside standard clinical monitoring.
89531292|NCT03120611|Active Comparator|Conventional exercise intradialysis|Exercise combining both aerobic (cycling) and strengthening exercise of lower limbs for patients during the hemodialysis session
88915754|NCT01619748||OSA patients highly compliant with CPAP|OSA patients established on CPAP therapy (high compliance, > 80% nightly use for ≥ 4 h per night)
88915755|NCT01619748||OSA patients poorly compliant with CPAP|OSA patients established on CPAP therapy (poor compliance, 10% < nightly use < 50% or < 4 h per night)
88915756|NCT01619748||Age and BMI-matched controls|Age and BMI-matched controls without OSA
89435149|NCT06292299||Patients in the neonatal unit, Royal Hospital for Children, Glasgow, at risk of central apnoea|Any patient currently in the Queen Elizabeth University Hospital campus neonatal unit at risk of central apnoea receiving standard care (this may include mechanically ventilated patients). Pneumowave device will collect data from patients alongside standard clinical monitoring.
89435150|NCT06292286|Experimental|Chemotherapy and surgery arm|Patients receive platinum-based chemotherapy with or without bevacizumab, and then undergo cytoreductive operation, for the first recurrence of EOC.
89435151|NCT06292273|Active Comparator|Group Bupivacain Plus dexamethasone|receiving plain bupivacaine 0.1%, 35 ml with dexmedetomidine 0.5
89435152|NCT06292273|Placebo Comparator|Group bupivacain|plain bupivacaine 0.25%, 25 ml bilaterally
89435153|NCT06292260|Experimental|With mHealth app|All healthcare providers will receive the mHealth app (eSkinHealth) to be used in their daily practices.
89435154|NCT06292234|Experimental|patient specific implants|Custom made designed implants
89435155|NCT06292234|Active Comparator|miniplates|Over the counter miniplates
89435156|NCT06292221|Experimental|Experimental|For this group of participants: The study clinicians will receive the weekly depression and behavioral assessment reports generated by the mHealth tool 'DepWatch' via a secure clinician portal
88915757|NCT01619761|Experimental|Treatment Plan 1 (NK cells, umbilical cord blood transplant)|Patients receive high-dose lenalidomide PO QD on days -8 to -2, fludarabine phosphate IV over 1 hour on days -7 to -4, and melphalan IV over 30 minutes on day -4. CD20 positive patients also receive rituximab IV over 6 hours on days -8 to -4.
88915758|NCT01619761|Experimental|Treatment Plan 2 (NK cells, umbilical cord blood transplant)|Patients receive high-dose lenalidomide PO QD on days -7 to -2, cyclophosphamide IV over 3 hours on day -7, and undergo TBI on day -3. Patients also receive rituximab and fludarabine phosphate as in Treatment Plan 1.
88915759|NCT01619891|Active Comparator|Vitamin D|Vitamin D 100mcg per day
88915760|NCT01619891|Placebo Comparator|Placebo|Standard optimal therapy
88915761|NCT01619904|Experimental|Goal-Directed Therapy|
88915762|NCT01619904|Active Comparator|Standard Therapy|
89435157|NCT06292221|Other|Control|For this group of participants: The study clinicians will NOT receive the weekly depression and behavioral assessment reports generated by the mHealth tool 'DepWatch'
89435158|NCT06292208|Experimental|IBD0333|
89435159|NCT06292195||Cohort VitDTracking: Group 1- Pregnant women with vitamin D Sufficiency (≥30 ng/mL)|
88915763|NCT01619930|Experimental|1a|"In phase 1, group 1 undergoes physical activation without added motivation interviewing. Post-treatment (phase 2), group 1 is divided by randomization into group 1a and 1b, where 1a receives relapse prevention and 1b does not. Both 1a and 1b undergo post-treatment measurements as previously described.~n = 50 + 12 = 62 (50 from group 1 + 12 from waiting list control group)"
88915764|NCT01619930|Experimental|1b|"In phase 1, group 1 undergoes physical activation without added motivation interviewing. Post-treatment (phase 2), group 1 is divided by randomization into group 1a and 1b, where 1a receives relapse prevention and 1b does not. Both 1a and 1b undergo post-treatment measurements as previously described.~n = 50 + 12 = 62 (50 from group 1 + 12 from waiting list control group)"
88915765|NCT01619930|Experimental|2a|"In phase 1, group 2 undergoes physical activation with added motivation interviewing. Post-treatment (phase 2), group 2 is divided by randomization into group 2a and 2b, where 2a receives relapse prevention and 2b does not. Both 2a and 2b undergo post-treatment measurements as previously described.~n = 50 + 12 = 62 (50 from group 2 + 12 from waiting list control group)"
88915766|NCT01619930|Experimental|2b|"In phase 1, group 2 undergoes physical activation with added motivation interviewing. Post-treatment (phase 2), group 2 is divided by randomization into group 2a and 2b, where 2a receives relapse prevention and 2b does not. Both 2a and 2b undergo post-treatment measurements as previously described.~n = 50 + 12 = 62 (50 from group 2 + 12 from waiting list control group)"
88915767|NCT01619930|Experimental|3a|"In phase 1, group 3 undergoes behavioral activation with added motivation interviewing. Post-treatment (phase 2), group 3 is divided by randomization into group 3a and 3b, where 3a receives relapse prevention and 3b does not. Both 3a and 3b undergo post-treatment measurements as previously described.~n = 50 + 12 = 62 (50 from group 3 + 12 from waiting list control group)"
88915768|NCT01619930|Experimental|3b|"In phase 1, group 3 undergoes behavioral activation with added motivation interviewing. Post-treatment (phase 2), group 3 is divided by randomization into group 3a and 3b, where 3a receives relapse prevention and 3b does not. Both 3a and 3b undergo post-treatment measurements as previously described.~n = 50 + 12 = 62 (50 from group 3 + 12 from waiting list control group)"
88915769|NCT01619930|Experimental|4a|"In phase 1, group 4 undergoes behavioral activation without added motivation interviewing. Post-treatment (phase 2), group 4 is divided by randomization into group 4a and 4b, where 4a receives relapse prevention and 4b does not. Both 4a and 4b undergo post-treatment measurements as previously described.~n = 50 + 12 = 62 (50 from group 4 + 12 from waiting list control group)"
89435160|NCT06292195||Cohort VitDTracking: Group 2 - Pregnant women with vitamin D Insufficiency (20-29 ng/mL)|
89435161|NCT06292195||Cohort VitDTracking: Group 3 - Pregnant women with vitamin D Deficiency (<20 ng/mL)|
89435162|NCT06292182|Experimental|Treatment start at baseline|
89435163|NCT06292182|Experimental|Delayed treatment start at 3 months from baseline|
89435164|NCT06292169|Experimental|RSA with pectoralis minor release|
89435165|NCT06292169|Active Comparator|RSA without pectoralis minor release|
89435166|NCT06291545|Experimental|Coronary artery scoring balloon dilation catheter（JW Medical Systems Ltd）|Patients with Coronary Artery Disease will be treated with Coronary artery scoring balloon dilation catheter（JW Medical Systems Ltd）
89435167|NCT06291545|Active Comparator|ScoreFlex NC Coronary Dilatation Catheter|Patients with Coronary Artery Disease will be treated with ScoreFlex NC Coronary Dilatation Catheter（OrbusNeich Medical [Netherlands] Ltd）
89435168|NCT06290882|Active Comparator|Robotic Heller Myotomy.|Patients with Achalasia, designated to receive a myotomy of the lower esophageal sphincter, who have been randomised into the Robotic Heller Myotomy group
89435169|NCT06290882|Active Comparator|Peroral Endoscopic Myotomy.|Patients with Achalasia, designated to receive a myotomy of the lower esophageal sphincter, who have been randomised into the Peroral Endoscopic Myotomy group
89435170|NCT06290778|Experimental|Brief Unified Protocol|This workshop includes education regarding basic human emotions, why we have emotions, how they help us, how they can get in the way, and how they are related to psychological health problems, including among firefighters. Skills that are helpful in managing strong or unwanted emotions will be taught and practiced during the workshop. A workshop manual will be provided. Brief videos summarizing the material will be emailed over the course of the month following the workshop.
89435171|NCT06290778|Active Comparator|Psychoeducation|This workshop provides education regarding signs and symptoms of psychological health challenges that are most commonly experienced by firefighters. These include posttraumatic stress, depression, anxiety, and alcohol and substance misuse. This workshop is a standard part of fire academy training. A workshop manual will be provided. Brief videos summarizing the material will be emailed over the course of the month following the workshop.
89435172|NCT06290726||living donor liver transplantations with anti-HBc (+) grafts|No intervention(s) had been administered.
89435173|NCT06290726||living donor liver transplantations with anti-HBc (-) grafts|No intervention(s) had been administered.
89435174|NCT06290622|Experimental|Dose Level Assignments|"Dose Level 1 Retifanlimab 375mg INCAGN02385 250mg INCAGN02390 200mg~Dose Level 2 Retifanlimab 500mg INCAGN02385 250mg INCAGN02390 200mg~Dose Level 3 Retifanlimab 750mg INCAGN02385 250mg INCAGN02390 200mg"
89435175|NCT06290583|Active Comparator|Group B|Patients will be given spinal anesthesia with bupivacaine (10 mg) added to morphine (100 microgram) and will be diluted with 0.9% saline to the 3 ml final volume to be injected.
89435176|NCT06290583|Active Comparator|Group P|Patients will be given spinal anesthesia with prilocaine (50 mg) added to morphine (100 microgram) and will be diluted with 0.9% saline to the 3 ml final volume to be injected.
89435177|NCT06290557|Experimental|Verum|Low Dose single application Low Dose multiple application High Dose single application high dose multiple application
88915770|NCT01619930|Experimental|4b|"In phase 1, group 4 undergoes behavioral activation with added motivation interviewing. Post-treatment (phase 2), group 4 is divided by randomization into group 4a and 4b, where 4a receives relapse prevention and 4b does not. Both 4a and 4b undergo post-treatment measurements as previously described.~n = 50 + 12 = 62 (50 from group 4 + 12 from waiting list control group)"
88915771|NCT01619930|No Intervention|Phase 1 Waiting list control group|Control group during phase 1, in parallel with treatment groups 1-4. Weekly self-report measurements, the results of which are conveyed in the form of individualized feedback. After 12 weeks, the participants of the control group (n = 100) are randomized to one four phase 1 active treatment groups (1-4) and receive treatment accordingly.
88915772|NCT01619943||Patients with minor head injury|MHI is defined as a blunt trauma to the head within 24 hours with a Glasgow Coma Scale (GCS) score of 13 to 15 and at least one of the following: history of loss of consciousness, short-term memory deficit, amnesia for the traumatic event, post-traumatic seizure, vomiting, headache, external evidence of injury above the clavicles, confusion, and neurologic deficit.
89435178|NCT06290557|Placebo Comparator|Placebo|placebo
89435179|NCT06289686|Experimental|BioEnthesis|Allogenic, acellular, biphasic allograft (BioEnthesis)
89435180|NCT06289686|Active Comparator|Standard of Care|Standard rotator cuff repair (suture and anchor based technique)
89435181|NCT06289439|Experimental|Green tea supplementation group|2 capsules for 10 consecutive weeks, distributed in a single daily oral intake with the main meal
89435182|NCT06289439|Placebo Comparator|Placebo supplementation group|2 capsules for 10 consecutive weeks, distributed in a single daily oral intake with the main meal
89435183|NCT06289387||Individuals with or without diabetes|
89435184|NCT06289322|Other|Digital Toolkit for assessment of pain and distress|a digital toolkit will be developed using facial emotional recognition and other instruments as well as questionnaires for the assessment of pain and distress in patients with dementia
89435185|NCT06289218|Experimental|interferential current plus exercise|interferential current plus exercise group
89435186|NCT06289218|Experimental|kinesio taping plus exercise|kinesio taping plus exercise group
89435187|NCT06289218|Other|Control group|Control group
89435188|NCT06289049|Experimental|Exercise Group|The exercise intervention will consist of 24 supervised, heavy lifting strength training exercise sessions over a 12 week period. The exercise frequency will be two times per week. Main exercises will consist of barbell back squat, bench press, and dead lift.
88915773|NCT01619956|Experimental|OSFE with grafting|OSFE with grafting (autogenous bone chips+xenograft material with a ratio of 1:4)
88915774|NCT01619956|Active Comparator|OSFE without grafting|OSFE without grafting. No grafting materials or autogenous bone chips were used.
88915775|NCT01619969|Experimental|Celgosivir|
88915776|NCT01619969|Placebo Comparator|Placebo|
88915777|NCT01620008|No Intervention|Immediate Cord Clamping (ICC)|The infant will be placed on the maternal abdomen and the umbilical cord will be clamped immediately after birth (routine care).
88915778|NCT01620008|Experimental|Delayed Cord Clamping (DCC)|At birth, infants will be placed on the maternal abdomen and the cord clamping will be delayed for 5 minutes. If the provider is unable to delay the cord clamping, the cord will be milked 5 times.
88915779|NCT01620021||Healthy|Ten healthy volunteers with no history of gait and balance issues will be recruited to participate in the study.The participants must be between 18 and 65 years of age.
88915780|NCT01620034|Active Comparator|11 Day Arm|
88915781|NCT01620034|Experimental|4 Day Arm|
88915782|NCT01620073|Other|Partner friendly arm|Proportion of males counseled and tested using routine standards of prenatal care
88915783|NCT01620073|Experimental|Home based arm|Proportion of male partners accepting HIV counseling and testing following home visits for couple HIV counseling and testing during pregnancy
88915784|NCT01620099|Experimental|Asthmatic nonsmokers|Asthmatic patients aged 18-50 years old, at stage 2-3 according to GINA international guidelines, on inhaled treatment (ICS alone or combination ICS/LABA) other than extrafine formulations, will be enrolled. This group includes patients who never smoked. Following the initial evaluation (cross-sectional - primary outcome) patients will be switched to an extrafine equipotent dose of the same compound (BDP-HFA if the patient was on ICS) or combination (BDP-HFA/F if the patient was on ICS/LABA combination). After 3-months patients will be reassessed for lung function and asthma control
88915785|NCT01620099|Active Comparator|Asthmatic smokers|Asthmatic patients aged 18-50 years old, at stage 2-3 according to GINA international guidelines, on inhaled treatment (ICS alone or combination ICS/LABA) other than extrafine formulations, will be enrolled. This group includes patients who smoked with a smoking habit ranging from 10 to 20 pack/years. Following the initial evaluation (cross-sectional - primary outcome) patients will be switched to an extrafine equipotent dose of the same compound (BDP-HFA if the patient was on ICS) or combination (BDP-HFA/F if the patient was on ICS/LABA combination). After 3-months patients will be reassessed for lung function and asthma control
88915786|NCT01620112|Active Comparator|low clonidine concentration|clonidine concentration 1 ml on 40 ml of lidocaine 1.5% for upper brachial plexus
88915787|NCT01620112|Active Comparator|lidocaine 20 ml 1,5%|lidocaine 20 ml 1,5% without clonidine for axillary brachial plexus block for upper limb surgery
88915788|NCT01620112|Active Comparator|high clonidine concentration|clonidine concentration 150 mcg on 20 ml of lidocaine 1,5% for upper brachial plexus
88915789|NCT01620112|Active Comparator|40 ml lidocaine 1,5%|40 ml of lidocaine 1,5% without clonidine for upper brachial plexus
88915790|NCT01620125|Other|Lactobacillus reuteri|Dietary supplementation with Lactobacillus reuteri DSM 17938
88915791|NCT01620151|No Intervention|No extended neck|Patient will not undergo thyroid surgery with extended neck
88915792|NCT01620151|Experimental|Extended neck|Patients who undergoing thyroid surgeries are positioned with extended neck by using pillow under shoulder in order to facilitate neck exposure and make the surgery easier.
88915793|NCT01620164|Other|Parkinsonian patients OFF/ON|9 patients will be evaluated with psychophysical measurements of 3D perception, in OFF then ON conditions
88915794|NCT01620164|Other|healthy subjects|Healthy subjects will be evaluated with psychophysical measurements of 3D perception, without treatment
88915795|NCT01620164|Other|Parkinsonian patients ON/OFF|9 patients will be evaluated with psychophysical measurements of 3D perception, in ON and then OFF conditions
88915796|NCT01620229|Experimental|Treatment (brentuximab vedotin)|Patients receive brentuximab vedotin IV on day 1. Treatment repeats every 21 days for up to 16 courses in the absence of disease progression or unacceptable toxicity.
88915797|NCT01620242|Experimental|Cabazitaxel|All patients are treated with Cabazitaxel.
88915798|NCT01620268|No Intervention|Control Group|Patients receive standard of care.
88915799|NCT01620268|Experimental|Treatment Group|Dose adjusted leflunomide plus 600 mg orotic acid.
88915800|NCT01620281|Experimental|Immediate treatment (IT)|Subjects from this group will receive the device immediately. Subjects will be instructed to treat themselves daily for 3 weeks, in up to three 10-minutes sessions. All subjects will receive a diary to record details of the daily use of the device (time of day, position of legs, and number of daily uses), degree of pain, a weekly ODI questionnaire, and record of any back/pain related events. After 3 weeks the subjects from the IT group will return the device and at 6 weeks they will visit again for the final evaluation.
88915801|NCT01620281|Other|Waiting List Control (WLC)|The WLC group will go through the same evaluations at the same time intervals but will begin treatments 3 weeks later during which they will fill the diary daily but not use the device.
88915802|NCT01620294|Experimental|triclosan|Two arms are separated by computer randomization at abdominal wall closure: application of triclosan-coated and non-coated PDS suture (PDS vs. PDS-Plus).
88915803|NCT01620294|Experimental|uncoated|Two arms are separated by computer randomization at abdominal wall closure: application of triclosan-coated and non-coated PDS suture (PDS vs. PDS-Plus).
88915804|NCT01620307|Active Comparator|with Rapamune treatment|"All patients were treated with Oseltamivir (Tamiflu, Roche) 50 mg twice a day for 10 days and oral prednisolone 20 mg/day for 14 days. At ICU admission, patients started on empiric antimicrobial therapy with moxifloxacin 500 mg per day until results of microbiological studies were available.~Each patient received best support treatment including mechanical ventilator, fluid resuscitation, gastrointestinal and thromboembolic prophylaxis, and enteral nutrition for most aspects of care. After radomization, patients were received Sirolimus (Rapamune 2mg/day, Pfizer)for a course of 14 days."
88915805|NCT01620307|Placebo Comparator|Without Rapamune treatment.|"All patients were treated with Oseltamivir (Tamiflu, Roche) 50 mg twice a day for 10 days and oral prednisolone 20 mg/day for 14 days. At ICU admission, patients started on empiric antimicrobial therapy with moxifloxacin 500 mg per day until results of microbiological studies were available.~Each patient received best support treatment including mechanical ventilator, fluid resuscitation, gastrointestinal and thromboembolic prophylaxis, and enteral nutrition for most aspects of care. After radomization, patients were not to receive Sirolimus (Rapamune 2mg/day, Pfizer)for a course of 14 days."
89435189|NCT06289049|No Intervention|Usual Care Group|Participants randomized to the usual care group will be asked to continue will their typical daily routine during the 12 week study period, and not begin any new exercise program to increase their exercise levels from baseline. They will not receive any information or education regarding exercise. After the postintervention assessments, participants in the usual care group will be offered a 4-week introduction to heavy lifting strength training program and/or referred to a community-based exercise program
89435190|NCT06288919|Experimental|Erythritol group|
89435191|NCT06288919|Active Comparator|Ultrasonic scaler|
89435192|NCT06288750|Experimental|Indocyanine green group|Identification of parathyroid glands (PGs) Near-infrared (NIR) fluorescence visualization of PGs, for only experimental group
89435193|NCT06288750|Active Comparator|Traditional surgery group|Conventional means of identification and assessment of PGs are mainly based on surgeon-dependent identification of their anatomical location and appearance (color, shape, etc.) by the naked eye.
89435194|NCT06288633|Active Comparator|Cardioneuroablation|Radiofrequency catheter transmyocardial ablation of the ganglion plexuses (GP) of the atria - cardioneuroablation. The procedure is performed under local anesthesia using intracardiac catheters. Radiofrequency applications will be applied to the endocardial surface of the left and/or right atria in places of typical localization of the densest GPs network in order to destroy nerve fibers and ganglia: in patients with sinus bradycardia - in the left and right atria (5 places with the highest concentration of ganglia); in patients with impaired atrioventricular conduction - in the right atrium and in the left atrium (1 place in the right atrium - at the ostium of the coronary sinus; 2 places in the left atrium - opposite the ostium of the coronary sinus and opposite the Marshall ligament/vein).
89435195|NCT06288633|Sham Comparator|Sham group|"In the control (sham) group, endocardial electrophysiological study will be performed, but patients will not know which procedure they performed (they are blinded in relation to the distribution group). The monitoring will be performed according to the same protocol as in the cardioneuroablation group. In case of recurrence of symptomatic bradycardia and/or (with) syncopal condition without traumatization of the patient in the control group, a transition to the cardioneuroablation group (cross-over) will be proposed. In case of disagreement, a pacemaker is implanted."
88915806|NCT01620320||Stress echography|Nine to twelve months after their left main angioplasty, patients will go through a stress echo and then the usual control angiography (done routinely in most patient in our center). Patients will act as their own control.
88915807|NCT01620333|Experimental|Treatment period 1|
88915808|NCT01620333|Experimental|Treatment period 2|
88915809|NCT01620346|Active Comparator|ICSI group|This group was provided with conventional intracytoplasmic sperm injection (ICSI). This treatment is routinely used to treat infertility. Sperm selection in the ICSI group is analysed under a magnification of 400x using an inverted microscope.
88915810|NCT01620346|Experimental|Intracytoplasmic morphologically selected sperm injection|Intracytoplasmic morphologically selected sperm injection (IMSI) is an established modified ICSI procedure. Sperm selection in the IMSI group is examined at high magnification using an inverted microscope equipped with high-power differential interference contrast optics (DIC/Nomarski). The total calculated magnification is x6.600. The sperm cells exhibiting normally shaped nuclei and normal nuclear chromatin content are selected for injection.
88915811|NCT01620359|Experimental|ExAblate|
88915812|NCT01620372||Treatment cohort (chemo/radiotherapy)|- those who have survived at least 5 years from the date of diagnosis
88915813|NCT01620372||Self-questionnaire cohort|- those with a complete address, who come of age, are still alive and sent back a signed consent agreement
88915814|NCT01620372||Medical Insurance cohort|- those who come of age and authorize the access to the medical facilities of the French Health Insurance Information System
88915815|NCT01620385|Experimental|ciPDA|
88915816|NCT01620398|Experimental|BALANCE group|BALANCE Program is composed by 3 concepts: a) a diet composed of 50-60% of energy from carbohydrate, 10-15% of energy from protein; 25-35% of energy from fat (<7% saturated fatty acid; <10% polyunsaturated fatty acid; <20% monounsaturated fatty acid, <1% trans fatty acid), <200 mg/day of cholesterol, 20-30 g/day of fiber and <2400 mg/day of sodium; b) Nutrition education program based on ludic strategies and indication of affordable foods; c) An intense follow up by individual and group visits and phone calls.
88915817|NCT01620398|Active Comparator|Control Diet group|generalized advices to follow a low fat, low energy, low sodium and low cholesterol diet are given.
89435196|NCT06288568||Nightshift workers|Nightshift worker in the health care and industrial sector. Night shift is defined as a work schedule that involves working at least 3 hours between 00:00 and 5:00, at least 2 consecutive nights/month.
89435197|NCT06288568||Dayshift workers|Dayshift worker in the health care and industrial sector. No night shifts.
89435198|NCT06288555||Diabetic patient|This study focused on a group of 274 patients with type 2 diabetes who were receiving services at Nong Khantee Subdistrict Health Promoting Hospital in Phra Phutthabat District, Saraburi Province. Participants underwent both the Ipswich touch test and the 10-g monofilament test.
89435199|NCT06288061|Experimental|Non-invasive Phrenic Nerve Neuromodulation|
89435200|NCT06288061|Placebo Comparator|Cervico-dorsal Massage|
89435201|NCT06287827||Simplified protocol|"The first cohort will be composed of all children between 6 and 59 months of age who attend predefined outpatient care points in the states Distrito Capital, Miranda, and La Guaira. These children must meet the inclusion criteria for the research. For those selected in these centers, the method of nutritional treatment for acute malnutrition will be the simplified protocol. Adaptations in this protocol include:~Use of a single treatment product (Ready to use therapeutic food).~Reduced dose.~Expanded cut-offs."
89435202|NCT06287827||Standard protocol|The second cohort will be composed of all children between 6 and 59 months of age who attend other predefined outpatient care points in the four states and met the inclusion criteria for this research. Nutritional treatment will be administered to these children, following the WHO Standard Protocol.
89435203|NCT06287190||Dental interns|Assessing dental intern confidence before and after finishing their rotation at the pediatric department
89435204|NCT06286462|Experimental|CATSystem Intervention|Participants enrolled at intervention sites will receive CATSytem-supported cervical cancer screening and treatment services. Interventions received will include: text messages to patients and algorithm-driven alerts to providers when guideline-adherent cervical cancer screening and treatment services are required including: initial and follow up cervical cancer screening, on site treatment, and referral tracking.
89435205|NCT06286462|No Intervention|Standard of care|Participants enrolled at control sites will receive standard of care PMTCT services, with no CATSystem tracking or follow up
89435206|NCT06285279|Experimental|Treatment arm|"Administration of FKC288 Four dose groups of 0.1×10^6 CAR-T/kg, 0.3×10^6 CAR-T/kg, 1.0×10^6 CAR-T/kg, and 3.0×10^6 CAR-T/kg FKC288 are designed in this study.~Each dose group plans to enroll 1-2 or 3-6 participants with relapsed or refractory autoimmune-mediated kidney diseases (such as lupus nephritis, ANCA-associated vasculitis, membranous nephropathy, IgG4-related diseases) according to observed DLT.~FKC288 will be intravenously infused at least 24 hours after lymphodepletion preconditioning. According to the assigned dose group, the designated dose of FKC288 will be infused in a single infusion within 30 minutes on day 0."
89435207|NCT06285045|Experimental|Roujin Formula group|Roujin Formula : angelica, bupleurum, radix paeoniae alba, etc. Medication method : oral 1 bag ( 150ml ) each time, 2 times a day. Treatment course : 8 weeks.
88915818|NCT01620411|Experimental|Comprehensive Medical Management (CMM)|This arm will receive standard of care treatment for injuries sustained while on active duty. Non-Invasive.
88915819|NCT01620411|Experimental|CMM + Spinal Cord Stimulator (SCS)|This arm will combine comprehensive medical management with placement of a spinal cord stimulator.
88915820|NCT01620424|Experimental|Dosing visit 1|
88915821|NCT01620424|Experimental|Dosing visit 2|
88915822|NCT01620437|Experimental|Formulation A|
88915823|NCT01620437|Experimental|Formulation B|
88915824|NCT01620450|Experimental|NN2000|
88915825|NCT01620450|Active Comparator|NN-X14|
88915826|NCT01620463|Experimental|NNC 90-1170|
88915827|NCT01620463|Placebo Comparator|Placebo|
88915828|NCT01620476|Experimental|5 mcg/kg|
89198351|NCT05435274|Experimental|HS-10376|"Phase 1a：Dose Escalation：Subjects with advanced NSCLC will be enrolled in dose escalation cohorts. Dose escalation of HS-10376 will be done to determine maximum tolerated dose.~Phase 1b：Dose Expansion：Depending on data obtained from the dose escalation part, dose expansion may proceed with multiple cohorts in subjects with advanced NSCLC having a EGFR/HER2 Exon 20 insertion mutation.~Phase 2：Subjects with locally advanced or metastatic EGFR Exon 20 insertion NSCLC will be enrolled in phase 2 part to evaluate the efficacy and sufficient safety of HS-10376 as monotherapy."
88915829|NCT01620476|Experimental|10 mcg/kg|
88915830|NCT01620476|Experimental|15 mcg/kg|
88915831|NCT01620502|Active Comparator|EPA 3.5 g/day|
88915832|NCT01620502|Placebo Comparator|Placebo capsules|oleic oil
89435208|NCT06285045|No Intervention|Control group|Placebo : According to the internationally accepted standard, one-tenth of the dose of Roujin Formula was used to prepare a placebo, which was similar to Roujin Formula in appearance, color, taste or smell, and packaging. Medication method : oral 1 bag ( 150ml ) each time, 2 times a day. Treatment course : 8 weeks.
89435209|NCT06284668|Placebo Comparator|Placebo Group of patients undergoing oocyte retrieval with normal saline|Patients undergoing oocyte retrieval were given 5ml 0.9% saline before anesthesia and surgery
89198352|NCT05351398||PDO group|Patients with stage III gastric cancer who need neoadjuvant chemotherapy before radical surgery are recruited. And they are treated with individualized neoadjuvant therapy under the guidance of a patient-derived organoid (PDO)-based drug sensitivity assay.
89198353|NCT05351398||Traditional group|Patients with stage III gastric cancer who need neoadjuvant chemotherapy before radical surgery are recruited. In this group, patients are treated with the SOX regimen.
89198354|NCT00860613|Experimental|1|women in this group received usual medical treatment and counseling from a nutritionist and diabetes educator. They received a specific diet using carbohydrate counting (40-45% of carbohydrates)and a moderate energy restriction. Weight gain, adequacy of diet, results of the self glucose monitoring, and ketonuria were evaluated every two weeks. They also received education on diabetes, diet and glucose monitoring.
89435210|NCT06284668|Active Comparator|Group of patients undergoing oocyte retrieval with esketamine|Patients undergoing oocyte retrieval were given esketamine 0.2mg/kg before anesthesia and surgery
89435211|NCT06284668|Active Comparator|Group of patients undergoing oocyte retrieval with remimazolam|Patients undergoing oocyte retrieval were given remimazolam 0.2mg/kg before anesthesia and surgery
88915833|NCT01620502|Experimental|DHA 1.75 g/day|DHA 1.75 g/day
88915834|NCT01620554|Experimental|BF2.649 5mg|
88915835|NCT01620554|Experimental|BF2.649 10mg|
88915836|NCT01620554|Experimental|BF2.649 20mg|
88915837|NCT01620554|Experimental|BF2.649 40mg|
89435212|NCT06278389|Experimental|Stage 1: ACC017 and placebo|The trial is conducted sequentially from the low-dose cohorts, namely, 5 mg, 20 mg, 40 mg, 80 mg, 120 mg and 160 mg（tentative), respectively. Participants are given a single dose of ACC017 tablets or placebo under the fasting condition.
89010121|NCT04549441||WALANT|The participants undergo distal radius plating surgery via wide-awake local anesthesia no tourniquet technique. In this group, mean arterial pressure, heart rate, and numeric rating scale for pain were measured by nursing staff in the operation theatre seven times perioperatively, namely before surgery (T0) and at the time of injection of local anesthesia (T1), skin incision (T2), fracture reduction (T3), plating and screwing (T4), skin closure (T5), surgery completion (T6).
89010122|NCT04549441||GA|The participants undergo distal radius plating surgery via general anesthesia induced by an anesthesiologist. The anesthesia team continuously monitored patients' intraoperative physiological status. MAP and HR in group B were marked after induction (T1) and at the other six same time points as in the group WALANT.
89010123|NCT00268398|Active Comparator|FOLFOX4|
89435213|NCT06278389|Experimental|Stage 2: ACC017 and FTC/TAF (Descovy）|Stage 2 is a single center, randomized, open-label FE and DDI study with a tentative dose of 40 mg. The stage was planned to enroll 12 healthy participants (both male and female) who are randomly assigned to either the fasting-postprandial or postprandial-fasting arm at a 1:1 ratio. Eligible healthy participants are admitted on D-1 and received a single oral dose of ACC017 tablets on the day of administration of each cycle under the fasting or postprandial condition with a washout period of 7 days during the two-week period. After completing the washout of the second cycle, participants are assessed by the investigator to enter into the DDI study and receive a single oral dose of ACC017 tablets with FTC/TAF tablets under the fasting condition.
89198355|NCT00860613|Experimental|2|Women in this group received usual medical treatment and counseling from a nutritionist and diabetes educator. The diet they received was based on carbohydrate counting (40-45% of carbohydrates), but recommended only low-moderate glycemic index foods. Weight gain, adequacy of diet, results of the self glucose monitoring, and ketonuria were evaluated every two weeks. They also received education on diabetes, diet and glucose monitoring.
89435214|NCT06276127|Experimental|Oral Bisoprolol|A single oral dose of 5 mg Bisoprolol (maximum dose of 5 mg)
89435215|NCT06276127|Other|Intravenous Diltiazem|single intravenous dose of Diltiazem at 0.25 mg/kg (to a maximum dose of 30 mg)
89435216|NCT06275204||Protocol I|"H. pylori positive patients who will be treated by bismuth-based quadruple therapy.~Participating centers: KBC Rijeka, Croatia; KBC Zagreb, Croatia; Beacon Hospital, Ireland; Uniwersytet medyczny we Wrocławiu, Poland; UMF Cluj-Napoca, Romania; NIJZ, Slovenia"
89435217|NCT06275204||Protocol II|"In case there will be a treatment failure after bismuth-based quadruple therapy, the remaining patients with a positive infection will be referred to a levofloxacin based quadruple therapy.~Participating centers: KBC Rijeka, Croatia; KBC Zagreb, Croatia; Beacon Hospital, Ireland; Uniwersytet medyczny we Wrocławiu, Poland; UMF Cluj-Napoca, Romania; NIJZ, Slovenia"
89435218|NCT06275204||Standard triple therapy|"H. pylori positive participants who will offered standard triple therapy.~Participating center: University of Latvia, Latvia"
89435219|NCT06275204||Second line treatment - levofloxacin-based|"In case there will be a treatment failure after standart triple therapy, the remaining patients with a positive infection will be referred to a second line treatment~Participating center: University of Latvia, Latvia"
89435220|NCT06274138|Experimental|haptonomy|Pregnant women in the intervention group will complete the Prenatal Attachment Scale and Marital Adjustment Scale, and fathers will complete the Antenatal Father Attachment Scale and Marital Adjustment Scale through face-to-face interviews. Information will be given that Haptonomy will consist of five sessions. Haptonomy will be applied by the researcher together with the partner. Each session will last for 40 minutes. The effectiveness and continuity of sessions will be planned between 3 to 7 days. One week after completing the five sessions of haptonomy, pregnant women will again complete the Prenatal Attachment Scale and Marital Adjustment Scale, and fathers will complete the Antenatal Father Attachment Scale and Marital Adjustment Scale through face-to-face interviews. The completion of the scales will take approximately 10-15 minutes.
89435221|NCT06274138|No Intervention|control|Explanation of the purpose of the study will be provided to pregnant women and their partners, obtaining verbal and written consent. Pregnant women in the control group will complete the Prenatal Attachment Scale and Marital Adjustment Scale, and fathers will complete the Antenatal Father Attachment Scale and Marital Adjustment Scale through face-to-face interviews. The completion of the scales will take approximately 10-15 minutes.
89435222|NCT06270108|Experimental|Treatment-resistant schizophrenia patients receiving riluzole|
89010124|NCT00268398|Experimental|FOLFOX7 followed by FOLFIRI|
89010125|NCT00235313|Experimental|1|adaptation of the nicotine patch with salivary cotinine
89010126|NCT00235313|Other|2|normal following with a nicotine patch
89010127|NCT04549285|Experimental|hCT-MSC infusion|Doses will be given on days 1, 2, 3, and a fourth, optional dose may be given on day 7 at the discretion of the investigator and the treating physician.
89010128|NCT04549753|Experimental|tDCS stimulation group|Patients receive four sessions of tDCS stimulation over C3 (patient with left-sided lesion) or C4 (patient with right-sided lesion) based on 10-20 system.
89435223|NCT06270108|No Intervention|Treatment-responsive schizophrenia patients|
89435224|NCT06270108|No Intervention|Healthy controls|
88915838|NCT01620554|Placebo Comparator|Placebo|
88915839|NCT01620580|Active Comparator|Self Management Strategies|"Participants in the intervention group will receive printed self management strategies each of the 5 symptoms, a symptom diary with the self-management strategies and a 15 minutes discussion. The intervention script will instruct participants on how to use the printed strategies by PI and RA #1.~Week 3."
88915840|NCT01620580|Active Comparator|Dietary Information|Control arm
88915841|NCT01620606|Experimental|SLCBT|Social Learning and Cognitive Behavioral Therapy
88915842|NCT01620606|Experimental|SLCBT-R|Phone-based Social Learning and Cognitive Behavioral Therapy
88915843|NCT01620606|Active Comparator|ES|Education and Support
88915844|NCT01620619|Active Comparator|Arthroscopic Bankart Repair & Rotator Interval Closure|
88915845|NCT01620619|Active Comparator|Arthoscopic Bankart Repair alone|
88915846|NCT01620632||Altered gastric anatomy|Patients who have an altered gastric who need an ERCP
88915847|NCT01620645||COPD, GOLD II severity or above|
88915848|NCT01620671|Active Comparator|Conventional surgery|The patients who will have a conventional surgical treatment will be included.
88915849|NCT01620671|Active Comparator|Fast-track surgery|The patients who will have fast-track surgery will be included.
88915850|NCT01620684|Active Comparator|metyrapone|Overnight metyrapone treatment (total dose of 30 mg/kg)
89435225|NCT06268496|Experimental|mild to moderate melasma|adult patients suffering from mild to moderate melasma (Investigator's Global Assessment (IGA) 1 or 2)
88915851|NCT01620684|Placebo Comparator|sugar pill|Overnight treatment with placebo capsules
88915852|NCT01620697||Perirenal fat|
88915853|NCT01620710|Other|prostate bed|"irradiation of the prostatic bed only (no higher risk of lymph node recurrence); helical IMRT of the prostate bed (18 x 3 Gy)~This arm has already finished recruitment"
88915854|NCT01620710|Other|prostate bed & lymph nodes|irradiation of the prostatic bed and the pelvic lymphatic drainage (in patients with higher risk of lymph node recurrence); helical IMRT of the prostate bed (18 x 3 Gy) and the pelvic lymph nodes (18 x 2.5 Gy)
88915855|NCT01620723|Experimental|New breastfeeding programme|"The breastfeeding programme consists of four core elements:~breastfeeding is a parental task~skin to skin contact during the first three days~frequent breastfeeding at least 8 times a day~good positioning, preferable in a laid back position~Moreover communication was supposed to enhance breastfeeding self-efficacy, using Banduras theory of self-efficacy"
88915856|NCT01620723|Active Comparator|Treatment as usual|Breastfeeding counselling uses the national handbook of breastfeeding as reference
88915857|NCT01620736|Experimental|Raltegravir|Treatment with raltegravir for 8 wks
88915858|NCT01620749|Experimental|MEL050|
88915859|NCT01620775|Experimental|Knee osteoarthritis (MRI, surveys, pain testing)|Subjects previously diagnosed with knee osteoarthritis will have an MRI with imaging that measures brain metabolites. There are surveys to complete and a session of pain tolerance testing.
89435226|NCT06268496|Experimental|mild to moderate acne induced PIHP|adult patients suffering from mild to moderate acne-induced PIHP (IGA 1 or 2) without active acne (i.e., less than 10 inflammatory lesions)
89435227|NCT06268496|Experimental|solar lentigo|adult patients suffering from solar lentigo with a pigmentation score > 5
89435228|NCT06263296|Experimental|Interventional Group|"For intervention group, principal investigator will assess subject health care needs prior to intervention. Two extra sessions, 20 minutes, face to face, individual self-management education with aid of computer, track log sheet will be provided to intervention group. Concept of motivational interviewing will be incorporated as complement teaching strategy to facilitate self-management learning. Principal investigator will be responsible to deliver burn self-management education upon discharge. Intervention group will receive Rehabilitation Booklet for Burn Patients upon discharge. After discharge, only intervention group subject receives two sessions, 10 minutes, telephone follow up calls and five personalized chat-based messaging follow up will be provided. Besides that, self-management education information will be delivered to intervention group via instant messaging service as well."
89435229|NCT06263296|No Intervention|Control Group|For control group, participants will receive usual care by ward nurses (provide burn discharge pamphlet upon discharge + regular plastic surgeon follow up)
89435230|NCT06261606|Experimental|Hybrid strategy|"A hybrid strategy inclusive of:~A one-page flashcard describing the adverse cardiovascular effects of air pollution and individual-level strategies to mitigate these effects~Alerting patients on polluted days (defined as air quality index (AQI) ≥ 131 [33]) by sending cell phone text messages and recommending to not go outdoors or minimize outdoor activities (especially exercising) on those days. This will also be accompanied by periodic phone calls to ascertain that the patients receive the messages and are attentive to them.~Wearing KN-95 facemasks (provided by the investigators of this study) as a physical barrier against air pollution on highly polluted days (defined as AQI ≥ 131) in case the patient cannot avoid going outdoors~Dietary intervention by encouraging patients to consume citrus fruits during days with AQI ≥ 131."
88915860|NCT01620775|Active Comparator|Healthy controls (MRI, surveys,pain testing)|Healthy volunteers will have an MRI with imaging that measures brain metabolites. There are surveys to complete and a session of pain tolerance testing.
89435231|NCT06261606|No Intervention|Usual care|No active strategy (usual care) without any clear recommendations related to air pollution. A control card will be shared with the patients randomized to the control group
89435232|NCT06261554|Experimental|Sesame immunotherapy|Children with sesame allergy receiving OIT.
89435233|NCT06261554|No Intervention|Sesame avoidance|Children with sesame allergy not undergoing OIT.
88915861|NCT01620775|Experimental|diabetic peripheral neuropathy|Subjects previously diagnosed with diabetic peripheral neuropathy will have an MRI with imaging that measures brain metabolites. There are surveys to complete and a session of pain tolerance testing.
88915862|NCT01620775|Experimental|chronic low back pain|Subjects previously diagnosed with chronic low back pain will have an MRI with imaging that measures brain metabolites. There are surveys to complete and a session of pain tolerance testing.
88915863|NCT01620801|Experimental|Low dose|AAV8-hFIX19
88915864|NCT01620801|Experimental|Middle dose|AAV8-hFIX19
88915865|NCT01620801|Experimental|High dose|AAV8-hFIX19
88915866|NCT01620814|Experimental|Dinoprostone and misoprostol|"For the purpose of cervical ripening none procedure will be performed to Group 1, while vaginal misoprostole of 200 mg and vaginal dinoprostone will be applied to Group 2 and 3, respectively. While misoprostol will be implanted 3 hours before procedure, but dinoprostone will be implanted 6 hours before procedure. Before drug implantation for determination of the cervical insufficiency and measure of the cervical canal's opening, bougies will be applied toward to back from 8 no- hegar bougie.~After drugs administration, cervical canal will be again evaluated with above mentioned way by bougie before hysteroscopy"
88915867|NCT01620814|Experimental|Misoprostol and control|For the purpose of cervical ripening none procedure will be performed to Group 1, while vaginal misoprostole of 200 mg and vaginal dinoprostone will be applied to Group 2 and 3, respectively. While misoprostol will be implanted 3 hours before procedure, but dinoprostone will be implanted 6 hours before procedure. Before drug implantation for determination of the cervical insufficiency and measure of the cervical canal's opening, bougies will be applied toward to back from 8 no- hegar bougie.
88915868|NCT01620814|Experimental|dinoprostone and control|For the purpose of cervical ripening none procedure will be performed to Group 1, while vaginal misoprostole of 200 mg and vaginal dinoprostone will be applied to Group 2 and 3, respectively. While misoprostol will be implanted 3 hours before procedure, but dinoprostone will be implanted 6 hours before procedure. Before drug implantation for determination of the cervical insufficiency and measure of the cervical canal's opening, bougies will be applied toward to back from 8 no- hegar bougie.
88915869|NCT01619319|Experimental|Cognitive Remediation Therapy|A computerised cognitive remediation intervention called the Brain Fitness program is compared against a placebo intervention consisting of computer games
89435234|NCT06259669||Infants of women exposed to ruxolitinib cream during pregnancy|
88915870|NCT01619319|Active Comparator|computer games|computer games
88915871|NCT01619826|Experimental|Treatment Group|Participants randomized to the physical activity-based afterschool intervention
88915872|NCT01619826|Placebo Comparator|Wait List Group|Participants in this group partake in their regular afterschool activities, without intervention from the study staff.
88915873|NCT01620827|Active Comparator|Hospital Landline|Subjects in this arm have all of their follow-up phone calls placed from a hospital landline number.
88915874|NCT01620827|Active Comparator|Private Cell Phone|Subjects in this arm have all of their follow-up phone calls placed from a private cell phone number.
88915875|NCT01620840||Lacosamid-i.v. treatment|
88915876|NCT01620866|Experimental|EMDR|
89435235|NCT06259669||Infants of women not exposed to ruxolitinib cream during pregnancy|
89435236|NCT06257979|Other|Experimental group|Operated patients with positive results for their pre-operative microbiological samples.
89435237|NCT06257979|Other|Control group|Operated patients with negative results for their pre-operative microbiological samples.
89435238|NCT06257186|Experimental|Art Therapy|Women in the experimental group will be offered a series of three to five art therapy sessions, depending on the participants' needs/preferences. The art therapy sessions will be given anytime after consent has been obtained till approximately 36 weeks of gestation. The art therapy sessions are in addition to routine antenatal care.
88915877|NCT01620866|No Intervention|TAU|Treatment as usual (TAU)
89435239|NCT06257186|No Intervention|Routine Antenatal Care|Women in the control group will receive routine antenatal care.
89435240|NCT06255600|Experimental|Experimental HD-tDCs|Patients will be randomly enrolled into this group. They will receive stimulation in the portion of the left primary motor cortex (M1) by HD-tDCS (lasting 20 minutes of 4x1 tDCS-HD) with anodal stimulus, twice a week for five weeks. The electric current will be supplied with an acceleration time of 30 seconds and will be maintained for 20 minutes and then reduced by 30 seconds
89435241|NCT06255600|Experimental|Experimental HD-tDCS and Chlorella|Patients will be randomly enrolled into this group. They will receive stimulation in the portion of the left primary motor cortex (M1) by HD-tDCS (lasting 20 minutes of 4x1 tDCS-HD) with anodal stimulus, twice a week for five weeks. The electric current will be supplied with an acceleration time of 30 seconds and will be maintained for 20 minutes and then reduced by 30 seconds. In addition, they will receive functional food that will be provided in the form of 10 tablets per day of Chlorella Pyrenoidosa (5g/day) containing 4mcg of B12, organically pressed into tablets (Registration with ANVISA/MS: 6.7273.000) for five weeks.
89435242|NCT06255600|Experimental|Experimental Chlorella|Patients will be randomly enrolled into this group. They will receive the functional food that will be provided in the form of 10 tablets per day of Chlorella Pyrenoidosa (5g/day) containing 4mcg of B12, organically pressed into tablets (Registration with ANVISA/MS: 6.7273.000) for five weeks.
89435243|NCT06255600|Sham Comparator|Placebo/Sham|Patients allocated to this group will receive a simulated 3mA current with 30 seconds of acceleration and 30 seconds of deceleration minutes of anodal HD-tDCS (4x1) for 10 sessions (twice a week in five weeks) and/or Placebo with maltodextrin (5g/day) being 10 capsules per day for five weeks.
88915878|NCT01620892||Unicondylar knee replacement|This is a non-intervational, retrospective, observational study of a case series cohort of patients who received a particular surgical operation during a specified time period.
88915879|NCT01620905|Experimental|Cervical spine manipulation|Subjects received cervical spine manipulation
88915880|NCT01620931|Experimental|RO5469754|
88915881|NCT01620931|Placebo Comparator|Placebo|
88915882|NCT01620957||Coma patients|
88915883|NCT01620970|Experimental|PF03446962|Investigational study drug, administered intravenously every 2 weeks until disease progression or unacceptable toxicity.
88915884|NCT01621022|Active Comparator|Active bupropion-Active gum|150 mg bupropion twice daily + 4 mg nicotine gum as needed (up to 12 pcs/day)
88915885|NCT01621022|Active Comparator|Active bupropion-Placebo gum|150mg bupropion twice daily + placebo gum as needed (up to 12 pcs/day)
89435244|NCT06253663|Experimental|MCL Cohort- KTE-X19|"Participants will receive cyclophosphamide 500 mg/m^2/day intravenously (IV) and fludarabine 30 mg/m^2/day IV lymphodepletion chemotherapy for 3 days followed by KTE-X19 administered intravenously at a target dose of 2 x 10^6 anti-cluster of differentiation (CD)19 chimeric antigen receptor (CAR) T cells/kg on Day 0.~For participants weighing ≥ 100 kg, a maximum flat dose of 2 x 10^8 anti-CD19 CAR T cells will be administered."
88915886|NCT01621022|Active Comparator|Placebo medication-Placebo gum|Placebo bupropion, twice daily, plus placebo gum as needed (up to 12 pcs/day)
88915887|NCT01621035||elderly (> 70 y)|
88915888|NCT01621061||High altitude pulmonary hypertension|Highlanders with high altitude pulmonary hypertension
88915889|NCT01621061||High altitude control|Healthy highlanders
88915890|NCT01621061||Low altitude control|Healthy lowlanders
88915891|NCT01621074|Active Comparator|Sodium bicarbonate|
88915892|NCT01621074|Placebo Comparator|Placebo|
88915893|NCT01621087|Experimental|Safflower oil|
88915894|NCT01621087|No Intervention|Control group (no diet instruction)|
88915895|NCT01621100|Experimental|OROS hydromorphone|Once-Daily OROS (Osmotic release oral system [a controlled release oral drug delivery system in the form of a tablet]) hydromorphone
88915896|NCT01621113|Experimental|Locomotor Training + Dalfampridine|Subjects randomized to this group will undergo 10 weeks of double-blind treatment with extended release dalfampridine tablets (10 mg twice daily) while simultaneously receiving locomotor training therapy (5 sessions per week x 10 weeks = 50 sessions total).
88915897|NCT01621113|Placebo Comparator|Locomotor Training + Placebo|Subjects randomized to this group will undergo identical treatment, but will take placebo tablets while simultaneously receiving locomotor training therapy (5 sessions per week x 10 weeks = 50 sessions total).
88915898|NCT01621139|Experimental|Real acupuncture|Real acupuncture group
88915899|NCT01621139|Sham Comparator|Sham acupuncture|Sham acupuncture group
88915900|NCT01621165|Active Comparator|prazosin|Add prazosin to usual medications and monitor manic symptoms and for adverse effects
88915901|NCT01621165|Placebo Comparator|Placebo|
88915902|NCT01621204|Experimental|Eltrombopag|Eltrombopag is a small molecule, non-peptide thrombopoietin (TPO) receptor agonist indicated for the treatment of thrombocytopenia in patients with chronic ITP who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. TPO receptor agonists are an effective new class of medications that are non-immunogenic agonists of the TPO receptor (c-Mpl) and work by increasing platelet production in ITP patients.
88915903|NCT01621204|Active Comparator|IVIG infusion|Intravenous immunoglobulin (IVIG) is used to rapidly increase platelet counts in ITP patients. IVIG is associated with a transient platelet count response in approximately 80% of patients, which occurs within 2 - 4 days. It is commonly used to improve platelet count numbers prior to surgery for patients with ITP.
88915904|NCT01621217|Experimental|Cetuximab, Mitomycin C, Fluoruracil|
89435245|NCT06253663|Experimental|ALL Cohort- KTE-X19|"Participants will receive cyclophosphamide 900 mg/m^2/day intravenously (IV) for 1 day and fludarabine 25 mg/m^2/day IV lymphodepletion chemotherapy for 3 days followed by KTE-X19 administered intravenously at a target dose of 1 x 10^6 19 CAR T cells/kg on Day 0.~For participants weighing ≥ 100 kg, a maximum flat dose of 1 x 10^8 anti-CD19 CAR T cells will be administered."
89435246|NCT06253234|Experimental|Treatment Sequence A|
88915905|NCT01621256|Experimental|Ancrod|Ancrod
88915906|NCT01621256|Placebo Comparator|Saline solution|Saline solution
88915907|NCT01621269|Experimental|Fingolimod|
88915908|NCT01621282|Experimental|Education|Departments passed 6-month interactive educational course
88915909|NCT01621282|No Intervention|No Education|Departments not passed 6-month interactive educational course
88915910|NCT01621308||IP insulin|Patients treated with continuous intraperitoneal insulin infusion using a implantable pump
88915911|NCT01621308||SC insulin|Patients treated with subcutaneous insulin, both multiple daily injections and continuous subcutaneous insulin infusion
88915912|NCT01621321|Experimental|Steroid group|
88915913|NCT01621321|Experimental|Voriconazole group|
89435247|NCT06253234|Experimental|Treatment Sequence B|
89198356|NCT00860613|No Intervention|3|women in this group received the current hospital treatment. They did not receive any intervention except for the self glucose monitoring that they did every two weeks. Weight gain and the results of the self glucose monitoring, were evaluated every two weeks.
88915914|NCT01621334|Experimental|Motivational Enhancement Therapy|Motivational Enhancement Therapy
88915915|NCT01621334|Other|Educational brochure|Intimate Partner Violence, Substance Abuse, and HIV risky behaviors Education
88915916|NCT01621360|Active Comparator|Arthroscopic surgery|Arthroscopic surgery of the hip plus optimized medical management
88915917|NCT01621360|Active Comparator|Conservative management|Physical therapy aimed at strengthening and stabilization of the hip and appropriate analgesic and anti-inflammatory medication.
88915918|NCT01621373|Other|propofol|All patients receive propofol. Dose will be defined based on response of previous patient in the same stratum.
88915919|NCT01621386|Experimental|All Participants|Participants (male or female) that are between 18-65 years of age with a clinical diagnosis of asthma will take montelukast for 2 weeks (treatment period 1) and then take prednisone for 2 weeks (treatment period 2)
88915920|NCT01621399|Placebo Comparator|Vehicle|Treatment with the vehicle (placebo)
88915921|NCT01621399|Experimental|Product 55394|Treatment with product 55394
88915922|NCT01621425||TAC regimen|Female subject diagnosed with breast carcinoma and will receive docetaxel treatment according to standard hospital protocol
88915923|NCT01621425||PRODOC regimen|male subject diagnosed with metastatic castration-resistant prostate carcinoma and will receive docetaxel treatment according to standard hospital protocol
89435248|NCT06252766|Experimental|Experiment (Clown)|During this process, the clown will continue to distract the children by playing games and blowing foam balloons. During the procedure, the child's pain and anxiety score will be evaluated by both the researcher, the parent, and the child. After the procedure is completed, children will be taken out of the blood collection room and taken to the waiting area in the next room, and after being allowed to rest for 1-2 minutes, surveys will be administered to the children.
89435249|NCT06252766|No Intervention|Control|Blood collection will be routine and surveys will be administered 1-2 minutes after the end of the procedure to determine the level of pain and anxiety during the procedure.
88915924|NCT01621451|Active Comparator|immediate|Patients who receive pantoprazole plus aspirin and/or clopidogrel within 3~4 days after EMR/ESD
88915925|NCT01621451|Active Comparator|2 weeks|Patients who receive pantoprazole plus aspirin and/or clopidogrel at 2 weeks after EMR/ESD
88915926|NCT01621464|Placebo Comparator|Control|Pacemaker implanted but NO pacing (mode DDI, 30 bpm and sub-threshold)
88915927|NCT01621464|Experimental|CLS group|pacemaker implanted programmed with the contractility sensor activated (mode DDD-CLS)
88915928|NCT01621516||Healthy controls|10 healthy volunteers
88915929|NCT01621516||Solitary small bowel transplant patients|3
88915930|NCT01621516||Liver/small bowel transplant patients|3
88915931|NCT01621555||PSOASS Patients|Patients undergoing elective arthroscopic shoulder surgery
88915932|NCT01621620|Experimental|yohimbin|
88915933|NCT01621646|Placebo Comparator|egg white (control)|egg whites, 4 ounces per day for six months
88915934|NCT01621646|Experimental|eggs|eggs, 2 large per day for 6 months
88915935|NCT01621685|Experimental|Spirometry, auscultation, questionnaire|>12% fall in FEV1, wheezing on auscultation, symptom questionnaire score >4
88915936|NCT01621698|Active Comparator|Early paravertebral block|The early group will have Local anaesthetic placed at the start of surgery and have normal saline placed at the close.
88915937|NCT01621698|Active Comparator|Late paravertebral block|The late group will have normal saline placed at the start of surgery and local anaesthetic placed at the close.
88915938|NCT01621724|Experimental|Single arm cohort study|WT1 TCR-transduced T cells
88915939|NCT01621750|Experimental|Clopidogrel|Clopidogrel tablets 300 mg of Dr. Reddy's Laboratories Limited
88915940|NCT01621750|Active Comparator|Plavix|Clopidogrel Tablet 300 mg
88915941|NCT01621763|Experimental|Clopidogrel|Clopidogrel tablets 300 mg of Dr. Reddy's Laboratories Limited
89435250|NCT06249399|Experimental|Aerobic Exercise Group|A behavioral treatment program will be applied to the patients. In addition, patients will be given submaximal aerobic exercise.
89435251|NCT06249399|Active Comparator|Control group|A behavioral treatment program will be applied to the patients.
89435252|NCT06244030|Experimental|Core Stabilization Group|The athletes in the core stabilization group will be applied a 15-20 repetition core stabilization exercise program 3 days a week for 6 weeks by the researcher. The duration of the exercise program is planned not to exceed 30 minutes. The values before and after the exercise program will be recorded.
88915942|NCT01621763|Active Comparator|Plavix|Clopidogrel Tablet 300 mg
88915943|NCT01621789|Experimental|dye of lutein, zeaxanthin, trypan blue|during the surgery will be evaluated if the dye is suitable for dyeing anterior lens capsule
88915944|NCT01621815|Active Comparator|Anxiety and Depression|Adolescents diagnosed with anxiety and/or depression
88915945|NCT01621815|Active Comparator|ADD|Adolescents diagnosed with ADD (without hyperactive element)
88915946|NCT01621815|Active Comparator|ADHD, Behavioral|Adolescents diagnosed with ADHD (with hyperactivity), with or without behavioral problems
88915947|NCT01621815|Active Comparator|PDD|Adolescents diagnosed with PDD Spectrum Disorders
88915948|NCT01621815|Active Comparator|Control|Adolescents without a psychiatric diagnosis
88915949|NCT01621841||Glaucoma subjects|
88915950|NCT01621841||heathly subjects|
88915951|NCT01621867|Active Comparator|pGM169/GL67A (CFTR Gene/Lipid Vector)|
89435253|NCT06244030|No Intervention|Control Group|The control group will not be given any exercise other than their own wrestling training program.
89435254|NCT06241573|Experimental|Patients treated in Part I of parent trial 1368-0098 (NCT05819398)|
89435255|NCT06241573|Experimental|Patients treated in Part II of parent trial 1368-0098 (NCT05819398)|
89435256|NCT06241573|Experimental|Patients treated in parent trial 1368-0100|
89435257|NCT06236295|Experimental|SHR6508|
88915952|NCT01621867|Placebo Comparator|Placebo|
88915953|NCT01621893||BML of the Knee|Subject has single bone marrow lesion of tibia, single BML of femur, or adjoining BML's of tibia & femur on which a Subchondroplasty procedure is performed
88915954|NCT01621932|Active Comparator|Surgical approach 1|Direct anterior surgical approach with capsulectomy
88915955|NCT01621932|Active Comparator|Surgical approach 2|Direct anterior approach without capsulectomy
88915956|NCT01621945||Bras A|children, born between the 06/04/2004 and the 17/04/2008, living around Neufchatel en Bray, before the fourth dose of MenBVac
88915957|NCT01621958|Experimental|Motor training|
88915958|NCT01621958|Placebo Comparator|Intensity control|
88915959|NCT01621971|Experimental|milrinone inhalation|inhaled milirinone and IV placebo (0.9% normal saline 0.05 ml/kg) are administered in Group IH.
89435258|NCT06233578|Experimental|RADPAD|Each cardiac catheterization procedure utilizes the standard guideline directed radiation protocol and a single RADPAD will be placed on the patient. All employee participants will wear a radiation detection device at the level of the left side of the chest facing the radiation source over any the protective apron worn by the participant.
89435259|NCT06233578|No Intervention|No RADPAD|Each cardiac catheterization procedure utilizes the standard guideline directed radiation protocol and no RADPAD will be used. All employee participants will wear a radiation detection device at the level of the left side of the chest facing the radiation source over any the protective apron worn by the participant.
89435260|NCT06232499|Experimental|Red-Blue Arm|Participants in this arm first receive 10 sessions of vascular laser treatment with red light, followed by a two-month washout period, and then receive 10 sessions of vascular laser treatment with blue light.
88915960|NCT01621971|Active Comparator|intravenous milrinone|After performing the sternotomy and achieving stable hemodynamics, but before the initiation of CPB, inhaled placebo (distilled water) and an IV bolus of milrinone (50 μg/kg) are administered in Group IV
89435261|NCT06232499|Experimental|Blue-Red Arm|Participants in this arm first receive 10 sessions of vascular laser treatment with blue light, followed by a two-month washout period, and then receive 10 sessions of vascular laser treatment with red light.
89435262|NCT06231394|Active Comparator|daytime incontinence|This group will consist of participants who will be diagnosed with daytime incontinence by a pediatric urologist according to the International Children's Continence Society criteria.
89435263|NCT06231394|Active Comparator|nocturnal enuresis|This group will consist of participants who will be diagnosed with nocturnal enuresis by a pediatric urologist according to the International Children's Continence Society criteria.
89435264|NCT06231394|Active Comparator|combined daytime incontinence and nocturnal enuresis|This group will consist of participants who will be diagnosed with combined daytime incontinence and nocturnal enuresis by a pediatric urologist according to the International Children's Continence Society criteria.
89435265|NCT06230068|Other|Expressive writing|The intervention consists of expressive writing during 20 minutes. The writing should be of the breast cancer, the treatment or other related topics. The patient is invited to write once every week in a separate place. The intervention ends after four weeks. The written text is not collected.
89435266|NCT06229652|Experimental|RASMUS Resilience Training|RASMUS is a systematic, behavior-oriented group training in which the following methods are used: mindfulness exercises, exercises in self-compassion/guided meditations, knowledge transfer by means of a teaching talk/lecture, working out the topics in individual and small group work, group exercises, group discussion and exchange, train coping strategies: somatic, cognitive, and emotional levels, independent reflection on what has been learned, homework, weekly protocols, transfer to everyday life, questionnaires on resilience factors, mindfulness, and self-compassion for self-control, linking the course topics with one another.
89435267|NCT06229652|Active Comparator|Body-oriented Yoga|The body-oriented yoga classes following the Ashtanga style will run in parallel to the RAMUS resilience group (one-hour, once a week). The yoga instructor will support each participant in the form of verbal and hands-on assistance.
89435268|NCT06228768|Other|Acupressure Arm 1|There are 5 acupoints with 4 of the acupoints performed on both the left and right sides of the body. Each of the 9 acupoints will be stimulated for 3 minutes per point with the AcuWand giving a total treatment time of 27 minutes daily. The relaxation acupoints are unlisted in order to maintain blinding.
88915961|NCT01621984|Experimental|Therapeutic Riding/ Hippotherapy|12 week Therapeutic Riding program that focused on gross motor function, gross motor performance, balance, spasticity, posture and quality of life
89435269|NCT06228768|Other|Acupressure Arm 2|There are 5 acupoints with 4 of the acupoints performed on both the left and right sides of the body. Each of the 9 acupoints will be stimulated for 3 minutes per point giving a total treatment time of 27 minutes daily. The acupoints are unlisted in order to maintain blinding.
88915962|NCT01621984|No Intervention|without Therapeutic Riding/ Hippotherapy|
88915963|NCT01621997|Experimental|operation inspection|During retraining the patients performed bag exchange under the supervision of a nurse. The nurse ensured that each error listed in the NAC form should be avoided, thus immediately corrected any wrong steps if only.
88915964|NCT01621997|Experimental|verbal education|"Patients in the oral education group also underwent retraining every 2 months. A nurse would address all items in the NAC form one by one, to remind the patient of the key points of bag exchange. Scores calculated by the sum of error items during the bag exchange for patients in technique inspection group, or by the sum of yes in the interactive quiz for patients in verbal education group."
88915965|NCT01621997|Experimental|usual care|Patients in the usual care group did not receive any retraining
88915966|NCT01622023|Experimental|Study group|intrauterine insemination after 24 hours
89198357|NCT02564666|Active Comparator|Telephone counseling|regular telephone counseling per week
89198358|NCT02564666|No Intervention|No telephone counseling|no regular telephone counseling
88915967|NCT01622023|Active Comparator|Control group|intrauterine insemination after 48 hours
88915968|NCT01622036||Cancer patients undergoing first medical oncology visit.|
88915969|NCT01622049||TTTS treatment method|This is an observational trial. Patients who meet eligibility criteria and give written informed consent will have SLPCV. All subjects will receive ongoing standard-of-care prenatal care for the duration of their pregnancy from their referring perinatologist or obstetrician.
89435270|NCT06228664|Active Comparator|foam rolling|foam rolling along with conventional physical therapy treatment
89435271|NCT06228664|Experimental|bowen therapy|bowen therapy along with conventional physical therapy treatment
89435272|NCT06228183|Experimental|the experimental group|Study lasts 21 days for each patient. The patients were given comprehensive rehabilitation therapy. The experimental group was provided the support of enteral nutrition by Intermittent Oro-esophageal Tube Feeding.
89435273|NCT06228183|Active Comparator|the control group|Study lasts 15 days for each patient. The patients were given comprehensive rehabilitation. The control group was provided the support of enteral nutrition by Nasogastric Tube Feeding.
89435274|NCT06225557|Experimental|ERAS society guidlines|The ERAS society guidelines for elective cesarean section will be followed.
89435275|NCT06225557|Experimental|Traditional methods|Traditional methods in postoperative care for elective cesarean section will be followed.
89435276|NCT06225076|Experimental|The observation group|Patients enrolled are firstly numbered for privacy with software and divided into the observation group and the control group with. Additionally, the staffs involved in assessment would not participate in the intervention of the study. The treatment lasts 20 days.
89435277|NCT06225076|Active Comparator|The control group|Patients enrolled are firstly numbered for privacy with software and divided into the observation group and the control group with. Additionally, the staffs involved in assessment would not participate in the intervention of the study. The treatment lasts 20 days.
89531293|NCT05041881|Active Comparator|Trifocal IOL group|Patients implanted during cataract or refractive surgery with trifocal lens, which allowed to see for far, intermediate and near distance, but due to optic design having unwanted effect like optical phenomena and lower contrast sensitivity
88915970|NCT01622075|Experimental|SeQuent® Please|Paclitaxel Drug-eluting Coronary Artery Balloon Catheter
88915971|NCT01622075|Active Comparator|Taxus Liberte|Paclitaxel Drug-eluting Coronary Stent and Conveying System
88915972|NCT01622101|Experimental|zantrex|The test compound was administered as tablets. The Zantrex-3® compound contained yerba maté, caffeine, guarana, damiana, green tea, kola nut, schizonepeta, piper nigrum, ginseng, maca root, and cocoa nut. The content of xantines (caffeine and caffeine-like stimulants) accounted for 365 mg per serving (2 capsules).
88915973|NCT01622101|Placebo Comparator|Control|The placebo supplement contained rice flower and could not be distinguished from the Zantrex-3® compound with regard to colour, taste, smell or appearance.
88915974|NCT01622114|Experimental|Menstralean group|"Represents a program which is designed to induce weight loss by taking into account the physiology of each menstrual phase in terms of adjusting diet and physical activity to the body's cyclic changes in energy demands.~The diet will be adjusted to match one menstrual cycle in duration (approx. 1 month) and will be separated into three phases corresponding to three menstrual phases: menstruation (days 1-5), the follicular phase (days 6-14), and the luteal phase (days 15-28). All women in this group will start the program at day 1 in their cycle. The diet will be repeated six times for each woman, which equals six months."
88915975|NCT01622114|Active Comparator|Control Group:|"Represents a program where subjects engage in a similar diet and exercise program as the Menstralean Group, specifically based on the educational diet system Eat for Life. Importantly, the subjects in Control group will start the program at a random time in their menstrual cycles.~Eat for Life is a simple tool for controlling the energy content and nutritional composition of your diet. The method is based on a system of counters that ensure strict control of the diet whilst still allowing a great deal of freedom of choice. The subjects in the Control Group will also receive exactly the same attention and undergo the same visits and measurements as the Menstralean Group."
88915976|NCT01622153|Placebo Comparator|Formocresol (control)|This will consist of patients who are ASA I or II status, 3-8 years old, males and females, and present with restorable primary molars with reversible pulpitis and free of clinical radiographic signs of pulp pathology. From these study participants, they will be randomly assigned to this or other group. Patients in this group will receive a pulpotomy. Cotton pellets are saturated with conventional 1:5 dilution of Buckley's formocresol into the canal orifice for 5 minutes for complete hemostasis. IRM (Zinc Oxide Eugenol) cement will then be placed to seal the pulp chamber. A stainless steel crown will be cemented with Ketac Cement that was triturated for 10 seconds to complete the pulpotomy procedure and final restoration.
88915977|NCT01622153|Active Comparator|Laser|This will consist of patients who are ASA I or II status, 3-8 years old, males and females, and present with restorable primary molars with reversible pulpitis and free of clinical radiographic signs of pulp pathology. From these study participants, they will be randomly assigned to this or other group. Patients in this group will receive a pulpotomy. Then a GENTLEray 980 Soft Tissue diode laser (Power: 3.0W, Mode: PW, Fiber: 300µm, Ton: 100ms, Toff: 100ms, Timer: cont) will be used to vaporize the residual pulp tissue and complete hemostasis. IRM (Zinc Oxide Eugenol) cement is then placed to seal the pulp chamber. A stainless steel crown cemented with Ketac Cement for the full coverage final restoration completes the pulpotomy procedure.
88915978|NCT01622166|Experimental|art therapy|12 sessions of art therapy / 6 weeks
88915979|NCT01622166|No Intervention|TAU|treatment as usual / 6 weeks
88915980|NCT01622179|Experimental|Indirectly|The epitenon was repaired and sewed indirectly.
88915981|NCT01622179|Placebo Comparator|Directly|The epitenon was unrepaired and sewed directly.
88915982|NCT01622205|Experimental|Active|Early supported discharge
88915983|NCT01622205|Other|Control|Ordinary rehabilitation
88915984|NCT01622218|Experimental|Medical Clown|Presence of clowns on child's postoperative pain levels, anxiety levels of the child and the accompanying parent and the effect of the intervention on the total consumption of analgesics and on the post- surgery inflammatory markers.
88915985|NCT01622218|No Intervention|Control|Assessment of child's postoperative pain levels, anxiety levels of the child and the accompanying parent and the effect on the total consumption of analgesics and on the post- surgery inflammatory markers.
88915986|NCT01622244|Experimental|Intervention arm|Participants will receive brief, intensive case management to connect them to health and social services and supports in the community
88915987|NCT01622244|Active Comparator|Counseling and Resource Education (CARE)|Participants will receive care as usual in the community. In addition, participants in this arm will receive an educational session and resource guide outlining available community-based services
89198359|NCT00868023|Experimental|1|CHF 1535 DPI : BDP/Formo 400/24 µg
89198360|NCT00868023|Active Comparator|2|CHF 1535 pMDI HFA : BDP/Formo 400/24 µg
88915988|NCT01622283|Experimental|Levocetirizine oral solution 5 mg|Levocetirizine oral solution 5 mg
88915989|NCT01622283|Active Comparator|Cetirizine dry syrup 10 mg|Cetirizine dry syrup 10 mg
88915990|NCT01622309|Active Comparator|eggplant meal|13 g meal of eggplant/day
88915991|NCT01622309|Placebo Comparator|cassava meal|13 g of placebo/day
88915992|NCT01622361|Active Comparator|Chemotherapy Group|Chemotherapy Adriamycin+Cyclophosphamide>Docetaxel
88915993|NCT01622361|Experimental|Endocrine therapy group|Endocrine therapy(GnRHa with Tamoxifen) group
88915994|NCT01622374|Active Comparator|Silence|the subjects received 10 minutes of silence through headphone
88915995|NCT01622374|Experimental|Music for the mind|
88915996|NCT01622374|Experimental|Mozart music|
88915997|NCT01622374|Experimental|Iranian traditional music|
88915998|NCT01622387|Experimental|Radial artery|Use of the radial artery as a conduit in CABG surgery
88915999|NCT01622387|Active Comparator|Long saphenous vein|Use of long saphenous vein as a conduit in CABG surgery
88916000|NCT01622400|Experimental|Therapeutic education HTA Vasc|125 subjects who participate in the therapeutic education program
89198361|NCT00868023|Experimental|3|CHF 1535 DPI : BDP/Formo 100/6 µg
89198362|NCT00868023|Active Comparator|4|CHF 1535 pMDI HFA : BDP/Formo 100/6 µg
89198363|NCT00868023|Placebo Comparator|5|Placebo
89198364|NCT05300386||generalized anxiety with oxygen desaturation index less than 5|we enrolled patients with generalized anxiety with oxygen desaturation index of less than 5 and examed the basic physical conditions and the effectiveness of antidepressant treatment.
88916001|NCT01622400|No Intervention|Control group|125 subjects who don't participate in the therapeutic education program
88916002|NCT01622413|Experimental|Endscopy|
88916003|NCT01622413|Active Comparator|Microsurgery|
88916004|NCT01622426|Active Comparator|New formula IgE mediated testing|Children with IgE-mediated CMA performed oral food challenge with the new formula
88916005|NCT01622426|Active Comparator|New formula non-IgE-mediated testing|Children with non-IgE-mediated CMA performed oral food challenge with the new formula
88916006|NCT01622439|Experimental|Single, open labeld.|
88916007|NCT01622465|Experimental|Ergometer cycling|Patients will participate of the exercises program with ergometer cycling and conventional exercises.
88916008|NCT01622465|Active Comparator|Conventional exercises|Patients will participate only of the conventional exercises program.
88916009|NCT01622478||Clinically node-positive patients before NAC|"Patients with clinically positive lymph node receiving neoadjuvant chemotherapy~Clinically negative-node after NAC~Clinically positive-node after NAC"
88916010|NCT01622491||Case control|A case-control study with cases (individuals hospitalized with influenza or pneumonia during the second wave of the pandemic) and controls (non-hospitalized individuals) identified using the MH Hospital Separation Abstract Database and the MH Population Registry, respectively. Information on receipt of vaccines will be obtained by record linkage to the MIMS.
88916011|NCT01622504|Experimental|Test Product Dose 1|
88916012|NCT01622504|Experimental|Test Product Dose 2|
88916013|NCT01622504|Active Comparator|Comparator Product|
88916014|NCT01622530||Amputees|upper limb amputees
88916015|NCT01622530||Non-amputees|No longer recruiting non-amputees
88916016|NCT01622556|Experimental|Reduced Intensity Conditioning with UCB Transplant|
88916017|NCT01622608|Experimental|Kiosk Users|
88916018|NCT01622608|No Intervention|Non-Kiosk Users|
88916019|NCT01622621|Active Comparator|Randomized Sublobar Resection|Randomized by computer to receive a sublobar resection.
88916020|NCT01622621|Active Comparator|Randomized SBRT|Randomized by computer to receive Stereotactic Body Radiotherapy (SBRT).
88916021|NCT01622621|Active Comparator|Observation Sublobar Resection|Patient decides with doctor to undergo a sublobar resection.
88916022|NCT01622621|Active Comparator|Observation SBRT|Patient decides with doctor to undergo SBRT.
88916023|NCT01622634|Active Comparator|Higher Protein Diet (PRO)|
88916024|NCT01622634|Active Comparator|Higher Carbohydrate Diet (CARB)|
88916025|NCT01622634|Active Comparator|PRO & Interval Exercise (PRO+EX)|
88916026|NCT01622634|Active Comparator|CARB & Interval Exercise (CARB+EX)|
88916027|NCT01622647|Active Comparator|NCPAP Group|Group of patients that do receive NCPAP treatment
88916028|NCT01622647|No Intervention|No NCPAP|subjects will not receive NCPAP
88916029|NCT01622686|No Intervention|Traditional prescription drug labels|Routine drug labels provided by the participating pharmacies
88916030|NCT01622686|Experimental|Reformatted medication labels|Prescription drug container labels that follow a new format and also include illustrations
88916031|NCT01622764|Experimental|Molecular imaging with 89Zr-RO5323441|
88916032|NCT01622777|Experimental|Rosuvastatin|20 mg daily of oral rosuvastatin
88916033|NCT01622777|Placebo Comparator|Placebo|
88916034|NCT01622790|Experimental|Arm 1|33 subjects will receive a single dose of each of a tablet formulation of dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg in Period 1followed by dolutegravir 50 mg plus EPZICOM (abacavir 600mg/lamivudine 300 mg) in Period 2. Approximately 6 of these subjects will return for a third period where they will receive a single dose of dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg after a high fat breakfast. There will be a screening visit within 30 days prior to first dose and a follow-up visit 7-14 days after the last dose.
88916035|NCT01622790|Experimental|Arm 2|33 subjects will receive dolutegravir 50 mg plus EPZICOM (abacavir 600mg/lamivudine 300 mg) in Period 1 followed by a single dose of a tablet formulation of dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg in Period 2. Approximately 6 of these subjects will return for a third period where they will receive a single dose of dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg after a high fat breakfast. There will be a screening visit within 30 days prior to first dose and a follow-up visit 7-14 days after the last dose.
88916036|NCT01622803|Active Comparator|parallel stent|parallel stent insertion group
88916037|NCT01622803|Active Comparator|Y-stent|Y-stent insertion group
88916038|NCT01622829|Experimental|group1|"Usual Physiotherapy, additional: Prescription for Activity with a structured fitness program and individual instructions to become more active in the daily living situation"
88916039|NCT01622829|Experimental|group 2|"usual Physiotherapy , additional: Prescription for Activity without instructions"
88916040|NCT01622829|No Intervention|group 3|control, usual physiotherapy
88916041|NCT01622842||Bioimpedance|8 females and 8 males BMI from 19 to 46 SBP from 119 to 182
88916042|NCT01622855|Experimental|PPRS video|Prevention of post sexual assault stress
88916043|NCT01622855|No Intervention|Standard care|Receipt of standard services
88916044|NCT01622881|Active Comparator|Nefopam|
88916045|NCT01622881|Placebo Comparator|Control|
88916046|NCT01622907||Pts Symptomatic Recurrent Persistent AF|Patients with Symptomatic Recurrent Persistent AF or Long standing AF,for > 1-year < 5 years duration
88916047|NCT01622920|Other|ultrasound enamel thickness measurements|Enamel thickness will be measured with ultrasound
88916048|NCT01622933|Experimental|Vaccine + IFN|"Subjects will receive the investigational vaccine, intradermally, every other week for a total of 3 vaccines. Approximately 30 days after the last vaccine subjects will receive IFN intravenously 5 days a week for 4 weeks.~Leukapheresis will be required to be performed for each subject to be able to produce the investigational vaccine and for research testing. Leukapheresis and biopsies will be performed before the first vaccine, after the 3rd vaccine, and after the IFN treatment."
88916049|NCT01622933|Experimental|Vaccine only|"Subjects will receive the investigational vaccine, intradermally, every other week for a total of 3 vaccines.~Leukapheresis will be required to be performed for each subject to be able to produce the investigational vaccine and for research testing. Leukapheresis and biopsies will be performed before the first vaccine, after the 3rd vaccine, and again approximately 2 months after the last vaccine."
88916050|NCT01622946|Active Comparator|Placebo|The patients who receive placebo form the control group. The results can be compared with the results of the patients who did receive TXA
88916051|NCT01622946|Placebo Comparator|Tranexamic acid|The patients will receive 3g topical TXA for 15 minutes or 2 hours after THA. 33% of the patients will receive 3g of TXA trough a suction drain for 15 minutes after total hip arthroplasty, then the suction drain is opened. 33% will receive the same amount of TXA but the suction drain will only be opened 2 hours after application. The other patients will receive a placebo in the same manner
88916052|NCT01622959|Active Comparator|acupuncture|"Inclusion criteria:~Traumatic and non traumatic acute pain with visual analog pain scale ( VAPS) > 40 (on a scale 0-100) Age ≥18 years Presigned consentement to participate in the study.~Exclusion criteria:~Temperature > 37.7° C, Anticoagulation medication use or the presence of a mechanical heart valve, Skin infections that would preclude certain acupuncture points being used, Refusal, inability to consent or communication difficulties, Acute major trauma, Any form of analgesia up to 60 minutes prior to study start, An initial pain score ≤ 40 on the pain scale (score range 0-100), Opiate contraindication, Pregnancy, Presentation to the ED > 4 times in the previous 3 months with the same condition."
88916053|NCT01622959|Sham Comparator|morphine|drug:5mg of morphine followed by intravenous administration of 2,5 mg morphine each 5 min, until VAPS becomes <30%.
89435278|NCT06224517||Patients of ischemic stroke|Inclusion criteria are as follows: first-onset cerebral ischemic stroke within the previous 3 months, which is confirmed clinically by computed tomography scans or magnetic resonance imaging; sufficient cognition to understand procedures and provide informed consent. Exclusion criteria are as follows: hemorrhagic stroke, cerebellar or brainstem lesions which may affect autonomic or balance; concurrent neurological or neurodegenerative diseases (e.g. Parkinson's disease, multiple sclerosis, etc.), brain tumor, malignancy, limb deficiency or amputation.
89435279|NCT06222710|Experimental|Patients with ultrasound-guided pharmacoacupuncture|20 patients with ultrasound-guided pharmacoacupuncture
89435280|NCT06222710|Active Comparator|Patients with blind pharmacoacupuncture|20 patients who treat pharmacoacupuncture without checking ultrasound images
89435281|NCT06221930|Experimental|attexis + TAU|"Participants allocated to the intervention group will receive access to attexis in addition to treatment as usual (TAU).~attexis is a digital health application designed for individuals with adult attention deficit hyperactivity disorder (ADHD), accessible through a web browser. The application focuses on treatment methods derived from cognitive behavioral therapy (CBT). Topics addressed by attexis are attention, self-image, impulsivity and physical exercise, problem-solving strategies, and resources.~The program operates through interactive dialogues, which are accompanied by illustrations, audio recordings, motivational text messages, worksheets, and summaries. Users are also encouraged to regularly complete short questionnaires to monitor their complaints. Once registered, the program remains accessible for 180 days."
89435282|NCT06221930|No Intervention|TAU|Participants allocated to the control group will receive access to treatment as usual (TAU).
89435283|NCT06220461|Experimental|Experimental group|Oral folic acid 50 mcg daily starts at 14 days of age
89435284|NCT06220461|No Intervention|Control|No additional folic acid supplementation
88916054|NCT01622972|Experimental|Group 1|Healthy volunteers in Group 1: To give sachet's A and B made up to 1 litre with tap water once on day 1 and once on day 2
88916055|NCT01622972|Experimental|Group 2|Healthy volunteers in group 2: To give 2x sachet's A and B made up to 2 litres with tap water on day 1.
88916056|NCT01622972|Experimental|Group 3|Patients with functional constipation and irritable bowel syndrome characterized by constipation: To give sachet's A and B made up to 1 litre with tap water once on day 1
88916057|NCT01623011|Experimental|Arthroscopic Sub-acromial Decompression|Arthroscopic sub-acromial decompression surgery.
88916058|NCT01623011|Active Comparator|Shoulder Arthroscopy|Shoulder arthroscopy only.
88916059|NCT01623011|Other|Active Monitoring with Specialist Reassessment|Active monitoring with specialist reassessment - non-operative control.
88916060|NCT01623024|Experimental|Vitamin D and Lifestyle counseling|
88916061|NCT01623024|Active Comparator|Lifestyle counseling|
88916062|NCT01623063|Experimental|Infertile|patients from our human reproduction center
88916063|NCT01623063|Active Comparator|Fertile|patients with comproved fertility
88916064|NCT01623089||severe asthma|
88916065|NCT01623102|Experimental|Arm I: bevacizumab plus chemotherapy|Patients in the experimental arm receive cisplatin and gemcitabine combination with Bevacizumab. GP chemotherapy (gemcitabine 1250mg/m2 IV D1 and D8 plus cisplatin 75mg/m2 IV D1, every 21-day cycle) plus bevacizumab (7.5 mg/kg IV on D1 of every 21-day cycle).
88916066|NCT01623102|Active Comparator|Arm II: chemotherapy|Patients receive gemcitabine combined with cisplatin chemotherapy((gemcitabine 1250mg/m2 IV D1 and D8 plus cisplatin 75mg/m2 IV D1, every 21-day cycle) ) every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
88916067|NCT01623128|Experimental|Breastfeeding video|Participants randomized to this arm view the intervention video - Injoy Videos Better Breastfeeding video.
88916068|NCT01623128|Placebo Comparator|Sham video|Participants randomized to this arm view the sham video Injoy Videos Your Healthy Pregnancy: Prenatal Nutrition and Exercise video.
88916069|NCT01623141||Patients with CRPS|18 patients with unilateral CPRS of the upper limb were included to the study
88916070|NCT01623141||Patients with limb pain of other origin|17 patients with unilateral upper limb pain of other origin served as control group
88916071|NCT01623141||Healthy subjects|18 healthy subjects were included to establish reference data for the pressure pain thresholds
88916072|NCT01623180|Experimental|BioFreedom™ Drug Coated Stent (DCS)|BA9 drug coated stent implantation for improving coronary luminal diameter in patients with de novo lesions in native coronary arteries with a reference vessel diameter between 2.25 mm and 4.0 mm.
88916073|NCT01623180|Active Comparator|Gazelle™ Bare Metal Coronary Stent (BMS)|GAZELLE™ bare metal stent implantation for improving coronary luminal diameter in patients with de novo lesions in native coronary arteries with a reference vessel diameter between 2.25 and 4.0 mm.
88916074|NCT01623206|Experimental|Desmopressin|Four dose levels and two dosing schedules with 3 patients in each group.
88916075|NCT01623219|Experimental|TeleMedicine Prolonged Exposure|Veterans will receive prolonged exposure therapy (PE)delivered via telemedicine instead of in person. For this study 9 weekly 90 minute sessions will be given over a period of up to 3 months. The first 2 sessions of each treatment will involve education, rational and treatment preparation. Sessions 3-9 will consist of recounting the traumatic event out loud and repeatedly. The purpose of this study is to determine if this treatment is effective when given through telehealth.
88916076|NCT01623232|Experimental|adjuvant plus 1 �g of HA antigen|MAS-1-adjuvant-formulated influenza vaccine, at three HA antigen dose levels containing 1 �g of HA antigen
88916077|NCT01623232|Experimental|adjuvant plus 3 �g of HA antigen|MAS-1-adjuvant-formulated influenza vaccine, at three HA antigen dose levels containing 3 �g of HA antigen
88916078|NCT01623232|Experimental|adjuvant plus 5 �g of HA antigen|MAS-1-adjuvant-formulated influenza vaccine, at three HA antigen dose levels containing 5 �g of HA antigen
88916079|NCT01623232|Active Comparator|licensed influenza vaccine|licensed, inactivated, standard dose influenza vaccine without adjuvant
88916080|NCT01623245||Hypertrophic Cardiomyopathy|In the population of Hypertrophic Cardiomyopathy patients, patients suffering from a cardiac amyloidosis
88916081|NCT01623258||Standard of Care|Standard histopathological evaluation using conventional paraffin embedding, sectioning and hematoxylin and eosin staining and microscopy without sentinel lymph node ultrastaging
89435285|NCT06220292|Experimental|The observation group|During the 15-day treatment, both groups of patients are hospitalized, while conventional care and enteral nutrition support are provided to the two groups. The observation group receives Intermittent Oral-esophageal Tube Feeding for enteral nutrition support
89435286|NCT06220292|Active Comparator|The control group|During the 15-day treatment, both groups of patients are hospitalized, while conventional care and enteral nutrition support are provided to the two groups. The control group receives Nasogastric Tube Feeding for enteral nutrition support
89435287|NCT06220136||single group|rocuronium drug administration TOFscan monitoring administration of sugammadex drug recording of classical TOF and modified TOF values
89435288|NCT06219694|Experimental|laser acupuncture|CM patients with unsatisfactory pharmacological effects receive laser acupuncture for 8 sessions that spanned 4 weeks. Laser stimulation energy of 4.5 J for 30 seconds at each of the following acupoints: bilateral Cuanzhu (BL2), Fengchi (GB20), Taiyang (EX-HN5), Shuaigu (GB8), Hegu (LI4), Taichong (LR3) and midline Yintang (EX-HN3)
89435289|NCT06219694|Sham Comparator|Sham treatment|CM patients with unsatisfactory pharmacological effects receive sham treatment for 8 sessions that spanned 4 weeks. Sham treatment had no laser output.
89435290|NCT06219187||Male breast cancer|
89435291|NCT06218355|Active Comparator|Intensive Education|"Women enrolled in the intensive education care model participate in intensive in-person education as well as ongoing virtual education via the electronic health record web portal in the form of strategically timed pushes of relevant and digestible educational elements via a Care Companion. These virtual education pushes will include to do list reminders to check vital signs and submit them for review to the care team. Positive reinforcement will be provided when tasks are completed."
89435292|NCT06218355|Active Comparator|Enhanced Virtual Care|"Women in the enhanced virtual care model will receive scheduled telehealth visits on the platform of their choice - either via video or audio-only synchronous visits. Patients in the virtual care model will check vital signs with home devices during the telehealth visit and report them directly to the provider. This pull approach to data collection directly contrasts with the push approach of comparator #1."
89435293|NCT06215859|Experimental|MR-107A-02|15 mg Twice daily (BID) during in patient phase (0-48 hours following randomization) 15 mg BID dosing morning and evening, during out patient phase (5 days) .
89435294|NCT06215859|Active Comparator|Tramadol|"50 mg, administered every 6 hours (q6h) during the in patient phase (0-48 hours following randomization).~Placebo will be administered during out patient phase."
88916082|NCT01623258||Research|SOC with sentinel lymph node analysis
89198365|NCT05300386||generalized anxiety with oxygen desaturation index more than 5|we enrolled patients with generalized anxiety with oxygen desaturation index of more than 5 and examed the basic physical conditions and the effectiveness of antidepressant treatment.
88916083|NCT01623284|Experimental|PiB and FDG positron emission tomography (PET)|All subjects will receive PiB and FDG PET diagnosis on approximately day 1 or day 2 of study to determine if they have beta-amyloid deposits in their brains.
88916084|NCT01623297||Laparoscopic colon surgery|Patients over age 65 having laparoscopic colon resection for colonic adenocarcinoma
88916085|NCT01623297||Open colon surgery|Patients over age 65 having open colon resection for colonic adenocarcinoma
88916086|NCT01623336|Active Comparator|Pegasys ®|Patients will receive Pegasys ® (peginterferon alfa-2a 40kDa) at a dose of 180 micrograms, subcutaneously, once a week, associated with ribavirin at a dose 1000-1250 mg,daily. For genotype 1 treatment time is 48 to 72 weeks and for genotypes 2 and 3, 24 weeks.
88916087|NCT01623336|Experimental|BIP 48 (Peginterferon alfa 2b 48kDA)|Patients will receive BIP 48, 180 micrograms a week, SC, for the same period as Pegasys ®.
88916088|NCT01623349|Experimental|Arm BKM|BKM120 and Olaparib
88916089|NCT01623349|Experimental|Arm BYL|BYL719 and Olaparib
88916090|NCT01623362|Experimental|Low-fluoride acidic dentifrice|
88916091|NCT01623362|No Intervention|Conventional dentifrice|1100µgF/g-pH7.0
88916092|NCT01623362|Experimental|neutral pH and low-fluoride dentifrice|550 ppm pH 7
89435295|NCT06215859|Placebo Comparator|Placebo|Placebo is administered every 6 hours (q6h) during the in patient phase (0-48 hours following randomization) and twice daily during the out patient phase.
89435296|NCT06215820|Experimental|MR-107A-02|15 mg Twice daily (BID) during in patient phase (0-48 hours following randomization) 15 mg BID dosing morning and evening, during out patient phase (5 days) .
88916093|NCT01623375|Experimental|s.c.|
88916094|NCT01623375|Experimental|i.v.|
88916095|NCT01623388||Phase I|
88916096|NCT01623401|Experimental|TR-701 FA|TR-701 FA 200 mg oral once daily
88916097|NCT01623414||Healthy schoolchildren|
88916098|NCT01623427|Experimental|Vacuum|the group of patients assigned to application of vacuum to the wound dressing
88916099|NCT01623427|Active Comparator|Control|The dressing for the umbilical port site will be the same as the experimental group, except for the application of vacuum. The control group will have no vacuum applied to the wound dressing.
88916100|NCT01623440||Placebo/Naltrexone and fMRI|A placebo or Naltrexone will be given before fMRI. All participants will undergo both procedures. Naltrexone/placebo are not used as an intervention.
88916101|NCT01623453||Low dose group|Group1. Low dose group
88916102|NCT01623453||High dose group|Group2. High dose group
88916103|NCT01623492||diagnosis of Eisenmenger Syndrome|subjects with diagnosis of Eisenmenger Syndrome
88916104|NCT01623505|Experimental|Champix|
88916105|NCT01623505|Experimental|Long & Combination patch treatment|
88916106|NCT01623505|Experimental|Standard patch treatment|
88916107|NCT01623518|Experimental|ChAdOx1-NP+M1|
88916108|NCT01623544||Symbicort|BFC patients new to ICS/LABA combination therapy
88916109|NCT01623544||Advair|FSC patients new to ICS/LABA combination therapy
88916110|NCT01623557|Active Comparator|Group 1: ChAd63-MVA CS|1 dose of ChAd63 CS 5 x 10^10 vp intramuscularly and 1 dose MVA CS 2 x 10^8 pfu intramuscularly 8 weeks later.
89435297|NCT06215820|Active Comparator|Tramadol|"50 mg, administered every 6 hours (q6h) during the in patient phase (0-48 hours following randomization).~Placebo will be administered during out patient phase."
88916111|NCT01623557|Active Comparator|Group 2: ChAd63-MVA ME-TRAP|1 dose of ChAd63 ME-TRAP 5 x 10^10 vp intramuscularly and 1 dose MVA ME-TRAP 2 x 10^8 pfu intramuscularly 8 weeks later.
88916112|NCT01623557|Active Comparator|Group 3: Unvaccinated Infectivity Controls|
88916113|NCT01623570|Experimental|Pergoveris: 150IU r-hFSH+ 75IU r-hLH|This is a prospective randomized study using two in-label treatments for the patient disease: Pergoveris and Menopur. Pergoveris arms can be considered as experimental for the aim of the study, anyway it is standard routine practice for HH women.
88916114|NCT01623570|Experimental|Menopur: hMG-HP (150IU)|This is a prospective randomized study using two in-label treatments for the patient disease: Pergoveris and Menopur. Menopur can be considered as experimental for the aim of the study, anyway it is standard routine practice for HH women
88916115|NCT01623583|Experimental|Enhanced Needle Phobia Intervention|Patients will receive enhanced needle phobia intervention comprising the standard intervention plus demonstration of Synera
88916116|NCT01623583|Active Comparator|Standard Needle Phobia Intervention|Patients will receive the standard intervention for needle phobia
88916117|NCT01623609|Experimental|A|Naloxol IR tablet 25 mg (naloxegol oxalate) commercial formulation under fasted conditions
88916118|NCT01623609|Experimental|B|Naloxol IR tablet 25 mg (naloxegol oxalate) commercial formulation under fed conditions
88916119|NCT01623609|Experimental|C|Naloxegol film-coated IR tablet 25 mg Phase III formulation under fasted conditions
88916120|NCT01623622|Experimental|HC-58 low dose|Low dose
88916121|NCT01623622|Experimental|HC-58 high dose|High dose
88916122|NCT01623622|Placebo Comparator|Placebo|
88916123|NCT01623635|Experimental|Case - adnexal|
88916124|NCT01623635|Placebo Comparator|placebo - adnexal|
88916125|NCT01623635|Experimental|case - uterine|
88916126|NCT01623635|Placebo Comparator|placebo - uterine|
88916127|NCT01623648|Experimental|Arm 1 Whey Breakfast|The arm 1 will be assigned to eating Whey protein in the breakfast (660 kcal), lunch (560 cal) and dinner (280 cal), with 42 g protein namely from whey at breakfast
88916128|NCT01623648|Active Comparator|Arm 2: No Whey Breakfast|The arm 2 will be assigned to intake other proteins (No Whey) in the breakfast (660 kcal), lunch (560 cal) and dinner (280 cal), with 42 g protein from other sources at breakfast
88916129|NCT01623648|Placebo Comparator|Arm 3: Low Protein Breakfast|The arm 3 will be assigned to intake low protein and high carbohydrate breakfast (660 kcal), lunch (560 cal) and dinner (280 cal), with 22 g protein from other sources at breakfast
88916130|NCT01623661|Other|hypertonic saline|hypertonic saline 3.0% (7 ml/kg)
88916131|NCT01623687|Active Comparator|Regenerex|
88916132|NCT01623687|Active Comparator|Lub cup|
88916133|NCT01623687|Active Comparator|SP II|
88916134|NCT01623687|Active Comparator|Corail|
88916135|NCT01623700||dual antiplatelet treatment 12 months after ACS event|
88916136|NCT01623700||dual antiplatelet treatment 6 months after ACS event|
88916137|NCT01623700||dual antiplatelet treatment 3 months after ACS event|
88916138|NCT01623713|Active Comparator|Risperidone|
88916139|NCT01623713|Experimental|iloperidone|
88916140|NCT01623726|Experimental|tDCS active|Active tDCS as foreseen in research protocol: daily sessions for 10 days with 2mA intensity stimulation during 20 minutes.
88916141|NCT01623726|Placebo Comparator|tDCS sham|Sham tDCS : as foreseen in research protocol: sham stimulation with initial stimulation followed by turning off the device during the same time of intervention as to guarantee blinding
88916142|NCT01623778||Add on ADV|Patients with inadequate response to interferon at 24 weeks received interferon add on ADV optimized therapy
89435298|NCT06215820|Placebo Comparator|Placebo|Placebo is administered every 6 hours (q6h) during the in patient phase (0-48 hours following randomization) and twice daily during the out patient phase.
89010129|NCT02214316|Experimental|Interventional 1|Interventional experimental arm with hypertonic saline
89010130|NCT04555876|Experimental|high tone external muscle stimulation|"- HiTop 191 appliance (gbo Medizintechnik AG, Rimbach, Germany) Device HiToP® 4 touch gbo Medizintechnik AG, this modern high-tech design with brushed aluminum surface and the 15 TFT LC D full color touch screen monitor offer to the health care professional an indispensable feature."
89435299|NCT06215794|Experimental|the experimental group|The study lasts 20d for each patient. During the treatment, All the participants are provided with the rehabilitation therapy. Based on this, the patients in the experimental group are provided with Stellate Ganglion Block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g), once a day.
89435300|NCT06215794|Active Comparator|the control group|The study lasts 20d for each patient. During the treatment, All the participants are provided with the rehabilitation therapy.
89435301|NCT06215742|Experimental|the experimental group|The study lasts 20d for each patient. During the treatment, All the participants are provided with the rehabilitation therapy. Based on this, the patients in the experimental group are provided with Stellate Ganglion Block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g), once a day.
89435302|NCT06215742|Active Comparator|the control group|The study lasts 20d for each patient. During the treatment, All the participants are provided with the rehabilitation therapy.
89435303|NCT06215729|Experimental|the experimental group|In this study, each patient received a continuous 15-day treatment. During the treatment, both groups of patients received routine rehabilitation treatment. The experimental group additionally underwent computer-assisted cognitive training, which generated training content of corresponding difficulty based on the patient's cognitive impairment assessment results. The training was conducted seven days a week, once a day, for a duration of 30-45 minutes per session.
89435304|NCT06215729|Active Comparator|the control group|In this study, each patient received a continuous 15-day treatment. During the treatment, both groups of patients received routine rehabilitation treatment.The control group was given conventional cognitive training.
89435305|NCT06213675|Experimental|the experimental group|The patients receive a 15-day treatment and are required to stay in the hospital during this period. Patients in the experimental group are given routine rehabilitation treatment and intra-articular injections. Lidocaine is used as the injected medication at a dose of 2ml, administered once every 5 days for a total of three injections.
89435306|NCT06213675|Active Comparator|The control group|The patients receive a 15-day treatment and are required to stay in the hospital during this period. Patients are given routine rehabilitation treatment.
89435307|NCT06213181|No Intervention|Control Group|Participants assigned to this group will receive general advice about the positive effects of regular physical activity. They will be given a guide of physical exercise recommendations, according to the World Health Organization for people over 65 years of age.
89435308|NCT06213181|Experimental|Mindfulness intervention|Participants assigned to this group will receive a mindfulness-based intervention for eight weeks with a weekly session lasting two hours per session. It is an experimental and interactive program that includes conscious movements, meditation, practical activities on attention in the present moment and the search for strategies to face complex situations from the collective and individual level. Participants will carry out daily practices at home during the week with the resources shared in each session.
89435309|NCT06212869|Experimental|tDCS Group|active tDCS with the prescribed medications for 20 minute. The intervention will conduct 3 consecutive days in a week.
89435310|NCT06212869|Sham Comparator|Sham tDCS Group|sham tDCS with the prescribed medications for 20 minute. The intervention will conduct 3 consecutive days in a week.
89435311|NCT06212869|Experimental|Green Light Group|green light exposure with the prescribed medications for 1-2 hour. The intervention will conduct 5 days in a week.
89435312|NCT06211777|Experimental|the observation group|Study lasts 15 days for each patient. The patients were given comprehensive rehabilitation therapy. The observation group was provided the support of enteral nutrition by Intermittent Oro-esophageal Tube Feeding.
89010131|NCT04555876|Experimental|stationary bicycle|supervised regular aerobic exercise program on stationary bicycle with moderate intensity, (score 12-14 on Borg scale for rate of perceived exertion) 40 minutes per session, 3 times per week, for 10 weeks.
89435313|NCT06211777|Active Comparator|the control group|Study lasts 15 days for each patient. The patients were given comprehensive rehabilitation. The observation group was provided the support of enteral nutrition by Nasogastric Tube Feeding.
89435314|NCT06211426|Experimental|the experimental group|All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy, to promote the development of motor and cognitive function, as well as to improve intellectual development. Besides, swallowing function training was also provided, including direct training, indirect training, and compensatory training.The experimental group was given Stellate Ganglion Block.
89435315|NCT06211426|Active Comparator|the control group|All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy, to promote the development of motor and cognitive function, as well as to improve intellectual development. Besides, swallowing function training was also provided, including direct training, indirect training, and compensatory training.
89010132|NCT02212444|Experimental|Dynamic elastomeric fabric orthoses (DEFO)|The DEFO will be provided after taking the baseline measures and orthoses measurements at the baseline session ~ 3 weeks later. The orthoses will be supplied via post and used for a period of 12 weeks.
89198366|NCT01050127|Experimental|Low dose ABT-436|ABT-436 or placebo administered once daily for 7 days.
89536403|NCT02446795|Placebo Comparator|Placebo Arm|Phase I Sunitinib: 50mg once daily orally schedule treatment according to Investigator's choice Placebo: 225mg twice a day (at 08 a.m. and at 4 p.m). Phase II Sunitinib: 50mg once daily orally schedule treatment according to Investigator's choice Placebo: 450 mg twice a day (at 08 a.m. and at 4 p.m).
89435316|NCT06206538|Experimental|The observation group|"The study lasted 20d for each patient. During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.~Particularly, due to dysphagia, the patients enrolled might face difficulty in eating. For patients who were able to finish intake via mouth by compensatory means, the consistency, type, and size of food bolus was arranged. For those who cannot acquire sufficient nutrition through oral intake, the nasogastric tube feeding (NGT) was provided.~Based on the invention above, the patients in the observation group were provided with stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g)"
89435317|NCT06206538|Active Comparator|The control group|"The study lasted 20d for each patient. During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.~Particularly, due to dysphagia, the patients enrolled might face difficulty in eating. For patients who were able to finish intake via mouth by compensatory means, the consistency, type, and size of food bolus was arranged. For those who cannot acquire sufficient nutrition through oral intake, the nasogastric tube feeding (NGT) was provided."
89435318|NCT06206122|Experimental|The observation group|"Assigned by the random number table. During the treatment, all patients were provided with comprehensive rehabilitation therapy as follows:~Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training.~The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube Feeding"
89435319|NCT06206122|Active Comparator|The control group|"Assigned by the random number table. During the treatment, all patients were provided with comprehensive rehabilitation therapy as follows:~Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training.~Besides, the control group was given enteral nutritional support with Nasogastric Tube Feeding according to the relevant guidelines."
89435320|NCT06202807|Experimental|the observation group|"Assigned randomly before the treatment, all patients were provided with comprehensive rehabilitation therapy as follows:~Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training.~The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure. The feeding content was formulated by the nutritionists based on the condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups"
89435321|NCT06202807|Active Comparator|the control group|"Assigned randomly before the treatment, all patients were provided with comprehensive rehabilitation therapy as follows:~Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training.~Besides, the control group was given enteral nutritional support with Nasogastric Tube according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements."
89435322|NCT06199778|Experimental|the observation group|Both groups of patients were provided with routine treatments, including pharmacological treatment, rehabilitation therapy.Based on this, the patients in the observation group were given enteral nutrition support with Intermittent Oro-esophageal Tube Feeding (Medical Device No. 20010234, developed by the Swallowing Disorders Research Institute of Zhengzhou University).
89198367|NCT01050127|Experimental|Mid Dose ABT-436|ABT-436 or placebo administered once daily for 7 days.
89198368|NCT01050127|Experimental|High Dose ABT-436|ABT-436 or placebo administered once daily for 14 days.
89198369|NCT00955396|Other|Period 1|
89435323|NCT06199778|Active Comparator|the control group|Both groups of patients were provided with routine treatments, including pharmacological treatment, rehabilitation therapy. The patients in the control group were provided nutrition support with Nasogastric tube feeding , while the feeding process strictly followed the relevant guideline
89435324|NCT06199375|Experimental|modified mirror therapy+Modified mirror therapy|The study lasted 30 days for each participant. The patients enrolled were randomly divided into the experimental group and the control group, all under routine rehabilitation therapy. Additionally, the patients in the experimental group were given modified mirror therapy.
89435325|NCT06199375|Active Comparator|routine rehabilitation therapy|The study lasted 30 days for each participant. The patients enrolled were randomly divided into the experimental group and the control group, all under routine rehabilitation therapy.
89435326|NCT06198153|Active Comparator|Stationary Cycling|This group will receive stationary cycling for 6 weeks.
89435327|NCT06198153|Experimental|Progressive Functional Training|This group will receive Progressive Functional Training programs for 6 weeks.
89435328|NCT06198101|Active Comparator|myofascial release technique|This group receive Myofascial Release Technique
89435329|NCT06198101|Experimental|Myofascial Release Technique along with segmental massage vibrator|this group receive Myofascial Release Technique along with segmental massage vibrator
89010133|NCT02212444|Active Comparator|Off-the-self orthotics|Off-the-shelf-Orthotics: Patients in the usual care group will be referred for off -the-shelf triplanar orthoses as indicated by a biomechanical assessment of foot posture while standing / walking on visit 1. The off the shelf orthotic will be provided after taking the baseline measures and orthoses measurements at the baseline session ~ 3 weeks later. The orthoses will be supplied via post and used for a period of 12 weeks.
89010134|NCT04549012|Active Comparator|group A|will receive oxytocin
89435330|NCT06196073|Experimental|Visceral osteopathy and conservative treatment|Osteoaptic manual treatment techniques
89010135|NCT04549012|Active Comparator|group B|will receive tranexamic acid plus oxytocin
89435331|NCT06196073|Experimental|conservative treatment|Nutritional supplements
89435332|NCT06193603|Experimental|True dry cupping therapy|Participants in the true dry cupping therapy group, who have chronic non-specific low back pain, will receive a combination of dry cupping therapy and routine physiotherapy. During the dry cupping therapy sessions, two cups will be applied to the lumbar region and moved in an up-down and down-up direction.
89435333|NCT06193603|Sham Comparator|Sham cupping therapy|Participants in the sham cupping therapy group, who have chronic non-specific low back pain, will undergo a combination of sham cupping therapy and routine physiotherapy. During the sham cupping therapy sessions, two cups with small holes will be placed stationary on the lumbar region.
89435334|NCT06192576||Olipudase alfa arm|
89531294|NCT05041881|Active Comparator|Accommodating IOL group|Patients implanted during cataract or refractive surgery with accommodating lens, which allowed to see for far and should improve intermediate distance better than monofocal lens do.
89010136|NCT04555642||therapy group|lymphoma patients planned chemotherapy or immunotherapy scheme
89010137|NCT04555642||healthy control group|Inclusion criteria for the controls were no known diseases or syndromes, within the age range from 18 to 35 years.
89010138|NCT02214394|Experimental|Propofol|Subjects will be given Propofol during routine surgery and then using the SMART Device the breath will be captured and compared to blood plasma using High-performance liquid chromatography Analysis.
89010139|NCT00235508|Active Comparator|1|Escitalopram oxalate 10 mg at bedtime
89010140|NCT00235508|Active Comparator|2|Eszopiclone 3 mg at bedtime
89435335|NCT06189560|Experimental|The observation group|Patients enrolled were firstly numbered for privacy with software and divided into the observation group (n=33) and the control group (n=33) with a random number table. Additionally, the staffs involved in assessment would not participate in the intervention of the study. The treatment lasted 20 days.
89435336|NCT06189560|Active Comparator|The control group|Patients enrolled were firstly numbered for privacy with software and divided into the observation group (n=33) and the control group (n=33) with a random number table. Additionally, the staffs involved in assessment would not participate in the intervention of the study. The treatment lasted 20 days.
89435337|NCT06189209|Experimental|Single arm, Open label study|Single agent Tenalisib [RP6530 (PI3k delta, gamma and SIK3 inhibitor)]
89435338|NCT06187675|Active Comparator|Choice|Participants will be given a choice of 3 strategies; Group A - they receive both nutrition and exercise components simultaneously, Group B - they receive the nutrition component first followed by introduction of the exercise component sequentially, or Group C - they receive the exercise component first followed by introduction of the nutrition component sequentially.
89435339|NCT06187675|Experimental|No choice|Participants will be yoked (matched) to a participant in the Choice group and they receive the same strategy as the person with a choice.
89435340|NCT06185738|Other|WCM app|WCM app evaluation at baseline, upon completion of WCM program and 4 weeks after completion of WCM program, by completing PROMIS and Self Efficacy for managing disease scale questionnaires
89435341|NCT06185504|Experimental|the observation group|All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy, to promote the development of motor and cognitive function, as well as to improve intellectual development. Besides, swallowing function training was also provided, including direct training, indirect training, and compensatory training.Within 4 hours of admission, the observation group were required to undergo nasogastric tube removal and initiated Intermittent Oro-Esophageal Tube Feeding for nutrition support.
89435342|NCT06185504|Active Comparator|The control group|All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy, to promote the development of motor and cognitive function, as well as to improve intellectual development. Besides, swallowing function training was also provided, including direct training, indirect training, and compensatory training.The control group was given nutrition support with persistent nasogastric tube feeding , of which the tube passed through the nasal cavity into the stomach.
89435343|NCT06180850||Cases|Participants with lipedema
89435344|NCT06180850||Controls|Participants without lipedema
89435345|NCT06179901|Active Comparator|Integrative Korean Medicine Treatment group(IKMT group)|
89435346|NCT06179901|Experimental|MSAT group|
89435347|NCT06179355|Experimental|manual Astigmatic Keratotomy|manual limbal Astigmatic Keratotomy using a diamond knife group
89435348|NCT06179355|Experimental|femtosecond laser Astigmatic Keratotomy|Femtosecond laser-guided astigmatic keratotomy group
89531295|NCT05041881|Active Comparator|Monofocal IOL group|Patients implanted during cataract or refractive surgery with standard monofocal lens, which allowed to see for far but patients do not experiences optical phenomena or low contrast sensitivity.
89531296|NCT04494191|Experimental|T test|Test drug (AphroFemine) 1 tablet contains 100 mg Flibanserin
89010141|NCT04548856|Other|IA-Microsurgical clipping group (ruptured aneurysms)|This subgroup includes patients who underwent microsurgical clipping of an acutely ruptured cerebral aneurysm
89010142|NCT04548856|Other|IB-Microsurgical clipping group (unruptured aneurysms)|This subgroup includes patients who underwent microsurgical clipping of unruptured cerebral aneurysm
89010143|NCT04548856|Other|IIA-Endovascular embolization group (ruptured aneurysms)|This subgroup includes patients who underwent endovascular embolization of an acutely ruptured cerebral aneurysm
88916143|NCT01623778||Switch to LDT|Patients with inadequate response to interferon at 24 weeks received switching to LDT therapy
88916144|NCT01623791||Group 1|Group 1: mild pre-eclamptic group Mild and severe pre-eclampsia were defined American College of Obstetrics and Gynecology criteria (ACOG practice bulletin no. 33: diagnosis and management of preeclampsia and eclampsia. January 2002.)
88916145|NCT01623791||Group 2|Group 2: severe pre-eclamptic group
88916146|NCT01623804|Active Comparator|Low intensity, pulsed ultrasound|
88916147|NCT01623804|Sham Comparator|Sham ultrasound|
88916148|NCT01623817|No Intervention|Vancomcyin, maintain dose|This arm is received only maintain dose of vancomycin (15mg/kg twice a day or 1g twice a day).
88916149|NCT01623817|Experimental|Vancomycin loading|This group is received loading dose 30mg/kg. Subsequent doses of vancomycin are considered standard of care.
88916150|NCT01623843|Active Comparator|Arthroscopic Lavage|Participants have three hip portals (antero-lateral, mid anterior, distal antero-lateral) with limited capsulotomy allowing for a complete assessment of the central and peripheral compartments. The participant has a diagnostic arthroscopy and lavage of the hip joint with three litres of normal saline. No osteochondroplasty or rim resection is completed in this group. No instruments are used to treat minor cartilage or labral damage. The labrum should only be repaired if mechanically unstable once probed with visible displacement or chondrolabral separation. The labrum will be refixated only if the above criteria for labral instability is met.
88916151|NCT01623843|Experimental|Arthroscopic Osteochondroplasty|After establishing standard portals, an inter-portal capsulotomy will be completed to allow for complete evaluation of the central compartment of the hip. Significant and obvious labral tears and cartilage damage will be addressed. The labrum will be repaired if mechanically unstable once probed with visible displacement or chondrolabral separation. The acetabular rim will be evaluated and any evident Pincer lesion will be resected using an arthroscopic burr under fluoroscopic guidance. Following this resection, the labrum will be refixated only if the criteria for labral instability is met. Following this, a limited capsulotomy will be completed along the head-neck junction of the femoral neck to allow for visualization and treatment of the impingement lesion in the peripheral compartment. For the FIRST-EPIC sub-study, participants will receive the osteochondroplasty intervention as per standard of care.
89010144|NCT04548856|Other|IIB-Endovascular embolization group (unruptured aneurysms)|This subgroup includes patients who underwent endovascular embolization of unruptured cerebral aneurysm
89198370|NCT00955396|Other|Period 2|
88916152|NCT01623856||Observational|DNA samples are analyzed by single nucleotide polymorphism and genotyped by fluorogenic polymerase chain reaction (PCR)-based allelic discrimination (Taqman) assays using the ABI Prism 7900HT reverse transcriptase (RT)-PCR system.
88916153|NCT01623908|Experimental|Zoledronate|
88916154|NCT01623921|Other|control|Group 1: control :(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal)
88916155|NCT01623921|Active Comparator|Celecoxib|Group 2: Celecoxib 200 mg × 2/d+:(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal)
88916156|NCT01623921|Active Comparator|rosuvastatin|Group 3: Rosuvastatin 40mg × 1/d+:(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal)
88916157|NCT01623921|Active Comparator|Combined therapy|Group 4: Combined therapy with Celecoxib 200 mg× 2/d + Rosuvastatin 40× 1/d +:(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal)
88916158|NCT01623934||Phase 1: Pregnant women|
89435349|NCT06178562|Experimental|IOE group|IOE groups were given systematic therapy according to the routine treatment plan for PRS for 4 weeks. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
89435350|NCT06178562|Active Comparator|PNG group|PNG groups were given systematic therapy according to the routine treatment plan for PRS for 4 weeks. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
89531297|NCT04494191|Active Comparator|B reference|Reference drug (Addyi) 1 tablet contains 100 mg Flibanserin
88916159|NCT01623934||Phase 2: Mother-offspring dyad|
88916160|NCT01623947|Placebo Comparator|Placebo|
88916161|NCT01623947|Active Comparator|2.8 g Sustamine|
88916162|NCT01623947|Active Comparator|19.6 g Sustamine|
88916163|NCT01623973|Experimental|With restraint|The group with restraint underwent specific training of paretic upper limb and use of restraint.
88916164|NCT01623973|Active Comparator|no restraint|"The group control without restraint submitted only to the specific training of paretic upper limb"
89435351|NCT06176586|Experimental|Exercise Group|Progressive mat Pilates exercises will be administered to by a physiotherapist in addition to the routine medical treatment.
89435352|NCT06176586|No Intervention|Control Group|Patients in control group will not receive any exercise intervention. They will continue to their routine medical treatment.
89435353|NCT06176365|Experimental|BI 456906 (survodutide) - 3.6 mg|
89435354|NCT06176365|Experimental|BI 456906 (survodutide) - 6.0 mg|
88916165|NCT01623986||St. Michael's Hospital Patients|Patients who are referred to the St. Michael's Hospital echocardiography (ECHO) lab.
88916166|NCT01624012|Active Comparator|NIV NAVA|Noninvasive ventilation in this group is practiced with NIV NAVA
89198371|NCT00863499|Active Comparator|A|Short Acting methylphenidate
89435355|NCT06176365|Placebo Comparator|Placebo group|
89435356|NCT06174168||Group 1|Patients who did not develop any complication in the EBUS-TBNA. Patients may experience intraoperative complications (bleeding, hypoxemia, hypotension, arrhythmia, bronchospasm, pneumothorax, subcutaneous emphysema/mediastinal emphysema, respiratory depression), and postoperative complications (bleeding, pneumonia, respiratory failure, atelectasis, pleural effusion/empyema, pulmonary embolism, pulmonary edema). Complications that develop (such as acute respiratory distress syndrome, delirium, and mortality) will be recorded. After the procedure, any complications that may develop in the patients within 30 days will be questioned and recorded.
89435357|NCT06174168||Group 2|Patients who developed complications during EBUS-TBNA. Patients may experience intraoperative complications (bleeding, hypoxemia, hypotension, arrhythmia, bronchospasm, pneumothorax, subcutaneous emphysema/mediastinal emphysema, respiratory depression), and postoperative complications (bleeding, pneumonia, respiratory failure, atelectasis, pleural effusion/empyema, pulmonary embolism, pulmonary edema). Complications that develop (such as acute respiratory distress syndrome, delirium, and mortality) will be recorded. After the procedure, any complications that may develop in the patients within 30 days will be questioned and recorded.
89435358|NCT06173570|Experimental|Arm A|AZD0780, Dose 1
89435359|NCT06173570|Experimental|Arm B|AZD0780, Dose 2
89435360|NCT06173570|Experimental|Arm C|AZD0780, Dose 3
89435361|NCT06173570|Experimental|Arm D|AZD0780, Dose 4
89435362|NCT06173570|Placebo Comparator|Arm E|Placebo, matched for appearance
89435363|NCT06173531|Experimental|Carbetocin|Carbetocin nasal spray 3.2 mg three times daily (TID)
89435364|NCT06173531|Placebo Comparator|Placebo|Placebo
89010145|NCT04548895||LTCF residents and involved health practitioners|"The intervention will take place in nursing homes, assisted living facilities and long-term care facilities (LTCF) in the United States (henceforth collectively referred to as LTCF).~Staff who work in the participating LTCF ≥ 20 hours/week and who have direct contact with the residents are also eligible to participate and to employ the biometric monitoring equipment in their private residences."
89010146|NCT04548934|Active Comparator|No PPE|Cardiopulmonary resuscitation without wearing personal protective equipment (PPE)
89010147|NCT04548934|Experimental|PPE|Cardiopulmonary resuscitation while wearing personal protective equipment (PPE)
89010148|NCT02214433|Experimental|Part A Period 1 Debio 1450 IV Solution|Part A Debio 1450 IV solution infused over two hours on Day 1 after fasting
89010149|NCT02214433|Experimental|Part A Period 2 Debio 1450 Tablet|Debio 1450 Tablet oral dosing once on Day 5, after fasting
89010150|NCT02214433|Experimental|Part A Period 3 Debio 1450 Tablet|Debio 1450 Tablet oral dosing once on Day 9, 30 minutes after a high calorie, high fat breakfast, after fasting
89010151|NCT02214433|Experimental|Part A Period 4 Debio 1450 Tablet|After preparation with Pantoprazole, Pantoprazole taken with Debio 1450 Tablet oral dosing once on Day 14, after fasting
89010152|NCT02214433|Placebo Comparator|Part B Placebo All Cohorts|Placebo IV solution on days 1-5 and then Placebo Tablet or Capsule on Days 6-10, according to the cohort dosing schedule
89198372|NCT00863499|Active Comparator|B|Long Acting Methylphenidate
89010153|NCT02214433|Experimental|Part B Debio 1450 Cohort 1|Debio 1450 IV solution, once daily on days 1-5, then Debio 1450 Tablet, once daily on days 6-10
89010154|NCT02214433|Experimental|Part B Debio 1450 Cohort 2a|Debio 1450 IV solution, once daily on day 1
89010155|NCT02214433|Experimental|Part B Debio 1450 Cohort 3|Debio 1450 IV solution, twice daily on days 1-5, then Debio 1450 Capsule, twice daily on days 6-10
89010156|NCT02214433|Experimental|Part B Debio 1450 Cohort 4|Debio 1450 IV solution, twice daily on days 1-5, then Debio 1450 Capsule, twice daily on days 6-10
89010157|NCT02214433|Experimental|Part B Debio 1450 Cohort 2b|Debio 1450 IV solution, once daily on days 1-5, then Debio 1450 Capsule, once daily on days 6-10
89010158|NCT02214433|Experimental|Part C Debio 1450|Debio 1450 (IV formulation in Period 1, capsule formulation in Periods 2, 4 and 5 (with Pantoprazole), and Debio 1450 oral solution in Period 3).
89010159|NCT04710407|Experimental|TBPM-PI-HBr|Healthy subjects meeting eligibility criteria will receive a total of five doses of TBPM-PI-HBr 600 mg orally every 8 hours.
89010160|NCT04548622|Experimental|Non-randomized bilateral rTMS|Active bilateral rTMS to left/right Wernicke's area and opposite side middle temporal gyrus
89010161|NCT04710251|Active Comparator|Colonoscopy with the speedometer|
89010162|NCT04710251|No Intervention|Colonoscopy without the speedometer|
89010163|NCT02212561|Experimental|Treatment Arm|Interventions: Selinexor, Fludarabine, and Cytarabine. Methotrexate/hydrocortisone/cytarabine (intrathecal triples) will be given prior to cycle 1.
89010164|NCT04555993|Active Comparator|Transversus abdomis plane block|Patients will receive Transversus abdomis plane block
89010165|NCT04555993|Experimental|Erector spinae plane block|Patients will receive Erector spinae plane block.
89198373|NCT00863499|No Intervention|C|Healthy Controls
89198374|NCT04061642|Experimental|Clinical Decision Aid|
89010166|NCT00268593|Experimental|130 mg PI-88 + docetaxel|130 mg PI-88 7 days/week + docetaxel 75 mg/m2
89010167|NCT00268593|Experimental|250 mg PI-88 + docetaxel|250 mg PI-88 4 days/week + docetaxel 75 mg/m2
89010168|NCT04555525|Experimental|sarecycline|weight-based dose per label by mouth once daily for 12 weeks
89010169|NCT04555525|Other|Centrum Adult Multivitamin|one tablet by mouth daily for 12 weeks
89010170|NCT02212600||Population|We will include male and female patients who are over 50 years of age and who have an acute, displaced or undisplaced proximal humerus fracture caused by low energy trauma
89010171|NCT04555486|Experimental|DCR-PHXC|Participants that are at least 12 years old will receive a single dose of 3 mg/kg DCR-PHXC (or nedosiran) via subcutaneous (SC) injection. Participants that are 6-11 years old will receive a single dose of 3.5 mg/kg DCR-PHXC (nedosiran) via SC injection.
89198375|NCT03992053|Active Comparator|Group 1|conventional 2-D fluoroscopy guidance as the first choice of guidance
89198376|NCT03992053|Active Comparator|Group 2|3-D CT guidance as the first choice of guidance
89198377|NCT00755118|Experimental|1|LoHP/AIO/Avastin->CPT-11/AIO/Erbitux
89435365|NCT06172829||At least 3 subjects shall be <1,000g in weight|
89435366|NCT06172829||At least 3 subjects shall be 1,000g to 2,000g in weight|
89435367|NCT06172829||At least 3 subjects shall be >2,000g|
89435368|NCT06172829||At least 3 subjects shall be >/= 29 days and < 1 year of age|
89435369|NCT06172829||At least 3 subjects shall be >/= 1 year and <3 years of age|
89435370|NCT06171841|Active Comparator|Low-Intensity Normoxia|Participants will be breathing room air, and perform low-intensity lower-body resistance exercise.
89435371|NCT06171841|Active Comparator|High-Intensity Normoxia|Participants will be breathing room air, and perform high-intensity lower-body resistance exercise.
89435372|NCT06171841|Experimental|Low-Intensity Normoxia with Blood Flow Restriction|Participants will be breathing room air, and perform low-intensity lower-body resistance exercise combined with blood flow restriction.
89435373|NCT06171841|Experimental|Low-Intensity Hypoxia|Participants will be breathing a 13% oxygen gas mixture, and perform low-intensity lower-body resistance exercise.
88916167|NCT01624012|Active Comparator|ncpap|Patients randomized to this arm will receive noninvasive ventilation with continuous nasal CPAP as routinely in neonatal intensive care unit.
88916168|NCT01624025|Experimental|HER2 positive|Both the patients with HER2 (+) and HER2 (-) patients will be treated with the same regimen.(Docetaxel 60 mg/m2, epirubicin 60 mg/m2, q3wks)
88916169|NCT01624025|Active Comparator|HER2 negative|"Both the patients with HER2 (+) and HER2 (-) patients will be treated with the same regimen.~(Docetaxel 60 mg/m2, epirubicin 60 mg/m2, q3wks)"
88916170|NCT01624038|Active Comparator|Hydroxyurea,blood transfusion|Hydroxyurea (Myers-Squibb, USA) was administered in dosages ranging from 15 up to 35 mg/kg/day orally over 7 days/week.
88916171|NCT01624038|Experimental|Hydroxyurea, Epiao|"Hydroxyurea (Myers-Squibb, USA) was administered in dosages ranging from 15 up to 35 mg/kg/day orally over 7 days/week. Hydroxyurea toxicity was defined as a white cell count of less than 2500/μL or a platelet count of less than 100,000/μL, in which case the drug was discontinued. White cell count and platelet count were determined on a monthly basis. Side effects such as nausea, vomiting, diarrhea, rashes, and malaise, experienced during the first 6 h after taking the HU will be considered as clinical toxicity.~Erythropiotien therapy (rHuEPO - Epiao) from 250 to 500 IU/kg rHuEPO subcutaneously three times a week."
88916172|NCT01624051|Active Comparator|Body Surface Area Dosing|Standard dosing arm based on body surface area
88916173|NCT01624051|Experimental|Lean Body Mass Dosing|Experimental dosing arm based on individual lean body mass
88916174|NCT01624064|Active Comparator|Enalapril, Proteinuria < 1g/day|
88916175|NCT01624064|Placebo Comparator|Calcium, Proteinuria < 1g/day|
88916176|NCT01624064|Active Comparator|Enalapril, Proteinuria > 1g/day|
88916177|NCT01624064|Placebo Comparator|Calcium, Proteinuria > 1g/day|
88916178|NCT01624077|Experimental|Regulatory T cells|Naïve CD4+ T cells isolated from peripheral blood mononuclear cells were stimulated with GMP anti-CD3/CD28 coated beads in the presence of IL-2 ,TGF-β.
88916179|NCT01624103|Experimental|Elderly (32 mL LA volume)|Population over age of 65 undergoing upper limb surgery using US-SCB receiving 32 ml of LA (50:50 mixture of 0.5% levobupivacaine and 2% lidocaine).
88916180|NCT01624103|Experimental|Elderly (20 ml LA volume)|Population over age of 65 undergoing upper limb surgery using US-SCB receiving 20 ml of LA (50:50 mixture of 0.5% levobupivacaine and 2% lidocaine).
88916181|NCT01624116|Active Comparator|Diet and lifestyle measures alone.|Type 2 diabetic subjects on lifestyle counselling as part of diabetes treatment would continue as such during Ramadan. They would receive acarbose on one day to be followed by CGMS for a 24 hour period
88916182|NCT01624116|Active Comparator|Metformin monotherapy|Type 2 diabetics on biguanide treatment.
88916183|NCT01624116|Active Comparator|Metformin + Sulphonylurea.|Type 2 diabetics on dual oral hypoglycaemics-metformin and glimepiride.
88916184|NCT01624116|Active Comparator|Metformin + Sitagliptin|Type 2 diabetics managed on dual oral hypoglycaemic therapies: metformin and sitagliptin.
88916185|NCT01624129||eosinophilic esophagitis|patients with histopathological defined eosinophilic esophagitis
88916186|NCT01624155|Experimental|Women taking teratogens|Women taking teratogens
88916187|NCT01624207|Experimental|Atorva|generic formulation (Atorva®) of atorvastatin 20mg once daily
88916188|NCT01624207|Active Comparator|Lipitor|branded formulation (Lipitor®) of atorvastatin 20mg once daily
88916189|NCT01624246|Experimental|Ceftaroline fosamil/Avibactam|
88916190|NCT01624272|No Intervention|Control|Usual care
88916191|NCT01624272|Experimental|Threshold Inspiratory Muscle Training|Inspiratory muscle training regime
88916192|NCT01624272|Experimental|Controlled breathing exercises|Yoga Pranayama breathing exercises
88916193|NCT01624298|No Intervention|Wait List Control Group|The wait list control group will be asked to wait for approximately 4 1/2 months before being reassessed and then, unless found to be ineffective or harmful, receive the intervention being provided by the counselor.
88916194|NCT01624298|Experimental|Intervention Group|Children randomized into the intervention group will immediately receive the Trauma Focused Cognitive Behavioral Therapy with a trained counselor for 12 weeks.
88916195|NCT01624311|Experimental|Adjunct Hypothermia Arm|Patients that receive adjunct therapeutic hypothermia in addition to standard of care therapy
88916196|NCT01624311|Other|Historic Controls|Patients that were treated with standard of care therapy for the same conditions at the sponsoring institution over the past 10 years.
88916197|NCT01624337|Experimental|DHA-piperaquine|DHA-piperaquine monthly 2 day treatment course
88916198|NCT01624337|Placebo Comparator|Placebo|Matching placebo control
88916199|NCT01624376|Active Comparator|DLX105|DLX105 local injection into the identified fistula(s)
88916200|NCT01624376|Placebo Comparator|Placebo Injection|
88916201|NCT01624389|Experimental|F18-AV45|
88916202|NCT01624402|Experimental|Ecosystem Focused Therapy (EFT)|Ecosystem Focused Therapy (EFT) follows a structured personalization approach based on the model of adaptive functioning, in which behavior is a function of the person's competence and the demands of the environment.
88916203|NCT01624402|Active Comparator|Education on Stroke and Depression (ESD)|Education on Stroke and Depression (ESD) is home-delivered and imparts education about depression, stroke, and the role of available treatments.
88916204|NCT01624428|Active Comparator|varenicline|
88916205|NCT01624428|Placebo Comparator|Placebo|
88916206|NCT01624441|Experimental|Treatment (dinaciclib and epirubicin hydrochloride)|Patients receive dinaciclib IV over 2 hours on day 1 and epirubicin hydrochloride IV over 30 minutes on day 2. Treatment repeats every 21 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
88916207|NCT01624454|Active Comparator|large volume|bowel cleansing with PEG
88916208|NCT01624454|Active Comparator|Osmotic|
88916209|NCT01624493|Experimental|Phase II Arm A|Phase II Arm A will randomize patients to treatment regimen of carboplatin and gemcitabine without BNC105P
88916210|NCT01624493|Experimental|Phase II Arm B|Phase II Arm B will randomize patients to treatment regimen of carboplatin and gemcitabine and will include BNC105P
88916211|NCT01624519|Other|1|
88916212|NCT01624545|Active Comparator|1|Patients in this study arm will receive a cranial CT scan on day 2 and day 30 after evacuation of a chronic subdural hematoma in addition to neurological evaluation on day 2 and 30.
89435374|NCT06171841|Experimental|Low-Intensity Hypoxia with Blood Flow Restriction|Participants will be breathing a 13% oxygen gas mixture, and perform low-intensity lower-body resistance exercise combined with blood flow restriction.
89435375|NCT06171711|Experimental|Exposure Therapy|Exp-AN will effectively target anxiety related to eating and weight gain via inhibitory learning, and improve treatment outcomes.
89435376|NCT06170671||Cohort 1|December 2023 - collecting data retrospectively from patients routinely initiated on acalabrutinib between January - December 2023
89435377|NCT06170671||Cohort 2|December 2024-collecting data retrospectively from patients routinely initated on acalabrutinib between January - December 2024
88916213|NCT01624545|No Intervention|2|Patients in this study arm will undergo neurological evaluation on day 2 and day 30 without follow-up CT scan.
88916214|NCT01624558|Experimental|Treatment (filter in circuit)|After baseline use of volatile anesthetic, this group will have carbon filter placed in-line.
88916215|NCT01624558|No Intervention|No Intervention Control|After baseline use of volatile anesthetic, this group will NOT have carbon filter placed in-line.
88916216|NCT01624571|Experimental|Group 1|300mg/day
88916217|NCT01624571|Experimental|Group 2|600mg/day
88916218|NCT01624571|Experimental|Group 3|900mg/day
88916219|NCT01624571|Placebo Comparator|Placebo|Control Group
88916220|NCT01624584|Experimental|Experimental treatment|6 sessions of anxiety treatment
88916221|NCT01624584|Active Comparator|Traditional Treatment|Six sessions of anxiety treatment
88916222|NCT01624597|No Intervention|Usual Care|Participants will have a passive in-vehicle video device installed in their car to measure driving errors and safety behaviors.
88916223|NCT01624597|Experimental|In-vehicle video feedback|Participants will receive feedback from an in-vehicle video system. A light on the system will blink when a driving event has been recorded. Parents will receive a weekly report card of driving errors.
88916224|NCT01624597|Experimental|In-vehicle video feedback, parent communication|Participants will receive feedback from an in-vehicle video system. A light on the system will blink when a driving event has been recorded. Parents will receive a weekly report card of driving errors. Parents will participate in an intervention that provides input on teaching and communicating about driving skills and safety behaviors.
88916225|NCT01624610|Active Comparator|Diet 1|Patients randomized to this arm will receive both written and face-to-face advice about how the components of Diet 1 can be used to control their IBS symptoms.
88916226|NCT01624610|Active Comparator|Diet 2|Patients randomized to this arm will receive both written and face-to-face advice about how the components of Diet 2 can be used to control their IBS symptoms.
88916227|NCT01624649||Patients with ADHD|Patients will receive methylphenidate hydrochloride or atomoxetine. The methylphenidate hydrochloride is available in three forms. 1) Immediate release 2) Extended release 3) Osmotic release oral system
88916228|NCT01624675|Experimental|Risperidone|Subjects weighing less than 20 kilogram (kg) received risperidone 0.25 milligram per day (mg/day) up to Day 4. On Day 4, dose was titrated in increments of 0.25 mg/day (up to a daily dose of 1.0 mg) at the regular study visit thereafter till Week 8. Subjects weighing greater than or equal to (>=) 20 kg received risperidone 0.5 mg/day up to Day 4. On Day 4, dose was titrated in increments of 0.5 mg per day (up to a daily dose of 2.5 mg) at the regular visit thereafter till Week 8. The maximum daily dose for subjects weighing >= 45 kg was 3.0 mg. For subjects weighing >=45 kg, the maximum daily dose was 3.0 mg.
88916229|NCT01624675|Placebo Comparator|Placebo|Subjects will receive placebo matching with risperidone orally up to 8 weeks.
88916230|NCT01624701|Experimental|Expanded|'Ex vivo expanded cord blood cells
89435378|NCT06169969|Experimental|Magnetic therapy group|receive magnetic therapy plus pelvic floor exercises.
89435379|NCT06169969|No Intervention|Pelvic floor exercises group|pelvic floor exercises only
89435380|NCT06167993|Experimental|Group receiving CDP in patients who underwent LVA|LVA: Group that underwent lymphovenous anastomosis surgery and CDP applied groups CDP:Complex Decongestive Physiotherapy
89435381|NCT06167993|Active Comparator|Group receiving CDP after lymphedema|Only CDP applied groups
88916231|NCT01624714|Experimental|Alemtuzumab Naive|Alemtuzumab Subjects (30) with prior treatment refractoriness and treatment experience EDSS 3.0-7.0 inclusive, without contraindications to alemtuzumab
88916232|NCT01624714|Experimental|Alemtuzumab Experienced|Subjects with treatment refractory MS and prior alemtuzumab therapy (30)
88916233|NCT01624727|No Intervention|Usual care|Those randomized to usual care will continue to follow the care provided by their cardiologist. They will have all the follow-up phone calls, visits and testing which the intervention group has.
88916234|NCT01624727|Active Comparator|Lovaza (Omega 3 ethyl esters)|
88916235|NCT01624753|Experimental|confocal microscopy|During bronchoscopy, one side of the bronchial tree will be examined (either right or left) and targeted based on pre-procedure HRCT/CT scan findings. A 1.4mm diameter Alveoflex Confocal MiniprobeTM (MaunaKea Technologies, France) will be deployed down the working channel of the standard bronchoscope and advanced distally into the alveoli. Images are acquired by gentle contact providing real-time imaging and microstructural detail of the alveolus which will be continuously recorded during the procedure and stored for further morphometric and cellular analyses. Up to 10 bronchoalveolar areas will be observed and the location of the corresponding lung segment will be registered according to the international bronchial nomenclature.
88916236|NCT01624766|Experimental|Arm I (everolimus, anakinra)|Participants receive everolimus PO daily and anakinra SC daily on days 1-28. Treatment repeats every 28 days in absence of disease progression or unacceptable toxicity.
89198378|NCT00868257||CHARTA study cohort|Primarily 5- to 10-year-old Ugandan children with HIV or AIDS who are taking ART, with some 1- to 4-year-olds included because of recent trends in treating younger children
89435382|NCT06166537|Other|EDPTP plus GCS|Control - Extended duration pharmacological thromboprophylaxis (EDPTP) and Graduated compression stockings (GCS).
89435383|NCT06166537|Other|EDPTP alone|Intervention - Extended duration pharmacological thromboprophylaxis (EDPTP) alone, no stockings
89435384|NCT06165341|Experimental|Fazirsiran 200 mg|Participants will receive fazirsiran 200 milligrams (mg), injection, subcutaneously on Day 1, at Week 4 and then every 12 weeks (Q12W) for up to Week 100.
89435385|NCT06165341|Placebo Comparator|Placebo|Participants will receive fazirsiran matching placebo injection, subcutaneously on Day 1, at Week 4 and Q12W for up to Week 100.
89435386|NCT06161337|Experimental|Experimental group|20 young (age 18-30), healthy, normal body mass index subjects for this study.
89435387|NCT06157749||3D Computerized Gait Analysis|The gait analysis will be conducted through 3D computerized gait analysis.
89435388|NCT06157749||Gait-Analyzer|The gait analysis will be performed using a smartphone application called Gait-Analyzer.
89435389|NCT06155955|Experimental|low dose emicizumab|2 mg per kilograms per dose in first month, loading every 2 weeks then every 4 weeks
88916237|NCT01624766|Experimental|Arm II (everolimus, denosumab)|Participants receive everolimus PO daily on days 1-28 and denosumab SC on day 1. Treatment repeats every 28 days in absence of disease progression or unacceptable toxicity.
88916238|NCT01624792|Experimental|Healthy older adults|Healthy controls will receive each intervention (olive oil or fish oil with 3.5 g EPA+DHA) one time and for only one day per intervention .
88916239|NCT01624792|Experimental|COPD patients|COPD patients will receive one out of three possible interventions (olive oil or fish oil with 3.5 g EPA+DHA or fish oil and placebo with 2 g EPA+DHA) for 4 (+/- 7 days) weeks.
88916240|NCT01624818|Experimental|Group 2, 6-7 years|18 children (6-7 years) with heart disease participating in a rehabilitation programme in Geilomo childrens hospital
88916241|NCT01624818|Experimental|Group 1, 11-12 years|18 children(11-12 years) with heart disease participating in a rehabilitation programme at Geilomo childrens hospital.
88916242|NCT01624831||Individuals with Longstanding Psychosis|Individuals with symptoms of psychosis that have been present for 5 or more years
88916243|NCT01624844|Experimental|Calculation of dural sac volume|
88916244|NCT01624857|Placebo Comparator|control group|Placebo for at least 5 days before the CABG surgery, then continue to take for a month after the surgery.
88916245|NCT01624857|Active Comparator|statin group|Rosuvastatin 20mg/d for at least 5 days before the CABG surgery, then continue to take for a month
88916246|NCT01624935|Experimental|psychotherapy|psychotherapy
88916247|NCT01624935|Other|treatment as usual|TAU control
88916248|NCT01624961|Experimental|50 PfSPZ IV|PfSPZ Challenge
88916249|NCT01624961|Experimental|200 PfSPZ IV|PfSPZ Challenge
88916250|NCT01624961|Experimental|800 PfSPZ IV|PfSPZ Challenge
88916251|NCT01624961|Experimental|3200 PfSPZ IV|PfSPZ Challenge
89198379|NCT00755352|Experimental|1|pravastatin tablets and Welchol tablets
89435390|NCT06155955|No Intervention|low dose factor VIII prophylaxis|factor VIII prophylaxis
89435391|NCT06152042|Experimental|Main Study|"The Main Study will enroll randomized participants with T1D diagnosed within 3 years and with C-peptide concentration ≥0.2 nmol/L (0.60 μg/L). The main study uses a randomized, double-blind, placebo-controlled design with parallel assignment among 3 treatment arms . The trial begins with a screening period of up to 35 days. Eligible participants will be randomly assigned to 1 of 3 arms using a 1:1:1 ratio:~Arm A: BMF-219 100 mg QD for 12 weeks~Arm B: BMF-219 200 mg QD for 12 weeks~Arm C: Matching placebo."
89531298|NCT05041725|Experimental|remimazolam infusion|Intraoperative remimazolam infusion for postoperative sedation
89531299|NCT03338075||CRT group|patients with brain metastases of more than 6 cc and treated with fractionated stereotactic radiotherapy plus concomitant Temozolomide.
89531300|NCT03338075||RT group|patients with brain metastases of more than 6 cc and treated with fractionated stereotactic radiotherapy alone.
88916252|NCT01624961|Experimental|2500 PfSPZ ID|PfSPZ Challenge
88916253|NCT01624987|Experimental|NET for Forensic Offender Rehabilitation|Narrative Exposure Therapy for Forensic Offender Rehabilitation (FORNET)
88916254|NCT01625026|Active Comparator|Morbid Obesity OCA|Obeticholic acid 25 mg/day in three weeks
88916255|NCT01625026|Placebo Comparator|Morbid Obesity Placebo|Obeticholic acid 25 mg/day matching placebo in three weeks
88916256|NCT01625026|Active Comparator|Gallstones OCA|Obeticholic acid 25 mg/day in three weeks
88916257|NCT01625026|Placebo Comparator|Gallstones Placebo|Obeticholic acid 25 mg/day matching placebo in three weeks
88916258|NCT01625039|Experimental|Intervention|Participated in weekly educational workshops
88916259|NCT01625039|Active Comparator|Control group|Received once off educational session and materials
88916260|NCT01625052|Experimental|Baska|
88916261|NCT01625065||pain patients|patients from a specific pain management department, patients with long duration of pain, mostly insufficiently treated pain
88916262|NCT01625065||pre-surgical patients|patients from a surgical outpatient department with current pain
88916263|NCT01625078|Experimental|Baska mask|
88916264|NCT01625117|No Intervention|Control Group|
88916265|NCT01625117|Experimental|A variant of Narrative exposure therapy|
88916266|NCT01625130|Active Comparator|broccoli sprout homogenate (BSH)|Two hundred grams of BSH is equivalent to approximately 111 grams fresh sprouts (about one 4 oz package). Commercially available Broccosprouts® (Brassica Protection Products LLC) will be homogenized with water.
89198380|NCT00755352|Placebo Comparator|2|pravastatin tablets and Welchol placebo tablets
89435392|NCT06152042|Experimental|Open Label Substudy|"The open-label substudy will enroll participants with T1D into 2 cohorts: participants with T1D diagnosed within 3 years with C-peptide concentration ≥0.2 nmol/L (0.60 μg/L) and participants with T1D diagnosed between 3 to 15 years with C-peptide concentration ≥0.08 nmol/L (0.24 μg/L).~The substudy uses a randomized, open-label design with parallel assignment between 2 treatment arms in each cohort. The substudy begins with a screening period of up to 35 days. Eligible participants will be randomly assigned by cohort to 1 of 2 treatment arms:~Cohort 1: Participants with T1D diagnosed within 3 years with C-peptide concentration~≥0.2 nmol/L (0.60 μg/L)~Arm A: BMF-219 100 mg QD for 12 weeks~Arm B: BMF-219 200 mg QD for 12 weeks~Cohort 2: Participants with T1D diagnosed between 3 to 15 years with C-peptide concentration ≥0.08 nmol/L (0.24 μg/L).~Arm A: BMF-219 100 mg QD for 12 weeks~Arm B: BMF-219 200 mg QD for 12 weeks"
89435393|NCT06152042|Placebo Comparator|Main Study Double Blind Arm C|Matching placebo.
89435394|NCT06149260|Experimental|Semaglutide|Participants will receive once-weekly semaglutide subcutaneous injection at escalating doses from 0.25 mg/week to 0.5 mg/week.
89435395|NCT06148662|Experimental|No intervention (negative control)|Negative control
89435396|NCT06148662|Experimental|Water (positive control)|Tap water
89435397|NCT06148662|Experimental|"Dental foam Biorepair PERIBIOMA"|"Ingredients:~Aqua, Sorbitol, Xylitol, Zinc Hydroxyapatite, Aroma, Pistacia Lentiscus (Mastic) Gum Oil, Lactobacillus, Bifidobacterium, Sodium Hyaluronate, Ascorbic Acid, Hamamelis Virginiana Leaf Extract, Spirulina Platensis Extract, Calendula Officinalis Flower Extract, Tocopheryl Acetate, Retinyl Palmitate, Eucalyptus Globulus Leaf Oil, PEG-40 Hydrogenated Castor Oil, Phenoxyethanol, Sodium Benzoate, Cocamidopropyl Betaine, Glycerin, Maltodextrin, Sodium Saccharin, Helianthus Annuus Seed Oil, Potassium Sorbate, BHT, Limonene, CI 16255."
89435398|NCT06148662|Experimental|"Dental foam WATER:DENT"|Aqua, Xylitol, PVP, PEG-40 Hydrogenated Castor Oil, Hippophae Rhamnoides Extract, Chamomilla Recutita Extract, Sodium Benzoate, Sodium Lauryl Sulfate, Aroma, Propylene Glycol, Olaflur, Potassium Sorbate, Sodium Phosphate, Disodium Phosphate, Menthol, Bisabolol, Menthyl Lactate, PPG-26 Buteth-26, Sodium Saccharin, Sodium Methylparaben, Citric Acid, Limonene.
89536404|NCT02477267|Experimental|Test-Reference Sequence|SL spray, followed by SL film
89536405|NCT02477267|Experimental|Reference-Test Sequence|SL film followed by SL spray
88916267|NCT01625130|Placebo Comparator|alfalfa sprout homogenate|Two hundred grams of commercially available alfalfa sprouts will be homogenized with water using a ratio of 1:1.2 in a clean blender. The homogenate will then be frozen in aliquots at -20 degrees C.
88916268|NCT01625143||Observational|Archived bone marrow samples, collected at the time of diagnosis and relapse, are analyzed for gene expression and histone modifications by microarray, chromatin immunoprecipitation (ChIP) sequencing, and quantitative real-time polymerase chain reaction (qRT-PCR).
88916269|NCT01625195|Placebo Comparator|Omega-3 fatty acid supplement|This study will use a randomized placebo-controlled double-blind design and the intervention period will be 6 months. Participants will be instructed to consume 4 x 1285 mg fish oil capsules/d, two capsules with eachthe breackfast and two capsules with dinner. The daily treatment will provide 1.4 g/d of DHA and 1.8 g/d of EPA (Ocean Nutrition Canada, Dartmouth, NS). All capsules will contain orange flavor to mask the fishy taste and odor of the LC-omega-3 oil and will be provided to the participants monthly.
88916270|NCT01625195|Active Comparator|Placebo|This study will use a randomized placebo-controlled double-blind design and the intervention period will be 6 months. Participants will be instructed to consume 4 x 1285 mg capsules/d, two capsules with each of the main daily meals. The placebo will be composed of 50:50% corn/soybean oil as used in other randomized placebo-controlled trials.
88916271|NCT01625208|Experimental|Combined nerve block|Participants in this group will receive a supraclavicular brachial plexus block plus a median or ulnar nerve block.
88916272|NCT01625208|Active Comparator|Single nerve block|Participants in this group will receive a supraclavicular brachial plexus block only.
88916273|NCT01625247|Experimental|1 arm|Patients under LC. Allocated to drain placement . Drainage was removed if the drainage amount was less than 20cc.
88916274|NCT01625247|Active Comparator|2 arm|Patients under LC. Allocation to sham drain,
88916275|NCT01625260|Experimental|Gemcitabine in combination with ALT-801|
88916276|NCT01625273|No Intervention|IF (Infant formula)|
88916277|NCT01625273|Experimental|IF with L. paracasei strain F19|
89435399|NCT06148662|Experimental|"Spray BUCCOTHERM"|Aqua (Castéra-Verduzan Thermal Spring water), Alcohol, Xylitol, Glycerin, Camellia sinensis leaf water, Mentha piperita leaf water, Hydrogenated starch hydrolysate, Aqua, Aroma, Limonene, Benzyl alcohol, Dehydroacetic acid.
89435400|NCT06146543|Experimental|neurology patients|Patients coming to the neurology clinic for lumbar puncture.
89435401|NCT06146465||Pediatrics|attending and resident pediatrics physicians involved in pediatric patient management
89435402|NCT06146465||Non-Pediatrics physicians|attending and resident non-pediatrics physicians involved in pediatric patient management
89435403|NCT06144502|Experimental|Intervention from November 2023|Pupils in this arm receive the teaching material from November 2023
88916278|NCT01625299|Experimental|Gluten and Milk group|Subject on a gluten and dairy free diet will receive supplement of gluten and dry milk daily
88916279|NCT01625299|Placebo Comparator|Rice flour|Subjects will be on a gluten and dairy free diet and receive daily supplement of rice flour (placebo)
88916280|NCT01625312||CABG group|Three-vessel disease patients undergoing CABG at index hospitalization
88916281|NCT01625312||PCI group|Three-vessel disease patients undergoing PCI at index hospitalization.
88916282|NCT01625312||OMT group|Three-vessel disease patients undergoing no revascularization at index hospitalization
88916283|NCT01625325||extremely obese|BMI ≥35kg/m2
88916284|NCT01625325||obese|BMI 30-34.9kg/m2
88916285|NCT01625351|Experimental|Treatment|"Participants to undergo transplantation. They receive alemtuzumab, fludarabine, sirolimus, busulfan, melphalan, and stem cells.~Participants treated after activation of protocol revision 2.3 on 06/05/2014 have not and will not receive sirolimus as part of their therapy.~Cells for infusion are prepared using the CliniMACS System."
88916286|NCT01625364|Experimental|Open Airways for Schools|OAS is a school-based non-academic asthma health education program for elementary students with asthma and their parents.
88916287|NCT01625364|Experimental|SHARP program|The Staying Health-Asthma Responsible & Prepared (SHARP) program is an academic and counseling asthma health education program for older school-age students with asthma and members of their social networks including their family caregiver.
88916288|NCT01625403|Experimental|rhBNP treated|standard of care with rhBNP
88916289|NCT01625403|Active Comparator|standard of care|standard of care
88916290|NCT01625429|Experimental|neoadjuvant|
88916291|NCT01625442|Active Comparator|Saffron|Saffron treatment group received saffron tablets daily for 45 days
88916292|NCT01625442|Active Comparator|Barberry|Barberry group received barberry tablets daily for 45 days
88916293|NCT01625442|Placebo Comparator|Placebo|Placebo group received placebo tablets daily for 45 days
88916294|NCT01625468|No Intervention|Control|Participant receives usual care
88916295|NCT01625468|Experimental|Intervention|Intervention group participants receive three sets of mailed educational materials about making their home smoke-free and one coaching call.
88916296|NCT01625481|Experimental|Seal-V|A vascular sealant intended to achieve adjunctive hemostasis by mechanically sealing areas of potential leakage in surgical reconstruction of large blood vessels.
88916297|NCT01625494|Experimental|Irbesartan/Amlodipine 150/5 mg fixed combination|"1 tablet once daily in the morning for 4 weeks Patient will be first treated with irbesartan 150mg or amlodipine 5mg, 1 tablet /day for 4 weeks.~If OBPM is controlled on monotherapy at week 4 (SBP <140 mmHg and DBP<90 mmHg), patient will be withdrawn from the study"
88916298|NCT01625494|Experimental|Irbesartan/Amlodipine 150/10 mg fixed combination|1 tablet once daily in the morning for 4 weeks
88916299|NCT01625494|Experimental|Irbesartan/Amlodipine 300/5 mg fixed combination|1 tablet once daily in the morning for 4 weeks
88916300|NCT01625494|Experimental|Irbesartan/Amlodipine 300/10 mg fixed combination|1 tablet once daily in the morning for 4 weeks. If OBPM is controlled at week 12, patients will continue on the same therapy until the end of the study
88916301|NCT01625520|Experimental|SOM230 alone or in combination with RAD001|Patients with progressive metastatic or postoperative persistent medullary thyroid cancer will start the study treatment as a mono therapy with SOM230. Patients benefiting from the treatment will continue with the monotherapy (stable disease or better according to RECIST). Patients progressing will be switched to the combination therapy with SOM230 and RAD001.
88916302|NCT01625533||SA group|Patients using SA for the diagnosis of coronary artery disease are assigned to the SA group.
88916303|NCT01625533||DARCA group|Patients using DARCA for the diagnosis of coronary artery disease are assigned to the DARCA group.
88916304|NCT01625546|Experimental|High intensity whole-body infrared heating|Subjects will be induced to levels of heat that increases core body temperature to approximately 37.5-38.5 °C using the Whole Body Hyperthermia system.
88916305|NCT01625546|Sham Comparator|Low intensity whole-body infrared heating|Subjects will be induced to levels of heat that causes only a minor increase in body temperature using Whole Body Hyperthermia system.
88916306|NCT01625572|No Intervention|general anesthesia and epidural catheter (control)|"General anaesthesia~total intravenous anaesthesia with propofol 5-10 mg / kg / h,~remifentanil 0.1 to 0.3 micrograms / kg / min and muscle relaxation with cis-atracurium~use of a bispectral index~monitoring with a target range of 40-60~at the end of the anaesthesia all patients get 0.1 mg / kg morphine intravenously epidural catheter~plant of the epidural catheter under sterile conditions at the intervertebral space of the vertebral body 8-10 of the thoracic spine• local anaesthesia with lidocaine 1%~puncture with a Tuohy 18 G- needle, Lost of resistance technique~after a negative test dose with bupivacaine 0,5% isobar we inject fractional ropivacaine 10 ml 0,2%, after that continuous administration of ropivacaine 0,2% via patient-controlled-analgesia-device with a sweep rate of 6 ml/h, all Patients also receive an intravenous morphine-patient-controlled-analgesia-device"
88922269|NCT05573373|Experimental|Pamiparib in combination with Targeted Therapy Drugs|The specific targeted therapy plan is formulated by the investigator. The dosage of targeted therapeutic drugs is selected according to the drug use guidelines. Combination medication, the initial dose is 40mg each time (2 capsules), 2 times a day, the total daily dose is 80mg. Can be taken with a meal or on an empty stomach. If the patient misses a dose, no additional dose should be taken, and the next prescribed dose should be taken normally at the planned time. Continue the treatment until the disease progresses or unacceptable adverse reactions occur, and the dose is adjusted.
88916307|NCT01625572|Experimental|general anesthesia and regional anesthesia|"General anesthesia~anesthesia with propofol 5-10 mg / kg / h, remifentanil 0.1 to 0.3 micrograms / kg / min and muscle relaxation with cis-atracurium~Bispektralindex monitoring with a target range of 40-60~at the end of the anesthesia all patients get 0.1 mg / kg morphine intravenously Transversus abdominis plane blockade~ultrasound visible needles, a special pin detection software~under visual control the needle moves into the space between Musculus obliquus internus and M. transversus abdominis~Under sonographic control we inject a local anesthetic depot (30 ml of ropivacaine 0.375%)~puncture is performed under constant protective nerve stimulation with a current of 1 mA, pulse duration 0.1 ms, frequency 2 Hz All Patients receive an i.v. Morphine-patient-controlled-analgesia-device"
88916308|NCT01625572|Experimental|general anaesthesia and intravenous pain therapy|"General anaesthesia~total intravenous anesthesia with propofol 5-10 mg / kg / h, remifentanil 0.1 to 0.3 micrograms / kg / min and muscle relaxation with cis-atracurium~we use a of BIS monitoring with a target range of 40-60~at the end of the aneasthesia all patients get 0.1 mg / kg morphine intravenously intravenous pain therapy with~Morphine-patient-controlled-analgesia-device"
89435404|NCT06144502|Other|Wait-list control from November 2023 and intervention from January 2024|Pupils in this arm constitute a control group from November 2023 until they receive the teaching material from January 2024
88916309|NCT01625585||Consecutive patients undergoing SBE for OGIB|
88916310|NCT01625598||People with diabetes|People with diabetes who are referred to an ophthalmologist for a dilated eye examination
88916311|NCT01625624|Placebo Comparator|Control Food Product|
88916312|NCT01625624|Experimental|Experimental Food Product|
88916313|NCT01625637|Experimental|AAT-avoid cigarette condition|Adolescent smokers are trained to avoid tobacco in a training AAT
88916314|NCT01625637|Placebo Comparator|AAT-no contingency continued assessment|
88916315|NCT01625650||Rheumatology|Patients who present at enrolling sites across the US are invited to enroll if eligible.
88916316|NCT01625663||Barth syndrome|Children (8-17 yrs) and adults (18-35 yrs)
88916317|NCT01625663||Controls|Children (8-15 yrs) and adults (18-35 yrs)
88916318|NCT01625676|Experimental|CIAT-Group|Patients received a modified constraint-induced therapy schedule
88916319|NCT01625676|Active Comparator|standard treatment group|patients received a standard aphasia therapy
88916320|NCT01625702|Experimental|cisplatin plus capecitabine|gastric cancer patients treated with capecitabine/cisplatin
88916321|NCT01625702|Experimental|capecitabine plus paclitaxel|gastric cancer patients treated with capecitabine/paclitaxel
88916322|NCT01625715|No Intervention|Case control|Routine therapy during peanut desensitization
88916323|NCT01625715|Experimental|ketotifen|rising doses of ketotifen
88916324|NCT01625728||Experimental group.|Participants are either student teachers or practicing teachers.
88916325|NCT01625728||Control Group.|Participants are no students teachers or practicing teachers.
88916326|NCT01625741|Experimental|rituximab|4 monthly administrations of rituximab
88916327|NCT01625754||Cardiac rehabilitation|This study recruits individuals that are currently participating in a cardiac rehabilitation exercise program.
88916328|NCT01625767|Experimental|Approach Avoidance Task experiment|Approach Avoidance Task experiment
88916329|NCT01625780|Experimental|Study group: 3-layer block|Patients in this group will receive the 3-layer ilioinguinal nerve block.
88916330|NCT01625780|Active Comparator|Control: single-shot block|Patients in this group will receive a standard, single-shot ilioinguinal nerve block.
88916331|NCT01625793|Active Comparator|HCV Interferon-alpha group|Subjects receiving treatment with interferon (IFN)-alpha for chronic hepatitis C virus infection.
88916332|NCT01625793|Placebo Comparator|HCV Control Group|Subjects delaying the start of treatment with interferon (IFN)-alpha for chronic hepatitis C virus infection by 7 weeks.
88916333|NCT01625806|Active Comparator|RO4602522|
88916334|NCT01625806|Experimental|RO4602522 + ketoconazole|
88916335|NCT01625819|Experimental|Tai Chi|32 1-hour group sessions of Tai Chi instruction
88916336|NCT01625819|Active Comparator|Resistance Band|32 1-hour bi-weekly group sessions of Resistance Band exercises
88916337|NCT01625819|Placebo Comparator|Health Education|32 1-hour bi-weekly group sessions of health education
88916338|NCT01625819|No Intervention|Care as Usual|Receive usual cardiology care for 4 months between pre- and post-treatment testing
88916339|NCT01625832|Experimental|1|CSO first
88916340|NCT01625832|Experimental|2|CSO second
88916341|NCT01625858||Supreme / other pediatric SGA|pediatric patients undergoing general anesthesia being treated with LMA Supreme or another pediatric supraglottic airway device
88916342|NCT01625871|Experimental|artemether-lumefantrine|tablets (containing 20mg artemether and 120 mg lumefantrine) for three days
88916343|NCT01625949|Active Comparator|Control Arm (Standard Therapy)|Control Arm Receiving The Standard Therapy including successful coronary intervention and stenting
88916344|NCT01625949|Experimental|Intracoronary stem cells|Intracoronary stem cells will be injected in the infarct related artery after a successful coronary dilatation and stenting
88916345|NCT01625962||mTBI|"Service members who have sustained impact-induced mTBI or blast-induced mTBI (n = 74 completers)"
88916346|NCT01625962||ECI|Service members who have sustained an extracranial injury (ECI) with no evidence of TBI (n = 32 completers)
88916347|NCT01625975||Growth modulation with Eight plate|Pediatric patients undergoing growth modulation with the Eight plate system
88916348|NCT01626001|Experimental|Cohort 1|Cohort of 18 subjects evaluated. Subject will receive 4DCT cine acquisition gated using a respiratory signal from real-time position management (RPM) gating system. Maximum number of allowable images that may be acquired increased from 3000 to 5999 images. Total imaging time for each subject < 60 minutes.
88916349|NCT01626001|Experimental|Cohort 2|Reproducibility of optimal 4DCT acquisition method determined from cohort 1 tested with cohort of 18 study subjects. Three 4DCT images acquired, all with acquisition method determined from cohort 1. Cohort also receives two spiral-mode 4DCT acquisitions.
88922270|NCT05572788|Active Comparator|Rectal Indomethacin|Patients assigned to the Indomethacin group will receive100 mg of indomethacin administered per rectal route (two tablets of 50 mg indomethacin suppositories)
89435405|NCT06143826|Experimental|Dementia caregiver|Caregivers will be asked to perform progressive muscle relaxation exercises 3 days a week for 3 months.
89435406|NCT06142812|Experimental|Intervention Group|Students will be required to log in with a Pin number using a nickname that allows them to remain anonymous. Questions will be displayed on a large screen with four graphic shapes along with a countdown timer, and students will respond using their internet-enabled digital device. Students will choose, from four options, the possible answer by selecting the graphical shape, which they believe is correct, and will receive instant feedback accordingly. After each question, the game will rank players based on their speed and accuracy. The system will award a higher score to the student who enters the correct answer first. At the end of the quiz, the names of the top five players will be displayed on the leaderboard. The results can then be downloaded to highlight problematic questions and identify students who may be struggling.
89435407|NCT06139848|Experimental|Maitland, Mackenzie Techniques and Conventional Treatment|posterior-anterior spinal mobilization and prone press up along with conventional treatment as Heating pad for 10 minutes Bridging exercises (10 rep, 3 sets) Paraspinal muscle stretch
89435408|NCT06139848|Active Comparator|Maitland Mobilization Techniques and Conventional Treatment|Posterior-anterior spinal mobilization along with conventional treatment as Heating pad for 10 minutes Bridging exercises (10 rep, 3 sets) Paraspinal muscle stretch
89435409|NCT06139848|Active Comparator|Meckinzie Techniques and Conventional Treatment|"Prone press up technique will be given along with conventional treatment as:~Heating pad for 10 minutes Bridging exercises (10 rep, 3 sets) Paraspinal muscle stretch"
89435410|NCT06136195|Experimental|Mavoglurant|Participants randomized to the Mavoglurant arm will take 100mg of Mavoglurant each day during the first medication period for 6-8 days. During the second medication period, participants will take 200mg of Mavoglurant each day for 6-8 days.
89435411|NCT06136195|Placebo Comparator|Placebo|Participants randomized to the placebo arm will take matching placebo tablets during both the first and second medication period.
89435412|NCT06133985|Experimental|Costovertebral mobilizations + Conventional Physiotherapy|"Costovertebral mobilizations along conventional treatment patient would receive costovertebral mobilization in side lying position for 10th to 6th ribs, in sitting position for 10th to 2nd rib and in supine position for 1 rib.~Frequency: 5 times/week for 3 weeks. Intensity: moderate intensity (pain free) Time: 20 mins Type: costovertebral joint mobilization to improve respiratory function and chest tightness.~Conventional treatment diaphragmatic breathing exercises and pursed-lip expiration exercises. Patient will receive diaphragmatic breathing and pursed lip breathing exercise in sitting position Frequency: 5 times/week for 3 weeks Intensity: moderate intensity (pain free) Time: 30 mins Type: breathing exercises to improve respiratory function and chest tightness."
89435413|NCT06133985|Other|Conventional Physiotherapy|diaphragmatic breathing exercises and pursed-lip expiration exercises Patient will receive diaphragmatic breathing and pursed lip breathing exercise in sitting position Frequency: 5 times/week for 3 weeks Intensity: moderate intensity (pain free) Time: 20 mins Type: breathing exercises to improve respiratory function and chest tightness.
88916350|NCT01626014|Experimental|Intervention Group|Using the Prototype System website: An interactive educational system for patients and their caregivers includes features allowing users to create their own profile, share a journal with others, and post to respective discussion forums. In addition, core intervention components include distress monitoring, educational items, details about the healthcare team and an areas to keep track of questions for providers.
88916351|NCT01626014|Active Comparator|Control Group|Using the Usual Care Educational Website : a website which will contain information regarding ovarian cancer however it will not be interactive. It will contain pdf documents of the material handed out in clinic (usual care).
88916352|NCT01626040||PEG-P prep|Children taking the one day polyethylene glycol powder preparation for outpatient colonoscopy
88916353|NCT01626053|No Intervention|control group|
88916354|NCT01626053|Experimental|lifestyle counseling|These participant received the ASMART interventions.
88916355|NCT01626066|Experimental|LUM015|Receive single dose of LUM015 through a vein in the arm the day prior to surgery
88916356|NCT01626131|Experimental|Exercise treatment|Aerobic and resistance training
88916357|NCT01626131|Experimental|Stretching treatment|
88916358|NCT01626144||Breast cancer, exemestane treatment|Breast cancer patients receiving standard of care exemestane
88916359|NCT01625156|Experimental|Treatment (tivantinib, temsirolimus)|Patients receive tivantinib PO BID and temsirolimus IV over 30 minutes on days 1, 8, 15, and 22 (days 8, 15, 22, and 29 of course 1). Courses repeat every 28 days (35 days in course 1) in the absence of disease progression or unacceptable toxicity.
88916360|NCT01626170||Correlative (laboratory biomarker analysis)|Archived tissue samples of matched primary-relapsed and non-matched primary are analyzed for genomic DNA, DNA methylation profiles, RNA sequencing, differences between alveolar rhabdomyosarcoma (ARMS) and embryonal rhabdomyosarcoma (ERMS), gene expression profiles, target-of-rapamycin complex 1 (TORC1) and TORC2 pathway intermediates, and paired box 3 (PAX3)/forkhead box O1 (FOXO1) translocation by microarray, immunohistochemical staining, and fluorescence in situ hybridization (FISH).
88916361|NCT01626196||Colonoscopy patients|Patients undergoing with bowel cleansing procedures according to the clinics' usual routine
88916362|NCT01626209|Experimental|BKM120 at: 80 and 100mg/day dose levels|
89435414|NCT06133855|Experimental|Pulsed electromagnetic field|the patients will receive pulsed electromagnetic field plus traditional physical therapy program three times a week for four weeks
89435415|NCT06133855|Active Comparator|traditional physical therapy program|the patients will receive traditional physical therapy program three times a week for four week
89435416|NCT06130917|Experimental|Experimental Group|Experimental group will receive education on diabetes and conventional treatment exercises. The interventional multisystem exercises program will consist of four components, with each exercise lasting for a duration of 10 minutes per session. These components encompass proprioception training, balance exercises, strengthening routines, and reaction time training. This total multisystem exercises session will be performed for 30 minute, 3 times a week for 8 weeks in total.
89435417|NCT06130917|Other|Control group|Control group will receive health education on diabetes. Conventional treatment will include Stretching, Range of motion (ROM) exercise , balance and strengthening for 10 minutes each exercise in one session. Each stretch holds for 15-20 sec. This exercise session will be performed for 30 minute, 3 times a week for 8 weeks in total.
89435418|NCT06130891|Experimental|Cognitive sensory motor relearning Group|Cognitive, sensory, and motor training
88916363|NCT01626222|Experimental|Everolimus & Exemestane|This study will be performed in 300 postmenopausal women with hormone receptor positive locally advanced or metastatic breast cancer progressing following prior therapy with non-steroidal aromatase inhibitors (NSAI) as defined by: 1. Recurrence while on or after completion of an adjuvant treatment including Letrozole or Anastrozole, or 2. Progression while on or following the completion of Letrozole or Anastrozole treatment for locally advanced or metastatic breast cancer. Except for prior use of mTOR inhibitors, there are no restrictions as to the last anticancer treatment prior to enrollment. Patients must have documented evidence of recurrence or progression on last therapy prior to enrollment. Written informed consent must be obtained prior to any screening procedures. The investigator or designee must ensure that only patients who meet all the following inclusion and none of the exclusion criteria are offered enrollment in the study.
89435419|NCT06130891|Experimental|Sensory Motor Relearning Group|Sensory and motor training
89435420|NCT06130891|Experimental|Motor Relearning Group|Motor training
89435421|NCT06130878|No Intervention|Control Group (CG)|This group does not receive any treatment.
89435422|NCT06130878|Experimental|EXPERIMENTAL GROUP (EG)|People assigned to this group will undergo a 12-week physical training intervention
89435423|NCT06124924|No Intervention|control|usual care. no medication will be prescribed by Dr. Murphy. Only a basic metabolic panel lab test will be ordered in EPIC for the study participant to be done approximately 2 weeks after discharge and the results of which are to be routed to Dr. Murphy. A post-AKI / post-discharge basic metabolic panel lab test is a usual care lab test, and Dr. Murphy reviews such lab test results in his usual clinical practice.
89435424|NCT06124924|Experimental|Experimental group|randomized to SGLT2i
89435425|NCT06124157|Active Comparator|Arm I (dasatinib, standard chemo)|See detailed description.
88916364|NCT01626235||NSAID only|Subjects have their pain treated post-ED care with NSAID medication alone
88916365|NCT01626235||Opioid only|Subjects have their pain treated post-ED care with opioid medication alone
88916366|NCT01626235||NSAID + Opioid|Subjects have their pain treated post-ED care with NSAID medication and opioid as PRN rescue analgesia
89435426|NCT06124157|Experimental|Arm II (blinatumomab)|See detailed description.
89435427|NCT06123182|Experimental|Episodic Future Thinking (EFT) + Positive Affective Imagery (PAI)|Assigned guided imagery will be delivered during each exercise session throughout the 6-week exercise program. The guided imagery recordings will be delivered via audio recording during warm-up and cool-down periods during in-lab exercise sessions. The EFT will always be delivered during warm-up and the PAI will always be delivered during cool-down.
88916367|NCT01626248||Group A TX Naive|Patient decided to start disease modifying treatment, either interferon beta-1a, glatiramer acetate or natalizumab. If interested and consented they would be assigned to Group A. Patient would have blood specimens taken up to 5 times over the next 19 months: Day 0; Day 28; Day 84: Day 336 and Day 508.
88916368|NCT01626248||Group B TY 4-12 doses|Patient is currently prescribed and is taking natalizumab, has 4 to 12 doses. If interested patient could be consented and assigned to Group B. Patients will have their blood drawn Day 0; and around the time of the patient's 18th dose.
88916369|NCT01626248||Group C 18 plus TY|Patient currently or close to being at 18 doses or 18 plus doses of natalizumab. If interested patient consented and assigned to Group C. Patient will have their blood drawn once: Day 0.
88916370|NCT01626248||Group D Other DMT 18 plus|Patient is close to or currently at 18 doses or more of interferon beta-1a or glatiramer acetate. If interested patient consented and assigned to Group D. Patient will have their blood drawn once: Day 0.
88916371|NCT01626248||Group E - Non-MS|10 participants without Multiple Sclerosis or other immunological illness. If interested participants consented and assigned to Group E. Participants will have their blood drawn once: Day 0.
89536406|NCT03196843|Experimental|Raltitrexed plus Radiation|Raltitrexed 2.5mg/m2, iv, every 3 weeks, concurrently with intensity modulated radiotherapy(IMRT)
88916372|NCT01626261||cardiac pacemaker|
88922271|NCT05572788|Placebo Comparator|Placebo|Patients assigned to the Placebo group will receive two glycerin suppositories.
89435428|NCT06123182|Experimental|Episodic Future Thinking (EFT) + Neutral Affective Imagery (NAI)|Assigned guided imagery will be delivered during each exercise session throughout the 6-week exercise program. The guided imagery recordings will be delivered via audio recording during warm-up and cool-down periods during in-lab exercise sessions. The EFT will always be delivered during warm-up and the NAI will always be delivered during cool-down.
89435429|NCT06123182|Experimental|Episodic Recent Thinking (ERT) + Positive Affective Imagery (PAI)|Assigned guided imagery will be delivered during each exercise session throughout the 6-week exercise program. The guided imagery recordings will be delivered via audio recording during warm-up and cool-down periods during in-lab exercise sessions. The ERT will always be delivered during warm-up and the PAI will always be delivered during cool-down.
88916373|NCT01626274|Experimental|Device: in-ear sensor|Patients who routinely undergo a polysomnography night (1 night) are monitored via in-ear sensor which will be embedded in the auditory canal. During this night vital signs parameters are monitored, processed and subsequently compared to the polysomnography data.
88916374|NCT01626287|Experimental|Black tea bag|
88916375|NCT01626287|Active Comparator|ice packs|20 randomly chosen participants will be given frozen ice packs for perineal pain relief
88916376|NCT01626326||Stop smoking app|Stop smoking iPhone research app provided at no charge via the iTunes store
88916377|NCT01626365|Active Comparator|non-thermosoftening|Double-lumen tube is put into a bottle of normal saline at room temperature (25°C) before intubation.
88916378|NCT01626365|Experimental|thermosoftening|Double-lumen tube is put into a bottle of warm normal saline (40°C) before intubation.
88916379|NCT01626417|No Intervention|Patient Population|Chronic post-stroke subjects with varied impairment level, who have completed routine rehabilitative physical therapy.
88916380|NCT01626430|Experimental|200 mg gd-TRF|
88916381|NCT01626430|Experimental|400 mg gd-TRF|
88916382|NCT01626430|Experimental|Placebo|
88916383|NCT01626443|Active Comparator|Folic acid|
88916384|NCT01626443|Experimental|Inofolic Combi|
88916385|NCT01626469|Active Comparator|Arm A|Captopril 25 mg (Admission 1, Day 1, low salt diet) Matched Placebo (Admission 1, Day 2, low salt diet) Captopril 25 mg (Admission 2, Day 1, high salt diet) Matched Placebo (Admission 2, Day 2, high salt diet)
88916386|NCT01626469|Placebo Comparator|Captopril|Matched Placebo (Admission 1, Day 1, low salt diet) Captopril 25 mg (Admission 1, Day 2, low salt diet) Matched Placebo (Admission 2, Day 1, high salt diet) Captopril 25 mg (Admission 2, Day 2, high salt diet)
88916387|NCT01626482|Placebo Comparator|Sham tape|
88916388|NCT01626482|Experimental|Kinesio Tape|
88916389|NCT01626521||COPD Exacerbation|Patients admitted to hospital with COPD exacerbation
88916390|NCT01626534|Active Comparator|clopidogrel group|
88916391|NCT01626534|Experimental|tricagrelor group|
89536407|NCT03196843|Active Comparator|Radiation|Intensity modulated radiotherapy(IMRT) alone radical radiotherapy:70Gy/2Gy/7 weeks preoperative and postoperative adjuvant radiotherapy:50-60Gy/2Gy/5-6 weeks
88916392|NCT01626560|Other|Daptomicina|
88916393|NCT01626560|Other|Vancomycin|
88916394|NCT01626586|Experimental|Group Therapy|"This study includes having an initial assessment completed; participating in a 6 session group therapy intervention over a 7 week time period; and returning at 2 and 4 months after group therapy intervention for booster follow-up sessions. During the group intervention sessions, the parent group and the youth group will each meet for about 45 minutes and then the families will come together to work on family goals for the last 15 to 20 minutes."
88916395|NCT01626586|Active Comparator|Individual Arm|"This study includes having an initial assessment completed; participating in a 6 session individual therapy intervention over a 7 week time period; and returning at 2 months after the individual therapy intervention for the booster follow-up session. During the individual intervention sessions, the youth and the parents will each meet for about 45 minutes and then the families will come together to work on family goals for the last 15 to 20 minutes."
88916396|NCT01626586|Active Comparator|Recently Diagnosed Arm|"This study includes enrolling patients with Type 1 Diabetes, who are recently diagnosed (<1 year) to participate in a 4 session group therapy intervention over a 4 week time period; and returning at 2 months after the last group session for the booster follow-up session. During the group sessions, the youth and the parents will each meet for about 45 minutes and then the families will come together to work on family goals for the last 15-20 minutes."
88916397|NCT01626612|Experimental|a strategy based on de-escalation|
88916398|NCT01626612|Active Comparator|a conservative strategy|
88916399|NCT01626625|Experimental|stem cells|stem cells + hydroxy apatite
88916400|NCT01626625|Active Comparator|autograft|
88916401|NCT01626638|Experimental|Experimental|
88916402|NCT01626651|Experimental|Ibrutinib and Ketoconazole|
88916403|NCT01626677|Experimental|CARTISTEM|A single dose of 500㎕/㎠ of cartilage defect
88916404|NCT01626677|Active Comparator|Microfracture|conventional treatment method
88916405|NCT01626703|Experimental|intervention|remiding call
88916406|NCT01626703|No Intervention|Control|No intervention
88916407|NCT01626716|Experimental|case management|patients who assigned to the intervention group will take 7 times phone calls from case manager
88916408|NCT01626716|No Intervention|control|usual care
88916409|NCT01626729|Experimental|Traffic Light|
88916410|NCT01626729|Experimental|Traffic Light+|
88916411|NCT01626729|Experimental|Facts Up Front|
88916412|NCT01626729|Experimental|Facts Up Front+|
88916413|NCT01626729|Placebo Comparator|No front of package label|
88916414|NCT01626742|Placebo Comparator|Ready to drink flavored beverage|
88916415|NCT01626742|Experimental|Ready to drink flavored beverage w/ AN 777|
88916416|NCT01626755|Experimental|Nerve block|"Optimized intravenous pain treatment during surgery and for 7 days postoperatively.~Definition: strong opioid patient-controlled analgesia, non-opioids, ketamine intravenously.~Sciatic nerve block: infusion of local anesthetic."
88916417|NCT01626755|Active Comparator|Control|"Optimized intravenous pain treatment during surgery and for 7 days postoperatively.~Definition: strong opioid patient-controlled analgesia, non-opioids, ketamine intravenously.~Sciatic nerve block: saline infusion."
88916418|NCT01626768||Enrolled patients|
88916419|NCT01626794|Experimental|VARIVAX™ VEP|
89435430|NCT06123182|Active Comparator|Episodic Recent Thinking (ERT) + Neutral Affective Imagery (NAI)|Assigned guided imagery will be delivered during each exercise session throughout the 6-week exercise program. The guided imagery recordings will be delivered via audio recording during warm-up and cool-down periods during in-lab exercise sessions. The ERT will always be delivered during warm-up and the NAI will always be delivered during cool-down.
89435431|NCT06121011||Cipaglucosidase alfa/Miglustat-treated patients|
88916420|NCT01626794|Active Comparator|VARIVAX™ 2007 Process|
88916421|NCT01626807|Experimental|Walking school bus|
88916422|NCT01626807|No Intervention|Usual care|
88916423|NCT01626833|Active Comparator|SOMATROPINE* : Norditropine® simplexx®|SOMATROPINE* : Norditropine® simplexx®
88916424|NCT01626833|Placebo Comparator|Placebo|Placebo
88916425|NCT01626846||NF1 teenagers|
88916426|NCT01626898|Experimental|HOLA en Grupos|The Spanish language HOLA en Grupos intervention consists of four 4-hour group sessions that combine presentations by facilitators who are trained Latino MSM community members, activities, and scenes from a DVD, and is delivered over a period of two weeks to groups of about 10 participants.
88916427|NCT01626898|Active Comparator|General health intervention|The Spanish language comparison condition consists of four 4-hour group sessions designed to increase participants' knowledge about cancer, diabetes, alcohol abuse, and cardiovascular disease, and is delivered over a period of two weeks to groups of about 10 participants.
88916428|NCT01626911|Experimental|CRAI|CRAI of LMWH in the celiac trunk
88916429|NCT01626911|Other|Conservative treatment|Conservative treatment without CRAI, control group
88916430|NCT01626924|Experimental|2-Iminobiotin|
89435432|NCT06121011||Other Enyzme Replacement Therapy (ERT)-treated patients|
88916431|NCT01626937|Experimental|Non invasive ventilation with conventional treatment|
88916432|NCT01626937|Active Comparator|conventional medical treatment|
88916433|NCT01626950||Cases - Stage III-IV breast cancer|The women in this group have been diagnosed with stage III-IV incident cancer.
88916434|NCT01626950||Controls: Stage I-II breast cancer|The women in this group have been diagnosed with stage I-II incident cancer.
88916435|NCT01626963|Experimental|SPA|Single-port access surgery
88916436|NCT01626963|Active Comparator|CL|Conventional Laparoscopic access
88916437|NCT01626976|Experimental|Cohort 1|
89435433|NCT06121011||Untreated patients (those who are not currently receiving any medical therapy for Pompe disease)|
89435434|NCT06120504|Experimental|SGN-35T|SGN-35T monotherapy
89435435|NCT06119282|Experimental|Test İnhaler|After the cesarean section, at the 8th hour postpartum, the VAS/GCA is evaluated, 4 drops of carrier oil are dropped on the upper and lower parts of the wick of the aroma stick, and then 15-20 drops of the prepared essential mixture are dropped and the woman is explained about its use. By the 8th hour of the postop, 4*1 women are allowed to sniff. Before the application, the 30th and 60th minutes VAS/GOC, vital parameters are evaluated.
89536408|NCT03196609|Experimental|Cohorte|"This cohort will consist of patients as described below:~15 patients with non-small cell lung cancer (NSCLC)~10 patients with hepatocellular cancer:~10 patients with colorectal cancer~10 patients with breast cancer~10 patients with prostate cancer~10 patients with glioblastoma"
88916438|NCT01626976|Experimental|Cohort 2|
88916439|NCT01626976|Experimental|Cohort 3|
88916440|NCT01626976|Experimental|Cohort 4|
88916441|NCT01626976|Experimental|Cohort 5|
88916442|NCT01627015|Experimental|Modified infant follow-on formula|Infants are fed a modified infant follow-on formula (modified carbohydrate composition) for 4 weeks, according to protocol
88916443|NCT01627015|Active Comparator|Standard infant follow-on formula|Infants are fed a commercial follow-on formula for 4 weeks, according to protocol
88916444|NCT01627041|Experimental|Arm I (daunorubicin hydrochloride, cytarabine)|Patients receive induction chemotherapy comprising daunorubicin hydrochloride IV daily on days 1-3 and cytarabine IV continuously on days 1-7 in the absence of disease progression or unacceptable toxicity. Patients who do not achieve a CR after the first induction-chemotherapy course receive a second identical induction course.
88916445|NCT01627041|Experimental|Arm II (decitabine, daunorubicin hydrochloride, cytarabine)|Patients receive decitabine IV over 1 hour on days -5 to -1. Patients then receive induction chemotherapy as in arm I in the absence of disease progression or unacceptable toxicity. Patients who do not achieve a CR after the first induction-chemotherapy course receive a second identical induction course.
88916446|NCT01627080||Cardiac Biomarkers|Patients with histologically proven esophageal cancer to be treated with radiation therapy with concurrent chemotherapy to a final dose of >/=40 Gy included in this study at UT MD Anderson Cancer Center in Houston, Texas.
88916447|NCT01627106|Experimental|Vernakalant|
88916448|NCT01627106|Active Comparator|Amiodarone|
88916449|NCT01627119||Gastric cancer patients|Gastric cancer patients who receive curative surgery at National Taiwan University Hospital
88916450|NCT01627132|Experimental|dasatinib|
88916451|NCT01627145|Experimental|antimuscariniz drug|
88916452|NCT01627158|Experimental|Budesonide/formoterol Easyhaler|Budesonide/formoterol Easyhaler
88916453|NCT01627158|Active Comparator|Symbicort Turbuhaler|Symbicort Turbuhaler
88916454|NCT01627158|Experimental|Charcoal and Budesonide/formoterol Easyhaler|
88916455|NCT01627158|Active Comparator|Charcoal and Symbicort Turbuhaler|
88916456|NCT01627171|Active Comparator|PEG Lyte|PEGlyte to be reconstituted with 4L of water and taken in the evening before the colonoscopy.
88916457|NCT01627171|Experimental|Pico Salax Split|Two sachets of Pico-Salax with 1 taken the night before colonoscopy and the second taken the morning of colonoscopy.
88916458|NCT01627171|Experimental|Pico Salax Night Before|2 sachets of Pico Salax mixed with water taken about 4 hours apart the night before colonoscopy
89435436|NCT06119282|Experimental|Test Massage|When the studies conducted with the massage method are examined, back massage is applied for 10-30 minutes. Considering the working conditions of the institution, it is thought that a 10-minute massage may be sufficient for the application. The massage application is started at the postpartum 8th hour and applied for 10 minutes on the postoperative 0th day 1*1, 2 times on the postoperative 1st and 2nd days when the woman feels ready. 30 and 60 minutes before application. then VAS/GCS, vital parameters are monitored.
89435437|NCT06119282|Active Comparator|Control Group|Pregnant women included in the control group will be left to clinical care, and pain and vital parameters will be monitored starting from the 8th postoperative hour. The scales applied to the experimental groups will be applied on the 2nd postoperative day. Women in the control group who completed the study will be informed about the postpartum use of aromatherapy. Women who want aromatherapy application will be directed to GETAT center.
89536409|NCT02446561|Active Comparator|MRXXX|Active comparator
89536410|NCT02446561|Experimental|MR1XXX|MR1XXX
88916459|NCT01627184||Athletes with diabetes mellitus|Athletes who are insulin-requiring and insulin-dependent diabetics undergoing high levels of activity over extended period of time
88916460|NCT01627197|Active Comparator|Intraaterial chemotherapy|"This is an open-label, prospective, multicenter, randomized, controlled phase 3 two-arm study.Patients with locally advanced TCC of the bladder are randomized to 1 of 2 treatment arms~Arm 1 (treatment):'Surgery of percutaneous catheter system for arterial chemotherapy is done in the Department of Invasive Technology. All medications were administered using percutaneous catheter system via a modified Seldinger technique.Gemcitabine 800 mg/m2 intra-arterial,cisplatin 25 mg/m2 intra-arterial once a week for 3 weeks followed by 1-week rest period. Maximum of 3 cycles. Treatment begins between 1-5 weeks after radical operation (within 40 days is recommended)."
88916461|NCT01627197|No Intervention|Watchful waiting|Arm 2 (control): No immediate post-surgery treatment. Patients undergo observation followed by cisplatin and gemcitabine as in arm I at local relapse, or receive intravenously chemotherapy with cisplatin and gemcitabine at multiple metastases
88916462|NCT01627223|Experimental|Lamivudine 100 mg p.o. q.d.|"To target 88 evaluable subjects, approximately 98 patients should be recruited into this trial. After enrollment, all eligible subjects will be randomly assigned to one of the antiviral treatments below.~Cohort 1: Lamivudine 100 mg p.o. q.d.~Cohort 2: Entecavir 0.5 mg p.o. q.d.~This process will be stratified by prolonged PT, < 4 sec / 4-6 sec / > 6 sec. Both lamivudine and entecavir will be taken once daily and the first dose of observational drug should be administered on Day 1. The observational period of individual subject will be 12 weeks; however, both treatments could be continued after the end of study based on physician's clinical judgment."
88916463|NCT01627223|Experimental|Entecavir 0.5 mg p.o. q.d|"To target 88 evaluable subjects, approximately 98 patients should be recruited into this trial. After enrollment, all eligible subjects will be randomly assigned to one of the antiviral treatments below.~Cohort 1: Lamivudine 100 mg p.o. q.d.~Cohort 2: Entecavir 0.5 mg p.o. q.d.~This process will be stratified by prolonged PT, < 4 sec / 4-6 sec / > 6 sec. Both lamivudine and entecavir will be taken once daily and the first dose of observational drug should be administered on Day 1. The observational period of individual subject will be 12 weeks; however, both treatments could be continued after the end of study based on physician's clinical judgment."
88916464|NCT01627236|Experimental|glucocorticoid treatment group|
88916465|NCT01627236|No Intervention|conventional treatment|
88916466|NCT01627262|Placebo Comparator|Placebo|
88916467|NCT01627262|Experimental|Mesalamine|
88916468|NCT01627275|Experimental|DLI from HLA-identical donor|Naive T Cell Depleted Donor Lymphocyte Infusion from HLA matched family member donor or 8/8 HLA matched unrelated donor.
88916469|NCT01627353|Active Comparator|Standard of Care|Current Standard of Care at Rockyview General Hospital for Post Hysterectomy Pain Prevention(no wound infiltration and routine anesthetic protocol).
88916470|NCT01627353|Experimental|Pre-emptive wound infiltration|The Wound Infiltration Group will receive 100 mL 0.25% marcaine plain distributed as follows: 50 mL subcutaneously prior to skin incision along entire length of planned incision line, 50 mL subfascially prior to fascial incision, with 10 mL infiltrated directly into the rectus muscles bilaterally.
88916471|NCT01627366|Experimental|Survivorship Care Plan|Receipt of a personalized survivorship care plan and an in-person session with a trained nurse to review the contents of the care plan.
88916472|NCT01627366|No Intervention|Usual care|Receipt of usual medical care.
88916473|NCT01627379|Active Comparator|Arm A: Cisplatin, 5-Fluorouracil|Chemotherapy will be administered every 3 weeks until progression of disease or any other reason for treatment withdrawal is fulfilled.
88916474|NCT01627379|Experimental|Arm B: Cisplatin, 5-Fluorouracil and Panitumumab|Chemotherapy plus Panitumumab will be administered every 3 weeks until progression of disease or any other reason for treatment withdrawal is fulfilled.
88916475|NCT01627392|Experimental|Smoking abstinence|
88916476|NCT01627418|Experimental|Voucher|"Receive the intervention (Energy Voucher) the first winter enrolled in the study. The intervention is a electricity voucher and a short pamphlet describing how to work out how much heat the voucher can buy."
88916477|NCT01627418|Other|Control|"Receive the intervention the second winter enrolled in the study (thus No intervention : control arm). The intervention is a electricity voucher and a short pamphlet describing how to work out how much heat the voucher can buy."
88916478|NCT01627431|Other|Antiplatelet therapy|Patients underwent peripheral revascularization procedures undergoing a double antiplatelet therapy
88916479|NCT01627444|Experimental|ear acupuncture|
88916480|NCT01627444|Placebo Comparator|Placebo acupuncture|No needle insertion, only stickers on acupuncture points.
88916481|NCT01627457|Experimental|GEx Training|CAD Patients in cardiac rehabilitation phase II (inpatient) and phase III (at home)in order to analyze data for quality of heart rate measurement and data acquisition by device as well as for practicability and technical problems at home.
88916482|NCT01627470||Cohort|Emergency Patients with applied arterial blood pressure measurement
88916483|NCT01627483|Experimental|Medication review|Assessment of risks of falls and fractures, medication review
88916484|NCT01627483|No Intervention|Controll|
88916485|NCT01627522|Active Comparator|Finastide low dose|2 weeks of daily 5mg finastride before operation
89435438|NCT06114446|Experimental|Experimental group|Participants will be educated with immersive virtual reality simulation for postoperative nursing care of a patient who underwent colorectal surgery
88916486|NCT01627522|Active Comparator|Finastide high dose|4 weeks of daily 5mg finastride before operation
88916487|NCT01627522|No Intervention|Control|Control
88916488|NCT01627535|Experimental|Optical Imaging|Patients undergo i2DOS
88916489|NCT01627561|Experimental|Cervarix Group|Healthy female subjects aged between, and including, 4 and 6 years, who received two doses of Cervarix vaccine at Day 0 and Month 6, administered intramuscularly in the deltoid muscle of the left upper arm.
89435439|NCT06114446|Other|Control group|Participants will be educated with simulation manikin for postoperative nursing care of a patient who underwent colorectal surgery
89536411|NCT02446561|Experimental|MR2XXX|MR2XXX
89536412|NCT02446561|Experimental|MR3XXX|MR3XXX
89536413|NCT02477189||Study Group|This was the group that received the penis implant, consented for participation and completed the follow-up questionnaire.
89536414|NCT02476955|Experimental|ARQ 092 + anastrozole|ARQ 092 will be administered orally at 150 milligrams (mg) every day (QD), 5 days on/9 days off of a 28 day cycle in combination with anastrozole which will be administered orally at 1 mg QD continuously. The combination treatment will continue until progression of disease (clinical or radiological), unacceptable toxicity, or another of the discontinuation criteria is documented.
89198381|NCT00549640|Active Comparator|Methylphenidate|54 mg Methylphenidate per day for 8 weeks. Allowing for a ramp up in the first two weeks (starting dose is 18 mg/day).
89536415|NCT04484389|Experimental|Study Group|Individual exercises will be applied to individuals with Chronic disease.
89536416|NCT04484389|Active Comparator|Control Group|Group to be given an exercise brochure
89198382|NCT00549640|Placebo Comparator|Placebo|non-active (sugar pill)designed to be a look-alike to the methylphenidate. Given at the same frequency and dosage look-alike to the active comparator (methylphenidate 54 mg)
89198383|NCT00868335|Active Comparator|1|Anterior cervical discectomy, no disc prosthesis
89536417|NCT02476877||Prescribed-drug treatment group|Eight hundred (800) subjects of which 200 subjects in each of the four mental illnesses will continue to receive prescription drug therapy (as prescribed by their physician/psychiatrist) and counseling to treat their mental illness.
88922272|NCT05564949|Experimental|Classic Ketogenic Diet|Patients will adhere to a classic ketogenic diet for a period of 3 months with a possible extension depending on their compliance on the diet.
89010172|NCT04555486|Placebo Comparator|Sterile Normal Saline (0.9% NaCl)|Participants will receive a single dose of Sterile Normal Saline (0.9% NaCl) for subcutaneous (SC) injection, administered at same injection volume as DCR-PHXC, to serve as placebo.
89010173|NCT04555213|Experimental|Dose Escalation Cohort 1 - NOX66 400mg|NOX66 400 mg suppository OD
89010174|NCT04555213|Experimental|Dos Escalation Cohort 2 - NOX66 600mg|NOX66 600 mg suppository OD
88922273|NCT05560412|Experimental|Zein nanocapsules|Subjects will consume daily a powder dissolved in water with nanoencapsulated zein
88922274|NCT05560412|Placebo Comparator|control|Subjects will consume daily a powder dissolved in water with zein
88922275|NCT05557396|Active Comparator|NEX (Control group)|"Nose-ear-xiphoid measurement method (NEX), (n=31)~The distance between the patient's nose tip and earlobe will be measured first, then the distance between the earlobe and the xiphoid (NEX method) Marking will be made on the nasogastric tube according to the length obtained from the measurement, The nasogastric tube will be advanced by the researcher from the patient's nose to the point where the marking is made, Immediately after the completion of the nasogastric tube placement procedure, an abdominal X-ray will be taken to confirm the tube location, the position of the distal end of the tube relative to the gastro-esophageal junction will be measured and recorded."
88922276|NCT05557396|Experimental|CoNEX|Corrected nose-earlobe-xiphoid measurement method (CoNEX), (n=31) The distance between the patient's nose tip and earlobe will be measured first, and then the distance between the earlobe and the xiphoid, The nasogastric tube length to be applied to the patient will be determined according to the formula (NEX x 0.38696) + 36.37 cm, The length determined according to the result obtained will be marked on the nasogastric tube, The nasogastric tube will be advanced by the researcher from the patient's nose to the point where the marking is made, Immediately after the completion of the nasogastric tube placement procedure, an abdominal X-ray will be taken to confirm the tube location, the position of the distal end of the tube relative to the gastro-esophageal junction will be measured and recorded.
88922277|NCT05557396|Experimental|XEN+10|"Xiphoid-earlobe-nose+10 cm (XEN+10), (n=31)~The distance between the patient's xiphoid and earlobe will be measured first, and then the distance between the earlobe and the tip of the nose will be measured and 10 cm will be added to the obtained measurement, The length determined according to the result obtained will be marked on the nasogastric tube, The nasogastric tube will be advanced by the researcher from the patient's nose to the point where the marking is made, Immediately after the completion of the nasogastric tube placement procedure, an abdominal X-ray will be taken to confirm the tube location, the position of the distal end of the tube relative to the gastro-esophageal junction will be measured and recorded."
89435440|NCT06109116|Experimental|Self myofascial release + Conventional PT|"The participant will be asked to sit on a chair and feet resting on the ground. A tennis ball is used on the sole of each foot behind the metatarsal heads to the heel concentrating on the medial arch for 2 minutes in sitting position, with as much pressure as they could, pushing into discomfort but not pain. Frequency: 3 times/week for 3 weeks Intensity: moderate intensity (pain free) Time: 35 mins Type: Self myofascial release to improve hamstring flexibility Conventional PT including Hot pack, Knee to chest exercise, bridging exercise, Straight leg raise exercise, Ankle pumping exercise, Superman position exercise.~."
89435441|NCT06109116|Other|Conventional PT|Hot pack, Knee to chest exercise, Bridging exercise, Straight leg raise exercise, Ankle pumping exercise, Superman position exercise Frequency: 3 times/week for 3 weeks Intensity: moderate intensity (pain free) Time: 30 mins Type: Self myofascial release to improve hamstring flexibility
88916490|NCT01627561|Active Comparator|Priorix + Infanrix Group|Healthy female subjects aged between, and including, 4 and 6 years, who received one dose of Priorix vaccine at Day 0 and one dose of Infanrix vaccine at Month 6, administered intramuscularly in the deltoid muscle of the left upper arm.
89435442|NCT06109038|Experimental|: Conventional PT + ITB release with graston technique|"An emollient will be applied to the leg from the lateral joint line along the tibial condyle to just below the iliac crest. The instrument GT-4 will be used for treatment. The tool was used to assess the soft tissue in three locations on the lateral leg: anterior to the ITB, over the ITB, and posterior to the ITB. Brushing and strumming strokes were performed to the tissue utilising the instrument's convex surface. Treatment time with the instrument is 8 -10 mins .~Conventional PT including Hot Pack for 5mins. Quadriceps setting exercises, short arc terminal knee extension, straight leg raise, ROM excercises, hamstring curls in prone lying position, quadriceps strengthening in high sitting position, gastrocnemius muscle stretching (10reps × 5sec × 2sets). Maitland mobilization (Grade 1, 2 and 3 for 10 repititions)."
89435443|NCT06109038|Other|Conventional PT|Conventional PT including Hot Pack for 5mins. Quadriceps setting exercises, short arc terminal knee extension, straight leg raise, ROM excercises, hamstring curls in prone lying position, quadriceps strengthening in high sitting position, gastrocnemius muscle stretching (10reps × 5sec × 2sets). Maitland mobilization (Grade 1, 2 and 3 for 10 repititions).
88916491|NCT01627587|Experimental|Ketoconazole-Part A|Healthy Female volunteers of child bearing potential will receive Treatment A, B and C
88916492|NCT01627587|Experimental|Food-Part B|Healthy Female Volunteers of child bearing potential will receive Treament D and E
88916493|NCT01627600||Atahualpa residents aged ≥ 40 years|All Atahualpa residentes aged 40 ≥ years will be screened by field questionnaires. Then, those with suspected stroke or ischemic heart disease will be evaluated by neurologists and cardiologists. Cardiovascular health metrics will be evaluated in those negative for stroke or ischemic heart disease.
88916494|NCT01627613|Experimental|AP301|Treatment group
89435444|NCT06100822|Placebo Comparator|Placebo Group, Placebo Capsules|Placebo Group (n=20) Week 1: One placebo capsule (500 mg) daily Week 2: Two placebo capsules (1,000 mg) daily Week 3: Three placebo capsules (1,500 mg) daily Week 4-16: Four placebo capsules (2,000 mg) daily
89435445|NCT06100822|Experimental|Treatment Group, Metformin Capsules|Treatment Group (n=20) Week 1: One metformin ER capsule (500 mg) daily Week 2: Two metformin (ER) capsules (1,000 mg) daily Week 3: Three metformin (ER) capsules (1,500 mg) daily Week 4-16: Four metformin (ER) capsules (2,000 mg) daily
89435446|NCT06096779|Experimental|Cohort A: Atezolizumab+Bevacizumab|Participants will receive Atezolizumab plus Bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
89435447|NCT06096779|Experimental|Cohort B: Atezolizumab|Participants will receive Atezolizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
89435448|NCT06094985||Patient with head and neck cancer|Patient diagnosed with head and neck cancer
89435449|NCT06088797||healthy subjects|First time :WISC V 40 minutes Second time :Completion of the 4 experimental tasks 105 minutes
88916495|NCT01627613|Placebo Comparator|saline solution|Placebo group
88916496|NCT01627626|Experimental|0.1% pilocarpine mouthwash|0.1% pilocarpine solution which diluted 2% pilocarpine hydrochloride eyedrop with 0.9% saline
88916497|NCT01627626|Placebo Comparator|0.9% saline mouthwash|0.9% saline as a mouthwash
88916498|NCT01627639|Active Comparator|Acetazolamide|Acetazolamide (1 g IV per day or 2 g IV per day if coprescription of loop diuretics) or Placebo (saline serum) when pure or mixed metabolic alkalosis being present until planned extubation
88916499|NCT01627639|Placebo Comparator|Placebo|Placebo
88916500|NCT01627652|Experimental|altitude|subjects will be studies at sea level and at high altitude
88916501|NCT01627665|Active Comparator|D->R->C+R|sequence of treatment: Dabigatran after rivaroxaban after chlarythromycin in association with rivaroxaban
88916502|NCT01627665|Active Comparator|D->R->C+D|sequence of treatment: Dabigatran after rivaroxaban after chlarythromycin in association with Dabigatran
88916503|NCT01627665|Active Comparator|R->D->C+D|sequence of treatment: rivaroxaban after Dabigatran after chlarythromycin in association with Dabigatran
89435450|NCT06088797||blind|First time :WISC V 40 minutes Second time :Completion of the 4 experimental tasks 105 minutes
89435451|NCT06088797||low visual acuity|First time :WISC V 40 minutes Second time :Completion of the 4 experimental tasks 105 minutes
88916504|NCT01627665|Active Comparator|R->D->C+R|sequence of treatment: rivaroxaban after Dabigatran after chlarythromycin in association with rivaroxaban
88916505|NCT01627678|Experimental|Arm 1= Arm A: Vacc-C5 /GM-CSF.|Arm 1=Arm A: Vacc-C5 with GM-CSF as adjuvant administered intradermally.
88916506|NCT01627678|Experimental|Arm 2=Arm B: Vacc-C5/Alhydrogel|Arm 2=Arm B: Vacc-C5 with Alhydrogel as adjuvant administered intramuscularly.
89435452|NCT06088797||reduced visual field|First time :WISC V 40 minutes Second time :Completion of the 4 experimental tasks 105 minutes
89435453|NCT06088576|Other|test group|"Following the inclusion interview, adolescents has access to the Together application.~During the duration of the support, he will have access to the news, chat and forum.~Teenager have 8 working days to appropriate the application. For 1 month, the chat can be used without any other means of communication. A chat is limited to 20-30 minutes, after that, a teleconsultation can be offer. At the end of the 1 month, teleconsultations or a home visit are possible (30 to 45 minutes). They are done between 1 to 4 sessions in the month. Following the orientation, the psychologists take over the visio for the next 2 months, up to 2 to 4 interviews per month. Teleconsultation appointments are made on the calendar of the application by the professional after obtaining advice from teenagers.~At the beginning of the 5th month of care, the professionals set up a mixed distance/presential care with the youth. They propose home visits, individual or group interviews on site."
89435454|NCT06087601|Active Comparator|Sham blocks|US-guided Bilateral genicular nerve block with 0,9% NaCl
89435455|NCT06087601|Active Comparator|Genicular nerve neurolysis|US-guided Bilateral genicular nerve neurolysis with 0,5ml 95% ethanol
89435456|NCT06086860|Experimental|Mulligan mobilization with dry needling.|Participants in this group will receive Mulligan mobilization with dry needling.
88916507|NCT01627704|Other|Fluoroestradiol (18F)|
88916508|NCT01627717|Experimental|Maraviroc Boceprevir|
88916509|NCT01627730|Experimental|3th year medical students|
88916510|NCT01627730|Experimental|nurses in critical care units|
88916511|NCT01627743||COPD patients grade C and D|
88916512|NCT01627756|Experimental|Ventilation Group|Volume controlled ventilation was done during the whole surgery.
88916513|NCT01627756|Active Comparator|Non-ventilation Group|In the non-ventilated group lungs were collapsed after completion of CPB until after weaning from the extracorporeal circulation.
88916514|NCT01627769||second degree blisters patients|blister fluids of second degree burns
88916515|NCT01627769||cryotherapy blisters|blister fluids of cryosurgery wounds
88916516|NCT01627795|Experimental|Oshadi D and Oshadi R|anti cancer agents
88916517|NCT01627834|Experimental|Ropinirole|Ropinirole Hydrochloride ER tablets 2 mg of Dr. Reddy's Laboratories Limited
88916518|NCT01627834|Active Comparator|Requip|Requip XL Tablets 2 mg of Glaxosmithkline, USA
88916519|NCT01627847|Experimental|Ropinirole|Ropinirole Hydrochloride ER tablets 2 mg of Dr. Reddy's Laboratories Limited
88916520|NCT01627847|Active Comparator|Requip|Requip XL Tablets 2 mg of Glaxosmithkline, USA
88916521|NCT01627873|Experimental|Remifentanyl|In group A induction of anesthesia will be performed with Propofol (2mg/kg), Cisatracurium (0.15mg/kg)and continous infusion of Remifentanil (0.15mcg/kg/min).Anesthesia will be maintained by Sevoflurane with oxygen (Fi=40%)and air, with a MAC value to maintain BIS between 40 and 60. Intraoperative analgesia will be obtained with Remifentanil 0.15-0.25mcg/kg/min. Additional boluses of Cisatracurium (0.02mcg/kg)will be administered as needed during surgery. At the beginning of closure of the peritoneum bolus of morphine (0.1mg/kg)and acetaminophen 1g will be administered. Propofol and remifentanil infusions will be interrupted at the end of wound closure.
89010175|NCT04555213|Experimental|Dose Escalation Cohort 3 - NOX66 800mg|NOX66 800 mg daily (400 mg suppository BID)
89010176|NCT04555213|Experimental|Dose Escalation Cohort 4 - NOX66 1200mg|NOX66 1200 mg daily (600 mg suppository BID)
89010177|NCT04555213|Experimental|Dose Escalation Cohort 5 - NOX66 1800mg|NOX66 1800 mg daily (600 mg suppository TID)
89010178|NCT04555213|Experimental|Dose Expansion - NOX66 Recommended Phase 2 Dose|Dose Expansion: NOX66 RP2D
89198384|NCT00868335|Experimental|2|Anterior cervical discectomy, with disc prosthesis
89435457|NCT06086860|Active Comparator|Mulligan mobilization without dry needling.|Participants in this group will receive Mulligan mobilization without dry needling.
89435458|NCT06083714|Experimental|Group 1|Participants in this group will receive scapular stabilization exercises in addition to Schroth exercises specific to scoliosis.
89435459|NCT06083714|Active Comparator|Group 2|Participants in this group will receive Schroth exercises specific to scoliosis only.
89435460|NCT06083428|Active Comparator|Iliopsoas Plane Block group|ultrasound guided iliopsoas plane block - 20ml 0,2% ropivacaine
89435461|NCT06083428|Active Comparator|ESPB group|ultrasound guided erector spinae plane block - 20ml 0,2% ropivacaine
89435462|NCT06083428|Active Comparator|Control group|Only spinal anesthesia - No peripheral nerve block
89435463|NCT06076135|Experimental|Cohort 1|1Gy/1F of ILDR + PD-1 inhibitors.
89435464|NCT06076135|Experimental|Cohort 2|1Gy/2F of ILDR + PD-1 inhibitors.
89435465|NCT06076135|Experimental|Cohort 3|1Gy/3F of ILDR + PD-1 inhibitors.
89435466|NCT06072183|Experimental|Arm 1- Ritlecitinib 100 milligrams (mg)|Randomized to Ritlecitinib 100 mg QD for 52 weeks before progressing into the up/down titration extension period, rerandomized according to responder status.
89435467|NCT06072183|Experimental|Arm 2- Ritlecitinib 50mg|Randomized to Ritlecitinib 50 mg QD for 52 weeks before progressing into the up/down titration extension period, rerandomized according to responder status.
89435468|NCT06072183|Placebo Comparator|Arm 3- Placebo|Randomized to Placebo QD for 52 weeks before progressing into the up/down titration extension period, rerandomized according to responder status.
89435469|NCT06072183|Experimental|Arm 4- Ritlecitinib 100mg|Non-randomized open-label Ritlecitinib 100mg QD for 52 weeks.
89435470|NCT06063694|No Intervention|Transmetatarsal amputation with primary closure|Transmetatarsal amputation with primary closure and no application of synthetic electrospun fiber matrix.
89435471|NCT06063694|Experimental|Transmetatarsal amputation with application of synthetic electrospun fiber matrix|Transmetatarsal amputation with application of synthetic electrospun fiber matrix
89435472|NCT06057038|Experimental|Monotherapy (Non-central Nervous System (non-CNS) Malignant Solid Tumors): GEN1042|
89435473|NCT06057038|Experimental|Combination Therapy Cohort1[Head & Neck Squamous Cell Carcinoma (HNSCC)]:GEN1042+Pembro+Chemotherapy|
89435474|NCT06057038|Experimental|Combination Therapy Cohort 2 [HNSCC and Non-small-cell Lung Cancer (NSCLC)]: GEN1042 + Pembro|
89435475|NCT06056661|Experimental|WMR group|Participants in this group will receive the WMR program for up to 5 weeks.
89435476|NCT06054178|Experimental|Fluorescein sodium during surgery|Subjects undergoing parotid surgery for benign conditions will have fluorescein sodium administered intravenously after induction, and fluorescence imaging will be performed to visualize nerves intraoperatively
89435477|NCT06052644|No Intervention|Control Group (CG)|The control group will not carry out any type of intervention. You will receive physical activity recommendations from the Pan American Health Organization, developed by sports science professionals.
89435478|NCT06052644|Experimental|EXPERIMENTAL GROUP 1 (EG1)|This group will engage in high-intensity physical exercise for 150 minutes per week, three days a week, with each session lasting 50 minutes. The session structure will include a 5-minute warm-up, 40 minutes of the core phase, and 5 minutes of cool down.
89435479|NCT06052644|Experimental|EXPERIMENTAL GROUP 2 (EG2)|Participants in this group will perform high-intensity exercise twice a week, with each session lasting 30 minutes. The session structure will include a 5-minute warm-up, 20 minutes of the core phase, and 5 minutes of cool down.
89435480|NCT06052644|Experimental|EXPERIMENTAL GROUP 3 (EG3)|This group will engage in high-intensity exercise four times a week, with each session lasting 50 minutes. The session structure will include a 5-minute warm-up, 40 minutes of the core phase, and 5 minutes of cool down.
89435481|NCT06052306|Experimental|Dose escalation of BAY3546828|Participants with advanced metastatic castration-resistant prostate cancer (mCRPC) will receive 225Ac-pelgi dose in a stepwise fashion, according to a predefined dose escalation scheme.
89435482|NCT06052306|Experimental|Dose expansion group A of BAY3546828|Participants with advanced mCRPC with at least 1 but no more than 2 prior taxane regimens. No prior radionuclide therapy
88916522|NCT01627873|Active Comparator|Fentanyl|In group B anesthesia will be induced by Propofol (2mg/kg), Fentanyl (2mcg/kg)and Cisatracurium (0.15mg/kg). Anesthesia will be maintained by Sevoflurane, oxygen (Fi=40%) and air and boluses of Fentanyl (50mcg). additional boluses of Cisatracurium (0.02mg/kg)will be administered as needed during surgery. At the beginning of closure of the peritoneum acetaminophen 1g will be administered.
88916523|NCT01627886|Experimental|Ibandronate sodium tablets 150 mg|Ibandronate sodium tablets 150 mg of Dr. Reddy's Laboratories Limited
88916524|NCT01627886|Active Comparator|Boniva|Boniva Tablets 150 mg of Roche Laboratories Inc, USA
88916525|NCT01627925|Experimental|Face mask and nasal mask without PEEP|Face mask ventilation and nasal mask ventilation without PEEP
88916526|NCT01627925|Experimental|Nasal mask and face mask with PEEP|Nasal mask ventilation and face mask ventilation with PEEP
88916527|NCT01627938|Experimental|Dexrazoxane (DRZ) plus Mitoxantrone (MX)|DRZ (600 mg/m2) : MX (12 mg/m2) ratio 50:1
88916528|NCT01627938|Placebo Comparator|Placebo plus Mitoxantrone (MX)|Placebo + MX (12 mg/m2)
88916529|NCT01627951|Active Comparator|NF54|Volunteers will be infected with the NF54 strain of Plasmodium falciparum through the bites of 5 infected Anopheline mosquitoes.
89010179|NCT04555369|Experimental|ct-DNA|The enrolled mCRC patients will perform ct-DNA testing to evaluate drug efficacy of chemotherapy, at the time of baseline and after the first cycle of chemotherapy.
89010180|NCT04555252||Cephalic Duodenopancreatectomy|Patients who underwent scheduled cephalic duodenopancreatectomy and hospitalized in intensive care.
89010181|NCT04555447|Experimental|Healthy-agavins|Agavins are branched neo-fructans and were supplemented for a 5-week dose-escalation period in lean participants
89010182|NCT04555447|Placebo Comparator|Healthy-placebo|Maltodextrin was used as placebo and supplemented for a 5-week dose-escalation period in lean participants
89010183|NCT04555447|Experimental|Obese-agavins|Agavins are branched neo-fructans that were supplemented for a 5-week dose-escalation period in obese participants
89010184|NCT04555447|Placebo Comparator|Obese-placebo|Maltodextrin was used as placebo and supplemented for a 5-week dose-escalation period in obese participants
89010185|NCT04554979||Group 1|Duration of COVID-19 symptoms less than 12 days
89435483|NCT06052306|Experimental|Dose expansion group B of BAY3546828|Participants with advanced mCRPC who have not received taxane chemotherapy since becoming castration-resistant. No prior radionuclide therapy.
89435484|NCT06052306|Experimental|Dose expansion group C of BAY3546828|Participants with advanced mCRPC after prior Lutetium-177 labeled PSMA ligand (177Lu-PSMA) treatment.
89435485|NCT06052306|Experimental|89Zr-pelgi PET/CT|A substudy utilizing the BAY2616505, referred to hereafter as 89Zr-pelgi imaging agent and Hybrid positron emission tomography and computed tomography scan (PET/CT) imaging will be performed during the dose escalation part of the study at selected sites.
89010186|NCT04554979||Group 2|Duration of COVID-19 symptoms equal or more than 12 days
89010187|NCT04555057|Experimental|Music therapy group|"One day before surgery, the participants of music therapy group choose the music they want to listen in the operating room. The total playing time of the selected music is recommended between 5 and 10 minutes.~On the day of surgery, after entering the operating room, listen to personally selected music through the speaker. After the music is over, start anesthesia induction."
89010188|NCT04555057|No Intervention|Control group|The participants of control group wear earmuff to block noise after entering the operating room until induction of anesthesia. All other treatments proceed as conventional treatments.
89010189|NCT04554628|Active Comparator|Urinary human neutrophil gelatinase-associated lipocalin|Urinary human neutrophil gelatinase-associated lipocalin (U-NGAL) measurement
89435486|NCT06051942|Experimental|Aquablation|
89435487|NCT06050941|Experimental|treatment group|Reduced intensive of 3 + 5 Idarubicin and Cytarabine plus Venetoclax as induction therapy
89010190|NCT04554628|Active Comparator|Urinary human kidney injury molecule 1 (U-KIM1)|Urinary human kidney injury molecule 1 (U-KIM1) measurement group
89010191|NCT04554823|Placebo Comparator|Control Group|Will attend lectures on health education.
89435488|NCT06049238|Experimental|Maitland Mobilization|Maitland mobilization will be applied 2-3 oscillations per second for 1 minute, 5 set each day, 5 days a week for 4 weeks.
89010192|NCT04554823|Experimental|Exercise Group|Will be subjected to a supervised training program of combined exercises for 24 weeks, with a frequency of 3 times weekly and duration of 60 minutes, an unsupervised flexibility training program 2 times a week and Will attend lectures on health education.
89010193|NCT04554589|Active Comparator|intervention group|receive Glycopyrrolate at dose of 0.2 mg IV every 8 hours daily .
89010194|NCT04554589|Placebo Comparator|placebo group|receive normal saline 2 ml IV every 8 hours daily .
89010195|NCT04554433|Active Comparator|Intervention|A ) Treatment group will receive a combination of Asprin in anti - inflammatory dose and controlled ethanol vapor inhalation in concentraions and technique according to their medical condition .
89010196|NCT04554433|No Intervention|Control|B ) Control group : will receive the standard protocol . Data collection will include : sociodemographic data , clinical history , results of follow up ( daily or according to clinical situation ) Follow up : to record any side effects of drugs , and swab will be taken for PCR .
89010197|NCT04721054|Active Comparator|group receiving thoracic epidural anesthesia|
89010198|NCT04721054|Active Comparator|group receiving thoracic general anesthesia|
89010199|NCT02212639|Experimental|Digoxin|All patients will receive Digoxin without interruption. Doses can be modified individually to reach a serum drug concentration of 0.6 to 1.2 ng/ml for patients <75 years and between 0.5-0.8 ng/ml in patients older than 75 years
89010200|NCT02212756|Experimental|B Group|1st oral administration of Metformin 1000mg and 2nd oral administration of Metformin 1000mg and DW1029M 1200mg
89010201|NCT02212756|Experimental|A Group|1st oral administration of DW1029M 1200mg and Metformin 1000mg and 2nd oral administration of Metformin 1000mg
89010202|NCT02212795|Experimental|A Group|1st oral administration of Zabofloxacin 183mg, 2nd oral administration of Zabofloxacin 367mg and 3rd oral administration of Levofloxacin 250mg
89010203|NCT02212795|Experimental|B Group|1st oral administration of Zabofloxacin 367mg, 2nd oral administration of Levofloxacin 250mg and 3rd oral administration of Zabofloxacin 367mg
89010204|NCT02212795|Experimental|C Group|1st oral administration of Levofloxacin 250mg, 2nd oral administration of Zabofloxacin 183mg and 3rd oral administration of Zabofloxacin 367mg
89010205|NCT00235820|Active Comparator|A|
89010206|NCT00235820|Active Comparator|B|
89010207|NCT00235820|Placebo Comparator|C|
89010208|NCT04554199|Experimental|EEG and MMSE measurements before receiving RPD|EEG and MMSE were measured for all participant before wearing the removable partial dentures.
89435489|NCT06049238|Active Comparator|post facilitation stretch|PFS will be performed 6-10s isometric contraction with 100 % force followed by 15s passive stretch, 4-5 repetitions per day, 5 days a week for 4 weeks.
89435490|NCT06047366|Experimental|Buffered|Buffered 2% lidocaine with 1:100,000 epinephrine Buffered 4% articaine with 1:100,000 epinephrine Buffered 3% mepivacaine Buffered local anesthetic (addition of sodium bicarbonate to make a 10% buffered solution)
89010209|NCT04554199|Experimental|EEG and MMSE measurements after receiving RPD|EEG and MMSE were measured for all participant after wearing the removable partial dentures
89435491|NCT06047366|Active Comparator|Unbuffered|Unbuffered 2% lidocaine with 1:100,000 epinephrine Unbuffered 4% articaine with 1:100,000 epinephrine Unbuffered 3% mepivacaine Standard local anesthetics
89435492|NCT06047145|Experimental|soy isoflavones|One oral capsule daily containing 200mg soy isoflavones for 84 days
89435493|NCT06047145|Placebo Comparator|placebo|One oral capsule daily containing equivalent placebo for 84 days
89435494|NCT06046313|Experimental|treatment group|Acute Myeloid Leukemia Myelodysplastic Syndrome
89435495|NCT06036836|Experimental|Favezelimab/Pembrolizumab|Participants will receive coformulated favezelimab/pembrolizumab (800 mg/200 mg) via an intravenous (IV) infusion every 3 weeks (Q3W) for 3 cycles in the neoadjuvant period and 14 cycles of adjuvant therapy. Each cycle is 21 days. Participants who do not complete all 3 neoadjuvant cycles should have additional cycles in the adjuvant period so that the total number of study intervention administrations is 17 treatment cycles.
89435496|NCT06036836|Experimental|Pembrolizumab|Participants will receive 200 mg pembrolizumab via an IV infusion Q3W for 3 cycles in the neoadjuvant period and 14 cycles of adjuvant therapy. Each cycle is 21 days. Participants who do not complete all 3 neoadjuvant cycles should have additional cycles in the adjuvant period so that the total number of study intervention administrations is 17 treatment cycles.
89435497|NCT06036836|Experimental|Favezelimab/Pembrolizumab + Lenvatinib (Cohort B)|Participants will receive coformulated favezelimab/pembrolizumab (800 mg/200 mg) via IV infusion Q3W for up to 35 cycles (each cycle is 21 days) PLUS lenvatinib every day (QD) 20 mg orally until disease progression, unacceptable toxicity, or discontinuation criteria are met.
89435498|NCT06036836|Experimental|Pembrolizumab + Lenvatinib (Cohort B)|Participants will receive 200 mg pembrolizumab via IV infusion Q3W for up to 35 cycles (each cycle is 21 days) PLUS lenvatinib QD 20 mg orally until disease progression, unacceptable toxicity, or discontinuation criteria are met.
89435499|NCT06035172|Experimental|guided imagery group|
89435500|NCT06035172|Experimental|music group|
89010210|NCT04554355|Experimental|Intervention group|Participants in this group will receive a three-month PA intervention (60 minutes/session, two sessions/week).
89435501|NCT06035172|No Intervention|Control group|
89010211|NCT04554355|No Intervention|Control group|No intervention will be provided, participants in this group need to attend the regular school activities as normal.
89435502|NCT06033261|Experimental|mRNA-1608 Dose A|Participants will receive 2 intramuscular (IM) injections of mRNA-1608 at Dose Level A, each dose administered at 0 and 2 months (Day 1 and Day 57).
89435503|NCT06033261|Experimental|mRNA-1608 Dose B|Participants will receive 2 IM injections of mRNA-1608 at Dose Level B, each dose administered at 0 and 2 months (Day 1 and Day 57).
89435504|NCT06033261|Experimental|mRNA-1608 Dose C|Participants will receive 2 IM injections of mRNA-1608 at Dose Level C, each dose administered at 0 and 2 months (Day 1 and Day 57).
89435505|NCT06033261|Other|BEXSERO|Participants will receive 2 IM injections of BEXSERO, each dose administered at 0 and 2 months (Day 1 and Day 57).
89010212|NCT04554238|Experimental|Armeo spring group|Regarding masking, it is impossible for the treating occupational therapist to be unaware of the treatment to be carried out by the treated patient, just as it is impossible for the patient not to identify the treatment to which they access, therefore, this study is single-blind, considering only who performs the evaluations of the study will not know which group corresponds to the evaluated patient.
89010213|NCT04554238|Active Comparator|Occupational Therapy group|It consists of 5 weeks of intervention, with 3 treatment sessions per week, 40 minutes each time. The patient performs active exercises of the paretic upper limb: bimanual play activities, weight bearing, reaches in various planes of motion that favor shoulder flexion, elbow extension, forearm supination, and dissociated finger movements. In addition to passive mobilizations of the shoulder, elbow and wrist and tactile and proprioceptive sensory stimulation and the use of paretic limbs as support or carrying out prehensions.
89010214|NCT02212873|No Intervention|Control|Equal number of age-matched overweight and obese students will be selected from a control school. There will be no intervention, and students will participate in their usual health and physical education classes plus any other curriculum activities provided by the school.
89010215|NCT02212873|Experimental|MyBFF@school program|Students will participate in all 3 components of MyFF@school for a total of 32 weeks; 1-hour of SSG thrice weekly plus 30 to 45 minutes of either nutrition or psychology classes once a week. All students including those in the control arm will be assessed at baseline, week-16 and at end of the study. They will undergo anthropometric measurements, body fat assessment, clinical examination and fitness test by modified Harvard step-test.
89435506|NCT06032806|Experimental|Group A (Moderate Intensity)|Warm up protocol to reach max HR 50% than moderate intensity exercise. Group A will be given moderate intensity exercise i.e Brisk walk (HR will be in between 50-60% of max HR) .
89010216|NCT04554082||Preoperative Clinical characteristics and metabolic biomarkers|BMI and biochemical parameters including trace elements in patients undergoing laparoscopic sleeve gastrectomy before surgery
89010217|NCT04554082||9 months' Postoperative metabolic biomarkers|BMI and biochemical parameters including trace elements in patients 9 months after laparoscopic sleeve gastrectomy
89010218|NCT02212912|Other|Improvement intervention|Improvement intervention is a multifaceted quality improvement method including evidence-based clinical pathway, standard operating procedures (SOP) of performance indicators, a quality coordinator, and monitoring and feedback system of performance measures.
89010219|NCT02212912|Other|no intervention|The control group indicated that the physicians will not be provided with the information of multifacet improvement tools including evidence-based clinical pathway, standard operating procedures (SOP) of performance indicators a quality coordinator, and monitoring and feedback system of performance measures. They just provide patients with routine care
89010220|NCT00261300|Experimental|1|Pantoprazole 40 mg
89435507|NCT06032806|Experimental|Group B (High Intensity)|Warm up protocol achieve 70% of max HR. Group B will be given high intensity exercise i.e Skipping rope (HR will be in between 70-85% of max HR).
89435508|NCT06032416|Other|Shoulder Arthroplasty|Patients in need of a shoulder arthroplasty
89435509|NCT06030986||ILCOR Utstein OHCA Core Outcome Positive|Respectively for all core outcomes defined.
89435510|NCT06030986||ILCOR Utstein OHCA Core Outcome Negative|Respectively for all core outcomes defined.
89010221|NCT02212990|Active Comparator|Acetaminophen Arm|Acetaminophen Suspension 160mg / 5mL Oral dose immediately following IIV and every 4 to 6 hours up to 24 hours (Maximum 5 oral doses)
89010222|NCT02212990|Placebo Comparator|Placebo Arm|Placebo Suspension Oral dose immediately following IIV and every 4 to 6 hours up to 24 hours (Maximum 5 oral doses)
89010223|NCT02212990|Active Comparator|Ibuprofen Arm|Ibuprofen Suspension 100mg / 5mL Oral dose immediately following IIV and every 6 to 8 hours up to 24 hours (Maximum 4 oral doses)
89010224|NCT02213029|Experimental|Oxytocin or Placebo challenge (Cohort 1)|Subjects will receive oxytocin and or placebo challenges as escalating intravenous (IV) infusions administered on the day of ovulation, followed by an IV bolus day 1 post ovulation, and an intramuscular (IM) injection day 2 post ovulation. The planed doses and routes of administration of oxytocin are as follows: IV infusion will be initiated at 5 milliunit/minute (mU/min) and maintained for 60 min, then the rate will be increased to 10 mU/min and maintained for 60 minutes, a final escalation to 20mU/min will be maintained for 60 minutes, after which the infusion will be stopped. For the IV bolus, a single 5 International unit (IU) IV bolus will be administered. For the IM dosing, a single 10 IU IM injection will be administered.
89198385|NCT00860691|Active Comparator|ARM I - Open colorectal surgery|Open colorectal surgery
89198386|NCT00860691|Experimental|ARM II - Laparoscopic colorectal surgery|Laparoscopic colorectal surgery
89435511|NCT06027112||Male|
89435512|NCT06027112||Female|
89435513|NCT06026475|Active Comparator|Intraoperative Goal Directed Fluid Therapy (GDFT) guided by Stroke Volume Variation (SVV)|When SVV values will increase above 11 colloid bolus 200ml will be administered. postbolus change in values of SVV , SV , SVI and CI shall be noted.
89435514|NCT06026475|Active Comparator|Intraoperative Conventional Fluid Therapy (CFT) guided by Central Venous Pressure (CVP) .|When CVP values will decrease below 8 cmsH20 colloid bolus 200ml will be administered .Postbolus change in values shall be noted .
88916530|NCT01627951|Experimental|NF135|Volunteers will be infected with the NF135 strain of Plasmodium falciparum through the bites of 5 infected Anopheline mosquitoes.
88916531|NCT01627951|Experimental|NF166|Volunteers will be infected with the NF166 strain of Plasmodium falciparum through the bites of 5 infected Anopheline mosquitoes.
89435515|NCT06024421|Experimental|level 1: experimental|D1: 2400 mg BID; D2 to D13: 1600 mg BID and D14: 1600 mg in the morning
89435516|NCT06024421|Experimental|level 2: experimental|D1: 2400 mg BID; D2 to D13: 2000 mg BID and D14: 2000 mg in the morning
89435517|NCT06024421|Experimental|level 3: experimental|D1: 2400 mg BID; D2 to D13: 2400 mg BID andD14: 2400 mg in the morning
89435518|NCT06024421|Placebo Comparator|level 1: placebo|D1: 2400 mg BID; D2 to D13: 1600 mg BID and D14: 1600 mg in the morning
88916532|NCT01627964||normal heart function|normal heart function
88916533|NCT01627964||abnormal heart function|abnormal heart function
88916534|NCT01627977|Experimental|Dye of Lutein/Zeaxanthin/Brilliant Blue|during the surgery will be evaluated if the dye is suitable for dyeing the internal limiting membrane as well as the epiretinal membrane
88916535|NCT01628003|Active Comparator|healthy persons|
88916536|NCT01628003|Experimental|patients after moderate-severe TBI|
88916537|NCT01628055|Experimental|Privigen|The IVIG preparation to be used is 10% liquid (Privigen). IVIG will be applied at a dose of 1.0g/kg, which is approximately 1/2 of the optimal dose used for other immuno/inflammatory indications. The infusion will start at 0.5 ml/kg/hr for the first 30 minutes, to watch for the signs of hypersensitivity to immunoglobulins, and then increased to 2.5 ml/kg/hr, two times slower than the recommended rate indicated in the product package insert (5 ml/kg/hr). Such a low, single dose has not been associated with hyperviscosity and together with a slow infusion will safeguard against occurrence of adverse events related to IVIG infusions. They will receive a total of 1g/kg and depending on patient's weight, it will take between 3.5 to 4+ hours to infuse that amount.
88916538|NCT01628055|Placebo Comparator|Normal Saline|The placebo is the normal saline. Since saline solution will be infused at the volume equivalent to that in which the intended dose of immunoglobulin molecules will be delivered, the placebo (comparator) arm will also serve as a control for the volume of fluid infused to the treatment arm participants.
88916539|NCT01628068|Active Comparator|Left atrial appendage occlusion|Left atrial appendage occlusion with Amplatzer device plus aspirine plus clopidogrel during 3 months
88916540|NCT01628068|No Intervention|Oral anticoagulation|Oral anticoagulation
88916541|NCT01628081|Experimental|Alga Dunaliella bardawil|After screen phase of maximum two weeks the subjects will be randomized to one of two treatments groups (1:1): Dunaliella or placebo.
88916542|NCT01628081|Placebo Comparator|Placebo|"Dosage Regimen and Treatment Groups~Daily oral administration of:~Dunaliella, 6 capsules/day (3 capsules in the morning, 3 in the evening).~Placebo, 6 capsules/day (3 capsules in the morning, 3 in the evening)."
88916543|NCT01628133||blood transfusion group|
88916544|NCT01628146|Experimental|SUPRACOR LASIK treatment|SUPRACOR LASIK treatment
88916545|NCT01628172|Experimental|Biosense Webster Celcius Thermacool catheter|These subjects will undergo catheter-based sympathetic renal denervation. Ablation arm
88916546|NCT01628172|No Intervention|renal angiogram only|Control Group: Control arm will not receive intervention but will be followed for 1 year.
88916547|NCT01628185||Pain Observations|Adult ICU patients who are not comatose with Richmond Agitation-Sedation Scale (RASS) score of -3 to 4 and unable to self-report pain. Patients will be excluded for neurological deficits (acute or chronic) that prevent observation of the muscle tonus or movement
88916548|NCT01628224||CCATT Team|Measurements will be taken on groups of 3 people each. There will be a total of 16 such teams, with total membership of 48 individuals
88916549|NCT01628237|Active Comparator|Monocolumn spinal cord stimulation|Specify 5-6-5 Lead (only one column)
88916550|NCT01628237|Experimental|Multicolumn spinal cord stimulation|Specify 5-6-5 Lead
88916551|NCT01628263|Experimental|Follow up Clinic|Participants will receive an offer of a follow up clinic two months post discharge, staffed by the unit Clinical Psychologist, a PICU doctor and PICU nurse.
88916552|NCT01628263|No Intervention|Control|Participants will not receive an offer of a follow up clinic
88916553|NCT01628276|Experimental|Rehab first|
88916554|NCT01628276|Experimental|Rehab Second|
88916555|NCT01628276|No Intervention|Non Rehab|
88916556|NCT01628289|Other|free screening group|Subjects in this group receive free diabetic retinopathy screening.
88916557|NCT01628289|Other|Pay screening group|Subjects in this group receive diabetic retinopathy screening with charging a co-payment.
88916558|NCT01628302|No Intervention|Normal salt diet|The group had normal salt diet (250mmol)for three weeks. Subjects had normal salt diet in their daily routine life for the following 2 weeks.According to crossover nature of the study, the group had low salt diet (50mmol) at the last 3 weeks of the study.
89435519|NCT06024421|Placebo Comparator|level 2: placebo|D1: 2400 mg BID; D2 to D13: 2000 mg BID and D14: 2000 mg in the morning
89435520|NCT06024421|Placebo Comparator|level 3: placebo|D1: 2400 mg BID; D2 to D13: 2400 mg BID andD14: 2400 mg in the morning
89536418|NCT02476877||Naïve drug group|Two hundred (200) subjects of which about 50 subjects in each of the four mental illnesses will be initially drug naïve (i.e. currently not taking psychotropic drugs) at the beginning of the study and continue to be drug naïve until the end of the study (6 months) as they receive counseling for their mental illness.
89536419|NCT02634801|Experimental|Ixekizumab|"160 milligrams (mg) ixekizumab given as two subcutaneous injections (SC) followed by 80 mg ixekizumab given SC every 2 weeks until week 12 and then 80 mg ixekizumab given SC every 4 weeks until week 24.~Extension Period: At week 24, participants have the option to continue ixekizumab treatment for up to 36 weeks."
89536420|NCT02634801|Active Comparator|Fumaric Acid Esters|"Starting dose of 105 mg FAE given orally followed by 215 mg FAE given orally 1 to 3 times per day until week 24.~Extension Period: At week 24, participants have the option to begin ixekizumab treatment for up to 36 weeks."
89536421|NCT02634801|Active Comparator|Methotrexate|"7.5 mg starting dose up to 30 mg MTX given orally once a week until week 24.~Extension Period: At week 24, participants have the option to begin ixekizumab treatment for up to 36 weeks."
88916559|NCT01628302|Experimental|Low salt diet|The group had low salt diet (50mmol)for three weeks. Subjects had normal salt diet in their daily routine life for the following 2 weeks.According to crossover nature of the study, the group had normal salt diet at the last 3 weeks of the study.
88916560|NCT01628315||Mulitple Sclerosis|Patients with relapsing-remitting MS who had a MRI as part of their participation in the ASA study.
88916561|NCT01628328||Stenting|patient who received colonic stenting for obstructive colorectal cancer
88916562|NCT01628328||Control|patients who had only colonoscopy without obstruction and without stenting
88916563|NCT01628341||Patients with diabetes (type 1 and 2)|
88916564|NCT01628380|Active Comparator|CRS + HIPEC|Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy with CDDP+Paclitaxel
88916565|NCT01628380|Active Comparator|CRS alone|Cytoreductive Surgery alone
88916566|NCT01628419|Experimental|Health intervention program|Health promotion intervention program will be implemented at each workplace and will include: exercise program, nutritional counseling for the kitchen service, lectures on different topics (physical activity, nutrition, sleeping behaviour etc.).
88916567|NCT01628432|Experimental|conservative hysterectomy I|bilateral salpingectomy during hysterectomy with conservation of the ovaries
88916568|NCT01628432|Active Comparator|conservative hysterectomy II|standard conservative hysterectomy with conservation of both ovaries and tubes
88916569|NCT01628445|Active Comparator|liraglutide|liraglutide 1.8 mg injected once daily
88916570|NCT01628445|Placebo Comparator|Placebo injection|
88916571|NCT01628458|Experimental|radiofrequency ablation|
88916572|NCT01628471|Experimental|Decitabine + genistein single arm|decitabine injectable, by infusion, 5 ascending doses (60 to 500 mg/m2) genisteine capsules, 3 x 50 mg capsules twice a day
88916573|NCT01628484|Other|Skin Preparation Testing|The methodology of this study is an intra-individual comparison. Each study participant is treated with three skin preparation techniques (pricking, tape stripping, microneedle array)on both volar forearms.
88916574|NCT01628497||Positive filariasis test|Those testing positive for filariasis
88916575|NCT01628497||Filariasis negative|
89536422|NCT03196453|Active Comparator|Probiotic|Lactobacillus rhamnosus GG
88916576|NCT01628562|Active Comparator|GroupE/Esmolol infusion|Heart rate control, Beta blocker
88916577|NCT01628562|Experimental|GroupR/Remifentanil infusion|Heart rate control, opioid
88916578|NCT01628575||PAO|patients undergoing orthodontic treatment with the addition of pretreatment periodontal surgery for bone decortication.
88916579|NCT01628627|Experimental|FREMS|Frequency Modulated Neural Stimulation (FREMS)
88916580|NCT01628627|Sham Comparator|Control|
88916581|NCT01628653|Experimental|U-SMART|U-SMART (Ubiquitous Spaced Retrieval-based Memory Advancement and Rehabilitation Training)
88916582|NCT01628666|Experimental|Conventional|Preoperative Antibiotics: Cefazolin preoperative, vancomycin in penicillin allergic patients.
88916583|NCT01628666|Experimental|Incremental|Preoperative antibiotics (Cefazolin and Vancomycin) Bacitracin pocket wash and 2 days of oral Cefalexin post operative.
88916584|NCT01628679|Experimental|physical therapy treatment|
88916585|NCT01628705|Sham Comparator|Nutritional intervention|The subjects were undergoing nutritional intervention.
88916586|NCT01628705|Experimental|Nutritional intervention with green tea|The subjects were undergoing nutritional intervention complemented with green tea.
88916587|NCT01628731|Active Comparator|furosemide|furosemide, 0.2 mg/kg/h up to 0.8 mg/kg/h for 72 hours
88916588|NCT01628731|Active Comparator|ethacryinic acid|ethacrynic acid, 0.2 mg/kg/h up to 0.8 mg/kg/h for 72 hours
88916589|NCT01628744||Patients with mycobacterial infection|
88916590|NCT01628757||neoadjuvant chemotherapy|
88916591|NCT01628770|Experimental|parenteral iron|dose will be calculated according to Ganzoni's formula, and will be administered by intravenous infusion
88916592|NCT01628770|Active Comparator|oral iron|oral iron in form of ferrous sulphate 200 mg twice daily
88916593|NCT01628783|Placebo Comparator|Placebo|Microgranular cellulose in gelatine capsules.
89435521|NCT06022926|Active Comparator|Group 1: Patients warmed with electric blankets|"Patients will be provided with electric blankets from the beginning to the end of the operation (approximately 1 hour)~all patients will receive standard general anesthesia~each patient will undergo tympanic temperature measurement immediately before induction of general anesthesia, 20 minutes after induction of anesthesia, immediately after extubation and during exit from the postanesthesia recovery unit.~the same electric blanket was used for this group of patients~each time the electric blankets were set to 38 degrees and the blankets were preheated to 38 degrees approximately 30 minutes before the patients were placed on the operating table.~heat measurements will be made with the same tympanic heat meter device"
89435522|NCT06022926|Other|Group 2: Control group (patients without warming)|"no electric blanket will be used, and no heating will be applied to this group of patients.~all patients will receive standard general anesthesia~all patients will undergo electrocardiogram, peripheral oxygen saturation by pulse oximetry, non-invasive blood pressure monitoring by automatic pneumatic manometer~mean arterial pressure, intraoperative opioid consumption, nausea-vomiting, agitation, tremor and pain assessment will be performed on each patient immediately before induction of general anesthesia, 20 minutes after induction of anesthesia, immediately after extubation and during discharge from the postanesthesia recovery unit.~temperature measurements will be performed with the same tympanic thermometer device"
89198387|NCT00860691|Other|Control - reference value|Blood samples from healthy volunteers will be obtained at one time point.Peripheral blood samples will be obtained into tubes with no additive (BD Vacutainer System, Plymouth, UK).Samples will be processed to serum. Serum concentrations of sFas will be quantitative determinated by a sandwich enzyme immunoassay technique (ELISA)using specific anti-Fas MoAbs, Human sFas Immunoassay. Serum concentrations of sFasL will be quantitative determinated by a sandwich enzyme immunoassay technique (ELISA) using specific anti-Fasl MoAbs, Human sFas Immunoassay. Serum concentration of IL - 17 will be quantitative determinated by a sandwich enzyme immunoassay technique (ELISA) using Human IL-17 Immunoassay. . Peripheral blood samples for measurement of oxidative burst in neutrophils will be collected into heparinised blood tube. burst neutrophil production will be determined quantitatively by flow cytometry as described by Rothe using a commercial kit Bursttest Kit.
89198388|NCT04444804||Rivaroxaban|The source population of this study will include all insured members of more than 60 German statutory health insurances (SHIs) contributing data to the InGef database.
89198389|NCT04444804||Low-molecular-weight heparin (LMWH) and Phenprocoumon|The source population of this study will include all insured members of more than 60 German statutory health insurances (SHIs) contributing data to the InGef database.
89435523|NCT06020963|Experimental|Group-1|Low intensive shockwave therapy 1000 shocks on each acupoint (CV-4, and bilateral ST-28) once a week for 8 weeks.
89435524|NCT06020963|Experimental|Group-2|Low intensive shockwave therapy 1000 shocks on each acupoint (CV-4, and bilateral SP-6) once a week for 8 weeks.
89435525|NCT06020963|Active Comparator|Group-3|Oral tamsulosin 0.2mg once daily for 8 weeks.
89435526|NCT06019689|Experimental|Intervention|Digitally delivered CMAP intervention through App. CMAP is a manual-assisted intervention which has been adapted from a self-help guide called Life After Self-Harm based on the principles of Cognitive behavioral therapy (CBT).
88916594|NCT01628783|Experimental|Escitalopram 10 mg|Escitalopram in gelatine capsule
88916595|NCT01628809|Active Comparator|Rest and Relaxation|three-day relaxation retreat without mindfulness components
89435527|NCT06019689|No Intervention|Standard Routine Care|Local medical, psychiatric and primary care services providing standard routine care to participant patients. Participants receiving an initial assessment along with TAU as ascertained by their treating doctor at the hospital or their primary care physician (general practitioner (GP)
89435528|NCT06019663|Experimental|Intervention|
89435529|NCT06019663|No Intervention|Standard Routine Care|Standard care for self-ham in Pakistan does not usually involve psychiatric or psychotherapy follow-up. Clinical teams in psychiatric departments or family medicine practices provide standard routine care according to their clinical judgment and available resources. We will obtain details of any treatment received by each participant
88916596|NCT01628809|Experimental|Mindfulness-Based Meditation|three-day mindfulness-based meditation retreat
89010225|NCT02213029|Experimental|Epelsiban or Placebo (Cohort 2)|Subjects in Cohort 2A will receive first dose of epelsiban (25mg) or placebo after receiving initial oxytocin challenge with dose selected in Cohort 1 followed by 30 minutes washout period. Subjects will receive second dose of epelsiban (150mg) or placebo 12 hours after first dose. Based on the results of Cohort 2A, additional doses may be investigated with a new Cohort 2B (<150mg) and Cohort 2C (>200mg) with repeated oxytocin challenges.
89435530|NCT06018129|Experimental|R/R CD30+ cHL Cohort|
88916597|NCT01628822|Experimental|Active relaxation|
88916598|NCT01628822|Placebo Comparator|Placebo relaxation|
88916599|NCT01628835|Experimental|Low dietary glycemic index diet|Based on the national diet and physical activity recommendations for pregnant women (total energy intake, protein and vitamin etc.), counseling for a low dietary glycemic index diet will be provided.
88916600|NCT01628835|Active Comparator|National recommendation diet|Provision of food and dietary counseling according to the national prenatal nutrition recommendation without GI information
88916601|NCT01628861|Active Comparator|education only|A short educational talk, read from a script, regarding the health risks of prolonged sitting, stating that standing every 30 minutes could be beneficial. A short information leaflet with the same message is also provided.
89435531|NCT06018129|Experimental|R/R CD30+ TCL Cohort|
89435532|NCT06017791|Experimental|PEEK shell in the anterior maxilla inserted by tunnel technique|use of a minimally invasive tunnel technique to fill the skeletal subnasal depression with a PEEK shell in patients with an exaggerated subnasal depression associated with lack of lip support and excessive lip translation
89435533|NCT06007690|Experimental|High dose bel-sar treatment arm & laser application|High dose of bel-sar + laser application
89435534|NCT06007690|Experimental|Low dose bel-sar treatment arm & laser application|Low dose of bel-sar + laser application
89435535|NCT06007690|Sham Comparator|Sham control arm & sham laser|Sham dose + sham laser
89435536|NCT06005571|Active Comparator|Control: traditional acid etch treatment group|Traditional acid etching to the tooth and old restoration surfaces and then adhesive application.
89435537|NCT06005571|Experimental|Silane-Adhesive treatment group|Acid cid etching of prepared tooth tissues and old restoration surfaces, silane solution application, and then adhesive application.
89435538|NCT06005571|Experimental|Sandblast-Silane-Adhesive treatment group|First sandblasting the old composite filling surfaces, then acid etching of prepared tooth tissues the restoration, then silane application followed by adhesive application.
89435539|NCT06001177|Experimental|Group 1|All eligible participants will receive 3 intravenous (IV) infusions of KAN-101
89435540|NCT06001177|Placebo Comparator|Group 2|All eligible participants will receive 3 intravenous (IV) infusions of placebo
89198390|NCT05226741|Experimental|Head protection|Participants are given a form of head protection
89010226|NCT02213029|Experimental|Biopsy cohort (Cohort 3)|Subjects will receive first dose of epelsiban 150mg without oxytocin challenge followed by second dose of epelsiban 150mg 24 hours after the first dose. Subsequently one hour after the second dose, subjects will undergo endometrial biopsies.
89010227|NCT02213146|Experimental|BioChaperone human insulin|BioChaperone Human Insulin
89010228|NCT02213146|Active Comparator|Human insulin|Huminsulin® Normal
89198391|NCT04010890|Experimental|Culturally adapted CBT|Ca_CBT will be delivered to the experimental group using the newly developed manual . The intervention will be delivered over 8-12 sessions. The Control group will receive standard CBT
89198392|NCT04010890|Active Comparator|Standard CBT|Participants in this group will receive standard CBT
89198393|NCT00921882||Oral glucose tolerance test|oral glucose tolerance test performed 48 hours post-partum and 8 weeks post-partum.
89010229|NCT02213146|Active Comparator|Insulin lispro|Humalog®
89435541|NCT06000657|Experimental|Treatment group|Chronic Hepatitis B patients who pretreated with Entecavir
89010230|NCT00268749|Experimental|1|
88813059|NCT03217838|Experimental|Group 2 Arm B (AZD2811 Dose 6 + Azacitidine 75 mg/m^2)|Participants with AML will receive Azacitidine 75 mg/m^2 of BSA by SC injection or IV infusion prior to the start of AZD2811 infusion on Days 1 through 7 or for 5 consecutive weekdays (Days 1 through 5) with treatment holidays on the 2 weekend days (Days 6 and 7), and the remaining azacitidine dosing will be administered on the first 2 weekdays of the 2nd week (Days 8 and 9) of each 28-day cycle. Participants will receive IV infusion of AZD2811 Dose 6 on Days 1, 4, 15, and 18 of each 28-day cycle. Participants will receive the treatment until disease progression, unacceptable toxicity, or the decision to discontinue treatment by the participant or the study physician, whichever occurs first.
89010231|NCT04553887|Experimental|Cohort 1|Previously treated NSCLC patients with EGFR exon 20 insertion mutantion
89435542|NCT06000657|Active Comparator|Comparator group|Chronic Hepatitis B patients who pretreated with Entecavir
89435543|NCT05999994|Experimental|Ramucirumab + Cyclophosphamide + Vinorelbine (DSRCT ISA)|Ramucirumab given intravenously (IV), cyclophosphamide given orally and vinorelbine given IV in 28-day cycles for desmoplastic small round cell tumor (DSRCT) intervention-specific appendix (ISA).
89435544|NCT05999994|Active Comparator|Cyclophosphamide + Vinorelbine (DSRCT ISA)|Cyclophosphamide given orally and vinorelbine given IV in 28-day cycles for DSRCT ISA.
89435545|NCT05999994|Experimental|Ramucirumab + Gemcitabine + Docetaxel (SS ISA)|Ramucirumab and gemcitabine given IV in 21-day cycles for synovial sarcoma (SS) ISA.
89435546|NCT05999994|Active Comparator|Gemcitabine + Docetaxel (SS ISA)|Gemcitabine and docetaxel given IV in 21-day cycles for SS ISA.
89435547|NCT05999994|Experimental|Abemaciclib + Irinotecan + Temozolomide (ES ISA)|Abemaciclib given orally, irinotecan given IV, and temozolomide given orally in 21-day cycles for Ewing's sarcoma (ES) ISA.
89435548|NCT05999994|Active Comparator|Irinotecan + Temozolomide (ES ISA)|Irinotecan given IV and temozolomide given orally in 21-day cycles for ES ISA.
89435549|NCT05999955|Active Comparator|Control|Subjects in Control group receive Neomycin Nasal Spray for 10 days.
89010232|NCT04553887|Experimental|Cohort 2|NSCLC Patients with uncommon EGFR Mutation
89435550|NCT05999955|Experimental|SPEROVID|"Subjects in Experimental group receive a nasal spray containing Bacillus subtilis DSM32444 (Sperovid) for 10 days."
89435551|NCT05999916|Experimental|60 min session of 40Hz tACS by Miamind Neurostimulator|The clinical study will enroll eight (8) participants who will undergo four (4) tACS sessions (one per day) within 4 consecutive days. The tACS intervention will last 60 min in total. The stimulation frequency will be 40 Hz with max 1 mA/electrode and total of max 2 mA across all active electrodes (peak-to-baseline).
89010233|NCT00235898|Experimental|1|CoFactor, 5-FU
89010234|NCT00235898|Active Comparator|2|Leucovorin, 5-FU
89010235|NCT02213185|Experimental|EMLA patches and SWI|EMLA patches 1.5 hrs before sterile water injections
89010236|NCT02213185|Active Comparator|EMLA patches and isotonic saline|EMLA patches 1.5 hrs before isotonic saline
89010237|NCT02213185|Placebo Comparator|Placebo patches and SWI|PLACEBO patches 1.5 hrs before sterile water injections
89010238|NCT02213185|Placebo Comparator|Placebo patches and isotonic saline|PLACEBO patches 1.5 hrs before isotonic saline
89010239|NCT02213224|Experimental|Perindopril|Perindopril 4mg qd taken in the morning;
89010240|NCT02213224|Experimental|Telmisartan|Telmisartan 80mg qd taken in the morning;
89010241|NCT02213224|Placebo Comparator|Amlodipine|Amlodipine；5mg qd taken in the morning.
89010242|NCT00268788|Active Comparator|1|Subcutaneous Ig given twice a week.
89010243|NCT00268788|Active Comparator|2|Intravenous Ig
89010244|NCT02213341||Positive blood test to milk, egg, and/or peanut|Family history to atopy
89010245|NCT02213341||Negative blood test to allergy|A negative skin prick test to egg, milk, and peanut and a negative Immunoglobulin E (IgE) to egg, milk, and peanut.
89010246|NCT04553614|Active Comparator|Exercise Referral Scheme|The active Sefton (AS_ERS) is a traditional exercise referral programme providing highly discounted access to council operated leisure centres and a number of partner gyms. Within this access patients will have access to gym and swimming facilities (£2 per visit) and exercises classes (£3 per visit). During the patients first meeting with their LDO a progressive personalised exercise programme will be developed. Following this the patient will attend their local gym or leisure centre for an induction with a staff member(£7 one off fee), enabling them to attend the centre at any time and complete the designed exercise programme. All exercise programmes will be different, but in general will include moderate intensity exercise on gym equipment (treadmill, ergometer etc.) and some basic resistance training. Patients may replace these gym sessions with exercises classes run by the facility. Patients will be encouraged to exercise 3-5 time per week.
89435552|NCT05999006|Experimental|ELIOS Procedure|ELIOS Procedure
89435553|NCT05991232|Experimental|Intravenous Ketamine|Open-label ketamine infusion
89435554|NCT05990738|Experimental|Part A: BI 764532 low dose + topotecan|
89435555|NCT05990738|Experimental|Part A: BI 764532 medium dose + topotecan|
89435556|NCT05990738|Experimental|Part A: BI 764532 high dose + topotecan|
89435557|NCT05990738|Experimental|Part B: BI 764532 + topotecan|
89435558|NCT05990088|Experimental|Heat Cured Conventional Complete Removable Dentures based on neutral zone concept|The patient will be provided by a complete removable denture designed based on the neutral zone concept to restore his missing teeth which will be manufactured by heat curing of Polymethyl methacrylate.
89435559|NCT05990088|Active Comparator|CAD/CAM Milled Methacrylate Complete Removable Dentures based on neutral zone concept.|The patient will be provided with a complete removable denture designed according to the neutral-concept to restore his missing teeth, which will be manufactured by CAD/CAM milling of monolithic methacrylate blanks.
89435560|NCT05986292|Experimental|LY3016859 Osteoarthritis ISA|Participants are randomized to receive either active LY3016859 or matching placebo
89435561|NCT05986292|Experimental|LY3016859 Diabetic Neuropathic Pain ISA|Participants are randomized to receive either active LY3016859 or matching placebo
89435562|NCT05986292|Experimental|LY3016859 Chronic Back Pain ISA|Participants are randomized to receive either active LY3016859 or matching placebo
89010247|NCT04553614|Experimental|Home-based HIIT|Participants will be instructed to complete each training session in a place of their choosing. The programme involves repeated 1 minute bouts of simple on the spot movements interspersed with 1 minute of rest. During the intervals participants will be advised to reach a heart rate of approx. 90% of their predicted maximum heart rate (220-age). The 1 minute interval will be split between 2 consecutive 30 second exercises. The research team have a library of 18 exercises, with 9 suggested exercise pairs. The participant will be advised to complete 4 intervals during weeks 1 and 2, with the number of intervals increasing by 1 every 2 weeks (maximum of 9 intervals). The participant will be advised to train 3x per week.
89435563|NCT05986292|Experimental|LY3556050 Osteoarthritis ISA|Participants are randomized to receive either active LY3556050 or matching placebo
89435564|NCT05986292|Experimental|LY3556050 Diabetic Neuropathic Pain ISA|Participants are randomized to receive either active LY3556050 or matching placebo
89435565|NCT05986292|Experimental|LY3556050 Chronic Back Pain ISA|Participants are randomized to receive either active LY3556050 or matching placebo
89435566|NCT05986292|Experimental|LY3526318 Osteoarthritis ISA|Participants are randomized to receive either active LY3526318 or matching placebo
89435567|NCT05986292|Experimental|LY3526318 Diabetic Neuropathic Pain ISA|Participants are randomized to receive either active LY3526318 or matching placebo
89435568|NCT05986292|Experimental|LY3526318 Chronic Back Pain ISA|Participants are randomized to receive either active LY3526318 or matching placebo
89435569|NCT05986292|Experimental|LY3857210 Osteoarthritis ISA|Participants are randomized to receive either active LY3857210 or matching placebo
89010248|NCT04553224|Other|All Subjects|Clinical and instrumental measurements
89010249|NCT04553653|No Intervention|Baseline|Data on diagnosis and care of patients presenting with acute severe hypertension will be collected at baseline (prior to the implementation of a checklist)
89010250|NCT04553653|Experimental|Intervention arm|The intervention arm will be enrolled after the checklist implementation.
89198394|NCT05351320|Experimental|WX-0593 single arm|"Part 1: Participants will receive WX-0593 monotherapy until disease progression or unacceptable toxicity.~Part 2: Participants will receive 1 or 2 cycles of WX-0593 monotherapy and subsequently with concurrent chemoradiation, followed by WX-0593 monotherapy until disease progression or unacceptable toxicity."
89198395|NCT00868413|Active Comparator|A|FCR+ABT-263
89198396|NCT00868413|Active Comparator|B|BR+ABT-263
89435570|NCT05986292|Experimental|LY3857210 Diabetic Neuropathic Pain ISA|Participants are randomized to receive either active LY3857210 or matching placebo
89435571|NCT05986292|Experimental|LY3857210 Chronic Back Pain ISA|Participants are randomized to receive either active LY3857210 or matching placebo
89435572|NCT05985655|Experimental|GTAEXS617|GTAEXS617 tablet for oral administration
89435573|NCT05985616|Experimental|Group A|"High intensity (80-85% of 1RM) will be administered at alternative days for 16 weeks.~The exercise will have three phases; Phase I consists of 2-3 sets of 8-15 repetitions, Phase II will follow the single set approach and Phase III will have the Superset approach.~The following activities will be incorporated via resistance training: latissimus front pulleys, rowing, back extension, inverse fly, bench press, shoulder press, lateral raises, butterfly with extended arms, crunches, leg presses, leg extension and curls, leg adduction, abduction."
89435574|NCT05985616|No Intervention|Group B|No intervention will be provided in this group. The participants in this group will follow their usual daily activities.
89435575|NCT05981833||Repair without DAA|repaired without dermal allograft augmentation (DAA).
89536423|NCT03196453|Active Comparator|Probiotic and protein|Lactobacillus rhamnosus GG and whey protein isolate
89536424|NCT03196453|Placebo Comparator|Placebo|Placebo
89536425|NCT05587595||children with complicated sickle cell disease hospitalised in pediatric intensive care unit (PICU)|
88916602|NCT01628861|Experimental|prompt + education|"A short educational talk, read from a script, regarding the health risks of prolonged sitting, stating that standing every 30 minutes could be beneficial. A short information leaflet with the same message is also provided. Prompting software (MyRestBreak 1.0 copyright Vikram Sharma) will be installed on the work computer. A prompt with the message stand up, take a break is placed on the screen of the work computer for 1 minutes every 30 minutes, from the time the computer is switched on in the morning. The prompt is contained in a window 11x9 cm in the centre of the screen. The prompt cannot be removed or minimised, but work can continue in any windows visible around the prompt. The prompt is on the computer for 5 days."
88916603|NCT01628887|Experimental|Supportive Care (BBCEI)|Participants undergo 2 tailored BBCEI sessions within 1 month. At the beginning of the first session the research nurse will present the participants with a list of common physical and social concerns. The participant will then be asked to identify 3 topics that she wants to discuss. The research nurse will discuss with the participant any relevant supportive care resources and make the appropriate referrals. At the second session the focus of the BBCEI will be on psychological and spiritual well-being.
88916604|NCT01628900|Active Comparator|ambulatory|Patient will be treated for 7 days at home, then 3 follow-up visit at hospital.
88916605|NCT01628900|Active Comparator|hospitalisation|7 days for mono-antibiotherapy at hospital.
88916606|NCT01628939||current low back pain|subjects with current low back pain (i.e. more than 30 days of low back pain in the last three months)
88916607|NCT01628939||controls|subjects with less than 30 days of low back pain in the last three months
88916608|NCT01628952|Experimental|TAP|
88916609|NCT01628952|Active Comparator|curare|Patients will be randomized into two parallel groups. One group will receive curare, another benefit of a bilateral TAP block
88916610|NCT01628978||Auscultation group|The depth of endotracheal tube placement is determined by auscultation.
88916611|NCT01628978||Ultrasonography group|The depth of placement of endotracheal tube placement is determined by ultrasonographic finding of pleural sliding sign.
88916612|NCT01628991|Experimental|behavioural intervention|Recieving interventional behavioural program
88916613|NCT01628991|Experimental|vaginal cone|intravaginal device insertion(vaginal cone)
88916614|NCT01629004|Other|Non-responders|"Non-responders to an initial mailed CRC screening invitation from their family physician.~FOBT kit. Mailed invitation."
88916615|NCT01629004|Other|Recall patients|"Those who responded to the initial mailed CRC screening invitation and are now due for repeat screening (i.e., recall patients).~FOBT kit. Mailed invitation."
88916616|NCT01629030||Coronary Artery Bypass Graft Group|Those underwent coronary artery bypass graft surgery with median sternotomy in Samsung Medical Center during the period of January 2008 and December 2011.
88916617|NCT01629056|Active Comparator|Contact ECI active|Contact ECI active
88916618|NCT01629056|Placebo Comparator|Contact information deactivated|RF ablation without contact data
88916619|NCT01629069|Active Comparator|Participant in MBRT|6 sessions of Mindfulness Based Resilience Training
88916620|NCT01629095||NAFLD|Patients who have already undergone liver transplantation for a confirmed diagnosis of NAFLD or cryptogenic cirrhosis are also eligible to participate.
88916621|NCT01629095||NASH|Patients with radiologic evidence of fatty liver and/or cirrhosis in which other causes havebeen ruled out are eligible to participate.
88916622|NCT01629121|Experimental|education intervention|The intervention delivered education about the benefits of bicycle helmet use and safety and was designed to be sensitive to the age and educational level of the study participant.
88916623|NCT01629121|No Intervention|control|Printed materials were given to the control group, along with a helmet for each participant.
88916624|NCT01629147|Experimental|Biogaia|5 drops containing Lactobacillus reuteri Protectis
88916625|NCT01629147|Placebo Comparator|Placebo|- 5 drops identical in appearance and taste
88916626|NCT01629173|Experimental|Dynamic impression insole|We sequentially padded P-cell, Ethylene Vinyl Acetate, and Multiform on the 9-mm thick plastazote under daily walking compression to make dynamic impression insole.
88916627|NCT01629173|Experimental|Custom molded insole|The custom molded insole was made by sequentially padded Multiform, P-cell, EVA, and cork on the positive plaster cast impressed by an impression box while holding the subtalar joint at a neutral position.
88916628|NCT01629173|Experimental|9-mm uncompressed Plastazote insole|We used 9-mm flat Plastazote as an insole
88916629|NCT01629173|Experimental|7-mm Ethylene Vinyl Acetate (EVA)|We used 7-mm flat Ethylene Vinyl Acetate (EVA) as an insole
88916630|NCT01629186|Experimental|outcome|"Cardiopulmonary parameters were measured and recorded at baseline, just before and at every minute during NC-AC, and at the end of the FB session. In infants who already had an arterial line, arterial blood gas (ABG) analyses were taken for study. Data was represented as mean ± SD. The results obtained from the baseline and different stages. The values were considered statistically significant only when p < 0.05.~Technique failure was defined as: any vital signs of hypoxia did not return to accepted levels(HR>100 beat/min, SpO2>90%, mean BP>50 mmHg)within 2 minutes of the experimental CPR technique. Then traditional CPR procedures involving bag-mask ventilation, endotracheal intubation, Ambu bag ventilation or even chest compressions were substituted."
88916631|NCT01629199|Experimental|rhEGF(recombinant human Epidermal Growth Factor)|BID
89536426|NCT05587595||children with complicated sickle cell disease hospitalised but not in intensive care unit|
89435576|NCT05973240||Sample derived from the first data collection round (MSA)|Patients have to be aged 18 years and older, cross in an anticoagulation clinic for at least three months, have appropriate cognitive functioning as determined by the six-item screener, and have the ability to give informed consent will be the inclusion criteria. Patients will be excluded if their Charlson Comorbidity Index (CCI) is high (CCI > 4) to account for any comorbidity-related variability and assure the homogeneity of the study sample.
89536427|NCT02476253|Experimental|Intervention|Intravenous 4.2% Sodium Bicarbonate 125ml to 250ml / 30min up to 1000ml/24h to maintain plasma pH equal or greater than 7.30
89536428|NCT02476253|No Intervention|Control|No intervention
89536429|NCT03196531|Experimental|Cohort 1: Sequence 1 (ABAB)|Participants will receive 10 milligram (mg) loratadine (1*10 mg oral tablet) as Xisimin (Treatment A) on Day 1 of Period 1 and Period 3 and 10 mg loratadine (1*10 mg oral tablet) administered as Clarityne (Treatment B) on Day 1 of Period 2 and Period 4 under fasted condition. A washout period of at least 7 days will be maintained between each treatment administration.
89435577|NCT05973240||Sample derived from the second data collection round (CFA)|Patients have to be aged 18 years and older, cross in an anticoagulation clinic for at least three months, have appropriate cognitive functioning as determined by the six-item screener, and have the ability to give informed consent will be the inclusion criteria. Patients will be excluded if their Charlson Comorbidity Index (CCI) is high (CCI > 4) to account for any comorbidity-related variability and assure the homogeneity of the study sample.
89435578|NCT05970861|Experimental|Main Group|Patients who had suffered from COVID-19 in the six months before the start of the study. Patients will receive Saumal (freeze-dried mare milk) for four weeks.
89435579|NCT05970861|No Intervention|Control Group|Patients who had suffered from COVID-19 in the six months before the start of the study. There will be no intervention.
88813060|NCT03217838|Experimental|Group 3 Arm A (AZD2811 Dose 2 + Venetoclax 200 mg)|Participants with AML will receive IV infusion of AZD2811 Dose 2 on Days 1 and 4 of each 28-day cycle and venetoclax 100 mg orally (PO) on Day 1 and 200 mg PO from Days 2 to 28 of each 28-day cycle until disease progression, unacceptable toxicity, or the decision to discontinue treatment by the participant or the study physician, whichever occurs first.
88813061|NCT03217838|Experimental|Group 3 Arm A (AZD2811 Dose 2 + Venetoclax 400 mg)|Participants with AML will receive IV infusion of AZD2811 Dose 2 on Days 1 and 4 of each 28-day cycle and venetoclax 100 mg orally (PO) on Day 1, 200 mg PO on Day 2, and 400 mg PO from Days 3 to 28 of each 28-day cycle until disease progression, unacceptable toxicity, or the decision to discontinue treatment by the participant or the study physician, whichever occurs first.
88813062|NCT01558661|Experimental|AG-013736 (AXITINIB)|This is a single-arm phase II study evaluating the clinical efficacy of axitinib in the treatment of patients with progressive, recurrent/metastatic adenoid cystic carcinoma (ACC).
88813063|NCT01835288|Experimental|Treatment (arsenic trioxide)|Patients receive arsenic trioxide IV over 1-2 hours daily for up to 45 days. Patients achieving complete remission, receive arsenic trioxide IV over 1-2 hours daily 5 days a week for 4 weeks. Treatment repeats every 8 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
88813064|NCT03212534|Experimental|Prediction Algorithm|
88813065|NCT03212534|No Intervention|Control|
88813066|NCT03212222|Experimental|Peek Acuity Screening|Cell phone application to be used for visual acuity screening.
88813067|NCT03212222|Active Comparator|Standard Visual Screening|Standard visual acuity screening administered at Duke University Eye Center regarded as the gold standard.
88916632|NCT01629199|Placebo Comparator|placebo|BID
89536430|NCT03196531|Experimental|Cohort 1: Sequence 2 (BABA)|Participants will receive Treatment B on Day 1 of Period 1 and Period 3 and Treatment A on Day 1 of Period 2 and Period 4 under fasted condition. A washout period of at least 7 days will be maintained between each treatment administration.
89536431|NCT03196531|Experimental|Cohort 2: Sequence 1 (ABAB)|Participants will receive Treatment A on Day 1 of Period 1 and Period 3 and Treatment B on Day 1 of Period 2 and Period 4 under fed condition. A washout period of at least 7 days will be maintained between each treatment administration.
89435580|NCT05969652|Experimental|Heavy slow resistance group (HSR group)|"The investigators are planning a 6-week rehabilitation program, 2 days a week. The same physiotherapy and home exercise program will be applied to both groups. The physiotherapy and home exercise program will include patient education, stretching, range of motion and posture exercises. Resistance training will consist of different exercise principles but the same types of exercises. Resistance training: Dumball will be used as exercise equipment. Exercise intensity determined using the Numerical Pain Rating Scale (NPRS).~Individual loading will be made according to the amount of weight. The maximum amount of pain producing pain less than 4 on the Numerical Pain Assessment Scale will be determined as exercise intensity. It will include 3 different exercises: 1) Full can. 2) External rotation in side lying. 3) Internal rotation in side lying."
89536432|NCT03196531|Experimental|Cohort 2: Sequence 2 (BABA)|Participants will receive Treatment B on Day 1 of Period 1 and Period 3 and Treatment A on Day 1 of Period 2 and Period 4 under fed condition. A washout period of at least 7 days will be maintained between each treatment administration.
89536433|NCT04996407|Active Comparator|survival thermal blanket|Patient will be using survival thermal blanket as substitute for perforated blanket with forced air warmer during anesthesia
88916633|NCT01629212|Experimental|Tiropramide HCl|
88916634|NCT01629212|Active Comparator|Octylonium bromide|
88916635|NCT01629225|No Intervention|candesartan|All antihypertensive agents were withdrawn before the start of a 4-6 week, single-blind, after which the patients received candesartan 10 mg or 20 mg once daily as monotherapy in a single-blind fashion. The doses were doubled after 1 weeks if DBP was ≥90 mmHg.
88916636|NCT01629238||group 1|group 1 = consumers of marketed drinkable low fat fermented milk enriched with plant sterol
88916637|NCT01629238||group 2|group 2 = non-consumers of marketed drinkable low fat fermented milk enriched with plant sterol
88916638|NCT01629251|Active Comparator|Closed-loop with standard meal insulin bolus|Subcutaneous basal insulin delivery will be adjusted following the advice by a computer-based algorithm, based on subcutaneous sensor glucose readings. Standard meal insulin dosing will be performed at each meal, following individual standard clinical practice.
88916639|NCT01629251|Experimental|Closed-loop with reduced meal insulin bolus|Subcutaneous basal insulin delivery will be adjusted following the advice by a computer-based algorithm, based on subcutaneous sensor glucose readings. The standard meal insulin dose will be reduced by 20 to 50%.
88916640|NCT01629277|Active Comparator|Control|Subcutaneous insulin delivery will be administered according the standard insulin pump settings
88916641|NCT01629277|Experimental|Closed-loop|Subcutaneous insulin delivery will be adjusted according to the computer-based algorithm advice, based on subcutaneous glucose readings
88916642|NCT01629303|Experimental|Arm on-off|"After the definitive implantation, stimulators are placed in position OFF during 8 weeks.~Then all the stimulators are switched OFF for 15 days. Finally stimulators are switched ON for the second arm during 8 weeks"
88916643|NCT01629303|Experimental|Arm off-on|"After the definitive implantation, stimulators are placed in position ON during 8 weeks.~Then all the stimulators are switched OFF for 15 days. Finally stimulators are maintained in position OFF during 8 weeks"
88916644|NCT01629316|Experimental|Text reminders, counseling, link coordinator|Text reminders, counseling, link coordination
88916645|NCT01629316|Active Comparator|Standard of care - control arm|
88916646|NCT01629342||Transient Ischemic Attack Patients|Patients discharged after a Transient Ischemic Attack
89198397|NCT05351008|Experimental|Cognitive Physical Therapy group|The group will receive 4 months 3 times per week of cognitive physical therapy.
89435581|NCT05969652|Active Comparator|Eccentric exercise training group (EE group)|"The investigators are planning a 6-week rehabilitation program, 2 days a week. The same physiotherapy and home exercise program will be applied to both groups. The physiotherapy and home exercise program will include patient education, stretching, range of motion and posture exercises. Resistance training will consist of different exercise principles but the same types of exercises. Resistance training: Dumball will be used as exercise equipment. Exercise intensity determined using the Numerical Pain Rating Scale (NPRS).~Individual loading will be made according to the amount of weight. The maximum amount of pain producing pain less than 4 on the Numerical Pain Assessment Scale will be determined as exercise intensity. It will include 3 different exercises: 1) Full can. 2) External rotation in side lying. 3) Internal rotation in side lying."
89435582|NCT05968599||Enzalutamide cohort|Patients with mCRPC initiating enzalutamide
88916647|NCT01629355||Schizophrenia|Five patients with diagnosed schizophrenia will be used to map changes in ABR/SD-BERA potentials compared to controls to establish the disease-specific pattern. Twelve patients with schizophrenia will then be studied blindly to evaluate the predictive value of the test.
88916648|NCT01629355||ADHD|Five patients with diagnosed ADHD will be used to map changes in ABR/SD-BERA potentials compared to controls to establish the disease-specific pattern.
88916649|NCT01629355||Bipolar disorder|Five patients with diagnosed Bipolar disorder will be used to map changes in ABR/SD-BERA potentials compared to controls to establish the disease-specific pattern. Twelve patients with Bipolar disorder will then be studied blindly to evaluate the predictive value of the test.
88916650|NCT01629355||Healthy controls|Fifteen healthy controls will be used to define normal pattern of ABR/SD-BERA potentials. Another twelve normal controls will be studied blindly to evaluate the predictive value of the test.
88916651|NCT01629368|Experimental|Dosing Period 1|
88916652|NCT01629368|Experimental|Dosing Period 2|
88916653|NCT01629394|Active Comparator|Group A: Sugammadex CBW-open|Group A patients will undergo open surgery and will receive sugammadex 2mg/kg corrected body weight [corrected body weight = ideal body weight + 40%( real body weight - ideal body weight)] when T2 arises in adductor pollicis.
89435583|NCT05968599||Abiraterone cohort|Patients with mCRPC initiating abiraterone acetate
89435584|NCT05968456||Thoracic surgery|Patient undergoing thoracic surgery
89435585|NCT05968456||Cardiac surgery|Patient undergoing cardiac surgery
89435586|NCT05968456||Vascular surgery|Patient undergoing vascular surgery
89435587|NCT05968014|Experimental|PENG block|Participants enrolled in this group received a pericapsular nerve group block with 20 ml of 0.2% ropivacaine. The block was performed with a 100 mm needle, inserted with an in-plane lateral to medial approach. Operator used a low frequency curvilinear probe.
89435588|NCT05968014|Experimental|FIC block|Patients allocated in this group received a fascia iliaca compartment block with 20 mL of 0.2% ropivacaine, using a 50 mm needle inserted with an in-plane approach. Operator used a linear probe.
89435589|NCT05963867|Experimental|Cohort 1|
89435590|NCT05963867|Experimental|Cohort 2|
89435591|NCT05963399|Experimental|older adults|Elderly adults who live independently in their own home in rural or urban areas.
89536434|NCT04996407|Active Comparator|draping fabric|Patient will be using draping fabrics as substitute for perforated blanket with forced air warmer during anesthesia
89536883|NCT03312179||diabetics never-incretin-users STEMI|Diabetics patients admitted for ST elevation myocardial infarction (STEMI) and associated with multi vessels coronary artery stenosis (Mv) non obstructive coronary artery stenosis (NOCS). These patients received percutaneous coronary intervention (PCI), and primary stenting (DES) of culprit lesion. Then these patients received full medical STEMI therapy. These diabetic patients were never treated by incretin therapy before study enrollment.
88916654|NCT01629394|Active Comparator|Group B: Sugammadex IBW-open|Group B patients will undergo open surgery and will receive sugammadex 2mg/kg ( ideal body weight ) when T2 arises in adductor pollicis.
88916655|NCT01629394|Active Comparator|Group C: Neostigmine CBW-open|Group C patients will undergo open surgery and will receive neostigmine 50μg/kg corrected body weight [corrected body weight = ideal body weight + 40%(real body weight - ideal body weight)]when T2 arises in adductor pollicis.
89536435|NCT02476799|Experimental|Rectus sheath block|Patients of RSB group will be performed ultrasound-guided bilateral RSB after induction of general anesthesia. After draping the needle insertion site, a 22-gauge, 50-mm needle will be inserted medial to the probe by the in-plane technique and advanced in a lateral direction on just lateral to umbilicus. 15 ml of 0.25% ropivacaine will be injected on the posterior border of rectus muscle. This procedure will be performed bilaterally and total 30 ml of 0.25% ropivacaine will be injected. After the surgery, a bandage will be attached on injection site where is same as the incision site of surgery. All patients will use total 100 ml of IV-PCA containing fentanyl and ketorolac for 48 hours postoperatively.
89010251|NCT04553380|Experimental|community patient group|The community doctor adjusts the basic insulin dosage daily according to the fasting blood glucose of the patient under the guidance of the specialist.
89435592|NCT05957874|Experimental|Experiment|Questionnaires will be applied to the children and their families who agree to participate. A one-week sleep hygiene training will be given for three consecutive days. On the first day of education, children will be given a checklist and tasks that will facilitate the transition to weekly sleep. In addition, within the scope of using technology positively, reminders including sleep hygiene principles will be sent to families every day for four weeks via a social media tool. Total intervention time is planned as 4 weeks. The researchers planned to start the trainings on Monday. At the beginning of each week, face-to-face interviews will be held with the students in the experimental group and it will be evaluated whether the tasks have been fulfilled. At the end of 4 weeks, the final test application of the experimental group will be made. Then, the questionnaires will be applied again after 2 weeks for control measurement.
89435593|NCT05957874|No Intervention|Control|"The children who agreed to participate in the class determined as the control group as a result of drawing lots and the children and their families who agreed to participate will fill in the Sociodemographic Characteristics and Introductory Information Form, the Sleep Deprivation Scale for Children and Adolescents and the mothers will fill in the Child Sleep Habits Questionnaire. At the end of 4 weeks, the post-test application of the control group will be made. After the tests are applied, training will be given to the control group on a suitable day for the class and the training booklet will be distributed."
89435594|NCT05957497||Pedestrian transport|Modality of transport currently used
89536884|NCT02468531|Other|Oxygen group|50% oxygen inhalation one hour before and after CPB,and Pulmonary Static Inflation with 50% oxygen during CPB.
88916656|NCT01629394|Active Comparator|Group D: Neostigmine-IBW|Group D patients will undergo open surgery and will receive neostigmine 50μg/kg ( ideal body weight ) when T2 arises in adductor pollicis.
88916657|NCT01629394|Active Comparator|Group E: Sugammadex CBW-Lap|Group E patients will undergo laparoscopic surgery and will receive sugammadex 2mg/kg corrected body weight [corrected body weight = ideal body weight + 40%( real body weight - ideal body weight)] when T2 arises in adductor pollicis.
88916658|NCT01629394|Active Comparator|Group F: Sugammadex IBW-Lap|Group F patients will undergo laparoscopic surgery and will receive sugammadex 2mg/kg ( ideal body weight ) when T2 arises in adductor pollicis.
89010252|NCT04553380|Active Comparator|inpatient group|Endocrinologists in the in-patient department use the same basic insulin dose adjustment regimen to treat patients.
89435595|NCT05957497||Drone transport|Innovative modality of transport
89435596|NCT05954520|Experimental|Perceptual measures|Perception will be measured for different algorithm settings and environmental variables (type of noise and signal-to-noise ratio)
89010253|NCT04553302||Psoriatic Arthritis|Patients diagnosed with PsA according to CASPAR criteria by the rheumatologist were included.
89010254|NCT04553302||Rheumatoid Arthritis|Patients diagnosed with RA according to ACR / EULAR 2010 criteria by the rheumatologist were included.
89010255|NCT04553302||Asymptomatic Healthy Group|Participants had any neurological and/or rheumatological diseases, no complaints about the upper extremity. Participants diagnosed with OA according to traditional clinical criteria were excluded from the study.
89010256|NCT00261378|Active Comparator|Transarterialchemoembolisation (TACE)|Conventional TACE with doxorubicin
89010257|NCT00261378|Other|DC Bead|DC Bead with doxorubicin
89010258|NCT04555408|Active Comparator|blue light group|The blue light will be applied five times a week for the first two weeks. For the next two weeks, this treatment will be applied three times a week.
88916659|NCT01629394|Active Comparator|Group G: Neostigmine CBW-Lap|Group C patients will undergo laparoscopic surgery and will receive neostigmine 50μg/kg corrected body weight [corrected body weight = ideal body weight + 40%(real body weight - ideal body weight)]when T2 arises in adductor pollicis.
88916660|NCT01629394|Active Comparator|Group H: Neostigmine IBW-Lap|Group D patients will undergo open surgery and will receive neostigmine 50μg/kg ( ideal body weight ) when T2 arises in adductor pollicis.
88916661|NCT01629407||Glaucoma|Patients with glaucoma
88916662|NCT01629420|Experimental|Drug:KLH-2109 lower dose|
88916663|NCT01629420|Experimental|Drug:KLH-2109 higher dose|
88916664|NCT01629433||botulinum A toxin|18 patients with neurogenic DO and 7 with idiopathic DO All the patients had overactive bladder (OAB) symptoms and DO refractory to conventional anticholinergics.
88916665|NCT01629446|Experimental|Lofexidine HCl with 14C tracer|
88916666|NCT01629459|Experimental|Resistance exercise training|Participants will undergo resistance exercise training 3x/wk for 12 weeks at a physical therapy or cardiac rehabilitation facility near the participant's home.
88916667|NCT01629472|Experimental|VSLA + gender dialogue groups: treatment|
88916668|NCT01629472|Active Comparator|VSLA only: control|
88916669|NCT01629485|Experimental|Whole Task|Trainees will undergo whole task mastery training in the TEP simulator after completing the video curriculum portion.
88916670|NCT01629485|Experimental|Part Task|Trainees will undergo a random part task mastery training in the TEP simulator after completing the video portion of the curriculum.
88916671|NCT01629511|Experimental|Treatment (combination chemotherapy, stem cell transplant)|Participants receive gemcitabine IV over 10-25 minutes on days -6 and -4, clofarabine IV over 1 hour and busulfan IV over 3 hours on days -6 to -3. Participants with matched unrelated donors also receive anti-thymocyte globulin IV over 4 hours on days -3 to -1. Starting day -2, participants receive tacrolimus PO daily for up to 6 months. Participants undergo hematopoietic allogeneic stem cell transplant on day 0, then receive methotrexate IV over 15 minutes on days 1, 3, 6 and 11, and filgrastim SC QD beginning 1 week after transplant until blood cell levels return to normal.
88916672|NCT01629524||Colorectal cancer patients|Colorectal cancer patients undergoing elective colorectal resection
88916673|NCT01629537|Other|Placebo|Subjects 1 month post in the placebo group who demonstrate either the same level of PTSD severity at enrollment or worsening of the condition (i.e., CAPS score greater than or equal to 40) will be offered SGB treatment and crossed over to active treatment. Patients who cross over from placebo to active SGB treatment will be followed one week, one month and three months after cross over.
88916674|NCT01629537|Experimental|Stellate Ganglion Block (SGB)|Subjects assigned to SGB arm will undergo SGB procedure and be followed one week, one month and three months after procedure or until CAPS score is below 40.
88916675|NCT01629550|Active Comparator|PVI paint|5% alcoholic povidone iodine paint
88916676|NCT01629550|Active Comparator|PVI scrub and paint|detersion with 4% povidone iodine scrub followed by 5% alcoholic povidone iodine paint
88916677|NCT01629550|Active Comparator|Chlorhexidine paint|2% alcoholic chlorhexidine paint
88916678|NCT01629550|Active Comparator|chlorhexidine scrub and paint|Detersion with 4% chlorhexidine scrub followed 2% alcoholic chlorhexidine paint
88916679|NCT01629576|No Intervention|control group|
88916680|NCT01629576|Experimental|low reward|economic incentive
88916681|NCT01629576|Experimental|high reward|economic incentive
88916682|NCT01629602|Experimental|vascularized nerve graft|The investigators combined the nerve branch with the boomerang flap for simultaneous repair of soft tissue loss and PDN defect in these awkward areas.
88916683|NCT01629628|Experimental|Adalimumab|
88916684|NCT01629628|Active Comparator|6-mercaptopurine|
88916685|NCT01629641||Normals|Texas Woman's University students from the School of Physical Therapy - Houston campus will be recruited to participate in this study. The participant will be excluded if they have pain in the shoulder on the day of testing, less than 90 degrees of active or passive shoulder abduction, less than 90 degrees of active or passive elbow flexion, have had any previous surgeries or procedures to either shoulder or identify by self-report any reason that they should not perform active external rotation at the shoulder.
88916686|NCT01629654|Experimental|Lifestyle counseling|Testing of the teory- and evidence based health promotion program. Patients will participate in a 13 weeks program.
88916687|NCT01629680|Experimental|Healthy subjects I|
88916688|NCT01629680|Placebo Comparator|Healthy subjects II|
88916689|NCT01629732|Experimental|Arm 1: Daclasasvir + BMS-986094 (100 mg) + Placebo|"Subjects will be re-randomized at Week 12 to complete therapy at this visit and enter post-treatment follow-up, or continue therapy for an additional 12 weeks (24 weeks of therapy)~Re-Randomized Arm 1 to Arm 1a and 1b (additional 12 weeks treatment)"
88916690|NCT01629732|Experimental|Arm 2: Daclasasvir + BMS-986094 (200 mg)|"Subjects will be re-randomized at Week 12 to complete therapy at this visit and enter post-treatment follow-up, or continue therapy for an additional 12 weeks (24 weeks of therapy)~Re-Randomized Arm 2 to Arm 2a and 2b (additional 12 weeks treatment)"
88916691|NCT01629732|Experimental|Arm 3: Daclasasvir + BMS-986094 (100 mg) + Placebo + Ribavirin|"Subjects will be re-randomized at Week 12 to complete therapy at this visit and enter post-treatment follow-up, or continue therapy for an additional 12 weeks (24 weeks of therapy)~Re-Randomized Arm 3 to Arm 3a and 3b (additional 12 weeks treatment)"
88916692|NCT01629732|Experimental|Arm 4: Daclasasvir + BMS-986094 (200 mg) + Ribavirin|"Subjects will be re-randomized at Week 12 to complete therapy at this visit and enter post-treatment follow-up, or continue therapy for an additional 12 weeks (24 weeks of therapy)~Re-Randomized Arm 4 to Arm 4a and 4b (additional 12 weeks treatment)"
88916693|NCT01629732|Experimental|Arm 5: Daclasasvir + BMS-986094 (200 mg)|Genotype 1 PI-failure subjects
88916694|NCT01629732|Experimental|Arm 6: Daclasasvir + BMS-986094 (200 mg)|Genotype 4 naive subjects
88916695|NCT01629732|Experimental|Arm 7: Daclasasvir + BMS-986094 (200 mg)|Genotype 2/3 NR/relapse Subjects
88916696|NCT01629758|Experimental|Part 1-Arm A: BMS-982470 (weekly x 4) + BMS-936558|Dose Escalation BMS-982470 10, 30, 50, 75 or 100 µg/kg Solution, Intravenous, During each 6 week cycle: weekly x 4 (i.e during weeks 1 through 4), Up to 2 years + BMS-936558 3 mg/kg Solution, Intravenous, During each 6 week cycle: every other week (i.e during weeks 1, 3, and 5), Up to 2 years
89435597|NCT05951582|Experimental|Group A (Plyometrics)|This group will receive 8 weeks of upper and lower body plyometric exercises protocol. The session will last for 60 minutes and 3 time per week. 1-minute rest period is there between each exercise and each repetition and 3-5 minute for each set.
88916697|NCT01629758|Experimental|Part 1-Arm B: BMS-982470 (3 times/week) + BMS-936558|Dose Escalation BMS-982470 10, 30, 50, 75 or 100 µg/kg Solution, Intravenous, During each 6 week cycle: 3 times/week during weeks 1 and 3, Up to 2 years + BMS-936558 3 mg/kg Solution, Intravenous, During each 6 week cycle: every other week (i.e during weeks 1, 3, and 5), Up to 2 years
88916698|NCT01629758|Experimental|Part 2-Arm A: BMS-982470 (weekly x 4) + BMS-936558|Cohort Expansion BMS-982470 (dose selected in Part 1) Solution, Intravenous, During each 6 week cycle: weekly x 4 (i.e during weeks 1 through 4), Up to 2 years + BMS-936558 3 mg/kg Solution, Intravenous, During each 6 week cycle: every other week (i.e during weeks 1, 3, and 5), Up to 2 years
88916699|NCT01629849|Experimental|BI 1021958 qd|Multiple rising dose
88916700|NCT01629849|Placebo Comparator|Placebo to BI 1021958 qd|Matching placebo as tablets
88916701|NCT01629849|Experimental|BI 1021958 bid|Multiple rising dose
89435598|NCT05951582|Experimental|Group B (Conventional)|This group will receive 8 weeks of upper and lower body strength exercises protocol. The session will last for 60 minutes and 3 times per week.
88916702|NCT01629849|Placebo Comparator|Placebo to BI 1021958 bid|Matching palcebo as tablet
88916703|NCT01629875|Experimental|DWP450|
88916704|NCT01629875|Active Comparator|Botox|
88916705|NCT01629888|Experimental|1 = Tested product|
88916706|NCT01629888|Placebo Comparator|2 = Control product|
88916707|NCT01629927||HED-affected males|Male subjects affected by HED
88916708|NCT01629927||Male controls|Male subjects not affected by HED
88916709|NCT01629940||Male HED-Affected Individuals|Male subjects affected by HED
88916710|NCT01629940||Male controls|Male subjects not affected by HED
88916711|NCT01629979|Experimental|A: Grafting of autologous epidermal harvested cells and UVB|"Grafting with epidermal cells: A superficial skin shaving excision will be obtained from pigmented skin using a dermatome. A cell suspension will be obtained by trypsinisation. Vitiligo skin will be dermabraded by Erbium: Yag laser after local anaesthesia. The cell suspension will be spread on the dermabraded skin area and fixed with dressings. Keratinocyte, and melanocyte counts will be performed on an aliquot of the cell suspension. One symmetrical patch of vitiligo will be chosen as control and left untreated.~Narrow-band UVB treatment: Four weeks after transplantation of epidermal cells, the grafted and control patch will be treated by Narrow-band UVB. Treatment will be performed 2 times a week. Narrow-band UVB treatment will be performed for at least 3 months or 24 treatments."
88916712|NCT01629979|Active Comparator|UVB treatment|UVB treatment twice a week during 3months
88916713|NCT01629992|Experimental|Preoperative counseling|The intervention group received preoperative counseling by both orally and written. A written leaflet containing information was provided to each patient of this group.
88916714|NCT01629992|No Intervention|Control|The control group received no preoperative counseling either oral or written.
88916715|NCT01630005|Experimental|Talk therapy|A cohort of 25 patients
88916716|NCT01630018|Active Comparator|Topotecan|Topotecan
88916717|NCT01630018|Active Comparator|Camtobell|Belotecan
88916718|NCT01630031||Control group|Use of the THERMOCOOL SF or EZ STEER THERMOCOOL Catheter, Biosense Webster, Inc.
88916719|NCT01630031||CF group|Use of THERMOCOOL SMARTTOUCH Catheter, Biosense Webster, Inc.
88916720|NCT01630044|Experimental|TNM device, active treatment|This is an active-only assessment of the experimental neuromodulation device
89536885|NCT02468531|Experimental|Xenon group|50% oxygen inhalation one hour before and after CPB,and Pulmonary Static Inflation with 50%,75% and 100% Xenon during CPB respectively.
89536886|NCT03312101|Experimental|Experimental|exercise program
89435599|NCT05948384|Active Comparator|PNF Group|For the PNF intervention, we applied a lower extremity hip extension-abduction-internal rotation with knee extension pattern, together with the rhythmic initiation of a repeated stretch and a combination of isotonic techniques. By this we'll target rectus femoris, medial gastrocnemius, lateral gastrocnemius, biceps femoris and semitendinosus musculature of the patient. The session will be given in 2 sets of 5 repetitions with rest of 45 seconds
89435600|NCT05948384|Other|Mirror Therapy Group|"Mirror treatment is a sort of motor imagery in which the patient exercises his unaffected limb while looking at himself in the mirror. It involves placing the affected limb behind a mirror. The mirror is positioned so the reflection of the opposing limb appears in place of the hidden limb. The patient then looks into the mirror on the side with unaffected limb and makes mirror symmetric movement. It will implemented for about 30 minutes with 2, 2 minutes rest in between. Patient will perform as many repetitions as they could of knee flexion & extension, ankle dorsiflexion & plantarflexion and functional tasks (rolling the foot over the roller, reaching would be accomplished by asking the patient to reach towards objects through his leg e.g. touching the feet to a certain object at a particular height and distance, cycling) depending on patient's ability to do so."
89435601|NCT05946070|Experimental|Intervention Group (ONKOSIS)|Patients in the intervention group will be instructed to use the mobile application. Patients in the experimental group will be able to access the application contents without restrictions and will be able to use the in-app messaging module as well as the risk factors, symptom findings, and intervention suggestions for symptom management.
89435602|NCT05946070|No Intervention|Control group|Patients in the control group will receive standard care as is currently available at their clinical site. They will use demo version of the mobile application only for assessing symptom severity. In the demo version used by the control group patients, there is no in-app messaging module as well as information such as risk factors, symptoms and intervention recommendations for symptom management.
88916721|NCT01630057|Experimental|Adjunctive Zonisamide|Patients will be gradually down-titrated from the first add-on following a drug-specific scheme decided by the investigator. Discontinued from the first add-on, patients will remain on duotherapy until the end of the study, or until the clinical situation mandates withdrawal from the study, e.g. in case of seizure worsening or adverse events.
88916722|NCT01630057|Active Comparator|Replacement with Zonisamide|Patients will continue to receive zonisamide as third drug
88916723|NCT01630070|Experimental|Self-expandable drug eluting stent|Self-Expanding Paclitaxel-Eluting stent
88916724|NCT01630083|Active Comparator|EOX Treatment|Participants will receive up to 8 cycles of epirubicin, oxaliplatin and capecitabine (EOX) chemotherapy treatment alone (50 mg/m^2 epirubicin intravenously on day 1 of each cycle, 130 mg/m^2 oxaliplatin intravenously on day 1 of each cycle, 625 mg/m^2 capecitabine orally twice daily on days 1 to 21 of each cycle). The first dose of capecitabine to be taken in the evening of day 1.
88916725|NCT01630083|Experimental|EOX+zolbetuximab 800/600 mg/m^2|Participants will received up to 8 cycles of EOX chemotherapy treatment in combination with zolbetuximab administered as loading dose of 800 mg/m^2 intravenously on day 1 of cycle 1 followed by 600 mg/m^2 intravenously on day 1 of each subsequent cycle. Zolbetuximab to be administered prior to EOX chemotherapy. After completion of the EOX treatment phase, participants will be permitted to continue zolbetuximab monotherapy (600 mg/m^2 every 3 weeks to be administered intravenously as a 2-hour infusion) until progressive disease (PD), withdrawal of consent or unacceptable toxicity. PD per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 is defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum on study, an absolute increase of at least 5mm must also be demonstrated, unequivocal progression of existing non-target lesions and appearance of one or more new lesions is considered progression.
88916726|NCT01630083|Experimental|EOX+zolbetuximab 1000 mg/m^2|Participants will receive up to 8 cycles of EOX chemotherapy treatment in combination with zolbetuximab 1000 mg/m^2 intravenously on day 1 of each cycle. Zolbetuximab to be administered prior to EOX chemotherapy. After completion of the EOX treatment phase, participants will be permitted to continue zolbetuximab monotherapy (1000 mg/m^2 every 3 weeks administered intravenously as a 2-hour infusion ) until PD, withdrawal of consent or unacceptable toxicity.
88916727|NCT01630096|Active Comparator|Nu-Lytely|Bowel prep solution.
88916728|NCT01630096|No Intervention|Control|Standard of care.
88916729|NCT01630122||patients newly diagnosed non small cell lung cancer|patients with presumed newly diagnosed non small cell lung cancer, where radiographic studies and clinical description favor a probable diagnosis of non small cell lung cancer
88916730|NCT01630148|Active Comparator|Bemiparin|group one will be women who are risky for venous thromboembolic diseases after benign gynaecological surgeries, each will receive Bemiparin
88916731|NCT01630148|No Intervention|control group|women will undergo benign gynaecological surgeries and are risky for venous thrombosis, they will not receive any intervention. The patients will be followed up to 30 days after surgery.
88916732|NCT01630161|Active Comparator|Usual Care|Participants randomized to the Usual Care condition will receive standard care following recruitment.
88916733|NCT01630161|Active Comparator|Relapse-Prevention Intervention|Participants randomized to the Smoking Relapse Prevention for Cancer Patients (SRP-CaP) intervention will receive standard care plus our self-help smoking-relapse prevention materials.
88916734|NCT01630187|Active Comparator|Carbetocin 100 mcg|
88916735|NCT01630187|Experimental|Carbetocin 50 mcg|
88916736|NCT01630226|Experimental|Neoadjuvant Cisplatin Chemotherapy|
89435603|NCT05945953|Experimental|Incentive spirometer as visual feedback|
88916737|NCT01630239|Experimental|Visualise Thermal Therapy System|
88916738|NCT01630252|Active Comparator|Part A2 - Active Treatment arm|PGL5001 for 8 weeks + one DMPA injection
89435604|NCT05945953|Active Comparator|Diaphragmatic breathing exercise (Mirror mediated therapy)|
89435605|NCT05945251||FAPDs|Children 8-17 years with FAPDs
88916739|NCT01630252|Placebo Comparator|Part A2 - Placebo Treatment arm|PGL5001 matching placebo for 8 weeks + one DMPA injection
88916740|NCT01630252|Active Comparator|Part B - Active treatment arm|PGL5001 for 20 weeks + two DMPA injections
88916741|NCT01630252|Placebo Comparator|Part B - Placebo Treatment arm|PGL5001 matching placebo for 20 weeks + two DMPA 150mg injections
88916742|NCT01630252|Experimental|Part A1 - Active Treatment arm|PGL5001 for 8 weeks + one unique DMPA 150 mg injection
88916743|NCT01630265|Active Comparator|Written Discharge Instructions|Group of caregivers who read written discharge instructions that are the standard discharge instructions given in our pediatric ED
88916744|NCT01630265|Experimental|Video Discharge Instructions|Group of caregivers who watched the 3-minute video covering the information in the standard written discharge instructions
89435606|NCT05945251||Controls|Children 8-17 years without FAPDs
89435607|NCT05937256|Active Comparator|Group Q|(n=30) will receive unilateral quadratus lumborum block type III
89435608|NCT05937256|Active Comparator|Group E|(n=30) will receive unilateral erector spinae plane block
89435609|NCT05937256|No Intervention|Group C|(n=30) will be control group receiving no intervention, managed only with conventional analgesia
88916745|NCT01630278|No Intervention|Small ductus|
88916746|NCT01630278|Experimental|Large ductus ibuprofen|Very premature infants with a large ductus, selected by an early echocardiogram, will receive ibuprofen before 12 hours of life
88916747|NCT01630278|Placebo Comparator|Large ductus placebo|Very premature infants with a large ductus, selected by an early echocardiogram, will receive placebo before 12 hours of life
88916748|NCT01630291|Experimental|Electrical stimulation|
89435610|NCT05934669|Experimental|Intranasal Midazolam|Dose/Concentration: 5mg/ml of 0.4mg/kg Midazolam (max dose 10mg). Adverse side effects include respiratory depression and hypotension. Intranasal Midazolam is standard of care for minimal procedures in pediatric ED.
89435611|NCT05934669|Experimental|Intranasal Dexmedetomidine|Dose/Concentration: 100mcg/ml of 2mcg/kg Dexmedetomidine (max dose 100mcg). Adverse side effects include Hypotension and Bradycardia at high dosages. IV Dexmedetomidine is FDA approved and widely used in sedation. IN form isn't FDA approved; however, it has been approved to conduct research studies that have showed its efficacy in pre-operative settings, imaging-CT or MRI, dental procedures, and much more. Specifically, in a pediatric ED setting, Neville et al conducted a study comparing intranasal Dexmedetomidine and intranasal Midazolam prior to laceration repair in a pediatric emergency department and showed safe administration of Dexmedetomidine.
89536887|NCT03312101|No Intervention|Control|observation
89536888|NCT03307733|No Intervention|Control Group|Control group received usual care plus a blinded Fitbit pedometer.
89435612|NCT05934669|Experimental|Intranasal Ketamine|Dose/Concentration: 100mg/ml of 3mg/kg Ketamine (max dose 100mg). Adverse side effect include Laryngospasm. IV Ketamine is FDA approved and widely used in procedural sedation in pediatric EDs. IN form isn't FDA approved in pediatric population; however, it has also been approved to conduct research studies especially in combination with other medications. Gutherie et al conducted a study demonstrating intranasal Ketamine providing safe and successful anxiolysis in pediatric patients in an ED setting.
89435613|NCT05934214||immune-related adverse event reaction|Reports of identified immune-related adverse event reaction
89435614|NCT05925530|Experimental|Durvalumab|Durvalumab will be administered to the participants via intravenous infusion (IV)
89435615|NCT05925257|Experimental|Intervention group|The intervention group will be given access to the ePRO application and proactive clinical care, including study nurses responding to ePROs and weekly health information videos for six months.
88916749|NCT01630304|Experimental|WelTel SMS service|"In addition to standard care, weekly text messages will be delivered to participants randomized to this arm for a one year period. Participants will be requested to respond to the outgoing message Mambo? within 48 hours; they may respond that they are doing well (sawa) or that they have a problem (shida). A clinician will call to follow-up with all participants who respond indicating a problem or who do not respond within 48 hours."
88916750|NCT01630304|No Intervention|Standard care|This arm will receive standard clinical care.
88916751|NCT01630317|Experimental|Peripheral acces|
88916752|NCT01630317|Placebo Comparator|Central access|
88916753|NCT01630330|Active Comparator|Contact Force Known|Ablation with contact force data known
88916754|NCT01630330|Experimental|Contact Force Not Known|Contact Force data unavailable during ablation
88916755|NCT01630343|Experimental|Regular oral Panadol and Tramadol|Geriatric (age >65) Patient having traumatic hip fracture will have three weeks of regular prescription of oral Panadol(500mg) and tramadol (50mg) three times a day. Operation will be done within 3 days usually followed by rehabilitation period.
88916756|NCT01630343|Experimental|Panadol and tramadol oral in prn basis|Control group is that patient having geriatric hip fracture will have oral analgesics ( Panadol 500mg Q4H and tramadol 50mg Q4H ) in prn basis.
88916757|NCT01630356|Experimental|Intervention group|
88916758|NCT01630356|Active Comparator|Control group|
88916759|NCT01630369|Experimental|Human Insulin|Dosage of human insulin (Insuman Basal/Comb/Rapid) will be individually adjusted in accordance with the Summary of Product Characteristics (SmPC). Patients will follow the titration algorithm recommended by the physician.
88916760|NCT01630395|No Intervention|conventional|Two-lung ventilation: tidal volume = 10 ml/kg, no PEEP. One-lung ventilation: tidal volume = 10 ml/kg, no PEEP
88916761|NCT01630395|Active Comparator|Protective|Two-lung ventilation: tidal volume 8 ml/kg, PEEP of 5 cmH2O. One-lung ventilation: tidal volume 6 ml/kg, PEEP of 5 cmH2O.
88916762|NCT01630395|Active Comparator|Recruitment|Two-lung ventilation: tidal volume 8 ml/kg, PEEP of 5 cmH2O. One-lung ventilation: tidal volume 6 ml/kg, PEEP of 5 cmH2O. Recruitment maneuver will be applied during one-lung ventilation.
88916763|NCT01630408|Experimental|Paricalcitol|Paricalcitol oral capsules (1 mcg per day for 48 weeks)
88916764|NCT01630473|Experimental|Corticotomy-assisted orthodontics|This group of patients will receive corticotomy surgical procedure at day 0. Orthodontic activation will start immediately after surgery.
88916765|NCT01630473|Active Comparator|Conventional orthodontics|This group of patients will receive conventional orthodontics starting at day 0.
88916766|NCT01630486||glomerulonephritis|adult CKD patients, whose underlying etiology is glomerulonephritis, either clinically diagnosed or pathologically proven
88916767|NCT01630486||hypertensive nephropathy|adult CKD patients, whose underlying etiology is hypertensive nephropathy
88916768|NCT01630486||polycystic kidney disease|adult CKD patients, whose underlying etiology is autosomal dominant polycystic kidney disease
89435616|NCT05925257|No Intervention|Control group|Participants of the control group will be provided with a list of electronic links to videos on breast cancer-relevant topics on the websites of recognised cancer associations and health institutions.
89435617|NCT05919238|Experimental|Part A|"will be a monotherapy light dose escalation with single dose of Padeliporfin at light laser doses of 200, 400 and 600 mW/cm for 10 minutes.~Part A will proceed with light dose escalation and will continue until the maximum tolerated light dose (MTD) and/or recommended phase 2 dose (RP2D) is defined."
89435618|NCT05919238|Experimental|Part B|will be a dose expansion part at MTD/RP2D dose level identified in Part A to further assess the safety, tolerability, and treatment effect of the MTD and/ or RP2D
89536889|NCT03307733|Active Comparator|Intervention|Intervention group received a Fitbit pedometer with individualised physical activity targets and behaviour change techniques which were delivered via a closed Facebook group
88916769|NCT01630486||diabetic nephropathy|adult CKD patients, whose underlying etiology is diabetic nephropathy
88916770|NCT01630499|Experimental|Tailored Lifestyle Intervention (TLI)|Participants randomized to the TLI condition will receive a 3-month weight management program tailored to the specific needs of women in remission from breast cancer.
88916771|NCT01630499|Active Comparator|Commercial Weight Loss Program (CLWP)|Participants randomized to the CWLP condition will receive a 3-month commercial weight loss program (i.e., Weight Watchers) at no cost.
88916772|NCT01630512|Experimental|MBCT|
88916773|NCT01630512|Experimental|CBT|
88916774|NCT01630512|No Intervention|Waitlist|
88916775|NCT01630525||Prodromal AD participants|
88916776|NCT01630525||Typical AD participants|
88916777|NCT01630525||Control participants|
88916778|NCT01630538|Experimental|Cyclophosphamide|Cyclophosphamide 1.5 mg/kg orally daily for 180 days (26 weeks) adjusted for renal function.
88916779|NCT01630551|Active Comparator|Fishoil nutritional supplement|90 day supply of daily oral administration of a fish oil nutritional supplement (TheraTears Nutrition; Advanced Vision Research, Woburn, MA)
88916780|NCT01630551|Placebo Comparator|Olive oil capsules|90 day supply of a daily dose of placebo olive oil capsules
88916781|NCT01630564|Experimental|Treatment (T-cell infusion)|Patients undergo ex vivo-expanded umbilical cord blood progenitor cell donor T cell infusion with aldesleukin 11-14 days after T-cell co-stimulation begins.
88916782|NCT01630577|Experimental|responder to fluid challenge|fluid challenge
88916783|NCT01630603||mother infants pairs|
88916784|NCT01630629||African-American Lactating Women|Healthy African-American women who are exclusively breast-feeding.
88916785|NCT01630629||Caucasian Lactating Women|Healthy Caucasian women who are exclusively breast-feeding.
88916786|NCT01630668|Experimental|One-a-Day L. reuteri NCIMB 30242 supplement capsule|
88916787|NCT01630668|Placebo Comparator|One-a-Day placebo capsule|
88916788|NCT01630681|Experimental|Internet-based stepped care|Internet-based stepped care comprises interactive support (Step 1) and Cognitive Behavioral Therapy (CBT; Step 2). Step 1 starts directly after randomization and extends over a 24 months period. Step 2 extends to a period of ten weeks.
88916789|NCT01630681|No Intervention|Standard care|
88916790|NCT01630720|Active Comparator|vitamin C|vitamin C 500 mg twice daily
88916791|NCT01630720|Active Comparator|vitamin D|vitamin D 5000 IU daily
88916792|NCT01630733|Experimental|Custirsen + Docetaxel|Custirsen: Three loading doses of custirsen 640mg IV over 2 hours administered in 5 to 9 days prior to Day 1 of Cycle 1, then custirsen 640 mg IV weekly every 21-day cycle Docetaxel: 75 mg/m2 IV over 1 hour on Day 1 of every 21-day cycle
88916793|NCT01630733|Active Comparator|Docetaxel|Docetaxel: 75 mg/m2 IV over 1 hour on Day 1 of every 21-day cycle Continue treatment until disease progression, unacceptable toxicity, withdrawal of consent or protocol specified parameters to stop treatment.
88916794|NCT01630746|Experimental|TAK-438 20 mg/day|
88916795|NCT01630746|Experimental|TAK-438 40 mg/day|
88916796|NCT01630759|Experimental|Telemonitoring|The telemonitoring group will receive usual care but be asked to download their blood sugar readings and take a blood pressure and weight measurement each week. This will be reviewed by their diabetes health care team to assess the possibility of replacing alternate anti-natal/diabetes clinics with telemonitoring review in a future study. Acceptability to staff and patients will be assessed through a questionnaire (patients only) and qualitative interviews.
88916797|NCT01630759|Active Comparator|Control group|Control group will consist of usual care and review at clinic.
88916798|NCT01630798|Experimental|Application of peptide|
88916799|NCT01630824|Other|Education|Kidney transplant recipients, who undergo the structured education program
88916800|NCT01630824|No Intervention|Control|Kidney transplant recipients without structured education programm
88916801|NCT01630837|Other|12h|Frequency of oral hygiene was 12 to 12 hours.
88916802|NCT01630837|Other|24h|Frequency of oral hygiene was 24 to 24 hours.
88916803|NCT01630837|Other|48h|Frequency of oral hygiene was 48 to 48 hours.
88916804|NCT01630837|Other|72h|Frequency of oral hygiene was 72 to 72 hours.
88916805|NCT01630863|Experimental|50% group|power of PDT is applied to the patients at 50% of the full energy based on TAP study.
88916806|NCT01630863|Experimental|40% group|Decreasing power of PDT is applied to the patients at 40% of the full energy based on TAP study.
88916807|NCT01630863|Experimental|30% group|Decreasing power of PDT is applied to the patients at 30% of the full energy based on TAP study.
88916808|NCT01630876|Sham Comparator|Vitrectomy only group|The patients who will underwent 23- gauge transconjunctival sutureless vitrectomy only.
88916809|NCT01630876|Experimental|Combined therapy group|The patients who will underwent 23- gauge transconjunctival sutureless vitrectomy with concomitant posterior subtenon Triamcinolone acetate injection.
88916810|NCT01630928|Experimental|Renal sympathetic denervation|Patients with treatment resistant hypertension
88916811|NCT01630941|Active Comparator|Denosumab|1 ml (60 mg) subcutaneous injection Denosumab give in the posterior part of the upper arm after surgery followed by another injection 6 months later
88916812|NCT01630941|Placebo Comparator|saline|1 ml subcutaneous injection 0.9% saline give in the posterior part of the upper arm after surgery followed by another injection 6 months later
88916813|NCT01630954|Active Comparator|Single evacuation of mole,|
88916814|NCT01630954|Active Comparator|Double evacuation of mole|
88916815|NCT01630967|Experimental|Degarelix|Degarelix 240mg subcutaneously loading dose, then 80mg sc every month until disease progression.
88916816|NCT01630993|Experimental|Umbilical Cord Milking|At birth, the infant will be held below the level of the placenta and umbilical cord will be milked 5 times after birth and before clamping the cord.
88916817|NCT01630993|No Intervention|Immediate Cord Clamping|At birth, the infant will be held at the level of the placenta and umbilical cord will be clamped within 10 seconds (routine practice).
88916818|NCT01631006|Sham Comparator|Low CPAP pressure|Patients are submmited to a CPAP with low pressure for 20 minutes
88916819|NCT01631006|Active Comparator|High CPAP pressure|Patients are submmited to a high pressure of CPAP for 20 minutes
88916820|NCT01631019|Active Comparator|with mobile phone assistance|In the mobile phone group, patients were asked to continue their exercise program at home at a fixed walking speed. During this period of time, the adherence to protocol was reinforced by telephone from health professionals whenever patients missed one day of their walking training detected by the central system. Patients were asked to continue their exercise program at home at a fixed walking speed, and return to the clinic at 1, 2, 3 and 6 months.
88916821|NCT01631019|Placebo Comparator|with free walk|Patients in the control group were educated the same exercise protocol, but were only verbally asked to freely take the walking exercise training at home. The adherence to the walking exercise at home was reported by the patients themselves at every return visits. All the patients received ISWT, spirometry and blood sample for inflammatory biomarkers at baseline, 1, 2, 3 and 6 months.
88916822|NCT01631032|Placebo Comparator|Control|control group receive placebo capsule with same look, smell and flavor compared with experiment group. The scheme for medication is 3 times a day, 3gm each time, total 9gm per day.
88916823|NCT01631032|Experimental|Chinese herbal products (CHP)|CHP group receive Qi-tonifying Chinese herbal products capsule, 3 times a day, 3gm each time, total 9gm per day
88916824|NCT01631045||15 min|Subjects post-meal brain MRI will be 15 minutes after breakfast.
88916825|NCT01631045||30 min|Subjects post-meal brain MRI will be 30 minutes after breakfast.
88916826|NCT01631045||60|Subjects post-meal brain MRI will be 60 minutes after breakfast.
88916827|NCT01631045||120|Subjects post-meal brain MRI will be 120 minutes after breakfast.
88916828|NCT01631045||180|Subjects post-meal brain MRI will be 180 minutes after breakfast.
88916829|NCT01631045||240|Subjects post-meal brain MRI will be 240 minutes after breakfast.
88916830|NCT01631045||300|Subjects post-meal brain MRI will be 300 minutes after breakfast.
88916831|NCT01631058|Experimental|Everolimus|"Number of patients: 45 Everolimus: initial dose of 1 mg BID. Doses will be adjusted in order to maintain Everolimus whole blood trough concentrations between 3-8 ng/ml.~Tacrolimus: initial dose of 0.1 mg/kg/day. Doses will be adjusted in order to maintain Tacrolimus whole blood trough concentrations between 2- 4 ng/ml thereafter.~Corticosteroids: as clinical practice."
88916832|NCT01631123|Experimental|Diet interventions|Sequential dietary intervention
88916833|NCT01631136|Active Comparator|Continuous maintenance Therapy|Induction chemotherapy by cisplatin + pemetrexed and maintenance therapy by pemetrexed
88916834|NCT01631136|Experimental|Maintenance according to the response of induction|"Induction chemotherapy by cisplatin + gemcitabine followed by :~continuous maintenance therapy by gemcitabine if response disease~switch maintenance therapy by pemetrexed if stable disease"
88916835|NCT01631162|No Intervention|lung disease|
88916836|NCT01631175|Experimental|(PO-Bado, FBK-R10, PHQ) Active Comparator|
88916837|NCT01631201|Experimental|Rifalazil 25 milligram|
88916838|NCT01631201|Active Comparator|Azithromycin 1 gram|Single dose of Azithromycin 1 gram to be administered on Day 1.
88916839|NCT01631240||Adults 18-39 years|Healthy adults aged 18-39 years
88916840|NCT01631253|Active Comparator|single-port access laparoscopic ovarian cyst enucleation|Procedure: Operative laparoscopic ovarian cyst enucleation was performed only through an umbilical single port. ( 2 cm longitudinal incision was made within the umbilicus and an wound retractor (Alexis Wound Retractor XS) was inserted into the wound opening. A surgical glove with three 5mm trocars inserted into three fingers was draped around the rim of the wound retractor.)
88916841|NCT01631253|Active Comparator|two-port laparoscopic access ovarian cyst enucleation|Procedure: Operative access laparoscopic ovarian cyst enucleation was performed using an umbilical single port ( 2 cm longitudinal incision was made within the umbilicus and an wound retractor (Alexis Wound Retractor XS) was inserted into the wound opening. A surgical glove with two 5mm trocars inserted into two fingers was draped around the rim of the wound retractor.) and one 5-mm trocar in the lower abdomen.
88916842|NCT01631253|Active Comparator|four-port access laparoscopic ovarian cyst enucleation|Procedure: : Operative laparoscopic ovarian cyst enucleation was performed through insertion of a 12-mm subumbilical trocar and three 5-mm trocars in the lower abdomen.
88916843|NCT01631266|Experimental|0.1 µg/0.1 mL C-Tb|The C-Tb and 2 T.U. Tuberculin PPD RT 23 SSI agents are given concomitantly to each volunteer in the RIGHT and LEFT forearms according to a double blind randomisation scheme
88916844|NCT01631266|Active Comparator|2 T.U. Tuberculin PPD RT 23 SSI|The C-Tb and 2 T.U. Tuberculin PPD RT 23 SSI agents are given concomitantly to each volunteer in the RIGHT and LEFT forearms according to a double blind randomisation scheme
88916845|NCT01631279|Experimental|PR610|
88916846|NCT01631305|Experimental|Levothyroxine|3 mcg/kg/day
88916847|NCT01631305|Placebo Comparator|Control|Calcium magnesia.
88916848|NCT01631344|No Intervention|Physical Therapy|Conventional Physical Therapy
88916849|NCT01631344|Experimental|Daily physical activity consultation, Using Stage of change|
88916850|NCT01631357|Experimental|Arm 1: CIK+CT|Arm 1: We design chemotherapy combination with CIK cell immunotherapy as a experimential arm.
88916851|NCT01631357|Active Comparator|Arm 2: CT|Arm 2: We design chemotherapy alone as a control arm
88916852|NCT01631370|Experimental|Renal denervation|The patients will be examined prior to renal denervation and 6 months after. Thus the patients are their own controls.
88916853|NCT01631383|Placebo Comparator|Placebo|
88916854|NCT01631383|Active Comparator|l-THP|
88916855|NCT01631396||Patients recieving Sugammadex|Sugammadex Group (n=20) - anesthesia induced by Rocuronium 0.4mg/kg body, additional Rocuronium 0.1-0.2 mg/kg body as needed during surgery (not more than x2), muscular blockage reversal using Sugammadex 2.0 mg/kg body.
88916856|NCT01631396||Patients recieving Neostigmine|Neostigmine Group (n=20) - anesthesia induced by Rocuronium 0.4mg/kg body, additional Rocuronium 0.1-0.2 mg/kg body as needed during surgery (not more than x2), muscular blockage reversal using Neostigmine 0.05 mg/kg body and atropine 0.1 mg/kg body.
88916857|NCT01631409||Cohort 0|"Cohort 0 is allocated for the following two patient groups:~The patients with suspicion of angina although in whom the thorough investigation has not revealed CHD and the pain syndrome has been received the extracardiac interpretation (e.g. vertebral osteochondrosis, left side humeroscapular periarthritis, herpes zoster, intercostal neuralgia Tietze syndrome etc.)~The patients with subclinical manifestation of coronary atherosclerosis without angina (Class 0 angina, here and further is according to the Canadian Cardiovascular Society Angina Classification). This subgroup of the patients is recommended the proper diet, life style modification, lipid targeting medications in some cases, and no antianginal treatment."
88916858|NCT01631409||Cohort I|Represents patients with Class 1 angina, who receive OMT.
88916859|NCT01631409||Cohort II|"Comprises the patients with Class 2-4 angina, they are on MAAMT. The cohort is further divided in two groups:~The patients for whom MAAMT is effective.~The patients for whom MAAMT is not effective or not sufficiently effective, although those patients have not received any invasive, surgical or CSWT interventions yet.~They are those patients who then form cohorts III-VI."
88916860|NCT01631409||Cohort III|Consists of patients already received PCA. They also continue various MAAMT.
88916861|NCT01631409||Cohort IV|Includes the patients after CABG. They also are on various MAAMT.
88916862|NCT01631409||Cohort V|Incorporates the patients who have already underwent CSWT. They also receive individualized MAAMT.
88916863|NCT01631409||Cohort VI|"The cohort is composed of the patients who for various reasons have not been exposed to any intervention except MAAMT and continue to be on it.~The algorithm of the cohort formation is graphically demonstrated in the Diagram The logic tree of the cohort formation (see the link at the bottom of the protocol)."
88916864|NCT01631422|Experimental|Single Arm|
88916865|NCT01631448|No Intervention|Control|Patients fron this group do not receive the fibrin sealant
88916866|NCT01631448|Active Comparator|Fibrin group|Patients from this group will receive the fibrin sealant
88916867|NCT01631461||1. Deep pain group|1. Deep pain group; Pain in the breast
88916868|NCT01631461||2. Superficial pain group|Pain on the nipple and/or aereola
88916869|NCT01631461||3. Control group|No pain or other breastfeeding problems
88916870|NCT01631487|Experimental|Japanese Group 1: JNJ-39439335/placebo (Part 1)|
88916871|NCT01631487|Experimental|Japanese Group 2: JNJ-39439335/placebo (Part 1)|
88916872|NCT01631487|Experimental|Japanese Group 3: JNJ-39439335/placebo (Part 1)|
88916873|NCT01631487|Experimental|Caucasian Group 1: JNJ-39439335/placebo (Part 1)|
88916874|NCT01631487|Experimental|Caucasian Group 2: JNJ-39439335/placebo (Part 1)|
88916875|NCT01631487|Experimental|Caucasian Group 3: JNJ-39439335/placebo (Part 1)|
88916876|NCT01631487|Experimental|Japanese Group 1: JNJ-39439335/placebo (Part 2)|
88916877|NCT01631487|Experimental|Japanese Group 2: JNJ-39439335/placebo (Part 2)|
88916878|NCT01631487|Experimental|Japanese Group 3: JNJ-39439335/placebo (Part 2)|
88916879|NCT01631500|Other|Conventional treatment|Patients receive usual treatments provided at primary care settings, e.g. antidepressants, sessions with a curator or psychotherapist and physiotherapy.
88916880|NCT01631500|Experimental|Integrative treatment|Person-centred dialogue combined with therapeutic acupuncture (mild manual acupuncture with deqi). Eight individual sessions, once a week, duration approximately 60 minutes
88916881|NCT01631500|Active Comparator|Terapeutic acupuncture|Therapeutic acupuncture alone, eight individual sessions, once a week. The participants received acupuncture needles in the appropriate acupuncture points, in the same way as the integrative treatment model, but without person-centred dialogue.
88916882|NCT01631513|Experimental|Nucynta ER|Nucynta ER will be 100 to 250 mg every 12 hours
88916883|NCT01631526|Experimental|Vitamin D|vitamin D 20,000 IU per day for 2 weeks followed by 10,000 IU per day for a further 7 days
88916884|NCT01631539|Other|Chemoembolization|chemoembolization with DC Bead™ loaded with Irinotecan
88916885|NCT01631565|No Intervention|Standard care|Usual care given to the patients. Treatment, follow-up.
89010259|NCT04555408|Active Comparator|bright light group|The bright light will be applied five times a week for the first two weeks. For the next two weeks, this treatment will be applied three times a week.
88916886|NCT01631565|Experimental|Early Palliative Care|"Intervention: Early allocation to palliative care. Intervention: Nutritional counseling. Intervention: patient and care-taker psychoeducation, depression and anxiety evaluation.~Standard of care: Oncological treatment according to stage of disease (IIIb/IV).~Treatment: Chemotherapy (platins, taxans, TKIs) Baseline: BMI, and anthropometric characteristics (weight, height). Follow-up: During 6 chemotherapy circles with: Quality of Life (EORTC qlq-c30), HADS, ESAS and ZARIT."
88916887|NCT01631578|Experimental|Injection of mitochondrial concentrate|A small volume of mitochondrial concentrate will be injected together with the spermatozoon during ICSI.
88916888|NCT01631578|Active Comparator|Control|ICSI will be performed conventionally.
88916889|NCT01631591||eosinophilic esophagitis|PATIENTS WITH A CURRENT DIAGNOSIS OF eosinophilic esophagitis.
89536436|NCT02476799|Sham Comparator|Control|Patients of Control group will be proceeded a surgery scheduled after induction of general anesthesia without any procedure such as placebo injection. After the surgery, a bandage will be attached on the incision site where is same as the block injection site of RSB group. All patients will use total 100 ml of IV-PCA containing fentanyl and ketorolac for 48 hours postoperatively.
88916890|NCT01631591||GERD|PATIENTS WITH A DIAGNOSIS WITH GERD.
88916891|NCT01631669|Experimental|Celebrex|Receive Celebrex
88916892|NCT01631669|No Intervention|Control|no placebo administered
88916893|NCT01631708|Active Comparator|Erythrocytapheresis|"Erythrocytapheresis is a procedure whereby whole blood is drawn from an individual and all elements except erythrocytes are returned to the donor. An automated filtration process removes the erythrocytes.~Those in arm 1 will have third weekly erythrocytapheresis until their SF is returned to the normal range."
88916894|NCT01631708|Sham Comparator|Plasmapheresis|"In plasmapheresis, the plasma is removed by the automated filtration process whilst other blood elements including erythrocytes are returned to the subject.~Those in arm 2 will have plasmapheresis with the approximate number of episodes of apheresis that would be required to reduce their SF to normal had they been randomised to the true treatment arm."
88916895|NCT01631760||MicroRNA ages 5-12 yrs old|As a prospective study, we would like to look for the differential expression of microRNA in different age groups (ages 5 to 12, 13 to 55, and 56 and older) of asthma patients with exacerbation. At least 20 patients for each group is anticipated.
88916896|NCT01631760||MicroRNA ages 13-55 yrs old|As a prospective study, we would like to look for the differential expression of microRNA in different age groups (ages 5 to 12, 13 to 55, and 56 and older) of asthma patients with exacerbation. At least 20 patients for each group is anticipated.
88916897|NCT01631760||MicroRNA ages 56-85 yrs old|As a prospective study, we would like to look for the differential expression of microRNA in different age groups (ages 5 to 12, 13 to 55, and 56 and older) of asthma patients with exacerbation. At least 20 patients for each group is anticipated.
88916898|NCT01631773||subjects w/ Nasal polyps & AERD disease|subjects with nasal polyps and Aspirin-exacerbated respiratory disease (AERD) disease
88916899|NCT01631773||subjects w/ nasal polyps without AERD|subjects with nasal polyps but without Aspirin-exacerbated respiratory disease (AERD)
88916900|NCT01631786||Preserved ovaries|Ovaries or ovarian segments that have been fixed in 10% Formalin
88916901|NCT01631786||Fresh/non-preserved ovaries|Ovaries that have been surgically removed and placed in sterile saline
88916902|NCT01631799|Active Comparator|Femoral Block|One group received a femoral block for analgesia after surgery. Ropivacain was administered continuously for three days.
88916903|NCT01631799|Active Comparator|Epidural Analgesia|One group received an epidural analgesia after surgery for three days.
88916904|NCT01631838|Experimental|Tocotrienol-rich fraction 400mg|
88916905|NCT01631838|Experimental|Placebo|
88916906|NCT01631877|Experimental|enoxaparin with acenocoumarol|Patients will receive enoxaparin 100mcg/kg for 5days along with acenocoumarol 2mg with titration of dose to maintain a target INR of 2-3.intially the INR will be monitored twice weekly with gradual escalation of dose to achieve target INR.After achieving the target INR this is to be repeated every 4th weekly. The Doppler Ultra Sonography screening will be done every 3monthly to assess the recanalization of portal vein thrombus but the medications will be continue for one year irrespective of recanalization.
88916907|NCT01631877|Placebo Comparator|Placebo|Injection placebo will be given for 5 days along with placebo tablets.
88916908|NCT01631890|Active Comparator|standard endotherapy|
88916909|NCT01631890|Experimental|Endoscopic Ultrasound assisted endoscopic glue injection|
89435619|NCT05918783|Experimental|Part A|"will be a monotherapy light dose escalation with single dose of Padeliporfin at light laser doses of 150, 250 and 400 mW/cm for 20 minutes.~Part A will proceed with light dose escalation and will continue until the maximum tolerated light dose (MTD) and/or recommended phase 2 dose (RP2D) is defined."
89435620|NCT05918783|Experimental|Part B|will be a dose expansion part at MTD/RP2D dose level identified in Part A to further assess the safety, tolerability, and treatment effect of the MTD and/ or RP2D
89435621|NCT05916638||Sarcoidosis|patients diagnosed with sarcoidosis
89435622|NCT05916638||Tuberculosis|patients diagnosed with tuberculosis
88916910|NCT01631903|Experimental|Arm 2 (3mg)|
88916911|NCT01631903|Experimental|Arm 3 (6 mg)|
88916912|NCT01631903|Experimental|Arm 4 (12 mg)|
89435623|NCT05915286|Experimental|Diuretic Therapy|
89435624|NCT05905562|Experimental|Spinal mobilization and core stabilization exercises group:|will have core muscle activation exercises along with lumber spine joint mobilization along with TENS and Ultrasound for 12 weeks and 3 sessions per week
89435625|NCT05905562|Active Comparator|Spinal mobilization techniques group|will have lumber spine joint mobilization along with TENS and Ultrasound duration of 12 weeks with 3 sessions per week.
89435626|NCT05904392|Experimental|Intervention|Music played prior to intravitreal injection
89435627|NCT05904392|No Intervention|Control|No music played.
89435628|NCT05903768|Experimental|Cyriax capsular stretching|Patient will be subjected to Hot Pack prior to treatment. Detailed intervention will include Active range of motion exercises,Home plan exercises.Anterior, Posterior and inferior capsular stretching.
89435629|NCT05903768|Active Comparator|Mobilization|Patient will be subjected to Hot Pack prior to treatment. Detailed intervention will include Active range of motion exercises,Home plan exercises and Maitland's Mobilization:
89435630|NCT05903183|Experimental|IVX-A12 Vaccine Formulation 1|Participants will receive a single dose of IVX-A12 intramuscular (IM) injection on Day 0.
89435631|NCT05903183|Experimental|IVX-A12 Vaccine Formulation 2|Participants will receive a single dose of IVX-A12 IM injection on Day 0.
89435632|NCT05903183|Placebo Comparator|Placebo|Participants will receive a single dose of placebo IM injection on Day 0.
89435633|NCT05900856|Experimental|low caloric diet regimn|patients will follow low caloric diet regimn (1600: 2000 Kcal/ day), lipids approximately (20: 35%) of total caloric intake, protein approximately (10: 35%) of total caloric intake and high complexed carbohydrate intake approximately (45: 65%) of total caloric intake (with increased fiber-rich whole grain breads, cereals, fruits and vegetables), for eight weeks.
89435634|NCT05900856|Experimental|ultrasound cavitation for 30 minutes, twice per week for eight weeks and low caloric diet regimn|"ultrasound cavitation, Dae Yang, Mabel 6, frequency (50: 60) Hz, power consumption 150 W, power input AC (100: 230) V, hand probe diameter 8.0 cm, serial number DY73-15037, produced by DAEYANG MEDICAL company, made in Korea. the device will be applied for 30 minutes on the abdominal area, twice per week for eight weeks.~low caloric diet regimn patients will follow low caloric diet regimn (1600: 2000 Kcal/ day), lipids approximately (20: 35%) of total caloric intake, protein approximately (10: 35%) of total caloric intake and high complexed carbohydrate intake approximately (45: 65%) of total caloric intake (with increased fiber-rich whole grain breads, cereals, fruits and vegetables), for eight weeks."
89435635|NCT05897424|Experimental|INBRX-101 Q3W|IV every 3-weeks (Q3W)
89435636|NCT05896774|Experimental|Maplirpacept (PF-07901801)|single arm study
88916913|NCT01631903|Experimental|Arm 5 (24 mg)|
88916914|NCT01631903|Experimental|PK arm (12 mg)|PK arm requires one additional 24 hour PK assessment at V3 and daily visits between visits 2 and 3 for drug trough sample collection
88916915|NCT01631916|Experimental|Corticosteroid|Dexamethasone 0.6 mg/kg/day or Methylprednisone 1 mg/kg/day
88916916|NCT01631916|No Intervention|Control|No intervention
88916917|NCT01631942|Experimental|Low dose (healthy subjects)|
88916918|NCT01631942|Experimental|Medium dose (subjects with haemophilia)|
88916919|NCT01631942|Experimental|High dose (subjects with haemophilia)|
88916920|NCT01631955||Cystitis|female with cystitis symptoms
88916921|NCT01631968|Experimental|Cement with erytromycin and colistin|In this group the knee arthroplasty was fixed with cement with erythromycin and colistin.
88916922|NCT01631968|Placebo Comparator|Cement without antibiotic|In this group the knee arthroplasty was fixed with standard cement, without any antibiotics.
88916923|NCT01631981|Experimental|PGL2001|PGL2001 + NETA followed by NETA-only follow-up period
88916924|NCT01631981|Placebo Comparator|Placebo|Placebo + NETA followed by NETA-only follow-up period
88916925|NCT01631994|Experimental|Oral Dissolving metoclopramide|Patient's in this arm will receive the oral dissolving metoclopramide along with the capsule during capsule endoscopy.
88916926|NCT01631994|No Intervention|control group|This is the control group that will only ingest the capsule during video capsule endoscopy.
88916927|NCT01632033||Investigation for lower limb arteries|Patients referred for investigation of assumed peripheral artery disease (PAD)
89435637|NCT05896189|Active Comparator|Arm 1: Computerized Cognitive Training-Global Stimulation Games|The global stimulation games active attention control intervention is composed of computerized games. These games are fully developed and are rated E (for everyone) by the Entertainment Software Rating Board. The program will present 8 non-speeded exercises that include spin-offs of such games as breaking hex, lineup four, battleship, gems swap, double klondike, solitaire, reversi, word search, and sudoku.
89435638|NCT05896189|Experimental|Arm 2: Computerized Cognitive Training-Neuroplasticity Games|The neuroplasticity games provide core elements necessary for inducing neuroplasticity. The five core elements include the principles of speed of processing, accuracy of processing, adaptivity, generalizability, and engagement. Importantly, all of the exercises adapt to user skill and ability. Behavioral tracking built within the program is used to monitor individual performance and ensure that the person is training at their uppermost threshold level. Specifically, we will use eight of these exercises which are designed to address cognitive concerns most noted in BCS including exercises to improve attention and working memory, processing speed, and executive function.
88916928|NCT01632046|Active Comparator|BicaVera, dialysis|Two Parallel arms. If patient randomised to the BicaVera arm he will be dialysed with bicarbonate based PD fluid (BicaVera) for 10 months. Dialysis prescription is determined according to clinical needs, dialysate glucose concentrations are 1.5, 2.3 and 4.25 %.
88916929|NCT01632046|Active Comparator|Balance, dialysis|If patient is randomised to the Balance arm, he will be dialysed with lactate based PD fluid (Balance) for 10 months. Dialysis prescription is determined according to clinical needs, dialysate glucose concentrations are 1.5, 2.3 and 4.25 %.
88916930|NCT01632059||septical patients|inclusion criteria are severe sepsis and septical shock and must be > 18 y/o
88916931|NCT01632072|Experimental|Nutritional counseling|Dietary supplement
88916932|NCT01632072|No Intervention|No nutritional counceling|
88916933|NCT01632085|Other|Group SU (Single use or Laryngobloc ®) ®)|In order to avoid an order effect, the patient acting as his own control, will randomly undergo a laryngoscopy with each laryngoscopes, the intubation being performed during the second laryngoscopy, here with the Laryngobloc ®.
88916934|NCT01632085|Other|Group R (Reusable handle)|In order to avoid an order effect, the patient acting as his own control, will randomly undergo a laryngoscopy with each laryngoscopes, the intubation being performed during the second laryngoscopy, here with the Disposable Metal Blade.
88916935|NCT01632163|Experimental|Lixisenatide|24-week treatment with lixisenatide once daily on top of basal insulin with or without metformin (at least 1.0g/day)
88916936|NCT01632163|Placebo Comparator|Placebo|24-week treatment with placebo once daily on top of basal insulin with or without metformin (at least 1.0g/day)
88916937|NCT01632176|No Intervention|Standard of care|Patients in the control group will not receive any intervention, but will receive standard care for dating abuse issues.
88916938|NCT01632176|Experimental|Intervention|Patients in the intervention group will participate in brief, motivational interview and one booster session to prevent adolescent dating abuse.
89198398|NCT05351008|Active Comparator|Physical therapy group|The group will receive 4 months 3 times per week of physical therapy.
88916939|NCT01632189|Experimental|Varenicline|Varenicline will be used at the same dosage regimen as used for smoking cessation, i.e. 0.5mg once daily for days 1-3, 0.5mg twice daily for days 4-7 followed by 1mg twice daily. The total duration of Varenicline treatment will be three months.
88916940|NCT01632254||Patients with ≥70% carotid artery stenosis|
88916941|NCT01632293|Experimental|exercise|Individuals with multiple sclerosis and age and gender matched healthy controls will participate in a supervised exercise program for 12 weeks.
88916942|NCT01632319|Experimental|MI + CBT|Motivational Interviewing (MI) and cognitive behavioral therapy (CBT). In this course of therapy students are asked questions about their drinking, receive personalized feedback about it and are taught coping skills for their depressive symptoms.
88916943|NCT01632319|Active Comparator|CBT|Cognitive behavior therapy (CBT)
88916944|NCT01632332|Experimental|Treatment (HER-2/neu peptide vaccine)|Patients receive HER-2/neu peptide vaccine ID every 28 days for up to 6 courses in the absence of disease recurrence or unacceptable toxicity.
88916945|NCT01632358|Experimental|TAP311 capsules|Patients will receive TAP311 capsule orally once daily for 14 days.
88916946|NCT01632358|Placebo Comparator|Placebo of TAP311 capsules|Matching placebo to TAP311 capsule, once daily for 14 days
88916947|NCT01632371|Experimental|Paclitaxel Eluting Balloon + Scoring Balloon|Dilatation of the lesion with an Paclitaxel Eluting Balloon before the utilization of a Scoring Balloon
88916948|NCT01632371|Active Comparator|Paclitaxel Eluting Balloon|Paclitaxel Eluting Balloon
88916949|NCT01632397|Experimental|CBT-based counseling|Cognitive behavioral based intervention to promote PrEP adherence.
88916950|NCT01632397|Active Comparator|Health education and supportive counseling|Time matched supportive counseling
88916951|NCT01632410||Study group 1|"Post hemispheral ischemic stroke cognitively intact. Exclusion: Subjects with severe visual or hearing impairments, stroke location brain steam.~The group will be divided in to 4 goups acording to stroke specific location as demonstrated in MRI."
88916952|NCT01632410||Control|Control: Healthy subjects resemble in age and sex
88916953|NCT01632410||Study -3|As explained the subjects will be divided into 4 groups acording to the stroke location. this is in order to evaluat the relationship between location and autonomic responed.
88916954|NCT01632410||Stydy -2|As explained the subjects will be divided into 4 groups acording to the stroke location. this is in order to evaluat the relationship between location and autonomic responed.
88916955|NCT01632410||Stydy- 4|As explained the subjects will be divided into 4 groups acording to the stroke location. this is in order to evaluat the relationship between location and autonomic responed.
88916956|NCT01632449|Experimental|1|Test product
88916957|NCT01632449|Experimental|2|Reference product
88916958|NCT01632462|Active Comparator|VSL#3 arm|15 patients with a diagnosis of Crohn's disease will be exposed to VSL#3 for 8 weeks
88916959|NCT01632462|Placebo Comparator|placebo group|15 patients affected by Crohn's disease will be exposed to a placebo for 8 weeks
88916960|NCT01632475||Pneumostem®|Low Dose Group (3 subjects): 1.0 x 10^7 cells/kg, High Dose Group (6 subjects): 2.0 x 10^7 cells/kg
88916961|NCT01632488||Irritable bowel syndrome|Patients admitted to outpatient department with symptoms meeting Rome III criteria of irritable bowel syndrome.
88916962|NCT01632488||Inflammation|Patients with long standing history or short onset of inflammatory bowel disease.
88916963|NCT01632488||Normal controls|Asymptomatic individuals admitted for health surveillance or patients for follow up after polypectomy.
88916964|NCT01632514|Active Comparator|Vitamin D deficiency treatment|subjects with 25OHD < 20 ng/mL that will receive 100,000U of cholecalciferol weekly for 4 weeks before surgery
88916965|NCT01632514|No Intervention|Vitamin D deficiency observation|subjects with 25OHD < 20 ng/mL that will not receive cholecalciferol before surgery
88916966|NCT01632514|No Intervention|Vitamin D sufficiency|controls with 25OHD >= 20 ng/mL that will not receive cholecalciferol before surgery
88916967|NCT01632527|Experimental|HuCNS-SC|HuCNS-SC cells
88916968|NCT01632540||Perennial Allergic Rhinitis patients|
88916969|NCT01632553||Cases|women who have experienced DVA
88916970|NCT01632553||Controls|women who have not experienced DVA
88916971|NCT01632592|Experimental|Growth Hormone Releasing Hormone|Growth Hormone Releasing Hormone analogue, 2mg subcutaneously every day for 12 months.
88916972|NCT01632592|Placebo Comparator|Placebo|
88916973|NCT01632605|Experimental|Sirolimus|Daily single oral dose of 1-3mg sirolimus with an initial loading dose of 6mg.
88916974|NCT01632618|Experimental|Trunk Muscle Training+NMES|Progressive exercise program for the stabilizing muscles of the trunk, as well as neuromuscular electrical stimulation to the lumbar paraspinals
88916975|NCT01632618|Active Comparator|Passive control intervention|Passive physical therapy interventions, including moist heat, ultrasound, massage and flexibility exercises
88916976|NCT01632670|Experimental|Music therapy|The music played will be by MusiCure, by Niels Eje (slow, relaxing music designed for therapeutic use), and will be played from an audio pillow beneath the patient's head.
88916977|NCT01632670|No Intervention|No music therapy|
89435639|NCT05895747|Experimental|Low Dose 5-hydroxytryptophan and Creatine Monohydrate|5-HTP 100mg PO BID plus creatine 5g PO Qday
88916978|NCT01632696|Experimental|I-124 PGN650 for PET/CT|
88916979|NCT01632722|Active Comparator|ArmA|
88916980|NCT01632722|Active Comparator|ArmB|
88916981|NCT01632748|Experimental|Modified Neurotech Vital Device|Checking to observe stimulation delivered using this device
88916982|NCT01632748|Active Comparator|Neurotech Vital Device|Checking to see if stimulation observed using this device
88916983|NCT01632761|Active Comparator|Vitamin D + fish oil|Dietary Supplement: Vitamin D3 (cholecalciferol), 2000 IU per day. Other Name: cholecalciferol Drug: omega-3 fatty acids (fish oil) Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).
88916984|NCT01632761|Active Comparator|Vitamin D + fish oil placebo|Dietary Supplement: Vitamin D3 (cholecalciferol), 2000 IU per day. Other Name: cholecalciferol Dietary Supplement: Fish oil placebo Fish oil placebo
88916985|NCT01632761|Active Comparator|Vitamin D placebo + fish oil|"Drug: omega-3 fatty acids (fish oil) Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).~Dietary Supplement: Vitamin D3 placebo Vitamin D placebo"
88916986|NCT01632761|Active Comparator|Vitamin D placebo + fish oil placebo|Dietary Supplement:Vitamin D3 placebo Vitamin D placebo Dietary Supplement: Fish oil placebo Fish oil placebo
88916987|NCT01632813||CHD group|Seven-year-old children with CHD who were four years old when they participated in Paediatric ICU follow-up study (i.e. first follow-up time point) (Neurocognitive development of children four years after critical illness and treatment with tight glucose control, Clinical Trials # NCT00214916). The children of the CHD-group underwent cardiac surgery as infants (=<1year).
88916988|NCT01632813||Control group|Seven-year-old healthy control children who were four years old when they participated in Paediatric ICU follow-up study (i.e. first follow-up time point) (Neurocognitive development of children four years after critical illness and treatment with tight glucose control, Clinical Trials # NCT00214916). These children have never undergone cardiac surgery.
88916989|NCT01632839||Vaginal surgery +prothesis +sexuality|The 50 patients included in this group will have undergone vaginal surgery for pelvic organ prolapse with placement of a prothesis; these patients are sexually active.
88916990|NCT01632839||Vaginal surgery +prothesis -sexuality|The 25 patients included in this group will have undergone vaginal surgery for pelvic organ prolapse with placement of a prothesis; these patients are NOT sexually active.
88916991|NCT01632839||Vaginal surgery -prothesis + sexuality|The 50 patients included in this group will have undergone vaginal surgery for pelvic organ prolapse WITHOUT placement of a prothesis; these patients are sexually active.
88916992|NCT01632839||Vaginal surgery -prothesis -sexuality|The 25 patients included in this group will have undergone vaginal surgery for pelvic organ prolapse WITHOUT placement of a prothesis; these patients are NOT sexually active.
88916993|NCT01632839||Abdominal surgery +sexuality|The 50 patients included in this group will have undergone abdominal surgery for pelvic organ prolapse; these patients are sexually active.
88916994|NCT01632839||Abdominal surgery -sexuality|The 25 patients included in this group will have undergone abdominal surgery for pelvic organ prolapse; these patients are NOT sexually active.
88916995|NCT01632839||Urinary incontinence surgery + sexuality|The 50 patients included in this group will have surgery for urinary incontinence; these patients are sexually active.
88916996|NCT01632839||Urinary incontinence surgery - sexuality|The 25 patients included in this group will have surgery for urinary incontinence; these patients are NOT sexually active.
88916997|NCT01632852|Experimental|CSL362|See Intervention Description
88916998|NCT01632865|Experimental|recanalization and stenting|
88916999|NCT01632917|Experimental|ATX-101 - EU|Open Label study in which subjects will receive ATX-101 (one of the two formulations) in one dosing session in the submental area
88917000|NCT01632917|Experimental|ATX-101 - US|Open Label study in which subjects will receive ATX-101 (one of the two formulations) in one dosing session in the submental area
89435640|NCT05895747|Experimental|High Dose 5-hydroxytryptophan and Creatine Monohydrate|5-HTP 200mg PO BID plus creatine 10mg PO Qday
89435641|NCT05895747|Placebo Comparator|Double Placebo|Creatine-matched placebo and 5-HTP-matched placebo
89435642|NCT05893134||Main|Information from entomological, housing condition, and sociodemographic surveys of the El Vergel neighborhood, Tapachula, Chiapas, obtained during the period from November to December 2019, will be used
88917001|NCT01632943|Experimental|Symplicity renal denervation system|
89435643|NCT05891236|Experimental|Part A: Single Ascending Dose (SAD): Dose escalation cohort 1: MAM01 and placebo Intravenous (IV)|2 sentinel participants will be randomized in a 1:1 ratio to receive MAM01 1.5 milligrams per kilogram (mg/kg) IV or placebo. Following at least a 24-hour safety review period, the 6 remaining participants of Cohort 1 will be randomized in a 5:1 ratio to receive MAM01 1.5 mg/kg IV or placebo.
89435644|NCT05891236|Experimental|Part A: SAD dosing: Dose escalation Cohort 2: MAM01 and placebo SC|7 participants will be randomly assigned in a 6:1 ratio to receive MAM01 5 mg/kg SC or placebo
89435645|NCT05891236|Experimental|Part A: SAD dosing: Dose escalation Cohort 3: MAM01 and placebo IV|7 participants will be randomly assigned in a 6:1 ratio to receive MAM01 5 mg/kg IV or placebo.
88917002|NCT01632969||families or next-of-kin of deceased patients|The families of deceased patients treated at MSKCC for non-cutaneous squamous cell carcinomas of the upper aerodigestive tract for whom contact information is available will be recruited by mail and by phone.
88917003|NCT01632982|Other|standard treatment|the standard drug counseling offered to patients in methadone maintenance treatment at the study site
89198399|NCT00860769|Experimental|ASHA Life|6-session educational group discussing HIV prevention, anti-retroviral therapy (ART), coping enhancement, nutrition, parenting and life skills.
89198400|NCT00860769|Active Comparator|Usual Care|3-session educational group focusing on HIV prevention, anti-retroviral therapy (ART) and parenting.
88917004|NCT01632982|Experimental|Mobile Therapeutic System (MTS)|The Mobile Therapeutic System (MTS) is a novel, interactive, mobile phone-delivered psychosocial intervention designed to promote skills acquisition and reduce drug use among adults in methadone maintenance treatment
88917005|NCT01632982|Active Comparator|mobile control|a mobile phone-based application that directs participants to the NIDA website's home page
88917006|NCT01633008|Experimental|1|Attend three 2-hour sessions held over two consecutive days
88917007|NCT01633047|Experimental|Electrical stimulation|The subjects on this group will be submitted to a conventional rehabilitation (ROM increase, strength recovery, functional training) associated with electrostimulation.
88917008|NCT01633047|Active Comparator|Physical therapy exercises|The subjects on this group will be submitted to a conventional rehabilitation (ROM increase, strength recovery, functional training).
88917009|NCT01633073|Active Comparator|LMA Supreme|
88917010|NCT01633073|Active Comparator|i-gel|
88917011|NCT01633086|Active Comparator|nitric oxide gel|"st gel: sodium nitrites~nd gel: maleic/ascorbic acids"
88917012|NCT01633086|Placebo Comparator|Placebo gel|"st gel: phosphate-buffered saline~nd gel: maleic/ascorbic acids"
88917013|NCT01633099|Other|Decitabine, CR rate,OS,EFS,RFS|Therapeutic effect and safety of 10 days of decitabine. Acute myeloid leukemia,no acute promyelocytic leukemia.
88917014|NCT01633125|Experimental|Group music therapy|Participants in the experimental group will take part in biweekly group music therapy for 10 weeks (20 sessions). Each group will be formed by 6 to 8 people, and each session will last for 90 minutes.The academically trained music therapist with previous relevant clinical experience will apply receptive and active music therapy techniques. The active techniques will include musical improvisation as a medium to work with participants according to therapeutic goals and participants' needs.
88917015|NCT01633125|No Intervention|No music therapy|Participants assigned to the control group will not receive any specific treatment in this study. The usual care that is normally available at the prison will continue to be available for all participants during the study.Due to ethical considerations, the control group will receive group music therapy or psychotherapy by academically qualified therapists for 5 weeks after the study is finished.
88917016|NCT01633138|Active Comparator|CRT-S|Cognitive Remediation Therapy - Standard
88917017|NCT01633138|Experimental|CRT-CM|Cognitive Remediation Therapy plus Contingency Management
88917018|NCT01633151||20 volunteers|
88917019|NCT01633164|Experimental|SCI Reinvention Protocol Participants|This group will receive 6 instructor-led 2 hour long didactic presentations regarding 8 key principles of self-efficacy and experiential exercises, including goal setting and problem solving with extensive group discussion. At the end of each session, tasks are assigned to participants to be completed outside the group during the week between sessions. Experiences from these activities and practice implementing the intervention principles will be shared and discussed each week, providing additional opportunities for problem solving and positive feedback.
88917020|NCT01633164|Other|Waitlist Group|This group will include individuals randomized to receive no treatment for the 30 weeks during which the interventional group will receive the active treatment and have their progress tracked.
88917021|NCT01633190||Rotavirus|- Children (0-16 years of age)admitted to hospital (through to December 31, 2020)
89435646|NCT05891236|Experimental|Part A: SAD dosing: Dose escalation Cohort 4: MAM01 and placebo IV|8 participants will be randomly assigned in a 6:2 ratio to receive MAM01 10 mg/kg IV or placebo.
89435647|NCT05891236|Experimental|Part A: SAD dosing: Dose escalation Cohort 5: MAM01 and placebo IV|7 participants will be randomly assigned in a 6:1 ratio to receive MAM01 40 mg/kg IV or placebo
89435648|NCT05891236|Experimental|Part A: Multiple Ascending Dose (MAD) (Repeat dosing): MAM01 and placebo SC|Participants from Cohort 2 and from Cohort 3 will receive 5 mg/kg MAM01 SC.
88917022|NCT01633203||locally advanced gastric cancer|Patients with resectable, locally advanced cT3-4 and/or N+ gastric carcinoma treated with 3 perioperative epirubicin cisplatin capecitabine polychemotherapy
88917023|NCT01633216|Active Comparator|Bivalent OPV 2 week interval|Group A will receive 3 doses of bOPV at 6, 8 and 10 weeks of age (2-week interval between doses).
88917024|NCT01633216|Active Comparator|Bivalent OPV 4 week interval|Group B will receive 3 doses of bOPV at 6, 10 and 14 weeks of age (4-week interval between doses).
88917025|NCT01633216|Active Comparator|Monovalent OPV 2week interval|Group C will receive 3 doses of mOPV1 at 6, 8 and 10 weeks of age (2-week interval between doses).
88917026|NCT01633216|Active Comparator|Monovalent OPV 4 week interval|Group D will receive 3 doses of mOPV1 at 6, 10 and 14 weeks of age (4-week interval between doses).
88917027|NCT01633216|Active Comparator|Trivalent OPV 4 week interval|Group E will receive 3 doses of tOPV at 6, 10 and 14 weeks of age (4-week interval between doses and similar to the current routine immunization schedule).
88917028|NCT01633281|Experimental|acupuncture treatment|
88917029|NCT01633294|Active Comparator|Antibiotic group|women submitted to antibiotic prophylaxis
88917030|NCT01633294|No Intervention|Control group|
88917031|NCT01633307|Experimental|Experimental|Intervention (Teaching program)
88917032|NCT01633307|No Intervention|Control group|No teaching program
88917033|NCT01633333|Experimental|Water exchange|Colonoscopy with water exchange as the sole modality to reach the cecum. Carbon dioxide can be used in case of intubation failure with the test method.
88917034|NCT01633333|Active Comparator|Carbon dioxide insufflation|Carbon dioxide insufflation will be used in standard fashion to reach the cecum.
88917035|NCT01633346||Tocilizumab treated patients|Rheumatoid arthritis patients
88917036|NCT01633359|Experimental|Intensive statin|"Fifty CAD subjects will receive intensive Atorvastatin administration and 50 CAD patients receiving the routine Atorvastatin administration as controls.~All subjects will receive the follow-up for 1 year, and peripheral blood VSELs, SDF-1/CXCR4 are tested, and the MACE (major adverse cardiovascular events) are recorded including angina, repeat myocardial infarction, repeat revascularization, major organ dysfunction, and death.~the Intensive Atorvastatin protocol indicates that 80mg Atorvastatin will be administrated before CAG, and then are followed with 20mg Atorvastatin during the entire study period."
88917037|NCT01633359|Experimental|Routine statin|"Fifty CAD subjects will receive intensive Atorvastatin administration and 50 CAD patients receiving the routine Atorvastatin administration as controls.~All subjects will receive the follow-up for 1 year, and peripheral blood VSELs, SDF-1/CXCR4 are tested, and the MACE (major adverse cardiovascular events) are recorded including angina, repeat myocardial infarction, repeat revascularization, major organ dysfunction, and death.~the Routine Atorvastatin protocol indicates that 20mg Atorvastatin daily during the entire study period."
88917038|NCT01633385||Subject-Group|Patients suffering from doctors diagnosed bronchiolitis obliterans
88917039|NCT01633385||Control Group|age- and sex matched to subject-group
88917040|NCT01633437|Placebo Comparator|Sugar pill|
88917041|NCT01633437|Experimental|CX157|CX157 is a reversible monoamine oxidase inhibitor (RIMA) in Phase II development for the treatment of depression.
88917042|NCT01633450|Experimental|Zinc biofortified rice|
88917043|NCT01633450|Active Comparator|Rice extrinsically fortified with zinc|
88917044|NCT01633476|Active Comparator|Valaciclovir|Active treatment with valaciclovir
88917045|NCT01633476|No Intervention|No additional treatment|No additional treatment
88917046|NCT01633515|Other|Intralesional cryotherapy|10 BCC (skin lesions) in the lower extremity of elderlies with risk factors for surgical complications.
89435649|NCT05891236|Experimental|Part B: Dose Expansion Cohort 6: Group 1: MAM01 and placebo SC (optional)|8 participants will receive a single SC dose of either MAM01 or placebo. The dose will be selected by applying a PK-pharmacodynamic (PD) model from the Part A data to estimate a (data-driven) protection threshold.
88917047|NCT01633528|Experimental|Asprin|With the onset of endometrial preparation and estrogen treatment, the study group will receive 100 mg of oral aspirin.
88917048|NCT01633528|Placebo Comparator|placebo|With the onset of endometrial preparation and estrogen treatment, the control group will receive placebo
88917049|NCT01633554||Chronic Hepatitis B Group|Patients with chronic hepatitis B
88917050|NCT01633554||Cirrhosis|Patients with liver cirrhosis
88917051|NCT01633554||Control Group|Control Group: Healthy Volunteers
88917052|NCT01633567|Experimental|Culturally Targeted Cessation Program|The culturally targeted program will include the same cognitive and behavioral approaches and smoking education content that is used in the standard program. As such, we will maintain the integrity of the core program. However, cultural targeting of that program has been informed by local LGBT focus group input and testing, the available literature on LGBT smoking rates and behaviors, feedback from a panel of LGBT health experts, and data collected as part of a previous study.
88917053|NCT01633567|Active Comparator|Non-Targeted Cessation Program|Non-culturally targeted program with cognitive and behavioral approaches and smoking education content.
88917054|NCT01633580|Placebo Comparator|Day 2 group|Patients undergo a standard treatment with a classical start of corifollitropin alfa in a GnRH antagonist protocol.
88917055|NCT01633580|Active Comparator|Day 4 group|Patients undergo an ovarian stimulation, but start on day 4 with corifollitropin alfa
88917056|NCT01633593|Experimental|donepezil|Donepezil 5mg/day during 2 weeks
88917057|NCT01633593|Placebo Comparator|placebo|placebo comparator to donepezil (double blind)
88917058|NCT01633606||Acute patients|Patients admitted to the surgical and general ICU (including burn unit), to the coronary care unit, to the emergency department high care zone, to the medical ICU, to the medical medium care unit
89198401|NCT04010500|Experimental|Rugby Players|
89010260|NCT04555408|Placebo Comparator|dim light group|The dim light will be applied five times a week for the first two weeks. For the next two weeks, this treatment will be applied three times a week.
89010261|NCT04553458||Favorable outcome|Cure or stable disease
89010262|NCT04553458||Unfavorable outcome|Progressive (deteriorate/Recurrence) or Death
89010263|NCT04552756|Experimental|Patients irradiated for high-grade glioma|Participants who receive radiotherapy or radiochemotherapy for glioblastoma (grade IV), anaplastic astrocytoma (grade III) or anaplastic oligodendroglioma (grade III).
89010264|NCT04553029||Group 1: Peri-menopausal woman|Grouping is based on Peri-menopausal woman
89010265|NCT04553029||Group 2: Post- menopausal woman|Grouping is based on Post-menopausal woman
89010266|NCT04553029||Group 3: Peri-menopausal woman: moderate-to-severe MR-VMS|Grouping is based on Peri-menopausal woman with moderate-to-severe vasomotor symptoms (MR-VMS)
89010267|NCT04553029||Group 4: Post-menopausal woman: moderate-to-severe MR-VMS|Grouping is based on Post-menopausal woman with moderate-to-severe vasomotor symptoms (MR-VMS)
89010268|NCT04552951|Active Comparator|Active|Receiving 1 dose of 100.000 iu of Cholecalciferol when the COVID 19 Disease is diagnosed
89010269|NCT04552951|No Intervention|Control|No vitamin D
89010270|NCT02213419|Experimental|ethanol double lavage|Endoscopic ultrasonography-guided double ethanol lavage
89010271|NCT04552483|Experimental|Nitazoxanide|Patients received nitazoxanide 500mg 8/8hours, for 5 days.
89010272|NCT04552483|Placebo Comparator|Placebo|Patients received placebo 500mg 8/8hours, for 5 days.
89010273|NCT02213536||VMAT WBRT|Patients requiring whole brain radiotherapy as part of their cancer managment.
89010274|NCT02213614|Experimental|Spring Lithium Water|"The Long term goal of this research project is the implementation of an effective, inexpensive therapy in communities with high risk of violence. Therapy will be based on a daily dietary supplement LIWA at appropriate doses.~The short-term objective is to prove that Lithium water (LIWA) as a daily supplement is an intervention that prevents gun violence from occurring, and is a factor that decrease the violence for gun in our communities Gun violence poses a serious threat to America's children and youth. Existing data clearly point to the need for improved strategies for keeping guns out of the hands of children and youth and those who would harm them."
89010275|NCT02213614|Experimental|Placebo: Natural Spring water|This group will be drink natural spring water for 4 months in tres cicles
89435650|NCT05891236|Experimental|Part B: Dose Expansion Cohort 6: Group 2: MAM01 and placebo SC (optional)|8 participants will receive a single SC dose of either MAM01 or placebo. The dose will be selected by applying a PK-PD model from the Part A data to estimate a (data-driven) protection threshold.
89198402|NCT04040829|Active Comparator|SE + TAU|"Supported education (SE) includes a variety of services ranging from orientation, study strategies or homework help. This intervention is personalized to the need of each patient in terms of services and frequency. Previous to this randomized controlled trial, we conducted interviews with each site that will provide SE. In these interviews, we explored the fidelity of their services to the Individual Placement and Support adapted to education. Information regarding the dosage of SE (frequency, length of session, type of support) will be collected and used as covariates for each participant since intensity treatment can impact outcomes.~Treatment as usual (TAU) consists of medication and routine contact with the clinical team. Patients will continue to receive their standard treatment, but we will collect information regarding the type of medication, the dosage, and all other relevant information and use it as covariate in our analyses."
89010276|NCT02213653|Experimental|Concomitant iron and I.V. epoietin zeta|
89010277|NCT02213653|Experimental|Iron and I.V. epoietin zeta sequential|
89010278|NCT02213653|Active Comparator|Epoietin zeta|
89010279|NCT02213692||Crush-clamping Method (group A)|Liver parenchymal is crushed by surgeon's fingers or basic surgical clamps to isolate small vessels and biliary radicals, and then divided by suture ligation, electrocautery, or vascular clips.
89010280|NCT02213692||Harmonic Scalpel Method (group B)|Liver parenchymal transection is transected by harmonic scalpel, and small vessels and biliary radicals (<3mm) is also divided by harmonic scalpel. Vessels and biliary radicals (≥ 3mm) were divided by suture ligation, electrocautery, or vascular clips.
89010281|NCT02213731|Other|Cryoballoon ablation|Subjects will wear holter monitors at baseline, 6 months and 12 months
89010282|NCT00268944|Experimental|1|
89010283|NCT04721093|Experimental|PBM(Photobiomodulation)|Subjects applied PBM(Color-DNA-WSF U, Color Seven; 610 nm±10nm wavelength; 3.0 mW/㎠±20%) therapy in the locations of the sternocleidomastoid muscle in the ICA area and the trapezius muscle in VA area. PBM was applied 5 times a week for 8 weeks, 30 minutes per session.
89010284|NCT04552444||the death group|Through the corresponding treatment, the patients who died within 28 days
89010285|NCT04552444||the survival group|Through the corresponding treatment, the patients who survived within 28 days
89010286|NCT04552600|Experimental|NuvastaticTM 1000 mg|NuvastaticTM 1000 mg(standardized extract of Orthosiphon Stamineus) will be given orally, three times per day for 12 months.
89010287|NCT04552600|Active Comparator|Placebo|NuvastaticTM (without active) will be given orally, three times per day for 12 months
89010288|NCT04552561|Experimental|My MS Toolkit|10 Participants asked to use My MS Toolkit and meet weekly with a study coach via telephone.
89010289|NCT04552678|Experimental|Healthy Eating, Active Play, Self-Regulation, Parent Education|Classrooms receive all curricula (Food Literacy, Healthy Eating, Active Play, Self-Regulation Curriculum) and Parent Education
89010290|NCT04552678|Experimental|Healthy Eating, Active Play, Self-Regulation|Classrooms receive all curricula (Food Literacy, Healthy Eating, Active Play, Self-Regulation Curriculum), but no Parent Education
89010291|NCT04552678|Experimental|Healthy Eating, Active Play, Parent Education|Classrooms receive the core Food Literacy Curriculum, the Healthy Eating Curriculum, the Active Play Curriculum, and Parent Education
89010292|NCT04552678|Experimental|Healthy Eating + Active Play|Classrooms receive the core Food Literacy Curriculum, the Healthy Eating Curriculum, the Active Play Curriculum, but no Parent Education
89010293|NCT04552678|Experimental|Healthy Eating, Self-Regulation, Parent Education|Classrooms receive the core Food Literacy Curriculum, the Healthy Eating Curriculum, the Self-Regulation Curriculum, and Parent Education
89010294|NCT04552678|Experimental|Healthy Eating + Self-Regulation|Classrooms receive the core Food Literacy Curriculum, the Healthy Eating Curriculum, the Self-Regulation Curriculum, but no Parent Education
89010295|NCT04552678|Experimental|Healthy Eating + Parent Education|Classrooms receive the core Food Literacy Curriculum, the Healthy Eating Curriculum, and Parent Education
89435651|NCT05891236|Experimental|Part B: Dose Expansion Cohort 6: Group 3: MAM01 and placebo SC (optional)|8 participants will receive a single SC dose of either MAM01 or placebo. The dose will be selected by applying a PK-PD model from the Part A data to estimate a (data-driven) protection threshold.
89435652|NCT05889793|Active Comparator|Emetine|Participant takes Emetine 6mg for 10 consecutive days
89435653|NCT05889793|Placebo Comparator|Placebo|Participant takes a placebo for 10 consecutive days
89435654|NCT05888805|Other|DIMS lens group|Participants will be prescribed with a pair of DIMS spectacle lenses for 24 months.
89010296|NCT04552678|Experimental|Healthy Eating Only|Classrooms receive the core Food Literacy Curriculum, the Healthy Eating Curriculum, but no Parent Education
89010297|NCT04552678|Experimental|Active Play, Self-Regulation, Parent Education|Classrooms receive the core Food Literacy Curriculum, the Active Play Curriculum, the Self-Regulation Curriculum, and Parent Education
89010298|NCT04552678|Experimental|Active Play + Self-Regulation|Classrooms receive the core Food Literacy Curriculum, the Active Play Curriculum, the Self-Regulation Curriculum, but no Parent Education
89010299|NCT04552678|Experimental|Active Play + Parent Education|Classrooms receive the core Food Literacy Curriculum, the Active Play Curriculum, and Parent Education
89010300|NCT04552678|Experimental|Active Play Only|Classrooms receive the core Food Literacy Curriculum, the Active Play Curriculum, but no Parent Education
89010301|NCT04552678|Experimental|Self-Regulation + Parent Education|Classrooms receive the core Food Literacy Curriculum, the Self-Regulation Curriculum, and Parent Education
89010302|NCT04552678|Experimental|Self-Regulation Only|Classrooms receive the core Food Literacy Curriculum, the Self-Regulation Curriculum, but no Parent Education
89010303|NCT04552678|Experimental|Food Literacy + Parent Education|Classrooms receive the core Food Literacy Curriculum, and parents are invited to complete web-based education modules.
89010304|NCT04552678|Experimental|Food Literacy Only|Classrooms only receive the core Food Literacy Curriculum, and no other intervention materials or parent education.
89010305|NCT04552639|Active Comparator|Treatment as usual|Treatment as usual is offered. This includes; individual therapy, group therapy, dietetic support, occupational therapy, nursing and psychiatry, excluding the NEAT group.
89010306|NCT04552639|Experimental|Treatment as usual and NEAT group|Treatment as usual is offered. This includes; individual therapy, group therapy, dietetic support, occupational therapy, nursing and psychiatry, alongside NEAT group.
89010307|NCT04552405|Other|FAP patients|FAP patients who underwent prophylactic total colectomy
89010308|NCT04552249||Group 1|
89010309|NCT04552249||Group 2|
89010310|NCT04552249||Group 3|
89010311|NCT04552249||Group 4|
89010312|NCT04552249||Group 5|
89010313|NCT04552249||Group 6|
89010314|NCT00236210|Active Comparator|VIP program|Risk assessment, lifestyle counselling, exercise program
89010315|NCT00236210|No Intervention|Standard Care|
89010316|NCT02213848|Experimental|Calcium|Administration of calcium chloride 5 mg/kg along with neostigmine 25 mcg/kg + atropine 15 mcg/kg
89435655|NCT05884593|Other|Arm 1|Single Arm. All participants undergoing posterior thoracolumbar arthrodesis procedures betweenT2-S1 in which preplanning is done using the Mazor X robotic system.
89435656|NCT05884307|Experimental|Trans and Nonbinary Adults|
89435657|NCT05880134|Active Comparator|conventional posterior nerve neurectomy|"A vertical incision is made behind the posterior fontanelle. The posterior end of the posterior fontanelle is identified by palpation with an elevator. .~The mucoperiosteum is raised gently using a Cottle elevator or a suction freer elevator, after making the initial incision. Care must be taken not to injure the sphenopalatine vessel during flap elevation.~The peripheral part of the posterior nasal nerve can usually be identified just behind the incision, about 4-5 mm inferior to the sphenopalatine artery or crista ethmoidalis.~I After identifying the nerve fibres, it is cauterised using monopolar suction cautery and cut using microscissors. It is essential to carry out this procedure on both sides for effective results."
89010317|NCT02213848|Placebo Comparator|control|In the control group, all the procedures were the same with calcium group, except for the fact that calcium chloride is not administered
89010318|NCT04548544|Experimental|TARA training|
89010319|NCT04548544|No Intervention|Control|
89010320|NCT04548388|Experimental|Bobath approach|Bobath approach
89010321|NCT04548388|Experimental|whole body vibration|whole body vibration
89010322|NCT04548466|No Intervention|CONTROL group|Chest physiotherapy depending on the location of the ribs fractures techniques are performed: 1. Postural control techniques; 2. Airways clearance techniques; 3. Breathing exercise (diaphragmatic breathing). 4. Early mobilization.
89010323|NCT04548466|Experimental|PEP group|Chest physiotherapy depending on the location of the ribs fractures techniques are performed: 1. Postural control techniques; 2. Airways clearance techniques; 3. Breathing exercise (diaphragmatic breathing). 4. Early mobilization. 5. Positive expiratory pressure breathing (PEP bottle)
89010324|NCT04548427|Experimental|CKD-352|
89010325|NCT04548427|Active Comparator|Diquafosol Sodium 3%|
89010326|NCT00413933|Experimental|Intrevention group|each subject in intervention group will get 15 weekly sessions (each session - 45 minutes) of specified exercise from a physical therapist that specializes in fall prevention and walking device recommendations. All subjects will get brochure for home exercise. It will be expected for intervention group to exercise twice daily, each time for 20 minutes in addition to the PT sessions
89435658|NCT05880134|Active Comparator|cartilage reinforcement after posterior nerve neurectomy|"A vertical incision is made behind the posterior fontanelle. The posterior end of the posterior fontanelle is identified by palpation with an elevator. .~The mucoperiosteum is raised gently using a Cottle elevator or a suction freer elevator, after making the initial incision. Care must be taken not to injure the sphenopalatine vessel during flap elevation.~The peripheral part of the posterior nasal nerve can usually be identified just behind the incision, about 4-5 mm inferior to the sphenopalatine artery or crista ethmoidalis.~I After identifying the nerve fibres, it is cauterised using monopolar suction cautery and cut using microscissors. It is essential to carry out this procedure on both sides for effective results."
89435659|NCT05879926|Active Comparator|Arm 1: Ovarian Function Suppression + Aromatase Inhibitor|Aromatase inhibitor co-administered with a GnRH agonist (gonadotropin releasing hormone) for 5 years. The choice of AI is per investigator discretion. The choice of GnRH agonist and dosing schedule is per investigator's discretion. Options commonly include goserelin, leuprolide, or triptorelin given monthly or every-three-months. The dose and schedule of AI should be consistent with the drug package insert. Endocrine treatment beyond 5 years is at the investigator's discretion. Bilateral oophorectomy may substitute for ovarian suppression if desired.
89435660|NCT05879926|Active Comparator|Arm 2 Adjuvant Chemotherapy + Ovarian Function Suppression + Aromatase Inhibitor|Adjuvant chemotherapy of investigator's choice followed by an aromatase inhibitor (AI) co-administered with an GnRH agonist for 5 years. The choice of AI is per investigator discretion. The choice of GnRH agonist and dosing schedule is per investigator's discretion. Options commonly include goserelin, leuprolide, or triptorelin given monthly or every-three-months. The dose and schedule of AI should be consistent with the drug package insert. Endocrine treatment beyond 5 years is at the investigator's discretion. Bilateral oophorectomy may substitute for ovarian suppression if desired.
89435661|NCT05877703|Experimental|Group A: close kinetic chain exercises|Group A will be treated with close kinetic chain exercises including static cycling with lifestyle modification and patient's education including quadriceps drill with lifestyle modification and patient's education about 30 minutes per session including 10 min of walking as a warm up for total duration of 12 weeks with 3 sessions per week. Assessment will be done by therapist at 0 week, 4 weeks, 8 weeks and 12 weeks
89536437|NCT02449369|Active Comparator|Control|Preop acetaminophen IV 1000 mg, Postop oral oxycodone & acetaminophen (5/325 mg) 1 to 2 tabs every 4 hours PRN, and Postop hydromorphone IV 0.5 mg every 4 hours PRN
89010327|NCT00413933|No Intervention|Control group|"Those who agree to participate in the study will fill in questionnaire about falls (causes, circumstance, results). All will pass through: cognitive assessment by the Mini-Mental State Examination (MMSE), affective assessment by the 15-item Geriatric Depression Scale (GDS), functional assessment by Barthel Index (BI), visual assessment by Snellen charts and basic gait assessment by a Timed get Up and Go test (TU&G).~Participants that fulfill inclusion criteria will be randomly assigned to the intervention group or the control group"
89010328|NCT04548271|Experimental|Camrelizumab+Apatinib|Patients with recurrent or metastatic nasopharyngeal carcinoma who failed to first-line platinum-based chemotherapy and had prior treatment with PD-1 antagonists. Every patients will receive apatinib 250mg orally every day starting 14 days prior to Camrelizumab. Then apatinib 250mg orally every day and Camrelizumab 200mg iv every 3 weeks until disease progression or intolerance of side effects.
89010329|NCT04541719|Active Comparator|Patient-controlled remifentanil analgesia|Patients will received Patient-controlled remifentanil analgesia starting from labour pain until delivery
89010330|NCT04541719|Placebo Comparator|Epidural analgesia|Patients will received continuous epidural analgesia starting from labour pain until delivery
89010331|NCT04548115|Experimental|ARTISAN Condition|Participants assigned to this arm will engage in ARTISAN, a 5-weekly, 15-hour group-based arts and heritage intervention programme with specific intervention components including curated museum tours, facilitated storytelling and professionally-led art-making. The weekly intervention covers the five ARTISAN themes of national heritage, social bonds, adversity and resilience, dreams and aspiration, and community art exhibition.
89010332|NCT04548115|Experimental|Intergenerational Participatory Arts Condition|Participants assigned to this arm will engage in the participatory arts-making component of the ARTISAN Intervention framework. Youths and senior participants in this condition will engage in a 5-weekly, 5-hour, group-based professionally-led art-making that covers the five ARTISAN themes.
89010333|NCT04548115|Experimental|Intergenerational Art-space Condition|Participants assigned to this arm will engage in the cultural space component of the ARTISAN Intervention framework. Youths and senior participants in this condition will engage in a 5-weekly, 5-hour, group-based a group-based curated museum tour that covers the five ARTISAN themes.
89010334|NCT04548115|Experimental|Inter-generational Storytelling Condition|Participants assigned to this arm will engage in the storytelling component of the ARTISAN Intervention framework. Youths and senior participants in this condition will be paired to engage in a 5-weekly, 5-hour, group-based guided storytelling activity that covers the five ARTISAN themes.
89435662|NCT05877703|Active Comparator|Group B: open kinetic chain exercises|Group B will be treated with open kinetic chain exercises including quadriceps drill with lifestyle modification and patient's education about 30 minutes per session including 10 min of walking as a warm up for total duration of 12 weeks with 3 sessions per week. Group B performed scar mobilization exercises only for 3 weeks. Assessment will be done by therapist at 0 week, 4 weeks, 8 weeks and 12 weeks
89435663|NCT05876754|Experimental|Ivosidenib|Ivosidenib 500 mg, taken orally as two 250 mg tablets once daily for an unlimited amount of continuous 28-day cycles
89435664|NCT05875701|Experimental|NVX CoV2373 (Ancestral strain)|1dose of NVX-COV2373 on Day 1
89010335|NCT04548115|Experimental|Control Condition|Participants assigned to this arm will engage in a 5-weekly, 5-hour, group-based physical activity session conducted in the community.
89010336|NCT04547764|Experimental|TAP group|
89010337|NCT04547764|Active Comparator|Vitapex group|
89010338|NCT04547608|Other|group PRi|received immediate injection of rocuronium after propofol administration,
89010339|NCT04547608|Other|group PRd|rocuronium injection when bispectral index score became below 60 after propofol administration
89435665|NCT05875701|Experimental|Updated COVID-19 Vaccine|1dose of updated COVID-19 vaccine on Day 1
89010340|NCT02214472|Experimental|Biofeedback|Abdomino-thoracic muscle activity after a challenge meal will be recorded by EMG and the signal will be displayed on a monitor in front of the patients; in the biofeedback group, patients will be instructed to control muscle activity.
89010341|NCT02214472|Placebo Comparator|Placebo medication|Electromyography will be recorded but not shown to the patients. Patients will take a pill of placebo.
89010342|NCT04547452|Experimental|Sintilimab Combined with SBRT|"Patients will be randomly placed in either of the two arms. Participants enrolled in this arm treated to a total dose of 35-80Gy in 5-8 fractions with stereotactic radiotherapy to a liver or lung or any metastatic lesion. The choice of radiation dose will be at the discretion of the treating radiation oncologist.~Sintilimab is administered intravenously at 200 mg every 3 weeks for up to 1 year."
89010343|NCT04547452|Active Comparator|Sintilimab|Participants enrolled in this arm treated with sintilimab administered intravenously at 200 mg every 3 weeks for up to 1 year.
89010344|NCT04547335||Voriconazole|All eligible patients will be followed up for voriconazole related adverse drug events and efficacy
89435666|NCT05865951|Experimental|chronic neck pain and isometric exercises group:|Group A performed exercises for 12 weeks. Participants performed isometric exercises along with conventional physical therapy treatment ( thermotherapy, manual mobilisation of cervical spine and trigger point therapy). All exercises were performed for 3 sessions per week for a period of 12 weeks.
89536438|NCT02449369|Active Comparator|Standard|Preop acetaminophen IV 1000 mg, Preop orphenadrine IV 60 mg, Postop oral orphenadrine 100 mg every 12 hours for 3 doses, Postop oral oxycodone & acetaminophen (5/325 mg) 1 to 2 tabs every 4 hours PRN, Postop hydromorphone IV 0.5 mg every 4 hours PRN
89435667|NCT05865951|Active Comparator|chronic neck pain and isotonic group|Group B performed exercises for 12 weeks. Participants performed isotonic exercises along with conventional physical therapy treatment ( thermotherapy, manual mobilisation of cervical spine and trigger point therapy). All exercises were performed for 3 sessions per week for a period of 12 weeks.
89530901|NCT02500433|Experimental|Device: Kinect-Xbox360TM|"Based around a webcam-style add-on peripheral for the Xbox 360 console, it enables users to control and interact with the Xbox 360 without the need to touch a game controller, through a natural user interface using gestures and spoken commands. Participants were asked to practice 30 minutes per day, 2 days per week for 2 months, added to their conventional treatment. The games used were Kinect Sports ITM, Kinect Joy RideTM and Kinect Disneyland AdventuresTM and involved balance and trunk movements, general and visual-manual coordination and limb tasks. Each subject followed instructions on the screen with the help of his physiotherapist, with points awarded based on degree and speed of movement and level of difficulty.~Participants were initially exposed to the games in an hour introductory session, 2 weeks before the study began. All the sessions were supervised by physiotherapist."
88917059|NCT01633632|Active Comparator|Cognitive behavioral therapy|This group will receive a standardized, 8-session cognitive behavioral therapy course that is offered to the public at our practice.
88917060|NCT01633632|Experimental|Cognitive behavioral therapy + yoga|This group will receive the standardized, 8-session cognitive behavioral therapy course + 8 sessions of Hatha yoga.
88917061|NCT01633632|Experimental|Hatha yoga|This group will receive 8 sessions of Hatha yoga and printed materials to assist with their quit attempt
88917062|NCT01633645|Experimental|Velcade/GEM/CDDP|Bortezomib / Gemcitabine / Cisplatin
88917063|NCT01633658|Active Comparator|Vitamin D Cholecalciferol|A single dose of 2500 micrograms cholecalciferol
88917064|NCT01633658|Experimental|25(OH)D|A single dose of 625 micrograms 25(OH)D
88917065|NCT01633671||Suspected APE|Post-surgical patients with clinically suspected acute pulmonary embolism
88917066|NCT01633684||Diabetes|patients with Type 1 Diabetes Mellitus
88917067|NCT01633684||Control|Age and sex matched control subjects
88917068|NCT01633697|Experimental|Education-Pranayama|Subjects will receive education about COPD with special attention to breathing techniques
88917069|NCT01633697|Sham Comparator|Education-Control|Subjects will receive education alone about COPD.
88917070|NCT01633723|Experimental|DA-6886|
88917071|NCT01633723|Placebo Comparator|DA-6886 placebo|
88917072|NCT01633736|Experimental|home progressive resistance exercise|
88917073|NCT01633749|Experimental|Trivalent influenza subunit vaccine Influvac|3x 15mcg HA per 0.5 ml,trivalent one injection at Day 1
88917074|NCT01633762|Experimental|meropenem, gentamicin, vancomycin|
88917075|NCT01633775||Ahmed glaucoma implant|
88917076|NCT01633775||Trabeculectomy with mitomycin C (MMC)|
88917077|NCT01633801|Other|High flows|
88917078|NCT01633801|Other|oxygen therapy|
88917079|NCT01633840|Active Comparator|Elemental E028 with added food allergens|
88917080|NCT01633840|Placebo Comparator|Elemental E028|
88917081|NCT01633879|Experimental|parent education|audio-CD parent EDC supporting positive parenting practices
88917082|NCT01633879|Experimental|parent and school intervention|health and success parent and school intervention
88917083|NCT01633879|No Intervention|print materials|brochures to parents
88917084|NCT01633905||alcohol-dependent patients|22 recently detoxified participants diagnosed as alcohol-dependant on the basis of DSM-IV criteria who will performed an emotion-detection task on unimodal (visual or auditory) or crossmodal (visuo-auditory) stimulations presented centrally or peripherally
88917085|NCT01633905||control group|22 healthy controls without any psychiatric or neurological diagnosis who will performed an emotion-detection task on unimodal (visual or auditory) or crossmodal (visuo-auditory) stimulations presented centrally or peripherally
88917086|NCT01633918|Experimental|Internet-supported FeetEnergy approach|Schools which integrate Internet-supported approach with two home works in three health education lessons on physical activity
88917087|NCT01633918|Active Comparator|Usual health education|Schools which follow their usual practices in carrying out health education classes on physical activity
88917088|NCT01633957|Experimental|Genotype-based Warfarin Initiation|
88917089|NCT01633957|Active Comparator|clinical factor-based warfarin initiation|
88917090|NCT01633970|Experimental|A: Atezolizumab + Bevacizumab|Participants will receive atezolizumab 10 milligrams per kilogram (mg/kg) intravenous (IV) infusion (or a selected dose level not to exceed the single agent MTD or MAD determined in Study PCD4989g) with bevacizumab 15 mg/kg every 3 weeks (q3w). After establishment of MTD or MAD, participants will receive bevacizumab 15 mg/kg IV infusion on Day 1 of Cycle 1 followed by atezolizumab 1200 mg IV infusion q3w after Days 5-7 and then atezolizumab 1200 mg q3w and bevacizumab 15 mg/kg q3w on Day 1 of all subsequent cycles until disease progression or unacceptable toxicity.
88917091|NCT01633970|Experimental|B: Atezolizumab + Bevacizumab + FOLFOX|Participants will receive FOLFOX IV infusion (oxaliplatin [85 milligrams per square meter {mg/m^2}], leucovorin [400 mg/m^2], 5-FU [400 mg/m^2]) on Day 1 of Cycle 1 and then atezolizumab 800 mg IV infusion every 2 weeks (q2w), bevacizumab 10 mg/kg IV infusion q3w and FOLFOX q2w on Day 1 of all subsequent cycles as per institutional guidelines until disease progression or unacceptable toxicity.
88917092|NCT01633970|Experimental|C: Atezolizumab + Carboplatin + Paclitaxel|Participants will receive atezolizumab 1200 mg IV infusion q3w in combination with paclitaxel 200 mg/m^2 IV infusion q3w and then carboplatin IV q3w (on Day 1 of every 3-week cycle) to achieve an initial target area under the curve (AUC) of 6 milligrams per milliliter*minute (mg/mL*min) until disease progression or unacceptable toxicity.
88917093|NCT01633970|Experimental|D: Atezolizumab + Carboplatin + Pemetrexed|Participants will receive atezolizumab 1200 mg IV infusion q3w in combination with premetrexed 500 mg/m^2 IV infusion q3w and then carboplatin IV q3w (on Day 1 of every 3-week cycle) to achieve an initial target AUC of 6 mg/mL*min until disease progression or unacceptable toxicity.
88917094|NCT01633970|Experimental|E: Atezolizumab + Carboplatin + Nab-paclitaxel|Participants will receive atezolizumab 1200 mg IV infusion q3w (on Day 1 of every 3-week cycle) in combination with nab-paclitaxel 100 mg/m^2 IV infusion once weekly (qw) (on Days 1, 8 and 15 of every 3-week cycle) and then carboplatin IV infusion q3w (on Day 1 of every 3-week cycle) to achieve an initial target AUC of 6 mg/mL*min until disease progression or unacceptable toxicity.
88917095|NCT01633970|Experimental|F: Atezolizumab + Nab-paclitaxel|Participants will receive atezolizumab 800 mg IV infusion q2w (Days 1 and 15) in combination with nab-paclitaxel 125 mg/m^2 IV infusion qw (on Days 1, 8 and 15 of every 3-week cycle) until disease progression or unacceptable toxicity.
88917096|NCT01633983|Experimental|Methotrexate|Chronic CSC will be given an immediate MTX treatment
88917097|NCT01633983|Experimental|Delayed treatment|Acute CSC will be followed for 3 months for a spontaneous resolution before the treatment is offered
88917098|NCT01633996|Experimental|Acupuncture|All participants received open acupuncture augmentation treatment per the uniform acupuncture treatment protocol that we developed according to Traditional Chinese Medicine (TCM) principles for treating depression (see Intervention Description).
88917099|NCT01634009|Active Comparator|Standard RUTF (control)|Children will receive standard RUTF in this arm and will be considered as control arm
88917100|NCT01634009|No Intervention|Standard RUTF|Will act as control
88917101|NCT01634022|Experimental|Acupuncture|Adults with depression who are not currently taking an antidepressant medication.
88917102|NCT01634035||diabetic hemodialysis|all patient diabetic and on hemodialysis were involved if they are on hemodialysis for more than 3 months
88917103|NCT01634061|Experimental|Dose escalation: BEZ235 + Zytiga®|BEZ235 oral twice daily: 200 mg, 300 mg, and 400 mg dose levels to be tested in the dose escalation part in combination with abiraterone acetate Zytiga® abiraterone acetate oral once daily: 1000 mg taken with low dose prednisone as per the label
88917104|NCT01634061|Experimental|Dose escalation: BKM120 + Zytiga®|BKM120 oral once daily: 60 mg, 80 mg and 100 mg dose levels to be tested in the dose escalation part in combination with abiraterone acetate Zytiga® abiraterone acetate oral once daily: 1000 mg taken with low dose prednisone as per the label
88917105|NCT01634061|Experimental|Dose expansion: BEZ235 + Zytiga®|"BEZ235 oral twice daily: 200 mg, 300 mg, and 400 mg dose levels to be tested in the dose escalation part in combination with abiraterone acetate~Zytiga® abiraterone acetate oral once daily: 1000 mg taken with low dose prednisone as per the label"
88917106|NCT01634061|Experimental|Dose Expansion: BKM120 + Zytiga®|BKM120 oral once daily: 60 mg, 80 mg and 100 mg dose levels to be tested in the dose escalation part in combination with abiraterone acetate Zytiga® abiraterone acetate oral once daily: 1000 mg taken with low dose prednisone as per the label
88917107|NCT01634074||OSA patients|Patients with Obstructive Sleep Apnea (OSA), or suspected OSA
88917108|NCT01634126|Active Comparator|1 FIT kit|
88917109|NCT01634126|Active Comparator|2 FIT kit|
88917110|NCT01634204|Experimental|KiloCoach|Study subjects use the KiloCoach program on at least 4 days per week within the first half of the 6 months intervention period. In the second half, program usage is ad libitum.
88917111|NCT01634204|No Intervention|Control|Study subjects try to reduce body weight on their own, without participating in an organized weight loss program, over a period of 6 months.
88917112|NCT01634217|Experimental|Cohort 1|Administered 3 x 10^6 iTregs/kg infusion
88917113|NCT01634217|Experimental|Cohort 2|Administered 3 x 10^7 iTregs/kg infusion
88917114|NCT01634217|Experimental|Cohort 3|Administered 3 x 10^8 iTregs/kg infusion
88917115|NCT01634217|Experimental|Cohort 4|Administered 10 x 10^8 iTregs/kg infusion
88917116|NCT01634217|Experimental|Cohort 5 Extension|Administered 10 x 10^8 iTregs/kg or best available dose using sirolimus/MMF as graft-versus-host disease (GVHD) prophylaxis. Immunosuppression will consist of a combination of sirolimus and mycophenolate mofetil (MMF). Sirolimus will be administered starting at day -3 with 8mg-12mg oral loading dose followed by single dose 4 mg/day. MMF will be administered starting on day -3 at a dose of 3 gram/day divided in 2 or 3 doses. Intravenous (IV) route between days -3 and +5, then may change to PO between days +6 and +30. Stop MMF at day +30 or 7 days after engraftment, whichever day is later, if no acute GVHD.
89435668|NCT05864976||Standard of care rsfMRI using the Support Vector Machine algorithm|"Once enrolled, clinical pre-surgical MRI will be done on Siemens 3T Prisma or Skyra scanners using a standard pre-surgical tumor protocol. Resting-state functional MRI (rsfMRI) will be acquired. The Support Vector Machine (SVM) algorithm will be used on this pre-surgical MRI.~Patients will undergo post-operative MRI at approximately 8-12 weeks following surgical resection to evaluate extent of resection. Patients will then undergo subsequent MRI imaging every 2-3 months as part of routine clinical care to monitor for recurrence. The following MR sequences will be acquired: pre-and post-contrast T1-weighted, T2-weighted FLAIR, diffusion weighted imaging. MRI scans will be reviewed by a board-certified neuroradiologist to determine date of radiographic progression/recurrence. Imaging features at recurrence including location, multifocality, and presence of diffuse or distant recurrence will also be recorded."
89435669|NCT05861804|Experimental|Block group|Participants who will be receiving a rhomboid intercostal nerve block
89435670|NCT05861804|No Intervention|Control group|Participant who will not be receiving any intervention
89435671|NCT05859997|Experimental|BRL-301|Allogeneic CD19-targeted Chimeric Antigen Receptor (CAR) T Cells
88917117|NCT01634282|Experimental|OPC-262|
88917118|NCT01634295|Experimental|CKD-828 2.5/40, 2.5/80, 5/80mg|
88917119|NCT01634295|Active Comparator|S-Amlodipine 2.5, 5mg|
88917120|NCT01634308|Experimental|Novosis(bongros/BMP-2)|
88917121|NCT01634308|Active Comparator|Bio-oss|
88917122|NCT01634321|Experimental|Luphere|
88917123|NCT01634334|Experimental|Real-time Intervention|
88917124|NCT01634334|Active Comparator|Usual Education|Participants will receive usual education about secondhand and thirdhand smoke.
88917125|NCT01634347|Experimental|Propranolol and memory reactivation|
88917126|NCT01634347|Placebo Comparator|Placebo and memory reactivation|
88917127|NCT01634412|Experimental|SL TNX-102 at pH 3.5|2.4 mg TNX-102 sublingual solution (2.4 mg/mL) in PBS at pH 3.5
88917128|NCT01634412|Experimental|SL TNX-102 at pH 7.1|2.4 mg TNX-102 sublingual solution (2.4 mg/mL) in PBS at pH 7.1
88917129|NCT01634412|Active Comparator|Cyclobenzaprine tablets|5 mg cyclobenzaprine tablet once
88917130|NCT01634412|Active Comparator|Cyclobenzaprine IV|2.4 mg cyclobenzaprine USP in PBS (0.6 mg/mL) at pH 7.4
88917131|NCT01634425|No Intervention|Group 1 - no pre-hospital biomarkers|Standard of Care
88917132|NCT01634425|Experimental|Group 2 - pre-hospital biomarkers|Troponin and BNP measured on a POC meter in the ambulance on the way to the hospital.
88917133|NCT01634438|Experimental|low dose heparin|30 units per kilogram of unfractionated heparin
88917134|NCT01634438|Active Comparator|High dose heparin|70 units per kilogram of unfractionated heparin (UFH) intravenously
88917135|NCT01634451|Active Comparator|Education Package|2 ICUs; one large and one small. Randomised to receive bespoke education package for the 9 month intervention period
88917136|NCT01634451|Active Comparator|Education and Feedback|2 ICUs; one large and one small. Randomised to receive a bespoke education package and real-time,site specific, outcome process feedback they will disseminate to their staff for the 9 month intervention period.
88917137|NCT01634451|Active Comparator|Education and Sedation Monitoring|2 ICUs; one large and one small. Randomised to receive a bespoke education package and a new novel sedation (responsiveness) monitor for the 9 month intervention period.
88917138|NCT01634451|Active Comparator|Education, Feedback, Sedation Monitoring|2 ICUs; one large and one small. Randomised to receive a bespoke education package, real-time,site specific, outcome process feedback they will disseminate to their staff and a new novel sedation (responsiveness) monitor for the 9 month intervention period.
88917139|NCT01634464||Control group|women with 18.5 > BMI < 25
88917140|NCT01634464||Pregnant women with overweight|BMI≥25 before the pregnancy
88917141|NCT01634464||Pregnant women with obesity|BMI≥30 before the pregnancy
88917142|NCT01634464||Pregnant women with gestational diabetes|Gestational diabetes
88917143|NCT01634477||HIV-infected patients group|HIV positive
88917144|NCT01634477||HIV-uninfected patients group|HIV negative
88917145|NCT01634490||infants receiving extensively hydrolysed casein formula|infants receiving extensively hydrolysed casein formula as substitutive formula
88917146|NCT01634490||extensively hydrolysed casein formula with Lactobacillus GG|infants receiving extensively hydrolysed casein with LGG as substitutive formula
88917147|NCT01634490||infants receiving rice hydrolyzed formula|infants receiving rice hydrolyzed formula as substitutive formula
88917148|NCT01634490||infants receiving soy-based formula|infants receiving soy-based formula as substitutive formula
88917149|NCT01634490||infants receiving amino-acid based formula|infants receiving amino-acid based formula as substitutive formula
88917150|NCT01634503|Experimental|1mg of GX-188E by electroporation|
88917151|NCT01634503|Experimental|2mg of GX-188E by electroporation|
88917152|NCT01634503|Experimental|4mg of GX-188E by electroporation|
88917153|NCT01634516|Experimental|Dietary support|Face to face intervention plus subsequent telephone support
88917154|NCT01634516|Placebo Comparator|No dietary support|No face to face intervention plus subsequent telephone support
89435672|NCT05857839|Experimental|Myofascial release with support belt|Group A get myofascial release on sacroiliac joint area for up to 600 seconds and total treatment sessions will be 12 in 4 weeks with support belt and a support belt should not be worn for longer than two to three hours at a time and it will be used 4 times a week.
89435673|NCT05857839|Active Comparator|Myofascial release without support belt:|Group B get myofascial release technique to sacroiliac joint area for up to 600 seconds and total treatment sessions will be 12 in 4 weeks but without support belt. Data will be collected and analyzed at baseline and at 4 weeks follow up.
89435674|NCT05857826|Experimental|soft tissue release with vaginal dilators|Group A will receive soft tissue release with vaginal diltors. Soft tissue release consists of myofacial release and deep intervaginal massage.Triggers points can be released vaginally or rectally they are so painfyul on palpation deep massage of pelvic floor muscle
89435675|NCT05857826|Active Comparator|soft tissue release only|will receive only soft tissue release using trigger point release vaginally or rectally and deep intervaginal massage
89435676|NCT05857046|Active Comparator|Melatonin group|Melatonin group will receive prolonged released melatonin tablet 10mg for 7 days, then 10 mg for 83 days.
89435677|NCT05857046|Placebo Comparator|Placebo group|Placebo group will receive placebo tablet for 7 days, then for 83 days.
89435678|NCT05856006|Active Comparator|Stretching Group|upper trapezius stretching plus neck isometrics
89435679|NCT05856006|Experimental|Stretching plus strengthening Group|upper trapezius stretching with mid-lower trapezius strengthening exercises plus neck isometrics
89435680|NCT05855564|Experimental|School-based Mindfulness program|Eight session of mindfulness-based program based on Mindfulness Matters developed by Eline Snel
89435681|NCT05853276|Experimental|Intervention group|This group downloads and uses Brush DJ app. Reminders are sent through this app to brush their teeth and along with this oral hygiene instructions are also given.
89435682|NCT05853276|No Intervention|Control group|This group receives standard oral hygiene instructions
89435683|NCT05852444|Experimental|Group A|Manual Dynamic Agitation Group: Irrigation in this group shall be done using a master gutta percha cone during root canal therapy
89435684|NCT05852444|Experimental|Group B|Passive Ultrasonic Activation Group: In this group, final activation during endodontic therapy shall be done using an ultrasonic activation device (Ultra X)
89435685|NCT05846594|Other|Basic Workup: Metastatic Lung Cancer Cohort|This cohort will enroll approximately 160 participants who have clinical evidence of de novo metastatic lung cancer and who have not had tissue biopsy performed prior to enrollment (classified as 'basic workup').
89435686|NCT05846594|Other|Basic Workup: Metastatic Gastrointestinal Cancer Cohort|This cohort will enroll approximately 160 participants who have clinical evidence of de novo metastatic gastrointestinal cancer and who have not had tissue biopsy performed prior to enrollment (classified as 'basic workup').
89435687|NCT05846594|Other|Extended Workup: Metastatic Lung Cancer Cohort|This cohort will enroll approximately 100 participants who have clinical evidence of de novo metastatic lung cancer and who have had tissue biopsy performed prior to enrollment (classified as 'extended workup').
89435688|NCT05846594|Other|Extended Workup: Metastatic Gastrointestinal Cancer Cohort|This cohort will enroll approximately 100 participants who have clinical evidence of de novo metastatic gastrointestinal cancer and who have had tissue biopsy performed prior to enrollment (classified as 'extended workup').
89435689|NCT05845008|Experimental|Acetaminophen/Naproxen Sodium Fixed Combination|Participants will self-administer a fixed combination of acetaminophen/naproxen sodium orally as multiple doses over a period of up to 10 days.
88917155|NCT01634529|Experimental|Single Ascending Dose|Single ascending doses of V158866 compared to Placebo
88917156|NCT01634529|Experimental|Multiple ascending doses|Multiple ascending doses of V158866 compared to Placebo
88917157|NCT01632956||in-person support group|This is a 1 year pilot study of the feasibility of participation in both in-person and virtual information-based, culturally tailored support groups for Chinese breast cancer patients.
88917158|NCT01632956||virtual support group|This is a 1 year pilot study of the feasibility of participation in both in-person and virtual information-based, culturally tailored support groups for Chinese breast cancer patients.
88917159|NCT01634542||Cohort|
88917160|NCT01634568|Experimental|Single Ascending Dose|Single Ascending Doses of V81444 compared to placebo
88917161|NCT01634568|Experimental|Multiple Ascending Doses|Multiple ascending doses of V81444 compared to placebo
88917162|NCT01634594|Experimental|sevoflurane-remifentanil (group R)|Continuous infusion of remifentanil at 0.05 ~ 2 mcg/kg/min with sevoflurane concentration of 1 MAC
89435690|NCT05836220|Experimental|Double-Blind Phase PLS240|
89435691|NCT05836220|Placebo Comparator|Double-Blind Phase Placebo|
88917163|NCT01634594|Active Comparator|sevoflurane-nicardipine (group N)|Continuous infusion of nicardipine at 1 ~ 7 mcg/kg/min with sevoflurane concentration of 1 MAC
88917164|NCT01634594|Active Comparator|sevoflurane-dexmedetomidine (group D)|Continuous infusion of dexmedetomidine at 0.2 ~ 1.0 mcg/kg/hr with sevoflurane concentration of 1 MAC
89435692|NCT05836220|Experimental|Open-Label Extension Phase PLS240|After completion of the Double-Blind Phase, all participants will have the opportunity to enroll in the 26 week Open-Label extension, where they will receive PLS240.
89435693|NCT05835297|Experimental|Exercise group|Physical exercise interventions for 45 min, twice a week plus usual care provided at the nursing home.
89435694|NCT05835297|No Intervention|Usual care|Usual care provided at the nursing home with no specific physical exercise intervention.
89435695|NCT05834478|Experimental|Transcutaneous Cervical Vagal Nerve Stimulation Device|Stimulation with the tcVNS
89435696|NCT05834478|Sham Comparator|Sham Stimulation Device|Stimulation with the sham device.
89435697|NCT05834166|Experimental|Upper back strengthening and Postural correction:|Group A performed exercises for 3 weeks. Participants performed upper back strengthening exercises and postural correction exercises for 10 to 15 minutes per session. All exercises were performed for 3 sessions per week for a period of 4 weeks. The re-assessment will be done at the 6th and 9th visits.
89435698|NCT05834166|No Intervention|Control group:|Group B: Group B will receive no intervention. Baseline treatment will include soft tissue mobilization, chest muscle stretch, trunk muscle stretch, and diaphragmatic breathing exercises for all patients
89435699|NCT05834153|Experimental|kinesiotaping|
89435700|NCT05834153|Active Comparator|electrical muscle stimulation|
89435701|NCT05833854|Experimental|Virtual reality glasses group|The study group (n=25) will watch a video with virtual reality glasses during the intramuscular injection.
89435702|NCT05833854|Experimental|Manual pressure group|In the study group (n=25), pressure will be applied to the area to be injected for 10 seconds before the intramuscular injection procedure.
89435703|NCT05833854|No Intervention|Control group|The control group (n=25) will not be subjected to any application other than intramuscular injection, which is routinely applied in pediatric emergency.
89435704|NCT05832931|Experimental|Double-Blind Phase PLS240|
89435705|NCT05832931|Placebo Comparator|Double-Blind Phase Placebo|
89435706|NCT05832931|Experimental|Open-Label Extension Phase PLS240|After completion of the Double-Blind Phase, all participants will have the opportunity to enroll in the 26 week Open-Label extension, where they will receive PLS240.
89435707|NCT05829928||Cryopreservation|Participants will have gonadal tissue removed and cryopreserved for future fertility applications.
89435708|NCT05819398|Experimental|Part I: Low dose group|
89435709|NCT05819398|Experimental|Part I: Medium dose group|
89435710|NCT05819398|Experimental|Part I: High dose group|
89435711|NCT05819398|Placebo Comparator|Part I: Placebo group|
89435712|NCT05819398|Experimental|Part II: Active (treatment) group|
89435713|NCT05819398|Placebo Comparator|Part II: Placebo group|
89435714|NCT05800743|Experimental|ASG device only in Ascending Aorta|Ascending Aortic Isolated Lesions, Pseudoaneurysms and Penetrating Aortic Ulcers in subjects at high-risk for surgical repair, treated with endovascular repair using the ASG device alone.
89435715|NCT05800743|Experimental|ASG + TBE|Ascending Aorta/Aortic Arch Isolated Lesions and Chronic De Novo Dissections in subjects at high-risk for surgical repair, treated with endovascular repair using the ASG and TBE devices.
89435716|NCT05800743|Other|Surgical Follow-up Cohort|Open surgical repair of ascending aorta in subjects at high-risk for surgical repair
89435717|NCT05799963|Experimental|BioMatrix Alpha|All patients will receive the BioMatrix Alpha as per treatment.
89435718|NCT05796245||Infliximab (Genetical Recombination)[Infliximab Biosimilar 3]|
88917165|NCT01634646|Placebo Comparator|Overweight, elevated total cholesterol|All individuates enrolled in this study are at least 15 lbs over their ideal weight as described on a BMI chart. Each individual must also have a total cholesterol of at least 200 mg/dl, or higher.
88917166|NCT01634672||hemodialysis patients|
88917167|NCT01634672||Peritoneal dialysis patients|
88917168|NCT01634685|Experimental|Bavituximab, Capecitabine, Radiation|one arm
88917169|NCT01634698|Experimental|RDR test (1500 UI vitamin A)|81 patients with several etiologies of liver cirrhosis at different stages in the progression of the disease received 1500 UI retinyl palmitate dosage at T0 (blood sample taken following a 12-hour fast). Following supplementation, we took further blood samples five and seven hours later (T5 and T7).
88917170|NCT01634698|Experimental|RDR test (2500 IU vitamin A)|81 patients with several etiologies of liver cirrhosis at different stages in the progression of the disease received 2500 UI retinyl palmitate dosage at T0 (blood sample taken following a 12-hour fast). Following supplementation, we took further blood samples five and seven hours later (T5 and T7).
88917171|NCT01634724|Experimental|GnRH agonist withdrawal|All the patients received a midluteal long GnRH agonist (GnRH-a) and a gonadotropins (recombinant FSH) stimulation protocol. When the diameter of one or more follicles was ≥ 14 mm, GnRHa (0.05mg/d) was withheld in the study group.
88917172|NCT01634724|No Intervention|control group|All the patients received a midluteal long GnRH agonist (GnRH-a) and a gonadotropins (recombinant FSH) stimulation protocol. In the control group, GnRHa (triptorelin, 0.05mg/d,)was used to the day of ovulation trigger.
88917173|NCT01634737||Patients with shellfish allergy|Patients with symptoms of allergy to shellfish (OAS-Oral allergy syndrome and/or systemic symptoms) and circulating IgE positive for the extract of shrimp (> 0.10 kU/L)
88917174|NCT01634737||Patients with respiratory allergy|Patients with respiratory allergy and IgE positive to dust mites, asymptomatic for shrimp or other shellfish and circulating IgE positive for shrimp
88917175|NCT01634750|Experimental|ManNac|
88917176|NCT01634750|Placebo Comparator|Placebo|
88917177|NCT01634763|Experimental|Dose-escalation|Open-label dose escalation study of LDK378, administered orally in Japanese patients with tumors characterized by genetic alterations in anaplastic lymphoma kinase (ALK)
88917178|NCT01634763|Experimental|Dose-expansion|Open-label study of LDK378, administered orally in Japanese patients with tumors characterized by genetic alterations in ALK to see further safety, anti-tumor activity, and PK data in patients who has progressed since prior therapy with alectinib
88917179|NCT01634776|Placebo Comparator|Corn oil|1288 mg/day corn oil
88917180|NCT01634776|Experimental|Flaxseed oil|1200 mg/day flaxseed oil
88917181|NCT01634789|Experimental|Test Treatment 1: bazedoxifene|Test Treatment 1
88917182|NCT01634789|Experimental|Test Treatment 2: bazedoxifene|Test Treatment 2
88917183|NCT01634789|Experimental|Test Treatment 3: bazedoxifene|Test Treatment 3
88917184|NCT01634789|Experimental|Reference Treatment: bazedoxifene/conjugated estrogens|Reference Treatment
88917185|NCT01634802|No Intervention|EMR Only|Clinics in this arm of the study will have a standard Electronic Medical Record (EMR) system installed - without a computerized decision support system.
88917186|NCT01634802|Experimental|EMR+CDSS|Clinics in this arm of the study will have an Electronic Medical Record (EMR) system with Clinical Decision Support System (CDSS) enhancement implemented as alerts to aid the clinician in decision making.
88917187|NCT01634815|Experimental|lactate group|
88917188|NCT01634828||Minimal blood loss patients|
88917189|NCT01634828||Moderate to heavy blood loss patients|
88917190|NCT01634841|Active Comparator|Walnut group|This group will have their habitual diet supplemented with 30 to 45g (1 to 1.5 oz) of walnuts daily.
89435719|NCT05796245||Remicade|
89435720|NCT05789537|Experimental|SerpinPC|Participants will receive SerpinPC 1.2 milligrams/kilogram (mg/kg) subcutaneous (SC) injection every 2 weeks (Q2W) for 48 weeks after a prospective observation of 12 weeks for all participants, either in a prior non-interventional study (AP-0105[NCT05605678]) or as part of the ongoing study observational period.
89435721|NCT05785754|Experimental|Phase 1a Dose Escalation Monotherapy|Dose escalation to investigate the safety and tolerability of DCSZ11.
89435722|NCT05785754|Experimental|Phase 1a Dose Escalation Combination|Dose escalation to investigate safety and tolerability, and determine DCSZ11 Phase 1b doses in combination with pembrolizumab.
89435723|NCT05785754|Experimental|Phase 1b Dose Expansions|Dose expansion to further investigate the safety, tolerability, and preliminary evidence of antitumor activity of the combination with pembrolizumab in select tumor indications.
88917191|NCT01634841|Active Comparator|Control group|This group will eat their habitual diet and refrain from eating walnuts.
88917192|NCT01634867||Intraosseous (IO) drug delivery|patients in whom intraosseous (IO) vascular access has been established for rapid sequence intubation drug delivery.
88917193|NCT01634867||Peripheral intravenous (IV) drug delivery|patients in whom peripheral intravenous (IV) vascular access has been established for rapid sequence intubation drug delivery.
88917194|NCT01634880|Experimental|Postoperative Radiotherapy and Panitumumab|
88917195|NCT01634893|Experimental|Sorafenib plus Hydroxychloroquine|"Dose escalation of sorafenib combined with hydroxychloroquine (HCQ) to a maximum of sorafenib 400 mg PO BID plus HCQ 400 mg PO QD.~Drugs are given on an intermittent schedule of days 1-5/week in a 28-day cycle.~Sorafenib alone is given in cycle 1, and HCQ is added in cycle 2."
88917196|NCT01634906|Experimental|Discontinuation of statin therapy|
88917197|NCT01634919||Chronic hepatitis C|Chronic hepatitis C
88917198|NCT01634932|Experimental|regular-iron millet|
88917199|NCT01634932|Experimental|iron-biofortified millet|
88917200|NCT01634932|Experimental|Post-harvest iron-fortified millet|
88917201|NCT01634945|Placebo Comparator|Placebo|Placebo
88917202|NCT01634945|Experimental|FeFum porridge + IPT of malaria|
88917203|NCT01634945|Experimental|IPT of malaria|
88917204|NCT01634945|Experimental|FeFum porridge|
88917205|NCT01634945|Experimental|FePP porridge|
88917206|NCT01634958|Experimental|10.000 DPP/ml suspension for s.c. inj.|
88917207|NCT01634958|Experimental|5.000 DPP/ml suspension for s.c. inj.|
88917208|NCT01634958|Experimental|1.000 DPP/ml suspension for s.c. inj.|
88917209|NCT01634958|Experimental|100 DPP/ml suspension for s.c. inj.|
88917210|NCT01634971|No Intervention|External Drainage of pancreatic duct|External Drainage of pancreatic duct was used in PD.
88917211|NCT01634971|Experimental|Internal Drainage of Pancreatic Duct|the Intervention name is: Internal Drainage of Pancreatic Duct after pancreatomy, a stent was placed in the pancreatic duct, external drainage of the stent is defined as control group(the stent will be tans-abdomen and as a drainage of pancreatic fluid), and internal drainage of the stent is defined as interventional(or experimental) group, with the stent very short(2cm) and placed in jejunum.
88917212|NCT01635010|No Intervention|Control|
88917213|NCT01635010|Experimental|Obstructive sleep apnea|
88917214|NCT01635023|Experimental|AZD6244 white capsule|75mg AZD6244 white (current Phase II) capsule
88917215|NCT01635023|Experimental|AZD6244 blue capsule|75mg AZD6244 blue (planned Phase III) capsule
88917216|NCT01635023|Experimental|AZD6244 solution|35mg AZD6244 oral solution
88917217|NCT01635036||Women undergoing IVF treatment|Women undergoing IVF treatment
88917218|NCT01635049||Women undergoing IVF treatment and CCS|•Women undergoing fresh IVF treatment and undergoing CCS, as recommended based on medical need by the clinical site reproductive endocrinologist.
88917219|NCT01635075|Experimental|Exercise|1-mile treadmill walk
88917220|NCT01635075|Placebo Comparator|Passive|20 min inactivity
88917221|NCT01635088|Other|Mometasone furoate 220 vs. Mometasone furoate 440|
88917222|NCT01635088|Active Comparator|Mometasone 220 mcg vs. 440 mcg|Inhaled steroid
88917223|NCT01635114|Active Comparator|resVida (resveratrol)|
88917224|NCT01635114|Placebo Comparator|Placebo|
88917225|NCT01635127|Experimental|Canakinumab|Monoclonal antibody inhibiting interleukin 1 beta
88917226|NCT01635127|Placebo Comparator|Placebo|Constituent, inactive
88917227|NCT01635140|Experimental|Hypofractionated arm|A total dose of 39 Gy in daily fractions of 3 Gy, 5 Fractions per week , by conformal radiotherapy sparing of the supratentorial brain. The planning target volume included the tumor as defined by the T2-weighted MRI images with a margin of 1.5-2.0 cm. Margins were adjusted for bony structures and tentorium. With exception of steroids, no neoadjuvant, concomitant, or adjuvant systemic treatment was allowed
88917228|NCT01635140|Other|Conventional arm|The same planning and treatment procedures will be performed with the established conventional regimen: 54 Gy in 30 fractions giving 1.8 Gy per fraction.
88917229|NCT01635166|Other|Delta Motion|A cementless acetabular cup with a pre-assembled ceramic liner for use in total hip replacement
88917230|NCT01635179|Experimental|Cricoid pressure|A cricoid pressure of 30 N is done to occlude esophagus under a rapid sequence induction.
88917231|NCT01635192|Active Comparator|VSL#3|
88917232|NCT01635192|Placebo Comparator|Inactive treatment|
88917233|NCT01635205|Experimental|paraspinous block|Paraspinous anesthetic block in the thoracolumbar region, in sensitized segments
88917234|NCT01635205|Sham Comparator|control|Subcutaneous puncture with no anesthetic effect
88917235|NCT01635231|Active Comparator|thiazide, diuretic|1.25 mg thiazide twice daily for 5 days
88917236|NCT01635231|Active Comparator|amiloride, diuretic|5 mg of amiloride twice daily
88917237|NCT01635231|Placebo Comparator|calcium|placebo twice daily for 5 days
88917238|NCT01635257||suspected pulmonary embolism patients|patients with clinical suspicion of PE and with a simplified Well's score>4 (PE likely) or with a D-dimer value ≥500ng/ml presenting to the emergency departments of Careggi University Hospital (Firenze), of San Luigi Gonzaga University Hospital (Torino) of Ospedale Pierantoni-Morgagni (Forlì)
88917239|NCT01635270|Experimental|midP arm|Patients treated with midP radiotherapy strategy.
88917240|NCT01635270|Active Comparator|ITV arm|Patient treated with radiotherapy ITV strategy
88917241|NCT01635296|Experimental|A: Previously untreated|
88917242|NCT01635296|Experimental|B: Relapse/Refractory|
88917243|NCT01635309||Non-cardiac surgical patients|>= 45 years old, undergoing non-cardiac surgery requiring regional or general anaesthetic and an overnight stay with cardiac risk factors
88917244|NCT01635322||Lumbar or thoraco-lumbar Adult Deformity|Lumbar or thoraco-lumbar Adult Deformity
88917245|NCT01635335|Experimental|HIV-specific|7-hour multiple family workshop focused on providing information and skills related to HIV prevention. Specific focus on parent-adolescent communication and parental monitoring.
88917246|NCT01635335|Active Comparator|General Health Promotion|7-hour multiple family workshop focused on providing information related to various adolescent health risk behaviors, including smoking, alcohol, violence, nutrition, and exercise.
88917247|NCT01635348|Experimental|motor skill gait exercise arm|motor skill gait exercise intervention: stepping and walking patterns, and speed interval treadmill-assisted walking to enhance timing and coordination in walking
88917248|NCT01635348|Active Comparator|aerobic gait exercise arm|aerobic gait exercise intervention: treadmill-assisted and overground walking exercise to enhance walking practice and improve endurance in walking
88917249|NCT01635361|Experimental|NMS|Patients in this arm will receive the full NMS service
88917250|NCT01635361|No Intervention|Current Practice|Patients in this arm will receive the normal advice with their new medicine as dictated by current professional practice
89010345|NCT04547296|Experimental|BRS group|After entering the operating room, this group were pre-dilated with sodium bicarbonate ringer's solution (30 min, 8 ml/kg), and maintained with 4-5 ml/kg/h sodium bicarbonate ringer's solution during the operation.
89010346|NCT04547296|Experimental|ARS group|After entering the operating room, this group were pre-dilated with acetate ringer ringer's solution (30 min, 8 ml/kg), and maintained with 4-5 ml/kg/h acetate ringer's solution during the operation.
89435724|NCT05780983|Other|education and coaching on developing healthy nighttime sleep and daytime activity behaviors|The intervention includes a four-session, in-person program delivered by a Master's-level provider. Each individual session will be approximately 30-45 minutes in length. Each session will include education and coaching on developing healthy nighttime sleep and daytime activity behaviors.
89435725|NCT05777538|Experimental|Foot exercise with hydrotherapy|Hydrotherapy will be performed by immersing the women's foot in a container filled with 3 liters water with a temperature of 30-32°C. The water level must cover the women's feet up to ankle. During the immersion the therapist will ask the women to perform exercise with legs being fully supported, then alternatively stretch and flex the ankle for 30 times. which will be followed by circling each foot at ankle in clock wise and anticlock wise direction, 30 times each. The duration of water immersion session will be (30 min) for 5 consecutive days
88917251|NCT01635374|Experimental|Per-Oral Endoscopic Esophagomyotomy|Patients will have a standard pre-operative work-up that may include upper endoscopy (EGD), endoscopic ultrasound (EUS), upper GI X-rays, high-resolution manometry, pH, FLIP and impedance measurement studies. Once a diagnosis of esophageal motility disorder is confirmed, patients will be offered POEM or standard treatment. Patients undergoing POEM will review and sign the study consent prior to their procedure. Patients will return and be evaluated two weeks following their procedure. At this visit, any post-operative complications will be noted in the patient's medical record. Also, at this visit and at the preoperative visit, patients will complete a standardized Quality of Life assessment. Perceived pain levels and type and frequency of pain medications will be recorded in the patient's medical record. Patients will then return at 6 weeks post-op to complete a second set of questionnaires and have a high resolution manometry performed to assess residual LES pressure.
88917252|NCT01635387|Experimental|Aliskiren|
88917253|NCT01635387|Placebo Comparator|Placebo|
88917254|NCT01635400|Other|UGT1A1 wild type (6/6)|
88917255|NCT01635400|Other|UGT1A1 heterozygous genotype (6/7)|
88917256|NCT01635400|Other|UGT1A1 homozygous genotype(7/7)|
89435726|NCT05777538|Active Comparator|Foot exercise|The therapist will ask the women to perform exercise with legs being fully supported, then alternatively stretch and flex the ankle for 30 times. which will be followed by circling each foot at ankle in clock wise and anticlock wise direction, 30 times each
89435727|NCT05771935|Experimental|(Group R)|receive radial artery cannulation using ultrasound
89435728|NCT05771935|Active Comparator|(Group U)|receive ulnar artery cannulation using ultrasound
89198403|NCT04040829|Experimental|CR + SE + TAU|"Cognitive remediation therapy (CR) will be conducted using CIRCuiTS, a computerized program designed to improve cognition (attention, memory, executive functioning) and metacognitive skills. CIRCuiTS has an integrated focus on the transfer of cognitive skills to daily living, using real-world goals and homework to facilitate in vivo use of new strategies, as well as a formulation-based approach, which takes into account the impact of cognitive strengths and difficulties with daily living skills. Each session includes about 4-8 tasks targeting a range of cognitive problems, which become more ecologically valid as the program progresses. The rate of delivery for CIRCuiTS will be two to three sessions per week, for a maximum of 40 sessions. The therapy will be provided entirely online with a therapist, using the platform Zoom.~This arm will include our active control condition : supported education (SE) as well as Treatment as usual (TAU) as previously described."
89435729|NCT05767515|Active Comparator|Metformin Group|Metformin will be used in dose of 500mg BD daily for 30 infertile female PCOS patients
89435730|NCT05767515|Experimental|Inositol isomers Group|Inositols isomers (Myo inositol and D- Chiro Inositol in its physiological ratio) will be used 2000mg BD Daily for 30 infertile female PCOS patients
89435731|NCT05767515|Experimental|Acetyl-L- Carnitine Group|Acetyl-L-Carnitine will be given in dose of 1000mgBD Daily for 30 infertile female PCOS patients
89435732|NCT05767515|Experimental|Combine Group|Inositol isomers and Acetyl-L-Carnitine will be given in dose of 2000mg and 1000mg respectively BD daily for 30 infertile female PCOS patients
89435733|NCT05765019|Experimental|Spinal mobilization group|
89435734|NCT05765019|Active Comparator|Core stabilization exercise group|
89435735|NCT05764330|Active Comparator|Arm I (CER)|Patients undergo CER intervention consisting of remote lesson containing information and behavioral strategies about weight loss, session with study interventionist to review lessons, and self-monitoring of body weight. Patients also undergo collection of blood samples throughout the trial.
89435736|NCT05764330|Experimental|Arm II (IF)|Patients undergo IF intervention consisting of remote lesson containing information and behavioral strategies about fasting, session with study interventionist to review lessons, and self-monitoring of body weight. Patients also undergo fasting 2 days per week and eat according to the NCI guidelines the remaining 5 days. Patients also undergo collection of blood samples throughout the trial.
89435737|NCT05760482|Experimental|Bruxism Group|
89435738|NCT05760482|Experimental|Control Group|
89435739|NCT05755061|Experimental|GEMS Plus|Home-based aerobic walking exercise that exceeds published physical activity guidelines for adults with MS
89435740|NCT05755061|Active Comparator|GEMS|Home-based aerobic walking exercise that meets published physical activity guidelines for adults with MS
89435741|NCT05751213|Experimental|knack technique.|pelvic floor muscle exercises with knack technique.
88917257|NCT01635413|Experimental|Arm I (strength training)|Patients attend strength training classes for 1 hour 2 days per week.
88917258|NCT01635413|Experimental|Arm II (tai chi)|Patients attend tai chi classes for 1 hour 2 days per week.
89435742|NCT05751213|Active Comparator|pelvic floor muscle exercises|pelvic floor muscle exercises
89435743|NCT05746585|Experimental|The TALK intervention for Black male adolescents and young adults (AYA)|The TALK, a parent-centered, adolescent-involved health promotion intervention for Black male adolescents and young adults (AYA). Through the use of entertainment videos and educational modules, investigators will provide parents with resources and tools for communicating with their adolescents about sexual health and experiences of racial discrimination, and how these experiences impact sexual health.
88917259|NCT01635413|Active Comparator|Arm III (control)|Patients attend supervised stretching and relaxation classes for 1 hour 2 days per week.
89435744|NCT05746130|Experimental|plastic-free diet program|Plastic-free nutrition program will include plastic-free diet, peer mentoring, interactive education and BPA exposure feedback.
88917260|NCT01635452||Patients treated with Esmya|
88917261|NCT01635465||Observation group:vinorelbine plus capecitabine|
88917262|NCT01635465||Control group:docetaxel plus capecitabine|
88917263|NCT01635517||Tolvaptan|Tolvaptan administration
88917264|NCT01635530|Active Comparator|Ceftriaxone|Treatment of intravenous ceftriaxone (2 g/day), three weeks
88917265|NCT01635530|Experimental|Doxycycline|Treatment with oral doxycycline (200mg / day), four weeks
89435745|NCT05746130|Active Comparator|plastic free diet education program|This group will take peer mentoring, interactive education and BPA exposure feedback.
89435746|NCT05746130|Active Comparator|BPA exposure feedback|This group will take only BPA exposure feedback.
89435747|NCT05744739|Experimental|Treatment (tomivosertib)|Tomivosertib will be dosed continuously on days 1-28 of each 28-day cycle.
89435748|NCT05744310|Active Comparator|ALS patients that choose life prolonging treatment with LTMV and their families|
89435749|NCT05744310|Active Comparator|ALS patients that decline life prolonging treatment with LTMV and their families|
89435750|NCT05741164|Experimental|Treatment (propranolol and pembrolizumab)|Patients receive propranolol PO and pembrolizumab IV while on study. Patients undergo CT scan, blood sample collection and may undergo tumor biopsy during screening and on study.
88917266|NCT01635543||Crohn's Disease with peri-anal fistulas|Identifying Crohn's Disease patients with peri-anal fistulas and suffering from sexual dysfunction.
88917267|NCT01635582|Active Comparator|Control group|Conventional hand exercise program
88917268|NCT01635582|Experimental|Experimental group|Computer gaming hand exercise regimen'
88917269|NCT01635595||Patients with BIM|Patients affected by adenocarcinoma of the distal esophagus and cardia with preoperative diagnosis of BIM underwent subtotal esophagectomy and gastric pull up.
89435751|NCT05740930|Experimental|Intervention group|The participants wear the partition defocus myopia management spectacle lens.
89435752|NCT05740930|Active Comparator|Control group|spectacle lenses with aspherical lenslets
89435753|NCT05740904|Experimental|New defocus spectacle lens|The children in the experimental group will wear new defocus spectacle lens and receive follow-up examinations every half year.
89435754|NCT05740904|Active Comparator|Conventional aspheric single-vision spectacle lenses|The children in the control group will wear conventional aspheric single-vision spectacles and receive follow-up examinations every half year.
89435755|NCT05737082|Experimental|Sequence 1|"Period 1, Period 3: RLD2205 + RLD2206~Period 2, Period 4: HCP2201"
89435756|NCT05737082|Experimental|Sequence 2|"Period 1, Period 3: HCP2201~Period 2, Period 4: RLD2205 + RLD2206"
88917270|NCT01635595||Patients without BIM|Patients affected by adenocarcinoma of the distal esophagus and cardia without preoperative diagnosis of BIM underwent subtotal esophagectomy at the azygos vein, total gastrectomy and esophagojejunostomy.
88917271|NCT01635608|Active Comparator|non-caloric water|500 mg paracetamol, 50 mg talinolol and 500 mg amoxicillin dissolved in 240 ml non-caloric water immediately before administration after overnight fasting
88917272|NCT01635608|Active Comparator|caloric water|500 mg paracetamol, 50 mg talinolol and 500 mg amoxicillin dissolved in 240 ml caloric water immediately before oral administration after overnight fasting
89435757|NCT05736653|Experimental|Task-specific PCMS, PCMS-rest, Task-specific sham-PCMS|"During Task-specific paired corticospinal-motor neuronal stimulation (PCMS) participants will receive PCMS [Transcranial Magnetic Stimulation (TMS) + Peripheral Nerve Stimulation (PNS)] with task-specific practice.~During PCMS rest participants will receive PCMS (TMS + PNS) without task-specific practice.~During Task-specific sham-PCMS participants will receive task-specific practice with sham PCMS (TMS + PNS)."
89435758|NCT05736653|Experimental|Task-specific PCMS, Task-specific sham-PCMS, PCMS-rest|"During Task-specific PCMS participants will receive PCMS (TMS + PNS) with task-specific practice.~During PCMS rest participants will receive PCMS (TMS + PNS) without task-specific practice.~During Task-specific sham-PCMS participants will receive task-specific practice with sham PCMS (TMS + PNS)."
88917273|NCT01635621|Experimental|OKZ 120 mg|
88917274|NCT01635621|Experimental|OKZ 240 mg|
88917275|NCT01635621|Experimental|OKZ 120 mg with 480 mg loading dose at Week 0|
88917276|NCT01635621|Placebo Comparator|Placebo|
88917277|NCT01635634|Sham Comparator|Sham Cupping|Dry Cupping Therapy 5 serial treatments twice weekly 4-8 cups at the upper and lower back
88917278|NCT01635634|Experimental|Cupping Therapy|Dry Cupping 5 serial treatments twice weekly 4-8 cups at the upper and lower back
88917279|NCT01635634|No Intervention|Wait list|Wait list control no specific intervention for 3 weeks study period
88917280|NCT01635647|Active Comparator|ChAd63 ME-TRAP and MVA ME-TRAP|ChAd63 ME-TRAP / MVA ME-TRAP heterologous prime-boost immunisation
88917281|NCT01635647|Placebo Comparator|Rabies vaccine|2 x 2.5IU Verorab
88917282|NCT01635660|Active Comparator|C-MAC System|
88917283|NCT01635660|Active Comparator|AP Advance|
88917284|NCT01635660|Active Comparator|King Vision|
88917285|NCT01635673|No Intervention|Control Group|A group that continues with their normal daily activities for the duration of the study
88917286|NCT01635673|Experimental|Exercise Group|This group exercises 3 times each week
88917287|NCT01635686|Experimental|DWP422|
88917288|NCT01635686|Active Comparator|ENBREL|
88917289|NCT01635712|Experimental|SNX-5422|Open label administration of SNX-5422 capsules every other day (QOD) for 21 days on a 28 day cycle. Dose escalation will be based on safety outcomes defined as 1 or less dose limiting toxicities during the first 28 day cycle at any dose level
88917290|NCT01635738|Experimental|LP GMNL-133 group|Arm: LP GMNL-133 group One capsule with 2x10^9 (cfu) LP GMNL-133, once daily, PO
88917291|NCT01635738|Experimental|LF GM-090 group|Arm: LF GM-090 group One capsule with 2x10^9 (cfu) LF GM-090, once daily, PO
88917292|NCT01635738|Experimental|LP GMNL-133+LF GM-090 group|One capsule with 2x10^9 (cfu) LP GMNL-133+ 2x10^9 (cfu)LF GM-090, once daily, PO
88917293|NCT01635738|Placebo Comparator|Placebo|
88917294|NCT01635751|Experimental|GLA5PR GLARS tablet 150mg(fasted)|
88917295|NCT01635751|Experimental|GLA5PR GLARS tablet 150mg(after high fat meal)|
89435759|NCT05736653|Experimental|PCMS-rest, Task-specific PCMS, Task-specific sham-PCMS|"During Task-specific PCMS participants will receive PCMS (TMS + PNS) with task-specific practice.~During PCMS rest participants will receive PCMS (TMS + PNS) without task-specific practice.~During Task-specific sham-PCMS participants will receive task-specific practice with sham PCMS (TMS + PNS)."
89435760|NCT05736653|Experimental|PCMS-rest, Task-specific sham-PCMS, Task-specific PCMS|"During Task-specific PCMS participants will receive PCMS (TMS + PNS) with task-specific practice.~During PCMS rest participants will receive PCMS (TMS + PNS) without task-specific practice.~During Task-specific sham-PCMS participants will receive task-specific practice with sham PCMS (TMS + PNS)."
88917296|NCT01635751|Active Comparator|Lyrica Capsule 75mg(fasted)|
88917297|NCT01635777|Experimental|12 weeks|miltefosine 12 weeks
88917298|NCT01635777|Experimental|8 weeks|miltefosine 8 weeks
88917299|NCT01635790|Active Comparator|Ranibizumab|0.5 mg ranibizumab. Given as monthly intravitreal injections during 6 months
88917300|NCT01635790|Active Comparator|Bevacizumab|1.25 mg of bevacizumab; Given as monthly intravitreal injections during 6 months
88917301|NCT01635803|Active Comparator|Ranibizumab|Monthly injections with ranibizumab during 6 months
88917302|NCT01635803|Active Comparator|Bevacizumab|Monthly injections with bevacizumab during 6 months
88917303|NCT01635816|Active Comparator|JE Vaccine existing facilities|will receive JE live attenuated SA 14-14-2 vaccine manufactured in the existing facility (250 infants).
88917304|NCT01635816|Active Comparator|JE vaccine new plant lot 1|Will receive Lot 1 JE live attenuated SA 14-14-2 vaccine manufactured in the new GMP facility (250 infants).
88917305|NCT01635816|Active Comparator|JE vaccine new plant lot 2|Will receive Lot 2 JE live attenuated SA 14-14-2 vaccine manufactured in the new GMP facility (250 infants).
88917306|NCT01635816|Active Comparator|JE vaccine new plant lot 3|Will receive will receive Lot 3 JE live attenuated SA 14-14-2 vaccine manufactured in the new GMP facility (250 infants).
88917307|NCT01635829|Experimental|Panel 1|Part 1 of Panel 1: Participants will receive telaprevir 750 mg every 8 hours from Day 1 to Day 9 followed by a single 750-mg dose in the morning on Day 10. Part 2 of Panel 1: Participants will receive phenytoin 200 mg every 12 hours from Day 1 to Day 16 followed by a single 200-mg dose in the morning on Day 17; and telaprevir 750 mg every 8 hours from Day 8 to Day 16 followed by a single 750-mg dose in the morning on Day 17.
88917308|NCT01635829|Experimental|Panel 2|"Part 1 of Panel 2: Participants will receive telaprevir 750 mg every 8 hours from Day 1 to Day 9 followed by a single 750-mg dose in the morning on Day 10. Part 2 of Panel 2: Participants will receive carbamazepine 200 mg every 12 hours from Day 1 to Day 16 followed by a single 200-mg dose in the morning on Day 17; and telaprevir 750 mg every 8 hours from Day 8 to Day 16 followed by a single 750-mg dose in the morning on Day 17.~brief description of the arm. This element may not be necessary if the associated intervention descriptions contain sufficient information to describe the arm."
88917309|NCT01635868||umbilical hernia repair|patients having umbilical or epigastric hernia repair from 2008-2010 in Zealand
88917310|NCT01635894|Experimental|nurse specialist|"Women were screened for a weak pelvic floor (modified Oxford score, MOS, ≤ 2) before being invited into the trial. The women were seen monthly after their initial assessment and training and were followed-up for their final assessment at 3 months."
88917311|NCT01635894|Experimental|practice nurse|"Women were screened for a weak pelvic floor (modified Oxford score, MOS, ≤ 2) before being invited into the trial. The women were seen monthly after their initial assessment and training and were followed-up for their final assessment at 3 months."
88917312|NCT01635894|No Intervention|Control|"Women were screened for a weak pelvic floor (modified Oxford score, MOS, ≤ 2) before being invited into the trial. The women were seen monthly after their initial assessment (but no training given) and were followed-up for their final assessment at 3 months."
88917313|NCT01635946|Experimental|Isavuconazole and atorvastatin|Atorvastatin on Days 1 and 12, Isavuconazole three times per day (TID) on Days 8 and 9, and once daily (QD) on Days 10 thru 15
88917314|NCT01635959||Patients with Gastrointestinal Trackt Symptoms|
88917315|NCT01635972|Experimental|Isavuconazole and bupropion|Bupropion hydrochloride on Days 1 and 15, Isavuconazole three times per day (TID) on Days 8 and 9, and once daily (QD) on Days 10 thru 20.
88917316|NCT01635985|Experimental|1|AZD5423 iv
88917317|NCT01635985|Experimental|2|AZD5423 inhalation, Spira
88917318|NCT01635985|Experimental|3|AZD5423 inhalation I-neb
88917319|NCT01635985|Experimental|4|AZD5423 oral
88917320|NCT01635985|Experimental|5|AZD5423 inhalation Turbuhaler
88917321|NCT01635985|Experimental|6|AZD5423, New Dry Powder Inhaler
88917322|NCT01636011|Experimental|OMM Treatment|In this group the subjects are given 5 different OMM treatments addressing the thoracic cage.
88917323|NCT01636011|Sham Comparator|Light Touch sham|In this group the physician uses the dorsum of his hand to the same areas and for the same time that the OMM treatment arm receives.
89435761|NCT05736653|Experimental|Task-specific sham-PCMS, Task-specific PCMS, PCMS-rest|"During Task-specific PCMS participants will receive PCMS (TMS + PNS) with task-specific practice.~During PCMS rest participants will receive PCMS (TMS + PNS) without task-specific practice.~During Task-specific sham-PCMS participants will receive task-specific practice with sham PCMS (TMS + PNS)."
89435762|NCT05736653|Experimental|Task-specific sham-PCMS, PCMS-rest, Task-specific PCMS|"During Task-specific PCMS participants will receive PCMS (TMS + PNS) with task-specific practice.~During PCMS rest participants will receive PCMS (TMS + PNS) without task-specific practice.~During Task-specific sham-PCMS participants will receive task-specific practice with sham PCMS (TMS + PNS)."
88917324|NCT01636024|Experimental|1|Subjects will participate in 1 of up to 9 groups in Part A (single ascending dose part) or 1 of 4 groups in Part B (multiple ascending dose part). Ratio of subjects receiving AZD7594 versus placebo is 6:2 in part A and 6:3 in Part B.
88917325|NCT01636024|Placebo Comparator|2|Subjects will participate in 1 of up to 9 groups in Part A or 1 of 4 groups in Part B. Ratio of subjects receiving AZD7594 versus placebo is 6:2 in part A and 6:3 in Part B.
88917326|NCT01636037|Experimental|L-Dopa (Sinemet)|Augmentation of current antipsychotic treatment with oral L-Dopa (levodopa/carbidopa) up to 900mg daily for 8 weeks
88917327|NCT01636050|Experimental|Training group|
88917328|NCT01636050|Experimental|Control group|
88917329|NCT01636089|Experimental|bicarbonates|sodium bicarbonates 1,4%
88917330|NCT01636089|Active Comparator|saline|sodium chloride 0,9%
88917331|NCT01636128|Experimental|Sulindac first (Treatment Sequence B)|Sulindac alone, washout, DFMO alone, then combination of sulindac and DFMO
88917332|NCT01636128|Experimental|DFMO first (Treatment Sequence A)|DFMO alone, followed by washout, sulindac alone, then combination of DFMO and sulindac
88917333|NCT01636141|Placebo Comparator|Placebo gel|Each study group consists of 6 subjects randomized in a 5:1 ratio to receive OLT1177 Gel or placebo gel in both Part A and B of the study. Eighteen subjects will be enrolled in Part A and 18 in Part B. A total of 30 subjects will receive OLT1177 Gel and 6 subjects will receive placebo gel.
88917334|NCT01636141|Active Comparator|OLT1177 Gel|Each study group consists of 6 subjects randomized in a 5:1 ratio to receive OLT1177 Gel or placebo gel in both Part A and B of the study. Eighteen subjects will be enrolled in Part A and 18 in Part B. A total of 30 subjects will receive OLT1177 Gel and 6 subjects will receive placebo gel.
88917335|NCT01636154|No Intervention|The basic treatment|Comply to the Chinese guidelines of acute ischemic stroke in 2010
88917336|NCT01636154|Other|Clearing heat|Treat with KDZ injection on the basis of the basic treatment
88917337|NCT01636154|Other|Promoting blood circulation|Treat with Xueshuantong injection on the basis of the basic treatment
88917338|NCT01636154|Experimental|Clearing heat & Promoting blood circulation|Treat with both KDZ injection and Xueshuantong injection on the basis of the basic treatment
88917339|NCT01636180|Experimental|Clopidogrel - Repeated Loading Dose|repeated loading dose of clopidogrel (600 mg) in addition to high dose of clopidogrel continuous therapy for 30 days (150 mg/day)
88917340|NCT01636180|Active Comparator|Clopidogrel - standard of care|no repeated loading dose of clopidogrel with clopidogrel continuous therapy for 30 days (75 mg/day)
89435763|NCT05735886|Placebo Comparator|Placebo|
89435764|NCT05735886|Active Comparator|Urolithin A (Mitopure)|
88917341|NCT01636193||Rota Group|Subjects will receive Rotarix® as per routine practice.
88917342|NCT01636232||ICU sepsis group|The ICU sepsis group consisting of 105 critically-ill cases diagnosed with sepsis upon admission and sampled within the first 24h of their ICU stay.
88917343|NCT01636232||ICU control group|the ICU control group including 51 critically-ill cases in whom sepsis was clinically excluded and from whom samples were taken upon admission.
88917344|NCT01636232||healthy control group|the healthy control group composed of 50 healthy control outpatients. For the healthy control outpatients, possibilities of acute or past chronic diseases were excluded. Moreover, we made sure that the healthy control subjects had not been hospitalized or taken vitamin-based substitutive drugs in the last 12 months, and proved normal in physical checkups and lab examinations.
88917345|NCT01636245|Experimental|Lot 1|inactivated vaccine (Lot 1) against EV71 of 400U /0.5ml in 350 infants aged 6 months to 5 years old on day 0,28
89435765|NCT05735704||Patients with Hematological Malignancies - Discovery stage|"The first stage (discovery phase) will include at least 30 patients from each of the following groups: MM, pre-MM conditions (SMM and MGUS), HL, aggressive NHL (DLBCL, HGL, FL, MZL, AML, MDS.~NOTE: Patients diagnosed with DLBCL that is transformed from FL or MZL, and patients diagnosed with AML secondary to MDS or MPN, that were treated for their primary disease (FL/MZL/MDS/MPN) prior to study enrollment, are eligible.~For patients, it is expected, after signing the informed consent, that the serial samplings will be performed during the disease follow-up according to the standard clinical practice and/or recommended schedule and disease assessment plan.~Bone marrow samples will be obtained at Tel-Aviv Sourasky Medical Center (TASMC) from up to 50 MM patients and up to 50 AML patients that undergo bone marrow aspiration as part of the standard care procedure."
88917346|NCT01636245|Experimental|Lot 2|inactivated vaccine (Lot 2) against EV71 of 400U /0.5ml in 350 infants aged 6 months to 5 years old on day 0,28
88917347|NCT01636245|Experimental|Lot 3|inactivated vaccine (Lot 3) against EV71 of 400U /0.5ml in 350 infants aged 6 months to 5 years old on day 0,28
88917348|NCT01636245|Placebo Comparator|Placebo|Placebo in 350 infants aged 6 months to 5 years old on day 0,28
88917349|NCT01636271||Group 1: subjects from LPL100601|randomized subjects in study LPL100601
88917350|NCT01636271||Group 2: subjects from SB480848/033|randomized subjects in study SB480848/033
88917351|NCT01636310|Active Comparator|Female Smokers (Mid-Luteal Phase; cycle days 18-22)|
88917352|NCT01636310|Active Comparator|Female Smokers (Early Follicular Phase; cycle days 4-8)|
88917353|NCT01636323|Active Comparator|Female Smokers (Mid-Luteal Phase; cycle days 18-22)|
88917354|NCT01636323|Active Comparator|Female Smokers (Early Follicular Phase; cycle days 4-8)|
89530902|NCT02500433|Other|Conventional therapy|"Conventional therapy was based on neurodevelopment treatment, psychomotor activities and kinesiotherapy during one month, twice per week, with 30 minutes per session.~The treatment includes: active and passive kinesitherapy, muscle and tendons stretching, training of gait and deambulation, such as coordination and handling."
88917355|NCT01636336|Active Comparator|Female Smokers (Mid-Luteal Phase; cycle days 18-22)|
88917356|NCT01636336|Active Comparator|Female Smokers (Early Follicular Phase; cycle days 4-8)|
88917357|NCT01636349|Experimental|Recreational soccer training|12 men participate in recreational soccer training for 6 months
88917358|NCT01636349|No Intervention|Control group|10 subjects serve as a control group with no change in lifestyle in the study period
88917359|NCT01636388|Experimental|Allogeneic Stem Cell Transplantation|Reduced intensity conditioning and allogeneic stem cell transplant from EBV positive HLA matched sibling or unrelated adult donor combined with post AlloSCT allogeneic donor derived LMP specific cytotoxic T-lymphocyte (CTL) infusions in EBV positive patients with poor risk Hodgkin Lymphoma.
88917360|NCT01636401|Active Comparator|aclidinium bromide|
88917361|NCT01636401|Placebo Comparator|Placebo|
89435766|NCT05735704||Patients with Hematological Malignancies - Second stage|In the second stage, at least 250 patients with MM and 250 patients with NHL and at least 100 patients with each of the remaining hematological malignancies mentioned above will be tested. Out of these patients, AML, lymphoma and MM patients will be followed-up at the clinical sites. Periodic sampling will be defined according to disease type and progression rate. Blood and plasma samples will be stored in the clinical sites until relapse diagnosis. At this stage, blood samples will be analyzed retrospectively on the HemaChip. The screening, enrollment, and sample collection can begin in the first stage of the trial, in order to allow a maximum follow-up period for at-risk subjects as part of the study and to meet the recruitment goals.
89435767|NCT05735704||subjects at risk of developing MM / lymphoproliferative disorder - Third stage|"The last stage consists of screening of a larger group of subjects at risk of developing MM / lymphoproliferative disorder. This stage will include 400 elderly patients (>65 years old) and 500 first-degree relatives of patients (and in particular siblings). The screening, enrollment, and sample collection can begin in the first stage of the trial, in order to meet the recruitment goals.~Follow-up patients, at-risk individuals for MM, and at-risk first-degree relatives will donate blood periodically according to the follow-up plan."
89435768|NCT05735704||Control subjects with no malignant disease- Discovery stage|"Control subjects with no malignant disease that serve as controls are expected to donate blood a single time. Following this donation, their participation will end.~At Tel-Aviv Sourasky Medical Center (TASMC) up to 50 bone marrow samples will be taken from healthy volunteers that will undergo hip or knee replacement surgery."
89435769|NCT05729282|Placebo Comparator|Placebo|Participants will ingest a placebo solution (27 doses over 14 days) formulated to approximate the taste of diazoxide oral suspension. Blinding will occur by completely covering single-dose oral syringes with labels.
89435770|NCT05729282|Experimental|Diazoxide oral suspension, 1 mg per kg per dose|Participants will ingest diazoxide oral suspension at 1 mg per kg body weight per dose (27 doses over 14 days). Blinding will occur by completely covering single-dose oral syringes with labels.
89435771|NCT05729282|Experimental|Diazoxide oral suspension, 2 mg per kg per dose|Participants will ingest diazoxide oral suspension at 2 mg per kg body weight per dose (27 doses over 14 days). Blinding will occur by completely covering single-dose oral syringes with labels.
89435772|NCT05728502||vericiguat arm|Chinese adult patients with Heart Failure with Reduced Ejection Fraction (HFrEF) who are prescribed vericiguat under routine treatment conditions. Data will be prospectively collected.
89435773|NCT05728502||external control arm|Chinese adult HFrEF patients who received SoC treatment will be collected from China Heart Failure Center registry database. This control arm will be retrospectively collected from the patients in the database in the same period, from FPFV to LPFV of the vericiguat arm, and matched by propensity score based on baseline characteristics.
89435774|NCT05726682|Experimental|High risk AML and MDS|Participants with high risk acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) undergoing allogeneic HSCT will receive 3 doses of SAR445419. A myeloablative conditioning (MAC) and a reduced intensity conditioning (RIC) cohort will be included.
89435775|NCT05722938|Experimental|Trimodulin|Trimodulin (human IgM, IgA, IgG solution) for intravenous (IV) administration.
89435776|NCT05722938|Placebo Comparator|Placebo|Human albumin 1%
89435777|NCT05722197|Experimental|Crisis Response Plan and Lethal Means Counseling|All participants will complete a narrative suicide risk assessment, collaboratively develop a Crisis Response Plan, and receive lethal means counseling. The Crisis Response Plan will include the following sections: (1) identifying personal warning signs for suicide; (2) identifying self-regulation strategies for reducing emotional distress; (3) identifying reasons for living; (4) identifying sources of social support; and (5) accessing professional crisis services. Participants will handwrite the plan on an index card, sheet of paper, or another similar medium. After completing the Crisis Response Planning, researchers will conduct lethal means counseling to develop a plan for restricting or limiting access to potentially lethal methods of suicide.
89435778|NCT05720923||MFS_f|Patients with Marfan syndrome with fatigue
89435779|NCT05720923||MFS_nf|Patients with Marfan syndrome without fatigue
89435780|NCT05720923||EDS_f|Patients with Ehlers Danlos syndrome with fatigue
88917362|NCT01636440|Other|Reliability|The same testing procedure is repeated after a delay of 7 days to test the reliability of the measure
89435781|NCT05720923||EDS_nf|Patients with Ehlers Danlos syndrome without fatigue
88917363|NCT01636479|Experimental|SAR405838|SAR405838 in escalating doses
88917364|NCT01636492|Experimental|Bitopertin|
88917365|NCT01636492|Placebo Comparator|Placebo|
88917366|NCT01636505|Active Comparator|short protocol|gnrh agonist versus gnrh antagonist
88917367|NCT01636505|Active Comparator|long protocol|
88917368|NCT01636518||Atrial Fibrillation|Patients with Atrial Fibrillation that undergo standard of care procedure at the University of Kansas Hospital
88917369|NCT01636531|Experimental|HCLF|
88917370|NCT01636531|Active Comparator|LyoF|
88917371|NCT01636557|Experimental|Sirukumab and 5-probe cocktail|The 5-probe cocktail will consist of oral doses of midazolam, warfarin/vitamin K, omeprazole, and caffeine.
88917372|NCT01636570|Active Comparator|Vitamin D3 (cholecalciferol)|10,000 International Units of vitamin D3 will be given daily for 6 months in vitamin D deficient heart failure patients.
88917373|NCT01636570|Placebo Comparator|Sugar Pill|Patients will be given an placebo that is identical in appearance to the active comparator. It will be given as 2 gelcaps per day.
88917374|NCT01636583|Experimental|LSF water without meal|Composition of test meal: 67Zn-labelled LSF-fortified water (1 mg 67Zn as ZnSO4 + 1 mg of eluted Zn from LSF device of natural isotopic composition)
88917375|NCT01636583|Active Comparator|LSF water and inhibitory meal|Composition of test meal: Maize porridge and 67Zn-labelled LSF-fortified water (1 mg 67Zn as ZnSO4 + 0.44 mg of eluted Zn from LSF device of natural isotopic composition)
88917376|NCT01636583|Active Comparator|Fortified inhibitory meal with water|Composition of test meal: Maize porridge (1 mg 67Zn as ZnSO4 + 0.44 mg Zn as ZnSO4 of natural isotopic composition) and high purity water
88917377|NCT01636609|Experimental|Arm I (tosedostat, cytarabine)|Participants receive tosedostat PO QD on days 1-28 and cytarabine SC BID on days 1-10. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88917378|NCT01636609|Experimental|Arm II (tosedostat, azacitidine)|Participants receive tosedostat PO QD on days 1-28 and azacitidine IV over 10-40 minutes or SC on days 1-7. Courses repeat every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
88917379|NCT01636622|Experimental|Vemurafenib + Carboplatin + Paclitaxel|"All 3 study drugs will start on day 1 of cycle 1. Cycle defined as 3 weeks. On day 1, paclitaxel and carboplatin will be administered first, and the vemurafenib administration will start in the evening that day.~Starting dose of Paclitaxel: 100 mg/m2 by vein every 3 weeks.~Starting dose of Carboplatin: AUC 5 by vein every 3 weeks.~Starting dose of Vemurafenib: 480 mg by mouth mouth in the evening on Day 1 of Cycle 1, then twice a day starting on Day 2 for a 3 week cycle."
88917380|NCT01636635|Active Comparator|Young (18-45 years)|Obese young women (18-45y) undergoing calorie restriction.
88917381|NCT01636635|Experimental|Older (>60 years)|Obese older women (>60y) undergoing calorie restriction.
89435782|NCT05720923||Volunteers|Healthy adult volunteers without fatigue
88917382|NCT01636700|Active Comparator|tramadol infiltration|infiltration of tramadol 2mg/kg
88917383|NCT01636700|Placebo Comparator|Saline solution|Infiltration of saline
88917384|NCT01636726||Patients with AMI|All patients of the study population with a record/diagnosis of AMI during the study period
88917385|NCT01636726||Patients without AMI|All patients of the study population without a record/diagnosis of AMI during the study period
88917386|NCT01636739||Rota Group|Subjects will receive Rotarix® as per routine practice
88917387|NCT01636752|Experimental|Deprexis|Online self-help with and without e-mail-support
88917388|NCT01636752|No Intervention|Control|
88917389|NCT01635426|Active Comparator|Aspirin|
88917390|NCT01635426|Active Comparator|Clopidogrel|
88917391|NCT01636791|Active Comparator|Cognitive Behavior Therapy|As the trial will include several different common mental disorders, the cognitive behavior therapy used in the study will be based on the protocols with best empirical support. Cognitive behavior therapy entails psychoeducational components, i.e. the patient is learns about the disorder and how to view it from a cognitive behavioral perspective. The most important part of the treatment is systematic behavior changes often targeted at exposure to feared stimuli. This is combined with cognitive interventions targeted at challenging negative automatic thoughts. All treatments will be delivered by licensed psychologists.
88917392|NCT01636791|Experimental|Return to work|Participants randomized to this arm will receive an experimental treatment, based in cognitive behavioral therapy, with primary aim to help patients return to work. Interventions are aimed at solving work-related problems and comprises problem-solving training and systematic employer-patient meetings aimed at facilitating a gradual return to the workplace. Licensed psychologists deliver all treatments.
88917393|NCT01636791|Experimental|CBT and Return to work|Participants randomized to this arm will receive a combination of cognitive behavior therapy and the return to work treatment. This arm is included in the study as the clinically most relevant therapy, would the return to work treatment be effective in reducing sick leave, is a treatment were patients are provided support to return to work but also is clinically effective in reducing psychiatric symptoms.
88917394|NCT01636804||Quicksite and Quickflex|Patients who have received the leads affected by the medical product advisory
88917395|NCT01636830|Active Comparator|Toothbrush type - medium|This is a crossover study, where the person used either a soft brush (control) and the medium brush (test).
88917396|NCT01636830|Active Comparator|Toothbrush type - soft|This is a crossover study, where the person used either a soft brush (control)and the medium brush(test).
88917397|NCT01636856|Active Comparator|1|Oropharyngeal exercises and oropharyngeal functions
88917398|NCT01636856|Sham Comparator|2|Nasal dilator, respiratory exercise, nasal lavage
88917399|NCT01636869|Experimental|bupicavaine|
88917400|NCT01636895|Experimental|SP-IPTp efficacy|Efficacy of suphladoxine/pyrimethamine as IPTp
88917401|NCT01636908|Experimental|Kinase inhibitor|Patients are cohort-wise treated with a registered (tyrosine) kinase inhibitor
88917402|NCT01636973|Experimental|Vaporizing humidifier|Vaporizing humidifier applying during one-lung ventilation
88917403|NCT01636999|Experimental|Butorphanol|The main study arm will be examining how well a 50% Nitrous Oxide/50% Oxygen gas mixture is in reducing labor pains in term labor patients with less than 5 cm cervical dilation, compared to 2mg of Butorphanol (a common synthetic opiod used for labor pains in this setting).
88917404|NCT01637012|Experimental|ALEX stent arm|implantation of ALEX stent during index procedure
88917405|NCT01637025|Experimental|Traumastem - oxidized cellulose strip|
88917406|NCT01637025|Active Comparator|Surgicel® Original - oxidized regenerated cellulose strip|
88917407|NCT01637038|No Intervention|Control Group|no intervention
88917408|NCT01637038|Experimental|RIPC group|Those undergoing remote ischemic postconditioning
88917409|NCT01637103|Experimental|Cognitive therapy of depression|
88917410|NCT01637103|Experimental|Bright light therapy|
88917411|NCT01637103|No Intervention|Waiting list|
88917412|NCT01637116||autoimmune chronic spontaneous urticaria|Patients with chronic spontaneous urticaria with a positive ASST, who also test positive in a cell activating assay (BHRA OR CD 63 activation of healthy donor basophils) and who exhibit anti-FcεRI and/or anti-IgE autoantibodies (=autoimmune chronic spontaneous urticaria).
88917413|NCT01637116||autoreactive, non-autoimmune chronic spontaneous urticaria|Patients with chronic spontaneous urticaria with a positive ASST, who test negative in cell activation assay or who do not exhibit anti-FcεRI or anti-IgE autoantibodies (=autoreactive, non-autoimmune chronic spontaneous urticaria)
88917414|NCT01637116||non-autoreactive chronic spontaneous urticaria|Patients with chronic spontaneous urticaria and a negative ASST (= non-autoreactive chronic spontaneous urticaria)
88917415|NCT01637129|Active Comparator|Magnetic Stimulation|Active Magnetic Stimulation with repetitive transcranial magnetic stimulation
88917416|NCT01637129|Placebo Comparator|No Intervention|Sham Magnetic Stimulation
88917417|NCT01637155|Experimental|Cholecalciferol|
88917418|NCT01637168|Experimental|Test Group|Panax Ginseng + Ginkgo Biloba + Polyminerals + Multivitamin - 1 tablet, 2 times a day (12/12 hours).
88917419|NCT01637168|Active Comparator|Comparator Group|Ginkgo Biloba (Tebonin ®) - 1 tablet, 2 times a day (12/12 hours).
88917420|NCT01637181|Active Comparator|EVLA 940 nm|
88917421|NCT01637181|Active Comparator|EVLA 1470 nm|
88917422|NCT01637194|Experimental|Treatment (enzyme inhibitor, monoclonal antibody therapy)|Patients receive everolimus PO QD on days -14 and then 1-28. Patients also receive cetuximab IV over 60-120 minutes on days -7 and then once weekly beginning on day 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88917423|NCT01637220||case, control|Blood volume collected specifically for this study
88917424|NCT01637233||NRTI + PI|This is the randomisation of the main study, Arm 1
88917425|NCT01637233||maraviroc + PI|this is the randomisation of the main study, Arm 2
88917426|NCT01637233||maraviroc + NRTI|this is the randomisation of the main study, Arm 3
88917427|NCT01637259|Active Comparator|NRTI + PI|arm 1
88917428|NCT01637259|Active Comparator|PI + maraviroc|arm 2
88917429|NCT01637259|Active Comparator|NRTI + maraviroc|arm 3
88917430|NCT01637285|Experimental|PF-04856883 Treatment Arm 1|
88917431|NCT01637285|Experimental|PF-04856883 Treatment Arm 2|
89435783|NCT05719584|Experimental|hypopressive exercises|pelvic floor muscle exercises along with hypopressive exercises
89435784|NCT05719584|Active Comparator|pelvic floor muscle training|pelvic floor muscle exercises alone
89435785|NCT05713851|Experimental|Dapaglifozin group|Dapagliflozin 10 mg, will be administered orally or by nasogastric tube every 24 h for 21 days.
89435786|NCT05713851|Placebo Comparator|Standard of care|Without receiving any of the interventional drugs.
89435787|NCT05713552|Experimental|Test/Control|Eligible subjects who are habitual soft contact lens wearers will be randomized into the Test/Control sequence, to wear two different study lenses, one at a time, over two wear periods (test then control) with a washout period of 15 minutes between wears. During each wear period the lenses will be worn bilaterally for at least one hour in-office.
89435788|NCT05713552|Experimental|Control/Test|Eligible subjects who are habitual soft contact lens wearers will be randomized into the Control/Test sequence, to wear two different study lenses, one at a time, over two wear periods (control then test) with a washout period of 15 minutes between wears. During each wear period the lenses will be worn bilaterally for at least one hour in-office.
89435789|NCT05711667|Experimental|ARM I (Letermovir prophylaxis)|Patients receive letermovir PO or IV over 60 minutes QD starting on day +1 post-transplant for 14 weeks. Patients undergo collection of blood samples for CMV PCR analysis weekly for 14 weeks, every 2 weeks until week 24, week 32, week 40 and week 52.
89435790|NCT05711667|Active Comparator|ARM II (No prophylaxis)|Patients undergo collection of blood samples for CMV PCR analysis weekly for 14 weeks, every 2 weeks until week 24, week 32, week 40 and week 52.
89530903|NCT02506595|Experimental|ERRT-M for Nightmares|Exposure, Relaxation, and Rescripting Therapy Military version (ERRT-M) -
89435791|NCT05707143|Active Comparator|home based stabilization exercises|knee rolls, the cat, spine curl, bridging, single knee to chest, pelvic tilt
89435792|NCT05707143|Experimental|kegel exercises|kegel exercises
89435793|NCT05705401|Active Comparator|Standard of Care Adjuvant Breast Radiation|Patients continue to receive their current planned adjuvant breast radiation and systemic HER2-targeted therapies
89435794|NCT05705401|Active Comparator|Standard of Care HER2-targeted Therapy Without Adjuvant Breast Radiation|Patients continue to receive their current systemic HER2-targeted therapy without breast adjuvant radiation
89435795|NCT05705115|No Intervention|LBNP 0 + no intravenous fluid|
88917432|NCT01637285|Experimental|PF-04856883 Treatment Arm 3|
89435796|NCT05705115|Experimental|LBNP 0 + Ringer's acetate|
89435797|NCT05705115|Active Comparator|LBNP 40 + no intravenous fluid|
89435798|NCT05705115|Experimental|LBNP 40 + Ringer's acetate|
88917433|NCT01637285|Experimental|PF-04856883 Treatment Arm 4|
88917434|NCT01637311|Experimental|Failed HM|Patients were eligible for enrollment in the study if they were age greater than 18 years and had recurrence/persistence of symptoms after primary HM with an Eckardt symptom score ≥ 4.
88917435|NCT01637337|Active Comparator|laparoscopic pyelolithotomy|
88917436|NCT01637337|Sham Comparator|percutaneous nephrolithotomy|
88917437|NCT01637350||Subtotal gastrectomy , BillrothⅠ|
88917438|NCT01637350||Subtotal gastrectomy , BillrothⅡ|
89435799|NCT05703893||Syndromic TAA|Patients presenting either clinical or genetic phenotype referring to a syndrome related to Thoracic Aortic Aneurysms
89435800|NCT05703893||Non-syndromic TAA|Patients presenting Thoracic Aortic Aneurysms
89435801|NCT05703854|Experimental|Chemotherapy and NK Cell Infusion|Participants will be assigned to a dose level of NK cells. A computer will decide by chance which of the dose level you will receive, and this will not be based on the doctor's or patient's decision. Up to 5 dose levels of NK cells will be tested. Each new patient will receive a different dose. If any dose shows to be not tolerable, this dose and the higher doses will not be given anymore.
89435802|NCT05703685|Other|one arm|All subjects will receive the same tests
89435803|NCT05703269|Active Comparator|SSRS = single fraction stereotactic radiosurgery|SSRS is an advanced radiation technique that delivers high dose precision radiation in a single dose to discrete intracranial lesions. SSRS has recently become a standard-of-care treatment for patients with 1-4 brain metastases and is also commonly used for patients with up to 15 metastases, due to improved neurocognitive outcomes compared to whole brain radiotherapy.
89435804|NCT05703269|Experimental|FSRS = fractionated stereotactic radiosurgery|FSRS is an advanced radiation technique that uses a lower dose precision radiation delivered over 3 to 5 treatments given daily or every other day to intracranial lesions.
89435805|NCT05702476||MFS Adult patients|Patients with clinical and/or gentic diagnosis of MFS older than 18 years
89435806|NCT05702476||MFS Paediatric patients|Patients with clinical and/or gentic diagnosis of MFS younger than 18 years
89435807|NCT05700539|Experimental|Internet-based cognitive behavioral therapy|
89435808|NCT05700539|No Intervention|Wait-list control|
89530904|NCT02506595|No Intervention|Waitlist control|Participants randomized to the Waitlist control condition will be contacted once weekly for 5 weeks to monitored status and then invited to participant in treatment.
89530905|NCT02508155|Experimental|MEDI7352 IV|Up to 11 cohorts of subjects are planned to be dosed by IV infusion, with single and multiple ascending doses.
89530906|NCT02508155|Placebo Comparator|IV Placebo|Up to 11 cohorts of subjects are planned to be dosed by IV infusion, with single and multiple ascending doses.
89435809|NCT05696964|Experimental|Enhanced Motivational Interviewing Training|Participating medical residents will all receive two successive interventions, motivational interviewing (MI) booster training and the use of a dashboard that provides MI metrics. The booster training will make use of an artificial intelligence tool developed by our study team, Real-time Assessment of Dialogue in Motivational Interviewing (ReadMI), that produces metrics on important conversational skills (e.g., talking time, use of open-ended questions). The dashboard will produce these metrics during clinical encounters as a way to provide cuing for the MI approach.
88917439|NCT01637350||total gastrectomy, jejunal interposition|
89435810|NCT05695430|Experimental|Brief Cognitive Behavioral Therapy for People with Physical Disabilities|
89435811|NCT05695365|Experimental|Resistance Exercise Training|Participants will complete a 16-week, twice/week program to increase strength.
89435812|NCT05693142|Experimental|RGX-202 Dose 1|A single IV infusion of RGX-202 at a dose of 1×10^14 GC/kg body weight
89435813|NCT05693142|Experimental|RGX-202 Dose 2|A single IV infusion of RGX-202 at a dose of 2x10^14 GC/kg body weight
89435814|NCT05691686|Experimental|Finely milled whole wheat-legume bread|Treatment with finely milled whole wheat-legume bread.
89435815|NCT05691686|Experimental|Less processed whole wheat-legume bread|Treatment with less processed whole wheat-legume bread.
88917440|NCT01637350||total gastrectomy , Roux-en-Y|
88917441|NCT01637363|No Intervention|Regular treatment|This group is offered regular treatment from the job center i.e. exercise, mindfulness
88917442|NCT01637363|Experimental|Psychoeducation|6 x 2 hours of psychoeducation
89435816|NCT05691686|Experimental|Less processed whole wheat bread|Treatment with of less processed whole wheat bread.
89435817|NCT05691686|Active Comparator|Reference Food (white wheat bread)|Treatment with reference food.
89435818|NCT05691530|Experimental|Flavivirus Naive|Those with <=50% neutralization at a 1:10 dilution to all four DENV serotypes, no history of flavivirus vaccination, or travel history that increases the likelihood of other flavivirus infections.
89435819|NCT05691530|Experimental|Polytypic DENV Antibody Profile|Those considered immune (a >=70% neutralization or plaques at a 1:40 dilution) to at least two serotypes.
89435820|NCT05691530|Experimental|Primary Heterotypic DENV Antibody Profile|Those who have a >=70% neutralization or plaques at a 1:40 dilution for a single serotype, either DENV1, DENV2, or DENV4.
89435821|NCT05687396|Experimental|Virtual reality|Virtual reality while cycling with ergometer in addition to conventional pulmonary rehabilitation. virtual reality designed as cylcling in the forest.
88917443|NCT01637389|No Intervention|Control Arm|All communities (independent units/clusters) start in the control and have no intervention. All control communities cross-over to the intervention in a randomized sequence over the course of 12-15 month study.
88917444|NCT01637389|Experimental|Basic Safe Water Program|The Basic program represents a variation in the implementation of the overall intervention: a community level safe-water program that is initiated with promotional meetings and followed by the offer to install Mesita Azul disinfection systems at the household level. Communities (independent units/cluster) cross-over from the control group to the intervention group in a randomized stepped-wedge fashion -- within each crossover group of 4 clusters, 2 are randomized to the Basic program.
88917445|NCT01637389|Experimental|Enhanced Safe Water Program|The Enhanced program represents a variation in the implementation of the overall intervention: a community level safe-water program that is initiated with promotional meetings and followed by the offer to install Mesita Azul disinfection systems at the household level. Communities (independent units/cluster) cross-over from the control group to the intervention group in a randomized stepped-wedge fashion -- within each crossover group of 4 clusters, 2 are randomized to the Enhanced program.
88917446|NCT01637441|Experimental|laparoscopic sacropexy|under laparoscopic vision, the vesico-vaginal space is dissected until the level of the bladder neck. a synthetic non absorbable mesh is placed between the bladder and the vagina. the mesh is sutured to the vagina and the apex (vaginal apex or uterus) and anchored to the prevertebral ligament in front of the promontorium.
88917447|NCT01637441|Experimental|vaginal mesh|after anterior sagittal colpotomy, the bladder is dissected under the fascia layer, and the paravesical fossa are entered. a synthetic non absorbable mesh is placed with 4 arms suspension (trans obturator or not). treatment of the apex is mandatory.
88917448|NCT01637454|Active Comparator|Terlipressin and Type-2 HRS|Patients in group A received terlipressin as an intravenous bolus of 0.5 mg every 6 h. If a significant reduction in serum creatinine level (≥1 mg/dL) was not observed during 3-day period, the dose of terlipressin was increased in a stepwise fashion every 3 days to a maximum of 2 mg every 6 hour.
88917449|NCT01637454|Active Comparator|Noradrenaline and Type-2 HRS|Patients in group B received a continuous infusion of noradrenaline at an initial dose of 0.5 mg/hour, designed to achieve an increase in mean arterial pressure (MAP) of at least 10mmHg or an increase in 4-h urine output to more than 200 mL. When one of these goals was not achieved, the noradrenaline dose increased every 4 hour in steps of 0.5 mg/hour, up to the maximum dose of 3 mg/hour
88917450|NCT01637467|Experimental|EMS intervention|The experimental group will received EMS at a therapeutic level.
88917451|NCT01637467|Sham Comparator|Sham|The sham group will receive EMS at a sub-therapeutic level.
88917452|NCT01637480|Experimental|Patellofemoral Pain Syndrome|Participants with Patellofemoral Pain Syndrome
88917453|NCT01637480|Active Comparator|Healthy control|Age- and gender-matched participants without Patellofemoral Pain Syndrome
88917454|NCT01637493|Experimental|Pegfilgrastim, 30mcg/kg|
88917455|NCT01637493|Experimental|Pegfilgrastim, 60mcg/kg|
88917456|NCT01637493|Experimental|Pegfilgrastim, 100mcg/kg|
88917457|NCT01637493|Experimental|Pegfilgrastim, 200mcg/kg|
89435822|NCT05687396|Experimental|Conventional pulmonary rehabilitation|Deep diafragmatic breathing exercise, chest expansion exercies, pursed lip exhalation, coughing and huffing, upper limp exercies with deep breathing exercise, standing up-right position, cycling with ergometer.
89530907|NCT02508155|Experimental|MEDI7352 Subcutaneous Injection|1 cohort of subjects is planned to be dosed by subcutaneous injection, one single ascending dose cohort.
89530908|NCT02508155|Placebo Comparator|Subcutaneous Placebo|1 cohort of subjects is planned to be dosed by subcutaneous injection, one single ascending dose cohort.
89435823|NCT05674409|Experimental|Cognitive Behavioral Therapy + Brief Family-Involved Treatment|"Approximately half of enrolled veterans and their treatment companion will be randomly assigned to the experimental group. The identified veteran participant wil receive 12 sessions of Cognitive Behavioral Therapy for Alcohol Use Disorder (CBT for AUD). In addition, both the identified veteran and their treatment companion will receive an additional 3 sessions of Brief Family-Involved Treatment (B-FIT).~B-FIT is a manualized, 3-session AUD intervention, designed to be implemented in combination with any existing alcohol treatment program."
89435824|NCT05674409|Active Comparator|Cognitive Behavioral Therapy|Approximately half of enrolled veterans and their treatment companion will be randomly assigned to the active comparator group. The identified veteran participant wil receive 12 sessions of Cognitive Behavioral Therapy for Alcohol Use Disorder (CBT for AUD).
88917458|NCT01637519||Ureteral stone|Ten (10) patients with a unilateral, mid- or distal, ureteral (tube connecting kidney and bladder in the urinary system) stone will be enrolled and brought to completion in this study.
88917459|NCT01637532|Other|Group 1|Carboplatin/Caelyx
88917460|NCT01637532|Experimental|Group 2|Carboplatin/Caelyx or doxorubicin plus Tocilizumab
88917461|NCT01637532|Experimental|Group 3|Carboplatin/Caelyx or doxorubicin plus Tocilizumab plus Peg-Intron
88917462|NCT01637545|Active Comparator|Preop. ramosetron 0.3mg i.v.|G1 - Ramosetron 0.3mg i.v. just before the beginning of the surgery
88917463|NCT01637545|Active Comparator|Postop. ramosetron 0.3mg i.v.|G2 - Ramosetron 0.3mg i.v. just after the end of the surgery and moving into the Recovery room
88917464|NCT01637545|Active Comparator|No Ramosetron|G3 - No medication but regular antiemetics injection if the patient wants
88917465|NCT01637558|No Intervention|Main TB cohort|Children with tuberculosis 0-12 years of age
88917466|NCT01637558|Experimental|Lopinavir/Ritonavir - Cases|children 3-20 kg with tuberculosis and indication for LPV/r-based ART
88917467|NCT01637558|Experimental|Lopinavir/Ritonavir - Controls|Children 3-20 kg on LPV/r-based ART; no TB
88917468|NCT01637558|Experimental|Nevirapine arm|children with TB and indication for nevi rapine-based ART
88917469|NCT01637571|Active Comparator|Dexilant|60mg of Dexilant QD for 12 weeks
88917470|NCT01637571|Placebo Comparator|Placebo|60mg of Dexilant placebo QD for 12 weeks
88917471|NCT01637610||PPROM|All women presenting to assessment at the labour and delivery unit at RUH with suspected PPROM between 16+0 and 36+6 weeks gestation.
88917472|NCT01637636|Experimental|Rifampin|
88917473|NCT01637636|Experimental|Ketoconazole|
88917474|NCT01637649||Stroke patients with dysphagia|Stroke patients with confirmed evidence of aspiration and severe dysphagia tha would require modified diet or nasogastric tube feeding
88917475|NCT01637649||Stroke patients without dysphagia|Stroke patients but with no gross evidence of dysphagia or with mild dysphagia with a Penetration aspiration scale of less than 4
88917476|NCT01637649||healthy volunteer group|healthy volunteers with no prior history of dysphagia or stroke and who are not included in the exclusion criteria
88917477|NCT01637662|Experimental|Healthy subjects|
88917478|NCT01637675|Active Comparator|20 mg sildenafil citrate tablets by mouth|20 mg sildenafil citrate tablets by mouth three times a day for 8 weeks
88917479|NCT01637675|Experimental|sodium tanshinone IIA sulfonate, sildenafil citrate tablets|sodium Tanshinone IIA sulfonate injection 80 mg diluted with 5% glucose solution(0.9% sodium chloride injection also permitted if necessary) 250ml ivdrip once a day for 8 weeks,20mg sildenafil citrate tablets by mouth three times a day for the same duration
88917480|NCT01637701|Active Comparator|PkEP|Patients in this group undergo PkEP using the Gyrus plasmakinetic tissue management system (Gyrus Medical Ltd,Bucks,UK).
88917481|NCT01637701|Active Comparator|B-TURP|Patients in this group undergo B-TURP using the Gyrus plasmakinetic tissue management system (Gyrus Medical Ltd,Bucks,UK).
88917482|NCT01637714|Experimental|Multi-strain probiotics|
88917483|NCT01637714|Placebo Comparator|Placebo powder|
88917484|NCT01637727||GDM1|The study group will include women who gave birth in Shaare Zedek Medical Center between the years 2000 and 2010. Women with a GDM history will be identified based on the gestational diabetes clinic files. Women without a history of GDM who will be the control group will be identified from the Shaare Zedek Medical Center birth registration records.
88917485|NCT01637727||GDM|The study group will include women who gave birth in Shaare Zedek Medical Center between the years 2000 and 2010. Women with a GDM history will be identified based on the gestational diabetes clinic files. Women without a history of GDM who will be the control group will be identified from the Shaare Zedek Medical Center birth registration records.
88917486|NCT01637740||eyes with pseudoexfoliation syndrome|cataract myopic eyes with pseudoexfoliation syndrome
89530909|NCT03344393|Active Comparator|ketamine hydrochloride|intravenous ketamine infusion in the intraoperative period
88917487|NCT01637740||eyes without pseudoexfoliation syndrome|cataract myopic eyes without pseudoexfoliation syndrome
89198404|NCT03897348|Experimental|Crossover Sequence A: Placebo, then Lacosamide 200 mg, then Lacosamide 100 mg|Participants receive a single dose of Placebo in ADP Session 1. After a 1 week washout period, they undergo ADP Session 2 in which they receive a single dose of Lacosamide 200 mg. After another 1 week washout period, they undergo ADP Session 3 in which they receive a single dose of Lacosamide 100 mg.
88917488|NCT01637753|Experimental|Carmustine Sustained Release Implant|
88917489|NCT01637753|Sham Comparator|Surgical control group|
88917490|NCT01637766|Experimental|Selective intra-arterial chemotherapy|Subjects recruited to this study will receive intra-arterial injections of chemotherapy (melphalan) in the branches of the arteries feeding the metastatic spinal tumor. Subjects will receive general anesthesia or conscious sedation. A catheter will be guided using X-ray from the femoral artery at the top of the leg to the arteries of the spine. A dye will be injected through the catheter to show the arteries in greater detail. The chemotherapy is then injected into the tumor. We will inject the maximum systemic dose adjusted to white blood count and platelet count. Subjects will undergo three cycles of chemotherapy three to six weeks apart.
88917491|NCT01637779|Experimental|fact sheet review|mothers will review a fact sheet containing information about pain management during immunization then complete a knowledge test afterward
88917492|NCT01637779|Placebo Comparator|control unrelated material|mothers will review material unrelated to pain management during immunization then complete a knowledge test
88917493|NCT01637779|Experimental|pre-test, review of fact sheet|mothers do a pre-test, then read a fact sheet about how to manage immunization pain, then repeat the test
88917494|NCT01637779|Placebo Comparator|pre-test, control unrelated information|mothers do a pre-test, then read unrelated material, then repeat the test
88917495|NCT01637792|Experimental|Three 2-liter exchanges group|A group of randomly assigned patients undergoing three 2-liter exchanges daily CAPD.
88917496|NCT01637792|Active Comparator|Four 2-liter exchanges group|A group of randomly assigned patients undergoing four 2-liter exchanges daily CAPD.
88917497|NCT01637805|Experimental|AAV-DC-CTL|
88917498|NCT01637818|Other|Lichtenstein's Operation|
88917499|NCT01637818|Other|Mesh Plug Repair|
88917500|NCT01637831|Experimental|Patients with OSA and IPF|Participants with Obstructive Sleep Apnea (OSA)and Idiopathic Pulmonary Fibrosis (IPF).This arm will complete pre-treatment questionnaires assessing sleep and quality of life, undergo six months of Continuous Positive Airway Pressure (CPAP) to treat OSA, and complete post-treatment the same questionnaires 1, 3 and 6 months later.
88917501|NCT01637844|Experimental|Telbivudine|HBsAg- and HBeAg-positive pregnant women at 28-32 weeks of gestation start to orally take telbivudine (600 mg/day) until 4 weeks after delivery. Newborn infants receive standard immunoprophylaxis.
88917502|NCT01637844|No Intervention|Control|Infants of HBsAg- and HBeAg-positive women who are not treated with telbivudine and any other antiviral agents serve as controls. The infants are administered standard immunoprophylaxis against mother-to-infant transmission of HBV, 100-200 IU hepatitis B immunoglobulin (HBIG) within 12 hours after birth and three doses hepatitis B vaccine at 0, 1 and 6-month schedule.
88917503|NCT01637857|Sham Comparator|lifestyle counseling|Group of patients treated with sham oligoantigenic diet
88917504|NCT01637857|Experimental|oligoantigenic diet|Treatment with oligoantigenic diat
88917505|NCT01637883|No Intervention|nothing|nothing will be dripped on the cuff of the endotracheal tube in the control group
88917506|NCT01637883|Experimental|benzydamine HCl|benzydamine HCl will be dripped on the cuff of the endotracheal tube 5 minutes before induction of general anesthesia
88917507|NCT01637896|Experimental|DEB+BMS|drug-eluting balloon predilation and bare metal stent implantation
88917508|NCT01637896|Active Comparator|POBA+DES|conventional balloon predilation and drug-eluting stent implantation
88917509|NCT01637909|Active Comparator|general management|
88917510|NCT01637909|Experimental|The treatment group1|Korean DASH diet with sodium reduction intervention
88917511|NCT01637909|Experimental|The treatment group2|Korean DASH diet with sodium reduction intervention and excersize intervention
88917512|NCT01637948|Active Comparator|Listerine|essential oil mouthrinse
88917513|NCT01637948|No Intervention|Negative control|without intervention
88917514|NCT01637948|Experimental|Chinese medicine mouthrinse|5% Fructus Mume extract and 2% sodium bicarbonate
88917515|NCT01637974|Experimental|with INTERCOAT|injection of intercoat into the euterine cavity at the end of hysteroscopy
88917516|NCT01637974|No Intervention|without INTERCOAT|without INTERCOAT
88917517|NCT01638026|Experimental|Gnrh agonist , hcg|Gnrh agonist for final oocyte maturation, hcg for luteal support
88917518|NCT01638039|Active Comparator|Diarrheal disease|
88917519|NCT01638039|Active Comparator|Control|Samples of stool, blood, urine saliva
88917520|NCT01638065||Standard|Standard IV Access without device
88917521|NCT01638065||VeinViewer|IV access with VeinViewer device
88917522|NCT01638078|Active Comparator|Thalidomide|Thalidomide
88917523|NCT01638078|Placebo Comparator|Placebo|Placebo
88917524|NCT01638091|Experimental|All participating endoscopists|All endoscopists will undergo ex vivo training and will participate in in vivo practice-based learning.
89435825|NCT05669482|Experimental|Gemcitabine + nab-paclitaxel + avutometinib (VS-6766) + defactinib|To determine the recommended phase 2 dose (RP2D) for gemcitabine Gemcitabine + nab-paclitaxel + avutometinib (VS-6766) + defactinib in patients with untreated metastatic PDAC.
89530910|NCT03344393|Active Comparator|normal saline|intravenous normal saline infusion in the intraoperative period
89435826|NCT05669482|Experimental|Gemcitabine + nab-paclitaxel + avutometinib (VS-6766) + defactinib RP2D|To determine the efficacy of the RP2D identified in Part A in untreated metastatic PDAC patients
89435827|NCT05668091|Experimental|Nirmatrelvir / Ritonavir|Participants receive nirmatrelvir plus ritonavir (Paxlovid) for 15 days. All 3 tablets (2 of nirmatrelvir and 1 of ritonavir) must be taken twice daily by mouth for 15 days.
89435828|NCT05668091|Placebo Comparator|Placebo / Ritonavir|Participants receive placebo to match nirmatrelvir plus ritonavir for 15 days. The control formulation includes 2 placebo tablets and 1 ritonavir tablet.
89435829|NCT05667792|Experimental|Study Group- 4-11 age|
89435830|NCT05667792|Placebo Comparator|Control Group-4-11 age|
89435831|NCT05667792|Experimental|Study Group- 12-18 age|
89435832|NCT05667792|Placebo Comparator|Control Group-12-18 age|
89435833|NCT05666518||vericiguat arm|Japanese patients with a diagnosis of chronic heart failure who received standard treatment and will start vericiguat therapy for chronic heart failure.
89435834|NCT05666518||control arm|Japanese patients a diagnosis of chronic heart failure who received standard treatment and will continue standard of care treatment for chronic heart failure.
89435835|NCT05664334|Experimental|IVX-A12 Vaccine - Low Dosage Level|Participants will receive IVX-A12 vaccine (bivalent combination formulation containing IVX-121 and IVX-241 virus-like particles [VLPs]), administered intramuscularly (IM) once on Day 0.
88917525|NCT01638104|Experimental|ANX-042: 0.001 mcg/kg/min (with low sodium diet)|0.001 dose unit equal to 1 millionth of a gram of an ANX-042 preparation / 1 kilogram of body mass administered / unit of time equal to 1 minute(mcg/kg/min), w/ diet restricted to 2.5 grams (gm) per day sodium (Na+) and 2.1 liters (L) fluid total daily intake
88917526|NCT01638104|Experimental|ANX-042: 0.001 mcg/kg/min|0.001 mcg/kg/min ANX-042 with diet restricted to 4 gm per day Na+ and 3.6 L fluid total daily intake
88917527|NCT01638104|Experimental|ANX-042: 0.003 mcg/kg/min (low sodium diet)|0.003 mcg/kg/min ANX-042 with diet restricted to 2.5 gm per day Na+ and 2.1 L fluid total daily intake
88917528|NCT01638104|Experimental|ANX-042: 0.003 mcg/kg/min|0.003 mcg/kg/min ANX-042 with diet restricted to 4 gm per day Na+ and 3.6 L fluid total daily intake
88917529|NCT01638104|Experimental|ANX-042: 0.0065 mcg/kg/min (low sodium diet)|0.0065 mcg/kg/min ANX-042 with diet restricted to 2.5 gm per day Na+ and 2.1 L fluid total daily intake
88917530|NCT01638104|Experimental|ANX-042: 0.01 mcg/kg/min (low sodium diet)|0.01 mcg/kg/min ANX-042 with diet restricted to 2.5 gm per day Na+ and 2.1 L fluid total daily intake
89435836|NCT05664334|Experimental|IVX-A12 Vaccine + MF59® - Low Dosage Level|Participants will receive IVX-A12 vaccine (bivalent combination formulation containing IVX-121 and IVX-241 VLPs), administered IM once on Day 0.
88917531|NCT01638104|Experimental|ANX-042: 0.01 mcg/kg/min|0.01 mcg/kg/min ANX-042 with diet restricted to 4 gm per day Na+ and 3.6 L fluid total daily intake
88917532|NCT01638104|Experimental|ANX-042: 0.03 mcg/kg/min|0.03 mcg/kg/min ANX-042 with diet restricted to 4 gm per day Na+ and 3.6 L fluid total daily intake
88917533|NCT01638104|Experimental|ANX-042: 0.1 mcg/kg/min|0.1 mcg/kg/min ANX-042 with diet restricted to 4 gm per day Na+ and 3.6 L fluid total daily intake
88917534|NCT01638104|Experimental|ANX-042: 0.3 mcg/kg/min|0.3 mcg/kg/min ANX-042 with diet restricted to 4 gm per day Na+ and 3.6 L fluid total daily intake
88917535|NCT01638104|Placebo Comparator|Placebo (low sodium diet)|Placebo and diet restricted to 2.5 gm per day Na+ and 2.1 L fluid total daily intake
89435837|NCT05664334|Experimental|IVX-A12 Vaccine - Medium Dosage Level|Participants will receive IVX-A12 vaccine (bivalent combination formulation containing IVX-121 and IVX-241 VLPs), administered IM once on Day 0.
89435838|NCT05664334|Experimental|IVX-A12 Vaccine + MF59® - Medium Dosage Level|Participants will receive IVX-A12 vaccine (bivalent combination formulation containing IVX-121 and IVX-241 VLPs), administered IM once on Day 0.
89435839|NCT05664334|Experimental|IVX-A12 Vaccine - High Dosage Level|Participants will receive IVX-A12 vaccine (bivalent combination formulation containing IVX-121 and IVX-241 VLPs), administered IM once on Day 0.
89435840|NCT05664334|Placebo Comparator|Placebo|Participants will receive placebo, administered IM once on Day 0.
89435841|NCT05663827|Experimental|Ruxolitinib add-on group|Once diagnosed with steroid-refractory GVHD, after discussion with family, as per their willing, Ruxolitinib will be administered as add-on therapy. Its dose depends on participants' age and body weight. Usually a dosage of 5mg once per day will be applied as initiation and titrated in accordance with clinical response.
89435842|NCT05660967|Experimental|Epcoritamab monotherapy|
89435843|NCT05660967|Experimental|Epcoritamab in combination with lenalidomide|
89435844|NCT05660746|Active Comparator|Conventional dosing|Induction Phase: 5-7.5 mg/kg at 0, 2, and 6 weeks. Maintenance Phase : 5-10 mg/kg at every 4-8 weeks based on results of drug concentration monitoring for a flat target of 5-10 μg/mL.
89536890|NCT05280431|Experimental|Experimental Group (AGREE)|15 sessions, 3 sessions per week. Each session consists of 45 minutes of training with the AGREE exoskeleton. The training session is customized to the patient's needs and can be adapted to his/her improvement during the intervention.
89435845|NCT05660746|Experimental|Precision dosing|Induction: 5-12.5 mg/kg at 0, 2, and 6 weeks to target a week6 concentration of 18-24 μg/mL with dosing support provided by the RoadMABTM clinical decision support tool. Maintenance: 5-15 mg/kg every 4-8 weeks to achieve apriori pharmacokinetic and pharmacodynamic targets (CRP, disease activity scores and fecal calprotectin) with dosing support provided by the RoadMABTM clinical decision support tool.
89435846|NCT05651126|Experimental|Placebo, Psilocybin_2, Psilocybin_5|Dose order: Placebo, Psilocybin 2mg, Psilocybin 5mg
89435847|NCT05651126|Experimental|Psilocybin_2, Placebo, Psilocybin_5|Dose order: Psilocybin 2mg, Placebo, Psilocybin 5mg
89435848|NCT05651126|Experimental|Psilocybin_2, Psilocybin_5, Placebo|Dose order: Psilocybin 2mg, Psilocybin 5mg, Placebo
89435849|NCT05648110|Experimental|Parent study Sentinel Safety Cohort - Subcohort 1a Gluteal - AZD5156|The Sentinel Safety Cohort of the Parent Study will enroll 56 healthy adults, 18 to 55 years of age, who will be randomized to receive AZD5156 (40 participants) or placebo (16 participants). Participants will be randomized to receive study intervention IM either in the gluteal or the anterolateral thigh. Dosing within the Sentinel Safety Cohort will be staggered, with participants allocated sequentially to 4 subcohorts (1a, 1b, 2a, and 2b).
89435850|NCT05648110|Placebo Comparator|Parent study Sentinel Safety Cohort - Subcohort 1a Gluteal - Placebo|The Sentinel Safety Cohort of the Parent study will enroll 56 healthy adults, 18 to 55 years of age, who will be randomized to receive AZD5156 (40 participants) or placebo (16 participants). Participants will be randomized to receive study intervention IM either in the gluteal or the anterolateral thigh. Dosing within the Sentinel Safety Cohort will be staggered, with participants allocated sequentially to 4 subcohorts (1a, 1b, 2a, and 2b).
88917536|NCT01638104|Placebo Comparator|Placebo|Placebo and diet restricted to 4 gm per day Na+ and 3.6 L fluid total daily intake
88917537|NCT01638117|Placebo Comparator|PAC14028-Vehicle|PAC-14028 Cream Vehicle
89435851|NCT05648110|Experimental|Parent study Sentinel Safety Cohort - Subcohort 1b Thigh - AZD5156|The Sentinel Safety Cohort of the Parent study will enroll 56 healthy adults, 18 to 55 years of age, who will be randomized to receive AZD5156 (40 participants) or placebo (16 participants). Participants will be randomized to receive study intervention IM either in the gluteal or the anterolateral thigh. Dosing within the Sentinel Safety Cohort will be staggered, with participants allocated sequentially to 4 subcohorts (1a, 1b, 2a, and 2b).
89530911|NCT04498793|Experimental|PD-1 group|"Participants receive tislelizumab every 3 weeks (Q3W) + nab-paclitaxel weekly x 4 cycles, followed by tislelizumab Q3W + (doxorubicin OR epirubicin) + cyclophosphamide Q3W x 4 cycles as neoadjuvant therapy prior to surgery; followed by 14 cycles of tislelizumab Q3W plus capecitabine (TNBC subtype) or endocrine therapy (Luminal subtype) as adjuvant therapy post-surgery.~Each cycle is 21 days."
89536439|NCT02449369|Experimental|IVAM|Preop acetaminophen IV 1000 mg, Preop orphenadrine IV 60 mg, Postop acetaminophen IV 1000 mg every 6 hours for 7 doses, Postop orphenadrine IV 60 mg every 12 hours for 3 doses, Postop oral oxycodone 5 mg 1 to 2 tabs every 4 hours PRN, Postop hydromorphone IV 0.5 mg every 4 hours PRN
88917538|NCT01638117|Experimental|PAC14028-0.1|PAC-14028 Cream 0.1%
88917539|NCT01638117|Experimental|PAC14028-0.3|PAC-14028 Cream 0.3%
88917540|NCT01638117|Experimental|PAC14028-1.0|PAC-14028 Cream 1%
88917541|NCT01638117|Placebo Comparator|Placebo|Saline
88917542|NCT01638117|Active Comparator|Positive control|Sodium Lauryl Sulfate, 0.5%
88917543|NCT01638143|Active Comparator|Gnosis P-1000 capsules|MK-7 capsules containing 75 µg of MK-7 (source: Gnosis, Italy).
88917544|NCT01638143|Active Comparator|Gnosis M1500 capsules|MK-7 capsules containing 75 µg of MK-7 (source Gnosis, Italy).
88917545|NCT01638143|Active Comparator|MenaQ7 M-1500 capsules|MK-7 capsules containing 75 µg of MK-7 (source: Nattopharma, Norway)
88917546|NCT01638169||20 children with DMD|
88917547|NCT01638182|Active Comparator|vitamin K1 capsules|27 participants received for three months 1 vitamin K1-capsule per day containing 52 µg of K1
88917548|NCT01638182|Active Comparator|Vitamin K2-capsules|27 participants received for three months 1 vitamin K2-capsule per day containing 75 µg of MK-7.
88917549|NCT01638182|Placebo Comparator|Placebo capsules|27 participants received for 3 months 1 placebo capsule per day
88917550|NCT01638195|Experimental|Externally Focused Ultrasound|
88917551|NCT01638208|Experimental|VSL#3|Patients with IBS-D as per ROME III
88917552|NCT01638208|No Intervention|Healthy Controls|Healthy controls
88917553|NCT01638221||heavy weight mesh|Surgipro mesh is a heavier weighted mesh with less flexibility after surgery
88917554|NCT01638221||light weight mesh|UltraPro mesh is a lighter weighted mesh with theoretically less stiffness and more flexibility compared to heavier weighted meshes
88917555|NCT01638234|Placebo Comparator|Starch pill|
88917556|NCT01638234|Experimental|Melatonin|
88917557|NCT01638247|Active Comparator|Tamoxifen|Tamoxifen alone (daily).
88917558|NCT01638247|Experimental|Tamoxifen and GnRH analogue|Tamoxifen (daily) + GnRH analogue (at randomisation and after three months).
88917559|NCT01638247|Experimental|Exemestane and GnRH analogue|Exemestane (daily) + GnRH analogue (at randomisation and after three months).
88917560|NCT01638260|Placebo Comparator|Liraglutide|Subjects will inject liraglutide once daily for 26 weeks
88917561|NCT01638260|Active Comparator|Liraglutide and NEAT|Subjects will inject liraglutide once daily and combine this treatment with activating lifestyle, by increasing NEAT.
88917562|NCT01638273|Experimental|GLA5PR GLARS tablet 150mg(mealed)|Pregabalin 150mg
89198405|NCT03897348|Experimental|Crossover Sequence B: Lacosamide 200 mg, then Lacosamide 100 mg, then Placebo|Participants receive a single dose of Lacosamide 200 mg in ADP Session 1. After a 1 week washout period, they undergo ADP Session 2 in which they receive a single dose of Lacosamide 100 mg. After another 1 week washout period, they undergo ADP Session 3 in which they receive a single dose of Placebo.
88917563|NCT01638273|Active Comparator|Lyrica Capsule 75mg(mealed)|Pregabalin 75mg
88917564|NCT01638286||Eperisone|
88917565|NCT01638286||Aceclofenac|
89435852|NCT05648110|Placebo Comparator|Parent study Sentinel Safety Cohort - Subcohort 1b Thigh - Placebo|The Sentinel Safety Cohort of the Parent study will enroll 56 healthy adults, 18 to 55 years of age, who will be randomized to receive AZD5156 (40 participants) or placebo (16 participants). Participants will be randomized to receive study intervention IM either in the gluteal or the anterolateral thigh. Dosing within the Sentinel Safety Cohort will be staggered, with participants allocated sequentially to 4 subcohorts (1a, 1b, 2a, and 2b).
89010347|NCT04547218||Elderly patients|"Above 65 year old patients undergoing elective surgery Inclusion criteria I. Geriatric patients ( age more than 65 y/o) II. All elective surgeries under GA~Exclusion criteria I. Refuse to participate in the study II. Patients with cognitive disorders such as dementia and Alzheimer's disease"
89010348|NCT02214511||MDD patients|emotional facial stimuli cyberball game
89435853|NCT05648110|Experimental|Parent study Sentinel Safety Cohort - Subcohort 2a Gluteal- AZD5156|The Sentinel Safety Cohort of the Parent study will enroll 56 healthy adults, 18 to 55 years of age, who will be randomized to receive AZD5156 (40 participants) or placebo (16 participants). Participants will be randomized to receive study intervention IM either in the gluteal or the anterolateral thigh. Dosing within the Sentinel Safety Cohort will be staggered, with participants allocated sequentially to 4 subcohorts (1a, 1b, 2a, and 2b).
89010349|NCT02214511||healthy subjects|emotional facial stimuli cyberball game
89010350|NCT02214589|Active Comparator|Oral glucose and NNS|Oral glucose and NNS
89010351|NCT02214589|Active Comparator|Oral glucose and facilitated tucking and NNS|Oral glucose, facilitated tucking and NNS
89010352|NCT02214589|Active Comparator|Facilitated Tucking and NNS|Facilitated tucking and NNS
89010353|NCT04546984|Experimental|Single dose of HEC96719 （Part 1，Fed/Fasting）|Following an overnight fast of at least 10 hours, a single dose of HEC96719 will be administered on 2 separate occasions (fasting and after meal) in a randomized crossover fashion with different food restrictions.
89010354|NCT04546984|Experimental|Mulltiple doses HEC96719（ Part 2, Cohort 1）|Healthy subjects receive multiple doses of HEC96719 or matching placebo
89010355|NCT04546984|Experimental|Mulltiple doses HEC96719（ Part 2, Cohort 2）|Healthy subjects receive multiple doses of HEC96719 or matching placebo
89010356|NCT04546984|Experimental|Mulltiple doses HEC96719（ Part 2, Cohort 3）|Healthy subjects receive multiple doses of HEC96719 or matching placebo
89435854|NCT05648110|Placebo Comparator|Parent study Sentinel Safety Cohort - Subcohort 2a Gluteal - Placebo|The Sentinel Safety Cohort of the Parent study will enroll 56 healthy adults, 18 to 55 years of age, who will be randomized to receive AZD5156 (40 participants) or placebo (16 participants). Participants will be randomized to receive study intervention IM either in the gluteal or the anterolateral thigh. Dosing within the Sentinel Safety Cohort will be staggered, with participants allocated sequentially to 4 subcohorts (1a, 1b, 2a, and 2b).
89530912|NCT04498793|Active Comparator|Control group|"Participants receive nab-paclitaxel weekly x 4 cycles followed by (doxorubicin OR epirubicin) + cyclophosphamide Q3W x 4 cycles as neoadjuvant therapy prior to surgery; followed by capecitabine (TNBC subtype) or endocrine therapy (Luminal subtype) as adjuvant therapy post-surgery.~Each cycle is 21 days."
88917566|NCT01638286||Eperisone hydrochloride, Aceclofenac|
88917567|NCT01638299|Experimental|Hypo-Hyper Minimizer (HHM) System|
88917568|NCT01638325|Active Comparator|Insulin Lispro|15 international units (IU) insulin lispro administered once subcutaneously (SC) during 1 of 3 dosing periods. There is a minimum 7 day washout between dosing periods.
88917569|NCT01638325|Experimental|BC106 Insulin Lispro|15 up to 30 IU BC106 insulin lispro administered once SC during 2 of 3 dosing periods. There is a minimum 7 day washout between dosing periods.
88917570|NCT01638338|Experimental|Web site|"A specific web site for randomization and risky alcohol consumption counseling will be beta tested and created. Risky drinkers allocated to this arm will receive web assisted brief motivational interview.~They will first be assessed towards risky alcohol consumption and Quality of life (AUDIT and EQ5D). Personal health status will also be assessed with a Likert scale. Brief Intervention will be administered following a consistent number of web pages reporting brief motivational interview Web assisted brief motivational interview on risky drinking"
88917571|NCT01638338|Experimental|Face to Face|Risky drinking brief motivational interview provided by the GP.
88917572|NCT01638351|Active Comparator|Usual care|Participants in this arm will receive a brochure specific for type 2 diabetes mellitus about the general principles of exercise, nutrition, and diet. They are asked to maintain their activity level.
88917573|NCT01638351|Experimental|Resistance exercise|Progressive resistance training, 3 times a week for 12 weeks
88917574|NCT01638364|Active Comparator|alcoholic beverage|95% USP alcohol given at a dose of 1.5 g/l of body water mixed with orange juice and tonic water.
88917575|NCT01638364|Placebo Comparator|non-alcoholic beverage|Orange juice and tonic water.
88917576|NCT01638377|Experimental|Naltrexone|Drug: Naltrexone 50 mg/day for 24 weeks.All participants will receive medical intervention in the form of medical management (MM) which will be delovered by a trained health care professional.
88917577|NCT01638377|Placebo Comparator|Control|Drug: Control Placebo (Lactose Monohydrate) for 24 weeks. All participants will receive medical intervention in the form of medical management (MM) which will be delivered by a trained health care professional.
88917578|NCT01638403|Experimental|BF2.649|BF2.649 (pitolisant) is a novel, highly potent, selective, orally active histamine H3 receptor antagonist/inverse agonist (Ki of 0.3 nM) at the human receptor.
88917579|NCT01638403|Active Comparator|Vigil|"Therapeutic indications Narcolepsy with and without cataplexy. Moderate to severe obstructive sleep apnoea syndrome with excessive daytime sleepiness despite adequate CPAP therapy.~Moderate to severe chronic shift work sleep disorder with excessive sleepiness in patients who work rotating night shifts, if other sleep hygiene measures did not lead to a satisfactory improvement."
88917580|NCT01638403|Placebo Comparator|Placebo|
88917581|NCT01638455|Experimental|Test Group|All subjects will be enrolled in the test group and will receive the noninvasive device
88917582|NCT01638520|Experimental|Pascolizumab|The dose of study medication will be calculated using the patient's body weight and the appropriate dosing regimen based on the cohort of enrollment. The medication will be administered by slow intravenous infusion over 1 hour under close medical supervision.
88917583|NCT01638520|Placebo Comparator|Placebo|For patients randomized to placebo, Sterile 0.9% w/v Sodium Chloride will be used for Injection, using the same volume that would have been prepared if the patient had been randomized to receive pascolizumab.
88917584|NCT01638572||neuroblastoma patients|
88917585|NCT01638585|No Intervention|standard therapy|patients receiving standard therapy for diabetic foot syndrome with critical limb ischemia, i. e. structured therapy of lesions with antibiosis, pressure relief and therapy of risk factors according to the relevant guidelines.
88917586|NCT01638585|Active Comparator|urokinase|patients receiving urokinase short infusions in addition to standard therapy
88917587|NCT01638598|Experimental|BI 1021958 dose group 1|subject to receive a tablet containing dose group 1 BI 1021958 single dose
88917588|NCT01638598|Experimental|BI 1021958 dose group 2|subject to receive a tablet containing dose group 2 BI 1021958 single dose
88917589|NCT01638598|Experimental|BI 1021958 dose group 3|subject to receive a tablet containing dose group 3 BI 1021958 single dose
88917590|NCT01638598|Experimental|BI 1021958 dose group 4|subject to receive a tablet containing dose group 4 BI 1021958 single dose
89530913|NCT03344315|Active Comparator|autologous connective tissue graft|Soft tissue harvesting from patient palate
89530914|NCT03344315|Experimental|collagen matrix|Mucograft collagen matrix manufactured by Geistlich AG, Switzerland Device: Collagen matrix
89530915|NCT02508233||Control|Healthy subjects (without ankle osteoarthritis) for validation of translation
89198406|NCT03897348|Experimental|Crossover Sequence C: Lacosamide 200 mg, then Placebo, then Lacosamide 100 mg|Participants receive a single dose of Lacosamide 200 mg in ADP Session 1. After a 1 week washout period, they undergo ADP Session 2 in which they receive a single dose of Placebo. After another 1 week washout period, they undergo ADP Session 3 in which they receive a single dose of Lacosamide 100 mg.
88917591|NCT01638598|Experimental|BI 1021958 dose group 5|subject to receive a tablet containing dose group 5 BI 1021958 single dose
88917592|NCT01638611|Active Comparator|HIP2B|Six subjects per dosing cohort will receive HIP2B
89435855|NCT05648110|Experimental|Parent study Sentinel Safety Cohort - Subcohort 2b Thigh - AZD5156|The Sentinel Safety Cohort of the Parent study will enroll 56 healthy adults, 18 to 55 years of age, who will be randomized to receive AZD5156 (40 participants) or placebo (16 participants). Participants will be randomized to receive study intervention IM either in the gluteal or the anterolateral thigh. Dosing within the Sentinel Safety Cohort will be staggered, with participants allocated sequentially to 4 subcohorts (1a, 1b, 2a, and 2b).
88917593|NCT01638611|Placebo Comparator|Placebo|Two subjects per dosing cohort will receive placebo.
89198407|NCT03897348|Experimental|Crossover Sequence D: Lacosamide 100 mg, then Lacosamide 200 mg, then Placebo|Participants receives a single dose of Lacosamide 100 mg in ADP Session 1. After a 1 week washout period, they undergo ADP Session 2 in which they receive a single dose of Lacosamide 200 mg. After another 1 week washout period, they undergo ADP Session 3 in which they receive a single dose of Placebo.
89198408|NCT04010734|Active Comparator|peroral Cholangioscopy examination|"Patient with suspected malignant biliary stricture (SMBS) is allowed:~to the peroral Cholangioscopy examination with both visual and tissue diagnosis. The visual diagnosis is based on morphological and vascular patterns (presence or not of nodular or papilary masses, irregularity of the surface, morphology of the vessels and the fragility of mucosa). The tissue diagnosis consists on cytopathological evaluation after tissue sampling using minuature biopsy forceps (SpyBite). During this, 5-8 samples are taken under visual control, from different parts of the lesion."
89198409|NCT04010734|Active Comparator|ERCP examination with sampling|"Patient with suspected malignant biliary stricture (SMBS) is allowed:~to ERCP examination with both sampling by brushing and forceps biopsy, with subsequent pathological evaluation and an additional fluorescence in situ hybridization(FISH) examination of the specimens.~ERCP (Endoscopic retrograde cholangiopancreatography) is the most widely used diagnostic procedure in patients with biliary obstruction. It enables to identify the biliary stricture, to determinate its location and help providing tissue sampling from the stricture for cytological evaluation. Brushing and endocanal forceps biopsies were the most used techniques, both with different specificity and sensitivity. It was demonstrated that Fluorescence in Situ Hybridization (FISH) improved the diagnostic yield of routine cytology. That is the reason why the investigators will combine FISH with the sampling methods to maximize the chance to make early diagnosis of the biliary stenosis."
89198410|NCT00955630|Active Comparator|Monthly injections|3 monthly injections of ranibizumab followed by prn injections
89198411|NCT00955630|Active Comparator|PRN injections|injections of ranibizumab on a prn basis from the start of the study
89198412|NCT00868569|Experimental|1|folfox4 chemotherapy was done within 28 days after primary surgery. Per 3 weeks, patients will receive one cycle. After 3 cycles, patients will received transhepatic arterial chemoembolision (TACE) using oxaliplatin, fudr, mmc and iodine. Then begin folfox4 again.
89198413|NCT00868569|Active Comparator|2|folfox4 chemotherapy was done within 28 days after primary surgery. Per 3 weeks, patients will receive one cycle. After 3 cycles, patients will received transhepatic arterial chemotherapy (TAC) using oxaliplatin, fudr and mmc. Then begin folfox4 again.
89198414|NCT00549562|Other|Paliperidone ER|8-Week Open-Label
89198415|NCT00860925|Experimental|active clonidine and active ASA|
89198416|NCT00860925|Experimental|active clonidine and ASA placebo|
89435856|NCT05648110|Placebo Comparator|Parent study Sentinel Safety Cohort - Subcohort 2b Thigh - Placebo|The Sentinel Safety Cohort of the Parent study will enroll 56 healthy adults, 18 to 55 years of age, who will be randomized to receive AZD5156 (40 participants) or placebo (16 participants). Participants will be randomized to receive study intervention IM either in the gluteal or the anterolateral thigh. Dosing within the Sentinel Safety Cohort will be staggered, with participants allocated sequentially to 4 subcohorts (1a, 1b, 2a, and 2b).
89530916|NCT02508233||ankle OA|Ankle osteoarthritis patients to ensure validity of translated scale
89530917|NCT02507999|Experimental|Goal Directed Therapy - Flotrac Use Arm|This arm will employ the use of the Flotrac device to monitor cardiac output, cardiac index, stroke volume, stroke volume variation, and blood pressure management.
89530918|NCT02507999|No Intervention|Non-Goal Directed Therapy|In this arm, patients will have the Flotrac machine attached to their arterial catheter but the screen that displays the monitor readings will be covered and machine alarms will be turned off. The anesthesiologist will not be aware of the Flotrac monitor readings.
88917594|NCT01638624|Active Comparator|Propofol|Propofol infusion group: Under spinal anesthesia, a continuous intravenous infusion (2mg/kg/h) of propofol will be use during the operation
88917595|NCT01638624|Placebo Comparator|Control group|Placebo group: Under spinal anesthesia, a continuous intravenous infusion of volume-equivalent placebo will use during the operation
88917596|NCT01638637||Specimen Collection|
88917597|NCT01638650|Experimental|Single Arm|
88917598|NCT01638663|Active Comparator|Tolvaptan|Oral administration of 15 mg Tolvaptan on each examination day.
88917599|NCT01638663|Placebo Comparator|Placebo|Oral administration of 15 mg Unikalk tablet on each examination day.
88917600|NCT01638676|Experimental|Vemurafenib and Metformin|
88917601|NCT01638702|Active Comparator|Right sided PICC placement|Insertion of PICC on the right arm
88917602|NCT01638702|Placebo Comparator|Left sided arm placement|Insertion of PICC on the left arm
88917603|NCT01638715|Experimental|Infliximab|Infliximab (Remicade®) will be administered i.v.at a dose of 3 mg/kg at 0 and 2 weeks, and 5 mg/kg at weeks 6, 14, and 22, 30, 38, and 46.
88917604|NCT01638715|Experimental|Abatacept|Abatacept (Orencia®) will be given i.v. at weeks 0, 2, 4, and then every 4 weeks until week 48 at a weight adjusted dose: <60 kg Body weight (BW): 500 mg; >60-100 kg BW: 750 mg; alternatively, based on preference and shared decision between patient and physician, patients randomized to the abatacept arm may receive s.c.application at a dose of 125mg weekly.
88917605|NCT01638715|Experimental|Tocilizumab|Tocilizumab (Ro-Actemra®) will be administered every 4 weeks at a dose of 8 mg/kg BW (maximum dose of 800 mg); The employed dosage will be calculated using manufacturer guidelines; alternatively, based on preference and shared decision between patient and physician, patients randomized to the tocilizumab arm may receive s.c. application at a dose of 162mg every week.
88917606|NCT01638715|Experimental|Rituximab|Rituximab (Mabthera®) will be given as 1000mg at weeks 0 and 2, and then repeated at weeks 24 and 26. Patients will receive 100 mg methylprednisolon i.v. before each infusion, as well as 1000mg paracetamol, as well as 50mg diphenhydramine hydrochloride (Dibondrin©).
88917607|NCT01638728||Endotracheal tube|
88917608|NCT01638767|Experimental|NuvaRing|Patients in the NuvaRing group will be inserting the vaginal ring for a period specified by the administrative nurse, ranging from 14 to 35 days.
88917609|NCT01638767|Active Comparator|Marvelon|Patients on Marvelon will be taking the medication for a period ranging from 14 to 21 days. This period will be determined by the administrative nurse.
88917610|NCT01638780|Placebo Comparator|placebo|A placebo will be given for 30 days, twice daily. One pill will be provided with lunch and the other pill will be provided with dinner.
88917611|NCT01638780|Active Comparator|resveratrol|resveratrol will be given for 30 days, twice daily. One pill, which contains 75 mg of resveratrol, will be provided with lunch, and the other pill of 75 mg will be provided with dinner. So in total 150 mg/day of resveratrol will be given.
88917612|NCT01638793|Experimental|Capnography|Capnographic respiration monitoring
88917613|NCT01638793|Active Comparator|Pulse-Oxymetry|pulse-oxymetric respiration monitoring
89435857|NCT05648110|Experimental|Parent study Main Cohort - AZD3152|The Main Cohort of the Parent study will enroll approximately 3200 participants. Dosing in the Main Cohort will be staggered, so that it starts with adult participants aged 18 years and older, with no adolescent participants dosed in the Main Cohort until safety data from Visit 2a (Day 8) and Visit 2b (Day 15) have been reviewed by the DSMB for at least 80 adult Main Cohort participants (which will include at least 40 participants who have received AZD3152). Participants in the Main Cohort will be randomized 1:1 to receive AZD3152 300 mg or comparator administered IM in the anterolateral thigh on Day 1. Participants will receive a second dose of their original randomized study intervention (ie, active treatment or comparator) 6 months after Visit 1.
89435858|NCT05648110|Active Comparator|Parent study Main Cohort - EVUSHELD™|"Participants in the Main Cohort of the Parent study will be randomized 1:1 to receive AZD3152 300 mg or comparator administered IM in the anterolateral thigh on Day 1. Participants will receive a second dose of their original randomized study intervention (ie, active treatment or comparator) 6 months after Visit 1.~At the request of regulatory authorities the active comparator will be changed to placebo. As the comparator is given on two occasions, this means that a participant randomized to the comparator arm may receive (a) two doses of EVUSHELD, (b) a dose of EVUSHELD and a dose of placebo, or (c) two doses of placebo."
89435859|NCT05648110|Placebo Comparator|Parent study Main Cohort - Placebo|"Participants in the Main Cohort of the Parent study will be randomized 1:1 to receive AZD3152 300 mg or comparator administered IM in the anterolateral thigh on Day 1. Participants will receive a second dose of their original randomized study intervention (ie, active treatment or comparator) 6 months after Visit 1.~At the request of regulatory authorities the active comparator will be changed to placebo. As the comparator is given on two occasions, this means that a participant randomized to the comparator arm may receive (a) two doses of EVUSHELD, (b) a dose of EVUSHELD and a dose of placebo, or (c) two doses of placebo."
89198417|NCT00860925|Experimental|Clonidine placebo and active ASA|
89435860|NCT05648110|Experimental|Sub-study - AZD3152|This sub-study will enroll approximately 450 participants, ≥ 18 years of age with a minimum weight of 40 kg. An initial Sentinel Safety Cohort will include 12 healthy volunteers; all other participants in the study will be either immunocompromised or immunocompetent (including healthy participants) with all degrees of SARS-CoV-2 infection risk.
88917614|NCT01638806|Experimental|Group I: PPCI|Patients are treated with Aspirin, ADP-blocker and heparin and field-triaged or transferred immediately to an invasive center for PPCI
88917615|NCT01638806|No Intervention|Conventional: Group II|Patients are treated as today: Admission to local hospital, Low-molecular-weight heparin (LMWH), Aspirin, ADP-blocker and within 72 hours transfer for angiography/angioplasty. Patients with a Grace score > 140 will be transferred for angiography/angioplasty within 24 hours. Patients with refractory angina, severe heart failure, life-threatening ventricular arrhythmias or haemodynamic instability will be transferred acutely for angiography/angioplasty according to the european guidelines.
88917616|NCT01638845|Active Comparator|continuous perineural catheter|
88917617|NCT01638845|No Intervention|Control|
88917618|NCT01638858|Experimental|Lucentis (Ranibizumab)|
88917619|NCT01638871|Experimental|Intervention Group|Study arm will complete the 8-week Internet-based pain coping skills program.
88917620|NCT01638871|No Intervention|Control Group|This study arm will only provide demographic and pain-related information.
88917621|NCT01638884|Experimental|Young Healthy Subjects|
88917622|NCT01638884|Experimental|Middle age Healthy Subjects|
89435861|NCT05648110|Active Comparator|Sub-study - AZD7442 (EVUSHELD™)|This sub-study will enroll approximately 450 participants, ≥ 18 years of age with a minimum weight of 40 kg. An initial Sentinel Safety Cohort will include 12 healthy volunteers; all other participants in the study will be either immunocompromised or immunocompetent (including healthy participants) with all degrees of SARS-CoV-2 infection risk.
88917623|NCT01638884|Experimental|Elderly Healthy Subjects|
88917624|NCT01638884|Experimental|Mild Cognitive Impairment patients|
88917625|NCT01638884|Experimental|Alzheimer Disease patients|
89435862|NCT05648110|Experimental|Sub-study - AZD7442 (EVUSHELD™) Immunocompromised participants offered AZD3152 1200mg IV|This sub-study will enroll approximately 450 participants, ≥ 18 years of age with a minimum weight of 40 kg. An initial Sentinel Safety Cohort will include 12 healthy volunteers; all other participants in the study will be either immunocompromised or immunocompetent (including healthy participants) with all degrees of SARS-CoV-2 infection risk.
89435863|NCT05643430|Experimental|BioFreedom Ultra|All patients will receive the BioFreedom Ultra as per treatment.
89198418|NCT00860925|Placebo Comparator|Clonidine placebo and ASA placebo|
89435864|NCT05642312|Experimental|Arm A|Participants will receive 4 low-dose vamikibart intravitreal (IVT) injections every 4 weeks (Q4W) to Week 12, followed by as-needed (PRN) dosing from Week 20 to Week 48.
89435865|NCT05642312|Experimental|Arm B|Participants will receive 4 high-dose vamikibart IVT injections Q4W to Week 12, followed by PRN dosing from Week 20 to Week 48.
88917626|NCT01638910|Experimental|EV/DNG (Qlaira, BAY86-5027)|
88917627|NCT01638923|Experimental|Arm 1|
88917628|NCT01638923|Placebo Comparator|Arm 2|
88917629|NCT01638936|Experimental|BT062|BT062 administered intravenously on days 1, 8 and 15 of each 28-day cycle, and lenalidomide or pomalidomide and dexamethasone administered orally to subjects with relapsed or relapsed/refractory MM
88917630|NCT01638962|Experimental|NEMEX|NEuroMuscular EXercise
88917631|NCT01638962|Active Comparator|PHARMA|PHARMAcological pain relief
88917632|NCT01638975|Experimental|Computerized response inhibition training|Participants in this condition receive 8 computerized training sessions over a 4 week period.
88917633|NCT01638975|No Intervention|Waitlist Control|Participants assigned to this condition wait without an intervention until the second assessment (4 weeks after the baseline assessment).
88917634|NCT01638988|Experimental|Metformin|
88917635|NCT01638988|Active Comparator|Clomiphene Citrate|
88917636|NCT01639014|Experimental|F2695|
88917637|NCT01639014|Placebo Comparator|placebo|
88917638|NCT01639027|Active Comparator|Drotaverine|Women who will receive 40 mg Drotaverine hydrochloride (Do-Spa) IV injection.
88917639|NCT01639027|Placebo Comparator|Placebo|Women who will receive 2ml of normal physiological saline (0.9% sodium chloride) I.V.
88917640|NCT01639066|Experimental|Tenofovir plus Entecavir combination|Tenofovir 300 mg/day orally and Entecavir 1 mg/day orally
88917641|NCT01639066|Active Comparator|Tenofovir monotherapy|Tenofovir 300 mg/day orally
88917642|NCT01639079|No Intervention|Usual Care for Smoking|Usual care for smoking cessation with access to the web site after 6 months
88917643|NCT01639079|Experimental|Internet Smoking Cessation Web Site|"Internet Stop Smoking site (TC5) offers a menu of several intervention elements from which the participants may choose as many as they wish. The links (URLs) to register for the study are:~English: www.stopsmoking.ucsf.edu Spanish: https://www.stopsmoking.ucsf.edu/es/intro/home.aspx"
88917644|NCT01639092|Experimental|Tenofovir monotherapy|Tenofovir 300 mg/day orally
88917645|NCT01639092|Active Comparator|Tenofovir plus Entecavir combination|Tenofovir 300 mg/day orally and Entecavir 1 mg/day orally
89010357|NCT04546984|Experimental|Mulltiple doses HEC96719（ Part 2, Cohort 4）|Healthy subjects receive multiple doses of HEC96719 or matching placebo
89010358|NCT04546984|Experimental|Mulltiple doses HEC96719（ Part 2, Cohort 5）|Healthy subjects receive multiple doses of HEC96719 or matching placebo
89198419|NCT00681564|Experimental|One-Stage Full-Mouth Disinfection|Scaling and root planing, four quadrants in one session Tongue brushing with a 1% chlorhexidine gel (1 minute) Mouth rinsing with a 0.2% chlorhexidine solution for (2 minutes) Subgingival chlorhexidine (1%) irrigation in all pockets Twice daily rinsing with clorhexidine (1 minute) during fourteen days after the periodontal intervention Basic oral hygiene instructions Dental extractions will be performed at the end of patient followup (only in cases of teeth that could not be saved)
89435866|NCT05642312|Sham Comparator|Arm C|Participants will receive 4 sham injections Q4W to Week 12, followed by PRN sham dosing from Week 20 to Week 48.
89435867|NCT05641844|Other|Treatment arm|Subjects will undergo debridement of the fistula tract and suturing of internal opening, followed by a. water leak test. RD2 Ver.02 will be applied to the fistula tract in the operating room.
89435868|NCT05641844|Other|Control arm|Subjects will undergo debridement of the fistula tract and suturing of internal opening, followed by a. water leak test. Saline will be applied to the fistula tract in the operating room.
89435869|NCT05634902|Experimental|Group 1: Pre-CME with Patient Education|"Physicians in hospitals that have not received the DIZZTINCT educational intervention.~Patients have received the DIZZTINCT educational intervention"
89435870|NCT05634902|No Intervention|Group 2: Pre-CME with Standard Patient Care|"Physicians in hospitals that have not received the DIZZTINCT educational intervention.~Patients have not received the DIZZTINCT educational intervention"
88917646|NCT01639170|Experimental|subjects undergoing abdominal surgery|"Subjects who undergone abdominal intervention and reported major symptoms and signs suggestive of gastrointestinal perforation (abdominal pain, leukocytosis, fever) within the third postoperative day.~Exclusion criteria: inability to consent to the study, age ≤18 yr, certain or probable pregnancy, inability to remain in upright position for more than 10 minutes."
88917647|NCT01639183|Experimental|Rotating-oscillating Power Toothbrush|Nursing home residents will be randomly assigned to receive power toothbrushing twice daily by their caregivers using a rotating-oscillating power toothbrush.
88917648|NCT01639183|Active Comparator|Standard Care|This arm comprises the control group where nursing home residents will receive standard daily oral care as usual.
89435871|NCT05634902|No Intervention|Group 3: Pre-CME with Chart Review Only|"Physicians in hospitals that have not received the DIZZTINCT educational intervention.~Eligible patient will have their medical records abstracted to assess the main study outcome"
89435872|NCT05634902|Experimental|Group 4: Post-CME with Patient Education|"Physicians in hospitals that have received the DIZZTINCT educational intervention.~Patients have receive the DIZZTINCT educational intervention"
88917649|NCT01639209|Experimental|Vitrectomy|
88917650|NCT01639209|Experimental|Pneumatic retinopexy|
88917651|NCT01639248|Experimental|ENMD-2076 Treatment|ENMD-2076
88917652|NCT01639274|Other|COPD|
88917653|NCT01639287||Painless|"Painless synovitis group(called cold synovitis)"
88917654|NCT01639287||Painful|Painful synovitis group
88917655|NCT01639300|Experimental|GNbAC1|
88917656|NCT01639300|Placebo Comparator|GNbAC1 placebo|
88917657|NCT01639326|Experimental|Irinotecan high doses|Patients will receive irinotecan dose of 300 mg / m² in patients UGT1A1 * 1 / * 1 and 260 mg / m² in patients UGT1A1 * 1 / * 28 intravenous infusion over 90 minutes and folinic acid at a dose of 400 mg / m² intravenous infusion over 2 hours and 5-FU at a dose of 400 mg / m² intravenous bolus and 5-FU 2400 mg / m² intravenous infusion for 46 hours.
88917658|NCT01639326|Active Comparator|Irinotecan standard doses|Patients will receive irinotecan at a dose of 180 mg / m² intravenous infusion over 90 minutes and folinic acid at a dose of 400 mg / m intravenous infusion over 2 hours and 5-FU at a dose of 400 mg / m² intravenous bolus and 5-FU 2400 mg / m² intravenous infusion for 46 hours
88917659|NCT01639378|Experimental|Renal Denervation|Subjects are treated with renal denervation after randomisation and maintained on heart failure medications
88917660|NCT01639378|No Intervention|Control group|Subject will have a sham procedure and not receive renal denervation. They will continue with the heart failure medications
88917661|NCT01639391|Experimental|patients|
89435873|NCT05634902|Experimental|Group 5: Post-CME with Standard Patient Care|"Physicians in hospitals that have received the DIZZTINCT educational intervention.~Patients have not receive the DIZZTINCT educational intervention"
89435874|NCT05634902|Experimental|Group 6: Post-CME with Chart Review Only|"Physicians in hospitals that have received the DIZZTINCT educational intervention.~Eligible patient will have their medical records abstracted to assess the main study outcome"
89435875|NCT05634811|Experimental|VLA15|Participants will receive 6-valent OspA-based Lyme disease vaccine (VLA15).
89010359|NCT04546789|Experimental|Group 1: Normal Hepatic Function|Healthy participants who have normal hepatic function with sex, age (± 10 years; >= 18 years old and =< 79 years old), and weight (± 10 percent; >= 50 kilogram (kg) and =< 120 kg) matching with the mild and moderate hepatic impairment cohorts will receive single oral dose of M2951 (BTK inhibitor).
89010360|NCT04546789|Experimental|Group 2: Mild Hepatic Impairment|Participants with mild hepatic impairment based on Child-Pugh Class A score of 5 or 6 will receive single oral dose of M2951 (BTK inhibitor).
89010361|NCT04546789|Experimental|Group 3: Moderate Hepatic Impairment|Participants with moderate hepatic impairment based on Child-Pugh Class B score of 7 to 9 will receive single oral dose of M2951 (BTK inhibitor).
89010362|NCT00261690|Experimental|1|Virtual Reality distraction
89010363|NCT04547179|Experimental|BLAfit® usage|In this arm, subjects will used the fixed orthotic device called BLAfit® for one minute of facial exercise a day for three months.
89010364|NCT04547179|Experimental|fremanezumab-vfrm|Subjects in this arm will receive three Ajovy® (fremanezumab-vfrm) injections at the start of month 2. This will be conducted in a double-blind fashion, as both the clinician providing the injection, and the subject, will not know if the injection is actually Ajovy® or just saline.
89010365|NCT04547179|Placebo Comparator|Saline injection|This is a placebo that is used to counter Arm #2- the Ajovy® injections. Subjects in this arm will receive three saline injections at the start of month 2 that will mimic the Ajovy® injections. This will be conducted in a double-blind fashion, as both the clinician providing the injection, and the subject, will not know if the injection is actually Ajovy® or just saline.
89010366|NCT04547101|Experimental|AK104|
89010367|NCT04546906|Experimental|CD22 CAR-T|Patients will be treated with CD22 CAR-T cells
89010368|NCT04546594||Orthopedic surgery|
89010369|NCT04546594||Thoracic surgery|
89010370|NCT04546594||Gynecological surgery|
89010371|NCT04546282||Osimertinib treated patients|Patients with metastatic adenocarcinoma of the lung for whom a 3rd generation TKI therapy is proposed and a search for resistance mutation by blood analysis as part of the usual management.
89010372|NCT04546321||HIE group (I)|All fullterm newborn admitted to the NICU with Hypoxic Ischemic Encephalopathy during the study period
89010373|NCT04546321||TTN group(II)|All fullterm babies with Transient Tachypnea of the Newborn admitted to the NICU during the study period
89010374|NCT04546048|Experimental|Exercise group (EG)|The exercise group (EG) were received an 8-week resistance training program in addition to standard post-transplant physiotherapy follow-up.
89010375|NCT04546048|No Intervention|Control Group (CG)|"The control group (CG) were received only standard physiotherapy program.~The usual post-transplant care consisting of preoperative patient education, respiratory physiotherapy program, active/active assistive exercises of cervical, upper and lower extremities, and early mobilization.~Patients were instructed about the postoperative physiotherapy process including all details within the preoperative education. Respiratory physiotherapy consisted of positioning, lung expansion exercises and bronchial hygiene techniques.~They were allowed to pursue their normal daily activities and mobilized as early as possible when clinically stable."
89010376|NCT04546165|Active Comparator|manipulation group|manipulation plus exercise
89010377|NCT04546165|Active Comparator|myofascial release group|suboccipital inhibition plus exercise
89010378|NCT04546165|Active Comparator|exercise group|only exercise
89010379|NCT04545970|Active Comparator|Anti-aging Serum|"Dosage form: Serum composed of water, thickener, and bioactive ingredients including antioxidants and peptides.~Frequency of Dosage: Two times daily. Subjects are asked to pump 2x and apply on global face morning and evening.~Study Duration: 12 weeks."
89010380|NCT04545970|Placebo Comparator|Placebo Serum|"Dosage form: Serum composed of water and thickener. Frequency of Dosage: Two times daily. Subjects are asked to pump 2x and apply on global face morning and evening.~Study Duration: 12 weeks."
89010381|NCT04545931|Experimental|Posterior tibial nerve stimulation|First arm will undergo posterior tibial nerve stimulation ( one session per week for 12 weeks )
89010382|NCT04545931|Experimental|Desmopressin|Second arm will receive medical treatment (desmopressin 0.2 mg . single evening dose ) for 12 weeks
89010383|NCT00261729|Experimental|1|paroxetine
89010384|NCT00261729|Placebo Comparator|2|placebo
89010385|NCT00261729|Experimental|3|prazosin
89010386|NCT04541836||healthy control|healthy volunteer with no clinically relevant finding on physical examination at screening visit will receive one baseline 18F-PMPBB3 tau PET scan, and another follow up scan 1.5yr later.
89010387|NCT04541836||PSP|"Patients fulfill the criteria of NINDS-SPSP clinical criteria for the diagnosis of PSP as possible or probably PSP will receive one baseline 18F-PMPBB3 tau PET scan, and another follow up scan 1.5yr later."
89010388|NCT04541758|Experimental|surgical treatment|Minimally invasive internal fixation under spontaneous respiratory anesthesia and analgesic treatment and chest strap fixation
89010389|NCT04541758|Experimental|Conservative treatment|analgesic treatment and chest strap fixation
89010390|NCT04541641|Experimental|osteotome group|
89010391|NCT04541641|Experimental|New Reverse Drilling technique|
89198420|NCT00681564|Active Comparator|Periodontal care|Basic oral hygiene instructions Supragingival plaque removal
89198421|NCT00863811||2|POAG patients with IOP under control by prostaglandins eye drops treatment and assuming two tablets per day of the food supplement KRONEK
89435876|NCT05634811|Placebo Comparator|Normal Saline (Placebo)|Participants will receive 0.9% sodium chloride solution for injection
89435877|NCT05634551||Questionnaires (All Participants)|If participants are found to be eligible and agree to take part in the study, information about you (such as age, gender, race, ethnicity, marital status, education, employment status, religious beliefs, and information about your cancer diagnosis and history, current therapy and goal of cancer therapy) will be collected.
89435878|NCT05634551||Interview (Some Participants)|Not every participant will be asked to have an interview. It is expected that about 20-30 participants will take part in the interview part of the study.
89435879|NCT05629286||Intervention Group 1|McConnell taping first and then patella stabilizing brace applied to healty participants and patients with PFPS
89435880|NCT05629286||Intervention Group 2|first patella stabilizing brace and then applied McConnell taping to healty participants and patients with PFPS
88917662|NCT01639404|Experimental|Umbilical Cord Blood and Rehabilitation|Allogeneic Umbilical Cord Blood Administration and Active Rehabilitation
89435881|NCT05629286||No Intervention Group|no intervention to healty participants and patients with PFPS
89435882|NCT05629234|Experimental|Osimertinib|Participants will receive Osimertinib
89435883|NCT05626270|Other|LunulaLaser OTC|The user will be presented with the device in its intended packaging as if receiving it at their place of employment. No additional information, instruction or training will be provided by the Study Observer, or any other individual associated with the study. The user will be left to work out how to operate the Erchonia LunulaLaser™ OTC as independently and naturally as possible without interference or influence from the Study Observer. While the user will have received the instructional information in the packaging as in intended use, he or she will not be instructed to use any of the information. It will be up to the user as to if or how he or she chooses to use that information to set up operation of the device as would occur under actual conditions of intended use.
89435884|NCT05626205|Experimental|Experimental Group|The Experimental Group will receive for 12 weeks a robotic training with Paro robot combined with traditional training.
89435885|NCT05626205|No Intervention|Control Group|The Control Group will receive only the traditional therapy.
88917663|NCT01639430||Geriatric patients ED|Consecutive patients >= 75 years in the emergency department.
88917664|NCT01639456|Experimental|Patients Using CD3-/CD19- NK cell product|Patients receive the apheresis product (collected day -1: enriched for NK cells using the CliniMACS® CD3 and CD19 Reagent System in combination with the large-scale tubing set (Miltenyi Biotec) to simultaneously deplete CD3+ cells to remove T-lymphocytes and deplete CD19+ cells to remove B-lymphocytes (CD3-/CD19- natural killer cells). Patients will also receive Cyclophosphamide, Fludarabine and Aldesleukin.
88917665|NCT01639456|Experimental|Patients Using CD3-/CD56+ purified NK cell product|Patients receive the apheresis product (collected day -1): purified for NK cells using the CliniMACS® CD3 Reagent System (Miltenyi Biotec) in combination with the large-scale tubing set to deplete CD3+ cells and then use the CliniMACS® CD56 Reagent System to enrich CD56+ NK cells (CD3-CD56+ natural killer cells). Patients will also receive Cyclophosphamide, Fludarabine and Aldesleukin.
88917666|NCT01639482||Citalopram|Patients with bipolar disorder
88917667|NCT01639482||Placebo|Patients with bipolar disorder
88917668|NCT01639521|Experimental|Arm A (gemcitabine hydrochloride, cisplatin)|Patients receive cisplatin IV on day 1 and gemcitabine hydrochloride IV over 1 hour on days 1 and 8. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
88917669|NCT01639521|Experimental|Arm B (MVAC)|Patients receive methotrexate IV on day 1 and vinblastine IV, doxorubicin hydrochloride IV, and cisplatin IV on day 2. Treatment repeats every 14 days for 4 courses in the absence of disease progression or unacceptable toxicity.
88917670|NCT01639534||Biomarkers, Carotid Stenting, Blood sample|Subjects requiring Carotid Stenting Procedure at Virginia Commonwealth University/Medical College of Virginia Health Systems
88917671|NCT01639547|Experimental|PEGASYS® plus ROBATROL® for 36 weeks|
88917672|NCT01639547|Active Comparator|PEGASYS® plus ROBATROL® for 48 weeks|
88917673|NCT01639612|Experimental|ALD-451|Autologous bone marrow derived ALD-451 cells administered intravenously following surgery, radiation therapy and temozolomide
88917674|NCT01639625|Experimental|CIGB300|
88917675|NCT01639638|Placebo Comparator|Placebo|
88917676|NCT01639638|Experimental|CIGB-300 - 5 mg|
88917677|NCT01639638|Experimental|CIGB-300 - 15 mg|
88917678|NCT01639651|Active Comparator|Control Group|
88917679|NCT01639651|Experimental|Mobilization Group|
88917680|NCT01639677|Experimental|Laparoscopic gastric bypass|
88917681|NCT01639677|Active Comparator|Laparoscopic VBG|Laparoscopic vertical banded gastroplasty
88917682|NCT01639716||Lymphoma group|
88917683|NCT01639716||healthy group|
89435886|NCT05624112|Experimental|AD patients|AD patients aged ≥12 and ≤ 65
89435887|NCT05624112|No Intervention|Healthy volunteers|Non-treatment healthy volunteers
89435888|NCT05618509|Active Comparator|Patient with STENDO|
89435889|NCT05618509|Placebo Comparator|Patient with placebo|
89435890|NCT05615610|Experimental|spine TENS|The participants will be received eighteen 45-minute sessions of intervention, 3 sessions per week for 6 weeks.
89435891|NCT05615610|Experimental|tVNS|The participants will be received eighteen 45-minute sessions of intervention, 3 sessions per week for 6 weeks.
89435892|NCT05615610|Placebo Comparator|Control|The participants will be received eighteen 45-minute sessions of intervention, 3 sessions per week for 6 weeks.
89435893|NCT05613088|Experimental|MORAb-202|
89435894|NCT05613088|Experimental|Investigator's Choice Chemotherapy|
89435895|NCT05602610||VL patients|VL infected individuals residing in/ with travel history to VL-endemic areas in Northern Ethiopia
89435896|NCT05599295|Experimental|Orbactiv|ORBACTIV is infused at 15mg/kg over 3 hours for all subjects not to exceed a dose of 1200mg.
89435897|NCT05599295|Experimental|Kimyrsa|"KIMYRSA is infused at 15mg/kg over 1 hour for subjects ≥12 years old and weighing >40 kg not to exceed a dose of 1200mg.~KIMYRSA is infused at 15mg/kg over 3 hours in subjects <12 years old or weighing ≤40 kg."
89435898|NCT05599295|Active Comparator|Standard of Care|"The following SoC medications below will be administered via IV infusion, per the package insert, and according to local rules and regulations. SoC medications cannot be used in combination with one another.~Vancomycin~Teicoplanin~Clindamycin~Daptomycin~Semi-synthetic penicillins (e.g., nafcillin, oxacillin, cloxacillin)~Cefazolin~Ceftaroline"
89435899|NCT05597618|No Intervention|No Intervantion Group|"Application Steps of Control Group New Graduated Nurses The control group nurses will be required to fill in the Introductory Information Questionnaire, Empowerment Information Evaluation Questionnaire, Nursing Structural Empowerment Scale, and Psychological Empowerment Scale in the randomization process."
88917684|NCT01639716||IL-10 high|
88917685|NCT01639716||IL-10 low|
88917686|NCT01639716||IL-4 high|
88917687|NCT01639716||IL-4 low|
88917688|NCT01639716||lymphopenia|
88917689|NCT01638494|Experimental|Colecalcium testing|administration of Colecalcium
88917690|NCT01639768|Placebo Comparator|SUBLIVAC FIX Birch 0 AUN/ml|
88917691|NCT01639768|Active Comparator|SUBLIVAC FIX Birch 3,333 AUN/ml|
88917692|NCT01639768|Active Comparator|SUBLIVAC FIX Birch 10,000 AUN/ml|
88917693|NCT01639768|Active Comparator|SUBLIVAC FIX Birch 20,000 AUN/ml|Evaluation of the SUBLIVAC FIX Birch 20,000 AUN/ml by an independent safety committee
88917694|NCT01639768|Active Comparator|SUBLIVAC FIX Birch 40,000 AUN/ml|Start of SUBLIVAC FIX Birch 40,000 AUN/ml arm depends on safety in the SUBLIVAC FIX Birch 20,000 AUN/ml arm evaluated by an independent safety committee
88917695|NCT01639781|Active Comparator|flavanol rich intervention|flavanol rich drink
88917696|NCT01639781|Placebo Comparator|flavanol free intervention|flavanol free drink
88917697|NCT01639794||Male patients with non-neurogenic LUTS taking VESITRIM|Male patients diagnosed with non-neurogenic Lower Urinary Tract Symptoms (LUTS) with bothersome storage disorder defined as urgency, and/or frequency and/or Urgency Urinary Incontinence (UUI)
88917698|NCT01639807|Active Comparator|latanoprost 2-8˚ C|latanoprost(0.005%)stored at 2-8˚ C
88917699|NCT01639807|Experimental|SLT|Selective laser Trabeculoplasty
88917700|NCT01639820|Experimental|Strategy A|Only identification of sentinel nodes (without pelvic lymph-node dissection)
88917701|NCT01639820|Other|Strategy B|Identification of sentinel nodes + full pelvic lymph-node dissection
88917702|NCT01639846|Experimental|RX-10045 active arm|RX-10045 Ophthalmic Solution, 0.09%
88917703|NCT01639846|Placebo Comparator|Vehicle for RX-10045 arm|Vehicle of RX-10045 Ophthalmic Solution
88917704|NCT01639859|Experimental|Elastography|
88917705|NCT01639885|No Intervention|Group 1|Patients will receive standard care (gemcitabine)
88917706|NCT01639885|Experimental|Group 2|Patients will receive standard care (gemcitabine) combined with interferon-alpha 2b (Peg-Intron)
88917707|NCT01639885|Experimental|Group 3|Patients will receive standard care (gemcitabine) combined with interferon-alpha 2b (Peg-Intron) and p53 SLP vaccin
88917708|NCT01639898|Experimental|"Group 1 (2-cycles trial)"|"The 2-cycles trial will be available to patients who can be treated by radiation or intensive treatment (75 % of cases occurring in front line); they will then undergo 2 cycles of the lenalidomide-dexamethasone combination before radiation or intensive treatment (Group 1)."
88917709|NCT01639898|Experimental|"Group 2 ( 9 cylces Trial)"|"The 9-cycles trial will be available to all other front-line patients (25 % of front-line patients) or patients in relapse or resistant, they will undergo 9 cycles of the lenalidomide-dexamethasone combination followed by maintenance therapy with lenalidomide alone for one year (Group 2)."
88917710|NCT01639911|Experimental|Treated Patients with Solid Tumor|Patients will receive alisertib orally twice a day for the first 7 days of a 21 day cycle. Patients will also receive pazopanib orally once a day continuously. Treatment continues until disease progression, unacceptable toxicity or patient refusal. The study consists of two components which are the dose finding component and optimally tolerated dose extension with pharmacokinetics component.
88917711|NCT01640119|Placebo Comparator|no intervention|
88917712|NCT01640119|Experimental|Bicarbonate|
88917713|NCT01640158|Experimental|Experimental Treatment|Computerized plasticity-based adaptive cognitive training, up to 65 hours
88917714|NCT01640158|Active Comparator|Active Comparator|Commercially available computerized training, up to 65 hours
88917715|NCT01640431|Experimental|Lumbar stabilization exercises|In the Segmental Stabilization group exercises the focus is on the transversus abdominis and lumbar multifidus muscles.
88917716|NCT01640431|Experimental|TENS group|In this group, patients are treated with TENS in the lumbar region for an hour.
88917717|NCT01640457|Experimental|NDplus|NOVOCART® Disc plus (Autologous Disc Chondrocyte Transplantation System)
88917718|NCT01640457|Placebo Comparator|NDbasic|NOVOCART® Disc basic (media with no active cell component)
88917719|NCT01640457|No Intervention|Sequestrectomy only (SC)|Sequestrectomy (standard of care)
89198422|NCT00863811||1|POAG patients compensated by the treatment of betablockers eye drops and taking two tablets per day of KRONEK
89198423|NCT05350852|Experimental|ThisCART19A 5×10^6 cells/kg for dose level 1|Patients will receive 5×10^6 cells/kg of ThisCART19A
89530919|NCT04498325|Experimental|NT-I7 (Phase I)|"In the phase I study, 3 dose levels of NT-I7 are planned. Dosing will be staggered such that there will be a minimum of 72 hours between the dosing of one participant and the dosing of the next participant~NT-I7 will be given by intramuscular injection on Day 0~Participants will also be given standard of care treatment for COVID-19"
89530920|NCT04498325|Experimental|NT-I7 (Pilot)|"NT-I7 (dose determined by Phase I portion of study) will be given by intramuscular injection on Day 0~Participants will also be given standard of care treatment for COVID-19"
88917720|NCT01640561|Experimental|MISC|The Mediational Interventions for Sensitizing Caregivers (MISC) model developed by Professor Pnina Klein (consultant) has been used to enhance the development of children throughout the developing world, with the support of such international aid agencies as the World Health Organization (WHO), UNICEF, Norwegian Agency for Development Cooperation (NORAD), and Redd Barna (Norway).
88917721|NCT01640561|Active Comparator|Enhanced Treatment as Usual|
88917722|NCT01640743|Experimental|Evertwist 1|Tacrolimus (10-14 ng/ml) + Methylprednisolone (16 mg).
88917723|NCT01640743|Experimental|Evertwist 2|Tacrolimus (4-6 ng/ml) + Everolimus (8-10 ng/ml) + Methylprednisolone (8 mg).
88917724|NCT01641016|Active Comparator|Continuous Therapy|Continue with current antiretroviral therapy regime as per standard care
88917725|NCT01641016|Experimental|Short Cycle Therapy|Take current antiretroviral therapy 5 days a week (2 days off) as instructed by clinician
88917726|NCT01641614|Experimental|Beating heart surgery|Group A (Beating heart) surgery was performed under normal temperature (36⁰ C) ,once CPB was established, the patient was placed in Trendelenburg position and a retrograde perfusion catheter was inserted into the coronary sinus and ligated by a simple suture line. Aorta cross clamping was immediately established and blood was oxygenated and delivered continuously through a catheter Mitral valve was exposed using the left atrial retractor. Mitral valve replacement (MVR) was performed using a metallic or bioprostheses substitution by interrupted suture De Vegas' technique.
88917727|NCT01641614|Active Comparator|heart surgery Group B|Group B (arrested heart) surgery was performed under moderate hypothermia (32⁰C) as technique requirement (3). After cardiac arrest, during the period of cross clamping, the aortic root was perfused through the cardioplegias's cannula with oxygenated blood at a rate between 200 mL/min to 300 mL/min for 2 minutes with 15 minutes intervals.Mitral valve replacement (MVR) was performed using a metallic or bioprostheses substitution by interrupted suture De Vegas' technique.
88917728|NCT01641705||Control Group|Group of nonsmokers individuals without respiratory disease.
88917729|NCT01641705||RA patients 1|RA patients nonsmokers with up to five years of disease.
88917730|NCT01641705||RA group 2|RA patients nonsmokers with six to ten years of disease.
88917731|NCT01641705||RA group 3|RA patients nonsmokers with eleven to fifteen years of disease.
88917732|NCT01641705||RA group 4|RA patients nonsmokers with sixteen or more years of disease
88917733|NCT01641757|Experimental|periodontal treatment group|non surgical periodontal therapy will be given to study subjects which will be selected by randomization from total study sample. at the end of study, serum albumin levels of both study and control groups will be compared.
88917734|NCT01642394|No Intervention|Standardized care|The control group will receive usual care for secondary prevention of type 2 diabetes according to usual care in Osakidetza's primary care.
88917735|NCT01642394|Experimental|Self-management education programme|Attendees will receive the Diabetes Self-Management Programme in spanish version (Manejo personal de la diabetes).
88917736|NCT01642511|Active Comparator|Control Group|conventional technique: 99mTc-labeled Sulfur Colloid was injected into the tumor quadrant 3-24 hours before surgery, lymphoscintigraphy was performed 30min before surgery. Four milliliters of methylthioninium was injected subcutaneously above the primary tumor or around the biopsy cavity 10 min before surgery. Axillary sentinel lymph node biopsy and Internal mammary sentinel lymph node biopsy was performed during surgery. Axillary lymph node dissection was performed if ASLN was positive.
88917737|NCT01642511|Experimental|Study Group|modified technique: 99mTc-labeled Sulfur Colloid was injected into 2 quadrants of the breast 3-24 hours before surgery, lymphoscintigraphy was performed 30min before surgery. Four milliliters of methylthioninium was injected subcutaneously above the primary tumor or around the biopsy cavity 10 min before surgery. Axillary sentinel lymph node biopsy and Internal mammary sentinel lymph node biopsy was performed during surgery. Axillary lymph node dissection was performed if ASLN was positive.
88917738|NCT01642771|Active Comparator|5-Fu/epirubicin/CTX following Docetaxel|Docetaxel for the first 3 cycles of chemotherapy followed by 3 cycles of FEC (Fluorouracil, epirubicin and cyclophosphamide) chemotherapy
88917739|NCT01642771|Experimental|Docetaxel/capecitabine followed by XEC|Docetaxel/ capecitabine (TX) for the first 3 cycles of chemotherapy followed by 3 cycles of capecitabine/epirubicin/cyclophosphamide (XEC) chemotherapy
88917740|NCT01642979|Experimental|Levamisole+cyclosporin A+Glucocorticoids|Levamisole+cyclosporin A+Glucocorticoids
88917741|NCT01642979|Active Comparator|cyclosporin A+Glucocorticoids|cyclosporin A+Glucocorticoids
88917742|NCT01642979|Active Comparator|Glucocorticoids|Glucocorticoids
88917743|NCT01643031|Experimental|Ticagrelor|Patients randomized to the ticagrelor group will receive ticagrelor at a dose of 180 mg given 1-2 hours before the coronary angiography, followed by 90 mg twice a day for 30 days after the PCI. After 30 days the patient will be invited to a special research clinic in the hospital and his treatment will be switched back to clopidogrel (to complete 1 year of treatment).
88917744|NCT01643031|Active Comparator|Continued Clopidogrel|Patients randomized to continued clopidogrel treatment will be given an additional 300 mg of clopidogrel loading 1-2 hours before coronary angiography (in addition to the previous 300 mg load or chronic clopidogrel therapy the patient received), followed by 75 mg a day for 1 year after the PCI
88917745|NCT01643148||breast cancer patients (cases)|36 subjects
88917746|NCT01643148||controls|36 subjects
88917747|NCT01643291|Experimental|Ultrasound|
88917748|NCT01640067|Experimental|Human Neural Stem Cells Suspension|50,000 cells/µl. Patients received either unilateral or bilateral hNSCs microinjections (3 microinjections on each side) into the lumbar spinal cord. Each microinjection consisted of 15 µl of the above 50,000cells/µl suspension, yielding a total of 750,000 cells per injection site.
88917749|NCT01643434|Active Comparator|Spironolactone|
88917750|NCT01643434|Active Comparator|Clonidine|
88917751|NCT01643694|Experimental|Electronic intervention|Completion of 1 self-directed activity from an electronically provided list sent to them weekly for 10 consecutive weeks
88917752|NCT01643694|No Intervention|control group|Completion of baseline and 3 mo survey
88917753|NCT01643941|Experimental|1|SA4Ag vaccine low dose
88917754|NCT01643941|Experimental|2|SA4Ag vaccine mid dose
89198424|NCT05350852|Experimental|ThisCART19A 8×10^6 cells/kg for dose level 2|Patients will receive 8×10^6 cells/kg of ThisCART19A
89198425|NCT05350852|Experimental|ThisCART19A 12×10^6 cells/kg for dose level 3|Patients will receive 12×10^6 cells/kg of ThisCART19A
89198426|NCT00955786|Experimental|CX-3543|
88917755|NCT01643941|Experimental|3|SA4Ag vaccine high dose
89435900|NCT05597618|Experimental|Experimental Group|"Application Steps of Experimental Group New Graduated Nurses In the first stage, the experimental group nurses will be required to fill in the Introductory Information Questionnaire, Information Evaluation Questionnaire for Empowerment, Nursing Structural Empowerment Scale, and Psychological Empowerment Scale in the randomization process.~In the second stage, the theoretical part of the training program will be given to nurses as group training in a physical environment. After the training, the first part of the Training Evaluation Form and the Empowerment Information Evaluation Questionnaire will be applied.~In the third stage, nurses will be required to use the developed mobile-compatible online training program for 6 months.~In the fourth stage, Education Evaluation Form, the Nursing Structural Empowerment Scale, the Psychological Empowerment Scale, and the Empowerment Information Evaluation Questionnaire will be applied to the nurses after 6 months."
89435901|NCT05592665|Other|Patient Perspective|Study participants will complete several questionnaires/assessments related to adverse events and quality of life.
89435902|NCT05588843|Experimental|SAR443122 level 1|Dose level 1
88917756|NCT01643941|Experimental|4|SA3Ag vaccine
88917757|NCT01643941|Placebo Comparator|5|Placebo
89435903|NCT05588843|Experimental|SAR443122 level 2|Dose level 2
89435904|NCT05588843|Experimental|SAR443122 level 3|Dose level 3
89435905|NCT05588843|Placebo Comparator|Placebo|Matching Placebo
89435906|NCT05586516|Experimental|IOA-289 in combination with gemcitabine/nab-paclitaxel|
88917758|NCT01643980|Experimental|Vaginal micronized progesterone|200 mg vaginal route per day
88917759|NCT01643980|Active Comparator|Cervical pessary|Cervical pessary certified by European Conformity (CE0482, MED/CERT ISO 9003/EN 46003;Dr Arabin, lower larger diameter 70 mm, height 30 mm,and upper smaller diameter 32 mm)
88917760|NCT01644123||Nursing home residents|
88917761|NCT01644214|No Intervention|Pessary Check at 3 months|Patients seen at 3 month intervals for pessary check-ups is the most common interval check in our clinic so this arm is considered the control group.
88917762|NCT01644214|Experimental|6 month Pessary Check|Those that will be seen at 6 month follow-up visits for pessary maintenance will be considered the experimental group of the study.
88917763|NCT01644318||authoimmıne thyroiditis and habitual abortus|
88917764|NCT01644318||authoimmune thyroiditis|
88917765|NCT01644318||healthy controls|
89198427|NCT04237012|Experimental|Dextenza|Treatment Arm-Dextenza insertion lower lid punctum at time of screening and use of OTC artificial tears as needed
89198428|NCT04237012|Active Comparator|Over the counter Artificial tears|Controlled arm: continuation of OTC artificial tears no placement of Dextenza intracanular insert
89198429|NCT00863889|Experimental|1|1cc Depomedrol, 4 cc 1% Lidocaine, 4 cc 0.25% Marcaine
89198430|NCT00863889|Placebo Comparator|2|4 cc 1% Lidocaine, 4 cc 0.25% Marcaine
89198431|NCT05299450|Experimental|Exercise intervention|12 week personalised exercise intervention with personal trainer and gym membership, fitbit
89435907|NCT05586321|Experimental|GEN1056 Monotherapy|
88917766|NCT01644708||Overweight, obese adult patients|Patients following a self empowerment group will be included in the study
88917767|NCT01644721|Experimental|Early measles vaccine|An additional measles vaccine at 4 months of age, at least 28 days after the third dose of pentavalent vaccine
88917768|NCT01644721|No Intervention|Control|Follows the normal vaccination schedule
88917769|NCT01644916|Other|Usual control|Usual control will be provided with usual standard management of COPD and psychiatric comorbidities.
88917770|NCT01644916|Other|Integrated care|Integrated care will be provided with integrated care management.
88917771|NCT01644929|Experimental|1 tDCS-Sham|tDC stimulation for 3 weeks, then cross-over to sham stimulation
88917772|NCT01644929|Experimental|2 Sham-tDCS|Sham stimulation for 3 weeks, then cross over to tDCS stimulation
88917773|NCT01644929|Sham Comparator|3 Sham-Sham|Treatment for 6 weeks daily with sham stimulation
88917774|NCT01645137|Experimental|OMT|patients under usual medical care plus osteopathic treatment
88917775|NCT01645137|Other|control|patients under usual medical care
88917776|NCT01645228||significant coronary artery stenosis|anyone coronary segment > 50% diameter stenosis
88917777|NCT01645566|Experimental|intervention|"instructions about focusing on relevant task elements by posing two task-focusing questions (what is the patient's condition?, what immediate action is needed?) when feeling overwhelmed by stress (intervention-group)"
88917778|NCT01645566|No Intervention|Control|No instructions
88917779|NCT01645722|Other|Procedure/Surgery: Enriched Fat grafting|Enriched Fat grafting
89198432|NCT05299450|Experimental|Beetroot juice|12 weeks daily Beet It (beetroot shots) containing nitrate, fitbit
89435908|NCT05585983|Experimental|Influenza vaccination|Influenza vaccine, 0.5 mL.
89435909|NCT05585983|Placebo Comparator|Placebo|Placebo, 0.5 mL saline.
89435910|NCT05585801|Experimental|Intervention Group|
89435911|NCT05585801|Active Comparator|Control Group|
89530921|NCT04498325|Placebo Comparator|Placebo (Pilot)|"Placebo will be given by intramuscular injection on Day 0~Participants will also be given standard of care treatment for COVID-19"
89435912|NCT05582356|Experimental|Carbohydrate group (Group OC)|Preoperative education will be provided by researchers to the patients on the ward before fluid intake. Solid food will be forbidden starting at 20:00 p.m, and drinking will be forbidden after 22:00 p.m the day before surgery. Group OC will consume carbohydrate fluid at 22.00 p.m. and two hours before the surgery
89435913|NCT05582356|Sham Comparator|Placebo group (Group OP)|Preoperative education will be provided by researchers to the patients on the ward before fluid intake. Solid food will be forbidden starting at 20:00 p.m, and drinking will be forbidden after 22:00 p.m the day before surgery. Group OP will consume an equal amount of water 22:00 p.m. and two hours before the surgery.
89435914|NCT05581641|Experimental|BNT165b1|Escalating dose levels
89435915|NCT05581641|Placebo Comparator|Placebo|
89435916|NCT05580562|Experimental|ONC201 Twice Weekly Group|
89435917|NCT05580562|Experimental|ONC201 Once Weekly Group|
89435918|NCT05580562|Placebo Comparator|Placebo Group|
89435919|NCT05578092|Experimental|Phase 1/1B Monotherapy|Dose Escalation/Evaluation
88917780|NCT01645839|Experimental|Systemic treatment with Depocyte|Intrathecal injection of Liposomal Cytarabine (Depocyte®) every 14 ± 2 days for a total of 5 cycles and then every 28 ± 4 days until progression.
88917781|NCT01645839|No Intervention|Systemic treatment without Depocyte|No intrathecal injection.
88917782|NCT01645995|Experimental|Reformulated products|Subjects were asked to supplement their habitual diet with reformulated sugar-reduced products for 8 weeks. Subjects were provided with reformulated beverages, sauces, condiments and snacks. They were asked to consume a minimum of 1 drink + 1 food portion intervention supplement daily, in exchange for habitually eaten equivalent foods.
88917783|NCT01645995|Experimental|Conventional products|Subjects were asked to supplement their habitual diet with conventional sugar products for 8 weeks. Subjects were provided with conventional beverages, sauces, condiments and snacks. They were asked to consume a minimum of 1 drink + 1 food portion intervention supplement daily, in exchange for habitually eaten equivalent foods.
88917784|NCT01646190|Active Comparator|Standard care|Preoperative: Fasting state after midnight, no intake of oral carbohydrate load Preanesthetic medication No preoperative utilization of inspirex Intraoperative: Effective perioperative analgesia Routine nasogastric tube and abdominal drainage at surgeon discretion Postoperative: Removal of the nasogastric tube after return of bowel function removal of abdominal drainage at surgeon discretion or if volume <50cc Oral liquids and stepwise oral nutrition (water to others liquids to progressive normal or low-fiber nutrition Switch to oral medication after oral nutrition tolerance Urinary catheter removal when the mobilization is satisfactory Mobilization: non standardized and encouraged stepwise mobilization Discharge criteria discussed at surgeon discretion
88917785|NCT01646190|Experimental|FT perioperative care|Preoperative carbohydrate load No preanesthetic medication General anesthesia and intravenous analgesia Transoesophageal US-Doppler for individualized i.v fluids therapy POD 0: No Nasogastric tube postoperatively Oral liquids 0.3-0.5L 6h after extubation First mobilization 6h after surgery (2h) Stimulation of inspirex utilization (6-8t/d) POD 1: Free oral liquids; progressive normal or low-fiber diet Switch to oral medication Urinary catheter removal Mobilization: >4 h out of bed (walking, chair) inspirex utilization POD 2: Free oral liquids; normal or low-fiber diet Mobilization: >6 h out of bed (walking, chair), inspirex utilization POD 3: Complete mobilization as preoperatively First evaluation of discharge criteria in the afternoon
88917786|NCT01646437|Experimental|Polycap vs. matching placebo|Polycap is a once daily capsule containing thiazide (25mg), atenolol (100mg), ramipril (10mg) and simvastatin (40mg) vs. matching placebo
88917787|NCT01646437|Experimental|Aspirin vs. matching placebo|Once daily 75mg tablet of Aspirin vs. matching placebo
88917788|NCT01646437|Experimental|Vitamin D vs. matching placebo|Monthly oral dosage of 60,000IU vs. matching placebo
88917789|NCT01646619|Active Comparator|Hypothermia + Magnesium Sulphate|
88917790|NCT01646619|Placebo Comparator|Hypothermia+ Placebo|
88917791|NCT01646749|Experimental|Protein intake of 5 energy percent (En%)|
88917792|NCT01646749|Experimental|Protein intake of 15 En%|
88917793|NCT01646749|Experimental|Protein intake of 30 En%|
88917794|NCT01646840|Experimental|PF-04958242 capsule|
88917795|NCT01646840|Active Comparator|PF-04958242 oral solution|
88917796|NCT01646866||Siblings of Children with Autism Spectrum Disorders|This group is comprised of 6-12 month old siblings of a child with an expert clinical diagnosis of autism spectrum disorders.
88917797|NCT01647490|Active Comparator|Right Ventricular Apex (RVA)|In the RVA group the right ventricular pacing lead will be implanted in the apex region of the right ventricle
88917798|NCT01647490|Experimental|Right Ventricular Septum (RVS)|In the RVS group the right ventricular pacing lead will be implanted in the septal region (mid septum) of the right ventricle
88917799|NCT01647750|Other|Lower dose of levothyroxine|Participants may be randomised to receive a lower dose of levothyroxine (lower than their usual dose) to achieve a target TSH level of 4.1 - 8.0 mU/L
89435920|NCT05578092|Experimental|Phase 1/1B Combination Therapy|Dose Escalation/Evaluation and Food Effect Assessment
89435921|NCT05578092|Experimental|Phase 2|MRTX0902 and adagrasib combination RP2D administered to separate cohorts of patients with selected solid tumor malignancies with KRAS G12C mutation to include the following: NSCLC, CRC, Other Solid Tumors
89435922|NCT05571527|Experimental|Menopause patients having genitourinary syndrome (PRP)|Preparation of PRP sample from the patient's own blood and then the volume immediately above the erythrocyte layer was collected. Calcium gluconate in conc. 1:9 will be used as an activator. After activation, in a period of less than 2 min, approximately 4 ml of the PRP will be injected into the vaginal wall. ( at 3,6 and 9 o clock)It will be repeated once a month for 3 times.
89435923|NCT05571527|Active Comparator|vaginal hyluronic acid supplement for GSM|Patients receive Vaginal Hyaluronic Acid supplement for 10 days, then once a week for 3 months.
89435924|NCT05565950|Experimental|AI-09 Dose 1|Dose 1 of botulinum toxin, Type A, intramuscular injection, administered once at baseline
89435925|NCT05565950|Placebo Comparator|Vehicle Dose 1|Vehicle, intramuscular injection, administered once at baseline
89435926|NCT05565950|Experimental|AI-09 Dose 2|Dose 2 of botulinum toxin, Type A, intra-muscular injection, administered once at baseline
89435927|NCT05565950|Placebo Comparator|Vehicle Dose 2|Vehicle, intramuscular injection, administered once at baseline
89435928|NCT05565950|Experimental|AI-09 Dose 3|Dose 3 of botulinum toxin, Type A, intra-muscular injection, administered once at baseline
89435929|NCT05565950|Placebo Comparator|Vehicle Dose 3|Vehicle, intramuscular injection, administered once at baseline
89435930|NCT05565950|Experimental|AI-09 Dose 4|Dose 4 of botulinum toxin, Type A, intra-muscular injection, administered once at baseline
89435931|NCT05565950|Placebo Comparator|Vehicle Dose 4|Vehicle, intramuscular injection, administered once at baseline
88917800|NCT01647750|Other|Standard dose of levothyroxine|Patients may be randomised to receive their usual dose of levothyroxine (target TSH level 0.4 - 4.0 mU/L)
88917801|NCT01647880|Experimental|Fingolimod (Gilenya®)|0,5 mg once a day in the morning, oral
88917802|NCT01647880|Active Comparator|Interferon beta-1b (Extavia®)|every second day, s.c.
88917803|NCT01647997|Experimental|study 1a|whole body lactate production after bacterial endotoxin challenge
88917804|NCT01647997|No Intervention|study 1b|basal whole body lactate production
88917805|NCT01647997|Experimental|study 2a|muscle lactate concentration after bacterial endotoxin challenge
88917806|NCT01647997|No Intervention|study 2b|basal muscle lactate concentrations
88917807|NCT01648218|Active Comparator|Neutral protamine hagedorn (NPH) insulin|"Drug: Neutral protamine hagedorn (NPH) insulin~Other Names:~Humulin N, Novolin N~Route: Subcutaneous; Dosage: No fixed dose, varies between subjects; Frequency: daily before breakfast; Duration: 12 hours; for duration subjects are concurrently administered once-daily glucocorticoid."
88917808|NCT01648218|Experimental|Regular or Aspart insulin|"Drug: Regular human insulin or Insulin Aspart~Other Names:~Humulin R, Novolin R, Novolog, NovoRapid~Route: Subcutaneous; Dosage: No fixed dose, varies between subjects; Frequency: daily before meals; Duration: 2 hours (Aspart) or 6 hours (Regular); for duration subjects are concurrently administered once-daily glucocorticoid."
88917809|NCT01648218|Experimental|Insulin glargine|"Drug: Insulin glargine~Other Names:~Lantus~Route: Subcutaneous; Dosage: No fixed dose, varies between subjects; Frequency: daily before breakfast; Duration: 24 hours; for duration subjects are concurrently administered once-daily glucocorticoid."
88917810|NCT01648465|Experimental|Everolimus|
88917811|NCT01648621|Experimental|Case Management|In addition to usual care, the intervention group will receive case management that includes: 40 minute standardized education session, an individualized action plan, an individualized care plan for management of COPD and comorbidities, standardized reinforcement/motivational interviewing and action plan teach-back sessions and assessment of symptoms, progress and problems, and problem solving by phone weekly for 12 weeks, then monthly for 9 months (21 sessions), tele-home monitoring, coordinated and improved communication between the patient, family caregivers, family physicians, specialists, and CCAC facilitated by the case manager, priority access to ambulatory clinics.
88917812|NCT01648621|Active Comparator|Usual care|Usual care for these patients comprises: Dictated patient summary, referral to an 8 week in-hospital rehabilitation and self-management education program, referral to a smoking cessation program (as applicable), individualized action plan developed with treating respirologist at the discretion of the attending respirologist, Referral to web based educational materials and resources.
88917813|NCT01648777|Experimental|L bupivacaine|Drug (L bupivacaine) and device (catheter) 750 patients undergoing cardiac surgery with sternotomy are treated with L-bupivacain in the multiperforated catheter of analgesia
88917814|NCT01648777|Placebo Comparator|placebo|Isotonic Nacl 9°/00 solution 750 patients undergoing cardiac surgery with sternotomy are treated with isotonic NaCl solution (placebo) in the multiperforated catheter of analgesia
88917815|NCT01648946|Active Comparator|Liberal Transfusion Strategy|Red blood cell (RBC) transfusion will be given when hemoglobin falls below 9 g/dL since ICU admission until the discharge of intensive care unit. Following administration of 1 RBC unit, a repetition of hemoglobin levels is performed; if a patient's hemoglobin level is 9 g/dL or higher, no additional transfusion is necessary.
88917816|NCT01648946|Active Comparator|Restrictive Transfusion Strategy|Red blood cell (RBC) transfusion will be only given when hemoglobin falls below 7 g/dL since ICU admission until the discharge of intensive care unit. Following administration of 1 RBC unit, a repetition of the hematocrit is performed; if a patient's hemoglobin is 7 g/dL or higher, no additional transfusion is necessary.
88917817|NCT01648998|Experimental|Fludrocortisone|Fludrocortisone 500 mg in capsule
88917818|NCT01648998|Placebo Comparator|Placebo|Placebo capsule, single dose, main ingredient lactose
88917819|NCT01649024|Experimental|single arm of Tremelimumab|Tremelimumab is administered at 15 mg/kg on day 1 every 12 weeks for 4 doses
89198433|NCT05299450|Experimental|Exercise and Beetroot|12 week personalised exercise intervention with personal trainer and gym membership and daily Beet It (beetroot shots) containing nitrate, fitbit
89435932|NCT05565950|Experimental|AI-09 Dose 5|Dose 5 of botulinum toxin, Type A, intra-muscular injection, administered once at baseline
89435933|NCT05565950|Placebo Comparator|Vehicle Dose 5|Vehicle, intramuscular injection, administered once at baseline
89435934|NCT05565950|Experimental|AI-09 Dose 6|Dose 6 of botulinum toxin, Type A, intra-muscular injection, administered once at baseline
89435935|NCT05565950|Placebo Comparator|Vehicle Dose 6|Vehicle, intramuscular injection, administered once at baseline
89435936|NCT05565950|Experimental|AI-09 Dose 7|Dose 7 of botulinum toxin, Type A, intra-muscular injection, administered once at baseline
89435937|NCT05565950|Placebo Comparator|Vehicle Dose 7|Vehicle, intramuscular injection, administered once at baseline
89435938|NCT05565118|Experimental|Standard Surgical Treatment + Intraoperative Electrocorticography|Each participant will undergo intraoperative electrocorticography (ECOG) through subdural grid (SDG) and depth electrode (DE) via FDA-cleared, standardized, brain recording technology. During this surgery, participants will also undergo a tissue biopsy at recording sites for correlation to neural recording data.
88917820|NCT01649843|Experimental|EA|Patients were eligible for enrollment in the study if they had an Eckardt symptom score ≥ 4. The diagnosis of achalasia was made on the basis of the absence of peristalsis and on impaired relaxation of the LES on established methods (barium swallow, manometry, esophagogastroduodenoscopy (EGD)).
88917821|NCT01649934|No Intervention|Scheduling as Usual|Participants will be subject to the current appointment scheduling procedures.
88917822|NCT01649934|Experimental|Contact Clinic|This group will be required to contact the clinic themselves to make appointments.
88917823|NCT01649934|Experimental|Implementation Intentions|This group will create Implementation Intentions to contact the clinic to make their appointments and to attend those appointments.
88917824|NCT01649960|Other|Rapamycin|Oral rapamycin was given during the nonrandomized phase of the study. The doses that were used of rapamycin were 0.5mg, 1mg, or 2mg.
88917825|NCT01650012|Experimental|Eplerenone|Target of 50 mg/day
88917826|NCT01650012|Placebo Comparator|Placebo|Matching placebo
88917827|NCT01650025|Placebo Comparator|VSL#3 placebo|The placebo comparator is administered in the same form and dose as the active ingredient. The patient will take 2 sachets a day for 4 months.
88917828|NCT01650025|Active Comparator|VSL#3 active probiotic|VSL#3 is a probiotic preparation containing 8 different strains of lactic acid bacteria and bifidobacteria. Each sachet contains 450 billion bacteria and the patient will be requested to take 2 sachets a day for 4 months
88917829|NCT01650038|Active Comparator|faecal transplantation; donor faeces|2 times treatment with faecal transplantation: faeces from a healthy donor processed for duodenal tube infusion. after bowel lavage with macrogol.
88917830|NCT01650038|Placebo Comparator|faecal transplantation; placebo|2 times treatment with (own) faecal transplantation: faeces from the patient processed for duodenal tube infusion. after bowel lavage with macrogol.
88917831|NCT01650090|Experimental|ILC|Inhaled Lipid Cisplatin (ILC) will be administered every two weeks via nebulization and inhalation.
88917832|NCT01650129|Experimental|BIAsp|
88917833|NCT01650129|Experimental|BHI|
88917834|NCT01650142||NF1GeneModif Cohort|Adult patients with neurofibromatosis 1
88917835|NCT01650155|Experimental|BI 1005273 i.v.|single dose i.v. infusion
88917836|NCT01650155|Placebo Comparator|BI 1005273 i.v. Placebo|single dose i.v. infusion (Placebo)
88917837|NCT01650155|Experimental|BI 1005273 s.c.|single dose s.c. injection
88917838|NCT01650155|Placebo Comparator|BI 1005273 s.c. Placebo|single dose s.c. injection (Placebo)
88917839|NCT01650168||NOMAC-E2|New users of NOMAC-E2
88917840|NCT01650168||LNG-COCs|New users of levonorgestrel-containing COCs
88917841|NCT01650181|Active Comparator|Metformin|Patients treated with diet, exercise and metformin
89198434|NCT05299450|Active Comparator|Control group|No intervention, fitbit
89435939|NCT05564416|Experimental|Arm I (erdafitinib)|Patients receive erdafitinib orally (PO). Patients undergo collection of blood and computed tomography (CT)/magnetic resonance imaging (MRI) at various time points throughout the trial and colposcopy at baseline.
88917842|NCT01650181|Active Comparator|Suplement|Patients treated with diet, exercise and metformin plus Siliphos (140mg) + Selenium (15mcg) -Methionine 3mg + Alpha Lipoic Acid (200mg).
89198435|NCT00861003||Schizophrenia, antipsychotics|Stable outpatient status of schizophrenia or schizoaffective disorder currently taking a single oral antipsychotic
88917843|NCT01650207|Experimental|EA group|To acupuncture the Juanyu (Li15) & Jugu (Li16) with sensation of de-qi, and then give 50 Hz electrical stimulation for 20 minutes.
88917844|NCT01650207|Experimental|TENS group|The electrical patches were placed on the Juanyu (Li15) & Jugu (Li16) or Juanyu (Li15), Quchi (Li11), Shousanli (Li10) & Hegu (Li4), connected to a TENS apparatus and then give 50 Hz electrical stimulation for 20 minutes.
88917845|NCT01650207|Sham Comparator|sham-acupuncutre|The Park's Sham Device were placed on the Juanyu (Li15) & Jugu (Li16).
88917846|NCT01650220||Veterans with a history of PTSD|
88917847|NCT01650220||Veterans without a history of PTSD|
88917848|NCT01650233|Experimental|Mindfulness-based stress reduction|The mindfulness-based stress reduction (MBSR) program was previously adapted for urban youth and here further adapted to 12 weekly 50-minute classes for use in school.
89198436|NCT01563250|No Intervention|Core Laboratory|Patients receiving serial routinely available cardiac biomarker testing in a core laboratory setting using Troponin T. (Roche Centaur)
89198437|NCT01563250|Active Comparator|Point of Care|Patients will receive the Point of Care testing intervention using serial cardiac biomarker testing at the bedside including myoglobin, Troponin I and CK-MB. (Triage Cardiac Panel, Alere)
88917849|NCT01650233|Placebo Comparator|Healthy Topics|An age-appropriate health education curriculum was used as a non-specific group comparison for the MBSR program to control for the effects of: positive adult instruction, interactive peer group instruction, learning new material, group size and location, time, and attention.
88917850|NCT01650272|Experimental|5%Minoxidil solution|"This arm AGA patient receive 5%Minoxidil solution ( Propylene glycol solvent ) to use for 6 month.~Record efficacy and safety as described."
88917851|NCT01650272|Experimental|5%Minoxidil milky lotion|This arm AGA patient receive 5%Minoxidil milky lotion to use for 6 month. Record efficacy and safety as described.
89435940|NCT05564416|Experimental|Arm II (erdafitinib, atezolizumab)|Patients receive erdafitinib PO and atezolizumab intravenously (IV). Patients undergo collection of blood and CT/MRI at various time points throughout the trial and colposcopy at baseline.
88917852|NCT01650337|Experimental|Smartphone Application|Patients will be given access to a smartphone application for weight loss and instructed on how to use it.
88917853|NCT01650337|No Intervention|Usual primary care|
88917854|NCT01650363|Active Comparator|Acupuncture, homeopathy, osteopathy and reflexology|patients will receive combinations of acupuncture, homeopathy, osteopathy and reflexology
88917855|NCT01650363|Placebo Comparator|homeopathic placebo medication|
88917856|NCT01650376|Experimental|Olaparib plus carboplatin and paclitaxel|
88917857|NCT01650389|Experimental|MVA85A|1 x 10(superscript'8') pfu MVA85A vaccine intradermal within 96 hours of birth
89435941|NCT05562921||Case|
89435942|NCT05562921||Control|
89435943|NCT05562752|Experimental|Active|Arm receiving investigational product (probiotic)
89198438|NCT00863967||1|no cardiovascular events
89198439|NCT00863967||2|proven cardiovascular events
89198440|NCT00863967||3|possible cardiovascular events
89435944|NCT05562752|Placebo Comparator|Placebo|Arm receiving placebo
89435945|NCT05562739|Experimental|Active|Arm receiving investigational product (postbiotic)
89435946|NCT05562739|Placebo Comparator|Placebo|Arm receiving placebo
89435947|NCT05561738|Experimental|Daily oral therapy with Nicotinamide Riboside Chloride (Niagen) + Standard Therapy|"Nicotinamide Riboside Chloride (Niagen) 75mg or 250mg capsules provided by ChromaDex, Inc. Dosing is recommended at 12.5mg/kg/day.~The dosing plan is as follows (in mg po qD):~20-25 kg 250mg; 25-30 kg 325mg; 30-35 kg 400mg; 35-40 kg 475mg; 40-45 kg 500mg; 45-50 kg 575mg; 50-55 kg 650mg; 55-60 kg 725mg; 60-65 kg 750mg; 65-70 kg 825mg; >70 kg 900mg (max dosing)."
89530922|NCT00708227||Whites ADRB2:ARG16ARG|All participants receive fluticasone for 2-weeks followed by fluticasone / salmeterol for 2-weeks at a dose commensurate with baseline inhaled corticosteroid dose. All participants receive ipratropium bromide for symptom rescue therapy.
88917858|NCT01650389|Active Comparator|Candin|Equal volume intradermal administration within 96 hours of birth
88917859|NCT01650415|Experimental|Erythropoietin and Rehabilitation|recombinant human erythropoietin injection and active rehabilitation
88917860|NCT01650415|Placebo Comparator|Placebo and Rehabilitation|Placebo erythropoietin and rehabilitation
88917861|NCT01650428|Experimental|FOLFOX & Bevacizumab|"Bevacizumab - 5 mg/kg IV over 30-90 minutes (cycles 1-5 only), Oxaliplatin - 85 mg/m2 IV over 2 hours, Folinic acid - 350 mg IV over 2 hours, 5-Fluorouracil - 3200 mg/m2 IV continuous infusion over 48 hour.~Treatment given every 2 weeks for 12 weeks (for 6 cycles)"
88917862|NCT01650428|Experimental|FOLFOXIRI & Bevacizumab|"Bevacizumab - 5 mg/kg IV over 30-90 minutes (cycles 1-5 only), Irinotecan - 165 mg/m2 IV over 1 hour, Oxaliplatin - 85 mg/m2 IV over 2 hours, Folinic acid - 350 mg IV over 2 hours, 5-Fluorouracil - 3200 mg/m2 IV continuous infusion over 48 hour.~Treatment given every 2 weeks for 12 weeks (for 6 cycles)"
88917863|NCT01650441|Experimental|beclomethasone dipropionate + formoterol fumarate|All patients will be treated with the active product. No placebo arm will be used. The active product is a fixed combination containing extra-fine beclometasone dipropionate and formoterol fumarate in a new dry powder inhaler device, NEXThaler® (Chiesi Farmaceutici, Parma, Italy).
88917864|NCT01650454|Experimental|Patients from Memento cohort.|"Patients with mild cognitive impairment included in MEMENTO cohort.~These patients will have a 2 night polysomnography, a battery of neuropsychological tests, a virtual reality test, and a subjective evaluation of sleep and somnolence at inclusion (Month 0) and Month 12."
88917865|NCT01650454|Experimental|Patients with memory disorders|Patients with mild cognitive impairment not included in MEMENTO cohort. For these patients a virtual reality test, and a subjective evaluation of sleep and somnolence will be performed at Inclusion (Month 0)
88917866|NCT01650454|Active Comparator|Healthy volunteers|Healthy volunteers matched in age, sex and educational level with patients. For these volunteers a virtual reality test, and a subjective evaluation of sleep and somnolence will be performed at Inclusion (Month 0)
88917867|NCT01650454|Active Comparator|control group|this group is composed with Healthy volunteers these volunteers will have a 2 night polysomnography, a battery of neuropsychological tests, a virtual reality test, and a subjective evaluation of sleep and somnolence at inclusion (Month 0) and Month 12.
88917868|NCT01650467||Healthy controls|60 healthy controls with no hematological pathologies
88917869|NCT01650467||Imatinib optimal response|30 CML patients who are optimal responders to imatinib treatment
88917870|NCT01650467||Imatinib primary resistance|30 CML patients who have primary resistance to imatinib treatment
88917871|NCT01650480|Experimental|Intervention group|
88917872|NCT01650480|No Intervention|Control group|
88917873|NCT01650493||Group A|Clinpro 5000
88917874|NCT01650493||Group B|MI Paste Plus
88917875|NCT01650493||Group C|Toms of Maine
88917876|NCT01650506|Experimental|Erlotinib + Metformin|This is a single arm phase 1 study. All patients will receive erlotinib and metformin.
88917877|NCT01650532|Experimental|Yoga Condition|Participants will be instructed to learn yoga postures as well as yoga based breathing and meditative practices by certified yoga instructors. Primary Hatha yoga postures will be performed using props like yoga mats, blocks, belts and blankets. Classes will be held 3 times a week for 8 weeks.
88917878|NCT01650532|Active Comparator|Stretching Condition|Exercises focusing on stretching and strengthening for all muscle groups will be performed at one-hour long sessions held 3 times a week for 8 weeks. Classes are led by trained exercise specialists.
88917879|NCT01650597|Experimental|Part 1 - Panel 1|The participants will receive 3 or 4 ascending doses (2.5, 10, 30, 100, 250, 500 mg) of JNJ-42165279 and placebo during the study.
88917880|NCT01650597|Experimental|Part 1 - Panel 2|The participants will receive 3 or 4 ascending doses (2.5, 10, 30, 100, 250, 500 mg) of JNJ-42165279 and placebo during the study.
88917881|NCT01650597|Experimental|Part 2 (parallel)- additional cohort|The participants will receive repeated daily dosing of 100 mg JNJ-42165279 or placebo for 6 consecutive days.
88917882|NCT01650610|Experimental|Gait training executive functions tasks|This group will perform a gait training associated with the tasks that require the main executive functions.
88917883|NCT01650623|Experimental|Gait training executive functions tasks|The experimental group will perform a gait training associated with the tasks that require the main executive functions (dual-task condition).
88917884|NCT01650623|Active Comparator|Gait training alone|The control group will perform a gait training alone, without associated tasks (single-task condition).
88917885|NCT01650649|Active Comparator|Lofexidine Titration in Methadone Maintained Subjects|Methadone maintained subjects will be titrated on lofexidine up to the target therapeutic dose of 0.8 mg QID (4 tablets QID) or to the highest level tolerated. Following this initial titration attempt, all subjects will have their methadone dose reduced by 50% and lofexidine titration efforts will resume.
88917886|NCT01650649|Placebo Comparator|Placebo titration in methadone maintained subjects|Methadone maintained subjects will be titrated on placebo tablets in ascending doses of 1 tablet starting with 2 tablets (e.g. Day 1 2 tablets QID, Day 2 3 tablets QID, etc) to mimic titration for subjects randomized to lofexidine.
89198441|NCT00677352|Experimental|1|
89198442|NCT00677352|Active Comparator|2|
89198443|NCT00861081|Experimental|1: Care management|
89530923|NCT00708227||Whites ADRB2:GLY16GLY|All participants receive fluticasone for 2-weeks followed by fluticasone / salmeterol for 2-weeks at a dose commensurate with baseline inhaled corticosteroid dose. All participants receive ipratropium bromide for symptom rescue therapy.
88917887|NCT01650662|Experimental|Cyclosporine A|"The investigational active treatment is CsA, an immunosuppressant indicated for the prevention of acute rejection after organ transplant, including cardiac transplantation.~The preparation used in the trial will be Sandimmun IV, containing CsA 50 mg/ml, Cremophor® EL and 94% ethyl alcohol in a 5 ml vial.~Patients will received Cyclosporine A on the top of recommended standard care for acute myocardial infarction."
88917888|NCT01650662|Experimental|Control group|The control group received on the top of recommended standard care for acute myocardial infarction.
88917889|NCT01650675|Placebo Comparator|Control|Participants randomized into the control condition complete assessment and a time-matched interactive session on infant nutrition.
88917890|NCT01650675|Experimental|Indirect intervention|Participants in this condition review a short series of parenting strengths that benefit infants, and are invited to consider their current status in each area. This list includes factors associated with drug use (e.g., safety, emotional health) as well as substance use itself.
88917891|NCT01650688||Epiblepharon|subjects demonstrating prominent corneal touch by cilia and/or related subjective symptoms
88917892|NCT01650714|Experimental|Full thickness gastric biopsy|Full thickness gastric biopsy
89198444|NCT00861081|Active Comparator|2: Written Materials|
89435948|NCT05561738|Experimental|Daily oral therapy with placebo + Standard Therapy|"Placebo 75mg or 250mg capsules provided by ChromaDex, Inc. Dosing is recommended at 12.5mg/kg/day.~The dosing plan is as follows (in mg po qD):~20-25 kg 250mg; 25-30 kg 325mg; 30-35 kg 400mg; 35-40 kg 475mg; 40-45 kg 500mg; 45-50 kg 575mg; 50-55 kg 650mg; 55-60 kg 725mg; 60-65 kg 750mg; 65-70 kg 825mg; >70 kg 900mg (max dosing)."
89435949|NCT05560568||Adult patients with type 1 diabetes|Adult patients with type 1 diabetes treated with insulin pumps according to current recommendations with an indication to switch to a hybrid closed-loop pump
89435950|NCT05559216|Other|Basketball Players|
88917893|NCT01650727|Experimental|Dinaciclib + Rituximab|"Rituximab will be administered in Cycles 1 and 3-13.~Dinaciclib will be administered in Cycles 2-13."
88917894|NCT01650740|Experimental|Open-label duloxetine|12 week treatment with duloxetine
88917895|NCT01650740|Experimental|Open-label Placebo|4 weeks of open label placebo with option to continue or switch to duloxetine for remaining 8 weeks.
88917896|NCT01650740|Experimental|Supportive clinical management|4 weeks of supportive clinical management visits with option to continue or switch to duloxetine for remaining 8 weeks.
88917897|NCT01650753|Experimental|Probiotic Powder|Probiotic: Bifidobacterium longum subsp longum AH1206
88917898|NCT01650753|Placebo Comparator|Placebo Powder|Equivalent amount (same volume) of maltodextrin
88917899|NCT01650818|Experimental|Aerobic exercise training|
88917900|NCT01650818|Active Comparator|Standard physical therapy|
88917901|NCT01650870|Active Comparator|Evening Only (full-dose)|The dosing regimen of Crystalline lactulose will be four 45-gram doses (one dose every 60 minutes for 4 straight hours) taken the evening before the colonoscopy procedure.
89435951|NCT05556616|Experimental|Group 1 (MM Maintenance) Arm 1: Modakafusp alfa + Lenalidomide|Modakafusp alfa, infusion intravenously (IV), once on Day 1, once every 4 weeks (Q4W), in combination with Lenalidomide capsules orally once daily continuously on Days 1 to 28, in a 28-day (4-week) treatment cycle until disease progression, unacceptable toxicity, or to a maximum of 2 years for MRD [-] negative participants, whichever occurs first. Participants who remain MRD positive with demonstrated clinical benefit after 2 years of maintenance therapy may continue treatment beyond 2 years with agreement of the sponsor/designee.
89435952|NCT05556616|Experimental|Group 2 (RRMM Doublets) Arm 2: Modakafusp alfa + Pomalidomide|Modakafusp alfa, infusion IV, once on Day 1, Q4W in combination with Pomalidomide capsules orally once daily on Days 1 to 21 in a 28-day (4-week) treatment cycle until disease progression, unacceptable toxicity, or until any other discontinuation criterion is met, whichever occurs first.
89435953|NCT05556616|Experimental|Group 2 (RRMM Doublets) Arm 3: Modakafusp alfa + Bortezomib|Modakafusp alfa, infusion IV, once on Day 1, Q4W in combination with Bortezomib injection subcutaneously on Days 8, 15, and 22 for the first 8 cycles and subsequently on Days 8 and 22 of a 28-day (4-week) treatment cycle until disease progression, unacceptable toxicity, or until any other discontinuation criterion is met, whichever occurs first.
88917902|NCT01650870|Experimental|Split-dose|The dosing regimen of Crystalline lactulose will be three 45-gram doses (one dose every 60 minutes for 3 straight hours) taken the evening before the colonoscopy procedure followed by one 45-gram dose the morning before the colonoscopy procedure.
89010392|NCT02215330|Placebo Comparator|Sugar pill|"Maltodextrin filled into capsules.~1 Pill starting dosage~Follow-up visits (every two weeks, beginning at week 4):~If subretinal fluid is present and the patient takes two pills a day dosage stays the same.~If no subretinal fluid is present, the patient will continue the present dosage for another 2 weeks and will then stop the medication.~If no subretinal fluid is present and the patient takes no medication everything stays the same.~If subretinal fluid is present again (recurrence) and the patient takes no medication, the medication will be re-started again, the patient has to take one tablet beginning at the following day"
89010393|NCT02215330|Experimental|Eplerenone|"Eplerenone 25mg pills triturated and filled into capsules.~1 Pill starting dosage~Follow-up visits (every two weeks, beginning at week 4):~If subretinal fluid is present and the patient takes two pills a day dosage stays the same.~If no subretinal fluid is present, the patient will continue the present dosage for another 2 weeks and will then stop the medication.~If no subretinal fluid is present and the patient takes no medication everything stays the same.~If subretinal fluid is present again (recurrence) and the patient takes no medication, the medication will be re-started again, the patient has to take one tablet beginning at the following day"
89010394|NCT00261768|Experimental|1|Noise reduction on
89435954|NCT05556616|Experimental|Group 2 (RRMM Doublets) Arm 4: Modakafusp alfa + Carfilzomib|"Modakafusp alfa, infusion IV, once on Day 1, Q4W in combination with Carfilzomib IV, on Day 1, 8 and 15 of a 28-day (4-week) treatment cycle until disease progression, unacceptable toxicity, or until any other discontinuation criterion is met, whichever occurs first.~This arm is closed for enrollment after 3 participants were enrolled."
89010395|NCT02214667|Experimental|DDMI-IGT|Subjects randomized to the experimental condition will receive adapted versions of dual-diagnosis motivational interviewing ([DDMI] one session before release from jail) and integrated group therapy ([IGT] 12 community-based sessions over a 2-month period).
89010396|NCT02214667|Active Comparator|Usual care|Subjects randomized to the usual care condition will receive jail and community-based behavioral health services.
89010397|NCT02278510|Experimental|Direct infusion of topotecan|The experimental Cleveland Multiport Catheter will be used to inject a chemotherapy, topotecan, and a contrast agent, gadolinium DTPA, into the high grade brain tumors of study participants
89010398|NCT04546243||osteosarcoma patients receiving resections|
89010399|NCT04546243||osteosarcoma patients receiving radiotherapy|
89010400|NCT02278627|Experimental|manual lymphatic drainage|We wish to complete the physiotherapist's support with manual lymphatic drainage (MLD) using a specific method based on pressure of finger splayed (PFS)
89010401|NCT02278627|No Intervention|Usual treatment|
89010402|NCT04545892|Experimental|Capsaicin|From an initial 0.1% capsaicin (Sigma-Aldrich, St. Louis, MO) stock solution in 95% ethanol; we prepared solutions with 33, 66, 99, 132 and 165 μMol/ml by diluting the stock solution with distilled water. We consecutively tested 6 participants for each dose of capsaicin alternating the stimulated side of the palate.
89010403|NCT04541563|Experimental|Immediate Treatment Arm|The immediate treatment arm participants will be shipped an active Fisher Wallace device limited to Level 2 output even if a participant raises the dial beyond that. The participant will remain with the active device for the full 8 weeks.
89435955|NCT05556616|Experimental|Group 3 (RRMM Triplets) Arm A: Modakafusp alfa + Pomalidomide + Bortezomib|Modakafusp alfa, infusion IV, once on Day 1, Q4W in combination with Pomalidomide capsules orally once daily on Days 1 to 21 in a 28-day (4-week) treatment cycle along with Bortezomib injection subcutaneously on Days 8, 15 and 22 for the first 8 cycles and subsequently on Days 8 and 22 of a 28-day (4-week) treatment cycle until disease progression, unacceptable toxicity, or until any other discontinuation criterion is met, whichever occurs first.
89435956|NCT05556616|Experimental|Group 3 (RRMM Triplets) Arm D: Modakafusp alfa + Daratumumab + Pomalidomide|Modakafusp alfa, infusion IV, once on Day 1, Q4W in combination with Daratumumab injection subcutaneously on Days 1, 8, 15 and 22 of Cycles 1 and 2, further followed by on Days 1 and 15 of Cycles 3 to 6, thereafter on Day 1 on a 28-day (4-week) treatment cycle along with Pomalidomide capsules orally once daily on Days 1 to 21 in a 28-day (4-week) treatment cycle until disease progression, unacceptable toxicity, or until any other discontinuation criterion is met, whichever occurs first.
89435957|NCT05552339||Type 2 Diabetes Mellitus patients|MyTherapy App users with Self-reported Type 2 Diabetes Mellitus who had been prescribed drugs for their T2DM.
88917903|NCT01650883|Experimental|Cholecaliferol 50,000 IU PO Q10 days x 40 days|Patients in this arm receive Cholecalciferol (vitamin D3) via PO route every 10 days for 40 days for a total of 200,000 IU of Vitamin D3. They also receive daily 1200 mg of Calcium Carbonate via PO route daily for 40 days.
88917904|NCT01650883|Experimental|Cholecalciferol 5,000 IU PO daily x 40 days|Patients in this arm receive 5,000 IU of Cholecalciferol (Vitamin D3) via PO route daily for 40 days for a total of 200,000 IU. These patients also receive 1200 mg of daily Calcium Carbonate via PO route for 40 days.
88917905|NCT01650896|No Intervention|General Medicine|
88917906|NCT01650896|Active Comparator|Geriatric Medicine|Daily medical review, adjust medications, treat infection, occupational therapy
88917907|NCT01650935|Active Comparator|Oxalate restricted|After a run-in period of 3 weeks patients are allocated into 2 groups. The Oxalate restricted group is prescribed an oxalate restricted diet. They are instructed to avoid oxalate-rich foods such as spinach, rhubarb, beets, chocolate, cereals, nuts, tea, wheat bran, and strawberries and to drink water in amounts of roughly 2 L during cold weather and 3 L during warm/hot weather.
88917908|NCT01650935|Active Comparator|DASH diet|The second group is asked to follow a calorie-controlled DASH diet plan. DASH is an eating pattern recommended by the 2005 Department of Health and Human Services Dietary Guidelines for Americans as a model of healthy eating for the majority of individuals in the population. This group eats a diet which includes higher fruit, vegetables, and low-fat dairy products and lower in saturated fat, total fat, and cholesterol, containing more whole grains and fewer refined grains, sweets, and red meat.
88917909|NCT01650948||AMD subjects with GA and/or RPED|All subjects will have AMD and GA and/or RPED.
88917910|NCT01650948||AMD subjects with CNV alone|All subjects will have the CNV form of AMD only.
89198445|NCT04010110||Patients on hydroxychloroquine|A data collection sheet was used to collect patient's information. All patients underwent a complete ophthalmic examination including assessment of visual acuity, anterior segment examination looking for corneal verticillata and a dilated fundus examination looking for retinal pigment epithelium (RPE) depigmentation either in a para-foveal or extra-macular distribution within the retina. Ancillary tests were done which included: visual field testing (10-2), spectral domain ocular coherence tomography (SDOCT). Fundus auto-fluorescence and mf-ERG were done if further ancillary testing was needed in doubtful cases or to confirm findings.
89198446|NCT00864045|Experimental|Sertindole|
88917911|NCT01650961|Experimental|Palonosetron|Intravenous administration of palonosetron 0.075 mg before the induction of general anesthesia
88917912|NCT01650961|Placebo Comparator|Control|Intravenous administration of normal saline before the induction of general anesthesia
88917913|NCT01650974|No Intervention|conventional oxygen therapy|conventional nasal prong with FiO2 ~0.4
88917914|NCT01650974|Experimental|HFNOT|high flow nasal oxygen therapy with starting FiO2 0.4 and Flow 40 L/min
88917915|NCT01650974|Sham Comparator|sham-HFNOT|same device with FiO2 ~0.4, NO high flow
88917916|NCT01650987||Col 1|Patient with uterus adenocarcinoma, treated by surgery, then surveillance without complementary treatment
88917917|NCT01650987||Col 2|Patient with uterus adenocarcinoma, treated by surgery then adjuvant radiotherapy
88917918|NCT01650987||Col 3|patient with uterus adenocarcinoma, treated by surgery then curietherapy of vaginal dome
88917919|NCT01650987||Endometrial 4|patient with cervix carcinoma stage IA2 to IIB, treated by surgery only
88917920|NCT01650987||endometrial 5|patient with cervix carcinoma stage IA2 to IIB, treated by surgery then curietherapy
89198447|NCT00864045|Active Comparator|Olanzapine|
89198448|NCT00755508|Experimental|Ramelteon 4 mg QD and Gabapentin 400 mg QD|
89198449|NCT00755508|Experimental|Ramelteon 8 mg QD and Gabapentin 800 mg QD|
89198450|NCT00755508|Experimental|Ramelteon 8 mg QD and Gabapentin Placebo QD|
89198451|NCT00755508|Active Comparator|Gabapentin 800 mg QD|
89198452|NCT00755508|Placebo Comparator|Placebo|
89198453|NCT02544087|No Intervention|The basic treatment|Comply to the Chinese guidlines of acute ischemic stroke in 2014
89198454|NCT02544087|Other|Clearing heat|Treat with KDZ injection on the basis of basic treatment
88917921|NCT01650987||endometrial 6|patient with cervix carcinoma stage IA2 to IIB, treated by surgery then curietherapy and radiotherapy
89198455|NCT02544087|Other|Promoting blood circulaton|Treat with Xueshuantong injection on the basis of basic treatment
89198456|NCT02544087|Experimental|Clearing heat&Promoting blood circulaton|Treat with both KDZ injection and Xueshuantong injection on the basis of basic treatment
89198457|NCT03680352|Experimental|cefepime/AAI101 combination|Investigational drug
89198458|NCT00955942|Experimental|Arm I|Patients consume flaxseed muffins once or twice daily beginning on the first day of radiotherapy and continuing for up to 9-10 weeks.
89198459|NCT00955942|Placebo Comparator|Arm II|Patients consume placebo muffins once or twice daily beginning on the first day of radiotherapy and continuing for up to 9-10 weeks.
89198460|NCT00864201|Experimental|bosentan|
89198461|NCT00864279|Experimental|A|Cetirizine Hydrochloride 10 mg tablets, single dose
89198462|NCT00864279|Active Comparator|B|Zyrtec® 10 mg tablets, single dose
89198463|NCT02559648|Active Comparator|Denosumab|In Group A, 60 mg Denosumab will be administered sc, every 6 months for 12 months for a total of 2 doses (day 0 and day 180)
89198464|NCT02559648|Placebo Comparator|Placebo|In Group B placebo will be administered sc, every 6 months for 12 months for a total of 2 doses (day 0 and day 180)
89198465|NCT05299372|Other|Telemonitoring via Careportal®|Participants will be prompted by the device to answer two sets of questions every week: 10 items (1 nested) in the morning and 16 items (4 nested) in the evening. Also on a weekly basis, patients will be prompted to perform overnight oximetry test, and upload patient-ventilator interaction data (PVI) via Careportal®.
89198466|NCT00755586|Experimental|A|
89198467|NCT00755586|Experimental|B|
89198468|NCT00755586|No Intervention|C|
88917922|NCT01651091|Experimental|Meditation Awareness Training|
88917923|NCT01651091|Active Comparator|Treatment as Usual|
88917924|NCT01651130|Active Comparator|Carbetocin 100mcg|Carbetocin 100mcg, once following delivery of the fetal head.
89198469|NCT00864357|Experimental|A|Oxycodone HCl 5 mg / Ibuprofen 400 mg tablets, single dose
89198470|NCT00864357|Active Comparator|B|COMBONOX® tablets, single dose
89198471|NCT02559492|Experimental|Group A: Itacitinib + epacadostat|Group A will utilize an open-label 3+3 dose-escalation design based on observing each dose level for a period of 21 days.
89198472|NCT02559492|Experimental|Group B: Itacitinib + INCB050465|Group B will utilize an open-label 3+3 dose-escalation design based on observing each dose level for a period of 21 days.
88917925|NCT01651130|Active Comparator|Carbetocin 20mcg|Carbetocin 20mcg, once following delivery of the fetal head.
88917926|NCT01651130|Active Comparator|Carbetocin 15mcg|Carbetocin 15mcg, once following delivery of the fetal head.
88917927|NCT01651130|Active Comparator|Carbetocin 10mcg|Carbetocin 10mcg, following delivery of the fetal head.
88917928|NCT01651130|Active Comparator|Carbetocin 5mcg|Carbetocin 5mcg, following delivery of the fetal head.
88917929|NCT01651130|Active Comparator|Carbetocin 2mcg|Carbetocin 2mcg, following delivery of the fetal head.
88917930|NCT01651156|Placebo Comparator|placebo|Frequency: once per day Duration: 7days
88917931|NCT01651156|Experimental|Tolvaptan|Tolvaptan tablet Frequency: once per day Duration: 7days
89198473|NCT00864435|Experimental|A|Carvedilol 12.5 mg Tablets, single dose
88917932|NCT01651169|Experimental|methylphenidate tablets (10mg), ADHD|Fifteen patients of ADHD
88917933|NCT01651169|Experimental|methylphenidate tablets, Methamphetamine abusers and ADHD|Fifteen patients of ADHD with Methamphetamine abuse for at least 2 years plus
88917934|NCT01651182|Placebo Comparator|Standard Care|No tranexamic acid
88917935|NCT01651182|Experimental|Dose 1|1 g bolus + 1 g infusion from induction over 8 hours
88917936|NCT01651182|Experimental|Dose 2|1 g bolus + 10 mg/kg/hr from induction until end of surgery
88917937|NCT01651221|Experimental|Olfactory|Habituation of olfactory response
88917938|NCT01651221|Experimental|gustatory|Habituation of gustatory response.
88917939|NCT01651221|Experimental|olfactory and gustatory|Habituation of olfactory and gustatory response
88917940|NCT01651234|Experimental|Active|
88917941|NCT01651234|Placebo Comparator|Placebo|
88917942|NCT01651247||Group A|Subjects received 3 doses of the combination DTaP-HepB-IPV vaccine or separately administered DTaP, HepB, and IPV vaccines at 2, 4, and 6 months of age, in a previous study (217744/085).
89198474|NCT00864435|Active Comparator|B|Coreg® 12.5 mg Tablets , single dose
89198475|NCT00755664|Active Comparator|Low-dose complex B-vitamins|Intervention group receives Low-dose complex B-vitamins every day. Low-dose complex B-vitamins contain 400µg of folic acid, 2mg of vitamin B6, 10µg of vitamin B12 and 50mg vitamin C. Daily supplementation lasts for 12 months
89198476|NCT00755664|Placebo Comparator|Vitamin C|Control group receives Vitamin C (50mg)every day. Daily supplementation lasts for 12 months.
89198477|NCT00956098|Placebo Comparator|placebo|
89198478|NCT00956098|Experimental|oltipraz|
89198479|NCT00864591||SPECT and stress CMR patients|"patients undergoing SPECT stress imaging, for the evaluation of myocardial ischemia.~The study group will include patients with either normal undergoing SPECT stress imaging or with mild to severe ischemia, to include the entire spectrum of coronary artery disease.~Patients will be pre selected and evaluated by a non-dependent cardiologist in order to verify that patients in whom the repeat stress might pose a serious risk will be excluded from the study."
89198480|NCT00870441|Experimental|1. ASP2151|
89198481|NCT00870441|Active Comparator|2. Valacyclovir|
88917943|NCT01651247||Group B|Subjects received a single dose of the combination DTaP-IPV vaccine or separately administered DTaP and IPV vaccines at 4-6 years of age, in a previous study (213503/048).
88917944|NCT01651273|Experimental|Arm 1: BMS-852927 (0.25 mg)|
88917945|NCT01651273|Experimental|Arm 2: BMS-852927 (1.0 mg)|
88917946|NCT01651273|Experimental|Arm 3: BMS-852927 (2.5 mg)|
88917947|NCT01651273|Placebo Comparator|Arm 4: Placebo|
88917948|NCT01651286|Experimental|nasal mask|when the patient is apneic after the injection of anesthetics in the operating room, a nasal mask will be applied with positive pressure ventilation for 1 min. Then the nasal mask will be replaced with a full face mask for 1 min. Subsequently, the face mask will be replaced with the nasal mask.
89435958|NCT05547035|Experimental|Wearable monitor collected phydiological measurements|This is a single arm study with a wearable monitor that collects physiological measures (falling in the categories physical activity, heart rate, heart rate variability, breathing rate and sleep) 24/7 in ambulatory.
88917949|NCT01651286|Active Comparator|full face mask|when the patient is apneic after the injection of anesthetics in the operating room, a full face mask will be applied with positive pressure ventilation for 1 min. Then the full face mask will be replaced with a nasal mask for 1 min. Subsequently, the nasal mask will be replaced with the full face mask.
88917950|NCT01651312|Experimental|14C-labeled YM178|Single oral administration of 14C-labeled YM178
88917951|NCT01651325|Experimental|Isavuconazole and dextromethorphan|Dextromethorphan on Day 1and Day 10, Isavuconazole three times per day (TID) on Days 6 and 7, and once daily (QD) on Days 8 thru 12.
88917952|NCT01651338|Experimental|accupuncture,|The patients went through acupuncture for 8 -10 sessions and either once or two times a week. The number and the place of needles were 8 -12 for each patient which were located on the right place.
88917953|NCT01651364|Placebo Comparator|Placebo|
88917954|NCT01651364|Active Comparator|Cabergoline|
88917955|NCT01651377|Placebo Comparator|Placebo|
88917956|NCT01651377|Active Comparator|Pramipexole|
88917957|NCT01651390|Experimental|Drug coated balloon|Percutaneous coronary intervention with the Pantera Lux drug coated balloon.
88917958|NCT01651390|Active Comparator|Drug eluting stent|Percutaneous coronary intervention with the Orsiro drug eluting stent.
88917959|NCT01651416|Active Comparator|HMM using short-acting ACT|Home management of malaria using Artemether-lumefantrine combination (a short-acting ACT) for treatment in children with malaria diagnosed using RDTs
89198482|NCT00870441|Placebo Comparator|3. Placebo|
89530924|NCT00708227||African American ADRB2:ARG16ARG|All participants receive fluticasone for 2-weeks followed by fluticasone / salmeterol for 2-weeks at a dose commensurate with baseline inhaled corticosteroid dose. All participants receive ipratropium bromide for symptom rescue therapy.
88917960|NCT01651416|Experimental|HMM using short-acting ACT plus SMC|Home management of malaria using using Artemether-lumefantrine combination (a short-acting ACT) for treatment in children with malaria diagnosed using RDTs plus seasonal malaria chemoprevention with Amodiaquine plus sulphadoxine-pyrimethamine combination.
88917961|NCT01651416|Experimental|HMM using a long-acting ACT|Home management of malaria using Dihydroartemisinin Piperaquine combination (a long-acting ACT) for treatment in children with malaria diagnosed using RDTs
88917962|NCT01651429|Experimental|Sleep deprivation|Participants will undergo 29 hours of sleep deprivation, 17 of which will be spent in the laboratory.
88917963|NCT01651455||Cohort first decade|Patients born between 01/01/1979 and 12/31/1984
88917964|NCT01651455||Cohort second decade|Patients born between 01/01/1991 and 12/31/1996
88917965|NCT01651468|Experimental|HEMOFIX|3 grams a day
88917966|NCT01651481|Experimental|TR|HCP1102(Singulair and Xyzal combination tablet) -> coadministration of Singulair and Xyzal
88917967|NCT01651481|Experimental|RT|coadministration of Singulair and Xyzal -> HCP1102(Singulair and Xyzal combination tablet)
88917968|NCT01651494|Active Comparator|DAS181-F04|DAS181-F04: 20 mg single-dose each day via inhalation for 3 days; 6 subjects
88917969|NCT01651494|Placebo Comparator|Placebo|Placebo: 20 mg single-dose each day via inhalation for 3 days; 3 subjects
88917970|NCT01651507||HLP|Patients with pulmonary LCH from eight teaching hospitals evaluated between June 1989 and February 2005 were considered for this study, if they were followed for at least 6 months and evaluated by ≥ 2 lung HRCT and lung function tests at the same time or within a 2 months period
88917971|NCT01651520|Experimental|Relapsing patients < 5 years|Relapsing patients < 5 years
89530925|NCT00708227||African American ADRB2:GLY16GLY|All participants receive fluticasone for 2-weeks followed by fluticasone / salmeterol for 2-weeks at a dose commensurate with baseline inhaled corticosteroid dose. All participants receive ipratropium bromide for symptom rescue therapy.
88917972|NCT01651520|Experimental|relapsing patients < 10 years|relapsing patients < 10 years
88917973|NCT01651520|Experimental|primary progressive patients < 10 years|primary progressive patients < 10 years
88917974|NCT01651520|Other|healthy volunteers|healthy volunteers
88917975|NCT01651546|Other|Cohort|Patients with dysvoiding function and chronic urinary retention, with an indication to CISC.
88917976|NCT01651572|Experimental|Cisatracurium|"Induction and maintaining of anaesthesia with Propofol. Analgesia either with Fentanyl or Fentanyl+Remifentanyl.~Cisatracurium (Nimbex):~initial dose: 0.2 mg/kg~maintaining dose: 0.1 mg/kg (repeated anytime TOF-count reaches 2 twitches)~At the end of the surgical operation, patients will be administered Neostigmine 0.04 mg/kg and Atropine 0.02 mg/kg.~Patients will be extubated with a TOF-Ratio of at least 0.90."
88917977|NCT01651572|Experimental|Rocuronium|"Induction and maintaining of anaesthesia with Propofol. Analgesia either with Fentanyl or Fentanyl+Remifentanyl~Rocuronium (Esmeron):~initial dose: 0.6 mg/kg~maintaining dose: 0.15 mg/kg (repeated anytime TOF-count reaches 2 twitches)~At the end of the surgical operation, patients will be administered Neostigmine 0.04 mg/kg and Atropine 0.02 mg/kg.~Patients will be extubated with a TOF-Ratio of at least 0.90."
88917978|NCT01651585|Experimental|Valacyclovir arrow|Experimental : Valacyclovir arrow 500mg give Valacyclovir arrow to all participants (open phase)
88917979|NCT01651598|Experimental|BI 144807|Subjects receive multiple BID doses of BI 144807 solution
88917980|NCT01651598|Placebo Comparator|Placebo|Subjects receive multiple BID doses of Placebo solution
88917981|NCT01651611|Experimental|Extensive TTA interaction|Persons interested in quitting smoking will receive multiple in-person visits from a peer Tobacco Treatment Advocate (TTA) who will provide motivational interviewing, basic smoking cessation counseling assistance, navigation to smoking cessation resources, and social support.
88917982|NCT01651611|Active Comparator|Minimal TTA interaction|Persons interested in quitting smoking will receive a single in-person visit from a peer Tobacco Treatment Advocate (TTA) who will provide basic smoking cessation counseling assistance.
88917983|NCT01651624|Experimental|Computed tomographic colonography (CTC), reduced prep|Subjects invited to undergo CTC with reduced cathartic preparation
88917984|NCT01651624|Experimental|Computed tomographic colonography (CTC), standard prep|Subjects invited to undergo CTC with standard bowel preparation
88917985|NCT01651624|Active Comparator|Faecal occult blood test (FOBT)|Subjects invited to undergo FOBT
88917986|NCT01651624|Experimental|Colonoscopy|Subjects invited to undergo colonoscopy
88917987|NCT01651637|Experimental|Synthetic Surfactant|Cohort Design
88917988|NCT01651650|Other|Inhalation of Placebo Dry Powder|Each patient will perform at least two inhalations using the Chiesi NEXThaler DPI device containing placebo dry powder. There is no comparator and all patients will receive the same study treatment.
88917989|NCT01651663|Experimental|Arbidol (Umifenovir)|
88917990|NCT01651663|Placebo Comparator|placebo|
88917991|NCT01651663|Experimental|Arbidol (Umifenovir) prophylaxis|
88917992|NCT01651663|Placebo Comparator|placebo prophylaxis|
89435959|NCT05545748|Experimental|Zero (0) Tolerance Program Group|"The intervention to this group consists of four parts.~Urine Cotinine Feedback: Explaining what the cotinine-sensitive dipstick test kit score and color scale mean. Cotinine-sensitive dipstick test kit is a simple, cost-effective test to determine smoking status. It is an easy-to-read test strip that can be used with either a saliva or a urine sample.~Giving reminder objects (Magnet, sticker): For example; at the entrance door of the house: 0 TOLERANCE magnet to cigarettes; No smoking in my home label.~Informative Materials (Information Notes and Brochures): Brochures on the harms of second-hand smoking (SHS) and third-hand smoking (THS), the diseases they cause, and how to protect them~Informative Telephone Text Messages: Reminder phone messages related to SHS and THS"
88917993|NCT01651676|Experimental|COPD arm|"VQ11 validation:~Stage II, III or IV COPD patients justifying a LABD will benefit from the studied VQ11 questionnaire"
88917994|NCT01651689||Scalp biopsy|Subjects are on scadule list for hair transplantation in Siriraj hospital. Scalp biopsy with punch biopsy No.4 Scalp biopsy by punch biopsy No.4 at occipital area was done in subjects who have hair transplantaion.
88917995|NCT01651702|Active Comparator|Carto|Patients in whom Carto system will be used
88917996|NCT01651702|Active Comparator|Ensite|Patients in whom Ensite system will be used
88917997|NCT01651715|Experimental|TAO1, oral homeopathic antibodies|TAO1 is an investigational medicinal product containing homeopathic dilutions (<10-24M) of antibodies purified from the serum of rabbit immunised against a synthetic peptide with an amino acid sequence selected in the human toll-like receptor type 3 sequence (anti-TLR3). It is intended for the treatment of viral Upper Respiratory Tract Infections (URTIs) such as common cold, influenza or influenza-like illnesses.
88917998|NCT01651715|Placebo Comparator|Placebo|Same characteristics as investigational medicinal Product except for homeopathic dilutions of oral antibodies to the TLR3 FYW peptide
88917999|NCT01651728|Experimental|Simvastatin|Tablet 20 mg once daily for 30 days
88918000|NCT01651728|Placebo Comparator|Placebo|Placebo tablet once daily for 30 days
88918001|NCT01651741|Experimental|Seaweed and Duolac7S|Seaweed: Real Seaweed granule, Duolac7S: Real probiotics
88918002|NCT01651741|Placebo Comparator|Seaweed and Duolac7S-P|Seaweed: Real Seaweed granule, Duolac7S-P: Placebo probiotics
88918003|NCT01651754|Other|Seasonal influenza vaccination|
89435960|NCT05545748|Active Comparator|Exposure Feedback Group|This group will receive only exposure feedback Urine Cotinine Feedback: Explaining what the cotinine-sensitive dipstick test kit score and color scale mean. Cotinine-sensitive dipstick test kit is a simple, cost-effective test to determine smoking status. It is an easy-to-read test strip that can be used with either a saliva or a urine sample.
89435961|NCT05533775|Experimental|Arm A|Participants will receive glofitamab + R-ICE chemoimmunotherapy for up to 3 cycles (cycle length = 21 days).
89435962|NCT05533775|Experimental|Arm B|Participants will receive glofitamab monotherapy for up to 12 cycles (cycle length = 21 days).
89435963|NCT05529758|Experimental|Intervention Group|Receives internalized weight bias intervention along with standard behavioral weight loss program
88918004|NCT01651767|Experimental|Panel I|Patients will be randomized to receive JNJ-47910382 at a dose of 30 mg or placebo as monotherapy once daily for 5 days.
89435964|NCT05526248|Experimental|Lead-in phase: Darolutamide treatment|Darolutamide treatment arm is single cohort in lead-in phase.
88918005|NCT01651767|Experimental|Panel II|Patients will be randomized to receive JNJ-47910382 at a dose of 90 mg or placebo as monotherapy once daily for 5 days.
88918006|NCT01651767|Experimental|Panel III|Patients will be randomized to receive JNJ-47910382 at a dose of 300 mg or placebo as monotherapy once daily for 5 days.
88918007|NCT01651767|Experimental|Panel IV|Patients will be randomized to receive JNJ-47910382 at a dose of 400 or 450 mg once daily or 300 mg twice daily (morning dose only on Day 5) or placebo as monotherapy for 5 days.
88918008|NCT01651819|Experimental|Urological physical therapy|Urologic physical therapy is going to be apply in 20 patients with HTLV-1 infection and overactive bladder symptoms like urgency, incontinence and nocturia. There will be 20 sessions with one hour duration and a interval of 3 or 4 days between the sections.
88918009|NCT01651832|No Intervention|usual care|routine care and case management
88918010|NCT01651832|Experimental|SCAN-Intervention|
88918011|NCT01651845||Image Guided Intervention|Standard of care white light visual wound assessment followed by fluorescence image-guided wound assessment
88918012|NCT01651858|Experimental|Nurigra Chewable tablet|
88918013|NCT01651858|Active Comparator|Viagra|
88918014|NCT01651884|Experimental|High-Definition tDCS|
88918015|NCT01651884|Experimental|Sponge tDCS|
88918016|NCT01651897||Delirious in the ED|Patients who were delirious in the ED at either the 0-hour or 3-hour delirium assessment.
88918017|NCT01651897||Non-Delirious in the ED|Patients who were non-delirious in the ED at both the 0-hour or 3-hour delirium assessment.
88918018|NCT01651923|Other|Group A|"First periody: Heparin Test Drug (Blau Farmacêutica S/A)~Secundy periody: Heparin Comparator Drug (APP Pharmaceuticals)"
88918019|NCT01651923|Other|Group B|"First periody: Heparin Comparator Drug (APP Pharmaceuticals)~Secundy periody: Heperin Test Drug (Blau Farmacêutica S/A)"
88918020|NCT01651962|Experimental|Terbutaline|Terbutaline 0.125mg i.v. x 1 dose prior to positioning for epidural placement; may repeat x1 PRN
88918021|NCT01651962|Active Comparator|Fentanyl|Fentanyl 100mcg i.v. x 1 dose prior to positioning for epidural placement; may repeat x1 PRN
88918022|NCT01651962|Placebo Comparator|Placebo|0.9% NaCl i.v. x 1 dose prior to positioning for epidural placement; may repeat x1 PRN
88918023|NCT01651975|Other|Thickenup|
88918024|NCT01651988|Active Comparator|Ketofol 1:1|1. Anesthesia-sedation KETOFOL 1-1: Two milligrams per kilogram of ketamine plus two milligrams per kilogram of propofol in a solution 1:1 (one milligram of ketamine per one milligram of propofol) was given to those patients randomly asigned to this group, who were scheduled for any short surgical procedures previously defined in the inclusion criteria.
88918025|NCT01651988|Experimental|Ketofol 1:2|2. Anesthesia-sedation KETOFOL 1-2: One milligram per kilogram of ketamine plus two milligrams per kilogram of propofol in a solution 1:2 (one milligram of ketamine per two milligrams of propofol) was given to those patients randomly asigned to this group, who were scheduled for any short surgical procedure previously defined in the inclusion criteria.
88918026|NCT01652014|Experimental|Arm I|"Double UCB transplantation~Patients receive conditioning comprising fludarabine phosphate IV over 30 minutes on days -6 to -2, cyclophosphamide IV over 1 hour on day -6, and undergo TBI on day -1. Patients also receive GVHD prophylaxis comprising tacrolimus IV continuously or PO beginning on day -3 with taper and mycophenolate mofetil PO BID days 1-30. Patients undergo double allogeneic UCB transplant on day 0."
88918027|NCT01652014|Experimental|Arm II|"Sub-threshold single UCB + irradiated PBMCs transplantation~Patients receive conditioning comprising fludarabine phosphate IV over 30 minutes on days -6 to -2, cyclophosphamide IV over 1 hour on day -6, and undergo TBI on day -1. Patients also receive GVHD prophylaxis comprising tacrolimus IV continuously or PO beginning on day -3 with taper and mycophenolate mofetil PO BID days 1-30. Patients undergo single allogeneic UCB transplant on day 0. Patients also undergo irradiated allogeneic PBMC transplant within 8 hours following the UCB infusion."
88918028|NCT01652027||Previously Untreated Patients with Hemophilia A|
88918029|NCT01652053||Disc Nucleus Replacement|Disc Nucleus Replacement (InterCushion DNP)
88918030|NCT01652066|Placebo Comparator|Placebo|oral consumption, once per day in the morning, fasting, with a glass of water
88918031|NCT01652066|Experimental|Mixture of probiotics|"at least 10x7 cfu/tablet of a mixture of probiotics~oral consumption, once per day in the morning, fasting, with a glass of water"
88918032|NCT01652079|Experimental|Treatment Arm|CRLX101
88918033|NCT01652105|Experimental|Diet|New developed diet
88918034|NCT01652105|Active Comparator|Prodimed|Standard VLCD
88918035|NCT01652118|Active Comparator|Clarithromycin|Fist group treated with clarithromycin which is include 10 days application.
88918036|NCT01652118|Placebo Comparator|placebo|Second group treated with salin as same as amount of clarithromycine volume
88918037|NCT01652131|Other|Tetrastarch (130/0.4)|In obese patients candidates to laparoscopic gastrojejunal bypass an infusion of Tetrastarch (130/0.4)) of 15mL/kg (of corrected weight) will be initiated after protocoled induction of general anesthesia. Blood samples will be taken at time 0 (after induction of anesthesia and before initiating infusion) and then every 5 minutes for half an hour and then every 15 minutes up to 90 minutes. Blood samples will be processed in the Institution's laboratory. Urine will be measured at the end of the intervention. With these data kinetic parameters will be estimated for each patient.
89198483|NCT04079452|Experimental|Doravirine + Descovy® TAF/FTC|Doravirine (MK-1439) 100 mg administered orally once daily in combination with Tenofovir alafenamide (TAF) and emtricitabine (FTC) coformulated as single tablet (Descovy® TAF/FTC 25/200 mg) and administered orally once daily during 4 weeks
89435965|NCT05526248|Experimental|Randomized phase: Darolutamide treatment|The conduct of the randomized phase is dependent on the results of the lead-in phase.
89435966|NCT05526248|Active Comparator|Randomized phase: Enzalutamide treatment|The conduct of the randomized phase is dependent on the results of the lead-in phase.
88918038|NCT01652157||Cystic fibrosis (CF) patients in the CF Patient Registry|Patients diagnosed with cystic fibrosis at participating sites who are providing data to the Cystic Fibrosis Patient Registry
88918039|NCT01652183|Placebo Comparator|Group Control (n=32):iv 1.5 ml/kg 0.9% NaCl|
88918040|NCT01652183|Active Comparator|Group Paracetamol(n=32):iv 15mg/kg paracetamol|The patients were randomly divided into two groups: Group P (Paracetamol group, n=32) received intravenous 15mg/kg paracetamol during the surgery and Group C (Control Group, n=32) received intravenous 1.5 ml/kg 0.9% NaCl solution 30 minutes before the of surgery.At the end of the surgery, all patients had an nephrostomy catheter and the insertion site was infiltrated with 20 ml 0.25% bupivacaine infiltration for postoperative analgesia. Each patient received patient-controlled intravenous analgesia by meperidine (10 mg bolus, 20-minute lock-out, no infusion dose and 4 hour limit) for postoperative analgesia. All patients were planned to receive tenoxicam 20 mg intravenously as a rescue analgesic when visual analogue scale (VAS) was >3.
89010404|NCT04541563|Sham Comparator|Delayed Treatment Arm|In the delayed treatment arm, the participants will receive a sham device that looks exactly the same, but only provides treatment for 2 seconds. At week 4, sham arm participants will be unblinded and shipped an active device (limited to Level 2 output even if a participant raises the dial beyond that). The delayed arm participants will continue with active devices for the remaining 4 weeks of the trial.
89010405|NCT02214706|Experimental|sirolimus topical 40microgram/cm2|sirolimus topical 40microgram/cm2
89010406|NCT02214706|Experimental|Pulsed Dye Laser + Erbium yag + sirolimus|Pulsed Dye Laser + Erbium yag laser + topical sirolimus
89198484|NCT00864669|Experimental|A|Metformin HCl 500 mg tablets, single dose
89198485|NCT00864669|Active Comparator|B|CLUCOPHAGE® XR 500 mg tablets, single dose
89435967|NCT05525572|Experimental|Shockwave Therapy (SWT) + Platelet-Rich Plasma (PRP) Group|Participants will receive a combination of 5 weekly extracorporeal shockwave therapy sessions (SWT) and two sessions of autologous platelet-rich plasma (PRP) penile injection.
89435968|NCT05524987|Experimental|INTERVENTION|"Participants in the ANDES intervention group will receive the ANDES implementation package consisting of health agent home visits for 12 consecutive months. Implementation package delivery will end after month 12, at which time intervention participants will be advised to obtain standard care from their local healthcare facility. ANDES is an adaptation of the World Health Organization (WHO) HEARTS package and consists of the following components:~A. Health agent-managed home care~BP monitoring~Health coaching~Health system navigation~Medication adherence support B. Text message-based health coaching Specifically, the ANDES strategy is aligned with four WHO HEARTS technical package components."
88918041|NCT01652196|Experimental|Aflibercept (combination chemotherapy)|Patients receive aflibercept and fluorouracil and then continuously over 46 hours on days 1 and 15.If leucovorin is not available due to drug shortages the regimen should be administered with the leucovorin omitted. Correlative Studies are required to be available before enrolling on the study. A fresh biopsy is only required if there is insufficient material for analysis. Repeat tumor biopsies after 8 weeks of therapy are optional and will only be performed at the Ohio State University Medical Center.DCE MRI (dynamic contrast-enhanced magnetic resonance imaging)images at weeks 0, and after 8 weeks +/- 1 week of treatment(after Cycle 2). 18FDG-PET is a functional imaging technique that relies on tumor uptake of radiolabeled tracer 18 fluorodeoxyglucose (18FDG).FDG-PET is a widely-used imaging modality in the detection and monitoring of a variety of metastatic cancers,including colorectal cancer (99-102).
88918042|NCT01652209|No Intervention|Control|"After implementing PCI, contemporary drug treatment is conducted.~*Contemporary drug treatment is a general drug treatment (Unfractionated heparin, Low Molecular Weight Heparin, Glycoprotein llb/llla inhibitor, Aspirin, clopidogrel or Ticlopidine, Nitrate, ACE inhibitor or ARB, β-blocker, CCB, Diuretics, Statin, etc.)"
88918043|NCT01652209|Experimental|Single dose of Hearticellgram-AMI|Within 30 days (+ / -7 days) after aspirating bone-marrow, approximately 1×10^6/kg (refer to usage/dosage according to mass) of autologous bone marrow-derived mesenchymal stem cells are adminstered into the infarct coronary artery using balloon tipped catheter. Furthermore, contemporary drug treatment is conducted.
88918044|NCT01652222|Experimental|CONEM-BETA + socio-educational training|"Caregivers will receive 4 socioeducational training sessions during an 8 week period. These sessions will focus on the description and process of the Alzheimer's disease (AD), and will also provide to the caregivers resources and strategies to cope with AD. During the last 4 weeks, they will also systematically play with the patient at home with the CONEM-BETA game.~After that period, caregivers will use the game based on their preference and frequence during a period of 6 more weeks."
88918045|NCT01652222|Active Comparator|Socio-educational training only|Caregivers will receive the same 4 socioeducational training sessions as the experimental group, during an 8 week period.
88918046|NCT01652222|No Intervention|Control|Caregivers of this group will behave with his/her patient during the trial as they have been doing so far, but will receive no intervention
88918047|NCT01652248|Placebo Comparator|Standard generator replacement|Standard generator replacement
88918048|NCT01652248|Active Comparator|Upgrade to cardiac resynchronisation therapy|Upgrade to CRT at the time of generator replacement
88918049|NCT01652261|Experimental|experimental arm|"An experimental arm (early FDG-PET/CT-response adapted), where all patients are initially treated with a single cycle of ABVD. Very early FDG-PET/CT-negative patients continue on ABVD therapy to a total of six cycles. Very early FDG-PET/CT-positive patients receive 3 cycles of BEACOPPesc followed by another 3 cycles of BEACOPPesc. Mid-treatment evaluation is performed after 4 cycles. In case of treatment failure (less than partial remission (PR)), the patient goes off protocol treatment.~Only patients with residual FDG-PET/CT-positive disease after chemotherapy will receive radiotherapy (36 Gy/18 fractions on the FDG-PET/CT-positive residual mass(es))."
88918050|NCT01652261|Active Comparator|standard arm|"A standard arm, where patients are treated with four cycles of BEACOPPesc followed by 2 cycles of BEACOPPesc. FDG-PET/CT is performed after one cycle, but with no therapeutic consequences. Mid-treatment evaluation is performed after four cycles. In case of treatment failure (less than PR), the patient goes off protocol treatment.~Only patients with residual FDG-PET/CT-positive disease after chemotherapy will receive radiotherapy (36 Gy/18 fractions on the FDG-PET/CT-positive residual mass(es))."
88918051|NCT01652274||Mother|study objectives to Mother only
88918052|NCT01652274||Father|study objectives to Father only
88918053|NCT01652300|Experimental|test group|For test group intervention was two educational sessions lasting 1 hour, focused on oral and dental health and especially on oral and dental health during pregnancy
88918054|NCT01652300|Other|control|received no education
88918055|NCT01652313|Experimental|Rasagiline|
88918056|NCT01652326||Benzodiazepine-resistant|those patients with either 1) a requirement of either 200 mg of diazepam (or diazepam equivalents) in 4 hrs; 2) >40mg of diazepam (or diazepam equivalents) in 1 hr; or 3) an individual dose of 40 mg or greater of intravenous diazepam for control of agitation
88918057|NCT01652339|Active Comparator|Exforge tab. 10/160mg|"amlodipine besylate (10mg as amlodipine)~valsartan 160mg"
88918058|NCT01652339|Experimental|Lodivixx tab. 5/160mg|"S-amlodipine nicotinate (5mg as S-amlodipine)~valsartan 160mg"
89010407|NCT02214706|Experimental|Pulsed Dye Laser + topical sirolimus|Pulsed Dye Laser + topical sirolimus
89435969|NCT05524987|No Intervention|CONTROL|Participants in the usual care group will be referred to their local healthcare facility for evaluation and/or to receive medical therapy per typical standard of care and at the discretion of the treating physician for the entirety of the ANDES study.
89010408|NCT02214706|Experimental|Pulsed Dye Laser|Pulsed Dye Laser
89010409|NCT04541485|Experimental|Experimental: Cohort 1 (96 mg)|24 mg/0.1 mL x 4 sites
89010410|NCT04541485|Experimental|Experimental: Cohort 2 (288 mg)|72 mg/0.3 mL x 4 sites
89010411|NCT04541485|Experimental|Experimental: Cohort 3 (480 mg)|120 mg/0.5 mL x 4 sites
89010412|NCT04541485|Experimental|Experimental: Cohort 4 (672 mg)|168 mg/0.7 mL x 4 sites
89010413|NCT04541485|Experimental|Experimental: Cohort 5 (960 mg)|240 mg/1.0 mL x 4 sites
89010414|NCT02214745||Mentally retarded Israeli Arab children|
89010415|NCT02214745||Israeli Arab children with cerebral palsy|
89010416|NCT02214745||Israeli Jewish children with cerebral palsy|
89010417|NCT02214745||Mentally retarded Israeli Jewish children|
89010418|NCT02214784|Active Comparator|Active Neurotech Vital Device|50% of 140 patients on a 12 week treatment programme with the device used 5 days out of 7 for 30minutes over 12 weeks.
89010419|NCT02214784|Placebo Comparator|Modified Neurotech Vital Device|50% of 140 patients on a 12 week treatment programme with the device used 5 days out of 7 for 30 minutes over 12 weeks.
89010420|NCT02214862|Experimental|[F18]-FDDNP|2-(1-{6-[(2-[F-18]fluoroethyl) (methyl)amino]-2-naphthyl} ethylidene) malononitrile Radiopharmaceutical tracer, intravenous, single dose of 360+/-20 megabecquerel
89010421|NCT00269295|Experimental|Cohort 1: Arm 1|12 subjects to receive vaccine dose 1: 5 X 10^7 cfu.
89010422|NCT00269295|Placebo Comparator|Cohort 1: Arm 2|6 subjects to receive placebo.
89010423|NCT00269295|Experimental|Cohort 2: Arm 1|12 subjects to receive vaccine dose 2: 5 X 10^8 cfu.
89435970|NCT05522673|Other|Subjects with major depression disorder (MDD)|Participants with major depressive disorder received 20 mCi of [11C](R)-rolipram intravenously for two PET scans, prior to and after ketamine infusion as well as brain MRI
89435971|NCT05521503||Biological specimens|Biological specimens taken from cardiovascular procedures
89010424|NCT00269295|Experimental|Cohort 3: Arm 1|12 subjects to receive vaccine dose 3: 5 X 10^9 cfu.
89010425|NCT00269295|Placebo Comparator|Cohort 3: Arm 2|6 subjects to receive placebo.
89010426|NCT00269295|Placebo Comparator|Cohort 2: Arm 2|6 subjects to receive placebo.
89010427|NCT04541134|Other|Group 1|
89010428|NCT04541134|Other|Group 2|
89010429|NCT04541368|Experimental|Administration of CS1 Targeted CAR T-cells|Dose escalation follows the standard 3+3 dose escalation design. A total of 3 dose levels are set for subjects.
89010430|NCT00261924|Experimental|Intercept Platelets|Study patients receiving platelets that have been processed with the INTERCEPT pathogen inactivation system
89010431|NCT00261924|Active Comparator|Conventional Platelets|Study patients receiving platelets processed by standard method without the INTERCEPT pathogen inactivation system
89010432|NCT04545463|Active Comparator|Insoluble Fibre|Cookies with insoluble fibre (wheat bran)
89010433|NCT04545463|Active Comparator|Soluble Fibre|Cookies with soluble fibre (Psyllium plantago)
89010434|NCT04545463|Experimental|FIBRACEP|Cookies with FIBRACEP
89010435|NCT04545697|Experimental|Patient Decision Support|Instructions will be provided for installation and use of a smartphone recording app 7-60 days before an oncology consultation. Participants will share the recording with the Patient Support Corps (PSC), who will summarize the recording, send it to the participant's oncologist for review, then return an annotated summary to the participant within a week of the consultation.
89010436|NCT02214901|Experimental|BIBW 2948 BS in single rising doses|
89010437|NCT02214901|Placebo Comparator|Placebo|
89010438|NCT04541251|Experimental|Camrelizumab + Nab-paclitaxel + Carboplatin|
89010439|NCT04540783|Active Comparator|Group 1 - G1|bitemporal anodal stimulation and cathodal stimulation at supraorbital region.
89010440|NCT04540783|Active Comparator|Group 2 - G2|dorsolateral prefrontal anodal stimulation and cathodal stimulation at contralateral supraorbital region.
89010441|NCT04540783|Sham Comparator|Group 3 - G3|sham anodal stimulation over bitemporal or dorsolateral prefrontal cortex (randomized) and sham cathodal over the orbitofrontal region.
89010442|NCT04545034|Experimental|Water aerobic exercise protocol|Walter aerobic exercise session would be used to treat blood pressure in elderly hypertensive people.
89010443|NCT04545034|No Intervention|Control Group|No exercise intervention would be used.
89010444|NCT04540549|Experimental|intervention group|Jogging or cycling ≥5 days/week, 30-60 min/d
89010445|NCT04540549|No Intervention|control group|The control group was encouraged to maintain their lifestyle.
89010446|NCT04545073||Post-refractive trifocal IOL|
89010447|NCT04545307|Experimental|Allogenic transplant of BM-MSCs|"Under sterile conditions, the patient will be locally anesthetized in the affected tooth area; the root canal of the affected tooth will be exposed and prepared to perform the MSC / MSC-Endo / PRP implant. At the same time, the culture medium supernatant is removed from each tube and the MSC / MSC-Endo button (pellet) is resuspended in autologous platelet-rich plasma (PRP). Subsequently to the MSC / MSC-Endo / PRP suspension, 5% CaCl2 and thrombin will be added. Immediately, and before the clot forms, 20 microliters of the MSC / MSC-Endo / PRP suspension will be placed in the root canal, covered with a collagen membrane. Subsequently, the obturation procedure with bioceramics will be carried out at the level of the pulp chamber, ionomeric glass to protect the bioceramic and later composite resin to restore the tooth."
89198486|NCT00760890|Experimental|A|Medicinal Iron
89435972|NCT05521126||high risk/ACL repair cohort|The high risk cohort will be subjects who have had an ACL reconstruction procedure 9-24 months prior to enrollment.
89435973|NCT05521126||control group|The control group will be individuals who have not had an ACL reconstruction procedure.
89435974|NCT05519150||Stone Donors|Evaluation for kidney donation > 2 years ago, had history of kidney stones or kidney stones on imaging and successfully donated a kidney
89435975|NCT05519150||Denied donors|Evaluation for kidney donation > 2 years ago, had history of kidney stones or kidney stones on imaging and were declined for donation due to history of kidney stones, Litholink abnormalities or Imaging findings
88918059|NCT01652352||Individuals with Disability|Power wheelchair-bound individuals with conditions which affect upper and lower body mobility, strength, or dexterity. Such conditions may include but are not limited to spinal cord injury, Multiple Sclerosis, Cerebral Palsy, or other conditions which affect overall mobility.
88918060|NCT01652352||Able-Bodied Individuals|Those who possess no condition or injury resulting in loss of mobility.
88918061|NCT01652365|Experimental|RDT Training and Subsidy Offered|Licensed drug shops within villages selected randomly to be in this arm will be invited to training on RDTs and offered access to subsidized RDTs available for purchase at a local wholesale pharmacy in Mbale, Uganda.
88918062|NCT01652365|Experimental|Information/Education Campaign|Community meetings describing RDTs and encouraging community members to be diagnosed prior to taking malaria treatment will be held in villages randomly assigned to this treatment arm.
88918063|NCT01652365|Experimental|RDT Training/Subsidy + Information/Education Campaign|Includes both the training and subsidy component and the information/education campaign component.
88918064|NCT01652365|No Intervention|Control|
88918065|NCT01652378||Cocaine-Addicted Participants|Group of participants diagnosed with cocaine dependence
88918066|NCT01652378||Control Participants|healthy control volunteers
88918067|NCT01652391|Experimental|Anodal transcranial direct current stimulation|Anodal transcranial direct current stimulation (tDCS) 20min, 1mA, F3 (EEG 10/20), reference right M. deltoideus
88918068|NCT01652391|Sham Comparator|Sham transcranial direct current stimulation|Sham transcranial direct current stimulation (tDCS) 40s, 1mA, F3 (EEG 10/20), reference right M. deltoideus
88918069|NCT01652404|Experimental|Procalcitonin-guided treatment|The duration of antibiotics will be determined by the procalcitonin levels.
88918070|NCT01652404|Active Comparator|Conventional treatment|The duration of antibiotics will be determined by the treating physician.
88918071|NCT01652417|No Intervention|oral prednisone|Oral prednisone 1 mg/kg/d for 30 days and progressive tapering of steroids, to get 0,5 mg/kg/d at M3 and 0,25 mg/kg/d at M6 and 5-10 mg at M12.
88918072|NCT01652417|Experimental|methylprednisolone bolus|methylprednisolone bolus 15 mg/kg/d for 3 days before oral prednisone 1 mg/kg/d for 30 days and progressive tapering of steroids, to get 0,5 mg/kg/d at M3 and 0,25 mg/kg/d at M6 and 5-10 mg at M12.
88918073|NCT01652430||PTSD cohort|
88918074|NCT01652430||No PTSD cohort|
88918075|NCT01652456|Experimental|Group A|
88918076|NCT01652456|No Intervention|Group B|
88918077|NCT01652508|Placebo Comparator|Control|Participants are given printed self-help leaflet on smoking cessation developed by the Department of Health, Hong Kong.
88918078|NCT01652508|Experimental|Acceptance and Commitment Therapy|All participants are given a self-help leaflet on smoking cessation. Participants are also given an initial session of face-to-face ACT at a primary health service clinic. In addition, two more subsequent ACT sessions are provided by telephone at one week and one month after the initial intervention.
88918079|NCT01652521||candidates for pleural fluid drainage|patients who are candidates for pleural fluid drainage.
88918080|NCT01652534|Active Comparator|Amantadine|Amantadine 100mg daily, for a week, if it is tolerated Amantadine will increase to 1 tab twice a day
88918081|NCT01652534|Placebo Comparator|placebo|Sugar Pill
88918082|NCT01652547|Experimental|Pasireotide sub-cutaneous formulation|Pasireotide, will be administered to all patients by s.c. injection, beginning with a dose of 300 μg administered three times daily (t.i.d.) for 2 weeks. If no pasireotide-related clinically meaningful/uncontrolled grade 3 or grade 4 adverse events occur the dose will be administered to all patients at an increased dose of 600 μg t.i.d. for 2 weeks, followed by 2 weeks of 900 μg t.i.d. and followed by 2 weeks of 1200 μg t.i.d. After the 8 weeks period, patients will be kept on treatment drug (highest dose without clinically meaningful/uncontrolled AEs), switched to the corresponding pasireotide LAR dose and followed up for an extra 6 months.
88918083|NCT01652547|Experimental|Pasireotide long acting release|At the start of the follow-up phase patients will be switched to pasireotide LAR administered intramuscularly every 28 days by using the following conversion algorithm so that the steady state PK exposure (Cmax and Ctrough) of pasireotide will be maintained: 300 μg s.c. t.i.d. fi 20mg LAR i.m. q 28 days 600 μg s.c. t.i.d. fi 40 mg LAR i.m. q 28 days 900 μg s.c. t.i.d. fi 60 mg LAR i.m. q 28 days 1200 μg s.c. t.id. fi 80 mg LAR i.m. q 28 days In addition, all patients will keep the treatment with pasireotide s.c. during the first 2 weeks of the LAR phase. The use of s.c. dosing during the initial 2 week period following the first LAR dose provides an appropriate level of medication during the LAR nadir.
88918084|NCT01652560||bevacizumab combined neoadjuvant chemotherapy|
88918085|NCT01652586|Experimental|dexmedetomidine-remifentanil|intravenous infusion of 0.2-0.7 µg/kg/h of dexmedetomidine after a loading dose of 1 µg/kg over 10 min
88918086|NCT01652586|Active Comparator|midazolam-remifentanil|remifentanil 3.6-7.2 mcg/kg/h midazolam 1-2mg
88918087|NCT01652599|Experimental|Eltrombopag and dexamethasone|
88918088|NCT01652612|No Intervention|Control|zero PEEP
88918089|NCT01652612|Experimental|OLV strategy: PEEP|1. apply 8 cm H2O positive end expiratory pressure during one lung ventilation and until the end of surgery
88918090|NCT01652612|Experimental|OLV strategy: PEEP followed by AR|"alveolar recruitment strategy before one lung ventilation~8 cmH2O positive end expiratory pressure during one lung ventilation and until the end of surgery"
88918091|NCT01652625|Experimental|Yunnan Baiyao toothpaste|The toothpaste containing 6.5 milligrams of Yunnan Baiyao was used twice daily as part of the patient's routine oral hygiene for 5 days.
88918092|NCT01652625|Active Comparator|placebo toothpaste|One gram of placebo toothpaste was used twice daily by the control group patients. Except for the active Yunnan Baiyao extract, all ingredients contained in the placebo-toothpaste were the same as that in the experimental toothpaste.
89198487|NCT00760890|Experimental|B|Iron fortified wet pack cereal
88918093|NCT01652638|Experimental|Group A|"First periody: Test Drug (Heparin Blau Farmacêutica S/A)~Secundy periody: Comparator Drug (Heparin APP Pharmaceuticals)"
88918094|NCT01652638|Experimental|Group B|"First periody: Comparator Drug (Heparin APP Pharmaceuticals)~Secundy periody: Test Drug (heparin Blau Farmacêutica S/A)"
88918095|NCT01652651|Experimental|Psychological Intervention|
88918096|NCT01652677|Experimental|Low-frequency stimulation|Stimulation mode: 1 Hz, 100% MT, 20 minutes, unaffected hemisphere
88918097|NCT01652677|Experimental|High frequency stimulation|Stimulation mode: 10 Hz, 80% MT, 2 seconds - stimulation, 58 seconds - rest. - 8 session; affected hemisphere
88918098|NCT01652677|Sham Comparator|Sham stimulation|Patients will receive standard treatment (kinesotherapy, physiotherapy) and simulate of transcranial magnetic stimulation. Also patients will not know about simulation (blind group)
88918099|NCT01652677|Experimental|Both hemispheric stimulation|Stimulation mode: low-frequency to unaffected hemisphere than high-frequency to affected.
88918100|NCT01652742|Experimental|BI 135585 XX|one single dose
88918101|NCT01652755||AKI group|patients with AKI after cardiopulmonary bypass surgery
88918102|NCT01652755||non-AKI group|patients without AKI during study period
88918103|NCT01652768|Active Comparator|Arm A: Usual Care Group|Usual care is defined as standard post-operative care on a surgical unit in University Hospitals Case Medical Center. Discharge planning will be provided by the assigned in-patient social worker. Referrals to the assigned outpatient social worker will be made as appropriate. Patients and caregivers will be seen in the ambulatory medical oncology setting about three to six weeks after surgery, depending on post-operative recovery time. The research assistant will administer the research questionnaires at week one post-surgery and 8-10 weeks post surgery.
88918104|NCT01652768|Experimental|Arm B: PRESENCE Intervention|The unique features of the PRESENCE Project (PP) Intervention are 1) the early palliative care intervention (immediately post-op) provided by the new palliative care brain tumor team (Social worker, advanced practice nurse (APN), medical oncology registered nurse); 2) an educational information session for patients and caregivers; and 3) frequent (every two week and as needed) telephone or clinic visits during the first ten weeks post operatively (Figure 1). In usual care, the patient and caregiver receive little supportive care until they begin cancer treatment. The intervention provides aggressive supportive care from the time of diagnosis.
88918105|NCT01652781|Experimental|5-day arm|azacitidine 75mg/m2 subcutaneously for 7 days every 28 days + best supportive care
88918106|NCT01652781|Active Comparator|7-day arm|azacitidine 75mg/m2 subcutaneously for 5 days every 28 days + best supportive care
88918107|NCT01652794|Experimental|Treatment (carboplatin, gemcitabine hydrochloride, and SBRT)|Patients also receive carboplatin IV over 30 minutes and gemcitabine hydrochloride IV over 30 minutes on day 1 and undergo SBRT on days 2-4.
88918108|NCT01652807|Experimental|Yoga|The yoga intervention will last eight weeks and include two 90-minute sessions each week. Each yoga session will consist of the same series of 26 Hatha yoga postures, two breathing exercise, and two savasanas (i.e., a resting/relaxation posture), in a room heated to 104 degrees Fahrenheit, which aids in safe muscle stretching.
88918109|NCT01652807|No Intervention|Waitlist (Delayed Yoga)|Participants assigned randomly to the control condition will provided an identical free two-month membership to Bikram Yoga Dallas after the week following their post-intervention session.
88918110|NCT01652820|Experimental|Docetaxel +Carboplatin +concomitant chemoradiation|Docetaxel 20 mg/m2/weekly plus carboplatin AUC 2/weekly (first, docetaxel will be administered and after that, carboplatin will be administered) and concomitant chemoradiation (total dose of 60 Gy: 2 Gy/day, 5 days(week for 6 weeks)
88918111|NCT01652820|Experimental|C) Docetax+ gemcit +concom. docetax + carbopl. + RDT concom|Docetaxel 40 mg/ m2 days 1, 8, 21 y 28 plus gemcitabine 1200 mg/ m2 days 1, 8, 21 y 28 followed by concomitant treatment Docetaxel 20 mg/m2/week plus carboplatin AUC 2/weekly and concomitant chemoradiation total dose of 60 Gy: 2 Gy/day, 5 days(week for 6 weeks)
88918112|NCT01652859|Experimental|Liposomal Amphotericin B|Generic drug
88918113|NCT01652859|Active Comparator|AmBisome|RLD
88918114|NCT01652898|Active Comparator|Esmolol hydrochloride|Esmolol hydrochloride administered as intravenous bolus injection at low (0,5mg/kg), medium (1mg/kg) and high dose (1,5mg/kg) in 15/30/45 seconds once per subject
89198488|NCT00760890|No Intervention|C|Control
89198489|NCT00864747|Experimental|A|Propranolol Hydrochloride Extended Release Capsules 160 mg, single dose
89198490|NCT00864747|Active Comparator|B|INDERAL® LA 160 mg Capsules, single dose
89198491|NCT05279716|Experimental|omidenepag isopropyl 0.02mg|Instill 1 drop of Eybelis ophthalmic solution 0.002% once a day into the affected eye.
89198492|NCT04619628|Placebo Comparator|Saline|Normal saline
89198493|NCT04619628|Experimental|Low dose cohort 1|COVI-VAC, single dose
89198494|NCT04619628|Experimental|Medium dose cohort 1|COVI-VAC, single dose
89198495|NCT04619628|Experimental|High dose cohort 1|COVI-VAC, single dose
89198496|NCT04619628|Experimental|Low dose cohort 2|COVI-VAC, two doses 28 days apart
89435976|NCT05519150||Non-Stone Donors|Evaluation for kidney donation > 2 years ago, with no history of kidney stones, or kidney stones on Imaging and successfully donated a kidney
89198497|NCT04619628|Experimental|Medium dose cohort 2|COVI-VAC, two doses 28 days apart
89435977|NCT05516147|Experimental|Treatment|SAFE at Home Intervention
89435978|NCT05512390|Experimental|Dose Escalation ABBV-319|Participants with relapsed or refractory (R/R) B cell lymphomas including diffuse large b-cell lymphoma (DLBCL) or follicular lymphoma (FL), and Chronic lymphocytic leukemia (CLL) will receive escalating doses of ABBV-319 in 21-day cycles, until the recommended Phase 2 dose (RP2D) is determined.
89435979|NCT05512390|Experimental|(ABBV-319) Diffuse Large B-cell Lymphoma (DLBCL) Participants|Participants with R/R DLBCL will receive ABBV-319 in 21-day cycles.
89435980|NCT05512390|Experimental|(ABBV-319) Follicular Lymphoma (FL) Participants|Participants with R/R FL will receive ABBV-319 in 21-day cycles.
89198498|NCT04619628|Experimental|High dose cohort 2|COVI-VAC, two doses 28 days apart
89435981|NCT05512390|Experimental|(ABBV-319) Chronic Lymphocytic Leukemia (CLL) Participants|Participants with R/R CLL will receive ABBV-319 in 21-day cycles.
89435982|NCT05511038|Experimental|Aflibercept|Participants will receive one aflibercept injection per month (every four weeks) for five consecutive doses, followed by one injection every alternate month (every 8 weeks) for rest of the duration
89435983|NCT05507658|Experimental|Tislelizumab combined with XELOX|"Tirelizumab 200mg, iv.gtt, D1, Q3W;~Chemotherapy:~Oxaliplatin (130 mg/m2), iv.gtt, D1, Q3W; Capecitabine (1000mg/m2), P.O.B.I.D., D1-D14, Q3W."
89435984|NCT05505851|Active Comparator|A: Control|Corrective Exercises Hip Flexor Stretch 30 seconds hold 3 repetitions on each side Thoracolumbar extensors stretch 30 second holds 3 repetitions Abdominal Curl ups with hands at side 10 repetitions 2 sets Progression: • Abdominal curl up with arms crossed • Abdominal curl ups with hands behind head Pelvic bridging 10 seconds hold 10 repetitions 2 sets
89010448|NCT04545190|Active Comparator|Glucose|"Glucose will be ingested at three time points during resistance training (RT): 30 min prior to RT (30 g glucose mixed with 300 ml sugar-free Fun light lemonade), immediately prior to RT (30 g, 300 ml), and immediately after completion of training (30 g, 300 ml).~Protein supplement will be ingested at two time points: 2 hours prior to RT (e.g. at 0700 hrs, 25 g) and immediately after completion of training (25 g).~Placebo will be ingested during the afternoon (i.e. not during training; between 1800 hrs and 1900 hrs): 3 x 100 mg Stevia powder mixed with 3 x 300 ml sugar-free Fun light lemonade.~(The dietary intervention spans from 2200 hrs on the evening prior to RT sessions to ~2.5 hrs after completion of RT. During this time frame, participants will ingest glucose and protein supplements only)"
89435985|NCT05505851|Experimental|B: Sequential Core Stability Corrective Exercise Approach|"Corrective Exercises~Diaphragm Training Program As per standardized pulmonary rehabilitation guidelines,. Participant will be advised to breathe in gently with an improved tidal volume for ten repetitions, then after a short interval of break 15 repetitions will be done again. 30 Repetitions in set of 15, 15 with the interval rest. 2 sets.~Pelvic floor Muscle training Participants will be asked to do pelvic floor training with high intensity (close to maximum) contractions with holding each muscle contraction for 6-8 seconds with relaxation of 6 seconds. Total 8 to 12 contractions.~Core Stability exercises~Beginning~Progressing~Advanced"
89435986|NCT05498220|Experimental|Single Arm|The subjects with diffuse large B-cell lymphoma were relapsed or refractory after the first treatment and receiving the study protocol treatment.
89435987|NCT05495334||All participants|Eligible and enrolled subjects with knee OA pain who require treatment on the target knee as a part of pain management.
89435988|NCT05490771|Experimental|Treatment (copanlisib)|Patients receive copanlisib IV over 1 hour on days 1, 8, and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo tumor biopsies at screening and end of treatment and CT or MRI at baseline, every 2 cycles for the first 26 cycles, and then every 3 cycles thereafter until progressive disease or start of another MATCH treatment step.
89435989|NCT05483868|Experimental|Intratumoral and intramural injection of AU-011 prior to TURBT (1b)|Intratumoral (50 μg) and intramural (50 μg) injection of AU-011 prior to the standard of care (TURBT) in patients with NMIBC.
89435990|NCT05483868|Experimental|Intratumoral and intramural injection of AU-011 with laser application before TURBT (4a)|Intratumoral (50 μg) and intramural (50 μg) injection of AU-011 with laser application before standard of care (TURBT) in patients with NMIBC.
89198499|NCT02543853|Active Comparator|veres needle entry arm|Vere needle will be used to provide penumoperiteum than postoperative gastrointestinal functions will be compared
89435991|NCT05483868|Experimental|Intratumoral injection of AU-011 with laser application before TURBT (4b)|Intratumoral injection of AU-011 (100 μg) with laser application before standard of care (TURBT) in patients with NMIBC.
89435992|NCT05483868|Experimental|Intratumoral injection of AU-011 with laser application before TURBT (4c)|Intratumoral injection of AU-011 (200 μg) with laser application before standard of care (TURBT) in patients with NMIBC.
89435993|NCT05483868|Experimental|AU-011 intratumoral injection with laser application prior to cystectomy (5a)|Intratumoral injection of AU-011 (100 μg) with laser application followed by standard of care (cystectomy) in patients with NMIBC or MIBC.
89435994|NCT05483868|Experimental|AU-011 intratumoral injection with laser application prior to cystectomy (5b)|Intratumoral injection of AU-011 (200 μg) with laser application followed by standard of care (cystectomy) in patients with NMIBC or MIBC.
89435995|NCT05477823|Experimental|EBRT + BTX + ADT, PET and MRI|Standard of care EBRT + BTX + ADT, with mid-treatment PET and MRI (or PET and CT) scans for research.
89435996|NCT05472961|Experimental|Within Subjects Experimental Design|All participants are tested in all conditions.
89435997|NCT05470322|Experimental|Laser Treatment|The parameters of the laser will be set according to optimal operation protocol and in accordance with guidelines set forth by Sciton. Each laser treatment will take approximately 10 to 15 minutes per subject to target HS scarring.
89435998|NCT05469048||Critically ill patients sepsis suspected|Patients suspected of sepsis and admitted to ICU
89435999|NCT05468099|Experimental|Orthodontic debonding|
89436000|NCT05466240|Active Comparator|AT-752 750-mg TID for 5 days|Tablet; 750-mg, Three (3) times a day for 5-days
88918115|NCT01652898|Active Comparator|ONO LDL50|ONO LDL50 administered as intravenous bolus injection at low (0,1mg/kg), medium (0,2mg/kg) and high dose (0,3mg/kg) in 15/30/45 seconds once per subject
88918116|NCT01652898|Experimental|AOP LDLA202|AOP LDLA202 administered as intravenous bolus injection at low (0,1mg/kg), medium (0,2mg/kg) and high dose (0,3mg/kg) in 15/30/45 seconds once per subject
88918117|NCT01652924|Experimental|Mechanical ventilation|1: Active Comparator Children 1 month-14 years of age Intervention:Mechanical ventilation with facial mask during anesthetic induction
88918118|NCT01652924|Active Comparator|Manual ventilation|2: Active Comparator Children 1 month-14 years of age Intervention: Manual ventilation with facial mask during anesthetic induction
88918119|NCT01652937|Placebo Comparator|Placebo + Background Therapy|Background therapy including DMARD(s) approved by protocol
88918120|NCT01652937|Experimental|BIIB057 Dose 1 + Background Therapy|Background therapy including DMARD(s) approved by protocol
88918121|NCT01652937|Experimental|BIIB057 Dose 2 + Background Therapy|Background therapy including DMARD(s) approved by protocol
88918122|NCT01652937|Experimental|BIIB057 Dose 3 + Background Therapy|Background therapy including DMARD(s) approved by protocol
88918123|NCT01652950|Experimental|Vitality Wellness program Direct Payment|In addition to the base program and supplementary communication, members of the Direct Payment group received a gift voucher, corresponding to their level of engagement. Members received payouts at the end of each month of registration, for 5 different levels of engagement. The payout for the lowest level of engagement corresponded to about 25% of the monthly subscription for the wellness program. The payout for the highest level of engagement was 3 times more than the monthly subscription for the wellness program. Enrollment into the trial took place for a period of 5 months, and the intervention took place over a period of 12 months following registration.
88918124|NCT01652950|Experimental|Vitality Wellness Program Lottery Incentive|Members of the Lottery Incentive group were entered into a cash-prize draw at the end of each month following registration, if they achieved physical activity targets. The chance of winning was set at one in fifty with an expected value identical to the direct payment group. Four lottery payouts corresponding to the member's levels of engagement were made at the end of each month following registration. Enrollment took place over a period of 5 months, and the intervention took place over a period of 12 months following registration.
88918125|NCT01652950|Experimental|Vitality Wellness Program Charity Incentive|Members of the Charity Incentive Group were offered a selection of charities to which earned rewards could be donated. Nominated charities received the payouts at the end of each month of registration, for 5 different levels of engagement of the individual members. Enrollment into the trial took place for a period of 5 months, and the intervention took place over a period of 12 months following registration.
88918126|NCT01652950|Experimental|Vitality Wellness Program Choice Incentive|Members of the Choice Incentive Group were asked to choose one of the three aforementioned incentive options on enrollment to the study. Enrollment into the trial took place for a period of 5 months, and the intervention took place over a period of 12 months following registration.
88918127|NCT01652950|Other|Vitality Wellness Program Standard of Care|The Vitality Wellness program is the incentive-based wellness initiative of Discovery Health Medical Aid Scheme, a national private health insurer in South Africa. The standard program includes membership to three national gym chains, which is subsidized to 80% of the normal monthly subscription cost. Members have the opportunity to earn points by attending gyms, which contribute, together with points earned from engagement in other wellness and preventive activities, to tier status (Blue, Bronze, Silver, Gold and Diamond). Tier status allows members to receive increasing discounts on a range of goods and services from commercial partners. Enrollment into the trial took place for a period of 5 months, and the intervention took place over a period of 12 months following registration.
88918128|NCT01652950|Active Comparator|Vitality Wellness Program Enhanced Communication|"In this group, members were offered the base program and, in addition, were sent bi-weekly communications by alternating email and text messaging which included information on the importance of physical activity, tips on accumulating fitness points on the base program, a status update of points earned and information on benefits and rewards offered on the program. Enrollment into the trial took place for a period of 5 months, and the intervention took place over a period of 12 months following registration."
88918129|NCT01652963|No Intervention|Control task|The no-intervention control task consists of a presentation of the stimuli used in the training task. Participants will see situations and listen to the simultaneous voice recordings. Unlike in the training task participants will not receive instructions to link situations and emotions. There is no task requirement, just a presentation of the situation stimuli to assure that potential training effects are due to the training programme and not merely to the presentation of scenarios. The duration of the presentation of stimulus materials in the control group will range between fifteen and thirty minutes. The variable duration is necessary so the primary investigator cannot assume a participant's intervention group based on the duration of the intervention task.
88918130|NCT01652963|Experimental|Reed and Clements Training Task|The training task consists of 2 blocks of 6 items with items presented randomly within each block and blocks being counterbalanced between participants. Block 1 presents a situation and prompts participants to identify whether they would feel happy or sad in the given situation. Block 2 presents an emotion (happy or sad) and prompts the participant to identify which of two situations (positive or negative) most likely preceded this emotion. Within each block there will be at least one and maximum three training rounds. The second and third training rounds will only consist of the items to which the participant responded incorrect in the previous round. Each item in rounds 2 and 3 will be followed by feedback.
89198500|NCT02543853|Active Comparator|direct trocar entry arm|Direct trocar entry will be used to provide penumoperiteum than postoperative gastrointestinal functions will be compared
89436001|NCT05466240|Active Comparator|AT-752 Dose A for 5 days|Tablet; Dose A, for 5-days
89436002|NCT05466240|Active Comparator|AT-752 Dose B for 5 days|Tablet; Dose B, for 5-days
89436003|NCT05462587|Experimental|AVTX-803|Approximately 4 subjects will receive AVTX-803 at a dose specified by the investigator up to 5 times a day not to exceed 1700 mg/kg/day for 8 weeks.
89436004|NCT05462587|No Intervention|Withdrawal|Subject will be in withdrawal for 8 weeks.
89436005|NCT05455450|Experimental|EMDR + NPC|8-16 eye movement desensitisation and reprocessing therapy (EMDR) sessions, plus 1 month follow up session after the therapy has ended. Participants will also attend neuropsychiatric follow-up appointments as part of standard medical care.
89436006|NCT05455450|Other|Neuropsychiatric Care (NPC)|Standard medical care
89436007|NCT05450601|Experimental|Experimental|HCP2102
89436008|NCT05450601|Active Comparator|Active Comparator|RLD2106
89198501|NCT02543931|Placebo Comparator|Placebo|Participants will take 4 placebo capsules twice a day for one month
89198502|NCT02543931|Experimental|Meriva, low dose|Participants will take 4 Meriva-250mg capsules twice a day for one month
89198503|NCT02543931|Experimental|Meriva, high dose|Participants will take 4 Meriva-500mg capsules twice a day for one month
89198504|NCT04604652|Experimental|Open-label|HTD1801 (BUDCA) 250 mg tablets. Dosed at 1000 mg BID with food.
89198505|NCT00870519|Experimental|I 123-MNI-168|
89198506|NCT00870519|Experimental|I123 MNI168|brain imaging using I123MNI168
89198507|NCT02559102|Experimental|Dex Group|Intravenous dexmedetomidine sedation prior to single shot caudal anaesthesia and maintenance infusion of dexmedetomidine during bilateral inguinal hernia surgery.
89198508|NCT02559102|Active Comparator|GA Group|General sevoflurane anaesthesia with endotracheal intubation and single shot caudal anaesthesia for inguinal hernia surgery. This is currently the standard anaesthetic technique for bilateral inguinal hernia surgery in neonates and infants in KKH.
89198509|NCT05348668|Experimental|Hybrid dose-fraction Radiotherapy Arm|Patients in this arm would receive hybrid dose-fraction radiotherapy combined with immune checkpoint inhibitors.
89198510|NCT05309044|Active Comparator|Planetary Health Diet Group|Diet proportional to the EAT-Lancet reference diet, in addition to a behavioral change protocol.
89198511|NCT05309044|Active Comparator|Low-fat diet group|Low-fat, low-calorie diet and a behavioral change protocol
89198512|NCT05309044|Placebo Comparator|Waiting list group|Waiting list group
89198513|NCT00864825|Experimental|Allopurinol|
89198514|NCT00864825|Placebo Comparator|Placebo|
89198515|NCT00870597|Experimental|1|Multifocal IOL implant associated with vitreous opacities that underwent 25-gauge vitrectomy were prospectively analyzed.
89198516|NCT00870597|Experimental|2|Multifocal IOL implantation without transconjunctival vitrectomy
89198517|NCT00864903||pediatric ER|any child undergoing a spinal tap due to suspected meningitis
89198518|NCT00956176|Experimental|Cidofovir|
89010449|NCT04545190|Placebo Comparator|Placebo|"Placebo will be ingested at three time points during resistance training (RT): 30 min prior to RT (100 mg Stevia powder mixed with 300 ml sugar-free Fun light lemonade), immediately prior to RT (100 mg, 300 ml), and immediately after completion of training (100 mg, 300 ml).~Protein supplement will be ingested at two time points: 2 hours prior to RT (e.g. at 0700 hrs, 25 g) and immediately after completion of training (25 g).~Glucose will be ingested during the afternoon (i.e. not during training; between 1800 hrs and 1900 hrs): 3 x 30 g glucose mixed with 3 x 300 ml sugar-free Fun light lemonade.~(The dietary intervention spans from 2200 hrs on the evening prior to RT sessions to ~2.5 hrs after completion of RT. I.e.: during this period, participants will ingest placebo and protein supplements only)"
89198519|NCT00864981|Experimental|1|Bupropion HCI ER Tablets, 150 mg
89010450|NCT04544878||Pediatric patients|All term children from birth to 18 years of age admitted in the PICU
89010451|NCT04544878||Adult patients|All patients >18 years of age
89010452|NCT04545268|Sham Comparator|Control group|
89010453|NCT04545268|Experimental|NMES group|
89010454|NCT04544644|Experimental|treatment arm|AK104+anlotinib
89010455|NCT04540627|Placebo Comparator|Placebo|Sodium Chloride 0.9% Solution (Normal Saline)
89010456|NCT04540627|Active Comparator|Palivizumab (Synagis™)|Sterile vial 50mg/0.5mL
89010457|NCT04540393|Experimental|Arm A|Single arm
89010458|NCT04544722|Experimental|Jianfei Kangfu Cao|The original treatment and Jianfei Kangfu Cao, once a day, 30 minutes each time.
89198520|NCT00864981|Active Comparator|2|WELLBUTRIN SR (Bupropion HCI) Sustained-Release Tablets, 150 mg
89198521|NCT00371683|Active Comparator|A1|+ placebo
89198522|NCT00371683|Experimental|A2|+ placebo
89198523|NCT05286580|Experimental|Intervention|o Sequential deployment of standardized M&M toolkit at a regional M&M conference.
89198524|NCT00876057|Active Comparator|TH|Total hysterectomy
89198525|NCT00876057|Active Comparator|SH|Subtotal hysterectomy
88918131|NCT01652989|Experimental|Weight loss maintenance intervention delivered via DVD|Weight loss maintenance intervention delivered via DVD (without a peer facilitator) to employee participants within the respective worksites randomized to this arm. Using DVD technology, a total of 11 additional sessions (designed for weight loss maintenance) over a 9-month period will be delivered to the participants of this arm using DVD-produced lessons of PILI Maintenance
88918132|NCT01652989|Experimental|Weight loss maintenance intervention Face-to-Face|The PILI Maintenance delivered face-to-face in a group setting by trained peer facilitators to employee participants within the respective worksites randomized to this arm. The trained peer facilitator will deliver a total of 11 additional sessions (designed for weight loss maintenance) over a 9-month period, meeting bi-weekly for the first 2 months and then monthly for the remaining 7 months with a group of 8 to 15 participants.
88918133|NCT01653002||Lung cancer with lymph node involvement|
88918134|NCT01653015|Experimental|Influenza vaccine LAIV|Live attenuated influenza vaccine (LAIV).
88918135|NCT01653015|Active Comparator|Influenza vaccine TIV|Trivalent inactivated vaccine (TIV).
88918136|NCT01653041|Experimental|Everolimus|Single arm
88918137|NCT01653054|Experimental|IBD patients ON Immunosuppression|
88918138|NCT01653054|Experimental|IBD Patients OFF Immunosuppression|
88918139|NCT01653067|Experimental|Rituximab, Temsirolimus, DHAP, intravenous|"This is a multicenter, open label, single arm, phase II study. There will be no placebo usage within this trial. In the part I, dose escalation part, of this trial 6 patients will be included in each dose level. There will be 4 cohorts, administering up to a maximum of 4 cycles 25 mg, 50 mg, 75mg or 100mg Temsirolimus in combination with Rituximab and DHAP.~Treatment regimen part I:~Part I - Cohort A, B, C, D, X Temsirolimus 25 (A), 50 (B), 75 (C),100 (D) or 15 (X) mg, Day 1, 8, Rituximab (375 mg/m² day 2) Dexamethasone 40mg day 3-6 Cisplatine 100 mg/m² day 3 Cytarabine 2x2 g/m² day 4~...repeat day 22, up to a maximum of 4 cycles~In the part II of the trial 40 patients will be included to receive the full target dose, established within the part I of the study."
88918140|NCT01653106|Experimental|Arm I (cryotherapy 120 minutes)|Beginning fifteen minutes before melphalan treatment, patients receive 1 ounce of shaved ice in their mouth, allow it to melt and then replenish it immediately for 120 minutes.
88918141|NCT01653106|Active Comparator|Arm II (cryotherapy 360 minutes)|Beginning fifteen minutes before melphalan treatment, patients receive 1 ounce of shaved ice in their mouth, allow it to melt and then replenish it immediately for 360 minutes.
88918142|NCT01653119|Active Comparator|High loading dose of rosuvastatin|rosuvastatin 20mg/d×1w
88918143|NCT01653119|Active Comparator|Routine rosuvastatin therapy|rosuvastatin 10mg/d×1w
88918144|NCT01653145|Active Comparator|Diet A|Low Fat High Energy Density (1.6 kcal/g)-50% Fat, 35% Carbohydrate, and 15% Protein
88918145|NCT01653145|Active Comparator|Diet B|High Fat Low Energy Density (1.05 kcal/g)-50% Fat, 35% Carbohydrate, and 15% Protein
88918146|NCT01653145|Active Comparator|Diet C|High Carbohydrate Low Energy Density (1.05 kcal/g)-20% Fat, 65% Carbohydrate, 15% Protein
88918147|NCT01653171|No Intervention|Control|Standard upper endoscopy withouth premedication
88918148|NCT01653171|Placebo Comparator|Water|100 mL of water, 20 minutes before upper endoscopy
88918149|NCT01653171|Experimental|Simethicone|Simethicone 200 mg, in water for up to 100 mL, to take 20 minutes prior to examination
88918150|NCT01653171|Experimental|N-acetylcysteine 500 mg + Simethicone|N-acetylcysteine 500 mg + Simethicone 200 mg in water for up to 100 mL, to take 20 minutes prior to examination
88918151|NCT01653171|Experimental|N-acetylcysteine 1000 mg + Simethicone|N-acetylcysteine 1000 mg + Simethicone 200 mg in water for up to 100 mL, to take 20 minutes prior to examination
88918152|NCT01653184|Experimental|Experimental: AREDS 2 Vitamin formula 1g|"Patients will receive oral supplementation with the commercially available AREDS2 vitamin formula (PreserVision AREDS 2 Eye Vitamin and Mineral Supplement. Bausch + Lomb Incorporated), consisting of vitamins C, E, zinc, lutein, zeaxanthin and 1g of omega-3 fatty acids in the ethyl ester formulation"
88918153|NCT01653184|Experimental|Eye Omega Advantage 2g|Patients will receive a similar vitamin combination in the second arm (Eye Omega Advantage® and Macular Vitamin Benefit. Physician Recommended Nutriceuticals) with 2g of omega-3 fatty acids in the triglyceride formulation (see attached document for supplement details)
88918154|NCT01653197|Experimental|Control|"On top of reminder, state: Here's a fun fact to cheer you on your way: and include a curiosity-inducing question and answer (e.g., Q: Which is the only state that allows you to cast absentee ballots from outer space? // A: Texas)"
88918155|NCT01653197|Experimental|Curiosity|"On top of reminder, state: Here's a fun fact to cheer you on your way. and include a curiosity-inducing question (e.g., Q: Which is the only state that allows you to cast absentee ballots from outer space?) Place the answer under a scratch-off patch (A: Texas)."
88918156|NCT01653197|Experimental|Curiosity linked to Action|"On top of reminder, state: Here's a fun fact to cheer you on your way. Reward yourself by scratching off the answer only after you've made your [colonoscopy/mammogram/etc.] appointment! and include a curiosity-inducing question (e.g., Q: Which is the only state that allows you to cast absentee ballots from outer space?) Place the answer under a scratch-off patch (A: Texas)"
88918157|NCT01653236|Experimental|Experimental Arm B|48 weeks of peginterferon alfa-2b and ribavirin Plus Boceprevir 800 mg
88918158|NCT01653236|Active Comparator|Control Arm|48 weeks of peginterferon alfa-2b and ribavirin
88918159|NCT01653249|Experimental|vaccination|an escalating dose study of a vaccine consisting of four HPV-16 E6 peptides in combination with Candin® to determine the clinically optimum dose (COD), immunologically optimal dose (IOD), and maximum tolerated dose (MTD). An additional 30 subjects will be vaccinated at the final dose (apparent COD) for further assessment of clinical response.
88918160|NCT01653275|Experimental|Mediterranean Diet|Subjects will receive key foods (olive oil, walnuts, frozen portions of high n-3 LCPUFA fish) and instructed in the quantity to consume each week. Olive oil : minimum of 3 tablespoons per day. Walnuts:10.5 oz/week (1.5 oz/day). High n-3 LCPUFA fish: 3 or more fish meals per week. Additional guidelines for altering diet include incorporation of fruits, vegetables, legumes, and whole grains to replace sweets, white bread and starches, red meat and highly processed foods.
88918161|NCT01653301|Experimental|XELOX-RT|"Xeloda: 1300 mg/m2 chronomodulated (h 8.00 a.m. 25% of total dose ; h 6.00 p.m. 25% of total dose; h 11.00 p.m. 50% of total dose), during the whole treatment time;~Oxaliplatin: 130mg/m2, days 1, 19, 38~RT: pelvic treatment is the same for both arms: 45 Gy are delivered to the whole pelvis at 1.8 Gy daily, 5 times per week; In the XELOX-RT arm a boost of 5.4 Gy is delivered to the mesorectum corresponding to GTV, at 1.8 Gy daily, in 3 fractions, to a total dose of 50.4 Gy. The boost will be delivered at the end of the irradiation of the pelvis (sequential boost)."
88918162|NCT01653301|Active Comparator|XELAC-RT|"Xeloda 1650mg/m2 chronomodulated (h 8.00 a.m. 25% of total dose ; h 6.00 p.m. 25% of total dose; h 11.00 p.m. 50% of total dose) during the whole treatment time.~RT: pelvic treatment is the same for both arms: 45 Gy are delivered to the whole pelvis at 1.8 Gy daily, 5 times per week.~In the XEL-ACRT arm a boost of 10 Gy is delivered to the mesorectum corresponding to the GTV, at 1 Gy for fraction to a total dose of 55 Gy, in 10 fractions over 5 weeks, 2 times a week. The daily dose of the boost will be delivered twice a week immediately after the daily dose administered to the pelvis (concomitant boost)."
88918163|NCT01653314|Experimental|Megavec|
88918164|NCT01653314|Active Comparator|Glivec|
88918165|NCT01653340|Experimental|High Frequency Spinal Cord Stimulation through Senza™|"During the trial implant of Senza™, High Frequency Spinal Cord Stimulator for Refractory Chronic Migraine, the 2 leads will be positioned to cover the C2-C3 cervical levels.~Over the following 2 weeks, the investigator will optimize therapy delivery by identifying the stimulation settings providing maximal headache pain relief.~The subject will be asked to attend the clinic at the end of the trial period. Together with his/her physician, the subject will discuss his/her experience over the past 2 weeks (satisfaction with the therapy), and decide whether or not move forward with a Nevro Senza IPG.~The Nevro Senza IPG will be implanted in the buttock or abdomen area as outlined in the Physician's Manual. Fluoroscopy and impedance measurements may be used during the procedure to confirm lead placement and location.~Before hospital discharge, the IPG will be programmed with the optimal settings identified during the trial phase."
88918166|NCT01653353|Experimental|Entire group|A peer-applied guideline will be applied to the physicians.
88918167|NCT01653366|Experimental|Arm A-Pedometer and Goal setting|"Physical Activity Goal Setting~Patients receive physical therapy (PT) consult, educational materials, and telephone calls and are contacted weekly/monthly for physical activity (PA) goal setting with registered nurse (RN). Physical Activity completed is measured with pedometers and recorded on patient log."
88918168|NCT01653366|No Intervention|ARM B|Patients receive standard physical activity recommendations and follow up.
88918169|NCT01653431|Experimental|Transcranial direct current stimulation|Transcranial direct current stimulation combined with cognitive training
88918170|NCT01653431|Sham Comparator|Sham transcranial direct current stimulation|Sham transcranial direct current stimulation combined with cognitive training
88918171|NCT01653444|Experimental|GC1119 0.5 mg/kg|0.5 mg/kg biweekly
88918172|NCT01653444|Experimental|GC1119 1.0 mg/kg|1.0 mg/kg biweekly
88918173|NCT01653457|Placebo Comparator|Placebo|
88918174|NCT01653457|Active Comparator|Memantine|
88918175|NCT01653470|Experimental|Arm A: Paclitaxel + BMS-906024|Paclitaxel 80 mg/m2 solution and BMS-906024 4 mg or 6 mg solution intravenously once weekly continuously until disease progression or unacceptable toxicity
88918176|NCT01653470|Experimental|Arm B: FOLFIRI (5FU, Leucovorin, Irinotecan) + BMS-906024|5FU Bolus 400 mg/m2, 5FU Infusion 2400 mg/m2, Irinotecan 180 mg/m2 solution, Leucovorin 400 mg/m2 solution intravenously once every 2 weeks and BMS- 906024 4 mg or 6 mg solution intravenously once weekly continuously until disease progression or unacceptable toxicity
88918177|NCT01653470|Experimental|Arm C: Carboplatin/Paclitaxel + BMS-906024|Carboplatin AUC 6 / Paclitaxel 200 mg/m2 solution once every 3 weeks and BMS-906024 4 mg or 6 mg solution once weekly intravenously continuously until disease progression or unacceptable toxicity
89198526|NCT05276128|Other|WWB Reference|White wheat bread (WWB) without lipid supplements. The effects of this high glycaemic product on postprandial glucose and insulin responses are well studied.
88918178|NCT01653470|Experimental|Arm D: Paclitaxel + BMS-906024|Paclitaxel 80 mg/m2 solution once weekly and BMS-906024 4 mg or 6 mg solution once every 2 weeks intravenously continuously until disease progression or unacceptable toxicity
88918179|NCT01653470|Experimental|Arm F: Carboplatin/Paclitaxcel and BMS-906024|Carboplatin AUC 6 / Paclitaxel 200 mg/m2 solution once every 3 weeks and BMS-906024 4 mg or 6 mg solution once every 3 weeks intravenously continuously until disease progression or unacceptable toxicity
89198527|NCT05276128|Experimental|WWB 5g active lipids|WWB supplemented with 5 g active lipids, and 10 g control lipids
88918180|NCT01653483|Experimental|GSK573719|Investigational treatment - Swedish Orange Coloured, opaque hard gelatin capsule
89198528|NCT05276128|Experimental|WWB 10g active lipids|WWB supplemented with 10g active lipids, and 5 g control lipids
88918181|NCT01653483|Placebo Comparator|GSK573719 matched-placebo|Placebo
88918182|NCT01653496|Experimental|Enhanced recovery after surgery|Patients who receive ERAS program after gastric cancer surgery
88918183|NCT01653522|Experimental|Triptan|
88918184|NCT01653522|Experimental|Doxycycline|
88918185|NCT01653522|Experimental|Triptan + Doxycycline|
88918186|NCT01653522|No Intervention|Control|
88918187|NCT01653548|Experimental|HR training + Portable HR|100 subjects who receive Habituation Reminder training and who have access to the HR via a cellular phone.
88918188|NCT01653548|Experimental|HR Training + no portable HR|50 subjects who receive Habituation Reminder training and who do not have access to the HR via a cellular phone.
88918189|NCT01653548|Experimental|No HR training|50 subjects who do not receive HR training.
88918190|NCT01653561|Experimental|Apatinib|Apatinib 500mg/d
88918191|NCT01653574|Experimental|Famitinib Malate|Famitinib 25mg/d
88918192|NCT01653600|Experimental|LifeStent|same to SMART CONTROL Stent
88918193|NCT01653600|Active Comparator|SMART CONTROL Stent|study design is 2x2 randomization design. First, before randomization, stratification will be performed according to lesion length 15cm criteria at web-based computerized program. Patients will be randomized in a 1:1 manner according to different two (SMART versus LifeStent) stents. And then, patients received aspirin and clopidogrel during one month. After one month from index procedure, clopidogrel will be stopped and changed into cilostazol. Patients were randomized to receive cilostazol 100mg bid either 11 month duration or 5 month duration in separate groups of SMART stent group and LifeStent group. Randomization procedure will be performed using a web-based program
88918194|NCT01653626|Experimental|package|
88918195|NCT01653639|Experimental|Arm 1|
88918196|NCT01653639|Experimental|Arm 2|
88918197|NCT01653652|Placebo Comparator|Placebo|maltodextrin powder to be taken daily
88918198|NCT01653652|Active Comparator|Probiotic|Probiotic blended in maltodextrin powder to be taken daily
88918199|NCT01653665|Active Comparator|Leukine (Sargramostim, GM-CSF)|Participants in dose finding study will receive either 3 or 6 micrograms per kilo per day as a daily subcutaneous injection for either 4 or 7 days. Within the Randomised controlled trial, participants will receive the dose as chosen following the dose finding study.
88918200|NCT01653665|Placebo Comparator|Placebo (normal saline)|Participants in the randomised controlled trial may be randomised to receive a daily subcutaneous injection of normal saline (placebo) for 4 or 7 days as decided following the results of the dose finding study
89436009|NCT05444023|Experimental|Transverse separated suturing technique|During pubocervical fascia reconstruction, the surgeon will perform suturing at the transverse plane with an intermittent stitching technique.
89436010|NCT05444023|Active Comparator|circular continue suturing technique|During pubocervical fascia reconstruction, the surgeon will perform a continuous stitching technique which includes the lateral parts of the anterior compartment defect.
89436011|NCT05437263|Experimental|Brepocitinib Dose Level 1 PO QD|
89436012|NCT05437263|Experimental|Brepocitinib Dose Level 2 PO QD|
89436013|NCT05437263|Placebo Comparator|Placebo PO QD|
89436014|NCT05435339|Experimental|GEN1053 Monotherapy|
88918201|NCT01653691|Active Comparator|Pulse Dye Laser, burn scars|A scar will be located on the study subject's torso or thigh and divided in half. Some subjects will receive laser to both sides of their scar, while others will not receive any intervention to one side and laser to the other side. Each side will be evaluated during outpatient visits. 12 months after treatment is completed, 2 burn experts will rate each side of the scar without knowing its treatment.
89436015|NCT05428137|Active Comparator|Probiotic|Live bacteria strain in a form of a capsule daily for 16 weeks
89436016|NCT05428137|Active Comparator|Postbiotic|Heat treated bacteria strain in a form of a capsule daily for 16 weeks
89436017|NCT05428137|Placebo Comparator|Placebo|Placebo in a form of a capsule administered for 16 weeks
89436018|NCT05426551|Experimental|Bolus-spi|The volunteers will consume the test-meal as a bolus in one time at t = 0, with 13C-spirulina as the reference protein
89436019|NCT05426551|Experimental|Plateau-spi|The volunteers will consume the test-meal in a plateau feeding protocol, with 13C-spirulina as the reference protein
89436020|NCT05426551|Experimental|Plateau-AA|"The volunteers will consume the test-meal in a plateau feeding protocol, with 13C-free AA mixture as the reference protein"
88918202|NCT01653691|Sham Comparator|No treatment to half of scar|A scar on the child's torso or thigh will be divided in half. One side will receive laser treatment and the other half will receive laser or sham treatment.
88918203|NCT01653717|Experimental|T-Cell Infusion + Chemotherapy|Peripheral blood mononuclear cells (PBMC) collected via venipuncture or steady state leukapheresis after enrollment. Clinically successful T-cell production defined as amount of T-cells required for dose level for which the patient is enrolled. Fludarabine 25 mg/m2 by vein on Days -5 to Day -3. Cyclophosphamide 250 mg/kg by vein on Days -5 to -3. Beginning dose of genetically modified cells is > 5x10^7/m2 but less than or equal to 5 x10^8/m2 infused on Day 0.
88918204|NCT01653730|Experimental|Eclipse 3 portable oxygen concentrator|Use of the Eclipse 3 portable oxygen concentrator set at maximum pulse-dose setting 10-minutes prior to, and during a 6-minute walk test.
88918205|NCT01653730|Experimental|iGo portable oxygen concentrator|Use of the iGo portable oxygen concentrator set at maximum pulse-dose setting 10-minutes prior to, and during a 6-minute walk test.
88918206|NCT01653730|Experimental|EverGo portable oxygen concentrator|Use of the iGo portable oxygen concentrator set at maximum pulse-dose setting 10-minutes prior to, and during a 6-minute walk test.
88918207|NCT01653730|No Intervention|Control portable oxygen concentrator|6-minute walk test completed using each patient's own oxygen delivery system set at their usual oxygen prescription for exercise
88918208|NCT01653756|Active Comparator|IPI-145|Capsules
88918209|NCT01653756|Placebo Comparator|Placebo|Capsules
88918210|NCT01653795|Active Comparator|LMA Unique|
88918211|NCT01653795|Active Comparator|LMA Supreme|
88918212|NCT01653808|Experimental|Elisio-210H with HD|hemodialysis patients treated with conventional hemodialysis (HD) modality using Elisio-210H dialyzer
88918213|NCT01653808|Active Comparator|Elisio-210H with on line HDF|hemodialysis patients treated with on line hemodiafiltration (HDF) modality using Elisio-210H dialyzer
88918214|NCT01653821|Experimental|Carotid body excision|Patients undergoing unilateral or bilateral removal of carotid body.
88918215|NCT01653834|Experimental|Lymphocyte harvesting & reinfusion|Patients with a newly diagnosed high grade glioma (Grade III or IV), have a post-operative treatment plan that includes standard radiation and temozolomide, and have normal bone marrow function with Hematocrit ≥ 30%, platelet ≥ 100K, ANC ≥ 1000, and absolute lymphocyte count ≥ 1000 prior entry to this study are eligible for enrollment.
88918216|NCT01653860|Experimental|The Brøset anger management model|Group treatment
88918217|NCT01653860|Active Comparator|ordinary group treatment|Group treatment
89436021|NCT05425056|Experimental|Treatment Arm|Subjects randomized to the treatment arm will undergo AV fistula surgery and will receive the Sirolimus eluting Collagen Implant (SeCI).
89436022|NCT05425056|No Intervention|Control Arm|Subjects randomized to the control arm will undergo AV fistula surgery alone and will not receive an implant.
89436023|NCT05419830|Active Comparator|AM antihypertensive dosing arm|participants will be asked to continue taking their antihypertensive medication within an hour of awakening
89436024|NCT05419830|Experimental|BBTI arm|participants will receive the behavioral treatment for insomnia BBTI by the study RN. Participants will also be asked to take their antihypertensive medication within an hour of awakening
89198529|NCT05276128|Experimental|WWB 15g active lipids|WWB supplemented with 15g active lipids, and 0 g control lipids
89436025|NCT05419830|Experimental|PM antihypertensive dosing or Chronotherapy arm|participants will be asked to switch their conventional once daily non-diuretic antihypertensive to bedtime
89436026|NCT05417282|Experimental|Safety and tolerability evaluation|"Part A: Open Label sentinel cohort 10 subjects will receive MW151 in an open label safety evaluation.~Part B: Open Label 30 subjects will receive MW151."
89436027|NCT05409976|Experimental|GORE® VIAFORT Vascular Stent|GORE® VIAFORT Vascular Stent
89436028|NCT05397093|Experimental|Phase 1a: Dose Escalation|Various doses will be tested in participants with EOC, NSCLC and RCC.
89436029|NCT05397093|Experimental|Phase 1b: Expansion|"Cohort 1: Participants with epithelial ovarian cancer (EOC)~Cohort 2: Participants with non-small cell lung cancer (NSCLC)~Cohort 3: Participants with renal cell carcinoma (RCC)"
89436030|NCT05396885|Experimental|anitocabtagene-autoleucel|Single dose of 115±10 x 10e-6 CAR+ anitocabtagene-autoleucel cells infused intravenously
89436031|NCT05394441||Healthy adults (16+)|Healthy students, faculty and staff of ITMO University older than 16 years
88918218|NCT01653886|Experimental|Pilot Group 1|Each Participant completed taste tests at breakfast, lunch and dinner consisting of the 4 menus (baseline, high fat-high energy density, high fat-low energy density, and high carbohydrate-low energy density).
88918219|NCT01653886|Experimental|Pilot Group 2|Each Participant completed taste tests at breakfast, lunch and dinner consisting of the 4 menus (baseline, high fat-high energy density, high fat-low energy density, and high carbohydrate-low energy density).
88918220|NCT01653886|Experimental|Pilot Group 3|Each Participant completed taste tests at breakfast, lunch and dinner consisting of the 4 menus (baseline, high fat-high energy density, high fat-low energy density, and high carbohydrate-low energy density).
88918221|NCT01653886|Experimental|Pilot Group 4|Each Participant completed taste tests at breakfast, lunch and dinner consisting of the 4 menus (baseline, high fat-high energy density, high fat-low energy density, and high carbohydrate-low energy density).
88918222|NCT01653938|No Intervention|control group|
88918223|NCT01653938|Experimental|Video Arm|Use of video decision aid in the experimental arm.
88918224|NCT01653951|Experimental|Nurse-led care management|Nurse-led care management involves a nurse care manager who performs a comprehensive assessment of the patient then presents those assessment findings to an interdisciplinary team. The team makes care recommendations that are implemented by the care manager in collaboration with the patient's PCP.
88918225|NCT01653951|Experimental|peer-led self managment|Peer-led self management follows the chronic disease self management model where peer counselors lead self management classes for 6 weeks, then conduct monthly support groups
88918226|NCT01653977|Active Comparator|CONTROL|In the CONTROL group, the administration of fluid (250-500ml crystalloids or colloids) and cardiovascular supportive drugs will be guided to maintain standard pressure-related parameters within a normal range: MAP > 65mmHg, HR < 90/min, CVP >8-12< cm H20, urinary output > 0.5 ml/kg/h. In line with the conventional approach, other physiological parameters will also be targeted: T° > 35.5°C, Sp02 > 95%, lactate < 2.5 mmol/L, normalisation of the BE. The maximal infused volume of hydroxyethyl starch (Voluven®) will be 33 ml/kg.
88918227|NCT01653977|Active Comparator|OPTIMIZED|"In the OPTIMIZED group, the central venous catheter and the 4-French artery catheter (femoral or humeral access site) will be connected to a dedicated haemodynamic monitor (Pulsiocath, PV2024L; Pulsion Medical Systems AG, Munich, Germany).~The administration of fluid (250-500ml crystalloids or colloids) and cardiovascular supportive drugs will be guided by an algorithm taking into account standard parameters (HR, MAP, lactate, Hb), as well as static and dynamic volumetric parameters (SVI, CI, GEDVI, EVLWI, SVV, PPV, PVI)."
88918228|NCT01653990|Experimental|moxifloxacin, pill|Oral dose of 400mg moxifloxacin
88918229|NCT01653990|Placebo Comparator|moxifloxacin-placebo,pill|A pill of moxifloxacin-placebo
88918230|NCT01654003|Active Comparator|CONTROL|"In the CONTROL group, the administration of fluid (250-500ml crystalloids or colloids) and cardiovascular supportive drugs will be guided to maintain standard pressure-related parameters within a normal range: MAP > 65mmHg, HR < 90/min, CVP >8-12< cm H20, urinary output > 0.5 ml/kg/h. In line with the conventional approach, other physiological parameters will also be targeted: T° > 35.5°C, Sp02 > 95%, lactate < 2.5 mmol/L, normalisation of the BE. The maximal infused volume of hydroxyethyl starch (Voluven®) will be 33 ml/kg.~At the discretion of the attending anaesthesiologist with the FMH level, a pulmonary artery catheter, a transoesophageal Doppler flow probe or the PiCCO monitor will be inserted to complement the standard hemodynamic monitoring if deemed necessary."
88918231|NCT01654003|Active Comparator|OPTIMIZED|"In the OPTIMIZED group, the central venous catheter and the 4-French artery catheter (femoral or humeral access site) will be connected to a dedicated haemodynamic monitor (Pulsiocath, PV2024L; Pulsion Medical Systems AG, Munich, Germany).~The administration of fluid (250-500ml crystalloids or colloids) and cardiovascular supportive drugs will be guided by an algorithm taking into account standard parameters (HR, MAP, lactate, Hb), as well as static and dynamic volumetric parameters (SVI, CI, GEDVI, EVLWI, SVV, PPV, PVI)."
88918232|NCT01654016|Active Comparator|Detralex|Detralex 500 mg twice daily for three month prior to surgery
88918233|NCT01654016|No Intervention|Not taking Detralex|Not taking Detralex for three months prior to surgery
88918234|NCT01654029|No Intervention|Control group receiving usual care|Usual care consists of speech language therapy for some patients. Most care is focused on swallowing assessments.
88918235|NCT01654029|Experimental|PCCI Intervention|The Patient-Centred Communication Intervention consists of 1) development of a communication care plan; 2)a workshop for staff focused on communication and behavioural management strategies,: and 3) implementing a staff support system.
88918236|NCT01654042|No Intervention|Standard interval between PT testing|Prothrombin time (PT) is tested every 4 weeks, according to American College of Chest Physicians (ACCP) Guidelines up to 2008 for stable patients on warfarin.
88918237|NCT01654042|Experimental|Prolonged interval between PT testing|Prothrombin time (PT) is tested every 12 weeks, according to suggestion in American College of Chest Physicians (ACCP) Guidelines of 2012 for stable patients on warfarin.
88918238|NCT01654081|Experimental|Irinotecan|Irinotecan 125 mg/m2 on days 1, 8, 15 and 22 of every 6- week cycle
88918239|NCT01654094|Experimental|P6 Low Adherent Dressing|All participants will serve as their own control. All participants will receive both the P6 Low Adherent Dressings and the Standard of Care (SOC).
88918240|NCT01654094|Active Comparator|Standard of Care (SOC)|All participants will serve as their own control. All participants will receive both the P6 Low Adherent Dressings and the Standard of Care (SOC).
88918241|NCT01654120|Experimental|liraglutide plus insulin|Patients were randomized to receive liraglutide plus insulin (LIRA) for 12 months.
88918242|NCT01654120|Active Comparator|Insulin titration only|Patients were randomized to receive insulin only (control) for 6 months. The controls were then crossed over to receive liraglutide plus insulin for 6 months after the initial control period.
89436032|NCT05391022|Experimental|Run-In Food Effect Period|Unblinded, open label drug will be administered once in a fasted state and twice in a fed state with a minimum of 5 days between each dose prior to entering the continuous treatment phase.
89436033|NCT05391022|Experimental|Continuous Treatment Period|Unblinded, open label drug will be administered once daily for 14 consecutive days followed by a 7 day break, which is considered 1 cycle of treatment (1 cycle = 21 days).
89436034|NCT05389293|Experimental|Participants with newly diagnosed Follicular Lymphoma|Participants with newly diagnosed FL in need of systemic therapy
89436035|NCT05384522||Parkinson's Disease subjects|Subjects with Parkinson Disease aged 65 years or more at Hoehn and Yahr stage ≤3
89436036|NCT05383365|Experimental|Suboccipital Myofascial Release|The therapist places the supinated forearm on the bed and positions the tips of the middle three fingers inferior to the occiput bone and the head is supported by the thenar eminences
89436037|NCT05383365|Experimental|Deep Neck Flexor Exercise|After placing the airbag of PBU under the occiput bone in the supine position and inflating it to a base pressure of 11 mmHg, the participant will increase the pressure to 12 mmHg by nodding action.
88918243|NCT01654146|Active Comparator|Arm 1 (Control Arm)|Carboplatin and paclitaxel on day 1 of a 21-day cycle for 6 cycles
88918244|NCT01654146|Experimental|Arm 2 (Research arm)|Carboplatin on day 1 and dose-fractionated weekly paclitaxel on day 1, 8 and 15 of a 21-day cycle for 6 cycles
89436038|NCT05374174||Measurement Group|All participants will have their arm spasticity to be measured using standard clinical scales
89436039|NCT05370326|Experimental|Enhanced Opioid Stewardship Program|Enhanced opioid stewardship program, tailored to the needs of hospitalized patients with chronic pain with opioid dependence, incorporating real-time guidance from an addiction medicine and pain-trained physician/pharmacist team
88918245|NCT01654146|Experimental|Arm 3 (Research arm)|Dose-fractionated weekly carboplatin and weekly paclitaxel on day 1, 8 and 15 of a 21-day cycle for 6 cycles.
88918246|NCT01654172|Experimental|High Flavanol Cocoa|"Cocoa drink containing ~450mg cocoa flavanols and 10g carbohydrate per serving.~Subject consumes 2 servings per day, for 7 days."
88918247|NCT01654172|Placebo Comparator|Low Flavanol Cocoa|"Cocoa drink containing ~25mg cocoa flavanols and 10g carbohydrate per serving.~Subject consumes 2 servings per day, for 7 days."
88918248|NCT01654185|Experimental|AI plus Dimethyldiguanide|AI 1 tablet qd plus Dimethyldiguanide 0.5 bid
89436040|NCT05370326|No Intervention|Standard of care|
89436041|NCT05362305|Experimental|Essential Coaching for Every Mother|Mothers in the intervention group will receive in-hospital education by a non-study nurse midwife while on the postnatal ward prior to discharge as per standard protocol on the unit. On the third day after birth, mothers will receive daily text messages to 6 weeks postpartum. The messages will be sent automatically each day based on the date of birth of the infant.
89436042|NCT05362305|No Intervention|Standard Care|Mothers will receive in-person education provided by a non-study nurse midwife while on the postnatal ward prior to discharge as per current standard protocol on the unit. Mothers in this group will not receive any further text messages from the program.
88918249|NCT01654185|Active Comparator|Aromatase Inhibitor|AI monotherapy
88918250|NCT01654198||Psoriatic arthritis|
88918251|NCT01654211|Experimental|Part 1: iv danoprevir|
88918252|NCT01654211|Placebo Comparator|Part 1: placebo|
88918253|NCT01654211|Experimental|Part 2 A: iv danoprevir|
88918254|NCT01654211|Active Comparator|Part 2 B: oral danoprevir|
88918255|NCT01654211|Active Comparator|Part 2 C: ritonavir|
88918256|NCT01654211|Experimental|Part 3 D: iv danoprevir|
88918257|NCT01654211|Experimental|Part 3 E: iv danoprevir + cyclosporine|
88918258|NCT01654237|No Intervention|Muskind|three questionnaires to be completed by the subjects
88918259|NCT01654328|Experimental|Arm A: sodium chloride tablets|Arm A: sodium chloride 1g/10kg of body weight /day per os on day -2 and -1 before contrast exposure. With a maximum dose of 10 gram sodium chloride a day.
88918260|NCT01654328|Active Comparator|B: isotonic saline intravenously|Sodium chloride solution (isotonic saline (NaCl 0.9%) total 1000ml in 4 hrs or (in case of heart failure or severe renal failure) 12 hrs before and in 4 or in 12 hrs after contrast administration.
88918261|NCT01654341|No Intervention|Usual Care Group|Subjects undergo usual standard of care
88918262|NCT01654341|Experimental|Intervention Group|Intervention with exercise, dietary and educational programs
88918263|NCT01654367|Experimental|Zoledronic Acid and Aromatase Inhibitors|Zoledronic Acid and Aromatase Inhibitors for Adjuvant Therapy
88918264|NCT01654393|Experimental|OAR group|Patients with ankle injuries who are assessed by OAR trained triage nurses applying the OAR.
88918265|NCT01654393|No Intervention|Control for OAR Triage Nurses|Patients with ankle injuries that are seen by OAR triage nurses but not assessed in accordance with the OAR.
88918266|NCT01654406|Active Comparator|Control|Pulsed dye laser (V-beam)
88918267|NCT01654406|Experimental|Experimental group|Fractional CO2 laser(eCO2)and pulsed dye laser (V-beam)
88918268|NCT01654419|Active Comparator|Class II elastics alone|Use of class II elastics alone to correct class II dental malocclusions
88918269|NCT01654419|Experimental|Class II elastics with Sliding Jig|Class II elastics with Sliding Jig for correction of dental class II malocclusion
88918270|NCT01654432|Placebo Comparator|General anaesthesia and sham nerve block|Breast cancer surgery under general anaesthesia
88918271|NCT01654432|Active Comparator|Paravertebral Blocks (PVB)|Breast cancer surgery under ultrasound-guided paravertebral blocks plus general anesthesia
88918272|NCT01654458|Experimental|Immediate Treatment Condition|Receives the 12-week GyneGals Support Group within a month of completing the baseline assessment.
88918273|NCT01654458|No Intervention|Waitlist Control Condition|Waitlist control group receives the 12-week GyneGals Support Group only after its involvement in the study has ended, as a courtesy.
89436043|NCT05360056|Experimental|Dexcom CGM|
88918274|NCT01654471||Medical treatment|only medical treatment (regardless of the kinds of medicine)
88918275|NCT01654471||Surgical or endovascular treatemnt group|patients underwent surgery or endovascular therapy
88918276|NCT01654484|Experimental|Low Dose DE-117|Monotherapy
88918277|NCT01654484|Experimental|Medium Dose DE-117|Monotherapy
88918278|NCT01654484|Experimental|High Dose DE-117|Monotherapy
88918279|NCT01654484|Experimental|Low Dose DE-117 and 0.0015% tafluprost|Adjunctive Therapy
88918280|NCT01654484|Experimental|Med. Dose DE-117 and 0.0015% tafluprost|Adjunctive Therapy
88918281|NCT01654484|Experimental|High Dose DE-117 and 0.0015% tafluprost|Adjunctive Therapy
88918282|NCT01654484|Active Comparator|0.0015% tafluprost|Monotherapy
88918283|NCT01654484|Placebo Comparator|Placebo|Monotherapy
88918284|NCT01654497|Experimental|Dexanabinol|
88918285|NCT01654510|Experimental|Cognitive Behavioral Therapy Group|
88918286|NCT01654510|Active Comparator|Vocational Services as Usual Control|Vocational services typically present in a comprehensive vocational service center.
88918287|NCT01654562|Experimental|CHM|Administration of 40mg simvastatin daily, orally for 5 weeks (4-6 weeks window), followed by 5 week (4-6 week window) washout period.
88918288|NCT01654562|Active Comparator|Age-matched controls|Administration of 40mg simvastatin daily, orally for 5 weeks (4-6 weeks window), followed by 5 week (4-6 week window) washout period.
88918289|NCT01654575|Experimental|Methotrexate|25mg/week orally
88918290|NCT01654575|Active Comparator|Placebo|"Placebo-sugar tablets identical in colour and shape to methotrexate given once a week for 16 weeks."
88918291|NCT01654614||Forme Fruste Keratoconus Group (FFKG)|Forme Fruste Keratoconus Group (FFKG) included patients diagnosed with FFK.
88918292|NCT01654614||Control Group (CG)|Control group(CG) was formed by refractive surgery candidates.
88918293|NCT01654627|Experimental|Regenecure AMCA GBR Dental membrane|16 patients will undergo the guided bone regeneration procedure using the Regenecure AMCA Membrane
88918294|NCT01654627|Active Comparator|Collagen membrane|16 patients will undergo the guided bone regeneration procedure using a commercially available collagen membrane
88918295|NCT01654640|Experimental|Metformin group|Metformin 500mg 1 tablet p.o. bid
88918296|NCT01654640|Placebo Comparator|Placebo group|1 tablet p.o. bid
89436044|NCT05358444|Active Comparator|Diabetes Prevention Program (DPP)|"Adult participants who are engaged in the Centers for Disease Control and Prevention's (CDC) National Diabetes Prevention Program lifestyle intervention (DPP) as delivered by the Johns Hopkins Brancati Center; this is a 12-month long, group-based lifestyle intervention, delivered by a certified lifestyle coach using a CDC-approved curriculum. This concurrent control group will consist of adults who are enrolled in the Brancati Center's DPP within 6 months of the intervention group start dates, who have children less than 18 years of age living in their households."
88918297|NCT01654653|Experimental|HSL(Totilac)|Hypertonic Sodium Lactate
88918298|NCT01654653|Active Comparator|6% HES (Voluven)|6% Hydroxyethyl Starch
88918299|NCT01654679|Active Comparator|wIRA irradiation|Patients in Group A received local water-filtered infrared A (wIRA) irradiation once for 20 min preoperatively.
88918300|NCT01654679|Sham Comparator|visible light only|Patients assigned to Group B only received normal visible light application for 20 min prior to surgery.
88918301|NCT01654692|Experimental|Single arm of ipilimumab and fotemustine|Ipilimumab in combination with Fotemustine
88918302|NCT01654705|Experimental|Pantoprazole Sodium Delayed release tablets|Pantoprazole Sodium Delayed release tablets USP 40 mg of OHM Laboratories Inc.,USA
88918303|NCT01654705|Active Comparator|Protonix® Delayed Release 40 mg tablets|Protonix® Delayed Release 40 mg tablets of Wyeth Pharmaceuticals Inc.USA
88918304|NCT01654718|Experimental|Pantoprazole Sodium Delayed release tablets|Pantoprazole Sodium Delayed release tablets USP 40 mg of OHM Laboratories Inc.,USA
88918305|NCT01654718|Active Comparator|Protonix® Delayed Release 40 mg tablets|Protonix® Delayed Release 40 mg tablets of Wyeth Pharmaceuticals Inc.USA
88918306|NCT01654770|Active Comparator|video capsule endoscopy|Video capsule endoscopy is performed every recruited patient.
88918307|NCT01654770|Active Comparator|double balloon enteroscopy|Double balloon enteroscopy is performed after video capsule endoscopy in every recruited patient. (Tandem study)
88918308|NCT01654783||5-ASA|Patient's treated with oral 5-ASA
88918309|NCT01654809|Experimental|evaluated vaccine|0.25 mL, Intramuscular (infant/children dose) 0.5 mL, Intramuscular (adult dose)
88918310|NCT01654809|Active Comparator|imported compared vaccine|0.25 mL, Intramuscular (infant/children dose) 0.5 mL, Intramuscular (adult dose)
88918311|NCT01654809|Active Comparator|domestic compared vaccine|0.25 mL, Intramuscular (infant/children dose) 0.5 mL, Intramuscular (adult dose)
88918312|NCT01654822|Placebo Comparator|olive oil with 10% d-limonene|Topical spray one-time administration 2 puffs of 100µl
88918313|NCT01654822|Experimental|AV2-DM antiviral spray|Topical spray one-time application 2 puffs of 100µl
88918314|NCT01654835|Active Comparator|low blood pressure alert|"A Low Blood Pressure condition as specified (SAP <80 mmHg)will trigger an page to be sent to all anesthesia providers in <1 min that will read: A Low Blood Pressure condition has been detected. Consider hemodynamic support."
88918315|NCT01654835|Placebo Comparator|no low blood pressure alert|The Low Blood Pressure condition will be monitored by treatment team, but additional alert will not be sent to treatment team.
88918316|NCT01654848||orthotopic Liver Transplantation|consecutive inclusion of all recipients
88918317|NCT01654874|Experimental|Preparation A|20 (±3) mCi 99mTc-MIP-1404 (preparation A)
88918318|NCT01654874|Experimental|Preparation B|20 (±3) mCi 99mTc-MIP-1404 (preparation B)
88918319|NCT01654900||Patients age >75 y who underwent open hear surgeary|The cohort study consist of all patients > 75 y, undergoing open heart surgery between 2008-2011 at Hadassah medical center.
88918320|NCT01654913|Experimental|surgical patients|patients studied just before induction of anesthesia
88918321|NCT01654926||Heart Failure patients|
88918322|NCT01654939|Experimental|rifaximin|All patients will be taking rifaximin 550 mg twice daily
88918323|NCT01654965|Experimental|Treatment (tivantinib, topotecan hydrochloride, pegfilgrastim)|Patients receive tivantinib PO BID on days 1-21, topotecan hydrochloride IV over 30 minutes on days 1-5, and pegfilgrastim SC on day 6. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
88918324|NCT01654991|Active Comparator|Clinic-Based Testing|Clinic-based STD screening using self-obtained urine samples in a local university clinical setting.
88918325|NCT01654991|Experimental|Home-Based Testing|Home-based STD screening using self-obtained urine samples and study paid postal return of samples.
88918326|NCT01655004|Experimental|exemestane standard treatment|Patients will receive exemestane 25mg daily orally after a meal until progression of disease, intolerable toxicities, voluntary withdrawal or termination of the study.
88918327|NCT01655017|Experimental|biopsy|Obesity with BMI> 40 kg/m² or obesity with BMI between >35 kg/m² with comorbidities (OSA, type 2 diabetes, hypertension etc…)
88918328|NCT01655017|No Intervention|healthy volunteers|biopsy during a surgery
88918329|NCT01655056|Experimental|low male dose|Japanese and Caucasian males
89010459|NCT04544722|Active Comparator|Lung rehabilitation training|The original treatment and the lung rehabilitation training, once a day, 30 minutes each time.
89436045|NCT05358444|Experimental|Family Diabetes Prevention Program (Family DPP)|"Adult participants will engage in the family-oriented Diabetes Prevention Program lifestyle intervention (Family DPP); this is an augmented version of the DPP lifestyle intervention. This 12-month, group-based lifestyle intervention will include all elements of the DPP lifestyle intervention as delivered by the Johns Hopkins Brancati Center using a CDC-approved curriculum, with additional child-focused sessions in which adult participants will learn about children's health-related behaviors. Children will be present at the child-focused sessions and family activities, and will be engaged in data collection. These groups will be mixed, in that non-study participants (adults who are eligible for the DPP), may also participate."
89436046|NCT05349682|Experimental|GAE and MRI treatment arm|GAE is geniculate artery embolization.
89436047|NCT05342545|Experimental|Alert|For patients randomly assigned to the BPA intervention group (alert group), an on-screen electronic alert will be issued during the outpatient clinical encounter that notifies the responsible provider that his or her T2DM patient should be evaluated for CKD with UACR assessment. The provider then will be given on-screen options to either order a UACR assessment or follow a link to learn more about CKD assessment in T2DM. Should the alert-recipient elect to omit an order for UACR assessment and decline to follow a link to learn more about CKD assessment in T2DM, the provider will be able to continue on with clinic visit-related EHR documentation but will need to select an acknowledge reason (rationale) for not following the evidence-based clinical practice recommendation highlighted in the alert.
89436048|NCT05342545|No Intervention|No Alert|"Providers in the No Alert group will not receive any on-screen notification"
89436049|NCT05337800|Experimental|stress management program|
89436050|NCT05337800|No Intervention|Control|
89436051|NCT05334797|Experimental|Hot application|After the patients come to the service after the surgery, a thermophore filled with hot water will be placed on the patient's shoulder according to the presence of shoulder pain and it will be ensured that he stays for 15 minutes. Pain assessment will be done before and after the application. However, 0-2-4-8-12-24. Routine pain assessment will be done at In addition, the type, route, effect and amount of analgesic done in this process will also be recorded. Response evaluation will follow. Response evaluation will follow. Hot application will be applied to every shoulder pain reported by the patients.
89436052|NCT05334797|No Intervention|control group|First, an individual information form will be filled in for the control group patients who meet the sampling criteria. 0-2-4-8-12-24 after the patients come to the service after the surgery. Routine pain assessment will be done at In addition, the type, route, effect and amount of analgesic done in this process will also be recorded. Response evaluation will follow.
89436053|NCT05333003|Experimental|Semaglutide|Semaglutide medication will be taken by participants on a weekly schedule, and adherence tracked
89436054|NCT05333003|Placebo Comparator|Placebo|Placebo will be taken by participants on a weekly schedule, and adherence tracked
89436055|NCT05322395|Experimental|ESC 0/1 pathway|"A two-arm parallel group, two-centre pragmatic randomised controlled trial of 0-1-hour high sensitivity troponin T (hs cTnT) compared to a 0-3-hour pathway as rules for rapid discharge of suspected ACS. (both incorporating single presentation sample limit of detection (LOD) high sensitive troponin as a rule for discharge, or cut-off selected by manufacturer).~The power of the study is on safety rather than percent discharge achieved by 4 hours as this is the primary focus for clinicians and health care institutions. (By virtue of the earlier sampling the 0-1 hour troponin sampling is likely to allow greater discharges by 4 hours and the sample size for safety easily accommodates this aspect)."
89530926|NCT02507843|Active Comparator|Vitamin D group|Cholecalciferol will be administered by monthly oral intake. During a prospective follow-up period of one year, the patients will get the normal care with some additional tests for the study.
88918330|NCT01655056|Experimental|medium male dose|Japanese and Caucasian males
88918331|NCT01655056|Experimental|high male dose|Japanese and Caucasian males
88918332|NCT01655056|Experimental|high female dose|Japanese and Caucasian females
88918333|NCT01655056|Experimental|highest male dose|Japanese and Caucasian males
88918334|NCT01655082|Experimental|V0116|One patch per day (during 24 hours) for 21 days
88918335|NCT01655082|Active Comparator|Reference|One patch per day (during 24 hours) for 21 days
88918336|NCT01655095|Experimental|PEG and Prucalopride|
88918337|NCT01655095|Experimental|Picosalax and Prucalopride|
89010460|NCT04544566|Experimental|Test product A new adhesive material|The adhesives in the ostomy tapes are developed to make the tape seal to the skin and thereby minimise the risk of leakage episodes. At the same time, the tape should be easy to remove without affecting the skin.
89010461|NCT04544566|Experimental|Test product B new adhesion material|The adhesives in the ostomy tapes are developed to make the tape seal to the skin and thereby minimise the risk of leakage episodes. At the same time, the tape should be easy to remove without affecting the skin.
89436056|NCT05322395|Active Comparator|ESC 0/3 hour pathway|"A two-arm parallel group, two-centre pragmatic randomised controlled trial of 0-1-hour high sensitivity troponin T (hs cTnT) compared to a 0-3-hour pathway as rules for rapid discharge of suspected ACS. (both incorporating single presentation sample limit of detection (LOD) high sensitive troponin as a rule for discharge, or cut-off selected by manufacturer).~The power of the study is on safety rather than percent discharge achieved by 4 hours as this is the primary focus for clinicians and health care institutions. (By virtue of the earlier sampling the 0-1 hour troponin sampling is likely to allow greater discharges by 4 hours and the sample size for safety easily accommodates this aspect)."
89436057|NCT05316142|Active Comparator|AGV with intraoperation MMC|Patients with neovascular glaucoma undergoing shunt implant surgery with MMC during surgery. This method will use Ahmad FP7 model valved shunt (New World Medical, LA), which is one of the most commonly used shunts in the world. First, MMC at a dose of 0.04% is placed in the shunt plate for two minutes and then rinsed. The shunt is fixed and then the shunt tube is inserted into the eye and fixed with nylon 10.0 thread. The conjunctiva is also swabbed with 8.0 vicryl sutures. After the operation, patients undergo regular examinations according to a specific protocol to evaluate the effectiveness as well as possible complications.
89010462|NCT04544566|Active Comparator|Comparator|The comparator product is Brava Elastic tape which is already on the market and will be used within the in-tended use in this clinical investigation.
89010463|NCT04540510|Active Comparator|OPEP therapy added to standard pneumonia care|The intervention group will be asked to use an OPEP device twice daily, with the help of study investigators, for a total of at least 5 minutes per session. This treatment will be in addition to the usual care that the hospital physician prescribe for them to treat the pneumonia.
89010464|NCT04540510|Active Comparator|Standard pneumonia care|The control group will continue to receive the usual care that their hospital team prescribe for them to treat the pneumonia.
89010465|NCT04540471|Experimental|MT group|The participants in MT group will receive music therapy 1 day per week for 1 hour with total 12hours in12 consecutive weeks after initial enrollment. Initial evaluation at the first session, including patient's vital sign, consciousness and spirit. The music therapy will consist of therapeutic singing, interpersonal communication, melody intonation therapy and rhythmic hands slapping. During therapeutic singing session, the music therapists will sing a song first and then the patients sing it after them. Interpersonal communication activity will be led by the music therapist and passed on to one patient to another patient. Melody intonation therapy will comprise communication, chatting and read aloud by using melody.
89530927|NCT02507843|Placebo Comparator|Placebo group|Placebo will be administered by monthly oral intake. During a prospective follow-up period of one year, the patients will get the normal care with some additional tests for the study.
89530928|NCT02500277|Active Comparator|Cryobiopsy|Pleural biopsy with a flexible cryoprobe
89010466|NCT04540471|Placebo Comparator|Control group|control groups will receive comprehensive in-patient education program for 12 consecutive weeks
89010467|NCT04540237||Case|Patients with idiopathic granulomatous mastitis
89010468|NCT04540237||Control|Healthy volunteers
89530929|NCT02500277|Active Comparator|Forceps biopsy|Pleural biopsy with a flexible forceps
89010469|NCT02215447|Experimental|NAB-Paclitaxel with carboplatin|NAB paclitaxel (100 mg/m2 IVI) every week (d1,8,15) in three weekly cycle. Carboplatin (AUC=5 IVI) (d1) in three weekly cycle. Study treatment will continue until progressive disease, unacceptable toxicity, or ceased by patient or clinician preference.
89010470|NCT00236990|Experimental|001|pentosan polysulfate sodium
89010471|NCT02215564||No treatment|Young adults tested by PCR for B. pertussis carriage
89010472|NCT04544371||normal weight patients|patients with body mass index =18-24.9 kg/m2 will be examined by abdominal ultrasound to assess gastric antrum cross sectional area in semi-sitting and right lateral positions
89010473|NCT04544371||obese patients|patients with body mass index >30 kg/m2 will be examined by abdominal ultrasound to assess gastric antrum cross sectional area semi-sitting and right lateral positions
89010474|NCT04539925||Industrial area|
89010475|NCT04539925||Non-industrial area|
89010476|NCT04544332||Unsweetened Supplement|Infants will receive 10 exposures to the unsweetened small quantity lipid nutritional supplement (SQ-LNS) at home
88918338|NCT01655108|Placebo Comparator|Saline|After having been properly diagnostic as having androgenetic alopecia, through biopsy of the scalp, trichogram and trichoscopy and randomized in the placebo group, thirty women will be subjected to intradermal application (mesotherapy) of saline; ten sessions will be held at weekly intervals. Eight weeks after the last session will be repeated all the tests for comparison of results.
88918339|NCT01655108|Active Comparator|Minoxidil 0.5% /2ml|After having been properly diagnostic as having androgenetic alopecia, through biopsy of the scalp, trichogram and trichoscopy and randomized in the drug active group, thirty women will be subjected to intradermal application (mesotherapy) of minoxidil 0.5%/2ml; ten sessions will be held at weekly intervals. Eight weeks after the last session will be repeated all the tests for comparison of results.
88918340|NCT01655121|Experimental|Autoimmune hepatitis (Non-cirrhotic)|A personalized high protein high fiber dietary plan will be provided to each participant from both groups. Each participant will receive nutritional counseling once a month during six months.
88918341|NCT01655121|Experimental|Autoimmune hepatitis (Cirrhotic)|A personalized high protein high fiber dietary plan will be provided to each participant from both groups. Each participant will receive nutritional counseling once a month during six months.
88918342|NCT01655147|Experimental|Abiraterone acetate + Rifampicin|Abiraterone acetate 1,000 mg (4 x 250 mg) on Day 1 of Period 1. Rifampicin 600 mg (2 x 300 mg) on Days 8 to 13, and Abiraterone acetate 1,000 mg (4 x 250 mg) on Day 14 of Period 2.
88918343|NCT01655160|Experimental|mirror therapy treatment|Three groups will be involved in this part of the whole project:MT with low-intensity group (MT-LI), MT with moderate-intensity group (MT-MI), MT with high-intensity group (MT-HI)
88918344|NCT01655160|Active Comparator|control intervention group|The part of this project will involve 1 treatment groups:control intervention group (CI)
88918345|NCT01655173|Experimental|Cognitive behaviour therapy|36 weekly sessions (1 calendar year) of Cognitive behaviour therapy in a group setting.
89436058|NCT05316142|Active Comparator|AGV with intraoperation MMC and postoperation 5FU|Patients with neovascular glaucoma undergoing shunt implant surgery with MMC during and 5FU after surgery .This method will use Ahmad FP7 model valved shunt (New World Medical, LA), which is one of the most commonly used shunts in the world. First, 5FU at a dose of 0.04% is placed in the shunt plate for two minutes and then rinsed. The shunt is fixed and then the shunt tube is inserted into the eye and fixed with nylon 10.0 thread. The conjunctiva is also swabbed with 8.0 vicryl sutures. After the operation, patients undergo regular examinations according to a specific protocol to evaluate the effectiveness as well as possible complications. Also in the first, third and fifth weeks, 5FU injections are given as a subconjugate with a volume of 0.1 ml containing 5 mg of the drug.
89436059|NCT05316129|Experimental|Intraperitoneal treatment- Dose Level 1|Participants will receive one infusion of Follicle-Stimulating Hormone Receptor T (FSHCER T) cells at a dose of 1 x 10^5. Intraperitoneal: Infusion will be administered through a thin membrane of the abdominal cavity.
89436060|NCT05316129|Experimental|Intravenous treatment - Dose Level 1|Participants will receive one infusion of Follicle-Stimulating Hormone Receptor T (FSHCER T) cells at a dose of 1 x 10^5 by Intravenous (IV).
89436061|NCT05316129|Experimental|Intraperitoneal treatment- Dose Level 2|Participants will receive one infusion of Follicle-Stimulating Hormone Receptor T (FSHCER T) cells at a dose of 3 x 10^5. Intraperitoneal: Infusion will be administered through a thin membrane of the abdominal cavity.
89436062|NCT05316129|Experimental|Intravenous treatment - Dose Level 2|Participants will receive one infusion of Follicle-Stimulating Hormone Receptor T (FSHCER T) cells at a dose of 3 x 10^5 by Intravenous (IV).
88918346|NCT01655173|Active Comparator|Recreational activity intervention|36 sessions (1 calendar year) of a group intervention to enable social interaction and to break social isolation.
88918347|NCT01655199|Experimental|COPD group|Moderate and/or severe COPD patients, corresponding to GOLD stages II and III.
88918348|NCT01655212|Experimental|Valganciclovir|Valganciclovir 32 mg/kg per day in two doses (16 mg/kg per dose) during 6 weeks in an oral solution.
88918349|NCT01655212|No Intervention|Control|Infants in the control group receive no antiviral therapy. Counseling and treatment assigned by an audiological center remains unchanged.
88918350|NCT01655238||95-99% BMI ASC|Patients having a BMI between 95-99% who are seen in the ambulatory surgery centers.
88918351|NCT01655238||95-99% BMI NCH main OR|Patients having a BMI between 95-99% who are seen in the main operating rooms.
89436063|NCT05316129|Experimental|Intraperitoneal treatment- Dose Level 3|Participants will receive one infusion of Follicle-Stimulating Hormone Receptor T (FSHCER T) cells at a dose of 1 x 10^6. Intraperitoneal: Infusion will be administered through a thin membrane of the abdominal cavity.
88918352|NCT01655238||>99% BMI NCH main OR|Patients having a BMI >99% who are seen in the main operating rooms.
88918353|NCT01655251|Experimental|Intervention|Video (DVD) discharge instructions
88918354|NCT01655251|No Intervention|Control|
88918355|NCT01655264|Active Comparator|Home-based self training exercises|The control group will receive home-based self-training exercises that are based on conventional therapy using principles of motor control and will include training of upper extremity movements in order to achieve better use of the affected arm in ADL. Each subject will receive a list of exercises to be performed in his home using a stand-alone poster as targets for the movements. In addition, each subject will be asked to write the dates and duration of time he/she did the each exercise. They will be in contact with a therapist once a week to monitor the self training program and adjust the level of exercise.
88918356|NCT01655264|Experimental|Tele-rehabilitation exercises|The experimental group will receive tele-rehabilitation treatment of comparable duration and intensity to those in the home-based self training exercise group. However, the treatment will be delivered via the Gertner Tele-Motion Rehabilitation system with remote online monitoring by the therapist. Treatment feedback will be given in the form of Knowledge of results (game scores) and Knowledge of performance (feedback of compensatory movements made while using the upper extremity) to enhance motor learning. The software will generate a report which will include the duration and type of exercises performed by the subject. If needed, a personal attendant may provide physical support in the tele home mock-up room.
89010477|NCT04544332||Sweetened Supplement|Infants will receive 10 exposures to the sweetened small quantity lipid nutritional supplement (SQ-LNS) at home
89010478|NCT02215603|No Intervention|Prolonged sitting|9 h of prolonged sitting
89436064|NCT05316129|Experimental|Intravenous treatment - Dose Level 3|Participants will receive one infusion of Follicle-Stimulating Hormone Receptor T (FSHCER T) cells at a dose of 1 x 10^6 by Intravenous (IV).
89436065|NCT05316129|Experimental|Intraperitoneal treatment- Dose Level 4|Participants will receive one infusion of Follicle-Stimulating Hormone Receptor T (FSHCER T) cells at a dose of 3 x 10^6. Intraperitoneal: Infusion will be administered through a thin membrane of the abdominal cavity.
89436066|NCT05316129|Experimental|Intravenous treatment - Dose Level 4|Participants will receive one infusion of Follicle-Stimulating Hormone Receptor T (FSHCER T) cells at a dose of 3 x 10^6 by Intravenous (IV).
88918357|NCT01655277|Experimental|Adductor Canal block first|This arm received an ultrasound guided adductor canal block with 15mL of chloroprocaine 3% followed by motor, sensory and balance assessments. Then the patients received an ultrasound guided femoral nerve block with 15mL of chloroprocaine 3% followed by sensory and motor assessments.
88918358|NCT01655277|Experimental|Femoral nerve block first|This arm received an ultrasound guided femoral nerve block with 15mL of chloroprocaine 3% followed by motor, sensory and balance assessments. Then the patients received an ultrasound guided adductor canal block with 15mL of chloroprocaine 3% followed by sensory and motor assessments.
88918359|NCT01655290|Experimental|Gadobutrol|first session gadobutrol second session gadobenate dimeglumin
88918360|NCT01655290|Experimental|Demeglumin|first session gadobenate dimeglumin second session gadobutrol
88918361|NCT01655303|Experimental|Metoprolol Per Oral|50 mg Metoprolol
88918362|NCT01655303|Experimental|Verapamil|40 mg Verapamil Per Oral
88918363|NCT01655303|Experimental|Propranolol|40 mg Propranolol Per Oral
88918364|NCT01655303|Experimental|Diltiazem|60 mg Diltiazem Per Oral
88918365|NCT01655316|Experimental|Verapamil|40 mg Verapamil Per Oral
88918366|NCT01655342||formocresol|
88918367|NCT01655355||Revison of the hip joint|
88918368|NCT01655368|Experimental|Interventional: STEM modules|8 sessions of psychoeducation + 3 sessions + 1 booster session of STEM module (for schizophrenia or depression)
88918369|NCT01655368|Other|Interventional Control|11 sessions + 1 booster session of psychoeducation for schizophrenia or depression)
88918370|NCT01655407|Experimental|Treatment|All patients will receive both Autologous Engineered Skin Substitute (ESS-W) and Split-Thickness Autograft (AG).
88918371|NCT01655407|Active Comparator|Control|All patients will receive both Autologous Engineered Skin Substitute (ESS-W) and Split-Thickness Autograft (AG).
88918372|NCT01655420||LASIK|Individuals aged 21 to 84 years planning to undergo refractive surgery using LASIK for myopia, hyperopia, or astigmatism
88918373|NCT01655433|Experimental|Therapeutic Hypothermia Treatment|
88918374|NCT01655433|Active Comparator|No Hypothermia Treatment|control group is no hypothermia treatment
88918375|NCT01655446|Experimental|Robotic Rehabilitation with FES|Robotic rehabilitation combined Functional Electrical Stimulation (FES)
88918376|NCT01655446|Experimental|Mirror Therapy|Mirror Therapy (MT)
88918377|NCT01655446|Active Comparator|Conventional Rehabilitation|Conventional Rehabilitation (CR) mainly focuses on occupational therapy training
88918378|NCT01655446|Experimental|Robotic Rehabilitation|Robotic Rehabilitation (RR)
88918379|NCT01655446|Placebo Comparator|Robotic Rehabilitation with PI|Robotic rehabilitation with Placebo Intervention (RR-PI)
88918380|NCT01655459||Ultrasound exam of upper airway|Following Internal Review Board approval(4-2011-0800) and written informed consent, total 100 patients(ASA I and II children aged 1 month to 6years) undergoing infra-umblicular urologic surgeries were included in the study. Children with upper respiratory tract infection, restricted mouth opening, congenital heart disease and those at risk for aspiration were excluded.
88918381|NCT01655472|Active Comparator|healthy parents|
88918382|NCT01655472|Active Comparator|schizophrenic parents|
88918383|NCT01655485|Experimental|Patient teaching|ipad application for social script book
88918384|NCT01655511|Experimental|Period 1|240 mg tafamidis arm
88918385|NCT01655511|Experimental|Period 2|480 mg arm
88918386|NCT01655511|Experimental|Period 3|TBD dose
88918387|NCT01655524|Experimental|ASSUAGE Protocol|There is only one arm in this cross-over design trial. Patients who had a standard regadenoson stress test will be invited to enroll in the study. All enrolled subjects will undergo an investigational (ASSUAGE) regadenoson stress test. Imaging scans from the same patients (scan 1 and scan 2) will be compared.
88918388|NCT01655550|Other|Standard of Care|Patients will get routine CT scans with Oral and Intravenous contrast prior to their CT scan as is routine, standard practice
88918389|NCT01655550|Experimental|Withold Oral Contrast|Subjects will not drink oral contrast, but instead water (in itself a type of contrast agent) prior to their CT. Intravenous contrast will be administered as is routine
88918390|NCT01655576|No Intervention|Routine clamping|After delivery of the newborn, umbilical cord at mothers end, will be left clamped until delivery of the placenta.
88918391|NCT01655576|Experimental|Placental drainage|After delivery of the newborn, umbilical cord at mothers end, will be left unclamped until delivery of the placenta.
88918392|NCT01655602|Experimental|upper edge trimming|Surgery: trichophytic closure The 1-millimetre trimming of upper edge of linear incision before wound closure
88918393|NCT01655602|Experimental|lower edge trimming|Surgery: trichophytic closure The 1-millimetre trimming of lower edge of linear incision before wound closure
88918394|NCT01655602|Experimental|Both edge trimming|Surgery: trichophytic closure The 0.5-millimetre trimming of both edge of linear incision before wound closure
89198530|NCT05276128|Active Comparator|WWB 15 g control lipids|WWB supplemented with 15g control lipids
89010479|NCT02215603|Experimental|Prolonged sitting + interval standing bouts|Stand bout for 15-min every 30 minutes during the 9 hours of sitting
89010480|NCT02215603|Experimental|Moderate exercise bout + Prolonged sitting|30-min moderate-intensity exercise bout followed by 8 h of sitting
89436067|NCT05316129|Experimental|Intraperitoneal treatment- Dose Level 5|Participants will receive one infusion of Follicle-Stimulating Hormone Receptor T (FSHCER T) cells at a dose of 1 x 10^7. Intraperitoneal: Infusion will be administered through a thin membrane of the abdominal cavity.
89436068|NCT05316129|Experimental|Intravenous treatment - Dose Level 5|Participants will receive one infusion of Follicle-Stimulating Hormone Receptor T (FSHCER T) cells at a dose of 1 x 10^7 by Intravenous (IV).
89436069|NCT05302986|Experimental|Surgery with intravenous injection of tranexamic acid|The dose will be 0.1 mg / kg (= 10 mg/kg) and diluted in a 100 mL infusion bag of sodium chloride. The product will have to be administered as a slow infusion over 10 minutes.
89436070|NCT05302986|Placebo Comparator|Surgery with intravenous injection of Placebo (0.9% sodium chloride)|A 100 mL infusion bag of sodium chloride will be administered as a slow infusion over 10 minutes.
89436071|NCT05300022|No Intervention|Arm 1: Semi-structured Interviews|Arm 1 will be conducted from months 0-15 and will use interviews to better understand existing challenges in diabetes technology educational practices. It is not a clinical trial, but is a crucial part of what builds to the clinical trial.
89436072|NCT05300022|Experimental|Arm 2: Designing an App Delivered Curriculum|Arm 2 will be conducted from months 10-33 and will use information learned in arm 1 to develop and beta test an educational curriculum. Arm 2 also is not a clinical trial, but is a crucial part of what builds to the clinical trial.
89436073|NCT05300022|Active Comparator|Arm 3: TeKnO T1D: Parents Pilot Study|Arm 3 will be conducted from months 30-60 and involves a pilot and feasibility study of the newly developed educational curriculum. This is the clinical trial.
89436074|NCT05287126|Experimental|Etrasimod|
89436075|NCT05286437|Experimental|Intervention|Oral lenvatinib + Intravenous (IV) pembrolizumab + Oral letrozole
89436076|NCT05275543|Experimental|Physical and Occupational Therapy with Paro Robot|10-30 minute semi-structured, prescriptive therapy sessions with Paro robot focused on the categories of 1) speech; 2) balance and endurance; 3) memory; 4) self-esteem; 5) fine motor; 6) sensory stimulation
89436077|NCT05275543|No Intervention|Physical and Occupational Therapy without Paro Robot|10-30 minute semi-structured, prescriptive therapy sessions without Paro robot focused on the categories of 1) speech; 2) balance and endurance; 3) memory; 4) self-esteem; 5) fine motor; 6) sensory stimulation
89436078|NCT05275543|Experimental|Parents/Guardians of Hospitalized Children who use Paro Robot|"Parents/guardians of hospitalized children who are assigned to the following arm Physical and Occupational Therapy with Paro Robot"
89010481|NCT02215603|Experimental|Moderate exercise bout + Prolonged sitting +Standing bouts|30-min moderate-intensity exercise bout and stand bout for 15-min every 30 minutes during the remaining 8 hours of sitting
89010482|NCT04544215|Experimental|MPCs-derived exosomes Dosage 1|low-dose group
89010483|NCT04544215|Experimental|MPCs-derived exosomes Dosage 2|high-dose group
89010484|NCT04544215|Placebo Comparator|No exosomes|No MPCs-derived exosomes
89010485|NCT00237107|Experimental|curettage|
89436079|NCT05275543|No Intervention|Parents/Guardians of Hospitalized Children who do not use Paro Robot|"Parents/guardians of hospitalized children who are assigned to the following arm Physical and Occupational Therapy with out Paro Robot"
89436080|NCT05274529|Experimental|Study group|All the participants will be in the same group and have the same intervention programmes options to choose from.
89436081|NCT05269849|Experimental|Oral sirolimus tablets|Sirolimus starting dose of 2 mg once daily, orally adjusted as need to maintain drug blood levels of 6-10 ng/ ml The first dose will be given at the week 12 visit and participants will be observed for 30 min
89436082|NCT05267886|Active Comparator|Inotrope|Participants randomized to receive the inotrope will be initiated on inotrope therapy at starting doses and titrated according to standard clinical care. During reassessment, the treating physicians will make a decision about adjustment of the inotrope dose (increase, maintain or decrease) based on hemodynamics, end-organ perfusion, vasopressor support and clinical exam. Dobutamine doses will be 2.5, 5.0, 7.5, 10 and >10 ug/kg/min and milrinone doses will be 0.125, 0.250, 0.375, 0.5 and >0.5 ug/kg/min. These dose stages are identical to those used in Capital Do-Re-Mi and reflect current standard of care.
89436083|NCT05267886|Placebo Comparator|Placebo|Participants in the placebo arm will have an intravenous solution of 0.9% NaCl running at a standardized rate, comparable to the infusion rate of the inotrope arm.
89436084|NCT05251428|Experimental|excision of the A1 pulley|
89436085|NCT05251428|Active Comparator|incision of the A1 pulley in the standard fashion|
89436086|NCT05242315|Active Comparator|Envarsus|Envarsus tablet Dose 0.11 - 0.13 mg/Kg/day Frequency: once per day
89436087|NCT05242315|Other|Prograf (SOC)|Prograf tablet Dose 0.10 - 0.15mg/Kg daily Frequency: 2 doses per day (dose above split in half for each dose)
88918395|NCT01655615|Experimental|Preventure programme|The interventions are conducted using manuals which incorporate psycho-educational, motivational enhancement therapy and cognitive-behavioural (CBT) components, and include real life 'scenarios' shared by local youth in with similar personality profiles. In the first session, participants are guided in a goal-setting exercise, designed to enhance motivation to change behaviour. Psycho-educational strategies are then used to teach participants about the target personality variable and associated problematic coping behaviours like avoidance, interpersonal dependence, aggression, risky behaviours and substance misuse.
88918396|NCT01655628|Experimental|GC chemotherapy plus CIK cells|A total of 40 patients enrolled will be accept 4 cycles GC chemotherapy(every 4 weeks),then they will randomized divided into two groups. 20 patients will maintain autologous CIK cells for 8 cycles (every 4 weeks); however,the other 20 patients will not accept CIK cells treatment. After the all 40 patients have accomplished 4 cycles GC regimen chemotherapy plus 8 cycles CIK cells treatment or 4 cycles GC chemotherapy alone, the early effects will be assessed and long-term efficacy such as OS and PFS will be evaluated.
88918397|NCT01655628|Active Comparator|GC chemotherapy|A total of 40 patients enrolled will be accept 4 cycles GC chemotherapy(every 4 weeks),then they will randomized divided into two groups. 20 patients will maintain autologous CIK cells for 8 cycles (every 4 weeks);the other 20 patients will not accept CIK cells treatment. After the all 40 patients have accomplished 4 cycles GC regimen chemotherapy plus CIK cells treatment or 4 cycles GC chemotherapy alone, the early effects will be assessed and long-term efficacy such as OS and PFS will be evaluated.
89436088|NCT05241249|Experimental|Bethanechol|Patients with borderline resectable pancreatic cancer and no contraindication to bethanechol therapy will receive bethanechol on day 1 and continue until 2 days prior to scheduled surgery for a minimum of 2 months.
89436089|NCT05237947|Experimental|Arm I (Gardasil 9)|Patients receive one dose of Gardasil 9 IM.
88918398|NCT01655641|Experimental|Tranexamic acid arm|"Along with the standard of care (routine surgical care involved in preventing blood loss during surgery) this arm will receive drug Tranexamic acid~1gm stat, preoperatively (30 mins) 10mg / kg body weight, 8 hourly for 5 days via IV for non-renal impaired subjects.~Alternate IV dosing for renally-impaired subjects: 10mg/Kg BID (1.36 - 2.83 mg/dl clearance); 10mg/Kg QD (2.84 - 5.66 mg/dl clearance; and 10mg/Kg Q48H or 5mg/Kg (.5.66mg/dl clearance)"
89436090|NCT05237947|Experimental|Arm II (Cervarix)|Patients receive one dose of Cervarix IM.
89436091|NCT05237947|Active Comparator|Arm III (Adacel)|Patients receive one dose of Adacel IM.
89436092|NCT05230147|Experimental|Spinal cord stimulation|"Before tilt testing, adhesive patches are applied to subjects' back skin. Single stimuli are delivered to the patches in order to define the stimulation threshold under the guidance of neuromyography. An investigator says loudly: I am initiating high-frequency stimulation. Stimulation is initiated within 2 min before tilting the table. Then verticalization of the table 45 degrees is performed, and the test is continued for 15-30 min. Beat-to-beat blood pressure recording is carried out and 10 min after blood pressure complete stabilization the test is ended."
89436093|NCT05230147|Sham Comparator|Sham stimulation|"Before tilt testing, adhesive patches are applied to subjects' back skin. Single stimuli are delivered to the patches in order to define stimulation threshold under the guidance of neuromyography. An investigator says loudly: I am initiating high-frequency stimulation. No stimulation is initiated. Two minutes after, verticalization of the table 45 degrees is performed, and the test is continued for 15-30 min. Beat-to-beat blood pressure recording is carried out and 10 min after blood pressure complete stabilization the test is ended."
89436094|NCT05223673|Experimental|Futuximab/modotuximab combined with trifluridine/tipiracil (Safety Lead-In and Phase III parts)|
88918399|NCT01655641|Active Comparator|Standard of care arm|Includes routine surgical care involved in preventing blood loss during and after surgery.
88918400|NCT01655654|No Intervention|Cohort 1|All employees within the acute care hospital that signed the informed consent form and provided their individual data.
88918401|NCT01655654|Active Comparator|Cohort 2|All subjects of cohort 1 who also are considered hypertensive and participated in one or more study interventions, which include behavioral interventions (an increase in physical activity, or dietary changes) or who have a primary care provider visit to discuss hypertension.
88918402|NCT01655667||Chronic Obstructive Pulmonary Disease|All patients with a coded diagnosis of COPD entered into their electronic clinical record between 1990 and 2009.
88918403|NCT01655706|Active Comparator|escitalopram (10-20mg)|Patients are on escitalopram for 8 weeks. At Week 8, patients will be assessed as 'responders' or 'non-responders'. 'Responders' will continue on escitalopram until study endpoint.
89436095|NCT05223673|Active Comparator|Trifluridine/tipiracil (Phase III part)|
89436096|NCT05221606|Experimental|Nurse AMIE Supportive Care Intervention|Participants in the intervention arm will receive the computer tablet with the Nurse AMIE program. Nurse AMIE will assess their symptoms daily and provide an intervention to help manage their symptoms.
89436097|NCT05221606|Active Comparator|Usual Care|Participants in the usual care arm will receive a book with some supportive care educational materials and recommendations.
89436098|NCT05212727||Healthy Control|Participant with no evidence or history of significant neurodegenerative disorder affecting brain function.
89436099|NCT05211986|Active Comparator|Cohort A|Participants will receive twice weekly intramuscular (im) administration of IMMUNA(IMM01-STEM) for 4 weeks with a dose of 225μg.
89436100|NCT05211986|Active Comparator|Cohort B|Participants will receive twice weekly intramuscular (im) administration of IMMUNA(IMM01-STEM) for 4 weeks with a dose of 450μg.
89436101|NCT05211986|Active Comparator|Cohort C|Participants will receive twice weekly intramuscular (im) administration of IMMUNA(IMM01-STEM) for 4 weeks with a dose of 900μg.
88918404|NCT01655706|Active Comparator|aripiprazole (2-10mg)|At Week 8, patients assessed as 'non-responders' will be given aripiprazole as an add-on treatment to escitalopram.
89436102|NCT05209295|Experimental|Group 1|
89436103|NCT05209295|Experimental|Group 2|
89436104|NCT05209295|Other|Group 3|Control - participants with normal hepatic function
89436105|NCT05208762|Experimental|SGN-PDL1V Monotherapy|SGN-PDL1V monotherapy
89436106|NCT05208762|Experimental|SGN-PDL1V Combination Therapy|SGN-PDL1V + pembrolizumab
88819405|NCT05119803||Healthy control group|"The cognitive status of the participants will be evaluated using the 'Standardized Mini Mental Test'. This scale is frequently used for the general determination of the cognitive status of individuals rather than for the purpose of diagnosis.~The upper extremity functions of healty control group will be evaluated with the '9-Hole Peg Test'.~Spinal posture will be assessed using the IDIAG M360 (IDIAG, Fehraltorf, Switzerland) Spinal Mouse. This device is an electronic computer aided measuring device that measures the range of motion of the spine and evaluates the angle and shape of the spine in the sagittal and frontal planes."
88819406|NCT00370929|Experimental|Meditation|
89436107|NCT05202509|Experimental|obicetrapib 10mg|one 10mg tablet, once daily.
89436108|NCT05202509|Placebo Comparator|Placebo|one placebo tablet, once daily
89436109|NCT05202301||Darolutamide cohort (Daro)|Participants received Second Generation Androgen Receptor Inhibitor (SGARI) Darolutamide as initial treatment
89436110|NCT05202301||Enzalutamide cohort (Enza)|Participants received Second Generation Androgen Receptor Inhibitor (SGARI) Enzalutamide as initial treatment
88819407|NCT04390737|Experimental|HH2853 administered on a BID schedule in continuous 28-day treatment cycles|"HH2853 is supplied as tables with dosage strength of 25mg and 200mg. HH2853 Tablet will be administered orally on a continuous twice daily (BID) schedule, on a flat scale of mg and not individually adjusted by weight or body surface area. A treatment cycle is defined as 28 days for the purposes of scheduling procedures and evaluations.~All patients will be treated with HH2853 orally on a continuous BID schedule, beginning on Cycle 1 Day 1. But patients in accelerated titration (ATD) part should be administered a single dose on the first day in order to evaluate the PK of a single dose administration. Dosing is twice daily from the second day thereafter."
88819408|NCT05099289|Experimental|AtaCor EV-ICD Lead System|Subjects inserted with the AtaCor EV-ICD Lead Model AC-7000
89436111|NCT05202301||Apalutamide cohort (Apa)|Participants received Second Generation Androgen Receptor Inhibitor (SGARI) Apalutamide as initial treatment
89436112|NCT05199337|Experimental|Treatment Arm|Subjects will receive ZN-d5 orally (PO), once (QD) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89436113|NCT05194072|Experimental|SGN-B7H4V|SGN-B7H4V monotherapy
89436114|NCT05190679||Cardiomyopathy Rare Variant Cases|Identified Pathogenic/Likely pathogenic rare variant in cardiomyopathy (CM) gene which include inherited CM syndromes.
89436115|NCT05190679||Arrhythmia Rare Variant Cases|Identified Pathogenic/Likely pathogenic rare variant in arrhythmia genes.
89436116|NCT05190679||Controls|No rare variant in CM, arrhythmia, or other atrial fibrillation gene.
89436117|NCT05182489|Experimental|Medtronic Adaptix™ titanium implants|This arm will use Medtronic Adaptix™ titanium implants supplemented with a pedicle screw system. Both cages will be used in conjunction with a 50:50 mixture of autograft: allograft using milled local autograft bone and GRAFTON™ DBM DBF (no iliac crest autograft will be utilized).
88819409|NCT02421510|Placebo Comparator|Placebo|Two placebo-matching sotagliflozin tablets, once daily, orally, before the first meal of the day for 24 weeks followed by a 28-week extension period.
88819410|NCT02421510|Experimental|Sotagliflozin 200 mg|Sotagliflozin 200 milligram (mg) (one 200 mg tablet and one placebo tablet), once daily, orally, before the first meal of the day for 24 weeks followed by a 28-week extension period.
88819411|NCT02421510|Experimental|Sotagliflozin 400 mg|Sotagliflozin 400 mg (two 200 mg tablets), once daily, orally, before the first meal of the day for 24 weeks followed by a 28-week extension period.
88819412|NCT05099133|Experimental|LEO 138559 Dose 1|LEO 138559 will be administered subcutaneously up to 3 injections per dosing
88819413|NCT05099133|Experimental|LEO 138559 Dose 2|LEO 138559 will be administered subcutaneously up to 3 injections per dosing
88819414|NCT05099133|Experimental|LEO 138559 Dose 3|LEO 138559 will be administered subcutaneously up to 3 injections per dosing
88819415|NCT05099133|Placebo Comparator|Placebo|LEO 138559 placebo will be administered subcutaneously up to 3 injections per dosing
88819416|NCT00552617|Placebo Comparator|Rocuronium + Placebo|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered intravenously (IV), followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of placebo was administered IV.
88819417|NCT00552617|Experimental|Rocuronium + 0.5 mg/kg Sugammadex|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 0.5 mg/kg sugammadex was administered IV.
89436118|NCT05182489|Active Comparator|Medtronic CAPSTONE® PEEK cage|This arm will use Medtronic CAPSTONE® PEEK cage supplemented with a pedicle screw system. Both cages will be used in conjunction with a 50:50 mixture of autograft: allograft using milled local autograft bone and GRAFTON™ DBM DBF (no iliac crest autograft will be utilized).
89530930|NCT02500199|Experimental|Pyrotinib|A two-part Phase I, open-label, dose escalation study to evaluate the safety, tolerability and pharmacokinetics of pyrotinib in patients with HER2-positive solid tumors whose disease progressed on prior HER2 targeted therapy
89530931|NCT04498091||A|Type 2 MI with COVID-19
89530932|NCT04498091||B|Type 2 without COVID-19
88918405|NCT01655732|Experimental|Atraumatic Restorative Treatment|ART is Atraumatic Restorative Treatment involving removal of soft carious enamel and dentine by hand instruments only and then restore the resulting cavity and adjacent pits and fissures with an adhesive restorative material.
88918406|NCT01655745|Experimental|FDG PET/MR, No Chemotherapy Arm|Patients that are NOT receiving chemotherapy but are only completing surgical intervention.
88918407|NCT01655745|Experimental|FDG PET/MR, Chemotherapy Arm|Patients that are receiving chemotherapy prior to completing surgical intervention. These patients will receive a FDG PET/MR prior to chemotherapy and after completion of chemotherapy (at the time of pre-op, before surgical intervention).
88918408|NCT01655758|Active Comparator|timolol|60-day treatment phase with 0.5% timolol eyedrops, b.i.d.
88918409|NCT01655758|Active Comparator|'timolol-dorzolamide fixed combination'|60-day treatment phase with the fixed combination of 0.5% timolol-2% dorzolamide, eyedrops, b.i.d.
88918410|NCT01655758|Active Comparator|xalatan|60-day treatment phase with 0.005% latanoprost, eyedrops, QD
88918411|NCT01655758|Active Comparator|travatan|60-day treatment phase with 0.004% travoprost, eyedrops, QD
88918412|NCT01655758|Active Comparator|lumigan|60-day treatment phase with 0.03% bimatoprost, eyedrops, QD
88918413|NCT01655771|Experimental|Elderly|TD-1211 Dose 1
88918414|NCT01655771|Experimental|Younger|TD-1211 Dose 2
88918415|NCT01655797|Experimental|CBT|The treatment group received manualized CBT-I using a adapted version of a manual designed for use by primary care personnel. Treatment comprised information about sleep and insomnia, methods for medication tapering, sleep hygiene, stimulus control, sleep restriction, progressive muscle relaxation, and dealing with sleep interfering thoughts.
88918416|NCT01655797|No Intervention|Wait-list|A deferred treatment wait-list condition, with no restrictions placed on the usual care.
88918417|NCT01655810|Active Comparator|Vitamin D 4000 IU|PO daily
88918418|NCT01655810|Active Comparator|Vitamin D 600 IU|PO daily
88918419|NCT01655849|Experimental|Z160|375mg BID
88918420|NCT01655849|Placebo Comparator|placebo|matching placebo control
88918421|NCT01655862||OnabotulinumtoxinA|OnabotulinumtoxinA injections at doses and frequencies as determined by the physician in accordance with clinical practice.
88918422|NCT01655875|Experimental|bone marrow transplant|
88918423|NCT01655888|Experimental|single arm with Tremelimumab|Tremelimumab: 10mg/Kg ev day 1 every 4 weeks for 6 doses in induction phase, then every 12 weeks in maintenance phase until disease progression of severe toxicity
88918424|NCT01655914|Active Comparator|Arm A|"Sequence of Exposure:~Sequence A (N=5) Week 1: S/L 1.1 mg Week 2: S/L 2.2 mg Week 3: IV 0.2 mg Week 4: S/L 2.2 mg with 240 ml water"
88918425|NCT01655914|Active Comparator|Arm B|Sequence B (N=5) Week 1: IV 0.2 mg Week 2: S/L 2.2 mg Week 3: S/L 1.1 mg Week 4: S/L 2.2 mg with high fat diet
88918426|NCT01655927|Experimental|Tranexamic Acid|15 mg/Kg Tranexamic Acid IV after anesthesic induction,and continues with a dose of 1mg/kg/h intraoperatory
88918427|NCT01655927|Placebo Comparator|Saline (Placebo)|15 mg/Kg of Saline IV after anesthesic induction,and continues with a dose of 1mg/kg/h intraoperatory
88918428|NCT01655940||Cardiac bypass patients|
88918429|NCT01655953|Experimental|Campaign 1|
88918430|NCT01655953|Experimental|Campaign 2|
88918431|NCT01655966|Active Comparator|Standard of care|Group A: comprises 40 treatment-naive chronic hepatitis c patients who will receive the standard of care treatment: peginterferon Alfa 2a 160 ug once weekly and weight-based ribavirin 1000 or 1200 mg/day (based on body weight < 75 kg or ≥ 75 kg, respectively) in divided doses for 48 weeks.
88918432|NCT01655966|Experimental|Triple therapy|Group B: comprises 40 treatment-naive chronic HCV patients who will receive oral vitamin D 1mcg once daily plus peginterferon alfa-2a (160ug once weekly) and weight-based ribavirin 1000-1200 mg daily (based on body weight < 75 kg or ≥ 75 kg, respectively) in divided doses for 48 weeks.
88918433|NCT01655979|Experimental|MEP-1|
88918434|NCT01655979|Experimental|MEP-2|
88918435|NCT01655992|Experimental|S1 generic|40mg／m2 bid four weeks on two weeks off
88918436|NCT01655992|Active Comparator|capecitabine|2500mg／m2／day divided into twice two weeks on one week off
88918437|NCT01656005|Experimental|Carvedilol|Beclometasone/Formoterol Beclometasone Tiotropium
88918438|NCT01656005|Active Comparator|Bisoprolol|Beclometasone/Formoterol Beclometasone Tiotropium
88918439|NCT01656018|Experimental|Arm 1A|Female participants will receive a single dose of long acting TMC278 1200 mg intramuscularly (IM) at baseline (Day 0) in Arm 1A.
88918440|NCT01656018|Experimental|Arm 1B|Male participants will receive a single dose of long acting TMC278 1200 mg IM at baseline in Arm 1B.
89010486|NCT02215681|Experimental|acupuncture|acupuncture treatment
89530933|NCT04498091||C|Type 2 MI with pneumonia without COVID-19
89530934|NCT04498091||D|Type 2 MI without pneumonia and without COVID-19
88918441|NCT01656018|Experimental|Arm 2A|Female participants will receive a single dose of long acting TMC278 600 mg IM at baseline in Arm 2A.
89436119|NCT05181917|Experimental|Intervention|Patients assigned to the intervention group will receive the STUDIA application on their mobile device, which has two functions, an insulin bolus calculator that estimates the amount of insulin according to the amount of carbohydrates that the patients compute, the insulin sensitivity factor, and the insulin/carbohydrate ratio provide by their treating physician. The application has a graphical interface that shows a glucose curve four hours after the meal. This graph is built using the estimations made by an MSBF based on some characteristics of the patient previously recorded in the same application, the amount of carbohydrates entered to calculate the insulin bolus, and an estimate of the fat and protein content of the meal.
89436120|NCT05181917|Active Comparator|Control|The patients assigned to the control group will also receive the STUDIA application on their mobile devices. The insulin dose calculation process is the same as that described for the intervention group. However, the simulation results will be kept hidden from the patient.
89436121|NCT05180474|Experimental|GEN1047|
89436122|NCT05179824||Group 1: Standard of Care (SOC) CGP|This group will facilitate collection of paired clinical and molecular data done as part of the standard of care or routine clinical care across a variety of institutions. The goal of Group 1 is to capture a broad range of participants to better understand longitudinal outcomes across institutions and standards of care.
88918442|NCT01656018|Experimental|Arm 2B|Male participants will receive a single dose of long acting TMC278 600 mg IM at baseline in Arm 2B.
88918443|NCT01656018|Experimental|Arm 3A|Female participants will receive 3 bi-monthly injections of long acting TMC278 1200 mg IM at baseline, Months 2 and 4 in Arm 3A.
88918444|NCT01656018|Experimental|Arm 3B|Male participants will receive 3 bi-monthly injections of long acting TMC278 1200 mg IM at baseline, Months 2 and 4 in Arm 3B.
88918445|NCT01656018|Experimental|Arm 4A|Female participants will receive a single dose of long acting TMC278 1200 mg IM at baseline followed by TMC278 900 mg at Months 2 and 4 in Arm 4A.
88918446|NCT01656018|Experimental|Arm 4B|Male participants will receive a single dose of long acting TMC278 1200 mg IM at baseline followed by TMC278 900 mg at Months 2 and 4 in Arm 4B.
88918447|NCT01656018|Experimental|Arm 5A|Female participants will receive a single dose of long acting TMC278 1200 mg IM at baseline followed by TMC278 600 mg at Months 2 and 4 in Arm 5A.
88918448|NCT01656018|Experimental|Arm 5B|Male participants will receive a single dose of long acting TMC278 1200 mg IM at baseline followed by TMC278 600 mg at Months 2 and 4 in Arm 5B.
88918449|NCT01656044|Active Comparator|Arm I (SSD)|Patients receive SSD over their closed laparotomy incision at the conclusion of their surgery.
88918450|NCT01656044|Experimental|Arm II (NPT)|Patients receive NPT dressing over their closed laparotomy incision at the conclusion of their surgery.
88918451|NCT01656057|Experimental|Acetaminophen+saline|Acetaminophen tablet 1500 mg via nasogastric tube + i.v. saline
88918452|NCT01656057|Experimental|Acetaminophen+CCK|Acetaminophen tablet 1500 mg via nasogastric tube + iv. CCK-8, 24 pmol/kg/hour
88918453|NCT01656057|Experimental|Metformin+saline|Metformin tablet 1500 mg + Acetaminophen tablet 1500 mg via nasogastric tube + i.v. saline
88918454|NCT01656057|Experimental|Metformin+CCK|Metformin tablet 1500 mg + Acetaminophen tablet 1500 mg via nasogastric tube + iv. CCK-8, 24 pmol/kg/hour
88918455|NCT01656057|Experimental|Colesevelam+saline|Colesevelam tablet 3750 mg + Acetaminophen tablet 1500 mg via nasogastric tube + iv. saline
88918456|NCT01656057|Experimental|Colesevelam+CCK|Colesevelam tablet 3750 mg + Acetaminophen tablet 1500 mg via nasogastric tube + iv. CCK-8, 24 pmol/kg/hour
89436123|NCT05172011||Extant, Clinical and De Novo Cohort -- INFECTED|SARS-CoV-2 infected children and young adults with and without current or prior PASC-like symptoms, including infected individuals with history of multisystem inflammatory syndrome in children (MIS-C), and infants born in the context of maternal SARS-CoV-2 infection during pregnancy
89436124|NCT05172011||Extant, Clinical and De Novo Cohort -- UNINFECTED|SARS-CoV-2 uninfected children and infants born to uninfected mothers
89198531|NCT00956332|Experimental|MGA - Low therapeutic dose|
88918457|NCT01656070|Experimental|Vitamin D|"oral cholecalciferol 1000000 UI (vitamin D3).~At 0, 3, 6 and 9 months, the vitamin D group received orally 100000 IU of cholecalciferol suspended in 2 mL of olive oil in sealed plastic syringes labeled with the unique identification numbers."
88918458|NCT01656070|Placebo Comparator|placebo|"placebo~At 0, 3, 6 and 9 months, the placebo group received 2 mL of olive oil, in sealed plastic syringes labeled with the unique identification numbers."
89436125|NCT05172011||Acute Cohort -- INFECTED|Newly SARS-CoV-2 infected individuals (≤4 weeks since onset of symptoms or positive laboratory testing)
88918459|NCT01656083||SM intervention + varenicline|In intervention group, SM is delivered by a standard designed SM platform system. The interactive SM supports are involved and trained professional staff will provide guidance regularly. The drug usage in two groups are the same.
89010487|NCT02215681|No Intervention|standard treament|watchful waiting
89436126|NCT05172011||Acute Cohort -- UNINFECTED|Contemporaneous SARS-CoV-2 uninfected individuals selected from the same population as newly SARS-CoV-2 infected individuals
88918460|NCT01656083||Non-SM intervention group: varenicline|varenicline only
88918461|NCT01656096|Experimental|Renal sympathetic denervation|Renal sympathetic denervation (Symplicity ablation catheter, Medtronic Inc. Minneapolis, Minnesota, USA)
88918462|NCT01656096|Sham Comparator|Sham procedure|Sham procedure mimicking the renal sympathetic denervation procedure in the experimental arm
88918463|NCT01656109|Experimental|PI-experience group|Using PI-based HAART for ≥6 months at the screening visit HIV-RNA viral load < 50 copies/ml at the screening visit No history of HIV-RNA ≥ 1,000 copies/ml while using PI-based HAART
88918464|NCT01656109|Experimental|PI-naïve group|Never been exposed to any PI-containing regimen HIV-RNA viral load ≥ 1,000 copies/ml at the screening visit
88918465|NCT01656122|Experimental|PK|PK of abacavir and lamivudine
89010488|NCT00237146|Experimental|Zoledronic Acid|
89198532|NCT00956332|Experimental|MGA - Intermediate therapeutic dose|
89198533|NCT00870675||ventriculomegaly|Pregnant women carrying a fetus with the ultrasound finding of enlarged ventricles (ventriculomegaly).
89198534|NCT00870753|Experimental|Yoga|90 min hatha yoga 2 times per week for 12 weeks.
89536440|NCT02476331|Experimental|Cognitive training|The neurocognitive training program will be provided by an online platform called BrainGymmer (https://www.braingymmer.com/en/brain-games/). The experimental group will complete the working memory training, which involves three games: N-back, Multi-Memory, and Moving Memory. These games are designed to engage processes involving updating and manipulation of information. All of the training games provided by BrainGymmer are adaptive, meaning that the level of difficulty increases as users develop expertise on a given task. Participants randomized to the cognitive training arm will complete the training games for 30 minutes per day, 5 days a week, for a total of 10 weeks.
89536441|NCT02476331|No Intervention|Control|The control group will wait 10-weeks, during which they will receive treatment-as-usual (TAU), which might involve pharmacotherapy, psychotherapy, or both. After the 10-week waiting period, participants will complete post-testing assessments.
89536442|NCT04989777|No Intervention|Control group|Patients with AMI and shock stage B were received Standardized treatment
89536443|NCT04989777|Experimental|IABP group|Patients with AMI and shock stage B were received Standardized treatment and IABP treatment
89536444|NCT03192943|Experimental|Dose Escalation|monotherapy and combination therapy
89536445|NCT02724839|Experimental|Biweekly Arm|6 group nutrition sessions co-led by a peer and a content expert, Fitbit given to parent-child dyads during second session. Sessions took place biweekly.
89536446|NCT02724839|Experimental|Monthly Arm|6 group nutrition sessions co-led by a peer and a content expert, Fitbit given to parent-child dyads during second session. Sessions took place monthly.
89536447|NCT02724839|Experimental|Weekly|6 group nutrition sessions co-led by a peer and a content expert, Fitbit given to parent-child dyads during second session. Sessions took place weekly.
89536448|NCT04986813|Active Comparator|Group Tranexamic Acid|50 patients were given 1 gram of Tranexamic acid (TXA) intravenously pre-operatively. Intravenous TXA was administered, at the time of start of surgical incision.
89198535|NCT00870753|No Intervention|Controls|Control group are offered the yoga intervention after finishing the study
88918466|NCT01656135|Other|Reference Group|"Basiliximab (Simulect®):~Day 0: 20mg IV ≤2h prior to surgery~Day 4: 20mg IV~Prednisolone:~Day 0: 500mg IV (250mg pre-op, 250mg intra-op)~Day 1: 125mg IV~Day 2 - 14: 20mg/day oral~Week 3 - 4: 15mg/day oral~Week 5 - 8: 10mg/day oral~Week 9 - 12: 5mg/day oral~Week 13 - 14: 2.5mg/day oral~Week 15 - Study End: Cessation~Steroid tapering should not proceed if graft rejection has occurred or if renal dysfunction is observed.~Mycophenolate Mofetil (MMF, or biologic equivalent):~Treatment with MMF should commence one day prior to transplantation (on Day -1) and should continue indefinitely, with a dose reduction after two weeks:~Day -1 - 14: 2g/day oral~Day 15 - Study End 1.5g/day oral (750mg twice daily)~Tacrolimus (or biologic equivalent):~Day -4 - 14: 3-12ng/ml~Week 3 - 12: 3-10ng/ml~Week 13 - 36: 3-8ng/ml~Week 37 - Study End: 3-6ng/ml"
88918467|NCT01656148|Experimental|Fampridine-SR|Initially all participants receive Fampridine-SR 10 mg BID in an open label enrichment phase lasting four weeks. Those 40% responding the most by SSST will go onto phase two. 50% of these will receive 10 mg Fampridine-SR BID for four weeks.
88918468|NCT01656148|Placebo Comparator|Placebo|In the intervention phase 50% will receive placebo BID
89198536|NCT03825718|Experimental|CAR-T treatment group|The patients will receive one dose of GC007F. GC007F dosage ranges from 6×10^4 to 2×10^6 CAR+T/Kg.
89536449|NCT04986813|Placebo Comparator|Control group|50 patients were kept as a control group and were not given TXA.
88918469|NCT01656174||No Treatment|
88918470|NCT01656213|Experimental|visual-feedback handgrip exercise|Subjects allocated to treatment will be trained in the laptop-based exercise that takes 20 minutes/session. Subjects will be encouraged to perform the exercise 2-3 times per dialysis session
88918471|NCT01656213|No Intervention|Control Arm|"60 similar ESRD stroke patients will be randomly assigned to the non-intervention arm. These patients will receive standard advice during dialysis (rest or gentle activity, e.g. reading).~Note that both groups of patients will also receive standard multidisciplinary rehabilitation care following a stroke, including therapy sessions at times other than receiving dialysis"
88918472|NCT01656226|Experimental|Eryfotona AK-NMSC® cream|
88918473|NCT01656226|Other|Sunscreen SPF 50+|
88918474|NCT01656265|Experimental|ARQ 197|
88918475|NCT01656278|Active Comparator|Conventional biochemical and clinical examinations|Biochemical and clinical examinations
88918476|NCT01656278|Experimental|Conventional biochemical and clinical examinations and MRI.|Biochemical and clinical examinations and MRI.
89436127|NCT05172011||Post-acute cohort -- INFECTED|Post-acute infected individuals (>4 weeks after initial symptoms or positive laboratory testing) in the extant, clinical and de novo cohorts, including infants born in the context of maternal SARS-CoV-2 infection during pregnancy, will be enrolled 1-24 months after initial SARS-CoV-2 infection.
89436128|NCT05172011||Post-acute cohort -- UNINFECTED|Uninfected individuals will be derived from a similar population with respect to age, sex, race and ethnicity, geographic origin, sociodemographics, and time of enrollment as the infected individuals.
89436129|NCT05172011||Post-COVID Vaccine Myocarditis|Individuals with history of myocarditis after receiving COVID-19 vaccine.
89436130|NCT05172011||Primary Caregivers|The primary caregiver of the child or young adult may optionally participate in the study.
89436131|NCT05172011||Biological Parent|If the primary caregiver is a biological parent, the other biological parent may optionally participate in the study
89436132|NCT05155332|Experimental|Part 1 (Monotherapy): Arm A|Arm A: Intratumoral (i.t.) administration
89436133|NCT05155332|Experimental|Part 1 (Monotherapy): Arm B|Arm B: Intravenous (i.v.) administration
89436134|NCT05155332|Experimental|Part 1 (Monotherapy): Arm C|Arm C: i.t.+i.v. administration
89198537|NCT00876135|Placebo Comparator|Inhaled Bronchodilator|
89436135|NCT05155332|Experimental|Part 2 (Combination therapy): Arm D|Arm D: Intratumoral (i.t.) administration
89436136|NCT05155332|Experimental|Part 2 (Combination therapy): Arm E|Arm E: Intravenous (i.v.) administration
88918477|NCT01656317|Active Comparator|Mobilisation of patients after SAH|"Patients which were treated after SAH in 2012 will receive early multidisciplinary rehabilitation consist of individualized stimulation and mobilisation.~Mobilisation will be initiated and completed according to mobilisations guidelines which are developed and adjusted to the patients in early stage after aneurysmal SAH."
88918478|NCT01656317|No Intervention|Patients after SAH from 2011|Patients after SAH from 2011 which did not receive early rehabilitation and mobilisation will be followed up 3-6 annd 12 months after SAH and outcome measures compared with patients from 2011.
88918479|NCT01656330|Experimental|Rivaroxaban + Profilnine SD|Rivaroxaban 20 mg twice a day on Days 1-4 followed by rivaroxaban 20 mg once a day on Day 5 administered 4 hours before a single bolus dose of Profilnine SD 50 IU/kg.
88918480|NCT01656330|Experimental|Rivaroxaban + Beriplex P/N|Rivaroxaban 20 mg twice a day on Days 1-4 followed by rivaroxaban 20 mg once a day on Day 5 administered 4 hours before a single bolus dose of Beriplex 50 IU/kg.
88918481|NCT01656330|Experimental|Rivaroxaban + Saline|Rivaroxaban 20 mg twice a day on Days 1-4 followed by rivaroxaban 20 mg once a day on Day 5 administered 4 hours before a single 100cc bolus of saline.
88918482|NCT01656356|Active Comparator|A/17/turkey/Turkey/05/133 (H5N2)|
88918483|NCT01656356|Placebo Comparator|Placebo|
88918484|NCT01656369|Active Comparator|Group I delorme operation only.|A circumferential incision was made in the rectal mucosa approximately 1 cm away from the dentate line. Using electrocautery, the mucosa was stripped to the apex of the prolapse. The muscular layers of the rectal wall were reduced as the mucosa was stripped. Mucosal stripping continued past the apex of the prolapse and then continued inside the prolapsed segment to a point internally that is equivalent to the point of the initial mucosal incision. The underling muscle was plicated by vicryl 2/0.The muscle bite was taken longitudinally from 8 sides to reach a horizontal line of plication at the end. The mucosa was then reanastomosed. Postoperatively, minimal pain medication was required. Early ambulation was encouraged, and patients' diets were advanced as tolerated.
88918485|NCT01656369|Active Comparator|delorme operation with post anal repair|In group II : post anal repair was added by making transverse incision 7cm behind the anal canal.dissection of intersphincteric plain,plication of internal sphincter by using 3/0 vicryl.The levator ani and external sphincter were then sutured to each other by vicryl 2/0 behind the anal canal followed by skin closure without drain.
88918486|NCT01656382|Active Comparator|5 mg/kg/d ABLC x 14 days|5 mg/kg/d of Amphotericin B Lipid Complex for 14 days
88918487|NCT01656382|Experimental|10/kg/kg/d x 7 days|10 mg/kg/d of Amphotericin B Lipid Complex for 7 days
88918488|NCT01656421||COPD|Patients with Chronic Obstructive Pulmonary Disease, including mild, moderate, severe and very severe airflow obstruction
89436137|NCT05155332|Experimental|Part 2 (Combination therapy): Arm F|Arm F: i.t.+i.v. administration
89436138|NCT05153330|Experimental|Dose Escalation Phase|"Experimental: ARM A:~Study participants who are not receiving a moderate or strong CYP3A4 inhibitor.~Dose Escalation Phase:~Cohort 1: Participants with acute leukemia~Cohort 2: Participants with diffuse large B-cell lymphoma~Cohort 3: Participants with multiple myeloma~Cohort 4: Participants with chronic lymphocytic leukemia/ small lymphocytic lymphoma~Participants will receive escalating dose BMF-219 orally once per day to identify the OBD/RP2D (Optimal Biologic Dose/Recommended Ph2 Dose).~Dose Expansion Phase:~Cohorts 1, 2, 3, and 4 will receive BMF-219 at the OBD/ RP2D to further assess the safety/ efficacy of the investigational drug."
88918489|NCT01656421||Comparators|Current or ex-smokers free from from Respiratory Disease
88918490|NCT01656473|Experimental|MI and DBT|Individual Motivational Interview session followed by 12-week Dialectical Behaviour Therapy skills group
88918491|NCT01656499|Active Comparator|Arabinoxylanoligosaccharides (AXOS)|AXOS (2 x 5g WBE/day)
88918492|NCT01656499|Placebo Comparator|Maltodextrine (placebo)|Maltodextrine (2 x 5g/day)
89436139|NCT05153330|Experimental|Dose Expansion|"Experimental: ARM B:~Study participants who are receiving a moderate or strong CYP3A4 inhibitor.~Dose Escalation Phase:~• Cohort 1: Participants with acute leukemia will receive escalating dose BMF-219 orally to identify the OBD/ RP2D (Optimal Biologic Dose/Recommended Ph2 Dose).~Dose Expansion Phase:~Cohort 1 will receive BMF-219 at the OBD/ RP2D to further assess the safety and efficacy of the investigational drug."
89436140|NCT05153317|Experimental|ELX/TEZ/IVA|Participants will receive ELX/TEZ/IVA in the morning and IVA in the evening.
88918493|NCT01656512|Active Comparator|Arm ( A)|Arm ( A) : patients will receive calcium & vitamin D
89436141|NCT05143658|Active Comparator|Laparoscopic Lateral Suspension Group (LLS)|Anterior and apical prolapse repair via LLS
89436142|NCT05143658|Experimental|Laparoscopic Pectopexy (LP)|Anterior and apical prolapse repair via LP
89436143|NCT05142163|Active Comparator|Stroke Volume Variation Guided Fluid Therapy|Patients will receive maintenance Fluids as crystalloids intraoperative to maintain SVV <11%, for values >11%colloid bolus 6%hydroxyethyl starch will be given and fluid responsiveness noted.
89436144|NCT05142163|Active Comparator|Plethysmography Variability Index Guided Fluid Therapy|Patients will receive maintenance Fluids as crystalloids intraoperative to maintain PVI <11%, for values >11%colloid bolus 6%hydroxyethyl starch will be given and fluid responsiveness noted.
89436145|NCT05140564|Experimental|STEADY intervention group|
89436146|NCT05140564|No Intervention|Treatment as usual group (control)|
89436147|NCT05140382|Experimental|AZD4573 (Monotherapy)|Eligible participants with either r/r PTCL, r/r NKTCL or r/r cHL will receive AZD4573 as monotherapy.
88918494|NCT01656512|Experimental|Arm (B)|we will give calcium and Vitamin D daily in addition to bisphosphonates (zolendronic acid ) every 3 months in the dose of
89436148|NCT05128487|Experimental|NDI-101150 (Monotherapy)|Patients in escalation and expansion, will receive NDI-101150 capsules orally once daily continuously in 4-week cycles (28 days).
89436149|NCT05128487|Experimental|NDI-101150-Pembrolizumab (Combination therapy)|Patients in escalation and expansion phase, will receive NDI-101150 capsules orally once daily continuously in 3-week cycles (21 days), along with pembrolizumab via intravenous (IV) infusion at a dose of 200 mg every 3 weeks.
89436150|NCT05125029|No Intervention|Placebo|Prior to injection, patients will wait in a temperature controlled room for 30 minutes in order to allow time for normalization of baseline digital temperature. Once a patient is randomly selected via our randomization process, BT will be reconstituted by clinic nursing staff with sterile saline per manufacturer recommendations such that the investigating hand surgeon who will be performing the injection will be sufficiently blinded. After proper cleansing of the skin with alcohol swabs, BT will be sterilely administered percutaneously via a small-gauge needle and syringe into the base of each digit by the investigating hand surgeons within the Upper Extremity Division. The volar metacarpal head will be used as a standardized anatomic landmark for injection both to lessen the probability and magnitude of risk to deep structures of the hand as well as maximize probability of proper anatomic placement of the drug.
89436151|NCT05125029|Active Comparator|10 units of BT per digit|Prior to injection, patients will wait in a temperature controlled room for 30 minutes in order to allow time for normalization of baseline digital temperature. Once a patient is randomly selected via our randomization process, BT will be reconstituted by clinic nursing staff with sterile saline per manufacturer recommendations such that the investigating hand surgeon who will be performing the injection will be sufficiently blinded. After proper cleansing of the skin with alcohol swabs, BT will be sterilely administered percutaneously via a small-gauge needle and syringe into the base of each digit by the investigating hand surgeons within the Upper Extremity Division. The volar metacarpal head will be used as a standardized anatomic landmark for injection both to lessen the probability and magnitude of risk to deep structures of the hand as well as maximize probability of proper anatomic placement of the drug.
89530935|NCT02425891|Experimental|Atezolizumab Plus Nab-Paclitaxel|Participants assigned to atezolizumab plus nab-paclitaxel received both agents until disease progression or unacceptable toxicity.
89530936|NCT02425891|Placebo Comparator|Placebo Plus Nab-Paclitaxel|Participants assigned to placebo plus nab-paclitaxel received both agents until disease progression or unacceptable toxicity.
88918495|NCT01656525|Experimental|1|
88918496|NCT01656525|Experimental|2|
88918497|NCT01656525|Experimental|3|
88918498|NCT01656525|Experimental|4|
88918499|NCT01656590|Other|High Protein and Exercise therapy along-with Nocturnal Enteral|
88918500|NCT01656616||EMS cyanide exposure patients|
88918501|NCT01656642|Experimental|Cohort 1 (C1): Ate+Vem - No Run-in|Participants will receive atezolizumab (Ate) 1200 milligrams (mg) every 3 weeks (q3w) along with vemurafenib (Vem) 720 mg twice daily (BID) for 21 days in each cycle followed by 7 days off treatment (28-day cycle). Treatment will continue until disease progression, unacceptable toxicity, or withdrawal of consent occurs.
88918502|NCT01656642|Experimental|Cohort 2 (C2): Ate+Vem (56 Day Run-in)|Run-in period (56 days): participants will receive vemurafenib 960 mg orally BID from Day 1 to 49 and vemurafenib 720 mg orally BID from Day 50 to 56. Combination treatment period: Participants will receive fixed dose of atezolizumab 1200 mg intravenous (IV) q3w in combination with vemurafenib 720 mg orally BID in 21 days cycle.
88918503|NCT01656642|Experimental|Cohort 3 (C3): Ate+Vem (28 Day Run-in)|Run-in period (28 days): participants will receive vemurafenib 960 mg orally BID for 21 days, then vemurafenib 720 mg orally BID for 7 days. Combination treatment period: Participants will receive fixed dose of atezolizumab 1200 mg IV q3w in combination with vemurafenib 720 mg orally BID in 21 days cycle.
88918504|NCT01656642|Experimental|Cohort 4 (C4): Ate+Vem+Cob (28 Day Run-in)|Run-in period (28 days): participants will receive vemurafenib 960 mg orally BID for 21 days, then vemurafenib 720 mg orally BID for 7 days in combination with cobimetinib (Cob) 60 mg IV once daily, 21 days on/7 days off schedule (21/7). Combination treatment period: Participants will receive fixed dose of atezolizumab 800 mg IV every 2 weeks (q2w) in combination with vemurafenib 720 mg orally BID and cobimetinib 60 mg orally once daily 21/7 in 28 days cycle.
89010489|NCT04544137|Experimental|BOKS + SFSP|Children randomized to the BOKS + SFSP will be invited to attend the one-hour BOKS program four days per week for eight weeks during the summer. The BOKS program will be run by Lifespan employed staff in the hour before the SFSP lunch service at two community locations.
89010490|NCT04544137|No Intervention|SFSP|Children randomized to the SFSP alone group will be asked to participate in the SFSP as they would have otherwise.
89198538|NCT05214742||Silver-Russell Syndrome|
89198539|NCT05214742||Beckwith-Wiedemann Syndrome|
89198540|NCT05214742||Temple Syndrome|
88918505|NCT01656642|Experimental|ECA: Ate+Vem+Cob (Mandatory Biopsy PD)|Expansion Cohort A (ECA): Approximately 10 participants who experienced disease progression (PD) after receiving prior checkpoint inhibitor therapy will be enrolled and treated with atezolizumab plus (+) vemurafenib + cobimetinib. Serial biopsy tissue sample collections of accessible lesions will be mandatory for all participants enrolled in this cohort. The doses will be decided based on the results of Cohorts 1-4.
88918506|NCT01656642|Experimental|ECB: Ate+Vem+Cob (Mandatory Biopsy)|Expansion Cohort B (ECB): Approximately 20 participants will be enrolled and treated with atezolizumab + vemurafenib + cobimetinib. Serial biopsy tissue sample collections of accessible lesions will be mandatory for all participants. The doses will be decided based on the results of Cohorts 1-4.
89436152|NCT05125029|Active Comparator|20 units of BT per digit|Prior to injection, patients will wait in a temperature controlled room for 30 minutes in order to allow time for normalization of baseline digital temperature. Once a patient is randomly selected via our randomization process, BT will be reconstituted by clinic nursing staff with sterile saline per manufacturer recommendations such that the investigating hand surgeon who will be performing the injection will be sufficiently blinded. After proper cleansing of the skin with alcohol swabs, BT will be sterilely administered percutaneously via a small-gauge needle and syringe into the base of each digit by the investigating hand surgeons within the Upper Extremity Division. The volar metacarpal head will be used as a standardized anatomic landmark for injection both to lessen the probability and magnitude of risk to deep structures of the hand as well as maximize probability of proper anatomic placement of the drug.
88918507|NCT01656642|Experimental|ECC: Ate+Vem+Cob (No Mandatory Biopsy)|Expansion Cohort C (ECC): Approximately 10 participants who experienced disease progression after receiving prior checkpoint inhibitor therapy will be enrolled and treated with atezolizumab + vemurafenib + cobimetinib. Serial biopsy tissue sample collections will be optional for all participants enrolled in this cohort. The doses will be decided based on the results of Cohorts 1-4.
88918508|NCT01656655||PTSD group|Patients with PTSD
88918509|NCT01656655||Control Group|non PTSD group
88918510|NCT01656668|Experimental|BC1036|BC1036 300 mg capsule capsule by mouth, twice daily, for 14 days.
88918511|NCT01656668|Placebo Comparator|Sugar Pill|Sugar placebo capsule by mouth, twice daily, for 14 days.
89436153|NCT05121103|Experimental|Open-label EZM0414|"Participants will receive EZM0414 in continuous 28-day cycles. EZM0414 will be administered orally once daily (QD) without food.~Participants who receive EZM0414 at Maximum tolerated dose (MTD) and do not have Dose limiting toxicities (DLT) in the dose escalation part of the study will be rolled over to a cohort of this dose expansion part.~Cohort 1 for R/R MM Participants. Cohort 2 for R/R MM Participants. Cohort 3 for Participants with R/R DLBCL."
89436154|NCT05115110|Experimental|RO7204239 + Risdiplam|"Participants who have not previously been treated with risdiplam will receive risdiplam for at least 8 weeks prior to randomization into a treatment group (Part 1 only). Participants that have been treated with risdiplam for at least 8 continuous weeks immediately prior to joining the study may be immediately randomized to combination therapy, or join the study run-in period (the period between screening and randomization to a treatment group) where they will continue to receive risdiplam monotherapy until randomization.~Participants enrolled in Part 1 will receive RO7204239 (low or high dose) + risdiplam for 24 weeks, followed by RO7204239 + risdiplam for 72 weeks.~Participants enrolled in Part 2 will receive risdiplam for 8 weeks and then treatment with RO7204239 + risdiplam for 72 weeks.~Once the treatment period has completed (Part 1 or Part 2), participants will have the option of treatment with RO7204239 + risdiplam for 2 additional years."
88918512|NCT01656681|Experimental|THIAA|"Stage 1 (the first 12 weeks of the study): all subjects participate in a structured lifestyle change program featuring a high-protein, high-phytonutrient food plan (HP2). Those randomized to THIAA arm additionally receive the THIAA tablet, 3 times a day.~Stage 2 (the subsequent 52-week study): All qualified subjects (i.e. those who have lost at least 7.5% of their body weight in Stage 1) participate in a less restrictive lifestyle change program featuring a Mediterranean-style Low-glycemic-load food plan (MLGL). Those randomized to THIAA arm additionally receive the THIAA tablet, 3 times a day."
88918513|NCT01656681|Active Comparator|Placebo|"Stage 1 (the first 12 weeks of the study): all subjects participate in a structured lifestyle change program featuring a high-protein, high-phytonutrient food plan (HP2). Those randomized to Placebo arm receive the placebo tablet, 3 times a day.~Stage 2 (the subsequent 52-week study): All qualified subjects (i.e. those who have lost at least 7.5% of their body weight in Stage 1) participate in a less restrictive lifestyle change program featuring a Mediterranean-style Low-glycemic-load food plan (MLGL). Those randomized to Placebo arm receive the placebo tablet, 3 times a day."
88918514|NCT01656707|Experimental|ACRA|Ten weekly 60-minute sessions of Adolescent Community Reinforcement Approach (ACRA) will be provided as an Adaptive treatment condition.
88918515|NCT01656707|Experimental|Cognitive Behavioral Therapy (CBT)|Ten weekly, 60-minute sessions of augmented individualized Cognitive Behavioral Therapy (CBT)will be provided as an Adaptive Treatment condition
88918516|NCT01656720|Placebo Comparator|Placebo|Placebo 2g Suppository
88918517|NCT01656720|Active Comparator|NRL001 5mg|5mg NRL001 in a 2g suppository
88918518|NCT01656720|Active Comparator|NRL001 7.5mg|7.5mg NRL001 in a 2g suppository
88918519|NCT01656720|Active Comparator|NRL001 10mg|10mg NRL001 in a 2g suppository
88918520|NCT01656746|Experimental|Treatment (single incision laparoscopic surgery)|Patients undergo single incision laparoscopic surgery with GelPort® attachment.
88918521|NCT01656785|Experimental|Brain 68Ga-BNOTA-PRGD2|We will perform brain 68Ga-BNOTA-PRGD2 PET/CT on stroke patients to determine its value.
89198541|NCT00870831||Islet Recipient|Subjects that have successfully received and maintained an Islet transplant at Washington University Center for Islet Transplantation
89198542|NCT00870831||Control|subjects that were similar in height, weight and age that did NOT have diabetes to act as the comparative group
88918522|NCT01656798|Experimental|fasted condition|
88918523|NCT01656798|Experimental|fec condition|
88918524|NCT01656811|Experimental|levalbuterol 90 mcg|levalbuterol 90 mcg delivered via metered dose inhaler (MDI)
88918525|NCT01656811|Experimental|levalbuterol 180 mcg|levalbuterol 180 mcg delivered via MDI
88918526|NCT01656811|Active Comparator|racemic albuterol 180 mcg|racemic albuterol 180 mcg delivered via MDI
89530937|NCT04495205|Experimental|Non-eugenol containing periodontal packs with PRF|Non-eugenol containing periodontal packs with PRF after gingival de-pigmentation
88918527|NCT01656811|Placebo Comparator|Placebo|Placebo delivered via MDI
88918528|NCT01656837|Experimental|MST-BSF|MST-BSF integrates two models with empirical support for their effectiveness, MST-CAN for child maltreatment (Swenson, Schaeffer, Henggeler, Faldowski, & Mayhew, 2012) and RBT for adult substance abuse (Tuten, Jones, Schaeffer, Wong, & Stitzer, 2012) into one comprehensive treatment package. MST-BSF is intended to be comprehensive. The major interventions within the MST-BSF arm include safety planning and implementation, functional analysis of the abuse incident, cognitive behavioral interventions for PTSD symptomatology and low anger management, family communication and problem solving, abuse clarification, and Reinforcement Based Treatment for adult substance abuse. RBT is an incentive-based drug treatment program for adults who abuse opiates, cocaine, or other illicit drugs.
88918529|NCT01656837|Experimental|Comprehensive Community Treatment|Families randomized to the CCT condition receive an array of services consistent with existing DCF practices. Project Safe community providers offer individual, couples, and family therapy for substance abuse/dependence, early intervention groups, treatment for co-occurring disorders, gender-specific trauma/substance abuse groups, and relapse prevention groups. The DCF caseworker also is responsible for coordinating care for the behavioral and mental health needs of the children. Services include individual outpatient treatment, family therapy, intensive in-home treatment, extended day programs, intensive outpatient, partial and inpatient hospitalization, residential programs/temporary housing (safe homes, shelters), emergency mobile psychiatric services, and crisis stabilization.
88918530|NCT01656863||Parents|Parents reporting to the emergency room with dehydrated children
88918531|NCT01656876|Experimental|Mirror therapy|mirror box training with or without sham mesh glove stimulation
88918532|NCT01656876|Experimental|Mirror therapy + Mesh glove stimulation|Mirror therapy combined with mesh glove stimulation
88918533|NCT01656876|Active Comparator|Controlled intervention|conventional interventions
88918534|NCT01656915||Healthy men|Healthy male subjects with normal weight
88918535|NCT01656915||Compromised men|pre-diabetic overweight, male subjects
88918536|NCT01656928|Other|Waiting-list control|Allocation to waiting-list Control. Receives intervention 6 months later.
88918537|NCT01656928|Active Comparator|Intervention|Allocation to intervention. Directly starts with nutritional intervention.
88918538|NCT01656941||d-Transposition of the Great Arteries|Neonates with d-transposition of the great arteries (dTGA) undergoing the arterial switch operation with cardiopulmonary bypass
88918539|NCT01656941||Single ventricle cardiac disease|Neonates with single ventricle cardiac disease (SVCD) undergoing stage I surgical palliation (Norwood) with cardiopulmonary bypass
88918540|NCT01656954||Anticipated volume/blood administration|Patients who may receive IV fluid boluses or blood products for restoration of vascular volume. Prior to receiving IV fluid boluses or blood products, the patient will undergo a passive leg raise. (PLR)
88918541|NCT01656980|Experimental|Carmustine Sustained Release Implant|For subjects in this group, they will accept intracranially implanted carmustine intraoperatively.
89530938|NCT04495205|Placebo Comparator|Non-eugenol containing periodontal packs|Non-eugenol containing periodontal packs after gingival de-pigmentation
89436155|NCT05115110|Active Comparator|Placebo + Risdiplam|"Participants who have not previously been treated with risdiplam will receive risdiplam for at least 8 weeks prior to randomization into a treatment group (Part 1 only). Participants that have been treated with risdiplam for at least 8 continuous weeks immediately prior to joining the study may be immediately randomized to combination therapy, or join the study run-in period (the period between screening and randomization to a treatment group) where they will continue to receive risdiplam monotherapy until randomization.~Participants enrolled in Part 1 will receive placebo (low or high dose-matched) + risdiplam for 24 weeks, followed by RO7204239 + risdiplam for 72 weeks.~Participants enrolled in Part 2 will receive risdiplam for 8 weeks and then treatment with placebo + risdiplam for 72 weeks.~Once the treatment period has completed (Part 1 or Part 2), participants will have the option of treatment with RO7204239 + risdiplam for 2 additional years."
89436156|NCT05104099|Experimental|Metvixia application for Photodynamic diagnosis|Patients who benefit Metvixia application to the vulva to realize fluorescence guided biopsies (Photodynamic diagnosis).
89436157|NCT05095311|Experimental|Experimental group|This subset of 12 individuals will complete all experimental study visits, and will ingest either 1) a placebo pill and placebo inhaler contents or 2) a cetirizine HCl pill (10 mg) and placebo inhaler contents in a randomized order and double-blind fashion.
89436158|NCT05095311|No Intervention|Selection pool|Twenty-four total individuals will be recruited for the initial portion of the study, and the aforementioned 12 (6 men, 6 women) will be a subset of the initial 24. The other 12 participants will not take part in further study.
89436159|NCT05077527|Experimental|Treatment (conditioning, axicabtagene ciloleucel)|Patients receive fludarabine IV over 30 minutes and cyclophosphamide IV over 1 hour on days -5, -4, and -3. Patients then receive axicabtagene ciloleucel IV over 30 minutes on day 0.
89436160|NCT05056207|Other|Cohort I (patients receiving annual lymphedema screening)|We will retrospectively retrieve information on patients who previously underwent preoperative perometer lymphedema screening during the past year who were treated definitively for their breast cancer with an ALND, and for whom no follow-up postoperative lymphedema screening was done.
89436161|NCT05056207|Other|Cohort II (patients followed intensively for lymphedema)|We will prospectively follow a cohort of 279 patients who have recently undergone ALND in this upcoming year with intensive lymphedema screening.
89436162|NCT05049772|Experimental|Telerehabilitation-based motor imagery group|Behavioral: Telerehabilitation-based motor imagery group Participants in the Telerehabilitation-based motor imagery group will imagine for the lumbar region exercises (e.g. bridges, knee-to-chest stretches, pelvic tilts) in the sessions in home using the study audio-video motor imagery script for 2 times per week; 30 min per day for 10 weeks. Phone calls will be performed for support and as a reminder for the assessment (after one week). In addition, the participants will be given stabilization exercises In addition, the participants will be given stabilization exercises for 10 weeks for 40 minutes, 2 days a week.
89530939|NCT02499809|Experimental|Passive|Passive recovery
89530940|NCT02499809|Experimental|Vibration|Vibration recovery
89530941|NCT04498013|Experimental|Treatment group|Patients will be treated with Cyclodynon 1 tablet per day 6 month in addition to lifestyle modification
89530942|NCT04498013|Other|Control group|Lifestyle modification only
89530943|NCT04497935||1LPEG|Patients receiving 1LPEG who had a colonoscopy in the morning were advised to follow a day-before dosing regimen, where, at 7:00 pm the day before the colonoscopy, they prepared the Dose 1 sachet in 500 mL of water and consumed it over a period of 30 minutes, followed by 500 mL of clear liquids. The second dose was then taken at 11:00 pm by mixing the two Dose 2 sachets in a single glass of 500 mL of water and consuming them over 30 minutes, followed by 500 mL of clear liquids. If the colonoscopy was scheduled for the afternoon, the same dosing instructions were given, but the first dose was taken at 7:00 am on the day of the procedure, and the second dose began at 10:00 am.
88918542|NCT01656980|Sham Comparator|Tumor Resection Surgery|For subjects in this control group, they accept no implants while gliomas maximally be resected.
88918543|NCT01656993||ASA activity|Participants (age 2.0 days to 12 months) undergoing cardiac surgery for a shunt and planned treatment with aspirin
88918544|NCT01657045|Experimental|Cohort 1|Subjects will be randomized to receive injections JVS-100 or placebo.
88918545|NCT01657045|Experimental|Cohort 2|Subjects will be randomized to receive injections JVS-100 or placebo.
88918546|NCT01657045|Experimental|Cohort 3|Subjects will be randomized to receive injections of JVS-100 or placebo.
89436163|NCT05049772|Active Comparator|Stabilization Exercises group|Behavioral: Stabilization Exercises group An exercise program consisting of lumbar stabilization exercises for the participants will be planned for the pelvic ring muscles to develop the neutral lumbar spine. Co-contraction of the transversus abdominus muscle and the multifidus muscle will form the basis of the exercises. Stabilization exercises will be given for 10 weeks for 40 minutes, 2 days a week.
89436164|NCT05049772|No Intervention|Healthy control group|no specific intervention
89436165|NCT05041426|Experimental|Letermovir|Participants who are CMV seropositive (CMV R+) will receive letermovir prophylaxis for 6 months, and participants who are CMV donor seropositive/recipient seronegative (CMV D+/R-) will receive letermovir prophylaxis for 12 months. Letermovir will be administered at a dose of 480 mg IV or oral once daily. IV administration will occur only for those patients unable to swallow tablets. If letermovir is co-administered with cyclosporine A, the dosage of letermovir will be decreased to 240 mg once daily.
89436166|NCT05041426|Active Comparator|Valganciclovir|Historical controls will be lung transplant recipients for idiopathic pulmonary fibrosis from 2010-2019 who are CMV R+ or CMV D+/R-. CMV prophylaxis in the historical controls was with valganciclovir for 6 months for CMV R+ and for 12 months for CMV D+/R-.
88918547|NCT01657058|Experimental|Treatment # 1|Soluble viscous fibre blend powder in hydrophobic matrix
89436167|NCT05041374||Study Cohort|Patients with known or suspected gastrointestinal disease
89436168|NCT05037318|Experimental|Stress arousal reappraisal|
89436169|NCT05037318|Experimental|Worked examples|
89436170|NCT05037318|Experimental|Stress arousal reappraisal + Worked examples|
89436171|NCT05037318|No Intervention|Control|
89436172|NCT05036525|Experimental|use HANBIO BarriGel|
88918548|NCT01657058|Experimental|Treatment # 2|Soluble viscous fibre blend in pre hydrated form
88918549|NCT01657058|Placebo Comparator|Control # 1|No soluble viscous fibre blend
88918550|NCT01657058|Experimental|Treatment # 3|Soluble viscous fibre blend premixed with ½ carbohydrate gel
88918551|NCT01657058|Placebo Comparator|Control # 2|No soluble viscous fibre blend, ½ carbohydrate jello
88918552|NCT01657071|Experimental|Group A|
88918553|NCT01657071|Active Comparator|Group B|
88918554|NCT01657084|Experimental|Tonic-clonic seizures|Patients with tonic-clonis seizures are observed in a video/EEG room. In the case of seizures, the treatment mask or dummy mask are administered, according to a randomized cross-over study design.
88918555|NCT01657084|Experimental|Generalized Paroxysms|Patients with generalized epileptic paroxysms are observed by EEG during baseline, treatment mask and dummy mask use, according to a randomized cross-over study design.
88918556|NCT01657084|Experimental|Group 3|Patients with epileptic paroxysms are observed by EEG during baseline, treatment mask and dummy mask use, according to a randomized cross-over study design.
88918557|NCT01657097|Experimental|INCS|Fluticasone propionate 400 microgram daily
88918558|NCT01657097|Placebo Comparator|Placebo|Placebo
89436173|NCT05036525|No Intervention|No anti-adhesive product|
89436174|NCT05015868|Experimental|IDENTIFICATION OF THE CAUSE OF THE EPILEPSY AND OF THE EPILEPTOGENIC ZONE (sequential approach)|"Step1: standard of care.~acquisition and updating of Electroencephalogram polygraphic data of wakefulness and sleep and neuroradiological data~complete neuropsychological assessment~genetic tests through Next generation sequencing epilepsies panel, or exome~Step 2: experimental~- combined Electroencephalogram-Functional brain magnetic resonance imaging registration.~Step 3: experimental~In the event that neither the cause nor the epileptogenic area has been identified, we will evaluate the execution of further tests, such as:~execution of High Density-Electroencephalogram recording at IRCCS Medea di Conegliano (TV, Italy) (approximately 3 patients / year) for a further electrophysiological definition;~7 Tesla brain magnetic resonance imaging performed at IRCCS Stella Maris in Calambrone(PI, Italy) (approximately 3 patients / year expected), to obtain greater spatial resolution and better neuroradiological definition."
89436175|NCT05005728|Experimental|Cohort A - AVPCa|
88918559|NCT01657110|Other|Tea tree oil|Pea-sized amount of tea tree oil medicated gel (containing 200mg/g tea tree oil) applied to the face twice daily for 12 weeks.
88918560|NCT01657123|Placebo Comparator|placebo|
88918561|NCT01657123|Experimental|hydrocortisone stress dosage|
88918562|NCT01657136|Active Comparator|Ivabradine|Ivabradine will be initiated at a dose of 5 mg twice daily. Dosage should be augmented up to 7.5 mg twice daily in case of symptoms persistence and/or HR > 85 bpm at rest ECG and eventually lowered up to 2.5 mg twice daily in the presence of side effects (phosphenes, diplopia and symptomatic bradycardia).
88918563|NCT01657136|Active Comparator|Beta blocker (Bisoprololo)|Bisoprololo will be initiated at a single dose of 5 mg daily. Dosage should be augmented up to 10 mg single dose daily in case of symptoms persistence and/or HR > 85 bpm at rest ECG and eventually lowered up to 2,5 mg single dose daily in the presence of side effects (symptomatic bradycardia, hypotension).
88918564|NCT01657149|Experimental|Research Group|receive lymphatic massage and individual physiotherapy
88918565|NCT01657149|Active Comparator|Control group|receive individual physiotherapy only
88918566|NCT01657175|Experimental|Supportive care|The patients randomized to the supportive care arm get an extended supportive care during the first year after surgery.
88918567|NCT01657175|No Intervention|Control|"The patients randomized to the control group get care as usual"
88918568|NCT01657188||Heart failure, sleep-disordered breathing|Patients with stable heart failure NYHA ≥ II, EF ≤ 45% with or without central sleep apnea (apnea-hypopnea index ≥ 15/h) with or without adaptive servoventilation
88918569|NCT01657201|Experimental|Sequence 1|SYP-1018 200mg → Voriconazole 200mg
88918570|NCT01657201|Experimental|Sequence 2|Voriconazole 200mg → SYP-1018 200mg
88918571|NCT01657214|Experimental|Dose escalation|SAR125844 will be administered as weekly IV infusion. Four weekly administrations are considered as 1 cycle. The starting dose will be either 1 dose level (DL) below the highest cleared dose level in a European TED11449 ongoing study or DL4 (260 mg/m^2), if the highest cleared dose in TED11449 is >340 mg/m^2.
88918572|NCT01657227|Experimental|Intervention to Patients|Only patients receive intervention
89436176|NCT05005728|Experimental|Cohort B - HRD/CDK12 PARP - Progressors|
89436177|NCT05005728|Experimental|Cohort C - HRD/CDK12 PARP Naïve|
89436178|NCT05005728|Experimental|Cohort D - MSI-H, MMRD or TMB-H|
89436179|NCT05005728|Experimental|Cohort E - No Targetable Mutations|
89436180|NCT04991870|Experimental|Group 1 (CB-NK-TGF-betaR2-/NR3C1- )|Patients receive CB-NK-TGF-betaR2-/NR3C1- intratumorally over 5-10 minutes weekly for up to 8 doses in the absence of disease progression or unacceptable toxicity.
89436181|NCT04991870|Experimental|Group 2 (CB-NK-TGF-betaR2-/NR3C1-, resection)|Patients receive CB-NK-TGF-betaR2-/NR3C1- intratumorally over 5-10 minutes on days 0, 7, and 14. Patients undergo standard of care surgical resection on day 15. Beginning 2 weeks after surgery, patients receive CB-NK-TGF-betaR2-/NR3C1- intratumorally over 5-10 minutes weekly for up to 5 doses (total of 8 doses) in the absence of disease progression or unacceptable toxicity.
88918573|NCT01657227|Experimental|Intervention to healthcare Professionals|Primary care physicians and nurses practitioners receive the intervention. Their associated patients do not receive direct intervention although indirect intervention through professionals
88918574|NCT01657227|Experimental|Mixed Intervention|Patients and healthcare professionals (primary care physicians and nurses practitioners) associated with these patients receive intervention
89436182|NCT04988074|Experimental|De-Escalated Therapy|Surgery (TORS) or Low-dose Radiation Therapy (42 Gy)
89436183|NCT04988074|Experimental|Non/Minimally De-Escalated Therapy|Surgery + Post-Operative Radiation Therapy (PORT) or 60 Gy Chemo-Radiation Therapy (CRT)
89436184|NCT04985916|Placebo Comparator|Vehicle|Vehicle, topical liniment, administered once at baseline
89436185|NCT04985916|Experimental|ET-01, Dose 1|Dose 1 of botulinum toxin, Type A, topical liniment, administered once at baseline. 250µm microneedle length
89436186|NCT04985916|Experimental|ET-01, Dose 2|Dose 2 of botulinum toxin, Type A, topical liniment, administered once at baseline. 250µm microneedle length
88918575|NCT01657227|Other|Control|Patients receive usual care
88918576|NCT01657240|Experimental|PRO-118|pro-118 ophthalmic solution, instill one drop in each eye once a day for 21 days
88918577|NCT01657240|Active Comparator|Olopatadine Hydrochloride|Olopatadine Hydrochloride ophthalmic solution 2%, instill one drop in each eye once a day for 21 days
88918578|NCT01657279|Experimental|Randomized clinical scenarios|Clinicians are randomized to a sequence of 5 clinical scenarios
88918579|NCT01657318||Chronic Wound Group|Treatment with Olivamine containing wound care products
88918580|NCT01657331|Experimental|Brentuximab Vedotin / Bendamustine|Subjects with relapsed or refractory Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma will receive Brentuximab Vedotin in combination with Bendamustine, and prophylactic Neulasta
88918581|NCT01657357||PAO, osteoarhritis, THA|
88918582|NCT01657409|Experimental|BoNT-A (10 injection)|100 U in 10ml, 1.0ml for each injection, totally 10 injections at bladder body
88918583|NCT01657409|Experimental|BoNT-A (20 injections)|100 U in 10ml, 0.5ml for each injection, totally 20 injections at bladder body
88918584|NCT01657409|Experimental|BoNT-A (40 injections)|100 U in 10ml, 0.25ml for each injection, totally 40 injections at bladder body
88918585|NCT01657422|Experimental|PACE+ Intervention|Intervention Group
88918586|NCT01657422|No Intervention|Sun Protection|Control / Comparison group. Patients assigned to the comparison group will receive intervention strategies over a the course of 2 years including: (1) completion of a 30-minute office-based computer program resulting in on-screen feedback to address excess sun exposure prevention, and (2) 4 phone calls and 4 mailings over a 24-month period conducted by PACE+ staff members.
88918587|NCT01657435||Ceramax COC 28mm Acetabular Cup|The 28 mm ceramic acetabular bearing insert component is manufactured from high purity, dense alumina matrix composite ceramic. The inserts secure to DePuy's Pinnacle acetabular shells by means of an interlocking mechanical taper. The Pinnacle acetabular shell is a hemispherical type acetabulum replacement prosthesis, is available in a range of outer diameter (OD) sizes, and is used with a 28mm femoral head. Pinnacle 100 shells will be used in this study. The BIOLOX® delta ceramic femoral head components are manufactured from the same ceramic material as the acetabular bearing insert components. The femoral head is secured to the femoral stem component with an interlocking taper.
88918588|NCT01657448|Experimental|Methenamine, Methylthioninium|
88918589|NCT01657448|Active Comparator|Phenazopyridine|
88918590|NCT01657474|Experimental|Weekly Application of EpiFix|Weekly application of EpiFix plus standard of care
88918591|NCT01657474|Experimental|Biweekly application of EpiFix|Biweekly application of EpiFix plus standard of care
88918592|NCT01657487|Experimental|Fluticasone/salmeterol high dose|COPD patients treating with high dose of ICS (Fluticasone 1000ug/day) combined with Salmeterol (25ug/day)
89436187|NCT04984811|Experimental|NT-I7 and atezolizumab|Participants with no prior systemic therapy for advanced NSCLC will receive 1200 μg/kg NT-I7 IM on Day 1 and every 6 weeks and atezolizumab IV 1200 mg every 3 weeks until disease progression.
89436188|NCT04984239|Other|Acceptance and Commitment Therapy adapted for aphasia|There is only a single study arm, in which the adapted intervention will be developed using a successive cohort design.
89436189|NCT04974528|Experimental|Afrezza (Technosphere Insulin) + Basal Insulin|"Individualized dose of Afrezza (Technosphere Insulin) for each patient before each meal (breakfast, lunch, and dinner) for 26 weeks.~Individualized basal insulin (insulin degludec, insulin glargine or insulin detemir) for each patient."
88918593|NCT01657487|Active Comparator|Fluticasone/Salmeterol medium dose|COPD patients treating with medium dose of ICS (Fluticasone 500ug/day) combined with Salmeterol (25ug/day)
88918594|NCT01657526|Experimental|Group A|Subjects in this group will receive GSK Biologicals' NTHi candidate vaccine in Step 1 of the study
88918595|NCT01657526|Placebo Comparator|Group B|Subjects in this group will receive placebo in Step 1 of the study
88918596|NCT01657526|Experimental|Group C|Subjects in this group will receive GSK Biologicals' NTHi candidate vaccine in Step 2 of the study
88918597|NCT01657526|Placebo Comparator|Group D|Subjects in this group will receive placebo in Step 2 of the study
88918598|NCT01657539|Experimental|Probiotics|Group of patients using yogurt containing probiotics during the experimental phase of the study.
88918599|NCT01657539|Placebo Comparator|Control Yogurt|Group of patients that will use a placebo yogurt for providing comparison with the experimental group.
89436190|NCT04974528|Active Comparator|RAA Injection + Basal Insulin|"Individualized dose of RAA injection (insulin aspart, insulin lispro or insulin glulisine) for each patient for 26 weeks.~Individualized basal insulin (insulin degludec, insulin glargine or insulin detemir) for each patient."
89436191|NCT04974307|Experimental|Device|use of OrCam MyEye 2.0
89436192|NCT04973410|Other|Group A|FFR negative/non-significant (>0.80) and IMR negative (<25)
89436193|NCT04973410|Other|Group B|FFR negative/non-significant (>0.80) and IMR positive (>25)
89436194|NCT04947163|Experimental|IMT group|"Standard exercise protocol according to ACSM's guidelines Standard exercise protocol according to ACSM's guidelines~Balance training - Otago Exercise Program (OEP)~warm-up (10-15 min)~strengthening exercises (~20 min)~balance activities (~20 min)~cool-down (5-10 min) Balance training - OEP~warm-up (10-15 min)~strengthening exercises (~20 min)~balance activities (~20 min)~cool-down (5-10 min)~IMT through POWERBREATHE~30 quick breaths twice daily at an adjustable resistance (equivalent to ~50% of [baseline] MIP).~Will be increased up to 35 breaths as per patient's tolerance Sham IMT~60 slow breaths once daily at a load setting of 0 (corresponding to ~15% [baseline] MIP)~training load adjustment will be prevented using sticky tape applied to the device's load adjuster."
88918600|NCT01657552|Experimental|Eltrombopag|Subjects will receive single oral dose of eltrombopag 200 mg in Period 1 with moderate-fat, low-calcium meal.
88918601|NCT01657552|Experimental|Boceprevir|Subjects will receive boceprevir 800 mg orally every 8 hours (hrs) for 10 days in Period 2 with moderate-fat meals.
88918602|NCT01657552|Experimental|Telaprevir|Subjects will receive telaprevir 750 mg orally every 8 hours hrs for 10 days in Period 2 with moderate-fat meals.
88918603|NCT01657552|Experimental|Eltrombopag and Broceprevir|Subjects will receive eltrombopag 200 mg as single oral dose and boceprevir 800 mg orally every 8 hrs for a day in Period 3 with moderate-fat meals.
88918604|NCT01657552|Experimental|Eltrombopag and Telaprevir|Subjects will receive eltrombopag 200 mg as single oral dose and telaprevir 750 mg orally every 8 hrs for a day in Period 3 with moderate-fat meals.
88918605|NCT01657565||open appendectomy|
88918606|NCT01657565||laparscopic appendectomy|
88918607|NCT01657578|Experimental|neonates of less than 32 weeks gestational age|omeprazole
88918608|NCT01657578|Experimental|neonates born between 32 and 35 weeks of GA|omeprazole
88918609|NCT01657578|Experimental|neonates of more than 36 weeks of GA|omeprazole
88918610|NCT01657630||Accu-Chek Combo|15 type 1 young patients under 6 years old who begin to use the Accu-Chek Combo System
88918611|NCT01657643|Placebo Comparator|Placebo|Every day for 12 weeks, subjects are asked to eat 5 grams of a placebo (strawberry-flavored candy powder)
88918612|NCT01657643|Experimental|Probiotics|Every day for 12 weeks, subjects are asked to eat 5 grams of a strawberry-flavored candy that contains probiotics [daily dose minimum of 1 billion CFU of each Lactobacillus rhamnosus LGG® (LGG®), and Bifidobacterium animalis ssp lactis BB-12® (BB-12®)]
88918613|NCT01657656|Experimental|Vitamin D group|Vitamin D supplement by Tishcon
88918614|NCT01657656|Placebo Comparator|Control group|Identically appearing capsules
88918615|NCT01657669|Other|Intravitreal Aflibercept injection|Intravitreal Aflibercept injection 2.0 mg dosed every 4 weeks (monthly) for the first 3 months followed by 2.0 mg (0.05mg) via intravitreal injection once every 8 weeks (2 months).
88918616|NCT01657708|Other|Shared Desicion Making Model|
88918617|NCT01657721|No Intervention|Wait-list Control|"Participants randomized to this group will not undergo The Cogmed Working Memory Training Program during the 5 week period, but will receive weekly phone calls from a member of the research team to review progress and advice on general time management, organization, and mnemonic strategies.~After a 5-week period, participants in this arm will have access to the working memory training."
88918618|NCT01657721|Experimental|15 Minute Training|Participants will receive a low intensity version of The Cogmed Working Memory Training Program. This involves undergoing 25 training sessions for 15 minutes per day, 5 days a week for 5 weeks. Participants will also receive weekly phone calls from a CogMed Coach to review progress and adjust the training as needed.
88918619|NCT01657721|Experimental|30 Minute Training|Participants will receive the standard-length version of The Cogmed Working Memory Training Program. This involves undergoing 25 training sessions for 30 minutes per day, 5 days a week for 5 weeks. Participants will also receive weekly phone calls from a CogMed Coach to review progress and adjust the training as needed.
88918620|NCT01657734||HGG2003|"**** patients enrolled in the HGG 2003 HGG-IMMUNO 2003 trial~Patients, older than 3 and younger than 60 years with relapse of high-grade glioma (anaplastic astrocytoma WHO grade III or glioblastoma multiforme WHO grade IV), histologically diagnosed in the first stage of the disease as well as after relapse or relapse of glioma which was grade II in the First phase but grade III or IV upon relapse are treated with dendritic cell therapy (immunotherapy) as single treatment approach (No radiotherapy and/or chemotherapy)."
89436195|NCT04947163|Sham Comparator|Sham IMT|"Standard exercise protocol according to ACSM's guidelines Standard exercise protocol according to ACSM's guidelines~Balance training - OEP~warm-up (10-15 min)~strengthening exercises (~20 min)~balance activities (~20 min)~cool-down (5-10 min) Balance training - OEP~warm-up (10-15 min)~strengthening exercises (~20 min)~balance activities (~20 min)~cool-down (5-10 min)~IMT through POWERBREATHE~30 quick breaths twice daily at an adjustable resistance (equivalent to ~50% of [baseline] MIP).~Will be increased up to 35 breaths as per patient's tolerance Sham IMT~60 slow breaths once daily at a load setting of 0 (corresponding to ~15% [baseline] MIP)~training load adjustment will be prevented using sticky tape applied to the device's load adjuster."
89436196|NCT04942028|Experimental|Internet-delivered exposure-based treatment|10 weeks of therapist-guided exposure-based treatment delivered via the Internet.
88918621|NCT01657734||HGG2010|"**** patients enrolled in the HGG 2010 HGG-IMMUNO 2010 trial~prospective double blind placebo controlled randomised clinical trial HGG-2010 for patients with newly diagnosed glioblastoma in which immunotherapy is integrated in the current standard of care (concommitant radiochemotherapy)."
88918622|NCT01657747|No Intervention|Not applicable (imaging study)|
89436197|NCT04942028|Active Comparator|Internet-delivered standardized education and prolonged assessment|10 weeks of therapist-guided intervention based on prolonged assessment and routine care educational material delivered via the Internet.
89436198|NCT04935125|Active Comparator|Standard Program|twelve 30-minute daily sessions of supervised incremental exercise training over a period of 3 weeks.
89436199|NCT04935125|Experimental|Strength training|twelve 30-minute daily sessions of supervised incremental exercise training over a period of 3 weeks twelve 30-minute daily sessions of supervised peripheral limb muscle training, 2 set of 6-12 repetitions
89436200|NCT04925128|Experimental|Experimental (Moderate Physical Activity + Conventional Physical Therapy)|"Conventional Physical Therapy group recieved Hot pack and TENS for 10 minutes at the affected shoulder. Passive shoulder mobilizations were performed initially at pain free range in anterior, posterior, and inferior direction (10 reps x 1 set). Shoulder rolls, pendulum stretch, cross body arm stretch and towel stretch (10 reps x 1 set) were actively performed by the patient with-in limits of pain~Moderate physical activity on treadmill, brisk walk was performed 5 days a week for 30 minutes at 4 mph speed (3-6 METs) with warm up for a 5 minutes at low speed and then at the end speed was also decreased for a 5 minutes"
89010491|NCT04544059|Experimental|Lenalidomide|Lenalidomide orally 25 mg per day was administered on days 1 through 10 of each cycle and delivered concomitantly with standard dose R-CHOP-21 regimen (rituximab 375 mg/m2, cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2 or Liposome doxorubicin 30mg/m2, vincristine 1.4 mg/m2 [capped at 2.0 mg], all on day 1; prednisone 100 mg per day on days 1 through 5). All patients received aspirin 100mg per day prophylaxis throughout, unless they were on therapeutic dose warfarin or low molecular weight heparin for intercurrent conditions. The treatment continued for a maximum of six to eight cycles or until disease progression. Tumor lysis prophylaxis, antiemetics, and supportive care were standard of care.
89010492|NCT04544176||Exposed Cohort|This group will include patients attending radiology outpatient appointments in 2020 in our period of interest from the peak of the first wave of the pandemic, who were subsequently tested for SARS-COV2 within 28-days of their attendance.
89010493|NCT04544176||Unexposed Cohort|This group will form the control group and comprises all individuals who attended radiological appointments during the same period for each hospital in 2019 but not 2020.
89010494|NCT04539769|Active Comparator|BI group|Conventional Billroth I reconstruction
89010495|NCT04539769|Experimental|BII group|Billroth II reconstruction with 100-cm long biliopancreatic limb
89010496|NCT04539769|Experimental|RY group|Roux-en-Y reconstruction with 100-cm long Roux limb
89010497|NCT00237224|Experimental|FEM345|
89010498|NCT04543747||Patients implanted with HVAD System|Patients who require treatment with HVAD for use as bridge to cardiac transplantation (BTT) or destination therapy (DT) within the re-examination period are eligible for enrollment into the MCS Korea PMS. Patient consent may be obtained prior to HVAD implant or after receiving HVAD implant. Waiver of consent may be allowed if allowed by site's Institutional Review Board (IRB) or Ethics Committee (EC).
89010499|NCT04539847|Experimental|High-end hearing aid|Patients will be fitted with premium level hearing aid technology
89010500|NCT04539847|Experimental|Basic hearing aid|Patients will be fitted with basic level hearing aid technology
89436201|NCT04925128|Active Comparator|Control (Conventional Physical Therapy)|Conventional Physical Therapy group recieved Hot pack and TENS for 10 minutes at the affected shoulder. Passive shoulder mobilizations were performed initially at pain free range in anterior, posterior, and inferior direction (10 reps x 1 set). Shoulder rolls, pendulum stretch, cross body arm stretch and towel stretch (10 reps x 1 set) were actively performed by the patient with-in limits of pain
89010501|NCT04539886|Experimental|CellFX System|The CellFX System consists of a electrical pulse console combined with a handpiece coupled with a sterile single patient-use treatment tip (1.5 x 1.5mm, 2.5 x 2.5mm, and 5.0 x 5.0mm). Based on the size of the SH lesion and treatment tip used, a predetermined treatment energy setting is selected to deliver a sequence of electrical pulses to the SH lesion area directly beneath the treatment tip.
89010502|NCT04539886|Active Comparator|Intralesional Electrodesiccation|Intralesional Electrodesiccation involves using a Hyfrecator electrosurgical unit and a non-insulated epilation needle electrode to apply a high-frequency electric current within the lesion.
89010503|NCT04543864|Experimental|electric welded metal framework|
89010504|NCT04543864|Experimental|conventional casted metal framework|
89010505|NCT04539613||group1|Group 1(50 case) which will receive hp FSH (fostimon ibsa) (150 IU per ampoule)will be started on day 2 of menstruation and then after six days, HMG (meriofert ibsa), 150 Iu, s.c) will be added
89010506|NCT04539613||group2|Group 2(50 case) will be treated with recombinant FSH alone (Gonal-F) (150 IU per ampoule)
89436202|NCT04920032|Experimental|TASIRI|"Patients randomized to the experimental arm (TASIRI) will be treated with TAS-102 25mg/m2 p.o. on days 1-5 and irinotecan 180mg/m2 i.v. on day 1 every 14 days. If ANC <1500/uL on day 1 of a cycle, then G-CSF will be added on day 6 for three days."
89436203|NCT04919226|Experimental|Peptide Receptor Radionuclide Therapy (PRRT) Arm|
89436204|NCT04919226|Active Comparator|CAPTEM(Capecitabine-Temozolomide), Everolimus, FOLFOX(Folinic acid + Fluorouracil + Oxaliplatin)|
89436205|NCT04909593|Experimental|Spinal Cord Stimulation|SCS trial systems including external trial stimulators, lead(s)/extensions(s), and operating room (OR) cable(s)/extender(s) and optional sensor.
89436206|NCT04909047|Experimental|Parasacral transcutaneous electrostimulation outpatient|electrostimulation device
89436207|NCT04909047|Experimental|transcutaneous tibial electrostimulation outpatient|electrostimulation device
89436208|NCT04909047|Experimental|home parasacral electrostimulation|electrostimulation device
89436209|NCT04888936||NCI RASopathies Clinical Center Cohort|includes Proband, Other carriers in family, Family Controls
89010507|NCT04543669|Experimental|Adacel®|All participants will receive one booster dose of commercially available Adacel® (TdaP-Tetanus, diphtheria, acellular pertussis) vaccine
89010508|NCT04539691|Experimental|Magnet group|"Women wearing magnet~a magnet, or sham device indistinguishable from the magnet (determined randomly), will be placed on her abdomen. If the pain is predominately in her abdomen, the device will be placed on the location with the most pain. If the pain is predominantly in the subjects back, the device will be placed on the lower abdomen on the midline between the umbilicus and the pubic bone."
89436210|NCT04888936||NCI RASopathies Field Cohort|includes Proband, Other carriers in family, Family Controls
89436211|NCT04886804|Experimental|Phase Ia - Dose escalation part|Consecutive cohorts of patients treated with escalating doses of BI 1810631 monotherapy.
89436212|NCT04886804|Experimental|Phase Ib - Dose expansion part: Cohort 1|
89436213|NCT04886804|Experimental|Phase Ib - Dose expansion part: Cohort 2|
89436214|NCT04886804|Experimental|Phase Ib - Dose expansion part: Cohort 3|
89436215|NCT04886804|Experimental|Phase Ib - Dose expansion part: Cohort 4|
89436216|NCT04886804|Experimental|Phase Ib - Dose expansion part: Cohort 5|
89436217|NCT04885569|Experimental|Motivational Interviewing with CBT (MICBT)|Participants in this arm will receive a total of 12 weekly sessions of CBT based Motivational Interviewing over a period of 12 weeks.
89436218|NCT04885569|Experimental|Mindfulness based Relapse Prevention Group (MBRP)|Participants in this arm will receive a total of 12 weekly sessions of mindfulness intervention over a period of 12 weeks.
89436219|NCT04885569|Experimental|Integrated MICBT and MBRP Group (CAMIAB)|This will be integrated MICBT plus MBRP intervention. Participants will receive a total of 12 weekly sessions of this integrated CAMIAB intervention.
88918623|NCT01657773||colorectal cancer, without nonalcoholic fatty liver disease|Patients were performed colonoscopy examination for colorectal cancer and who had been foud colorectal cancer proven by biopsy.Then the colorectal cancer patients who had not been diagnosed with nonalcoholic fatty liver disease was based on blood tests and abdomen ultrasound examination.
88918624|NCT01657773||colorectal cancer, with nonalcoholic fatty liver disease|Patients were performed colonoscopy examination for colorectal cancer and who had been foud colorectal cancer proven by biopsy.Then the colorectal cancer patients who had been diagnosed with nonalcoholic fatty liver disease was based on blood tests and abdomen ultrasound examination ultrasonography.
88918625|NCT01657786|Experimental|Ondansetron administration group|
88918626|NCT01657812|Experimental|dexmedetomidine|Drug:dexmedetomidine,dexmedetomidine 1.0μg/kg intravenous injection within 15 minutes before the induction of general anesthesia and followed by Dex 0.4μg/kg/h until 40min before the end of surgery
88918627|NCT01657812|Active Comparator|epidural|Epidural:continuous epidural block (T8-9) 4 mL of 1.6% lidocaine as a test dose and continous infusion of 0.375% ropivacaine(5 mL/h) during the surgery
88918628|NCT01657812|Placebo Comparator|control|Drug: normalsaline
88918629|NCT01657825|Experimental|Isavuconazole and warfarin|Isavuconazole three times daily (TID) for 2 days followed by once daily (QD) dosing for 11 days and warfarin single doses on Days 1 and 20
88918630|NCT01657838|Experimental|Arm 1: isavuconazole only|Single dose of isavuconazole on Day 1
88918631|NCT01657838|Experimental|Arm 2: isavuconazole + ketoconazole|Single dose of isavuconazole on Day 4 and ketoconazole twice daily (BID) for 24 days
88918632|NCT01657851|Experimental|dutasteride/tamsulosin|The present study is planned to establish bioequivalence of Duodart® 0.5mg/0.4mg manufactured by GlaxoSmithKline to concomitant dosing with separate capsules of dutasteride 0.5 mg and tamsulosin hydrochloride 0.4 mg formulations commercially available in Russia.
89436220|NCT04885569|No Intervention|Treatment as usual (TAU)|This will be routine care psychological treatment that they will be receiving.
89436221|NCT04885244||Operative|Multicenter, prospective, nonrandomized analysis of ASD patients w/diagnosis of congenital, degenerative, idiopathic, neuromuscular, inflammatory or iatrogenic spinal deformity. Participants must be scheduled to have 3 or more levels of Percutaneous posterior spinal instrumentation or 3 level stand alone lateral surgery within next 6 months.
88918633|NCT01657851|Active Comparator|dutasteride|Dutasteride (Avodart®) is an approved potent dual type I and II, 5-alpha-reductase inhibitor indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to improve symptoms, reduce the risk of acute urinary retention and reduce the risk of the need for BPH-related surgery.
89436222|NCT04880707|Active Comparator|Twin Block with Local Anesthetic|Following lower third molar extraction under intravenous sedation, the patient randomized to this arm with receive the Twin block local anesthetic nerve block using the standard dental local anesthetic, i.e,. 2% lidocaine with 1:100,000 epinephrine, on the day after extraction, if the patient has pain greater than or equal to 5 on 10 in their jaw-closer muscles (Numerical Pain rating scale).
89436223|NCT04880707|Placebo Comparator|Twin Block with sterile normal saline|Following lower third molar extraction under intravenous sedation, the patient randomized to this arm with receive the Twin block using sterile normal saline, on the day after extraction, if the patient has pain greater than or equal to 5 on 10 in their jaw-closer muscles (Numerical Pain rating scale).
88918634|NCT01657851|Active Comparator|tamsulosin|Tamsulosin (Omnic®) is an alpha-1A-adrenocepter blocking agent approved for the treatment of signs and symptoms of benign prostatic hyperplasia
88918635|NCT01657864||Patients with aseptic meningitis|All patients of the study population with a record/diagnosis of aseptic meningitis during the study period
88918636|NCT01657864||Patients without aseptic meningitis|All patients of the study population without a record/diagnosis of aseptic meningitis during the study period
88918637|NCT01657890|Experimental|Arm 1: Isavuconazole in healthy non-elderly male subjects|age 18 to 45 years
88918638|NCT01657890|Experimental|Arm 2: Isavuconazole in healthy non-elderly female subjects|age 18 to 45 years
88918639|NCT01657890|Experimental|Arm 3: Isavuconazole in healthy elderly male subjects|age 65 years and older
88918640|NCT01657890|Experimental|Arm 4: Isavuconazole in healthy elderly female subjects|age 65 years and older
88918641|NCT01657916||5 year sling implants|Patients who underwent implant of the Align Urethral Support System between June 2007 and December 2008
88918642|NCT01657929|Experimental|20 µg H5-VLP + 2.5 µg GLA-AF given ID|
88918643|NCT01657929|Experimental|20 µg H5-VLP + 2.5 µg GLA-AF given IM|
88918644|NCT01657929|Active Comparator|20 µg H5-VLP alone given ID|
88918645|NCT01657929|Active Comparator|20 µg H5-VLP + 1 mg Alhydrogel(R) given IM|
88918646|NCT01657929|Active Comparator|90 µg licensed H5N1 vaccine|
89436224|NCT04879654|Experimental|endonasal endoscopic surgery with adjuvant therapy|endonasal endoscopic surgery followed by Toripalimab,radiotherapy and/or chemotherapy
89536450|NCT04996329|Experimental|comprehensive smoking cessation intervention group|Early health warning intervention combined with brief smoking cessation intervention Early health warning intervention is to tell the subjects that smoking leads to the rapid decline of their lung function, and they are at the high risk of developing COPD
89436225|NCT04878627|Experimental|Cannabidiol (CBD)|"Days 1 to 7: Patients will receive CBD 2.5 mg/kg in divided doses BID for 7 days. Days 8 to 14: Patients will receive an increase dose of 7.5 mg/kg of CBD in divided doses.~Days 15 to 21: Patients will receive an increased dose of 12.5 mg/kg CBD, in divided doses. If patients experience dose limiting side-effects, they ill be maintained on the lowest tolerated dose."
89436226|NCT04878627|Placebo Comparator|Placebo|Days 1 to 7: Patients will receive placebo in divided doses BID for 7 days. Days 8 to 14: Patients will continue to receive placebo in divided doses. Days 15 to 21: Patients will receive continue to receive placebo in divided doses.
89436227|NCT04874519||Participants with Fibrolamellar Carcinoma/FLC|Participants will have a personal history of histologically proven fibrolamellar carcinoma (clinical or radiographical suspicion of FLC must be confirmed at MSK or an external hospital)
89436228|NCT04866953||<30 units PRBC|Patients who underwent surgery within 24 hours of admission and received less than 30 units of pRBC within 24 hours.
89436229|NCT04866953||>/=30 units PRBC|Patients who underwent surgery within 24 hours of admission and received >/=30 units of pRBC within 24 hours.
89436230|NCT04866680|Experimental|Personalized Circulating DNA follow-up|FFPE tissue sample + blood sample (20ml)
89436231|NCT04862247|Experimental|Imaginal Exposure Condition|Participants will complete one phone session including education about the treatment followed by four online sessions of imaginal exposure across a one month time period. Each session is separated by 1 week.
89436232|NCT04862247|Active Comparator|Writing and Thinking Condition|Participants will complete one phone session including education about the treatment followed by four online sessions of a writing and thinking intervention across a one month time period. Each session is separated by 1 week.
89436233|NCT04861610|Experimental|Brief mindfulness based program|A four session program, each last for 2.5 hours. Brief mindfulness exercises promote stress reduction, with an introduction of mindfulness to caregivers and home practice is encouraged with guidance.
88918647|NCT01657942|Experimental|ExABlate MR Guided Focus Ultrasound|ExAblate MR Guided Focused Ultrasound - Local treatment of prostate lesions using Magnetic Resonance Imaging guided endorectally applied focused ultrasound energy.
89436234|NCT04861610|Active Comparator|Psychoeducation|A four session program, each last for 2.5 hours. It promotes the coping and problem solving of caregivers. Brief home application included.
89436235|NCT04861610|No Intervention|Treatment-as-usual|
89436236|NCT04852887|Active Comparator|Arm 1: Breast Radiation Therapy + Endocrine Therapy|Radiation therapy to the breast and hormonal drug for at least 5 years. Tamoxifen 20 mg daily Anastrozole 1 mg daily Letrozole 2.5 mg daily Exemestane 25 mg daily
89436237|NCT04852887|Active Comparator|Arm 2: No Breast Radiation Therapy + Endocrine Therapy|No radiation therapy, only hormonal drug for at least 5 years. Tamoxifen 20 mg daily Anastrozole 1 mg daily Letrozole 2.5 mg daily Exemestane 25 mg daily
89436238|NCT04846491|Experimental|Nucleot(s)ide-treated patients-Experimental Group 1|
88918648|NCT01657955|Experimental|Bendamustine Hydrochloride Injection|d1-d2,i.v.gtt, 100mg/m2/d, 28 days per cycle, at most 6 cycles.
88918649|NCT01657955|Active Comparator|Chlorambucil|d1-d2, d15-d16, p.o., 0.4mg/kg/day, 28 days per cycle, at most 6 cycles(if WBC≥4×109 /L at d12-d14 ); d1-d2, p.o., 0.4mg/kg/day, 28 days per cycle, at most 6 cycles(if WBC<4×109 /L at d12-d14 );
88918650|NCT01657968||Acute tonsillitis|Patients with acute tonsillitis aged 15 to 40 years meeting at least two of Centors criteria.
89436239|NCT04846491|Experimental|Nucleot(s)ide-treated patients-Experimental Group 2|
89436240|NCT04846491|Active Comparator|Nucleot(s)ide-treated patients-Control Group|
89436241|NCT04846491|Other|Treatment Naive Group|
89436242|NCT04843566|Active Comparator|Transrectal|Patients will receive a transrectal MRI-guided prostate biopsy.
89436243|NCT04843566|Active Comparator|Transperineal|Patients will receive a transperineal MRI-guided prostate biopsy.
88918651|NCT01657968||Healthy control patients|Control patients aged 15 to 40 years.
88918652|NCT01657513|Experimental|tnf-alfa treatment (infliximab, adalimumab, or etanercept)|This arm includes all the patients of the study. They are patients who are start treatment with a tnf-alfa blocking drug
88918653|NCT01657981|Experimental|Treatment arm 1|
88918654|NCT01657994|Experimental|therapy plus fes|robotic gait training plus functional electrical stimulation
89436244|NCT04824794|Experimental|GEN3014|"Experimental: GEN3014 Participants in Dose Escalation phase with~Relapsed or refractory myeloid myeloma (RRMM)~R/R acute myeloid leukemia (AML)~Participants in Expansion Part A with~RRMM (anti-CD38 mAb-naïve)~RRMM (anti-CD38 mAb-refractory)~R/R diffuse large B-cell lymphoma (DLBCL)~R/R AML~Participants in Expansion Part B with~• RRMM (anti-CD38 mAb-naïve)"
89436245|NCT04824794|Active Comparator|Daratumumab|"Participants in Expansion Part B with~- RRMM (anti-CD38 mAb-naïve)"
89436246|NCT04815876|Active Comparator|Transrectal|Patients will receive a transrectal MRI-guided prostate biopsy.
89436247|NCT04815876|Active Comparator|Transperineal|Patients will receive a transperineal MRI-guided prostate biopsy.
89536451|NCT04996329|Active Comparator|brief smoking cessation intervention group|brief smoking cessation intervention only
89536452|NCT04995783||Ulcerative Colitis|
89536453|NCT04995783||Crohn's Disease|
89536454|NCT04995783||Rheumatoid Arthritis|
89436248|NCT04803825|Experimental|Heavy Slow Exercise|One dedicated physiotherapist will supervise and instruct the exercise program on an individual basis. If the patient doesn't have access to a dumbbell, it will be offered free rental from the physiotherapy ward. Follow-up on the exercises will be scheduled as needed and tele rehabilitation will be offered as an option. Additionally to HSR exercises, participants will be instructed to perform daily stretches of the forearm.
89010509|NCT04539691|Sham Comparator|Sham group|"Women wearing sham~a magnet, or sham device indistinguishable from the magnet (determined randomly), will be placed on her abdomen. If the pain is predominately in her abdomen, the device will be placed on the location with the most pain. If the pain is predominantly in the subjects back, the device will be placed on the lower abdomen on the midline between the umbilicus and the pubic bone."
89010510|NCT02214940|Experimental|BI 11634|multiple rising dose
89010511|NCT02214940|Placebo Comparator|Placebo|
89010512|NCT04539652|Experimental|Experimental group|
89010513|NCT02214979|Experimental|Telmisartan/Ramipril|
89010514|NCT02214979|Active Comparator|Telmisartan + Ramipril capsule|
89436249|NCT04803825|Active Comparator|Extracorporeal Shock wave therapy|The patients will receive rESWT (SwissDolodClast/EMS) once a week for three sessions. The treatment will be given by a physiotherapist trained in using rESWT. The rESWT is given on the ECRB tendon insertion area.
89436250|NCT04803825|Active Comparator|Information and advice|The information and advice group are given a single face-to-face session with a physiotherapist, lasting up to 60 minutes.
89436251|NCT04799236|Active Comparator|Group 1: Oral Miltefosine|Miltefosine will be administered per os at 150 mg/day [50 mg tid] for 28 days. This is the standard regimen of miltefosine for persons >45 kg.
89436252|NCT04799236|Active Comparator|Group 2: Intravenous pentavalent antimony|IV pentavalent antimony (meglumine antimoniate) will be administrated at 20 mg x kg x d during 20 consecutive days. Antimony will be diluted in 10 times its volume in 5%Dextrose in destilled water and injected IV in 20 minutes
89436253|NCT04799236|Experimental|Group 3: Intravenous liposomal amphotericin B|LAMB will be administered IV at 3 ampules [150 mg] on each of days 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, and 27. Three ampules is the individual dose suggested by Aronson et al [2016] and equals 2.5 mg/kg/dose for a 60 kg person. 15 doses of 3 ampules (total of 2250 mg) equals 37.5 mg/kg for a 60 kg person.
89436254|NCT04799054|Experimental|Part 1 Monotherapy Dose Escalation and Optimization: TransCon TLR7/8 Agonist|TransCon TLR7/8 Agonist in escalating doses to evaluate safety/tolerability and to determine the MTD and RP2D.
89436255|NCT04799054|Experimental|Part 2 Combination Dose Escalation and Optimization: TransCon TLR7/8 Agonist with Pembrolizumab|TransCon TLR7/8 Agonist with Pembrolizumab in escalating doses to evaluate safety/tolerability and determine the MTD and RP2D.
89436256|NCT04799054|Experimental|Part 3 Phase 2 Combination Dose Expansion: TransCon TLR7/8 Agonist with Pembrolizumab|TransCon TLR7/8 Agonist with Pembrolizumab using RP2D from Part 2 to evaluate safety/tolerability and anti-tumor activity of the combination in indication-specific dose expansion cohorts.
89436257|NCT04785456|Experimental|Active TBS|"Daily, 4-week, 5-days per week treatment sessions, each consisting of:~First, intermittent TBS (iTBS) over the L-DLPFC: triplet 50 Hz bursts, repeated at 5 Hz, 2 s on and 8 s off, (600 pulses per session, total duration of 3 min 9 s), then continuous TBS (cTBS) over the R-DLPFC as 40 s uninterrupted bursts (600 pulses). Intensity at 120% resting motor threshold (RMT)."
89436258|NCT04785456|Sham Comparator|Sham TBS|Daily, 4-week, 5-days per week treatment sessions. The sham coil will generate auditory and somatosensory (vibratory) stimuli identical to the active stimulation.
89436259|NCT04776252|Experimental|MK-8591A|Fixed dose combination (FDC) tablet of 100 mg doravirine, 0.75 mg islatravir taken orally, once daily for up to 192 weeks.
89436260|NCT04774393|Experimental|Arm A (decitabine/cedazuridine, venetoclax, ivosidenib)|Patients receive decitabine/cedazuridine PO daily on days 1-5, venetoclax PO daily on days 1-14, and ivosidenib PO daily on days 1-28. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity.
89436261|NCT04774393|Experimental|Arm B (decitabine/cedazuridine, venetoclax, enasidenib)|Patients receive decitabine/cedazuridine PO daily on days 1-5, venetoclax PO daily on days 1-14, and enasidenib PO daily on days 1-28. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity.
89436262|NCT04773834|Experimental|Experimental group|Participants will be enrolled virtually into a digital diabetes prevention program through the Noom app and willing to receive text messages based on their engagement levels in Noom from the study team, as well as complete text-based surveys.
89436263|NCT04773834|Other|Control group|Participants will be enrolled virtually into the digital diabetes prevention program through the Noom app and willing to receive general text messages from the study team
89436264|NCT04771754|Experimental|Arm 1|"Dolutegravir - 50 mg once daily, orally administered for the first 28 days of the study.~No treatment for the last 44 days of the study."
89436265|NCT04771754|Experimental|Arm 2|"No treatment for the first 28 days of the study.~Dolutegravir - 50 mg once daily, orally administered for the last 28 days of the study (day 44-72)."
89436266|NCT04760873|Experimental|Cryotherapy for GAVE|Subjects will undergo cryotherapy for GAVE
89436267|NCT04750915||AARP|Members of AARP, aged 50-71 years and who resided in one of six states or in two metropolitan areas in the United States
89436268|NCT04736628|Experimental|Dose group 1: BI 685509|Low dose.
89436269|NCT04736628|Placebo Comparator|Dose group 1: Matching placebo|Matching placebo for low dose.
89010515|NCT02214979|Active Comparator|Telmisartam + Ramipril tablet|
89010516|NCT04539496|Experimental|dose confirmation and the phase II study|To determine the MTD and RP2D of XZP-3287; To determine the RP2D of XZP-3287 combined with endocrine therapy; To determine the efficacy and safety of XZP-3287 in HR positive HER2 negative advanced breast cancer
89010517|NCT04539301||Derivation cohort|In the derivation cohort, we will determined the conversion factor linking apixaban, rivaroxaban, fondaparinux, or danaparoid measured level, on the one hand, and heparin anti-Xa activity, on the other hand.
89010518|NCT04539301||Validation cohort|"In the validation cohort, for each tested anticoagulant, we will used the conversion factor determined in the derivation cohort to infer the estimated level of anticoagulant from heparin anti-Xa activity:~estimated anticoagulant level = conversion factor for this anticoagulant × heparin anti-Xa activity~The agreement between measured and estimated levels of each factor-Xa inhibitor will be assessed."
88918655|NCT01658007|Experimental|Sirolimus|Adding sirolimus to established induction and consolidation chemotherapy for relapsed/refractory acute lymphoblastic leuk
88918656|NCT01658033|Experimental|Avastin + mFOLFOX6|Avastin plus FOLFOX6 regimen in the management of her-2 negative breast cancer patients.
88918657|NCT01658046|Experimental|NMES group|10 weeks neuromuscular electrical stimulation plus endurance training and quadriceps strength training.
88918658|NCT01658046|Sham Comparator|Control group|10 weeks sham neuromuscular electrical stimulation plus endurance training and quadriceps strength training.
88918659|NCT01658085||Study group: HARMONIC FOCUS®|Total thyroidectomy (total bilateral extracapsular lobectomy) for Multinodular Goiter with HARMONIC FOCUS®
88918660|NCT01658085||Control group: ACE14S|Total thyroidectomy (total bilateral extracapsular lobectomy) for Multinodular Goiter with ACE14S
88918661|NCT01658098||4-6 weeks after delivery|all patients on their 4th-6th weeks after delivery
88918662|NCT01658124|Experimental|Tranexamic acid|(total dose 8 grams)
88918663|NCT01658124|Placebo Comparator|Placebo|(Sodium Chloride 0.9%)
88918664|NCT01658137|Active Comparator|Typical Western Diet|"The comparator dietary pattern (Typical Western Diet) approximates the inflammatory dietary pattern typically consumed by North Americans. It contains refined grains, processed foods, dairy fat, meats, sugar and high glycemic index foods, and few fruits, nuts, legumes, and vegetables. The fruits and vegetables are highly processed (e.g. juices) and lower in micronutrients than those in the intervention diet. The saturated fat content of this diet does not meet national guidelines for health. The polyunsaturated fat:saturated fat ratio is ~0.5 (low)."
88918665|NCT01658137|Experimental|Prudent Diet|"The experimental dietary pattern (Prudent Diet) is based on intakes of foods hypothesized to have beneficial effects on inflammation and long-term health. This dietary pattern includes micronutrient and macronutrient levels consistent with healthy eating in epidemiological studies and randomized controlled trials. The diet is constructed with low-fat dairy products, fish, chicken, and lean meats to minimize saturated fat and increase protein and calcium. The diet is rich in fruits, vegetables, whole grains, nuts, legumes, and seeds that are good sources of potassium, magnesium, and dietary fiber. This diet provides a 'favorable' macronutrient profile that is low in saturated fat, has a polyunsaturated/saturated fat ratio of ~1.0 (high), and low in high glycemic index carbohydrates."
88918666|NCT01658176|Experimental|PF-04691502 + Exemestane|PF-04691502 in combination with Exemestane
88918667|NCT01658176|Active Comparator|Exemestane|Exemestane alone
88918668|NCT01658202|Other|Sequence 1|"After a 24h washout period free of any nicotine exposure, subjects will be randomly assigned to one of 2 treatment-sequence groups, separated by a 48h-intervals.~Each patch will be applied for 24h."
88918669|NCT01658202|Other|Sequence 2|"After a 24h washout period free of any nicotine exposure, subjects will be randomly assigned to one of 2 treatment-sequence groups, separated by a 48h-intervals.~Each patch will be applied for 24h."
88918670|NCT01658215|Other|Sequence 1|"Subjects will be randomly assigned to one of 2 treatment-sequence groups with 2 treatment periods. The duration of each treatment period will be 3 days.~Each patch will be applied for 24 hours."
88918671|NCT01658215|Other|Sequence 2|"Subjects will be randomly assigned to one of 2 treatment-sequence groups with 2 treatment periods. The duration of each treatment period will be 3 days.~Each patch will be applied for 24 hours."
88918672|NCT01658254|Experimental|Survey by email|One arm of investigators will receive the survey to answer by email, reminding the necessity of posting basic results
88918673|NCT01658254|No Intervention|Non interventional arm|This arm will receive no intervention (no email with the survey)
88918674|NCT01658267|Experimental|Nutritional Supplement|Instructions and techniques to improve the quality of the diet to meet the child's daily nutritional requirements will be provided.
88918675|NCT01658280|Active Comparator|Conventional TBNA + ROSE|"Patients allocated in this group will undergo conventional TBNA, performed in a bronchoscopy suite by the same operator under conscious sedation, using 19-G needle size. Three needle passes for each approachable station will be performed. The samples obtained will be examined on-site by experienced blinded cytopathologist.~In case of samples obtained from conventional TBNA defined as non diagnostic, the operator will shift to the EBUS procedure.All specimens obtained will be send to definitive cytological and histological evaluation and the final diagnosis will be collected and reported on CRFs"
88918676|NCT01658280|Experimental|EBUS-TBNA + ROSE|Patients allocated in the intervention group will undergo EBUS-TBNA procedure, performed in a bronchoscopy suite by the same operator under conscious sedation Three needle passes for each approachable station will be performed. The samples obtained will be examined on-site by experienced blinded cytopathologist.All specimens obtained will be send to definitive cytological and histological evaluation and the final diagnosis will be collected and reported on CRFs
89436270|NCT04736628|Experimental|Dose group 2: BI 685509|Low dose followed by up-titration to medium dose.
88918677|NCT01658306|Experimental|remote ischemic preconditioning|Receiving remote ischemic preconditioning (RIPC) treatment with pressure set at 200 mmHg.
88918678|NCT01658306|Sham Comparator|placebo remote ischemic preconditioning|Receiving sham RIPC treatment with pressure set at 50 mmHg
89436271|NCT04736628|Placebo Comparator|Dose group 2: Matching placebo|Matching placebo for low dose followed by up-titration to medium dose.
89436272|NCT04736628|Experimental|Dose group 3: BI 685509|Low dose followed by up-titration to medium dose, followed by up-titration to high-dose.
89436273|NCT04736628|Placebo Comparator|Dose group 3: Matching placebo|Matching placebo for low dose followed by up-titration to medium dose, followed by up-titration to high dose.
89436274|NCT04727242|Experimental|Cytoreductive Surgery+HIPEC gemcitabine+dacarbazine|"Cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC) with gemcitabine followed by postoperative systemic chemotherapy with dacarbazine. Conceptually, HIPEC will be administered as a 60 minute heated intraperitoneal infusion (ie, intraperitoneal wash or lavage).~HIPEC: Gemcitabine will be instilled at a dose of 1000 mg/m2 for 60 minutes at temperatures of 42° to 43°C.~Systemic adjuvant chemotherapy starting 30 days ± 14 days post surgery. Dacarbazine 1000 mg/m2 IV every 3 weeks x 6 cycles"
89436275|NCT04716946|Experimental|Participants with Early-stage Non-Small Cell Lung Cancer|Participants will be diagnosed with Stage I-IIIA NSCLC and will be ineligible for surgery and will have any level of PD-L1
89536455|NCT04995783||Psoriasis|
89536456|NCT04995783||Control|
89536457|NCT03069729||Control group|non-diabetic; no intervention
89536458|NCT03069729||Diabetics without DPN|diabetics without DPN; no intervention
89536459|NCT03069729||Diabetics with DPN|diabetics with DPN; no intervention
88918679|NCT01657396|Active Comparator|Standard Oral Hygiene|Oral hygiene provided by current local standard of care - minimum q2h mouthcare with a green Toothette swab dipped in sterile water, with excess liquid aspirated using a Yankauer suction. Brushing of teeth (if applicable) with a toothbrush and standard toothpaste q12h. Replacement of Yankauer suction device daily.
88918680|NCT01657396|Active Comparator|SAGE Q-care q2|Oral hygiene provided with a commercial pre-packaged product (SAGE Q-care q2 Oral Cleansing and Suctioning System) - minimum q2h mouthcare using the supplied applicator swabs and covered Yankauer suction device using supplied Perox-A-Mint (a hydrogen peroxide based oral hygiene solution) alternating with alcohol-free mouthwash. Brushing of teeth (if applicable) with supplied applicator using Antiplaque solution (a cetylpyridinium based solution) q12h. Use of a new kit (which includes new covered Yankauer suction device) daily.
88918681|NCT01657396|Active Comparator|SAGE Q-care q2 with Chlorhexidine|Oral hygiene provided with a commercial pre-packaged product with chlorhexidine (SAGE Q-care Rx q2 Oral Cleansing and Suctioning System with CHG) - minimum q2h mouthcare using the supplied applicator swabs and covered Yankauer suction device using supplied Perox-A-Mint (a hydrogen peroxide based oral hygiene solution) alternating with alcohol-free mouthwash. Brushing of teeth (if applicable) with supplied applicator using chlorhexidine oral rinse (solution containing 0.12% chlorhexidine) q12h. Use of a new kit (which includes new covered Yankauer suction device) daily.
88918682|NCT01658319|Experimental|Treatment (chemotherapy)|Patients receive fludarabine phosphate IV over 30 minutes on days 1-5 and methoxyamine IV over 1 hour on day 1 (day 2 of course 1). Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
88918683|NCT01658332|Experimental|specific procedure|Circulating tumor cells will be search with the Veridex method at inclusion and after the third chimiotherapy
88918684|NCT01658358|Experimental|Phase I part :Systemic Therapy|"Drug: Lapatinib~Drug: Lipo-Dox"
88918685|NCT01658358|Experimental|Phase II part|"Drug: Lapatinib~Drug: Lipo-Dox Patients will receive recommended dose according to phase I study result. at least 8 cycles, then, with continue combination treatment cycles or single lapatinib treatment (start with 1500 mg per day) at investigator's discretion."
88918686|NCT01658371||efavirenz|HIV patients on efavirenz
88918687|NCT01658384||cognitive evolution, observational,MS|multiple sclerosis tysabri treated patients
88918688|NCT01658397|Experimental|Fasting|Ten day fast
88918689|NCT01658410|Active Comparator|BQ-123|
88918690|NCT01658410|Placebo Comparator|NaCl|
88918691|NCT01658423||Junior high school student|All subjects participated in measurements of body composition, muscle strength and motor fitness
88918692|NCT01658449|Experimental|group A|
88918693|NCT01658449|Experimental|group B|
88918694|NCT01658462|Experimental|Arm A|Docetaxel + Nintedanib
88918695|NCT01658462|Active Comparator|Arm B|Docetaxel + increase of the dose
88918696|NCT01658475||periodontitis|those with periodontitis and those without periodontitis
88918697|NCT01658488|Other|Regular Rice|2 servings per day of non-fortified rice
88918698|NCT01658488|Other|Iron-fortified Rice|2 servings per day of Rice enriched in iron for women with iron-deficient anemia to restore their blood counts more efficiently than the standard rice not enriched with iron.
88918699|NCT01658527|Experimental|Orteronel, 300 mg twice daily|
88918700|NCT01658527|Active Comparator|Bicalutamide 50 mg per day|
88918701|NCT01658553|Experimental|GSK1120212 Qtc study|Single-Sequence, Placebo-Controlled, Single-Blind Study to Evaluate the Effect of Repeat Oral Dosing of GSK1120212 on Cardiac Repolarization in Subjects with Solid Tumors
88918702|NCT01658592|Experimental|NAC-VC Deep Brain Stimulation|The contractors located in NAc and VC are ON at the same time
88918703|NCT01658592|Sham Comparator|Placebo A|Stimulator setting is OFF
88918704|NCT01658592|Experimental|Placebo B|The contractor located in NAc is on
88918705|NCT01658592|Experimental|Placebo C|The contactor located in VC is on
88918706|NCT01658605|Experimental|GSK1605786|Administered orally for 16 weeks in a 2:1 ratio
88918707|NCT01658605|Placebo Comparator|Placebo|Administered orally for 16 weeks in a 2:1 ratio
89536460|NCT03109301|Experimental|Arm 1|Patients > 18 years of age
89536461|NCT03109301|Experimental|Arm 2|Patients < 18 years of age
88918708|NCT01658631||Anesthesia|Arterial pressure measurement using Nexfin (a noninvasive finger cuff system) during the induction of anesthesia
88918709|NCT01658631||Intensive Care Unit patients|Arterial pressure measurement using Nexfin (a noninvasive finger cuff system) during a passive legs raising test
88918710|NCT01658644|No Intervention|Group A|Patients participating in group A, will not be exposed to any interventions, they will partake in the typical hospital and communication experience.
88918711|NCT01658644|Experimental|Group B (text handout)|Patients assigned to group B will be provided with a paper or electronic version displaying a list of the names and roles of their clinical care staff; each name will NOT be accompanied by the respective photograph of each clinician. This document will be presented to the patient at the earliest possible time after admission to the hospital.
89010519|NCT04539535|Experimental|Down syndrome|We did the General Movements Assessment on standard mattress and experimental mattress in infants with Down syndrome on the same day.
89536891|NCT05280431|Experimental|Experimental Group (FEXO)|15 sessions, 3 sessions per week. Each session consists of 45 minutes of training with the FEXO exoskeleton. The training session is customized to the patient's needs and can be adapted to his/her improvement during the intervention.
89436276|NCT04714736|Active Comparator|DyeVert group|Patients will receive intravenous 0.9% sodium chloride as soon as in the catheterization laboratory. The hydration regimen will be defined according to the hemodynamic conditions and modulated according to the left ventricular end diastolic pressure (LVEDP). During the PCI the CM injection will be handled by the DyeVert TM system.
89436277|NCT04714736|Sham Comparator|Control group|"Patients will receive intravenous 0.9% sodium chloride as soon as in the catheterization laboratory. The hydration regimen will be defined according to the hemodynamic conditions and modulated according to the left ventricular end diastolic pressure (LVEDP). During the PCI the CM injection will be carried out by a conventional manual injection syringe. Strategies for limiting CM volume are:~angiograms will be performed with injection of contrast using a 3-cm 3 syringe; this provides strict control of CM delivery by limiting the volume of contrast that can be administered in a single injection;~catheters with sideholes will be strictly avoided during percutaneous intervention;~when exchanging catheters, unused contrast is withdrawn from the catheter lumen (e.g., by back-bleeding through an opened ''Y''-connector or by aspirating residual contrast from the catheter using a syringe)~''tests'' with ''puffs'' of CM are discouraged."
89436278|NCT04710004|Experimental|Brain stimulation via clinically implanted electrodes|Brain will be stimulated in different patterns including synchronized or asynchronous current.
89436279|NCT04708782|Placebo Comparator|Placebo|Matching placebo inhaled using an ultrasonic nebulizer QID
89436280|NCT04708782|Experimental|Inhaled Treprostinil|Treprostinil for inhalation solution (0.6 mg/mL) delivered via an ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath. Inhaled QID and titrated up to a target of 12 breaths QID or until the subject reaches their maximum clinically tolerated dose.
88819418|NCT00552617|Experimental|Rocuronium + 1.0 mg/kg Sugammadex|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 1.0 mg/kg sugammadex was administered IV.
88918712|NCT01658644|Experimental|Group C (text & image handout)|Patients assigned to group C will be provided with a paper or electronic version displaying a list of the names and roles of their clinical care staff; each name will also be accompanied by the respective photograph of each clinician. This document will be presented to the patient at the earliest possible time after admission to the hospital.
88918713|NCT01658696|Active Comparator|ChAd63 ME-TRAP and MVA ME-TRAP|ChAd63 ME-TRAP / MVA ME-TRAP heterologous prime-boost immunisation
88918714|NCT01658696|Placebo Comparator|Rabies vaccine|2 x 2.5IU Verorab
88918715|NCT01658709||Ankle Injured|Volunteers with an ankle injury
88918716|NCT01658709||Healthy|Healthy Volunteers
88918717|NCT01658722||Observational|Long term follow-up
88918718|NCT01658748|Active Comparator|Week 0 Medtronic 3387 electrodes/Activa PC amygdala DBS|Patients randomized to this arm will have stimulators turned on approximately 1 week after the 3-4 week post-surgery EEG telemetry session that determines safety parameters for stimulator settings. Subjects will be followed weekly for the next 12 weeks, with adjustments in stimulator settings according to prescribed protocol based on changes in rating scale scores (CAPS, CGI-I, ADIPS, LFIPS, HAMA, MADRS, YMRS).
89436281|NCT04699123|Experimental|Arm 1a - NC318 only|At the discretion of the treating physician, advanced NSCLC patients on arm 1a will receive NC318 alone.
89436282|NCT04699123|Experimental|Arm 1b - NC318 and Pembrolizumab|At the discretion of the treating physician, advanced NSCLC patients on arm 1b will receive combination therapy with NC318 and pembrolizumab.
88918719|NCT01658748|Sham Comparator|Week 12 Medtronic 3387 electrodes/Activa PC amygdala DBS|Patients randomized to this arm will undergo the same procedures and same visit frequency as those in the week 0 stimulation arm, except that the actual stimulation settings will be kept at 0 V, 0 Hz, and the patient, study psychiatrist who does the ratings, and study neurosurgeon who does neurological clinical assessments will be blind to whether the subject is receiving actual or sham stimulation. Only the study neurophysiologist will know whether the patient is in the active or sham stimulation arm during these 12 weeks. After week 12, subjects in this week will begin to receive active stimulation according to pre-specified protocol.
88918720|NCT01658761|Experimental|Myopic traction maculopathy|The 71 eyes of 64 patients (14 men and 50 women) with myopic traction maculopathy in highly myopic eyes (refractive errors ≤-8.0 diopters and axial length ≥26.0 mm) who underwent vitrectomy were retrospectively reviewed.
88918721|NCT01658774|Active Comparator|Albendazole & Vitamin C|Anthelmintics. A single dose of Albendazole (400mg) at month 0 and single dose of Vitamin C (500 mg) at 3, 6, 9 and 12 months.
89436283|NCT04699123|Experimental|Arm 1c - NC318 and Pembrolizumab|At the discretion of the treating physician, advanced NSCLC patients on arm 1b will receive combination therapy with NC318 and pembrolizumab.
89436284|NCT04699123|Experimental|Arm 2 (naïve to PD-1 axis inhibitor)- NC318 and Pembrolizumab|Arm 2 will enroll patients with advanced NSCLC who are naïve to PD-1 axis inhibitor therapy to receive therapy with NC318 in combination with pembrolizumab.
89436285|NCT04699123|Experimental|Arm 2a (naïve to PD-1 axis inhibitor)- NC318 and Pembrolizumab|Arm 2a will enroll patients with advanced NSCLC who are naïve to PD-1 axis inhibitor therapy to receive combination therapy with NC318 and pembrolizumab.
89436286|NCT04690608|Experimental|resistant diabetic macular edema and central retinal vein occlusion|"Prospective non randomized interventional study on 60 eyes of 40 patients with previously diagnosed macular edema secondary to type 1 or 2 diabetes mellitus will be included.~The study will be conducted from January 2021 to June 2021.~For transition to suprachoroidal injection of TAAC a diagnosis of resistant DME is required.~Cases with recent onset central retinal vein occlusion less than 2 months duration will be included"
89436287|NCT04662554|Experimental|Novel PET Camera|Patients already undergoing a PET/CT scan for HNC will afterwards undergo a PET scan with the proposed device, thus no additional radioactivity is needed as part of this study.
89436288|NCT04657432|Experimental|Dose 1|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 1 is five sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
89436289|NCT04657432|Experimental|Dose 2|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 2 is 10 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
88918722|NCT01658774|Experimental|Albendazole|Anthelmintics. A single does of Albendazole (400mg) every three months for 12 months
88918723|NCT01658800|Experimental|VAX161C vaccine|Subjects will be injected into the arm on 2 occasions during the study, once on Day 0 and then again on Day 21 with the vaccine VAX161C
88918724|NCT01658852|Active Comparator|Metronidazole|active drug: metronidazole 500mg three time per day for 10 days
88918725|NCT01658852|Placebo Comparator|Placebo|Placebo three times per day for 10days
88918726|NCT01658865||Transnasal endoscopy|Healthy volunteers and patients with esophageal motor symptom will be enrolled and esophageal motility assessed by transnasal endoscopy according to clinical and manometric diagnosis
88918727|NCT01658891|Experimental|CHF 1535 50/6 µg|
88918728|NCT01658891|Active Comparator|beclomethasone dipropionate 100µg + Formoterol fumarate 6µg|
89436290|NCT04657432|Experimental|Dose 3|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 3 is 15 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
89436291|NCT04657432|Experimental|Dose 4|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 4 is 20 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
89436292|NCT04657432|Experimental|Dose 5|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 5 is 20 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
88918729|NCT01658956|Experimental|Subcutaneous GCSF 5 µg/kg days 8 and 12|Prophylactic administration of GCSF on days 8 and 12 following chemotherapy
88918730|NCT01658956|No Intervention|No intervention|
88918731|NCT01658982||cirrhotic patients|cardiopulmonary exercise testing
88918732|NCT01659008|Experimental|estradiol|estradiol PO 0.5mg 2 tabs three times a day for 2 days
88918733|NCT01659008|Experimental|Lysteda|Lysteda 650mg PO 2 tabs three times a day for 2 days
88918734|NCT01659034|Experimental|Thienopyridine|Thienopyridine treatment for 3 months after implantation of everolimus-eluting Stents
88918735|NCT01659047|Experimental|GS-1101|GS-1101 (oral; 150 mg BID)
88918736|NCT01659060|Experimental|Dark chocolate|
88918737|NCT01659060|Placebo Comparator|Placebo chocolate|
88918738|NCT01659073|Experimental|Caloric Vestibular Stimulation|Caloric vestibular stimulation performed by a modified stethescope ear attachment attached to an MRI compatible infusion pump.
88918739|NCT01659086|Experimental|Group A|Subjects will receive the investigational vaccine GSK2654911A formulation 1 and placebo
88918740|NCT01659086|Experimental|Group B|Subjects will receive the investigational vaccine GSK2654911A formulation 2 and placebo
88918741|NCT01659086|Experimental|Group C|Subjects will receive the investigational vaccine GSK2654911A formulation 3 and placebo
88918742|NCT01659086|Experimental|Group D|Subjects will receive the investigational vaccine GSK2654911A formulation 4 and placebo
88918743|NCT01659086|Experimental|Group E|Subjects will receive the investigational vaccine GSK2654909A and placebo
88918744|NCT01659086|Experimental|Group F|Subjects will receive the investigational vaccine GSK2654911A formulation 5
88918745|NCT01659086|Experimental|Group G|Subjects will receive the investigational vaccine GSK2654911A formulation 6
88918746|NCT01659086|Experimental|Group H|Subjects will receive the investigational vaccine GSK2654911A formulation 7
88918747|NCT01659086|Experimental|Group I|Subjects will receive the investigational vaccine GSK2654911A formulation 8
88918748|NCT01659086|Experimental|Group J|Subjects will receive the investigational vaccine GSK2654909A
88918749|NCT01659086|Placebo Comparator|Placebo Group|Subjects will receive Placebo
88918750|NCT01659099|Experimental|GA101|GA101 - Chemotherapy (ACVBP or CHOP)
88918751|NCT01659099|Active Comparator|Rituximab|Rituximab - Chemotherapy (ACVBP or CHOP)
88918752|NCT01659112|Experimental|Stabilization Group|A core stabilization plus traditional upper extremity rehabilitation approach was performed.
88918753|NCT01659112|Active Comparator|Control Group|A traditional upper extremity rehabilitation-only approach was performed.
88918754|NCT01659164|Experimental|Group treatment (uncontrolled)|Psychological treatment in group for adults with ADHD (pilot) during 14 weeks with focus on decreasing disabilities due to the condition.
88918755|NCT01659177|Experimental|LY2140023 fasting|Single oral dose of 80 mg LY2140023 given in fasted state
88918756|NCT01659177|Experimental|LY2140023 + food|Single oral dose of 80 mg LY2140023 given after standardized high-fat breakfast
89436293|NCT04657432|Experimental|Dose 6|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 6 is 25 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
89436294|NCT04657432|Experimental|Dose 7|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 7 is 30 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
89436295|NCT04657432|Experimental|Dose 8|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 8 is 35 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
89436296|NCT04657432|Experimental|Dose 9|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 9 is 40 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
89436297|NCT04657432|Experimental|Dose 10|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 10 is 40 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
89436298|NCT04657432|Experimental|Study 2: 10 Active Doses|All participants will be assigned to 10 sessions (per treatment day) of accelerated rTMS for 5 treatment days. All doses are active and within established therapeutic levels of rTMS. Dose 10 is 50 active sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
89436299|NCT04654468|Experimental|Crovalimab|Participants will receive a loading series of crovalimab comprised of an intravenous (IV) dose on Day 1, followed by weekly crovalimab subcutaneous (SC) doses for 4 weeks on Week 1 Day 2, then on Weeks 2, 3, and 4. Maintenance SC dosing will begin at Week 5 and will continue Q4W (every 4 weeks) thereafter for a total of 24 weeks of study treatment. After 24 weeks of crovalimab treatment, participants who derive benefit from the drug may continue to receive crovalimab.
89436300|NCT04650581|Experimental|Ipatasertib + Fulvestrant|
89436301|NCT04650581|Placebo Comparator|Placebo|
89436302|NCT04649359|Experimental|Elranatamab (cohort A)|BCMA-CD3 bispecific antibody
89436303|NCT04649359|Experimental|Elranatamab (cohort B)|BCMA-CD3 bispecific antibody
88918757|NCT01659190|Experimental|Oiled-limestone liniment|the removal of the collecting bag is made with the Oiled-limestone liniment.
88918758|NCT01659190|No Intervention|without Oiled-limestone liniment|the removal of the collecting bag is made without any special precautions
88918759|NCT01659203|Experimental|Treatment Arm IMPT|IG-IMPT with SIB to the high risk margin
88918760|NCT01659203|Experimental|Treatment Arm IMRT|IG IMRT with SIB to the high risk margin
88918761|NCT01659216||patients improved by EPNS; follow-up|Ninety female UFS patients with ≥50% symptom improvement at the end of EPNS treatment (Jul. 2001 to Jun. 2005) were followed up by a telephone questionnaire for at least 5 years.
88918762|NCT01659229||PFC CR 150 total knee implant|Study group implant: PFC CR 150 Control group implant: PFC CR standard
88918763|NCT01659229||PFC CR Standard|study group implant: PFC CR 150 control group implant: PFC CR Standard
88918764|NCT01659242|Active Comparator|Methotrexate plus sulfasalazine|"ARM 1(Methotrexate(MTX) plus Sulfasalazine(SSZ))~SSZ:Oral form, 2g/day, with escalation regime starting from 1g/day for the first week and increase to 1.5g/day in the next week and increasing to 2g/day by the third week. Total treatment period is 16 weeks. After reaching 2g/day, if patients conditions warrants (and no contraindication), SSZ may be increased at 0.5g per clinic visit) up to a maximum of 3g/day.~MTX:Kept at the highest optimal dose."
88918765|NCT01659242|Active Comparator|Leflunomide|"ARM 2:Leflunomide(LEF)~LEF: Oral form, 20mg every other day for first 2 weeks then increasing to 20mg per day by the third week. Total treatment period is 16 weeks.~Methotrexate:Off"
89436304|NCT04649229|Experimental|placebo, aprepitant, placebo, aprepitant|After a 48-hr washout, participants in this arm will be given LCZ696 50 mg and placebo (vehicle). After a 96-hr washout period, subjects will be given LCZ696 50 mg and aprepitant. Participants will then undergo uptitration of LCZ696 over seven weeks. On the 7th and 10th days of the 200 mg bid or highest tolerated dose of LCZ696, participants in this arm will receive placebo and aprepitant, respectively.
89436305|NCT04649229|Experimental|placebo, aprepitant, aprepitant, placebo|After a 48-hr washout, participants in this arm will be given LCZ696 50 mg and placebo (vehicle). After a 96-hr washout period, subjects will be given LCZ696 50 mg and aprepitant. Participants will then undergo uptitration of LCZ696 over seven weeks. On the 7th and 10th days of the 200 mg bid or highest tolerated dose of LCZ696, participants in this arm will receive aprepitant and placebo, respectively.
88918766|NCT01659281|Active Comparator|1|2-day oral treatment with: Artesunate 6mg/kg at 0 and 24 hours Mefloquine 25 mg/kg total dose split into 2 doses of 15 mg/kg at 0 hours and and 10 mg/kg given 6-24 hours later Primaquine 0.5 mg/kg single dose at 24 hours
88918767|NCT01659281|Active Comparator|2|3 days oral treatment with: Artesunate 4 mg/kg/day for 3 days Mefloquine 8 mg/kg/day for 3 days Primaquine 0.5 mg/kg single dose at 24 hours
88918768|NCT01659294|Experimental|nurse case management|nurse case management of diabetic variables
88918769|NCT01659294|Active Comparator|standard diabetologist care|standard diabetologist care
88918770|NCT01659333||Peritoneal dialysis, hypervolemia|All calculations are automatically performed by the software of the BCM device. Absolute over hydration (OH) is the difference between the expected patient's ECW under normal physiological conditions and the actual ECW, whereas the relative over hydration (Rel. OH) is defined as the OH to ECW ratio. Normohydration is defined when OH is between the 10th and the 90th percentile for healthy, age- and gender-matched individuals from the reference population, i.e., between 10th percentile (-1.1 L) to 90th percentile (+1.1 L), while volumes below and above this range define underhydration and overhydration, respectively.
89010520|NCT04539535|Experimental|Typically infants|We did the General Movements Assessment on standard mattress and experimental mattress in typically infants on the same day.
89198543|NCT03588286|Experimental|Intervention Arm (Early EPS)|"The intervention group all undergo electrophysiologic study early after myocardial infarction (within 40 days of MI).~If the study is positive (inducible monomorphic ventricular tachycardia of cycle length greater than or equal to 200ms) participants have an ICD implanted. Participants with a negative study (no inducible arrhythmia or induced ventricular fibrillation/ ventricular flutter cycle length <200ms) are discharged without an ICD.~A proportion of trial patients from both the intervention and control arms at >48 hours following revascularisation for STEMI will undergo CMR to enable correlation with (1) inducible VT at EPS and (2) SCD and non-fatal arrhythmia on follow up. CMR will simultaneously assess left ventricular function, ventricular strain, myocardial infarction size, and peri-infarction injury."
89198544|NCT03588286|Active Comparator|Control Arm (Standard Care)|"The control group receive ongoing standard care according to the practise of their institution. This includes discharge from hospital as per their treating physician and follow up as usual in the community. Participants in this group would be eligible to receive an ICD according to the standard practise of their cardiologist (guideline recommendations are after 40 days following myocardial infarction or 90 days following revascularisation only in patients with left ventricular ejection fraction less than or equal to 30% or less than or equal to 35% in the presence of heart failure).~A proportion of trial patients from both the intervention and control arms at >48 hours following revascularisation for STEMI will undergo CMR to enable correlation with (1) inducible VT at EPS and (2) SCD and non-fatal arrhythmia on follow up. CMR will simultaneously assess left ventricular function, ventricular strain, myocardial infarction size, and peri-infarction injury."
89198545|NCT00876291|Placebo Comparator|Placebo|placebo which consisted of capsules identical in taste and appearance to the active study product except for the absence of freeze-dried LGG (and cryoprotectants)
88918771|NCT01659333||Peritoneal dialysis, normovolemia|All calculations are automatically performed by the software of the BCM device. Absolute over hydration (OH) is the difference between the expected patient's ECW under normal physiological conditions and the actual ECW, whereas the relative over hydration (Rel. OH) is defined as the OH to ECW ratio. Normohydration is defined when OH is between the 10th and the 90th percentile for healthy, age- and gender-matched individuals from the reference population, i.e., between 10th percentile (-1.1 L) to 90th percentile (+1.1 L), while volumes below and above this range define underhydration and overhydration, respectively.
88918772|NCT01659346|Experimental|Endoscopic Variceal Ligation|Endoscopic Variceal Ligation every 3 weeks till eradication
88918773|NCT01659346|Active Comparator|Carvedilol|Carvedilol 3.125mg BD increased after 1 week to reach 6.25mg BD
88918774|NCT01659359|Experimental|virtual reality glasses and Lidocaine|virtual reality glasses and 5 ml Lidocaine 2%
88918775|NCT01659359|Experimental|Lidocaine|5 cc Lidocaine2%
89436306|NCT04649229|Experimental|aprepitant, placebo, placebo, aprepitant|After a 48-hr washout, participants in this arm will be given LCZ696 50 mg and aprepitant. After a 96-hr washout period, subjects will be given LCZ696 50 mg and placebo. Participants will then undergo uptitration of LCZ696 over seven weeks. On the 7th and 10th days of the 200 mg bid or highest tolerated dose of LCZ696, participants in this arm will receive placebo and aprepitant, respectively.
89198546|NCT00876291|Active Comparator|Probiotic|LGG capsules: each cp containing 3 × 109 colony forming units, CFU
89198547|NCT03563482|Experimental|Experimental|Biopsy and PET scan
89436307|NCT04649229|Experimental|aprepitant, placebo, aprepitant, placebo|After a 48-hr washout, participants in this arm will be given LCZ696 50 mg and aprepitant. After a 96-hr washout period, subjects will be given LCZ696 50 mg and placebo. Participants will then undergo uptitration of LCZ696 over seven weeks. On the 7th and 10th days of the 200 mg bid or highest tolerated dose of LCZ696, participants in this arm will receive aprepitant and placebo, respectively.
89436308|NCT04640142|Experimental|Newnorm|Newnorm is a 20% human normal immunoglobulin for SC infusion
89436309|NCT04633239|Experimental|Treatment (abemaciclib, olaparib, biospecimen collection)|Patients receive olaparib PO BID on days 1-28 and abemaciclib PO BID on days 8-28 of cycle 1 and days 1-28 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood and undergo tumor biopsy on study.
89436310|NCT04628494|Experimental|Epcoritamab (GEN3013; DuoBody®CD3xCD20)|Epcoritamab will be administered in Cycles of 28 days until any of the discontinuation criteria is met
89436311|NCT04628494|Active Comparator|Investigator's choice of chemotherapy|"R-GemOx will be administrated in Cycles of 28 days until maximum cycles completion or any of the discontinuation criteria is met~BR will be administrated in Cycles of 21 days until maximum cycles completion or any of the discontinuation criteria is met"
89436312|NCT04625413|Experimental|Experimental: Experimental Arm: single|The UR-GOAL tool will incorporate conjoint analysis to elicit patient preferences as well as assessments of fitness and prognostic awareness.
89436313|NCT04624230|Experimental|tofacitinib|Open label tofacitinib 5 mg BID weight based adult equivalent with the option for individual dose increase to 10 mg BID weight based adult equivalent for a limited time if dose escalation criteria are met, prior to returning to 5 mg BID.
89436314|NCT04623541|Experimental|Epcoritamab in R/R CLL/SLL|In both study phases. Participants in the expansion phase will be treated at the RP2D defined in the dose-escalation phase.
88918776|NCT01659372|Experimental|Low level laser therapy|this arm recieves low level laser therapy treatment for 12 sessions.
88918777|NCT01659372|Experimental|naproxen|this arm takes naproxen 500 mg twice daily for 3weeks
88918778|NCT01659398|Experimental|Enhanced external counterpulsation (EECP)|
88918779|NCT01659398|No Intervention|Subjects not receiving EECP|Control group to measure data from experimental group against.
88918780|NCT01659411||Adult CHD Patients|observational
88918781|NCT01659424|Other|Single Arm|This is a single arm study.
88918782|NCT01659437|Active Comparator|SR8|Streptomycin (S: 15 mg/kg per day, intramuscularly) in combination with rifampicin (R: 10 mg/kg per day, orally) for 8 weeks
88918783|NCT01659437|Experimental|CR8|Clarithromycin (C: 15 mg/kg per day, oral extended release formulation) in combination with rifampicin (10 mg/kg per day, orally) for 8 weeks
88918784|NCT01659450|Experimental|Low energy dense|Diet of the LED group contained 30%fat, 15% protein and 55% carbohydrate. Most of the consumed carbohydrates in the LED diet group were fruits, vegetables and whole grains. In addition, this group received more servings of vegetables groups daily in the form of liquid diets or some menus contain more vegetables
88918785|NCT01659450|Experimental|control|In the group with a control diet, 35% of the energy was provided by fat, 15% by protein and 50% by carbohydrate
88918786|NCT01659463|Experimental|ICON - low viscosity resin|APPLICATION OF A LOW VISCOSITY RESIN IN EARLY PROXIMAL CARIES LESIONS
88918787|NCT01659463|Active Comparator|INSTRUCTIONS ORAL HYGIENE|INSTRUCTION ORAL HYGIENE AND DIET AND TOOPICAL FLUORIDE APPLICATIONS
88918788|NCT01659476|Experimental|Asthma|Individuals diagnosed with asthma.
88918789|NCT01659476|Experimental|Cough Variant Asthma|Individuals diagnosed with cough variant asthma.
88918790|NCT01659476|Experimental|Mch-induced cough w/normal airway sensitivity|Individuals with chronic cough normal PC20 MCh(>16 mg/mL) & who cough during Mch challenge testing.
88918791|NCT01659476|Experimental|Normal|Individuals with no history of asthma or chronic cough
89198548|NCT00870909|Active Comparator|active tDCS|"tDCS active; - Intensity = 2 milliamps (mA) during 20 minutes. ramp up/ramp down 30sec anodal tDCS applied over the left DLPFC combined with cathodal tDCS applied over the left temporoparietal junction (TPJ).~10 sessions, 2 per day"
89436315|NCT04623541|Experimental|Epcoritamab in RS|Only in expansion phase.
88918792|NCT01659489||women undergoing laproscopy fo rsuspected adnexal torsion|
88918793|NCT01659502|Experimental|TL-118 alone or with pancreas cancer chemotherapy|
88918794|NCT01659580|Experimental|T89 high dose|T89 225mg bid
88918795|NCT01659580|Experimental|T89 low dose|T89 150mg bid
88918796|NCT01659580|Experimental|Sanqi+Bingpian|225mg bid
88918797|NCT01659580|Placebo Comparator|Placebo|225mg bid
88918798|NCT01659593|Experimental|procog|cognitive remedial program 13 sessions over a 6-month period
88918799|NCT01659593|Placebo Comparator|DISINT|Interactive discussion program of 13 group sessions in a 6-month period
88918800|NCT01659619|Experimental|erythromycin|
88918801|NCT01659619|No Intervention|saline|
88918802|NCT01659645|Experimental|FACBC|
88918803|NCT01659671|Active Comparator|Uvulopalatopharyngoplasty|One arm is Uvulopalatopharyngoplasty(intervention group of 32 patients), one arm is expectancy (control group of 33 patients). After six months the controls have delayed surgery and then both groups are followed for two years
88918804|NCT01659671|Active Comparator|Control|After six months the controls have delayed surgery then are followed for 2 year
88918805|NCT01659684|Experimental|standard intravenous immunoglobulin|Single arm evaluation of neurological consequences of congenital CMV infection in comparison with historical untreated controls.
88918806|NCT01659697||Intensive Lifestyle counseling|
88918807|NCT01659697||usual lifestyle counseling|
88918808|NCT01659710||Study Babies|Study video at 50-55 weeks gestational age, motor assessments at 24m (+/- 6 months) and again at 4 years (+/- 1 year).
88918809|NCT01659710||Control Babies|Video at 50-55 weeks gestational age, motor assessment at 24 months (+/- 6 months).
88918810|NCT01659723|Active Comparator|A - Immediate start|Start of treatment within 6 weeks of inclusion in the study. 100% oxygen at 240-250 kPa will be delivered to the patents for 80-90 minutes while sitting or lying in a hyperbaric oxygen chamber. Patients will receive treatment once every day, except week-ends, for 40 days.
89198549|NCT00870909|Placebo Comparator|sham tDCS|tDCS placebo same electrode montage than in the active group. 30 sec of active tDCS in the beginning of the stimulation sessions; ramp up/ramp down 30 sec
89198550|NCT04039815|Experimental|ABC group (Ascorbic acid-Vitamin B1-Hydrocortisone) group|"patients in study group, so called ABC (Ascorbic acid-Vitamin B1-Hydrocortisone) group, would receive intravenous Thiamine (200mg in 50 mL of 0.9% normal saline and was administered as a 30-min infusion every 12 hours for 4 days or until ICU discharge), Vitamin C (1.5g mixed in a 100-mL solution of normal saline and was administered as an infusion over 30 to 60 min every 6 hours for four days or until ICU discharge) as well as hydrocortisone 50mg every 6 hours (or other equivalent products) for 7 days"
89536462|NCT03069651|Active Comparator|Virtual Care|"Subjects randomly allocated to receive 'virtual care' will be shown how to use the oximeter and spirometer, as well as the videoconferencing software.~'Virtual care' subjects will be asked to perform a lung function test (using the spirometer) and record their oxygen saturations (using the oximeter) twice weekly during the videoconference with the CF team."
89536463|NCT03069651|Placebo Comparator|Routine Care|Usual clinical care.
89536464|NCT03109223|Active Comparator|Commercially availabel infant formula|
89536465|NCT03109223|Experimental|Test formula with 2-FL|
88918811|NCT01659723|No Intervention|B - delayed start|Delayed start: Start of treatment not before 6 months of inclusion in the study. No intervention is given during the initial period.
88918812|NCT01659762|Experimental|autologous mesenchymal stromal cells|
88918813|NCT01659788|Experimental|Coenzyme Q10 concomitant treatment|"Coenzyme Q10 concomitant treatment to fertility drugs as part of an IVF treatment~Dose: 600 mg by mouth daily beginning 3 months prior to IVF cycle. Patient will stop taking the CoEnzyme Q10 if conceives or when the study is completed.~Other name: Ubiquinone"
88918814|NCT01659788|Placebo Comparator|Placebo|1 capsule by mouth daily beginning 3 months prior to IVF cycle. Patient will stop taking the placebo when she conceives or when the study is completed.
88918815|NCT01659814||Individuals with Major Depressive Disorder|
88918816|NCT01659814||Healthy Control Individuals|
88918817|NCT01659827|Sham Comparator|Control|Initial injections of Marcaine and Saline (one each)
88918818|NCT01659827|Experimental|0.5cc AmnioFix Injectable|Initial injections of Marcaine and 0.5cc AmnioFix (one each)
88918819|NCT01659827|Experimental|1.25cc AmnioFix Injectable|Initial injections of Marcaine and 1.25cc AmnioFix (one each)
88918820|NCT01659840|Other|Red laser|On the pain points of muscle, laser was applied (8J/cm ²) with an interval of 48 hours between applications. In the joints with sensitivity, a dose of 4J/cm2 laser was applied with an interval of 48 hours between applications.
88918821|NCT01659840|Other|Infrared laser|On the pain points of muscle, laser was applied (8J/cm ²) with an interval of 48 hours between applications. In the joints with sensitivity, a dose of 4J/cm2 laser was applied with an interval of 48 hours between applications.
88918822|NCT01659892|Active Comparator|Montelukast|5 mg Chewable Tablet
88918823|NCT01659892|Active Comparator|Singulair|5 mg Chewable Tablet
88918824|NCT01659905|Active Comparator|Montelukast|5 mg Chewable Tablet
88918825|NCT01659905|Active Comparator|Singulair|5 mg Chewable Tablet
88918826|NCT01659918|Active Comparator|Montelukast|10 mg Tablet
88918827|NCT01659918|Active Comparator|Singulair|10 mg Tablet
88918828|NCT01659931|Active Comparator|Montelukast|10 mg Tablet
88918829|NCT01659931|Active Comparator|Singulair|10 mg Tablet
88918830|NCT01659944|Experimental|Metoprolol alone then eliglustat + metoprolol|In Period 1 all participants will receive a single oral dose of metoprolol 50 mg on Day 1. In Period 2, participants will receive repeat oral doses of eliglustat 150 mg twice a day from Day 3 to Day 8 and a single oral dose of metoprolol 50 mg on Day 7.
88918831|NCT01659957|Experimental|Group Couples Couseling|Patients randomized to this arm will receive group couples counseling plus 12-step oriented alcoholism counseling.
88918832|NCT01659957|Experimental|One-on-One Couples Couseling|Patients randomized to this arm will receive one-on-one couples counseling plus 12-step oriented alcoholism counseling.
88918833|NCT01659970||Cohort|
88918834|NCT01659983|Experimental|Primary wound closure|A wound will be sutured immediately after the operative procedure uisng non-absorbable monofilament suture or stapler at intervals of one centimeter apart and 0.5 cm back from a wound edge.
88918835|NCT01659983|Active Comparator|Delayed primary wound closure|A wound will be left open with saline-soaked gauze packing after the operative procedure and will be sutured around day 3 to 7 after operation
88918836|NCT01660009|Experimental|Hypoglycemia First|Individuals will undergo a hyperinsulinemic hypoglycemic clamp in their 1st study visit after passing screening, and a euglycemic clamp in their second visit.
88918837|NCT01660009|Experimental|Euglycemia First|Individuals will undergo a hyperinsulinemic euglycemic clamp in their 1st study visit after passing screening, and a euglycemic clamp in their second visit.
88918838|NCT01660048|Experimental|SILS TEP repair|Half of the patients will undergo laparoscopic total extraperitoneal inguinal hernia repair using a single port (Triport)
88918839|NCT01660048|Active Comparator|Multiports TEP repair|Half of the patients will undergo the conventional multiports total extraperitoneal inguinal hernia repair
88918840|NCT01660061||APS patients|Patients with antiphospholipid syndrome requiring long-term anticoagulant therapy with vitamin-K antagonists
88918841|NCT01660061||Controls|Patients without antiphospholipid antibodies requiring anticoagulant therapy with vitamin-K antagonists
88918842|NCT01660074|Experimental|Test food, reference food|Test food group of subject need to comsume 50g available carbohydrate of test food. One test food for one ocassion. Reference food need to comsume same 50g available carbohydrate of reference food, usually white bread or glucose syrup.
88918843|NCT01659775|Experimental|Sancuso patch|
88918844|NCT01659775|Active Comparator|Zofran|
88918845|NCT01660100|Active Comparator|Pulmonary vein antrum isolation (PVAI)|Pulmonary vein antrum isolation (PVAI)
89536466|NCT03109223|Active Comparator|Breast Fed|
89536467|NCT03069885|Active Comparator|Standard postoperative dressing group|30 patients treated with conventional post-operative dressing.
89536468|NCT03069885|Experimental|Prevena group|30 patients treated with PrevenaTM (incisional negative pressure wound therapy)
89198551|NCT04039815|Placebo Comparator|normal saline group|patients would receive 50mL 0.9% normal saline, 100 mL 0.9% normal saline with the same infusion rate and hydrocortisone dependent on the discretion of the attending physician
89198552|NCT00870987|Experimental|1|DNA vaccine prime Given at 0, 4, and 8 weeks
89436316|NCT04623541|Experimental|Epcoritamab + Venetoclax in R/R CLL/SLL|In both study phases. Participants in the expansion phase will be treated at the RP2D defined in the dose-escalation phase.
89436317|NCT04623541|Experimental|Epcoritamab + Lenalidomide in RS|Only in expansion phase.
89436318|NCT04623541|Experimental|Epcoritamab + R-CHOP in RS|Only in expansion phase.
89436319|NCT04609566|Experimental|Combination Therapy|brentuximab vedotin + pembrolizumab
89198553|NCT00870987|Experimental|2|adenovirus type 5 vaccine boost Given at 24 weeks
89198554|NCT03951766|Other|Smiling Instead of Smoking App|This is a pilot study; all participants will use the app in the same manner/time period.
89436320|NCT04603625|Experimental|sitting position centering femoral heads|sitting position centering femoral heads according to Lespargot diagram
89436321|NCT04603625|Active Comparator|Usual postural management|sitting with the trunk aligned and hips abducted to facilitate activities of daily living
89436322|NCT04585984|Placebo Comparator|Control|140 men will be taking a placebo once a day during 21 days prior to the start of the IVF/ICSI cycle.
88918846|NCT01660100|Active Comparator|PVAI plus left atrial posterior wall (LAPW) isolation|PVAI plus left atrial posterior wall (LAPW) isolation
89436323|NCT04585984|Experimental|Experimental|140 men will be taking the probiotic compound (50% of each probiotic: Lactobacillus rhamnosus and Bifidobacterium longum at a dose of 10^9 cfu/day) once a day for 21 days prior to the start of the IVF/ICSI cycle.
89436324|NCT04585789|Experimental|Panel 1: JNJ-73763989+ NA|Ongoing and new participants will receive JNJ-73763989 subcutaneous (SC) injection once every 4 weeks (last injection at Week 44) and nucleos(t)ide analog (NA) treatment (either entecavir [ETV], tenofovir disoproxil or tenofovir alafenamide [TAF] tablets) once daily up to 48 weeks. Participants may receive optional treatment with pegylated interferon alpha-2a (PegIFN-alpha-2a) after the Week 40 for a duration of either 12 or 24 weeks at the investigator's discretion. As per amendment-5, JNJ-56136379 is no longer included as part of the study intervention and all participants are counted as single arm in each panel.
89436325|NCT04585789|Experimental|Panel 2: JNJ-73763989+ NA|Ongoing and new participants will receive JNJ-73763989 SC injection once every 4 weeks (last injection at Week 44) and NA treatment (ETV, tenofovir disoproxil or TAF tablets) once daily up to 48 weeks. Participants may receive optional treatment with PegIFN-alpha-2a after the Week 40 for a duration of either 12 or 24 weeks at the investigator's discretion. As per amendment-5, JNJ-56136379 is no longer included as part of the study intervention and all participants are counted as single arm in each panel.
89436326|NCT04574440||multichannel fNIRS monitoring|Patients who will be enrolled in this study will be monitored during cardiac surgery using multichannel fNIRS monitoring. This consists of wearing the NIRS cap during surgery. The patient's surgery and subsequent medical care will not be altered.
89436327|NCT04573023|Experimental|JR-141 2.0 mg/kg/week|
89436328|NCT04573023|Other|administered as the standard of care: idursulfase (ELAPRASE®)|standard of care-controlled study
89436329|NCT04573023|Other|Rescue arm|
89436330|NCT04565626|Experimental|Intervention|Participants will receive additional exercise by independent use of a peddle bike on the weekends. This is in addition to their usual physiotherapy
89436331|NCT04565626|No Intervention|Control|This arm will receive usual physiotherapy
89436332|NCT04555577|Experimental|Stage I (Peposertib, Radiation therapy, Temozolomide)|"CONCURRENT: Patients undergo standard of care radiation therapy daily (Monday-Friday) for 30 fractions. Patients also receive Peposertib PO on each day of radiation therapy and given 1-2 hours before each treatment fraction. Treatment continues for 6 weeks in the absence of disease progression or unacceptable toxicity.~ADJUVANT: Patients receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity."
89436333|NCT04555577|Experimental|Stage II (Peposertib, Radiation, Temozolomide, Surgery)|"CONCURRENT: Patients receive Peposertib and undergo standard of care radiation therapy as in Stage I. Within 1-14 days after the completion of radiation therapy, patients undergo surgical resection.~ADJUVANT: Patients receive temozolomide as in Stage I."
89436334|NCT04552327|Experimental|Solcera|
89436335|NCT04552327|Placebo Comparator|Placebo|
89436336|NCT04552327|Active Comparator|Solaraze|
88918847|NCT01660126|Active Comparator|Levothyroxine|Oral Levothyroxine, starting dose 25 or 50 micrograms increased to a maximum of 150 micrograms once daily.
88918848|NCT01660126|Placebo Comparator|Placebo|Matched placebo
88918849|NCT01660139||Dermatology Clinic Patients|Patient attending dermatology clinics
88918850|NCT01660139||Primary Clinic Patients|Patient attending primary care clinics
89436337|NCT04549116|Experimental|Investigational|Progesterone-IBSA 25mg, twice daily (BID) subcutaneous (SC) injection every 12 hours and Crinone Placebo, once daily (QD) intravaginally.
89436338|NCT04549116|Active Comparator|Comparator|Crinone 8%, 90 mg, QD intravaginally and Progesterone-IBSA Placebo, BID SC Injection every 12 hours
89436339|NCT04542824|Experimental|arm 1: epcoritamab|In subjects with DLBCL/FL
89436340|NCT04542824|Experimental|arm 2: epcoritamab + rituximab + lenalidomide|In subjects with relapsed/refractory FL
89436341|NCT04542824|Experimental|arm 3: epcoritamab + rituximab + cyclophosphamide+ doxorubicin+ vincristine + prednisone|In subjects with previously untreated DLBCL
89536469|NCT02475941|Experimental|Early Weight Bearing|Surgeon based prospective cohort supported in the literature to answer research questions in which surgeons have a preferred treatment type. Early weight bearing are those who are permitted in the post operative instructions to be Weight Bear as tolerated after fracture fixation.
88918851|NCT01660152|Experimental|Group A (vacuum therapy, holding erection for 2 minutes)|Patients receive daily vacuum therapy over 10 minutes while holding erection for 2 minutes after undergoing RALP. Patients complete erection process 5 times. SHIM questionnaire administration will be completed prior to surgery and at 3, 6, 12 months and the compliance questionnaire at 3, 6, 12 months.
88918852|NCT01660152|Experimental|Group B (vacuum therapy, holding erection for 5 minutes)|Patients receive daily vacuum therapy over 10 minutes while holding erection for 5 minutes after undergoing RALP. Patients complete erection process 2 times.Patients complete erection process 5 times. SHIM questionnaire administration will be completed prior to surgery and at 3, 6, 12 months and the compliance questionnaire at 3, 6, 12 months.
89436342|NCT04542824|Experimental|arm 4: epcoritamab + gemcitabine + oxaliplatin|In subjects with relapsed/refractory DLBCL
89436343|NCT04542824|Experimental|arm 5: epcoritamab maintenance|In subjects with FL in complete response (CR) or in partial response (PR) following first line or second line SOC treatment
89436344|NCT04542317|Experimental|REACH VN|A multi-component behavioral intervention to support family caregivers of persons with dementia. Participants will receive 4-6 sessions in-person or by phone over the course of 2-3 months.
89436345|NCT04542317|Placebo Comparator|Enhanced control|A single session focused on education about the nature of dementia.
89436346|NCT04540939|Experimental|Mindfulness-Based Cognitive Therapy (MBCT)|"MBCT is a mindfulness-based intervention group intervention involving in session and at home practicve of mindfulness meditation and other mindfulness practices. There are8 sessions each with a specific theme and and these are ~2 hours long. Over the 8-weeks participants will learn several mindfulness meditation techniques. Each session will involve group discussion and feedback. Participants will be asked to practice these techniques at home, and keep a log of mood, and stress ratings.~Audio files with exercises will be given to participants so that they can practice at home between sessions."
88918853|NCT01660165||Observational|Pregnant women
88918854|NCT01660204|Active Comparator|Betalactam monotherapy|Preferred empirical treatment for patients in this arm is Beta-lactam monotherapy e.g. co-amoxiclav or ceftriaxone
88918855|NCT01660204|Active Comparator|Betalactam combination with macrolide|Preferred empirical treatment for patients in this arm is beta-lactam combination therapy with a macrolide e.g. ceftriaxone and erythromycin
88918856|NCT01660204|Active Comparator|Quinolone monotherapy|Preferred empirical treatment for patients in this arm is quinolone monotherapy e.g. moxifloxacin or levofloxacin
88918857|NCT01660217|Experimental|Initial Verbal Instruction Group|"The group who initially received only verbal instruction, and then later (in the crossover portion) received a written Eczema Action Plan (EAP)"
88918858|NCT01660217|Experimental|Written Eczema Action Plan (EAP)|The group given a written EAP after verbal instruction
88918859|NCT01660295|Experimental|Certoparin control|Participants receive Certoparin 3,000 IU during period 1. Participants will receive 8,000 IU during period 2, if qualified as per medical criteria.
88918860|NCT01660295|Experimental|Certoparin Renal|"Participants receive dose escalation upon medical criteria qualification at each period:~Certoparin 3,000 IU once a day during period 1. Certoparin 3,000 IU twice a day during period 2. Certoparin 8,000 IU once a day during period 3. Certoparin 8,000 IU in the morning and 3,000 IU in the evening during period 4 OR Certoparin 8,000 IU twice a day during period 4."
88918861|NCT01660308||Tumor induced osteomalcia|
88918862|NCT01660347|Experimental|Supportive care (allogeneic PBSCT boost)|Patients undergo allogeneic PBSCT boost from cells selected for CD34+ using the CliniMACS CD34 Reagent System.
88918863|NCT01660360|Experimental|Tanibirumab|The total dose of Tanibirumab for each patient will depend on dose level assignment and the patient's weight. Dose levels to be potentially tested in Phase I include: 1 mg/kg, 2 mg/kg, 4 mg/kg, 8 mg/kg, 12 mg/kg, 16 mg/kg, and 20 mg/kg.
88918864|NCT01660373|Experimental|Ticagrelor|loading dose(180mg) followed by maintenance dose(90mg bid)
88918865|NCT01660373|Active Comparator|Tirofiban|0.4ug/kg/min for 30min followed by 0.1ug/kg/min
88918866|NCT01660386|Experimental|Sitagliptin|the subjects are asked to take one pill of sitagliptin(100mg po once) in 7am of experimental day then start bi-phase hyperglycaemic clamp at 9am.
88918867|NCT01660386|Experimental|Saxagliptin|the subjects are asked to take one pill of saxagliptin(5mg po once) in 7am of experimental day then start bi-phase hyperglycaemic clamp at 9am.
88918868|NCT01660386|Experimental|Glimepiride|the subjects are asked to take one pill of glimepiride(2mg po once) in 7am of experimental day then start bi-phase hyperglycaemic clamp at 9am.
88918869|NCT01660386|Other|Blank control|the subjects take no medication at experimental day and start bi-phase hyperglycaemic clamp at 9am.
88918870|NCT01660399|Experimental|Docetaxel/Boanmycin|Docetaxel 75mg/m2, intravenous infusion, day 1; Boanmycin 5-6 mg/m2 + DXM 5mg IVD or IM, day 3,5,10,12, 21days a cycle.
88918871|NCT01660399|Placebo Comparator|Docetaxel|Docetaxel 75mg/m2, intravenous infusion, day 1, 21days a cycle.
88918872|NCT01660425|No Intervention|treatment as usual with MPH|In the first twelve months of intervention the children receive treatment as usual with MPH and do not get any further intervention. Afterwards, the families get the opportunity to take part in the program which is then conducted for a duration of four months. Measurements are performed at the beginning of the program, after six moths, after 12 months and additionally after 16 months.
88918873|NCT01660425|Active Comparator|Psychosocial intervention|Parenting Enhancement Training as a form of psychosocial intervention is a guided program. Parents get the opportunity to discuss written information with a therapist in 20 minutes telephone calls. 14 telephone calls are offered. The whole intervention lasts for a period of one year. Booklets are mailed via post within the first 4 months. First 9 telephone calls are also within the first 4 months, usually every two weeks. Telephone calls 10 and 11 are within 5th or 6th month, telephone calls 12 to 14 are within 7th to 12th month with a two monthly time period in between.
89436347|NCT04540939|Active Comparator|Muscle Relaxation Therapy|"PMR is a relaxation-based group intervention similar to other relaxation interventions commonly used for anxiety and PTSD. It involves in session and at home practicve of relaxation techniques including tensing and relaxing muscle groups, but no specifici mindfulness or meta-cogntive awaremess instructions. This PMR group has been designed as an active comparator with similar stucture to MBCT, but without mindfulness instruction. There are 8 sessions each with a specific theme and these are ~2 hours long. Over the 8-weeks participants will learn several relaxation techniques. Each session will involve group discussion and feedback. Participants will be asked to practice these techniques at home, and keep a log of mood, and stress ratings.~Audio files with exercises will be given to participants so that they can practice at home between sessions."
88918874|NCT01660438||Stress urinary incontinence|Stress urinary incontinence
88918875|NCT01660464|Experimental|ADHD-Team|Intervention
88918876|NCT01660477|Experimental|Arm 1: isavuconazole only|Isavuconazole three times per day (TID) on Days 1-2, and once daily (QD) on Days 3 thru 13
88918877|NCT01660477|Experimental|Arm 2 : LPV/RTV only|Lopinavir/ritonavir (LPV/RTV) twice daily (BID) on Days 1-12 and once on Day 13
88918878|NCT01660477|Experimental|Arm 3: isavuconazole and LPV/RTV|Isavuconazole three times per day (TID) on Days 1-2, and once daily (QD) on Days 3 thru 13 in combination with lopinavir/ritonavir twice daily (BID) on Days 1-13
88918879|NCT01660490||Proximal femur fractures with ORIF|Proximal femur fractures treated with ORIF
88918880|NCT01660503|Placebo Comparator|No SCF|Twice daily consumption of snack foods containing no SCF.
88918881|NCT01660503|Experimental|10 grams SCF|Twice daily consumption of snack foods, each containing 5 grams SCF
88918882|NCT01660503|Experimental|20 grams SCF|Twice daily consumption of snack foods, each containing 10 grams SCF
88918883|NCT01660516||Tea|Black tea ingestion
88918884|NCT01660529|Experimental|hTERT/Survivin Multi-Peptide Vaccination|single-arm Phase I study for patients with metastatic breast cancer who have failed at least one regimen for metastatic disease
88918885|NCT01660542|Experimental|doxorubicin/cyclophosphamide|Neoadjuvant Chemotherapy with Docetaxel(Monotaxel®) after Doxorubicin plus Cyclophosphamide
88918886|NCT01660555||Patiënts scheduled for colonoscopy|Ill prepared colon during index colonoscopy or sigmoidoscopy: Boston scale <3
88918887|NCT01660568||relapsed or refractory NK/T cell lymphoma with gemcitabine|
89198555|NCT00876603||1|
89198556|NCT00876603||2|
89198557|NCT00876603||CSM - ACDF|Cervical spondylotic myelopathy treated with anterior cervical decompression and fusion
89198558|NCT00876603||CSM - Cervical laminoplasty|Cervical spondylotic myelopathy treated with cervical laminoplasty
88918888|NCT01660581|Experimental|CD133+|intramyocardial injection (electromechanical mapping based) of autological CD133+ cells, isolated from bone marrow
88918889|NCT01660581|Placebo Comparator|Placebo|intramyocardial injection (electromechanical mapping based) of placebo - 0,9% NaCl plus 0,5% solution of patients' serum
88918890|NCT01660594||Stable chest pain|All patients presenting with stable chest pain and referred by their general practitioners to the chest pain clinic in the hospital who had CT calcium scoring performed besides standard assessment.
89198559|NCT00371137|Placebo Comparator|1|
88918891|NCT01660620|Experimental|betaxolol|betaxolol 0.25% 2 per day for 3 weeks
88918892|NCT01660620|Placebo Comparator|placebo|masked labeling also 2 per day administration
88918893|NCT01660646|Other|Behavioral: community sensitization|Behavioral, enhanced case finding (ECF) by community sensitization via audiovisual presentation in local languages, a session for questions and answers and opportunity to provide sputum specimens for detection of TB
88918894|NCT01660646|No Intervention|control|
88918895|NCT01660659|Experimental|cooking with Biomass Briquettes and Rocket Stove|cooking with Biomass Briquettes and Rocket Stove
88918896|NCT01660659|No Intervention|standard cooking|standard way of cooking
88918897|NCT01660685|Experimental|Tracking + Journaling + Website|In addition to standard care, participants will complete daily tracking and journaling and receive weekly feedback based on their individual entries.
88918898|NCT01660685|Active Comparator|Enhanced Usual Care|Participants receive standard care
88918899|NCT01660750|Experimental|Carfilzomib, Cyclophosphamide, Dexamethasone|All eligible subjects will receive Carfilzomib, Cyclophosphamide, and Dexamethasone.
88918900|NCT01660776||DLBCL (diffuse large B-cell lymphoma)|DLBCL (diffuse large B-cell lymphoma)
88918901|NCT01660776||Hodgkin's lymphoma|Hodgkin's lymphoma
88918902|NCT01660776||metastatic breast cancer|metastatic breast cancer or with lymph node involvement
88918903|NCT01660776||immune thrombocytopenia (ITP)|immune thrombocytopenia (ITP)
89198560|NCT00371137|Experimental|2|
88918904|NCT01660776||healthy volunteers|healthy volunteers
88918905|NCT01660776||non-small cell lung cancer|non-small cell lung cancer
88918906|NCT01660789|Other|Lifestyle intervention|Lifestyle intervention.
88918907|NCT01660828|Active Comparator|Intensive cycling test preceded by RIPC|Intensive cycling test preceded by a RIPC protocol.
89198561|NCT01050283|Experimental|1|[18F]-FDG-PET/CT (Computed Tomography) Imaging
89198562|NCT00961870|Experimental|Healthy postmenopausal women|Forearm vibration will be applied in women without postmenopausal osteoporosis
89198563|NCT00961870|Experimental|Osteoporotic postmenopausal women|Forearm vibration will be applied in women with postmenopausal osteoporosis
89198564|NCT00961870|Experimental|Healthy young adult women|Forearm vibration will be applied in healthy young adult women
88918908|NCT01660828|No Intervention|No intervention/ RIPC|Intensive cycling test not preceded by a RIPC protocol.
88918909|NCT01660841|Experimental|Arm 1|
88918910|NCT01660854|Experimental|Heterologous challenge|"Biological: Heterologous challenge with 5 infected mosquito bites (NF135) after previous CPS immunization and challenge.~Drug: Malarone treatment When thick smear positive, of at day 21 after challenge, all volunteers will be treated with malarone.~Other Name: atovaquone/proguanil"
89436348|NCT04537416||Women with recurrent pregnancy loss|consecutive women at least 18 years old but not greater than 40 years old with a chief complaint of recurrent pregnancy loss
89436349|NCT04535128||COVID-19 Positive|Patients with positive COVID-19 PCR
89436350|NCT04529707|Experimental|Sleep Intervention|All participants will engage in a 10-week, parent mediated sleep intervention with weekly education sessions.
89436351|NCT04526730|Experimental|Neoadjuvant Treatment|"Neoadjuvant Phase: (3 x 4-week cycles, total 12 weeks): At every cycle, intratumoral tavo-EP will be administered (on Days 1 and 8) concurrently with 480 mg nivolumab IV infusion on Day 8 of each cycle (tavo-EP will be administered prior to nivolumab infusion).~Definitive Surgery Phase: Surgery may be scheduled about 2-4 weeks after the last dose of nivolumab following radiologic and clinical assessment at that point. Pathologic response will be determined by institutional pathologist.~Adjuvant Phase: Adjuvant therapy with nivolumab monotherapy will begin approximately 2-4 weeks following definitive surgery; recovery from surgery is required (Day 1 of Cycle 4 will be determined by the treating investigator once the subject is cleared to initiate systemic therapy). Nivolumab (480 mg IV infusion on Day 1 of each 4-week cycle) will be administered for up to 9 cycles during the Adjuvant phase."
88918911|NCT01660854|Active Comparator|Challenge control|"Biological: Plasmodium falciparum mosquito challenge by the bites of 5 Plasmodium falciparum infected mosquitoes (NF135).~Drug: Malarone treatment When thick smear positive, of at day 21 after challenge, all volunteers will be treated with malarone.~Other Name: atovaquone/proguanil"
89198565|NCT00961870|Experimental|Healthy young adult men|Forearm vibration will be applied in healthy young adult men
89436352|NCT04526106|Experimental|Part 1: Dose Escalation|Multiple doses of RLY-4008 for oral administration.
89436353|NCT04526106|Experimental|Part 2: Dose Expansion|Oral dose of RLY-4008 as determined during Part 1 Dose Escalation.
89436354|NCT04526106|Experimental|Part 3: Extension|Oral dose of RLY-4008 as determined during Part 1 Dose Escalation.
89436355|NCT04526002|Experimental|Concurrent TBS/fNIRS with iTBS and followed by cTBS after 1h|self-explanatory, see Arm Title
88918912|NCT01660867|Placebo Comparator|0.9% saline + oral placebo|nebulized epinephrine + 0.9% saline + placebo => epinephrine + 0.9% saline
88918913|NCT01660867|Experimental|3% saline + oral placebo|nebulized epinephrine + 3% saline + placebo => nebulized epinephrine + 3% saline
88918914|NCT01660867|Active Comparator|0.9% saline + oral dexamethasone|nebulized epinephrine + 0.9% saline + dexamethasone => nebulized epinephrine + 0.9% saline
88918915|NCT01660880||aripiprazole|Patient group who is treated with aripiprazole
88918916|NCT01660919|Placebo Comparator|placebo|placebo
88918917|NCT01660919|Active Comparator|rosuvastatin 5|rosuvastatin 5 mg
88918918|NCT01660919|Active Comparator|rosuvastatin 10|rosuvastatin 10 mg
88918919|NCT01660919|Active Comparator|rosuvastatin 20|rosuvastatin 20 mg
88918920|NCT01660932|Placebo Comparator|placebo|placebo
88918921|NCT01660932|Active Comparator|omega 1|omega 1 gm
88918922|NCT01660932|Active Comparator|omega 2|omega 2 gm
88918923|NCT01660932|Active Comparator|omega 4|omega 4 gm
88918924|NCT01660945|Placebo Comparator|placebo|placebo
88918925|NCT01660945|Active Comparator|vytorin 10|vytorin 10 mg
88918926|NCT01660945|Active Comparator|vytorin 20|vytorin 20 mg
88918927|NCT01660958|Experimental|Infants: MNP|• Infants will receive sachets of multiple micronutrient powder (MNP) vs. placebo.
88918928|NCT01660958|Experimental|Infants: Early Learning|• Infant will receive early learning messages delivered in the home by village level workers vs. routine care.
88918929|NCT01660958|No Intervention|Infants: No intervention|"Placebo intervention include exposure to a single vitamin (B2 or riboflavin), plus the filler (maltodextrin).~Infant phase. Routine care - no early learning intervention"
88918930|NCT01660958|Experimental|Infants: MNP/Early Learning|"Infants receive the MNP plus early learning intervention by receiving MNP sachets~Caregivers receive early learning messaged delivered at home biweekly for one year"
88918931|NCT01660958|Experimental|Preschoolers:MNP/High qual preschool|"Preschoolers will receive MNP fortified food in their Anganwadi Centers at the mid-day meal.~Preschool quality will be assessed through observations using the Indian-modified ECERS and HOME Inventory for preschools. Using a median split, preschools will be classified as high/low quality. Using a randomization procedure, MNP vs. placebo will be assigned, nested within high/low-quality preschools.~Preschools that are classified as high quality preschools."
88918932|NCT01660958|No Intervention|Preschoolers:Placebo/High qual preschool|"Placebo intervention include exposure to a single vitamin (B2 or riboflavin), plus the filler (maltodextrin).~Preschool quality will be assessed through observations using the Indian-modified ECERS and HOME Inventory for preschools. Using a median split, preschools will be classified as high/low quality. Using a randomization procedure, MNP vs. placebo will be assigned, nested within high/low-quality preschools.~Preschools that are classified as high quality preschools."
88918933|NCT01660958|Experimental|Preschoolers:MNP/Low qual preschool|"Preschoolers will receive MNP fortified food in their Anganwadi Centers at the mid-day meal.~Preschool quality will be assessed through observations using the Indian-modified ECERS and HOME Inventory for preschools. Using a median split, preschools will be classified as high/low quality. Using a randomization procedure, MNP vs. placebo will be assigned, nested within high/low-quality preschools.~Preschools that are classified as low quality preschools."
88918934|NCT01660958|No Intervention|Preschoolers:Placebo/Low qual preschool|"Placebo intervention include exposure to a single vitamin (B2 or riboflavin), plus the filler (maltodextrin).~Preschool quality will be assessed through observations using the Indian-modified ECERS and HOME Inventory for preschools. Using a median split, preschools will be classified as high/low quality. Using a randomization procedure, MNP vs. placebo will be assigned, nested within high/low-quality preschools.~Preschools that are classified as low quality preschools."
88918935|NCT01661075||mTBI|These individuals will have had an mTBI during their respective collegiate athletic season.
88918936|NCT01661075||healthy controls|Recruitment of healthy controls who have not suffered an mTBI for balancing testing.
88918937|NCT01661101|Experimental|Dabigatran|Dabigatran 110 mg capsule taken twice daily
88918938|NCT01661101|Experimental|Omeprazole|Omeprazole 20 mg capsule taken once daily
88918939|NCT01661101|Placebo Comparator|Placebo (dabigatran)|Dabigatran placebo taken twice daily
88918940|NCT01661101|Placebo Comparator|Placebo (omeprazole)|Omeprazole placebo taken once daily
88918941|NCT01661153||Cohort|
89198566|NCT05175417||Case|Patients being considered for functional neurosurgical procedures, such as deep brain stimulation (DBS), radiofrequency ablation (RFA), gamma knife radiosurgery (GKR), or magnetic resonance-guided focused ultrasound (MRgFUS).
89198567|NCT05175417||Control|Healthy control volunteers.
88918942|NCT01661192|Experimental|AAT( Alpha 1 Antitrypsin)|Subjects who maintained peak stimulated C-peptide secretion ≥ 0.2nmol/L will continue treatment with AAT according to the dosage group they were allocated to at the previous study(40mg/kg or 60mg/kg or 80mg/kg), intravenously, once a week for 6 consecutive weeks, at 24-week intervals for a duration of ~54 weeks.
88918943|NCT01661192|No Intervention|Follow up group|Subjects who have not maintained peak stimulated C-peptide secretion ≥ 0.2nmol/L or subjects with peak stimulated C -peptide secretion ≥ 0.2nmol/L who are reluctant to receive additional study drug, will be followed up only with no administration of investigational product
88918944|NCT01661218||complications|catheter-related venous thrombosis catheter-related infections
88918945|NCT01661231|Experimental|Investigational Stents|Device: Astron/Pulsar-18 Stents Implantation of self-expanding, bare-metal, nitinol stents for treatment of peripheral artery disease.
88918946|NCT01661244|Experimental|Part A - Single dose escalation|
88918947|NCT01661244|Experimental|Part B - 14 day repeat dose escalation|
88918948|NCT01661257|Experimental|TIM-3|T-cell immunoglobulin- and mucin-domain-containing molecule 3 (TIM-3) is a novel transmembrane protein that is involved in the regulation of Th1-cell-mediated immunity.
88918949|NCT01661296|Active Comparator|Sodium stibogluconate|Intralesional SSG was administered in dose of 50 mg cm -2 of lesion once a week for 6 weeks (total six injections)
88918950|NCT01661296|Active Comparator|RFH therapy|RFH therapy was administered by a single, controlled and localized delivery of radio frequencies into the lesion for 30-60 seconds under local anesthesia (1% lidocaine) using a current field radio-frequency generator (ThermoMed 1.8, Thermosurgery Inc).
88918951|NCT01661309|Placebo Comparator|Inactive lozenge|Inactive lozenge containing 2mg sucrose dissolved in the mouth taken after a meal every other day for 16 weeks
88918952|NCT01661309|Experimental|Methylcobalamin|Methylcobalamin 1mg lozenge dissolved in the mouth following a meal taken every other day for 16 weeks.
88918953|NCT01661322|Active Comparator|Intensive antiplatelet therapy|Participants in the intensive antiplatelet group will receive Aspirin+Dipyridamole+Clopidogrel triple therapy for 28-30 days (to cover the period of maximum risk of recurrence) along with standard 'best care' (including lifestyle advice, BP and lipid lowering). Clop will be given as a loading dose of 300 mg,12 then 75 mg daily, Asp as a loading dose of 300 mg,22 then 75 mg daily, and Dip modified release 200 mg twice daily 9 for 28-30 days.
88918954|NCT01661322|No Intervention|Guideline antiplatelet therapy|This may be one or two antiplatelet drugs, as per standard treatment. Clopidogrel or aspirin and dipyridamole.
88918955|NCT01661335|Experimental|Ondansetron, dexamethasone, aprepitant|Arm A: Ondansetron 0.15 mg/kg (max 16 mg) IV or PO every 8 hours for at least 3 days, but no longer than 5 days; dexamethasone 0.2mg/kg (max 10 mg) IV or PO daily for at least 3 days, but no longer than 5 days; and aprepitant 3 mg/kg (max 125 mg) PO on day 1, and aprepitant 2 mg/kg (max 80 mg) PO on days 2 and 3 during the first investigational antiemetic cycle. During the next investigational antiemetic cycle, members of this arm will be crossed-over into the placebo arm, where the aprepitant will be replaced by placebo and the dexamethasone dose will be increased to 0.4 mg/kg (max 20 mg) daily.
88918956|NCT01661335|Placebo Comparator|Ondansetron, Dexamethasone, placebo|Arm B: Ondansetron 0.15 mg/kg (max 16 mg) IV or PO every 8 hours for at least 3 days, but no more than 5 days; dexamethasone 0.4 mg/kg (max 20 mg) IV or PO daily for at least 3 days, but no more than 5 days; and a PO placebo for 3 days during the first investigational antiemetic cycle. During the second cycle, members this group will be crossed-over to the experimental arm, where the placebo will be replaced by aprepitant and the dexamethasone will be decreased by 50%.
88918957|NCT01661348||Prevena System placement|Subjects randomized to this group will receive standard skin preparation and closure followed by application of Prevena Incision Management System (Kinetic Concepts, Inc; San Antonio, TX) negative pressure wound therapy unit (experimental group).
88918958|NCT01661348||Standard of care postoperative care|Subjects randomized to this group will receive a standard surgical skin preparation, closure, and dressing (control group).
88918959|NCT01661361||vancomycin cohort|
88918960|NCT01661374||Mechanically Ventilated|
88918961|NCT01661374||Chronic obstructive pulmonary disease (COPD).|
88918962|NCT01661387||Plenadren|Modified release hydrocortisone
88918963|NCT01661387||Other Glucocorticoid Replacement Therapy|
88918964|NCT01661413||Acute Leukemia|Children diagnosed with acute leukemia, undergoing chemotherapy. Patients with acute leukemia will receive intrathecal methotrexate on day 1 plus intravenous vincristine on day 1 plus oral steroid on days 1-5 plus their regularly scheduled and ongoing daily oral 6-mercaptopurine at the start of a maintenance therapy cycle.
88918965|NCT01661439||Low molecular weight heparin|SC LMWH IN patients with recurrent pregnancy loss
88918966|NCT01661452||patients in UAB ER,|
88918967|NCT01661478||Emergency Department personnel|survey
88918968|NCT01661478||Department of Psychiatry personnel|survey
88918969|NCT01661504|No Intervention|Referral Card Only|Women participants at control clinics will be given a referral card containing general information on IPV and a list of resources specific to their community
88918970|NCT01661504|Experimental|Integrated Screening|The intervention arm will consist of the following components (described in detail below): a) integrated IPV/Sexual and Reproductive Health Screening, b) supportive care, c) safety planning and harm reduction counseling, d) supported referrals, e) booster counseling sessions at 3 months post-baseline / initial counseling
88918971|NCT01661517|Experimental|Lifestyle Counseling|motivational interviewer
88918972|NCT01661530|Experimental|Vitamin E enhanced diet|Range of three vitamin E enhanced soups (400g/tin) containing 18-20mg vitamin in natural food form. Three portions per week
89198568|NCT01047787||CHF Patients|Congestive Heart Failure Patients
89010521|NCT00237380|Experimental|Ataluren|"Cycle 1: Within the first 28-day period, ataluren treatment will be taken 3 times per day with meals for 14 days at doses of 4 milligrams/kilogram (mg/kg) (breakfast), 4 mg/kg (lunch), and 8 mg/kg (dinner); there will then be an interval of 14 days without treatment.~Cycle 2: Within the second 28-day period, ataluren treatment will be taken 3 times per day with meals for 14 days at doses of 10 mg/kg (breakfast), 10 mg/kg (lunch), and 20 mg/kg (dinner); there will then be an interval of 14 days without treatment."
89010522|NCT04543708|Active Comparator|Incision drainage|"Adult with clinical suspicion of tonsillar abscess who underwent a CT-scan confirming the abscess will be randomly assigned to one arm or the other. Incision drainage arm will benefit from drainage of the tonsillar abscess under local anesthesia and then be hospitalized for intravenous antibiotics. If the incision drainage fails, they will get a tonsillectomy under general anesthesia."
89010523|NCT04543708|Active Comparator|Tonsillectomy|"Adult with clinical suspicion of tonsillar abscess who underwent a CT-scan confirming the abscess will be randomly assigned to one arm or the other. Tonsillectomy arm will benefit from tonsillectomy under general anesthesia and then be hospitalized for intravenous antibiotics."
89010524|NCT04539145|Experimental|Chocolate PTA balloon|
89010525|NCT04539145|Other|POBA|Intervention with regular baloon
89010526|NCT04543318|Experimental|Deep temporal nerves group|this group will use deep temporal nerves for reactivation of affected upper facial nerve branch
89010527|NCT04543318|Active Comparator|Masseteric nerve group|this group will use masseteric nerve for reactivation of affected upper facial nerve branch (gold standard)
89010528|NCT04539340|Other|Cohort 1 GNR-055 (0.3 mg/kg)|GNR-055 (0.3 mg/kg) Single intravenous administration GNR-055
89010529|NCT04539340|Other|Cohort 2 GNR-055 (0.5 mg/kg)|GNR-055 (0.5 mg/kg) Single intravenous administration GNR-055
89010530|NCT04539340|Other|Cohort 3 GNR-055 (1 mg/kg)|GNR-055 (1 mg/kg) Single intravenous administration GNR-055
89010531|NCT04539340|Other|Cohort 4 GNR-055 ( 2 mg/kg)|GNR-055 ( 2 mg/kg) Single intravenous administration GNR-055
89010532|NCT04539340|Other|Cohort 5 GNR-055 (3 mg/kg)|GNR-055 (3 mg/kg) Single intravenous administration GNR-055
89010533|NCT04543552||Bladder Scan|Subjects who are scheduled to undergo urodynamic studies.
89010534|NCT04543474|Active Comparator|Group 1|Patients starting with a low lactose diet for 3 weeks, followed by a wash out phase of 3 week, before crossing over to the low FODMAP diet for 3 weeks
89010535|NCT04543474|Active Comparator|Group 2|Patients starting with a low FODMAP diet for 3 weeks, followed by a wash out phase of 3 week, before crossing over to the low lactose diet for 3 weeks.
89010536|NCT00237497|Experimental|Ramelteon 8 mg QD|
89010537|NCT00237497|Active Comparator|Zopiclone 7.5 mg QD|
89010538|NCT00237497|Placebo Comparator|Placebo QD|
89010539|NCT00416130|Experimental|Vorinostat|A phase I portion that will determine the safety of 400mg Vorinostat once a day, continuously in the Asian population. A pre-determined dose reduction schema will be followed in the event of significant dose-limiting toxicities at this dose. Phase II will recruit additional patients at the determined dose with the goal of evaluating drug efficacy.
89010540|NCT04543162||patients with Mild Traumatic Brain Injury|patients with Mild Traumatic Brain Injury
89010541|NCT04543084|Other|Single-Subject Design|Each participant will go through a baseline phase and then an intervention phase.
89010542|NCT02215720|Experimental|Cetuximab + Temsirolimus|Cetuximab: 400mg/m² IV for 120 minutes Temsirolimus: 15mg IV for 60 minutes
89010543|NCT02215759|Experimental|BI 44370 TA|
89010544|NCT02215759|Placebo Comparator|Placebo|
89010545|NCT00416208|Experimental|Bortezomib|Bortezomib 1.6 mg/m2 i.v. d1 d8 d15 d22 for 4 cycles each of 35 days
89010546|NCT00416208|No Intervention|Observation|Observational arm
89010547|NCT02215798||Cymbalta|
89010548|NCT02215018|Experimental|BI 44370 TA solution|
89010549|NCT02215018|Experimental|BI 44370 TA tablet|
89010550|NCT02215018|Placebo Comparator|Placebo solution|
89010551|NCT02215018|Placebo Comparator|Placebo tablet|
89010552|NCT02215837|Sham Comparator|Chemotherapy|After accepting chemotherapy according to NCCN guidelines, patients will just regularly follow up.
89010553|NCT02215837|Experimental|Ag-D-CIK|After accepting chemotherapy according to NCCN guidelines,patients will receive 3 cycles of autologous tumor lysate pulsed D-CIK treatment.
89010554|NCT02215057|Experimental|Group 2|topical anesthetic drops patients were prepared for bilateral ICL/TICL procedure on the same day.Group I (1 eye) received topical anesthetic drops
89010555|NCT02215057|Experimental|Group 1|received topical anesthesia plus intracameral lidocaine 1% topical anesthesia plus intracameral lidocaine 1%'
89010556|NCT04710095|Active Comparator|Brief Alcohol Intervention|A brief intervention consisting of a 30-45 minute individual face-to-face session based on the principles of motivational interviewing.
89010557|NCT04710095|Sham Comparator|Attention-Matched Control Condition|Brief attention-matched control condition.
89010558|NCT02215135|Experimental|Corifollitropin in PCOS|In GnRH antagonist protocol, a single dose corifollitropin alfa was administered for ovarian stimulation following rFSH daily injection to stimulate follicle development. GnRH agonist was given to trigger final oocyte maturation when three follicles reached 17 mm in size. The IVF or ICSI was planned then all embryos were elective cryopreserved.
89010559|NCT04543123|Sham Comparator|sham tDCS treatment group|the current rose slowly for 30 seconds, descended for 30 seconds, and then remained at zero for 29 minutes
89010560|NCT04543123|Experimental|active tDCS treatment group|2mA of current was delivered during the 30 minutes of treatment
89010561|NCT04539418|Active Comparator|Vitamn K2 Treated patients|Vitamin K2 will be given to patients randomized to ARM 1 three times a week at the end of each dialysis session to prevent it being lost through the ultrafiltration membrane (in order to use the same dialysis access) intravenously to ensure its bioavailability.
89010562|NCT04539418|Placebo Comparator|Placebo Group|Placebo will be given to patients randomized three times a week to ARM 2 at the end of each dialysis session to prevent it being lost through the ultrafiltration membrane (in order to use the same dialysis access) intravenously to ensure its bioavailability.
88918973|NCT01661530|Placebo Comparator|Non-enhanced dietary intervention|Range of three similar looking and tasting soups (400g/tin) with naturally low (<3mg) vitamin E content. Three portions per week
88918974|NCT01661543|Experimental|Bean consumption to lower cholesterol|This arm will consume 90 grams of beans per day for 5 out of 7 days for 6 weeks.
88918975|NCT01661543|Placebo Comparator|Control (rice) consumed to show results|The control group will consume 90 grams of rice per day for 5 out of 7 days for 6 weeks.
88918976|NCT01661543|Experimental|Peas consumed to lower cholesterol|This arm will consume 90g of peas per day for 5 days out of each week for 6 weeks.
88918977|NCT01661556|Experimental|Miconazole|OTC topical prescription used for fungal treatment that can be useful to the treatment of melasma due to its depigmenting properties.
88918978|NCT01661556|Active Comparator|Hydroquinone|Hydroquinone 4% cream (Topical use) a depigmenting agent used as reference will be used as control. It will be applied twice a day for 9 weeks.
88918979|NCT01661556|Placebo Comparator|Placebo|Moisturizer cream without pharmacological effects will be used as a control.
88918980|NCT01661569|Experimental|Headspace On-the-go app|Participants were given access to a 45-day mindfulness meditation programme via the Headspace smartphone app
88918981|NCT01661569|No Intervention|Waitlist control|Participants will be asked to wait for 8 weeks before starting the intervention
88918982|NCT01661582|Placebo Comparator|Filtered Air Exposure|Subjects will be exposed to filtered air for 1 hour during intermittent exercise in a purpose-built exposure facility
88918983|NCT01661582|Experimental|Dilute Diesel Exhaust Exposure|Subjects will be exposed to dilute diesel exhaust (~300 mcg/m3) for 1 hour during intermittent exercise in a purpose-built exposure facility
88918984|NCT01661608|Experimental|EOS|Collecting data on the use of the EOS for gastric tissue approximation during primary gastric restrictive procedures
88918985|NCT01661673|Experimental|Arm 1|10 mg EVP-0962 Orally administered once daily for 14 days
88918986|NCT01661673|Experimental|Arm 2|50 mg EVP-0962 Orally administered once daily for 14 days
88918987|NCT01661673|Experimental|Arm 3|100 mg EVP-0962 Orally administered once daily for 14 days
89010563|NCT04542928|Placebo Comparator|routine care|The controlled group will receive routine functional treatment activities, a facial cleansing instruction and five facial cleansing videos.
89436356|NCT04525989|Experimental|Proton therapy|5 x 5 Gy External radiation therapy with Protons
89010564|NCT04542928|Experimental|experimental group|experimental group is required to receive a nurse leading 50- minute face care group every two weeks
89010565|NCT04543006|Other|Covid-19|only arm: Covid-19 proven by PCR
89436357|NCT04525989|Active Comparator|Photon therapy|5 x 5 Gy External radiation therapy with Photons
89010566|NCT04710017|Other|Tranexamic acid group|will tranexamic acid 500 mg 4 times daily in one group,
89010567|NCT04710017|Other|Medroxyprogesterone acetate|will receive 150mg of medroxyprogesterone acetate once intramuscular.
89010568|NCT04538521|Experimental|Niacin in early-stage mitochondrial myopathy patients|The arm includes mitochondrial myopathy patients supplemented with niacin.
89010569|NCT04543630|Active Comparator|Particulated autogenous bone|Particulated autogenous bone is considered the gold standard for sinus floor augmentation. The bone will be harvested locally
89010570|NCT04543630|Experimental|Advanced platelet-rich fibrin|Advanced platelet-rich fibrin will be be obtained through a blood sample from the participant
89010571|NCT04542967|No Intervention|Control group|They will receive the standard care for critically ill inpatients.
89010572|NCT04542967|Experimental|Convalescent plasma group.|They will receive standard care for patients with severe COVID-19 disease and convalescent plasma disease.
89010573|NCT04542811|Experimental|Intervention group|Intervention group will take 12 sessions of acupuncture addition to their prophylaxis treatment. Acupuncture points will be bilateral LI-4, LI-11, ST-8, ST-44, SP-6, GB-1, GB-14, GB-20, LR-3, and GV-14, GV-20. Sterile and single-use stainless steel acupuncture needles measuring 0.25x25 mm will be inserted to a depth of 10 mm and be retained for 30 minute without any further stimulation. Acupuncture will be performed by an acupuncturist with an acupuncture practitioner licence from the Turkish Ministry of Health. Adverse events will be monitored for all acupuncture sessions.
89436358|NCT04516694|No Intervention|Control|Usual care reflects the standard treatment currently provided to T1D patients. All adolescent participants in the study will have access to the multidisciplinary care team including a diabetes provider, registered diabetes nurse, social worker, and nutritionist. Telephone consultations are available 24/7 as often as necessary between clinic visits.
88918988|NCT01661673|Experimental|Arm 4|200 mg EVP-0962 Orally administered once daily for 14 days
88918989|NCT01661673|Placebo Comparator|Arm 5|Placebo orally administered for 14 days
88918990|NCT01661699||Sleep apnea|Those suspected of sleep apnea and scheduled for polysomnography and treated with CPAP therapy.
88918991|NCT01661725|Experimental|Group ACYW135 Meningococcal Polysaccharide Vaccine|0.5ml/ vial
88918992|NCT01661738|Experimental|Group ACYW135 Meningococcal Polysaccharide Vaccine|0.5 ml/ vial
88918993|NCT01661751|Experimental|ACYW135 Meningococcal Vaccine|0.5 ml/ dose, containing 50 μg of each antigen; lot No.: 20040601, manufacturing date: June 9, 2004 and the expiration date: till June 2006
88918994|NCT01661751|Active Comparator|A+C Meningococcal Vaccine|0.5 ml/ dose; each ampoule or dose contains 100 μg (one single human dose) and 50 μg of each antigen; lot No.: 20050805 and the expiration date: Aug. 24, 2007
88918995|NCT01661777|Other|Nasal steroid and Antihistamine|Patients with ETD will be given nasal steroid and antihistamine for 8 weeks.
88918996|NCT01661777|Active Comparator|Myringotomy tubes|Patients who fail nasal steroid and antihistamine treatment will have myringotomy tubes placed.
88918997|NCT01661777|Active Comparator|Low salt diet and diuretic|Patient's who fail to improve with myringotomy tubes will be treated with low salt det and diuretic
88918998|NCT01661803||group-A and group-B|Group-A (0.5% hyperbaric bupivacaine 0.4 mg/kg for 5-15 kg or 0.3mg/kg for >15kg) and Group-B (0.5% hyperbaric bupivacaine 0.4 mg/kg for 5-15 kg or 0.3mg/kg for >15 with 1 mcg/kg preservative free clonidine).
88918999|NCT01661803||group-A and group--B|Group-A (0.5% hyperbaric bupivacaine 0.4 mg/kg for 5-15 kg or 0.3mg/kg for >15kg) and Group-B (0.5% hyperbaric bupivacaine 0.4 mg/kg for 5-15 kg or 0.3mg/kg for >15 with 1 mcg/kg preservative free clonidine).
88919000|NCT01661816||Within chemotherapy|30 couples, interviewed within chemotherapy (6 to 8 months after diagnosis)
88919001|NCT01661816||within Herceptin|30 couples, within herceptin treatment (the first year after diagnosis)
88919002|NCT01661816||within hormonotherapy|30 couples, within hormonotherapy (between 2 and 7 years after diagnosis)
88919003|NCT01661816||without hormonotherapy|30 couples, did not received hormonotherapy (1 year after diagnosis)
89198569|NCT00871299|Experimental|1|Mindfulness Based Cognitive Therapy (MBCT) + medication management
88919004|NCT01661816||end of treatment|30 couples, after end of treatments for patients who did received hormonotherapy (7 years after diagnosis)
88919005|NCT01661829||Biofeedback|Patients will undergo biofeedback therapy between 1st adjuvant chemotherapy and stoma closure(= after 3rd ajduvant chemotherapy)
88919006|NCT01661829||Kegel|Patients will be trained to take excersise for their anal sphincter by Kegel.
88919007|NCT01661842|Experimental|Conventional plus UC-MSC treatment|"Participants will receive conventional treatment plus a dose of UC-MSC from day 0 through the week 12 study visit.~Participants will then be followed until the week 96 study visit."
88919008|NCT01661842|Experimental|Conventional plus placebo treatment|Participants will receive conventional plus placebo treatment from day 0 through the week 12 study visit. Participants will then be followed until the week 96 study visit.
88919009|NCT01661855|Active Comparator|Riluzole|
88919010|NCT01661855|Placebo Comparator|Placebo|
88919011|NCT01661868|Active Comparator|PARP Inhibitor Naive|Patients with no prior PARP inhibitor treatment
88919012|NCT01661868|Active Comparator|Prior PARP Inhibitor|Patients previously treated with a PARP inhibitor other than olaparib
88919013|NCT01661894|Active Comparator|Intervention|Subjects will undergo the BrainpalTM intervention for 24 sessions over the span of 8 weeks. Each session will take 30-minute to complete. The intervention group will undergo the BrainpalTM treatment in the first 8 weeks of the trial.
88919014|NCT01661894|No Intervention|Wait-List Control|The waitlist control will start their 8 week treatment after the completion of the intervention group from week 9 onwards. They will undergo the BCI intervention for 24 sessions over the span of 8 weeks.
88919015|NCT01661907|Experimental|Combined Epi-GA/PCEA|"Patients assigned to this group (experimental group) will receive combined epidural-general anesthesia (combined Epi-GA) and patient-controlled epidural analgesia (PCEA).~An epidural catheter will be placed before anesthesia induction. General anesthesia will be induced and maintained in the same manner as in the control group, with the addition of a continuous infusion or intermittent boluses of 0.375%-0.5% ropivacaine given through the epidural catheter for analgesia maintenance. Patient-controlled epidural analgesia will be provided for postoperative analgesia (established with 0.12% ropivacaine and 0.5 μg/mL sufentanil in 250 mL normal saline, programmed to deliver a 2-mL bolus with a lockout interval of 20 minutes and a background infusion of 4 mL/hr)."
88919016|NCT01661907|Active Comparator|GA/PCIA|"Patients assigned to this group (control group) will receive general anesthesia (GA) and patient-controlled intravenous analgesia (PCIA).~General anesthesia will be induced with midazolam, sufentanil, propofol and rocuronium. Anesthesia will then be maintained by inhalation of sevoflurane with or without nitrous oxide, and/or continuous intravenous infusion of propofol. Sufentanil and rocuronium will be given when needed. Patient-controlled intravenous analgesia will be provided for postoperative analgesia (established with 50 mg morphine in 100 mL normal saline, programmed to deliver a 2-mL bolus with a 6-10 minutes lockout interval and a 1 mL/hr background infusion)."
88919017|NCT01661920|Experimental|INTERVENTION GROUP|Patients with diagnosis of CAP with shorten treatment, defined as 5 days antibiotic treatment.
88919018|NCT01661920|Active Comparator|CONTROL GROUP|Patients with diagnosis of CAP which antibiotic treatment duration will be not modified by their doctors.
89198570|NCT00871299|Active Comparator|2|The Health Enhancement Program (HEP) + medication management
89198571|NCT02534545|Experimental|Doctormate® (200mmHg)|Patients will be treated with Renqiao Remote Ischemic Conditioning Device (Doctormate®) (200mmHg) once daily for 12 months
89198572|NCT02534545|Sham Comparator|Doctormate® (60mmHg)|Patients will be treated with the Renqiao Remote Ischemic Conditioning Device (Doctormate®) (60mmHg) once daily for 12 months
89198573|NCT00962026|Experimental|Rilonacept|
89198574|NCT03753789|Experimental|Microwave Ablation|NEUWAVE Microwave Ablation System with AC software for patients undergoing a percutaneous ablation of a soft tissue liver lesion by an interventional radiologist.
89198575|NCT00876681|Active Comparator|1. Ultrasound|Ultrasound method of placement is selected randomly, using a computer program. The patient is asked their pain and discomfort using a 0-10 scale where 0=no pain/discomfort and 10=worst pain/discomfort imaginable. The patient is asked this question prior to surgery, but after catheter placement and then again the first day after surgery. Time of placement is also measured and begins when the ultrasound probe first touches the skin. Patients are also asked the numbness of their foot and toes based on a 0-10 scale where 0=no numbness and 10=completely numb.
89436359|NCT04516694|Experimental|Gain-framed incentive|"Participants will start off with nothing at the beginning of the treatment period. For each day that participants' meet goals, value will be added to their incentive balance.~All adolescent participants in the study will have access to the multidisciplinary care team including a diabetes provider, registered diabetes nurse, social worker, and nutritionist. Telephone consultations are available 24/7 as often as necessary between clinic visits."
88919019|NCT01662011|Experimental|NAVA group|Patients ventilated with the mode of neurally adjusted ventilatory assist
88919020|NCT01662011|Active Comparator|PSV group|Patients ventilated with the mode of pressure support ventilation.
88919021|NCT01662037|Experimental|Bosentan group|Bosentan 2mg/kg/dose twice a day and routinely therapy in children with functional single ventricle during the period of staged Fontan procedure with high risk of increased PVR.
88919022|NCT01662037|No Intervention|Routinely group|Routinely therapy in children with functional single ventricle during the period of staged Fontan procedure with high risk of increased PVR.
88919023|NCT01662076|Experimental|Sublingual or Oral Liquid Homeopathy|The homeopathic remedy will be administered as 1 lactose/sucrose globule 2.5 mm in diameter to be administered sublingually up to 3 times per day or as 0.2 ml of a 30% ethanol based liquid homeopathic remedy administered orally up to 3 times per day. The homeopathic remedy and/or the homeopathic remedy potency can be changed on a daily basis during the course of treatment. However, only one homeopathic remedy and potency will be administered at a given time.
88919024|NCT01660724|Experimental|Ultrasound guided arterial puncture|Patients randomised to the this arm has arterial puncture performed using simultaneously ultrasound in order to guide the passage of the syringe from the patient's skin to the artery
88919025|NCT01660724|Active Comparator|Conventional arterial puncture technique|Patients randomised to the active comparator arm has arterial puncture performed using the conventional technique
88919026|NCT01662089|Experimental|Chelate zinc suppliment|15mg Chelate zinc suppliment : additional to standard 5% minoxidil
88919027|NCT01662089|Placebo Comparator|Placebo drug|Placebo drug to compare with 15mg chelated Zn : additional to standard 5% minoxidil
88919028|NCT01662128|Experimental|Xeloda|Xeloda
88919029|NCT01662154|Experimental|Nerve stimulator|Patients in this group will have their nerve blocks assessed with a common nerve stimulator (Stimuplex HNS 12, B.Braun, Germany).
88919030|NCT01662154|Active Comparator|Neurometer|Patients in this group will have their nerve block assessed using the Neurometer.
88919031|NCT01662167|Experimental|Multiple dose mtx|mtx
88919032|NCT01662167|Experimental|Single Dose|In the single dose regimen, 50 mg/m2 intramuscular methotrexate was given on day one and hCG level was measured on days four and seven. If the hCG level did not decrease by 15% between day four and seven, a second dose of methotrexate was injected on day seven, hCG level was measured weekly until a level of 15 mlU/ml or less was achieved
88919033|NCT01662180||Subfertile couples|"Subfertile couples presenting at fertility clinics with an indication for IUI in stimulated cycles~All patients will receive a fixed 75 IU recombinant follicle stimulating hormone per day conform normal stimulation protocol starting from cycle day 3, 4 or 5. Once the dominant follicle(s) reach a mean diameter of 16-18 mm, hCG (5000IU or 250 mcg) will be applied and insemination will be scheduled 36-42 hours later. Patients will be followed for the time of one menstrual cycle."
88919034|NCT01662193|Experimental|vitamin D3|vitamin D3 supplement 50000 IU vitamin D3 per week
89536470|NCT02475941|Active Comparator|Non Weight Bearing|Surgeon based prospective cohort supported in the literature to answer research questions in which surgeons have a preferred treatment type. Non weight bearing are those who are NOT permitted in the post operative instructions to be Weight Bear after fracture fixation.
88919035|NCT01662193|Experimental|calcium supplement|calcium supplement 1000 mg calcium carbonate daily
88919036|NCT01662193|Experimental|vitamin D and calcium supplement|vitamin D3 and calcium supplementation 50000 IU vitamin D3 per week and 1000 mg calcium carbonate daily
88919037|NCT01662193|Placebo Comparator|placebo|placebo
88919038|NCT01662206|Experimental|Probiotic|Capsules containing Lactobacillus gasseri, Bifidobacterium bifidum, and Bifidobacterium longum
88919039|NCT01662206|Placebo Comparator|Placebo|Capsules containing placebo
88919040|NCT01662219|Experimental|superficial cervical plexus block|superficial cervical plexus block for experimental group
88919041|NCT01662219|No Intervention|No Block|no superficial cervical plexus block for the no intervention group
88919042|NCT01662232|Active Comparator|Green tea beverage|200 mg EGCG as green tea beverage.
88919043|NCT01662232|Active Comparator|Green tea extract|200 mg EGCG as green tea extract and same volume water as for tea beverage.
88919044|NCT01662232|Active Comparator|Epigallocatechin-3-gallate (EGCG)|200 mg EGCG and same volume water as for tea beverage.
88919045|NCT01662232|Placebo Comparator|Placebo (Water)|Same volume water as for all intervention arms.
88919046|NCT01662258|Experimental|Point-of-Care diagnostic laboratory test|Adult patients with community-acquired pneumonia (CAP) who are in the Targeted strategy group will undergo point-of-care (POC) diagnostic laboratory tests.
88919047|NCT01662258|No Intervention|Empiric therapy|Option of no application of POC laboratory tests
89436360|NCT04516694|Experimental|Loss-framed incentive|"Participants will start off at the maximum incentive balance at the beginning of the treatment period and for each day that participants' fail to meet goals, value will be subtracted from their incentive balance over the 12-week.~All adolescent participants in the study will have access to the multidisciplinary care team including a diabetes provider, registered diabetes nurse, social worker, and nutritionist. Telephone consultations are available 24/7 as often as necessary between clinic visits."
88919048|NCT01662271||adolescents with extreme obesity|BMI ≥35kg/m2
88919049|NCT01662271||adolescents with obesity|BMI 30-34.9kg/m2
88919050|NCT01662284||Triple Negative Breast|124I-NM404 in triple negative breast cancer
88919051|NCT01662284||Prostate|124I-NM404 in prostate cancer
88919052|NCT01662284||Colorectal|124I-NM404 in colorectal cancer
88919053|NCT01662284||Gastric|124I-NM404 in gastric cancer
88919054|NCT01662284||Ovarian|124I-NM404 in ovarian cancer
89436361|NCT04508530|Experimental|Panzyga|Panzyga 10% IVIG
89436362|NCT04508530|Placebo Comparator|Placebo|Placebo
89436363|NCT04502693|Experimental|MenB_0_2_6 Group|Participants received 3 doses of rMenB+OMV NZ vaccine on Day 1, Day 61 and Day 181. Participants received 1 dose of MenACWY vaccine at Day 211 as a standard of care.
88919055|NCT01662284||Pancreatic|124I-NM404 in pancreatic cancer
88919056|NCT01662284||Esophageal|124I-NM404 in esophageal cancer
88919057|NCT01662284||Sarcoma|124I-NM404 in soft tissue sarcoma
88919058|NCT01662284||Head & Neck|124I-NM404 in head and neck cancer
88919059|NCT01662323|Active Comparator|Training of the GP's, intervention|General practitioners are trained to diagnose and treat heart failure according the recommendations of the NHG-standard.
88919060|NCT01662323|Active Comparator|Controle|General practitioners giving care as usual to their heart failure patients.
88919061|NCT01662349|Experimental|Plasma|Plasma applied to back for up to 20 minutes, twice/week for 4 weeks
88919062|NCT01662375||MIII|
88919063|NCT01662388|Experimental|automatrix band, Separation ring|The prepared teeth received Automatrix band (similar to the control group, product code# 62422513). The Automatrix was burnished against the adjacent tooth gently. Anatomical wedges were applied in the proximal area and then the separation ring (BiTine® round ring by Palodent systems, Dentsply International, DE, USA product # 659040) placed with the help of retainer forceps.
88919064|NCT01662388|Active Comparator|automatrix band|Teeth received Automatrix band alone (Wide-Regular type, dimensions 7.9 mm height and 0.05mm thickness, product code # 62422513). It was secured on the prepared tooth and burnished against the adjacent tooth gently. Anatomical wedges were placed in the inter-proximal area gingival to the cavity preparation.
88919065|NCT01662401|Experimental|Peripheral Nerve Block|bilateral rectus sheath and ilioinguinal nerve blocks under ultrasound guidance after induction of general anesthesia administered to subject
88919066|NCT01662401|Experimental|local anesthetic infiltration|local anesthetic infiltration will be administered after induction of general anesthesia
88919067|NCT01662414|Active Comparator|HMS 90®|
88919068|NCT01662414|Placebo Comparator|Placebo (Soy protein)|
88919069|NCT01662427||Questionniare|
88919070|NCT01662466|Active Comparator|DHEA+Testosterone|These patients will be administered the testosterone cream along with standard DHEA supplements
88919071|NCT01662466|Placebo Comparator|DHEA+Placebo|These patients will receive the placebo cream along with her DHEA supplements. In other words, no testosterone will be administered.
88919072|NCT01662518|Experimental|DDS-25|Intravitreal injection of DDS-25(Dexamethasone drug delivery system )
88919073|NCT01662544|Experimental|HHFNC|Heated High Flow arm
88919074|NCT01662544|Active Comparator|Standard Nasal Cannula|Standard treatment
88919075|NCT01662557|Active Comparator|Family Behavior Modification|Family-based behavior modification with parent and child using goal setting, self monitoring, reinforcement, behavioral skills training, and tasting opportunities.
88919076|NCT01662557|Other|Minimal Nutrition Information|Weekly mailings emphasizing healthy eating guidelines for families.
89010574|NCT04542811|No Intervention|Control Group|Control group will take only their migraine prophylaxis treatment. Participants will followed-up 3 months.
89198576|NCT00876681|Active Comparator|2. Electrical Stimulation|Electrical stimulation (nerve stimulation) method of placement is selected randomly, using a computer program. The patient is asked their pain and discomfort using a 0-10 scale where 0=no pain/discomfort and 10=worst pain/discomfort imaginable. The patient is asked this question prior to surgery, but after catheter placement, and then again the first day after surgery. Time of placement is also measured and begins when the nerve stimulation needle first touches the skin. Patients are also asked the numbness of their foot and toes based on a 0-10 scale where 0=no numbness and 10=completely numb.
89198577|NCT05299840|Experimental|Oncogramme group|The oncologist has access to the results of the Oncogramme® Device and decides on the treatment according to the recommendations of the Oncogramme® Device
89198578|NCT05299840|Other|Control group|The oncologist does not have access to the results of the Oncogramme® Device and decides on the treatment according to the standard of care.
88919077|NCT01662570|Active Comparator|Beverage Choice Lifestyle Modification|The family-based BCLM intervention trained children and parents in self monitoring of sugar sweetened beverage intake and goal-setting, incorporated feedback and reinforcement, and provided water bottles and water filters to promote a reduction in sugar sweetened beverages and overall energy intake.
88919078|NCT01662570|Other|Nutrition Education (NE)|This treatment for parents and children addressed a variety of topics in nutrition including benefits of fruits and vegetables, the food pyramid, vitamins, benefits of eating a variety of foods, and healthy beverage selections. No behavioral change training component was included.
88919079|NCT01662622|Experimental|Sevoflurane|Anaesthesia was induced by 8% sevoflurane. Cisatracurium 0.15mg kg-1 was administered after loss of the lash reﬂex, then ventilated manually until the amplitude of T1 decreased to 0. Intubation was performed and switched to mechanical ventilation with a fresh gas flow 2L min-1. Gas concentrations were analysed using a gas analyser.The end-tidal concentration of carbon dioxide was maintained at 4.7kPa; an esophageal temperature probe was inserted and a warming unit was used if necessary to maintain normothermia (35.5°-38.5°). The surgical incision was performed at least 30min after tracheal intubation. When arterial blood pressure (MAP) decrease exceeding 20% of baseline values. Phenylephrine 0.1mg was administered intravenously if necessary to maintained MAP and recorded.
88919080|NCT01662661|Experimental|Arm AB|Treatment A: 200 mg dose of JNJ-47910382 formulated as a suspension followed by Treatment B: 200 mg JNJ-47910382 formulated as an uncoated tablet, administered on Day 1.
88919081|NCT01662661|Experimental|Arm BA|Treatment B: 200 mg JNJ-47910382 formulated as an uncoated tablet followed by Treatment A: 200 mg dose of JNJ-47910382 formulated as a suspension, administered on Day 1.
88919082|NCT01662674|Experimental|G+M|Coadministration of gemigliptin 50mg and metformin HCl extended release 1000mg
88919083|NCT01662674|Experimental|C|Combination of gemigliptin50mg/metformin HCl extended release 1000mg
88919084|NCT01662687|Experimental|Sancuso patch|
88919085|NCT01662687|Active Comparator|Kytril|
88919086|NCT01662700|Experimental|AS2|"Artesunate 2 mg/kg/day for 5 days Combine with~Primaquine 15 mg is given daily for 14 days.~Or primaquine 45 mg is given once a week for 8 weeks in G6PD deficiency patients."
88919087|NCT01662700|Active Comparator|Chloroquine|"CH25: Chloroquine 25 mg/kg: 15 mg base/kg on the first days (D0), followed by 5 mg base/kg daily on the second and third day (day1-2) (total 25 mg base/ kg).~Combine with~Primaquine 15 mg is given daily for 14 days.~Or primaquine 45 mg is given once a week for 8 weeks in G6PD deficiency patients."
88919088|NCT01662726|Experimental|Irosustat|Irosustat 40mg OD for a minimum of 2 weeks until follow up FLT-PET/CT. For those patients consented to a repeat tumour biopsy, treatment will be extended to that day before the procedure.
88919089|NCT01662804|Experimental|hu3F8 and rIL-2|This phase I single arm trial assesses the toxicity of escalating doses of hu3F8 (day 1 and day 8) in the presence of 6 × 10^6 U rIL-2/m^2/d x 5 days sc (day 8 through day 12). These 2 doses of hu3F8 and 5 doses of rIL-2 constitute a treatment cycle.
88919090|NCT01662817||Intervention|Intervention group primary care physician (PCP) receives one day training in depression screening guidelines and uses guidelines for six months
89436364|NCT04502693|Experimental|MenB_0_6 Group|Participants received 2 doses of rMenB+OMV NZ vaccine on Day 1, and Day 181, 1 dose of MenACWY vaccine on Day 61. Participants received 1 dose of Placebo on Day 211 to maintain blinding.
89436365|NCT04502693|Experimental|ABCWY-1 Group|Participants received 2 doses of MenABCWY lot 1 vaccine at Day 1 and Day 181 and 2 doses of placebo at Day 61 and Day 211.
89436366|NCT04502693|Experimental|ABCWY-2 Group|Participants received 2 doses of MenABCWY lot 2 vaccine at Day 1 and Day 181 and 2 doses of placebo at Day 61 and Day 211.
89436367|NCT04502693|Experimental|ABCWY-3 Group|Participants received 2 doses of MenABCWY lot 3 vaccine at Day 1 and Day 181 and 2 doses of placebo at Day 61 and Day 211.
88919091|NCT01662817||Control|Control group PCP manages depression in the usual way for six months
88919092|NCT01662830||MWCC clients|This study will be a systematic retrospective chart review of clients participating in the Jump Start (5 & 1) Plan at three different MWCC locations in Texas during the years 2007 - 2010.
88919093|NCT01662843||BRIPPED scan|Patients presenting with undifferentiated shortness of breath who receive the ultrasound scan in addition to standard of care
88919094|NCT01662843||Control|Patients who only receive the standard of care for undifferentiated shortness of breath
88919095|NCT01662869|Experimental|Onartuzumab+mFOLFOX6|Participants will receive onartuzumab 10 milligrams per kilogram (mg/kg) intravenous (IV) infusion + mFOLFOX6 (oxaliplatin, folinic acid, and 5-fluoruracil) regimen. Participants will receive a maximum of 12 cycles (each cycle is 14 days) of mFOLFOX6 with onartuzumab. Participants whose disease has not progressed after 12 cycles of mFOLFOX6 with onartuzumab will continue treatment with onartuzumab until disease progression, unacceptable toxicity, or death.
88919096|NCT01662869|Placebo Comparator|Placebo+mFOLFOX6|Participants will receive onartuzumab matching placebo + mFOLFOX6. Participants will receive a maximum of 12 cycles (each cycle is 14 days) of mFOLFOX6 with placebo. Participants whose disease has not progressed after 12 cycles of mFOLFOX6 with placebo will continue treatment with placebo until disease progression, unacceptable toxicity, or death.
89010575|NCT00269802|Experimental|001|OROS methylphenidate HCl
89010576|NCT00269802|Active Comparator|002|Ritalin
89010577|NCT00269802|Placebo Comparator|003|Placebo
89436368|NCT04502693|Active Comparator|ACWY Group|Participants received 1 dose of MenACWY vaccine at Day 1,1 dose of placebo at Day 61 and 1 dose of rMenB+OMV NZ vaccine on Day 181. Participants received 1 dose of rMenB+OMV NZ vaccine on Day 211 as standard of care.
89536471|NCT02475863|Experimental|Warfarin dosing aid|A pharmacokinetic/pharmacodynamic model-based dosing algorithm for warfarin.
89536472|NCT02475863|Active Comparator|Standard practice|Dosing adjustments according to the normal unit protocol
89536473|NCT03071055|Active Comparator|ranibizumab|ranibizumab 0.5mg in commercially available vial
89536474|NCT03071055|Experimental|ranibizumab pre filled-syringe|ranibizumab 0.5mg in soon to be available pre-filled syringe
88919097|NCT01662921|Active Comparator|NPH and insulin lispro|Patients diagnosed with diabetes during pregnancy will be randomized to long acting insulin NPH and short acting insulin lispro in a basal bolus regimen to treat post prandial hyperglycemia using a dosing schedule of 50% NPH calculated by the patients weight and gestational age and 50% lispro pending their last three SMPG average.
88919098|NCT01662921|Active Comparator|NPH and insulin glulisine|Patients with a diagnosis of diabetes during pregnancy will be randomized to using long acting insulin NPH and short acting insulin glulisine as treatment for post prandial hyperglycemia with a 50% NPH dosing schedule based on the weight and gestational age and 50% glulisine schedule based on their last three SMBG result average.
88919099|NCT01662934|Sham Comparator|Sham|Using not functioning device
88919100|NCT01662934|Experimental|Experimental|Using functioning device
88919101|NCT01662947|Experimental|DUT Arm|"DUT: Transtek Wrist Blood Pressure Monitor TMB-1117~Measurement: Blood Pressure~Groups/Cohorts: DUT"
88919102|NCT01662947|Experimental|Reference Arm|"Reference Device: Yuyue Medical Blood Pressure Meter, YYBP-212, accuracy: ±1mmHg and range: 0-300mmHg.~Measurement: Blood Pressure~Groups/Cohorts: Reference"
88919103|NCT01662973|Experimental|Conventional plus UC-MSC treatment|"Participants will receive conventional treatment plus a dose of UC-MSC from day 0 through the week 12 study visit.~Participants will then be followed until the week 48 study visit."
88919104|NCT01662973|Placebo Comparator|Conventional plus placebo treatment|Participants will receive conventional plus placebo treatment from day 0 through the week 12 study visit. Participants will then be followed until the week 48 study visit.
88919105|NCT01663025|Experimental|Hand Reflexology|Participants in this condition will receive hand reflexology, performed by a trained reflexologist during their treatment. This will be in addition to usual standard care therefore the surgeon will speak to the participant occasionally to ensure they are comfortable.
88919106|NCT01663025|No Intervention|Control|Participants in condition will form the control group for the study. They will receive usual standard care during treatment which will involve the surgeon speaking to them occasionally to ensure that they are comfortable.
88919107|NCT01663038|Active Comparator|Clopidogrel and Aspirin|
88919108|NCT01663038|Experimental|Copidogrel|
89536475|NCT04433559|Active Comparator|Group Active Tadalafile|One oral tablet of 1.5 mg IPDE daily for 14 weeks of treatment.
89536476|NCT04433559|Placebo Comparator|Group Placebo|One oral tablet of placebo daily for 14 weeks of treatment.
89536477|NCT03071211|Experimental|Plug-unplug Group|Participants randomized to plug-unplug catheter management. Participants plug and unplug catheters when they feel urge to void or at least every 4 hours during the day. Participants are given the option to use a large drainage bag for convenience overnight.
89536478|NCT03071211|Active Comparator|Continuous Drainage Group|Participants randomized to continuous drainage catheter management. Catheters are attached to a leg bag during the day and large drainage bag for convenience overnight.
88919109|NCT01663051||Stent|Stent
89536479|NCT03071211|No Intervention|Reference Group|Participants that do not fail inpatient voiding trial and go home without a catheter.
88919110|NCT01663064|Experimental|Endovascular|Endovascular treatment
88919111|NCT01663077|Experimental|Clozapine|Clozapine tablet 150 mg at the day and 150 mg in the evening by mouth per day for 3 month
88919112|NCT01663090|Experimental|Nanoparticle enhanced MRI|
88919113|NCT01663116|Experimental|Treatment|"first cohort: 1 million stem cells/kg administered at days 1, 8 and 15~second cohort: 2 million stem cells / kg administered at days 1, 8 and 15~third cohort: 4 million stem cells / kg administered at days 1, 8 and 15"
88919114|NCT01663116|Placebo Comparator|Placebo|Lactate Ringer´s solution
88919115|NCT01663129||Leukemia Patient Group|Acute Lymphoblastic Leukemia (ALL)
88919116|NCT01663129||Rheumatic Disease Patient Group|"Juvenile Idiopathic Arthritis (JIA)~Systemic Lupus Erythematosis~Juvenile Dermatomyositis~Scleroderma~Overlap Syndromes~Sjogren's syndrome~Sarcoidosis~Systemic Vasculitis (excluding Kawasaki's disease and Henoch-Schonlein Purpura)~Systemic vasculitis as defined by the Chapel Hill Concensus Conference on Nomenclature. Other forms of systemic vasculitis, including Giant cell (temporal) arteritis, Takayasu's arteritis, Polyarteritis nodosa, Wegener's granulomatosis, Churg-Strauss syndrome, Microscopic polyangiitis, Essential cryoglobulinemic vasculitis, Cutaneous leukocytoclastic angiitis, Behcet's disease, Other vasculitis~Other rheumatic disease"
88919117|NCT01663129||Nephrotic Syndrome Patient Group|"Nephrotic syndrome will be classified according to the following categories:~Idiopathic nephrotic syndrome, without renal biopsy histology, presumed minimal change disease (MCD), Focal segmental glomerulosclerosis (FSGS), confirmed on biopsy, Minimal change disease, confirmed on biopsy Nephrotic syndrome with Henoch-Schonlein Purpura (HSP)."
88919118|NCT01663155||all enrolled subjects|Intervention is chest x-ray and CT scan. The chest x-ray image is read first without computer aided detection (CAD) and then a second time with computer aided detection (CAD) the CT scan is read by one reader. Subjects are asked to contribute breath and blood samples.
88919119|NCT01663168|Active Comparator|Rifabutin three times a week|Rifabutin 150mg tablet three times a week (Mon-Wed-Fri) in combination with daily lopinavir/ritonavir taken as part of second-line ART for duration of TB treatment (24 weeks)
88919120|NCT01663168|Experimental|Rifabutin daily|Rifabutin 150mg tablet daily in combination with daily lopinavir/ritonavir taken as part of second-line ART for duration of TB treatment (24 weeks)
88919121|NCT01663194||N/L ratio tertile 2|patients were divided in to the tertiles
88919122|NCT01663194||N/L ratio tertile 3|patients were divided in to the tertiles
88919123|NCT01663194||N/L ratio tertile 1|patients were divided in to the tertiles
88919124|NCT01663207||obese individuals with prediabetes|
88919125|NCT01663220||obese individuals with type 2 diabetes mellitus|
88919126|NCT01663246|Active Comparator|Healthy Adults|Healthy adults over the age of 18, with no history of surgery to the salivary glands, or cancer therapy.
88919127|NCT01663246|Active Comparator|Radiation for Head and Neck Cancer|History of radiation therapy for head and neck cancer.
88919128|NCT01663298||Control group|Subjects must have never smoked and must be non-diabetic.
88919129|NCT01663298||Smoking group|Subjects must have had at least 5 pack-years of self-reported smoking history, must be currently smoking and must be non-diabetic.
88919130|NCT01663298||Diabetic group|Subjects must have type 2 diabetes. The condition must be diagnosed subjects must be treated by medications and/or insulin. A HbA1C test result either within past 3 months or performed in the first visit must be available. They must have never smoked.
88919131|NCT01663311|Experimental|Medial Frontal rTMS Double-Cone-Coil|High frequency rTMS ( Alpine Biomed Mag Pro Option) applied over medial superior frontal cortex (supplementary motor cortex) (Brodman area 6/8),Double-Cone-water-cooled-Coil (2000 Stimuli of 10 Hz each session), 110% motor threshold; followed by: low frequency rTMS ( Alpine Biomed Mag Pro Option) applied over left temporoparietal cortex, Butterfly-water-cooled-Coil (2000 Stimuli of 1 Hz each session), 110% motor threshold.
88919132|NCT01663311|Experimental|Left DLPFC Butterfly Coil|High frequency rTMS ( Alpine Biomed Mag Pro Option): 2000 stimuli of 20 Hz over the left DLPFC (each session), Butterfly-water-cooled-Coil, 110% motor threshold; followed by: low frequency rTMS ( Alpine Biomed Mag Pro Option) applied over left temporoparietal cortex, Butterfly-water-cooled-Coil (2000 Stimuli of 1 Hz each session), 110% motor threshold.
88919133|NCT01663324|Experimental|single site rTMS|"Low frequency temporoparietal transcranial magnetic stimulation~Intervention: Device: rTMS intervention 1"
88919134|NCT01663324|Experimental|multisite rTMS|"Combined high frequency dorsolateral prefrontal (unilateral) and low frequency temporoparietal (bilateral) stimulation~Intervention: Device: rTMS Intervention 2"
88919135|NCT01663337|Active Comparator|Cognitive Processing Therapy (CPT)|
88919136|NCT01663337|Active Comparator|Relapse Prevention Therapy (RP)|
89198579|NCT03991897|Experimental|Ketogenic diet|"the intervention will consist of 3 phases: a one week run-in period, 24 weeks strict KD and 24 weeks Modified Atkins Diet.~Every day, 40 g of KetoCal, a nutritionally complete ready-to-drink liquid, is foreseen to ensure adequate amounts of vitamins and minerals and to ensure ketosis during the night (some patients drink some sips of the shake during the night). During this run-in period, patients will become familiar with their diet and, in particular, they will learn which foods are allowed and which are not."
89198580|NCT03991897|Active Comparator|Isocaloric diet|During the run-in period, the dietician will discuss the diet and maintenance of an isocaloric diet with the patients. As such, the diet of the control group will not change from their normal dietary pattern, unless a patient is following an Atkins-like diet. In the latter case, the patient will be asked to change the diet to a normal Belgian diet.
89198581|NCT00616239|Active Comparator|A|Subjects randomized to have the right side of the face peeled with salicylic acid every 2 weeks for a total of 4 peels (first 2 at 20% and last 2 at 30%). Subjects will apply 4% hydroquinone cream to affected areas on entire face for 14 weeks.
89198582|NCT00616239|Active Comparator|B|Subjects randomized to have the left side of the face peeled with salicylic acid every 2 weeks for a total of 4 peels (first 2 at 20% and last 2 at 30%). Subjects will apply 4% hydroquinone cream to affected areas on entire face for 14 weeks.
89198583|NCT01045213|Experimental|Proactive Integrated Care|COPD education, self-management education, remote monitoring (Health Buddy, pulse oximeter, pedometer, spirometer) and enhance communication with cell phone contact with a coordinator.
89536480|NCT02475785|Experimental|FFRD and mini plates group|"Upper will be bonded, levelled and aligned until reaching 0.019 x 0.025 ss archwires.~2 Y shaped mini plates will be inserted in the mandibular symphysis Insertion of the FFRD with Direct application over the mandibular mini plates"
88919137|NCT01663337|No Intervention|Assessment Only (AO)|AO functions as a benchmark comparison condition. Consists of baseline assessment, daily interactive voice response (IVR) monitoring, and immediate post-test assessment. Not an active treatment
88919138|NCT01663350||All-risk pregnant women|All-risk pregnancies undergoing conventional forms of prenatal screening
88919139|NCT01663389|Experimental|GSK1322322 1000 mg IV|On Day 1 of Period 1, after an overnight fast, subjects will receive GSK1322322 1000 mg IV single dose (containing approximately 45.5 microcurie [μCi] radioactive 14C-GSK1322322) for intravenous infusion over 60 minutes.
88919140|NCT01663389|Experimental|GSK1322322 1200 mg Oral Solution|On Day 1 of Period 2, after an overnight fast, subjects will receive GSK1322322 1200 mg oral solution single dose (containing approximately 54.5 μCi radioactive 14C-GSK1322322).
88919141|NCT01663415|Experimental|Enzalutamide|
88919142|NCT01663428|Experimental|Sup-ER Splint|Experimental group that will receive Sup-ER splint.
88919143|NCT01663428|Active Comparator|Control (Currently accepted treatment)|Control group that will receive the currently accepted treatment.
88919144|NCT01663441|Experimental|A1|"Patients in this treatment group will receive NL201(5μg/kg) in the first Chemotherapy cycle.Then，in the second Chemotherapy cycle，receive NL201(7.5μg/kg).~Only for Dose-finding in Phase Ⅲa."
88919145|NCT01663441|Experimental|A2|"Patients in this treatment group will receive NL201(7.5μg/kg) in the first Chemotherapy cycle.Then，in the second Chemotherapy cycle，receive NL201(5μg/kg).~Only for Dose-finding in Phase Ⅲa."
88919146|NCT01663441|Active Comparator|A|"Patients in this treatment group will receive NL201（optimal dosing dose）in the first Chemotherapy cycle.Then，in the second Chemotherapy cycle，receive rhIL-11(25μg/kg).~Only in Phase Ⅲb."
88919147|NCT01663441|Active Comparator|B|"Patients in this treatment group will receive rhIL-11(25μg/kg) in the first Chemotherapy cycle.Then，in the second Chemotherapy cycle，receive NL201（optimal dosing dose）.~Only in Phase Ⅲb."
88919148|NCT01663454|Experimental|Cogmed Robomemo working memory training|Participants will complete 25 sessions (5 weeks) of Cogmed Robomemo (Pearson assessment) working memory training
88919149|NCT01661985|Active Comparator|Drug: Azithromycin 1g|Azithromycin 1 g,single dose (per os)
88919150|NCT01661985|Active Comparator|Drug: Doxycycline/lymecycline 9/10days|Tetracycline either as Doxycycline or during June and July lymecycline (due to lower risk of photo-sensitivity) given for treatment in 9(10)days (per os).
88919151|NCT01661985|Active Comparator|Azithromycin 1.5 g|Patients not randomized but receiving the first line treatment when a confirmed Mg infection
88919152|NCT01663467|Active Comparator|Ginkgo biloba only|control group Ginexin-F 80mg tablet will be given twice a day for 6 months.
88919153|NCT01663467|Experimental|Ginkgo biloba + modified TRT|"experimental group modified TRT (tinnitus retraining therapy) using smartphone and web based materials will be added with Ginkgo biloba.~Ginexin-F 80mg tablet will be given twice a day for 6 months."
88919154|NCT01663493|Other|Fine needle aspiration needle|standard Beacon FNA needle
88919155|NCT01663493|Other|fine needle biopsy needle|SharkCore fine needle biopsy needle
88919156|NCT01663519|Experimental|Prefabricated insoles|Prefabricated insoles with support in medial arch and metatarsal pad. A 2 mm top layer of cushioned material.
88919157|NCT01663519|Experimental|Custom made insoles 35 shore|Custom made insoles formed over an individual cast positive. 35 shore of hardness in material Ethyl Vinyl Acetate
88919158|NCT01663519|Experimental|55 shore Custom made insoles|Custom made insoles formed over an individual cast positive. 55 shore of hardness in material Ethyl Vinyl Acetate
88919159|NCT01663558|Active Comparator|imiquimod|"i. Each subject will use an imiquimod anal suppository three times weekly (overnight on Monday, Wednesday, Friday) for 12 weeks.~ii. Each subject will be asked to abstain from receptive anal sex during therapy period (12 weeks).~iii. If local imiquimod adverse effects are severe, a 7-day period off of treatment will be permitted.~iv. During 12 week therapy period, each subject will be evaluated 2, 4, 8, and 12 weeks after starting therapy. At each visit, subject will complete a therapy questionnaire and undergo anal Pap, HRA with biopsies as indicated, and anal HPV testing.~v. After therapy completed (12 weeks), subject will enter 12 month observation period."
88919160|NCT01663558|Active Comparator|ablative|"i. Subject will be referred to colorectal surgeon, will complete a therapy questionnaire, and will be treated in accordance with treatment algorithm which is already in use.~ii. Subject will be asked to abstain from receptive anal sex for 12 weeks after ablative therapy.~iii. After therapy, subject will enter 12 month observation period."
88919161|NCT01663558|No Intervention|Observation|"i. Given lack of accepted guidelines and outcome data on dysplasia management, the study PI will thoroughly discuss risks and benefits of observation/monitoring and treatment of dysplasia.~ii. If treatment is chosen, subject will be randomized to 1) ablative group, or 2) imiquimod group and begin therapy. Observation subjects will continue observation visits (observation questionnaire, anal Pap, HRA with biopsies as indicated, and anal HPV testing) every 3 months for 12 months (4 additional study visits)."
88919162|NCT01663597||Cohort 1|40 subjects with high grarde myopia ranging from -10 diopters to -4.01 diopters
88919163|NCT01663597||Cohort 2|40 subjects with moderate myopia ranging from -4 diopters to -1.01 diopter
88919164|NCT01663597||Cohort 3|40 subjects with emmetropia, -1 diopter to +1 diopter
88919165|NCT01663597||Cohort 4|40 subjects with hyperopia, +1.01 diopter and more
88919166|NCT01663610|Experimental|VardagsSMART|VardagsSMART Internet-based course with therapist support during 6 weeks
88919167|NCT01663610|No Intervention|Wait List Control (CONT)|Weekly registrations only. After 6 weeks the Internet-based course without therapist support well be offered (SelfSMART)
89010578|NCT02215174|Experimental|Asians|Drug: Rosuvastatin Rosuvastatin 20mg po x1 Other Name: Crestor
89010579|NCT02215174|Experimental|Caucasians|Drug: Rosuvastatin Rosuvastatin 20mg po x1 Other Name: Crestor
89198584|NCT00876759|Active Comparator|WBRT|standard WBRT to a total dose of 30 Gy in 10 fractions
88919168|NCT01663649|Experimental|Deprexis|Deprexis (Web-based intervention deprexis consists of ten online modules (plus one introductory and one summary module) representing different psychotherapeutic strategies with a strong focus on evidence-based cognitive-behavioral techniques (e.g. interpersonal skills). Each module lasts approximately 10-60 minutes (e.g. depending on the user´s reading speed). Modules are sequential and organized as simulated dialogues. Each module refers and builds upon previous one. The program is delivered at no cost to participants.)
88919169|NCT01663649|Active Comparator|Wait-list|Wait-list group (Subjects receive access to deprexis after six months)
88919170|NCT01663662|Active Comparator|Tolvaptan Arm|"Tolvaptan 30 mg qd x 3 days and Low Dose Loop Continuous Infusion - Initial Dosing:~Furosemide - 10 mg/hr Bumentanide - 0.25 mg/hr Torsemide - 5 mg/hr"
88919171|NCT01663662|Placebo Comparator|Placebo|Placebo x 3 days and standard of care continuous infusion diuretic
88919172|NCT01663675||Trisomy 21 (Down syndrome)|Trisomy 21 (Down syndrome)
88919173|NCT01663688||Normative Data Collection|
88919174|NCT01663701|Active Comparator|Usual care|Patients are managed according to admitting doctors' orders. Blood cultures are drawn in all patients. Antibiotics are specified by the admitting doctors.
88919175|NCT01663701|Experimental|Simplified Severe Sepsis Protocol|This protocol consists of an early aggressive fluid strategy, early blood cultures and antibiotics, and, when appropriate, blood transfusion and titratable dopamine. Monitoring is based on physical exam findings. Antibiotics are specified by the admitting doctors.
88919176|NCT01663753|Experimental|18F-FDG-PET|The 18F-FDG-PET will be performed 8 weeks following completion of brachytherapy (date of inclusion)
88919177|NCT01663766|Experimental|Milatuzumab|Milatuzumab will be added to the standard GVHD reduced intensity consitioning and prophylaxis regimen of fludarabine, busulfan, tacrolimus and low-dose methotrexate.
88919178|NCT01663792|Placebo Comparator|Placebo|5 g/d placebo (maltodextrin)in 10 500-mg capsules for 1 month
88919179|NCT01663792|Experimental|Seaweed|Seaweed (Undaria pinnatifida) given orally in ten 500-mg capsules for 1 month
88919180|NCT01663792|Placebo Comparator|Placebo2|5 g/d placebo in 10 500-mg capsules for one month
88919181|NCT01663805|Active Comparator|Everolimus|SCD/ECD: BXB (2x20mg, D1 and D4) + EVL (3.0 -8.0ng/ml) + MYF (1440mg/d)+ Prednisone
88919182|NCT01663805|No Intervention|mycophenolate sodium|SCD/ECD: BXB (2x20mg, D1 and D4) + TAC + MYF (1440mg/d)+ Prednisone
88919183|NCT01663818|Experimental|Treatment group|Treatment with Tack-IT Endovascular Staple
88919184|NCT01663831|Experimental|Topical Repellent & LLIN|
88919185|NCT01663831|No Intervention|Long Lasting Insecticidal Nets|"Brand Name LLIN: Olyset Net~Active ingredient: permethrin"
88919186|NCT01663870||Breast Cancer Survivors|Patients in the LBJ General Hospital Cancer Survivorship Clinic.
88919187|NCT01663870||Clinic Stakeholders|Survivorship clinic stakeholders include clinic nurses, physicians, case managers, oncology patient navigators currently working with those in active treatment, information technology support professionals from the Harris County Hospital District (HCHD).
88919188|NCT01663883|Experimental|Healthy subjects|
88919189|NCT01663909|No Intervention|Standard care|
88919190|NCT01663909|Experimental|Guided imagery|
88919191|NCT01663948||Patients with Plastic bronchitis|
88919192|NCT01663961|Experimental|YM178 OCAS + digoxin|
88919193|NCT01663974||Bipolar disorder patients|
88919194|NCT01664000|Experimental|Kevetrin|thioureidobutyronitrile intravenous once/week for 3 weeks/ cycle
88919195|NCT01664013|Experimental|Neuronox|Neuronox® is a botulinum toxin type A (BoNT/A) product developed by Medytox Inc. (Medytox) of Korea. Neuronox® was first approved by the Korean Food and Drug Administration in 2006, and by Thai Food and Drug Administration in 2008.
88919196|NCT01664026|No Intervention|Control|Subjects assigned to the usual care group will receive general lifestyle recommendations as per their country standards of care.
88919197|NCT01664026|Experimental|Web|Access to a web-based lifestyle modification program of 6-month duration that covers all aspects of a healthy lifestyle including physical activity, nutrition and weight maintenance.
88919198|NCT01664026|Experimental|Web+|Access to a web-based lifestyle modification program of 6-month duration that covers all aspects of a healthy lifestyle including physical activity, nutrition and weight maintenance plus telephone counseling support by health coaches on a weekly or bi-weekly basis.
89536481|NCT02475785|Active Comparator|conventional FFRD|"Upper and lower arches will be bonded, levelled and aligned until reaching 0.019 x 0.025 ss archwires.~Insertion of FFRD with application over the lower archwire"
88919199|NCT01664065|Experimental|AZ drug: A|200 mg Ceftaroline fosamil 1h infusion
88919200|NCT01664065|Experimental|AZ drug: B|600 mg Ceftaroline fosamil 1h infusion
88919201|NCT01664143|Placebo Comparator|Placebo|
88919202|NCT01664143|Experimental|RO5508887|
88919203|NCT01664156|Experimental|Korean red ginseng|The patients will receive Korean red ginseng(Korean Red Ginseng Powder Capsule®; Korea Ginseng Corporation, Daejeon, Korea). Patients will be requested to take 6 capsules 2 times a day (1h after breakfast and dinner).
88919204|NCT01664156|Placebo Comparator|placebo|Placebo Korean red ginseng capsule contain cornstarch powder with the same color and taste as Korean red ginseng. Patients will be requested to take 6 capsules 2 times a day (1h after breakfast and dinner).
88919205|NCT01664169||Single group|"The samples required for this study are stored in the CALGB Pathology Coordinating Office at The Ohio State University from patients enrolled on protocol CALGB-80303. No additional samples are required from patients.~The following markers are analyzed in EDTA plasma samples using the IMPACT a Roche proprietary multiplex ELISA platform: VEGF-A, VEGF-C, VEGF-R1, VEGF-R2, E-selectin, VEGF-R3, IL-8, bFGF, PDGF-C, ICAM-1, and PlGF."
88919206|NCT01664195|Other|Group A|Epoetin alfa Test drug in the first period and comparator drug in the second period.
88919207|NCT01664195|Other|Group B|Epoetin alfa Comparator Drug in the first period and test drug in the second period
88919208|NCT01664221|Experimental|Eritromax|Eritromax (Epoetin alfa) intravenous administration, dose: 100 IU/kg
88919209|NCT01664221|Active Comparator|Eprex|Eprex (Epoetin alfa) intravenous administration: 100 IU/kg
88919210|NCT01664260|Experimental|N-acetylcysteine + Escitalopram|The subjects with posttraumatic stress disorder, treated with N-acetylcysteine in addition to escitalopram
88919211|NCT01664260|Placebo Comparator|Placebo + Escitalopram|The subjects with posttraumatic stress disorder, treated with placebo in addition to escitalopram
89436369|NCT04502693|Experimental|ABCWY_Pooled|"Participants received 2 doses of either MenABCWY Lot 1, Lot 2, or Lot 3 vaccine on Day 1 and Day 181 and 1 dose of placebo on Day 61. Participants received 1 dose of placebo on Day 211 to maintain blinding.~To evaluate the effectiveness of 2 doses of the MenABCWY vaccines against rMenB+OMV and MenACWY vaccines, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group."
89436370|NCT04500587|Experimental|ZN-d5 Single Agent Dose Escalation - NHL|Non-Hodgkin Lymphoma
89436371|NCT04500587|Experimental|ZN-d5 Single Agent Dose Escalation - AML|Acute Myeloid Leukemia
89436372|NCT04485949|Experimental|IGV-001|Participants will be implanted with biodiffusion chambers containing IGV-001 on Day 1 and explanted on Day 3 (at approximately 48 hours following implantation). After 6 weeks, participants will receive radiotherapy (RT) per institutional standards for 5 days per week along with temozolomide 75 mg/m^2 orally, once daily (QD) for up to 12 weeks followed by temozolomide 150 to 200 mg/m^2, orally, on Days 1 to 5 of each 28-day cycle for up to 6 cycles (Week 41).
88919212|NCT01664520|Experimental|Dexmedetomine infusion|
88919213|NCT01664546||Molecular blastocyst karyotype|Trophectoderm biopsy for genetic study by aCGH
88919214|NCT01664572||Healthy subjects|
88919215|NCT01664585|Experimental|Training group|"The rationale and means for the exercise program are to~Motivate and teach participants for postural and motor control and strengthening exercises~Monitor and motivate to continue exercise training, and to increase their physical activity~Training is organised six times as a 60-min session during six months: two individually supervised sessions, and four following training sessions will be accomplished in groups of 10 participants guided by an experienced physical therapist. Three weekly similar home training sessions are recommended for participants. Information on amount of exercise sessions per week and repetitions of each exercise will be collected via exercise diary. To perform home training, a DVD and/or booklet will be provided to participants in the training group."
88919216|NCT01664585|Sham Comparator|Control|The control group will receive six sessions of Transcutaneous Nervous Stimulation treatment (TNS) as a placebo treatment (0), and the participants in this group are recommended and encouraged to maintain their previous normal level of physical activity and exercise habits throughout the study without any supervision or home training programs.
88919217|NCT01664611|Experimental|Treatment arm|Participants in this arm will receive remote ischaemic conditioning on a daily basis for 4 weeks post MI
88919218|NCT01664611|Sham Comparator|Sham arm|Participants in this arm will receive sham ischaemic conditioning on a daily basis for 4 weeks post MI
88919219|NCT01664637|Experimental|TZP-102 three times a day|10 mg TZP-102 will be taken 30 minutes prior to each main meal for a total of three daily doses.
88919220|NCT01664637|Placebo Comparator|Placebo three times a day|Placebo will be taken 30 minutes prior to each main meal for a total of three daily doses.
88919221|NCT01664650|Placebo Comparator|Lifestyle counseling|Placebo tablets. All participants were counseled on an moderate hypocaloric, Mediterranean-style diet composed of 25% to 30% energy from fat, less than 10% energy from saturated fatty acids, 55% to 60% energy from carbohydrates, and 15% energy from protein, with a cholesterol intake less than 300 mg/d and fiber intake of 35 g/d or greater.
88919222|NCT01664650|Experimental|Genistein|Genistein 54 mg/day in 2 tablets for 12 months. All participants were counseled on an moderate hypocaloric, Mediterranean-style diet composed of 25% to 30% energy from fat, less than 10% energy from saturated fatty acids, 55% to 60% energy from carbohydrates, and 15% energy from protein, with a cholesterol intake less than 300 mg/d and fiber intake of 35 g/d or greater.
88919223|NCT01664663|Active Comparator|Arm A:Standard radiochemotherapy|Radiotherapy with 2 Gy per fractions 5 fractions a week to 68 Gy to the planning target volume. Three courses of cisplatin 75 mg/m2 day 1and vinorelbine 25 mg/m2 day 1+8. Two courses concomitant with radiation.
88919224|NCT01664663|Experimental|Arm B Escalated radiochemotherapy|Radiotherapy with 2 Gy per fraction 5 or 6 times a week to 68-84 Gy to the planning target volume due to normal tissue tolerance constraints. Dose to lung tissue, esophagus and spinal cord will be considered. Three courses of cisplatin 75 mg/m2 day 1 and vinorelbine 25 mg/m2 day 1+8 will be given, two courses concomitant with radiation.
88919225|NCT01664676|Experimental|Liraglutide|1.2 mg liraglutide sc. (single-dose)
88919226|NCT01664676|Placebo Comparator|Placebo-liraglutide|Placebo liraglutide sc. (single-dose)
88919227|NCT01664689|Active Comparator|DiscoVisc|microcoaxial phacoemulsification performed with discovisc
88919228|NCT01664689|Active Comparator|Healon 5|microcoaxial phacoemulsification using healon 5
88919229|NCT01664689|Active Comparator|Celoftal|microcoaxial phacoemulsification using celoftal
89536482|NCT02475785|No Intervention|untreated control group|Patients will be observed for an average duration of 6-8 months
88919230|NCT01664702|Experimental|Recommended dairy diet|Recommended servings of dairy products per day
88919231|NCT01664702|Experimental|Low dairy diet|One or fewer dairy servings per day
88919232|NCT01664728|Experimental|Abiraterone acetate|
88919233|NCT01664754|Experimental|Treatment (exemestane, pemetrexed disodium, and carboplatin)|Patients receive exemestane PO QD on days 1-28 and pemetrexed disodium IV over 15 minutes and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
88919234|NCT01664767|Experimental|Thermal water inhalation|Patients will perform 12 days of sulfur thermal water inhalation
88919235|NCT01664767|Placebo Comparator|Isotonic saline inhalation|Patients will perform 12 days of isotonic saline inhalation
88919236|NCT01664780||Patients after liver transplantation|
89536483|NCT04989153||non-atrophic gastritis|No atrophic gastritis, The OLGA-0 group;OLGA :Operative Link on Gastritis Assessment)
89436373|NCT04485949|Placebo Comparator|Placebo|Participants will be implanted with biodiffusion chambers containing placebo on Day 1 and explanted on Day 3 (at approximately 48 hours following implantation). After 6 weeks, participants will receive RT per institutional standards for 5 days per week along with temozolomide 75 mg/m^2 orally, QD for up to 12 weeks followed by temozolomide 150 to 200 mg/m^2, orally, on Days 1 to 5 of each 28-day cycle for up to 6 cycles (Week 41).
88919237|NCT01664819|Active Comparator|Antioxidant supplementation|Randomized to receive antioxidant supplementation (vitamin C, 500 mg; beta carotene, 15 mg; and alpha-tocopherol, 400 IU) three times per week for five years.
88919238|NCT01664819|Placebo Comparator|Placebo|Randomized to receive placebo three times per week for five years
88919239|NCT01664832|Experimental|S-nIMV|nIMV synchronized using abdominal pressure capsule sensor device
88919240|NCT01664832|Placebo Comparator|nIMV|non-synchronized nasal intermittent mandatory ventilation group
88919241|NCT01664845|Active Comparator|metformin, pegylated-IFN, ribavirin|metformin,pegylated-IFN and ribavirin
88919242|NCT01664845|Placebo Comparator|Pegylated-IFN and ribavirin|pegylated -IFN and ribavirin
88919243|NCT01664871|Experimental|Levels of SIlver and Fluoride in Plasma|
88919244|NCT01664884||Bipolar Disorder Patients|Bipolar Disorder Patients, with age between 18 to 40 years old, at euthymic phase.
88919245|NCT01664884||Schizophrenia Patients|Schizophrenia Patients, with age between 18 to 40 years old, with minimum or none positive symptoms.
88919246|NCT01664936||pts receiving a PET/CT scan with Metastatic LNs|This study seeks to optically image the Cerenkov emissions from the PET tracer 18F-FDG and the radiotherapeutic 131I in a cohort of patients with primary tumor sites and from pathologic lymph nodes after routine 18F-FDG PET 31I radiotherapy and/or investigational study scans. We will include a subset of patients with normal lymph nodes during screening. This subset of patients will be imaged as a negative control for this study.
88919247|NCT01664962||Patients|Women with severe Vulvodynia
88919248|NCT01664962||Healthy controls|Women without vulvodynia
88919249|NCT01665001|Experimental|Multiagent induction-consolidation|Induction, consolidation, HSCT, maintenance for adults with newly diagnosed precursor lymphoid neoplasms
88919250|NCT01665014|Experimental|Total marrow irradiation|Double autologous hematopoietic stem cell transplantation using TMI and HD-Mel
89436374|NCT04477538||Participants with prepectoral reconstruction|-Participants will complete the post-mastectomy breast reconstruction physical well-being survey
89436375|NCT04477538||Participants with postpectoral reconstruction|-Participants will complete the post-mastectomy breast reconstruction physical well-being survey
88919251|NCT01665027|Experimental|vacuum|Vacuum is an instrument that is using for helping delivery when there is no possibility of spontaneous delivery. First report of using vacuum was in 1962 by Solomon for delivery of fetal head. He suggested that using this instrument will lower pressure on fetal head and decrease delivery time (and then decrease fetal hypoxemia). Also it decreases spreading of incision and vascular injury (during manual maneuvers).
88919252|NCT01665027|Experimental|routine manual maneuvers for fetal head extraction|"Procedure/Surgery:~fetal head techniques like fundal pushing, pulling technique or reverse breech extraction"
88919253|NCT01665066|Active Comparator|Own Brand cigarette|Smoke Own Brand cigarette, 15 puff of cigarette.
88919254|NCT01665066|Experimental|One High 2,4% nicotine|Smoke electronic cigarette One High 2,4% nicotine for a day, 15 puff of e-cigarette.
88919255|NCT01665066|Experimental|Original 7,4 mg nicotine|Smoke electronic cigarette Original 7,4 mg nicotine for a day. 15 puff of e-cigarette.
88919256|NCT01665066|Placebo Comparator|Nicotine Free|Smoke electronic cigarette nicotine free (15 puff)
88919257|NCT01665066|Experimental|EGO 9mg|Smoke electronic cigarette EGO for a day (15 puff)
88919258|NCT01665079|Experimental|Propofol|14 obese patients(IMC>35 kg m-2) scheduled for laparoscopic bariatric surgery
88919259|NCT01665105|Experimental|Zusanli Group|electroacupuncture at both Zusanli on the leg, and record simultaneously the pulse rate variability as well as take the skin blood flow and skin temperature recordings at Hoku's and Zhongzhu's region of right hand.
88919260|NCT01665105|Active Comparator|Yanlingquan Group|electroacupuncture at both Yanglingquan on the leg, and record simultaneously the pulse rate variability as well as take the skin blood flow and skin temperature recordings at Hoku's and Zhongzhu's region of right hand.
88919261|NCT01665105|Sham Comparator|Sham Group|acupuncture without electrical stimulation at non-acupoint on the leg, and record simultaneously pulse rate variability as well as take the skin blood flow and skin temperature recordings at Hoku's and Zhongzhu's region of right hand.
89536484|NCT04989153||mild-moderate atrophic gastritis|The OLGA I-II group;OLGA :Operative Link on Gastritis Assessment)
88919262|NCT01665131|Experimental|Subcutaneous ICD group|
88919263|NCT01665183|Experimental|ADI-PEG 20|arginine deiminase formulated with polyethylene glycol
88919264|NCT01665196|Experimental|18F-FDG PET/CT scanning|18F-FDG PET/CT scanning will be performed in patients with IgG4RD to determine the pictorial characteristics and measure the standardized uptake values (SUVs) of the lesions and their response to treatment.
88919265|NCT01665209|Experimental|Morphine Sulfate 60mg Extended-release tablets|A single oral dose of Morphine Sulfate 60mg Extended-release tablets of Ohm Laboratories Inc.
88919266|NCT01665209|Active Comparator|MS Contin® 60 mg Controlled-release tablets|A single oral dose of MS Contin® 60 mg Controlled-release tablets of Purdue Pharma L.P.
88919267|NCT01665222|Experimental|Morphine Sulfate 60mg Extended-release tablets|A single oral dose of Morphine Sulfate 60mg Extended-release tablets of Ohm Laboratories Inc.
88919268|NCT01665222|Active Comparator|MS Contin® 60 mg Controlled-release tablets|A single oral dose of MS Contin® 60 mg Controlled-release tablets of Purdue Pharma L.P.
88919269|NCT01665235|Active Comparator|amlodipine|The amlodipine - based antihypertensive treatment group (you can add a diuretic or other )
88919270|NCT01665235|Experimental|ACEI / ARB|ACEI / ARB -based antihypertensive treatment group ( you can add the B - blockers or other)
88919271|NCT01665248|Other|stable angina pectoris or acute coronary syndrome|
88919272|NCT01665313||participants|Full-time faculty with morning and afternoon outpatient clinics on the same day in SNUH
88919273|NCT01665339|Experimental|preload|subjects in preload group consumed salad, yogurt and water 15 minutes before the main meal.
88919274|NCT01665339|Experimental|control|subjects in control group consumed salad and yogurt with meal.
88919275|NCT01665365|Experimental|1. Remote ischemic perconditioning|Intermittent arm ischemia through four cycles of 5-min inflation and 5-min deflation of a blood-pressure cuff started in the ambulance before admission to primary percutaneous coronary intervention (intervention group).
88919276|NCT01665365|No Intervention|2.|Primary percutaneous coronary intervention (control group).
88919277|NCT01665378|Experimental|Multiple micronutrient - 1|"The study population has been divided into 6 arms receiving 3 different pre-pregnancy interventions. The study uses a double blind design therefore the supplements are differentiated by a letter and a color: P/Purple, Q/Black, S/Brown, M/Green, T/Orange, H/Red. Multiple micronutrient groups 1 and 2 receive:~Vitamin A (μg) 800 Vitamin D (IU) 600 Vitamin E (mg) 10 Vitamin C (mg) 70 Thiamine (mg) 1.4 Riboflavin (mg) 1.4 Niacin (mg) 18 Vitamin B6 (mg) 1.9 Vitamin B12 (μg) 2.6 Folic acid (μg)* 2800 Iron (mg)* 60 Zinc (mg) 15 Copper (mg) 2 Selenium (μg) 65 Iodine (μg) 150"
88919278|NCT01665378|Active Comparator|Iron and folic acid - 1|The study population has been divided into 6 arms receiving 3 different pre-pregnancy interventions. The study uses a double blind design therefore the supplements are differentiated by a letter and a color: P/Purple, Q/Black, S/Brown, M/Green, T/Orange, H/Red. Iron and folic acid groups 1 and 2 receive: iron (60mg) and folic acid (2800μg), based on current WHO recommendations for WRA.
89198585|NCT00876759|Experimental|WBRT with simulatneous boost|The experimental group will be treated with helical tomotherapy giving 3 Gy per fraction to the whole brain up to a total dose of 30 Gy in 10 fractions and raising the prescribed dose to the brain metastases to 5 Gy per fraction. The dose fall off to the normal brain should be as steep as possible around each brain metastasis. The optic chiasm and the optic nerves should not receive more than 3.5 Gy per fraction.
89530944|NCT04497935||2LPEG|Patients receiving 2LPEG who had a colonoscopy in the morning were asked to follow a similar day-before dosing regimen, where, at 7:00 pm the day before the colonoscopy, the first 1L dose was consumed over a 1-hour period, followed by the second dose at 11:00 pm. For 2LPEG patients with procedures in the afternoon, they took Dose 1 at 7:00 am and Dose 2 at 10:00 am. Any patient receiving 2LPEG was also told to consume 1L of clear liquids during the preparation procedure.
88919279|NCT01665378|Placebo Comparator|Folic Acid - 1|The study population has been divided into 6 arms receiving 3 different pre-pregnancy interventions. The study uses a double blind design therefore the supplements are differentiated by a letter and a color: P/Purple, Q/Black, S/Brown, M/Green, T/Orange, H/Red. Folic acid groups 1 and 2 receive: 2800 μg FA once a week during the pre-pregnancy period.
88919280|NCT01665378|Experimental|Multiple Micronutrient - 2|"The study population has been divided into 6 arms receiving 3 different pre-pregnancy interventions. The study uses a double blind design therefore the supplements are differentiated by a letter and a color: P/Purple, Q/Black, S/Brown, M/Green, T/Orange, H/Red. Multiple micronutrient groups 1 and 2 receive:~Vitamin A (μg) 800 Vitamin D (IU) 600 Vitamin E (mg) 10 Vitamin C (mg) 70 Thiamine (mg) 1.4 Riboflavin (mg) 1.4 Niacin (mg) 18 Vitamin B6 (mg) 1.9 Vitamin B12 (μg) 2.6 Folic acid (μg)* 2800 Iron (mg)* 60 Zinc (mg) 15 Copper (mg) 2 Selenium (μg) 65 Iodine (μg) 150"
88919281|NCT01665378|Active Comparator|Iron and Folic Acid - 2|The study population has been divided into 6 arms receiving 3 different pre-pregnancy interventions. The study uses a double blind design therefore the supplements are differentiated by a letter and a color: P/Purple, Q/Black, S/Brown, M/Green, T/Orange, H/Red. Iron and folic acid groups 1 and 2 receive: iron (60mg) and folic acid (2800μg), based on current WHO recommendations for WRA.
88919282|NCT01665378|Placebo Comparator|Folic acid - 2|The study population has been divided into 6 arms receiving 3 different pre-pregnancy interventions. The study uses a double blind design therefore the supplements are differentiated by a letter and a color: P/Purple, Q/Black, S/Brown, M/Green, T/Orange, H/Red. Folic acid groups 1 and 2 receive: 2800 μg FA once a week during the pre-pregnancy period.
88919283|NCT01665404|Experimental|Dosing Period 1|
88919284|NCT01665404|Experimental|Dosing Period 2|
88919285|NCT01665417|Experimental|Experimental Icotinib|Icotinib: 125mg, oral administration, three times per day.
89436376|NCT04472767|Experimental|Cabozantinib with Ipilimumab/Nivolumab and TACE|"Subjects receive Cabozantinib 40 mg daily on days 1-28 of a 28 day cycle, this is to be started 7-14 days after the last TACE procedure.~Nivolumab 480 mg IV on day 1 of a 28 day cycle (cycle 2 and beyond), this is to be started 7-14 days after the last TACE procedure.~Nivolumab: 3mg/kg IV on day 1 of a 21 day cycle x 1 dose.~Ipilimumab: 1 mg/kg on day 1 of a 21 day cycle x 1 dose~TACE: Within 3-4 weeks of cycle 1 day 1; may be done up to 3 times (9-12 weeks total), the intervals between each TACE treatment can vary based on investigator's discretion"
89436377|NCT04461639||Damoctocog alfa pegol|Participants with hemophilia A received damoctocog alfa pegol as prophylaxis treatment prescribed by the physician as part of normal clinical practice.
89436378|NCT04457401|Experimental|Probiotic|1 capsule daily for 8 weeks, containing 3 x 10^9 colony forming units/capsule of a Bifidobacterium strain
89436379|NCT04457401|Placebo Comparator|Placebo|1 capsule daily for 8 weeks containing the same carrier material and is similar in size, shape and taste to probiotic
89436380|NCT04457076|Experimental|LevoCept|LevoCept™ Intrauterine Contraceptive
89436381|NCT04454723|Experimental|Tranfusions and blood collection|"Patients enrolled will receive one unit each of blood and/or platelet transfusions once a week based on trigger symptoms of anemia and/or thrombocytopenia, along with blood sample collections.~Data on patient demographics, disease, and length of hospice stay will also be collected."
88919286|NCT01665417|Active Comparator|Chemotherapy Regimen 1|Chemotherapy Regimen 1：Pemetrexe 500 mg/m^2 on Day 1, Cisplatin 75 mg/m^2 on Day 1, 21 days/1 cycle, 2/4 cycles totally, until progression, withdrawal of consent, or unacceptable toxicity.
88919287|NCT01665417|Active Comparator|Chemotherapy Regimen 2|Chemotherapy Regimen 2：Docetaxel 75 mg/m^2 on Day 1, Cisplatin 75 mg/m^2 on Day 1, 21 days/1 cycle, 2/4 cycles totally, until progression, withdrawal of consent, or unacceptable toxicity.
88919288|NCT01665456||Cases (women with complications)|Cases are women aged 15-49 years who delivered within 12 months prior to data collection and had experienced obstetric complication(s) that either necessitated treatment or hospitalization in order to prevent the likelihood of death of the mother.
88919289|NCT01665456||Control (women who did not experience any complications)|Controls are women aged 15-49 years who delivered within 12 months prior to data collection. They did not have or develop any of the complications which cases experienced or suffered from.Although controls did not have complications, they were individually matched on the basis of age and location. The idea was to compare how many cases were exposed versus how many controls were exposed.
88919290|NCT01665469|Placebo Comparator|Placebo|Soft gel capsule without test material
88919291|NCT01665469|Experimental|Tomato extracted lycopene|Soft gel cups for oral use
88919292|NCT01665482|Active Comparator|Saturated fat rich diet|
89198586|NCT01045291|Active Comparator|Fusion Pacing OFF|Subjects initially randomized to the Fusion Pacing OFF Arm will receive the Fusion Pacing software download at the implant visit, but the Fusion Pacing software will be programmed OFF. At 4 months subjects in this arm will crossover to the Fusion Pacing ON Arm.
89436382|NCT04454450|Experimental|Imaged prior to primary debulking surgery|Imaging will include research PET/MRI of pelvis within 30 days of multiregion tissue collection. Concretely, in patients triaged to primary debulking surgery (PDS), PET/MRI will be obtained within 30 days preceding multi-region tissue collection at the time of PDS (already being done under IRB# 06-107).
89436383|NCT04454450|Experimental|Imaged pre/postneoadjuvant chemotherapy (NACT)|In patients triaged to neoadjuvant chemotherapy (NACT) and interval debulking surgery (IDS), PET/MRI will be obtained at two time points, i.e. first within 30 days preceding NACT/ multi-region laparoscopic tissue sampling (already being done under IRB# 06-107) and, second, any time after completion of NACT and before multi-region tissue collection at the time of interval debulking surgery (already being done under IRB# 06-107).
88919293|NCT01665482|Active Comparator|Monounsaturated fat rich diet|
88919294|NCT01665482|Active Comparator|Carbohydrate/ Low fat diet|
88919295|NCT01664988|Experimental|muscular relaxation|muscular relaxation was done using Jacobson by contracting and relaxing selected groups of muscles until total relaxation
88919296|NCT01664988|Experimental|breath control|include deep diaphragmatic breathing and decrease breath rate to 6-10/min
88919297|NCT01664988|Other|control|received routine care of clinic or health center and control their blood pressure weekly and use drugs if necessary
88919298|NCT01665495|No Intervention|Pericardiocentesis|Pericardial fluid drained by simple echo-guided pericardiocentesis
88919299|NCT01665495|Active Comparator|Extended pericardial drainage|Extended pericardial drainage will include pericardiocentesis followed by an intermittent pericardial catheter drainage. Pericardial drainage will be kept till daily fluid return<30ml
89010580|NCT04538326|Other|Single|Participants exercised in two counter balanced blocks: repeated (standard of care and self-paced repeated custom game) and random (Kinect game and game-paced random custom game). Exercise bouts were for 8.5 minutes with ten minutes of rest in between so they could return to physiological baseline. Data were collected in a single session lasting two hours.
89010581|NCT00269841|Experimental|Infliximab 10 mg/kg|Infliximab (anti-TNF chimeric monoclonal antibody [cA2]) 10 milligram per kilogram (mg/kg) will be administered as infusion at Week 0, 2 and 6.
89010582|NCT00269841|Experimental|Infliximab 5 mg/kg|Infliximab (anti-TNF chimeric monoclonal antibody [cA2]) 5 mg/kg will be administered as infusion at Week 0, 2 and 6.
89010583|NCT00269841|Placebo Comparator|Placebo|Matching placebo will be administered at Week 0, 2 and 6.
89010584|NCT04538443||hemodialysis group|One hundred children with ESRD who are treated with hemodialysis and their caregivers will participate in this study. They will be recruited from Nephrology Unit at Abo-Elreesh Hospital, Cairo University
89010585|NCT04538872|Experimental|MS group implicit|
89010586|NCT04538872|Experimental|MS group explicit|
89010587|NCT04538872|Active Comparator|HC group implicit (Healthy Controls)|
89010588|NCT04538872|Active Comparator|HC group explicit (Healthy controls)|
89010589|NCT00414128|Experimental|mycophenolate mofetil|Mycophenolate mofetil for 3-6 months until in stable remission, dose 2-3g/day
89010590|NCT00414128|Active Comparator|cyclophosphamide|pulsed intravenous cyclophosphamide 15mg/kg for 3-6 months (6-10 doses)until in stable remission
89010591|NCT04538677||F2F-Group|Patients who preferred a traditional F2F-appointment were seen at the outpatient clinic.
89010592|NCT04538677||VC-group|Patients who preferred a video consult were seen over a video connection.
89010593|NCT04538365|Active Comparator|Hand antisepsis with propanolol-1 60%|Effectiveness of pre-surgical hand washing in reducing bacterial load using propanolol-1 60% as control
89010594|NCT04538365|Experimental|Hand antisepsis with triclosan solution|Effectiveness of pre-surgical hand washing in reducing bacterial load using triclosan 0.5% solution
89010595|NCT04542772|Experimental|Mirror Therapy + Standard of Care|Participants in this group will receive standard of care based on their needs along with mirror therapy education.
89010596|NCT04542772|Active Comparator|Standard of Care|Participants in this group will receive only standard of care based on their needs.
89198587|NCT01045291|Experimental|Fusion Pacing ON|Subjects initially randomized to the Fusion Pacing ON Arm will receive the Fusion Pacing software download at the implant visit, and the Fusion Pacing software will be programmed ON. At 4 months subjects in this arm will crossover to the Fusion Pacing OFF Arm.
89198588|NCT05167539||Mechanical aortic valve replacement|simple procedure but need long term of anticoagulant
89198589|NCT05167539||Aortic root replacement|complicated procedure but without anticoagulant
89198590|NCT01047943|Experimental|Psoriasis therapy|
89010597|NCT00269880|Placebo Comparator|Placebo and Standard Dose of Heparin|Participants will receive bolus placebo followed by 12-hour infusion of placebo and bolus heparin at a dose of 100 units per kilogram of body weight.
89010598|NCT00269880|Active Comparator|Abciximab and Low Dose of Heparin|Participants will receive bolus abciximab at a dose of 0.25 milligram per kilogram (mg/kg) of body weight followed by 12-hour infusion of 0.125 microgram per kilogram per minute (mcg/kg/min) and bolus heparin at a dose of 70 units per kilogram of body weight.
89010599|NCT00269880|Active Comparator|Abciximab and Standard Dose Heparin|Participants will receive bolus abciximab at a dose of 0.25 mg/kg of body weight followed by 12-hour infusion of 0.125 mcg/kg/min and bolus heparin at a dose of 100 units per kilogram of body weight.
89010600|NCT04542655|Other|Cycling first|Ergometer cycling then treadmill running then rest
89010601|NCT04542655|Other|Running first|Treadmill running then ergometer cycling then rest
89010602|NCT04542538||COVID-19 critical care patients|All patients who have received intensive care with COVID-19 in Sweden until May 27, 2020. Patients are identified in the Swedish Intensive care registry, to which all Swedish intensive care units (ICU) are reporting all intensive care patients.
89010603|NCT04542538||Sepsis critical care patients|All patients who have received intensive care with severe sepsis or septic shock in Sweden between 2011 and 2016. Patients are identified in the Swedish Intensive care registry, to which all Swedish intensive care units (ICU) are reporting all intensive care patients.
89010604|NCT04542538||ARDS critical care patients|All patients who have received intensive care with ARDS in Sweden between 2011 and 2016. Patients are identified in the Swedish Intensive care registry, to which all Swedish intensive care units (ICU) are reporting all intensive care patients.
89010605|NCT04539067|Experimental|HMG group|Induction of ovulation from 2nd day of cycle Follow diameter of follicle When follicle 18:22mm Receive HMG
89010606|NCT04539067|Experimental|H FSH plus HHMG|Follow up ovulation from the 2nd day to 5th of menstruation cycle When follicle diameter 18mm to 22mm made induction of ovulation
89010607|NCT04538248||Continuous|Continuous
89010608|NCT04538248||Discontinuous|Discontinuous
89010609|NCT04538014|Experimental|Lu AF88434|
89198591|NCT00547534|Experimental|Lymphoma Subjects receiving protocol therapy|Subjects that met all eligibility criteria and were treated with Bendamustine, Rituxan and Bortezomib.
89436384|NCT04443179||Infants a family history of ASD/ADHD|
89010610|NCT04538209||canditates for variceal eradication|patients with documented liver cirrhosis (Based on clinical, laboratory and ultrasonographic findings) undergoing either primary or secondary prophylaxis variceal eradication at endoscopy unit of El-Rajhi hospital, Assuit University
89010611|NCT02215876|Experimental|Single Arm|Doxorubucin and Cyclophosphamide q2 or q3 weekly x 4 cycles plus Eribulin on days 1 and 8 of a 21 day cycle x 4 cycles
89010612|NCT00237731|Experimental|1|morphine 0.05
89010613|NCT00237731|Active Comparator|2|morphine 0.10
89010614|NCT04542226||Adult patients hospitalized with COVID-19|Patients eligible for enrollment into the study
89010615|NCT01641874|Experimental|Specific directional exercise|During the assessment a specific exercise will be identified for this group. The exercise will consist of a repeated specific end range movement of the knee
89436385|NCT04443179||Infants without a family history of ASD/ADHD|
89010616|NCT01641874|Active Comparator|Evidence based exercise|Quadriceps strengthening and advice on aerobic exercises will be given
89010617|NCT01641874|No Intervention|No intervention|Patient waits on the surgeons waiting list for next appointment or for planned knee surgery
89010618|NCT04537975|Active Comparator|C2Rx|Hemofiltration device
89010619|NCT04537975|Active Comparator|Standard of Care (SOC)|Standard of Care based on protocol inclusion/exclusion criteria
89010620|NCT04538131|Active Comparator|conventional SCS|
89010621|NCT04538131|Experimental|sensor-driven position-adaptive SCS|
89010622|NCT00262392|Experimental|Pamidronate|Pamidronate
89010623|NCT00262392|Active Comparator|radiation|radiation
89198592|NCT00871455|Experimental|1|Subjects will receive 20 mg baclofen for 8 weeks, followed by 40 mg baclofen for 8 weeks.
89436386|NCT04438265||quadratus lumborum|analgesic technique. The evaluation of the patient will consist of 2 stages. The first of these will consist of the evaluation consultation (clinical history, EVN evaluation, WOMAC) and initial treatment (QL2 block). In the second stage, the patient will be followed up with interviews at 3 weeks, 3 and 6 months.
89010624|NCT04537780|Placebo Comparator|group 1|(Control group n= 22): Patients will receive Placebo once daily at bedtime for 12 weeks..
89010625|NCT04537780|Experimental|Group 2|"Treatment group n= 22): Patients will receive Montelukast 10 mg daily at bedtime.~The treatment duration will be 12 weeks."
89010626|NCT04537858|Experimental|Virtual reality therapy first|Subjects with COVID-19 who will start the first day of the protocol with Virtual Reality tasks in the morning and then in the second period, in the afternoon, will perform the conventional exercises (n = 25)
89010627|NCT04537858|Experimental|Conventional therapy first|Subjects with COVID-19 who will start the first day with conventional exercises in the morning and in the second period, in the afternoon, will perform activity with virtual reality (n = 25).
89010628|NCT04537819|Experimental|The main group|"1. soft diet; 2. Elimination of factors that irritate the mucous membrane of the pharynx (thermal, chemical); 4. Local NSAIDs - benzydamine hydrochloride. 5. Imupret oral drops in the age-related dosage of 6 times per day for 6 days with the subsequent transition to the regime of 15 drops / 3 times in a day according to the patient's condition.~6. Paracetamol as antipyretic, if necessary."
89010629|NCT04537819|Other|The comparison group|1. soft diet; 2. Elimination of factors that irritate the mucous membrane of the pharynx (thermal, chemical); 4. Local NSAIDs - benzydamine hydrochloride. 5. Paracetamol as antipyretic, if necessary.
89010630|NCT02215915|Experimental|IVUS guided DES implantation|Stent size and length were selected by online IVUS measurements, and adjunct high-pressure dilation was performed according to the discretion of operators based on the IVUS criteria for stent optimization.
89010631|NCT02215915|Active Comparator|Angiography guided DES implantation|Stent size and length were chosen by visual estimation, and adjunct high-pressure dilation was performed if an optimal result was not achieved, which was defined as angiographic residual diameter stenosis 20% and absence of angiographically detected dissection.
89010632|NCT00262431|Active Comparator|Early (A)|Patients of the EARLY group (A) will be submitted to tracheostomy on day 3-5 from oro/nasotracheal intubation.
89010633|NCT00262431|Active Comparator|Late (B)|Patients of the LATE group (B) will undergo tracheostomy on day 10-12 from oro/nasotracheal intubation.
89010634|NCT00237926|Experimental|1|aerobic exercise
89010635|NCT00237926|Experimental|2|Resistance Training
89010636|NCT02215993|Active Comparator|Prasugrel|After 300mg or 600mg loading dose of clopidogrel, this medication will be replaced by 60 mg prasugrel followed by 10mg per day for 30 days.
89010637|NCT02215993|Active Comparator|Ticagrelor|After 300mg or 600mg loading dose of clopidogrel, this medication will be replaced by 180 mg ticagrelor followed by 90mg twice a day for 30 days.
89010638|NCT04537546|Experimental|Elasto compression belt|all patients must wear the belt 2 months after laparoscopic digestive surgery.
89010639|NCT04537702|Active Comparator|Tradition Counseling Group (TG)|After completion of baseline surveys, the TG subjects will be referred to a formal pre-test consultation with a genetic counselor. TG subjects will complete an electronic family history questionnaire (FHQ) within one week of the primary visit. A member of the genetics team will curate the results by contacting the subject to review errors and clarify any ambiguities in the pedigree. The TG subjects will then meet with the genetic counselor. After counseling, participants will be given the option to undergo a multi-gene panel genetic test. Those who agree to testing will also complete the standard genetic testing consent form. As per standard practice, patients will also be asked to provide consent for somatic tumor testing of surgical (non-cytologic) specimen. Subjects will complete a post-education distress and anxiety survey (IES) either via an email link to a confidential REDCap survey link 1-2 weeks after formal consultation.
89198593|NCT00876837||Adults with pediatric-onset SCI|
89198594|NCT00962182|Experimental|Enzyme treatment|Enzyme for 12 weeks
89198595|NCT00962182|Placebo Comparator|Placebo control|Placebo enzyme for 12 weeks
89436387|NCT04438265||Control|Current analgesia , no QL block apply
88919300|NCT01665534|Experimental|Effect of salt intake|During the high salt intake period, patients received a 10-20 mmol sodium diet plus sodium tablets (180 mEq/die) to achieve a 200 mmol intake /day for two weeks. During the low salt intake period, patients received a 10-20 mmol sodium diet + placebo tablets for two weeks.
88919301|NCT01664507|Active Comparator|conventional dose epinephrine|L-epinephrine (1:1000) 0.5 mL/kg (maximum 5mL) + normal saline : total 5mL
88919302|NCT01664507|Experimental|low dose epinephrine|L-epinephrine (1:1000) 0.1 mL/kg (maximum 1mL) + normal saline : total 5mL
88919303|NCT01665547|Active Comparator|l-carnitine|adding 3gm l-carnitine from day 1 to day 12 of induced the menstrual cycle by 50 mg clomiphene
88919304|NCT01665560||Smokers--Currently Smoking|Individuals that are right handed, and not claustrophobic were recruited. This same group was used for the smoking-group and refrain from smoking was evaluated by CO2 evaluation. To be classified as smokers, they had to report smoking 3-10 cigarettes daily for at least the last year and have a carbon monoxide reading of CO >10 ppm.
88919305|NCT01665560||Non-Smoker|Healthy individuals meeting the inclusion criteria who claim to not smoke. This is confirmed w/ CO testing.
88919306|NCT01665586|Placebo Comparator|Group C|: Spinal anesthesia with 6mg bupivacaine and intrathecal placebo(normal saline) added
88919307|NCT01665586|Active Comparator|Group F|: Spinal anesthesia with 6mg bupivacaine and intrathecal small dose of fentanyl(20micro gram)
88919308|NCT01665612|Experimental|MPDS1|Contact lens care solution
88919309|NCT01665612|Active Comparator|MPDS2|Contact lens care solution
88919310|NCT01665612|Active Comparator|MPDS3|Contact lens care solution
88919311|NCT01665625|Experimental|regional interventional chemotherapy group|
88919312|NCT01665625|No Intervention|systemic chemotherapy|
88919313|NCT01665638|Experimental|Treatment Sequence Group AB|
88919314|NCT01665638|Experimental|Treatment Sequence Group BA|
88919315|NCT01665651|Placebo Comparator|kidney Yin deficiency with placebo|chronic renal insufficiency patients with kidney Yin deficiency evaluated with traditional Chinese medicine will be given Zuogui granules placebo treatment besides basic treatment.
88919316|NCT01665651|Placebo Comparator|kidney Yang deficiency with placebo|chronic renal insufficiency patients with kidney Yang deficiency evaluated with traditional Chinese medicine will be given Yougui granules placebo treatment besides basic treatment.
88919317|NCT01665651|Experimental|kidney Yin deficiency with Zuogui|chronic renal insufficiency patients with kidney Yin deficiency evaluated with traditional Chinese medicine will be given Zuogui granules treatment besides basic treatment.
89436388|NCT04417088|Experimental|Exablate BBBD with carboplatin|Carboplatin will be administered via IV infusion about every 4 weeks for up to 6 cycles. The dosage will be calculated based on subject's creatinine level. On the day of planned carboplatin therapy, subjects will undergo Exablate procedure to open the blood-brain-barrier in the targeted cancerous brain areas prior to Carboplatin administration.
88919318|NCT01665651|Experimental|kidney Yang deficiency with Yougui|chronic renal insufficiency patients with kidney Yang deficiency evaluated with traditional Chinese medicine will be given Yougui granules treatment besides basic treatment.
88919319|NCT01665664|Other|Hypocaloric feeding group|intervention - Daily calorimetry for the first 6 days will be performed with determination of REE and the required amount of calories needed for the next 24 hours. In this group only 20% of REE will be provided but not less than 300 kcal/day.
89436389|NCT04409353|Experimental|Virtual Reality Program A|This arm will include software that provides immersive skills-based content for pain reduction.
89436390|NCT04409353|Active Comparator|Virtual Reality Program B|This arm will include software that provides immersive distraction based content for pain reduction.
88919320|NCT01665664|No Intervention|Full energy feeding group|Daily calorimetry for the first 6 days will be performed with determination of REE and the required amount of calories needed for the next 24 hours. In this group only 100% of REE will be provided.
88919321|NCT01665690|Experimental|Intervention period|The study will include 23 WA state local health jurisdictions (LHJ). Each LHJ will be a randomized unit and a unit in which we will measure outcomes. (LHJs are governmental administrative units that usually correspond with a county.) Because this is a stepped-wedge randomized trial, the study will have two groups (intervention and control). However, each LHJ will be in both groups depending on the time period.
88919322|NCT01665690|No Intervention|Control Period|The study will include 23 WA state local health jurisdictions (LHJ). Each LHJ will be a randomized unit and a unit in which we will measure outcomes. (LHJs are governmental administrative units that usually correspond with a county.) Because this is a stepped-wedge randomized trial, the study will have two groups (intervention and control). However, each LHJ will be in both groups depending on the time period.
88919323|NCT01665703|Experimental|FDG PET/MR|Participents will undergo a gadolinium enhanced FDG PET/MR study.
88919324|NCT01665729||artery-artery embolus|There is no hypoperfusion ( contralateral compensatory is good )
88919325|NCT01665729||Hypoperfusion|Contralateral compensatory not sufficient
88919326|NCT01665729||Hypoperfusion and embolus amotic|Hypoperfusion and embolus amotic
89536485|NCT04989153||severe atrophic gastritis|The OLGA III-IV group;OLGA :Operative Link on Gastritis Assessment)
89436391|NCT04409353|Sham Comparator|Virtual Reality Program C|This arm will include software that provides nonimmersive distraction based content for pain reduction.
89436392|NCT04352270|Active Comparator|Group 1- Printed educational materials|Parent-child dyads randomized to this group will receive printed educational materials in English or Spanish about atopic dermatitis.
89536486|NCT04989153||gastric cancer|gastric cancer
88919327|NCT01665742|Active Comparator|Anti-inflammatory supplement|"8-weeks of daily supplementation with:~1 x fruit juice fortified with fish oil, and 4 x film-coated tablets containing vitamin C, alpha-tocopherol, green tea extract and lycopene~in conjunction with a weight management programme"
88919328|NCT01665742|Placebo Comparator|Placebo supplement|"8 weeks of daily supplementation with:~1 x fruit juice fortified with high-oleic sunflower oil, and 4 x film-coated placebo tablets~in conjunction with a weight management programme"
88919329|NCT01665755|Experimental|Precompression|Control arm
88919330|NCT01665755|Active Comparator|Upstroke Compression|Intervention arm
88919331|NCT01665781|Experimental|Erythropoietin|Erythropoietin 10,000U, weekly, for 4 weeks Last dose: 1 week before departure (10days before high altitude)
88919332|NCT01665781|No Intervention|Control|No erythropoietin
88919333|NCT01665820||Auscultate with mechanical stethoscope|Cardiologist & Medical Resident auscultate using mechanical stethoscope
88919334|NCT01665820||Auscultate with electronic stethoscope|Cardiologist & Medical Resident auscultate using electronic stethoscope
88919335|NCT01665846|Experimental|Ferumoxotyol|Brain MRI will be performed before and 48 +/- 8 hours after ferumoxytol administration.
88919336|NCT01665885|Active Comparator|Endovascular cooling|Endovascular cooling using the cooling device ZOLL Thermogard XP with ZOLL Quattro cooling catheter
88919337|NCT01665885|Active Comparator|Surface cooling|Surface cooling using the cooling device BARD/Medivance Arctic Sun 5000 with BARD/Medivance Arctic Gel Pads
88919338|NCT01665885|No Intervention|Control group|Best medical treatment following international stroke guidelines
88919339|NCT01665898|Active Comparator|Cold biopsy forceps|Cold biopsy forceps for removal of colon polyps
88919340|NCT01665898|Active Comparator|Cold Snare Biopsy|Cold snare biopsy for removal of colon polyps
88919341|NCT01665924|Experimental|40-50 years old|GLPG0634 100mg capsule once a day for 10 days in healthy subjects between 40 and 50 years old
88919342|NCT01665924|Experimental|65-74 years old|GLPG0634 100mg capsule once a day for 10 days in healthy subjects between 65 and 74 years old
88919343|NCT01665924|Experimental|75 years and older|GLPG0634 100mg capsule once a day for 10 days in healthy subjects of 75 years and older
88919344|NCT01665937|Experimental|STA-9090|Patients receiving STA-9090
88919345|NCT01665963|Active Comparator|TopClosure(c) Treated Wound|Pressure Bandage using the TopClosure(C) System
88919346|NCT01665963|Active Comparator|Traditional Wound Closure Treatment|Pressure Bandage
88919347|NCT01665976|Experimental|A: film coated tablets, fasted condition|
88919348|NCT01665976|Experimental|B: film coated tablets, fed condition|
88919349|NCT01665976|Experimental|C: hard gelatin capsules|
88919350|NCT01665976|Experimental|D: oral suspension|
88919351|NCT01665989|Experimental|Group Lifestyle program|The group lifestyle program used in the IDOLc study is adapted from the first 6 months of the Look AHEAD program and will include 19 group sessions offered over a six month period. Each of 2 groups will contain up to 15 patients with type 2 diabetes and will last 1-1.5 hours. The program curriculum focuses on nutrition, activity, and behavioral topics and incorporates the use of meal replacements for the first 4-16 weeks to enhance weight loss success. The program fosters the development of knowledge and lifestyle skills to change diet and exercise habits through use of goal setting, problem solving, stimulus control and other behavioral techniques that have resulted in weight loss, weight maintenance and improved glycemic control.
88919352|NCT01665989|Active Comparator|Usual Care|A research assistant will provide the usual care group participants with brief (~15-20 minutes) counseling which reviews an educational handout emphasizing that modest weight loss (5 - 10%) via caloric restriction and gradual adoption of moderate increases in daily physical activity (equivalent to brisk walking for 30 minutes daily) is safe and effective in managing diabetes; and refer them to Nutrition Services for follow up.
88919353|NCT01666015|Experimental|Exercise (EX)|This group will perform two phases of an EX program.
88919354|NCT01666015|Active Comparator|Standard Care|This group will follow the standard care without any EX prescription.
88919355|NCT01666028|Experimental|Closed Loop Glucose control|Subject's glucose level is controlled by the automated closed loop glucose control system
88919356|NCT01666028|Active Comparator|CSII with real-time CGM|Subject glucose level controlled by usual insulin pump therapy in conjunction with real time continuous glucose monitoring (CGM)
88919357|NCT01666041|Placebo Comparator|placebo|placebo
88919358|NCT01666041|Active Comparator|fenofibrate/omega|fenofibrate/omega
88919359|NCT01666041|Active Comparator|fenofibrate|fenofibrate
88919360|NCT01666054|Active Comparator|Proportional Assist Ventilation (PAV)|Proportional Assist Ventilation (PAV+ on the PB840 ventilator) will be used according to a weaning algorithm. If patients develop distress despite maximum levels of support on PAV+, they will be temporarily switched to assist control mode.
88919361|NCT01666054|Active Comparator|Pressure Support Ventilation (PSV)|Pressure Support Ventilation on the PV840 ventilator will be used according to a weaning algorithm. If patients develop distress despite maximal level of support on PSV, they will be temporarily switched to assist-control mode.
88919362|NCT01666067|Active Comparator|placebo|placebo
88919363|NCT01666067|Active Comparator|vytorin|vytorin
88919364|NCT01666067|Active Comparator|simvastatin|simvastatin
88919365|NCT01666093|Other|revascularization group|patients will revascularized after a conservative treatment failure of at least 4 weeks
88919366|NCT01666106||Subjects with cancer and ONJ|Subjects with cancer and positively adjudicated ONJ
88919367|NCT01666132|Experimental|Intramyocardial injection of BM cells|
89436393|NCT04352270|Experimental|Group 2- Educational videos|Parent-child dyads randomized to this group will receive an investigator developed educational video in English or Spanish about atopic dermatitis.
88919368|NCT01666132|Experimental|Intramyocardial / intracoronary injection of BM cells|
88919369|NCT01666132|Other|control|
88919370|NCT01666158|Active Comparator|Exercise|Patients in this group will follow standard MUHC protocol of nutritional counseling and supplementation as needed in order to maintain caloric and protein requirements in the preoperative period. Additionally, these patients will be given a specific physical exercise program before and after surgery by kinesiologist.
88919371|NCT01666158|No Intervention|Standard nutrition counselling|Patients in this group will follow standard MUHC protocol of nutritional counseling and supplementation as needed in order to maintain caloric and protein requirements in the preoperative period. This group will receive general instructions on exercises (breathing, ankle rotation) to be done during hospital stay by kinesiologist.
88919372|NCT01666223|Experimental|Colesevelam|
88919373|NCT01666223|Experimental|Chenodeoxycholic acid|
88919374|NCT01666223|Experimental|Colesevelam + chenodeoxycholic acid|
88919375|NCT01666223|Experimental|Placebo|
88919376|NCT01666236|Other|Triple Therapy|"The treatment (single group) will be treated with reduced-fluence Photodynamic Therapy (Visudyne -Verteporfin infused over 10 minutes at a dose of 6mg/m2 and following by activating light [wavelength of 689 nm] applied 15 minutes after the start of infusion with a light dose of either 25 J/cm2 for 83 seconds), followed by an Intra-vitreous triamcinolone (4mg/0.1ml) on the same day.~After 10 days, patients will be subjected to an injection of Intra-vitreous ranibizumab (0.5 mg/0.05 ml). After this first injection, Intra-vitreous ranibizumab will be repeated twice, on a monthly basis, for a total of three injections"
88919377|NCT01666249|Experimental|Immunoglobulin Anti-RhD|Participants will receive a single intramuscular administration of 300 mcg/2mL, correponding 1500 UI of Human Immunoglobulin Anti-RhD (Kamrho-D - Panamerican), up to 72 hours post exposition (child-birth).
88919378|NCT01666262|Experimental|A/17/CA/2009/38 (H1N1)|
88919379|NCT01666262|Placebo Comparator|Stabilizer|
88919380|NCT01666275||Aspirin desensitization|This group of patients has AERD (aspirin exacerbated respiratory disease) and is undergoing aspirin desensitization.
89436394|NCT04343872|Active Comparator|Receive lifestyle modification alone (DPP)|Participants in this arm will receive a lifestyle modification intervention program facilitated by Peer Coach (PC) services
89436395|NCT04343872|Experimental|Receive lifestyle modification with metformin therapy|Participants in this arm will receive a lifestyle modification intervention program facilitated by Peer Coach (PC) services plus metformin recommendation
88919381|NCT01666288||IT Anaphylaxis|Blood samples will be taken from patient that develop anaphylaxis to routine outpatient allergen or venom immunotherapy.
88919382|NCT01666301|Active Comparator|C.E.R.A.|C.E.R.A. every 4 and then every 2 weeks
89436396|NCT04340947|Other|Menthol very low nicotine cigarette|Participants will smoke menthol flavored very low nicotine cigarettes in their home environment for 7 days. At the end of 7-days, they will also smoke one menthol flavored very low nicotine cigarette in the laboratory.
89436397|NCT04340947|Other|Non-menthol very low nicotine cigarette|Participants will smoke non-menthol flavored very low nicotine cigarettes in their home environment for 7 days. At the end of 7-days, they will also smoke one non-menthol flavored very low nicotine cigarette in the laboratory.
88919383|NCT01666301|Active Comparator|Darbepoetin|Darbepoetin alfa every 4 and then every 2 weeks
88919384|NCT01666327|Experimental|MT-1303|
88919385|NCT01666353|Experimental|Therapeutic response for solid tumors|Adult patients, with documented metastatic melanoma, RCC or NSCLC, about to initiate any line of immune checkpoint blockade therapy will receive a FDG PET scan during mid treatment to check for change in disease.
88919386|NCT01666366|Active Comparator|In Situ Bilateral mammary grafting|Coronary artery bypass grafting: BITA in situ (LITA to the LAD and RITA to the marginal branches into the transverse sinus)
88919387|NCT01666366|Active Comparator|Y composite Bilateral mammary grafting|Coronary artery bypass grafting: BITA Y (LITA to the LAD and RITA to the marginal branches but anastomozed proximally to the LITA in a Y configuration
88919388|NCT01666379|Experimental|Fentanyl|
88919389|NCT01666379|Placebo Comparator|placebo|
88919390|NCT01666392|Experimental|Fish oil (Omega-3 fatty acid)|2 capsules/day of ProOmega providing 650mg EPA and 450mg DHA
88919391|NCT01666392|Placebo Comparator|Soybean oil|2 capsules/day
88919392|NCT01666405|Experimental|Urgent(R) PC Neuromodulation System|Urgent(R) PC Neuromodulation System
88919393|NCT01666418|Other|Pazopanib/Paclitaxel|
88919394|NCT01666431|Other|Lapatinib|
88919395|NCT01666457||Pre-SOFFI infants|Infants discharged from the NICU prior to the implementation of the SOFFI infant driven feeding program with NICU staff.
88919396|NCT01666457||Post SOFFI infants|Subject infants discharged from the NICU at least 6 months after the implementation of the SOFFI infant driven feeding program and
88919397|NCT01666470||Drug allergy patients|Patients with a history of drug allergy in Thailand
89436398|NCT04323423|No Intervention|Control (CON)|1) Condition A (CON): This will be the control condition. It will consist of uninterrupted sitting from 8 am until 7 pm, only rising from the chair to void.
89436399|NCT04323423|Experimental|one 10 minute bout - (LONG)|will consist of completing one 10-minute bout of light intensity walking (RPE 6-9) 30 minutes post-prandial. Participants will rise from their seated position to walk ~10 metres to a treadmill to perform this bout. The participant will repeat this after lunch and dinner, for an accumulated total of 30 minutes of light walking.
89536487|NCT04911959|Active Comparator|control group|patients receive transcatheter arterial chemoembolization (TACE) only.
88919398|NCT01664715|Active Comparator|150 Minutes per Week|Performs 150 minutes of physical activity per week.
88919399|NCT01664715|Active Comparator|225 Minutes per Week|Performs 225 minutes of physical activity per week.
88919400|NCT01664715|Active Comparator|300 Minutes per Week|Performs 300 minutes of physical activity per week.
88919401|NCT01666483|Active Comparator|micro-laparoscopy|M-LPS hysterectomy was performed through one optical trans-umbilical 5 mm trocar and three 3 mm sovra-pubic ancillary ports. A 5 mm 0° endoscope and 3 mm laparoscopic instruments were utilized, choosing among graspers, cold scissors, suction/irrigation and bipolar coagulator.
88919402|NCT01666483|Active Comparator|laparoendoscopic single site surgery|LESS hysterectomy was performed through a multi-channel single trocar inserted in the umbilicus using an open technique (1.5-2 cm cutaneous incision), as previously reported. Intra-abdominal visualization was obtained with a 0° 5-mm telescope with a flexible tip.Working straight 5-mm instruments were inserted into the remaining 2 ports, choosing among graspers, cold scissors, suction/irrigation bipolar coagulator and a multifunctional versatile laparoscopic device, which grasps, coagulates and transects simultaneously. In order to prevent clashing between instruments and surgeon's hands and to facilitate surgical manoeuvres, the combination of one 33 cm-long instrument with a 43 cm-long instrument was adopted. The umbilical fascia was closed with a figure-of-eight 0-Vicryl.
88919403|NCT01666496|Experimental|Experimental Video Game|Participants will play the experimental videogame for 6 weeks. The intervention will be provided during 12 sessions, twice weekly for 6 weeks; each session will involve one and one-quarter hour of game play.
88919404|NCT01666496|Other|Off the Shelf Video Game|Participants will play the off the shelf videogame for 6 weeks. The intervention be provided during 12 sessions, twice weekly for 6 weeks; each session will involve one and one-quarter hour of game play.
88919405|NCT01666509|Experimental|Rossoseq™|Gel, topically applied twice daily
88919406|NCT01666509|Placebo Comparator|Vehicle|Gel, topically applied twice
88919407|NCT01666522|Experimental|Vitamin D|vitamin D-oral cholecalciferol 2000 IU/day for 4 months
88919408|NCT01666522|Active Comparator|Physical activity|A 3-day/week exercise programme lasting 60 minutes each day for 4 months was instigated.
88919409|NCT01666522|Experimental|Vitamin D and Physical activity|Vitamin D -oral cholecalciferol 2000 IU/day and Physical activity-60-minute 3-day/week exercise programme
88919410|NCT01666522|Placebo Comparator|Control|The control group was provided with health education using videotaped presentations, physician talks on topics concerning bone and muscle health.
88919411|NCT01666535|Other|Influenza vaccination Timing #1|Influenza vaccination administered on the same day as infliximab administration (Day 0 to 4).
88919412|NCT01666535|Other|Influenza vaccination Timing #2|Influenza vaccination administered at the mid-point between infliximab infusions (Day 21 to 28)
88919413|NCT01666561|Experimental|Breakfast Test Cereal 1, Oat based|"Test cereal 1, Oat based breakfast cereal- you will be randomly presented with a breakfast consisting of either:~Oat-based breakfast cereal with lactose-free, fat-free milk to drink or ready-to-eat cereal in lactose-free, fat -free milk with water to drink. Then you will complete a visual analog scale at 30, 60, 120. 180, and 240 minutes following the start of breakfast meal."
88919414|NCT01666561|Experimental|Breakfast Test Cereal 2, Oat-based|"Test Cereal 2, Oat-based breakfast cereal. You will be randomly presented with a breakfast consisting of either:~Oat-based breakfast cereal with lactose-free, fat-free milk to drink or ready-to-eat oat brand cereal in lactose-free, fat -free milk with water to drink. Then you will complete a visual analog scale at 30, 60, 120. 180, and 240 minutes following the start of breakfast meal."
88919415|NCT01666561|Experimental|Ready-to-eat cereal|"Ready-to-eat cereal, Oat based breakfast cereal- you will be randomly presented with a breakfast consisting of either:~one Oat-based breakfast cereal with lactose-free, fat-free milk to drink or ready-to-eat cereal in lactose-free, fat -free milk with water to drink. Then you will complete a visual analog scale at 30, 60, 120. 180, and 240 minutes following the start of breakfast meal."
88919416|NCT01666574|Experimental|Test cereal 1, Oat-based|The purpose of this arm is to determine if a breakfast containing 250 kcal of Oat based cereal will cause people to eat less at lunch.
88919417|NCT01666574|Experimental|Test Cereal 2, Oat based|The purpose of this arm is to determine if a breakfast containing 250 kcal of Oat based ready-to-eat cereal will cause people to eat less at lunch.
88919418|NCT01666587|No Intervention|control|Control trial to determine the impact of the ischemic injury on vascular function without intervention
88919419|NCT01666587|Experimental|Antioxidant load|Trial to determine the impact of an antioxidant load before the ischemic injury on vascular function recovery
88919420|NCT01666587|Experimental|Prostaglandin inhibition|Trial to determine the impact of a non-selective prostaglandin inhibitor before the ischemic injury on vascular function recovery
88919421|NCT01666587|Experimental|Combined|Trial to determine the impact of an antioxidant load and prostaglandin inhibitor before the ischemic injury on vascular function recovery
88919422|NCT01666600|Experimental|BIBF 1120 + reirradiation|2 x minimal tolerated dose BIBF 1120 per day in combination with radiotherapy (2 Gy / fraction; 36 Gy in total)
88919423|NCT01666600|Active Comparator|reirradiation alone|radiotherapy (2 Gy / fraction; 36 Gy in total)
88919424|NCT01666613|Experimental|1|AZD8683 iv
88919425|NCT01666613|Experimental|2|AZD8683 oral
88919426|NCT01666613|Experimental|3|AZD8683 inhalation New Dry Powder Inhaler
88919427|NCT01666613|Experimental|4|AZD8683 inhalation Turbuhaler™
88919428|NCT01666626||Crohn's Inpatients|Crohn's Inpatients, with clinical small bowel obstruction All undergo ultrasound stiffness imaging (USI) of distal affected ileum.
88919429|NCT01666626||Crohn's Outpatients|Crohn's Outpatients, starting anti-TNF therapy All undergo ultrasound stiffness imaging (USI) at week 0, 6, 14
88919430|NCT01666639|Active Comparator|Control Group|
88919431|NCT01666639|Experimental|Intervention Group|
88919432|NCT01666665|Active Comparator|metformin|Metformin up to 1000mg/m2 body surface area by mouth of feeding tube up to 3 times each day for 12 months
88919433|NCT01666665|Placebo Comparator|Sugar pill|sugar pill up to 3 times per day for 12 months
88919434|NCT01666678|Experimental|Arm 1|
88919435|NCT01666678|Active Comparator|Arm 2|
88919436|NCT01666678|Active Comparator|Arm 3|
88919437|NCT01666678|Experimental|Arm 4|
88919438|NCT01666691|Placebo Comparator|Placebo|ZGN-440 sterile diluent
88919439|NCT01666691|Experimental|0.3 mg Beloranib|0.3 mg ZGN-440 for injectable suspension
88919440|NCT01666691|Experimental|0.6 mg Beloranib|0.6 mg ZGN-440 for injectable suspension
88919441|NCT01666691|Experimental|1.2 mg Beloranib|1.2 mg ZGN-440 for injectable suspension
88919442|NCT01666691|Experimental|2.4 mg Beloranib|2.4 mg ZGN-440 for injectable suspension
88919443|NCT01666691|Experimental|3.2 mg Beloranib|3.2 mg ZGN-440 for injectable suspension
88919444|NCT01666704|Experimental|Treatment A: BMS-823778 (2mg)|
88919445|NCT01666704|Experimental|Treatment B: BMS-823778 (15mg)|
88919446|NCT01666704|Placebo Comparator|Treatment C: Placebo|
88919447|NCT01666717||Healthy controls (HC)|HC
88919448|NCT01666717||Inflammatory Bowel Disease (IBD) patients|Crohn's disease (CD), Ulcerative colitis (UC) and pouchitis
88919449|NCT01666743|Experimental|Ceftaroline fosamil|IV ceftaroline fosamil 600 mg infused over 60 (± 10) minutes every 12 hours (dosing may be adjusted for renal impairment)
88919450|NCT01666756|Experimental|Treatment (Chinese herbal formulation PHY906 and sorafenib)|Patients receive Chinese herbal formulation PHY906 PO BID on days 1-4, 8-11, 15-18, 21-24 and sorafenib tosylate PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88919451|NCT01666769|Other|Treatment Dosing|Age group: 0 - <2y, Micafungin 8 mg/kg/day IV
88919452|NCT01666769|Other|Prophylaxis dosing|Age group: 0-<2y, Micafungin 4 mg/kg/day IV
88919453|NCT01666769|Other|Standard of care Dosing|Age group: 2-17.85 y, Micafungin standard of care dosing (decided by treating physician)
88919454|NCT01666795||IVIG therapy in ITP|IVIG therapy in untreated adults with severe ITP
88919455|NCT01666821||early and intermediate-stage AMD|Follow-up observation was implemented in whose fundus examination show lesions in the early and intermediate-stage AMD
88919456|NCT01666847|Experimental|Cord Milking|Infant receiving cord milking intervention before umbilical cord clamped.
88919457|NCT01666847|No Intervention|Immediate Cord Clamping|Infant whose umbilical cord is immediately clamped after delivery.
88919458|NCT01666860||Anterior Lumbar Interbody Fusion procedure|
88919459|NCT01666886|Experimental|Mandibular Advancement Device (MAD)|Mandibular advancement during therapy with a mandibular advancement device (MAD) in 90% of maximal protrusion
88919460|NCT01666899|Experimental|Skin and blood vessel procedures|All patients will be placed into Arm 1. They will undergo punch biopsies of the breast skin at the time of mastectomy and at 2, 4, 6, 8 and 12 months after completion of radiation therapy. Three more biopsies will be taken at 3, 6, and 12 months after completion of reconstruction. Patients will also undergo skin blood flow studies with a laser imaging device prior to each biopsy procedure. Ultrasound studies of the chest vessels will be performed 4 times over the course of the study- once prior to radiation and at 2, 6 and 12 months after radiation.
88919461|NCT01666925|Experimental|ChAd63 ME-TRAP and MVA ME-TRAP|ChAd63 ME-TRAP / MVA ME-TRAP heterologous prime-boost immunisation
88919462|NCT01666925|Active Comparator|Rabies vaccine|2 x 2.5IU Verorab
89436400|NCT04323423|Experimental|four 2.5 minute bouts SHORT|will consist of interrupting sitting with four 2.5-minute bouts of light walking at 30 minutes, 60 minutes, 90 minutes and 120 minutes post-prandial. Participants will rise from their seated position to walk ~10 metres to a treadmill to perform these bouts. The participant will repeat this after breakfast, lunch and dinner for an accumulated total of 30 minutes of light walking.
88919463|NCT01666938|Experimental|Diabetes Education Group & Telephone counseling|This step was done for four months.
88919464|NCT01666938|Active Comparator|Telephone counseling about physical activity|This step was done for four months.
88919465|NCT01666964||3 months post-injury|Male and female combat veterans age 18 years and older with the diagnosis of Traumatic Brain Injury caused by a blast that occurred 3 months prior to enrollment, 50% mild, 50% moderate and severe
88919466|NCT01666964||6 months post-injury|Male and female combat veterans age 18 years and older with the diagnosis of Traumatic Brain Injury caused by a blast that occurred 6 months prior to enrollment, 50% mild, 50% moderate and severe
88919467|NCT01666990|Experimental|TwHF, lifestyle counseling|Participants will receive TwHF (20mg each time, 3 times per day, for 48 weeks) from Day 0 through the Week 48 study visit.
88919468|NCT01666990|Placebo Comparator|placebo, Lifestyle|Participants will receive placebo treatment (20mg each time, three times per day for 48 weeks) from Day 0 through the Week 48 study visit.
88919469|NCT01667003||Orsiro DES|
88919470|NCT01667016||Orsiro DES|
88919471|NCT01667042||Without Interstitial lung disease (ILD)|
88919472|NCT01667042||With Interstitial lung disease (ILD)|
88919473|NCT01667055||Patients with suspected drug allergy|Patients with a history of hypersensitivity reaction to beta-lactam antibiotics
88919474|NCT01667068||Regional Ruhrgebiets Cohort|HIV-positive patients in the German Ruhr-Region from out-patient clinics of hospitals and HIV-physicians pratices
88919475|NCT01667094|Active Comparator|Intermittent, short infusion|"Infusion over 30 minutes of either:~Cefepime 1g q8/24 OR Ceftazidime 2g q8/24 OR Meropenem 1g q8/24 OR Piperacillin-Tazobactam 4.5g q8/24 OR Ticarcillin-clavulanate 3.1g q6/24~Antibiotic chosen by treating physician"
88919476|NCT01667094|Experimental|Continuous infusion|"Continuous infusion of either:~Cefepime 1.5g over 12h, q12/24 after initial loading dose of 500mg OR Ceftazidime 3g over 12h, q12/24 after initial loading dose 1g OR Meropenem 1.5g over 12h, q12/24 after initial loading dose 500mg OR Piperacillin-tazobactam 13.5g over 24h after initial loading dose 2.25g OR Ticarcillin-clavulanate 12.4g over 24h after initial loading dose 1.55g~Antibiotic chosen by treating physician"
88919477|NCT01667146|Experimental|PHARLAP ventilation group|PHARLAP mechanical ventilation strategy
88919478|NCT01667146|Active Comparator|Control group ventilation|Control group mechanical ventilation strategy
88919479|NCT01667159|Experimental|Integrated Cognitive Behavioral Therapy|Adolescents and their parent(s) will receive integrated cognitive behavioral therapy.
88919480|NCT01667159|Active Comparator|Standard Care|Adolescents and their parent(s) will receive treatment as usual through a community intensive outpatient program.
88919481|NCT01667172|Other|point-of-care test for CRP|
88919482|NCT01667185||Pediatric subjects with diabetes mellitus|
88919483|NCT01667198|Experimental|Train the leaders course|
88919484|NCT01667198|Active Comparator|Audit and feedback|
88919485|NCT01667211|Experimental|albumin-bound paclitaxel plus nedaplatin|albumin-bound paclitaxel plus nedaplatin: Intravenous albumin-bound paclitaxel, 175-200 mg/m2, d 1, was given every 3 weeks, combined with intravenous nedaplatin, 80- 100 mg/m2, d 2. At least 2 cycles will be completed for each patient, for whom responds to study treatment, 4-6 cycles will be completed.
88919486|NCT01667237|Experimental|Pulmonary rehabilitation|
88919487|NCT01667263|Experimental|All-trans retinoic acid ＆Danazol|Danazol 400mg po and ATRA 10mg bid po
88919488|NCT01667263|Active Comparator|Danazol|Danazol 400mg po
88919489|NCT01667289|Active Comparator|Radiotherapy alone|Radiotherapy alone Technique: IMRT Total Dose: 50 Gy Per fraction: 2 Gy
88919490|NCT01667289|Experimental|Concurrent chemoradiation|"Concurrent chemoradiation~Chemotherapy:~Methotrexate 40 mg/m2 weekly X 5 Radiotherapy Technique: IMRT Total dose: 50 Gy Per Fraction: 2 Gy"
88919491|NCT01667302|Experimental|Radiotherapy followed by chemotherapy|Radiotherapy Technique: IMRT Total dose: 50 Gy Per fraction: 2 Gy Chemotherapy: q3w Dexamethasone 40 mg d1-4 Ifosfamide 1200mg/m2 d1-4 Etoposide 60 mg/m2 d1-4 Cisplatin 20mg/m2 d1-4 Peg-asparaginase 2000 IU/m2 d1
88919492|NCT01667315|Experimental|Bupivacaine|Bupivacaine 0,375%
88919493|NCT01667328|Experimental|Massage therapy|This group will received presurgical massage
88919494|NCT01667328|Placebo Comparator|Control|Standard of care with no massage
88919495|NCT01667354|Experimental|Intervention Clinics|Providers in intervention clinics will receive a training followed by telephone coaching and follow-up visits for six months.
88919496|NCT01667354|No Intervention|Control Clinics|Control clinics will receive all intervention materials at the completion of the study.
88919497|NCT01667367|Placebo Comparator|Placebo|
88919498|NCT01667367|Experimental|RG1662|
88919499|NCT01667380||Cohort|
88919500|NCT01667393|Experimental|IDEV SUPERA Stent|Following PTA of the target lesion, the SUPERA stent will be delivered to the treated segment.
88919501|NCT01667393|Active Comparator|Percutaneous Transluminal Angioplasty|The target lesion will be treated by PTA alone.
88919502|NCT01667445|Experimental|epimorph|single dose administration of 150mcg epimorph
88919503|NCT01667445|Active Comparator|spinal analgesia|spinal alone
88919504|NCT01667458||Cohort|
88919505|NCT01667484|Placebo Comparator|Placebo|treatment group #1
88919506|NCT01667484|Active Comparator|Adderall XR 5mg|treatment group #2
88919507|NCT01667484|Active Comparator|Adderal XR 10mg|treatment group #3
88919508|NCT01667497|Experimental|Fampridine SR|Fampridine SR 10mg BID
88919509|NCT01667497|Placebo Comparator|Placebo|non-drug
88919510|NCT01667510|Experimental|Cardio Mato|Soft gel capsule for oral use (Grade A Lyc-O-Mato, a tomato extracted lycopene)
88919511|NCT01667510|Placebo Comparator|Placebo|Soft gel capsule without test material, for oral use
88919512|NCT01667523|Experimental|Capsaicin|
88919513|NCT01667523|Experimental|Cinnamaldehyde|
88919514|NCT01667523|Placebo Comparator|Placebo|Physiological saline
88919515|NCT01667575|Experimental|10 day Quadruple Therapy|Esomeprazole 20mg, Amoxicillin 1.0g, Clarithromycin 500mg and Bismuth Potassium Citrate 220mg,twice a day for 10 days
88919516|NCT01667575|Active Comparator|10 day Triple therapy|Esomeprazole 20mg, Amoxicillin 1.0g,and Clarithromycin 500mg, twice a day, for ten days
89198596|NCT00962182|Experimental|Enzyme + gluten|Enzyme and 500 mg gluten b.i.d. for 12 weeks
88919517|NCT01667575|Active Comparator|14 day quadruple therapy|Esomeprazole 20mg, Amoxicillin 1.0g, Clarithromycin 500mg and Bismuth Potassium Citrate 220mg,twice a day for 14 days
88919518|NCT01667588||Pre-Dialysis|
88919519|NCT01667588||Dialysis|
88919520|NCT01667601|Experimental|Mindfulness-based program|A structured, researcher-designed mindfulness-based psycho-education program (6 months), comprised of 12 bi-weekly, 2-hour group sessions (10-12 patients per group). The program was based on the psycho-education programs by Chien et al. (2010) and Lehman et al. (2004), as well as the 8-session Mindfulness-Based Stress Reduction Program by Kabat-Zinn (1990).
88919521|NCT01667601|Other|Routine Care|Routine psychiatric outpatient care, including medication, psychiatric consultation in outpatient clinic, brief education by psychiatric nurses, financial and social welfare advices by social workers, and individual counseling by clinical psychologist.
88919522|NCT01667601|Active Comparator|Psychoeducation group|"A psychoeducation group program (12 sessions, bi-weekly) based on Dr. Macpherson's Family Psychoeducation Program in 1996 and Chien and Bressington's one in 2014/15 will be used.~References:~Chien WT, Bressington D. A randomized controlled trial of a nurse-led structured psychosocial intervention program for people with first-onset mental illness in psychiatric outpatient clinics. Psychiatry Res 2015;229:277-86.~Macpherson R, Jerrom B, Hughes AA. controlled study of education about drug treatment in schizophrenia. Br J Psychiatry 1996;168:709-17."
88919523|NCT01667614|No Intervention|ACE/ARB|In 62 patients previously treated with enalapril (10-30 mg daily) + losartan (50-100 mg daily), this regimen was continued.
88919524|NCT01667614|Active Comparator|Spironolactone/ARB|spironolacone 25 mg tablets added to losartan
88919525|NCT01667627|Active Comparator|BIO-25, Probiotic-mixture|Two capsules a day.
88919526|NCT01667627|Placebo Comparator|Placebo|Identical to the Bio-25 capsule: same taste, same colour, same appearance
88919527|NCT01667640|Active Comparator|whole brain irradiation|whole brain irradiation with 40 Gy, with fixation mask, radiation of the entire brain, skull base and meninges
88919528|NCT01667640|Experimental|sector irradiation|irradiation of the resection margin plus 5 mm safety margin with 30 Gy in 5 fractions
88919529|NCT01667653|Experimental|Augmentin/Probiotic|Participants are provided in double blinded fashion probiotic to take with antibiotics
88919530|NCT01667653|Experimental|Augmentin/placebo|Participants are provided in double blinded fashion placebo to take with antibiotics
88919531|NCT01667666|Experimental|Nebulized HTS|The first 5 patients will receive 3% Nebulized hypertonic saline, the second 5 patients will receive 4.5% Nebulized hypertonic saline, the third group 6% Nebulized hypertonic saline, and the fourth group of 5 patients will receive 7% Nebulized hypertonic saline. The nebulizer is dosed 2-3 times a day for 36 hours.
88919532|NCT01667692|Experimental|azithromycin|Azithromycin (Zithromax, Azithrocin ) is an azalide, a subclass of macrolide antibiotics. Azithromycin is one of the world's best-selling antibiotics. It is derived from erythromycin, with a methyl-substituted nitrogen atom incorporated into the lactone ring, thus making the lactone ring 15-membered.
88919533|NCT01667692|Experimental|clarithromycin|Clarithromycin is a macrolide antibiotic used to treat pharyngitis, tonsillitis, acute maxillary sinusitis, acute bacterial exacerbation of chronic bronchitis, pneumonia (especially atypical pneumonias associated with Chlamydophila pneumoniae), skin and skin structure infections. In addition, it is sometimes used to treat legionellosis, Helicobacter pylori, and lyme disease.
88919534|NCT01667705||SkyCeiling during CT-Suite visit|Patients in the trial group are exposed to the SkyCeiling during their procedure.
88919535|NCT01667705||No SkyCeiling during CT-Suite visit|Patients in the trial group are not exposed to the SkyCeiling during their procedure.
88919536|NCT01667718|Active Comparator|Levofloxacin-triple therapy|Lansoprazole (Proton Pump Inhibitor), Levofloxacin, Amoxicillin
89010640|NCT04537702|Experimental|Streamlined Group (SG)|"After completion of the baseline surveys, the SG subjects will watch an approximately eight minute long genetics education video. All subjects will then have the option to opt out and receive formal genetic counseling prior to making a decision about testing. If the subject elects to undergo genetic testing, she will fill out the standard genetic testing consent form. As per standard practice of the clinical genetic service at Duke Cancer Institute (DCI), patients will also be asked to provide consent for somatic tumor testing of surgical (non-cytologic) specimen. SG subjects will complete an FHQ within one week of the primary visit. A member of the genetics team will curate the results by contacting the subject to review common errors and clarify any ambiguities in the pedigree. Subjects will complete a post-education distress and anxiety survey (IES) via either an email link to a confidential REDCap survey link or over the phone 1-2 weeks after education."
89010641|NCT04719351|Experimental|Condition 1: Positive: no; Workload: no; Controllability: no; Open: no; Prompt: no;|"Component list:~Questions about positive emotions: not included;~Questions about workload/work environment: not included;~Questions about controllability: not included;~Questions with open answers: not included;~Behavioral prompts: not included;"
89010642|NCT04719351|Experimental|Condition 2: Positive: yes; Workload: no; Controllability: no; Open: no; Prompt: no;|"Component list:~Questions about positive emotions: included;~Questions about workload/work environment: not included;~Questions about controllability: not included;~Questions with open answers: not included;~Behavioral prompts: not included;"
89010643|NCT04719351|Experimental|Condition 3: Positive: no; Workload: yes; Controllability: no; Open: no; Prompt: no;|"Component list:~Questions about positive emotions: not included;~Questions about workload/work environment: included;~Questions about controllability: not included;~Questions with open answers: not included;~Behavioral prompts: not included;"
89010644|NCT04719351|Experimental|Condition 4: Positive: yes; Workload: yes; Controllability: no; Open: no; Prompt: no;|"Component list:~Questions about positive emotions: included;~Questions about workload/work environment: included;~Questions about controllability: not included;~Questions with open answers: not included;~Behavioral prompts: not included;"
89010645|NCT04719351|Experimental|Condition 5: Positive: no; Workload: no; Controllability: yes; Open: no; Prompt: no;|"Component list:~Questions about positive emotions: not included;~Questions about workload/work environment: not included;~Questions about controllability: included;~Questions with open answers: not included;~Behavioral prompts: not included;"
89010646|NCT04719351|Experimental|Condition 6: Positive: yes; Workload: no; Controllability: yes; Open: no; Prompt: no;|"Component list:~Questions about positive emotions: included;~Questions about workload/work environment: not included;~Questions about controllability: included;~Questions with open answers: not included;~Behavioral prompts: not included;"
89010647|NCT04719351|Experimental|Condition 7: Positive: no; Workload: yes; Controllability: yes; Open: no; Prompt: no;|"Component list:~Questions about positive emotions: not included;~Questions about workload/work environment: included;~Questions about controllability: included;~Questions with open answers: not included;~Behavioral prompts: not included;"
89010648|NCT04719351|Experimental|Condition 8: Positive: yes; Workload: yes; Controllability: yes; Open: no; Prompt: no;|"Component list:~Questions about positive emotions: included;~Questions about workload/work environment: included;~Questions about controllability: included;~Questions with open answers: not included;~Behavioral prompts: not included;"
89010649|NCT04719351|Experimental|Condition 9: Positive: no; Workload: no; Controllability: no; Open: yes; Prompt: no;|"Component list:~Questions about positive emotions: not included;~Questions about workload/work environment: not included;~Questions about controllability: not included;~Questions with open answers: included;~Behavioral prompts: not included;"
89010650|NCT04719351|Experimental|Condition 10: Positive: yes; Workload: no; Controllability: no; Open: yes; Prompt: no;|"Component list:~Questions about positive emotions: included;~Questions about workload/work environment: not included;~Questions about controllability: not included;~Questions with open answers: included;~Behavioral prompts: not included;"
89010651|NCT04719351|Experimental|Condition 11: Positive: no; Workload: yes; Controllability: no; Open: yes; Prompt: no;|"Component list:~Questions about positive emotions: not included;~Questions about workload/work environment: included;~Questions about controllability: not included;~Questions with open answers: included;~Behavioral prompts: not included;"
89010652|NCT04719351|Experimental|Condition 12: Positive: yes; Workload: yes; Controllability: no; Open: yes; Prompt: no;|"Component list:~Questions about positive emotions: included;~Questions about workload/work environment: included;~Questions about controllability: not included;~Questions with open answers: included;~Behavioral prompts: not included;"
89010653|NCT04719351|Experimental|Condition 13: Positive: no; Workload: no; Controllability: yes; Open: yes; Prompt: no;|"Component list:~Questions about positive emotions: not included;~Questions about workload/work environment: not included;~Questions about controllability: included;~Questions with open answers: included;~Behavioral prompts: not included;"
89198597|NCT00871533|Experimental|1|"REGIONAL PEG IFN MAINTENANCE: Regional PEG IFN-a2b given subcutaneously at MAINTENANCE dose level. (This arm has completed enrollment; non-evaluable subjects as defined in section 9.5 may be replaced at any point during study."
88919537|NCT01667718|Experimental|Levofloxacin-quadruple therapy|Lansoprazole (Proton Pump Inhibitor),Bismuth, Levofloxacin, Amoxicillin
88919538|NCT01667757||low post DES FFR group (<0.9)|the patient with FFR values less than 0.9 after DES procedure
88919539|NCT01667757||high post DES FFR group (≥0.9)|the patient with FFR values greater than 0.9 after DES procedure
88919540|NCT01667770|Active Comparator|surgery - autologous graft|surgical intervention: decompression of Chiari malformation by suboccipital craniectomy using autologous graft
88819419|NCT00552617|Experimental|Rocuronium + 2.0 mg/kg Sugammadex|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 2.0 mg/kg sugammadex was administered IV.
88919541|NCT01667770|Active Comparator|surgery - non-autologous graft|surgical intervention: decompression of Chiari malformation by suboccipital craniectomy using using non-autologous graft
88919542|NCT01667783|Active Comparator|Gastric Banding|Laparoscopic Adjustable Gastric Banding
88919543|NCT01667783|Active Comparator|Medical Weight Loss|Medical Weight Loss using a comprehensive lifestyle intervention consisting of diet (meal replacements), physical activity and behavioral techniques
88919544|NCT01667783|Active Comparator|Gastric Bypass|Roux-en-Y Gastric Bypass
88919545|NCT01667809|Active Comparator|Cognitive Behavior Therapy|As the trial will include several different common subclinical mental disorders, the cognitive behavior therapy used in the study will be based on the protocols with best empirical support. Cognitive behavior therapy entails psychoeducational components, i.e. the patient is learns about the disorder and how to view it from a cognitive behavioral perspective. The most important part of the treatment is systematic behavior changes often targeted at exposure to feared stimuli. This is combined with cognitive interventions targeted at challenging negative automatic thoughts. All treatments will be delivered by licensed psychologists.
88919546|NCT01667809|Experimental|Return to work|Participants randomized to this arm will receive an experimental treatment, based in cognitive behavioral therapy, with primary aim to help patients return to work. Interventions are aimed at solving work-related problems and comprises problem-solving training and systematic employer-patient meetings aimed at facilitating a gradual return to the workplace. Licensed psychologists deliver all treatments.
88919547|NCT01667822|Active Comparator|Continued guided self help CBT|Continued guided self help CBT. Participants will receive CBT through self-help books with minimal therapist contact (3 sessions in total).
88919548|NCT01667822|Experimental|CBT individual therapy|After the initial face of self help CBT, patients in this arm receive individual CBT. The cognitive behavior therapy used in the study will be based on the protocols with best empirical support.The therapy is delivered by the same psychologist as in the first face and the second face builds on the learning's from the first face.
88919549|NCT01667835|Experimental|Yoga Intervention|
88919550|NCT01667835|No Intervention|Control|
88919551|NCT01667861||(Wind) musicians|Members of (professional) orchestras, especially wind instrument players.
88919552|NCT01667874|No Intervention|No Collatamp sponge|Joint infection treated without the use of the Collatamp G sponge.
88819420|NCT00552617|Experimental|Rocuronium + 4.0 mg/kg Sugammadex|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 4.0 mg/kg sugammadex was administered IV.
89436401|NCT04305600||Aim 1|Aim 1 participants will be recruited from participants in the first BRAIN study at VUMC.
89436402|NCT04305600||Aim 2|Aim 2 participants will be recruited from the ICU populations at both VUMC and RUMC.
89436403|NCT04302051||Study Group|The hepatic fat estimation will be performed on the same subjects with the use of the thermo-acoustic device and by MRI-PDFF. The data obtained from the two estimations will be compared.
89436404|NCT04291521||Adult trauma patients requiring RSI|Patients who received an induction medication for intubation.
89530945|NCT02507531|Experimental|Treatment|Placement of study device (currently called NeXsys) into target aneurysm via standard endovascular procedure.
89536488|NCT04911959|Experimental|Intervention group|patients receive transcatheter arterial chemoembolization (TACE) and lenvatinib 8mg per day.
89536489|NCT03070665|Experimental|Increasing blood pressure|Using norepinephrine pump as the initial dose is 0.05μg/Kg.min to increase the patient's blood pressure up to about 150 mmHg for 5 min during ESD.
89536490|NCT03070665|No Intervention|Control group|Patients received normal ESD manipulation.
88813068|NCT02502864|Experimental|Standard of Care + Surveys|Standard of Care Docetaxel and Cyclophosphamide (TC) Chemotherapy + Surveys. TC Regimen with Function Assessment of Cancer Therapy (FACT) Surveys. All participants will receive TC for cycle 1 with subsequent cycles repeated every 3 weeks for a total of 4 cycles. All initial dosing will be based on actual body weight and height. Participants will receive up to 4 doses of chemotherapy. Following their 4th dose of chemotherapy, or the last dose of chemotherapy in which blood level monitoring was performed, participants will be assessed for side effects from the chemotherapy and complete their final written 53 question survey about their quality of life.
88813069|NCT03211598|Other|TACE with Surefire|Subjects enrolled in the study will have their TACE procedure with the Surefire Infusion System.
88813070|NCT01835600|Active Comparator|with PEEP|10 cmH2O PEEP added to the respiratory curcuit during suspension of mechanical ventilation
88813071|NCT01835600|Placebo Comparator|without PEEP|0 cmH2O PEEP added to the respiratory curcuit during suspension of mechanical ventilation
88813072|NCT01835834|Experimental|zirconia bridge restoration|"The device is a ceramic core made of shaded zirconium with an anatomic contour core with a minimum of 0.6 mm** thickness and minimal connector size of 4.0 x 3.0 / 9.4 (height x width [mm] / area [mm2])** of high strength zirconia framework providing homogenous veneering material thickness as an external coating with 1.0 - 2.0 mm* wall thickness. The core is veneered with dental porcelain at the dental laboratory.~Intended use and indications:~NobelProceraTM Bridge Shaded Zirconia consists of an individualized, supporting substructure in a ceramic bridge construction for tooth/teeth replacement.~NobelProceraTM Bridge Zirconia is intended for patients in need of prosthetic oral reconstruction in order to restore chewing function. Zirconia bridges for natural tooth restorations are customized, designed, and milled from pre-sintered blanks of zirconia. The multi-unit restorations can be placed in all positions in the mouth."
89198598|NCT00871533|Experimental|2|No intervention / no injection control.
89536491|NCT04988919|Experimental|4D dietary supplement|Multi-ingredient supplement containing a proprietary blend with 150mg of caffeine, and other ingredients including vitamins, electrolytes, and BCAA blend (150mg).
89536492|NCT04988919|Placebo Comparator|placebo|flavored water (raspberry lemonade Crystal Light®)
89536493|NCT05382533|Experimental|Hypertriglyceridemia intervention (group A)|"Carbohydrates: ≤ 50 en% (sucrose + glucose + fructose ≤ 10 en%, where sucrose ≤ 5 en% and fructose ≤ 20 g/d)~Fat: 30-35 En%~Protein: 20 En%~marine n3 PUFA (EPA/DHA): ≥ 4000 mg/d (10 g fish oil)"
89536494|NCT05382533|No Intervention|Hypertriglyceridemia control (group B)|no menu plans, no study foods
88813073|NCT03217760||Patients|The main aim of the study is to examine the patient's induced stress during endodontic treatment in order to offer customised solutions to lessen stress. The other aims is also to evaluate the patient's pain and discomfort during endodontic treatment.
88813074|NCT03217760||Young dentists practitioners.|The other aims are to evaluate the young dentist's induced stress and to examine and compare the patient's induced stress and the young dentist's induced stress.
88813075|NCT03211910|Placebo Comparator|Standard Care of Treatment|Participants will be treated with standard of care treatment.
88813076|NCT03211910|Active Comparator|SacralSaver|SacralSaver
88813077|NCT01457417|Experimental|75 milligram (mg) DKN-01 Part A|"DKN-01: DKN-01 was administered intravenously (IV) once a week over a minimum of 30 minutes and up to a maximum of 2 hours for dose levels of 75 mg, 150 mg and 300 mg. At the 600 mg dose level, DKN-01 was administered by IV on days 1 and 15 of each cycle.~PART A - Dose Escalation: Study group of 3 participants were treated with a 28 day cycle of DKN-01 at an assigned dose level until disease progression. Dose escalation occurred sequentially over the doses of 75, 150, 300, and 600 mg until the criteria for reaching the maximum tolerated dose (MTD) were met or the highest planned dose study group was completed. Cycle 1 defined the dose limiting toxicity (DLT) period that governs dose escalation. The dose escalation method was guided by the incidence of DLTs during the first cycle."
88813078|NCT01457417|Experimental|150 mg DKN-01 Part A|"DKN-01: DKN-01 was administered intravenously (IV) once a week over a minimum of 30 minutes and up to a maximum of 2 hours for dose levels of 75 mg, 150 mg and 300 mg. At the 600 mg dose level, DKN-01 was administered by IV on days 1 and 15 of each cycle.~PART A - Dose Escalation: Study group of 3 participants were treated with a 28 day cycle of DKN-01 at an assigned dose level until disease progression. Dose escalation occurred sequentially over the doses of 75, 150, 300, and 600 mg until the criteria for reaching the maximum tolerated dose (MTD) were met or the highest planned dose study group was completed. Cycle 1 defined the dose limiting toxicity (DLT) period that governs dose escalation. The dose escalation method was guided by the incidence of DLTs during the first cycle."
88813079|NCT01457417|Experimental|300 mg DKN-01 Part A|"DKN-01: DKN-01 was administered intravenously (IV) once a week over a minimum of 30 minutes and up to a maximum of 2 hours for dose levels of 75 mg, 150 mg and 300 mg. At the 600 mg dose level, DKN-01 was administered by IV on days 1 and 15 of each cycle.~PART A - Dose Escalation: Study group of 3 participants were treated with a 28 day cycle of DKN-01 at an assigned dose level until disease progression. Dose escalation occurred sequentially over the doses of 75, 150, 300, and 600 mg until the criteria for reaching the maximum tolerated dose (MTD) were met or the highest planned dose study group was completed. Cycle 1 defined the dose limiting toxicity (DLT) period that governs dose escalation. The dose escalation method was guided by the incidence of DLTs during the first cycle."
89010654|NCT04719351|Experimental|Condition 14: Positive: yes; Workload: no; Controllability: yes; Open: yes; Prompt: no;|"Component list:~Questions about positive emotions: included;~Questions about workload/work environment: not included;~Questions about controllability: included;~Questions with open answers: included;~Behavioral prompts: not included;"
89010655|NCT04719351|Experimental|Condition 15: Positive: no; Workload: yes; Controllability: yes; Open: yes; Prompt: no;|"Component list:~Questions about positive emotions: not included;~Questions about workload/work environment: included;~Questions about controllability: included;~Questions with open answers: included;~Behavioral prompts: not included;"
89010656|NCT04719351|Experimental|Condition 16: Positive: yes; Workload: yes; Controllability: yes; Open: yes; Prompt: no;|"Component list:~Questions about positive emotions: included;~Questions about workload/work environment: included;~Questions about controllability: included;~Questions with open answers: included;~Behavioral prompts: not included;"
89010657|NCT04719351|Experimental|Condition 17: Positive: no; Workload: no; Controllability: no; Open: no; Prompt: yes;|"Component list:~Questions about positive emotions: not included;~Questions about workload/work environment: not included;~Questions about controllability: not included;~Questions with open answers: not included;~Behavioral prompts: included;"
89010658|NCT04719351|Experimental|Condition 18: Positive: yes; Workload: no; Controllability: no; Open: no; Prompt: yes;|"Component list:~Questions about positive emotions: included;~Questions about workload/work environment: not included;~Questions about controllability: not included;~Questions with open answers: not included;~Behavioral prompts: included;"
89010659|NCT04719351|Experimental|Condition 19: Positive: no; Workload: yes; Controllability: no; Open: no; Prompt: yes;|"Component list:~Questions about positive emotions: not included;~Questions about workload/work environment: included;~Questions about controllability: not included;~Questions with open answers: not included;~Behavioral prompts: included;"
89010660|NCT04719351|Experimental|Condition 20: Positive: yes; Workload: yes; Controllability: no; Open: no; Prompt: yes;|"Component list:~Questions about positive emotions: included;~Questions about workload/work environment: included;~Questions about controllability: not included;~Questions with open answers: not included;~Behavioral prompts: included;"
89010661|NCT04719351|Experimental|Condition 21: Positive: no; Workload: no; Controllability: yes; Open: no; Prompt: yes;|"Component list:~Questions about positive emotions: not included;~Questions about workload/work environment: not included;~Questions about controllability: included;~Questions with open answers: not included;~Behavioral prompts: included;"
89010662|NCT04719351|Experimental|Condition 22: Positive: yes; Workload: no; Controllability: yes; Open: no; Prompt: yes;|"Component list:~Questions about positive emotions: included;~Questions about workload/work environment: not included;~Questions about controllability: included;~Questions with open answers: not included;~Behavioral prompts: included;"
89436405|NCT04277442|Experimental|Treatment (nivolumab, decitabine, venetoclax)|"INDUCTION: Patients receive nivolumab IV over 30 minutes on day 15 of cycle 1 and days 1 and 15 of subsequent cycles, decitabine IV over 60 minutes on days 1-10 of induction cycle 1 (and cycles 2 and 3 if needed), and venetoclax PO QD on days 1-21. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients who achieve a CR or CRi receive nivolumab IV over 30 minutes on days 1 and 15, decitabine IV over 60 minutes on days 1-5, and venetoclax PO QD on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
89436406|NCT04269200|Active Comparator|Arm A (control)|Platinum-based chemotherapy and durvalumab placebo followed by maintenance durvalumab placebo and olaparib placebo (tablets).
89436407|NCT04269200|Experimental|Arm B (durvalumab+placebo)|Platinum-based chemotherapy and durvalumab followed by maintenance durvalumab and olaparib placebo
89436408|NCT04269200|Experimental|Arm C (durvalumab+olaparib)|Platinum-based chemotherapy and durvalumab followed by maintenance durvalumab and olaparib.
89010663|NCT04719351|Experimental|Condition 23: Positive: no; Workload: yes; Controllability: yes; Open: no; Prompt: yes;|"Component list:~Questions about positive emotions: not included;~Questions about workload/work environment: included;~Questions about controllability: included;~Questions with open answers: not included;~Behavioral prompts: included;"
89010664|NCT04719351|Experimental|Condition 24: Positive: yes; Workload: yes; Controllability: yes; Open: no; Prompt: yes;|"Component list:~Questions about positive emotions: included;~Questions about workload/work environment: included;~Questions about controllability: included;~Questions with open answers: not included;~Behavioral prompts: included;"
89010665|NCT04719351|Experimental|Condition 25: Positive: no; Workload: no; Controllability: no; Open: yes; Prompt: yes;|"Component list:~Questions about positive emotions: not included;~Questions about workload/work environment: not included;~Questions about controllability: not included;~Questions with open answers: included;~Behavioral prompts: included;"
89198599|NCT00871533|Experimental|3|"PEG IFN INDUCTION: System PEG IFN-a2b given subcutaneously at INDUCTION dose level"
89436409|NCT04259281|Experimental|GTX-102 Cohort 1|3.3 mg starting dose followed by intra-patient dose escalation up to 36 mg and then a maintenance phase (in U.S participants 4 to <17 years of age)
89436410|NCT04259281|Experimental|GTX-102 Cohort 2|10 mg starting dose followed by intra-patient dose escalation up to 36 mg and then a maintenance phase (in U.S participants 4 to <17 years of age)
88919553|NCT01667874|Experimental|Collatamp G sponge|Use of Collatamp G Gentamicin impregnated sponge for the treatment of early total joint infections
88919554|NCT01667887||Femur Fractures|Patients with Distal Femur Fractures
88919555|NCT01667913|No Intervention|6 minutes walking test|
88919556|NCT01667939|Experimental|pregnancy diet|Healthy Eating Index (HEI) in supervised pregnancies
88919557|NCT01667939|No Intervention|unsupervised pregnancy|women attending the obstetrics unit who did not follow a supervised diet
88919558|NCT01667965||pts receiving palliative radiation therapy|The design of the study will be a prospective non-randomized cohort study with structured questionnaires administered to all enrolled patients at two or three time-points.
88919559|NCT01668043|Experimental|Antibody UB-421 Cohort 1|10 mg/kg BW, 8 weekly doses for 8-week treatment period
88919560|NCT01668043|Experimental|Antibody UB-421 Cohort 2|25 mg/kg BW, 4 biweekly doses for 8-week treatment period
88919561|NCT01668056|Active Comparator|Control|Patients will be stimulated according to the conventional flexible GnRH antagonist protocol for IVF. Alfa follitropin (150IU a day) will be started on the third day of the menstrual cycle. Treatment monitoring will be done with transvaginal ultrasound scans and serum determinations of estradiol and progesterone 5 days after the start of gonadotropins and every each day thereafter. Once the leading follicle reaches 13 mm in mean diameter 0,25mg of cetrorelix acetate will be administered daily. Once at least two follicles reach 18mm or more in mean diameter 250 micrograms of choriogonadotropin alfa will be administered and 36 hours latter patients will undergo follicle aspiration for IVF. Embryos will be cryopreserved (vitrification) on the third or fifth day of development. Two months after women will undergo uterine preparation for embryo transfer.
88919562|NCT01668056|Experimental|Ovulation induction|Patients will be monitored with daily transvaginal ultrasound scans from the tenth day of the menstrual cycle on. When the dominant follicle reaches a mean diameter of 16mm or more, patients will receive 250 micrograms of choriogonadotropin alfa subcutaneously. Daily transvaginal ultrasound scans will be done starting two days after the administration of the medication until a cohort of ovarian follicles between 4-6 mm is seen (follicular wave emergence). From this point on patients will undergo the same stimulation protocol as Controls, i.e., flexible GnRH antagonist protocol.
88919563|NCT01668056|Experimental|Dominant follicle aspiration|Patients will be monitored with daily transvaginal ultrasound scans from the tenth day of the menstrual cycle on. When the dominant follicle reaches a mean diameter of 16mm or more, patients will then undergo aspiration of the dominant and all follicles greater than 10mm in mean diameter. aspiration will be transvaginal ultrasound guided and under sedation, as for oocyte retrieval. Oocytes eventually obtained at this first aspiration will not be used for IVF. Daily transvaginal ultrasound scans will be done starting the day after the follicular aspiration until a cohort of follicles between 4-6 mm is seen (follicular wave emergence). From this point on patients will undergo the same stimulation protocol as Controls, i.e., flexible GnRH antagonist protocol.
88919564|NCT01668069|Experimental|Ondansetron|study drug
88919565|NCT01668069|No Intervention|Doxylamine and Pyridoxine (vitamin B6)|other nausea treatment in use
88919566|NCT01668095||Ancillary-Correlative (biomarker analysis)|Immunohistochemistry is performed for each candidate target (Pax3, Pax7, and Patched-1) in each disease (alveolar, embryonal, and anaplastic rhabdomyosarcoma) for tissue microarray analysis.
88919567|NCT01668108||carcinoma, Paclitaxel onkovis (Paclitaxel)|treatment in mono- or combination therapy with Paclitaxel of breast-, non-small cell lung- and ovarial cancer.
88919568|NCT01668121|Experimental|Symbicort Turbohaler|Symbicort Turbohaler
88919569|NCT01668121|Active Comparator|Budesonide/formoterol Easyhaler|Budesonide/formoterol Easyhaler
88919570|NCT01668134|Experimental|Stereotactic radiation|
88919571|NCT01668160|Experimental|Revision Total Hip|patients recieving a revision total hip replacement will be assessed for implant stability and wear using RSA. Tantalum beads will be placed in the polyethylene and surrounding pelvic and femoral bone.
88919572|NCT01668199|Experimental|14C TZP-101|
88919573|NCT01668212||natural In Vitro Fertilization cycle|Patient doing following natural In Vitro fertilization cycle
88919574|NCT01668238||malignant tumor|Inpatients with malignant tumors of thyroid and breast
88919575|NCT01668238||benign tumor|Inpatients with benign tumors of thyroid and breast
89198600|NCT00871533|Experimental|4|"REGIONAL HDI MAINTENANCE: Regional HDI given subcutaneously at MAINTENANCE dose level per standard HDI regimen"
88919576|NCT01668238||Healthy volunteers|Volunteers without thyroid or breast tumors
88919577|NCT01668251||Fetal ascertainment|Girls who are diagnosed with Turner syndrome because of concerns raised by an abnormal fetal ultrasound.
88919578|NCT01668251||Maternal ascertainment|Girls who are diagnosed with Turner syndrome because their mothers had an amniocentesis for a reason other than an abnormal fetal ultrasound concerning for Turner syndrome. For example an amniocentesis was done because of advanced maternal age or because of an abnormal triple screen or because another condition was being screened for such as trisomy 21.
88919579|NCT01668264|Experimental|Magnetic Resonance Imaging (MRI)|Subjects with congenital heart disease will undergo an echocardiograph, as well as an MRI.
88919580|NCT01668264|Experimental|Echocardiograph|Subjects with congenital heart disease will undergo an echocardiograph, as well as an MRI.
88919581|NCT01668277|Experimental|3 ml/kg 7.2% NaCl|The test fluids 7.2% NaCl 3 ml/kg will be infused over 10 min. The hemodynamic parameters will be determined before and after infusion by a cardiologist blinded to the type of infusion.
88919582|NCT01668277|Active Comparator|3 ml/kg 0.9% NaCl|The test fluids 0.9% NaCl 3 ml/kg will be infused over 10 min. The hemodynamic parameters will be determined before and after infusion by a cardiologist blinded to the type of infusion.
88919583|NCT01668277|Active Comparator|20 ml/kg 0.9% NaCl|The test fluids 0.9% NaCl 20 ml/kg will be infused over 10 min. The hemodynamic parameters will be determined before and after infusion by a cardiologist blinded to the type of infusion.
88919584|NCT01668290||Stress Echocardiography|Patients will be randomized to one of three imaging modalities. One imaging modality thay can be randomized to is Stress Echocardiography.
88919585|NCT01668290||SPECT|Patients will be randomized to one of three imaging modalities. One imaging modality thay can be randomized to is Single Photon Emission Computed Tomography (SPECT)
88919586|NCT01668290||CCTA|Patients will be randomized to one of three imaging modalities. One imaging modality thay can be randomized to is Cardiac Computed Tomographic Angiography (CCTA)
88919587|NCT01668303|Experimental|Miami Juvenile Drug Court-MDFT|Multidimensional family therapy (MDFT) is primarily a family-based approach (Liddle, 2002)which conducts individual sessions with the teen and parent[s] but not peer-group sessions.
88919588|NCT01668303|Other|Miami Juvenile Drug Court -TAU|The Treatment as Usual (TAU) condition is primarily a peer group-based and individual approach that uses cognitive-behavioral principles and interventions.
88919589|NCT01668316|Experimental|Weight loss|12 week weight loss program with biweekly meetings with a Registered Dietitian. Participants will be given a nutrition prescription and asked to record dietary intake online. Participants will be given a pedometer and record daily physical activity.
88919590|NCT01668316|No Intervention|Control|Participants asked to not change dietary and physical activity habits.
88919591|NCT01668342|Experimental|SMS assessments & feedback|Daily symptom assessments of headaches, trouble ocncentrating and irritability/anxiety with self-care feedback based on response severity.
88919592|NCT01668342|No Intervention|Control|Standard of care
88919593|NCT01668368|Other|Esophageal balloon group|"Esophageal balloon will be inserted, and esophageal pressure will be measured in patients with acute respiratory failure.~Intervention - PEEP and Inspiratory pressure will be adjusted according to the measured esophageal pressure."
88919594|NCT01668381||HCC patients|Hepatocellular carcinoma patients treated by radiofrequency ablation
88919595|NCT01668394|Active Comparator|Learning and coping arm|Participation of experienced patients as co-educators. Completion of two individual clarifying interviews. Teaching style: situated, reflective, inductive.
88919596|NCT01668394|Placebo Comparator|Control arm|Usual care. Teaching style: deductive.
88919597|NCT01668420|Experimental|noxious thermal stimulation|Heat-pain:46-47°C and Cold-pain:2-3°C alternately (intervention) 3 times /week and total 24 TS while conventional rehabilitation program was given
88919598|NCT01668420|Active Comparator|thermal stimulation (innocuous)|Heat:40-41°C and Cold:23-24°C alternately (intervention) 3 times /week and total 24 TS while conventional rehabilitation program was given
88919599|NCT01668433|Active Comparator|G6PD Normal|Subjects will be given either primaquine, 45 mg single dose or methylene blue, 600 mg single dose with a washout period of 7 days then followed by either methylene blue, 600 mg single dose or primaquine, 45 mg single dose.
88919600|NCT01668433|Experimental|G6PD deficiency|Subjects will be given either primaquine, 45 mg single dose or methylene blue, 600 mg single dose with a washout period of 7 days then followed by either methylene blue, 600 mg single dose or primaquine, 45 mg single dose.
88919601|NCT01668446|Experimental|sildenafil|"One of two group to prepare the endometrium give estradiol by step up method with menstruation.~From first to fourth day of menstrual cycle, estradiol valerat tablet 2 mg daily From Fifth to eighth day of menstrual cycle, estradiol valerat tablet 4 mg daily From Ninth to twelfth day of menstrual , estradiol valerat tablet 6 mg daily The second group in addition to the above treatment protocol from First day of cycle until day of starting progesterone will be given sildenafil tablets(50 mg) daily."
89198601|NCT00871533|No Intervention|5|"HDI Induction: Systemic HDI given intravenously at INDUCTION dose level per the standard HDI regimen."
89010666|NCT04719351|Experimental|Condition 26: Positive: yes; Workload: no; Controllability: no; Open: yes; Prompt: yes;|"Component list:~Questions about positive emotions: included;~Questions about workload/work environment: not included;~Questions about controllability: not included;~Questions with open answers: included;~Behavioral prompts: included;"
89010667|NCT04719351|Experimental|Condition 27: Positive: no; Workload: yes; Controllability: no; Open: yes; Prompt: yes;|"Component list:~Questions about positive emotions: not included;~Questions about workload/work environment: included;~Questions about controllability: not included;~Questions with open answers: included;~Behavioral prompts: included;"
89436411|NCT04259281|Experimental|GTX-102 Cohort 3|20 mg starting dose followed by intra-patient dose escalation up to 55 mg and then a maintenance phase (in U.S participants 4 to <17 years of age)
89436412|NCT04259281|Experimental|GTX-102 Cohort 4|3.3 mg starting dose followed by slow intra-patient dose escalation up to 5 mg and then a maintenance phase (in Ex-U.S participants 4 to <8 years of age)
89436413|NCT04259281|Experimental|GTX-102 Cohort 5|5 mg starting dose followed by slow intra-patient dose escalation up to 7.5 mg and then a maintenance phase (in Ex-U.S participants ≥ 8 to 17 years of age)
89010668|NCT04719351|Experimental|Condition 28: Positive: yes; Workload: yes; Controllability: no; Open: yes; Prompt: yes;|"Component list:~Questions about positive emotions: included;~Questions about workload/work environment: included;~Questions about controllability: not included;~Questions with open answers: included;~Behavioral prompts: included;"
89436414|NCT04259281|Experimental|GTX-102 Cohort 6|7.5 mg starting dose followed by slow intra-patient dose escalation up to 10 mg and then a maintenance phase (in Ex-U.S participants 4 to <8 years of age)
89436415|NCT04259281|Experimental|GTX-102 Cohort 7|10 mg starting dose followed by slow intra-patient dose escalation up to 12 mg and then a maintenance phase (in Ex-U.S participants ≥ 8 to 17 years of age)
89436416|NCT04259281|Experimental|GTX-102 Cohort US|2 mg for 4 monthly doses followed by a quarterly maintenance regimen
89010669|NCT04719351|Experimental|Condition 29: Positive: no; Workload: no; Controllability: yes; Open: yes; Prompt: yes;|"Component list:~Questions about positive emotions: not included;~Questions about workload/work environment: not included;~Questions about controllability: included;~Questions with open answers: included;~Behavioral prompts: included;"
89436417|NCT04259281|Experimental|GTX-102 Expanded Enrollment Cohort A|Sponsor selected dose followed by slow intra-patient dose escalation and then a maintenance phase (in Ex-U.S participants 4 to <8 years of age)
89436418|NCT04259281|Experimental|GTX-102 Expanded Enrollment Cohort B|Sponsor selected dose followed by slow intra-patient dose escalation and then a maintenance phase (in Ex-U.S participants ≥ 8 to 17 years of age)
89436419|NCT04259281|Experimental|GTX-102 Expanded Enrollment Cohort C|Sponsor selected dose followed by slow intra-patient dose escalation and then a maintenance phase (in U.S participants 4 to <8 years of age)
89436420|NCT04259281|Experimental|GTX-102 Expanded Enrollment Cohort D|Sponsor selected dose followed by slow intra-patient dose escalation and then a maintenance phase (in U.S participants ≥ 8 to 17 years of age)
89436421|NCT04259281|Experimental|GTX-102 Cohort E|Sponsor selected dose followed by slow intra-patient dose escalation and then a maintenance phase (in participants that transition from GTX-102 US Cohort only)
89436422|NCT04228367|Experimental|Meniscal repair|Patients in need of meniscal repair
89436423|NCT04227769|Experimental|healthy individuals|Two crossover visits with a washout period of at least 4 days in-between visits and at most two weeks: A) subcutaneous saline injection 3h before an oral standardized meal, B) subcutaneous injection of 100 mg of the IL-1 receptor antagonist anakinra 3h before an oral standardized meal. Treatments will be placebo controlled, crossover, double blinded. Standard dose of Anakinra (Kineret®; r-metHuIL-1ra, Swedish Orphan Biovitrum AB), i. e. 100 mg/ 0.67 ml s. c. or 0.67 ml of saline s. c. (placebo)
89536495|NCT05382533|Experimental|Prediabetes intervention (group C)|"Carbohydrates: 40 ± 2 En%~Sucrose + glucose + fructose ≤ 10 En%~Free sugars < 5% of daily energy~Fat: 40 ± 2%~Protein: 20 ± 2 En%~n3 PUFA: ≥ 500 mg/d"
88819421|NCT00552617|Placebo Comparator|Vecuronium + Placebo|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of placebo was administered IV.
89436424|NCT04227769|Experimental|obese patients with type 2 diabetes|Three crossover visits with a washout period of at least 4 days in-between: A) subcutaneous saline injection 3h before an oral standardized meal, B) subcutaneous injection of 100 mg of the IL-1 receptor antagonist anakinra 3h before an oral standardized meal, C) Additionally, after the second study day, participant in group 2 will be trained to self-inject the medication for 6 days. On the 7th day, an oral standardized meal test will be performed. Standard dose of Anakinra (Kineret®; r-metHuIL-1ra, Swedish Orphan Biovitrum AB), i. e. 100 mg/ 0.67 ml s. c. or 0.67 ml of saline s. c. (placebo)
89436425|NCT04224883|Active Comparator|24-hours group|"The critical patients randomized to 24-hours group will be received enteral nutrition preparation by 24 hours of continuously pumping through stomach tube every day.~Feeding will be started within 24 hours in admission of ICU. The time of therapy is 5 days."
89436426|NCT04224883|Experimental|16-hours group|"The critical patients randomized to 16-hours group will be received enteral nutrition preparation by 16 hours of continuously pumping through stomach tube every day.~Feeding will be started within 24 hours in admission of ICU. The time of therapy is 5 days."
89436427|NCT04224883|Experimental|intermittent group|The critical patients randomized to intermittent group will be received enteral nutrition preparations by four meals every day(08:00,12:00 18:00,22:00), each meal are pumped within 60min or 120min through stomach tube.Feeding will be started within 24 hours in admission of ICU. The time of therapy is 5 days
89436428|NCT04215692|Experimental|Ultrasound Guided Fluid Therapy|
89436429|NCT04215692|No Intervention|Conventional Fluid Therapy|
89436430|NCT04199728|Experimental|Investigational group|Participants randomized to liraglutide will be started at a low dose (0.6 mg once per day) which will be gradually increased until 1.8 mg/day is reached for the 3-dose intervention and 3 mg/day is reached for the 5-dose intervention. Liraglutide will be administered by injection pen.
88919602|NCT01668446|Experimental|Sildenafil and estradiol valerat|"One of two group to prepare the endometrium give estradiol by step up method with menstruation.~From first to fourth day of menstrual cycle, estradiol valerat tablet 2 mg daily From Fifth to eighth day of menstrual cycle, estradiol valerat tablet 4 mg daily From Ninth to twelfth day of menstrual , estradiol valerat tablet 6 mg daily The second group in addition to the above treatment protocol from First day of cycle until day of starting progesterone will be given sildenafil tablets(50 mg) daily."
88819422|NCT00552617|Experimental|Vecuronium + 0.5 mg/kg Sugammadex|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 0.5 mg/kg sugammadex was administered IV.
88919603|NCT01668459|Experimental|Cabazitaxel|6 cycles (3 weekly) of 25 mg/m^2 IV infusion
88919604|NCT01668459|Other|Best Supportive Care|Best supportive care including single agent chemotherapy as determined by the patient's study doctor
88919605|NCT01668485|Experimental|Islet transplant recipients|Hypoglycemic and euglycemic glucose clamp
88919606|NCT01668485|Placebo Comparator|Type 1 diabetic subjects|Hypoglycemic and euglycemic glucose clamp.
88919607|NCT01668485|Active Comparator|Non-diabetic subjects|Hypoglycemic and euglycemic glucose clamp
88919608|NCT01668498|Experimental|Erythromycin|Experimental Arm (ARM A) skin- treatment: erythromycin cream 2% daily at bedtime doxycycline 100mg b.i.d.if skin toxicity CTC° ≥2 skin moisturizer daily at morning, sunscreen before going outdoors for 8 weeks
88919609|NCT01668498|Active Comparator|Doxycyline|Standard Arm (ARM B) skin- treatment:doxycycline 100mg b.i.d. skin moisturizer daily at morning, sunscreen before going outdoors for 8 weeks
88919610|NCT01668511|Experimental|Group 1|Randomized 7 drug/2 placebo by group
88919611|NCT01668511|Experimental|Group 2|Randomized 7 drug/2 placebo by group
88919612|NCT01668511|Experimental|Group 3|Randomized 7 drug/2 placebo by group
88919613|NCT01668511|Experimental|Group 4|Randomized 7 drug/2 placebo by group
88919614|NCT01668524|Experimental|Single Arm: ATS907|Single-cohort, dose-escalation
88919615|NCT01668641|Experimental|capsule, 30mg GLPG0634 once a day|3 capsules of 10 mg once a day
89436431|NCT04199728|Placebo Comparator|Control group|Participants in the control group will have placebo administered by injection pen following the same low dose titration to 3.0 mg once per day.
88819423|NCT00552617|Experimental|Vecuronium + 1.0 mg/kg Sugammadex|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 1.0 mg/kg sugammadex was administered IV.
88819424|NCT00552617|Experimental|Vecuronium + 2.0 mg/kg Sugammadex|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 2.0 mg/kg sugammadex was administered IV.
88919616|NCT01668641|Experimental|capsules, 75mg GLPG0634 once a day|3 capsules of 25mg once a day
88919617|NCT01668641|Experimental|capsules, 150mg GLPG0634 once a day|3 capsules of 50mg once a day
88919618|NCT01668641|Experimental|capsules, 300mg GLPG0634 once a day|3 capsules of 100mg once a day
88919619|NCT01668641|Placebo Comparator|capsules, placebo once a day|3 capsules placebo once a day
88919620|NCT01668680|Experimental|LDM anti-angiogenic chemotherapy|LDM (Low Dose Metronomic) anti-angiogenic chemotherapy includes daily oral treatment with CAPECITABINE, CELECOXIB and METHOTREXATE.
88919621|NCT01668680|No Intervention|observation|observation only
88919622|NCT01668693|Active Comparator|RIF ERA Receptive 1|"With the receptive results from the first Endometrial Receptivity Array (ERA), the patients will undergo embryo transfer on Day 5 of Progesterone administration in the cycle following the ERA diagnosis."
89198602|NCT05157022|Active Comparator|Focus extracorporeal shock wave therapy|A total of 4 sessions of ESWT at 1-week intervals were applied to to the sacrococcygeal area
89436432|NCT04197921|Other|Sham/Active ExAblate Treatment Stage 1 and 2|Subject will undergo both Treatment 1 (sham) and Treatment 2 (with enhanced intensity). Subjects are blinded to the order of the sham vs active treatment.
89530946|NCT03344081||Meditators|Meditators will have practiced meditation for at least the 5 years, at least 90 minutes weekly. They will have completed at least 14 days of retreat practice in the past 5 years. At least half of their meditation practice will include attention to the breath and body. All participants will be MRI-compatible, healthy with no health conditions that affect breathing, have no current psychiatric disorder, and not be taking psychotropic medications.
89436433|NCT04194996||Operative|"Inclusion criteria:~≥18 years old at time of treatment~Diagnosis of cervical deformity- must meet one or more of the following criteria:~C2-C7 sagittal kyphosis (Cobb > 15o)~T1S-CL > 35o~Segmental cervical kyphosis > 10o between any 2 vertebra between C2-T1 or > 15o across any 3 vertebra between C2-T1~Cervical scoliosis > 10o (Cobb angle must include end vertebra within the cervical spine)~C2-C7 SVA > 4cm~McGregor's slope > 20 degrees or CBVA > 25 degrees~Plan for surgical correction of cervical deformity in the next 6 months"
89436434|NCT04194138||Operative|"A. Multicenter, prospective, nonrandomized analysis of operatively treated complex ASD patients meeting the following Inclusion Criteria~18 years of age or greater at the time of treatment~Diagnosis of adult congenital, degenerative, idiopathic or iatrogenic spinal deformity~Full body EOS radiographic assessment (sagittal and coronal visualization from skull to foot)~Complex patients are defined as and meeting any one of the subsequent criteria:~a. Radiographic criteria: i. PI-LL ≥ 25 degrees ii. TPA ≥ 30 degrees iii. SVA>15cm iv. Thoracic scoliosis ≥ 70 degrees v. Thoracolumbar/lumbar scoliosis ≥ 50 degrees vi. Global coronal malalignment >7cm b. Procedural criteria: i. Posterior spinal fusion > 12 levels ii. 3 column osteotomy or ACR c. Geriatric criteria: i. Age >65 years and minimum 7 levels of spinal instrumentation during surgery"
89436435|NCT04190953|Experimental|Twin Block then Hyrax|Patients will undergo mandibular advancement prior to maxillary expansion using Twin block prior to Hyrax
89436436|NCT04190953|Experimental|Hyrax then Twin block|Patients will undergo maxillary expansion prior to mandibular advancement using Hyrax prior to Twin block
88919623|NCT01668693|Experimental|RIF ERA Non Receptive|"The Non Receptive results of the ERA diagnotic tool will indicate how many more days of Progesterone are necesary in order to obtain the Receptive daignosis. A second ERA will take place to confirm receptivity and in the following cycle, the personalized embryo transfer will take place on the day predicted by this diagnostic tool."
88919624|NCT01668706||Methadone maintenance treatment (MMT)|
88919625|NCT01668706||Buprenorphine-Naloxone treatment (BNT)|
88919626|NCT01668706||Medication-free ex-addicts(MF)|
88919627|NCT01668706||Normal control (NC)|
88919628|NCT01668732||community heroin addicts|
88919629|NCT01668745|Experimental|Early measles vaccine|The intervention is about to administer an early standard dose of Edmonston-Zagreb (EZ) measles vaccine in addition to the conventional dose. As such children will be randomised to receive either an early measles vaccine at 4 months after DTP3 or not. Thereafter both groups of children will receive the recommended EZ measles vaccine at 9 months of age according to WHO policy.
88919630|NCT01668745|No Intervention|Control|
88919631|NCT01668810||Beijing region|include six hospitals
88919632|NCT01668810||Guangdong Province|include 3 hospitals
88919633|NCT01668810||Jiangsu province|include 3 hospitals
88919634|NCT01668810||Hebei province|include 6 hospitals
88919635|NCT01668810||Hubei Province|include 7 hospitals
88919636|NCT01668810||Shanxi province|include 3 hospitals
89436437|NCT04190953|No Intervention|Control|Patients will wait 1,5 years before the start of treatment
89536496|NCT05382533|No Intervention|Prediabetes control (group D)|no menu plans, no study foods
88919637|NCT01668810||Jiangxi province|include 3 hospitals
88919638|NCT01668810||Jilin province|include 6 hospitals
88919639|NCT01668810||Sichuan province|include 3 hospitals
88919640|NCT01668810||Shaanxi province|include 3 hospitals
88919641|NCT01668823|Experimental|Treatment (PDT using HPPH)|Patients receive HPPH IV over 1 hour on day 1. Patients then photodynamic therapy with laser light on day 3. Patients also undergo therapeutic bronchoscopy for endoscopic debridement on day 5.
88919642|NCT01668862|Other|Study arm A|Subjects will receive one injection of Autologous Human Platelet lysate in the lateral epicondyle space
88919643|NCT01668862|Other|Control Arm B|Subjects will receive one injection of Corticosteroid in the lateral epicondyle space
88919644|NCT01668875|Experimental|Treatment condition|In intervention period patients were received head-down 30 degree postural drainage position for 10 min.
88919645|NCT01668875|Experimental|Sham condition|In intervention period patients were received horizontal supine lying for 10 min.
88919646|NCT01668888||Apparently Helathy Subjects|
88919647|NCT01668901|Experimental|warfarin|medication
88919648|NCT01668901|Active Comparator|aspirin|medication
88919649|NCT01668914|Experimental|clinically positive axillary nodes|3~18 hours before surgery, under ultrasonographic guidance, 0.5~1.0 mCi 99mTc-SC in sterile saline (total volume 0.2~2.0 mL) is injected intraparenchymally into 2 quadrants of breast. Subsequently, LSG is performed 0.5~1.0 hour before surgery. Methylthioninium was injected intraparenchymally. IM-SLNB is performed during the surgery and the IMSLNs were sent to histologic examination
88919650|NCT01668927|Experimental|tetracycline/furazolidone|one of the four empirical rescue therapies
88919651|NCT01668927|Experimental|amoxicillin/tetracycline|one of the four empirical rescue therapies
88919652|NCT01668927|Experimental|amoxicillin/furazolidone|one of the four empirical rescue therapies
88919653|NCT01668927|Active Comparator|tetracycline /metronidazole|Classical rescue therapy
88919654|NCT01668979||new system to detect Near Falls|the new system comprises of a treadmill and a virtual reality simulation that will be used to induce Near Falls in healthy older adults with a history of falls.
88919655|NCT01668992|Experimental|Family intervention|Families receive 12-week program on parenting skills, discipline methods and family communication.
88919656|NCT01668992|No Intervention|Waitlist control|Families are on a waitlist and receive the intervention only after the trial is complete.
88919657|NCT01669005||Bone marrow transplant unit patients|hospitalized patients in the bone marrow transplant unit for an autologous or allogeneic hematopoietic stem cells transplantation or induction/consolidation chemotherapy
88919658|NCT01669018|Active Comparator|Lumbar ultrasound trident (LUT)|Lumbar plexus block using LUT technique
88919659|NCT01669018|Experimental|Supra Sacral Parallel Shift (SSPS)|Lumbar plexus block using SSPS technique
88919660|NCT01669031|No Intervention|Control Group|No practice tests are performed in this arm
89198603|NCT05157022|Active Comparator|Radial extracorporeal shock wave therapy|A total of 4 sessions of ESWT at 1-week intervals were applied to to the sacrococcygeal area
89536497|NCT02475473|Experimental|Intervention|"The acute intervention will consist of 1 session of training following the program:~Resistance Training Exercises. Each participant in the intervention group will perform resistance-training exercises in the form of a circuit. The circuit will consist of 10 repetitions per exercise of 7 exercises: leg press, bent-over row, bench press, squats, dumbbell jump squats with raises, dead-lifts and weighted abdominal crunches, with approximately 30 sec of rest in between each exercise (based on the estimated time needed to move from one position to the next). Initial intensity 6-7 of RPE and ending the set at 9-10. Each participant will move through the circuit 3 times, with 2 to 3 minutes of rest between each round."
89536498|NCT02475473|No Intervention|Control|Control
88919661|NCT01669031|Experimental|Practice Program|"At the 3 study visits exposed to a training session (simulated visual field test on a computer).~Visit 1 they get 2 simulated tests tests per eye. At visits 2 and 3 they get 1 simulated test per eye. Each simulated test takes 3-15 minutes"
88919662|NCT01669044||dexmedetomidine,hemodynamics,injection|Group 1:when the patient can be roused after major abdominal surgery ，we will inject dexmedetomidine at 1μg/kg in 10 minutes as a loading dose, followed by a continuous infusion at 0.3μg/kg/h for 6 to 24hours.then adjust the infusion dose to maintain the ramsay scale at 3-4 scores.
88919663|NCT01669044||propofol,hemodynamics,injection|Group 2 :when the patient can be roused after major abdominal surgery ，we will inject propofol at 0.5mg/kg as a loading dose, followed by a continuous infusion at 0.5mg/kg.h for 6 to 24hours.then adjust the infusion dose to maintain the ramsay scale at 3-4 scores
88919664|NCT01669057||Congenital heart defect（CHD） group|
88919665|NCT01669057||Normal control group|
88919666|NCT01669070|Experimental|FF 50 mcg powder inhalation|Each subject will receive a single dose of 300 mcg FF (6 inhalations of 50 mcg FF) on Day 1 of the respective period per randomization sequence, followed by 50 mcg FF once daily for 7 days, on Days 3-9 inclusive, administered from the NDPI.
88919667|NCT01669070|Experimental|FF 100 mcg powder inhalation|Each subject will receive a single dose of 600 mcg FF (6 inhalations of 100 mcg FF) on Day 1 of the respective period per randomization sequence, followed by 100 mcg FF once daily for 7 days, on Days 3-9 inclusive, administered from the NDPI.
88919668|NCT01669070|Experimental|FF 200 mcg powder inhalation|Each subject will receive a single dose of 1200 mcg FF (6 inhalations of 200 mcg FF) on Day 1 of the respective period per randomization sequence, followed by 200 mcg FF once daily for 7 days, on Days 3-9 inclusive, administered from the NDPI.
88919669|NCT01669070|Experimental|FF 250 mcg IV|Each subject will receive a single dose of 250 mcg FF, administered as an IV infusion over 20 minutes on Day 1 of the respective period per randomization sequence.
88919670|NCT01669083|Experimental|Cohort 1: GSK557296 10 mg|GSK557296 10 mg single dose on Day 1 followed by repeat dosing (4 times a day) on Days 2-6
88919671|NCT01669083|Experimental|Cohort 2: GSK557296 150 mg|GSK557296 150 mg as a single dose on Day 1 followed by repeat nominal dosing of the same dose (either 2, 3 or 4 times a day based on half-life demonstrated in treatment A) on Days 9-13
88919672|NCT01669083|Experimental|Cohort 3|This study had an adaptive design and additional cohorts may be added depending on the PK profiles of Cohort 1 and Cohort 2. Subjects in this optional Cohort 3 will receive GSK557296 (dose to be determined) as a single dose on Day 1 followed by repeat nominal dosing of the same dose (either 2, 3 or 4 times a day based on half-life demonstrated in Cohort 1 and Cohort 2) on Days 2-6
88919673|NCT01669083|Experimental|Cohort 4|This study had an adaptive design and additional cohorts may be added depending on the PK profiles of Cohort 1 and Cohort 1. Subjects in this optional Cohort 4 will receive GSK557296 (dose to be determined) by PK of prior doses, 10-150 mg single dose on Day 1 followed by repeat dosing (either 2, 3 or 4 times a day dependent on half-life demonstrated in prior groups) on Days 2-6
88919674|NCT01669109|Experimental|Hatha yoga|"10 weeks of Hatha yoga, designed for patients with colorectal cancer, as a group intervention~1 weekly class (90 minutes)"
88919675|NCT01669109|No Intervention|Usual care|Patients continue their self-directed usual care
88919676|NCT01669135|Other|Spinal Anesthesia with cerebral oxygen saturation monitoring|The cerebral oxygen saturation of the right and left frontal lobe as well as the thigh oxygen saturation are monitored during spinal anesthesia by means of the near-infrared spectroscopy. Hemodynamic variables were recorded at the same time points.
88919677|NCT01669161|Experimental|VNS|VNS (vagus nerve stimulation) paired with rehabilitation as provided by the Vivistim System.
88919678|NCT01669161|Active Comparator|Rehab Only|Rehabilitation only (no implant, no VNS)
88919679|NCT01669213|Active Comparator|ramosetron 0.3 mg|preparation of ramosetron 0.3 mg
88919680|NCT01669213|Active Comparator|ondansetron 8 mg|preparation of ondansetron 8mg
88919681|NCT01669213|Active Comparator|ondansetron 4 mg|preparation of ondansetron 4mg
88919682|NCT01669213|Placebo Comparator|non 5-HT3 receptor antagonist|preparation of normal saline 5 ml
88919683|NCT01669226|Experimental|Regimen B, PEip and TCiv therapy|Weekly IP cisplatin plus etoposide followed by IV paclitaxel plus carboplatin or docetaxel plus carboplatin
88919684|NCT01669226|Active Comparator|Regimen A: Standard TCiv therapy|IV paclitaxel plus carboplatin or docetaxel plus carboplatin
88919685|NCT01669239|Experimental|Liposomal Doxorubicin|"Six cycles of:~Trastuzumab 4 mg/kg loading dose on Day 1 of the first cycle, then 2 mg/kg on Days 8 and 15 of the first cycle and on Days 1, 8, and 15 of the subsequent cycles, every 3 weeks~Pertuzumab 840 mg loading dose on Day 1 of the first cycle, then 420 mg on Day 1, every 3 weeks~Liposomal doxorubicin 50 mg/m2 on Day 1, every 3 weeks~Paclitaxel 80 mg/m2 on Days 1, 8, and 15, every 3 weeks"
88919686|NCT01669252|Experimental|Eribulin|1.23 mg/m2 eribulin ready to use solution (equivalent to 1.4 mg/m2 eribulin mesilate) IV on Days 1 and 8 of every 21-day cycle, for 4 cycles.
88919687|NCT01669265||OSNA|Patient cases with cT1-3, N0 early breast cancer, who previously had intraoperative sentinel lymph node (SLN) evaluation by one-step nucleic acid amplification (OSNA) assay with a complete axillary dissection.
88919688|NCT01669278|No Intervention|Traditional flexible nasopharyngolaryngoscopy|No sheath procedure
88919689|NCT01669278|Active Comparator|Sheath flexible nasopharyngolaryngoscopy|Flexible nasopharyngolaryngoscopy using endosheath
89198604|NCT05157022|Sham Comparator|Sham extracorporeal shock wave therapy|A total of 4 sessions of ESWT at 1-week intervals were applied to to the sacrococcygeal area
88919690|NCT01669291|Active Comparator|Bravelle & Menopur Agonist Long Protocol|Patients will use an LH agonist (Lupron) starting on day 18 of the oral contraceptive pill (OCP), 5 units b.i.d. followed by 5 units q.d. beginning on day one of stimulation medications. The 5 units q.d. dose will continue until the day of hCG administration.Patients will administer Bravelle and Menopur for ovarian stimulation.
88919691|NCT01669291|Active Comparator|Bravelle & Menopur Antagonist Protocol|Patients will complete standard dose of oral contraceptive pill (OCP) and will then administer GnRH antagonist (ganirelix acetate or cetrorelix acetate) 0.25 mg q.d. during the stimulation phase when the lead follicle size reaches 12mm. The antagonist will continue until the day of hCG administration. Patients will administer Bravelle and Menopur for ovarian stimulation.
88919692|NCT01669304|Experimental|Verapamil|Verapamil extended release oral tablets administered in a flexible dose format ranging from 120 mg to 360 mg daily, as determined by severity of headache and dizziness.
88919693|NCT01669304|Experimental|Sertraline|Sertraline oral tablets administered in a flexible dose format ranging from 25 mg to 150 mg daily depending on severity of headache and dizziness.
88919694|NCT01669317|Experimental|Cherry Juice Standardized|You will be given an 8-ounce glass of cherry juice to drink when you arrive at the Sleep Laboratory.
88919695|NCT01669317|Placebo Comparator|Artificial Cherry Juice|You will be given an 8-ounce glass of artificial cherry juice to drink when you arrive at the Sleep Laboratory.
88919696|NCT01669330|Active Comparator|Total fundoplication|Procedure: Laparoscopic Nissen fundoplication
88919697|NCT01669330|Active Comparator|Anterior partial fundoplication|Procedure: Laparoscopic anterior partial fundoplication
88919698|NCT01669356|Experimental|PN supplement|Parenteral supplement with enteral nutrition for patients after esophagectomy
88919699|NCT01669356|Active Comparator|EN alone|Enteral nutrition alone for patients after esophagectomy
88919700|NCT01669369|Placebo Comparator|Placebo|The shape,color and smell of placebo are similar to Lithium Carbonate tablet used in the treatment arm.Patients in this arm take placebo twice a day.
88919701|NCT01669369|Experimental|Lithium Carbonate|Patients in this arm take Lithium Carbonate twice a day with a dose of 20-25mg/kg/d.
88919702|NCT01669382|Active Comparator|Exo Seal system|Percutaneous coronary intervention
88919703|NCT01669382|Active Comparator|AngioSeal system|percutaneous coronary intervention
89436438|NCT04181229|Experimental|DBS Treatment|Patients in the treatment arm will receive DBS of bilateral centromedian nucleus (2 electrodes per patient). DBS is a standard of care treatment option for drug-resistant epilepsy patients who have previously failed VNS at 12 months or more after instigation and optimization of therapy.
88919704|NCT01669395|Experimental|Early homebased rehabilitation|After discharge from the hospital patients are offered a homebased rehabilitation program lasting 6 weeks.
88919705|NCT01669395|Experimental|control group: Ususal care|After discharge from the hospital the patients are offered the usual symptom-oriented and preventive medical care and psychosocial support
88919706|NCT01669408|Active Comparator|Cold infusions|Infusion of 1L cold crystalloid solution (4°C) over 15 minutes
88919707|NCT01669408|No Intervention|Control group|Best medical treatment following international stroke guidelines
88919708|NCT01669447|Experimental|ranibizumab|"Interventional study, prospective will be conducted in a single eye of twenty consecutive patients who will receive intravitreal ranibizumab for neovascular membrane active subfoveal choroidal active due to AMD and visual acuity of 20/40 and 20/320.~To establish the presence of active neovascularization evaluated the presence of leakage seen on fluorescein angiography and fluid, as seen in optical coherence tomography (OCT), located both intra and subretinal, or below the retinal pigment epithelium.~Treatment with ranibizumab will be offered after extensive Discussing the pathogenesis of AMD, the treatment alternatives, as well as the possible risks of treatment with ranibizumab. Term of consent shall be obtained prior to treatment."
88919709|NCT01669460|Experimental|Red Bull™ Sugar-Free Drink|Red Bull™ Sugar-Free Drink: two (250mL) cans per day for 28 days
88919710|NCT01669473|Experimental|Intervention Arm|"EHR Based Strategy to promote Safe and Appropriate Drug Use~Patients randomized to the intervention arm will be given (3) print tools to assist in safe and appropriate medication use. These include a Medreview, Medsheet,and Medlist."
88919711|NCT01669473|No Intervention|Standard Care Arm|The control group will receive regular standard care at the Clinic. They will not receive any print tools.
88919712|NCT01669486||ICU patients|All patients admitted to ICU for a minimal hospitalization of 24 hours, invasive mechanically ventilated, will be evaluated with CPOT and BPS scores, during nurses work, in particular before and after nurses manoeuvers.
88919713|NCT01669499|Placebo Comparator|Placebo|Placebo on day 0-3
88919714|NCT01669499|Active Comparator|Dexamethasone acetate day 0|8 mg dexamethasone on day 0
88919715|NCT01669499|Active Comparator|Dexamethasone acetate day 0-3|8 mg dexamethasone on day 0-3
88919716|NCT01669512|Active Comparator|Control Regimen|ChAd63 ME-TRAP 5 x 1010 vp on Day 0 and MVA ME-TRAP 2 x 108 pfu on Day 56 6 Volunteers
88919717|NCT01669512|Experimental|Low Dose Matrix M Regimen|ChAd63 ME-TRAP 5 x 1010 vp mixed with Matrix M-1 25μg on Day 0 and MVA ME-TRAP 2 x 108 pfu mixed with Matrix M-1 25μg on Day 56 8 Volunteers
89198605|NCT00877149|Experimental|A|
89436439|NCT04181229|No Intervention|Continued VNS (control)|For the control arm, the patients will be monitored for one year with the same standard assessments used for the measurement of seizure frequency and severity. No changes will be made to these patients' treatment plan. These patients will be placed on a wait list for CM-DBS treatment of seizures if that is the desire of the patient and/or their family. After the 12 months of observation, these patients can choose to undergo DBS surgery.
89436440|NCT04179864|Experimental|Phase 1b: Tazemetostat in Combination with Abiraterone/Prednisone|In Phase 1b, abiraterone/prednisone will be administered in combination with tazemetostat in cycle 1 (28 days) to establish the recommended dose of tazemetostat in this combination; participants may continue treatment in additional 28-day cycles, as tolerated, until progression or unacceptable toxicity
89436441|NCT04179864|Experimental|Phase 1b: Tazemetostat in Combination with Enzalutamide|In Phase 1b, enzalutamide will be administered in combination with tazemetostat in cycle 1 (28 days) to establish the recommended dose of tazemetostat in this combination; participants may continue treatment in additional 28-day cycles, as tolerated, until progression or unacceptable toxicity
89436442|NCT04179864|Experimental|Phase 2: Tazemetostat in Combination with Enzalutamide|"Participants will receive the newly established recommended phase 2 dose, orally twice daily when given in combination with enzalutamide) as determined in phase 1b part of the study) or enzalutamide alone.~All participants will receive treatment in 28-day cycles."
89436443|NCT04179864|Active Comparator|Phase 2: Enzalutamide only|In Phase 2, Enzalutamide will be administered on cycle 1 day 1
89436444|NCT04168203|Experimental|Extended Duration Thromboprophylaxis|apixaban 2.5 mg orally twice daily for a duration of 12 months
89436445|NCT04168203|Placebo Comparator|Control|oral placebo for a duration of 12 months
88919718|NCT01669512|Experimental|Standard Dose Matrix M Regimen|ChAd63 ME-TRAP 5 x 1010 vp mixed with Matrix M-1 50μg on Day 0 and MVA ME-TRAP 2 x 108 pfu mixed with Matrix M-1 50μg on Day 56 8 Volunteers
88919719|NCT01669525||No treatment|Singleton pregnancies presenting to the Genetic Counselor for Sequential Screening prior to 14 weeks gestation.
89436446|NCT04155749|Experimental|ARM 1|Phase I study of BCMA-specific CAR-modified T-cell therapy using alternative binding domain, for the treatment of patients with relapsed and refractory multiple myeloma
89436447|NCT04152018|Experimental|Dose Escalation|Single Agent Dose Escalation
88919720|NCT01669551||Structural or Valvular Heart Disease|
88919721|NCT01669564|Active Comparator|Activated Patients|Will use HIT patient feedback to activate patients.
88919722|NCT01669564|Other|Control patients|Patients will not receive HIT patient feedback.
88919723|NCT01669564|Other|Intervention Physicians|Will use HIT patient feedback to activate patients.
88919724|NCT01669564|Other|Control Physicians|Patients will not receive HIT patient feedback.
88919725|NCT01669590||old (60-75yr)|
89436448|NCT04152018|Experimental|Dose Finding Anti-PD-1 Combination 1|Part 1B PF-06940434 plus anti-PD-1
89436449|NCT04152018|Experimental|Dose Expansion Arm A|PF-06940434 with anti-PD-1 in SCCHN
88919726|NCT01669590||young (18-35y)|
88919727|NCT01669668|Experimental|RFA|Patients undergo laparoscopic ultrasound followed by RFA.
88919728|NCT01669681||Included in the cohort COBRA|
89436450|NCT04152018|Experimental|Dose Expansion Arm B|PF-06940434 with anti-PD-1 in RCC
89436451|NCT04152018|Experimental|Dose Expansion, Arm C|PF-06940434 with anti-PD-1 (both Q3W)
89436452|NCT04146818|Experimental|Adapted Tango Dancing arm|Treatment will include sessions of Adapted Tango (90 min per week for a total of 6 months) together with sessions of comprehensive cognitive intervention (90 min per week for a total of 6 months)
89436453|NCT04146818|Placebo Comparator|Control arm|Sessions of psycho-education and advice on healthy life-style (once per month for a total of 6 months)
88919729|NCT01669694||Women with Pelvic Pain|Women with Pelvic Pain undergoing pelvic floor PT in the Beaumont Women's Urology Center
88919730|NCT01669707|Experimental|Endostar -Continued Pumping into+GP|Endostar that is Continued Pumping into vein Combining With Gemcitabine -Cisplatin
88919731|NCT01669707|Active Comparator|Endostar -injecting into +GP|Endostar that is injecting into vein with Gemcitabine -Cisplatin
88919732|NCT01669733|Experimental|Live/Recorded Music Group|The music therapist will prepare a preferred song to be performed live in the preoperative room. Subjects in the live music group will listen to recorded music intraoperatively.
88919733|NCT01669733|Experimental|Recorded Music Group|Recorded music group will be given an iPod and headphones and will listen to a recorded version of a preferred song.
88919734|NCT01669733|Active Comparator|No Music (Standard of care)|The control group will receive standard of care and no music.
88919735|NCT01669746|Experimental|Treatment|
88919736|NCT01669759||fatigue|
88919737|NCT01669772|Other|DA-9701 and placebo|Administer DA-9701 for 1week and assess the study outcomes. After 1 week of washout period, administer placebo for 1week and assess the outcomes again.
88919738|NCT01669772|Other|Placebo and DA-9701|Administer placebo for 1 week and study the outcome parameters. After 1 week of washout, administer DA-9701 for 1 week and assess the outcome parameters again.
88919739|NCT01669837||Patient group|Administration of surgical tissue glue.
88919740|NCT01669850|Experimental|Clipped anastomosis|A vascular clip device will be used to create the anastomosis during arteriovenous fistula creation.
88919741|NCT01669850|Active Comparator|Handsewn anastomosis|A handsewn technique will be used to create the anastomosis in arteriovenous fistula creation.
88919742|NCT01669876|Active Comparator|Dietary Supplement: Anatabloc(R)|Study product, as mint-flavored lozenge (3 mg anatabine per lozenge) to be taken 2-3 times each day
89436454|NCT04128683|Experimental|Healthy Controls|Healthy Control Subjects
89536499|NCT03070743||PCDR surgery|Posterior Approach Compression Distraction Reduction Surgery is performed.All of patients received this procedure routinely in the department of neurosurgery at Xuanwu Hospital.
88919743|NCT01669876|Placebo Comparator|Placebo|Placebo, as mint-flavored lozenge, to be taken 2-3 times each day
88919744|NCT01669889||Cohort|
89436455|NCT04128683|Experimental|Anorexia Nervosa|Anorexia Nervosa Subjects
89436456|NCT04113421||Anticoagulation|Inpatients diagnosed with acute PE, in whom clinical providers have elected to prescribe anticoagulation alone for treatment based on clinical grounds at BWH. In this population, a single follow-up contrast-enhanced chest CT will be performed to compare off-line with the contrast-enhanced chest CT done at baseline for the diagnosis of PE.
89436457|NCT04113109|Experimental|placebo, icatibant, placebo, icatibant|After a 48-hr washout, participants in this arm will be given LCZ696 50 mg and placebo (vehicle). After a 96-hr washout period, subjects will be given LCZ696 50 mg and icatibant. Participants will then undergo uptitration of LCZ696 over seven weeks. On the 7th and 10th days of the 200 mg bid or highest tolerated dose of LCZ696, participants in this arm will receive placebo and icatibant, respectively.
89436458|NCT04113109|Experimental|placebo, icatibant, icatibant, placebo|After a 48-hr washout, participants in this arm will be given LCZ696 50 mg and placebo (vehicle). After a 96-hr washout period, subjects will be given LCZ696 50 mg and icatibant. Participants will then undergo uptitration of LCZ696 over seven weeks. On the 7th and 10th days of the 200 mg bid or highest tolerated dose of LCZ696, participants in this arm will receive icatibant and placebo, respectively.
89536500|NCT02475551|Experimental|Treatment|IdeS as a single infusion
88919745|NCT01669941|Experimental|IPTp-DP|At each ANC visit, women will be given treatment with Dihydroartemisinin-piperaquine for three days, with the daily number of tablets depending on the weight of the woman; two tablets for women weighing 24- 35.9kg, three tablets for women weighing 36 to 74.9 kg, and four tablets for women weighing 75kg or more. The first dose will be observed; the woman will be given the additional 2 doses to take at home and there may be a home visit to confirm that the tablets were taken.
88919746|NCT01669941|Experimental|ISTp-DP|At each ANC visit, women will be screened for malaria using a combined HRP-2/ pLDH (P. falciparum/ pan-malaria) rapid diagnostic test, and if they test positive, will be treated with dihydroartemisinin-piperaquine (DP). Each tablet will contain 40 mg dihydroartemisinin and 320 mg piperaquine. Treatment will be given for three days, with the daily number of tablets depending on the weight of the woman; two tablets for women weighing 24- 35.9kg, three tablets for women weighing 36 to 74.9 kg, and four tablets for women weighing 75kg or more. The first dose will be observed; the woman will be given the additional 2 doses to take at home
88919747|NCT01669941|Active Comparator|IPTp-SP|Treatment with a single dose of three tablets of sulfadoxine-pyrimethamine, each containing sulfadoxine (500 mg) and pyrimethamine (25 mg) at each FANC visit. This is the standard regimen.
88919748|NCT01669954||Controls, females|Controls who are presumed HIV uninfected, females, aged 18 or above
88919749|NCT01669954||Controls, males|Controls presumed HIV uninfected, males, aged 18 or above
88919750|NCT01669954||HIV infected patients, males|HIV patients, males, aged 18 or above
88919751|NCT01669954||HIV patients,|HIV patients, females, aged 18 or above
88919752|NCT01669967|Placebo Comparator|Diphenhydramine(Benadryl)|
88919753|NCT01669967|Active Comparator|Lidocaine|
88919754|NCT01670149|Placebo Comparator|Placebo|Identical looking tablet
88919755|NCT01670149|Active Comparator|Rifaximin , Xifaxanta™|2 weeks of Rifaximin 400mg thrice daily then 2 weeks of Rifaximin 200mg thrice daily Modified Xifaxanta™ (rifaximin film-coated tablet) manufactured by Alfa Wasermann (AW),
88919756|NCT01670370|Experimental|Rituximab+Gemcitabine+oxaliplatin (R-GemOx)|Rituximab: 375 mg/m2 IV day1, Gemcitabine 1g/m2 IV day 2, oxaliplatin 100mg/m2 IV day2(every 14 days)
88919757|NCT01670552|Experimental|Nimesulide + Pantoprazole|Nimesulide + Pantoprazole- 1 tablet each 12 hours for 14 days
88919758|NCT01670552|Active Comparator|Naproxen + Esomeprazole|Naproxen + Esomeprazole - 1 tablet each 12 hours for 14 days
88919759|NCT01670578|Experimental|PRP Group|Patients (n=96) randomized to this group of treatment will receive 3 blinded knee intra-articular injections of autologous Platelet-Rich Plasma one week apart each other.
88919760|NCT01670578|Active Comparator|Hyaluronan Group|Patients (n=96) randomized to this group of treatment will receive 3 blinded knee intra-articular injections of hyaluronic acid ( Hyalubrix 30 mg/2ml, Fidia Farmaceutici Spa, Italy) one week apart each other.
89436459|NCT04113109|Experimental|icatibant, placebo, placebo, icatibant|After a 48-hr washout, participants in this arm will be given LCZ696 50 mg and icatibant. After a 96-hr washout period, subjects will be given LCZ696 50 mg and placebo. Participants will then undergo uptitration of LCZ696 over seven weeks. On the 7th and 10th days of the 200 mg bid or highest tolerated dose of LCZ696, participants in this arm will receive placebo and icatibant, respectively.
89536501|NCT04995705|Experimental|Experimental Group Based ACT|Stroke survivors and individuals with brain injury were randomised into an adapted acceptance and commitment therapy (ACT) group-based intervention. This consisted of 2.5 hour sessions over 5 consecutive weeks.
89536892|NCT05280431|Other|Control Group (Conventional therapy)|15 sessions, 3 sessions per week. Each session consists of 45 minutes and consists of different training modalities typically used in the rehabilitation of the arm after stroke.
89010670|NCT04719351|Experimental|Condition 30: Positive: yes; Workload: no; Controllability: yes; Open: yes; Prompt: yes;|"Component list:~Questions about positive emotions: included;~Questions about workload/work environment: not included;~Questions about controllability: included;~Questions with open answers: included;~Behavioral prompts: included;"
89010671|NCT04719351|Experimental|Condition 31: Positive: no; Workload: yes; Controllability: yes; Open: yes; Prompt: yes;|"Component list:~Questions about positive emotions: not included;~Questions about workload/work environment: included;~Questions about controllability: included;~Questions with open answers: included;~Behavioral prompts: included;"
89010672|NCT04719351|Experimental|Condition 32: Positive: yes; Workload: yes; Controllability: yes; Open: yes; Prompt: yes;|"Component list:~Questions about positive emotions: included;~Questions about workload/work environment: included;~Questions about controllability: included;~Questions with open answers: included;~Behavioral prompts: included;"
89010673|NCT04537585|Experimental|Tomeka|Number of participants with treatment-TOMEKA® usage as assessed by Education [ Time Frame: 18 months ] Change people's behaviour
89010674|NCT04537585|Experimental|"Vernonia amygdalina"|"Number of participants with Vernonia amygdalina herbs usage as assessed by Education [ Time Frame: 18 months ] Change people's behaviour"
89010675|NCT02216110||Surgery group|Patients who underwent surgery as treatment of early gastric cancer
89010676|NCT02216110||ESD group|Patients who underwent endoscopic submucosal dissection (ESD) as treatment of early gastric cancer, instead of surgery
89010677|NCT02216149|Experimental|S-1 plus oxaliplatin (SOX)|Oxaliplatin 130 mg/m2 d. 1 followed by oral S-1 25 mg/m2/day BID d1-14.
89010678|NCT02216149|Active Comparator|Oxaliplatin plus capecitabine (XELOX)|Intravenous oxaliplatin 130 mg/m2 d.1 followed by oral capecitabine 2000 mg/m2/day divided in 2 daily doses d1-14.
89010679|NCT04537468|Other|Skin sample collection|Skin sample collection for gene expression analyses.
89010680|NCT04537390|Other|Blood sample collection|Blood samples are collected for diagnostically assessing how the blood AMH levels correspond to a female's reproductive development
89010681|NCT04536883|Experimental|Microscopy confocal|"The fibroscopy is carried out according to the usual procedure of the service. During the fibroscopy, for all patient, the confocal microscopy procedure begins.~After the end of confocal procedure, 5 to 6 transbronchial biopsies are performing"
89010682|NCT04536844|Experimental|Telehealth follow-up group|Rheumatoid arthritis patients in remission who will be followed by an electronic app
89010683|NCT04536844|Placebo Comparator|Conventional follow-up group|Rheumatoid arthritis patients in remission who will attend conventional prescheduled visits in the outpatient clinic
89010684|NCT00415584|Experimental|Cinacalcet HCl|
89010685|NCT04537273||Localy advanced Cervical Cancer|Patients with Localy advanced Cervical Cancer confirmed by pathology, clinical exams and computed tomography scan, treated with concurrent chemoradiotherapy.
89010686|NCT04536922|Experimental|iTCR + Pembro|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + Individual Patient TCR-Transduced PBL + high- or low-dose aldesleukin + pembrolizumab prior to cell administration and 3 additional doses every 3 weeks following cell infusion
89010687|NCT04536961|Experimental|Part A: Reference Treatment|
89010688|NCT04536961|Experimental|Part A Prototype|
89010689|NCT04536961|Experimental|Part C Reference Treatment|
88819425|NCT00552617|Experimental|Vecuronium + 4.0 mg/kg Sugammadex|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 4.0 mg/kg sugammadex was administered IV.
88819426|NCT04298307||Patients with calcified coronary artery disease|Patients with calcified coronary artery disease require an ICL using the Shockwave catheter.
88819427|NCT02421120|Experimental|Ceftolozane/Tazobactam|Ceftolozane/Tazobactam 3 grams every 8 hours intravenously for 4-6 doses
89010690|NCT04536961|Experimental|Part C: Prototype|
89010691|NCT04536961|Experimental|Part B: Treatment 1|
89010692|NCT04536961|Experimental|Part B: Treatment 2|
89010693|NCT04536961|Experimental|Part B: Treatment 3|
89010694|NCT04536961|Experimental|Part B: Treatment 4|
89010695|NCT04536961|Experimental|Part B: Treatment 5|
89010696|NCT04537117||Pediatric dentists|Pediatric dentists following Facebook groups for pediatric dentists and practicing dentistry nowadays
89010697|NCT04542265|Experimental|Oat product 1|The test portion is based on 50 gram available carbohydrates with added vegetable oil A. Test portion consumed as a breakfast meal prior to determinations of test variables in the morning.
89010698|NCT04542265|Experimental|Oat product 2|The test portion is based on 50 gram available carbohydrates with added vegetable oil B. Test portion consumed as a breakfast meal prior to determinations of test variables in the morning.
89010699|NCT04542265|Experimental|Oat product 3|The test portion is based on 50 gram available carbohydrates with added vegetable oil A + vegetable oil B. Test portion consumed as a breakfast meal prior to determinations of test variables in the morning.
89010700|NCT04542265|Placebo Comparator|Control Product|The test portion is based on 50 gram available carbohydrates without added vegetable oil. Test portion consumed as a breakfast meal prior to determinations of test variables in the morning.
89010701|NCT04536610|Experimental|Experimental group|Providing structured OP education in addition to the informative leaflet. (The leaflet contained the same information as the OP education program)
89010702|NCT04536610|Active Comparator|Control group|Giving only the informative leaflet. (The leaflet contained the same information as the OP education program)
89010703|NCT04536649|Experimental|Standard-dose Photon Radiotherapy|The patients will receive standard-dose photon radiation (60Gy/30F for high-risk area) with concurrent temozolomide (75mg/m2, qd), adjuvant temozolomide (150-200mg/m2, qd, D1-5, 28d/cycle)
89010704|NCT04536649|Experimental|Standard-dose Proton Radiotherapy|The patients will receive standard-dose proton radiation (60GyE/30F for high-risk area) with concurrent temozolomide (75mg/m2, qd), adjuvant temozolomide (150-200mg/m2, qd, D1-5, 28d/cycle).
89010705|NCT04536649|Experimental|Standard-dose Proton Radiotherapy plus Carbon-Ion Boost|The patients will receive carbon-ion radiation boost (15GyE/3F for residual lesion) priot to standard-dose proton radiation (60GyE/30F for high-risk area) with concurrent temozolomide (75mg/m2, qd), then adjuvant temozolomide (150-200mg/m2, qd, D1-5, 28d/cycle).
89010706|NCT04536454|Experimental|[18F]FPyGal|"Cancer patients will first be treated with a tumor type-specific neo-adjuvant chemotherapy regimen (standard-of-care); subsequently, they will undergo surgical resection of their primary tumors in a curative intention.~After the end of the neo-adjuvant therapy a tracer injection with [18F]FPyGal solution will be administered (study intervention). Immediately after the injection a dynamic PET/MR imaging of the tumor sites including heart or large arterial blood pools will be conducted over 90 minutes."
89436460|NCT04113109|Experimental|icatibant, placebo, icatibant placebo|After a 48-hr washout, participants in this arm will be given LCZ696 50 mg and icatibant. After a 96-hr washout period, subjects will be given LCZ696 50 mg and placebo. Participants will then undergo uptitration of LCZ696 over seven weeks. On the 7th and 10th days of the 200 mg bid or highest tolerated dose of LCZ696, participants in this arm will receive icatibant and placebo, respectively.
89436461|NCT04093492|Experimental|Preemie Prep for Parents (P3) Outpatient Mobile Intervention|The P3 mobile intervention in its current form sends participants text messages according to a schedule based on their gestational age. These text messages contain links to short videos uploaded to the P3 site, focusing on topics related to preterm labor and premature infants.
89010707|NCT00415701|Experimental|1|Etomidate as a single induction dose
89010708|NCT00415701|Active Comparator|2|Propofol as a single induction dose
89010709|NCT00415701|Other|3|Hydrocortisone substitution or placebo (50-50%) in etomidate-group
89010710|NCT02961998|Experimental|Celecoxib group|Patients were treated with sorafenib taking capsules celecoxib (Celebrex) at the same time, 200mg/day, last 6 months
89010711|NCT02961998|Active Comparator|Control group|Patients take sorafenib only.
89010712|NCT04536727|Experimental|Intervention|The 8-week intervention will consist of the Fit & Strong! program adapted to address the impact of exercise on enhancing positive affect and reducing negative affect and depressive symptoms. Exercise classes will meet three times per week for 90 minutes per session for eight weeks. Each class is divided into 60 minutes of strength training, flexibility, and cardiovascular exercise and 30 minutes of group education/discussion, which has been adapted to include affect-oriented content.
89536893|NCT03311945|Experimental|Raltegravir + Lamivudine|Lamivudine (300 mg QD) plusRaltegravir (1200 mg QD)
89010713|NCT04536727|Placebo Comparator|Wait list|Participants randomized to the wait list group, receive the 8-week Fit & Strong! intervention after the intervention group has completed it.
89436462|NCT04093492|Active Comparator|ACOG links|Participants in the active control condition will receive links to patient education handouts about preterm birth provided by the American College of Obstetricians and Gynecologists.
89436463|NCT04090125|Experimental|Physical Activity and Symmetry (PAS) Intervention|Participants assigned to the PAS intervention will receive 4 sessions on balance training and physical activity coaching delivered by a physical therapist, in addition to their usual post-TKA physical therapy (PT) care.
89436464|NCT04090125|Placebo Comparator|Attention Control|Participants assigned to the ATT group will receive usual post-TKA physical therapy (PT) care, followed by two additional sessions with their physical therapist.
88919761|NCT01670604|Experimental|VOL group|patients will receive 6% HES 130/0.4 in NaCl 0.9% (Voluven, Fresenius Kabi, Bad Hom-bourg, Germany)
89436465|NCT04083599|Experimental|Monotherapy - Dose Escalation and Dose Expansion parts|Escalating doses of GEN1042 monotherapy in subjects with non-central nervous system (CNS) solid malignant tumors followed by monotherapy expansion cohorts at selected dose(s) in subjects with relapsed or refractory, advanced and/or metastatic melanoma, or non-small-cell lung cancer (NSCLC), or colorectal cancer (CRC).
89436466|NCT04083599|Experimental|Combination Therapy - Dose Expansion Part|GEN1042 safety and efficacy will be evaluated in combination with pembrolizumab with or without chemotherapy in treatment-naive subjects with advanced or metastatic melanoma, non-small-cell lung cancer [NSCLC], head and neck squamous cell carcinoma [HNSCC], and pancreatic cancer.
89436467|NCT04068103|Active Comparator|Arm I (blood stored and tested for ctDNA later)|Patients undergo active surveillance.
89436468|NCT04068103|Experimental|Arm II (blood tested for ctDNA at baseline)|"Patients are assigned to 1 of 2 groups.~GROUP I (ctDNA DETECTED): At the discretion of the investigator, patients receive either oxaliplatin IV over 2 hours on day 1, leucovorin IV over 2 hours on day 1, and fluorouracil IV bolus over 2-4 minutes on day 1 and then by continuous IV over 46-48 hours repeated every 14 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity or oxaliplatin IV over 2 hours on day 1 and capecitabine PO BID on days 1-14 repeated every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity at the discretion of the investigator.~GROUP II (ctDNA NOT DETECTED): Patients undergo active surveillance."
88919762|NCT01670604|Experimental|TET group|patient will receive 6% HES 130/0.42 in a balanced electrolyte containing Na+140 mmol/L, Cl- 118 mmol/L, K +4 mmol/L, Ca++ 2.5 mmol/L, Mg++ 1 mmol/L, acetate- 24 mmol/L and malate-- 5 mmol/L
88919763|NCT01670617|Other|DeNovo NT Graft|DeNovo NT Graft stratified by lesion location - femur or patella
88919764|NCT01670812|Experimental|FFP+HDMP+Rituximab|Fresh frozen plasma 400ml IV day0, Rituximab: 375 mg/m2 IV day0(after infusion of FFP), methylprednisolone 1g/m2(up to 1.5g) IV day1-day5.
88919765|NCT01670916||Probiotics|Capsule with 1 x 10**9 Lactobacillus rhamnosus GG and 1 x 10**8 Bifidobacterium BB12. Two capsules once a day. The capsules are opened and the content is dissolved in mother's milk or water if the baby is given any milk. In tube fed infants, two drops are given in the mouth and the rest in the nasogastric tube.
88919766|NCT01670916||Control|Probiotics never given
89436469|NCT04057937|Experimental|Placebo then Apremilast 30mg BID|Participants received matched placebo as oral tablets twice daily (BID) for up to 16 weeks (Week 0 to Week 16). Participants who completed the placebo-controlled phase entered the active-treatment phase and received apremilast 30 mg as oral tablets BID for up to an additional 16 weeks (Week 16 to Week 32).
89436470|NCT04057937|Experimental|Apremilast 30 mg BID then Apremilast 30 mg BID|Participants received apremilast 30 mg as oral tablets BID for up to 16 weeks (Week 0 to Week 16). Participants who completed the placebo-controlled phase entered the active-treatment phase and received apremilast 30 mg as oral tablets BID for up to an additional 16 weeks (Week 16 to Week 32).
89436471|NCT04056520||Arm 1|Subjects undergoing posterior cervicothoracic fusions between C2 and upper thoracic will be enrolled
89436472|NCT04041791|Active Comparator|Benzyl penicillin/ampicillin + gentamicin & IV fluids|"Participants are assigned to receive benzyl penicillin at 50,000 IU/kg every 6 hours or ampicillin 50mg/kg every 8 hours plus gentamicin 7.5 mg/kg once daily given intravenously (IV) or via intramuscular (IM) injection for a minimum of 48 hours and for up to 7 days.~Maintenance fluids will be given as a continuous infusion for at least 24 hours."
89436473|NCT04041791|Experimental|Ceftriaxone and IV fluids|"Participants are assigned to receive ceftriaxone at 50 mg/kg every 12 hours given IV or IM for a minimum of 48 hours and for up to 7 days.~Intravenous fluids will be given as a continuous infusion for at least 24 hours."
89436474|NCT04041791|Experimental|Amoxicillin-clavulanate and IV fluids|"Participants are assigned to receive amoxicillin clavulanic acid at 30 mg/kg every 8 hours given IV or IM for a minimum of 48 hours and for up to 7 days.~Intravenous fluids will be given as a continuous infusion for at least 24 hours."
89436475|NCT04041791|Experimental|Benzyl penicillin/ampicillin + gentamicin & NG feeds|"Participants are assigned to receive Benzyl penicillin at 50,000 IU/kg every 6 hours or ampicillin 50mg/kg every 8 hours plus gentamicin 7.5 mg/kg once daily given intravenously (IV) or via intramuscular (IM) injection for a minimum of 48 hours and for up to 7 days.~Nasogastric feeds will be given 3 hourly for at least 24 hours."
89436476|NCT04041791|Experimental|Ceftriaxone and NG feeds|"Participants are assigned to receive ceftriaxone at 50 mg/kg every 12 hours given IV or IM for up to 7 days.~Nasogastric feeds will be given 3 hourly for at least 24 hours."
89436477|NCT04041791|Experimental|Amoxicillin-clavulanic acid and NG feeds|"Participants are assigned to receive amoxicillin clavulanic acid at 30 mg/kg every 8 hours given IV or IM for up to 7 days.~Nasogastric feeds will be given 3 hourly for at least 24 hours."
89536894|NCT03307655|Experimental|Control (fertile semen donors)|Sperm from fertile men (donors who attend the IVI Murcia clinic) will be included in this arm.
89010714|NCT04536415|Experimental|Oseltamivir Phosphate 75 mg capsules (Yangtze River)|During the study session, healthy participants will be administered a single dose of Oseltamivir Phosphate capsules 75 mg of Yangtze River Pharmaceutical (Group) Co., Ltd., China under Fed condition.
89010715|NCT04536415|Active Comparator|Tamiflu capsules 75 mg (Genentech, Inc.)|During the study session, healthy participants will be administered a single dose of Tamiflu capsules 75 mg of Genentech, Inc. under Fed condition.
89436478|NCT04041310|Experimental|Cohort A - Dose-escalation|"Phase I. Part 1. Dose escalation cohort. Subjects treated with low dose or with high dose of GAd20-209-FSP prime and MVA-209-FSP boosts to define the RP2D, in combination with pembrolizumab.~Phase I. Part 2 - Extended Follow-up from week 27 to week 110. Subjects with unresectable or metastatic deficient mismatch repair (dMMR) or MSI-H CRC, gastric, or gastro-esophageal junction (G-E junction) tumors."
89436479|NCT04041310|Experimental|Cohort B - Expansion Cohort Phase I|"Phase I. Part 1. Expansion cohort at RP2D. Subjects treated with RP2D dose of GAd20-209-FSP prime and MVA-209-FSP boosts, in combination with pembrolizumab.~Phase I. Part 2 - Extended Follow-up from week 27 to week 110. Subjects with unresectable or metastatic dMMR or MSI-H CRC, gastric, or G-E junction tumors."
89436480|NCT04041310|Experimental|Cohort C - Expansion cohort Phase II|Phase II. Subjects with locally advanced unresectable or metastatic, microsatellite instability high (MSI-H) or dMMR CRC who are eligible for anti-PD-1 1st line of treatment. Subjects will be randomized with an allocation ratio 2:1 to Nous-209 vaccine plus Keytruda® (pembrolizumab) combination therapy versus pembrolizumab monotherapy.
89436481|NCT04041310|Experimental|Cohort D - Expansion cohort Phase II|Phase II. Subjects with locally advanced unresectable or metastatic, microsatellite instability high (MSI-H) or dMMR CRC who have had radiographic progression (PD) after having a best response of stable disease (SD) or better on/after anti-PD1 treatment. Nous-209 vaccine plus Keytruda® (pembrolizumab) combination therapy.
89436482|NCT04016662|Active Comparator|Hybrid Closed Loop Control (HCL)|The HCL intervention arm will utilize the Tandom t:slim X2 with Control-IQ Technology and Dexcom G6 CGM
89436483|NCT04016662|Active Comparator|Predictive Low-Glucose Insulin Suspension (PLGS)|The PLGS intervention arm will utilize the Tandom t:slim X2 with Basal-IQ Technology and Dexcom G6 CGM
89436484|NCT04016662|No Intervention|Sensor-Augmented Pump (SAP)|The SAP arm will utilize the Tandem t:slim X2 without HCL or PLGS features turned on and Dexcom G6 CGM
89436485|NCT04015180|Experimental|Aflibercept arm|No study treatment will be administered. The treatments to be evaluated in this study were administered in Study 20090.
89436486|NCT04015180|Active Comparator|Laser photocoagulation arm|No study treatment will be administered. The treatments to be evaluated in this study were administered in Study 20090.
89436487|NCT04010825|Experimental|Hypnosis Arm|"In parallel with an inpatient pulmonary rehabilitation program, nine visits will be carried out :~V0 : an inclusion visit~V1 : a randomization visit~V2 to V6 : five visits with hypnosis sessions~V7 : a end-stay visit~V8 : a 6-month post-rehabilitation visit ( by phone call)~The five hypnosis sessions (V2 to V6) will be spread over three weeks of rehabilitation program (1 to 2 hypnosis sessions per week).~For V1, V7 and V8 : questionnaires will be filled about : quality of life (CAT questionnaire), the three dimensions of dyspnea (mMRC, LCADL and MDP questionnaires), anxiety and depression (HADS questionnaire), post-traumatic stress ( PCLS questionnaire), sedentarity and physical activity (SIMPAQ questionnaire). Other data will be also collected on : previous experiences with hypnosis, self-hypnosis and relaxation, number of exacerbations and hospitalizations in the past 6 months, drug treatment, psychotropic drug use and dosage and psychological follow-up."
89530947|NCT03344081||Controls|Control participants will be age- and gender-matched to each meditators. They will have little to no previous meditation experience. All participants will be MRI-compatible, healthy with no health conditions that affect breathing, have no current psychiatric disorder, and not be taking psychotropic medications.
89530948|NCT02499965|Active Comparator|Topical Ethyl Chloride (Product B)|Ethyl Chloride Topical Aerosol Anesthetic applied to arm
89530949|NCT02499965|Placebo Comparator|Topical Sterile Water (Product A)|Nature's Tears Sterile water in an aerosol can
89010718|NCT00262587|Placebo Comparator|Placebo|Placebo inhaler (sugar powder)
89010719|NCT00262587|Active Comparator|Seretide|Seretide inhaler
89198606|NCT00877227|Experimental|folinic acid|Folinic acid was given for two weeks as 5-formyltetrahydrofolate (10 mg/ml) (Pharmachemie bv). This solution was administered either intravenously (first week) or orally. To lower homocysteine in adults 5 mg/day folic acid is frequently used. Using an average bodyweight of 70 kg for adults we calculated a daily dose of 70 microgram/kg/day for our newborns
89198607|NCT00877227|No Intervention|2|control subjects admitted at the Neonatal Intensive Care Unit (NICU)
89436488|NCT04010825|No Intervention|Control Arm|"In parallel with an inpatient pulmonary rehabilitation program, no additional intervention will be carry out and four visits will be carried out :~V0 : an inclusion visit~V1 : a randomization visit~V7 : a end-stay visit~V8 : a 6-month post-rehabilitation visit ( by phone call)~For V1, V7 and V8 : questionnaires will be filled about : quality of life (CAT questionnaire), the three dimensions of dyspnea (mMRC, LCADL and MDP questionnaires), anxiety and depression (HADS questionnaire), post-traumatic stress ( PCLS questionnaire), sedentarity and physical activity (SIMPAQ questionnaire). Other data will be also collected on : previous experiences with hypnosis, self-hypnosis and relaxation, number of exacerbations and hospitalizations in the past 6 months, drug treatment, psychotropic drug use and dosage and psychological follow-up."
89436489|NCT04003636|Experimental|Arm A (Pembrolizumab+Gemcitabine+Cisplatin)|Pembrolizumab, 200 mg, every 3 weeks (Q3W), Day 1 of each 3-week cycle for up to 35 cycles PLUS Gemcitabine, 1000 mg/m^2, Q3W, Day 1 and Day 8 of each cycle until progressive disease or unacceptable toxicity PLUS Cisplatin, 25 mg/m^2, Q3W, Day 1 and Day 8 of each cycle for up to 8 cycles.
89436490|NCT04003636|Placebo Comparator|Arm B (Placebo+Gemcitabine+Cisplatin)|Placebo to Pembrolizumab, 200 mg, every 3 weeks (Q3W), Day 1 of each 3-week cycle for up to 35 cycles PLUS Gemcitabine, 1000 mg/m^2, Q3W, Day 1 and Day 8 of each cycle until progressive disease or unacceptable toxicity PLUS Cisplatin, 25 mg/m^2, Q3W, Day 1 and Day 8 of each cycle for up to 8 cycles.
89436491|NCT03998202||Adults 60-74 years|
89436492|NCT03998202||Adults >= 75 years|
89436493|NCT03992404|Experimental|NT 201 (IncobotulinumtoxinA, Xeomin)|"Main Period (1 treatment cycle): subjects to receive intramuscular injection of NT 201 (400 units) into muscles of the lower limb.~Open Label Extension Period (4-5 treatment cycles): subjects to receive intramuscular injection of NT 201 (up to 800 units) into muscles of the lower limb and upper limb, if indicated."
88919767|NCT01671241|Experimental|Total body polyethylene wrap (body plus head)|The entire body surface (body plus head) is covered by a polyethylene wrap
88919768|NCT01671241|Active Comparator|Polyethylene wrap (body)|A polyethylene wrap covers the patient's body up to the neck
88919769|NCT01671267|Experimental|Strength training|Strength training of the shoulder, arm and hand muscles for 3 x 10 minutes a week.
88919770|NCT01671267|Active Comparator|Ergonomic|Receives counseling on workstation adjustment and optimal use of the work tools.
88919771|NCT01671358||Isolation Rooms for MRSA|Rooms that currently have a patient in them that are in isolation status due to MRSA
88919772|NCT01671358||Non-isolation rooms|Rooms that have not been occupied by a patient in isolation due to MRSA for 14 days
88919773|NCT01671371|Other|Immediate Ultrasound|A point-of-care ultrasound will be performed during the initial evaluation of the patient after randomization (Defined as Time 0)
88919774|NCT01671371|Other|Delayed Ultrasound|A point-of-care ultrasound will be performed by the provider at 60 min after initial randomization
88919775|NCT01671449|Active Comparator|S-1 plus Cisplatin|"S-1: 40 mg/m2, twice daily, p.o., day 1-14 (see Table 6 for dose calculation of S-1 according to body surface area)~: If S-1 is started on the evening of day 1, last dose of S-1 will be administered at the morning of day 15.~Cisplatin: 60 mg/ m2/day, i.v., day 1~Every 3 weeks"
88919776|NCT01671449|Experimental|S-1 plus Oxaliplatin|"S-1: 40 mg/m2, twice daily, p.o., day 1-14 (see Table 6 for dose calculation of S-1 according to body surface area)~: If S-1 is started on the evening of day 1, last dose of S-1 will be administered at the morning of day 15.~Oxaliplatin: 130 mg/ m2/day, i.v., day 1~Every 3 weeks"
88919777|NCT01671475|Experimental|Routine care plus microEEG|Subjects allocated to this group will undergo an EEG using microEEG device in addition to their routine care. The microEEG device will be used with commercially available electrodes in a headpiece configuration.
88919778|NCT01671475|No Intervention|Routine care only (control group)|Subjects allocated to the control group will receive routine care without microEEG. The treating physician may request a standard EEG, which will be performed by the hospital EEG laboratory, if available.
89198608|NCT05149846|Other|Pre-conditioning|Pre-conditioning by three consecutive 60 seconds balloon inflations, spaced 120 seconds apart followed by 10 minutes rest prior to PCI
89198609|NCT05149846|No Intervention|Controll|No pre-conditioning, standard care
89198610|NCT00871767|Experimental|1|40 or 100mg AZD5672, Reference formulation
89536895|NCT03307655|Experimental|Patients (subfertile men)|Sperm from patients (subfertile men, i.e. men who possess one altered spermiogram parameter, according to the WHO 2010 guidelines) will be included in this arm.
89010720|NCT04536259|Experimental|Video Default|"The case and response options participants in this group will be asked to consider is provided below.~Imagine that a hospital clinician you have been seeing for over a year tells you that that upon reviewing your patient notes they would like you to attend your next consultation by video.~Consider each of the response options below, and select the one that best describes how you would respond to your clinician.~A) Yes, I would be happy to attend a video consultation. B) If possible, I would rather attend the appointment in person."
89010721|NCT04536259|Experimental|In-Person Default|"The case and response options participants in this group will be asked to consider is provided below.~Imagine that a hospital clinician you have been seeing for over a year tells you that that upon reviewing your patient notes they would like you to attend your next consultation in person.~Consider each of the response options below, and select the one that best describes how you would respond to your clinician.~A) Yes, I would be happy to attend an in-person consultation. B) If possible, I would rather attend the appointment by video."
89010722|NCT04536259|Experimental|Active Choice|"The case and response options participants in this group will be asked to consider is provided below.~Imagine that a hospital clinician you have been seeing for over a year tells you that that upon reviewing your patient notes they would like you to attend a consultation by video or in person.~Consider each of the response options below, and select the one that best describes how you would respond to your clinician.~A) I would prefer a video consultation. B) I would prefer an in-person consultation."
89010723|NCT04536493|Active Comparator|1 application|Patients receive single dose LET
89010724|NCT04536493|Active Comparator|3 applications|Patients receive 3 doses of LET
89010725|NCT04536181|Placebo Comparator|3 months group|Subjects will receive 12-weeks of placebo following randomization
89010726|NCT04536181|Experimental|6 months group|12 Weeks of Prednisolone Therapy Subjects will add an additional 12 weeks of Prednisolone to follow pre-randomization standard of care prednisolone.
89010727|NCT04535869|No Intervention|A)standard therapy group|No intervention COVID- 19 patients who received a standard therapy group according to the ministry of health protocol
89010728|NCT04535869|Active Comparator|B)Standard Therapy group plus Ant-HCV drugs|Intervention COVID- 19 patients who received a standard therapy group according to the ministry of health protocol plus sofosbuvir 400 mg and Daclatasvir 200mg
89010729|NCT02216188|Experimental|A: AFFITOPE® PD01A + Adjuvant|one injection of 15µg AFFITOPE® PD01A/ adjuvanted
89010730|NCT02216188|Experimental|B: AFFITOPE® PD01A + Adjuvant|one injection of 75µg AFFITOPE® PD01A/ adjuvanted
89010731|NCT02216188|Other|Control|Untreated control group
89010732|NCT02216227|Experimental|Surgical Site Infection Checklist|"Patient has a known positive Staph aureus pre-op screening result (MRSA or MSSA):~ecolonize with intranasal Mupirocin ointment BID x 5 days~hlorhexidine gluconate (CHG) bathing (daily x 5 days, using wipes or liquid)~efazolin plus Vancomycin (no Vanco for MSSA positive)~Patient has a known negative Staph aureus pre-op screening result:~HG bathing (night before & morning of surgery using wipes or liquid)~efazolin~Patient was not screened or results are unknown at time of surgery:~ecolonize with intranasal Mupirocin ointment (start BID x 5 days; discontinue if negative screen)~HG bathing (start daily bath 5 days before operation if possible; at a minimum bathe the night before & morning of surgery using wipes or liquid)~efazolin plus Vancomycin"
89010733|NCT00262665|Experimental|Org 24448|ampa receptor potentiator for the treatment of MDD
89010734|NCT00262665|Placebo Comparator|Placebo|matching placebo pill
89010735|NCT02216266|Active Comparator|Physostigmine|Physostigmine administered intravenously at a dose of 24 mg + 25 min a 0,04 mg/kg milligram(s)/kilogram
89010736|NCT02216266|Placebo Comparator|Sodium Chloride solution|solution administered intravenously 24 mg + 25 min a 0,04 mg/kg milligram(s)/kilogram
89010737|NCT04535830|Experimental|Flash glucose monitor system(FSL)|Except at baseline and at the end of the experiment,participants at the FSL group will be asked to wear a flash glucose monitoring sensor for a period of 2 weeks and have a care visit every month.
89010738|NCT04535830|No Intervention|Self-monitoring blood glucose(SMBG)|People at SMBG group will wear the sensor at baseline and at the end of the experiment for data analysis only,and will have a care visit every month.
89010739|NCT00262704|No Intervention|Group A|Control group
89010740|NCT00262704|Active Comparator|Group B|Simulated case-based customized learning
89010741|NCT00262704|Active Comparator|Group C|Simulated case based customized learning + leader feedback
89010742|NCT04535752|Experimental|ANX009, Single Ascending Doses|Single dose of ANX009 with a 7-day follow-up before escalation to the next dose level.
89010743|NCT04535752|Placebo Comparator|Placebo, Single Ascending Doses|Single doses of matching placebo
89010744|NCT04535752|Experimental|ANX009, Multiple Ascending Doses|ANX009 once daily on Days 1-14
89010745|NCT04535752|Placebo Comparator|Placebo, Multiple doses|Matching placebo once daily on Days 1-14
89010746|NCT00238316|Active Comparator|Letrozole|
89010747|NCT00238316|Placebo Comparator|Placebo|
89010748|NCT04535518|Active Comparator|the standard group|"IVIG 2 g/kg once, given within 12 to 24 hours;~Aspirin 30 mg/kg in oral per day (given in 3 divided doses), then 3 to 5 mg/kg per day when fever subsides for 72 hours and C-reactive protein (CRP) is normal. Aspirin will be continued for at least 6 weeks after onset of illness."
89010749|NCT04535518|Experimental|the standard + infliximab group|"IVIG 2 g/kg once, given within 12 to 24 hours;~Aspirin 30 mg/kg in oral per day (given in 3 divided doses), then 3 to 5 mg/kg per day when fever subsides for 72 hours and C-reactive protein (CRP) is normal. Aspirin will be continued for at least 6 weeks after onset of illness.~Intravenous infliximab at single dose of 5 mg/kg, given more than 2 hours."
89010750|NCT02216344||Pulse Oximeter (the device)|The pulse oximetry devices were placed on subjects per the protocol. The subjects underwent gradual hypoxia and the output of the devices under test was compared to the SaO2 value as measured by a CO-Oximeter (the reference value), as outlined by ISO 80601, to ensure that the devices meet the specified performance claims.
89010751|NCT02216383|Experimental|Carbetocin|One dose of 100 micrograms intramuscular Carbetocin given for active management of the third stage of labour, immediately after the birth of the baby
89436494|NCT03992404|Placebo Comparator|Placebo|"Main Period (1 treatment cycle): subjects to receive intramuscular placebo injection into muscles of the lower limb.~Open Label Extension Period (4-5 treatment cycles): subjects to receive intramuscular injection of NT 201 (up to 800 units) into muscles of the lower limb and upper limb, if indicated."
89436495|NCT03988283|Experimental|Personalized neoantigen DNA vaccine|Patients will receive the vaccine monthly (+/- 3 days) for 6 doses as a priming phase followed by booster injections quarterly Q3mo thereafter. If sufficient quantities of vaccine are available, vaccination may continue until development of intolerance or disease progression in the case of fatal high grade neoplasms or for up to one year. Additionally, patients with non-fatal tumors who complete one year of vaccinations and have stable disease at the completion of treatment will be given the option of resuming vaccinations if they develop subsequent progression.
89436496|NCT03985800|Active Comparator|TEAM-care as usual approach|Patients will be triaged based on their physical health (PH) and behavioral health (BH) complexity to determine the frequency of in-person visits and how much of these visits will be devoted to medical versus BH issues
89436497|NCT03985800|Active Comparator|TECH-telehealth approach|Each patient will have an initial face-to-face visit with the core treatment team described above and undergo the same triage process to determine their PH/BH care needs. Each TECH patient will participate in one face-to-face treatment team visit per year unless more frequent visits are deemed to be medically necessary; however, all other interactions will be conducted via technology-supported modalities
89436498|NCT03980717|Experimental|Fetal Endotracheal Occlusion (FETO)|Placement and retrieval of the GoldBAL4 or GoldBAL2 Detachable balloon using the plug/unplug method, using BALTACCIDBPE100 Delivery Catheter.
89436499|NCT03980717|No Intervention|non-FETO|The control group will consist of patients who did not undergo the FETO procedure who fit the same fetal inclusion/exclusion criteria as our FETO subjects and will be matched by variables including maternal age, body mass index, gestational age, severity of CDH and site of CDH (left- or right-sided).
89436500|NCT03969186|Experimental|Daily telehealth follow-up|The intervention arm will receive a simple telehealth intervention utilizing the Way to Health Platform engineered at the University of Pennsylvania. This platform will be used to send daily SMS messages to patients for 90 days following discharge and alert the research team to changes in patients' status. In addition, the patients in the intervention arm will receive a weekly phone call administered by members of the research team to assess their overall progress and well-being.
89436501|NCT03969186|No Intervention|Standard of care follow-up|Standard of care
88919779|NCT01671501|Experimental|Motivational Interviewing|The intervention consists of one 45-minute in-person session followed by two 20-minute telephone sessions.The first telephone MI session will occur approximately 10 days after the in-person session. The second call will occur 30 days after the first call. The same research clinician will conduct both the in-person session and phone sessions. The calls will include a review of material covered in the initial session, questions on alcohol use, open-ended questions regarding patients' current motivational level, and a review of the patient's initial goals regarding alcohol consumption and will last about 20 minutes. If after six months hazardous drinking is noted, three more motivational interviewing phone sessions will be delivered by the research clinician.
89010752|NCT02216383|Active Comparator|Syntocinon|One dose of 10 International Units intramuscular Syntocinon given for active management of the third stage of labour, immediately after the birth of the baby
89198611|NCT00871767|Experimental|2|40 or 100mg AZD5672, Test formulation
89436502|NCT03950232|Experimental|Etrasimod 2 mg|
89530950|NCT05504057||Patients with chronic treatment with antihistamines or amantadine|The % of patients having antihistamines or amantadine as chronic treatment that suffered COVID would be compared to the population of the Terrassa Health Consortium (THC) of the same age groups.
89010753|NCT02216383|Active Comparator|Syntometrine|One dose of 500micrograms/5 International Units intramuscular Syntometrine given for active management of the third stage of labour, immediately after the birth of the baby
89010754|NCT00262782|Experimental|Fludarabine|
89010755|NCT00262782|No Intervention|watch & wait|
89436503|NCT03935282|Experimental|Intervention - AH-HA tool|With assistance from the study team, the clinic will implement the AH-HA tool in the clinics' EPIC EHR. Providers at the intervention sites will be trained to use the tool during routine follow-up care with survivors. During a routine follow-up care appointment, the provider will use the AH-HA tool with enrolled patients.
89436504|NCT03935282|No Intervention|Usual Care|Usual care practices will conduct routine follow-up care visits for enrolled survivors following typical clinic practice, without use of the AH-HA tool.
89436505|NCT03934697|Experimental|Imaginal Exposure Session|All participants will complete the same arm, which is ten sessions of imaginal exposure across a ten week time period. Each session is separated by 1 week.
89436506|NCT03929666|Experimental|ZW25 + FP|ZW25 plus fluorouracil (5-FU) and cisplatin
89436507|NCT03929666|Experimental|ZW25 + mFOLFOX6|ZW25 plus 5-FU, leucovorin, and oxaliplatin
89436508|NCT03929666|Experimental|ZW25 + XELOX|ZW25 plus capecitabine and oxaliplatin
89436509|NCT03929666|Experimental|ZW25 + mFOLFOX6 with bevacizumab|ZW25 plus 5-FU, leucovorin, oxaliplatin, and bevacizumab
89436510|NCT03929666|Experimental|ZW25 + CisGem|ZW25 plus cisplatin and gemcitabine
89436511|NCT03888027|No Intervention|Control|Patients receive no intervention
89436512|NCT03888027|Active Comparator|WalkMORE group|"Patients will be randomized via REDCap (Research Electronic Data Capture), a secure, centralized web-based randomization module to:~Standard of care; or~WalkMORE Ambulation program + Standard of care. Patients will ambulate with a trained WalkMORE volunteer two times per day; once in the morning (0900-1200hrs) and once in the afternoon (1300-1700hrs), Monday- Friday, until hospital discharge. Patients randomized to the WalkMORE intervention will be assessed daily by the Research Coordinator to ensure patients remain fit for independent ambulation. The duration of each walking session will be determined daily by the RC and the medical team."
89436513|NCT03879434||Ostenil® Mini|1-3 injections of sodium hyaluronate 1.0 % (10 milligrams (mg) / 1,0 millilitres (ml)) in weekly interval.
89010756|NCT00238394|Experimental|Treatment (cediranib maleate)|Patients receive oral AZD2171 once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a CR receive 2 additional courses beyond CR. Patients experiencing disease progression within 5 years after completion of study treatment may receive additional courses of study treatment.
89010757|NCT04535284|Experimental|Coaching|"Health Coaching-in-Context includes coaching by trained coaches up to 10 sessions over teleconference."
89010758|NCT04535284|No Intervention|Usual Care|The usual care group does not get any intervention but continues with any of their usual activities that would otherwise would have been provided to them.
89010759|NCT02216461|Experimental|Low dose of BIBW 2948 BS|
89010760|NCT02216461|Experimental|Medium dose of BIBW 2948 BS|
89010761|NCT02216461|Experimental|High dose of BIBW 2948 BS|
89436514|NCT03874793|Experimental|Mindfulness-Based Cognitive Therapy|Participants will have 8 weeks of group therapy and will be asked to do MBCT exercises for approximately 20-30 minutes on 5 or more days/week.
89436515|NCT03874793|Active Comparator|Muscle Relaxation Therapy (MRG)|Participants will have 8 weeks of group therapy participants and will be asked to do MRG exercises for approximately 20-30 minutes on 5 or more days/week.
89436516|NCT03871348|Experimental|SAR441000 Dose Escalation Phase|SAR441000 will be administered as intratumoral injection as monotherapy in patients with solid tumors over a 28-day cycle
89010762|NCT02216461|Placebo Comparator|Placebo|
89010763|NCT04535206||With AT-Ⅲ, PC, PS activity decreased|Any decreased in AT-Ⅲ, PC, PS activity before catheter intubation is regarded as the exposure group
89010764|NCT04535206||AT-Ⅲ, PC, PS activity are at normal value|The activities of AT-Ⅲ, PC and PS are all at normal values before catheter intubation
89010765|NCT04534621||Brazilian chiropractors|A cross-sectional survey will be performed with this population (Brazilian chiropractors) to assess outcomes regarding what is the current impact and what measures they have implemented while facing the COVID-19 pandemic.
89436517|NCT03871348|Experimental|SAR441000 + cemiplimab - Dose Escalation Phase|SAR441000 will be administered as intratumoral injection in patients with solid tumors in combination with cemiplimab over a 21-day cycle
89436518|NCT03871348|Experimental|SAR441000 + cemiplimab Expansion Melanoma, anti-PD-1 failure|SAR441000 will be administered intratumorally at the determined recommended dose in combination with cemiplimab to patients with advanced melanoma who have failed anti-PD-1/PD-L1 therapy. Treatment is administered over a 21-day cycle
89436519|NCT03871348|Experimental|SAR441000 + cemiplimab Expansion Melanoma, anti-PD-1 naive|SAR441000 will be administered intratumorally at the determined recommended dose in combination with cemiplimab to patients with advanced anti-PD-1/PD-L1 naïve melanoma over a 21-day cycle
89530951|NCT05504057||Other population of the THC|The % of patients of the Terrassa Health Consortium that suffered COVID19 infection of the same age groups.
89198612|NCT05279248|Experimental|Group A|Participants in this arm will be simultaneously administrated with one dose of HPV 16/18 bivalent vaccine and one dose of MMR vaccine. six month later, they are going to receive a second dose of HPV 16/18 bivalent vaccine.
89436520|NCT03871348|Experimental|SAR441000 + cemiplimab Expansion CSCC, anti-PD-1 naive|SAR441000 will be administered intratumorally at the determined recommended dose in combination with cemiplimab to patients with advanced anti-PD-1/PD-L1 naïve Cutaneous Squamous Cell Carcinoma (CSCC) over a 21-day cycle
89436521|NCT03871348|Experimental|SAR441000 + cemiplimab Expansion HNSCC, anti-PD-1 naive|SAR441000 will be administered intratumorally at the determined recommended dose in combination with cemiplimab to patients with advanced anti-PD-1/PD-L1 naïve Head and Neck Squamous Cell Cancer (HNSCC) over a 21-day cycle
89436522|NCT03861793|Experimental|ALKS 4230|Administered via SC injection once every 7 days or once every 21 days at escalating doses
89436523|NCT03861793|Experimental|ALKS 4230 + pembrolizumab|ALKS 4230 will be administered via SC injection once every 7 or 21 days at escalating doses or at the recommended phase 2 dose and schedule; pembrolizumab will be administered as an intravenous infusion given over 30 minutes; the dose level for pembrolizumab will be 200 mg per the approved label. In December 2020, an RP2D of 3 mg with an administration schedule of q7d was determined for SC ALKS 4230.
89436524|NCT03829540|Experimental|Treatment|"Redirected autologous T cells transduced with the anti-CD4 lentiviral vector (referred to as CD4CAR cells)"
89436525|NCT03809962||Ostenil® Plus|1-3 injections of sodium hyaluronate 2% (40 milligrams (mg) / 2,0 millilitres (ml)) in weekly interval.
89010766|NCT00262899|Experimental|Rapid genetic counseling|Following randomization, participants will be informed about whether they are assigned to Usual Care (UC) or Rapid Genetic Counseling (RGC). Participants in the UC arm can schedule a genetic counseling appointment at any time during the study if they wish. Participants in the RGC agree to obtain genetic counseling as soon as possible, before they make a definitive surgery decision. RGC can be accomplished by telephone or in-person. The RGC intervention is delivered by highly experienced genetic counselors at each site. This counseling is identical to our standard genetic counseling procedure for newly diagnosed patients. Immediate DNA collection via blood or buccal cell collection is available following counseling. Phone counseling participants will be been mailed a kit for DNA collection or have the option of having the sample collected at at LCCC.
89010767|NCT00262899|No Intervention|Usual Care|Usual Care (UC) for newly diagnosed breast cancer patients does not typically include a pre-surgical genetic referral. These patients may obtain genetic counseling at their own discretion.
89010768|NCT04534855|Experimental|Treprilimab treatment group|Treprilimab 240mg ivdrip Q3W until progression or unacceptable toxicity
89010769|NCT02216539|Experimental|Self-hypnosis|Patients trained to self-hypnosis before surgery
89010770|NCT02216539|Active Comparator|Usual pain management|Patients receiving the usual post-operative pain management protocols
89010771|NCT04534816|Experimental|Indocyanine Green|patients abdominal injuries and repair will be investigated using Indocyanine Green
89010772|NCT00262938|Active Comparator|Lifestyle counseling|Patients undergo weekly contact with a dietitian; exercise intervention for 6 months; and physician counseling.Patients undergo quality of life, exercise, and clinical assessments at baseline and at 3, 6, and 12 months.
89010773|NCT00262938|Active Comparator|Without Counseling|Patients undergo quality of life, exercise, and clinical assessments at baseline and at 3, 6, and 12 months.
89010774|NCT04534894||DM group and DCM group|DM group: type 2 diabetes with normal diastolic function DCM group: type 2 diabetes with diastolic dysfunction
89010775|NCT02216617|Experimental|Induction chemotherapy TPA|"3 Cycles of induction chemotherapy TPA : (Taxotere, Cisplatin, Afatinib)~1 cycle = 3 weeks, three cycles of treatment in total (or 9 weeks)~Docetaxel 75 mg / m2 at D1 Cisplatin 75 mg / m 2 at D1 Afatinib: x mg / day D2 to D21 by level: (Level 1: 20 mg / day; Level 2: 30 mg / day; Level 3: 40 mg / day)"
89010776|NCT04534504|Experimental|SG-uncut JJB|For SG-uncut JJB procedure, the jejunum was not transected, only 200-cm jejunum 20-cm distal to Treiz ligament was measured and side-to-side jejunojejunal anastomosis was made. And the jejunum 3-5cm distal to the anastomosis was ligated with 10# suture.
89010777|NCT04534504|Active Comparator|SG-JJB|For SG-JJB procedure, after SG was finished, the jejunum was transected 20-cm distal to Treiz ligament. After that, another 200-cm jejunum was measured and side-to-side jejunojejunal anastomosis was made. The anastomotic and mesenteric defects were closed by hand suture.
89436526|NCT03794011|Experimental|fetoscopic surgical repair|Single arm study. All patients will receive the fetoscopic repair.
89436527|NCT03786796|Experimental|Olaparib|Participants with metastatic renal cell carcinoma that harbor an inactivating mutation in BAP-1, ATM, BRCA1, BRCA2, PALB2, CHEK2, BRIP1, RAD51C, BARD1, CDK12, CHEK1, FANCL, PP2R2A, RAD51B, RAD51D, or RAD54L that have had prior treatment with at least one immune checkpoint inhibitor or anti-VEGF therapy with measureable disease on CT imaging according to RECIST 1.1 criteria. Participants will be initially treated with olaparib 150mg by mouth twice daily for one month. After one month of therapy, the dose will be increased to 300mg by mouth twice daily provided there are no grade 3 or greater adverse events experienced. Reassessment will occur at least monthly for toxicity. Radiological scans will be performed every 3 months to assess disease response. Treatment will be continued until clinical and/or radiographic progression according to RECIST 1.1 criteria or unmanageable toxicity requiring cessation.
89436528|NCT03777436|Experimental|Arm A- Apremilast with Placebo|Subjects randomized to the apremilast 30 mg BID treatment group will receive apremilast 30 mg tablets orally twice daily for the first 16 weeks Subjects randomized to the placebo treatment group will receive placebo tablets (identical in appearance to apremilast 30 mg tablets) orally twice daily for the first 16 weeks
89436529|NCT03777436|Experimental|Arm B - Apremilast 30 mg|All subjects will receive apremilast 30 mg tablets orally twice daily after the Week 16 Visit through the end of the Apremilast Extension Phase of the study
89436530|NCT03771716|Experimental|African Dance|This is the experimental group. Dance classes will be held 3 times per week for 1 hour. Participants will learn traditional Africana dance moves and sequences.
89436531|NCT03771716|Active Comparator|African Cultural Immersion|This is the active control group. Participants will participate in a variety of educational activities related to African Culture, including traditional cooking, lectures, crafts, music and films. They will meet 3 times per week for the same duration as the Dance group. However, they will not participate in aerobic activity during the classes, and most activities will be conducted in a seated position.
89436532|NCT03758742|Experimental|High-Fruit Diet|Whole fruit-rich diet (~50% of calories from whole fruit)
89436533|NCT03744715|Experimental|Poziotinib|Poziotinib will be taken by the patient orally, once daily with food and a glass of water at approximately the same time. The dose will be the last dose received or at the standard starting dose of 16 mg poziotinib. If a dose is missed, it may be taken any time during the day preferably with food, but at least 8 hours prior to the next scheduled dose.
89436534|NCT03738878|Active Comparator|valsartan then LCZ696|"After four-week treatment with valsartan, participants will receive intra-arterial infusions of bradykinin, substance P, and BNP in the presence and absence of sitagliptin.~Then, after three-week washout and four week therapy with LCZ696, participants will receive intra-arterial infusions of bradykinin, substance P, and BNP in the presence and absence of sitagliptin."
89436535|NCT03738878|Active Comparator|LCZ696 then valsartan|"After four-week treatment with LCZ696, participants will receive intra-arterial infusions of bradykinin, substance P, and BNP in the presence and absence of sitagliptin.~Then, after three-week washout and four week therapy with valsartan, participants will receive intra-arterial infusions of bradykinin, substance P, and BNP in the presence and absence of sitagliptin."
89436536|NCT03735433|No Intervention|81 mg daily aspirin dose|obese women >30 BMI at risk for preeclampsia will receive recommended 81mg ASA
89436537|NCT03735433|Active Comparator|162mg daily aspirin dose|obese women >30 BMI at risk for preeclampsia will receive increased dose of 162mg ASA
89436538|NCT03734315||Ostenil®|3-5 injections of sodium hyaluronate 1 % (20 milligrams (mg) / 2.0 millilitres (ml)) in weekly interval.
89436539|NCT03729544|Experimental|Alert|On-screen computerized decision support alert during the outpatient clinical encounter that notifies the provider that the patient should be screened for CTEPH
89436540|NCT03729544|No Intervention|No Alert|No provider notification
89010778|NCT00238667|Active Comparator|Anti-platelet therapy|Aspirin, Dipyridamole, clopidogrel alone or in dual therapy
89010779|NCT00238667|Active Comparator|Anti-coagulant|Warfarin, unfractionated heparin, enoxaparin, dalteparin, tinzaparin aiming for an INR in range of 2-3. Local protocols for Heparin can be used
89436541|NCT03724058|Experimental|Trident® II Clusterhole HA Acetabular Shell|Hip arthroplasty using Trident II Clusterhole HA Acetabular Shells
89436542|NCT03724058|Active Comparator|Trident® Hemispherical Acetabular Shell|Hip arthroplasty using Trident Hemispherical Acetabular Shell
89436543|NCT03721172|Experimental|Placebo-controlled Phase:|Participants received placebo as oral tablets twice daily (BID) for up to 16 weeks (Week 0 to Week 16).
89436544|NCT03721172|Experimental|Placebo-controlled Phase: Apremilast 30 mg|Participants received apremilast 30 mg as oral tablets BID for up to 16 weeks (Week 0 to Week 16).
89010780|NCT04534426|Active Comparator|Postoperative topical arnica montana cream|In this arm, Arnica group consisted of 20 patients who were treated with topical arnica in addition to standard therapy (amoxicillin/clavulanic acid 500/125 mg twice a day and diclofenac potassium 50 mg twice a day) after mandibular impacted third molar surgery.
89010781|NCT04534426|Active Comparator|Postoperative topical mucopolysaccharide polysulfate cream|In this arm, Mucopolysaccharide polysulfate group consisted of 20 patients who were treated with topical arnica in addition to standard therapy (amoxicillin/clavulanic acid 500/125 mg twice a day and diclofenac potassium 50 mg twice a day) after mandibular impacted third molar surgery.
89436545|NCT03721172|Experimental|Extension Phase: Apremilast 30 mg|Eligible participants who completed the placebocontrolled phase entered the extension phase and received apremilast 30 mg as oral tablets BID for up to an additional 16 weeks (Week 16 to Week 32).
89436546|NCT03712878|Experimental|Treatment (TBI, DLI, chemotherapy, HSCT, tacrolimus, MMF)|"Description CONDITIONING REGIMEN: Participants undergo TBI BID on days -9 to -6.~TRANSPLANT: Participants receive donor lymphocytes IV on day -6 after the last dose of TBI.~CONDITIONING REGIMEN: Participants receive cyclophosphamide IV on days -3 and -2.~TRANSPLANT: Participants undergo hematopoietic stem cell transplantation on day 0.~GVHD PROPHYLAXIS: Participants receive tacrolimus IV beginning on day -1 with taper beginning on day 42 in the absence of GVHD, a suspicion of GVHD, or previous history of GVHD requiring a taper delay. Participants also receive mycophenolate mofetil IV BID beginning on day -1 through day 28 in the absence of GVHD."
89536896|NCT03311867|Active Comparator|Braided Suture|Patient in this group will have a cerclage with ethibond suture material
89010782|NCT04534426|Other|Control group|In this arm control group consisted of 20 patients who were treated with only standard therapy (amoxicillin/clavulanic acid 500/125 mg twice a day and diclofenac potassium 50 mg twice a day) after mandibular impacted third molar surgery.
89010783|NCT04534465|Experimental|Dosing arm 1|MiraLAX Sachet (17g) + Flavor blend (2g mannitol total)
89010784|NCT04534465|Experimental|Dosing arm 2|MiraLAX Sachet (17g) + Flavor blend + additional 2g mannitol (4g mannitol total)
89010785|NCT04534465|Experimental|Dosing arm 3|MiraLAX Sachet (17g) + Flavor blend + additional 4g mannitol (6g mannitol total)
89010786|NCT04534465|Experimental|Dosing arm 4|MiraLAX Sachet (17g) + Flavor blend + additional 6g mannitol (8g mannitol total)
89010787|NCT04534465|Experimental|Dosing arm 5|MiraLAX Sachet (17g) + Flavor blend + additional 8g mannitol (10g mannitol total)
89010788|NCT02216656|Placebo Comparator|Plascebo|
89010789|NCT02216656|Experimental|KHK7580 low dose|
89436547|NCT03709082|Experimental|Phase 1: Palbociclib 75 mg|Palbociclib 75 milligrams (mg) by mouth (PO) daily Letrozole 2.5 mg PO Daily Ado-trastuzumab Emtansine (T-DM1) 3.6 milligrams per kilograms (mg/kg) intravenous (IV) Day 1
89436548|NCT03709082|Experimental|Phase 1: Palbociclib 100 mg|Palbociclib 100 milligrams (mg) by mouth (PO) daily Letrozole 2.5 mg PO Daily Ado-trastuzumab Emtansine (T-DM1) 3.6 milligrams per kilograms (mg/kg) intravenous (IV) Day 1
89436549|NCT03709082|Experimental|Phase 1: Palbociclib 125 mg|Palbociclib 125 milligrams (mg) by mouth (PO) daily Letrozole 2.5 mg PO Daily Ado-trastuzumab Emtansine (T-DM1) 3.6 milligrams per kilograms (mg/kg) intravenous (IV) Day 1
89010790|NCT02216656|Experimental|KHK7580 middle dose|
89010791|NCT02216656|Experimental|KHK7580 high dose|
89010792|NCT02216656|Active Comparator|KRN1493|
89010793|NCT04534348||Control|All central-line-associated blood stream infections (CLABSI) diagnosed during the year previous the implementation of 70% isopropyl alcohol-impregnated Curos catheter caps
89010794|NCT04534348||CUROS|All central-line-associated blood stream infections (CLABSI) diagnosed during the year after the implementation of 70% isopropyl alcohol-impregnated Curos catheter caps
89436550|NCT03709082|Experimental|Phase 2: RP2D|Recommended Phase 2 dose (RP2D; determined during Phase 1 Safety Run In) Palbociclib by mouth (PO) daily Letrozole 2.5 mg PO Daily Ado-trastuzumab Emtansine (T-DM1) 3.6 milligrams per kilograms (mg/kg) intravenous (IV) Day 1
89436551|NCT03701828|Experimental|Weight loss|Participants will undergo weight loss surgery
89436552|NCT03677440|Experimental|Treadmill Walking Exercise Training|"This condition will include 3-months of supervised, progressive light, moderate, and vigorous intensity treadmill walking exercise training based on ACSM guidelines for maximizing adaptations with exercise training. Exercise intensities will be prescribed based on percent oxygen consumption reserve (% VO2R) using values derived from the baseline graded exercise test.~The exercise training itself will be led by trained exercise leaders who are not involved in the collection of outcome assessments. At the outset of each session, participants will be fitted with a Polar HR Monitor (Oy, Finland), and HR will be monitored continuously throughout each session. Each session will begin with a 5-10 min warm-up, followed by the exercise; the target heart rate reserve (HRR) range associated with the VO2R range will be maintained for as long as possible during each exercise period. This will be followed by a 5-10 min cool-down."
89536502|NCT04995705|Active Comparator|Waitlist Control Group -|Stroke survivors and individuals with brain injury were randomised into an adapted acceptance and commitment therapy (ACT) group-based intervention. Participants within the waitlist control arm of the study had to wait six weeks before they were offered the same intervention as the intervention arm. They received treatment as usual.
89536503|NCT04891133|Experimental|Active arm|4mg Baricitinib up to 14 days + SoC
89536504|NCT04891133|Placebo Comparator|Comparator|Matching placebo up to 14 days + SoC
89010795|NCT04534192|Experimental|JADE balloon|Non-compliant high pressure JADE balloon for the treatment of infrainguinal stenotic occlusive or stenotic TASC C & D lesions in patients with chronic limb threatening ischemia.
89010796|NCT04534036|Active Comparator|Multi-Strain Synbiotic (PDS-08)|PDS-08 is a rationally defined microbial consortium consisting of 9 strains, with FOS-inulin as prebiotic. Participants will be instructed to take 1 sachet daily for the duration of the trial.
89010797|NCT04534036|Placebo Comparator|Placebo|Placebo sachets for PDS-08 will contain potato or tapioca maltodextrin matched for color and texture. Participants will be instructed to take 1 sachet daily for the duration of the trial.
89010798|NCT04533724|Experimental|Study group|Recruit 30 outpatient/inpatient schizophrenia patients (dominant negative symptoms) in Shanghai Mental Health Center .
89010799|NCT04533724|No Intervention|Healthy control group|15 cases of normal healthy people (control group) with similar eating habits and ages in the same region were matched with study group.
89010800|NCT04533685|Active Comparator|Direct scheduling + Pre-commitment + Pre-appt reminder|Participants receive 1) reminder/recall messages regarding influenza vaccination via the patient portal with a link enabling direct scheduling, 2) a pre-commitment prompt and 3) pre-appointment reminders that mention asking the provider for a flu vaccine
89010801|NCT04533685|Active Comparator|Direct scheduling + Pre-commitment|Participants receive 1) reminder/recall messages regarding influenza vaccination via the patient portal with a link enabling direct scheduling and 2) a pre-commitment prompt
89010802|NCT04533685|Active Comparator|Direct scheduling + Pre-appt reminder|Participants receive 1) reminder/recall messages regarding influenza vaccination via the patient portal with a link enabling direct scheduling and 2) pre-appointment reminders that mention asking the provider for a flu vaccine
89010803|NCT04533685|Active Comparator|Direct scheduling|Participants receive 1) reminder/recall messages regarding influenza vaccination via the patient portal with a link enabling direct scheduling
89010804|NCT04533685|Active Comparator|No direct scheduling + Pre-commitment + Pre-Appt reminder|Participants receive 1) reminder/recall messages regarding influenza vaccination via the patient portal without a link enabling direct scheduling, 2) a pre-commitment prompt and 3) pre-appointment reminders that mention asking the provider for a flu vaccine
89010805|NCT04533685|Active Comparator|No direct scheduling + Pre-commitment|Participants receive 1) reminder/recall messages regarding influenza vaccination via the patient portal without a link enabling direct scheduling and 2) a pre-commitment prompt
89436553|NCT03677440|Active Comparator|Stretching-and-Toning Exercise Training|The active, non-aerobic exercise condition will involve stretching-and-toning activities using the same frequency and duration of the treadmill walking exercise condition. These activities will be based on a manual provided by the National Multiple Sclerosis Society and sessions will be led by trained exercise leaders who are not involved in the collection of outcome assessments. Activities will target the head/neck, shoulder, elbow/forearm, hand/wrist, trunk/hip, ankle/foot. The progression of activities over the 3-month period will involve performing additional exercises and sets along with using progressively thicker elastic resistance bands that provide minimal resistance. Each session is designed to last up to 60 minutes in total. Each session will begin with a warm-up of up to 10 minutes, followed by stretching-and-toning (following the same duration as the treadmill walking exercise training condition) activities, and a cool-down of up to 10 minutes.
89436554|NCT03677427|Experimental|5 fractions|
89436555|NCT03677427|Experimental|15 fractions|
89436556|NCT03671889|Experimental|Blood Brain Barrier (BBB) Disruption|ExAblate Model 4000 Type 2.0 System
89436557|NCT03646461|Experimental|Arm A: Ibrutinib + Cetuximab|Ibrutinib 560mg PO daily (Imbruvica) PLUS Cetuximab 400mg/m2 x 1 then 250 mg/m2 weekly 28 day cycle
89436558|NCT03646461|Experimental|Arm B: Ibrutinib + Nivolumab|Ibrutinib 560mg PO daily (Imbruvica) PLUS Nivolumab 3mg/kg biweekly 28 day cycle
89436559|NCT03625986|Experimental|Nicotine-Containing Electronic Cigarette|The experimental group will be provided with and encouraged to use a Standardized Research Electronic Cigarette (SREC) with liquid containing 58 mg/ml nicotine for the duration of 6 weeks.
89436560|NCT03625986|Placebo Comparator|Non-Nicotine Electronic Cigarette|The placebo group will be provided with and encouraged to use a Standardized Research Electronic Cigarette (SREC) with liquid containing 0 mg/ml nicotine for the duration of 6 weeks.
89436561|NCT03616587|Experimental|AZD9833 monotherapy dose escalation|
89436562|NCT03616587|Experimental|AZD9833 monotherapy dose expansion|
89436563|NCT03616587|Experimental|AZD9833 with palbociclib dose escalation|
88919780|NCT01671501|Experimental|Email Feedback|Each participant will receive up to three detailed emails, (if participants respond to a first, initial email with information on alcohol use risks). The initial and subsequent emails will be brief in length, and will include specific information on hazardous drinking levels, standard drink size; as well as advice to reduce drinking to non-hazardous levels. Each email will conclude with contact numbers for patients to receive further information and assistance if needed, including information on how to easily access SU treatment; and will encourage participants to respond to the research clinician with questions. If after six months hazardous drinking is detected, up to 3 more detailed emails will be delivered to the participant.
89436564|NCT03616587|Experimental|AZD9833 with palbociclib dose expansion|
88919781|NCT01671501|Other|Usual Care|Participants in this arm will receive routine primary care services only. Usual care in this health care setting may include alcohol screening, brief intervention and referral to treatment (SBIRT) delivered by usual care clinic staff
88919782|NCT01669187|Active Comparator|Education brochure|The control group will receive a standard education brochure which will be provided pre-operatively to the participants.
88919783|NCT01669187|Experimental|Live education and exercise instruction|The intervention group will receive one to two physical therapy visits consisting of education on the lymphedema risks and prevention factors, along with detailed information about what to except post-surgery as well as with radiation/chemotherapy. Additionally, those in the intervention group will be instructed on exercises to maintain or increase glenohumeral and scapulothoracic joint ROM post surgery and will be set up with a walking program.
88919784|NCT01671800|Experimental|Botulinum Type B (Myobloc)|Each vial of active drug will contain 5000 unit/ml of Myobloc, with a total volume of 1 mL. The injections will be spaces 6 cm apart and will cover the entire area to be injected. Each site will receive a volume of 0.08 ml (400 units).
88919785|NCT01671800|Placebo Comparator|Saline solution|The volume to be injected will be calculated assuming the injectate is an active drug, and will therefore be an equivalent volume as an active drug (i.e. 0.08 mL per injection site with a 6 cm spacing interval)
88919786|NCT01671826||above 65 years old|
89436565|NCT03616587|Experimental|AZD9833 with everolimus dose expansion|
89436566|NCT03616587|Experimental|AZD9833 with everolimus dose escalation|
89436567|NCT03616587|Experimental|AZD9833 with abemaciclib (± anastrozole) dose escalation|
89436568|NCT03616587|Experimental|AZD9833 with abemaciclib (± anastrozole)dose expansion|
88919787|NCT01671917|Experimental|Educational and exercise program|
89436569|NCT03616587|Experimental|AZD9833 with capivasertib dose escalation|
89436570|NCT03616587|Experimental|AZD9833 with capivasertib dose expansion|
89436571|NCT03616587|Experimental|AZD9833 with ribociclib (± anastrozole) dose escalation|
89436572|NCT03616587|Experimental|AZD9833 with ribociclib (± anastrozole) dose expansion|
89436573|NCT03616587|Experimental|AZD9833 with anastrozole dose escalation|
89436574|NCT03616587|Experimental|AZD9833 with anastrozole dose expansion|
89436575|NCT03607422|Placebo Comparator|Placebo / Upadacitinib|Participants will receive placebo orally once a day (QD) for 16 weeks in the double-blind treatment period. At Week 16 participants will be re-randomized to receive either upadacitinib 15 mg or upadacitinib 30 mg QD up to Week 260.
89436576|NCT03607422|Experimental|Upadacitinib 15 mg QD|Participants will receive upadacitinib 15 mg orally once a day for up to 260 weeks.
89436577|NCT03607422|Experimental|Upadacitinib 30 mg QD|Participants will receive upadacitinib 30 mg orally once a day for up to 260 weeks.
89436578|NCT03603808|Experimental|Treatment (VGX-3100, electroporation)|Patients receive HPV DNA plasmids therapeutic vaccine VGX-3100 IM and then undergo electroporation over 10 seconds for 4 doses in week 0, 4, 12, and 24 in the absence of disease progression or unacceptable toxicity.
88919788|NCT01671917|Active Comparator|Usual care|
88919789|NCT01671995|Experimental|Nurse monitored heart failure program|To assess whether a nurse monitored management programme at the hospital outpatient clinic would improve quality of life, as compared to standard primary health care.
88919790|NCT01671995|Active Comparator|Standard primary health care|To assess whether a nurse monitored management programme at the hospital outpatient clinic would improve quality of life, as compared to standard primary health care.
89010806|NCT04533685|Active Comparator|No direct scheduling + Pre-appt reminder|Participants receive 1) reminder/recall messages regarding influenza vaccination via the patient portal without a link enabling direct scheduling and 2) pre-appointment reminders that mention asking the provider for a flu vaccine
89010807|NCT04533685|Active Comparator|No direct scheduling|Participants receive 1) reminder/recall messages regarding influenza vaccination via the patient portal without a link enabling direct scheduling for a flu vaccine appointment
89010808|NCT04533685|No Intervention|Control Arm|Participants will not receive any reminder/recall messages regarding influenza vaccination via the patient portal or other intervention components
89436579|NCT03569293|Placebo Comparator|Placebo / Upadacitinib|Participants will receive placebo orally once a day (QD) for 16 weeks in the double-blind treatment period. At Week 16 participants will be re-randomized to receive either upadacitinib 15 mg or upadacitinib 30 mg QD up to Week 260.
89010809|NCT04533490|Experimental|SHR-1210|After the subjects were enrolled in the study, the patients were treated with SHR-1210 (200mg ivgtt q3w) from 1 to 2 months after operation until disease progression or intolerable toxicity, and the longest medication period was no more than 12 months
89010810|NCT04533139||Vaccine, pre-transplant|cohort consists of individuals waiting for lung transplantation. Inactivated influenza vaccine will be administered intramuscularly annually.
89010811|NCT04533139||Vaccine, post-transplant|Cohort consist of individuals who have received lung transplants Inactivated influenza vaccine will be administered intramuscularly annually.
89010812|NCT04533139||Vaccine, not receiving transplant|Cohort consists of healthy individuals who received the influenza vaccine Inactivated influenza vaccine will be administered intramuscularly annually.
89436580|NCT03569293|Experimental|Upadacitinib 15 mg QD|Participants will receive upadacitinib 15 mg orally once a day for up to 260 weeks.
89436581|NCT03569293|Experimental|Upadacitinib 30 mg QD|Participants will receive upadacitinib 30 mg orally once a day for up to 260 weeks.
89010813|NCT04533217|Active Comparator|Vertebroplasty|Patients treated with vertebroplasty in addition to regular medical treatment.
89010814|NCT04533217|No Intervention|Regular treatment|Patients treated with regular medical treatment.
89010815|NCT04533178|Active Comparator|Restriction of sports activities|No sports during the 6 week treatment period
89010816|NCT04533178|Experimental|Restriction of sports activities and soft spinal brace|No sports and use of a soft spinal brace 16 hours per day during the 6 week treatment period
89010817|NCT04533295|Experimental|Acupuncture and IVF|Acupuncture and IVF
89010818|NCT04533295|Sham Comparator|Sham acupuncture and IVF|Sham acupuncture and IVF
89010819|NCT04532944|Other|patients with MS|20 relapsing-remitting and 20 progressive MS patients
89010820|NCT04532944|Other|healthy controls|15 age- and sex-matched healthy controls
89010821|NCT04533061||Lung Transplant, Vaccine|Cohort consist of individuals who have received lung transplants Inactivated influenza vaccine will be administered intramuscularly annually.
89010822|NCT04533061||Healthy Control, Vaccine|Cohort consists of healthy individuals who received the influenza vaccine Inactivated influenza vaccine will be administered intramuscularly annually.
89010823|NCT04532905|Sham Comparator|without previous strength training experience|control (untrained) group will receive intervention as five exercises: dumbbell bent row over, dumbbell deadlift, dumbbell lunge. dumbbell shoulder press, and dumbbell squat
89010824|NCT04532905|Experimental|with previous strength training experience|experimental (trained) group will receive intervention as five exercises: dumbbell bent row over, dumbbell deadlift, dumbbell lunge. dumbbell shoulder press, and dumbbell squat
89198613|NCT05279248|Active Comparator|Group B|Participants in this arm will be receieve HPV 16/18 bivalent vaccine according to 2-dose schedule (0,6 months) first. After finished HPV vaccination, they are going to receive MMR vaccine at the 7th month.
89436582|NCT03562039|Experimental|M-MIST (group A)|M-MIST(incomplete granulation tissue removal)
89436583|NCT03562039|Active Comparator|M-MIST (group B)|conventional M-MIST.
89436584|NCT03556839|Active Comparator|Arm A|Cisplatin 50mg/m2 or carboplatin AUC 5 + paclitaxel 175mg/m2+ bevacizumab 15mg/kg i.v D1 Q3W. Patients who achieve a complete response after ≥6 treatment cycles may be allowed to continue only on biologic therapy, namely bevacizumab, upon investigator discussion.
89436585|NCT03556839|Experimental|Arm B|cisplatin 50mg/m2 or carboplatin AUC 5 + paclitaxel 175mg/m2 + bevacizumab 15mg/kg + atezolizumab 1200mg i.v, D1 Q3W.Patients who achieve a complete response after ≥6 treatment cycles may be allowed to continue only on biologics therapy, namely bevacizumab plus atezolizumab, upon investigator discussion.
89010825|NCT02216734|Experimental|Mother support groups for HIV+ mothers|Facility-based mother support groups (MSGs) for HIV+ mothers. MSGs were established prior to study enrolment. MSGs are facilitated by volunteer mothers. Groups meet every two weeks. Health information is provided by health workers during MSGs. Mothers receive HIV prevention, psychosocial and treatment support, reinforce safe feeding practices, promote linkages with family planning services and support disclosure by HIV+ mothers to partners, male attendance and male HIV treatment. Mothers leave MSGs 6 months postnatally. Volunteer MSG coordinators contact defaulting mothers visits using cell phones; VHWs may conduct home visits to to defaulting MSG members to reduce LTFU;
89010826|NCT02216734|No Intervention|Standard of Care Arm|Standard of Care: Nurses may identify HIV+ mothers lost to follow-up (LTFU); village health workers (VHWs) may conduct home visits to reduce LTFU of HIV+ mothers. LTFU activities are not standardised throughout all Ministry of Health and Child Care facilities.
89010827|NCT02216890|Experimental|SGN-CD70A|
89010828|NCT04532983|Active Comparator|fixation group|; group A; patients underwent laparoscopic TAPP repair of inguinal hernia and the mesh prosthesis was fixed in position using absorbable Vicryl tacks (abstack30 medtronic),
89010829|NCT04532983|Active Comparator|non fixation group|group B patient underwent laparoscopic TAPP repair of inguinal hernia and the mesh prosthesis was placed in position without fixation.
89010830|NCT04532476|Experimental|Laser treated side|Group of 22 participants whose mucose around right maxillary permanent molar was treated with laser.
89010831|NCT04532476|Placebo Comparator|Placebo side|Placebo side was LEFT side.It was treated the same way as right with the difference that the laser was switched off, but with the maintained sound signal, implying laser was working, so participants were blinded to the allocation of the group, only the operator knew whether the side is laser treated or placebo.
89010832|NCT04532671|Other|Poly ether ether ketone (PEEK)|Poly ether ether keton (PEEK) is acknowledged as a high-performance polymer in engineering & medical applications due to its favorable mechanical and chemical properties.
89010833|NCT04532671|Other|CADCAM poly ether ether ketone (PEEK)|PEEK was predominantly processed out of CAD/CAM-supported milled out of prefabricated blanks.
89010834|NCT04532671|Active Comparator|indirect resin composite|In CAD/CAM resin composite blocks, properties of flexibility and ease of use similar to that of resin composite are combined with durability and surface finish properties similar to that of ceramics
89010835|NCT04532593|Experimental|Stem cell group|
89010836|NCT04532593|Placebo Comparator|Control|
89010837|NCT02216968|Experimental|AA - Increase vegetable intake|"60 African-American (AA) preschool children will participate in the Intervention Group. 60 AA children will belong to the Control Group.~6-week Intervention: 120 AA and HA children will be shown the Puppet Shows and will be given a bag of ingredients to prepare the vegetable highlighted that week in the Puppet Show. The 6 week intervention includes a baseline assessment (1 week), followed by the intervention (4 weeks), and post assessment (1 week). The primary hypothesis to be tested is children who receive the PUPPET intervention with a parent/teacher component will demonstrate increase vegetable intake in pre-school children."
89010838|NCT02216968|Experimental|HA - Increase vegetable intake|"60 Hispanic-American (HA) preschool children will participate in the Intervention Group. 60 HA children will belong to the Control Group.~6-week Intervention: 120 AA and HA children will be shown the Puppet Shows and will be given a bag of ingredients to prepare the vegetable highlighted that week in the Puppet Show. The 6 week intervention includes a baseline assessment (1 week), followed by the intervention (4 weeks), and post assessment (1 week). The primary hypothesis to be tested is children who receive the PUPPET intervention with a parent/teacher component will demonstrate increase vegetable intake in pre-school children."
89010839|NCT02217007|Experimental|SNC-102 sustained release tablet|SNC-102 oral tablet 4 weeks at 800mg BID plus 4 weeks at 1600mg in the morning and 800mg in the evening
89010840|NCT02217046|Experimental|device replacement|remove previously inserted cardiac device and posterior pocket capsule. the pocket that will receive the heart mechanism is sterilized with a hydroperoxide soaked gauze
89010841|NCT02217046|No Intervention|control group|remove previously inserted cardiac device and the pocket that will receive the heart mechanism is sterilized with a hydroperoxide soaked gauze
89010842|NCT02217124|Experimental|Apple group|twenty four participants will be randomly selected for the apple group, in which they will receive 37.5 grams equal to 120kcal of dried apples twice a day for eight weeks. This snack of apples will be eaten once between breakfast and lunch and once between lunch and dinner and both will be consumed with an eight ounce bottle of water.
89010843|NCT02217124|Placebo Comparator|Muffin control|twenty four participants will be randomly selected to make up the muffin control group, in which one 120kcal muffin control snack will be consumed twice each day for eight weeks. The muffin control will be consumed one between breakfast and lunch and one between lunch and dinner, each snack will be consumed with an eight ounce bottled water.
89010844|NCT05897879|Other|Children between 0 and 15 years with suspected pertussis|
89010845|NCT05897762|Other|Clinic Grup|the same exercises were performed in the clinical setting, accompanied by a physiotherapist. The evaluations were made before and after the treatment.
89010846|NCT05897749|Experimental|Experimental group: Brucea javanica oil emulsion injection+The best supportive treatment|
89010847|NCT05897749|Active Comparator|control group:The best supportive treatment|
89010848|NCT05897736||peri-implant patient|Patients with diagnosed peri-implantitis
89436586|NCT03551249|Experimental|Focused Ultrasound (FUS)|The ExAblate Model 4000 Type 2 system is intended for use as a tool to induce localized and temporary blood-brain barrier disruption in patients with glioblastoma undergoing initial standard of care chemotherapy.
89436587|NCT03526874|Experimental|Greater Occipital Nerve (GON) Block with Lidocaine|"Subjects randomized to this arm receive 2 mL injection of lidocaine 2% over the right and left greater occipital nerve at the baseline study visit.~All subjects then complete daily headache-related questions through a Headache Diary and other assessments for 28 days."
89436588|NCT03526874|Placebo Comparator|Greater Occipital Nerve (GON) Block with Saline|"Subjects randomized to this arm receive 2 mL injection of preservative-free normal saline over the right and left greater occipital nerve at the baseline study visit.~All subjects then complete daily headache-related questions through a Headache Diary and other assessments for 28 days."
88819428|NCT02989337||hyperemesis gravidarum with dehydration|The first group was formed of the patients diagnosed hyperemesis gravidarum with dehydration
88819429|NCT02989337||Control group|The control group was formed of the patients who were healthy pregnant women admitted to the clinic just for routine examination without any symptoms
89530952|NCT03241225|Experimental|EM/PROTECT|This group of participants will receive the EM/PROTECT intervention, a behavioral intervention for depressed elder mistreatment (EM) victims designed to work in synergy with EM mistreatment resolution services that provide safety planning, support services, and links to legal services.
89530953|NCT03241225|Active Comparator|EM/MH|This group of participants experiencing elder mistreatment will receive support services from staff trained in linking elder mistreatment victims to community mental health services.
88819430|NCT03022877|Placebo Comparator|Placebo|Placebo is given as a Bolus (instead of Bolus application of Levosimendan) over 10 min i.v., starting 10 min before recanalization.
89436589|NCT03526835|Experimental|MCLA-158|"In Part 1, the dose escalation phase, patients with metastatic CRC will receive escalating doses of MCLA-158 (every 2 weeks) until MTD or RP2D is reached. Each Cycle is 28 days. Single agent treatment. In Part 2, the expansion phase, participants with metastatic CRC and certain other solid tumors will receive intravenous infusion of MCLA-158 at the recommended Phase II dose (RP2D) every 2 weeks, at Day 1 and Day 15. The duration of each treatment cycle is 28 days.~In the expansion phase, 2 doses (1100 mg and 1500 mg) of MCLA-158 will be evaluated in a cohort of head and neck squamous cell carcinoma patients"
89436590|NCT03526835|Experimental|MCLA-158 + Pembrolizumab|MCLA-158 in combination with pembrolizumab will be explored first in head and neck squamous cell carcinoma patients eligible to receive pembrolizumab as first-line monotherapy.
89436591|NCT03526822|Experimental|patients with newly diagnosed glioblastoma|
89436592|NCT03506594|Active Comparator|Radiofrequency ON and Kinesiotherapy|The radiofrequency application protocol with CAPENERGY device, which has two electrodes: an active one, which will be introduced into the vagina, using a condom and gel to the emission of radiofrequency and another electrode, dispersive, coupled to the patient's hip, which will function as earth. The temperature used in the treatment will be 41° C, which this parameter will be placed in the equipment, maintained for 2 minutes at the anterior wall and 2 others minutes at the posterior wall. Five RF sessions will be performed, with a seven-day interval between them. For the application, participants will be placed in supine position. The session will be quick, with an average duration of 20 minutes. Kinesiotherapy will be done once a week, totaling five sessions. Initially, verbal information about location, function, and the correct way to contract the pelvic floor (PA) will be given.
89436593|NCT03506594|Placebo Comparator|Radiofrequency OFF and Kinesiotherapy|"The patient will be in supine decubitus, the vaginal probe of the radiofrequency apparatus will be introduced, with the gel previously heated. The radiofrequency will be off.~Kinesiotherapy will be done once a week, totaling five sessions. Initially, verbal information about location, function, and the correct way to contract the pelvic floor (PA) will be given."
89436594|NCT03500107|Experimental|Blue LED 401 +/- 5 nm|The Blue LED 401 +/- 5 nm will be applied in the participant, in a closed room by a physiotherapist for 1 hour. The apparatus will be supported on a tripod, statically, externally, 5 cm away from the vulva abd vaginal region, with the patient naked, in gynecological stretcher and lithotomy position. The protocol consists of only one session. This part of the study will see if there is bactericidal effect of the blue LED.
89436595|NCT03496610|Active Comparator|Quadratus Lumborum (QL) Block|Patients will receive a bilateral ultrasound guided QL block by the anesthesia team.
89436596|NCT03496610|Active Comparator|Surgical wound infiltration|Patients will receive 266 mg of liposomal bupivacaine mixed with 50 mg non-liposomal bupivacaine infiltrated into the wound by the surgeon.
89436597|NCT03484819|Experimental|Treatment (copanlisib hydrochloride, nivolumab)|Patients receive copanlisib hydrochloride IV over 1 hour on days 1, 8 and 15 of cycles 1-8 and days 1 and 15 of subsequent cycles. Patients also receive nivolumab IV over 30 minutes on days 1 and 15 of cycles 1-8 and on day 1 of subsequent cycles. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
89436598|NCT03422198|Experimental|Short course vaginal cuff brachytherapy|Participants undergo short course vaginal cuff brachytherapy for 2 fractions with 1 week apart.
89436599|NCT03422198|Active Comparator|Vaginal cuff brachytherapy|Participants undergo standard of care vaginal cuff brachytherapy for 3-5 fractions over no more than 3 weeks.
89436600|NCT03414775|Active Comparator|Pediasure|Patients assigned to this arm will receive Pediasure
89436601|NCT03414775|Active Comparator|Nourish|Patients assigned to this arm will receive Nourish
89530954|NCT03344003||Wilate or Nuwiq prospective cohort|Evaluable haemophilia A patients with an inhibitor against FVIII enrolled prospectively
89530955|NCT03344003||Wilate or Nuwiq retrospective cohort|Evaluable haemophilia A patients with an inhibitor against FVIII enrolled retrospectively
89010850|NCT05897710|Active Comparator|Center-Based Cardiac Rehab (CBCR)|Standard of care for participants' center-based cardiac rehabilitation program. Traditional 12-week, in-person program.
89010851|NCT05897710|Experimental|Virtual World-Based Cardiac Rehab (VWCR)|Telehealth delivery of cardiac rehabilitation via Second Life virtual world platform. 12-week, home-based program.
89010852|NCT05897606|Experimental|effect multivitamin and minerals on NAFLD for 12 weeks|The intervention group received one capsule of multivitamin and minerals supplements every day, one hour after breakfast, for 12 weeks.
89010853|NCT05897606|Placebo Comparator|Placebo|the control group took a placebo prepared with the same shape and size of supplements.
89198614|NCT05279248|Active Comparator|Group C|Participants in this arm will be receieve MMR vaccine first. One month later, they are going to receieve HPV 16/18 bivalent vaccine according to 2-dose schedule (1,7 months)
89198615|NCT00384397|Experimental|Group 1: Menactra® Vaccine|Participants will receive Menactra® vaccine at age 9 months and 12 months, respectively.
89536897|NCT03311867|Active Comparator|Non- Braided Suture|Patient in this group will have a cerclage with prolene suture material
88819431|NCT03022877|Active Comparator|Bolus Levosimendan|Levosimendan is given as Bolus (12 µg/kg over 10 min i.v.), starting 10 min before recanalization.
88819432|NCT03022877|Active Comparator|Bolus and infusion Levosimendan|Levosimendan is given as Bolus (12 µg/kg over 10 min i.v.), starting 10 min before recanalization and additionally as continuous infusion (0.1-0.2 µg/kg/min i. v. for 24 hours).
89436602|NCT03410654|Experimental|adult kidney transplant recipients|Adult kidney transplant recipients on tacrolimus immediate release for at least six months who are being converted to tacrolimus extended release Envarsus XR® (TAC XR) for any reason by a transplant nephrologist and are willing to participate in cognitive assessment will be offered the opportunity to participate in the study. An assessment is also made at the 3 month point as baseline.
89436603|NCT03399318|Experimental|Aggressive Antipyretics|regardless of temperature, children allocated to this arm will receive acetaminophen (30 milligrams (mg)/ kilogram (kg) load then 15mg/kg Q6 hours) and ibuprofen (10mg/kg Q 6 hours) for 72 hours. Pediatric syrup formulations of both agents will be administered orally or via nasogastric tube. For temperatures over 38.5 degrees Celsius, placebo will be added and if the fever persists, a cooling fan will be added.
89436604|NCT03399318|Placebo Comparator|Usual Care|will receive placebo for acetaminophen and placebo for ibuprofen. If they have a temperature over 38.5 degrees Celsius, they will receive acetaminophen (15mg/kg, Q6 hours), as needed. If the fever persists, a cooling fan will be added.
89436605|NCT03397706|Experimental|Phase 1b Dose Escalation|"VRx-3996 (cohort 1) and valganciclovir~VRx-3996 (cohort 2) and valganciclovir~VRx-3996 (cohort 3) and valganciclovir~VRx-3996 (cohort 4) and valganciclovir~VRx-3996 (cohort 5) and valganciclovir"
89436606|NCT03397706|Experimental|Phase 2 Dose Expansion|VRx-3996 (RP2D: recommended phase 2 dose) and valganciclovir
89436607|NCT03397706|Experimental|PK Cohort|Assessment of VRx-3996 tablet and valganciclovir PK parameters at the RP2D
89436608|NCT03397004|Active Comparator|doxycycline Hyclate|subjects will be treated with a 6-month course of doxycycline oral capsule at a dose of 100mg twice daily
89436609|NCT03397004|Placebo Comparator|Placebo|subjects will be given a placebo oral capsule twice daily for 6-months
88819433|NCT02420262|Experimental|IDegLira|
88819434|NCT02420262|Active Comparator|IGlar plus IAsp|
88819435|NCT05037747|Experimental|Time-restricted feeding(TRF)|The TRF group was asked to restrict the eating window to 8 hours a day, during waking hours and also continue a low-protein diet.
88819436|NCT05037747|No Intervention|Control|The control group was asked to continue their usual low-protein diet eating schedule and pattern.
88819437|NCT02468427|Experimental|hands-on Teaching|Medical students receive a 30 minutes hands-on training session. All study probands perform assisted delivery (operative vaginal delivery) by vacuum extraction on a pelvic model immediately after the training.
88819438|NCT02468427|Active Comparator|Frontal teaching|Medical students receive a 30 minutes frontal teaching session using a training video demonstrating how to perform assisted delivery (operative vaginal delivery) by vacuum extraction on a pelvic model immediately after the training.
88819439|NCT04264455||Biomonitor only|Patients receive a Biomonitor only
88819440|NCT04264455||Wearable Cardioverter-Defibrillator (Life Vest) + Biomonitor|Patients receive a Wearable Cardioverter-Defibrillator (Life Vest) combined with a Biomonitor
88819441|NCT04264455||ICD Implantation|Patients receive an ICD only
89436610|NCT03375307|Experimental|Cohort I (olaparib)|Patients that have cancer-associated DNA-repair gene mutations receive olaparib PO BID on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89436611|NCT03375307|Experimental|Cohort II (biospecimen collection)|Patients that do not have cancer-associated DNA-repair gene mutations undergo blood sample collection at baseline.
89436612|NCT03369210|Experimental|Liberal|Liberal group (patients receive a RBC unit each time Hb falls ≤ 9 g/dl (≤ 5.6mmol/l) with a target range for the post-transfusion Hb level of 9-10.5 g/dl (5.6-6.5 mmol/l)).
89436613|NCT03369210|Active Comparator|Restrictive|Restrictive group (patients receive a single RBC unit each time Hb falls ≤ 7.5 g/dl (≤ 4.7 mmol/l) with a target range for the post-transfusion Hb level of 7.5-9 g/dl (4.7-5.6 mmol/l).
89436614|NCT03339921|Experimental|Botulinum toxin injections|Botulinum toxin injections for chronic compartment syndrome
89436615|NCT03339921|Active Comparator|surgical fasciotomy|surgical fasciotomy for chronic compartment syndrome
89436616|NCT03338790|Experimental|nivolumab + rucaparib|Specified dose on specified days
89436617|NCT03338790|Experimental|nivolumab + docetaxel + prednisone|Specified dose on specified days
89436618|NCT03338790|Experimental|nivolumab + enzalutamide|Specified dose on specified days
89436619|NCT03306979|Active Comparator|N-acetylcysteine|Participants randomized into the N-acetylcysteine arm will be receiving N-acetylcysteine for 24 weeks.
89436620|NCT03306979|Placebo Comparator|Placebo|Participants randomized into the placebo arm will be receiving placebo for 24 weeks.
89436621|NCT03278509|Experimental|Oral beta-blocker treatment|Patients randomized to beta-blockade will be prescribed oral beta-blocker (metoprolol succinate or bisoprolol) at a dose according to the treating physician. Metoprolol succinate will be strongly recommended as first choice. Bisoprolol will be allowed as an alternative. Atenolol (or any other beta-blocker therapy) will not be allowed. The treating physician will be encouraged to aim for a dose of ≥ 100 mg for metoprolol succinate and ≥ 5 mg for bisoprolol. Prescribed treatment and dosing will be registered. Initiation (whether the prescribed drug is dispensed) and adherence (defined as proportion of prescribed tablets that are dispensed), and persistence (time on treatment) will also be recorded via the Drug prescription registry.
89436622|NCT03278509|No Intervention|No beta-blocker treatment|Patients randomized to no beta-blockade will be discouraged to use beta-blockade as long as there is no other indication than strictly secondary prevention after myocardial infarction. Patients assigned to no beta-blockade also receive best evidence-based care, without beta-blockers. For blood pressure control, other drugs than beta-blockers will be recommended as first-line treatment. Regarding later use of beta-blockade, follow up is performed in the Drug prescription registry. Patients will be asked to provide future physicians with the written information about the study when beta-blockade treatment is discussed.
89198616|NCT00384397|Experimental|Group 2: Menactra® + MMRV|Participants will receive Menactra® at age 9 months followed by Menactra® and Measles-Mumps-Rubella-Varicella (MMRV) vaccines at Age 12 Months
88819444|NCT04176549||Ectopic Pregnancy|Patients diagnosed with ectopic pregnancy Samples collected: Plasma, Serum, Urine, Oral swab, Vaginal Swab If surgery required for tubal ectopic: Fallopian tube, peritoneal washing, trophoblast
88819445|NCT04176549||Surgical termination of pregnancy|Patients undergoing elective surgical termination of pregnancy Samples collected: Plasma, Serum, Urine, Oral swab Vaginal swab, Trophoblast
88819446|NCT04176549||Elective hysterectomy and salpingo-oophorectomy|Patients undergoing elective hysterectomy and salpingo-oophorectomy Samples collected: Fallopian tube, peritoneal washing
88819447|NCT00552305|Experimental|Lacosamide|50mg and 100mg tablets up to 800 mg/day as twice a day (BID) dosing
88819448|NCT04738305|Other|Dignity Therapy Intervention|All the patients that accepted to participate in the study were provided with Dignity Therapy Intervention. A short-term intervention aimed at reducing existential distress of patients facing with advanced illness.
88819449|NCT02989181|Experimental|Continues Positive Airway Pressure|Use of Continues Positive Airway Pressure (CPAP) mask every night under six months period.
88819450|NCT02989181|No Intervention|Consultation of conservative measures|Study participants with DCM and OSA (no-CPAP), participants receive consultation of conservative measures such as avoiding alcohol before bedrest, sleeping on the side...
88819451|NCT04168671|Other|Asthma|Asthma and symptomatic during exercise
88819452|NCT04168671|Other|Severe asthma|Severe asthma and symptomatic during exercise
88819453|NCT02664077|Experimental|Group 1: Regorafenib|Patients receive regorafenib orally once daily for 21 days of a 28 day cycle for a total of 26 cycles.
88819454|NCT02664077|Placebo Comparator|Group 2: Placebo|Patients receive placebo orally once daily for 21 days of a 28 day cycle for a total of 26 cycles.
88819455|NCT04152993|Experimental|RNS group|This study consists in only one arm. In this arm, the patients will undergo the placement of the RNS implant and the subsequent RNS programming to optimize the PTSD symptoms.
88819456|NCT02618993|Placebo Comparator|Control group|Control group: Realization of the V3 block with a placebo in maxillofacial surgeries
88819457|NCT02618993|Experimental|Loco-regional anesthesia (LRA) group|Loco-regional anesthesia (LRA) group: Realization of the V3 block with Ropivacaine in maxillofacial surgeries
88819458|NCT02277665|Active Comparator|CUD Treatment Only|12 Week Behavioral Treatment that included weekly computer-assisted counseling and contingency management for CUD
88819459|NCT02277665|Experimental|CUD and Tobacco Treatment|12 Week Behavioral Treatment that included weekly computer-assisted counseling and contingency management for CUD, and behavioral counseling and nicotine replacement therapy (NRT) for tobacco
88819460|NCT04987749|Active Comparator|Active|"Participants received the real intervention of TBS (iTBS 600) over the right inferior frontal gyrus for 8 weeks (2 days/week).~*iTBS = intermittent theta burst stimulation"
88819461|NCT04987749|Sham Comparator|Sham|Participants received the sham intervention of TBS (coil tilted one-wing 90° off the head) over the right inferior frontal gyrus for 8 weeks (2 days/week).
88819462|NCT04690439|Experimental|Group A|Group A will receive first PBM + manual lymphatic drainage for 9 weeks (2 sessions/week), followed by 9 weeks only manual lymphatic drainage.
88819463|NCT04690439|Active Comparator|Group B|Group B will first receive only manual lymphatic drainage for 9 weeks, followed by the combination of PBM and manual lymphatic drainage for 9 weeks (2x/week).
88819464|NCT01854255|Experimental|Intraperitoneal Chemotherapy|Patients will receive doxorubicin 1.5 mg/m2 body surface in 50 ml NaCl 0,9% and cisplatin 7.5 mg/m2 in 50 ml NaCl 0,9% q 4-6 weeks, applied intraperitoneally as pressurized aerosol chemotherapy. Duration of treatment will be 3 single doses in 6 weeks intervals, thus the duration of treatment is 18 weeks.
88819465|NCT01555281|Experimental|Nelfinavir and Lenalidomide/Dexamethasone|"Phase I: Cycles 1-4 (1 cycle = 28 days) Lenalidomide: 25 mg per day p.o., day 1 to 21 Dexamethasone: 40/20 mg per day p.o., days 1, 8, 15, 22 Nelfinavir: Dose escalation in cohorts of 3 patients~Phase II: Cycles 1-4 (1 cycle = 28 days) Lenalidomide: 25 mg per day p.o., day 1 to 21 Dexamethasone: 40/20 mg per day p.o., days 1, 8, 15, 22 Nelfinavir: Dose established in phase I twice daily p.o., day 1 to 21"
88819466|NCT04945629|Active Comparator|Simple suture|Atraumatic exodontia followed by simple suture
88819467|NCT04945629|Experimental|PRGF-Endoret|Atraumatic exodontia followed by simple suture
88919791|NCT01672359|Experimental|Ginkgo Synergy® and Choline|Ginkgo Synergy® (120 mg/day Ginkgo biloba leaf with 80 mg/day Ginkgo biloba whole extract combined with 40 mg/day Grape Seed extract) and Choline (700 mg choline/day)
88919792|NCT01672359|Experimental|OPC Synergy® and Catalyn|OPC Synergy® (100 mg/day of Grape Seed extract with 50 mg/day Green Tea extract (60% catechins)) and Catalyn® (1,248 IU/day of Vitamin D, 4,800 IU/day of Vitamin A, combined with vitamin C, thiamine, riboflavin, and vitamin B6)
88919793|NCT01672359|Placebo Comparator|Placebo|cellulose pills to simulate actual products
88919794|NCT01672437|Experimental|Birth and parent preparation|"The following subjects will be covered in the sessions:~Session 1 (25 weeks gestation):~Common challenges in the transition to parenthood and in the relationship~Couple communication~Session 2 (33 weeks gestation):~Expectations in relation to birth~The normal course of labour~Obstetric intervention~Pain relief,coping strategies~Partner support~Session 3 (35 weeks gestation):~Feeding a newborn~Interpreting the newborn's signs, symptoms and behaviour~Taking care of a newborn~Mood swings, postnatal depressive symptomatology~Session 4 (5 weeks post-partum):~Birth experiences~Mood swings, postnatal depressive symptomatology~The first time at home with a newborn~Couplehood - partner support, communication, division of household tasks"
88919795|NCT01672437|No Intervention|control group|The control group are offered two lectures in an auditorium during pregnancy - one on breastfeeding and one on labour. This is standard care.
88919796|NCT01672541|Experimental|Dating Matters Comprehensive Approach|Schools randomly assigned to the comprehensive approach will: implement 6th, 7th, and 8th grade student curricula in English to all the students in these grades; offer parent programs for parents of 6th, 7th, and 8th graders;implement a communications campaign involving brand ambassadors, a text message campaign, and social media campaign;encourage all educators to take an online training about teen dating violence for educators;be supported in assessing and informing local school or community policies relevant to teen dating violence.
88919797|NCT01672541|Active Comparator|Standard of Care Safe Dates Approach|Schools randomly assigned to the standard of care approach will implement Safe Dates as it is published in their schools 8th grade classes.
88919798|NCT01672645|Experimental|PF-05402536|
88919799|NCT01672645|Experimental|PF-06413367|Intramuscular, multiple dose
88919800|NCT01672645|Placebo Comparator|Placebo|Intramuscular
88919801|NCT01673035|Experimental|internet-based CBT|Cognitive behavior therapy delivered via the internet: 12 weeks, therapist-guided
88919802|NCT01673035|Active Comparator|internet-based BSM|behavioral stress management delivered via the internet: 12 weeks, therapist-guided
88919803|NCT01673165|Active Comparator|Specialized Formula|25 infants of mothers who do not have breast milk or do not want to use the skimming technique. These infants will receive our standard of care - specialized formula for the treatment of chylothorax
88919804|NCT01673165|Experimental|Skimmed mother's milk|25 infants of mothers who have breast milk and who also want to learn the skimming technique will be taught the technique. The infants will then receive the skimmed breast milk for the treatment of chylothorax
88919805|NCT01673308|Experimental|Treatment arm|Lenalidomide treatment arm
88919806|NCT01673503|Active Comparator|Carl Zeiss Meditech VisuMax laser - ReLEx flex|>30 patients will receive treatment for myopia with a VisuMax femtosecond laser from Carl Zeiss. The laser can cut with two different settings, called ReLEx flex and ReLEx smile. One eye will recieve ReLEx flex, and the other ReLEx smile
88919807|NCT01673503|Active Comparator|Carl Zeiss Meditech VisuMax laser - ReLEx smile|>30 patients will receive treatment for myopia with a VisuMax femtosecond laser from Carl Zeiss. The laser can cut with two different settings, called ReLEx flex and ReLEx smile. One eye will recieve ReLEx flex, and the other ReLEx smile
89436623|NCT03277976||ThermoCool SmartTouch 1|In this cohort are included patients who will undergo atrial fibrillation ablation using the ThermoCool SmartTouch Catheter and Ablation Index range: 380 for the posterior wall and 500 for the anterior wall
89436624|NCT03277976||ThermoCool SmartTouch 2|In this cohort are included patients who will undergo atrial fibrillation ablation using the ThermoCool SmartTouch Catheter and Ablation Index range: 330 for the posterior wall and 450 for the anterior wall
89436625|NCT03277976||ThermoCool SmartTouch SF 1|In this cohort are included patients who will undergo atrial fibrillation ablation using the ThermoCool SmartTouch SF Catheter and Ablation Index range: 330 for the posterior wall and 450 for the anterior wall
89436626|NCT03277976||ThermoCool SmartTouch SF 2|In this cohort are included patients who will undergo atrial fibrillation ablation using the ThermoCool SmartTouch SF Catheter and Ablation Index range: 380 for the posterior wall and 500 for the anterior wall
89436627|NCT03270059|Experimental|Group I (gadolinium, ferumoxytol, MRI)|Patients receive gadolinium IV and then ferumoxytol IV and undergo MRI over 60 minutes on day 1.
89436628|NCT03270059|Experimental|Group II (ferumoxytol, gadolinium, MRI)|Patients receive ferumoxytol IV and then gadolinium IV and undergo MRI over 60 minutes on day 1.
89436629|NCT03259503|Experimental|Treatment (olaparib, high-dose chemotherapy, transplant)|Patients receive olaparib PO BID on days -11 to -3, vorinostat PO on days -10 to -3, gemcitabine IV over 4.5 hours on days -9 and -4, busulfan IV over 3 hours on day -9 to -6, melphalan IV over 30 minutes on days -4 and -3, and undergo peripheral blood stem cell transplant IV over 30-60 minutes on day 0. Patients with CD20+ tumors also receive rituximab IV over 3-6 hours on day -10.
89436630|NCT03240588|Active Comparator|De Novo Cohort|Study subjects who have not previously attempted a Neurostimulator trial will be followed up to 36 months post-Neurostimulation trial procedure or IPG Activation on the use of their Neurostimulation system.
89436631|NCT03240588|Active Comparator|Existing Cohort|Study subjects who have completed permanent neurostimulator IPG implant and are in various stages of follow-up will be followed up to 36 months post-Neurostimulation trial or IPG Activation procedure on the use of their Neurostimulation system.
89436632|NCT03228537|Experimental|Treatment (chemotherapy, surgery, RT)|"NEOADJUVANT: Patients receive atezolizumab IV over 30-60 minutes, pemetrexed disodium IV over 10 minutes, and cisplatin IV over 2 hours on day 1. Cycles repeats every 21 days for 4 cycles in the absence of disease progression or unexpected toxicity.~SURGERY: Within 21-90 days after completion of neoadjuvant therapy, patients undergo EPP or PD. Patients who undergo EPP will then undergo RT.~MAINTENANCE: Within 90 days after completion of either PD or radiation (post-EPP), patients receive atezolizumab IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 1 year in the absence of disease progression or unexpected toxicity."
89436633|NCT03213171|No Intervention|Usual care|Usual care / Standard of care No intervention implemented
88919808|NCT01673516|Active Comparator|group Co|"group Co receives intensive medical therapy utilizing integrated hemodynamic management calculated by impedance cardiography of The HOTMAN® System"
88919809|NCT01673516|Active Comparator|group RDN|"For patients who will be randomly assigned to undergo renal denervation by The SymplicityTM Renal Denervation System, the femoral artery will be accessed with the standard endovascular technique and the catheter will be advanced into the renal artery and connected to a radiofrequency generator. As in Symplicity HTN 1 and 2 trials, four-to-six discrete, low-power radiofrequency ablations lasting up to 2 min each and of 8 watts or less to obtain up to four-six ablations separated both longitudinally and rotationally within each renal artery. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm."
88919810|NCT01673737|Experimental|Part A Monotherapy|Dose escalation of daily or twice daily SAR260301 within a 28-day cycle, followed by an expansion phase at the maximal tolerated dose
88919811|NCT01673737|Experimental|Part B Combination|Dose escalation of twice-daily SAR260301 within a 28-day cycle and in combination with 720 or 960 mg twice daily of Vemurafenib, followed by an expansion phase at the maximal tolerated dose of SAR260301 in combination
88919812|NCT01673815|Experimental|1st: R eye video. 2nd: L eye no video|The right eye will be examined first with video, followed by the left eye without video.
88919813|NCT01673815|Experimental|1st: R eye no video. 2nd: L eye video|The right eye will be examined without video, followed by the left eye with video.
88919814|NCT01673815|Experimental|1st: L eye video. 2nd: R eye no video|The left eye will be examined first with video, followed by the right eye without video.
88919815|NCT01673815|Experimental|1st: L eye no video. 2nd: R eye video|The left eye will be examined first without video, followed by the right eye with video.
88919816|NCT01674114|Experimental|TAP block|transversus abdominis plane block (TAP block). Ultrasound guided TAP-block at the end of surgery using 20 ml bupivacaine 0,25% with Adrenaline 5mcg/ml bilaterally by the anaesthesiologist, and 20 ml NaCl intracutaneously in the operating wound performed by the obstetrician
88919817|NCT01674114|Active Comparator|control|Ultrasound guided TAP block at the end of surgery with 20 ml NaCl bilaterally and 20 ml bupivacaine 0,25% with Adrenaline 5mcg/ml intracutaneously in the surgical wound(standard practice)
89436634|NCT03213171|Experimental|Intervention|Reception staff providing handout; Mobile tablet that provides the immediate opportunity for patients to register in the waiting room
89530956|NCT02506751|Experimental|Liothyronine|"Subjects will take oral liothyronine for a total of 24 weeks following the below titration schedule:~0-6 weeks: liothyronine 10mcg po daily (5mcg po BID)~6-12 weeks: liothyronine 20mcg po daily (10mcg po BID)~12-18 weeks: liothyronine 50mcg po daily (25mcg po BID)~18-24 weeks: liothyronine 1mcg/kg/day (0.5mcg/kg po BID), not to exceed 75mcg po daily"
89536505|NCT02472509|Experimental|Open Label|32 patients with hemolytic disorders meeting the inclusion and exclusion criteria will be commenced on Ursodeoxycholic acid (UDCA).
89010854|NCT05897580|Experimental|Heart Rate Variability-Biofeedback (HRV-BF)|"Heart Rate Variability-Biofeedback (HRV-BF) is a process by which physiological markers such as heart rate, respiration, and HRV are measured and fed back to the person on a computer screen. Guided paced slowed breathing, a skill taught in HRV-BF, maximizes the natural acceleration of heart rate with inspiration and deceleration with expiration and produces a rhythmic stimulation of the vagus nerve, providing the basis for the overall increase in parasympathetic/vagal tone over time if practiced regularly."
89010855|NCT05897580|Active Comparator|Health Promotion (HP)|The Health Promotion (HP) active control group was originally developed utilizing community-based participatory research elements, including the establishment of a Community Advisory Board (CAB), with community stakeholders, social service providers and academicians and a manualized program was developed for the HP program. The 8-week program focused on the most common physical chronic diseases PEH experience, and included discussions of hypertension, diabetes, heart disease and arthritis; total over eight weeks, along with full discussion and referrals provided based on needs expressed by PEH.
89010856|NCT05897567|Experimental|ketogenic diet|Participants will perform a single exercise bout after 4 weeks of resistance training combined with a ketogenic diet (KD group).
89010857|NCT05897567|Active Comparator|western diet|Participants will perform a single exercise bout after 4 weeks of resistance training combined with a western diet (WD group).
89010858|NCT05897528||Diabetes Mellitus Positive Group|All patient that have a diagnosis of diabetes mellitus and COVID-19 Diagnosis
89010859|NCT05897528||Diabetes Mellitus Negative Group|All patient that do not have a diagnosis of diabetes mellitus but do have a diagnosis of COVID-19.
89010860|NCT05897515|Other|Blinded, Prospective Arm|"Clinical specimens shall be collected prospectively from patients with signs or symptoms of respiratory tract infection. Nasal swab in Copan UTM 3mL for comparator testing should be collected by a healthcare professional.~Where subjects are willing and able, up to 40% of nasal swab for the investigational device will be self-collected under the guidance and supervision of a healthcare professional.~Nasopharyngeal specimens (optional) should only be collected by a healthcare professional. All specimens collected from children 13 years or younger should only be collected by a trained healthcare professional. Follow CDC guidelines for collecting nasopharyngeal swabs, unless otherwise specified by DiaSorin."
89010861|NCT05897476|Experimental|ultrasound arm|every patient will be examine with ultrasound
89010862|NCT05897463||Neurotized|
89010863|NCT05897463||Non-neurotized|
89010864|NCT05897411|Experimental|Deconditioning|
89010865|NCT05897411|Sham Comparator|Sham deconditioning|
89010866|NCT05897372|Active Comparator|Standard of Care|Maximally tolerated dose of ACEi or ARB (but not both), SGLT2i, and finerenone. Blood pressure target <130/80 mm Hg
89010867|NCT05897372|Experimental|Albuminuria-reduction protocol|"Maximally tolerated dose of ACEi or ARB (but not both), SGLT2i, and finerenone. Thereafter addition of semaglutide, pentoxifylline, hydrochlorothiazide, and baricitinib.~Blood pressure target <130/80 mm Hg, but if still UACR >300 further reduction in blood pressure will be attempted as tolerated."
89010868|NCT05897359|Experimental|bCBTMI|bCBTMI care for IA.
89010869|NCT05897359|Placebo Comparator|Control|Routine care for IA.
89010870|NCT05897346|Experimental|Intervention group|Secondary school students will be required to join a 3-phase 'Learning while serving' program.
89010871|NCT05897346|Other|Control group|Secondary school students will be only required to attend a 3-hour training workshops.
89010872|NCT05897333||Isolated coronary ectasia|Includes the patients with isolated coronary artery ectasia without coronary stenosis.
89010873|NCT05897333||Coronary artery disease|Includes the patients with ≥50% stenosis in a vessel ≥2 mm in diameter.
89010874|NCT05897255|Active Comparator|Control Group|"In Control group, conventional method to reduce diastasis recti will be provided.~Commonly used exercises in the treatment of DRA including abdominal hollowing, curl-ups, sit-ups, pelvic bridging, SLR will be performed by the patients.~The conventional exercise program will be given 3days/week for 6 weeks and will include 2 sets of 5 reps of each exercise."
89010875|NCT05897255|Experimental|Experimental Group A|"In experimental group A, Kinesiotape along with core strengthening exercises will be provided.~The core strengthening exercise program will be given 45 minutes of session 3days/week for 6 weeks. Each exercise will have 5-10 repetitions with a period of rest in between to avoid fatigue and muscle spasm."
89010876|NCT05897255|Experimental|Experimental Group B|"In experimental group B, SEMG biofeedback assisted core strengthening exercises with kinesiotaping will be provided.~Surface EMG activity will be recorded from the left and right abdominal muscles while the exercises will be performed in different positions."
89010877|NCT05897203|Active Comparator|Investigational Medicinal product A (IMP A) + Standard of Care (SoC)|Participants in this arm will receive the both the Investigational medicinal product (IMP A) and the standard of care
89010878|NCT05897203|Active Comparator|Investigational Medicinal product B (IMP B) + Standard of Care (SoC)|Participants in this arm will receive the both the Investigational medicinal product (IMP B) and the standard of care
88919818|NCT01674153|Experimental|HD-Exercise-HDF|Prescribe intra-dialytic exercise of three bouts in 4 hours dialysis session.
88919819|NCT01674335|No Intervention|Delayed-Intervention|A total of 120 participants with fibromyalgia will be randomly assigned to one of four intervention groups (Operant Learning (OL), Energy Conservation (EC), delayed-OL and delayed-EC). The delayed groups will receive the AP intervention 3 months later and will serve as a Usual Care control group. All groups will continue to receive any concomitant interventions that they are receiving (pharmacological and non-pharmacological) at the time of enrollment.
88919820|NCT01674335|Active Comparator|Operant Learning|
88919821|NCT01674335|Active Comparator|Energy Conservation|
88919822|NCT01674426|Experimental|Cognitive behavior therapy|Cognitive behavior therapy consisting of 16 sessions over 20 weeks
88919823|NCT01674426|Placebo Comparator|observation|Subjects were called by telephone but were not given cognitive behavior therapy until the study phase was completed
88919824|NCT01674439|Experimental|With supplementation of ADRC|Fat graft with supplementation of ADRC
88919825|NCT01674439|Active Comparator|Without supplementation of ADRC|Fat grafts without supplementation of ADRC
88919826|NCT01674556|Experimental|Contrast-enhanced ultrasound (CEUS)|
88919827|NCT01674595|Experimental|Immunotherapy|AVANZ
88919828|NCT01675115|Active Comparator|BNG-1 plus Aspirin|BNG-1 3 grams TID plus Aspirin 100mg QD for 4 weeks
89436635|NCT03198026|Experimental|Treatment (ibrutinib, obinutuzumab)|"Patients receive ibrutinib orally (PO) once daily (QD) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive obinutuzumab intravenously (IV) on days 1, 8, and 15 of cycle 1 and day 1 of subsequent cycles. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Beginning 2 months after cycle 6, patients with stable disease will continue to receive obinutuzumab every 2 months for a total of 12 doses.~After completion of study treatment, patients are followed up monthly for 1 year, every 3-6 months for 4 years, and then annually for up to 2 years."
89436636|NCT03187405|No Intervention|EVD alone|In the EVD alone group group, the EVD will be managed as usual - i.e. will only be used to drain CSF.
88919829|NCT01675115|Sham Comparator|Aspirin|Aspirin 100mg QD for 4 weeks
89436637|NCT03187405|Experimental|EVD + IVF with Alteplase|Intraventricular fibrinolysis: Injection through the EVD of 1mg in 1 mL of Alteplase every eight hours during 3 days (9 doses).
88919830|NCT01675271|Active Comparator|individual exercise|individualized exercise program
88919831|NCT01675271|Active Comparator|general exercise|general exercise program
88919832|NCT01675271|No Intervention|control|No exercise and dietary counselling
88919833|NCT01675310|Experimental|medical nutrition therapy + metformin|medical nutrition therapy plus trans-gestational metformin (850mg 2 times day)
88919834|NCT01675310|Active Comparator|medical nutrition therapy|medical nutrition therapy without trans-gestational metformin
88919835|NCT01675401|Experimental|Weight-loss treatment|A very-low energy diet (Modifast Intensive) for 4-5 weeks providing 2.1 MJ/day in order to reduce body weight. After 4-5 weeks a mixed solid energy-restricted diet up to 4.2 MJ/day with a recommended composition for the following 1-2 weeks. Then, a diet matching their energy requirements to maintain newly achieved body weights (weight-stable conditions) for at least 2 weeks.
88919836|NCT01675401|Other|No-weight loss treatment|Maintenance of habitual diet and physical activity for 8 weeks to maintain body weights.
88919837|NCT01675674||Dried blood spot test for MPS|"For the prospective study, subjects will be drawn from all children (aged 6 months to 18 years) with a history of presenting to selected clinics (pediatric rheumatology, pediatric hand, or skeletal dysplasia clinic), with at least ONE highly suspicious symptom or at least TWO less suspicious symptoms that may be indicative of an MPS disorder (see inclusion criteria).~For the retrospective chart review, subjects will be drawn from all children who were 6 months to 18 years of age at the time of first presentation to selected clinics (pediatric rheumatology, pediatric hand, or skeletal dysplasia clinic), with at least ONE highly suspicious symptom or at least TWO less suspicious symptoms that may be indicative of an MPS disorder (see inclusion criteria)."
88919838|NCT01675713|Experimental|Lifestyle intervention|10-14 weeks intensive lifestyle intervention
88919839|NCT01675713|No Intervention|Controls|No treatment, waiting list
88919840|NCT01676103|Experimental|Tyrosine|Tyrosine supplementation (500 mg 2x daily) for 7 days
88919841|NCT01676103|Placebo Comparator|Sugar pill|Placebo sugar pills (2x daily) for 7 days
89436638|NCT03173248|Experimental|AG-120 + Azacitidine|Participants received AG-120 500 mg orally, once daily (QD) in combination with azacitidine 75 milligrams per square meter per day (mg/m^2/day) subcutaneously (SC) or intravenously (IV), on Days 1-7, or on Days 1-5 and 8-9, of each 28-day cycle for a minimum of 6 cycles until death, disease relapse, disease progression, development of unacceptable toxicity (adverse event), confirmed pregnancy, withdrawal by participant or protocol violation.
89536506|NCT04985877|Experimental|Sarcopenia group|Yakult light 300 supplementation with sarcopenia patient
89536507|NCT04985877|No Intervention|Non sarcopenia group|no intervention to sarcopenia patient
89536508|NCT04985877|No Intervention|Control group|no intervention to non-sarcopenia people
88919842|NCT01676324||Inflammatory Bowel Disease|Those with Inflammatory Bowel Disease (known) and those with no Inflammatory Bowel Disease (not previously diagnosed)
88919843|NCT01676649|Experimental|A|Arm A: Carboplatin (week 1, week 4, week 7, week 10, and week 13) Paclitaxel (week 1, week 4, week 7, week 10, and week 13) Ipilimumab (week 4, week 7, week 10, and week 13)
88919844|NCT01676649|Experimental|B|Carboplatin (week 1, week 4, week 7, week 10, and week 13) Paclitaxel (week 1, week 4, week 7, week 10, and week 13) Ipilimumab (week 5, week 8, week 11, and week 14)
88919845|NCT01676883|Experimental|body composition assessment|Bioelectric impedance measurement pre- and post removal of calluses and corns (pedicure), then air-displacement plethysmography (gold standard)
88919846|NCT01676987|Experimental|Fixed Combination of Budesonide and formoterol|Group 1 (experimental): Fixed Combination of Budesonide and formoterol
88919847|NCT01676987|Active Comparator|Budesonide|Group 2 (comparator): Budesonide
88919848|NCT01677039|Active Comparator|Treatment A|
88919849|NCT01677039|Experimental|Treatment B|
88919850|NCT01677039|Experimental|Treatment C|
88919851|NCT01677065||Treatment A|Controlled release oxycodone test formulation 40 mg
89436639|NCT03173248|Placebo Comparator|Placebo + Azacitidine|Participants received AG-120 matching placebo orally, QD in combination with azacitidine 75 mg/m^2/day SC or IV, on Days 1-7, or on Days 1-5 and 8-9, of each 28-day cycle for a minimum of 6 cycles until death, disease relapse, disease progression, development of unacceptable toxicity (adverse event), confirmed pregnancy, withdrawal by participant or protocol violation .
89436640|NCT03164616|Experimental|Treatment Arm 1|durvalumab + tremelimumab combination therapy + SoC chemotherapy
89436641|NCT03164616|Experimental|Treatment Arm 2|durvalumab monotherapy + SoC chemotherapy
88919852|NCT01677065||Treatment B|Immediate release oxycodone reference drug 20 mg
88919853|NCT01677247|Experimental|Group I (Test)|Test : glimepiride 4 mg tablet of PT Dexa Medica
88919854|NCT01677247|Active Comparator|Group II (Reference)|Reference : glimepiride (Amaryl) 4 mg tablet of PT Sanofi-Aventis, Indonesia
88919855|NCT01677260|Experimental|Group I|500 mg metformin hydrochloride extended release caplet (PT Ferron Par Pharmaceuticals)
88919856|NCT01677260|Active Comparator|Group II|500 mg metformin hydrochloride prolonged release tablet (PT Merck Pharmaceuticals)
88919857|NCT01677572|Experimental|Low-dose #1 Aducanumab|Intravenous doses of low-dose level #1 Aducanumab administered approximately 4 weeks apart over approximately 52 weeks (a total of 14 doses). Qualifying participants can continue into the long-term extension at a dose administered approximately 4 weeks apart for up to an additional 112 doses.
88919858|NCT01677572|Experimental|Low-dose #2 Aducanumab|Intravenous doses of low-dose level #2 Aducanumab administered approximately 4 weeks apart over approximately 52 weeks (a total of 14 doses). Qualifying participants can continue into the long-term extension at a dose administered approximately 4 weeks apart for up to an additional 112 doses.
88919859|NCT01677572|Placebo Comparator|Placebo (low dose group)|Intravenous doses of placebo administered approximately 4 weeks apart over approximately 52 weeks (a total of 14 doses). Qualifying participants can continue into the long-term extension at a dose approximately 4 weeks apart for up to an additional 112 doses.
88919860|NCT01677572|Experimental|Mid-dose Aducanumab|Intravenous doses of mid-dose Aducanumab administered approximately 4 weeks apart over approximately 52 weeks (a total of 14 doses). Qualifying participants can continue into the long-term extension at a dose administered approximately 4 weeks apart for up to an additional 112 doses.
88919861|NCT01677572|Placebo Comparator|Placebo (mid dose group)|Intravenous doses of placebo administered approximately 4 weeks apart over approximately 52 weeks (a total of 14 doses). Qualifying participants can continue into the long-term extension at a dose administered approximately 4 weeks apart for up to an additional 112 doses.
88919862|NCT01677572|Experimental|High-dose Aducanumab|Intravenous doses of high-dose Aducanumab administered approximately 4 weeks apart over approximately 52 weeks (a total of 14 doses). Qualifying participants can continue into the long-term extension at a dose administered approximately 4 weeks apart for up to an additional 112 doses.
88919863|NCT01677572|Placebo Comparator|Placebo (high dose group)|Intravenous doses of placebo administered approximately 4 weeks apart over approximately 52 weeks (a total of 14 doses). Qualifying participants can continue into the long-term extension at a dose administered approximately 4 weeks apart for up to an additional 112 doses.
88919864|NCT01677572|Experimental|Aducanumab Titration|Intravenous doses of Aducanumab administered approximately 4 weeks apart over approximately 52 weeks (a total of 14 doses). Qualifying participants can continue into the long-term extension at a dose approximately 4 weeks apart for up to an additional 112 doses.
88919865|NCT01677572|Placebo Comparator|Placebo (Titration Group)|Intravenous doses of placebo administered approximately 4 weeks apart over approximately 52 weeks (a total of 14 doses). Qualifying participants can continue into the long-term extension at a dose approximately 4 weeks apart for up to an additional 112 doses.
88919866|NCT01677650|Active Comparator|Methadone 0.5 mg/kg|Methadone 0.5 mg/kg
88919867|NCT01677650|Experimental|Methadone 0.4 mg/kg|Methadone 0.4 mg/kg
88919868|NCT01677650|Active Comparator|Methadone 0.3 mg/kg|Methadone 0.3 mg/kg
88919869|NCT01677650|Active Comparator|Methadone 0.2 mg/kg|Methadone 0.2 mg/kg
88919870|NCT01677650|Active Comparator|Methadone 0.15 mg/kg|Methadone 0.15 mg/kg
88919871|NCT01678053|Experimental|PPI and BOTOX|onabotulinumtoxinA (BOTOX), injection, 10 units, one time; omeprazole 40mg po bid (standard of care) for 3 months
88919872|NCT01678053|Other|Proton pump inhibitor only|omeprazole 40mg po bid for 3 months(standard of care)
88919873|NCT01678326|Active Comparator|EUS-Rendezvous or direct intervention|EUS rendezvous or direct intervention involves: (1) using endoscopic-ultrasound technology to access the bile duct with a small needle and manipulate a wire across the biliary orifice and into the duodenum to be then retrieved endoscopically for ERCP (rendezvous ERCP), or (2) using endoscopic-ultrasound technology to directly puncture and perform intended biliary therapy
88919874|NCT01678326|Active Comparator|Advanced ERCP Biliary Access Techniques|Advanced ERCP techniques involve the following: precut access sphincterotomy and needle-knife fistulotomy. These are accepted techniques for biliary access in cases of difficult cannulation.
88919875|NCT01678391|Experimental|Patients with common bile duct stones.|Common bile duct stone removal without fluoroscopy
89010879|NCT05897203|Other|Standard of care (SoC)|Participants in this arm will receive only the standard of care
89436642|NCT03164616|Active Comparator|Treatment Arm 3|SoC chemotherapy alone
89436643|NCT03158688|Active Comparator|Kd - Carfilzomib and Dexamethasone|"Carfilzomib was administered intravenously (IV) at 20 mg/m^2 in Cycle 1: days 1 and 2; at 56 mg/m^2 in Cycle 1: days 8, 9, 15 and 16. The 56 mg/m^2 dosage was continued in Cycles 2+ on days 1, 2, 8, 9, 15 and 16.~Dexamethasone was taken by IV infusion at 20 mg on Cycle 1, days 1 and 2 (in Cycles 2+, days 1 and 2 could be either oral or IV) and either orally or by IV infusion on days 8, 9, 15 and 16 and at 40 mg on day 22 of all 28-day cycles."
89536509|NCT02475161|Experimental|JNJ-42847922 Plus Rabeprazole|Participants will receive JNJ-42847922, 20 milligram (mg) on Day 1 and Day 6. Participants will receive rabeprazole 20 mg once daily from Day 2 to Day 6.
89536510|NCT03074097|Active Comparator|Rectus Sheath|Each patient received bilateral single shot ultrasound guided rectus sheath block under complete aseptic condition in a dose of 30 ml of bupivacaine 0.25% in each side immediately after induction of general anaesthesia
89536511|NCT03074097|No Intervention|Control|Control group: the patients did not receive any intervention after anaesthesia induction.
89536512|NCT02472587||Pap test|Women attending our institute in order to do Pap test
89536513|NCT04433481|Experimental|DABIGATRAN|150mg BD for 12 months
89536514|NCT04433481|Placebo Comparator|Placebo|Placebo
89536515|NCT04986111|Experimental|Linear skin closure with wound drain|Reduce fluid collection and dead space by inserting drain into the subcutaneous layer using the wound closure method previously used in the experimental center. The linear suture has a relatively quick time to stitch out.
88919876|NCT01678937||Control Group|"Ten Healthy individuals will have blood drawn (4 green top tubes(40 ml = 8 tsp.)) at one time point at Northwestern for control purposes. Blood will be drawn to conduct the following tests:~Dendritic cell assays: myeloid vs. lymphoid (CD11c; CD123); maturation and ability to process antigens (CD83; CD205); markers that have been shown to induce regulatory T cells (ILT3; ILT4).~Regulatory/Suppressor Cells (CD4+CD25+FOXP3+CD127low; and CD8+ CD28- FOXP3+CD127low cells), and~HLA microchimerism & HLA G."
88919877|NCT01678937||Monotherapy Group|"Monotherapy patients [cyclosporine (CyA) (10 patients), Tacrolimus (5 patients), mycophenolate mofetil (MMF) (10 patients), rapamycin (10 patients)]: Blood will be drawn at one time point (4 green top tubes (40 ml = 8 tsp.)) to conduct the following tests:~Dendritic cell assays: myeloid vs. lymphoid (CD11c; CD123); maturation and ability to process antigens (CD83; CD205); markers that have been shown to induce regulatory T cells (ILT3; ILT4).~Regulatory/Suppressor Cells (CD4+CD25+FOXP3+CD127low; and CD8+ CD28- FOXP3+CD127low cells), and~HLA microchimerism & HLA G."
88919878|NCT01678937||Conversion Group|Ten CNI monotherapy/dual therapy (CNI + MMF) patients pre-selected for conversion to rapamycin or wean to MMF monotherapy. Assays performed 2 weeks prior to conversion, 3-6 months following successful conversion. Liver function/drug levels monitored weekly during conversion until stable levels achieved. Patients converting from CNI monotherapy to rapamycin monotherapy (2-4 wks.): CNI discontinued when 2 therapeutic rapamycin levels (5-10) reached, graft function stable (clinical care protocol). MMF conversion: MMF dose slowly increased to 3 g/day (max.) while CNI therapy reduced by 1-2 mg/day (FK506) or 25-50 mg/day (CyA) monthly until CNI discontinued (1-6 months) (clinical care protocol). Monthly liver function/drug levels performed after successful conversion (standard of care).
88919879|NCT01679041|Experimental|Single Arm|Conditioning regimens with Alemtuzumab, Fludarabine, and Cyclophosphamide will be used for all patients.
88919880|NCT01679093|Active Comparator|ONDANSETRON (OS)|patients receiving ondansetron at the beginning of the surgery to prevent postoperative nausea and vomiting (PONV); and paracetamol at the end of the surgery for postoperative analgesia.
88919881|NCT01679093|Active Comparator|DROPERIDOL (DRO)|patients receiving droperidol at the beginning of the surgery to prevent PONV; and paracetamol at the end of the surgey for postoperative analgesia.
88919882|NCT01679093|Active Comparator|DEXAMETHASONE (DEXA)|patients receiving dexamethasone at the beginning of the surgery to prevent PONV; and paracetamol at the end of the surgey for postoperative analgesia.
88919883|NCT01679145||Alcohol- dependent patients|Detoxified alcohol- dependent patients in an inpatient setting
88919884|NCT01679145||Control group|Age- and gender matched healthy controls
88919885|NCT01679210|Experimental|Lifestyle Intervention|Stage-matched physical activity and diet intervention materials and health education.
88919886|NCT01679210|No Intervention|Health and Wellness|HW served as the comparison group and received the same number of in-person sessions, telephone calls, and mailings at the same time points as LI. Content was limited to general information available to the public from the ACOG and the American Academy of Pediatrics and did not mention exercise behavior change.
88919887|NCT01679418|Active Comparator|Drain placement (Group A)|Patients in group A received a wound drain after surgery.
88919888|NCT01679418|Sham Comparator|No-drain placement (group B)|Patients assigned to group B, did not receive a wound drain after surgery.
88919889|NCT01679431||Patients with aortic stenosis|"Patients have every year: 1) an assessment of cardiometabolic risk profile with measure of body mass index, waist circumference and fasting blood sample and 2) a comprehensive Doppler-echocardiography exam.~Computed tomography and magnetic resonance imaging are performed every 2 years."
88919890|NCT01679496|Experimental|Food items|Food items low in saturated fat and high in polyunsaturated fat
88919891|NCT01679496|Placebo Comparator|Control food items|Food items containing saturated fat and polyunsaturated fat according to a traditional Norwegian diet
88919892|NCT01679587|Experimental|Molidustat, 80 mg|Subjects received a single oral dose of 80 mg BAY 85-3934 in the first period and placebo in the second period, separated by a wash-out period of at least 1 week.
88919893|NCT01679587|Experimental|Molidustat, 120 mg|Subjects received a single oral dose of 120 mg BAY 85-3934 in the first period and placebo in the second period, separated by a wash-out period of at least 1 week.
89436644|NCT03158688|Experimental|KdD - Carfilzomib, Dexamethasone and Daratumumab|"Carfilzomib was administered intravenously (IV) at 20 mg/m^2 in Cycle 1: days 1 and 2; at 56 mg/m^2 in Cycle 1: days 8, 9, 15 and 16. The 56 mg/m^2 dosage was continued in Cycles 2+ on days 1, 2, 8, 9, 15 and 16.~Dexamethasone was taken by IV infusion at 20 mg on Cycle 1, days 1 and 2 (in Cycles 2+, days 1 and 2 could be either oral or IV) and either orally or by IV infusion on days 8, 9, 15 and 16 and at 40 mg on day 22 of all 28-day cycles. The administration of dexamethasone was given on carfilzomib and/or daratumumab IV infusion days.~Daratumumab was administered by IV at 8 mg/kg on Cycle 1: days 1 and 2; at 16 mg/kg on Cycle 1: days 8, 15 and 22, and Cycle 2: days 1, 8, 15, and 22. The 16 mg/kg dosage was continued on Cycles 3-6: days 1 and 15. The 16 mg/kg was further continued on Cycles 7+: day 1 only."
89436645|NCT03156023|Experimental|Rozibafusp Alfa|"Participants will receive rozibafusp alfa administered subcutaneously once every 2 weeks for up to 10 weeks (6 doses). Rozibafusp alfa doses will range from 70 to 420 mg.~Escalation to a higher dose cohort will be contingent on a review indicating that the previous dose regimen has been found to demonstrate an acceptable safety and tolerability profile at a dose level review meeting (DLRM)."
89436646|NCT03156023|Placebo Comparator|Placebo|Participants will receive matching placebo to rozibafusp alfa administered subcutaneously once every 2 weeks for up to 10 weeks (6 doses).
89436647|NCT03151707|Experimental|Nicotinamide riboside 2g/day|Participants will receive NR at a dose of 2g/day
89436648|NCT03130491|Other|TAVR + Embolic protection|subjects with severe native aortic valve stenosis who meet the commercially approved indications for transcatheter aortic valve replacement
88919894|NCT01679587|Experimental|Molidustat, 40 mg|Subjects received a single oral dose of 40 mg BAY 85-3934 in the first period and placebo in the second period, separated by a wash-out period of at least 1 week. This is an optional dose escalation step.
88919895|NCT01679587|Experimental|Molidustat, 160 mg|Subjects received a single oral dose of 160 mg BAY 85-3934 in the first period and placebo in the second period, separated by a wash-out period of at least 1 week. This is an optional dose escalation step.
88919896|NCT01679743|Experimental|A|Breast Cancer Cohort
88919897|NCT01679743|Experimental|B|Non-Small Cell Lung Cancer Cohort
88919898|NCT01679977|Active Comparator|Legpress|"Subjects in the LP group train on a custom built, computer controlled, linear electric motor powered leg press device. The so called swinging vibrational-proprioceptive mode is used, which means that constant velocity of the pedals (0.3 m/s and 0.2 m/s for concentric and eccentric phase, respectively) are interrupted by short stops (every 8 mm), resulting in short force peaks appearing throughout the movement. Training load is progressively increased throughout the training."
88919899|NCT01679977|Active Comparator|E-Stim|ES training is performed with a custom-built battery-powered stimulator. The subject are seated over the edge of the therapeutic table with the trunk upright and lower legs freely swinging. Two conductive rubber electrodes covered by wet sponge are placed on the anterior thigh on each side of the body. The electrode pairs are connected to the independent channels of the stimulator and the left and the right thigh are stimulated in an alternative manner. Each repetition (i.e. ES evoked muscle contraction) is evoked by a 3.5 s train (60 Hz) of electrical pulses (rectangular, biphasic, width 0.6 ms). Consecutive contractions of the same thigh are separated by 4.5 s off intervals. Maximal tolerable intensity should be used and is monitored during the training sessions. In all the subjects this should induce a tetanic contraction of the stimulated muscles.
88919900|NCT01679977|No Intervention|Control|This group only perform the same measurements as the intervention groups and lives their live as usual in between.
88919901|NCT01680094|Experimental|Panobinostat|20 mg panobinostat will be administered orally on days 1, 3, and 5 (TIW) every other week (QOW) for a period of 8 weeks while maintaining background HAART
88919902|NCT01680120|Experimental|Continuous spinal anaesthesia|
88919903|NCT01680198|Placebo Comparator|Placebo|Placebo capsules daily for 12 weeks.
88919904|NCT01680198|Experimental|Paracalcitol|"see Intervention description for details."
89010880|NCT05897112|Active Comparator|Group A received cryotherapy|Group A were subjected to weekly cryotherapy with a cotton stick dip ped in Liquid Nitrogen for 02 Freezes and Thaw Cycle of 07 seconds with each cycle 10 seconds apart for 3 weeks
89436649|NCT03127722|Experimental|ESSURE (BAY1454032)|Subjects selecting hysteroscopic sterilization who are not contraindicated for the Essure procedure according to the most current approved version of the Essure IFU. Subject willing to use alternative contraception for at least 3 months post-Essure placement procedure, until a satisfactory Essure Confirmation Test is documented.
89436650|NCT03127722|Active Comparator|Laparoscopic tubal sterilization|Subjects selecting laparoscopic sterilization who are not contraindicated for laparoscopic tubal sterilization according to common clinical practice standard of care
89436651|NCT03117751|Experimental|B-ALL and B-LLy, Low-risk|"Patients with low-risk B ALL and LLy will have Induction (6 weeks), Consolidation (8 weeks), and Continuation (120 weeks). During Remission Induction therapy, prednisone dose is 40mg/m^2 and 1-2 doses of daunorubicin (based on day 8 peripheral blood MRD in patients with ETV6-RUNX1 or hyperdiploid) are given. Dasatinib is given for patients with ABL-class fusion. Blinatumomab will be given to patients with certain genetic subtypes and those with Down syndrome.~Interventions: Prednisone, vincristine, daunorubicin, pegaspargase (or Erwinase®, Rylaze™ or Calaspargase pegol), cyclophosphamide, cytarabine, mercaptopurine, dasatinib, thioguanine, methotrexate, dexamethasone, blinatumomab."
89536516|NCT04986111|Active Comparator|Purse-string skin closure with negative pressure wound therapy|Close the wound with a purse-string suture which is better in terms of surgical site infection but known to take a long time for wound healing, and use negative pressure wound therapy to help granulation of tissues and help healing.
89010881|NCT05897112|Active Comparator|Group B received 10% Potassium Hydroxide Solution|Group B applied 10% Potassium Hydroxide solution twice daily with the help of a cotton tip applicator until lesion showed signs of inflammation or clearance for 3 weeks
89010882|NCT05897060|Experimental|Patients undergoing TAVI procedure|The study is interventional and consists of a single group of patients undergoing a Transcatheter Aortic Valve Implantation (TAVI), receiving in addition to the usual treatment, an optical fiber placed retrograde in the jugular bulb, in order to record the values of SJVO2 every second.
89010883|NCT05897047|Experimental|"Intervention group Additional telemedical management"|Patients in the interventional arm will receive a predefined additional telemedical management including regular telemedicine visits and automatic data transfer (e.g. vital signs, well-being, medication plan laboratory data and chat) between the patient at home and KTC through a certified smartphone application.
89010884|NCT05897047|No Intervention|"Control group Routine posttransplant aftercare"|Patients in the control group will receive routine posttransplant aftercare.
89010885|NCT05896982|No Intervention|Care as usual|Patients in this group will not receive any additional information materials or support on top of care as usual, but information videos will be made available after completion of the MPI procedures.
89536517|NCT02472431|Experimental|ADRC injection|
89536518|NCT03070821|Experimental|Healthy elderly experimental group|Feedback of the parahippocampal gyrus using rtfMRI neurofeedback training (using 3T MRI).
89536519|NCT03070821|Experimental|Patient group|Feedback of the parahippocampal gyrus using rtfMRI neurofeedback training (using 3T MRI).
89010886|NCT05896982|Experimental|Care as usual with information support|Patients in this group will primarily receive additional information on the diagnostic process that they will go through with the use of video materials. Supportive coaching will not be provided in this group.
89536520|NCT03070821|Sham Comparator|Healthy elderly sham-feedback group|Feedback of the postcentral gyrus using rtfMRI neurofeedback training (using 3T MRI).
89536521|NCT02475083|Experimental|Virtual Reality Group|Rehabilitation with virtual reality using games with balance training goal.
88819468|NCT04932369|Experimental|ER GROUP|The training sessions were based on the Dialectical Behavior Therapy Skills (Linehan, 2015). Each group received eight 90-min sessions of the emotion regulation training (one session per week) carried out by qualified clinical psychologist. The training includes group gathering, homework and telephone consultation as needed.
88819469|NCT04932369|No Intervention|Control group|They completed two assessments, 3-months apart
88819470|NCT03996057|Experimental|Methenamine augmentation|2g methenamine hippurate twice daily for 90 days added to a baseline regimen of low dose vaginal estrogen (two to three times per week) and d-mannose (1000 mg twice daily)
88819471|NCT03996057|Active Comparator|No methenamine augmentation|Baseline regimen of low dose vaginal estrogen (two to three times per week) and d-mannose (1000 mg twice daily)
88819472|NCT04338243|Experimental|Glumetinib+Osimertinib|The investigational product Glumetinib will be orally administrated when fasting at dose level of 300mg QD and Osimertinib will be orally administrated when fasting at dose level of 80mg QD
88819473|NCT03966729||HFrEF|"HFrEF (Heart failure with reduced ejection fraction): ESC Guideline heart failure 2016: patients with LVEF < 40%.~LVEF = Left ventricular ejection fraction"
88819474|NCT03966729||HFmrEF|"HFmrEF (Heart failure with mid-range reduced ejection fraction): ESC Guideline heart failure 2016: patients with LVEF 40-49%.~LVEF = Left ventricular ejection fraction"
88819475|NCT03966729||HFpEF|"HFmrEF (Heart failure with preserved ejection fraction): ESC Guideline heart failure 2016: patients with LVEF > 50%.~LVEF = Left ventricular ejection fraction"
88819476|NCT04910919|Active Comparator|Standard of Care|The first 50 participants will receive treatment as usual (alternating weight-based dosing of acetaminophen and ibuprofen with a PRN three-day supply of opioid analgesic).
88819477|NCT04910919|Experimental|Honey Intervention|Participants 51 - 100 will receive the standard of care treatment as usual plus 1 tsp of honey with every dose of acetaminophen.
88819478|NCT03150875|Experimental|IBI308|injection; dosage form: 10ml:100mg; frequency: 200mgQ3W; duration: randomization to the date of the first documented tumor progression per RECIST v1.1 criteria
88819479|NCT03150875|Active Comparator|docetaxel|injection; dosage form: 1ml:40mg; Frequency: 75mg/m2 Q3W; duration: randomization to the date of the first documented tumor progression per RECIST v1.1 criteria
88819480|NCT00552071|Experimental|Ultrasound-guided IM injections of octreotide LAR|Subjects received octreotide LAR 30 mg injection via ultrasound-guided IM gluteal injection every 28 days for 3 months.
88819481|NCT00552071|Active Comparator|Regular IM injections of octreotide LAR|Subjects received octreotide LAR 30 mg injection via regular IM gluteal injections every 28 days for 3 months
88819482|NCT02988557|Experimental|Treadmill|
88819483|NCT04880889|Experimental|BL 3000 (active) and Pantogar matching Placebo|One capsule, once a day for 180 days for BL3000 and one capsule three times a day for Pantogar-Placebo.
88819484|NCT04880889|Active Comparator|Pantogar and BL3000 matching placebo|One capsule, three times a day for 180 days
88819485|NCT04738383|Experimental|Version 1: Paramedic|Physician is replaced by a paramedic, but the physician still acts as a supervisor.
88819486|NCT04738383|Experimental|Version 2: Physician-on-call|Physician is not present, but is on call.
88819487|NCT04738383|Experimental|Version 3: Trained instructor|Physician acts as a supervisor, but is not constantly present. The instructor received a special training preparing for emergency cases.
88819488|NCT04738383|No Intervention|Control group|The sessions take place in the usual way, meaning that a physician is present in every session.
88819489|NCT03833427|Experimental|Selumetinib at Dose Level 1 + Pembrolizumab|Participants receive 200 mg pembrolizumab (IV infusion; every three weeks [Q3W]) in combination with selumetinib at dose level 1 (dosed orally; twice daily [BID]) for up to 35 treatment cycles (cycle length: 3 weeks). During each 3-week cycle, selumetinib will be administered only for the first two weeks.
88819490|NCT03833427|Experimental|Selumetinib at Dose Level 2 + Pembrolizumab|Participants receive 200 mg pembrolizumab (IV infusion; Q3W) in combination with selumetinib at dose level 2 (dosed orally; BID) for up to 35 treatment cycles (cycle length: 3 weeks). During each 3-week cycle, selumetinib will be administered only for the first two weeks.
88819491|NCT03833427|Experimental|Selumetinib at Dose Level 3 + Pembrolizumab|Participants receive 200 mg pembrolizumab (IV infusion; Q3W) in combination with selumetinib at dose level 3 (dosed orally; BID) for up to 35 treatment cycles (cycle length: 3 weeks). During each 3-week cycle, selumetinib will be administered only for the first two weeks.
88919905|NCT01680224|Active Comparator|Healthy Weight|The main goal of the Healthy Weight intervention is to make small, sustainable changes to input and output on a weekly basis to achieve a balance between caloric intake and output. All sessions begin with a brief review of what was covered in the previous session, presentation of educational handouts, careful review of previous behavior change goals, and the development of healthy behavior change plans for the next session. Home exercises for all sessions consist of following individualized diet and exercise goals, and keeping a food and exercise log to determine areas for future healthy changes.
88919906|NCT01680224|Experimental|Project Health|Project Health adds dissonance-inducing activities, discussions, and homework activities to the Healthy Weight basic intervention. Each session begins with a verbal commitment to participate (to underscore the voluntary nature of participation), includes discussions of completed home practice assignments and in-session writing/sharing exercises (to create accountability), and concludes with home exercises (to increase level of effort). Completed home assignments are videotaped in subsequent sessions to increase accountability.
88919907|NCT01680224|Placebo Comparator|Control|"Some participants will be randomized to control condition whereby they will be given an psychoeducational video (Weight of the World)to view."
88919908|NCT01680289|Experimental|Three adhesive coats|Consecutive application of three one-bottle adhesive coats
88919909|NCT01680289|Active Comparator|Two adhesive coats|Consecutive application of two one-bottle adhesive coats
88919910|NCT01680315|Experimental|Calorie information|"Low calorie yogurt~High calorie yogurt~with low calorie information sheet"
88919911|NCT01680315|Experimental|Calorie information (high)|"Low calorie yogurt~High calorie yogurt~High calorie information sheet"
88919912|NCT05597111||Blood DHA levels of patients with PCOS|The patients diagnosed as PCOS according to Rotterdam criteria will be the study group. The DHA leves in blood sample of the patients will be recorded
88919913|NCT05597111||BloodDHA levels of the control group|The patients without PCOS will be control group. The DHA leves in blood sample of the patients will be recorded
89536522|NCT02475083|Active Comparator|Conventional Group|Conventional physiotherapy with exercises for balance training.
89536523|NCT03074019|Experimental|Xylooligosaccharide (Low Dose)|1.5g XOS95 + 1.5g Maltodextrin powder, taken orally mixed in water, once daily
89536524|NCT03074019|Experimental|Xylooligosaccharide (High Dose)|3g XOS95 powder, taken orally mixed in water, once daily
89536525|NCT03074019|Placebo Comparator|Placebo|3g maltodextrin powder, taken orally mixed in water, once daily
89536526|NCT02475239|Experimental|Postural restriction|The patients were instructed to avoid head movements, wear a soft collar during the daytime, wear a supporting pillow and sleep in the semi-upright position at a 45 degree head elevation from the horizontal plane during the nighttime for 48 hours.
88919914|NCT05597072|Experimental|Intervention|In the evening before an elective surgery the sterile surgical goods will be prepared under calm circumstances with only 2 persons in the OR (intervention). Thereafter, the sterile goods will be protected with sterile covers and time pending surgery will be approximately 12 hours (intervention).
88919915|NCT05597072|Active Comparator|Control|The control is to prepare the sterile goods in the morning with more people in the OR (approximately 4-5 persons).
88919916|NCT05596981||sorafenib group|FLT3-ITD+ AML patients who receive sorafenib maintenance therapy after Allo-HSCT. Sorafenib will be used from day 30 to 180 post-transplantation. The initial dose of sorafenib is 400 mg orally twice daily and is adjusted in case of suspected toxicity or resistance (dose range, 200-800 mg daily).
88919917|NCT05596981||non-sorafenib group|FLT3-ITD+ AML patients who do not receive sorafenib maintenance therapy after Allo-HSCT.
88919918|NCT05596968||sorafenib group|FLT3-ITD+ AML patients who receive sorafenib maintenance therapy after allo-HSCT. Sorafenib will be used from day 30 to 180 post-transplantation. The initial dose of sorafenib is 400 mg orally twice daily and is adjusted in case of suspected toxicity or resistance (dose range, 200-800 mg daily).
88919919|NCT05596942|Experimental|Albumin Chana Striata Extract|
88919920|NCT05596942|Active Comparator|Human Albumin|
88919921|NCT05596890|Experimental|Neoadjuvant immunochemotherapy +/- short-term radiotherapy|Tislelizumab + cisplatin/carboplatin + albumin-bounded paclitaxel +/- radiotherapy
88919922|NCT05596864||Experimental group|Patients with gastric cancer underwent contrast-enhanced CT scan and gastric filling ultrasound, respectively.
88919923|NCT05596812|Experimental|Intervention (Risk Stratification Pathway)|"Those randomized to Intervention (Risk Stratification Pathway) will have their demographic and clinical data entered into the risk stratification screening calculator, and will be assigned to either Low Risk (Novel (Low Impact) Care Pathway) or High Risk (Routine Care Pathway) groups.~Women in the Routine Care Pathway group will be followed in the DIP clinic according to routine care protocols and will provide bi-weekly glucometer data.~Women in the Novel (Low Impact) Care Pathway group will be followed in the New Care Pathway, which will include continuation of lifestyle and dietary modification, continuation of capillary self blood glucose monitoring, and routine prenatal care."
88919924|NCT05596812|No Intervention|Control (Routine Care)|Those randomized to Control (Routine Care) will continue in-person and virtual visits as per routine care protocols. This group will also provide bi-weekly glucometer data.
88919925|NCT05596669|Active Comparator|Effect of Ketamine on Postoperative Morphine Consumption|cases in Group I received infusion of 0.15 mg/kg/h for the duration. Following a parenteral bolus dose of magnesium and ketamine (0.3mg/kg),
88919926|NCT05596669|Active Comparator|Effect of Ketamine Magnesium on Postoperative Morphine Consumption|cases in Group II received Ketamine Magnesium group were given a continuous infusion of (0.15mg/kg/h) of ketamine and (10mg/kg/h) of magnesium
88919927|NCT05596643||Patients diagnosed with Familial Mediterranean Fever|
88919928|NCT05596643||Healthy Controls|
88919929|NCT05596617|No Intervention|Standard of Care|Standard of care management of severe Covid-19 patients
89536527|NCT02475239|Active Comparator|Normal daily activity|The patients did not follow any postural restrictions and were asked to live as normally as possible.
88919930|NCT05596617|Experimental|Oral bedtime melatonin|Standard of care with oral bedtime melatonin
88919931|NCT05596565|Experimental|Experimental group 1|Supervised Exercise by a physiotherapist via face to face Participants in this group will be included in an exercise program for 6 weeks, 2 days a week and 45 minutes each session with supervised by a physiotherapist via face to face. The exercises will focus on breathing exercises, passive range of motion exercises and strengthening exercises.
88919932|NCT05596565|Experimental|Experimental group 2|Supervised Exercise by a physiotherapist via video conference Participants in this group will be included in an exercise program for 6 weeks, 2 days a week and 45 minutes each session with supervised by a physiotherapist via video conference. The exercises will focus on breathing exercises, passive range of motion exercises and strengthening exercises.
88919933|NCT05596565|No Intervention|Control group|No Intervention: Control group: Unsupervised exercise Home based exercises will be explained to the patients and they will be asked to perform these exercises 2 days a week for 6 weeks.
88919934|NCT05596552|Active Comparator|Bupivacaine-Dexmedetomidine group|
89198617|NCT00384397|Experimental|Group 3: Menactra® + PCV|Participants will receive Menactra® at age 9 months followed by Menactra® and Pneumococcal Conjugate (PCV) vaccines at Age 12 Months
88919935|NCT05596552|Active Comparator|Bupivacaine-Fentanyl group|
88919936|NCT05596526|Experimental|MS patients on anti-CD20|Participants aged 18 and above will receive two doses of the recombinant Zoster vaccine (Shingrix®)
88919937|NCT05596526|Experimental|Healthy controls|Healthy participants aged 50 to 59 will receive two doses of the recombinant Zoster vaccine (Shingrix®)
88919938|NCT05596500|Experimental|Blueberry-protein gel|Blueberry polyphenols (1 cup fresh blueberries equivalent) from extract with 20 grams rice-pea protein in a gel.
88919939|NCT05596500|Active Comparator|Blueberry gel|Blueberry polyphenols (1 cup fresh blueberries equivalent) from extract in a gel.
88919940|NCT05596500|Placebo Comparator|Placebo|All proximate matched ingredients except for the blueberry polyphenols and plant protein.
88919941|NCT05596487|Experimental|experimental: repetitive standardized patient simulation|In the study, an end-of-life care nursing education program was applied to all students. In the second stage, the standard patient-based practice was performed once with the control group nursing students and twice with the intervention group students.
88919942|NCT05596487|No Intervention|control grup|
89536528|NCT04988607|Experimental|osimertinib plus bevacizumab|Osimertinib 80 mg (QD) in combination with Bevacizumab (15 mg/kg) (Q3W)
89536529|NCT04988607|Active Comparator|osimertinib|All patients randomized into this will only receive Osimertinib 80mg (QD)
89010887|NCT05896982|Experimental|Care as usual with supportive coaching|Patients in this group will receive supportive coaching throughout their clinic visit. The coach is available for questions as well as specific support for each patient. Information support using video materials will not be supplied to the patients during the diagnostic process in this group, but will be made available after completion of the MPI procedures.
89010888|NCT05896982|Experimental|Care as usual with information support and supportive coaching|Patients in this group will receive both information support as well as supportive coaching during their diagnostic clinic visit.
89010889|NCT05896956||Patients with benign or malignant tumors of the biliary system|Patients enrolled should be clinically diagnosed with benign or malignant tumors of the biliary system, including unoperated patients with preliminary diagnosis of benign or malignant tumors of the biliary tract based on imaging examinations and laboratory test results, or pathological examination of patients treated with surgery confirmed as benign and malignant tumors of the gallbladder; The primary tumor is located in the extrahepatic bile ducts, intrahepatic bile ducts, gallbladder floor, gallbladder body, gallbladder neck, or gallbladder duct.
89010890|NCT05896930|Experimental|Group 1 Arm 1|Meropenem 6g IV over 6 hours plus amoxicillin/CA
89010891|NCT05896930|Experimental|Group 1 Arm 2|Ertapenem 1g IM plus amoxicillin/CA
89536530|NCT04995471|Experimental|In presence RRT - prototype software|10 biweekly in presence sessions of 45 minutes supervised by a trainer
89010892|NCT05896930|Experimental|Group 2 Arm 1|Meropenem 3g over 1 hour twice daily plus amoxicillin/CA
89010893|NCT05896930|Experimental|Group 2 Arm 2|Ertapenem 1g IV plus amoxicillin/CA
89010894|NCT05896930|Experimental|Group 2 Arm 3|Amoxicillin; CA
89010895|NCT05896930|Experimental|Group 2 Arm 4|Rifampicin 35mg/kg plus amoxicillin/CA
89010896|NCT05896930|Experimental|Group 2 Arm 5|Meropenem 6g or 4g IV over 60 minutes plus amoxicillin/CA
89010897|NCT05896930|Active Comparator|Group 1|Rifafour e-275
89010898|NCT05896904|Experimental|Echocardiography|
89010899|NCT05896852|Experimental|Intervention Arm|Participants will increase their physical activity over 6 months as tolerated,
89010900|NCT05896826|Other|healthy volunteers|
89010901|NCT05896826|Experimental|chest pain patients who will receive ECG, biomarkers, or non-invasive imaging examination|
89010902|NCT05896813|Experimental|CMOP+Chi|Cyclophosphamide: 750 mg/m2, d1; Mitoxantrone Hydrochloride Liposome: 20 mg/m2, d1; Vincristine: 1.4 g/m2, d1 (maximum dose of 2 mg), or vindesine 3 mg/m2, d1; Prednisone: 60 mg/m2, d1-d5; Chidamide:20 mg, biw. The treatment is administered every 3 weeks as a cycle and lasts for a total of 6 cycles.
89010903|NCT05896787|Experimental|AK104 plus nab-paclitaxel and carboplatin|"In the induction period, AK104 (10mg/kg, iv, Q2W) is given for one cycle;~and then AK104 (10mg/kg, iv, Q3W) is combined with nab-paclitaxel (130mg/m2 ivgtt d1，d8, Q3W) and carboplatin ((AUC=5) d1，Q3W) for 2 cycles;~After R0 surgery, AK104 (10mg/kg, iv, Q3W) is given as adjuvant therapy for up to 12 months for those who do not achieve pCR."
89010904|NCT05896722||Study group|27 young adults aged 17-26 who scored 4 or more according to the Beighton scoring
89010905|NCT05896722||Control group|27 young adults aged 17-26 who scored less than 4 points according to the Beighton scoring
89010906|NCT05896631|Active Comparator|7.5 mg hyperbaric bupivacaine|Patients undergoing spinal anesthesia in the lateral decubitus position with 7.5 mg of hyperbaric bupivacaine will be included.
89010907|NCT05896631|Active Comparator|5 mg hyperbaric bupivacaine|Patients undergoing spinal anesthesia in the lateral decubitus position with 5 mg of hyperbaric bupivacaine will be included.
89010908|NCT05896605|Active Comparator|1 month after AZA treatment|Before medication, TPMT activity was normal, and azathioprine was started at small doses and added every two weeks after no adverse effects, namely 50 mg qd for two weeks, 50mg bid for two weeks, and maintained at 50mg tid. Low-dose hormone therapy was administered to all patients simultaneously.Blood (5ml) was collected from peripheral veins in 1 month after AZA treatment.
89010909|NCT05896605|Active Comparator|6 months after AZA treatment|Before medication, TPMT activity was normal, and azathioprine was started at small doses and added every two weeks after no adverse effects, namely 50 mg qd for two weeks, 50mg bid for two weeks, and maintained at 50mg tid. Low-dose hormone therapy was administered to all patients simultaneously.Blood (5ml) was collected from peripheral veins in 6 months after AZA treatment.
89010910|NCT05896605|Active Comparator|over 1 year after AZA treatment|Before medication, TPMT activity was normal, and azathioprine was started at small doses and added every two weeks after no adverse effects, namely 50 mg qd for two weeks, 50mg bid for two weeks, and maintained at 50mg tid. Low-dose hormone therapy was administered to all patients simultaneously.Blood (5ml) was collected from peripheral veins over 1 year after AZA treatment.
89010911|NCT05896605|No Intervention|healthy control|Ten healthy volunteers with physical examination in our hospital were selected as the healthy control (HC) group. Serum samples from healthy controls were collected.
89010912|NCT05896553|Experimental|Oxytoxin group|Drug: intranasal Oxytocin(24IU)
89010913|NCT05896553|Placebo Comparator|Placebo group|Drug: intranasal Placebo
89010914|NCT05896540|Experimental|STUDY GROUP ENFOCATE|The selected students will be randomly divided into the study and control groups; the intervention will take place in the same schools that the students attend. The assignment to groups will use simple random sampling, performed in two stages. In the first stage the available schools will be randomly assigned to the study and control groups, while the second stage will select randomly the groups in each school that will participate in the study. The study groups will receive a 10-session intervention in sexual education, covering topics related to preventive sexual conduct, gender equity and mental health.
89198618|NCT00877305|Active Comparator|RIPC|Remote Ischemic Preconditioning
89536531|NCT04995471|Experimental|In presence RRT - online platform|10 biweekly in presence sessions of 45 minutes supervised by a trainer
88919943|NCT05596448|Active Comparator|Cocygeal nerve radiofrequency ablation group|During the procedure, after imaging the sacral and coccygeal corns with ultrasonography, a radiofrequency ablation needle is inserted at the level of the coccygeal horn and radiofrequency ablation is applied at 90 degrees for 60 seconds.
88919944|NCT05596448|No Intervention|Conservative treatment group|This group includes patients receiving conservative treatment such as nonsteroidal anti-inflammatory group drugs, physical therapy, and exercise for coccygeal pain.
88919945|NCT05596435||Stage I-III pancreatic cancer|Cell-free DNA collected from plasma samples of 260 patients with stage I-III pancreatic cancer will undergo whole-genome sequencing
88919946|NCT05596435||Pancreatic disease|Cell-free DNA collected from plasma samples of 80 patients with pancreatic benign disease will undergo whole-genome sequencing
88919947|NCT05596435||Healthy controls|Cell-free DNA collected from plasma samples of 100 non-cancer individuals will serve as controls
88919948|NCT05596396|Experimental|LifeHack|Participants assigned to this arm will receive a 6-week guided e-health intervention to increase positive mental health and well-being.
88919949|NCT05596396|Active Comparator|LifeHack-C|Participants assigned to this arm will receive the same intervention, delivered over 2 to 6 weeks.
88919950|NCT05596305|Experimental|undergraduate medical students|an educational anti-stigma intervention delivered to undergraduate medical students comparing the outcomes of the study before and after the intervention at two time intervals
88919951|NCT05596279|Experimental|Intravascular ultrasound|Hybrid IVUS-OCT and control IVUS were performed after stenting
88919952|NCT05596279|Experimental|Optical coherence tomography|Hybrid IVUS-OCT and control OCT were performed after stenting
88919953|NCT05596266|Experimental|CD5 CAR-T|This cohort will be administrated with T cells transduced with lentivirus vectors expressing CD5 CAR.
88919954|NCT05596227|Placebo Comparator|control group|Patients will not recieve either erector spinae plane block nor thoracolumbar interfascial plane block
88919955|NCT05596227|Active Comparator|Erector spinae plane block|Patients will recieve ultrasound guided erector spinae plane block.
89536532|NCT04995471|Experimental|Tele-RRT - prototype software|10 biweekly telerehabilitation sessions of 45 minutes supervised by a trainer
89536533|NCT04995471|Experimental|Tele-RRT - online platform|10 biweekly telerehabilitation sessions of 45 minutes supervised by a trainer
88919956|NCT05596227|Active Comparator|Thoracolumbar interfascial plane block|Patients will recieve ultrasound guided thoracolumbar interfascial plane block.
89198619|NCT00877305|Placebo Comparator|CONTROL|Control
88919957|NCT05596149|Active Comparator|Toothpaste without fluoride|A group of participants that will be using toothpaste without fluoride.
88919958|NCT05596149|Experimental|Toothpaste with sodium fluoride|A group of participants that will be using toothpaste with sodium fluoride.
88919959|NCT05596149|Experimental|Toothpaste with sodium monofluorophosphate|A group of participants that will be using toothpaste with sodium monofluorophosphate.
88919960|NCT05596149|Experimental|Toothpaste with amine fluoride|A group of participants that will be using toothpaste with amine fluoride.
88919961|NCT05596097|Experimental|experimental group|According to the initial treatment plan of the patients, the patients were divided into R-CHOP and R-chemo groups. Both groups received zanubrutinib 160 mg bid p.o. d1-28 maintenance treatment for 12 months after induction and consolidation therapy reached the maximum efficacy.
88919962|NCT05596071|Experimental|Sufentanyl+Epidural analgesia|Combined use of sufentanil and ropivacaine for intraoperative and postoperative analgesia
88919963|NCT05596071|Sham Comparator|Epidural analgesia|Only use of ropivacaine for intraoperative and postoperative analgesia
88919964|NCT05595928||Supine|supine
88919965|NCT05595928||15° left-lateral tilt position|15° left-lateral tilt position.
88919966|NCT05595928||30° left-lateral tilt position.|30° left-lateral tilt position.
88919967|NCT05595824|Experimental|JCBC00101 (Molnupiravir, Esperavir)|Group 1 (n=120) received the study drug JCBC00101, capsules 800 mg, 2 times a day with 12 ±2 hours interval for 5 days in the setting of pathogenetic and symptomatic therapy provided by Interim Guidelines for the prevention, diagnosis and treatment of COVID-19 approved by the Russian Ministry of Health (version 14, December 27, 2021) or valid as of the time of the study
89010915|NCT05896540|No Intervention|CONTROL GROUP|The control groups will not receive intervention; they will continue with the sexual orientation that each school provides to its students.
89198620|NCT04039659|No Intervention|Control Group|Patients will be cured with dressings wound everyday or before if there are complications in surgical incisions.
89198621|NCT04039659|Active Comparator|PICO group|Patients will carry the device for 7 days uninterrupted until its withdrawal.
89198622|NCT02715388|Experimental|Silicon oil removal 3D visualization|
89198623|NCT05119894|Experimental|Brexpiprazole LAI: Dose 1|
89198624|NCT05119894|Experimental|Brexpiprazole LAI: Dose 2|
89198625|NCT05119894|Experimental|Brexpiprazole LAI: Dose 3|
89198626|NCT05119894|Experimental|Brexpiprazole LAI: Dose 4|
89198627|NCT00877539|Experimental|PF-03526299|
89198628|NCT00877539|Placebo Comparator|Placebo|
89536534|NCT04995471|No Intervention|No intervention|5 weeks no intervention period
89536535|NCT02475317|Placebo Comparator|Placebo|Participants will receive placebo matched to maralixibat 10 milligram (mg), 20 mg, 50 mg once daily (QD), 50 mg twice daily (BID), 100 mg liquid formulation and volixibat 10 mg, 20 mg capsule orally for 7 days.
89536536|NCT02475317|Experimental|Maralixibat 10mg|Participants will receive maralixibat 10 mg liquid formulation orally QD for 7 days.
89536537|NCT02475317|Experimental|Volixibat 10mg|Participants will receive volixibat 10 mg capsule orally QD for 7 days.
89536538|NCT02475317|Experimental|Maralixibat 20mg|Participants will receive maralixibat 20 mg liquid formulation orally QD for 7 days.
89536539|NCT02475317|Experimental|Volixibat 20mg|Participants will receive volixibat 20 mg capsule orally QD for 7 days.
89436652|NCT03117751|Experimental|B-ALL and B-LLy, Standard-risk|"Induction (6wks), Early Intensification (4wks), Consolidation (8wks) and Continuation (120 wks). Remission Induction: Prednisone dose is 40mg/m^2 and 2 doses daunorubicin are given. Dasatinib: given for patients with Ph+ and those with ABL-class fusion. Ruxolitinib: given for patients with activation of JAK-STAT signaling; ALL patients with Day 15 or Day 22 MRD ≥5%, LLy patients who don't qualify for complete response at end of Remission Induction and all patients with ETP and T/M MPAL. Bortezomib is given to patients without targetable lesions and Day 15 or Day 22 MRD >5%. Blinatumomab will be given to patients with residual disease at the end of induction (≥0.01% and <1%), certain genetic subtypes and Down syndrome.~Interventions: prednisone, vincristine, daunorubicin, pegaspargase (or Erwinase®, Rylaze™ or Calaspargase pegol), cyclophosphamide, cytarabine, mercaptopurine, dasatinib, bortezomib, ruxolitinib, blinatumomab, thioguanine, methotrexate, dexamethasone, doxorubicin"
89436653|NCT03117751|Experimental|B-ALL and B-LLy, High-risk|"Induction (6 weeks), Early Intensification (4 weeks), Consolidation (8 weeks), and Immunotherapy (chimeric antigen receptor [CAR] T cells). Patients who do not respond to Immunotherapy will receive Reintensification therapy. During Remission Induction therapy, prednisone dose is 40mg/m^2 and 2 doses of daunorubicin are given. Dasatinib, ruxolitinib, and bortezomib are given as done for patients with standard-risk B-ALL but are discontinued in Immunotherapy and Reintensification therapy. Blinatumomab will be given to patients who are not able to receive CAR T cell therapy and patients with certain genetic subtypes and those with Down syndrome.~Interventions: prednisone, vincristine, daunorubicin, pegaspargase (or Erwinase®, Rylaze™ or Calaspargase pegol), cyclophosphamide, cytarabine, mercaptopurine, dasatinib, bortezomib, ruxolitinib, blinatumomab, etoposide, dexamethasone, clofarabine, thioguanine, methotrexate."
89536540|NCT02475317|Experimental|Maralixibat 50mg|Participants will receive maralixibat 50 mg liquid formulation orally QD for 7 days.
89536541|NCT02475317|Experimental|Maralixibat 50mg BID|Participants will receive maralixibat 50 mg liquid formulation orally BID for 7 days.
89010916|NCT05896488||Cystic fibrosis|No intervention - only assessments
89010917|NCT05896488||Healthy Control|No intervention- only assessments
89198629|NCT00877539|Active Comparator|Fluticasone propionate|
89198630|NCT04039737|Experimental|Treatment Group|Take Qingpeng ointment (produced by Tibet Qizheng Tibetan Medicine Co., Ltd.) and apply it evenly on the shoulder joints, wrist joints and palms of the upper limbs. Press for 20 minutes and have rehabilitation training afer 10 minutes.
89198631|NCT04039737|No Intervention|Control Group|
89198632|NCT00872157|Experimental|BMTP-11|Starting Dose of 6 mg/m2 by vein over 2 hours on Days 1, 8, 15, and 22.
89198633|NCT00872235|Experimental|1|fixed-dose combination of quinapril 20 mg and hydrochlorothiazide 25 mg tablets of OHM Laboratories Inc.(division of Ranbaxy Laboratories Limited)
89198634|NCT00872235|Active Comparator|2|Accuretic tablets (fixed dose combination of quinapril 20 mg and hydrochlorothiazide 25 mg)
89198635|NCT00872235|Experimental|3|fixed-dose combination of quinapril 20 mg and hydrochlorothiazide 25 mg tablets of OHM Laboratories Inc.(division of Ranbaxy Laboratories Limited)
89198636|NCT00872235|Active Comparator|4|Accuretic tablets (fixed dose combination of quinapril 20 mg and hydrochlorothiazide 25 mg)
89198637|NCT00872313||1|Psychoses within the first 3 months postpartum
89198638|NCT00872313||2|Psychoses > 3 months to 6 months postpartum
89198639|NCT00877617||QOL Questionnaire|
89198640|NCT00877695|Experimental|Motive8 2 Change FtF|This arm of the motivational enhancement intervention (MEI) will be delivered face to face (FtF) using a real-time, dynamic implementation approach. The intervention consisted of 2 sessions lasting approximately 60 to 90 minutes. The sessions focused on increasing participants' awareness of the multiple influences on behaviors from self, family, culture and community and how these influences impact the way we think and behave including sexually. Through a series of exercises the participant develops strategies for understanding and managing his own triggers that helps them to make healthy life choices. Both Motiv8 2Change arms used the exact same intervention, with the exception that one was delivered face to face and the other through the internet.
88819492|NCT03833427|Experimental|Selumetinib at Dose Level 4 + Pembrolizumab|Participants receive 200 mg pembrolizumab (IV infusion; Q3W) in combination with selumetinib at dose level 4 (dosed orally; BID) for up to 35 treatment cycles (cycle length: 3 weeks). During each 3-week cycle, selumetinib will be administered only for the first two weeks.
88819493|NCT03833427|Experimental|Selumetinib at Dose Level 5 + Pembrolizumab|Participants receive 200 mg pembrolizumab (IV infusion; Q3W) in combination with selumetinib at dose level 5 (dosed orally; BID) for up to 35 treatment cycles (cycle length: 3 weeks). During each 3-week cycle, selumetinib will be administered only for the first two weeks.
89010918|NCT05896462|Active Comparator|Povidone iodine (PI) group|10% povidone iodine-soaked gauze dressing was used to cover the apposed skin edge.
89536542|NCT02475317|Experimental|Maralixibat 100mg|Participants will receive maralixibat 100 mg liquid formulation orally QD for 7 days.
89010919|NCT05896462|No Intervention|Control (C) group|The apposed skin edge covered with dry sterile gauze
89010920|NCT05896449|Experimental|PET/CT before surgery|[68Ga]Ga-PSMA-11 PET/CT before surgery
89010921|NCT05896345|Active Comparator|SWL|Shockwave Lithotripsy (SWL)
89198641|NCT00877695|Experimental|Motive8 2Change -Internet|This arm of the motivational enhancement intervention (MEI) will be delivered via the Internet face to face (FtF) using a real-time, dynamic implementation approach.The intervention consisted of 2 sessions lasting approximately 60 to 90 minutes. The sessions focused on increasing participants' awareness of the multiple influences on behaviors from self, family, culture and community and how these influences impact the way we think and behave including sexually. Through a series of exercises the participant develops strategies for understanding and managing his own triggers that helps them to make healthy life choices. Both Motiv8 2Change arms used the exact same intervention, with the exception that one was delivered face to face and the other through the internet.
89198642|NCT00877695|No Intervention|delayed|
89198643|NCT00877695|Active Comparator|Motiv8 2Change Careers|Comparable in number of sessions and duration to the experimental arms, but focused on resume development and interviewing skills. This arm consisted of 2 sessions. In the first session participants reviewed different career choices and created a winning resume. The second session focused on job interviewing skills. It included role plays with feedback. It also contains ethically mandated information regarding HIV prevention. It was delivered on line by a trained facilitator.
89010922|NCT05896345|Active Comparator|SWL and ODT|Shockwave Lithotripsy (SWL) and Oral Dissolution Therapy (ODT)
89198644|NCT00872391|Experimental|Hypofractionated LINAC radiotherapy|
89198645|NCT00872469|Active Comparator|Tranexamic acid|
89198646|NCT00872469|Placebo Comparator|placebo|
89198647|NCT00872547|Active Comparator|1|Resurfacing system
89198648|NCT00872547|Active Comparator|2|Large Metal-on-Metal Total Hip Replacement
89198649|NCT05225883||Autoimmune encephalitis and paraneoplastic neurological syndromes|Patients with well-characterized antibodies against onconeural antigens, synaptic or cell-surface antigens
89198650|NCT00878007|Experimental|1|"Intermittent screening and treatment (IST) for malaria.~This intervention is a change from a previous intervention based on intermittent preventive treatment for malaria owning to the withdrawal of amodiaquine (one of the previous IPT drugs) in Kenya in 2009."
89198651|NCT00878007|Experimental|2|Enhanced teacher training on literacy instruction.
89198652|NCT00878007|Experimental|3|Intermittent screening and treatment (IST) for malaria and enhanced teacher training on literacy instruction
89198653|NCT00878007|No Intervention|4|
89198654|NCT00872625|Experimental|Cyberknife|
89198655|NCT00878085|Experimental|1|Robot Therapy with activities of daily living (ADLs)
89198656|NCT00878085|Active Comparator|2|Standard Occupational Therapy
89536543|NCT02472041|Experimental|Reanimator Group|Reanimator of Muller Group (intermittent positive pressure): Patients allocated to this group received intermittent positive pressure breathing (resuscitator Muller, Engemed, Brazil), adjusting the positive pressure around 1.5 kgf / cm2, which corresponds to 15 20 cm / H2O, positive pressure was applied through a face mask (Respironics®), which was connected in a circuit extending along the Muller Resuscitator equipment applied continuously for four series 10 of the patient breaths active and with an interval of two minutes between them in Fowler 45 position
89198657|NCT00872703||1|
89198658|NCT00872703||2|
89198659|NCT00878319|Active Comparator|Surgical|Surgical intervention: open reduction and internal fixation (ORIF)
88919968|NCT05595824|Active Comparator|Standard of care|Group 2 (n=120) patients receive standard therapy prescribed in accordance with the recommended treatment regimens included in the Interim Guidelines for the prevention, diagnosis and treatment of COVID-19 approved by the Russian Ministry of Health (version 14, December 27, 2021) or valid as of the time of the study by decision of the investigator and taking into accountthe availability of drugs at the study site (Favipiravir, Umifenovir, IFN α, used incombination with each other).
88919969|NCT05595759|Experimental|Male patients with a diagnosis of alcohol and substance abuse|Male patients with a diagnosis of alcohol and substance abuse
88919970|NCT05595759|Other|Routine service operation|Male patients with a diagnosis of alcohol and substance abuse
88919971|NCT05595733|No Intervention|conventional group|Using conventional mode to compare mechanical ventilation day with experimental group
88919972|NCT05595733|Experimental|experimental group|Using neurally adjusted ventilatory assist mode to compare mechanical ventilation day with conventional group
88919973|NCT05595590|Experimental|Tislelizumab + Pulse radiation|Participants receive pulsed radiationtherapy concurrent with 3 cycles of Tislelizumab followed by an additional 32 cycles of Tislelizumab alone as maintenance therapy.
88919974|NCT05595564|Experimental|Hypoxia|Participant developed running activity on a treadmill in hypoxic condition, submitted or not to photobiomodulation therapy.
88919975|NCT05595564|Active Comparator|Normoxia|Participant developed treadmill running activity in normoxic condition, submitted or not to photobiomodulation therapy.
88919976|NCT05595538|Experimental|Intubated COVID-19 patients admitted to the ICU.|Participants intubated who consent immediately before intubation to receive more than one dose of COVID-19 convalescent plasma.
88919977|NCT05595525|Experimental|Group A = right side face treated with 1064nm and left with 755nm|subject will have their right half of their face treated with the 1064nm picosecond laser with diffractive lens array. Then the contralateral, left half will be treated with the 755nm picosecond laser with diffractive lens array. Subjects will receive three (3) treatments, four (4) weeks ± 7 days apart to each facial half.
88919978|NCT05595525|Experimental|Group B = left side face treated with 1064nm and right with 755nm|subject will have their left half of their face treated with the 1064nm picosecond laser with diffractive lens array. Then the contralateral, right half will be treated with the 755nm picosecond laser with diffractive lens array. Subjects will receive three (3) treatments, four (4) weeks ± 7 days apart to each facial half.
88919979|NCT05595473|Experimental|Cohort 1|
88919980|NCT05595473|Experimental|Cohort 2|
88919981|NCT05595473|Experimental|Cohort 3|
88919982|NCT05595473|Experimental|Cohort 4|
88919983|NCT05595408||adjuvant chemotherapy group|muscle invasive upper tract urothelial carcinoma after radical nephroureterectomy receiving adjuvant chemotherapy
88919984|NCT05595408||adjuvant immunotherapy group|muscle invasive upper tract urothelial carcinoma after radical nephroureterectomy receiving adjuvant immunotherapy
88919985|NCT05593822|Other|patient with STEMI|
89198660|NCT00878319|Active Comparator|Non-surgical|Sugartong splint followed by transition to functional co-aptation brace
89198661|NCT00872781|Experimental|1|fixed dose combination of Quinapril HCl 20 mg and Hydrochlorothiazide 25 mg tablets of OHM Laboratories Inc (a subsidiary of Ranbaxy pharmaceuticals Inc)
88919986|NCT05577455|Experimental|administration for 2 menstrual cycles group|This group will receive TCM treatment before 2 menstrual cycles of IVF-ET.
88919987|NCT05577455|Active Comparator|administration for 3 menstrual cycles group|This group will receive TCM treatment before 3 menstrual cycles of IVF-ET.
88919988|NCT05567822|Active Comparator|esmolol group|loading dose of esmolol 0.05 mL/kg and maintenance dose of esmolol 0.3 mL/kg/h
88919989|NCT05567822|Placebo Comparator|placebo group|loading dose of 0.9% sodium chloride 0.05 mL/kg and maintenance dose of 0.9% sodium chloride 0.3 mL/kg/h
88919990|NCT05557253|Experimental|remimazolam group|General anesthesia is induced and maintained with remimazolam.
88919991|NCT05557253|Active Comparator|balanced group|General anesthesia is induced with propofol and maintained with desflurane.
88919992|NCT05546372|Experimental|Endobiliary RFA + stent placement|
88919993|NCT05546372|Active Comparator|Stent placement only|
88919994|NCT05539924|Active Comparator|Group P|The patients in this group will receive 150 mg pregabalin tablets P.O 1 hours before surgery then after half hour morphine 0.1 mg/kg will be administered intramuscularly.
88919995|NCT05539924|Active Comparator|Group G|The patients in this group will receive 400 mg Gababentin4 tablets P.O 1 hours before surgery then after half hour morphine 0.1 mg/kg will be administered intramuscularly.
89198662|NCT00872781|Active Comparator|2|ACCURETICTM tablets (containing fixed dose combination of Quinapril HCl 20 mg and Hydrochlorothiazide 25 mg)
89198663|NCT00384085|Experimental|Lantus/Apidra-3|Insulin glargine (Lantus) plus up to 3 injections of insulin glulisine (Apidra) added to oral agents.
89198664|NCT00384085|Experimental|Lantus/Apidra-1|Insulin glargine (Lantus) plus up to 1 injection of insulin glulisine (Apidra) added to oral agents.
89198665|NCT00384085|Experimental|Novolog Mix 70/30|Premixed insulin (Novolog® Mix 70/30) added to oral agents.
89198666|NCT00878397|Experimental|1|Free distribution of long lasting insecticide nets to school children and their younger siblings
88919996|NCT05539924|Placebo Comparator|Group C|The patients in this group will receive vitamin B12 (100µg) as placebo tablets P.O hours before surgery then after half hour morphine 0.1 mg/kg will be administered intramuscularly.
88919997|NCT05530096||MRD level group|Participants will be defined as diagnosed with multiple myeloma
88919998|NCT05528250||İndividuals with do regular physical activity|International Physical Activity Questionnaire (IPAQ)-Short Form ,Anthropometric Measurements and Evaluation Body Weight and Height, Electromyogram (EMG), Digital Dynamometer measurement ,Static Balance Measurements ,Dynamic Balance Measurements ,Tecnobody Balance Measurement , Mini-Balance Evaluation (MiniBESTest) Systems Test ,Y Balance Test ,Flamingo Balance Test ,Modified Borg Scale will be applied to individuals with do regular physical activity is declared.
89010923|NCT05896319|Experimental|Treatment group|Postoperative application of hyaluronic acid gels 3 times per day for 7 days after tooth extraction
89198667|NCT00878397|Experimental|2|No school-based delivery of long lasting insecticide nets in the first year, followed by free delivery in the second year
89198668|NCT00872859|Experimental|1|Dermamatrix with radiation
89198669|NCT00872859|Experimental|2|Dermamatrix without radiation
89198670|NCT00872859|Experimental|3|Alloderm with radiation
89198671|NCT00872859|Experimental|4|Alloderm without radiation
89198672|NCT00878475||Group with obstructive causes of dyspnea|Criteria for clinical assessment of severe asthma (diffuse polyphonic bilateral and particular expiratory wheezes, chest tightness, shortness of breath, using accessory muscles of breathing, signs of hyperinflation, atopic condition, personal or family history of asthma, tachypnea, previous asthma and asthma medications, and the value of modified Boston criteria for HF ≤ 5) and criteria for chronic obstructive pulmonary disease (COPD) exacerbation (history of COPD, COPD medications, cough, worsening dyspnea, increased sputum production and volume, increased sputum purulence, rhonchi and rales, modified Boston criteria for HF ≤ 5)
89198673|NCT00878475||Heart failure group|The investigators protocol for clinical assessment of HF-related acute dyspnea (the prehospital clinical assessment for HF) was designed based on Boston (13) and Framingham criteria for HF (14) (Table 1). The investigators did not use certain criteria from the original protocols, which were not available in the prehospital setting (e.g., chest radiography).
89198674|NCT00361231|Experimental|Bevacizumab, Gemcitabine, Oxaliplatin|"The chemotherapy drugs are given twice every 28 days. This 28 day period is called a cycle of study treatment.~Bevacizumab will be administered by IV over 90 minutes on day 1 and day 15. Gemcitabine will be administered by IV over 1 hour and 40 minutes on days 1 and 15 of each cycle. Oxaliplatin will be administered by IV for 2 hours on days 1 and 15 of each cycle.~Participants will continue to receive cycles of study treatment as long as their disease does not progress and they are not experiencing any serious side effects."
89198675|NCT01050361|Experimental|Echo Guided HEmodyanmic Management (EGHEM)|EGHEM - Echo Guided HEmodyanmic Management - will receive their intraoperative maintenance fluid and possible drug therapy (furosemide) based on their hourly intraoperative Left Ventricular Diastolic Dysfunction (LVDD) grade.
89198676|NCT01050361|No Intervention|Standard HEmodynamic Management (SHEM)|SHEM - Standard HEmodynamic Management - will NOT receive the study intervention, but will receive standard anesthesia and hemodynamic management based on current standards within the institution (control group).
89198677|NCT01048021||Supraclavicular Block|
89198678|NCT01050439|Experimental|UDAlloSCT + Therapy|This is a non-randomized study to test the safety and response of unrelated matched donor allogeneic stem cell transplantation (UDAlloSCT) with either myleoablative (full intensity) or reduced intensity conditioning therapy in patients with selected malignant and non-malignant disorders. UDAlloSCT has been performed in both adults and children as an alternative transplant for patients who lack and HLA-matched family donor in both malignant and non-malignant disease with varying degrees of response.
88919999|NCT05528250||Sedentary individuals with do not have regular physical activity|International Physical Activity Questionnaire (IPAQ)-Short Form ,Anthropometric Measurements and Evaluation Body Weight and Height, Electromyogram (EMG), Digital Dynamometer measurement ,Static Balance Measurements ,Dynamic Balance Measurements ,Tecnobody Balance Measurement , Mini-Balance Evaluation (MiniBESTest) Systems Test ,Y Balance Test ,Flamingo Balance Test ,Modified Borg Scale will be applied to sedentary individuals with do not have regular physical activity is declared.
89198679|NCT00676650|Experimental|A|Treatment Arm A - sunitinib + prednisone
89198680|NCT00676650|Placebo Comparator|B|Treatment Arm B - placebo + prednisone
89198681|NCT01045369|Experimental|Kaletra And Intelence|This is a Phase IV, 48-week, open-label, pilot study in 30 ARV-naïve patients examining the safety, viral response, and tolerability of Kaletra® and Intelence™ tablets.
89536898|NCT03311789|Experimental|PD-1 inhibitor + Gemcitabine+Cisplatin|Patients will be enrolled in the experimental arm and will receive Gemcitabine on day 1 and 5 (1000mg/m2 ) +Cisplatin on day 1(75mg/m2)+ PD-1 inhibitor on day 3 (Nivolumab 3mg/kg, or SHR-1210 200mg) every 3 weeks. If there is continued benefit after 6 months, PD-1 inhibitor will be administered as maintenance treatment until tumor progression or death.
89010924|NCT05896319|No Intervention|Control group|No adjunctive therapy undergoing natural healing
89436654|NCT03117751|Experimental|T-ALL and T-LLy, Standard-risk|"Induction (6 wks), Early Intensification (4 wks), Consolidation (8 wks), and Continuation (120 wks). During Remission Induction therapy, prednisone dose is 60mg/m^2 and 3 doses daunorubicin are given. Dasatinib is given for patients with Ph+ and those with ABL-class fusion. Ruxolitinib is given for patients with activation of JAK-STAT signaling; ALL patients with Day 15 or Day 22 MRD ≥5% and all patients with ETP and T/M MPAL and LLy patients who don't qualify for complete response at end of Remission Induction. Bortezomib is given to patients without targetable lesions and Day 15 or Day 22 MRD ≥ 5%.~Interventions: prednisone, vincristine, daunorubicin, pegaspargase (or Erwinase®, Rylaze™ or Calaspargase pegol), cyclophosphamide, cytarabine, mercaptopurine, dasatinib, bortezomib, ruxolitinib, methotrexate, dexamethasone, doxorubicin, nelarabine, thioguanine."
89010925|NCT05896241||Patients taking Dospray = 63|Patients who were prescribed Dospray as part of routine medical practice
89010926|NCT05896241||Рatients on other alternative treatment = 63|Patients who have been prescribed other alternative treatment as part of routine medical practice
89010927|NCT05896176||Pediatric Sleep Questionnaire (PSQ) +|Patient who obtained a score of 7 or more on the PSQ
89010928|NCT05896176||Pediatric Sleep Questionnaire (PSQ) -|Patient who obtained a PSQ score less than 7
89010929|NCT05896111|Experimental|designed physiotherapy program|"These exercises included:~Passive stretching exercises for elbow and wrist flexors. Weight-bearing exercises for the upper limbs. Stimulation of the protective reactions of the upper limbs in all directions. Strengthening exercises for antagonists of the spastic muscles, including elbow and wrist extensors, using different toys and motivation to encourage the children to perform the desired exercises (El-shamy, 2018).~The treatment session for 1hour 5 days / week for 4 weeks."
89010930|NCT05896111|Experimental|Whole body vibration.|Each child will be seated on an armless chair in front of the platform and instructed to flex both shoulders at 90°, slightly bend both elbows, and then bend the trunk forward to allow both hands to be placed on the platform. Each subject will be allowed to hold the palms slightly off the platform to minimize discomfort and prevent strong stimulation of the organs, eyes, and head.
89010931|NCT05896072|Experimental|ESP Group|"Erector Spinae Plane Block Group~Drug: 0,25% Bupivacaine 0,5ml/kg (max.20ml) will be used for blocks"
89010932|NCT05896072|Active Comparator|Caudal Group|"Caudal Block Group~Drug: 0,25% Bupivacaine 0,5ml/kg (max.20ml) will be used for blocks"
89010933|NCT05896059|Experimental|Tislelizumab combined with Anlotinib|
89010934|NCT05895994|Experimental|RD13-02 cell infusion|
89010935|NCT05895942||Imatinib treatment group|Chinese patients with unresectable C-kit9/11-mutated GIST were selected as the research subjects, and the therapeutic effect was observed after standard treatment with imatinib mesylate
88920000|NCT05514782|Active Comparator|Anti-Aging Daily Serum|Daily serum composed of a patent-pending botanical extract, bioavailable peptide, antioxidants, postbiotic(s), short term and long-term moisturizers. New product in development.
89536544|NCT02472041|Experimental|Control Group|Control Group: In position Fowler 45, patients assigned to this group was administered as treatment lung expansion exercises using the incentive inspiratory flow (Respiron, NCS, Mexico) and concomitantly blocking contralateral to the drain maneuvers were performed, compression / decompression associated with the incentive spirometry (Respiron) consisting of 4 sets of 10 active patient breaths with an interval of two minutes between sets. Since the load of the respiratory stimulator will be zero throughout treatment (Table 1). Guidelines to the active, progressive and early mobilization.
88920001|NCT05514782|Placebo Comparator|Placebo-Control|Vehicle control of the anti-aging daily serum.
88920002|NCT05512065|Experimental|Ultrasound|Ultrasound will be used to measure velocimetric indices of both right and left uterine arteries and umbilical artery.
88920003|NCT05501925|Experimental|GlideSheath Slender®|Placement of 6 French GlideSheath Slender® for cardiovascular intervention via distal radial artery
88920004|NCT05501925|Active Comparator|Conventional Sheath|Placement of 6 French conventional Sheath (TERUMO, Introducer II ) for cardiovascular intervention via distal radial artery
88920005|NCT05479370|Experimental|Frequently vaccinated Group 1: QIV-R|Frequently vaccinated participants (3 or more influenza vaccinations during the preceding 5 years) received a 0.5mL dose of Flublok Quadrivalent vaccine, intra-muscularly, at Day 0.
88920006|NCT05479370|Experimental|Frequently vaccinated Group 2: QIV-E|Frequently vaccinated participants (3 or more influenza vaccinations during the preceding 5 years) received a 0.5mL dose of Fluarix Quadrivalent vaccine, intra-muscularly, at Day 0.
88920007|NCT05479370|Experimental|Frequently vaccinated Group 3: QIV-C|Frequently vaccinated participants (3 or more influenza vaccinations during the preceding 5 years) received a 0.5mL dose of Flucelvax Quadrivalent vaccine, intra-muscularly, at Day 0.
88920008|NCT05479370|Experimental|Infrequently vaccinated Group 4: QIV-R|Infrequently vaccinated participants (0 or 1 influenza vaccination during the preceding 5 years) received a 0.5mL dose of Flublok Quadrivalent vaccine, intra-muscularly, at Day 0.
88920009|NCT05479370|Experimental|Infrequently vaccinated Group 5: QIV-E|Infrequently vaccinated participants (0 or 1 influenza vaccination during the preceding 5 years) received a 0.5mL dose of Fluarix Quadrivalent vaccine, intra-muscularly, at Day 0.
88920010|NCT05479370|Experimental|Infrequently vaccinated Group 6: QIV-C|Infrequently vaccinated participants (0 or 1 influenza vaccination during the preceding 5 years) received a 0.5mL dose of Flucelvax Quadrivalent vaccine, intra-muscularly, at Day 0.
88920011|NCT05479136|Experimental|PET study|Single intravenous administration of 18F fluciclovine for PET Scan
88920012|NCT05478369|Experimental|storybook|anxiety and fear
88920013|NCT05478369|No Intervention|control|not anxiety and fear
88920014|NCT05475821|Experimental|Group 1|Participants will receive ABBV-990 Dose A or matching placebo.
88920015|NCT05475821|Experimental|Group 2|Participants will receive ABBV-990 Dose B or matching placebo.
88920016|NCT05475821|Experimental|Group 3|Participants will receive ABBV-990 Dose C or matching placebo.
88920017|NCT05475821|Experimental|Group 4|Participants will receive ABBV-990 Dose D or matching placebo.
88920018|NCT05475821|Experimental|Group 5|Participants will receive ABBV-990 Dose E or matching placebo.
89198682|NCT00573183|Experimental|STAGE-12|STAGE-12 received 3 individual and 5 group 12-step facilitation sessions focusing on 12-step principles plus an intensive referral in which counselors linked participants to community-based 12-step volunteers. These sessions took the place of 3 individual and 5 group sessions in the standard intensive outpatient drug treatment program and were integrated into treatment as usual.
88920019|NCT05454098|Experimental|Fed states in healthy subjects|A single 40mg dose of Clifutinib administered in a fed state.
88920020|NCT05454098|Experimental|Fasted states in healthy subjects|A single 40mg dose of Clifutinib administered in a Fasted state.
88920021|NCT05451901|Experimental|Immediate necrosectomy|Endoscopic necrosectomy will be conducted in the same session of EUS-guided drainage (or at least within 72 hours of randomization) and be repeated until clinical success.
88920022|NCT05451901|Active Comparator|Step-up approach|Step-up treatment will be conducted if a patient's condition does not improve after EUS-guided drainage. The step-up approach includes increasing the number of stents, adding another EUS-guided drainage, and performing percutaneous drainage after 72-96 hours of the initial drainage. Endoscopic necrosectomy is considered when clinical improvement is not observed even after two times of step-up treatment.
88920023|NCT05451602|Experimental|HEC169096|Multiple doses of HEC169096
88920024|NCT05433402|Active Comparator|Control|
88920025|NCT05433402|Experimental|Chloropromazine|
88920026|NCT05406596|Experimental|LiquID GCE Use|
88920027|NCT05406076|Active Comparator|Oral Motor Therapy/ABA|"Eighty subjects who met the inclusion/exclusion criteria were randomly divided into 2 groups according to a 1:1 ratio. The experimental group was first treated with 2 months of ABA + oral motor therapy, followed by 2 months of ABA treatment.~Oral motor therapy appliances can be used during mouth muscle training sessions, depending on the individual needs of the child. 30-40 min/session, 1 session/day, 5 sessions/week.~ABA training time is at least 20 hours per week. The therapist is fully aware of each stage of the child's training during the teaching process and can make an accurate assessment of the child."
89010936|NCT05895916|Experimental|Extreme exercise group|1,144 km of road cycling on seven consecutive days
89010937|NCT05895877|Active Comparator|Goofice®|"Active ingredient:~Elobixibat 5mg/tab~Dosage and Frequency:~Once daily before breakfast. The starting dose is total 10 mg of Goofice® (2 tablets). After 7 days of the start of the study treatment, the dosage may be adjusted according to symptoms among the dose levels of 5, 10, and 15 mg.However, the maximum daily dose is 15 mg (3 tablets)."
89436655|NCT03117751|Experimental|T-ALL and T-LLy, High-risk|"Induction (6 wks), Early Intensification (4 wks), Consolidation (8 wks), and Reintensification. During Remission Induction therapy, prednisone dose is 60mg/m^2 and 3 doses daunorubicin are given. Dasatinib, ruxolitinib, and bortezomib given as done for patients with standard-risk T-ALL but are discontinued in Reintensification therapy.~Interventions: prednisone, vincristine, daunorubicin, pegaspargase (or Erwinase®, Rylaze™ or Calaspargase pegol), cyclophosphamide, cytarabine, mercaptopurine, dasatinib, bortezomib, ruxolitinib, methotrexate, etoposide, dexamethasone, clofarabine, vorinostat, idarubicin, nelarabine, thioguanine.."
89436656|NCT03117751|Experimental|ALL, CEP72 T/T, Vincristine|"Patients with the CEP72 rs904627T/T genotype (~16% of patients) will be randomized (unblinded design, only those who evaluate neuropathy are blinded) to receive either 1.5 mg/m^2 or 1 mg/m^2 of vincristine after Continuation Week 1. Patients in low- risk will complete vincristine in Week 49 and those in standard/high-risk will complete in Week 101.~Intervention: vincristine."
88920028|NCT05406076|Active Comparator|ABA/Oral Motor Therapy|"Eighty subjects who met the inclusion/exclusion criteria were randomly divided into 2 groups according to a 1:1 ratio. The control group was treated with 2 months of ABA followed by 2 months of ABA + oral motor therapy.~Oral motor therapy appliances can be used during mouth muscle training sessions, depending on the individual needs of the child. 30-40 min/session, 1 session/day, 5 sessions/week.~ABA training time is at least 20 hours per week. The therapist is fully aware of each stage of the child's training during the teaching process and can make an accurate assessment of the child."
88920029|NCT05405621|Experimental|Cohort 1|Experimental: BAT8009 for Injection 0.6 mg/kg (frequency: Q3W)
88920030|NCT05405621|Experimental|Cohort 2|Drug: BAT8009 for Injection 1.2 mg/kg (frequency: Q3W)
88920031|NCT05405621|Experimental|Cohort 3|Drug: BAT8009 for Injection 2.4 mg/kg (frequency: Q3W)
88920032|NCT05405621|Experimental|Cohort 4|Drug: BAT8009 for Injection 3.6mg/kg (frequency: Q3W)
88920033|NCT05405621|Experimental|Cohort 5|Drug: BAT8009 for Injection 4.8mg/kg (frequency: Q3W)
88920034|NCT05405621|Experimental|Cohort6|Drug: BAT8009 for Injection 6.0mg/kg (frequency: Q3W)
88920035|NCT05405621|Experimental|Cohort 7|Drug: BAT8009 for Injection 7.2mg/kg (frequency: Q3W)
88920036|NCT05405621|Experimental|Cohort 8|Drug: BAT8009 for Injection 8.4mg/kg (frequency: Q3W)
88920037|NCT05400395|Experimental|GNX|GNX / 80mg / BID / PO
88920038|NCT05400395|Placebo Comparator|Placebo|Placebo / BID / PO
88920039|NCT05374941|Experimental|Stimulation not synchronized with breathing|Participants will be injected with the StimAire Model S Injectable neurostimulator for the hypoglossal nerve, using a wearable without a breathing sensor.
88920040|NCT05374941|Experimental|Stimulation during inhalation only|Participants will be injected with the StimAire Model S Injectable neurostimulator for the hypoglossal nerve, using a wearable with a breathing sensor.
88920041|NCT05351333|Experimental|Conditioning Open-Label Placebo|Days 1 to 3 will include the acquisition phase where the opioid medication will be prescribed on a schedule of 3-4 times per day and paired with an open-label placebo. Day 4 and 6 will be the evoked phase, and patients will receive only the open-label placebo pill. On day 5 the opioid medication will be re-introduced as pharmacological reinforcement.
89536545|NCT03070509|Experimental|RYGB|Single dose of lisdexamfetamine 50 mg in RYGB patients
89536546|NCT03070509|Experimental|Nonsurgical Controls|Single dose of lisdexamfetamine 50 mg in non-surgical controls
89536547|NCT04844489|Other|Blood samples|
89536899|NCT02722499|Experimental|High Frequency Financial Incentive|This arm will receive telephone delivered diabetes education and skills training in combination with the high frequency incentive structure
89436657|NCT03117751|Experimental|ALL, CEP72 C/T or C/C, Vincristine|"Patients with either a CEP72 rs904627 C/T or C/C genotype (~84% of patients) will be randomized (unblinded design, only those who evaluate neuropathy are blinded) to receive vincristine (2 mg/m^2 per dose except during Reinduction I and Reinduction II when 3 weekly doses of 1.5 mg/m^2 will be given) and dexamethasone pulses through Week 49 of Continuation Treatment or through Week 101 of Continuation Treatment. Patients at low-risk will complete vincristine in Week 49.~Interventions: vincristine, dexamethasone, methotrexate, mercaptopurine."
88819494|NCT03833427|Experimental|Selumetinib at Dose Level 6 + Pembrolizumab|Participants receive 200 mg pembrolizumab (IV infusion; Q3W) in combination with selumetinib at dose level 6 (dosed orally; BID) for up to 35 treatment cycles (cycle length: 3 weeks). During each 3-week cycle, selumetinib will be administered only for the first two weeks.
89198683|NCT00573183|Active Comparator|Treatment as Usual|Treatment as usual received standard care provided in intensive outpatient drug treatment program without the STAGE-12 components.
89436658|NCT03111147|Experimental|0 degrees humeral component version|Reverse Total Shoulder Arthroplasty with humeral component positioned in 0 degrees of version
89436659|NCT03111147|Experimental|30 degrees humeral component retroversion|Reverse Total Shoulder Arthroplasty with humeral component positioned in 30 degrees of retroversion
89436660|NCT03099174|Experimental|Cohort A|Xentuzumab + Abemaciclib (Dose 1)
89436661|NCT03099174|Experimental|Cohort B|Xentuzumab + Abemaciclib + Letrozole (Dose 2)
89436662|NCT03099174|Experimental|Cohort C|Xentuzumab + Abemaciclib + Anastrozole (Dose 3)
89436663|NCT03099174|Experimental|Cohort D|Xentuzumab + Abemaciclib + Fulvestrant (Dose 4)
89436664|NCT03099174|Experimental|Cohort E|Xentuzumab + Abemaciclib (Dose 1)
89436665|NCT03099174|Experimental|Cohort F|Xentuzumab + Abemaciclib + Fulvestrant (Dose 4)
89436666|NCT03099174|Experimental|Cohort D1|Xentuzumab + Abemaciclib + Fulvestrant (Dose 4)
89436667|NCT03099174|Experimental|Cohort D2|Xentuzumab + Abemaciclib + Fulvestrant (Dose 4)
89436668|NCT03088852|Active Comparator|Experimental group|After initial intravenous treatment, participants (those with magnesium level ≥1 mg/dL) will be randomized, and oral magnesium therapy ( or no treatment) will be started. The experimental group will receive 400mg magnesium daily in two divided doses. Patients in the experimental group will be discharged with one month's supply of magnesium and continued for at least three months.
89436669|NCT03088852|No Intervention|Control group|control group will receive standard care (no treatment). Patient will have their blood tested and will come for follow up visit every month for 3 months after discharge.
88819495|NCT03833427|Experimental|Selumetinib at Dose Level 7 + Pembrolizumab|Participants receive 200 mg pembrolizumab (IV infusion; Q3W) in combination with selumetinib at dose level 7 (dosed orally; BID) for up to 35 treatment cycles (cycle length: 3 weeks). During each 3-week cycle, selumetinib will be administered only for the first two weeks.
88819496|NCT00371085|Experimental|1|Video-based patient education on heart failure self care
88819497|NCT04856241|Experimental|Supported Implementation (Intervention)|Our supported implementation approach is designed to improve uptake of Prep-to-Play. The Prep-to-Play program consists of four components: dynamic warm-up, strength training, football fundamentals, and education. At the start of the intervention period, Prep-to-Play Physiotherapists will conduct a 3-hour workshop for coaches and influential players. Ongoing support will be provided via a range of strategies. Prep-to-Play Physiotherapists will attend training (two times) during and immediately post implementation to provide coaches with support (feedback on missing components, player technique, questions). Monthly Coaches Shed; Online drop-in session with education component to meet other coaches (peer support & networking) and ask questions. Refresher workshops will be run in pre-season 2022 for the teams who have received the intervention in 2021.
88819498|NCT04856241|Active Comparator|Unsupported implementation (Control)|"The unsupported implementation arm will be usual care. Access to the Prep-to-Play resources, including videos, downloadable manuals and posters, are freely available to coaches online. The online resources incorporate the same four concepts as described in the supported implementation - dynamic warm-up, strength exercises, football fundamentals, and education. In the control arm, no additional resources, education, or support will be provided."
88819499|NCT04849377|Experimental|Group I - 50 Gy/200 mg/m2|Patient Characteristics: <20 Pack-Years, HPV16, OP, T1,T2 N0 RT 5 days per week for 6 weeks and Cisplatin weekly for 5 weeks
88819500|NCT04849377|Experimental|Group II - 54 Gy/200mg/m2|Patient Characteristics: <20 Pack-Years, HPV16, OP, T1-T2, N1-N2b, T3 N0-N2b RT 5 days per week for 6 weeks and Cisplatin weekly for 6 weeks
88819501|NCT04849377|Experimental|Group III - 60 Gy/240 mg/m2|Patient Characteristics: 20-40 Pack-Years, Non-HPV16, Non-OP, T1-T2, N1-N2b, T3 N0-N2b RT 5 days per week for 6 weeks and Cisplatin weekly for 6 weeks
88819502|NCT04849377|Experimental|Group IV - TPF Induction followed by 60 Gy and Carboplatin AUC 1.5|Patient Characteristics: 20-40 Pack-Years, Non-HPV16, Non-OP, T4, N2c, >3 nodes, ENE, or Matted Nodes Induction Therapy: Cisplatin, Docetaxel, Fluorouracil followed by RT 60 GY + Carboplatin AUC 9.0 Docetaxel every 21 days for 3 cycles, Cisplatin every 21 days for 3 cycles, Fluorouracil continuous infusion over 4 days (every 21 days for 3 cycles). Followed by RT 5 days per week for 6 weeks and Carboplatin weekly for 6 weeks.
88819503|NCT03032237|Experimental|Protein-rich assortment|The intervention groups receives protein-rich meals and protein-rich dairy products.
88819504|NCT03032237|Placebo Comparator|Standard assortment|The control group receives standard meals and food products.
88819505|NCT04738227|Experimental|Low level Laser Therapy Group|"Laser therapy will be performed with a continuous wave diode laser device previously calibrated by the manufacturer.~6 points that will be the skin overlying the right hand side parotid gland and 3 points on the skin overlying the location of the right hand side submandibular gland).~Following are the parameters which will be employed for the laser:~Wavelength - 635nm (visible spectrum), Output power 100 milliwatt, Mean dose per point - 3 J/cm2 , Irradiation time per point 15 s Energy per point 3 J Energy per session 60 J , Laser spot tip will be 0.08cm2 Two laser sessions will be done each week, during 12 weeks, which will bring the total number of laser sessions to All the major salivary glands will be treated with the tip of the laser hand-piece in contact with patients tissues.~A sum total of 22 points will receive LLLT per session involving all three major salivary glands."
88819506|NCT05441553|Experimental|VGB-R04|Single intravenous (i.v.) infusion of VGB-R04 Intervention: Gene Therapy / Gene Transfer
88819507|NCT04768595|Placebo Comparator|Placebo|1g corn oil capsules
88920042|NCT05351333|No Intervention|Treatment as usual|Patients in the standard of care group will receive their analgesic treatment through Spaulding Pharmacy as prescribed by their treating physicians. The treatment regime will include an opioid medication at the standard recommended dosage. Participants in this group will receive the treatment orally for 6 consecutive days.
88920043|NCT05339828||unroofing curettage|Surgery was performed with the patient lying in the prone position under local anesthesia. Next, a local anesthetic agent comprising a solution of lidocaine (20 mg/mL) and adrenaline (0.0125 mg/mL) was diluted with distilled water in a 1:2 ratio and applied. The tract was identified by passing small artery forceps along its length and was then opened by cutting directly down onto the forceps. The sinus and all its tracts were completely unroofed, and the base was curetted to remove all necrotic content, hair, and granulation tissue using a dry gauze. The fibrotic back wall was left as intact as possible to avoid delayed healing.
88920044|NCT05339672||Morphine|The participating patients are treated with morphine before start of enzalutamide (according to label).
88920045|NCT05339672||Edoxaban|The participating patients are treated with edoxaban before start of enzalutamide (according to label).
88920046|NCT05322200|Active Comparator|Active drug|Oral Semaglutide + conventional therapy (includes dual antiplatelets, Statin, Angiotensin-converting enzyme inhibitors (ACE inhibitors) and beta-blockers)
88920047|NCT05322200|Placebo Comparator|Placebo|placebo (same dose and administration route) + conventional therapy (includes dual antiplatelets, Statin, Angiotensin-converting enzyme inhibitors (ACE inhibitors) and beta-blockers)
88920048|NCT05303974|Experimental|Novices|Measurement of competence
88920049|NCT05303974|Experimental|Intermediates|Measurement of competence
88920050|NCT05303974|Experimental|Experts|Measurement of competence
88920051|NCT05299346||Post ICU covid survivors|Patients having survived and discharged from ICU care as a result of Covid 19
88920052|NCT05261477|Experimental|Intervention group|Intervention group receives one in person education session using the 1stBIEN booklet, video education via mobile phones and care coordination from a bilingual Patient Navigator-PN for 3-months. PN follow up patients weekly for the first month and once a month for two months. Video education is done weekly. Videos cover problem solving training, brain injury concepts, rehabilitation treatments and school resources individualized to patient and family needs. PNs facilitate transition to outpatient care, follow-up with specialists and primary care providers; use of community resources; and communication with teachers and school administrators. PN provides observational and experiential learning opportunities for parents, using three way calls for scheduling of services and interactions with clinics and schools. PN calls use a problem-solving training format, to reinforce parental experiential learning and improve self-efficacy. Expert MD providers (Co-investigators) will supervise PNs.
88920053|NCT05261477|No Intervention|Attention Control group|Attention Control group receives one in person education session using the 1stBIEN booklet, monthly well-child texts and usual post-injury care including routine follow-up by specialists and primary care providers, per guidelines at each recruiting institution. Control patients have access to a list of community resources included in the 1stBIEN booklet. While education using the 1stBIEN booklet is not part of the current usual care at participating institutions, providing all families with initial education at the time of discharge addresses ethical and practical considerations. It standardizes discharge processes at participating institutions while delineating differences in the intensity of education and care coordination activities.
88920054|NCT05256355|Other|MSUS novices|Measurement of competence
88920055|NCT05256355|Other|MSUS intermediates|Measurement of competence
88920056|NCT05256355|Other|MSUS experts|Measurement of competence
89536548|NCT04259463||Concious sedation|Patients undergoing third molars extraction under concious sedation. The patient is fully familiarized with the sedation procedure. The anesthesiologist suppresses the patient's consciousness with the help of intravenous medication;
89536900|NCT02722499|Experimental|Moderate Frequency Financial Incentive|This arm will receive telephone delivered diabetes education and skills training in combination with the moderate frequency incentive structure
88819508|NCT04768595|Experimental|Ceto 10|1g capsules containing oil from north atlantic fish containing broad spectrum marine oil.
88819509|NCT04768595|Active Comparator|Omega-3|1 g capsules containing traditional, commericially available omega-3 marine oil.
88819510|NCT00371163||Contact Dermatitis|Males or females with contact dermatitis
88819511|NCT00371163||Psoriasis|Males or females with psoriasis
88819512|NCT00371163||No skin disease|Males or females with no skin diseases
88819513|NCT00371163||Atopic Dermatitis|Males of females with atopic dermatitis
88819514|NCT02874443|Experimental|Intervention centers|"Application of a knowledge translation strategy, of new clinical practice guidelines on labor management, to physicians and nurses caring for women in labor.~Intervention centers will receive knowledge translation of labor management guidelines"
88819515|NCT02874443|No Intervention|Control centers|No intervention at control centers
88819516|NCT04738539||Patients with or being evaluated for neurogenic bladder|Pediatric patients presenting to UVA Pediatric Urology for follow up or repeat urodynamics testing.
88819517|NCT05511779|Experimental|Dose Escalation Phase: Cohort 1: BCV 0.3 mg/kg BIW|BCV: 0.3 mg/kg administered as a continuous IV infusion over 2 hours on Day1 and Day4 for 8 weeks (up to a maximum of 14 weeks).
88819518|NCT05511779|Experimental|Dose Escalation Phase: Cohort 2: BCV 0.4 mg/kg BIW|BCV: 0.4 mg/kg administered as a continuous IV infusion over 2 hours on Day1 and Day4 for 8 weeks (up to a maximum of 14 weeks).
88819519|NCT05511779|Experimental|Expansion Phase: BCV Recommended dosage regimen in the Dose Escalation Phase|BCV: Recommended dosage administered as a continuous IV infusion over 2 hours on Day1 and Day4 for 8 weeks (up to a maximum of 14 weeks).
88819520|NCT04832139|Experimental|Marstacimab Prefilled Pen (PFP), then marstacimab Preflled Syringe (PFS)|Participants will first receive single dose PFP, then PFS, then repeating single dose PFP, then single dose PFS with a minimum of 21 days between single doses.
88819521|NCT04832139|Experimental|Marstacimab PFS, then marstacimab PFP|Participants will first receive single dose PFS, then PFP, then repeating single dose PFS, then single dose PFP with a minimum of 21 days between single doses.
88819522|NCT05510921|No Intervention|Control group|The control group will not receive any intervention
88819523|NCT05510921|Experimental|Minimalist music group|a live session of minimalist music piano piece
88819524|NCT05510921|Experimental|Minimalist music plus birdsongs group|a live session of minimalist music piano piece with the superposition of bird song sounds
88819525|NCT05454501|Active Comparator|Exercise Training|8-week real-time online exercise training will be provided. The content of the training will be aerobic based exercises, strength and flexibility exercises with warm up and cool down phases.
88819526|NCT05454501|Active Comparator|Patient Education|Patients will be given face-to-face education about their disease, the importance of physical activity and how to do it safely. They will be followed up with information leaflets and weekly phone calls.
88819527|NCT00551525|Experimental|Radiotherapy + Samarium 153|Samarium 153 infusion followed by radiotherapy 12 weeks later
88819528|NCT05454423|Experimental|aquatic exercise + Traditional physical therapy + anti-hyperuricemia medication|consisted of 50 Patients received aquatic exercise and Traditional physical therapy in addition to anti-hyperuricemia medication (a potent purine xanthine oxidase (XO) inhibitor) in therapeutic dose.
88819529|NCT05454423|Placebo Comparator|traditional physical therapy + anti-hyperuricemia medication|consisted of 50 Patients received traditional physical therapy in addition to anti-hyperuricemia medication (a potent purine xanthine oxidase (XO) inhibitor) in therapeutic dose.
88819530|NCT04806321|Experimental|Project SOLVE|"This program is self-guided, digital, and approximately 30 minutes in length. Content is designed to help adolescents solve, rather than be overwhelmed by, everyday problems. The program includes: (1) An introduction to problem solving; (2) Testimonials from valued others (older adolescents; celebrities) describing their use of problem solving skills; (3) Evidence from studies that our brains are capable of problem solving and that problem solving can be helpful; and (4) Activities designed to enable adolescents to practice sequential problem solving using a few steps (SOLVE Steps)."
88819531|NCT04806321|Active Comparator|Project SUCCESS|"This program is self-guided, digital, and approximately 30 minutes in length. Content is designed to help adolescents improve their study skills. This program includes: (1) An introduction to study skills; (2) Testimonials from valued others describing their use of study skills; (3) Description of helpful and commonly used study skills (e.g., note-taking); and (4) Activities designed to encourage adolescents to practice these skills in their daily lives."
88819532|NCT04802031|Experimental|Treatment (isatuximab)|Participants receive their first rapid infusion of isatuximab IV over 30 minutes. If a >=Grade 2 iRR occurs, then participants will revert to a SOC infusion time and be removed from the study. If a Grade 1 or no IRR occurs, then participants will receive another rapid infusion of 30 minutes. Participants will continue to receive RI and IRR assessment after each dose up to at least 6 doses or until a grade 2 or higher IRR occurs.
88819533|NCT03706989|Experimental|EEG for cardiac surgery patients|Patients who undergo elective cardiac surgery with cardiopulmonary bypass, from 18 to >75 years old.
88819534|NCT05454345|Experimental|The three-month Rifapentine&Isoniazid&Pyrazinamide&Sitafloxacin-containing regimen|Thirteen weeks of daily treatment with rifapentine, isoniazid, pyrazinamide, and Sitafloxacin.
88819535|NCT05454345|Experimental|The three-month Rifapentine&Isoniazid&Pyrazinamide&Sitafloxacin&SMZ/TMP-containing regimen|Six weeks of daily treatment with rifapentine, isoniazid, pyrazinamide, and Sitafloxacin, followed by seven weeks of daily treatment with rifapentine, isoniazid, ,SMZ/TMP and Sitafloxacin.
88819536|NCT05454345|Active Comparator|The six-month standard Rifampin&Isoniazid&Pyrazinamide&Ethambutol-containing regimen|Eight weeks of daily treatment with rifampin, isoniazid, pyrazinamide, and ethambutol, followed by Eighteen weeks of daily treatment with rifampin and isoniazid.
89010938|NCT05895877|Placebo Comparator|Goofice® Placebo|"Active ingredient/Excipients:~The placebo drug is identical in appearance to the Goofice ® tablet with the same excipient ingredients, but without the active compound.~Dosage and Frequency:~Once daily before breakfast. The dosage and frequency is the same as active drug"
89010939|NCT05895864|Experimental|Utidelone|Utidelone Injection: 35 mg/m2/day, IV on day 1-day 5 of each 21 day cycle, administered to enrolled patients with recurrent or metastatic urothelial carcinoma Number of Cycles: until progression or unacceptable toxicity develops or up to 8 cycles.
89010940|NCT05895851||RON|
89010941|NCT05895851||non-RON|non-RON but with radiiation treatment
89010942|NCT05895851||Normal|
89010943|NCT05895812|Experimental|Arm 1|Mild Renal Impairment
89010944|NCT05895812|Experimental|Arm 2|Moderate Renal Impairment
89010945|NCT05895812|Experimental|Arm 3|Healthy subjects
89010946|NCT05895799|Active Comparator|Clinical teaching from an expert after LC1|Medical students who had early intervention, i.e. teaching from an expert trainer, in the randomized controlled waitlist design.
89010947|NCT05895799|Active Comparator|Clinical teaching from an expert after LC2|Medical students who had a late intervention, i.e. teaching from an expert trainer, in the randomized controlled waitlist design.
89010948|NCT05895760|Experimental|Multi-component physical exercise online intervention (MPE)|The exercise program included endurance, strength, coordination, balance, and flexibility exercises which were carried out for 3 months.
89010949|NCT05895760|No Intervention|Control group|The control group received educational sessions on health prevention related to physical exercise.
89010950|NCT05895708|Experimental|Specified strengthening and stretching|The program consisted of two strengthening (deep cervical flexors and shoulder retractors) and two stretching (cervical extensors and pectoral muscles) exercises based on Harman and Mostafa et al's approach. This exercise program will be repeated 4 times per week for 10 weeks, and each session lasted for 30 minutes.
89010951|NCT05895708|Sham Comparator|General Exercise group|The program will consist of regular general postural exercises such as postural awareness exercises as well as general strengthening exercises such as range of motion exercises for the upper quadrant. The program will also be repeated 4 times per week for 10 weeks, with each session lasting 30 minutes
89010952|NCT05895422|Experimental|vascular hitch|displacement of the lower polar crossing vessels causing the UPJO
89010953|NCT05895422|Active Comparator|Dismembered pyeloplasty|classic Anderson-Hynes procedure
89010954|NCT05895331||Dexmedetomidine used group in Coronary Bypass Surgery|
89010955|NCT05895331||Dexmedetomidine non-used group in Coronary Bypass Surgery|
89010956|NCT05894759|Experimental|Music therapy|Patients will undergo music therapy, delivered online, for 1 month.
89010957|NCT05894759|Sham Comparator|Relaxing stories|Patients will listen to relaxing stories, online, for 1 month.
89010958|NCT05894759|No Intervention|Treatment as usual|Dermatological treatment as per national guidelines.
89010959|NCT05892965|Experimental|Intervention group|Receive iCBT based EMI with message content, delivery frequency and timing personalised to participants' preferences.
89010960|NCT05892965|No Intervention|Control group|Receive general mental health information through instant message.
89010961|NCT05892640|Experimental|Low-Salt Diet|Low-salt diet (LS diet) according to DASH eating plan, with sodium intake of 1500 mg (3.75 g of salt), within the period of 14 days
89010962|NCT05892458|Experimental|Abdominal massage group|The researchers demonstrated the key points of abdominal massage to patients through a video and provided a detailed explanation of the technique. Patients were encouraged to repeat and practice the massage technique after the video session. To track patient compliance, patients were required to document the frequency of their daily massages, and a designated individual collected this information via WeChat. Follow-up consultations were conducted at 1 month after enrollment and every 3 months thereafter. Patients were encouraged to contact their doctors at any time if they experienced discomfort during the study period.
89010963|NCT05892458|No Intervention|Control group|The control group did not receive any special intervention and were only followed up at 1 month after inclusion and every 3 months thereafter. Patients in this group were advised to contact their doctors if they experienced discomfort during the study period.
89010964|NCT05891015|Experimental|MIED+TAU group|Mindfulness Intervention for Emotional Distress (MIED) program provide standard audio instructions for mindfulness exercises, introduce the nature and law of anxiety, depression and other emotions, the source of anxiety, depression and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems.
89010965|NCT05891015|No Intervention|the TAU-only group|treatment as usual (TAU) group consisted of all medicinal and psychological treatments received between baseline and follow-up (about five months). Medicinal treatments included receiving Lorazepam, Olanzapine, Paroxetine Hydrochloride, Sertraline, etc. Psychological treatments included receiving cognitive behavior therapy or psychodynamic therap
89010966|NCT05887752|Experimental|Standard rehab plus 20-session Hunova rehabilitation|"Patients will receive the Standard rehabilitation for a period of 4 weeks.~In the same 4 weeks and days, the Hunova® rehabilitation (20 sessions in total) will also be administered."
89010967|NCT05887752|Other|Standard rehab plus 10-session, delayed, Hunova rehabilitation|"Patients will receive the Standard rehabilitation for a period of 4 weeks.~During the last 2 weeks, in the same days, the Hunova® rehabilitation (10 sessions in total) will be also administered."
89010968|NCT05882552|Experimental|Tilted Gaze Target Test+Conventional Examinations|Tilted gaze target test is before conventional examination
89010969|NCT05882552|Active Comparator|Conventional Examinations +Tilted Gaze Target Test|Conventional examination is before tilted gaze target test
89010970|NCT05876715|Experimental|Phase 1/2 study using lurbinectedin, ipilimumab and nivolumab for advanced soft tissue sarcoma|"This is an open label, dose-seeking phase 1/2 study using escalating doses of LURBINECTEDIN administered intravenously with fixed doses of IPILIMUMAB and NIVOLUMAB administered intravenously.~I. Dose Escalation Phase 1 of Study: The study will employ the standard cohort of three design (Storer, 1989).~II.Phase 2 of Study: Following completion of dose escalation, an additional 28-34 previously untreated participants will receive LURBINECTEDIN at the MTD and fixed doses of IPILIMUMAB and NIVOLUMAB to assess overall safety and potential efficacy in a larger number of participants."
89010971|NCT05853120|Active Comparator|Doxycycline 100 mg|Doxycycline 100mg Participants will receive the first assigned dose of Doxycycline at the clinic on days 0 and 3 at the clinic. The other three doses of the medication will be taken at home on days 7 and 1
89010972|NCT05853120|Active Comparator|Doxycycline 200 mg|Doxycycline - 200 mg Participants will receive the first assigned dose of Doxycycline at the clinic on days 0 and 3 at the clinic. The other three doses of the medication will be taken at home on days 7 and 10
89010973|NCT05841160|Experimental|200 mg ecopipam HCL|Single 200 mg dose of ecopipam HCL given as 2 x 100 mg ecopipam HCL oral tablets and 4 placebo oral tablets
89010974|NCT05841160|Experimental|600 mg ecopipam HCL|Single 600 mg dose of ecopipam HCL given as 6 x 100 mg ecopipam HCL oral tablets
89010975|NCT05841160|Active Comparator|400 mg moxifloxacin|Single 400 mg dose of moxifloxacin given as 1 x 400 mg oral tablet
89010976|NCT05841160|Placebo Comparator|Placebo|Single oral dose of 6 x placebo tablets
89010977|NCT05813613||Healthy Group|"Will perform squatting exercise while reporting subjective muscle fatigue levels periodically, until maximal subjective fatigue is reached~Will have sEMG for vastus lateralis and rectus femoris, chest expansion, goniometry for the knee recording using the Biopac."
89436670|NCT03085212|Experimental|Online stress management program|Participants will receive free access to Stress Free Now, which is an online stress management program developed by the Cleveland Clinic that uses mindfulness and cognitive-behavior therapy to help individuals learn to manage their stress.
89436671|NCT03085212|Active Comparator|Wait list control|Participants in this arm will receive free access to the Stress Free Now program at the end of the study.
89436672|NCT03074175|Experimental|hyperfractionated radiotherapy group|According to the size of lung lesions,we divided the patients with lesion ≤5cm in diameterand into hyperfractionated radiotherapy group（50Gy/11F/2W).
89436673|NCT03074175|Experimental|conventional fractionated radiotherapy group|According to the size of lung lesions,we divided the patients with lesion >5cm in diameterand into conventional fractionated radiotherapy group（60Gy/30F/6W）.
89436674|NCT03069131|Experimental|Active rifaximin|
89436675|NCT03069131|Placebo Comparator|Rifaximin placebo|
89436676|NCT03047746|Other|TCRalpha/beta Tcell Depletion for BMF with trilineage aplasia|Patients with acquired or inherited bone marrow failure (iBMF) with trilineage aplasia excluding Fanconi Anemia will be given previously established, disease-specific chemotherapy and/or radiation based conditioning regimens prior to hematopoietic stem cell transplantation using TCRalpha/beta and B cell depleted peripheral blood stem cells from unrelated or partially matched related donors.
89436677|NCT03047746|Other|TCRalpha/beta Tcell Depletion for BMF w/o trilineage aplasia|Patients with acquired or inherited bone marrow failure (iBMF) without trilineage aplasia will be given previously established, disease-specific chemotherapy and/or radiation based conditioning regimens prior to hematopoietic stem cell transplantation using TCRalpha/beta and B cell depleted peripheral blood stem cells from unrelated or partially matched related donors.
89436678|NCT03047746|Other|TCRalpha/beta Tcell Depletion for BMF w/ Fanconi Anemia|Patients with acquired or inherited bone marrow failure (iBMF) with Fanconi Anemia and related DNA Repair Disorders will be given previously established, disease-specific chemotherapy and/or radiation based conditioning regimens prior to hematopoietic stem cell transplantation using TCRalpha/beta and B cell depleted peripheral blood stem cells from unrelated or partially matched related donors.
89436679|NCT03037398|Active Comparator|Novel Arm|Programming completed by a novel method
89436680|NCT03037398|Other|Standard of Care Arm|Programming completed as Standard of care
89436681|NCT03032822||All Patients|All cystectomy patients who consent for the study
89436682|NCT02974621|Experimental|Arm A (olaparib, cediranib maleate)|Patients receive olaparib PO BID and cediranib maleate PO once QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89436683|NCT02974621|Experimental|Arm B (bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes every 2 weeks. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89436684|NCT02968849|Active Comparator|ALVAC-HIV + subtype C gp120/MF59|2700 participants will receive an IM injection of ALVAC-HIV (vCP2438) at months 0 and 1, and an IM injection of ALVAC-HIV (vCP2438) + Bivalent Subtype C gp120/MF59 at months 3, 6, and 12.
89436685|NCT02968849|Placebo Comparator|Placebo|2700 participants will receive Sodium Chloride for injection, 0.9% at months 0, 1, 3, 6, and 12.
89010978|NCT05813613||Post Covid-19 Group|"Will perform squatting exercise while reporting subjective muscle fatigue levels periodically, until maximal subjective fatigue is reached~Will have sEMG for vastus lateralis and rectus femoris, chest expansion, goniometry for the knee recording using the Biopac."
89536901|NCT02722499|Experimental|Low Frequency Financial Incentive|This arm will receive telephone delivered diabetes education and skills training in combination with the low frequency incentive structure
89536902|NCT03307499|Experimental|Treatment|NeoPatch
89536903|NCT02468999|Active Comparator|insulin nasal spray|160 Units of human insulin as nasal spray
89010987|NCT05755373||Cardiologists|Cardiologists treating patients with ASCVD and CKD
89010988|NCT05729997|Experimental|Intervention group|The intervention group listened for 4 weeks to live classical music during HD sessions lasting 30 to 40 minutes each.
89010989|NCT05729997|No Intervention|Control group|the control group carried out the usual treatment
89010990|NCT05726604|No Intervention|3D CT Scan|Assesment of an usual cardiac dosimetry based on 3D CT scan. Only this dosimetry will be used to treat the patients. Because of the crossover model, patients are included in both arms.
89010991|NCT05726604|Experimental|4D CT scan with respiratory gating|Assesment of an experimental cardiac dosimetry based on 4D CT scan. Not used to treat the patients. Because of the crossover model, patients are included in both arms.
89010992|NCT05726058|Other|Control|All control participants will be first be imaged pre-intervention.
89010993|NCT05726058|Other|Glaucoma|All participants with glaucoma will be first be imaged pre-intervention.
89010994|NCT05726058|Other|Pre-perimetric Glaucoma|All participants with pre-perimetric glaucoma will be first be imaged pre-intervention.
89010995|NCT05723913|Experimental|Nutritional strategy based on functional foods|Participants will be provided with a nutritional strategy based on functional foods to use over the 2 week trial. These will be nopal, chía seeds, inulin, soy protein, agave extract and genistein.
89010996|NCT05709743|Experimental|Within-Subjects Attentional Information|Within-Subjects, all participants receive all interventions
89010997|NCT05694533|Experimental|INDV-2000 BID + Midazolam|Participants will receive a single oral dose of 5 mg midazolam on Day 1. Participants will receive 400 mg INDV-2000 twice a day (BID) from Days 2 to 15. On Day 15 participants will also receive a single oral dose of 5 mg midazolam co-administered with the INDV-2000 morning dose.
89010998|NCT05681390|Experimental|Tislelizumab Combined With Anlotinib and Chemotherapy|Tislelizumab iv drip, every 3 weeks; Anlotinib, oral，once a day; chemotherapy will be choiced by investigator according guildline.
89010999|NCT05669547|No Intervention|Control|Patients currently on multiple daily injections (MDI) + continuous or flash glucose monitoring (CGM; FGM) or on a hybrid closed loop (HCL).
89011000|NCT05669547|Experimental|Intervention|Patients on dual hormone fully closed loop (DHFCL) therapy.
89011001|NCT05669261|Experimental|ATCell Treatment Group|"A single administration of expanded autologous lines at a total dose exposure of 150 million cells (ATCell™) will be administered to this group."
89011002|NCT05669261|Placebo Comparator|Placebo|a single administration of Placebo (Sham Treatment) IV infusion of Ringers Lactate with 5% Dextrose will be administered to this group.
89436686|NCT02923180|Experimental|Enoblituzumab|Men with localized intermediate and high-risk prostate cancer will be given neoadjuvant Enoblituzumab 15mg/kg IV weekly for 6 weeks followed by radical prostatectomy on day 50, with follow-up visits 30 days and 90 days post-prostatectomy. PSA values will be tracked for 3 years post-prostatectomy.
89436687|NCT02857933|Other|Frequency Level 1 - Daily Therapy|Level 1 daily physical therapy is 2 hours of one-on-one physical therapy per day for 20 straight weekdays
89436688|NCT02857933|Other|Frequency Level 2 - Intermediate Therapy|Level 2 intermediate physical therapy is 2 hours of therapy per day 3 days per week for 6.6 weeks
89436689|NCT02857933|Other|Frequency Level 3 - Usual Therapy|Level 3 usual weekly physical therapy is 2 hours of therapy one day per week for 20 weeks.
89436690|NCT02828904||Users of Chlormadinone Acetate (CMA) combined with Ethinylestradiol (EE)|"CMA/EE users are defined as~aged 15 to 49 years~Participation in one of the 4 observational studies conducted between 2000 and 2019 (LASS/EURAS-OC, INAS-OC, INAS-SCORE, INAS-FOCUS)~COC new user (starters, switchers, and re-starters)"
89436691|NCT02828904||Users of Levonorgestrel (LNG) combined with Ethinylestradiol (EE)|"LNG/EE users are defined as~aged 15 to 49 years~Participation in one of the 4 observational studies conducted between 2000 and 2019 (LASS/EURAS-OC, INAS-OC, INAS-SCORE, INAS-FOCUS)~COC new user (starters, switchers, and re-starters)"
89436692|NCT02797548|Experimental|Aspirin only|
89436693|NCT02797548|Active Comparator|No antiplatelet therapy|
89436694|NCT02795858|Experimental|Ramucirumab In Combination With Somatostatin Analog|"Patients will receive treatment with ramucirumab starting at a dose of 8 mg/kg intravenously every 14 days of a 28-day treatment cycle. Patients already receiving a somatostatin analog continued somatostatin analog therapy at their current dose. Patients not already receiving a somatostatin analog initiated treatment at an approved dose, according to institutional guidelines.~Toxicity and adverse events will be examined in the first 10 patients who complete one cycle of therapy before expanding enrollment."
89436695|NCT02759419|Experimental|BAY63-2521|Single-arm, uncontrolled
89436696|NCT02723773|Experimental|LTFU Group|Long-Term Follow-Up of the subjects who received at least one dose of the HZ/su vaccine in the primary studies ZOSTER-006/022
89436697|NCT02723773|Experimental|Additional Dose Group (1AdD Group)|Subjects who received 2 doses of the HZ/su vaccine in the primary studies ZOSTER-006/022 and will receive 1 additional dose of the HZ/su vaccine in the current study.
88819537|NCT05454345|Active Comparator|The four-month Rifapentine&Isoniazid&Pyrazinamide&Moxifloxacin -containing regimen|Eight weeks of daily treatment with rifapentine, isoniazid, pyrazinamide, and moxifloxacin, followed by Nine weeks of daily treatment with rifapentine, isoniazid, and moxifloxacin.
88819538|NCT05454111|Active Comparator|CARTO-Finder-guided ablation plus PVI|Pulmonary vein circumferential isolation + + ablation of sites recognized by CARTO-Finder module as the core of rotors.
88819539|NCT05454111|Experimental|Multiscale entropy-guided ablation plus PVI|Pulmonary vein circumferential isolation + ablation of sites recognized by multiscale entropy analysis as the core of rotors.
88819540|NCT04459611|Experimental|sintilimab+chemotherapy(2 cycles of neoadjuvant chemotherapy)|Patients with nonsquamous NSCLC (including adenocarcinoma, large cell carcinoma and unspecified type) : sintilimab + pemetrexed + carboplatin; Patients with squamous NSCLC : sintilimab + albumin-bound paclitaxel + carboplatin; Followed by surgery within the 4th week after the second dose of sintilimab; Followed by 2 cycles of adjuvant chemotherapy, the researcher will decide whether to radiotherapy or not according to the clinical situation and pathological stage of the patient; Followed by the maintenance treatment of sintilimab for up to 1 year according to the requirements of patients.
88819541|NCT04459611|Experimental|sintilimab+chemotherapy(3 cycles of neoadjuvant chemotherapy)|Patients with nonsquamous NSCLC (including adenocarcinoma, large cell carcinoma and unspecified type) : sintilimab + pemetrexed + carboplatin; Patients with squamous NSCLC : sintilimab + albumin-bound paclitaxel + carboplatin; Followed by surgery within the 4th week after the third dose of sintilimab; Followed by 1 cycles of adjuvant chemotherapy, the researcher will decide whether to radiotherapy or not according to the clinical situation and pathological stage of the patient; Followed by the maintenance treatment of sintilimab for up to 1 year according to the requirements of patients.
89436698|NCT02723773|Experimental|Revaccination Group (Rev Group)|Subjects who received 2 doses of the HZ/su vaccine in the primary studies ZOSTER-006/022 and will receive 2 additional doses of the HZ/su vaccine in the current study on a 0, 2 Month schedule (N=60).
89436699|NCT02723773|Sham Comparator|Control Group (Ctrl Group)|Subjects who received 2 doses of the HZ/su vaccine in the primary studies ZOSTER-006/022 and will receive no additional doses of the HZ/su vaccine in the current study and will control for the 1-Additional and Revaccination groups
89436700|NCT02723006|Experimental|TAK-580 + nivolumab|TAK-580 orally, once weekly along with nivolumab, intravenous, every 2 weeks.
89536904|NCT02468999|Placebo Comparator|placebo nasal spray|Nasal spray containing placebo solution
88819542|NCT01437098|Experimental|MDT-2111 CoreValve TAVI|Transcatheter Aortic Valve Implantation (TAVI) with MDT-2111 CoreValve system. Access sites for the implant include: Iliofemoral, Subclavian and Direct Aortic.
88819543|NCT03514875|Experimental|MitoQ-Placebo|Subjects will be tested on two different days, first day will be baseline and MitoQ intake, and second day will be placebo intake. Testing will take place 40-minutes after MitoQ and placebo intake. There will be a 2-week washout between testing days.
89198684|NCT00615459|Experimental|Sequence 1: Placebo,Tiotropium, Indacaterol 150 μg|In period I, placebo to indacaterol (150 or 300 μg) delivered via SDDPI. The placebo for blinding tiotropium was delivered via the tiotropium inhalation device. In period II, tiotropium (18 μg) once daily delivered via inhalation device and matching placebo to indacaterol delivered once daily via single dose dry powder inhaler (SDDPI). In period III, indacaterol 150 μg once daily delivered via SDDPI and placebo to tiotropium was delivered once daily via the tiotropium inhalation device. Daily inhaled corticosteroid (ICS) monotherapy (where applicable) was provided to remain stable throughout study. The Short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
88920057|NCT05226923|Experimental|KSP-1007 single ascending dose|Single, ascending intravenous dose of KSP-1007
88920058|NCT05226923|Placebo Comparator|Placebo single dose|Single dose of placebo (0.9% normal saline)
88920059|NCT05226923|Experimental|KSP-1007 multiple ascending dose|Multiple, ascending, intravenous doses of KSP-1007
88920060|NCT05226923|Placebo Comparator|Placebo multiple dose|Multiple doses of placebo (0.9% saline)
88920061|NCT05226923|Experimental|KSP-1007 multiple ascending dose + Meropenem multiple dose|Multiple, ascending intravenous doses of KSP-1007 and multiple doses of meropenem (fixed dose)
89198685|NCT00615459|Experimental|Sequence 2: Indacaterol 300 μg, Indacaterol 150 μg, Tiotropium|In period I,indacaterol 300 μg once daily delivered via single dose dry powder inhaler (SDDPI)and matching placebo to tiotropium delivered once daily via tiotropium inhalation device. In period II, indacaterol 150 μg once daily delivered via SDDPI and matching placebo to tiotropium delivered once daily via tiotropium inhalation device. In period III, tiotropium (18 μg) once daily delivered via inhalation device and matching placebo to indacaterol delivered once daily via SDDPI. Daily ICS monotherapy (where applicable) was provided to remain stable throughout study. The SABA was available for rescue use throughout the study.
89436701|NCT02723006|Experimental|TAK-202 (plozalizumab) + nivolumab|TAK-202 (plozalizumab) 2 milligram (mg), intravenous, once in Week 1, 3, 5, 9, and every 4 weeks thereafter with nivolumab infusion, intravenous, every 2 weeks.
88920062|NCT05226923|Placebo Comparator|Placebo + Meropenem multiple dose|Multiple doses of placebo (0.9% normal saline) plus multiple doses of meropenem (fixed dose)
88920063|NCT05209464|Experimental|Tele-Tai Chi|Study participants will follow a 12-week simplified Tele-Tai-Chi (TC) program delivered via a mobile application.
89436702|NCT02723006|Experimental|vedolizumab + nivolumab + ipilimumab|Vedolizumab intravenous, once in Week 1, 3, 5, and 13 along with nivolumab infusion, intravenous, once in Week 1, 4, 7, 10, and 13 and every 2 weeks thereafter, along with ipilimumab intravenous, once in Week 1, 4, 7, and 10.
88920064|NCT05209165|Experimental|Semaglutide|
88920065|NCT05209165|Placebo Comparator|Placebo|
88920066|NCT05202769||Healthy Volunteers|20 healthy volunteers above the age of 18 in a laboratory setting with video clips taken under varying conditions of lighting, distance between the cameras and the participants' faces and with various positions and limb movements involved.
89011003|NCT05669079|Experimental|Arm A|decitabine (Chia Tai Tianqing Pharma) 15 mg/m2 daily intravenously for consecutive 3 days (day 1 to day 3), combined with umbilical cord blood infusion (day 8)
89011004|NCT05669079|Active Comparator|Arm B|Supportive therapy: G-CSF for patients with absolute neutrophil count ≤ 1.5 × 109/L, rhTPO/TPO-R with platelet count ≤ 30 × 109/L, EPO with hemoglobin ≤ 85g/L.
89011005|NCT05630625|Experimental|Drinking Dashboard|Day-level feedback on alcohol use and consequences
89011006|NCT05630625|No Intervention|Assessment Only|Daily assessment control group
89011007|NCT05611905||11C-para-aminobenzoic acid PET/CT|
89011008|NCT05607173|Experimental|Participants with mild HI|Mild HI is defined as a total score ranging from 5 to 6, inclusive (Child-Pugh score A)
89011009|NCT05607173|Experimental|Participants with moderate HI|Moderate HI is defined as a total score ranging from 7 to 9, inclusive (Child-Pugh score B)
89436703|NCT02632344|Experimental|Pembrolizumab|Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks. Treatment will be administered on Day 1 of each cycle after all procedures/assessments have been completed
89436704|NCT02618967|Experimental|AMG 570 - 7 mg|Participants will receive a single dose 7 mg dose of AMG 570 administered subcutaneously.
89436705|NCT02618967|Experimental|AMG 570 - 21 mg|Participants will receive a single 21 mg dose of AMG 570 administered subcutaneously.
89436706|NCT02618967|Experimental|AMG 570 - 70 mg|Participants will receive a single 70 mg dose of AMG 570 administered subcutaneously.
89436707|NCT02618967|Experimental|AMG 570 - 140 mg|Participants will receive a single 140 mg dose of AMG 570 administered subcutaneously.
89436708|NCT02618967|Experimental|AMG 570 - 210 mg|Participants will receive a single 210 mg dose of AMG 570 administered subcutaneously.
89436709|NCT02618967|Experimental|AMG 570 - 420 mg|Participants will receive a single 420 mg dose of AMG 570 administered subcutaneously.
89436710|NCT02618967|Experimental|AMG 570 - 700 mg|Participants will receive a single 700 mg dose of AMG 570 administered subcutaneously.
89436711|NCT02618967|Placebo Comparator|Placebo|Participants will receive a single dose of the matching AMG 570 placebo administered subcutaneously.
89011010|NCT05607173|Experimental|Participants with normal hepatic function|Participants with normal hepatic function matched to participants
89011011|NCT05586373|Active Comparator|Group 1|Ibuprofen 400mg 6/6h, oral, maximum 5 days
89536905|NCT03311477|Experimental|ABBV-399|ABBV-399 via intravenous administration at escalating dose levels.
89011012|NCT05586373|Experimental|Group 2|Dipyrone 1g 6/6h, oral, maximum 5 days
89011013|NCT05549401|Experimental|Sequence 1|Period 1: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition Period 2: CKD-348(4) F1 - A single oral dose of 1 tablet under fasting condition Period 3: CKD-348(4) F2 - A single oral dose of 1 tablet under fasting condition
89011014|NCT05549401|Experimental|Sequence 2|Period 1: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition Period 2: CKD-348(4) F2 - A single oral dose of 1 tablet under fasting condition Period 3: CKD-348(4) F1 - A single oral dose of 1 tablet under fasting condition
89011015|NCT05549401|Experimental|Sequence 3|Period 1: CKD-348(4) F1 - A single oral dose of 1 tablet under fasting condition Period 2: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition Period 3: CKD-348(4) F2 - A single oral dose of 1 tablet under fasting condition
89011016|NCT05549401|Experimental|Sequence 4|Period 1: CKD-348(4) F1 - A single oral dose of 1 tablet under fasting condition Period 2: CKD-348(4) F2 - A single oral dose of 1 tablet under fasting condition Period 3: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition
89011017|NCT05549401|Experimental|Sequence 5|Period 1: CKD-348(4) F2 - A single oral dose of 1 tablet under fasting condition Period 2: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition Period 3: CKD-348(4) F1 - A single oral dose of 1 tablet under fasting condition
89011018|NCT05549401|Experimental|Sequence 6|Period 1: CKD-348(4) F2 - A single oral dose of 1 tablet under fasting condition Period 2: CKD-348(4) F1 - A single oral dose of 1 tablet under fasting condition Period 3: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition
89011019|NCT05491668||Coronary Physiology Assessment|Patients undergoing coronary angiogram who are found to have >/= 70% coronary stenosis and planned for percutaneous coronary intervention (PCI)/stent placement, will undergo pre and post PCI invasive physiologic assessment with a coronary pressure-sensing wire (OpSens OptoWire III) using non-hyperemic pressure ratio (NHPR) indices (diastolic pressure ratio [dPR]). Both the patient and interventional cardiologist will be blinded to the results of the invasive physiologic assessment. Angiogram co-registration will be performed on pullback of coronary pressure-sensing wire.
89011020|NCT05472519|Other|Loeys-Dietz syndrome|Patients aged ≥ 5 years with Loeys-Dietz syndrome with a diagnosis confirmed by the presence of a TGF-βR 1 or R2 mutation.
89436712|NCT02618252|Experimental|Zonare|108 patients are randomized to receive the intervention of using ultrasound machine (Zonare ZS3 machine) for IV cannulation. These patients will first undergo IV cannulation with assistance of the ultrasound machine.
89436713|NCT02618252|Experimental|Veinviewer|108 Patients are randomized to receive the Intervention of using the Veinviewer Flex machine for IV cannulation. These patients will first undergo IV cannulation with assistance of the Veinviewer Flex machine.
89436714|NCT02592356|Experimental|Cabozantinib or Lenvatinib|Patients treated with cabozantinib s-malate or lenvatinib mesylate are observed for body weight, skeletal muscle and adipose tissue changes. Patients complete 3 to 4 questionnaires every 2 weeks for 6 months and then monthly up to 12 months. Patients also undergo physical assessments and body composition measurements by DXA and CT scans at baseline, months 3, 6, and 12.
89436715|NCT02562235|Experimental|Riociguat|Participants with age ≥6 to <18 years received riociguat up to 2.5 mg three times a day (titration between 1.0 mg and 2.5 mg) for up to 8 weeks during the individual dose titration (IDT) phase, and followed with the last dose administered in the IDT phase for up to 16 weeks during the maintenance phase. Down-titration (up to 0.5 mg) of the dose for safety reasons was allowed at any time.
89436716|NCT02517684|Experimental|Top-down|Infliximab and azathioprine; patients will receive 5 infliximab infusions of 5 mg/kg (IFX induction at week 0, 2 and 6, followed by 2 maintenance infusions every 8 weeks). IFX will be discontinued after 5 IFX infusions. Patients will also receive oral azathioprine 2-3 mg/kg, once daily as maintenance treatment.
88920067|NCT05202769||ICU patients|Group/Cohort Description: 20 patients above the age of 18 years and able to provide consent, admitted to the ICU with various underlying conditions and comorbidities. Video clips are taken under varying conditions of lighting, positions and with ongoing care and procedures.
88920068|NCT05158933|Experimental|Treatment Group (AlloRx)|Single intravenous infusion of 100 million cells
88920069|NCT05158114|Experimental|Treatment Group (AlloRx)|Single intravenous infusion of 100 million cells
88920070|NCT05158101|Experimental|Treatment Group (AlloRx)|Single intravenous infusion of 100 million cells
88920071|NCT05152368|Experimental|Treatment Group (AlloRx)|Single intravenous infusion of 100 million cells
88920072|NCT05147701|Experimental|Treatment Group (AlloRx)|intravenous and sub-tenon delivery (total dose of 100 million cells)
88920073|NCT05137275|Experimental|Anti-5T4 CAR-raNK Cells|
88920074|NCT05126316|Experimental|Lu AG09222 Low Dose|Participants will receive Lu AG09222 injection at a low dose level 3 times with 4 weeks between each administration.
88920075|NCT05126316|Experimental|Lu AG09222 High Dose|Participants will receive Lu AG09222 injection at a high dose level 3 times with 4 weeks between each administration.
88920076|NCT05126316|Placebo Comparator|Placebo|Participants will receive placebo matching to Lu AG09222 injection 3 times with 4 weeks between each administration.
88920077|NCT05094713|Other|Flossing - control|Control group where flossing wrapping pressure is between 20 and 30 mmHg
88920078|NCT05094713|Experimental|Flossing with medium wrapping pressure|A flossing band will be applied over tight musculature with medium wrapping pressure
88920079|NCT05071729|Experimental|Moderate renal impairment|Participants with estimated glomerular filtration rate (eGFR) of 30 to 59 mL/min/1.73 m^2
88920080|NCT05071729|Experimental|Severe renal impairment|Participants with eGFR < 30 mL/min/ 1.73 m^2
88920081|NCT05071729|Experimental|Normal renal function|Participants with ≥ 90 mL/min/1.73 m^2
88920082|NCT05059886||lower limb amputee|No intervention, pure observational study
88920083|NCT05057949|Experimental|Part A, Treatment Sequence(Larotinib-Larotinib/Rifampin)|Larotinib , capsules (150mg*2+50mg*1), at Hour 0 on Day 1 followed by an overnight fast. On Days 15 to 26, participants received rifampin 600 mg as capsules, orally, once daily (QD) and Larotinib 350 mg as capsules, orally was coadministered on Day 20. There was a washout period of 13 days between the two treatments.
88920084|NCT05057949|Experimental|Part B, Treatment Sequence(Larotinib-Larotinib/itraconazole)|Larotinib , capsules (150mg*2+50mg*1), at Hour 0 on Day 1 followed by an overnight fast. On Days 15 to Day 25, participants received itraconazole 200 mg solution, orally, once daily (QD) on Days 15 to Day 25 and a single oral dose of Larotinib 350 mg as capsule was coadministered on Day 19 (Treatment B). There was a washout period of 13 days between the two treatments.
88920085|NCT05048368|Experimental|Cohort A-Larotinib|Cohort A:Healthy participants with normal hepatic function （match to subjects with mild hepatic impairment_cohort B）
88920086|NCT05048368|Experimental|Cohort B-Larotinib|Subjects with mild hepatic impairment
88920087|NCT05048368|Experimental|Cohort C-Larotinib|Healthy participants with normal hepatic function （match to subjects with moderate hepatic impairment_cohort D）
88920088|NCT05048368|Experimental|Cohort D-Larotinib|Subjects with moderate hepatic impairment.
88920089|NCT05047159|Experimental|drug therapy group|Drug: drug therapy There is no restriction on the choice of therapeutic drugs.
88920090|NCT05047159|Experimental|drug therapy combined with repetitive transcranial magnetic stimulation (rTMS) group|"Device: rTMS Stimulation will be performed for 20 working days once a day (4 weeks). Extend course to 30 sessions (6 weeks) in responders who have not achieved symptom remission.~Frequency: 10Hz; Intensity: 110% RMT; Coil-type: F8; Sessions-pulse: 3000; Site: the left dorsolateral prefrontal cortex.~Drug: drug therapy There is no restriction on the choice of therapeutic drugs."
88920091|NCT05047159|Experimental|drug therapy combined with light therapy group|"Device: light therapy Active 10,000-lux fluorescent white light box for 30 min/d in the early morning for 6 weeks.~Drug: drug therapy There is no restriction on the choice of therapeutic drugs."
88920092|NCT05047159|Experimental|drug therapy combined with electroconvulsive therapy (ECT) group|"Device: ECT The electrode placements are bifrontal (BF); the electrical intensity is 1.5 to 2.0 times the seizure threshold (ST); 3 times per week.~Drug: drug therapy There is no restriction on the choice of therapeutic drugs."
88920093|NCT05047159|Experimental|drug therapy combined with magnetic seizure therapy (MST) group|"Device: MST A coil placement at the vertex (i.e., Cz in 10-20 electroencephalogram [EEG] system) with a frequency of stimulation of 100 Hz, pulse width of 0.2 to 0.4 ms, and stimulation duration of 10 seconds; 2 times per week.~Drug: drug therapy There is no restriction on the choice of therapeutic drugs."
88920094|NCT05033431|Experimental|Group 1 [Healthy Chinese Participants]|Participants will receive a single intravenous (IV) infusion of brazikumab dose 1 on Day 1.
88920095|NCT05033431|Experimental|Group 2 [Healthy Chinese Participants]|Participants will receive a single IV infusion of brazikumab dose 2 on Day 1.
88920096|NCT05033431|Experimental|Group 3 [Healthy Chinese Participants]|Participants will receive a single subcutaneous (SC) injection of brazikumab dose 3 on Day 1.
88920097|NCT05033431|Experimental|Group 4 [Healthy Chinese Participants]|Participants will receive a single SC injection of brazikumab dose 4 on Day 1.
88920098|NCT05033431|Experimental|Group 5 [healthy White participants]|Participants will receive a single IV infusion of brazikumab dose 2 on Day 1.
88920099|NCT05033431|Experimental|Group 6 [healthy White participants]|Participants will receive a single SC injection of brazikumab dose 4 on Day 1.
89011021|NCT05472519|Other|Healthy Group|Subjects aged ≥ 5 years.
89198686|NCT00615459|Experimental|Sequence 3: Indacaterol 150 μg, Indacaterol 300 μg, Placebo|In period I, indacaterol 150 μg once daily delivered via SDDPI and matching placebo to tiotropium delivered once daily via tiotropium inhalation device. In period II, indacaterol 300 μg once daily delivered via SDDPI and matching placebo to tiotropium delivered once daily via tiotropium inhalation device. In period III, placebo to indacaterol (150 or 300 μg) delivered via SDDPI. The placebo for blinding tiotropium was delivered via the tiotropium inhalation device. Daily ICS monotherapy (where applicable) was provided to remain stable throughout study. The SABA was available for rescue use throughout the study.
89198687|NCT00615459|Experimental|Sequence 4: Tiotropium, Placebo, Indacaterol 300 μg|In period I, tiotropium (18 μg) once daily delivered via inhalation device and matching placebo to indacaterol delivered once daily via SDDPI. In period II, placebo to indacaterol (150 or 300 μg) delivered via SDDPI. The placebo for blinding tiotropium was delivered via the tiotropium inhalation device. In period III, indacaterol 300 μg once daily delivered via SDDPI and matching placebo to tiotropium delivered once daily via tiotropium inhalation device. Daily ICS monotherapy (where applicable) was provided to remain stable throughout study. The SABA was available for rescue use throughout the study.
89198688|NCT04048902|Placebo Comparator|Pilates and Shortwave placebo|In this group the patients will receive 20 minutes of short wave placebo application. The equipment will keep the timer on and the intensity will remain at zero. The patient will be informed that the dose is subsensory and therefore there will be no perception of the passage of the short waves through the body.The application will be performed with two coplanar plates in parallel, arranged on the right and left side of the lumbar region, maintaining a distance of 5 to 10 cm between them, with the patient lying in the dorsal decubitus position
88819544|NCT03514875|Experimental|Placebo-MitoQ|Subjects will be tested on two different days, first day will be baseline and placebo intake, and second day will be MitoQ intake. Testing will take place 40-minutes after placebo and MitoQ intake. There will be a 2-week washout between testing days.
88920100|NCT05023616|Experimental|Real-time home CPR training|Online real-time home CPR(cardiopulmonary resuscitation) training will be provided to participants
89436717|NCT02517684|Active Comparator|Step-up|Step-up treatment will consist of standard induction treatment by either oral prednisolone 1 mg/kg (maximum 40 mg) once daily for 4 weeks, followed by tapering in 6 weeks until stop, or EEN with polymeric feeding for 6-8 weeks after which normal foods are gradually reintroduced within 2-3 weeks. Either of these induction treatments will be combined with oral AZA 2-3 mg, once daily, as maintenance treatment.
88819545|NCT03497871|Experimental|HeartMan intervention group|"80 patients are in the intervention group (40 in Belgium and 40 in Italy).~They use the HeartMan system in addition to receiving standard care."
89436718|NCT02498600|Active Comparator|Group I (nivolumab)|"INDUCTION: Patients receive nivolumab IV over 30 minutes every 2 weeks. Treatment repeats every 4 weeks for 2 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive nivolumab IV over 30 minutes every 2 weeks. Treatment repeats every 4 weeks for up to 21 cycles in the absence of disease progression or unacceptable toxicity."
89436719|NCT02498600|Experimental|Group II (nivolumab, ipilimumab)|"INDUCTION: Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 90 minutes. Treatment repeats every 3 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive nivolumab IV over 30 minutes every 2 weeks. Treatment repeats every 4 weeks for up to 21 cycles in the absence of disease progression or unacceptable toxicity."
89436720|NCT02487095|Experimental|1/Phase I VX-970 (M6620) + topotecan|VX-970 (M6620) + topotecan at escalating doses
89436721|NCT02487095|Experimental|2/Phase II VX-970 (M6620) + topotecan|VX-970 (M6620) + topotecan at maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D)
89436722|NCT02486315||AXXESS stent|"all consecutive patients with de novo bifurcation lesions treated at the Clinica Mediterranea (Naples) and at the Sapienza University (Rome) were screened for potential inclusion in the present study. Inclusion angiographic criteria were: 1) significant (≥70% diameter stenosis) bifurcation lesion; 2) MV reference diameter between 2.75 and 4.75 mm by visually estimated, 3) SB reference diameter ≥2.25 mm by visual estimate; 4) bifurcation angle (between the distal MV and the SB) <70° by visual estimate. Both protected and unprotected left main bifurcation lesions were allowed to be included, provided that all previous angiographic criteria were satisfied. Patients deemed eligible underwent AXXESS stent implantation"
89436723|NCT02486315||Control group|"The control group is represented by patients with coronary bifurcation lesions treated with conventional techniques and standard balloon expandable drud eluting stents.~This group was found retrospectively through a propensity score matching."
89436724|NCT02466321|Experimental|Inverse / Reverse Shoulder|Patient treated with a inverse / reverse shoulder device.
89436725|NCT02465398|Other|Fracture device|Patient were treated with an Anatomical Shoulder Fracture device.
89436726|NCT02451683|Other|Electrophysiology Assessment of Time Domain|Assessment of electrophysiology in the time domain to examin temporal organization of corticospinal function
89436727|NCT02451683|Experimental|Electrophysiology Assessment of Location|Assessment of electrophysiology to examine spatial organization of corticospinal function
89436728|NCT02451683|Active Comparator|Training with some stimulation|Training with non-invasive stimulation and training with sham stimulation
89436729|NCT02446600|Active Comparator|Arm I (platinum-based chemotherapy)|See detailed description.
89436730|NCT02446600|Experimental|Arm II (olaparib)|Patients receive olaparib PO BID. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO or MUGA during screening. Patients also undergo CT or MRI as well as blood sample collection throughout the trial.
89436731|NCT02446600|Experimental|Arm III (olaparib, cediranib maleate)|Patients receive olaparib PO BID and cediranib maleate PO QD. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO or MUGA during screening and as clinically indicated on study. Patients also undergo CT or MRI as well as blood sample collection throughout the trial.
89436732|NCT02428192|Experimental|Cohort A (nivolumab - closed to accrual on 21-Oct-2015)|Patients receive nivolumab IV over approximately 60 minutes once every 2 weeks for up to 46 doses in the absence of disease progression or unacceptable toxicity.
89436733|NCT02428192|Experimental|Cohort B (nivolumab and Ipilimumab)|Patients receive nivolumab IV over approximately 60 minutes followed by a saline flush and ipilimumab IV over 90 minutes. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
89436734|NCT02345265|Experimental|Treatment (olaparib and cediranib maleate)|Patients receive olaparib PO BID and cediranib maleate PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo a biopsy of tumor, blood sample collection, MUGA or echocardiogram, and CT scan or MRI scan throughout the study.
88920101|NCT05023616|Active Comparator|Conventional CPR training|Conventional CPR training will be provided to participants
88920102|NCT05018858|Experimental|Treatment Group (AlloRx)|Single intravenous infusion of 100 million cells
88920103|NCT05018845|Experimental|Treatment Group (AlloRx)|Single intravenous infusion of 100 million cells
88920104|NCT05018819|Experimental|Treatment Group|Single intravenous infusion of 100 million cells
88920105|NCT05016817|Experimental|Treatment Group|Single intravenous infusion of 100 million cells
88920106|NCT05016804|Experimental|Treatment Group|Single intravenous infusion of 100 million cells
88920107|NCT05003947|Experimental|Treatment Group|Single intravenous infusion of 100 million cells
88920108|NCT05003934|Experimental|Treatment Group|Single intravenous infusion of 100 million cells
88920109|NCT05001581|Active Comparator|Treatment with biceps augmentation|Complete repair of ISP if possible with partial SSP repair and biceps augmentation after its tenodesis
88920110|NCT05001581|Active Comparator|Treatment without biceps augmentation|Complete repair of ISP if possible with partial SSP repair and biceps tenotomy
88920111|NCT04980365|Experimental|Mindfulness|Participants will be asked to use the app Mindfulness Coach 10 minutes for 14 days.
88920112|NCT04980365|Experimental|Gratitude|Participants will be asked to use the app Grateful 10 minutes for 14 days.
88920113|NCT04980365|Active Comparator|Control|Participants will be asked to use the app Day One daily for 10 minutes. Participants will be writing a daily journal entry describing what they ate during the previous day for 14 days.
88920114|NCT04959162|Experimental|E-learning preparation|Will receive e-learning prior to a hands-on course in musculoskeletal ultrasound
89198689|NCT04048902|Active Comparator|Pilates and Shortwave active|In this group the patients will receive 20 minutes of application of the Shortwave Active continuous mode (thermal effect), with vigorous local thermal sensation.The application will be performed with two coplanar plates in parallel, arranged on the right and left side of the lumbar region, maintaining a distance of 5 to 10 cm between them, with the patient lying in the dorsal decubitus position
88920115|NCT04959162|Active Comparator|Conventional preparation|Will receive standard information (time, place etc) prior to a hands-on course in musculoskeletal ultrasound
88920116|NCT04936620|Active Comparator|Duroplasty|Duroplasty (includes Surgery with Laminectomy)
88920117|NCT04936620|Active Comparator|No duroplasty|No duroplasty (but includes surgery with Laminectomy)
88920118|NCT04904432|Other|young ACS patients|
88920119|NCT04901312|Experimental|Enhanced A-CRA (E-ACRA)|Higher intensity
88920120|NCT04901312|Experimental|Assertive Community Support (ACS)|Lower intensity
88920121|NCT04886297|Placebo Comparator|placebo|"The placebo capsules only contained pullulan and maltodextrin. During the trial period, the participants were instructed to consume two Mega Resveratrol® placebo capsules once daily (30 min after breakfast).~Intervention: Drug: Mega Resveratrol® capsules"
88920122|NCT04886297|Experimental|100mg/d resveratrol|"During the trial period, the participants will be instructed to consume one Mega Resveratrol® capsules and one Mega Resveratrol® placebo capsules 30 min after breakfast. The resveratrol capsules (100 mg anthocyanins per capsule) will provid a total daily intake of 100 mg resveratrol.~Intervention: Drug: Mega Resveratrol® capsules"
88920123|NCT04886297|Experimental|300mg/d resveratrol|"During the trial period, the participants will be instructed to consume one Mega Resveratrol® capsules and one Mega Resveratrol® placebo capsules 30 min after breakfast. The resveratrol capsules (300 mg anthocyanins per capsule) will provid a total daily intake of 300 mg resveratrol.~Intervention: Drug: Mega Resveratrol® capsules"
88920124|NCT04886297|Experimental|600mg/d resveratrol|"During the trial period, the participants will be instructed to consume two Mega Resveratrol® capsules 30 min after breakfast. The resveratrol capsules (300 mg anthocyanins per capsule, 2 per day) will provid a total daily intake of 600 mg resveratrol.~Intervention: Drug: Mega Resveratrol® capsules"
88920125|NCT04810793||Amoxicillin-Levofloxacin-Esomeprazole-containing quadruple group|Patients in amoxicillin-levofloxacin-esomeprazole-containing quadruple group will receive esomeprazole (Nexium) 40mg po bid, amoxicillin 1000mg po bid, bismuth potassium citrate(Lizhudele) 220mg po bid, and levofloxacin 500mg po qd for 14d.
88920126|NCT04810793||Amoxicillin-Furazolidone-Esomeprazole-containing quadruple group|Patients in amoxicillin-furazolidone-esomeprazole-containing quadruple group will receive esomeprazole (Nexium) 40mg po bid, amoxicillin 1000mg po bid, bismuth potassium citrate(Lizhudele) 220mg po bid, and furazolidone (Liteling) 100mg po bid for 14d.
88920127|NCT04810793||Tetracycline-Furazolidone-Esomeprazole-containing quadruple group|Patients in tetracycline-furazolidone-esomeprazole-containing quadruple group will receive esomeprazole (Nexium) 40mg po bid, tetracycline 500mg po qid, bismuth potassium citrate(Lizhudele) 220mg po bid, and furazolidone (Liteling) 100mg po bid for 14d.
88920128|NCT04810793||Amoxicillin-Levofloxacin-Vonoprazan fumarate-containing quadruple group|Patients in amoxicillin-levofloxacin-vonoprazan fumarate-containing quadruple group will receive vonoprazan fumarate 20mg po bid, amoxicillin 1000mg po bid, bismuth potassium citrate(Lizhudele) 220mg po bid, and levofloxacin 500mg po qd for 14d.
88920129|NCT04810793||Amoxicillin-Furazolidone-Vonoprazan fumarate-containing quadruple group|Patients in amoxicillin-furazolidone-vonoprazan fumarate-containing quadruple group will receive vonoprazan fumarate 20mg po bid, amoxicillin 1000mg po bid, bismuth potassium citrate(Lizhudele) 220mg po bid, and furazolidone (Liteling) 100mg po bid for 14d.
88920130|NCT04810793||Tetracycline-Furazolidone-Vonoprazan fumarate-containing quadruple group|Patients in tetracycline-furazolidone-vonoprazan fumarate-containing quadruple group will receive vonoprazan fumarate 20mg po bid, tetracycline 500mg po qid, bismuth potassium citrate(Lizhudele) 220mg po bid, and furazolidone (Liteling) 100mg po bid for 14d.
88920131|NCT04797832|Active Comparator|Treatment|100 patients receiving IV Iron during index hospitalisation.
88920132|NCT04797832|No Intervention|No treatment|100 patients not receiving IV Iron above standout treatment.
88920133|NCT04742647|Experimental|Single Cerclage|Standard single cervical cerclage will be placed
88920134|NCT04742647|Experimental|Double Cerclage|Double cerclage placement
89436735|NCT02338986||Healthy Volunteers|Collection of Plasma From Subjects That Recovered From or Were Vaccinated To Emerging Infectious Diseases
89436736|NCT02320435|Experimental|Pertuzumab (Single-Agent or Combination Therapy)|Pertuzumab will continue to be administered as a single agent or in combination with other anti-cancer therapies at the same dose, schedule, and guidelines that were in effect at the end of the Parent study.
88920135|NCT04709575|Experimental|REGN5713-5714-5715|REGN5713-5714-5715 administered subcutaneously
88920136|NCT04709575|Placebo Comparator|Placebo Only|Placebo matching REGN5713-5714-5715 administered subcutaneously
88920137|NCT04684511|Experimental|TRM-201 (Rofecoxib)|1 TRM-201 tablet taken orally once daily for 12 weeks in Part I and orally once daily for an additional 52 weeks in Part II
89536549|NCT04259463||Full anesthesia|Patients undergoing third molars extraction under full anesthesia. . The patient is fully acquainted with the procedure of general anesthesia. It is a controlled state of unconsciousness when protective reflexes disappear, the patient cannot breathe and does not respond to verbal commands. A special intubation tube is introduced into the airways.
89536550|NCT04995393|Active Comparator|Glove|A heated glove containing water.
88920138|NCT04684511|Placebo Comparator|Placebo|1 placebo tablet (to match TRM-201) taken orally once daily for 12 weeks in Part I and then 1 TRM-201 tablet taken orally once daily for an additional 52 weeks in Part II
89536551|NCT04995393|Active Comparator|Blanket|A heated blanket.
89536552|NCT04995393|Active Comparator|Gel pack|A heated gel pack.
88920141|NCT04673149|Experimental|GLS-5310 0.6mg [Group 1a]|0.6mg of GLS-5310 will be intradermally administered on Day 0 and Week 8.
88920142|NCT04673149|Experimental|GLS-5310 1.2mg [Group 1b]|1.2mg of GLS-5310 will be intradermally administered on Day 0 and Week 8.
88920143|NCT04673149|Experimental|GLS-5310 1.2mg [Group 1c]|1.2mg of GLS-5310 will be intradermally administered on Day 0 and Week 12.
88920144|NCT04673149|Placebo Comparator|Placebo [Group 2a]|Placebo will be intradermally administered on Day 0 and Week 8 (or Week 12).
89536553|NCT02472119|Experimental|rusks made with treated flour|Gluten-free diet adding rusks (100g / day) produced with commercial wheat flour enzymatically treated with mTGasi and lysine ethyl ester.
88920145|NCT04673149|Experimental|GLS-5310 1.2mg [Group 2b]|1.2mg of GLS-5310 will be intradermally administered on Day 0 and Week 8 (or Week 12).
88920146|NCT04669652|No Intervention|ICSI|Traditional microinjection (ICSI) is performed on oocytes.
88920147|NCT04669652|Experimental|Piezo-ICSI|Microinjection (ICSI) is performed using the Piezo-ICSI technique.
88920148|NCT04644978||Trainees and specialists in child and adult psychiatry|"The responder must be a practising specialist or trainee in psychiatry or child and adolescent psychiatry in the participating European countries on the basis of his / her own declaration. Responders could provide their consent by choosing I agree on the website, after reading the information leaflet and the informed consent form."
88920149|NCT04637438|Active Comparator|Fecal Microbiota Transplantation|
88920150|NCT04637438|Placebo Comparator|Plasebo|
88920151|NCT04912648||Women age 18 years and older|"baseline anthropometry~bloods for metabolic phenotype; targeted and nontargeted Metabolomics~saliva and urine for steroid Metabolomics~bioimpedance~muscle biopsy for transcriptomics"
88920152|NCT04636164|Experimental|DNN group|using deep neural networks for skin lesion diagnosis
88920153|NCT04636164|No Intervention|Control group|conventional diagnosis
88920154|NCT04565171|Experimental|Participants with renal impairment|Participants with End-stage renal disease will receive a single dose of Yimitasvir Phosphate Capsule.
88920155|NCT04565171|Experimental|Participants with normal renal function|Participants with normal renal function will receive a single dose of Yimitasvir Phosphate Capsule.
88920156|NCT04528238|Experimental|Relaxing Visual Immersion|The patients will benefit a Relaxing Visual Immersion during the intravenous treatment for their cancer.
88920157|NCT04528238|No Intervention|No sensitive stimulation|The patients will not receive Relaxing Visual Immersion during the intravenous treatment for their cancer.
88920158|NCT04505449||Left heart catheterization|Symptomatic patients who underwent left heart catheterization and coronary angiography.
88920161|NCT04450407|Experimental|LY3209590 Algorithm 1 (Paper)|Algorithm 1 is a paper-based algorithm where dose adjustments were manually determined by the investigator based on fasting glucose and hypoglycemia data. LY3209590 was provided in a 20 milligram (mg) vial of reconstitutable lyophilized powder. Participants received individualized LY3209590 loading dose based on the basal insulin dose prior randomization and baseline fasting glucose by subcutaneous (SC) injection on day 1 followed by weekly adjustments for the first 12 weeks, then every 4 weeks, of a 26-week treatment period, to achieve target fasting glucose of <=100 milligrams per deciliter (mg/dL).
88920162|NCT04450407|Experimental|LY3209590 Algorithm 2 (Digital)|"Algorithm 2 is a computer-based algorithm to determine dose adjustments. LY3209590 was provided in a 20 mg vial of reconstitutable lyophilized powder. Participants received individualized LY3209590 loading dose based on the basal insulin dose prior randomization and baseline fasting glucose by SC injection on day 1 followed by weekly adjustments for the first 12 weeks, then every 4 weeks, of a 26-week treatment period, to achieve target fasting glucose of <=100 mg/dL.~As per protocol amendment (d) approved on 28-Oct-2020, this arm was terminated during the early enrollment phase due to technical issues with data entry."
88920163|NCT04450407|Active Comparator|Insulin Degludec|Insulin degludec was provided as 100 units/milliliter (U/mL) in a prefilled pen. Participants received individually adjusted doses once daily by SC injection with a starting dose same as basal insulin dose prior randomization, during the 26-week treatment period, to achieve target fasting blood glucose of <=100 mg/dL.
88920164|NCT04396886|Experimental|Bintrafusp Alfa|Single group assignment of bintrafusp alfa in previously treated patients with recurrent and metastatic (R/M) nonkeratinizing nasopharyngeal carcinoma (NPC)
88920165|NCT04388826|Experimental|Veru-111 18 mg|Veru-111 18mg capsules
88920166|NCT04388826|Placebo Comparator|Placebo|Placebo capsules
89536554|NCT02472119|Active Comparator|rusks made with not-treated flour|Gluten-free diet adding rusks (100g / day) produced with untreated wheat flour.
89536555|NCT04988139|Active Comparator|Intervention group|traditional rehabilitation programs with additional individualized educational training
89536556|NCT04988139|No Intervention|Control group|traditional rehabilitation programs without additional individualized educational training
89536557|NCT04995159|Experimental|Poststent SAPT treatment cohort|receiving the treatment with NeoVas™ Bioabsorbable Coronary Artery Rapamycin-eluting Stent System of Lepu Medical combined with SAPT strategy
89536558|NCT04995159|Active Comparator|Poststent DAPT treatment cohort|receiving the treatment with NeoVas™ Bioabsorbable Coronary Artery Rapamycin-eluting Stent System of Lepu Medical combined with DAPT strategy
89536559|NCT02472275|Experimental|Treatment (PLX3397, radiation therapy, ADT)|Patients receive multitargeted tyrosine kinase inhibitor PLX3397 PO BID for 6 months, undergo radiation therapy for 2 months daily (Monday-Friday) beginning at month 3, and undergo ADT with leuprolide acetate, goserelin acetate, or degarelix injections in any month.
88920167|NCT04334681||UC Group|Patients operated on the un-roofing curettage method in the treatment of pilonidal disease will be analyzed in this group.
88920168|NCT04334681||LF Group|Patients who have been operated with the modified Limberg flap method after rhomboid excision in the treatment of pilonidal disease will be analyzed in this group.
88920169|NCT04309292|Experimental|Treatment Arm|protein supplementation plus prebiotic supplementation
88920170|NCT04309292|Placebo Comparator|Placebo Arm|Protein supplementation plus placebo
88920171|NCT04306601|Experimental|Low-Intensity focused ultrasound brain stimulation|Low-intensity focused ultrasound brain stimulation using focused ultrasound system (NS-US100; NEUROSONA Co. Ltd., Seoul, Korea)
88920172|NCT04301544|Experimental|INDAK & Standardized Vascular Care Group|The experimental arm will receive training on the ballroom dance modules called INDAK (Improving Neurocognition through Dance and Kinesthetics), nutrition counseling and vascular risk management
89536560|NCT03109067|Experimental|Standardized meal|"Standardized meal for :~50 patients with a TaqIB AA polymorphism 50 patients with a TaqIB GG polymorphism"
89536561|NCT04491773||Patients undergoing Tadalafil|Patients after radical prostatectomy, undergoing Tadalafil 20 mg orally, on alternative days, for more than 6 months
89536562|NCT04491773||Control Group|Healthy controls without previous surgery of radical prostatectomy.
89536563|NCT02472197|Experimental|morcellation|
88920173|NCT04301544|Active Comparator|Standardized Vascular Care Group|The control group will receive nutrition counseling and vascular risk management
88920174|NCT04284319|Experimental|DCD Heart Transplantation Using NRP|Heart Transplantation Using Normothermic Regional Perfusion (NRP) Donation After Circulatory Death (DCD)
88920175|NCT04231838|Active Comparator|Standard Arm (Arm A)|Participant continues smoking their own cigarette brand.
88920176|NCT04231838|Active Comparator|Intervention Arm (Arm B)|Participant switches to using C-F NDS
88920177|NCT04218266|Experimental|BAY2433334 50mg+Apixaban matching placebo|
88920178|NCT04218266|Experimental|BAY2433334 20mg+Apixaban matching placebo|
88920179|NCT04218266|Active Comparator|BAY2433334 matching placebo+Apixaban|Apixaban usual dose is 5 mg, reduced to 2.5 mg for participants with any 2 of the following criteria: age 80 years or older, body weight less than 60 kg, or serum creatinine level of 1.5 mg per dL or more.
88920180|NCT04172363|No Intervention|Standard Care|Octenisept will be used as standard care antiseptic for dressing change
88920181|NCT04172363|Experimental|Resistance testing|Patients will be first tested on resistance to Octenisept and Serasept and will receive the appropriate antiseptic after reviewing the results
88920182|NCT04155684||HIV + with COPD|COPD will be defined as Subjects with FEV1/FVC<0.70 or FEV1 and DLco < 80% predicted
88920183|NCT04155684||HIV+ normal|Normal PFT's
88920184|NCT04104490||Severe pulmonary arterial hypertension.|"This cohort will consist of patients with severe pulmonary arterial hypertension.~This is defined as mean pulmonary arterial pressure 25 mm Hg or greater and pulmonary artery occlusion pressure 15 mmHg or less measured by right cardiac catheterization and a clinical diagnosis of severe disease.~Participants will be without signs of left heart disease, lung disease and or hypoxia, chronic thromboembolic pulmonary hypertension or pulmonary hypertension of unclear multifactorial mechanisms.~This is an observational study with no interventions."
88920185|NCT04104490||Mild-moderate pulmonary arterial hypertension|"This cohort will consist of patients with mild-moderate pulmonary arterial hypertension.~This is defined as mean pulmonary arterial pressure 25 mm Hg or greater and pulmonary artery occlusion pressure 15 mmHg or less measured by right cardiac catheterization and a clinical diagnosis of mild-moderate disease.~Participants will be without signs of left heart disease, lung disease and or hypoxia, chronic thromboembolic pulmonary hypertension or pulmonary hypertension of unclear multifactorial mechanisms.~This is an observational study with no interventions."
88920186|NCT04104490||Reference subjects without pulmonary hypertension|Reference subjects will be healthy people, age- and sex-matched to the other two cohorts, who have no pulmonary artery hypertension.
88920187|NCT04087304|No Intervention|Low Risk Group|
88920188|NCT04087304|No Intervention|Mild Risk Group|
88920189|NCT04087304|Active Comparator|Moderate Risk Group|
88920190|NCT04087304|Active Comparator|High Risk Group|
88920191|NCT04074603|Experimental|Group A|needle-free before needle
88920192|NCT04074603|Experimental|Group B|needlebefore needle-free
88920193|NCT04068246|Placebo Comparator|Control group|patients will receive the standard therapy (methotrexate) plus placebo tablets
88920194|NCT04068246|Experimental|Metformin group|patients will receive the standard therapy plus 1 g metformin daily.
88920195|NCT04063033|Experimental|IV Iron treatment|Patients will be administered IV Iron for 3-5 days. 125 mg per day.
88920196|NCT04063033|No Intervention|No IV Iron treatment|Patients will receive standard treatment for heart failure without IV Iron.
88920197|NCT04061915|Experimental|Infographic Intervention|Participants in the intervention arm will view an HIV self-testing infographic.
88920198|NCT04061915|Active Comparator|Control|Participants in the control arm will read paper-based HIV self-testing instructions.
88920199|NCT04012333|Experimental|Intervention|Patients will receive standard care plus OLIMEL 7,6%E or if no central venous access available PeriOLIMEL 2,5%E to reach protein targets: >2.2g/kg/day
88920200|NCT04012333|No Intervention|Standard Care|Patients will receive standard care (enteral nutrition only) to stay below the protein level: <1.2g/kg/day
88920201|NCT03993184|Experimental|90-minute Hot Yoga Classes|This group will complete 3, 90-minute hot yoga classes weekly for 12 weeks.
88920202|NCT03993184|Experimental|60-minute Hot Yoga Classes|This group will complete 3, 60-minute hot yoga classes weekly for 12 weeks.
88920203|NCT03993184|No Intervention|Control|This group will maintain their current physical activity for 12 weeks.
88920204|NCT03926819|Active Comparator|Single Ascending Dose|
88920205|NCT03926819|Active Comparator|Multiple Ascending Dose|
88920206|NCT03910959|Experimental|Animal-assisted therapy|Patients receive three weeks of two AAT sessions, each lasting ca 30 minutes.
89536564|NCT02472197|Active Comparator|standard resection|
89536565|NCT03070353|Experimental|Dextran 40|Dextran 40 infusion
88920207|NCT03910959|Active Comparator|treatment as usual|Patients receive three weeks of two control sessions, each lasting ca 30 minutes.
88920208|NCT03909204|Other|LAPEC|Patients with cecal percutaneous catheter placement.
88920209|NCT03907800|Experimental|Nab-paclitaxel + Carboplatin ± Herceptin|
88920210|NCT03900117|Experimental|split-course radiotherapy|The radiotherapy is delivered using simultaneous integrated boost (SIB)-intensity-modulated radiotherapy (IMRT). Patients are irradiation at a palliative dose at the initial course: 40Gy/10f to gross tumor. The disease is re-evaluated one month after the end of the initial course using CT. The patient who achieved a partial remission according to the RECIST criteria and had a recovery of lung function should get the additional boost. At the second course, the tumor is re-simulated. The residual tumor was then treated with the second course of radiotherapy. A dose of 28Gy/7f is delivered to the residue tumor. Concurrent chemotherapy consists of weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡), each of 1 day's duration.
89011022|NCT05434546|Experimental|Sepranolone|Sepranolone 10 mg sc twice weekly for 12 weeks alongside the patient's standard of care Tourette treatment.
89011023|NCT05434546|No Intervention|No Intervention|Continuation of the patient's standard of care Tourette treatment for 12 weeks.
89536566|NCT04743245|Experimental|PCI with SSO2 therapy|AMI subjects treated with SSO2 Therapy following PCI with stenting
89536567|NCT04743245|Active Comparator|anterior AMI patients treated with PCI and stenting within 6 hours|Control group receiving PCI with stenting alone
88920211|NCT03894904|Experimental|Papaverine plus heparin during procedure, with rescue papaverine as needed|1 mL bolus of papaverine (0.12 mg/mL) plus heparin (2 units/mL) in saline (NaCl 0.9%) will be administered as soon as the arterial catheter is placed and secured, and a 1 mL bolus of papaverine (0.12 mg/mL) plus heparin (2 units/mL) in saline (NaCl 0.9%) will be administered one hour after initial bolus. If the arterial catheter spasm/patency or waveform does not improve 10 minutes after the second bolus, then the anesthesiology care team will consider treating clinically with 0.3 mg of papaverine.
88920212|NCT03894904|Active Comparator|Heparin during procedure, with rescue papaverine as needed|1 mL bolus of heparin (2 units/mL) in saline (NaCl 0.9%) will be administered as soon as the arterial catheter is placed and secured, and a 1 mL bolus of heparin (2 units/mL) in saline (NaCl 0.9%) will be administered one hour after initial bolus. If the arterial catheter spasm/patency or waveform does not improve 10 minutes after the second bolus, then the anesthesiology care team will consider treating clinically with 0.3 mg of papaverine.
89436737|NCT02281955|Experimental|De-escalated Radiation and Chemotherapy|Patients will receive Intensity Modulated Radiotherapy Treatments (IMRT), 60 Gy at 2 Gy/fx. The acceptable weekly chemotherapy regimens are Cisplatin 30 to 40 mg/m2 (first choice), Cetuximab 250mg/m2 (second choice), Carboplatin AUC 1.5 and paclitaxel 45 mg/m2 (third choice), Carboplatin AUC 3 (fourth choice). Chemotherapy will be given intravenously weekly during IMRT, 6 total doses. Chemotherapy will not be given to patients with T0-2 N0-1 disease, ≤ 10 pack years smoking history. Decision for surgical evaluation will be based on the results of the PET/CT and clinical exam 10-16 weeks after CRT. Patients with a positive PET/CT scan will undergo surgical evaluation at the discretion of the surgeon. Patients with a negative PET/CT scan will be observed.
89436738|NCT02275533|Experimental|Arm I (nivolumab)|Patients receive nivolumab IV over 60 minutes once every 2 weeks. Treatment repeats every 2 weeks for 46 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow biopsy at screening, months 3, 6, and 12, as clinically indicated, and during off-study evaluation. Patients also undergo collection of blood samples at screening, weeks 9, 13, 25, and 53, and during off-study evaluation or at time of clinically suspected relapse. Patients may undergo ECHO as clinically indicated.
88920213|NCT03811158|Experimental|HHHFNC group|On HHHFNC FiO2 will setting as same as SBT before extubation Flow rate: 50L/min
88920214|NCT03811158|Sham Comparator|UHFOM group|On Aerosol mask FiO2 will setting as same as SBT before extubation Flow rate: 15L/min
88920215|NCT03797833|No Intervention|Standard treatment|ECV according to standard practice.
88920216|NCT03797833|Active Comparator|Spinal anaesthesia|ECV after low dose spinal anaesthesia (Bupivacain 2,5 mg plus Sufentanil 5 micrograms (µg)
88920217|NCT03789630||Monitoring arm|Monitoring subjects undergoing total knee replacement surgery using the wearable biosensor to continuously monitor physiology biomarkers.
88920218|NCT03771014|Experimental|Early mobility|Patients will receive standard physiotherapy regimen plus 2 x 30 minute rehabilitation sessions 5 days per week.
88920219|NCT03771014|No Intervention|Standard care|Patients will receive standard physiotherapy regimen
88920220|NCT03749174|Active Comparator|Long acting anesthetic block/plaster|Intervention 1: Blockade will be given supraclavicularly with Long acting local Anesthetic (n=30) combined with post operative plaster immobilization.
88920221|NCT03749174|Active Comparator|Short acting anesthetic block/plaster|Intervention 2: Blockade will be given supraclavicularly with Short acting local anesthetic (n=30) combined with plaster immobilisation postoperatively
88920222|NCT03749174|Active Comparator|Short acting anesthetic block/orthotic|Intervention 3: Blockade will be given supraclavicularly with Short acting local anesthetic (n=30) and combined with orthosis for postoperative immobilisation
88920223|NCT03749174|Active Comparator|General Anesthesia and plaster|Intervention 4: General anesthesia wil be administered for surgical procedure combined with postoperative plaster immobilisation (n=30),
88920224|NCT03722927|Experimental|Bupivacaine Group|Participants will be randomized to the Bupivacaine Group and receive a bilateral mastectomy with immediate implant based breast reconstruction
88920225|NCT03722927|Experimental|Liposomal Bupivacaine Group|Participants will be randomized to the Liposomal Bupivacaine Group and receive a bilateral mastectomy with immediate implant based breast reconstruction
88920226|NCT03698084||Active|200 infants enrolled; family demographics collected and samples at day 5 (venepuncture, nasopharyngeal swab, urine and stool), actively followed up through their first RSV season for signs of respiratory symptoms. If respiratory symptoms are due to RSV infection (by point of care testing) samples as taken at day 5 are repeated at time of infection and again 7 weeks later. Annual questionnaire enquiring into respiratory illness, hospitalisations and family health and health quality of life, for up to 3 years.
89536568|NCT04994847||APOE Unimpaired Observational Trial|300 participants who are cognitively unimpaired; Yearly procedures: blood draw Every Two Year Procedures: cognitive and clinical assessments, CSF collection, MRI, and Tau and Amyloid PET scans
89536569|NCT03073863|Active Comparator|Atorvastatin 10mg|5006 patients received continuous medication with atorvastatin 10mg/day after run-in period.
89011024|NCT05433090|Experimental|Experimental|Patients will participate in an inpatient advance care planning intervention.
88920227|NCT03698084||Passive|1800 infants enrolled; family demographics collected. Questionnaire follow up at 1 year of age enquiring into respiratory illness, hospitalisations and family health and health quality of life. If infant was hospitalised in first year of life, follow up will continue for up to 3 years.
89436739|NCT02275533|Active Comparator|Arm II (observation)|Patients undergo standard of care clinical observation for up to 2 years. Upon disease relapse, patients may cross-over to Arm I. Patients also undergo bone marrow biopsy at screening, months 3, 6, and 12, as clinically indicated, and during off-study evaluation. Patients also undergo collection of blood samples at screening, weeks 9, 13, 25, and 53, and during off-study evaluation or at time of clinically suspected relapse. Patients may undergo ECHO as clinically indicated.
89436740|NCT02264678|Experimental|Module 2 Part A1|Module 2 Part A1: ascending doses of ceralasertib will be administered alone to define the maximum tolerated dose (MTD) and/or a continuous, tolerable Recommended Dose (RD) to take into Module 2 Part A2.
88920228|NCT03696485|Experimental|group 1: low dose|One intrathecal (IT) administration of SCM-010 at baseline visit
88920229|NCT03696485|Experimental|group 2: high dose|One intrathecal (IT) administration of SCM-010 at baseline visit
88920230|NCT03578198|Experimental|Rituximab + MG4101|"Drug: Rituximab + MG4101~Induction phase:~Rituximab (Truxima) 375mg/m2 IV Weekly (X4) MG4101 3x107 cells/kg IV Weekly (X4) Maintenance phase~Rituximab (Truxima) 375mg/m2 IV q 4 weeks (X4) MG4101 3x107 cells/kg IV q 4 weeks (X4)"
88920231|NCT03554200|Experimental|Empagliflozin|Patients will receive empagliflozin 10 mg qd for a period of 30 days.
88920232|NCT03554200|Placebo Comparator|Placebo|Patients of the placebo arm will receive placebo tablets qd for a period of 30 days.
88920233|NCT03517176|Experimental|Part A (Dose Escalation)|Safety of ascending dose levels of CEND-1 in combination with gemcitabine and nab-paclitaxel will be evaluated. Patients will receive an IV bolus of CEND-1 on Day 1 of the 1-week run-in period. This is followed by one treatment cycle (28 days) with the CEND-1 / nab-paclitaxel (125mg/m^2) / gemcitabine (1000mg/m^2) combination given on Days 1, 8, 15.
88920234|NCT03517176|Experimental|Part B (Expansion)|Safety and early efficacy of CEND-1 in combination with nab-paclitaxel (125mg/m^2) and gemcitabine (1000mg/m^2) will be evaluated (dosing on Days 1, 8, 15 of the 28-day treatment cycle). Treatment cycles will be repeated every 4 weeks based on toxicity and response. Treatment may continue as long as there is perceived benefit or until disease progression.
88920235|NCT03512964|Other|Rapid HIV Treatment Initiation|Initiation and reinitiation of antiretroviral therapy with dolutegravir 50 mg by mouth once daily and descovy 1 tablet by mouth once daily the same-day as HIV diagnosis and/or first clinic visit for people newly diagnosed with HIV and patients previously diagnosed with HIV but not on medications and not in care for over six months.
89198690|NCT00383149|Experimental|Ixabepilone plus Cetuximab|All participants were administered ixabepilone at a starting dose of 32 mg/m^2 as a 3-hour intravenous (IV) infusion every 3 weeks. In addition, all participants were administered an initial dose of cetuximab (400 mg/m^2 IV over 2 hours) followed by a weekly lower dose (250 mg/m^2 IV over 1 hour).
89436741|NCT02264678|Experimental|Module 2 Part A2|Module 2 Part A2: ascending doses of ceralasertib will be administered in combination with olaparib to patients to define the dose, frequency and schedule of ceralasertib and olaparib to take into Module 2 Part B.
89436742|NCT02264678|Experimental|Module 2 Part B1|Module 2 Part B1: Patients with second line 'ATM deficient' gastric adenocarcinoma including GEJ adenocarcinoma will receive ceralasertib with olaparib, at dose, frequency and schedule recommended from Module 2 Part A2.
89436743|NCT02264678|Experimental|Module 2 Part B2|Module 2 part B2: Patients with second line 'ATM proficient' gastric adenocarcinoma including GEJ adenocarcinoma will receive ceralasertib with olaparib, at dose, frequency and schedule recommended from Module 2 Part A2.
89436744|NCT02264678|Experimental|Module 2 Part B3|Module 2 Part B3: Patient with second or third line breast cancer with BRCA mutations (somatic or germline), excluding HER2 positive breast cancer will receive ceralasertib with olaparib, at dose, frequency and schedule recommended from Module 2 Part A2.
89536570|NCT03073863|Experimental|Atorvastatin 80mg|4995 patients received medication with atorvastatin 80mg/day after run-in period.
89536571|NCT04994925|Active Comparator|Control ready meal|Control supermarket brand ready meal with high energy density
88920236|NCT03478384|Experimental|Coaching group|Patient coaching
88920237|NCT03478384|No Intervention|Control group|Control group - no additional coaching provided
88920238|NCT03476109|Active Comparator|Omalizumab|"Patients randomized to omalizumab and then prolonged or not (based on their response at 4 months) until the end of the study (22mo).~Non responders will be switched to mepolizumab arm."
89436745|NCT02264678|Experimental|Module 2 Part B4|Module Part B4: Patients with second or third line triple negative breast cancer with no known BRCA mutations. This expansion will be enriched for patients with disease harbouring a HRR-related gene mutation (HRRm) will receive ceralasertib with olaparib, at dose, frequency and schedule recommended from Module 2 Part A2.
89436746|NCT02264678|Experimental|Module 3 Part A|Module 3 Part A: cohort escalation of ceralasertib in combination with durvalumab in HNSCC or NSCLC patients to define the dose, frequency and schedule of ceralasertib and durvalumab to take into Module 3 Part B. Additionally, Module 3 Part A will include a serial tumour biopsy cohort to evaluate the Proof of Mechanism of ceralasertib in HNSCC and NSCLC patients.
89436747|NCT02264678|Experimental|Module 3 Part B|Module 3 Part B: cohort expansions of ceralasertib in combination with durvalumab in HNSCC or NSCLC patients at dose, frequency and schedule from Module 3 Part A.
89436748|NCT02264678|Experimental|Module 2 Part B5|Patients with BRCA mutant or RAD51C/D mutant (either germline or somatic) or HRD-positive status epithelial ovarian, fallopian tube, or primary peritoneal cancer according to local testing. Patients must be platinum sensitive and previously progressed on a licensed PARPi. The cohort will be split into 2 groups: Cohort 1 - without intervening chemotherapy following progression on a PARPi, Cohort 2 - with intervening chemotherapy following progression on a PARPi. Patients will receive ceralasertib and olaparib, at the RP2D dose, frequency and schedule established from Module 2 Part A2.
89436749|NCT02264678|Experimental|Module 4 (FE/QT)|Ceralasertib monotherapy will be administered on a number of days during Cycle 0 to assess the effect of food on ceralasertib absorption and effect of ceralasertib on ECG parameters under various conditions (fasted, fed, steady state). From C1 onwards, patients who participated in C0 will be allocated to either ceralasertib in combination with olaparib or durvalumab, or ceralasertib monotherapy and assessed for safety.
88920239|NCT03476109|Active Comparator|Mepolizumab|"Patients randomized to mepolizumab and then prolonged or not (based on their response at 6 months) until the end of the study (22mo).~Non responders will be switched to omalizumab arm."
88920240|NCT03463499|Experimental|Hyaluronic Acid and Chondroitin Sulfate|Intravesical instillation of Hyaluronic Acid and Chondroitin Sulfate After Transurethral Resection of Hunner Lesion in Interstitial Cystitis/Bladder Pain Syndrome Patients.
88920241|NCT03366974|Experimental|CYP inhibition + IV/PO midazolam|"Period 1: Administration of Midazolam (IV) on day 1, Co-administration of Midazolam (IV) and Grapefruit juice on day 2~Period 2: Administration of Midazolam (PO) on day 8, Co-administration of Midazolam (PO) and Grapefruit juice on day 9~Period 3: Self-administration of Clarithromycin (PO) bid regimen on day 12-14, Co-administration of Midazolam (IV) and Clarithromycin (PO) on day 15, Co-administration of Midazolam (PO) and Clarithromycin (PO) on day 16"
88920242|NCT03294083|Experimental|Part 1, Dose escalation|"Pexa-Vec will be administered via IV infusion at a dose of 3 x 10^8 pfu once per week for 4 treatments. Based on the occurrence of dose-limiting toxicities, patients may subsequently be enrolled to receive Pexa-Vec on the same schedule at a dose of 1 x 10^9 pfu.~Cemiplimab will be administered via IV infusion every 3 weeks."
88920243|NCT03294083|Experimental|Part 2-Arm A, Pexa-Vec (IT) and Cemiplimab|"Pexa-Vec will be administered via IT (intratumoral) injection every 2 weeks for 3 treatments.~Cemiplimab will be administered via IV infusion every 3 weeks."
88920244|NCT03294083|Experimental|Part 2-Arm B, Cemiplimab|"Cemiplimab will be administered via IV infusion every 3 weeks.~At disease progression, Pexa-Vec will be administered via IT (intratumoral) injection every 2 weeks for 3 treatments. Cemiplimab will continue every 3 weeks."
88920245|NCT03294083|Experimental|Part 2-Arm C, Pexa-Vec (IV) and Cemiplimab|"Pexa-Vec will be administered via IV infusion once per week for 4 treatments.~Cemiplimab will be administered via IV infusion every 3 weeks."
88920246|NCT03294083|Experimental|Part 2-Arm D, Pexa-Vec (IV) and Cemiplimab|"Pexa-Vec will be administered via IV infusion once per week for 4 treatments.~Cemiplimab will be administered via IV infusion every 3 weeks."
89436750|NCT02264678|Experimental|Module 5 Part A|Module 5 Part A: ascending doses of ceralasertib will be administered in combination with AZD5305 to patients to define the MTD, RP2D.
88920248|NCT03134885||VigilanS Nord-Pas de Calais cohort|All patients leaving in the Nord-Pas de Calais region and entering in the VigilanS program after a suicide attempt
88920249|NCT03128138|Experimental|25 mg SPH3127 tablet-Dose 1|"6 Volunteers, Single dose of SPH3127 tablet, 25mg, po. 1 tablet.~2 Volunteers, Single dose of Placebo tablet, 25mg, po. 1 tablet."
89436751|NCT02264678|Experimental|Module 5 Part B|Module 5 Part B: cohort expansions of ceralasertib in combination with AZD5305 in ovarian patients at dose, frequency and schedule from Module 5 Part A.
88920250|NCT03128138|Experimental|50 mg SPH3127 tablet-Dose 2|"6 Volunteers, Single dose of SPH3127 tablet, 50mg, po. 1 tablet.~2 Volunteers, Single dose of Placebo tablet, 50mg, po. 1 tablet."
88920251|NCT03128138|Experimental|100 mg SPH3127 tablet-Dose 3|"6 Volunteers, Single dose of SPH3127 tablet, 100mg, po. 1 tablet.~2 Volunteers, Single dose of Placebo tablet, 100mg, po. 1 tablet."
88920252|NCT03128138|Experimental|200 mg SPH3127 tablet-Dose 4|"6 Volunteers, Single dose of SPH3127 tablet,100mg, po. 2 tablet.~2 Volunteers, Single dose of Placebo tablet, 100mg, po. 2 tablet."
88920253|NCT03128138|Experimental|400 mg SPH3127 tablet-Dose 5|"6 Volunteers, Single dose of SPH3127 tablet,100mg, po. 4 tablet.~2 Volunteers, Single dose of Placebo tablet, 100mg, po. 4 tablet."
88920254|NCT03128138|Experimental|800 mg SPH3127 tablet-Dose 6|"6 Volunteers, Single dose of SPH3127 tablet,100mg, po. 8 tablet.~2 Volunteers, Single dose of Placebo tablet, 100mg, po. 8 tablet."
88920255|NCT03119038|Active Comparator|Combination Medication Injection|Intraoperative periarticular injection of 300 mg of 0.5% ropivacaine, 30 mg ketorolac, 200 mcg epinephrine, and 100 mcg clonidine in a 100 mL 0.9% saline solution
88920256|NCT03119038|Active Comparator|Single Medication Injection|Intraoperative periarticular injection of 30 mL of a 0.25% solution bupivacaine with epinephrine and 30 mL 0.25% bupivacaine without epinephrine
89536572|NCT04994925|Experimental|Test ready meal with low energy density|Slimming world test ready meal with low energy density
89011025|NCT05419622|Experimental|lung MRI|The procedure under study is lung MRI, performed on a 1.5T magnet (AERA dot 1.5T, Siemens), without anesthesia and without injection or inhalation of contrast agent.
89011026|NCT05405998|Experimental|Experimental group : proactive course|"The strategy is based on the implementation of an optimized proactive care pathway, combining elements that promote city-hospital coordination in setting up the pump and elements that promote patient education."
89011027|NCT05405998|No Intervention|Control group : optimized medical treatment|At the end of the inclusion visit (see previous chapter), the patient will be invited to come to the hospital two weeks later for pump placement.
89011028|NCT05376917|Experimental|Zeiss CT Asphina / Zeiss CT Asphina|Monovision with refractive target of -1.50 Diopters (D) on the dominated eye
89011029|NCT05376917|Experimental|Zeiss AT Lara/ Zeiss AT Lisa Tri|Zeiss AT Lara (dominant eye) / Zeiss AT Lisa Tri (non-dominant eye)
89011030|NCT05376917|Experimental|Zeiss CT Asphina/ Zeiss AT Lara|Zeiss CT Asphina/ Zeiss AT Lara (non-dominant eye)
89011031|NCT05376917|Experimental|Zeiss AT Lara / Zeiss AT Lara|Micro-monovision with refractive target of -0.75 Diopters (D) on the non-dominant eye
89011032|NCT05372055||Indwelling Pleural Catheter|Patients with malignant pleural effusions managed by IPC insertion as per standard of care
89011033|NCT05367778|Experimental|HS-10370（Phase 1a：Dose Escalation）|Subjects with advanced solid tumors will be enrolled in dose escalation cohorts. Dose escalation of HS-10370 will be done to determine maximum tolerated dose.
89011034|NCT05367778|Experimental|HS-10370（Phase 1b：Dose Expansion ）|Depending on data obtained from the dose escalation part, dose expansion may proceed with multiple cohorts in subjects with advanced solid tumors having a KRAS G12C mutation.
89011035|NCT05367778|Experimental|HS-10370（Phase 2 ）|Subjects with locally advanced or metastatic KRAS G12C mutant NSCLC will be enrolled in phase 2 part to evaluate the efficacy and sufficient safety of HS-10370 as monotherapy.
89011036|NCT05362981|Experimental|CAT|induction of cognitive dissonance
89011037|NCT05362981|Experimental|MBCT|TCA-specific mindfulness approach
89011038|NCT05362981|No Intervention|TAU|usual support
89011039|NCT05354934||People living with HIV|"The questionnaire includes the following modules~Demography and socio-economic conditions~Screening and modalities of discovery and announcement of HIV infection~Time and modalities of introduction of antiretroviral drugs after diagnosis~Knowledge of HIV infection~The perception of follow-up in the health care service~Experiences of stigma~Barriers to accessing care~Periods of loss of sight and reasons for this~Perceived health status, mental health (PHQ4), chronic illness, functional limitations~Addictions~Social network and support~Clinical data Date of HIV diagnosis Date of introduction of antiretrovirals CD4 count at diagnosis Viral load at diagnosis Period without follow-up for more than 12 months CD4 nadir Last CD4 count Last viral load Antiretroviral treatment at last consultation Comorbidities Initial hospitalisation Recent hospitalization"
89011040|NCT05335044|Experimental|Sequence A|"Period 1: EX5619 - A single oral dose of 1 tablet under fasting condition~Period 2: CKD-331 - A single oral dose of 2 tablets under fasting condition~Period 3: EX5619 - A single oral dose of 1 tablet under fasting condition~Period 4: CKD-331 - A single oral dose of 2 tablets under fasting condition"
89011041|NCT05335044|Experimental|Sequence B|"Period 1: CKD-331 - A single oral dose of 2 tablets under fasting condition~Period 2: EX5619 - A single oral dose of 1 tablet under fasting condition~Period 3: CKD-331 - A single oral dose of 2 tablets under fasting condition~Period 4: EX5619 - A single oral dose of 1 tablet under fasting condition"
89011042|NCT05332275|Experimental|Intervention Arm - T.E.C.H. Parenting|"Intervention Arm participants will enroll in a web-based psychoeducational group (15 parents per group across 4 groups). Participants will receive psychoeducational information on media parenting, and they will be invited to participate in an online group discussion board to share their experiences with other parents in the intervention. In weeks 2-5, participants will learn about 4 domains of media parenting: 1) Talk to your child about media; 2) Educate your child about media-related risks; 3) Co-View/Co-Use media and technology actively with your child; and 4) establish House rules for media usage. Week 6 will review information and provide an expert clinician to support parent problem solving. Participants will receive 2-3 weekly push messages via text messaging prompting practice of skills learned in the group setting. Participants will be assessed at baseline, immediately following the 6 week intervention, and 3 months after the intervention is completed."
89436752|NCT02264678|Experimental|Module 1 Part A|Module 1 Part A: ascending doses of ceralasertib in combination with carboplatin AUC5 will be administered to patients to define the maximum tolerated dose (MTD) and/or a continuous, tolerable Recommended Dose (RD).
89011043|NCT05332275|Active Comparator|Control Arm - General Positive Parenting|The Control Arm of the RCT is the attention control group. These participants will enroll in a web-based psychoeducational group (four groups of 15 parents each). They will receive 6 weeks of online psychoeducational material, including 2-3 push messages prompting skill practice. Parents will have access to an online discussion board to share experiences with other parents. This group will match the intervention arm of the study in number of study staff contacts, time of start/duration of the group, peer support, and availability of a professional in week six for consultation on parenting issues. Control participants will not receive information on media parenting. Participants in this group will be assessed at baseline, immediately following the six-week intervention period, and 3 months after intervention completion. Participants will be asked about exposure to TECH Parenting content at baseline and follow up to address potential contamination effects across study arms.
89011044|NCT05286177|Experimental|Volume-based EN|Volume-based EN algorithm arm.
89011045|NCT05286177|Active Comparator|Rate-based EN|Rate-based EN algorithm (standard of care).
89011046|NCT05250947|Experimental|PRP Injection Arm|The FDA cleared Angel® Concentrated Platelet Rich Plasma System and Angel® cPRP Processing Set will be used to process the PRP. The targeted final PRP volume of 6 ml will be injected in up to 4 facet joints (2 levels) at 1.5 ml per joint.
89198691|NCT00873171||1. OMT|This procedure consist of Sacral rocking is performed by placing the heel of the practitioner's hand over the sacrum and by using the palpatory skills of an osteopathic physician; rock the sacrum into a position with no restriction. Myofascial release will utilize various physical motions to place the patients lumbosacral region in a position of maximal comfort and tissue release.
89198692|NCT00873171||2. Attention control OMT|The procedure consist of light pressure applied to certain painful areas of the body and back to decrease pain and help patient relax. The physician will look for areas of the body that hurt, lay his/her hands on the those places, and apply light pressure.
89198693|NCT00873171||3. Standard of Care|This procedure consists of various conservative treatments that can help reduce stress. Those include dietary modifications, pharmaceuticals, bladder training, and neuromodulation. If these treatments are not successful, minimally invasive surgical procedures is performed.
89198694|NCT03364296|Other|Patients hospitalized for stroke|
89198695|NCT00878631|Active Comparator|1 Normal Saline|infusion of 250 ccs of Normal Saline within 4 hours of the accident
89198696|NCT00878631|Experimental|2 - hypertonic saline mixed with dextran|a single dose 250 ml of 7.5% hypertonic saline in 6% dextran 70 infused within 4 hours of the accident
89198697|NCT00921960|No Intervention|Usual Care|Usual Care will involve ongoing management from the general practitioner, nurse-led assessment of cardiovascular risk at the general practice and referral to specialist services as deemed necessary.
89198698|NCT00921960|Other|Intervention|Intervention Care is defined as a collaborative cardiovascular management between primary care and specialist hospital based services. This will involve natriuretic peptide guided evaluation of LVD and follow-up as appropriate
89198699|NCT00878787|Experimental|Theta-burst Trancranial Magnetic Stim|
89198700|NCT00382993|Other|Combination Product - Placebo|Combination Product (sumatriptan and naproxen sodium) [Attack 1] followed by Placebo [Attack 2]
89436753|NCT02264678|Experimental|Module 1 Part B|Module 1 Part B: patients with advanced lung adenocarcinoma with low expression of ATM will receive ceralasertib and carboplatin, at the dose, frequency and schedule recommended from Module 1 Part A.
89436754|NCT02261883|Active Comparator|IV Remodulin|The starting dose was 1 ng/kg/min (not to exceed to 2 ng/kg/min) and was titrated by up to 2 ng/kg/min every 2 hours, as tolerated and clinically indicated by the Investigator. Doses were titrated and maximized throughout the study until the desired clinical effect was observed or to each individual subject's maximally tolerated dose. There was no maximum dose.
89436755|NCT02261883|Placebo Comparator|Placebo|The starting dose was 1 ng/kg/min (not to exceed to 2 ng/kg/min) and was titrated by up to 2 ng/kg/min every 2 hours, as tolerated and clinically indicated by the Investigator. Doses were titrated and maximized throughout the study until the desired clinical effect was observed or to each individual subject's maximally tolerated dose. There was no maximum dose.
89436756|NCT02257528|Experimental|Treatment (nivolumab)|Patients receive nivolumab IV over approximately 60 minutes every 2 weeks for a maximum of 46 doses over 92 weeks in the absence of disease progression or unacceptable toxicity.
89436757|NCT02247349|Experimental|Dose Escalation (Monotherapy) Dose -1|BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity
89436758|NCT02247349|Experimental|Dose Escalation (Monotherapy) Dose 1|BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity
89436759|NCT02247349|Experimental|Dose Escalation (Monotherapy) Dose 2|BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity
88920257|NCT03099265|Experimental|patients with borderline resectable pancreatic adenocarcinoma|Borderline resectable disease will be defined by NCCN criteria, and determined centrally by review of a diagnostic pancreas protocol CT scan and/or MRI scan with contrast by a dedicated surgical oncologist and radiologist.
88920258|NCT03033459|Experimental|Motivational Interviewing|Participants assigned to the Motivational Interviewing condition will receive an approximately 45 (± 5) minute intervention provided by a female masters-level supervised psychologist with training in Motivational Interviewing.
88920259|NCT03033459|Active Comparator|Psychoeducation Control|Participants who have been randomly assigned to participate in the attention-control group session will receive approximately 45 (± 5) minutes of psychoeducation on typical developmental stages and infant feeding methods. The psychoeducation will be provided by a female masters-level supervised psychologist.
88920260|NCT02975362|Experimental|Acupuncture combined rehabilitation|Acupuncture Treatment Rehabilitation Treatment
88920261|NCT02975362|Experimental|Rehabilitation|Rehabilitation Treatment
88920262|NCT02975037|Experimental|sildenafil+clarithromycin|Sildenafil 25 mg PO (single dose); Clarithromycin 250 mg PO (3 doses); Sildenafil 25 mg PO + Clarithromycin 250 mg PO (single dose)
88920263|NCT02975037|Experimental|sildenafil+itraconazole|Sildenafil 25 mg PO (single dose); Itraconazole 100 mg PO (3 doses); Sildenafil 25 mg PO + Itraconazole 100 mg PO (single dose)
88920264|NCT02970591|Experimental|Diet A|Low carbohydrate diet
88920265|NCT02970591|Active Comparator|Medical treatment|Optimized Medical treatment
88920266|NCT02970591|Experimental|Diet B|Traditional dietary advice and low FODMAP content
88920267|NCT02931890|Active Comparator|neo-adjuvant chemotherapy followed by surgery|4 courses of 3 weekly DOC followed by surgery
88920268|NCT02931890|Active Comparator|neo-adjuvant chemo and subsequent CRT followed by surgery|2 courses of 3 weekly DOC and subsequent CRT followed by surgery
88920269|NCT02931890|Active Comparator|neo-adjuvant chemoradiotherapy followed by surgery|chemoradiotherapy followed by surgery
88920270|NCT02893670|Other|Tailored re-evaluation|"Radiologic (MRE) or endoscopic (sigmoidoscopy) evaluation:~Following enrollment each patient will undergo a structured re-evaluation and transition process which will include radiologic intervention (MRE) for Crohn's patients and endoscopic intervention (sigmoidoscopy) for UC patients"
88920271|NCT02812862|Experimental|Treatment group|"20 male and female patients suffering from chronic heart failure and chronic obstructive pulmonary disease.~Patients will be treated with Spiolto® Respimat® (the LABA/ LAMA combination)"
88920272|NCT02734979|Experimental|Biobridge and lymph node transfer|The investigators will investigate whether addition of the Biobridge scaffold to the standard surgery for vascularized lymph node transfer will improve the outcome of surgical treatment in lymphedema of the upper arm. The investigators will perform lymph scans (lymphoscintigrams) before surgery and one year following surgery to determine the success of the surgery. In addition, the volume of the operated arm will be monitored by repeated measurement with a tape measure. The investigators will also track bioimpedance, a painless technique to detect fluid in the tissues. The investigators will obtain small skin biopsies and blood samples to detect the biological changes that may occur as a result of successful surgery.
88920273|NCT02658656|Active Comparator|Exoskeleton + Standard of Care (SOC)|Patient will receive exoskeletal-assisted walking device for in home use for 4 months
89198701|NCT00382993|Other|Placebo - Combination Product|Placebo [Attack 1] followed by Combination Product (sumatriptan and naproxen sodium) [Attack 2]
89436760|NCT02247349|Experimental|Dose Escalation (Monotherapy) Dose 3|BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity
89436761|NCT02247349|Experimental|Dose Escalation (Monotherapy) Dose 4|BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity
89436762|NCT02247349|Experimental|Dose Expansion (Monotherapy)- Cohort A (Refractory)|BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity
89536573|NCT02474849|Active Comparator|Conventional cigarette|
89536574|NCT02474849|Experimental|First-generation e-cigarette|
88920274|NCT02658656|No Intervention|Standard of Care (SOC)|Patient will receive standard of care (wheelchair use)
89436763|NCT02247349|Experimental|Dose Expansion (Monotherapy) Cohort B (Refractory)|BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity
89436764|NCT02247349|Experimental|Dose Expansion (Monotherapy) Cohort C (Sensitive)|BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity
88920275|NCT02588846|Experimental|Stage 1: Optimise nodal treatment margin|During Stage 1: Optimise nodal treatment margin, Combined real-time use of 'Multi-Leaf Collimator Adaptation' and 'kV Intrafraction Monitoring' will be used to reshape the radiation beam in real-time. The nodal target position stability will be evaluated by the cone beam computed tomography (CBCT) imaging before and after each treatment session for the first 10 patients.
88920276|NCT02588846|Experimental|Stage 2: Use treatment margin|During Stage 2: Use treatment margin, Combined real-time use of 'Multi-Leaf Collimator Adaptation' and 'kV Intrafraction Monitoring' will be used to reshape the radiation beam in real-time. At the same time, multi-leaf collimator (MLC) tracking will be used to reshape the radiation beam in real-time using the margin size determined in Stage 1.
88920277|NCT02587312|Active Comparator|Normal Nicotine Content Cigarettes|SPECTRUM cigarette: 0.8 mg nicotine with 10.5 mg tar (standard nicotine and tar yields of commercially available cigarettes; control condition)
88920278|NCT02587312|Experimental|Very Low Nicotine Content Cigarettes|SPECTRUM cigarette: 0.03 mg nicotine with 9 mg tar
88920279|NCT02549677|Experimental|EC regimen|Epirubicin, cyclophosphamide
89436765|NCT02247349|Experimental|Dose Expansion (Monotherapy) Cohort D (Sensitive)|BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity
89436766|NCT02247349|Experimental|Dose Escalation (Combination) Dose 1|BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity in combination with Nivolumab specified dose on specified days
89436767|NCT02247349|Experimental|Dose Escalation (Combination) Dose 2|BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity in combination with Nivolumab specified dose on specified days
89436768|NCT02247349|Experimental|Dose Expansion (Combination)- (Refractory and Sensitive)|BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity in combination with Nivolumab specified dose on specified days
88920280|NCT02549677|Active Comparator|TC regimen|docetaxel, cyclophosphamide
89436769|NCT02230072|Experimental|fetoscopic surgical repair|Single arm study. All patients will receive the fetoscopic repair.
88920281|NCT02549599|Other|Delayed Treatment|Participants will receive a baseline survey and be routed to the Planned Parenthood website. No subsequent survey will be administered.
88920282|NCT02549599|Experimental|Chat/Text Program|Participants will receive real-time answers to questions they have about sexual and reproductive health topics from trained chat agents via the digital intervention program.
88920283|NCT02549599|Other|Website Content|Participants will be routed to the Planned Parenthood website to information and content about issues regarding sexual and reproductive health.
88920284|NCT02540655|Experimental|Stemchymal®|Infusion of Stemchymal®
88920285|NCT02540655|Placebo Comparator|Vehicle|Infusion of excipients
88920286|NCT02450253|Active Comparator|Active Treatment|Tadalafil 20mg Capsule Stat single dose 2 x MRI scans (pre and post dose) Neuropsychological tests pre and post IMP dose Cognitive functioning prior to 1st MRI scan of that visit
89436770|NCT02182687|Other|Arm A|Stereotactic Body Radiation Therapy (SBRT)
89436771|NCT02182687|Other|Arm B|Trans-Arterial Chemoembolization (TACE) Drug: Doxorubin
89436772|NCT02159066|Experimental|LGX818 + MEK162|
89436773|NCT02159066|Experimental|LGX818 + MEK162 + LEE011|
89436774|NCT02159066|Experimental|LGX818 + MEK162 + BGJ398|
89436775|NCT02159066|Experimental|LGX818 + MEK162 + BKM120|
89436776|NCT02159066|Experimental|LGX818 + MEK162 + INC280|
89436777|NCT02152995|Experimental|Cohort A (iodine I-124 PET/CT, trametinib, iodine I-131)|Patients with RAS gene mutations undergo iodine I-124 PET/CT on day 5 of week 1. Beginning day 6, patients receive trametinib PO daily for 4 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo second iodine I-124 PET/CT on week 5. If I-124 PET/CT shows enough iodine absorption, patients may receive iodine I-131 PO and continue receiving trametinib for another 2 days. If I-124 shows that the thyroid is not absorbing iodine, patients have the option to be assigned to Cohort C.
89436778|NCT02152995|Experimental|Cohort B (iodine I-124 PET/CT, trametinib, iodine I-131)|Patients without BRAF/RAS gene mutations undergo iodine I-124 PET/CT on day 5 of week 1. Beginning day 6, patients receive trametinib PO daily for 4 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo second iodine I-124 PET/CT on week 5. If I-124 PET/CT shows enough iodine absorption, patients may receive iodine I-131 PO and continue receiving trametinib for another 2 days. If I-124 shows that the thyroid is not absorbing iodine, patients have the option to be assigned to Cohort C.
89436779|NCT02152995|Experimental|Cohort C (trametinib)|Patients may continue trametinib at the doctor's discretion and do not receive iodine I-131.
89436780|NCT02135133|Experimental|Idelalisib & Ofatumumab|Idelalisib will be given orally continuously at 150 mg BID. On day 57, ofatumumab will begin with the 300 mg dose, given after idelalisib is taken. Ofatumumab will then be administered at 1000 mg weekly to complete 8 weeks (days 64, 71, 78, 85, 92, 99, 106) throughout Cycles 3 and 4. This will be followed by monthly ofatumumab on weeks 20, 24, 28, 32 to complete 4 additional cycles (5-8). The overall induction treatment period will then be 8 months, comprised of two months of single agent idelalisib followed by 6 months of ofatumumab with idelalisib. After the completion of the induction treatment, idelalisib will continue indefinitely in arbitrarily defined 28 day cycles in all participants who have not had excessive toxicity and do not have progressive disease.
89436781|NCT02025010|Experimental|abiraterone acetate|"Participants will be treated with four 250 mg tablets (1,000 mg) of abiraterone acetate (AA) orally on 28-day cycles. For participants who experience persistent or severe mineralocorticoid excess or have PSA progression, prednisone 5 mg by mouth twice daily will be added.~Patients will be treated until radiographic disease progression and unacceptable AE or taken off study for other reason."
89436782|NCT02000427|Experimental|Blinatumomab|"Participants will receive blinatumomab by continuous intravenous (CIVI) infusion over 4 weeks followed by a treatment-free interval of 2 weeks for 2 cycles. Participants who achieve a complete remission or complete remission with partial or incomplete hematologic recovery within 2 induction cycles of treatment could receive up to 3 additional consolidation cycles of blinatumomab.~The initial dose will be 9 μg/day for the first 7 days of treatment, increased to 28 μg/day starting on day 8 for all subsequent cycles of treatment."
89436783|NCT01979094||spinal arthrodesis and/or arthroplasty procedures|
89436784|NCT01948882|Experimental|ESS505|All subjects that sign the informed consent and meet the eligibility criteria will be scheduled for an implant procedure.
89436785|NCT01943695|Experimental|Aerobic Training During Chemotherapy|The ultimate goal is for participants to complete approximately 3 exercise sessions week of non-linear aerobic training an intensity of at 55% to 100% of the individually determined exercise capacity VO2peak), concurrent with chemotherapy. VO2peak will be determined by the CPET performed at baseline. The weekly exercise will be achieved via 3 individual aerobic training sessions ranging from approximately 20-45 min/session. All sessions are required to be supervised unless otherwise specified by EP discretion.
89436786|NCT01943695|Experimental|Aerobic Training After Chemotherapy|The ultimate goal is for participants to complete approximately 3 exercise sessions week of non-linear aerobic training at an intensity 55% to 100% of the individually determined exercise capacity (VO2peak), after the completion of chemotherapy. VO2peak will be determined by the CPET performed at midpoint, or pre-surgery for neoadjuvant patients. For patients receiving adjuvant therapy, (except those who have additional surgery after chemotherapy), the aerobic training intervention must begin within 2 weeks of the patient's midpoint CPET. For patients receiving neoadjuvant or adjuvant therapy and have additional surgery after chemotherapy, the aerobic training intervention will begin within approximately 6 weeks of surgery, per the discretion of the treating physician. The weekly exercise will be achieved via 3 individual aerobic training sessions ranging from approximately 20-45 min/session. All sessions are required to be supervised unless otherwise specified by EP discretion.
89436787|NCT01943695|Experimental|Continuous Aerobic Training|The ultimate goal is for participants to complete 3 exercise sessions week of non-linear aerobic training at 55% to 100% of the individually determined exercise capacity (VO2peak), during and after chemotherapy. For patients receiving adjuvant therapy (except those who have additional surgery after chemotherapy), VO2peak will be determined by the CPETs performed at baseline and midpoint. For patients receiving neoadjuvant or adjuvant therapy and have additional surgery after chemotherapy, VO2peak will be determined by the CPETs or at baseline, pre- surgery, and post-surgery. The weekly exercise will be achieved via 3 individual aerobic training sessions ranging from approximately 20-45 min/session. All sessions are required to be supervised unless otherwise specified by EP discretion.
89536575|NCT02474849|Experimental|Rechargeable cig-like e-cigarette|
88920287|NCT02450253|Placebo Comparator|Control|Matched placebo Capsule Stat single dose 2 x MRI scans (pre and post dose) Neuropsychological tests pre and post IMP dose Cognitive functioning prior to 1st MRI scan of that visit
88920288|NCT02411812|Experimental|Herbst appliance with skeletal anchorage|Group treated with the Herbst appliance with indirect skeletal anchorage in mini-implants.
88920289|NCT02411812|Active Comparator|Herbst appliance with dental anchorage|Group treated with the conventional Herbst appliance with dental anchorage.
88920290|NCT02411812|Active Comparator|Twin-Block appliances|Group treated with Twin-Block appliance.
88920291|NCT02263807|Experimental|MPFL group|Arthroscopy and MPFL reconstruction
88920292|NCT02263807|Active Comparator|Control|Arhroscopy and rehabilitation
88920293|NCT02257970|Experimental|Part 1: Exploratory Group|"Ketoprofen 225-300 mgs daily, taken orally~Ketoprofen-exploratory group: 225-300 mgs daily for four to six months"
88920294|NCT02257970|Experimental|Part 2: Open-label Group|"Ketoprofen 225 mg daily, taken orally~Open-label group: 75 mgs, three times daily, for four months"
88920295|NCT02257970|Placebo Comparator|Part 3: Placebo Group|"Participants randomized to receive placebo: placebo, three times daily, taken orally~Placebo: 1 capsule, three times daily, for four months"
88920296|NCT02257970|Active Comparator|Part 3: Ketoprofen Group|"Participants randomized to receive active medication: ketoprofen 75 mgs., three times daily, taken orally~Ketoprofen: 1 capsule, three times daily, for four months"
88920297|NCT02246413|Experimental|RAINBOW Intervention Program|An integrated intervention program for helping to improve mood and weight in adults who may be at risk for diabetes and heart disease.
88920298|NCT02246413|No Intervention|Usual Care|Usual Care.
89198702|NCT04585464|Experimental|Healthy Volunteer: Single Ascending Dose|"Single oral ascending dose in healthy volunteers~Interventions:~Drug: EDG-5506 Drug: Placebo"
88920301|NCT05838651|Active Comparator|Bone Graft Alone|Socket preservation sites with bone graft (MinerOss® X Plug) alone without complete flap closure (secondary intention healing) (n=10)
88920302|NCT05838651|Experimental|Bone Graft + Membrane|Socket preservation sites with bone graft (MinerOss® X Plug) and a non-crosslinked collagen membrane without complete flap closure (secondary intention healing) (n=10)
88920303|NCT05838612|Experimental|Heat Acclimation|Participants will undergo an exercise heat stress test prior to and following seven consecutive days of warm-water immersion (~40°C) of 1-hour duration with core temperature clamped at 38.5°C. During the exercise-heat stress test participants will perform three, successive 30-minute bouts of semi-recumbent cycling performed at increasing fixed loads of metabolic heat production of 150, 200 and 250 W/m2 (i.e., exercise bout 1, exercise bout 2 and exercise bout 3, respectively), each separated by 15-minute of rest break with the final recovery extended to 1-hour.
88920304|NCT05838547||Patients treated with Optimal Medical Therapy (OMT) alone.|Asymptomatic carotid artery stenosis (ACAS) patients with known carotid artery atherosclerosis by ultrasound/Doppler ≥ 60% diameter stenosis who are clinically referred for OMT alone.
88920305|NCT05838547||Patients treated with OMT and carotid endarterectomy (CEA).|Asymptomatic carotid artery stenosis (ACAS) patients with known carotid artery atherosclerosis by ultrasound/Doppler ≥ 60% diameter stenosis who are clinically referred for OMT and CEA.
88920306|NCT05838534||Normal Skin|
88920307|NCT05838534||Mild Acne Vulgaris|
88920308|NCT05838534||Moderate Acne Vulgaris|
88920309|NCT05838534||Severe Acne Vulgaris|
88920310|NCT05838508|Experimental|Exercise A-B Intervention|The Exercise A first, then the Exercise B intervention.
88920311|NCT05838508|Experimental|Exercise B-A Intervention|The Exercise B first, then the Exercise A intervention.
89436788|NCT01943695|Experimental|General Physical Activity Group|Patients will receive a home-based, general physical activity program. Specifically, all patients assigned to general physical activity will receive an initial, consultation with a staff exercise physiologist outlining a structured home-based aerobic walking program with a goal up to 150 minutes per week outside of their normal daily activity. Patients can be provided with a fitness tracker (e.g. FitBit) to evaluate exercise duration and intensity. Patients may also be provided with an exercise log to record type, duration, and average heart rate during sessions. The exercise log is provided as a guidance tool and may be, although is not required to be, returned to study staff. Staff exercise physiologists will contact patients to check progress, and answer questions.
89436789|NCT01909453|Experimental|LGX818 450 mg + MEK162|LGX818 450 mg QD + MEK162 45 mg BID
89436790|NCT01909453|Active Comparator|Vemurafenib|Vemurafenib 960 mg BID
89436791|NCT01909453|Experimental|LGX818 300 mg + MEK162|LGX818 300 mg QD + MEK162 45 mg BID
89436792|NCT01909453|Experimental|LGX818|LGX818 300 mg QD
89436793|NCT01806129|Active Comparator|Arm A (no intervention)|Patients undergo usual standard practice related to reproductive health.
89436794|NCT01806129|Experimental|Arm B (reproductive health program)|Patients undergo reproductive health program comprising didactics, reproductive health assessment and navigating algorithm, and network development.
89436795|NCT01733082||Cohort|
88920312|NCT05838469|Experimental|Strip Crown|This is a single-arm study. High viscosity glass ionomer strip crowns will be performed to all patients.
88920313|NCT05838365|Experimental|Immediate loading zirconia implant|Loading of zirconia dental implant within 7 days after implant placement
89436796|NCT01700543||Experimental: Sidus Shoulder|Patients indicated for hemi or total shoulder arthroplasty with good bone stock who fulfill all inclusion and none of the exclusion criteria.
89436797|NCT01658930|Active Comparator|Radical Hysterectomy|
89436798|NCT01658930|Experimental|Simple Hysterectomy|
89436799|NCT01633268||Healthy Volunteers|Healthy men and women aged 18-65
89436800|NCT01585233|Experimental|Cohort 1|ASKP1240 lowest dose
89436801|NCT01585233|Experimental|Cohort 2|ASKP1240 low dose
89436802|NCT01585233|Experimental|Cohort 3|ASKP1240 high dose
89436803|NCT01585233|Experimental|Cohort 4|ASKP1240 highest dose
89436804|NCT01585233|Placebo Comparator|Placebo|
89436805|NCT01466036|Experimental|Metastatic or Unresectable PNET|An anticipated 35 patients with pancreatic neuroendocrine tumors receiving cabozantinib
89436806|NCT01466036|Experimental|Metastatic or Unresectable Carcinoid|An anticipated 35 patients with advanced or metastatic carcinoid tumor receiving cabozantinib
89436807|NCT01247207|Experimental|Ataluren|Participants will receive 3 doses of ataluren oral suspension per day (10 mg/kg in the morning, 10 mg/kg at mid-day and 20 mg/kg in the evening).
89436808|NCT01136109||Bedside ultrasound only|Bedside ultrasound to determine the dimensions of the inferior vena cava
89436809|NCT01136109||Ultrasound with ventilator changes|Bedside ultrasound to determine the dimensions of the inferior vena cava pre and post ventilator changes.
89436810|NCT01012817|Experimental|Treatment (veliparib and topotecan hydrochloride)|Patients receive veliparib PO on days 1-3, 8-10, and 15-17 (veliparib is omitted on days 1-3 of course 2) and topotecan hydrochloride IV over 30 minutes on days 2, 9, and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89436811|NCT00895388|Other|Structured Rehabilitation program|
88920314|NCT05838365|Active Comparator|Delayed loading zirconia implant|Loading of zirconia dental implants after at least 2 months of healing
89011047|NCT05250817||Cohort 1|Participants with early stage and advanced/metastatic non-small cell lung cancer (NSCLC)
89011048|NCT05250817||Cohort 2|Participants from the general population
89436812|NCT00895388|No Intervention|Controls|
89436813|NCT00738439||Operative|Diagnosis of adult degenerative or idiopathic scoliosis with a curvature of the spine measuring greater than or equal to 20 degrees requiring surgery.
89436814|NCT00738439||Nonoperative|Diagnosis of adult degenerative or idiopathic scoliosis with a curvature of the spine measuring greater than or equal to 20 degrees not requiring surgery.
89436815|NCT00673842|Experimental|Implantable Cardioverter Defibrillator + Usual Care|Medtronic ICD
89436816|NCT00673842|Active Comparator|Usual Care|Usual post-MI care
89436817|NCT00581906||pts undergoing surgery or chemo-radiation treatment|
89436818|NCT00428805|Experimental|intervention 1|This transcommunity study has one intervention and one control group. The intervention, described elsewhere has 6 components--classroom curriculum, family component,grocery store component, health care provider component, training for Head Start food service workers,and training for Head Start teachers/aides.
89436819|NCT00428805|No Intervention|control 2|measurement only control arm
89436820|NCT00278915|Experimental|Fulvestrant|Participants will receive intramuscular injection of fulvestrant 2 mg/kg or 4 mg/kg (First 10 participants will be dosed at 2 mg/kg then increased to 4 mg/kg. All subsequent participants will be dosed at 4 mg/kg) into the buttock or thigh monthly for 12 months or until the participant demonstrates lack of efficacy based upon one or more of the primary endpoints or experiences a serious drug-related toxicity requiring treatment discontinuation.
89436821|NCT05052957|Experimental|stem cell mobilization after radiation therapy|Participants at University Hospitals-Seidman Cancer Center (UH-SCC) will receive stem cell mobilization after 6 weeks of standard of care (SOC) radiotherapy. Followed by SOC chemotherapy.
89436822|NCT05052866|Experimental|Robot Intervetnion|Participants in this Arm will interact with Ryan Companionbot.
89536576|NCT02474849|Experimental|Closed modular system e-cigarette A|
89536577|NCT02474849|Experimental|Closed modular system e-cigarette B|
89536578|NCT03068403|Other|Chemotherapy and Radiochemotherapy|
89011049|NCT05250791|Active Comparator|lidocaine|An intravenous bolus of 2% lidocaine will be administered following the induction of anaesthesia at 1.5mg/kg ideal body weight over 20 minutes followed by intravenous infusion of 1.5 mg/kg/hour ideal body weight with a maximum rate of 120mg/hour for 24 hours.
89011050|NCT05250791|Placebo Comparator|0.9% sterile Sodium Chloride solution for injection|An equivalent infusion rate (ml) of placebo will be administered following the induction of anaesthesia over 20 minutes followed by hourly equivalent intravenous infusion in ml/hr of placebo with a maximum rate of 6mls/hr (equivalent of 120mg/hour for lidocaine) for 24 hours.
89011051|NCT05230342|Experimental|Nutritional strategy based on functional foods|Participants will be provided with a nutritional strategy based on functional foods to use over the 2 week trial. These will be nopal, chía seeds, inulin, soy protein and genistein.
89011052|NCT05230342|Placebo Comparator|Placebo Ingredient Group|The placebo group will receive a comparable set of food items that contain an equivalent number of calories per portion but without the added functional ingredients
89198703|NCT04585464|Experimental|Healthy Volunteer: Multiple Ascending Dose|"Multiple oral ascending doses in healthy volunteers~Interventions:~Drug: EDG-5506 Drug: Placebo"
89198704|NCT04585464|Experimental|Becker Muscular Dystrophy: Multiple Ascending Dose|"Multiple oral ascending doses in adults with Becker muscular dystrophy~Interventions:~Drug: EDG-5506 Drug: Placebo"
89198705|NCT00873405|Active Comparator|SRSG|Silastic® ring sleeve gastrectomy (SRSG).
89198706|NCT00873405|Other|SRGB|Silastic® ring gastric bypass.
89011053|NCT05217082||Cohort 1|Participants with relapsed/refractory multiple myeloma (RRMM) who have already received a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody
89011054|NCT05200520|Experimental|Appetite Self-Regulation|Participants will attend 12-weekly classes, delivered through virtual small group sessions (via zoom), self-monitor the participant's episodes of hunger and satiety with digital eating behavior website, weigh daily with a wireless Wi-Fi enabled scale, and use a FitBit to track physical activity. Participants will also receive weekly tailored feedback on eating, physical activity, and weight trends. Assessments will be conducted at 0, 3, and 6 months.
89011055|NCT05197322|Other|Tumour Mutation Burden high or medium (or MSI-High)|"Patients will one cycle of pembrolizumab 200 mg IV (a cycle is 21 days). Prior to cycle 2 the result of the FOUNDATIONONE®CDx test should be available and patients will continue their treatment as follows:~TMB-high (defined as ≥20 mutations per Mb) or medium (defined as 6-19 mutations per Mb); FOUNDATIONONE®CDx (or MSI-H if FM1 test is not evaluable):~A further two cycles of pembrolizumab 200 mg IV every 21 days~Planned surgery to remove the CRC 4 - 6 weeks after last dose of pembrolizumab"
89011056|NCT05197322|Other|Tumour Mutation Burden low or unevaluable|"Patients will one cycle of pembrolizumab 200 mg IV (a cycle is 21 days). Prior to cycle 2 the result of the FOUNDATIONONE®CDx test should be available and patients will continue their treatment as follows:~TMB-low (defined as ≤5 mutations per Mb); FOUNDATIONONE®CDx (or if FM1 test and PCR are not evaluable):~• Planned surgery to remove the CRC 4 - 6 weeks after last dose of pembrolizumab"
88920315|NCT05838326|Active Comparator|Symmetrical high flow nasal cannula (HFNO)|"After a 'baseline' trial using Venturi Mask, within the first 120 minutes after extubation, and assessing a arterial oxygen pressure (PaO2) and inspiratory oxygen fraction (FiO2) ratio < 300, patients will be randomly assigned to a first 1h-phase of 'conventional HFNO' or 'DUET HFNO'. At the end of each session several clinical parameters (i.e. DUS, EIT, ABGs, comfort, VAS) will be collected.~Specifically, Gas-flow rate will be set at a maximum of 60 L/min, temperature at a maximum of 37°C, while FiO2 will be adjusted to maintain a peripheral saturation (SpO2) between 92 and 98%."
88920316|NCT05838326|Active Comparator|Asymmetrical high flow nasal cannula (DUET HFNO)|"After a 'baseline' trial using Venturi Mask, within the first 120 minutes after extubation, and assessing a PaO2/FiO2 ratio < 300 (as described above), patients will be randomly assigned to a second 1h-phase of 'DUET HFNO' vs 'conventional HFNO'. At the end of each session several clinical parameters (i.e. DUS, EIT, ABGs, comfort, VAS) will be collected.~Specifically, Gas-flow rate will be set at a maximum of 60L/min, temperature at a maximum of 37°C, while FiO2 will be adjusted to maintain SpO2 between 92 and 98%."
89198707|NCT04049682||Pre Time-change|Daily activity, sleep duration, subjective sleepiness, and response time before change in school start time
89198708|NCT04049682||Post Time-change|Daily activity, sleep duration, subjective sleepiness, and response time after change in school start time
88920319|NCT05838261||Children with cleft palate with velopharyngeal insufficiency undergoing surgical treatment|Children with combined or isolated cleft palate with velopharyngeal insufficiency undergoing surgical treatment with pharyngeal flap
88920320|NCT05838248|Active Comparator|under 65 years simple appendicitis restricted duration|simple appendicitis restricted duration of no postop antibiotics
88920321|NCT05838248|Active Comparator|Under 65 simple appendicitis liberal duration|simple appendicitis liberal duration of 24 hours postop antibiotics
88920322|NCT05838248|Active Comparator|Under 65 complex appendicitis restricted duration|complex appendicitis restricted duration of 24 hours postop antibiotics
88920323|NCT05838248|Active Comparator|Under 65 complex appendicitis liberal duration|complex appendicitis liberal duration of 4 days of postop antibiotics
88920324|NCT05838248|Active Comparator|Over 65 simple appendicitis restricted antibiotic duration|see above for under 65
88920325|NCT05838248|Active Comparator|Over 65 simple appendicitis liberal antibiotic duration|see above for under 65
88920326|NCT05838248|Active Comparator|Over 65 complex appendicitis restricted antibiotic duration|see above for under 65
88920327|NCT05838248|Active Comparator|Over 65 appendicitis liberal antibiotic duration|see above for under 65
88920328|NCT05838235|Experimental|6 month adapted physical activity|"The various assessments will be carried out during 2 visits at 6 months interval as part of the usual follow-up at the Toulouse University Hospital. Standard cardiopulmonary exercise test assessment will be coupled with an assessment by an APA coach on the same day.~The APA program built from the initial assessment will be returned to the child and his family during a videoconference.~In addition, a regular reassessment and adjustment of this program will be made every 15 days during phone calls by the APA coach."
88920329|NCT05838157||Girls and women aged 16 to 40 years who receiving at least one dose of HPV vaccination|Girls and women aged 16 to 40 years who receiving HPV vaccination ( including 2vHPV、4vHPV、9vHPV) in Cancer Prevention Center, Sun Yat-sen University Cancer Center during April 10th 2023 to April 30th 2023.
88920330|NCT05838118|Other|Washed Microbiota Transplantation to treat Chronic Kidney Disease|
88920331|NCT05838118|Other|Standard of Care for Chronic Kidney Disease|
88920332|NCT05838105|Active Comparator|Study group|"Patients will receive luteal support with GNRH agonist and HCG according to departmental protocol:~Cleavage stage embryo:~ET day (embryo day 2-3) - Ovitrelle 125mcg~Day 3 after ET - Ovitrelle 125mcg + Decapeptyl 0.1mg~Day 6 after ET- Ovitrelle 125mcg~Day 9 after ET - Ovitrelle 125mcg~Embryo blastocyst stage:~ET day (embryo day 5-6) - Ovitrelle 125mcg + Decapeptyl 0.1mg~Day 3 after ET - Ovitrelle 125mcg~Day 6 after ET - Ovitrelle 125mcg"
88920333|NCT05838105|Active Comparator|Control group|Patients will receive luteal support with vaginal progesterone - 100 mg Endometrin twice daily until week 8 of pregnancy.
88920334|NCT05838079||New-borns (CBHS-I)|New-borns, within the first 30 days of birth.
88920335|NCT05838079||Children (CBH and CBHS-I)|Children, 3-13 years of age. The children from the original inclusion in CBH, and those included in CBHS-I.
88920336|NCT05838079||Family members|Children and adults, age 1-99 years of age. Some subprojects will invite the family members of the participating child for family examinations.
88920337|NCT05838066|Experimental|KN026+HB1801|Subjects will receive an intravenous (IV) infusion of KN026 plus HB1801. All subjects are required to receive study treatment as planned until investigator-assessed loss of benefit, toxic intolerance, withdrawal of consent, loss to follow-up, or death, whichever occurrs first.
88920338|NCT05838066|Active Comparator|Trastuzumab + Pertuzumab + Docetaxel|On Day 1 of each 21-day cycle, patients will receive an intravenous (IV) infusion of Pertuzumab 840 mg loading dose followed by 420 mg per cycle, IV, D1, Q3W, in combination with trastuzumab 8 mg/kg loading dose followed by 6 mg/kg per cycle, IV, D1, Q3W and docetaxel 75 mg/m^2. All subjects are required to receive study treatment as planned until investigator-assessed loss of benefit, toxic intolerance, withdrawal of consent, loss to follow-up, or death, whichever occurred first.
88920339|NCT05838014|Active Comparator|Normal sleep|Participants will complete three 30-minute bouts of semi-recumbent cycling at incrementally increasing fixed metabolic heat loads (150, 200 and 250 W/m2) in a hot, dry condition (40°C, 15% relative humidity). Each exercise bout will be separated by a 15 minute period of rest, with the final recovery 1 hour in duration. Exercise will commence between the hours of 7 AM and 9 AM following a period of normal sleep (~8 hours) (Control condition).
88920340|NCT05838014|Experimental|Sleep deprivation|Participants will complete three 30-minute bouts of semi-recumbent cycling at incrementally increasing fixed metabolic heat loads (150, 200 and 250 W/m2) in a hot, dry condition (40°C, 15% relative humidity). Each exercise bout will be separated by a 15 minute period of rest, with the final recovery 1 hour in duration. Exercise will commence between the hours of 7 AM and 9 AM following a period of 24 hour of sleep deprivation (Sleep deprivation condition).
89198709|NCT00760968|Experimental|TAK-783 100 mg QD + Methotrexate|
89198710|NCT00760968|Active Comparator|Methotrexate|
88920341|NCT05838001|Experimental|patients after neoadjuvant therapy-combined localization|
88920342|NCT05838001|Active Comparator|patients after neoadjuvant therapy-single localization|
88920343|NCT05837988||MHD patients|Cross sectional survey, no intervention measures involved
89436823|NCT05049746|Other|Intervention Arm|"Participants in the intervention arm only will then be asked to look at the decision tool that includes educational materials about the diagnosis and treatment of breast cancer.~These could be written information, graphics, videos, animations, or questionnaires.~This decision tool will personalize the decision to you specifically and support your decision-making process"
89436824|NCT05049746|No Intervention|Non-Intervention Arm|Participants undergo interviews and complete questionnaires over 1-2 hours. Patients and physicians also participate in a discussion and complete shared decision-making questionnaire over 15-30 minutes.
88920344|NCT05837962|Experimental|Nursing intervention to improve knowledge and self-care behaviors in the face of HDP|Behavioral: Educational, behavioral and motivational intervention developed by nurses aimed at improving the level of knowledge and self-care behaviors of pregnant women in the face of HDP.
88920345|NCT05837962|No Intervention|Usual management during prenatal care|Behavioral: Nursing education about maternal care and usual education in maternity preparation course
88920346|NCT05837949|Experimental|MS FIT: Falls Insight Track|Participants in this arm will receive 12 months use of MS FIT mobile tool intervention
88920347|NCT05837871||Cross sectional arm|Patients with Sickle Cell Anaemia aged 2 to 18 years. Assessed for clinical severity, Complete Blood Count, foetal haemoglobin and Haemoglobin Haplotype
89198711|NCT00369967|Experimental|Quick start|Start contraceptive method (NuvaRing) day of enrollment
89536579|NCT03068403|Other|Radiochemotherapy|
89536580|NCT02471963|Active Comparator|Empagliflozin|Empagliflozin, 25 mg/day, oral administration, 6 weeks
89536581|NCT02471963|Placebo Comparator|Placebo|Placebo, oral administration, 6 weeks
89198712|NCT00369967|Active Comparator|Traditional start|Start contraceptive method (NuvaRing) after next menses (per package insert)
88920348|NCT05837871||Longitudinal arm|"Patients with Sickle Cell Anaemia recruited at 9 months of age then followed up at 12 months, 18 months and 24 months.~Assessed for clinical severity, Complete Blood Count, foetal haemoglobin and Haemoglobin Haplotype~Both parents assesed for Haemoglobin Haplotype~Genotype - Haplotype assessment to be carried out"
88920349|NCT05837793||frail|The mFi categorizes patients with a score of 0.27 or higher as frail and those with a score below that as the non-frail group.
88920350|NCT05837793||and non-frail|The mFi categorizes patients with a score of 0.27 or higher as frail and those with a score below that as the non-frail group.
88920351|NCT05837780|Experimental|conventionally constructed nasoalveolar molding devices (control group)|control group: patients receiving conventionally constructed nasoalveolar molding devices
88920352|NCT05837780|Experimental|Digitally constructed nasoalveolar molding devices (test group)|test group: patients receiving digitally constructed nasoalveolar molding devices
88920353|NCT05837572|Other|Group 1|Each participant will attend the laboratory twice to perform two identical trials in order to asses validity (first trial) and reproducibility (second trial)
88920354|NCT05837559|Active Comparator|Traditional WHO Partograph for Uncomplicated Labour|With the Traditional WHO partograph, uterine contractions will be assessed every 30 minutes, fetal heart will be assessed every 30 minutes and maternal pulse 30 minutes, blood pressure is recorded every 4 hourly and temperature is recorded every 2 hourly. Urine output is recorded every time urine is passed. The woman is encouraged to pass urine every 2 hourly in labour and each specimen is tested for protein and ketones. Drugs, IV fluids, Drugs (Oxytocin) are recorded in the space provided.
88920355|NCT05837559|Experimental|Korle-Bu Modified WHO Partograph for Uncomplicated Labour|With the Korle-Bu modified partograph, uterine contractions will be assessed every hour (60 minutes), fetal heart will be assessed every 30 minutes and maternal pulse every hour. All other assessments remain as for the traditional partograph.
88920356|NCT05837520|Experimental|i-BiSSkApp Group|This group will complete daily swallowing behavioral exercises with simultaneous at-home sEMG biofeedback using a tablet application. Participants will participate in weekly clinic visits and at-home therapy for 12 weeks.
88920357|NCT05837520|Active Comparator|Traditional Treatment|This group will receive traditional swallowing therapy once a week for 12 weeks using standard therapy practices. They will also complete at-home daily practice of these exercises.
88920358|NCT05837442|Experimental|Osteopathic Manual Therapy Group (OMTG)|The total duration of all techniques applied is 30 minutes. The techniques used in the extremities were applied to both extremities.
88920359|NCT05837442|No Intervention|Control Group (CG)|No intervention was made to the patients in the control group.
88920360|NCT05837429|Experimental|Low Volume High Intensity Exercise Training|Patients in the intervention group will be given a warm-up phase for 3 minutes at 50% VO2max, 1 minute at 80-100% VO2max and 1 minute at 50% VO2max in 10 cycles, and finally a cool-down phase for 3 minutes at 50% VO2max.
88920361|NCT05837429|Active Comparator|Aerobic Exercise|Patients in the control group will be given exercise training on a bicycle ergometer for 5 minutes warm-up phase at 40% of maximal oxygen consumption (VO2max), 20 minutes exercise phase at 60% of VO2max and 5 minutes cool down phase at 40% of VO2max for a total of 30 minutes.
88920362|NCT05837416|Experimental|Oxygen Releasing Oral Gel (blue®m) with Coe-Pak dressing|topical application of Oxygen Releasing Oral Gel (blue®m) on the surgical site followed by Coe-Pak immediately after gingival depigmentation surgery, then 1 week postoperatively
88920363|NCT05837416|Experimental|Nano-emulsion complex propolis and vitamin C (NBF GINGIVAL GEL®) with Coe-Pak dressing|topical application of Nano-emulsion complex propolis and vitamin C (NBF GINGIVAL GEL®) on surgical site followed by Coe-Pak immediately after surgery, then 1 week postoperatively
88920364|NCT05837416|Active Comparator|COE-PAK periodontal dressing only|Periodontal dressing (COE-PAK) will be applied on surgical site only .
88920365|NCT05837299|Experimental|IMC008 dose 1-3|a certain number of IMC008 cell per kg will be infused
88920366|NCT05837286|Experimental|Experimental Group with Cortisone Injection of affected digit(s) and nighttime orthosis|The experimental group will consist of receiving a PIP joint on the day they receive their cortisone injection. The Oval-8 ® will be issued to the subject by an Occupational Therapist to ensure correct fit and comfort as well as given written instructions for night use. The orthosis will be worn at night for 6-week duration. Participants will have 1 follow up phone call or email at the 6-week mark and then 1 follow up phone call or email at the 12 week mark by a member of the research team from the time they received their cortisone injection where the time for resolution of trigger finger symptoms, VAS (Visual Analogue Scale), subjective questionnaire and QuickDASH scores will all be recorded in their medical research file.
88920367|NCT05837286|Active Comparator|Control Group-No Orthosis|The control group will be identical to the experimental group except without the use of a nighttime orthosis. Participants will have 1 follow up phone call or email at the 6-week mark and then 1 follow up phone call or email at the 12 week mark by a member of the research team from the time they received their cortisone injection where the time for resolution of trigger finger symptoms, VAS (Visual Analogue Scale), subjective questionnaire and QuickDASH scores will all be recorded in their medical research file.
88920368|NCT05837273|Experimental|Fully immersive leisure-based virtual reality|
88920369|NCT05837273|Experimental|Conventional cognitive training|
88920370|NCT05837273|No Intervention|control group|
88920371|NCT05837195||Control group|"Standard care:~Doppler velocimetry: UA & MCA PI, DV PIV, CPR; Indirect cardiotocography (CTG) Biophysical profile (BPP)"
88920372|NCT05837195||DDA Doppler group|Standard care plus DDA Doppler monitoring
88920373|NCT05837130|Experimental|Cohort A|Cohort A will include LRRK2 G2019S symptomatic carriers, idiopathic PD patients, and healthy volunteers. It will involve a blood sample collection and an optional cerebrospinal fluid (CSF) collection.
89536582|NCT05290181|Experimental|Pilates exercise and whatsapp text message group|A support program including pilates exercises and sending text messages will be applied to the students in the intervention group for 8 weeks. Online pilates exercises will be done 2 days a week and individual short messages will be sent to their smartphones via the Whatsapp application 3 days a week. Participants will be provided with Pre Pilates exercises, Pilates Mat Program: Beginner Level, Pilates Mat Program: Intermediate Level, Pilates Mat Program: Advanced level exercises. The exercises will be done online in the presence of a research physiotherapist with The Australian Physiotherapy & Pilates InstituteMatwork Level 1 (APPI) certificate.
89536583|NCT05290181|No Intervention|Control group|No intervention will be made in the control group.
88920374|NCT05837130|Experimental|Cohort B|Cohort B will include LRRK2 G2019S carriers, idiopathic PD patients, and heathy volunteers. It will involve only a blood sample collection.
88920375|NCT05837078|Active Comparator|control group|patients had ridge splitting without laser bio stimulation and received two implants supported peek overdenture
88920376|NCT05837078|Active Comparator|study group|patients had ridge splitting with laser bio stimulation and received two implants supported peek overdenture
88920377|NCT05837065||training cohort|HCC patients receiving curative hepatic resection
88920378|NCT05837065||validation cohort|HCC patients receiving curative hepatic resection
89536584|NCT03068325|Experimental|TF-EAT|
89536585|NCT03068481|Experimental|Healthy volunteer part -Single dose|Single oral dose of KDT-3594
88920379|NCT05837026|Experimental|Enhanced Outreach Intervention plus Care as Usual (CAU)|Participants will receive the Enhanced Outreach Intervention (EOI) plus care as usual for 12 weeks after ED discharge.
89436825|NCT05047042|Experimental|Advanced Cancer Support in Virtual Rehabilitation and Exercise|The intervention will take place in participants' homes, at times convenient for the participant. Programming will be administered virtually through the University of Alberta's Cancer Rehabilitation Clinic, which is fully equipped for virtual delivery of services. The study intervention will be tailored to the individual with respect to their baseline strength, symptom profile and prior experience with exercise. Pre- and post-testing will be done virtually. The mode, intensity and duration of each exercise session will be based on the participant's baseline fitness and status that day. Variations on each exercise will be provided to ensure an appropriate movement and intensity and to allow for individual prescription. Resistance bands will be used to provide resistance during strengthening and balance retraining exercises. The interactive group class will be led virtually by an exercise or rehabilitation specialist.
89436826|NCT05046080||Observational (medical record review)|Patients' medical records are reviewed retrospectively, and archival tumor tissue analyzed by immunohistochemistry and next generation sequencing.
89436827|NCT05046067|Experimental|Diagnostic (CT)|Patients undergo 4 CT scans during standard of care surgery.
89436828|NCT05045768|Experimental|Postinfectious ibs and diarrhea predominant classical IBS|Capsule containing Tamarind seed polysaccharide containing xyloglucan, combined with a pea protein reticulated with grape seed extractand a prebiotic, the xilooligosaccharide (Gelsectan, Devintec sagl) twice daily
89436829|NCT05045352|Active Comparator|Echogenic needle|venous access performed under ultrasound guidance with echogenic needles
89436830|NCT05045352|No Intervention|Non-Echogenic needles|venous access performed under ultrasound guidance with non-echogenic needles
89436831|NCT05042544||People at risk of HCV acquisition|This is an observational cohort study. Participants will be recruited from settings that provide services to people with a risk factor for the acquisition of HCV infection. Participants will attend a single visit to receive point-of-care HCV testing and complete a self-administered survey. Testing will be performed using point-of-care HCV antibody testing (results within 1-20 minutes, depending on the test) and if positive, HCV RNA testing will be performed. Participants who have previously had HCV infection or previously received HCV treatment will be tested using point-of-care HCV RNA testing. Participants will not receive treatment as a part of this study. Participants who are HCV RNA detectable will be linked to standard of care for any other clinical assessments and treatment initiation.
89436832|NCT05041023||Relative volunteers|For each situation of death of a patient in ICU following a decision to withdraw LST and for which OD has been discussed with the relatives, a relative can be included after information and acceptance of the study. One relative per situation can be included : the most involved personn in the relationship with the resuscitation team.
89436833|NCT05041023||Caregivers|For each situation of death of a patient in ICU following a decision to withdraw LST and for which OD has been considered, 2 to 3 caregivers who are present at the time the WLST is initiated can be included (1 physician and 1 or 2 paramedics).
89436834|NCT05040685|Experimental|Axillary mapping reverse|Application of axillary mapping reverse technique
89436835|NCT05033925|Placebo Comparator|Placebo|receive a plasebo capsule 2 doses per day
89436836|NCT05033925|Experimental|FADA 800 mg/day|receive FADA capsules twice a day (each 400 mg)
89436837|NCT05033925|Experimental|FADA 2000 mg/day|receive FADA capsules twice a day (each 1000 mg)
89436838|NCT05032521|Active Comparator|standard practice|
89436839|NCT05032521|Experimental|algorithm|
89436840|NCT05032313||Remnant/ Leftover specimens|Specimens that meet inclusion/exclusions criteria and are leftover from routine flow cytometry testing for hematological disorders.
89436841|NCT05031078|Experimental|Group 1: Lymph node sampling at D-30 to D0, D14 and D30|"Participants will receive 3 doses of 9-valent HPV vaccine (Gardasil 9) at D0, D60, and D180.~Group 1 will have lymph node sampling done D-30 to D0, D14 and D30. Bone marrow sampling will be done for all groups at D730."
89436842|NCT05031078|Experimental|Group 2: Lymph node sampling at D60, D74 and D90|"Participants will receive 3 doses of 9-valent HPV vaccine (Gardasil 9) at D0, D60, and D180.~Group 2 will have lymph node sampling done at D60, D74 and D90. Bone marrow sampling will be done for all groups at D730."
89436843|NCT05031078|Experimental|Group 3: Lymph node sampling at D180, D194 and D210|"Participants will receive 3 doses of 9-valent HPV vaccine (Gardasil 9) at D0, D60, and D180.~Group 3 will have lymph node sampling D180, D194 and D210. Bone marrow sampling will be done for all groups at D730."
89436844|NCT05029557|No Intervention|Control group patients|The patients in the Control Group will continue their routine procedures.
89436845|NCT05029557|Experimental|Education and telephone follow ups based on the Chronic Care Model|Intervention Group will be given training (0 months) with the training booklet, which is prepared by the researcher based on the Chronic Care Model, and which includes information and suggestions about self-management strategies. The training will be organized in one single session in a way not to exceed approximately 45-50 minutes. The patients, who will be included in the Intervention Group, will be followed up by phone every two weeks. Also, reminders and informative information based on the training booklet will be sent to patients every week in the form of a short message.
89436846|NCT05023278|Placebo Comparator|Placebo|Subjects in placebo arm will receive inactive placebo capsule daily for 7 consecutive days starting on day of primary arthroplasty surgery.
89436847|NCT05023278|Experimental|Venlafaxine|Subjects in venlafaxine arm will receive venlafaxine 37.5mg daily for 7 consecutive days starting on day of primary arthroplasty surgery.
88920380|NCT05837026|Other|Care as Usual (CAU)|Participants will receive the standard care (i.e., CAU) that the hospital provides to patients who present with suicidal thoughts.
89436848|NCT05022407||Cohort 1 (SARS-CoV-2 uninfected)|Participants who test negative on the SARS-CoV-2 rapid test and are not considered at risk of COVID-19 or who have a negative RNA-PCR SARS-CoV-2 test result at baseline.
89436849|NCT05022407||Cohort 2 (SARS-CoV-2 infected)|Participants who test positive on RNA-PCR SARS-CoV-2.
89436850|NCT05022407||Cohort 3 (SARS-CoV-2 exposed)|Participants who have a positive SARS-CoV-2 rapid test result and are not considered to be at risk of active COVID-19 infection or have a negative RNA-PCR SARS-CoV-2 test.
88920381|NCT05836961|Experimental|BNP enrolled|Pregnant women in their first or second trimester who have been enrolled in BNP
88920382|NCT05836961|No Intervention|BNP non-enrolled|Pregnant women in their first or second trimester who are not enrolled in BNP
89536586|NCT03068481|Experimental|Healthy volunteer part -Multiple dose|Multiple oral doses of KDT-3594
89536587|NCT03068481|Placebo Comparator|Healthy volunteer part -Placebo|Multiple oral doses of Placebo
89536588|NCT03068481|Experimental|Patient part -Single dose|Single oral dose of KDT-3594
88920384|NCT05836831|Experimental|Intervention Arm|The treatment arm will consist of giving intravenously 2 grams of Tranexamic Acid in 100 ml sodium chloride 0.9 % adminsitered over 45 minutes. Intensive systolic blood pressure reduction to less than 140 mmHg will be done using antihypertensive agents (intravenous and/or oral) which is to be achieved within one hour and has to be maintained over seven days. BP monitoring is done for every 15 minutes in the first hour and thereafter every hour for the next six hours after the initiation of intensive BP control. The choice of antihypertensive will depend on the clinician's preference.
88920385|NCT05836831|No Intervention|Control Arm|The control arm will receive a standard of care management as per the institutional practice. Intensive systolic blood pressure reduction to less than 140 mmHg will be done using antihypertensive (intravenous and/or oral) which is to be achieved within one hour and has to be maintained over seven days. BP monitoring is done for every 15 minutes in the first hour and thereafter every hour for the next six hours after the initiation of intensive BP control. The choice of antihypertensive will depend on the clinician's preference.
88920386|NCT05836805|Experimental|[14C]XZP-3621|Eligible healthy 6 volunteers will receive a single oral dose of 400 mg/200 µCi [14C]XZP-3621 administered by mouth, as a suspension solution.
88920387|NCT05836649|Experimental|Active VR then Passive VR|Participant will conduct the experiment using active VR first and then passive VR
88920388|NCT05836649|Experimental|Passive VR then Active VR|Participant will conduct the experiment using passive VR first and then active VR
89198713|NCT00878865|Experimental|Alprazolam 1 mg tablet|Alprazolam 1 mg tablet
89198714|NCT00878865|Active Comparator|Xanax 1 mg tablet|Xanax 1 mg tablet
89198715|NCT03838653||Left main bronchus (LMB) intubation|Thoracic surgery patient is intubated with left side double lumen tube (L-DLT) and a fiberoptic bronchoscope is used to verify optimal positioning. The patient is designated as this group when the endobronchial lumen is observed to be in the left main bronchus (correct placement).
89198716|NCT03838653||Right main bronchus (RMB) intubation|Thoracic surgery patient is intubated with left side double lumen tube (L-DLT) and a fiberoptic bronchoscope is used to verify optimal positioning. The patient is designated as this group when the endobronchial lumen is observed to be in the right main bronchus (incorrect placement).
89198717|NCT00873483|Experimental|Arm 1|
89198718|NCT01050517|Active Comparator|1|albendazole + ivermectin + praziquantel
89198719|NCT01050517|Placebo Comparator|2|albendazole + ivermectin + (1 week later) praziquantel
88920389|NCT05836545|Active Comparator|Midazolam|The patient with midazolam
88920390|NCT05836545|Experimental|Remimazolam|The patient with remimazolam
89198720|NCT02534467|Experimental|Montelukast-Standard|8 weeks of montelukast and standard therapy crossing over to 8 weeks of only standard therapy
89536589|NCT03068481|Experimental|Patient part -Multiple dose|Multiple oral doses of KDT-3594
88920391|NCT05836519||Individuals with a pes planus|Navicular drop test, International Physical Activity Questionnaire (IPAQ), Digital dynamometer measurement, SF-36 quality of life Questionnaire, 6 Minutes Walk test, Foot Function Index, borg value, heart rate, blood pressure, oxyhemoglobin values will be measured for individuals with pes planus.
89198721|NCT02534467|Active Comparator|Standard-Montelukast|8 weeks of standard therapy only crossing over to 8 weeks of montelukast and standard therapy
89198722|NCT01050595|Active Comparator|Methylnaltrexone Bromide|
89198723|NCT01050595|Placebo Comparator|Placebo|
89198724|NCT03991975|Experimental|Anlotinib + TQB2450|TQB2450 1200 mg IV on Day 1 of each 21-day cycle plus Anlotinib capsules given orally in fasting conditions , once daily in 21-day cycles (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
89198725|NCT04039269|Active Comparator|Multiple (watch > 3 times)|Preoperative video information
89198726|NCT04039269|Active Comparator|single (watch 1 time)|Preoperative video information
89198727|NCT04039269|No Intervention|conventional (do not watch)|Do not watch video
89198728|NCT02534311||Tocilizumab|Participants will receive tocilizumab (162 milligrams [mg]) SC injection for 48 weeks.
89198729|NCT00873561|Active Comparator|1 Experimental|NBI-6024 0.1 mg
89198730|NCT00873561|Active Comparator|2 Experimental|NBI-6024 0.5 mg
89198731|NCT00873561|Active Comparator|3 Experimental|NBI-6024 1 mg
89536590|NCT01375751|Placebo Comparator|Placebo|Participants received placebo subcutaneous injection once every 4 weeks for 12 weeks.
89536591|NCT01375751|Experimental|Evolocumab 350 mg|Participants received 350 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
88920392|NCT05836519||Individuals Without Giving Up Planus|Navicular drop test, International Physical Activity Questionnaire (IPAQ), Digital dynamometer measurement, SF-36 quality of life Questionnaire, 6 Minutes Walk test, Foot Function Index, borg value, heart rate, blood pressure, oxyhemoglobin values will be measured for individuals with pes planus.
88920393|NCT05836493||Ring annuloplasty|
88920394|NCT05836493||Suture procedure|
89198732|NCT00873561|No Intervention|4 placebo|Placebo injection
89436851|NCT05022407||Cohort 4 ( Vaccinated)|Participants who declare having received at least one dose of COVID-19 vaccine (verbally or by showing vaccination card) at inclusion (for HCW or PLHIV) or at any follow-up visit (PLHIV) will be followed in this cohort.
89436852|NCT05022134|Experimental|Intervention (CHOICE-AYA)|The impact of CHOICE-AYA contraceptive counseling on contraceptive use, satisfaction, and continuation will be assessed.
89436853|NCT05017012|Experimental|MK-3475A (Pembrolizumab Conc1 [dose 1] + MK-5180)|Participants receive MK-3475A (pembrolizumab Conc1 [dose 1] + MK-5180) SC on Day 1 of Cycles 1 and 3 plus 400 mg pembrolizumab intravenously (IV) on Day 1 of Cycles 2 and 4 to 18, with or without background standard of care (SOC) chemotherapy as appropriate for the indication. A cycle is 42 days.
89436854|NCT05017012|Experimental|MK-3475A (Pembrolizumab Conc2 [dose 1] + MK-5180)|Participants receive MK-3475A (pembrolizumab Conc2 [dose 1] + MK-5180) SC on Day 1 of Cycles 1 and 3 plus 400 mg pembrolizumab IV on Day 1 of Cycles 2 and 4 to 18, with or without background SOC chemotherapy as appropriate for the indication. A cycle is 42 days.
89436855|NCT05017012|Experimental|MK-3475A (Pembrolizumab Conc1 [dose 1] + MK-5180) + SOC Chemotherapy|Participants in Japan receive MK-3475A (pembrolizumab Conc1 [dose 1] + MK-5180) SC on Day 1 of Cycle 1, with background SOC chemotherapy, and then receive 400 mg pembrolizumab IV on Day 1 of Cycles 2 to 18, with background SOC chemotherapy. A cycle is 42 days.
89436856|NCT05017012|Experimental|MK-3475A (Pembrolizumab Conc1 [dose 2] + MK-5180)|Participants receive MK-3475A (pembrolizumab Conc1 [dose 2] + MK-5180) SC on Day 1 of Cycles 1 to 35 without background standard of care (SOC) chemotherapy. A cycle is 21 days.
89436857|NCT05013060|Active Comparator|The mixture of probiotics and microcapsulated sodium butyrate|One billion of the following strains: Bifidobacterium lactis FloraActive 32269, Bifidobacterium longum FloraActive 32946, Bifidobacterium bifidum FloraActive 32043, Lactobacillus rhamnosus FloraActive 19070-2, Lactobacillus acidophilus FloraActive 32418 and 150 mg microcapsulated sodium butyrate, and 64 mg fructooligosaccharides
89436858|NCT05013060|Placebo Comparator|Placebo|Maltodextrin
89436859|NCT05012124|Experimental|Arm I (t-CoCM)|Patients use the t-CoCM digital app platform and clinic care managers use the t-CoCM web-based registry platform to support delivery of collaborative care. Patient's complete surveys at baseline, 3, 6 and 9 months. Some patients also participate in an interview or focus group about their user experience with the t-CoCM digital platform. Care managers also participate in interviews regarding their experience with CoCM and the newly developed web-based platform.
89436860|NCT05012124|Active Comparator|Arm II (u-CoCM)|Patients receive usual care and clinic care managers deliver usual CoCM. Patients complete surveys at baseline, 3, 6 and 9 months.
89436861|NCT05010473|Experimental|Neurotypical Human Participants|Native speakers of Chinese and native speakers of English
89436862|NCT05010369|Experimental|non-hodgkin lymphoma|patients diagnosed with non-hodgkin lymphoma
89436863|NCT05010369|Experimental|hodgkin lymphoma|patients diagnosed with hodgkin lymphoma
88920395|NCT05836480||Suboptimal repair|Patients discharged with a residual mitral regurgitation of at least moderate (2+)degree
88920396|NCT05836480||Optimal repair|Patients discharged with a residual mitral regurgitation of mild (1+) or less degree (trace or 0)
88920397|NCT05836441|Active Comparator|White spot irradiation group|Exposure to white patches
88920398|NCT05836441|Experimental|White spot edge irradiation group|Exposure to edge of white patches and normal skin around white patches
88920399|NCT05836428||Persistent post-COVID-19 headache|post-COVID-19 patients with persistent headache
88920400|NCT05836428||controls|Mild Neuro-COVID-19 patients without persistent headache and other neurological diseases
88920401|NCT05836376||Function Atrial MR|
88920402|NCT05836376||Functiona Non-atrial MR|
88920403|NCT05836350|Active Comparator|4.8 g/m^2/day NaPB|12-week oral administration of 4.8 g/m^2/day Sodium-phenylbutyrate (NaPB) (in the form of Pheburane)
88920404|NCT05836350|Placebo Comparator|4.8 g/m^2/day Placebo|12-week oral administration of 4.8 g/m2/day identical placebo granules.
88920405|NCT05836337|Experimental|Tattoo- Black Eye|to mark the biopsied axillary lymph node by tattooing
88920406|NCT05836337|Active Comparator|clip- HydroMARK|To mark the biopsied axillary lymph node by clip placement
88920407|NCT05836233||Enrolled patients - LVAD candidates|"Inclusion criteria~Age over 18 years old.~Diagnosis of advanced heart failure with an indication for LVAD implantation.~Mean Arterial Pressure (MAP) > 60 mmHg; Mean Pulmonary Arterial Pressure (mPAP) > 20 mmHg; Pulmonary Artery Wedge Pressure >15 mmHg.~Vasodilator Challenge performed through NTP infusion.~Exclusion criteria~State of pregnancy.~Inability to perform vasodilator challenge~Need for extracorporeal membrane oxygenator or short-term right ventricular assist devices.~Planned right ventricular assist device implantation in the peri-procedural setting."
88920408|NCT05836207|Experimental|Abstinence-focused Contingency Management (CM)|Youths receive 12 weeks of outpatient abstinence-focused CM consisting of providing incentives for cannabis abstinence, based on twice-weekly rapid test urinalysis.
88920409|NCT05836207|Active Comparator|Cognitive Behavioural Therapy (CBT)|Youths receive 12 weeks of outpatient usual care CBT consisting of once-weekly 60-minute sessions according to the standard CBT youth protocol by a trained psychologist.
88920410|NCT05836181|Experimental|Eye Movement Desensitization and Reprocessing intervention|The goal of EMDR is to help manage physical and mental unpleasant experiences due to hypertension. The intervention group received EMDR therapy included eight phases, each lasting 60-90 minutes, and the intervention consisted of four weekly. In this study, a Nurse practitioner trained in EMDR performs an intervention in an outpatient clinic's quiet, empty room.
88920411|NCT05836181|No Intervention|Eye Movement Desensitization and Reprocessing control|The control group received routine care and treatment as usual. They did not receive EMDR intervention or counseling.
89436864|NCT05010369|Experimental|squamous cell carcinoma|patients diagnosed with squamous cell carcinoma
89436865|NCT05010369|Experimental|reactive|patients diagnosed with a reactive (non-cancerous) lymph node
89436866|NCT05010369|Experimental|other|none of the above. Other cancer and non-cancer conditions
89436867|NCT05008107|Experimental|Virtual Reality|Virtual reality (VR) will be provided to families of patients undergoing ambulatory pediatric surgery. VR will provide personalized education to patients and their families about the entire continuum of the child's surgical experience. This will range from the hospital registration, the peri-operative experience, including the separation of the child from the parent in the pre-operative area and the anesthetic induction process, and the post-operative hospital ward.
89436868|NCT05008107|No Intervention|Control|Families will receive standard pre-operative instructions.
89436869|NCT05005806|Active Comparator|Omega 3 soft gel|participants in this group (1)omega 3 fatty acid soft gel 1000 mg will be given to participants twice daily for two months.
89436870|NCT05005806|Placebo Comparator|placebo|placebo group ,placebo soft gel designed same as omega 3 contain Vitamin A 1000 mg twice daily for two months
88920412|NCT05836116||Individuals with Scoliosis|Humans with scoliosis, between age 18-35
88920413|NCT05836116||Healthy Group (Control group)|Healthy human subjects between age 18-35
89436871|NCT05005273|Experimental|Arm A|
89436872|NCT05005273|Experimental|Arm B|
89436873|NCT04999969|Experimental|AZD0171 + Durvalumab + chemotherapy|Participants will receive AZD0171 (intravenous [IV]) along with durvalumab (IV) in combination with standard-of-care chemotherapy IV (gemcitabine and nab-paclitaxel).
89436874|NCT04999436|Experimental|Counseling Training Program|The APOL1 counseling training program is designed for transplant nephrologists who evaluate live kidney donor candidates of African ancestry who are at risk for having APOL1 risk variants and kidney failure post-donation. The training program aims to increase transplant nephrologists' practical knowledge, self-efficacy, and skills in counseling live donor candidates about APOL1 in a culturally competent manner. The program will include training in: current APOL1 data; the value of APOL1 testing and meaning of positive test results for living donor clinical evaluation; risks of having two APOL1 gene variants on the donor's kidney health; how to engage in shared decision making about donation; how to address cultural concerns about genetic testing; and how to protect donor candidates' privacy and confidentiality with APOL1 test results. The APOL1 counseling training program will be delivered by a genetic counselor through webinars and other interactive modalities and last 2-4 hours.
89436875|NCT04999228|Experimental|Infliximab treatment group|For newly diagnosed moderate to severe Pediatric ulcerative colitis, infliximab will be used as first-line treatment
88920414|NCT05836077|Experimental|Pecha kucha method|Patients will be trained by pecha kucha method using computer with powepoint presentation.
88920415|NCT05836077|No Intervention|Control group|Routine maintenance will be applied
88920416|NCT05835726||Cases (prospective cohort)|Patients who fulfill the inclusion criteria (newly diagnosed multiple myeloma patients undergoing daratumumab-containing induction regimens).
89436876|NCT04999228|Active Comparator|Corticosteroid treatment group|For newly diagnosed moderate to severe Pediatric ulcerative colitis, corticosteroids will be used as first-line treatment
88920417|NCT05835726||Controls|Patients with newly diagnosed multiple myeloma who received standard VTD (VTD:bortezomib-thalidomide and dexamethasone) induction, subsequent stem cell mobilization, and tandem autologous stem cell transplant before the introduction of daratumumab in our local practice from January 2020 to December 2021.
88920418|NCT05835037|Experimental|Zinc treatment|Research subjects administered zinc acetate for 1 year (one 25 mg tablet per day)
88920419|NCT05835037|Placebo Comparator|Placebo|Research subjects administered placebo for 1 year (1 tablet per day)
89011057|NCT05192356|Experimental|Sequence 1|"Period 1: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition~Period 2: CKD-348(3) - A single oral dose of 1 tablet under fasting condition~Period 3: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition~Period 4: CKD-348(3) - A single oral dose of 1 tablet under fasting condition"
89436877|NCT04996823|Experimental|Ipilimumab + Axtinib|Participants will receive treatment with ipilimumab 3 mg/kg IV q3 weeks x 4 doses and axitinib at 5 mg by mouth twice daily. Each cycle is 3 weeks/21 days
89436878|NCT04994509|Experimental|Blinded Phase: LEN + Placebo-to-match (PTM) F/TAF|"Participants will receive the following for at least 52 weeks:~Subcutaneous (SC) lenacapavir (LEN) 927 mg every 26 weeks~Oral PTM Emtricitabine/Tenofovir Alafenamide (F/TAF) once daily~Oral LEN 600 mg on Days 1 and 2"
89436879|NCT04994509|Experimental|Blinded Phase: LEN + PTM F/TDF|"Participants will receive the following for at least 52 weeks:~SC LEN 927 mg every 26 weeks~Oral PTM Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) once daily~Oral LEN 600 mg on Days 1 and 2"
88920420|NCT05834660|Experimental|Safe Alternatives for Teens and Youth-Acute for Schools (SAFETY-A for Schools)|SAFETY-A is a brief, family centered, cognitive-behavioral approach to therapeutic risk assessment and safety planning that can be delivered via school-based providers. The intervention is delivered in one session during which the youth at risk for suicidal behavior works with the provider to identify strengths, supports, understand emotional antecedents and warning signs, identify alternative coping behaviors and thoughts, and ways to keep the environment safe. Youth and families receive follow-up contacts after the SAFETY-A session. The primary focus is on the therapeutic mechanisms of hope, reduced intensity of suicidal urges, increased confidence in ability to keep safe. Adaptation of SAFETY-A for Schools will target mechanisms that are presumed to drive disparities in mental health service use among Asian American and Latinx youth: (1) trust in mental health services, (2) internalized stigma, and (3) comfort communicating distress.
88920421|NCT05833308||POD group|Patients who were determined to have incident postoperative delirium by a positive confusion assessment method (CAM) questionnaire after operation were defined as the POD group.
88920422|NCT05833308||Non-POD group|Patients who did not suffer from delirium after surgery consisted of the Non-POD group.
88920423|NCT05833217|No Intervention|Chart Review (not actively recruiting)|Chart review of previously consented participants from the entire NIH RECOVER cohort, comprised of 15,000 infected and 2,600 noninfected patients across the country.
88920424|NCT05833217|Experimental|COVID infected and healthy controls|Participants will perform a needle fat biopsy for tissue harvesting in the subacute phase (15-30d) of Covid-19 infection or as a healthy control. Our goal is 20 COVID-19 infected participants and 10 healthy controls.
88920425|NCT05833217|Experimental|Healthy Controls Only|"We are looking for 20 healthy controls for 2 in-person visits on separate days.~An Insulin Sensitivity Test (SSPG: Steady State Plasma Glucose) is performed to determine if the participant is insulin-sensitive or insulin resistant.~A Needle Fat Biopsy: After an overnight fast, approximately 1-2 grams of subcutaneous fat will be removed by a needle. Patients will have a local anesthetic prior to the procedure."
88920426|NCT05832021||WALANT|Patients with distal radius fracture who underwent surgical treatment under WALANT.
88920427|NCT05832021||Peripheral nerve block|Patients with distal radius fracture who underwent surgical treatment under peripheral nerve block.
88920428|NCT05830682|Experimental|Intervention Group|Participants in this study group asked to walk with using a walking aid during the first three mobilizations in the intensive care unit on the first postoperative day.
88920429|NCT05830682|No Intervention|Control Group|Participants in this study group asked to walk with the help of 2 nurses during the first three mobilizations in the intensive care unit on the first postoperative day.
89436880|NCT04994509|Experimental|Blinded Phase: Placebo LEN + F/TAF|"Participants will receive the following for at least 52 weeks:~SC placebo LEN every 26 weeks~Oral F/TAF 200/25 mg once daily~Oral PTM LEN on Days 1 and 2"
89436881|NCT04994509|Experimental|Blinded Phase: Placebo LEN + F/TDF|"Participants will receive the following for at least 52 weeks:~SC placebo LEN every 26 weeks~Oral F/TDF 200/300 mg once daily~Oral PTM LEN on Days 1 and 2"
88920430|NCT05823857|Experimental|Aquatic Therapy|Aquatic exercise program including trunk stabilization, upper body, lower body strengthening and flexibility exercises and aerobic conditioning. Supervised 10-week program, 2 times a week.
88920431|NCT05823857|Experimental|Standard Care|Standard care program including strengthening, flexibility, aerobic conditioning, modalities and manual mobilization techniques. Supervised 10-week program, 2 times a week.
88920432|NCT05814744|Sham Comparator|Group (A)|bupivacaine 0.25% only
89436882|NCT04994509|Experimental|LEN Open-Label Extension (OLE) Phase|"After completion of the Blinded phase, participants will be offered entry into the LEN OLE Phase.~Participants randomized to LEN will continue to receive SC LEN 927 mg every 26 weeks for a total of 2 doses.~Participants randomized to F/TAF or F/TDF will receive SC LEN 927 mg on OLE Day 1 and OLE Week 26, and will also receive oral LEN 600 mg on OLE Days 1 and 2."
89436883|NCT04994509|Experimental|Pharmacokinetic (PK) Tail Coverage Phase|"At the completion of the LEN OLE phase, participants will transition into the PK Tail Coverage phase.~Additionally, participants that either prematurely discontinue the study drug during the blinded phase or choose not to continue in the LEN OLE phase (if randomized to LEN in the blinded phase) or who discontinue the study drug in the LEN OLE phase are also eligible to transition to the PK Tail Coverage phase.~Participants will receive oral F/TDF once daily for 78 weeks beginning 26 weeks after the last LEN injection."
89436884|NCT04990791|Other|Aspirin 20mg|Aspirin 75 mg OD for 14(-2) days then aspirin 20 mg BD plus rivaroxaban 2.5 mg BD for 14(-2) days then aspirin 75 mg OD plus rivaroxaban 2.5 mg BD
88920433|NCT05814744|Active Comparator|Group (B)|bupivacaine 0.25% and dexmedetomidine
88920434|NCT05798221|Experimental|Complementary self-help strategies in addition to treatment as usual|The experimental group consists of 10 weeks of group treatments with educative and actively practicing elements. The patients will also receive a booklet with self-help basics and descriptions of the techniques, which should facilitate the correct practice at home. Parallel treatment as usual is allowed.
88920435|NCT05798221|Active Comparator|Treatment as usual|The active control group consists a 16-week waiting period, where treatment as usual is allowed. In case of acute worsening/progression of the symptoms, consultations with the study physician are offered anytime. After the waiting period, the control group will be offered the same units as in the experimental group.
89436885|NCT04990791|Other|Asprin 75mg|Aspirin 75 mg OD for 14(-2) days then aspirin 75 mg OD plus rivaroxaban 2.5 mg BD for 14(-2) days then aspirin 20 mg BD plus rivaroxaban 2.5 mg BD
89436886|NCT04990713|Placebo Comparator|Serratus Plane Block (Placebo) and Intercostal Block (Local Anesthestic)|Patients randomized to this group will receive the intercostal block with local anesthetic and the serratus plane block with saline placebo. Local anesthetic administered will be ropivacaine 0.2%.
89436887|NCT04990713|Experimental|Serratus Plane Block (Local Anesthetic) and Intercostal Block (Local Anesthetic)|Patients randomized to this group will receive the intercostal block with local anesthetic and the serratus plane block with local anesthetic. Local anesthetic administered will be ropivacaine 0.2%.
89436888|NCT04989348|Placebo Comparator|Antagonist group|Women will receive antagonist (Cetrorelix 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger.
89436889|NCT04989348|Active Comparator|PPOS group|"Women will receive oral medroxyprogesterone 10 mg daily or Duphaston 10mg bd from Day 3 till the day of ovulation trigger.~Gonadotrophin (human menopausal gonadotrophin or recombinant FSH) injections will be started. Ovarian response will be monitored by transvaginal scanning with or without serum hormonal level. Human chorionic gonadotrophin (hCG 1,000 IU) and GnRH agonist (decepepty 0.2mg) will be given for triggering of final maturation when at least 3 follicles reach >17mm in diameter. Blood will be checked for serum estradiol and progesterone levels. Transvaginal USS-guided oocyte retrieval will be performed 36 hours after the trigger."
89436890|NCT04984551|Experimental|Arm I: ECHO Participants (ECHO clinics, workshop, education)|Participants participate in online ECHO clinics over 1 hour twice monthly for 12 months and in-country workshops twice per year. Participants also receive 5 core lectures through an internet-based professional education curriculum.
89436891|NCT04984551|Experimental|Arm II: Patients (questionnaire, medical chart review)|Patients complete 3 in-person or phone questionnaires over a total of 20 minutes every 3 months for 2 years about their symptoms, emotional and physical well-being, and their experience and satisfaction with outpatient oncology care. Patients' medical charts are reviewed for data collection. Patients complete a 15 minute interview in person or phone about the care they received by their physician at baseline, end of month 4 and month 12.
89436892|NCT04984551|Experimental|Arm III: Caregivers (questionnaire)|Caregivers complete an in-person or phone questionnaire over 5 minutes up to 8 times about their experience and satisfaction with the cancer care their family member has received. Caregivers complete a 15-minute interview in person or by phone their family member received by their physician.
89436893|NCT04980222|Experimental|Glofitamab + R-CHOP Immunochemotherapy|"Participants will receive step-up doses of glofitamab, starting on Day 8 of Cycle 3 (2.5 mg), Day 15 of Cycle 3 (10 mg), then 30 mg glofitamab will be given every three weeks (Q3W) onwards, on Day 8 of Cycles 4-6 and on Day 1 of Cycles 7-10. (cycle length = 21 days)~Participants will receive rituximab, cyclophosphamide, doxorubicin, and vincristine Q3W on Day 1 of Cycles 1-6. Prednisone or prednisolone will be administered daily (QD) on Days 1-5 of Cycles 1-6. (cycle length = 21 days)"
89436894|NCT04977869|Active Comparator|RIC+Standard medical treatment|RIC+Standard medical treatment Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mm Hg. RIC will be conducted twice daily for 7 days after endovascular thrombectomy. Additionally, the patients will be treated with standard medical treatment according to the Guidelines for diagnosis and treatment of acute ischemic stroke in China 2018.
88920436|NCT05797558|Active Comparator|Surgically Treated Primary Aldosteronism|Standard therapy
89436895|NCT04977869|Placebo Comparator|Sham RIC+Standard medical treatment|Sham RIC+Standard medical treatment Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mm Hg. RIC will be conducted twice daily for 7 days after endovascular thrombectomy. Additionally, the patients will be treated with standard medical treatment according to the Guidelines for diagnosis and treatment of acute ischemic stroke in China 2018.
89536592|NCT01375751|Experimental|Evolocumab 420 mg|Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
88920437|NCT05797558|Active Comparator|Medically Treated Unilateral Primary Aldosteronism|Open label eplerenone treatment
88920438|NCT05789095||Case-group|13 adolescents, 9-16 years, with Osgood-Schlatter Disease.
88920439|NCT05789095||Control-group|13 healthy adolescents, 9-16 years, without any knee pain, matched on age, sex and type of sport on the group-level.
88920440|NCT05786820|Active Comparator|Pycnogenol Group|Professional mechanical plaque removal + Pycnogenol capsule
88920441|NCT05786820|Placebo Comparator|Placebo Group|Professional mechanical plaque removal + placebo capsule
89536593|NCT04984863|Experimental|magnetically controlled capsule endoscopy|magnetically controlled capsule endoscopy to evaluate the efficacy of the treatment of gastroesophageal varices
88920442|NCT05781308|Other|Arm A: paclitaxel + bevacizumab|Bevacizumab 15 mg/kg and paclitaxel 200 mg/m² intravenously every three weeks until progression.
88920443|NCT05781308|Experimental|Arm B: paclitaxel + bevacizumab + atezolizumab|Atezolizumab 1200 mg, bevacizumab 15 mg/kg and paclitaxel 200 mg/m² intravenously every three weeks until progression.
88920444|NCT05772156|Experimental|Prophylactic methylergonovine|Prophylactic methylergonovine 200mcg IM
88920445|NCT05772156|Placebo Comparator|Control group/placebo|Matching placebo
88920446|NCT05769868|Experimental|Single Arm|1 conventional echocardiography without esmolol administration followed by 1 echocardiography with esmolol administration at Baseline and other study visits.
88920447|NCT05756894|Experimental|Neurostimulation for respiratory function after spinal cord injury|Efficacy of STDP on respiratory function.
88920448|NCT05727579|Other|low-sodium diet; placebo|
88920449|NCT05727579|Other|low-sodium diet; ertugliflozin 15 once daily|
88920450|NCT05727579|Other|high-sodium diet; placebo|
88920451|NCT05727579|Other|High-sodium diet; ertugliflozin 15 mg once daily|
88920452|NCT05715879||diseased|covid infection patients
88920453|NCT05685186||PCD Cohort|"The PCD cohort will include individuals who have a genetically confirmed diagnosis of PCD with 2 identified pathogenetic variants within 1 of 4 genetic/ultrastructural variants:~DNAI1 ODA defect~Other ODA defect~IDA-MTD defect, CCDC39 or CCDC40~Radial Spoke defect"
88920454|NCT05685186||Healthy Volunteer Cohort|The healthy volunteer cohort will include health individuals.
88920455|NCT05668117||Control|Historical patient data from other published studies in the literature
88920456|NCT05668117||Study participants|Adult patients with non-pathologic distal femur and femoral shaft fractures treated with the Depuy Synthes Advanced Retrograde femoral nail who had at least 6 months of follow up.
88920457|NCT05666778|Other|Intervention Arm|After completing 12 months observation of usual practices of menstrual hygiene management, all participants will be provided reusable menstrual cups that can be worn during sex. The menstrual cup training is comprised of a 2 hour group session that covers basic information on reproductive health, menstrual health, and menstrual hygiene, cup use (insertion/removal), storage, cleaning. In the first three months after intervention delivery, there are monthly phone calls to assess usage and for trouble shooting. There are 12 months of observation in the menstrual cup arm, with Bacterial vaginosis (BV) and vaginal microbiome (VMB) assessment at the beginning of the 12-month period, at 6 months, and at 12 months. Sexually transmitted infection (STI) is measured at the beginning of the 12- month intervention period, and then at 12 months.
88920458|NCT05652764|Experimental|Immuno-SelfCare|
88920459|NCT05652764|No Intervention|Control Group|
88920460|NCT05650827|No Intervention|Standard Care Control|"Participants allocated to control receive first line chemotherapy the standard patient care program, as provided by Rigshospitalet, Copenhagen, Denmark.~Participants allocated to control are allowed to exercise on their own initiative or participate in any standard care hospital- or municipality-based exercise training program. There will be no diet restrictions."
88920461|NCT05650827|Experimental|Exercise and protein supplements intervention group|"Participants allocated to intervention receive first line chemotherapy and the standard patient care program, as provided by Rigshospitalet, Copenhagen, Denmark.~The intervention consists of resistance training and a daily protein supplement."
88920462|NCT05639296||MSUS experts|Physicians with extensive experience with MSUS (performed more than 1000 examinations).
88920463|NCT05603364|Experimental|EOF group：early carbohydrate feeding|The EOF group drank 10.5% of 5 ml/kg body weight (100ml containing 12.5g maltodextrin, fructose and glucose) after extubation in the resuscitation room.
89536594|NCT04985175|Experimental|QPL group|receive 2-pages ESRD QPL leaflets, circle the questions they want to ask before consultation. encourage asking questions with doctor during consultation. receive the nurse-led coaching of shared decision-making (SDM)
88920464|NCT05603364|Experimental|Control group：conventional feeding|Patients in group C were observed with 60minutes of abnormal vital signs after extubation, and returned to the ward for fasting and fasting for at least 6 hours, and began to eat gradually through the mouth after anal exhaust.
88920465|NCT05597254|Experimental|Probiotic with niacin and berry extract|
88920466|NCT05597254|Active Comparator|Probiotic without niacin and berry extract|
88920467|NCT05597254|Placebo Comparator|Placebo|
88920468|NCT05583994|No Intervention|Usual care ( control)|All participants in the trial will continue with their usual care as deemed appropriate by health care providers, this will usually comprise attendance at medical clinics, medication, and visits from PD nurse specialists. Participants may attend group activities or access resources as part of their usual care, though from experience such sessions are rarely intensive or prolonged. Participants will be asked to record their usual care and encouraged to avoid changing that practice unless specifically requested by a health care worker during the time they are participating in the trial.
88920469|NCT05583994|Experimental|Optim Park Intervention|"A central component of the Optim-Park II intervention is to offer a single point of contact with a coordinator (appointed for the purpose of delivering the Optim-Park II intervention) to assess participants needs, have a discussion with participants to identify 3 main problems/targets PwPD and carers would most like to address based on their needs and then link up and refer participants to available community resources.~The coordinators will deliver the Optim-Park intervention for PwPD and their carers in three consultations: a consultation after the baseline assessment and randomization has been undertaken at the point of entrance to the study; a consultation in the middle of this period; and a follow-up consultation at exit at 3 months. Each consultation can last between 30 min and up to 2 hours. Each consultation can be with the pair of PwPD and carer or if appropriate, separately."
88920470|NCT05579340|No Intervention|Usual care|
88920471|NCT05579340|Experimental|Ex1|Low exercise volume (150 min/week)
88920472|NCT05579340|Experimental|Ex2|High exercise volume (300 min/week)
89436896|NCT04973137|Experimental|Birtamimab plus Standard of Care Chemotherapy- For Double-blind Phase and OLE Phase of study|"Intravenous administration of 24 mg/kg birtamimab every 28 days.~Drug: Standard of Care Chemotherapy. Bortezomib-containing chemotherapy regimen (e.g. cyclophosphamide, bortezomib, and dexamethasone (CyBorD) according to the institutional standard of care.~The initiation of daratumumab treatment at randomization is allowed at the discretion of the Investigator; initiation at any other time during the Double-blind Phase is prohibited. For subjects who did not initiate daratumumab at randomization during the Double-blind Phase, daratumumab may be initiated at any time during the OLE Phase at the Investigator's discretion. Initiation of daratumumab at randomization allowed at the discretion of the investigator for Double-blind Phase"
89436897|NCT04973137|Placebo Comparator|Placebo plus Standard of Care Chemotherapy- For Double-blind Phase of study|"Intravenous 0.9% Saline administration as a placebo every 28 days.~Drug: Standard of Care Chemotherapy. Bortezomib-containing chemotherapy regimen (e.g. cyclophosphamide, bortezomib, and dexamethasone (CyBorD) according to the institutional standard of care. Initiation of daratumumab at randomization allowed at the discretion of the investigator."
89436898|NCT04972136|Active Comparator|Active bilateral theta burst stimulation|An X100 stimulator with a B65 A/P type coil (Magventure Inc.) will be used. The coil is positioned under MRI guidance using real-time neuronavigation using Brainsight [x,y,z= -38, 44, 26(left), +38, 44, 26 (right). BL-TBS will be delivered at 90% RMT, corrected for scalp to cortex distance, to targeted left and right DLPFC sites, differing only in stimulation pattern and total number of pulses (triplet 50 Hz bursts, repeated at 200 msec (i.e., 5 Hz); right DLPFC (continuous TBS, cTBS): 120 seconds uninterrupted bursts (total of 600 pulses); left DLPFC (intermittent TBS, iTBS: 2 seconds on and 8 seconds off; 600 pulses per session; total duration of 3 min 9 seconds/hemisphere).
89536595|NCT04985175|No Intervention|Usual care group|without receiving provision of QPL encourage asking questions with doctor during consultation. receive the nurse-led coaching of shared decision-making (SDM)
89536596|NCT05264597||ACLR group|Patients after ACLR with a standardized followup in the Sport Medicine department
88920473|NCT05576415|Experimental|OC-01|
88920474|NCT05557188|Placebo Comparator|Sham Grounding|Each pregnant woman in the placebo group is going to be informed about the Sham grounding stick and how to use it, with a 2-minute video showing. Participants walk on the ground for 30 minutes daily and go on for four weeks. During the program, the pregnant women will be called to their homes every week and necessary reminders will be made.
88920475|NCT05557188|Active Comparator|Grounding|Each pregnant woman in the placebo group is going to be informed about the grounding stick and how to use it, with a 2-minute video showing. Participants walk on the ground for 30 minutes daily and go on for four weeks. During the program, the pregnant women will be called to their homes every week and necessary reminders will be made.
88920476|NCT05549596|Experimental|Traction treatment|About 40 minutes spine traction including temperature application, Spine Scan, Pre-stroke, and Main Stroke
89536597|NCT05264597||Control group|Age and sexe-matches volunteers
88920477|NCT05549596|Active Comparator|Physical Therapy|About 40 minutes standard physical therapy including temperature application and traction
88920478|NCT05511064|Experimental|blood circulation treatment|Blood circulation treatment for the risk group for Deep Vein Thrombosis (DVT)
88920479|NCT05507151||Endoscopic Sleeve Gastroplasty|endoscopic suturing of the stomach
88920480|NCT05506436|Experimental|Implementation group|Four sessions are conducted with the nurses of the center assigned to the intervention group to agree on the implementation strategy together with the professionals. Once the strategy is defined, the implementation of the intervention will be launched in this group for 6 months. After this period, the final evaluation will be carried out, as well as a qualitative evaluation through a focus group.
88920481|NCT05506436|Active Comparator|Control group|A single session will be scheduled to introduce the nurses of the center assigned to this group to the EVIDENT 3 intervention, and access and downloading will be allowed for free use in their practice.
88920482|NCT05490069|Experimental|Intervention group|Receive iCBT based EMI with message content, delivery frequency and timing personalised to participants' preferences.
88920483|NCT05490069|No Intervention|Control group|Receive general mental health information through instant message.
88920484|NCT05482672|Experimental|GetHealthy-OA|The GetHealthy-OA program combines a 6-week mind-body program delivered via live video with the oral supplement fisetin. Oral fisetin will be taken for 2 consecutive days (day 1 and 2), a 28-day wash-out period, and then another 2-day course (days 31 and 32).
88920485|NCT05482672|Placebo Comparator|Minimally Enhanced Usual Care|The minimally enhanced usual care group will be given a health education booklet at the date of baseline testing and will take an oral placebo for 2 consecutive days (day 1 and 2) and then again 28 days later (days 29 and 30).
88920486|NCT05472532|Experimental|6 cohort|Prostate Cohorte : Castrate resistant metastatic prostate cancer patient Breast cohort : HER2+ ou RH+ metastatic breast cancer patient Lung cohort : Non-small cell lung metastatic lung cancer patient Ovarian cohort : Ovarian cancer with peritoneal carcinomatosis Colorectal cohort : Colorectal cancer with peritoneal carcinomatosis Gastric cancer : Gastric cancer with peritoneal carcinomatosis
88920487|NCT05469295|Experimental|CGM_MB_1701 treatment|Subjects will be treated with the study device for about 36 minutes.
88920488|NCT05469295|Sham Comparator|Sham (CGM MB1701C) treament|Subjects will be treated with the Sham device for about 36 minutes.
88920489|NCT05468476||Women with PCOS (PCOS group)|PCOS women with obesity previously diagnosed with PCOS（meet the 2003 Rotterdam diagnostic criteria） not using hormonal therapy and without other significant health or endocrine issues.
88920490|NCT05468476||Women without PCOS (Non-PCOS group)|This study enrolled age- and body mass index (BMI)-matched subjects with normal menstrual cycles, not using hormonal therapy, and without any significant health or endocrine issues.
88920491|NCT05465044|Experimental|Twice-Weekly Hemodialysis|Twice-weekly hemodialysis with incremental crossover to thrice-weekly hemodialysis as indicated
88920492|NCT05465044|Placebo Comparator|Thrice-Weekly Hemodialysis|Outright thrice-weekly hemodialysis without option to switch to less frequent dialysis schedule
88920493|NCT05463003|Active Comparator|OCT1 and CYP2D6 wildtype genotypes|In this group, the participants are OCT1 and CYP2D6 wildtype genotypes. The participants are selected to achieve best matching according to sex, age, BMI, alcohol consumption and smoking between arm (cohort) 1 and arm (cohort) 2 and 3, respectively.
89436899|NCT04972136|Sham Comparator|Sham bilateral theta burst stimulation|"An X100 stimulator with a B65 A/P type coil (Magventure Inc.) will be used with the active coil facing away from the scalp, for sham stimulation. The coil is positioned under MRI guidance using real-time neuronavigation using Brainsight [x,y,z= -38, 44, 26(left), +38, 44, 26 (right). To reproduce the nociceptive qualities of the stimulation, the B65-type stimulation coil - sham side - includes a built in electrical stimulator in the coil connector which fires a synchronous electrical pulse along with the TMS stimulus through electrodes mounted on the forehead or near the area of stimulation, to generate auditory and somatosensory (vibration) stimuli."
89436900|NCT04971785|Experimental|SEMA + CILO/FIR FDC|Participants will receive semaglutide (SEMA) 0.24-2.4 mg once weekly (dose escalation every 4 weeks) and fixed-dose combination (FDC) of cilofexor and firsocostat (CILO/FIR 30 mg/20 mg) once daily for 72 weeks
89436901|NCT04971785|Experimental|SEMA + Placebo-To-Match (PTM) CILO/FIR|Participants will receive SEMA 0.24-2.4 mg once weekly (dose escalation every 4 weeks) and PTM CILO/FIR administered once daily for 72 weeks
89436902|NCT04971785|Experimental|PTM SEMA + CILO/FIR FDC|PTM Semaglutide once weekly and CILO/FIR 30 mg/20 mg FDC administered once daily for 72 weeks
89436903|NCT04971785|Placebo Comparator|PTM SEMA + PTM CILO/FIR|PTM Semaglutide once weekly and PTM CILO/FIR once daily for 72 weeks
89436904|NCT04967183|Experimental|Group I|Annual FIT surveillance
89436905|NCT04967183|Active Comparator|Group II|Endoscopic surveillance
88920494|NCT05463003|Active Comparator|OCT1 deficient and CYP2D6 wildtype genotypes|In this group, the participants are OCT1 deficient and CYP2D6 wildtype genotype.
88920495|NCT05463003|Active Comparator|OCT1 wildtype and CYP2D6 deficient genotypes|In this group, the participants are OCT1 wildtype and CYP2D6 deficient genotype.
88920496|NCT05458778||Women who are trying to conceive|
89436906|NCT04955405|Experimental|Seven telemedicine visits|Will receive the seven visit telemedicine protocol
89436907|NCT04955405|No Intervention|Control - Usual Care|Will not receive the protocol
89536598|NCT04985019|Experimental|I (Prepectoral)|VR treatment group Participants received the Self-Guided Virtual Reality-based Cognitive Behavioral Therapy for panic disorder.
89536599|NCT04985019|No Intervention|II (Subpectoral)|Waiting list Participants in a waiting list.
89536600|NCT05249621|Experimental|MZE001|MZE001 is a small molecule inhibitor of muscle glycogen synthase for the potential treatment of Pompe disease.
88920497|NCT05456516|Experimental|Health|Children will rate foods on health
88920498|NCT05456516|Experimental|Taste|Children will rate foods on taste
88920499|NCT05456516|Experimental|Wanting|Children will rate foods on desire to eat
88920500|NCT05434286||Cirrhosis/ACLF of any etiology|Cirrhosis with hepatorenal syndrome-acute kidney injury (HRS-AKI) as per International Ascites Club criteria.
88920501|NCT05410327|Experimental|Chokeberry consumption|Participants will be given 100ml of a water-infused chokeberry juice to consume twice per day for a period of 6 weeks.
88920502|NCT05409443|Active Comparator|Nimbus Sacroiliac Joint Radiofrequency Ablation (N-SIJRFA)|"N-SIJRFA - using a bipolar palisade technique to create a continuous strip lesion."
88920503|NCT05409443|Active Comparator|Conventional Sacroiliac Joint Radiofrequency Ablation (C-SIJRFA)|C-SIJRFA - using conventional monopolar periforaminal technique
88920504|NCT05401409|Experimental|Nitrate-rich beetroot juice|Beetroot juice containing naturally occurring nitrate (400mg total nitrate)
88920505|NCT05401409|Placebo Comparator|Nitrate-depleted beetroot juice|Beetroot juice with nitrate removed
88920506|NCT05401175|Experimental|Autologous blood transfusion support therapy group|Bone aspiration and bone marrow examination before concurrent chemoradiotherapy.Peripheral blood stem cells were mobilized, frozen and stored before treatment. Resuscitate and reinfusion autologous peripheral blood 24 hours after completion of concurrent chemoradiotherapy.
88920507|NCT05401175|No Intervention|Conventional treatment group|Bone aspiration and bone marrow examination before concurrent chemoradiotherapy.Undergo standard radiotherapy for cervical cancer.
88920508|NCT05388422|Experimental|Severe cerebral palsy (GMFCS IV and V)|This study included patients with severe cerebral palsy (GMFCS IV and V)
88920509|NCT05337995||Non-Specific Low Back Pain patients|Participants must have pain located between the thoracolumbar hinge and the lower gluteal fold, with or without pain in either leg, present for more than 12 weeks, on a daily or almost daily basis (at least 4 days out of 7).
88920510|NCT05337995||Control group|Participant with no current or past chronic pain
88920511|NCT05324761|Active Comparator|Pregabalin|A dose of 75 mg of Pregabalin twice daily for one month will be prescribed to each patient enrolled this study arm
88920512|NCT05324761|Active Comparator|Gabapentin|A dose of 300 mg of Gabapentin twice daily for one month will be prescribed to each patient enrolled this study arm
88920513|NCT05318807|Experimental|Personalised prehabilitation|A personalised plan of diet, exercise and emotional support for patients having chemotherapy, radiotherapy and/or immunotherapy treatment for lung cancer.
88920514|NCT05317403|Other|AML without Down Syndrome|The subject receives 2 courses of therapy approximately 35 days each. Venetoclax: Days 1-14 Azacitidine and Vorinostat: Days 1-5 Filgrastim Days: 5 start and continue until post-nadir ANC > 500 cells/mm3 Fludarabine and Cytarabine Days 6 - 10 IT Cytarabine Day 0 or 1, optional between day 35 and 42
88920515|NCT05317403|Other|AML with Down Syndrome|The subject receives 2 courses of therapy approximately 35 days each. Venetoclax: Days 1-14 Azacitidine and Vorinostat: Days 1-5 Filgrastim Days: 5 start and continue until post-nadir ANC > 500 cells/mm3 Fludarabine and Cytarabine Days 6 - 10 IT Cytarabine Day 0 or 1, optional between day 35 and 42
88920516|NCT05312242|Active Comparator|IFA + Standard of Care|Iron and Folic Acid (IFA) tablets dispensed 30 tablets at a time + standard of care [Represents standard of care comparison]
88920517|NCT05312242|Experimental|MMS 30 + novel counseling|MMS dispensed 30 tablets at a time (MMS 30) with novel counseling
88920518|NCT05312242|Experimental|MMS 180 + novel counseling|MMS dispensed 180 tablets at a time (MMS 30) with novel counseling
88920519|NCT05298813|Experimental|Active|
88920520|NCT05298813|Placebo Comparator|Placebo|
89198733|NCT04039425||cancer patient|"Recently diagnosed cancer stage 1, 2, or 3~Assigned to receive immunosuppressive chemotherapy treatment~Natural hair that has not been dyed or permed in the past 3 months"
89436908|NCT04944225|No Intervention|Control group: Pain management during the standard of care phase|In the standard of care phase, anesthetic and surgical care will be as per standard practice (according to local hospital protocol) for both the control and the intervention group. Generally, this means patients will be maintained on a more liberal opioid regime than in the opioid reduction strategy phase and will receive opioid and other medications for the acute postoperative pain. The choice of opioids will be at the discretion of the managing team. There will be a minimum 2-month baseline period before entry of the first randomized cluster to the intervention arm.
89436909|NCT04944225|Experimental|Intervention group: Pain management in the opioid reduction strategy phase|The intervention will involve a multi-faceted 3 component approach involving 1) opioid prescription caps (default maximum number of tablets for discharge prescriptions, as defined by evidence-based guidelines) 2) patient education tools (e.g. What is a normal pain trajectory? How to manage the pain? Benefits and potential harms of pharmacologic analgesia. Non-pharmacologic analgesia management? What to do if pain is excessive?), 3) provider education tools (e.g. including procedure-specific evidence-based recommendations for multi-modal analgesia; comparison of local baseline prescribing patterns with exemplary prescribing patterns; defining targeted reduction if baseline prescribing is at odds with best evidence; review of best evidence about optimal analgesia perioperatively), and 4) bi-weekly cumulative prescriber feedback on opioid prescribing patterns post-intervention and until end-of-study.
89536601|NCT05249621|Placebo Comparator|Placebo|Excipients containing no active ingredients.
88920521|NCT05292352|Experimental|Low Free Sugar Diet (LFSD) Intervention|The 1-year dietary intervention will be accomplished by adapting and extending a Social Cognitive Theory (SCT) guided low sugar intervention. SCT is a framework that helps explain how people regulate their behavior through control and reinforcement to achieve goal-directed behavior that can be maintained over time.
88920522|NCT05292352|No Intervention|Usual Care Control|Usual Care (Control group): Parents of enrolled children in the usual care group will be provided printed material on healthy family lifestyle at the beginning of the study. The control group will complete all of the same research visits and assessments as the intervention group.
89436910|NCT04941482|Experimental|Multi-intervention program|A multi-intervention program will design for stroke patients including [1] periodic health examination for assessment of physical and mental health, recurrence risks, and harmful behaviors; [2] guiding the appropriate rehabilitation exercises for improving the physical status and monitoring through daily online report; [3] using the motivational interviewing methods to improve and prevent mental disorder; [4] applicating the technique of functional near-infrared spectroscopy (fNIRS) for measurement of oxy-hemoglobin on cortex prefrontal to early detect mental disorder and stroke recurrence risks.
89436911|NCT04941482|Active Comparator|Standard care|Standard health check and fNIRS measure
88920523|NCT05288829|Experimental|ALXN1210 SC|Participants received ALXN1210 SC.
88920524|NCT05288829|Experimental|ALXN1210 IV|Participants received ALXN1210 IV.
88920525|NCT05288829|Placebo Comparator|Placebo SC|Participants received placebo SC.
88920526|NCT05282368|Experimental|Intervention (PHM)|This pathway is intended to be a tool to enhance support for a mother/birthing person and her caregiving partner, facilitate communication with healthcare providers, and promote development of caregiving to optimize maternal-fetal, infant, and family health.
88920527|NCT05282368|No Intervention|Usual Care Group (UC)|The control group participants will receive care as usual.
88920528|NCT05250726|Experimental|MENISC-T|Segmented, devitalized and sterile meniscus graft
88920529|NCT05236049|Experimental|SclerFIX|Strip of umbilical cord lining membrane allograft wrapped around the bioceramic enucleation implant. The assembly is placed inside the void orbital cavity and the muscles are sutured to the SclerFIX strips.
88920530|NCT05233566|Experimental|Ketamine Arm|Following surgery and extubation, patients will receive ketamine 0.5 mg/kg over 10 minutes followed by an infusion of 0.3 mg/kg/h for 2 hours 50 minutes.
88920531|NCT05233566|Placebo Comparator|Control Arm|Following surgery and extubation, patients will receive normal saline at an equal rate to that used in the ketamine arm.
88920532|NCT05229601|Experimental|HFB301001|Participants will receive HFB301001 via intravenous infusions
88920533|NCT05216848||nulliparas with no existing complications in the third trimester|"The investigators involve every nullipara giving birth in a period of two years.~Exclusion criteria: unwilling to participate, minors (under 18 years old), high risk pregnancy, foetus mortus or perinatal death of the newborn, with slovak language"
88920534|NCT05216848||multiparas with no existing complications in the third trimester|"The investigators involve every multipara giving birth in a period of two years.~Exclusion criteria: unwilling to participate, minors (under 18 years old), high risk pregnancy, foetus mortus or perinatal death of the newborn, with slovak language, previous caesarean section"
88920535|NCT05210517|No Intervention|No intervention|
88920536|NCT05210517|Experimental|Empagliflozin|Empagliflozin 25 mg once daily for one week
88920537|NCT05210517|Experimental|Benzbromarone|Benzbromarone 100 mg once daily for one week
88920538|NCT05210517|Experimental|Empagliflozin-Benzbromarone|Empagliflozin 25 mg once daily for one week combined with Benzbromarone 100 mg once daily for one week
88920539|NCT05199155|Experimental|NerVFIX|Biological regeneration nerve conduit of allogeneic artery or vein from umbilical cord used as a conduit for gap < 2 cm or as a wrap after peripheral nerve suture
88920540|NCT05191628|Experimental|Visio-AMTRIX|Disk of amniotic membrane apposed or buried on recurrent macular hole by the Investigator after vitrectomy and fluid-gas exchange.
88920541|NCT05180994|Experimental|Topical infliximab following PKP surgery|Additionally to standard post-operative regimen, patients who will be undergoing their first PKP surgery and who meet all inclusion and no exclusion criteria will be included in the experimental group. These patients will administer topical infliximab four times per day for 3 months.
88920542|NCT05180994|Active Comparator|No topical infliximab following PKP surgery|Patients who will be undergoing their first PKP surgery, but who are not qualified to receive infliximab or who refuse to receive infliximab, will be included in the control group. These patients will only administer the standard post-operative regimen following their PKP surgery and will not administer topical infliximab. They will be followed with the same follow-up schedule, questionnaires, examinations and non-invasive tests (excluding lab work) as patients in the interventional group.
88920543|NCT05141175|Experimental|Hypertension patients|Patients with documented diagnosis of hypertension and their most recent office systolic BP average measured using automated office BP is ≥140 mmHg systolic or ≥90 mmHg diastolic and they are currently prescribed at least one BP-lowering medication will be recruited.
88920544|NCT05141123||Preloaded Fenestrated Stent-graft Designs for Endovascular Aortic Procedures|Patients presenting with an acute (up to two weeks from the onset) and subacute (between 3 and 12 weeks from the onset) type B dissection with a proximal suitable non-dissected landing zone in the aortic arch or descending thoracic aorta (supra-aortic trunks debranching may be employed to obtain an adequate proximal landing zone)
88920545|NCT05119959|Experimental|Arm 1- CHEU + ECD intervention|Participants randomized to this arm will receive a bi-weekly community health worker-delivered ECD intervention for CHEUs
89011058|NCT05192356|Experimental|Sequence 2|"Period 1: CKD-348(3) - A single oral dose of 1 tablet under fasting condition~Period 2: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition~Period 3: CKD-348(3) - A single oral dose of 1 tablet under fasting condition~Period 4: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition"
89011059|NCT05187000|Sham Comparator|Sham Stimulation Group for Cross Study|Sham stimulation will be delivered on the patients head using a sham coil in the crossover study.
89011060|NCT05187000|Experimental|Individualized rTMS Group for Cross Study|Real stimulation will be delivered on individualized target using a real coil in the crossover study.
89011061|NCT05160012|No Intervention|Control|This group will not receive peer comparison messages and will continue with usual care.
89011062|NCT05160012|Experimental|Intervention|This group will receive peer comparison messages.
89011063|NCT05145764|Experimental|Suvorexant|Nightly dosing of suvorexant
89011064|NCT05145764|Placebo Comparator|Placebo|Nightly dosing of placebo
89011065|NCT05142826|Active Comparator|School as Usual|School procedures as typically used and implemented.
89011066|NCT05142826|Experimental|Immediate Relative Age Effect Intervention|Relative age effect intervention administered in the Fall in school.
89011067|NCT05142826|Experimental|Delayed Relative Age Effect Intervention|Relative age effect intervention administered after the Winter break in school.
89011068|NCT05128812|Placebo Comparator|CONTROL GROUP|Nutraceutical placebo intake group
89011069|NCT05128812|Experimental|PLX400mg GROUP|Intake of natural herbal dietary supplement composed of lemon verbena extract (Lippia citriodora).
89011070|NCT05123235|Experimental|Physical Activity|The intervention will last 11 weeks, and participants in the intervention group will have individual weekly web-meeting using a video conferencing platform. The weekly meeting is expected to last approximately 30 minutes. During this meeting, participants will report on the past week's physical activity goals, failures and successes, set goals for the next week, discuss that week's behavioral strategy to promote physical activity for that week, and engage around 5 minutes of physical activity. The topics that will be discussed in the newsletters and weekly meetings will include behavioral strategies for physical activity changes. Those in the control group will also be contacted weekly for 11 weeks and will be asked about their physical activity levels for the past week. These meetings will also occur using video conferencing and last 5 minutes.
89011071|NCT05123235|No Intervention|Control|During the 11 weeks the participants in the control group will have a weekly check in meeting using a video conferencing platform. The weekly meeting is expected to last approximately 5 minutes. During this meeting, participants will report on the past week's physical activity levels.
89011072|NCT05113693|Experimental|1|"Period 1 - A single dose of 4 tablets(CKD-501 1T, D759 1T, H053 2T) under fed condition.~Period 2 - A single dose of 2 tablets(CKD-393 2T) under fed condition."
89011073|NCT05113693|Experimental|2|"Period 1 - A single dose of 2 tablets(CKD-393 2T) under fed condition.~Period 2 - A single dose of 4 tablets(CKD-501 1T, D759 1T, H053 2T) under fed condition."
89011074|NCT05087342|Active Comparator|Intervention Group|"Will receive active medication semaglutide subcutaneously, once weekly, self-injection.~Month 1 - 0.24 mg SC once weekly x 4 weeks.(IE-1) Month 2- 0.5 mg SC once weekly x 4 weeks.(IE-2) Month 3 -1 mg SC once weekly x 4 weeks.(IE-3) Month 4 - 1.7 mg SC once weekly x 4 weeks.(IE-4) Month 5 - 2.4 mg SC once weekly x 4 weeks. (IE-5) Month 6 - 2.4 mg SC continue once weekly x 8 weeks.(IE-6) Month 7 - completion visit (IE-7)"
89011075|NCT05087342|Placebo Comparator|Control Group|Will receive placebo, subcutaneously, once weekly, self-injection throughout study duration.
89011076|NCT05078476|Active Comparator|Manchester Short Splint|Dorsal splint ending shortly behind the wrist. The splint will be worn for 6 weeks after surgery and the patient will perform active and passive exercises in the splint.
89011077|NCT05078476|Experimental|Relative Motion Flexion|In the relative motion splint the injured finger is positioned in relative flexion in the MCP joint to the adjacent fingers. Additionally to the relative motion flexion splint a wrist orthosis is adapted. Passive and active exercises will be performed out of the splint.
89011078|NCT05060146|No Intervention|Standard care|
89011079|NCT05060146|Experimental|Structured medico-pharmaceutical collaboration|
89011080|NCT05044715|Experimental|Treatment as Usual|Participants in this arm will receive treatment as usual (TAU) as an intervention.
89011081|NCT05044715|Experimental|Compassion-Focused Therapy|Participants in this arm will be enrolled in a CFT group intervention.
89011082|NCT04983836|Experimental|Serratus Block|
89011083|NCT04983836|Other|Paravertebral Block|
89011084|NCT04971967|Experimental|Crowdsourced HIV PS Group|Participants in the intervention group will receive crowdsourced partner services intervention, including postcards from the crowdsourcing contest that promote PS, provider referral and dual referral services, and take-home HIV self testing kits.
89011085|NCT04971967|No Intervention|Conventional HIV PS Group|Participants in the control group will receive traditional partner services intervention, including referral cards that encourage the index patient to notify their partners by themselves.
89011086|NCT04946851||non-treatment-seeking individuals|Participants across the spectrum of drinking (from non-drinkers to heavy drinkers) who are not interested in treatment for alcohol use disorder
89011087|NCT04946851||treatment-seeking individuals with alcohol use disorder|Volunteers with an AUD diagnosis who are seeking treatment for the condition
89011088|NCT04933383|Experimental|AQ001S 0.125 mg/ml|AQ001S 0.125 mg/ml is a budesonide inhalation solution administered by nebulization once daily.
89011089|NCT04933383|Active Comparator|budesonide inhalation suspension 0.125 mg/ml|Budesonide 0.125 mg/ml is a budesonide inhalation suspension administered by nebulization once daily.
89011090|NCT04923906|Experimental|Aumolertinib and platinum-based chemotherapy|
89011091|NCT04923906|Active Comparator|Aumolertinib|
89198734|NCT02534389|Experimental|fish oil group|4 soft gel with omega-3 fish oil
89198735|NCT02534389|No Intervention|control group|without intervention
89198736|NCT00873639||A|
89011092|NCT04923776|Experimental|Experimental: Chemotherapy+SBRT|"Addition of SBRT, directed at liver metastases, to standard of care (SOC) treatment atezolizumab+chemotherapy in SCLC. All patients must undergo a mandatory biopsy of a liver lesion prior to chemotherapy initiation.~Cycle 1 of chemoimmunotherapy will be administered as per standard of care, with radiation planning to be done subsequently in anticipation of liver-directed SBRT."
89011093|NCT04903691|Experimental|Exercise training|130 patients who underwent open heart surgery and are cleared for exercise.These will include patients who enter supervised cardiac rehabilitation as well as patients who enter a supervised exercise program focusing strength training, endurance of functional training.
89011094|NCT04903691|No Intervention|Additional controls|5 patients who choose not to enter any organized exercise program.
88920546|NCT05119959|Active Comparator|Arm 2- CHEU without ECD intervention|Participants randomized to this arm will receive the current Ministry of Health (MoH) standard of care with no formalized routine assessment of neurodevelopment.
89198737|NCT00879021|Placebo Comparator|Pregabalin, (other name) Lyrica|Study subjects wil be randomized to either the Pregabalin or Placebo group. There is a 5o ,50 chance of being in either group.
89198738|NCT00879021|Placebo Comparator|pregabalin, drug|study subjects that are randomized to the placebo group will receive matching placebo
89198739|NCT00879099|Active Comparator|Paroxetine|
89198740|NCT00879099|Placebo Comparator|Gelatine capsule|
89198741|NCT00879099|Experimental|Timolol 0.5 % eye drops|The plasm levels of timolol will be measured after one drop of timolol has been administered into both eyes.
89198742|NCT00879099|Experimental|Timosan 0.1% eye gel|The plasm levels of timolol will be measured after one drop of timolol has been administered into both eyes.
89436912|NCT04940689|Active Comparator|Standard arm|"General anesthesia strategy with morphine:~Within 10 minutes before the induction of general anesthesia: administration of a placebo of 50 mL of 0.9% NaCl by slow IV~The anesthetic induction will be carried out by an intravenous hypnotic (propofol or etomidate) combined with IV curare and remifentanil (morphine derivative) IV for a concentration target of 4 ng / mL.~Maintenance of anesthesia will be carried out with propofol or a halogenated gas (sevoflurane or desflurane) in continuous administration (qs bispectral index 40-60) and remifentanil (target concentration 1-10 ng / mL). The administration of curare will be carried out as needed. In order to anticipate the sudden end of the analgesia, an administration of morphine 0.15 mg / kg IV will be carried out 30 minutes before the end of the intervention as recommended"
89436913|NCT04940689|Experimental|OFA arm|"General anesthesia strategy without morphine~Within 10 minutes before the induction of general anesthesia: pre-induction dose of dexmedetomidine 0.5 g / kg and lidocaine 1.5 mg / kg by slow IV.~The anesthetic induction will be carried out by an intravenous hypnotic (propofol or etomidate) combined with an IV curare~The maintenance of the anesthesia will be carried out by propofol or a halogenated gas (sevoflurane or desflurane) in continuous administration (qsp bispectral index 40-60), dexmedetomidine 0.5-1.0 g / kg / h, lidocaine 2 mg / kg / h. The administration of curare will be carried out as needed."
89436914|NCT04938427|Experimental|Soticlestat|"Participants weighing <45 kg: Soticlestat, mini-tablets, at the dose of 40 mg to 200 mg, orally or via gastrostomy tube (G-tube) or low-profile gastric tube (MIC-KEY button) or jejunostomy tube (J-tube), twice daily (BID) based on body weight up to 4 weeks in Titration Period. Participants will continue to receive the dose that they are on at the end of the titration period, for 12 weeks in the Maintenance Period. Total duration of the treatment will be up to 16 weeks (Treatment Period). Dose will be tapered down if participants decide to discontinue the treatment.~Participants weighing ≥45 kg: Soticlestat mini-tablets or tablets with a starting dose of 100 mg BID followed by 200 mg BID and, then 300 mg BID, up to 4 weeks in Titration Period. Participants will continue to receive 300 mg BID for 12 weeks in the Maintenance Period. Total duration of the treatment will be up to 16 weeks (Treatment Period). Dose will be tapered down if participants decide to discontinue the treatment."
89436915|NCT04938427|Placebo Comparator|Placebo|Soticlestat placebo-matching mini-tablets or tablets, orally or via G-tube or MIC-KEY button or J-tube, BID, up to 4 weeks in the Titration Period. Participants will continue to receive the soticlestat placebo-matching mini-tablets or tablets for 12 weeks in the Maintenance Period. The total duration of the treatment will be up to 16 weeks (Treatment Period). Soticlestat matching tapering will be done to maintain the blind if participants decide to discontinue the treatment.
89436916|NCT04936971|Experimental|Everolimus|"Kidney transplant induction with Rabbit Anti-Thymocyte globulin (rATG) as per local practice.~Kidney transplant manteinance treatment with Tacrolimus (TAC) to achieve 4-6 ng/mL trough levels, Everolimus (EVL) to achieve 3-8 ng/mL trough levels and Corticosteroids (CS) as per local practice."
89436917|NCT04936971|Active Comparator|Mycophenolate Mofetil|"Kidney transplant induction with Rabbit Anti-Thymocyte globulin (rATG) as per local practice.~Kidney transplant manteinance treatment with Tacrolimus (TAC) to achieve 4-6 ng/mL trough levels, Mycofenolate Mofetil (MMF) 500mg/bid and Corticosteroids (CS) as per local practice."
89436918|NCT04935359|Experimental|Safety run-in part: NIS793+gemcitabine+nab-paclitaxel|In the safety run-in part, participants will receive a combination of NIS793, gemcitabine and nab-paclitaxel.
89436919|NCT04935359|Experimental|Randomized part: NIS793+gemcitabine+nab-paclitaxel|"Participants will receive a combination of NIS793, gemcitabine and nab-paclitaxel~Note: As of 07-Jul-2023, treatment with NIS793/placebo was stopped."
89436920|NCT04935359|Placebo Comparator|Randomized part: placebo+gemcitabine+nab-paclitaxel|"Participants will receive a combination of placebo, gemcitabine and nab-paclitaxel~Note: As of 07-Jul-2023, treatment with NIS793/placebo was stopped."
89436921|NCT04934306||Patients without cleft|Patients without developmental speech disorder (including articulation disorder) or hearing impairment
89436922|NCT04934306||Patients with a cleft|Patients with a hard and/or soft palate cleft and for whom the perceptual speech-language pathology evaluation revealed a velopharyngeal insufficiency
89436923|NCT04927143|Active Comparator|Control|Participants in this group will have access to the DynamiCare app; however, no behavioral incentives will be provided to this group.
89436924|NCT04927143|Experimental|Escalating Low|"Participants will have access to the DynamiCare app. Through the app, participants will receive incentive amounts for drug negative saliva tests. Incentive amounts increase with every negative drug test up to a ceiling and reset to the lowest amount when a test is positive or missed. The Low group will receive incentives worth $2-$8."
89536602|NCT03073707||Household|Sample collection will be anticipated for 20 cases of NTS infections and household/environment in order to analyze 10 combinations of NTS strains in the index patient and its environment
89536603|NCT02475005|Experimental|Mobile self management app on smartphone|Mobile self management app on smartphone
89198743|NCT00369655|Experimental|Treatment (ziv-afibercept)|Patients receive VEGF Trap IV over 1 hour on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
89198744|NCT00615069|Experimental|31 mm GORE EXCLUDER® Test Subjects|GORE EXCLUDER® AAA Endoprosthesis - 31 mm device implanted for the primary treatment of infrarenal abdominal aortic aneurysms (AAA)
89198745|NCT01050751|Experimental|Lersivirine (new formulation)|
89198746|NCT01050751|Active Comparator|Lersivirine (old formulation)|
89011095|NCT04902521|Experimental|Transcranial magnetic stimulation with constraint induced movement therapy|CIMT/TMS: Five participants will receive a one-hour weekly occupational therapy session of CIMT with 2-hours of daily home program for a total of 6 weeks; immediately prior to initiation of each CIMT session, participants will receive 20 minutes of TMS 1HZ.
89011096|NCT04902521|Sham Comparator|constraint induced movement therapy Sham transcrianial magnetic stimulation|(CIMT/sham TMS): Five participants will receive a one-hour weekly session of CIMT with 2-hours daily of home program for a total of 6 weeks; immediately prior to initiation of each CIMT session, participants will receive 20 minutes of sham TMS 1HZ.
89011097|NCT04902144|Experimental|Screening (medical records, coaching)|"PHASE I: Patients' medical data are collected.~PHASE II: Patients complete questionnaires and their medical data is collected. SCCA subject matter experts and OMC providers review patients' medical data at bi-monthly virtual conferences. OMC providers receive coaching from SCCA subject matter experts for guidance on providing genetic counseling and testing to their patients."
89011098|NCT04871542||Observational (biospecimen collection, questionnaire)|Patients undergo collection of a tissue sample at the start of their routine cancer treatment. Patients complete questionnaires at the start of cancer treatment, weeks 4, 12, 24, and 52. Patients will have the option of providing blood samples at several time points during the study.
89011099|NCT04826718||Cohort|All Health Care Worker (HCW) from Hospital in Santiago and S. Vicente islands, Cabo Verde
89011100|NCT04826718||Control|HCW who report no SARS-CoV-2 infection in the period prior to the interview and/or suspected COVID-19 in the period prior to the interview
89011101|NCT04826718||Cases|HCW who report positive SARS-CoV-2 infection confirmed by performing a positive PCR test and/or positive Rapid Antigen Test in the period prior to the interview
89011102|NCT04822311|Experimental|Investigate the effects of an exercise intervention on retired APF players|20 retired APF players (≥ 18 years of age), who suffer from chronic pain, will be enrolled.
89011103|NCT04815824|Experimental|Stationary Cycling|All participants will complete one, 60-minute bout of stationary cycling
89011104|NCT04815824|Experimental|Treadmill Walking|All participants will complete one, 60-minute bout of treadmill walking
89011105|NCT04791215||Prospective Sample Collection|Prospective sample collection from participants treated with pembrolizumab monotherapy at Columbia University Irving Medical Center under standard of care treatment. Prospective cohort subjects must consent to provide available archived tumor and blood for whole exome sequencing (WES) (matched tumor and normal) for creation of plasma ctDNA panels. The tumor sample must be from a site that was not previously irradiated or has progressed after radiation.
89536604|NCT02475005|No Intervention|Treatment as usual|Treatment as usual (control group)
89011106|NCT04791215||Retrospective Sample Collection|Retrospective sample collection from participants that consent to provide genetic data from previous whole exome sequencing (WES) in the form of files for creation of plasma ctDNA panels.
89011107|NCT04744051|Active Comparator|50 million cell infusion|Each participant in this arm will receive a single dose of 50 million cultured adipose derived stem cells derived from their own adipose (fat) tissue via infusion therapy delivery over the course of one hour.
89011108|NCT04744051|Active Comparator|150 million cell infusion|Each participant in this arm will receive a single dose of 150 million cultured adipose derived stem cells derived from their own adipose (fat) tissue via infusion therapy delivery over the course of one hour.
89011109|NCT04744051|Active Comparator|300 million cell infusion|Each participant in this arm will receive a single dose of 300 million cultured adipose derived stem cells derived from their own adipose (fat) tissue via infusion therapy delivery over the course of one hour.
89011110|NCT04744051|Placebo Comparator|Placebo|Each participant in this arm will receive a single dose of placebo. Upon completion of the study each placebo participant with be given the option to be treated with their cultured adipose derived stem cells derived from their own adipose (fat) tissue via infusion therapy delivery over the course of one hour. Dosage for the crossover will be determined by the PI following review of data collected from the other arms of the study.
89011111|NCT04743856|Active Comparator|PAT (Physical activity monitor)|Participants will receive a physical activity tracker and encouragement to increase physical activity.
89011112|NCT04743856|Experimental|ActiveGOALSv2|Participants will receive the ActiveGOALS online program with an integrated activity tracker.
89011113|NCT04655937|No Intervention|non-randomised no treatment arm|Participants who do not opt in to group support will only provide self-report data on their wellbeing and quality of life every 3 months for up to 12 months. Data collected through online survey platforms using validated questionnaires
89011114|NCT04655937|Experimental|invite Acceptance and Commitment Therapy (ACT) Group|Only those who opt in to invites for group support will invited and allocated into treatment groups at random. Participants in this arm will be invited to 9 weekly ACT-informed therapy sessions involving core values identification, mindfulness practices and committed action plans. There will be homework in between sessions.
89011115|NCT04652479|Experimental|Avexitide 45 mg twice daily then avexitide 90 mg once daily|Patients will receive one of the two dosing regimens of avexitide for 14 days followed by the other dosing regimen of avextide for 14 days
89011116|NCT04652479|Experimental|Avexitide 45 mg once daily then avexitide 90 mg twice daily|Patients will receive one of the two dosing regimens of avexitide for 14 days followed by the other dosing regimen of avextide for 14 days
89011117|NCT04642599|Experimental|Chronic Cerebellar Stroke|Participants with a chronic cerebellar stroke
89011118|NCT04642599|Active Comparator|Healthy Individuals (Controls)|healthy participants
89011119|NCT04634617||Observational (questionnaires)|Patients complete questionnaires over 45-60 minutes consisting of demographic, treatment, lifestyle, disease, and comorbidity questions, as well as multiple study instruments assessing quality of life as it pertains to common toxicities of uterine cancer treatment.
89011120|NCT04582266||Arm 1|Pregnant women hospitalized and receiving RDV for treatment of COVID-19.
89011121|NCT04582266||Arm 2|Non-pregnant women of childbearing potential hospitalized and receiving RDV for treatment of COVID-19.
89011122|NCT04528134|Experimental|Extended Contact RMGI Varnish/5% Sodium Fluoride Varnish|This group will receive extended contact (XT) varnish on their upper left and lower right teeth, and traditional 5% sodium fluoride varnish on their upper right and lower left teeth.
89011123|NCT04528134|Experimental|Placebo Varnish/Extended Contact RMGI Varnish|This group will receive placebo varnish on their upper left and lower right teeth, and extended contact (XT) varnish on their upper right and lower left teeth.
89011124|NCT04528134|Active Comparator|5% Sodium Fluoride Varnish/Placebo Varnish|This group will receive traditional 5% sodium fluoride varnish on their upper left and lower right teeth, and placebo varnish on their upper right and lower left teeth.
89011125|NCT04521920|Experimental|Medication and telemedicine follow up|All participants are provided with Suboxone and/or PrEP and follow up visits will be conducted via telemedicine
89011126|NCT04521894||Primary PCa without metastases Group|Participants who are suspected of prostate cancer due to elevated PSA or clinical symptoms but have not received any treatment and eventually confirmed prostate cancer after surgery or biopsies.
89011127|NCT04521894||Primary PCa with metastases Group|Participants who are suspected of prostate cancer due to elevated PSA or clinical symptoms but have not received any treatment and eventually confirmed prostate cancer after surgery or biopsies. And the 18F-PSMA-PET/CT scan confirmed metastases.
89011128|NCT04521894||Oligometastatic PCa group|"Oligometastaticis a subgroup of metastatic patients with a limited number of secondary lesions (threshold ranging from 3 to 5) in one or few organs."
89011129|NCT04521894||Biochemical recurrence Group|Proven biochemical recurrence after radical therapy (PSA >0.2 ng/mL after radical prostatectomy, PSA ≥2 ng/mL above the nadir after external-beam radiotherapy) or persisting PSA after radical treatment with rising PSA values.
89011130|NCT04521894||Control Group|Prostate cancer benign prostatic hypertrophy or normal prostate.
89011131|NCT04475510|Experimental|Antiplatelet treatment discontinuation|At 12 months post-PFO closure, patients will discontinue the antiplatelet treatment. All patients will undergo a clinical evaluation and cerebral MRI at 12 months (before antiplatelet treatment cessation) and at 24 months post-PFO closure.
89011132|NCT04459338|Experimental|Saline, Then Exendin-9,39|A week or two after screening, participants were admitted to the CRTU and Saline was infused during a hyperglycemic clamp during which escalating doses of glucagon were infused. After completion of this study participants underwent a washout period of 2 weeks after which they were readmitted to the CRTU and Exendin-9,39 was infused at 300pmol/kg/min was infused during a hyperglycemic clamp during which escalating doses of glucagon were infused.
89011133|NCT04459338|Experimental|Exendin-9,39, Then Saline|A week or two after screening, participants were admitted to the CRTU and Exendin-9,39 was infused at 300pmol/kg/min during a hyperglycemic clamp during which escalating doses of glucagon were infused. After completion of this study participants underwent a washout period of 2 weeks after which they were readmitted to the CRTU and Saline was infused during a hyperglycemic clamp during which escalating doses of glucagon were infused.
89011136|NCT04278118|Experimental|Cohort I (hypofractionated radiation therapy)|Patients with benign and radiographically diagnosed intracranial tumors undergo hypofractionated proton or photon radiation therapy daily, Monday-Friday over 17 fractions for 3.5-4 weeks in the absence of disease progression or unacceptable toxicity.
89011137|NCT04278118|Experimental|Cohort II (hypofractionated radiation therapy)|Patients with pathologically confirmed World Health Organization (WHO) grade 2-3 meningiomas undergo hypofractionated proton or photon radiation therapy daily, Monday-Friday over 20 fractions for 3.5-4 weeks in the absence of disease progression or unacceptable toxicity.
89011138|NCT04273269|Experimental|8x10^12 vg/Kg LYS-GM101|Subjects will receive a single infusion: 8x10^12 vg/Kg LYS-GM101
89011139|NCT04234646|Active Comparator|Group 1: One-on-One Patient Navigation|One-on-one Patient Navigation will be based on a Case Management Model where patients navigators perform appointment scheduling and reminders; facilitate communication between patients and care teams; and identify and reduce patient barriers through education, outreach, and referrals to community, local, and state resources.
89011140|NCT04234646|Experimental|Group 2: Patient Navigation 2.0 Checklist|The PN 2.0 Checklist intervention is centered on a learning health system checklist that enumerates a patient's Social Determinants of Health (SDoH) related barriers and tracks completion of services to address SDoH (at community oncology and community social service settings) as well as completion of USPSTF recommended cancer-related screenings, behavioral counseling, and immunizations.
89011141|NCT04141748|Active Comparator|Hand Casting|hand cast will be taken using a circumferential plaster of Paris or fiber glass wrap of the residual limb with the subject in a seated position
89011142|NCT04141748|Active Comparator|standing hydrostatic pressure casting with a water cylinder|hand cast will be taken using a circumferential plaster of Paris wrap of the residual limb with the subject in a seated position. The residual limb is then placed into the Symphonie Aqua System while in a weight bearing standing position.
89011143|NCT04139616||No ECG changes in patients without pre-existing RBBB|Patients with no new conduction disturbances on the ECG performed immediately post-TAVR (and no episodes of HAVB/CHB during the procedure) have a very low risk of developing HAVB/CHB or any conduction disturbance within the hours-days following the procedure. In these cases, temporary pacing will be discontinued at the end of the procedure. However, continuous ECG monitoring until hospital discharge is recommended. A 12-lead ECG is recommended 24 hours after the procedure. If no arrhythmic episodes and no ECG changes occur within the 24 hours post-procedure, the patient can be safely discharged (the day after TAVR) with no other monitoring measures in case of otherwise uneventful clinical course (absence of other TAVR related adverse events). If the patient has to remain hospitalized because of other reasons or TAVR complications, telemetry would be recommended (but no strictly required) for the detection of post-TAVR tachyarrhythmias or late ECG changes.
89011144|NCT04139616||Patients with pre-existing RBBB|A temporary pacing wire is recommended to be maintained for 24 hours (or at least overnight) in all patients with prior RBBB, along with telemetry and daily ECG during the entire hospitalization period (minimum of 2 days). If any ECG changes occur during the initial 2-3 days, patients can be managed according to the proposed strategy (see management strategies for groups 3 and 5). If no ECG changes or significant bradyarrythmias occur within the 2-3 days following the procedure, the patient can be discharged. Considering that the increased risk of life threatening bradyarrhythmias in these patients may extend beyond the hospitalization period, the use of continuous ECG monitoring systems (minimum of 48 hours, up to 4 weeks) may be considered.
89011145|NCT04139616||ECG changes in patients with prior conduction disturbances|"Any significant increase in PR or QRS interval will indicate to continuing the temporary pacing for 24 hrs, with daily ECG and telemetry for 1-2 days. If the ECG changes regress in <24 hrs, an earlier removal of the temporary pacing may be considered. Also, a strategy of multiple ECGs during the first 24 hrs may be considered. If ECG changes regress or no further changes occur the patient can be discharged with no PPM at 2 days post-TAVR.~If 24 hrs post-TAVR, the PR and QRS interval remain stable but >240 or >150 ms, respectively, and ≥20 ms longer than baseline, maintaining the temporary pacing wire for another 24 hrs is recommended. If no decrease in the PR or QRS duration occurs at day 2, the patient can be considered at risk for more advanced conduction disturbances requiring PPM. The use of an EP study may be a reasonable option for deciding PPM in those patients with prior conduction disturbances with worsening of ECG changes post-TAVR"
89011146|NCT04139616||New-onset LBBB|"Temporary pacing for 24 hrs is recommended, in all patients with new-onset LBBB post-TAVR. Earlier removal of the temporary pacing and discharged at day 1 can be considered if LBBB resolves in <24 hrs.~If LBBB persists but no further progression of the duration of the QRS or PR interval is observed at day 1, temporary pacing can be discontinued. If no further ECG changes are observed up to day 2-3 post-TAVR, the patient can be discharged. These patients are however at increased risk of HAVB/CHB requiring PPM, and continuous ECG monitoring and/or EP studies may be considered.~If further prolongation of the QRS or PR interval is observed at day 1, the temporary pacing is recommended for an additional 24 hrs. If the prolongation of the QRS or PR intervals continues at day 2, evaluation with EP studies or PPM implantation may be considered.~The occurrence of any episode of HAVB/CHB following TAVR in a patient with new-onset LBBB will be considered an indication for PPM"
89198747|NCT00879177|Active Comparator|Group A|Study drug (varenicline) for 12 weeks, brief smoking cessation counseling for 5 weeks, and ambulatory blood pressure monitoring at Weeks 6 and 24.
89011147|NCT04139616||HAVB/CHB during the periprocedural period|"Maintaining temporary pacing in patients with procedural persistent HAVB/CHB, and monitoring in intensive care unit are recommended. If HAVB/CHB persists at 24 hrs, PPM is recommended. If HAVB/CHB recovers the day after TAVR, the temporary pacing can be removed and the patient can remain hospitalized for 1 day. If another episode of HAVB/CHB occurs, PPM is recommended. If no other episode of HAVB/CHB occurs, and no other features potentially justifying PPM exist the patient can be discharged.~Temporary pacing is recommended for 24 hrs in patients with transient HAVB during the procedure, with telemetry and daily ECG for 2 days. Discontinuing temporary pacing may be considered in those cases with brief episodes of HAVB/CHB and normal ECG. If no recurrent episodes of HAVB/CHB occur, and the patient has no other potential indications for PPM the patient can be discharged at day 2. PPM would be indicated if any recurrent episode of HAVB/CHB occurs during the hospitalization period."
89436925|NCT04927143|Experimental|Escalating High|"Participants will have access to the DynamiCare app. Through the app, participants will receive incentive amounts for drug negative saliva tests. Incentive amounts increase with every negative drug test up to a ceiling and reset to the lowest amount when a test is positive or missed. The High group will receive incentives worth $4-$16."
89436926|NCT04927143|Experimental|De-Escalating Low|"Participants will have access to the DynamiCare app. Through the app, participants will receive incentive amounts for drug negative saliva tests. Incentive amounts increase with every positive drug tests (up to a ceiling), and decrease by the same increment with every negative drug test (down to a floor). The Low group will receive incentives worth $6-12."
89436927|NCT04927143|Experimental|De-Escalating High|"Participants will have access to the DynamiCare app. Through the app, participants will receive incentive amounts for drug negative saliva tests. Incentive amounts increase with every positive drug tests (up to a ceiling), and decrease by the same increment with every negative drug test (down to a floor). The High group will receive incentives worth $10-$20."
89436928|NCT04927143|Experimental|Constant High|"In the Constant groups, incentive amounts will remain unchanged across time. The High group will receive incentives worth $16."
89436929|NCT04927143|Experimental|Constant Low|"In the Constant groups, incentive amounts will remain unchanged across time. The Low group will receive incentives worth $8 every test."
89436930|NCT04925934|Experimental|VIB7734 SC (dosing interval 1)|
89436931|NCT04925934|Experimental|VIB7734 SC (dosing interval 2)|
89436932|NCT04925934|Placebo Comparator|Placebo SC (dosing interval 3)|
89436933|NCT04921358|Experimental|Arm A: Tislelizumab in combination with Sitravatinib|tislelizumab 200 mg intravenously once every 3 weeks in combination with sitravatinib 100 mg orally once a day
89436934|NCT04921358|Active Comparator|Arm B: Docetaxel|docetaxel 75 mg/m2 intravenously once every 3 weeks
89436935|NCT04916132||Peolpe with T2DM and albuminuria|Prospectively we will collect research kidney biopsies and other biomarkers from blood, faeces, urine, proteomic- and metabolomic profiles and DNA-variants. The biopsies will be thoroughly investigated with cutting-edge molecular technologies and associated to the biomarkers, disease course and clinical outcome.
89436936|NCT04915495|Experimental|Singe-arm Study|Experimental device being evaluated for sensitivity and specificity.
89436937|NCT04910581|Active Comparator|Experimental stimulation|Patients receive an inhibitor treatment of rTMS using activ coil (MCF B65 coil) for 30 minutes at 1Hz at 80% of the resting motor threshold (MagPro stimulator; MagVenture A / S, Farum, Denmark) onto the left laryngeal cortex located thanks to a neuronavigation device (Syneika one [SYN1], Syneika, Cesson-Sévigné, France).
89436938|NCT04910581|Placebo Comparator|Sham stimulation|Patients receive a treatment of rTMS using placebo coil (MCF P B65 coil) for 30 minutes at 1Hz (MagPro stimulator; MagVenture A / S, Farum, Denmark) onto the left laryngeal cortex located thanks to a neuronavigation device (Syneika one [SYN1], Syneika, Cesson-Sévigné, France).
89436939|NCT04909450|Experimental|CSB-001 Investigational Treatment Arm|One drop CSB-001 four times daily for 8 weeks in the study eye
89436940|NCT04909450|Placebo Comparator|Vehicle Control Arm|One drop matching vehicle four times daily for 8 weeks in the study eye
89436941|NCT04908202|Experimental|Deucravacitinib|
89436942|NCT04908202|Placebo Comparator|Placebo|
89436943|NCT04907227|Experimental|Pembrolizumab+Docetaxel|Participants receive pembrolizumab 200 mg by intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W) for up to a maximum of 35 cycles (approximately 2 years) PLUS docetaxel 75 mg/m^2 by IV infusion Q3W for a maximum of 10 cycles (approximately 7 months). Participants also receive dexamethasone 8 mg by oral tablets at 12 hours, 3 hours, and 1 hour prior to docetaxel administration and prednisone 5 mg by oral tablets twice daily during each docetaxel cycle.
89436944|NCT04907227|Placebo Comparator|Placebo+Docetaxel|Participants receive placebo by IV infusion on Day 1 of each 21-day cycle (Q3W) for up to a maximum of 35 cycles (approximately 2 years) PLUS docetaxel 75 mg/m^2 by IV infusion Q3W for a maximum of 10 cycles (approximately 7 months). Participants also receive dexamethasone 8 mg by oral tablets at 12 hours, 3 hours, and 1 hour prior to docetaxel administration and prednisone 5 mg by oral tablets twice daily during each docetaxel cycle.
89436945|NCT04906902|Experimental|Acalabrutinib Dose Escalation|"Phase 1 Dose escalation will occur using a 3+3 dose escalation approach, evaluating three separate dose levels.~Acalabrutinib 200mg 2x daily~Acalabrutinib 300mg 2x daily~Acalabrutinib 400mg 2x daily"
89436946|NCT04906902|Experimental|Acalabrutinib Dose Expansion|"Phase 2~Participants will receive Acalabrutinib at the pre-determined dosage established in Phase 1."
89436947|NCT04906460|Experimental|WVE-N531|
89436948|NCT04906330||PPHM-0000-21|50-70 year old female patients, without a personal history of oncological pathology, who attend for gynecological and mammographic control.
89436949|NCT04906213|Active Comparator|Arm I: With Type II Diabetes|Kidney Transplant recipient with Type II diabetes, randomized to either Empagliflozin or a placebo.
89436950|NCT04906213|Active Comparator|Arm 2: Without Diabetes|Kidney Transplant recipient without Type II diabetes, randomized to either Empagliflozin or a placebo
89436951|NCT04903028|Sham Comparator|Sham rTMS|Investigators will use electrode stimulation with 10 Hz over DLPFC, total 3000 pulses. The sham-TMS scalp discomfort was matched to that of active TMS. During real TMS there was no current flowing through the scalp electrodes.
89011148|NCT04131842|Experimental|ExFOCUS Visual|Participants will complete 12 sessions over 4-weeks of impairment-based rehabilitation that incorporates ankle range of motion, ankle strength, balance, and functional activity exercises. For the balance and functional activity exercises, participants will use traditional instability tools and will receive external focus of attention visual feedback.
89011149|NCT04131842|Experimental|ExFOCUS Auditory|Participants will complete 12 sessions over 4-weeks of impairment-based rehabilitation that incorporates ankle range of motion, ankle strength, balance, and functional activity exercises. For the balance and functional activity exercises, participants will use traditional instability tools and will receive auditory feedback.
89011150|NCT04131842|Experimental|InFOCUS Visual|Participants will complete 12 sessions over 4-weeks of impairment-based rehabilitation that incorporates ankle range of motion, ankle strength, balance, and functional activity exercises. For the balance and functional activity exercises, participants will use traditional instability tools and will receive internal focus of attention visual feedback via video.
89198748|NCT00879177|Experimental|Group B|Study drug (varenicline) for 12 weeks, brief smoking cessation counseling for 5 weeks, ambulatory blood pressure monitoring at Weeks 6 and 24, and behavioral therapy for Weeks 2-5.
89011151|NCT04131842|Active Comparator|NoFeedback|Participants will complete 12 sessions over 4-weeks of impairment-based rehabilitation that incorporates ankle range of motion, ankle strength, balance, and functional activity exercises. For the balance and functional activity exercises, participants will use traditional instability tools and receive no feedback.
89011152|NCT04130711|Other|TEST 1: Visual virtual Conditions|"50 subjects (30 healthy volunteers and 20 patients after stroke)~3 different situations of vibration applications, without EGG neurofeedback session"
89011153|NCT04130711|Other|TEST 2: Standard EEG|"20 subjects (healthy volunteers)~3 separate electroencephalographic recording conditions without Neurofeedback"
89011154|NCT04130711|Other|TEST 3: Neurofeedback Training Stroke Patients|"26 patients after stroke~12 neurofeedback sessions spread over 6 weeks according to the feedback modality that will be drawn (visual or visuo-vibratory)"
89011155|NCT04120285|No Intervention|Primary Care Treatment|The participant will receive treatment as usual as prescribed by the primary care physician for MDD.
89011156|NCT04120285|Active Comparator|Primary care treatment with eCBT|The participant will receive treatment as usual as prescribed by the primary care physician with the addition of eCBT for MDD.
89011157|NCT04120285|Active Comparator|Primary care treatment with guided eCBT|The participant will receive treatment as usual as prescribed by the primary care physician with the addition of guided eCBT for MDD.
89011158|NCT04108897|Experimental|Doxycycline 40mg/day|Doxycycline 40mg will be administered once a day per oral for 28 days.
89011159|NCT04108897|Experimental|Doxycycline 50mg/day|Doxycycline 50mg will be administered once a day per oral for 28 days.
89011160|NCT04108897|Experimental|Doxycycline 100mg/day|Doxycycline 100mg will be administered once a day per oral for 28 days.
89011161|NCT04108897|Experimental|Doxycycline 200mg/day|Doxycycline 100mg will be administered twice a day per oral for 28 days.
89011162|NCT04108897|Experimental|Topical ivermectin(1%)|Topical ivermectin will be applied once a day for 28 days.
89011163|NCT04108897|No Intervention|Control|No intervention will be performed.
89011164|NCT04101877|Experimental|Avastin|bevacizumab 25 mg/ml, intravitreal administration, 0.05 ml (1.25 mg)
89011165|NCT04101877|Active Comparator|Eylea|aflibercept 40 mg/ml, intravitreal administration, 0.05 ml (2 mg)
89011166|NCT04101838|Active Comparator|Fluzone Younger|10 adults 18-50 years old, will receive a single dose of the Fluzone influenza vaccine each year for two sequential years
89011167|NCT04101838|Active Comparator|Flucelvax|10 adults 18-50 years old, will receive a single dose of the Flucelvax influenza vaccine each year for two sequential years
89011168|NCT04101838|Active Comparator|Fluzone Older|10 adults 65-80 years old, will receive a single dose of the Fluzone influenza vaccine
89011169|NCT04101838|Active Comparator|Fluzone High Dose|10 adults 65-80 years old, will receive a single dose of the Fluzone High-Dose influenza vaccine
89011170|NCT04101838|Active Comparator|Fluad|10 adults 65-80 years old, will receive a single dose of the Fluad influenza vaccine
89011171|NCT04061044|Experimental|Treatment|
89011172|NCT04047121||Truven Health MarketScan|The Truven Health MarketScan Research Databases reflects the combined healthcare service use of individuals covered by Truven Health clients (including employers, health plans, and hospitals) nationwide.
89011173|NCT04026958|Experimental|Clarithromycin|Participants in this study arm will receive clarithromycin for 14 days.
89011174|NCT04026958|Placebo Comparator|Placebo|Participants in this study arm will receive a placebo to match clarithromycin for 14 days.
89011175|NCT04016376|Experimental|PVB|Patient will be placed in the prone, lateral, or sitting position. With an ultrasound probe placed in the parasagittal or transverse position, the paravertebral space will be identified. Injections will be done in an in-plane manner relative to the ultrasound probe. Local anesthesia will be injected to cover T1-T6 dermatomes.
89011176|NCT04016376|Experimental|PVB + PECS-1|"Patient will be placed in the prone, lateral, or sitting position. With an ultrasound probe placed in the parasagittal or transverse position, the paravertebral space will be identified. Injections will be done in an in-plane manner relative to the ultrasound probe. Local anesthesia will be injected to cover T1-T6 dermatomes.~For PECS-1, the patient will be placed in the supine position with an ultrasound probe placed inferolaterally starting at the mid-clavicular level the pectoralis major and minor will be identified. Injection of local anesthesia will be performed between the pectoralis major and minor."
89198749|NCT01050829|Experimental|Arm 1|
89011177|NCT04016376|Experimental|Serratus + PECS-1|"For PECS-1, the patient will be placed in the supine position with an ultrasound probe placed inferolaterally starting at the mid-clavicular level the pectoralis major and minor will be identified. Injection of local anesthesia will be performed between the pectoralis major and minor.~For the serratus block, the patient will be placed in the supine or lateral decubitus position and with an ultrasound probe, in the parasagittal plane, the serratus muscles will be identified. Injections will be done in-plane below the serratus anterior."
89011178|NCT03975790||Truven Health MarketScan Research Database|Compare treatment patterns including dosing, concomitant medication use, adherence, persistence, and switching among tofacitinb+MTX patients who withdraw MTX vs. persist with MTX or experience interrupted MTX
89011179|NCT03939481||Observational (non-study chemo, questionnaire, assessments)|Patients receive chemotherapy regimen per treating physician for 52 weeks in the absence of disease progression or unacceptable toxicity. Patients also complete questionnaires at weeks 4, 8, 12, 24 and 52.
89011180|NCT03939182|Experimental|Abexinostat and Ibrutinib|The investigational agents to be used in this study are ibrutinib and abexinostat. Ibrutinib will be administered once daily on a 28-day cycle. Abexinostat will be administered orally twice daily (approximately 4-6 hours apart) for 7 days a week given every other week on a 28-day cycle.
89011181|NCT03935633|Experimental|First Dosage|The dose of CN128 is 20 mg/kg bw， bid.
89011182|NCT03935633|Experimental|Second Dosage|The dose of CN128 is 15 mg/kg bw， bid.
89198750|NCT01050829|Active Comparator|Arm 2|
88920547|NCT05119959|Active Comparator|Arm 3- HIV Unexposed (HUU) without ECD intervention|Participants randomized to this arm will receive the current Ministry of Health (MoH) standard of care with no formalized routine assessment of neurodevelopment.
88920548|NCT05118685|Active Comparator|the first group estrogen group|they will receive estrogen conjugate vaginal cream one tube every night for 14 nights; then, one tube 2 nights in 1 week (two tubes every week) for 10 weeks.
88920549|NCT05118685|Experimental|the second group PRP group|they will receive a Platelet-rich plasma injection every 3 weeks for 4 times. PRP will be administered to the anterior vaginal wall using 27-G needles o and it is mainly injected into the anterior wall of the vagina to increase the tactile sensitivity of the injection site.
88920550|NCT05112185|Experimental|Healthy Beverage Access and Promotion|Intervention group will receive BPA-free self-serve pitchers and cups for serving water at mealtimes, individualized education to help families set healthy drinks goals for their family, and a curricula focused on increasing intake of water and healthy beverages.
88920551|NCT05112185|No Intervention|Control|Usual care.
88920552|NCT05109650|Experimental|0.1mg/kg of BAT6026 + 300mg of BAT1308|0.1mg/kg of BAT6026 Ⅳ infusions at cycle 1(monotherapy), and 0.1mg/kg of BAT6026 IV infusions + 300mg of BAT1308 IV infusions(combination therapy) from cycle 2 until end of treatment
88920553|NCT05109650|Experimental|0.3mg/kg of BAT6026 + 300mg of BAT1308|0.3mg/kg of BAT6026 Ⅳ infusions at cycle 1(monotherapy), and 0.3mg/kg of BAT6026 IV infusions + 300mg of BAT1308 IV infusions(combination therapy) from cycle 2 until end of treatment
88920554|NCT05109650|Experimental|1mg/kg of BAT6026 + 300mg of BAT1308|1mg/kg of BAT6026 Ⅳ infusions at cycle 1(monotherapy), and 1mg/kg of BAT6026 IV infusions + 300mg of BAT1308 IV infusions(combination therapy) from cycle 2 until end of treatment
88920555|NCT05109650|Experimental|3mg/kg of BAT6026 + 300mg of BAT1308|3mg/kg of BAT6026 Ⅳ infusions at cycle 1(monotherapy), and 3mg/kg of BAT6026 IV infusions + 300mg of BAT1308 IV infusions(combination therapy) from cycle 2 until end of treatment
88920556|NCT05109650|Experimental|6mg/kg of BAT6026 + 300mg of BAT1308|6mg/kg of BAT6026 Ⅳ infusions at cycle 1(monotherapy), and 6mg/kg of BAT6026 IV infusions + 300mg of BAT1308 IV infusions(combination therapy) from cycle 2 until end of treatment
88920557|NCT05109650|Experimental|10mg/kg of BAT6026 + 300mg of BAT1308|10mg/kg of BAT6026 Ⅳ infusions at cycle 1(monotherapy), and 10mg/kg of BAT6026 IV infusions + 300mg of BAT1308 IV infusions(combination therapy) from cycle 2 until end of treatment
88920558|NCT05108259|Experimental|PBP1502|Adalimumab single dose 40 mg (100 mg/mL) by SC injection via pre-filled syringe (PFS)
88920559|NCT05108259|Active Comparator|EU-licensed Humira|Adalimumab single dose 40 mg (100 mg/mL) by SC injection via PFS
88920560|NCT05108259|Active Comparator|US-licensed Humira|Adalimumab single dose 40 mg (100 mg/mL) by SC injection via PFS
88920561|NCT05107271||Chronic Liver Disease|
88920562|NCT05107271||Post Liver Transplantation|
88920563|NCT05087823|Experimental|Lipid, Glucose, and Mixed Meal Challenges|Participants will take part in three different meal challenges on three separate days with approximately two weeks in between. The first meal challenge is the lipid challenge, the second meal challenge is the glucose challenge and third meal challenge is the mixed-meal challenge.
88920564|NCT05084833|Experimental|Group1: Control (C)|Electronic educational materials (C).
88920565|NCT05084833|Experimental|Group 2: Patient Activation (PA)|C + patient activation (PA) consisting of interactive tailored text messages with links to videos and resources
88920566|NCT05084833|Experimental|Group 3: Patient Activation and PCP Activation (PA + PCP)|C + PA + PCP activation (PA+PCP) with physician materials about colorectal cancer risk in this population
88920567|NCT05062447||Adaptive emotions, non-metastatic disease|Participants who are categorized as having 'adaptive emotions' and have a non-metastatic disease
88920568|NCT05062447||Adaptive emotions, metastatic disease|Participants who are categorized as having 'adaptive emotions' and have a metastatic disease
88920569|NCT05062447||maladaptive emotions, non-metastatic disease|Participants who are categorized as having 'maladaptive emotions' and have a non-metastatic disease
88920570|NCT05062447||maladaptive emotions, metastatic disease|Participants who are categorized as having 'maladaptive emotions' and have a metastatic disease
88920571|NCT05059795||Cirrhosis/ACLF of any etiology|
88920572|NCT05055817||bloody stool group|bloody stool appear in the hospitalized neonate
88920573|NCT05055817||non-bloody stool group|bloody stool do not appear in the hospitalized neonate
88920574|NCT05053269||good body weight growth|body weight growth after birth is consistent with the growth curve
88920575|NCT05053269||poor body weight growth|body weight growth after birth is inconsistent with the growth curve
88920576|NCT05050383|Other|Drug-Induced Sleep Endoscopy|Drug-Induced Sleep Endoscopy
88920577|NCT05048485||LEOPARD Cohort 1|"Control group: The study will enroll 50 newly diagnosed smear-positive (>/=1+ AFB) pulmonary TB patients whose household contacts are enrolled in the TB-LION study and who are not receiving nutritional supplementation.~TB LION group: The study will enroll 50 newly diagnosed smear-positive (>/=1+ AFB) pulmonary TB patients whose household contacts are enrolled in the TB-LION study and who are receiving nutritional supplementation."
88920578|NCT05048485||LEOPARD Cohort 2|The study will enroll 300 newly diagnosed smear-positive (>/=1+ AFB) pulmonary TB patients whose household contacts are not enrolled in the TB-LION study.
88920579|NCT05032118|Experimental|Ketamine|Intravenous ketamine will be initiated following aneurysm securement at 0.5mg/kg/h and will be titratable by 0.2mg/kg/h every 20min to a Richmond Agitation Sedation Scale (RASS) goal of 0 to -1 (or as otherwise clinically indicated). Ketamine boluses will be available at 0.5mg/kg every 1hr as needed for inadequate sedation or breakthrough agitation. An additional 0.5mg/kg bolus may be utilized prior to initiating the ketamine infusion, or as needed at the discretion of the clinician. The maximum ketamine infusion dose will be limited to 4mg/kg/h. A fixed-dose propofol infusion at 10mcg/kg/min will simultaneously be administered to minimize the potential psychomimetic side effects of ketamine. This sedation paradigm will continue for up to 10 days post-bleed or until the study participant no longer requires sedation, whichever occurs earlier. If the RASS goal is not met with this sedation regimen, additional agents will be at the discretion of the intensivist.
88920580|NCT05032118|Active Comparator|Standard of Care|Intravenous titratable propofol will be initiated as needed per current standard of care, which generally consists of initiating the infusion at 10-20mcg/kg/min with titration parameters of 5-10mcg/kg/min every 5-10min for a RASS goal of 0 to -1 (or as otherwise clinically indicated). Propofol boluses are available at 10-20mg (or higher dosages if clinically required) every 15min as needed for inadequate sedation or breakthrough agitation. The maximum infusion dose is generally limited to 50mcg/kg/min. If the RASS goal is not met with this sedation regimen, additional agents will be at the discretion of the intensivist.
88920581|NCT05021679|Experimental|AMP Implementation|
88920582|NCT05000970|Experimental|TRIO PLUS tablet and nurse at day 3|Virtual nurse encounter at 3 days
88920583|NCT05000970|Experimental|TRIO PLUS Tablet and nurse at day 3 and 7|Virtual nurse encounter at 3 days and 7 days
88920584|NCT05000970|Placebo Comparator|TRIO PLUS Group|No encounter
88920585|NCT04921696||RBC transfusion|RBC was transfused to the infants.
88920586|NCT04921696||no-RBC transfusion|RBC was not transfused to the infants.
88920587|NCT04913493|No Intervention|Control group|Patients will only receive FloTrac/Vigileo monitoring which is standard of care.
88920588|NCT04913493|Experimental|Experimental group|Patients will receive an additional medical imaging intervention. Namely sublingual microcirculation imaging with Cytocam-IDF.
88920589|NCT04880681|Experimental|Novel needle|Novel needle (18 G, 25 cm with 19 mm sample notch) in a new actuator.
88920590|NCT04880681|Active Comparator|Standard Tru Cut needle|Standard tru cut biopsy needle (Argon 18G, 25 cm biopsy needle with a 19 mm sample notch) in a standard actuator (Möller Medical Blue RBG-1000-10-1000).
88920591|NCT04869345|Experimental|LARKSPUR intervention|Lessons in Affect Regulation to Keep Stress and Pain UndeR control
88920592|NCT04869345|No Intervention|Attention Control Condition|Daily emotion reporting/no intervention
88920593|NCT04867850|Active Comparator|Usual Care|Clinicians and patients will receive no further interventions beyond usual practice. Usual care for clinicians includes a nudge consisting of targeted text messages identifying patients at high risk of predicted 6-month mortality based on a validated machine learning prognostic algorithm.
88920594|NCT04867850|Experimental|Clinician Nudge|Clinicians receive a nudge consisting of targeted text messages identifying patients at high risk of predicted 6-month mortality based on a validated machine learning prognostic algorithm as well as performance feedback compared to peers.
88920595|NCT04867850|Experimental|Patient Nudge|Patients receive a nudge consisting of a normalizing message prompting patients to complete an electronic questionnaire designed to prime patients towards having an SIC.
88920596|NCT04867850|Experimental|Clinician and Patient Nudge|Both strategies described above will be used.
88920597|NCT04862234|Experimental|Continuous Glucose Monitoring|Aim 1 participants will have a continuous glucose monitor (CGM) placed preoperatively and will wear the CGM throughout hospitalization.
88920598|NCT04862234|Experimental|Dulaglutide|Aim 2 participants randomized to receive dulaglutide within 72 hours prior to a planned surgery.
88920599|NCT04862234|Placebo Comparator|Placebo|Aim 2 participants randomized to receive a placebo to match dulaglutide within 72 hours prior to a planned surgery.
89011183|NCT03901807|Experimental|PMX Treatment|Standard medical care for septic shock plus treatment with the PMX cartridge (twice approximately 24 hours apart)
89011184|NCT03901807|No Intervention|Control|Standard medical care alone
89436952|NCT04903028|Active Comparator|Active rTMS 10 Hz DLPFC|A stimulation frequency of 10 Hz, pulse train duration (on time) of 5 seconds, inter-train interval (off time) of 10 seconds (15 second cycle time), E-field-modeling to determine TMS intensity and coil orientation, total of 60 trains, session time of 15 minutes, and 3000-total pulses per day, will be delivered over the left DLPFC.
89436953|NCT04900337|Experimental|AMOR 18 Powder & Inhalation|"AMOR_inhaled Double Pack- Each kit contains two tubes that after mixing result with 1.14 % ACC in 10 ml suspension.~AMOR_powder- ACC in a dry powder (up to 2000mg Calcium/day sublingually)."
89436954|NCT04900337|Placebo Comparator|Placebo|"Placebo_Inhaled Double Pack - Each kit contains two tubes of saline at different volumes (similar to investigational product) after mixing the results remains saline at a final volume of 10ml.~Placebo_Powder: Each sachet contains powder at the same particle size and weight as the powder of the investigational product."
89011188|NCT03878589|Active Comparator|Oxytocin Crossover Placebo Group|During Phase 1 of the intervention, participants will self-administer via intranasal spray 24 IUs of oxytocin (OT) twice a day at home, at 8-9AM and again at 5-6PM. After a four-week washout period, Phase 2 will consist of a second four weeks of intervention, this time intranasal spray 24 IUs of placebo (P) twice a day will be self-administered.
89011189|NCT03878589|Active Comparator|Placebo Crossover Oxytocin Group|During Phase 1 of the intervention, participants will self-administer via intranasal spray 24 IUs of placebo (P) twice a day at home, at 8-9AM and again at 5-6PM. After a four-week washout period, Phase 2 will consist of a second four weeks of intervention, this time intranasal spray 24 IUs of oxytocin (OT) twice a day will be self-administered.
89011190|NCT03875326|Sham Comparator|Sham Stimulation|Sham (placebo) dose of HD-tDCS treatment for 30 minutes, for between 5-30 sessions.
89011191|NCT03875326|Experimental|1 mA Dosage Stimulation|1 milliAmp dose of HD-tDCS treatment for 30 minutes, for between 5-30 sessions.
89011192|NCT03875326|Experimental|2 mA Dosage Stimulation|2 milliAmp dose of HD-tDCS treatment for 30 minutes, for between 5-30 sessions.
89011193|NCT03875326|Experimental|3 mA Dosage Stimulation|3 milliAmp dose of HD-tDCS treatment for 30 minutes, for between 5-30 sessions.
89011194|NCT03843190|Experimental|Take Off Pounds Sensibly (TOPS)|This group will receive TOPS intervention at the start of the study.
89011195|NCT03843190|Other|Waitlist control|This group will be the control group for 6 months. Then at the completion of the study they will receive the vouchers to participate in TOPS chapters in the community.
89011196|NCT03832829|Experimental|Indirect restorations with SR Nexco|Large posterior defects with at least one or more cuspal coverage in molars will be restored using the materials listed (SR Nexco). Procedures will be done using local anesthesia. The procedure, starts with removal of caries or defective restorations and coronal relocation of the the margins using flowable composite with maximum thickness 1 to 1.5 mm and followed by resin composite build-up. Defined principles of morphology driven preparation technique will be followed Impression making, fabrication of indirect restoration with SR Nexco and adhesive cementation will be completed according to manufacturer's instructions.
89011197|NCT03827850|Active Comparator|Cohort 1 FGFR trans|Cohort 1: Activating (high confidence) FGFR translocations (max. 15 patients) under daily Erdaifitinib treatment
89011198|NCT03827850|Active Comparator|Cohort 2 FGFR mut|Cohort 2: Activating (high confidence) hotspot FGFR mutations (max. 15 patients) under daily Erdafitinib treatment
89011199|NCT03827850|Active Comparator|Cohort 3 FGFR other|Cohort 3: Activating (low confidence) FGFR alteration (max. 20 patients)
89198751|NCT00873717|Experimental|Dentary|Intervention: trimestrial follow-up of patients and counseling for appropriate care (if needed), in order to restore a minimum masticatory function, associated with particular focus on the realization of daily oral wash.
89011200|NCT03813836|Experimental|pembrolizumab + best supportive care|Best supportive care and pembrolizumab 200mg every 3 weeks for a maximum duration of 24 months
89198752|NCT00873717|Experimental|Nutrition|control of the administration of dietary prescriptions, incitement to eat.
89198753|NCT00873717|Experimental|Dentary + nutrition|cleaning-up of oral cavity, with trimestrial dental and oral check-up with counseling for appropriate care (if needed) associated with control of the administration of dietary prescriptions, incitement to eat.
89198754|NCT00873717|No Intervention|Control|usual care
89198755|NCT00676338|Experimental|Exenatide Once Weekly|
89198756|NCT00676338|Active Comparator|Metformin|
89198757|NCT00676338|Active Comparator|Sitagliptin|
89436955|NCT04898946||BNT162b2|Subjects who receive mRNA vaccine BNT162b2.
88920600|NCT04846738||brain damaged patients|"All major brain damaged patients (stroke or head trauma) admitted to reanimation will be included.~In the usual practice, they have a Transcranial Doppler and the measurement of the photomotor reflex by quantitative Pupillometry.~It is planned to collect the simultaneous values of the different parameters during 2,000 measurements.~The data will be collected retrospectively from 01/12/2020, and prospectively from 01/04/2021."
88920601|NCT04842643|Experimental|Epoch 2 in previous study: Immune Globulin Subcutaneous 20% Solution (IGSC)|Participants will receive between 50 and 200 mg/kg of Immunoglobulin Globulin subcutaneous (IGSC) infusion, 20 percent (%) once a week until the study drug becomes commercially available (approximately 3 years). All participants of this arm will have assigned Epoch 2 of previous study (TAK-664-3001). The dose of IGSC will be established in previous study.
88920602|NCT04842643|Experimental|Epoch 3 in previous study: Immune Globulin Subcutaneous 20% Solution (IGSC)|"Participants will receive between 100 and 400 mg/kg of Immunoglobulin Globulin subcutaneous (IGSC) infusion, 20 percent (%) once every 2 weeks until the study drug becomes commercially available (approximately 3 years). All participants of this arm will have assigned Epoch 3 of previous study (TAK-664-3001).The dose of IGSC will be established in previous study (TAK-664-3001).~For participants who discontinue Epoch 3 and enter Study TAK-664-3002, the dose regimen will be determined on a case-by-case basis."
88920603|NCT04821336||Thyroid tissue samples|from 30 patients, tissue samples , frozen and embedded paraffin have been collected and preserved for research. For this study, tumoral tissue and healthy tissue will be used;
88920604|NCT04777747||viral infection|a child is infected by virus only
88920605|NCT04777747||viral and bacterial infection|a child is infected by virus and progress to bacterial infection
88920606|NCT04775368|Experimental|Diagnosis orientation group|For this study, there is only one arm. Each patient complete diagnosis questionnaires.
88920607|NCT04747353|Experimental|Catheter ablation procedure with heart 3D model|Experimental: Catheter ablation procedure performed as part of standard care, although with the addition of an image-based 3D heart model including detailed anatomy and primary ablation targets
88920608|NCT04745234|Experimental|Mogamulizumab|
88920609|NCT04733469|Experimental|Multimedia Psychoeducational Intervention + Enhanced Usual Care|Intervention participants receive the Multimedia Psychoeducational Intervention in addition to Enhanced Usual Care
88920610|NCT04733469|Other|Enhanced Usual Care|Control participants receive Enhanced Usual Care
88920611|NCT04688567|Experimental|Patient-driven iCBT|Participants who are randomized to the experimental condition are asked to make choices regarding the structure of their treatment program
88920612|NCT04688567|Active Comparator|Standardized iCBT (TAU)|Patients who are randomized to the control condition undergo the usual iCBT program available for anxiety disorders for a standardized time period of 8 weeks
88920613|NCT04641637|Other|Selective catheterization of segmental or more peripheral arteries in TACE|From the digital subtraction angiography (DSA), the number of arterial tumor feeders to the HCC is identified. One or more feeder(s) is to be catheterized for delivery of therapeutic agent using a 2.4 French microcatheter (Merit Maestro, Merit Medical Systems, Utah, USA), and the other feeder(s) is occluded with a balloon catheter using 0.1 to 0.2mL diluted contrast for inflation (4mm x 10mm Temporary Occlusion Balloon Catheter, Occlusafe, Terumo Clinial Supply, Gifu, Japan). The occlusion target could be a feeder or a common trunk leading to a number of feeders.
88920614|NCT04635917|Experimental|Personalized diet - Black adults|Young Black adults in this group will receive tailored nutrition counseling from a dietitian. To facilitate meeting their dietary goals, participants will be provided with nuts, fruits, and vegetables.
88920615|NCT04635917|Experimental|Personalized diet - White adults|Young White adults in this group will receive tailored nutrition counseling from a dietitian. To facilitate meeting their dietary goals, participants will be provided with nuts, fruits, and vegetables.
88920616|NCT04635917|Other|Conventional dietary advice- Black adults|Young Black adults will receive non-personalized, conventional dietary advice based on the MyPlate guidelines.
88920617|NCT04635917|Other|Conventional dietary advice- White adults|Young White adults will receive non-personalized, conventional dietary advice based on the MyPlate guidelines.
88920618|NCT04612972|Experimental|Investigational vaccine 1. Wuhan|Inactivated SARS-CoV-2 vaccine (Vero cell); 200WU/dose for per human use, 0.5 mL/ dose; Intramuscular injection; Two doses: one dose/21-28 days; 4000 participants per arm
88920619|NCT04612972|Experimental|Investigational vaccine 2. Beijing|Inactivated SARS-CoV-2 vaccine (Vero cell); 4μg/dose for per human use, 0.5 mL/ dose; Intramuscular injection; Two doses: one dose/21-28 days; 4000 participants per arm
88920620|NCT04612972|Placebo Comparator|Placebo/Aluminum Adjuvant of Inactivated SARS CoV|Placebo/Aluminum Adjuvant of Inactivated SARS-CoV-2 vaccine; Active Ingredient: None; Virus Contents: None; Adjuvant: aluminum hydroxide; Specification: 0.5 mL/ dose, 0.5mL for per human use; Intramuscular injection; Two doses: one dose/21-28 days; 4000 participants per arm
88920621|NCT04586868|Experimental|A psychotic disorder|Patients, age 13-18 years old, diagnosed with a psychotic disorder (WHO ICD-10 )
89198758|NCT00676338|Active Comparator|Pioglitazone|
89436956|NCT04898946||CoronaVac|Subjects who receive inactivated vaccine, CoronaVac.
88920622|NCT04536766|Experimental|Enhanced Sleep Health Education|50 families will be randomly assigned to receive sleep health education delivered in two telephone sessions by Beds for Kids staff members, in addition to receiving the standard Beds for Kids program (bed, bedding, written sleep education materials). The first session will occur approximately 2-3 days before bed delivery. The second 15-20-minute session will occur approximately one week following bed delivery. Sleep health education training and supervision of Beds for Kids staff members will be provided by board-certified Behavioral Sleep Medicine providers. Sleep health information will be manualized and will consist of evidence-based pediatric sleep health behaviors: ensuring adequate sleep duration, developing a bedtime routine, keeping a regular sleep schedule, avoiding caffeine, and eliminating electronics in the bedroom and at bedtime. The enhanced sleep health intervention sessions will also include individualized problem-solving and tailoring to meet the family's needs.
88920623|NCT04536766|Active Comparator|Beds for Kids Standard Program|50 families will be randomly assigned to the standard Beds for Kids program, which includes a bed, bedding, and written sleep education materials.
88920624|NCT04534075|Experimental|Additional dietary fiber through Psyllium husk|The participants are allocated to intake the fifteen capsules per day, for example, five capsules three times per day. Altogether the fifteen capsules contains 5.5 g dietary fiber in psyllium husk.
88920625|NCT04534075|Placebo Comparator|Placebo (no additional dietary fiber)|The participants are allocated to intake the fifteen capsules per day, for example, five capsules three times per day. The capsules contain placebo (maltodextrin) and have a similar look as in the experimental arm.
89198759|NCT02534623|Active Comparator|Spinal anesthesia|Transurethral resection of the bladder performed under spinal anesthesia.
89198760|NCT02534623|Active Comparator|General anesthesia|Transurethral resection of the bladder performed under general anesthesia.
88920626|NCT04505878|Experimental|Vitamin C Arm|Ascorbic Acid will be administered at a dose of 1500 mg in 100 mL of saline over 30 minutes intravenously once every 6 hours for a total of 72 hours
88920627|NCT04505189|Experimental|Treatment|Psilocybin
88920628|NCT04496830|Experimental|Relapsing Remitting Multiple Sclerosis|"Blood sample collection~Vital signs, weight, height and BMI.~Complete neurological examination documented in NeurEx (recorded with an iPAD).~Clinical data questionnaire~25FW & non-dominant hand 9HPT (required for calculating CombiWISE & MS-DSS).~Smartphone Apps (include 25FW, SDMT and tests that correlate highly w 9HPT - can be acquired in patient-autonomous manner with minimal assistance).~Optical Coherence Tomography (OCT)~CSF Analysis"
88920629|NCT04496830|Experimental|Progressive Multiple Sclerosis|"Blood sample collection~Vital signs, weight, height and BMI.~Complete neurological examination documented in NeurEx (recorded with an iPAD).~Clinical data questionnaire~25FW & non-dominant hand 9HPT (required for calculating CombiWISE & MS-DSS).~Smartphone Apps (include 25FW, SDMT and tests that correlate highly w 9HPT - can be acquired in patient-autonomous manner with minimal assistance).~Optical Coherence Tomography (OCT)~CSF Analysis"
88920630|NCT04496830|Experimental|Non-Inflammatory Neurological Diseases|"Clinical data questionnaire~CSF Analysis"
88920631|NCT04496830|Experimental|Other Non-Inflammatory Neurological Diseases|"Clinical data questionnaire~CSF Analysis"
88920632|NCT04404881|Experimental|Bevacizumab|"The research study procedures include: screening for eligibility, pretreatment period, study treatment, end-of-study visit, and follow-up visit. Each period consists of 12 weeks, for a total of 36 weeks.~Pretreatment Period:Hematologic Support: iron transfusions and red cell transfusions as determined by study doctor.~Induction Period (first 3 months of bevacizumab treatment):~Hematologic Support: iron transfusions and red cell transfusions as determined by study doctor.~Bevacizumab: once every 2 weeks via intravenous infusion for up to 12 weeks.~Maintenance Period (second 3 months of bevacizumab treatment):~Hematologic Support: Iron transfusions and red cell transfusions as determined by study doctor.~Bevacizumab: once every 4 weeks via intravenous infusion for up to 12 weeks."
88920633|NCT04342325|Experimental|ADR-001|Intravenous infusion of ADR-001 (Mesenchymal stem cell)
88920634|NCT04335058|Experimental|Group A: Lactoferrin plus oral iron|Treated for 2 months regularly with oral administration of 100 mg Lactoferrin tablet twice a day before meals with oral administration of 100 mg of elemental iron capsules, one capsule twice daily on an empty stomach, at least 1 hour before or 2 hours after meals
88920635|NCT04335058|Active Comparator|Oral iron alone|Oral administration of 100 mg of elemental iron capsules, one capsule twice daily on an empty stomach, at least 1 hour before or 2 hours after meals
89198761|NCT00873795|Experimental|aripiprazole and sertraline|The patients of this arm receive ten weeks of treatment with a combination of sertraline 50mg/day and aripiprazole 2.5mg/day.The effect of this arm is assessed for HAM-D17, CGI, SF-36 and BSRS-50.
89436957|NCT04898465|Experimental|Social Paediatric Intervention|Multiprofessional social paediatric meeting with the family.
88920636|NCT04325594|Experimental|Main Group|Patients of the main group will undergo cardiac catheterization with intracoronary administration of 1×10 (7) umbilical cord-derived mesenchymal stromal cells and and will continue to receive optimal pharmacological therapy
88920637|NCT04325594|Active Comparator|Control Group|Patients in the control group will only have cardiac catheterization and will continue to receive optimal pharmacological therapy
88920638|NCT04319224|Experimental|Vopratelimab|Participants will continue to receive vopratelimab monotherapy per parent protocol.
88920639|NCT04319224|Experimental|Vopratelimab with ipilimumab|Participants will continue to receive vopratelimab in combination with ipilimumab per parent protocol.
88920640|NCT04319224|Experimental|Vopratelimab with nivolumab|Participants will continue to receive vopratelimab in combination with nivolumab per parent protocol.
88920641|NCT04318626|Other|PMPBB3|"Name: [18F] PMPBB3，[18F]1-Fluoro-3-((2-((1E,3E)-4-(6-(methylamino)pyridin-3-yl)buta-1,3-dien-1-yl)ben~Dosage form: intravenous injection~Dose(s): 7mCi~Dosing schedule: Visit 2~Mechanism of action (if known): high affinity radiotracer for the tau protein~Pharmacological category：Radio pharmaceutical"
88920642|NCT04318626|Other|THK|"Name: [18F]THK5351，(S)-6-[(3-Fluoro-2-hydroxy)propoxy]-2-(2-Methylaminopyrid-5-yl)-quinoline~Dosage form: intravenous injection~Dose(s): 10mCi~Dosing schedule: Visit 2~Mechanism of action (if known): high affinity radiotracer for the tau protein~Pharmacological category：Radio pharmaceutical"
88920643|NCT04309253|Other|PMPBB3|"Primary endpoint(s):~A. To determine the distribution patterns of cerebral amyloid plaques and Tau protein among AD/MCI, VCI and FTP patients as well as normal controls.~Secondary endpoints:~A. To correlate vascular burden, [18F]AV45 and [18F]MNI-958(PMPBB3) retention with clinical presentation and cognitive performance among different groups of subjects B. To determine the impacts of vascular burden, [18F]AV45 and [18F]MNI-958(PMPBB3) retention changes on cognitive trajectory over the 18-month follow-up period."
88920644|NCT04309253|Other|AV45|"Primary endpoint(s):~A. To determine the distribution patterns of cerebral amyloid plaques and Tau protein among AD/MCI, VCI and FTP patients as well as normal controls.~Secondary endpoints:~A. To correlate vascular burden, [18F]AV45 and [18F]MNI-958(PMPBB3) retention with clinical presentation and cognitive performance among different groups of subjects B. To determine the impacts of vascular burden, [18F]AV45 and [18F]MNI-958(PMPBB3) retention changes on cognitive trajectory over the 18-month follow-up period."
88920645|NCT04307589||Caregiving grandparents|
88920646|NCT04307589||Non-caregiving grandparents|
88920647|NCT04307589||Middle-aged and older adults not being a grandparent|
88920648|NCT04294693||Pediatric Population|The investigator intends to collect information on all total joint arthroplasty patients identified within the surgical practice of Dr. Nathan Donaldson for non-tumor related diagnoses at Children's Hospital Colorado.
88920649|NCT04257448|Experimental|Romidepsin/nab-Paclitaxel/Gemcitabine (Arm A)|Part 1a: Romidepsin (2 mg/m² or 3.3 mg/m² or 7 mg/m²) will be administered in combination with nab-Paclitaxel (125 mg/m²)/Gemcitabine (1000 mg/m²) on Day 1, Day 8 and Day 15 (every 28 days) of each treatment cycle. Study treatment is given until intolerable toxicity or will escalate until the recommended dose for expansion for a maximum of 3 cycles.
88920650|NCT04257448|Experimental|Azacitidine/nab-Paclitaxel/Gemcitabine (Arm B)|Part 1a: Azacitidine (20 mg/m² or 30 mg/m² or 40 mg/m²) will be administered on Days -7 to Day -3 of each treatment cycle. Additionally nab-Paclitaxel (125 mg/m²)/Gemcitabine (1000 mg/m²) will be given on Day 1, Day 8 and Day 15 (every 28 days) of each treatment cycle. Study treatment is given until intolerable toxicity or will escalate until the recommended dose for expansion for a maximum of 3 cycles.
88920651|NCT04257448|Experimental|Romidepin/Azacitidine/nab-Paclitaxel/Gemcitabine (Arm C)|Part 1a: The intervention to be administered depends on the determined dose in Arm A and Arm B. Additionally nab-Paclitaxel (125 mg/m²)/Gemcitabine (1000 mg/m²) will be given on Day 1, Day 8 and Day 15 (every 28 days) of each treatment cycle. Study treatment is given until intolerable toxicity or will escalate until the recommended dose for expansion for a maximum of 3 cycles.
88920652|NCT04257448|Active Comparator|nab-Paclitaxel/Gemcitabine (Standard Arm)|nab-Paclitaxel (125 mg/m²)/Gemcitabine (1000 mg/m²) will be administered on Day 1, Day 8 and Day 15 (every 28 days) of each treatment cycle.
88920653|NCT04257448|Experimental|Arm C or B or A|In Part 1b (expansion part) of the study, one of the treatment arms (Arm C over Arm B over Arm A) will be continued. Treatment will only be performed with the study drug that were tolerable in Part 1a (dose escalation).
88920654|NCT04257448|Experimental|Durvalumab/Lenalidomide|Part 2: All patients from Part 1 who have not progressed after three cycles receive standard fixed dose Durvalumab (1500 mg) on Day 1 of each 28-day treatment cycle by IV infusion in combination with orally administered low-dose Lenalidomide (10 mg) on Days 1 to 21 until documented disease progression. Study treatment is given for a maximum of 13 cycles.
88920655|NCT04221789|Experimental|intervention: TB treatment assistant|Patients receiving instructions to use phone application
88920656|NCT04221789|No Intervention|Control|Patients receiving instructions for usual care self administered treatment
88920657|NCT04195113||Direct Oral Anticoagulants (DOACs)|In this study, DOACs include apixaban, dabigatran, edoxaban and/or rivaroxaban.
88920658|NCT04195113||Vitamin K Antagonist (VKA)|In this study, the VKA is warfarin.
88920659|NCT04105751|Experimental|Use of Device with post-use interview/questionnaire|All patients will be asked to utilize device and will then be asked to provide feedback on their experiences. This may be done by interview or a questionnaire. There could be up to three sessions using the device. Each session is expected to last between 10 and 30 minutes. If the subject is interested in continuing, session could last up to one hour.
88920660|NCT04097756|Experimental|Part1：dose escalation|The investigational product for this study is LX-039 tablets,which can be administered orally. 6~8 ascending dose level until MTD and the specification included 50 mg, 100 mg, 200 mg, 400 mg, 600 mg , 800 mg,1050 mg and 1400 mg. LX-039 tablets will be administered in a therapeutic cycle of 28 days once a day orally. The subjects will continue therapy with LX-039 if good safety and tolerability were assessed by investigators after one cycle treatment. The treatment will continue until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
88920661|NCT04097756|Experimental|Part 2：dose expansion|2~3 selected tolerable dose will be selected according to the tolerance and FES PET results of dose escalation phase.The subjects will continue therapy with LX-039 if good safety and tolerability were assessed by investigators after one cycle treatment. The treatment will continue until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
88920662|NCT04093388|Experimental|Self-PAP|Each patient will participate in both arms of the study on the day of the clinical examination. This arm includes the self-administered Papanicolaou (Pap) smear. They will be compared to each other for congruence and accuracy.
88920663|NCT04093388|Experimental|Traditional Pap|Each patient will participate in both arms of the study on the day of the clinical examination. This arm includes the traditional, healthcare provider obtained Papanicolaou (Pap) smear specimen. They will be compared to each other for congruence and accuracy.
88920664|NCT04082234|Experimental|Integrated Individualized Behavioral Parent Training|Partnering to Achieve School Success (PASS) is a personalized, enhanced behavioral intervention for ADHD that includes evidence-based behavior therapy strategies and enhancements to promote family engagement in treatment, team-based care, and high quality therapy. Caregivers engage in up to 12 sessions with a behavioral health provider over the course of 16 weeks that are specifically tailored to caregiver goals and values.
88920665|NCT04082234|Active Comparator|Treatment as Usual|The control condition will be TAU informed by AAP guidelines for managing ADHD and facilitated by electronic practice supports, which have been successfully incorporated into the electronic health record (EHR) to guide primary care providers (PCPs) in implementing ADHD guidelines. At CHOP, PCPs across the primary care network were invited to participate in a distance learning, quality improvement initiative to promote implementation of AAP guidelines, including strategies to educate families about ADHD and evidence-based treatments, engage families in shared decision making, titrate medication, and monitor treatment effects. The six practices participating in this study participated in that project.
88920666|NCT04081454||Children with chronic pain|
88920667|NCT04081454||Caregivers of children with chronic pain|
88920668|NCT04055467|Other|[F18]-ASEM + Contingency Management|PET radiopharmaceutical 3-(1,4-diazabicyclo[3.2.2]nonan-4-yl)-6 [18F]fluorodibenzo[b,d]thiophene 5,5-dioxide with incentive payments.
88920669|NCT04006561||newly-diagnosed patients with primary CNS lymphoma|
88920670|NCT04004169|Experimental|Arm 1: Intervention (stimulation ON)|This is a crossover trial. Each patient will receive 6 wks of stimulation ON (arm 1), stimulation OFF (arm 2), and Stimulation ON Active Control (sham biomarker) (arm 3) in random order. After 6 months of intervening therapy, this 3-period crossover study will be repeated.
88920671|NCT04004169|Sham Comparator|Arm 2: Sham Control (stimulation OFF)|This is a crossover trial. Each patient will receive 6 wks of stimulation ON (arm 1), stimulation OFF (arm 2), and Stimulation ON Active Control (sham biomarker) (arm 3) in random order. After 6 months of intervening therapy, this 3-period crossover study will be repeated.
88920672|NCT04004169|Active Comparator|Arm 3: Active Control (stimulation ON triggered by sham biomarker)|This is a crossover trial. Each patient will receive 6 wks of stimulation ON (arm 1), stimulation OFF (arm 2), and stimulation ON Active Control (sham biomarker) (arm 3) in random order. After 6 months of intervening therapy, this 3-period crossover study will be repeated.
89436958|NCT04898465|No Intervention|Control group|Normal post-DGA dental programme.
89436959|NCT04895696|Experimental|Afimetoran: Dose 1|
88920673|NCT03999658|Experimental|Extranodal NK/T-cell lymphoma (ENKTL)|Intravenous STI-3031 (anti-PD-L1 antibody)
88920674|NCT03999658|Experimental|Peripheral T-cell lymphomas (PTCL)|Intravenous STI-3031 (anti-PD-L1 antibody)
88920675|NCT03999658|Experimental|Diffuse large B-cell lymphoma (DLBCL)|Intravenous STI-3031 (anti-PD-L1 antibody)
88920676|NCT03999658|Experimental|Biliary tract cancers (BTC)|Intravenous STI-3031 (anti-PD-L1 antibody)
88920677|NCT03959566|Active Comparator|Arm 1 (U0)|"Participants receive the following medication for the duration of 12 weeks (with Bedaquiline, Delamanid and Moxifloxacin as per licensed dose):~400 mg Bedaquiline orally once daily for the first 14 days, then 200 mg three times a week.~200 mg Delamanid orally in two daily doses of 100 mg.~400 mg Moxifloxacin orally once daily"
88920678|NCT03959566|Experimental|Arm 2 (U600)|"Participants receive the following medication for the duration of 12 weeks (with Bedaquiline, Delamanid and Moxifloxacin as per licensed dose):~400 mg Bedaquiline orally once daily for the first 14 days, then 200 mg three times a week.~200 mg Delamanid orally in two daily doses of 100 mg.~400 mg Moxifloxacin orally once daily~600 mg Sutezolid orally once daily"
88920679|NCT03959566|Experimental|Arm 3 (U1200)|"Participants receive the following medication for the duration of 12 weeks (with Bedaquiline, Delamanid and Moxifloxacin as per licensed dose):~400 mg Bedaquiline orally once daily for the first 14 days, then 200 mg three times a week.~200 mg Delamanid orally in two daily doses of 100 mg.~400 mg Moxifloxacin orally once daily~1200 mg Sutezolid orally once daily"
88920680|NCT03959566|Experimental|Arm 4 (U600BD)|"Participants receive the following medication for the duration of 12 weeks (with Bedaquiline, Delamanid and Moxifloxacin as per licensed dose):~400 mg Bedaquiline orally once daily for the first 14 days, then 200 mg three times a week.~200 mg Delamanid orally in two daily doses of 100 mg.~400 mg Moxifloxacin orally once daily~600 mg Sutezolid orally twice daily"
89436960|NCT04895696|Experimental|Afimetoran: Dose 2|
89436961|NCT04895696|Experimental|Afimetoran: Dose 3|
89436962|NCT04895696|Placebo Comparator|Placebo|
89436963|NCT04894006|Experimental|Home visit intervention by community health workers|The caregiver-centered, culturally and language specific home visit intervention with wearable devices (smartwatch/ring) will be delivered by trained bilingual community health workers (CHW) for Latino, Vietnamese, Korean, non-Hispanic White caregivers of PWD. The home visit intervention components will include (1) stress reduction techniques; mindful breathing and compassionate support/listening and (2) weekly education on dementia caregiving skills to handle difficult behaviors of PWD and knowledge of resources available for dementia care. The duration of the intervention will be 12 weeks that include 6 home visits (4 times for the first month and then once a month for two months) carried out in the participant's home. The on-site home visit intervention delivered by CHWs will focus on stress reduction techniques and caregiving skills education for 4 weeks and two monthly caregiver-driven topics for the following two sessions.
89198762|NCT00873795|Placebo Comparator|sertraline and placebo|The patients of this arm receive ten weeks of treatment with a combination of sertraline 50mg/day and placebo.The effect of this arm is assessed for HAM-D17, CGI, SF-36 and BSRS-50.
89436964|NCT04894006|Active Comparator|Attention Control with wearable smartwatch/ring|The caregivers randomly assigned to the Attention Control (AC) group will be asked to wear smartwatch during the day time and smart ring during the night for 3 months in order to monitor their physiological measures (heart rate variability, heart rate, activities, sleep quality). CHW will give AC participants an overview of WIOT instruction at the baseline home visit. Caregivers will also receive resource information regarding Alzheimer's association and local social service information. CHWs will contact them monthly via phone for 6 months asking about the WIoT technology and answering general questions from participants. CHW will also visit participants' home at baseline, 3 months, and 6 months to administer survey assessments.
89436965|NCT04894006|Placebo Comparator|Usual Care Group|The caregivers randomly assigned to Usual Care (UC) group will receive resource information regarding Alzheimer's association and local social service information at the baseline home visit by CHW. At recruitment, the participants will be told that at the end of the 6 months they will receive a smartwatch and a smartring for their participation. CHWs will contact them monthly for 6 months by phone answering only general questions from participants. CHW will also visit participants' home at baseline, 3 months, and 6 months to administer survey assessments.
89436966|NCT04883463|Experimental|Epidural Stimulation for Respiratory Function|Self-controlled longitudinal safety and feasibility of stimulation and respiratory training.
89436967|NCT04883190||1. after SARS-CoV-2 infection|"All participants in the study and control group of the FSC19-KN study will be contacted either by email or by post.~We plan to write to around 200-250 patients after SARS-CoV-2 infection and 200-250 test subjects in the control group."
89436968|NCT04883190||2. control group with negative antibody test|"All participants in the study and control group of the FSC19-KN study will be contacted either by email or by post.~We plan to write to around 200-250 patients after SARS-CoV-2 infection and 200-250 test subjects in the control group."
89436969|NCT04878510|Experimental|Dexmedetomidine Intervention|Patients randomized to the experimental arm will receive dexmedetomidine. At initiation, a bolus will NOT be administered. In keeping with Health Canada. Guidelines, the infusion will start at a mid-range dose of 0.6mcg/kg/h with titration either up or down by 0.1mcg/kg/h every 20-30 minutes to a maximum rate of 1.2mcg/kg/h to maintain light sedation (Richmond Agitation-Sedation Scale [RASS] = -2 to +1 or Riker Sedation-Agitation Scale [SAS] 3-4).
89436970|NCT04878510|Placebo Comparator|Control Intervention|Those in the control group will receive a placebo that is identical in colour and packaging and at equal volume to the intervention group. Each bag of placebo contains 50mL of 0.9% sodium chloride and labeled as per Health Canada guidance for labelling pharmaceutical drugs for use in humans.
89536605|NCT05217563|No Intervention|Standard Care|Standard Care Control Group (Group 1). Parents in the standard care control group will receive a pamphlet containing evidence-based information on needle pain management. Parents in the standard care control group will not receive any information regarding pain memory reframing, nor will they be encouraged to talk about their children's pain vaccine injection experience. Parents in the standard care control group will receive text/email reminders to use needle pain management strategies before each second vaccination appointment.
88920681|NCT03959566|Experimental|Arm 5 (U800BD)|"Participants receive the following medication for the duration of 12 weeks (with Bedaquiline, Delamanid and Moxifloxacin as per licensed dose):~400 mg Bedaquiline orally once daily for the first 14 days, then 200 mg three times a week.~200 mg Delamanid orally in two daily doses of 100 mg.~400 mg Moxifloxacin orally once daily~800 mg Sutezolid orally twice daily~2 mg Midazolam orally once per day on day-1 and day 14"
88920682|NCT03948295|Experimental|Lipid Challenge Intervention|Participants of all weights will receive the lipid challenge intervention.
88920683|NCT03946163|Experimental|first group|each patient will receive sixty capsules, each capsule contained 1gm of cinnamon bark powder and instructed to use it twice daily for one month
88920684|NCT03946163|Placebo Comparator|second group|each patient will receive sixty capsules, each capsule contained placebo and instructed to use it twice daily for one month
89436971|NCT04878198|Experimental|Jogging intervention|This intervention will be a 10-week jogging program consisting of 50 sessions (5 sessions per week, 30 min per session) in each participating school. The jogging program is confined to morning sessions based on the favourable sleep outcomes from previous study. To counteract the possible influence of natural sunlight exposure, all jogging sessions will be confined to indoor setting. Each session will be conducted in an identical format with 5 minutes of warm-up activities, followed by 20 minutes of jogging (intervention), and 5 minutes of cool-down activities. Participants are instructed to jog at a moderate intensity level. The intensity level of jogging will be measured by heart rate monitor (Polar H1). Meanwhile, questionnaire will be given to the research staff assisting the jogging intervention to assess the adherence of the intervention at T2.
89436972|NCT04878198|Experimental|Melatonin supplement group|Participants in this intervention group will undergo a 10-week melatonin supplement intervention period, where melatonin supplement (Natrol®, Chatsworth CA) will be provided 30 minutes before bedtime. The prescription time (i.e. 30 minutes before bedtime) and the dosage of 3mg will be used because these are optimal for most of the participants as suggested by Malow and colleagues. 1 mg and 9 mg are not suggested to ensure the effectiveness of the intervention while preventing the potential daytime sleepiness. Similar to the aforementioned intervention, adherence of the intervention will be assessed at T2.
89436973|NCT04878198|Experimental|Combination group|Participants will receive the jogging program and supplemental melatonin dose with identical format as that in the intervention A and B (e.g., identical duration, identical manpower, identical warm-up and cool-down, identical dose, identical acclimation procedure before the intervention adherence of the intervention for this group will also be assessed at T2.
89436974|NCT04878198|No Intervention|Control group|Participants in the placebo control group will receive no jogging and melatonin supplement dosing activity. However, they will be given a placebo flavored similar to the melatonin supplement (compounded by Pharmacare, Mt. Juliet, NT®). Meanwhile, they will also be required to wear an actigraph to control for their physical activity level at the assessment points (i.e. T1, T2, and T3). They will be expected for following their daily routine without participating in any additional formal physical exercise training program throughout the whole study period (T1-T3). After T3, they will be assisted with jogging program to recognize their contribution as controls.
89436975|NCT04877093|Experimental|Clonidine Phase|Participants will receive clonidine titrations across 6 weeks. Note that this is a crossover design, so patients will move across phases.
89436976|NCT04877093|Placebo Comparator|Placebo Phase|Participants will receive placebo titrations across 6 weeks. Note that this is a crossover design, so patients will move across phases.
89436977|NCT04873362|Active Comparator|Arm A: Placebo + Trastuzumab Emtansine|Participants will receive an intravenous (IV) infusion of placebo prior to the IV infusion of trastuzumab emtansine on Day 1 of each 21-day cycle for a total of 14 cycles.
88920685|NCT03909529|Experimental|LANOXIN® (Digoxin) USP 250 mcg (substrate drug) {Treatment A}|"14 Subjects first administered with LANOXIN® (digoxin) USP 250 mcg (Substrate drug) on Day 6 of in house, after overnight fasting of at least 10.00 hours.~After washout period of 28 days, these 14 subjects were administered with Spironolactone Oral Suspension 100 mg (perpetrator, Carospir® Oral Suspension 20 mL of 25 mg / 5 mL) from day 1 to day 5 and on day 6 the after overnight fasting of at least 10.00 hours, subject was administered with LANOXIN® (digoxin) USP 250 mcg (substrate drug) + Spironolactone Oral Suspension 100 mg (perpetrator; Carospir® Oral Suspension 20 mL of 25 mg / 5 mL). From day 7 to day 9 the subjects were administered with Spironolactone Oral Suspension 100 mg (perpetrator; Carospir® Oral Suspension 20 mL of 25 mg / 5 mL)."
88920686|NCT03909529|Experimental|LANOXIN® (Digoxin) USP 250mcg and Carospir® Oral Suspension 20mL of 25 mg/5mL-Treatment B|"14 Subjects first administered with Spironolactone Oral Suspension 100 mg (perpetrator, Carospir® Oral Suspension 20 mL of 25 mg / 5 mL) from day 1 to day 5 and on day 6 the after overnight fasting of at least 10.00 hours, subject was administered with LANOXIN® (digoxin) USP 250 mcg (substrate drug) + Spironolactone Oral Suspension 100 mg (perpetrator; Carospir® Oral Suspension 20 mL of 25 mg / 5 mL). From day 7 to day 9 the subjects were administered with Spironolactone Oral Suspension 100 mg (perpetrator; Carospir® Oral Suspension 20 mL of 25 mg / 5 mL).~After washout period of 28 days these 14 Subjects administered with LANOXIN® (digoxin) USP 250 mcg (Substrate drug) on Day 6 of in house, after overnight fasting of at least 10.00 hours"
88920687|NCT03884517|Experimental|BAT8003 0.2mg/kg|BAT8003，0.2mg/kg，intravenous infusion, sample size 1-3
88920688|NCT03884517|Experimental|BAT8003 0.5mg/kg|BAT8003，0.5mg/kg，intravenous infusion, sample size 1-3
88920689|NCT03884517|Experimental|BAT8003 1mg/kg|BAT8003，1mg/kg，intravenous infusion, sample size 3
88920690|NCT03884517|Experimental|BAT8003 2mg/kg|BAT8003，2mg/kg，intravenous infusion, sample size 3
88920691|NCT03884517|Experimental|BAT8003 4mg/kg|BAT8003，4mg/kg，intravenous infusion, sample size 3
88920692|NCT03884517|Experimental|BAT8003 6mg/kg|BAT8003，6mg/kg，intravenous infusion, sample size 3
88920693|NCT03884517|Experimental|BAT8003 8mg/kg|BAT8003，8mg/kg，intravenous infusion, sample size 3
88920694|NCT03884517|Experimental|BAT8003 10mg/kg|BAT8003，10mg/kg，intravenous infusion, sample size 3
88920695|NCT03884517|Experimental|Amplification group|BAT8003，intravenous infusion，choose one proper dose from 0.2、0.5、1、2、4、6、8、10mg/kg
88920696|NCT03875755|Experimental|Myo Inositol|The women will receive 2 caps of Myo Inositol with acid folic a day, until delivery
88920697|NCT03875755|Placebo Comparator|Placebo|The women will receive 2 caps of placebo (acid folic) a day, until delivery
88920698|NCT03819686|Experimental|Living ACTS website|In addition to the provision of standard transplant education procedures, a patient will watch the Living ACTS video (embedded in the Living ACTS website) along with any family members or friends who are accompanying a patient. Plus minimum of 5 minutes navigating the website (aside from watching the 20-minute video).
89011201|NCT03801330|Active Comparator|Usual Care|Participants in the Usual Care Pulmonary Rehabilitation will receive usual care pulmonary rehab program. Usual care programs typically consist of exercises including upper extremity strengthening, lower extremity strengthening, aerobic exercises such as walking and balance training. Each program is personalized as per the participant's ability. The intervention is usual care exercise and education, which is personalized for each participant. No drugs are being tested in this study.
89436978|NCT04873362|Experimental|Arm B: Atezolizumab + Trastuzumab Emtansine|Participants will receive an IV infusion of atezolizumab prior to the IV infusion of trastuzumab emtansine on Day 1 of each 21-day cycle for a total of 14 cycles.
89436979|NCT04848740|Other|FRESH CORNEAL LENTICULE IMPLANTATION|"The aim in our study is to describe the importance of stroma as criteria of corneal thickness at implanting human fresh corneal lenticule in progressive corneal disease.~We have conclude that every biomechanical instability of corneal stroma function(abnormal increase collagen activity,decrease proteinase inhibitors,excessive premature keratocyte apoptosis) describe the role of stroma in corneal thickness."
89436980|NCT04846569|Experimental|Transition Theory-based Intervention|Participants in the intervention arm will receive the Transition Theory-based intervention consisting of 4 sessions with a community health worker (2 during pregnancy, 2 postpartum) to support their transition from pregnancy to postpartum.
89436981|NCT04846569|Active Comparator|Enhanced Standard of Care Control|Participants in the control arm will receive the standard of care plus one session with a community health worker.
89436982|NCT04844827||malignant pleural effusion|Patients with malignant pleural effusion who underwent pleural biopsies and blood tests under general anesthesia
88920699|NCT03819686|Other|Standard transplant education procedures|Usual Care, which involves the provision of standard transplant education procedures at each transplant center, which entail reviewing a packet of information with the pre-transplant coordinator. The packet serves to inform transplant candidates and their families about the option living donor kidney transplantation (LDKT). In addition, participants will be provided an iPad/tablet to watch two 10-minute National Kidney Foundation videos about kidney disease and transplantation in their private room during their regularly scheduled KT evaluation. This video discusses information about transplant, but does not specifically address LDKT and is not culturally-sensitive to African American population.
88920700|NCT03794323|Experimental|SRD part: BI 764122 4 mg|4 uncoated tablets of 1 milligram (mg) BI 764122 (total: 4 mg) were administered as single oral dose with 240 milliliter (mL) of water after an overnight fast of at least 10 hours (h). Single rising dose (SRD) part.
88920701|NCT03794323|Experimental|SRD part: BI 764122 12 mg|1 film-coated tablet of 10 mg and 2 uncoated tablets of 1 mg BI 764122 (total: 12 mg) were administered as single oral dose with 240 mL of water after an overnight fast of at least 10 h. SRD part.
88920702|NCT03794323|Experimental|SRD part: BI 764122 25 mg|2 film-coated tablets of 10 mg and 5 uncoated tablets of 1 mg BI 764122 (total: 25 mg) were administered as single oral dose with 240 mL of water after an overnight fast of at least 10 h. SRD part.
88920703|NCT03794323|Experimental|SRD part: BI 764122 50 mg|5 film-coated tablets of 10 mg BI 764122 (total 50 mg) were administered as single oral dose with 240 mL of water after an overnight fast of at least 10 h. SRD part.
88920704|NCT03794323|Experimental|SRD part: BI 764122 100 mg|1 film-coated tablet of 100 mg BI 764122 (total: 100 mg) was administered as single oral dose with 240 mL of water after an overnight fast of at least 10 h. SRD part.
88920705|NCT03794323|Experimental|SRD part: BI 764122 200 mg|2 film-coated tablets of 100 mg BI 764122 (total: 200 mg) were administered as single oral dose with 240 mL of water after an overnight fast of at least 10 h. SRD part.
88920706|NCT03794323|Experimental|SRD part: BI 764122 300 mg|3 film-coated tablets of 100 mg BI 764122 (total: 300 mg) were administered as single oral dose with 240 mL of water after an overnight fast of at least 10 h. SRD part.
88920707|NCT03794323|Experimental|SRD part: BI 764122 400 mg|4 film-coated tablets of 100 mg BI 764122 (total: 400 mg) were administered as single oral dose with 240 mL of water after an overnight fast of at least 10 h. SRD part.
89198763|NCT00382291|Experimental|Regular Titration|Regular titration of Sertraline plus cognitive behavioral therapy. The titration schedule used a flexible upward titration from 25 mg/day to 200 mg/day over 9 weeks unless higher doses were not tolerated, after which the dosage was adjusted as a function of tolerability. If tolerated, maximum dose could be achieved in 5 weeks.
89198764|NCT00382291|Placebo Comparator|Placebo|Placebo plus cognitive behavioral therapy
89198765|NCT00382291|Experimental|Slow Titration|Slow titration of Sertraline plus cognitive behavior therapy. The titration schedule utilized a slower titration schedule relative to the RegSert arm. Unless unable to tolerate higher doses, children remained on 25mg/day for the first two weeks, 50mg/day from weeks 3-4, 75mg/day for weeks 5-6, 100mg/day for week 7, 150mg/day for week 8, and 200mg/day for week 9 until the end of the study.
89436983|NCT04829669||Participants with Major Depressive Disorder (MDD) and Active Suicidal Ideation with Intent|Participants with MDD (moderate or severe) and active suicidal ideation with intent as defined/confirmed by healthcare team will be enrolled and treated in accordance with routine clinical practice. The primary data source for this study will be the medical chart review, carer and clinician-reported outcome measures records of each participant.
89436984|NCT04821089|Experimental|IPN10200 group|Several cohorts of participants will be randomized in a ratio of 3:1 in a dose-escalation manner. The decision to escalate to the next dose for each cohort will be based on Data Monitoring Committee recommendation.
88920708|NCT03794323|Experimental|FE part: BI 764122 50 mg fasted/ BI 764122 50 mg fed|5 film-coated tablets of 10 mg BI 764122 (total: 50 mg) were administered as single oral dose with 240 mL water after an overnight fast of at least 10 h, followed by wash-out period of at least 7 days followed by 5 film-coated tablets of 10 mg BI 764122 (total: 50 mg) administered as single oral dose with 240 mL water after a standardized high-fat, high-calorie breakfast. Food effect (FE) part.
88920709|NCT03794323|Experimental|FE part: BI 764122 50 mg fed/ BI 764122 50 mg fasted|5 film-coated tablets of 10 mg BI 764122 (total: 50 mg) were administered as single oral dose with 240 mL water after a standardized high-fat, high-calorie breakfast, followed by wash-out period of at least 7 days followed by 5 film-coated tablets of 10 mg BI 764122 (total: 50 mg) administered as single oral dose with 240 mL water after an overnight fast of at least 10 h. FE part.
88920710|NCT03794323|Placebo Comparator|Placebo|placebo matching in size and weight to corresponding uncoated or film-coated BI 764122 tablets were administered as single oral dose with 240 milliliter (mL) of water after an overnight fast of at least 10 hours (h). Single rising dose (SRD) part.
88920711|NCT03763942|Experimental|HealthMindr App|Participants in the intervention arm will receive access to all HealthMindr app capabilities. The app information will cover the importance of testing, links to HIV prevention resources, resources to locate HIV testing and PrEP services, the Substance Abuse and Mental Health Services Administration (SAMHSA) substance abuse treatment resource locator, and other prevention information specific to their area.
88920712|NCT03763942|Placebo Comparator|Control App|Participants in the control arm will be directed to download a study app that allows study staff to interact with them.
89436985|NCT04821089|Placebo Comparator|Placebo group|Several cohorts of participants will be randomized in a ratio of 3:1 in a dose-escalation manner. The decision to escalate to the next dose for each cohort will be based on Data Monitoring Committee recommendation.
89436986|NCT04821089|Active Comparator|Dysport group (stage 1 / step 2 only)|
88920713|NCT03736707|Experimental|Selective HFOV|Selective HFOV will be provided
88920714|NCT03736707|Active Comparator|CMV|CMV will be provided
89436987|NCT04815187|Experimental|Montelukast 10 mg|Subjects will be instructed to take one pill at night for 90 days
89436988|NCT04815187|Placebo Comparator|Placebo|Subjects will be instructed to take one pill at night for 90 days
89436989|NCT04814134|Experimental|CPNS Therapy|Treatment with CPNS system: Endovascular stimulation of the cardiac autonomic nerves in addition to standard of care
89436990|NCT04814134|Other|Standard of Care|Available standard treatment
89436991|NCT04812366|Active Comparator|Group 1a|LHRHa plus apalutamide.
89436992|NCT04812366|Active Comparator|Group 1b|LHRHa plus apalutamide plus abiraterone acetate plus prednisone.
89436993|NCT04812366|Active Comparator|Group 2a|LHRHa plus abiraterone acetate plus prednisone.
89436994|NCT04812366|Active Comparator|Group 2b|LHRHa plus abiraterone acetate plus prednisone plus docetaxel.
89436995|NCT04812366|Active Comparator|Group 3|LHRHa plus abiraterone acetate plus prednisone plus niraparib
89436996|NCT04812366|Active Comparator|Group 4|LHRHa plus apalutamide plus atezolizumab
89436997|NCT04799015|Experimental|Dexamethasone|Dexamethasone 10mg IV + metoclopramide 10mg IV
89436998|NCT04799015|Placebo Comparator|Placebo|Placebo IV + metoclopramide 10mg IV
89436999|NCT04798768|Experimental|Patients implanted with S-ICD and leadless cardiac pacemaker|Patients implanted with an S-ICD and leadless cardiac pacemaker that complete intended testing based on the study protocol
89437000|NCT04790903|Experimental|Venetoclax (Schedule A)|"Participants enrolled in dosing Schedule A will receive a total of six 21-day cycles of venetoclax treatment for 5 days in combination with Polatuzumab Vedotin + R-CHP (Rituximab, Cyclophosphamide, Doxorubicin and Prednisone) as described below:~Schedule A: Participants will self-administer Venetoclax orally (PO) once daily (QD) at a dose of 800 mg for 5 consecutive days as follows:~Cycle 1: 5 consecutive days of dosing on Days 4-8. Cycles 2-6: 5 consecutive days of dosing on Days 1-5."
89437001|NCT04790903|Experimental|Venetoclax (Schedule B)|"Participants enrolled in dosing Schedule B will receive a total of six 21-day cycles of venetoclax treatment for 10 days in combination with Polatuzumab Vedotin + R-CHP as described below:~Schedule B: Participants will self-administer Venetoclax orally (PO) once daily (QD) at a dose of 800 mg for 10 consecutive days as follows:~Cycle 1: 10 consecutive days of dosing on Days 4-10. Cycles 2-6: 10 consecutive days of dosing on Days 1-10."
89437002|NCT04784416|Experimental|Transcranial Photobiomodulation (t-PBM)|
89437003|NCT04784416|Sham Comparator|Sham|
89437004|NCT04783779|Experimental|STARgraft-2|Participants will be implanted with 6mm diameter STARgraft-2 grafts as an upper arm Brachial Artery to Axillary Vein shunt for hemodialysis access.
89437005|NCT04775719|Other|Outcome Prediction Group|Patient-Specific Prediction of Functional Outcome and Standard Pre-Operative Total Knee Arthroplasty Information
89437006|NCT04775719|Other|Standard Care Group|Standard Pre-Operative Total Knee Arthroplasty Information
89437007|NCT04774913|Experimental|Invest CTO PCI|A pre-planned two staged procedure in high-risk CTO PCI
89437008|NCT04773509|Active Comparator|PVB group|Patients of the PVB group are performed PVB with 0.2% ropivacaine on both sides
89437009|NCT04773509|No Intervention|Control group|PVB are not performed in the control group.
89437010|NCT04770142|Experimental|TIRA|treated with transcatheter RF ablation system (TIRA catheter with its supplemental devices)
88920715|NCT03727906|Other|Non-insomnia Group|"Non-insomnia participants will not meet criteria for current DSM-5 Insomnia Disorder or have a past history of insomnia.~Interventions (order is randomly assigned):~no pre-sleep arousal manipulation night;~pre-sleep arousal down-regulation night~pre-sleep arousal up-regulation night."
88920716|NCT03727906|Other|Insomnia Group|"Insomnia Group participants will have to meet DSM-5 criteria for current Insomnia Disorder.~Interventions (order is randomly assigned):~no pre-sleep arousal manipulation night;~pre-sleep arousal down-regulation night~pre-sleep arousal up-regulation night."
88920717|NCT03704805|Experimental|Problem-Solving Therapy|Participants in the intervention group receive the friendship bench intervention in addition to all services provided according to enhanced standard of care.
88920718|NCT03704805|Active Comparator|Enhanced Standard of Care|Participants in the control group receive enhanced standard of care.
88920719|NCT03667079|Experimental|Integrated|Intervention 'integrated delivery of deworming and vaccination' will be delivered to this arm of the study
88920720|NCT03667079|Active Comparator|Deworming only|Intervention 'Mass deworming only' will be delivered to villages in this arm of the study
89437011|NCT04764214|Experimental|3rd generation EGFR-TKI+ SRT|Patients were treated with the intent to ablate all residual disease with consolidative SRT. EGFR-TKI treatment was continued during and after consolidative SRT until disease progression or intolerable toxicity.
89437012|NCT04759625|Experimental|Biscuit enriched with mushroom powder|Daily consumption of a novel biscuit enriched with mushroom powder containing 3g of β-glucans
89437013|NCT04759625|Placebo Comparator|Placebo biscuit|Daily consumption of a placebo biscuit
89437014|NCT04758247|Active Comparator|Active|
89437015|NCT04758247|Sham Comparator|Sham|
89437016|NCT04753073|Experimental|NIPP|Treatment of the NIPP group with physical low-temperature plasma, subsequently within 8 weeks LEEP-Exzision
89437017|NCT04753073|No Intervention|Controll|LEEP-Exzision
89437018|NCT04751929|Experimental|Biomarker-Unselected Abemaciclib Monotherapy (Randomized)|"Participants in the Biomarker-Unselected Cohort, defined as those whose tumors are not known to have mutations in the CDK12 gene will be randomized to either receive Abemaciclib as monotherapy or in combination with Atezolizumab~Monotherapy : Participants will receive Abemaciclib orally 2x daily"
88920721|NCT03667079|Active Comparator|Rabies vaccination only|Villages assigned to this arm received mass vaccination of dogs against rabies only
89437019|NCT04751929|Experimental|Biomarker-Unselected Abemaciclib + Atezolizumab (Randomized)|"Participants in the Biomarker-Unselected Cohort, defined as those whose tumors are not known to have mutations in the CDK12 gene will be randomized to either receive Abemaciclib as monotherapy or in combination with Atezolizumab~Combination Therapy: Participants will receive Abemaciclib orally 2x daily and Atezolizumab intravenously Day 1 of each 21-Day cycle"
89437020|NCT04751929|Experimental|CDK12 Mutation Atezolizumab Monotherapy (Non-Randomized)|"Participants in the CDK12 Mutation Cohort defined as those whose tumors are known to have mutations in the CDK12 gene are not randomized but are assigned to receive either Atezolizumab monotherapy or in combination with Abemaciclib based on how many participants in this cohort previously received study treatment.~Atezolizumab monotherapy will be given to participants 1-5, these participants will receive Atezolizumab intravenously Day 1 of each 21-Day cycle"
89437021|NCT04751929|Experimental|CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized)|"Participants in the CDK12 Mutation Cohort defined as those whose tumors are known to have mutations in the CDK12 gene are not randomized but are assigned to receive either Atezolizumab monotherapy or in combination with Abemaciclib based on how many participants in this cohort previously received study treatment.~Combination Therapy will be given to participants 6-21, these participants will receive Abemaciclib orally 2x daily and Atezolizumab intravenously Day 1 of each 21-Day cycle"
89437022|NCT04750798||Participants Diagnosed with Cardiac Arrhythmias|Patients diagnosed with cardiac arrhythmias who are scheduled to undergo an ablation procedure in routine clinical practice for management of their arrhythmia with a BWI therapeutic catheter will be observed.
89437023|NCT04750499|Experimental|Treatment|Patients with complex anal fistulas, non related to Crohn's disease.
88920722|NCT03630003|Experimental|Use of MOCS with post-use interview|"The patients in this arm will be asked to utilize the Manually Operated Communication System (MOCS) device and will then be asked to provide feedback on their experiences.~Subjects will be asked to complete up to 3 sessions using the device. Each session is expected to last between 10 and 30 minutes. If the subject is interested in continuing, the session may last up to one hour.~The study team will perform post-study interviews with each subject to ask about their experience with MOCS. The data collection forms will be filled out during the session by a member of the research team."
89437024|NCT04745299|Experimental|Single cycle administration group|Study drug injections twice in a 26-day interval followed by three times comparator injections every three months.
89437025|NCT04745299|Experimental|Multiple administation group|Study drug injections twice in a 26-day interval followed by repeated three times study drug injections every three months.
89437026|NCT04745299|Placebo Comparator|Control group|Comparator injections twice in a 26-day interval followed by three times comparator injections every three months.
89437027|NCT04741802|Experimental|TOPS|weight loss program (Take Off Pounds Sensibly, TOPS) for overweight and obese African American breast cancer survivors
89437028|NCT04733040|Experimental|MOR202 Arm 1|5 doses administered on Day 1, 8, 15, 29, and 57
89437029|NCT04733040|Experimental|MOR202 Arm 2|2 doses administered on Day 1 and 15
89437030|NCT04732156|Other|Prospective multicenter cohort|"Constitution of a prospective multicenter cohort of 420 patients with suspected prostate cancer that will undergo prostate multiparametric MRI followed by systematic and targeted biopsy.~When available (i.e., at the end of the RHU PERFUSE program, November 2022), the final version of the CAD will be used retrospectively to assess the risk that the prostate/targeted lesions harbor ISUP ≥2 cancer.~In addition, a blood sample will be taken in all patients before the biopsy to assess the performance of the PHI index in predicting the presence of ISUP ≥2 cancer at systematic and targeted biopsy (ancillary study, secondary objective)."
89437031|NCT04729387|Experimental|Alpelisib+olaparib|Alpelisib 200 mg orally once daily and olaparib 200 mg orally twice daily on a continuous dosing schedule.
89437032|NCT04729387|Active Comparator|Paclitaxel or PLD|Investigator's choice of one of 2 single agent cytotoxic chemotherapies: Paclitaxel 80 mg/m2 intravenously weekly or Pegylated liposomal Doxorubicin (PLD) 40-50 mg/m2 (physician discretion) intravenously every 28 days.
89437033|NCT04724434||Study group|Patients with positive test for SARS-CoV-2 by PCR
89437034|NCT04724434||Control group|Patients with negative SARS-CoV-2 antibody test
89437035|NCT04715542|Experimental|Stibium metallicum praeparatum 6x|Patients are treated with Stibium metallicum praeparatum 6x (subcutaneus injection), which is authorized in Switzerland and is listed by Swissmedic as an authorized anthroposophic medicinal product.
89437036|NCT04715542|Placebo Comparator|Saline subcutaneous injection|Placebo (a saline subcutaneous injection) is chosen as comparator to the treatment group.
89437037|NCT04713085|Active Comparator|Sacral Neuromodulation|"Sacral neuromodulation is surgically implanted within two surgeries:~Implantation of the final electrode (tined-lead electrode): This electrode is implanted to neuronal fibers of S3/4. Both sides are tested intraoperatively, the side with a sufficient response at lower intensity levels is finally implanted. Stimulation is conducted via an external pulse generator.~Implantation of the internal pacemaker system 4 weeks after the electrode's implantation.~Stimulation parameters: Single current, frequency 15Hz, duration 210μs. Stimulation intensity is individually determined beyond the pain threshold (adjustable amplitude between 0-10mA, depending on the intraoperative response).~Start point of clinical evaluation is time of implantation of tined lead electrode.~Medical and behavioral therapy is to be continued as started before intervention."
89437038|NCT04713085|Active Comparator|Non-invasive Sacral Neuromodulation|"Two adhesive electrodes are placed paravertebrally between L1 and L4 and periumbilically, generating an electrical field by single current with a 15 Hz frequency for a duration of 210μs. Stimulation intensity is individually determined to achieve an effective and comfortable stimulation beyond the pain threshold (adjustable amplitude between 0-10mA).~Start point of clinical evaluation is start of external stimulation.~Medical and behavioral therapy is to be continued as started before intervention."
89437039|NCT04698031|Experimental|Clopidogrel|"After randomization, patients will receive clopidogrel mg daily for the duration of the study. The VA Research Pharmacy will dispense similar looking pills (using a dummy pill) with Arm 2 to ensure the double-blind nature of the intervention. Clopidogrel is FDA approved for secondary prevention of stroke. Patients will be followed for 24 months with repeat brain MRI scans obtained at 24 months."
89437040|NCT04698031|Experimental|Aspirin|"After randomization, patients will receive aspirin daily for the duration of the study. The VA Research Pharmacy will dispense similar looking pills (using a dummy pill) with Arm 1 to ensure the double-blind nature of the intervention. Aspirin is FDA approved for secondary prevention of stroke. Patients will be followed for 24 months with repeat brain MRI scans obtained at 24 months."
89437041|NCT04697095|Experimental|early / intermediate AMD without neovessels and without macular atrophy|
89437042|NCT04697095|Experimental|Late exsudative AMD with neovessels|
89437043|NCT04697095|Experimental|Late AMD with macular atrophy without neovessels|
89437044|NCT04697095|Sham Comparator|Patientes with No AMD|
89437045|NCT04696744||CTCO|adults with squamous cell carcinoma of the oropharynx with a curative aim
89437046|NCT04695366||Diffuse large B-cell lymphoma patients in year 1 and 2 of clinical follow-up|Patients (Diffuse Large B-cell Lymphoma) in complete remission after primary treatment and entering the regular follow-up program at the clinic. Baseline is defined as date of end-of-treatment visit.
89437047|NCT04694690|Experimental|RelyX U200 Automix Self Adhesive Resin Cement|Self Adhesive Resin Cement
89437048|NCT04694690|Active Comparator|G-Cem LinkForce Resin Cement|Resin Cement system used after surface treatment
88920723|NCT03617939||Biospeciman and Data Collection|Patients with cancer or who are at risk of having cancer who have given consent to have blood, tissue, other biological samples and their associated data (survey data, medical records data, cancer registry data, and other related data) collected and stored for the advancement of medicine.
88920724|NCT03603145|Experimental|Immediate insertion|Randomized to insertion within 48 hours of medical abortion
88920725|NCT03603145|No Intervention|Standard Insertion|Insertion at 2-4 weeks post medical abortion
88920726|NCT03591796|Experimental|HFOV|Ventilated infants were randomized to HFOV.
88920727|NCT03591796|Active Comparator|CMV|Ventilated infants were randomized to CMV.
88920728|NCT03537183|No Intervention|Usual activity level|12 weeks of usual activity level
88920729|NCT03537183|Active Comparator|Exercise training|12 weeks of moderate intensity exercise training, 3 hours a week
88920730|NCT03534050|Experimental|postoperative adjuvant RT|In this prospective observational study, all potentially eligible patients are clinically indicated for receiving postoperative adjuvant RT. Namely, partial cranial irradiation will be initiated within one month approximately after enrollment. Prescription dose will be 5000 - 6000 cGy in 25 - 30 fraction during 5 - 7 weeks.
88920731|NCT03380546|Experimental|acarbose|The women will receive acarbose with a progressive increase of dose according to post prandial glucose values and digestive tolerance, with a maximal dose of 3 x 100 mg /day
88920732|NCT03380546|Active Comparator|prandial insulin|The women will receive prandial insulin according to usual practice (routine care according to French recommendations): before each meal, with dose titration according to post prandial values.
89198766|NCT00873951|Experimental|Intact casein|Subjects undergo an intestinal and metabolic exploration following the ingestion of a standard mixed meal containing 15% of energy as 15N-labelled intact casein
89437049|NCT04684706|Other|Compressed iTBS schedule|Stimulation 3-pulse 50-Hz bursts at 5-Hz for 2-s trains, with trains every 10 s, for 10 minutes, 10 times a day, for 5 consecutive days.
88920733|NCT03378063|Experimental|transplantation of mesenchymal stem cell|transplantation of mesenchymal stem cell will be given to the infants with BPD.
88920734|NCT03378063|Active Comparator|no transplantation of mesenchymal stem cell|transplantation of mesenchymal stem cell will be not given to the infants with BPD.
88920735|NCT03329157|Other|Rebuilding Bridges|This is a one-group study and the group will receive the Rebuilding Bridges intervention
88920736|NCT03321929|Experimental|LUM Imaging System|Single dose of LUM015 (1.0 mg/kg) will be administered by intravenous injection between 2 to 6 hours prior to surgery. All subjects undergo lumpectomy as standard of care and will have the study intervention, guidance by intraoperative imaging using the LUM Imaging Device
88920737|NCT03318094|Placebo Comparator|Intact Day|Saline
88920738|NCT03318094|Experimental|Blocked Day|Phentolamine
88920739|NCT03318094|Active Comparator|Vasodilator Comparison|Sodium Nitroprusside
88920740|NCT03268499|Active Comparator|Lipiodol-cisplatin suspension|
88920741|NCT03268499|Active Comparator|Lipiodol-cisplatin emulsion|
88920742|NCT03250624|Experimental|CD5024 0.3% cream|
88920743|NCT03250624|Placebo Comparator|Placebo|
89437050|NCT04680026|Experimental|Drug: HBI-3000, Stage A Dose Level 1|Stage A Open Label HBI-3000 Dose Level 1: 200 mg
89437051|NCT04680026|Experimental|Drug: HBI-3000, Stage A Dose Level 2|Stage A Open Label HBI-3000 Dose Level 2: 350 mg planned
89437052|NCT04680026|Experimental|Drug: HBI-3000, Stage A Dose Level 3|Stage A Open Label HBI-3000 Dose Level 2: 500 mg planned
89437053|NCT04680026|Experimental|Drug: HBI-3000, Stage B Dose Level 1|Stage B Double-blind placebo controlled, Cohort 1 HBI-3000 Dose Level 1: Selected based on Stage A results
89437054|NCT04680026|Experimental|Drug: HBI-3000, Stage B Dose Level 2|Stage B Double-blind placebo controlled, Cohort 2 HBI-3000 Dose Level 2: Selected based on Stage A, and Stage B Cohort 1 results
89536606|NCT05217563|Active Comparator|Intervention Group (Pamphlet and video only)|Intervention Group (Group 2; Pamphlet and video Only). Parents in this intervention group will receive a pamphlet containing evidence-based information on needle pain management and a pamphlet summarizing memory reframing principles. The pamphlet will have a link to a video summarizing the memory reframing strategies.
88920744|NCT03223675|Experimental|Hippocampus-sparing WBRT plus SIB|All studied patients should undergo a computed tomography (CT) simulation scan encompassing the entire head region with 1.25-mm slice thickness using a thermoplastic mask for immobilization. To achieve conformal hippocampal sparing during the delivery of whole brain radiation (WBRT) and simultaneous integrated boost(s) (SIB), the technique of volumetric modulated arc therapy (VMAT) via Linac-based RapidArc®.In terms of dose prescription, a dose of 30 Gy in 12 fractions was prescribed to whole-brain planning target volume (PTV) containing the normal brain parenchyma; an simultaneous integrated boost up to 120 - 150% is attempted to irradiate the gross metastatic foci.
88920745|NCT03204955|Experimental|Sodium chloride /sodium acetate (16.4%)|50cc doses of sodium-chloride/sodium-acetate (16.4%) along with 30cc bag of dummy solution (PlasmaLyte).
88920746|NCT03204955|Active Comparator|Sodium chloride (23.4%)|30cc per dose of sodium chloride (23.4%) along with 50cc dummy solution bag (PlasmaLyte)
88920747|NCT03189485||Normal Controls and MCI|All subjects will receive 18F-AV-1451 PET scan.
88920748|NCT03159481|Experimental|Usual Care + Health Promotion Intervention|Usual glaucoma care along with telehealth-based brief culturally informed health promotion intervention
88920749|NCT03159481|No Intervention|Usual Care Only|Usual glaucoma management only, no intervention.
88920750|NCT03059043|Experimental|viscoelastic-free system|Eyes in this group will use viscoelastic-free implantation system during the surgery
88920751|NCT03059043|Active Comparator|viscoelastic-assisted system|Eyes in this group will utilize the standard viscoelastic-assisted Implantation system during the surgery
88920752|NCT03015740|Experimental|Treatment (sitravatinib, nivolumab)|Patients receive sitravatinib PO QD on days 1-14 and receive nivolumab IV over 60 minutes on day 1 starting cycle 2. Cycles repeat every 14 days for cycles 1-6 and then every 28 days for subsequent cycles in the absence of disease progression or unacceptable toxicity. Patients who receive at least 6 infusions of nivolumab with no DLTs related to nivolumab, may then receive nivolumab every 4 weeks.
88920753|NCT03011294|Active Comparator|CPAP (in the partner)|Positive airway pressure for treating OSA in the bed partner.
88920754|NCT03011294|Placebo Comparator|Nasal strips (in the partner)|Nasal dilator as a placebo for treating OSA in the bed partner.
88920755|NCT02946905||SCD participant|No intervention
88920756|NCT02946905||Non-SCD participant|No intervention
88920757|NCT02946242|Other|General Ultrasound Exam|Each subject may elect to participate in up to five (5) study scans per day lasting up to 60 cumulative minutes each with approximately a 15 minute break before starting another study scan. Ophthalmic scanning will be limited to no more than 15 cumulative minutes of scan time per eye, per day.
88920758|NCT02881242|Experimental|Treatment (trametinib)|Patients receive trametinib PO QD. Treatment continues in the absence of disease progression or unacceptable toxicity.
88920759|NCT02841462|Experimental|Bursitis|Intra-bursal thermal ablation
88920760|NCT02785263|Other|Standard radiotherapy|Daily on weekdays: 2.15 gray for tumor and verified lymph node metastases and 1.8 gray for the elective volume. A total of 28 treatments
88920761|NCT02785263|Other|High dose radiotherapy|Daily on weekdays: 2.15 gray for tumor and verified lymph node metastases and 1.8 gray for the elective volume. A total of 28 treatments
88920762|NCT02785263|Other|Low dose radiotherapy|Daily on weekdays: 2.15 gray for tumor and verified lymph node metastases and 1.8 gray for the elective volume. A total of 25 treatments
88920763|NCT02717234|Active Comparator|Impact Advanced Recovery|Oral nutrition supplement intended for consumption at 3 servings per day
88920764|NCT02717234|Experimental|Impact Advanced Recovery-R|Oral nutrition supplement intended for consumption at 3 servings per day
88920765|NCT02655744||newly-diagnosed patients with primary CNS lymphoma|
88920766|NCT02638519|Other|Healthy Volunteers|Healthy volunteers will inhale NeuroXene using various breathing methods. The CMRS 1H-129Xe dual-tuned quadrature head coil will be used to acquire MRI images of the human brain after inhalation of NeuroXene. The coil permits the acquisition of both conventional proton and HP xenon gas images. Two types of MRI scans will be performed: Traditional proton fMRI and Hyperpolarized Xenon-129 fMRI. The order of scans will be randomized to account for bias caused by scan order.
88920767|NCT02638519|Other|Alzheimer's Disease Participants|Alzheimer's disease participants will inhale NeuroXene using various breathing methods. The CMRS 1H-129Xe dual-tuned quadrature head coil will be used to acquire MRI images of the human brain after inhalation of NeuroXene. The coil permits the acquisition of both conventional proton and HP xenon gas images. Two types of MRI scans will be performed: Traditional proton fMRI and Hyperpolarized Xenon-129 fMRI. The order of scans will be randomized to account for bias caused by scan order.
89198767|NCT00873951|Experimental|Hydrolyzed casein|Subjects undergo an intestinal and metabolic exploration following the ingestion of a standard mixed meal containing 15% of energy as 15N-labelled hydrolyzed casein
89198768|NCT00873951|Experimental|AA|Subjects undergo an intestinal and metabolic exploration following the ingestion of a standard mixed meal containing 15% of energy as a mixture of AA mimicking the composition of casein but devoid in serine
89198769|NCT00874107|Experimental|1|Imprime PGG + bevacizumab + paclitaxel/carboplatin
89198770|NCT00874107|Other|2|bevacizumab + paclitaxel/carboplatin
89198771|NCT01983553||CYD Dengue Vaccine Group|Participants who received 3 injections of 0.5 milliliter (mL) CYD dengue vaccine, 1 injection each at 0, 6, and 12 months, subcutaneously in study CYD23, were followed up for safety in this study for 4 years after the 3rd vaccination at Month 12 in CYD23.
88920768|NCT02608762||pediatric/adolescent patients with brain tumors|A prospectively recruited of newly-diagnosed pediatric/adolescent patients with brain tumors or head/neck cancers
88920769|NCT02507297|Experimental|PAP Group|Positive airway pressure (PAP) delivered through an auto-titrating machine, to be used nightly
88920770|NCT02507297|No Intervention|TAU Group|Treatment as usual through obstetrics
88920771|NCT02504788|Experimental|Hippocampal-sparing WBRT|All studied patients should undergo a computed tomography (CT) simulation scan encompassing the entire head region with 1.25-mm slice thickness using a thermoplastic mask for immobilization. To achieve conformal hippocampal sparing during the delivery of whole brain radiation (WBRT), the technique of volumetric modulated arc therapy (VMAT) via Linac-based RapidArc®.In terms of dose prescription, a dose of 30 Gy in 12 fractions was prescribed to whole-brain planning target volume (PTV) if the role of RT was considered either adjuvant following craniotomy with tumor removal or therapeutic for treating oligometastatic brain disease.
88920772|NCT02448992|Experimental|PCI via hippocampal-sparing WBRT|All studied patients should undergo a computed tomography (CT) simulation scan encompassing the entire head region with 1.25-mm slice thickness using a thermoplastic mask for immobilization. To achieve conformal hippocampal sparing during the delivery of WBRT, the technique of volumetric modulated arc therapy (VMAT) via Linac-based RapidArc® or TrueBeamTM is employed in our treatment planning. All treatment plans are delivered by using the Linac Varian-iX or TrueBeamTM. In terms of dose prescription, a dose of 30 Gy in 15 fractions is prescribed to whole-brain planning target volume (PTV) under the setting of prophylactic cranial irradiation for NSCLC patients.
88920773|NCT02448992|No Intervention|observation without PCI|
88920774|NCT02376699|Experimental|IV Monotherapy in Solid Tumors|SEA-CD40 administered IV
88920775|NCT02376699|Experimental|IV Monotherapy in Lymphomas|SEA-CD40 administered IV
88920776|NCT02376699|Experimental|Combination Therapy in Solid Tumors|SEA-CD40 (administered IV) + pembrolizumab
89198772|NCT01983553||Control Group|Participants who received either 0.5 mL Rabies vaccine (Verorab®) or placebo control, subcutaneously as a first injection on Day 0, placebo for second and third injections at 6 and 12 months, respectively in the study CYD23, were followed up for safety in this study for 4 years after the 3rd vaccination at Month 12 in CYD23.
89198773|NCT00874185||Questionnaire|filling in questionnaires
89198774|NCT00761358|Experimental|Z-338|
89198775|NCT00761358|Placebo Comparator|placebo|
89198776|NCT05213637|Experimental|EAL Treatment Group|The patients with primary HCC will receive 12~20 doses of EAL infusion (1×10^9~2×10^10 cells per dose) in combination of a single transarterial chemoembolization (TACE) after radical resection.
89198777|NCT05213637|Active Comparator|Control Group|The patients with primary HCC will receive a single TACE after radical resection.
89198778|NCT03992989|Experimental|Phonak Bolero M90-M|The Phonak Bolero M90-M is a Behind-the-Ear Hearing aid with direct connectivity functionality from Phonak which will be fitted to the participants individual Hearing loss
89198779|NCT03992989|Active Comparator|Roger Select|The Roger Select is an accessory which can be connected to a compatible hearing aid. It offers an external microphone which streams signals directly to the connected hearing aid.
89198780|NCT00879723|Experimental|Vitamin and mineral supplementation|Intravenous micronutrient solution or an oral micronutrient supplementation twice per day for 14 days. Treatment is determined by percent total body surface area burned.
89198781|NCT00879723|No Intervention|Control|current vitamin regimen as listed on the Memorial medical Center Order Set for burn unit admission.
89198782|NCT00874341|No Intervention|1|
89198783|NCT00874341|Active Comparator|2|4 portions fruit and vegetables daily for 12 weeks
89198784|NCT00874341|Active Comparator|3|7 portions of fruit and vegetables daily for 12 weeks
89198785|NCT00874419|Experimental|erlotinib|Arm 1 receive erlotinib 150 mg oral, once a day until progression or unacceptable toxicity
89198786|NCT00874419|Active Comparator|gemcitabine/carboplatin|gemcitabine 1000mg/m2 on d1,8 with carboplatin AUC=5 on d1 intravenously, every 3 weeks, up to 4 cycles
89198787|NCT00547378|Other|1|InterStim Therapy
89198788|NCT00547378|Active Comparator|2|Standard Medical Therapy
89198789|NCT00381043|Active Comparator|1- Acamprosate|The study is a double-blind, randomized, placebo-controlled clinical trial in which participants will receive 333 mg t.i.d. oral acamprosate or matching placebo for a 12-week period. Each participant will also receive brief behavioral intervention at each visit.
89198790|NCT00381043|Placebo Comparator|2 - Sugar Pill - Placebo|The study is a double-blind, randomized, placebo-controlled clinical trial in which participants will receive 333 mg t.i.d. oral acamprosate or matching placebo for a 12-week period. Each participant will also receive brief behavioral intervention at each visit.
89198791|NCT00879801||Subjects with IGR|Subjects at high risk of diabetes, such as those with impaired glucose regulation (IFG and or IGT)
89198792|NCT02534701||ERIC® and SOFIA™|ERIC® device in combination with SOFIA™ Distal Access Catheter
89198793|NCT00962338||lap. inguinal herniorrhaphy|Patients undergoing planned lap. inguinal herniorrhaphy
89198794|NCT01050985|Experimental|temsirolimus and capecitabine|Treatment with the combination of temsirolimus and capecitabine
89198795|NCT04010656|Experimental|PVR-based home self-catheterization|Patients will learn to self-catheterize preoperatively prior to urogynecology surgery requiring trial of void. First post-operative void will be used to collect basic information about voiding function. All participants will leave the hospital and self-catheterize until they achieve two sequential voids with post-void residual (PVR) less than half the volume voided. The cases of urinary retention captured with abnormal PVR will be used to compare the diagnostic accuracy of several commonly-used, pre-defined parameters for trial of void.
89198796|NCT00962416|Active Comparator|1|Biolimus eluting Stent (Biomatrix)
89198797|NCT00962416|Active Comparator|2|Bare metal stent (Gazelle)
89198798|NCT00614991|Active Comparator|Group A|Period 1-Raltegravir 400mg BID Period 2-Fosamprenavir 1400mg BID Period 3-Fosamprenavir 1400mg BID + Raltegravir 400mg BID
88920777|NCT02376699|Experimental|SC Monotherapy in Solid Tumors|SEA-CD40 administered SC
88920778|NCT02376699|Experimental|SC Monotherapy in Lymphomas|SEA-CD40 administered SC
88920779|NCT02376699|Experimental|Combination Therapy in Pancreatic Cancer|SEA-CD40 (administered IV) + pembrolizumab + gemcitabine + nab-paclitaxel
88920780|NCT02213874|Other|Questionnaire|A questionnaire will be administered during the early stages of prenatal care & again during the postpartum period. The initial questionnaire will assess trust in the health care system, locus of control, religiosity, health literacy & collect information about demographics, contraceptive & reproductive history, future pregnancy intentions, & baseline knowledge about contraception. The postpartum questionnaire will repeat questions about future pregnancy & contraception intentions, trust in the health care system, knowledge of contraception and collect new information about characteristics of antenatal contraceptive counseling received including whether a provider recommended a specific method of contraception, the amount of counseling received, & the type of counseling received.
88920781|NCT02174315|Experimental|Contingency Management|
88920782|NCT02174315|No Intervention|Non-Contingent Control Group|
88920783|NCT02141542|Experimental|Tremelimumab and MEDI3617|"Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.~Tremelimumab-Fixed doses of Tremelimumab are given once per cycle~MEDI3617-MEDI3617 is administered twice per cycle"
88920784|NCT01984710|Experimental|DBS for Treatment Resistant Depression|"DBS for TRD: Exploration of LFP with the Medtronic Activa PC+S Brain Radio system"
88920785|NCT01930955|Active Comparator|Amoxicillin|Amoxicillin were given to the children with acute upper respiratory tract infection characterized by fever and vomiting.
88920786|NCT01930955|No Intervention|control|Non-antibiotics were given to the children with acute upper respiratory tract infection characterized by fever and vomiting.
88920787|NCT01333514|Experimental|Carbohydrate based prandial insulin dosing|Subjects will received prandial insulin based on the amount of carbohydrates consumed.
88920788|NCT01333514|Active Comparator|Usual Care Prandial insulin dosing|Subjects will received prandial insulin if they consume 50% or more of their meal-tray as is the usual care.
88920789|NCT00587561|Experimental|1 Social Cognition Interaction Training|Will receive 20-26 sessions of a manualized group treatment called Social Cognition Interaction Training
88920790|NCT00587561|Other|2 Wait List Control|Wait list control; 6 months of treatment as usual followed by Social Cognition Interaction Training group
88920791|NCT02098512|Experimental|Allogeneic Transplant and Immunotherapy|We intend to utilize reduced intensity conditioning and allogeneic stem cell transplant from HLA matched sibling or unrelated adult donor followed by post-AlloSCT Brentuximab Vedotin in patients with poor risk Hodgkin Lymphoma.
88920792|NCT02066636|Experimental|Cohort A: Nivolumab|Nivolumab 3 mg/kg solution intravenous infusion over 30 minutes every two weeks until disease progression, unacceptable toxicity, or withdrawal of informed consent
88920793|NCT02066636|Experimental|Cohort B: Nivolumab|"Nivolumab 3 mg/kg solution intravenous infusion over 30 minutes every two weeks until 1 year (52 weeks).~Discontinue treatment and at progression, retreatment allowed"
88920794|NCT02036086|Experimental|Vemurafenib, pill, twice daily|Vemurafenib, 960 mg, oral, twice daily plus Cobimetinib, 60 mg, oral, four times daily
88920795|NCT01878435|Experimental|SMS reminder|
88920796|NCT01878435|Experimental|SMS reminder and Travel subsidy|
88920797|NCT01878435|No Intervention|Control|
88920798|NCT01878435|Experimental|SMS reminder and Travel subsidy 2|
88920799|NCT01719146||UofL Subjects|Subjects undergoing Specimen Collection at University Kidney Center, University of Louisville, Louisville, KY
88920800|NCT01719146||Duke Subjects|Subjects undergoing Specimen Collection at Duke University, Durham, NC
88920801|NCT01719146||WNERTA Subjects|Subject undergoing Specimen Collection at Western New England Renal and Transplant Associates, Springfield, MA
88920802|NCT01486264|Active Comparator|Xeomin® Short Flex|short flex dosing of Xeomin. It is a botulinum toxin type A produced from fermentation of Hall strain Clostridium botulinum serotype A.
88920803|NCT01486264|Active Comparator|Xeomin® Long Flex|long flex dosing of Xeomin. It is a botulinum toxin type A produced from fermentation of Hall strain Clostridium botulinum serotype A.
88920804|NCT01323270|Experimental|rLP2086|rLP2086 and Repevax
88920805|NCT01323270|Placebo Comparator|Saline and Repevax|Saline and Repevax
88920806|NCT01300728|Experimental|intravenous immunoglobulin (IVIG)|IVIG (NewGam 10%)at 0.4 g/kg
88920807|NCT01300728|Placebo Comparator|Saline solution|0.9% saline solution
88920808|NCT01299480|Experimental|Group 1|rLP2086 vaccine at visits 1, 2 and 5, saline at visit 3
88920809|NCT01299480|Experimental|Group 2|rLP2086 vaccine at visits 1, 3, and 5, saline at visit 2
88920810|NCT01299480|Experimental|Group 3|rLP2086 vaccine at visits 1, and 5, saline at visits 2 and 3
89011202|NCT03801330|Experimental|Software Tool|Participants in the Pulmonary Rehabilitation Software-Based Home Program will use a digital software tool (APP) to obtain the pulmonary rehab home program. Home programs typically consist of exercises including upper extremity strengthening, lower extremity strengthening, aerobic exercises such as walking and balance training. Each program is personalized as per the participant's ability. The intervention is exercise and education, which is personalized for each participant. No drugs are being tested in this study.
89437055|NCT04678310||Intervention Group|A patient will be assessed as 'eligible' for participation in the iLIVE Volunteer Study if they have an advanced, incurable illness that is unlikely to be cured, and they have been assessed by their clinical team as being in the last month of life. If patients meet this criteria, they will be offered support from the hospital palliative and end of life care volunteer service (developed for this study). Patients who agree to support will be recruited to the 'Intervention Group'.
89011204|NCT03740048|Experimental|Hemodialysis and Pharmacologic Therapy|Hemodialysis regimen at the initiation of dialysis treatment: Twice-weekly hemodialysis plus adjunctive pharmacologic therapy (loop diuretic, potassium-binding agent, and sodium bicarbonate) for six consecutive weeks, continued by thrice-weekly hemodialysis (intervention group)
89437056|NCT04678310||Case Control Comparison Group|If a patient is 'eligible' to receive support from the hospital palliative and end of life care volunteer service (see 'Intervention Group'), but declines involvement, they will be approached for inclusion in the study, as part of the 'Case Control Comparison' group for comparative analysis to assess the 'impact' of the volunteer service.
89437057|NCT04672148||A|Patient who died in the 30 days after receiving mechanical thrombectomy, no matter the mortality cause
89437058|NCT04672148||B|Non-30-day-mortality group after receiving mechanical thrombectomy
89437059|NCT04666155|Experimental|Intermittent Colon Exoperistalsis (ICE)|Intermittent Colon Exoperistalsis (ICE) Treatment with Mowoot device. 20min daily for 12 weeks
89437060|NCT04666155|Active Comparator|Standard-of-care with Trans-anal Irrigation (Soc TAI)|Standard-of-care with Trans-anal Irrigation (Soc TAI) for chronic constipation for 12 weeks.
89437061|NCT04662619|Experimental|B. infantis|A once-daily feeding of activated B. infantis EVC001 (8.0 *10^9 colony forming units [CFU]) will be provided to infants for 12 weeks.
89437062|NCT04662619|Placebo Comparator|Placebo|A once-daily oral feeding of lactose placebo will be provided to infants for 12 weeks.
89437063|NCT04661124||Adult Normal Eyes|see Inclusion/Exclusion criteria; imaged with OCT and/or OCTA
89437064|NCT04661124||Adult Pathology Eyes|see Inclusion/Exclusion criteria; imaged with OCT and/or OCTA
89437065|NCT04661007|Experimental|Part 1 : tafasitimab monotherapy|Dose-finding to evaluate the safety and tolerability and to determine the RP2Ds of single-agent tafasitamab in Japanese participants with NHL. Part 1 consists of 2 groups: Group 1 will evaluate weight-based doses of tafasitamab, and Group 2 will evaluate fixed doses of tafasitamab.
89437066|NCT04661007|Experimental|Part 2 : tafasitamab combination therapy|tafasitamab will be combined with lenalidomide (Group 3) or parsaclisib (Group 4a) in R/R DLBCL participants or lenalidomide plus R-CHOP (Group 5) in previously untreated DLBCL participants. The dose of tafasitamab will be based on the weight-based RP2D that is deemed safe and tolerable in Part 1.
89437067|NCT04661007|Experimental|Part 3 : Dose Expansion of tafasitamab +parsaclisib|tafasitamab in combination with parsaclisib will be further evaluated in Group 4b at RP2D determined in Part 2
89011205|NCT03740048|Active Comparator|Conventional Hemodialysis Regimen|Hemodialysis regimen at the initiation of dialysis treatment: thrice-weekly hemodialysis
89198799|NCT00614991|Active Comparator|Group B|Period 1-Raltegravir 400mg BID Period2-Fosamprenavir 1400mg BID + Raltegravir 400mg BID Period 3-Fosamprenavir 1400mg BID
89198800|NCT00614991|Active Comparator|Group C|Period 1-Raltegravir 400mg BID Period 2-Fosamprenavir 700mg BID + Ritonavir 100mg BID Period 3-Fosamprenavir 700mg BID + Ritonavir 100mg BID + Raltegravir 400mg BID
89198801|NCT00614991|Active Comparator|Group D|Period 1-Raltegravir 400mg BID Period 2-Fosamprenavir 700mg BID + Ritonavir 100mg BID + Raltegravir 400mg BID Period 3-Fosamprenavir 700mg BID + Raltegravir 100mg BID
89437068|NCT04661007|Experimental|Part 4: tafasitamab combination therapy|tafasitamiab in combination with lenalidomide will be further evaluated in Group 6 at RP2D determined in Part 2.
89437069|NCT04656184|Experimental|KINERET|The patients will receive anakinra, an analogue of the IL-1 receptor antagonist, at a starting dose of 4 mg/kg. If patients are still febrile with 12 hours (H12) of treatment, they will receive a supplementary dose of 2 mg/Kg; otherwise, they will remain at a starting dose of 4 mg/kg. If they are still febrile at H24, they will receive a dose of 8mg/kg; otherwise, they will maintain their dose of 6 mg/kg. Patients with temperature <38°C at any point between initiation and day 14, but who develop secondary fever due to KD could have further escalation dose of anakinra until a maximum dose of 8mg/Kg. Patients will receive anakinra during 14 days independently of the period of escalation dose if any. After the last escalation dose, if any necessary, the primary criteria will be measured. Patients not responding to anakinra will follow usual standard care and will complete information related to all the study visits
89437070|NCT04656184|Active Comparator|Intravenous Immunoglobulin|The patients will receive a standard therapy, IVIG infusion of 2g/kg, and their treatment will follow usual standard care. Patients in the IVIG treatment will complete information related to the study visits.
89437071|NCT04650230|Active Comparator|high flow nasal cannula (HFNC)|Participants in the HFNC group received heated and humidified gas flow with the Fisher & Paykel Healthcare HFNC system. The flow rate was usually started at the maximum flow rate for the size of cannula and a constant flow temperature of 37 °C.The flow rate will be progressively decreased when inspired fraction of oxygen (FiO2) was inferior to 30 percent (%).
89437072|NCT04650230|Active Comparator|nasal continuous positive airway pressure / nasal positive pressure ventilation (NCPAP/NPPV)|Participants in the CPAP/NPPV group received for first CPAP using a neonatal ventilator. The recommended starting pressure for CPAP was +6 centimeter of water (cmH2O). Positive continuous pressure could be increased to a maximum of +8 cmH2O. Optimal positive end expiratory pressure (PEEP) was what could maintain SpO2 at 94 per cent using the lowest fraction of inspired oxygen. PEEP will be decreased progressively of 1cmH2O every 6 hours from the optimal PEEP when FiO2 was inferior to 30% and there is no increase of work of breath.
89437073|NCT04642027|Active Comparator|Conventional|Conventional sEBRT
89437074|NCT04642027|Experimental|Hypofractionation|Hypofractionated sEBRT
89437075|NCT04641871|Experimental|Sym021+Sym022 [ARM A] for BTC patients|Sym021 will be infused over approximately 30 minutes (+10 minutes), followed by a 30-minute post-dosing interval before infusion of Sym022 over approximately 30 minutes (+10 minutes). The duration of each infusion may be extended by 30 minutes, or longer, if indicated.
89437076|NCT04641871|Experimental|Sym021+Sym023 [ARM B] for BTC patients|Sym021 will be infused over approximately 30 minutes (+10 minutes), followed by a 30-minute post-dosing interval before infusion of Sym023 over approximately 30 minutes (+10 minutes). The duration of each infusion may be extended by 30 minutes, or longer, if indicated.
89437077|NCT04641871|Experimental|Sym021+Sym023+irrinotecan for BTC patients|Sym021 will be infused over approximately 30 minutes (+10 minutes), followed by a 30-minute post-dosing interval before infusion of Sym023 over approximately 30 minutes (+10 minutes). The duration of each infusion may be extended by 30 minutes, or longer, if indicated. After another 30-minute post-dosing interval, irinotecan will be infused over 90 minutes.
89437078|NCT04641871|Experimental|Sym021+Sym023+irrinotecan for ESCC patients|Sym021 will be infused over approximately 30 minutes (+10 minutes), followed by a 30-minute post-dosing interval before infusion of Sym023 over approximately 30 minutes (+10 minutes). The duration of each infusion may be extended by 30 minutes, or longer, if indicated. After another 30-minute post-dosing interval, irinotecan will be infused over 90 minutes.
89437079|NCT04641078|Experimental|Arm A|SBRT + 6 months of darolutamide (600 mg b.i.d.)
89437080|NCT04641078|Other|Arm B|SBRT only
88920811|NCT01299480|Experimental|Group 4|rLP2086 at visits 1 and 3, saline at visits 2 and 5
88920812|NCT01299480|Experimental|Group 5|rLP2086 at visits 3 and 5, saline at visits 1 and 2
88920813|NCT01680419|Experimental|Mission Reconnect only|Autonomous use of the Mission Reconnect multimedia instructional program at home.
89437081|NCT04638348|Experimental|New Biofeedback|Women allocated to the new biofeedback group will be instructed to attach the biofeedback device to their underpants and then perform pelvic floor muscle training.
89437082|NCT04638348|Active Comparator|Conventional Biofeedback|Women allocated to the conventional biofeedback group will undergo pelvic floor muscle training with the conventional biofeedback probe inserted in the vagina
89437083|NCT04638348|Active Comparator|Control group|The control group will perform pelvic floor muscle training without any biofeedback device.
89437084|NCT04636619|Experimental|On-line training course|Each participant will receive the global data, the results obtained by all the endoscopists (anonymously except for each interested party, the rest being identified by codes), as well as a detailed analysis of their results, comparing them with the joint data and the 3 tertiles.
89437085|NCT04629248|Experimental|Open Label Treatment: Obinutuzumab|Participants will be randomized at a 1:1 ratio to receive open-label treatment with obinutuzumab according to region and anti-phospholipase A2 receptor (PLA2R) autoantibody titer (using Euroimmun ELISA).
89437086|NCT04629248|Active Comparator|Open Label Treatment: Tacrolimus|Participants will be randomized at a 1:1 ratio to receive open-label treatment with tacrolimus according to region and anti-PLA2R autoantibody titer (using Euroimmun ELISA).
89437087|NCT04626583|Active Comparator|Low dose of allogeneic MSC|Escalating doses of allogeneic MSC subconjunctival injection will be assigned 1,000,000 cells/50 µL at the low dose level.
89437088|NCT04626583|Active Comparator|Medium dose of allogeneic MSC|Escalating doses of allogeneic MSC subconjunctival injection will be assigned 3,000,000 cells/150 µL at the medium dose level.
88920814|NCT01680419|Active Comparator|PREP only|Participation in a standard PREP for Strong Bonds weekend retreat program.
88920815|NCT01680419|Active Comparator|PREP plus Mission Reconnect|Participation in a standard PREP for Strong Bonds weekend retreat followed by autonomous use of the Mission Reconnect multimedia instructional program at home.
88920816|NCT01680419|No Intervention|Wait-list control|No intervention, followed by delivery of the Mission Reconnect multimedia program materials for home use after the end of the study period.
88920817|NCT01680705|Active Comparator|Frequency: Once Daily|Patients will use high volume saline irrigation once daily post operatively.
88920818|NCT01680705|Active Comparator|Frequency: Twice Daily|Patients will use high volume saline irrigation twice daily post operatively.
88920819|NCT01680705|Active Comparator|Frequency: Three Times Daily|Patients will use high volume saline irrigation three times daily post operatively.
88920820|NCT01681017|Other|Facilities|Have appropriate staff trained in HBB and have HBB equipment provided
88920821|NCT01681017|Other|Master Trainers|Receive appropriate HBB training
88920822|NCT01681017|Other|Facilitators|Receive appropriate HBB training
88920823|NCT01681017|Other|Learners|Receive appropriate HBB training
88920824|NCT01681225|Experimental|EPVent|"The overall goals for the EPVent group (esophageal-pressure guided mechanical ventilation) are to employ an open-lung strategy that includes low tidal volumes and maintenance of a positive transpulmonary pressure at end-expiration [Ptpexp]. Fraction of inspired oxygen [FiO2] and transpulmonary pressure pressure during an expiratory hold will be changed to achieve values shown in one of the columns of a protocol-specified table to meet the oxygenation target."
88920825|NCT01681225|Active Comparator|Control|The overall goals for the Control group are similar to those for the EPVent group: to employ an open-lung strategy that includes low tidal volumes using an alternative high positive end-expiratory pressure [PEEP] strategy. The control group PEEP and tidal volume will be managed without reference to the esophageal pressure measurements, and instead will follow an empiric high PEEP mechanical ventilation strategy. PEEP and FiO2 will be raised or lowered to achieve the oxygenation target level specified in a study table.
88920826|NCT01681238|Other|Protocol group 1|Using standard hemodynamic therapy
88920827|NCT01681238|Experimental|Protocol group 2|Using goal-directed therapy
88920828|NCT01681251|Experimental|Intervention|Fluid titrated with the use of arterial pulse contour cardiac output monitor if SVV >13%
88920829|NCT01681251|Active Comparator|Control|Fluid titrated at the discretion of the attending anesthesiologist.
88920830|NCT01681446|Active Comparator|interferon-alpha (IFN-alpha)|interferon-alpha is intramuscularly or subcutaneously injected at 30 μg three times a week or 50 μg twice a week for 18 months
88920831|NCT01681446|No Intervention|control|no anti-cancer interventions were assigned
88920832|NCT01681602|Active Comparator|Intervention group|16 weeks of aerobic exercise
88920833|NCT01681602|No Intervention|Control group|Usual care.
88920834|NCT01681615|Active Comparator|Acetylsalicylate|Acetylsalicylic Acid Eyedrops
88920835|NCT01681615|Placebo Comparator|isotonic NaCl|Saline Eyedrops
88920836|NCT01681797|Experimental|add-on fluorescence angiography|"The surgeon will prescribe the usual morphological assessment of the proposed flap:~CT angiography for an anterolateral thigh flap or an epigastric inferior flap~A Doppler ultrasonography for a fibula flap.~In addition to the usual radiological technique used to locate the perforating arteries, the patient will have a fluorescence angiography prior to surgery, another just after the end of surgery and then one every six hours during the next 4 days."
88920837|NCT01681875|Experimental|0.8 mg nicotine with 9 mg tar|"very low nicotine content cigarettes~SPECTRUM Cigarette: 0.8 (±0.15) mg nicotine with 9 (±1.5) mg tar (standard nicotine and tar yields of commercially-available cigarettes; control condition)"
88920838|NCT01681875|Experimental|0.26 mg nicotine with 9 mg tar|"very low nicotine content cigarettes~SPECTRUM Cigarette: 0.26 (±0.06) mg nicotine with 9 (±1.5) mg tar"
88920839|NCT01681875|Experimental|0.12 mg nicotine with 9 mg tar|"very low nicotine content cigarettes~SPECTRUM Cigarette: 0.12 (±0.03) mg nicotine with 9 (±1.5) mg tar"
89198802|NCT00614991|Active Comparator|Group E|Period 1-Raltegravir 400mg BID Period 2-Fosamprenavir 1400mg QD + Ritonavir 100mg QD Period 3-Fosamprenavir 1400mg QD + Ritonavir 100mg QD + Raltegravir 400mg BID
89198803|NCT00614991|Active Comparator|Group F|Period 1-Raltegravir 400mg BID Period 2-Fosamprenavir 1400mg QD + Ritonavir 100mg QD + Raltegravir 400mg BID Period 3-Fosamprenavir 1400mg QD + Ritonavir 100mg QD
89198804|NCT00962494|Experimental|online workshop|
89198805|NCT04010032|Experimental|PIEB (Programmed intermittent epidural bolus)|bolus administration of 0.15 ml of ropivacaine 0.15 ml / kg into epidural space every hour(intermittent bolus injection)
89198806|NCT04010032|Active Comparator|CEI (Continuous epidural infusion)|Continuous infusion of 0.15% ropivacaine 0.15 ml / kg / h into the epidural space using PCA device
88920840|NCT01681875|Experimental|0.07 mg nicotine with 9 mg tar|"very low nicotine content cigarettes~SPECTRUM Cigarette: 0.07 (±0.02) mg nicotine with 9 (±1.5) mg tar"
88920841|NCT01681875|Experimental|0.03 mg nicotine with 9 mg tar|"very low nicotine content cigarettes~SPECTRUM Cigarette: 0.03 (±0.01) mg nicotine with 9 (±1.5) mg tar"
88920842|NCT01681875|Experimental|0.04 mg nicotine with 13 mg tar|"very low nicotine content cigarettes~SPECTRUM Cigarette: 0.04 (±0.02) mg nicotine with 13 (±2) mg tar"
88920843|NCT01681875|Other|Usual brand|"very low nicotine content cigarettes~Usual brand cigarettes (control condition)"
88920844|NCT01681953|Active Comparator|Lamazym|1 mg Lamazym/kg body weight
88920845|NCT01681953|Placebo Comparator|Placebo|Placebo is formulated as an isotonic phosphate buffer with glycine and mannitol
89011206|NCT03733951|Experimental|KN046|
88920846|NCT01682239|Experimental|RVAP lead|"Pacemaker lead implantation:~Pacemaker leads will be placed in specific predefined RA and RV sites according to randomization. In this arm pacemaker leads will be placed in the RV apex. The successful lead positioning at its target location will be verified by surface ECG and by fluoroscopy."
88920847|NCT01682239|Experimental|RVSP arm|"Pacemaker lead implantation:~Pacemaker leads will be placed in specific predefined RA and RV sites according to randomization. In this arm pacemaker leads will be placed in the RV septum. The successful lead positioning at its target location will be verified by surface ECG and by fluoroscopy."
88920848|NCT06225388|Experimental|Compression socks|For the intervention, compression socks will be used, composed of 81% polyamide, 15% elastane and 4% polypropylene (Kendall sports, Kendall, São Paulo, Brazil). The sock offers compression of 20 to 30 mmHg in a decreasing manner with greater pressure at the ankle and less pressure at the knee joint line. Based on the manufacturer's guidelines, the sock size will be determined by measuring the calf and ankle circumference.
88920849|NCT06225388|Placebo Comparator|Placebo socks|The placebo sock will be represented by a commercial sock composed of 70% polyamide, 24% cotton and 5% elastodiene without the purpose of providing compression.
88920850|NCT06225375|Other|Treatment with Restorelle Flat Mesh|Subjects shall undergo transvaginal mesh surgery per the surgeon's specifications. Briefly, a sheet of Restorelle® Flat Mesh-(XL) shall be cut to the dimensions of the former Restorelle® Direct Fix Anterior and Posterior Mesh
88920851|NCT06225310|Other|Experimental: Selinexor/Ruxolitinib/Steroids|The regimen will follow a 3+3 dose escalation schedule starting at dose level 0. Subjects enrolled at dose level 0 will receive 1) selinexor (once weekly) starting at 40 mg, 2) ruxolitinib (twice a day (BID) on days 1-28) starting at 10 mg, and 3) oral methylprednisolone (every other day (QOD)) a set dose at 40 mg. Subjects at dose level 1 will receive 1) selinexor (once weekly) 60 mg, 2) ruxolitinib (BID) on days 1-28 10 mg, and 3) methylprednisolone (QOD) 40 mg. Subjects at dose level 2 will receive 1) selinexor (once weekly) 60 mg, 2) ruxolitinib (BID) on days 1-28 15 mg, and 3) oral methylprednisolone (QOD) 40 mg.
88920852|NCT06225297|Experimental|Intervention clusters|"will receive the following interventions:~Distribution of meganets, defined as conventional insecticide-treated nets (ITNs) sewn together to adapt to taalibés sleeping conditions~Three monthly cycles of targeted chemoprevention with dihydroartemisinin-piperaquine (DHA-PQ) for all daara residents, regardless of resident age~Social behavior change (SBC) to promote intervention uptake"
88920853|NCT06225297|No Intervention|Control clusters|"will receive standard-of-care malaria interventions, which include:~Distribution of conventional ITNs~Three monthly cycles of SMC with sulfadoxine-pyrimethamine- amodiaquine (SP-AQ) given to children 3-120 months"
89198807|NCT00360529|Experimental|fibanserin|flibanserin 50 mg q.h.s.
88920854|NCT06225271|Experimental|Intervention group|Participants in the intervention group will receive group intervention and individual intervention. Group interventions will include participants' communication meeting and other approach, such as self-management group. They will also receive the combined intervention of physical activity, fruit, and vitamin supplementation 3 times a week for 2 months (the 1st and 6th months).
88920855|NCT06225271|No Intervention|Control group|Participants in the control arm will not receive any intervention.
88920856|NCT06225258|No Intervention|Group C|Patients are treated according to the recommendations of the Surviving Sepsis Campaign.
88920857|NCT06225258|Experimental|Group Xn|Patients, who are admitted to the Intensive Care Unit (ICU) due to septic shock in the early, acute phase. Patients are treated according to the recommendations of the Surviving Sepsis Campaign and receive xanthohumol at a dose of 2 mg per kg body weight administered via nasogastric tube as supportive therapy.
88920858|NCT06225245|Experimental|Epidural Spinal Stimulation (ESS)|ESS will be delivered using The CoverEdgeX 32 Surgical Lead at frequencies of 0.2 to 60 Hz with intensity up to 10 mA, adjusted to induce motor threshold responses in the target muscle for the above motor task (e.g., biceps brachii for elbow flexion) [31-33]. The ESS controller will only be operated by trained study team members. Therefore, stimulation will only be delivered during study visits. Stimulation will be administered for a maximum duration of 1 hour total per visit, varying according to the individual's tolerance and fatigue levels, with 5 - 10 minutes breaks interspersed between intervals of stimulation.
88920859|NCT06225232|Experimental|Single Arm|This is an open-label single arm intervention trial. Participants in this arm will be offered both drug and psychotherapy as part of their 9-week intervention.
89198808|NCT00360529|Experimental|flibanserin|flibanserin 100 mg q.h.s.
89198809|NCT00360529|Placebo Comparator|placebo|placebo q.h.s.
89198810|NCT04858971||Control|No source will be indicated on information provided for review
88920862|NCT06225141||Patients|
88920863|NCT06225141||Controls|
88920864|NCT06225128||Patients with AML|
88920865|NCT06225102|Experimental|experimental group|"The intervention group was first given training on the definition of kegel exercises, diagnostic criteria, treatment, benefits and how to do kegel exercises on the Zoom platform.~A second meeting was held for the participants of the initiative group who could not attend this training.~At the same time, a message was sent to the WhatsApp application group where the intervention group was located three times a day by the researchers to remind them to do kegel exercises in the morning, noon and evening."
88920866|NCT06225102|No Intervention|control group|No intervention was made in the control group
88920867|NCT06225063|Experimental|Pilates Group|In the first session participants will received the 6 basic principles of the technique. All the other sessions will last 50 minutes and consist of warm-up, main program and cool-down exercises. The degree of difficulty of the exercises of the main part will progress every 2 weeks.
88920868|NCT06225063|Experimental|Cognitive Functional Therapy|In this group the participants will receive personalized treatment and therefore the sessions will be done individually for each one. All interventions will include a) a cognitive component, b) specific functional training and c) lifestylwe changes
88920869|NCT06225050|Experimental|HSC Recipient|PBSC grafts from haploidentical donors depleted of TCRaβ+ cells and CD45RA+ cells using CliniMACS Prodigy® will be infused into patients intravenously (IV)
88920870|NCT06225037|Experimental|Group 1: EEG Monitoring|EEG sensor placed with the EEG monitored.
88920871|NCT06225037|Active Comparator|Group 2: Standard Care|EEG sensor placed with the output concealed.
88920872|NCT06225011|Experimental|Treatment (fluoxetine)|Patients receive fluoxetine PO once QD for 10 days prior to surgery.
89198811|NCT04858971||Government source|A government logo will be shown on information provided for review
89198812|NCT04858971||Medical source|A medical logo will be shown on information provided for review
89198813|NCT04858971||Social media source|A social media logo will be shown on information provided for review
89198814|NCT02247388|Experimental|AB-CASI|Automated Bilingual Computerized Alcohol Screening and Brief Negotiated Interview(BNI) Intervention
88920873|NCT06224998|Experimental|Schroth exercises|Schroth technique, one of these exercise approaches, is primarily based on isometric muscle contraction exercises that aim to rotate, lengthen and stabilize the spine. The key component of the Schroth method is autocorrection, defined as the patient's ability to reduce spinal deformity through active postural realignment of the spine in three dimensions. Automatic correction is achieved through self-extension and specific segmental corrections adapted to each curve pattern. The International Scoliosis Orthopedic Treatment and Rehabilitation Association considers automatic correction to be the most important element of scoliosis-specific exercise therapy.
89011207|NCT03730649|Active Comparator|Sulforaphane without light challenge|Participants with moderate photodamage and moderate intrinsic skin aging will apply sulforaphane (broccoli sprout extract) in jojoba oil nightly (without any UV or visible light irradiation) for up to 6 months and have up to 9 biopsies taken just before treatment and occurring at regular intervals during the study
89198815|NCT02247388|No Intervention|Standard Care|Standard Care
89198816|NCT00874575|Placebo Comparator|1|Control
89198817|NCT00874575|Experimental|2|Beta-hydroxy-Beta-methylbutyrate, 3 g/d
89198818|NCT00874575|Experimental|3|Vitamin D, 2000 IU/d
89198819|NCT00874575|Experimental|4|Beta-hydroxy-Beta-methylbutyrate (3 g/d) + Vitamin D (2000 IU/d)
89198820|NCT02009800|No Intervention|2 dose of quadrivalent HPV vaccine|The participants who have already received 2 doses of the quadrivalent HPV vaccine (0, 6 months schedule) 5 years before recruitment will not receive an additional dose.
89437089|NCT04626583|Active Comparator|High dose of allogeneic MSC|Escalating doses of allogeneic MSC subconjunctival injection will be assigned 6,000,000 cells total consisting of injection at 2 sites of 3,000,000 cells/150 µL each at the high dose level.
89437090|NCT04623086|Experimental|Insulin Glargine and Insulin Degludec|Insulin glargine, 100 units per mL injected subcutaneously daily Insulin Degludec, 100 units per mL injected subcutaneously daily
89437091|NCT04623086|Placebo Comparator|Insulin Degludec and placebo|Insulin Degludec, 100 units per mL injected subcutaneously daily Placebo, 9g/L sodium chloride (normal saline) injected subcutaneously daily
89437092|NCT04619797|Experimental|Tiragolumab+Atezolizumab+Pemetrexed+Carboplatin or Cisplatin|Induction treatment with tiragolumab in combination with atezolizumab plus pemetrexed and cisplatin or carboplatin will be administered to participants on Day 1 of each 21-day cycle for 4 cycles. Following the induction phase, participants will continue maintenance therapy with tiragolumab in combination with atezolizumab and pemetrexed on Day 1 of each 21-day cycle.
89437093|NCT04619797|Placebo Comparator|Placebo+Pembrolizumab+Pemetrexed+Carboplatin or Cisplatin|Induction treatment with placebo in combination with pembrolizumab plus pemetrexed and cisplatin or carboplatin will be administered to participants on Day 1 of each 21-day cycle for 4 cycles. Following the induction phase, participants will continue maintenance therapy with placebo in combination with pembrolizumab and pemetrexed on Day 1 of each 21-day cycle.
89437094|NCT04614792|Experimental|active treatment|open label experimental treatment
88819572|NCT05451381|Experimental|Dexmedetomidine and propofol group|"Patient sedation after cardiac surgery at the intensive care unit.~Sedation group DEX+PR:~continuous infusion of propofol using a syringe pump at the dose of 0.5-1.5 mg / kg / h and dexmedetomidine 0.2-0.7 mcg\kg\h"
89437095|NCT04612907|Active Comparator|Moderate hypo-fractionation|Radiotherapy to the prostate delivered in 3Gy fractions x 19
89437096|NCT04612907|Experimental|Ultra hypo-fractionation|Radiotherapy to the prostate delivered in 6.1Gy fractions x 6
89437097|NCT04604613||Ancillary-Correlative (biospecimen collection, node mapping)|Patients undergo hysterectomy and sentinel lymph node mapping. Patients may also undergo bilateral salpingo-oophorectomy at the direction of the treating physician. If peritoneal disease or other contraindications to lymphatic mapping are detected at the time of surgery, mapping and sentinel node biopsy are performed at the surgeon's discretion. At the time of hysterectomy, patients undergo collection of tissue for molecular testing. Before and after surgery, patients also undergo collection of blood samples for tumor marker analysis.
88920874|NCT06224998|Experimental|Pilates exercises|Pilates exercise training improves flexibility and overall physical health by emphasizing strength, posture and coordination of respiratory-related movements. Pilates improves body awareness by working the body as a whole, using gravity and springs to increase resistance and assist in the execution of movements. Pilates, used in neuromuscular training and functional activity training in physiotherapy, is widely used for stimulation of blood circulation, development of flexibility, muscle endurance and strength, postural harmony and body awareness. Pilates has been reported to be an effective physical technique for pain, symptom management, and improving the Cobb angle in scoliosis. Pilates has been reported to be effective in improving scoliosis by correcting poor posture, strengthening the muscles necessary for postural correction, and maintaining body balance.
88920875|NCT06224972||Observational group|The study is observational study - one group.
88920876|NCT06224946||women under 37 weeks of gestation age|217 women under 37 weeks of gestation age
88920877|NCT06224946||women above 37 weeks of gestation age|97 women above 37 weeks of gestation age
88920878|NCT06224933|Experimental|Patients Undergoing Augmented Reality Image-Guided Needle Procedures|Patients will undergo their standard of care image-guided needle biopsy, aspiration, or injection with the Augmented Reality system. Patients will be monitored for adverse events for two weeks following their procedure.
88920879|NCT06224920||Alzheimer´s disease spectrum|"MCI-AD patients Evidence of minor cognitive impairment with essentially preserved everyday competence and evidence of reduced Aβ42 concentration in the cerebrospinal fluid. Score in the CERAD word list 1.5 SD below the normal range.~Patients with AD-dementia Evidence of pronounced cognitive impairment and relevant impairment of everyday life and evidence of reduced Aβ42 concentration in the cerebrospinal fluid (diagnostic criteria (NIA-AA fulfilled))."
88920880|NCT06224920||corticobasal syndrome due to probable 4 repeat taupathy|Evidence of the typical clinical picture of an atypical Parkinson's syndrome with onset of symptoms > 1 year. No evidence of reduced Aβ42 concentration in the cerebrospinal fluid. Fulfillment of the revised Armstrong criteria for probable CBS or the Movement Disorder's Society criteria for suggestive/possible PSP-CBS.
88920881|NCT06224920||subjective congnitive decline|Subjective memory impairment, with age-appropriate unremarkable neurocognitive test battery (CERAD) and no evidence of reduced Aβ42 concentration or increased total tau or phospho-tau concentration in the cerebrospinal fluid. Subjective cognitive deterioration over a period of 6 months to 5 years.
88920882|NCT06224907|Experimental|Valoctocogene roxaparvovec|Single administration of valoctocogene roxaparvovec at a dose of 6E13 vg/kg
89011208|NCT03730649|Active Comparator|Sulforaphane with light challenge|Participants will have 2 test areas irradiated with up to 5 UV or visible light treatments and biopsies taken before and within 7 days after UV or visible light irradiation; one of the UV/visible light treated areas will be pre-treated with sulforaphane (broccoli sprout extract) for up to 28 consecutive nights and the other UV/visible light treated areas will be pre-treated with jojoba oil.
89011209|NCT03683355||Edwards Sapien 3|Patients who underwent transcatheter aortic valve replacement with the Edwards Sapien 3 valve
89198821|NCT02009800|Experimental|3 doses of quadrivalent HPV vaccine|The participants will receive a 3rd dose of quadrivalent HPV vaccine at recruitment visit, which is 5 years after having received two doses of vaccine given 6 months apart in grade 4 (0, 6, 60 months Schedule)
89437098|NCT04604002||Subjects with Normal Eyes|OCT, Color Fundus Photography and OCT Angiography as per protocol in subjects without ophthalmic pathology
89437099|NCT04604002||Subjects with Pathology|OCT, Color Fundus Photography and OCT Angiography as per protocol in subjects with retinal vascular pathology
89437100|NCT04600817|Experimental|TJ107|
89437101|NCT04600817|Placebo Comparator|TJ107Placebo|
89437102|NCT04600791|Experimental|BATwire Kit|Subjects will be implanted using the BATwire Implant Kit
89437103|NCT04597866||CRPS|
89437104|NCT04594642|Experimental|Part 1, Arm A: AZD0486 Monotherapy Dose Escalation in Subjects with RR B-NHL|AZD0486 monotherapy will be administered intravenously on day 1 and 15 of 28 day cycles for a maximum of 24 cycles or until disease progression. Depending on cohort, subjects may receive priming or step-up dosing during cycle 1 before reaching the target dose. While on study, subjects will be monitored for safety and efficacy with periodic disease assessment with PET/CT. If subject achieves two consecutive CRs after completing C6, then they may be eligible for monthly dosing
89437105|NCT04594642|Experimental|Part 2, Arm B: Monotherapy Dose Expansion in Subjects with RR DLBCL/HGBL|An expansion cohort in subjects with DLBCL or HGBL will be enrolled after RP2D is established.
89011210|NCT03683355||Core Valve Evolut R|Patients who underwent transcatheter aortic valve replacement with the Core Valve Evolut R valve
89011211|NCT03645031|Experimental|ALS Group|Participants will complete a single 45 minute session of acute intermittent hypoxia (AIH), as well as, the 45 minute sham AIH session, consisting of breathing air with normal oxygen levels. Breathing, muscle activity and heart activity will be monitored before, during and after both procedures.
89011212|NCT03645031|Experimental|Healthy Control Group|Participants will complete a single 45 minute session of acute intermittent hypoxia (AIH), as well as, the 45 minute sham AIH session, consisting of breathing air with normal oxygen levels. Breathing, muscle activity and heart activity will be monitored before, during and after both procedures.
89011213|NCT03612596|Experimental|Narrative visualization|Wearable activity monitor, app, and enhanced motivational scrapbook materials (instant camera, stickers, markers, enhanced content)
89011214|NCT03612596|Active Comparator|Standard self-regulation|Wearable activity monitor, app, and standard workbook materials (markers, a workbook with a calendar log to keep track of steps over time)
89011215|NCT03598426|Active Comparator|Conventional|Oral dexamethasone (20 mg) at home, 12 hours and 6 hours prior to paclitaxel infusion. On the day of treatment at the clinic, an intravenous administration of diphenhydramine 50 mg and famotidine 20 mg, administered 30 minutes prior to paclitaxel infusion.
89011216|NCT03598426|Active Comparator|Short-Course|Intravenous administration of dexamethasone 20 mg, along with an intravenous administration of diphenhydramine 50 mg and famotidine 20 mg, administered 30 minutes prior to paclitaxel infusion.
89437106|NCT04594642|Experimental|Part 2, Arm C: Monotherapy Dose Expansion in Subjects with RR FL|An expansion cohort in subjects with FL will be enrolled after RP2D is established.
89011217|NCT03598426|Active Comparator|Combined|Oral dexamethasone (20 mg) at home, 12 hours prior to paclitaxel infusion. On the day of treatment at the clinic, an additional intravenous administration of dexamethasone 20 mg, along with an intravenous administration of diphenhydramine 50 mg and famotidine 20 mg, administered 30 minutes prior to paclitaxel infusion.
89011218|NCT03561805|Other|Prolonged continuous ECG monitoring|Patients will undergo a prolonged continuous ECG monitoring using the CardioSTAT® device within the 3 months prior to the TAVI procedure. The duration of the ECG monitoring will be of 1 week.
89011219|NCT03558204||CMC denervation|Patients will undergo denervation of the thumb CMC joint
89437107|NCT04594161|Active Comparator|Percutaneous Nephrostomy|drainage of the kidney by means of a percutaneous Nephrostomy
89437108|NCT04594161|Active Comparator|Double J catheter|drainage of the kidney by means of a double J catheter
89011220|NCT03558204||trapeziectomy with ligament reconstruction (LRTI)|Patients will undergo excision of the trapezium and suspension of the thumb metacarpal with the flexor carpi radialis tendon
89011221|NCT03521037|Experimental|no name|Group 1: patients with normal hepatic function Group 2: patients who have moderate hepatic impairment
89011222|NCT03507777|Active Comparator|Coronary PCI guided by OCT|"Intervention = Coronary stenting with planned drug eluting stent (DES).~Stenting will be performed with OCT guidance according to the algorithm described in the protocol. OCT imaging is required pre and post stent implantation.~At the end of the procedure, a final OCT imaging run must be performed."
89011223|NCT03507777|Active Comparator|Coronary PCI guided by Angiography|"Intervention = Coronary stenting with planned drug eluting stent (DES).~Stenting will be performed with angiography guidance according to local standard practice.~At the end of the procedure, a blinded OCT shall be performed to document final stent dimensions and results."
89011224|NCT03499444|Experimental|Oral Rucaparib monotherapy|Part I: Dose Escalation, Part II: Dose Expansion (Additional patients will be enrolled at the recommended dose as defined in Part I of the study.)
89198822|NCT05205213||lateral retromuscular preperitoneal group|All patients undergoing open lateral retromuscular preperitoneal repair through the previous lateral incision for L3-L4 IHs between February 2012 and January 2020
89198823|NCT05205213||Reverse TAR group|All patients undergoing open reverse TAR repair through the previous lateral incision for L3-L4 IHs between February 2012 and January 2020
89198824|NCT05205057||Pre-menopausal|Pre-menopausal women
89437109|NCT04593615|Experimental|Group A|Laparoscopic gastrectomy Group with the use of near-infrared imaging (ICG group)
89437110|NCT04593615|Placebo Comparator|Group B|Laparoscopic gastrectomy Group without the use of near-infrared imaging (Non-ICG group)
89437111|NCT04592237|Experimental|Group I (niraparib)|"INDUCTION: Patients receive cabazitaxel IV over 60 minutes and carboplatin IV over 60 minutes on day 1. Beginning cycle 2, patients also receive cetrelimab IV over 30-60 minutes on day 1. Treatment repeats for up to 6 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive niraparib orally PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
89437112|NCT04592237|Experimental|Group II (cetrelimab, niraparib)|"INDUCTION: Patients receive cabazitaxel IV over 60 minutes and carboplatin IV over 60 minutes on day 1. Beginning cycle 2, patients also receive cetrelimab IV over 30-60 minutes on day 1. Treatment repeats for up to 6 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive cetrelimab IV over 30 minutes on day 1 and niraparib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
89437113|NCT04589650|Experimental|Adult cohort (group 1)- Alpelisib|During double-blind randomized study period (from baseline up to Week 16), adult participants will be randomized to receive alpelisib (125 mg, oral, once daily). After Week 16, participants will continue their active treatment at the same dose level.
89437114|NCT04589650|Placebo Comparator|Adult cohort (group 1)- Placebo|During double-blind randomized study period (from baseline up to Week 16), adult participants will be randomized to receive placebo (125 mg, oral, once daily). After Week 16, participants will be switched to active treatment with alpelisib at the placebo dose level received at the end of the placebo period.
89437115|NCT04589650|Experimental|Pediatric cohort (group 2: 6 to 17 years old) -Alpelisib|During double-blind randomized study period (from baseline up to Week 16, pediatric participants (6 to 17 years old) will be randomized to receive alpelisib (50 mg, oral, once daily). After Week 16, participants will continue their active treatment at the same dose level.
89198825|NCT05205057||Post-menopausal women|post-menopausal women
89437116|NCT04589650|Placebo Comparator|Pediatric cohort (group 2: 6 to 17 years old)-Placebo|During double-blind randomized study period (from baseline up to Week 16), pediatric participants (6 to 17 years old) will be randomized to receive Placebo (50mg, oral, once daily). After Week 16, participants will be switched to active treatment with alpelisib at the placebo dose level received at the end of the placebo period.
89198826|NCT00874653||Group 1|
89198827|NCT00369577|Placebo Comparator|Inhaled Placebo|Inhaled Staccato Placebo, single dose
89198828|NCT00369577|Experimental|Inhaled Loxapine 5 mg|Inhaled Staccato Loxapine 5 mg, single dose
89437117|NCT04589650|Experimental|Pediatric cohort (group 3: 2 to 5 years old)- Alpelisib granules|Pediatric participants (2 to 5 years old) will receive alpelisib with the alpelisib granules formulation at dose determined based on the primary analysis for efficacy, safety and PK of alpelisib in Groups 1 and 2 in addition to the data from Group 4 and 5 as available. An extrapolation approach will be used for dose selection for this group.
89437118|NCT04589650|Experimental|Pediatric cohort (group 4: 2 to 5 years old)- Alpelisib FCT|Pediatric participants (2 to 5 years old) will receive 50 mg of alpelisib film-coated tablets (FCT) once daily in an open-label setting.
89011225|NCT03494322|Experimental|Avelumab + cetuximab|"Patients will receive treatment in 4-week cycles and treatment may continue for up to 1 year.~Avelumab + cetuximab combination therapy:~Cycle 1~Day 1: Cetuximab 500* mg/m2 given IV over approx 3 hrs~Day 15: Cetuximab 500* mg/m2 given IV over approx 2 hrs + avelumab 10 mg/kg given IV over approx 1 hr~All other cycles:~- Days 1 and 15: Cetuximab 500* mg/m2 given IV over approx 2 hrs + avelumab 10 mg/kg given IV over approx 1 hr~*Cetuximab dose will be dependent on outcome of safety run-in.~There must be a 60 minute break between the administration of cetuximab and avelumab."
89011226|NCT03494322|Other|Avelumab monotherapy|"Patients will receive treatment in 4-week cycles and treatment may continue for up to 1 year.~Avelumab monotherapy will be given as follows:~All cycles Avelumab 10 mg/kg on days 1 and 15 given IV over approximately 1 hour"
89011227|NCT03441633||Group 1. Apixaban|"Patients who are on treatment with apixaban.~1a. patients who have initiated with apixaban as treatment naïve (no prior prescription of VKA previous to the 12 months before index date).~1b. patients who previously have been treated with VKA in the 12 months before index date."
89011228|NCT03441633||Group 2. VKA|"Patients who are on treatment with VKA.~2a. patients who have initiated with VKA as treatment naïve (no prior prescription of VKA previous to the 12 months before index date).~2b. patients who previously have been treated with VKA in the 12 months before index date."
89011229|NCT03441633||Group 3. Dabigatran|"Patients who are on treatment with dabigatran.~3a. patients who have initiated with dabigatran as treatment naïve (no prior prescription of VKA previous to the 12 months before index date).~3b. patients who previously have been treated with VKA in the 12 months before index date."
89011230|NCT03441633||Group 4. Rivaroxaban|"Patients who are on treatment with rivaroxaban.~4a. patients who have initiated with rivaroxaban as treatment naïve (no prior prescription of VKA previous to the 12 months before index date).~4b. patients who previously have been treated with VKA in the 12 months before index date."
89011231|NCT03397394|Experimental|Rucaparib|Oral rucaparib (monotherapy)
89437119|NCT04589650|Experimental|Pediatric cohort (group 5: 6-17 years old)-Alpelisib FCT|Pediatric participants (6 to 17 year old) will receive 125 mg alpelisib film-coated (FCT) once daily, in an open-label setting.
89011232|NCT03373760|Experimental|Treatment (tremelimumab, durvalumab)|Patients receive tremelimumab IV over 60 minutes on day 1 for courses 1-4 and durvalumab IV over 60 minutes on day 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89011233|NCT03324880|Placebo Comparator|Placebo|Participants received placebo matched to rhPTH (1-84) as subcutaneous (SC) injection once daily (QD) with active vitamin D and calcium supplements up to 31.3 weeks.
89011234|NCT03324880|Experimental|rhPTH (1-84)|Participants received rhPTH (1-84) 50 microgram (mcg) SC injection QD, titrated within the dose range of 25-100 mcg QD as an adjunctive treatment with active vitamin D and calcium supplements based on metabolic response up to 32 weeks.
89011235|NCT03290794||Decision to treat with intravitreal aflibercept for wet AMD|Adult patients with a diagnosis of wet AMD, as an indication approved by the local health authorities for use with intravitreal aflibercept.
89011236|NCT03107897|No Intervention|Pre-procedure standard of care|No prehab prior to TAVR.
89011237|NCT03107897|Active Comparator|Prehab prior to TAVR procedure.|Individuals participate in prehabilitation prior to TAVR.
89011238|NCT03053440|Experimental|Arm A : Ibrutinib|Participants with the MYD88 mutation received Ibrutinib
89011239|NCT03053440|Active Comparator|Arm B: Zanubrutinib|Participants with the MYD88 mutation received zanubrutinib
88920883|NCT06224894|Experimental|music therapy|"The child in the music therapy group will receive a standard antiemetic treatment procedure 15 minutes before the cisplatin infusion. Music therapy will be applied with the start of cisplatin infusion. The song The Happiest Child, developed by creating rhythms and developed by Fulya Merve KOS, a researcher with a RhythmotherapistTM certificate issued by the Ministry of National Education, will be used in music therapy. The sound will be adjusted to 45 db. The speaker will be placed at the end of the foot, approximately 30 cm from the child's ear, five minutes before the procedure and will be played to the child during the procedure. After the infusion, music therapy will be terminated and the level of nausea, irritability and anxiety will be evaluated with data collection forms."
88920884|NCT06224894|Experimental|antiemetic treatment|Standard approach; Granisetron IV 40mcg/kg/24, Aprepitant PO 125 mg/24 hour and Dexamethasone 6 mg/m2 IV/PO are administered to children receiving cisplatin treatment.
88920885|NCT06224881|Active Comparator|Vitamin C group|Ascorbic acid (Vitamin C) was given parenterally (2 gm every 8hrs) for 4 days.
88920886|NCT06224881|Placebo Comparator|Control group|No vit C given
88920887|NCT06224868|Active Comparator|PEEP 0|After the patient is intubated, PEEP 0 will be set on the mechanical ventilator.
89437120|NCT04588883|Experimental|Intervention Arm|Patients, adults and adolescents, will be recruited from patient registries at 7 government operated HIV clinics in Meru County, Kenya. Patients will complete validated questionnaires at baseline, 1.5 year and 3 years into a novel adaptation of a community empowerment program. The program utilizes savings- and internal-lending/group-based microfinance process to facilitate exchange of savings amongst patients and adolescent guardians. A byproduct of this process is the development of social capital, which will be used to facilitate education, peer learning, and collective problem solving to improve determinants of well-being and clinical adherence among participants. Expected outcomes include improved viral suppression, ART adherence, clinical attendance, and mental health.
89437121|NCT04587336||Aim 0 - Cognitive Interview|Cognitive Interviews: Examine the understanding and interpretation of diabetes distress and the Diabetes Distress Scale in Veterans with T2D.
89437122|NCT04587336||Aim 1 - Baseline Survey|Conduct Baseline Survey: Examine the association of psychosocial factors (depression, PTSD), environmental factors (finances, support), self-management behaviors, and HbA1c with DD.
88920888|NCT06224868|Active Comparator|PEEP 5|After the patient is intubated, PEEP 5 will be set on the mechanical ventilator.
88920889|NCT06224868|Active Comparator|PEEP 10|After the patient is intubated, PEEP 10 will be set on the mechanical ventilator.
88920890|NCT06224842|Experimental|mitoxantrone liposome and azacitidine treatment|In the dose escalation phase, the mitoxantrone liposome will start at a dose of 16 mg/m^2 on day1 via intravenous infusion, combined with subcutaneous injection of azacitidine at a dose of 75 mg/m^2 on days 1-7, with each cycle lasting 4 weeks (28 days). Three predetermined dose groups for mitoxantrone liposome are 16, 18, and 20 mg/m^2. In the dose expansion phase, 10-20 cases will be included with the mitoxantrone liposome injection at the recommended phase II dose (RP2D) based on the results of the dose escalation phase.
88920891|NCT06224829|Experimental|Pain Inducing Massage|Participants will receive 60 seconds of manual pressure applied to one point in their neck followed by 30 seconds of complete pressure release 4 times for a total contact time of 240 seconds. Pressure will be applied such that the participant rates the pain = 5/10 on an 11-point numeric pain rating scale with 0 indicating no pain and 10 indicating the most severe pain imaginable.
88920892|NCT06224829|Active Comparator|Pain Free Massage|Participants will receive 60 seconds of manual pressure applied to one point in their neck followed by 30 seconds of complete pressure release 4 times for a total contact time of 240 seconds. Pressure will be applied such that the participant rates the pain = 0/10 on an 11-point numeric pain rating scale with 0 indicating no pain and 10 indicating the most severe pain imaginable.
88920893|NCT06224829|Active Comparator|Cold Water Bath|Participants will place their non-dominant hand into water cooled by a refrigeration unit (NESLAB RTE 7 Digital One, Thermo Scientific Co., Massachusetts, USA) that circulates water continuously to maintain a constant temperature of 6 degrees Celsius (males) or 8 degrees Celsius (females). The participant will place his or her hand in the cooled water for 60 seconds followed by a 30 second break in which the participant will remove his or her hand from the water. This will occur 4 times for a total immersion time of 240 seconds.
88920894|NCT06224816|Experimental|3D Mask (3DM)|Custom 3D mask (3DM) application in neonate during 4 hours. Each patient included will be their own control at the same time, receiving each of the different mask models every 4 hours alternately. The study period will be a maximum of 7 days.
88920895|NCT06224816|Active Comparator|Traditional Mask (TM)|Traditional Mask (TM) application in neonate during 4 hours. Each patient included will be their own control at the same time, receiving each of the different mask models every 4 hours alternately. The study period will be a maximum of 7 days.
88920896|NCT06224803|Experimental|Dibifree|Take Dibifree 3 times a day, 10 capsules each time, 5 to 10 minutes before meals
88920897|NCT06224803|Placebo Comparator|Control|Take Placebo 3 times a day, 10 capsules each time, 5 to 10 minutes before meals
88920898|NCT06224790|Experimental|Group A (Pirfenidone)|Capsule Pirfenidone 200mg, 2 X 8hrly for 3 months
88920899|NCT06224790|Placebo Comparator|Group B|Placebo capsules - 2 X 8hrly for 3 months
88920900|NCT06224777|Experimental|Albumin Group A|5% Albumin solution will be administered on day 2 @0.5ml/kg/%burn over 8 hours,in addition to required crystalloids.
88920901|NCT06224777|Active Comparator|Crystalloid Group B|Routine Crystalloids will be administered according to weight of the patient.
88920902|NCT06224738|Experimental|human HER2-targeted CAR-M cell|"Recombinant human granulocyte stimulating factor treatment mobilized bone marrow stem cells, when the mononuclear cells rose to more than 8×10^8/L, the collection of peripheral blood single nuclei cells, the total number of mononuclear cells collected 1.5×10^9-1.8×10^9. Intraperitoneal infusion of anti-human HER2 CAR-M cells 3×10^8 cells/person, in a single administration.According to the principle of 3+3 dose increment, enter dose 2 and dose 3. Dose2: the monocyte rises to more than 9.5×10^8/L and collect peripheral blood single nucleus cells. Reinfuse anti-human HER2 CAR-M cells 5×10^8 cells/person, 1 person/bag/dose, 100 ml/bag. Dose3: the mononuclear cell rises to more than 1.3×10^9/L and collect peripheral blood single nucleus cells. Reinfuse anti-human HER2 CAR-M cells 1×10^9 cells/person, 1 person/bag/dose, 200 ml/bag."
88920903|NCT06224699|Experimental|Test group|Use of toothpaste with sodium carbonate 67%
88920904|NCT06224699|Placebo Comparator|Control|Use of toothpaste without sodium carbonate 67%
88920905|NCT06224686|Experimental|The experimental group|conventional dysphagia treatment and motor imagery based on action observation treatment
88920906|NCT06224686|Active Comparator|The control group|conventional dysphagia treatment
88920907|NCT06224660|Experimental|Low Dose|SRD-001
88920908|NCT06224660|Experimental|High Dose|SRD-001
88920909|NCT06224660|No Intervention|Control|No-Intervention Control
88920910|NCT06224621|Experimental|Study group|Percutaneous Endocardial Septal Radiofrequency Ablation (PESA) is used to ablatethe hypertrophied septum of obstructive hypertrophic cardiomyopathy (oHCM) patients.
88920911|NCT06224608|Experimental|Pulmonary tuberculosis patients|Experimental drug of low-dose (2.5 μg/ml), medium-dose (5 μg/ml), and high-dose (10 μg/ml) will be conducted separately for 30 Pulmonary tuberculosis patients aged 18-65 years old ，each dose for10 cases.
88920912|NCT06224608|Experimental|Healthy subjects|Experimental drug of low-dose (2.5 μg/ml), medium-dose (5 μg/ml), and high-dose (10 μg/ml) will be conducted separately for 30 healthy subjects aged 18-65 years old ，each dose for10 cases.
88920913|NCT06224582|Experimental|Yinxingmihuan group|standardized medical treatment regimen plus Yinxingmihuan oral solution (oral, 10 ml once, 3 times a day)
88920914|NCT06224582|Placebo Comparator|Placebo group|standardized medical treatment regimen plus Placebo oral solution (oral, 10 ml once, 3 times a day)
88920915|NCT06224556|Experimental|Intervention Group|"All the 608 patients will be evaluated by their General Practitioners through the Brief-MPI scale, which is based on the Comprehensive Geriatric Assessment (CGA).~Based on the score obtained at the Brief-MPI, the patient will receive a Personalised Prevention Program (PPP) concerning the following domains: 1) motor, 2) cognitive, 3) nutritional, 4) polypharmacotherapy, 5) vaccination prevention, 6) basal and instrumental activities, 7) co-habitation. Patients will receive brochures containing practical advice and recommendations to be implemented over a 12-month period; in the case of high Brief-MPI risk scores, patients will be referred for specialist examinations and/or in-depth diagnostics.~In addition, saliva samples will be collected to assess biomarkers of oxidative stress and, in a subsample of 210 subjects, the composition of the oral microbiota will also be analysed."
88920916|NCT06224556|No Intervention|Control group|Patients will receive the standard clinical practice by their General Practitioners, without being evaluated by the CGA or receiving the personalized prevention program (PPP). No saliva sample will be collected.
88920917|NCT06224530|Experimental|Levetiracetam, then Placebo|Participants will receive two levetiracetam 250mg capsules on the first scanning visit. On the second scanning visit they will receive two 37.5mg capsules of ascorbic acid.
88920918|NCT06224530|Experimental|Placebo, then Levetiracetam|Participants will receive two 37.5mg capsules of ascorbic acid on the first scanning visit. On the second scanning visit they will receive two levetiracetam 250mg capsules.
88920919|NCT06224504|Experimental|the intervention group|routine health education ， psychological nursing， MBSR therapy ， exercise therapy
88920920|NCT06224504|Active Comparator|the control group|routine health education ， psychological nursing
88920921|NCT06224491|Sham Comparator|Placebo tactile stimulation|From a standardized starting position for 10 minutes tactile contact in the area outside the description of reflex zones in reflex locomotion according to Vojta.
88920922|NCT06224491|Experimental|Reflex locomotion zone stimulation|From a standardized starting position tactile stimulation in the area of the zone in reflex locomotion according to Vojta for 10 minutes .
88920923|NCT06224478||Hypodivergent|
88920924|NCT06224478||Normodivergent|
88920925|NCT06224478||Hyperdivergent|
88920926|NCT06224465|Placebo Comparator|control group|Antiaging diet instructions
88920927|NCT06224465|Experimental|intervention group|"aerobic exercises: walking :30 min on treadmill 30min at least three times per week for 12 weeks~Muscle strength Exercises:~For upper extremity : hand grip exercise, arm flexion exercise ten repeatation for each exercise three times per week.~Theraband exercises for upper limb exercise ten repeatation for each exercise three times per week.~Flexibility Exercise :~Curl up exercise and Seat and reach up exercises exercise ten repetition for each exercise three times per week.~Lateral flexibility exercises for ten repetition for each exercise three times per week,for 12 weeks and anti aging diet instruction"
88920928|NCT06224439|Active Comparator|spinal anaesthesia|25 gauge quincke needle will be used for spinal anaesthesia. After the lateral position is given to the patient with the side to be operated on, the patient will be entered through the appropriate interval (L3-4 or L4-5) to apply hypobaric spinal anaesthesia, and after the feeling of falling in the subdural area is obtained, Cerebro Spinal Fluid arrival will be seen and the drug consisting of 0.5% Bupivacain and distilled water with bupivacaine hydrochloride active ingredient will be applied in the range of 2-4cc according to the patient's height and weight.
88920929|NCT06224439|Active Comparator|lumbar plexus block|A 10-15 cm peripheral block needle, ultrasound and nerve stimulator will be used for lumbar plexus block. Buvicaine with 0.5% Bupivacaine Hydrochloride active substance will be used. It will be diluted half and half with saline. It will be applied in accordance with the patient's height and weight, not exceeding 2mg/kg.
88920930|NCT06224413||All Participants|Participants with CALD treated with eli-cel in the post marketing setting will be followed in this registry study for up to 15 years after eli-cel infusion to collect real-world longitudinal data, and evaluate the outcomes.
88920931|NCT06224400|Experimental|ENC1018 for SAD|6 of out 8 subjects per cohort will be randomized to receive ENC1018
88920932|NCT06224400|Placebo Comparator|Placebo for SAD|2 of out 8 subjects per cohort will be randomized to receive placebo
88920933|NCT06224400|Experimental|ENC1018 for MAD|6 of out 8 subjects per cohort will be randomized to receive ENC1018
88920934|NCT06224400|Placebo Comparator|Placebo for MAD|2 of out 8 subjects per cohort will be randomized to receive placebo
88920935|NCT06224387|Experimental|Dose Escalation/Dose Expansion|"Cohort 1: Histologically or cytologically confirmed locally advanced or metastatic solid tumors,QD,4 dose groups are pre-specified.~Cohort 2:Histologically or cytologically confirmed locally advanced or metastatic solid tumors,QD, 2-weeks-on and 1-week-off, 4 dose groups are pre-specified.~Cohort 3:Histologically or cytologically confirmed locally advanced or metastatic solid tumors,QD,5-days-on and 2-days-off,4 dose groups are pre-specified.~Cohort 4: Pancreatic cancer with specified doses. Cohort 5: Non-small cell lung cancer (NSCLC) with specified doses. Cohort 6: Triple-negative breast cancer (TNBC) with specified doses. Cohort 7: Other types of solid tumor with specified doses."
88920936|NCT06224374||Validity and Reliability|"Participants will be evaluated with the Postural Stability Test, Limits of Stability Test, Sensory Integration Test and Bilateral Comparison Test within the AlBalance and Biodex Balance Evaluation System. To calculate the test-retest reliability and validity of the devices, these measurements will be made by the same evaluator in two sessions, 7 days apart. To eliminate the learning effect, participants who try AlBalance first in the first session will be the first to try Biodex in the second session (reverse test order will be used). Participants who complete all evaluations with the first device will rest for 5 minutes and move on to the other device. Then, parallel clinical tests will be applied to the participants, Functional Reaching Test and One Leg Standing Test. The relationship of outcome measurements between devices and measurements of each test will be evaluated with statistical methods."
88920937|NCT06224361||Reliability|"Participants will be evaluated with the Postural Stability Test, Limits of Stability Test, Sensory Integration Test and Bilateral Comparison Test within the AlBalance Balance Evaluation System. To calculate the test-retest reliability of the device, these measurements will be made by the same evaluator, will last 30 seconds and will be repeated a total of 3 times with a 1-minute rest between tests. These measurements will be repeated after 7 days to evaluate reliability. Then, parallel clinical tests will be applied to the participants, Functional Reaching Test and One Leg Standing Test."
88920938|NCT06224296|Experimental|Group A: Inflammatory cytokine group|Self-control
88920939|NCT06224296|Experimental|Group B: Lipid group|Self-control
88920940|NCT06224296|Experimental|Group C: Toxic metal ions group|Self-control
88920941|NCT06224257|Experimental|Linperlisib|Linperlisib was administered at 80 mg every day, orally in a 28-day cycle until disease progression or intolerable toxicity occurred.
88920942|NCT06224244|Active Comparator|Simultaneous integrated boost to 40 Gy (SIB 40)|"Patients with the following clinico-pathological characteristics~pTis G3,~pT1 pN0/pN1mic, G1-G3 luminal biology or Her-2 positive"
88920943|NCT06224244|Active Comparator|Simultaneous integrated boost to 43 Gy (SIB 43)|"Patients with the following clinico-pathological characteristics:~Triple negative disease,~pT2 pN0/pN1mic,~≤ 50 years not Luminal A"
88920944|NCT06224218|Active Comparator|Single Port Robotic Prostatectomy|Removal of the prostate using single port robot
88920945|NCT06224218|Active Comparator|Laser Enucleation of the Prostate|Enucleation of the prostate with laser surgery
88920946|NCT06224153||Patients with chronic kidney disease|
88920947|NCT06224127|Active Comparator|Active heat and placebo c tactile stimulation|Subjects will receive an active heating device and a sham c tactile stimulation device.
88920948|NCT06224127|Active Comparator|Placebo heat and active c tactile stimulation|Subjects will receive an active c tactile stimulation device and a sham heating device.
88920949|NCT06224127|Active Comparator|Active heat and active c tactile stimulation|Subjects will receive an active c tactile stimulation device and an active heating device.
88920950|NCT06224114|Experimental|Coloured light 1 group|Coloured light 1 group will be provided with a coloured-light torch and instructed to apply it to their study eye for 3 minutes at home each morning between 8 - 10 am for 28 days.
88920951|NCT06224114|Placebo Comparator|Coloured light 2 group|Coloured light 2 group will be provided with a different coloured-light torch and instructed to apply it to their study eye for 3 minutes at home each morning between 8 - 10 am for 28 days.
88920952|NCT06224075|Experimental|Task-specific training|
88920953|NCT06224075|Other|Usual care|
88920954|NCT06224062|Experimental|children|reconstituted fully functional respiratory epithelium obtained from children (0 -18 years old)
88920955|NCT06224062|Experimental|adults|reconstituted fully functional respiratory epithelium obtained from adults (18 to 60 years old)
88920956|NCT06224062|Experimental|elderly|reconstituted fully functional respiratory epithelium obtained from adults (over 60 years old)
88920957|NCT06224036|Experimental|First group|JDB0131 Benzenesulfonate tablets,100mg BID group,12 cases
89011240|NCT03001804||Cohort A|Lenalidomide 25mg or 10mg (reduced renal function 30 ≤ ClCr < 50mg/min) capsules by mouth (PO) on days 1 through 21 of a 28 day cycle and Dexamethasone 40mg PO (≤75 years) or 20mg (>75years) on Days 1, 8, 15, 22 of a 28 day cycle until progression or unacceptable toxicity
88920958|NCT06224036|Experimental|Second group|JDB0131 Benzenesulfonate tablets 200mg QD group,12 cases
88920959|NCT06224036|Experimental|Third group|JDB0131 Benzenesulfonate tablets 200mg BID group,12 cases
88920960|NCT06224036|Active Comparator|Forth group|Ethylpyrazine rifampicide (II) QD group,8 cases
88920961|NCT06224036|Active Comparator|Fifth group|Delamanid Tablets 100mg BID group,8 cases
88920962|NCT06224010||Non-COVID|"This group includes patients diagnosed with Acute Respiratory Distress Syndrome (ARDS) caused by etiologies other than COVID-19.~ARDS was defined following Berlin criteria (2012)"
89198829|NCT00369577|Experimental|Inhaled Loxapine 10 mg|Inhaled Staccato Loxapine 10 mg, single dose
89198830|NCT02559336|No Intervention|Control|Usual care: Oncology team refers patients to palliative care team if deemed appropriate
89198831|NCT02559336|Experimental|Intervention|Integrated oncology care and palliative care
89437123|NCT04587336||Aim 3a- TARDIS Photo Elicitation|TARDIS Photo Elicitation: To further understand Diabetes Distress by expanding on what we have learned thus far in cognitive and semi-structured interviews with Veterans. Visual-based qualitative methods will help identify and more robustly describe DD in Veterans.
89437124|NCT04587336||Aim 3b - TARDIS Pilot|TARDIS Intervention: Design & pilot test an innovative, tailored self-management information and supportive services intervention for Veterans with T2D, to promote engagement in self-management behaviors
88920963|NCT06224010||COVID-Moderate|"Moderate COVID indicates a less severe level of hypoxemia compared to the Severe COVID group (according to Berlin criteria).~The moderate COVID group is further characterized by a diagnosis of moderate Acute Respiratory Distress Syndrome (ARDS), based on a P/F ratio (partial pressure of oxygen/fraction of inspired oxygen) at ICU admission.~The diagnosis of COVID-19 in these patients was confirmed using the Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) technique.~RT-PCR involves collecting a sample from the lower respiratory tract and detecting the presence of SARS-CoV-2 viral RNA."
88920964|NCT06224010||COVID-Severe|"The severe COVID group has a diagnosis of Acute Respiratory Distress Syndrome (ARDS)~The severity of COVID-19 in this group is determined by a P/F ratio at ICU admission, indicating a higher level of hypoxemia and a more critical clinical condition.~The diagnosis of COVID-19 in these patients was confirmed using the Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) technique.~RT-PCR involves collecting a sample from the lower respiratory tract and detecting the presence of SARS-CoV-2 viral RNA."
88920965|NCT06223984|Active Comparator|the group receiving standard treatment|In the group receiving standard treatment, hydroxychloroquine (400 mg/day for 5 days), low moleculer weight heparin, acetylsalicylic acid, favipiravir (3200 mg on day 1, 1200 mg on days 2-5).
88920966|NCT06223984|Active Comparator|the group receiving IVIG and pulse steroid|In the IVIG and pulse steroid group, patients received pulse steroid (250 mg/day methylprednisolone for 5 days) and intravenous immunoglobulin (400 mg/kg/day for 5 days) in addition to standard treatment. The IVIG preparations given to the patients were in 100 ml volume and 10% concentration, and the commercial name was Nanogam.
88920967|NCT06223945|Active Comparator|Thrombotic and hemorrhagic complications of COVID-19|
88920968|NCT06223945|Active Comparator|Prevention of thrombohemorrhagic complications in COVID-19|
88920969|NCT06223932||COVID-19 diagnosed patients receiving molnupiravir|COVID-19 diagnosed patients receiving molnupiravir treatment
88920970|NCT06223893|Other|CirrhoCare management system|
88920971|NCT06223893|No Intervention|Standard of Care|
88920972|NCT06223880|Experimental|AXS-05|AXS-05 tablets, taken twice daily
89437125|NCT04587193|Experimental|PD participants|Subjects will participate in a total of 10 walking sessions, twice per week for 5 weeks, while wearing a robotic-assist gait training device. There will also be 3 additional visits for assessments at: baseline (up to 1 prior to treatment), post (1 week after last treatment), and final (4-6 weeks after last treatment).
89437126|NCT04581941||Patients with essential tremor|Patients with essential tremor who have clinically been deemed candidates for DBS (Deep Brain Stimulation) surgery. Deep brain stimulation is an FDA approved therapy that involves surgical implantation of electrodes in deep brain targets and an implantable pulse generator delivers electrical pulses. This intervention is not part of the study. The investigators are going to recruit patients who receive the Medtronic Percept device, which allows for brain signal recordings (this feature is FDA approved). The investigators will be conducting an observational study using this device to collect data that the subjects receive as standard of care.
89437127|NCT04576455|Experimental|Giredestrant|
88920973|NCT06223880|Active Comparator|Bupropion|Bupropion tablets, taken twice daily
89437128|NCT04576455|Active Comparator|Physician Choice of Endocrine Monotherapy|The physician choice of endocrine monotherapy will be limited to fulvestrant or an aromatase inhibitor.
88920974|NCT06223867|Active Comparator|Enhanced treatment as usual (ETAU) alone|Subjects in this arm will receive the usual care for patients with suicidal risk at UMass Memorial ED that may include a behavioral health evaluation by a trained clinician, and environmental safety precautions dictated by risk level (Mild, Moderate, High). Individuals deemed appropriate for discharge undergo discharge planning and offered a personalized safety plan using the Stanley-Brown Safety Planning Intervention, including lethal means safety counseling.
88920975|NCT06223867|Experimental|Jaspr intervention with enhanced treatment as usual (ETAU)|"Subjects in this arm will receive ETAU in addition, they will complete a guided Suicide Status Interview (SSI), Safety Planning, and Lethal means counseling on the Jaspr tablet-based app before open access to the Jaspr resource library.~Subjects can sign up to receive JAH mobile app."
88920976|NCT06223802|Experimental|trained group|women group with a number of 29 women receiving 3-time biodex training per week, every time will be 10 minutes for 12 weeks
88920977|NCT06223802|No Intervention|non trained group|this group will serve as a control group that will receive no intervention
88920978|NCT06223776|No Intervention|Normal sleep|The night before the experimental session, where participants will follow their habitual sleep-wake routines.
88920979|NCT06223776|Experimental|Sleep restriction|The night before the experimental session (with sleep restrictions (SR)), where participants will experience acute sleep restriction the night before the test session (i.e., 3 h of early sleep restriction versus normal sleep).
88920980|NCT06223763||Primary cytoreductive surgery|Patients underwent primary cytoreductive surgery between January 1, 2018, and December 31, 2019. After that, they underwent adjuvant therapy.
88920981|NCT06223763||Interval cytoreductive surgery|Patients underwent primary first course of neoadjuvant chemotherapy between January 1, 2018, and December 31, 2019. After neoadjuvant chemotherapy, the patient underwent interval cytoreductive surgery and then, adjuvant chemotherapy.
88920982|NCT06223750|Other|Patient contact via mail with a letter and laboratory requisition|Patient contact via mail with a letter and laboratory requisition for serum creatinine and urine albumin to creatinine ratio
88920983|NCT06223750|Other|Patient and primary care network contact via mail with a letter but no laboratory requisition|
88920984|NCT06223737|Active Comparator|patients non-operated|Each patient will be measured for an EOS x-ray and at the human performance lab at the clinic for optoelectronic motion capture of the spinal movements.
88920985|NCT06223737|Active Comparator|patients operated|Each patient will be measured for an EOS x-ray and at the human performance lab at the clinic for optoelectronic motion capture of the spinal movement
88920986|NCT06223737|Other|healthy controls|Each participant will be measured as control group for an EOS x-ray and at the human performance lab at the clinic for optoelectronic motion capture of the spinal movement
88920987|NCT06223711|Experimental|Treatment|"Thoracic Radiochemotherapy concomitant 2 cycles of etoposide/platinum + durvalumab~Stereotactic radiotherapy of further tumor locations + durvalumab maintenance"
88920988|NCT06223698|Experimental|Cohort 1: Aromatase inhibitors for 5 years|Cohort 1 (premenopausal at diagnosis => postmenopausal at randomization) 5-year tamoxifen => Randomized to Arm A (switching to aromatase inhibitors for 5 years).
88920989|NCT06223698|Active Comparator|Cohort 1: Tamoxifen for 5 years|Cohort 1 (premenopausal at diagnosis => postmenopausal at randomization) 5-year tamoxifen => Randomized to Arm B (continuing with tamoxifen for 5 years).
88920990|NCT06223698|Experimental|Cohort 2: Tamoxifen for 5 years|Cohort 2 (postmenopausal at diagnosis) 5-year aromatase inhibitors => Randomized to Arm A (switching to tamoxifen for 5 years).
88920991|NCT06223698|Active Comparator|Cohort 2: Aromatase inhibitors for 2 years|Cohort 2 (postmenopausal at diagnosis) 5-year aromatase inhibitors => Randomized to Arm B (continuing with AI for 2 years).
88920992|NCT06223659|Placebo Comparator|Cohort 2 (placebo cream)|Patients apply placebo cream topically to skin 30 minutes prior to Tc99 lymphoscintigraphy procedure.
88920993|NCT06223659|Experimental|Cohort 1 (EMLA cream)|Patients apply EMLA cream topically to skin 30 minutes prior to Tc99 lymphoscintigraphy procedure.
89437129|NCT04574635||Cohort 1 (surgery patients)|Patients undergo collection of blood samples at baseline prior to surgery, at 6 weeks, 3, 6, and 12 months post-surgery, every 6 months during year 2, and at the time of recurrence (if applicable).
89437130|NCT04574635||Cohort 2 (post-operative radiation +/- chemotherapy patients)|Patients undergo collection of blood samples at baseline prior to the first fraction of radiation, during week 4 of radiotherapy, at 6 weeks, 3, 6, and 12 months post-radiotherapy, every 6 months during year 2, and at the time of recurrence (if applicable).
89437131|NCT04574635||Cohort 3 (definitive chemoradiotherapy patients)|Patients undergo collection of blood samples at baseline prior to the first fraction of radiation, during week 4 of radiotherapy, on the day of the final fraction of radiotherapy, at 3 months post-radiotherapy, every 3 months during years 1 and 2, and at the time of recurrence (if applicable).
89437132|NCT04574635||Cohort 4 (systemic treatment patients)|Patients undergo collection of blood samples at baseline prior to initiation of chemotherapy or immunotherapy, at 4 weeks and 8 weeks after initiation of chemotherapy or immunotherapy, every 3 months during years 1 and 2, and at the time of recurrence (if applicable).
89437133|NCT04569773||Participants undergoing surgery for clinical|Participants will be undergoing surgery for clinical stage I endometrioid endometrial cancer
89437134|NCT04566991|Experimental|Deferoxamine lower dose|Deferoxamine 32 Milligram Per Kilogram (mg/kg)
89437135|NCT04566991|Experimental|Deferoxamine higher dose|Deferoxamine 48 mg/kg
89437136|NCT04566991|Placebo Comparator|Placebo|normal saline
88920994|NCT06223646|Experimental|Phase 1: Low dose group|Infusion of KQ-2003 CAR T-cells by single dose of 1.0×10^6 CAR-T cells/kg
88920995|NCT06223646|Experimental|Phase 1: Medium dose group|Infusion of KQ-2003 CAR T-cells by single dose of 2.0×10^6 CAR-T cells/kg
88920996|NCT06223646|Experimental|Phase 1: High dose group|Infusion of KQ-2003 CAR T-cells by single dose of 3.0×10^6 CAR-T cells/kg
88920997|NCT06223646|Experimental|Phase 2a: RP2D|After all subjects in the Phase 1 dose-escalation study completed DLT observation, RP2D was determined based on the analysis results for the phase 2a expansion study.
88920998|NCT06223633|Experimental|PK Papyrus Covered Coronary Stent System|PK Papyrus Covered Coronary Stent System has been approved for use in the treatment of free perforations, defined as free contrast extravasation into the pericardium, in native coronary vessels or saphenous vein bypass grafts greater than or equal to 2.75mm in diameter.
88920999|NCT06223529|Experimental|Music intervention|Music-based exercises for arm/hand coordination, range of movement and dexterity using a selection of hand percussion, stand-mounted percussion and tablet with touchscreen instruments.
88921000|NCT06223516|Experimental|ABBV-383 Dose A|Participants will receive Dose A of ABBV-383 as a subcutaneous (SC) injection and intravenous (IV) infusions, during the 151 week study duration.
88921001|NCT06223516|Experimental|ABBV-383 Dose B|Participants will receive Dose B of ABBV-383 as an SC injection and IV infusions, during the 151 week study duration.
88921002|NCT06223516|Experimental|ABBV-383 Expansion|Participants will receive the selected dose from Arm A of ABBV-383 as SC injections, during the 151 week study duration.
88921003|NCT06223490|Active Comparator|Cryolipolysis Group|About 30 obese females with type 2 diabetes and will face cryolypolysis in addition to exercise therapy treatment
88921004|NCT06223490|Active Comparator|Group of Exercise|About 30 obese females with type 2 diabetes and will face exercise therapy treatment only.
88921005|NCT06223477|Experimental|Platelet-rich Fibrin|A 20 ml blood sample will be drawn from the median cubital vein into a PRF tube. Centrifugation will be done at 700 rpm for 3 minutes and the liquid of PRF will be suctioned out using a separate syringe. PRF will be injected distal to the canine on the experimental side three times; at the beginning of canine retraction (T0), 1 month after the start of canine retraction (T1), and 2 months after the start of canine retraction (T2).
88921006|NCT06223477|Experimental|Vitamin D3|Subjects will receive vitamin Dꝫ injection distal to the canine on the experimental side three times; at the beginning of canine retraction (T0), 1 month after the start of canine retraction (T1), and 2 months after the start of canine retraction (T2).
88921007|NCT06223464||Adenomyosis-Case Group|The study will include those diagnosed with adenomyosis who were evaluated by gynecological examination and ultrasonographic imaging after the application to Etlik City Hospital Gynecology and Obstetrics Clinic, aged 18-45 reproductive period, pregnancy status excluded, without cervical infection, pathology and anomaly, without systemic disease findings and diagnoses, without chronic drug use.
89437137|NCT04562246||PCR positive subjects|Patients who receive positive test result from RT-PCR for SARS-CoV-2.
89437138|NCT04553081|Active Comparator|Dovato|We aim to include 134 adult HIV-infected patients with HIV RNA < 50 copies/mL for at least 3 months on any stable 2nd generation integrase based triple therapy antiretroviral regimen. Patients will be randomized 1:2 to switch to or stay on the triple regimen BIC/TAF/FTC (Biktarvy) (N=45) or to switch to the dual regimen DTG/3TC (Dovato) (N=89).
89437139|NCT04553081|Active Comparator|Biktarvy|We aim to include 134 adult HIV-infected patients with HIV RNA < 50 copies/mL for at least 3 months on any stable 2nd generation integrase based triple therapy antiretroviral regimen. Patients will be randomized 1:2 to switch to or stay on the triple regimen BIC/TAF/FTC (Biktarvy) (N=45) or to switch to the dual regimen DTG/3TC (Dovato) (N=89).
89437140|NCT04543617|Experimental|Arm A: Tiragolumab + Atezolizumab|Participants will receive atezolizumab followed by tiragolumab.
89437141|NCT04543617|Experimental|Arm B: Tiragolumab Placebo + Atezolizumab|Participants will receive atezolizumab followed by tiragolumab matching placebo.
89437142|NCT04543617|Placebo Comparator|Arm C: Tiragolumab Placebo + Atezolizumab Placebo|Participants will receive matching placebos to tiragolumab and atezolizumab.
88921008|NCT06223464||Healthy patients-Control|The study will include those who have been gynecologically examined and evaluated with ultrasonographic imaging after the application to Etlik City Hospital Gynecology and Obstetrics Clinic, aged 18-45 reproductive period, pregnancy status excluded, without cervical infection, pathology and anomaly, without systemic disease findings and diagnoses, without chronic drug use, without adenomyosis diagnosis.
88921009|NCT06223451|Active Comparator|Active repetitive transcranial magnetic stimulation in stroke patients with unilateral neglect.|Inhibitory repetitive transcranial magnetic stimulation will be applied to 11 patients with unilateral neglect due to ischemic stroke under the supervision of a doctor for a total of 10 sessions over 2 weeks with conventional rehabilitation. Each session will last for 20 minutes,total of 1200 pulses, 1 Hz repetitive transcranial manyetic stimulation over the unaffected left posterior parietal cortex.
88921010|NCT06223451|Sham Comparator|Sham repetitive transcranial magnetic stimulation in stroke patients with unilateral neglect.|Patients in the sham group will receive sham transcranial magnetic stimulation with sham coil for 20 minutes a day, 10 sessions in total, together with conventional rehabilitation.
88921011|NCT06223438||Cognitively normal (CN)|"Participants must have an MMSE score of ≥26 and meet clinical criteria for cognitively normal based on National Institute of Aging (NIA) criteria verified in medical records or clinical assessment at first visit;~● Based on the judgment of the site PI, no evidence of functional decline based on the Functional Activities Questionnaire (FAQ) or equivalent assessment;"
88921012|NCT06223438||Mild Cognitive Impairment (MCI) with known amyloid status.|"Cognitive concern, reflecting a change in cognition reported by the participant, informant (family member, caregiver), or clinician;~Participants must have an MMSE score of ≥24 and meet clinical criteria for MCI based on National Institute of Aging (NIA) criteria and verified through medical records or clinical evaluation at first visit;~Based on the judgment of the site PI, minimal to mild functional impairment but with preservation of independence in functional abilities based on the Functional Activities Questionnaire (FAQ) or equivalent assessment;"
88921013|NCT06223425|Experimental|virtual reality Situation-Based Flipped Learning|students exposed to virtual reality Situation-Based Flipped Learning
88921014|NCT06223425|No Intervention|traditional teaching strategies|Students exposed to traditional Learning
88921015|NCT06223412|Experimental|interventional group|The participants in this group received an empowerment-based intervention in terms of interactive digital-based educational program regarding the promoting literacy, pro-environmental attitudes, self-efficacy, and reducing climate anxiety.
88921016|NCT06223412|Placebo Comparator|control group|The participants in this group received routine nursing care.
88921017|NCT06223399|Experimental|Imaging-based|66 patients with Parkinson's disease will receive imaging-based DBS programming
88921018|NCT06223399|Active Comparator|Threshold assessment-based|66 patients with Parkinson's disease will receive DBS programming based on the threshold assessment
88921019|NCT06223386|Placebo Comparator|Traditional model|Designed course A with 3-month consultation with the dietitians
88921020|NCT06223386|Experimental|Multi-oriented lifestyle education|Designed course B with 3-month consultation with the dietitians
88921021|NCT06223386|Experimental|Multi-oriented lifestyle education with dietary assessment|Designed course B with 3-month consultation with the dietitians + 3-month daily dietary assessment by the dietitians
88921022|NCT06223386|Experimental|Multi-oriented lifestyle education with longer period of dietary assessment|Designed course B with 6-month consultation with the dietitians + 6-month daily dietary assessment by the dietitians
88921023|NCT06223308|Experimental|HB0028|HB0028 IV every 3 weeks (q3w)
88921024|NCT06223282|Experimental|short inter-set rest|3 multi-joints resistance exercise with short (60s) inter-set rest
88921025|NCT06223282|Experimental|medium inter-set rest|3 multi-joints resistance exercise with medium(120s) inter-set rest
88921026|NCT06223282|Experimental|long inter-set rest|3 multi-joints resistance exercise with long (180s) inter-set rest
88921027|NCT06223282|Experimental|medium inter-set rest with failure|3 multi-joints resistance exercise with medium (120s) inter-set rest repeated to failure each set
88921028|NCT06223282|No Intervention|control|stayed sedentary during the period.
88921029|NCT06223269|Experimental|Skin Xenotransplant|After surgical preparation of the wound beds, subjects will receive approximately 150 square centimeters of realSKIN® at one site, and autograft at the other site, per the standard of care, in accordance with the randomization schedule.
88921030|NCT06223269|Active Comparator|Autograft|The comparator control for the study is autografting: the current standard of care procedure for the treatment of severe burns involves the removal of a sheet of healthy skin from an uninjured site on the patient and using it to cover the original burn wound to achieve complete and durable wound closure.
88921031|NCT06223243|Experimental|stingless bee honey|stingless bee honey mouthrinse was prescribed to participants assigned to this group.
88921032|NCT06223243|Active Comparator|chlorhexidine|chlorhexidine mouthrinse was prescribed to participants assigned to this group.
88921033|NCT06223243|Placebo Comparator|normal saline|Normal saline mouthrinse was prescribed to participants assigned to this group.
88921034|NCT06223217||Experiment group|Patients who undergoing endoluminal treatment for lower extremity peripheral arterial disease will complete the Modified version of the VascuQoL scale, the Chinese version of the VascuQoL scale, EQ-5D-5L Scale and the ABI test according to follow-up plan.
88921035|NCT06223204|Other|Controlled euglycemia, hypoglycemia and hyperglycemia|
88921036|NCT06223191|Experimental|Brief Negotiated Interview|The BNI helps health care providers explore health behavior change with patients in a respectful, non-judgmental way within a finite time period. Instead of telling the patient what changes he/she should make, the BNI is intentionally designed to elicit reasons for change and action steps from the patient. It gives the patient voice and choice, making any potential behavior changes all the more empowering to the patient.
88921037|NCT06223191|Placebo Comparator|Narrative Interview|The Narrative Interview is a therapeutic approach that aims to motivate the individual's conscious and transformative knowledge, skills, and capabilities. This interview is based on the technical components of narrative therapy, where the patient narrates their story, using externalizing language and considering social and political aspects related to the issue. It will focus on exploring past and present feelings, thoughts, and actions.
88921038|NCT06223191|No Intervention|Standards of Care|This arm includes the use of benzodiazepines (Diazepam or Lorazepam) when CIWA-Ar scale is ≥9. Other medications may include Thiamine, Potassium Chloride, oral rehydration salts, parenteral fluids, antiemetics, and gastric protectants if medically necessary. Patients undergo a psychological evaluation on the third day of admission. All patients receive at least one psychoeducational session on alcohol and substance use during their hospitalization. Psychiatric evaluation is available for those with dual diagnoses such as mood disorders, anxiety disorders, psychotic disorders, or multiple substance use. The total hospitalization time in the ward is 8 days.
88921039|NCT06223165|Experimental|Foundations, Condoms & Contraception, Family Strengthening, and Gender & Relationships|This arm receives the constant session (Foundations in Sexual Risk Prevention) and all three other workshop sessions: 1) Condoms & Contraception, 2) Family Strengthening, and 3) Gender & Relationships.
88921040|NCT06223165|Experimental|Foundations, Condoms & Contraception, and Family Strengthening|This arm receives the constant session (Foundations in Sexual Risk Prevention) and two other workshop sessions: 1) Condoms & Contraception and 2) Family Strengthening.
88921041|NCT06223165|Experimental|Foundations, Condoms & Contraception, Gender & Relationships|This arm receives the constant session (Foundations in Sexual Risk Prevention) and two other workshop sessions: 1) Condoms & Contraception and 2) Gender & Relationships.
89437143|NCT04543071|Experimental|Motixafortide, Cemiplimab, Gemcitabine, Nab-Paclitaxel|Participants will receive standard FDA-approved doses of gemcitabine and nab-paclitaxel for pancreas cancer and cemiplimab at the dose that is approved for participants with skin cancer. Participants will also receive motixafortide at a dose that has been deemed safe in previous studies when used in combination with immunotherapy and chemotherapy. If the combination study treatment causes a serious side effect in participants, the study treatment will be modified.
88921042|NCT06223165|Experimental|Foundations, Family Strengthening, and Gender & Relationships|This arm receives the constant session (Foundations in Sexual Risk Prevention) and two other workshop sessions: 1) Family Strengthening and 2) Gender & Relationships.
88921043|NCT06223165|Experimental|Foundations and Condoms & Contraception|This arm receives the constant session (Foundations in Sexual Risk Prevention) and one other workshop session: Condoms & Contraception.
88921044|NCT06223165|Experimental|Foundations and Family Strengthening|This arm receives the constant session (Foundations in Sexual Risk Prevention) and one other workshop session: Family Strengthening.
88921045|NCT06223165|Experimental|Foundations and Gender & Partner Relationships|This arm receives the constant session (Foundations in Sexual Risk Prevention) and one other workshop session: Gender & Relationships.
88921046|NCT06223165|Experimental|Foundations|This arm receives the constant session (Foundations in Sexual Risk Prevention) only.
88921047|NCT06223152|Experimental|deaf children and parents|
88921048|NCT06223139||COPD|COPD patients aged 40 years or older with a post-bronchodilator ratio of forced expiratory volume in one second (FEV1) to forced vital capacity (FVC) <0.7.
88921049|NCT06223087||control|group not practicing winter swimming
88921050|NCT06223087||winter swimmers|group practicing winter swimming
88921051|NCT06223074|Active Comparator|Standard Intravenous Methylprednisolone treatment in relapsing-remittent multiple sclerosis|"Intravenous methylprednisolone is the standard treatment for a multiple sclerosis relapse. Thus, 40 randomly enrolled patients aged 18-65 years with relapsing-remitting multiple sclerosis that assist to the hospital and confirmed with a relapse, will be treated with intravenous methylprednisolone, 1000 mg, once a day for 3 days for moderate relapses or 5 days for severe ones.~A written informed consent will be obtained from each participant or a legal representative whenever the participant could not provide consent."
88921052|NCT06223074|Experimental|Intranasal Methylprednisolone administration in relapsing-remittent multiple sclerosis|"Nasal Methylprednisolone Administration For this group, 40 randomly enrolled patients aged 18-65 years with relapsing-remitting multiple sclerosis that assist to the hospital and confirmed with a relapse, will be treated with intranasal methylprednisolone administration (1000 mg once a day for 3 days for moderate relapses or 5 days for severe ones) using a Mucosal Atomization Device (MAD Nasal).~A written informed consent will be obtained from each participant or a legal representative whenever the participant could not provide consent"
88921053|NCT06223035|Experimental|Secretome characterization and signaling to the adipose tissue|To identify possible exercise stimulated secreted proteins which signal to the adipose tissue, subcutaneous adipose and blood will be collected both before and at multiple timepoints following a VO2max test. Adipose will be collected from the abdominal subcutaneous region and blood will be collected from the arm. Blood will be analyzed for change in protein abundance and adipose will be analyzed for change in gene expression.
89437144|NCT04541147|Experimental|Dexamethasone plus analgesics|oral dexamethasone of 0.5mg/kg/day (max of 8mg/day), administered on post-operative days 1,3,5,7 in addition to standardized course of analgesics (opioids/acetaminophen/NSAIDs).
89437145|NCT04541147|Active Comparator|analgesics alone|standardized course of analgesics (opioids/acetaminophen/NSAIDs)
89198832|NCT00879957|Active Comparator|Heparin group|The heparin group is the arm of the study in which all of the subjects will be treated according to current standard medical therapy. All fluids to be infused through their PICCs will have 0.5 units heparin per milliliter of intravenous fluid.
89437146|NCT04540705|Experimental|Part 1A (Part 1): Nivolumab + Axitinib|
89437147|NCT04540705|Experimental|Part 1B (Part 1): Nivolumab + Cabozantinib|
89437148|NCT04539964|Experimental|Treatment|Active stimulation for 1 min once per day
89437149|NCT04539964|Sham Comparator|Control|Non-active stimulation for 1 min once per day
88921054|NCT06223009|Experimental|Single ascending doses of cNP8|Subjects will be randomized to receive either a single dose of cNP8 or placebo (6:2). The doses will be studied sequentially starting with the lowest cNP8 dose.
88921055|NCT06223009|Placebo Comparator|Single doses of placebo administered|Subjects will be randomized to receive either a single dose of cNP8 or placebo (6:2).
88921056|NCT06222996|Experimental|Arms|the experimental group will be given web page supported training created by the researcher
88921057|NCT06222996|No Intervention|Control|there will be no interference
88921058|NCT06222983||CEA group|CEA for atherosclerosis
88921059|NCT06222983||CAS group|CEA for atherosclerosis
88921060|NCT06222944|Experimental|Anlotinib, TQB2450 and Albumin-bound Paclitaxel|"Cohort 1: Anlotinib + albumin-bound paclitaxel;~Cohort 2: TQB2450 + albumin-bound paclitaxel;~Cohort 3: Anlotinib + TQB2450 + albumin-bound paclitaxel.~Anlotinib: 12mg PO, QD, D1-14, Q3W;~TQB2450: 1200 mg, IV, D1, Q3W;~Albumin-bound paclitaxel: 125mg/m2 IV Day 1,8, Q3W.~Until disease progression or intolerable toxicity or patient withdrawal of consent."
88921061|NCT06222931|Experimental|Triplanar Vibration (synchronous)|Triplanar vibration, performed at 25 Hz and 4 mm peak-to-peak displacement, for 5 minutes each session, three times a week. Participants will be positioned standing, with knees semi-flexed at 30º.
88921062|NCT06222931|Experimental|Side-alternating vibration|Vibration with alternating side of the base, performed at 25 Hz and 4 mm peak-to-peak displacement, for 5 minutes each session, three times a week. Participants will be positioned standing, with knees semi-flexed at 30º.
88921063|NCT06222931|Sham Comparator|False vibration|Platform identical to the other two used by the experimental groups, configured at 25 Hz, however, without peak-to-peak displacement. The platform starts the engine and emits an operating sound identical to a vibrating platform in operation, but does not generate any mechanical vibration. Participants will be positioned standing, with knees semi-flexed at 30º and must remain on the equipment for 5 minutes each session, three times a week.
88921064|NCT06222918|No Intervention|Supragingival margins|
88921065|NCT06222918|Active Comparator|Subgingival margins (G-ænial Universal Injectable)|"Matrix: Methacrylate monomer %31. Fillers: Silica, Barium Glass %69~G-ænial Universal injectable is a light-cured, radiopaque universal high-strength composite that can be used for all restorative indications while offering excellent viscosity and perfect direct syringe application. It has enhanced thixotropic properties that allow you to create the most beautiful & durable restorations with a minimum of manipulation."
88921066|NCT06222892|Experimental|Part 1: Participants with moderate hepatic impairment receiving Camlipixant|Participants with moderate hepatic impairment will receive Camlipixant
88921067|NCT06222892|Experimental|Part 1: Healthy participants (matched to moderate hepatic impairment) receiving Camlipixant|Healthy participants (matched to moderate hepatic impairment) will receive Camlipixant
88921068|NCT06222892|Experimental|Part 2: Participants with mild hepatic impairment receiving Camlipixant|Participants with mild hepatic impairment will receive Camlipixant
88921069|NCT06222892|Experimental|Part 2: Participants with severe hepatic impairment receiving Camlipixant|Participants with severe hepatic impairment will receive Camlipixant
88921070|NCT06222892|Experimental|Part 2:Healthy participants(matched to mild and/or severe hepatic impairment)receiving Camlipixant|Healthy participants(matched to mild and/or severe hepatic impairment)will receive Camlipixant
88921071|NCT06222879|Experimental|Part A|
88921072|NCT06222879|Experimental|Part B|
88921073|NCT06222879|Experimental|Part C|
88921074|NCT06222866||Patients after cardiovascular surgery who received anticoagulation|The investigated population comprises all patients after cardiovascular surgery who received anticoagulation. Subgroup analyses based on the level of inflammation, delirium, anticoagulation, and others will be conducted.
88921075|NCT06222853|Experimental|CAR-T treatment group|The trial consists of two phases, Dose Exploration (Part A) and Dose Expansion (Part B). In Part A, three dose groups (1×105/kg, 3×105/kg, 5×105/kg) are set up, starting from the low dose group to explore the safe and effective dose. If the optimal effective dose is still not explored in the highest dose group, the dose can be increased according to the situation, and the highest dose is no more than 10×105/kg. Upon the completion of Part A, 1~2 optimal doses are selected by the comprehensive judgment of the investigator and the technical partner to enter into the Part B stage. Each dose group will then be enrolled in 3~6 cases to continue to validate the safety and efficacy. A total enrollment of 10-19 patients is expected in the whole process of the trial.
88921076|NCT06222840||Arm 1|cases with SYN1 gene mutation
88921077|NCT06222840||Arm 2|control cases
88921078|NCT06222814|Active Comparator|Reconstruction group|Patients with ACL injury and antero-lateral knee instability undergo ACL reconstruction combined with anterolateral ligament reconstruction using peroneus longus autograft
89198833|NCT00879957|Experimental|No heparin group|This group will only receive the prescribed fluids to infuse through their PICCs. No heparin will be added to the intravenous infusions.
89437150|NCT04539041|Experimental|Cohort A NIO752|4 injections of NIO752 at dose A
89437151|NCT04539041|Experimental|Cohort B NIO752|4 injections of NIO752 at dose B
89437152|NCT04539041|Placebo Comparator|Placebo|4 injections of placebo
89437153|NCT04539041|Experimental|Cohort C NIO752|4 injections of NIO752 at dose C
89437154|NCT04539041|Experimental|Cohort D NIO752|4 injections of NIO752 at dose D
89437155|NCT04539041|Experimental|Cohort E NIO752|4 injections of NIO752 at dose E
89437156|NCT04527393|Experimental|individualized opioid analgesia regimen group|The dose of oral morphine for patients in the individualized group is determined according to the results of fentanyl test.
88921079|NCT06222814|Active Comparator|Tenodesis group|Patients with ACL injury and antero-lateral knee instability undergo ACL reconstruction combined with extra-articular tenodesis (Modified Lemaire).
88921080|NCT06222762|No Intervention|Control arm|Patient in the control arm will not beneficiate from a follow-up in adapted physical activities (commun practice)
89437157|NCT04527393|Active Comparator|conventional opioid analgesia regimen group|Patients in the conventional group are given routine dose of oral morphine.
89437158|NCT04524949|Experimental|IMCY-0098, low dose|The dose A (Cohort 1) will consist of subcutaneous administrations of 450 µg of the peptide in two separate injections of 225 µg each (500 µL each).
89437159|NCT04524949|Experimental|IMCY-0098, high dose|The dose B (Cohort 2) will consist of subcutaneous administrations of 1350 µg of the peptide in two separate injections of 675 µg each (500 µL each).
89437160|NCT04524949|Placebo Comparator|Placebo|Participants randomized to placebo will receive subcutaneous administrations of identical volumes of placebo solution to maintain study blind.
89437161|NCT04522596|Experimental|Umeclidinium/vilanterol|Umeclidinium/vilanterol 55/22 μg inhaled once a day for 14 days.
89437162|NCT04522596|Placebo Comparator|Placebo|Placebo inhaled once a day for 14 days.
89437163|NCT04520776|Experimental|BAGUERA®C|surgical placement of the BAGUERA®C Cervical Disc Prosthesis
89437164|NCT04520776|Active Comparator|Mobi-C®|surgical placement of the Mobi-C® Cervical Disc
89437165|NCT04513925|Experimental|Atezolizumab + Tiragolumab|Participants will receive atezolizumab administered intravenously (IV) on Day 1 of each 28-day cycle followed by tiragolumab administered IV on Day 1 of each 28-day cycle for a maximum of 13 cycles.
89437166|NCT04513925|Active Comparator|Durvalumab|Participants will receive durvalumab administered IV during each 28-day cycle for a maximum of 13 cycles.
88921081|NCT06222762|Experimental|Experimental arm|Patient in the control arm will beneficiate from a follow-up in adapted physical activities
88921082|NCT06222736|Experimental|Rocabado exercises group|The most commonly known form of exercise for Temporomandibular Disfunction is Rocabado exercises, which use 6 types of exercises 6 times a day.
88921083|NCT06222736|Experimental|Servical Core Exercises Group|The purpose of core exercises is to support the vertebral column, especially by activating the stabilizing muscles, and to develop and maintain proper cervical posture by increasing kinesthetic awareness. At the beginning of the exercises, the patient is taught to contract the deep stabilizer muscles in a controlled manner, in isolation, without contraction of the superficial muscles. Exercises 2 days a week for 8 weeks, maximum 30 minutes. The session will be actively applied by the patient for a period of time.
88921084|NCT06222736|Experimental|Rocabado Exercises and Servical Core Exercises Group|The most commonly known form of exercise for Temporomandibular Disfunction is Rocabado exercises, which use 6 types of exercises 6 times a day. The purpose of Servical Core exercises is to support the vertebral column, especially by activating the stabilizing muscles, and to develop and maintain proper cervical posture by increasing kinesthetic awareness. At the beginning of the exercises, the patient is taught to contract the deep stabilizer muscles in a controlled manner, in isolation, without contraction of the superficial muscles. Exercises 2 days a week for 8 weeks, maximum 30 minutes. The session will be actively applied by the patient for a period of time.
88921085|NCT06222723|Active Comparator|Standard of care|Standard of care antiviral ribavirin therapy
88921086|NCT06222723|Experimental|Standard of care + dexamethasone|Standard of care antiviral ribavirin therapy + dexamethasone
88921087|NCT06222671|Experimental|608 Dose A|608 Dose A subcutaneous (SC) injection.
88921088|NCT06222671|Experimental|608 Dose B|608 Dose B subcutaneous (SC) injection.
88921089|NCT06222671|Placebo Comparator|Placebo|Placebo subcutaneous (SC) injection.
88921090|NCT06222658|Experimental|Patient assigned to pharmacomechanichal thrombectomy|
89198834|NCT00874809|Other|Insulin Treatment|There is only one arm for this study using lispro insulin administered by insulin pump.
89437167|NCT04512209|Experimental|DCE-MRI|
89437168|NCT04509791|Placebo Comparator|placebo|placebo arm
89437169|NCT04509791|Active Comparator|2.5 mg ATG/kg|the trial consists of 7 cohorts. The first cohort of 30 participants will be randomised to placebo, 2.5 mg/kg, 1.5 mg/kg, 0.5 mg/kg en 0.1 mg/kg in a 1:1:1:1:1 allocation ratio
89437170|NCT04509791|Active Comparator|1.5 mg ATG/kg|the next two cohorts of 12 participants will be randomised to placebo, 2.5 mg/Kg, and 2 specified middle ATG total doses in a 1:1:1:1 allocation ratio
88921094|NCT06222619||Resection without PVE|Resection of bile duct and associated hemi-liver without portal vein embilzation
88921095|NCT06222619||Resection after PVE|Resection of bile duct and associated hemi-liver after portal vein embilzation
88921096|NCT06222619||No resection after PVE|No resection of bile duct and associated hemi-liver after portal vein embilzation
88921097|NCT06222606|No Intervention|Control group|Patients randomized to the experimental group will have surgery performed in the exact same manner as in the control group.
89437171|NCT04509791|Active Comparator|0.5 mg ATG/kg|The next four cohorts of 15 participants will be randomised to placebo, 2.5 mg/kg and a single selected middle ATG total dose in a 1:1:1 allocation ratio
89437172|NCT04509791|Active Comparator|0.1 mg ATG/kg|the trial consists of 7 cohorts. The first cohort of 30 participants will be randomised to placebo, 2.5 mg/kg, 1.5 mg/kg, 0.5 mg/kg en 0.1 mg/kg in a 1:1:1:1:1 allocation ratio
89437173|NCT04504357|No Intervention|Arm A- No intervention|Participants randomized to Arm A will receive no research intervention.
89437174|NCT04504357|Experimental|Arm B- U=U app|"Participants randomized to Arm B will receive controlled exposure to the tablet-based U=U app."
89437175|NCT04504357|Active Comparator|Arm C- clinical exposure demonstration|Participants randomized to Arm C will be shown U=U videos in clinic waiting rooms and the tablet-based app will be integrated into routine counseling
89437176|NCT04503668|Active Comparator|Nk1-RA|Nk1-RA will be given on day 1 of each 3-week chemotherapy cycle, for up to 6 cycles.
89437177|NCT04503668|Experimental|Olanzapine|Olanzapine will be given on days 1-4 of each 3-week chemotherapy cycle, for up to 6 cycles.
89437178|NCT04503616|Experimental|HSCT Patients|Adult patients with hematological malignancies undergoing HLA-haploidentical HSCT from first-or second-degree family donors.
88921098|NCT06222606|Experimental|Surgery with EleVision IR camera system|In the experimental group, the surgeon will use the EleVision IR camera system (Medtronic, USA) to visualize PGs during surgery. The surgeon will use AF at minimum two timepoints on each side of the neck: First, when the thyroid lobe is exposed and mobilized, and secondly after removal of the thyroid lobe. This is repeated in the contralateral side of the neck in case of TT. If a central neck dissection is performed, the specimen is also examined with AF following removal. Autotransplantation of inadvertently removed PGs may be performed after frozen section histology.
88921099|NCT06221644||MSA patients group|The patient cohort consisted of 30 MSA-C and 30 MSA-P cases, diagnosed according to the 2008 Second Consensus Criteria and confirmed by two experienced neurologists
88921100|NCT06221644||healthy controls (HCs) group|30 gender and age-matched HCs were included
88921101|NCT06221462|Experimental|treatment arm|
89198835|NCT02534155|Active Comparator|MitraClip® Therapy|MitraClip® system is a CE marked medical device, which consists of two parts (Clip Delivery System and Steerable Guide Catheter). It is a single sized, percutaneously implanted mechanical Clip. The MitraClip® device grasps and coapts the mitral valve leaflets resulting in fixed approximation of the mitral leaflets throughout the cardiac cycle. The procedure is performed in the cardiac catheterisation laboratory with echocardiographic and fluoroscopic guidance while the patient is under general anaesthesia.
89437179|NCT04496141||With COVID-19 infection|Subjects with a positive SARS-CoV-2 PCR
88921102|NCT06221332|Active Comparator|SACRAL EREKTÖR SPİNAE PLANE BLOK|Pregnant women in Group S will be given 10 cc bupivacaine solution of 0.25% bupivacaine on both sides.
88921103|NCT06221332|Active Comparator|control group|Pregnant women in Group K will be injected with 10 cc of saline on both sides.
88921104|NCT06221319|No Intervention|control group|Group K IV to patients paracetamol 1 gr. It will be administered 3x1 + Dexketoprofen 50 mg 2x1. All patients will be administered 1mg/kg tramadol as rescue analgesic when NRS is 3 and above . 4mg IV to all patients with nausea and vomiting Ondansetron will be administered.
88921105|NCT06221319|Active Comparator|Sacral erektör spinae plane group|sacral erector spinae plane will be applied to patients in Group S
88921106|NCT06220903|Experimental|Treatment Group|Complex DecongestivePhysiotherapy program was planned for the affected extremity of the cases. The treatment was performed 5 days a week, for 4 weeks, for a total of 20 sessions and each session was 60 minutes. The treatment included Manual Lymph Drainage, skin care, multi-layer bandaging, exercise and compression stockings.
88921107|NCT06220682||normal group|25 patients angiographically normal coronaries
88921108|NCT06220682||atherosclerotic non dilated group|25 patients angiographically had atherosclerotic plaques with no coronary dilatations
88921109|NCT06220682||dilated non atherosclerotic group|25 patients angiographically involved coronary dilatations with no atherosclerotic plaques
88921110|NCT06220682||dilated atherosclerotic group|25 patients angiographically had both coronary dilatations and atherosclerotic plaques
88921111|NCT06220448||BAGI|patients suffering from thoraco-abdominal blunt trauma with and without blunt adrenal gland injury
88921112|NCT06220344|Experimental|Honey|Participants will get honey dressings in their follow-up visits to the dressing room.
88921113|NCT06220344|Active Comparator|Aseptic Iodine|Participants will get iodine solution dressings in their follow-up visits to the dressing room.
88921114|NCT06220318|Experimental|C019199 plus Sintilimab|Patients with selected tumors will received oral C019199 at a starting dose of 100mg once daily in combination with intravenous Sintilimab 200mg every 3 weeks ( Q3W ) on a 21-day treatment cycle until disease progression, development of unacceptable toxicity, or withdrawal of consent .
88921115|NCT06220071||Vertebral metastases|Patients affected by spinal metastases that are not surgically treated
89437180|NCT04496141||Without COVID-19 infection|Subjects with COVID-19 negative serum
89437181|NCT04493996|Experimental|Cognitive training group|
89437182|NCT04493996|No Intervention|Control group|
89437183|NCT04491084|Experimental|FLT3 ligand (CDX-301), anti-CD40 antibody (CDX-1140), and SBRT|"Subjects on either study arm with limited disease will receive SBRT to all evident sites of active disease. Subjects on Arm 1 with extensive disease will initially receive SBRT to a single site of disease but may receive additional cycles of FLT3 ligand, anti-CD40 antibody, and SBRT at later time points."
89437184|NCT04491084|Active Comparator|Standard care|Subjects on either study arm with limited disease will receive SBRT to all evident sites of active disease.Subjects on Arm 2 with extensive disease are expected to receive some form of standard systemic therapy (e.g., docetaxel). Subjects on Arm 2 with limited disease may also receive standard systemic therapy following completion of SBRT to all sites of evident disease, at the discretion of the treating physicians.
89437185|NCT04484441||Fetal surgical intervention group|Pregnant adult women carrying a fetus with a diagnosed congenital anomaly and scheduled to undergo fetal surgical intervention at Mayo Clinic.
89437186|NCT04484441||Control group - normal pregnancy|Pregnant adult women with normal ultrasound findings. These women will be matched with the subjects enrolled in the intervention cohort for parity, maternal age, ethnicity, fetal sex and gestational age at time of surgical intervention.
89437187|NCT04482595|Experimental|BIO 300 Oral Suspension (genistein 1500 mg)|BIO 300 Oral Suspension (genistein 1500 mg) will be self-administered daily for 7 days each week for 12 weeks.
89437188|NCT04482595|Placebo Comparator|Placebo|BIO 300 Oral Suspension matched placebo will be self-administered daily for 7 days each week for 12 weeks.
89437189|NCT04480255|Active Comparator|Group 1: Standard of Care|Parents of infants born from date July 2020-December 2020
89437190|NCT04480255|Active Comparator|Group 2: NICU2HOME+ app|Parents of infants born from mid Jan 2021-May2021
89437191|NCT04479514|Experimental|Preventative Skin Care Routine|"Participants will perform a preventative skin care routine that includes daily sun protection, daily gentle skin care and every-other-day dilute bleach baths for the duration of the study.~Participants will receive skin examinations and complete a survey about their skin condition at the initial visit when anti-cancer treatment is started, at six weeks after the start of treatment, and at twelve weeks after the start of treatment."
89437192|NCT04478773|Experimental|Experimental|Patient will receive MRI
89437193|NCT04475744|No Intervention|Control arm|POI women radomized to control arm will undergo a 3-month follow up for: AFC, AMH, FSH and E2 determinations.COS will be initiated if growing antral follicles detected. In the second phase, POI women allocated to control group after completed the follow up period will undergo the 4-step ASCOT technique, as described in the previous phase but only one ovary will be injected, then they will undergo a 6-month follow up period as described above.
89437194|NCT04475744|Experimental|4-step ASCOT arm|POI women randomized to the 4-step ASCOT technique will receive a direct ovarian injection of G-CSF mobilized and activated PRP. For each patient, both ovaries will be directly injected with the G-CFS activated PRP (4-step ASCOT). Follow up (AFC, AMH, FSH and E2 determinations) will be developed for 6 months and COS initiated if growing antral follicles detected.
89437195|NCT04470791|Experimental|F(ab')2 antivenom plus local cryotherapy.|Group A: patients with a Crotalus snakebite, and grade II envenomation received F(ab')2 antivenom therapy and application of local cryotherapy.
89437196|NCT04470791|Active Comparator|F(ab')2 antivenom.|Group B: patients who received only F(ab')2 antivenom therapy.
89437197|NCT04463706||COVID19 REDISSEC|Patients admitted (confirmed cases) by CoVid-19, excluding paediatric population. No losses are expected. A case of SARS-CoV-2 infection is defined as one that meets the laboratory criteria: PCR positive for a specific gene [RdRp or S gene] or PCR positive for at least 2 genes used for screening [E or N gene].
89437198|NCT04463706||COVID19 Basque Country|All people from thw Basque Country positive to CoVid-19. A case of SARS-CoV-2 infection is defined as one that meets the laboratory criteria: PCR positive for a specific gene [RdRp or S gene] or PCR positive for at least 2 genes used for screening [E or N gene], or, as well and in the general population of the Basque Country, by detection of COVID-19 IgM or IgG antibodies.
89437199|NCT04462471|Experimental|Participants with thyroid cancer|Eligible participants will have a diagnosis of BRAF mutant RAIR thyroid cancer
89437200|NCT04461509|Experimental|ARM 1 (HIFU) - 18F-PSMA|10 mCi ±20% F18-PSMA injection
88921116|NCT06219759||ALS patients|"Patients enrolled prior to determination of diagnosis on referral to neurophysiological examination. When the diagnosis is later established they get categorized as ALS patients.~ALS patients with recent diagnosis might also be included directly."
89437201|NCT04461509|Experimental|ARM 2 (RP) - 18F-PSMA|10 mCi ±20% F18-PSMA injection
89437202|NCT04454944|No Intervention|Control|All individuals in each arm will have a well-functioning LPG cookstove and gas cylinder. Participants in the control arm will receive no other intervention.
89437203|NCT04454944|Experimental|No subsidy, distance variation|All individuals in each arm will have a well-functioning LPG cookstove and gas cylinder. This intervention arm will receive an assigned depot where they have to make liquefied petroleum gas (LPG) purchases.
89198836|NCT02534155|Active Comparator|Surgery|Surgical therapy of degenerative mitral regurgitation: repair or replacement of mitral valve, clinical standard
89198837|NCT00880035|Experimental|Group A|Group A: day 1 = music, day 2 = washout, day 3 = headphone without music
88921117|NCT06219759||ALS mimic disease patients|Patients enrolled prior to determination of diagnosis on referral to neurophysiological examination. When diagnosis is later established and the diagnosis is NOT ALS they get categorized as ALS mimic disease patients.
88921118|NCT06219759||Healthy controls|Healthy controls.
88921119|NCT06219759||Disease controls|Patients with another motor neuron disease than ALS with slow progression.
88921120|NCT06218537|Experimental|Test group|The test group - 10 minutes before upper GI endoscopy, patients will drink a solution of 50ml water + 2 capsules of KREON 25000 UI, opened (with minimicrospheres, pellets) + 1.2g sodium bicarbonate, mixed. Adding sodium bicarbonate is necessary to dissolve the minimicrospheres of KREON.
88921121|NCT06218537|Sham Comparator|Control group|The control group - 10 minutes before upper GI endoscopy, patients will drink a solution of 50ml water + 1.2g sodium bicarbonate, mixed.
88921122|NCT06217198|Experimental|Deprexis|Deprexis: an internet-delivered psychosocial treatment for depressive symptoms and related functional impairment.
88921123|NCT06217198|No Intervention|Treatment-as-Usual|Access to standard non-study care
88921124|NCT06217120|Active Comparator|COLCHICINE|
88921125|NCT06217120|Placebo Comparator|PLACEBO|
88921126|NCT06212388|Experimental|group A: IFN-α1B+ γδ T cells|"Stage 1: Neoadjuvant stage (Week 1-9, 3 cycles)~Stage 2: Surgical period (2 weeks, ±7 days after the last dose of neoadjuvant therapy) After multidisciplinary MDT team evaluation, the primary lesion and metastasis were resected in the corresponding departments.~Stage 3: Postoperative adjuvant period (3 weeks ±7 days -45 weeks, 15 cycles) γδ T cells administered intravenously every three weeks. Recombinant human interferon α1b administered 300μg every other day."
88921127|NCT06212388|Active Comparator|group B: Palizizumab+ γδ T cells|"Stage 1: Neoadjuvant stage (Week 1-9, 3 cycles)~Stage 2: Surgical period (2 weeks, ±7 days after the last dose of neoadjuvant therapy) After multidisciplinary MDT team evaluation, the primary lesion and metastasis were resected in the corresponding departments.~Stage 3: Postoperative adjuvant period (3 weeks ±7 days -45 weeks, 15 cycles) γδ T cells administered intravenously every three weeks.Pembrolizumab administered 200mg intravenously every three weeks."
88921128|NCT06212284|Other|citalopram first, placebo second|Citalopram was taken first. Placebo was taken at least 7 days later.
88921129|NCT06212284|Other|placebo first, citalopram second|Placebo was taken first. Citalopram was taken at least 7 days later.
88921130|NCT06212232|Experimental|Experimental: Test Group|Use of a new piezoelectric technique in third molar surgery
88921131|NCT06212232|Active Comparator|Traditional: Control Group|Use of the traditional technique in third molar surgery
88921132|NCT06211257|No Intervention|Control group : standard PCP|Patient will receive standard support PCP
88921133|NCT06211257|Experimental|Experimental group : demateralized PCP|Patient will receive standard support PCP and dematerialized PCP (ePCP)
88921134|NCT06207734|Active Comparator|Control arm CDK4/6 continuation|"Continuation of CDK4/6 inhibitor treatment~Continuation of endocrine treatment"
88921135|NCT06207734|Experimental|Experimental arm CDK4/6 inhibitor discontinuation|"Discontinuation of CDK4/6 inhibitor treatment~Continuation of endocrine treatment"
88921136|NCT06206707|Experimental|Faecal microbiota transplantation (FMT)|Patients receive two applications of capsule FMT with 3-7 days between applications.
88921137|NCT06206707|Placebo Comparator|Placebo|Patients receive two applications of placebo capsules with 3-7 days between applications.
88921138|NCT06206603||Colorectal polyps|Biopsies will be obtained from the polyp and from adjacent healthy intestinal mucosa. A blood sample will be collected to investigate if certain microRNA/mRNA profiles are traceable in the blood.
88921139|NCT06206603||Colorectal cancer|Biopsies will be obtained from the cancer and from adjacent healthy intestinal mucosa. A blood sample will be collected to investigate if certain microRNA/mRNA profiles are traceable in the blood.
88921140|NCT06206603||Healthy controls|Biopsies will be obtained from predefined locations in the colon and rectum. A blood sample will be collected to investigate if certain microRNA/mRNA profiles are traceable in the blood.
88921141|NCT06204848|Experimental|Imaging using the SVO-ID|Patients will have their eyes imaged with the SVO-ID as part of a study visit.
88921142|NCT06204276|Experimental|Asymmetrical high-flow nasal cannula|"Asymmetrical nasal cannula (Optiflow+ Duet nasal cannula)~Airvo-2 (Fisher&Paykel)"
88921143|NCT06204276|Active Comparator|Conventional high-flow nasal cannula|"Conventional nasal cannula (Optiflow+ nasal cannula)~Airvo-2 (Fisher&Paykel)"
88921144|NCT06202274|Experimental|Treatment|Treatment will be performed with commercial products manufactured by Candela and may also include non-Candela products. All devices will be used per the manufacturer's instructions.
88921145|NCT06201741|Experimental|[131I]/[18F]/[68Ga]ZT-111|[131I]/[18F]/[68Ga]ZT-111, single dose
88921146|NCT06199232|Experimental|Treatment Arm|HAIC combined with targeted therapy and PD-1 inhibitor
88921147|NCT06196905|Experimental|MT-2990|MT-2990 will be administered intravenously every 4 weeks for a total of 6 doses.
89437204|NCT04454944|Experimental|Subsidy, no distance variation|All individuals in each arm will have a well-functioning LPG cookstove and gas cylinder. This intervention arm receives a price subsidy on liquefied petroleum gas (LPG) purchases.
88921149|NCT06192160|Active Comparator|Arm 1: Standard of Care (SOC)|"Weeks 1-8: INH 300 mg, RIF 600 mg, PZA weight-based, EMB weight-based~Weeks 9-26: INH 300 mg, RIF 600 mg"
88921150|NCT06192160|Experimental|Arm 2: Bedaquiline (BDQ), Pretomanid (Pa), and Linezolid (LZD)|"Weeks 1-8: BDQ 400 mg for 2 weeks and then 200 mg for 6 weeks, Pa 200 mg, LZD 600 mg~Weeks 9-26: INH 300 mg, RIF 600 mg"
88921151|NCT06192160|Experimental|Arm 3A: BDQ, Pa and TBI-223 (1200 mg)|"Weeks 1-8: BDQ 400 mg for 2 weeks and then 200 mg for 6 weeks, Pa 200 mg, TBI-223 1200 mg~Weeks 9-26: INH 300 mg, RIF 600 mg"
88921152|NCT06192160|Experimental|Arm 3B: BDQ, Pa and TBI-223 (2400 mg)|"Weeks 1-8: BDQ 400 mg for 2 weeks and then 200 mg for 6 weeks, Pa 200 mg, TBI-223 2400 mg~Weeks 9-26: INH 300 mg, RIF 600 mg"
88921153|NCT06192160|Experimental|Arm 4A: BDQ, Pa and Sutezolid (SZD) (800 mg)|"Weeks 1-8: BDQ 400 mg for 2 weeks and then 200 mg for 6 weeks, Pa 200 mg, SZD 800 mg~Weeks 9-26: INH 300 mg, RIF 600 mg"
88921154|NCT06192160|Experimental|Arm 4B: BDQ, Pa and SZD (1600 mg)|"Weeks 1-8: BDQ 400 mg for 2 weeks and then 200 mg for 6 weeks, Pa 200 mg, SZD 1600 mg~Weeks 9-26: INH 300 mg, RIF 600 mg"
88921155|NCT06187168||intraoperative hypotension|The exposure is intra-operative hypotension during the ERCP procedure (hypotension is defined as a 20% reduction in the mean arterial blood pressure (MAP) or systolic arterial blood pressure (SAP) < 90 mmHg during CBD manipulation or after obstruction relief). The basal blood pressure (BP) will be the immediate reading before the endoscope insertion while the patient is in his left lateral position.
88921156|NCT06187168||No intraoperative hypotension|Not meeting the above definition of hypotension per our protocol (by timing, threshold, and method).
88921157|NCT06179212||CPETs|Patients will perform all 4 maximal cardiopulmonary exercise tests in randomized order. The protocols they will perform are: Modified Bruce, modified Naughton, modified Balke and the UOHI Slow Ramp.
88921158|NCT06171633|Experimental|Intervention Group / year 1|Beginning in year 1, participants access online video modules through an online learning platform for up to 9 months.
88921159|NCT06171633|Experimental|Control Condition Group / year 1|Beginning in year 1, participants access online video modules through an online learning platform for up to 9 months.
88921160|NCT06171633|Experimental|Intervention Group / year 2|Beginning in year 2, participants access online video modules through an online learning platform for up to 9 months.
88921161|NCT06171633|Experimental|Control Condition Group / year 2|Beginning in year 2, participants access online video modules through an online learning platform for up to 9 months.
89437205|NCT04454944|Experimental|Subsidy, distance variation|All individuals in each arm will have a well-functioning LPG cookstove and gas cylinder. This intervention arm receives a price subsidy on liquefied petroleum gas) (LPG) purchases an assigned depot where they have to make liquefied petroleum gas (LPG) purchases.
89437206|NCT04442126|Experimental|NM21-1480 Treatment arm|
88921162|NCT06168318|Experimental|Part 1 - Regimen A|VH4004280 Formulation A tablet administered in fed conditions.
88921163|NCT06168318|Experimental|Part 1 - Regimen B|VH4004280 Formulation B tablet administered in fed conditions.
88921164|NCT06168318|Experimental|Part 1 - Regimen C|VH4004280 Formulation C tablet administered in fed conditions.
88921165|NCT06168318|Experimental|Part 1 - Optional Regimen D|VH4004280 Formulation D tablet administered in fed conditions.
88921166|NCT06168318|Experimental|Part 1 - Optional Regimen E|VH4004280 Formulation E tablet administered in fed conditions.
88921167|NCT06168318|Experimental|Part 2 - Regimen A|VH4004280 Formulation A tablet administered in fasted conditions.
88921168|NCT06168318|Experimental|Part 2- Optional Regimen 1|VH4004280 Formulation B, C, D, or E tablet administered in fasted conditions.
88921169|NCT06168318|Experimental|Part 2- Optional Regimen 2|VH4004280 Formulation B, C, D, or E tablet administered in fasted conditions.
88921170|NCT06168318|Experimental|Part 2- Optional Regimen 3|VH4004280 Formulation B, C, D, or E tablet administered in fasted conditions.
88921171|NCT06153797|Experimental|PATH-C|"Participants will be recruited from the Dana-Farber Cancer Institute and randomized in a 1:1 fashion, stratified by transplant type (autologous versus allogeneic), to PATH-C versus usual care.~Caregivers of patients undergoing HSCT will receive the PATH-C intervention to learn to reflect on their positive emotions and consistently use and incorporate positive psychology exercises in their daily routine, as well as learn how to set goals and track their physical activity (i.e., with an activity tracker) daily while caring for a loved one undergoing HSCT.~Participants will complete questionnaires (in person, over the computer or telephone, or by mail) at predetermined days per protocol."
88921172|NCT06153797|No Intervention|Usual Care|"Participants will be recruited from the Dana-Farber Cancer Institute and randomized in a 1:1 fashion, stratified by transplant type (autologous versus allogeneic), to PATH-C versus usual care.~Participants will complete questionnaires (in person, over the computer or telephone, or by mail) at predetermined days per protocol.~Participants in the usual care arm will receive their usual support from the HSCT team as caregivers of patients undergoing HSCT, including all routine supportive care resources (e.g., support from social work) offered by the HSCT team.~Patients in the usual care and PATH-C groups will be permitted to use all supportive care services per standard care. The investigators will track referrals to supportive care services in both groups by reviewing the Electronic Health Record (EHR)."
88921173|NCT06152744||High-altitude group|
88921174|NCT06152744||Low-altitude group|
88921175|NCT06148597||Group M-TAPA|
88921176|NCT06148597||Group Control|
88921177|NCT06144944|Experimental|Neoadjuvant pyrotinib combined with chemotherapy|
88921178|NCT06144944|Placebo Comparator|Neoadjuvant chemotherapy|
88921179|NCT06142955|Experimental|ASD with depression, iTBS then Sham|Participants having ASD with depression will undergo EEG and ET with TMS prior to and following a single iTBS session. Participants first received iTBS then sham approximately one week apart.
89437207|NCT04436991||Amoxicillin-clavulanate|Administration of amoxicillin-clavulanate as standard care therapy (4x or 6x 1g/d). Blood sampling in early and steady state dose (up to 5 samplings per dose). Collection of hemocultures, urine samples and sputum samples when possible.
88921180|NCT06142955|Experimental|ASD with depression, Sham then iTBS|Participants having ASD with depression will undergo EEG and ET with TMS prior to and following a single iTBS session.Participants first received sham then iTBS approximately one week apart.
88921181|NCT06142955|Experimental|ASD without depression, iTBS then Sham|Participants having ASD without depression will undergo EEG and ET with TMS prior to and following a single iTBS session. Participants first received iTBS then sham approximately one week apart.
89437208|NCT04436991||Piperacillin-tazobactam|Administration of piperacillin-tazobactam as standard care therapy (4x 4g/d). Blood sampling in early and steady state dose (up to 5 samplings per dose). Collection of hemocultures, urine samples and sputum samples when possible.
89437209|NCT04436991||Temocillin|Administration of temocillin as standard care therapy (2x or 3x 2g/d). Blood sampling in early and steady state dose (up to 5 samplings per dose). Collection of hemocultures, urine samples and sputum samples when possible.
89437210|NCT04435626|Experimental|Arm 1_BAY94-8862|Adult patients receive BAY94-8862
89437211|NCT04435626|Placebo Comparator|Arm 2_Placebo|Adult patients receive placebo
89437212|NCT04431206|Experimental|Oxytocin|Oxytocin administered by IV infusion
89437213|NCT04429945|Experimental|Immersive Virtual Reality|A Virtual Reality headset will be used for 30 minutes twice per day outside of usual therapy times while in bed with bedrails raised. Virtual Reality games will be selected that will help with relaxation, pain, and arm and hand recovery after a stroke.
89437214|NCT04416815|No Intervention|Usual care|The participants allocated to the control group received no intervention. However, they could, on their own initiative, approach the usual range of community or health services (e.g., home help services, rehabilitation, or medical care).
89437215|NCT04416815|Experimental|eHealth|The intervention will be delivered for 6 months on top of usual care.
89437216|NCT04416412||Open Fracture Cohort|"Patients 18 years of age or older. Open extremity fracture. Planned definitive fracture management with external fixation, internal fixation, or joint fusion.~Open fracture wound management that includes formal surgical debridement within 72 hours of their injury.~Will have all planned fracture care surgeries performed by a participating surgeon or delegate.~Provision of informed consent."
89437217|NCT04416061||Subjects underwent COVID-19 test|Subjects who underwent COVID-19 test in HKSH during the study period
89437218|NCT04414540|Experimental|Arm 1: Metformin before Pembrolizumab|Metformin ER 1000mg daily D-14 to D-7. Metformin ER 2000mg daily D-7 to D1. D1 Begin Pembrolizumab 200mg every 3 weeks, while continuing Metformin ER 2000mg daily.
89437219|NCT04414540|Experimental|Arm 2: Metformin after Pembrolizumab|D-21 Begin Pembrolizumab 200mg. D-7 begin Metformin ER 1000mg daily. D1 begin Metformin ER 2000mg daily. Continue Pembrolizumab 200mg every 3 weeks.
89437220|NCT04411810|Experimental|Participants with skin lesions|Participants who have up to 3 concerning skin lesions will be evaluated by both an in-person dermatologist and a team of three teledermatologists(board-certified dermatologists). The teledermatoogy team will deliver a consensus recommendation. If either the in-person dermatologist or teledermatologists are concerned that the skin spot(s) may be a skin cancer, a biopsy will be recommended and can be performed at no charge. Or if both agree that the spot(s) are not concerning for skin cancer, no biopsy will be needed.
89437221|NCT04409639|Experimental|Treatment: all patients|Cobimetinib is taken on a 28-day cycle. Each dose consists of three 20 mg tablets (60 mg) and should be taken once daily for 21 consecutive days (Days 1 to 21-treatment period); followed by a 7-day break (Days 22 to 28-treatment break). Each subsequent cobimetinib treatment cycle should start after a 7-day treatment break has elapsed.
89437222|NCT04408482|Active Comparator|Pancreatic sphincterotomy|Pancreatic sphincterotomy performed in difficult cannulation
89437223|NCT04408482|Active Comparator|Pancreatic sphincterotomy + pancreatic stent|Pancreatic sphincterotomy performed in difficult cannulation + pancreatic stent placement
88921182|NCT06142955|Experimental|ASD without depression, Sham then iTBS|Participants having ASD without depression will undergo EEG and ET with TMS prior to and following a single iTBS session.Participants first received sham then iTBS approximately one week apart.
88921183|NCT06142955|Experimental|TD with depression, iTBS then Sham|Participants that are TD with depression will undergo EEG and ET with TMS prior to and following a single iTBS session. Participants first received iTBS then sham approximately one week apart.
88921184|NCT06142955|Experimental|TD with depression, Sham then iTBS|Participants that are TD with depression will undergo EEG and ET with TMS prior to and following a single iTBS session. Participants first received sham then iTBS approximately one week apart.
89198838|NCT00880035|Experimental|Group B|Group B: day 1 = headphone without music, day 2 = washout, day 3 = music
89198839|NCT00761436|Experimental|Arm 1|
89437224|NCT04408352|Active Comparator|RF Trigone Ablation Treatment Arm|A compatible standard cystoscopy lens (30°) will be inserted into the Hologic trigone RF Device. The bladder will be emptied of urine and saline infused into the bladder to allow adequate visualization and working space. Ablations at the trigone will be created using the Hologic trigone RF ablation device together with the compatible standard commercially available RF cannula and generator. It is expected that a subject would receive between 4-6 ablations to completely treat the appropriate area of the trigone. At the completion of the procedure, 200 ml of saline is instilled into the bladder to allow for assessment of voiding function prior to discharge.
88921185|NCT06142955|Experimental|TD without depression, iTBS then Sham|Participants that are TD without depression will undergo EEG and ET with TMS prior to and following a single iTBS session. Participants first received iTBS then sham approximately one week apart.
89198840|NCT00880113||Acute stroke|Patients over 18 years of age with acute stroke symptoms of less then 9 hours duration and no hemorrhage on non-contrast CT.
89011241|NCT03001804||Cohort B|Initial treatment (up to 8 cycles): Lenalidomide 25mg or 10mg (reduced renal function 30 ≤ ClCr < 50mg/min) capsule by mouth (PO) on day 1 through 14 of a 21 day cycle, Bortezomib 1.3mg/m2 s.c. on day 1, 4, 8, and 11 of a 21 day cycle, and Dexamethasone 20mg PO on days 1,2,4,5,8,9,11,12 of a 21 day cycle; Successive Treatment: Lenalidomide 25mg or 10mg (reduced renal function 30 ≤ ClCr < 50mg/min) capsules by mouth (PO) on days 1 through 21 of a 28 day cycle and Dexamethasone 40mg PO (≤75 years) or 20mg (>75years) on Days 1, 8, 15, 22 of a 28 day cycle until progression or unacceptable toxicity
89011242|NCT02986100|Experimental|C-14 labeled rucaparib|"Each patient will receive a single oral dose of 600 mg [14C] rucaparib (approximately 140 µCi) in the fasted state. Patients will be confined at the study site for the collection of blood samples and excreta for a maximum of 13 days, from Day -1. The patient can be discharged sooner than Day 13, if the discharge criteria are met.~After completion of Part I, patients with a deleterious BRCA mutation will have the option to participate in Part II by receiving 600 mg BID rucaparib tablets orally in 28 day cycles until disease progression, unacceptable toxicity, death, or discontinuation for other reasons"
89011243|NCT02985684|Experimental|Device|ASD closure with the GORE® CARDIOFORM ASD Occluder
89011244|NCT02959450|Experimental|Modified consistency and volume diet|Modified consistency diet, with a certain viscosity and controlled volume. The nectar consistency had a viscosity of 51 to 350 centiPoises (cP) and the pudding consistency menus with a higher viscosity at 1,750 cP.
89011245|NCT02959450|No Intervention|Control Group|Standard treatment consisting of a modified consistency diet with adequate intake of energy and protein and general recommendations on diet prescribed by the treating physician
89011246|NCT02952534|Experimental|Rucaparib|Oral rucaparib (monotherapy)
89011247|NCT02949934|Placebo Comparator|Placebo/rs4680 val/val|"Placebo three times per day for eight days~Individuals with the rs4680 val/val genotype"
89011248|NCT02949934|Active Comparator|Tolcapone/rs4680 val/val|"Tolcapone 100 mg three times per day for three days Tolcapone 200 mg three times per day for five days~Individuals with the rs4680 val/val genotype"
89011249|NCT02949934|Placebo Comparator|Placebo/rs4680 val/met|"Placebo three times per day for eight days~Individuals with the rs4680 val/met genotype"
89011250|NCT02949934|Active Comparator|Tolcapone/rs4680 val/met|"Tolcapone 100 mg three times per day for three days Tolcapone 200 mg three times per day for five days~Individuals with the rs4680 val/met genotype"
89011251|NCT02949934|Placebo Comparator|Placebo/rs4680 met/met|"Placebo three times per day for eight days~Individuals with the rs4680 met/met genotype"
89011252|NCT02949934|Active Comparator|Tolcapone/rs4680 met/met|"Tolcapone 100 mg three times per day for three days Tolcapone 200 mg three times per day for five days~Individuals with the rs4680 met/met genotype"
89011253|NCT02935634|Active Comparator|Nivolumab + Ipilimumab|
89011254|NCT02935634|Experimental|Nivolumab + Relatlimab|
89011255|NCT02935634|Experimental|Nivolumab + BMS-986205|
89011256|NCT02935634|Experimental|Nivolumab + Rucaparib|
89011257|NCT02935634|Experimental|Ipilimumab + Rucaparib|
89011258|NCT02935634|Experimental|Nivolumab + Ipilimumab + Rucaparib|
89011259|NCT02864992|Other|Part 1: Cohort A: METex14 Skipping Alterations|Participants received 500 milligram (mg) of tepotinib once daily in cycles of 21-day duration until disease progression, death, adverse event (AE) leading to discontinuation or withdrawal of consent.
89011260|NCT02864992|Other|Part 1: Cohort B: MET Amplification|Participants received 500 milligram (mg) of tepotinib once daily in cycles of 21-day duration until disease progression, death, adverse event (AE) leading to discontinuation or withdrawal of consent.
89011261|NCT02864992|Other|Part 2: Cohort C: Confirmatory Part for METex14 Skipping Alterations|Participants received 500 milligram (mg) of tepotinib once daily in cycles of 21-day duration until disease progression, death, adverse event (AE) leading to discontinuation or withdrawal of consent.
89011262|NCT02740712|Other|single arm probe drugs and rucaparib|Caffeine Warfarin Vitamin K Omeprazole Midazolam Digoxin rucaparib
89198841|NCT00880347|Other|Alzheimer's Disease|Group of patients clinically diagnosed with probable AD
89536607|NCT05217563|Active Comparator|Intervention Group (Pamphlet, video, and verbal Instructions).|Intervention Group (Group 3; Handout and Verbal Instructions). Parents in this intervention group will receive a pamphlet containing evidence-based information on needle pain management, a pamphlet summarizing memory reframing principles (with a video link), and verbal instructions on how to use the intervention principles with their children. The instructions will be provided via telephone or video conferencing and will last approximately 10 to 15 minutes. Trained graduate students or post-doctoral fellows will deliver the instructions. Similar to previous interventions, to boost mastery of the material, the researcher will provide suggestions for specific questions and remarks to make while reminiscing. The instructions will be audio-recorded to allow fidelity coding.
88921186|NCT06142955|Experimental|TD without depression, Sham then iTBS|Participants that are TD without depression will undergo EEG and ET with TMS prior to and following a single iTBS session. Participants first received sham then iTBS approximately one week apart.
88921187|NCT06139523||Group 1: Healthy adult volunteers|Healthy adult volunteers recruited from the patient population, students or employees of Duke University or Duke Eye Center (n=10)
88921188|NCT06139523||Pediatric participants|Pediatric patients with eye disease recruited from the patient population of Duke Eye Center (n=20)
88921189|NCT06131801||Children and Young Adults|Children and Young Adults who are prescribed venetoclax made from crushed tablets as part of their clinical care.
88921190|NCT06128421|Experimental|Trail Group|30 patients will receive dietary counseling and individual nutrition support treatment based on Oral nutrition supplements and supplemented by parenteral nutrition.
88921191|NCT06128421|No Intervention|Control Group|30 patients will receive standard care food provided by the hospital kitchen according to their ability and desire, standard care food provided by the hospital kitchen.
88921194|NCT06101394|Experimental|cetuximab-IRDye800|Infusion of the study drug will be performed 2-5 days before the surgery: the patients will receive 100 mg of cetuximab intravenously over 30 minutes and a dose 50 mg of cetuximab IRDye800 over 30 minutes to 1 hour.
88921195|NCT06098456|Experimental|Treatment|The patients in this group undergo treatment with Epigallocatechin gallate 200mg, Hyaluronic acid 50mg, Vitamin B12 1mg and Folic acid 400mcg by oral route once per day.
88921196|NCT06098456|No Intervention|Control|The patients in this group follow the routine clinical practice, namely the clinical monitoring.
88921197|NCT06084338|Experimental|Arm 1|Metastasis directed therapy with stereotactic ablative radiotherapy to all detectable sites of disease plus PSMA radiopharmaceutical therapy and discontinuation of castration
88921198|NCT06084338|Experimental|Arm 2|Metastasis directed therapy with stereotactic ablative radiotherapy to all detectable sites of disease plus PSMA radiopharmaceutical therapy and discontinuation of castration, followed by restoration of physiologic testosterone
88921199|NCT06081465|Experimental|SAD Cohort 1|In SAD Cohort 1, 8 subjects will be randomized to receive a single dose of VG290131 (1 mg) (n=6) or matching placebo (n=2), respectively. To ensure the safety of the subjects, two sentinel subjects will be enrolled first: one subject will be randomized to receive VG290131, and the other subject will be randomized to receive a placebo. After the investigator reviews safety/tolerability information available on the sentinel subjects after 24 h and no significant safety issues are observed, the subsequent subjects in the cohort will be randomized to receive VG290131 (n=5) and placebo (n=1).
88921200|NCT06081465|Experimental|SAD Cohort 2 (FE Study)|SAD Cohort 2 (FE study) is a two-sequence, two-period crossover study. A total of 14 healthy subjects will be randomized to two dosing sequences in a 1:1 ratio. Subjects in sequence 1 will receive a single dose of VG290131 (5 mg) or placebo under fasted condition in Period 1 and under fed condition in Period 2. Subjects in sequence 2 will be administered under fed condition in Period 1 and under fasted condition in Period 2. There will be a 7-day washout between the two dosing periods. Two sentinel subjects will be enrolled in the two dosing sequences of Period 1, respectively: one subject will be randomized to receive VG290131 (5 mg), and the other subject will be randomized to receive placebo. After the investigator reviews safety/tolerability information on the sentinel subjects after 24 h and no significant safety issues are observed, the subsequent subjects in that sequences will be randomized to receive VG290131 (n=4) and placebo (n=1). No sentinel subjects in Period 2.
88921201|NCT06081465|Experimental|SAD Cohort 3|In SAD Cohort 3, 8 subjects will be randomized to receive a single dose of VG290131 (25 mg) (n=6) or matching placebo (n=2), respectively. To ensure the safety of the subjects, two sentinel subjects will be enrolled first: one subject will be randomized to receive VG290131, and the other subject will be randomized to receive a placebo. After the investigator reviews safety/tolerability information available on the sentinel subjects after 24 h and no significant safety issues are observed, the subsequent subjects in the cohort will be randomized to receive VG290131 (n=5) and placebo (n=1).
88921202|NCT06081465|Experimental|SAD Cohort 4|In SAD Cohort 4, 8 subjects will be randomized to receive a single dose of VG290131 (50 mg) (n=6) or matching placebo (n=2), respectively. To ensure the safety of the subjects, two sentinel subjects will be enrolled first: one subject will be randomized to receive VG290131, and the other subject will be randomized to receive a placebo. After the investigator reviews safety/tolerability information available on the sentinel subjects after 24 h and no significant safety issues are observed, the subsequent subjects in the cohort will be randomized to receive VG290131 (n=5) and placebo (n=1).
88921203|NCT06081465|Experimental|SAD Cohort 5|In SAD Cohort 5, 8 subjects will be randomized to receive a single dose of VG290131 (100 mg) (n=6) or matching placebo (n=2), respectively. To ensure the safety of the subjects, two sentinel subjects will be enrolled first: one subject will be randomized to receive VG290131, and the other subject will be randomized to receive a placebo. After the investigator reviews safety/tolerability information available on the sentinel subjects after 24 h and no significant safety issues are observed, the subsequent subjects in the cohort will be randomized to receive VG290131 (n=5) and placebo (n=1).
88921204|NCT06081465|Experimental|SAD Cohort 6|In SAD Cohort 6, 8 subjects will be randomized to receive a single dose of VG290131 (200 mg) (n=6) or matching placebo (n=2), respectively. To ensure the safety of the subjects, two sentinel subjects will be enrolled first: one subject will be randomized to receive VG290131, and the other subject will be randomized to receive a placebo. After the investigator reviews safety/tolerability information available on the sentinel subjects after 24 h and no significant safety issues are observed, the subsequent subjects in the cohort will be randomized to receive VG290131 (n=5) and placebo (n=1).
89198842|NCT00880347|Other|Non-AD dementia|Group of patients clinically diagnosed with one of the 5 most frequent non-AD dementia : vascular dementia, mixed dementia, frontotemporal dementia, Lewy bodies dementia, Parkinson's disease dementia.
89198843|NCT00880347|Other|control subjects|Group of control subjects without any clinical cognitive impairment.
89530957|NCT03235531|Experimental|CIWA Protocol/BZD and Valproate|"Interventions to decrease symptoms of AWS will be made based on the CIWA tool.~CIWA Score 9-14: 1 mg IV push lorazepam~CIWA Score >15: 2 mg IV push lorazepam~Patients who have a known history of alcohol withdrawal seizures or who have received greater than 4 mg IV lorazepam per CIWA protocol will be placed on a scheduled lorazepam regimen, 1 mg every 6 hours. The primary managing service may increase the scheduled lorazepam regimen above 1mg every 6 hours if needed to control withdrawal symptoms. Scheduled lorazepam will be discontinued or de-escalated following a 24-hour period in which no additional lorazepam was received per CIWA protocol.~The treatment group will also receive scheduled valproate (VPA), 15 mg/kg divided over 4 doses, rounded up to the nearest increment of 50mg (i.e. a 70 kg person would be administered 300 mg IV VPA every 6 hours) for 96 hours."
89198844|NCT00874965|Active Comparator|ES|Electrostimulation
89198845|NCT00874965|Placebo Comparator|Sham ES|Sham stimulation
89198846|NCT00875043||1. flat Jackson table|All measurements previously described will be done with the patient in the prone postion and Jackson table flat.
89198847|NCT00875043||2. Elevated Jackson tablet|All measurements previously described will be performed with subjects placed prone on the elevated Jackson table.
89437225|NCT04408352|Sham Comparator|RF Trigone Ablation Sham Arm|"The sham procedure will mimic the Hologic trigone RF ablation device procedure to maintain subject blinding and provide the most accurate assessment of control data while minimizing risk to the subject.~The bladder will be emptied of urine and saline infused into the bladder to allow adequate visualization and working space. Suction will be applied to the bladder wall and the cannulas (needles) will be introduced into the bladder wall. Energy will not be delivered to the tissue when each sham ablation is started. In order to maintain blinding of the subject, the typical sounds that Hologic trigone RF ablation device makes during actual ablation/fulguration will be replicated. The simulated ablation procedure will be repeated as many times as necessary to cover the area of the trigone. 4 to 6 sham ablations would be required. At the completion of the procedure, 200ml of saline is instilled into the bladder to allow for assessment of voiding function prior to discharge."
89011263|NCT02684578|Experimental|Metformin|This arm will be receiving the study drug, Metformin, for the duration of the 24 month study. They will begin this drug on a low dose of Metformin, increasing the dosage in a step-wise fashion to avoid unwanted gastrointestinal discomfort, a common side effect when patients begin taking Metformin. During the 24 month study, subjects assigned to this arm will have 4 follow-up exams after the initial enrollment exam, at 6 month intervals.
89011264|NCT02684578|No Intervention|Observe|This arm will maintain standard of care for dry AMD, which is observation. During the 24 month study, subjects assigned to this arm will have 4 follow-up exams after the initial enrollment exam, at 6 month intervals.
89437226|NCT04404166|Experimental|PINGS 2|
89437227|NCT04404166|No Intervention|Standard of Care|
89437228|NCT04403204||Established SSI Fracture Cohort|Patients 18 years of age or older. Extremity fracture. Prior definitive fracture management with external fixation, internal fixation, or joint fusion. Superficial, deep, or organ space SSI (as per CDC criteria) at the fracture site that requires operative management. Will have all fracture care surgeries performed by a participating surgeon or delegate. Provision of informed consent
89437229|NCT04403204||Established SSI Fracture Cohort Subset (DCE-MRI)|Patients 18 years of age or older. Extremity fracture. Prior definitive fracture management with external fixation, internal fixation, or joint fusion. Superficial, deep, or organ space SSI (as per CDC criteria) at the fracture site that requires operative management. Will have all fracture care surgeries performed by a participating surgeon or delegate. Provision of informed consent
89437230|NCT04401800|Experimental|Part 1: Safety Run-in|Lenvatinib at a dose of 8 mg or 12 mg based on body weight + tislelizumab for one 21-day cycle
89437231|NCT04401800|Experimental|Part 2: Lenvatinib|Lenvatinib at the recommended phase 2 dose (RP2D) determined from Part 1 + tislelizumab in 21-day cycles for up to 12 months
89437232|NCT04397263|Experimental|Guselkumab|Participants will receive guselkumab by intravenous (IV) infusion, followed by guselkumab by subcutaneous (SC) injection. Participants who are eligible and willing to continue guselkumab may enter the Long-term extension (LTE) phase and continue to receive guselkumab.
89437233|NCT04389918|Experimental|Tality|Participants will receive TalityTM as their sole intake for nutritional purposes for a 4 week period.
89437234|NCT04386057|Experimental|Safety Lead-In Cohort|"The research study procedures include screening for eligibility and study treatment. Study treatment will include evaluations, biopsies, and follow up visits. A treatment cycle will be defined as 28 consecutive days. Treatment will be administered on an outpatient basis.~Test the safety of study drugs in combination and define dose levels.~LY3214996~HCQ"
89437235|NCT04386057|Experimental|LY3214996 and HCQ Combination|"The research study procedures include screening for eligibility and study treatment. Study treatment will include evaluations, biopsies, and follow up visits. A treatment cycle will be defined as 28 consecutive days. Treatment will be administered on an outpatient basis. Combined dosage per determined Lead-In Cohort~LY3214996~HCQ"
89437236|NCT04386057|Experimental|LY3214996-Monotherapy|"The research study procedures include screening for eligibility and study treatment. Study treatment will include evaluations, biopsies, and follow up visits. A treatment cycle will be defined as 28 consecutive days.Treatment will be administered on an outpatient basis.~-LY3214996"
89437237|NCT04386057|Experimental|Cross Over Arm|"Participants who are enrolled to Arm 2 who experience radiologic disease progression on monotherapy will have the option to cross-over to receive treatment with the combination. Crossover will occur at the treating investigator's discretion following consultation and approval from the overall principal investigator. Combined dosage per determined Lead-In Cohort~LY3214996~HCQ"
89536608|NCT02471729|Experimental|Renal Denervation|patients with chronique heart failure will undergo EnligHTN™ Renal Denervation System as a complementary treatment of their therapy
89198848|NCT00875199|Active Comparator|A|Participants assigned to Group A will receive the DPP manual (Wing & Gillis, 1996), a behavioral weight-loss program with demonstrated efficacy in facilitating weight loss. Participants in Group A will be instructed to read a section of the manual each week and complete suggested activities. They will also meet with the research staff once a week for weigh-in and supportive counseling.
89011265|NCT02612129|Experimental|Arimoclomol Single PK Dose|Participants less than 12 years received a single oral dose of arimoclomol capsule, based on participant's body weight, on Day 1.
89011266|NCT02612129|Experimental|Arimoclomol (12-month Double-blind Phase)|Participants received arimoclomol capsules orally three times a day (TID) for 12 months. The dose was 31-124 mg arimoclomol base TID (equivalent to 50-200 mg arimoclomol citrate TID), based on participant's body weight.
89011267|NCT02612129|Placebo Comparator|Placebo (12-month Double-blind Phase)|Participants received matching placebo capsules (with regard to weight, appearance, smell, flavor etc.) orally TID for 12 months.
89437238|NCT04375033|Experimental|Sublingual Arm|"The sublingual buprenorphine contains naloxone in a ratio of 4:1 and will be prescribed. Consistent with the SAMHSA TIP 40 guidelines 75, before SL-BUP/NLX is prescribed, participants will be evaluated for recent (within 24 hours) drug use and associated symptoms.~The randomization dose will be determined based on the maintenance dose identified during the induction period, with a target dose of 16-24mg that is standard practice. While the target dose is 16-24mg, doses may go as low as 8mg as occasionally patients prefer lower doses. SL-BUP/NLX will be prescribed at the randomization visit (28-day supply), then every 4 weeks until week 48."
89437239|NCT04375033|Experimental|Injectable Arm|Injectable buprenorphine consists of a depot injectable formulation in polymeric solution and releases buprenorphine over a 28-day (4-week) period by diffusion as the polymer biodegrades. The injection will be administered subcutaneously in the abdomen at each 28-day visit. The target dose is 300mg, there is the option to use 100mg dose. The final study dose of injectable buprenorphine will be given at Week 48.
89437240|NCT04372628|Active Comparator|Group 1 - Lopinavir/Ritonavir|Lopinavir/Ritonavir 400 mg/100 mg orally twice daily for twenty-eight doses (Days 1-14)
89437241|NCT04372628|Placebo Comparator|Control Group|Placebo unmatched orally twice daily for 14 days
88921205|NCT06081465|Experimental|MAD Cohort 1|In MAD Cohort 1, 8 subjects will be randomized 3:1 to receive a once or twice daily dose of VG290131 (1 mg) (n=6) or matching placebo (n=2) for 7 consecutive days depending on the PK profiles of the SAD study, respectively.
88921206|NCT06081465|Experimental|MAD Cohort 2|In MAD Cohort 1, 8 subjects will be randomized 3:1 to receive a once or twice daily dose of VG290131 (5 mg) (n=6) or matching placebo (n=2) for 7 consecutive days depending on the PK profiles of the SAD study, respectively.
88921207|NCT06081465|Experimental|MAD Cohort 3|In MAD Cohort 1, 8 subjects will be randomized 3:1 to receive a once or twice daily dose of VG290131 (25 mg) (n=6) or matching placebo (n=2) for 7 consecutive days depending on the PK profiles of the SAD study, respectively.
88921208|NCT06081465|Experimental|MAD Cohort 4|In MAD Cohort 1, 8 subjects will be randomized 3:1 to receive a once or twice daily dose of VG290131 (100 mg) (n=6) or matching placebo (n=2) for 7 consecutive days depending on the PK profiles of the SAD study, respectively.
88921209|NCT06079580||Patients with Lumbar spinal stenosis with balance disorders|According to the single-leg balance test, patients who maintain static balance for less than 10 seconds will be grouped as having impaired balance.
88921210|NCT06079580||Patients with Lumbar spinal stenosis with normal balance|According to the single-leg balance test, patients who maintain their static balance for more than 10 seconds will be grouped as having normal balance.
88921213|NCT06066021|Other|Health education sessions for type 2 diabetic patients|"Patients will be pre-selected according to their risk of developing DR. It will be done through the Retina Risk® application. Will be invited to participate and followed. Retrospective and prospective data will be collected on medical and ophthalmological history (HbA1c value, if performed. 3 questionnaires will be carried out: DM disease, self-care, and emotional state, before and after awareness intervention about self-care through educational sessions in areas of greatest need (physical activity, nutrition, mental health, and self-care). The impact of the previously described sessions on the patients' health status will be assessed using 2 methods: By telephone and by physical examination. Repetition of the 3 questionnaires applied in V1.~The Interventions will be made, through information sessions on the topics: mental health, nutrition, physical exercise, and care that diabetics must take to take care of their body."
88921214|NCT06061796|Experimental|prone position extended|prone position extended all patients included
88921215|NCT06061211|Experimental|Treadmill with TENS training|PRECOR 964i treadmill& MH8001 Portable tens Treadmill walking initially will begin exercising at 2 mph (3.2 km/h) at a 0% grade. They will walk until their claudication pain and determine site of pain then we will apply TENS on pain site and starting frequency at 2 HZ, then will increase inclination of treadmill gradually together with increasing frequancy of TENS up to 120 HZ if patient will report any feeling of pain, pain became moderately severe (4 of 5 on the claudication scale), throughout 45-minute exercise session. When a participant will be able to walk for 8 minutes at the initial workload without having to stop because of moderately severe claudication, the treadmill grade will be increased by increments of 0.5% until an 8-10% grade will be achieved. Subsequently, exercise intensity will be increased during training sessions by increasing the treadmill speed by increments of 0.1-0.2 mph (0.2-0.3 km/h) as tolerated
88921216|NCT06061211|Other|Treadmill training|Over the past 30 years, treadmill-based SET programs have been shown to be consistently beneficial in improving walking ability as assessed by graded treadmill testing and to be effective in patients with PAD both with and without classic symptoms of claudication. Treadmill-based exercise therapy for patients with PAD consists of intermittent bouts of walking exercise to moderate to moderately severe discomfort (4 of 5 on the claudication scale) followed by short periods of rest until symptoms resolve. These exercise/rest bouts are repeated over a 30- to 45-minute exercise session. Exercise capability is most commonly measured as COT/COD and PWT/PWD.
88921217|NCT06056596|Experimental|Lamivudine|Lamivudine 300mg PO once daily for three days
88921218|NCT06056596|Placebo Comparator|Placebo|Placebo once daily for three days
88921219|NCT06053216|Experimental|Individualised energy delivery|Energy delivery will be guided by indirect calorimetry, with the aim to meet 80-100% of the most recent energy expenditure measurement from day 4 to 28 of hospital admission.
88921220|NCT06053216|Active Comparator|Standard care nutrition|Energy delivery will be according to predictive equation estimates and usual site practice from day 4 to 28 of hospital admission.
88921221|NCT06050083|Experimental|Treatment|8 weeks of access to online hypnosis recordings
88921222|NCT06050083|Active Comparator|Waitlist Control|4 weeks of waitlist (no access to recordings) and then 4 weeks of access to hypnosis recordings
88921223|NCT06037707||Ancestral variant|Ancestral variant is the first subtype of SARS CoV-2 virus which is the agent of first COVID-19 infection in Wuhan. Thromboembolic complications of this group were detected among patients which were infected with ancestral variant of COVID-19
89437242|NCT04367311|Experimental|NSC: Non-squamous cell tumors|Atezolizumab 1200mg, Pemetrexed 500 mg/m^2, Cisplatin 60-75 mg/m^2
89437243|NCT04367311|Experimental|SC: Squamous cell tumors|Atezolizumab 1200mg, Docetaxel 60-75 mg/m^2, Cisplatin 60-75 mg/m^2
89437244|NCT04353297|Experimental|BCI Group|(EEG-)BCI- assisted MI training delivered as add-on regimen (Standard physiotherapy-3 h/day, 5 day/week).
89437245|NCT04353297|Active Comparator|Control Group|MI training without BCI support delivered as add-on regimen (Standard physiotherapy-3 h/day, 5 day/week).
89437246|NCT04353115||Training with Serious Game|Trained group, 5 weeks training with the serious game; patients have a vestibular impairment.
89437247|NCT04348825||Patients, depression|Patients who receive ECT as part of clinical care
89198849|NCT00875199|Experimental|B|Participants assigned to Group B will receive the DPP manual and will meet with research staff each week for weigh-in and supportive counseling. They will also receive contingency management or the opportunity to earn draws with the chance of winning prizes for losing weight and completing healthy activities.
89198850|NCT00875355|Experimental|Arm I|Patients undergo isocentric radiotherapy to the brain 5 times a week for 2 weeks.
89198851|NCT00875355|Experimental|Arm II|Patients undergo radiotherapy as in arm I and receive oral temozolomide once daily for 2 weeks.
89198852|NCT00678288|Experimental|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400 mg (two 200 mg tablets) twice daily (bid) per os (po), continuously.
89198853|NCT00678288|Experimental|Sorafenib (Nexavar, BAY43-9006) + Interferon|Sorafenib 400 mg (two 200 mg tablets) twice daily (bid) per os (po), continuously plus Interferon (IFN) alpha-2a 3 millions of international unit (MIU) five times a week (FIW) subcutaneous (s.c.), from Monday to Friday (total weekly dose 15 MIU) s.c., to start one week after commencing sorafenib.
89198854|NCT04772859|Experimental|Online Lifestyle Intervention|Online sessions of nutrition education, physical activity, and family participation.
89198855|NCT04772859|Other|Control Group|General nutrition recommendations
89198856|NCT00880659|Experimental|1|Promotion of handwashing with soap and maintenance of a fully stocked handwashing station.
89198857|NCT00880659|No Intervention|2|Practice of routine handwashing among the household members
89198858|NCT04038879||Mitral/Aortic Regurgitation|Subjects identified with mitral or aortic regurgitation will be asked to undergo testing with trans thoracic echocardiogram, stress echocardiography, and cardiac MRI with and without contrast. In addition, patients will be asked to answer the KCC and EQ5DL questionnaires.
89198859|NCT00880737||Stable PE patients|Hemodynamically stable patients with acute symptomatic pulmonary embolism
89198860|NCT00880815|Experimental|Treatment (chemotherapy, stem cell transplant, rituximab)|Participants receive rituximab IV over 5-7 hours on days -13 and -6, fludarabine IV over 1 hour and bendamustine IV over 1 hour on days -5 to -3, and tacrolimus IV starting on day -2 and PO after hospital discharge for 6 to 8 months. Participants with MUD receive thymoglobulin on days -2 and -1. Participants undergo allogenic stem cell transplant over 30-45 minutes on day 0. Participants receive rituximab IV over 5-7 hours on days 1 and 8 and methotrexate IV over 30 minutes on days 1, 3, and 6. Participants with MUD also receive methotrexate IV on day 11. Participants receive G-CSF SC once daily starting on day 7 until white blood cell counts recover.
89198861|NCT00369343|Experimental|A|
89198862|NCT00369343|Placebo Comparator|B|
89198863|NCT00880971|Experimental|PORT|Patients undergo thoracic radiotherapy using 3D-CRT or IMRT (50 Gy, 2 Gy once daily over 5 weeks) after postoperative chemotherapy.
89198864|NCT00880971|No Intervention|Non-PORT|Patients undergo postoperative chemotherapy.
89198865|NCT03992599||Laparoscopic modified central mesocolic excision|Patients receiving laparoscopic colectomy with the concept of modified complete mesocolic excision for right-sided colon cancer
89437248|NCT04348825||Healthy|Healthy controls who do not receive ECT but otherwise the same assessments.
89437249|NCT04348825||Patients, atrial fibrilation|Patients who receive Electro Cardio Version (ECV) due to Atrial Fibrilation
89198866|NCT00881127|Experimental|1|Cetirizine HCl/Pseudoephedrine HCl 5 mg/120 mg (Sandoz, USA)
89198867|NCT00881127|Active Comparator|2|Zyrtec-D 12 Hour 5 mg/120 mg Extended Release Tablets (Pfizer, USA)
89198868|NCT00369265|Experimental|Lansoprazole|Lansoprazole 30 mg Twice Daily
89198869|NCT00369265|Placebo Comparator|Sugar pill|placebo
89198870|NCT00875745|Experimental|Sorafenib-Vorinostat|This is a single-arm, non-randomized feasibility and safety Phase I trial of a combination of Sorafenib and Vorinostat, both administered orally.
89198871|NCT00368875|Experimental|vorinostat, paclitaxel, bevacizumab|Vorinostat BID on days 1-3, 8-10, and 15-17, paclitaxel IV over 1 hour on days 2, 9, and 16, bevacizumab IV over 30-90 minutes on days 2 and 16, repeat every 28 days.
89198872|NCT00614055|Active Comparator|Insulin glargine|
89198873|NCT00614055|Experimental|SIAC 30 (B)|
89198874|NCT00614055|Experimental|SIAC 45 (B)|
89198875|NCT01051141|Active Comparator|CBI in ED with AMET at 3 months|computer brief intervention (CBI) at baseline with adapted motivational enhancement therapy-AMET at 3 months
89198876|NCT01051141|Active Comparator|CBI in ED with EUC at 3 months|
89198877|NCT01051141|Active Comparator|IBI in ED with AMET at 3 months|
89198878|NCT01051141|Active Comparator|IBI in ED with EUC at 3 months|
89198879|NCT01051141|Active Comparator|EUC in ED with AMET at 3 months|
89198880|NCT01051141|No Intervention|EUC in ED with EUC at 3 months|
89198881|NCT00875823||PH Patients|"Patients with:~Primary Hyperoxaluria Type I Primary Hyperoxaluria Type II Primary Hyperoxaluria NonI-NonII"
89198882|NCT04040127|Experimental|Cord blood stem cells|cord blood stem cells from Invitrx
89198883|NCT04040127|Placebo Comparator|0.9% sodium chloride (saline)|canal will be rinsed by saline solution.
89198884|NCT00613821|Experimental|Lidocaine infusion|5 milliliter intrauterine infusion of 4% lidocaine, infusion will be placed slowly over 3 minutes.
89198885|NCT00613821|Active Comparator|Paracervical block only|Standard paracervical block (8 milliliter 1% lidocaine at 4 and 8 o'clock at the cervical-vaginal reflection) will be placed.
89198886|NCT04038723|Experimental|Pre- and Post-HIIT|Participants will be evaluated before and after exercise training.
89198887|NCT00882765|Experimental|Arm I|Patients receive neoadjuvant oral genistein once daily for 2 weeks in the absence of disease progression or unacceptable toxicity.
89198888|NCT00882765|No Intervention|No intervention|Patients receive no specific neoadjuvant therapy.
89198889|NCT00881283||cured Cushing's disease|
89198890|NCT00882843||Group 1|Healthy Able bodied Control
89198891|NCT00882843||Group 2|Spinal Cord Injury
89198892|NCT00548548|Experimental|Bevacizumab|Participants received intravenous (IV) bevacizumab 7.5 mg/kg every 3 weeks, oral capecitabine 1,000 mg/m˄2 twice daily for 14 days every 3 weeks, or 5-fluorouracil (5-FU) at a dose of 800 mg/m˄2/day as a continuous IV infusion over the first 5 days of every 3 week cycle, and cisplatin 80 mg/m˄2 as an IV infusion every 3 weeks for a maximum of 6 cycles. Bevacizumab and capecitabine/5-FU were administered until disease progression or unacceptable toxicity.
88921224|NCT06037707||Delta Variant|Delta variant is the subtype of SARS CoV-2 virus which is first COVID-19 subtype identified in India. Thromboembolic complications of this group were detected among patients which were infected with delta variant of COVID-19
88921225|NCT06037707||Alpha variant|Alpha variant is the subtype of SARS CoV-2 virus which is first identified COVID-19 subtype in United Kingdom. Thromboembolic complications of this group were detected among patients which were infected with alpha variant of COVID-19
88921226|NCT06037707||Other variants|Other variants is the subtype of SARS CoV-2 virus which were identified in Brazil, South Africa..etc. Thromboembolic complications of this group were detected among patients which were infected with alpha variant of COVID-19
89437250|NCT04340960|No Intervention|Control Group|"The control group will not be monitored with continuity of care. After this period, 30-day emergency department visits will be measured and compared between the two groups, along with 30-day readmission rates, in-hospital length of stay, mortality, quality of recovery 40 item scale (QoR-40), European Quality of Life 5 Dimensions (EQ5D), patient satisfaction score, and societal and hospital cost.~No intervention will be administered."
88921227|NCT06033586|Experimental|Open-label rusfertide|Open-label rusfertide
88921228|NCT06025656|Other|Experimental group|adolescent tennis player
88921229|NCT06024408|Placebo Comparator|Part A: Placebo|Participants who are homozygous for the PNPLA3 rs738409:G risk allele will be randomized 1:1:1:1
88921230|NCT06024408|Experimental|Part A: Low Dose|Participants who are homozygous for the PNPLA3 rs738409:G risk allele will be randomized 1:1:1:1
88921231|NCT06024408|Experimental|Part A: Mid Dose|Participants who are homozygous for the PNPLA3 rs738409:G risk allele will be randomized 1:1:1:1
88921232|NCT06024408|Experimental|Part A: High Dose|Participants who are homozygous for the PNPLA3 rs738409:G risk allele will be randomized 1:1:1:1
88921233|NCT06024408|Placebo Comparator|Part B: Placebo|Participants who are homozygous for the PNPLA3 rs738409:G risk allele will be randomized 1:1:1:1
88921234|NCT06024408|Experimental|Part B : Low Dose|Participants who are homozygous for the PNPLA3 rs738409:G risk allele will be randomized 1:1:1:1
88921235|NCT06024408|Experimental|Part B: Mid Dose|Participants who are homozygous for the PNPLA3 rs738409:G risk allele will be randomized 1:1:1:1
88921236|NCT06024408|Experimental|Part B: High Dose|Participants who are homozygous for the PNPLA3 rs738409:G risk allele will be randomized 1:1:1:1
88921237|NCT06024408|Placebo Comparator|Part C: Placebo (Optional)|Sponsor may elect to enroll participants who are heterozygous for the PNPLA3 rs738409:G risk allele and may be randomized 1:1
88921238|NCT06024408|Experimental|Part C: High Dose (Optional)|Sponsor may elect to enroll participants who are heterozygous for the PNPLA3 rs738409:G risk allele and may be randomized 1:1
88921239|NCT06023641|Experimental|Low -risk|"The participant will receive 12 weeks (4 cycles) of VAC chemotherapy (vincristine, dactinomycin and cyclophosphamide) followed by 12 weeks (4 cycles) of VA chemotherapy (vincristine, dactinomycin).~Each cycle of VAC/VA chemotherapy will last for 3 weeks, for a total of 12 weeks (VAC or VA will be given in Week 1 of each cycle and vincristine will be given Weeks 2 and 3). At week 12, the participant will have scans and tests to reevaluate your tumor's response to the treatment. After surgery and radiation, the participant will receive an additional 12 weeks (4 cycles) of the same chemotherapy without cyclophosphamide. Vincristine and dactinomycin, also called VA. After 4 cycles of VA, The investigator will re-evaluate the tumor again at week 24 and the patient will not get any more chemotherapy, but will be closely watched for any signs of tumor recurrence."
88921240|NCT06023641|Experimental|Intermediate-risk|"The purpose of this part of the study is to find out if adding a drug called liposomal irinotecan (also called Onivyde) to standard chemotherapy/radiation/surgery will result in better treatment outcomes for patients with intermediate and high risk rhabdomyosarcoma. The investigators also want to find the best radiation dose to give for intermediate and high risk patients who have large tumors (> 5 cm).~The patient will receive 42 weeks of VAC chemotherapy (vincristine, actinomycin D/dactinomycin and cyclophosphamide) alternating with VLI chemotherapy (vincristine/liposomal irinotecan). The participant will also have surgery to remove the tumor and radiation therapy during this time. After this therapy is completed you will get an additional 6 months of maintenance chemotherapy with vinorelbine and oral (by mouth) cyclophosphamide."
88921241|NCT06023641|Experimental|High-risk|"The purpose of this part of the study is to find out if adding a drug called liposomal irinotecan (also called Onivyde) to standard chemotherapy/radiation/surgery will result in better treatment outcomes for patients with high risk rhabdomyosarcoma. The investigator also want to find the best radiation dose to give for high risk patients who have large tumors (> 5 cm).~The patient will receive 42 weeks of VAC chemotherapy (vincristine, actinomycin D/dactinomycin and cyclophosphamide) alternating with VLIT chemotherapy (vincristine/liposomal irinotecan/temozolomide). Also having surgery to remove the participants tumor and radiation therapy during this time. After this therapy is completed the patient will get an additional 6 months of maintenance chemotherapy with vinorelbine and oral (by mouth) cyclophosphamide."
88921242|NCT06012136|Experimental|Participants Receiving VH4004280|
88921243|NCT06012136|Placebo Comparator|Participants Receiving Placebo|
88921244|NCT06012136|Experimental|Participants Receiving VH4011499|
89536609|NCT03068559||Study population|"Patient must have an initial confirmed squamous cell carcinoma of the oral cavity, oropharynx, larynx, or hypopharynx.~Patient has to be aged ≥ 18~Patient has to be able to complete questionnaire in French~Patient must benefit from health insurance~Patient must sign an informed consent form~Patient treatment must be validated in a medical multidisciplinary team meeting: surgery, radiotherapy (RT), chemotherapy (CT), radiochemotherapy (RTCT), induction chemotherapy followed by radiochemotherapy (IND+RTCT), surgery followed by radiotherapy (surgery+RT), surgery followed by radiochemotherapy (surgery+RTCT)."
89536610|NCT04984707|Experimental|Experimental Group -KX0826|KX0826 is tropically applied to the scalp of healthy male subjects with Androgenetic Alopecia with a single dose.The applied dosage cohorts are 3mg, 12mg, 48mg and 96mg.
89198893|NCT00548548|Placebo Comparator|Placebo|Participants received intravenous (IV) placebo infusion every 3 weeks, oral capecitabine 1,000 mg/m˄2 twice daily for 14 days every 3 weeks, or 5-fluorouracil (5-FU) at a dose of 800 mg/m˄2/day as a continuous IV infusion over the first 5 days of every 3 week cycle, and cisplatin 80 mg/m˄2 as an IV infusion every 3 weeks for a maximum of 6 cycles. The placebo and capecitabine/5-FU were administered until disease progression or unacceptable toxicity.
89198894|NCT00613509|Experimental|Study Group 1: ALVAC melanoma vaccine|Participants will receive a multi-antigen of modified canarypox virus (ALVAC[2]) melanoma vaccine and granulocyte macrophage colony stimulating factor (GM-CSF) every 3 weeks, followed by 4 weeks of high-dose interferon alpha-2b 5 times per week.
88921245|NCT06009055|Experimental|Remimazolam group|
88921246|NCT06009055|Active Comparator|Propofol group|
88921247|NCT06008574|Experimental|MBCR (mindfulness-based cancer survivorship group) (AmDTx-PCSP)|Patients randomized to the MBCR group will receive remote AmDTx-PCSP in the perioperative period (initiated at least 2 weeks before surgery). AmDTx-PCSP will be continued after surgery, for a minimum of 6 weeks total. AmDTx-PCSP is a step-by-step program including meditation training and other activities relevant for people living with cancer. The participants are asked to use AmDTx for about 20-30 minutes per day, at least 4 days per week, for 6 weeks. The participants are free to proceed at a faster pace and use AmDTx more than 20-30 per day if they choose. The first 3 modules of the program are required, and then the participant will be able to pick 3 additional modules based on topics that are most meaningful to them.
88921248|NCT06008574|Active Comparator|CI (control) group (AmDTx-2048)|"Patients randomized to the CI group will use a game called 2048, a cognitive training app, which is used as an control condition to control for expectancy and daily engagement. The participants will use AmDTx-2048 to engage in cognitive training with a puzzle game. The participants are asked to use AmDTx for about 20-30 minutes per day, at least 4 days per week, for 6 weeks. The participants are free to proceed at a faster pace and use AmDTx more than 20-30 per day if you choose. In this puzzle game, the participants will slide numbered tiles around a grid, matching tiles of the same value to combine them into one new tile displaying the sum of the previous two numbers. The goal is to match tiles until the sum of 2048 is reached on a single tile. There is no time limit."
88921249|NCT06007508|No Intervention|Standard of Care|Subjects presenting to ED with diagnosis of DKA and receiving intravenous short acting insulin will not have orders for subcutaneous insulin glargine placed for research purposes.
88921250|NCT06007508|Active Comparator|Intervention|Subjects presenting to ED with diagnosis of DKA will receive study medication set to begin within 2 hours after initiation of the IV insulin infusion. The dose will come from IV pharmacy and dispensed in a 1 mL insulin syringe. If the patient was not taking basal insulin prior to admission, the patient will receive 0.2 units/kg insulin glargine. If the patient was taking basal insulin prior to admission, the patient will receive their home insulin glargine dose.
88921251|NCT06004622|No Intervention|control group|The control group receives care according to the standard intensive care unit nursing guidelines.
89437251|NCT04340960|Experimental|Home Monitoring Group|At the time of hospital discharge, the control group will be discharged without receipt of home monitoring, and the intervention group will receive a home monitoring kit with (NIBP (non-invasive blood pressure) and SPO2 (pulse oximetry) with instructions on how to use these devices. Patients in the intervention groups will receive digital communication for four weeks and have their NIBP, HR (heart rate), SPO2 and pain scores evaluated twice a day for two weeks.
88921252|NCT06004622|Experimental|experimental group|The experimental group, in addition to following the standard guidelines, undergoes two brief therapeutic sessions using the Calgary Family Intervention Model. Each session lasts approximately 20 minutes. Both groups complete three questionnaires during the study period. Furthermore, after the study concludes, the experimental group participates in an interview lasting approximately 15 minutes before returning home.
88921253|NCT06000059|Experimental|Radio Drama|Participants in this group will participate in three listening sessions. The first and third listening sessions will consist of information unrelated to mental illness. The second listening session will be the radio theater intervention that is being developed.
88921254|NCT06000059|No Intervention|Control|Participants in this group will participate in three listening sessions all unrelated to mental illness.
88921255|NCT06000059|No Intervention|Randomly selected community members|randomly selected members of the community that have not had exposure to the intervention over the course
88921256|NCT05998629|Experimental|Healthy control subjects experimental device|a skin-interfaced colorimetric bifluidic sweat device with two synchronous channels for healthy control subjects
88921257|NCT05998629|Active Comparator|Healthy control subjects standard of care|standard clinical laboratory procedures routinely performed in the Clinical Laboratory at Penn State Health Milton S. Hershey Medical Center (PSH-HMC), Hershey, PA for measurement of sweat chloride concentrations for healthy control subjects
88921258|NCT05998629|Experimental|Cystic Fibrosis Subjects experimental device|a skin-interfaced colorimetric bifluidic sweat device with two synchronous channels for cystic fibrosis subjects
88921259|NCT05998629|Active Comparator|Cystic Fibrosis Subjects standard of care|standard clinical laboratory procedures routinely performed in the Clinical Laboratory at Penn State Health Milton S. Hershey Medical Center (PSH-HMC), Hershey, PA for measurement of sweat chloride concentrations for cystic fibrosis subjects
88921260|NCT05995535|Experimental|LFX/PGB|"PGB/day 1=400mg, day 2-7=600mg each day, day 8=400mg, day 9=200mg, day 10=100mg~LFX/day 1=1.62mg, day 2-7=2.16mg each day, day 8=1.44mg, day 9=0.72mg, day 10=0.72mg"
88921261|NCT05995535|Active Comparator|LFX/PLA-PGB|"PLA-PGB/day 1-7= 0mg each day, day 8, 9, and 10 =0mg each day~LFX/ day 1=1.62mg, day 2-7=2.16mg each day, day 8=1.44mg, day 9=0.72mg, day 10=0.72mg"
88921262|NCT05994287|Active Comparator|Drug: celecoxib|The patients received celecoxib in a dose of 400 mg orally daily. The drug was prescribed from the second day of the operation for 5 days.
88921263|NCT05994287|Experimental|Drug: aspirin with ketorolac|The patients received aspirin in a dose of 100 mg and ketorolac 90 mg orally daily. The drugs were prescribed from the second day of the operation for 5 days.
88921264|NCT05994287|Experimental|Drug: ketorolac and celecoxib|The patients received ketorolac in a dose of 90 mg and celecoxib 400 mg orally daily. The drugs were prescribed from the second day of the operation for 5 days.
88921265|NCT05994287|Active Comparator|Drug: aspirin, ketorolac and celecoxib|The patients received aspirin in a dose of 200 mg, ketorolac 90 mg, and celecoxib 400 mg orally daily. The drugs were prescribed from the second day of the operation for 5 days.
88921266|NCT05992428|Experimental|Part 1 or 2|[Part 1] DA-8010 5mg + Paroxetine 20mg [Part 2] DA-8010 5mg + Mirabegron 50mg
88921267|NCT05991401|Experimental|Period 1 or 2 or 3|[Period 1] DA-8010 5mg [Period 2] DA-8010 5mg, Clarithromycin 500mg [Period 3] DA-8010 5mg, Rifampicin 600mg
88921268|NCT05988762|Experimental|Supramaximal Walkout|Walkout set performed at 110% 1RM
88921269|NCT05988762|Experimental|Control (Submaximal Walkout)|Walkout set performed at 30% 1RM
88921270|NCT05984654|Experimental|Target ulcer Group 1(Injectable PRP)|Under aseptic conditions, 2 mL of autologous PRP will be injected with 30 G needle at multiple sites in and around target ulcer approximately 1.5 cm apart at 0, 4, 8, and 12 weeks after local anesthesia.
89011268|NCT02580305|Active Comparator|Experimental: SUVN-502 Low dose (50 mg)|SUVN-502 Low dose adjunct to base treatment with Donepezil and Memantine
89198895|NCT00613509|Active Comparator|Study Group 2: Interferon alpha-2b|Participants on 4 weeks of high-dose interferon alpha-2b 5 times per week. Participants who showed disease progression after Cycle 1 will be permitted to cross over to Group 1 treatment.
89437252|NCT04340050|Experimental|Treatment with anti-SARS-CoV-2 convalescent plasma|Infusion of one unit of anti-SARS-CoV-2 convalescent plasma ~300 mL over 4 hours
89437253|NCT04339764|Experimental|Participants receiving intervention|Participants receiving intervention
89437254|NCT04336982|Experimental|CC-90009 in combination with venetoclax and azacitidine|"CC-90009 will be administered intravenously per dosing schedule in a 28-day cycle. Venetoclax will be administered orally QD.~Azacitidine will be administered intravenously or subcutaneously on planned dosing days for each cycle."
89437255|NCT04336982|Experimental|CC-90009 in combination with gilteritinib|CC-90009 will be administered intravenously per dosing schedule in a 28-day cycle. Gilteritinib will be administered orally QD.
89437256|NCT04330820|Experimental|Venetoclax+Cytarabin+ Mitoxantron|The treatment plan combines a fixed dose of venetoclax and mitoxantrone with increasing doses of cytarabine (V-MAC).
89437257|NCT04319783|Experimental|Darolutamide|Darolutimide 600mg BD
89437258|NCT04319783|Experimental|Local consolidation Radiotherapy + Darolutamide|Darolutimide 600mg BD + local consolidative radiotherapy, with a biological equivalent dose of 30Gy/10fx or greater if delivered with SABR. SABR is the preferred treatment approach, however conventional radiotherapy is acceptable. To up to 5 sites of disease
89437259|NCT04313504|Experimental|Niraparib & Dostarlimab|"Niraparib starting on Day 0. Niraparib will be administered as continuous daily dose, orally 200 or 300 mg.~Dostarlimab IV administered via a 30-minute infusion on Day 1 of every 21 day cycle. 500mg for first 4 doses followed by 1000 mg every 6 weeks."
89437260|NCT04310735|Experimental|Experimental: Expect-Yes|Participants assigned to this condition will undergo a verbal smoking expectancy manipulation such that they will perceive an opportunity to smoke during the experimental session.
89437261|NCT04310735|Experimental|Experimental: Expect-No|Participants assigned to this condition will undergo a verbal smoking expectancy manipulation such that they will not perceive an opportunity to smoke during the experimental session.
89437262|NCT04307277|Other|Control arm|
89437263|NCT04307277|Experimental|Experimental arm|
89437264|NCT04305327|Experimental|Brodalumab|Brodalumab for 52 weeks. The dose will be determined by the participant's body weight.
89437265|NCT04305327|Active Comparator|Ustekinumab|Ustekinumab for 52 weeks. The dose will be determined by the participant's body weight.
89437266|NCT04305327|Placebo Comparator|Placebo/brodalumab|Placebo for the first 12 weeks and brodalumab for the following 40 weeks. The dose will be determined by the participant's body weight.
89437267|NCT04305327|Placebo Comparator|Placebo/ustekinumab|Placebo for the first 12 weeks and ustekinumab for the following 40 weeks. The dose will be determined by the participant's body weight.
89437268|NCT04302454|Active Comparator|Radiotherapy without hormonal therapy|Metastase-directed radiotherapy without the addition of hormonal therapy
89437269|NCT04302454|Experimental|Radiotherapy combined with hormonal therapy|Metastase-directed radiotherapy with the addition of of short-term hormonal therapy (6 months)
89437270|NCT04302311|Active Comparator|Standard of Care|Holter monitoring
89437271|NCT04302311|Active Comparator|Enhanced Monitoring|Kardia/AliveCor monitoring with additional Holter monitoring as needed
89437272|NCT04299191|Experimental|Dose Escalation|"The dose level corresponds to 80% of the maximum tolerated dose of LAM561 in adult patients when adjusted for body surface area. The escalation will be to the 100%, and 120% of the maximum tolerated dose of LAM561 in adult patients when adjusted for body surface area. Dose escalation decisions will be made by all active Investigators in collaboration with the Medical Monitor when at least three patients have completed the DLT observation period (Cycle 1) at each dose level. When the third patient at any given dose level has received 14 days of therapy, an escalation teleconference will be scheduled after that patient has completed the DLT observation period (Cycle 1). The decision to progress to the next dose level will be made on the basis of review of all significant LAM561-related toxicities."
89437273|NCT04296123|Experimental|Intervention|
89437274|NCT04296123|No Intervention|Control|
89437275|NCT04289194|Experimental|HCR040 (Phase 1)|Participants with moderate to severe acute respiratory distress syndrome (6 patients)
89011269|NCT02580305|Active Comparator|Experimental: SUVN-502 High dose (100 mg)|SUVN-502 High dose adjunct to base treatment with Donepezil and Memantine
89011270|NCT02580305|Placebo Comparator|Placebo|Placebo adjunct to base treatment with Donepezil and Memantine
89011271|NCT02449512||complete|individuals with somato-sensory complete spinal cord injury
89011272|NCT02449512||incomplete|individuals with somato-sensory incomplete spinal cord injury
89011273|NCT02279394|Experimental|Elo / Len / Dex|"•Drug: Elotuzumab 10 mg/kg IV; Days 1, 8,15, 22 Cycles 1-2 10 mg/kg IV; Days 1 & 15 Cycles 3-8~Other Name: HuLuc63~•Drug: Lenalidomide 25 mg Oral; Days 1-21 days Cycles 1-24~Other Name: REVLIMID~•Drug: Dexamethasone 40 mg Oral; Days 1, 8, 15, 22 Cycles 1-2 40 mg Oral; Days 1, 8, 15 Cycles 3-8~Other Name: Decadron"
89011274|NCT02279394|Experimental|Elo / Len|"•Drug: Elotuzumab 10 mg/kg IV; Days 1, 8,15, 22 Cycles 1-2 10 mg/kg IV; Days 1 & 15 Cycles 3-8~Other Name: HuLuc63~•Drug: Lenalidomide 25 mg Oral; Days 1-21 days Cycles 1-24~Other Name: REVLIMID"
89011275|NCT02229578||Lidocaine Treatment Group|Subjects in this group will receive a nonpyrogenic solution of lidocaine 2% in isotonic saline (Solution A) sprayed on the donor site of the grafted skin prior to emergence from general anesthesia. A total maximum of 7mg/kg of lidocaine solution will be available for administration. Prior to spraying of the Solution A, the donor site will be soaked with epinephrine soaked towels as per routine burn care. The site will then be covered with TheraBond dressing as per standard burn care.
89011276|NCT02229578||Placebo Treatment Group|Subjects in this group will receive a nonpyrogenic solution of isotonic saline (Solution B) sprayed over the donor site. Prior to spraying of the Solution B, the donor site will be soaked with epinephrine soaked towels as per routine burn care. The site will then be covered with TheraBond dressing as per standard burn care.
89011277|NCT02151513||Cancer Pain|Placement of an intrathecal pump
89011278|NCT02054741|Experimental|Arm I (GA intervention)|Patients complete a geriatric assessment. Patients and physicians are provided with the geriatric assessment information and recommendations.
89011279|NCT02054741|No Intervention|Arm II (usual care)|Patients complete a geriatric assessment, but information other than clinically significant cognitive impairment and depression is not provided to the oncology teams.
89011280|NCT01821781|Experimental|Preparative|
89011281|NCT01555463|Experimental|Azelaic acid foam, 15% (BAY39-6251)|0.5 g azelaic acid (AzA) foam, 15% applied twice daily (BID) topical and nonocclusive on facial skin for 12 weeks.
89011282|NCT01555463|Placebo Comparator|Vehicle foam|0.5 g vehicle foam applied twice daily topical and nonocclusive on facial skin for 12 weeks.
89011283|NCT01534104|Experimental|pts who have primary or secondary brain tumors|The study will prospectively enroll subjects who have primary or secondary brain tumors located near the motor pathway (corticospinal tract) or language pathway (arcuate fasciculus). This is a nonrandomized study in which each subject will receive the standard of care as per the treating neurosurgeon.
89437276|NCT04289194|Placebo Comparator|Control group (Phase 2)|Participants with moderate to severe acute respiratory distress syndrome (10 patients)
89011284|NCT01482715|Experimental|Part 1 (Phase 1)|Rucaparib 40, 80, 160, 300, 500 mg QD and 240, 360, 480, 600, 840 mg BID, for continuous 21-day cycles. Patients in Part 1 were initially treated in a Dose-escalation Evaluation Period (Cycle 1) and could then continue to receive treatment in an optional Treatment-extension Period (Cycle 2 and beyond).
89011285|NCT01482715|Experimental|Part 2A (Phase 2)|Rucaparib 600 mg BID for 21-day cycles.
89011286|NCT01482715|Experimental|Part 2B (Phase 2)|Rucaparib 600 mg BID for 21-day cycles.
89011287|NCT01482715|Experimental|Part 3 (Phase 2)|Rucaparib 600 mg BID for 21-day cycles. Patients also received a single administration of 600 mg rucaparib on both Day -7 and Day 1 for assessing the effect of food on PK.
89011288|NCT01378871|Experimental|Antibody Therapy|Treatment with Imtox-25 intravenously over 4 hours every other day for 4 doses. Hospital admission is required during this treatment.
89011289|NCT01360606|Other|SBRT|
89011290|NCT01257919|Experimental|Azelaic Acid Foam 15%|Dermal application of Azelaic Acid Foam 15%
89011291|NCT01257919|Active Comparator|Azelaic Acid Gel 15%|Dermal application of Azelaic Acid Gel 15%
89011292|NCT00915837|Experimental|Slow release formulation|Slow release formulation, helical intravitreal triamcinolone implant
89011293|NCT00915837|Experimental|fast release formulation|fast release formulation, helical intravitreal triamcinolone implant
89011294|NCT00722189||A|All patients treated
89011295|NCT04532398|Other|Swallowing test|
89011296|NCT04532554|Experimental|Growth hormone|Recombinant GH will be used for those patients
89011297|NCT04532554|Placebo Comparator|Placebo|Saline will be used
89011298|NCT04532281|Experimental|Administration of Murine CD19 CAR T-cells|
89011299|NCT04532203|Experimental|Administration of CAR T-cells|Dose escalation follows the standard 3+3 doseescalation design. A total of 3 dose levels are set for subjects.
89011300|NCT02217163|Experimental|Single Arm|The combination therapy of Carfilzomib, cyclophosphamide and dexamethasone (KCyd) will be used to treat eligible patients for up to 6 cycles.This will be followed by an autologous bone marrow transplantation and 2 further consolidation cycles of KCyd. Depending on their disease response, patients will be managed expectantly or be started on maintenance.
89011301|NCT02217202|Experimental|ConvaTec Ag|Use of ConvaTec Ag sugical cover dressing post-operatively until wound has healed.
89011302|NCT04531852||At risk older adults|Home-dwelling older adults entitled to preventive home visit, who had a risk profile for loss of physical function and disability identified through a multi-domain screening instrument
89011303|NCT04531774|Experimental|RECHARGE|4 1-hour sessions of RECHARGE are delivered online using Skype for Business within 2 weeks.
89011304|NCT04531774|Active Comparator|Online self-study of stress management strategies|Self study during 2 weeks.
89011305|NCT04531930||Surgery Group|Colorectal surgery
88921271|NCT05984654|Experimental|Target ulcer Group 2(Topical PRP)|Under aseptic conditions, 2 mL of autologous PRP will be applied topically followed by a Platelet poor plasma solution soaked dressing on the second target ulcer at 0, 4, 8, and 12 weeks.
88921272|NCT05984654|No Intervention|Target ulcer Group 3(No treatment)|Target ulcer in the control group will receive standard wound care only.
88921273|NCT05953077|Experimental|Easy first|Children are treated for an emergent grammatical form that is used correctly at least 60% during three pre-treatment probe sessions. This form is treated until children generalize it's use an average of 90% or more across 3 probe sessions. Their treatment target is then switched to a grammatical form that is used less than 30% correct across 3 pre-treatment probe sessions.
88921274|NCT05953077|Active Comparator|Hard first|Children are treated for a grammatical form that is used accurately less than 30% of the time during 3 pre-treatment probe sessions. This form is treated until children generalize it's use an average of 90% or more across 3 probe sessions. Their treatment target is then switched to a grammatical form that is used less than 30% correct across 3 pre-treatment probe sessions.
88921275|NCT05939531|Active Comparator|Standard Care|Standard post-stroke care
88921276|NCT05939531|Experimental|Intervention|BOUNCE Program
88921277|NCT05937581|Experimental|Part A (SAD): CSL040 (minimum dose)|Single Intravenous (IV) administration
88921278|NCT05937581|Experimental|Part A (SAD): CSL040 (lower dose)|Single IV Administration
88921279|NCT05937581|Experimental|Part A (SAD): CSL040 (low dose)|Single IV Administration
88921280|NCT05937581|Experimental|Part A (SAD): CSL040 (medium dose)|Single IV Administration
88921281|NCT05937581|Experimental|Part A (SAD): CSL040 (medium-high dose)|Single IV Administration
88921282|NCT05937581|Experimental|Part A (SAD): CSL040 (maximum dose)|Single IV Administration
88921283|NCT05937581|Placebo Comparator|Part A (SAD): Placebo|Single IV Administration
88921284|NCT05937581|Experimental|Part B (MAD): CSL040 (minimum dose)|IV Administration not to exceed 5 doses over 14 days)
88921285|NCT05937581|Experimental|Part B (MAD): CSL040 (medium dose)|IV Administration not to exceed 5 doses over 14 days
88921286|NCT05937581|Experimental|Part B (MAD): CSL040 (high dose)|IV Administration not to exceed 5 doses over 14 days
88921287|NCT05937581|Placebo Comparator|Part B (MAD): Placebo|IV Administration not go exceed 5 doses over 14 days
88921288|NCT05935358|Experimental|Nuwiq|All patients receiving Nuwiq (recombinant FVIII). Nuwiq will be administered intravenously in accordance with the relevant prescribing information. Treatment will be repeated as necessary every 8-24 hours until adequate wound healing, then - if required - for at least another 7 days to maintain FVIII plasma levels of 30-60 IU/dL.
88921289|NCT05933265|Experimental|Phase 1 Single Arm Multicenter Study to Assess the Safety and Tolerability of LP-184|Phase 1 Single Arm Multicenter Study to Assess the Safety and Tolerability of LP-184 in Patients with Advanced Solid Tumors
88921290|NCT05932862|Experimental|Part 1 - Dose Escalation|Patients will receive XL309 once daily in sequential cohorts of increasing doses.
88921291|NCT05932862|Experimental|Part 2 - Dose optimization|Participants will be randomized to receive one of the two selected dose levels of XL309 once daily determined by Study Review Committee.
88921292|NCT05930431|Experimental|Physical activity variety intervention|Participants in the variety condition will be sent the link to their condition's website via email. The variety website will contain nine distinct high intensity interval training (HIIT) videos. The videos will be 30-minutes containing a five-minute warm-up, 20-minute workout, and a five-minute cool down. The website will emphasize the importance of having variety in one's physical activity routine. This will include reminders to have variety in selected workouts and the benefits associated with doing so. This emphasis will be supported through the counseling sessions provided to participants in the variety condition.
88921293|NCT05930431|Active Comparator|Physical activity consistency comparison condition|Upon the completion of randomization, participants in the consistency condition will be sent the link to their condition's website via email. The consistency website will contain one HIIT video. The video will be 30-minutes and include a five-minute warm-up, 20-minute workout, and a five-minute cool down. The website will emphasize the importance of having consistency in one's physical activity routine. This will include reminders to be consistent in workouts and the benefits associated with doing so (Guiney & Machado, 2013). This emphasis will be supported through the counseling sessions provided to participants in the consistency condition.
88921294|NCT05915039|Experimental|Group A|This is the initial experimental group who will be exposed to the CAL module 48 hours before the first retesting period 2 months out from initial baseline measurement.
88921295|NCT05915039|No Intervention|Group B|This is the initial control group who will not be exposed to the CAL module 48 hours before the first retesting period 2 months out from initial baseline measurement.
89536611|NCT04984707|Placebo Comparator|Control Group- Placebo|Placebo is tropically applied to the scalp of healthy male subjects with Androgenetic Alopecia with a single dose.
89198896|NCT00881439|Placebo Comparator|Placebo|
89536612|NCT02474615|Experimental|TOOTH ENDODONTIC SURGERY - PBEA|Endodontic surgery 15 teeth - PBEA
88921298|NCT05903664||Single group assignment|The participant will undergo a single retinal imaging session with the Optina MHRC device, on one or both eyes.
88921299|NCT05902338|Experimental|Group with music|"L400 Over Ear Music Headset Glowing Cat Ear Headphones 7 branded headphones will be used for music intervention."
88921300|NCT05902338|No Intervention|Group without music|Music will not be used while performing motor skills.
89536613|NCT02474615|Experimental|TOOTH ENDODONTIC SURGERY -MTA|Endodontic surgery 15 teeth - MTA
88921301|NCT05899127|Experimental|Lidocaine|Lidocaine will be injected intravenously at 1.5mg/kg during anesthesia induction and intravenously pumped at 1.5mg/kg/h during anesthesia induction.
88921302|NCT05899127|Placebo Comparator|Control group|Normal saline will be injected intravenously at 1.5mg/kg during the induction period and intravenously pumped at 1.5mg/kg/h during the induction period.
88921303|NCT05897593|Experimental|Augmented Reality Delivered Therapy + Standard Clinical Care|The GlenXRose augmented reality therapies will be delivered to participants using a head-mounted device to allow acquired brain injury rehabilitation therapy and practice. Participants will also receive routine clinical care provided by clinicians.
88921304|NCT05897593|No Intervention|Standard Clinical Care|Participants will receive routine clinical care provided by clinicians.
88921305|NCT05894681|Experimental|intervention group|To the intervention group; Training and Care Guide psychoeducation program based on Watson Human Care Theory, prepared for the prevention of postpartum depression, will be implemented as six interviews and each interview will be 90 minutes. Before the psychoeducation, the pregnant women were asked to fill out the Personal Information Form, Edinburgh Postpartum Depression Scale, and the Multidimensional Scale of Perceived Social Support. After the diagnosis with a detailed anamnesis, the Training and Care Guide for the Prevention of Postpartum Depression was applied to the pregnant women with the psychoeducation program and a guide booklet was given to them. The interview was done face to face. Pregnant women were given counseling over the phone when they had questions about education. In the last interview, pregnant women were asked to fill out the Patient Satisfaction Evaluation Form according to Watson Improvement Processes.
88921306|NCT05894681|Experimental|control group|Personal Information Form, Edinburgh Postpartum Depression Scale, and Multidimensional Scale of Perceived Social Support were filled in to the control group during the interview. Pregnant women were given routine care applied to pregnant women who applied for antenatal controls in FHCs. The interview was done face to face.
88921307|NCT05890313|Experimental|Group MoCA/MMSE (Interventional Group)|A training session about dementia management and standardized criteria for referral will be provided to participant PCCs, complemented with training in the administration of MMSE and MoCA, provided also to resident clinicians responsible for administration of the tests. MMSE will be administered if the patient has three to four years of schooling, and the MoCA will be used if the patient has more than four years of schooling. Patients with less than three years of education will be evaluated through regular clinical practice.
88921308|NCT05890313|Experimental|Group Brain on Track/MoCA/MMSE (Interventional Group)|The training sessions mentioned in group MoCA/MMSE will be similarly provided in this group. Brain on Track is a web-based platform, used to remotely monitor cognitive function. There will be a first assessment with the aim of training eligible patients to correctly use Brain on Track, and a second assessment, one week after the first session. Depending on the score obtained in the second assessment, patients will be immediately referred to a specialized consultation, will not be referred or will be followed up during a period of 12 months with remote self monitorization, every three months. According to the total score from the four self-assessments performed in the follow-up period, PCCs will decide whether to refer or not. Patients who are illiterate will be evaluated through regular clinical practice, or MMSE or MoCA tests, according to years of schooling, if they are literate, but do not gather the inclusion criteria for the administration of Brain on Track.
88921309|NCT05890313|No Intervention|Control Group|Regular clinical practice complemented with the provision of standardized criteria for referring patients with a suspected diagnosis of MCI or early dementia to PCCs.
89011306|NCT04531930||Enhanced Colonoscopy Group|Enhanced colonoscopic treatment and surveillance
89198897|NCT00881439|Active Comparator|Aliskiren|
89437277|NCT04289194|Experimental|HCR040 (Phase 2)|Participants with moderate to severe acute respiratory distress syndrome (10 patients)
89437278|NCT04285671|Experimental|Treatment (necitumumab, trastuzumab, osimertinib)|Patients receive necitumumab IV over 60 minutes and trastuzumab IV over 30-90 minutes on days 1 and 15. Patients also receive osimertinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89437279|NCT04283552|Experimental|Dynamic PET Imaging|"Dynamic PET/CT imaging will begin at approximately the same time as the clinically prescribed radiotracer injection and will continue until approximately the start of the clinical scan~A subset of patients (up to 30 scheduled to undergo FDG or DOTATATE PET/CT imaging) will be asked to return within 7 days for a repeat imaging study."
89437280|NCT04281875|Experimental|NIRAF Detection Technology +|Parathyroid gland identification will be performed with PTeye using NIRAF detection technology as an adjunctive tool in patients who undergo total thyroidectomy (TTx) with or without lymph node dissection (LND).
89437281|NCT04281875|No Intervention|NIRAF Detection Technology -|Parathyroid gland identification will be performed with the naked eye of the surgeon without using PTeye - NIRAF detection technology in patients who undergo total thyroidectomy (TTx) with or without lymph node dissection (LND).
89536614|NCT02474537|Experimental|Normal hepatic function|Subjects with normal hepatic function
88921310|NCT05870800|Experimental|Neoadjuvant Therapy Arm|Subjects will receive 4 cycles of neoadjuvant atezolizumab in combination with 4 cycles of CAPEOX before standard of care surgical resection. After surgery, patients who are still considered high risk for recurrence (per the treating medical oncologist) will be offered adjuvant therapy. Adjuvant therapy will consist of mFOLFOX6 Q2 weeks x 6 cycles (12 weeks) or CAPEOX Q3 weeks x 4 cycles (12 weeks).
88921311|NCT05855603|Experimental|Cardioneuroablation|Bi-atrial ablation of GPs: CARDIONEUROABLATION (Group A, n = 45)
88921312|NCT05855603|Active Comparator|Dual-chamber pacemaker|"Implant of a dual-chamber CLS PACEMAKER* (Group B, n = 45).~*or failing this, a dual-chamber pacemaker with RDR algorithm"
88921313|NCT05854784|Experimental|Afamelanotide|
89437282|NCT04281030|Experimental|Progressive Muscle Relaxation (PMR) Therapy|After the PMR APP is loaded onto the subject's smartphone, the subject will perform PMR in the ED and discuss the optimal time and place to practice PMR at home. All subjects will be asked to keep records of headache occurrence, side effects, compliance, and medication changes on the APP.
89437283|NCT04281030|Active Comparator|Monitored Usual Care (MUC)|Subjects will be given general educational information consisting of basic migraine information such as evidence-based ways to treat migraine: treat early, limit acute medications < 2-3 days/week, and call the primary care physician (PCP) if abortive medications are used more frequently. Any migraine treatment decisions on discharge will be left up to the ED attending. The research coordinator (RC) will load the APP onto the subjects' smart phones but the PMR component will be blocked on the version of the APP that the MUC subjects receive. All subjects will be asked to keep records of headache occurrence, side effects, compliance, and medication changes on the APP.
88921314|NCT05837767|Experimental|Participants with metastatic solid tumors|Participants will have metastatic solid tumors and at least two sites of measurable extra-cranial disease
88921315|NCT05832281|Active Comparator|Synthetic CBD 4-Week Trial Arm|For one week they will titrate up to the maintenance dose of 600 mg/day of Purysis, a synthetic, liquid form of CBD, which they will continue for 4 weeks. Upon completion of the 4-week trial, they will be re-assessed, followed by one week of titrating down to discontinuation.
88921316|NCT05832281|Placebo Comparator|Placebo 4-Week Trial Arm|For one week they will titrate up to the maintenance dose of 600 mg/day of placebo for Purysis, a synthetic, liquid form of CBD, which they will continue for 4 weeks. Upon completion of the 4-week trial, they will be re-assessed, followed by one week of titrating down to discontinuation.
88921317|NCT05819424|Experimental|Placebo intervention first and Active intervention one week later|Participants will be consuming a placebo on a clinic day at least one week prior to a clinic day where they will consume the active intervention.
88921318|NCT05819424|Experimental|Active intervention first and Placebo intervention one week later|Participants will be consuming active intervention on a clinic day at least 1 week prior to a clinic day where they will consume the placebo.
88921319|NCT05818930|Other|REMI vs Conventional EEG|REMI EEG is as Diagnostically useful as conventional EEG at monitoring patients with suspected seizure events.
89011307|NCT04531930||Self Choice Group|The patients choose the interventional methods, even do nothing.
89011308|NCT04532008|No Intervention|Control Group|No intervention
89437284|NCT04267718|Experimental|Patients with the Padua and IMPROVE Bleeding scores|A number of centres will be randomized to systematically evaluate all eligible patients with the Padua and IMPROVE Bleeding scores within 48 h after hospitalization.
89437285|NCT04267718|No Intervention|Patients will be evaluated according to clinical judgment only|A number of centres will be randomized to the Control arm of the study, in which patients will be evaluated for their thrombotic and hemorrhagic risk according to clinical judgment only.
89437286|NCT04265703|Active Comparator|Internal jugular vein site|Ultrasound-guided central venous catheterization at internal jugular vein site
89437287|NCT04265703|Active Comparator|Subclavian vein site|Ultrasound-guided central venous catheterization at subclavian vein site
89437288|NCT04265703|Active Comparator|Innominate vein site|Ultrasound-guided central venous catheterization at innominate vein site
89437289|NCT04257422|Experimental|Intentional Rounding|In the centers randomized to Intentional Rounding the ward nurses will have to adopt a new proactive care method towards hospitalized patients
89198898|NCT01573390||1|Healthy participants.
89437290|NCT04257422|No Intervention|Control|In randomized controlled centers, nurses guarantee the standard care provided by the ward
89198899|NCT00881517|Experimental|Cytotect|
89437291|NCT04255615|Other|3D Ultrasound with AI|AI tool to assess antral follicle count using 3 D Ultrasound
89437292|NCT04251533|Experimental|alpelisib + nab-paclitaxel|Double-blinded, Randomized in a 1:1 ratio in Study Parts A and B2 Single arm Open label in Study Part B1
89011309|NCT04532008|Experimental|Treatment Group|Experimental group received 12 session of group based depression treatment, a matched savings program, financial literacy training, agricultural training, and a cash transfer.
89011310|NCT00263367|Other|hyperbaric oxygen at 1.3 ATA|Hyperbaric Oxygen at 1.3 ATA for one hour followed by measurement of glutathione in the blood
89011311|NCT04531735||Group 1|COVID positive infants
89011312|NCT04531735||Group 2|RSV positive infants
89011313|NCT04531423|Experimental|SSRI + golimumab|Participants will be administered with SSRI+golimumab . Golimumab will be administered at the dose of 50mg every month during the acute phase.
89011314|NCT04531423|Active Comparator|SSRI +placebo|Participants will be administered with SSRI+placebo
89011315|NCT04531657||Vaccine, Post-transplant|Cohort consist of individuals who have received lung transplants Inactivated influenza vaccine will be administered intramuscularly annually.
89011316|NCT04531657||Vaccine, Healthy Control|Cohort consists of healthy individuals who received the influenza vaccine Inactivated influenza vaccine will be administered intramuscularly annually.
89011317|NCT04531306|Active Comparator|Pre-tape|
89011318|NCT04531306|Experimental|With tape 1|
89011319|NCT04531306|Experimental|With tape 2|
89011320|NCT04531306|Experimental|Post-tape|
89011321|NCT04531267|Active Comparator|Individualized nutrition|Participants' diet will be assessed by food frequency questionnaire to obtain calcium and magnesium intake. Individualized dosage of dietary supplements will be provided to maintain a calcium/magnesium ratio as 2.3. Participants will stay with the original medication plan.
89011322|NCT04531267|No Intervention|Control group|Participants do not receive any supplements, they stay with the original medication plan.
89011323|NCT04531228|Experimental|Experimental: TACE-HAIC plus lenvatinib|chemo-lipiodolization, followed by FOLFOX-based chemotherapy artery infusion (HAIC). Lenvatinib was administrated two or four days after TACE-HAIC.
89011324|NCT04531150|Experimental|Cohort 1|Subjects will be randomized to receive either placebo or 20 mg INV-101
89011325|NCT04531150|Experimental|Cohort 2|Subjects will be randomized to receive either placebo or 80 mg INV-101
89011326|NCT04531150|Experimental|Cohort 3|Subjects will be randomized to receive either placebo or 160 mg INV-101
89011327|NCT04531150|Experimental|Cohort 4|Subjects will be randomized to receive either placebo or 320 mg INV-101
89011328|NCT04531150|Experimental|Cohort 5|Subjects will be randomized to receive either placebo or 500 mg INV-101
89011329|NCT04531345||Case Group|Patients with Covid 19 PCR (+) results
89011330|NCT04531345||Control Group|Healthy volunteers
89011331|NCT04531072|Experimental|ATVr-arm|10 participants living with HIV and having uncomplicated Falciparum malaria were administered: Atazanavir-ritonavir (300/100 mg) one tablet once daily continuously + tenofovir-lamivudine (300/300 mg) one tablet once daily continuously and artemether-lumefantrine (80/480 mg) one tablet twice daily for three days at 0, 8, 24, 36, 48 and 60 hour.
89011332|NCT04531072|Active Comparator|AL-arm (Control)|10 participants who were HIV negative but having uncomplicated Falciparum malaria were administered: Artemether-lumefantrine 80/480 mg, one tablet twice daily for three days at 0, 8, 24, 36, 48 and 60 hour.
89011333|NCT04530955|No Intervention|Control Arm|"Patients randomized to the Control Arm that have been implanted with the valve-gated pump will be started on an equivalent dose (without change to the medication concentration) as prior to implant. If at any time during the patients' treatment it is determined by the investigator that the patients' treatment dose needs to be modified, the dose can be modified as clinically indicated. Multiple dosing decreases may be performed if the patient is clinically demonstrating a reduction in spasticity that is profound and negatively impacting function, or if the patient is demonstrating signs of baclofen overdose.~The criteria for dosing decrease will be clinical discretion."
89011334|NCT04530955|Active Comparator|Study Arm|"Patients randomized to the Study Arm will be started on a 20% dose reduction (without change to the medication concentration) through the newly implanted valve-gated pump. If at any time during the patients' treatment it is determined by the investigator that the patients' treatment dose needs to be increased or decreased, the dose can be increased/decreased as clinically indicated. If the dose increases with the valve-gated pump reach the patients' baseline dose and the patient's spasticity is worse than his or her spasticity at baseline, then the patient will be considered a primary endpoint failure.~The criteria for dosing increase will be clinical discretion."
89437293|NCT04251533|Placebo Comparator|placebo + nab-paclitaxel|Double-blinded, Randomized in a 1:1 ratio in Study Parts A and B2 Not applicable in Study Part B1
89011335|NCT00263484|Experimental|"dtZ regimen, Initial therapy"|"To test the efficacy of the dtZ regimen in previously untreated patients with multiple myeloma."
89011336|NCT04531033|Placebo Comparator|Placebo|Taken once prior to the first testing session, 3x a day every day for the 7 days of supplementation, and taken one last time during second testing session.
89011337|NCT04531033|Experimental|Low dose 10 billion CFU per day|Taken once prior to the first testing session, 3x a day every day for the 7 days of supplementation, and taken one last time during second testing session.
89011338|NCT04531033|Experimental|High dose 15 billion CFU per day|Taken once prior to the first testing session, 3x a day every day for the 7 days of supplementation, and taken one last time during second testing session.
89011339|NCT04530721||stroke group|
89011340|NCT04530721||normal group|
89011341|NCT04530370|Experimental|Recovered covid 19 plasma|
89011342|NCT04530370|Placebo Comparator|controlled|
89011343|NCT00414401|Other|Arm 1|
89011344|NCT04530331|Experimental|Intervention group|Providing nutrition education.
89437294|NCT04249232|Active Comparator|abaloparatide prefilled syringe|Abaloparatide-SC is supplied as a liquid, 3120 micrograms per 1.56 milliliter (2000 mcg/mL) in a single patient multi-use prefilled pen. The prefilled pen delivers 30 doses of abaloparatide, each containing 80 mcg of abaloparatide in 40 microliters of a sterile, clear, colorless solution. To be administered subcutaneously daily.
89437295|NCT04249232|Placebo Comparator|Placebo prefilled syringe|For the placebo-SC a prefilled multi-use pen injector cartridge is designed to deliver 30 doses of placebo each in 40 microliters of sterile, clear, colorless solution to be administered subcutaneously daily.
89437296|NCT04245943|Experimental|Exercise|18 weeks supervised strength and aerobic exercise training
89437297|NCT04242602|Other|Study Subjects|
89437298|NCT04238819|Experimental|Dose Escalation: Abemaciclib + Irinotecan + Temozolomide|Abemaciclib given orally, irinotecan given intravenously (IV) and temozolomide given orally.
89437299|NCT04238819|Experimental|Dose Expansion: Abemaciclib + Irinotecan + Temozolomide|Abemaciclib given orally, irinotecan given IV and temozolomide given orally.
89437300|NCT04238819|Experimental|Dose Escalation: Abemaciclib + Temozolomide|Abemaciclib and temozolomide given orally.
89437301|NCT04238819|Experimental|Dose Expansion: Abemaciclib + Temozolomide|Abemaciclib and temozolomide given orally.
89437302|NCT04238819|Experimental|Part C Stage 1: Abemaciclib in Combination with Dinutuximab, GM-CSF, Irinotecan, and Temozolomide|Abemaciclib given orally, dinutuximab given IV, granulocyte macrophage colony-stimulating factor (GM-CSF) given subcutaneously (subQ), irinotecan given IV and temozolomide given orally or IV.
89437303|NCT04238819|Experimental|Part C Stage 2: Abemaciclib in Combination with Dinutuximab, GM-CSF, Irinotecan, and Temozolomide|Abemaciclib given orally, dinutuximab given IV, GM-CSF given subQ, irinotecan given IV and temozolomide given orally or IV.
89437304|NCT04238169|Experimental|SBRT+Toripalimab|"Immunotherapy：Toripalimab: 240 mg once every three weeks，Until progress of disease or investigators determine that clinical benefit is no longer available or there are intolerable toxicity.~SBRT：30-50Gy/5F（2-4 locations)."
89437305|NCT04238169|Experimental|SBRT+Bevacizumab+Toripalimab|"Immunotherapy：Toripalimab: 240 mg once every three weeks，Until progress of disease or investigators determine that clinical benefit is no longer available or there are intolerable toxicity.~SBRT：30-50 Grays(Gy) in 5 fractions（2-4 locations）. Bevacizumab：7.5mg/kg once every three weeks."
89437306|NCT04235777|Experimental|Arm 1|Treatment with M7824 and de-escalating doses of M9241 if appropriate
89536615|NCT02474537|Experimental|Mild hepatic impairment|Subjects with mild hepatic impairment
88921320|NCT05817890|Experimental|Up to 8 subjects will be enrolled and studied as a single group|The purpose of this study is to determine the absorption, metabolism, and excretion (AME) of [14C]CYC065 and to characterize and determine, where possible, the metabolites present in plasma, urine, and feces in healthy male subjects following a single oral administration.
88921321|NCT05814666|Experimental|Danvatirsen plus pembrolizumab|"Danvatirsen dosing:~Week 1: Danvatirsen intravenously (IV) on Days 1, 3, and 5~Week 2 and subsequent weeks: Danvatirsen IV weekly~Pembrolizumab dosing:~Pembrolizumab every 3 weeks after the Danvatirsen dose."
88921322|NCT05814666|Active Comparator|Pembrolizumab|Pembrolizumab IV every 3 weeks after the Danvatirsen dose.
88921323|NCT05804838|Experimental|Mindfulness Group|"Research inclusion criteria~Being between 20-35 years old~Being her first pregnancy~Being between 13 and 24 weeks of gestation~Having applied to the pregnant outpatient clinic where the research will be conducted.~Not having a hearing-visual impairment~Ability to read and write Turkish~Volunteering to participate in the research~Not having a diagnosis that would constitute an obstacle to physical activity~Agreeing to participate in the 8-week MBSR training~Being able to use ZOOM Cloud Meetings program"
88921324|NCT05804383|Experimental|50 mg active|BMS-984923 50 mg in healthy participants
88921325|NCT05804383|Placebo Comparator|50 mg Placebo|Placebo 50 mg in healthy participants
88921326|NCT05804383|Experimental|100 mg Active|BMS-984923 100 mg in healthy participants
88921327|NCT05804383|Placebo Comparator|100 mg Placebo|Placebo 100 mg in healthy participants
88921328|NCT05804383|Experimental|100 mg Active 20d|BMS-984923 100 mg in healthy participants 20 days
88921329|NCT05804383|Placebo Comparator|100 mg Placebo 20d|Placebo 100 mg in healthy participants 20 days
88921330|NCT05804383|Experimental|150 mg Active 20d|BMS-984923 150 mg in healthy participants 20 days
88921331|NCT05804383|Placebo Comparator|150 mg Placebo 20d|Placebo 150 mg in healthy participants 20 days
88921332|NCT05804383|Experimental|50 mg Active-AD|BMS-984923 50 mg
89437307|NCT04235777|Experimental|Arm 2|Treatment with M7824 and de-escalating doses of M9241 (if appropriate) with sequential SBRT
89437308|NCT04235777|Experimental|Arm 3|Treatment with M7824 and de-escalating doses of M9241 (if appropriate) with concurrent SBRT
89437309|NCT04228952||Smokers with very low or no CYP2A6 activity|Japanese American smokers (daily > 5 cigarettes) with little or no CYP2A6 activity (CYP2A6 activity defined as a ratio of trans-3-hydroxycotinine:cotinine ratio of <0.6).
89437310|NCT04228952||Smokers with high CYP2A6 activity|Japanese American smokers (daily > 5 cigarettes) with high CYP2A6 activity (CYP2A6 activity defined as a ratio of trans-3-hydroxycotinine:cotinine ratio of > 3.0)
89437311|NCT04220619|No Intervention|Conventional ACLS|Patients who have conventional ACLS during in-hospital Cardiac arrest, they will not have RescueTEE
89437312|NCT04220619|Experimental|RescueTEE guided ACLS|Patients who have RescueTEE guided ACLS
89437313|NCT04217057|Experimental|64Cu-DOTA-ECL1i-PET/CT|-64CU-DOTA-ECL1i-PET/CT imaging consisting of a dynamic scan centered at the level of the known tumor followed by a limited body scan of the head/neck and upper chest will be performed
89437314|NCT04214834|Active Comparator|Rapid-wean|15% decrements from the stabilization dose of morphine/methadone
89437315|NCT04214834|Active Comparator|Slow-wean|10% decrements from the stabilization dose of morphine/methadone
89437316|NCT04208178|Experimental|Part 1: Alpelisib + Trastuzumab + Pertuzumab|"In the Part 1, up to 3 alpelisib dose levels may be sequentially tested in 3 cohorts of subjects:~Cohort A: Alpelisib 300mg + trastuzumab (6mg/kg) + pertuzumab (420 mg) Cohort B: Alpelisib 250 mg+ trastuzumab (6mg/kg) + pertuzumab (420 mg) Cohort C: Alpelisib 200mg + trastuzumab (6mg/kg) + pertuzumab (420 mg)"
89437317|NCT04208178|Experimental|Part 2: Alpelisib + Trastuzumab + Pertuzumab|Trastuzumab (6mg/kg) + pertuzumab (420 mg) in combination with 200mg alpelisib, with potential for intra-participant dose escalation to 250 mg
89536616|NCT02474537|Experimental|Moderate hepatic impairment|Subjects with moderate hepatic impairment
88921333|NCT05804383|Experimental|100 mg Active-AD|BMS-984923 100 mg
88921334|NCT05804383|Placebo Comparator|Placebo-AD|Placebo matching
88921335|NCT05803603|Experimental|Intervention Arm|Individuals will receive $500 monthly stipend for the first months of the study and will receive twelve months of social work supports to help individuals find permanent housing.
88921336|NCT05781295|Experimental|TauroLock™|The patient will be followed up to a maximum of 6 months after randomization after have a Taurlock™ injected each time catheter will be used.
88921337|NCT05781295|Placebo Comparator|Physiological serum (NaCl 0.9%)|The patient will be followed up to a maximum of 6 months after randomization after have a Physiological serum injected each time catheter will be used.
88921338|NCT05777486|Experimental|TikTok Influencer Ads with Food|Participants randomized to view TikTok influencers' posts with food will view 4 ads associated with their condition and 2 filler ads, all of which are presented in counterbalanced order. They will report their reaction to the ads using the icons available on the TikTok platform (i.e. like, comment, or share). After viewing all of the TikTok ads, youth participants will complete the virtual snack selection task where they will see a virtual vending machine. All items will cost $2. Participants will be asked to select one snack and one beverage from the vending machine. After the snack selection task, participants will review the TikTok ads again and complete survey questions.
88921339|NCT05777486|Experimental|TikTok Influencer Ads without Food|Participants randomized to view TikTok influencers' posts without food will view 4 ads associated with their condition and 2 filler ads, all of which are presented in counterbalanced order. They will report their reaction to the ads using the icons available on the TikTok platform (i.e. like, comment, or share). After viewing all of the TikTok ads, youth participants will complete the virtual snack selection task where they will see a virtual vending machine. All items will cost $2. Participants will be asked to select one snack and one beverage from the vending machine. After the snack selection task, participants will review the TikTok ads again and complete survey questions.
88921340|NCT05763563|Experimental|Exercise prehabilitation|Participants will take part in an exercise program in which they will be encouraged to perform approximately 30 minutes of resistance training exercises approximately twice per week until they undergo CAR-T therapy (Approximately 4-6 weeks). Participants will also be encouraged to perform moderate aerobic exercise such as brisk walking or using stationary aerobic equipment at least 3 times per week. Participants will wear a FitBit fitness watch to monitor aerobic exercise.
88921341|NCT05753956|Experimental|Cohort A: Dose A single dose|A single dose of GH002 or placebo administered by i.v. bolus injection (randomized as 6 active and 2 placebo subjects)
88921342|NCT05753956|Experimental|Cohort B: Dose B single dose|A single dose of GH002 or placebo administered by i.v. bolus injection (randomized as 6 active and 2 placebo subjects)
88921343|NCT05753956|Experimental|Cohort C: Dose C single dose|A single dose of GH002 or placebo administered by i.v. bolus injection (randomized as 6 active and 2 placebo subjects)
88921344|NCT05753956|Experimental|Cohort D: Dose D single dose|A single dose of GH002 or placebo administered by i.v. bolus injection (randomized as 6 active and 2 placebo subjects)
88921345|NCT05753956|Experimental|Cohort E: Dose E single dose|A single dose of GH002 or placebo administered by i.v. bolus injection (randomized as 6 active and 2 placebo subjects)
88921346|NCT05753956|Experimental|Cohort F: Dose F single dose|A single dose of GH002 or placebo administered by i.v. bolus injection (randomized as 6 active and 2 placebo subjects)
88921347|NCT05753956|Experimental|Cohort G: Dose G single dose|A single dose of GH002 or placebo administered by i.v. bolus injection (randomized as 6 active and 2 placebo subjects)
88921348|NCT05753956|Experimental|Cohort J: Individualized Dosing Regimen|Administration of up to 3 doses of GH002 within a single day (doses to be confirmed following review of data from single-dose part)
88921349|NCT05748197|Experimental|ADCLEC.syn1 CAR T cells|The dose escalation cohort size of 3 patients in each cohort will be infused with escalating doses of ADCLEC.syn1 CAR T cells to inform the RP2D. There are 4 planned flat-dose levels: 25 × 10^6, 75 × 10^6 , 225 × 10^6 , and 450 × 10^6 CAR T cells and 1 de-escalation dose: 10 × 10^6 CAR T cells. After dose escalation, one or two dose levels will be selected for dose expansion cohort(s).Two to 7 days following completion of the conditioning chemotherapy, the frozen CAR T cells will be thawed and administered. Conditioning chemotherapy may occur either outpatient or inpatient, and T cell infusions will occur as inpatient. Up to approximately 12 additional patients each if two doses are selected or approximately 16 additional patients, if one dose is selected, will be treated in the dose expansion phase to determine RP2D.
88921350|NCT05747027|Experimental|laparoscopic abdominal ventral rectopexy|
88921351|NCT05747027|Experimental|transvaginal sacrospinous rectopexy|
88921352|NCT05745480||Pre-Intervention Period: Usual Care with Ad-Hoc Addiction Consults|UW Hospital launched an Addiction Medicine inpatient consult service in 1991 to address the high prevalence of substance use disorders in hospitalized adults. Currently, a single screening item queries 'marijuana or other recreational drug use,' but no formal screening process was in place specifically targeting opioid misuse. For patients at risk of an opioid use disorder, the practice was ad-hoc consultations at the discretion of the primary provider.
88921353|NCT05745480||Post-Intervention Period: Artificial intelligence-driven clinical decision support|The technical architecture that enabled the real-time, NLP CDS tool incorporated industry-leading and emerging technological capabilities. The NLP CDS infrastructure exports the notes from the EHR, organizes them and feeds them into an NLP pipeline, inputed the processed text features into the opioid screener deep learning model, and delivered the resultant scores back to the bedside electronic health record as a best practice alert.
88921354|NCT05745376|Experimental|Intervention Center|The intervention will include: (1) assisting ECEs with conducting self-assessments; (2) connecting ECEs with local farmers and food producers; (3) providing technical assistance for menu changes, procuring healthy food, identifying and implementing best feeding practices and policies for the environment; (4) delivering nutrition education; and (5) connecting parents/guardians with local food resources and affordable fresh food to be consumed at home
88921355|NCT05745376|No Intervention|Comparison|No programming at center, only surveys
88921356|NCT05743881|Experimental|Part A: mRNA-1345, Dose 1 (Age Group: 8 to <24 months)|Participants will receive mRNA-1345 vaccine by intramuscular (IM) injection on Days 1, 57 and 113.
89536617|NCT02474537|Experimental|Severe hepatic impairment|Subjects with severe hepatic impairment
88921357|NCT05743881|Experimental|Part A: mRNA-1365, Dose 1 (Age Group: 8 to <24 months)|Participants will receive mRNA-1365 vaccine by IM injection on Days 1, 57 and 113.
88921358|NCT05743881|Placebo Comparator|Part A: Placebo (Age Group: 8 to <24 months)|Participants will receive mRNA-1345/ mRNA-1365 vaccine matching placebo by IM injection on Days 1, 57 and 113. In countries where applicable, participants may receive Nimenrix instead of placebo on Day 113.
88921359|NCT05743881|Experimental|Part B: mRNA-1345, Dose 2 (Age Group: 5 to <8 months)|Participants will receive mRNA-1345 by IM injection on Days 1, 57 and 113.
88921360|NCT05743881|Experimental|Part B: mRNA-1365, Dose 2 (Age Group: 5 to <8 months)|Participants will receive mRNA-1365 by IM injection on Days 1, 57 and 113.
88921361|NCT05743881|Experimental|Part B: mRNA-1345 Dose 1 (Age Group: 5 to <8 months)|Participants will receive mRNA-1345 by IM injection on Days 1, 57 and 113.
88921362|NCT05743881|Experimental|Part B: mRNA-1365 Dose 1 (Age Group: 5 to <8 months)|Participants will receive mRNA-1365 by IM injection on Days 1, 57 and 113.
88921363|NCT05743881|Placebo Comparator|Part B: Placebo (Age Group: 5 to <8 months)|Participants will receive mRNA-1345/ mRNA-1365 vaccine matching placebo by IM injection on Days 1, 57 and 113. In countries where applicable, participants may receive Nimenrix instead of placebo on Day 113.
88921364|NCT05738902||Women affected by gynecological cancer.|Women affected by confirmed gynecological cancer treated with open access surgery and managed according to ERAS guidelines.
88921365|NCT05736146||Case: GWI|This group includes participants who served in the Gulf War during 1990 -1991 and have Gulf War Illness based on either the Kansas or CDC symptom criteria.
88921366|NCT05736146||Control|This group includes participants who served in the Gulf War during 1990 -1991 and have no symptoms of Gulf War Illness based on both the Kansas and CDC symptom criteria.
88921367|NCT05734586|Other|DYSPHAGING Interventional group|"Step 1: delivery of the EAT-10 questionnaire for swallowing disorders screening;~Step 2: in case of EAT≥2 score, immediate implementation of upper airway protection measures in 3 areas:~1: Postural adjustments; 2 : Hygienic and dietary rules ; 3: Food textures The hypothesis is that allied health professionals in acute geriatric wards, rehabilitation units, and Long Term Care Units are able to implement the current recommendations for screening for sarcopenic dysphagia and to implement preventive measures but in a systematic way.~Patient characteristics will be collected at each site at the end of the study by a clinical research assistant based on their medical records.~At the end of the study, each allied health professionals who has been involved in the care of at least one patient will fill out a satisfaction questionnaire."
88921368|NCT05734040|Experimental|OVX836 480µg + Fluarix Tetra at commercial dose|OVX836: Adjuvant-free recombinant influenza candidate vaccine based on Nucleoprotein of the influenza virus. One single administration intramuscularly of 480µg dose on Day 1 AND Fluarix Tetra: Inactivated and purified split influenza vaccine. One single administration intramuscularly in the opposite arm on Day 1.
88921369|NCT05734040|Experimental|OVX836 480µg + Afluria Quad at commercial dose|OVX836: Adjuvant-free recombinant influenza candidate vaccine based on Nucleoprotein of the influenza virus. One single administration intramuscularly of 480µg dose on Day 1 AND Afluria Quad: Inactivated and purified split influenza vaccine. One single administration intramuscularly in the opposite arm on Day 1.
88921370|NCT05734040|Active Comparator|Fluarix Tetra at commercial dose + Placebo|"Fluarix Tetra: Inactivated and purified split influenza vaccine. One single administration intramuscularly in the opposite arm on Day 1.~AND Placebo Comparator: Saline solution (B. Braun Ecoflac Plus) Saline solution (NaCl 0,9%), B. Braun Ecoflac Plus 50 milliliter. One single administration intramuscularly of a 0.8 milliliter dose in the opposite arm on Day 1."
88921371|NCT05734040|Active Comparator|Afluria Quad at commercial dose + Placebo|"Afluria Quad: Inactivated and purified split influenza vaccine. One single administration intramuscularly on Day 1.~AND Placebo Comparator: Saline solution (B. Braun Ecoflac Plus) Saline solution (NaCl 0,9%), B. Braun Ecoflac Plus 50 milliliter. One single administration intramuscularly of a 0.8 milliliter dose in the opposite arm on Day 1."
88921372|NCT05734040|Placebo Comparator|OVX836 480µg + Placebo|OVX836: Adjuvant-free recombinant influenza candidate vaccine based on Nucleoprotein of the influenza virus. One single administration intramuscularly of 480µg dose on Day 1 AND Placebo Comparator: Saline solution (B. Braun Ecoflac Plus) Saline solution (NaCl 0,9%), B. Braun Ecoflac Plus 50 milliliter. One single administration intramuscularly of a 0.8 milliliter dose in the opposite arm on Day 1.
88921373|NCT05734040|Placebo Comparator|Placebo + Placebo|Placebo Comparator: Saline solution (B. Braun Ecoflac Plus) Saline solution (NaCl 0,9%), B. Braun Ecoflac Plus 50 milliliter. One single administration intramuscularly of a 0.8 milliliter dose on Day 1 AND Placebo Comparator: Saline solution (B. Braun Ecoflac Plus) Saline solution (NaCl 0,9%), B. Braun Ecoflac Plus 50 milliliter. One single administration intramuscularly of a 0.8 milliliter dose in the opposite arm on Day 1.
88921374|NCT05732961|Experimental|Participants with gene mutations other than SF3B1|Participants with lower risk MDS or non-proliferative MDS/MPN with somatic splicing gene mutations other than SF3B1
88921375|NCT05732961|Experimental|Participants with SF3B1 mutation|Participants with lower risk MDS or non-proliferative MDS/MPN with SF3B1 mutation who had received hypomethylating agents and or lenalidomide.
88921376|NCT05721261|Experimental|Active treatment|
88921377|NCT05721261|Sham Comparator|Sham treatment|
88921378|NCT05714826|Experimental|Intervention Arm|Preop intervention Arm Referral to Perioperative Optimization of Senior Health (POSH) Program Remote patient monitoring device orientation, initial intake, and education UTSW ERAS protocol perioperatively Inpatient geriatrics co-management Monitored recovery Post-operative monitoring with Acticare for 90 days Post-op specialist continuity of care
88921379|NCT05714826|Active Comparator|Control Arm|Enhanced Recovery After Surgery Usual referral and recovery care as needed Standard follow-up protocol
88921380|NCT05706870|Experimental|GN-037 cream|"Psoriatic patients will receive GN-037 cream in 2:2:1 ratio~Psoriatic patients will receive GN-037 cream twice daily on a selected body target lesion~GN-037 cream will be applied as a thin film layer for 4 weeks."
88921381|NCT05706870|Active Comparator|Clobetasol 17-propionate cream|"Clobetasol 17-propionate cream will be applied in 2:2:1 ratio~Psoriatic patients will receive clobetasol 17-propionate cream twice daily on a selected body target lesion~Clobetasol 17-propionate will be applied as a thin film layer for 4 weeks."
89011345|NCT04530331|No Intervention|Control group|Without any intervention.
88921382|NCT05706870|Placebo Comparator|Placebo|"Placebo cream will be applied in 2:2:1 ratio~Psoriatic patients will receive placebo cream twice daily on a selected body target lesion~Placebo cream will be applied as a thin film layer for 4 weeks."
89437318|NCT04208178|Placebo Comparator|Part 2: Alpelisib matching Placebo + Trastuzumab + Pertuzumab|Trastuzumab (6mg/kg) + pertuzumab (420 mg) in combination with 200 mg alpelisib matching placebo, with potential for intra-participant dose escalation to 250 mg
89437319|NCT04207944|Experimental|Sulindac|Patients will be randomized to receive standard radiographic/endoscopic surveillance plus sulindac. The sulindac starting dose is 200 mg by mouth 2x daily. Patients will continue drug for 3 years during follow-up.
89437320|NCT04207944|Placebo Comparator|Placebo|Patients will be randomized to receive standard radiographic/endoscopic surveillance plus placebo. Patients will continue placebo for 3 years during follow-up.
89437321|NCT04202003|Experimental|TJ011133|This is an open-label Phase 1/2a clinical study. The study will be conducted in two parts: Part I: Phase 1 dose escalation, TJ011133 is tentatively scheduled to be administered once weekly in 28-day treatment cycles;Part II: Phase 2a study TJ011133 will be administered at a dose of 30 mg/kg once weekly, and AZA will be administered at a dose of 75 mg/m2 by subcutaneous injection for 7 consecutive days from D1 to D7 in 28-day treatment cycles.
88921383|NCT05700201|Experimental|Intervention|Healthy lifestyle intervention
89437322|NCT04200144|Active Comparator|active endoscopic treatment|Patients that will undergo Endoscopic Sleeve Gastroplasty
89437323|NCT04200144|Active Comparator|standard medical therapy control diet group|Patients that will undergo diet
89437324|NCT04193215|Experimental|V114|Participants will receive an intramuscular (IM) injection.
88921384|NCT05700201|Experimental|Control|Standard care (psychotherapy)
88921385|NCT05695209|Experimental|Coaching and Decision Aid|Individual coaching sessions and Decision Aid
88921386|NCT05695209|No Intervention|Control|Wait-list control group
89011346|NCT02217319|Active Comparator|Sevoflurane|Patients receive Sevoflurane 1 MAC (minimal alveolar concentration) after induction of anesthesia with propofol, remifentanil and atracurium for 30 minutes as preconditioning.
89437325|NCT04193215|Other|Control|
89437326|NCT04191460|Experimental|WP-I dose A|n=7. Injection of 0.05 mg/kg cRGD-ZW800-1, within 16-20 hours before imaging/surgery
88921387|NCT05694364|Experimental|Phase 1 Dose Escalation (Group A)|"Participants from group A (hematologic malignancies) will undergo leukapheresis followed by lymphodepletion and infusion of PRGN-3007. Lymphodepletion will include 3 days of treatment with fludarabine (30 mg/m^2) and cyclophosphamide (500 mg/m^2) prior to study day 0.~Participants will then receive PRGN-3007 in 3 dose levels beginning at Dose Level 1, using a standard 3+3 escalation design to determine Maximum Tolerated Dose (MTD). The target maximum doses infused at each dose level is:~Dose Level 1: 1x10^6 cells/kg Dose Level 2: 3x10^6 cells/kg Dose Level 3: 1x10^7 cells/kg"
89437327|NCT04191460|Experimental|WP-I dose B|n=7. Injection of (to be determined) mg/kg RGD-ZW800-1, within (to be determined) hours before imaging/surgery.
89437328|NCT04191460|Experimental|WP-II selected dose|n=14: expansion cohort (n=14) will be added to the group of patients that had received the selected dose in WP-I. Injection of 0.05 ór (to be determined) mg/kg cRGD-ZW800-1, within 48 hours before imaging/surgery.
89437329|NCT04162431||non-hodgkin lymphoma|patients diagnosed with non-hodgkin lymphoma
89437330|NCT04162431||hodgkin lymphoma|patients diagnosed with hodgkin lymphoma
89437331|NCT04162431||squamous cell carcinoma|patients diagnosed with squamous cell carcinoma
89437332|NCT04162431||reactive|patients diagnosed with a reactive (non-cancerous) lymph node
89437333|NCT04162431||other|none of the above. Other cancer and non-cancer conditions
89437334|NCT04159103|Experimental|Part 1: Dose Optimization and Part 2: Dose Expansion|"Part 1 (Dose Optimization): Participants will receive single dose of mRNA-3927 by intravenous (IV) infusion every 2 weeks (Q2W) or every 3 weeks (Q3W) or every 4 weeks (Q4W) for up to 10 doses.~Part 2 (Dose Expansion): Participants will receive single dose of mRNA-3927 (identified during Dose Optimization Phase) by IV infusion Q2W or Q3W or Q4W for up to 12 months."
89437335|NCT04156126||Infertility - Frozen Embryo Transfer|Adult females undergoing a frozen embryo transfer
89437336|NCT04156126||Spontaneous Conception|Adult females presenting with positive pregnancy test to the Obstetrics Department
88921388|NCT05694364|Experimental|Phase 1 Dose Escalation (Group B)|"Participants from group B (solid tumors) will undergo leukapheresis followed by lymphodepletion and infusion of PRGN-3007. Lymphodepletion will include 2 days of cyclophosphamide (500 mg/m^2) prior to study day 0.~Participants will then receive PRGN-3007 in 3 dose levels beginning at Dose Level 1, using a standard 3+3 escalation design to determine Maximum Tolerated Dose (MTD). The target maximum doses infused at each dose level is:~Dose Level 1: 1x10^6 cells/kg Dose Level 2: 3x10^6 cells/kg Dose Level 3: 1x10^7 cells/kg"
88921389|NCT05694364|Experimental|Phase 1b Dose Expansion (Group A)|Participants from group A (hematologic malignancies) will undergo leukapheresis followed by lymphodepletion and infusion of PRGN-3007. Lymphodepletion will include 3 days of treatment with fludarabine (30 mg/m^2) and cyclophosphamide (500 mg/m^2) prior to study day 0. Participants will then receive PRGN-3007 at the dose level determined to be the Maximum Tolerated Dose (MTD) in the dose escalation portion of the study.
88921390|NCT05694364|Experimental|Phase 1b Dose Expansion (Group B)|Participants from group B (solid tumors) will undergo leukapheresis followed by lymphodepletion and infusion of PRGN-3007. Lymphodepletion will include 2 days of cyclophosphamide (500 mg/m^2) prior to study day 0.Participants will then receive PRGN-3007 at the dose level determined to be the Maximum Tolerated Dose (MTD) in the dose escalation portion of the study.
88921391|NCT05677360|Experimental|Wave 1: Initial Community Health Centers|Initial group of community health centers to receive intervention
88921392|NCT05677360|Experimental|Wave 2: Second Community Health Centers|Second group of community health centers to receive intervention
88921393|NCT05673109|Experimental|AC176|Single agent dose escalation of AC176. AC176 will be given orally (PO) on a 28-day cycle.
88921394|NCT05655689||Bacterial keratitis|Microbial keratitis patients diagnosed with bacterial keratitis and treated with the empiric topical antibiotics eye drops at the usual doses for the management of bacterial keratitis, as part of routine medical care.
88921395|NCT05655689||Fungal keratitis|Microbial keratitis patients diagnosed with fungal keratitis and treated with the empiric topical antifungals eye drops at the usual doses for the management of fungal keratitis, as part of routine medical care.
88921396|NCT05655689||Mixed bacterial and fungal keratitis|Microbial keratitis patients diagnosed with mixed bacterial and fungal keratitis and treated with the empiric topical antibiotics and antifungals eye drops at the usual doses for the management of mixed bacterial and fungal keratitis, as part of routine medical care.
88921397|NCT05639153|Experimental|DR30303|DR30303 injection treatment. This phase 1 trial will include two stages, a dose escalation stage and an expansion stage.
88921398|NCT05637203|Experimental|THRIVE + Discharge / Safety Planning|"Participants assigned to the intervention condition will receive THRIVE Crisis Recovery and Care Transition Program, which consists of group-based reflections on giving and belonging and a plan for community connection and treatment, followed by 3-4 coaching calls to reinforce and troubleshoot the plans."
88921399|NCT05637203|Active Comparator|Discharge / Safety Planning Alone|Participants assigned to the control condition will receive Discharge/Safety Planning as it is practiced by Connections Health Solutions per industry best practices.
88921400|NCT05626257||Xolair|patients who prescribed with Xolair according to the current label information in Korea.
89437337|NCT04145869|Experimental|Fluorescent cholangiography|Intraoperative fluorescent cholangiography using an intravenous injection of 5mg Indocyanine green
89437338|NCT04145869|Active Comparator|X-ray cholangiography|Intraoperative X-ray cholangiography using an intraductal (cystic duct) injection of Iohexol
88921404|NCT05608265|Experimental|Retinal Imaging using the OSNAT800 IO device|Patients will have their eyes imaged with the OSNAT800 IO device in addition to a routine standard of care appointment.
88921405|NCT05598294|No Intervention|Control Group|Standard treatment and mobilization recommendations will be given to this group.
88921406|NCT05598294|Experimental|Mobilization Group|Mobilization of patients will be encouraged.
88921407|NCT05590247|Experimental|Intermittent Fasting Group|Patients in this group will do intermittent fasting dieting for 12 weeks, meaning they will only eat for 8 hours per day. They may choose whichever 8 hours they want. Only water can be consumed during the fasting period. For the last 12 weeks of the study, they will resume their normal diet.
88921408|NCT05590247|No Intervention|Standard Routine Diet Group|Patients will continue with their normal diets for the 24 week duration of the study.
88921409|NCT05581407|Active Comparator|Licensed seasonal influenza vaccine|
88921410|NCT05581407|Experimental|1/5th of licensed seasonal influenza vaccine plus 1 mg LiteVax Adjuvant|
88921411|NCT05581407|Experimental|1/5th of licensed seasonal influenza vaccine plus 4 mg LiteVax Adjuvant|
89198900|NCT00881517|Placebo Comparator|placebo|
88921412|NCT05579639|Experimental|Xylitol|Xylitol, a naturally occurring sugar alcohol found in plums, strawberries, and various vegetables such as cauliflower, has been approved for use in food by the US FDA since 1963. Spiffies Xylitol Wipes will be used.
88921413|NCT05579639|Placebo Comparator|Grape-flavored Wipes|Grape-flavored wipes will be used with 2 drops of PCCA colorless grape flavoring. The grape-flavored wipes each contain a solution of 0.9% Sodium Chloride, purified water, and Benzalkonium chloride. PCCA artificial colorless grape flavoring will be used. The PCCA grape flavoring contains propylene glycol, ethyl alcohol, and artificial flavoring.
88921414|NCT05573022|Experimental|Arm A1: Breast cancer patients|
88921415|NCT05573022|Active Comparator|Arm B1: Breast cancer patients|
88921416|NCT05573022|Experimental|Arm A2: Colorectal cancer patients|
88921417|NCT05573022|Active Comparator|Arm B2: Colorectal cancer patients|
88921418|NCT05570123|Placebo Comparator|Placebo|
88921419|NCT05570123|Experimental|Flexofytol Forte|
88921420|NCT05566847|No Intervention|Arm 1: Usual Care|Participants will receive standard care for newly diagnosed Type 2 Diabetes.
88921421|NCT05566847|Experimental|Arm 2: Physician Education|Physicians in service areas randomized to this arm were invited to a physician education session on therapeutic inertia.
88921422|NCT05566847|Experimental|Arm 3: Physician Education + Accountable Population Manager Outreach|Physicians in service areas randomized to this arm were invited to a physician education session on therapeutic inertia. Patients enrolled in this arm may receive proactive outreach from an Accountable Population Manager (APM).
88921423|NCT05539053|Experimental|NAC short course|patient received CMT(Paclitaxel) and NAC 2400 mg/day one week per each cycle of CMT
88921424|NCT05539053|Experimental|NAC long course|patient received CMT(Paclitaxel) and NAC 2400 mg/day every day for 9 weeks
88921425|NCT05539053|No Intervention|control|patient received CMT(Paclitaxel) only
88921426|NCT05536011||Pitolisant-exposed participants with narcolepsy|Pregnant women with a diagnosis of narcolepsy who are exposed to pitolisant at any time during pregnancy
88921427|NCT05536011||Unexposed participants with narcolepsy|Pregnant women with a diagnosis of narcolepsy who are not exposed to pitolisant or a comparator product at any time during pregnancy
88921428|NCT05536011||Comparator-exposed participants with narcolepsy|Pregnant women with a diagnosis of narcolepsy who are not exposed to pitolisant at any time during pregnancy but who are exposed to comparator products at any time during pregnancy
88921429|NCT05536011||Pitolisant-exposed participants without narcolepsy|Pregnant women without a diagnosis of narcolepsy who are exposed to pitolisant at any time during pregnancy
89536618|NCT04985097|Active Comparator|Experimental group|Half an hour of active visual training per day for a period of 20 consecutive days with the Optictrain software
88921430|NCT05536011||Comparator-exposed participants without narcolepsy|Pregnant women without a diagnosis of narcolepsy who are not exposed to pitolisant at any time during pregnancy but who are exposed to a comparator product at any time during pregnancy
88921431|NCT05533697|Experimental|Arm 1a (Dose Escalation): mRNA-4359 Alone|Participants will be administered mRNA-4359 at an applicable dose as monotherapy.
89536619|NCT04985097|Sham Comparator|Control group|Half an hour of using a videogame without specific stimuli to improve visual performance (Fun Kid Racing 3.53 for Android) per day for a period of 20 consecutive days
88921432|NCT05533697|Experimental|Arm 1b (Dose Confirmation): mRNA-4359 in Combination with Pembrolizumab|Participants will be administered mRNA-4359 in combination with pembrolizumab at an applicable dose.
88921433|NCT05533697|Experimental|Arm 2 (Dose Expansion): mRNA-4359 in Combination with Pembrolizumab|Participants will be administered mRNA-4359 in combination with pembrolizumab at an applicable dose.
88921434|NCT05529251|Experimental|ARM A|RADIOTHERAPY boost 20 to 30 Gy on lymph nodes
88921435|NCT05529251|Experimental|ARM B|One cycle of CARBOPLATIN AUC7
89536620|NCT05338853|Experimental|Gongs Mmobilization|to deal adhesive capsulitis
88921436|NCT05529251|Other|ARM C|3 cycles of ETOPOSIDE and CISPLATIN
88921437|NCT05529251|No Intervention|OBSERVATIONAL COHORT|STANDARD RADIOTHERAPY on lymph nodes
88921438|NCT05528133|Experimental|Radiosensitivity Index optimized|Participants will be assigned to optimized arm based on their RSI score. Participants will receive whole breast radiation therapy with or without regional lymph node irradiation as appropriate with or without a boost to the lumpectomy cavity.
88921439|NCT05528133|Active Comparator|Radiosensitivity Index not optimized|Participants will receive standard of care whole breast radiation therapy with or without regional lymph node irradiation as appropriate with a boost to the lumpectomy cavity.
88921440|NCT05527977|No Intervention|Baseline Period|Run-in non-incentivized period for all participants.
88921441|NCT05527977|Experimental|Incentivized Period|3 month period during which time clinicians will receive compensation incentives for their performance in the program to improve clinical documentation.
89437339|NCT04142398||Screening (health information collection)|Participants receive a questionnaire and undergo a targeted physical and anal clinical exam at months 0, 6, and 12. Participants also undergo a penile skin cell and anal swab at months 0, 6, and 12 for cytology, HPV DNA, and CD4+ T-cell count at months 0 and 6 and HIV viral load testing at months 0 and 12. Participants also undergo HRA and penile clinical exam at month 12.
89437340|NCT04142385||Observational (health information collection)|Participants receive a questionnaire, undergo a targeted physical and anal clinical exam, undergo blood collection and urethral swab for STIs, and a penile skin cell and anal swab for cytology and HPV DNA at months 0, 6, and 12. Participants also undergo HRA and penile clinical exam at month 12.
89437341|NCT04129242|Active Comparator|"paired taVNS + Task Specific Training"|
89437342|NCT04129242|Active Comparator|"unpaired taVNS + Task Specific Training"|
89437343|NCT04128579|Experimental|EQ001 Type A cohort|EQ001 administered in an unblinded dose escalating cohort fashion by subcutaneous injection every two weeks for a total of 2 doses (up to 5 cohorts with dosing to be determined in the range of 0.4 -- 3.2 mg/kg).
89437344|NCT04128579|Experimental|EQ001 for Type B cohort|EQ001 administered in an unblinded single dose cohort by subcutaneous injection every two weeks for a total of 13 doses (1.6 mg/kg).
89437345|NCT04124588|Experimental|Test group|"After achieving initial hemostasis only with the standard-of-care, endoscopic hemostatic therapie(s)"
88921442|NCT05516134|Experimental|Treatment|Participants who receive the intervention (all)
89011347|NCT02217319|Placebo Comparator|TIVA|Patients received the standard total intravenous anesthesia (TIVA) with propofol, remifentanil and atracurium.
89011348|NCT00263601|Experimental|Allergovit 6-grasses immunotherapy|Seven injections (with 7 to 14 day intervals between each one) to reach maximum dose, followed by maintenance injections starting with 2 week intervals, followed by 4 week intervals until onset of the grass pollen season.
89437346|NCT04124588|Active Comparator|Control gruop|"After achieving initial hemostasis only with the standard-of-care, Wrap up the first endoscopy without adding an additional procedure."
89437347|NCT04122443|Active Comparator|Acetaminophen|Acetaminophen alone
89437348|NCT04122443|Active Comparator|Oxycodone/ acetaminophen|Oxycodone + acetaminophen
89437349|NCT04114669|Experimental|Regret lottery|"Will receive a lottery incentive (regret lottery) for 6 months"
89437350|NCT04114669|Placebo Comparator|Control Condition|Will complete a total of 3 in-person study visits, approximately one hour each.
89437351|NCT04112914|No Intervention|Education as usual|Participants receive education/healthcare provider communication as usual during their visit to the ED for concussion care.
89437352|NCT04112914|Experimental|New education|Participants receive the newly developed educational intervention.
89437353|NCT04105036||45-54 years of age|Divided into two subgroups: individuals who are and are not socially deprived
89437354|NCT04105036||54-64 years of age|Divided into two subgroups: individuals who are and are not socially deprived
89437355|NCT04105036||65-74 years of age|Divided into two subgroups: individuals who are and are not socially deprived
89437356|NCT04105036||75-85 years of age|Divided into two subgroups: individuals who are and are not socially deprived
89437357|NCT04103398|Experimental|Transarterial chemoembolization combined with sorafenib|The initial dose of sorafenib is 400mg BID and the drug therapy will last till outcome events happen or the trial ends. TACE will start one day following oral sorafenib. Either conventional TACE (cTACE) or drug-eluting beads TACE (dTACE) is optional. TACE will be performed via injecting chemotherapy drugs (doxorubicin 50mg for cTACE or 75mg for dTACE) and embolizing agents (gelatin sponge for cTACE or microsphere for dTACE) into blood vessels that help tumor grow.
89437358|NCT04103398|Active Comparator|Transarterial chemoembolization alone|Either conventional TACE (cTACE) or drug-eluting beads TACE (dTACE) is optional. TACE will be performed via injecting chemotherapy drugs (oxaliplatin 200mg, raltitrexed 4mg, epirubicin 20mg in cTACE or 70mg in dTACE) and embolizing agents (gelatin sponge for cTACE or microsphere for dTACE) into blood vessels that help tumor grow.
89437359|NCT04090723|Experimental|Computer-delivered brief alcohol intervention (CBI-CC)|Participants will be offered only the Computer-delivered brief alcohol intervention with peer navigation from beginning of study to the end.
89437360|NCT04088331||AMS 800 Artificial Urinary Sphincter Recipients|Adult males with moderate to severe primary stress urinary incontinence (as assessed by a baseline pad weight test) due to ISD who meet the indications for surgical correction of urinary incontinence.
89437361|NCT04088019||Observational cohort group|"Subjects: idiopathic uveitis with IGRA positive.~Examinations:~Clinical improvement examinations at day 0, second week, week 8, month 3, month 6 and month 12.~Blood sampling at day 0, second week, month 6 for analysing type 1 IFN gene expression scoring using RT-qPCR methods."
89437362|NCT04087642|Experimental|Intraoperative Crede manoeuver|"Method 1 (M1) consists in intraoperative Crede maneuver: After POP surgical reduction, the bladder will be retrograde filled with 300 ml of sterile water through a catheter that will then be removed. Brief and forceful suprapubic pressure will be applied. The test is positive if the surgeon visualizes a urinary leak.~In this group, the intraoperative Crede manoeuver will determine if an anti-incontinence procedure should be performed concomitantly."
89437363|NCT04087642|Active Comparator|Preoperative prolapse reduction cough stress test|"An examiner will perform the test preoperatively in the office, at the same visit as the recruitment. With a volume of 250-350 mL of urine in the bladder (confirmed by bladder scanner), a prolapse reduction cough stress test will be performed (posterior speculum blade for reduction). The test is positive if the examiner visualizes a urinary leak.~In this group, the preoperative prolapse reduction cough stress test will determine if an anti-incontinence procedure should be performed concomitantly."
89437364|NCT04083963|Other|Single arm|Low dose weekly carboplatin in combination with standard neoadjuvant chemotherapy
89437365|NCT04078269|Experimental|DC immunotherapy|Intra-patient dose escalation of intravenous MIDRIXNEO-LUNG autologous DC vaccine
89437366|NCT04077047|Experimental|iEngage|The intervention is a network-based, social support intervention to improve ALWH retention in HIV care and ART adherence. The specific intervention will be developed during Aim 2 of the study and uses qualitative findings, along with data from Aim 1, to develop an interventions that integrates participant feedback and borrows components from two existing interventions
89437367|NCT04075396|Experimental|Part D: Outside of Korea|Participants from outside of Korea with progressive disease and on prior epidermal growth factor receptor (EGFR) Tyrosine kinase inhibitor (TKI) therapy will receive recommended phase 2 doses based on safety, tolerability, efficacy and pharmacokinetics (PK) of Lazertinib.
89437368|NCT04074759|Experimental|FPT155 monotherapy|The study consists of dose escalation and cohort expansions
88921443|NCT05508984||Single Arm|"Anywhere from 14 to 0 days prior to treatment, enrolled subjects will complete the following questionnaires, and their hair will be photographed by research staff.~Once enrolled, subjects will be provided the Amma device by the clinic on days of chemotherapy treatment, and upon completion of treatment it will be returned to the clinic for safekeeping. Upon completion of chemotherapy, anywhere from 3-6 weeks following treatment, subjects will repeat the questionnaires and their hair will be photographed again.~Subjects will then complete their enrollment in the study."
88921444|NCT05493280|Other|Healthy Participants- Pre-Ttreatment Only|"Subjects who are interested in treatment for hyperpigmentation will be enrolled for this study.~Subjects will be pre-treated with tretinoin/hydroquinone prior to treatments. No post-treatment care."
88921445|NCT05493280|Other|Healthy Participants- Post-Treatment Only|"Subjects who are interested in treatment for hyperpigmentation will be enrolled for this study.~Subjects will wash out of any topical medications and will receive treatment. Post-treatment care will include use of temovate for 4 days."
88921446|NCT05489679|Experimental|AC682|This arm will evaluate AC682 monotherapy administered in 28-day cycles. The participants will participate in this dose escalation arm.
88921447|NCT05486208|Experimental|LY3844583 (Part A)|Single doses of LY3844583 administered subcutaneously (SC) and/or intravenously (IV).
88921448|NCT05486208|Experimental|LY3844583 (Part B)|Multiple doses of LY3844583 administered SC and/or IV.
88921449|NCT05486208|Experimental|LY3844583 (Part C)|Repeat doses of LY3844583 administered SC and/or IV.
88921450|NCT05486208|Placebo Comparator|Placebo (Part A)|Placebo administered SC and/or IV.
88921451|NCT05486208|Placebo Comparator|Placebo (Part B)|Placebo administered SC and/or IV.
89198901|NCT00881595|Other|Proton Chemoradiotherapy followed by surgery|Proton Chemoradiotherapy followed by surgery. Temozolomide five days per week during radiotherapy for 5 weeks. Proton radiation five days per week for 5 weeks Standard surgery will take place 4-6 weeks after completion of chemoradiation.
89437369|NCT04074759|Experimental|FPT155 in combination with pembrolizumab|The study consists of dose escalation and cohort expansions
89437370|NCT04058132|Other|Group 1: acute/subacute Traumatic Brain Injury|Any gender, age 18-55 years who have had a traumatic brain injury within 30 days
89437371|NCT04058132|Other|Group 2: Non-TBI healthy control (HC)|Any gender, age 18-55 years with no history of traumatic brain injury
89437372|NCT04055025|Other|Sleeve gastrectomy operated patients|Six test days in a randomized, patient-blinded, cross-over design
89437373|NCT04047433|Experimental|women with external anal sphincter injury|The study cohort will be composed of women undergoing vaginal delivery and diagnosed with external anal sphincter injury after a vaginal delivery.
88921452|NCT05486208|Placebo Comparator|Placebo (Part C)|Placebo administered SC and/or IV.
88921453|NCT05474014|Active Comparator|superior trunk block|"Ultrasound guided superior trunk block with 10 ml % 0.25 bupivacaine~+ 400 mg tramadol, IV 4 mg/ mL tramadol solution into 100 mL normal saline; PCA (patient-controlled analgesia): 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg."
89536621|NCT05338853|Experimental|scapular mobilization|to deal adhesive capsulitis
89437374|NCT04047433|Experimental|women without external anal sphincter injury|The control group will be women who had a vaginal delivery without any clinically apparent perineal laceration
88921454|NCT05474014|Active Comparator|tramadol|400 mg tramadol, IV 4 mg/ mL tramadol solution into 100 mL normal saline; PCA (patient-controlled analgesia): 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.
88921455|NCT05473520|Experimental|Doxycycline + standard anti-tuberculous treatment|Doxycycline 100 mg twice daily with once daily anti-tuberculous treatment comprising of rifampicin 10 mg/kg, isoniazid 5 mg/kg, ethambutol 15 - 20 mg/kg, ± pyrazinamide 25 mg/kg and pyridoxine 10-50 mg per day according to managing physicians' discretion. Where needed, the drugs will be adjusted according to renal function. These will be given daily for 8 weeks. Subsequently doxycycline will be ceased and patients are to continue with their standard anti-tuberculous treatment and duration according to their managing physician
89437375|NCT04038918|Experimental|Progressive Muscle Relaxation Exercise Group|Standard postoperative physiotherapy program plus progressive muscle relaxation (PMR) exercise will be applied.
88921456|NCT05473520|Placebo Comparator|Placebo + standard anti-tuberculous treatment|Placebo twice daily with once daily anti-tuberculous treatment comprising of rifampicin 10 mg/kg, isoniazid 5 mg/kg, ethambutol 15-20 mg/kg, ± pyrazinamide 25 mg/kg and pyridoxine 10-50 mg per day according to managing physicians' discretion. Where needed, the drugs will be adjusted according to renal function. These will be given daily for 8 weeks. Subsequently placebo will be ceased and patients are to continue with their standard anti-tuberculous treatment and duration according to their managing physician.
88921457|NCT05466279|Experimental|Remazolam general anesthesia group (R group)|
88921458|NCT05466279|Active Comparator|Propofol + midazolam general anesthesia control group (group P)|
88921459|NCT05459636|Active Comparator|High-resistance inspiratory muscle strength training|Participants will perform high-resistance inspiratory muscle strength training on a daily basis for eight weeks using a handheld device that produces resistance that increases the effort of breathing in.
88921460|NCT05459636|Sham Comparator|Very-low resistance inspiratory muscle strength training|Participants will perform very-low-resistance inspiratory muscle strength training on a daily basis for eight weeks using a handheld device that produces resistance that increases the effort of breathing in.
88921461|NCT05458128|Other|Pitolisant|Week 1: 8.9 mg pitolisant administered once daily in the morning upon wakening; Week 2: 17.8 mg pitolisant administered once daily in the morning upon wakening; Weeks 3 through end of treatment: 17.8 mg to 35.6 mg pitolisant administered once daily in the morning upon wakening.
88921462|NCT05457257|Experimental|Olaparib|Olaparib is available as a film-coated tablet containing 150 mg or 100 mg of olaparib. Subjects will be administered study treatment orally at a dose of 300 mg twice daily (bid). The planned dose of 300 mg bid will be made up of two x 150 mg tablets twice daily, with 100 mg tablets used to manage dose reductions
88921463|NCT05457257|Active Comparator|Enzalutamide OR abiraterone acetate|"Enzalutamide:~Enzalutamide is available as capsules or tablets containing 40 mg of enzalutamide. Subjects will be administered study treatment orally at a dose of 160 mg once daily.~Abiraterone acetate with prednisone: Abiraterone acetate is available as tablets containing 250 mg of abiraterone acetate. Subjects will be administered study treatment orally at a dose of 1,000 mg once daily. Prednisone is 5mg twice daily. Prednisolone is permitted for use instead of prednisone if necessary."
88921464|NCT05456581|Experimental|Condition 1 - 'Scotoma awareness' Training|Participants will be asked to report the emotion of an emoji face ('happy' vs 'sad') that could appear anywhere on screen. For the entire duration of the training, an explicit, sharp outlined occluder surrounding the participant's true retinal scotoma will be rendered on screen. This occluder will be generated through a gaze-contingent display. The size and the contrast of the target will change adaptively in response to the patient's performance.
88921465|NCT05456581|Experimental|Condition 2 - Control Training|In the control condition, participants will perform the same task as the scotoma awareness training, without the artificial visible scotoma.
88921466|NCT05456256|Experimental|LP-300 in Combination with Pemetrexed and Carboplatin|"LP-300 (investigational drug) + Pemetrexed and Carboplatin (standard of care chemotherapies)~Dosing occurs on Day 1 of a 21-day cycle."
88921467|NCT05456256|Active Comparator|Pemetrexed and Carboplatin (Standard of Care)|"Pemetrexed and Carboplatin Only (standard of care chemotherapies)~Dosing occurs on Day 1 of a 21-day cycle."
89437376|NCT04038918|Other|Control Group|Standard postoperative physiotherapy program will be applied.
89437377|NCT04031677|Other|Standard arm|Surgery alone
89437378|NCT04031677|Experimental|Experimental arm|Preoperative chemotherapy and surgery
89437379|NCT04023591||Surgery|Surgery/ Occupational Therapy
89437380|NCT04021485|Other|neurodevelopmental assessment|"As part of the usual follow-up of premature children, a follow-up consultation is planned around the age of 5 years. During this visit, a neurodevelopmental assessment will be carried out for the Betanino study. The duration of this evaluation is evaluated around 3h in total.~Interventions will include:~Standardized neurological exam~Morphometric measurements including height, weight, head circumference~Blood pressure measurement~Multiple aspects of cognition using ancillary indexes of WPPSI-IV subtests, NEPSY-II subtests,~Social Relativeness, using Social Relativeness Scale parental questionnaire,~Parental stress using PSI questionnaire"
89536622|NCT03073551|No Intervention|Control Group|Participants in this group will receive diabetic care and education as per the standard of care. They will also be given a pedometer and will be instructed to record their number of steps at the end of each day
88921468|NCT05438602|Experimental|Nirmatrelvir plus ritonavir for 5 days|Nirmatrelvir (2 tablets) plus ritonavir (1 capsule) will be given by mouth every 12 hours for 5 days followed by placebo for nirmatrelvir (2 tablets) plus placebo for ritonavir (1 capsule) every 12 hours for 10 days
88921469|NCT05438602|Experimental|Nirmatrelvir plus ritonavir for 10 days|Nirmatrelvir (2 tablets) plus ritonavir (1 capsule) will be given by mouth every 12 hours for 10 days followed by placebo for nirmatrelvir (2 tablets) plus placebo for ritonavir (1 capsule) every 12 hours for 5 days
88921470|NCT05438602|Experimental|Nirmatrelvir plus ritonavir for 15 days|Nirmatrelvir (2 tablets) plus ritonavir (1 capsule) will be given by mouth every 12 hours for 15 days.
88921471|NCT05436093|Experimental|68Ga-ACN376|Imaging cohort All study participants will be allocated to this arm (single-arm study). Study participants will undergo 68Ga-ACN376 PET/CT scan.
88921472|NCT05432817|Experimental|Cognitive Processing Therapy (CPT) group|Arm = Cognitive Processing Therapy (CPT) Group = 4 groups of 10 (40 total; 20F/20M) receive CPT to treat PTSD
88921473|NCT05432817|Experimental|Therapist-facilitated Support group|Arm = Therapist-facilitated Support Group Group = 4 groups of 10 (40 total; 20F/20M) receive support as active control group for PTSD treatment
88921474|NCT05428826|Experimental|Prednisone|Dose : 1mg/kg/day at inclusion Route of administration : oral Duration of treatment: 9 to 21 months.
88921475|NCT05422222|Experimental|Part A: VX-121/TEZ/D-IVA|Participants will receive VX-121/TEZ/D-IVA in the morning.
88921476|NCT05422222|Experimental|Part B: VX-121/TEZ/D-IVA|Participants will receive VX-121/TEZ/D-IVA in the morning with the dose(s) to be based on the outcome of Part A.
88921477|NCT05414474|Active Comparator|Reference|Ferrum Hausmann 100 mg is consumed with 200 mL nanopure water with labelled ferrous fumarate (3 mg 54Fe).
88921478|NCT05414474|Experimental|Ascorbic acid (AA) 500 mg|Ferrum Hausmann 100 mg is consumed with 200 mL nanopure water with labelled ferrous fumarate (3 mg 57Fe) and 500 mg AA.
88921479|NCT05414474|Experimental|Ascorbic acid (AA) 80 mg|Ferrum Hausmann 100 mg is consumed with 200 mL nanopure water with labelled ferrous fumarate (3 mg 58Fe) and 80 mg AA.
88921480|NCT05414474|Experimental|Coffee|Ferrum Hausmann 100 mg is consumed with 200 mL nanopure water with labelled ferrous fumarate (3 mg 54Fe) and 150 mL coffee.
88921481|NCT05414474|Experimental|Breakfast|Ferrum Hausmann 100 mg is consumed with 200 mL nanopure water with labelled ferrous fumarate (3 mg 57Fe) and 1 bread roll (~100 g) with butter and honey, 1 cup of plain yoghurt (180 mL), 1 cup of coffee (150 mL) and 1 glass of orange juice (250 mL).
88921482|NCT05414474|Experimental|Afternoon|Ferrum Hausmann 100 mg is consumed with 200 mL nanopure water with labelled ferrous fumarate (3 mg 58Fe) in the afternoon .
88921483|NCT05399381|Experimental|Frontoparietal Slow Theta Stimulation|Participants will receive multi-electrode transcranial alternating current stimulation over the prefrontal and parietal brain regions that induces frontal-to-parietal traveling wave at the frequency of 4 Hz with the intensity of up to 2 mA and duration up to 20 min.
88921484|NCT05399381|Experimental|Frontoparietal Fast Theta Stimulation|Participants will receive multi-electrode transcranial alternating current stimulation over the prefrontal and parietal brain regions that induces frontal-to-parietal traveling wave at the frequency of 7 Hz with the intensity of up to 2 mA and duration up to 20 min.
88921485|NCT05399381|Experimental|Parietofrontal Slow Theta Stimulation|Participants will receive multi-electrode transcranial alternating current stimulation over the prefrontal and parietal brain regions that induces parietal-to-frontal traveling wave at the frequency of 4 Hz with the intensity of up to 2 mA and duration up to 20 min.
88921486|NCT05399381|Experimental|Parietofrontal Fast Theta Stimulation|Participants will receive multi-electrode transcranial alternating current stimulation over the prefrontal and parietal brain regions that induces parietal-to-frontal traveling wave at the frequency of 7 Hz with the intensity of up to 2 mA and duration up to 20 min.
88921487|NCT05374928||Cohort 1: Newly Diagnosed Idiopathic Generalized Epilepsy (IGE)|Cohort 1 will have IGE that was diagnosed within the prior year. We will follow these participants for a minimum of two years.
88921488|NCT05374928||Cohort 2: Longstanding Treatment Responsive|Cohort 2 will consist of subjects with established IGE who have been responsive to treatment.
88921489|NCT05374928||Cohort 3: Longstanding IGE, Treatment Resistant|Cohort 3 will consist of patients with established treatment-resistant IGE.
88921490|NCT05369208|Other|Avatrombopag|Avatrombopag 20 mg oral tablet
88921491|NCT05363111|Experimental|Treatment (daratumumab, 225Ac/111In-DOTA-daratumumab)|Patients receive daratumumab IV over 45 minutes. Two hours later, patients receive 111In-DOTA-daratumumab and 225Ac-DOTA-daratumumab IV over 20-30 minutes.
88921492|NCT06235424|Active Comparator|del Nido cardioplegia group|A group of patients that received high potassium cardioplegic solution with the addition of lidocaine, mixed with the patient's blood in 4:1 ratio
89536623|NCT03073551|Active Comparator|Wii Group|Participants in this group will receive diabetic care and education as per the standard of care. They will also be given a Wii console and game to take home. Participants will be instructed on how to set up and use the Wii. These participants will also be given a pedometer and will be instructed to record their number of steps at the end of each day.
89536624|NCT04601129||patients|undergoing a minimally invasive nephrectomy, eligible to an Enhanced Recovery After Surgery Program.
89536625|NCT00705575|Experimental|Aliskiren/hydrochlorothiazide (HCTZ) (300/25 mg)|
89536626|NCT00705575|Active Comparator|Aliskiren (300 mg)|
88921493|NCT06235424|Active Comparator|Bretschneider-HTK cardioplegia group|A group of patients that received low sodium cardioplegic solution with the addition of histidine, tryptophan and alpha-ketoglutarate
88921494|NCT06235411|Experimental|Experimental group|
88921495|NCT06235411|Placebo Comparator|Control group|
88921496|NCT06235398|Experimental|Adults with Myelodysplasic Syndrome diagnosis|Adults (Age ≥ 50 and ≤ 70 years) patients with MDS diagnosis for whom transplantation is indicated from a related donor identified.
88921497|NCT06235359|Other|intercostal tube|"A chest tube is a hollow, flexible tube placed into the chest. It acts as a drain.~Chest tubes drain blood, fluid, or air from around your lungs, heart, or esophagus.~The tube around your lung is placed between your ribs and into the space between the inner lining and the outer lining of your chest cavity. This is called the pleural space. It allows your lungs to fully expand."
88921498|NCT06235346||Control Group|Eyes of subjects with no history of use of any substance
88921499|NCT06235346||Seronegative Synthetic Cannabinoids Group|Eyes of patients declaring no present use of any substance and as verified by three consecutive negative urine toxicology tests performed two weeks apart
88921500|NCT06235346||Seropositive Synthetic Cannabinoids Group|Eyes of patients with positive urine toxicology tests proving present use of synthetic cannabinoids
88819573|NCT05450913|Other|patients with unilateral hip and leg pain|"Musculoskeletal system examination, neurological examination, visual analog scale (VAS) score and DN4 (Douleur Neuropathique 4 Questions) of patients presenting with unilateral hip and/or leg pain, 3 tests frequently used in the diagnosis of priformis (Freiberg test, Pace sign, FADIR) ) will be applied.~Patients with suspected priformis syndrome will be given an intramuscular injection If the pain intensity decreases by 50% or more after the intramuscular injection, the diagnosis of piriformis will be made."
89198902|NCT00881595|Active Comparator|Chemoradiotherapy Temozolomide|Chemoradiotherapy Temozolomide: 75 mg/m2 five days per week during radiotherapy for 5 weeks. Temozolomide should be taken orally 1 hour before each session of radiotherapy during weekdays (Monday through Friday). The dose will be determined using the body surface area (BSA) calculated at the beginning of the concurrent treatment. The BSA will be calculated from the height obtained at the pretreatment visit and the weight obtained before the first day of treatment. The concurrent treatment will last until the end of radiotherapy.
88819574|NCT02370420|Experimental|Unique application of PRP|Patients will be applied a unique application of platelet-rich plasma for knee osteoarthritis, and will be given rehabilitation exercises at home
89198903|NCT00881595|Active Comparator|Proton Therapy|50 cobalt gray equivalent(CGE), 25 daily fractions, 5 weeks (2 CGE/fx)
89198904|NCT00883077||Inflammation|Patients with long standing history or short onset of ulcerative colitis.
89198905|NCT00883077||Healthy controls|Asymptomatic individuals admitted for health surveillance or patients for follow up after polypectomy.
89198906|NCT00883077||Irritable bowel syndrome|Patients admitted to outpatient department with symptoms meeting ROME III criteria of irritable bowel syndrome.
89198907|NCT00883155|Experimental|1|Bupropion HCl 100 mg Tablets (Invamed Inc.)
89198908|NCT00883155|Active Comparator|2|Wellbutrin 100 mg Tablets (Glaxo Wellcome)
89198909|NCT01505062|Experimental|SAR421869 (Cohort 1)|Starting dose of SAR421869 given through one subretinal injection.
89198910|NCT01505062|Experimental|SAR421869 (Cohort 2)|Escalating dose of SAR421869 given through one subretinal injection.
89536627|NCT04994379|Experimental|1 mA tDCS|Participants receive the stimulation with an intensity of 1 mA.
89536628|NCT04994379|Experimental|1.5 mA tDCS|Participants receive the stimulation with an intensity of 1.5 mA.
88819575|NCT02370420|Active Comparator|Triple application of PRP|Patients will be applied a triple application of platelet-rich plasma for knee osteoarthritis, with a interval of two weeks between each, and will be given rehabilitation exercises at home
88819576|NCT02215070|Experimental|Pasireotide + Preparatory Regimen|Eligible subjects will receive pasireotide daily for 5 days before stem cell transplant, the day of the stem cell transplant, and daily for 8 days following the stem cell transplant. Preparatory regimen will be given 4 days before stem cell transplant.
88819577|NCT04338477|Experimental|Nephrosolid|Acute dosis day 1: 3X2 Nephrosolid tablets 0.5 h before intake of a meal Long-term dosis days 2-28: 2x1 Nephrosolid tablets 0.5 h before intake of a meal
88819578|NCT04000737|Experimental|Sorafenib + YIV-906|Patients in the study arm will be treated orally for 28-day courses with YIV-906 + sorafenib
88819579|NCT04000737|Active Comparator|Sorafenib + Placebo|Patients in the placebo arm will be given sorafenib with placebo
88819580|NCT02209064|Other|EpiAccess|EpiAccess will be used to gain access to the normal, non-distended pericardial space in subjects presenting with the need for pericardial access as determined by the patient's physician.
88819581|NCT02347098|Experimental|intensive LDL-lowering therapy (ILLT)|Patient of acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) is randomized to LDL-apheresis and an oral daily dose of 40-80mg of Atorvastatin or equivalent.
88819582|NCT02347098|Active Comparator|standard statin monotherapy (SMT)|Patient of acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) is randomized to an oral daily dose of 40-80mg of Atorvastatin or equivalent without LDL-apheresis
88819583|NCT01556204|Experimental|Robotic Surgery|Robotic surgery using the da Vinci Surgical System
88819584|NCT01556204|Active Comparator|Laparoscopy|Laparoscopic assisted resection of endometriosis will be performed using up to five 5mm ports.
88819585|NCT03708237|Placebo Comparator|Placebos|Placebo Dose: Not Applicable Route: Mouth Regimen: Daily 2 hours before bed Duration: 6 months
88819586|NCT03708237|Experimental|Ropinirole|Drug: ropinirole Dose: 0.25 - 2 mg as tolerated Route: Mouth Regimen: Daily 2 hours before bed Duration: 6 months
88819587|NCT03708237|Experimental|Gabapentin|Drug: gabapentin Dose: 100 - 300 mg as tolerated Route: Mouth Regimen: Daily 2 hours before bed Duration: 6 months
88819588|NCT03702777|Experimental|ASP8302 100mg|Participants will receive ASP8302 100mg capsules orally once daily for up to 4 weeks.
88819589|NCT03702777|Placebo Comparator|Placebo|Participants will receive ASP8302 matching placebo orally once daily for up to 4 weeks.
88819590|NCT02346708|Experimental|Real TMS|TMS will be administered using a 70-mm diameter air-cooled figure-of-8 coil and SuperRapid2 Magstim Stimulator. Repetitive pulses will be delivered to the right and left pre-frontal cortex (Brodmann area 46) using a frameless stereotactic navigation system and the subject's magnetic resonance imaging (MRI) in Brainsight software. Stimuli will be delivered at 20 Hz at 90% resting motor threshold (rMT) for 25 trains of 30 pulses per train, inter-train interval of 30 seconds for a total of 750 pulses per hemisphere. This dose and duration of repetitive TMS (rTMS) is based on physiological studies of healthy adults and treatment studies of cognition in PD and Alzheimer's disease.52, 123 Side of first stimulation (left vs right hemisphere) will be counterbalanced across subjects.
88819591|NCT02346708|Sham Comparator|Sham TMS|Sham stimulation will be delivered using a sham coil fitted with electrodes to mimic both the auditory and somatic sensation of real TMS.
88819592|NCT02751879||Non small cell lung cancer (NSCLC)|patients with Epidermal growth factor receptor (EGFR) mutation (common mutations), TKI-naïve advanced non small cell lung cancer (NSCLC), treated with Gi(l)otrif® as the first-line treatment for NSCLC within the approved label
88819593|NCT01556594|Experimental|Nasal Glucagon 1 mg|Nasal glucagon (NG) administered as single dose of 1 milligram (mg).
88819594|NCT01556594|Experimental|Nasal Glucagon 2 mg|NG administered as single dose of 2 mg.
88921501|NCT06235333|Experimental|Screening Intervention|Individuals will take part in a branching problem/responsible gambling information sharing experience before completing a multi-item brief gambling screen and receiving tailored feedback about their risk for gambling-related problems, and including problem/responsible gambling resources for their state of residence and national resources.
88921502|NCT06235333|Active Comparator|Informational Control|Individuals will take part in a limited problem/responsible gambling information sharing experience.
88921503|NCT06235307|Experimental|motivational interviewing|
88921504|NCT06235307|Active Comparator|Control|
88921505|NCT06235294|Experimental|Resveratrol|Daily capsule of 200 mg Polygonum cuspidatum yielding 100 mg/day resveratrol (trans-3,5,4'-trihydroxystilbene)
88921506|NCT06235294|Placebo Comparator|Placebo|Daily capsule of 400 mcg folic acid.
89536629|NCT04994379|Sham Comparator|Sham tDCS|Participants receive the sham stimulation (zero electric current after a short initial increase).
88921508|NCT06235255|Experimental|Guided Imagery Intervention|Participants randomly assigned to this group will be provided with a MP3 Player which will have three guided imagery programs. The Guided Imagery Programs include: 1.Relaxation and Wellness; 2. Immune System Imagery and 3. Healing Trauma. The study measures are completed upon entry and 21 days post entry into the study and include: PKPCT and 21 days post entry into the study and include: PKPCT and the SF-36v2.
88921509|NCT06235255|Experimental|Cognitive Power Intervention|The participant is randomly assigned to this group completes The Power as Knowing Participation in Change (PKPCT) to determine: 1. Freedom to Act Intentionally; 2. Involvement in creating change; 3.Freedom to act intestinally and 4. My involvement in creating change. The study measures are completed upon entry and 21 days post entry into the study and include: PKPCT and the SF-36v2.
88921510|NCT06235255|Experimental|Combined Guided Imagery and Cognitive Power Intervention|The participants are randomly assigned to this group completes The Power as Knowing Participation in Change (PKPCT) and the Guided Imagery Intervention as described above. The study measures are completed upon entry and 21 days after entry and include the PKPCT and the SF-36v2.
88921511|NCT06235255|No Intervention|Control Group (No intervention)|The participants are randomly assigned to this group complete all study measures PKPCT and the SF-36v2 measures upon entry into the study and 21 days after entry.
88921512|NCT06235216|Experimental|Experimental|Sacituzumab govitecan (10 mg/kg) administered intravenously on Days 1 and 8 of a 21-day cycle. Patients will be treated until progression, death, study withdrawal, or unacceptable toxicity.
88921513|NCT06235203|Active Comparator|The control group|Endoscopic surgery + adjuvant therapy
88921514|NCT06235203|Experimental|The experimental group|Neoadjuvant therapy +endoscopic surgery + adjuvant therapy
88921515|NCT06235190|Experimental|Felix NeuroAI Wristband|
88921516|NCT06235190|Sham Comparator|Sham Device|
88921517|NCT06235177|Experimental|Intervention Techniques for Psychoneuromentalism Disorder|"The Interventions to be administered will be as follows:~Ashwagandha Herb Tincture and Supplement~Damiana Herb Tincture~Passion Flower Herb Tincture~Grapeseed Extract- Capsule~Rhodiola- Herb Tincture~Sea Moss Supplement Capsule~Theocentric Psychological Counseling~Clinical Yoga~Meditation~Mental Imagery~Decompartmentalization Framework~Dietary Supplements~Applied Relaxation (Music Meditation, Breathing Techniques)~Pain Relaxation Techniques~Meridian Acupuncture"
88921518|NCT06235164||neoadjuvant immunochemotherapy group|The immune checkpoint inhibitors (ICIs) used for neoadjuvant immunotherapy in this study included sintilimab, nivolumab, and camrelizumab. Neoadjuvant chemotherapy regimens were primarily categorized into two- and three-agent regimens. The two-agent regimens included: SOX (S-1 + oxaliplatin), CapeOx (capecitabine + oxaliplatin), AS (S-1 + nab-paclitaxel), FOLFOX (oxaliplatin + fluorouracil) and DS (S-1 + docetaxel). The three-agent regimens included: FLOT (docetaxel + oxaliplatin + fluorouracil), DOS (docetaxel + oxaliplatin + S-1) and POF (paclitaxel + oxaliplatin + fluorouracil). Dosages were calculated based on drug monographs, guidelines, and patient body surface area. The patients underwent LG within 4-6 weeks after completing neoadjuvant therapy.
88921519|NCT06235164||neoadjuvant chemotherapy group|Neoadjuvant chemotherapy regimens were primarily categorized into two- and three-agent regimens. The two-agent regimens included: SOX (S-1 + oxaliplatin), CapeOx (capecitabine + oxaliplatin), AS (S-1 + nab-paclitaxel), FOLFOX (oxaliplatin + fluorouracil) and DS (S-1 + docetaxel). The three-agent regimens included: FLOT (docetaxel + oxaliplatin + fluorouracil), DOS (docetaxel + oxaliplatin + S-1) and POF (paclitaxel + oxaliplatin + fluorouracil). Dosages were calculated based on drug monographs, guidelines, and patient body surface area. The patients underwent LG within 4-6 weeks after completing neoadjuvant therapy.
88921520|NCT06235151|Experimental|Diagnostic Imaging with Copper Cu 64 PSMA I&T|Copper Cu 64 PSMA I&T Injection
88921521|NCT06235125|Experimental|Cytalux with Near Infrared Imaging|All participants will receive Cytalux and undergo near infrared imaging.
88921522|NCT06235112|Experimental|Notification of Coronary Artery Calcification|"Notification to providers of the presence of coronary artery calcification automatically detected by AI based device (software) on chest CT.~Recommendation of preventive therapy."
88921523|NCT06235112|No Intervention|Non-notification of Coronary Artery Calcification|"No notification to providers of the presence of coronary artery calcification on chest CT automatically detected by AI based device (software) on chest CT.~No recommendation of preventive therapy."
88921524|NCT06235099|Experimental|Diagnostic imaging with Copper Cu 64 PSMA I&T|Copper Cu 64 PSMA I&T Injection
88921525|NCT06235086|Experimental|TG103, 7.5 mg|TG103 (7.5 mg) will be administered via subcutaneous injection once a week in subjects with type 2 diabetes.
88921526|NCT06235086|Experimental|TG103, 15 mg|TG103 (15 mg) will be administered via subcutaneous injection once a week in subjects with type 2 diabetes.
89536630|NCT04993989||Pharmacy based survey|Patients received a questionnaire, which was filled out and returned to the Contract Research Organization (CRO) or, alternatively to the pharmacy.
88819595|NCT01556594|Active Comparator|SC Glucagon|Glucagon solution dose of 1 mg administered as a single subcutaneous (SC) injection.
89011349|NCT00263601|Placebo Comparator|Placebo|Placebo injections was given the same way: Seven injections (with 7 to 14 day intervals between each one) to reach maximum dose, followed by maintenance injections starting with 2 week intervals, followed by 4 week intervals until onset of the grass pollen season.
89011350|NCT02217397|Experimental|OA, CPAPm, combination therapy|
89011351|NCT00414479||children 9-12 years of age|Children with schistosomiasis, malaria and anaemia
89011352|NCT02217514|Experimental|Treatment sequence 1 in male subjects|Midazolam alone and 1 h after low dose BI44370BS in male subjects
89011353|NCT02217514|Experimental|Treatment sequence 1 in female subjects|Midazolam alone and 1 h after low dose BI44370BS followed by medium dose BI 44370 in an additional visit in female subjects
89011354|NCT02217514|Experimental|Treatment sequence 2|Midazolam before and 48 h after high dose BI44370BS
89011355|NCT02217514|Experimental|Treatment sequence 3|Midazolam before and 24 h after high dose BI44370BS
89011356|NCT02217514|Experimental|Treatment sequence 4|Midazolam before and 1 h after high dose BI44370BS
89011357|NCT02217553|Experimental|vitamin D (cholecalciferol)|All study participants will receive vitamin D supplementation (soft gel capsule containing cholecalciferol 400 IU) to be consumed 2 soft gel capsules daily for three consecutive months. The effect on the platelet parameters specified above will be determined before start cholecalciferol supplementation and after three months.
89011358|NCT04719312|Experimental|transconjunctival Y modification|
89011359|NCT02217631|Experimental|BI 653048 BS H3PO4|dose escalation
89011360|NCT02217631|Active Comparator|Prednisolone low dose|
89011361|NCT02217631|Active Comparator|Prednisolone high dose|
89011362|NCT02217631|Placebo Comparator|Placebo|
89011363|NCT02217670|Experimental|Metformin (test)|single oral dose of Metformin 1000 mg granules
89011364|NCT02217670|Active Comparator|Metformin (reference)|Single dose of Glucophage 1000 mg film-coated tablet
89011365|NCT02217748|Experimental|Survey questionnaire version 1|Name generator order: leisure, money, support
89011366|NCT02217748|Experimental|Survey questionnaire version 2|Name generator order: leisure, support, money
89011367|NCT02217748|Experimental|Survey questionnaire version 3|Name generator order: money, leisure, support
89011368|NCT02217748|Experimental|Survey questionnaire version 4|Name generator order: money, support, leisure
89011369|NCT02217748|Experimental|Survey questionnaire version 5|Name generator order: support, leisure, money
89536631|NCT03068247|Experimental|Interventional|10 weeks of duloxetine beginning at 30 mg per day for week 1, then 60 mg / day thereafter.
89011370|NCT02217748|Experimental|Survey questionnaire version 6|Name generator order: support, money, leisure
89011371|NCT00263640|Placebo Comparator|Placebo|Placebo was given the same way as a subcutaneous (just under the skin) injection. Children received lifestyle counselling.
89011372|NCT00263640|Experimental|Acaroid|The drug tested in this study (aluminium hydroxide-adsorbed house dust mite (D. pteronyssinus) allergoid preparation) was given as a subcutaneous injections of increasing doses.
89011373|NCT02217826|Experimental|DG3173|
89011374|NCT02217826|Placebo Comparator|Saline|
89011375|NCT02217826|Active Comparator|Octreotide|
89011376|NCT04530097|Experimental|RFA+MLT|Radiofrequency ablation was performed immediately after enrollment, and melatonin treatment was given for 6 months after 1 week after radiofrequency.
89011377|NCT04530097|No Intervention|RFA|Radiofrequency ablation was performed immediately after enrollment, and a placebo treatment program was given for 6 months after 1 week after radiofrequency.
89011378|NCT02218021|Experimental|Samidorphan Dose 1|
89011379|NCT02218021|Experimental|Samidorphan Dose 2|
89011380|NCT02218021|Experimental|Samidorphan Dose 3|
89011381|NCT02218021|Placebo Comparator|Placebo|
89011382|NCT02218021|Active Comparator|Oxycodone Dose 1|
89011383|NCT02218021|Active Comparator|Oxycodone Dose 2|
89011384|NCT04719234|Other|lung ultrasound|lung ultrasonography protocol will be applied.
89011385|NCT02218060|Experimental|Force|Patients receiving coronary CT angiography on the SOMATOM Force before clinically indicated cardiac catheterization or after clinically indicated nuclear stress test
89011386|NCT02218060|Other|Control|Patients who have already received comparable CT examinations on current routine 2nd generation dual-source CT systems
89011387|NCT04529746|Experimental|EVERYbody Project: Professional facilitator version|"The EVERYbody Project is a dissonance body image intervention created from focus group feedback (Ciao, Ohls, & Pringle, 2017) and through an iterative process of student-driven feedback. The Body Project manual (Stice et al., 2006) was adapted to retain key dissonance activities while expanding the gender focus, adding an exploration of the diversity characteristics within appearance ideals, and adjusting activities to be inclusive of diversity characteristics. Several adapted versions of the intervention were piloted with groups of college students and further adapted based on feedback.~Facilitators received 16 hours of training on the EVERYbody Project manual and facilitation guidelines."
89011388|NCT04529746|No Intervention|Waitlist control group|Participants allocated to the waitlist completed assessments at time points parallel to those in the EVERYbody Project condition and were offered the EVERYbody Project upon completing the one-month follow-up assessment.
89011389|NCT04529668|Experimental|group I|twenty-five patients with the clinical diagnosis of chronic rhinosinusitis with nasal Polyposis will receive vitamin D supplementation
89011390|NCT04529668|Active Comparator|group II|twenty-five patients with the clinical diagnosis of chronic rhinosinusitis with nasal Polyposis will NOT receive vitamin D supplementation
89011391|NCT04529590||Patients with cardiovascular events after 18 years|"Analyzing metabolic markers screened and optimized by multivariate statistical with plasma metabolic profiles from peripheral blood samples of different groups.~Positive patients' samples will be collected at baseline."
89011392|NCT04529590||Patients without cardiovascular events after 18 years|For negative patients' samples will be collected at baseline as negative control.
89011393|NCT02218099|Experimental|1: Single dose of ASP8232|Subjects receive a single oral dose of ASP8232
89011394|NCT02218099|Experimental|2: Multiple doses of ASP8232 or placebo|Subjects receive multiple oral doses of ASP8232 or placebo
89011395|NCT02218138|Experimental|Learning 2 BREATHE|Learning 2 BREATHE, Mindfulness-based group program
89011396|NCT02218138|Experimental|Colorado Blues|Colorado Blues, Cognitive-behavioral depression prevention group
89011397|NCT02218177||Non-responders receiving aflibercept therapy|Non-responders to ranibizumab who are now receiving aflibercept therapy
89011398|NCT02218177||Non-responders receiving PDT combo therapy|patients who are non-responders to ranibizumab who have been switched to combination photodynamic therapy (PDT)
89011399|NCT02218177||Responders to ranibizumab|Patients who are responders to ranibizumab and are continuing monthly injections.
89011400|NCT02218255|Active Comparator|Day 3 eSET combined with Eeva|Traditional Morphology + Eeva™ results
89011401|NCT02218255|Active Comparator|Day 5 eSET combined with Eeva|Traditional Morphology + Eeva™ results
89011402|NCT02218255|No Intervention|Day 5 eSET with Traditonal Morphology|
89011403|NCT02218294|Experimental|[14C] BCX4161|Includes a radiolabelled dose of [14C] BCX4161 and unlabelled BCX4161
89011404|NCT02218333|Placebo Comparator|Control drink|An isocaloric drink to milk
89011405|NCT02218333|Experimental|Milk|Protein enriched milk (Styrk)
89011406|NCT02218528|Placebo Comparator|Starchy meal|No Plant-based ingredient added to a starchy meal
89011407|NCT02218528|Active Comparator|Low dose added to starchy meal|Plant-based ingredient in low dose added to starchy meal
89011408|NCT02218528|Placebo Comparator|Starchy meal and side dish|No Plant-based ingredient added to starchy meal and side dish
89011409|NCT02218528|Active Comparator|Low dose added to starchy meal and side dish|Plant-based ingredient in low dose added to starchy meal and side dish
89011410|NCT02218528|Active Comparator|Medium dose added to starchy meal and side dish|Plant-based ingredient in medium dose added to starchy meal and side dish
89011411|NCT02218528|Active Comparator|High dose added to starchy meal and side dish|Plant-based ingredient in high dose added to starchy meal and side dish
89011412|NCT02218567|Other|Patients|
89011413|NCT02218567|Other|Caregivers|
89011414|NCT02218645|Experimental|WE 941 OD|
89011415|NCT02218645|Active Comparator|Brotizolam|
89011416|NCT02218684|Experimental|Telmisartan + Lacidipine - low dose|
89011417|NCT02218684|Experimental|Telmisartan + Lacidipine - medium dose|
89011418|NCT02218684|Experimental|Telmisartan + Lacidipine - high dose|
89011419|NCT02218684|Placebo Comparator|Placebo|
89011420|NCT02278822|Experimental|Low dose oral liposomal glutathione|Intervention: low dose oral liposomal glutathione supplementation. 500 mg oral liposomal glutathione each day for 4 weeks.
89011421|NCT02278822|Experimental|High dose oral liposomal glutathione|Intervention: high dose oral liposomal glutathione supplementation. 1000 mg oral liposomal glutathione each day for 4 weeks.
89011422|NCT02278861|Active Comparator|Oral isotretinoin 10mg/day|Oral isotretinoin 10mg/day for 6 months The dose could be reduced if there were any significant laboratory alterations or clinical adverse events, along with sunscreen FPS 60 every 3 hours during the day.
89011423|NCT02278861|Active Comparator|Tretinoin 0,05% cream|"An every other night application of tretinoin 0,05% cream in the face and forearms for 6 months, along with sunscreen FPS 60 every 3 hours during the day.~If there were any clinical adverse events the drug could be reduced to twice a week."
89011424|NCT01641913|Experimental|Absorbable sugars|Lactulose (1,000 mg) and mannitol (200 mg). For the liquid formulation, these sugars will be administered in 250 ml of water. After oral ingestion of the sugars in liquid form, urine will be collected every 30 minutes for the first 2 hours.
89198911|NCT01505062|Experimental|SAR421869 (Cohort 3)|Escalating dose of SAR421869 given through one subretinal injection.
89198912|NCT01505062|Experimental|SAR421869 (Cohort 4)|Maximum tolerated dose (MTD) of SAR421869 given through one subretinal injection.
89536632|NCT03068247|Placebo Comparator|Placebo|10 weeks of placebo once daily for 1 week, then twice daily therafter.
89011425|NCT01642030|Other|Methadone Maintenance|
89011426|NCT01642030|Other|Buprenorphine Maintenance|
89011427|NCT01642069||Observational|Cryopreserved specimens are analyzed for NUP98 fusion to NSD1, JARID1A, and TOP1, myeloid/lymphoid or MLL-rearrangements, and other gene expression profiling by RT-PCR and karyotyping or FISH. Results are then compared with each patient's outcome data.
89011428|NCT00263796|Experimental|Pitocin|
89011429|NCT00263796|Placebo Comparator|Placebo|
89011430|NCT01642108|Other|Sitagliptin|
89011431|NCT01642264|No Intervention|Control (Delayed Training) Condition|Participants in this condition were assessed at 1 week, 1 month and 3 months post-enrollment, and were provided access to the WeBREATHe training website upon completion of their 3-month assessment.
89011432|NCT01642264|Experimental|Intervention (Training) Condition|In this condition, participants used the WeBREATHe training program website for 1 week, and completed assessments at 1 week, 1 month, and 3 months post-training.
89011433|NCT01642303|Experimental|vodcasting|students who listen to downloaded vodcasting
89011434|NCT01642303|No Intervention|control|listen to the student book listening file
89011435|NCT01642381|Active Comparator|Psychotherapy|
89011436|NCT01642381|No Intervention|"Self-Change Control (SCC)"|SCC participants will be told that they should attempt to reduce their drinking over the course of 8 weeks. (If unsuccessful, they will be offered Full Motivational Interviewing therapy sessions.)
89011437|NCT01642420||Mild cognitive impairment|Patients diagnosed with mild cognitive impairment
89011438|NCT01642420||Alzheimers disease|Patients diagnosed with mild Alzheimers disease
89011439|NCT01642420||Healthy control persons|Age matched healthy persons
89011440|NCT01642459|Experimental|Same direction cannulation|The inserted direction of arterial needle is same as the direction of blood flow.
89011441|NCT01642459|Active Comparator|Opposite direction cannulation|The inserted direction of arterial needle is opposite to the direction of blood flow.
89011442|NCT01642498|Experimental|Group A|ROX Coupler + continuing standard antihypertensive medications
89011443|NCT01642498|No Intervention|Group B|Continuing standard antihypertensive medications
89011444|NCT01642537|Other|Rhythmia Mapping System & Catheter|This is a single arm diagnostic feasibility study with the Rhythmia Mapping System and the Rhythmia Mapping Catheter
89198913|NCT01505062|Experimental|SAR421869 (Cohort 5)|MTD of SAR421869 given through one subretinal injection.
89198914|NCT00881673|Experimental|1|
88921527|NCT06235086|Experimental|Dulaglutide|Dulaglutide will be administered via subcutaneous injection once a week in subjects with type 2 diabetes.
88921528|NCT06235073||Manual implantation|
88921529|NCT06235073||Robot assisted implantation|
88921530|NCT06235060|Experimental|CAST GROUP|After the training given with the demonstration method, the training videos on https://www.montgomerycollege.edu/academics/departments/nursing-tpss/nursing-simulation-scenario-library.html were shown to the participants using interactive training methods in parallel with this training. Each session lasted approximately 30-45 minutes. The sessions were repeated in the same environment on the same day and time, once a week, for a total of four weeks (four times).
88921531|NCT06235060|Experimental|Imagery GROUP|After the training given with the demonstration method, scenarios suitable for the imagery technique were prepared by the second trainer (Ö.S.A.) in parallel with this training and CAST training. The internal mental visualization format (as if the students were doing the events themselves) was preferred for the imagery technique. The content of the scenarios was examined by three academic nurses who completed their doctoral education in addition to the authors, and expert opinions were taken. The flow of the scenarios was discussed with the experts until a consensus was reached and the final scenario was created. This technique lasted approximately 30-35 minutes.
88921532|NCT06235034|Experimental|diagnostic CT|patients will have their palliative radiotherapy designed on their diagnostic CT
88921533|NCT06235021|Experimental|Saffron|The experimental group will receive scaling and root debridement and will be instructed to use a mouthwash containing aqueous extract of saffron twice a day for 6 weeks.
88921534|NCT06235021|Placebo Comparator|chlorhexidine mouthwash.|The control group will receive scaling and root debridement and gargle their mouth with commercial product of 0.2% chlorhexidine mouthwash.
88921535|NCT06234995|Experimental|Patients with Parkinson's Disease|Patients with PD complete motor response inhibitions tasks under multiple conditions, depending on the study aim they are participating in. Those who are participants in Aim 1 of the study are able to also participate in Aims 2 and 3 if they are having a clinically indicated DBS leads implanted. Patients with PD will participate in the study for approximately 18 months which includes one preoperative visit, intraoperative data collection and two post-operative visits. As part of the motor inhibition tasks, EEG signals will be recorded. A cap similar to a swim cap will be placed on the head of the subject, and gel will be applied to the hair to get a good signal. Electrodes will be attached to the cap for recording of brain signals. A few additional flat electrodes will be placed on the skin to record hand muscle activity (for GNG task) and near the eyes to record eye movements. Accelerometer sensors will be utilized to record arm movements (for MSS task).
88921536|NCT06234995|No Intervention|Healthy Controls|Healthy participants complete motor response inhibition tasks during two study visits. Healthy controls will participate for approximately one month, which includes two study visits. As part of the motor inhibition tasks, EEG signals will be recorded. A cap similar to a swim cap will be placed on the head of the subject, and gel will be applied to the hair to get a good signal. Electrodes will be attached to the cap for recording of brain signals. A few additional flat electrodes will be placed on the skin to record hand muscle activity (for GNG task) and near the eyes to record eye movements. Accelerometer sensors will be utilized to record arm movements (for MSS task).
88921537|NCT06234943|Other|Participants requesting test(s) and treatment assessment for CT and NG infection|Chlamydia trachomatis (CT) and Neisseria gonorrhea (NG) self-swab(s) and urine collection for asymptomatic testing by a pharmacist. Selection of swab(s) or urine-based testing will be determined by the individual's sexual risk factors. Participants who have positive CT and/or NG test results will undergo clinical assessment of the CT and/or NG infection by the pharmacist and prescription(s) will be issued for treatment as appropriate.
88921538|NCT06234930|Experimental|Active and Sham Audiovisual Stimulation (Mild AD):|Both active and sham stimulation conditions will be delivered to 30 participants with Mild AD to demonstrate the mechanism of action of the intervention.
88921539|NCT06234930|Experimental|Active and Sham Audiovisual Stimulation (Cognitively Normal):|Both active and sham stimulation conditions will be delivered to 30 cognitively normal participants to demonstrate the mechanism of action of the intervention.
88921540|NCT06234917|Experimental|EEG-NFB protocol aimed at increasing the low-β(SMR)/high-β ratio|EEG neuromodulation at central (rolandic) cortical level
88921541|NCT06234917|Active Comparator|EEG-NFB protocol aimed at increasing the α(μ)/θ ratio|EEG neuromodulation at central (rolandic) cortical level
88921542|NCT06234904|Experimental|IBR733 Cell Injection|
88921543|NCT06234852|Active Comparator|Glucocorticoid maintenance group|Maintenance of 5-mg of prednisolone daily over 24 weeks
88921544|NCT06234852|Placebo Comparator|Glucocorticoid withdrawal group|Gradual withdrawal of daily 5-mg prednisolone to daily 0-mg prednisolone over 20-24 weeks
89011445|NCT01642576|Experimental|diet modification|counselling on caloric restriction and healthy eating
89198915|NCT00881673|Active Comparator|2|
89198916|NCT00881673|Placebo Comparator|3|
89198917|NCT00881829||Healthy volunteer|Smoker or non-smoker
88819596|NCT01556594|Experimental|Nasal Glucagon 3 mg|NG administered as single dose of 3 mg (composed of one dose of 1 mg NG immediately followed by one dose of 2mg NG).
88819597|NCT02974101|Experimental|spinal cord stimulation(RestoreSensor)|
88819598|NCT01556906|Experimental|Lomitapide|This is an open label trial where all patients receive lomitapide (AEGR733/BMS-201038)at escalating doses
88819599|NCT00371319|Active Comparator|Tacrolimus|Tacrolimus treatment
88819600|NCT00371319|Active Comparator|mycophenolate mofetil|mycophenolate mofetil
88819601|NCT01439594|Experimental|MGH OFDI Imaging|OFDI imaging
88819602|NCT01439672|Experimental|Insulin Sensitivity|Single arm. Each subject will consume a mixed meal beverage along with insulin administration in order to calculate insulin sensitivity.
88819603|NCT02209532|Active Comparator|Blue - PINPOINT|The cervix will be injected 4 times with a 1ml solution of 1% Isosulfan blue followed by injection 4 times of 1 ml of 1.25 mg/ml solution of ICG. LN mapping with Blue dye will be performed until the investigator identifies all blue nodes or determines that blue nodes cannot be identified. Once complete, the Investigator will begin mapping with PINPOINT until all 'ICG' nodes are identified or the investigator determines that 'ICG' nodes cannot be identified. Once mapping with both Blue dye and PINPOINT have been completed and documented, LNs identified with Blue dye or PINPOINT will be excised.
88921545|NCT06234839|Experimental|Probiotic group|The experimental group received conventional mechanical periodontal therapy and oral anti-plaque hygiene training, plus the administration of two daily tablets, containing both L. reuteri strains, for 30 days.
88921546|NCT06234839|No Intervention|No probiotic group|The control group also received conventional mechanical periodontal therapy and oral anti-plaque hygiene training; however, this group did not receive the administration of the probiotic tablets.
88921547|NCT06234813|Experimental|Glanzmann Thrombasthenia Group|Patient with a clear diagnosis of Glanzmann Thrombasthenia, whatever the subtype of disease
88921548|NCT06234813|Active Comparator|Healthy donors|Healthy donor without haemorrhagic ant thrombotic medical history
88921549|NCT06234748|Experimental|Treatment Arm|Patients will initially receive a single prescription of 70 Gy to PTVhigh in 35 fractions with RT given once daily, 5 days a week along with weekly platinum (standard therapy). All fields must be treated daily. On days when chemotherapy is given, it will be administered prior to RT. Prescription to high risk PTV will be 70Gy in 35 fractions and to PTV2 will be 56Gy in 35 fractions.
88921550|NCT06234722|Placebo Comparator|Rural - Conventional Cigarette|Participants who reside in rural locales of Appalachian KY and receive conventional cigarettes during the sampling period.
88921551|NCT06234722|Placebo Comparator|Peri-Urban - Conventional Cigarette|Participants who reside in peri-urban locales of Appalachian KY and receive conventional cigarettes during the sampling period.
88921552|NCT06234722|Active Comparator|Peri-Urban - Very Low Nicotine Cigarette|Participants who reside in peri-urban locales of Appalachian KY and receive very low nicotine cigarettes during the sampling period.
88921553|NCT06234722|Active Comparator|Rural - Very Low Nicotine Cigarette|Participants who reside in rural locales of Appalachian KY and receive very low nicotine cigarettes during the sampling period.
88921554|NCT06234696|Experimental|experimental group|"The group consists of 30 people and this group will be given psychoeducation for 4 weeks.~Training will be provided 2 days a week (monday and friday)."
88921555|NCT06234696|No Intervention|control group|The group consists of 30 people and this group will not be trained.
88921556|NCT06234683|Active Comparator|Web-based educational video on pneumococcal vaccination and reminder email to be vaccinated|
88921557|NCT06234683|Placebo Comparator|Reminder email to be vaccinated|
88921558|NCT06234670||Patients with uterine fibroids accepted myomectomy.|Complete the observation and follow-up, to identify the outcome （recur or not recur).
88921559|NCT06234657|Experimental|telerehabilitation for stroke patient|
88921560|NCT06234644|Active Comparator|Group A|The Group A (experimental group) will receive the treatment with Standardized walking obstacle course (SWOC).
88921561|NCT06234644|Active Comparator|Group B|The Group B (Control group) will receive the treatment with conventional Gait training.
88921562|NCT06234618||stroke patients|Stroke patients who can walk without assistance in their daily life.
89536633|NCT03108833|Experimental|Low Dose Experimental Group|Recombinant Human Prourokinase:40mg
89536634|NCT03108833|Experimental|High Dose Experimental Group|Recombinant Human Prourokinase:50mg
89536635|NCT03108833|Active Comparator|Active Comparator Controlled Group|Alteplase:100mg if weight>=65kg, 1.5mg/kg if weight<65kg
89536636|NCT02636595|Experimental|ABT-493/ABT-530|ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 12 weeks.
89198918|NCT01293448|Experimental|Intervention|CryoBalloon ablation of esophageal tissue in patients scheduled for esophagectomy for reasons unrelated to the objective of the study.
89198919|NCT00961714|Experimental|OsseoFix|Osseofix is an titanium expandable device similar to a vascular stent that is placed in the fractured vertebral body to provide a structure in which bone cement (polymethylmethacrylate) is inserted. It is intended to be used in the thoracolumbar spine between levels T6 through L5.
89198920|NCT00881907|Experimental|Group A|Group A subjects will be asked to attend a recall visit 2 months following completion of the treatment visits.
89198921|NCT00881907|Experimental|Group B|Group B subjects will be asked to attend a recall visit at 4 months following completion of the treatment visits.
89198922|NCT00881907|Experimental|Group C|Group C subjects will be asked to attend a recall visit at 6 months following completion of the treatment visits.
89198923|NCT04487925|Active Comparator|Up to 3 modified natural cycles|
89198924|NCT04487925|Experimental|Controlled ovarian stimulation|
89198925|NCT00547300|Experimental|Nebivolol|Nebivolol 5 mg, 10 mg or 20 mg
89198926|NCT00547300|Active Comparator|Metoprolol ER|Metoprolol ER 50 mg, 100 mg or 200 mg
89536637|NCT03108911|Experimental|Group I (GFD)|Patients receive GFD prepared by the hospital per dietary/nutrition pharmacy standards from the initiation of induction chemotherapy until hospital discharge (approximately 30 days). Patients also complete a daily food intake diary. A stool sample is collected from patients at baseline, day 14, and on the day of hospital discharge for gut microbiome analysis.
89536638|NCT03108911|Experimental|Group II (standard diet)|Patients receive a standard diet for from the initiation of induction chemotherapy until hospital discharge (approximately 30 days). Patients also complete a daily food intake diary. A stool sample is collected from patients at baseline, day 14, and on the day of hospital discharge for gut microbiome analysis.
88921569|NCT06234592|Experimental|Angiotensin II Infusion|Angiotensin II infusion commenced alongside standard care vasopressor therapy (norepinephrine). Angiotensin II up titrated in a protocolised manner to a target/maximum dose of 40 ng/kg/min whilst noradrenaline down titrated in order to achieve/maintain target mean arterial pressure (MAP) as directed by attending clinician.
88921570|NCT06234592|Experimental|Vasopressin Infusion|Vasopressin infusion commenced alongside standard care vasopressor therapy (norepinephrine). Vasopressin up titrated in a protocolised manner to a target/maximum dose of 0.04 IU/min whilst noradrenaline down titrated in order to achieve/maintain target mean arterial pressure (MAP) as directed by attending clinician.
89536639|NCT02636361|Experimental|LY900014 Test B|Test formulation B: Single dose of LY900014 formulation administered subcutaneously (SC) in one of five periods
89536640|NCT02636361|Experimental|LY900014 Test A|Test formulation B: Single dose of LY900014 formulation administered SC in one of five periods
88921571|NCT06234592|Active Comparator|Norepinephrine Infusion|Standard care vasopressor therapy which recruited participants already receiving, titrated to achieve/maintain target mean arterial pressure (MAP) as directed by attending clinician.
88921572|NCT06234579||ALK+ NSCLC|The GALILEO project is an Italian observational prospective cohort study on advanced ALK+ NSCLC patient progressing on first-line therapy with alectinib
88921573|NCT06234566|Experimental|Low Speed Drilling Without Irrigation|
88921574|NCT06234566|Active Comparator|Conventional Drilling with Irrigation|
88921575|NCT06234540|Experimental|aPRP 1|a-PRP intrauterine instillation on Menstruation Cycle Day 8 during frozen thaw cycle procedure
88921576|NCT06234540|Experimental|aPRP 2|a-PRP intrauterine instillation on Menstruation Cycle Day 8 and Day 10 during frozen thaw cycle procedure
88921577|NCT06234540|Experimental|Controlled|Standard treatment of frozen thaw cycle
88921578|NCT06234527|Experimental|mild to moderate melasma|adult patients suffering from mild to moderate melasma (Investigator's Global Assessment (IGA) 1 or 2)
88921579|NCT06234527|Experimental|mild to moderate acne induced PIHP|adult patients suffering from mild to moderate acne-induced PIHP (IGA 1 or 2) without active acne (i.e. less than 10 inflammatory lesions)
88921580|NCT06234527|Experimental|solar lentigo|adult patients suffering from solar lentigo with a pigmentation score > 5
88921581|NCT06234514|Experimental|Combination Therapy Group|"During the initial month, the patient consumed Jueling Mingmu decoction daily for one month.~Patients received monthly intravitreal injections of 0.5mg ranibizumab for the initial three months, followed by additional injections in the subsequent nine months for those who met eligibility criteria."
88921582|NCT06234514|Active Comparator|Intravitreal Ranibizumab Group|Patients received monthly intravitreal injections of 0.5mg ranibizumab for the initial three months, followed by additional injections in the subsequent nine months for those who met eligibility criteria.
88921583|NCT06234501|Experimental|Vitamin-B6|Participants will consume one high-dose Vitamin B6 100 mg tablet orally once daily for one month. Vitamin B6 will be provided as Pyridoxal-5'-Phosphate (PLP)
88921584|NCT06234501|Placebo Comparator|Placebo|Participants will consume a Placebo tablet matching the appearance of the Vitamin B6 tablets in the Experimental arm orally once daily for one month.
88921585|NCT06234462|Active Comparator|Standard of Care|Participants in this arm will receive current standard of care for PASC symptoms which may include: PT, OT, SLP, provider counseling, and/or pharmacologic interventions for targeted symptom management.
88921586|NCT06234462|Experimental|Standard of Care + Amantadine|Participants in this arm will review standard of care and amantadine.
88921587|NCT06234436|Experimental|Plasma exchange|1-20 plasma exchanges.
88921588|NCT06234410||Patients waitlisted for kidney transplantation|Patients who have been placed on the waiting list for a kidney transplant within Scotland
88921589|NCT06234371|Experimental|Treatment|The treatment group will be offered a $500 gift card for completing 6, 12, and 18 counseling sessions; up to $1,500 in total. Because RRC's typical practice involves prescribing and scheduling counseling in 6-session blocks, the financial awards are revealed to veterans in the treatment group in stages. After intake, treatment group individuals are told that they will receive a $500 gift card for completing the first 6 sessions; later sessions and awards are not mentioned. If the counselor decides that another 6-session block should be prescribed, then at the completion of the 5th session (i) the next 6 sessions are scheduled (i.e., sessions 7 through 12) and (ii) the counselor reveals that the participant can earn another $500 for completing the 12th session. The same process takes place during session 11. As part of RRC's typical practice, no veterans are offered more than 18 sessions.
88921590|NCT06234371|No Intervention|Control|"The control group will have access to the normal counseling services provided by RRC staff. Those in the control group will receive business as usual services offered by the RRC, which includes the same counseling services and evaluation of how many sessions an individual is recommended to receive."
88921591|NCT06234358||Calcanail cohort|Patients implanted with medical device under study between January 2012 and January 2020.
89011446|NCT01642576|Experimental|weight management program|dietician and sports trainer, physician counselling on weight loss
89011447|NCT01642654|Active Comparator|Control|
88921592|NCT06234345|Experimental|Fluticasone Propionate 250 mcg/Formoterol Fumarate dihydrate 12 mcg/Glycopyrronium Bromide 25 mcg|Fluticasone Propionate 250 mcg/Formoterol Fumarate dihydrate 12 mcg/Glycopyrronium Bromide 25 mcg in the pharmaceutical form of hard capsule with powder for inhalation - 1 capsule per inhalation twice a day
88921593|NCT06234345|Active Comparator|Trimbow® (Beclomethasone 100 mcg/Formoterol 6 mcg/Glycopyrronium 12.5 mcg)|Beclomethasone Dipropionate 100 mcg/Formoterol Fumarate dihydrate 6 mcg/Glycopyrronium Bromide 12.5 mcg in pharmaceutical form aerosol solution in pressurized metered dose device (pMDI) for inhalation (Trimbow® - Chiesi Farmacêutica Ltda.) - 2 triggering twice a day
88921594|NCT06234332||Exposure group|Group with environmental, nutritional or lifestyle exposures
88921595|NCT06234332||Non-exposed group|Group without any environmental, nutritional and lifestyle exposures
88921596|NCT06234280||Eluvia|Patients treated with Eluvia stent
88921597|NCT06234254|Experimental|Virtual Reality|Participants will be immersed in a virtual environment. Calming scenery will be shown via the headset for 20-30 minutes
88921598|NCT06234254|No Intervention|Control|No intervention (i.e. virtual reality headset) will be applied to the participant.
88921599|NCT06234215|Active Comparator|control group had functional task training|this group doing functional task training exercise for 50 min 3 times per week for two months
88921600|NCT06234215|Experimental|study group had functional task training combined with electrical stimulation|this group doing functional task training exercise combined with electrical stimulation for 50 min 3 times per week for two months
88921601|NCT06234176|Experimental|Personalised psychomotor therapy group|1 psychomotor therapy session of 45 minutes per week for 12 weeks + Duke Health Scale.
88921602|NCT06234176|Active Comparator|Usual treatment group|Standard treatment for depression administered by a doctor + a weekly telephone interview for 12 weeks to administer the Duke Health Scale.
88921603|NCT06234163|No Intervention|Control Group|"No intervention will be made to the nurses in the control group (n = 35). In-service training is provided to nurses in this group in the clinic. After the study is completed, written material (brochure) will be given to the nurses in the control group.Descriptive Survey Form will be applied at the beginning of the study. Other measurement tools, Enteral and Parenteral Nutrition Care Knowledge Test and Care Behavior Scale-24 (BDI-24) will be applied three times as pre-test, post-test and follow-up test (three weeks later)."
88921604|NCT06234163|Experimental|Experimental Group|"It was planned to give Enteral and Parenteral Nutrition Training to the nurses in the experimental group, based on the literature (Weimann et al., 2021; Atabek Aştı and Karadağ; 2020; Koçhan and Akn., 2018; Şenoğlu, 2016; Gök and Özdemir; 2015). The content of the training guide will be sent to ten experts in the field and content validity will be made. Enteral and parenteral nutrition training will be given face to face, in 15-20 minutes, using verbal presentation and written materials (brochures). Descriptive Survey Form will be applied to the experimental group (n=35) at the beginning of the research. Other measurement tools, Enteral and Parenteral Nutrition Care Knowledge Test and Care Behavior Scale-24 (BDI-24) will be administered three times: before the training, within one or two days of the training and three weeks after the training."
88921605|NCT06234137|Experimental|treatment arm|
88921606|NCT06234098|Experimental|AT-1965 Liposome Injection|
88921607|NCT06234085|Experimental|Intervention|Participants will be provided with access to a feedback report in the VCA app that contains 1) crowdsourced ratings of their error disclosure communication, 2) access to recordings of their responses to the completed VCA cases, 3) a recording of a highly-rated peer response and 4) learning points summarizing what laypeople would like the doctor to say in response to the case.
88921608|NCT06234085|No Intervention|Control|Participants will not have access to a feedback report.
88921609|NCT06234059|Experimental|Healthy Adult Speakers|healthy adult participants across the lifespan in three groups:18-35, 36-55, and 56+
88921610|NCT06234046|Active Comparator|group (1)|Group (1) included 40 cases received Rifaximin as 550 mg twice daily dose for a six-months period.
88921611|NCT06234046|Active Comparator|group (2)|Group (2) included 40 cases received Ciprofloxacin as 750 mg once weekly dose for a six-months period.
88921612|NCT06234033||Children with Autism Spectrum Disorder|Children with a confirmed diagnosis of autism spectrum disorder made by a qualified psychiatrist.
88921613|NCT06234033||Children with Attention-Deficit Hyperactivity Disorder|Children with a confirmed diagnosis of attention-deficit hyperactivity disorder made by a qualified psychiatrist.
88921614|NCT06234033||Neurotypical children|Children without a known or presumed psychiatric diagnosis.
88921615|NCT06233994|Experimental|ZG005+Donafenib|Participants will receive ZG005 plus Donafenib until unacceptable toxicity or loss of clinical benefit.
88921616|NCT06233994|Experimental|ZG005+Bevacizumab|Participants will receive ZG005 plus bevacizumab until unacceptable toxicity or loss of clinical benefit.
88921617|NCT06233981|Experimental|Radiotherapy and Tislelizumab|Moderate-dose hypofractionated intensity-modulated radiotherapy with a gross tumor dose of 25Gy/5f and a maximum dose of 35Gy/5f at the tumor center concurrent with Tislelizumab, followed Tislelizumab±lenvatinib for maintenance.
88921618|NCT06233955|Experimental|Group A|Group A received LLLT and Maitland mobilization technique along with conventional physical therapy,
88921619|NCT06233955|Experimental|Group B|received LLLT and conventional physical therapy
88921620|NCT06233955|Experimental|Group C|received Maitland mobilization and conventional physical therapy.
89536641|NCT02636361|Experimental|LY900014 Test C|Test formulation C: Single dose of LY900014 formulation administered SC in one of five periods
88921621|NCT06233890||Fatigue|"Group 1: Fatigue present for more than 6 months with impairment in daily life activities.~Fatigue will be assessed using two validated fatigue questionnaires completed at the screening visit. The Chalder fatigue scale (CFQ) is an 11 item scale which assesses the severity of fatigue over the last 90 days and the Modified Fatigue Impact scale (MFIS), commonly used to determine the impact of fatigue on quality of life, assesses fatigue over the previous 30 days. Both scales are diagnostic tools in chronic disease associated fatigue. Scores on these scales will determine if patients are eligible. For this group a score > or = 5 for Chalder score and > or = 43 for the MFIS score."
89011448|NCT01642654|Experimental|Treatment|
89011449|NCT01642693|Experimental|Teeth with intrusive movement and low power laser|Histological changes and root resorption were assesed in Teeth with intrusive movement after a low power laser application
88921622|NCT06233890||Non -Fatigue|Group 2: no significant symptoms of fatigue on TKI therapy. Fatigue will be assessed using two validated fatigue questionnaires completed at the screening visit. The Chalder fatigue scale (CFQ) is an 11 item scale which assesses the severity of fatigue over the last 90 days and the Modified Fatigue Impact scale (MFIS), commonly used to determine the impact of fatigue on quality of life, assesses fatigue over the previous 30 days. Both scales are diagnostic tools in chronic disease associated fatigue. Scores on these scales will determine if patients are eligible. For this group a score < or = 2 for Chalder score and < or = 33 for the MFIS score.
88921623|NCT06233851||mTBI patient|Children <16 years-old who suffered a head trauma in the last 24 hours with signs of mild traumatic brain injury
88921624|NCT06233851||control|Children <16 years-old who have a scheduled blood test for any reason
89536642|NCT02636361|Experimental|LY900014 Test D|Formulation D: Single dose of LY900014 formulation administered SC in one of five periods
88921625|NCT06233838|Experimental|KHA80 hemoperfusion treatment|The experimental group (197 cases) were randomly assigned to receive Jianfan KHA80 hemoperfusion treatment on the basis of hemodialysis or hemodiafiltration treatment, and the frequency of hemoperfusion treatment was ≥2 times/month.
88921626|NCT06233838|No Intervention|Routine hemodialysis|Randomly assign the control group (197 cases) to receive hemodialysis or hemodialysis filtration treatment, and the frequency of treatment is ≥2 times/week.
88921627|NCT06233812|Active Comparator|Half A of the FTSG|"A (superior or left relative to the patient, depending on the shape of the wound)"
88921628|NCT06233812|Active Comparator|Half B of the FTSG|"B (inferior or right relative to the patient)."
88921629|NCT06233799|Experimental|XR-NTX/BUP-XL|Participants randomized to the (XR-NTX/BUP-XL) arm will receive 450 mg of once-daily oral extended-release bupropion tablets and once every three weeks (Weeks 1, 4, 7, and 10) injections of extended-release naltrexone (Vivitrol®)
88921630|NCT06233799|Placebo Comparator|PLB/PLB|Participants randomized to the PLB arm will receive once-daily placebo tablets and once every three weeks (Weeks 1, 4, 7, and 10) placebo injections.
88921631|NCT06233786|Experimental|TENS in the bleeding phase|After completing the screening questionnaire and being evaluated, they receive TENS stimulation in the menstrual phase between days 25-28 (days before bleeding and where symptoms may begin) and 1-3 (first days of bleeding). They are evaluated again immediately after treatment and at the beginning of the next bleeding phase, being 28 days after the intervention.
88921632|NCT06233786|Experimental|TENS in the luteal phase|After completing the screening questionnaire and being evaluated, they receive TENS stimulation TENS stimulation in the luteal phase between days 17 to 24 of the menstrual cycle after the start of bleeding. They are evaluated again at the beginning of the next bleeding phase, being 7 days after the intervention, as well as 28 days after, being the next cycle.
88921633|NCT06233786|Sham Comparator|Sham TENS in the bleeding phase|Same procedure as TENS in the bleeding phase, but without TENS stimulation.
89011450|NCT01642693|Experimental|Teeth with intrusive movements with no laser|Histological changes and root resorption in Teeth with intrusive movements with no laser
89011451|NCT01642810|Active Comparator|Treatment-as-usual|Participants continue their pre-study treatment plan, based on their physician/other professional recommendations
89011452|NCT01642810|Experimental|Online ABBT treatment + TAU|Participants to complete a 6-unit online Acceptance-based behavioural treatment including training in pacing, mindfulness, acceptance, cognitive defusion, willingness, and exercise while also maintaining their pre-study treatment.
89011453|NCT00239564|Experimental|Experimental: carbidopa and levodopa|Subjects receive IPX054 100 mg, IPX054 150 mg, IPX054 200 mg, IPX054 250 mg, or IPX054 300 mg to achieve optimum dosage and dosing frequency as directed by the Investigator for 5 weeks.
89011454|NCT02961036|Experimental|Group 1 Information|Group 1 Information about the prize draw incentive for 100% of an Amazon gift (or currency equivalent) in the invitation letter.
89011455|NCT02961036|Active Comparator|Group 2 Information|Group 2 Information about the prize draw incentive for 75% of an Amazon gift (or currency equivalent) in the invitation letter.
89011456|NCT02961036|Active Comparator|Group 3 Information|Group 3 Information about the prize draw incentive for 50% of an Amazon gift (or currency equivalent) in the invitation letter.
89011457|NCT02961036|Active Comparator|Group 4 Information|Group 4 Information about the prize draw incentive for 25% of an Amazon gift (or currency equivalent) in the invitation letter.
89536643|NCT02636361|Active Comparator|Insulin Lispro|Reference formulation: Single dose of lispro administered SC in one of five periods
89536644|NCT05199935|Experimental|Intervention|Are shown the intervention video after filling out baseline questionnaire
89536645|NCT05199935|Other|Control|Are shown a control at Time 0, baseline and the intervention video after main outcome data is collected at Time 1
88921634|NCT06233721|No Intervention|Control group|Identifying Information Form (IIF), Medication Adherence Report Scale (MARS), and Duke Anticoagulation Satisfaction Scale (DASS) were applied to the control group two times, once in the first interview and once in the interview held a month later. The control group was not provided with education. In line with ethical principles, education and education booklet was provided to this group after the scales were applied in the last interview held in the outpatient clinic control. The application of the scales took 20-25 minutes on average.
88921635|NCT06233721|Experimental|Face-to-face education group|Identifying Information Form (IIF), Medication Adherence Report Scale (MARS), and Duke Anticoagulation Satisfaction Scale (DASS) were applied to the face-to-face group in the first interview. They were provided with face-to-face education on the determined date and in the specified environment. At the end of the education, education booklet was given to the individuals. Then, an appointment was made for a month later in hospital environment. In the interview held one month later, the scales were applied again for the last time.
89011458|NCT02961036|Active Comparator|Group 5 No Information|Group 5 No Information incentive for an Amazon gift certificate (or currency equivalent) in the invitation letter.
89011459|NCT02961036|Experimental|Group A reminder|One survey reminder at 14 days
89011460|NCT02961036|Active Comparator|Group B reminders|Two survey reminders 14 days and 28 days
89011461|NCT01642849|Experimental|high protein diet|12 subjects will be place on a high protein diet
89011462|NCT01642849|Experimental|high carbohydrate diet|12 subjects will be put on a high carbohydrate diet for 6 months
88921636|NCT06233721|Experimental|Online education group|IIF, MARS, and DASS were also applied to the online education group in the first interview. On the predetermined date and time, online education was given to individuals through video calls held on TEAMS, Google MEET, or WhatsApp. Then, the education booklet was sent to the participants through the application. An appointment date was determined to have another interview a month later. In the interview held a month later, the relevant scales were applied for the last time. At the end of the education, an evaluation was made, and the parts that were seen to be deficient and the issues/questions that the participants raised were repeated. Accordingly, the individuals in both intervention groups were requested to come for control a month later, and the scales were applied for the last time. Education was provided to the participants by the same researcher using the two methods, and the same education content and booklet was used.
88921637|NCT06233708||NSBB group|The NSBB group was defined as those who received NSBBs for at least 30 consecutive days within the 3 months prior to LT.
88921638|NCT06233708||Control group|Those who did not meet the above criteria were classified as the control group.
88921639|NCT06233682|Experimental|Enriched environment group|35 people with stroke recruited from the in-patient ward of the Neurology Clinic, meeting the inclusion criteria.
88921640|NCT06233682|No Intervention|No intervention|35 people with stroke recruited from the in-patient ward of the Neurology Clinic, meeting the inclusion criteria.
88921641|NCT06233643|Experimental|The group received acupuncture combined with intradermal sterile water|These acute renal colic patients who will received acupuncture combined with intradermal sterile water
88921642|NCT06233643|Active Comparator|The group received intramuscular inject phloroglucinol|These acute renal colic patients who will received intramuscular inject phloroglucinol.
88921643|NCT06233630|Placebo Comparator|Placebo|Only spinal anaesthesia - No peripheral nerve block
88921644|NCT06233630|Active Comparator|Erector Spinae Plane Block|spinal anaesthesia and unilateral ultrasound guided erector spinae plane block - 20ml 0.2% ropivacaine
88921645|NCT06233630|Active Comparator|Infiltration Popliteal Artery and Capsule of the Knee and Adductor Canal Block|"spinal anaesthesia and ultrasound guided Infiltration of local anesthetic between the Popliteal Artery and Capsule of the Knee (iPACK) block - 20ml 0.2% ropivacaine~+ ultrasound guided Adductor Canal Block - 10ml 0.2% ropivacaine"
88921646|NCT06233617|Placebo Comparator|placebo|0.2% ropivacaine for erector spinae plane block
88921647|NCT06233617|Active Comparator|Dexamethasone|0.2% ropivacaine + 4mg Dexamethasone for erector spinae plane block
88921648|NCT06233617|Active Comparator|Dexmedetomidine|0.2% ropivacaine + 50ug Dexmedetomidine for erector spinae plane block
88921649|NCT06233604|Placebo Comparator|Placebo|0.2% ropivacaine for erector spinae plane block
88921650|NCT06233604|Experimental|Dexamethasone|0.2% ropivacaine + 4mg Dexamethasone for erector spinae plane block
88921651|NCT06233604|Experimental|Dexmedetomidine|0.2% ropivacaine + 50ug Dexmedetomidine for erector spinae plane block
88921652|NCT06233591|Experimental|LP-10 0.25mg|0.25mg LP-10 / 10 mL twice daily oral rinse
88921653|NCT06233591|Experimental|LP-10 0.5 mg|0.5mg LP-10 / 10 mL twice daily oral rinse
88921654|NCT06233591|Experimental|LP-10 1.0 mg|1.0mg LP-10 / 10 mL twice daily oral rinse
89536646|NCT02471885|Experimental|Remote ischaemic conditioning|Remote ischaemic conditioning in the form of a blood pressure cuff on upper arm inflated upto 200 mm Hg (or systolic BP + 20 mm Hg if low platelets e.g. 50-150 x10^9/L, skip remote ischaemic conditioning (RIC) if platelets < 50 x 10^9/L) for 5 minutes, then deflated to 0 mm Hg for 5 minutes, for 4 cycles before beginning of chemotherapy infusion. The entire pre-conditioning phase will last 40 minutes.
88921655|NCT06233565|Placebo Comparator|Placebo|0.2% ropivacaine for popliteal nerve block
88921656|NCT06233565|Active Comparator|Dexamethasone|0.2% ropivacaine + 0.1mg/kg Dexamethasone for popliteal nerve block
88921657|NCT06233565|Active Comparator|Dexmedetomidine|0.2% ropivacaine + 0.1ug/kg Dexmedetomidine for popliteal nerve block
88921658|NCT06233552|Active Comparator|conventional denture conversion|a conventional denture conversion will be done following the conventional fabrication technique.
88921659|NCT06233552|Experimental|digital denture conversion|An alternative workflow for construction of the fixed interim requires impressions, model production, and jaw relation records then digitizing all these data then designing and milling the restoration.
88921660|NCT06233539||Retrospective section|
88921661|NCT06233539||Prospective section|
88921662|NCT06233526|Experimental|Individualized treatment group|Treating the R/R AML patients based on the transcriptomic profile and in vitro drug sensitivity Test
88921663|NCT06233500|Active Comparator|Group A: eyes will be treated without ILM flap|Group A: Only wide ILM peeling up to the arcades well be done
89198927|NCT04386759||Healthcare workers|"Up to protocol v2.0: Filling when including a first self-survey concerning the period of the last fifteen days. The following questionnaires will be completed online every week until the end of the study. For healthcare worker who have already presented a symptomatic infection at the time of inclusion, only the self-survey inclusion will be completed, it will relate to the period of fifteen days preceding the diagnosis.~From protocol v3.0: After performing a RT-PCR or an antigenic test for COVID diagnosis, the healthcare workers will complete a unique self-questionnaire about individual and contextual risks factors during the 15 days preceding the test."
89198928|NCT00958516|Experimental|LEO 29102 cream|
88921664|NCT06233500|Active Comparator|Group B : eyes will be treated by ILM flap|Group B: ILM peeling with flap well be done
88921665|NCT06233487|Other|Double measurements|All included children will have double measurements of the investigated ultrasound methodologies performed by two separate musculoskeletal radiologists.
88921666|NCT06233435|Other|PADSS at 6 hours|
88921667|NCT06233435|Other|PADSS at 24 hours|
88921668|NCT06233422||Major Depressive Disorder (MDD) Group|MDD group will consist of 70 participants with MDD, aged between 18-65, with a Patient Health Questionnaire-9 (PHQ-9) score of at least 10; who are also experiencing at least 1 sleep or circadian problem in the past 3 months.
88921669|NCT06233422||Healthy Control Group|Healthy control group will consist of 70 healthy control participants, aged between 18-65, with a Patient Health Questionnaire-9 (PHQ-9) score of below 5, indicating minimal or no depressive symptoms.
88921670|NCT06233409||lenticules group|Morphology of cornea and intra-ocular pressure were obtained by optical coherence tomography, Non-contact tonometer, Slit-lamp photography
88921671|NCT06233409||Penetrating keratoplasty group|Morphology of cornea and intra-ocular pressure were obtained by optical coherence tomography, Non-contact tonometer, Slit-lamp photography
88921672|NCT06233383||Adopters|Individuals responsible for deciding to institute screening CBE in Soweto's primary care clinics (e.g., policymakers, clinic administrators, nurse managers)
88921673|NCT06233383||Implementers|Individuals responsible for actually performing the screening CBE in Soweto's primary care clinics (e.g., nurses, doctors, fieldworkers, clerical workers)
88921674|NCT06233383||Recipients|Individuals eligible for a screening CBE (e.g., women over the age of 40 years from the community surrounding study clinics)
88921675|NCT06233370|Experimental|Over ground walking exercise|Participants will walk around a square hallway at a step rate of ~100 steps per minute for 20 minutes while wearing a Fitbit around the waist for measuring steps.
88921676|NCT06233370|Experimental|Treadmill walking exercise|Participants will walk on a motor-driven treadmill at a step rate of ~100 steps per minute for 20 minutes while wearing a Fitbit around the waist for measuring steps.
89437381|NCT04011189|Experimental|Videotaping|"First phase: Patients will complete questionnaire, pain score in pre-anaesthetic clinic. Their face and body pose are videotaped. Patients are reviewed on pain scores with videotaping at 12-36 hrs, 36 hrs till before discharge post-operatively.~Second phase: Patients will complete questionnaires, pain score, videotaping in pre-operative/-procedural/inpatient/outpatient consultation waiting areas. After surgery/procedure/consultation, i) Surgery: Patients rate pain scores with videotaping at 12-36 hrs, 36 hrs till before discharge.~ii) Procedure: Patients are asked on questionnaire, pain score, videotaping. iii) Consultation: Patients are asked on questionnaire, pain score, videotaping on next consultation.~Third phase: Patients will complete questionnaire and pain score in preoperative areas. They are videotaped while wearing a physiological wristband to monitor heart rate and body temperature. After surgery, pain score is rated while being videotaped with wristband."
89437382|NCT04009174|Experimental|Imaging Panel|Patients who provided written informed consent and found to be eligible for study were asked to complete Positron Emission Tomography (PET) + Dynamic CT imaging, PET/MRI (with endorectal coil) and 3D-Transrectal ultrasound prior to standard of care radical prostatectomy.
88921677|NCT06233344|Experimental|Mindfulness-assisted psilocybin therapy|8 weeks of mindfulness training plus one 25mg dose of psilocybin
88921678|NCT06233344|Active Comparator|Psilocybin only|One 25mg dose of psilocybin
88921679|NCT06233331|Experimental|Level 1|Initial three study participants will be enrolled in Dose Level 1, 2.5% ACU-D1 twice daily for 4 weeks.
88921680|NCT06233331|Experimental|Level 2|If there are no DLTs to Dose Level 1 then, 3 new study participants will proceed to Dose Level 2 at 5% ACU-D1.
88921681|NCT06233331|Experimental|Level 3|If there are no DLTs to Dose Level 2 then, 3 new study participants will proceed to Dose Level 3 at 10 % ACU-D1.
88921682|NCT06233318|Active Comparator|Pecto-intercostal fascial block|Pecto-intercostal Fascial Block with 20 ml of 0.35% ropivacaine injected to each side under ultrasound visualization.
88921683|NCT06233318|Placebo Comparator|Placebo|Pecto-intercostal Fascial Block with 20ml of normal saline injected to each side under ultrasound visualization.
88921684|NCT06233292|Experimental|Part 1: Dose Escalation|The study will begin with open-label dose escalation in ZG005 monotherapy treatment to determine the Maximum tolerated dose (MTD).
88921685|NCT06233292|Experimental|Part 2: Dose Expansion: Recommended Phase 2 Dose (RP2D) of ZG005 monotherapy|The dose-expansion stage will commence after the Recommended Phase 2 Dose (RP2D) is determined during the dose-escalation stage.Single drug dose expansion was performed in different tumors, such as :Non-small cell lung cancer, small cell lung cancer, Esophageal squamous cell carcinoma, Alveolar soft part sarcoma
88921686|NCT06233279|Experimental|Experimental Group|Charge-Balanced, Symmetric Nerve Stimulation device is used during night sleep for eight hours each day for 4 weeks (28 days).
88921687|NCT06233279|Sham Comparator|Control Group|Sham Stimulation device is used during night sleep for eight hours each day for 4 weeks (28 days).
88921688|NCT06233266|Experimental|Sequence 1-Ticagrelor test product and then reference product|Participants will receive treatment 1 in period 1 and treatment 2 in period 2. Where treatment 1= Ticagrelor Tablets 90 mg test product, treatment 2= Ticagrelor Tablets 90 mg reference product.
88921689|NCT06233266|Experimental|Sequence 2-Ticagrelor reference product and then test product|Participants will receive treatment 2 in period 1 and treatment 1 in period 2. Where treatment 1= Ticagrelor Tablets 90 mg test product, treatment 2= Ticagrelor Tablets 90 mg reference product.
88921690|NCT06233253|Active Comparator|Group I (usual care)|Patients receive usual care prior to their scheduled screening colonoscopy.
88921691|NCT06233253|Experimental|Group II (online mindfulness intervention)|Patients receive an online mindfulness intervention including infographics and 5-minute meditations QD for 5 days prior to their scheduled screening colonoscopy.
88921692|NCT06233240|Experimental|Sequence 1-Sitagliptin and Metformin Hydrochloride Tablets test product|Participants will receive treatment 1 in period 1 and treatment 2 in period 2. Where treatment 1= Sitagliptin and Metformin Hydrochloride Tablets 50 mg/1000 mg test product, treatment 2= Sitagliptin and Metformin Hydrochloride Tablets 50 mg/1000 mg reference product.
89198929|NCT00881985|Active Comparator|continuous positive airway pressure|
89437383|NCT04001829|Experimental|Arm A (paclitaxel)|Patients receive paclitaxel IV over 3 hours once weekly. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients may also receive trastuzumab and/or pertuzumab per institution routine care per treating physician's discretion.
89437384|NCT04001829|Experimental|Arm B (docetaxel)|Patients receive docetaxel IV over 1 hour once every 3 weeks. Treatment repeats every 21 days for 4-6 cycles in the absence of disease progression or unacceptable toxicity. Patients may also receive cyclophosphamide, doxorubicin, trastuzumab, and/or pertuzumab per institution routine care per treating physician's discretion.
88921693|NCT06233240|Experimental|Sequence 2-Sitagliptin and Metformin Hydrochloride Tablets reference product|Participants will receive treatment 2 in period 1 and treatment 1 in period 2. Where treatment 1= Sitagliptin and Metformin Hydrochloride Tablets 50 mg/1000 mg test product, treatment 2= Sitagliptin and Metformin Hydrochloride Tablets 50 mg/1000 mg reference product.
88921694|NCT06233227|Experimental|Sequence 1- Dutasteride test product and then reference product|Participants will receive treatment 1 in period 1 and treatment 2 in period 2. Where treatment 1= dutasteride 0.5 mg capsule test product, treatment 2= dutasteride 0.5 mg capsule reference product.
88921695|NCT06233227|Experimental|Sequence 2-Dutasteride reference product and then test product|Participants will receive treatment 2 in period 1 and treatment 1 in period 2. Where treatment 1= dutasteride 0.5 mg capsule test product, treatment 2= dutasteride 0.5 mg capsule reference product.
88921696|NCT06233214|Experimental|vein imaging device|"During the PIC application attempt, the parents of the children in the experimental group will be ensured to be with their children throughout the procedure.~PIC placement attempt will be performed on the experimental group with the help of a vein imaging device."
88921697|NCT06233214|No Intervention|control group|PIC placement attempt will be performed in the control group using the traditional application method without device support.
88921698|NCT06233201|Experimental|Sequence 1-Sitagliptin and Metformin Hydrochloride Tablets test product|Participants will receive treatment 1 in period 1 and treatment 2 in period 2. Where treatment 1= Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg test product, treatment 2= Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg reference product.
88921699|NCT06233201|Experimental|Sequence 2-Sitagliptin and Metformin Hydrochloride Tablets reference product|Participants will receive treatment 2 in period 1 and treatment 1 in period 2. Where treatment 1= Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg test product, treatment 2= Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg reference product.
88921700|NCT06233188|Active Comparator|study group|In the study group, lateral nasal osteotomy was performed 2 mm less than the measured distance in the axial section
88921701|NCT06233188|Active Comparator|conventional group|n the conventional osteotomy group, lateral nasal osteotomy was performed 25 mm for female and 30 mm for male patients, as suggested in the literature.
88921702|NCT06233175|Active Comparator|conventional group|patients take conventional trans cutaneous electrical stimulation (tens) with a frequency of 100 Hz , a pulse duration of 60 micro seconds for 20 min. ,hot backs for 15 min,stretching exercises for hamstring ,quadriceps ,calf muscles
88921703|NCT06233175|Experimental|interventional group|patients take conventional tens with a frequency of 100 Hz , a pulse duration of 60 micro seconds for 20 min. ,hot backs for 15 min,stretching exercises for hamstring ,quadriceps ,calf muscles with combined kinetic chain exercises (terminal knee extension,semi squat (wall slide) ,foreword step up and down ,straight leg raise ,seated knee extension )
88921704|NCT06233162|Experimental|Sequence 1-Febuxostat test product and then reference product|Participants will receive treatment 1 in period 1 and treatment 2 in period 2. Where treatment 1= Febuxostat 80 mg tablets test product, treatment 2= Febuxostat 80 mg tablets reference product.
88921705|NCT06233162|Experimental|Sequence 2-Febuxostat reference product and then test product|Participants will receive treatment 2 in period 1 and treatment 1 in period 2. Where treatment 1= Febuxostat 80 mg tablets test product, treatment 2= Febuxostat 80 mg tablets reference product.
88921706|NCT06233149|Experimental|Sequence 1-Esomeprazole magnesium dihydrate test product and then reference product|Participants will receive treatment 1 in period 1 and treatment 2 in period 2. Where treatment 1= Esomeprazole magnesium dihydrate 40 mg tablets test product, treatment 2= Esomeprazole magnesium dihydrate 40 mg tablets reference product.
88921707|NCT06233149|Experimental|Sequence 2-Esomeprazole magnesium dihydrate product and then test product|Participants will receive treatment 2 in period 1 and treatment 1 in period 2. Where treatment 1= Esomeprazole magnesium dihydrate 40 mg tablets test product, treatment 2= Esomeprazole magnesium dihydrate 40 mg tablets reference product.
88921708|NCT06233136|Experimental|Leg Pedalling exercise and designed physical therapy program|"Each child in the experimental group will be positioned in semi-reclined position with 45 degree trunk flexion during the application of cycling Sessions will be 30 minutes per session, three times per week, for two successive months The designed physical therapy program It will be applied for all participated children in both groups. It includes;~Flexibility exercises~Static and dynamic balance exercises~Functional training Sessions will be 45 minutes per session, three times per week, for two successive month"
89536647|NCT02471885|Placebo Comparator|Control|Blood pressure cuff on upper arm inflated to 10 mm Hg for 5 minutes, then deflated to 0 mm Hg for 5 minutes, for 4 cycles before beginning of chemotherapy infusion. The entire control comparator will last 40 minutes
89011463|NCT01642888|Experimental|0.1 µg/0.1 mL C-Tb|The C-Tb and 2 T.U. Tuberculin PPD RT 23 SSI agents are given concomitantly to each volunteer in the RIGHT and LEFT forearms according to a double blind randomisation scheme
89536648|NCT02636283|Active Comparator|Entresto|oral route
88921709|NCT06233136|Active Comparator|Designed physical therapy program|"The designed physical therapy program It will be applied for all participated children in both groups. It includes;~Flexibility exercises~Static and dynamic balance exercises~Functional training Sessions will be 45 minutes per session, three times per week, for two successive month"
88921710|NCT06233123|Experimental|Application|intervention group that will download the Medisafe android application (https://www.medisafe.com). This mobile application uses simple English language and figures to remind the patient about the dose
88921711|NCT06233123|No Intervention|control|control group with Standard Care and Medication Monitoring
88921712|NCT06233110|Experimental|Dose escalation phase: Dose level 0|Fostamatinib at dose level 0 (dose of 50mg QAM) in combination with standard of care ruxolitinib 10mg BID
88921713|NCT06233110|Experimental|Dose escalation phase: Dose level 1|Fostamatinib at dose level 1 (dose of 100mg QAM) in combination with standard of care ruxolitinib 10mg BID
88921714|NCT06233110|Experimental|Dose escalation phase: Dose level 2|Fostamatinib at dose level 2 (dose of 150mg QAM) in combination with standard of care ruxolitinib 10mg BID
88921715|NCT06233110|Experimental|Dose escalation phase: Dose level 3|Fostamatinib at dose level 3 (dose of 100mg BID) in combination with standard of care ruxolitinib 10mg BID
88921716|NCT06233110|Experimental|Candidate Dose #1|In the safety expansion cohort, subjects will be randomized to one of two candidate doses of fostamatinib (identified from the dose escalation phase) in combination with ruxolitinib 10mg BID.
88921717|NCT06233110|Experimental|Candidate Dose #2|In the safety expansion cohort, subjects will be randomized to one of two candidate doses of fostamatinib (identified from the dose escalation phase) in combination with ruxolitinib 10mg BID.
88921718|NCT06233097|Experimental|Sequence 1-Esomeprazole magnesium dihydrate test product and then reference product|Participants will receive treatment 1 in period 1 and treatment 2 in period 2. Where treatment 1= Esomeprazole magnesium dihydrate 40 mg tablets test product, treatment 2= Esomeprazole magnesium dihydrate 40 mg tablets reference product.
88921719|NCT06233097|Experimental|Sequence 2-Esomeprazole magnesium dihydrate reference product and then test product|Participants will receive treatment 2 in period 1 and treatment 1 in period 2. Where treatment 1= Esomeprazole magnesium dihydrate 40 mg tablets test product, treatment 2= Esomeprazole magnesium dihydrate 40 mg tablets reference product.
88921720|NCT06233084|Experimental|Sequence 1- Desogestrel test product and then reference product|Participants will receive treatment 1 in period 1 and treatment 2 in period 2. Where treatment 1= Desogestrel tablets 0.075 mg test product, treatment 2= Desogestrel tablets 0.075 mg reference product.
88921721|NCT06233084|Experimental|Sequence 2-Desogestrel reference product and then test product|Participants will receive treatment 2 in period 1 and treatment 1 in period 2. Where treatment 1= Desogestrel tablets 0.075 mg test product, treatment 2= Desogestrel tablets 0.075 mg reference product.
88921722|NCT06233058|Experimental|Sequence 1-Drospirenone+ Ethinyl Estradiol test product and then reference product|Participants will receive treatment 1 in period 1 and treatment 2 in period 2. Where treatment 1= Drospirenone 3 mg + Ethinyl Estradiol 0.03 mg Tablets test product, treatment 2= Drospirenone 3 mg + Ethinyl Estradiol 0.03 mg Tablets reference product.
88921723|NCT06233058|Experimental|Sequence 1-Drospirenone+ Ethinyl Estradiol reference product and then test product|Participants will receive treatment 2 in period 1 and treatment 1 in period 2. Where treatment 1= Drospirenone 3 mg + Ethinyl Estradiol 0.03 mg Tablets test product, treatment 2= Drospirenone 3 mg + Ethinyl Estradiol 0.03 mg Tablets reference product.
88921724|NCT06233045|Experimental|Sequence 1- Dapagliflozin test product and then reference product|Participants will receive treatment 1 in period 1 and treatment 2 in period 2. Where treatment 1= Dapagliflozin tablet 10 mg test product, treatment 2= Dapagliflozin tablet 10 mg reference product.
88921725|NCT06233045|Experimental|Sequence 2-Dapagliflozin reference product and then test product|Participants will receive treatment 2 in period 1 and treatment 1 in period 2. Where treatment 1= Dapagliflozin tablet 10 mg test product, treatment 2= Dapagliflozin tablet 10 mg reference product.
88921726|NCT06233032|Experimental|Group E|
88921727|NCT06233032|Experimental|Group D|
88921728|NCT06233019|Other|efficacy of glycolic acid 15%plus salicylic acid 2% gel in treatment of Plane wart .|
88921729|NCT06233006||Non Spesific Neck Pain|Patients with Non Spesific Neck Pain
88921730|NCT06233006||Healthy Control|Individuals with similar age
88921731|NCT06232993|Experimental|occlusal splint|A 0.5 mm thick hard thermoplastic acrylic plate was adapted to the model in the laboratory and prepared to cover the occlusal, buccal, and lingual surfaces of the teeth
88921732|NCT06232993|Experimental|kinesio taping|The tape was cut into 2 pieces of an 'I' shape, approximately 5 cm long and 2.5 cm wide, according to the instructions in the manual.
88921733|NCT06232993|Experimental|exercises|Participants in the EG group performed the exercises twice a day, with 10 repetitions and 3 sets for 5 weeks.
88921734|NCT06232967||Primary tumor resection (PTR group)|includes wedge resection, segmentectomy, or lobectomy.
88921735|NCT06232967||Exploratory thoracotomy (ET group)|JSimply open and close surgery.
88921736|NCT06232954|Experimental|Intervention|All recruited households within the intervention arm will receive the Mossie-Go device containing transfluthrin treated discs and will be provided with refill transfluthrin discs at monthly intervals to provide sustained protection.
88921737|NCT06232954|Placebo Comparator|Control|All recruited households within the control arm will receive the Mossie-Go device containing untreated blank discs and will be provided with refill untreated blank discs at monthly intervals.
88921738|NCT06232941|Experimental|Odontocem pulpotomy agent|calcium silicate-based technology containing 0.2% of the low steroid triamcinolone acetonide and has outstanding biocompatibility, handling properties and least amount of staining potential
88921739|NCT06232941|Active Comparator|NeoPutty bioceramic|premixed format of tricalcium silicate-based material (Bioceramic). It's composed of tantalum oxide, tricalcium silicate, calcium aluminate, dicalcium silicate, tricalcium aluminate, and calcium sulfate
88921740|NCT06232941|Active Comparator|Mineral Trioxide Aggregate material|hydrophilic and biocompatible endodontic biomaterial, capable of stimulating healing and osteogenesis
89198930|NCT00881985|No Intervention|observation|
89437385|NCT03998527|Experimental|Non-Disabled (ND) and Spinal Cord Injured (SCI) controls|The ND Control group (n=6) and SCI Control group (n=6) will be used to assess related values as acute effects of transcutaneous electrical spinal cord stimulation (TcESCS) itself and will not receive any training intervention. The ND group will receive baseline assessments, then up to 12 (4-Respiratory function, 4-Arm function, and 4-Trunk function) TcESCS mapping experiments, followed by repeating the assessments in the presence of TcESCS. The investigators will decide which stimulation type should be used for the post-mapping assessments.
89437386|NCT03998527|Experimental|Spinal Cord Injured (SCI) intervention groups|The respiratory training (RT) group (n=6) will receive the respiratory training intervention only); the transcutaneous electrical spinal cord stimulation (TcESCS) group (n=6) will receive transcutaneous spinal cord stimulation only; TcESCS + RT group (n=6) will receive TcESCS combined with RT; TcESCS + Arm Training (AT) group (n=6) will receive TcESCS combined with AT; and TcESCS + Trunk Training (TT) group (n=6) will receive TcESCS combined with TT.
88921741|NCT06232928|Experimental|1-Early group|for the early group, patients were instructed to wear immediate light short Class II elastics from upper canines to lower second premolars for 24 hours except while eating and change the elastics every 12 hours.
88921742|NCT06232928|Active Comparator|2-Conventional group|for the conventional group, conventional class II elastics were used on rigid stainless steel arch wires. patients were instructed to wear Class II elastics from upper canines to lower first molars for 24 hours except while eating and change the elastics every 12 hours.
88921743|NCT06232915||Mechanical ventilation|Children requiring mechanical ventilation during a surgical procedure.
88921744|NCT06232902|Experimental|QL1101|QL1101, intravenous infusion 90 min (±5min), D1 (Day 1, single dose)
88921745|NCT06232902|Active Comparator|Avastin®|Avastin®, intravenous infusion 90 min (±5min), D1 (Day 1, single dose)
88921746|NCT06232876|Sham Comparator|Blinded continuous monitoring|Continuous ward monitoring with vital signs recorded but not available to patients, clinicians, or investigators.
88921747|NCT06232876|Experimental|Unblinded continuous monitoring|Continuous ward monitoring with vital signs available to patients, clinicians, and investigators.
88921748|NCT06232837||Macintosh blade size 3|Patients intubated using Macintosh blade size 3
88921749|NCT06232837||Macintosh blade size 4|Patients intubated using Macintosh blade size 4
88921750|NCT06232824|Experimental|Intervention|"Participants in the intervention group coud only view the rehabilitation content that needs to be carried out at the current phase every day and confirm whether to execute it on the application. Participants could communicate with therapists on the mobile phone application by sending text, voice, images, and videos throughout the entire experiment.~Participants in the intervention group received detailed education and rehabilitation program on the mobile phone application including text, photos, and videos. On the first day of enrollment, the doctor inform the participants of the importance of rehabilitation and how to use the mobile phone application. The postoperative rehabilitation protocol includes four phases: Phase 1 (0-2 weeks), Phase 2 (3-4 weeks), Phase 3 (5-8 weeks), Phase 4 (9-12 weeks), and Phase 5 (after 13 weeks)."
88921751|NCT06232824|No Intervention|Control|"Participants in the control group could only receive a graphic and textual minimal postoperative rehabilitation plan on the mobile phone application. However, the participants was not informed the frequency and intensity of the rehabilitation items. They could not communicate with therapists online. Participants in the control group was expected to exercise unsupervised postoperatively.~At the 2, 4, 8, 12, and 24 weeks after ACLR, all participants went to the outpatient clinic for follow-up by physiotherapist to provide face-to-face guidance for exercise methods. Physiotherapist would clarify the content of the rehabilitation plan if any doubt, but will not provide information extending the prearranged scope."
88921752|NCT06232811||Preterm|preterm infants with gestational age <34 weeks
88921753|NCT06232811||Term|term infants with gestational age >37 weeks
88921754|NCT06232785|Experimental|Ibuprofen Group|Participants received 0.8g ibuprofen intravenously 30 minutes before the end of the procedure
88921755|NCT06232785|Placebo Comparator|Sufentanil Group|Participants received 0.2ug/kg of sufentanil intravenously 30 minutes before the end of the procedure
88921756|NCT06232746|Experimental|Magnet System, DI Biofragmentable|GT Metabolic Solutions DI Biofragmentable Magnetic Anastomosis System (Magnet System, DI Biofragmentable)
89198931|NCT00612807|Active Comparator|Control|Medication management with a study doctor every other week.
89437387|NCT03993535|Other|SSRI or cognitive behavioral therapy|selective serotonin reuptake inhibitors (fluoxetine, sertraline, citalopram, escitalopram, paroxetine or fluvoxamine) or cognitive-behavioral therapy, depending on availability and patient preference
89437388|NCT03982693|Active Comparator|Active|edetate disodium (EDTA)dff active infusion
89437389|NCT03982693|Placebo Comparator|Placebo|Placebo infusion
89437390|NCT03981302|Experimental|Family nursing conversations|The intervention will consist of structured family nursing conversations between a nurse, the patient and their selected family members. The patients will receive the intervention and usual treatment.
89437391|NCT03981302|No Intervention|Usual treatment|The patients will receive usual treatment.
88921757|NCT06232694|Experimental|Induction therapy and consolidation therapy after remission|Induction therapy:Venetoclax + idarubicin + cytarabine Consolidation therapy after remission:Venetoclax + cytarabineIf The patient meets the criteria for autologous hematopoietic stem cell transplantation (ASCT) during the treatment process, they can undergo ASCT.If the patient meets the criteria for transplantation and there is a suitable donor, they can undergo allogeneic hematopoietic stem cell transplantation (allo-HSCT).
88921758|NCT06232668||Cases group|Women recruited between 9 and 14 gestational weeks diagnosed with preeclampsia or other complication at the end of pregnancy.
88921759|NCT06232668||Control group|Women recruited between 9 and 14 gestational weeks without diagnosis of preeclampsia or other complication at the end of the pregnancy
88921760|NCT06232642|Active Comparator|Lactoferrin in Whey Protein|Lactoferrin (200 mg), iron (6 mg), and B12 (5.2 ug) in a whey protein isolate drink (20 grams of protein) to be taken 2 times daily; once before the morning meal and once before the evening meal.
88921761|NCT06232642|Active Comparator|Lactoferrin in Rice Protein|Lactoferrin (200 mg), iron (6 mg), and B12 (5.2 ug) in a rice protein drink (20 grams of protein) to be taken 2 times daily; once before the morning meal and once before the evening meal.
89198932|NCT00612807|Experimental|Combination|Medication management with a study doctor every other week plus weekly marital therapy.
89011464|NCT01642888|Active Comparator|2 T.U. Tuberculin PPD RT 23 SSI|The C-Tb and 2 T.U. Tuberculin PPD RT 23 SSI agents are given concomitantly to each volunteer in the RIGHT and LEFT forearms according to a double blind randomisation scheme
89011465|NCT01642927||Intra-Aortic Balloon Pump (IABP) Group|Advanced Heart Failure and/or pre-LVAD surgical patient with IABP
89437392|NCT03979313|Experimental|MEDI8897|Anti-RSV monoclonal antibody with an extended half-life
89198933|NCT00962806|Active Comparator|Exercise|8 week intensive exercise group
89198934|NCT00962806|Other|Control Lifestyle counseling|Lifestyle counseling without intensive exercise
89437393|NCT03979313|Placebo Comparator|Placebo|Commercially available 0.9% (w/v) saline
89437394|NCT03978117|Experimental|Freeze Dried Powder Preparation|
89437395|NCT03978117|Placebo Comparator|Placebo|
89198935|NCT04038801|Active Comparator|Quadrant-wise scaling and root planning (Q-SRP)|Quadrant-wise scaling and root planing were performed over four visits at 1-weekly intervals using an assortment of manual periodontal curettes.
89198936|NCT04038801|Experimental|Full-mouth ultrasonic debridement (FMUD)|Subgingival debridement were performed by a piezoceramic ultrasonic inserts in two visits of the same day.
89437396|NCT03976674|Experimental|Patients in preparation for bariatric surgery|Patients in preparation for bariatric surgery in the endocrinology department will follow a cognitive behavioural therapy
89437397|NCT03976674|No Intervention|Control group|Standard practice
89437398|NCT03976362|Experimental|Pembrolizumab + Carboplatin + Taxane + Olaparib|"For the Induction Phase, participants receive 4 cycles:~Pembrolizumab 200 mg, intravenous (IV) on Day 1 of each 21-day cycle PLUS carboplatin PLUS a taxane (either paclitaxel or nab-paclitaxel) for 4 cycles (21-day cycles). If the participant has a complete or partial response or stable disease to induction therapy, the participant is randomized to maintenance therapy.~For the Maintenance Phase, participants receive pembrolizumab IV on Day 1 of each 21-day for up to 31 cycles PLUS maintenance oral olaparib 300 mg twice daily. In the Maintenance Phase, the participant continues to receive maintenance olaparib until centrally verified progressive disease, physician decision or intolerable toxicity."
89536649|NCT02636283|Placebo Comparator|Placebo group|Oral placebo
89011466|NCT01642927||IABP/LVAD Group|Post-LVAD surgical patients with IABP
89011467|NCT01642927||Post-LVAD Group|LVAD patients 3 months or greater post-implantation undergoing echocardiography
89011468|NCT01642927||LVAD Event Group|LVAD patients who have developed LVAD thrombosis or GI hemorrhage related to LVAD
89011469|NCT01642927||Arrhythmia group|LVAD patient with an irregular heartbeat.
89011470|NCT01642927||Valvular disease group|LVAD patient with valvular heart disease
89011471|NCT01642927||Normal control group|Healthy participant without any known heart disease (Control group).
89011472|NCT01642966|Active Comparator|Prasugrel|Prasugrel 10mg/day for 15 days
89011473|NCT01642966|Experimental|Ticagrelor|Ticagrelor 90mg twice a day for 15 days
89011474|NCT01643005|Active Comparator|Active Control Group|For the active control group we will use Nurturing Parenting Groups currently being run by the community collaborator.
89011475|NCT01643005|Experimental|Relationship Strengthening HIV Prevent.|The relationship strengthening HIV intervention will build on the structure of the Nurturing Parenting Groups and will be integrated so that participants will receive the Nurturing Parenting Groups plus the relationship strengthening HIV intervention.
88921762|NCT06232642|Active Comparator|Lactoferrin Control|Lactoferrin (200 mg), iron (6 mg), and B12 (5.2 ug) in a maltodextrin drink (0 grams of protein) to be taken 2 times daily; once before the morning meal and once before the evening meal.
88921763|NCT06232590|Experimental|Control Lens, then Test Lens|Participants will wear the Control Lens for 1 month, then the Test Lens for 1 month
88921764|NCT06232590|Experimental|Test Lens, then Control Lens|Participants will wear the Test Lens for 1 month, then the Control Lens for 1 month
89536650|NCT05317949|Experimental|Integrated neuromuscular training program group|Integrated neuromuscular training program group will perform exercise in three major domains
89536651|NCT05317949|Active Comparator|General fitness exercises program group|General fitness exercises program group will perform general fitness exercises
88921767|NCT06231550|Experimental|FC084CSA|
89198937|NCT04038801|Experimental|Full-mouth disinfection (FMD)|Subgingival debridement were performed by a piezoceramic ultrasonic inserts and an intensive regime of chlorhexidine in two visits of the same day.
89198938|NCT00962962|Other|Low-Amount/Moderate Intensity Exercise|Aerobic exercise at 50% peak oxygen use/consumption expending approximately 1,000 calories per week equaling approximately 10 miles per week OR 2.5-3.5 hours per week
88921770|NCT06231030||Multiple Sclerosis Group|Method Description Study data will be collected multicenter. It will be obtained from individuals diagnosed with MS who applied to Niğde Ömer Halisdemir University Training and Research Hospital Neurology Polyclinic and Hacettepe University, Faculty of Medicine, Department of Neurology and referred to Gazi University, Faculty of Health Sciences, Department of Physiotherapy and Rehabilitation.
88921771|NCT06230757|Experimental|Psilocybin|Participants receive Psilocybin 25mg capsule orally, administered with psychological support, on dosing day.
89536652|NCT02471573|Active Comparator|Freeze-all protocol|Embryos are selected for cryopreservation using vitrification technique. Two vitrified embryos will be warmed and transferred in subsequent cycle.
88921772|NCT06230757|Placebo Comparator|Active Placebo|Participants receive Psilocybin 1mg capsule (identical to the Psilocybin 25mg capsule) orally, administered with psychological support, on dosing day.
89536653|NCT02471573|Active Comparator|Fresh transfer protocol|Two embryos are selected and transferred fresh in the same cycle.
88921773|NCT06230744|Other|Lifestyle Intervention|Diet and exercise coaching
88921774|NCT06230744|Experimental|Lifestyle Intervention II|Diet and exercise coaching
88921775|NCT06230718|Experimental|Intervention group|"The intervention group will receive 3 experimental procedures~Placebo control~Motor Imagery- Active Comparator~Action Observation (OA) Active comparator muscle activation control by surface electromyography will be recorded in these three situations"
88921776|NCT06230627|Experimental|Rehabilitation program|The Home-Based Rehabilitation Program (HBRP) As a first procedure, detailed interviews were conducted with each participant at the beginning of the study to gather information about their physical, psychological, and social well-being. This information helped the authors create personalized rehabilitation plans for each participant to ensure their participation in the study for the entire 6 months period. Through our study objectives, the authors used body composition such as height, weight, BMI and some anthropometric measurements for body parts circumferences by using tape measurements. Also, muscle strength tests were performed on participants&#39; lower and upper extremities, head, and trunk to measure various movements. The 2nd control group completed their measurements and tests at college. Additionally, a clinical test using the American Spinal Injury Association scale (ASIA) was conducted on each participant to assess sensory feeling.
88921777|NCT06230627|No Intervention|First Control Group Five People with SCI|This group only conducted the pre-post1 and post2-tests
88921778|NCT06230627|No Intervention|Healthy Group Five people|This group only conducted the pre-post1 and post2-tests
88921779|NCT06230107|Experimental|Participants diagnosed with Binge Eating Disorder|The intervention was divided into 8 individual weekly meetings, guided by Mindful eating session, nutritional educational dynamics, cooking workshop, food sensory analysis and applications of questionnaires
88921780|NCT06229912|Experimental|Arm 1|Participants found to be eligible to take part in this study, will take revumenib 2 times a day (each dose about 12 hours apart), every day of each 28-day study cycle.
88921781|NCT06229886|Experimental|Study Participants|Application of positive-end-expiratory-pressure on mechanically ventilated patients while performing point-of-care-ultrasound.
88921782|NCT06229821|Other|Intervention group|
88921783|NCT06229418|Experimental|DFR AED Program|Real-time and simulated out-of-hospital cardiac arrests that occur across 6 communities (4 rural, 2 urban)
89536654|NCT02471417|Experimental|Nitrate rich beetroot juice|Concentrated, beetroot juice is a rich source of dietary nitrate.
88921784|NCT06229327|Experimental|PEDİATRİC|Children in the intervention group were played a therapeutic game explaining the procedure before indwelling catheter intervention. Children in the control group did not undergo any intervention other than the hospital's normal procedure before indwelling catheter intervention.
88921785|NCT06227494|Experimental|Fiber Intervention|Individuals in this arm will be given instruction on how to increase fiber intake,
88921786|NCT06227494|Active Comparator|Standard Weight Loss Education|Individuals in this arm will be given standard weight loss education
88921787|NCT06227494|Experimental|Fiber Intervention + Standard Weight Loss Education|Individuals in this arm will be given education on both fiber and standard weight loss
88921788|NCT06227234|Experimental|LV - DC - AT|Order: LifeVac then Dechoker then Abdominal Thrusts
88921789|NCT06227234|Experimental|LV - AT - DC|Order: LifeVac then Abdominal Thrusts then Dechoker
88921790|NCT06227234|Experimental|DC - AT - LV|Order: Dechoker then Abdominal Thrusts then LifeVac
88921791|NCT06227234|Experimental|DC - LV - AT|Order: Dechoker then LifeVac then Abdominal Thrusts
88921792|NCT06227234|Experimental|AT - LV - DC|Order: Abdominal Thrusts then LifeVac then Dechoker
88921793|NCT06227234|Experimental|AT - DC - LV|Order: Abdominal Thrusts then Dechoker then LifeVac
88921794|NCT06227143||Opioid-free anesthesia|"Patients undergoing laparoscopic surgery under general anesthesia. Drugs used for the purpose of anesthesia:~Ketamine Dexmedetomidine Propofol Sevoflurane Lidocaine Betamethasone Paracetamol NSAID"
88921795|NCT06227143||Target Controlled Infusion|"Patients undergoing laparoscopic surgery under general anesthesia. Drugs used for the purpose of anesthesia:~Propofol Remifentanil Oxycodone Paracetamol NSAID Bethametasone"
88921796|NCT06227143||Volatile anesthetics|"Patients undergoing laparoscopic surgery under general anesthesia. Drugs used for the purpose of anesthesia:~Sevoflurane Propofol Remifentanil Oxycodone Paracetmol NSAID Bethametasone"
88921797|NCT06225856|Experimental|Study treatment|Method of Administration: Single dose period: Single oral administration under fasting state; Multiple dose period: Oral administration under fasting state, QD.
89198939|NCT00962962|Other|High-Amount/Moderate-Intensity Exercise|Aerobic exercise at 50% peak oxygen use/consumption expending approximately 1,600 calories per week equaling approximately 16 miles per week OR 4-6 hours per week
88921798|NCT06220266|Placebo Comparator|Placebo|starch, no active substance
88921799|NCT06220266|Experimental|PM1|Pueraria mirifica 1 Subspecies: A Process/Extraction: C Planting location: E
88921800|NCT06220266|Experimental|PM2|Pueraria mirifica 2 Subspecies: B Process/Extraction: C Planting location: F
88921801|NCT06220266|Experimental|PM3|Pueraria mirifica 3 Subspecies: B Process/Extraction: D Planting location: G
88921802|NCT06211231|Experimental|Self-guided digital intervention|The program consists of 10 online sessions that teach and guide different endometriosis-related themes. The sessions include mindfulness-meditation, yoga, written assignments and patient-education, that are accessed through the digital platform. Participants continue medical treatment as usual.
88921803|NCT06211231|Experimental|Therapist-guided digital intervention|The program consists of 10 online sessions that teach and guide different endometriosis-related themes. The sessions include mindfulness-meditation, yoga, written assignments and patient-education, that are accessed through the digital platform. This arm includes 11 online video-consultations with a therapist (one prior to starting and one for each session.) Participants continue medical treatment as usual.
88921804|NCT06211231|No Intervention|No-treatment control group (waiting list)|Participants randomized to the waiting list will be offered one of the two experimental treatments. Participants continue medical treatment as usual.
88921805|NCT06211140|Experimental|Depressive disorders|"Three conductive electrodes will be placed overhead. Based on the 10/20 international placement system, a 4.45 x 9.53 cm electrode is placed on the forehead corresponding to Fpz, Fp1 and Fp2. Two 3.18 x 3.81 cm electrodes are placed on the mastoid region of each side.~The tACS stimulation waveform includes ramp-up and ramp-down periods of 180 and 12 s, respectively. It is a square-wave with an average amplitude of 15 mA and is equally distributed from the frontal region to the mastoid areas (amplitudes are reported as zero-to-peak).~All participants with major depression disorder will receive a total of 20 sessions in four weeks, once daily on weekdays, with tACS stimulation at 77.5 Hz and 15 mA.~From Monday to Friday, each session will last 40 min at a fixed daytime interval."
88921806|NCT06211140|Other|Healthy controls|Without the tACS stimulation in this group
88921807|NCT06209515||Patients with neurodegenerative disease|Patient diagnosed with neurodegenerative disease (ICD-10 diagnosis code) between 2010-2021
88921808|NCT06209515||Matched controls|Age, gender, and place of residency matched for those of a patient that was alive at the end of the year of the diagnosis
88921809|NCT06207851|Experimental|Experimental|If abnormal blood vessels related to pain are identified by angiography, selective embolization is performed using Nexsphere-F.
88921810|NCT06202339|Experimental|DaRT Seeds|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds
88921811|NCT06198816||DVT patients|
88921812|NCT06195540|Experimental|Rivaroxaban arm|
88921813|NCT06195540|Active Comparator|Low-molecular-weight heparin arm|"Treatment with LMWH is the standard-of-care in this population of lower limb trauma patients at risk of thrombosis.~The control group is therefore the group of patients who receive prophylactic anticoagulant treatment with LMWH for the duration of immobilization (i.e. until full mobilization with weight-bearing)."
88921814|NCT06193512|Experimental|SwishKit + Oral care treatment as usual|SwishKit + Oral care Treatment as usual (TAU)
88921815|NCT06193512|Active Comparator|Oral care treatment as usual|Oral care Treatment as usual (TAU)
88921816|NCT06192420|Experimental|Test product|Traumed® gel (human gel galenic form of Traumeel®)
88921817|NCT06192420|Active Comparator|Reference product|Diclofenac sodium gel 1%
88921818|NCT06192420|Placebo Comparator|Placebo therapy|Corresponding placebo gel
89198940|NCT00962962|Other|High-Amount/Vigorous-Intensity Exercise|Aerobic exercise at 75% peak oxygen use/consumption expending approximately 1,600 calories per week equaling approximately 16 miles per week OR 2-3 hours per week
89437399|NCT03976362|Active Comparator|Pembrolizumab + Carboplatin + Taxane + Olaparib Placebo|"For the Induction Phase, participants receive 4 cycles:~Pembrolizumab 200 mg, intravenous (IV) on Day 1 of each 21-day cycle PLUS carboplatin PLUS a taxane (either paclitaxel or nab-paclitaxel) for 4 cycles (21-day cycles). If the participant has a complete or partial response or stable disease to induction therapy, the participant is randomized to maintenance therapy.~For the Maintenance Phase, participants receive pembrolizumab IV on Day 1 of each 21-day for up to 31 cycles PLUS matching maintenance olaparib placebo twice daily. In the Maintenance Phase, the participant continues to receive maintenance olaparib placebo until centrally verified progressive disease, physician decision or intolerable toxicity."
89437400|NCT03975829|Experimental|Dabrafenib and/or trametinib|"Patients in this study may receive one of the following treatments received in the parent study which are:~Patients who received monotherapy of either of dabrafenib or trametinib~Patients who received combination of dabrafenib and trametinib~Patients who discontinued treatment on parent study are still offered to participate in long-term follow-up"
89437401|NCT03970538|Experimental|Treatment Arm|Treated with the LimFlow System
88921819|NCT06192355|Experimental|Single-use gastroscope|A disposable endoscope designed for a one-time use during a Gastroscopy, eliminating the need for reprocessing or sterilization. After a single procedure, the entire gastroscope is discarded, reducing the risk of cross-contamination and ensuring a fresh, sterile instrument for each patient intervention
88921820|NCT06192355|Active Comparator|reusable gastroscope|A durable endoscope designed for multiple uses after thorough reprocessing and sterilization
88921821|NCT06185257||Patient with chronic kidney disease under dialysis|
88921822|NCT06185257||Patients with nephrotic syndrome|
88921823|NCT06185257||C. Normal control group|
88921824|NCT06183502||MSM using or not using Pre-exposure prophylaxis|"60% of MSM using PrEP at baseline in Atlanta, Chicago, and San Diego to develop knowledge around PrEP use and adherence, condom use, sexual risk-taking behavior, and substance-using behaviors.~40% of MSM not using PrEP at baseline in Atlanta, Chicago, and San Diego to develop knowledge around PrEP use and adherence, condom use, sexual risk-taking behavior, and substance-using behaviors."
88921825|NCT06182124|Experimental|Phase 1 (Stage 1): Multivalent Pneumococcal Vaccine - Formulation 1|Participants to receive a single injection of Multivalent Pneumococcal Vaccine - Formulation 1. This is a possible candidate for continuation in Phase 2 (Stage 2).
88921826|NCT06182124|Experimental|Phase 1 (Stage 1): Multivalent Pneumococcal Vaccine - Formulation 2|Participants to receive a single injection of Multivalent Pneumococcal Vaccine - Formulation 2. This is a possible candidate for continuation in Phase 2 (Stage 2).
88921827|NCT06182124|Active Comparator|Phase 1 (Stage 1) and Phase 2 (Stage 2): 20-valent pneumococcal conjugate vaccine (20vPnC)|Participants to receive a single injection of 20vPnC.
88921828|NCT06181136|Experimental|Cohort A1|Participants with MPS IIIA
88921829|NCT06181136|Experimental|Cohort A2|Participants with MPS IIIA
88921830|NCT06181136|Experimental|Cohort B|Participants with MPS IIIA
88921831|NCT06181136|Experimental|Cohort C (Optional)|Participants with MPS IIIA
88921832|NCT06181136|Experimental|Cohort D (Optional)|Participants with MPS IIIA
88921833|NCT06181136|Experimental|Cohort E (Optional)|Participants with MPS IIIA
88921834|NCT06180694|Experimental|Reminiscence group|The research will be conducted in a pre-test post-test single-group, quasi-experimental research design.In this research, reminiscence therapies will be administered to individuals with dementia in sessions of approximately 45 minutes, once a week for 8 weeks. In order to hold group discussions where life stages are discussed in the program, individuals with dementia will be divided into 4 groups of 7 people each. It is aimed for the groups to be distributed homogeneously. In this regard, 4 groups consisting of similar individuals will be created, taking into account sociodemographic variables (age, gender, etc.) and dementia stage.
88921835|NCT06177184|Experimental|Donor Human Milk|Infants randomized to the intervention group will receive DHM each time supplementation is required for the first 7 days of life.
88921836|NCT06177184|No Intervention|Standard Care (Infant Formula)|Infants randomized to the standard care group will receive formula each time supplementation is required for the first 7 days of life.
88921837|NCT06172413|Experimental|active transcranial alternating current stimulation (tACS)|true stimulation.
88921838|NCT06172413|Sham Comparator|Sham tACS|no active stimulation
88921839|NCT06171477|Experimental|20-40-60|
88921840|NCT06171477|Experimental|60-40-20|
88921841|NCT06171477|Experimental|40-60-20|
88921842|NCT06166758|Experimental|Educational Video|Educational video about germline genetic testing, which is 7 minutes long
88921843|NCT06165367|No Intervention|Blastocysts exposed to normal media (NEG)|Blastocysts exposed to routine-in use medium No intervention
88921844|NCT06165367|Active Comparator|Blastocysts exposed to EmbryoGlue (EG)|Blastocysts exposed to EmbryoGlue
88921845|NCT06164613|Experimental|Intervention|1000 mg orally of Cinnamomum Verum oil extract per day for 21-28 days
88921846|NCT06164613|Placebo Comparator|Placebo|400 mg orally of canola oil per day for 21-28 days
88921847|NCT06155968|Active Comparator|PCA group|: the PCA pump will be connected in a separate cannula. The pump contains 0.5 mg nalbuphine/ ml. the basal rate is 5ml/h and lock out time is 10 min.
88921848|NCT06155968|Active Comparator|QL block group|". Patients will receive bilateral ultrasonography (USG) guided block with 20 ml of 0.25 % bupivacaine on each side. The block is performed by anaesthesia consultants having experience of 5 years in ultrasound guided blocks. The procedure will be performed using aseptic technique (gown, gloves, facemask and protective sheath for the ultrasound probe).~The curvilinear probe (2 5 MHz, SonoSite Turbo M) is placed in the transverse axial plane just cranial to the iliac crest. The shamrock sign was visualised (viz., the transverse process (TP) of vertebra L4 is the stem, whereas the erector spinae muscle (ESM) posteriorly, quadratus lumborum (QL) muscle laterally and the psoas major (PM) muscle anteriorly represent the three leaves). The needle is introduced using an in plane technique from the posterior end of the transducer through the QL muscle. The target for injection is the fascial plane between the QL and PM muscles."
89437402|NCT03968653|Experimental|Dose Escalation: Group A: Debio 0123|"Participants will receive Debio 0123 as monotherapy (Day -3), orally, daily for 3 days during Cycle 1 then in combination with carboplatin intravenous infusion from Cycle 2 onwards.~Depending on pharmacokinetics (PK) and safety results from previous cohorts, the Debio 0123 dosing regimen may be modified for subsequent cohorts."
89437403|NCT03968653|Experimental|Dose Escalation: Group B: Debio 0123|Participants will receive Debio 0123, orally, daily, for 6 days during each cycle in combination with carboplatin IV infusion.
89437404|NCT03968653|Experimental|Dose Expansion: Debio 0123|Participants with platinum-resistant selected solid tumors will receive Debio 0123, orally, daily, depending on the RP2D determined in the previous part, for 3 or 6 days during each cycle in combination with carboplatin IV infusion.
89437405|NCT03965468|Experimental|Immunotherapy, chemotherapy, radiotherapy and surgery|"Durvalumab 1500 mg administered intravenously every 3 weeks for the first 4-6 cycles (during chemotherapy);~Tremelimumab 75mg administered intravenously every 3 weeks for the first 4-6 cycles (only cohort 2)~4-6 cycles of chemotherapy, carboplatin AUC5 every 3 weeks plus paclitaxel 175 mg/m2, every 3 weeks;~Stereotactic body radiotherapy (SBRT) of all oligo-metastatic lesions, in a maximum of 10 treatment fractions over 2 weeks, starting after week one of chemotherapy cycle 1 and completed within four weeks after start of durvalumab treatment;~Restaging at 3 months; if no disease progression, proceed to definitive local treatment (surgical resection of primary tumour or radiotherapy at a minimum dose of 60-66Gy to the primary tumour). Durvalumab continues at 1500 mg intravenously every 4 weeks until progression of disease or for a maximum of 1 year from start of treatment."
89437406|NCT03961568|Experimental|Core Study Placebo|"Subjects who did not receive Cenobamate in the Core Study will receive Cenobamate 12.5 mg tablet once a day for two weeks, 25 mg tablet once a day for two weeks, 50 mg tablet once a day for two weeks, 100 mg tablets once a day for two weeks, 150 mg tablets once a day for two weeks and 200 mg tablets once a day for twelve weeks.~The adolescent subjects will follow the same regimen in an oral suspension adolescent equivalent dose based on weight."
89437407|NCT03961568|Experimental|Core Study Active|"Subjects who received cenobamate in the Core study will continue to receive the same daily dose (150 mg or 200mg).~The adolescent subjects will follow the same regimen in an oral suspension adolescent equivalent dose based on weight."
89437408|NCT03959085|Experimental|Arm I (HR-FAV B-ALL)|See detailed description for Arm I
89437409|NCT03959085|Active Comparator|Arm II (HR B-ALL CONTROL)|See detailed description for Arm II.
88921849|NCT06155032|Experimental|Endovascular therapy|"Patients in this group will receive best medical management plus EVT including mechanical thrombectomy, aspiration thrombectomy, intra-arterial thrombolysis, angioplasty or stenting.~In the procedure, the methods including mechanical thrombectomy, aspiration thrombectomy, intra-arterial thrombolysis, angioplasty and stenting can be used according to the local interventionalists' choice. Mechanical thrombectomy or aspiration thrombectomy will be recommended as the primary treatment."
89437410|NCT03959085|Experimental|Arm III (HR B-ALL EXPERIMENTAL)|See detailed description for Arm III.
89437411|NCT03959085|Experimental|Arm IV (MPAL)|See detailed description for Arm IV.
89437412|NCT03959085|Experimental|ARM V (B-LLY)|See detailed description for Arm V.
89437413|NCT03953976|Experimental|PET-CT at 3 months and ENT evaluation|Treatment to the gross primary and nodal disease (70 Gy), with suspicious nodes treated to 66.5 Gy, all in 35 fractions. CT and PET-CT are required for nodal assessment. Restaging PET-CT must be performed between 11-14 weeks from the completion of treatment. The patient must see an otolaryngologist after the PET-CT to decide on post-treatment neck dissection per the surgeon's judgement. Patients will then be seen every 3 months (+/- 2 weeks) for the first year, and then at least every 6 months (+/-2 weeks) until the 36 month. Subsequent and intervening follow-up visits will be made per physician preference
89437414|NCT03950271|Experimental|SHR-1210+ Trastuzumab + Oxaliplatin + Capecitabine|trastuzumab + SHR-1210 + capecitabine + oxaliplatin for neoadjuvant chemotherapy 4-cycle.Then D2 radical surgery. The patients continued to receive capecitabine plus oxaliplatin for adjuvant therapy, and the total number of chemotherapy cycles was 8 cycles.
89437415|NCT03948971|Other|Venogram Group|Participants in this group have a scheduled clinically indicated a cerebral angiogram procedure and will undergo a Venogram.
89437416|NCT03946111|Experimental|Naltrexone/Bupropion|
89437417|NCT03946111|Placebo Comparator|Placebo|
89437418|NCT03945305|Active Comparator|RIC group|Patients are treated with previous antihypertensive treatment plus remote ischemic conditioning.
89437419|NCT03945305|Other|Control group|Patients are only treated with previous antihypertensive treatment.
89437420|NCT03941652||Women with gestational diabetes without a prior GDM|The investigators will evaluate the usability of the sensors and define what features the application should have and how the data should be presented to the users. Participants (n=up to 10) use the sensors for one week and fill out logbooks for physical activity, sleep and diet. Participants fill questionnaires before and after the usage period, and take part in semi-structured interview.
89437421|NCT03941652||Women with gestational diabetes with or without a prior GDM|The investigators define major usability issues with different versions of functional prototypes of eMOM GDM application developed in the project before moving to phase 2 of the study. GDM women (n=up to 12) will use the available version of the application for one week, and afterward the participants with GDM will take part in semi-structured interview.
89536655|NCT02471417|Placebo Comparator|Nitrate depleted placebo beetroot juice|Placebo beetroot juice is identical to active beetroot juice in every way except nitrate content.
88921850|NCT06155032|Active Comparator|Best medical management|Patients in this group will receive best medical management alone. All the patients enrolled received standard guideline-directed medical therapy including: monitor vital signs, management of blood pressure, glucose and lipids, antithrombotic (antiplatelet or anticoagulant therapy determined by treating physician) therapy if appropriate.
88921851|NCT06154785||International cohort|This is an international cohort (France and other international centers) which consists of including patients undergoing colorectal surgery performed at low pressure for benign or malignant pathology.This stage 2b cohort study is a pilot study assessing the best operative association with stable low-pressure pneumoperitoneum in order to optimize postoperative outcomes after mini invasive colorectal surgery.
88921852|NCT06152302|Experimental|Mobility Assessment|This study involves a single arm, without a comparator group. The comparison will be made between the data for movements in conditions outside the water and inside the water.
89536656|NCT04450953|Active Comparator|Eplerenone group A (cross over design)|Patient will receive eplerenone 50mg/day taken orally for 6 months, followed by a 8 to 10 weeks wash-out period, then a 6-month period without eplerenone, until the end of the study.
88921853|NCT06152250|Other|Liver Fine-Needle Aspiration, blood sampling and clinical evaluation|"At the time of inclusion, when liver biopsy will be performed as part of routine medical management, fine-needle aspiration and blood sampling will also be made in all patients.~The procedure will be performed in the Day Hospital, immediately after the liver biopsy and after the same local anaesthetic. Specific blood sampling will be made the same day (20mL of plasma in Ethylenediaminetetraacetic Acid Tetrasodium (EDTA) tubes and 20 mL of plasma in heparin tubes).~Clinical information will be collected in electronic Case Report Form (e-CRF). After the procedure, the patient will be monitored as part of the usual protocol. No follow-up data are expected with Profile-NASH."
88921854|NCT06149715|Experimental|Bottle Filter Arm|Receive a filter which attaches to a bottle. If the household does not have an eligible tap, they are randomly assigned to either this arm or the Bucket Filter Arm.
88921855|NCT06149715|Experimental|Bucket Filter Arm|Receive a filter which attaches to a bucket. If the household does not have an eligible tap, they are randomly assigned to either this arm or the Bottle Filter Arm.
88921856|NCT06149715|Experimental|Tap Filter Arm|All households with an eligible tap (compatible with filter and runs) will receive a tap filter.
88921857|NCT06148246|Experimental|Family Fit Condition (Intervention)|
88921858|NCT06148246|Active Comparator|Fitbit Only Condition|
89536657|NCT04450953|Active Comparator|Eplerenone group B (cross over design)|Eplerenone-free for 6 months, followed by a 8 to 10 weeks wash-out period, then a 6-month period in which patients will receive eplerenone 50 mg/day as a single dose taken orally.
88921860|NCT06142994|Experimental|Verum group|"10 days of treatment with 3 daily doses of 420 mg (available in an capsule of 210 mg), as recommended by the manufacturer.~6 capsules daily for 10 days: 2 capsules in the morning (30 minutes before breakfast), 2 capsules at noon (30 minutes before lunch), 2 capsules in the evening (30 minutes before dinner)"
88921861|NCT06142994|Placebo Comparator|Placebo|"10 days treatment with a 3-day dose of 420 mg placebo capsules (available in an indistinguishable capsule of 210 mg).~6 capsules daily for 10 days: 2 capsules in the morning (30 minutes before breakfast), 2 capsules at noon (30 minutes before lunch), 2 capsules in the evening (30 minutes before dinner)"
88921862|NCT06142799|Experimental|immediate overlay placement|Immediately after root canal treatment an overlay is cemented, and the patient is asked to record the pain after 6, 12, 24, 48 and 72 hours after treatment
88921863|NCT06142799|Active Comparator|delayed overlay placement|After root canal treatment the tooth is left in infraoclussion and the patient is asked to record the pain after 6, 12, 24, 48 and 72 hours
88921864|NCT06136390|Active Comparator|Oxytocin|The patients received a spray of the synthetic oxytocin (24 I.U. Syntocinon®) in combination with mindfulness-based group therapy (MBGT) over 4 weeks once a week. Due to an effect latency of 30-80 mins after intranasal administration of oxytocin on social behavior, the dose was administered 45 min before the 50-min session.
88921865|NCT06136390|Placebo Comparator|Placebo|The patients received a spray of placebo (24 I.U. Syntocinon®) in combination with mindfulness-based group therapy (MBGT) over 4 weeks once a week. Due to an effect latency of 30-80 mins after intranasal administration of oxytocin on social behavior, the dose was administered 45 min before the 50-min session.
88921866|NCT06134934|Experimental|Telemonitoring design 1|"Self-Monitoring of Blood Glucose (SMBG)~Sleep~Mental health~Blood pressure~Activity"
88921867|NCT06134934|Experimental|Telemonitoring design 2|"Self-Monitoring of Blood Glucose (SMBG)~Sleep~Mental health"
88921868|NCT06134362|Experimental|CAB LA 600 mg (Q8W)|All enrolled participants have previously received CAB LA as part of the HPTN 083 and HPTN 084 parent studies or their sub-studies. Participants will continue receiving CAB LA 600 mg via gluteal intramuscular (IM) injection.
89198941|NCT00962962|Other|Low-Amount/Moderate-Intensity Exercise + Diet|"Exercise - 150 minutes per week (30 minutes / 5 days per week) of aerobic exercise at 50% peak oxygen use/consumption equaling approximately 10 miles per week~Diet - The CLI sessions will provide training on needed skills (e.g., calorie counting, portion size estimation) as well as motivation and support in a group counseling setting designed to achieve a weight loss goal of 5 to 7% of baseline body weight."
88921870|NCT06132477||GLP-1 Agonist Group|This cohort will consist of patients undergoing bariatric surgery who are currently receiving a GLP-1 Agonists for weight loss and/or diabetes management, that will be maintained on their preoperative dose of GLP-1 agonist following their bariatric surgery. This includes semaglutide, tirzepitide, among others. The dosage will be variable, but will be the same dose the patient is on prior to the bariatric surgery. Duration will be one of the aims of the study.
88921871|NCT06132477||Non-GLP-1 Agonist Group|This cohort will consist of patients undergoing bariatric surgery who are currently receiving a GLP-1 Agonist for weight loss and/or diabetes management that will be required to stop taking their preoperative dose of GLP-1 agonist following their bariatric surgery. Dosage preoperative will be variable based on what the patient is currently taking, as well as the medication being taken.
88921872|NCT06131450|Experimental|BL-M07D1|Participants receive BL-M07D1 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
88921873|NCT06129487|Experimental|Narrative Pictorial Warning Labels|Participants in this arm will be presented with three narrative pictorial warning labels for alcoholic beverages.
88921874|NCT06129487|Experimental|Non-Narrative Pictorial Warning Labels|Participants in this arm will be presented with three non-narrative pictorial warning labels for alcoholic beverages.
88921875|NCT06129240||Cohort A|PH-ILD
88921876|NCT06129019|Experimental|Experimental:|Reiki application will be done
89536658|NCT02474381|Experimental|EPCs plus PTA|Intra-arterial infusion of autologous CD133+ cells on diabetic subjects with PAD,plus angioplasty
89536659|NCT02474381|Active Comparator|Single PTA|Angioplasty of arteries below tibial plateau level only
89536660|NCT04983537|Active Comparator|Gam-COVID-Vac / Gam-COVID-Vac|
88921877|NCT06129019|No Intervention|Control|Reiki application will not be done
89437422|NCT03941652||General pregnant women|The investigators will define major usability issues with different versions of functional prototypes of eMOM GDM application developed in the project before moving to phase 2 of the study. General pregnant women (n=up to 30) will use the available version of the application for one week, and afterward the general pregnant women will fill out a web form of usability of the application after the application week.
89437423|NCT03941652||Health care professionals|Nurses/midwifes (n=up to 15) will be interviewed for collecting user requirements for the professional eMOM GDM application in semi-structured interviews. Also the usability of the user interface prototypes will be evaluated using cognitive walkthrough.
89536661|NCT04983537|Active Comparator|Gam-COVID-Vac / ChAdOx1 nCoV-19|
88921878|NCT06126666|Experimental|ABL103|ABL103 will be administered biweekly of every 28-day cycle in the dose-escalation. The dosing interval to be used in tumor-expansion part will be evaluated based on the emerging safety and PK data from the dose-escalation part of the study.
88921879|NCT06125743|Other|Usual Care|
88921880|NCT06125743|Experimental|In-Person LEF-SMP|
88921881|NCT06125743|Experimental|Telehealth LEF-SMP|
89198942|NCT00882063|Experimental|P276-00|Starting dose level of P276-00 is 50 mg/m2/day. The drug will be administered intravenously in 200 ml of 5% dextrose (D5W) over a period of 30 min. Subjects will be enrolled at different dose levels of P276-00 to determine maximum tolerated dose of P276-00.
89536662|NCT04983537|Active Comparator|Gam-COVID-Vac / BBIBP-CorV|
88921882|NCT06124638|Experimental|Self-Testing Group|Lay users (self-tester or caregiver) will be provided with a Panbio™ COVID-19/Flu A&B Rapid Panel Self-Test kit. Each lay user will collect one mid-turbinate nasal swab from both nostrils, perform and interpret the Panbio™ COVID-19/Flu A&B Rapid Panel Self-Test. All procedures for testing and result interpretation, including sample collection and extraction will be conducted by the lay user following the Instructions for Use provided in the kit. Participants will be asked to document their result interpretation and will pass the test to site staff, who will document their interpretation of the result. In addition, a second swab will be collected by study staff and eluted in Viral Transport Medium (VTM).
88921883|NCT06123754|Experimental|Envalfolimab plus platinum-based doublet chemotherapy|Envalfolimab plus platinum-based doublet chemotherapy for a total of 3-4 cycles of neoadjuvant therapy (determined by the investigator), Envafolimab will be administered after surgery at 600 mg every 3 weeks(Q3W) for 16 cycles at most.
89198943|NCT00958750|Active Comparator|5% MTF|5% minoxidil topical foam used once daily
89198944|NCT00958750|Active Comparator|2% MTS|2% minoxidil topical solution twice daily use
89198945|NCT00882141|Experimental|1|Weight loss
89536663|NCT02474303|Other|HIV Pre-exposure Prophylaxis (PrEP)|Truvada
89198946|NCT00882141|Experimental|2|Exercise plus weight loss
89536664|NCT03664713|Experimental|EMDR plus TAU|Individual Eye Movement Desensitization and Reprocessing (EMDR) Therapy: This consists of 25 individual sessions of 60 minutes each, applying the standard protocol with the existing validated modifications for specific pathologies. The standard EMDR protocol consists of 8 phases: 1) Patient history; 2) Patient preparation; 3) Evaluation of the main aspects of the traumatic memory; 4) Desensitization of the memory; 5) Installation of the positive cognition; 6) Body scan; 7) Close and 8) Reevaluation.
89011476|NCT04529317|No Intervention|Regular diet|The study was a cross-over pilot clinical study consisting of two periods. The first period was only an observational and monitoring phase where participants just continued with their regular diet (RD), for this reason all participants initiated this period and wash-out term was no needed.
89011477|NCT04529317|Experimental|Quinoa diet|With the data of the first phase obtained, the subjects began the second period in which they had to undergo a nutritional intervention with a quinoa diet (QD).
89011478|NCT01643083|Active Comparator|Rifaximin|
89011479|NCT01643083|Placebo Comparator|Placebo|
89011480|NCT01643122||Group 1|
89011481|NCT01643122||Group 2|
89011482|NCT01643161|Experimental|TAU+GSH|Treatment As Usual plus Guided Self Help.
89011483|NCT01643161|Active Comparator|TAU|Treatment AS Usual.
89011484|NCT01643239|Experimental|Hospital-based mCIT with individualized intervention|Hospital-based modified constraint-induced therapy(mCIT)
89011485|NCT01643239|Experimental|Hospital-based mCIT with group therapy|Hospital-based modified constraint-induced therapy(mCIT)
89011486|NCT01643239|Other|Hospital-based TR|Hospital-based traditional rehabilitation (TR)
89011487|NCT01643278|Experimental|Treatment (dasatinib and ipilimumab)|Patients receive dasatinib PO QD for 7 days. Patients then receive dasatinib PO QD and ipilimumab IV once on weeks 1, 4, 7 and 10. Beginning on week 24, patients then receive dasatinib PO QD and ipilimumab IV once every 12 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
89011510|NCT01644019|Experimental|Device: Teleconsultation|"In cases of suspected acute stroke (including intracranial hemorrhage), if patients give informed consent the paramedics can use this system to contact a so called tele-EMS physician who has an audio-connection to the EMS team and receives vital parameters (e.g., ECG, pulse oximetry, non-invasive blood pressure) in real-time. The transmission of still pictures (taken with a smartphone), 12-lead-ECGs and video streaming from the inside of the ambulance can also be carried out, if indicated. The tele-EMS physician supports the EMS team in obtaining all relevant medical history, neurological diagnosis, general diagnosis and can delegate the application of medications. This can be carried out to bridge the time to the arrival of an EMS physician or in less severe cases without an EMS physician on-scene. The quality of prehospital care and the possible influences on the initial inhospital phase should be investigated and compared with regular EMS."
89011511|NCT01644097|Experimental|Arm I (probiotic mix)|Patients receive a mixture of Lactobacillus plantarum strain 299v, Bifidobacterium lactis probiotic supplement, and Lactobacillus acidophilus probiotic PO BID for 9 weeks. Treatment continues in the absence of unacceptable toxicity.
89011512|NCT01644097|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID 9 weeks. Treatment continues in the absence of unacceptable toxicity.
89011513|NCT01644136|Experimental|Supportive care (microsphere-mediated lymphocele prevention)|Patients undergo standard robotic assisted laparoscopic prostatectomy with pelvic lymph node dissection. After lymph node dissection, patients undergo microsphere-mediated lymphocele prevention to the lymph node basin on one side of the pelvis.
89011514|NCT01644253|Experimental|Cohort 1 - Previously Untreated CLL|20 mg/kg TRU-016 + Rituximab
89011515|NCT01644253|Experimental|Cohort 2 - Relapsed CLL|20 mg/kg TRU-016 + Rituximab
89011516|NCT01644253|Experimental|Cohort 3 - Previously Untreated CLL|10 mg/kg TRU-016 + Rituximab
89011517|NCT01644253|Experimental|Cohort 4 - Previously Untreated CLL|20 mg/kg TRU-016 20 + Obinutuzumab
89011518|NCT01644253|Experimental|Cohort 5 - Relapse CLL|20 mg/kg TRU-016 + idelalisib + rituximab
89011519|NCT01644253|Experimental|Cohort 6 - With CLL on ibrutinib with no complete response|20 mg/kg TRU-016 + ibrutinib
89011520|NCT01644253|Experimental|Cohort 7 - With CLL on ibrutinib with stable disease|20 mg/kg TRU-016 + ibrutinib
89011521|NCT01644253|Experimental|Cohort 8 - With relapsed or refractory PTCL|20 mg/kg TRU-016 + 90 mg/m2 bendamustine
89011522|NCT01644370|Other|HIV positive with aeroallergen|positive for aeroallergen at baseline
89011523|NCT01644370|Other|HIV positive without aeroallergen|negative for aeroallergen at baseline
89011524|NCT01644370|No Intervention|control|HIV negative children (n=10)
89011525|NCT01644448|Other|Study arm A|Subjects will receive one dose of 5 ml of Autologous Human Platelet Lysate with simultaneous micro-needling on day 2
89011526|NCT01644448|Other|Control Arm B|Topical Applications of the standard therapy as directed by the investigator
89011527|NCT01644487|Experimental|Primary stenting|A group of patients who will undergo subsequent primary stenting following successful conventional balloon angioplasty
89011528|NCT01644487|Active Comparator|Balloon only|A group of patients who will undergo routine conventional balloon angioplasty alone without stenting
89011529|NCT01644526|Experimental|Hemoaccess Valve System|Valve system for use with AV graft
89011530|NCT01644604|Experimental|Renal denervation|Subjects are treated with the renal denervation procedure after randomization and are maintained on baseline anti-hypertensive medications.
89011531|NCT01644604|No Intervention|Control Group|Subjects are maintained on baseline anti-hypertensive medications
89011532|NCT01644682|Experimental|Arm-1|In each country, this arm constitute with 6 clusters where 2 from high, 2 from medium and 2 from low shadfly destiny. Each cluster has 50 households. It will receive IWFPL intervention.
89011533|NCT01644682|Experimental|Arm-2|In each country, this arm constitute with 6 clusters where 2 from high, 2 from medium and 2 from low shadfly destiny. Each cluster has 50 households. It will receive IDWL intervention.
89011534|NCT01644682|Experimental|Arm-3|In each country, this arm constitute with 6 clusters where 2 from high, 2 from medium and 2 from low shadfly destiny. Each cluster has 50 households. It will receive ITN intervention.
89011535|NCT01644682|No Intervention|Control|In each country, this arm constitute with 6 clusters where 2 from high, 2 from medium and 2 from low shadfly destiny. Each cluster has 50 households. It will not receive any intervention, Control group
89011536|NCT01644760|Experimental|Study population|Healthy subjects with spontaneous ventilation, 18 to 50 years of age.
89536665|NCT03664713|No Intervention|TAU only|Treatment As Usual (TAU): The patients in this condition will participate in the psychosocial activities proposed by the inpatient unit (with a focus on autonomy, psychoeducation, treatment adherence, insight, functioning and family interventions). Patients who receive EMDR therapy will also participate in these activities.
88921884|NCT06123754|Active Comparator|Placebo plus platinum-based doublet chemotherapy|Placebo plus platinum-based doublet chemotherapy for a total of 3-4 cycles of neoadjuvant therapy (determined by the investigator), placebo will be administered after surgery every 3 weeks(Q3W) for 16 cycles at most.
88921885|NCT06119854|Experimental|Attitudinal inoculation intervention|"Participants randomized to this arm will view a brief video addressing one anti-vaccine meta-narrative or issue (e.g., concerns about the vaccine not working) most salient to the entire CHASING COVID study population (per recent historical data) and focused on bolstering resistance to mis/disinformation."
88921886|NCT06119854|Experimental|Cognitive behavioral therapy-informed intervention|Participants randomized to this arm will view a brief video using a CBT-informed approach and focused on addressing barriers to vaccination, with no inoculation messaging.
88921887|NCT06119854|Active Comparator|Conventional public health messaging|Participants randomized to this arm will view a brief video conveying conventional public health messaging adapted from a review of public health public service announcements, with no inoculation or CBT-informed messaging.
88921888|NCT06118333|Experimental|Experimental group|Participants receive BL-B01D1 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
88921889|NCT06118333|Experimental|Control group|Participants receive capecitabine, gemcitabine, docetaxel in the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
88921890|NCT06116955||S-M group|Midazolam combines with sufentanil to titrate to moderate sedation for bronchoscopy.
88921891|NCT06116955||S-M-P group|Midazolam and sufentanil combine with low-dose propofol to titrate to deep sedation for bronchoscopy.
88921892|NCT06116955||S-R group|Remazolam combines with sufentanil to titrate to moderate sedation for bronchoscopy.
88921893|NCT06116955||S-R-P group|Remazolam and sufentanil combine with low-dose propofol to titrate to deep sedation for bronchoscopy.
88921894|NCT06114511|Experimental|BL-M07D1|Participants receive BL-M07D1 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
88921895|NCT06113276||tidal hyperinflation|As the study aim to identify whether tidal hyperinflation is an independent predictor for ARDS mortality, and as this variable will be entered as a quantitative predictor in the multivariate model, the study encompass a single group of patient (i.e. all included patients)
89011488|NCT01643356|Active Comparator|Fiber Cereal|Women assigned to this arm will receive the group based behavioral intervention plus the recommendation to consume provided high fiber cereal to manage hunger.
89536666|NCT04491851|Experimental|LM3 group|In this arm, patients will undergo PET/CT using 68Ga-NODAGA-LM3 (40ug peptide/150-200MBq) and 68Ga-DOTA-LM3 (40ug peptide/150-200MBq) on two consecutive days. The scan will be acquired at 1hour post-injection.
89437424|NCT03939585|Experimental|NK/γδ T cell-enriched cell therapy product|"This study will treat 10 participants with the donor NK/TCR-γδ T cell product. Of those 10 participants, 5 would have 10/10 HLA matched sibling donors (MSD) while 5 would have partially matched, related (haplo) donors.~27 days post transplant, the participant's donor will undergo a second, non-mobilized leukapheresis to obtain peripheral blood mononuclear cells (PBMCs).~Donor PBMCs will be processed next day (Day T+28) to obtain the NK cell/TCRγδ T cell product for same day infusion if the participant remains aGVHD free and clinically stable.~Participants will continue routine post-transplant and GVHD monitoring, as well as disease assessment at 56 days, 100 days, 6 months and 1 year following transplant.~Blood samples will be obtained on T=0, T+7, 14, 21 and 28 days and then weekly until T + 56 days, then on T+100 days, + 6 months and + 12 months. If immune-mediated adverse events occur (GVHD, CRS etc) additional blood samples will be obtained at onset and resolution."
89437425|NCT03938103|Experimental|Enhanced Go NAPSACC|Enhanced delivery model
89437426|NCT03938103|Active Comparator|Basic Go NAPSACC|Basic delivery model
89437427|NCT03937752||Anal fistula|Patients with anal fistulas, no previous fistula procedures. Ultrasound investigation done as a part of surgical treatment, such as loose seton or fistulotomy.
89437428|NCT03930732|Experimental|Dupilumab|Participants received dupilumab 300 mg administered as SC injections q2w up to a maximum of 52 weeks (last dose administered at Week 50, EOT visit occurred 2 weeks after last administration of treatment i.e., at Week 52).
88921896|NCT06112392|Experimental|Parkinson's disease group|"Diagnostic criteria: Patients with Parkinson's disease who met the diagnostic criteria for MDS as probable PD or confirmed PD in 2016~Inclusion criteria:~Age 40-85;~Patients with Parkinson's disease who met the diagnostic criteria of MDS as probable PD or confirmed PD in 2016;~The patient or his/her legal guardian agrees to participate in the study and signs the informed consent;~Hoehn-yahr (H&Y) 3 ~ 5;"
89437429|NCT03930732|Placebo Comparator|Placebo|Participants received placebo matched to dupilumab 300 mg as subcutaneous (SC) injections q2w up to a maximum of 52 weeks (last dose administered at Week 50, end of treatment [EOT] visit occurred 2 weeks after last administration of treatment i.e., at Week 52).
89437430|NCT03928626|Active Comparator|CRAVING REGULATION|"In the CRAVING REGULATION condition, participants will first read a brief essay about the adverse consequences of drinking alcohol. Then, participants may complete a comprehension check consisting of questions to ensure that they understood and encoded the content of the essays. Participants will be trained to use the information to inform the strategy they will use in the regulation of craving training (ROC-T). A single trial in the regulation of craving training will have two possible instructions: (a) STRATEGY: implement the strategy (bring to mind the negative facts from the essay) and (b) LOOK: to merely observe the image and allow natural responses to come. Participants will follow the instructions; followed by an alcohol-related picture, a brief delay, and will then rate their craving. Participants will then be instructed to use this strategy in daily life situations when they might drink."
89437431|NCT03928626|Placebo Comparator|CONTROL (NO REGULATION)|In the CONTROL condition, participants will first read a brief essay about a non-alcohol-related topic (e.g., color perception). Then, participants will complete a comprehension check consisting of questions to ensure that they understood and encoded the content of the essays. Participants will view images of objects that are unrelated to alcohol. Furthermore, participants in the control condition will not practice any strategy in the regulation of craving task (ROC-T). That is, in the CONTROL condition, participants would merely observe the image and allow natural responses to come (i.e., LOOK instruction) and rate how colorful is each item (this controls for task time and experiment setting).
89437432|NCT03924193|Active Comparator|LDX|
89437433|NCT03924193|Active Comparator|Cognitive-Behavioral Therapy|
89536667|NCT04491851|Experimental|NODAGA group|In this arm, patients will undergo PET/CT using 68Ga-NODAGA-LM3 (40ug peptide/150-200MBq) and 68Ga-NODAGA-JR11 (40ug peptide/150-200MBq) on two consecutive days. The scan will be acquired at 1hour post-injection.
88921897|NCT06112392|Experimental|Non-parkinson's disease group|"Exclusion criteria:~Allergic to local anesthetic drugs;~Unable to cooperate with motor or non-motor function monitoring;~Patients with Parkinson's superposition syndrome, such as cortical basal ganglia degeneration, lewy body dementia, multisystem atrophy and progressive supranuclear palsy, were excluded; Patients with secondary Parkinson's disease, such as vascular Parkinson's disease, drug toxicity or traumatic Parkinson's disease;~Refuse to sign the consent form."
88921898|NCT06110897|Experimental|High Dose Resistance Exercise Training|Participants will complete a 16-week, twice/week progressive program beginning at a moderate intensity. Each session will last ~60 minutes and begin and end with a 5-minute warm-up/cool-down. Training will begin with standard familiarization sessions to introduce participants to the machines, teach correct lifting techniques, and ensure participant safety and comfort with each exercise machine. Participants will perform 3 sets of 8-12 repetitions on 9 different machines (i.e., leg press, hamstring curl, quadriceps extension, chest press, lat pulldown, shoulder press, biceps curl, triceps extension) and one body weight/free-weight abdominal exercise. Workload will begin at 60% of estimated 1-RM and will systematically and progressively increase during the intervention.
88921899|NCT06110897|Active Comparator|Low Dose Resistance Exercise Training|Participants will complete a 16-week, twice/week progressive program beginning at a low intensity. Each session will last ~60 minutes and begin and end with a 5-minute warm-up/cool-down. Training will begin with standard familiarization sessions to introduce participants to the machines, teach correct lifting techniques, and ensure participant safety and comfort with each exercise machine. Participants will perform 3 sets of 8-12 repetitions on 9 different machines (i.e., leg press, hamstring curl, quadriceps extension, chest press, lat pulldown, shoulder press, biceps curl, triceps extension) and one body weight/free-weight abdominal exercise. Workload will begin at 30% of estimated 1-RM and will systematically and progressively increase during the intervention.
88921900|NCT06105853|Experimental|Experimental|"All participants will be exposed to the Trier Social Stress Test, followed by an alcohol cue-exposure in a barlab environment and functional magnetic resonance imaging assessing neural alcohol cue-reactivity, inhibition performance, emotion processing and resting state functional connectivity twice on two consecutive days.~Interventions:~Behavioral: Trier Social Stress Test~Behavioral: Cue-Exposure to the favorite drink in a barlab setting"
89437434|NCT03924193|Active Comparator|LDX and Cognitive Behavioral Therapy|
89437435|NCT03921502|Experimental|ERCP with sphincterotomy + gall bladder drainage with LAMS|An ERCP with biliary sphincterotomy will be performed. The performance of other techniques (balloon extraction, dilation, placement of biliary prosthesis ...) is at the expense of the endoscopist. After this, transmural drainage of the gallbladder will be performed by placing a LAMS Axios (Boston Scientific) usually 15x10 mm or 10x10 mm to allow direct cholecystoscopy with a conventional gastroscope or transnasal gastroscope. The placement of the drainage will be performed in the same endoscopic act, by means of an Olympus® sectorial echoendoscope, assisted with X-rays, which allows puncturing the vesicle from the gastric antrum or the duodenal bulb to generate a cholecysto-gastrostomy or cholecysto-duodenostomy respectively. After the puncture of the vesicle from the most optimal anatomical point, it will be tutored with guidance and a Hot Axios® PAL will be placed on it to generate the anastomosis between the aforementioned structures.
89437436|NCT03921502|Active Comparator|ERCP with sphincterotomy|An ERCP with biliary sphincterotomy will be performed. The performance of other techniques (balloon extraction, dilation, placement of biliary prosthesis ...) is at the expense of the endoscopist.
89437437|NCT03919981||nephropathic cystinosis patients receiving cysteamine|nephropathic cystinosis patients receiving cysteamine. The blood samples of the group will be used to evaluate the action of cysteamine on osteoclastic differentiation and resorption activity of NC patients, depending on the underlying genotype.
88921901|NCT06102941|Experimental|Cognitive Training for Obsessive-Compulsive Disorder|This is an open-label, one-arm study. Children who meet DSM-V diagnostic criteria for OCD and have clinically significant obsessive-compulsive symptoms (CY-BOCS score>16) will complete 4-weeks of at-home cognitive training.
88921902|NCT06101472||Pseudophakic subjects implanted with the ASQELIO toric IOL|Adult subjects undergoing cataract surgery by routine clinical practice with ASQELIO Toric Biaspheric Monofocal Lens in at least one eye.
88921903|NCT06100614|Experimental|Presepsin-guided therapy|The decision to start empirical antibiotics in this group will be based on presepsin measurement within four hours after birth. When the presepsin value is above the cut-off value of 645 pg/ml, antibiotics will be ordered and administered within 4 hours of life and discontinued following the criteria of the Dutch EOS guideline. When the presepsin level is below the cut-off value of 645 pg/ml, the treating physician will not start antibiotic treatment. These infants will be closely observed for at least 72 hours. In case of deterioration of the clinical condition within this observation period, the clinician can decide to perform a sepsis evaluation and start with antibiotic treatment.
88921904|NCT06100614|Active Comparator|Standard care|Standard care according to the Dutch EOS guideline. Presepsin will be determined with the treating physician blinded for the test result. In the Dutch EOS guideline maternal and neonatal risk factors for EOS are categorized as red flags or minor criteria. In the presence of 1 red flag or ≥ 2 minor criteria it is advised to perform a blood culture (= sepsis evaluation) and start empirical antibiotics for EOS suspicion. Antibiotic treatment will be advised to discontinue when blood culture turns back negative, reassuring the infants clinical condition with no other indicators of possible infection (e.g. CRP).
88921905|NCT06092801||Individuals suspected of coronary artery disease|Individuals suspected of coronary artery disease and referred for evaluation
88921906|NCT06092580|Experimental|AWT020|Participants receiving intravenous infusion of AWT020
88921907|NCT06089850|Experimental|HSC donors|Completion of questionnaires + socio-demographic data
88921908|NCT06089460|Experimental|Beef|Individuals will be asked to consume beef as their only source of protein and follow an individualized meal plan for 4 weeks. Thereafter, they will be instructed to continue beef consumption with any other foods desired for 4 weeks.
88921909|NCT06089460|Experimental|Meat analogue|Individuals will be asked to consume a commercial meat analogue product as their only source of protein and follow an individualized meal plan for 4 weeks. Thereafter, they will be instructed to continue the meat analogue consumption with any other foods desired for 4 weeks.
88921910|NCT06089460|Experimental|Beans/legumes|Individuals will be asked to consume beans/legumes as their only source of protein and follow an individualized meal plan for 4 weeks. Thereafter, they will be instructed to continue the bean/legume consumption with any other foods desired for 4 weeks.
88921911|NCT06077461|Experimental|Experimental:mandala painting|Patients in this group will be subjected to mandala painting.
88921912|NCT06077461|No Intervention|Control|Patients in this group will not be subjected to mandala painting.
88921913|NCT06074458|No Intervention|Standard of Care|Participants in this arm follow standard of care procedures.
89011489|NCT01643356|No Intervention|Control Group|Women assigned to this arm of the study will receive routine clinical care and no additional interventions.
88922278|NCT05557396|Experimental|GWNUF|"Gender-weight-nose-umblikus-head flat (GWNUF), (n=31)~The patient's body weight will be measured without clothes on, When the patient is in the supine position, the distance between the tip of the nose and the umbilicus will be measured, The length of the nasogastric tube to be applied to the patient according to the formula 29.38 + (4.53 x gender) + (0.34 x distance between the tip of the nose and the umbilicus) - (0.06 x patient weight), (gender = 1 for male patient, 0 for female patient) to be determined, The length determined according to the result obtained will be marked on the nasogastric tube, The nasogastric tube will be advanced by the researcher from the patient's nose to the point where the marking is made, Immediately after the completion of the insertion procedure, an abdominal X-ray will be taken to confirm the tube location, the position of the distal end of the tube relative to the gastro-esophageal junction will be measured and recorded."
88922279|NCT05557396|Experimental|EXU-NE|The distance between the patient's xiphoid and earlobe will be measured first (Measurement 1), (n=31) The distance between the patient's xiphoid and the midline of the umbilicus will be measured (Measurement 2), The two obtained measurement values will be added (Measurement 1 + Measurement 2), The distance between the patient's nose tip and earlobe will be measured (Measurement 3), Measurement 3 value will be subtracted from the sum of Measurement 1 and Measurement 2 values, The length determined according to the result obtained will be marked on the nasogastric tube, The nasogastric tube will be advanced by the researcher from the patient's nose to the point where the marking is made, Immediately after the completion of the insertion procedure, an abdominal X-ray will be taken to confirm the tube location, the position of the distal end of the tube relative to the gastro-esophageal junction will be measured and recorded.
88922280|NCT05556187|No Intervention|Usual fixed oxygen dose|"The oxygen dose will be as usual.~The patient's activity level will be monitored using SENS.~The patient will be asked to wear a wrist pulse oximeter to monitor pulse rate and saturation."
88922281|NCT05556187|Experimental|Automated oxygen titration|"The O2matic equipment will be installed in the home of the patients. The SpO2-target will be set at 90-94%~The patient's activity level will be monitored using SENS.~The patient will be asked to wear a wrist pulse oximeter to monitor pulse rate and saturation and send the information to O2matic. O2matic will adjust the oxygen flow between 0.5-8 l/min according to the algorithm in the devise aiming at the SpO2-target interval.~The patients will use their usual portable oxygen devises for use when being active outdoor. They are allowed a higher oxygenflow if needed."
88922282|NCT05542446|Experimental|Critically ill patients with ECMO|The subjects connected to ECMO will be treated with colistin ain approved dosing - a loading dose of 9 MIU intravenously over 30 minutes followed after 12 hours by a maintenance dose of 4,5 MIU intravenously over 30 minutes every 12 hours. Only in patients requiring continuous renal replacement methods will the interval of the maintenance doses be 8 hours.
88922283|NCT05542446|Active Comparator|Critically ill patients without ECMO|The subjects not connected to ECMO will be treated with colistin ain approved dosing - a loading dose of 9 MIU intravenously over 30 minutes followed after 12 hours by a maintenance dose of 4,5 MIU intravenously over 30 minutes every 12 hours. Only in patients requiring continuous renal replacement methods will the interval of the maintenance doses be 8 hours.
88922284|NCT05541640|Placebo Comparator|control group|
88922285|NCT05541640|Active Comparator|lidocaine group|
89538421|NCT02459015|Experimental|Reaxon® Nerve Guide|Implantation of Reaxon® Nerve Guide: If the subject is randomized to the Reaxon® Nerve Guide group, the surgeon will implant a Reaxon® Nerve Guide of ≤ 30 mm to bridge a nerve defect of ≤ 26 mm according to the method described in the instructions for use.
88922288|NCT05532813|Experimental|Metformin arm|Patients randomized in Metformin arm will take metformin orally.
88922289|NCT05532813|Placebo Comparator|Placebo receivers|Patients randomized in placebo arm will take placebo orally in the same procedure as metformin taken.
88922290|NCT05504070|Experimental|GSV/SSV|Incompetent Great and Small Saphenous Veins
88922291|NCT05504070|Experimental|IPV|Incompetent Perforator Veins
88922292|NCT05492344|Experimental|Personalized ventilation|If a patient is assigned to the intervention group, ventilator settings will be adjusted based on the lung morphology (focal or non focal) results of the lung ultrasound.
88922293|NCT05492344|Active Comparator|Standard care|Patients assigned to the control group will be ventilated according to the current standard of care.
88922294|NCT05488938|Experimental|Immediate intervention (Group 1)|Group 1 will start the rehabilitative intervention immediately after the first evaluation (T1) and carry it out for 10 months with remote supervision until the second evaluation meeting (T2). Then they will be invited to continue the intervention for the next 10 months (between T2 and T3) until the third evaluation meeting but without remote supervision.
88922295|NCT05488938|Experimental|Delayed intervention (Group 2)|Group 2 will not conduct the rehabilitative intervetion between T1 and T2. They will start the rehabilitative intervention immediately after the second evaluation (T2) and carry it out for 10 months with remote supervision until the third evaluation meeting (T2).
88922296|NCT05485753|Experimental|Study treatment|Participants receive GNC-038 as intravenous infusion for the first cycle (2 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
88922297|NCT05478993|Experimental|Selinexor, pomalidomide and dexamethasone|Patients diagnosed with multiple myeloma with CNS involvement to receive SPD treatment.
88922298|NCT05471349|Active Comparator|Hope message|Participants will view a hope-based video message and flyer.
88922299|NCT05471349|Active Comparator|Fear message|Participants will view a fear-based video message and flyer.
88922300|NCT05471349|Placebo Comparator|Control message|Participants will view a water advertisement video and flyer.
88922301|NCT05470348|Experimental|BL-B01D1|Participants receive BL-B01D1 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
88922302|NCT05464407|Experimental|Cubitan|2 x oral nutritional supplement daily
88922303|NCT05464407|No Intervention|Usual care|usual care
88922304|NCT05463029||Healthy Controls|Healthy control participants will be recruited from the general population through the use of flyers and other means of advertising.
88922305|NCT05463029||Affected Patients|Research staff locate eligible patients in the hospital through real-time medical record review at the time of initial presentation to the NICU or request for neurology consultation for patients in the MICU or CCU. Once potential patients have been identified, research staff will approach their Legally Authorized Representative to introduce the study and initiate the informed consent process, if appropriate.
88922306|NCT05461768|Experimental|Study treatment|Participants receive BL-M07D1 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
89199207|NCT05953779|Experimental|Personalized Intervention|"The intervention approach taken in this RCT is focused on unmet psychological needs (predictability, belonging, competence, self-worth, autonomy, and playfulness). For each need, a specific 90-minute intervention has been developed.~The primary unmet need for each individual will be determined by a conditional entropy algorithm. Simply, the presence versus absence of subjective distress will be measured eight times per day for 30 days. Concurrently, the presence versus absence of need frustration will also be measured eight times per day for 30 days. Utilizing a k-fold cross-validated estimation, conditional entropy will be used to determine the need that best reduces the uncertainty in subjective distress (that is, best explains its presentation probabilistically).~At both sites, the experimental condition will consist of an algorithmically-chosen intervention. The choice will be made based on data collected during thirty days of ecological momentary assessment."
89199208|NCT05953779|Active Comparator|Non-personalized Intervention|"The intervention approach taken in this RCT is focused on unmet psychological needs (predictability, belonging, competence, self-worth, autonomy, and playfulness). For each need, a specific 90-minute intervention has been developed.~At the BIU site, the active control condition will consist of an intervention chosen randomly (out of the six mentioned above).~At the UCB site, the active control condition will consist of a standard intervention addressing emotion regulation difficulties."
89199209|NCT05953727|Experimental|Low level laser therapy with proprioceptive stimulation|Patients will be treated with low level laser therapy and proprioceptive stimulation will also be given.
89199210|NCT05953727|Active Comparator|Low level laser therapy without proprioceptive stimulation|Patients will be treated with low level laser therapy only.
89199211|NCT05953714|Experimental|CHLORHEXIDINE GLUCONATE GROUP|Section area is cleaned with preoperative application chlorhexidine gluconate
89199212|NCT05953714|No Intervention|POVIDONE IODINE GROUP|Section area is cleaned with preoperative application povidone iodine
89199213|NCT05953714|Experimental|CHLORHEXIDINE GLUCONATE SHOWER GROUP|Section area is cleaned with preoperative application chlorhexidine gluconate shower
89199214|NCT05953675|Active Comparator|Control arm|Standard procedure of isotonic saline with heparin as lock-solution
89199215|NCT05953675|Experimental|Intervention arm|3 mL of 70% ethanol as lock-solution
89199216|NCT05953649|Active Comparator|Control group|In the control condition, patients received conventional physiotherapy (CPT) according to standard clinic procedures.
88922307|NCT05455112|Experimental|RUTI|Single injection of RUTI 25µg of FCMtb at day 0.
89199217|NCT05953649|Experimental|experimental group 1|the experimental group uses Extracorporeal Diaphragm Pacing (EDP) on the basis of the control group.
89199218|NCT05953649|Experimental|experimental group 2|the experimental group used Extracorporeal Diaphragm Pacing (EDP) combined with Tilt Table Verticalization (TTV) on the basis of the control group.
89199219|NCT05953623|Experimental|Intra-arterial albumin infusion|
89199220|NCT05953571||GroupA|Laparoscopic assisted dismembered pyeloplasty in poorly function kidney
89199221|NCT05953571||Group B|Open dismembered pyeloplasty in poorly function kidney
89501605|NCT02392689|No Intervention|Standard of Care|Blood samples are taken on day 0 and day 1 and stored for later analysis. The investigator treats the patients according to standard of care.
89501606|NCT02150291|Active Comparator|Group A|one capsule of 5 mg of Folic acid twice daily and a tablet of Neurobion three times per day during hepatitis C treatment
88922308|NCT05455112|Placebo Comparator|Placebo|Single injection of saline at day 0.
88922309|NCT05453474|Experimental|WGA|DNA from the cells are amplified by whole genome amplification prior to genetic testing.
88922310|NCT05453474|No Intervention|No-WGA|DNA from the cells are tested directly without whole genome amplification
88922311|NCT05451017|Experimental|AEF0117 1.0 mg in fasted condition|16 participants receive 1 dose of AEF0117 1 mg in fasted condition
88922312|NCT05451017|Experimental|AEF0117 1.0 mg once daily (QD) in fed condition|16 participants receive 1 dose of AEF0117 1 mg fed condition
88922313|NCT05441605|Experimental|First group|1% chlorhexidine, n=24 patients.
88922314|NCT05441605|Experimental|Second group|2% chlorhexidine, n=24 patients.
88922315|NCT05441605|Experimental|Third group|4% chlorhexidine, n=24 patients.
88922316|NCT05441605|Other|Fourth group|control group, 70% iso-propyl alcohol, n=24 patients.
88956392|NCT05405660|Placebo Comparator|Placebo Comparator in patients with Symptomatic Dermographism|Placebo injection subcutaneous every 4 weeks for 20 weeks
89437602|NCT03514459|Experimental|Intervention with SAIA|Clinics randomized to the intervention arm will be introduced to the five steps of SAIA by study staff. The cascade analysis will be performed within the FP clinic to identify drop-offs in cervical cancer screening and referrals, using an Excel-based tool adapted from previous SAIA trials. Flow mapping performed by clinic and study staff will describe the cervical cancer screening process including who the client interacts with, timing of these interactions, any cervical cancer screening performed, and any referrals made. Initial drafts will be reviewed together with clinic and study stuff to ensure adequate and complete representations of processes. Study staff will work with clinic staff to identify bottlenecks in the process and potential solutions to improve flow. Proposed solutions will be implemented, and the process will be examined again to determine the effect of the implemented changes. The cycle will be repeated approximately every 6-8 weeks during the RCT.
89437603|NCT03501368|Experimental|Trametinib + Ceritinib Treatment|Study treatment will be given in cycles. Each cycle will be 4 weeks (28 days). Post-Treatment (follow-up) Period: Participants will return to the study site between 30-40 days after the last dose of trametinib + ceritinib for an end-of-treatment assessment. Additional follow-up will occur for related Adverse Events (AEs) that are not resolved by this time and related Serious Adverse Events (SAEs) that occur after the time of this visit. Participants will be followed for survival every 3 months for the first year following end of treatment, and then every 6 months for up to 5 years after end of treatment.
89437604|NCT03491761|Experimental|PRP Treatment|PRP is injected using 22 gauge needles through the classic approach (lateral midpatellar) in a sterile setting. The PRP is obtained from a maximum 16 cc sample of the patients' blood drawn at the time of treatment. Using sterile technique, the venous blood is transferred to a centrifuge and prepared by the centrifugation process for 5 minutes. 4-7 mL of PRP is transferred from the large outer syringe into the small inner syringe and injected within 30 minutes of being spun to negate the need of anticoagulants. The procedure will take approximately 20-30 minutes.
89437605|NCT03491761|Active Comparator|HA Treatment|HA is injected using 22 gauge needles through the classic approach (lateral midpatellar) in a sterile setting. Euflexxa will be prepared according to the package insert.
89437606|NCT03483662|Experimental|Multicomponent Intervention|Protocol-based treatment using the SPRINT stepped-care intensive BP management algorithm, dissemination of SPRINT study findings among provider-teams, patients, and administrators, team-based collaborative care, BP audit and feedback, home BP monitoring, and health coaching on antihypertensive medication adherence and lifestyle modification
89437607|NCT03483662|Active Comparator|Enhanced Usual Care|Webinar education session for providers on the new ACC/AHA hypertensive clinical guideline and the SPRINT study findings
89437608|NCT03481023|Experimental|Esophageal thermal regulation device|
89437609|NCT03481023|Active Comparator|LET monitoring|
89437610|NCT03477175|Experimental|Cohort A : Lenvatinib|The roll-over eligible participants from Eisai-sponsored lenvatinib studies who received lenvatinib monotherapy or who crossed over from a comparator arm to receive lenvatinib monotherapy in their parent study will continue to receive lenvatinib monotherapy.
89437611|NCT03477175|Experimental|Cohort B: Lenvatinib plus Comparator drug|The roll-over eligible participants from Eisai-sponsored lenvatinib studies who received lenvatinib combination therapy or who crossed over from a comparator arm to receive lenvatinib combination therapy in their parent study will continue to receive lenvatinib combination therapy.
89501607|NCT02150291|Active Comparator|Group B|Patients will receive one capsule of 5 mg of Folic acid twice daily during hepatitis C treatment
89501608|NCT02150291|Active Comparator|Group C|Patients will receive a tablet of Neurobion three times per day during hepatitis C treatment
89501609|NCT02150291|Placebo Comparator|Group D|Patients will receive matching placebo capsule to take during hepatitis C treatment
88956393|NCT05405660|Experimental|barzolvolimab 150 mg in patients with Chronic Inducible Cold Urticaria|barzolvolimab 150 mg injection subcutaneous every 4 weeks for 20 weeks
88956394|NCT05405660|Experimental|barzolvolimab 300 mg in patients with Chronic Inducible Cold Urticaria|barzolvolimab 300 mg injection subcutaneous every 8 weeks for 20 weeks
88956395|NCT05405660|Placebo Comparator|Placebo Comparator in patients with Chronic Inducible Cold Urticaria|Placebo injection subcutaneous every 4 weeks for 20 weeks
88956396|NCT05398263|Experimental|Tezepelumab|Tezepelumab subcutaneous injection, in an accessorised pre-filled syringe.
88956397|NCT05398263|Placebo Comparator|Placebo|Placebo subcutaneous injection, in an accessorised pre-filled syringe.
88956400|NCT05389410|Experimental|Revision Hip surgery|Participants will be randomised to PICO 7 or PICO 14 intervention.
88956401|NCT05389410|Active Comparator|Revision knee surgery|Participants will be randomised to PICO 7 or PICO 14 intervention.
88956402|NCT05385783|Experimental|A: MDD Participants - CYB003 in 2 of 2 Medicine Sessions|Arm A MDD participants will receive CYB003 in 2 of 2 medicine sessions, approximately three weeks apart. The CYB003 dose received will depend on the cohort/time of enrollment. All MDD participants will receive supportive EMBARK psychotherapy throughout the study.
88956403|NCT05385783|Placebo Comparator|B: MDD Participants - Placebo in Medicine Session 1, CYB003 in Medicine Session 2|Arm B MDD participants will receive placebo in Medicine Session 1, and approximately three weeks later will receive CYB003 in Medicine Session 2. The CYB003 dose received will depend on the cohort/time of enrollment. All MDD participants will receive supportive EMBARK psychotherapy throughout the study.
88956404|NCT05385783|Experimental|C: Healthy Volunteers - CYB003 in 2 of 2 Medicine Sessions|Arm C healthy volunteers will receive CYB003 in 2 of 2 medicine sessions, approximately one to two weeks apart. The CYB003 dose received will depend on the cohort/time of enrollment. All healthy volunteers will receive psychological support throughout the study.
88956405|NCT05385783|Placebo Comparator|D: Healthy Volunteers - Placebo in Medicine Session 1, CYB003 in Medicine Session 2|Arm D healthy volunteers will receive placebo in Medicine Session 1, and approximately one to two weeks later will receive CYB003 in Medicine Session 2. The CYB003 dose received will depend on the cohort/time of enrollment. All healthy volunteers will receive psychological support throughout the study.
88956406|NCT05385783|Experimental|E: Healthy Volunteers - CYB003 in 3 of 3 Medicine Sessions|Arm E healthy volunteers will receive CYB003 in 3 of 3 medicine sessions, approximately one week apart from each other, to assess bioavailability and food effect. The CYB003 dose received will depend on the safety review committee selection/time of enrollment. All healthy volunteers will receive psychological support throughout the study.
88821723|NCT02408406|Active Comparator|Arm II (usual care)|Patients receive usual care, including a one-time use of SupportScreen, a touchscreen questionnaire system that identifies patient issues before appointments, at the clinic during the first treatment consultation after diagnosis. Consultation, printed education materials, and specialist referrals may be generated based on SupportScreen responses.
88956407|NCT05384769|Experimental|Cohort A (liquid biopsy, optional LDCT)|Participants undergo collection of blood sample (liquid biopsy), with option to undergo LDCT if liquid biopsy results are positive.
89199222|NCT05953519|Experimental|Unified Protocol intervention|The Unified Protocol consists of 12-weeks, virtual, group sessions focused on reducing depression and anxiety through: (1) Increasing emotional awareness; (2) Cognitive restructuring against dysfunctional beliefs; (3) Changing action tendencies associated with disordered emotions; (4) Preventing emotional avoidance and utilizing emotion exposure techniques; (5) Providing mutual help among group members; and (6) Providing opportunities for corrective experiences.
89199223|NCT05953519|No Intervention|Control group|The control group will not receive any intervention and will complete the same baseline and follow-up assessments.
89199224|NCT05953506|Experimental|HS-10506|Healthy participants will be enrolled in dose escalation cohorts. Healthy participants will be receive either HS-10506 or matching placebo on Day 1.
89199225|NCT05953506|Experimental|HS-10506 Placebo|Healthy participants will be enrolled in dose escalation cohorts. Healthy participants will be receive either HS-10506 or matching placebo on Day 1.
89199226|NCT05953493||GKS1|Patients with a Glasgow coma scale between 9 and 12
89199227|NCT05953493||GKS2|Patients with a Glasgow coma scale between 13 and 15
89199228|NCT05953454|Experimental|Group Pain Neuroscience Education|"A single face-to-face group session of approximately 60-80 minutes provided through active participation. Five key domains will be structured from the Fear and Belief Avoidance Questionnaire that will serve as a guide for the sessions through a Powerpoint presentation. In addition, participants will be encouraged to be active by walking for 20-30 minutes 3-5 times a week and will be taught an exercise to improve transverse abdominis activation (abdominal corset or follow-through).~With the main ones, a brochure will be delivered and informative capsules will be made to which the participants will have access (5 videos of 15 minutes, one per domain). Participants will be instructed to record on a calendar the days they read the brochure and/or reviewed the information capsules to assess treatment compliance and for each domain invent a metaphor or script for how they would explain it to another person. This activity must be delivered in the second evaluation."
89199229|NCT05953454|Experimental|Individual Pain Neuroscience Education|"A single one-on-one face-to-face session of approximately 60-80 minutes provided through active participation. Five key domains will be structured from the Fear and Belief Avoidance Questionnaire that will serve as a guide for the sessions through a Powerpoint presentation. In addition, participants will be encouraged to be active by walking for 20-30 minutes 3-5 times a week and will be taught an exercise to improve transverse abdominis activation (abdominal corset or follow-through).~With the main ones, a brochure will be delivered and informative capsules will be made to which the participants will have access (5 videos of 15 minutes, one per domain). Participants will be instructed to record on a calendar the days they read the brochure and/or reviewed the information capsules to assess treatment compliance and for each domain invent a metaphor or script for how they would explain it to another person. This activity must be delivered in the second evaluation."
89199230|NCT05953454|No Intervention|Control|no intervention
89199231|NCT05953441|Experimental|AI-powered group|Participants participated in a 2-hour Virtual Reality Simulation (VRS), which consisted of 2 simulation scenarios. Participants had to perform nursing assessment and management of virtual patient, followed by communicating with an AI virtual doctor.
89199232|NCT05953441|Active Comparator|Human-controlled group|Participants participated in a 2-hour Virtual Reality Simulation (VRS), which consisted of 2 simulation scenarios. Participants had to perform nursing assessment and management of virtual patient, followed by communicating with a doctor avatar controlled by the medical student.
89536907|NCT03307421|Other|debriefing with instructor|"The team debriefing with an instructor will begin immediately after the simulator run and will be governed by the principle of no judgment described by Rudolph .~A portion of the video of the participants' pass may be reviewed and used to support the debriefing (depending on the utility judged by the debrief). Each center will use its own team of trainers, but it will have a predefined plan and predefined objectives, which are provided in advance in order to obtain a standardized debriefing. Moreover, these trainers will not be beginners but will have some expertise in the pedagogy of simulation. They will have to have a DU in a simulation or pedagogy trainer (recommendations from SofraSim) and will have to carry out 15 debriefings per year"
89536908|NCT03311399|Experimental|Home Visit|"Individuals in Arm 1 will be visited at home by the sCHW who will administer the optimized SSI protocol via the mHealth device. Intervention: SSI Screening Tool used in home visits by CHWs"
89536909|NCT03311399|Experimental|Phone Call|"Individuals in Arm 2 will be phoned by the sCHW who will administer the SSI protocol over the phone. Intervention: SSI Screening Tool used via phone call follow-up"
88821724|NCT02386774|Other|an ocular or ocular adnexa disease|patient presenting with an ocular or ocular adnexa disease in the Dermatology or Ophthalmology ward.
88821725|NCT02386774|Other|diabetic patients|
88821726|NCT02354963|No Intervention|Control arm|No intervention is performed. Assessment of antral follicle count. IVF treatment.
88821727|NCT02354963|Experimental|Experimental arm|"Perform intervention described: Laparoscopy. In vitro fragmentation of the ovarian tissue.~Assessment of antral follicle count. IVF treatment."
88821728|NCT02333227|No Intervention|Control|Cluster of sites not receiving xylitol gum. This is a cluster randomized trial, whereby 4 sites will not receive the intervention of xylitol gum in the prepregnancy and early pregnancy interval.
88821729|NCT02333227|Experimental|Xylitol|Cluster of sites receiving xylitol gum.
89199233|NCT05953402||Ozanimod-exposed participants with UC|Pregnant women with a diagnosis of UC who are exposed to ozanimod at any time during pregnancy
89199234|NCT05953402||Conventional therapy-exposed participants with UC|Pregnant women with a diagnosis of UC who are exposed to conventional therapies (aminosalicylates and/or thiopurines) but not exposed to ozanimod, other S1P therapies, or advanced therapies for UC (biologics and/or small molecules) at any time during pregnancy
89536910|NCT03311399|No Intervention|Standard of Care|Individuals in Arm 3 will not have any additional contact beyond standard of care.
89536911|NCT03307265|Experimental|Imbalance correction|
88956408|NCT05384769|Experimental|Cohort B (LDCT, optional liquid biopsy)|Participants undergo low dose CT with optional liquid biopsy on the same day as LDCT.
88956409|NCT05378347|Experimental|Medtronic Endurant II/IIs|Subjects are randomized on a 1:1 basis to receive an EVAR procedure with either a Medtronic Endurant II/IIs endoprothesis or Gore's Excluder / Excluder Conformable.
89536912|NCT03307265|Active Comparator|Control|
89536913|NCT03311321|Placebo Comparator|Placebo-Control|The placebo-control group will take four placebo softgel capsules (similar in taste and appearance to the vitamin K2 supplements) every day for 8 weeks.
89536914|NCT03311321|Experimental|Vitamin K2 (360-mcg/d)|The experimental group will take four 90-mcg of vitamin K2 (menaquinone-7; 360-mcg) softgel capsules every day for 8 weeks.
89536915|NCT03311243|Experimental|β-Thalassemia major (TM- β)|
89536916|NCT03311243|Active Comparator|Systemically healthy controls|
88956410|NCT05378347|Experimental|Gore Excluder / Excluder Conformable|Subjects are randomized on a 1:1 basis to receive an EVAR procedure with either a Medtronic Endurant II/IIs endoprothesis or Gore's Excluder / Excluder Conformable.
88956411|NCT05377528|Experimental|Dose Escalation: AGEN1571|Participants will receive AGEN1571 monotherapy.
88956412|NCT05377528|Experimental|Dose Escalation: AGEN1571 + Balstilimab|Participants will receive AGEN1571 with balstilimab.
88956413|NCT05377528|Experimental|Dose Escalation: AGEN1571 + Botensilimab|Participants will receive AGEN1571 with botensilimab.
88956414|NCT05377528|Experimental|Dose Escalation: AGEN1571 + Balstilimab + Botensilimab|Participants will receive AGEN1571 with balstilimab and botensilimab.
88956415|NCT05377528|Experimental|Dose Expansion|AGEN1571 administered at the RP2D for monotherapy or any combination therapy.
88956416|NCT05375136||All Participants|Participants who are prescribed with lenvatinib/pembrolizumab combination per approved prescribing information of lenvatinib and pembrolizumab in the post marketing setting will be enrolled and observed for up to 48 weeks or until clinical benefit or unacceptable toxicity occurs or discontinuation of therapy due to any reason, whichever occurs first.
88956418|NCT05368285|Experimental|barzolvolimab 75 mg then 150 mg|barzolvolimab 75 mg injection subcutaneous every 4 weeks for 16 weeks and then 150 mg injection subcutaneous every 4 weeks for 36 weeks
88956419|NCT05368285|Experimental|barzolvolimab 75 mg then 300 mg|barzolvolimab 75 mg injection subcutaneous every 4 weeks for 16 weeks and then 300 mg injection subcutaneous every 8 weeks for 36 weeks
88956420|NCT05368285|Experimental|barzolvolimab 150 mg|barzolvolimab 150 mg injection subcutaneous every 4 weeks for 52 weeks
88956421|NCT05368285|Experimental|barzolvolimab 300 mg|barzolvolimab 300 mg injection subcutaneous every 8 weeks for 52 weeks
88956422|NCT05368285|Experimental|Placebo then barzolvolimab 150 mg|Placebo injection subcutaneous every 4 weeks for 16 weeks and then barzolvolimab 150 mg injection subcutaneous every 4 weeks for 36 weeks
88956423|NCT05368285|Experimental|Placebo then barzolvolimab 300 mg|Placebo injection subcutaneous every 4 weeks for 16 weeks and then barzolvolimab 300 mg injection subcutaneous every 8 weeks for 36 weeks
88956424|NCT05365646|Experimental|Fall risk assessment|Participants will wear study hearing aids that are equipped with embedded sensors and artificial intelligence. This will help track their movement and signal if the participant falls or is at fall risk.
88956425|NCT05365646|Experimental|Speech intelligibility|Participants will wear study hearing aids that are equipped with embedded sensors and artificial intelligence. This will help track their movement and signal if the participant falls or is at fall risk.
88956426|NCT05365581|Experimental|Dose Escalation (Phase 1)|"A dose escalation design will be used to determine the Maximum Tolerated Dose (MTD) and/ or the Recommended Phase 2 Dose (RP2D) regimens to be further evaluated in the Dose Expansion arms.~Dose escalation part consists of six parts (Part A, B, C, D, E, and F), and up to 75 patients would be enrolled in total. Participants will be assigned to sequentially escalating dose cohorts of ASP2138 in each part. The study will open with the Part A dosing schedule, while subsequent cohorts will be opened sequentially or in parallel based upon sponsor review of emerging data."
88956427|NCT05365581|Experimental|Dose Expansion (Phase 1b) Gastric/GEJ cancer|Participants will receive ASP2138 at the RP2D regimens determined in Dose Escalation arm.
88956428|NCT05365581|Experimental|Dose Expansion (Phase 1b) Pancreatic cancer|Participants will receive ASP2138 at the RP2D regimens determined in Dose Escalation arm.
88956429|NCT05334472||Kesimpta|Patients or caregivers of patients administered Kesimpta
88956430|NCT05323097||Drowning-related OHCA|Drowning-related OHCA: YES
88956431|NCT05323097||All other OHCA|Drowning-related OHCA: NO
88956432|NCT05283265|Experimental|Intracranial patients|All participants with epilepsy undergoing intracranial monitoring for clinical purposes will be approached to participate in an experiment that is recording-only and an experiment that involves stimulation with simultaneous recording.
88956433|NCT05266495||Brolucizumab|patients who received their first injection of Brolucizumab either during the active recruitment period (1 year prospective) or during the 6 months pre-start of the recruitment (6 months retrospective)
88956438|NCT05247879|Active Comparator|Commercial reduced-osmolarity oral rehydration solution (ORS|
88956439|NCT05247879|Experimental|VS011, new children's ORS, a sugar-free blend of amino acids and electrolytes|
88956442|NCT05232838|Experimental|Treatment Arm|The Treatment Arm receives the eShunt Implant.
88956443|NCT05203341|Placebo Comparator|Placebo|Participants will receive placebo orally once a day.
88956444|NCT05203341|Experimental|NBI-1065845 Low Dose|Participants will receive low-dose NBI-1065845 orally once a day.
88956445|NCT05203341|Experimental|NBI-1065845 High Dose|Participants will receive high-dose NBI-1065845 orally once a day.
89199235|NCT05953402||Advanced therapy-exposed participants with UC|Pregnant women with a diagnosis of UC who are exposed to advanced therapies for UC (biologics and/or small molecules) but not exposed to ozanimod or other S1P therapies at any time during pregnancy
89199236|NCT05953389|Experimental|Pitolisant|One tablet of pitolisant 5 mg, two tablets of pitolisant 5 mg, one tablet of pitolisant 20 mg or two tablets of pitolisant 20 mg per day for 12 weeks.
88922317|NCT05432635|Experimental|Treatment (CMV-specific CD19-CAR T cells, triplex vaccine)|"CONDITIONING REGIMEN: Patients receive standard conditioning regimen (typically carmustine, etoposide, cytarabine, melphalan) beginning approximately on day -9 in the absence of disease progression or unacceptable toxicity.~TRANSPLANTATION: Patients undergo autoHSCT on day -2.~CAR T-CELLS AND VACCINATION: Patients receive CMV-specific CD19-CAR T cells IV on day 0 and CMV-MVA triplex vaccine IM on days 28 and 56 in the absence of disease progression or unacceptable toxicity."
88922318|NCT05426174|Experimental|Group 1 mRNA NA: Low dose Level|Participants will receive a low dose of mRNA vaccine
88922319|NCT05426174|Experimental|Group 2 mRNA NA: Medium dose level|Participants will receive a medium dose of mRNA vaccine
88922320|NCT05426174|Experimental|Group 3 mRNA NA: High dose level|Participants will receive a high dose of mRNA vaccine
88922321|NCT05426174|Active Comparator|Group 4: QIV-HD|Participants will receive QIV-HD (high dose quadrivalent influenza) vaccine
88922322|NCT05424367||NH Hispanic/Latino Adults|New Hampshire adults(at least 18 years of age) with cultural background in a Spanish-speaking Latin American country or territory surveyed between March 2021 - March 2022.
88922323|NCT05415358||Single Arm|Biomarkers and ctDNA data generated from patients with metastatic non-small cell lung carcinoma who have completed first line pembrolizumab monotherapy or pembrolizumab-platinum doublet combination therapy, and have, at immunotherapy discontinuation, completed at least 20 of an anticipated 24 months of pembrolizumab.
88922324|NCT05413005|Experimental|Group A (ECP regular-intensity arm)|ECP in a regular-intensity arm plus T1DM standard of care
88922325|NCT05413005|Experimental|Group B (ECP accelerated-intensity arm)|ECP in an accelerated-intensity arm plus T1DM standard of care
88922326|NCT05407779|Experimental|Cohort 1|"The Cohort 1 include one subject (sentinel volunteer) to receive BCD-180 at a dose 1"
88922327|NCT05407779|Experimental|Cohort 2|The Cohort 2 include 3 subjects to receive BCD-180 at a dose 2
88922328|NCT05407779|Experimental|Cohort 3|The Cohort 3 include 3 subjects to receive BCD-180 at a dose 3
88922329|NCT05407779|Experimental|Cohort 4|The Cohort 4 include 3 subjects to receive BCD-180 at a dose 4
88922330|NCT05407779|Experimental|Cohort 5|The Cohort 5 include 3 subjects to receive BCD-180 at a dose 5
88922331|NCT05407779|Experimental|Cohort 6|The Cohort 6 include 3 subjects to receive BCD-180 at a dose 6
88922332|NCT05407779|Experimental|Cohort 7|The Cohort 7 include 3 subjects to receive BCD-180 at a dose 7
88922333|NCT05407779|Experimental|Cohort 8|The Cohort 8 include 3 subjects to receive BCD-180 at one of two selected for the further development doses
88922334|NCT05407779|Experimental|Cohort 9|The Cohort 9 include 3 subjects to receive BCD-180 at one of two selected for the further development doses
88956446|NCT05197192|Experimental|GAVe-Arm|Acalabrutinib plus Venetoclax plus Obinutuzumab plus (GAVe)
89199237|NCT05953389|Placebo Comparator|Placebo|One or two tablets of matching placebo per day for 12 weeks.
89011550|NCT04528888|Experimental|LMWH + steroids group|"The treatments will be initiated as soon as possible after randomization (maximum allowed starting time 12h after randomization).~Patients in this group will receive enoxaparin and methylprednisolone. Enoxaparin will be administered at standard prophylactic dose (i.e., 4000 UI once day, increased to 6000 UI once day for patients weighting more than 90 kg). The treatment will be administered subcutaneously daily up to ICU discharge. After ICU discharge it may be continued or interrupted in the destination ward up to clinical judgement of the attending physician. Methylprednisolone will be administered intravenously with an initial bolus of 0,5 mg/kg followed by administration of 0,5 mg/kg 4 times daily for 7 days, 0,5 mg/kg 3 times daily from day 8 to day 10, 0,5 mg/kg 2 times daily at days 11 and 12 and 0,5 mg/kg once daily at days 13 and 14."
89011551|NCT04528888|Experimental|UFH + steroid group|The treatments will be initiated as soon as possible after randomization (maximum 12h). Patients will receive unfractionated heparin and methylprednisolone. Unfractionated heparin will be administered intravenously at therapeutic doses. The infusion will be started at an infusion rate of 18 IU/kg/hour and then modified to attain APTT Ratio in the range 1.5-2.0. aPTT will be periodically checked at intervals no longer than 12 hours. The treatment with unfractionated heparin will be administered up to ICU discharge. After ICU discharge anticoagulant therapy may be interrupted or switched to prophylaxis with LMWH in the destination ward up to clinical judgement of the attending physician. Methylprednisolone will be administered intravenously with an initial bolus of 0,5 mg/kg followed by administration of 0,5 mg/kg 4 times daily for 7 days, 0,5 mg/kg 3 times daily from day 8 to day 10, 0,5 mg/kg 2 times daily at days 11 and 12 and 0,5 mg/kg once daily at days 13 and 14.
89011552|NCT00250224|Experimental|Stent|
89011553|NCT04528615|Experimental|CCK In-Person Sessions|This group received the in-person CCK intervention.
89011554|NCT04528615|Active Comparator|CCK Printed Materials|This group received select printed CCK materials.
89011555|NCT01645267|Experimental|Osteotomy|Using hydroxyapatite bone graft material
88956447|NCT05197192|Experimental|GVe-Arm|Obinutuzumab plus Venetoclax (GVe)
89011556|NCT01645345|Other|RF Pixel handpiece treatment|There is only one arm, and that is a treatment arm. For patients with wrinkles and acne scars, they are being treated with the RF Pixel handpiece to decrease the appearance of these cosmetic deficiencies. The improvement is documented in before and after photographs.
89011557|NCT01645384|Experimental|Atorvastatin Calcium Tablets, 40 mg|Atorvastatin Calcium Tablets, 40 mg of Dr. Reddy's Laboratories Limited
89011558|NCT01645384|Active Comparator|Lipitor® 40 mg Tablets|Lipitor® 40 mg Tablets of Pfizer Ireland Pharmaceuticals
89011559|NCT01645423|Experimental|Atorvastatin Calcium Tablets, 80 mg|Atorvastatin Calcium Tablets, 80 mg of Dr. Reddy's Laboratories Limited
89011560|NCT01645423|Active Comparator|Lipitor 80 mg Tablets|Lipitor 80 mg Tablets of Pfizer Ireland Pharmaceuticals
89011561|NCT01645774|Experimental|10s injections duration|10s injections duration
89011562|NCT01645774|Experimental|10s injection duration , waiting 10s|10s injection duration and waiting 10s before withdrawing the needle
89011563|NCT01645774|Experimental|15s injection duration,waiting 5s|15s injection duration and waiting 5s before withdrawing the needle
89199238|NCT05953376|Experimental|Empiric calcium administration|Patients in this arm will receive 2g IV calcium with the initial transfusion
89199239|NCT05953376|No Intervention|No empiric calcium administration|Patients in this arm will only receive calcium supplementation based on routine ionized calcium levels and/or physician discretion
89199240|NCT05953350|Experimental|Phase Ib clinical trial|600mg bid dose of hydroxychloroquine group combined with three predefined dose groups of palbociclib: 100mg QD, 150mg QD, and 200mg QD, separately.
89199241|NCT05953350|Experimental|Phase II clinical trial|After MTD was determined, RP2D dose was selected for phase II clinical trial.
88956448|NCT05183035|Active Comparator|Arm A: Control Arm without Venetoclax|"During cycle 1 (each cycle is 42 days), participants will receive 30 mg/m^2 of fludarabine followed by 2 g/m^2 of cytarabine on Days 1-5. Gemtuzumab 3 mg/m^2 will be given on Day 6 (only for participants with CD33 expression on leukemia blasts).~During cycle 2 participants will receive 30 mg/m^2 of fludarabine followed by 2 g/m^2 of cytarabine on Days 1-5.~After cycle 2 participants are assessed for hematopoietic stem cell transplantation (HSCT) or azacitidine maintenance therapy."
89011564|NCT01645774|Experimental|5s injection duration , waiting 15s|5s injection duration and waiting 15s before withdrawing the needle
89011565|NCT01645852|No Intervention|Control|No specified diet for one week prior to hepatic resection.
89011566|NCT01645852|Active Comparator|Low calorie diet|Low calorie diet (five units of Optifast 800 {Nestle Nutrition, Vevey, Switzerland} plus an unlimited volume of calorie free fluids per day) for one week prior to hepatic resection.
89011567|NCT01645969||Cohort|
89011568|NCT01646008||respiratory|
89011569|NCT01646047|Experimental|supplement - no retinopathy|subjects receiving active supplement and with no retinopathy based on clinical examination
89011570|NCT01646047|Placebo Comparator|placebo - no retinopathy|patients receiving placebo and who have no diabetic retinopathy based on clinical examination
89011571|NCT01646047|Experimental|supplement - retinopathy|patients receiving the active supplement and who have mild to moderate non-proliferative diabetic retinopathy based on clinical examination
89011572|NCT01646047|Placebo Comparator|placebo - retinopathy|patients receiving placebo and who have mild to moderate non-proliferative diabetic retinopathy based on clinical examination
89011573|NCT00264030|Other|1|PTCA
89011574|NCT00264030|Other|2|PTCA with angioguard
89011575|NCT01646086|Experimental|weekly weight tracking|12 month behavioral weight loss intervention
89011576|NCT01646086|Active Comparator|daily weight tracking|12 month behavioral weight loss intervention
89011577|NCT01646086|Active Comparator|no weight tracking|12 month behavioral weight loss intervention
89502013|NCT05496218|Experimental|Control Group|Control group are women aged 18-45 surgically verified not to have endometriosis. At study entry, we will collect morning blood samples.
89502014|NCT04001582||Participants with FSHD|
89437612|NCT03477175|Experimental|Cohort C: Comparator drug|"The roll-over eligible participants from Eisai-sponsored lenvatinib studies who received comparator treatment in their parent study will continue to receive comparator treatment, with exception of participants receiving placebo.~For China only: The roll-over eligible participants from Eisai-sponsored lenvatinib studies who received comparator treatment in their parent study will continue to receive sorafenib, with exception of participants receiving placebo."
89437613|NCT03475004|Other|Safety run-in|Ten patients will be accrued to stage 1 and treated with standard doses of pembrolizumab, binimetinib and bevacizumab. If the standard doses are not tolerable and 2 or more patients experience a DLT, then patients would be enrolled in dose level -1 which would comprise of standard doses of pembrolizumab and bevacizumab but binimetinib would be at a dose lower of 30 mg PO BID. If 2 or more patients experience a DLT at dose level -1, then patients will be enrolled in dose level -2 which will comprise of standard doses of pembrolizumab and bevacizumab but a lower dose of binimetinib at 15 mg BID. Upon determination of the safety and tolerability of the treatment regimen, the study will proceed to stage 2.
89437614|NCT03475004|Experimental|Cohort A|Patients will start with 7-day run-in of binimetinib on day -7 of cycle 1 only. Pembrolizumab and bevacizumab will then be added to binimetinib on cycle 1 day +1. Cycle 1 will end on day 21. Patients will start treatment with pembrolizumab, binimetinib, and bevacizumab on day 1 of all subsequent cycles.
89199242|NCT05953324|Experimental|Cases|consumed two medium-size kiwifruit group [21] (cases) 1 hour before bedtime every night for 6 weeks (42 days in total).Randomization was performed by giving participants a note identifying the condition to which they were randomized; the note was placed in a sealed envelope. Blindness was not applicable since cases received kiwifruit and controls did not receive. Total number of kiwis consumed should be (14 kiwis (number of kiwis in one week) x 6 (number of weeks) = 84 kiwis in total. Participants consuming the kiwifruit were asked to keep a diary to record if they consumed them every day. During the 6-week intervention period, participants received their kiwifruit every week on the first day of the week (Sunday) that is adequate for a week (14 kiwi fruits brand name: Sharbatly Co. Ltd, variety: Hayward, country of origin: Italy). The kiwifruits were supplied at optimum ripeness for consumption and were instructed to keep the kiwi in the fridge to prevent damage.
89437615|NCT03475004|Experimental|Cohort B|Patients will be treated with pembrolizumab, bevacizumab, and binimetinib together on day 1 of all cycles including cycle 1. Patients will start treatment with pembrolizumab, binimetinib, and bevacizumab on day 1 of all subsequent cycles.
89437616|NCT03467958|Experimental|Administration of oral Ozanimod|
89437617|NCT03440372|Experimental|Administration of oral Ozanimod|
89199243|NCT05953324|No Intervention|Controls|Had poor sleep quality however did not consume kiwifruit
89199244|NCT05953311||ICU survivors|Cohort of patients who survive an ICU stay of at least 7 days
89199245|NCT05953298|Experimental|Patients with COPD|Patients with COPD in stable condition fitted with long-term NIV
89437618|NCT03440372|Placebo Comparator|Administration of Placebo|
89437619|NCT03423628|Experimental|AZD1390 + Radiation Therapy|AZD1390 + Radiation Therapy
89437620|NCT03414229|Experimental|UPS, Liposarcoma or pleomorphic liposarcoma|Undifferentiated Pleomorphic Sarcoma (UPS) or Liposarcoma (dedifferentiated or pleomorphic liposarcoma) Epacadostat 100mg Twice daily Continuously days 1-21 of each 3 week cycle Oral Pembrolizumab 200mg Every 3 weeks Day 1 of each 3 week cycle IV infusion
89437621|NCT03414229|Experimental|Leiomyosarcoma|Epacadostat 100mg Twice daily Continuously days 1-21 of each 3 week cycle Oral Pembrolizumab 200mg Every 3 weeks Day 1 of each 3 week cycle IV infusion
89502015|NCT05498714|Active Comparator|the control group|The dosing regimen of high-risk patients will be PEG combined with lactulose.
88922335|NCT05403658|Experimental|Family Navigation + Usual Care|Participants assigned to this arm will receive the Family Navigation (FN) intervention in addition to standard pediatric obesity management (Usual Care).
88922336|NCT05403658|Active Comparator|Usual Care|Participants assigned to this arm will standard pediatric obesity management only.
88922337|NCT05400317|Experimental|Active Comparator : Test group|AD-218
88922338|NCT05400317|Active Comparator|Active Comparator : Control group|AD-218A
88922339|NCT05398185|No Intervention|Control|The control includes standard health services offered at each site (e.g., mental health services, case-management, referral to clinical care) and a brief adherence educational session.
88922340|NCT05398185|Experimental|Intervention|WiseApp that delivers medication adherence reminders
88922341|NCT05396638|Experimental|Contingency Management|Abstinence will be rewarded following a contingency management (CM) payment scale.
88922342|NCT05396014|Active Comparator|Treatment Period 1: Enhanced Self-Care (ESC)|"This arm includes participants who are randomized to ESC in Treatment Period 1.~Depending on their response to Treatment 1 measured at 12 Weeks post-initial randomization, participants in this arm will stay on ESC or be randomized to augment ESC with an additional treatment during Treatment Period 2."
88922343|NCT05396014|Active Comparator|Treatment Period 1: Acceptance and Commitment Therapy (ACT)|"This arm includes participants who are randomized to ACT in Treatment Period 1.~Depending on their response to Treatment 1 measured at 12 Weeks post-initial randomization, participants in this arm will stay on ACT, augment ACT with an additional treatment, or switch to a new treatment during Treatment Period 2."
88922344|NCT05396014|Active Comparator|Treatment Period 1: Evidence-Based Exercise and Manual Therapy (EBEM)|"This arm includes participants who are randomized to EBEM in Treatment Period 1.~Depending on their response to Treatment 1 measured at 12 Weeks post-initial randomization, participants in this arm will stay on EBEM, augment EBEM with an additional treatment, or switch to a new treatment during Treatment Period 2."
88922345|NCT05396014|Active Comparator|Treatment Period 1: Duloxetine|"This arm includes participants who are randomized to Duloxetine in Treatment Period 1.~Depending on their response to Treatment 1 measured at 12 Weeks post-initial randomization, participants in this arm will stay on Duloxetine, augment Duloxetine with an additional treatment, or switch to a new treatment during Treatment Period 2."
88922346|NCT05393427|Experimental|Study treatment|Participants receive BL-B01D1 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
88922347|NCT05391308|Experimental|Experimental arm|All patients will have pre-polysomnographie and post-polysomnographie mesurement.
88922348|NCT05390710|Experimental|Triple combination|LAE005+Afuresertib+Nab-Paclitaxel
88922349|NCT05388669|Experimental|Arm A: Lazertinib with Amivantamab SC-CF|Lazertinib 240 mg will be administered orally once daily. Participants will receive Amivantamab subcutaneous and co-formulated with recombinant human hyaluronidase (SC-CF), 1600 milligrams (mg)/ 2240 mg depending on the body weight by manual injection.
88922350|NCT05388669|Experimental|Arm B: Lazertinib with Amivantamab Intravenous (IV) Infusion|Lazertinib 240 mg will be administered orally once. Participants will receive amivantamab, 1050 mg or 1400 mg depending on the body weight as an IV infusion.
89538422|NCT02459015|Active Comparator|Autologous Nerve Graft|Implantation of an autologous nerve graft: If the subject is randomized to the conventional treatment, the surgeon will repair the nerve by interposing an autologous nerve graft of ≤ 26 mm between the nerve ends.
89538423|NCT03267407||CrAg(+) and CM(-)|(1) Patients with CrAg positive without meningitis results will receive preemptive high-dose fluconazole to prevent developing meningitis.
89437622|NCT03414229|Experimental|Vascular Sarcoma Subtypes|Including angiosarcoma and Epithelioid Hemangioendothelioma (EHE). Epacadostat 100mg Twice daily Continuously days 1-21 of each 3 week cycle Oral Pembrolizumab 200mg Every 3 weeks Day 1 of each 3 week cycle IV infusion
88922355|NCT05385692|Experimental|Study treatment|Participants receive BL-M02D1 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
88922356|NCT05384691|Other|Luspatercept|Single-arm design: All patients are treated with 1.75 mg Luspatercept per kg body weight subcutaneously on day 1 of each 21 day cycle for up to 24 weeks and in case of response for up to 1.5 years.
88922357|NCT05378503|Experimental|Active|"1. Administration of Qsymia 3.75mg/23mg once a daily for 2-week(W2), and then administration of Qsymia 7.5mg/46mg once a daily for 12-week(W14).~2-1. At W14, if the weight loss rate is 3% or more, administration of Qsymia 7.5mg/46mg once a daily by the end of visit(W56).~2-2. At W14, if the weight loss rate is NOT 3% or more, administration of Qsymia 11.25mg/69mg once a daily for 2-week(W16), and then administration of Qsymia 15mg/92mg once a daily by the end of visit(W56)."
88922358|NCT05378503|Placebo Comparator|Placebo|Administration of Qsymia placebo once a daily by the end of visit(W56).
88922359|NCT05375292|Experimental|PREHABILITATION GROUP|"Initial visit with the adaptive rehabilitation physician, 6-8 weeks prior to surgery:~Clinical examination with Wood classification description of impairments, activity limits and participation restrictions.~Assessment of environmental resources~Definition with the patient of the extended ambulatory pre-habilitation protocol, identification with the post-operative rehabilitation pathway,~Provide the patient with a follow-up workbook of the personalized pre-approval protocol and, if the patient's condition requires it, orders for physiotherapy.~Then apply the ambulatory pre-approval protocol defined with the adaptive rehabilitation physician.~- Post-operative follow-up visits with the surgeon (gathering the necessary information for comparative follow-up).~Mail-out of WHODAS 2.0 EQ-5D-5L and DIJON questionnaires at 3 and 6 months post-operative."
88922360|NCT05375292|No Intervention|CONTROL GROUP|"Support without pre-approval with application of other common practices of the service.~Post-operative follow-up visits with the surgeon (gathering the necessary information for comparative follow-up).~Mail-out of WHODAS 2.0 EQ-5D-5L and DIJON questionnaires at 3 and 6 months post-operative."
88922361|NCT05367492|Experimental|Double Bline Varenicline|"Participants will...~Receive the drug varenicline, in tablet form, up to 1 mg BID for 12 weeks.~Attend QuitVaping behavioral support sessions, completed in-person or via video-conferencing, once per week for 12 weeks.~Be encouraged to sign up for This Is Quitting (TIQ), a text message vaping cessation program for adolescents."
88922362|NCT05367492|Placebo Comparator|Double Blind Placebo|"Participants will...~Receive placebo tablets, identical in appearance to varenicline, up to 1 mg BID for 12 weeks.~Attend QuitVaping behavioral support sessions, completed in-person or via video-conferencing, once per week for 12 weeks.~Be encouraged to sign up for This Is Quitting (TIQ), a text message vaping cessation program for adolescents."
88922363|NCT05367492|No Intervention|Single Blind Monitoring only|"Participants will...~Receive NO drug intervention.~Attend NO behavioral support sessions.~Will not be encouraged to sign up for text message vaping cessation support."
88922364|NCT05346549|Experimental|High energy|"Child will be given a high energy drink: sugar free ribena squash (2kcal/100ml) plus a weighed amount of super soluble maxijul. Super Soluble Maxijul is a powdered carbohydrate energy source, which can be mixed with sweet or savoury foods/ liquids. It is safe for use in both children and adults that require fortification with a high or readily available carbohydrate. It is flavourless and tasteless offering little to no change in taste, flavor and texture of food being added to. It supplies 380 kcal energy per 100g powder. The amount given will supply 10% of the child's daily energy requirements per Kg - for example a 3-year old child weighing about 16 kg requires approximately 1300 kcal/day. Hence the high energy drink will supply the child with 130kcal.~They will be given 10 minutes to drink the preload and 30 minutes after this they will eat standardized weighed buffet lunch of known energy content suitable for their age, chosen in consultation with the parents."
88922365|NCT05346549|Experimental|Low energy|"Child will be given a low energy drink of the same volume selected to be as similar as possible to the high energy drink: sugar free ribena squash containing 2kcal per 100ml.~They will be given 10 minutes to drink the preload and 30 minutes after this they will eat lunch containing the same range of weighed buffet foods as above."
89437623|NCT03414229|Experimental|Other|Epacadostat 100mg Twice daily Continuously days 1-21 of each 3 week cycle Oral Pembrolizumab 200mg Every 3 weeks Day 1 of each 3 week cycle IV infusion
89437624|NCT03403257||Subjects with cognitive impairment|Subjects with MoCA <26
89437625|NCT03403257||Caregivers|Primary caregivers of subjects
89437626|NCT03396614||EEG, ECG, CT, MRI|
89199246|NCT05953272|Experimental|EMG Biofeedback therapy and Bobath therapy|The experimental group will receive EMG Biofeedback therapy for 15 minutes along with Bobath therapy for 45 minutes and home exercise program. The EMG Biofeedback therapy and Bobath therapy will be given for 16 sessions (4 sessions per week for 4 weeks). Patient will perform the home exercise program once a day in home during 4 weeks of treatment period.
89437627|NCT03394495|Experimental|BCE Combination group|"16-week BCE programme with exercise training.~Six 1-hour sessions of BCE programme and a weekly 45-60 minute centre-based exercise programme from week 4 to week 16."
89437628|NCT03394495|No Intervention|Exercise group|"16-week programme with health talks and exercise training.~Six 1-hour sessions of health talks and a weekly 45-60 minutes centre-based exercise programme from week 4 to week 16."
89437629|NCT03394495|No Intervention|Control group|Six sessions of centre-based health talks on the management of different health issues with the exception of fatigue.
89437630|NCT03393975|Experimental|Prophylaxis Cohort I|Participants randomized to SOC arm in prophylactic treatment cohort will receive a single dose intravenous (IV) infusions of 40 international units per kilogram (IU/kg) BAX-930 ORT product followed by a PK dose of their current SoC at 14 days later in PK I with a washout period of 14 days (+ or - 2 days). In period 1 participants will receive SOC for 6 months followed by IV infusions of 40 IU/kg dose of BAX-930 ORT once every 2 weeks (Q2W) in period 2 for the next six months. After period 2, participants will receive a single dose IV infusions of 40 IU/kg BAX-930 ORT followed by IV infusions of 40 IU/kg BAX-930 SIN in PK II with a washout period of 14 days (+ or - 2 days). All the participants in period 3 will receive BAX-930 SIN prophylactic dose of IV infusions of 40 IU/kg for another 6 months.
89437631|NCT03393975|Experimental|Prophylaxis Cohort II|Participants randomized to BAX-930 arm in prophylactic cohort will receive a PK dose of their current SoC product followed by a single dose IV infusions of 40 IU/kg BAX-930 ORT at 14 days later in PK I with a washout period of 14 days (+ or - 2 days). In period 1 participants will receive a single dose IV infusions of 40 IU/kg BAX-930 ORT once Q2W for the next six months followed by SOC for 6 months in period 2. Thereafter participants will receive a single dose IV infusions of 40 IU/kg BAX-930 SIN followed by IV infusions of 40 IU/kg BAX-930 ORT in PK II with a washout period of 14 days (+ or - 2 days). All the participants in period 3 will receive BAX-930 SIN prophylactic dose IV infusions of 40 IU/kg for another 6 months.
89437632|NCT03393975|Experimental|On Demand Cohort I|Participants randomized to SOC arm in On-demand cohort will receive the investigator-recommended SOC and dosing regimen during the acute event. In period 1 participants will receive IV infusions of 40 IU/kg dose of BAX-930 ORT once every 2 weeks (Q2W) for 6 months followed by SOC in period 2 for the next six months. Thereafter participants will receive a single dose IV infusions of 40 IU/kg BAX-930 ORT followed by IV infusions of 40 IU/kg BAX-930 SIN in PK II with a washout period of 14 days (+ or - 2 days). All the participants in period 3 will receive BAX-930 SIN prophylactic dose IV infusions of 40 IU/kg for another 6 months.
89437633|NCT03393975|Experimental|On Demand Cohort II|Participants randomized to BAX-930 arm in On-demand cohort will receive initial dose of IV infusions 40 IU/kg [+/- 4 IU/kg] BAX-930 ORT or BAX-930 SIN infusion then a subsequent dose IV infusions of 20 IU/kg [+/- 2 IU/kg] BAX-930 ORT or BAX-930 SIN infusion on Day 2 and an additional daily dose IV infusions of 15 IU/kg [+/- 1.5 IU/kg] BAX 930 until 2 days after the acute event is resolved. In period 1 participants will receive SOC for the next six months followed by IV infusions of 40 IU/kg dose of BAX-930 ORT once Q2W for 6 months in period 2. Thereafter participants will receive a single dose IV infusions of 40 IU/kg BAX-930 SIN followed by IV infusions of 40 IU/kg BAX-930 ORT in PK II with a washout period of 14 days (+ or - 2 days). All the participants in period 3 will receive BAX-930 SIN prophylactic dose IV infusions of 40 IU/kg for another 6 months.
89437634|NCT03393598|Experimental|pre-expansion using Kiwi® VAC-6000M|Expansion will be performed using a complete vacuum delivery system called Kiwi® VAC-6000M with the PalmPumpTM (Clinical Innovations, South Murray, Utah, USA).
89538424|NCT03267407||CrAg(+) and CM(+)|(2) Patients with CrAg positive and meningitis results will receive standard treatment for cryptococcal meningitis, following national guidelines.
88922366|NCT05339685|Experimental|Study treatment|Participants receive BL-M02D1 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
89011578|NCT04709510|Other|AllPatients|There is only one cohort in this study. They all received the same follow up and ultrasound protocol.
89011579|NCT01646164||Dill seed|used dill seed infusion (1 tablespoon whole dill seed seeped in a half or whole cup boiling water for 3-4 min)
89011580|NCT01646164||No used Dill seed|those who had not used any herbal drugs were placed at the control group
89011581|NCT01646242|Experimental|Cold snare polypectomy|
89199247|NCT05953272|Active Comparator|Bobath therapy only|This group will receive only Bobath therapy for 45 minutes and home exercise program. The Bobath therapy will be given for 16 sessions (4 sessions per week for 4 weeks). Patient will perform the home exercise program once a day in home during 4 weeks of treatment period.
88922368|NCT05338151|Other|Brief Negotiated Interview (with referral and telephone booster) alone|All participants will receive BNI with referral and a 15-20 minute telephone booster delivered by a trained Health Promotion Advocate (HPA) at 2 weeks. The purpose of the BNI is to assist patients in recognizing and changing levels of alcohol consumption that pose health risks. The main goals of the BNI are to: 1) lessen ambivalence about reducing alcohol use; and 2) negotiate strategies for change. During BNI, the HPA will: 1) Raise the subject of alcohol; 2) Provide feedback: review the patient's alcohol consumption, make a connection to the patient's medical condition and reason for hospitalization; review guidelines for lower risk alcohol use; 3) Enhance motivation: have the patient identify on a readiness change ruler and develop discrepancy; and 4) Negotiate and Advise: negotiate goal, give advice, have patient complete drinking agreement; summarize and arrange follow-up.
88922369|NCT05338151|Active Comparator|BNI+MAUD|For either BNI+facilitated provision of MAUD or BNI+facilitated provision of MAUD+CBT4CBT, the HPA will provide education and counseling regarding MAUD as part of the BNI to the participant and communicate to the primary medical team that MAUD is indicated. The specific MAUD chosen will be made at the discretion of the patient and the primary medical team with recommendations from the study physicians, with a goal of prioritizing FDA approved medications. Participants will be encouraged to initiate (or receive as in the case of injectable naltrexone) MAUD prior to discharge and will be provided a prescription for a 30-day supply. Medications will be obtained through regular means and not provided directly through the study. During the BNI telephone booster, the HPA will inquire about and address any barriers to MAUD and encourage continued adherence.
88922370|NCT05338151|Experimental|BNI+MAUD+CBT4CBT|Participants randomized to BNI+facilitated provision of MAUD+CBT4CBT will be given a username and password to access the web-based program and be encouraged to begin accessing the program during their hospitalization. The HPA will assist each participant with login during the first session and be available to answer any questions. Participants will be asked to complete no more than two modules per week, with an expectation of completing all seven modules by the end of the 34-day post-discharge. The program tracks, for each participant, time logged onto the program, modules accessed, progress through the program from session to session, completion of homework assignments, and learning of CBT principles through brief quizzes. Participants will be allowed to repeat modules as desired. During the BNI telephone booster, the HPA will inquire about engagement with CBT4CBT, address any questions and problems with the program, and encourage practice of coping activities (i.e., homework).
88922371|NCT05335434|Experimental|INTRAORAL PBMT IN PATIENTS UNDERGOING alloHCT|"The research study procedures include: screening for eligibility and study treatment including daily PBMT and clinical evaluations. Participants will receive the study treatment daily from the start of conditioning chemotherapy to day +20, or discharge (if you are able to be discharged from the hospital prior to day +20), whichever occurs first~-THOR LX2.3 with LED Lollipop"
88922372|NCT05327595|Experimental|LY3549492 (Part A)|LY3549492 administered orally as multiple ascending doses.
88922373|NCT05327595|Placebo Comparator|Placebo (Part A)|Placebo administered orally.
88922374|NCT05327595|Experimental|LY3549492 + Midazolam + Atorvastatin (Part B)|LY3549492 coadministered orally with midazolam and atorvastatin.
88922375|NCT05327595|Placebo Comparator|Placebo + Midazolam + Atorvastatin (Part B)|Placebo coadministered orally with midazolam and atorvastatin.
89011582|NCT01646242|Experimental|Double biopsy polypectomy|
89011583|NCT02961075|Experimental|Cricothyroid|local surface anesthesia by Cricothyroid
89199248|NCT05953259|Active Comparator|STERN FIX|Combination of at least one STERN FIX device and surgical wires to close median sternotomy (total of 5 fixation points)
89199249|NCT05953259|Active Comparator|Wires|Standard of care median sternotomy closure method with surgical wires
89199250|NCT05953220||Smoking|People who smoke tobacco cigarettes at least daily and have not vaped an e-cigarette (except one or two puffs on a less than monthly basis), used NRT, smoking cessation medication or other tobacco products for the past 6 months.
89199251|NCT05953220||Vaping|People who vape e-cigarettes at least daily and have not smoked tobacco cigarettes (except one or two puffs on a less than monthly basis), used NRT, smoking cessation medication, or any other tobacco product for the past 6 months.
89437635|NCT03393598|Experimental|pre-heating using Hilotherm Calido®.|Pre-Heating will be preformed using a Hiloterm Calido® System.
88922376|NCT05322941|Experimental|AEF0117|The current study tests 3 doses of AEF0117 (1.0, 0.3, and 0.1 mg).AEF0117 capsules ; dose range 0.1 to 1.0mg by mouth, once a day for 12 weeks.
88922377|NCT05322941|Placebo Comparator|Placebo|corn oil capsules once a day for 12 weeks.
88922378|NCT05321121|Experimental|Precedex arm|The intervention arm will receive an infusion of dexmedetomidine (precedex) at 0.4-0.6 mcg/kg/h (Based off ideal body weight).
88922379|NCT05321121|Placebo Comparator|Control arm|The control arm will receive an infusion of normal saline. Medication distribution and management will be handled by the Investigational Drug Service (IDS) at UCI medical center.
88922380|NCT05319067||Cases|Children aged 1 to 3 years with vesico ureteral reflux of grade 3 or higher, under antibiotic prophylaxis
88922381|NCT05319067||Controls|Children aged 1 to 3 years with uropathy, without antibiotic prophylaxis
88922382|NCT05319067||Healthy Controls|Healthy children aged 1 to 3 years.
88922383|NCT05318092|Experimental|AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 PE|Single Arm Study - Use of AngioDynamics' AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 PE for the treatment of acute pulmonary embolism
88922384|NCT05300620|Experimental|Original Shoe Liner|This condition will be administered by inserting the original liner in the shoe and have the participants run with this shoe condition.
88922385|NCT05300620|Experimental|Custom Foot Orthotic made out of Ethyl Vinyl Acetate material|This condition will be administered by inserting a custom EVA orthotic in the shoe and have the participants run with this shoe condition.
88922386|NCT05300620|Experimental|Custom Foot Orthotic made of thermoplastic poly-urethane material|This condition will be administered by inserting a custom TPU orthotic in the shoe and have the participants run with this shoe condition.
88922387|NCT05300620|Experimental|Hybrid - Orthotic made of EVA and TPU material|This condition will be administered by inserting a custom EVA/TPU orthotic in the shoe and have the participants run with this shoe condition.
88922388|NCT05298501||AMYWEB-Normative|This cohort assessed over six recruitment and test phases, will be sampled to be as closely representative of the demographic population as possible.
88922389|NCT05298501||AMYWEB-Diversity|This cohort assessed over two recruitment and test phases will oversample participants from minority and mixed ethnic and racial backgrounds as well as participants from lower educational backgrounds.
88922390|NCT05298501||AMYWEB-MCI|This cohort assessed and recruited over one test phase, will include participants with a reported diagnosis of mild cognitive impairment or dementia.
88922391|NCT05297539|No Intervention|Control Group|Control group who will do usual rehabilitation + visualization of videos representing monuments + a 3-meter round-trip walk
88922392|NCT05297539|Experimental|Experimental group 1|Experimental group 1 who will do usual rehabilitation + visualization of non focused point-light human actions + a 3-meter round-trip walk
89199252|NCT05953220||Dual|"Dual users (predominant vapers): people who vape e-cigarettes at least daily and also smoke cigarettes at least weekly, and have not used NRT, smoking cessation medication, or any other tobacco product for the past 6 months.~Dual users (predominant smokers): people who smoke tobacco cigarettes at least daily and also vape e-cigarettes at least weekly, and have not used NRT, smoking cessation medication, or any other tobacco product for the past 6 months."
89199253|NCT05953220||Non-use|People who have neither smoked, vaped, used NRT, smoking cessation medication, nor any other tobacco product for the past 12 months.
89199254|NCT05953181|Experimental|Active surveillance|
89199255|NCT05953181|Active Comparator|Standard esophagectomy|
89199256|NCT05949034|Experimental|E-Cigarette Flavor 1 Condition|Participants will self-administer a flavored e-cigarette.
89199257|NCT05949034|Experimental|E-Cigarette Flavor 2 Condition|Participants will self-administer a flavored e-cigarette.
89199258|NCT05949034|Experimental|E-Cigarette Flavor 3 Condition|Participants will self-administer a flavored e-cigarette.
89199259|NCT05947578|Experimental|CLZ-2002|CLZ-2002 injection is intramuscular in lower limbs on Day 1.
89199260|NCT05945472|Experimental|Positive reinforcement method|"The people who form the intervention groups will receive a facial cosmetic of natural components to be administered for 28 days, for which they will be given the cream.~The cream will be provided to the participants on the 1st day of the talk. The container containing the facial cosmetic will be applied twice a day, morning and evening.~Afterwards, in the experimental group, the participants will be given a talk on how to administer it according to the positive reinforcement method."
89199261|NCT05945472|Active Comparator|Standard method|"The people who form the intervention groups will receive a facial cosmetic of natural components to be administered for 28 days, for which they will be given the cream.~The cream will be provided to the participants on the 1st day of the talk. The container containing the facial cosmetic will be applied twice a day, morning and evening."
88922393|NCT05297539|Experimental|Experimental group 2|Experimental group 2 who will do usual rehabilitation + visualization of focused point-light human actions + a 3-meter round-trip walk
89199262|NCT05945472|No Intervention|Control|This group will continue to use their usual cosmetics and complete the questionnaire on the first day of the study and on the last day of the study (28 days later).
89199263|NCT05942833|Experimental|Group A (Early)|Early left hemicolectomy immediately up to a maximum of 2 days after 7-10 days lasting initial conservative or interventional treatment (e.g: antibiotics, analgesics, drainage) and CT scan/ultrasound proven left-sided colonic diverticulitis
89437636|NCT03393598|Experimental|pre-expansion-heating|Both preconditioning methods Hilotherm Calido® plus Kiwi® VAC-6000M- will be applied.
89437637|NCT03393598|No Intervention|Control|No preconditioning methods will be applied.
89437638|NCT03391778|Experimental|Participants receiving GSK adoptive cell therapy|
88922394|NCT05293561||COVID-19 cases|O2 saturation readings, Mini-mental state examination (MMSE), Hamilton's anxiety (HAM-A) Hamilton's depression rating scales (HAM-D)
88922395|NCT05293561||control|O2 saturation readings, Mini-mental state examination (MMSE), Hamilton's anxiety (HAM-A) Hamilton's depression rating scales (HAM-D)
89011584|NCT02961075|Experimental|Laryngeal tube|local surface anesthesia by Laryngeal tube
89437639|NCT03382639|Experimental|Luvadaxistat 50 milligrams (mg)|Participants received luvadaxistat 50 mg orally once daily (QD) for 12 weeks (Days 1 to 84).
89011585|NCT01646281|Active Comparator|Flecainide|Patients randomized to flecainide will receive a 10-minute infusion of 2 mg/kg (maximal 150 mg) flecainide. If the patient is still in AF 1 hour after the infusion, electrical cardioversion will be performed according to protocol.
89437640|NCT03382639|Experimental|Luvadaxistat 125 mg|Participants received luvadaxistat 125 mg orally QD for 12 weeks (Days 1 to 84).
89437641|NCT03382639|Experimental|Luvadaxistat 500 mg|Participants received luvadaxistat 500 mg orally QD for 12 weeks (Days 1 to 84).
89437642|NCT03382639|Placebo Comparator|Placebo|Participants received placebo (matching luvadaxistat) orally QD for 12 weeks (Days 1 to 84).
89437643|NCT03366129||Cohort|Stroke patients with white matter hyperintensities (WMH)
89437644|NCT03359785|Experimental|Luvadaxistat 500 mg, then Placebo|Participants first received luvadaxistat 500 mg orally once daily (QD) for 8 days during treatment period 1. After a washout of 14 to 21 days, participants then received matching placebo orally QD for 8 days during treatment period 2.
89437645|NCT03359785|Experimental|Placebo, then Luvadaxistat 500 mg|Participants first received matching placebo orally QD for 8 days during treatment period 1. After a washout of 14 to 21 days, participants then received luvadaxistat 500 mg orally QD for 8 days during treatment period 2.
88922396|NCT05292521|Experimental|Group A (QOL fact sheet)|Patients receive study QOL intervention fact sheet during the initial consult that occurs 4 weeks prior to the standard of care surgery or SBRT. Patients have an opportunity to review the QOL fact sheet in person and discuss any questions with the treating physician(s).
88922397|NCT05292521|Active Comparator|Group B (usual care)|Patients receive usual care during the initial consult that occurs 4 weeks prior to the standard of care surgery or SBRT.
88922398|NCT05292105||Coronary Artery Disease (CAD)|
88922399|NCT05292092||Coronary Artery Disease (CAD)|
88922400|NCT05287945|Experimental|Orellanine 0.05-4.9 mg/kg single intravenous administration following hemodialysis|
88922401|NCT05278858|Experimental|MedJet Device|"The Med-Jet-MBX needle-free injector (Med-Jet) is a novel, needle-free drug-delivery system, which we believe may be a solution to the pain and fear associated with needles. It uses regulated compressed air as a power source to accelerate an injectable fluid through a 0.005 orifice (6x smaller than a 30G needle) to penetrate the skin and deliver medication to a specific anatomical region (MedJet) The drug-delivery device is highly configurable allowing adjustable depth and volume parameters (MedJet). In addition, the high-performance design allows for triggering multiple injection sites rapidly which is practical when needing to treat large surface areas (MedJet)."
89437646|NCT03359785|Experimental|Luvadaxistat 50 mg, then Placebo|Participants first received luvadaxistat 50 mg orally QD for 8 days during treatment period 1. After a washout of 14 to 21 days, participants then received matching placebo orally QD for 8 days during treatment period 2.
89437647|NCT03359785|Experimental|Placebo, then Luvadaxistat 50 mg|Participants first received matching placebo orally QD for 8 days during treatment period 1. After a washout of 14 to 21 days, participants then received luvadaxistat 50 mg orally QD for 8 days during treatment period 2.
89437648|NCT03355560|Experimental|Nivolumab|Nivolumab starting 4-11 weeks after surgery for 6 doses.
88922402|NCT05268172|Experimental|IFN- Y combined with T cells|First, IFN-γ was combined with CIK cells. After three failed treatments, the CIK cells were replaced with T cells. After three failed treatments, CART cells were finally replaced.
88922403|NCT05265455|Experimental|Plant sterol supplementation|2.5 g of phytosterols in pre-dosed sticks (oral supplementation)
88922404|NCT05265455|Placebo Comparator|Placebo|Placebo in pre-dosed sticks (the same matrix without plant sterols) (oral supplementation)
88922405|NCT05265039|Experimental|Cognitive Processing Therapy (CPT)|
88922406|NCT05265039|Active Comparator|Relaxation Training (RT)|
89437649|NCT03351764|Other|arm 1|these are within subject repeated measures studies across a number of conditions
89437650|NCT03351764|Placebo Comparator|arm 2|
89437651|NCT03343535|Experimental|OCS Preservation|
89437652|NCT03343301|Experimental|Bemarituzumab 6 mg/kg + mFOLFOX6|Participants received 6 mg/kg bemarituzumab administered every 2 weeks (Q2W) and mFOLFOX6 chemotherapy administered Q2W until unacceptable toxicity, disease progression, or death.
88922407|NCT05264961|Other|control group|dysphonic children without behavioral abnormalities
88922408|NCT05264961|Other|study group|dysphonic children with behavioral abnormalities
88922409|NCT05262491|Experimental|Study treatment|Participants receive BL-B01D1 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
88922410|NCT05261139|Experimental|Cohort 1 nirmatrelvir/ritonavir|"nirmatrelvir/ritonavir will be given by tablets or powder by mouth twice a day for 5 days (10 doses total).~Weight ≥40 kg~≥12 to <18 years~≥6 to <12 years"
88922411|NCT05261139|Experimental|Cohort 2 nirmatrelvir/ritonavir|nirmatrelvir/ritonavir will be given as powder by mouth twice a day for 5 days (10 doses total) Weight ≥20 to <40 kg, ≥6 to <18 years
88922412|NCT05261139|Experimental|Cohort 3 nirmatrelvir/ritonavir|"nirmatrelvir/ritonavir~≥2 to <6 years"
88922413|NCT05261139|Experimental|Cohort 4 nirmatrelvir/ritonavir|"nirmatrelvir/ritonavir~≥1 month (≥28 days) to <2 years"
88922414|NCT05261139|Experimental|Cohort 5 nirmatrelvir/ritonavir|nirmatrelvir/ritonavir <1 month (<28 days) old
88922415|NCT05258786|Experimental|Intervention group|Transabdominal ultrasound will be applied to optimize the training program of contracting pelvic floor muscles, aiming to decrease postpartum urinary and fecal incontinence. Transperineal ultrasound will be used for pre-labor-coached maternal pushing aiming to improve pushing during the second stage of labor, reduce operative deliveries, the incidence of perineal tears, and urinary and fecal incontinence.
88922416|NCT05258786|No Intervention|Control group|A pelvic floor physiotherapist will provide the participants with a verbal explanation of how to contract pelvic floor muscles. without ultrasound.
88922417|NCT05258786|No Intervention|Standard care|Questionnaires only at four timeline points - before delivery at recruitment (T0), a week later (T2), immediately postpartum (T3), and two months postpartum (T4)
88922418|NCT05255393||Standard lymphadenectomy(LND) with sentinel lymph node mapping (SLN)|"Patients will receive up to two mailings or messages and two phone calls if they do not respond. Self-addressed, stamped envelopes will be provided for return of questionnaires.~No other interventions are planned."
88922419|NCT05255393||Standard lymphadenectomy(LND) alone|"Patients will receive up to two mailings or messages and two phone calls if they do not respond. Self-addressed, stamped envelopes will be provided for return of questionnaires.~No other interventions are planned."
88922420|NCT05247242|Experimental|Tarrant Community Fitness Program: LOF-VR|LOF-VR
88922421|NCT05247242|Experimental|Tarrant Community Fitness Program: VR-LOF|VR-LOF
88922422|NCT05247034|Experimental|Intervention group|Diet for patients with diabetes + 4 capsules of cocoa powder, 500 mg each, daily for 12 weeks.
88922423|NCT05247034|Placebo Comparator|Control group|Diet for patients with diabetes + 4 capsules of methylcellulose 500 mg each, daily for 12 weeks.
89437653|NCT03343301|Experimental|Bemarituzumab 15 mg/kg + mFOLFOX6|Participants received 15 mg/kg bemarituzumab administered Q2W with a single additional bemarituzumab 7.5 mg/kg dose on cycle 1 day 8. Participants also received mFOLFOX6 chemotherapy administered Q2W. Treatment continued until unacceptable toxicity, disease progression, or death.
88922424|NCT05243212|Experimental|'low' dose|The dose escalation stage will involve recruitment of 3 RRMM patients for 'low' dose (6 x 106 CAR-T cells/kg) CAR-T therapy. After 14 days of follow-up for each of the 3 subjects, the DSC will determine whether the next subject can be recruited. After 14 days follow-up for the 3rd subject, DSC will review data for the 3rd subject and consider the data for the first 3 subjects.
88922425|NCT05243212|Experimental|'high' dose|In the absence of dose limiting toxicities (DLTs), the DSC may recommend recruitment of 3 subjects to be treated with the 'high' dose (9x106 CAR-T cells/kg) CAR-T therapy, with similar staggering.
89437654|NCT03340506|Experimental|dabrafenib monotherapy|"Patients in this study may receive:~- monotherapy of dabrafenib"
89437655|NCT03340506|Experimental|trametinib monotherapy|"Patients in this study may receive:~- monotherapy of trametinib"
89437656|NCT03340506|Experimental|Combination therapy (dabrafenib & trametinib)|"Patients in this study may receive:~- the combination of dabrafenib and trametinib"
89437657|NCT03335787|Experimental|Intervention|Taping will be applied three times and will be reapplied one and two weeks later prior to first application for two weeks.
89437658|NCT03335787|Other|Control|Control group would not receive any taping in order to prevent sham taping sensory stimulation effect.
88922426|NCT05239221|Experimental|AZP-3601|subcutaneous (sc) administration once daily
88922427|NCT05239221|Placebo Comparator|Placebo (Parts A and B)|subcutaneous (sc) administration once daily
88922428|NCT05238519|Experimental|Motivational Interview|Motivational interview arm will receive a message to schedule a follow up motivational interview via telephone or video after the baseline survey as well as follow up surveys.
88922429|NCT05238519|No Intervention|Usual Care|Usual care arm will receive baseline and follow up surveys only.
89437659|NCT03268473|Experimental|Experimental: Non-surgical periodontal therapy in patient with OSAS and Periodontitis|Non-surgical periodontal therapy consisted of scaling and root planing and supportive periodontal therapy during 3 months Individuals: with both OSAS and periodontitis Intervention: Procedure: Non-surgical periodontal therapy
89437660|NCT03268473|Active Comparator|Control: non-surgical periodontal therapy in Periodontitis|Non-surgical periodontal therapy consisted of scaling and root planing and supportive periodontal therapy during 3 months Individuals: only periodontitis Intervention: Procedure: Non-surgical periodontal therapy
88922432|NCT05225545|Experimental|Sucrosomial Iron|These patients will receive Sucrosomial Iron 30 mg + 70 mg ascorbic acid (Sideral Forte) twice daily
88922433|NCT05225545|Active Comparator|Oral Iron Therapy|These patients will receive Oral Iron therapy at a dose of 195 mg twice daily for the same period of time
88922434|NCT05222802|Experimental|Dose Escalation (Part 1)|ERAS-801 will be orally administered to study participants with recurrent GBM in sequential ascending doses until unacceptable toxicity, disease progression, or withdrawal of consent.
88922435|NCT05222802|Experimental|Dose Expansion (Part 2)|ERAS-801 will be orally administered at the recommended dose (as determined from Part 1) to study participants with recurrent GBM harboring alterations in EGFR.
88922436|NCT05216926|Experimental|Hypoglycemia predicition and preventive treatment|
88922437|NCT05216926|Other|Corrective hypoglycemia treament (at hypogylcemia)|
88922438|NCT05209477|Other|Lung ultrasound|"n patients undergoing invasive mechanical ventilation with an arterial oxygen tension on inspired oxygen fraction ratio < 200 mmHg requiring recruitment maneuver and prone positioning as a rescue therapy, lung aeration will be evaluated at:~baseline, in supine position under protective ventilation after two minute of recruitment maneuver in pressure controlled ventilation at 1 hour following prone positioning application"
88922439|NCT05208697|Experimental|Tele-Harm Reduction (THR)|THR utilizes 2 components. Component 1: telehealth technology facilitated by a peer harm reduction counselor to connect the participant with medical case managers and enroll patients in Ryan White/AIDS Drug Assistance Program (ADAP). Component 2: utilizes the syringe services program (SSP)-based peer harm reduction counselor to work with participants in identifying individual-specific barriers and facilitators to medication adherence.
88922440|NCT05208697|Active Comparator|off-site linkage to HIV care|introduces the participant to an SSP HIV/HCV linkage specialist and discusses linkage to a traditional Ryan White clinic
88922441|NCT05207943|Experimental|Non-invasive Neuromodulation|Intervention with microcurrents: application of 6 electrodes per extremity and an adhesive electrode at C7 level and and in the popliteal fossa.
88922442|NCT05207943|Sham Comparator|Placebo Non-invasive Neuromodulation|Placebo microcurrents Intervention with microcurrents: application of 6 electrodes per extremity and an adhesive electrode at C7 level and in the popliteal fossa.
88922443|NCT05207943|No Intervention|Control|Participant will maintain the conventional rehabilitation treatment
88922444|NCT05196451|Active Comparator|Short-time rehabilitation|The intervention consists of an individualized numbers of outpatient encounters (min. 2, max. 8) with medical doctors and physiotherapists at Kysthospitalet, Stavern, Norway. The encounters aim to foster a rehabilitation process based upon principles from Cognitive Behavioral Therapy (CBT)
89437661|NCT03262467|Active Comparator|Aneurysmorrhaphy with external porous prosthesis (Provena©)|
89437662|NCT03262467|Placebo Comparator|Aneurysmorrhaphy without external porous prosthesis|
89437663|NCT03259932|Other|usual management|
89437664|NCT03259932|Experimental|physical training|
89437665|NCT03242915|Experimental|Pembrolizumab/Carboplatin/Pemetrexed|Pembrolizumab 200 mg with carboplatin at AUC (area under the curve dosing) 5 and pemetrexed at 500 mg/m2 administered intravenously every 3 weeks
88922445|NCT05196451|No Intervention|Care as usual|
88922446|NCT05195775|Experimental|Tadalafil plus BOLD-MRI (Schedule A)|The intervention is the same as in Schedule B; this arm will use BOLD-MRI as the technique to monitor drug impact on skeletal muscle.
89437666|NCT03241706|Placebo Comparator|Controls-saline|Each subject from Group 1 will undergo a metabolic study where saline is infused so as to not stimulate liver glucose uptake and glycogen deposition.
89437667|NCT03241706|Active Comparator|Controls-high fructose|A second group of control subjects will undergo a single metabolic study using a higher dose of fructose (6.5 mg/kg/min).
89437668|NCT03241706|Active Comparator|Controls-low fructose|Each subject from Group 1 will undergo another metabolic study where fructose (1.3 mg/kg/min) is infused so as to stimulate liver glucose uptake and glycogen deposition.
89437669|NCT03233854|Experimental|Treatment (CD19/CD22 CAR T cells, chemotherapy, NKTR-255)|Patients receive cyclophosphamide IV over 60 minutes and fludarabine phosphate IV over 30 minutes on days -5 to -3. Patients then receive CD19/CD22 CAR T cells IV over 10-20 minutes on day 0. On Day 14 after CAR-T, eligible patients will be given NKTR-255 IV over 30 minutes, and it will be repeated every 28 days for up to 6 cycles. Patients that benefited from the first dose of CD19/CD22 CAR T cells, had no unacceptable side effects, and have enough cells left over may receive 2 or 3 additional doses of CD19/CD22 CAR T cells.
89437670|NCT03198598|Experimental|MS patients with EDSS from 0 to 5.5 for yoga|Three months of Iyengar Yoga practice.
89437671|NCT03198598|No Intervention|MS patients with EDSS from 0 to 5.5 for control|
89437672|NCT03198598|Experimental|MS patients with EDSS from 6 to 8 for yoga|Receive a smartphone application that has an eight-week program including meditation practices, Yoga exercises that can be done in a seated or laid position and daily care tips
89437673|NCT03198598|No Intervention|MS patients with EDSS from 6 to 8 for control|
89437674|NCT03198598|No Intervention|Healthy subjects|
89437675|NCT03190239|Experimental|Apatinib XQonc-0007|Pemetrexed 500 mg/m2, qm; Apatinib 250 mg Po qd
89437676|NCT03189875||Observation|Cohort of patients with moderate-to-severe SLE
89437677|NCT03179163|No Intervention|Normotensive|Blood Pressure <120/80 mmHg
89437678|NCT03179163|Experimental|Hypertensive - ACE inhibitor with sulfahydrl donor (ACEi +SH)|Captopril Pill intervention Blood Pressure ≥140/90 mmHg and <160/110 mmHg
89437679|NCT03179163|Experimental|Hypertensive - ACE inhibitor (ACEi)|Enalapril Pill intervention Blood Pressure ≥140/90 mmHg and <160/110 mmHg
89437680|NCT03179163|Active Comparator|Hypertensive - Diuretic|Hydrochlorothiazide intervention Blood Pressure ≥140/90 mmHg and <160/110 mmHg
88922447|NCT05195775|Experimental|Tadalafil plus Doppler ultrasound (Schedule B)|The intervention is the same as in Schedule A; this arm will use Doppler ultrasound as the technique to monitor drug impact on skeletal muscle.
88922448|NCT05194748||camptocormia group|Diaphragmatic thickness will be measured by ultrasonography. Respiratory function will be evaluated by spirometric measurements. Postural deviations of the spine, knees, and hips will be recorded through photographs taken from the side and back
88922449|NCT05194748||no camptocormia group|Diaphragmatic thickness will be measured by ultrasonography. Respiratory function will be evaluated by spirometric measurements. Postural deviations of the spine, knees, and hips will be recorded through photographs taken from the side and back
88922450|NCT05194111|Experimental|Arm 1: Sacubitril-valsartan|Sacubitril-valsartan administered orally twice daily at a maximally tolerate dose (max dose 97mg/103mg twice daily).
88922451|NCT05194111|Experimental|Arm 2: Valsartan|Valsartan administered orally twice daily at a maximally tolerate dose (max dose 160mg twice daily)
88922452|NCT05189379|Experimental|Olfaction First|Participants assigned to this arm will undergo the experiment in the following order: Odour based Cue Reactivity Task, Monetary Incentive Delay Task, Image based Cue Reactivity Task
88922453|NCT05189379|Experimental|Image First|Participants assigned to this arm will undergo the experiment in the following order: Image based Cue Reactivity Task, Monetary Incentive Delay Task, Odour based Cue Reactivity Task
88922454|NCT05188027|Experimental|All participants|All participants will take part in all three testing conditions
88922455|NCT05184816|Experimental|Deferoxamine (DFO)|This study is an open-label, non-randomized, single-center, dose escalation phase 1a study of intrathecal deferoxamine (IT-DFO) in patients with leptomeningeal metastases (LM) from solid tumor malignancies, followed by a phase 1b dose expansion cohort at the recommended phase 2 dose (RP2D) in patients with LM from non-small cell lung cancer (NSCLC). Study objectives will include safety (1a/1b), pharmacokinetics (PK) and pharmacodynamics (PD) of IT-DFO (1a/1b), and preliminary anti-tumoral efficacy in patients with LM from NSCLC (1b).
88922456|NCT05182307|Experimental|Treatment|DurAVR™ THV System
88922457|NCT05182255||Esophageal Stent Systems|Freedom from endoscopic re-intervention due to recurrence of dysphagia
88922458|NCT05178901|Experimental|PHV02 2x10^5 pfu|
88922459|NCT05178901|Experimental|PHV02 2x10^6 pfu|
88922460|NCT05178901|Experimental|PHV02 2x10^7 pfu|
88922461|NCT05178901|Placebo Comparator|Placebo|
88922462|NCT05178901|Experimental|PHV02 5x10^8 pfu (Boost)|
88922463|NCT05178901|Experimental|PHV02 5x10^8 pfu (Prime)|
88922464|NCT05176457|No Intervention|BEFORE PICT'REA introduction|Patients will have the usual communication tools (pen and paper, hands gestures...)
88922465|NCT05176457|Experimental|AFTER PICT'REA introduction|Patients will be given a tablet to communicate with the caregivers whenever needed
88922466|NCT05164783|Experimental|Participants|Intervention: use of SCP
88922467|NCT05160545|Experimental|GNC-035|Patients receive GNC-035 intravenous infusion (IV, QW) for 2 weeks (a 2-week cycle). Participants with no intolerable AEs could continue for another three cycles
89199264|NCT05942833|Other|Group B (Late)|Elective left hemicolectomy 6 to 8 weeks after 7-10 days lasting initial conservative or interventional treatment (e.g: antibiotics, analgesics, drainage) and CT scan/ultrasound proven left-sided colonic diverticulitis
89437681|NCT03175809|Active Comparator|PFM training|4 sessions (40 minutes approximately), Twice a week for 2 weeks of pelvic floor training with electromyographic biofeedback.
89437682|NCT03175809|Experimental|PFM training plus dry needling|PFM training associated with the use of dry needling over abdominal, gluteal and lombar miofascial trigger points.
89437683|NCT03168971|Experimental|Managing Anxiety from Cancer (MAC)|Older adults with cancer and their primary informal caregiver will receive a seven-session cognitive-behavior therapy intervention administered over the telephone by a trained study interventionist. The intervention is administered weekly and each session is 45-50 minutes in length. Patients and caregivers will receive the intervention independently and from separate therapists.
89437684|NCT03168971|No Intervention|Usual Care|Older adults with cancer and their primary informal caregiver will receive standard care provided by their medical team. These participants will not receive any intervention from the research team.
89437685|NCT03168672|Other|Global ICON|The study device is the GLOBAL ICON stemless humeral component, consisting of the Anchor Plate and Humeral Head.
89437686|NCT03164278|Experimental|Immediate Training (no follow up)|Individuals may decide to participate in the research study training program, but not in any follow up questionnaires. This group will have immediate access to the independent transfer training materials. They will complete data collection measures embedded in the transfer training program, including demographics, Online Learning Readiness Scale (OLRS), Moorong Self Efficacy Scale (MSES), Patient Reported Outcome Measurement Information System (PROMIS), Transfer Assessment Instrument Questionnaire (TAI-Q), and the Wheelchair User Shoulder Pain Index (WUSPI).
89437687|NCT03164278|Experimental|Immediate Training (with follow up)|Individuals may decide to participate in the research study, but do not want to be randomized. After consent is obtained, these individuals will be directed immediately to the baseline questionnaires (see above) before and after the independent transfer training. Participants may also be asked to complete a user satisfaction survey.
89437688|NCT03164278|Experimental|Randomized Training|Individuals may decide to participate in the research study and agree to be randomized. These individuals will be immediately randomized into an immediate or a wait list control group. The immediate will receive the independent transfer training program after completing the baseline questionnaires. The wait list control group will wait approximately 6 months before receiving the independent transfer training program.
89437689|NCT03157635|Experimental|Part 1 (Healthy Volunteers): Crovalimab|Healthy participants will receive a single dose of crovalimab in each dose-escalation cohort of Part 1. Crovalimab will be administered at a starting dose of 75 milligrams (mg) intravenous (IV) infusion. Doses are planned to be escalated up to Cohort 5.
89437690|NCT03157635|Placebo Comparator|Part 1 (Healthy Volunteers): Placebo|Healthy participants will receive a single dose of crovalimab matching placebo in each dose-escalation cohort of Part 1.
89437691|NCT03157635|Experimental|Part 2 (PNH Participants): Crovalimab|PNH participants will receive 3 single ascending doses (375 mg IV, 500 mg IV, 1000 mg IV of crovalimab) on Days 1, 8, and 22 followed by weekly crovalimab administrations up to a maximum of 5 months. Weekly crovalimab administrations will start no earlier than Day 36. The starting dose of Part 2 is based on data from Part 1 of the study.
89437692|NCT03157635|Experimental|Part 3 (PNH Participants): Crovalimab QW|Participants will receive crovalimab at a dose of 1000 mg on Day 1 and 170 mg weekly (QW) starting on Day 8 for a maximum treatment duration of 5 months.
89437693|NCT03157635|Experimental|Part 3 (PNH Participants): Crovalimab Q2W|Participants will receive crovalimab at a dose of 1000 mg on Day 1 and 340 mg every 2 weeks (Q2W) for a maximum treatment duration of 5 months.
89437694|NCT03157635|Experimental|Part 3 (PNH Participants): Crovalimab Q4W|Participants will receive crovalimab at a dose of 1000 mg on Day 1 and 680 mg every 4 weeks (Q4W) starting on Day 8 for a maximum treatment duration of 5 months.
88922468|NCT05149313|Experimental|Lebrikizumab|Lebrikizumab administered subcutaneously (SC), 250 milligram (mg) dose once every two weeks (Q2W) in the induction period for 16 weeks. Participants achieving EASI75 at Week 16 will receive 1 injection each of 250 mg lebrikizumab and placebo at Week 16, no injections at Week 18 followed by 1 injection of lebrikizumab 250 mg once every four weeks (Q4W) after Week 20 up to Week 36. Participants not achieving EASI75 at Week 16 will receive 1 injection each of 250 mg lebrikizumab and placebo at Week 16 and 18, followed by 1 injection of lebrikizumab 250 mg Q2W after Week 20 up to Week 52.
88922469|NCT05149313|Placebo Comparator|Lebrikizumab-matching Placebo|Lebrikizumab-matching Placebo administered SC, 250 mg dose, Q2W in the induction period for 16 weeks. Participants will receive 2 injections each of 250 mg lebrikizumab-matching placebo at Week 16, no injections at Week 18 followed by 1 injection of lebrikizumab- matching placebo 250 mg Q4W after Week 20 up to Week 36.
88922470|NCT05145907|Experimental|TJ107+Pembrolizumab|TJ107 1200ug/Kg,Q12W + Pembrolizumab 200mg Q3W
88922471|NCT05144009|Experimental|Cohort A : Loncastuximab Tesirine + Rituximab (Lonca-R)|"Participants who are unfit (per sGA) will receive Lonca-R for 3 cycles. Participants who achieve a complete response (CR) will receive Lonca-R for 1 additional cycle. Participants who achieve a partial response (PR) will receive Lonca-R for 3 additional cycles.~Lonca-R will be administered as rituximab 375 mg/m^2 on Day 1 of Cycle 1 and loncastuximab tesirine 150 µg/kg on Day 2 of Cycle 1. During Cycle 2, Lonca-R will be administered as rituximab* 375 mg/m^2 and loncastuximab tesirine 150 µg/kg on Day 1. For cycles 3 and beyond, Lonca-R will be administered as rituximab 375 mg/m^2 and loncastuximab tesirine 75 µg/kg on Day 1.~*subcutaneous rituximab 1400mg/dose may be used during Cycle 2 and beyond"
88922472|NCT05144009|Experimental|Cohort B : Loncastuximab Tesirine + Rituximab (Lonca-R)|"Participants who are frail (per sGA) or participants with cardiac comorbidities will receive Lonca-R for 3 cycles. Participants who achieve a CR will receive Lonca-R for 1 additional cycle. Participants who achieve a PR will receive Lonca-R for 3 additional cycles for a total of up to 6 cycles. Only participants enrolled in Cohort B, who achieve stable disease (SD) and deriving clinical benefit per the treating physician, may also receive Lonca-R for an additional 3 cycles.~Lonca-R will be administered as rituximab 375 mg/m^2 on Day 1 of Cycle 1 and loncastuximab tesirine 150 µg/kg on Day 2 of Cycle 1. During Cycle 2, Lonca-R will be administered as rituximab* 375 mg/m^2 and loncastuximab tesirine 150 µg/kg on Day 1. For cycles 3 and beyond, Lonca-R will be administered as rituximab 375 mg/m^2 and loncastuximab tesirine 75 µg/kg on Day 1.~*subcutaneous rituximab 1400mg/dose may be used during Cycle 2 and beyond"
88922473|NCT05142995||Behcet disease|Hamilton Anxiety Rating Scale Hamilton Depression Rating Scale SF36 questionnaire Epworth sleepiness scale Pittsburgh sleep quality index
88922474|NCT05142995||control|Hamilton Anxiety Rating Scale Hamilton Depression Rating Scale SF36 questionnaire Epworth sleepiness scale Pittsburgh sleep quality index
89199265|NCT05937113|Experimental|Safety of a 3-dose regimen of RABIVAX-S in healthy participants aged 5 to 60 years|RABIVAX-S is a pure, sterile inactivated rabies vaccine produced on vero cells. RABIVAX-S vaccine is lyophilized and is supplied with rehydration solution (1 vial containing 1 dose of lyophilized vaccine and 1 vial of rehydration solution).
89502016|NCT05498714|Experimental|CSP+lactulose group|The dosing regimen of high-risk patients will be CSP combined with lactulose.
89437695|NCT03157635|Experimental|Part 4 (eculizumab pretreated PNH Participants): Crovalimab|"PNH Participants pretreated with eculizumab will receive crovalimab:~Participants >/= 100 kilograms (kg): loading dose of 1500 mg IV on Day 1; Participants < 100 kg: loading dose of 1000 mg IV on Day 1. In all Participants, the remainder of the loading series schedule will be 340 mg subcutaneous (SC) on Days 2, 8, 15, and 22. For Participants >/= 100 kg, maintenance dosing will be 1020 mg SC on week 5 and then Q4W thereafter. Patients < 100 kg will receive a maintenance dose of 680 mg SC on the same schedule."
89437696|NCT03157635|Experimental|Part 4 (treatment naïve PNH Participants): Crovalimab|"Treatment naïve PNH Participants will receive:~Participants >/= 100 kg: loading dose of 1500 mg IV on day 1; Participants < 100 kg: loading dose of 1000 mg IV on day 1. In all Participants, the remainder of the loading series schedule will be 340 mg SC on Days 2, 8, 15, and 22. For Participants >/= 100 kg, maintenance dosing will be 1020 mg SC on week 5 and then Q4W thereafter. Patients < 100 kg will receive a maintenance dose of 680 mg SC on the same schedule."
89437697|NCT03157635|Experimental|OLE (PNH Participants): Crovalimab|PNH Participants who participated in Parts 2, 3 and 4 and who derive clinical benefit from crovalimab may enroll into OLE. Participants will either receive 680 mg SC Q4W (body weight >/= 40 kg to < 100 kg) or 1020 mg SC Q4W (body weight >/= 100 kg) for up to a maximum treatment duration of ten years from entry into OLE.
89437698|NCT03144765|Experimental|taTME|Enrolled subjects will undergo the study procedure, laparoscopically-assisted Transanal Total Mesorectal Excision (taTME).
89011586|NCT01646281|Active Comparator|Vernakalant|Patients randomized to vernakalant will receive a 10-minute infusion of 3 mg/kg vernakalant, followed by a 15 minute observation period. If the patient is still in atrial fibrillation, an additional 10-minute infusion of 2 mg/kg vernakalant will be given. If the patient is still in AF 1 hour after the infusion, electrical cardioversion will be performed according to protocol.
89011587|NCT01646359|Experimental|corrected flow time|
89011588|NCT01646476|Active Comparator|Covered stent (Bona stent, pyloric/duodenal covered)|WAVE covered self-expandable metallic stent (BONASTENT, Standard Sci Tech, Ltd., Seoul, Korea)
89437699|NCT03142152|Experimental|Intervention Group|Carillon Mitral Contour System and Guideline Directed Heart Failure Medication
89437700|NCT03142152|Active Comparator|Control Group|Guideline Directed Heart Failure Medication
89437701|NCT03107403|Experimental|Healthy subjects|
89437702|NCT03060096|Experimental|Moderate Anxiety/depression: Low Intensity Stepped care|participants with moderate symptoms (PHQ-9-14; GAD-7: 10-14) will be randomized to either low-intensity stepped care or enhanced usual care. Stepped care consist of a self-guided cognitive behavioral therapy (CBT) workbook to reduce anxiety and depressive symptoms and biweekly (every two weeks) check-in calls from research staff to assess changes in symptom severity/immediate need for psychiatric treatment and provide minimal support.
89437703|NCT03060096|Experimental|Severe Anxiety/depression: High Intensity Stepped Care|Participants with severe symptoms (PHQ-9: 15-27; GAD-7: 15-21) will be randomized to high intensity stepped care (consist of a CBT workbook with accompanying psychotherapy by a Master's-level therapist delivered by telephone) or EUC. EUC consist of information about referrals/resources locally and nationally.
89538425|NCT03267407||CrAg(-)|(3) Patients with CrAg negative results will be managed as other HIV infected patients with the standard of care, following national guidelines.
89538426|NCT03267329|Experimental|Duowell® Tab.|Once daily during 16 wks
89011589|NCT01646476|Active Comparator|Uncovered stent (Bona stent, pyloric/duodenal)|uncovered self-expandable metallic stent (BONASTENT, Standard Sci Tech, Ltd., Seoul, Korea)
89011590|NCT01646554|Active Comparator|Arm A: modified FOLFOX6 and Surgery|"6 cycles before and 6 cycles after surgery consisting in:~Hour 0: Oxaliplatin 85 mg/m² IV 2-h infusion~Hour 0: Folinic Acid 400 mg/m² (DL form) or 200 mg/m2 (L form) IV 2-h infusion~Hour 2: 5-FU 400 mg/m² IV bolus over 2-4 minutes~Hour 2: 5-FU 2400 mg/m² given as a continuous infusion over 46h.~On day 1 of a 14 day cycle"
89011591|NCT01646554|Experimental|Arm B: modified FOLFOX6 + Aflibercept and Surgery|"6 cycles before and 6 cycles after surgery consisting in:~Hour 0: Aflibercept 4 mg/kg intravenous infusion 1-h~Hour 1: Oxaliplatin 85 mg/m2 2-h infusion~Hour 1: Folinic Acid 400 mg/m2 (DL form) or 200 mg/m2 (L form) 2-h infusion~Hour 3: 5-FU bolus 400 mg/m2 IV bolus over 2-4 minutes~Hour 3: 5-FU 2400 mg/m² given as a continuous infusion over 46h.~Day 1 of a 14 day cycle~Aflibercept should be given in all cycles, except cycle 6 of pre-operative treatment."
89011592|NCT00250263|Placebo Comparator|1|Matching placebo- control arm (first year)
89011593|NCT00250263|Active Comparator|2|Drug Staloral (active group)
89011594|NCT02279368|Experimental|Intervention Group|Nurses delivered the supportive intervention along with family counselling from last term of pregnancy through three months and then were followed till the first birthday of the child.
89011595|NCT02279368|No Intervention|Control Group|Control group families were followed in usual care.
89011596|NCT02279446||20/20ND group|This group will have 20/20 visual acuity both in distant and near.
89011597|NCT02279446||20/20D group|This group will have 20/20 distant visual acuity and variable near visual acuity.
89437704|NCT03060096|Active Comparator|Enhanced Usual Care Control (EUC)|"Participants randomized to EUC will receive information about local referrals/resources (support groups, mental health providers, etc.). They will also be provided Facing Forward: Life after Cancer Treatment, a book developed by the NCI to assist with transition from active treatment to survivorship. Participants will receive information on self-help workbooks for anxiety & depressive symptoms. EUC control will receive a copy of the CBT workbook on completion of the study."
89437705|NCT03057314|Experimental|Amorphous calcium carbonate|"The investigation product will include:~ACC tablets, containing 200 mg elemental calcium~1% ACC (i.e. 0.3% calcium) + 5 mL Water for Injection, as a sterile suspension"
89437706|NCT03055377|Experimental|N-acetylcysteine|N-acetylcysteine 1200 mg twice daily for 12 weeks
89437707|NCT03055377|Placebo Comparator|Placebo|Placebo (matched in appearance to N-acetylcysteine to preserve double-blind) twice daily for 12 weeks
89437708|NCT03051516|Experimental|Arm I (recombinant human papillomavirus nonavalent vaccine)|Patients receive recombinant human papillomavirus nonavalent vaccine IM at baseline, 2 months, and 6 months.
88922475|NCT05142787|Other|axillary lymph nodes requiring localisation prior to surgical excision|"The Magseed Pro® marker is intended to be placed percutaneously in suspicious/biopsy proven positive axillary lymph nodes under imaging guidance to mark tissue intended for selective surgical removal.~The Magseed Pro® marker is localised using the Sentimag® Gen3 system handheld probes and surgically removed within/from the target tissue."
88922476|NCT05142787|Other|breast lesions requiring localisation|"The Magseed Pro® marker is intended to be placed percutaneously in breast lesions under imaging guidance to mark tissue intended for selective surgical removal.~The Magseed Pro® marker is localised using the Sentimag® Gen3 system handheld probes and surgically removed within/from the target tissue."
88922477|NCT05142410||Plasma from women with normal pregnancies|Plasma collected from women with normal pregnancies will be analyzed by mass spectrometry
88922478|NCT05142410||Plasma from women with placenta-mediated complications|Plasma collected from women who developed preeclampsia during pregnancy will be analyzed by mass spectrometry
88922479|NCT05139251|Experimental|Recovering from Intimate partner violence through Strengths and Empowerment (RISE) +ePALS|
88922480|NCT05137158|Experimental|iTBS stimulation|The patients in iTBS stimulation group will receive iTBS stimulation on the target of the left dorsolateral prefrontal cortex for 10 consecutive days and 3 times per day.There will have at least 30 minutes interval between each intervention.
88922481|NCT05137158|Sham Comparator|Sham stimulation|The participants in sham stimulation will receive sham stimulation, as the coil vertical to the brain surface, for 10 consecutive days and 3 times per day.There will have at least 30 minutes interval between each intervention.
88922482|NCT05134714|Experimental|Group 1(study group): CAD/CAM zircon band and loop space maintainer|Solid monolithic zirconia material which utilizes CAD/CAM technology for its designing and milling of the restoration will be used for fabrication of the space maintainer.
88922483|NCT05134714|Active Comparator|Group 2(control): Conventional metal band and loop space maintainer|Stainless steel band and loop space maintainer will be made. Stainless steel appropriate band will be selected according to the size of the abutment teeth then design of the loop will be obtained, then will be send to the laboratory for soldering.
88922484|NCT05134012|Experimental|[O-15]-Water PET Myocardial Perfusion Imaging (MPI)|All participants with suspected CAD will receive two doses of [15-O]-H2O as part of a single PET imaging session (one dose at rest and one during pharmacological stress with adenosine).
88922485|NCT05128734|Experimental|Temozolomide Arm|Temozolomide: 50 mg/m2 daily in cycles of 21 days
88922486|NCT05128734|Experimental|Temozolomide+Olaparib Arm|Temozolomide 75 mg/m2 day 1 to day 7 with Olaparib 200 mg BID, oral, day 1 to day 7 in cycles of 21 days
88922487|NCT05126758|Experimental|CAP-1002|"Cohort A: Approximatetly 29 subjects will receive CAP-1002A active treatment consisting of 150 million cardiosphere-derived cells (CDCs) via intravenous infusion every 3 months~Cohort B: Approximately 22 participants will receive CAP-1002B active treatment consisting of 150 million cardiosphere-derived cells (CDCs) via intravenous infusion every 3 months"
88922488|NCT05126758|Placebo Comparator|Placebo|"Cohort A: Approximately 29 subjects will receive a Placebo solution via intravenous infusion every 3 months~Cohort B: Approximately 22 participants will receive a Placebo solution via intravenous infusion every 3 months"
89437709|NCT03051516|Placebo Comparator|Arm II (placebo)|Patients receive placebo IM at baseline, 2 months, and 6 months.
89437710|NCT03042754|Other|suspected TB|Patients suspected with TB will be sent for XpertMTB/RIF and urine LAM test
89437711|NCT03041688|Experimental|Treatment (decitabine, navtemadlin, venetoclax)|"Patients receive decitabine IV over 1 hour on days 1-10, navtemadlin PO QD on days 1-7, and venetoclax PO QD on days 1-21. Treatment repeats every 28 days for up to 4 cycles in patients with evidence of persistent AML.~Starting cycle 2, patients with no morphologic evidence of AML receive decitabine IV over 1 hour on days 1-5, navtemadlin PO QD on days 1-7, and venetoclax PO QD on days 1-14. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Patients also undergo bone marrow aspiration and biopsy, and blood sample collection throughout the trial."
89437712|NCT03035123|No Intervention|"Usual care"|Patients will attend an appointment with the therapeutic education nurse before discharge, after which they will have no further contact with the education team. The Research team members will telephone the patient three times during the year (after 2, 6 and 12 months) to collect data on HF treatments, blood tests results, health-related events and hospitalizations.
89502017|NCT05490836|Active Comparator|continuous treatment arm|
88922489|NCT05117086|Experimental|Dietary Intervention Arm|Subjects will receive the active intervention of nutrition education and medical nutrition therapy counseling for dietary and behavioral lifestyle changes. The focus will be on DASH diet implementation and adherence for management of heart failure. The subjects will have 4 study visits with a Registered Dietitian over 6 months (visits at 1, 2, 3, and 6 months). Outcome measures will be assessed at baseline, 3 and 6 months.
88922490|NCT05112991|Experimental|Envafolimab + Lenvatinib|Subjects receive lenvatinib daily and envafolimab once on Day 1 and 15 of the first cycle and at the beginning of each subsequent 4 week treatment cycle D1.
88922491|NCT05112991|Experimental|Envafolimab|Subjects receive envafolimab once on Day 1 and 15 of the first cycle and at the beginning of each subsequent 4 week treatment cycle D1.
88922492|NCT05107856|Experimental|PRT1419 Monotherapy|PRT1419 will be administered by intravenous infusion once weekly on a 28-day treatment cycle at the dose level assigned.
88922493|NCT05107856|Experimental|PRT1419/Azacitidine Combination|PRT1419 will be administered by intravenous infusion once weekly on a 28-day treatment cycle at the dose level assigned and Azacitidine will be administered by intravenous or subcutaneous on Days 1 through 7 (or alternatively on Days 1 through 5, 8 and 9) of each 28-day treatment cycle.
88922494|NCT05107856|Experimental|PRT1419/Venetoclax Combination|PRT1419 will be administered by intravenous infusion once weekly on a 28-day treatment cycle at the dose level assigned and Venetoclax will be administered orally after either a 3-day or 5-week ramp-up period to reach 400 mg daily administration, prior to commencing PRT1419 administration.
88922495|NCT05101148|Experimental|selumetinib single arm|This is a sequential study consisting of a screening period lasting up to 28 days, a 28 day (1 cycle) treatment period (T1) in a fed state, a 7 day washout period, a further 1 cycle treatment period (T2) in a fasted state and an extension to T2 until results from the primary analysis are available. During Treatment Period 1 and 2 all participants will receive selumetinib (25 mg/m2 bid). If a third treatment period (T3) is required, participants will enter a 7 day washout period followed by a treatment period in a fed state at an adjusted dose for 3 cycles.
88922496|NCT05101109|Experimental|ABL501|ABL501 will be administered biweekly of every 28-day cycle in the dose-escalation.
88922497|NCT05099536|Experimental|3D011-08|
88922498|NCT05089955|Experimental|Intervention group|MRI examination with Ambient Experience with paediatric content
88922499|NCT05089955|No Intervention|Control group|MRI examination without Ambient Experience (standard of care)
88922500|NCT05083611|No Intervention|Control group|The control group will receive an information session on phantom limb pain (1 hour) and will continue with the usual treatment received.
88922501|NCT05083611|Experimental|Experimental group|The experimental group will receive an educational session on phantom limb pain and the previously designed GraMI protocol through a systematic review and validation through a study with Delphi methodology. This protocol contains the three techniques with their defined intensity, frequency, duration and progression.
88922502|NCT05067634|Experimental|12 to < 18 year olds|
88922503|NCT05067634|Experimental|6 to <12 years old|
88922504|NCT05067634|Experimental|4 to <6 years old|
88922505|NCT05067634|Experimental|2 to <4 years old|
88922506|NCT05067426|Experimental|HIIT-HV|"HIIT-HV - high intensity interval training high volume~Participants complete a total of 10 HIIT sessions over a 7-day period consisting of 5 x 4-minute intervals at an intensity of 90-95% of their individual maximum heart rate (HRmax), interspersed with a 2.5-minute active recovery period. Each training session is followed by 30 minutes of low-intensity training (total of 300 minutes of additional low-intensity training during this period)."
88922507|NCT05067426|Experimental|HIIT-LV|"HIIT- LV - high intensity interval training low volume~Participants complete a total of 10 HIIT sessions over a 7-day period consisting of 5 x 4-minute intervals at an intensity of 90-95% of their individual maximum heart rate (HRmax), interspersed with a 2.5-minute active recovery period."
88922508|NCT05067426|No Intervention|Control group|Participants continue with their regular training program.
88922509|NCT05065268|Experimental|Interventional|Immersive virtual-reality stimulation (IVR): 1 session of 3 blocks of 15 trials of 20 seconds each. Rest time is 1-2 minute(s) between blocks. 1 session lasts 19 minutes.1 session every 2 days for 4 weeks (15 sessions total).
88922510|NCT05054439|Experimental|SI-B001 combined with paclitaxel|SI-B001 in combination with paclitaxel for the treatment of recurrent metastatic head and neck squamous cell carcinoma (non-nasopharyngeal carcinoma) with disease progression or intolerance.； The patient had previously received anti-PD-1 mab ± platinum-based chemotherapy； Patients' previous treatment line should be ≤2L.
88922511|NCT05052736|Experimental|Non-invasive Neuromodulation|Non-invasive Neuromodulation Intervention with microcurrents: application of 6 electrodes per extremity and an adhesive electrode at C7 level.
88922512|NCT05052736|Placebo Comparator|Placebo Non-invasive Neuromodulation|Intervention with microcurrents: application of 6 electrodes per extremity and an adhesive electrode at C7.
88922513|NCT05044897|Experimental|Study treatment|"SI-B001 is a bispecific antibody targeting EGFR and HER3, which is administered weekly by intravenous infusion（QW）.~The 4-week cycle was maintained until disease progression or cessation due to intolerable toxicity or other reasons (e.g., withdrawal of informed consent or death). From C1D1, efficacy was evaluated every 8 weeks ±7 days in the first year and every 12 weeks ±7 days in the second year."
88922514|NCT05039892|Experimental|All eligible subjects|
88922515|NCT05036915|Experimental|Control group (Pacifier randomly 30 min)|Pacifier is randomly given to the infant for 30 min independent from feeding during the day
88922516|NCT05036915|Experimental|Experimental Group (Pacifier randomly 30 min+ routine 5 min before each feeding)|Pacifier is randomly given to the infant for 30 min independent from feeding during the day. In addition, pacifier is given to the infant for 5 min before each feeding.
88922517|NCT05031026|Active Comparator|donor group|where donors only will receive dexmedetomidine
88922518|NCT05031026|Active Comparator|recpient group|where recepients only will receive dexmedetomidine
88922519|NCT05031026|Placebo Comparator|control group|both donors and recipients will receive a placebo
88922520|NCT05024214|Experimental|Phase Ib arm|Subjects with advanced or metastatic solid tumor (excluding hepatocellular carcinoma and thyroid cancer) with disease progression or intolerance or no effective treatment after standard therapy
88922521|NCT05024214|Experimental|Phase II cohort1-NSCLC|Subjects with non-small cell lung cancer, resistant after previous treatment with PD-(L)1 inhibitors
88922522|NCT05024214|Experimental|II Phase cohort1-RCC|Subjects with renal cell carcinoma, resistant after previous treatment with PD-(L)1 inhibitors
88922523|NCT05024214|Experimental|Phase II cohort1-HCC|Subjects with hepatocellular carcinoma, resistant after previous treatment with PD-(L)1 inhibitors
88922524|NCT05024214|Experimental|Phase II cohor2-experiment group|Subjects with renal cell carcinoma, no previous systemic treatment for advanced disease
88922525|NCT05024214|Experimental|Phase II cohort2-control group|Subjects with renal cell carcinoma, no previous systemic treatment for advanced disease
88922526|NCT05023785|Experimental|Cardio-Oncology Rehabilitation (CORE)|"Participants in the CORE group will have~A personalized, supervised exercise program ((in-person at intuition and virtual/ homebased exercises)~CV risk factor management,~behavioural support for the first 6 months. The behavioural support will continue for CORE participants from months 7-24. Behavioural support includes professionally guided and peer-enhanced exercise behavioural support based on behaviour change stage theories.~CORE participants will be provided a wrist-worn heart and physical activity monitor to use throughout the 24-month observation period."
88922527|NCT05023785|No Intervention|Standard of Care (CON)|Participants in the CON group will receive standard medical care and physical activity will be monitored by a wrist-worn activity tracker for 2 years.
88922528|NCT05022654|Experimental|SI-B001 combined with irinotecan|Patients with recurrent metastatic esophageal squamous cell carcinoma who had failed first-line therapy with PD-1(L1) monoclonal antibody plus platinum-based chemotherapy were enrolled.
88922529|NCT05020457|Experimental|SI-B001 combined with AP or TP_A|SI-B001 combined with Platinum-based chemotherapy(AP or TP). Patients enrolled with EGFRwt/ALKwt NSCLC progressed or were intolerant after first-line treatment with anti-PD-1 /L1 mab alone.
88922530|NCT05020457|Experimental|SI-B001 combined with Docetaxel_B|Patients with EGFRwt/ALKwt non-small cell lung cancer were included and progressed or were intolerant after first-line treatment with platinum-based two-drug chemotherapy plus anti-PD-1 /L1 mab.
88922531|NCT05020457|Experimental|SI-B001 combined with Docetaxel_C|Patients enrolled with EGFRwt/ALKwt NSCLC progressed or were intolerant to treatment with anti-PD-1 /PD-L1 monoclonal antibody after first-line or above chemotherapy.
88922532|NCT05017987|Active Comparator|Sequence A=Reference-Test|"T(Test drug): ATB-101 R1(Reference drug1): ATB-1011 R2(Reference drug2): ATB-1012~First stage: co-administration of R1 and R2, single dose and then Washout: 7days and then Second stage: administration of T, single dose"
88922533|NCT05017987|Active Comparator|Sequence B=Test-Reference|First stage: administration of T, single dose and then Washout: 7days and then Second stage: co-administration of R1 and R2, single dose
88922534|NCT05013476|Active Comparator|In-Person ultrasound participants|In-Person ultrasound participant's will receive ultrasound training that is guided by online modules (identical to virtual) with trained faculty in the same room with a ration of 4 students to 1 instructor.
88922535|NCT05013476|Active Comparator|Virtual ultrasound participants|Virtual ultrasound participants will receive ultrasound training that is guided by online modules (identical to in-person) with trained faculty present in a private zoom classroom. Faculty will be rotating between breakout rooms and will share the same ratio of participants to staff.
89538427|NCT03267329|Active Comparator|Telmisartan|Once daily during 16 wks
88922536|NCT04993742|Experimental|MOMS Intervention|"Women that are currently in the Mentors Offering Maternal Support (M-O-M-S) research program as well as pregnant women entering prenatal care in the first trimester, who are not in the M-O-M-S program may participate in the study.~Arms Assigned Interventions Experimental: M-O-M-S Intervention M-O-M-S intervention is 10, 1 hour prenatal mentored support groups~No Intervention: Routine Prenatal Care Routine prenatal care in accordance with the Department of Defense Pregnancy Guidelines"
89011598|NCT02279446||20/20N group|This group will have 20/20 near visual acuity and variable distant visual acuity.
89011599|NCT02279446||s20/20ND group|This group will have variable near and distant visual acuity (both less than 20/20)
89199266|NCT05937113|Experimental|immunogenicityof a 3-dose regimen of RABIVAX-S in subgroup of participants|RABIVAX-S is a pure, sterile inactivated rabies vaccine produced on vero cells. RABIVAX-S vaccine is lyophilized and is supplied with rehydration solution (1 vial containing 1 dose of lyophilized vaccine and 1 vial of rehydration solution).
89199267|NCT05936944||Natural Light|Group of patients enrolled in the first ICU, with natural lighting
89199268|NCT05936944||Artificial Light|Group of patients enrolled in the second ICU, with totally artificial lighting
89199269|NCT05931419||Robot assisted radical prostatectomy (RARP)|Robot-assisted radical prostatectomy, potentially as part of multimodality therapy with adjuvant radiotherapy or with (neo)adjuvant androgen deprivation therapy. Pelvic lymph node dissection (PLND) may be performed for staging purposes. The presence of positive lymph nodes (pN1) upon PLND is not a reason for exclusion and may be followed by adjuvant treatment such as lymph node irradiation.
89199270|NCT05931419||External beam radiotherapy (EBRT) combined with androgen deprivation therapy (ADT)|External beam radiotherapy (hypofractionated or conventionally fractionated) at a biologically effective dose converted to 2Gy fractions (α/β:1.5) of at least 76Gy. EBRT may be combined with a brachytherapy boost and PLND may be performed for staging purposes. The presence of positive lymph nodes (pN1) upon PLND is not a reason for exclusion and lymph node irradiation may be performed. Patients should receive ADT for at least 6 months.
89199271|NCT05928312|Experimental|Advanced CRC|Patients with Advanced CRC were given Fruquintinib Combine With Chemotherapy.
89199272|NCT05926687|Active Comparator|Social Communication + Reduce Frequency|"Starting Intervention: Social Communication Who: Parent & Child & Therapist Frequency: 1-hour twice/week~Secondary Intervention: Reduce Frequency of Social Communication Intervention Intervention: Social Communication Who: Parent & Child & Therapist Reduce Frequency: 1-hour once/week"
89199273|NCT05926687|Active Comparator|Social Communication + Add Tools|"Starting Intervention: Social Communication Who: Parent & Child & Therapist Frequency: 1-hour twice/week~Secondary Intervention: Add Tools to Social Communication Intervention Intervention: Social Communication Who: Parent & Child & Therapist Frequency: 1-hour twice/week Add: Video feedback"
89199274|NCT05926687|Active Comparator|Social Communication + Switch Intervention to Disruptive Behavior|"Starting Intervention: Social Communication Who: Parent & Child & Therapist Frequency: 1-hour twice/week~Secondary Intervention: Switch to Disruptive Behavior Intervention Who: Parent & Therapist only Frequency: 1-hour once/week"
88922537|NCT04990804|Active Comparator|Standard Perioperative Pain Regimen|Patients will be provided a prescription for low dose opioids for 5 days postoperatively (Hydrocodone/Acetaminophen 5/325mg or Oxycodone/Acetaminophen 5/325mg) to be taken every 6 hours as needed for pain. Refills may be provided (Hydrocodone/Acetaminophen 5/325mg or Oxycodone/Acetaminophen 5/325mg) if requested by the patient at the providers discretion. In addition, patients will also be prescribed Gabapentin 300mg q8 hours or Pregabalin 75mg twice daily and a muscle relaxer (Methocarbamol 750mg BID or Flexeril 5-10 mg TID) as needed for spasms. Alternative muscle relaxers (Metaxalone 800 mg TID or Tizanidine 2-6 mg TID) may be utilized if contraindications to methocarbamol and cyclobenzaprine exist.
88922538|NCT04990804|Experimental|Opioid-Free Perioperative Pain Regimen|Patients will receive no opioids. Pain will be managed with Acetaminophen 1000mg q8 hours, Ketorolac 10mg every 6 hours (for 5 days), Gabapentin 300mg q8 hours or Pregabalin 75mg twice daily, and a muscle relaxer (Methocarbamol 750mg BID or Cyclobenzaprine 5-10 mg TID) all to be taken as scheduled for the first 2 weeks (except Ketorolac - 5 days) postoperatively as side effects permit. Other NSAIDS (Naprosyn 500 mg BID or Ibuprofen 800 mg TID) may be utilized if contraindications to Ketorolac exist. Famotidine (20mg BID) or Omeprazole (20mg daily) will be prescribed along with NSAIDS for GI prophylaxis. Alternative muscle relaxers (Metaxalone 800 mg TID or Tizanidine 2-6 mg TID) may be utilized if contraindications to methocarbamol and cyclobenzaprine exist.
89199275|NCT05926687|Active Comparator|Disruptive Behavior + Reduce Frequency|"Starting Intervention: Disruptive Behavior Who: Parent & Therapist only Frequency: 1-hour once/week~Secondary Intervention: Reduce Frequency of Disruptive Behavior Intervention Intervention: Disruptive Behavior Who: Parent & Therapist only Reduce Frequency: 1-hour every other week"
88922539|NCT04990687|Experimental|Intervention Group|Treatment effects will be measured using standard rating scales including the HDRS-17, MADRS, SF-36, CSSR-S, CGI-I, CGI-S, which will be completed at each visit. The following scales will be completed at every other visit following the screening visit: Social Anhedonia Scale, the Motivation and Energy Inventory and the Physical Anhedonia Scale. At each study visit safety assessments including vital sign assessment and adverse event assessment will be completed. Subjects will also undergo physical examination and an ECG for safety during screening, after 8 weeks of treatment and at the end of 12 weeks of treatment.
89538428|NCT03267173|Experimental|CAR-T|A single dose of Chimeric antigen receptor T cells will be administered by vascular interventional mediated as one dose infusions. According to the patient's condition and weight, the intervention dose of aE7 CAR-T cells per kilogram of body weight was treated once.
89538429|NCT03266939|Placebo Comparator|Placebo|
88922542|NCT04981808|Experimental|Telemonitoring|The subjects will be telemonitored. All subject will use a CGM, a fit bit, and a smart pen during the entire trial period. Staff at the endocinology clinics will monitor the data and contact the subjects continuously throughout the trial (depending on the individual needs of each subject)
88922543|NCT04981808|No Intervention|Usual Care|The subjects will wear a blinded CGM the first and final 20 days of the trial. The subjects will use a blinded smart pen throughout the trial period. Hence, the subjects are unable to see their measured data during the trial, and they will not be monitored.
88922544|NCT04977349|Experimental|Wind Musicians|Isometric exercises for: cranial protrusion, mouth opening, laterality cervical movement and cervical coordination by laser assesment. And the manual therapy from the Active Comparator group.
88922545|NCT04977349|Active Comparator|Wind musicians|This group will be treated by manual therapy: suboccipital inhibition, myofascial extracavitary treatment in (superior trapezius fibers, Sternocleidomastoid (ECOM), masseter and temporalis) and intracavitary muscles (medialis and lateral pterygoid muscles).
88922546|NCT04976530|Sham Comparator|Control|Standard of care with Sham set-up
89199276|NCT05926687|Active Comparator|Disruptive Behavior + Add Tools|"Starting Intervention: Disruptive Behavior Who: Parent & Therapist only Frequency: 1-hour once/week~Secondary Intervention: Add Tools to Disruptive Behavior Intervention Intervention: Disruptive Behavior Who: Parent & Therapist & Child Frequency: 1-hour once/week Add: Video feedback"
89538430|NCT03266939|Active Comparator|Active Medication|
89437713|NCT03035123|Experimental|Interventional|"Before discharge, patients will attend an appointment with a nurse trained in therapeutic education, in which the nurse will evaluate the overall knowledge and the skills of the patient about HF. The nurse will then define specific educational objectives with the patient, based on the patient's medical history, state of disease, comorbidities, alarm signs, fears and knowledge.~Each patient will receive six telephone calls and two home-visits during the 1 year of follow-up. Each contact between the nurse and the patient will be dedicated to HF education. The patient will also receive regular short text messages containing health advice and appointment reminders.~To help the patient regain his/her autonomy, intervals between education sessions will be progressively longer."
89437714|NCT03012620|Experimental|Pembrolizumab|Pembrolizumab 200 mg IV as a 30 minute infusion on Day 1 of every 21 day cycle
89437715|NCT03012581|Experimental|Nivolumab|Nivolumab 240 mg IV over 60 minutes every 14 days.
89437716|NCT03000231||Healthy Controls|Matched by age, race, gender and BMI to adrenal insufficiency subjects
89437717|NCT03000231||Adrenal Insufficiency Patients|Eligible patients will have either primary adrenal insufficiency or secondary adrenal insufficiency and will be age 18 and older.
89437718|NCT02999009|Other|Trident II Tritanium Acetabular Shell|
89437719|NCT02981628|Experimental|Cohort I (inotuzumab ozogamicin)|Patients receive inotuzumab ozogamicin IV over 60 minutes on days 1, 8, and 15 of each cycle. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. (COMPLETE)
89437720|NCT02981628|Experimental|Cohort II (inotuzumab ozogamicin, mBFM chemotherapy)|See Detailed Description
89437721|NCT02946658|Experimental|Lipoaspiration Arm 1|Acquisition of Adipose-Derived tissue Stromal Vascular Fraction (AD-tSVF) via closed syringe harvest subdermal fat
89437722|NCT02946658|Experimental|AD-cSVF Arm 2|Isolation of cellular stem/stromal cells from subdermal adipose-derived cellular stromal vascular fraction (AD-cSVF)
88922547|NCT04976530|Experimental|DrugSorb-ATR Intervention|Standard of care + DrugSorb-ATR system
88922548|NCT04976452|Experimental|Group 1|Group 1 will include first year Physical Therapy students who will be trained for Blood Pressure (BP) measurement using a brief powerpoint lecture, completion of an interactive BP measurement module from the American Medical Association which includes a quiz assessment and certificate of completion, and a competency examination during the lab portion of class.
89437723|NCT02946658|Experimental|Normal Saline IV Arm 3|Normal Saline IV with AD-cSVF cells
88922549|NCT04976452|No Intervention|Group 2|Group 2 consists of second year PT students who only had a powerpoint lecture on Blood Pressure measurement that was done virtually with no lab component or American Medical Association interactive module training.
89437724|NCT02944955|Experimental|BLEX 404 Oral Liquid|"Part I:~Part I-1: Low Dose BLEX 404 Oral Liquid (3 mg/kg, BID) is administered in combination with 2 cycles of azacitidine.~Part I-2: High Dose BLEX 404 Oral Liquid (4.5 mg/kg, BID) is administered in combination with 2 cycles of azacitidine.~Part II:~Recommended Dose Level (RDL) of BLEX 404 Oral Liquid will be determined by results from Part I.~BLEX 404 Oral Liquid at RDL is administered in combination with 6 cycles of azacitidine."
89437725|NCT02917083|Experimental|CD30.CAR T Cells|Each patient will receive one infusion of CAR modified T cells.
89437726|NCT02914366|Experimental|Ambroxol high dose (1050 mg)|Participants randomized to the 1050 mg/day group will begin with a dose of 225mg (3 mg/kg/day), increasing bi-weekly by ~3mg/kg to a dose of 1050 mg/day (~l5 mg/kg/day).
89437727|NCT02914366|Placebo Comparator|Placebo|Participants receive capsules visually identical to the experimental groups but without active ingredients.
89437728|NCT02864784|Experimental|Amorphous calcium carbonate|Subjects in this arm of the study will receive ACC tablets, containing 200 mg elemental calcium in addition to the standard treatment with ZA or Denosumab (4 mg once every 4 weeks for ZA and 120mg (1.7ml injection) every 4 weeks for Denosumab)
89437729|NCT02864784|Placebo Comparator|Placebo|Subjects in this arm of the study will receive Placebo tablets in addition to standard treatment with ZA or Denosumab (4 mg once every 4 weeks for ZA and 120mg (1.7ml injection) every 4 weeks for Denosumab)
89437730|NCT02857010|Experimental|Allogenic Mesenchymal stem cells|Intravenous allogenic bone marrow derived mesenchymal stem cells: 4 doses of 2 x 106/kg administered on days 1, 4, 11 and 18
89437731|NCT02857010|Placebo Comparator|Placebo|Solution without cells on days 1, 4, 11 and 18
89437732|NCT02850406|Experimental|Voxelotor|"Subjects to receive daily oral dosing of voxelotor according to which Part (A, B, C, or D), the subject is participating in:~Part A: Subjects to receive daily oral dosing of voxelotor for 1 day (single dose)~Part B: Subjects to receive daily oral dosing of voxelotor for up to 24 weeks (multiple dose)~Part C: Subjects to receive daily oral dosing of voxelotor for up to 48 weeks (1500mg or 1500mg equivalent dose)~Part D: Subjects to receive daily oral dosing of voxelotor for up to 48 weeks (1500mg equivalent dose)"
88922552|NCT04971863||Clareon Monofocal IOL|Patients bilaterally implanted with the Clareon monofocal IOL
88922553|NCT04971863||Asqelio Monofocal IOL|Patients bilaterally implanted with the Asqelio monofocal IOL
89437733|NCT02849067|Experimental|Group Treatment|Patients in this group will watch a comedy show that will will not exceed 30 minutes. This group will have until five patients.
89437734|NCT02849067|Other|Group Control|patients in this group will watch a documentary that will not exceed 30 minutes. This will have until five patients
89437735|NCT02823652|Experimental|Arm A (Step 1: internet-based intervention)|Patients receive web-based genetic education consisting of general information about testing tumors for genetic mutations.
89437736|NCT02823652|Active Comparator|Arm B (Step 1: usual care control)|Patients receive standard genetic education consisting of conversations with the treating physicians, interaction with and information from the clinical staff, and information from usual resources about testing for genetic mutations.
89437737|NCT02823652|Experimental|Step 2 - genetic counseling|Patients who meet the criteria for the remote counseling substudy will receive genetic counseling over the telephone and undergo germline testing.
88922554|NCT04941326|Active Comparator|Spinal mobilization group|Spinal mobilization will be applied to the application group for 4 weeks in addition to the treatments applied to the sham group
88922555|NCT04941326|Sham Comparator|Sham group|Diaphragmatic stimulation with proprioceptive neuromuscular facilitation techniques (PNF), diaphragmatic breathing techniques, costal mobilization treatments and sham mobilization will be applied to the sham group.
89502018|NCT05490836|Experimental|pulse treatment arm|
89437738|NCT02794571|Experimental|Phase Ia Dose-Escalation Stage: Tiragolumab|Cohorts of at least 3 participants each will be treated with escalating doses of tiragolumab.
89011600|NCT02279485|Experimental|Perampanel - Group 1|"Treatment A: Single oral dose of a 12-mg perampanel tablet under fasted condition.~Treatment B: Single 12 mg dose of perampanel oral suspension under fasted condition.~Subjects will be randomized on Study Day 1 for Treatment Period 1 to Treatment A or Treatment B. On Study Day 43 the subject will then receive the alternate Treatment for Treatment Period 2."
89011601|NCT02279485|Experimental|Perampanel - Group 2|"Treatment C: Single oral dose of a 12-mg perampanel tablet co-administered with high fat meal.~Treatment D: Single 12 mg dose of perampanel oral suspension co-administered with high fat meal.~Subjects will be randomized on Study Day 1 for Treatment Period 1 to Treatment C or Treatment D. On Study Day 43 the subject will then receive the alternate Treatment for Treatment Period 2."
89011602|NCT00264069||001|
89011603|NCT00264069||002|
89011604|NCT01646632|Experimental|Physical exercise intervention|Progressive resistance training, balance training, functional training
89437739|NCT02794571|Experimental|Phase Ia Dose-Expansion Stage: Tiragolumab|Participants will be treated with tiragolumab at or below the maximum tolerated dose (MTD) or maximum administered dose (MAD) in the study.
89011605|NCT01646632|Placebo Comparator|Lifestyle counseling|Recreational sessions
89011606|NCT01646710|Experimental|Food Based Recommendations|Developing and pretesting tool for FBRs for infants 9 to 11 months old
89011607|NCT01646788|Experimental|Experimental|NMB's PTA Balloon catheter with Paclitaxel drug
89011608|NCT01647178|Active Comparator|Manual closure|Patients are closed with a manual, straight wire, conventional closure technique
89011609|NCT01647178|Active Comparator|TORQ closure|Patients are undergo a TORQ assisted sternal closure
89011610|NCT02961699|Experimental|Transpose ® RT System|Adipose-derived stem cells (also known as stromal vascular fraction or SVF) will be injected subcutaneously around the rim of the wound bed following standard would debridement. The standard collagen dressing material will also be saturated with SVF after placement within the would itself. Normal (standard) dressing of wound will be placed over wound.
89011611|NCT02961699|Active Comparator|debridement/dressing of wound|Wound will be debrided and collagen dressing placed within wound bed as per standard of care. Standard dressing will cover wound. No adipose-derived stem cells (SVF) will be applied to control subject wounds.
89011612|NCT01647256|Experimental|Nikkomycin Z fed - fasting|"Period 1:~Day 1: Nikkomycin Z 500 mg with high fat breakfast~Period 2:~Day 1: Nikkomycin Z 500 mg under fasted conditions"
89011613|NCT01647256|Experimental|Nikkomycin Z fasting - fed|"Period 1:~Day 1: Nikkomycin Z 500 mg under fasted conditions~Period 2:~Day 1: Nikkomycin Z 500 mg with high fat breakfast"
89011614|NCT04528927|Experimental|HCQ+Azithromycin|"Hydroxychloroquine (HCQ): 600 mg on the 1st day as a starting dose then 200 mg * 2 / D for 9 days~Azithromycin: 500 mg (1st day) then 250 mg / D for 4 days~Usual standard treatment"
89011615|NCT04528927|Experimental|HCQ+Azithromycin+Zinc|"HCQ: 600 mg on the 1st day as a starting dose then 200 mg * 2 / D for 9 days~Azithromycin: 500 mg (1st day) then 250 mg / D for 4 days~Zinc: 220 mg per day for 10 days~Usual standard treatment"
89011616|NCT04528927|Experimental|Azithromycin+Doxycycline|"Azithromycin: 500 mg (1st day) then 250 mg / D for 4 days~Doxycycline: 200 mg per day for 10 days.~Usual standard treatment"
89437740|NCT02794571|Experimental|Phase Ib Q3W Dose-Escalation Stage: Tiragolumab+Atezolizumab|A minimum of 3 participants will be treated for each dose level of tiragolumab in combination with a fixed dose of atezolizumab with tiragolumab being administered prior to atezolizumab.
89437741|NCT02794571|Experimental|Phase Ib Q3W Dose-Expansion Stage: Tiragolumab+Atezolizumab|Participants will be treated every 3 weeks (Q3W) with tiragolumab at or below the MTD or MAD in combination with a fixed dose of atezolizumab with tiragolumab being administered prior to atezolizumab.
89502019|NCT01338025|Active Comparator|Arm A, non-suppressive HAART regimen|"In Step 1, subjects were randomized to continue their non-suppressive HAART regimen.~In Step 2, subjects either began a new HAART regimen, continued randomized treatment, or discontinued therapy while remaining on follow-up, as decided by their provider."
89011617|NCT04720287|Active Comparator|Group 1(QL group)|
89011618|NCT04720287|Active Comparator|Group 2 (CB group)|
89011619|NCT04528654|Experimental|Intervention App Group|The intervention group will be instructed to download the chosen hypertension mobile health app (Sphygmo BP) via a link provided on the platform. The hypertension app has blood pressure tracking and monitoring features and they are instructed to use the app. They will also receive a link to the Heart and Stroke foundation website which includes information on hypertension management and measuring blood pressure.
89011620|NCT04528654|No Intervention|Educational Control Group|The control will comprise usual care including any anti-hypertensive medication and lifestyle changes, and the link to the Heart and Stroke Foundation website which includes information on hypertension management and measuring blood pressure.
89011621|NCT00239993|Experimental|1|skin reactions with the use of warm compress prior to performing a Copaxone® injection
89011622|NCT00239993|Experimental|2|skin reactions without the use of warm compress prior to performing a Copaxone® injection
89011623|NCT01647334|Experimental|Shrinking Target Adaptive Radiotherapy|Shrinking Target Adaptive Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer
89011624|NCT00264108||1|Epoetin alfa 40 000 IU once weekly variable treatment length.
89011625|NCT00264108||2|Darbepoetin alfa Either 150 ug once weekly or 500 ug once every 3 wks variable treatment length.
89011626|NCT01647412|Active Comparator|Growth Hormone, Exclusion Diet, and Nutraceutical therapy|The experimental group will receive the exclusion diet and nutraceutical therapy (DNT) and daily subcutaneously administered recombinant human growth hormone (rhGH) for the first 26 weeks. After 26 weeks this group will continue on the exclusion diet nutraceutical therapy for the remaining 26 weeks of the study.
89011627|NCT01647412|Placebo Comparator|rhGH placebo, Exclusion diet, and nutraceutical therapy|The experimental group will receive the exclusion diet and nutraceutical therapy (DNT) and daily subcutaneously administered placebo injections for the first 26 weeks. After 26 weeks this group will continue on the exclusion diet and nutraceutical therapy for the remaining 26 weeks of the study.
89011628|NCT01647529|Experimental|Ganciclovir|Treatment with topical ganciclovir ointment
89011629|NCT00240032|Active Comparator|Copaxone® with Zyrtec|
89011630|NCT00240032|Experimental|Copaxone® with placebo|
89011631|NCT01647568||Control|Patients who are not on any anti-platelet/anti-coagulant therapy and present to our lab for a elective colonoscopy.
89011632|NCT01647568||Thienopyridine Users|Patients on Clopidogrel or prasugrel when they present for an elective colonoscopy.
89011633|NCT01647607|Experimental|Young Women's Intervention (YWI)|This arm involves administration of an educational intervention that focuses on issues unique to young women with breast cancer, including career development, starting/raising a family, body image, and genetic predispositions to breast cancer.
89011634|NCT01647607|Active Comparator|Physical Activity Intervention (PAI)|This arm involves administration of an educational intervention that focuses on developing and/or maintaining a healthy lifestyle for young women with breast cancer, including the benefits of exercise and resources to enhance physical activity after diagnosis.
89011635|NCT04528849|Active Comparator|Early dose increment|Patients who have received 25 IU gonadotropin dose increment on 7th day of ovulation induction
89011636|NCT04528849|Active Comparator|Late dose increment|Patients who have received 25 IU gonadotropin dose increment on 14th day of ovulation induction
89011637|NCT01647646|Active Comparator|Symbicort|"We will evaluate the efficacy fot Symbicort use. The usage was 2 doses bid for one year period.~Intervention drug: Seretide fixed doses therapy"
89011638|NCT01647646|Experimental|Seretide|In non-well asthma controlled patients, experimental study with Seretide regular doses (125 2 doses bid for one year) and higher doses (250 2 doses bid) for one year
89437742|NCT02794571|Experimental|Phase Ib Chemotherapy Dose-Expansion Stage: Cohort A|In Cohort A, carboplatin or cisplatin and pemetrexed chemotherapy will be administered after atezolizumab and tiragolumab intravenous (IV) infusion. During induction phase, participants will receive atezolizumab and tiragolumab in combination with carboplatin or cisplatin and pemetrexed on Day 1 of each 21-day cycle for 4 to 6 cycles. During maintenance phase, participants will receive atezolizumab and tiragolumab in combination with pemetrexed on Day 1 of each 21-day cycle.
89437743|NCT02794571|Experimental|Phase Ib Chemotherapy Dose-Expansion Stage: Cohort B|In Cohort B, carboplatin and paclitaxel chemotherapy will be administered after atezolizumab and tiragolumab IV infusion. During induction phase, participants will receive atezolizumab and tiragolumab in combination with carboplatin and paclitaxel on Day 1 of each 21-day cycle for 4 to 6 cycles. During maintenance phase, participants will receive atezolizumab and tiragolumab on Day 1 of each 21-day cycle (participants enrolled under protocol version 4) or Day 1 of each 28-day cycle (participants enrolled under protocol version 5).
89011639|NCT01647685|Active Comparator|Nanocort|Two weekly IV infusions of 144 mg Nanocort (PEG-liposomal prednisolone sodium phosphate).
89011640|NCT01647685|Active Comparator|Methylprednisolone|Methylprednisolone sodium succinate 125 mg infusion.
89011641|NCT01647685|Placebo Comparator|Saline|Saline solution (same solution brand as used to dilute/prepare Nanocort injection)
89437744|NCT02794571|Experimental|Phase Ib Chemotherapy Dose-Expansion Stage: Cohort C|In Cohort C, carboplatin or cisplatin and etoposide chemotherapy will be administered after atezolizumab and tiragolumab IV infusion. During induction phase, participants will receive atezolizumab and tiragolumab in combination with carboplatin or cisplatin on Day 1 of each 21-day cycle and etoposide on Day 1 to 3 of each 21-day cycle for 4 cycles. During maintenance phase, participants will receive atezolizumab and tiragolumab on Day 1 of each 28-day cycle.
89437745|NCT02794571|Experimental|Phase Ib Chemotherapy Dose-Expansion Stage: Cohort D|In Cohort D, participants will receive atezolizumab and tiragolumab on Day 1 and capecitabine on Day 1-14 of each 21-day cycle.
89437746|NCT02794571|Experimental|Phase Ib Q4W Sequential Dose-Expansion Stage: Tiragolumab+Atezolizumab|Participants will be treated every 4 weeks (Q4W) with fixed doses of tiragolumab and atezolizumab with tiragolumab being administered prior to atezolizumab.
89437747|NCT02794571|Experimental|Phase Ib Q4W Coinfusion Expansion Cohort Tiragolumab+Atezolizumab|Participants will be treated Q4W with fixed doses of tiragolumab and atezolizumab mixed and administered in one IV bag.
89011642|NCT01647724||control 1|standard recall letter to perform HPV test at the clinic
89011643|NCT01647724||Intervention 1|direct mailing of the self sampling device at home
89011644|NCT01647724||intervention 2|invitation to retire the self sampling device in local pharmacy
89011645|NCT00240188|Other|1|
89011646|NCT01647802|Experimental|Turner-Vertic'Easy-Tina|Standing will be attempted with the three devices in the following order: (1) Turner; (2) Vertic'Easy; (3) Tina.
89011647|NCT01647802|Experimental|Turner-Tina-Vertic'Easy|Standing will be attempted with the three devices in the following order: (1) Turner; (2) Tina; (3) Vertic'Easy.
89011648|NCT01647802|Experimental|Vertic'Easy-Turner-Tina|Standing will be attempted with the three devices in the following order: (1) Vertic'Easy; (2) Turner; (3) Tina.
89011649|NCT01647802|Experimental|Vertic'Easy-Tina-Turner|Standing will be attempted with the three devices in the following order: (1) Vertic'Easy; (2) Tina; (3) Turner.
89437748|NCT02794571|Experimental|Phase Ib Non-Chemotherapy Dose-Expansion Stage: Cohort NC1|In Cohort NC1, participants will receive atezolizumab and tiragolumab in combination with bevacizumab on Day 1 of each 21-day cycle.
89437749|NCT02794571|Experimental|Phase Ib Non-Chemotherapy Dose-Expansion Stage: Cohort NC2|In Cohort NC2, participants will receive tiragolumab in combination with pembrolizumab on Day 1 of each 21-day cycle.
89437750|NCT02793921|Experimental|Moderate-intensity aerobic exercise|Participants engage in a supervised 6-month moderate-intensity aerobic exercise intervention.
89437751|NCT02793921|No Intervention|Usual Care|Physical activity neither limited nor withheld. Participants engage in activity in the same manner as if they were not part of an active intervention.
89437752|NCT02790515|Experimental|Treatment|"Participants receive a conditioning regimen of antithymocyte globulin (rabbit), cyclophosphamide, mesna, fludarabine, thiotepa, tacrolimus (first 5 participants enrolled), sirolimus (used beginning with 6th enrolled participant), melphalan, rituximab. This is followed by HPC,A infusion (transplant), then by G-CSF and blinatumomab.~Cells for infusion are prepared using the CliniMACS System."
89437753|NCT02787785|No Intervention|Conventional Medical Therapy|This arm of the trial continues with their current conventional medical therapy.
89437754|NCT02787785|Active Comparator|Subcutaneous Implantable Cardioverter Defibrillator|This arm of the trial receives a subcutaneous implantable defibrillator.
89437755|NCT02780583|Placebo Comparator|placebo|methylprednisolone intravenously, placebo shots every 6 hours
89437756|NCT02780583|Experimental|anakinra (Kineret)|methylprednisolone intravenously, anakinra shots every 6 hours
89437757|NCT02773030|Experimental|Cohort A: CC-220 Monotherapy - Part 1|Oral CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle
89437758|NCT02773030|Experimental|Cohort B: CC-220 in combination with Dexamethasone (DEX) - Part 1|"Oral CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle.~For subjects ≤ 75 years old, oral DEX 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle. For subjects >75 years old, DEX will be administered at 20 mg on Days 1, 8,15, and 22 of each 28-day cycle. Subjects who surpass the age of 75 years while on treatment may be switched to the 20 mg QD dosage based on the investigator's best judgment."
89437759|NCT02773030|Experimental|Cohort D: CC-220 in combination with Dexamethasone - Part 2|"Oral CC-220 at Recommended Phase 2 dose (RP2D) from Day 1-21 of each 28-day cycle~For subjects ≤ 75 years old, oral DEX 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle. For subjects >75 years old, DEX will be administered at 20 mg on Days 1, 8, 15, and 22 of each 28-day cycle"
89437760|NCT02773030|Experimental|Cohort E: CC-220 with DEX and daratumumab (DARA) - Part 1|"Oral CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle.~Oral DEX for subjects ≤ 75 years old at 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle. For subjects >75 years old, oral DEX at 20 mg on Days 1, 8, 15, and 22 of each 28-day cycle.~Intravenous DARA at dose 16mg/kg on Days 1, 8, 15, and 22 at cycle 1-2, Days 1, 15 at cycle 3-6, and Day 1 at cycle ≥7 of each 28-day cycle.~Once the MTD and/or RP2D is determined in Cohort E (CC-220Dd), subjects will be enrolled at a dose of Subcutaneous DARA at 1800 mg over 3 to 5minutes on Days 1, 8, 15,and 22 at cycle 1-2 of a 28-day cycle, Days1, and 15 at cycle 3-6 of a 28-day cycle, and Day1 at cycle ≥7 of each 28-day cycle."
89011650|NCT01647802|Experimental|Tina-Turner-Vertic'Easy|Standing will be attempted with the three devices in the following order: (1) Tina; (2) Turner; (3) Vertic'Easy.
89011651|NCT01647802|Experimental|Tina-Vertic'Easy-Turner|Standing will be attempted with the three devices in the following order: (1) Tina; (2) Vertic'Easy; (3) Turner.
89011652|NCT01647841||Pregnant women and infants|HIV+ and HIV- pregnant women, HIV-exposed and HIV-unexposed infants, ARV-exposed and ARV-unexposed infants
89011653|NCT01647919|Experimental|cogniVida™ 100 mg/day|
89011654|NCT01647919|Placebo Comparator|Placebo|
89011655|NCT01648036|Experimental|Unfractionated Heparin|
89011656|NCT01648036|Active Comparator|Dalteparin|Standard of care
89011657|NCT01648075|Experimental|Experimental: Probiotic enriched milk|150 ml of skimmed milk enriched with probiotic (Lactobacillus rhamnosus LRH08) once a day
89437761|NCT02773030|Experimental|Cohort F: CC-220 with DEX and bortezomib - Part 1|"Oral CC-220 at dose specified by cohort dose level from Day 1-14 of each 21-day cycle.~Oral DEX for subjects ≤ 75 years old at 40 mg on Days 1, 8, and 15 of each 21-day cycle. For subjects >75 years old, oral DEX at 20 mg on Days 1, 8, and 15 of each 21-day cycle.~Subcutaneous BTZ at dose 1.3 mg/m^2 on Days 1, 4, 8 and 11 at cycle 1-8, and Days 1, and 8 at cycle ≥9 of each 21-day cycle."
88922556|NCT04935710|Experimental|R34#1 Aim 2 COPE2Thrive Intervention|Randomly clustered youth who have completed the screening will be randomized to receive a resilience based digital intervention, COPE2Thrive.
88922557|NCT04935710|Active Comparator|Control arm|The comparator arm is treatment as usual. For each monthly crossover, 12 students in a cluster are eligible to receive C2T in a stepped wedge study design. Student outcomes prior to receiving C2T will be compared to outcomes after receiving C2T.
88922558|NCT04927091|No Intervention|Specialty Addiction Clinic|
88922559|NCT04927091|Experimental|ECHO-IC/QI-enhanced primary care clinic|
88922560|NCT04927091|Active Comparator|ECHO-IC/QI-enhanced primary care clinic with Pay for Performance|
88922561|NCT04921215|Active Comparator|0 hours of sleep restriction|Bedtime will be the same as baseline.
88922562|NCT04921215|Experimental|1.5 hours of sleep restriction|Bedtime will be 1.5 hours later than baseline.
88922563|NCT04921215|Experimental|3 hours of sleep restriction|Bedtime will be 3 hours later than baseline.
88922564|NCT04921215|Experimental|4.5 hours of sleep restriction|Bedtime will be 4.5 hours later than baseline.
88922565|NCT04915092|Experimental|Intervention group|The app is explained and installed during the recruitment to the family in the intervention group. Some families in this group will be selected to take part to the qualitative research.
88922566|NCT04915092|No Intervention|Control group|Every months during the first year of study a newsletter is sent only to the members of the control group.
88922567|NCT04906772|Experimental|Group KD|participants received loading of ketamine 1 mg/kg and dexmedetomidine 1µg/kg over 10 minutes then continue by a dose of 0.25 mg/kg/hr ketamine and 0.25µg/kg/hr dexmedetomidine throughout the procedure.
88922568|NCT04906772|Active Comparator|Group KP|participants received loading of ketamine 1 mg/kg and propofol 1 mg/kg over 10 minutes then continue by a dose of 0.25 mg/kg/hr propofol and 0.25 µg/kg/hr dexmedetomidine throughout the procedure.
88922569|NCT04896073|Experimental|1/Minnelide|Minnelide 2mg Days 1-21 of 28 day cycle (x12)
88922570|NCT04893798|Experimental|Sayana Press, Upper Arm injection|Sayana Press, administered subcutaneously into upper arm
88922571|NCT04893798|Active Comparator|Sayana Press, anterior thigh|Sayana Press, administered subcutaneously into anterior thigh
88922572|NCT04893798|Active Comparator|Sayana Press, abdomen|Sayana Press, administered subcutaneously into abdomen
88922573|NCT04885218|Experimental|Cohort 1：SHR-1209 / placebo|
88922574|NCT04885218|Experimental|Cohort 2：SHR-1209 /placebo|
88922575|NCT04885218|Experimental|Cohort 3：SHR-1209 / placebo|
88922576|NCT04883281|Active Comparator|Involved Nodal Radiotherapy with conventional margins w or w/o chemotherapy|If a patient loses a significant amount of weight on treatment, or the tumor contour changes substantially, repeat CT simulation and re-planning is allowed in the CM arm. However, the gross tumor volume may not be reduced due to tumor shrinkage. The original extent of disease must be included in the replanned GTV.
88922577|NCT04883281|Experimental|Involved Nodal Radiotherapy with marginless Daily Adaptive Radiotherapy w or w/o chemotherapy|Patients in the ML/DART Arm will have their radiation plan adapted with every fraction. The adaptation process will be performed automatically on the Varian Ethos adaptive therapy software under the supervision of the treating physician.
89502020|NCT01338025|Active Comparator|Arm B, 3TC or FTC monotherapy|"In step 1, subjects were randomized to receive 3TC or FTC (the choice of 3TC or FTC was left to the provider).~In Step 2, subjects either began a new HAART regimen, continued randomized treatment, or discontinued therapy while remaining on follow-up, as decided by their provider."
89502021|NCT05498636|Experimental|SPEL|
88922578|NCT04874207|Experimental|Patients|Patients
88922579|NCT04870203|Experimental|baricitinib + anti-TNF|
88922580|NCT04870203|Placebo Comparator|baricitinib + placebo|
89011658|NCT01648075|Placebo Comparator|Skimmed Milk|150 ml of skimmed milk once a day
89437762|NCT02773030|Experimental|Cohort G1: CC-220 in combination with CFZ and DEX - Part 1|"Oral CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle~Intravenous (IV) CFZ (Carfilzomib)administered at a starting dose of 20 mg/m2 on C1D1; and at a dose specified by cohort dose level thereafter on days 1, 8, and 15 of each 28-day cycle.~Oral DEX (Dexamethasone) on Days 1, 8, 15, and 22 of each 28-day cycle. For subjects ≤ 75 years old, the DEX dose will be 40 mg. For subjects > 75 years old, the DEX dose will be 20 mg"
89437763|NCT02773030|Experimental|Cohort G2 - CC-220 in combination with CFZ and DEX - Part 1|"Oral CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle.~Intravenous (IV) CFZ administered at a starting dose of 20 mg/m2 on C1D1 and C1D2; and at a dose level specified by cohort dose level thereafter Days 1, 2, 8, 9, 15, 16 of each 28-day cycle.~Oral DEX on Days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle. The DEX dose will be 20 mg."
88922581|NCT04862767|Experimental|TASO-001|level 1 of TASO-001 in combination with recombinant IL-2(Aldesleukin)(3+3) next than level 2 or level -1 of TASO-001 in combination with recombinant IL-2(Aldesleukin)
89437764|NCT02773030|Experimental|Cohort I: CC-220 in combination with DEX in post BCMA RRMM - Part 2|"Oral CC-220 at Recommended Phase 2 dose (RP2D) from Day 1-21 of each 28-day cycle~Oral DEX 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle. For subjects >75 years old, oral DEX will be administered at 20 mg on Days 1, 8, 15, and 22 of each 28-day cycle."
89502022|NCT05498558||Ovulation occurs on the healthy side|In tubal-presering patient who received treatment of tubal ectopic pregnancy,only when ovulation occurs on the healthy side of ovary,it may be considered to try to conceive; otherwise, contraception is recommended.
89502023|NCT05498558||Ovulation occurs on the either side|In tubal-presering patient who received treatment of tubal ectopic pregnancy,ovulation occurs on the either side of ovary,it may be considered to try to conceive.
88922582|NCT04860713|Active Comparator|AOK Group|Drug: Proprietary oral formulation of 0.85mg/kg of ketamine + 324mg of aspirin
88922583|NCT04860713|Active Comparator|Nurtec (Rimegepant) Group|Drug: 75 mg of ODT
88922584|NCT04860635|Experimental|F14 (sustained release celecoxib)|Intra-articular F14 administration immediately following TKR surgery, and concurrent with multimodal standard of care analgesia
88922585|NCT04848064|Experimental|Treatment (mogamulizumab, chemotherapy, NK cells)|Patients receive mogamulizumab IV over 60 minutes on day -7 and fludarabine IV and cyclophosphamide IV on days -5 to -3. Patients receive NK cell infusion on day 0. Patients then receive mogamulizumab IV over 60 minutes on days 0, 7, 14, and 28, then every 2 weeks thereafter in the absence of disease progression or unacceptable toxicity.
88922586|NCT04836247|Experimental|Disclosure Intervention Arm|Participants will be guided through a workbook and accompanying worksheet designed to help them: (1) decide whether or not they want to share information about their substance use with others, and (2) build skills for disclosing (e.g., planning what to say). Importantly, the intervention is not designed to encourage participants to disclose or not disclose, but rather to help participants decide whether they want to disclose based on their own goals and values.
88922587|NCT04836247|Active Comparator|Control Arm|Participants will be able to choose from several guided meditations to promote mindfulness.
88922588|NCT04823377|Other|Period A: Usual management|Period of end-of-life care as usual
88922589|NCT04823377|Other|Period B: Process of optimization of the medical decision|Period of systematic and iterative use of a device for optimizing the decision to continue an anti-cancer treatment.
88922590|NCT04822350||Locally advanced or metastatic urothelial carcinoma patients treated with avelumab|
88922591|NCT04820985||Women undergoing IVF|
88922592|NCT04819191|Experimental|SHARING Choices|"Components of SHARING Choices include:~A letter from the clinic introducing an initiative to prepare persons and families for Advance Care Planning (ACP); Access to a facilitator trained to lead ACP discussions; Patient-family agenda-setting to align perspectives about the role of family and stimulate discussion about ACP; Facilitated registration to the patient portal (for patient and family) as desired; Education & resources about Alzheimer's Disease and Related Dementias (ADRD) for clinic staff."
88922593|NCT04819191|No Intervention|Usual care|Usual care
88922594|NCT04819009||Central District|The ETMI method will be implemented in this group
88922595|NCT04819009||North District|control
88922596|NCT04819009||Hasharon District|control
88922597|NCT04819009||South District|control
89011659|NCT01648114|No Intervention|Control|Usual outpatient antenatal care consists of routine checking of the maternal and foetal health by either clinic midwives or obstetricians along with health education to promote a healthy pregnancy.
89011660|NCT01648114|Experimental|Antenatal Breastfeeding Intervention|Antenatal intervention group will receive usual care plus a 20 to 30-minute one-to-one educational intervention about breastfeeding.
89011661|NCT01648192|Experimental|2.5 mg|Losmapimod for single dose
89011662|NCT01648192|Experimental|7.5 mg|Losmapimod for single dose
89011663|NCT01648192|Experimental|20 mg|Losmapimod for single dose
89011664|NCT01648192|Placebo Comparator|Placebo|Placebo
89011665|NCT01648192|Experimental|7.5 mg BID|Losmapimod for repeat dose (14 days)
89011666|NCT01648192|Placebo Comparator|Placebo BID|Placebo
89011667|NCT01648231|Other|Treatment Period 1|1 x 5mg amlodipine tablet and 1 x 100mg losartan tablet administered in fasted state
89011668|NCT01648231|Other|Treatment Period 2|1 x 5mg amlodipine / 100mg losartan tablet administered in fasted state
89011669|NCT01648231|Other|Treatment Period 3|1 x 5mg amlodipine / 100mg losartan tablet administered in fasted state
89011670|NCT01648309||TAVI|patients with significant aortic stenosis that are candidates for transvascular aortic valve implantation
89011671|NCT01648504|Experimental|Intervention with eGuide to colonoscopy|The investigators will prospectively enroll and follow patients who receive the eGuide to Colonoscopy and determine benefit and satisfaction with the intervention as part of a pilot study.
89011672|NCT01648543|Active Comparator|block method: angle|The entry angle of angular method which is one method of lumbar sympathetic ganglion block is 30 degree of anterior-posterior view of C-arm.
89011673|NCT01648543|Active Comparator|block method: distance|The entry point of modified Reid method which is popular method of lumbar sympathetic ganglion block is 7~7.5cm from midline of spinous process of lumbar spine.
89011674|NCT01648660|Active Comparator|D2x - D1x|"Cross Over from double dosage to single dosage:~daily supplementation with 10mg Lutein, 1mg Zeaxanthin, 255 mg Omega-3-FAabout two years after one year with 20mg Lutein, 2mg Zeaxanthin, 510 mg Omega-3-FA"
89437765|NCT02773030|Experimental|Cohort J1: CC-220 in combination with DEX and BTZ in NDMM - Part 2|"Oral CC-220 at 1.0mg, 1.3mg or 1.6mg administered at cycles 1 to 8 on Days 1 to 14 of each 21-day cycle and cycles ≥ 9 on Days 1 to 21 of each 28-day cycle.~Oral DEX at Cycles 1 to 8, 20 mg (≤ 75 years old) or 10 mg (> 75 years old) on Days 1, 2, 4, 5, 8, 9, 11 and 12 of each 21-day cycle and Cycles ≥ 9, 40 mg (≤ 75 years old) or 20 mg (> 75 years old) on Days 1, 8, 15, and 22 of each 28-day cycle.~Subcutaneous BTZ at dose 1.3 mg/m2 on Days 1, 4, 8 and 11 at Cycle 1-8 of each 21-day cycle."
89437766|NCT02773030|Experimental|Cohort J2: CC-220 in combination with DEX and BTZ in NDMM - Part 2|"Oral CC-220 at Recommended Phase 2 Dose from Day 1-14 of each 21-day cycle.~Oral DEX at 20 mg/day (≤ 75 years old) or 10 mg/day (> 75 years old) for Cycles 1 to 6 on Days 1, 2, 4, 5, 8, 9, 11 and 12 of a 21-day cycle.~Subcutaneous BTZ at dose 1.3 mg/m2 on Days 1, 4, 8 and 11 at Cycle 1-6 of each 21-day cycle."
89437767|NCT02773030|Experimental|Cohort K: CC-220 with DEX and DARA in NDMM and not autologous stem cell transplant eligible - Part 2|"Oral CC-220 at 1.0mg, 1.3mg or 1.6mg from Days 1-21 of each 28-day cycle.~Oral DEX 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle. For subjects >75 years old, oral DEX will be administered at 20 mg on Days 1, 8, 15, and 22 of each 28-day cycle.~Subcutaneous DARA at 1800 mg over 3 to 5minutes on Days 1, 8, 15, and 22 at cycle 1-2 of a 28-day cycle, Days1, and 15 at cycle 3-6 of a 28-day cycle, and Day1 at cycle ≥7 of each 28-day cycle."
89437768|NCT02773030|Experimental|Cohort C: CC-220 Monotherapy in RRMM - Part 2|CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle.
89011675|NCT01648660|Active Comparator|D1x - D2x|"Cross Over from double dosage to single dosage:~daily supplementation with 20mg Lutein, 2mg Zeaxanthin, 510 mg Omega-3-FA about two years after one year with 10mg Lutein, 1mg Zeaxanthin, 255 mg Omega-3-FA"
89011676|NCT01648660|Active Comparator|D1x - D1x|single dosage: daily supplementation about two years after one year with 10mg Lutein, 1mg Zeaxanthin, 255 mg Omega-3-FA (dosage remains existing)
89011677|NCT01648738|Experimental|Spa therapy, exercise and educational therapy|Spa therapy, exercise and educational therapy
89011678|NCT01648738|Active Comparator|Usual care and counselling (Back book)|Usual care and counselling (Back book)
89011679|NCT01648855||Preterm babies|Intra uterine growth restricted preterm babies born before 30 weeks of gestational age from mother with preeclampsia
89011680|NCT01648933|Experimental|Sarcoidosis|"Rubidium PET:~Myocardial Perfusion Imaging"
89011681|NCT01648972|Experimental|Gastrografin|
89011682|NCT01648972|Placebo Comparator|Placebo|
89011683|NCT01649011||Scores of the ODI and RMQ for low back pain|
89011684|NCT01649050|Experimental|BGG492|BGG492 tablets administered orally
89011685|NCT01649050|Placebo Comparator|Placebo|Matching placebo administered orally
89011686|NCT02279563|Experimental|Azelastine HCl and Fluticasone Propionate Nasal Spray|"The investigational product was administered via nasal inhalation with one spray in each nostril twice daily.~Batch Number KL1981, Expiry Date Mar 2015."
89011687|NCT02279563|Active Comparator|Dymista™ Nasal Spray|"The reference product was administered via nasal inhalation with one spray in each nostril twice daily.~Batch Number G30349, Expiry Date Mar 2015."
89011688|NCT02279563|Placebo Comparator|Placebo Nasal Spray|"The placebo was administered via nasal inhalation with one spray in each nostril twice daily.~Batch Number KL0781, Expiry Date Mar 2015."
89011689|NCT00240461|Active Comparator|1|200 mg COLD-fX Natural health products 2 times daily for six months
89011690|NCT00240461|Active Comparator|Arm 2|Arm 2 - 400 mg COLD FX Natural health product - 2 times daily for 6 months
89011691|NCT00240461|Placebo Comparator|3|Inactive crystalline substance. This is the placebo arm in which subject receive 200 mg of the placebo 2 times daily for 6 months. Placebo is an inactive crystalline substance.
89011692|NCT02279680|Other|Patients|Adults between 18 and 30 years old right handing Patients with ASD
89011693|NCT02279680|Other|Healthy volunteers|Adults between 18 and 30 years old Right handing Healthy
89011694|NCT02279758|Experimental|METFORMIN|850mg of metformin every 12 hours.
89011695|NCT01649167||Overweight/obesity|Pregnant women with overweight/obesity
89011696|NCT01649167||gestational diabetes|Pregnant women with gestational diabetes
89437769|NCT02766322||Gastric Bypass longitudinal|Morbidly obese subjects undergoing gastric bypass surgery. Subjects will be assessed in four testing sessions about 1 week apart in a randomized cross-over fashion before surgery. During the first two sessions, their response to alcohol or nonalcoholic (placebo) beverage will be evaluated. During testing sessions three and four, their response to alcohol administered intravenously will be evaluated. These four testing sessions will be repeated when subjects loose ~ 16% of their presurgery body weight.
89011697|NCT01649167||normal weight|Pregnant women with normal weight
89011698|NCT00264264|Active Comparator|Direct Compression|
89011699|NCT00264264|Active Comparator|Closure Device|
89011700|NCT01649206|Experimental|Group A: RTA|Percutaneous Radiofrequency Thermal Ablation (RTA).
89011701|NCT01649206|No Intervention|Group B: untreated|No treatment, only follow-up
89011702|NCT01649245|Experimental|Reiferon retard plus ribavirin|Eligible subjects will be treated with Reiferon Retard® 160 µg weekly by subcutaneous injection for 48 weeks, together with weight-based oral ribavirin (1200 mg/day if body weight is >75 kg and 1000 mg/day if body weight is ≤ 75 kg) in divided doses
89011703|NCT04721210|Experimental|Frequency of 1 Hz|continuous stimulation with a frequency of 1 Hz, 2000 pulses, 10 days-daily;
89011704|NCT04721210|Experimental|Frequency of 10 Hz|continuous stimulation with a frequency of 10 Hz-10 seconds with a pause of 50 seconds, 2000 pulses, 10 days-daily;
89011705|NCT04721210|Placebo Comparator|Continuous stimulation placebo|continuous stimulation placebo
89011706|NCT01649401|Active Comparator|Standard nubulizer|"Nebulizer sessions for the patients in this arm will be administerd using our standard nebulizer: Micro Mist, ref 41894, Hudson RCI, distributed by Téléflex Médical."
89011707|NCT01649401|Experimental|Experimental nebulizer|"Nebulizer sessions for the patients in this arm will be administerd using the PARI LC Sprint Sp nebulizer.~Manufacturer: PARI GmbH Germany"
89011708|NCT01649440||Normal control|Healthy volunteers
89011709|NCT01649440||SIRS|"temperature >38 ℃ or <36℃;~pulse rate>90 beats/min;~ventilatory rate>20 breaths/min or hyperventilation with partial pressure of arterial carbon dioxide (PaCO2)<32mmHg;~white blood cell count>12,000μL-1 or <4000μL-1 or >10% immature cells"
89011710|NCT01649440||sepsis|sepsis is defined as SIRS plus confirmed infection.
89011711|NCT01649440||severe sepsis|"sepsis associated with organ dysfunction, hypoperfusion, or hypotension.~sepsis with arterial hypotension, despite adequate fluid resuscitation."
89011712|NCT01649440||death|sepsis patients within 48 hours before death.
89011713|NCT01649479|Other|Suspected Obstetrical APS; confirmed APS|"The patients included in this study are women actively addressed to the participating departments because of clinical symptoms corresponding to suspected obstetrical anti-phospholipid syndrome.~Bloodwork later confirms that these patients have APS.~All patients included in this study will have the following interventions:~antiphospholipid antibody tests~thrombophilia bloodwork~psychiatric evaluation"
89011714|NCT01649479|Other|Sus. Obst. APS, confirmed thrombophilia|"The patients included in this study are women actively addressed to the participating departments because of clinical symptoms corresponding to suspected obstetrical anti-phospholipid syndrome.~Bloodwork later confirms that these patients are thrombophilic.~All patients included in this study will have the following interventions:~antiphospholipid antibody tests~thrombophilia bloodwork~psychiatric evaluation"
89011715|NCT01649479|Other|Suspected Obstectrical APS; unconfirmed|"The patients included in this study are women actively addressed to the participating departments because of clinical symptoms corresponding to suspected obstetrical anti-phospholipid syndrome.~Bloodwork cannot confirm APS, nor thrombophilia.~All patients included in this study will have the following interventions:~antiphospholipid antibody tests~thrombophilia bloodwork~psychiatric evaluation"
89011716|NCT01649635|Experimental|Cabazitaxel|25 mg/m2, administered as a 1-hour intravenous infusion, on Day 1 of each cycle, every 21 days Prednisone: 10 mg daily throughout the treatment with cabazitaxel Ciprofloxacin: at a dose of 500 mg for 8 days twice daily (total dose 1.0 g) Granulocyte-Colony Stimulating Factors: maximum dose of 600ug for 7 days or until Absolute Neutrophils Count reaches level ≥ 10.000/mm3
89011717|NCT00240617|Active Comparator|arm 1|Treximet (sumatriptan/naproxen sodium) formerly known as TREXIMA
89011718|NCT00240617|Placebo Comparator|arm 2|placebo to match
89011719|NCT01649713|Experimental|Fluval AB vaccination|In this uncontrolled, open, multi-centre immunogenicity and tolerability study subjects will be enrolled into one vaccination group and will be vaccinated by a single injection of Fluval AB suspension for injection.
89011720|NCT01649752|Experimental|Differentiated stem cell therapy group|After ovum pick-up, MSC differentiated to endometrium is deposited in the uterine cavity.Embryo transfer will be done at day 5 at the blastocyst stage.
89011721|NCT01649752|Experimental|undifferentiated stem cell therapy group|Immediately postmenstrual undifferentiated MSC is deposited in the uterine cavity. Ovum pick-up will be done as usual.Embryo transfer will be done at day 5 at the blastocyst stage.
89437770|NCT02766322||Gastric Banding longitudinal|Morbidly obese subjects undergoing laparoscopic gastric banding surgery. Subjects will be assessed in four testing sessions about 1 week apart in a randomized cross-over fashion before surgery. During the first two sessions, their response to alcohol or nonalcoholic (placebo) beverage will be evaluated. During testing sessions three and four, their response to alcohol administered intravenously will be evaluated. These four testing sessions will be repeated when subjects loose ~ 16% of their presurgery body weight.
89437771|NCT02766322||Sleeve gastrectomy longitudinal|Morbidly obese subjects undergoing sleeve gastrectomy surgery. Subjects will be assessed in four testing sessions about 1 week apart in a randomized cross-over fashion before surgery. During the first two sessions, their response to alcohol or nonalcoholic (placebo) beverage will be evaluated. During testing sessions three and four, their response to alcohol administered intravenously will be evaluated. These four testing sessions will be repeated when subjects loose ~ 16% of their presurgery body weight..
88922598|NCT04819009||Jerusalem and Hasfhela District|control
88922599|NCT04802174|Experimental|1/ Phase I|Dose escalation of Berzosertib + lurbinectedin
88922600|NCT04802174|Experimental|2/ Phase II|Berzosertib + lurbinectedin at MTD
88922601|NCT04794972|Experimental|Study treatment|After the completion of the first cycle of treatment, if the patient has no intolerable toxic side effects during the first cycle of treatment, the investigator can communicate with the patient whether to continue the treatment during the 2-8 cycle.
88922602|NCT04782375|Experimental|Treatment Arm A|discontinue antiviral treatment
88922603|NCT04777994|Experimental|Monotherapy Dose Escalation|ABBV-CLS-484 will be administered as a monotherapy in subjects with solid tumors
88922604|NCT04777994|Experimental|Combination Dose Escalation with PD-1 Inhibitor|ABBV-CLS-484 will be administered in combination with Programmed Cell Death-1 Inhibitor in subjects with solid tumors
88922605|NCT04777994|Experimental|Monotherapy Expansion|ABBV-CLS-484 will be administered at the determined recommended dose in subjects with locally advanced or metastatic, relapsed or refractory head and neck squamous cell carcinoma (HNSCC), relapsed or refractory non-small cell lung cancer (NSCLC), and advanced clear cell renal cell carcinoma (ccRCC)
88922606|NCT04777994|Experimental|Combination Expansion with PD-1 Inhibitor|ABBV-CLS-484 will be administered at the determined recommended dose in combination with Programmed Cell Death-1 Inhibitor in subjects with locally advanced or metastatic, HNSCC, NSCLC, MSI-H tumors refractory to PD-1/PD-L1, and advanced ccRCC.
88922607|NCT04777994|Experimental|Combination Dose Escalation with VEGFR TKI|ABBV-CLS-484 will be administered in combination with a Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI) in subjects with solid tumors
88922608|NCT04777994|Experimental|Combination Expansion|ABBV-CLS-484 will be administered at the determined recommended dose in combination with VEGFR TKI in subjects with locally advanced or metastatic, HNSCC, NSCLC, MSI-H tumors refractory to PD-1/PD-L1, and advanced ccRCC.
88922609|NCT04777916||Standard intensive 3+7 YOUNG OR ELDERLY|Standard intensive 3+7 (anthracycline + cytarabine) chemotherapy ± an approved FLT3 inhibitor (midostaurine, Rydapt®), according to different dose schedules in older versus younger patients
88922610|NCT04777916||GO, Mylotarg®) with 3+7|Combination of sequential gemtuzumab ozogamicin (GO, Mylotarg®) with 3+7
88922611|NCT04777916||CPX-351, Vyxeos®)|Liposomal formulation of daunorubicin + cytarabine (CPX-351, Vyxeos®)
88922612|NCT04777916||Lower intensity chemotherapy with azacytidine or low dose cytarabine (LDAC)|Lower intensity chemotherapy with azacytidine or low dose cytarabine (LDAC) in patients considered as not eligible for the more intensive options above
88922613|NCT04777916||Refractory or relapsed AML|"Secondly, no specific salvage regimen has emerged as a standard in patients with primary refractory or relapsed AML (R/R AML). R/R AML is thus an important field for investigational new drugs (INDs) and precision medicine development. To date, the only IND approved to treat R/R AML is gilteritinib for FLT3-mutated AML patients. The French agency ANSM also allow to use GO for treating R/R AML patients in the frame of a RTU (Recommendation Temporaire d'Utilisation).~In the real life, because of the multiplicity of treatments used in these patients, some of them being now quite efficient, it has become difficult to accurately describe the general outcome of R/R AML patients."
88922614|NCT04762498|Experimental|Pegloticase 16mg cohort|16 mg IV dose of pegloticase q4 weeks with 15 mg methotrexate (MTX) weekly
88922615|NCT04762498|Experimental|Pegloticase 24/32mg cohort|24 to 32 mg IV dose of pegloticase q4 weeks with 15 mg MTX weekly
88922616|NCT04751656|Experimental|Steady Intervention|Participants asked to engage in Steady Intervention for 12 months
88922617|NCT04745065|Experimental|Connect2BWell Condition|The Connect2BWell program delivers feedback on SUD risk, 3 brief online intervention sessions over 3 months, and text messages for 6 months. Sessions and text messages are tailored to the patient's most problematic drug based on the ASSIST; stage of change for quitting or reducing use of that drug; and stage of change for seeking treatment, if indicated. Online sessions are followed by a dashboard-guided telehealth session with a nurse care manager. The dashboard summarizes the patient's ASSIST risk scores and stage of change data; presents patients' responses to key questions in the online session; and provides tools for collaborating with the patient to select action steps matched to risk level and stage and stage of change for seeking treatment, if indicated. The program provides a patient portal with activities, resources, and tools for tracking progress on action steps.
88922618|NCT04745065|No Intervention|Comparison Condition|Patients assigned to the Comparison Condition will receive a brief SBIRT session delivered via telehealth by a member of their clinic care team. The session will include the clinic's standard scripted feedback matched to level of risk for alcohol use and for other drug use; encouragement to quit; and referral to specialty treatment, if indicated.
88922619|NCT04734626||Mitochondrial Disease|Individuals with suspected (based on clinical presentation) or definite genetic mitochondrial disease
88922620|NCT04734626||Healthy Controls/Volunteers|Individuals with no history of suspected (based on clinical presentation) or definite genetic mitochondrial disease
88922621|NCT04723810|Experimental|Cohort 1|Patients scheduled to undergo surgical resection for the following cancers (known or suspected) that the safety and dosing/timing of indocyanine green has not been fully studied will be enrolled: glioma, breast cancer, colon cancer, rectal cancer, head and neck cancer, pulmonary metastasectomy (colorectal mets), thymoma, ovarian cancer, prostate cancer, renal cell carcinoma, thyroid cancer, parathyroid adenoma, mesothelioma, esophageal cancer, pancreas cancer, stomach cancer.
88922622|NCT04723810|Experimental|Cohort 2|Patients scheduled to undergo surgical resection for the following cancers (known or suspected) that the safety and dosing/timing of indocyanine green has been fully studied will be enrolled: non-small cell lung cancer, metastatic sarcoma to the lung, brain meningioma.
88922623|NCT04713449|Experimental|Empowered Survivor online|The online intervention, called Empowered Survivor (ES) is a self-management intervention for patients with head and neck cancer. The intervention contains the following modules: Introduction; Difficulty Swallowing and Muscle Strength; Oral Care; Long-term Follow-Up Care/Oral exams; Calm and Connect; and Maintaining.
88922624|NCT04713449|Active Comparator|Springboard Beyond Cancer|Springboard Beyond Cancer is a general resource for survivors of all cancer. It is a free self-management program for cancer survivors developed by trusted sources, the ACS and the NCI.
88922625|NCT04701203|Experimental|TransCon PTH|TransCon PTH at a starting dose of 18 mcg delivered once daily by subcutaneous injection
88922626|NCT04701203|Placebo Comparator|Placebo|Placebo for TransCon PTH delivered once daily by subcutaneous injection
88922627|NCT04696159|Experimental|Endoscopic Per-Oral Pyloromyotomy (POP)|The study cohort will include 40 patients with a HbA1c >7.5% with medically refractory gastroparesis who are scheduled to undergo POP. Each patient will undergo two 10-day periods of CGM at an interval of approximately seven months, one month prior to the procedure and six months after. Symptoms and diabetes management improvement will be measured by the Gastroparesis Cardinal Symptom Index (GCSI) scores and the Diabetes Self-Management Questionnaire (DSMQ).
88922628|NCT04688710|Active Comparator|Self-Hypnosis (HYP)|Participants receive an instructional manual and instructional audio recording to explain the study treatment and how to use audio recordings. Participants then receive a set of audio recordings once per week for 4 weeks teaching Self-Hypnosis. Following the 4 weeks of training to use treatment recordings, you will have 6 months of access to the recordings. Participants may access the recordings to use when convenient and are encouraged to access recordings daily for practice.
88922629|NCT04688710|Active Comparator|Mindfulness Meditation (MM)|Participants receive an instructional manual and instructional audio recording to explain the study treatment and how to use audio recordings. Participants then receive a set of audio recordings once per week for 4 weeks teaching Mindfulness Meditation. Following the 4 weeks of training to use treatment recordings, you will have 6 months of access to the recordings. Participants may access the recordings to use when convenient and are encouraged to access recordings daily for practice.
88922630|NCT04688710|No Intervention|Treatment as Usual (TAU)|Participants will not receive treatment from the study during the treatment phase. Participants will continue to receive their normal care outside of the study for MS and fatigue. Participants will have the option to access either the Self-Hypnosis or Mindfulness Meditation treatment after all study assessments have been completed.
88922631|NCT04682847||Primary and metastatic liver tumors and hepatic cirrhosis|This study is a single arm prospective study that will enroll 25 patients with primary and metastatic liver tumors and hepatic cirrhosis eligible for liver SBRT who will be receiving treatment at a single center - Allegheny General Hospital.
88922632|NCT04682366|Experimental|Tamsulosin|Patients in this arm will receive 10 days of 0.4 mg of oral tamsulosin once daily starting 5 days pre-operatively and continuing until all pills are completed.
88922633|NCT04682366|Placebo Comparator|Placebo|Patients in this arm will receive 10 days of identical-appearing placebo once daily starting 5 days pre-operatively and continuing until all pills are completed.
88922634|NCT04679818|Active Comparator|Control Group|Clinicians will be blinded to PMD-200 NOL monitoring and use clinical judgement to determine how much fentanyl should be given, and when.
88922635|NCT04679818|Active Comparator|PMD-200 NOL group|Clinicians will titrate fentanyl to keep PMD-200 NOL under 25 - always using good clinical judgement for individual patients
88922636|NCT04677738|Placebo Comparator|Placebo|Placebo delivered in capsule format. Participants will be instructed to take 2 capsules of placebo for 4 weeks during the run-in period. On day 1 participants will be instructed to take 2 capsules of placebo in the morning before breakfast for 12 weeks.
88922637|NCT04677738|Experimental|B. breve|Capsule containing B breve. Participants will be instructed to take 2 capsules of placebo for 4 weeks during the run-in period. On day 1 participants will be instructed to take 2 capsules of B. breve B-3 in the morning before breakfast for 12 weeks.
88922638|NCT04658381|Experimental|Genetic analysis|
88922639|NCT04656873||ICI treatment|Adult cancer patients starting ICI monotherapy or combination therapy at UNC Chapel Hill per clinical standard of care and willing to allow specimens from surplus tissue to be banked for research purposes (in the case of resections) AND willing to have additional specimens taken for research purposes (in the case of biopsies). Patients will be followed for samples and clinical data from medical records from before starting ICI therapy until 2 years after the end of ICI treatment.
89011722|NCT01649752|No Intervention|Control group|ovum pick-up as usual and embryo transfer at day 5 at the blastocyst stage.
89437772|NCT02766322||Gastric Bypass (cross-sectional)|Subjects who underwent gastric bypass surgery 1-5 years ago. Subjects will be assessed in four testing sessions about 1 week apart in a randomized cross-over fashion after surgery. During the first two sessions, their response to alcohol or nonalcoholic (placebo) beverage will be evaluated. During testing sessions three and four, their response to alcohol administered intravenously will be evaluated.
89437773|NCT02766322||Gastric Banding (cross-sectional)|Subjects who underwent gastric banding surgery 1-5 years ago. Subjects will be assessed in four testing sessions about 1 week apart in a randomized cross-over fashion after surgery. During the first two sessions, their response to alcohol or nonalcoholic (placebo) beverage will be evaluated. During testing sessions three and four, their response to alcohol administered intravenously will be evaluated.
89437774|NCT02766322||Sleeve gastrectomy (cross-sectional)|Subjects who underwent sleeve gastrectomy surgery 1-5 years ago. Subjects will be assessed in four testing sessions about 1 week apart in a randomized cross-over fashion after surgery. During the first two sessions, their response to alcohol or nonalcoholic (placebo) beverage will be evaluated. During testing sessions three and four, their response to alcohol administered intravenously will be evaluated.
89437775|NCT02766322||Non-surgical group|Subjects who are age and body mass index equivalent to gastric bypass (cross-sectional) and Sleeve gastrectomy (cross-sectional) but did not undergo any type of bariatric surgery. Subjects will be assessed in four testing sessions about 1 week apart in a randomized cross-over fashion after surgery. During the first two sessions, their response to alcohol or nonalcoholic (placebo) beverage will be evaluated. During testing sessions three and four, their response to alcohol administered intravenously will be evaluated.
89437776|NCT02738359||1rst arm: optical colonoscopy (OC)|t0: optical colonoscopy; Follow-up: yearly by phone call for three years
89437777|NCT02738359||2nd arm: colon capsule endoscopy (CC)|t0: colon capsule endoscopy -> if positive: OC; At three years: OC for those patients with negative initial CC; Follow-up: yearly by phone call for 3 years
89437778|NCT02738359||3rd arm: fecal immunological test (FIT)|"FIT yearly for two years:~t0: FIT -> if positive : OC; t = 1 year: FIT -> if positive : OC; t = 2 years: FIT -> if positive : OC; At three years: OC for those patients with negative FIT during the study Follow-up: yearly by phone call for 3 years"
89437779|NCT02735707|Other|Antibiotic Domain|"Patients with community-acquired pneumonia admitted to participating intensive care units and requiring empiric antibiotic therapy will be randomised one of five antibiotic interventions.~Note: the ceftaroline + macrolide intervention has been closed to recruitment."
89437780|NCT02735707|Other|Macrolide Duration Domain|Patients with community-acquired pneumonia admitted to participating intensive care units who have been allocated to a beta-lactam antibiotic intervention in the Antibiotic Domain will be randomised to either a standard course or extended course of macrolide therapy
89437781|NCT02735707|Other|Corticosteroid Domain|"Patients with community acquired pneumonia (CAP) admitted to participating hospitals will be randomised to a steroid use strategy.~Note: this domain is now closed to patients with suspected or proven COVID-19. It remains open to patients with CAP without COVID-19."
89437782|NCT02735707|Other|Influenza Antiviral Domain|Patients with community-acquired pneumonia admitted to participating hospitals with microbiological testing confirmed influenza infection will be randomised to one of six interventions.
89437783|NCT02735707|Other|COVID-19 Antiviral Domain|"Patients admitted to participating hospitals with suspected or microbiological testing confirmed COVID-19 will be randomised to no ivermectin or ivermectin.~Note: an earlier version of this domain evaluated lopinavir-ritonavir, hydroxychloroquine, and combination lopinavir-ritonavir and hydroxychloroquine against a 'no antiviral' control.~This domain is now closed."
89437784|NCT02735707|Other|COVID-19 Immune Modulation Domain|"Patients admitted to participating hospitals with suspected or microbiological testing confirmed COVID-19 will be randomised to one of up to five interventions.~Note: this domain is now closed."
89538431|NCT02458937||Osteonecrosis|"Observational measures of functional outcomes will be obtained from all participants who consent to and complete the study.~Interventions: Functional Mobility Assessment (FMA), GAITRite® System, and Range of Motion."
88922640|NCT04655963|Experimental|Dose 1|All participants would receive open-label treatment for approximately eight, 3-minute sessions of intermittent theta burst rTMS on each of three days within a seven-day span. A single session=600 pulses at 120% rMT, iTBS triplets at 50 Hz for 2 s and repeated every 10 s for a total of 190 s to left dlPFC. Total pulses=14,400.
88922641|NCT04644497||Transphyseal drilling technique|
88922642|NCT04644497||Physeal sparing drilling technique|
88922647|NCT04631926|Other|Hip Muscle Exercises|Hip Muscle Exercises
88922648|NCT04628663|Active Comparator|DEX group|Dexmedetomidine given at a bolus dose of 1,0 μg/kg 10min before induction of anesthesia and then after as a continuous infusion 0,4-0,8 μg/kg/h until the end of the surgery.
88922649|NCT04628663|Placebo Comparator|Placebo group|Normal saline given as a bolus dose 10min before induction of anesthesia and then after as a continuous infusion until the end of the surgery.
88922650|NCT04622969|Experimental|Intervention|Provide the 15-week Healthy Child Development Program intervention
88922651|NCT04622969|No Intervention|Wait list control|
88922652|NCT04621500|Other|Open label|All enrolled subjects will receive vitamin D3 at 4,000 IU daily for approximately one year.
88922653|NCT04615104||Pelvic Ring Fracture|Patients with pelvic ring fractures.
88922654|NCT04615104||Acetabular Fracture|Patients with acetabular fractures.
88922655|NCT04612478|Other|Clinic-Based Physical Therapy|Patients will be referred to PT by the orthopaedic surgeon for enrollment into a clinic-based PT program per usual referral patterns at the surgeon's center. Patients will receive services based on their health care benefits defined by his or her insurance plan.
88922656|NCT04612478|Other|Self-Directed Exercise Program|The full SDEP program, which will be developed by physical therapists, orthopaedic trauma surgeons, and investigators with experience in health behavior change, will be designed to maximize adherence/compliance with the program. The SDEP manual will provide detailed instructions on exercises, such as repetitions, frequency, and required equipment, which can be implemented in the home environment. The basis for the exercise regimen is derived from the American Academy of Orthopaedic Surgeons (AAOS) sample home based exercise program available in handout form. The program provides instructions on exercises, repetitions or duration, frequency, and required equipment which can be implemented in the home environment.
89437785|NCT02735707|Other|Anticoagulation Domain|"Patients admitted to participating intensive care units with suspected or microbiological testing confirmed COVID-19 will be randomised to an anticoagulation strategy.~Note: A previous version of this domain evaluated local standard venous thromboprophylaxis against therapeutic dose anticoagulation. This domain is now closed."
89437786|NCT02735707|Other|Immunoglobulin Domain|"Immunosuppressed patients admitted to participating hospitals with microbiological testing confirmed COVID-19 will be randomised to receive no immunoglobulin for COVID-19, or to receive high-titre convalescent plasma.~Note: an earlier version of this domain was not restricted to immunosuppressed patients."
89437787|NCT02735707|Other|Vitamin C Domain|"Patients admitted to participating hospitals with community-acquired pneumonia will be randomised to receive no vitamin C, or vitamin C.~Note: this domain is now closed."
89437788|NCT02735707|Other|Simvastatin Domain|"Patients admitted to participating hospitals with suspected or microbiological testing confirmed COVID-19 will be randomised to receive no simvastatin, or simvastatin.~Note: this domain is now closed."
89437789|NCT02735707|Other|Antiplatelet Domain|"Patients admitted to participating hospitals with suspected or microbiological testing confirmed COVID-19 will be randomised to receive no antiplatelet, aspirin, or site-preferred P2Y12 inhibitor.~Note: this domain is now closed."
89437790|NCT02735707|Other|Mechanical Ventilation Domain|Patients with community-acquired pneumonia admitted to participating intensive care units who are intubated and receiving invasive mechanical ventilation will be randomised to protocolised mechanical ventilation strategy, or clinician-preferred mechanical ventilation strategy
89437791|NCT02735707|Other|COVID-19 Immune Modulation (2) Domain|"Patients admitted to participating hospitals with microbiological testing confirmed COVID-19 will be randomised to receive one of three interventions.~Note: this domain is now closed."
89437792|NCT02735707|Other|ACE2 RAS Domain|"Patients admitted to participating hospitals with suspected or microbiological testing confirmed COVID-19 will be randomised to one of up to five renin-angiotensin system blockade strategies.~Note: this domain is now closed."
89437793|NCT02735707|Other|Cysteamine Domain|"Patients admitted to participating hospitals with severe community-acquired pneumonia, including patients with suspected or proven influenza or COVID-19, will be randomised to receive no cysteamine, or cysteamine.~Note: this domain is now closed."
89437794|NCT02735707|Other|Endothelial Domain|Patients admitted to participating hospitals with severe community-acquired pneumonia, including patients with suspected or proven influenza or COVID-19, will be randomised to receive no endothelial modulator or enteral imatinib.
89437795|NCT02735707|Other|Influenza Immune Modulation|Patients with community-acquired pneumonia admitted to participating intensive care units with microbiological testing confirmed influenza infection will be randomised to one of three interventions.
89437796|NCT02735707|Other|COVID-19 Antiviral (II) Domain|Patients admitted to participating hospitals with microbiological testing confirmed COVID-19 will be randomised to one of up to four interventions.
89437797|NCT02726243||IBD without CRC|
89437798|NCT02726243||IBD with CRC|
89437799|NCT02726243||IBD with dysplasia|
89437800|NCT02726243||non IBD without CRC|
88922657|NCT04612478|No Intervention|Observational|Patients who are unwilling to be randomized will be enrolled in an observational arm of the study. They will be asked to complete all baseline and follow-up assessments, and participation in formal PT or SDEP will be documented.
88922658|NCT04606472|Experimental|Study treatment|Participants receive SI-B003 as intravenous infusion for the first cycle (4 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
89437801|NCT02726243||non IBD with CRC|
89437802|NCT02726243||IBD-PSC without CRC|
89437803|NCT02726243||IBD-PSC with CRC|
89437804|NCT02726243||IBD-PSC with dysplasia or healthy subjects|IBD-PSC with dysplasia or healthy subjects for whom a colonoscopy is scheduled
88922662|NCT04603287|Experimental|Study treatment|Participants receive SI-B001 as intravenous infusion for the first cycle (4 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
88922663|NCT04600713|Experimental|PT-X and IMT|Physiotherapist-led exercise-based cardiac rehabilitation (PT-X) and inspiratory muscle training (IMT).
88922664|NCT04600713|No Intervention|Control|The participants in the control group will be offered PT-X at the end of the control period.
88922665|NCT04596319|Experimental|AP-PA02|Anti-pseudomonal bacteriophage
88922666|NCT04596319|Placebo Comparator|Placebo|Inactive isotonic solution
88922667|NCT04584047|Experimental|Intervention group|This arm has blood collected either at the time of CVS.
88922668|NCT04564417|Experimental|Monotherapy dose escalation: W0180|Participants will receive W0180 in a 21-day cycle until the maximum tolerated dose (MTD)/ recommended dose for expansion (RDE) for the single-agent identified.
88922669|NCT04564417|Experimental|Combination dose escalation: W0180+Pembrolizumab|Participants will receive Pembrolizumab 200 mg flat dose as IV infusion every three weeks (Q3W) followed by W0180 in a 21-day Cycle until the MTD in combination is identified or an RDE in combination is established.
88922670|NCT04564417|Experimental|Dose expansion|Participants will receive Pembrolizumab 200 mg flat dose as IV infusion Q3W followed by an RDE dose of W0180 in a 21-day cycle.
88922671|NCT04562870|Experimental|Arm S: Selinexor|Participants with MF who had previously received at least 6 months of treatment with JAK 1/2 inhibitor will receive a dose of selinexor 80 mg in first 2 cycles followed by selinexor 60 mg in subsequent cycles orally on Days 1, 8, 15, and 22 of each 28-day cycle to participants on Arm S.
88922672|NCT04562870|Active Comparator|Arm PC: Physician's Choice Treatment|Participants with MF who had previously received at least 6 months of treatment with JAK 1/2 inhibitor will receive Physician's choice treatment which will be administered as per clinical practice.
89538432|NCT05074199|Active Comparator|W-plasty|"The cosmetic appearance of scars closed in a in a zig-zag  fashion (W-plasty)."
88922673|NCT04562389|Experimental|Phase 1a: Cohort 1: Selinexor 40 mg + Ruxolitinib BID|Participants with MF will receive a dose of 40 milligrams (mg) selinexor oral tablets once weekly (QW) on Days 1, 8, 15, and 22 of each 28-day cycle in combination with 15 or 20 mg ruxolitinib twice a day (BID) based on the participants baseline platelet count.
89199277|NCT05926687|Active Comparator|Disruptive Behavior + Switch Intervention to Social Communication|"Starting Intervention: Disruptive Behavior Who: Parent & Therapist only Frequency: 1-hour once/week~Secondary Intervention: Switch to Social Communication Intervention Who: Parent & Child & Therapist Frequency: 1-hour twice/week"
89437805|NCT02724579|Experimental|Treatment (reduced radiation therapy and chemotherapy)|"RADIATION THERAPY: Beginning 4-5 weeks after surgery, patients undergo craniospinal radiation therapy 5 days a week for 6 weeks.~MAINTENANCE THERAPY (WEEKS 1, 3, 5, and 7): Beginning 4-6 weeks after completion of radiation therapy patients receive lomustine PO on day 1, vincristine sulfate IV over 1 minute or via minibag on days 1, 8, and 15, and cisplatin IV over 6 hours on day 1. Treatment repeats every 42 days in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY (WEEKS 2, 4, AND 6): Patients receive cyclophosphamide IV over 30-60 minutes on days 1 and 2, mesna IV over 15-30 minutes on days 1 and 2, and vincristine sulfate IV over 1 minute or via minibag on days 1 and 8. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.~Patients also undergo MRI throughout the trial."
89437806|NCT02699606|Experimental|Erdafitinib|Participants will receive a 8 milligram (mg) starting dose once daily with option to up-titrate to 9 mg on a 28-day cycle. The dose of study drug may be modified, delayed, or terminated based on guidelines provided in the protocol.
89437807|NCT02674230||Extreme obesity|BMI ≥35kg/m2
89437808|NCT02674230||Obesity|BMI 24-34.9kg/m2
89437809|NCT02674230||Normal subjects|BMI <24kg/m2. No systemic disease, including hypertension, diabetes, liver cirrhosis, chronic kidney disease, and psychiatric disease.
89437810|NCT02656823|Experimental|ANKYLOS C/X Implant A 6.6|ANKYLOS C/X Implant A 6.6 mm
89437811|NCT02652949|Experimental|Endovascular Repair|Valiant Evo Thoracic Stent Graft System
89437812|NCT02634190||Triple negative women|Women 30 years of age or older coming for routine cervical screening who tested triple negative at baseline with the interventions: Thinprep® LBC, HR HC2® HPV DNA and APTIMA® HPV Assay
89437813|NCT02634190||Women tested positive|Women who tested positive in any of the tests Thinprep® LBC, HR HC2® HPV DNA or APTIMA® HPV Assay will undergo colposcopy and be followed up over a ten year period and subjects who tested positive during the follow up assessment will be followed up over a 5 year period on a yearly basis
89437814|NCT02625324|Experimental|Endovascular repair|Valiant Evo Thoracic Stent Graft System
89437815|NCT02616965|Experimental|Treatment|Treatment consists of the combination of Romidepsin given 10mg/m2 or 14mg/m2 on days 1, 8 and 15 every 28 days and Brentuximab vedotin given 0.9mg/kg or 1.2mg/kg on days 1 and 15 every 28 days for 16 cycles.
89437816|NCT02584933|Experimental|ceritinib|The starting dose of study treatment for patients in this protocol should be the same as the dose provided in the parent ceritinib study at the time of the rollover.
89437817|NCT02574234|Experimental|Patients with orthopedic surgery|"Patients will be included in the consultation of anesthesia. The usual laboratory tests will be carried out and a determination of apelin and inflammatory cytokines. Assessment of cognitive functions using the Informant Questionnaire on Cognitive Decline in the Elderly (ICQODE), Mini Mental State examination (MMS) and the scale of Instrumental activities of daily living (IADL).~Day of surgery: liquid sampling cerebrospinal. Day 1 to day 7 postoperatively: determination of inflammatory cytokines and apelin, postoperative delirium research (Confusion Assessment Method (CAM)), residual cognitive dysfunction research (MMS, IADL, IQCODE).~3 months after operation: evaluation of cognitive performance (IQCODE, IADL)"
89437818|NCT02567227|Experimental|Cognitive Remediation|An individualized computerized cognitive remediation program.
89437819|NCT02567227|Active Comparator|Active control|Individualized computer based exposure and interactive health education classes.
89437820|NCT02535702|Experimental|Attentional Bias Task|Subjects will briefly see two images side by side on a screen. Immediately after, a dot appears on the left or on the right. The subjects task is to press the left or right button, following the position of the image (left or right). Images can contain food-related items. We will also show short 1-minute food-related movies. Subjects will be asked to fast for three hours before this task begins.
89437821|NCT02535702|Experimental|Cue Reactivity Task|In this task subjects will view pictures of various items on the screen in front of them. Subjects will rate the items by how much they would like to have them. Subjects will choose how much they want the item by pressing a button.
89437822|NCT02535702|Experimental|Delay Discounting Task|Subjects will be asked to imagine whether they would receive money now or money later (in the future). The future money option may be several days from now or as far out as 6 weeks from now. For example, a s ubject may see a $100 option in 6 weeks or a $10 option now. Subjects will not receive actual money for participation in this task
89199278|NCT05924009|Experimental|All participants|All participants
89437823|NCT02535702|Experimental|Motivational Reward Task|Subjects will make a choice among some items presented on the screen in front of them. One of the items will be the winner item. The other items will be loser items. Each time a subject is presented with various items, they will choose the item they think is the winner item. Subjects will start with bonus points at the beginning of the task, so they can add more points to this amount as they continue to choose winner items.
89437824|NCT02535702|Experimental|NSPRD Task|During the MRI scan, subjects will get small electric shocks through electrodes placed on one of their toes. The shocks feel like an elastic band snapping against the skin. Right after a shock, subjects will see a dot on the computer screen. Subejcts will press a button to rate the intensity of the shock.
89437825|NCT02535702|Experimental|Reasoning Task|Subjects will identify changes in various shapes when they are displayed on the screen in front of them. Some changes of the shapes may be that they were rotated, enlarged, or multiplied. Subjects will choose the changes in the shapes by pressing a button.
89538433|NCT05074199|Active Comparator|Linear closure|"The cosmetic appearance of scars closed in a standard straight line fashion (linear closure)."
89538434|NCT03267095|Experimental|Study|.Patient in stduy Arm will receive music therapy sessions
89538435|NCT03267095|No Intervention|Control|Patient in control Arm will have cosuling for mother and follow up
89538436|NCT03267017||Patient scheduled for surgery under general anesthesia|
89437826|NCT02535702|Experimental|Respiratory Challenge (RC) Task|Participants will be visually instructed to take a brief deep breath (inhale) and release the breath (exhale). They will inhale and exhale one more time with visual cues at specific times (60 seconds, 120 seconds, 180 seconds, 240 seconds, etc. with successive 60 seconds intervals). A black cross will remain centered on a grey slide during the normal respiration periods. To signal the RC periods, the slide will change color to yellow READY slide, then to green BREATHE IN slide, then to blue BREATHE OUT slide. The sequence will repeat one more time to Breath In and Breath Out and then finally go back to the yellow Breathe Normally slide. The instruction words will be written on the slides. Each slide will be shown for 3 seconds. The task will take a total of 15 minutes (total of 900 seconds with 14 RC periods).
89437827|NCT02535702|Experimental|Self-control Task|During the MRI scan, subjects will do a task that requires close concentration. Subjects will be asked to respond quickly to images on the computer screen, during which they will hear distracting noises. The subject will be able to remove the distraction in order to complete the task. During some sub-study sessions, subjects will start with no money ($0) and may be able to earn up to $40 if they do not remove the distraction. At other sub-study sessions, subjects will start with $40 and may lose between 25 to $1 each time they remove the distraction. Subjects cannot lose more than $40 in these sessions. Compensation for this sub-study is up to $40 per session, depending on their performance.
89437828|NCT02535702|Experimental|Spinner Task and MID Task (monetary incentive delay task)|The Spinner task requires the subject to participate in a game of chance while lying in the MRI scanner. Subjects will be asked to respond by pressing a button. The MID task is a reaction time task. The MID Task tests how quickly a subject can press a button to hit a target on the screen in front of them. If the subject presses the button as soon as the target appears, the subject will score points. Subjects should try to score as many points as you can.
89437829|NCT02497664|Other|Active Breathing Control|Planning-CT will be made of patients using the Active Breathing Control Technique (in expiration and inspiration phase)
89437830|NCT02484404|Experimental|P1 Durvalumab+C|Ph I Durvalumab + cediranib dose escalation
89437831|NCT02484404|Experimental|P1 Durvalumab+O|Ph I Durvalumab + olaparib dose escalation
89437832|NCT02484404|Experimental|P1 Durvalumab+O+C|Ph I Durvalumab + olaparib + cediranib dose escalation
89437833|NCT02484404|Experimental|P2 Durvalumab+C|Ph II Durvalumab + cediranib at RP2D
89437834|NCT02484404|Experimental|P2 Durvalumab+O|Ph II Durvalumab + olaparib at RP2D
89437835|NCT02484404|Experimental|P2 Durvalumab+O+C|Ph II Durvalumab + olaparib + cediranib at RP2D
89437836|NCT02471430|Experimental|Arm A|Participants in Arm A will receive panobinostat as an oral tablet on days 0, 2, and 4 of the treatment week. The dose of panobinostat will be a 15 mg tablet.
89437837|NCT02471430|Experimental|Arm B|Participants in Arm B will receive one subcutaneous injection of pegylated interferon-alpha2a on day 0. The dose of pegylated IFN-alpha2a will be 180 mcg. Simultaneously with interferon-alpha2a, a 15 mg tablet of panobinostat will be administered on day 0. Participants will also receive panobinostat as an oral tablet on days 2 and 4 of the treatment week.
88922674|NCT04562389|Experimental|Phase 1a: Cohort 2: Selinexor 60 mg + Ruxolitinib BID|Participants with MF will receive a dose of 60 mg selinexor oral tablets QW on Days 1, 8, 15, and 22 of each 28-day cycle in combination with 15 or 20 mg ruxolitinib BID based on the participants baseline platelet count.
88922675|NCT04562389|Experimental|Phase 1b: Selinexor and Ruxolitinib BID|Participants with MF will receive a dose of 40 or 60 mg selinexor oral tablets QW on Days 1, 8, 15, and 22 of each 28-day cycle in combination with 15 or 20 mg ruxolitinib BID based on the participants baseline platelet count.
88922676|NCT04562389|Experimental|Phase 3: Selinexor 60 mg + Ruxolitinib BID|Participants with MF will receive a fixed starting dose of 60 mg selinexor (RD) oral tablets QW on Days 1, 8, 15, and 22 of each 28-day cycle in combination with a starting dose of 15 or 20 mg ruxolitinib BID based on the participants baseline platelet count.
89437838|NCT02471430|Experimental|Arm C|Participants in Arm C will receive one subcutaneous injection of pegylated interferon-alpha2a on day 0.The dose of pegylated IFN-alpha2a will be 180 mcg.
89437839|NCT02396823|Experimental|Respiratory Muscle Training|Each training session will last about 45-60 min and will occur five times weekly during one month. During the RMT sessions, the patient will remain in their personal wheelchair. They will be asked to breath through a special device with regulated resistance to breathing air. In the 20 sessions starting from the lowest resistance, the goal will be to train the muscles they use to breathe by slowly increasing this resistance. They will perform six work sets, 5 minutes in duration, separated by rest intervals lasting 1-3 minutes.
89437840|NCT02396823|No Intervention|Control|Following screening process and recruiting, subjects from both Healthy Control and SCI Control groups will undergo the same procedures as subjects from SCI group excluding the training intervention.
89437841|NCT02390635|Experimental|Diagnostic (18F-FDG PET/CT, whole body PET/MRI)|Patients receive gadolinium IV and undergo whole body PET/MRI comprising diffusion weighted imaging and 3D FSPGR-DE with and without fiducial markers. Patients then undergo 18F-FDG PET/CT before start treatment for acute myeloid leukemia.
88922677|NCT04562389|Active Comparator|Phase 3: Placebo + Ruxolitinib BID|Participants with MF will receive a matching placebo of selinexor oral tablets QW on Days 1, 8, 15, and 22 of each 28-day cycle in combination with a starting dose of 15 or 20 mg ruxolitinib BID based on the participants baseline platelet count.
89538437|NCT05074043||covid19|covid 19 proven by clinical, PCR. not associated with mucor
88922678|NCT04551417|Active Comparator|Dorsal onlay graft urethroplasty|
88922679|NCT04551417|Experimental|Ventral onlay graft urethroplasty|
88922680|NCT04545593|Experimental|Positive Minds Strong Bodies Enhanced|The Positive Minds Strong Bodies Enhanced intervention (PMSB-E) consists of 10 sessions focused on mental health (PM) and 36 sessions focused on physical health (SB), along with a group maintenance component.
88922681|NCT04545593|Active Comparator|Enhanced Usual Care|The Enhanced Usual Care condition includes written materials on depression and anxiety and 4 calls to participants over the course of 6 months to assess symptoms and safety.
88922682|NCT04538144||Younger participants|Individuals aged 18-39 years
89199279|NCT05922774||Group 1|Patients with recurrent BPPV
88922683|NCT04538144||Older participants|Individuals aged 65 years or older
89199280|NCT05922774||Group 2|Patients with non recurrent BPPV
89199281|NCT05922774||Group 3|Healthy controls
88922684|NCT04511702|Experimental|Pegloticase 60 Minute Infusion with methotrexate (MTX)|Pegloticase 60 Minute Infusion with methotrexate (MTX). Participants will receive MTX (15 mg) (weekly) during the Run-in Period, then pegloticase (every 2 weeks) with MTX (weekly) for 24 weeks
88922685|NCT04511702|Experimental|Pegloticase 45 Minute Infusion with methotrexate (MTX)|Pegloticase 45 Minute Infusion with methotrexate (MTX). Participants will receive MTX (15 mg) (weekly) during the Run-in Period, then pegloticase (every 2 weeks) with MTX (weekly) for 24 weeks
88922686|NCT04511702|Experimental|Pegloticase 30 Minute Infusion with methotrexate (MTX)|Pegloticase 30 Minute Infusion with methotrexate (MTX). Participants will receive MTX (15 mg) (weekly) during the Run-in Period, then pegloticase (every 2 weeks) with MTX (weekly) for 24 weeks
88922687|NCT04502095|Experimental|Group I (trimethoprim-sulfamethoxazole, nitrofurantoin)|Patients receive ertapenem PO, levofloxacin PO, or clindamycin PO induction therapy per standard of care. At the time of full diet, patients receive trimethoprim-sulfamethoxazole PO daily or nitrofurantoin PO daily on days 1-30. Patients complete a drug diary for each day they receive the antibiotic.
88922688|NCT04502095|Active Comparator|Group II (standard of care)|Patients receive ertapenem PO, levofloxacin PO, or clindamycin PO induction therapy per standard of care.
88922689|NCT04501276|Experimental|Part A : Dose escalation of ADG116 monotherapy|
88922690|NCT04501276|Experimental|Part B : Dose escalation of ADG116 combined with anti PD1 drug|
88922691|NCT04501276|Experimental|Part C : Dose escalation of ADG116 combined with ADG106|
88922692|NCT04485793|Active Comparator|Active Comparator|Dietary supplement
88922693|NCT04485793|Placebo Comparator|Placebo comparator|Placebo
88922694|NCT04481451|Experimental|Erector spinae supplemental block|Single-shot T9/T10 operative side erector spinae block using ropivacaine 0.2%, 0.5ml/kg.
88922695|NCT04481451|Active Comparator|Quadratus lumborum supplemental block|Single-shot T9/T10 operative side quadratus lumborum (type 1) block using ropivacaine 0.2%, 0.5ml/kg.
88922696|NCT04476862||Cerliponase alfa patients|Patients who are currently on or plan to start taking cerliponase alfa within 60 days of signing the study informed consent form.
88922697|NCT04466475|Experimental|Treatment (211At-OKT10-B10, melphalan, PBSC transplantation)|Patients receive 211At-OKT10-B10 IV continuously on day -10 to day - 4 (approximately day -7) and melphalan via infusion on day -2. Patients then undergo HCT on day 0.
88922698|NCT04458545|Placebo Comparator|Placebo Vaccine|
88922699|NCT04458545|Experimental|Low Dose Vaccine (100 μg)|
88922700|NCT04458545|Experimental|High Dose Vaccine (400 μg)|
88922701|NCT04455789|Experimental|conventional mechanical ventilation|routine mechanical ventilation will be adjusted based on conventional mechanical ventilation settings with tidal volume of 8 ml/kg and PEEP level of 5
88922702|NCT04455789|Experimental|mechanical ventilation adjusted according to driving pressure|routine mechanical ventilation adjusted based on driving pressure during lateral position. After patients are put to lateral position incremental increase in PEEP will be applied and the driving pressures will be recorded for each PEEP level and the patients will be ventilated with this PEEP during anesthesia. the other setting will be same with conventional group. tidal volume of 8 ml/kg
88922703|NCT04454671|Experimental|ultrasound-guided percutaneous neuromodulation|Technique based on electrical stimulation of a peripheral nerve through an ultrasound-guided needle or a muscle at a motor point. The stimulation is performed with low or medium frequency currents in which a sensory and / or motor response is sought by stimulating the peripheral nerve
88922704|NCT04454671|Placebo Comparator|Ultrasound-guided dry needling|Dry needling technique applied by ultrasound-guided but without electrical stimulation of a peripheral nerve.
88922705|NCT04443660||Group A|without medical history or risk factors, with a normal pregnancy
88922706|NCT04443660||Group B|without medical history or risk factors, developing a pregnancy complication
89538438|NCT05074043||covid19 associated with mucor|covid19 associated with mucor proven by clinical, histopathological
88922707|NCT04443660||Group C|with risk of complication, having a normal pregnancy
88922708|NCT04443660||Group D|with a risk of complication, developing a pregnancy complication
88922709|NCT04440839|Experimental|Intervention|Telemedicine specialty consultation for patients
88922710|NCT04440839|No Intervention|Standard Care|Standard in person referral to a specialist
88922711|NCT04438369|Active Comparator|Erector spinae block|"Group ESPB: Multimodal analgesia comprising of preoperative paracetamol adjusted for weight (2000 milligrams (mg) >70 kilograms (kg) <70 years, 1500 mg <70 kg >70 years, 1000 mg <50 kg) and diclofenac adjusted for weight (100 mg >70 kg <70 years, 50 mg <70 kg >70 years). After the operation they receive paracetamol 1000 mg x4 and diclofenac 50 mg x3 a day, as well as PCA with iv oxycodon 1 mg/ml.~Preoperatively positioned bilateral catheters at level T7 injected with ropivacaine 2,5 mg/ml, 30 ml on each side. Postoperative maintenance treatment with injection of 2 mg/ml ropivacaine 30 ml on each side every 6 hours postoperatively. Maximum allowed bolus preoperative ropivacaine dose is 3 mg/kg body weight (BW), while the maximum 24 hour dose postoperatively is 11 mg/kg to avoid local anesthesia systemic toxicity (LAST). The catheter will be discontinued 24 hours after the original procedure. The container with ropivacaine will be masked for blinding of the personnel on the ward."
89538439|NCT03266705|Experimental|61 mgA tafamidis free acid soft gelatin capsule|
89437842|NCT02390427|Experimental|Arm A|"Arm A~- Taselisib with Trastuzumab emtansine (also called T-DM1)~Taselisib administered orally, daily in each treatment cycle (3 weeks).~Trastuzumab emtansine (also called T-DM1) administered once via IV per treatment cycle (3 weeks)."
88922712|NCT04438369|Placebo Comparator|Control|"Control group with standard multimodal analgesia: Preoperative paracetamol adjusted for weight (2000 milligrams (mg) >70 kilograms (kg) <70 years, 1500 mg <70 kg >70 years, 1000 mg <50 kg) and diclofenac adjusted for weight (100 mg >70 kg <70 years, 50 mg <70 kg >70 years). After the operation they receive paracetamol 1000 mg x4 and diclofenac 50 mg x3 a day, as well as PCA with iv oxycodone 1 mg/ml.~Insertion of bilateral catheters preoperatively. Injection of 30 ml saline preoperatively and every 6 hours postoperatively. The catheter will be discontinued 24 hours after the original procedure. The container with saline will be masked for blinding of the personnel on the ward."
88922713|NCT04420702|Experimental|Early Detection Cohort (MRI with DBSI)|"Magnetic resonance imaging (MRI) with DBSI analysis prior to prostate biopsy~Standard of care prostate biopsy will be performed within 12 weeks of MRI~Some participants may go on to receive standard of care radical prostatectomy and those participants may have their prostatectomy specimens scanned via MRI with DBSI imaging"
88922714|NCT04420702|Experimental|Active Surveillance Cohort (MRI with DBSI)|"Magnetic resonance imaging (MRI) with DBSI analysis prior to prostate biopsy~Standard of care prostate biopsy will be performed within 12 weeks of MRI~Some participants may go on to receive standard of care radical prostatectomy and those participants may have their prostatectomy specimens scanned via MRI with DBSI imaging"
88922715|NCT04411420|Active Comparator|Integrated Care Pathway|The integrated care pathway provides both on-site physical therapy services and centrally-delivered services via telephone or video from study providers at the Durham VA.
88922716|NCT04411420|Active Comparator|Coordinated Care Management Pathway|The care management pathway involves a referral of patients from a physician to a pain navigator on site at the local VA who is knowledgeable in current recommended treatment guidelines for low back pain.
88922717|NCT04404387|Experimental|Experimental arm|vitamin C 50 mg/kg every 6 hours for 96 hours.
88922718|NCT04404387|Placebo Comparator|Control arm|Placebo administration
88922719|NCT04403282|Active Comparator|Paired(right and left neck) comparison group eflornithine|randomized, double-blinded, placebo-controlled, paired (right and left neck) comparison study examining eflornithine versus placebo for the treatment of PFB.
88922720|NCT04403282|Placebo Comparator|Paired(right and left neck) comparison group placebo|randomized, double-blinded, placebo-controlled, paired (right and left neck) comparison study examining eflornithine versus placebo for the treatment of PFB.
89538440|NCT03266705|Experimental|4x20 mg tafamidis meglumine soft gelatin capsule|
89538441|NCT05073965|Experimental|Intervention Group|Subject receive a 1000IU vitamin D supplement dose daily for 6 months
89437843|NCT02390427|Experimental|Arm B|"Arm B~-Taselisib with T-DM1 and Pertuzumab~Taselisib is administered oral, daily or every other day per treatment cycle (3 weeks).~Trastuzumab emtansine (also called T-DM1) administered once via IV per treatment cycle (3 weeks).~Pertuzumab- administered once via IV per treatment cycle (3 weeks)."
88922721|NCT04393558||COVID-19|Individuals experiencing COVID-19 like symptoms.
88922722|NCT04393558||Healthy Controls|Individuals without any known significant health problems
88922723|NCT04390243|Experimental|Treatment (encorafenib, binimetinib)|Patients receive encorafenib PO QD and binimetinib PO BID on days 1-25. Treatment repeats every 28 days for up to 36 cycles in the absence of disease progression or unacceptable toxicity.
88922724|NCT04386811|Experimental|Calcitriol|
88922725|NCT04386811|Placebo Comparator|Placebo|
88922726|NCT04378270|Experimental|PopSole™ offloading device|This is an external insole device that fits into a shoe and is reusable for a given subject, not for one-time use. It is comparable to other off-the-shelf insoles readily available and presents minimal risk to the participant during the four weeks of study participation.
88922727|NCT04354649|Experimental|Hydroxychloroquine, plus prednisone|Hydroxychloroquine 5mg/kg PO daily, plus prednisone starting at 20 mg PO daily for 8 weeks tapering dose.
88922728|NCT04354649|Placebo Comparator|Hydroxychloroquine-matching placebo, plus prednisone|Matching placebo daily, plus prednisone starting at 20 mg PO daily for 8 weeks tapering dose.
88922729|NCT04335422|Experimental|Robotic group|Robotic group will receive both routine physical and rehabilitation medicine program and additional upper extremity robot-assisted training by Armeo Spring. Routine physical and rehabilitation medicine program, including physical therapy and exercises, walking and balance training, and occupational therapy to improve activities of daily living will last nearly 2 hours/day and robotic therapy one hour/day. Routine PRM program and robotic therapy will be given through 6 weeks, 5 days a week (A total of 30 sessions of routine PRM program plus robotic therapy).
89437844|NCT02390427|Experimental|Arm C|"Arm C:~Taselisib with Pertuzumab and Trastuzumab~Cohort C will not open without additional authorization from Genentech~Taselisib is administered oral, daily in each treatment cycle (3 weeks).~Trastuzumab administered once via IV per treatment cycle (3 weeks).~Pertuzumab- administered once via IV per treatment cycle (3 weeks)."
89538442|NCT05073965|Placebo Comparator|Placebo group|Subject receive a placebo daily for 6 months
88922730|NCT04335422|Active Comparator|Control group|Control group will receive only routine physical and rehabilitation medicine program. Routine physical and rehabilitation medicine program, including physical therapy and exercises, walking and balance training, and occupational therapy to improve activities of daily living will last nearly 2 hours/day and will be given through 6 weeks, 5 days a week (A total of 30 sessions of routine PRM program only).
88922731|NCT04325204|Experimental|Caregivers|Caregivers of a person living with dementia will participate in the Faith-HAT intervention for 6 weeks.
88922732|NCT04325204|Experimental|Persons living with dementia|Persons living with dementia will participate in the Faith-HAT intervention for 6 weeks.
88922733|NCT04322357|No Intervention|Daily Glucocorticoid (GC)|Existing data from age-matched, ambulatory, on daily GC therapy, and similar exclusion criteria will be selected from the ImagingDMD database to serve as a historical control.
89199282|NCT05919602|No Intervention|Control group|Subjects on the waiting list for upper limb surgery that on the day of surgery, only anxiety will be evaluated before the operation and no intervention would be performed before the operation.
89437845|NCT02390427|Experimental|Arm D|"Arm D~Taselisib with Pertuzumab, Trastuzumab, and Paclitaxel~Cohort will not be opened without additional authorization from Genentech~Taselisib- administered oral, daily in each treatment cycle (3 weeks).~Pertuzumab- administered once via IV per treatment cycle (3 weeks).~Trastuzumab administered once via IV per treatment cycle (3 weeks).~Paclitaxel- administered via IV, weekly for 3 weeks within each cycle."
89437846|NCT02389309|Experimental|Treatment (dasatinib, cyclophosphamide, temsirolimus)|Patients receive dasatinib PO BID on days 1-21, cyclophosphamide PO QD on days 1-21, and temsirolimus IV over 30-60 minutes on days 1, 8, and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients experiencing stable disease or better may continue treatment with the approval of the Study Chair.
89437847|NCT02381886|Experimental|IDH305|
89437848|NCT02378298|Active Comparator|Non-responder RTX+MTX|"Patients with moderate-severe TAO with an inflammatory CAS of ≥ 4 that do not respond to iv GC (deltaCAS <2 compared to baseline after 4 weeks of iv GC ) or do relapse (deltaCAS ≥2 and total CAS ≥4) after steroid treatment compared to previous CAS measurement at 12 weeks. Rituximab (1000 mg iv with 2 weeks in between) is combined with methotrexate (15-20 mg once a week) to minimize the risk of antibody developement. MTX is always combined with RTX and is never given as a monotherapy in this study.~rituximab and methotrexate"
89437849|NCT02378298|Active Comparator|Relapse RTX+MTX|Patients that respond to iv GC (Methylprednisolone iv) but relapse after 6 weeks will be randomised to either RTX+MTX or per oral GC (po GC+MTX) rituximab and methotrexate
89437850|NCT02378298|Active Comparator|Relapse po GC+MTX|"Patients that respond to iv GC but relapse after 6 weeks will be randomised to either RTX+MTX or per oral GC (po GC+MTX) This is the conventional therapy arm.~methotrexate and methylprednisolone"
89437851|NCT02378298|No Intervention|Responders without relapse|Patients that respond to iv GC and have no relapse at 18 weeks of study.
89437852|NCT02378298|Active Comparator|Methylprednisolone iv|All patients in the study have a 4 weeks period of 500 mg methylprednisolone iv/week. Depending of the response patients are classified as non- responders (and are given RTX and MTX) or responders. The responders continue with intravenous infusion of Methylprednisolone 500 mg /week in 2 weeks and thereafter 250 mg iv/week in 6 weeks.
89437853|NCT02378246|Experimental|Tablet with vitamins and minerals, containing 150 ug iodine, 1 tablet daily|"Table of contents:~Vitamin B2 1.4 mg, Vitamin B12 15 µg, Iron 12 mg, Zinc 12 mg, Iodine 150 µg, Selenium 50 µg, Calcium 250 mg"
89437854|NCT02378246|Placebo Comparator|Placebo: non-iodine containing multivitamin, 1 tablet daily|"Table of contents:~Vitamin A 400 µg, Vitamin B1 1.4 mg, Vitamin B2 1.7 mg, Vitamin B6 1.8 mg, Vitamin B12 3 µg, Vitamin C 60 mg, Vitamin D 5 µg, Vitamin E 10 mg, Niacin 19 mg, Folic acid 200 µg"
88922734|NCT04322357|Active Comparator|Twice weekly glucocorticoid with or without exercise|"Patients will be randomized to one of 2 groups:~Twice weekly prednisone alone for 12 months~Twice weekly prednisone for 6 months followed by twice weekly prednisone plus 6 months of structured, supervised and home-based exercise training."
88922735|NCT04322357|Active Comparator|Daily glucocorticoid with exercise|Patients on daily glucocorticoids will undergo 6 months of structured, supervised and home-based exercise training.
88922736|NCT04312841|Experimental|Treatment (letermovir)|Beginning within 7 days of the first administration of standard alemtuzumab, patients receive letermovir PO (or IV over 1 hour if patient is unable to take PO for an extended period of time) daily on days 1-28. Cycles repeat every 28 days for up to 3 months after the last dose of alemtuzumab in the absence of unacceptable toxicity.
88922737|NCT04309630|Active Comparator|intercostal block|patients received intercostal block will be evaluated by visual analog score for pain assesment
88922738|NCT04309630|Experimental|erector spina plane block|patients received erector spina plane block will be evaluated by visual analog score for pain assesment
88922739|NCT04305665||HIV-1 positive persons|
88922740|NCT04286373|Experimental|Group A: active stimulation then placebo stimulation|"VNS active stimulation: Use of device (Tens Eco Plus SCHWA MEDICO™) for 8 weeks, then VNS placebo for 8 weeks.~The two stimulation periods will be separated by a 4 +/- 1 weeks wash-out period.~The VNS placebo stimulation period being the control one."
89437855|NCT02362464|Experimental|Long Term T-cell Receptor Alternate Reading Frame Protein (TARP) Peptide Vaccinations|Intradermally given vaccine given at weeks 3, 6, 9, 12, 15 and 24.
89199283|NCT05919602|Experimental|Intervention group|Subjects on the waiting list for upper limb surgery on the day of surgery, anxiety will be evaluated before the operation and intervention would be performed before the operation.
89199284|NCT05919147|Experimental|Pioglitazone|
89437856|NCT02359968|Active Comparator|FOLFOX|"Fluorouracil 400 mg/m², IV bolus dose on day 1, followed by continuous IV infusion of fluorouracil 1600 mg/m² over 2 days~Oxaliplatin 85 mg/m², 2-hr IV infusion on day 1~Folinic acid 200 mg/m² 2-hr IV infusion on day 1~3 cycles, q14"
89437857|NCT02359968|Experimental|CarboP-pacliT|"Carboplatin (carboP) AUC=2, given by intravenous infusion~Paclitaxel (pacliT) 50 mg/m², given by intravenous infusion~on days 1, 8, 15, 22 and 29"
89437858|NCT02326974|Experimental|T-DM1 and Pertuzumab|T-DM1 3.6 mg per kg of body weight via IV every 3 weeks for 6 doses and Pertuzumab loading dose of 840 mg via IV on Cycle 1 Day 1 followed by maintenance dose of 420 mg via IV every 3 weeks for 6 doses. Excision of tumor/mastectomy of biopsy residual tumor within 42 days of the last cycle of therapy.
89199285|NCT05919147|Placebo Comparator|Placebo|
88922741|NCT04286373|Experimental|Group B: placebo stimulation then active stimulation|"VNS placebo for 8 weeks, then VNS active stimulation Use of device (Tens Eco Plus SCHWA MEDICO™) for 8 weeks.~The two stimulation periods will be separated by a 4 +/- 1 weeks wash-out period.~The VNS placebo stimulation period being the control one."
88922742|NCT04277598|Experimental|Lead In Phase: APO-2: 25U/ml|Topical administration of APO-2, 25 U/ml; Approximalety 0.5 ml per square cm wound;
89437859|NCT02318771|Experimental|A1: RT (1 fraction, 8 Gy) + MK-3475|Patients undergo RT on day 1 per standard of care and then undergo biopsy 3-10 days later. Beginning 0-7 days after biopsy, patients receive MK-3475 IV over 30 minutes on day 1. Courses of MK-3475 repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89437860|NCT02318771|Experimental|A2: RT (5 fractions, 4 Gy) + MK-3475|Patients undergo RT on days 1-5 and then undergo biopsy 3-10 days later. Beginning 0-7 days after biopsy, patients receive MK-3475 as in Arm A1.
89437861|NCT02318771|Experimental|B1: MK-3475 + RT (1 fraction, 8 Gy) + MK-3475|Patients receive one dose of MK-3475 IV over 30 minutes on day 1 and then undergo 1 fraction of RT. Patients then receive MK-3475 IV over 30 minutes in the absence of disease progression or unacceptable toxicity.
88922743|NCT04277598|Placebo Comparator|Lead In Phase: Placebo|Topical administration of placebo; Approximalety 0.5 ml per square cm wound;
89437862|NCT02318771|Experimental|B2: MK-3475 + RT (5 fractions, 4 Gy) + MK-3475|Patients receive MK-3475 as in Arm B1 and undergo 5 fractions of RT.
89437863|NCT02283281|Experimental|Cannabis oil high dose|Single-dose, before anesthetic induction: 21.6 mg tetrahydrocannabinol + 20 mg cannabidiol, Sub-linguistic
89437864|NCT02283281|Experimental|Cannabis oil low dose|Single-dose, before anesthetic induction: 10.8 mg tetrahydrocannabinol + 10 mg cannabidiol, Sub-linguistic.
89437865|NCT02283281|Placebo Comparator|Control|Single-dose, before anesthetic induction: Dummy oromucosal spray containing alcohol vehicle without Cannabis oil .
89437866|NCT02281084|Experimental|Monotherapy: Oral Azacitidine|Oral azacitidine (AZA) 100 mg, 150 mg, or 200 mg tablets twice daily (BID) on days 1 to 21 of each 28-day treatment cycle. Participants continued to receive their assigned study treatment unless disease progression, unacceptable toxicity, lost to follow-up or withdrawal by participant occurred.
89437867|NCT02281084|Experimental|Combination Therapy: Oral Azacitidine and Durvalumab|Oral Azacitidine 100 mg oral azacitidine tablets BID on days 1 to 14 or days 1 to 21 of each 28-day treatment cycle and durvalumab 1500 mg by intravenous (IV) infusion on day 1 of each 28-day treatment cycle; participants continued to receive their assigned study treatment unless disease progression, unacceptable toxicity, lost to follow-up or withdrawal by participant occurred.
89536917|NCT03307187|Experimental|GLB-AIM|GLB-AIM (Group Lifestyle Balance program, Adapted for individuals with Impaired Mobility) is a 12-month intervention that promotes 5% weight loss by reducing calories and increasing exercise (150 minutes of moderate physical activity). The 23 GLB-AIM sessions were delivered through monthly in-person and teleconference calls and participants were encouraged to self-monitor daily caloric/fat intake and physical activity using materials to accurately measure daily calories and exercise, which included a food scale, measuring cups and spoons and a loaned Garmin vívofit® activity tracker and heart rate monitor. Participants shared their logs with lifestyle coaches over the 13 core sessions and lifestyle coaches provided positive reinforcement, feedback, and problem solving techniques as needed.
89536918|NCT03307187|No Intervention|wait-list control|During the initial 6 month intervention period the control group received several contacts from the study staff via mail that included information on general health (e.g., managing stress, getting good sleep), holiday cards, and scheduling reminders for the 3 and 6 month testing.
89536919|NCT03307031|Experimental|High Volume Group|Performed four weekly sessions, during 10 weeks with 45 to 55 minutes per session.
89536920|NCT03307031|Experimental|Low Volume Group|Performed only twice a week, during 10 weeks with 45 to 55 minutes per session.
89536921|NCT03307031|Placebo Comparator|Control Group|Did not exercise, during 10 weeks.
89536922|NCT03306953|Active Comparator|Rectus muscle approximation|Three sutures will be done for the the purpose of rectus muscle approximation in cesarean section.
89536923|NCT03306953|No Intervention|Control|No approximation for the rectus muscle will be done for the control group in cesarean section.
89536924|NCT03306875|Experimental|Cognitive Training|Individuals will take part in a computer-based cognitive training program. The program is aimed at building attention, processing speed, memory, and executive function.
89536925|NCT02468765||Depressive MS patients|Neuropsychological and emotional evaluation with monitoring
89536926|NCT02468765||Non depressive MS patients|Neuropsychological and emotional evaluation with monitoring
89536927|NCT02468765||Control|Neuropsychological and emotional evaluation with monitoring
89536928|NCT02468843||Biphasic DBS stimulations|Subjects in this group with have Biphasic DBS stimulation setting performed, Unified Dystonia Rating Scale (UDRS), and Burke-Fahn- Marsden scale (BFMDRS), tremor accelerometer, kinesia accelerometer, and GaitRite walking assessments performed.
89536929|NCT03306797|Experimental|SONICHAND|The intervention is similar to the standard protocol (15 minutes of warm-up plus 20 minute of training) but involves the sonification of the exercises (4 weeks, daily)
89536930|NCT03306797|Other|STANDARD REHAB|The rehabilitative standard intervention (Occupational Therapy) consists of 15 minutes of warm-up exercises plus a 20 minutes training for 4 weeks (daily)
89536931|NCT03306719||Study Group|The intervention group will be women with premature preterm rupture of membranes (pProm), suffering from IAI
89536932|NCT03306719||Control Group|Pregnant women without IAI
89536933|NCT04442321|Active Comparator|PENS plus exercise group|Experimental: PENS plus exercise group 4-week intervention program with 1 weekly treatment session, one of percutaneous electrical stimulation. In addition, self-management loaded exercise, prescribed by the physical therapist but completed by the patient independently . It involved isometric exercises, eccentric exercise, eccentric-concentric with weight or resistive therapeutic band.
89536934|NCT04442321|Sham Comparator|Sham PENS plus exercise group|Sham Comparator: Sham PENS plus exercise group 4-week intervention program with 1 weekly treatment session, one of percutaneous electrical stimulation. In addition, self-management loaded exercise, prescribed by the physical therapist but completed by the patient independently. It involved isometric exercises, eccentric exercise, eccentric-concentric with weight or resistive therapeutic band.
89011723|NCT01649830|Experimental|Radiotherapy plus adjuvant temozolomide|Radiation therapy will start within 8 weeks after neurosurgical procedures. The residue gliomas will receive a total dose of 54.0 Gy in 27 - 30 fractions over 6 - 7 weeks. Four weeks after radiotherapy, patients will then receive 6 cycle of temozolomide dosed at 200 mg/m2 (150 mg/m2 for the first cycle) daily for 5 consecutive days, repeated every 28 days.
89199286|NCT05919030|Experimental|Chemoradiation + Tislelizumab|"Intensity-modulated radiotherapy (IMRT):~Esophageal primary tumor: 39.6Gy/2.2Gy Bone metastasis: 30Gy/3Gy Lung, liver, brain metastases, metastatic lymph nodes: 45Gy/3Gy~During concurrent radiation therapy:~Drug: Tislelizumab 200 mg IV Q3W Drug: Nab Paclitaxel 75 mg/m² IV QW Drug: Cisplatin 25 mg/m² IV QW~During consolidation therapy:~Drug: Tislelizumab 200 mg IV Q3W Drug: Nab Paclitaxel 220 mg/m² IV Q3W Drug: Cisplatin 75 mg/m² IV Q3W"
89199287|NCT05919030|Active Comparator|Chemotherapy + Tislelizumab|Drug: Tislelizumab 200 mg IV Q3W Drug: Nab Paclitaxel 220 mg/m² IV Q3W Drug: Cisplatin 75 mg/m² IV Q3W
89437868|NCT02159989|Experimental|Treatment (sapanisertib, ziv-aflibercept)|Patients receive sapanisertib PO QD on days 2-4, 9-11, 16-18, and 23-25 and ziv-aflibercept IV over 60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89437869|NCT02154412|Experimental|Respiratory training|Subjects will be seated in own wheelchair with head-up tilt. Assembled together, a threshold Positive Expiratory Pressure Device (Respironics, Inc.) & an Inspiratory Muscle Trainer (IMT, Respironics Inc.) with mouthpiece will be used. Subjects will perform maximal inspiratory and expiratory efforts against a pressure load. Participants will be asked to train 45 minutes per day, 5 days per week, for 4 weeks. The training will be initiated with a load equal to 20% of their individual PImax and PEmax with progressive increases as tolerated up to 40% of their baseline PImax or PEmax.
89199288|NCT05917509|Experimental|Participants Receiving DTG/3TC Fixed Dose Combination (FDC)|
89199289|NCT05917509|Experimental|Participants Receiving CAB + RPV LA|
88922744|NCT04277598|Experimental|Main Phase: APO-2: 12.5 U/ml|Topical administration of APO-2, 12.5 U/ml; Approximalety 0.5 ml per square cm wound;
88922745|NCT04277598|Experimental|Main Phase: APO-2: 25 U/ml|Topical administration of APO-2, 25 U/ml; Approximalety 0.5 ml per square cm wound;
88922746|NCT04277598|Experimental|Main Phase: APO-2: 50 U/ml|Topical administration of APO-2, 50 U/ml; Approximalety 0.5 ml per square cm wound;
88922747|NCT04277598|Placebo Comparator|Main Phase: Placebo|Topical administration of placebo; Approximalety 0.5 ml per square cm wound;
88922748|NCT04254627|Experimental|Mifepristone 300 mg|All participants will receive etanercept 50 mg weekly for 12 weeks. After completion of the etanercept course, participants will be randomized between two Arms of mifepristone. Participants randomized to Arm 1 will receive one week of mifepristone at 300 mg daily.
88922749|NCT04254627|Experimental|Mifepristone 600 mg|All participants will receive etanercept 50 mg weekly for 12 weeks. After completion of the etanercept course, participants will be randomized between two Arms of mifepristone. Participants randomized to Arm 2 will receive one week of mifepristone at 600 mg (2x300 mg) daily.
88922750|NCT04250805|Active Comparator|Lidocaine|Patients will receive Lidocaine alone during percutaneous gastrostomy under radiological guidance
88922751|NCT04250805|Experimental|Lidocaine and Ropivacaine|Patients will receive Lidocaine and Ropivacaine during percutaneous gastrostomy under radiological guidance
88922752|NCT04248335|Experimental|In Weight Management Program|Evaluate the effect of liver fat on pharmacology of PPI's, and if applicable midazolam
88922753|NCT04248335|Experimental|Not in Weight Management Program|Evaluate the effect of liver fat on drug metabolism of PPI's, and if applicable midazolam
88922754|NCT04245085|Active Comparator|Arm A|"Atezolizumab (1200 mg) Q3W, until PD~Bevacizumab (15 mg/kg), Q3W, until PD~Carboplatin (AUC5) Q3W, 4-6 cycles~Paclitaxel (175-200 mg/m2), Q3W, 4-6 cycles"
88922755|NCT04245085|Active Comparator|Arm B|"Atezolizumab (1200 mg), Q3W, until PD~Bevacizumab (15 mg/kg), Q3W, until PD~Pemetrexed (500 mg/m2), Q3W, until PD"
88922756|NCT04234724|Experimental|Variant|Volunteers with known ANGPTL3 variants
88922757|NCT04234724|Other|Non-variant|Healthy volunteers with no ANGPTL3 variants
88922758|NCT04231019||Dental practitioners (general, specialists or students)|Two self-administered questionnaires will be used in the study one to general practitioners and specialists and another one with a plain language describing the study will be distributed to the fifth year dental students in Egypt with total 1000 dentist to assess their knowledge, awareness and perception regarding MIH.
88922759|NCT04221204|Experimental|Open-Label, Dose-Escalation|"The starting dose in this dose-escalation study is 50 mg, and the preset 6 dose-escalation cohorts are 50 mg, 100 mg, 150 mg, 200 mg, 250 mg, and 300 mg, respectively. This study adopts an i3+3 method for dose escalation.~All subjects in each cohort will receive a single oral dose of 3D185, followed by a 7-day washout period (i.e. single-dose PK study period). Then, subjects will receive consecutive daily doses (Once daily [QD], 28 days/cycle) until disease progression, death, unacceptable toxicity, or withdraw of informed consent, whichever comes first"
89437870|NCT02154412|No Intervention|No respiratory training|Participants will not participate in the respiratory muscle training.
89437871|NCT02126579|Experimental|Arm A (Part 1)|"Peptide Vaccine (LPV7) + Tetanus peptide + IFA administered in one skin location rotated to different sites on an extremity clinically uninvolved with melanoma.~Vaccines will be administered on Days 1, 8, 15, 36, 57, and 78."
89437872|NCT02126579|Experimental|Arm B (Part 1)|"Peptide Vaccine (LPV7) + Tetanus peptide + PolyICLC vaccine administered in one skin location that is rotated to different sites on an extremity clinically uninvolved with melanoma.~Vaccines will be administered on Days 1, 8, 15, 36, 57, and 78."
88922760|NCT04209569|Active Comparator|NIPP|The NIPP group is a standard social behavior change (SBCC) intervention that tackles a set of underlying causes of malnutrition, with the potential to have both a curative and preventative impact on child malnutrition. The approach in this group/arm involves training and pragmatic behavior change education reinforced by practical activities over a 12-week period to both men and women in selected communities. It aims to utilize easy, viable and accessible solutions within the community that can be used to improve and protect household health and nutrition. The 12-week lesson plans for the circles are divided into 3 components, i) hands-on behavior change sessions that focus on the key pre-identified causes of malnutrition to improve awareness and practice ii) micro-gardening for improved household nutrition security and iii) participatory cooking demonstrations to stimulate improvements in nutritional status and care practices.
88922761|NCT04209569|Experimental|NIPP+|In addition to establishing the circles and implementing the three NIPP components also implemented in the NIPP arm, those randomized to the NIPP+ arm will be provided access to innovations to allow and encourage the households and communities to translate the knowledge into positive practices. The innovations and access to vendors who sell innovations will be made available during the training to the NIPP+ volunteers who will provide trainings and access to vendors during the circle meetings. Most of the additions will be made accessible at a subsidized/low cost. The NIPP+ officers from the program will support NIPP+ volunteers in collaboration with agricultural extension officers.
89437873|NCT02126579|Experimental|Arm C (Part 1)|"Peptide Vaccine (LPV7) + Tetanus peptide vaccine administered in one skin location that is rotated to different sites on an extremity clinically uninvolved with melanoma.~Resiquimod will be applied to the vaccine site immediately after the vaccine administration.~Vaccines will be administered on Days 1, 8, 15, 36, 57, and 78."
89437874|NCT02126579|Experimental|Arm D (Part 1)|"Peptide Vaccine (LPV7) + Tetanus peptide + PolyICLC vaccines administered in one skin location that is rotated to different sites on an extremity clinically uninvolved with melanoma.~Resiquimod will be applied to the vaccine site immediately after vaccine administration.~Vaccines will be administered on Days 1, 8, 15, 36, 57, and 78."
89437875|NCT02126579|Experimental|Arm E (Part 1)|"Peptide Vaccine (LPV7) + Tetanus peptide + IFA + PolyICLC vaccines administered in one skin location that is rotated to different sites on an extremity clinically uninvolved with melanoma.~Vaccines will be administered on Days 1, 8, 15, 36, 57, and 78."
89437876|NCT02126579|Experimental|Arm F (Part 1)|"Peptide Vaccine (LPV7) + Tetanus peptide + IFA vaccines administered in one skin location that is rotated to different sites on an extremity clinically uninvolved with melanoma.~Resiquimod will be applied to the vaccine site immediately after vaccine administration.~Vaccines will be administered on Days 1, 8, 15, 36, 57, and 78."
89437877|NCT02126579|Experimental|Arm G(Part 1)|"Peptide Vaccine (LPV7) + Tetanus peptide + PolyICLC + IFA vaccines administered in one skin location that is rotated to different sites on an extremity clinically uninvolved with melanoma.~Resiquimod will be applied to the vaccine site immediately after vaccine administration.~Vaccines will be administered on Days 1, 8, 15, 36, 57, and 78."
89437878|NCT02126579|Experimental|Arm E2|"Peptide Vaccine (LPV7) + IFA + PolyICLC vaccines administered in one skin location. Each vaccine will be administered in the same skin site for all 6 vaccines.~Vaccines will be administered on Days 1, 8, 15, 36, 57, and 78."
89437879|NCT01961557|Experimental|There is a single study arm in this feasibility study.|All participants will be evaluated using the different configurations of the EA-KAFO (see Table 1 in the protocol), which includes the configuration that contains the Active Motorized KAFO and the configuration that contains the Powerwalk Knee Exoskeleton. Each subject will serve as their own control to assess the effect of each configuration of the EA-KAFO interventions.
89437880|NCT01953900|Experimental|GD2 T cells plus VZV vaccine|In this study we will be administering from 1 x 10^6 to 1 x 10^9 transduced autologous VZV-specific CTLs, derived from VZV-specific memory T cells, so there will be no risk of alloreactivity. 6.1.1 Pre-infusion lymphodepletion for dose levels 9-11: Patients will receive 3 daily doses of cyclophosphamide together with fludarabine to induce lymphopenia, finishing at least 24 hours before T cell infusion. Cyclophosphamide will be given at a dose of 500 mg/m2/day followed by Fludarabine 30 mg/m2/day.
89437881|NCT01950988|Other|Children|
88922762|NCT04209569|No Intervention|Control|No Intervention
88922763|NCT04200651|Experimental|DEXTENZA® arm|This arm will receive the DEXTENZA® insert after cataract surgery and MIGS.
88922764|NCT04200651|Active Comparator|Prednisolone acetate 1% arm|This arm will receive the prescription for daily prednisolone acetate 1% eye drops after cataract surgery and MIGS.
89437882|NCT01950988|Other|Adults|
89437883|NCT01950988|Other|Elderly people|
89437884|NCT01944332|Experimental|gamete treatment- oocytes and sperm|The spermatozoa will be prepared in the standard fashion and utilized for injection after exposure to a membrane permeabilizing agent. Patient specimen will be selected through a synthetic, sterile, single-use, culture-tested mesh. The specimen will then be placed in a 37°C environment. After 30 minutes, the selected portion is retrieved from the other side of the mesh. The injected oocytes will be then exposed to the previously mentioned activating agents for the purpose of inducing embryo development. The successfully fertilized oocytes will be further kept in culture for up to 5 days as per standard IVF/ICSI.
89437885|NCT01935778|Active Comparator|capecitabine and oxaliplatin|Capecitabine 1,000 mg/m² bid(D1-14) Oxaliplatin 130 mg/m² IV Day 1
88922765|NCT04163042|Experimental|Group A: Videoconferencing intervention|Participants allocated to group A will receive a behavioural support intervention via real-time videoconferencing.
88922766|NCT04163042|No Intervention|Group B: Usual care|Participants allocated to group B will receive usual care and will be advised to continue with their regular activities of daily living.
89437886|NCT01935778|Experimental|Docetaxel and capecitabine and oxaliplatin|"Docetaxel 60 mg/m² will be intravenously infused over at least 1 hour on Day 1 every 3 weeks.~Oxaliplatin 100 mg/m² will be intravenously infused over at least 2 hours on Day 1 every 3 weeks.~Capecitabine 800 mg/m² will be orally administered twice daily from Day 1 evening to Day 15 morning every 3 weeks. (Total 1,600 mg/m² daily)"
89437887|NCT01935713|Experimental|Electronic Cigarette|Participants received the electronic cigarette for use instead of cigarettes when in the presence of their child(ren) for up to 8 weeks.
89437888|NCT01935713|Experimental|Dissolvable Tobacco Lozenge|Participants received the dissolvable tobacco lozenge for use instead of cigarettes when in the presence of their child(ren) for up to 8 weeks.
89437889|NCT01935713|Experimental|Dissolvable Nicotine Lozenge (Nicorette)|Participants received the dissolvable nicotine lozenge (Nicorette) for use instead of cigarettes when in the presence of their child(ren) for up to 8 weeks.
89437890|NCT01904929|Experimental|Reconditioning in the effort|
89437891|NCT01892371|Experimental|Phase 1 Arm I (quizartinib, azacitidine)|Patients receive quizartinib PO QD on days 5-28 of cycle 1 and on days 1-28 of subsequent cycles and azacitidine SC or IV over 10-40 minutes on days 1-7. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89437892|NCT01892371|Experimental|Phase 1 Arm II (quizartinib, cytarabine)|Patients receive quizartinib PO QD on days 5-28 of cycle 1 and on days 1-28 of subsequent cycles and cytarabine SC BID on days 1-10. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89437893|NCT01892371|Experimental|Phase 2 Arm I (quizartinib, azacitidine)|Patients receive quizartinib PO QD on days 5-28 of cycle 1 and on days 1-28 of subsequent cycles and azacitidine SC or IV over 10-40 minutes on days 1-7. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89437894|NCT01892371|Experimental|Phase 2 Arm II (quizartinib, cytarabine)|Patients receive quizartinib PO QD on days 5-28 of cycle 1 and on days 1-28 of subsequent cycles and cytarabine SC BID on days 1-10. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88922767|NCT04159688|Experimental|Alcohol Challenge|Alcohol Challenge, I.V. infusion, 60 mg/dL in 6% saline (v/v), Given once
89437895|NCT01886872|Active Comparator|Arm I (rituximab, bendamustine hydrochloride)|Patients receive rituximab IV on day 1 (day 0 course 1) and bendamustine hydrochloride IV over 30 minutes on days 1-2. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients experiencing disease progression may crossover to Arm II.
88922768|NCT04159155|Experimental|Early Stage Cohort - Arm A|Pelvic EBRT at 45Gy in 25 fractions, in 1.8Gy fractions daily, 5 days per week
89437896|NCT01886872|Experimental|Arm II (ibrutinib)|Patients receive ibrutinib PO daily. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89437897|NCT01886872|Experimental|Arm III (ibrutinib, rituximab)|Patients receive ibrutinib as in Arm II. Patients receive rituximab IV on days 1, 8, 15, and 22 of course 2 and on day 1 of courses 3-6. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89437898|NCT01868230|Experimental|Lifestyle Intervention|Stage-matched physical activity and diet intervention materials and health education.
89437899|NCT01868230|No Intervention|Health and Wellness|HW served as the comparison group and received the same number of in-person sessions, telephone calls, and mailings at the same time points as LI. Content was limited to general information available to the public from the ACOG and the American Academy of Pediatrics and did not mention exercise behavior change.
89437900|NCT01854775|Experimental|Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg|HIV-infected, ARV treatment-naive adolescents (12 to < 18 years of age weighing ≥ 35 kg) will receive E/C/F/TAF (150/150/200/10 mg) fixed-dose combination (FDC) once daily for 48 weeks. Participants who complete 48 weeks of study treatment will have the option to receive E/C/F/TAF in an extension phase of the study until: a) the participant turns 18 years old and E/C/F/TAF is commercially available for adults in the country in which the participant is enrolled; b) age-appropriate E/C/F/TAF become commercially available in the country in which the participant is enrolled; or c) Gilead elects to terminate development of E/C/F/TAF in that country.
89437901|NCT01854775|Experimental|Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg|Virologically suppressed HIV-infected children (6 to < 12 years of age weighing ≥ 25 kg) will receive E/C/F/TAF (150/150/200/10 mg) FDC once daily for 48 weeks. Participants who complete 48 weeks of study treatment will have the option to receive E/C/F/TAF in an extension phase of the study until: a) the participant turns 18 years old and E/C/F/TAF is commercially available for adults in the country in which the participant is enrolled; b) age-appropriate E/C/F/TAF become commercially available in the country in which the participant is enrolled; or c) Gilead elects to terminate development of E/C/F/TAF in that country.
89536935|NCT03306563|Experimental|Patients with suspected TBI|The group will consist of patients who have arrived in the hospital with head injury and suspected isolated TBI. Sample collection (up to five times) and assessment of neurological status.
88922769|NCT04159155|Experimental|Early Stage Cohort - Arm B1|Vaginal high-dose rate brachytherapy 21 Gy in 3 fractions, prescribed to 5mm (i.e. 100% isodose at 5mm) from the cylinder/applicator surface and top along the upper third to half of the vagina (minimum 3cm, maximum 4cm).
88922770|NCT04159155|Active Comparator|Advanced Stage Cohort Arm C|Observation
89501610|NCT04907071|Experimental|Malperfusion Primary Cohort|"Patients presenting to hospital with AAD meeting criteria for malperfusion syndrome preoperatively which includes both components:~Imaging findings indicating reduced flow to the Celiac Trunk, Superior mesenteric artery, either renal artery or either iliac artery~Clinical stigmata of end organ ischemia (abdominal pain, distended abdomen, oliguria/anuria, reduced pulses, signs of limb ischemia) OR Laboratory findings suggestive of end organ ischemia (lactic acidosis, elevated LFTs, Elevated Creatinine, Rhabdomyolysis, Electrolyte abnormalities)"
89536936|NCT03306563|Active Comparator|Orthopedic patients|The group will consist of patients with orthopedic injury, but without a head injury and suspected TBI. Sample collection (once).
88922771|NCT04159155|Experimental|Advanced Stage Cohort Arm D1|Investigational agent (niraparib), orally, at a dose of 200 mg, or 300 mg, once daily, based on baseline platelet count and weight.
88922772|NCT04152421|Experimental|Software user|
88922773|NCT04147923|Active Comparator|Floradapt Mature Immune Defense|A multivitamin will also be consumed.
88922774|NCT04147923|Placebo Comparator|Placebo|A multivitamin will also be consumed.
88922775|NCT04111172|Experimental|Arm A (low dose)|Patients receive low dose Ad5.F35-hGCC-PADRE vaccine IM on day 1 of weeks 1, 5, and 9 in the absence of disease progression or unacceptable toxicity.
88922776|NCT04111172|Experimental|Arm B (medium dose)|Patients receive medium dose Ad5.F35-hGCC-PADRE vaccine IM on day 1 of weeks 1, 5, and 9 in the absence of disease progression or unacceptable toxicity.
88922777|NCT04111172|Experimental|Arm C (high dose)|Patients receive high dose Ad5.F35-hGCC-PADRE vaccine IM on day 1 of weeks 1, 5, and 9 in the absence of disease progression or unacceptable toxicity.
88922778|NCT04109079|Experimental|No axillary treatment|Patients in this arm will not receive axillary treatment (axillary lymph node dissection or axillary radiotherapy). Supraclavicular fossa radiotherapy is not allowed when randomised to this arm.
88922779|NCT04109079|Active Comparator|Axillary treatment|Patients in this arm will receive axillary treatment. Axillary treatment can be axillary lymph node dissection or axillary radiotherapy.
88922780|NCT04108091||Treatment for TTR amyloidosis|Transthyretin amyloid cardiomyopathy (wild-type or variants) patients administered Vyndaqel and Vynmac.
88922781|NCT04094311|Experimental|Group A: pALL|Pediatric/young adult patients with r/r pALL who meet the indication in the Health Authority-approved CTL019 package insert in the respective country/region whose final manufactured product is OOS for commercial release, but it is considered that the benefit-risk profile may remain favorable and the usual expected benefits of infusing such a product outweigh the potential risks for the patient.
88922782|NCT04094311|Experimental|Group B: r/r LBCL|Adult patients with r/r LBCL including DLBCL not otherwise specified, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma, that is consistent with the Health Authority-approved indication in the package insert for CTL019 in the respective country/region whose final manufactured product is OOS for commercial release, but it is considered that the benefit-risk profile may remain favorable and the usual expected benefits of infusing such a product outweigh the potential risks for the patient.
88922783|NCT04094311|Experimental|Group C: r/r NHL|Adult patients with r/r NHL in consistent with the Health Authority approved indication in the package insert for CTL019 in Japan whose final manufactured product is OOS for commercial release, but it is considered that the benefit-risk profile may remain favorable and the usual expected benefits of infusing such a product outweigh the potential risks for the patient.
88922784|NCT04079166|Experimental|SCIB1|SCIB1 administered by intramuscular needle-free injection
89011724|NCT01649830|Active Comparator|Radiotherapy|Radiation therapy will start within 8 weeks after neurosurgical procedures. The residue gliomas will receive a total dose of 54.0 Gy in 27 - 30 fractions over 6 - 7 weeks.
89199290|NCT05902520|Experimental|DP CD8 TIL|Adoptive Cell Transfer of tumor infiltrating lymphocytes that were selected for tumor reactivity by the expression of cell surface proteins CD39 an CD103 and expanded in vitro. A suspension of 1-40 billion cells will be delivered one time by intravenous infusion.
89199291|NCT05902520|Experimental|DP CD8 TIL KD|Adoptive Cell Transfer of tumor infiltrating lymphocytes that were selected for tumor reactivity by the expression of cell surface proteins CD39 and CD103 and expanded in vitro in the presence of PH-762, a silencing RNA that reduces the expression of the checkpoint inhibitor PD-1. A suspension of 1-40 billion cells will be delivered one time by intravenous infusion.
89536937|NCT03306563|Sham Comparator|Controls|The group will consist of healthy controls who do not have a recent trauma history. Sample collection (once).
89536938|NCT02468297|Experimental|Electronic Acupuncture Shoe|"Experiment group receives a one-hour treatment given by Electronic Acupuncture Shoe three times a week. 6 weeks of treatment was given. Subjects took placebo only in the first week. No placebo or medicine was prescribed to the subjects since the second week."
89536939|NCT02468297|Placebo Comparator|Control group|Control group received the six-week treatment as well, yet the subjects received pseudo electrotherapy. Subjects took ibuprofen(400mg, TID) only in the first week. No placebo or medicine was prescribed to the subjects since the second week.
89536940|NCT03304925|Experimental|Fat Reduction|The treatments are designed to see if the fat can be reduced in the flanks with a new applicator design.
89536941|NCT03306407|No Intervention|Baseline Group|Group screened for colonization with ESBL-producing Enterobacteriaceae pre- and post-travel after having received standard pre-travel advice
89536942|NCT03306407|Active Comparator|Intervention Group|Group screened for colonization with ESBL-producing Enterobacteriaceae pre- and post-travel after having received pre-travel advice with special focus on improved hand hygiene including the use of hand gel sanitizer (Hartmann Sterillium) (bundle intervention)
89536943|NCT03304769|No Intervention|IV placement no Virtual reality|Patient will have IV placed in traditional manner, with no virtual reality headset
89536944|NCT03304769|Experimental|IV placement with Virtual Reality|Patient will have IV placed with Virtual Reality headset distraction
89536945|NCT02468375|Experimental|mirabegron 50mg|about 434 OAB patients intake mirabegrone 50mg/day for 12 weeks.
89536946|NCT02468453|Experimental|Cohort 1 -facial skin disorders|Pulsed dye laser/bipolar radiofrequency (Velos) treatment of facial skin disorders including photo-damage, age spots, lentigos, solar telangiectasia and general facial telangiectasia
89437902|NCT01854775|Experimental|Cohort 3: Age ≥2 Years and Weight ≥ 14 to <25 kg|Virologically suppressed HIV-infected children (≥ 2 years of age weighing ≥ 14 to < 25 kg) will receive E/C/F/TAF (90/90/120/6 mg) FDC once daily for 48 weeks. Participants who attain a weight of ≥ 25 kg during the course of the study will switch to adult E/C/F/TAF (150/150/200/10 mg) tablets. Participants who complete 48 weeks of study treatment will have the option to receive E/C/F/TAF in an extension phase of the study until: a) the participant turns 18 years old and E/C/F/TAF is commercially available for adults in the country in which the participant is enrolled; b) age-appropriate E/C/F/TAF became commercially available in the country in which the participant is enrolled; or c) Gilead elects to terminate development of E/C/F/TAF in that country.
89437903|NCT01842724|Active Comparator|Motec total wrist arthroplasty|
89437904|NCT01842724|Active Comparator|Remotion total wrist arthroplasty|
89437905|NCT01819376|Experimental|Intervention: Facebook updates|The experimental group will be encouraged to update their Facebook status regarding healthy lifestyle decisions at least once a day.
89437906|NCT01819376|No Intervention|Control: No Facebook|This group will be encouraged not to share their healthy lifestyle decisions on Facebook.
89437907|NCT01802034||Native, Renal Tissue Preservation Group|Subjects who have a renal biopsy and the tissue is possessed and maintained by the RENAL AID repository.
89437908|NCT01802034||Native, Non-tissue Preservation Group|"Subjects who have had a renal biopsy but the tissue is not held by RENAL AID repository; and/or~Subjects with diabetes and renal disease who have not had a renal biopsy."
89437909|NCT01802034||Transplant Nephropathy Group|"Subjects who have had a renal transplant and require a transplant biopsy for either surveillance or for-cause indications."
89437910|NCT01793831|Experimental|Fecal microbiota transplantation|Standard fecal microbiota transplantation, once.
89437911|NCT01793519|Active Comparator|Anti-tumor necrosis factor agent|Anti-TNF agent - etanercept, infliximab, adalimumab - administered parentally at standard dosage and frequencies
89437912|NCT01793519|Placebo Comparator|Placebo|Administered appropriately to active comparator
89437913|NCT01790061|Experimental|Standardized FMT|endoscopy Tubing Once or repeat
89437914|NCT01790061|Experimental|Traditional treatments|Oral Tubing
89437915|NCT01764633|Placebo Comparator|Placebo|Participants received placebo subcutaneous injections either once every 2 weeks (Q2W) or once a month (QM) according to their own preference.
88922785|NCT04051242|Experimental|XenMatrix AB Surgical Graft|This study proposes to use XenMatrix™ AB Surgical Graft which has 510(k) approval [#K162193] intended for implantation to reinforce soft tissue where weakness exists and for surgical repair of damaged or ruptured soft tissue. This trial proposes to test the applicability and utility of XenMatrix™ AB Surgical Graft in the restoration of function in the setting of volumetric muscle loss after trauma
88922786|NCT04029337|Experimental|Transcatheter Mitral Valve Replacement|HighLife TMVR System is a novel and innovative approach developed as an alternative treatment for severe MR when medical treatment is maximal and surgical interventions not possible or at high risk. The HighLife TMVR system is composed of a Transcatheter Mitral Valve (TMV), a sub-annular implant (SAI), and their delivery systems and loading tools.
88922787|NCT04027036|Active Comparator|fIPV Intramuscular|180 children will receive 0,1 ml of inactivated poliovirus vaccine intramuscularly
88922788|NCT04027036|Active Comparator|fIPV Intradermal|180 children will receive 0,1ml of inactivated poliovirus vaccine intradermally
88922789|NCT04013971|Other|AGRF Biofeedback Game Followed by the Traditional biofeedback Interface|Post-stroke participants randomized to receive the two gait training biofeedback interfaces in the order of the AGRF biofeedback game first and the traditional, non-game-based, interface second. Participants will also complete a control condition where no biofeedback is provided.
88922790|NCT04013971|Other|Traditional biofeedback Interface Followed by the AGRF Biofeedback Game|Post-stroke participants randomized to receive the three gait training biofeedback interfaces in the order of the traditional, non-game-based, interface first and the AGRF biofeedback game second. Participants will also complete a control condition where no biofeedback is provided.
88922791|NCT04013971|Other|Optional Game with VR|Post-stroke participants attending a separate, optional, session to complete preliminary or exploratory testing of the VR version of the biofeedback game (head-mounted AR or VR display), which will be used to determine feasibility and preliminary effects of VR-based feedback on gait.
88922792|NCT04002479|Experimental|DaRT Seeds|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds
88922793|NCT03977467|Experimental|Arm A (Chemo + Atezolizumab)|In Arm A, patients with NSCLC will receive chemotherapy plus atezolizumab at a flat dose of 1200 mg intravenously (IV) every 3 weeks. Standard of care chemotherapy is defined as a platinum-doublet therapy (or triplet if bevacizumab is used) of the Investigator's choice.
88922794|NCT03977467|Experimental|Arm B (Atezolizumab and Tiragolumab)|In Arm B, patients with advanced solid tumors will be treated with atezolizumab at a flat dose of 1200 mg IV every 3 weeks in combination with tiragolumab at a flat dose of 600 mg IV every 3 weeks until progression or unacceptable toxicity.
88922795|NCT03967002|Experimental|Test group with corticotomy surgery|Orthodontic treatment and minimally invasive corticotomy surgery with piezoelectric device and surgical guide
88922796|NCT03967002|No Intervention|Control group without corticotomy surgery|Standard orthodontic treatment without surgery
88922797|NCT03964571|Experimental|Diabetic foot patients|
88922798|NCT03952091|Experimental|TJ202, Lenalidomide and Dexamethasone|
88922799|NCT03952091|Active Comparator|Lenalidomide and Dexamethasone|
88922800|NCT03944837|Experimental|Severe fetal congenital heart disease (CHD)|Mothers whose fetuses have a diagnosis of CHD will be exposed to 10-15 L/minute of oxygen while undergoing echocardiogaphy and MRI scanning
88922801|NCT03939624||Sodium-glucose cotransporter 2 (SGLT2) inhibitors|Patients who received a SGLT2 inhibitor alone (canagliflozin, dapagliflozin, empagliflozin) or in combination with non-DPP4 inhibitor drugs at cohort entry date.
89199292|NCT05895201|Experimental|Sitagliptin + Bortezomib + Cyclophosphamide|
89437916|NCT01764633|Experimental|Evolocumab|Participants received evolocumab 140 mg Q2W or 420 mg QM subcutaneous injections according to their own preference.
89437917|NCT01724190|Active Comparator|Vitamin D|Subjects will receive oral vitamin D supplementation, 3000 IU daily over the course of 9 months.
89437918|NCT01724190|Placebo Comparator|Placebo|Subjects will receive a placebo solution daily over the course of 9 months.
89437919|NCT01719016||Cardiac PET, Coronary catheterization|"Cardiac PET scan:~Injection of N-13 Ammonia radionuclide. 2 doses of 10 milliCuries and 20 milliCuries each.~Injection of Lexiscan.~Coronary catheterization:~Pressure and flow readings using Combowire~Injection of Adenosine."
88922802|NCT03939624||Dipeptidyl peptidase-4 (DPP-4) inhibitors|Patients who received a DPP-4 inhibitor (alogliptin, linagliptin, saxagliptin, sitagliptin, vildagliptin) alone or in combination with non-SGLT2 inhibitor drugs at cohort entry date.
88922803|NCT03919292|Experimental|Neratinib + Divalproex Sodium - Dose Escalation Cohort|Neratinib by mouth (PO) once daily + Divalproex Sodium (Valproate) by mouth (PO) twice daily on days 1-28 of each course.
88922804|NCT03919292|Experimental|Colon|Colon Cancer (RAS-mutated) - Phase II dose expansion at recommended phase II dose (RP2D)
88922805|NCT03919292|Experimental|Glioblastoma (GBM)|Glioblastoma with a RAS-mutation or EGFR alteration at RP2D
88922806|NCT03919292|Experimental|Ocular Melanoma (OM)|Phase II dose expansion at RP2D
89199293|NCT05891106||AONDA Therapeutic|Lotrafilcon A contact lenses worn therapeutically as a bandage lens as instructed by the eye care professional
89437920|NCT01626508||breast-milk bank|breast milk collected and processed by the breast-milk bank before being used
89437921|NCT01626508||breast milk|breast milk used without any treatment, directly by children
89437922|NCT01562834|Experimental|Somatropin|
89437923|NCT01562834|Placebo Comparator|Placebo|
89437924|NCT01540045||BASELINE|Outpatients from National Cancer Institute with stage III and IV NSCLC candidates for 1 st line chemotherapy paclitaxel-cisplatin based agreeing to participate in the study
89437925|NCT01482858|Experimental|Gastrolith|Gelatin capsules, each containing 500 mg of GASP (comprised of 125 ±5 mg elemental calcium) for oral use.
88922807|NCT03919292|Experimental|Other Cancer|"Other Cancer (RAS-mutated) at RP2D"
88922808|NCT03919292|Experimental|Pancreatic Cancer|RAS-mutated pancreatic cancer at RP2D
88922809|NCT03899649||IRE Cohort|Patients who received SOC and received IRE
89437926|NCT01482858|Placebo Comparator|Placebo|Gelatin capsules, each containing 500 mg [comprised of 312.5 mg calcium carbonate (125 ±5 mg elemental calcium) and 187.5 mg of sucrose] for oral use as placebo
89437927|NCT01340222|Other|Patients|
89437928|NCT01340222|Other|Volunteers|
88922810|NCT03899649||SOC Cohort|Patients who received SOC and did not receive IRE
88922811|NCT03886259|Experimental|Exercise and pain neuroscience education|Subjects with chronic pain after total knee replacement will receive 24 sessions of neuromuscular exercise therapy, supervised by a physiotherapist, and two sessions of pain neuroscience education, conducted by a physiotherapist
89437929|NCT01334957|Experimental|Intravenous ibuprofen|Intravenous ibuprofen (800 mg intravenous ibuprofen administered intravenously over 5-10 minutes) will be administered as a single dose during the 10 minute Treatment Period.
89437930|NCT01276470||Antisynthetase Negative|Subjects with myositis without antisynthetase syndrome
89437931|NCT01276470||Antisynthetase Positive|Subject with myositis with antisynthetase syndrome
89437932|NCT01276470||Healthy Control|Subjects without autoimmune disease
89437933|NCT01255748||Treatment with Radiation Therapy|Includes 16 different arms to capture patient data by disease site
89437934|NCT01251601||Raltegravir in Pregnancy|HIV positive pregnant women currently on raltegravir as part of combination antiretroviral therapy
89437935|NCT01222741||Healthy Voluntary|Healthy voluntary
89437936|NCT01222741||Patients|affected patient
89437937|NCT01222741||relatives|family member to patient
89437938|NCT01167712|Experimental|Arm I (adjuvant chemotherapy suboptimally debulked)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 6 courses.
89437939|NCT01167712|Experimental|Arm II (neoadjuvant chemotherapy)|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15 and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 6 courses. Patients undergo interval cytoreductive surgery between courses 3 and 4.
89437940|NCT01134770||Prenatal Cocaine|Use of cocaine at anytime during pregnancy. Subjects may also have used other drugs in combination with Cocaine
89437941|NCT01134770||Prenatal Nicotine-Alcohol-Marijuana|Subjects may have used any of these drugs during pregnancy, alone or in combination. This group has not used cocaine during pregnancy.
89437942|NCT01134770||Drug-Free Pregnancy|"Subjects did not use any of the following drugs during pregnancy:~cocaine, nicotine, alcohol, marijuana."
89437943|NCT01116648|Experimental|Arm I (cediranib maleate and olaparib)|Patients receive cediranib maleate PO QD and olaparib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO or MUGA during screening and as clinically indicated on study. Patients also undergo CT or MRI as well as blood sample collection on the trial. Patients may also optionally undergo a tissue biopsy on the trial.
89437944|NCT01116648|Active Comparator|Arm II (olaparib)|Patients receive olaparib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO or MUGA during screening and as clinically indicated on study. Patients also undergo CT or MRI as well as blood sample collection on the trial. Patients may also optionally undergo a tissue biopsy on the trial.
89437945|NCT01051245|Active Comparator|Case management|Patients followed-up by case manager. Interventions based on the Chronic Care Model. Interventions are self management education, motivational interviewing, individualized counseling on non-pharmacological treatment to modify and sustain healthy lifestyle behaviours, and follow-up. Close contact with primary care physician and/or specialist by case manager, if clinical targets out of recommended standards. Pharmacological treatment not suggested, managed by personal criteria of health care professionals. Focus on targets.
89437946|NCT01051245|Placebo Comparator|Usual care group|Usual care provided by primary care physician and/or specialist. Free access to diabetes educational workshops. Regular delivery of educational brochures (not personally targeted).
89437947|NCT01047865||pancreas-kidney transplant|pancreas-kidney transplant recipients with type 1 diabetes.
89437948|NCT01001910|Experimental|Treatment (pemetrexed disodium, carboplatin)|Patients receive pemetrexed disodium IV over 8-15 minutes and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for at least 6 courses in the absence of disease progression or unacceptable toxicity.
89437949|NCT00912041|Other|BrainGate|BrainGate Neural Interface System
89437950|NCT00775853||Individuals at risk for developing PD|Individuals who may be at risk for developing PD because of genetic risk, olfactory dysfunction, symptomatic rapid eye movement sleep behavior disorder, or orthostatic hypotension
89437951|NCT00709033|Experimental|autologous or syngeneic PBTLs and EBV-CTLs|The subject will be assigned a dose of CD19-CD28 chimeric receptor T cells at study entry.
88922812|NCT03886259|Active Comparator|Pain neuroscience education|Subjects with chronic pain after total knee replacement will receive two sessions of pain neuroscience education, conducted by a physiotherapist
88922813|NCT03881488|Experimental|Arm 1 Part 1 Dose Escalation|Escalating doses of CTX-471 depending on cohort at enrollment
88922814|NCT03881488|Experimental|Arm 1 Part 2 Dose Expansion|Two dose groups of CTX-471 (0.3 mg/kg and 0.6 mg/kg)
88922815|NCT03881488|Experimental|Arm 2 Part 1 Dose Escalation|Escalating doses of CTX-471 in combination with pembrolizumab (KEYTRUDA® ) depending on cohort at enrollment
88922816|NCT03881488|Experimental|Arm 2 Part 2 Dose Expansion|Two cohorts of CTX-471 (0.3 mg/kg and 0.6 mg/kg) in combination with pembrolizumab (KEYTRUDA® ) (400 mg) in three tumor type subgroups. Cohort 1 - Group 1A - NSCLC , Group 1B -SCLC and Group 1C - Melanoma. Cohort 2 Group 2A - NSCLC, Group 2B - SCLC and Group 2C -Melanoma.
88922817|NCT03877796||Ovarian cancer patients|with formalin-fixed paraffin-embedded (FFPE) tumor tissue available
88922818|NCT03873207|Experimental|Intervention|Pedal fat grafting followed by PopSole™ offloading device
88922819|NCT03873207|Other|Standard of care|Pedal fat grafting followed by standard post-operative care with padding of the insoles
89437952|NCT00618657|Experimental|Arm I (HER-2 positive)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes, carboplatin IV over 60 minutes, and trastuzumab IV over 90 minutes , then weekly over 30-60 minutes. Treatment repeats every week for 12 weeks in the absence of disease progression or unacceptable toxicity. In both arms, beginning 21-40 days later, patients undergo surgery.
89437953|NCT00618657|Experimental|Arm II (HER-2 negative)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation and carboplatin as in Arm I. Patients also receive bevacizumab IV over 90 or 60 or 30 minutes once every two weeks for 5 doses in the absence of disease progression or unacceptable toxicity. In both arms, beginning 21-40 days later, patients undergo surgery.
89437954|NCT00609154|Experimental|Diabetic Group|Participants with Type 2 diabetes
89437955|NCT00609154|Active Comparator|Non-diabetic Group|Participants who are non-diabetic will serve as control. treatment is matched to experimental group
89437956|NCT00558584|Active Comparator|IA/IgG group|immunoadsorption using IA columns and subsequent IgG substitution
89437957|NCT00558584|Placebo Comparator|control group|pseudo-immunoadsorption followed by an intravenous infusion without IgG
88922820|NCT03865706|Experimental|Inulin 32 g/day|Critically ill adults who are receiving broad-spectrum antibiotics will also receive inulin oral suspension (16g twice daily) for a minimum of 7 days.
89437958|NCT00482794||1|Individuals with APS who also have one or more of their family members affected specifically by APS
89437959|NCT00482794||2|Individuals with APS who also have one or more of their family members affected by another type of autoimmune disorder, such as lupus or rheumatoid arthritis.
89437960|NCT00482794||3|Individuals with APS and no family or no family affected with APS or another autoimmune disorder
89437961|NCT00476606||Long-term pediatric cohort|Long-term follow-up cohort since 2003
89437962|NCT00344188||1|This population of patients are referred from their physicians both regionally and nationally.
89437963|NCT00304070|Experimental|Stratum I (surgery, observation)|Patients undergo primary tumor resection and retroperitoneal lymph node sampling followed by observation. Patients who have undergone prior surgery without nodal sampling undergo observation only.
89437964|NCT00304070|Experimental|Stratum II (exploratory surgery, observation)|Patients undergo primary tumor resection and extended regional lymph node dissection followed by observation. Patients who have undergone prior surgery with simple resection of the primary tumor undergo exploratory surgery with extended regional lymph node dissection followed by observation.
89437965|NCT00304070|Experimental|Stratum III (chemotherapy, surgery)|Patients receive combination chemotherapy with filgrastim (G-CSF) for up to 30 weeks (10 courses) followed by mitotane alone for an additional 2 months. Some patients undergo surgery after chemotherapy course 2 or 4. Some patients undergo additional surgery after finishing all chemotherapy.
89437966|NCT02126943||Opsumit (macitentan)|10 mg tablets
89437967|NCT02121015|Active Comparator|Self-Directed|Access to the e-health intervention (an interactive website with didactic material and interactive tools) for participants to use at their own pace for 8 weeks (Self-Directed)
88922821|NCT03865706|Experimental|Inulin 16 g/day|Critically ill adults who are receiving broad-spectrum antibiotics will also receive inulin oral suspension (8g twice daily) for a minimum of 7 days.
88922822|NCT03865706|Placebo Comparator|Placebo|Critically ill adults who are receiving broad-spectrum antibiotics will also receive placebo oral suspension for a minimum of 7 days.
89437968|NCT02121015|Experimental|Share|Access to the same e-health intervention + an internet social networking component consisting of up to 12 other pregnant women (Share).
88922823|NCT03860038|Experimental|TJ202|
89437969|NCT02121093|No Intervention|alpha band of the EEG and electromyographic activity|- 20 will be in the evaluation group (EG); then review the alpha band of EEG and EMG activity.
89437970|NCT02121093|Experimental|Vibration|"• 20 vai participar no grupo de baixa freqüência de vibração estimulação (LFVS);~20 no grupo de estimulação da vibração de média freqüência (MFVS);~20 vai participar no grupo de alta freqüência de vibração estimulação (HFVS). then review the alpha band of EEG and EMG activity."
88922824|NCT03848689||FQ PPA Group|Fluoroquinolone Preprescription Authorization from Infection Control consult, once, prior to prescribing fluoroquinolone
88922825|NCT03848689||Control Group|No preprescription authorization needed from Infection control prior to prescribing fluoroquinolone
88922826|NCT03843957|Experimental|"Clinic Patients Eligible for CRC Screening on high touch Strategy (Post-Implementation)"|"English or Spanish-speaking patients aged 50-74 who are eligible for CRC screening who are seen in the study clinics randomized to mPATH utilizing the high touch implementation strategy in the 12 months after implementation."
89011725|NCT04708743||CKD group|patients with CKD stage 3-5 including dialysis, followed tongue images by Automatic Tongue Diagnosis System
89437971|NCT02127021|Experimental|Norzyme® 40000 IU|Single capsule of Norzyme® 40000 IU will be prescribed three times a day while taking a meal meal.
89437972|NCT02127021|Placebo Comparator|Placebo|Single capsule of placebo drug with the same appearance of Norzyme® 40000 IU will be prescribed three times a day while taking a meal meal. The formulation and the form of placebo is same with the Norzyme® 40000 IU. Placebo contains microcrystalline cellulose as the main component, titanium oxide, colloidal silica, yellow iron oxide, brown iron oxide, black iron oxide, magnesium stearate, triethyl citrate, talc, and simethicone emulsion in very small amount
89437973|NCT03551847|Experimental|Oral antibiotic therapy group|This group will receive preoperative oral antibiotic therapy tailored to the infecting organism (if identified) for two weeks before the time of revision surgery
89437974|NCT03551847|Active Comparator|No antibiotic therapy group|This group will not receive preoperative oral antibiotic therapy.
89437975|NCT02121171|Experimental|Ologen Collagen Matrix Intervention|Combined trabeculotomy-trabeculectomy with subconjuncitval Ologen matrix implant implantation is a new procedure that has less post operative complications with good results, it is to be applied in children.
89437976|NCT02121171|Active Comparator|Combined trabeculotomy-trabeculectomy|Combined trabeculotomy and trabeculectomy is a standard surgery for congenital glaucoma, however, it has its known complications.
89437977|NCT02127099||Patients with OSA|Post operative patients with OSA
89437978|NCT02127099||Post-operative Patients without OSA|All post operative patients without OSA
89437979|NCT02127177|Experimental|Cpap|
88922827|NCT03843957|Experimental|"Clinic Patients Eligible for CRC Screening on low touch Strategy (Post-Implementation)"|"English or Spanish-speaking patients aged 50-74 who are eligible for CRC screening who are seen in the study clinics randomized to mPATH utilizing the low touch implementation strategy in the 12 months after implementation."
88922828|NCT03843957|Experimental|"Clinic personnel on high touch Strategy (Post-Implementation)"|"Clinic personnel (e.g., administrators, nurses, providers) who are involved with the implementation of mPATH-CRC, in the study clinics randomized to mPATH utilizing the high touch implementation strategy in the 12 months after implementation."
88922829|NCT03843957|Experimental|"Clinic personnel on low touch Strategy (Post-Implementation)"|"Clinic personnel (e.g., administrators, nurses, providers) who are involved with the implementation of mPATH-CRC, in the study clinics randomized to mPATH utilizing the low touch implementation strategy in the 12 months after implementation."
88922830|NCT03843957|Experimental|"All Adult Clinic Patients on high touch Strategy (Post-Implementation)"|"English or Spanish-speaking patients aged 18 or older who are seen in the study clinics randomized to mPATH utilizing the high touch implementation strategy in the 12 months after implementation."
88922831|NCT03843957|Experimental|"All Adult Clinic Patients on low touch Strategy (Post-Implementation)"|"English or Spanish-speaking patients aged 18 or older who are seen in the study clinics randomized to mPATH utilizing the low touch implementation strategy in the 12 months after implementation."
89011726|NCT04708743||Health group|patients who had no past history or systemic disease, CKD followed tongue images by Automatic Tongue Diagnosis System
89437980|NCT02127177|No Intervention|No Cpap|
89437981|NCT02127255|Active Comparator|A (Acupuncturist 1)|Manual acupuncture implemented by acupuncturist 1 (clinical experience >15 years)
89437982|NCT02127255|Active Comparator|B (Acupuncturist 2)|Manual acupuncture implemented by acupuncturist 2 (clinical experience < 5 years)
89437983|NCT03551223||Women undergoing cesarean delivery with general anesthesia|Preeclamptic parturients undergoing cesarean delivery under general anesthesia
89437984|NCT03551223||Women undergoing cesarean delivery with spinal anesth|Preeclamptic parturients undergoing cesarean delivery under regional-spinal anesthesia
89437985|NCT02121249|Experimental|Robot assisted pedicle screw fixation|posterior lumbar interbody fusion using Robot assisted pedicle screw fixation (Renaissance, Mazor Robotics Ltd, Caesare, Israel)
89437986|NCT02121249|Active Comparator|Free hand technique|using Free hand technique, posterior lumbar interbody fusion (No specific device)
89437987|NCT02121327|Active Comparator|usual care|usual care group receive regular outpatient treatment
89437988|NCT02121327|Experimental|disease management|desease management program include self management education by nurse on 6months.
89437989|NCT02121561|Experimental|Self-Acceptance Group Therapy|Participants receive Self-Acceptance Group Therapy
89437990|NCT00150462|Experimental|CFZ 1.2 mg/m²|Participants received carfilzomib (CFZ) 1.2 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.
89437991|NCT00150462|Experimental|CFZ 2.4 mg/m²|Participants received carfilzomib 2.4 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.
89437992|NCT00150462|Experimental|CFZ 4.0 mg/m²|Participants received carfilzomib 4.0 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.
89437993|NCT00150462|Experimental|CFZ 6.0 mg/m²|Participants received carfilzomib 6.0 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.
89437994|NCT00150462|Experimental|CFZ 8.4 mg/m²|Participants received carfilzomib 8.4 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.
89437995|NCT00150462|Experimental|CFZ 11.0 mg/m²|Participants received carfilzomib 11.0 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.
89437996|NCT00150462|Experimental|CFZ 15.0 mg/m²|Participants received carfilzomib 115.0 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.
89437997|NCT00150462|Experimental|CFZ 20.0 mg/m²|Participants received carfilzomib 20.0 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.
89437998|NCT00150462|Experimental|CFZ 27.0 mg/m²|Participants received carfilzomib 27.0 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.
89536947|NCT02468453|Experimental|Cohort 2 - leg veins|Pulsed dye laser/bipolar radiofrequency (Velos) treatment of leg veins of diameter of at least 1mm, i.e., venulectasia and reticular leg veins.
89536948|NCT02468453|Experimental|Cohort 3-general skin rejuvenation|Pulsed dye laser/bipolar radiofrequency (Velos) treatment treatment of general skin rejuvenation including Rosacea, erythematous scars (including acne), and erythematous striae (subjects enrolled in this group must have at least two of the above mentioned treatment indications.
89437999|NCT00150462|Experimental|CFZ 20/27 mg/m²|Participants received carfilzomib 20 mg/m² administered by intravenous bolus on Cycle 1 Days 1, 2, 8, 9, 15 and 16, then 27 mg/m² in all subsequent cycles, for up to 12 cycles.
89438000|NCT00150462|Experimental|CFZ 20/27 mg/m² + DEX|Participants received carfilzomib 20 mg/m² administered by intravenous bolus on Cycle 1 Days 1, 2, 8, 9, 15 and 16, then 27 mg/m² in all subsequent cycles, for up to 12 cycles. Participants also received 20 mg dexamethasone (DEX) administered before each dose of carfilzomib (i.e. 40 mg weekly).
89438001|NCT02287740|Experimental|Tai Ji Quan: Moving for Better Balance|This protocol involves training 2 times a week for 6 months.
89438002|NCT02287740|Active Comparator|Multimodal Exercise|This protocol involves training 2 times a week for 6 months.
89438003|NCT02287740|Sham Comparator|Stretching|This protocol involves participation of 2 times a week for 6 months.
89438004|NCT00095550|Experimental|A1|
89438005|NCT00095550|Active Comparator|A2|
89438006|NCT00095550|Active Comparator|A3|
88922832|NCT03843957|Other|"Clinic Patients Eligible for CRC Screening on high touch Strategy (Pre-Implementation)"|"English or Spanish-speaking patients aged 50-74 who are eligible for CRC screening who are seen in the study clinics randomized to mPATH utilizing the high touch implementation strategy but in 8 months before implementation."
88922833|NCT03843957|Other|"Clinic Patients Eligible for CRC Screening on low touch Strategy (Pre-Implementation)"|"English or Spanish-speaking patients aged 50-74 who are eligible for CRC screening who are seen in the study clinics randomized to mPATH utilizing the low touch implementation strategy but in 8 months before implementation."
88922834|NCT03838107||Inpatients|Observation and measure of trajectory of recovery in CRPS. This group will include children diagnosed with CRPS and undergoing regular therapy at the inpatient FIRST clinic at CCHMC and one of their parents or legal guardian.
88922835|NCT03838107||Outpatients|Observation and measure of trajectory of recovery in CRPS. This group will include children diagnosed with CRPS and undergoing regular therapy at the outpatient Pain Management Center at CCHMC and one of their parents or legal guardian.
88922836|NCT03838107||Healthy Controls|For comparison purposes, healthy controls and one of their parents or legal guardian will be enrolled in this study as well.
88922837|NCT03837483|Experimental|Gene Therapy|OTL-103, Autologous CD34+ hematopoietic stem cells transduced ex vivo with a lentiviral vector encoding the human WAS gene
88922838|NCT03823144|Experimental|Arm 1|Determine the feasibility and clinical utility of performing Human Intravital Microscopy (HIVM) in patients with solid tumors during surgical resection.
88922839|NCT03815045|Active Comparator|Landmark-based lumbar puncture|Landmark-based LP
88922840|NCT03815045|Active Comparator|Ultrasound-guided lumbar puncture|Ultrasound-guided LP
88922841|NCT03813147|Experimental|Treatment (cytarabine, azacitidine, pevonedistat, fludarabine)|Patients receive cytarabine intrathecally on day 0 at least 24 hours prior to the start of each cycle. Patients then receive azacitidine IV over 15 minutes QD on days 1-5, pevonedistat IV over 60 minutes on days 1, 3, and 5, and fludarabine phosphate IV over 30 minutes QD and cytarabine IV over 1-3 hours QD on days 6-10. Patients with CNS2 or CNS3 receive cytarabine intrathecally or methotrexate intrathecally, hydrocortisone intrathecally, and cytarabine intrathecally on days 8 and 11-34. Cycles continue for 35 days in the absence of disease progression or unacceptable toxicity. Patients with stable or greater with non-hematologic toxicities probably or definitely related to pevonedistat may receive an additional cycle of treatment.
88922842|NCT03798782|Experimental|Ross procedure|The patient will undergo the Ross procedure where the surgeon will replace the aortic valve using a pulmonary autograft (Ross procedure) with pulmonary homograft replacement of the pulmonary root.
88922843|NCT03798782|Active Comparator|Conventional aortic valve replacement|The patient will undergo Conventional aortic valve replacement where the surgeon will replace the aortic valve with another prosthesis which can include a mechanical prosthesis, a stented biological prosthesis, a stentless biological valve or root, or a catheter valve.
88922844|NCT03772977|Experimental|Brain Health Champion (BHC)|"A health coach intervention with weekly phone calls"
89011727|NCT01649908||sectional cross clamping|
89011728|NCT01649908||simultaniously cross clamping|
89438007|NCT00095394|Experimental|A1|
89438008|NCT00095394|Active Comparator|A2|
89438009|NCT00093132|Experimental|Satraplatin|Satraplatin
89438010|NCT00093054|Active Comparator|1|Cranberry juice
89438011|NCT00093054|Placebo Comparator|2|Placebo juice
89438012|NCT00089466|Experimental|A|200 mg AMD11070 every 12 hours
89438013|NCT00089466|Experimental|B|400 mg AMD11070 every 12 hours
89438014|NCT00089466|Experimental|C|600 mg AMD11070 every 12 hours
89438015|NCT00089466|Experimental|D|800 mg AMD11070 every 12 hours
89438016|NCT00089466|Experimental|E|1000 mg AMD11070 daily
89438017|NCT00089466|Experimental|F|1500 mg AMD11070 daily
89438018|NCT00089466|Experimental|G|1000 mg AMD11070 every 12 hours
89438019|NCT00089466|Experimental|H|2000 mg AMD11070 daily
89438020|NCT00080106|Experimental|1|Participants in the experimental arm will receive the MRK Ad5 HIV-1 gag vaccine on Day 1, Week 4 and Week 26. Participants will take their antiretroviral medications during the first 3 months of the study.
89438021|NCT00080106|Placebo Comparator|2|Participants in Arm 2 will receive a placebo vaccine on Day 1, Week 4 and Week 26. Participants will take their antiretroviral medications during the first 3 months of the study.
89438022|NCT00335244|Experimental|1|Intravenous L-citrulline
89438023|NCT00335244|Placebo Comparator|2|Placebo of intravenous L-citrulline
89438024|NCT00333216|Experimental|15 mg Anecortave Acetate|Anecortave Acetate Sterile Suspension, 30 mg/mL, one injection of 0.5 mL in the study eye every 6 months for 48 months
89438025|NCT00333216|Experimental|30 mg Anecortave Acetate|Anecortave Acetate Sterile Suspension, 60 mg/mL, one injection of 0.5 mL in the study eye every 6 months for 48 months
89438026|NCT00333216|Sham Comparator|Anecortave Acetate Vehicle|Anecortave Acetate Vehicle, one sham injection in the study eye every 6 months for 48 months
89011729|NCT01649908||EVAR|
89011730|NCT01649986|Active Comparator|Non-pharmacologic intervention|Patients assigned by their own general practitioner to have non-pharmacologic intervention and prevention strategies will be given details on lifestyle approaches and dietary strategies
89011731|NCT01649986|Active Comparator|Nutraceuticals|Patients assigned by their own general practitioner to receive nutraceuticals, along with non-pharmacologic intervention and prevention strategies, will have for 1 year also 1 capsule/day containing red yeast rice 200 mg, policosanol 10 mg, and berberine 500 mg,
89011732|NCT01645696|Experimental|BD Continuous Glucose Monitor (CGM) with outer layer|A subcutaneous glucose binding protein sensing device to continuously monitor glucose in diabetics.
89011733|NCT01645696|Experimental|BD CGM without outer layer|A continuous glucose binding protein sensing device used to monitor glucose in Diabetics
89011734|NCT01645696|Active Comparator|Medtronic iPro 2 Professional CGM|Commercial glucose oxidase continuous glucose monitor
89011735|NCT01647451|Experimental|Active|
89011736|NCT01647451|Placebo Comparator|Placebo|
89011737|NCT00250575|Experimental|1|
89011738|NCT01640899|Other|Single-arm study|This is a single-arm study. Just one group (i.e. the patients)
89011739|NCT04528381|Other|Laparoscopy|Diagnostic and therapeutic laparoscopy
89011740|NCT04528186||1|Low eating index scores(50-70)
89011741|NCT04528186||2|High eating index scores(Above 70)
89011742|NCT01645072|Experimental|Low glycemic index diet|The patients will be started on low glycemic index diet.
89011743|NCT01645072|Other|Control group|Standard care. The control group will receive their usual diet without any alteration. No changes will be made to the patients' antiepileptic medication during the 4-week baseline or the 3-month study periods in both the intervention and control groups, unless medically indicated; e.g. drug side effects, or status epilepticus; in which case appropriate changes will be made to their medications and same will be documented.
89011744|NCT01645891|Active Comparator|CDO with standard MWT|CDO (continuously supply pure oxygen) with standard Moist Wound Therapy
89011745|NCT01645891|Sham Comparator|Moist Wound Therapy|Moist Wound Therapy. De-activated Sham device placed to wound in order to blind patient and study staff.
89011746|NCT04720248||Metamizol postoperatively|Patients submitted to scheduled craniotomy receiving metamizol as analgesic medication postoperatively
89011747|NCT04720248||Paracetamol or other analgesics postoperatively|Patients submitted to scheduled craniotomy receiving paracetamol or other drugs as analgesic medication postoperatively
89011748|NCT01646515|Placebo Comparator|placebo arm|Capsule that is identically appearing with udenafil will be administered to patients in placebo group. For the first 4 weeks, patients will receive 50 mg of placebo drug two times a day, and then the dosage will be doubled to 100 mg two times a day for next 8 weeks.
89011749|NCT01646515|Active Comparator|Udenafil|Patients will receive 50 mg of udenafil two times a day, and then the dosage will be doubled to 100 mg two times a day for next 8 weeks.
89011750|NCT00240773|Experimental|001|acetaminophen 4 grams daily for 12 months
89011751|NCT00240773|Active Comparator|002|naproxen 750 mg daily for 12 months
89011752|NCT00240773|Experimental|003|acetaminophen 4 grams daily for six months
89011753|NCT00240773|Active Comparator|004|naproxen 750 mg daily for six months
89011754|NCT01688401|Experimental|IA melphalan|IA melphalan is administered via the basilar artery.
89199294|NCT05887895|Experimental|Treatment group sequence 1|Subjects were given HR20014, INS068, or INS062 injections subcutaneously once in three cycles. The interval of each dosing visit was 7 to 21 days.
89011755|NCT04708821|Experimental|DEXTENZA|DEXTENZA (dexamethasone ophthalmic insert) 0.4 mg, for intracanalicular use
89011756|NCT04708821|Active Comparator|Antihistamine|PAZEO (olopatadine hydrochloride ophthalmic solution) 0.7% for topical ophthalmic administration.
89011757|NCT04708821|Active Comparator|Topical Steroid|ALREX® (loteprednol etabonate ophthalmic suspension) contains a sterile, topical anti-inflammatory corticosteroid for ophthalmic use.
89011758|NCT01688440|Experimental|#1 Respiratory Care Solution|Low sodium physiologically based airway care solution.
89011759|NCT01688479|Experimental|Calendula Weleda® cream (Weleda)|Calendula Officinalis (marigold plant) is applied twice daily on the skin in the radiated area during the entire treatment period and until the skin reaction subsided
89011760|NCT01688479|Active Comparator|Essex® cream (Schering-Plough)|Essex cream is applied twice daily on the skin in the radiated area during the entire treatment period and until the skin reaction subsided
89011761|NCT01688518|Active Comparator|Synera® for 30min & Lidoderm® for 4 hours|Heated Lidocaine/Tetracaine (Synera®)applied to one forearm for either 30 minutes or 4 hours and a 5% Lidocaine (Lidoderm®) patch applied to the alternate forearm for the alternate time period.
89199295|NCT05887895|Experimental|Treatment group sequence 2|Subjects were given HR20014, INS062, or INS068 injections subcutaneously once in three cycles. The interval of each dosing visit was 7 to 21 days.
89536949|NCT02468453|Experimental|Cohort 4-improving skin laxity|Velos (Bipolar radiofrequency only) treatment for improving skin laxity or skin tightness/firmness
89438027|NCT05715372|Active Comparator|Intervention group of menopausal women on hormone replacement|This group of women on hormone replacement will have specific, structured diet, physical activity, and mindfulness-based stress reduction programs.
89438028|NCT05715372|Placebo Comparator|Control group of menopausal women on hormone replacement|This group of women on hormone replacement will be given unstructured guidelines for diet, physical activity, and stress-reduction.
89438029|NCT05715372|Active Comparator|Intervention group of menopausal women without hormone replacement|This group of women will have specific, structured diet, physical activity, and mindfulness-based stress reduction programs.
88922845|NCT03772977|No Intervention|Standard of Care (SOC)|The current physician/provider counseling on brain health to reduce cognitive decline or incidence of cognitive impairment that occurs, per providers' own practice
88922846|NCT03772145||Tofacitinib|Adult patients, age 18 years or older, with UC, who within 2 weeks have been started on tofacitinib therapy for moderate to severe UC or who plan to start this therapy within the next 2 weeks. The start of the tofacitinib therapy must have been or be initiated in the setting of standard of care therapy
89438030|NCT05715372|Placebo Comparator|Control group of menopausal women without hormone replacement|This group of women will be given unstructured guidelines for diet, physical activity, and stress-reduction.
89438031|NCT00329082|Experimental|1|
89438032|NCT00329082|Experimental|2|
89438033|NCT00329082|Experimental|3|
88922847|NCT03771534|Experimental|Oxygen gas|10-15 L/min of oxygen by face mask for up to 45 minutes for the MRI and up to 30 minutes for the echocardiogram.
88922848|NCT03770832||Infants at Risk for Atypical Motor Development (high-risk)|
88922849|NCT03770832||Infants Expected to Have Typical Motor Development (low-risk)|
89199296|NCT05887895|Experimental|Treatment group sequence 3|Subjects were given INS068, HR20014, or INS062 injections subcutaneously once in three cycles. The interval of each dosing visit was 7 to 21 days.
89438034|NCT00329082|Experimental|4|
89438035|NCT00329082|Placebo Comparator|5|
89438036|NCT03530436|Other|Native turmeric extract|6 capsules of native curcumin (207 mg curcumin)
89438037|NCT03530436|Experimental|Native turmeric extract with 7-9% volatile turmeric oils|6 capsules of the formulation; dosage normalized to 207 mg curcumin
89438038|NCT03530436|Experimental|Turmeric extract plus mixture of phytochemicals|6 capsules of the formulation; dosage normalized to 207 mg curcumin
89438039|NCT03530436|Experimental|Cyclodextrin complex of curcuminoids|6 capsules of the formulation; dosage normalized to 207 mg curcumin
89438040|NCT03530436|Experimental|Turmeric oleoresin|6 capsules of the formulation; dosage normalized to 207 mg curcumin
89438041|NCT03530436|Experimental|Liposomal curcumin|6 capsules of the formulation; dosage normalized to 207 mg curcumin
89438042|NCT03530436|Experimental|Phytosomal curcumin|6 capsules of the formulation; dosage normalized to 207 mg curcumin
89438043|NCT03530436|Experimental|Micellar turmeric extract|6 capsules of the formulation; dosage normalized to 207 mg curcumin
89438044|NCT03530280|Active Comparator|pregabalin (lyrica)|pregabalin (lyrica) 150 mg preoperative 1 hour before and the postoperative sham block will perform.
89438045|NCT03530280|Placebo Comparator|placebo group|a placebo capsule 1 hour before surgery and the postoperative sham block will perform.
89438046|NCT03530280|Active Comparator|adductor channel block group|A preoperative placebo capsule will be given.This group will receive postoperative adductor channel block including 10 mL of 0.25% bupivacaine with 5 μg/mL epinephrine
89438047|NCT00079482|Active Comparator|1|Induction chemotherapy with or without sequential treatment with oral CEP-701 at 80 mg bid. For patients with duration of first CR of 1 to 6 months, the induction regimen will be MEC.
89438048|NCT00079482|Active Comparator|2|Induction chemotherapy with or without sequential treatment with oral CEP-701 at 80 mg bid. For patients with duration of first CR of more than 6 months to 24 months, the induction regimen will be HiDAC.
89438049|NCT00073398|Experimental|1|Ph II Arm 1
89438050|NCT00325650|Experimental|Rimonabant|Rimonabant 20 mg once daily
88922850|NCT03768440|Experimental|continuous erector spinae block|An erector spinae block is placed at end of the thoracotomy procedure, bolused with 1ml/kg 0.2% ropivacaine, then started on a 0.2ml/kg/hour continuous infusion of 0.2% ropivacaine. patients will have access to rescue opiates as needed by means of the standard PCA/NCA demand protocols utilized at BCH. Rescue analgesic consumption will be tabulated at 24, 48 and 72 hours, rendered as total opiate equivalents.
88922851|NCT03768440|Active Comparator|continuous paravertebral block|A paravertebral block is placed at end of the thoracotomy procedure, bolused with 1ml/kg 0.2% ropivacaine, then started on a 0.2ml/kg/hour continuous infusion of 0.2% ropivacaine. patients will have access to rescue opiates as needed by means of the standard PCA/NCA demand protocols utilized at BCH. Rescue analgesic consumption will be tabulated at 24, 48 and 72 hours, rendered as total opiate equivalents.
88922852|NCT03767582|Experimental|Phase I - GVAX/Nivolumab/CCR2/CCR5 dual antagonist|
89438051|NCT00325650|Placebo Comparator|Placebo|Placebo (for Rimonabant) once daily.
89438052|NCT03133572|Experimental|Supraglottic airway|All newborns in need of resuscitation in this arm will receive initial treatment with positive pressure ventilation using a supraglottic airway and a bag.
88922853|NCT03767582|Experimental|Phase II - Arm A: Nivolumab/CCR2/CCR5 dual antagonist|
88922854|NCT03767582|Experimental|Phase II - Arm B: Nivolumab/GVAX/CCR2/CCR5 dual antagonist|
88922855|NCT03739931|Experimental|Arm A: mRNA-2752|Participants will be administered mRNA-2752 at an applicable dose as monotherapy.
88922856|NCT03739931|Experimental|Arm B: mRNA-2752 + Durvalumab|Participants will be administered mRNA-2752 at an applicable dose in combination with durvalumab.
88922857|NCT03739931|Experimental|Arm C: mRNA-2752 Alone or mRNA-2752 + Durvalumab|Participants will be administered mRNA-2752 at an applicable dose as monotherapy or in combination with durvalumab.
88922858|NCT03739775|Other|Blood sampling|
89438053|NCT03133572|Active Comparator|Face-mask|All newborns in need of resuscitation in this arm will receive initial treatment with positive pressure ventilation using a face-mask and a bag.
89438054|NCT00317694|Experimental|1|
89438055|NCT00317694|Placebo Comparator|2|
89438056|NCT00067782|Active Comparator|1|
89438057|NCT00067782|Active Comparator|2|
89438058|NCT00058266|Experimental|Group A|Patients receive oral genistein once daily for 1-2 months, undergo radical prostatectomy, and then continue oral genistein once daily for 1-2 months afterward (for a total of 3 months of therapy).
89438059|NCT00058266|Experimental|Group B|Patients undergo radical prostatectomy. Beginning 1 month after surgery, patients receive genistein as in arm I for 3 months.
89438060|NCT03530202|Experimental|HVRT + Creatine Monohydrate|Participants will perform 8-weeks of high-velocity resistance training, defined as performing the concentric phase of a lift as fast as possible and taking two seconds to perform the eccentric phase of the lift, on six exercises (bilateral legpress, leg extension, leg curl, chest press, triceps extension, and biceps curl) and consume creatine monohydrate powder. The load will be 80% of the participants one-repetition max (1RM; the maximum weight that can be successfully lifted one time with proper form).
88922859|NCT03698461|Experimental|Atezolizumab, Bevacizumab, FOLFOX|Atezolizumab 1200mg IV Once, Atezolizumab (840mg IV D1 of C1-12) + Bevacizumab (5mg/kg IV D1 of C1-12) + FOLFOX(Oxaliplatin 85mg/m2 IV D1 of C1-12, Levoleucovorin 200mg/m2 IV D1 of C1-12, 5-FU - bolus 400mg/m2 IV D1 of C1-12, - infusional 2400mg/m2 IV continuous(46 hours) D1-3 of C1-12)
88922860|NCT03691207|Experimental|SINGLE-ARM|AL101 is an inhibitor of gamma secretase-mediated Notch signaling.
89438061|NCT03530202|Placebo Comparator|HVRT + Maltodextrin Powder|Participants will perform 8-weeks of high-velocity resistance training, defined as performing the concentric phase of a lift as fast as possible and taking two seconds to perform the eccentric phase of the lift, on six exercises (bilateral legpress, leg extension, leg curl, chest press, triceps extension, and biceps curl) and consume maltodexterin powder. The load will be 80% of the participants one-repetition max (1RM; the maximum weight that can be successfully lifted one time with proper form).
89438062|NCT03530046|Experimental|High SID fluid|Group 1: half-normal saline with addition of 75mEq/L sodium bicarbonate
89438063|NCT03530046|Active Comparator|Hartmann's solution|Group 2: Hartmann's Solution
89438064|NCT00313794|Experimental|1|single arm
89438065|NCT03529968||Italian Siewert I-II adenocarcinoma|Patients with Siewert type I adenocarcinoma underwent subtotal esophagectomy and proximal gastrectomy with intrathoracic esophagogastric anastomosis. Patients with Siewert type II adenocarcinoma underwent total gastrectomy and esophageal resection at the level of the azygos vein and Roux-en-Y esophagojejunostomy. A right anterolateral thoracotomy and an upper midline laparotomy were performed as previously described. Lymphadenectomy included chest stations classified according to the AJCC TNM 7th edition (L/R = left/right; 3, 4R, 7, 2R, 8 and 9 and abdominal stations classified according to the Japanese Classification of Gastric Carcinoma (stations 1-12)
89438066|NCT03529968||Finnish Siewert I-II adenocarcinoma|All Siewert type I/II patients underwent minimally invasive esophagectomy and reconstruction with gastric tube. Laparoscopy and right-sided thoracoscopy in decubitus position were used as previously described. Thoracic lymphadenectomy consisted of stations 7-9 (AJCC TNM 7th edition) and abdominal stations 1-3 and 7-11 according to the Japanese Classification of Gastric carcinoma.
89438067|NCT00040404|Experimental|CEP-1347 10mg|CEP-1347 was administered at a dosage of 10mg twice daily (bid); capsule strengths were 5, 12.5, and 25 mg. Each patient took 2 capsules at each dosing time, approximately 12 hours apart, within 30 minutes after the morning and evening meals) for a total of 4 capsules per day.Patients were randomly assigned to CEP-1347 or placebo treatment in a 1:1:1:1 ratio. A blocked randomization scheme was used to ensure approximately equal numbers of patients in each of the 4 treatment groups at each center.
89438068|NCT00040404|Experimental|CEP-1347 25mg|CEP-1347 was administered at a dosage of 25mg twice daily (bid); capsule strengths were 5, 12.5, and 25 mg. Each patient took 2 capsules at each dosing time, approximately 12 hours apart, within 30 minutes after the morning and evening meals) for a total of 4 capsules per day.Patients were randomly assigned to CEP-1347 or placebo treatment in a 1:1:1:1 ratio. A blocked randomization scheme was used to ensure approximately equal numbers of patients in each of the 4 treatment groups at each center.
89438069|NCT00040404|Experimental|CEP-1347 50mg|CEP-1347 was administered at a dosage of 50mg twice daily (bid); capsule strengths were 5, 12.5, and 25 mg. Each patient took 2 capsules at each dosing time, approximately 12 hours apart, within 30 minutes after the morning and evening meals) for a total of 4 capsules per day.Patients were randomly assigned to CEP-1347 or placebo treatment in a 1:1:1:1 ratio. A blocked randomization scheme was used to ensure approximately equal numbers of patients in each of the 4 treatment groups at each center.
89438070|NCT00040404|Placebo Comparator|Placebo|Placebo capsules matching the CEP-1347 capsules were administered in the same manner.
89438071|NCT00313248|Experimental|Arm 1|
89438072|NCT00313248|Experimental|Arm 2|
89438073|NCT00310830|No Intervention|1|
89438074|NCT00310830|Experimental|2|
89438075|NCT00030186|Experimental|Cycle 1|60mg
89438076|NCT00030186|Experimental|Cycle 2|80mg dependent upon response to Cycle 1
89438077|NCT00030186|Experimental|Cycle 2b|40mg dependent upon response to Cycle 1
89438078|NCT03529812|Experimental|Early-start group for CBCT-informed training|Hospital chaplain residents receiving the Cognitively-Based Compassion Training (CBCT) education during the first unit of their year-long residency.
89536950|NCT02467985|No Intervention|Control|
88922861|NCT03688139|Experimental|Engage Therapy|Participants receive Engage therapy for 9 weeks.
88922862|NCT03688139|Active Comparator|Supportive Therapy|Participants receive supportive therapy for 9 weeks.
88922863|NCT03677739|Experimental|Arm 1 Young melanoma Family Facebook focusing on skin cancer|Participants join a secret Young melanoma Family Facebook Group and view post messages focusing on skin cancer for 12 weeks.
88922864|NCT03677739|Experimental|Arm 2 Healthy Lifestyle Facebook focusing on healthy lifestyle|Participants join a secret Healthy Lifestyle Facebook Group and view post messages focusing on healthy lifestyle for 12 weeks.
88922865|NCT03667170|Experimental|Subjects with MSI-H/dMMR|patients receive 600 mg of the KN035 Subcutaneously every 3 weeks
88922866|NCT03630224|Experimental|Plasmalyte Viaflo|Intervention type: drug (Plasmalyte Viaflo) Intervention name: plasmalyte Intervention description: fluid resuscitation using exclusively Plasmalyte up to 20L during the first 5 days
88922867|NCT03630224|Active Comparator|NaCl 0.9%|Intervention type: drug (NaCl 0.9%) Intervention name: NaCl 0.9% Intervention description: fluid resuscitation using exclusively NaCl 0.9% up to 20L during the first 5 days
88922868|NCT03621137||Patients with moderate-to-severe atopic eczema|Adult and pediatric patients that start treatment with phototherapy or systemic immunomodulating therapy for their atopic eczema
88922869|NCT03599765|Experimental|Arm I (LCT, routine therapy)|Patients receive up-front standard of care LCT including but not limited to surgical resection, cryotherapy, and radiofrequency ablation. Patients then receive routine drug therapy.
88922870|NCT03599765|Experimental|Arm II (routine therapy)|Patients receive routine drug therapy. Patients may later receive LCT at the discretion of doctor.
88922871|NCT03599752|Experimental|Group 1A (chemotherapy, metastasectomy)|Low risk patients receive standard of care chemotherapy for 3 months prior to and 3 months after undergoing metastasectomy in the absence of disease progression or unacceptable toxicity.
88922872|NCT03599752|Experimental|Group 1B (metastasectomy)|Low risk patients undergo metastasectomy.
88922873|NCT03599752|Experimental|Group 2A (metastasectomy)|High risk patients undergo metastasectomy.
89438079|NCT03529812|Active Comparator|Delayed-start group for CBCT-informed training|Hospital chaplain residents receiving the Cognitively-Based Compassion Training (CBCT) education midway through their year-long residency.
89438080|NCT02287974|Experimental|Autologous mononuclear stem cell from the bone marrow|Autologous mononuclear stem cell from the bone marrow in an unique infusion of 150-250 millions of cells
88922874|NCT03599752|Experimental|Group 2B (chemotherapy)|High risk patients continue standard of care chemotherapy for 6 months in the absence of disease progression or unacceptable toxicity. Patients with stable disease or radiographic response after 6 months may then cross over to Group 2A.
88922875|NCT03599219|Other|case|donors with an hemorrhagic score >2 and / or hematoma (more than 4 cm) that occurred during blood donation
88922876|NCT03599219|Other|control|donors with an hemorrhagic score <2.
88922877|NCT03583866|Experimental|Candesartan|Sub chronic (7 days) Candesartan (16 mg/day)
88922878|NCT03583866|Placebo Comparator|Placebo|Endothelial function will be determined following a seven day treatment of placebo
88922879|NCT03560752|Experimental|Donor (multi-peptide CMV-modified vaccinia Ankara vaccine)|Donors receive multi-peptide CMV-modified vaccinia Ankara vaccine injection between days -60 and -10 prior to granulocyte colony stimulating factor mobilization.
88922880|NCT03560752|Experimental|Receipient (multi-peptide CMV-modified vaccinia Ankara vaccine)|Participants undergo hematopoietic cell transplantation on day 0 and receive multi-peptide CMV-modified Vaccinia Ankara vaccine injection on days 28 and 56.
88922881|NCT03555331||INSIGHT participants|Mother-child dyads who enrolled in the INSIGHT Study and participated from early infancy to age 3 years will be followed through age 9 years.
88922882|NCT03511664|Experimental|177Lu-PSMA-617 plus best supportive/best standard of care (BS/BSOC)|Patients randomized to receive the investigational product received 7.4 GBq (+/- 10%) 177Lu-PSMA-617 intravenously every 6 weeks (+/- 1 week) for a maximum of 6 cycles. Best supportive/best standard of care (BS/BSOC) might be used
88922883|NCT03511664|Other|Best supportive/best standard of care (BS/BSOC) alone|Patients randomized to this arm received best supportive/best standard of care (BS/BSOC) as determined by the investigator
88922884|NCT03508232|Placebo Comparator|Placebo control|Two placebo capsules upon enrollment, followed by one placebo capsule p.o. every 12 hours for 7 days
88922885|NCT03508232|Experimental|Doxycycline hyclate|Two 100mg doxycycline capsules (200 mg) p.o. upon enrollment, followed by one 100 mg capsule p.o. every 12 hours for 7 days
88922886|NCT03503630|Experimental|Locally advanced rectal cancer patients|"Week 1: D1-5: radiotherapy 25 Gy in 5 fractions~mFOLFOX-6: Oxaliplatin 85 mg/m2 in a 2-hour infusion Leucovorin 400 mg/m² over 2 hours Bolus fluorouracil 400 mg/m² followed by a 48-hour infusion of fluorouracil 2,400 mg/m² + COMPOUND 2055269 10 mg/kg every 2 weeks (first administration at D15, for a total of 6 cycles)~Week 16 or 17 (2 to 3 weeks after last cycle of chemotherapy + COMPOUND 2055269): Total Mesorectal Excision"
88922887|NCT03489252|Experimental|Device Feasibility (Fitbit Charge 3)|Participants wear the Fitbit Charge 3 device from the time of CT simulation for RT planning throughout the entire RT course.
88922888|NCT03479671|No Intervention|Saline|Insulin sensitivity (rate of glucose disposal)
88922889|NCT03479671|Experimental|Low Dose Fatty Acids|Insulin sensitivity (rate of glucose disposal) in response to 30 ml/hr fatty acid infusion
88922890|NCT03479671|Experimental|Medium Dose Fatty Acids|Insulin sensitivity (rate of glucose disposal) in response to 60 ml/hr fatty acid infusion
88922891|NCT03478488|Experimental|KN035|"KN035 plus Gemcitabine & oxaliplatin KN035 2.5 mg/Kg, administered as subcutaneous injection, weekly of each 21-day cycle.~Gemcitabine 1000 mg/m^2, IV infusion on Day 1 and Day 8, and oxaliplatin 85 mg/m^2, IV infusion on Day 1 of each 21-day cycle for no more than 6 cycles."
89438081|NCT02287974|Experimental|Autologous endothelial stem cell from the bone marrow|Autologous endothelial progenitor CD133 stem cell from the bone marrow in an unique infusion of 2 - 7 millions of CD133 cells
88922892|NCT03478488|Active Comparator|Gemcitabine & oxaliplatin|Gemcitabine 1000 mg/m^2, IV infusion on Day 1 and Day 8, and oxaliplatin 85 mg/m^2, IV infusion on Day 1 of each 21-day cycle for no more than 6 cycles.
88922893|NCT03460769||Pancreatic Cancer|The Coordinating and Data Management Center (CDMC) at MD Anderson Cancer will be responsible for the coordination and data management for the Evaluation of a mixed meal test for Diagnosis and characterization of Type 3c diabetes mellitus secondary to pancreatic cancer and chronic pancreatitis (DETECT).
88922894|NCT03460769||Chronic Pancreatitis|The Coordinating and Data Management Center (CDMC) at MD Anderson Cancer will be responsible for the coordination and data management for the Evaluation of a mixed meal test for Diagnosis and characterization of Type 3c diabetes mellitus secondary to pancreatic cancer and chronic pancreatitis (DETECT).
88922895|NCT03460769||Type 3c Diabetes Mellitus|The Coordinating and Data Management Center (CDMC) at MD Anderson Cancer will be responsible for the coordination and data management for the Evaluation of a mixed meal test for Diagnosis and characterization of Type 3c diabetes mellitus secondary to pancreatic cancer and chronic pancreatitis (DETECT).
88922896|NCT03457194||Pregnant women|"150 participants (pregnant women at least 18 years of age and meeting eligibility criteria) will be enrolled and administered the FluQuadri, the quadrivalent influenza vaccine which will be administered by single-dose intramuscular injection.~Single-dose intramuscular injection of Adacel - DTP vaccine (multiple actives) will also be administered to all enrolled pregnant women who are at gestation 28 weeks or greater at the time of enrolment.~Where the vaccines are to be co-administered, FluQuadri will be administered into the dominant arm and Adacel into the non-dominant arm.~Pregnant women will be at a gestation of 20 weeks or greater at the time of enrolment. The vaccines administered are currently licensed and recommended in Australia to be given during pregnancy."
88922897|NCT03433456|Experimental|Home visitation + HABITS Program|The HABITS module will target 5 key behaviors (physical activity, increasing fruit and vegetable consumption, decreasing sugary beverages, decreasing fried foods, and encouraging regular self-monitoring and self-weighing) aimed at reducing obesity risk in mothers or primary caregivers and children. Participants will receive the HABITS module in addition to their standard home visitation services.
88922898|NCT03433456|Active Comparator|Standard home visitation program|Participants will receive the standard of care home visitation regularly delivered through the existing home visitation program without the HABITS module.
88922899|NCT03419260||Cohort|Critically ill child undergoing clinically indicated EEG monitoring and electrographic seizure management.
88922900|NCT03412812|Experimental|Dose Escalated 5 Fraction Stereotactic Radiosurgery|Patients will undergo dose escalated five fraction stereotactic radiosurgery for diagnosed brain metastases. Tumors must fall into one of two categories: 2.1-4.0cm diameter or 4.1-6.0 cm diameter. Only single largest tumor will be treated with dose escalation. All other tumors (if present) will be treated with standard of care five fraction stereotactic radiosurgery.
88922901|NCT03399981||Tysabri (TOUCH Cohort)|Participants from the Tysabri TOUCH prescribing programme who have switched to Tysabri from newer DMTs (including fingolimod, dimethyl fumarate and teriflunomide) and the established DMTs (interferon beta and glatiramer acetate).
88922902|NCT03399981||Tysabri (EU MS Cohort)|Participants from the EU MS registry who have switched to Tysabri from newer DMTs (including fingolimod, dimethyl fumarate and teriflunomide) and the established DMTs (interferon beta and glatiramer acetate).
88922903|NCT03376438||Prospective observational cohorts|1) Atrial flutter without fetal hydrops; 2) Atrial flutter with fetal hydrops; 3) Supraventricular tachycardia without fetal hydrops; and 4) Supraventricular tachycardia with fetal hydrops
88922904|NCT03372057|Experimental|Dose Optimization Phase: Cohort 1|Duvelisib PO BID at a starting dose of 25 mg, with potential escalation on a per-patient basis to 50 mg and then 75 mg, based on the patient's response to and tolerance of therapy, in 28-day cycles.
88922905|NCT03372057|Experimental|Dose Optimization Phase: Cohort 2|Duvelisib 75 mg PO BID, administered in 28-day cycles.
88922906|NCT03372057|Experimental|Expansion Phase|Duvelisib PO BID at a starting dose of 75 mg for the first 2 cycles, followed by a mandatory reduction to 25 mg BID thereafter for those patients with complete response (CR), partial response (PR) or stable disease (SD), in 28-day cycles (dose determined in Optimization Phase).
88922907|NCT03367754|Experimental|1|single dose of 200 mg (IV) infusion
88922908|NCT03367754|Placebo Comparator|2|single dose (IV infusion)
88922909|NCT03339349|Experimental|Enoxaparin Metabolism|Eligible patients will have steady state peak and trough anti-Xa levels drawn after the third enoxaparin dose. For patients in-range (levels 0.2-0.4 IU/mL), no intervention will be undertaken. For patients out of range, enoxaparin dose will be adjusted according to an established dose adjustment algorithm. Repeat levels will be checked after the third administration of the new dose.
88922910|NCT03334006|No Intervention|Control arm|Standard of Care treatment
88922911|NCT03334006|Active Comparator|Verum arm|Standard of Care treatment + Pentaglobin®
88922912|NCT03300648|No Intervention|Usual care|Hospitalization in a high dependency pediatric unit with skilled nursing, intravenous artesunate followed by oral artemisinin combination therapy, intravenous fluids, nasogastric feeding, elevation of the head of the bed by 30 degrees
88922913|NCT03300648|Experimental|Mechanical ventilation|Hospitalization in a high dependency pediatric unit with skilled nursing, intravenous artesunate followed by oral artemisinin combination therapy, intravenous fluids, nasogastric feeding, elevation of the head of the bed by 30 degrees, along with intubation and mechanical ventilation for a maximum of 7 days
88922914|NCT03300648|Experimental|Hypertonic saline|Hospitalization in a high dependency pediatric unit with skilled nursing, intravenous artesunate followed by oral artemisinin combination therapy, intravenous fluids, nasogastric feeding, elevation of the head of the bed by 30 degrees, along with intravenous 3% hypertonic saline for a maximum of 7 days
88922915|NCT03289962|Experimental|Phase 1a Flat Dose Escalation: Autogene Cevumeran|Participants will receive autogene cevumeran at escalated dosages.
88922916|NCT03289962|Experimental|Phase 1b Flat Dose Escalation: Autogene Cevumeran + Atezolizumab|Participants will receive autogene cevumeran at escalated dosages along with atezolizumab at a fixed dose of 1200 milligrams (mg)
88922917|NCT03289962|Experimental|Phase Ib: Dose Exploration: Autogene Cevumeran + Atezolizumab|Non-small cell lung cancer (NSCLC) or melanoma cancer immunotherapy (CIT)-treated participants will receive autogene cevumeran (at dosage lower than maximum tolerated dose [MTD] based on available safety data) along with atezolizumab at a fixed dose of 1200 mg.
89199297|NCT05887895|Experimental|Treatment group sequence 4|Subjects were given INS068, INS062, or HR20014 injections subcutaneously once in three cycles. The interval of each dosing visit was 7 to 21 days.
89438082|NCT02287974|Experimental|Autologous mesenchymal stem cells from the adiposite tissue|Autologous mesenchymal stem cells from the adipose tissue in an unique infusion of 0.5 millions of cells
89438083|NCT02287974|Active Comparator|Current medication for the disease|Current medication for the disease
89438084|NCT03529734|Experimental|12 min running group|This group will perform a 12 min high intensity running with the goal to cover maximal possible distance.
89438085|NCT03529734|Experimental|Local strengthening exercise group|This group will perform local strengthening exercises (curl-ups, left side trunk flexion, trunk extension, right side trunk flexion). Each participant will have to perform three sets of each exercise with the maximal possible number of repetitions with a slow tempo (1s concentric phase and 2 s eccentric phase). Between sets, minimal rest (15 s) will be administered.
89438086|NCT03529656|No Intervention|Pre-ERP|A group of patients who underwent liver transplantation surgery before the early rehabilitation program
89438087|NCT03529656|Experimental|Post-ERP|A group of immediate liver transplant patients who had an early rehabilitation program in ICU care
89438088|NCT00307398|Experimental|AL-3789|One injection to the study eye by the posterior juxtascleral depot procedure at 6-month intervals for 42 months.
89438089|NCT00307398|Sham Comparator|Anecortave Acetate Vehicle|One sham injection to the study eye at 6-month intervals for 42 months. Syringe containing AA vehicle was not inserted into the eye.
89438090|NCT01368081|Experimental|BI 10773 low dose|BI 10773 low dose tablet once daily
89438091|NCT01368081|Experimental|BI 10773 high dose|BI 10773 high dose tablet once daily
89438092|NCT01368081|Active Comparator|Metformin|Metformin tablets 500-2250 mg a day (twice or three times per day)
89438093|NCT02127333||CAD patients with COPD|
89438094|NCT02127333||CAD patients without COPD|
89438095|NCT02127333||healthy volunteers|
88922918|NCT03289962|Experimental|Phase 1b Expansion: Autogene Cevumeran + Atezolizumab|Participants with different indications as per inclusion criteria will receive autogene cevumeran (at multiple dose levels below MTD based on available safety data) along with atezolizumab at a fixed dose of 1200 mg.
88922919|NCT03289962|Experimental|Phase 1b Expansion: Autogene Cevumeran + Atezolizumab (Serial Biopsy)|CIT-naive patients with selected tumor types who consent to optional serial biopsies will receive autogene cevumeran (at multiple dose levels below MTD based on available safety data) along with atezolizumab at a dixed dose of 1200 mg.
88922920|NCT03278548|Experimental|Volulyte 6%|Volulyte 6% solution for infusion
88922921|NCT03278548|Active Comparator|Ionolyte|Ionolyte solution for infusion
88922922|NCT03246984|Experimental|VasQ device implantation|
89438096|NCT02127411|Experimental|Mindfulness-based relapse prevention|Mindfulness-Based Relapse Prevention
89438097|NCT02127411|No Intervention|Waitlist|this group will stay in the waitlist until the end of follow-up assessments, when they will receive the intervention
89438098|NCT02127489|Active Comparator|Midazolam|1 mL/kg bupivacaine 0.25%.
89438099|NCT02127489|Placebo Comparator|saline|5mL rectal saline
89438100|NCT02127645|Experimental|Early Rectal Cancer|patients with T1 - T2, N0, G1-2 rectal cancer
89438101|NCT02124135|Active Comparator|Clinic-based counseling|Participants in this arm will receive 1 baseline phone call with the registered dietitian to get preliminary dietary counseling tailored to their family's needs. They will then have 3 sessions in-person in a group setting with another family and the registered dietitian where a set dietary curriculum geared at promoting weight loss and/or maintenance of a healthy weight will be emphasized. All in-person visits will take place in the clinic setting.
88922923|NCT03245489|Experimental|Group 1|Group 1 will be treated with Regimen A, followed by Regimen B. Regimen A is pembrolizumab, ASA and clopidogrel daily for 6 weeks. Regimen B is pembrolizumab alone for 6 weeks.
88922924|NCT03245489|Experimental|Group 2|Group 2 will be treated with Regimen B, followed by Regimen A. Regimen B is pembrolizumab alone for 6 weeks. Regimen A is pembrolizumab, ASA and clopidogrel daily for 6 weeks.
88922925|NCT03225586||Adults|Between 35 to 70 years of age at time of enrollment
88922926|NCT03197922|Experimental|MIE Treatment for Two Weeks|Participants in this arm will receive the Multidisciplinary Intervention for Encopresis (MIE) for two weeks. MIE consists of daily clinic appointments, each of which lasts until a continent bowel movement occurs or 3 hours elapse. These participants will discontinue the use of medication previously prescribed for the treatment of constipation, other than the suppositories used in the MIE treatment. During MIE, medical professionals resolve any constipation and oversee a regimen of over the counter medications that increase the predictability of a bowel movement.
89438102|NCT02124135|Experimental|Restaurant-based counseling|Participants in this arm will receive 1 baseline phone call with the registered dietitian to get preliminary dietary counseling tailored to their family's needs. They will then have 3 sessions in-person in a group setting with another family and the registered dietitian where a set dietary curriculum geared at promoting weight loss and/or maintenance of a healthy weight will be emphasized. All in-person visits will take place in a restaurant, while dining.
89438103|NCT02124213|Experimental|Cohor 1 - 30 mg|Cohort will include approximately 4 HVs/completers who will receive a single 30 mg dose of PF-06412562.
89438104|NCT02124213|Experimental|Cohort 2 ( adaptive dose, optional)|Cohort 2 will include approximately 4 HVs/completers who will receive a single dose of PF-06412562. The dose will be selected based on the results obtained for Cohort 1.
89438105|NCT02124213|Experimental|Cohort 3 ( adaptive dose, optional)|Cohort 2 will include approximately 4 HVs/completers who will receive a single dose of PF-06412562. The dose will be selected based on the results obtained for Cohort 1 and Cohort 2.
89438106|NCT00303498|Experimental|Sitaxsentan sodium|
89438107|NCT00303498|Placebo Comparator|Placebo|
89438108|NCT02124291|No Intervention|No Assisted Hatching|No Assisted Hatching
89438109|NCT02124291|Active Comparator|Assisted Hatching|Mechanical Assisted Hatching - artificial rupture of the embryo external glycoprotein layer (Zona Pellucida) before embryo transfer.
89438110|NCT02588092|Experimental|Part 1: ADCT-301 (dose escalation)|"Weekly administration - Participants will receive an IV infusion of ADCT-301, on Days 1, 8, and 15 of each 3-week (21-day) cycle.~3-week administration - Participants will receive an IV infusion of ADCT-301, on Day 1 of each 3-week (21-day) cycle.~The dose escalation will be conducted according to a 3+3 design."
89438111|NCT02588092|Experimental|Part 2: ADCT-301 (dose expansion)|Participants will be assigned to receive the recommended dose and/or schedule of ADCT-301 as determined by the Dose Escalation Steering Committee.
89438112|NCT02121717|Experimental|Arm 1|Patients administrate Chiglitazar 32mg once daily for 52 weeks
89438113|NCT02121717|Experimental|Arm 2|Patients administrate Chiglitazar 48mg once daily for 52 weeks
89438114|NCT02121717|Placebo Comparator|Arm 3|Patients administrate placebo for 24 weeks.From week 25 to 52, patients are randomly switched to Arm 1 and Arm 2, and receive the treatment accordingly.
89438115|NCT03529578|Experimental|dHACM|Standard of Care plus Weekly Application of dHACM
89438116|NCT02124447|Active Comparator|PEG+E|Split dose 4 liter polyethylene glycol with electrolytes
89438117|NCT02124447|Active Comparator|PEG+Asc|Split dose 2 liter polyethylene glycol with ascorbic acid
89438118|NCT02124447|Active Comparator|P+MC|Split dose sodium picosulfate, magnesium oxide, and anhydrous citric acid
89438119|NCT02124447|Active Comparator|sulfate|Split dose sodium sulfate, magnesium sulfate, and potassium sulfate solution
88922927|NCT03197922|Active Comparator|Treatment as Usual (TAU)|Participants randomized to the Treatment as Usual (TAU) group will continue to receive outpatient medical treatment of encopresis according to best practice guidelines by the pediatric gastroenterologist. Additionally, participants in the TAU group will receive a 2-hour long individual appointment with a doctoral level clinician with extensive experience in behavioral treatments for encopresis.
88922928|NCT03197922|Experimental|MIE Treatment for One Week|Participants in this arm will receive the Multidisciplinary Intervention for Encopresis (MIE) for one week. This study arm was discontinued in October 2019.
88922929|NCT03177460|Experimental|Arm A (daratumumab)|Patients receive daratumumab IV over 4-8 hours once weekly for 4 weeks in the absence of disease progression or unacceptable toxicity. Patients then undergo radical prostatectomy during week 6.
88922930|NCT03177460|Experimental|Arm B (FMS inhibitor JNJ-40346527)|Patients receive FMS inhibitor JNJ-40346527 PO BID for 4-5 weeks in the absence of disease progression or unacceptable toxicity. After a 3 day wash-out period, patients undergo radical prostatectomy.
88922931|NCT03152409|Active Comparator|Aspirin augmentation to treatment|Participants who meet inclusion criteria for the study and are randomized to the active treatment arm will be given pills for the ensuing 8 weeks, consisting of a daily dose of aspirin 325 mg to be taken every evening before bed.
88922932|NCT03152409|Placebo Comparator|Placebo augmentation to treatment|Participants randomized to the placebo arm will receive a placebo oral tablet of the same size, shape, and color as the aspirin tablet. Participants will be instructed to take their pills in the evening before bed.
88922933|NCT03110770|Experimental|Part A, Group 1: VRC-ZKADNA090-00-VP (4 mg), 2 injections|Zika virus wildtype (ZIKVwt) DNA vaccine (VRC-ZKADNA090-00-VP), in 2 limbs (both arms) on Day 0, Day 28 (+/-7 days), and Day 56 (-7/+14 days); 4 mg of vaccine administered intramuscularly (IM) by a needle-free injection device
88922934|NCT03110770|Experimental|Part A, Group 2: VRC-ZKADNA090-00-VP (4 mg), 4 injections|ZIKVwt DNA vaccine (VRC-ZKADNA090-00-VP), in 4 limbs (both arms and legs) on Day 0, Day 28 (+/-7 days), and Day 56 (-7/+14 days); 4 mg of vaccine administered IM by a needle-free injection device
88922935|NCT03110770|Experimental|Part A, Group 3: VRC-ZKADNA090-00-VP (8 mg), 4 injections|ZIKVwt DNA vaccine (VRC-ZKADNA090-00-VP), in 4 limbs (both arms and legs) on Day 0, Day 28 (+/-7 days), and Day 56 (-7/+14 days); 8 mg of vaccine administered IM by a needle-free injection device
88922936|NCT03110770|Experimental|Part B, Group 4: VRC-ZKADNA090-00-VP (4 mg), 2 injections|ZIKVwt DNA vaccine (VRC-ZKADNA090-00-VP), in 2 limbs (both arms) on Day 0, Day 28 (+/-7 days), and Day 56 (-7/+14 days); 4 mg of vaccine administered IM by a needle-free injection device
88922937|NCT03110770|Placebo Comparator|Part B, Group 5: Placebo (VRC-PBSPLA043-00-VP), 2 injections|Sterile phosphate-buffered saline (PBS) (VRC-PBSPLA043-00-VP), the placebo, in 2 limbs (both arms) on Day 0, Day 28 (+/-7 days), and Day 56 (-7/+14 days); 1 mL of placebo administered IM by a needle-free injection device
89438120|NCT03551769|Experimental|Cohort 1, Period 1|Study drug administered concurrently with a standard meal
89438121|NCT03551769|Experimental|Cohort 1, Period 2|Study drug administered 30 minutes after a standard meal
89438122|NCT03551769|Experimental|Cohort 1, Period 3|Study drug administered 30 minutes after a high-fat meal
88922938|NCT03110354|Experimental|DS-3201b 100 mg|Participants who received 100 mg DS-3201b administered orally to participants with AML or ALL.
89438123|NCT03551769|Experimental|Cohort 1, Period 4|Study drug administered after an overnight fast
89438124|NCT03551769|Experimental|Cohort 2, Period 1|Study drug administered 30 minutes after a standard meal (Asian)
89438125|NCT03551769|Experimental|Cohort 2, Period 2|Study drug administered after an overnight fast (Asian)
89438126|NCT04426162|Experimental|Memory Boot Camp Participants|All subjects undergo a 12-week control period, followed by a multi-domain 12-week memory program.
89438127|NCT02127801|Experimental|Group A|Participants in group A will receive REGN1908-1909
89438128|NCT02127801|Experimental|Group B|Participants in group B will receive placebo
88922939|NCT03110354|Experimental|DS-3201b 150 mg|Participants who received 150 mg DS-3201b administered orally to participants with AML or ALL.
88922940|NCT03110354|Experimental|DS-3201b 250 mg|Participants who received 250 mg DS-3201b administered orally to participants with AML or ALL.
88922941|NCT03110354|Experimental|DS-3201b 500 mg|Participants who received 500 mg DS-3201b administered orally to participants with AML or ALL.
88922942|NCT03110354|Experimental|DS-3201b 700 mg|Participants who received 700 mg DS-3201b administered orally to participants with AML or ALL.
89438129|NCT05725590|Experimental|external pancreatic duct stent|
89438130|NCT05725590|Experimental|internal pancreatic duct stent|
89438131|NCT05474482|Experimental|kinesio taping with 75 to 100 % stretch and exercises|Kinesio taping with stretching exercises and yoga will be given to patients for 8 weeks.
89438132|NCT05474482|Experimental|kinesio taping without exercises|Kinesio taping alone will be given to patients for 8 weeks.
89438133|NCT05474482|Active Comparator|kinesio taping without stretch to tape|kinesio taping without any stretch, applied as control for 8 weeks.
89438134|NCT02127879|Experimental|Transcranial Magnetic Stimulation|Active Treatment 10 Hz rTMS of left dorsolateral prefrontal cortex (DLPFC)
89438135|NCT02127879|Sham Comparator|Transcranial Magnetic Stimulation with sham coil|Sham coil Treatment 10 Hz rTMS of left dorsolateral prefrontal cortex (DLPFC)
89438136|NCT03529500||Adequate nutritional status|Dental caries experience was recorded using the dmft index. Active visible white spots were also recorded. Samples of non-stimulated saliva were collected from the participants for five minutes. The salivary flow volume was calculated and expressed as ml/min. After the measurement of salivary flow, an aliquot of 1 ml was transferred to a test tube with 3 ml of hydrochloric acid (HCl 5 mM) for titration and the determination of salivary buffering capacity (SBC).
89438137|NCT03529500||Mild malnutrition|Dental caries experience was recorded using the dmft index. Active visible white spots were also recorded. Samples of non-stimulated saliva were collected from the participants for five minutes. The salivary flow volume was calculated and expressed as ml/min. After the measurement of salivary flow, an aliquot of 1 ml was transferred to a test tube with 3 ml of hydrochloric acid (HCl 5 mM) for titration and the determination of salivary buffering capacity (SBC).
89199298|NCT05887895|Experimental|Treatment group sequence 5|Subjects were given INS062, HR20014, or INS068 injections subcutaneously once in three cycles. The interval of each dosing visit was 7 to 21 days.
89438138|NCT03529500||Moderate malnutrition|Dental caries experience was recorded using the dmft index. Active visible white spots were also recorded. Samples of non-stimulated saliva were collected from the participants for five minutes. The salivary flow volume was calculated and expressed as ml/min. After the measurement of salivary flow, an aliquot of 1 ml was transferred to a test tube with 3 ml of hydrochloric acid (HCl 5 mM) for titration and the determination of salivary buffering capacity (SBC).
89438139|NCT03529500||Severe malnutrition|Dental caries experience was recorded using the dmft index. Active visible white spots were also recorded. Samples of non-stimulated saliva were collected from the participants for five minutes. The salivary flow volume was calculated and expressed as ml/min. After the measurement of salivary flow, an aliquot of 1 ml was transferred to a test tube with 3 ml of hydrochloric acid (HCl 5 mM) for titration and the determination of salivary buffering capacity (SBC).
89438140|NCT03551145|Experimental|Acellular collagen matrix|In a test group, partial thickness-flap will be elevation will be performed, in order to create the vascular recipient bed for the randomized graft. Implant surface will be treated with ultrasound device, glycine powder and implantoplasty in case of the exposure of the rough surface. Acellular collagen matrix will be adapted and suture to the vascular bed.
89438141|NCT03551145|Active Comparator|Autogenous free gingival graft|In a control group, partial thickness-flap will be elevation will be performed, in order to create the vascular recipient bed for the randomized graft. Implant surface will be treated with ultrasound device, glycine powder and implantoplasty in case of the exposure of the rough surface. Free gingival graft will be harvested from the zone of the posterior palate, and then adapted and sutured to the vascular bed.
89438142|NCT04441476||ICU staff|
89438143|NCT05474326|Experimental|pregnant women with idiopathic oligohydramnios|women with singleton pregnancy between 32-41 weeks oligohydramnios diagnosed by ultrasound by the amniotic fluid index (AFI) method oligohydramnios is diagnosed if AFI index is less than 5 cm
89438144|NCT02127957|Other|Exercise|Exercise group will have 6 visit and 8 phone call. Subject will have to do prescribed exercice for 1h, 3 times a week for 12 weeks.
89438145|NCT02127957|No Intervention|Control|Control group will have 4 visit and 3 phone call. They will receive standard counselling for exercise in cystic fibrosis, but no prescribed exercice will be given.
88922943|NCT03109080|Experimental|Olaparib + radiation therapy|One week of Olaparib alone followed by 5 weeks of Olaparib and concurrent loco-regional radiotherapy. Five levels of dose of Olaparib are expected.
88922944|NCT03073811|Experimental|PeriHab|Provided nutrition counseling and prescribed to consume 1.6 g/kg/body weight as well as provided 30 grams of high quality protein three times per day for two weeks before and four weeks after surgery.
88922945|NCT03073811|Active Comparator|PoshControl|Provided nutrition counseling and prescribed to consume 1.0 g/kg/body weight in the form of educational handouts explained by a Registered Dietitian and one oral nutrition supplement per day for two weeks before surgery.
88922946|NCT03026998|Other|MRI|
88922947|NCT03016819|Experimental|Indication A: ASPS AL3818 Arm - CLOSED|All subjects with ASPS will be assigned to the open-label AL3818 arm to receive 12 mg AL3818 capsules orally once daily in 21-day cycles (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
89438146|NCT04441398|Experimental|nitazoxanide|Subjects will receive nitazonanide 600 mg TID.
89438147|NCT04441398|Placebo Comparator|Placebo|Subjects will receive placebo TID.
88922948|NCT03016819|Experimental|Indication B: LMS AL3818 Arm - CLOSED|Subjects with LMS will be randomized in a 2:1 ratio to receive either AL3818 or IV dacarbazine. Subjects randomized to AL3818 will receive 12 mg AL3818 capsules orally once daily in 21-day cycles (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
88922949|NCT03016819|Active Comparator|Indication B: LMS Dacarbazine Arm - CLOSED|Subjects with LMS will be randomized in a 2:1 ratio to receive either AL3818 or IV dacarbazine. Subjects randomized to IV dacarbazine will receive dacarbazine at a dose of 1000 mg/m^2 as a 20-120 minute IV infusion on Day 1 of each 21-day treatment cycle.
88922950|NCT03016819|Experimental|Indication C: SS AL3818 Arm - CLOSED|Subjects with SS will be randomized in a 2:1 ratio to receive either AL3818 or IV dacarbazine. Subjects randomized to AL3818 will receive 12 mg AL3818 capsules orally once daily in 21-day cycles (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
88922951|NCT03016819|Active Comparator|Indication C: SS Dacarbazine Arm - CLOSED|Subjects with SS will be randomized in a 2:1 ratio to receive either AL3818 or IV dacarbazine. Subjects randomized to IV dacarbazine will receive dacarbazine at a dose of 1000 mg/m^2 as a 20-120 minute IV infusion on Day 1 of each 21-day treatment cycle.
89011762|NCT01688518|Active Comparator|Lidoderm® for 30min & Synera® for 4 hours|Heated Lidocaine/Tetracaine (Synera®)applied to one forearm for either 30 minutes or 4 hours and a 5% Lidocaine (Lidoderm®) patch applied to the alternate forearm for the alternate time period.
89199299|NCT05887895|Experimental|Treatment group sequence 6|Subjects were given INS062, INS068, or HR20014 injections subcutaneously once in three cycles. The interval of each dosing visit was 7 to 21 days.
89199300|NCT05880368|Experimental|Patient partnership tool|Study participants as patients visiting primary care providers in the clinics using the study patient engagement tools aimed to reduce preventable adverse drug events.
89011763|NCT05140681|Experimental|apical group|FibReORS with apically flap positioning 2 mm below the bone crest (apical group)
89011764|NCT05140681|Active Comparator|Crestal group|FibReORS with apically flap positioning at the level of bone crest (crestal group).
88922952|NCT03016819|Placebo Comparator|Indication D: LMS AL3818 or Placebo Arm - CLOSED|Subjects with LMS will be randomized in a 2:1 ratio to receive either AL3818 or placebo in a double-blind manner. AL3818 or placebo will be administrated as one 12 mg capsule orally once daily in 21-day cycles for 14 days on treatment (Days 1-14) and 7 days off treatment (Days 15-21).
88922953|NCT03016377|Experimental|iC9-CAR19 cells|The 3+3 design in adult subjects and an independent study using 3+3 design in pediatric subjects. The starting dose of 5 x 10^5 transduced cells/kg will enroll 3 adult subjects in the initial cohort. If there are no dose limiting toxicities w/in 4 weeks of the cell infusion in these 3 subjects, then the next cohort will evaluate 1 x10^6 transduced cells/kg in adults. If there is toxicity in 1/3 patients in the initial cohort, the cohort will be expanded to enroll up to 6 adult patients. If the dose level 1 is determined to be above the tolerated cell dose, de-escalation would occur to dose level -1 where subjects would receive 1 x 10^5 transduced cells/kg. All subjects will receive a lymphodepleting regimen of fludarabine and cyclophosphamide before administration of iC9-CAR19 T cells.
88922954|NCT03016377|Experimental|Expansion Cohort Second Administration of iC9-CAR19 cells|"After the recommended phase 2 dose (RP2D) of iC9-CAR19 T cells has been determined in adults, up to 18 additional adult subjects will be enrolled in an expansion cohort at the RP2D. In the expansion cohort, subjects will be offered a second infusion of iC9-CAR19 T cells based on B-cell recovery and minimal residual disease (MRD) status. All subjects will receive a lymphodepleting regimen of fludarabine and cyclophosphamide before second administration of iC9-CAR19 T cells.~Subjects in the expansion cohort who experience ≥grade 2 CRS or ICANS, did not respond to the initial dose of the standard of care treatment will be enrolled in a sub-study of rimiducid."
88922955|NCT03012230|Experimental|Treatment (pembrolizumab, ruxolitinib phosphate)|Patients receive pembrolizumab IV over 30 minutes on day 1 and ruxolitinib phosphate PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
88922956|NCT02997709||Radiation Therapy Group|Participants with prostate cancer diagnosis who are scheduled to undergo standard of care radiotherapy with or without the addition of Androgen Deprivation Therapy (ADT) will be evaluated
88922957|NCT02997709||Prostatectomy Group|Participants with prostate cancer diagnosis who are scheduled to undergo prostatectomy will be evaluated
88922958|NCT02996227|Experimental|TAP block with Exparel|Bilateral Transversus Abdominis Plane (TAP) block procedure following injection of liposomal bupivacaine (Exparel)
88922959|NCT02996227|Active Comparator|Epidural analgesia with Bupivacaine|Epidural catheters with an infusion of Bupivacaine standard solution without additives
88922960|NCT02966548|Experimental|Monotherapy|Relatlimab (BMS-986016) administered every 2 weeks as a single agent intravenous formulation
88922961|NCT02966548|Experimental|Combination Therapy|Relatlimab (BMS-986016) will be administered in combination with Nivolumab every 2 weeks or every 4 weeks as an intravenous formulation
89011765|NCT00240851|Experimental|001|acetaminophen extended release
89011766|NCT01688557|Experimental|Innovative colonoscopy|Innovative colonoscopy performed using narrow band imaging and dual focus function (NBI + Dual Focus).
89438148|NCT02128035|No Intervention|Without Lead Shield|"All routine measures to reduce radiation exposure (including lead aprons, lead collar, lead lenses, movable ceiling suspended lead shield with a long lead skirt attached to its lower margin) will be used as done routinely and will be left to the operators' discretion.~The LEAD SHIELD will not be used in this group.~Interventional cardiologists who will perform the procedure will wear a radiation protection cap in all procedures."
89199301|NCT05880368|No Intervention|Control|Study participants as patients visiting primary care providers in the clinics without the study patient engagement tools.
89438149|NCT02128035|Experimental|With Lead Shield|"All routine measures to reduce radiation exposure (including lead aprons, lead collar, lead lenses, movable ceiling suspended lead shield with a long lead skirt attached to its lower margin) will be used as done routinely and will be left to the operators' discretion.~In this group, a LEAD SHIELD will be used. The Pelvic lead shield will be draped on patient from umbilicus to knees.~Interventional cardiologists who will perform the procedure will wear a radiation protection cap in all procedures."
89438150|NCT05474248|Experimental|Diaphragmatic Breathing Training|The experimental group will undergo the diaphragmatic breathing training assisted with StressEraser to breath slowly 4-6 times per minute and practice 15 minutes twice daily.
89438151|NCT05474248|No Intervention|Control group|Usual care
89438152|NCT03551067|Active Comparator|Dexmedetomidine|Patients received Dexmedetomidine (4 µg/kg) mixed with apple juice to fill the syringe up to 10 ml given orally once.
88922962|NCT02948400|Experimental|Google Cardboard virtual environment|pedestrian safety training using the Google Cardboard device and delivery of a pedestrian virtual environment by mobile smartphone. Note that children in this arm will be trained using an immersive virtual environment delivered by smartphone, which is different from the other arm that is trained using a semi-immersive virtual environment delivered in a kiosk. The intervention is pedestrian safety training for both arms.
88922963|NCT02948400|Active Comparator|semi-immersive virtual environment|pedestrian safety training using a semi-immersive virtual pedestrian environment kiosk. Note that children in this arm will be trained using a semi-immersive virtual environment delivered in a kiosk, which is different from the other arm that is trained using an immersive virtual environment delivered by smartphone. The intervention is pedestrian safety training for both arms.
88922964|NCT02875652|Experimental|Blood sampling|
88922965|NCT02866136|Other|(IV)Intravenous chemotherapy, laser diode|"Group 1 - Multicentric non randomised, phase II study for patients with retinoblastoma (unilateral group A,B according to age, group C according to the age and the vitreous seeding or bilateral groups A,B and C excluding the bilateral groups D or patients with bilateral macular threat).~Treatment by chemoreduction (VP16, carboplatin) followed by Carboplatin + laser day 1 (chemothermotherapy) without laser treatment at day 8 (decreasing laser sessions) combined to local treatments from third course (laser, cryoapplication, I125 radioactive plaques or intravitreal Melphalan)."
89011767|NCT01688557|Active Comparator|Conventional colonoscopy|Conventional colonoscopy performed without innovative techniques assessed in this study.
89011768|NCT01688674|Placebo Comparator|Bolus arm|two hourly dextrose boluses administered via an intravenous cannula
89199302|NCT05876494||patients with ulcerative colitis|any patients with ulcerative colitis
89438153|NCT03551067|Active Comparator|Midazolam/Ketamine|Patients received Midazolam (0.5 mg/kg) and Ketamine (1 mg/kg) mixed with apple juice to fill the syringe up to 10 ml given orally once.
89438154|NCT05474170|Experimental|AHA --> ERC|This group will first apply the AHA resuscitation sequence, then the ERC one
89438155|NCT05474170|Active Comparator|ERC --> AHA|This group will first apply the ERC resuscitation sequence, then the AHA one
89438156|NCT02288052|Experimental|Writing program|The program will train participants in maintaining writing amplitude, writing speed, writing fluently and automatization of writing.
89438157|NCT02288052|Placebo Comparator|Stretch & Relaxation program|The program will learn participants to alleviate tension in the upper limbs and will consist of exercises performed while lying down or sitting.
89438158|NCT03552237|Experimental|dietary fiber intervention group|
89438159|NCT03529266|Experimental|A(Surgery+PFS)|Arm A consists of the concurrent application of Porcine Fibrin Sealant (PFS) on the gastroesophageal or coloesophageal anastomosis during Mckeown surgery .
89438160|NCT02128191|Active Comparator|Oral ibuprofen|Initial dose of 10 mg/kg of oral ibuprofen, followed by 2 doses of 5 mg/kg 24 and 48 h later
89438161|NCT02128191|Placebo Comparator|Normal saline|Initial dose of normal saline followed by second and third dose 24 and 48 hours later, at equal volume to ibuprofen arm
89438162|NCT04393636|No Intervention|Control arm|Participants will receive at the different time intervals through our custom-made Digital Cardiac Counselling platform different questionnaires related to the different known risk factors for the perioperative cardiac care and measured outcomes.Additional to known risk factors a Covid-19 module will be used as well.
89438163|NCT04393636|Active Comparator|Intervention arm|All participants will receive at the different time intervals through our custom-made Digital Cardiac Counseling platform different questionnaires related to the different known risk factors for the perioperative cardiac care and measured outcomes. Additional to above participants in the intervention group will receive through the Digital Cardiac Counseling platform different modules with E-counseling for risk factors evaluated in the questionnaires. Additional to known risk factors a Covid-19 module will be used as well.
89438164|NCT02121951|Active Comparator|Local Anesthetic infiltration and MAC|"Local Anesthetic infiltration with 1% lignocaine~MAC with IV Midazolam Img\ml and Fentanyl 10 mic\ml"
89199303|NCT05873387||Echocardiography ground-truth|Subjects with ECG/PCG recordings labeled against echocardiography
89199304|NCT05873387||Right heart catheterization ground-truth|Subjects with ECG/PCG recordings labeled against right heart catheterization
89199305|NCT05870956||IPF patients initiated on nintedanib during 10/01/2014 to 12/31/2018|
89199306|NCT05870527|Experimental|Vagal Nerve Stimulation during Cochlear Implantation Surgery|Participants undergoing cochlear implantation will receive electrical stimulation during the procedure to stimulate the Arnold's nerve to measure pupil dilation.
89438165|NCT02121951|Experimental|Quadratus Lumborum block and MAC|"QL block with 0.25% levobupivacaine (Chirocaine, Abbott, Ireland) and 1% lignocaine~MAC with IV Midazolam Img\ml and Fentanyl 10 mic\ml"
89438166|NCT05473858|Experimental|laser group|Patients will be undergoing anesthesia revision by diode laser
89438167|NCT05473858|Experimental|oraverse group|Patients will be undergoing anesthesia revision by oraverse
89438168|NCT04363528|Other|Doppler Echo|patients will have a Doppler Echo when they enter ICU (within 48 hours) and a second Doppler Echo 7 days later
89438169|NCT03552159|Experimental|Behavioral Activation|For the first 4 weeks,participants received psychoeducation about the symptoms and associated behavioral changes of dementia and the possible effects on the caregivers, t the physical, social and psychological consequences of stress, event scheduling and communication skills. After psychoeducation, eight bi-weekly behavioral activation sessions were administered, focusing pleasant event scheduling and effective communications.
89438170|NCT03552159|Active Comparator|Psychoeducation|For the first 4 weeks, participants were taught about the symptoms and associated behavioral changes of dementia and the possible effects on the caregivers, the physical, social and psychological consequences of stress, event scheduling and communication skills. After psychoeducation, eight biweekly phone sessions of general support but not behavioral activation.
89438171|NCT02252367|Experimental|Tadalafil|43 male subjects affected by BPH (benign prostatic hyperplasia) planned for simple prostatectomy will be randomized to tadalafil 5 mg - 1 film-coated tablet orally once daily for 12 weeks.
89438172|NCT02252367|Placebo Comparator|Placebo|43 male subjects affected by BPH (benign prostatic hyperplasia) planned for simple prostatectomy will be randomized to placebo.
89438173|NCT02122029|Experimental|Bariatric Surgery|
89438174|NCT02122029|Experimental|Lifestyle counselling|
89438175|NCT05556460|Experimental|DragonFly-T Tricuspid Valve Repair System|The experimental group is allocated to use a novel tricuspid valve repair system for edge-to-edge repair manufactured by Hangzhou Valgen Medtech Co., Ltd.
89438176|NCT05201742|Active Comparator|Inspiratory muscle trainer|Inspiratory muscle trainer group - Inspiratory muscle training was performed.
89438177|NCT05201742|Active Comparator|Incentive spirometer|Incentive spirometer group - Incentive spirometry was performed.
89438178|NCT02124525|Placebo Comparator|N-acetylcysteine|"Subjects receiving N-acetylcysteine (NAC): 6 pills/ day of N-acetylcysteine 500mg.~Duration: 12 weeks"
89438179|NCT02124525|Placebo Comparator|Placebo|Placebo will be taken for 12 weeks
89438180|NCT02122263||NAFLD after sleeve gastrectomy surgery|
89438181|NCT02124681|Placebo Comparator|Placebo|Placebo PO
89438182|NCT02124681|Experimental|Hydroxychloroquine|Hydroxychloroquine sulfate 400mg PO QD
89438183|NCT03551613|Active Comparator|honey group|malnourished children supplemented with honey in dose of 2ml/kg
89438184|NCT03551613|Placebo Comparator|malnourished control group|no honey supplementation only nutrition rehabilitation
89438185|NCT03551613|No Intervention|healthy children|healthy children with no suplementation
89438186|NCT05556304|Other|assessment in the 8th month of pregnancy and during delivery|The study design includes a consultation during pregnancy between 36 and 38 weeks of gestation and an assessment in the delivery room during childbirth
89438187|NCT02128347|Other|Electronic Patient Portal|RelayHealth is a web-based application that allows patients and healthcare workers to communicate through a secure, password protected online portal with data transfer capabilities. Effectiveness of the portal in improving several health outcomes from baseline-12 months will be assessed in this study.
89438188|NCT05556070|Experimental|Arm 1|
89438189|NCT05556070|Experimental|Arm 2|
89438190|NCT05556070|Active Comparator|Arm 3|
89438191|NCT02128425|Experimental|FOLFOXIRI|FOLFOXIRI
89438192|NCT02128425|Active Comparator|FOLFOX|FOLFOX
89438193|NCT05555992|Experimental|Treatment|
89438194|NCT02122419||lateral|spinal anesthesia performed during lateral position
89438195|NCT02122419||sitting|spinal anesthesia performed during sitting position
89199307|NCT05870527|No Intervention|Vagal Nerve Stimulator Implantation|Control cohort undergoing vagal nerve stimulator implantation.
89438196|NCT05639790|Sham Comparator|Counselling|Health counselling from a licensed mental health counselor
89011769|NCT01688674|Experimental|infusion|10% dextrose infusion by burettes
89199308|NCT05870384|Experimental|Psychotherapy|Group psychotherapy will be applied to a single intervention group.
89438197|NCT05639790|Experimental|Eletronic cigarette|Ad libitum use of electronic cigarettes for 1 month and health counselling from a licensed mental health counselor
89438198|NCT05555680||PCOS patients with clinical or biochemical hyperandrogenism|Clinical hyperandrogenism consists of patients with one of the following conditions: Acne, Hirsutism (using modified Ferriman-Gallwey (FG) score) or Androgenic alopecia Biochemical hyperandrogenism consists of elevated serum level of at least one of the following hormones: Total testosterone, free testosterone, DHEAS, androstenedione using the cut-offs adopted by the laboratory.
89438199|NCT05555680||PCOS patients with no clinical or biochemical hyperandrogenism|In this cohort, women have not be affected by either clinical of biochemical hyperandrogenism. The PCOS diagnosis will be based on oligo-anovulation and on polycystic ovaries during an ultrasound
89438200|NCT02122497||abdominal aortic aneurysm (AAA) endovascular|endovascular aortic repair
89438201|NCT02122497||abdominal aortic aneurysm (AAA) open|open surgical repair
89438202|NCT02122497||abdominal aortic occlusive disease (AOD)|open surgical repair
89438203|NCT02128503|Other|HBV DNA level monitoring|Group with HBV DNV level being monitored regularly
89011770|NCT05140603||Cases|Patients who received a doravirine-based regimen.
89199309|NCT05848908|Experimental|Telehealth Visit|telemedicine visit and follow-up surveys
89438204|NCT02128581|Placebo Comparator|Saline|a saline infusion will be started and maintained till the end of the study at 1300 (300 minutes).
89438205|NCT02128581|Active Comparator|Exendin-9,39 @ 300|Exendin-9,39 @ 300pmol/kg/min
89438206|NCT02128581|Active Comparator|Exendin-9,39 @ 750|Exendin-9,39 @ 750pmol/kg/min
89438207|NCT03532620|Experimental|pitavastatin|Pitavastatin Calcium + lifestyle modification
89438208|NCT03532620|Active Comparator|atorvastatin|Atorvastatin Calcium + lifestyle modification
89438209|NCT02122575||1|Males and females between the ages of 21 and 37
88922966|NCT02866136|Other|(IA) Intraarterial Melphalan|"Group 2 - Multicentric non randomised, phase II study for the patients with bilateral very asymmetric disease (group D retinoblastoma on one of the eye, and the other amenable to a local treatment without chemotherapy) or unilateral presentation group D and groups B/C according to the age and vitreous seeding.~Treatment by Melphalan chemotherapy administered by superselective catheterization of the ophthalmic artery and combined to local treatments (laser, cryoapplication, I125 radioactive plaques or intravitreal Melphalan)."
88922967|NCT02866136|Other|(IV-PM) Intravenous 3 drugs chemotherapy|Group 3 - Multicentric non randomised, phase II study for the patients with bilateral group D retinoblastoma or with a group D retinoblastoma on the only remaining eye. Treatment by 6 cycles of three drugs (VP16, carboplatin, vincristin) regimen combined to local treatments from the third cycle (laser, cryoapplication, I125 radioactive plaques or intravitreal Melphalan).
88922968|NCT02853500|Experimental|TACE Procedure With TriNav|"Patients will receive a single administration of intra-arterial chemotherapy (Doxorubicin) during the TACE procedure via TriNav.~Patients will undergo structural follow-up for a timeframe of one year post treatment~Post-procedural, contrast-enhanced Magnetic Resonance Imaging (MRI) will be performed one month after trial entry, and at regular intervals thereafter for a total of one year to assess tumor response"
88922969|NCT02853500|Active Comparator|TACE Procedure Traditional Delivery|"Patients will receive a single administration of intra-arterial chemotherapy (Doxorubicin) during the TACE procedure via Traditional Delivery.~Patients will undergo structural follow-up for a timeframe of one year post treatment~Post-procedural, contrast-enhanced Magnetic Resonance Imaging (MRI) will be performed one month after trial entry, and at regular intervals thereafter for a total of one year to assess tumor response"
88922970|NCT02851940|Experimental|A (Rubber Band Ligation)|15 patients
88922971|NCT02851940|Experimental|B (Hypertonic Saline Infusion)|15 patients
88922972|NCT02849145|Experimental|Biological/Vaccine|
88922973|NCT02842723|Experimental|Protontherapy|
88922974|NCT02841371||chronic kidney disease (CKD)|chronic kidney disease (CKD) is defined as abnormalities of kidney structure (markers of kidney damage) or function (decreased GFR by 99mTc-DTPA renal clearance and/or eGFR), present for more than 3 months.
88922975|NCT02841371||no CKD|Suspected chronic kidney disease but no chronic kidney disease after screening by abnormalities of kidney structure (markers of kidney damage) or function (decreased GFR by 99mTc-DTPA renal clearance and/or eGFR), present for less than 3 months, or no abnormalities of kidney structure or function.
88922976|NCT02840409|Active Comparator|Arm A|68 weeks of single agent Vinblastine administered once weekly IV
88922977|NCT02840409|Experimental|Arm B|68 weeks of Vinblastine administered weekly IV with the addition of 12 doses of Bevacizumab administered every two weeks IV for the initial 24 weeks.
88922978|NCT02839473|Experimental|Hydrosorb® arm|Hydrogel Hydrosorb®
88922979|NCT02839473|Placebo Comparator|Placebo arm|Castalie water spray
88922980|NCT02834494|Other|3D Shear Wave Elastography (SWE)|
88922981|NCT02831634|Other|Blood sampling|
89438210|NCT05612854|Active Comparator|catheter directed therapy group in intermediate risk pulmonary embolism patients|"in this arm, intermediated risk pulmonary embolism patients is treated by intervention in the form of:~A. Mechanical embolectomy: by hydromechanical defragmentation by pigta~B. Suction embolectomy: using The Penumbra Indigo aspiration system~C. Catheter directed thrombolysis:"
89438211|NCT05612854|Active Comparator|medical therapy group in intermediate risk pulmonary embolism patients|in this arm, intermediated risk pulmonary embolism patients is treated by routine anticoagulation only.
88922982|NCT02772562|Experimental|PROSTVAC-V/F|
88922983|NCT02768337|Other|Arm 1: Afatinib only at Recommended Phase 2 dose (RP2D)|No targeted radiotherapy. Afatinib at Recommended Phase 2 Dose for 11 days.
88922984|NCT02768337|Experimental|Arm 2: Afatinib RP2D + 2 Gy targeted radiotherapy|Patient will receive the RP2D of afatinib for 11 days and will receive targeted radiotherapy at a dose level of 2 Gy on Day 10 of treatment.
88922985|NCT02768337|Experimental|Arm 3: Afatinib RP2D + 4 Gy targeted radiotherapy|Patient will receive the RP2D of afatinib for 11 days and will receive targeted radiotherapy at a dose level of 4 Gy on Day 10 of treatment.
88922986|NCT02747589|Experimental|Treatment Group|Subjects will be implanted to assess the feasibility of stimulating visual cortex to restore vision in blind volunteers.
88922987|NCT02695628|Experimental|Diagnostic (18F-fluoromisonidazole, PET/CT, embolization)|Patients undergo transcatheter arterial embolization. Patients also receive 18F-fluoromisonidazole IV and undergo PET/CT scans 4 weeks prior to embolization treatment and in the 20 hours following completion of treatment.
88922988|NCT02690064|Experimental|Acute Antioxidant Treatment|Following an overnight fast, blood samples, flow-mediated dilation, lung function, and exercise capacity (VO2 peak) (post only) will be performed at baseline and 2 hours following either a single dose oral 1) antioxidant cocktail (1000 mg Vitamin C, 600 IU vitamin E, 600 mg Alpha Lipoic Acid) 2) Resveratrol (1500 mg) 3) Mitoquinol (10 mg) or placebo on two days separated by at least 72 hours.
88922989|NCT02690064|Experimental|Chronic Antioxidant Treatment|Following the completion of Arm 1, blood samples, flow-mediated dilation, lung function, and exercise capacity (VO2 peak) will be performed, only in patients with CF, at baseline, 4 weeks, 8 weeks, and 12 weeks following one of the following: 1) an anti-oxidant cocktail (vitamin C 1000 mg, vitamin E 400 IU, and alpha lipoic acid 600 mg) taken once a day, 2) 1500 mg Resveratrol once a day or 3) 10 mg Mitoquinol once a day.
88922990|NCT02683889|Experimental|One arm|One arm will receive acthar to measure rate of recurrence of FSGS after transplant. There are no other arms. We do have previous data that FSGS recurs in 23% of kidney transplants.
89438212|NCT02122653|Experimental|Older WT|Older people with weight training
89438213|NCT02122653|Experimental|Older WT and ES|Older people with weight training combined electrical stimulation.
89438214|NCT02122653|No Intervention|Young control group|Young people with control group
89438215|NCT05612776|Experimental|HIIT-based training|The HIIT group will train according to a predefined high intensity training program
89438216|NCT05612776|Experimental|HRV-based training|The training prescribed to the HRV group will depend on the subjects' diary HRV
89536951|NCT02467985|Experimental|intervention|Flow of insufflation will be set to 2-3L / min. After the intervention, the CO2 insufflation is discontinued, accessories trocars are removed under direct vision and the incisions the sites of these trocars will be closed. Patients will be placed in the Trendelenburg position 30 degrees, head tilted down. The umbilical trocar is opened. Suction is inserted into the trocar, taking care to stay inside the jacket of the trocar. Active suction gas will during lung recruitment. This maneuver will be performed by the anesthesiologist who applies 5 subsequent forced breaths, up to 40 cm H2O pressure, taking care to maintain the insufflation last 5 sec. Once completed, the suction will be removed, the laparoscope is inserted into the trocar to verify the absence of trauma to underlying structures.
89536952|NCT03306329|Experimental|DNS-7801 (low-dose)|
89536953|NCT03306329|Experimental|DNS-7801 (high-dose)|
89536954|NCT03306329|Placebo Comparator|Placebo|
89536955|NCT03304457|Active Comparator|Olanzapine|Olanzapine will be prescribed at a dose of 10mg once daily orally for 6 weeks
89536956|NCT03304457|Experimental|Lurasidone|Lurasidone will be prescribed at a dose of 80mg/day once daily orally for 6 weeks
89536957|NCT03306095||Early refeeding group|Food Intake by patient with in 4 hours i.e <4 hours after the EVL procedure
89536958|NCT03306095||Delayed refeeding group|Food Intake by patient with in 4 hours i.e > 4 hours after the EVL procedure
88922991|NCT02671435|Experimental|Dose-escalation Cohort 1: Monalizumab 22.5 mg Q2W + Durvalumab 1500 mg Q4W|Participants will receive intravenous (IV) infusions of durvalumab 1500 mg every 4 weeks (Q4W) in combination with monalizumab 22.5 mg every 2 weeks (Q2W) up to 3 years until unacceptable toxicity, documentation of confirmed disease progression (PD), or documentation of subject withdrawal for another reason.
88922992|NCT02671435|Experimental|Dose-escalation Cohort 2: Monalizumab 75 mg Q2W + Durvalumab 1500 mg Q4W|Participants will receive IV infusions of durvalumab 1500 mg Q4W in combination with monalizumab 75 mg Q2W up to 3 years until unacceptable toxicity, documentation of confirmed PD, or documentation of subject withdrawal for another reason.
88922993|NCT02671435|Experimental|Dose-escalation Cohort 3: Monalizumab 225 mg Q2W + Durvalumab 1500 mg Q4W|Participants will receive IV infusions of durvalumab 1500 mg Q4W in combination with monalizumab 225 mg Q2W up to 3 years until unacceptable toxicity, documentation of confirmed PD, or documentation of subject withdrawal for another reason.
88922994|NCT02671435|Experimental|Dose-escalation Cohort 4: Monalizumab 750 mg Q2W + Durvalumab 1500 mg Q4W|Participants will receive IV infusions of durvalumab 1500 mg Q4W in combination with monalizumab 750 mg Q2W up to 3 years until unacceptable toxicity, documentation of confirmed PD, or documentation of subject withdrawal for another reason.
88922995|NCT02671435|Experimental|Dose-escalation Cohort 5: Monalizumab 750 mg Q4W + Durvalumab 1500 mg Q4W|Participants will receive IV infusions of durvalumab 1500 mg Q4W in combination with monalizumab 750 mg Q4W up to 3 years until unacceptable toxicity, documentation of confirmed PD, or documentation of subject withdrawal for another reason.
88922996|NCT02671435|Experimental|Dose-expansion Cohort: Monalizumab 750 mg Q2W + Durvalumab 1500 mg Q4W (MSS-CRC)|Participants with microsatellite-stable colorectal cancer (MSS-CRC) will receive IV infusions of durvalumab 1500 mg Q4W in combination with monalizumab 750 mg Q2W up to 3 years until unacceptable toxicity, documentation of confirmed PD, or documentation of subject withdrawal for another reason.
88922997|NCT02671435|Experimental|Dose-expansion Cohort: Monalizumab 750 mg Q2W + Durvalumab 1500 mg Q4W (ovarian)|Participants with ovarian cancer will receive IV infusions of durvalumab 1500 mg Q4W in combination with monalizumab 750 mg Q2W up to 3 years until unacceptable toxicity, documentation of confirmed PD, or documentation of subject withdrawal for another reason.
88922998|NCT02671435|Experimental|Dose-expansion Cohort: Monalizumab 750 mg Q2W + Durvalumab 1500 mg Q4W (Endometrial MSS)|Participants with endometrial MSS will receive IV infusions of durvalumab 1500 mg Q4W in combination with monalizumab 750 mg Q2W up to 3 years until unacceptable toxicity, documentation of confirmed PD, or documentation of subject withdrawal for another reason.
88922999|NCT02671435|Experimental|Dose-expansion Cohort: Monalizumab 750 mg Q2W + Durvalumab 1500 mg Q4W (NSCLC)|Participants with non-small cell lung cancer (NSCLC) will receive IV infusions of durvalumab 1500 mg Q4W in combination with monalizumab 750 mg Q2W up to 3 years until unacceptable toxicity, documentation of confirmed PD, or documentation of subject withdrawal for another reason.
88923000|NCT02671435|Experimental|Exploration Cohort A1: Monalizumab 750 mg Q2W+Durvalumab 1500 mg Q4W+mFOLFOX6 Q2W+Bevacizumab Q2W|Participants with first-line (1L) MSS-CRC will receive IV infusions of durvalumab 1500 mg Q4W in combination with monalizumab 750 mg Q2W plus mFOLFOX (oxaliplatin 85 mg/m^2 IV infusion, folinic acid 400 mg/m^2 infusion, fluorouracil 400 mg/m^2 IV bolus, followed by 2400 mg/m^2 continuous IV infusion over 46 to 48 hours on Day 1) Q2W plus IV infusion of bevacizumab 5 mg/kg Q2W up to 3 years until unacceptable toxicity, documentation of confirmed PD, or documentation of subject withdrawal for another reason.
89438217|NCT02288130|Active Comparator|GnRHa and placebo tablets|11.25 mg Leuproreline injections at the onset of pretreatment with placebo tablets (once daily)
89438218|NCT02288130|Active Comparator|Ulipristal|Three months of Ulipristal 5 mg once daily combined with a single saline injection at the onset of pretreatment (produced as placebo of Leuproreline)
89438219|NCT02288130|No Intervention|Control|No pre-treatment prior to laparoscopic myomectomy
89438220|NCT02128659|Experimental|SHE Project|Receives SHE Project Intervention during Week 1 of enrollment
88923001|NCT02671435|Experimental|Exploration CohortA2: Monalizumab 750 mg Q2W + Durvalumab 1500 mg Q4W + mFOLFOX6 Q2W + Cetuximab Q2W|Participants with 1L MSS-CRC will receive IV infusions of durvalumab 1500 mg Q4W in combination with monalizumab 750 mg Q2W, plus mFOLFOX6 (oxaliplatin 85 mg/m^2, folinic acid 400 mg/m^2, fluorouracil 400 mg/m^2 IV bolus, followed by 2400 mg/m^2 continuous IV infusion over 46 to 48 hours on Day 1) Q2W plus IV infusion of cetuximab (loading dose of 400 mg/m^2 on Day 1, followed by maintenance dose of 250 mg/m^2 IV infusion every week starting on Day 8, then changed to 500 mg/m^2 IV infusion Q2W) up to 3 years until unacceptable toxicity, documentation of confirmed PD, or documentation of subject withdrawal for another reason.
88923002|NCT02671435|Experimental|Exploration Cohort C1A: Monalizumab 750 mg Q2W + Durvalumab 1500 mg Q4W + Cetuximab Q2W|Participants with recurrent or metastatic third-line (3L) RAS mutant MSS-CRC will receive IV infusions of durvalumab 1500 mg Q4W in combination with monalizumab 750 mg Q2W plus IV infusion of cetuximab 500 mg/m^2 on Day 1 then 500 mg/m^2 IV infusion Q2W starting on Day 15 up to 3 years until unacceptable toxicity, documentation of confirmed PD, or documentation of subject withdrawal for another reason.
88923003|NCT02671435|Experimental|Exploration Cohort C1B: Monalizumab 750 mg Q2W + Cetuximab Q2W|Participants with recurrent or metastatic 3L RAS mutant MSS-CRC will receive IV infusion of monalizumab 750 mg Q2W plus IV infusion of cetuximab 500 mg/m^2 on Day 1 then 500 mg/m^2 IV infusion Q2W starting on Day 15 up to 3 years until unacceptable toxicity, documentation of confirmed PD, or documentation of subject withdrawal for another reason.
88923004|NCT02671435|Experimental|Exploration Cohort C2A: Monalizumab 750 mg Q2W + Durvalumab 1500 mg Q4W + Cetuximab Q2W|Participants with recurrent or metastatic 3L RAS/BRAF wild type MSS-CRC will receive IV infusions of durvalumab 1500 mg Q4W in combination with monalizumab 750 mg Q2W plus IV infusion of cetuximab 500 mg/m^2 on Day 1 then 500 mg/m^2 IV infusion Q2W starting on Day 15 up to 3 years until unacceptable toxicity, documentation of confirmed PD, or documentation of subject withdrawal for another reason.
88923005|NCT02671435|Experimental|Exploration Cohort C2B: Monalizumab 750 mg Q2W + Cetuximab Q2W|Participants with recurrent or metastatic 3L RAS/BRAF wild type MSS-CRC will receive IV infusion of monalizumab 750 mg Q2W plus IV infusion of cetuximab 500 mg/m^2 on Day 1 then 500 mg/m^2 IV infusion Q2W starting on Day 15 up to 3 years until unacceptable toxicity, documentation of confirmed PD, or documentation of subject withdrawal for another reason.
88923006|NCT02649166|Experimental|Deep brain stimulation|All participants will undergo unilateral deep brain stimulation (DBS) implantation for essential tremor. Medtronic Summit RC+S devices will be used because these are capable of recording brain signals, as well as delivering DBS. Participants will receive continuous (open-loop) and closed-loop deep brain stimulation interventions, which will be compared for efficacy.
88923007|NCT02624765|Active Comparator|RCT A (1st arm): AF without hydrops|Atrial Flutter (AF) without hydrops: Treatment with Digoxin as monotherapy.
88923008|NCT02624765|Active Comparator|RCT A (2nd arm): AF without hydrops|Atrial Flutter (AF) without hydrops: Treatment with Sotalol as monotherapy.
88923009|NCT02624765|Active Comparator|RCT B (1st arm): SVT without hydrops|Supraventricular Tachycardia (SVT) without hydrops: Treatment with Digoxin as monotherapy.
88923010|NCT02624765|Active Comparator|RCT B (2nd arm): SVT without hydrops|Supraventricular Tachycardia (SVT) without hydrops: Treatment with Flecainide as monotherapy.
88923011|NCT02624765|Active Comparator|RCT C (1st arm): SVT with hydrops|Supraventricular Tachycardia (SVT) with hydrops: Treatment with Digoxin and Sotalol.
88923012|NCT02624765|Active Comparator|RCT C (2nd arm): SVT with hydrops|Supraventricular Tachycardia (SVT) with hydrops: Treatment with Digoxin and Flecainide.
88923013|NCT02619838||Aptus CCS 5.0 or/and 7.0 screws|Procedure/Surgery: Subtalar, Double or Triple Arthrodesis of the talonavicular joint, the subtalar joint, and the calcaneal-cuboid joint of the foot with the Aptus CCS 5.0 or/and 7.0 screws
88923014|NCT02608346|Other|Blood sampling|
89011771|NCT04708977|Active Comparator|Group 1: Indirect Decompression|Lateral lumbar interbody fusion (LLIF), with indirect decompression
89438221|NCT02128659|Active Comparator|Wait-List Control|Receive SHE Project intervention during Week 2 of Enrollment
89438222|NCT03529032|No Intervention|Fentanyl group|Drug: Fentanyl Fentanyl group 3µg/kg to start surgery TIVA: general anesthesia will be based on Fentanyl an Propofol, titrated to achieve bispectral index (BIS) between 40-60.
89438223|NCT03529032|Experimental|methadone group|Drug: methadone methadone group 0.2mg/kg to start surgery TIVA: general anesthesia will be based on Fentanyl an Propofol, titrated to achieve bispectral index (BIS) between 40-60.
89438224|NCT02128737|No Intervention|Control|10 hours time-in-bed all nights of study
89438225|NCT02128737|Experimental|1 Recovery Night|2 baseline nights, five nights sleep restriction, 1 recovery night, five nights sleep restriction, 4 recovery nights
89438226|NCT02128737|Experimental|3 Recovery Nights|2 baseline nights, five nights sleep restriction, 3 recovery nights, five nights sleep restriction, 2 recovery nights
89438227|NCT02128737|Experimental|5 Recovery Nights|2 baseline nights, five nights sleep restriction, 5 recovery nights, five nights sleep restriction, 1 recovery nights
89438228|NCT02122731|Experimental|Amiloride|This is a non-randomized and non-controlled study with only one treatment arm with amiloride.
89438229|NCT05458726|Experimental|Osimertinib|Osimertinib 80mg po daily
89438230|NCT05458726|Sham Comparator|Other treatments|chemotherapy or continuation of TKI monotherapy or in combination of anti-angiogenic agents
89438231|NCT01367847|Active Comparator|Helping the Noncompliant Child (HNC)|Standard HNC (see HNC Arm/Title) Program plus Technology-Enhancement (smartphones, which are being used for mid-week video calls to check-in re: skill-building, videotaping of family practice of skills at home, daily surveys re: skills practice & child behavior, reminders re: practice & sessions.
89438232|NCT01367847|Experimental|Technology-Enhanced HNC (TE-HNC)|Standard HNC (see HNC Arm/Title) Program plus Technology-Enhancement (smartphones, which are being used for mid-week video calls to check-in re: skill-building, videotaping of family practice of skills at home, daily surveys re: skills practice & child behavior, reminders re: practice & sessions.
89438233|NCT05612698|Experimental|Aerobic training|Aerobic Training intervention (AT): Perform 50 minutes/day, 3 days/week, totalling 150 min/week at moderate intensity, as recommended by WHO, in a range of 65-75% HRMax.
89438234|NCT05612698|Experimental|Aerobic training + resistance training|Aerobic Training plus Resistance Training intervention (AT+RT): Perform 50 minutes/day, 3 days/week, starting with 50% of 1-repetition maximum (1-RM) and follow a progression of increasing loads up to 75% of 1-RM for optimal gains in strength and insulin action.
88923015|NCT02604277|Experimental|Group Intervention Program|Patients diagnosed with Bipolar Disorder will receive therapy in a group setting of 4 to 12 male and female participants.
88923016|NCT02546453|Other|Tumoral specific genetic alterations|NGS techniques (next generation sequencing) will be used to identify specific genetic alterations of tumoral cells of a patient. If specific genetic alterations is detected, they will be used to detect circulating tumor DNA and/or circulating/disseminated tumoral cells (CTC/DTC) in peripheral samples (blood, bone marrow, cerebral spinal fluid) collected before, during and after treatment.
88923017|NCT02543255|Experimental|Abiraterone acetate + prednisone + leuprolide + cabazitaxel|Participants randomized to this arm will receive abiraterone acetate (1000 mg/day), prednisone (5 mg twice daily), leuprolide (22.5 mg every 3 months), and cabazitaxel (20 mg/m2, with 6 mg pegfilgrastim administered 24 h following cabazitaxel) prior to radical prostatectomy.
88923018|NCT02543255|Active Comparator|Abiraterone acetate + prednisone + leuprolide|Participants randomized to this arm will receive abiraterone acetate (1000 mg/day) , prednisone (5 mg twice daily), and leuprolide (22.5 mg every 3 months) prior to radical prostatectomy.
88923019|NCT02465333|Other|Pathway A|"Screening visit followed by heel fat grafting procedure with local anesthetic and visits at:~1 week Post op study visit 2 (1 month) Post op study visit 3 (2 month) Post op study visit 4 (6 month) Post op study visit 5 (12 month) Crossover to standard podiatry visits Study visit 6 (18 months) Study visit 7 (24 months)"
88923020|NCT02465333|Other|Pathway B|"Screening visit followed by:~Study visit 1 (6 months) Study Visit 2 (12 months) Crossover to Pathway A~Heel fat grafting procedure and local anesthetic and visits at:~1 week Post op study visit 2 (1 month post procedure) Post op study visit 3 (2 month post procedure) Post op study visit 4 (6 month post procedure) Post op study visit 5 (12 month post procedure)"
88923021|NCT02438202|Experimental|Electroconvulsive Therapy (ECT)|A modified Electroconvulsive Therapy Series in Patients with Alzheimer's Disease. Device for the intervention ECT will be the Thymatron IV device (Somatics, LLC. Lake Bluff, Illinois, USA).
88923022|NCT02430129|Active Comparator|Total knee arthroplasty/Persona|Total knee arthroplasty with Zimmer Persona posterior cruciate retaining prosthesis (Zimmer, Warsaw, IN)
88923023|NCT02430129|Experimental|Unicompartment knee arthroplasty/Oxford|Unicompartmental knee arthroplasty with Biomet Oxford mobile-bearing unicompartmental knee prosthesis (Biomet, Warsaw, IN)
88923024|NCT02340676|Experimental|ECP plus IL-2|"Extracorporeal Photopheresis (ECP) standard-of-care~Daily subcutaneous (SC) interleukin-2 (IL-2) (Proleukin®) during predetermined weeks of treatment cycle"
88923025|NCT02262117|Placebo Comparator|standard care|No specific treatment (standard care)
88923026|NCT02262117|Experimental|specific treatment|As a deregulation has been diagnosed by immune analysis, a personalization of the medical care for this IVF/ICSI attempt will be dispensed Personalization of treatment should follow a step-to step decision tree.
89438235|NCT05612698|Experimental|High Intensive Interval Training intervention|High Intensive Interval Training intervention (HIIT): To be considered high intensive the heart rate needs to be above ≥85%. Perform 25 minutes/day, 3 days/week, totalling 75 min/week at a vigorous intensity, as recommended by WHO.
89438236|NCT05612698|No Intervention|Control|Participants in the control group will receive written standard PA recommendations in this phase.
89438237|NCT05612620||RPL|Samples from the vagina, fornix and cervical canal and rectum will be taken by introducing a flocked nylon swab to the vagina via a speculum and circular swabbing for 5-10 seconds before using any antiseptics.
89438238|NCT05612620||Healthy|Samples from the vagina, fornix and cervical canal and rectum will be taken by introducing a flocked nylon swab to the vagina via a speculum and circular swabbing for 5-10 seconds before using any antiseptics.
89438239|NCT02122809|Experimental|Chiauranib|Patients take a single dose of Chiauranib capsules for the pharmacokinetic study,then off for 5 days before the first cycle begins. In the subsequent treatment cycles, Chiauranib capsules are given orally once daily, 28 days as a cycle.
89438240|NCT02124837|No Intervention|Control group|Participants continue their normal lunch routine.
89438241|NCT02124837|Experimental|Relaxation exercise during lunch break|Participants perform relaxation exercises during each lunch break during work for a period of 2 working weeks.
89438242|NCT02124837|Experimental|Park walk during lunch break|Participants go for a walk in the closest park nearby each lunch break during work for a period of 2 working weeks.
88923027|NCT02213003|Experimental|Islet transplantation|Transplantation of at least 5000 islet equivalents/kg of body weight onto the omentum.
88923028|NCT02206230|Experimental|Hypofractionated radiation therapy|Hypofractionated radiation therapy of 60 Gy in 20 fractions (3 Gy per fraction) with concurrent temozolomide 75 mg/m2 given 7 days/week. After a 4-week break, temozolomide days 1-5 every 28 days for 6-12 cycles(as per institutional standard)..
89438243|NCT03552081|Experimental|fragmented DNA evaluation in blood and semen samples|20 men followed for smoking cessation will be included in the study in order to evaluate the time required for the repair of the sperm abnormalities and in particular the DNA of the gametes generated by the smoking
89438244|NCT00150618|Experimental|SPD503 (Guanfacine HCl) (1 mg)|
89438245|NCT00150618|Experimental|SPD503 (2 mg)|
89438246|NCT00150618|Experimental|SPD503 (3 mg)|
89438247|NCT00150618|Experimental|SPD503 (4 mg)|
89438248|NCT00150618|Placebo Comparator|Placebo|
89438249|NCT02124915||Transtibial amputees|
89438250|NCT05610904|No Intervention|Surgeon evaluation|
89438251|NCT05610904|Experimental|Surgeon combining with model evaluation|
89438252|NCT02124993||Sleeve gastrectomy surgery Participants|Male or female who will undergo a sleeve gastrectomy for obesity by Dr. Drake Bellanger.
88923029|NCT02206230|Active Comparator|Standard radiation therapy|Standard radiation therapy of 60 Gy in 30 fractions (2 Gy per fraction) with concurrent temozolomide 75 mg/m2 given 7 days/week. After a 4-week break, temozolomide days 1-5 every 28 days for 6-12 cycles(as per institutional standard)..
88923030|NCT02188381||Normal controls without hypertension|Control subjects will have a systolic BP <140mmHg with no cardiovascular disease. These subjects will provide a one time stool sample and a blood sample.
89438253|NCT02128815|Experimental|Coaching|diabetes health coaching + usual diabetes self-management education
89438254|NCT02128815|No Intervention|Usual Care|Usual care or self-management education
88923031|NCT02188381||Controlled hypertension|Subjects with controlled hypertension will provide a one time stool sample and a blood sample.
88923032|NCT02188381||Resistant hypertension|Resistant hypertension subjects will have systolic blood pressure (BP) ≥140 mmHg despite ≥3 anti-hypertensive medications of different classes. These subjects will provide a one time stool sample and a blood sample.
88923033|NCT02188381||Prior enrolled in NCT 02133872|These subject will be asked to provide two stool samples and two blood samples. One at baseline and one after 3 months of therapy.
88923034|NCT02188381||Remodeled Resistent Hypertension|Subjects with controlled hypertension will provide a one time stool sample and a blood sample.
88923035|NCT02150902|Experimental|Augmented- WACA|Augmented- wide area circumferential catheter ablation for atrial fibrillation
88923036|NCT02150902|Active Comparator|WACA|Wide area circumferential catheter ablation procedure for atrial fibrillation
88923037|NCT02128152|Experimental|Ekso Training Safety and Efficacy|
88923038|NCT02116335|Experimental|Bosentan|Sub-Chronic (3 days) Bosentan 250mg/day.
89438255|NCT03532464|Experimental|Patient treated by doxycycline|"The patients in the doxycycline group take one tablet of 100 mg twice a day for seven days.~Antibiotics will be dispensed in their usual packaging with a clinical trial label."
88923039|NCT02116335|Placebo Comparator|Placebo|Stress response and endothelial function will be determined following a three day treatment of placebo
88923040|NCT01999361|Experimental|Myfortic treatment|Treatment with Myfortic
88923041|NCT01937468|Experimental|Treg-enriched infusion plus 8-week low-dose Interleukin-2|Treg-enriched Cell Dose: Participants will be targeted to a defined dose of donor Treg-enriched total nucleated cells. Initial enrollment will be at target dose-level A. Subsequent cohorts will be dose escalated/de-escalated per the schema. Interleukin-2: Starting the day of Treg-enriched cell infusion, each participant will receive daily subcutaneous IL-2 for self-administration for 8 weeks, followed by a 4-week hiatus. IL-2 will be administered on an outpatient basis. Expected toxicities and potential risks as well as dose modifications are described in Section 6 (Expected Toxicities and Dosing Delays/Dose Modification).
88923042|NCT01932125|Experimental|Cohort|
89438256|NCT03532464|Active Comparator|Patients treated by azithromycin|"The patients in the azithromycin group take 4 tablets of 250 mg in the morning as a single dose.~Antibiotics will be dispensed in their usual packaging with a clinical trial label."
89438257|NCT02128893|Experimental|Isavuconazole alone|Isavuconazole three times a day on Days 1 and 2 and once a day on Days 3, 4, and 5
88923043|NCT01922076|Experimental|Treatment (adavosertib, radiation therapy)|Patients undergo radiation therapy 5 days a week for 6 weeks (up to 30 fractions). Patients also receive adavosertib PO on days 1-5 of weeks 1, 3, and 5; days 1-5 of weeks 1, 3, and 5 AND days 1, 3, and 5 of weeks 2, 4, and 6; OR days 1-5 of weeks 1-6 depending on dose level assignment. Treatment continues in the absence of disease progression or unacceptable toxicity.
88923044|NCT01913275|Active Comparator|endoscopic stenting|endoscopic stenting to reduce preoperative jaundice
88923045|NCT01913275|Active Comparator|cholecystojejunostomy|surgical procedure to decrease preoperative jaundice
88923046|NCT01868269|Other|Dexamethasone Cyclophosphamide Rituximab|
89438258|NCT02128893|Experimental|Isavuconazole and Esomeprazole|Esomeprazole daily for 10 days starting on Day 1 and isavuconazole three times a day on Days 6 and 7 and once a day on Days 8, 9, and 10
89438259|NCT02124369|Other|Abraxane & gemictabine|Abraxane, IV, 125mg/m2 and gemcitabine, IV, 1000mg/m2, on days 1,8 & 15 per 28 day cycle, up to a maximum of 6 cycles.
89438260|NCT05555602|No Intervention|Control group: CO2 fractional laser alone|This group of patients is the treatment control group. During the treatment period, the cold-air cooling device Cryo 6 will be placed next to the laser equipment but not started. The air outlet position is about 3 to 7 centimeters away from the skin, and it will move slowly and synchronously according to the laser position. The skin temperature will be synchronously monitored and recorded by hand-held infrared thermometry. After the operation, the investigators use hospital's routine aftercare procedures, and continue to use hand-held infrared thermometry to synchronously monitor the skin temperature.
89438261|NCT05555602|Experimental|Combination group: CO2 fractional laser combined with Cryo 6|During the CO2 fractional laser treatment, cool the skin with cold-air cooling device Cryo 6. Set the wind to level 5, and the maximum time to 30 minutes. The air outlet position is about 3 to 7 centimeters away from the skin, and it will move slowly and synchronously according to the laser position. The skin temperature will be synchronously monitored by hand-held infrared thermometry and maintained at 0°C to 5°C. After the operation, the investigators use hospital's routine aftercare procedures and cooling with Cryo 6 on the skin synchronously. The wind level can be selected by patients themselves from level 3 to 7, and the time can be set for 5 minutes. Put the air outlet about 3 to 7 centimeters away from the skin, and move it slowly and dynamically in this area of skin to monitor and record the skin temperature synchronously.
89438262|NCT05725356|Experimental|Experimental|Receiving physical exercise treatment (basic body awareness therapy and neck-specific training exercises) and ergonomic modification
89438263|NCT05725356|Other|Control|Receiving ergonomic modification only
89438264|NCT05299905|Experimental|Semi-CAVE|
89438265|NCT05299905|Experimental|Head-mounted display system|
89438266|NCT02128971|Active Comparator|Ferrochel® 90 mg|Ferrochel® capsule 90 mg OD for 30 days
89438267|NCT02128971|Active Comparator|Sumalate® 90 mg|Sumalate® capsule 90 mg OD for 30 days
89438268|NCT02128971|Active Comparator|Ferrous Fumarate 90 mg|Ferrous Fumarate capsule 90 mg OD for 30 days
89438269|NCT02128971|Active Comparator|Ferrous Sulfate 90 mg|Ferrous Sulfate capsule 90 mg OD for 30 days
89438270|NCT02128971|Active Comparator|Ferric glycinate 90 mg|Ferric glycinate capsule 90 mg OD for 30 days
89438271|NCT02128971|Active Comparator|Placebo|Placebo capsule OD for 30 days
88923047|NCT01742299|Experimental|imatinib mesylate|The starting dose of imatinib should be the same as the last dose that was given in the parent imatinib study (400 mg/day to 600 mg/day). After this, the dose of imatinib is based on the investigator's judgment.
89438272|NCT05555446|Experimental|Bovine colostrum|Participant will receive 18g of bovine colostrum with apple sauce and 1g of gluten.
89438273|NCT05555446|Placebo Comparator|Placebo|Participant will receive 18g of placebo with apple sauce and 1g of gluten.
89438274|NCT02288208|Experimental|Antiviral Therapy & Birinapant|Antiviral therapy (tenofovir 300 mg or entecavir 0.5 mg) taken once daily by mouth, and birinapant administered as a 30 minute IV infusion once weekly for four weeks.
89438275|NCT02288208|Placebo Comparator|Antiviral Therapy & Placebo|Antiviral therapy (tenofovir 300 mg or entecavir 0.5 mg) taken once daily by mouth, and placebo (for birinapant) administered as a 30 minute infusion once weekly for four weeks.
89501611|NCT04907071|Experimental|Malperfusion Secondary Cohort:|"Patients who develop new clinical signs or laboratory results indicating distal malperfusion after proximal repair of the AAD is complete and proximal blood flow is redirected into the true lumen.~New Clinical signs include: Loss of femoral pulses, distended abdomen, reduced urine output, dusky extremities~New Laboratory signs include: Rising lactate (>50% above baseline), Rising Creatinine, Metabolic Acidosis, Rising LFTs"
88923048|NCT01687608|Experimental|AskBio009 Dose Escalation|Single Dose of a Self-Complementing Optimized Adeno-associated Virus (AAV) Serotype 8 Factor IX Gene Therapy
88923049|NCT01684397|Experimental|Treatment (pazopanib hydrochloride and bevacizumab)|Patients receive pazopanib hydrochloride PO on days 1-28 and bevacizumab IV over 30-90 minutes on days 36 and 50. Courses repeat every 70 days in the absence of disease progression or unacceptable toxicity.
88923050|NCT01680549|Active Comparator|Gabapentin|Gabapentin 600mg PO pre-operatively and continued postoperatively 300 mg PO q8 hours x 3 days.
88923051|NCT01680549|Placebo Comparator|Placebo|Placebo 600 mg po preoperatively and continued postoperatively 300 mg po q8hours X 3 days
88923052|NCT01661400|No Intervention|Control|No intervention
88923053|NCT01661400|Experimental|Metronomic Cyclophosphamide|Cyclophosphamide will be given PO once daily at 2.5 mg/kg/day for children < 40kg or 100 mg daily for children > 40kg beginning Day + 30 (30 days post transplant) and continue until at least Day +86
88923054|NCT01661400|Experimental|Thalidomide|Thalidomide will be initiated at 3mg/kg PO daily beginning Day + 30 (30 days post transplant) and continue until Day +86
88923055|NCT01515462|Experimental|OTL-103 gene therapy|Eligible subjects will receive intravenous (IV) infusion of OTL-103 gene therapy. Subjects affected by WAS who don't have a suitable matched donor for allogenic hematopoietic stem cell transplantation will be included
88923056|NCT01366092|Experimental|Interleukin-2|Each study participant will receive daily subcutaneous IL-2 (1 x 106 IU/m2/day) for self-administration for 12 weeks, followed by a 4-week hiatus. IL-2 will be typically administered on an outpatient basis. After completing the 16 week study (12 weeks of IL-2 study treatment and a mandatory 4 weeks off-IL-2), patients experiencing clinical benefit (complete or partial response; as well as minor response not meeting NIH criteria for partial response) with an acceptable toxicity profile will be permitted to continue extended-duration treatment indefinitely at the discretion of the treating physician.
89501612|NCT04907071|Experimental|No Malperfusion Cohort|Patients presenting with AAD with no evidence of malperfusion syndrome preoperatively and postoperatively.
89501613|NCT05744505|Experimental|Laser group|Every 3 weeks, a fixed 1 / 2 of the alopecia area was treated with a 1565-nm non-ablative fractional laser.
89501614|NCT05744505|Placebo Comparator|control group|There was no treatment for the other half of the alopecia area in the patients.
88923057|NCT01351870|Active Comparator|Standard Fractionation Regimen|"1.8 Gy daily, 5 fractions per week~Cranio-spinal axis:~23.4 Gy in 13 fractions of 1.8 Gy~Posterior fossa:~30.6 Gy in 17 fractions of 1.8 Gy"
88923058|NCT01351870|Experimental|Hyperfractionated radiotherapy|"1 Gy b.d. (minimum interval between fractions 8 hours). 10 fractions per week~Craniospinal axis:~36 Gy in 36 fractions of 1 Gy~Posterior fossa:~24 Gy in 24 fractions of 1 Gy~Tumour Bed:~8 Gy in 8 fractions of 1 Gy"
88923059|NCT01350908|Other|Blood sampling|
88923060|NCT01334008|Other|Blood sampling|
88923061|NCT01316250|Other|Nilotinib, cytogenetic response|Newly diagnosed CML patients
88923062|NCT01192555|Experimental|Treatment Plan|Neuroblastoma Vaccine (unmodified SKNLP, with gene-modified SJNB-JF-IL2 and SJNB-JF-LTN neuroblastoma cells) and Cytoxan (Cyclophosphamide)
88923063|NCT01167270|Active Comparator|Parenting Insight|Educational program contains messages to provide developmentally appropriate guidance to parents of infants on responsive parenting and healthy lifestyle that will prevent rapid weight gain in infancy and overweight at age 3 years.
89438276|NCT05700682||Diagnostic|The investigators will target VA patients with clinically-ordered knee, hip and shoulder MRIs for recruitment (40 for each joint). Patients who elect to participate will undergo perfusion MRI add-on sequence at the end of their clinical MRI. Arterial-phase maximum intensity projection images from the perfusion MR data will be generated, and the presence of abnormal vascularity about each joint will be assessed by the study principal investigators. Participants who have focal or generalized peri-articular hypervascularity will be offered enrollment in the Therapeutic Arm of the study. Those participants who decline enrollment into the Therapeutic Arm, and those without significant peri-articular vascularity on perfusion MRI, will be asked to return for follow-up clinical and imaging visits so that the natural history of pain/imaging parameters in the absence of treatment can be evaluated.
89438277|NCT05700682||Therapeutic|"Of 40 participants enrolled for each joint, the investigators anticipate 20 will choose to enroll in an embolization pilot study. Participants must have peri-articular hypervascularity on perfusion MRI and must have failed at least one first line therapy for their pain to be eligible.~Embolization will be performed as an outpatient procedure under conscious sedation. Further description of this procedure is available in the study protocol and literature. Technical success will be defined as selective embolization of at least one abnormal peri-articular artery.~After embolization, participants will return for clinical follow-up at 1, 3, 6 and 12 months with perfusion MRI performed at the 3- and 12-month visits. Clinical follow-up at 3, 6 and 12 months will consist only of surveys (WOMAC/WORC). Participants will be instructed to avoid additional treatments for their joint pain when possible, and if a second treatment is initiated to report it to the study investigators."
89438278|NCT03550833||Rheumatoid Arthritis patients|patients affected by RA according to ACR/EULAR 2010 criteria, with a disease duration less than 2 years
88923064|NCT01167270|Placebo Comparator|Child Safety Insights|A child safety intervention with messages focused on the infant's environment and interactions with parents. They will be guided by the AAP guidelines and the Academy's guide for health supervision, Bright Futures
88923065|NCT01112813|Experimental|Lithium|Lithium Carbonate, 0.4-0.8 mmol/L for 2 months
88923066|NCT01049347|Active Comparator|amitriptyline|
88923067|NCT01049347|Active Comparator|paroxetine|
88923068|NCT00703222|Experimental|Dose Level 1|SNJB-JF-IL2 and SJNB-JF-Lptn + Dose Level 1 SKNLP
88923069|NCT00703222|Experimental|Dose Level 2|SNJB-JF-IL2 and SJNB-JF-Lptn + Dose Level 2 SKNLP
88923070|NCT00390026|Experimental|Avastin|
88923071|NCT00390026|Active Comparator|Visudyne|
88923072|NCT00320086||diabetes group|6 to 18 years old males and females, with confirmed diagnosis of Type I or Type II Diabetes with no history of: kidney disease, documented urinary tract infection, cardiovascular disease, liver disease, nocturnal enuresis, metabolic disease other that diabetes, abnormal body temperature at start of study visit, no strenuous exercise 24 hours prior to start of study visit.
88923073|NCT00320086||control group|6 to 18 years old males and females, with no history of: Type I or Type II Diabetes and/or other metabolic disease, kidney disease, documented urinary tract infection, cardiovascular disease, liver disease, nocturnal enuresis, abnormal body temperature at start of study visit, no strenuous exercise 24 hours prior to start of study visit.
88923074|NCT00306098|Experimental|Islet transplantation|
88923075|NCT00099086|Experimental|Experimental Arm|
88923076|NCT00083512||1/Glioblastoma multiforme patients|Patients with histologically confirmed supratentorial Glioblastoma multiforme
88923077|NCT00005398||1; no experimental groups in this study|Observational cohort study
88923078|NCT05356741|Experimental|Part 1 (dose escalation)|Participants will receive single-agent AMX-818
88923079|NCT05356741|Experimental|Part 2 (dose escalation)|Participants will receive AMX-818 plus pembrolizumab
88923080|NCT05356741|Experimental|Part 3 (dose expansion)|Participants will receive single-agent AMX-818
89438279|NCT03550833||control patients|patients with a visceral surgery for less than 2 years (appendectomy, cholecystectomy, bowel obstruction, hernia, eventration…)
89438280|NCT02129049|Experimental|Supportive care (Enhancing Connections Telephone Program)|See Detailed Description.
89438281|NCT02125071||Hepabig|Those who receiving I.V. Hepabig injection used for prevention of hepatitis B relapse after liver transplantation
89438282|NCT02288286|Experimental|2.5IU/ml in humans aged 10-20 years old|freeze-dried rabies vaccines(MRC-5 cell) of 2.5IU/ml in 200 humans aged 10-20 years old on days 0,3,7,14,28
89438283|NCT02288286|Experimental|2.5IU/ml in humans aged 21-50|freeze-dried rabies vaccines(MRC-5 cell) of 2.5IU/ml in 200 humans aged 21-50 years old on days 0,3,7,14,28
89438284|NCT02288286|Experimental|2.5IU/ml in humans aged 51-60|freeze-dried rabies vaccines(MRC-5 cell) of 2.5IU/ml in 200 humans aged 51-60 years old on days 0,3,7,14,28
88923081|NCT05356741|Experimental|Part 4 (dose expansion|Participants will receive AMX-818 plus pembrolizumab
88923082|NCT05337943|Experimental|Cognitive Behavioral Therapy-Insomnia (CBT-I)|CBT-I treatment will receive 1 session every week, for 8 weeks (8 total sessions). The CBT-I sessions will be provided by a pool of clinical PhD psychology students by a trained professional. Each visit will be conducted via telehealth. Sessions will include discussions regarding such topics as sleep restriction, stimulus control and sleep hygiene. Review of sleep diaries will occur during the sessions.
89438285|NCT02288286|Placebo Comparator|2.5IU/ml in humans(from 10-20 years old)|freeze-dried rabies vaccines(vero cell) of 2.5IU/ml in 200 humans aged 10-20 years old on days 0,3,7,14,28
89438286|NCT02288286|Placebo Comparator|2.5IU/ml in humans(from 21-50 years old)|freeze-dried rabies vaccines(vero cell) of 2.5IU/ml in 200 humans aged 21-50 years old on days 0,3,7,14,28
89438287|NCT02288286|Placebo Comparator|2.5IU/ml in humans(from 51-60 years old)|freeze-dried rabies vaccines(vero cell) of 2.5IU/ml in 200 humans aged 51-60 years old on days 0,3,7,14,28
89438288|NCT02251977|Experimental|Adjuvant Chemotherapy plus GM1|Patients will receive mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin) or XELOX (capecitabine and oxaliplatin) for adjuvant chemotherapy. While GM1 will be delivered to patients through the day before the initiation of chemotherapy (Day0) to the completion of chemotherapy (Day4), and the dosages of GM1 for patients who receive mFOLFOX6 or XELOX are 80mg or 120mg per day.
89438289|NCT02251977|Placebo Comparator|Adjuvant Chemotherapy plus placebo|Patients will receive mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin) or XELOX (capecitabine and oxaliplatin) for adjuvant chemotherapy. While placebo will be delivered to patients through the day before the initiation of chemotherapy (Day0) to the completion of chemotherapy (Day4).
89438290|NCT03528954|Active Comparator|Propofol|Received intravenous 0.5mg/kg propofol
88923083|NCT05337943|Experimental|Bright Light Therapy|Bright Light treatment will consist of 8 weeks of daily use of the Re-timer device. The Re-timer is worn like a pair of glasses and contains light emitting diodes mounted on the lower portion of the frame. The Re-timer emits blue-green 500 nm light with an intensity of ~500 lux lm/m2. Subjects will be instructed to use the device for 30 minutes within two hours of waking, in the morning on the full brightness setting.
88923084|NCT05337943|No Intervention|Standard Care|Subjects will continue the care they routinely receive.
88923085|NCT05333822|Experimental|Bashan|a vegetable plant based compound drink add after three meals for 14 days
88923086|NCT05333822|Placebo Comparator|Water|water as placebo
88923087|NCT05332535|Experimental|Serious game web aplication|Nursing students played the serious game for two weeks.
88923088|NCT05332535|No Intervention|Control grup|
88923089|NCT05325671|Experimental|transarticular multimodal drug infiltration|infiltration the mixture into intraarticular by catheter guided approach
88923090|NCT05325671|Active Comparator|periarticular multimodal drug infiltration|"3 location of infiltration~hip capsule~gluteus medius and short external rotator~gluteus maximus"
88923091|NCT05321316|Experimental|68Ga-N188|Imaging cohort All study participants will be allocated to this arm (single-arm study). Study participants will undergo 68Ga-N188 PET/CT scan.
88923092|NCT05316116|Experimental|Siltuximab|Siltuximab will be given every 3 weeks, for between 18 and 36 weeks
88923093|NCT05314517|Experimental|Treatment Arm 1|Namilumab
88923094|NCT05314517|Placebo Comparator|Treatment Arm 2|Placebo
88923095|NCT05313321||Primary total hip arthroplasty receiving the Insignia Stem|Patients undergoing primary total hip arthroplasty that will likely receive the Insignia Stem and associated Stryker Acetabular Component.
88923096|NCT05308654|Experimental|Part 1: Monotherapy Dose Escalation|Participants with relapsed or refractory (R/R) multiple myeloma (MM) will receive escalating doses of ABBV-453, until the maximum tolerated dose (MTD) is determined.
88923097|NCT05308654|Experimental|Part 2: Arm 1|Participants will receive continuous doses of ABBV-453 in combination with dexamethasone in 28-day cycles.
89199310|NCT05847348|Experimental|Treatment (68Ga-PSMA-11)|"111 ~ 259 MBq 68Ga-PSMA-11 will be administered intravenously to participants over 3- 5 minutes.~After 50-100 minutes post 68Ga-PSMA-11 injection, participants will be scanned (PET/CT or PET/MRI) from the mid-thigh to the apex of the skull. Participants will be placed in a supine position with the arms raised overhead."
89438291|NCT03528954|No Intervention|Control|Do not received intravenous 0.5 mg/kg propofol
88923098|NCT05308654|Experimental|Part 2: Arm 2|Participants will receive continuous doses of ABBV-453 in combination with daratumumab and dexamethasone in 28-day cycles.
88923099|NCT05308654|Experimental|Part 2: Arm 3|Participants will receive continuous doses of ABBV-453 in combination with daratumumab, lenalidomide, and dexamethasone in 28-day cycles.
88923100|NCT05308654|Experimental|Japan Cohort|Participants with R/R MM will receive escalating doses of ABBV-453, until the MTD is determined.
88923101|NCT05304078|Experimental|TASK III Group|The Telehealth Assessment and Skill-Building Kit (TASK III) group
88923102|NCT05304078|Active Comparator|ISR Group|The Information, Support, and Referral (ISR) group
88923103|NCT05301283|Experimental|Treatment|"Participants will receive pretreatment diagnostic MRIs to generate MRI habitats (images of tumor regions/subregions in different sequences). These images will identify radioresistant cells within the tumor to allow for more precise and higher doses of radiation to the resistant cells.~Participants will then be treated with neoadjuvant external beam radiation by using the intensity modulated radiation (IMRT) technique, with dose painting (simultaneous integrated boost/SIB) to 70 Gray Units (Gy), 60 Gy, and 50 Gy in 25 fractions for habitats 1, 2, and 3, respectively."
88923104|NCT05299554|Experimental|Chronocort (hydrocortisone modified-release capsule)|Chronocort (hydrocortisone modified-release capsules) supplied as 5 mg and 10 mg per capsule for oral administration.
88923105|NCT05295771|Experimental|Test arm|Geistlich Fibro-Gide ®.
88923106|NCT05295771|Active Comparator|Control|Autogenous Connective Tissue Graft.
88923107|NCT05284552|Experimental|Intervention Arm|Drug: Tinzaparin (Innohep®), solution for injection. Administration form: Subcutaneous injection. Dosage: 4500 IU (for subjects weighing below 90 kg) or 8000 IU (for subjects weighing 90 kg and above) daily for 21-28 weeks.
89011772|NCT04708977|Active Comparator|Group 2: Direct Decompression|Lateral lumbar interbody fusion (LLIF), with direct decompression
89438292|NCT02252055|Experimental|ATDC Treatment|"ATDC treatment (1 x 106 cells/kg BW slow peripheral venous) occurs the day before transplantation.~Recipients also receive prednisolone, Mycophenolate Mofetil and tacrolimus, as detailed below :~Prednidolone :~D 0: 500 mg IV~D 1: 125 mg IV~D 2 to 14: 20.0 mg/d~Wk 3 to 4: 15.0 mg/d~Wk 5 to 8: 10.0 mg/d~Wk 9 to 12: 5.0 mg/d~Wk 13 to 14: 2.5 mg/d~Wk 15 to End:Cessation~MMF (or biologic equiv.):~D -7 to -2: 500 mg/d (250mg 2x/d)~D -1 to 14: 2000 mg/d~Wk 3 to 36: 1000 mg/d~Wk 37 to 40: 750 mg/d~Wk 41 to 44: 500 mg/d~Wk 45 to 48: 250 mg/d~Wk 49 to End:Cessation Note : MMF tapering will only happen if the 36-week protocol biopsy shows no signs of subclinical rejection and there is evidence of declining renal function or if the clinician has any other concern about MMF dose reduction.~Tacrolimus :~≤ 48 h pre-Tx to D 14: 3-12 ng/ml~Wk 3 to 12: 3-10 ng/ml~Wk 13 to 36: 3-8 ng/ml~Wk 37 to End: 3-6 ng/ml"
89438293|NCT03532386||Study group|Infertile men with oligoasthenospermia with non-tense vaginal hydrocele subjected to ICSI
89011773|NCT05140486|Experimental|Shortwave diathermy and perceptual training|The subjects in this group will receive shortwave diathermy 5 days per week for 4 weeks and perceptual training 5 days per week for 10 weeks after endoscopic optic nerve decompression surgery.
89011774|NCT05140486|No Intervention|Nonrehabilitation|The subjects in the nonrehabilitation group will not only receive any rehabilitation therapy after endoscopic optic nerve decompression surgery.
89011775|NCT05140447|Active Comparator|Admira 50º C|in this subgroup the patient's teeth was restored with Admira fusion extra resin composite preheated to 50º C
89011776|NCT05140447|Active Comparator|Admira 70º C|in this subgroup the patient's teeth was restored with Admira fusion extra resin composite preheated to 70º C
89199311|NCT05843383|Experimental|Ciprofol group|Ciprofol-based total intravenous anesthesia is given for maintenance of general anesthesia
89438294|NCT03532386||Control group|infertile men with oligoasthenospermia without hydrocele subjected to ICSI
89438295|NCT02131077|Experimental|treatment|ALLO-ASC-TI injection
89438296|NCT02131077|Placebo Comparator|Placebo|Saline injection
89438297|NCT05612464||Primary dystonia group (genetic or idiopathic)|
89438298|NCT05612464||Dystonic cerebral palsy group|
89438299|NCT05612464||Control group|
89438300|NCT02288442|No Intervention|control|
89438301|NCT02288442|Experimental|exercise|exercise intervention during 8 weeks
89438302|NCT02125227|Experimental|Group 1 of Study A|single dosing of Rosuvastatin and Metformin 14 days later, single dosing of YH14755
89199312|NCT05843383|Experimental|Propofol group|Propofol-based total intravenous anesthesia is given for maintenance of general anesthesia
89199313|NCT05842668|Experimental|ESWL Group|
89438303|NCT02125227|Experimental|Group 2 of Study A|single dosing of YH14755 14 days later, single dosing of Rosuvastatin and Metformin
89438304|NCT02125227|Experimental|Group 1 of Study B|single dosing of YH14755 with fasting state 14 days later, single dosing of YH14755 after having breakfast
89011777|NCT05140447|Active Comparator|Viscalor 50º C|in this subgroup the patient's teeth was restored with Viscalor resin composite preheated to 50º C
89011778|NCT05140447|Active Comparator|Viscalor 70º C|in this subgroup the patient's teeth was restored with Viscalor resin composite preheated to 70º C
89011779|NCT01688713|Experimental|Icotinib,Brain metastases|
89011780|NCT01688752||Sibling Controls|Healthy siblings of acute lymphoblastic leukemia (ALL) subjects frequency matched by age and sex.
89438305|NCT02125227|Experimental|Group 2 of Study B|single dosing of YH14755 after having breakfast 14 days later, single dosing of YH14755 with fasting state
89438306|NCT03532230||Experimental Group|90 new patients seeking treatment for chronic low back pain. This group will receive standard care plus osteopathic manipulative treatment (OMT) for low back pain.
89438307|NCT03532230||Control Group|90 new patients seeking treatment for chronic low back pain. This group will receive only standard care without osteopathic manipulative treatment (OMT) for low back pain.
89438308|NCT02129127|Experimental|Drug Coated Chocolate|Paclitaxel Coated Chocolate Balloon Angioplasty
89438309|NCT05555134|No Intervention|CONTROL|receive usual care
89438310|NCT05555134|Experimental|EXPERIMENTAL|receive the educational intervention, along with usual care
89438311|NCT03532152|Active Comparator|Pure Purr VR technology|"The arm will use the virtual reality headset reproduces a dynamic video content that is visually perceived with the help of the high-resolution screen.~The total length of the audio-video sequence is 6 minutes 11 seconds, of which 1 minute 11 seconds is the Pure Purr promotional video, and the duration of the investigational audio-visual sequence itself is 5 minutes."
89501615|NCT04589767||children admitted in PICU|children enrolled will be evaluated by two nurses using CAPD Italian version. One nurse will repeat the evaluation two minutes later.
89501616|NCT02151539||Observational (medical chart review)|Study data are collected and managed using REDCap tools at baseline and on days 5, 28, and 56.
89501617|NCT03743909||patients with aberrant CD markers|by flowcytometry from hospital information system
89438312|NCT03532152|Sham Comparator|Sham VR technology|"The arm will use the headset with audio-visual sequence is similar to the one in the investigational version of the software. The key difference is that the audio sequence has not been modified with the binaural effect and has not been synchronized with the tact of respiratory movements and the frequency of heart rate.~The total length of the audio-video sequence is 6 minutes 11 seconds, of which 1 minute 11 seconds is the Pure Purr promotional video, and the duration of the investigational audio-visual sequence itself is 5 minutes."
88923108|NCT05284552|No Intervention|Control Arm|
88923109|NCT05282277|Experimental|Perimenopausal women with mild-to-moderate anhedonia + absent-to-mild psychosis, active group|Participants will be randomly assigned to take 100 μg/day of transdermal estradiol for 3 weeks followed by 1 week of combined 100 μg/day of transdermal estradiol and 200 mg/day progesterone.
88923110|NCT05282277|Experimental|Perimenopausal women with mild-to-moderate anhedonia + absent-to-mild psychosis, placebo group|Participants will be randomly assigned to receive a matching placebo patch for 3 weeks.
88923111|NCT05282277|Experimental|Perimenopausal women with mild-to-moderate anhedonia + moderate psychosis, active group|Participants will be randomly assigned to take 100 μg/day of transdermal estradiol for 3 weeks followed by 1 week of combined 100 μg/day of transdermal estradiol and 200 mg/day progesterone.
88923112|NCT05282277|Experimental|Perimenopausal women with mild-to-moderate anhedonia + moderate psychosis, placebo group|Participants will be randomly assigned to receive a matching placebo patch for 3 weeks.
88923113|NCT05282277|Experimental|Perimenopausal women with high anhedonia + absent-to-mild psychosis, active group|Participants will be randomly assigned to take 100 μg/day of transdermal estradiol for 3 weeks followed by 1 week of combined 100 μg/day of transdermal estradiol and 200 mg/day progesterone.
88923114|NCT05282277|Experimental|Perimenopausal women with high anhedonia + absent-to-mild psychosis, placebo group|Participants will be randomly assigned to receive a matching placebo patch for 3 weeks.
88923115|NCT05282277|Experimental|Perimenopausal women with high anhedonia + moderate psychosis, active group|Participants will be randomly assigned to take 100 μg/day of transdermal estradiol for 3 weeks followed by 1 week of combined 100 μg/day of transdermal estradiol and 200 mg/day progesterone.
88923116|NCT05282277|Experimental|Perimenopausal women with high anhedonia + moderate psychosis, placebo group|Participants will be randomly assigned to receive a matching placebo patch for 3 weeks.
88923117|NCT05280821|Active Comparator|Consecutive Day Dosing|This arm will daily receive iron capsules for 3 months, followed by daily placebo capsules for 3 months.
88923118|NCT05280821|Experimental|Alternate Day Dosing|This arm will receive iron capsules alternating with placebo capsules for 6 months.
88923119|NCT05266703|Other|Isotopically labelled iron sulfate 15mg|
88923120|NCT05261633||Healthy Volunteers|
88923121|NCT05261633||Known Liver Metastases|
88923122|NCT05259150|Experimental|Internal Champion (IC) Strategy|In the Planning for Health intervention, the IC implementation strategy will include trainings on transformational leadership principles that address challenges that health leaders face in the church setting to assist them in independently planning the cardiovascular health programming for congregants. Limited assistance from staff will be provided in the Preparing for Health and the Delivery of Health interventions.
89536959|NCT03304301|Experimental|experimental group|Participants will be encouraged to reduce time spent on bed and bedroom. We will also take participants outdoors and expose to sunlight (if the UV index is over 8 according to the forecast of Center Weather Bureau, the participants will be asked to stay inside) five days a week for three months.
89536960|NCT03304301|No Intervention|control group|Participants will receive routine care.
89536961|NCT04490759||Healthy volunteers|Blood samples from healthy volunteers analyzed on the Quantra System
89536962|NCT03306017|Experimental|LAVD implantation|Ten patients before and after LAVD implantation had blood sampling
89536963|NCT03304067|Experimental|Intervention|
89536964|NCT03304067|No Intervention|Control|
89536965|NCT03305939|Experimental|Intervention|Participants randomized in to the intervention group will receive group sessions, monthly phone calls, and telephonic prompts (text/voice recording).
89536966|NCT03305939|No Intervention|Control|Control group participants will be referred to their usual doctor for ongoing management, with no attempt made to influence this. They will not get any part of the intervention but will receive the usual care (if any exists). Any abnormal OGTT results during the follow-up visits will be provided to the patient and their doctor. This is entirely consistent with current usual care.
89536967|NCT03305861|Experimental|ThuLEP|Thulium laser enucleation of prostate
89536968|NCT03305861|Experimental|Green LEP|Greenlight laser enucleation of prostate
89536969|NCT03305705|Experimental|Treatment Arm 1|Patients will be treated with 0.9% sodium chloride (placebo) at Visit 1 and with iron carboxymaltose in 6 weeks at Visit 2. The patients will be blinded with respect to the treatment sequence.
89536970|NCT03305705|Experimental|Treatment Arm 2|Patients will be treated with 0.9% sodium chloride (placebo) at Visit 1 and with iron carboxymaltose in 6 weeks at Visit 2. The patients will be blinded with respect to the treatment sequence.
89536971|NCT04490837||COVID-19 positive|Patients with clinical, radiological and/or PCR positive for COVID-19 infection
89536972|NCT04490837||Normal|Normal human serum from blood donnors before COVID-19 pandemia
89536973|NCT04490837||Pathological controls|Patients with other positive virological serologies
89536974|NCT04491149|Experimental|women using virtual glass during amniocentesis/foeticide|
89536975|NCT04491149|No Intervention|women undergoing amniocentesis/foeticide|
89536976|NCT02468219|Active Comparator|aortic valve replacement|patients with aortic stenosis submitted to aortic valve replacement procedure
89536977|NCT02468219|Experimental|transcatheter aortic valve implantation|patients with aortic stenosis who underwent to transcatheter aortic valve implantation
89536978|NCT03303833||Persons with Lynch syndrome|
89536979|NCT02468141|Experimental|SJDBT group|Herbal medicine
89536980|NCT02468141|Placebo Comparator|Placebo|Placebo control
89536981|NCT03305549|Active Comparator|TIW Dialysis Strategy|Conventional thrice-weekly acute intermittent hemodialysis treatment schedule.
89536982|NCT03305549|Experimental|Conservative Dialysis Strategy|Conservative acute intermittent hemodialysis strategy, in which hemodialysis is not continued unless specific metabolic or clinical indications for RRT are present.
89536983|NCT03305471|Experimental|Part A: DS-2330b PIB, then Tablet|On a non-dialysis day, participants are given a single 250 mg dose of DS-2330b PIB [Treatment A1] right after breakfast. At least 3 days will be allowed to let the first dose wash out. Then on a non-dialysis day the participants are given a single 250 mg dose of DS-2330b in tablet form [Treatment A2] right after breakfast.
89536984|NCT03305471|Experimental|Part A: DS-2330b Tablet, then PIB|On a non-dialysis day, participants are given a single 250 mg dose of DS-2330b in tablet form [Treatment A2] right after breakfast. At least 3 days will be allowed to let the first dose wash out. Then on a non-dialysis day the participants are given a single 250 mg dose of DS-2330b PIB [Treatment A1] right after breakfast.
89536985|NCT03305471|Placebo Comparator|Part B: Placebo|Participants are given placebo three times daily [Treatment B1]
89536986|NCT03305471|Experimental|Part B: DS-2330b PIB|Participants are given 400 mg of DS-2330b PIB three times daily [Treatment B2]
89536987|NCT03305471|Experimental|Part B: DS-2330b PIB + Sevelamer|Participants are given 400 mg of DS-2330b PIB along with 1.6 grams of sevelamer three times daily [Treatment B3]
89536988|NCT03305471|Experimental|Part B: Placebo + Sevelamer|Participants are given placebo along with 1.6 grams of sevelamer three times daily [Treatment B4]
89536989|NCT03305471|Experimental|Part C: DS-2330b Tablet + Sevelamer|Participants are given one 250 mg dose of DS-2330b in tablet form along with 1.6 grams of sevelamer three times daily [Treatment C]
89536990|NCT03303677|Active Comparator|Saline|Post operative endoscopic sinus surgery patients using Saline nasal sinus irrigations to be performed twice daily. All patients will begin with normal saline irrigations immediately following surgery as per our department's standard of care. At their first one week post op appointment they will then begin treatment per the treatment arm.
89536991|NCT03303677|Experimental|Saline and budesonide|Post operative endoscopic sinus surgery patients using saline + budesonide nasal sinus irrigations to be performed twice daily. All patients will begin with normal saline irrigations immediately following surgery as per our department's standard of care. At their first one week post op appointment they will then begin treatment per the treatment arm.
89538443|NCT03266549|Experimental|Botulinum toxin augmented surgery group|unilateral recess-resect procedure, or bilateral rectus muscle recession plus intraoperative injection of 2.5 to 5 units of botulinum toxin A into the recessed muscle.
89438313|NCT03550599||patients accessing to Radiotherapy Unit|patients accessing to Radiotherapy Unit for oncologic treatment
89438314|NCT03528876|Other|Single arm intervention study|Biweekly FOLFOX for two cycles alternating with FOLFIRI for two cycles (FOLFOX-FOLFIRI)
89438315|NCT03550755|Experimental|V3-Cervix|Biological: V3-Cervix V3-Cervix is a tableted immunotherapeutic derived from hydrolyzed, heat-inactivated, pooled blood and tumor tissue from women with cervical cancer
89438316|NCT05554900|No Intervention|The control group|The control group received traditional amputation.The proximal nerve is blocked with lidocaine and cut off. The end of the nerve retracted as far as possible and the bleeding point is ligated if necessary.
89438317|NCT05554900|Experimental|The experimental group（RPNIs group）|The experimental group received regenerative peripheral nerve interface（RPNI） surgery.
89438318|NCT02129283|Experimental|Simulation training|End-of-life simulation training of critical care physicians and nurses using standardized patients to improve communication and interpersonal skills.
89438319|NCT02129283|No Intervention|Control|No simulation training
89438320|NCT00264732|Experimental|1|
89438321|NCT00264732|Experimental|2|
89438322|NCT00264732|Placebo Comparator|3|
89438323|NCT05554822|Experimental|Single antiplatelet therapy (SAPT)|"Single antiplatelet therapy composed of aspirin 100 mg OD, organized as follows:~Aspirin-naïve: aspirin 325 mg will be given 12-24 hours before the procedure and continued after the intervention at the dose of 100 mg OD up to 6-month follow-up.~Aspirin-treated: periprocedural aspirin 100 mg OD will be given and continued up to 6-month followup."
89438324|NCT05554822|Active Comparator|Double antiplatelet therapy (DAPT)|"Double antiplatelet therapy composed of aspirin 100 mg OD plus Clopidogrel 75 mg OD, organized as follows:~Aspirin-naïve: aspirin 325 mg will be given 12-24 hours before the procedure and continued after the intervention at the dose of 100 mg OD up to 6-month follow-up. Clopidogrel will be given with a 300 mg loading dose of clopidogrel approximately 12 hours before the procedure and then clopidogrel 75 mg OD will be given from the day of intervention up to 3 months. At 3 months clopidogrel will be stopped.~Aspirin-treated: periprocedural aspirin 100 mg OD will be given and continued up to 6-month followup. Clopidogrel will be given with a 300 mg loading dose of clopidogrel approximately 12 hours before the procedure and then clopidogrel 75 mg OD will be given from the day of intervention up to 3 months. At 3 months clopidogrel will be stopped."
89438325|NCT02125305|Experimental|Metformin|Metformin 750mg(D1), Metformin 500mg(D2)
89438326|NCT02125383|Experimental|Active tDCS|Receives 20 minutes of anodal tDCS three times while sleeping during the night.
89438327|NCT02125383|Sham Comparator|Sham tDCS|Receives 20 minutes of sham tDCS three times while sleeping during the night.
89438328|NCT05554744|Experimental|MEN1-1-related pNETs|The patients with MEN1-1-related pNETs will undergo EUS-FNI with ethanol or lauromacrogol
89438329|NCT02131389|Other|Iconacy Hip System|Iconacy hip system prosthesis components
89438330|NCT04469322|Experimental|Pharmacogenetic Test Guided|Treating physician for this group receives a detailed pharmacogenetic report for the patient, prioritizing 53 psychoactive medications into 4 use categories: preferential use, use as directed, may have significant limitations, and may have severe adverse reactions.
89438331|NCT04469322|Sham Comparator|Treatment As Usual|Treating physician receives a sham report listing the names of all drugs and treats patients according to standard of care.
89438332|NCT04330222||Patients with lacunar stroke due to SVD|
89438333|NCT04330222||Healthy stroke free volunteers|
89438334|NCT04469400|No Intervention|Group1|Researchers conduct health education on patients, including dietary guidance, physical activity guidance, psychological behavior counseling, etc.
89438335|NCT04469400|Experimental|Group2|In addition to education, the subjects will consume 2 composite protein solid drinks per day, in conjunction with the three-meal diet to increase satiety and intake of sufficient nutrients
89438336|NCT04469400|Experimental|Group3|In addition to education, the subjects will consume 2 nutrition bars daily to replace the staple food of daily lunch and dinner to help reduce carbohydrate intake and intake of sufficient nutrients
89438337|NCT02125539|Experimental|Navigating my Journey program|Client participants of counselors who were randomized to the experimental condition will receive the following intervention: The online Navigating my Journey relapse prevention program is an adjunct to outpatient treatment. We will ask client participants to complete at least 12 Navigating my Journey sessions and discuss them with their counselors.
89438338|NCT02125539|Active Comparator|Attention Control|Client participants of counselors who were randomized to the control condition will receive their typical course of counseling and a link to online online health information in PDF form as an attention control.
89438339|NCT05554588|Active Comparator|Intrathrombus thrombolysis|Intrathrombus thrombolysis with microcatheter or pierced bolloon during PPCI
89438340|NCT05554588|Active Comparator|Aspiration thrombectomy|Aspiration thrombectomy during PPCI
89438341|NCT05329324||Study Group - Lipedema|Questionnaire for study group
89438342|NCT05329324||Control Group - Acute Subacromial Impingement|Questionnaire for control group
89501618|NCT03743909||patients without aberrant CD markers|by flowcytometry from hospital information system
89501619|NCT03166137|Experimental|Carbon dioxide laser group|(group A): thirty patients will be treated by application of carbon dioxide laser.
88923123|NCT05259150|Experimental|Expert Professional (EP) Strategy|In the Planning for Health intervention, the EP implementation strategy will include the use of external professionals to assist health leaders in the planning of cardiovascular health programming for congregants. Staff will assist health leaders in the Preparing for Health and the Delivery of Health interventions.
88923124|NCT05259150|Active Comparator|Comparison Group Strategy|In the Planning for Health intervention, the Comparison Group strategy will include process activities with the health leaders (identification of health leaders, meetings of health leaders, assistance of health leaders with recruitment of congregants for research). Except for data collection, participants (health leaders and congregants) will not be involved in the Preparing for Health or the Delivery of Health interventions.
88923125|NCT05254743|Experimental|Pirtobrutinib|Administered orally.
88923126|NCT05254743|Active Comparator|Ibrutinib|Administered orally.
88923127|NCT05251675|Active Comparator|Coaching Group|This arm will receive physician led coaching during the first 6 months of the study.
89199314|NCT05842668|No Intervention|Control Group|
89199315|NCT05836753|Active Comparator|Sarecycline treatment group|The first dose should be given immediately after randomization (within 30 minutes); Take one tablet once a day for 7 days continuously (the patient with dysphagia will be administrated through a nasal feeding tube).
89199316|NCT05836753|Placebo Comparator|Sarecycline placebo control group|The control group received Sarecycline placebo tablets (each containing Sarecycline 0 mg) in the same way as the experimental group.
88923128|NCT05251675|Placebo Comparator|Non-Coached Group|This arm will not receive physician led coaching until after the Coaching Group is finished with their coaching.
89199317|NCT05831280|Experimental|Experimantal Group|In the study, 8 sessions of laughter yoga will be applied to the women in the experimental group twice a week for 4 weeks.
89199318|NCT05831280|No Intervention|Control Group|no intervention will be applied to the control group
89199319|NCT05830123|Experimental|cohort 1 at HS-20093 8mg/kg (Phase 2a)|Participants in cohort 1 will be randomized to receive HS-20093 at 8 mg/kg.
89199320|NCT05830123|Experimental|cohort 1 at HS-20093 12mg/kg (Phase 2a)|Participants in cohort 1 will be randomized to receive HS-20093 at 12 mg/kg.
89199321|NCT05830123|Experimental|cohort 2 at HS-20093 12mg/kg (Phase 2a)|Participants in cohort 2 will receive HS-20093 at 12 mg/kg.
89199322|NCT05830123|Experimental|HS-20093(Phase 2b)|Participants will receive HS-20093 at the recommended dose from Phase 2a.
89199323|NCT05828407||Cohort|"Population:~Critically ill patient with:~cardio circulatory insufficiency as defined by vasopressor requirement and at least one of the following criteria: arterial lactate >2mmol/L ; capillary refill time >3s ; mottling score >1 ; diuresis <0,5mL/h for more than 6hours~diameter of inferior vena cava >20mm~Protocol:~Administration of a fluid challenge (4mL/kg of Ringer Lactate) over 5 to 10 min.~Point of care ultrasound evaluation of portal vein pulsatility index and Vexus criteria before and after the fluid challenge ; fluid challenge induced cardiac index variations estimated by pulse contour analysis"
89199324|NCT05827211|Experimental|Test group|Participants in this group will receive Doxycycline 200 mg 1 h pre-op and 100 mg for 9 days post-op in combination with dental implant therapy.
89199325|NCT05827211|Placebo Comparator|Control group|Participants in this group will receive a placebo 200 mg 1 h pre-op and 100 mg for 9 days post-op in combination with dental implant therapy.
89199326|NCT05822063|Active Comparator|Lidocaine group|the skin site will be prepped first and then two puffs of lidocaine (20 mg) will be sprayed by the researcher from a 5-cm distance on the dermal surface near the needle insertion point. Five minutes after spraying, the skin surface at the site of arterial needle insertion will be disinfected with 70% alcohol-soaked cotton pads and the specific hemodialysis needles will be inserted into the vessels of the fistula area by the ward nurse
89199327|NCT05822063|Active Comparator|cold packs|In the ice pack method, 5 pieces of ice measuring 5*5 will be placed in latex gloves and covered with material cover. They were placed after the passage of 2 min on the hand at the site of fistula 5 min before making the puncture. Next, specific hemodialysis needles will be inserted in the vessels of fistula area by the ward nurse after disinfecting the fistula area with 70% alcohol-soaked cotton pads.
89199328|NCT05822063|Active Comparator|flash lights|the patient's face will be photographed. The photograph will be taken with a camera [(Sony HVLHFL1 with luminance intensity approximately 100 cd, lighting distance approximately 11 Lux, flash shooting distance (1-5 m)].
89199329|NCT05822063|No Intervention|control|no intervention
89199330|NCT05820503|Experimental|R group :Ultrasound-guided lower abdominis rectus sheath block group|Under ultrasound guidance, the probe was transversely placed at the lateral level of the umbilicus . Using the in-plane technique, the needle was advanced until the posterior aspect of the rectus muscle was penetrated. No blood and no gas were drawn back; furthermore, a small volume of saline was initially injected to ensure that the needle tip was correctly positioned. When the needle was located between the posterior rectus muscle and posterior sheath, 5ml of 0.25% ropivacaine was injected bilaterally.
89199331|NCT05820503|No Intervention|Control group|Do nothing with it
89199332|NCT05820503|Experimental|Local anesthesia infiltration Group|Local anesthesia drugs were injected into the peri-umbilicus cord
89199333|NCT05817097||DPP4i|used DPP-4 inhibitors as anti-diabetic drugs before cerebral infarction(requiring thrombolysis or endovascular recanalization) Combination therpay is acceptable.
89199334|NCT05817097||except DPP4i|patients that did not use DPP-4 inhibitors as anti-diabetic drugs before cerebral infarction(requiring thrombolysis or endovascular recanalization)
89199335|NCT05814354|Experimental|SHR-A1811|
89199336|NCT05814354|Active Comparator|Physician's Choice|Capecitabine/Eribulin/Gemcitabine/Paclitaxel/Nab-paclitaxel
89199337|NCT05812222|Experimental|intervention group (skin-to-skin contact group)|"Skin-to-skin contact: It is the laying of the newborn in the prone position on the mother's bare chest area with only a diaper on.~The stress levels of newborns were determined using the Neonatal Stress Scale immediately after birth, under a radiant heater, 5 minutes after SSC administration, and during IM K vit injection while SSC was administered (4 different time periods).~The suction sufficiency of newborns was evaluated by the investigator using the LATCH Breastfeeding Assessment Tool, 5 minutes after the initiation of early SSC immediately after birth, within the first hour after birth in the maternity ward, and 24 hours after birth."
89199338|NCT05812222|No Intervention|control group|"The routine applications of the hospital were applied to the mothers and newborns in the control group.~The stress level of newborns was determined immediately after birth, under a radiant heater, and during IM K vit injection (3 different time periods) using the Neonatal Stress Scale.~The suction sufficiency of newborns within the first hour after birth and 24 hours after birth was evaluated by the researcher using the LATCH Breastfeeding Assessment Tool."
89199339|NCT05796674||Clareon UVA IOL|Eyes that underwent cataract surgery and received a Clareon UVA IOL with the use of the WaveTec Optiwave Refractive Analysis (ORA) System
89199340|NCT05794659|Experimental|AST-301|"AST-201 with rhuGM-CSF (3-week interval, 3 cycles in total)~Standard chemotherapy (paclitaxel/carboplatin) (3-week interval, 6 cycles in total)~* Both AST-201/rhuGM-CSF or Placebo/rhuGM-CSF will be given intradermally 2 weeks after each combination chemotherapy (on Day 15 of each cycle) for 3 cycles"
89199341|NCT05794659|Placebo Comparator|Placebo|"Placebo with rhuGM-CSF (3-week interval, 3 cycles in total)~Standard chemotherapy (paclitaxel/carboplatin) (3-week interval, 6 cycles in total)~*Both AST-201/rhuGM-CSF or Placebo/rhuGM-CSF will be given intradermally 2 weeks after each combination chemotherapy (on Day 15 of each cycle) for 3 cycles"
89438343|NCT05725278|Experimental|Users of Tiko Platform|These participants accessed various services on Tiko platform such as buying contraceptives, visiting doctors for ANC etc. They earned Tiko Miles/Points for such health seeking behaviours which they could then redeem at network of grocery shops, pharmacies, beauty salon etc. Tiko card also enabled them to get discounts at pharmacies and at health care providers. These participants were free to access any other government or private health care facility as free economic agents. Users of Tiko platform were identified by the backend system that recorded all health seeking behaviours / actions, reward point accumulation, and use of those reward points.
89438344|NCT05725278|Active Comparator|Non-Users of Tiko Platform|These participants registered on Tiko platform on basis of recruitment drive and pitch by Pro agents, but they did not access any service and became dormant. However, These participants were free to access any other government or private health care facility and could access fame family planning and ANC products and services. They could even access Tiko network doctors and pharmacies but they would not get any Tiko Miles/Points or discounts without the use of Tiko card. Non Users were identified as those registered women who did not have any record of using services using Tiko card as per the backend system
89438345|NCT00254904|Experimental|A|Standard of Care chemotherapy plus experimental intervention (PF-3512676)
89438346|NCT00254904|Active Comparator|B|Standard of Care chemotherapy
89438347|NCT04329988||Primary care patients aged 18 or more|All patients consulting in a general practitioner office, aged 18 or more, who completed the questionnaire
89438348|NCT05295082|Experimental|guided trephination-based protocol|"The drilling process will be performed by guided trephination protocol.~An appropriate trephine drill (Helmut Zepf Medizintechnik GmbH, Germany) will be used to create an initial osteotomy.~The guide will be removed, and the depth and angulation of this initial osteotomy will be evaluated.~The final drill of the chosen implant system will be used to complete the osteotomy.~The implant (NeoBiotech Implant System, Neobiotech Co. Ltd. Korea) then will be placed freehand in a conventional manner."
89438349|NCT05295082|Active Comparator|guided conventional drilling-based protocol|"The drilling process will be performed by a guided conventional drilling protocol.~Drilling (Neo NaviGuide System - Neobiotech Co. Ltd. Korea) will be performed throughout the guiding sleeve from the first drill to the final drill.~The guide will be removed.~The implant (NeoBiotech Implant System, Neobiotech Co. Ltd. Korea) then will be placed freehand in a conventional manner."
89438350|NCT05725122|Active Comparator|ESWL alone|Extracorporeal shock wave lithotripsy will be given to the patient
89438351|NCT05725122|Active Comparator|ESWL combined with tamsulosin therapy|Extracorporeal shock wave lithotripsy combined with tamsulosin therapy will be given to the patient
89438352|NCT03880396||hypofractionated Rth with weekly cisplatin 40mg/m2|hypofractionated radioyherapy with weekly cisplatin 40mg/m2
89438353|NCT03532074|Other|laparoscopic approach|assessment of bowel symptoms before surgery; assessment of rectosigmoid perfusion using indocyanine green; removal of rectosigmoid endometriosis nodule using a laparoscopic approach; follow up and assessment of bowel symptoms after surgery
89438354|NCT03532074|Other|robot-assisted approach|assessment of bowel symptoms before surgery; assessment of rectosigmoid perfusion using indocyanine green; removal of rectosigmoid endometriosis nodule using a robot-assisted approach; follow up and assessment of bowel symptoms after surgery
89438355|NCT04441164|Experimental|Observation of Virtual Actions (steps 1 and 3)|If the patient is included in the Virtual Reality group, he/she will be asked to observe Virtual Motor Actions (their own avatar moving in a virtual environment) using a headset once a day for 9 days during 5 minutes, followed by 5 minutes of relaxation performed using soothing music played through headphones.
89438356|NCT04441164|Placebo Comparator|Relaxation|If the patient is included in the Relaxation group, he/she will be offered 10 minutes of relaxation performed using soothing music played in headphones once a day for 9 days.
89438357|NCT04441164|Other|Patients|It will be offered to patients hospitalized in these 2 services and presenting post-resuscitation ICU-weakness, especially in the aftermath of COVID infection, to complete an acceptability questionnaire (a priori) concerning the use of a Virtual Reality tool intended to improve walking in the ICU. The duration of filling in this questionnaire is estimated at 30 minutes.
89438358|NCT04441164|Other|Caregivers|It will be offered to caregivers of the ICU of the Rennes University Hospital, to complete an acceptability questionnaire (a priori) concerning the use of a Virtual Reality tool intended to improve walking in the ICU. The duration of filling in this questionnaire is estimated at 30 minutes.
89438359|NCT04441164|Experimental|Relaxation (step 3)|If the patient is included in the Relaxation group, he/she will be offered 10 minutes of relaxation performed using soothing music played in headphones once a day for 9 days.
89438360|NCT04441164|Experimental|Performing Virtual Actions|If the patient is included in the group Performing Virtual Actions, he/she will be asked to perform Virtual Actions of the lower limbs by controlling the legs of his avatar (virtual double) in order to move around in a virtual environment for 10 minutes per day, once a day for 9 days.
89438361|NCT04441164|Placebo Comparator|Observation of Virtual Actions|If the patient is included in the Observation of Virtual Actions group, he/she will be asked to observe for 10 minutes once a day for 9 days Virtual Motor Actions (avatar moving in a virtual environment) using a Virtual Reality headset.
89199342|NCT05793645|Experimental|Personalized care plan|A personalized care plan will be deployed according to patient profile/ disease characteristics
89501620|NCT03166137|Active Comparator|Cryotherapy group|(group B): thirty patients will be treated by cryotherapy application.
89199343|NCT05784857|Other|No Intervention and Touch Group|"Each intubated infant will be follewed up during 3 aspiration procedures. Different touching techniques will be used for preterm infants in each aspiration application.~The first aspiration procedure will be performed without intervention. During the second aspiration procedure, yakson touch will be applied.Third aspiration procedure, gentle human touch will be applied."
88923129|NCT05239000|Experimental|geriatric co-management|Geriatric co-management involves a consultation with a geriatrician prior to initiating head and neck radiation and chemotherapy. Consultation with geriatricians can occur in-person or remotely via telemedicine. During this visit, the geriatrician will review the results of the eRFA and create a plan to manage geriatric deficits. Geriatric co-management involves optimization of comorbid conditions, management of polypharmacy, and supportive care referrals to address geriatric deficits. Geriatricians also work in conjunction with the treating oncologists to ensure patients have appropriate pain management and bowel regimens. Additional follow up visits after the initial consultation are at the discretion of the geriatrician may vary between patients depending on the clinical need.
88923130|NCT05239000|Experimental|geriatric guided supportive care|Geriatric guided supportive care will be carried out by oncologists. After the patient completes the eRFA, an automated report is generated that identifies the patient's geriatric deficits. The automated report also includes suggested interventions for each deficit (e.g, referral to physical therapy. For instance, automated suggestions for a patient with a history of falls include consultation with physical therapy, neurologic evaluation, a home safety evaluation, or use of supportive devices. Automated recommendations for patient with high level of distress or depression include referral to psychiatry or social work, involvement in a cancer support group, or additional time spent addressing questions and fears. The oncology team will review the automated report from the eRFA and create an intervention plan prior to initiation of head and neck radiation and chemotherapy.
88923131|NCT05233956|Experimental|LNG IUS|Levonorgestrel intrauterine system
88923132|NCT05233956|Active Comparator|COC|Combined oral contraceptives with ferrous fumarate tablets in regimen
88923133|NCT05225558|Experimental|Combination therapy - Vancomycin IV plus Delpazolid 800 mg, PO, BID|"Intravenous vancomycin dosed as per 2020 IDSA guideline~Doses of 15 to 20 mg/kg (based on actual body weight) administered every 8 to 12 hours as an intermittent infusion are recommended for most patients with normal renal function when assuming a MICBMD of 1 mg/L.~Depending on the investigator's judgment, it is allowed to change to daptomycin after at least one week of administration of vancomycin, and also it is allowed to change to oral antibiotics other than oxazolidinones after two weeks of administration of vancomycin (including daptomycin)."
88923134|NCT05225558|Placebo Comparator|Monotherapy - Vancomycin IV plus Placebo of Delpazolid|"Intravenous vancomycin dosed as per 2020 IDSA guideline~Doses of 15 to 20 mg/kg (based on actual body weight) administered every 8 to 12 hours as an intermittent infusion are recommended for most patients with normal renal function when assuming a MICBMD of 1 mg/L.~Depending on the investigator's judgment, it is allowed to change to daptomycin after at least one week of administration of vancomycin, and also it is allowed to change to oral antibiotics other than oxazolidinones after two weeks of administration of vancomycin (including daptomycin)."
88923135|NCT05215613||Patients implanted with the Zimmer® Plates and Screws System|
88923136|NCT05209737|Experimental|Trendelenburg position|Position: 10-degree Head-down position
88923137|NCT05209737|Active Comparator|Semirecumbent position|Position: 30-degree Head-up position
88923138|NCT05203445|Experimental|Olaparib in Combination with Pembrolizumab|Pembrolizumab 400 mg will be administered as a 30 minute IV infusion every 6 weeks in conjunction with olaparib (for the first 12 weeks) and cytotoxic chemotherapy (after olaparib has been completed) if administered prior to surgery and if the patient is not deemed to have tumor growth.
88923139|NCT05195151|Experimental|Probiotics|taking a capsule containing the probiotics 15 d before and 15 d after booster shot.
88923140|NCT05195151|Placebo Comparator|Control|taking a capsule containing a placebo 15 d before and 15 d after booster shot.
88923141|NCT05186740|Active Comparator|Device: The ProVee Urethral Expander System|The ProVee Urethral Expander System consists of two components: a nitinol Expander implant and a 19Fr Delivery System designed to allow the Expander to be deployed under direct vision for the treatment arm.
88923142|NCT05186740|Sham Comparator|Sham: Ureteroscope and urethral access sheath|An ureteroscope housed within the inner lumen of an urethral access sheath will be used under direct vision for the Sham procedure.
88923143|NCT05186740|Other|Crossover ProVee Urethral Expander System|"All subjects shall be unblinded following the 3 month follow-up visit. Those subjects randomized to the Sham Arm will be given the opportunity to crossover to the ProVee Urethral Expander System."
88923144|NCT05181540|Experimental|AB-205 plus standard-of-care preventive and supportive therapies.|
88923145|NCT05181540|Placebo Comparator|Placebo plus standard-of-care preventive and supportive therapies.|
88923146|NCT05162599|Experimental|Diagnostic study, experimental evaluative cross-sectional study|Evaluate the performance of the Cardiags Trimod medical device, compared to a reference examination, echocardiography, for the detection of heart murmurs Verification of the performance of the Cardiags Trimod medical device compared to a reference examination (ECG, Cardiologist interpretation) for the detection of rythm abnormalities Verification of the repeatability of measurements Verification of safety and suitability for use Verification of acceptability
88923147|NCT05147298|Experimental|Environmental group intervention (E only)|Changing the environment surrounding the PHDs making it more amenable to walking and advocating for changes to the built environment
89438362|NCT04441164|Experimental|Haptic stimulation|Depending on the superiority or not of the Realization of Virtual Actions or the Observation of Virtual Actions, we will test the most effective condition of step 4 in combination with haptic stimulation (sensory feedback through vibrators positioned in the lower limbs to give a feeling of walking), once a day for 10 minutes for 9 days.
89438363|NCT04441164|Placebo Comparator|Without haptic stimulation|Without haptic stimulation Depending on the superiority or not of the Realization of Virtual Actions or the Observation of Virtual Actions, we will test the most effective condition of Step 4 in combination without haptic stimulation (without sensory feedback through vibrators positioned in the lower limbs to give a feeling of walking), once a day for 10 minutes for 9 days.
89438364|NCT01359046|Experimental|silver SPC|Subjects randomized to receive silver-impregnated SPC.
89438365|NCT01359046|Active Comparator|standard SPC|subjects randomized to receive standard SPC.
89438366|NCT00253968|Experimental|Eplivanserin|Eplivanserin 5 mg/day
89438367|NCT00253968|Placebo Comparator|Placebo|Placebo of Eplivanserin 5 mg /day
89438368|NCT05612308|Experimental|Verical Oscillatory Pressure (VOP)|Vertical Oscillatory Pressure (VOP) will be administered with the patient lying prone on a couch. The researcher will place the thumb reinforced with the other thumb on the implicated lumbar vertebra, then apply pressure posterior anteriorly on the spinous process and oscillate for a maximum of 60 seconds. This will be done on each patient in this group twice a week for 6 weeks after an initial assessment both subjective and objective (Egwu et al, 2007).
89438369|NCT05612308|Experimental|Sustained Natural Apophyzeal Glides|Participant in this group will undergo SNAG technique on lumbar vertebra with active spinal movement according to Mulligan, (2004). Participants will be in a sitting position on the edge of the couch while both feet will be on a footrest. A stabilization belt will be used around the patient's waist and the therapist's hips and the researcher standing behind the patient well supported with stabilization belt. The researcher places one thumb or hypothenar eminence (pisiform bone) reinforced by the other on the spinous process of the implicated lumbar vertebra and then apply pressure posterior-anteriorly on the spinous process, the pressure will be sustained and the patient concurrently performs active spinal movement. SNAGS will be applied with 3 repetitions on the first day and 10 repetitions from next visit. SNAG will be used twice a week for 6 weeks.
89438370|NCT05612230||Hospitalized patients|The diseases were included based on the results of the preliminary data exploration and standardization according to ICD-10.
88923148|NCT05147298|Experimental|Individual-level eHealth phone program intervention (I only)|An automated telephone-based physical activity program.
88923149|NCT05147298|Experimental|Combined group (E and I interventions)|Changing the environment surrounding the PHDs making it more amenable to walking and advocating for changes to the built environment and an automated telephone-based physical activity program.
88923150|NCT05147298|No Intervention|Control group (no interventions)|No interventions for residents to increase activity levels.
88923151|NCT05132933|Experimental|Shunt-group|Test of three different levels of positive end-expiratory pressure (PEEP)
88923152|NCT05130216||Total Knee Arthroplasty|Patients who have undergone total knee arthroplasty post one-year.
88923153|NCT05126238|Experimental|Lithium|In preoperative period patients will take 300mg of lithium carbonate on 1-1-1 regimen during 2 days prior to surgery. On the day of surgery, they will take 300mg of lithium carbonate 2 hours before surgery. After the surgery, patients will take 300mg of lithium carbonate in the afternoon and 300mg of lithium carbonate in the evening.
88923154|NCT05126238|Placebo Comparator|Placebo|In preoperative period patients will take placebo on 1-1-1 regimen during 2 days prior to surgery. On the day of surgery, they will take placebo 2 hours before surgery. After the surgery, patients will take placebo in the afternoon and in the evening.
88923155|NCT05117255|Experimental|Experimental: Computer-delivered cognitive behavioral therapy hybrid for comorbidity|Four, approximately 60 minute each, computerized therapy sessions delivered on an interactive computerized platform. All participants are undergoing a standard 28 day residential alcohol treatment program.
89438371|NCT05543304||patients with response to systemic therapies|Patients shown complete response (CR) and partial response (PR) after treatments. The clinical data and radiomics data are collected through electronic medical record system.
89438372|NCT05543304||patients with no response to systemic therapies|Patients shown progressive disease (PD) and stable disease (SD) after treatments. The clinical data and radiomics data are collected through electronic medical record system.
89438373|NCT05612152|Active Comparator|Referral to Quitline|Patients who indicate they are ready to quit in the next 30 days are offered an electronic referral to the state quitline for tobacco cessation services.
89438374|NCT05612152|Experimental|Choose2Quit|Patients who indicate they are ready to quit in the next 30 days are offered an electronic referral to the Choose2Quit tobacco treatment navigator who walks the patient through choices for tobacco cessation counseling, tobacco cessation medications and other supports (e.g. texting, apps) and facilitates placing referrals, orders and providing information.
89438375|NCT05549986||Mortality group|Patients encountered in-hospital mortality or 30-day mortality
89438376|NCT05549986||Survival group|Patients did not encounter in-hospital mortality or 30-day mortality
89438377|NCT05549830|Experimental|Intervention Group|"During the night before surgery and for the first 36 hours after surgery, the participants assigned to the intervention group will be placed in positions different from surgical positions.~After surgery the patient will be placed in a different position compared to during surgery, with repositioning being undertaken every two hours until the first 36th postoperative hour, and the development of pressure injuries will be evaluated at the 36th hour. If no pressure injury has developed in this period, the patient will be placed in the surgical position for a duration that will not exceed 30 minutes, and then repositioning will be applied at two-hour intervals. If pressure injuries have developed, different repositioning techniques will continue to be applied at two-hour intervals."
89438378|NCT05549830|No Intervention|Control Group|The control group will only receive routine care. The positions of the patients in this group will be monitored and recorded at two-hour intervals.
89438379|NCT05700604||Cystic Fibrosis|10-18 year-old children with Cystic Fibrosis
88923156|NCT05117255|Active Comparator|Control: Progressive Muscle Relaxation Training (PMRT)|Four, one-hour computerized segments delivered on an interactive computerized platform teaching Progressive Muscle Relaxation Training (PMRT). All participants are undergoing a standard 28 day residential alcohol treatment program.
89438380|NCT05700604||Healthy Controls|age and sex matched healthy controls
89438381|NCT03544606|Experimental|isosorbide mononitrate group|isosorbide mononitrate group (study group) 70 patients are induced by Intra vaginal isosorbide mono nitrate at 36, 24 , 12 before induction
89438382|NCT03544606|Placebo Comparator|placebos group|70 patients induced by placebo (pyridoxine) placebo tablet of the same size and shape as the isosorbide mononitrate. administered in the posterior vaginal fornix at 36, 24 , 12 before induction
89438383|NCT02741310|Placebo Comparator|Placebo|Participants received a placebo intravenous (IV) infusion on day 1 then 12 mg subcutaneous sumatriptan on day 2 (Part 1). After a 2-day washout participants received another placebo IV infusion on day 4 followed by 12 mg subcutaneous sumatriptan on day 5 (Part 2).
89438384|NCT02741310|Experimental|Erenumab|Participants received a placebo intravenous (IV) infusion on day 1 then 12 mg subcutaneous sumatriptan on day 2 (Part 1). After a 2-day washout participants received 140 mg erenumab IV infusion on day 4 followed by 12 mg subcutaneous sumatriptan on day 5 (Part 2).
89438385|NCT03531684|Experimental|MMFS-205-SR|Oral MMFS-205-SR twice daily (2,000, 3,000, or 4,000 mg/day total, depending on lean body mass and response to initial dose at Week 12) for 24 weeks
89438386|NCT03531684|Placebo Comparator|Placebo|Oral inactive placebo twice daily for 24 weeks
89438387|NCT03532360|No Intervention|Control|Following randomization, this arm will receive no intervention. After twelve months, participants in this group will undergo a singe-blind, placebo-controlled oral food challenge
88923157|NCT05117255|No Intervention|Treatment as Usual (TAU)|Participants are undergoing a standard 28 day residential alcohol treatment program. No study intervention.
88923158|NCT05098210|Experimental|Treatment (poly ICLC, PNV21 vaccine, nivolumab)|Patients receive poly ICLC IM once weekly in weeks when no vaccine is given. Beginning 2 weeks after starting poly ICLC, patients receive personalized neo-antigen peptide vaccine IM once every 4 weeks and nivolumab every 2 or 4 weeks. Treatment continuous for 25 weeks in the absence of disease progression or unacceptable toxicity. Patients then receive nivolumab every 2 or 4 weeks for up to 12 months in the absence of disease progression or unacceptable toxicity.
88923159|NCT05096390|Experimental|axitinib + pembrolizumab|"Axitinib will be administrated orally 5 mg twice a day, with a dose adaptations to the manufacturer recommendations in both groups. Doses can be increased up to 10 mg twice daily.~Pembrolizumab will be administrated intravenously (IV) over 30 minutes at the dose of 200 mg every 3 weeks according to recent summary of product characteristics (SPC) together with axitinib."
88923160|NCT05096390|Active Comparator|axitinib alone (control)|Axitinib will be administrated orally 5 mg twice a day, with a dose adaptations to the manufacturer recommendations in both groups. Doses can be increased up to 10 mg twice daily.
88923161|NCT05065905|Experimental|Interferon|"All participants receive subcutaneous interferon-gamma (Ingaron®) 500,000 IU alternated with Interal® (interferon alpha) 3,000,000 IU every other day~Interventions:~Drug: Ingaron® Drug: Interal® Drug: Antituberculosis complex therapy"
88923162|NCT05065905|Experimental|Interferon daily|"All participants receive subcutaneous interferon-gamma (Ingaron®) 500,000 IU given with Interal® (interferon alpha) 3,000,000 IU every day~Interventions:~Drug: Ingaron® Drug: Interal® Drug: Antituberculosis complex therapy"
88923163|NCT05065905|No Intervention|Control|"All participants receive only basic antimicrobial treatment~Interventions:~Drug: Antituberculosis complex therapy"
88923164|NCT05056064|Experimental|CA oral cavity|Standard Treatment+Oral exercise
88923165|NCT05056064|No Intervention|control|Standard treatment
88923166|NCT05043389|Experimental|Obstructive sleep apnea|myofunctional therapy program
88923167|NCT05043389|No Intervention|control|standard treatment
88923168|NCT05020873||Crizanlizumab|Patients initiated on treatment with commercially available crizanlizumab
88923169|NCT05003531|Experimental|IBI112 dose 1|Participants will receive IBI112 dose 1 subcutaneous injection(SC)
88923170|NCT05003531|Experimental|IBI112 dose 4|Participants will receive IBI112 dose 4 subcutaneous injection(SC)
89199344|NCT05775133|Experimental|Indocyanine green (ICG)|"Patients in this arm will receive an intravenous injection of indocyanine green (ICG) 45 minutes prior to the start of surgery. This will be used to visualize the biliary anatomy using ActivSight, a device that is FDA 510(k)-cleared for this indication.~The surgeon will perform the procedure in their standard fashion using ActivSight.~ActivInsight artificial intelligence will be used to analyze the surgical video in real time to identify anatomic structures and phases of surgery."
88923171|NCT05003531|Experimental|IBI112 dose 2|Participants will receive IBI112 dose 2 subcutaneous injection(SC)
88923172|NCT05003531|Experimental|IBI112 dose 3|Participants will receive IBI112 dose 3 subcutaneous injection(SC)
88923173|NCT05003531|Placebo Comparator|Placebo|Participants will receive placebo subcutaneous injection(SC)
88923174|NCT04995003|Experimental|Arm A|autologous HER2 CAR T cells infused in combination with lymphodepletion chemotherapy and the PD-1 antibody pembrolizumab
89011781|NCT01688752||Acute Lymphoblastic Leukemia Survivors|Survivors of acute lymphoblastic leukemia (ALL) who recently completed therapy.
89438388|NCT03532360|Active Comparator|Low-dose|Following randomization, participants in this group will receive escalating doses of the appropriate allergen, up to a dose of 30 mg. Once they attain that dose, they will maintain it for six months. At the end of this maintenance period, they will undergo a singe-blind, placebo-controlled oral food challenge
89438389|NCT03532360|Active Comparator|High-dose|Following randomization, participants in this group will receive escalating doses of the appropriate allergen, up to a dose of 300 mg. Once they attain that dose, they will maintain it for six months. At the end of this maintenance period, they will undergo a singe-blind, placebo-controlled oral food challenge
89011782|NCT01688791|Experimental|Part A: Vintafolide BIW|Vintafolide, intravenously (IV), on Days 1, 4, 8, and 11 of each 21-day cycle. Carboplatin, IV, at a dose of area under the curve (AUC)5, administered on Day 1 of each 21-day cycle. Paclitaxel, IV, at a dose of 175 mg/m^2, administered on Day 1 of each 21-day cycle
89011783|NCT01688791|Experimental|Part A: Vintafolide TIW|Vintafolide, intravenously (IV) on Days 1, 3, 5, 8, 10, and 12 of each 21-day cycle. Carboplatin, IV, at a dose of area under the curve (AUC)5, administered on Day 1 of each 21-day cycle. Paclitaxel, IV, at a dose of 175 mg/m^2, administered on Day 1 of each 21-day cycle
89011784|NCT01688791|Experimental|Parts B & C: Vintafolide Single Dose & Weekly (QW)|Single dose, dose escalation, vintafolide (Part B) followed by 2 week observation. Those completing Part B will have the option to continue on to Part C (weekly dosing, dose finding, on Days 1, 8, and 15 in a 21-day cycle until disease progression or toxicity) unless they experience severe and/or persistent drug related toxicity.
89011785|NCT01688908|No Intervention|Control Arm|Participants in this arm will not accept the endoscopic screening and only baseline and follow-up interview will be conducted in this arm.
89011786|NCT01688908|Experimental|Screening Arm|Participants in this arm will accept a baseline endoscopic screening, questionnaire investigation and follow-up interview. Subsequent re-examination and further medical services would be arranged among individuals who already have high-grade lesions found at baseline screening.
89011787|NCT00240968|Experimental|3|Subjects will receive a single 45 mcg IM dose of the influenza A/H5N1 virus vaccine.
89011788|NCT00240968|Experimental|4|Subjects will receive a single 90 mcg IM dose of the influenza A/H5N1 virus vaccine.
89011789|NCT00240968|Experimental|1|Subjects will receive a single 7.5 mcg IM dose of the influenza A/H5N1 virus vaccine.
89011790|NCT00240968|Experimental|2|Subjects will receive a single 15 mcg IM dose of the influenza A/H5N1 virus vaccine.
89011791|NCT01688947|Experimental|V116517 - 50 mg|V116517 50-mg tablets
89011792|NCT01688947|Experimental|V116517 - 30 mg|V116517 30-mg tablets
89011793|NCT01688947|Active Comparator|Pregabalin|Pregabalin capsules
89011794|NCT01688947|Placebo Comparator|Placebo|Placebo
89011795|NCT00250731|Experimental|1|Telephone support and behavior change for couples
89011796|NCT00250731|Active Comparator|2|Telephone support and behavior change for individuals
89199345|NCT05775133|No Intervention|Non-Indocyanine Green (Non-ICG)|"The surgeon will perform the procedure in their standard fashion without the use of ICG.~ActivInsight artificial intelligence will be used to analyze the surgical video in real time to identify anatomic structures and phases of surgery."
89501621|NCT04881877|Experimental|Synthetic nitrite Condom|Participants will be randomized to condom use order. Participants will be provided with 5 synthetic nitrite condoms at the first visit and switched to 5 of either the latex graphene condom or latex condom at visit 2 and 3. All couples will use each of the 3 condom types during the study
89011797|NCT00250731|Placebo Comparator|3|Limited diabetes self-management education
89011798|NCT01689025|Experimental|NNC0114-0006|
89011799|NCT01689025|Placebo Comparator|Placebo|
89011800|NCT01689142|Experimental|New formulation of insulin glargine|once daily in the evening on-top of oral antihyperglycemic drug (OADs)
89011801|NCT01689142|Active Comparator|Lantus (insulin glargine)|once daily in the evening on-top of OADs
89011802|NCT01689181||chronic schizophrenic patients|
89011803|NCT01689181||healthy volunteers|
89011804|NCT01689220|Experimental|SP-02L|
89011805|NCT01689259|Experimental|SL TNX-102 at 2.4 mg|1 x TNX-102 SL Tablets at 2.4 mg
89011806|NCT01689259|Experimental|SL TNX-102 at 4.8 mg|2 x TNX-102 SL Tablets at 2.4 mg
89011807|NCT01689259|Experimental|SL TNX-102-A at 2.4 mg|1 x TNX-102-A (without phosphate) SL Tablet at 2.4 mg
89011808|NCT01689259|Active Comparator|Cyclobenzaprine tablets|1 x 5 mg cyclobenzaprine oral tablet
89011809|NCT01689298|Active Comparator|No drug pre-treatment|A control sample from each patient (no uterotonic drug will be applied during pre-treatment) will be measured concurrently with samples pre-treated with oxytocin. Controls will undergo the same dose response of oxytocin or carbetocin after pre-treatment period as the groups given oxytocin for pre-treatment.
89011810|NCT01689298|Active Comparator|Drug pre-treatment|A sample from each patient will be pre-treated with oxytocin 10-5mol/L. These samples will undergo the same dose response of oxytocin or carbetocin after pre-treatment period as the groups given no drug for pre-treatment (controls).
89011811|NCT02272075|Active Comparator|active colposcope|Mobile OCT M3 scope
89011812|NCT02272075|No Intervention|Standard of Care|Standard of Care
89199346|NCT05771584|Experimental|Total 300 μg of AST-301|AST-301/rhuGM-CSF (3-week interval, 3 cycles in total)
89438390|NCT03531606|Experimental|Experimental|"Using placebo comparator with experimental one, it will be compared between two group for comparison of placebo comparator with experimental one.~The patients enrolled into expeimental group will take one pack of 'Mechnicov probiotics' twice a day for 4 weeks from 1 week before surgery.~(1 week before surgery and 3 weeks after surgery)~The patients in placebo and experimental group should take a part in this clinical trial under the condition of 'anterior resection of colon cancer'"
89438391|NCT03531606|Placebo Comparator|Placebo comparator|"Using placebo comparator with experimental one, it will be compared between two group for comparison of placebo comparator with experimental one.~The patients enrolled into placebo comparator group will take one pack of 'Placebo' which is composed of lactose and simulates a 'Mechnicov probiotics' twice a day for 4 weeks from 1 week before surgery.~(1 week before surgery and 3 weeks after surgery)~The patients in placebo and experimental group should take a part in this clinical trial under the condition of 'anterior resection of colon cancer'"
89438392|NCT01367457||Patients that received treatment with Temsirolimus|Patients with Renal Cell Carcinoma or Mantle Cell Lymphoma that have been treated with Temsirolimus as per clinical practice.
89438393|NCT05553652|Active Comparator|ASTARTE™ oral capsule|"The capsule will contain a mixture of four probiotic strains with a combined potency of 5 x10^9 (CFU)/capsule:~Lactobacillus crispatus LBV88, 2 x10^9 CFU/g Lactobacillus rhamnosus LBV96, 2 x10^9 CFU/g Lactobacillus gasseri LBV150N , 0.6 x10^9 CFU/g Lactobacillus jensenii LBV116, 0.4 x10^9 CFU/g Corn starch 79 mg, Magnesium salts of fatty acid 3 mg, Silicon dioxide 3 mg, Vegetal capsule size 1 DR white 75 mg, Fructooligosaccharides 30mg"
89438394|NCT05553652|Placebo Comparator|Placebo oral capsule|The placebo oral capsules is identical to the ASTARTE™ capsules and contains Corn starch 79 mg, Magnesium salts of fatty acid 3 mg, Silicon dioxide 3 mg, Vegetal capsule size 1 DR white 75 mg, Fructooligosaccharides 30mg
89438395|NCT05553496|Active Comparator|RTX in Refractory Nephrotic syndrome patients on conventional treatment|Refratory Nephrotic syndrome participants will receive a 375 mg/m2 weekly rituximab for four doses, with retreatment every 2 months till 6 months regardless of proteinuria response in addition to triple optimized immunosuppression therapy including steroids ± Calcineurine inhibitors (CNI) (e.g: Tacrolimus), Mycophenloatemofetil (MMF) and Cyclophosphamide (CTX)
89438396|NCT05553496|Active Comparator|Refractory Nephrotic Syndrome patients on Conventional therapy|Nephrotic syndrome participants will receive conventional therapy treatment only including steroids ± Tacrolimus (TAC), Cyclosporine (CsA), Mycophenloatemofetil (MMF), and Cyclophosphamide (CTX) then if become refractory to conventional treatment will continue on the same treatment.
89438397|NCT00239694|Experimental|1|Previously vaccinated
89438398|NCT00239694|Experimental|2|Never vaccinated
89438399|NCT02129361|Experimental|Adapted Screening and Brief Intervention|Adapted Screening and Brief Intervention: Participants will be screened for substance use, receive education regarding the effects of substance misuse, participate in a motivation interview, and participate in a booster session one month later
89199347|NCT05771584|Experimental|Total 600 μg of AST-301|AST-301/rhuGM-CSF (3-week interval, 6 cycles in total)
89438400|NCT02129361|Active Comparator|Screening & Education Attention Control|Screening & Education Attention Control: Participants will be screened for substance use, receive education regarding the effects of substance misuse, and participate in a booster session one month later
89438401|NCT02129439|Experimental|SB012|"SB012 will be available in this clinical trial in a concentration of 7.5 mg/ml hgd40 in 30ml PBS. The maximum daily dose will not exceed 225mg.~The study will be continued until 18 subjects have completed the four-week treatment phase according to te protocol. 12 of the 18 subjects will receive verum SB012 (in a 2:1 randomization SB012:Placebo)"
89438402|NCT02129439|Placebo Comparator|Placebo|"Placebo will be administered with an identical volume of 30ml PBS.~The study will be continued until 18 subjects have completed the four-week treatment phase according to te protocol. 6 of the 18 subjects will receive placebo (in a 2:1 randomization SB012:Placebo)"
89438403|NCT05549440|Experimental|Orsiro|
89438404|NCT05549440|Active Comparator|Resolute Onyx|
89438405|NCT00235326||2|Unexposed to gastroenteritis
89438406|NCT00235326||1|Exposed to gastroenteritis
89438407|NCT02131467|Experimental|Perampanel|Perampanel 2 mg tablets will be initiated once daily at bedtime. The dose will be titrated over 6 weeks starting at 2 mg OD at baseline visit for 1 week, followed by 2mg increases every 1 week to a maximum of 12 mg/day. If side effects occur then patients will be decreased to previous dose level. If unable to tolerate increases, patients will enter the maintenance phase at previously tolerated dose, for minimum 4 weeks. Patients reaching 12 mg (maximal dose) will be maintained at that dose for 4 weeks. Taper will be over 2 weeks 1 tablet every 2 days from a maximum of 6 tablets per day to stop.
89438408|NCT05549284|Experimental|Orelabrutinib,Rituximab and Methotrexate|Rituximab 375 mg/m2 d1; MTX 3.5mg/m2,d2; Orelabrutinib 150g/day; every three week/cycle.
89438409|NCT03531528|Experimental|Experimental|A 4-week protein-sparing, very low-calorie, ketogenic diet and a subsequent 6-week hypocaloric, low glycemic index, Mediterranean-like diet
89438410|NCT02129517|Experimental|Arm I (IMPACT Intervention)|Oncology nurses watch tailored, web-based informational video clips addressing knowledge, attitudes, subjective norms, and perceived behavioral control (barriers of discussing clinical trials with patients). They also watch role-play video clips to help improve perceived behavioral control and address attitudinal barriers.
89438411|NCT02129517|Active Comparator|Arm II (online educational materials)|Oncology nurses view online clinical trials educational materials developed based upon NCI clinical trials educational materials for health care providers. The educational materials contain text and tables as presented on the NCI Website.
89438412|NCT03065218|Experimental|99mTc sestamilbi|25 mCi 99mTc sestamibi intravenous injection, once. Then imaged for 45 minutes. More imaging might be required and this will be determined by a nuclear medicine physician onsite
89438413|NCT00232752|Experimental|1|
89438414|NCT02125617||Castration-resistant prostate cancer, Progression after taxane|Treated with abiraterone 1000 mg/day Prednisolone 10 mg/day
89438415|NCT05553262|Experimental|Behavioral support|Usual clinical intervention and in addition: visual pedagogy, instruction of caregivers, a visit every two months for three years, fixed duration of the visit (one hour) regardless of patients' collaboration. General anesthesia if needed.
89438416|NCT05553262|No Intervention|Control No behavioral support|Usual clinical treatment (dentist visit and treatments). No visual pedagogy and instruction of caregivers. Twice a year schedule (more if needed), duration of the visits according to compliance. General anesthesia if needed.
89438417|NCT02288598|Experimental|Anodal TDCS|Participants will receive anodal TDCS over the left inferior frontal cortex. TDCS will be delivered at 1milliampere (mA) intensity for 20 minutes during speech fluency training (5 consecutive days).
89438418|NCT02288598|Sham Comparator|Sham TDCS|Participants will receive sham TDCS over the left inferior frontal cortex. Sham stimulation will involve 30 seconds stimulation at the beginning of the 20 minutes of speech fluency training (5 consecutive days).
89438419|NCT02131545|Experimental|Quetiapine|Quetiapine 25 mg
89438420|NCT00229008|Experimental|001|ceftobiprole plus placebo ceftobiprole 500 mg every 8 hours as a 120 minute intravenous infusion and placebo administered every 12 hours as a 60-minute intravenous infusion for 7 to 14 days
89438421|NCT00229008|Active Comparator|002|linezolid plus ceftazidime linezolid 600 mg every 12 hours as a 60-minute intravenous infusion plus ceftazidime 2 g every 8 hours as a 120-minute intravenous infusion for 7 to 14 days
89438422|NCT02125695||Healthy Volunteers|Skin taping; blood sampling; optional biopsy
89438423|NCT02125695||Cutaneous lupus erythematosus|This group consists of participants affected with lupus (DLE, SCLE). Skin taping; blood sampling; optional skin biopsy (DLE participants); required skin biopsy (SCLE participants)
89438424|NCT02125695||Atopic dermatitis|Skin taping; blood sampling; optional skin biopsy
89438425|NCT03551535|Experimental|Physical Activity Intervention|Patients will be allocated to a physical activity intervention to be performed 3-5 days per week
89438426|NCT03551535|No Intervention|Control|Patients will receive standard counseling regarding activity recommendations in pregnancy
89438427|NCT05549128|Experimental|photobiomodulation|laser therapy application for 10 minutes
89438428|NCT05549128|Sham Comparator|Sham photobiomodulation|sham laser therapy application for 10 minutes
89438429|NCT03528564|Experimental|Epoetin alfa|Preoperative treatment of anemia with iron sucrose (Venofer) plus Epoetin Alfa (Eprex)
89438430|NCT03528564|Placebo Comparator|Intravenous Iron|Preoperative treatment of anemia with iron sucrose (Venofer) plus placebo (saline)
89438431|NCT02131623||Validation Group|Subjects with ALGS or PFIC and/or their caregivers
89438432|NCT03028792|Experimental|Attention Modification Training|Attention Modification Program Active computer-based attention training treatment designed to directly but implicitly modify biased attention patterns in anxious patients in service of symptom relief. AMP is a modified version of the dot-probe paradigm similar to the original task used by MacLeod, Mathews, and Tata. This paradigm has been modified to facilitate an attention bias away from threatening material. In this case, the probe always replaces the neutral stimuli.
89011813|NCT02277106|Experimental|Stage 1 (Double-blind): SAGE 547, Then Placebo|Participants received a 12-hour intravenous (IV) infusion of SAGE 547, at ascending doses of 29, 58, and 86 micrograms per kilogram of body weight per hour (μg/kg/h), 4 hours each, on Day 1 of Stage 1 [Treatment Period 1 (TP 1)]. After a washout period of approximately 7 days, participants received a 12-hour IV infusion of SAGE-547 matching-placebo, on Day 10 of Stage 1 [Treatment Period 2 (TP 2)].
89011814|NCT02277106|Experimental|Stage 1 (Double-blind): Placebo, Then SAGE-547|Participants received a 12-hour IV infusion of SAGE-547 matching-placebo on Day 1 of Stage 1 (TP 1). After a washout period of approximately 7 days, participants received a 12-hour IV infusion of SAGE 547 at ascending doses of 29, 58, and 86 μg/kg/h, 4 hours each, on Day 10 of Stage 1 (TP 2).
89011815|NCT02277106|Experimental|Stage 2 (Open Label): SAGE-547|Participants who completed Stage 1 were invited to receive a 10-hour IV infusion of SAGE 547, at ascending doses of 90 μg/kg/h for 1 hour, 120 μg/kg/h for 1 hour, and 150 μg/kg/h for 8 hours on Day 1 of Stage 2.
89011816|NCT00414804|Active Comparator|Spinal Cord Stimulation (SCS) Group|Spinal Cord Stimulation (SCS) Treatment Group
89011817|NCT00414804|Active Comparator|Nerve Blocks and PT|
89011818|NCT02279602|Experimental|Single Arm|Subjects will receive fosbretabulin at the same dose and frequency as in study OX4218s
89011819|NCT02276209|Experimental|Dasotraline 4 mg|Dasotraline 4 mg once daily
89011820|NCT02276209|Experimental|Dasotraline 6 mg|Dasotraline 6 mg once daily
89011821|NCT02276209|Placebo Comparator|Placebo|Placebo once daily
89011822|NCT01689493|No Intervention|usual care|usual care arm, without SMS reminder
89011823|NCT01689493|Active Comparator|patient education and daily SMS|Multifaceted patient centered intervention including : collaborative care, patient education , and daily SMS.
89011824|NCT01689571|Placebo Comparator|Placebo DPI|Placebo by inhalation for 9 days
89011825|NCT01689571|Experimental|CHF6001 DPI Dose 2|CHF6001 by inhalation for 9 days
89011826|NCT01689571|Experimental|CHF6001 DPI Dose1|CHF6001 by inhalation for 9 days
88923175|NCT04995003|Experimental|Arm 2|autologous HER2 CAR T cells infused in combination with lymphodepletion chemotherapy and the PD-1 antibody nivolumab
88923176|NCT04983810|Experimental|Phase I Dose escalation|"Phase I = Fadraciclib administered orally in escalating doses starting at 50mg bid MWF for 3 weeks of a 4 week cycle. Subsequent cohorts will escalate in dose and schedule until optimized phase 2 dose and schedule is achieved.~Phase 2 = Recommended Fadraciclib phase 2 dose and schedule administered orally in 28 day cycles."
88923177|NCT04982445|Experimental|Participants receiving CABENUVA|
88923178|NCT04975139||IDH-mutant astrocytoma or oligodendroglioma|After enrollment and before beginning standard of care radiation therapy (RT), MRI will be obtained for RT planning as per standard of care (SOC), and the RS-fMRI sequences will be performed at the same time. At approximately 6 months, 2 years, 5 years, and 10 years from the completion of RT, RS-fMRIs will be performed.
88923179|NCT04975139||IDH-wildtype astrocytoma|After enrollment and before beginning standard of care radiation therapy (RT), MRI will be obtained for RT planning as per standard of care (SOC), and the RS-fMRI sequences will be performed at the same time. At approximately 6 months, 2 years, 5 years, and 10 years from the completion of RT, RS-fMRIs will be performed.
88923180|NCT04975139||Benign Brain Tumor|After enrollment and before beginning standard of care radiation therapy (RT), MRI will be obtained for RT planning as per standard of care (SOC), and the RS-fMRI sequences will be performed at the same time. At approximately 6 months, 2 years, 5 years, and 10 years from the completion of RT, RS-fMRIs will be performed.
88923181|NCT04972526||Out-of-hospital Cardiac Arrest|Patients receiving TEE as part of their clinical evaluation during cardiac arrest that occurred outside the hospital (e.g. in/at a home or residence, in a public area, during transport to the emergency department, etc.)
88923182|NCT04972526||In-hospital Cardiac Arrest|Patients receiving TEE as part of the clinical evaluation during cardiac arrest that occurred within a hospital (e.g in the emergency department, an Intensive Care Unit, a hospital ward, the operating room, etc.)
88923183|NCT04972526||Undifferentiated Shock or Acute Hemodynamic Decompensation|Patients receiving TEE as part of the initial evaluation of undifferentiated shock or acute hemodynamic decompensation
88923184|NCT04972526||Hemodynamic Monitoring in a Critically Ill Patient|Critically ill patients receiving TEE as part of hemodynamic monitoring
88923185|NCT04972526||Procedural Guidance|Patients receiving TEE as a means to assist providers performing procedures (e.g. intravenous pacemaker placement, veno-arterial or veno-venous extracorporeal membrane oxygenation [ECMO], impella heart pump placement, intra-aortic balloon pump placement, etc.)
88923186|NCT04970966|Experimental|PuraSinus|Placement of PuraSinus in ethmoid cavity following ESS
88923187|NCT04970966|Active Comparator|Bioresorbable Nasal Dressing|Placement of bioresorbable nasal dressing (PosiSep X) in ethmoid cavity following ESS
88923188|NCT04967469|Experimental|take calcitriol|End-stage renal failure patients who is Hyperparathyroid with ESRD take calcitriol
88923189|NCT04967469|Experimental|take alphacalcidol|End-stage renal failure patients who is Hyperparathyroid with ESRD take 1-hydroxycholecalciferol (alfacalcidol)
88923190|NCT04967469|No Intervention|control|End-stage renal failure patients who is Hyperparathyroid with ESRD take standard treatment
88923191|NCT04967001|Experimental|PSMAPET-MRI|
88923192|NCT04967001|Experimental|MRI-PSMAPET|
88923193|NCT04958226|Experimental|Treatment (Midazolam + Capivasertib)|Midazolam will be administered on Cycle 1 Day 1 and Cycle 1 Day 8. Capivasertib will be administrated from Cycle 1 Day 2 as an intermittent schedule (4 days on/3 days off) until discontinuation. On Cycle 1 Day 12, Midazolam will be administrated with Capivasertib.
88923194|NCT04947722|Experimental|PREVENT Program|
88923195|NCT04947722|No Intervention|Control Group|Residents in homes allocated to the control group will receive usual care as provided within their home.
88923196|NCT04938245||Observed Cohort|Participants with chronic pain scheduled to undergo externalized trial for assessment of spinal cord stimulation will undergo intraoperative stimulation and up to three postoperative visits where already externalized electrodes (used clinically for stimulation) will be used to record and stimulate using evoked complex action potentials (ECAPs) while also measuring other electrophysiological responses.
88923197|NCT04923542|Experimental|Phase 1: Radiation Therapy and Abemaciclib|Treatment will be initiated with one week of abemaciclib followed by stereotactic radiation to sites of brain metastases or post-operative cavities with continued abemaciclib. In the phase I portion, safety will be monitored initially by a 3+3 design. If unexpected neurologic toxicities are noted, the dose of radiation therapy will be modified.
88923198|NCT04923542|Experimental|Phase 2: Radiation Therapy and Abemaciclib|Treatment will be initiated with one week of abemaciclib followed by stereotactic radiation at the phase 1 dose to sites of brain metastases or post-operative cavities with continued abemaciclib.
88923199|NCT04912089|Experimental|Cognitive Training Low Dose|Cognitive training completed for 8 sessions
88923200|NCT04912089|Experimental|Cognitive Training High Dose|Cognitive training completed for 16 sessions
88923201|NCT04912089|No Intervention|Repeat Assessment|
88923202|NCT04911088||Analgesic calibration|Participants will receive calibration of electromyography at state entropy of 90.
88923203|NCT04911088||Sedated calibration|Calibration will be started at state entropy of 70.
88923204|NCT04911088||No calibration|Participants will not receive calibration of electromyography. Measurements will start simultaneously to the standard electromyography with a default current of 60mA at state entropy of 50.
88923205|NCT04903795|Experimental|hEGFRvIII-CD3 (BRiTE) infusion|Four escalating doses of BRiTE are planned: #1: 57.0 ng/kg, #2: 570.0 ng/kg, #3: 5700.0 ng/kg, and #4: 57000.0 ng/kg.
88923206|NCT04897022|Experimental|Participants with malignant pleural mesothelioma (MPM)|Participants will be diagnosed with malignant pleural mesothelioma and be deemed unresectable per thoracic surgeon assessment
88923207|NCT04895761|Experimental|Arm A: DPX-Survivac, Letrozole|Letrozole 2.5 mg po daily, DPX-Survivac 0.25 mL SC week 2 and Week 5
88923208|NCT04895761|Experimental|Arm B: DPX-Survivac, Letrozole, Radiation|Letrozole 2.5 mg po daily, XRT 10 Gy x 2, DPX-Survivac 0.25 mL SC week 2 and Week 5
88923209|NCT04895761|Experimental|Arm C: DPX-Survivac, Letrozole, cyclophosphamide|Letrozole 2.5 mg po daily, cyclophosphamide 50 mg po BID, DPX-Survivac 0.25 mL SC week 2 and Week 5
88923210|NCT04883970|Experimental|Imaging cohort|All study participants will be allocated to this arm (single-arm study). Study participants will undergo 124I-18B10(10L) PET/CT scans
89438433|NCT03028792|Sham Comparator|Attention Control Training|Placebo Comparator: Attention Control Condition Control computer-based attention training task, which is not designed to modify biased attention patterns in anxious patients. ACC is a modified version of the dot-probe paradigm similar to the original task used by MacLeod, Mathews, and Tata. In this case, the probe randomly replaces the neutral stimuli or the threat stimuli.
89438434|NCT02131701|Active Comparator|Training group|The training group received individualized information about moderate training and was also offered training in group twice a week during 12 months. The training included both endurance training (nordic walking, water gymnastics) and training in gym.
89438435|NCT02131701|Active Comparator|Prescription of exercise|Individualized sessions for exercise prescription aiming at moderate exercise of 30 minutes at least 5 days a week
89438436|NCT05724810|Experimental|Active deep transcranial magnetic stimulation (dTMS)|Each treatment consists of 60 trains, each lasting 3 sec and interleaved with a 15 sec delay. The entire treatment is delivered over 20 min. The treatment goes for 5 days/week and for a total of 3 weeks.
89438437|NCT05724810|Sham Comparator|Sham|Active and sham cards do not differ in appearance, and both coils are enclosed within the same helmet, enabling double-blind administration. The same procedure will be done, the only difference is that the sham card does not deliver any stimulation.
88923211|NCT04883346|Experimental|Liraglutide|Treated with Liraglutide
88923212|NCT04874961|Experimental|Standardized olive extract (Tensiofytol®)|3 capsules/day during dinner Per day: 334 mg olive leave dry extract and 106 mg olive fruit dry extract (Olea europaea L.), equivalent to 100 mg oleuropein and 20 mg hydroxytyrosol
88923213|NCT04874961|Placebo Comparator|Placebo|3 capsules/day during dinner
88923214|NCT04869813||Heart failure patients|"Inclusion criteria:~Age > or = 40 yrs~Stable chronic heart failure~Systolic dysfunction determined by cardiac MRI with left ventricle ejection fraction 40% or less~Exclusion criteria:~• Advanced liver disease, advanced cancer, advanced chronic obstructive pulmonary disease~Contraindications to MRI such as:~Heart pacemaker/defibrillator~Electronic/implanted stimulators or devices, including deep brain stimulator, vagus nerve stimulator, bladder stimulator, spine stimulator, neurostimulators; implanted electrodes or wires~Cochlear implant or other ear implants~Implanted drug pumps (insulin, narcotic/pain medications, drugs to treat spasticity)~Programmable shunt~Aneurysm clips and coils~Stents • Filters (for example, blood clot filters)~Metal fragment in body or eye (eg, BBs, bullets, shrapnel, metal pieces or shavings)"
88923215|NCT04869813||Healthy volunteers (Controls)|"Inclusion criteria:~Age > or = 40 yrs~No diagnosed heart failure or sarcopenia~Exclusion criteria~• Advanced liver disease, advanced cancer, advanced chronic obstructive pulmonary disease~Contraindications to MRI such as:~Heart pacemaker/defibrillator~Electronic/implanted stimulators or devices, including deep brain stimulator, vagus nerve stimulator, bladder stimulator, spine stimulator, neurostimulators; implanted electrodes or wires~Cochlear implant or other ear implants~Implanted drug pumps (insulin, narcotic/pain medications, drugs to treat spasticity)~Programmable shunt~Aneurysm clips and coils~Stents~Filters (for example, blood clot filters)~Metal fragment in body or eye (eg, BBs, bullets, shrapnel, metal pieces or shavings)"
88923216|NCT04863417|Experimental|Cohort 1 (2000 cm2 Body Surface Area)|
88923217|NCT04863417|Experimental|Cohort 2 (4000 cm2 Body Surface Area)|
88923218|NCT04854096|Experimental|NS-018|Self-administered NS-018 300 mg orally, twice daily, preferably at the same time each day in consecutive 4-week (28-day) cycles
88923219|NCT04854096|Active Comparator|Best Available Therapy (BAT)|Single agent per Investigator discretion or no therapy
88923220|NCT04848688|Experimental|Moxidectin|8 mg Moxidectin at day 0 administered orally
88923221|NCT04848688|Experimental|Ivermectin|200 ug/kg Ivermectin at day 0 administered orally
88923222|NCT04822753|Experimental|Platelet Rich Plasma injection to lumbar facet joint|Platelet Rich Plasma injection to lumbar facet joint
88923223|NCT04822753|Placebo Comparator|Placebo injection to lumbar facet joint|Placebo injection to lumbar facet joint
88923224|NCT04799795||healthy subjects|Age-matched healthy participants will be recruited via flyers at public education facilities and online advertisement. Participants need to be healthy and without central nervous system disorders and substance abuse. The investigators will also exclude pregnant women from the experiment.
88923225|NCT04799795||patients with absence epilepsy|Apart from the diagnosis of epilepsy, patients need to be of good health and without central nervous system disorders and substance abuse. The investigators will also exclude pregnant women from the experiment.
88923226|NCT04795661|Experimental|Cohort Colorectal cancer (CRC)|Pembrolizumab prior to surgery
89438438|NCT04322734||ASD (General)|150 children with ASD and unknown MD status
89438439|NCT04322734||ASD (With MD)|50 children with ASD and confirmed MD
89438440|NCT04322734||ASD (No MD)|50 children with ASD and ruled out MD
89438441|NCT04322734||Epilepsy|50 children with epilepsy (primary) and no ASD
89438442|NCT04322734||Brain Tumor|50 children with brain tumor (primary) and no ASD
89438443|NCT04322734||Psychiatric Disorder|50 children with psychiatric disorder (primary) and no ASD, using lithium treatments
88923227|NCT04795661|Experimental|Cohort Oesogastric cancer|Pembrolizumab prior to surgery
88923228|NCT04795661|Experimental|Cohort Endometrial cancer|Pembrolizumab prior to surgery
88923229|NCT04795661|Experimental|Cohort Other cancer|Pembrolizumab prior to surgery
89438444|NCT04322734||MD (No ASD)|50 children with MD (primary) and no ASD
89438445|NCT04322734||TD (With ASD Sibling)|50 TD children with a sibling with ASD/neurodevelopmental delay
89438446|NCT04322734||TD (No ASD Sibling)|50 TD children with no siblings with ASD/neurodevelopmental delay
89438447|NCT03550521|Experimental|Mindfulness condition|The brief mindfulness induction will be modeled after basic mindfulness skills commonly used in mindfulness-based interventions and tailored to target distressing thoughts and feelings.
89438448|NCT03550521|No Intervention|Control condition|"Participants assigned to the control task will be instructed to let your mind wander freely without trying to focus on anything in particular."
89438449|NCT02926768|Experimental|Daily dose of CK-101|Daily oral dose of CK-101
89438450|NCT03531372|Experimental|Mipolixin®|Mipolixin® (Advanced Natural Antacid - AdNA)
89438451|NCT03531372|Active Comparator|Poliprotect®|Poliprotect® (Neobianacid)
89438452|NCT02129595|Active Comparator|resveratrol|resveratrol will be given for 30 or 34 days (if included in brown adipose tissue measurement), twice daily. One pill, which contains 75 mg of resveratrol, will be provided with lunch, and the other pill of 75 mg will be provided with dinner. So in total 150 mg/day of resveratrol will be given.
89438453|NCT02129595|Placebo Comparator|placebo|A placebo will be given for 30 or 34 days (if included in brown adipose tissue measurement), twice daily. One pill will be provided with lunch and the other pill will be provided with dinner.
89438454|NCT02648620|Experimental|SurVeil Drug Coated Balloon catheter|Paclitaxel Coated Balloon catheter for angioplasty
89438455|NCT02131857|Experimental|Staff|active interventional program based on Mindfulness training
89438456|NCT02131857|Experimental|Parents|active interventional program based on Mindfulness training
89438457|NCT02131857|Experimental|Patients with CF|active interventional program based on Mindfulness training
89438458|NCT05548894|Active Comparator|stabilization splint|acrylic splint in the maxillary arch with flat surface
89438459|NCT05548894|Active Comparator|laser therapy|laser beam directed to the affected part cause activation of blood circulation
89438460|NCT05548894|Active Comparator|stabilization splint and laser therapy|using both laser therapy and stabilization splint for more improvement
89438461|NCT02129673|Experimental|VS101 Insert Dose A|VS101 Insert Dose A placed under the conjunctiva
88923230|NCT04785586|Experimental|Individual|"HWC protocol + three individual face-to-face sessions via video"
88923231|NCT04785586|Experimental|Group|"HWC protocol + three face-to-face group sessions via video"
88923232|NCT04785586|Active Comparator|Control|Standard HWC protocol
88923233|NCT04776941|Experimental|Arm I (questionnaires, messages, writing)|Patients complete questionnaires over 30 minutes about their mood, health, and income at baseline, and 1, 3, and 6 months. Patients also read brief positive messages and write essays about their experiences over 30 minutes (non-stop) QW for 3 weeks.
88923234|NCT04776941|Active Comparator|Arm II (questionnaires, messages, writing)|Patients complete questionnaires over 30 minutes about their mood, health, and income at baseline, and 1, 3, and 6 months. Patients also read brief neutral messages and write essays about neutral topics over 30 minutes (non-stop) QW for 3 weeks.
88923235|NCT04770870|Other|Treatment Arm|All subjects who meet eligibility, consented, and enrolled into the study will receive treatment.
88923236|NCT04763343|Experimental|Ketamine Treatment + CAMS Therapy|
88923237|NCT04763343|Placebo Comparator|Saline Placebo Treatment + CAMS Therapy|
88923238|NCT04761393||Patients with emphysema and eosinophilia in blood and sputum|blood eosinophils ≥300 cells/μL and sputum eosinophils >3%
88923239|NCT04761393||Patients with emphysema and paucicellular inflammation|sputum neutrophils <65% and eosinophils <3%
88923240|NCT04761393||Patients with emphysema and sputum neutrophilia|sputum neutrophils >65% and sputum eosinophils < 3%
88923241|NCT04747795|Placebo Comparator|standard care + placebo|The 'standard care' group will receive intermittent infusion of normal saline (3 ampoules of 5 ml 9mg/ml normal saline diluted in 50 ml of normal saline, every 6 hours) during 4 days or until hospital discharge and is started within 6 hours after presentation (time of triage) in the ED.
88923242|NCT04747795|Active Comparator|standard care + Vitamin C|The 'standard care + Vitamin C' group will receive intermittent infusion of Vitamin C (3 ampoules of 500 mg/5ml Vitamin C diluted in 50 ml of normal saline, every 6 hours) during 4 days or until hospital discharge and is started within 6 hours after presentation (time of triage) in the ED.
88923243|NCT04731363|Experimental|Xylitol, 30g|oral xylitol, a potent artificial sweetener
88923244|NCT04731363|Experimental|Erythritol, 30g|oral erythritol, a potent artificial sweetener
88923245|NCT04731363|Experimental|Xylitol, 5g|oral xylitol, a potent artificial sweetener
88923246|NCT04731363|Active Comparator|Glucose, 30g|oral glucose, delivered as dextrose
88923247|NCT04715425|Active Comparator|Thoracoscopic ablation|Thoracoscopic ablation
88923248|NCT04715425|Active Comparator|Catheter ablation|Catheter ablation
88923249|NCT04710134|Active Comparator|Reslizumab 3 mg/kg|All patients will initially receive reslizumab 3 mg/kg for at least 16 weeks.
88923250|NCT04710134|Active Comparator|Reslizumab 4 mg/kg|Patients who have uncontrolled sputum eosinophilia at 16 weeks will receive an increased dose of 4 mg/kg for the next 16 weeks. The patients with controlled eosinophilia will continue to receive 3 mg/kg.
88923251|NCT04710134|Active Comparator|Reslizumab 5 mg/kg|Patients who have uncontrolled sputum eosinophilia who were previously receiving reslizumab at 4 mg/kg at 32 weeks will receive an increased dose of 5 mg/kg for the next 16 weeks. The patients remaining patients will continue on the dose they were receiving (i.e., either 3 mg/kg or 4 mg/kg).
89011827|NCT01689610||Adult female patients with MBC|This is an observational study, no interventions are specified
89199348|NCT05761041|Experimental|Naf + MI|Sodium Fluoride Varnish 5% (Applied biannually) + two MI sessions: baseline face-to-face session and phone call after 3months.
89438462|NCT02129673|Experimental|VS101 Insert Dose B|VS101 Insert Dose B placed under the conjunctiva
89438463|NCT02129673|Experimental|VS101 Insert Dose C|VS101 Insert Dose C placed under the conjunctiva
89438464|NCT02129673|Active Comparator|Latanoprost 0.005% eye drops|Latanoprost 0.005% eye drops administered once daily on the eye
89438465|NCT05724732|Experimental|GT201 treatment group|Autologous tumor infiltrating lymphocyte injection
89438466|NCT02125773|Experimental|Informed Risk Score|Subjects in the intervention arm will receive an estimate of their risk of HIV infection as estimated by the UCSD calculator.
89438467|NCT02125773|No Intervention|Control|Subjects in the control arm will not be provided with the results of the risk calculators.
88923252|NCT04708886|Experimental|Females with Chronic SCI|12-month treatment with monthly subcutaneous romosozumab injections (210 mg), followed by 12-month treatment with weekly oral alendronate tablets (70 mg)
89438468|NCT05552872||Pulmonary Infection with DM group|Patients with diabetes and pulmonary infection
89438469|NCT05552872||Pulmonary Infection group|Patients with pulmonary infection while the fasting blood-glucose in the normal range.
89501622|NCT04881877|Experimental|Latex and graphene Condom|Participants will be randomized to condom use order. Participants will be provided with 5 latex graphene condoms at the first visit and switched to 5 of either the synthetic nitrite condom or latex condom at visit 2 and 3. All couples will use each of the 3 condom types during the study.
88923253|NCT04700137|Active Comparator|Caring Contacts + Introductory Phone Call (CC+)|"Healthcare provider and staff participants who are randomized to both caring text messages and an introductory phone call.~Adult and adolescent participants who are randomized to both caring text messages and an introductory phone call."
88923254|NCT04700137|Active Comparator|Caring Contacts (without phone call) (CC)|"Healthcare provider and staff participants who are randomized to only caring text messages.~Adult and adolescent patient participants who are randomized to only caring text messages."
88923255|NCT04693468|Experimental|Arm I (talazoparib, palbociclib)|Patients receive talazoparib PO QD on days 1-21 or 1-28 and palbociclib PO QD on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patient may continue treatment even if there is progression of disease as long as the patient remains clinically stable, per the treating physician's discretion.
88923256|NCT04693468|Experimental|Arm II (talazoparib, axitinib)|Patients receive talazoparib PO QD on days 1-28 and axitinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patient may continue treatment even if there is progression of disease as long as the patient remains clinically stable, per the treating physician's discretion.
88923257|NCT04693468|Experimental|Arm III (talazoparib, crizotinib)|Patients receive talazoparib PO QD on days 1-28 and crizotinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patient may continue treatment even if there is progression of disease as long as the patient remains clinically stable, per the treating physician's discretion.
88923258|NCT04693169|Experimental|[Al18F]PSMA137 PET/CT imaging|All study participants will be allocated to this arm (single-arm study).Study participants will undergo [Al18F]PSMA137 PET/CT scans.
88923259|NCT04678297|Experimental|Physical activity + emotion regulation group|Participants randomized to the experimental group attend two group-based class sessions per week, each 1.25hours long, that are led by certified instructors who guide participants through various exercises. Participants are encouraged to practice the activities at home for 20 minutes each day.
88923260|NCT04678297|Active Comparator|Physical activity control group|Participants randomized to the control group attend two group-based class sessions per week, each 1.25hours long, that are led by trained therapists who guide participants through a series of stretching exercises. Participants are encouraged to practice the activities at home for 20 minutes each day.
88923261|NCT04675515|No Intervention|Usual Tobacco Treatment|All individuals who are identified as tobacco users are offered tobacco treatment which includes proactive, as needed, contacts via in person, telehealth or telephone visits. for tobacco treatment, pharmacotherapy as indicated, and Quitline and SmokefreeTXT referrals
88923262|NCT04675515|Experimental|Intensive Tobacco Treatment|"Patients who consent to study participation will meet with a tobacco treatment specialist in-person initially, then biweekly via telephone or telehealth or face-to-face (or more frequently as needed). They will receive tobacco treatment counseling and support from certified tobacco treatment specialist, which may include pharmacotherapy as indicated. At enrollment, participants will undergo carbon monoxide testing using a carbon monoxide monitor. At baseline, participants will complete the Fagerström Test for Nicotine Dependence, and the Cancer Patient Tobacco Use Questionnaire (C-TUQ).~These tobacco related survey measures will be completed at 3 additional time points: 30 days, 3 months and 6 months."
88923263|NCT04667767|Experimental|Intervention|"In addition to the national standard outpatient treatment for uncomplicated severe acute malnutrition, caregivers of participants will receive a WASH kit containing a plastic container, a supply of Aquatabs® (effervescent chlorine tablets), and training in their use and associated hygiene practices."
88923264|NCT04667767|Active Comparator|Control|National standard outpatient treatment for uncomplicated severe acute malnutrition
88923265|NCT04662255|Experimental|Arm A (Pirtobrutinib)|Orally
88923266|NCT04662255|Active Comparator|Arm B (Ibrutinib, Acalabrutinib, or Zanubrutinib)|Investigator's choice (based on local availability) of ibrutinib, acalabrutinib or zanubrutinib orally. Options are limited to those that are available/approved in the specific country.
88923267|NCT04658771|Experimental|All patients|"Patients will undergo MR-HIFU ablation procedure of OO under general anesthesia. Patients will be monitored for disease status and adverse events for 12 months following procedure. Patients with incomplete or partial response at 28 days after MR-HIFU will be permitted a second MR-HIFU procedure.~If there is still incomplete pain relief without medication use by 28 days following the second MR-HIFU treatment, patients will be offered standard of care treatment with RFA and followed for one year."
89438470|NCT02125851|Experimental|Xanthan Gum|"A total of 12 subject will be administered sucralose slurry and the xanthan gum slurry. Six will get sucralose first (then an hour later the xanthan gum) and 6 will receive the xanthan gum first (then an hour later the sucralose slurry).~The sucralose slurry will which will consist of a 1mg dose of budesonide inhalation solution (respule) mixed with 10 grams of sucralose and 1 millicurie (mCi) of Tc99m-Sulfur Colloid.~The xanthan gum-budesonide slurry will consist of a 1mg dose of budesonide inhalation solution (respule) mixed with 1ml of xanthan gum gel, crystallized orange flavoring agent, and 1mCi of Tc99-Sulfur colloid."
89438471|NCT02125851|Experimental|Honey|"A total of 12 subject will be administered sucralose slurry and the honey slurry. Six will get sucralose first (then an hour later the honey) and 6 will receive the honey first (then an hour later the sucralose slurry).~The sucralose slurry will which will consist of a 1mg dose of budesonide inhalation solution (respule) mixed with 10 grams of sucralose and 1 millicurie (mCi) of Tc99m-Sulfur Colloid.~The honey-budesonide slurry will consist of a 1mg dose of budesonide inhalation solution (respule) mixed with 6ml of honey and 1mCi of Tc99-Sulfur Colloid."
89438472|NCT02260557|Experimental|Selexipag|Selexipag is initiated at 200 µg twice daily (b.i.d.) and up-titrated every 3 days in 200 μg b.i.d. increments up to the maximum tolerated dose (MTD) for each individual patient but not above 1600 µg during the 3-week titration phase. This is followed by a 5-week maintenance phase, during which patients continue the treatment at their individual MTD.
89438473|NCT02260557|Experimental|Placebo|Placebo matching selexipag tablets is administered according to the same schedule as selexipag
89438474|NCT04469166|Active Comparator|Tourniquet|Group of tourniquet
89438475|NCT04469166|Active Comparator|No tourniquet|Group of no tourniquet
89438476|NCT02553616|Experimental|Behavioral intervention|Intervention to promote healthy behaviors.
89438477|NCT02125929|Experimental|robotic arm|robotic surgery for enucleation benign Pancreatic Neuroendocrine Tumors Case number = 50
89438478|NCT02125929|Experimental|Laparoscopic surgery|laparoscopic surgery for enucleation benign Pancreatic Neuroendocrine Tumors Case number = 50
89438479|NCT02125929|Experimental|Open surgery|Open surgery for enucleation benign Pancreatic Neuroendocrine Tumors Case number = 100
89438480|NCT04468854|Experimental|Experimental intervention|In the experimental phase we will administer 500 mg Luteolin (2x250 mg capsules) per day formulated for oral administration for 7.5 days (first intake: visit 1/3 in the morning; last intake: visit 2/4 in the morning). The last intake on visits 2 resp. 4 is important as the participants then have to recall the learned material from visits 1 resp. 3 during a steady-state status of Luteolin.
89438481|NCT04468854|Placebo Comparator|Control Intervention|Control intervention consists of identical looking placebo capsules containing mannitol formulated for oral administration to be taken twice daily (e.g. every morning and evening) for 7.5 days (first intake: visit 1/3 in the morning; last intake: visit 2/4 in the morning) with water.
89438482|NCT02129829||Observational Group|Patients whose viral load, ALT value and fibrosis status does not meet EASL criteria for treatment and are observed 6 monthly
89438483|NCT02129829||Treatment Group (Tenofovir disoproxil)|Patients who meet EASL treatment criteria who receive Tenofovir disoproxil
89438484|NCT02288754||Stage II or III curative surgery (closed to accrual)|Patients with stage II or III solid tumors undergoing curative intend surgery enrolled before surgery.
89438485|NCT02288754||Stage II or III neoadjuvant therapy cohort (closed to accrual)|Patients with stage II or III solid tumors undergoing neoadjuvant therapy followed by curative intend surgery enrolled before neoadjuvant therapy.
89438486|NCT02288754||Metastatic disease|Patients with advanced, recurrent and/or metastatic disease requiring systemic therapy with chemotherapy, targeted therapy, immunotherapy or a combination of any before initiation of any therapy or a new line of therapy following documentation of disease progression on prior therapy.
89438487|NCT04468698||Global cohort|A global cohort is built merging data from three studies
89438488|NCT02131935||ISR Group|Patients Group Experienced In-Stent Restenosis (ISR)
89438489|NCT02131935||Non-ISR|Patients Group Without in-stent restenosis (ISR)
89438490|NCT02479126||Interstitial Lung Disease|Patients will be identified from a specified 5 year period based on an International Classification of Diseases-9 (ICD-9) code diagnosis of Interstitial Lung disease (515) or Idiopathic Pulmonary Fibrosis (516.3). The patients will be obtained from the records of the Veterans Integrated Service Network (VISN) 6: VA Mid-Atlantic Health Care Network.
89438491|NCT02129985|Experimental|Exenatide|patients were all received a short-term intensive insulin therapy,then randomised to Exenatide group(10 ug two times a day for three months)
89011828|NCT01689688||EES-XIENCE V|Groups who were treated with XIENCE V® everolimus eluting stent
89438492|NCT02129985|Active Comparator|Metformin|patients were all received a short-term intensive insulin therapy,then randomised to metformin group(850mg two times a day for three months)
89438493|NCT01730638|Experimental|TF2 antibody/68Ga-IMP-288|TF2 coupled with 68 Ga-IMP-288
89438494|NCT02126007|Experimental|Sleep and Rhythm Intervention|This arm receives a 4-week behavioral intervention aimed at improving sleep and circadian rhythms, and thereby reducing fatigue.
89438495|NCT02126007|Placebo Comparator|Dietary Modifications|This arm receives a 4-week placebo intervention focused on dietary modifications for reducing fatigue.
89438496|NCT05700136||MOMENT cohort|The cohort will be recruited at third trimester of pregnancy and required to fill up questionnaires and complete saliva collection. We will then follow up with the cohort at 3 months after birth to collect follow up data of the mother and infant. Lastly, we will collect growth outcomes of the infant at 6 months.
89438497|NCT00162942|Active Comparator|Adacolumn|Adacolumn, ten apheresis sessions within 9 weeks
89438498|NCT00162942|Sham Comparator|Sham|Sham, ten apheresis sessions within 9 weeks
89438499|NCT02132013|Experimental|Intervention SUBLIME|Intervention group
89438500|NCT02132013|No Intervention|Control|Regular care
89438501|NCT05548504|Active Comparator|Photon therapy|50-66Gy/ 24 fractions, inhomogeneous dose distribution Photon therapy
89011829|NCT00264420|Experimental|1|zoledronic acid plus radiation therapy
89438502|NCT05548504|Experimental|Proton therapy|50-66Gy/ 24 fractions, inhomogeneous dose distribution Proton therapy
89438503|NCT02252523|Experimental|DEXMEDETOMIDINE|
89438504|NCT05552170||day case group|Patients who underwent loop ileostomy with age ≤ 65 and ASA II or III were enrolled and underwent ALIR after rigorous evaluation.
89011830|NCT01689805||Patients with atopic dermatitis|
89438505|NCT02132091|Experimental|Intermittent Fasting|Intermittent Fasting
89438506|NCT02132091|Experimental|Intermittent Fasting + Antioxidants|Intermittent Fasting; 400 IU Vitamin E; 1000 mg Vitamin C
89438507|NCT05552014|Active Comparator|Natural Psychotherapy|Intervention using natural psychotherapy for OCD patients for two to three hours once a week for eight weeks
89438508|NCT05552014|Placebo Comparator|Mental Health Education|Mental health education was given to another group of OCD patients for two hours once a week for eight weeks
89438509|NCT02130141|Experimental|Dark chocolate, dietary counselling|Mildly hypertensive subject will replace their usual snacks with with 50 g dark chocolate daily for a period of 8 weeks.
89011831|NCT01689805||Non-atopic controls|
89438510|NCT02130141|Active Comparator|Dietary counselling|Usual snacks are limited.
89438511|NCT05548348|Experimental|Furmonertinib treatment|Furmonertinib will be administered orally at a dose of 160 mg per time, Q.D.
89438512|NCT03550365|Experimental|Rye bran bread intervention|4 week rye bran bread diet intervention with dietary fibre intake of 30g
89438513|NCT03550365|Experimental|Rye bread intervention|4 week rye bread diet intervention with dietary fibre intake of 30g
89438514|NCT03550365|Active Comparator|Wheat bread intervention|4 week wheat bread diet intervention with dietary fibre intake of 5-20g prior to two other arms
89438515|NCT02130219|Experimental|Chronic daily headache group|"Patients with chronic daily headache with suspicion of intracranial hypertension selected. Selection based on clinical symptoms (headache description, leading symptoms)and para-clinical pathological findings (optical nerve papilla edema). Not enough evidence to diagnose any other headache type. Simultaneous CSF pressure measurements and non-invasive ICP measurement will be performed.~Interventions: non-invasive intracranial pressure measurement; lumbar puncture and cerebrospinal fluid pressure measurement; brain MRI/CT."
89438516|NCT02130219|Experimental|Multiple sclerosis group|"Multiple sclerosis (MS) group patients selected based on clinical symptoms and brain MRI changes typical for the disease. Diagnosis based on McDonalds criteria. CSF test for oligoclonal bands required as supporting diagnostic criteria. Patients selected with disease relapse symptoms. Simultaneous noninvasive ICP and CSF pressure measured.~Interventions: non-invasive intracranial pressure measurement; lumbar puncture and cerebrospinal fluid pressure measurement; brain MRI/CT"
89438517|NCT02130219|Experimental|Stroke group|"Patients selected for this group have stroke/intracranial hemorrhage that might be complicated with intracranial hypertension. Stroke/intracranial hemorrhage diagnosed based on clinical findings and changes on brain CT/MRI. Patients with stroke less than 33% of middle cerebral artery territory included. Patients with intracranial hemorrhage 20-40 ml volume included. Patients unable to cooperate or sign informed consent excluded.~Bilateral non-invasive ICP measurements performed. Results compared with brain MRI/CT lesion volume, mid-line shift.~Interventions: non-invasive intracranial pressure measurement; brain MRI/CT"
89438518|NCT02130219|Experimental|Normal pressure hydrocephalus group|"Patients meeting normal pressure hydrocephalus diagnosis criteria selected to compare invasive CSF pressure versus non-invasive ICP.~Interventions: non-invasive intracranial pressure measurement; lumbar puncture and cerebrospinal fluid pressure measurement; brain MRI/CT"
89438519|NCT02130375|Experimental|stress urinary incontinence|Women with stress urinary incontinence
89438520|NCT02126085|Active Comparator|Intubation|Intubation and invasive mechanical ventilation + endovascular recanalisation
89438521|NCT02126085|Experimental|No Intubation|Conscious sedation and non-invasive ventilatory support + endovascular recanalisation
89438522|NCT03528330|Active Comparator|Internal hexagon connection|"Small flaps will be elevated to reduce any kind of injury on the periosteum and maintain the blood supply during the healing period.~Patients will receive 2 implants. One implant (assigned randomly) will have internal hexagon connection.~The Internal Hex (IH) implant has a 2.5mm internal hexagon and a 90° cone. The platform diameter is Ø3.5mm."
89438523|NCT03528330|Experimental|Conical connection|"Small flaps will be elevated to reduce any kind of injury on the periosteum and maintain the blood supply during the healing period.~Patients will receive 2 implants. One implant (assigned randomly) will have internal hexagon connection.~The Conical Standard (CS) implant has a 2.5mm internal hexagon and 22° cone. The platform diameter is Ø3.1mm."
89438524|NCT03550053|Active Comparator|Intraoperative plate bending|Plate will be bent intraoperatively, which is the standard of care, for this surgery
89438525|NCT03550053|Active Comparator|Preoperative plate bending|A 3D printed model of the patient's mandible will be used to bend the plate preoperatively by the surgeon. The pre-bent plate will be brought into the operating room on the day of surgery.
89438526|NCT02126163|Experimental|Treatment Group|The treatment group will receive three interactive Computer Tailored Intervention (CTI) sessions during the course of six months, which will include tailored feedback based on the user's responses, and two assessment only follow-up sessions at twelve and eighteen months.
89438527|NCT02126163|No Intervention|Control Group|The control group will receive four assessment only sessions during 18 months.
89438528|NCT04440852|Experimental|TEACCH intervention|TEACCH intervention for ASD
89199349|NCT05761041|Active Comparator|SDF|Silver Diamine fluoride 38% (Applied biannually)
89438529|NCT04440852|No Intervention|conventional rehabilitation group|Other conventional interventions
89438530|NCT02126241|Experimental|NICaS guided CRT optimization|For each subject, we will determine a set of AV and VV delays values, for which the NICaS measured CO will be maximum. In each patient, the CRT device will then be programmed according to these values.
89438531|NCT04469010|Experimental|Iron and Vitamin C|28mg iron bis-glycinate chelate and 240mg vitamin C
89438532|NCT04469010|Active Comparator|Iron|28mg iron bis-glycinate chelate
89438533|NCT04469010|Placebo Comparator|Placebo|Matched placebo tablets
89438534|NCT02130531|Experimental|Cohort 1|"Two dose periods in any sequence (subjects will be assigned to 1 of 2 possible sequences):~Emixustat HCl Tablet Strength B (mid dose); 1 tablet once daily & 1 placebo tablet once daily for 7 days~Emixustat HCl Tablet Strength A (low dose); 1 tablet twice daily for 7 days"
89199350|NCT05760339|Experimental|Time-restricted feeding|Subjects will follow a daily time-restricted feeding regimen consisting of an 8h ad libitum eating period and a 16h water fasting period during the last two weeks before surgery, followed by routine preoperative fasting before surgery.
89438535|NCT02130531|Experimental|Cohort 2|"Three dose periods in any sequence (subjects will be assigned to 1 of 6 possible sequences):~Emixustat HCl Tablet Strength A (low dose); 1 tablet daily for 7 days~Emixustat HCl Tablet Strength B (mid dose); 1 tablet daily for 7 days~Emixustat HCl Tablet Strength C (high dose); 1 tablet daily for 7 days"
89438536|NCT01121224|Active Comparator|BMS Group|Patients who receive a bare metal stent in the saphenous vein graft target lesion(s).
89438537|NCT01121224|Experimental|DES Group|Patients who receive a drug-eluting stent in the saphenous vein graft target lesion(s).
89438538|NCT02130609|Experimental|Skintel|
89438539|NCT02252601|Experimental|Well patients aged 11 and over|Will have the HFDT test compared to the gold standard (the Pure tone Audiogram) as well as other tests that have previously been suggested as a screening test for ototoxicity.
89438540|NCT02252601|Experimental|Acute exacerbation aged 11 and over|Will have the HFDT test compared to the gold standard (the Pure tone Audiogram) as well as other tests that have previously been suggested as a screening test for ototoxicity at the beginning of a course of IV antibiotics and at their convalescent clinic visit.
89438541|NCT02252601|Experimental|Children with CF aged 5-10 years|Will have the HFDT test compared to the gold standard (the Pure tone Audiogram) as well as other tests that have previously been suggested as a screening test for ototoxicity.
88923268|NCT04655404|Experimental|Feasibility Cohort|Larotrectinib administered PO, BID @100 mg/m2 on a 28-day cycle schedule.
89438542|NCT02252601|Active Comparator|Healthy Control Children age 5-10 years.|Will have the HFDT test compared to the gold standard (the Pure tone Audiogram) as well as other tests that have previously been suggested as a screening test for ototoxicity.
89438543|NCT02132325|Experimental|Dignity Therapy|
89438544|NCT02130843||MALE PATIENTS BEFORE UDS|MALE PATIENTS BEFORE UDS WITH DIFFICULT CATHETERIZATION
89438545|NCT02126397|Active Comparator|polyps resection with Laser Diode|application of the laser diode by hysteroscopy to remove the endometrial polyp
89438546|NCT02126397|Active Comparator|polyps resection with bipolar electrode|application of the bipolar electrode Versapoint by hysteroscopy to remove the endometrial polyp
89438547|NCT03531294|Experimental|Group 1|Treatment based on central reading center reading evaluation of DRSS (diabetic retinopathy severity scale) level based on OPTOS funds photos.
89438548|NCT03531294|Experimental|Group 2|Treatment based on central reading center reading evaluation of DRSS (diabetic retinopathy severity scale) level based leakage index of OPTOS wide field fluorescein angiography.
89438549|NCT05551702|Experimental|Treatment|This arm will receive 8 weeks of the text-based intervention (CBT-txt). CBT-txt is a version of Cognitive Behavioral Therapy tailored to be delivered by automated text message. This arm will also complete surveys at baseline, 1 month, 2 months, and 3 months.
89438550|NCT05551702|No Intervention|Waitlist Control|This arm will not receive the text-based intervention during study participation. These participants will only complete surveys at baseline, 1 month, 2 months, and 3 months and will be given the option to receive CBT-txt after they complete study participation.
89438551|NCT03549975|Experimental|Botulinum toxin type A injection|Botulinum toxin type A injection followed by functional electrical stimulation
89438552|NCT05482152|No Intervention|Standard physician led care|Consultation by physician (pain specialist)
89438553|NCT05482152|Experimental|Nurse-led care|Preclinical nurse-led consultation and standard care by physician (pain specialist)
89438554|NCT05551624|Experimental|Atorvastatin + N-acetylcysteine|Patients included in the study received an oral treatment of Atorvastatin 40 mg daily and N-acetylcysteine 400 mg every 8 hours, for at least 1 month (up to 12 months)
89438555|NCT02786901|Experimental|Loteprednol Etabonate Ophthalmic Gel dosed TID|Gel
88923269|NCT04655404|Experimental|Surgical Cohort|Larotrectinib administered PO, BID @100 mg/m2 3-5 days prior to definitive surgery, followed by Larotrectinib administered PO, BID @100 mg/m2 on a 28-day cycle schedule.
88923270|NCT04648358|Active Comparator|Control group|The control group will receive scalp nerve blocks with 0.5% bupivacaine, plus normal saline with epinephrine at 1:200,000
88923271|NCT04648358|Experimental|DEX4mg group|DEX4mg group will receive scalp nerve blocks with 0.5% bupivacaine, plus 4 mg dexamethasone with epinephrine at 1:200,000.
88923272|NCT04633434|Experimental|The Talk Parenting Skill for Alexa|52 parents will be assessed at enrollment, then provided an Amazon Echo Dot and exposed to the prototype Bedtime Routine module of the Talk Parenting program for 4 weeks, and then re-assessed at 4 weeks (at treatment completion)
88923273|NCT04632238|No Intervention|Control|
88923274|NCT04632238|Experimental|Metrics-driven quality improvement (MDQI) intervention|
88923275|NCT04629326|Experimental|Imaging cohort|All study participants will be allocated to this arm (single-arm study).Study participants will undergo 68Ga-WL12 PET/CT scans
88923276|NCT04623593|Active Comparator|ACDF|Anterior cervical discectomy and fusion.
88923277|NCT04623593|Experimental|ACDA|Anterior cervical discectomy with arthroplasty.
89199351|NCT05760339|Active Comparator|Carbohydrate loading|Subjects will follow their usual diet in the pre-surgical weeks and will receive a maltodextrin beverage on the evening before surgery, as well as two hours before induction of anaesthesia
88923278|NCT04605380||Novices|Junior doctors/interns
88923279|NCT04605380||Intermediates|Specialist trainees/Residents
88923280|NCT04605380||Experts|Consultants/Attendings
88923281|NCT04589468|Experimental|Dose-Finding/Escalation|Fifty (n=50) post-treatment patients with colorectal cancer or breast cancer, deemed high-risk of relapse. The study will use an adaptive continuous reassessment method (CRM) design to assign patients sequentially at trial entry to one of five escalated doses depending on the feasibility / tolerability of exercise therapy evaluated over the total treatment period. The primary objective of this phase 1a trial is to identify the RP2D of exercise therapy for further evaluation in the phase 1b trial.
88923282|NCT04589468|Experimental|Dose Expansion|An independent cohort of 30 post-treatment patients with colorectal (n=15) or breast (n=15) cancer deemed high-risk of relapse. This cohort expansion trial will only evaluate the RP2D identified in the phase 1a trial. The primary objective of this phase 1b trial is to further evaluate the feasibility, safety, and biological activity of the RP2D.
89438556|NCT02786901|Experimental|Loteprednol Etabonate Ophthalmic Gel dosed BID|Gel
89438557|NCT02786901|Placebo Comparator|Vehicle Gel|Vehicle
89011832|NCT01689844|Active Comparator|Behavioral, DASH Plus - Dietary advice|This group will receive DASH diet advice and guided ordering of fruits, vegetables, nuts and beans that are high in potassium from a local supermarket.
89438558|NCT02130921|No Intervention|Control|Community Health Workers (CHWs) in the control group will be invited to one group lecture didactically reviewing medical ethics, and the attending CHWs will be requested to pay a home visit to participating IDUs and FMs after the lecture.
89438559|NCT02130921|Experimental|Intervention|"Intervention for CHWs: 3 sessions will cover the understanding stigma and its impact, self-protection and universal precaution adherence, effective communication with patients and family members, and motivational enhancement for behavioral change.~Intervention for IDUs: CHWs who participate in the intervention will be required to conduct 3 individual sessions with participating IDUs covering the following topics: physical health, risk reduction behaviors, mental health, and community integration.~Intervention for FMs: CHWs who participate in the intervention will be required to conduct 2 group sessions with participating FMs covering the following topics: healthy family routine, coping with caregiver burdens, enhance family relationships, support positive behavior change."
89011833|NCT01689844|Other|DASH - C|DASH C Group will receive brief DASH diet advice and will be able to make non- guided purchases of food products from the local supermarket.
89438560|NCT03550677|Experimental|Group General Anesthesia|These group patients will be monitored with ECG, pulse oximetry and noninvasive blood pressure. Anesthesia will be induced using 2-2.5 mg/kg propofol, 1-2 mcg/kg fentanyl, 10 mg-20 mg rocuronium and a proper size laryngeal mask airway will be placed to secure the airway. The lungs will be ventilated with a mixture of 50% and 50% oxygen.
89438561|NCT03550677|Experimental|Group Ankle Block|These group patients will be monitored with ECG, pulse oximetry and noninvasive blood pressure. Anesthesia will be induced using 2-2.5 mg/kg propofol, 1-2 mcg/kg fentanyl, 10 mg-20 mg rocuronium and a proper size laryngeal mask airway will be placed to secure the airway. The lungs will be ventilated with a mixture of 50% and 50% oxygen. After than an ankle block will be performed in patient group block patients using a mixture of 5 ml of 2% lidocaine and 10 ml of 0.5 bupivacaine the same amount placebo (saline) in group placebo under the guidance of peripheral nerve stimulator then the anesthesia will be disconnected and LMA will be removed. The patients will be transferred from postoperative care unit toward after they are eligible for discharge according to the modified scoring system.
89438562|NCT02132403|Experimental|IMPRIME PGG, BTH1704, & Gemcitabine|Imprime PGG with BTH1704 at assigned doses administered on days 1, 8, 15, and 22 of a 28-day cycle with Gemcitabine on days 1, 8, and 15, at assigned doses, of a 28-day cycle.
89438563|NCT02126475||Healthy volunteers|
89438564|NCT02126475||Park patients|
89438565|NCT05700058|Experimental|Super-Whey protein Dose 1|All protein sources will be given in doses that are considered low/normal, both in relation to recommended dietary advice and commercially available supplements. As such, no adverse reactions or side effects are expected through consumption of these supplementations
89438566|NCT05700058|Experimental|Super-Whey protein Dose 2|All protein sources will be given in doses that are considered low/normal, both in relation to recommended dietary advice and commercially available supplements. As such, no adverse reactions or side effects are expected through consumption of these supplementations
89438567|NCT05700058|Experimental|Super-Whey protein Dose 3|All protein sources will be given in doses that are considered low/normal, both in relation to recommended dietary advice and commercially available supplements. As such, no adverse reactions or side effects are expected through consumption of these supplementations
89438568|NCT04264806|Experimental|Azacitidine: Participants with MDS or CMML|Participants with higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) will receive azacitidine 75 milligram per meter square (mg/m^2) body surface area (BSA) subcutaneously or Intravenously per local label on Days 1 through Day 7 of each 28-day cycle. Participants will be treated until disease progression; relapse from complete remission (CR), partial remission (PR), or marrow complete remission (mCR); transformation to acute myeloid leukemia (AML); death; or unacceptable toxicity.
89438569|NCT04264806|Experimental|Azacitidine and Cusatuzumab: Participants with MDS or CMML|Participants with higher-risk MDS or CMML will receive azacitidine 75 mg/m^2 BSA subcutaneously or Intravenously per local label on Days 1 through 7 and cusatuzumab 20 mg/kg IV on Days 3 and 17 of each 28-day cycle. Participants will be treated until disease progression; relapse from CR, PR, mCR; transformation to AML; death; or unacceptable toxicity.
89438570|NCT02132481|Experimental|EMA Only|See intervention
89438571|NCT02132481|Experimental|EMI Only|See intervention
89438572|NCT02132481|Experimental|EMA+EMI|See intervention
89438573|NCT02132481|Active Comparator|Neither - RSAU|See intervention
89438574|NCT05699902|Active Comparator|PECs block group|Female undergone mastectomy and received pectoral nerve block
89438575|NCT05699902|Sham Comparator|Non PECs block group|Female undergone mastectomy and not received pectoral nerve block but have received conventional analgesic methods
89438576|NCT02135991|Experimental|Project CHOICE + Getting To Outcomes|Boys and Girls Club sites will receive a) training and materials for Project CHOICE and b) training, ongoing technical assistance for two years, and materials for Getting To Outcomes
89438577|NCT02135991|Active Comparator|Project CHOICE only|Boys and Girls Club sites will receive a) training and materials for Project CHOICE
89438578|NCT02132559||DHEA administration,no treatment|The patients of study group received DHEA 25 mg orally,three times a day before the IVF cycle. Except for IVF, the control group of patients did not receive any pre-treatment.
89438579|NCT05551468|Experimental|Monitoring + Intervention modules|"Monitoring: Ecological Momentary Assessment (EMA) of affect, thoughts and social company. Optionally with a wearable to measure activity level. Six times per day for two weeks.~Timepoints: T0-T4.~Intervention modules: StayFine guided app-based personalised intervention modules. Each individual receives six of eight modules of which three are mandatory and three others are selected based on a personalization procedure.~Time point: after T0 over the course of three months."
89438580|NCT05551468|Active Comparator|Monitoring|"Monitoring:Ecological Momentary Assessment (EMA) of affect, thoughts and social company. Optionally with a wearable to measure activity level. Six times per day for two weeks.~Timepoints: T0-T4."
89438581|NCT00126984|Experimental|Group A|Subjects of 12-14 months of age or 3-5 years of age who will receive formulation A
89438582|NCT00126984|Experimental|Group B|Subjects of 12-14 months of age or 3-5 years of age who will receive formulation B
89438583|NCT00126984|Experimental|Group C|Subjects of 12-14 months of age or 3-5 years of age who will receive formulation C
89438584|NCT00126984|Experimental|Group D|Subjects of 12-14 months of age or 3-5 years of age who will receive formulation D
88923283|NCT04562129|Experimental|Treatment|HD IL2 (600,000 units/kg/dose IV) will be given during week 1 of the 2 initial cycles or each course. Ipilimumab will be given concurrently at the low dose of 1 mg/kg during week one of the 2 initial cycles of each course for up to 2 doses, total. Nivolumab will be given on during week one of the 3rd cycle of each course. No systemic treatment will be administered during the 4th cycle. Patients without evidence of disease progression (RECIST v.1.1) or limiting toxicities will be offered additional courses of treatment for up to a maximum of 3 courses, total.
89438585|NCT00126984|Active Comparator|Group E|Subjects of 12-14 months of age who will receive Meningitec and subjects of 3-5 years of age who will receive Mencevax ACWY.
89438586|NCT05700370|Experimental|Sample collected with preceding DRE, then without|All subjects participate in the control and experimental collection event sequentially. The control group will consist of urine samples collected post-DRE, and the experimental group will consist of urine samples collected by the same subjects without preceding DRE.
89438587|NCT05551390|Experimental|one-time umbilical cord milking|"Before UCM procedures, in the case of vaginal delivery, the maternity doctor or nurse held the newborn below the level of the introitus. In the case of a cesarean section, the surgeon carries the newborn below the level of the incision.~Then maternity nurse or doctor swiped blood in length 20 centimeters of umbilical cord into the newborn, according to the number of swipes that assigned, then cutting the umbilical cord by the international standard methods. Newborns after birth were cared for and assessed according to the newborn nursing standards of QSMH in the department of pediatrics."
89438588|NCT05551390|Experimental|three-time umbilical cord milking|"Before UCM procedures, in the case of vaginal delivery, the maternity doctor or nurse held the newborn below the level of the introitus. In the case of a cesarean section, the surgeon carries the newborn below the level of the incision.~Then maternity nurse or doctor swiped blood in length 20 centimeters of umbilical cord into the newborn, according to the number of swipes that assigned, then cutting the umbilical cord by the international standard methods. Newborns after birth were cared for and assessed according to the newborn nursing standards of QSMH in the department of pediatrics."
89438589|NCT02132715|Active Comparator|Resistance exercise|Traditional isotonic lower-extremity resistance training
89438590|NCT02132715|Experimental|KAATSU exercise|Lower-extremity exercise with blood flow mildly restricted
89438591|NCT05558722|Experimental|Anlotinib|Anlotinib is an oral multi-targeted tyrosine kinase inhibitor (TKI) that strongly inhibits VEGFR, PDGFR, FGFR, and c-kit. Anlotinib (12 mg qd, d1-14; 21 days per cycle; total 5 cycles) Combined TAC×6 cycles.
89438592|NCT03551379||Endoscopic procedure|A double balloon endoscopic platform will be used during an ESD procedure
89438593|NCT05699746|Experimental|CAPEOX|Drug CAPEOX (Oxaliplatin 130 mg/m2 IV day 1, Capecitabine 1000 mg/m2, twice daily PO for 14 days, repeat every 3 weeks) for at most 8 cycles.
88923284|NCT04560725|Experimental|[68Ga] P137|Imaging cohort. All study participants will be allocated to this arm (single-arm study).Study participants will undergo [68Ga]P137 PET/CT scans.
88923285|NCT04560335|Experimental|Coach to fit|CoachToFit: Those randomized to CoachToFit will have the CoachToFit app downloaded to their phone by the peer coach and will work with the coach to initialize the app. Individuals will receive an activity tracker compatible with Android OS and iOS (Amazfit Bit) and a Bluetooth scale (Smart Body scale). Participants will be instructed by the peer to complete at least two CoachToFit modules per week. Modules take about 15 minutes to complete and have embedded knowledge quizzes and end with a choice of three goals to practice over the next week. They will also set up a time for the first 20-minute coaching call, which will then continue weekly.
88923286|NCT04560335|Other|Treatment as usual|Veterans randomized to the treatment as usual arm will continue to access all services of the VA Pittsburgh, and will participate in three research interviews. After the first meeting, all participants will meet with a peer coach (peer specialists) who will discuss with them the importance of losing weight (using a structured conversation that follows a handout which is provided to the participant). The handout was developed with input from a VA dietitian as well as Veterans and is graphically appealing, with a simple layout, and provides information on diet and activity as well as the local MOVE! schedule
88923287|NCT04557423|Active Comparator|Evidence-Based Intervention|Culturally appropriate educational intervention focused on cervical cancer screening, with navigation assistance provided.
89438594|NCT05699746|No Intervention|Observation|Patients undergo active surveillance
89438595|NCT02136225|Experimental|Counseling|Intervention: Means restriction counseling. Health care providers will counsel parents on the risks of having a gun, particularly an unlocked gun in the home where youth are present.
88923288|NCT04557423|Experimental|HPV Self-Sampling|Previously tested evidence-based intervention (i.e. culturally appropriate educational intervention focused on cervical cancer screening, with navigation assistance provided). Participants will also receive a self-sampling kit.
89199352|NCT05760339|No Intervention|Control group|Subjects will continue their usual diet and proceed with standard preoperative fasting (i.e., eat up until 6 hours and take clear liquids up until 2 hours before induction of anaesthesia).
89438596|NCT02136225|Experimental|Counseling and locking devices|Intervention: Means restriction counseling and locking devices. Health care providers will counsel parents on the risks of having a gun, particularly an unlocked gun, in the home where youth are present. Parents will also receive locking devices to store their guns securely.
89438597|NCT02136225|No Intervention|Control group|Youth in the control group will receive usual care.
89438598|NCT05551312|Experimental|Intervention|Virtual Essential Newborn Care (vENC) Training
89438599|NCT05551312|No Intervention|Control|Standard of Care
89438600|NCT02136303|Placebo Comparator|S1-Placebo|placebo capsule with all ingredients, but without active compound, intervention for 4 weeks, S1: Dosage-dependency
89438601|NCT02136303|Experimental|S1-1L|capsule containing 1 mg lutein out of kale, intervention for 4 weeks, S1: Dosage-dependency
89438602|NCT02136303|Experimental|S1-2L|capsule containing 2 mg lutein out of kale, intervention for 4 weeks, S1: Dosage-dependency
89438603|NCT02136303|Experimental|S1-5L|capsule containing 5 mg lutein out of kale, intervention for 4 weeks, S1: Dosage-dependency
89438604|NCT02136303|Experimental|S2-Kale_extract|
89438605|NCT02136303|Experimental|S2-Kale_purée|
89438606|NCT02136303|Placebo Comparator|S3-Placebo|
89438607|NCT02136303|Experimental|S3-AMD-Patients|
89438608|NCT02136303|Experimental|S3-non-AMD|
89438609|NCT02136303|Placebo Comparator|S1-Placebo-Tagetes|capsule containing all ingredients, but without active compound, intervention for 4 weeks, S1: Dosage-dependency
89438610|NCT02136303|Experimental|S1-1L-Tagetes|capsule containing 1 mg lutein out of tagetes, intervention for 4 weeks, S1: Dosage-dependency
89438611|NCT02136303|Experimental|S1-2L-Tagetes|capsule containing 2 mg lutein out of tagetes, intervention for 4 weeks, S1: Dosage-dependency
89438612|NCT02136303|Experimental|S1-5L-Tagetes|capsule containing 5 mg lutein out of tagetes, intervention for 4 weeks, S1: Dosage-dependency
89438613|NCT02136303|Experimental|S1-10L-Tagetes|capsule containing 10 mg lutein out of tagetes, intervention for 4 weeks, S1: Dosage-dependency
89438614|NCT04324372|Experimental|HEC68498|HEC68498 will be administered daily
89438615|NCT02132793|Active Comparator|Anger Management Therapy|Anger Management Therapy (AMT) is a 12-session manual-driven cognitive-behavioral intervention found efficacious for anger management treatment.
89438616|NCT02132793|Experimental|Anger Management Therapy & RELAX app|Anger Management Therapy (AMT) is a 12-session manual-driven cognitive-behavioral intervention found efficacious for anger management treatment. RELAX app (1) enables the practice of anger management strategies remotely through mobile phone interfaces; (2) integrates with evidence-based treatments through implementing an existing CBT anger management course; (3) provides information, direction, and feedback through physiological sensors; and (4) supports communication and direction by the therapist through a web-based therapist interface and a remote and secure patient data server.
89438617|NCT05551234||Isolated senior|
89438618|NCT05551234||Children|
89438619|NCT03549897|Placebo Comparator|Placebo Product|One actuation each from two different placebo Reference inhalation aerosols and one actuation each from two different placebo Test inhalation aerosols
89438620|NCT03549897|Active Comparator|90 mcg Reference Product|One actuation each from the Reference inhalation aerosol and the placebo Reference inhalation aerosol and one actuation each from two different placebo Test inhalation aerosols
88923289|NCT04554602||Patient with endometriosis or suspicion of endometriosis|"Information and collection of the non-objection before inclusion~Interrogation, clinical examination, EHP30 and SF36 form at inclusion~MRI, pelvic ultrasound (coupled with fusion ultrasound)~Laparoscopy if indicated after MRI, ultrasound and fusion ultrasound~Monitoring by form and fusion ultrasound at 6 months and then once a year for 3 years"
88923290|NCT04554602||Patient with other gynaecological pathology|"Information and collection of the non-opposition before inclusion~Interrogation, clinical examination, EHP30 and SF36 form at inclusion~MRI, pelvic ultrasound (coupled with fusion ultrasound)~laparoscopy if indicated after MRI, ultrasound and fusion ultrasound"
88923291|NCT04553536|Active Comparator|Opioid analgesics|Mu-opioid receptor agonists (remifentanil, sulfentanil) will be used as the only analgesic(s) in the surgery.
88923292|NCT04553536|Experimental|Ketamine|Esketamine will be used as the only anagesic in the surgey.
88923293|NCT04548219|Experimental|Mirikizumab (Reference)|200 milligram (mg) of mirikizumab as reference formulation (100 mg/mL), 2 × 1-mL pre-filled syringe administered as a subcutaneous (SC) injection into the arm/thigh/abdomen on day 1.
89438621|NCT03549897|Active Comparator|180 mcg Reference Product|One actuation each from two different Reference inhalation aerosol and one actuation each from two different placebo Test inhalation aerosols
89438622|NCT03549897|Experimental|90 mcg Test Product|One actuation each from the Test inhalation aerosol and the placebo Test inhalation aerosol and one actuation each from two different placebo Reference inhalation aerosols
89438623|NCT05551078||pregnant women with severe IUGR|
88923294|NCT04548219|Experimental|Mirikizumab (Test)|200 mg of mirikizumab as test formulation (100 mg/mL), 2 × 1-mL pre-filled syringe administered as a SC injection into the arm/thigh/abdomen on day 1.
89011834|NCT01689883|Other|Current stimulator|The investigators have developed a device to deliver very small currents to the arm. The device will be used while subjects perform upper-limb movements using a device for upper-limb rehabilitation. Subjects will perform multiple trials of movement. During half of the trials, they will receive actual stimulation. During the other half, they will receive sham stimulation.
89438624|NCT02132871||1|
89438625|NCT02136381|Experimental|LEAP intervention|A newly developed internet-based lifestyle programme (Living, Eating, Activity and Planning through retirement (LEAP)) will promote three key health and social behaviours; healthy eating following a Mediterranean diet, increasing physical activity and improve social connectedness.
89438626|NCT02136381|Other|Control|"Thirty participants will be randomised to a minimal intervention comparator condition, where participants will be emailed a direct link to the National Health Service (NHS) choices 'LiveWell' website (http://www.nhs.uk/LiveWell/Pages/Livewellhub.aspx).~This website contains general information on improving life style and health."
89438627|NCT05547802||Heterologous vaccination cohort|Subjects with two doses of BBIBP-CorV vaccine and third (second booster) dose of the BNT162b2 vaccine.
89438628|NCT05547802||Homologous vaccination cohort|Subjects receiving three doses of BNT162b2 vaccine.
89438629|NCT02133027|Experimental|Rouviere's Sulcus|Rouviere's sulcus is a 2 to 5 cm sulcus running to the right of the liver hilum anterior to the caudate process and usually containing the right portal triad or its branches.Dissection may be started safely by division of the peritoneum immediately ventral to the sulcus and continued in a triangle bounded by the liver surface, the neck of the gallbladder and the plane of the sulcus.
89438630|NCT02133027|Other|traditional anatomy method|Ratcheted grasper is inserted through the lateral 5-mm port to retract the gallbladder fundus in cephalad fashion. An atraumatic grasper is inserted through the middle 5-mm port to retract the gallbladder infundibulum laterally, exposing the anteromedial aspect of the triangle of Calot.
89438631|NCT05700838|Experimental|Cough Skill Training|During cough skill training, participants will be seated in front of a computer with real-time visualization of their cough waveform. A target line will be provided, and participants will be instructed to perform a single voluntary cough so that their peak flow is within the target's range. Participants will be instructed to continue the cough training regardless of initial accuracy.
89438632|NCT02252289||Problematic severe asthmatics|"Approximately 75 Children aged 5 to 17 years with problematic severe asthma (PSA). Two groups of PSA children will be recruited: those who have already been assessed as part of the Difficult Asthma protocol and classified as DA (difficult asthma)/ STRA (severe therapy resistant asthma) (training set) and those newly referred to the protocol (validation set).~Previous enrolment or new referral to the Royal Brompton Hospital Difficult Asthma Protocol."
89438633|NCT02252289||Control group of moderate asthmatics|A control group of 30 children aged 5 to 17 years with mild to moderate asthma.
89438634|NCT05551000|Experimental|Intervention|This group will use a functional training system developed specifically for elderlies to improve everyday movements, physical strength and balance.
89438635|NCT05551000|Active Comparator|Positive control|This group will use a general training system developed for elderlies to improve everyday movements, physical strength and balance.
89438636|NCT05551000|No Intervention|Negative control|Control group: A group that is not treated.
89438637|NCT02136459|Experimental|Small tube size|Size 6.5 ETT for female, size 7.0 ETT for male
89438638|NCT02136459|Active Comparator|Large tube size|Normal tube size, size 7.5 for female, size 8 for male
89438639|NCT02136537|Active Comparator|Best medical therapy|Claudicants treated according to local protocol - no added treatment
89438640|NCT02136537|Experimental|Best medical therapy plus NMES|In addition to best medical therapy, subjects will receive bilateral neuromuscular stimulation of their legs, 4 hours per day.
89438641|NCT02136615||overweight and obese male volunteers|BMI between 23-40 kg/m2
89438642|NCT04468620|Experimental|ASSET Intervention|13-session group intervention
89438643|NCT02133105|Active Comparator|Levosimendan|Levosimendan administration is initiated with a loading dose of 12μg/kg given over 10 min followed by a continuous infusion of 0.1 μg/kg/min for 65 min.
89199353|NCT05756946|Experimental|Test group|Test group will receive GTR + periodontal dressing (Coe-pak)
89438644|NCT02133105|Active Comparator|Dobutamine|Dobutamine is given as a continuous infusion without a bolus dose. The infusion rate is started at 5.0 μg/kg/min for 10 minutes, and thereafter increased to 7,5 μg/kg/min for 65 min.
89438645|NCT04468464|Active Comparator|Control Group|Occlusal Splint
89438646|NCT04468464|Experimental|Study Group|Osteopathic Manuel Therapy
89438647|NCT02136693|Placebo Comparator|Placebo|3.5 g /day of inert compound for 180 days after STARR
89438648|NCT02136693|Experimental|Psyllium fiber|3.5 g /day of pure Psyllium fiber for 180 days after STARR
89438649|NCT05547334|Other|A non-concurrent multiple baseline design|A non-concurrent multiple baseline design
89438650|NCT03767127||Appropriate transfusion policy|Patients transfused with high arterial-venous oxygen difference (≥3.7 ml/dl) or non-transfused with low arterial-venous oxygen difference (<3.7 ml/dl)
89011835|NCT01689922||AlterG and Physical therapy|2) Standard postoperative rehabilitation program with addition of lower body positive pressure (LBPP) treadmill training
89011836|NCT01689922||Control group|1) Standard postoperative rehabilitation program
89011837|NCT01689961|Experimental|Nutrition+Exercise Intervention|"Structured + monitored nutrition and exercise intervention:~The exercise intervention includes a custom-designed pregnancy-specific group walking class of 30-60 min. 1x/week and a prescribed at-home walking program for 10,000 steps/day. The nutrition intervention is a high protein (25% energy) low-fat dairy food plan designed to meet energy needs and with individualized counselling. The intervention will include 2 x/month weight monitoring and records of nutrition and activity to ensure adherence"
89011838|NCT01689961|No Intervention|Usual Prenatal Care|Mothers in the Control Group will be followed by their primary care provider and have usual access to public health services. In addition, they will be asked to attend 2 focus group sessions exploring women's experiences with exercise, nutrition, and weight gain in pregnancy. Women will receive information about healthy pregnancy from Health Canada.
89011839|NCT01686061||Blepharospasm Survey Group|
89011840|NCT01685359|Experimental|Test Drug|Test Drug (Human Recombinant Epoetin alfa - Blau) dosage: 100 IU/kg intravenous administration
89011841|NCT01685359|Active Comparator|Eprex|Eprex (Janssen-Cilag, Epoetin alfa) dosage: 100 IU/kg intravenous administration
89438651|NCT03767127||Non-Appropriate transfusion policy|Patients transfused despite low arterial-venous oxygen difference or non-transfused with high arterial-venous oxygen difference
89438652|NCT05451186|Experimental|Eye patch and headphones|Eye patch and headphones
89438653|NCT05451186|No Intervention|Control group|Routine maintenance will be applied
89438654|NCT02133339|Experimental|TRN-157|
89438655|NCT02133339|Placebo Comparator|Placebo|
89438656|NCT02136771|Active Comparator|Vitamin D3|The treatment group receives 2,800 IU vitamin D3 per day as oily drops (Oleovit D3; producer: Fresenius Kabi Austria, A-8055 Graz) for 8 weeks
89438657|NCT02136771|Placebo Comparator|Placebo|Oily drops as placebo
89438658|NCT00125970|Experimental|1|DNA HIV vaccine administered at study entry and at Months 1 and 2 and adenoviral vector HIV vaccine administered at Month 6
89438659|NCT00125970|Placebo Comparator|2|DNA HIV vaccine placebo administered at study entry and at Months 1 and 2 and adenoviral vector HIV vaccine placebo administered at Month 6
89438660|NCT05579457||elderly people living in rural areas|
89011842|NCT01682824||Group I (questionnaire, nutritional assessment)|Patients complete the TFEQ-R18v2 questionnaire, a dietary intake assessment, and the EQ-EMA questionnaire online.
89011843|NCT01682824||Group II (questionnaire, nutritional assessment)|Patients complete the EQ-EMA questionnaire, a dietary intake assessment and the TFEQ-R18v2 questionnaire.
89011844|NCT01687738|Experimental|Communication Intervention|Specially trained communicator addresses factual understanding and elicits other barriers to care
89011845|NCT01687738|Experimental|Real Time Registry and data feedback only|Patients are enrolled in registry and clinicians receive warnings about delayed or missed care.
89199354|NCT05756946|Active Comparator|Control group|Control group will receive GTR only
89438661|NCT05579457||elderly people living in urban areas|
89438662|NCT03528252|Active Comparator|LDL Cholesterol|Will receive dietary advice effective for reducing LDL cholesterol.
89438663|NCT03528252|Sham Comparator|Triglycerides|Will not be aware that they are in fact Control Group. Will receive dietary advice effective for reducing Triglycerides, but neutral for LDL cholesterol.
89438664|NCT02133417||Women|Women with mammographically-detected breast lesions
89011846|NCT02278978|Experimental|FGFR3 mutated|BIBF 1120 in patients with advanced FGFR3 mutated
89438665|NCT03527940||Patients with STEMI|
89438666|NCT01561521|Experimental|AKF-1 0.025%|
89438667|NCT01561521|Experimental|AKF-1 0.035%|
89438668|NCT01561521|Placebo Comparator|AKF-1 0%|
89438669|NCT03531216|Active Comparator|Topical application of rosemary oil|Rosemary essential oil (10% )
89438670|NCT03531216|Placebo Comparator|Placebo|Pharmaceutical quality olive oil
89438671|NCT02253303|Experimental|Midline incision|The extraction-site incision in laparoscopic colectomy is middline
89438672|NCT02253303|Active Comparator|off-midline incision|The extraction-site incision in laparoscopic colectomy is off-middline
89011847|NCT02278978|Experimental|FGFR3 overexpressed|BIBF 1120 in patients with advanced FGFR3 overexpressed
89011848|NCT02278978|Experimental|FGFR3 wild type|BIBF 1120 in patients with advanced FGFR3 wild type
89023492|NCT05344339|Experimental|Billroth-II modified|An opening will be made at jejunum 25 cm from Treitz's ligament. Another at greater curvature of the stomach right above transected line. A straight stapling device will be used to make isoperistaltic anastomosis at posterior wall of the stomach. After checking for bleeding, common entry hole will be closed using running suture and 3 -5 sutures to attach afferent loop to the remnant stomach
89438673|NCT03531138|Experimental|Pulmonary rehabilitation group|All patients will undergo supervised pulmonary rehabilitation program on 2 days per week for 3 months. Apart from that, they will ask to perform the home exercise program which is scheduled as 3 days per week.
89438674|NCT03531060|Experimental|IRL790|IRL790 Capsule 10 mg, oral administration
89438675|NCT03531060|Placebo Comparator|Placebo|Placebo capsule, identical appearance, oral administration
89438676|NCT02136927|Experimental|SPARC1210|Intravenous administration of SPARC1210
89438677|NCT02136927|Active Comparator|Reference1210|Intravenous administration of Reference1210
89438678|NCT03527784|Active Comparator|Parietene Macro|Parietene Macro is a macroporous synthetic mesh.
89438679|NCT03527784|Active Comparator|Parietex Parastomal|Parietex Parastomal is a synthetic mesh with resorbable collagen lining to prevent attachments.
89438680|NCT03527784|Active Comparator|Dynamesh IPST|Dynamesh IPST is synthetic mesh with central tube to accommodate bowel tightly designed to prevent and treat parastomal hernia.
89438681|NCT02133495|Experimental|open label|Non Cadaveric human BellaDerm Acellular dermal tissue
89438682|NCT05723952|Experimental|Barcelona scoliosis physical therapy school|procedure for treating scoliosis
89438683|NCT05723952|Experimental|International scoliosis schroth therapy|procedure for treating scoliosis
89438684|NCT02260713|No Intervention|Control|control subjects with acute complete spinal cord injury who would not receive any bone marrow transplantation.
89438685|NCT02260713|Experimental|Transplantation via intrathecal route|Subjects with acute complete spinal cord injury who receive autologous bone marrow cell transplantation via lumber puncture
89438686|NCT02260713|Experimental|Transplantation via intralesional route|Subjects with acute complete spinal cord injury who receive autologous bone marrow cell transplantation via durotomy and injection at the lesional site .
89438687|NCT03133494|Active Comparator|Laparoscopic cholecystectomy in smokers|ABG analysis of patients with history of smoking posted for laparoscopic cholecystectomy was collected
89438688|NCT03133494|Placebo Comparator|Laparoscopic cholecystectomy nonsmokers|ABG analysis of patients without history of smoking posted for laparoscopic cholecystectomy was collected
89438689|NCT02137005||Cerebral Palsy|Patients with cerebral palsy who were seen at the Center for Gait and Movement Analysis (CGMA) at Children's Hospital Colorado as children.
89438690|NCT05723796|Experimental|chronic HP patients|
89438691|NCT03549663|Experimental|Tacrolimus monotherapy|
89438692|NCT03549663|Active Comparator|Tacrolimus combined with hormone therapy|
89438693|NCT02137083|Experimental|Docetaxel Plus Fulvestrant|"Docetaxel:75mg/m2 D2 every 21 days~Fulvestrant:500mg D1, D15, D29, D57, every 28 days later"
89438694|NCT02137083|Active Comparator|Docetaxel|Docetaxel:75mg/m2 D2 every 21 days
88923295|NCT04523818|Experimental|Treatment (CXRT, chemotherapy, surgery)|Patients receive CXRT consisting of radiation therapy 5 days a week (Monday through Friday) for 2 weeks (10 treatments) and standard of care chemotherapy consisting of capecitabine PO BID or fluorouracil IV continuous Monday to Friday of each radiation week. About 2 weeks later, patients receive standard of care chemotherapy for up to 2 months in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgery 3-8 weeks post-chemotherapy completion.
88923296|NCT04516967|Active Comparator|Experimental: Avatrombopag|Study is 3:1 randomization ratio (avatrombopag to placebo). Investigational product administered orally once daily for 12 weeks
88923297|NCT04516967|Placebo Comparator|Placebo Comparator:Placebo|Study is 3:1 randomization ratio (avatrombopag to placebo). Investigational product administered orally once daily for 12 weeks
88923298|NCT04474847|Experimental|Blinded Abatacept|Participants will receive blinded abatacept 125 mg administered by subcutaneous injection once a week for at least 12 months. Subjects may be removed from treatment earlier due to a disease relapse, disease worsening, or if they have not achieved remission.
88923299|NCT04474847|Placebo Comparator|Blinded Placebo|Participants will receive blinded placebo. Placebo will be administered by subcutaneous injection once a week for at least 12 months. Subjects may be removed from treatment earlier due to a disease relapse, disease worsening, or if they have not achieved remission.
89438695|NCT05428800|Experimental|Experimental|Progressive relaxation exercises will be performed for 25-30 minutes every day for 8 weeks, and at the end of 8 weeks, the group will be evaluated again with PMSS.
89438696|NCT05428800|No Intervention|Control|They will continue their routine coping habits for 8 weeks, and at the end of 8 weeks, the group will be evaluated again with PMSS.
89438697|NCT02137161|Active Comparator|Dexamethasone+Tobramycin eye drop|An antibiotic and steroid eye drop association will be given starting the day after the surgery for two weeks, dosed QID for the first week and BID for the second week, to 31 patients.
89438698|NCT02137161|Experimental|Bromfenac|Bromfenac eye drops (BID for two weeks starting the day after surgery) plus an antibiotic and steroid eye drop association (QID for the first week and BID for the second week) will be given concurrently to 31 patients.
89438699|NCT02252991|Other|Arm A with physical activity during the treatment|In the arm A, patients will realise physical activity during the treatment. Blood samples will be realised. Questionnaries will be given to the patients.
89438700|NCT02252991|Other|Arm B with physical activity after the treatment|In the arm B, the physical activity will be realised after treatment. Blood samples will be realised. Questionnaries will be given to the patients.
89438701|NCT05405400||Treatment group|Families in the treatment group received one welcome visit, 12 visits from a community-based volunteer trained in the Sugira Muryango intervention over 3-4 months, as well as booster visits at 3 and 6 months. The primary caregiver, secondary caregiver if applicable, and any children ages 6-36 months participated in the sessions. Other family members were welcome to join as available.
89438702|NCT05405400||Control group|Usual childcare (no intervention)
89438703|NCT05211999|Experimental|Precede-Proceed Model Based Simulation Experience|
89438704|NCT05211999|No Intervention|Control Group|
89438705|NCT05401266|No Intervention|normal blood carbonic acid level|After propofol infusion was stopped, ventilation parameters were adjusted to maintain end-expiratory carbon dioxide (ETCO2) 35-40 mmHg until spontaneous respiration was restored.
89438706|NCT05401266|Experimental|mild hypercapnia|After propofol infusion was stopped, ventilation parameters were adjusted to achieve and maintain ETCO2 50-55 mmHg until spontaneous respiration was restored.
89438707|NCT02253069|Experimental|PHMB-based antiseptic|Applying Prontosan antiseptic solution to tie-over dressings
89438708|NCT02253069|Placebo Comparator|Control|Applying water to tie-over dressings
89438709|NCT03528096|Experimental|Intervention night|Vestibular stimulation, in the form of gentle rocking movements, is provided using the Somnomat B rocking bed. Stimulation is provided for the first 60 minutes of the night and for 10 minutes upon detection of symptoms. The stimulation frequency is in the range of 0.25-2 Hz.
89023493|NCT05344339|Active Comparator|Roux-en-Y|Jejunum will be transected 25 to 30 cm from Treitz's ligament. Marginal vessels will be transected if needed to make sure the loop will reach the stomach without tension. Isoperistaltic gastrojejunostomy will be made at posterior wall of the stomach. After checking for bleeding, common entry hole will be closed using running suture. Jejunojejunal mesenteric defect and Petersen's defect will be closed.
89438710|NCT03528096|Sham Comparator|Baseline night|The sound of the moving bed is played back to the participant at the right sound intensity level.
89438711|NCT05362656|Experimental|Atrial mapping and dispersion auto-tagging with VX1+|
89023494|NCT05342623|Experimental|Difelikefalin 1 mg Oral Tablet|Patients receive oral difelikefalin 1 mg once daily
89438712|NCT03528018|Other|Control|Conventional physical therapy
89438713|NCT03528018|Experimental|Experimental|Combined tDCS and VR-based intervention
89438714|NCT03530982|Experimental|Intervention group|Intensive goal training of relevant activities reported by adolescents in the beginning of the study. Therapists will grade the level of complexity of the proposed activities, considering the relevant movements, task demands and contextual factors involved in the performance of each task. Adolescents will be asked to practice these activities at home (1 hour/daily) and to discuss their difficulties and improvements with the therapists. The intervention will be provided in a day-camp model.
89438715|NCT03527628|Other|Patients with PET-2 Negative Result|"After 2 ABVD cycles an interim PET-2 will be performed, and treatment will be adapted according to to PET results~PET-2 negative patients will be treated with 4 cycles of ACVD (Adriamycin, Cyclophosphamide, Vinblastine And Dacarbazine)"
89438716|NCT03527628|Other|Patients with PET-2 Positive Result|"After 2 ABVD cycles an interim PET-2 will be performed, and treatment will be adapted according to to PET results~PET-2 positive patients will be treated with 4 cycles of ACVD with addition of Brentuximab Vedotin"
89438717|NCT03530904|Active Comparator|early mobilization after cardiac device implantation|mobilization after 4 hours
89438718|NCT03530904|Active Comparator|Late mobilization after cardiac device implantation|Mobilization after 24 hours
89438719|NCT03530748||Patients with Renal Artery Stenosis|Patients with simple renal artery stenosis or aortic dissection with renal artery obstruction
89438720|NCT04466748|Experimental|Anaprazole Sodium enteric-coated tablet|"Multiple ascendinng dose, anaprazole 20mg QD(20mg QD group), 40mg QD(40mg QD group), 20mg Bid(20mg Bid group) , 6 days, fasting oral administration."
89438721|NCT04466748|Placebo Comparator|Placebo|Multiple dose, 1 tablet QD (20mg QD and 40mg QD group), 1 tablet Bid (20mg Bid group), 6 days, fasting oral administration.
89438722|NCT04466670|No Intervention|phase 1|Observational arm
89438723|NCT04466670|Experimental|phase 2A|Acetylsalicylic acid
89023495|NCT05342623|Placebo Comparator|Placebo Oral Tablet|Patients receive oral placebo once daily
89438724|NCT04466670|Experimental|phase 2B|inhaled unfractionated heparin
89438725|NCT04466670|Placebo Comparator|Placebo|Placebo arm for Phase 2A
89438726|NCT04468542|Experimental|Bupivacaine/triamcinolone injection|2-cc injection (mixture consisting of 1-cc of 0.5% Bupivacaine injection and 1cc of 40mg/cc triamcinolone acetonide suspension injection) will be delivered percutaneously into the region of the proximal superior laryngeal nerve, every 1-2 weeks, for total of 2 to 3 injections
89438727|NCT04468542|Placebo Comparator|Saline injection|2-cc injection of normal saline will be delivered percutaneously into the region of the proximal superior laryngeal nerve, every 1-2 weeks, for total of 2 to 3 injections
89438728|NCT04468308||Senile Cataract|Patient with senile cataract, whose cataract surgery was postponed in the COVID-19 pandemic
89438729|NCT04615260|Other|Single arm subject is own control|Posterolateral fusion is bilateral, patients will receive the Nanobone graft on the right side of their spine and the local bone graft on their left side.
89438730|NCT03525522|Experimental|Nd:YAG Laser|Three sessions of Nd:YAG laser (1064 nm) treatment with Dynamis (Fotona, Slovenia)
89438731|NCT03525522|Active Comparator|Topical Corticosteroid Diprosone|Topical corticosteroid betamethasone (Diprosone, Merck Sharp & Dohme, d.o.o.) for 3 months.
89438732|NCT04466436||CABG group|
89438733|NCT04466436||spine group|
89023496|NCT05335733||Postmenopausal women|
89438734|NCT04466514|Experimental|Treatment A - Fasting|Fasting conditions
89023497|NCT05335733||Premenopausal women|
89438735|NCT04466514|Experimental|Treatment B - Fed|High-fat/high-calorie breakfast
89438736|NCT04466514|Experimental|Treatment C - Fed|Low-fat/low-calorie breakfast
89438737|NCT04500834|Experimental|Positive reactions, Concordance with reference allergen|All subjects will be patch tested with 11 experimental and 11 reference allergens. Rates of positive reactions will be evaluated using Cohen's kappa calculation.
89438738|NCT04467450|Experimental|Botox injection|half of the hemiplegic patients will be injected by botulinum toxin A in the inflamed subacromial-subdeltoid bursa guided by musculoskeletal ultrasound
89438739|NCT04467450|Active Comparator|methyl prednisolonate injection|the other half of the hemiplegic patients will be injected by methylprednisolonate in the inflamed subacromial-subdeltoid bursa guided by musculoskeletal ultrasound
89011849|NCT02218723|Active Comparator|Sequence ABECD|Subject will be administered treatment in sequence ABECD. Where, A: a single dose of FF [100 microgram (mcg) per blister from 0.6% blend] delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; B: a single dose of FF (80mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 320mcg; C: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; D: a single dose of FF (140mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 560mcg; E: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the ELLIPTA DPI by inhalation of 4 Blisters giving a total dose of 400mcg
89011850|NCT02218723|Active Comparator|Sequence BCADE|Subject will be administered treatment in sequence BCADE. Where, A: a single dose of FF (100mcg per blister from 0.6% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; B: a single dose of FF (80mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 320mcg; C: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; D: a single dose of FF (140mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 560mcg; E: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the ELLIPTA DPI by inhalation of 4 Blisters giving a total dose of 400mcg
89011851|NCT02218723|Active Comparator|Sequence CDBEA|Subject will be administered treatment in sequence CDBEA. Where, A: a single dose of FF (100mcg per blister from 0.6% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; B: a single dose of FF (80mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 320mcg; C: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; D: a single dose of FF (140mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 560mcg; E: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the ELLIPTA DPI by inhalation of 4 Blisters giving a total dose of 400mcg
89011852|NCT02218723|Active Comparator|Sequence DECAB|Subject will be administered treatment in sequence DECAB. Where, A: a single dose of FF (100mcg per blister from 0.6% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; B: a single dose of FF (80mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 320mcg; C: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; D: a single dose of FF (140mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 560mcg; E: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the ELLIPTA DPI by inhalation of 4 Blisters giving a total dose of 400mcg
89023498|NCT05328622|Experimental|Adherence Incentives Program|The intervention administered to participants is an incentive program designed to motivate participants to attend to/adhere to their prescribed prenatal course of care via the Aqueduct platform.
89438740|NCT04466046||PONV group|Patients with PONV after administration of midazolam 0.05mg/kg with ramosetron 0.3mg or palonosetron 0.075mg
89438741|NCT04466046||no PONV group|Patients with no PONV after administration of midazolam 0.05mg/kg with ramosetron 0.3mg or palonosetron 0.075mg
89438742|NCT03008382|Other|Double-Blind Randomized Drug|"Participants with Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) and/or Myofascial Pelvic Pain (MPP) will be randomized to take 8 weeks of Metoprolol Tartrate Oral Tablet or Placebo Oral Tablet, followed by a 4-Week washout period, and then 8 weeks of Placebo or Metoprolol.~This intervention aims at finding if subjects with IC/BPS have higher baseline HR compared to HCs. After 4 weeks baseline, subjects will receive a bottle with capsules containing 25 mg of metoprolol tartrate or placebo distributed in a double-blind manner by each site's investigational pharmacy. Subjects will start at 25 mg once daily and increase to the goal dose of 25 mg 2/day after one week, if HR has not decreased below 55 bpm at rest. Subjects will report daily rest HR for the first week. The subjects will then washout for 4 weeks and enter crossover in similar manner."
89501623|NCT04881877|Experimental|Standard latex condom:|Participants will be randomized to condom use order. Participants will be provided with 5 latex condom at the first visit and switched to 5 of either the latex graphene condom or synthetic nitrite condoms at visit 2 and 3. All couples will use each of the 3 condom types during the study.
88923300|NCT04458766|Experimental|Interventions|"All subjects in this trial will receive the following interventions:~Pre-Intervention (Days 0-14): Subjects given access to Wellth application reminders, no incentives provided. A virtual check in with the study team will occur at the end of the pre-intervention period (14 days).~Intervention (Days 15-74): Subjects will use Wellth app for 60 days, with incentives provided at the 30- and 60-day mark. At the end of the intervention period (Day 60), the subject will attend a clinic visit with the medical provider and a fasting lipid panel and MMAS will also be collected at this time.~Post-intervention (Days 74-134): Subjects will continue to use the Wellth app and receive reminders, but with no incentives provided, for 60 days. A clinic visit, fasting lipid profile, and MMAS will also be collected following the post-intervention period."
88923301|NCT04417699|Experimental|TAS102 plus Oxaliplatin|Oxaliplatin 85mg/m2 IV over 2 hours and TAS-102 (35 mg/m2/dose) orally BID
88923302|NCT04414306|Experimental|Experimental Arm 1|Attendees at in-person events (e.g. health fairs) who meet eligibility criteria will be able to enroll and participate in-person, with some participating in online or telephone survey follow-up.
88923303|NCT04414306|Experimental|Experimental Arm 2|People with social medial accounts (e.g. Facebook) will receive a message about the study (e.g. via an age and geospatially targeted Facebook ad) and have the option to enroll in the study if meeting eligibility criteria, with some participating in online or telephone follow-up.
88923304|NCT04414306|Experimental|Experimental Arm 3|People with social medial accounts (e.g. Facebook) will receive a message about the study (e.g. via an age and geospatially targeted Facebook ad) and have the option to enroll in the study if meeting eligibility criteria, with some participating in online or telephone follow-up. This arms will serve as an experimental arm for assessing study aim 2 and as a control arm for study aim 1.
88923305|NCT04414306|Experimental|Experimental Arm 4|Patients identified by one or more healthcare systems to be due or overdue for colorectal cancer screening will be informed by their healthcare provider or healthcare system (e.g. via the healthcare system's patient portal) that they are due for screening and will be informed how to schedule an colorectal cancer screening related appointment (e.g. discussion with primary care provider about colorectal cancer screening options) along with the option to receive education about colorectal cancer screening. Patients who are interested in receiving education may view the education with or without participating in the research study. Patients who elect to be study participants will participate in consenting, eligibility screening, pre-test, post-test, and possible three- and six-month using a parallel structure to study arms two and three.
88923306|NCT04413097|Active Comparator|DCC and Low Oxygen Concentration|During 90 seconds of delayed cord clamping, the infant will receive gentle stimulation and start CPAP by 30 seconds of life at an FiO2 .30, with CPAP of 5 cmH20. If the infant is apneic or there is no Pedicap color change the team will begin positive pressure ventilation (starting PIP of 20 cmH20) by 60 seconds of life. The infant will remain on this support up until the umbilical cord is clamped at 90 seconds or greater. Once the cord is clamped the infant resuscitation will continue according to unit protocol.
88923307|NCT04413097|Experimental|DCC and High Oxygen Concentration|During 90 seconds of delayed cord clamping, the infant will receive gentle stimulation and start CPAP by 30 seconds of life at an FiO2 1.0, with CPAP of 5 cmH20. If the infant is apneic or there is no Pedicap color change the team will begin positive pressure ventilation (starting PIP of 20 cmH20) by 60 seconds of life. The infant will remain on this support up until the umbilical cord is clamped at 90 seconds or greater. Once the cord is clamped the infant resuscitation will continue according to unit protocol.
88923308|NCT04404075||Group 1 patients|"Age 18 and above~Eczema Area and Severity Index (EASI) score ≥ 10~Investigator Global Assessment (IGA) ≥ 3"
88923309|NCT04404075||Group 2 patients|"Age 18 and above~Eczema Area and Severity Index (EASI) score ≥ 1 but < 10~Investigator Global Assessment (IGA) 1 or 2"
88923310|NCT04404075||Group 3 patients|"Age 12 to 17~Eczema Area and Severity Index (EASI) score ≥ 10~Investigator Global Assessment (IGA) ≥ 3"
88923311|NCT04404075||Group 4 patients|"Age 12 to 17~Eczema Area and Severity Index (EASI) score ≥ 1 but < 10~Investigator Global Assessment (IGA) 1 or 2"
88923312|NCT04390763|Experimental|Safety Run-in|Combination of NIS793 + spartalizumab + gemcitabine + nab-paclitaxel
88923313|NCT04390763|Experimental|Randomized Arm 1|Combination of NIS793 + spartalizumab + gemcitabine + nab-paclitaxel
88923314|NCT04390763|Experimental|Randomized Arm 2|Combination of NIS793 + gemcitabine + nab-paclitaxel
88923315|NCT04390763|Active Comparator|Randomized Arm 3|gemcitabine + nab-paclitaxel
88923316|NCT04378075|Experimental|Vatiquinone|15 milligrams/kilogram (mg/kg) if body weight <13 kg, and 200 mg if body weight ≥13 kg, administered orally, 3 times per day (TID) or up to 72 weeks
88923317|NCT04378075|Placebo Comparator|Placebo|Vatiquinone-matching placebo, administered orally, TID for up to 24 weeks followed by vatiquinone 15 mg/kg if body weight <13 kg, and 200 mg if body weight ≥13 kg, administered orally, TID for up to 48 weeks.
88923318|NCT04339062|Experimental|Cohort 1 Cemiplimab|"Participants who received allogeneic hematopoietic stem cell transplant~-- Cemiplimab: via IV, flat predetermined dosage every 21 days"
88923319|NCT04339062|Experimental|Cohort 2 Cemiplimab + Everolimus/Sirolimus + Prednisone|"Participants who received a kidney transplant will receive~Cemiplimab via IV, flat predetermined dosage every 21 days~Everolimus or Sirolimus-least 7-10 days prior to receiving the first dose of cemiplimab (Cycle 1, Day 1) and then daily while receiving Cemiplimab~Prednisone 40 mg orally the day prior to the start of cemiplimab dosing (Cycle 1, Day 1) and then daily at tapering doses while receiving Cemiplimab"
88923320|NCT04330729|Experimental|Dialysis patients|Patients will tablet acetylsalicylic acid 75mg x 1 for 4 weeks.
89023499|NCT05315973|Experimental|Sensor group|
89011853|NCT02218723|Active Comparator|Sequence EADBC|Subject will be administered treatment in sequence EADBC. Where, A: a single dose of FF (100mcg per blister from 0.6% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; B: a single dose of FF (80mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 320mcg; C: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; D: a single dose of FF (140mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 560mcg; E: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the ELLIPTA DPI by inhalation of 4 Blisters giving a total dose of 400mcg
89011854|NCT02218723|Active Comparator|Sequence DCEBA|Subject will be administered treatment in sequence DCEBA. Where, A: a single dose of FF (100mcg per blister from 0.6% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; B: a single dose of FF (80mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 320mcg; C: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; D: a single dose of FF (140mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 560mcg; E: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the ELLIPTA DPI by inhalation of 4 Blisters giving a total dose of 400mcg
89438743|NCT03008382|Other|Double-Blind Randomized Placebo|"Participants with Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) and/or Myofascial Pelvic Pain (MPP) will be randomized to take 8 weeks of Metoprolol Tartrate Oral Tablet or Placebo Oral Tablet, followed by a 4-Week washout period, and then 8 weeks of Placebo or Metoprolol.~This intervention aims at finding if subjects with IC/BPS have higher baseline HR compared to HCs. After 4 weeks baseline, subjects will receive a bottle with capsules containing 25 mg of metoprolol tartrate or placebo distributed in a double-blind manner by each site's investigational pharmacy. Subjects will start at 25 mg once daily and increase to the goal dose of 25 mg 2/day after one week, if HR has not decreased below 55 bpm at rest. Subjects will report daily rest HR for the first week. The subjects will then washout for 4 weeks and enter crossover in similar manner."
89011855|NCT02218723|Active Comparator|Sequence EDACB|Subject will be administered treatment in sequence EDACB. Where, A: a single dose of FF (100mcg per blister from 0.6% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; B: a single dose of FF (80mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 320mcg; C: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; D: a single dose of FF (140mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 560mcg; E: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the ELLIPTA DPI by inhalation of 4 Blisters giving a total dose of 400mcg
89011856|NCT02218723|Active Comparator|Sequence AEBDC|Subject will be administered treatment in sequence AEBDC. Where, A: a single dose of FF (100mcg per blister from 0.6% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; B: a single dose of FF (80mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 320mcg; C: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; D: a single dose of FF (140mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 560mcg; E: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the ELLIPTA DPI by inhalation of 4 Blisters giving a total dose of 400mcg
89011857|NCT02218723|Active Comparator|Sequence BACED|Subject will be administered treatment in sequence BACED. Where, A: a single dose of FF (100mcg per blister from 0.6% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; B: a single dose of FF (80mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 320mcg; C: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; D: a single dose of FF (140mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 560mcg; E: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the ELLIPTA DPI by inhalation of 4 Blisters giving a total dose of 400mcg
89011858|NCT02218723|Active Comparator|Sequence CBDAE|Subject will be administered treatment in sequence CBDAE. Where, A: a single dose of FF (100mcg per blister from 0.6% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; B: a single dose of FF (80mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 320mcg; C: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; D: a single dose of FF (140mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 560mcg; E: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the ELLIPTA DPI by inhalation of 4 Blisters giving a total dose of 400mcg
89011859|NCT02218762|Experimental|Sequence 1|Subjects will receive FSC 100/50 mcg delivered via the Ddpi (Treatment A) and FSC 100/50 mcg delivered via the Rdpi (Treatment B) in the sequence of A-B-B-A in four treatment periods of 10 days each. Subjects will receive both active treatment and matching placebo at the same time from two separate devices twice daily. There will be no wash-out between treatment periods
89438744|NCT02137239|Experimental|Belatacept + Everolimus|Thymoglobulin (i.v. infusion) induction, daily (or less frequently, as tolerated) not to exceed 10 days, to reach a total cumulative dose between 3.0 and 5.5 mg/kg; belatacept (infusion) regimen of 10 mg/kg i.v. on Day 1, Weeks 1, 2, 4, 8 and 12 post transplant and then a maintenance dose of 5 mg/kg every 4 weeks after 12 weeks post transplant; everolimus (tablet) daily dosing at 3.0 mg/day, 2 divided doses, starting on Day 3 dosing adjusted based on blood sample tests; methylprednisolone (infusion) prior to each Thymoglobulin infusion and prednisone (tablet), once methylprednisolone is no longer needed. (Corticosteroids to be discontinued by Day 7 or as soon thereafter as thymoglobulin infusions are completed)
89501624|NCT02150369||Patient, care partner, primary nurse case|In Phase I of this pilot, a case is comprised of the metastatic RCC patient receiving IL-2, their care partner, and their primary nurse. In Phase II, the IL-2 patient can either have MM or metastatic RCC. The care partner for this study will be the family member or friend staying with the IL-2 patient throughout treatment.
88923321|NCT04318327|Experimental|PHE885 (Part A)|Relapsed and/or refractory multiple myeloma (r/r MM) patients will receive PHE885.
88923322|NCT04318327|Experimental|PHE885 (Part B)|Newly diagnosed multiple myeloma (NDMM) patients will receive PHE885.
88923323|NCT04304066|Experimental|Imaging cohort|All study participants will be allocated to this arm (single-arm study).Study participants will undergo 18F-WL12 or 68Ga-WL12 PET/CT scans
88923324|NCT04303364||Subjects without T2DM and without HF|
88923325|NCT04303364||Patients without T2DM and with HFpEF|
88923326|NCT04303364||Patients with T2DM and without HFpEF|
88923327|NCT04303364||Patients with T2DM and HFpEF|
88923328|NCT04303364||Patients without T2DM and with hypertrophic cardiomyopathy|
88923329|NCT04303364||Patients with T2DM and with hypertrophic cardiomyopathy|
88923330|NCT04260191|Experimental|Cohort 1: AMG 910 6.5 μg|For Cycles 1 and 2, participants received AMG 910 as a short-term intravenous (IV) infusion (approximately 60 minutes) at a dose of 6.5 μg twice a week on Days 1 and 3 of each week in a 28-day cycle. For Cycles 3 to 6, participants received AMG 910 as a short-term IV infusion (approximately 60 minutes) at a dose of 6.5 μg weekly, ie, Days 1, 8, 15 and 22 in a 28-day cycle.
88923331|NCT04260191|Experimental|Cohort 1b: AMG 910 6.5 μg|For Cycle 1 Week 1, participants received AMG 910 as an extended IV (eIV) infusion (approximately 96 hours) at a dose of 6.5 μg. For the remainder of Cycles 1 and 2, participants received AMG 910 as a short-term IV infusion (approximately 60 minutes) at a dose of 6.5 μg twice a week on Days 1 and 3 of each week in a 28-day cycle. For Cycles 3 to 6, participants received AMG 910 as a short-term IV infusion (approximately 60 minutes) at a dose of 6.5 μg weekly, ie, Days 1, 8, 15 and 22 in a 28-day cycle.
88923332|NCT04260191|Experimental|Cohort 2b: AMG 910 15 μg|For Cycle 1 Week 1, participants received AMG 910 as an eIV infusion (approximately 96 hours) at a dose of 15 μg. For the remainder of Cycles 1 and 2, participants received AMG 910 as a short-term IV infusion (approximately 60 minutes) at a dose of 15 μg twice a week on Days 1 and 3 of each week in a 28-day cycle. For Cycles 3 to 6, participants received AMG 910 as a short-term IV infusion (approximately 60 minutes) at a dose of 15 μg weekly, ie, Days 1, 8, 15 and 22 in a 28-day cycle.
88923333|NCT04248543|Experimental|quantitative MRI at 4 weeks|
88923334|NCT04144517|Experimental|ALKS 4230 + pembrolizumab|
88923335|NCT04140942|Experimental|Services as usual + Virtual Reality Job Interview Training|In addition to the services as usual, participants will participate in Virtual Reality Job Interview Training.
88923336|NCT04140942|Active Comparator|Services as Usual|Study participants will be receiving their Vocational Village services as usual that may include but not limited to vocational skill training, and social skill training.
89023500|NCT05313334|Experimental|PTSD Group|The PTSD Group will receive the GAMBIT intervention and complete all study tasks and assessments at every study visit (Visits 0-4). N=20 participants will be recruited for this arm.
89438745|NCT02137239|Experimental|Tacrolimus + Mycophenolate mofetil|Thymoglobulin (i.v. infusion) induction, daily (or less frequently, as tolerated) not to exceed 10 days, to reach a total cumulative dose between 3.0 and 5.5 mg/kg; tacrolimus (tablet) daily dosing beginning at 0.1 mg/kg/day, then adjusted based on blood sample tests; MMF (tablet) daily dosing between 0.5 to 2.0 g/day divided in 2 doses (up to 3 g/day if African Americans/Blacks); methylprednisolone (infusion) prior to each Thymoglobulin infusion and prednisone (tablet), once methylprednisolone is no longer needed. (Corticosteroids to be discontinued by Day 7 or as soon thereafter as thymoglobulin infusions are completed)
89438746|NCT05229354|Experimental|Intervention followed by challenge|Participants receiving TV005 and then challenged with the rDEN2Δ30-7169 attenuated virus strain.
89438747|NCT05229354|Experimental|Placebo followed by challenge|Participants receiving placebo and then challenged with the rDEN2Δ30-7169 attenuated virus strain.
89438748|NCT05227794|Experimental|Compassion-Based Intervention|Participants in this condition are assigned to an empirically supported 8-week online compassion-based intervention protocol. The intervention includes a weekly 2-hour educational session and a recommendation of 15-30-mins of daily meditation, and real-world assignments to practice compassion.
89438749|NCT05227794|Experimental|Mindfulness-Based Intervention|Participants in this condition are assigned to an empirically supported 8-week online mindfulness-based intervention protocol. The intervention includes a weekly 2-hour educational session, a recommendation of 15-30 minutes of daily meditation, and an optional 6-hour one-day retreat.
89438750|NCT05227794|No Intervention|Waitlist Control (WL)|The WL control group will complete all study assessments on the same schedule as the intervention arms. At the time of the final follow-up assessment, participants will be randomly assigned to one of the interventions (CCT or MBSR) with the same instructors.
89438751|NCT04468152|Experimental|Case|
89438752|NCT04468152|No Intervention|Control|
89438753|NCT02137317|Experimental|LAPPE/DP|In the LAPPE experiment the farmer will work as usual (mixing/loading/application/cleaning). wearing the LAPPE solution and carrying a new hand pressured backpack sprayer with a standardized nozzle. Conditions such as dosage, work practices and weather conditions will remain uncontrolled but be observed. After one week this process will be repeated wearing the DP solution.
89438754|NCT02137317|Active Comparator|DP/LAPPE|In the DP experiment the farmer will work as usual (mixing/loading/application/cleaning) wearing the DP solution and carrying his usual backpack sprayer with his usual nozzle. Conditions such as dosage, work practices and weather conditions will remain uncontrolled but be observed. After one week this process will be repeated wearing the LAPPE solution.
89438755|NCT03522792|Experimental|Saline + ad libitum meal|This will serve as the placebo / control day for the NT + ad libitum meal study day.
89438756|NCT03522792|Experimental|NT + ad libitum meal|Neurotensin (NT) infusion followed by an ad libitum meal to study the effect of NT on ad libitum food intake.
89438757|NCT03522792|Experimental|Saline + liquid meal + ad libitum meal|Saline infusion followed a standardized liquid mixed meal followed by an ad libitum meal. This will serve as the placebo / control day for the NT + standardized liquid mixed meal + ad libitum meal study day. Investigating the effect of NT on the second meal effect.
89438758|NCT03522792|Experimental|NT + liquid meal + ad libitum meal|NT infusion followed a standardized liquid mixed meal followed by an ad libitum meal. This study day aims to study the effect of NT on the second meal effect.
89438759|NCT03522792|Experimental|Neurotensin|Acclimatization day
89438760|NCT02137395|Experimental|Dexamethasone|Patients are received dexamethasone via intravenous (iv) route of 0.5 mg.kg-1 (maximum dose of 8 mg) in group D at the induction of anesthesia.
89438761|NCT02137395|Placebo Comparator|Placebo|An equal volume of saline iv in group S at the induction of anesthesia.
89438762|NCT02137551|Experimental|ABM Intervention in FQHC|Pharmacy technicians within El Rio will implement the ABM
89438763|NCT02137551|Experimental|ABM Intervention in a Supermarket Pharmacy|Pharmacists within Fry's will implement the ABM
89438764|NCT02137551|No Intervention|Usual care|Patients will refill prescriptions at their usual pharmacy in the customary way.
89438765|NCT02137629||Korean patients|All Korean patients intended to be treated with Vidaza® according to the approved package insert
89438766|NCT02137707||Gilenya treatment|Gilenya oral form once a day
89438767|NCT03522636||Treatment|Prehospital blood products resuscitation up to 2 units of blood products as follows: 1 unit of packed human plasma and 1 unit of packed red blood cells
89438768|NCT03522636||Historic control|No prehospital blood products available
89438769|NCT05579301||PSP patients|Patients with PSP according to the inclusion and exclusion criteria
89438770|NCT05579301||healthy controls|age-matched healthy controls according to the inclusion and exclusion criteria
89438771|NCT02253381|Active Comparator|Right lateral decubitus position|Right lateral decubitus position during spinal anesthesia
89438772|NCT02253381|Active Comparator|Left lateral decubitus position|Left lateral decubitus position during spinal anesthesia
89438773|NCT04252014|No Intervention|Non-Tobacco Messages|Participants in the control group will receive messages about health topics unrelated to tobacco use (e.g., sun safety). Messages will be delivered online through 4 brief study communications.
89438774|NCT04252014|Experimental|Hookah Tobacco Messages|Participants in the hookah tobacco messaging group will receive hookah tobacco public education messages delivered online through 4 brief study communications. Messages will communicate about the risks of hookah tobacco use in the following theme areas: 1) Health Harms; 2) Addictiveness; 3) Social Use; 4) Flavorings. The order of message themes delivered in each study communication will be randomized.
89438775|NCT02261025|Experimental|Aspirin group|Aspirin 75-100mg,per day，oral
89011860|NCT02218762|Experimental|Sequence 2|Subjects will receive FSC 100/50 mcg delivered via the Ddpi (Treatment A) and FSC 100/50 mcg delivered via the Rdpi (Treatment B) in the sequence of B-A-A-B in four treatment periods of 10 days each. Subjects will receive both active treatment and matching placebo at the same time from two separate devices twice daily. There will be no wash-out between treatment periods
89011861|NCT00264459|Placebo Comparator|Placebo|Placebo was given the same way as a sublingual preparation.
89011862|NCT00264459|Experimental|Liquid formulation of an extract of a 6 grass pollen mixture|"Sublingual application containing allergen extracts of 6 grass pollen species (Holcus lanatus, Dactylus glomerata, Lolium perenne, Phleum pratense, Poa pratensis, Festuca pratensis) pollen allergen extract.~The study solution was applied sublingually, kept under the tongue for 3 minutes, and swallowed thereafter. Initial treatment was applied on the first day of treatment with a starting dose of 25% of the maintenance dose. Increasing doses of 50% were applied with the second and 100% with the third dose to give the maximum (=maintenance) dose. This was followed by a daily patient selfadministered treatment with the maintenance dose."
89011863|NCT02218879||Patients with relapsing MS|
89011864|NCT02218918|Active Comparator|Supervised Treadmill Walk Training|Based on 6 minute walk distance, treadmill speed initiated and progression on basis new 6 minute walk distance every 2 weeks
89011865|NCT02218918|Experimental|Supervised Ground walk training|Ground walk training progressed on the basis of 6 minute walk distance (70 - 90%), Weekly 3 days and for 6 weeks
89011866|NCT02218957|Active Comparator|Standard RYGB|Standard RYGB
89011867|NCT02218957|Experimental|Extended Pouch RYGB|Restrictive/extended pouch RYGB
89011868|NCT02219035||stroke-ischaemic|no interventions
89011869|NCT02219035||stroke -haemorrhagic|no intervention
89011870|NCT02219035||stroke: not confirmed|no intervention
89011871|NCT02219074|Experimental|Sebacia microparticle and laser treatment|
89011872|NCT02219074|Sham Comparator|Vehicle and laser treatment|
89011873|NCT02219113|Experimental|ADRC injection|Subjects will undergo liposuction under local anesthesia. Lipoaspirate will be processed to isolate and concentrate adipose-derived regenerative cells (ADRC). After ADRC isolation autologous cells suspension will be injected intraarticularly into knee joint.
89011874|NCT02279017|Other|Weight Loss|We will send the study participate a daily text message for 2 months to their phone at 8 A.M. and a weekly text message for 6 months asking them to report their weight through a 2-question online survey. After that, a monthly text message for 18 months asking them to report their weight.
89011875|NCT02219152|Experimental|tranexamic acid|tranexamic acid will be administrated using the bronchoscope
89011876|NCT02219152|Placebo Comparator|saline|the saline will be administrated using an infusion during the biopsy.
89011877|NCT02219191|Experimental|puerarin tablet 50 mg|Patients were orally administrated with 50 mg puerarin tablet three times a day for 24 weeks. Furthermore, patients receive stable treatment with oral anti-rheumatic agents and/or non-steroidal anti-inflammatory drugs, prednisone, aspirin, bone metabolism regulators and gastric mucosal protective agents on as-needed basis.
89011878|NCT02219191|Active Comparator|Atorvastatin tablet 20 mg|Patients were orally administrated with 20 mg Atorvastatin tablet once a day for 24 weeks. Furthermore, patients receive stable treatment with oral anti-rheumatic agents and/or non-steroidal anti-inflammatory drugs, prednisone, aspirin, bone metabolism regulators and gastric mucosal protective agents on as-needed basis.
89011879|NCT02219347|Other|DMARD cessation|All patients recruited to the study who have a Disease Activity in 28 Joints C-Reactive Protein (DAS28-CRP) score of < 2.4 and who do not have power Doppler synovitis on a 7-joint musculoskeletal ultrasound scan will stop their DMARD therapy. These patients will then be followed-up for a period of 6 months or until flare of their arthritis activity, whichever is sooner.
89011880|NCT04529512|Experimental|Receiving DEXTENZA® 1-3 days prior to surgery|Participants to receive DEXTENZA® 1-3 days prior to surgery
89011881|NCT04529512|Experimental|Receiving DEXTENZA® 1-2 weeks prior to surgery|Participants to receive DEXTENZA® 1-2 weeks prior to surgery
89011882|NCT04529512|Experimental|Receiving DEXTENZA® 1 month prior to surgery|Participants to receive DEXTENZA® 1 month prior to surgery
89011883|NCT04529512|No Intervention|Not receiving the DEXTENZA® implant|Participants will not receive the DEXTENZA® implant
89011884|NCT02219386|Active Comparator|Deep dry needling|The group of DDN receive this treatment and stretch
89438776|NCT02261025|No Intervention|non-aspirin group|No interventions
89438777|NCT05579067|Experimental|Evaluation of functional results and survival rate of peroneus longus tendon used for ACLR.|
89438778|NCT05579067|Active Comparator|Evaluation of functional results and survival rate of hamstring tendon used for ACL reconstruction.|
89438779|NCT05578989|Experimental|Group watching video with virtual reality glasses|Women in the intervention group watched a video with virtual reality glasses during the episiotomy. (25 women)
89438780|NCT05578989|No Intervention|Comparisongroup that does not use virtual glasses|The women in the control group were treated with without watching videos during the episiotomy. (25 women)
89011885|NCT02219386|Other|muscle stretch|The stretch applied was as described by Simons et al. (Simons et al., 1999). During the stretch the physiotherapist took up the slack, avoiding pain elicitation, maintaining the tension for four seconds and releasing the tension for eight seconds; this cycle was repeated three times
89011886|NCT02219425|Other|endometrial biopsy|
89011887|NCT02219542|Placebo Comparator|a standard general anesthesia|a standard general anesthesia and with transversus abdominis plane block 20 ml 0.9% sodium chloride
89011888|NCT02219542|Experimental|transversus abdominis plane block|a standard general anesthesia with transversus abdominis plane block 20 mL 0.25% ropivacaine
89438781|NCT03527082||Women attending gynaecology clinics|"150 women attending gynaecology clinics that fulfil inclusion criteria~Inclusion criteria:~Inclusion criteria~Over the age of 18~attending gynaecology clinics~Able to read and comprehend the details of the study in patient information sheet.~Mentally competent at signing the consent form.~English -speaking, if not then translator available"
89438782|NCT02137863|Placebo Comparator|Control|"Before the angiography 0.9 % sodium chloride 3 ml/kg/h administered for 12 hours.~During the angiography and 12 hours after angiography 1 ml/kg/h 0.9 % sodium chloride administered.~100 ml/10min 0.9 % NaCl administered intravenously just before the angiography.~1 ml/kg/h 0.9 % sodium chloride administered intravenously during the procedure and was continued 1 hour after the angiography."
89501625|NCT02229565||Caucasian|Caucasian subjects having a biopsy or prostatectomy.
89501626|NCT02229565||African American|African American subjects having a biopsy or prostatectomy.
88923337|NCT04090567|Experimental|Arm I (olaparib plus cediranib)|Patients receive olaparib PO BID and cediranib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88923338|NCT04090567|Experimental|Arm II (olaparib plus ceralasertib)|Patients receive olaparib PO BID on days 1-28 and ceralasertib PO QD on days 1-7. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89501627|NCT02563106|Experimental|SYN-004|SYN-004 150 mg
88923339|NCT04083378|Active Comparator|Arm I (standard of care ablation)|Patients undergo standard of care ablation.
88923340|NCT04083378|Experimental|Arm II (standard of care ablation, software-aided imaging)|Patients undergo standard of care ablation with software-aided imaging (Morfeus).
88923341|NCT04075799|Experimental|training|8 weeks using stair climbing with a frequency of thrice a week. For the first week of the stair training exercise program subjects will meet at UNM's Teaching Education Building (Stair Case 2). The following 7 weeks subjects can perform the exercise program at a staircase most convenient to them and approved by the research team. The warm-up will consist of 2 minutes of ascending and descending the stairs at a comfortable pace. The high-intensity intermittent exercise will be comprised of 6-12 x 30-seconds bout of ascending at an all-effort. A 30- seconds walking recovery will occur between the exercise bouts. After the exercise session the subject will walk during a 2-minute cool down. Every session will last between 10 to 15 minutes. The number of bouts (6-12) will be increased progressively over the weeks.
88923342|NCT04074031|Experimental|minimally invasive method for performing thalamotomy|We will study patients with essential tremor with significant disability despite well-conducted drug therapy who have a contraindication to deep brain stimulation or who refuse treatment. In this population, unilateral thalamotomy of Vim by radiosurgery is already considered a valid indication and performed routinely with proven efficacy and morbidity deemed acceptable. It is therefore the population of choice to evaluate for the first time in France the efficacy and safety of a new, minimally invasive method for performing thalamotomy: targeted ultrasound thermal injury at high intensity. This same population will also make it possible to study, for the first time in humans in this indication, the potential of neuromodulation by low frequency low frequency ultrasound beams to improve the guidance before the lesion is achieved.
88923346|NCT04066361|Experimental|Chatbot|"Participant is given a pamphlet introducing genetic testing~Participant is given information utilized for clinical, standard of care testing.~Will receive genetic information with a virtual interactive Chatbot prior to genetic testing. After the Chatbot education, participant is asked if they would like to proceed with genetic testing.~Participant is asked to complete an electronic family history tool"
88923347|NCT04066361|Experimental|Video Education|"Participant is given a pamphlet introducing genetic testing~Participant is given information utilized for clinical, standard of care testing.~Participant will watch a brief educational video that is approximately 8 minutes in length about the genetic testing process and what to expect prior to genetic testing. After the video education, participant is asked if they would like to proceed with genetic testing.~Participant is asked to complete an electronic family history tool"
88923348|NCT04033146|Experimental|Economical muscle dynamics|The investigators are trying to figure out how to optimize muscle contractile conditions for mobility. To do this, the investigators are systematically altering muscle contraction conditions for all participants.
88923349|NCT04017546|Experimental|CYC065 and venetoclax|CYC065 will be administered intravenously via 4-hour infusion on Day 1 and Day 15. Venetoclax will be taken daily on Day 1 through Day 15. One cycle will be 28 days or 4 weeks.
88923350|NCT04013802|Experimental|HLA-matched VSTs|"Partially HLA-matched VSTs will be thawed and given by intravenous injection. Patients will receive 2 x 107 partially HLA-matched VSTs/m2 as a single infusion. In the rare case where insufficient banked cell product is available, a lower number of cells may be infused with agreement of the principal investigator, patient and/or guardian and the treatment team~Additional doses may be from the same donor or a different donor based on available cell lines and patient/disease factors. Decision to switch to a different donor can be made by the principal investigator based on factors that include sequential treatment of different viral infections, concerns for immune escape of the targeted virus and/or availability of a better matched or otherwise superior VST line. Additional treatments will only be given following the agreement of the patient, treating physician, and investigator. This process can be repeated as needed."
89011889|NCT02219620|Experimental|Music, Imagery, Movement intervention|Music, Imagery, Movement intervention: psychosocial intervention incorporating Music, Imagery and Movement
88923351|NCT03981640|Experimental|African American Adults|African American adults will undergo the interventions of acute exercise, a cold pressor test, and a mental stress test while beat-to-beat renal blood flow velocity, mean arterial blood pressure, and heart rate are recorded.
88923352|NCT03981640|Experimental|White Adults|White adults will undergo the interventions of acute exercise, a cold pressor test, and a mental stress test while beat-to-beat renal blood flow velocity, mean arterial blood pressure, and heart rate are recorded.
88923353|NCT03979001||Patients|Patients referred for polysomnography diagnosis of obstructive sleep apnea syndrome
88923354|NCT03979001||Controls|Person without obstructive sleep apnea syndrome
88923355|NCT03963960|Experimental|Hemodialysis with low dialysate flow|
88923356|NCT03963960|Active Comparator|Conventional triweekly high-flow hemodialysis|
89438783|NCT02137863|Active Comparator|Dexmedetomidine|"Before the angiography 0.9 % sodium chloride 3 ml/kg/h administered for 12 hours.~During the angiography and 12 hours after angiography 1 ml/kg/h 0.9 % sodium chloride administered.~Dexmedetomidine was diluted as 1 μg/ml. 1 μg/kg/10min dexmedetomidine administered intravenously just before the angiography.~1 μg/kg/h dexmedetomidine administered intravenously during the procedure and was continued 1 hour after the angiography."
89438784|NCT02137941|Active Comparator|techniques to optimize potential (TOP)|
88923359|NCT03938324|Experimental|PiCASO Intervention Group|Peer coaching intervention delivered by young adults with a childhood onset chronic condition and trained in coaching curriculum that includes motivational interviewing techniques and the benefits of peer relationships over a shared experience such as a chronic condition. The peer coach supports the AYA to identify their goals and feel a sense of success in making change towards goals within a supportive environment. This process involves goal-setting, development of self-discovery and accountability for changes in health behavior. The peer coach elicits the AYA's vision of optimal health and identifies the AYAs values. As the AYAs identify a vision of wellness and develop goals and action steps to progress towards that vision, the peer coach elicits the AYA's intrinsic motivation and activates skill development in self-advocacy and communication and empowers the AYA to take leadership in managing their condition.
88923360|NCT03938324|Sham Comparator|Attention Control Group|Over 12 months the attention control group participants will receive a monthly electronic newsletter with educational content about childhood onset chronic condition management and the differences between pediatric and adult health care systems, as well as a monthly phone call from study staff to ensure receipt of the newsletter and to answer questions regarding content, and an opportunity to link them to other resources. If participants report health concerns they will be directed to contact their health care team.
88923361|NCT03917927|Experimental|Eztetic dental implant|Eztetic 3.1mm diameter, lengths 8, 10, 11.5, 13, 16 mm
88923362|NCT03891602||Clinicians|Primary care clinicians (general internists, family physicians, nurse practitioners, physician assistants) who treat lung cancer screening eligible patients
88923363|NCT03891602||Smokers/Former Smokers|Current smoker or former smoker who has quit within the past 15 years
88923364|NCT03872908||Cohort 1|Evaluation of patient's satisfaction when wearing surgical gloves (dominant hand) versus chilled gloves (non-dominant hand) at the end of paclitaxel administration.
88923365|NCT03872908||Cohort 2|Evaluation of the efficacy of the compression induced by surgical gloves against peripheral neuropathies in patients treated by oxaliplatine after a 595 mg/m2 cumulated dose.
89199355|NCT05750966|Experimental|Very short-course antibiotics|The antibiotic regimens will be according to the local hospital's antibiotic guideline for cholangitis (e.g. dosage form, dosage, frequency)and/or the national SWAB guideline in the Netherlands. In the experimental group, duration of ABT after adequate drainage will be 1 day. The duration will be 4 days and can be extended to 7 days in case of gram-negative bacteraemia, according to the national SWAB guideline regarding gram-negative sepsis.
89199356|NCT05750966|Active Comparator|Standard course antibiotics|"The antibiotic regimens will be according to the local hospital's antibiotic guideline for cholangitis, which are based on the previously mentioned national SWAB guideline. This means that the type of ABT, dosage and frequency will be comparable to the experimental group.~In the comparator group treatment duration with ABT after ERCP will be according to the international well known and widely used TG18. The duration will be 4 days and can be extended to 7 days in case of gram-negative bacteraemia, according to the national SWAB guideline regarding gram-negative sepsis."
89199357|NCT05737901|No Intervention|Standard care group|The standard discharge training of the clinic was carried out in the patient's room on the day of discharge in an average of 5 minutes, in the form of verbally explaining the information deemed important by the physician and/or nurse to the patient. No intervention was made in this group.
89199358|NCT05737901|Experimental|Education Booklet Group|Discharge training was given by the researcher the day before the surgery in an average of 60 minutes in the meeting room of the clinic through the booklet.
88923366|NCT03865589|Experimental|Patients Undergoing HCT|All patients enrolled will undergo US SWE at specific time points as outlined in the protocol based on disease course.
89438785|NCT02137941|Active Comparator|heart coherence (HC)|
89438786|NCT02137941|Placebo Comparator|controls|
89438787|NCT02133729|Experimental|Gestational diabete|
89438788|NCT03522558|Experimental|Standardized Medical Nutrition Therapy|Standardized Medical Nutrition Therapy will include nutrition assessment provided by a registered dietitian (RD) at initial clinic visit or first Well Child Check (WCC) and regularly scheduled nutrition follow-up at each WCC visit thereafter.
89501628|NCT02563106|Placebo Comparator|Placebo|Matching placebo
89501629|NCT03166059|Experimental|Single arm|CaveoVasc® Thrombolysis Protection System
88923367|NCT03846193|Experimental|GT005 Dose 1|A single dose of GT005 will be administered via subretinal injection
88923368|NCT03846193|Experimental|GT005 Dose 2|A single dose of GT005 will be administered via subretinal injection
88923369|NCT03846193|Experimental|GT005 Dose 3|A single dose of GT005 will be administered via subretinal injection
88923370|NCT03846193|Experimental|GT005 Dose 1, 2 or 3|A single dose of GT005 will be administered via subretinal injection. This dose will be determined by dose levels determined to be tolerable in Arms 1,2 and 3
88923371|NCT03846193|Experimental|GT005 Dose 2 with Orbit Subretinal Delivery System|A single dose of GT005 will be administered with subretinal injection via suprachoroidal cannulation approach
88923372|NCT03846193|Experimental|GT005 Dose 3 with Orbit Subretinal Delivery System|A single dose of GT005 will be administered with subretinal injection via suprachoroidal cannulation approach
88923373|NCT03846193|Experimental|GT005 Dose 3 with Orbit Subretinal Delivery Sysem|A single dose of GT005 will be administered with subretinal injection via suprachoroidal cannulation approach
88923374|NCT03828513|Active Comparator|High flow nasal cannula oxygen applied|High flow nasal cannula oxygen is start at a flow rate of 80 L/min with 100% oxygen in the preoperative period.
88923375|NCT03828513|Active Comparator|High flow nasal cannula oxygen is not applied|Preoxygenation will be applied with an oxygen supplement of 5 l/min to an endtidal O2> 90%.
88923376|NCT03800355||Male breast cancer|The study target population is all cases of male breast cancer (MBC), diagnosed with invasive breast cancer between the years 2000 and 2019, and treated in the Medical Oncology Departments of participating sites.
88923377|NCT03780894|Experimental|Experimental treatment|The active treatment consists of intravenous injection of 2g of fibrinogen concentrate, 1g of tranexamic acid, 2 red bood cells concentrate O Rh(D) negative (Banc de Sang i Teixits, Barcelona, Spain), and crystalloids at pre-hospital phase of care.
88923378|NCT03780894|Active Comparator|Standard treatment|Patients in the control arm will be treated according the existing protocols based on crystalloids and tranexamic acid administration.
88923379|NCT03739723|No Intervention|Control Arm|Programs will continue to conduct normal educational activities.
88923380|NCT03739723|Experimental|Intervention Arm|The intent of the intervention arm is to provide programs with data and resources to inform and improve surgical learning environments and resident wellness.
88956449|NCT05183035|Experimental|Arm B: Experimental Arm with Venetoclax|"During cycle 1 (each cycle is 42 days), participants will receive 300 mg adult dose equivalent of venetoclax once on Day 1 followed by 600 mg adult dose equivalent of venetoclax on Days 2-21. Participants will also receive 30 mg/m^2 of fludarabine followed by 2 g/m^2 of cytarabine on Days 8-12. Gemtuzumab 3 mg/m^2 will be given on Day 13 (only for participants with CD33 expression on leukemia blasts).~During cycle 2, participants will receive 600 mg adult dose equivalent of venetoclax on Days 1-21. Participants will receive 30 mg/m^2 of fludarabine followed by 2 g/m^2 of cytarabine on Days 1-5.~After cycle 2 participants are assessed for HSCT or azacitidine maintenance therapy in combination with venetoclax."
88956450|NCT05180942|Experimental|Statin treatment|Atorvastatin 40mg, daily, orally for 18 months
88956451|NCT05180942|No Intervention|No statin treatment|No comparator treatment/placebo allocated
88956452|NCT05176951|Experimental|Treprostinil Palmitil|Participants will be administered TPIP once per day at a starting dose of 80 micrograms (μg). Participants will be titrated up to the highest tolerated dose for each individual participant of between 80 μg and 640 μg during the initial 3 weeks of treatment. The overall treatment period will be 16 weeks.
88956453|NCT05176951|Placebo Comparator|Placebo|Participants will be administered a placebo matching TPIP once daily.
88956454|NCT05172258|Experimental|Arm I (ipatasertib, pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1 and ipatasertib PO QD on days 1-14 of each cycle. Cycles repeat every 21 days for a period of 24 months in the absence of disease progression or unacceptable toxicity. Patients also undergo biopsy on study, undergo collection of blood samples on study and during follow up, and undergo CT scans throughout the trial.
88956455|NCT05172258|Active Comparator|Arm II (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 21 days for a period of 24 months in the absence of disease progression or unacceptable toxicity. Patients also undergo biopsy on study, undergo collection of blood samples on study and during follow up, and undergo CT scans throughout the trial.
89438789|NCT03522558|Active Comparator|Usual Care|At the primary care provider's discretion, a nutrition consult can be requested for the RD to perform nutrition assessment or discuss the patient's plan without full nutrition assessment, as is current practice. Currently in the Neonatal High-Risk Clinic (NHRC) and High Risk Children's Clinic (HRCC) at UTHealth, providers consult the RD as deemed appropriate with no established criteria for when to include the RD in patient care. Usual care will not be modified by the study protocol.
89438790|NCT02138019|Experimental|Fibrin glue|In ophthalmic field, the use of organic glues has provided good results for the repair of leaking blebs and perforated corneal ulcers, conjunctival closure in strabismus surgery, surgery for retinal detachment, cataract surgery, trabeculectomy, and mucous membrane grafting to repair lesions of the conjunctival fornix. In this study, the investigators try to evaluate the effect of Fibrin Glue assisted external eye surgery.
89438791|NCT02252679||Osteoporosis|Postmenopausal women, men > age 50 years, or other patients with well-established causes of secondary osteoporosis (incl. glucocorticoid-induced osteoporosis, transplantation-related osteoporosis, disuse osteoporosis, etc.) N=20 treated with antiresorptive drugs N=10 treated with osteoanabolic drugs (e.g. teriparatide, Forsteo)
89438792|NCT02252679||Calcium malabsorption|N=10 Patients with clinically obvious potential causes of calcium malabsorption (incl. severe vitamin D-deficiency, Scopinaro or other bariatric surgery, exocrine pancreatic insufficiency/steatorrhea, cystic fibrosis, inflammatory bowel disease, celiac disease, anorexia nervosa/eating disorders, malnutrition, etc.), with or without bone pains, muscle weakness and other typical osteomalacia symptoms. Confirmed by 24h urine collection showing calciuria <100 mg/24h.
89438793|NCT02252679||Various disorders|Exploratory, heterogeneous group of calcium-related disorders (incl.hypercalcemia, hypocalcemia, primary/secondary/tertiary hyperparathyroidism, hypoparathyroidism, vitamin D deficiency, X-linked/autosomal dominant hypophosphatemic rickets, familial hypocalciuric hypocalcemia,etc.) N=20
89438794|NCT02252679||Normal control subjects|N=40 Men and women ≤ 40 years recruited from the population
89438795|NCT02133807|Experimental|Specific Lp(a) apheresis & Atorvastatin|"Specific Lp(a) apheresis was performed with Lp(a) Lipopak immunosorbent columns (POCARD Ltd., Moscow, Russia) with sheep polyclonal monospecific antibodies against human Lp(a)/apo(a) weekly during 18 months. On the background - standard medical therapy in accordance with the recommendations for secondary prevention of CHD."
89438796|NCT02133807|No Intervention|Atorvastatin|Standard medical therapy in accordance with the recommendations for secondary prevention of CHD
89438797|NCT02138331|Experimental|Exosomes|The exosomes have exosome-associated proteins such as the tetraspanin proteins, CD9 and CD81, Alix, Tsg101, and RNA that consists primarily of short RNAs of less than 300 nm. Some of these RNAs are microRNAs that are predominantly pre-microRNAs..Additionally, CB-SC displayed very low immunogenicity as indicated by expression of a very low level of major histocompatibility complex (MHC) antigens and failure to stimulate the proliferation of allogeneic lymphocytes.
89438798|NCT05578521|Placebo Comparator|Cerebralcare pills placebo group|This group will receive Cerebralcare pills placebo, 2 packages, twice a day, from the day of randomization to 6 months.
89438799|NCT05578521|Experimental|Cerebralcare pills group|This group will receive Cerebralcare pills, 2 packages, twice a day, from the day of randomization to 6 months.
89438800|NCT02133963||women with no history of depression|Non-Probability Sample of women with no history of depression
89438801|NCT02133963||women with a past depression history|Non-Probability Sample of women with a past history of depression
89438802|NCT03548649|Experimental|exoskeleton robot training group|subjects will receive exoskeleton robot training for 20 sessions (1 hr/session).
89438803|NCT02138409|Experimental|ON FSS 100 µg|Participants classified as opioid-naïve (ON), randomized to receive one dose of fentanyl sublingual spray (FSS) 10 minutes before treatment procedure, and further randomized to a dose of 100 µg
89438804|NCT02138409|Experimental|ON FSS 200 µg|Participants classified as opioid-naïve (ON), randomized to receive one dose of fentanyl sublingual spray (FSS) 10 minutes before treatment procedure, and further randomized to a dose of 200 µg
89438805|NCT02138409|Experimental|OE FSS 400 µg|Participants classified as opioid-experienced (OE), randomized to receive one dose of fentanyl sublingual spray (FSS) 10 minutes before treatment procedure, at a dose of 400 µg
89438806|NCT02138409|Placebo Comparator|ON PSS|Participants classified as opioid-naïve (ON) and randomized to receive one dose of matching placebo sublingual spray (PSS) 10 minutes before treatment procedure
89438807|NCT02138409|Placebo Comparator|OE PSS|Participants classified as opioid-experienced (OE) and randomized to receive one dose of matching placebo sublingual spray (PSS) 10 minutes before treatment procedure
89438808|NCT02138487|Active Comparator|Restricted postoperative activity|"Women in the restricted postoperative activity group must abstain from exercise and heavy lifting for 3 months postoperatively"
89438809|NCT02138487|Experimental|Liberal postoperative activity|"Women in the liberal postoperative activity group will be allowed to resume their normal activities without restriction."
88923381|NCT03739554|Experimental|CYC065 and venetoclax|CYC065 will be administered intravenously via 4-hour infusion on Day 1 and Day 15 after the venetoclax ramp-up schedule is completed. Venetoclax will be taken daily at a dose that is deemed safe and tolerable after the ramp-up schedule. One cycle will be 28 days or 4 weeks.
89438810|NCT02134041||traumatic brain injury|mild traumatic brain injury
89438811|NCT02134041||without TBI|without TBI
89438812|NCT02134197|Experimental|Lupartumab Amadotin (BAY1129980)|Dose escalation with consecutive expansion at MTD (maximum tolerated dose) with BAY1129980.
89438813|NCT02138565|Experimental|Bariatric surgery|
88923382|NCT03729271|Experimental|Rifaximin and breath tests|Rifaximin 550mg three times a day for 14 days. Breath tests (glucose and lactulose) will be completed prior to Rifaximin treatment and at week 13 of the study.
88956456|NCT05171387|Experimental|Darolutamide in addition to Androgen deprivation therapy|
89011890|NCT02219620|Active Comparator|Social Control|social control/interaction group
89011891|NCT00241670|Experimental|5-aminolevulinic acid|
89011892|NCT00241670|No Intervention|Conventional resection|
89011893|NCT02219737|Experimental|Treatment (ibrutinib, R-ICE)|Patients receive ibrutinib PO QD on days 1-21, rituximab IV on day 1, ifosfamide IV on day 3, carboplatin IVPB on day 3, and etoposide IVPB on days 2-4. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
89011894|NCT02219854|Experimental|Laparoscopic gastrectomy|Laparoscopic distal subtotal gastrectomy with D2 lymphadenectomy will be performed for the treatment of patients assigned to this group.
89011895|NCT02219854|Active Comparator|Open gastrectomy|Open distal subtotal gastrectomy with D2 lymphadenectomy will be performed for the treatment of patients assigned to this group.
89011896|NCT02219893|Experimental|MOC31PE Immunotoxin|Drug to be instilled on day 1 after cytoreductive surgery and HIPEC.
89011897|NCT02219971|Experimental|Kukoamine B Mesilate 0.005mg/kg|Pre-test,open study: Kukoamine B Mesilate 0.005mg/kg single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
89011898|NCT02219971|Experimental|Kukoamine B Mesilate 0.02mg/kg + Placebo|"Dose Escalation: Kukoamine B Mesilate 0.02mg/kg single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.~Placebo: single and intravenous(IV) drip for 1 hour in healthy volunteers."
89011899|NCT02219971|Experimental|Kukoamine B Mesilate 0.04mg/kg +Placebo|"Dose Escalation: Kukoamine B Mesilate 0.04mg/kg single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.~Placebo: single and intravenous(IV) drip for 1 hour in healthy volunteers."
89011900|NCT02219971|Experimental|Kukoamine B Mesilate 0.08mg/kg + Placebo|"Dose Escalation: Kukoamine B Mesilate 0.08mg/kg single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.~Placebo: single and intravenous(IV) drip for 1 hour in healthy volunteers."
89011901|NCT02219971|Experimental|Kukoamine B Mesilate 0.12mg/kg + Placebo|"Dose Escalation: Kukoamine B Mesilate 0.12mg/kg single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.~Placebo: single and intravenous(IV) drip for 1 hour in healthy volunteers."
89011902|NCT02219971|Experimental|Kukoamine B Mesilate 0.24mg/kg + Placebo|"Dose Escalation: Kukoamine B Mesilate 0.24mg/kg single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.~Placebo: single and intravenous(IV) drip for 1 hour in healthy volunteers."
89011903|NCT02219971|Experimental|Kukoamine B Mesilate 0.48mg/kg + Placebo|"Dose Escalation: Kukoamine B Mesilate 0.48mg/kg single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.~Placebo: single and intravenous(IV) drip for 1 hour in healthy volunteers."
89011904|NCT04720170|Other|Single Arm|This is a 26 week, single arm, single-site, Investigator-initiated, exploratory trial evaluating the efficacy of the standard of care revascularization of the lower extremity with the addition of revascularization of the lateral plantar artery and anterior pedal loop of the foot as treatment for participants with PAD, diabetic neuropathy and have a clinical diagnosis of type 1 or type 2 diabetes whose main symptoms are numbness and/or tingling of the feet with or without pain.
89011905|NCT00241748||1|Rhabdomyolysis Case Subjects
89011906|NCT00241748||2|Heart and Vascular Health Study statin users - control group 1
89011907|NCT00241748||3|Cardiovascular Health Study statin users - control group 2
89011908|NCT02218801||Colorectal adenocarcinoma liver metastasis|Unresectable, borderline or initially unresectable liver metastasis from a colorectal cancer
89011909|NCT02217865||Colorectal Cancer Participants|Colorectal cancer participants undergoing follow-up after curative resection of colorectal cancer.
89438814|NCT02138643|Active Comparator|Endoscopic surgery|Patients with symptomatic achalasia confirmed by clinical and laboratory tests, which meet the criteria for inclusion and exclusion. These will be treated with Endoscopic surgery - Peroral endoscopic myotomy (POEM)
89438815|NCT02138643|Sham Comparator|Laparoscopic surgery|Patients with symptomatic achalasia confirmed by clinical and laboratory tests, which meet the criteria for inclusion and exclusion. These will be treated with Laparoscopic surgery - Laparoscopic Heller myotomy.
89438816|NCT02138799|Experimental|1: single dose of enzalutamide|
89011910|NCT02217865||Caregivers of Colorectal Cancer Participants|Caregivers of colorectal cancer participants undergoing follow-up after curative resection of colorectal cancer.
89011911|NCT02210650|Other|Symptomatic stone removal|Group 1 will receive the standard treatment of having only the symptomatic stone removed
89011912|NCT02210650|Other|Asymptomatic kidney stones and symptomatic stone removed|Group 2 will include the step of having the asymptomatic kidney stones removed in addition to the symptomatic stone
89011913|NCT04720014|Experimental|SMART-3RP Group Intervention|Residents will participate in 9 structured weekly group sessions which incorporates stress management and relaxation training.
89011914|NCT02212951|Experimental|BIOD-531 pre-meal|Subcutaneous injection of 0.6 U/kg immediately before the start of the standardized breakfast
89011915|NCT02212951|Active Comparator|Humalog Mix 75/25 pre-meal|Subcutaneous injection of 0.6 U/kg immediately before the start of the standardized breakfast
89011916|NCT02212951|Active Comparator|Humulin R U-500|Subcutaneous injection of 0.6 U/kg immediately before the start of a standardized breakfast
89011917|NCT02212951|Experimental|BIOD-531 post-meal|Subcutaneous injection of 0.6 U/kg 20 minutes after the start of the standardized breakfast
89011918|NCT02211508|Active Comparator|12-week RINCE|RINCE - active RINCE therapy involving 24 total treatment applications from NeuroPoint device
89011919|NCT02211508|Sham Comparator|Sham RINCE|Sham RINCE - sham RINCE therapy involving 24 total sham applications from NeuroPoint device
89011920|NCT02210806|Active Comparator|Treatment T1|One inhalation of 110 mcg A006 DPI. Total 110 mcg.
89438817|NCT02138799|Experimental|2: multiple doses of rifampin and single dose of enzalutamide|
89438818|NCT02138877|Active Comparator|After coming stent|Dismembered pyeloplasty with insertion of an after coming stent
89438819|NCT02138877|Active Comparator|Stentless|Stentless dismembered pyeloplasty
89438820|NCT02134275|Experimental|Whole body vibration training|Whole body vibration training (timed stand on vibration platform) 3 20-minute sessions per week for 6 months
89438821|NCT02134275|Placebo Comparator|Control group|No significant changes to diet, exercise and lifestyle.
89011921|NCT02210806|Active Comparator|Treatment T2|One inhalation of 220 mcg A006 DPI. Total 220 mcg.
89011922|NCT02210806|Placebo Comparator|Placebo|One inhalation of placebo DPI . Total 0 mcg
89011923|NCT02210806|Active Comparator|Treatment R1|One inhalation of Proventil® MDI Total 90 mcg
89011924|NCT02210806|Active Comparator|Treatment R2|Two inhalations of Proventil® MDI, 180 mcg total
89011925|NCT02210026|Experimental|Experimental|Infants will be assessed on standard bubble nasal CPAP, then on Seattle-PAP bubble nasal CPAP, then again on standard bubble nasal CPAP.
89011926|NCT02219230|Experimental|Prosthetic knee|Subjects crossed over between interventions (three different prosthetic knees). Knee conditions include 1) Active knee (Ossur Power Knee II); 2) Adaptive knee (Ossur Rheo); and 3) Passive knee (Various manufacturers)
89011927|NCT02219659|Active Comparator|Sedation protocol with interruption|Continuous infusion of fentanyl and midazolam is started per protocol. Both drugs are titrated to target pain score (0 to 3) using Critical Care Pain Observation Tool (CPOT) and target sedation score (0 to -3) using Richmond Agitation Sedation Scale (RASS). Every morning both drugs are stopped (Daily Interruption) and patient's wakefulness is assessed per protocol. If patient's pain and RASS score stays within the target, both drugs are kept off. If patient shows any signs and symptoms of pain or agitation (described in the study protocol), both drugs are restarted at a half dose of the previous dose and titrated to target pain and RASS score. Every morning both drugs are stopped and when patient is awake and met the SBT safety screen, 120-min continuous positive airway pressure (CPAP) trial is performed.
89438822|NCT02975271|Experimental|Serlopitant|Dose of experimental drug Serlopitant
89438823|NCT02975271|Placebo Comparator|Placebo|Matching dose of Placebo
89438824|NCT02741076|Experimental|Structured discontinuation opioid therapy Suboptimal Responder|
89011928|NCT02219659|Active Comparator|Sedation protocol without Interruption|Continuous infusion of fentanyl and midazolam is started per protocol. Both drugs are titrated to target pain score (0 to 3) using Critical Care Pain Observation Tool (CPOT) and target sedation score (0 to -3) using Richmond Agitation Sedation Scale (RASS). Daily interruption of fentanyl and midazolam is not performed. Every morning 120-min CPAP trial is performed as long as the patient's RASS score is 0 to -2 and the patient passes the SBT safety screen.
89011929|NCT02219659|Active Comparator|Fentanyl push first|This arm attempts to manage patient's pain and agitation with analgesia first. Fentanyl intravenous (IV) pushes are administered every 5 minutes as needed to target pain and sedation score, up to 4 doses per hour. Every morning 120-min CPAP trial is performed as long as patient's RASS score is 0 to -2 and patient passes the SBT safety screen. If fentanyl IV push doses alone cannot manage patient's pain and agitation (could not reach the target score), notify the study team. Fentanyl infusion is started and titrated to target pain and sedation score up to 6 hours. If fentanyl infusion is titrated up twice consecutively and target pain and sedation score are not met, notify the study team. Propofol infusion is started and titrated to target RASS score up to 6 hours.
89011930|NCT00264693||P - A|Prophylactic Dosage, GFR >= 60 mL/min/1.73m^2
89011931|NCT00264693||P - B|Prophylactic Dosage, GFR 30-59 mL/min/1.73m^2
89011932|NCT00264693||P - C|Prophylactic Dosage, GFR < 30 mL/min/1.73m^2
89011933|NCT00264693||P - CAPD|Prophylactic Dosage, CAPD
89011934|NCT00264693||T - A|Therapeutic Dosage, GFR >= 60 mL/min/1.73m^2
89011935|NCT00264693||T - B|Therapeutic Dosage, GFR 30-59 mL/min/1.73m^2
89011936|NCT00264693||T - C|Therapeutic Dosage, GFR < 30 mL/min/1.73m^2
89011937|NCT00264693||T - CAPD|Therapeutic Dosage, CAPD
89011938|NCT02212015|Experimental|Pazopanib + Paclitaxel|Paclitaxel administered every 28 days at day 1, day 8 and day 15 as a 2h intravenous infusion in a dose of 70mg/m2 in combination with pazopanib in a daily oral dose of 800mg (2x400mg)
89438825|NCT02741076|Experimental|Structured discontinuation opioid therapy Optimal responders|
89438826|NCT02741076|Experimental|Continuation of opioid therapy Suboptimal responders|
89438827|NCT02741076|Experimental|Structured Continuation of opioid therapy Optimal responders|
89438828|NCT02973633|Active Comparator|Healthy Volunteers|DTI will be performed in healthy volunteers to characterize normal fiber architecture in the heart and provide a comparison group for the patients imaged in the other arms.
89438829|NCT02973633|Active Comparator|Patients with Recent Myocardial Infarction|Patients with recent ST elevation myocardial infarcts will be recruited and imaged serially with DTI to detect changes in fiber architecture and their correlation with remodeling of the left ventricle.
89438830|NCT02973633|Active Comparator|Patients with Left Ventricular Hypertrophy|Patients with left ventricular hypertrophy and a history of heart failure will be recruited and imaged serially with DTI to detect changes in fiber architecture and their correlation with the onset and progression of heart failure.
89438831|NCT02139033|Experimental|Arm 1|Retain 1-2 drops, bilaterally, BID
89438832|NCT01666444|Experimental|PLD 40 mg/m2 plus VTX-2337|The dosing schedule will be be based on a 28-day cycle. The starting dose schedule is PLD on Day 1 plus VTX-2337 on Day 3, Day 10, and Day 17 for the first 4 cycles. Starting with cycle 5, the dose regimen will be PLD on Day 1 plus VTX-2337 on Day 3 only, without additional doses of VTX-2337 on Days 10 and Day 17.
89438833|NCT01666444|Active Comparator|PLD 40 mg/m2 plus placebo|The dosing schedule will be based on a 28-day cycle. The starting dose schedule is PLD on Day 1 plus placebo on Day 3, Day 10, and Day 17 for the first 4 cycles. Starting with cycle 5, the dose regimen will be PLD on Day 1 plus placebo on Day 3 only.
89438834|NCT02134431||HIV positive|HIV-positive subjects ages 10-14 years old and 18-21 years old taking tenofovir in their antiretroviral regimen.HIV positive subjects will undergo lower endoscopy (specifically either flexible sigmoidoscopy or colonoscopy) with biopsies to obtain colorectal tissue samples. HIV-1 levels and tenofovir levels in tissue will be measured.
89438835|NCT02134431||HIV negative|HIV-negative subjects ages 10-14 years old and 18-21 years old. HIV negative subjects will undergo lower endoscopy (specifically either flexible sigmoidoscopy or colonoscopy) with biopsies to obtain colorectal tissue samples. These tissue samples will be pretreated with tenofovir and challenged with laboratory HIV-1.
89438836|NCT02253225||Bipolar Disorder|Clinical status will be determined using the Mini International Neuropsychiatric Interview (M.I.N.I) for 20 patients with bipolar disorder (BPAD).
89438837|NCT02253225||Major Depressive Disorder|Clinical status will be determined using the Mini International Neuropsychiatric Interview (M.I.N.I) for 20 patients with major depression (MDD).
89438838|NCT02253225||Healthy Control|Clinical status will be determined using the Mini International Neuropsychiatric Interview (M.I.N.I) for 20 normal, healthy volunteers.
89438839|NCT02134509|Experimental|Experimental App|This is a 3-week smartphone-based training program that trains behavioral strategies for smoking cessation by helping smokers self-monitor their smoking habits, recognize when and how often they smoke, identify triggers for smoking, and learn methods to become more mindful of triggers, to quit smoking with a target quit date of 3 weeks.
89438840|NCT02134509|Active Comparator|Active comparator app|This is a 3-week smartphone application for smoking cessation in which smokers self-monitor their smoking habits, mood, and experience, to quit smoking with a target quit date of 3 weeks.
89438841|NCT05159622|Experimental|Intervention|Description of behavioral intervention Water Up! at Home: The intervention is theory-based and was designed to be sensitive to the context, perceptions and needs of this high risk population. It was collaboratively developed with key stakeholders in the predominantly Latino immigrant community. The curriculum consists of 12 infographics and lessons (bilingual Spanish/English) designed to increase knowledge of drinking water health benefits, safety/cleanliness, cost/convenience, prior experience. The 12-week intervention will be delivered in participants' home by the home visitor. Participants will receive a water filter for use in their home in addition to educational information about water and sugary beverages. Throughout the lessons, they will be asked to complete various activities such as taking pictures and engaging in discussions about their water drinking habits.
89438842|NCT05159622|No Intervention|Control|Participants will receive the standard educational curriculum from the home visiting program (and also a water filter as a token of appreciation).
89438843|NCT02139111|Placebo Comparator|Placebo|Placebo Arm
89438844|NCT02139111|Active Comparator|PRC-063 25 mg and Placebo|PRC-063 25 mg and placebo capsule by mouth once daily
89438845|NCT02139111|Active Comparator|PRC-063 45 mg and Placebo|PRC-063 45 mg and placebo capsule by mouth once daily
89438846|NCT02139111|Active Comparator|PRC-063 70 mg and Placebo|PRC-063 70 mg and placebo capsule by mouth once daily
89438847|NCT02139111|Active Comparator|PRC-063 85 mg and Placebo|PRC-063 85 mg and placebo capsule by mouth once daily
88923383|NCT03721822|Experimental|Traditional Cigarette Smokers|Reported current cigarette smoking of at least 5 cigarettes per day, 5 days per week for the past 1 year with no history of e-cigarette use (cannabis or nicotine) during the 30 days prior to study enrollment
88923384|NCT03721822|Experimental|Non-Smokers|Reported non-smoking history or < 100 lifetime cigarettes, < 100 e-cigarette use episodes and < 100 lifetime cannabis use episodes
88923385|NCT03721822|Experimental|Nicotine Vapers|Reported current e-cigarette use of nicotine at least 5 days per week for the past year with no current combustible cigarette use, cannabis vaping or cannabis smoking during the 30 days prior to study enrollment
88923386|NCT03721822|Experimental|Cannabis Vapers|Reported current e-cigarette use of cannabis at least 5 days per week for the past year, no current combustible cigarette use, cannabis smoking or nicotine vaping during the 30 days prior to study enrollment
88923387|NCT03721822|Experimental|Dual Smokers/Vapers|Reported current e-cigarette use of cannabis and/or nicotine at least 5 days per week for the past year with cigarette or cannabis smoking during the 30 days prior to study enrollment
89011939|NCT04720859|Experimental|Patients with PHH following Roux-en-Y-gastric bypass (cases)|Patients diagnosed with PHH following Roux-en-Y-gastric bypass.
89011940|NCT04720859|No Intervention|Healthy individuals (controls)|Healthy normoweight individuals, matched by age and gender with the cases.
89011941|NCT02279056|Experimental|Self-help book|A self-help book for insomnia (written in Norwegian). Earlier proven to be effective among insomnia patients (without OSA co-morbidity).
89011942|NCT02279056|Placebo Comparator|Sleep hygiene advice|A sheet of paper with sleep hygiene advice.
89011943|NCT02961842|Experimental|Combination|500 mL colloid preload and 500 mL crystalloid coload. Cesarean delivery performed under spinal anesthesia (intrathecal bupivacaine 12.5 mg and intrathecal fentanyl 15 µg). Ultrasound assessment of the Inferior vena cava diameter. Intravenous ephedrine will be administered.
89011944|NCT02961842|Active Comparator|Coload|1000 mL crystalloid coload. Cesarean delivery performed under spinal anesthesia (intrathecal bupivacaine 12.5 mg and intrathecal fentanyl 15 µg). Ultrasound assessment of the Inferior vena cava diameter. Intravenous ephedrine will be administered.
89011945|NCT00416481||Patient assessment|"Patients undergo assessments of cognition and performance status using the healthcare professional-rated Karnofsky performance scale. These assessments are performed by healthcare personnel. Body mass index and the percentage of unintentional weight loss and the number of falls in the past 6 months are also assessed.~Patients also complete self-administered questionnaires that measure level of functioning and need for services. It also includes questionnaires that measure higher levels of physical functioning, performance related to survival and clinically significant illness and measures of comorbidity and the impact on daily activities. Lastly, questionnaires are administered to measure the impact of cancer on patients' social functioning and perceived availability of social support.~Patients then begin planned treatment."
89011946|NCT00265005|Experimental|All|All subjects receive active drug up to a total of 3 doses
89011947|NCT00265044|Other|Arm 1|
89011948|NCT02962037|No Intervention|Base line|the subject will take the tests in the morning and the evening
89011949|NCT02962037|Experimental|After treatment|the subject will take the tests in the morning and the evening
89011950|NCT04720586|Experimental|triple procedure|lower eyelid retractors plication , transcutaneous blepharoplasty and wedge resection
89011951|NCT04720586|Active Comparator|combined procedure|lower eyelid retractors plication and transcutaneous blepharoplasty
89011952|NCT00282399|Experimental|DACO-019 2mg/m^2|DACO-019 2mg/m^2 twice daily (BID)
89502024|NCT02262715|Experimental|Part 1|Participants will receive in random order Treatment A (VX-787, 600 mg tablet 2 times a day on Day 1 to 4, followed by VX 787, 600 mg tablet on Day 5); Treatment B (Oseltamivir, 75 mg capsule 2 times a day on Day 1 to 4, followed by oseltamivir 75 mg capsule in the morning on Day 5) or Treatment C (VX-787, 600 mg tablet, 2 times a day orally + oseltamivir, 75 mg capsule, 2 times a day on Day 1 to 4, followed by a single dose of VX-787, 600 mg + oseltamivir, 75 mg capsule on Day 5). Each participant will receive all three treatments (Treatment A, B and C) in a random sequence.
89011953|NCT00282399|Experimental|DACO-019 5mg/m^2|DACO-019 5mg/m^2 BID
89011954|NCT00282399|Experimental|DACO-019 10mg/m^2|DACO-019 10mg/m^2 BID
89011955|NCT00242606|Active Comparator|1|Levetiracetam 2000mg/day
89011956|NCT00242606|Active Comparator|2|Lamotrigine
89011957|NCT00273312|Experimental|Patupilone|was administered at 10 mg/m2, as a single intravenous infusion over 20 minutes, once every 3 weeks
89011958|NCT00243035|Experimental|Treatment (bortezomib, tipifarnib)|"Phase I: Patients receive bortezomib IV on days 1, 4, 8, and 11 and oral tipifarnib twice daily on days 1-14. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of tipifarnib until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. An additional 6 patients are treated at the MTD.~Phase II: Patients receive bortezomib as in phase I and tipifarnib as in phase I at the MTD."
89011959|NCT00282711||1|Standard Exercise treadmill test
89011960|NCT00282711||2|Exercise treadmill testing with nuclear imaging
89502025|NCT02262715|Experimental|Part 2 VX-787|Participants will receive VX-787, 600 mg, tablet 2 times a day, orally on Day 1 to Day 9, followed by single dose of VX-787, 600 mg on Day 10.
89011961|NCT00282906|Experimental|PET-CT|
89023501|NCT05313334|Experimental|Healthy Control Group|The Healthy Control Group will receive the GAMBIT intervention and complete all study tasks and assessments at every study visit (Visits 0-4). N=20 participants will be recruited for this arm. Additionally, N=10 Healthy Control participants will be recruited for the Pilot Phase of the study.
89023503|NCT05295940|Experimental|LY3841136 (Part A)|Single ascending doses of LY3841136 administered subcutaneously (SC).
89502026|NCT02262715|Experimental|Part 2 Placebo|Participants will receive placebo matching to VX-787, 2 times a day, orally on Day 1 to Day 9, followed by single dose of matching placebo on Day 10.
88923388|NCT03719768|Experimental|Avelumab and Whole Brain Radiotherapy|Avelumab 800 mg intravenously (IV) and 3000 centriGray units (cGy) Whole Brain Radiotherapy once every 2 weeks
88923389|NCT03701399|Experimental|Arm 1: BHV-4157|Troriluzole 200mg by mouth
88923390|NCT03701399|Placebo Comparator|Arm 2: Placebo|Placebo 200mg by mouth
88923391|NCT03699709|Experimental|Intervention Arm|
88923392|NCT03699709|No Intervention|Control Arm|
88923393|NCT03689972|Experimental|Part 1: Standard Interval Dosing (SID) IV|Participants will receive natalizumab 300 milligram (mg) intravenous (IV) infusion every 4 weeks (-2/+5 days) up to Week 72.
88923394|NCT03689972|Experimental|Part 1: Extended Interval Dosing (EID) IV|Participants will receive natalizumab 300 mg IV infusion every 6 weeks (-2/+5 days) up to Week 72.
88923395|NCT03689972|Experimental|Part 2: EID SC, then EID IV|Participants will receive natalizumab 300 mg SC injection every 6 weeks from Week 108 through Week 126 followed by natalizumab 300 mg IV infusion every 6 weeks from Week 132 through Week 150.
88923396|NCT03689972|Experimental|Part 2: EID IV, then EID SC|Participants will receive natalizumab 300 mg IV infusion every 6 weeks from Week 108 through Week 126 followed by natalizumab 300 mg SC injection every 6 weeks from Week 132 through Week 150.
88923397|NCT03666845||Sciatic nerve block|Patients scheduled for foot and ankle surgery under sciatic nerve block and who had chronic kidney disease
88923398|NCT03662100|Experimental|Test 1: 250 mg LY3074828|Participants received 250 mg LY3074828 solution formulation (1 x 2-mL 125-milligram/milliliter [mg/mL]) administered subcutaneously (SC) via an auto-injector (AI) in arm.
88923399|NCT03662100|Experimental|Test 2: 250 mg LY3074828|Participants received 250 mg LY3074828 solution formulation (1 x 2-mL 125-mg/mL) administered SC via an AI in thigh.
88923400|NCT03662100|Experimental|Test 3: 250 mg LY3074828|Participants received 250 mg LY3074828 solution formulation (1 x 2-mL 125-mg/mL) administered SC via an AI in abdomen.
88923401|NCT03662100|Experimental|Reference 1: 250 mg LY3074828|"Participants received 250 mg LY3074828 solution formulation (2 x 1-mL 125-mg/mL) in pre-filled syringe (PFS) administered as subcutaneous (SC) injection in arm.~The second injection was administered 20 (±2) minutes after the first injection."
88923402|NCT03662100|Experimental|Reference 2: 250 mg LY3074828|"Participants received 250 mg LY3074828 solution formulation (2 x 1-mL 125-mg/mL) in PFS administered as SC injection in thigh.~The second injection was administered 20 (±2) minutes after the first injection."
88923403|NCT03662100|Experimental|Reference 3: 250 mg LY3074828|"Participants received 250 mg LY3074828 solution formulation (2 x 1-mL 125-mg/mL) in PFS administered as SC injection in abdomen.~The second injection was administered 20 (±2) minutes after the first injection."
88923404|NCT03656133|Experimental|Radiotherapy Fractionation|"Investigators will use an individual patient proliferation saturation index (PSI) to select radiotherapy fractionation (conventional fractionation or hyperfractionation) to improve the likelihood of a rapid response (defined as ≥ 32% reduction in volume at 4 weeks).~Radiotherapy fractionation: Standard fractionation at 2Gy once daily or Hyperfractionation at 1.2 Gy twice daily (≥ 6 hours apart)"
88923405|NCT03648905||Control patients (iatrogenic CAF)|Patients with iatrogenic chronic autonomic failure (CAF) (e.g., status-post cardiac transplantation, pre/post bilateral thoracic sympathectomies)
88923406|NCT03648905||Control patients (PD No OH)|Patients with Parkinson's disease (PD) without orthostatic hypotension (PD no OH)
88923407|NCT03648905||Healthy Volunteers|Healthy Volunteers, includes people with genetic risk of PD or studied as concurrent controls
88923408|NCT03648905||Patients with neurodegenerative chronic autonomic failure (CAF)|Includes patients with orthostatic hypotension (OH) due to sympathetic neurocirculatory failure (nOH), and people with multiple system atrophy (MSA).
88923409|NCT03605550|Experimental|Treatment (PTC596)|PTC596 administered orally twice weekly (M/Th or T/F schedule) concomitantly with RT for 6 -7 weeks. Each subsequent cycle is defined as 28 days. Post RT patients will continue to receive PTC596 twice weekly for up to 26 cycles at RP2D of 200mg/m2 with a maximum dose capped at 400mg for patients with BSA ≥2.0
89502027|NCT04314362|Experimental|AZR-MD-001 Active|AZR-MD-001 ointment/semi-solid drug (1.0%)
89502028|NCT04314362|Experimental|AZR-MD-001 Active + Conventional Treatment|AZR-MD-001 ointment/semi-solid drug (1.0%) plus Hylo-Forte®
89502029|NCT04314362|Experimental|AZR-MD-001 vehicle|AZR-MD-001 vehicle control
89011962|NCT02962154||Coronary Artery Disease (CAD)|"Patients with known coronary artery disease (CAD) as defined by prior PCI, CABG, prior MI, prior abnormal stress test, or invasive coronary angiography (ICA) and who are hemodynamically stable~They will undergo the following:~Radiation: Coronary CT Angiography Other: Mood Symptom Scale Other: Anxiety Symptom Scale Other: Chronic Stress Inventories Other: Psychosocial Function Questionnaires Other: General Health and quality of life questionnaires Other: Magnetic Resonance Imaging"
89011963|NCT02962154||Major Depressive Disorder|"Patients with a diagnosis of major depressive disorder and/or a diagnosis of bipolar 1 or bipolar 2 disorder~They will undergo the following:~Radiation: Coronary CT Angiography Other: Mood Symptom Scale Other: Anxiety Symptom Scale Other: Chronic Stress Inventories Other: Psychosocial Function Questionnaires Other: General Health and quality of life questionnaires Other: Magnetic Resonance Imaging"
89011964|NCT00283023|Experimental|A|Progenitor cells from the patinets with Craniotomy with V-P Shunt or ventriculostomy will be collected and cultured.
89011965|NCT00283101|Experimental|1|SGN-40
89011966|NCT00273741|Experimental|1|methylphenidate at 20mg per day during 7 days, at 20mg or 40mg per day during 7 days and 20, 40 or 60mg per day during 14 days
89011967|NCT00273741|Placebo Comparator|2|placebo capsules
89011968|NCT02279134|No Intervention|Surgery alone|No adjuvant treatment after radical resection is developed in this arm
89011969|NCT02279134|Experimental|Adjuvant Chemoradiation|Adjuvant chemoradiation after radical resection is developed in this arm
89502030|NCT02235025|Other|Asymptomatic mild COPD|Subjects of this group have GOLD grade I COPD (post-bronchodilator FEV1 > 80% predicted and FEV1/FVC < 0.7). They also have a modified Medical Research Council (mMRC) score equal to zero and are free of respiratory symptoms including chronic cough and/or chronic expectoration and/or chronic wheeze.
89011970|NCT02279134|Active Comparator|Adjuvant Radiation|Adjuvant radiation after radical resection is developed in this arm
89011971|NCT00243893|Active Comparator|Brain AVMs|This trial is to investigate the use of minocycline or doxycycline as medical therapy, can minocycline or doxycycline induce biologically significant changes in the enzyme system thought to be related to spontaneous growth/rupture of these malformations. Finally, can patients safely tolerate these medications over an extended period of time.
89011972|NCT00243893|Active Comparator|Aneurysms|
89011973|NCT00244049|Experimental|Brief clinician advice|
89011974|NCT00273780|Active Comparator|Adherence counseling|
89011975|NCT00273780|Active Comparator|Alarm device|
89011976|NCT00273780|Active Comparator|Counseling and alarm|Participants in this arm will receive both education counseling and a pocket alarm device.
89011977|NCT00273780|No Intervention|Control|
89011978|NCT00283335|Active Comparator|Gemfibrozil|1200 mg slow-release gemfibrozil (Lopid-SR) once per day
89011979|NCT00283335|Placebo Comparator|Placebo|Matching placebo tablets taken once per day
89011980|NCT00244439|Experimental|1|MALG
89011981|NCT00244439|Active Comparator|2|Ovide
89011982|NCT00244439|Active Comparator|3|Permethrin 1%
89011983|NCT00244478|Experimental|Soy Protein Dietary Supplement|The soy-based meal replacements will contain 20 g soy protein and 161.2 mg isoflavones, 220-240 kcal, 31-36 g total carbohydrates, 0-2 g dietary fiber, 500 mg calcium, and 2.0-2.5 g total fat per serving.
89011984|NCT00244478|Placebo Comparator|Placebo|The control shake will have 20 g casein substituted for soy protein, and will be otherwise identical to the soy shakes. The shakes will be available in two flavors: chocolate and vanilla.
89011985|NCT04709588|Placebo Comparator|placebo group|subjects drank 50 ml every night for 14, 28 days
89011986|NCT04709588|Experimental|collagen drinks|subjects drank 50 ml every night for 14, 28 days
89011987|NCT00244517|Active Comparator|I|Isoflurane (only in part I)
89011988|NCT00244517|Active Comparator|II|Sevoflurane
89011989|NCT00244517|Active Comparator|III|Desflurane
89011990|NCT00283413|Experimental|1|Symbiot Covered Stent System
89011991|NCT00283413|Active Comparator|2|Commercially available bare metal stent
89011992|NCT00244790|Experimental|low protein|
89011993|NCT00283452|Experimental|Intervention Group|Participation in phone/mail-based intervention to maintain physical activity.
89011994|NCT00283452|No Intervention|Control|No intervention; participation in surveys only
89011995|NCT02961530|Experimental|Group 1.|"The participants randomly allocated to this arm will undergo a muscular rehabilitation program based on the isokinetic eccentric exercise for the extensor muscles of the operated knee.~The contralateral non-operated lower limb will be used as control, so it will not undergo any muscular rehabilitation program."
89011996|NCT02961530|Active Comparator|Group 2.|"The participants randomly allocated to this arm will undergo a muscular rehabilitation program based on the isotonic eccentric exercise for the extensor muscles of the operated knee.~The contralateral non-operated lower limb will be used as control, so it will not undergo any muscular rehabilitation program."
89011997|NCT00283491|Active Comparator|A|
89011998|NCT00283491|Placebo Comparator|B|
89011999|NCT00274209||IBD patients at risk for neoplasia|Patients with long-standing ulcerative colitis or Crohn's colitis at risk for neoplasia.
89012000|NCT00244907|Active Comparator|Genistein vs. Risedronate|Healthy post menopausal women who have been dosed with Ca41. Intervention, 100 mg Gensitein from soy protein isolate for 50 days. After a 50 day washout risedronate (Actonel- 5mg per day) for 50 days
89012001|NCT00244907|Active Comparator|Genistein dose and source|Healthy post menopausal women will consume 5 products containing varying quantities of genistein from different sources for 50 days each in a randomized order. Each intervention period is separated by a 50 day washout period. Intervention: A) 50 mg genistein from soy protein isolate, B) 100 mg genistein from soy protein isolate, C)50 mg genistein from Novasoy, D) 100 mg genistein from Novasoy, E) 100 ng genistein from 50% Novasoy and 50% soy protein isolate
89012002|NCT00244946|Experimental|Autologous lymphocytes,carmustine,etoposide, melphalan, PBSCT|"minus Day 8 ADMIT for Hydration~minus Day 7 Carmustine 300 mg/m2 x 1 dose~minus Day 6 Etoposide 100 mg/m2 q 12 hr; Cytarabine 100 mg/m2 q 12 hr~minus Day 5 Etoposide 100 mg/m2 q 12 hr; Cytarabine 100 mg/m2 q 12 hr~minus Day 4 Etoposide 100 mg/m2 q 12 hr; Cytarabine 100 mg/m2 q 12 hr~minus Day 3 Etoposide 100 mg/m2 q 12 hr; Cytarabine 100 mg/m2 q 12 hr~minus Day 2 Melphalan 140 mg/m2 x 1 dose~minus Day 1 Day of Rest~Day 0 Transplant"
89012003|NCT00283608||Anastrozole|Blood draws for baseline and six to twelve weeks.
89012004|NCT00283608||Exemestane|Blood draws for baseline and six to twelve weeks
89012005|NCT00245180|No Intervention|control|Primary and secondary data collected as in intervention arm. Dental screenings will be done once a year as a service.
89012006|NCT00416637|Experimental|Bevacizumab (Avastin)|Bevacizumab given and then BP checked and skin biopsies obtained.
89012007|NCT00283725||Galantamine|
89012008|NCT00283725||No Alzheimer's disease (AD) treatment|
89012009|NCT02961803|Experimental|MD1003|MD1003 100mg capsules, 1 capsule tid for 24 months
89012010|NCT02961803|Placebo Comparator|Placebo|Placebo capsule, 1 capsule tid for 12 months, then switch to MD1003 100mg capsule, 1 capsule tid for 12 months
89012011|NCT00245336|Experimental|1|rThrombin
89012012|NCT00245336|Active Comparator|2|bThrombin
89012013|NCT00274443|Experimental|ABI-007 and Carboplatin|ABI-007 and Carboplatin in patients with Advanced Non-Small Cell Lung Cancer.
89012014|NCT00245414|Experimental|1|Interferon (IFN)-Treated
89012015|NCT00245414|Experimental|2|Interferon (IFN)-Untreated and Quantitative serum HCV-RNA is positive at week 1
89012016|NCT00245414|Experimental|3|Interferon (IFN)-Untreated and Quantitative serum HCV-RNA is negative at week 1
89012017|NCT00245414|Experimental|4|Interferon (IFN)-Untreated and Quantitative serum HCV-RNA is negative at week 1
89012018|NCT00245453|Active Comparator|1 Azithromycin|
89012019|NCT00245453|Active Comparator|2 Clarythromycin|
89012020|NCT00245453|Active Comparator|3 Telithromycin|
89012021|NCT00245492|Experimental|1|Chromocolonoscopy
89012022|NCT00245531||+IDU/+HIV or -HIV|
89502031|NCT02235025|Other|Symptomatic mild COPD|Subjects of this group have GOLD grade I COPD (post-bronchodilator FEV1 > 80% predicted and FEV1/FVC < 0.7). They also have a modified Medical Research Council (mMRC) score > 0.
89012023|NCT00245531||-IDU and -HIV (controls)|
89012024|NCT00245726|Active Comparator|1|Passive (Motor Assist) Cycle
89012025|NCT00245726|Active Comparator|2|
89012026|NCT00245726|Experimental|3|
89012027|NCT02961569|Other|One open-label arm|Patients suspected of pulmonary TB will have sputum collection for acid fast bacilli by the classical strategy (Day 1, Day 2 and Day 3) and the intervention sputum collection for acid fast bacilli by the same day strategy (Hour 1, 2 and 3)
89012028|NCT00245804||Adult dyslexia|Adult dyslexia
89012029|NCT00245804||Minor-Dyslexia|Minor-Dyslexia
89012030|NCT00245804||Adult-Control|Adult-Control
89012031|NCT00245804||Minor-Control|Minor-Control
89012032|NCT00274677|Placebo Comparator|Placebo|
89012033|NCT00274677|Experimental|lamotrigine|
89012034|NCT00245882|Active Comparator|Care Coordination|Care Coordination with monthly follow-up by a diabetes nurse educator
89012035|NCT00245882|Active Comparator|Home Telemedicine|Active Care Management with Home Telemedicine
89012036|NCT00274794|Other|Rituxan + Etoposide + G-CSF|
89012037|NCT00274794|Other|Etoposide + G-CSF|
89012038|NCT00284193|Experimental|feiba-VIIa, hemophilia A-inhibitor therapy|COMBINED PATIENT- TAILORED THERAPY WITH CONCOMITANT ADMINISTRATION OF BOTH DRUGS , FOLLOWING EX VIVO THROMBIN GENERATION PREDICTING ASSAYS
89012039|NCT00246194||Patients with schizophrenia|Long-acting injectable of risperidone given as per the prescription from the prescribing physician (Observational study).
89012040|NCT00274833|Experimental|Radiation Therapy, Temozolomide, and Erlotinib|
89012041|NCT04709666||Endsocopic Retrograde ColangioPancreatography (ERCP)|Endsocopic Retrograde ColangioPancreatography (ERCP)
89012042|NCT00284115|Experimental|Mechanical gait repetitive training|Body weight support treadmill training technique enabling nonambulatory patients to have the repetitive practice of a gate-like movement
89012043|NCT00284115|Active Comparator|Conventional rehabilitation program|Physiotherapeutic conventional rehabilitation program
89012044|NCT00246350|Active Comparator|1|8 light massage treatments
89012045|NCT00246350|Active Comparator|2|16 light massage treatments
89012046|NCT00246350|Experimental|3|8 spinal manipulation treatments
89012047|NCT00246350|Experimental|4|16 spinal manipulation treatments
89012048|NCT00246428|Experimental|1|MI
89012049|NCT00246506|Active Comparator|I.|Those randomized to have clomiphene/IUI treatments first will initiate therapy with two cycles of the fertility pill called clomiphene combined with (IUI) intrauterine insemination. If not pregnant after 2 IUI cycles, the couples will then proceed to IVF.
89012050|NCT00246506|Active Comparator|II.|Those randomized to have gonadotropins/IUI treatments first will initiate therapy with two cycles of the fertility injections called FSH or gonadotropins combined with (IUI) intrauterine insemination. If not pregnant after 2 IUI cycles, the couples will then proceed to IVF.
89012051|NCT00246506|Active Comparator|III.|Those couples randomized to (IVF) in vitro fertilization will bypass IUI treatments and start IVF therapy immediately.
89012052|NCT00284427|Experimental|1|Vitamin C
89012053|NCT00246662|Experimental|Sch A (18 mg/m2 vosaroxin initially)|Once weekly intravenous on days 1, 8, 15 up to 4 cycles
89012054|NCT00246662|Experimental|Sch B (9 mg/m2 vosaroxin initially)|Twice weekly intravenous administration on days 1, 4, 8, 11 up to 4 cycles
89012055|NCT00246701|Active Comparator|Simvastatin|Simvastatin + placebo
89012056|NCT00246701|Experimental|Simvastatin + Lovaza|Simvastatin + Lovaza (omega-3-acid ethyl esters)
89012057|NCT00277368||001|
89012058|NCT00246974|Active Comparator|1|Cisplatin + Gemcitabin
89012059|NCT00246974|Experimental|2|Cisplatin + Gemcitabin + Gefitinib
89012060|NCT00247052|Active Comparator|diclofenac|diclofenac
89012061|NCT00247052|Placebo Comparator|2|
89012062|NCT00277641|Experimental|1|lamotrigine
89012063|NCT00277641|Placebo Comparator|2|
89012064|NCT00284661|Experimental|FAST FIX|Inetrvention is Fast Fix repair of meniscal tear
89012065|NCT00284661|Experimental|Meniscal suturing|Intervention is Standard suturing of meniscal tear
89012066|NCT00247130|Active Comparator|Omeprazole|Omeprazole (20 mg), intravenous, 2x /day
89012067|NCT00247130|Active Comparator|Ranitidine|Ranitidine (100 mg), intravenous drip infusion, 2x /day.
89012068|NCT00247208|Active Comparator|1|Express 2 bare metal stent
89012069|NCT00247208|Experimental|2|Taxus, paclitaxel-eluting stent
89012070|NCT00277758|Experimental|1|Interventions: 12 weeks of interleukin-2 administration, followed by 48 weeks of interleukin-2 + Ribavirin + interferon-alpha therapy, followed by 24 weeks off therapy
89012071|NCT00277758|Active Comparator|2|48 weeks of therapy with Ribavirin + interferon-alpha, followed by 24 weeks off therapy
89012072|NCT00247286|Experimental|a|Weighted vaginal cones used to perform pelvic floor exercises
89012073|NCT00247286|Active Comparator|b|Biofeedback
89012074|NCT00284817|Experimental|1|MEDI-522
89012075|NCT00284817|Experimental|2|MEDI-522
89012076|NCT00284817|Experimental|3|MEDI-522
89012077|NCT00284817|Experimental|4|MEDI-522
89012078|NCT00284817|Experimental|5|MEDI-522
89012079|NCT00277797|Active Comparator|Biowave first|First Treatment: Biowave; Second Treatment: TENS
89012080|NCT00277797|Active Comparator|TENS first|First Treatment: TENS; Second Treatment: Biowave
89199359|NCT05737901|Experimental|Mobile Application Group|The mobile application was introduced to the patient by the researcher the day before the surgery. During the presentation phase, the patient was informed about the titles and contents of the training videos, and after explaining the technical features related to turning the tablet on and off, raising and lowering the volume, logging into the account using the username and password for training, using the buttons on the main screen and the keyboard, the patient was asked to apply them. All these stages took an average of 20 minutes. In addition, information about logging in, such as how to switch on and off the device, the patient's user name and password, were added to the back of the tablet in writing.
89199360|NCT05730374|No Intervention|Control group|children with thalassemia will receive only routine care of hospital during blood transfusion.
89199361|NCT05730374|Experimental|Benson's Relaxation Group|children with thalassemia will receive Benson's relaxation intervention beside routine care of hospital during blood transfusion
88923410|NCT03593473|Experimental|Intranasal Oxytocin|Participants block randomized to Oxytocin intranasal spray by risk status at enrollment in the Mood, Mother and Infant (MMI) study and as verified by structured clinical diagnostic interview (no history of depression or anxiety, past depression or anxiety, current depression or anxiety).
88923411|NCT03593473|Placebo Comparator|Placebo|Participants block randomized to placebo Intranasal spray with all equivalent ingredients except oxytocin. Blocks will be stratified by risk status at enrollment in the Mood, Mother and Infant (MMI) study and as verified by structured clinical diagnostic interview (no history of depression or anxiety, past depression or anxiety, current depression or anxiety).
88923412|NCT03552276|Experimental|SUNPG18_07 q4 weeks, high dose|
88923413|NCT03552276|Experimental|SUNPG18_07 q12 weeks, high dose|
88923414|NCT03552276|Experimental|SUNPG18_07 q12 weeks, low dose|
88923415|NCT03535688|Experimental|D-cycloserine|D-cycloserine 200 mg twice daily
88923416|NCT03535688|Placebo Comparator|Placebo|Placebo twice daily
88923417|NCT03511118||Tranexamic acid (TXA)|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
88923418|NCT03511118||labetalol|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
88923419|NCT03511118||metformin|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
88923420|NCT03511118||nifedipine|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
89012081|NCT00247403|Experimental|2DG|
89012082|NCT00424814|Experimental|1|Kaletra (lopinavir/ritonavir)
89199362|NCT05730374|Experimental|Music Therapy Group|children with thalassemia will receive music therapy intervention beside routine care of hospital during blood transfusion.
89199363|NCT05725096|Active Comparator|CCTA-based strategy group|Subjects will be managed following the CCTA -based coronary heart disease prevention strategy for lipid-lowering treatment and follow-up.
89199364|NCT05725096|Sham Comparator|Chinese guidelines for lipid management (2023)|The baseline assessment will be completed on the same day as consent is gained. Every subjects will complete a comprehensive assessment including questionnaires and objective assessments.
89199365|NCT05722587|Experimental|Pain education day|Pain education day, lecture and experiential
89199366|NCT05722587|No Intervention|Control|No intervention
89199367|NCT05721274|Experimental|Intervention|"The study will adopt a pretest/post-test quasi-experimental design. The approach of the proposed project is to implement a participatory community engagement and demand creation strategy with trust-building community mobilization and a conditional community-based incentive scheme to reduce the refusals to vaccination and improve polio immunization coverage in intervention UCs. Clusters will be formed on a population of 1500-2000 in each intervention UC. Committees would be formed with approximately 5-7 prominent members of the community.~Intervention Non-cash, incentives would be given and decided with consensus by UC committees and aim to improve infrastructure linked to health including water and sanitation and toilets in the community."
89199368|NCT05721274|No Intervention|Control arm|This would be the standard of care
88923421|NCT03511118||clindamycin|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
88923422|NCT03511118||oxycodone|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
88923423|NCT03511118||azithromycin|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
88923424|NCT03511118||escitalopram|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
88923425|NCT03511118||sertraline|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
88923426|NCT03511118||ondansetron|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
88923427|NCT03511118||Ciprofloxacin|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
88923428|NCT03511118||Doxycycline|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
88923429|NCT03511118||Levofloxacin|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
88923430|NCT03511118||Methylphenidate|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
88923431|NCT03511118||Sumatriptan|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
88923432|NCT03511118||Citalopram|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
88923433|NCT03511118||Cyclobenzaprine|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
88923434|NCT03511118||Furosemide|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
88923435|NCT03511118||Gabapentin|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
88923436|NCT03511118||Hydrochlorothiazide|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
88923437|NCT03511118||Hydroxyurea|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
88923438|NCT03511118||Rosuvastatin|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
88923439|NCT03511118||Topiramate|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
88923440|NCT03511118||Trazodone|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
88923441|NCT03511118||Valganciclovir|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
89012083|NCT00424814|Active Comparator|2|Kaletra (lopinavir/ritonavir) + Combivir (zidovudine/lamivudine)
89438848|NCT03522480|Other|Group A: Education & Gaming|Children will participate in 1 initial training session where they will be taught by a RT to use autogenic drainage (AD). Patients will be sent home & prescribed to practice the technique 15 minutes 3 times / week. At week 8 +/- 1 week patients will return and will be tested by a software program designed to evaluate their ability to perform the AD sequence (percent accuracy). At the 8 week visit, the Jamboxx gaming device will be introduced, which will contain a game to guide them through the proper sequence of breathing for the AD technique. Patients will be sent home with a Jamboxx device and requested to do 15 minutes of AD training 3 times / week. Patients will return at week 16 and again will be tested via software program for ability to perform the AD technique.
89438849|NCT03522480|Experimental|Group B: Gaming Only|Children will participate in an initial training session at Albany Med where they will be taught by a RT to use the Jamboxx respiratory therapy device to guide them through autogenic drainage (AD): a series of controlled breathing exercises that mobilizes mucous without inducing wheezing in patients with reactive airways. Patients will be sent home and prescribed to use the Jamboxx respiratory therapy device 15 minutes three times per week. At week 8 and week 16 +/- 1 week patients will return and will be tested by a software program designed to evaluate their ability to perform AD sequence (percent accuracy).
89438850|NCT02139189|Experimental|P-ECM Implant|P-ECM Implant into damaged ischemic and/or infarcted myocardium
89438851|NCT05550688||NAFLD and NAFLD-free cohort|The investigators diagnosed nonalcoholic fatty liver based on abdominal ultrasonography and ruled out excessive alcohol consumption and other etiologies of liver disease according to the Chinese Liver Disease Association.
89438852|NCT05120934|Experimental|Duloxetine and Placebo|Subjects will receive 30mg of Duloxetine for blinded period 1 (first 4 week treatment period) and 30mg of Duloxetine plus 30mg Placebo for blinded period 2 (additional 4 weeks treatment period). After this, subjects will be unblinded and receive routine clinical care for follow up phase (up to 52 weeks).
89438853|NCT05120934|Experimental|Duloxetine dose escalation|Subjects will receive 30mg of Duloxetine for blinded period 1 (first 4 week treatment period) and 60mg of Duloxetine for blinded period 2 (additional 4 weeks treatment period). After this, subjects will be unblinded and receive routine clinical care for follow up phase (up to 52 weeks).
89438854|NCT05120934|Experimental|Amitriptyline and Placebo|Subjects will receive 25mg of Amitriptyline for blinded period 1 (first 4 week treatment period) and 25mg of Amitriptyline plus 30mg Placebo for blinded period 2 (additional 4 weeks treatment period). After this, subjects will be unblinded and receive routine clinical care for follow up phase (up to 52 weeks).
89438855|NCT05120934|Experimental|Amitriptyline dose escalation|Subjects will receive 25mg of Amitriptyline for blinded period 1 (first 4 week treatment period) and 50mg of Amitriptyline for blinded period 2 (additional 4 weeks treatment period). After this, subjects will be unblinded and receive routine clinical care for follow up phase (up to 52 weeks).
89438856|NCT05120934|Placebo Comparator|Placebo|Subjects will receive 30mg of Placebo for blinded period 1 (first 4 week treatment period) and 60mg of Placebo for blinded period 2 (additional 4 weeks treatment period). After this, subjects will be unblinded and receive routine clinical care for follow up phase (up to 52 weeks).
89438857|NCT03548493|Experimental|Magnesium (M) group|Magnesium (M) group (n=17) , in which magnesium sulphate is given as adjuvant to propofol for sedation
89438858|NCT03548493|Active Comparator|Fentanyl (F) group|Fentanyl (F) group (n=17), in which fentanyl is given as adjuvant to propofol for sedation
89438859|NCT05550610|Experimental|Mindfulness and Yoga|Mindfulness-Based Attention Training (MBAT) was delivered in 4, 2-hour sessions over 4 weeks. Yoga was delivered 6 days/week, 30 minutes per day.
89438860|NCT05550610|No Intervention|Training as Usual|Training as usual included standard exercises 30 minutes per day during warm-up (15 min) and cool-down (15 min) as part of Army physical readiness training.
89438861|NCT03525132|Experimental|Healthy subjects|120 healthy subjects in the first session and 30 in the second Intervention : Laser Doppler Velocimetry + Optic Adaptative Camera
89438862|NCT03525132|Experimental|Glaucoma|60 subjects with glaucoma Intervention : Laser Doppler Velocimetry + Optic Adaptative Camera
89438863|NCT03525132|Experimental|Retinal vein occlusion|80 subjects with retinal vein occlusion including 40 with peripheric occlusion and 40 with central occlusion Intervention : Laser Doppler Velocimetry + Optic Adaptative Camera
89438864|NCT02134665||severe acute pancreatitis|patients who received vancomycin therapy and whose serum vancomycin level was monitored, and who also had diagnosed as severe acute pancreatitis.
89438865|NCT02134665||Pneumonia|patients who received vancomycin therapy and whose serum vancomycin level was monitored, and who also had diagnosed as pneumonia.
89438866|NCT02139267|Experimental|1mg of GX-188E per dose|1mg of GX-188E per dose will be administered on 1mg group participants through intramuscular route using EP device. The injection points are at 0 week, 4 week and 12 week.
89438867|NCT02139267|Experimental|4mg of GX-188E per dose|4mg of GX-188E per dose will be administered on 4mg group participants through intramuscular route using EP device. The injection points are at 0 week, 4 week and 12week.
88923442|NCT03511118||Venlafaxine|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
88923443|NCT03511118||Verapamil|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
88923444|NCT03511118||Remdesivir|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
88923445|NCT03511118||Anakinra|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
88923446|NCT03511118||Tocilizumab|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
88923447|NCT03511118||Fluvoxamine|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
88923448|NCT03511118||Amoxicillin|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
88923449|NCT03511118||Bupropion|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
88923450|NCT03511118||Buprenorphine|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
88923451|NCT03511118||Hydrocodone|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
88923452|NCT03511118||Levetiracetam|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
88923453|NCT03511118||Paroxetine|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
88923454|NCT03511118||Duloxetine|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
88923455|NCT03446417|Experimental|Phase 1|Up to 9 sequential dose escalation cohorts to determine maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) is identified.
88923456|NCT03446417|Experimental|Phase 2|"MTD/RP2D in subjects:~Cohort 1: with T790M mutation in epidermal growth factor receptor (EGFR) gene, and are osimertinib naïve.~Cohort 2: EGFRm amenable to EGFR inhibitor therapy (eg, exon 19 del, L858R) and who have never been treated with EGFRis."
88923457|NCT03445858|Experimental|Pembrolizumab, Decitabine, Radiation|Patients will receive pembrolizumab and decitabine every 28 days, and a single 3 day course of fixed-dose hypofractionated radiotherapy to one or more index lesions.
88923458|NCT03442556|Experimental|Treatment (docetaxel, carboplatin, rucaparib camsylate)|"INDUCTION: Patients receive docetaxel IV and carboplatin IV on day 1. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive rucaparib camsylate PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
88923459|NCT03433274|Experimental|Randomized Cohort - Treatment Group|Treatment of mitral regurgitation with the Tendyne Transcatheter Mitral Valve System
88923460|NCT03433274|Active Comparator|Randomized Cohort - Control Group|Treatment of mitral regurgitation within commercially approved MitraClip system indications
88923461|NCT03433274|Experimental|Non-repairable Cohort|Treatment of mitral regurgitation with the Tendyne Transcatheter Mitral Valve System
88923462|NCT03433274|Experimental|Severe Mitral Annular Calcification (MAC) Cohort|Treatment of mitral regurgitation and mitral annular calcification with the Tendyne Transcatheter Mitral Valve System
88923463|NCT03433274|Experimental|Severe Mitral Annular Calcification Continued Access Protocol (MAC CAP) Cohort|Treatment of mitral regurgitation and mitral annular calcification with the Tendyne Transcatheter Mitral Valve System after the completion of enrollment in the Severe MAC Cohort
88923464|NCT03389802|Experimental|Stratum 1|The recurrent, progressive, or refractory primary malignant non-brainstem CNS tumor patients will be treated with APX005M.
88923465|NCT03389802|Experimental|Stratum 2|The newly diagnosed diffuse intrinsic pontine gliomas (DIPGs) patients will be treated with APX005M.
89012084|NCT04719039|Experimental|Yoga Group|Restorative Yoga intervention
89012085|NCT04719039|No Intervention|Waitlist Control Group|Participants in the waitlist control group will receive the intervention after the immediate post-treatment assessment
89012086|NCT00285051|Experimental|Group 1|Chemo cycle 1 - IV Ondansetron Chemo cycle 2 - 300 mcg of delta-8-THC per dose
89438868|NCT02139345|Experimental|TC-A PS|Subject will be implanted with the TC-A PS Total Knee Replacement System
89438869|NCT02139345|Active Comparator|TC-PLUS Solution PS|Subject will be implanted with the TC-PLUS Solution PS Total Knee Replacement System.
89438870|NCT03549819|Experimental|Cannabidiol (CBD) Oil Capsules|Pure CBD in sunflower lecithin oil, flexibly dosed at 200-800 mg per day
89438871|NCT03549819|Placebo Comparator|Sunflower Lecithin Oil in Capsule|1-4 capsules daily
89438872|NCT02139423|Experimental|All newborns who fail universal newborn|CMV PCR
89438873|NCT01665430|Experimental|Tocilizumab|Participants will receive tocilizumab 8 milligrams per kilogram (mg/kg) intravenous infusion every 4 weeks up to 104 weeks.
89199369|NCT05713422||Operative procedure; standard treatment|Vaginal level I and/or level II repair will be performed as usual (eg anterior and/or posterior colporrhaphy, sacrospinous fixation etc.) without perineoplasty as decided by surgeon and patient. This procedure is considered as the control group.
89438874|NCT03524976||Embolization with Squid|All patients with DAVFs are treated with SQUID™ aiming at complete occlusion of the fistula. Each participating center will include patients with DAVFs in whom the liquid embolic agent SQUID™ is planned to be used consecutively in the study. The
89438875|NCT05578053||locally advanced/metastatic HR+ breast cancer patients|HR+ postmenopausal or premenopausal and locally advanced or metastatic breast cancer patients who had received or had not received prior systemic therapy.
89438876|NCT02134743|Experimental|Experimental Group|At this group the patients will receive dental implants which have a modified SLA surface. These surface have wettability, which could improve and accelerate the osseointegration.Intervention: implant placement.
89438877|NCT02134743|Active Comparator|Control Group|The patient of this group will receive implant with conventional surface, SLA (Sandblasted and Acid-Etched Surface).Intervention: implant placement.
89438878|NCT04466202|Experimental|Music Group with Structured Verbal Training|Music with structured verbal training was applied during transrectal ultrasound guided prostate biopsy.
88923466|NCT03377023|Experimental|Phase 1 - Dose Escalation|"Nivolumab + Ipilimumab + Nintedanib dose escalation.~Nivolumab: 3 mg/kg IV Q2 weeks.~Ipilimumab: 1 mg/kg Q6 weeks.~Nintedanib Level -1: 100 mg by mouth (PO) once a day (QD) Days 1-14 (Daily dose =100 mg).~Nintedanib Level 0:150 mg by mouth (PO) once a day (QD) Days 1-14 (Daily dose =150 mg)~Nintedanib Level 1: 100 mg PO twice daily (BID) Days 2-28 (Daily dose = 200 mg).~Nintedanib Level 2: 150 mg PO BID Days 1-14 (Daily dose = 300 mg).~Nintedanib Level 3: 200 mg PO BID Days 1-14 (Daily dose = 400 mg)."
88923467|NCT03377023|Active Comparator|Phase 2 - Arm A|"Arm A: Newly diagnosed or treatment-naïve patients, with a target overall response rate (ORR) of 50%.~Nivolumab + Ipilimumab + Nintedanib at RP2D."
88923468|NCT03377023|Active Comparator|Phase 2 - Arm B|"Arm B: Patients who have been previously exposed to immunotherapy, such as anti-PD-1, anti-PD-L1 or anti-CTLA-4, with a target ORR of 20%.~Nivolumab + Ipilimumab + Nintedanib at RP2D."
88923469|NCT03311126|Experimental|Bendamustine + Obinutuzumab (BO)|"Induction chemoimmunotherapy (28 day cycles):~Bendamustine 90 mg/m2 IV days 1 & 2 every 28 days X 4-6 cycles~Obinutuzumab:~Cycle 1: 100 mg IV day 1, 900 mg IV day 2, 1000 mg IV days 8 & 15~Cycles 2-6: 1000 mg IV day 1~Consolidation phase:~Obinutuzumab 1000 mg IV weekly X 4 doses~Maintenance phase (8 week cycles):~Obinutuzumab 1000 mg IV on day 1 of cycles 1-8"
88923470|NCT03309033||Observational (questionnaire, biospecimen collection)|Patients complete a short questionnaire regarding risk factors for HPV infection and undergo collection of blood samples for testing HPV16 and HPV18 levels on study.
89023504|NCT05295940|Experimental|LY3841136 (Part B)|Multiple ascending doses of LY3841136 administered SC.
89438879|NCT04466202|No Intervention|Control Group|The control group did not listen to music during the procedure, and they received routine training.
89438880|NCT05542888|Experimental|Experimental group|Postural education Hot pack(10 min) Antenatal exercises(i.e. deep breathing(5 min), stretching(5 min), kegel exercises(5 min), Mitchells physiologic relaxation technique(10 min) and walk(10 min) Sacro iliac joint mobilization(5 min) Total duration:50 min/session
89438881|NCT05542888|Active Comparator|Control group|Postural education Hot pack(10 min) Antenatal exercises(i.e.deep breathing(5 min), stretching(5 min), kegel exercises(5 min), Mitchells physiologic relaxation technique(10 min) and walk(10 min) Total duration:45 min/session
89438882|NCT03549741|Experimental|study group|will receive a dose of Clomiphene citrate 50 mg tablet , 1 tab twice daily for 5 days from the third day of menses to the seven day and cabergoline 0.25 mg (half tablet) every 3 days (one package) first three months then Clomiphene citrate 50 mg tablet , 2 tabs twice daily for 5 days from the third day of menses to the seven day and cabergoline 0.25 mg (half tablet) every 3 days (one package)
89438883|NCT03549741|Active Comparator|control group|will receive a dose of Clomiphene citrate and placebo tablets with same dose and duration
89438884|NCT05542810|Experimental|Sports drinks are polyethylene glycol solvents|
89438885|NCT05542810|No Intervention|Water is a polyethylene glycol solvent|
89438886|NCT03522402|Experimental|30 degree rotated lateral position|19 patients American Society of Anesthesiologists (ASA) class I or II aged 2-8 years undergoing tonsillectomy surgery were randomized to the head in 30 degree rotated lateral position. The end-tidal (ET) sevoflurane concentration used for each patient was determined using the Dixon's up-and-down method. The ratio of the end-tidal to predetermined end-tidal concentrations was maintained at 0.95-1.0 for at least 10 minutes to establish equilibration before device insertion was attempted. The first patient received a 5.0% sevoflurane concentration and the step size of increase/decrease was 0.5%.
89438887|NCT03522402|Active Comparator|neutral position|19 patients American Society of Anesthesiologists (ASA) class I or II aged 2-8 years undergoing tonsillectomy surgery were randomized to the head in the neutral position.The end-tidal (ET) sevoflurane concentration used for each patient was determined using the Dixon's up-and-down method. The ratio of the end-tidal to predetermined end-tidal concentrations was maintained at 0.95-1.0 for at least 10 minutes to establish equilibration before device insertion was attempted. The first patient received a 5.0% sevoflurane concentration and the step size of increase/decrease was 0.5%.
89438888|NCT05577975|Experimental|Intervention Arm|The program will consist of three face-to-face (F-T-F) horticultural activity training session for a group of 6-8 participants and then biweekly telephone follow-up for 8-week home-based horticultural intervention.
89012087|NCT00285051|Experimental|Group 2|Chemo cycle 1 - IV Ondansetron Chemo cycle 2 - 600 mcg of delta-8-THC per dose
89012088|NCT00285051|Experimental|Group 3|Chemo cycle 1 - 300 mcg of delta-8-THC per dose, Chemo cycle 2 - IV Ondansetron
89012089|NCT00285051|Experimental|Group 4|Chemo cycle 1 - 600 mcg of delta-8-THC per dose Chemo cycle 2 - IV Ondansetron
89012090|NCT02961725|Experimental|UCMSC treatment|UCMSC: umbilical cord mesenchymal stem cells
89012091|NCT00247715|Other|Step-up|"Stepwise treatment:~step1: antacid (+placebo proton pump inhibitor)~step2: H2-receptor antagonist~step3: proton pump inhibitor (+ placebo antacid)"
89012092|NCT00247715|Other|step-down|"Stepwise treatment:~step1: proton pump inhibitor (+placebo antacid)~step2: H2-receptor antagonist~step3: antacid (+proton pump inhibitor)"
89012093|NCT00285090|Experimental|Early Treatment|
89438889|NCT05542732|Experimental|Single group|Each participant wore one CW2 sensor attached to the back of the wrist with a wrist band. Additionally, each participant wore a reference pulse oximeter (Nellcor PM10) attached to the middle finger of the ipsilateral hand. This enabled the comparison of the paired results of the CW2 sensor and reference pulse oximeter equipment for SpO2 measurements at different oxygen saturation levels. Twelve subjects of the 24 participants received an arterial catheter in the contralateral radial artery for exvivo SaO2 determination by CO-oximetry and in order to define the final accuracy of CW2 for SpO2 measurement.
89012094|NCT00285090|Experimental|LateTreatment|
89012095|NCT00285090|Experimental|Total Treatment|
89438890|NCT05698966|Active Comparator|betamethasone 12 mg|3 mg betamethasone sodium phosphate and 3 mg betamethasone acetate per milliliter. The first dose of study drug medication will be administered at randomization as 2 ml injection; the next dose of 2 ml will be administered 24 hours later
89012096|NCT00285090|Placebo Comparator|No Treatment|
89012097|NCT00417222|Active Comparator|Olmesartan medoxomil|olmesartan medoxomil
89012098|NCT00417222|No Intervention|Standard therapy|Standard therapy
89012099|NCT00247832|No Intervention|1|
89012100|NCT00247832|Experimental|2|Self-directed motivation
89012101|NCT00247832|Experimental|3|Personal motivational interviewing
89012102|NCT00278070|Active Comparator|1|
89012103|NCT00278070|Active Comparator|2|
89012104|NCT00278070|Active Comparator|3|
89012105|NCT00417261|Experimental|1|ATF936
89012106|NCT00417261|Experimental|2|AXT914
89012107|NCT00417261|Placebo Comparator|3|Placebo
89012108|NCT00424983|Experimental|Zometa q 4 weeks|
89012109|NCT00424983|Active Comparator|Zometa q 12 weeks|
89012110|NCT04718610|Active Comparator|Control|Patients will receive only caner treatment. No osteopathic treatment.
89012111|NCT04718610|Experimental|Osteopathic intervention|Patients will receive cancer treatment associated with osteopathic intervention
89012112|NCT00248105|Experimental|PAM|
89012113|NCT00248105|No Intervention|PC|Participants not in the PAM group will be in the PC (physician counseling) group and will receive advice on lifestyle physical activity from their rheumatologist or primary care physician.
89012114|NCT00278265|Experimental|MTX followed by fludarabine|MTX is given with a dose of 10-20mg weekly Fludarabine is dosed with 25mg/m2 day 1-3 of 28 days, up to 4 cycles
89012115|NCT00278343|Experimental|Treatment (cediranib maleate)|Patients receive cediranib maleate PO QD every 4 weeks in the absence of disease progression or unacceptable toxicity.
89012116|NCT00285168||1 - Control|Usual Bone Density Report
89012117|NCT00285168||2 - Intervention|Bone Density Report with Absolute 10-year Fracture Risk Decision Aide
89012118|NCT00278382|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily in the absence of disease progression or unacceptable toxicity.
89012119|NCT00248339|Active Comparator|1|PEG-interferon-alpha-2b 1.5 μg/kg QW plus ribavirin ~13.3 mg/kg QD
89012120|NCT00248339|Active Comparator|2|PEG-interferon-alpha-2b 1.5 μg/kg QW plus standard dose ribavirin, ~13.3 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week.
89012121|NCT00248339|Active Comparator|3|PEG-interferon-alpha-2b 1.5 μg/kg QW plus high dose ribavirin, ~15.2 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week.
89438891|NCT05698966|Experimental|betamethasone 3 mg|3 mg betamethasone sodium phosphate and 3 mg betamethasone acetate per milliliter. The first dose of study drug medication will be administered at randomization as 0.5 ml injection; the next dose of 0.5 ml will be administered 24 hours later
89438892|NCT02139501|Experimental|rhTPO, 300Units/kg ,daily for 14 consecutive days|10 enrolled patients randomly receive rhTPO at a dose of 300Units/kg ,daily for 14 consecutive days
89438893|NCT02139501|Experimental|rhTPO, 300Units/kg ,one times every other day for 7 times|10 enrolled patients randomly receive rhTPO at a dose of 300Units/kg ,one times every other day for 7 times.
89438894|NCT02139501|Experimental|rhTPO, 300Units/kg ,daily for 7 consecutive days|10 enrolled patients randomly receive rhTPO at a dose of 300Units/kg ,daily for 7consecutive days.
89438895|NCT02134821||Low pain sensitivity group|total Pain Sensitivity Questionnaire score <6.5
89438896|NCT02134821||High pain sensitivity group|total pain sensitivity questionnaire score ≥ 6.5
89438897|NCT05577897|Experimental|Patient Education|The intervention group was given 45 minutes of training.
89438898|NCT05577897|No Intervention|Control Group|Routine nursing care was given to the patients in this group without any training.
89438899|NCT02134899|Experimental|Everolimus|everolimus based immunosuppression
89438900|NCT02134899|Active Comparator|Calcineurin|Calcineurin inhibitors maintenance
89438901|NCT02135055|Experimental|Normal immune function|The value of monocyte human leukocyte antigen-DR (mHLA-DR) is equal to or more than 15000 monoclonal antibody.
89438902|NCT02135055|Experimental|Moderate immunosuppression|The value of mHLA-DR is equal to or more than 10000 and less than 15000 monoclonal antibody.
89438903|NCT02135055|Experimental|Sever immunosuppression|The value of mHLA-DR is equal to or more than 5000 and less than 10000 monoclonal antibody.
89438904|NCT02135055|Experimental|Immune paralysis|The value of mHLA-DR is less than 5000 monoclonal antibody.
89438905|NCT02139579|Experimental|Avastin|bevacizumab 7.5mg/kg+paclitaxel 200mg/m2＋carboplatin area under curve(AUC)=6, every 3 weeks，maximum 4 cycles
89438906|NCT04425928|Active Comparator|activity group|Participants received an activity-based home program that was performed for 4 weeks.
89438907|NCT04425928|Experimental|exercise group|Participants received an exercise-based home program was performed that was performed for 4 weeks.
89438908|NCT04425928|No Intervention|control group|No intervention
89438909|NCT02139657|Experimental|RIG-C|Single 20 IU/kg dose of RIG-C by intramuscular injection
89438910|NCT03526926||Vyxeos|A minimum of 50 patients who receive at least one infusion of prescribed VYXEOS.
89438911|NCT02135211|Experimental|Lifestyle counseling|This is a single arm, quasi-experimental, pre- and post- test study design to test the feasibility and acceptability of a multiple risk factor, lifestyle intervention in patients receiving surgical treatment for lung cancer or those suspected of having lung cancer.
89438912|NCT04076826|Experimental|Protocol A (Dexmedetomidine)|Dexmedetomidine will be administered in accordance with hospital standard operating procedures (SOP).
89438913|NCT04076826|Active Comparator|Protocol B (Propofol / Midazolam)|Propofol and/or Midazolam will be administered in accordance with hospital standard operating procedures (SOP).
89438914|NCT02139735|Experimental|Ultrasound|3 MHz (Mega Hertz) ultrasound in continuous mode with an intensity of 1.0 W / cm ² was applied for 3 minutes in the TMJ (Temporomandibular joint) and masseter muscles bilaterally
89438915|NCT02139735|Experimental|Ultrasound associated with stretchting|"3 MHz ultrasound in continuous mode with an intensity of 1.0 W / cm ² was applied for 3 minutes in the TMJ and masseter muscles bilaterally.~Active stretching of the masseter muscles with mouth opening and closed lips"
89438916|NCT02139735|Experimental|Placebo|Turned off ultrasound application on area of TMJ and masseter muscle, bilaterally.
89438917|NCT05535634||Children referred for tympanostomy tube insertion|Study Sound Ear Check (SEC) hearing test among 3-10 years old otherwise healthy children referred to tympanostomy tube placement. SEC test prior surgery (with middle ear fluid) and at 1 month control visit (dry middle ear with ventilation tube). Otitis media 6 questionnaire prior surgery and at the 1 month control visit.
89438918|NCT05577585|Active Comparator|Ketamine|Participants will undergo one infusion of ketamine as active comparator. (R,S-ketamine 50mg/ml solution for injection, dose: 0,5 mg per kg bodyweight) Both medications will be diluted in 100 ml saline and will be adjusted for infusion over 40 minutes, administered with a syringe pump.
89438919|NCT05577585|Placebo Comparator|Midazolam|Participants will undergo one infusion of midazolam as comparator. (0,045 mg/kg bodyweight) Both medications will be diluted in 100 ml saline and will be adjusted for infusion over 40 minutes, administered with a syringe pump.
89438920|NCT02135289||IMID patients|Patients with IMID
89438921|NCT02135289||Control - subjects without IBD|Patients without IBD
89438922|NCT04465968|Experimental|CRT + Durvalumab ± Surgery + Durvalumab|Concurrent chemoradiotherapy (cisplatin+S-1+radiotherapy 66Gy)+2 courses of durvalumab followed by Surgery and adjuvant durvalumab for resectable SST or chemoradiotherapy (cisplatin+S-1+radiotherapy 66Gy) followed by maintenance durvalumab for unresectable SST.
89438923|NCT02139813|Experimental|Laparoscopic Omega Loop Bypass|Laparoscopic Mini-gastric bypass
89438924|NCT02139813|Active Comparator|Laparoscopic Roux-en-Y Gastric ByPass|Procedure of reference in bariatric surgery
89438925|NCT03526770|Active Comparator|Group 1: no intervention|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva.The subject is then given 100 ml of test carbonated drink, Coco cola ® to drink. The subject will sip, swish and swallow the drink within 2 minutes.~Unstimulated saliva samples are collected from the subject to measure the pH of saliva after 5, 15, 30, 45 and 60 minutes of consumption of the test carbonated drink."
89438926|NCT03526770|Experimental|Group 2: tap water gargle|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva.The subject is then given 100 ml of test carbonated drink, Coco cola ® to drink. The subject will sip, swish and swallow the drink within 2 minutes.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test carbonated drink.~The subject will use 10 ml of tap water as mouth rinse to swish for 60 seconds and spit. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention"
89438927|NCT03526770|Experimental|Group 3: 0.2% chlorhexidine|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva.The subject is then given 100 ml of test carbonated drink, Coco cola ® to drink. The subject will sip, swish and swallow the drink within 2 minutes.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test carbonated drink.~The subject will use 10 ml of 0.2% Chlorhexidine mouth rinse (Rexidine®, Indoco Remidies Ltd, Mumbai, India) to swish for 60 seconds and spit. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention."
89438928|NCT03526770|Experimental|Group 4: fluoridated tooth paste|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva.The subject is then given 100 ml of test carbonated drink, Coco cola ® to drink. The subject will sip, swish and swallow the drink within 2 minutes.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test carbonated drink.~The subject will Brush with fluoridated toothpaste-(Colgate Total®, Colgate-Palmolive Company, Mumbai, India) for 2 minutes using soft brush.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the tooth paste as an intervention."
89438929|NCT03526770|Experimental|Group 5: Polyol containing gum|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva.The subject is then given 100 ml of test carbonated drink, Coco cola ® to drink. The subject will sip, swish and swallow the drink within 2 minutes.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test carbonated drink.~The subject will chew polyol containing gum (Orbit®, WrigleyCompany) for 5 minutes and spit.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the chewing gum as an intervention."
89438930|NCT03526770|Experimental|Group 6: 1% sodium bicarbonate solution|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva.The subject is then given 100 ml of test carbonated drink, Coco cola ® to drink. The subject will sip, swish and swallow the drink within 2 minutes.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test carbonated drink.~The subject will use 10 ml freshly prepared 1% sodium bicarbonate w/v solution to swish for 60 seconds and spit.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention"
89438931|NCT02135367|Experimental|PRP|This group of patients will be treated by three weekly Platelet rich Plasma intra-articular injections in the knee.
89438932|NCT02135367|Active Comparator|HA|"This group of patients will be treated by three weekly hyaluronic acid (HA) intra-articular injections in the knee.~The HA used is Hyalubrix 30 mg/2ml (Fidia Farmaceutici Spa, Padova, Italy)"
89438933|NCT02139891|Experimental|"MultiPoint Pacing On"|Patients will be randomized to the MPP-ON Arm vs MPP-OFF in in crossover fashion with 3 months in each period.
89438934|NCT02139891|Active Comparator|"MultiPoint Pacing Off"|Patients will be randomized to the MPP-OFF arm vs MPP-ON in crossover fashion with 3 months in each period.
89438935|NCT02135523|Experimental|single arm: involved-field radiation therapy group|
89438936|NCT05535400|Experimental|The Physical-Psychological Integrative (PPI) intervention group|The PPI intervention will include eight weekly online group sessions (with each session lasts for 60-90 minutes). At the beginning of each online group meeting, the intervention provider will use motivational interviewing techniques to promote participants' adherence to the physical activity program, followed by on-line group psychological intervention
89438937|NCT05535400|Active Comparator|The brief online didactic education control group|Participants in the control group will receive a short video call (approximately 20 minutes each week for eight weeks) from the trained research assistant, i.e., RA 2 to provide general physical and psychological suggestions (e.g., encouragement of performing physical activities, and communication skills with family members/friends, and engagement in the community life). This is to control the contact effects of the PPI intervention.
89438938|NCT05577429|Placebo Comparator|Moderate intensity exercise under normoxia|The participants will perform low-moderate intensity cycling exercise at 90% lactate threshold (LT) (determined during LT test) under normoxia (FiO2: 20.9%) for 60 minutes on a cycle ergometer. Immediately after exercise oral glucose tolerance test (OGTT) will be determined with 24-hour glucose concentration will be monitored continuously. Circulatory factors will be determined pre, immediately after exercise and 24 hours after exercise.
89438939|NCT05577429|Experimental|Moderate intensity exercise under hypoxia|The participants will perform low-moderate intensity cycling exercise at 90% lactate threshold (LT) (determined during LT test) under hypoxia (FiO2: 16.5-14.8%) for 60 minutes on a cycle ergometer. Immediately after exercise oral glucose tolerance test (OGTT) will be determined with 24-hour glucose concentration will be monitored continuously. Circulatory factors will be determined pre, immediately after exercise and 24 hours after exercise.
89438940|NCT05542186|Experimental|Kinesiotaping|
89438941|NCT01565655|Experimental|ASP015K lowest dose|ASP015K lowest dose once daily
89438942|NCT01565655|Experimental|ASP015K low dose|ASP015K low dose once daily
89438943|NCT01565655|Experimental|ASP015K medium dose|ASP015K medium dose once daily
89438944|NCT01565655|Experimental|ASP015K high dose|ASP015K high dose once daily
89438945|NCT01565655|Placebo Comparator|Placebo|Matching placebo once daily
89438946|NCT05535322||GLP-1RA|All GLP-1RA users: all T2D adults treated with GLP-1RA or initiating a GLP-1RA during the study period
89438947|NCT05535322||SGLT2i|SGLT2 inhibitors users with no GLP-1RA prescription: all T2D adults treated with SGLT2i or initiating treatment with SGLT2i during the study period and who were not treated with a GLP-1RA
89438948|NCT05535322||Insulin|Insulin users with no GLP-1RA and/or SGLT2i prescriptions: all T2D adults treated with insulin or initiating insulin treatment during the study period and who were not treated with GLP-1RA/SGLT2i
89438949|NCT05535322||Miscellany|Other glucose-lowering agents users: all T2D adults who were not treated with GLP-1RA and/or SGLT2i and/or insulin during the study period.
89438950|NCT05592574||Spondyloarthritis without biological treatment and in failure of 2 NSAIDS|
89438951|NCT02135601|No Intervention|Air colonoscopy|Colonoscopy will be performed without medications and with judicious air insufflation during colonoscope insertion.
89438952|NCT02135601|Other|Water colonoscopy|Colonoscopy will be performed without medications and aided by water infusion in-lieu of air insufflation during insertion of the colonoscope.
89438953|NCT05577273|Experimental|Antibiotic prophylaxis|Single dose of p.o. antibiotic given 1 hour before catheter removal. The antibiotic of choice is Cefuroxime axetil 500 mg. For penicillin allergy, trimethoprim/sulfamethoxazole 160mg/800mg.
89438954|NCT05577273|No Intervention|No treatment|
89438955|NCT02252913|Experimental|Volitinib+docetaxel|"Dose escalation stage: oral administration, Volitinib 600mg/800 QD + docetaxel 75mg/m2.~If the dose of docetaxel 75mg/m2 is not tolerable, docetaxel dose will be reduced to 60mg/m2 while keep volitinib at 600mg QD as the initial dose. Volitinib dose escalation will be re-started and end at the dose of 800mg QD.~Dose expansion Stage:Volitinib with docetaxel. Use the prefer dose from escalation stage"
89438956|NCT03548259|Experimental|Experimental|Platelet-rich plasma
89438957|NCT03548259|Placebo Comparator|Platelet-poor plasma|Platelet-poor plasma
89438958|NCT05542108|Experimental|Multisensory Stimulation and Family Education Group (MSG)|"Parents of the MSG will be asked to carry out up to two treatment sessions per day with their child, until they reach the 8th post-term week. Sessions will initially be carried out together with a therapist who will have the task of transmitting the necessary skills to parents/caregivers.~In addition, all families will receive the evidence-based program of Family Education which is based on the promotion of the parent-child relationship through the recognition of behavioral states, methods of interaction, facilitation strategies in the relationship.~The family education group sessions involve about 6 meetings (1-2 a week) of 30-45 minutes that are carried out during the hospitalization in the NIC directly at the child's bed between the operator and one or both parents. Each meeting involves the discussion of one of the following topics."
88923471|NCT03301064|Experimental|Intervention Condition: MET/SBCM|The combined Motivational Enhancement Therapy and Strengths Based Case Management (MET/SBCM) intervention will be used in the proposed study. The intervention consists of three 1-hour sessions. The sessions are structured to provide feedback to participants about their risks associated with alcohol use and to help them identify barriers and motivators to change. The sessions will aim to reduce drinking by promoting self-efficacy to change, setting goals and fostering utilization of medical, mental health and social services as needed. A comprehensive list of referrals will be provided. Sessions will occur 1-2 weeks apart.
89012122|NCT00278421|Active Comparator|Interventional: 6 R-CHOP-21|Arm I: Patients receive R-CHOP immunochemotherapy comprising rituximab IV, cyclophosphamide IV over 15 minutes, doxorubicin hydrochloride IV, and vincristine IV on day 1 and oral prednisone once daily on days 1-5. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo restaging of their disease. Patients with disease progression proceed to salvage therapy off study. All other patients receive 3 more courses of R-CHOP.
89438959|NCT05542108|Active Comparator|Family Education Only Group (FEG)|"Parents of the FEG group infants will be asked to participate in an evidence based program for parents of NICU infants that includes 6-8 visits with a a trained healthcare provider operator.~This evidence-based program of early intervention based on the promotion of the parent-child relationship through the recognition of behavioral states, methods of interaction, facilitation strategies in the relationship.~The program takes its conceptual basis from the Mother Infant Transaction Program (MITP).~It involves about 6 meetings (1-2 a week) of 30-45 minutes that are carried out during the hospitalization in the NICU directly at the child's bed between the operator and one or both parents."
89438960|NCT05698576|Experimental|TPF-LITT ARM|partial gland ablation of the prostate using laser device and imaging fusion
89438961|NCT02135835|Experimental|Shenfu Zhusheye|80 ml Shenfu Zhusheye + 70 ml 5% glucose injection, ivdrip, once a day for 7 days.
89438962|NCT02135835|Placebo Comparator|5% glucose injection|150 ml 5% glucose injection, ivdrip, once a day for 7 days.
89438963|NCT02253459|Experimental|UTD1 Injection plus capecitabine|"UTD1 Injection: 30 mg/m2/day, IV on day 1-day 5 of each 21 day cycle; Capecitabine: 2000 mg/m2/day, oral bid on day 1-day 14 of each 21 day cycle.~Number of Cycles: until progression or unacceptable toxicity develops."
89438964|NCT02253459|Active Comparator|capecitabine|"Capecitabine: 2500 mg/m2/day, oral bid on day 1-day 14 of each 21 day cycle.~Number of Cycles: until progression or unacceptable toxicity develops."
89438965|NCT02140047|Experimental|MT-2301-Low|
89438966|NCT02140047|Experimental|MT-2301-High|
89438967|NCT02140047|Active Comparator|ActHib|
89438968|NCT02135913|Experimental|Viatamin D|All children enrolled into the study will be prescribed standard of care vitamin D.
88923472|NCT03301064|Active Comparator|Control Condition: Alcohol education brochure|Participants randomized to the control condition will be receive a Spanish-language version of an alcohol education brochure. Participants will be encouraged to read the brochure. The brochure will provide information about defining heavy drinking, harmful effects of drinking and symptoms of an alcohol use disorder. Control group participants will also receive a list of available clinics and resources from Providence staff. After the baseline visit participants in the control group will be contacted by phone twice over the next 4 weeks by the promotores to remind them about the 3-month follow-up appointment.
88923473|NCT03300505|Experimental|ARRx + Enzalutamide|"Phase 1b: All registered subjects will be treated with ARRx (ASO) in combination with enzalutamide. ARRx will be given intravenously on Days 1, 4, 8, 11, 15 on cycle 1, then on days 1, 8, 15 in subsequent 21-day cycles. Enzalutamide will be taken daily in 21 day cycles starting Day 1 of cycle 1. Treatment will continue until clinical or radiologic progression or unacceptable toxicity.~Phase 2: Subjects will be treated with ARRx (ASO) at the maximum tolerated (MTD), in combination with enzalutamide until clinical or radiologic progression or unacceptable toxicity. (Schedule of administration as in phase 1b.)"
88923474|NCT03295240|Experimental|BR-I in combination with VEN|The BR-I (bendamustine, rituximab, ibrutinib) regimen will be administered in combination with VEN (Venetoclax).
88923475|NCT03280225||VAMC's receiving implementation support for REACH VET|This cohort consists of 28 VA Medical Centers (VAMC's) needing additional implementation support to fully implement REACH VET as identified by Veteran Integrated Service Network (VISN) leadership, and that agreed to participate.
88923476|NCT03264235|Experimental|Group 1 Exoskeleton|Both training groups will undergo inpatient physical therapy of the same duration and intensity. Group 1 will complete stair training wearing the Keeogo Exoskeleton in inpatient physical therapy.
88923477|NCT03264235|Active Comparator|Group 2 Traditional Therapy|Group 2 will complete traditional stair training in inpatient physical therapy.
88923478|NCT03223883|Experimental|Curcumin|Patients will receive curcumin (Lonvida) 2000 mg PO once a day
88923479|NCT03223883|Placebo Comparator|Placebo|Patients will receive placebo pill identical in appearance and taste to the supplement
88923480|NCT03188510|Experimental|Reference: 250 mg LY3074828|250 mg LY3074828 lyophilized formulation administered subcutaneously (SC) as 3 injections
88923481|NCT03188510|Experimental|Test 1: 250 mg LY3074828|250 mg LY3074828 solution formulation administered as SC injections in two prefilled syringes
88923482|NCT03188510|Experimental|Test 2: 500 mg LY3074828|500 mg LY3074828 solution formulation administered as SC injections in four prefilled syringes
88923483|NCT03129880|Placebo Comparator|Weekly Voice Therapy|Participants are randomized to receiving weekly voice therapy sessions
88923484|NCT03129880|Active Comparator|Intensive Voice Therapy|Participants are randomized to receiving multiple sessions of voice therapy in one day
88923485|NCT03120780|Active Comparator|Low Dose Fentanyl|Low dose epidural fentanyl combined with local anesthetic as 10mL of 0.125% bupivacaine with 20 mcg fentanyl (Fentanyl 20 mcg)
88923486|NCT03120780|Experimental|High Dose Fentanyl|High dose epidural fentanyl combined with local anesthetic as 10mL of 0.125% bupivacaine with 100 mcg fentanyl (Fentanyl 100 mcg)
88923487|NCT03118505|Experimental|Group 1|Infuse Bone Graft [4.2 mg per operative level] + Mastergraft Strip + local bone autograft + posterior fixation
88923488|NCT03118505|Experimental|Group 2|Infuse Bone Graft [6 mg per operative level] + Mastergraft Strip + local bone autograft + posterior fixation
88923489|NCT03118505|Experimental|Group 3|Infuse Bone Graft [12 mg per operative level] + Mastergraft Strip + local bone autograft + posterior fixation
88923490|NCT03118505|Active Comparator|Control|Medtronic DBM + local bone autograft (and supplemented with iliac crest bone graft (ICBG), if needed) + posterior fixation.
88923491|NCT03102125|Experimental|Nonspecific allograft dysfunction|Patients with nonspecific allograft dysfunction will undergo stress cardiac MRI with regadenoson in addition to performing late gadolinium enhancement and obtaining mean segmental T1 values of the heart. Peripheral blood and endomycardial biopsies will also be obtained for single cell RNAseq analyses.
88923492|NCT03102125|Experimental|Normal graft function|Patients with normal graft function will undergo stress cardiac MRI with regadenoson in addition to performing late gadolinium enhancement and obtaining mean segmental T1 values of the heart. Peripheral blood and endomycardial biopsies will also be obtained for single cell RNAseq analyses.
88923493|NCT03102125|Experimental|Cardiac allograft vasculopathy|Patients with allograft dysfunction from known cardiac allograft dysfunction will undergo stress cardiac MRI with regadenoson in addition to performing late gadolinium enhancement and obtaining mean segmental T1 values of the heart. Peripheral blood and endomycardial biopsies will also be obtained for single cell RNAseq analyses.
89438969|NCT02140125|Experimental|ASP2408 low dose group|
89438970|NCT02140125|Experimental|ASP2408 middle dose group|
89438971|NCT02140125|Experimental|ASP2408 high dose group|
89438972|NCT02140125|Placebo Comparator|Placebo group|
89438973|NCT02140203|Active Comparator|Young Yoga Group|People who are younger than 60 year-old They have received Yoga training in one-year experimental period
89438974|NCT02140203|No Intervention|Young Control Group|People who are younger than 60 year-old No Yoga training through out the one-year experimental period
89438975|NCT02140203|No Intervention|Aged Control Group|People who are equal or older than 60 year-old They have not received any yoga training during the one-year experimental period
89438976|NCT02140203|Active Comparator|Aged Yoga Group|People who are equal or older than 60 year-old They have received any yoga training during the one-year experimental period
89438977|NCT05576961|Experimental|regular dose of RX-af01|RX-af01 in combination with toripalimab
89438978|NCT05576961|Experimental|high dose of RX-af01|5 times dose of RX-af01 in combination with toripalimab
89438979|NCT05576961|Experimental|Mixed bacteria|Mixed bacteria in combination with toripalimab
89023505|NCT05295940|Placebo Comparator|Placebo (Part A)|Placebo administered SC.
88923494|NCT03102125|Experimental|ACR/AMR|Patients with allograft dysfunction from prior episodes of acute cellular or antibody mediated rejection will undergo stress cardiac MRI with regadenoson in addition to performing late gadolinium enhancement and obtaining mean segmental T1 values of the heart. Peripheral blood and endomycardial biopsies will also be obtained for single cell RNAseq analyses.
88923495|NCT03100149|Experimental|Part 1: RO7046015 High Dose|Participants will receive RO7046015 at high dose level as intravenous infusion every 4 weeks (Q4W) up to 52 weeks in Part 1.
88923496|NCT03100149|Experimental|Part 1: RO7046015 Low Dose|Participants will receive RO7046015 at low dose level as intravenous infusion Q4W up to 52 weeks in Part 1.
88923497|NCT03100149|Placebo Comparator|Part 1: Placebo|Participants will receive placebo as intravenous infusion Q4W up to 52 weeks in Part 1.
88923498|NCT03100149|Experimental|Part 2: RO7046015 High Dose|Part 1 RO7046015 high dose group participants and placebo group participants randomized to high dose level will receive RO7046015 at high dose level as intravenous infusion Q4W for additional 52 weeks in Part 2.
88923499|NCT03100149|Experimental|Part 2: RO7046015 Low Dose|Part 1 RO7046015 low dose group participants and placebo group participants randomized to low dose level will receive RO7046015 at low dose level as intravenous infusion Q4W for additional 52 weeks in Part 2.
88923500|NCT03100149|Experimental|Part 3: RO7046015 Low Dose|Part 2 RO7046015 low dose group participants and high dose group participants will receive RO7046015 at low dose level as intravenous infusion Q4W for additional 5 years in Part 3.
88923501|NCT03077841|Experimental|Arm I (hypofractionated partial breast irradiation)|Patients undergo hypofractionated partial breast irradiation daily for 5 days. Patients may then receive 3 additional boost fractions at the discretion of the doctor.
88923502|NCT03077841|Active Comparator|Arm II (hypofractionated partial breast irradiation)|Patients undergo standard breast irradiation daily for 15 days. Patients may then receive 5 additional boost fractions at the discretion of the doctor.
88923503|NCT03075527|Experimental|Tremelimumab + Durvalumab|Subjects will receive durvalumab and tremelimumab both via intravenous infusion once per day for every 28 day cycles (+ 7 days). Participants will receive tremelimumab for up to 4 cycles (4 doses). Beginning with cycle 5 day 1, subjects will continue to receive durvalumab alone, until clinical or radiological progression.
88923504|NCT03068624|Experimental|Treatment (cyclophosphamide, T-cells, aldesleukin, ipilimumab)|"PREPARATIVE REGIMEN: Patients receive cyclophosphamide IV over 30-60 minutes on day -2.~T-CELL INFUSION: Patients receive autologous CD8+ SLC45A2-specific T lymphocytes via hepatic arterial infusion via central catheter over 60 minutes on day 0. Within 6 hours of T-cell infusion, patients also receive aldesleukin BID SC for 14 days in the absence of disease progression or unacceptable toxicity.~POST T-CELL INFUSION: Patients receive ipilimumab IV over 90 minutes on days 1, 22, 43, and 64 in the absence of disease progression or unacceptable toxicity."
88923505|NCT02931253|Experimental|Metformin Group|"Metformin 500 mg daily initiated 6 weeks prior to scheduled ablation.~Metformin increased to 2000 mg daily (1000 mg twice a day) as tolerated over the initial 3 weeks."
88923506|NCT02931253|No Intervention|Control Group|Standard of care - ablation only
88923507|NCT02819882||Luminal A-like subtype|Patients that express Estrogen receptor (ER), express Progesterone Receptor (PgR)+ (≥ 20%), don't express HER2 and have Ki-67 'low' (< 14%).
88923508|NCT02819882||Luminal B-like (HER2 negative) subtype:|Patients that express ER and are either PgR- or low (< 20%) and/or Ki67 'high' (≥ 14%).
88923509|NCT02819882||Luminal B-like (HER2 positive) subtype:|Patients that express ER and HER2 irrespective of PgR or Ki67 status.
88923510|NCT02819882||HER2-enriched subtype|Patients that express HER2 and don't express ER or PgR.
88923511|NCT02819882||Triple Negative (TN) subtype|Patients who are negative for the expression of ER, PgR and HER2.
88923512|NCT02812524|Experimental|Intratumoral Ipilimumab|Patients receive a 3mg intratumoral injection of ipilimumab during a biopsy procedure.
88923513|NCT02784496|Experimental|Treatment (ruxolitinib, follow-up)|Patients continue to receive ruxolitinib PO QD or BID. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo follow-up assessment for safety over 10 minutes every 3 cycles.
88923514|NCT02734004|Experimental|Arm 1|Includes initial stage cohorts (modules 1 to 4): Olaparib twice daily starting on week 1 day 1 and MEDI4736 every 4 weeks starting on week 5 day 1
88923515|NCT02734004|Experimental|Arm 2|Includes 2nd stage cohorts (modules 5 & 7): Olaparib twice daily starting on week 1 day 1 and MEDI4736 every 4 weeks starting on week 1 day 1
88923516|NCT02734004|Experimental|Arm 3|Includes 2nd stage cohort (module 6): Olaparib twice daily starting on week 1 day 1 / MEDI4736 every 4 weeks starting on week 1 day 1 / Bevacizumab every 2 weeks starting on week 1 day 1
88923517|NCT02688712|Experimental|LY2157299 + Chemoradiation + Surgery|Patients will receive a 14 day course of LY2157299. On day 15 patients will begin chemoradiation treatment with Capecitabine or Fluorouracil. On day 29, patients will undergo another fourteen day course of LY2157299 concurrent with their ongoing chemoradiation treatment. Six to ten weeks after completing their neoadjuvant therapy, patient will undergo a tumor specific mesorectal excision as per standard of care.
89023506|NCT05295940|Placebo Comparator|Placebo (Part B)|Placebo administered SC.
89438980|NCT05592496|Active Comparator|Block group|Patients after laparotomic gastrectomy and musculus rectus sheath block and continuous analgesia with 0,125% bupivacaine solution for 72h
89438981|NCT05592496|Placebo Comparator|Control group|"Patients after laparotomic gastrectomy, musculus rectus sheath block and induction of 0,9% NaCl Solution by using easy pump system for 72 h"
89438982|NCT05576727||Unruptured Intracranial Aneurysm|
88923518|NCT02687360|Active Comparator|Active rTMS stimulation|This arm will receive high-frequency rTMS pulses directed at the medial prefrontal and anterior cingulate cortices.
88923519|NCT02687360|Sham Comparator|Sham rTMS stimulation|The sham coil setting is designed to mimic the auditory artifact and the scalp sensations evoked by the real coil and to produce activation of facial muscles similar to the effect of active rTMS without stimulating the brain itself.
88923520|NCT02677922|Experimental|AG-120 + Azacitidine|
88923521|NCT02677922|Experimental|AG-221 + Azacitidine|
88923522|NCT02677922|Experimental|Azacitidine|
88923523|NCT02641847|Experimental|High risk group A|TA(E)C x 4 cycles to GP x 4 cycles (docetaxel + doxorubicin (epirubicin) + cyclophosphamide to gemcitabine + cisplatin), docetaxel: 75 mg/m2 IV on day 1; doxorubicin: 50 mg/m2 IV on day 1 or epirubicin 75 mg/m2 IV on day 1; cyclophosphamide: 500 mg/m2 IV on day 1; gemcitabine: 1250 mg/m2 IV on day 1 and 8; cisplatin: 75 mg/m2 IV on day 1, dosing interval is 21 days.
88923524|NCT02641847|Active Comparator|High risk group B|A(E)C x 4 cycles to T x 4 cycles (doxorubicin (epirubicin) + cyclophosphamide to docetaxel), doxorubicin: 60 mg/m2 IV on day 1 or epirubicin 90 mg/m2 IV on day 1; cyclophosphamide: 600 mg/m2 IV on day 1; docetaxel: 100 mg/m2 IV on day 1, dosing interval is 21 days.
88923525|NCT02641847|Other|Low risk group C|A(E)C x 4 cycles to T x 4 cycles (doxorubicin (epirubicin) + cyclophosphamide to docetaxel), doxorubicin: 60 mg/m2 IV on day 1 or epirubicin 90 mg/m2 IV on day 1; cyclophosphamide: 600 mg/m2 IV on day 1; docetaxel: 100 mg/m2 IV on day 1, dosing interval is 21 days.
88923526|NCT02567799|Experimental|Single-arm|Ascending dose evaluation of BIO 300 Oral Suspension (3 dose levels) given in combination with paclitaxel/carboplatin and radiotherapy.
88923527|NCT02552953|Experimental|CYC065 - 4 hour infusion (Part 1 completed)|CYC065 will be administered by 4 -hour infusion every 3 weeks.
88923528|NCT02552953|Experimental|CYC065 - 1 hour infusion (Part 2 - ongoing)|CYC065 will be administered by 1 - hour infusion on Days 1, 2, 8, and 9 every 3 weeks
88923529|NCT02552953|Experimental|CYC065 - Oral (Part 3 - ongoing)|CYC065 will be administered orally on Days 1, 2, 8 and 9 every 3 weeks
88923530|NCT02532452|Experimental|Viral Specific VST Infusion|3rd party VST infusion
89438983|NCT05697796||patients had pelvic organ prolapse who undergone Sacrospinal ligament fixation|
89438984|NCT05697796||patients had pelvic organ prolapse who undergone Extraperitoneal high sacral ligament suspension|
89438985|NCT03548181|Experimental|"Intervention group tele-rehabilitation"|"Each patient will have the opportunity to have minimum one Video Consultation (VC) per week the first month, one VC each second week the second month one VC a month the rest of the trial.~Workout Sessions with a Virtual Physiotherapist Agent (VPA): The patient will train according to what is decided by the physiotherapist and the patient in the VC or chat meetings. Normally, the patients will train 10-20 minutes daily at home with its individual and tailored VPA. Instead of ergometer bike training, the patient will receive some easy training tools such as elastics, weights and a fitness-step that can be used in the different exercises showed by the VPA to reach the same intensity of workout. The VPA will then be animated to motivate and encourage the patient to exercises at home. A digital diary will automatically register the data obtained by the system on patient's performance."
89438986|NCT03548181|Active Comparator|Control|Patients will be followed, but they do not get any other kind of treatment comparable to the intervention group treatment.
89438987|NCT05545696|Sham Comparator|AI on scanning|The lower jaw of the participants was scanned with ''AI on'' scanning in line with recommended scanning protocol, and the IOS software automatically recorded the obtained data.
89438988|NCT05545696|Active Comparator|AI off scanning|The lower jaw of the participants was scanned with ''AI off'' scanning in line with recommended scanning protocol, and the IOS software automatically recorded the obtained data.
89438989|NCT05492643|Experimental|Group A：2 doses of inactivated SARS-CoV-2 vaccine|Group A: will enrol 500 participants who have received 2 doses of inactivated SARS-CoV-2 vaccine according to national immunization planning, whose last dose was given at least 6 months ago. They will be given one dose of the study vaccine (SYS6006) after enrolment.
89438990|NCT05492643|Experimental|Group B：3 doses of inactivated SARS-CoV-2 vaccine|Group B: will enrol 500 participants who have received 3 doses of inactivated SARS-CoV-2 vaccine according to national immunization planning, whose last dose was given at least 6 months ago. They will be given one dose of the study vaccine (SYS6006) after enrolment.
89438991|NCT02739594|Experimental|Ibandronate|Participants with multiple myeloma will be randomized to receive ibandronate every 4 weeks for a planned duration of 92 weeks.
89438992|NCT02739594|Active Comparator|Zoledronate|Participants with multiple myeloma will be randomized to receive zoledronate every 4 weeks for a planned duration of 92 weeks.
89438993|NCT05545618||CCTA imaging with 18F-FDG-PET/CT assessment|Group of patients with 18F-FDG-PET/CT imaging and Coronary Computed Tomographic Angiography within 90 days
89502032|NCT02235025|Other|Healthy controls|Healthy controls have normal baseline spirometry (FEV1 > 80% predicted, FEV1/FVC > 0.7). They don't have any health problems, including cardiovascular, metabolic, neuromuscular, musculoskeletal, or respiratory diseases that could contribute to breathlessness or exercise limitation. They have a mMRC score equal to zero and do not complain any respiratory symptoms including chronic cough and/or chronic expectoration and/or chronic wheeze and/or chronic respiratory related medication.
89438994|NCT05541562||PVT group|The diagnosis of LC was based on clinical, laboratory, and radiological analyses, and/or liver biopsies. PVT was diagnosed according to the consensus for management of PVT in LC (2020, Shanghai) [1]. The inclusion criteria were as follows: (I) age ≥18 years, (II) Doppler ultrasound was the first-choice imaging modality; however, enhanced computed tomography or magnetic resonance imaging could also be used for confirmation at the time of admission to our hospital, and (III) patients with PVT on imaging examination but with insufficient evidence for the diagnosis of cirrhosis, hepatic vein pressure gradient measurement, and liver biopsy. Patients with primary or secondary hepatic malignant tumors, other malignant tumors, hematologic diseases, Budd-Chiari syndrome, non-cirrhotic PVT, inflammatory diseases, and other severe diseases were excluded.
89438995|NCT05541562||Non-PVT group|(1) Patients with cirrhosis diagnosed in accordance with the 2019 Guidelines for the Diagnosis and Treatment of Cirrhosis;(2)Color ultrasound, CT, MRI, and other imaging studies confirmed the absence of portal vein thrombosis and the specific location of the thrombosis.
89438996|NCT03548025|Experimental|Treatment Group|Treated group of subjects, serves as its own control
89438997|NCT02140281|Experimental|Sequence 1 (Treatment A/B)|Subjects will be randomised to receive Treatment A in Period 1 followed by Treatment B in period 2
89438998|NCT02140281|Experimental|Sequence 2 (Treatment B/A)|Subjects will be randomised to receive Treatment B in Period 1 followed by Treatment A in period 2
89438999|NCT05592106||PHLF group and non-PHLF group|group with and without PHLF
89439000|NCT02385162||Observation|Patients with a diagnosis of Glycogen storage diseases based upon biochemical and/or genetic criteria or profound suspicion for Glycogen storage disease
89439001|NCT05489133|Experimental|Modified prolonged exposure (add on)|The psychological intervention modified Prolonged Exposure Therapy (mPE) is applied, in addition to Treatment as usual (TAU) (that is, an Add-on). mPE is a trauma-focused evidence-based cognitive behavioral therapy (CBT) shown to be effective in treating PTSD. We will use imaginal exposure in the sessions with the patient describing the traumatic event in detail while being recorded for later listening and homework, and in vivo exposure for visiting specific places or people. Psychoeducation and controlled breathing exercises play a secondary role in PE. We have adapted the mPE to the current SAC settings in Norway where nurses or social workers, not psychologist, as a rule are performing the psychosocial follow-up for rape victims. In this project we plan for three to five once or twice weekly nurse-/social worker-led mPE interventions, given early after the assault.
89439002|NCT05489133|No Intervention|Treatment as usual (TAU)|Standard care at the sexual assault center (SAC), that is mostly nurse-/social worker-led psychoeducation at varying intervals and extent, and medical follow-up at the SAC.
89439003|NCT05541328||Tisagenlecleucel therapy|The trial cohort is defined as the cohort of patients enrolled in JULIET who were assigned to receive tisagenlecleucel infusion
89439004|NCT05541328||Standard of care|The real-world cohort is defined as the cohort of patients derived from the FHRD receiving SOC as the third line of therapy or later
89439005|NCT05545462|Experimental|COMPARISON OF DOXYCYCLINE AND COMMON SALT FOR TREATMENT OF UMBILICAL GRANULOMA IN CHILDREN|to study the comparison of doxycycline and common salt for the treatment of umbilical granuloma to check which is more effective safe timesaving and can be performed by even parents it showed that common salt is more effective than doxycycline
89439006|NCT05545462|Experimental|COMPARISON BETWEEN COMMON SALT AND SOXYCYLIN FOR TREATMENT OF UMBILICAL GRANULOMA|to study the comparison of doxycycline and common salt for the treatment of umbilical granuloma to check which is more effective safe timesaving and can be performed by even parents it showed that common salt is more effective than doxycycline
89439007|NCT05699356||Surgical treatment of Poly cystic ovary for infertility by laparoscopic drilling|laparoscopic drilling response in Poly Cystic Ovary case
88923531|NCT02306954|Active Comparator|High Dose IL-2|"Patients will receive IL-2 at 600,000 international units per kg IVB every 8 hours for 14 planned doses with an additional cycle 14 days after the first. Responding patients with regressing disease are eligible for up to 6 IL-2 cycles.~Patients assigned to the IL-2 arm who have disease progression after the first two IL-2 cycles have the option to receive SBRT followed by 2 additional cycles of IL-2."
88923532|NCT02306954|Experimental|High Dose IL-2 and SBRT|Patients assigned to SBRT arm will receive two doses of SBRT at 20 Gy on the Wednesday and Friday before IL-2 starts (the following Monday). Patients will receive IL-2 at 600,000 international units per kg IVB every 8 hours for14 planned doses with an additional cycle 14 days after the first. Responding patients with regressing disease are eligible for up to 6 IL-2 cycles.
88923533|NCT02088060|Experimental|Cannabidiol|Cannabidiol capsules 2x200 mg twice a day and placebo olanzapine capsule once a day over 4 weeks
88923534|NCT02088060|Active Comparator|Olanzapine|Olanzapine capsule 15mg once a day and placebo cannabidiol capsules twice a day over 4 weeks
88923535|NCT02088060|Placebo Comparator|Placebo|Placebo cannabidiol capsules twice a day and placebo olanzapine capsule once a day over 4 weeks
88923536|NCT02078427||rAHF-PFM|Participants treated with rAHF-PFM alone
89439008|NCT05699356||Non-surgical treatment of Poly cystic ovary for infertility|induction,Anti estrogen,Insulin sensitizing agent, Aromatase Inhibitor,Gonadotropin
89439009|NCT05699356||Treatment of Poly cystic ovary for infertility by Life style modification|Life style modification response in Poly Cystic Ovary case for treatment of infertility
89502033|NCT02235103||Clinical Pregnancy|Patients who are clinically pregnant after first treatment cycle with intra-uterine insemination.
88923537|NCT02078427||rAHF-PEG|Participants treated with rAHF-PEG alone
88923538|NCT02078427||rAHF-PFM then rAHF-PEG|Participants treated with rAHF-PFM and subsequently switched to rAHF-PEG
88923539|NCT02073968|Experimental|Treatment (PET-adjusted IMRT, carboplatin, paclitaxel)|"RADIOTHERAPY: Patients undergo PET-adjusted IMRT or proton beam radiation therapy five days a week for 5 weeks.~CONCURRENT CHEMOTHERAPY: Patients receive carboplatin IV over 3 hours and paclitaxel IV over 1 hour once weekly for 6 weeks beginning week 1 of thoracic radiotherapy.~CONSOLIDATION CHEMOTHERAPY: Beginning approximately 4-6 weeks after the completion of all radiation therapy and when esophagitis and chemotherapy-induced neuropathy are grade 1 or less, ANC > 1500, and platelet count > 100,000, patients may receive carboplatin IV over 30 minutes and paclitaxel IV over 3 hours on day 1. Treatment may repeat every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity at the discretion of the treating physicians."
88923540|NCT01696994|No Intervention|Control|Participants receive standard medical care. Participants complete a DHQ at baseline.
89199370|NCT05713422||Operative procedure; standard treatment including level III repair|Vaginal level I and/or level II repair will be performed as usual, but now including perineoplasty (level III repair) as decided by surgeon and patient. The decision of a perineoplasty to vaginal level I and/or level II repair is based on a shared decision made by surgeon together with the patient. The considerations upon which this decision has been established in a consensus meeting of Dutch urogynecologists and will be collected by a questionnaire, This group is considered as the 'intervention' group.
89199371|NCT05711953|Experimental|Egyfil Pain Lotion|Interventional study on Egyil 50mL will be topically administered ad libitum for three days.
89199372|NCT05709964||Study group|All patients included in this study. Investigators will record both self-reported and measured height, weight, and neck circumference in all of these patients.
89439010|NCT05699356||Treatment of Poly cystic ovary for infertility by Assisted reproductive technique|Assisted reproductive technique response in Poly Cystic Ovary case for treatment of infertility
89439011|NCT05699356||Treatment of Poly cystic ovary for infertility by controlling menstrual disorders|Controlling menstrual disorders response in Poly Cystic Ovary case for treatment of infertility
89439012|NCT05699356||Treatment of Poly cystic ovary for infertility by Cutaneous manifestation|Cutaneous manifestation response in Poly Cystic Ovary case for treatment of infertility
88923541|NCT01696994|Active Comparator|Ovarian Screening|Participants undergo blood sample collection for CA125 analysis at baseline annually for 5 years. Serum that is not used in the study will be stored in an NCI biorepository. Participants also undergo an OVR (discontinued in December 1998) and TVU at baseline and annually for 3 years. Participants complete a DQX at baseline and DHQ at year 3. An ADU (previously referred to as the PSH questionnaire) is mailed to each participant annually for 13 years to identify all prevalent and incident cancers of the ovaries as all deaths that occur among both screened and control subjects during the trial.
88923542|NCT01696981|Active Comparator|Colorectal Screening|Participants undergo a colorectal examination with a flexible sigmoidoscope at baseline and year 5. Participants complete a DQX at baseline and DHQ at year 3. An ADU (previously referred to as the PSH questionnaire) is mailed to each participant annually for 13 years to identify all prevalent and incident colorectal cancers as all deaths that occur among both screened and control subjects during the trial.
89199373|NCT05709769||Training Group|A primary cohort of eligible patients from the cancer center of Zhejiang Provincial People's Hospital is used for developing the radiomics-based nomogram prediction model. In the training cohort, a sample size of 88 was required to accept the hypothesis that the prediction accuracy of the radiomics-based nomogram model was greater than 45% with 90% power and to reject the hypothesis that the prediction accuracy rate was less than 30% with an α error of 5%. Initially, we planned to enroll 77 patients in the first stage. If 27 or more prediction accuracy rates were observed, we planned to continue to the second stage for a total of 88 patients for the analysis. Considering some deviant cases, the preplanned accrual number was set to 100 patients in the training cohort.
89199374|NCT05709769||Validation Group|An independent cohort of eligible patients is used for external validation. we are planning to enroll an additional 50 patients to further validate this radiomics-based nomogram prediction model.
89199375|NCT05703542|Experimental|Dose Escalation BXCL701|"Dose escalation will occur using a 3+3 dose escalation approach, evaluating 4 different dose levels of BXCL701.~During each 28 day study cycle participants will take BXCL701 2x daily for up to 12 cycles."
89199376|NCT05701293||LEAD patients undergoing endovascular treatment with implantation of Renzan stent|
89199377|NCT05688397|Experimental|Experimental 1|L. gasseri oral capsule
89199378|NCT05688397|Experimental|Experimental 2|L. gasseri + L. crispatus oral capsule
89199379|NCT05688397|Placebo Comparator|Placebo|Maltodextrin (E1400, qs) oral capsule once a day
89199380|NCT05683327|Active Comparator|Hyaluronic Acid 150 mg|Take 150 mg/day of hyaluronic acid.
89199381|NCT05683327|Active Comparator|Hyaluronic Acid 80 mg|Take 80 mg/day of hyaluronic acid.
89199382|NCT05683327|Placebo Comparator|Placebo|Take 0 mg/day of hyaluronic acid.
89199383|NCT05679921|Experimental|PP1|pembrolizumab in combination with pazopanib
89199384|NCT05679921|Experimental|PP2|pembrolizumab for patients progressing on pazopanib.
89199385|NCT05673317|Experimental|Experiment Arm|The participant will receive usual breastfeeding care such as counseling by her physician, access to lactation consults, nursing assistance in the hospital, access to our online resources. The participant will also receive the breastfeeding application at admission to labor and delivery or in the immediate postpartum period. The participant will be taught how to use the application, and will have access to the study to continue use throughout the duration of follow-up.
89439013|NCT05478447|Experimental|Vibration group|Vibration (WBV, and tendon vibration) and sympathetic activation maneuvers will be applied to participants
89439014|NCT05591872|Active Comparator|LD+I+TRB|"Patient will get heparin dose according to their weight i.e. (<60 Kg-2000 IU; 60-80 Kg-2500 IU; >80 Kg-3000 IU)~And access site will be secured with InnoSEAL patch plus TRB"
89502034|NCT02235103||No Clinical Pregnancy|Patients who are not clinically pregnant after first treatment cycle with intra-uterine insemination.
88923543|NCT01696981|No Intervention|Control|Participants receive standard medical care. Participants complete a DHQ at baseline.
88923544|NCT01696968|No Intervention|Control|Participants receive standard medical care. Participants complete a DHQ at baseline.
89439015|NCT05591872|Active Comparator|LD+TRB|"Patient will get heparin dose according to their weight i.e. (<60 Kg-2000 IU; 60-80 Kg-2500 IU; >80 Kg-3000 IU)~And access site will be secured with TRB alone"
89439016|NCT05591872|Active Comparator|SD+I+TRB|"Patient will get standard heparin dose of 5000 IU.~And access site will be secured with InnoSEAL patch plus TRB"
89439017|NCT05591872|No Intervention|SD+TRB|"This is the control arm. Patient will get standard heparin dose of 5000 IU.~And access site will be secured with TRB."
89439018|NCT02140359|No Intervention|Control Group: Usual Care|Residents of a housing first permanent supporting housing program will be randomly assigned to this arm after screening and baseline assessments. They will meet with case managers according to the usual procedures for new residents and will be given a standard case manager interaction.
89439019|NCT02140359|Experimental|Motivational Network Interview Recipients|Residents of a housing first permanent supporting housing program will be randomly assigned to this arm after screening and baseline assessments. They will meet roughly every two weeks with a case manager and answer questions about their social network, will be shown visual feedback about their networks, and will participate in a motivational interview conducted by the case managers. The questions and visualizations will be facilitated by an electronic tool for presenting screens with questions, capturing responses, processing and visualizing social network data.
89439020|NCT03989232|Experimental|Semaglutide 2.0 mg|All participants will receive one injection per week during a 12-week dose escalation period, until the target dose for semaglutide 2.0 mg is reached. From week 13 to week 40, semaglutide will be given in two weekly injections of 1.0 mg each.
88923545|NCT01696968|Active Comparator|Lung Screening|"Participants undergo a chest x-ray (one postero-anterior view) at baseline and annually for 2 years. Participants classified as smokers undergo an additional chest x-ray at year 3. Participants complete a BQF/M at baseline. Participants complete a DQX at baseline and DHQ at year 3. An ADU (previously referred to as the PSH questionnaire) is mailed to each participant annually for 13 years to identify all prevalent and incident lung cancers as all deaths that occur among both screened and control subjects during the trial."
88923546|NCT01180361||Active SLE patients|Age 18-65; female and male. No methotrexate or statin therapy in prior 3 months. Not on biological therapies. Fulfill 1982 ACR revised criteria for SLE. SLE activity status designated using the SLEDAI disease activity index. Patients excluded if previous documentation of a connective tissue disorder other than SLE.
88923547|NCT01180361||Psoriatic arthritis|Age 18-65; female and male. No methotrexate or statin therapy in prior 3 months. Not on biological therapies. Diagnosed according to criteria described by McGonagle et al (McGonagle, D., Conaghan, P.G., and Emery, P. Psoriatic arthritis: a unified concept twenty years on. Arthritis Rheum 1999; 42: 1080-1086.)
88923548|NCT01180361||Normal controls|Age 18-65; female and male. No methotrexate or statin therapy in prior 3 months. Not on biological therapies. Healthy volunteers. Not on corticosteroids.
88923549|NCT01180361||Active RA patients|Age 18-65, male and female, no methotrexate or statin therapy in prior 3 months. Not on biological therapies. satisfy at least 4 of the 7 revised criteria (1987) for the classification of RA
88923550|NCT01155050|Active Comparator|Tele-health Home Monitoring|Participants will use the tele-health monitoring equipment to measure daily weight.
88923551|NCT01155050|No Intervention|Self-Directed Group|Participants will receive information on physical activity recommendations and guidelines on nutrition aimed at promoting weight loss.
88923552|NCT01155050|Active Comparator|TrestleTree Telephone Coaching|Participants will speak to Trestletree health coaches for 15 to 60 minutes each session. During these sessions, the coaches will identify the participant's stage of change and intervene accordingly. The telephone calls will be centered on weight loss.
88923553|NCT01155050|Active Comparator|Home monitoring + telephone coach|System to track stage of change in weight loss.
88923554|NCT01148563|No Intervention|Standard Care|The Standard Care group will continue regular LSU HCSD disease management care for heart failure patients with no additional intervention.
88923555|NCT01148563|Active Comparator|Tele-health Monitoring Group|The tele-monitoring intervention group will have the continual standard care from their physician plus the tele-health monitoring. The tele-health monitor will collect the following data: weight, blood pressure, pulse oximetry, pulse rate, & patient responses to disease-specific questions regarding changes in state of health for 6 months.
88923556|NCT01050504||Ancillary-correlative (blood and tissue collection)|Patients undergo collection of blood and tissue samples for analysis via mutation mapping, DNA sequencing, gene expression microarray, and gene profiling.
88923557|NCT00906997|Active Comparator|Fecal occult blood testing|
88923558|NCT00906997|Active Comparator|Colonoscopy|
88923559|NCT00587886||Cases|Cases will be women with newly diagnosed endometrial or ovarian cancer who are residents of six counties in New Jersey.
88923560|NCT00587886||Controls|Controls will be selected from the general population in those counties by use of random digit dialing for those under 65 years of age, from Centers for Medicare and Medicaid Services (CMS) lists for those aged 65 years and over, and from neighborhood sampling.
88923561|NCT00002540|No Intervention|Control|Participants receive standard medical care. Participants complete a DHQ at baseline.
88923562|NCT00002540|Active Comparator|Prostate Screening|Participants undergo blood sample collection for PSA analysis at baseline and annually for 5 years. Serum that is not used in the study will be stored in an NCI biorepository. Participants also undergo a DRE at baseline and annually for 3 years. Participants complete a DQX at baseline and DHQ at year 3. An ADU (previously referred to as the PSH questionnaire) is mailed to each participant annually for 13 years to identify all prevalent and incident prostate cancers as all deaths that occur among both screened and control subjects during the trial.
88923563|NCT01682486|Experimental|BIP ETT, Bactigaurd coated endotracheal tube|
88923564|NCT01682486|Placebo Comparator|Standard ETT, un-coated endotracheal tube|
89439021|NCT03989232|Active Comparator|Semaglutide 1.0 mg|All participants will receive one injection per week during a 12-week dose escalation period. From week 13 to week 40, the 1.0 mg group will receive an additional injection of semaglutide placebo in order to maintain the blinding.
89439022|NCT02140437|Experimental|Fulvestrant and anastrozole|Anastrozole 1 mg PO QD Fulvestrant 500mg IM d1,15, 29 and 4 weeks after
89439023|NCT02140437|Active Comparator|Anastrozole|Anastrozole 1 mg PO QD
89439024|NCT05697640|Active Comparator|Vericiguat Oral Tablet|"Tested IMP: Vericiguat (film-coated tablet). Authorization status: Not authorised in this targeted therapeutic indication; Vericiguat is authorized for the dosages that will be administered in this trial for another indication. The tablets used in this trial are no trade product, but a special trial product produced and provided by the marketing authorization holder Bayer.~Administration: Once daily (oral). Planned dosage: Three different dosages starting with 2.5 mg for two weeks, followed by 5 mg for two weeks and 10 mg for six weeks. The general IMP titration regimen was investigated and proven to be safe (max. dosages 10 mg/day) in patients with heart failure and reduced ejection fraction (Armstrong et al., 2020)."
89439025|NCT05697640|Placebo Comparator|Placebo Oral Tablet|"Comparator IMP: Placebo (film-coated tablet). Authorization status: Not authorised. The tablets used in this trial are no trade product, but a special trial product produced and provided by the marketing authorization holder Bayer.~Administration: Once daily (oral). Planned dosage: Three different dosages starting with 2.5 mg for two weeks, followed by 5 mg for two weeks and 10 mg for six weeks to have identical conditions to verum."
89439026|NCT03549195|Active Comparator|ICG|
89439027|NCT03549195|Active Comparator|ICG-CP|CP, control peptide
89439028|NCT03549195|Experimental|ICG-TMTP1|also named as TMTP1-ICG
89439029|NCT05697562|Placebo Comparator|anticoagulation group with DG HAL|
89439030|NCT05697562|Active Comparator|anticoagulation group with SRAE|
89439031|NCT05697562|Placebo Comparator|no anticoagulation group with RBL|
89439032|NCT05697562|Active Comparator|no anticoagulation group with SRAE|
89199386|NCT05673317|No Intervention|Control Arm|The participant will receive usual breastfeeding care such as counseling by her physician, access to lactation consults, nursing assistance in the hospital, access to our online resources.
89439033|NCT05697484|Active Comparator|intervention group|
89439034|NCT05697484|No Intervention|control group|
89439035|NCT05545228|Experimental|Intervention group|Participants will receive treatment as usual plus a link work intervention to support access to dental services.
89439036|NCT05545228|No Intervention|Treatment as usual group|Participants to receive treatment as usual and will not receive the intervention.
89439037|NCT03547401||General anesthesia|Patient (15 to 40 years old) undergoing elective surgery requiring general anesthesia in supine position.
89439038|NCT03526692|Experimental|Sensorimotor/delta NF training group|"Three interventions will be administered:~An electroencephalography recording (EEG) for 30 minutes.We will use an electrocap of 19 scalp locations according to the International 10-20 EEG placement system.~The second intervention is the neuropsychological assessments and questionnaires. They will be done in one session for approximately 2 hours.~The third intervention is the neurofeedback training sensorimotor/delta ratio that will be recorded at channel Cz according to the International 10-20 system."
89502035|NCT05490758|Experimental|sensorimotor training|sensorimotor training group did sensorimotor activities e.g play with dough,peg games 5 days a week for 4 weeks.
89502036|NCT05490758|Experimental|constraint induced movement therapy|constraint induced movement therapy group in which affected arm was constraint for 6 hours a day for 5 days a week for 4 weeks.
89439039|NCT03526692|Experimental|Beta1/theta NF training group|"Three interventions will be administered:~An electroencephalography recording (EEG) for 30 minutes.We will use an electrocap of 19 scalp locations according to the International 10-20 EEG placement system.~The second intervention is the neuropsychological assessments and questionnaires. They will be done in one session for approximately 2 hours.~The third intervention is the neurofeedback training Beta1/theta ratio that will be recorded at channel Fz according to the International 10-20 system."
89439040|NCT03526692|No Intervention|Control group|"Three interventions will be administered:~An electroencephalography recording for 30 minutes.We will use an electrocap of 19 scalp locations according to the International 10-20 EEG placement system.~The second intervention is the neuropsychological assessments and questionnaires. They will be done in one session for approximately 2 hours.~The psychopedagogical care : Each session will be organized using the same video material than for the NF training sessions."
89439041|NCT03761355||medical student of 6th Year|Students of medical faculty of 6th Year in Medical University of Bialystok, Poland.
89439042|NCT03940872|Experimental|3PDQ self-questionnaire validation|200 patients will be included for this step in 10 French Parkinson expert centers.
89439043|NCT05575713||Major depressive disorder|Patients diagnosed with severe depressive episode according to the diagnostic and Statistical Manual of mental disorders, 5th Edition (DSM-V);
89439044|NCT05575713||healthy volunteer|Person who did not meet the DSM-V diagnosis of any mental disease, had no family history of psychiatric disease, and had no history of suicidal behavior.
89439045|NCT05451069||Multiple sclerosis patients|MS patients according to 2017 Macdonald criteria
89439046|NCT05451069||Non Multiple sclerosis persons|Control persons
89439047|NCT05591638||GROUP 1|There will be 45 patients diagnosed with preeclampsia in the study group
89439048|NCT05591638||GROUP 2|There will be 45 normal pregnant women in the control group
88923565|NCT01682577|Experimental|Perindopril 4 mg tablets of PT Dexa Medica|"Group I (Test product): each tablet contains perindopril tert-butylamine salt 4 mg.~A single dose of perindopril tablet of PT Dexa Medica was given to each of study subjects."
88923566|NCT01682577|Active Comparator|Perindopril 4 mg tablets of Servier|"Group II (Reference product) : each tablet contains perindopril tert-butylamine salt 4 mg.~A single dose of perindopril (Prexum) tablets of Servier was given to each of study subjects."
88923567|NCT01682707|Active Comparator|Laryngoscopy|Laryngoscopy Track Light teaqueal intubation
88923568|NCT01682707|Active Comparator|Track Light|
88923569|NCT01683227|Experimental|Screening/motivational drug intervention|Screening and brief intervention counseling matched to patient's risk level delivered in the ER
88923570|NCT01683227|Placebo Comparator|Motivational placebo intervention|Screening and brief intervention for driving and traffic safety
88923571|NCT01683240|Experimental|Frimberger cholangioscope|Patients with need for cholangioscopy due to gallstones or histological evaluation of strictures
88923572|NCT01683357||Multiple Bilobar CLM|Patients selected for hepatectomy because carrier of multiple (> or = to 4), bilobar CLM
88923573|NCT01683578|Active Comparator|Variable Ventilation|Variable tidal volumes with mean at 8 mL/kg of predicted body weight
88923574|NCT01683578|No Intervention|Non-variable Ventilation|Conventional mechanical ventilation with tidal volume 8 mL/kg of predicted body weight
88923575|NCT01683643|Experimental|SBIRT Group|Baseline demographic data will be collected. Subjects will be screened for substance use risk using The Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST) developed by the World Health Organization. Experimental subjects, in addition to their risk score and informational materials, will also receive a brief intervention and a referral to treatment appropriate to their risk score from trained health educators. The health educators will be provided by Homeless Health Care, Los Angeles.
88923576|NCT01683643|Active Comparator|Control Group|Baseline demographic data will be collected. Subjects will be screened for substance use risk using The Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST) developed by the World Health Organization. Control subjects will receive only their risk score and informational materials regarding the health risks of substance use.
88923577|NCT01683669|Other|Noisy-PSV 1|different levels of variable pressure support
88923578|NCT01683669|Other|Noisy-PSV 2|different levels of variable pressure support
88923579|NCT01683760|Experimental|Population PK|
88923580|NCT01684124|Placebo Comparator|standard care|normal treatment
88923581|NCT01684124|Active Comparator|conservative O2 therapy|a value of 90-92% O2 saturation will be targeted
88923582|NCT01684280||gender|Paired samples of abdominal subcutaneous and intrabdominal omental adipose tissue were obtained from men and women who underwent bariatric surgery.
89439049|NCT05575635|Experimental|fruquintinib + mFOLFOX6 + radiotherapy|fruquintinib + mFOLFOX6 + radiotherapy
89439050|NCT05591560|Placebo Comparator|Group I Placebo group|Group I (Placebo group; n=33) which will be treated with chemotherapy which includes paclitaxel 60 mg/m2 IV over 1 hour followed by carboplatin area under the curve 2 (AUC 2) IV over 30 minutes Day 1, 8, and 15 which will be repeated every 21 days for 6 cycles 12 plus 4 placebo capsules for 5 days (two days before chemotherapy, the day of chemotherapy after receiving it, and two days after chemotherapy).
89439051|NCT05591560|Active Comparator|Group II Itraconazole group|Group II: (Itraconazole group; n=33) which will be treated with chemotherapy which includes paclitaxel 60 mg/m2 IV over 1 hour followed by carboplatin AUC 2 IV over 30 minutes Day 1, 8, and 15 repeated every 21 days for 6 cycles 12 plus oral itraconazole 400 mg (4 capsules, each of 100 mg) for 5 days (two days before chemotherapy, the day of chemotherapy after receiving it, and two days after chemotherapy).
89439052|NCT05575479||Idiopathic Parkinson's Patients|Patients with idiopathic parkinson's disease
89502037|NCT04424420|Experimental|Paracetamol|Study phase 1 (single dosing): 1000 mg once. Study phase 2 (multiple dosing): 1000 mg twice daily for a minimum of 12 and a maximum of 14 days.
89502038|NCT04424420|Active Comparator|Ibuprofen|Study phase 1 (single dosing): 800 mg once.
89502039|NCT04424420|Placebo Comparator|Placebo|Study phase 1 (single dosing): Once. Study phase 2 (multiple dosing): Twice daily for a minimum of 12 and a maximum of 14 days.
89439053|NCT05540470|Experimental|Module A|• Module A - PART (Presumptive anti-relapse treatment): This is the core of the strategy for targeting the P. vivax reservoir by identifying individuals with a high probability of being asymptomatic carriers of blood forms and/or hypnozoites (by epidemiological criteria combined with a rapid serological test), and treating these individualswith chloroquine (by 150mgs tablet, according to the following posology: 600mgs on the first day, 450mgs on the second and 300mgs on the third day, or weight-adjusted dosing) and primaquine (in a short regimen of 30 mg per day for seven days, or weight-adjusted dosing) or tafenoquine (300 mg as a single observed dose), after exclusion of contraindications to these treatments. This intervention aims to reduce the likelihood of relapse of a previous infection, and subsequent transmission in forest and urban settings, ultimately helping to reduce the circulation of P. vivax.
89439054|NCT05540470|Other|Module B|• Module B - Malakit: distribution of a self-test and self-treatment kit to individuals in the target population who agree to be trained (and demonstrate understanding of the use of the kit), in order to maintain access to quality test and treatment for malaria attacks that occur in extreme isolation in illegal mining towns in French Guiana
88923583|NCT01684488|Active Comparator|Waitlist+EducAid|Immediately following enrollment, participants do not immediately receive any intervention. At 3 months, they are enrolled in EducAid educational programming for the 2012-2013 academic year.
88923584|NCT01684488|No Intervention|Waitlist|Participants do not receive any intervention throughout the trial period. Once the trial has concluded, participants are invited to enroll in EducAid educational programming for the 2013-2014 academic year.
88923585|NCT01684488|Experimental|YRI only|Immediately following enrollment, participants complete the YRI. They are then placed on a waitlist for the remainder of the trial. At the end of the trial, participants are invited to enroll in EducAid educational programming for the 2013-2014 academic year.
88923586|NCT01684488|Experimental|YRI+EducAid|Immediately following enrollment, participants complete the YRI. Participants are then immediately enrolled in EducAid educational programming for the 2012-2013 academic year.
88923587|NCT01684514|Experimental|colitis, ulcerative|Enrolled patients will be examined by conventional colonoscopy and confocal laser endomicroscopy before and after initiation of topical treatment, respectively.
88923588|NCT01684514|Sham Comparator|Control group|A control group will be examined by conventional colonoscopy and confocal laser endomicroscopy.
88923589|NCT01684644|Experimental|New Forest Parenting Programme|The New Forest Parenting Programme is a parent training programme specifically developed to treat ADHD in preschool children. The programme is delivered as an 8 week intervention for individual parents and their child.
88923590|NCT01684644|Other|Treatment as Usual|Treatment as usual for preschool ADHD consists of psychoeducation groups for parents.
88923591|NCT01684813|Active Comparator|Clopidogrel|This group will receive after PCI the standard dose of clopidogrel, a daily dose of 75 mg.
88923592|NCT01684813|Experimental|Prasugrel|This group will receive after PCI a loading dose of 60 mg prasugrel (6 x 10 mg tablets) followed by a daily dose of prasugrel (10 mg tablet).
88923593|NCT01684982|Experimental|everolimus eluting stent|second generation drug eluting stent
88923594|NCT01684982|Active Comparator|sirolimus eluting stent|first generation drug eluting stent
88923595|NCT01685034|Experimental|Allergy Immunotherapy Group|There is only one active experimental group as this is a pilot study comparing clinical/histologic/endoscopic changes before and after treatment.
88923596|NCT01685151|Experimental|Ramelteon SL (Dose 1)|Ramelteon SL tablets, sublingual, once daily, at night time for up to 12 months.
88923597|NCT01685151|Experimental|Ramelteon SL (Dose 2)|Ramelteon SL tablets, sublingual, once daily, at nigh time for up to 12 months
88923598|NCT01685151|Placebo Comparator|Placebo|Ramelteon SL placebo-matching tablets, sublingual, once daily, at night time for up to 12 months.
88923599|NCT01685307|Experimental|intense cooking process|Test meal: 150g of beef cooked at intense temperature. Beef proteins are intrinsically labelled with 15 N protein
88923600|NCT01685307|Experimental|mild cooking process|Test meal: 150 g of beef cooked at moderate intensity. Beef proteins are intrinsically labeled with 15N.
88923601|NCT01685489|Experimental|Docetaxel, PSK®|A 21-day lead-in oral PSK alone is followed by the addition of standard intravenous docetaxel at 75 mg/m2 evey 3 weeks for three cycles. After the third dose of docetaxel, study drug will be discontinued on day 14 to allow for a 7-day washout period before a fourth dose of docetaxel is administered.
88923602|NCT01685489|Placebo Comparator|Docetaxel, Placebo|A 21-day lead-in oral placebo alone is followed by the addition of standard intravenous docetaxel at 75 mg/m2 every 3 weeks for three cycles. After the third dose of docetaxel, the placebo will be discontinued on day 14 to allow for a 7-day washout period before a fourth dose of docetaxel is administered.
88923603|NCT01685775|Experimental|Transvaginal/transumbilical cholecystectomy|Transvaginal/transumbilical group: we will use a 5 mm trocar in the umbilicus and a 10 mm trocar together with a 5 mm seizing forceps through the posterior vaginal vault to perform the cholecystectomy in the Zornig style
88923604|NCT01685775|Active Comparator|Needlescopic cholecystectomy|Needlescopic cholecystectomy with 3 trocars: we will use two 2-3 mm working trocars and one 10 mm optic trocar, its access is also used for extraction of the gallbladder
88923605|NCT01686087|Active Comparator|Continuation of SRI|Patients who achieve minimal to mild OCD symptoms and are not currently depressed at end of preparatory phase will be randomized to stay on SRI. They will receive 45 minute EX/RP booster sessions once per month.
88923606|NCT01686087|Placebo Comparator|Replace SRI w/placebo|Patients who achieve minimal to mild OCD symptoms and are not currently depressed at end of preparatory phase will be randomized to gradual replacement with pill placebo. They will receive 45 minute EX/RP booster sessions once per month.
88923607|NCT01686100|Active Comparator|No touch vein grafts|The grafts were harvested with there surrounding tissues.
88923608|NCT01686100|Active Comparator|Conventional vein grafts.|The grafts were stripped from surrounding tissue.
89199387|NCT05673304|Experimental|Interventional group|Patients will be treated on the primary tumour with a total dose of 24 Gy (8 Gy x 3 fractions QD) within 2 weeks from the start of neoadjuvant chemotherapy
89439055|NCT05540470|Other|Pre/post intervention surveys|Two cross-sectional surveys will be conducted in the inclusion sites before and at the end of intervention implementation, during the same period of the year (preferably the last quarter of 2022 and 2024), in order to limit biases associated with seasonality.
89439056|NCT05540470|Other|QUALITATIVE STUDY|The CUREMA project includes qualitative research that will be conducted before, during and after the intervention by a trained social science researcher. The aim of this research will be to analyse the specific constraints and levers of the intervention under study and the pre-elimination context, in order to draw out lessons that are context-specific but also potentially of universal value. As described above, the study population will be broader and include not only the garimpeiros, but also the study field workers as well as other stakeholders.
89439057|NCT05429073|Experimental|RGLS8429, first dose level|Eligible participants will receive subcutaneous injection of the first dose level RGLS8429 or placebo
89439058|NCT05429073|Experimental|RGLS8429, second dose level|Eligible participants will receive subcutaneous injection of the second dose level RGLS8429 or placebo
89439059|NCT05429073|Experimental|RGLS8429, third dose level|Eligible participants will receive subcutaneous injection of the third dose level RGLS8429 or placebo
89439060|NCT05429073|Experimental|RGLS8429, fourth dose level|Eligible participants will receive subcutaneous injection of the fourth dose level RGLS8429 or placebo
89439061|NCT02140515|Active Comparator|Luveris|Evaluation the effect of Luveris protocol on Induction of ovulation in Patients with Hypogonadotropic Hypogonadism
89439062|NCT02140515|Active Comparator|Gonal-F& Luveris|Evaluation the effect of Gonal-F& Luveris protocols of Induction of ovulation in Patients with Hypogonadotropic Hypogonadism
89439063|NCT05544838|No Intervention|LMA with standard insertion technique|Standard LMA insertion technique; LMA held like a pen and index finger placed at the junction of LMA tube and cuff. Index finger used to press LMA against hard palate and posterior pharyngeal wall until definite resistance felt at the base of hypopharynx. LMA then held with non- dominant hand and index finger removed.
89439064|NCT05544838|Experimental|Rotational LMA insertion technique|Rotational LMA insertion; LMA inserted like guedel airway insertion: LMA proximally grasped close to anaesthesia circuit attachment. Insertion was conducted with LMA cuff facing towards nose, hard palate and then advanced into the base of hypopharynx until resistance was felt. At this point, LMA rotated at 180 degree anti-clockwise and LMA tube black line positioned and confirmed on the nasal side.
89439065|NCT05579535|Active Comparator|group A|classical gait training
89439066|NCT05579535|Experimental|group B|gait training while using weight around ankle
89439067|NCT05591326|Experimental|Cases in RT1 class according to gingival recession depth|Depth of gingival recession in mandibular anterior teeth, according to the 2017 Periodontal Classification, cases in RT1 class will be included.
89439068|NCT02260947|Experimental|1|
89439069|NCT02260947|Experimental|2|
89439070|NCT02260947|Active Comparator|3|
89439071|NCT02260947|Active Comparator|4|
89439072|NCT02260947|Placebo Comparator|5|
89439073|NCT05698498|Active Comparator|Usual Care|Participants in the active comparator control group will receive usual care, which includes usual public benefit, assistance and social service programs that are available at the local, county, state, and federal levels to all residents of Santa Clara County. They will also be offered the option to attend a Public Benefits Information Session.
89439074|NCT05698498|Experimental|Guaranteed Income|Participants in the intervention group will receive guaranteed income gift payments equivalent to $1,000/month for a total of 24 months in addition to usual care. They will also have the option to attend the same Public Benefits Information Session being offered to the control group as above.
89439075|NCT05415423|Active Comparator|Study 1 Low-Intensity Group|Control group which receives less intense electrical stimuli than the other.
89439076|NCT05415423|Experimental|Study 1 High-Intensity Group|Group which receives more intense electrical stimuli than the other.
89439077|NCT05415423|Active Comparator|Study 2 Low-Intensity Group|Control group which receives less intense heat stimuli than the other.
89439078|NCT05415423|Experimental|Study 2 High-Intensity Group|Group which receives more intense heat stimuli than the other.
89439079|NCT05415423|Placebo Comparator|Study 3 Placebo group|A group that receives a placebo cream.
89439080|NCT05415423|Experimental|Study 3 Painkiller group|A group that receives a topical analgesic such as EMLA cream.
89439081|NCT05415423|No Intervention|Study 4 test-retest reliability group|Participants who participated in either Study 1 or 2 are recruited. They will experience both electrical and heat stimuli.
89439082|NCT05540236|Experimental|The experimental group were given therapeutic intervention|The experimental group were given therapeutic intervention of single ear auricular pellet acupressure at the stomach(CO4), cardia(CO3), liver(CO12), occiput(AT3), shenmen(TF4) and subcortex(AT4) acupuncture points
89439083|NCT05540236|Placebo Comparator|The control group were given sham intervention|The control group were given sham intervention of single ear auricular pellet acupressure at the knee(AH4) and thoracic vertebrae(AH11) acupuncture points
89439084|NCT05574855||Group I subjects (T)|Neonates with gestational age ≥35, who experienced an episode of perinatal ischaemia and who were qualified for hypothermia treatment according to the Standards of Medical care of Neonates in Poland will be enrolled to the subject group (T)
89439085|NCT05574855||Group II controls (N)|Healthy, term neonates, who underwent echocardiography on days 3-7 of life (after closure of ductus arteriosus, or with trace, insignificant haemodynamic ductus arteriosus) for reasons such as difficult adaptation, gestational diabetes of the mother etc.
89439086|NCT05589532|Experimental|Prosthetic single-tooth prosthesis using PEEK|An implant-supported single tooth prosthesis using a PEEK polymer in its composition
89439087|NCT03547791|Active Comparator|ACS (Group 1)|Intramuscular injection of betamethason sodium phosphate 12mg (3ml) twice 24hours apart
89439088|NCT03547791|Placebo Comparator|Placebo (Group 2)|Intramuscular injection of normal saline 3ml twice 24hours apart
89439089|NCT04809129|Experimental|External mechanical loading|"Following bariatric surgery (RYGB or SG) patients will be asked to wear a weighted vest for a minimum of 8 hours daily and during physical exercise for three months postoperatively.~Weight will be incrementally added on a weekly basis to maintain the baseline weight as patients lose weight following surgery up to a maximum of 15%."
88923609|NCT01686139|Experimental|ABDM-MSC|"The patient will receive multiple injections in one session during the study. The injections will take place in the chronic wound bed and in the third distal part of the treated shin (in the form of a ring).~Maximal amount of ABMD-MSC cells injected: 10-20*10^6 cells (up to volume of 20mL, depending on the wound size & patient weight)."
89439090|NCT04809129|No Intervention|Standard postoperative care|Patients following bariatric surgery (RYGB or SG) will receive standard postoperative care.
88923610|NCT01686178|Experimental|Anti-smoking social marketing campaign|"In prior research, a high risk subpopulation of young adults was identified in San Diego, CA: the hipster subculture. We developed a yearlong pilot social branding intervention to decrease smoking among this group, using social events and social leaders to promote a strong nonsmoking lifestyle. The intervention rationale is based on utilizing industry market research tools to define the target audience and directly countering tobacco industry lifestyle marketing strategies. We now propose to extend this intervention to three other cities (tailoring the intervention to a high-risk subpopulation of young adults in each city) and evaluate it in a multicenter quasi-experimental controlled trial."
88923611|NCT01686178|No Intervention|Control|Survey research data will be collected in control cities with the same schedule as data collection in the cities where the intervention is taking place.
88923612|NCT01686204|Active Comparator|Non-obese individuals|Daily consumption of 12 oz lowfat yogurt or soy pudding for 9 weeks.
88923613|NCT01686204|Experimental|Obese individuals|Consumption of 12 oz of soy pudding or low fat dairy yogurt daily for 9 weeks.
88923614|NCT01686386|Experimental|Dose escalation benda lena dexa|"Phase I: Participants will be treated in groups (cohorts) of three to six subjects per cohort, according to a modified Fibonacci design. The dose of Bendamustine and Lenalidomide (from 0 to 5) will be increased from one cohort to the next. Regardless of the treatment cohort, participants will receive treatment in cycles lasting 28 days. In the first phase of the study, the dose of B and L given with will be gradually escalated to reach the MTD.~Phase II: Dexamethasone will be given in combination with the MTD of Bendamustine and Lenalidomide in cycles lasting 28 days."
88923615|NCT01686594|Active Comparator|PUVA maintenance treatment|Psoralen plus UVA (PUVA) treatment. The patients receive a standardized dose of oral 8-methoxypsoralen (Oxsoralen) 1 hour before UVA exposure
88923616|NCT01686594|No Intervention|No maintenance treatment|observation
88923617|NCT01686776|Active Comparator|123 I-HSA + 125 I-HSA|Healthy Volunteers, N=16
88923618|NCT01686776|Experimental|123 I- HSA + 125 I-HSA|Patients, planned for elective Major Abdominal Surgery, N=16
88923619|NCT01686776|Experimental|123-I-HSA+125 I-HSA|Patients, with a acute pancreatitis or cholecystitis, N=16
88923620|NCT01687192|Experimental|Girls and young womens receiving immunosuppressive treatment|
88923621|NCT01687465|Active Comparator|Argon laser trabeculoplasty|Up to the year 2005, the vast majority of ophthalmologists used Argon laser trabeculoplasty (ALT) as the mode of laser therapy. ALT is effective but its most significant problem is that its effectiveness decreases with re-treatment since the tissue it targets (the trabecular meshwork) is changed by the laser rendering repeat treatments less effective.
88923622|NCT01687465|Active Comparator|selective laser trabeculoplasty|Post 2005, a newer mode of laser therapy, selective laser trabeculoplasty (SLT) has emerged as the standard of care laser. There are many potential advantages to SLT but to date these advantages are only theoretical. The most important potential clinical advantage of SLT is that it causes less damage to the tissue it targets.
88923623|NCT01687517|Experimental|Patient|90 patients suffering from sarcoidosis
88923624|NCT01687517|Active Comparator|Volunteer|100 volunteers
88923625|NCT01687556|Active Comparator|Topical EGCG 1%|Seventeen subjects were designated to use 1% EGCG .Since baseline visits, affected areas of randomly allocated half sides were treated with 1% solution twice daily, whereas those of the opposite sides were treated with vehicle only (3% ethanol).
88923626|NCT01687556|Experimental|topical EGCG 5%|Eighteen subjects were designated to use 5% EGCG, to evaluate a dose-response relationship. Since baseline visits, affected areas of randomly allocated half sides were treated with 5% EGCG solution twice daily, whereas those of the opposite sides were treated with vehicle only (3% ethanol).
88923627|NCT01687686||All cohort|Initially healthy patients in General Practise Research Database (GPRD) meeting the inclusion criteria at any point between 1st January 2001 and 25th March 2010
88923628|NCT01687751|Experimental|Dexmedetomidine|Dexmedetomidine 0.2 to 1.1 mcg/kg/hr by continuous subcutaneous infusion for up to 10 days
88923629|NCT01687751|Active Comparator|Midazolam|Midazolam 10 to 100 mcg/kg/hr by continuous subcutaneous infusion for up to 10 days
88923630|NCT01687777|Active Comparator|Mesenchymal stem cells (MSCs)|Mesenchymal stem cells with a collagen type I membrane (OrthoADAPT)
88923631|NCT01687777|Placebo Comparator|OrthADAPT|Membrane of collagen type I (OrthoADAPT)
88923632|NCT01687881|Sham Comparator|Sham Chiropractic|Sham Chiropractic manipulative therapy.
88923633|NCT01687881|No Intervention|Control group|No intervention: Control group.
88923634|NCT01687881|Active Comparator|Chiropractic Spinal Manipulative Therapy|Active intervention: Chiropractic Spinal Manipulative Therapy
88923635|NCT01688362|Experimental|platelet-rich plasma protein (PRP)|Subjects in this group will receive 2 injections with PRP. Each injection separated by two weeks.
88923636|NCT01688362|Active Comparator|Corticosteroid|Subjects in this group will receive one injection with corticosteroids and then one injection with local anesthetic two weeks later.
89502040|NCT00457951|Experimental|Open Label|Initial six subjects treated with ODSH open-label to confirm safety in subjects with an acute exacerbation of COPD; six additional patients will be enrolled following safety review.
89439091|NCT05544370|Experimental|Intensive high intensity intervallic training group|The intensive high intensity intervallic training group performs 6 sets of 60 seconds of work and 60 seconds of rest. During the first two weeks we work at an intensity of 80-85% of the reserve heart rate during the work phase and 50-55% of the reserve heart rate during the rest time. In weeks 3 and 4 the intensity in the work phase is increased by 5%, reaching from the fifth week onwards a work intensity of 95-95% of the reserve heart rate. The program duration is 8 weeks and the frequency of intervention is 2 sessions per week.
89502041|NCT00457951|Placebo Comparator|0.9% Sodium Chloride|Placebo Comparator: Placebo-Control Arm 0.9% Sodium Chloride Solution bolus; dose of 0.375mg/kg/hr over 96 hours.
89502042|NCT00457951|Active Comparator|Randomized, Blinded, ODSH Arm|Subjects will receive standard of care treatment. ODSH is administered in bolus doses estimated to inhibit inflammatory mediators randomized 1:1 to ODSH 8mg/kg or placebo. The continuous infusion dose will be 0.375 mg/kg/hr over 96 hours.
88923637|NCT01688375|Experimental|Ursodeoxycholic acid|Ursodeoxycholic acid administration UDCA administration will begin twenty-four hours after endoscopic or surgical procedure and will last fourteen days. UDCA dose will be administered at 750 mg/day, divided into three doses.
88923638|NCT01688427|Experimental|Standard IPV Assessment|Test the effectiveness of the eMOCHA DOVE application using mHealth technology for routine assessment of IPV vs. Pencil and paper.
88923639|NCT01688427|Experimental|Standard DOVE intervention|The standard DOVE intervention has already been developed and tested (NR009093). The standard DOVE intervention is a brochure based 10 minute intervention that the home visitor reviews with the women. It consists of information about IPV, its effects on pregnancy and infant health, community resources and a plan for individual safety options. For the eMOCHA DOVE intervention, the DOVE 10 minute brochure intervention will be converted from the paper format to a visually colorful interactive presentation loaded into the home visitor device using the eMOCHA application. The format will be completely activated and implemented by the women. She uses small ear buds and a touch screen, so how she responds and interacts with the media enhanced eMOCHA DOVE intervention is private.
88923640|NCT01688453|Active Comparator|Group 1:|Socially advantaged overweight or obese adolescents are allocated to the standard care management.
88923641|NCT01688453|Experimental|Group 2|Socially less advantaged overweight or obese adolescents are allocated to the standard care management.
88923642|NCT01688453|Experimental|Group 3|Socially less advantaged overweight or obese adolescents are allocated to the strengthened care management.
88923643|NCT01688778|Experimental|Telemedicine|Monthly video consultations with a nurse as add-on to standard treatment.
88923644|NCT01688778|No Intervention|Standard treatment|Standard diabetes control at a Diabetes Clinic or GP
88923645|NCT01689064|Active Comparator|Posterior Septectomy|Patient will be randomized to a study arm. The patient will be blinded to the approach. The surgeon will have performed at least 10 procedures previous for each approach. The surgeon will maintain the following surgical practives: preservation of both middle turbinates, preservation of one superior turbinate (to minimize olfactory injury), elevation of a nasoseptal flap, the use of a combination of gelform, surgicel and nasapore dissolvable spacer placed within the surgical defect. These practices are all standard of care. Patient will start Neilmed high volume low pressure saline irrigation three times daily starting on post operative day five. Patients will receive prophylactic antibiotics for fourteen days post operatively.
88923646|NCT01689064|Experimental|Stamm Approach|Patient will be randomized a study arm. The patient will be blinded to the approach. The surgeon will have performed at least 10 procedures previous for each approach. The surgeon will maintain the following surgical practives: preservation of both middle turbinates, preservation of one superior turbinate (to minimize olfactory injury), elevation of a nasoseptal flap, the use of a combination of gelform, surgicel and nasapore dissolvable spacer placed within the surgical defect. These practices are all standard of care. Patient will start Neilmed high volume low pressure saline irrigation three times daily starting on post operative day five. Patients will receive prophylactic antibiotics for fourteen days post operatively.
88923647|NCT01689077|Active Comparator|24 hours hypothermia|24 hours hypothermia
88923648|NCT01689077|Experimental|48 hours hypothermoa|48 hours hypothermia
88923649|NCT01689428||IVF treatment EmbryoGen|Embryo culture in EmbryoGen medium
88923650|NCT01689428||IVF treatment ISM1|Embryo culture in ISM1 medium
88923651|NCT01689454||IVF treatment ISM1|Embryo culture in ISM1 medium
88923652|NCT01689454||IVF treatment EG|Embryo culture in EmbryoGen medium
88923653|NCT01689753|Experimental|TEGO® connector|The TEGO® connector is used during 3 consecutive hemodialyse. After each dialysis session, the dead space of the catheter is flushed with NaCl 0.9%.
88923654|NCT01689753|Active Comparator|Trisodium citrate|After each dialysis, the dead space of the catheter is filled with trisodium citrate 46.7% (Citralock®).
88923655|NCT01690013||Klinefelter|Men with Klinefelter syndrome
88923656|NCT01690013||Control|Men from the general population, matched by age, education and zipcode.
88923657|NCT01690026|Other|Brief intervention|Motivational intervention based brief intervention
88923658|NCT01690026|Other|Standard intervention|Standard intervention condition
88923659|NCT01690039||All study participants|Furosemide-Fludrocortisone-Test and Ammonium chloride-Loading Test will be performed in renal stone patients.
88923660|NCT01690065|Experimental|Nilotinib+AD induction|"Nilotinib plus AD induction chemotherapy~AD regimen : Cytarabine 200 mg/m2/day by continuous iv infusion over 24 hours daily for 7 days (D 1-7) plus Daunorubicin 90 mg/m2/day iv daily for 3 days (D 1-3)~Nilotinib 400mg bid PO (continuous without interruption from D8 of induction chemotherapy)~Re-induction chemotherapy AD regimen : Cytarabine 200 mg/m2/day by continuous iv infusion over 24 hours daily for 5 days (D 1-5) plus Daunorubicin 45 mg/m2/day iv daily for 2 days (D 1-2)"
89199388|NCT05673304|No Intervention|observational cohort|This cohort will include patients fulfilling inclusion criteria who refuse enrollment in the interventional cohort and patients where SBRT boost appears not feasible after enrollment for technical issues
89199389|NCT05672797|No Intervention|Control|Participants in the control group will not receive additional adherence reminders or financial incentives during the 9-month study.
89206077|NCT02549976|Experimental|Evaluation group|"Digestive damage will be assessed on patients by using the methods described in the Lemann index protocol, dependant of Crohn's disease locations.~All patients will have clinical examination and abdominal magnetic resonance imaging analyses. Upper endoscopy, colonoscopy, and pelvic magnetic resonance imaging analyses will be performed according to disease locations :~Upper tract location : upper endoscopy~Colorectal location : colonoscopy~Perianal location : pelvic MRI~All patients : abdominal MRI"
89439092|NCT05544370|Experimental|Extensive high-intensity intervallic training group|The extensive high-intensity intervallic training group performs 3 sets of 120 seconds of work and 120 seconds of rest at an intensity of 70-75% of the reserve heart rate during the work phase and an intensity of 50-55% of the reserve heart rate during the rest phase. In weeks 3 and 4 the intensity in the work phase is increased by 5%, reaching from the fifth week onwards a work intensity of 80-85% of the reserve heart rate. The program duration is 8 weeks and the frequency of intervention is 2 sessions per week.
88923661|NCT01690078||Cross sectional|Cross sectional study where subjects with PRS, micrognathia, or SGS will have a single study visit that will be scheduled within 14 days of a clinically indicated upper airway endoscopy. CT scans of the neck or maxillofacial CT will be obtained in all subjects. During upper airway endoscopy, airway measurements will be conducted. Cohort may include subjects who have previously undergone medical or surgical intervention for their airway obstruction, or who are currently undergoing multidisciplinary team management. The following data will be collected: clinical parameters, Obstructive Sleep Apnea (OSA)OSA-18 (quality of life) questionnaire, and lung function tests (subjects > 4 years of age). Clinically indicated swallowing studies and voice evaluations will be collected.
88923662|NCT01690078||Longitudinal|The prospective, longitudinal cohort arm of the study is designed to describe the effects of treatment on clinical and computational model endpoints. This is performed in a subset of subjects with PRS, micrognathia, or SGS who are scheduled for clinically indicated upper airway endoscopy and who are scheduled to complete a definitive treatment course which necessitates multiple endoscopic evaluations and follow-up imaging. Subjects will have an entry visit comparable to the cross-sectional entry visit. Longitudinal subjects will have up to 3 additional study visits over a 12 to 15-month period.
88923663|NCT01690078||Normal Control Data|Normal de-identified control data is retrospectively collected from clinically indicated CT scans of the neck and maxillofacial CT scans in children less than 18 years of age.
88923664|NCT01690091|Experimental|Metformin|500 mg per day(1/2 tbl 1000 mg once a day - in the morning) after a week increase the dose to 1 tbl á 1000 mg after two weeks increase the dose to 2 x tbl 1000 mg (in the morning and in the evening), duration: 3 months
88923665|NCT01690091|Placebo Comparator|Placebo|500 mg per day(1/2 tbl 1000 mg once a day - in the morning) after a week increase the dose to 1 tbl á 1000 mg after two weeks increase the dose to 2 x tbl 1000 mg (in the morning and in the evening), duration:3 months
88923666|NCT01690104|Active Comparator|Rifampicin|Rifampicin 600 mg daily
88923667|NCT01690104|Placebo Comparator|Placebo|Placebo daily
88923668|NCT01690169|Experimental|NNC0113-0987|
88923669|NCT01690169|Placebo Comparator|Placebo|
88923670|NCT01690182|Experimental|Study test meal 1|High volume, high energy density test meal. Volunteers will be given 490 mL of a high energy test meal once in the morning
88923671|NCT01690182|Experimental|Study test meal 2|High volume, low energy density test meal. Volunteers will be given 490 mL of a high volume low energy density test meal once in the morning
88923672|NCT01690182|Experimental|Study test meal 3|A low volume, high energy test meal. Volunteers will be given 140 mL high energy density test meal once in the morning.
88923673|NCT01690195|Experimental|ABT-126|ABT-126 Open-label dose
88923674|NCT01690208|Experimental|EMERALD|Patients assigned to the EMERALD group will be invited to join the multi-component program which will last for 1 year. This program will be held on a 4-weekly basis for the first 3-4 months followed by a maintenance program involving 2-4 group activities every year. Between clinic visits, patients in this group will also receive telephone reminders from the staff and peer supporters to reinforce compliance and for social support.
89206078|NCT00586469|Experimental|Old Bulk|This group receives a full dose of Fluviral made from aged bulk material
89439093|NCT05544370|No Intervention|Control group|The control group will carry out their usual physical education classes which consist of games, jumping, moving, balance and different sports.
89439094|NCT04799691||Invasive strategy group|Patients admitted in ICU with Covid-19 related pneumonia during COVID19 first period.
88923675|NCT01690208|Active Comparator|Usual Care|"Irrespective of the assignment group, all patients will undergo a baseline comprehensive assessment using the JADE portal disease management system. All patients will also receive a 2-hour session on how to interpret their individualised JADE report and risk profiles, whilst the importance of achieving targets and optimizing self care will be reinforced.~Patients assigned to the UC group will be followed up in their usual clinic according to the 'standard' practice."
88923676|NCT01690221|Experimental|VEN 307|diltiazem hydrochloride 2% cream
88923677|NCT01690221|Placebo Comparator|Placebo|Placebo Cream
88923678|NCT01690234|Experimental|Multidisciplinary intervention|Early coordinated multidisciplinary intervention. Physiotherapist, chiropractor, rheumatologist, psychologist, occupational physician, ergonomist and social worker/case manager.
88923679|NCT01690234|Active Comparator|Usual care|Intervention from physiotherapist, chiropractor, rheumatologist and social worker.
88923680|NCT01690247|Experimental|Conventional plus UC-MSC|Participants will receive conventional treatment plus a dose of UC-MSC from day 0 through the week 12 study visit. Participants will then be followed until the week 48 study visit
88923681|NCT01690247|Placebo Comparator|Conventional plus placebo|Participants will receive conventional plus placebo treatment from day 0 through the week 12 study visit. Participants will then be followed until the week 48 study visit.
88923682|NCT01690260|Experimental|Bone Morphogenetic Protein 2|Condition of bone healing will be evaluated at serial radiological examinations and by clinical results according to a standard score system.
88923683|NCT01690260|Experimental|Autologous bone graft|Condition of bone healing will be evaluated at serial radiological examinations after 1,2,3,4,5,6,9 and 12 months. Blood tests and urine samples will also be examined for monitoring the bone healing process.
88923684|NCT01690286|Experimental|Group 1: JNJ-38518168 3 mg/ ketoconazole|
88923685|NCT01690286|Experimental|Group 2: JNJ-38518168 30 mg/ ketoconazole|
88923686|NCT01690286|Experimental|Group 3: JNJ-38518168 10 mg/ ketoconazole (optional)|
88923687|NCT01690312|Experimental|1 (Dietary Supplement - Fish Oil)|"On Day 1 & Day 29, the researcher will obtain anthropometric measurements as specified in the study protocol. A venous catheter will be inserted and a fasted blood sample will be drawn, which will be analyzed for study primary and secondary endpoints. Participants will consume a Breakfast Meal (which will represent t0) and will have blood drawn at a total of 7 time points. Blood samples drawn at30, t60, t120, and t180 will be analyzed for glucose and insulin; blood samples drawn at t60, t120, t180, t240, t300 and t360 will be analyzed for triglycerides. Upon completion of the 6 hour blood draw period, the venous catheter will be removed.~On Day 15, the researcher will obtain anthropometric measurements as specified in the study protocol."
88923688|NCT01690312|Experimental|2 (Placebo)|"On Day 1 & Day 29, the researcher will obtain anthropometric measurements as specified in the study protocol. A venous catheter will be inserted and a fasted blood sample will be drawn, which will be analyzed for study primary and secondary endpoints. Participants will consume a Breakfast Meal (which will represent t0) and will have blood drawn at a total of 7 time points. Blood samples drawn at30, t60, t120, and t180 will be analyzed for glucose and insulin; blood samples drawn at t60, t120, t180, t240, t300 and t360 will be analyzed for triglycerides. Upon completion of the 6 hour blood draw period, the venous catheter will be removed.~On Day 15, the researcher will obtain anthropometric measurements as specified in the study protocol."
88923689|NCT01690325|Experimental|Docetaxel, Avastin, Herceptin; adjuv. Epirubicin, Cyclophos.|Arm A: Neoadjuvant: 6 cycles of Docetaxel every 21 days together with 6 cycles of Avastin and Herceptin; Adjuvant: 4 cycles of Epirubicin and Cyclophosphamid every 21 days together with 12 cycles of Herceptin every 21 days.
88923690|NCT01690325|Experimental|Docetaxel, Avastin; adjuvant Epirubicin, Cyclophosphamid|Arm B: neoadjuvant: 6 cycles of Docetaxel and Avastin every 21 days. Adjuvant: 4 cycles of Epirubicin and Cyclophosphamid every 21 days.
88923691|NCT01690338|Active Comparator|Vecuronium Bromide|Patients who will be performed general anesthesia and tracheal intubation. Vecuronium will be used during surgery and tracheal extubation is scheduled when surgery is over.
89206079|NCT00586469|Active Comparator|New Bulk|This group receives a full dose of Fluviral made from new material
89439095|NCT04799691||Non-invasive strategy group|Patients admitted in ICU with Covid-19 related pneumonia during COVID19 second period.
89439096|NCT04776057|Other|lying|after cataract lying for 1 hour
89439097|NCT04776057|Other|sitting, walkin|after cataract sitting or walking for 1 hour
89439098|NCT05539768|Experimental|HS-IT101 monotherapy|1x10^9-6x10^10 in vitro expanded autologous TIL (HS-IT101) will be infused i.v. to patients with advanced solid tumor after lymphodepletion treatment with fludarabine and cyclophosphamide, and then followed by the administration of a regimen of IL-2.
89439099|NCT04775745|Experimental|Dose Escalation Phase|Three to six subjects per treatment cohort will be assigned to receive sequentially higher oral doses of LP-168 on a once or twice daily schedule for 28 days, starting at a dose of 100 mg/day.
89439100|NCT04775745|Experimental|Dose Expansion Phase|Additional subjects will be recruited to further explore the safety, tolerability, PK, and efficacy in specific subject subgroups.
89439101|NCT04425460|Experimental|Favipiravir|Favipiravir Tablets, 200 mg/tablet Favipiravir combined with supportive care recommended in the current National/Local guidelines. Favipiravir dosage and method of administration: Day 1: 1800mg, BID; Day 2 and thereafter: 600mg, TID, for a maximum of 14 days.
89439102|NCT04425460|Placebo Comparator|Placebo|Placebo control group Favipiravir combined with supportive care recommended in the current National/Local guidelines
89439103|NCT03547323|Experimental|Theranova 400 Dialyzer|One treatment session in an in-center setting.
89439104|NCT03547323|Active Comparator|FX80 Dialyzer|One treatment session in an in-center setting.
89439105|NCT03547713|Experimental|Study group|social feedback and neuropsychological assessment
89439106|NCT05576272|Experimental|QL1706 Combined with Gemcitabine and Cisplatin|
89439107|NCT05576272|Active Comparator|Carrilizumab Combined with Gemcitabine and Cisplatin|
88923692|NCT01690338|Active Comparator|cisatracurium|Patients who will be performed general anesthesia and tracheal intubation. Cisatracurium will be used during surgery and tracheal extubation is scheduled when surgery is over.
88923693|NCT01690338|Active Comparator|rocuronium|Patients who will be performed general anesthesia and tracheal intubation. Rocuronium will be used during surgery and tracheal extubation is scheduled when surgery is over.
88923694|NCT01690351|Experimental|PF-05089771 Oral Dispersion fasted|Oral dispersion TS formulation- fasted
88923695|NCT01690351|Experimental|PF-05089771 TS formulation fasted|Capsules TS formulation- fasted
88923696|NCT01690364|Experimental|Cisatracurium Group|MEP monitoring with continuous infusion of cisatracurium during general anesthesia
88923697|NCT01690364|Active Comparator|Vecuronium Group|MEP monitoring with continuous infusion of vecuronium during general anesthesia
88923698|NCT01690377|Experimental|1|PDC or myDC
88923699|NCT01690390|Active Comparator|Icotinib of Routine Dose|Oral Drug icotinib 125 mg three times per day
88923700|NCT01690390|Experimental|Icotinib of High Dose|Oral Drug icotinib 250 mg three times per day
88923701|NCT01690403|Experimental|cohort 1|Period 1 (15 days) : ATRIPLA™ Period 2 (21 days) : ATRIPLA™ + oral rifapentine (regimen 1).
88923702|NCT01690403|Experimental|cohort 2|Period 1 (15 days) : ATRIPLA™ Period 2 (21 days) : ATRIPLA™ + oral rifapentine (regimen 2).
88923703|NCT01690403|Experimental|cohort 3 (optional)|Period 1 (15 days) : ATRIPLA™ Period 2 (21 days) : ATRIPLA™ + oral rifapentine (regimen 3).
88923704|NCT01690416|Active Comparator|Ultrasound DNTP|the catheter will be placed using ultrasound and DNTT and Lidocaine as local anesthesia, by the same fellow as the one who performs the puncture with the traditional method
88923705|NCT01690416|Active Comparator|Traditional palpation technique|arteria cannulation by traditional palpation technique, using preprocedural lidocaine for anesthetic and palpation method by a fellow
88923706|NCT01690429|Other|OSA Patients|
88923707|NCT01690442|Experimental|Couples Based HIV/STI Risk Reduction Intervention (CHSR)|The intervention includes a combination of empowerment and couple self-efficacy building strategies, which are employed to help couples overcome resistance to risk reduction.
89206080|NCT00820560|Experimental|INCB07839 100mg, immediate release (IR) capsules|
89206081|NCT00820560|Experimental|INCB07839 200 mg IR capsules|
89439108|NCT05576116|Experimental|Group 1: Staggered Approach|The first 10 participants enrolled will undergo Sleeve Gastrectomy a minimum of 3 months prior to Pancreas Transplant.
89439109|NCT05576116|Experimental|Group 2: Combined Approach|Eligible participants will undergo SG and pancreas transplantation simultaneously
89012123|NCT00278421|Active Comparator|Interventional: 4 R-CHOP-21 + 2 x R|Arm II: Patients receive R-CHOP as in arm I. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo restaging of their disease. Patients with disease progression proceed to salvage therapy off study. All other patients receive 1 more course of R-CHOP followed by 2 courses of rituximab alone.
89012124|NCT00248768|Other|Arm 1|
89012125|NCT00278499||1|Female sex workers
89012126|NCT00278499||2|Female sex workers' clients (miners)
89012127|NCT00248846|No Intervention|Control Group|This group received follow-up every 2-months for one year. Follow-up included questions about their heart disease progression and how well they had been able to engage in their doctor approved physical activity goal.
89012128|NCT00248846|Experimental|Intervention Group|This group received follow-up every 2-months for one year. Follow-up included questions about their heart disease progression and how well they had been able to engage in their doctor approved physical activity goal, which was the same as the control arm. Additionally, subjects in this arm were encouraged to use positive affect and self-affirmation techniques to motivate an increased level of participation in their physical activity goal. These subjects also received small token gifts to remind them of their study participation.
89012129|NCT00278577|Experimental|Autologous Hematopoietic Stem Cell Transplant|
89012130|NCT00248885|Active Comparator|1|In this group (Low) the goal was to maintain MAP between 50-60 mm Hg during CPB.
89012131|NCT00248885|Experimental|2|In this group (High), the goal was to maintain MAP between 80-100 mm Hg during CPB.
89012132|NCT00285402|Experimental|A|
89012133|NCT00285402|Experimental|B|
89012134|NCT00285402|Placebo Comparator|C|
89012135|NCT00278694|Experimental|Chemoradiation|Neoadjuvant chemotherapy and chemoradiation
89012136|NCT04720508||Group A (patient group)|"included 25 patients with BC admitted to department of medical Oncology, South Egypt Cancer Institute, Assiut University.~blood samples will be obtained after getting informed consent."
89012137|NCT04720508||Group B (control group)|included 25 controls age-matched , sex-matched and apparently healthy. blood samples will be obtained after getting informed consent .
89012138|NCT00249041|Experimental|Etanercept liquid|
89012139|NCT00278772|Experimental|1|Divalproex
89012140|NCT00278772|Placebo Comparator|2|
89439110|NCT05381025|Experimental|Active to Placebo (Cohort 1)|Participants randomly allocated to Cohort 1 for Phase 1 will begin the study taking the active ingredient and will cross-over to taking placebo in Phase 2 of the study after a washout period.
89012141|NCT00285558|Experimental|CBT with peer-enhanced activities|Cognitive behavioral treatment (CBT) with peer-enhanced adventure therapy. The peer intervention, ''adventure therapy,'' is based on the principles of Outward Bound and was expected to affect weight status through a positive effect on self-concept.
89012142|NCT00285558|Active Comparator|CBT with supervised aerobic exercise|Cognitive behavioral treatment (CBT) with supervised aerobic exercise. Activities for the supervised exercise intervention included use of treadmills, stationary bicycles, and other aerobic activities selected by participants, including dance videos and brisk walking within the clinic setting.
89012143|NCT00414713|Active Comparator|1|Regular transfusion
89012144|NCT00414713|Active Comparator|2|Restricted transfusion
89206082|NCT05244694|Experimental|Insulin|Participants will complete a 60 minute hyperinsulinemic-euglycemic infusion.
89206083|NCT00820638|Experimental|1|observational
89206084|NCT04023383|Placebo Comparator|Control|The patients in the control group had 40 cc sterile saline solution compatible with the body temperature.
89439111|NCT05381025|Experimental|Placebo to Active (Cohort 2)|Participants randomly allocated to Cohort 2 for Phase 1 will begin the study taking the placebo and will cross-over to taking the active ingredient in Phase 2 of the study after a washout period.
89439112|NCT05539690|Experimental|Balance training group|A single training group
89439113|NCT05504512||Parapelvic cyst|
89439114|NCT05478460||Group A|Before operation,patients were performed CT -guided hook wire localization(20G×120mm, PAJUNK medizintechnologie, Geisingen in Germany). patients were placed on a CT table in a suitable position(supine, prone, lateral) to obtain the shortest needle insertion route for their initial CT scan. Local anesthesia of the skin and planned puncture tract was performed using 10ml Lidocaine 1%. Next, the needle was inserted into or near the pulmonary nodule.
89439115|NCT05478460||Group B|without hookwire localization
89439116|NCT05337501|Experimental|Patients group|
89012145|NCT02215096|Experimental|Phase 1-Dose Escalation|Subject receiving a stable dose of enzalutamide 160 mg once daily will receive GSK2636771 following a modified 3+3 dose escalation procedure (Cohort -1: 200 mg, Cohort 1: 300 mg and Cohort 2: 400 mg) to evaluate the safety and PK for each combination dose level and to guide selection of the RP2D of the combination. If the combination doses in Cohort 1 are not tolerable, lower doses as defined in the de-escalation cohort (Cohort -1) will be evaluated. If the de-escalation cohort (Cohort -1) is not tolerable, further dose-escalation using a continuous daily dosing schedule for both compounds simultaneously will be terminated. Additional dose levels of GSK2636771 or alternative dosing schedules may be explored based upon ongoing assessment of safety and PK. Dose modification decisions will be made utilizing all available data at the end of each DLT determination period (28 days).
89012146|NCT02215096|Experimental|Phase 2- Dose Expansion|Additional 20 subjects will be assigned to receive GSK2636771 at the MTD or RP2D determined in the Dose-Escalation Phase while continuing treatment with enzalutamide to evaluate the long-term safety of the combination as well as the 12-week non-PD rate
89536992|NCT03303677|Experimental|saline, budesonide, and topical antibiotic|Post operative endoscopic sinus surgery patients using saline + budesonide + topical antibiotic nasal sinus irrigations. The antibiotic would be chosen based on intra operative culture sensitives as is our standard practice. The antibiotic would be selected from Levaquin, Vancomycin, Gentamicin, Ciprofloxacin, Mupirocin, and Trimethoprim/Sulfamethoxazole. All patients will begin with normal saline irrigations immediately following surgery as per our department's standard of care. At their first one week post op appointment they will then begin treatment per the treatment arm.
89012147|NCT02961647||Asymptomatic patients|Patients with asymptomatic severe mitral valve regurgitation not undergoing surgical repair of the valve.
89012148|NCT02961647||Symptomatic patients|Patients with symptomatic severe mitral valve regurgitation undergoing surgical repair of the valve.
89536993|NCT02468063|Experimental|Noradrenaline + low dose terlipressin|
89536994|NCT02468063|Active Comparator|Noradrenaline|
89012149|NCT02215408|No Intervention|Control|Patient received usual care from the provider in the local clinic.
89012150|NCT02215408|Experimental|CVRS Intervention|CVRS pharmacist followed the patient for 12 months in order to decrease the patient's risk of developing cardiovascular disease.
89012151|NCT00249431|Placebo Comparator|Placebo and Relapse Prevention|Patients will be treated with Relapse Prevention Therapy plus placebo
89012152|NCT00249431|Active Comparator|Sertraline and Relapse Prevention|Patients will be treated with Relapse Prevention Therapy plus Sertraline.
89012153|NCT00249587|Experimental|1|Methadone plus behavioral counseling consisting of adherence, self-monitoring, and motivational interviewing
89012154|NCT00249587|Active Comparator|2|Methadone plus behavioral counseling consisting of adherence
88923708|NCT01690442|Active Comparator|Renaissance Wellness Promotion (WP)|This intervention employs a psychoeducational approach to promote wellness, focusing on: maintaining a healthy diet on a low budget, exercising and fitness, stress reducing strategies and specific health related issues that affect IDUs, such as overdose.
88923709|NCT01690455||Cohort|
88923710|NCT01690468|Experimental|Triciribine & Carboplatin|"Phase I/II: 25mg/m^2 Triciribine and Carboplatin AUC 4. Triciribine escalated to 30, 35, 45mg/m^2 if toxicities are not encountered.~Phase II: Recommended phase II dose of triciribine and carboplatin."
88923711|NCT01690494|Experimental|PACT + TAU|4-session PACT delivered to both partners together + standard treatment of care services (TAU) delivered to the male participant
88923712|NCT01690494|Active Comparator|TAU|TAU control condition delivered to the male participant
88923713|NCT01690507|Other|DCAG plus HLI|
88923714|NCT01690533||Group 1|
88923715|NCT01690559||Group 1|Patient treated with Ciproxan without dilution treatment in daily clinical practice
88923716|NCT01690572|Active Comparator|Paclitaxel coated balloon catheter|"Paclitaxel coated balloon catheter IN.PACT Falcon"
88923717|NCT01690572|Active Comparator|uncoated balloon catheter|"uncoated balloon catheter sprinter legend"
88923718|NCT01690585|Experimental|Ferinject 1000 mg|Intravenous Administration of 1000 mg of ferinject Volume of infusion : 250 mL
88923719|NCT01690585|Placebo Comparator|Placebo|Intravenous administration of 250 ml of sodium chlorure 0.9 %
88923720|NCT01690598|Experimental|Veliparib and Topotecan|
88923721|NCT01690611|Experimental|Walking & Visual Feedback|Individuals in this arm will walk on a treadmill while viewing real time visual feedback regarding their body motions and use the visual feedback to correct their body motions.
88923722|NCT01690611|Active Comparator|Walking & No Visual Feedback|Individuals in this arm will walk on a treadmill without viewing real time visual feedback regarding their body motion.
88923723|NCT01690624|Experimental|Patients with relapsed or refractoryAML|Patients with acute myeloid leukemia who have relapsed after 1 prior treatment.
88923724|NCT01690637|Active Comparator|Oseltamivir phosphate suspension|Participants assigned to the oseltamivir phosphate treatment arm will receive the appropriate weight-based dose of oseltamivir phosphate every 12 hours for 10 doses. For children 0-11 months of age, oseltamivir phosphate will be dosed as 3mg/kg/dose every 12 hours. For children 12 months and older, oseltamivir phosphate will be dosed as follows: 30 mg every 12 hours for children up to 15kg, 45mg every 12 hours for children greater than 15kg up to 23 kg, 60mg every 12 hours for children greater than 23 up to 40kg, and 75mg every 12 hours for children greater than 40kg.
88923725|NCT01690637|Placebo Comparator|Placebo|
88923726|NCT01690650|Experimental|Oxygen + Cerebral NIRS|Induced changes in oxygen supply (100% vs. room air). Continuously monitoring of cerebral oxygen saturation.
88923727|NCT01690676|Active Comparator|Epicatechin|The subjects will receive the study product and corresponding placebo once a day for 4 weeks in randomised order. There will be a four to five-weeks wash-out between the treatment periods.
88923728|NCT01690676|Placebo Comparator|Microcrystalline cellulose|The subjects will receive the study product and corresponding placebo once a day for 4 weeks in randomised order. There will be a four to five-weeks wash-out between the treatment periods.
88923729|NCT01690689|Experimental|Surgery|Implant surgery
88923730|NCT01690702|Active Comparator|dtEC-dtD|Epirubicin and Cyclophosphamide with a tailored dose 4 cycles q2w followed by one additional week followed by Docetaxel with a tailored dose 4 cycles q2w.
88923731|NCT01690702|Experimental|EnPC|Epirubicin 150mg/qm 3 cycles q2w followed by nabPaclitaxel 260-330mg/qm (to be determined in run-in-phase) 3 cycles q2w followed by Cyclophosphamide 2000mg/qm 3 cycles q2w
88923732|NCT01690741|Experimental|Nerofe|Nerofe administered intravenously 3x/week
88923733|NCT01690754|No Intervention|Control|This arm will receive the regular standard of care given by TB clinics.
88923734|NCT01690754|Experimental|Interactive Reminders|Patients randomized to this arm will receive Interactive SMS reminders daily.
88923735|NCT01690767|Experimental|Topical and intraurethral 2% lidocaine|2% lidocaine gel will be applied for 5 minutes to the external urethral opening. This will be followed immediately by 2% lidocaine gel administration into the urethra using a 24 gauge angiocath for 5 minutes prior to catheterization for urine specimen collection. Children < 7 kg and > 7 kg will receive 1 cc and 1.5 cc, respectively.
88923736|NCT01690767|Active Comparator|Standard of care|According to standard nursing practice, the urethra will be catheterized without anaesthetic gel but using lubricant gel only. Intervention is Health Care Lubricating Jelly.
88923737|NCT01690780|Active Comparator|Ibuprofen|
88923738|NCT01690780|Experimental|Oral morphine|
88923739|NCT01690806||dexamethasone|Patients who receive dexamethasone (8 mg; Decadron; Merck Sharp & Dohme) intravenously 90 min before skin incision
88923740|NCT01690806||placebo|Patients who receive saline placebo intravenously 90 min before skin incision
89439117|NCT05543980|Sham Comparator|Sham control|Participants will be provided a leg heat therapy system and will be instructed to apply the therapy daily (90 min/day) for 12 consecutive weeks. The water heater will circulate water at 33ºC.
88923741|NCT01690819|Active Comparator|Conventional Ventilatory Strategy|Conventional Ventilatory Strategy
88923742|NCT01690819|Experimental|Protective Ventilatory Strategy|Protective ventilatory strategy
88923743|NCT01690832|Active Comparator|standard saline infusion|standard i.v. 1 ml/kg/h saline infusion from 6 hours before the procedure to 12 hours after the procedure.
88923744|NCT01690832|Active Comparator|fenoldopam infusion|combination of i.v. 1 ml/kg/h saline infusion and fenoldopam administration (0.08 mcg/Kg/min) from 6 hours before the procedure to 12 hours after the procedure.
88923745|NCT01690845|No Intervention|Control|Patients with severe HH will be treated with standard medical therapy (i.e. vasopressor support with norepinephrine in refractory hypotension = RR mean < 65 mmHg, positive inotropic support with dobutamine if the central venous oxygen saturation < 70%, renal replacement therapy in case of severe metabolic acidosis and/or renal failure, antibiotic treatment in case of suspected or proven infection, mechanical ventilation in case of severe hypoxemia or hypercapnia and/or GCS <= 8.
88923746|NCT01690845|Experimental|MARS-Group|20 patients will be allocated by randomization to the MARS arm. Additionally to standard medical therapy they will receive 4 MARS sessions on three consecutive days, MARS® therapy will be applied for at least 12 hours per session. Thereafter, MARS® treatment will be continued if the patient still has increasing aminotransferase levels, requires vasopressor support or suffers from cholestasis (defined as serum bilirubin levels > 5 mg/dL) for 3 sessions again. There will be a maximum of 7 MARS ® sessions per patient.
88923747|NCT01690858||females with medical history of repeated foetal losses|The females can be pregnant
88923748|NCT01690858||females without medical history of repeated foetal losses|The females can be pregnant
88923749|NCT01690871|Experimental|BEZ235|BEZ235 will be supplied in 200mg, 300mg and 400mg sachets packaged in boxes. Each box will contain only sachets of one strength.
88923750|NCT01690884|Placebo Comparator|Placebo|To determine if there is an increase in adenosine interstitial levels in the forearm.
88923751|NCT01690884|Active Comparator|Dipyridamole|To determine if there is an increase in adenosine interstitial levels in the forearm.
88923752|NCT01690884|Experimental|Ticagrelor|To determine if there is an increase in adenosine interstitial levels in the forearm.
88923753|NCT01690897|Experimental|MBCT group|Women randomized into the MBCT group will undergo pre-treatment testing (questionnaires, saliva sample collection, and physiological assessment) within 2.5 months of beginning the mindfulness-based treatment.
88923754|NCT01690897|Active Comparator|Support group|Women randomized into the support group will undergo pre-treatment testing (questionnaires, saliva sample collection, and physiological assessment) within 2.5 months of beginning the sex therapy, education, and support treatment.
88923755|NCT01690936|Experimental|Breakfast|Almonds (43g/day) were consumed with breakfast for four weeks.
88923756|NCT01690936|Experimental|Morning snack|Almonds (43g/day) were consumed alone as morning snacks for four weeks.
88923757|NCT01690936|Experimental|Lunch|Almonds (43g/day) were consumed with lunch for four weeks.
88923758|NCT01690936|Experimental|Afternoon snack|Almonds (43g/day) were consumed alone as afternoon snacks for four weeks.
88923759|NCT01690936|No Intervention|Control no nuts|Avoided all nuts and seeds
88923760|NCT01690949|Experimental|PUR118 low dose|
88923761|NCT01690949|Experimental|PUR118 mid dose|
88923762|NCT01690949|Experimental|PUR118 high dose|
88923763|NCT01690962|Experimental|Vegan diet and vitamin B12 supplement|The diet/supplement group will be asked to follow a low-fat, vegan diet for 20 weeks, and take a vitamin B12 supplement daily.
88923764|NCT01690962|Active Comparator|Vitamin B12 supplement|The supplement group will be asked to take a daily vitamin B12 supplement, and to make no changes to their current diet.
88923765|NCT01690975|Placebo Comparator|Placebo|Placebo Control
88923766|NCT01690975|Experimental|Benzonatate|Benzonatate Active
88923767|NCT01691001|Experimental|dexmedetomidine|
88923768|NCT01691001|Placebo Comparator|placebo group|normal saline
88923769|NCT01691040|Experimental|Open-label pilot group|Twice weekly administration of NOX-H94
88923770|NCT01691053|Active Comparator|Spironolactone|
88923771|NCT01691053|Placebo Comparator|Placebo|
88923772|NCT01691066|Experimental|Infant Toddler Years PRT|Infant Toddler PRT in an evidence-based, manualized treatment for children with autism spectrum disorder that involves specific motivational behavioral procedures adapted to be developmentally appropriate for 12-15 month old infants who present with developmental delays.
88923773|NCT01691066|No Intervention|Community Treatment|Community Treatment includes the treatments offered by early intervention services (e.g., speech-language therapy, special education instruction).
88923774|NCT01691118|Active Comparator|Fimasartan|Fimasartan 60mg qd added on conventional antihypertensive treatment for 10 months.
88923775|NCT01691118|Placebo Comparator|Placebo|Conventional antihypetensive treatment
88923776|NCT01691131|Other|Exercise training on land|High intensity exercise training on land.
88923777|NCT01691131|Other|Exercise training on water|High intensity exercise training on water.
88923778|NCT01691157|Active Comparator|Usual physiotherapy without exercise|Will receive 6 sessions of modified usual physiotherapy care that can consist of any physiotherapeutic modalities normally provided except exercise. this may consist of postural advice, taping, electrotherapy, acupuncture, manual joint mobilizations of the shoulder, cervical or thoracic spine.
89439118|NCT05543980|Experimental|Heat therapy|Participants will be provided a leg heat therapy system and will be instructed to apply the therapy daily (90 min/day) for 12 consecutive weeks. The water heater will circulate water at 42ºC.
88923779|NCT01691157|Experimental|Exercise|Will receive an evidence based exercise protocol but no other physiotherapeutic modalities
88923780|NCT01691170|Active Comparator|Quadriceps Strengthening|
88923781|NCT01691170|Active Comparator|Stretching Hamstring|
88923782|NCT01691183||Study Subjects|Subjects with or without orbital disease that present to clinic for scheduled appointments.
88923783|NCT01691209|Experimental|Phoenix|Application over 29 days twice daily
89439119|NCT04725981|Experimental|Arm A (test surgical technique)|Colpotomy closure technique: 3 Z-suture with PDS 0 and 1 continuous suture with V-Loc 2-0
89439120|NCT04725981|Active Comparator|Arm B (control surgical technique)|Colpotomy closure technique: 3 Z-suture with PDS 0
88923784|NCT01691209|Active Comparator|Hydrocortison|Application over 29 days twice daily
88923785|NCT01691209|No Intervention|Untreated skin|Participants will be observed over 29 days without study treatment
88923786|NCT01691222|Other|Double lumen endotracheal tube tracheostomy|Tracheostomy with a dedicated double lumen endotracheal tube
88923787|NCT01691235||Arm 1|Subjects in this arm will receive their medication (telaprevir, interferon and ribavirin) dispensed using the Simpill device. The study staff will have access to data from the device during therapy and will be able to give subjects feedback on adherence during the course of therapy. The study team will refill the device as the medication is needed. The device will be configured to remind a subject each time a dose is missed. Subjects in this study arm will receive a text message each time a dose of medication is missed. This message will only go to the telephone number specified by the subject and will not go to members of the study team.
88923788|NCT01691235||Arm 2|Subjects in this arm will receive their medication (telaprevir, interferon and ribavirin) as standard of care therapy where the SIMpill device will not be used.
88923789|NCT01691274|Experimental|PF-04895162|
88923790|NCT01691274|Placebo Comparator|Placebo|
88923791|NCT01691287|Experimental|Michael Method|14 group meeting, taking place once a week during 14 consecutive weeks
88923792|NCT01691300|Experimental|ACT PET/CT|Dual-tracer ACT/FDG PET/CT and WB-DCE-MRI at baseline (pretreatment), post-induction and post-ASCT (if eligible)
88923793|NCT01691352|Active Comparator|Wick|Patients with wick placed in their wound at the time of ostomy reversal
88923794|NCT01691352|Sham Comparator|No wick|patients with non-wicked dressing placed on their wound
88923795|NCT01691365|Active Comparator|vitamins pills|"antioxidant and B vitamins vitamins vitamin~--------------------------------------------------------------------------------"
88923796|NCT01691365|Placebo Comparator|pills|MICROCRYSTALLINE CELLULOSE
88923797|NCT01691391||Advanced CRC, candidates for anti-EGFR antibody monotherapy|Patients with histopathologically confirmed advanced CRC with K-Ras and BRAF wild type, aged ≥ 18 years, with a life expectancy of at least 12 weeks, who are candidates for anti-EGFR antibody monotherapy (3rd line palliative treatment).
88923798|NCT01691404|Active Comparator|Epicatechin|Subjects will be asked to consume supplements containing 100mg of epicatechin daily
88923799|NCT01691404|Active Comparator|Quercetin|Subjects will be asked to consume supplements containing 160mg of quercetin-3-glucoside daily
88923800|NCT01691404|Placebo Comparator|Placebo|Subjects will be asked to consume capsules containing a placebo (cellulose) daily
88923801|NCT01691417|Experimental|Pneumatic Sleeves|
88923802|NCT01691417|Experimental|Congestive Heart Failure Patients|
88923803|NCT01691443|Experimental|Use of the glove|The subject wear the glove for the time of the trial
88923804|NCT01691456|Experimental|Montelukast Sodium Oral Granules|Montelukast Sodium Oral Granules 4mg of Dr. Reddy's Laboratories Limited
88923805|NCT01691456|Active Comparator|SINGULAIR|(Montelukast sodium) Oral Granules 4mg of Merck Sharp & Dohme Ltd., USA
88923806|NCT01691469|Experimental|Montelukast Sodium Oral Granules|Montelukast Sodium Oral Granules 4mg of Dr. Reddy's Laboratories Limited
88923807|NCT01691469|Active Comparator|SINGULAIR|(Montelukast sodium) Oral Granules 4mg of Merck Sharp & Dohme Ltd., USA
89439121|NCT05543902|Experimental|Intervention group: Breastfeeding Problems Management Model (BPMM)|The women in the intervention group were provided with nursing interventions according to the BPMM by the researcher. LATCH (pre-test) was administered before discharge from the hospital; women were given the education booklet; and their contact information was recorded. After discharge from the hospital, the women were called by phone in the 1st, 2nd, and 6th weeks, BES was read, and the scale was filled in by the researcher based on the women's responses. Women who were found to experience breastfeeding problems in these phone calls were provided with consultancy and home visits. In the 8th week, home visits were done and the education was repeated. The women were administered the BES, LATCH (post-test), and BMS.
89439122|NCT05543902|No Intervention|No Intervention: Standard care group|The women in standard care group were not provided with any interventions by the researcher. They were provided with standard care at the hospital. Before discharge from the hospital, the LATCH (pre-test) was administered and women's contact information was recorded. After discharge from the hospital, the women were called by phone in the 1st, 2nd, and 6th weeks. BES were read on the phone, and the scale was filled in by the researcher based on the women's responses. Home visits were performed in the 8th week, and the women were administered the BES, LATCH (post-test), and BMS
89199390|NCT05672797|Experimental|Wellth|Participants will be eligible to receive $30 at the end of three consecutive 30-day periods ($90 in total) if they demonstrate complete medication adherence through the Wellth app (i.e. taking a daily picture of their pills in their hand and submitting it through the Wellth app). Photos must be submitted within a 4-hour window around a specific time of day chosen by the participant and set at the start of each 30-day period. They will lose $2 (from their $30 total) for every day they miss a medication check-in within their pre-set 4-hour window with the Wellth app. The Wellth app will also provide reminders at the end of the day if participants have not yet completed their daily check-in.
89199391|NCT05672797|Experimental|Wellth + Habit Training|Participants will also be eligible for $30 at the end of three consecutive 30-day periods ($90 in total) if they submit daily evidence of their medication adherence habit using the Wellth app (i.e. one photo that provides evidence of pill-taking and one photo that provides evidence of their contextual cue, which participants will select and specify on their comprehension survey at the start of the study). Similar to T1, participants will lose $2 (from their $30 total) for every day they miss a check-in with the Wellth app within a 4-hour window around the time of day of their choosing at the start of each 30-day period. Participants will not have to pay money, i.e. they lose $2 per missed check-in from the $30 of incentives until their incentives equal $0. Thus, participants will be ineligible for any financial incentives if they miss more than 15 days in a 30-day period, where this group's check-in includes one photo of pill-taking and one photo of their contextual cue.
89199392|NCT05667129|Experimental|XEN-101|Capsule formulation
88923808|NCT01691495||Superficial Vein Thrombosis (SVT)|A representative of geographical regions of patients with Superficial Vein Thrombosis (SVT) who live in several EU countries.
88923809|NCT01691547|Experimental|UMEC/VI+FF|UMEC (500 µg)/VI(100 µg) (blended together) and FF (400 µg) will be administered as single dose (4 inhalations); as dry powder in NDPI device once in 7 days in one of the 4 Treatment Periods of the study.
88923810|NCT01691547|Experimental|UMEC+VI|UMEC (500 µg) and VI (100 µg) will be administered as single dose (4 inhalations); as dry powder in NDPI device once in 7 days in one of the 4 Treatment Periods of the study.
88923811|NCT01691547|Experimental|FF+VI|FF (400 µg) and VI (100 µg) will be administered as single dose (4 inhalations); as dry powder in NDPI device once in 7 days in one of the 4 Treatment Periods of the study.
88923812|NCT01691547|Experimental|FF+UMEC|FF (400 µg) and UMEC (500 µg) will be administered as single dose (4 inhalations); as dry powder in NDPI device once in 7 days in one of the 4 Treatment Periods of the study.
88923813|NCT01691586|Experimental|Remote patient management|Remote patient management system + yearly in-clinic follow-up
88923814|NCT01691586|Other|In-Clinic follow-up|In-clinic follow-up according to standard practice (every 3-6 months)
88923815|NCT01691599||Tibia fractures|Patients with open and closed tibia fracture treated with internal fixation in India
89199393|NCT05667129|Placebo Comparator|Placebo|Capsule formulation
89199394|NCT05661500|Experimental|Creative Darama Group|"Postmortem care content including The concept of death, Postmortem Care, Postmortem Care and Postmortem Care Practices will be given to the students in the Creative Darama group in six sessions consisting of the preparation/warm-up, animation and evaluation stages of creative drama."
89199395|NCT05661500|Active Comparator|Classical Education Group|"Theoretical training titled Post-Death Care and The Concept of Death, Post-Death Changes, Post-Death Care and Post-Death Care Practices will be conveyed to the students in the classical education group by the researcher using the method of direct expression. After the theoretical training, the students will be taken to the application laboratory and post-mortem care applications will be explained with the demonstration method."
89199396|NCT05658380|Active Comparator|atropine|
89199397|NCT05658380|Placebo Comparator|normal saline|
89199398|NCT05650957||Non-COVID-19 ARDS|To be included in this analysis the cause for ARDS was a pulmonary infection other than COVID-19 and meeting all aspects of the Berlin definition.
89199399|NCT05650957||COVID-19 ARDS|To be included in this analysis the cause for ARDS was COVID-19 and meeting all aspects of the Berlin definition.
89199400|NCT05649800||Healthy|Healthy adults ages over 65 years
89536995|NCT03303599||HCV Genotypes 1, 2, 3, 4, 5, or 6 participants|Participants receiving combination therapy with the glecaprevir plus pibrentasvir (GLE/PIB) regimen according to standard of care, international guidelines and in line with the current local label.
88923816|NCT01691625|Experimental|concurrent chemoradiotherapy plus DC-CIK immunotherapy|patients will receive concurrent chemoradiotherapy plur DC-CIK immunotherapy
88923817|NCT01691625|Active Comparator|Concurrent chemoradiation only|patients will receive concurrent chemoradiotherapy only
88923818|NCT01691638||Periodontitis|
88923819|NCT01691638||Control|
88923820|NCT01691651|Active Comparator|Botulinum toxin type A|The group that will be subjected to the injection of botulinum toxin (subcutaneous injection of botulinum toxin type A).Subcutaneous botulinum toxin A injection will be performed in this group, (2.5 units per point application), at two points in a nasal and temporal extent of the orbicularis muscle.
88923821|NCT01691651|No Intervention|Control|The group that will not be subjected to any intervention.
89199401|NCT05649800||Stroke|Stroke patients aged over 65 years
89199402|NCT05649800||Dementia|Dementia patients aged over 65 years
89199403|NCT05649800||Depression|Depression patients aged over 65 years
89199404|NCT05649800||Delirium|Delirium patients aged over 65 years
89199405|NCT05647902||Healthy Group|70 systemically healthy patients; 35 healthy gingiva is divided into 2 subgroups, 35 of which are periodontitis. Asprosin levels will be examined biochemically in serum samples taken from patients.
89199406|NCT05647902||Myocard Infactus Group|50 patients with myocardial infarction; 25 healthy gingiva is divided into 2 subgroups, 25 of which are periodontitis. Asprosin levels will be examined biochemically in serum samples taken from patients.
89199407|NCT05646251|Experimental|EC-LBBAP Participant|A heart ultrasound will be used during a pacemaker implant procedure
89199408|NCT05646251|No Intervention|Control participant|A pacemaker will be implanted using routine protocol. This is retrospectively collected; patients are not actively enrolled in this arm.
89199409|NCT05642052|Sham Comparator|10 days control diet|Participants stay on their regular diet while glucose is continuously monitored, heart rate and number of steps is measured for 10 days.
89439123|NCT05543824||Epidural and arterial catheter|Patients who require placement of an epidural catheter to control postoperative pain and invasive blood pressure will be identified, allowing advanced monitoring using the MostCare Up® device. After identification, the objective of the study will be explained and their consent will be requested to collect the data after the intervention, recording the hemodynamic data before and after the initial bolus of local anesthetic administered: 0.25% levobupivacaine, the dose of which is calculated with the Takasaki formula: 0.05ml x weight (kg) x number of dermatomes to anesthetize.
89439124|NCT05698420||The Theranova 400 group, also known as the MCO group.|Patients undergoing maintenance hemodialysis will receive dialysis treatment using the Theranova 400 device.
89439125|NCT05698420||The FX80 group, also known as the high-flux group.|Patients undergoing maintenance hemodialysis will receive dialysis treatment using the FX80 device.
89439126|NCT04703673||Sinolpan® group|Sinolpan® group: patients suffering from rhinosinusitis and, where appropriate, from bronchitis; intake of Sinolpan® 100 mg or Sinolpan® forte 200 mg (cineol) according to the instructions for use; before and after treatment for rhinosinusitis and, where appropriate, from bronchitis, patients complete a questionnaire that contains the Rhinosinusitis Quality of Life questionnaire and Questions about the severity of bronchitis symptoms. The latter should only be answered by patients who suffer from bronchitis in addition to rhinosinusitis.
89439127|NCT04703673||Nasal spray group|Control group: patients with rhinosinusitis; Use of nasal decongestants according to the instructions for use. Before and after treatment for rhinosinusitis, patients complete a questionnaire that includes the Rhinosinusitis Quality of Life questionnaire.
88923822|NCT01691664|Active Comparator|Only radiation therapy|Radiotherapy:Patients will be conducted CT simulation, and three-dimensional conformal radiation therapy (3DCRT) or Intensity-modulated radiation therapy(IMRT)was performed. 1.8-2.0 Gy/fraction, 5 fractions a week, with a total dose of 50Gy will be delivered for all patients by 6-MV-X-ray of linear accelerator.
88923823|NCT01691664|Experimental|Radiation therapy plus DC-CIK cellular therapy|"Radiotherapy:Patients will be conducted CT simulation, and three-dimensional conformal radiation therapy (3DCRT) or Intensity-modulated radiation therapy(IMRT)was performed. 1.8-2.0 Gy/fraction, 5 fractions a week, with a total dose of 50Gy will be delivered for all patients by 6-MV-X-ray of linear accelerator.~DC-CIK cellular therapy:Mononuclear cells were collected aseptically with blood cell separator composition apheresis 3 days before radiation, and cultured DC-CIK cells for 10 days. Cells were infused back to the patients in 3 times between the radiation intermittent period."
89439128|NCT03526536|Other|Patients with diabetes and ESRD|Patients with diabetes and end stage renal disease (ESRD)
89439129|NCT03526536|Other|Patients with diabetes and no ESRD|Patients with diabetes and no end stage renal disease (ESRD)
88923824|NCT01691677|Experimental|beclomethasone dipropionate|beclomethasone dipropionate 800 mcg/2 ml suspension for nebulization,one administration b.i.d. for 14 days
88923825|NCT01691677|Placebo Comparator|placebo|placebo 2 ml suspension for nebulization, one administration b.i.d. for 14 days
89012155|NCT04720352|Sham Comparator|Sham Comparator|Sham delivers non therapeutic levels of radiofrequency and cryogen
89012156|NCT04720352|Experimental|Active Arm|Active arm delivers radiofrequency and cryogen
89012157|NCT00249704|Experimental|C|
89012158|NCT00249704|Experimental|B|
89012159|NCT00249704|Experimental|A|
89012160|NCT00249704|Placebo Comparator|D|
89012161|NCT00249860|Experimental|Interferon-beta-1a|
89439130|NCT05543590|Experimental|Experimental group: receiving plasmapheresis|
89439131|NCT05543590|Other|Control group : no treatment|
89439132|NCT03512184|Other|YMCA Class|This Arm's objective is to determine the effect of the YMCA's Diabetes Prevention Program on NAFLD as determined by comparison of liver enzymes pre- and post- program.
89439133|NCT05573529|Experimental|Edof IOL vs. multifocal IOL I|The investigational devices are approved intraocular lenses (IOLs) intended to be implanted after phacoemulsification in individuals suffering from age-related cataract with the need of cataract surgery. In Arm one (I) participants will receive Edof IOL one (I) vs. multifocal IOL one (I).
89439134|NCT05573529|Experimental|Edof IOL vs. multifocal IOL II|The investigational devices are approved intraocular lenses (IOLs) intended to be implanted after phacoemulsification in individuals suffering from age-related cataract with the need of cataract surgery. In Arm two (II) participants will receive Edof IOL one (I) vs. multifocal IOL two (II).
89439135|NCT03546309|Experimental|RIC group|Patients allocated to the RIC group will undergo RIC procedure during which bilateral arm cuffs are inflated to a pressure of 50 mmHg over systolic blood pressure for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
88923826|NCT01691703|Experimental|Videolaryngoscope and Bonfils|First, the Macintosh videolaryngoscope (Karl Storz, Tuttlingen, Germany) will be used to achieve the best possible view and space of the laryngeal inlet for the insertion and manoeuvring of the Bonfils® (Karl Storz, Tuttlingen, Germany). Once the anaesthesiologist considers the view achieved to be the best view possible, a picture will be taken using C-CAMTM for C-MAC (Karl Storz, Tuttlingen, Germany), not showing any part of the videolaryngoscope. Thereafter the Bonfils® intubation scope, which will be preloaded with the endotracheal tube, will be brought into position in front of the laryngeal inlet. Again a picture not showing any part of one of the two devices will be taken. Once the Bonfils® has entered the trachea, the tracheal tube will be placed in the correct position.
88923827|NCT01691716|Experimental|Tendoactive|Tendoactive dosage: 3 capsules per day
88923828|NCT01691716|Active Comparator|Eccentric training|Protocol published by Alfredson et al 1998 (Am J Sports Med 1998 26: 360)
88923829|NCT01691716|Active Comparator|Tendoactive and eccentric training|Tendoactive dosage: 3 capsules per day. Eccentric training: protocol described by Alfredson et al 1998 (Am J Sports Med 1998 26: 360)
88923830|NCT01691742|Placebo Comparator|Placebo|Placebo maltodextrin 17g powder daily for 5 days postoperatively following urogynecologic surgery
88923831|NCT01691742|Active Comparator|MiraLax|MiraLax 17g powder daily for 5 days postoperatively following urogynecologic surgery
88923832|NCT01691807|Experimental|Arm A|bendamustine and ofatumumab treatment of NHL
88923833|NCT01691807|Experimental|Arm B|ofatumumab only treatment of NHL
88923834|NCT01691872|Experimental|Japanese|Retigabine 300mg single-dose
88923835|NCT01691872|Experimental|Caucasian|Retigabine 300mg single-dose
89012162|NCT00249860|Active Comparator|Ribavarin plus interferon-beta-1a|
89012163|NCT00249899|Experimental|Lapaquistat Acetate 100 mg QD|(and stable statin therapy)
89439136|NCT03546309|Sham Comparator|sham group|patients allocated to the sham group will undergo a sham RIC procedure during which bilateral arm cuffs are inflated to a pressure of 30 mmHg for five cycles of 5 min, followed by 5 min of relaxation of the cuffs.
89012164|NCT00249899|Active Comparator|Stable statin therapy|
89012165|NCT00279435|Placebo Comparator|placebo|
89439137|NCT05439850|Active Comparator|Control Group|Surgical treatment alone, consisting of arthroscopic rotator cuff repair. Ultrasound postoperatively at 1 year.
89439138|NCT05439850|Experimental|Study Group|Identical surgical treatment as control group plus bio-inductive patch implant. Ultrasound postoperatively at 1 year.
89439139|NCT03524586|Experimental|Ipsilateral rotation of head|Head was laterally rotated to the same side against fixed tube
89439140|NCT03524586|Active Comparator|Contralateral rotation of head|Head was laterally rotated to the opposite side against fixed tube
89439141|NCT03526380|Experimental|Treatment|Participants receive the OPT-IN Brief Intervention.
89439142|NCT03526380|No Intervention|Control|Participants will only complete the baseline and follow-up surveys.
89012166|NCT00279435|Experimental|visilizumab|
89439143|NCT05539222|Active Comparator|Food voucher plus health and nutritional education|Intervention and control group individuals received 120 euros/month during 3 months in food vouchers to be spent in supermarkets (60 euros/month if under 12y) plus a 10-week nutrition education for the intervention group.
89439144|NCT05539222|No Intervention|Food voucher|Intervention and control group individuals received 120 euros/month during 3 months in food vouchers to be spent in supermarkets (60 euros/month if under 12y) plus a 10-week nutrition education for the intervention group.
89012167|NCT00286026|Experimental|Arm 1|Subjects residing in villages assigned to treatment arm 1 will receive a clinical evaluation for trachoma and provide a swab specimen of conjunctivae of the R eye at enrollment (Day 0); will be treated with Azithromycin at Day 30; will be re-screened (clinical evaluation and swab specimen of R eye collected) at Day 60; and again at Day 360.
89012168|NCT00286026|Experimental|Arm 2|Subjects residing in villages assigned to treatment arm 2 will receive a clinical evaluation for trachoma and provide a swab specimen of conjunctivae of the R eye at enrollment (Day 0), as well as receive an initial treatment with Azithromycin; will receive a second dose of Azithromycin at Day 30; will be re-screened (clinical evaluation and swab specimen of R eye collected) at Day 60; and again at Day 360.
89439145|NCT05543434|Experimental|hyaluronic acid|Application of crosslinked HA gel in pockets after subgingival debridement immediately and one week after.
89439146|NCT05543434|Active Comparator|scaling and root planing|scaling and root planing using ultrasonic scaler and hand instruments.
89439147|NCT01567449||the case group|The case group referred to SAH patients with aneurysm rebleeding
89439148|NCT01567449||the control group|the control group referred to SAH patients not with aneurysm rebleeding
89439149|NCT04963140|Experimental|Intervention|Intervention subjects will monitor their lung function daily by Forced Oscillation Technique (FOT) device. The embedded algorithm signals when an increased risk of exacerbation is detected and subjects shall modify their treatment based on the action plan prescribed by the study doctor at enrolment and used for the self-management of their asthma
89439150|NCT04963140|Sham Comparator|Control|Control subjects will monitor their lung function daily by Forced Oscillation Technique (FOT) device. The embedded algorithm used in the intervention arm is disabled. Subjects will follow the action plan prescribed by the study doctor at enrolment for the self-management of their asthma
89439151|NCT05289141||Patients treated by high flow nasal oxygen therapy (Optiflow™)|
89439152|NCT05289141||Patients treated by other non-invasive ventilation or high concentration oxygen masks|
89439153|NCT05539144|Experimental|new delineation approach for oral cavity, oropharynx, larynx and hypopharynx.|An investigative IMRT plan was generated based on a standard treatment planning protocol, but used a new delineation approach for oral cavity, oropharynx, larynx and hypopharynx.
89439154|NCT04675047||healthy control|healthy control
89012169|NCT02961608|Experimental|study group|
89012170|NCT00286104|Active Comparator|1|Bactiseal ventricular catheter (Rifampicin- and Clindamycin-impregnated)
89012171|NCT00286104|Placebo Comparator|2|Plain ventricular catheter
89012172|NCT00286143|Active Comparator|A|Fentanyl added to Bupivacaine via epidural catheter.
89012173|NCT00279630|Experimental|type of exericse|type of exercise
89012174|NCT00250406|Active Comparator|1|Percuflex Plus Ureteral Stent
89012175|NCT00250406|Experimental|2|TRIUMPH stent (triclosan-eluting stent)
89012176|NCT02960841|Experimental|Intracavitary Manual Lymphatic Drainage|Intracavitary Manual Lymphatic Drainage technique.
89012177|NCT02960841|Active Comparator|Conventional treatment|Conventional treatment active comparator
89199410|NCT05642052|Active Comparator|10 days low carb diet|Participants will eat a low carb diet while glucose is continuously monitored, heart rate and number of steps is measured for 10 days.
89439155|NCT05539066|Experimental|AI health assistant|An AI health assistant suitable for diabetes patients has been developed. It has the functions of automatically uploading blood pressure, blood glucose data, intelligent reminder, automatic analysis of reports inside and outside the hospital, intelligent question and answer, etc. it is simple to operate, highly interactive, and maximizes the management level of diabetes patients outside the hospital.
89439156|NCT05539066|No Intervention|Routine treatment group|Perform routine management and follow-up without using AI health assistant
89439157|NCT05538988|Experimental|Cemiplimab|Study treatment includes administration of cemiplimab 350 mg intravenous every 21 days (+/﹣ 3 days)
89439158|NCT04467060|Experimental|Anaprazole Sodium enteric-coated tablet|Single ascendinng dose (2.5mg, 5mg, 10mg, 20mg, 40mg, 80mg, 120mg, 160mg), fasting oral administration.
89439159|NCT04467060|Placebo Comparator|Placebo|single dose, fasting oral administration
89439160|NCT04667637|Placebo Comparator|0.9% NaCl|Intravenous injections of 0.9% NaCl BID for 12 ±2days.
89439161|NCT04667637|Experimental|Edaravone Dexborneol|Intravenous injections of edaravone dexborneol (37.5mg in 0·9% NaCl) BID for 12 ±2days.
89439162|NCT03871894|Active Comparator|Control arm|This is the group of critically ill cirrhotic patients on mechanical ventilator support who would receive the nutritional therapy as per the standard enteral nutritional practice in a critical care setting in cirrhotics till the period admitted in ICU(Intensive care unit) 35-40 Kcal/Kg IBW/day; 1.5g protein per kg per day.
89206085|NCT04023383|Experimental|HyaRegen NCH gel group|In the intervention group had 40 mL of HyaRegen NCH gel instilled into the peritoneal cavity through a large-bore cannula following standard laparoscopic procedures.
89206086|NCT03989843||Frozen embryo transfer|Frozen embryo transfer
89536996|NCT03305393|Other|Adaptiv CRT|Adaptiv CRT algorithm in Medtronic FDA approved CRT devices to be programmed as ON at 6 month follow-up visit
89536997|NCT03305315||Cases|Diseases of the temporomandibular joint
88923836|NCT01691911|Experimental|Remote preconditioning|Preconditioning will be performed in the same manner as several previous trials. Immediately after induction of anaesthesia, a standard, CE-approved blood pressure cuff will be placed around one arm of the patient. It will then be inflated to a pressure of 200mmHg for 5 minutes. For patients with a systolic blood pressure >185mmHg, the cuff will be inflated to at least 15mmHg above the patient's systolic blood pressure. The cuff will then be deflated and the arm allowed reperfuse for 5 minutes. This will be repeated so that each patient receives a total of 4 ischaemia-reperfusion cycles. In all other respects, the procedure and peri-operative care will follow the routine practices of the surgeons and anaesthetists involved.
88923837|NCT01691911|No Intervention|Remote preconditioning control|Patients randomised to this group will receive routine pre-operative, peri-operative and post operative care.
88923838|NCT01691924|Placebo Comparator|Placebo|Placebo capsules: solid microcrystalline cellulose c.s.p
88923839|NCT01691924|Experimental|PBF-509|The initial dose-escalation scheme includes the following eight doses: 10 mg, 20 mg, 40 mg,80 mg, 160 mg, 320 mg, 480 mg and 620 mg. This dose-escalation scheme has been built with the aim to reach the Minimum Intolerated Dose (MID), i.e. when investigator should stop escalating, and consequently the MTD.
88923840|NCT01691937|Experimental|PVB + PCA|Continuous Paravertebral block with ropivacaine and Patient-controlled analgesia with sufentanil
88923841|NCT01691937|Placebo Comparator|Placebo PVB + PCA|Continuous Paravertebral Block with Saline and Patient-controlled analgesia with sufentanil
89012178|NCT04720235|Other|Subject Self-Collection and Specimen Testing|Subjects will be provided with the Lucira COVID-19 Test Kit and collect one (1) nasal swab according to the QRI and test the sample on the Lucira COVID-19 All-In-One Test. HCP will observe subject during this process and document any observations and deviations from the QRI.
89012179|NCT00250523||Traumatic injury|ICU Patients with blunt or penetrating injury
89012180|NCT00250523||2|Healthy volunteers
89206087|NCT03989843||Fresh embryo transfer|Fresh embryo transfer
89206088|NCT00626028|Experimental|Nitric Oxide First, Oxygen Last|10 minute dose of Nitric Oxide (NO) at 80 ppm, then 10 minute dose of NO plus Oxygen, then 10 minute washout, then 10 minute dose of 100% Oxygen on Day 1.
89536998|NCT03305315||Controls|Asymptomatic subjects
89536999|NCT03303443||Younger|20-40 years old patients
89537000|NCT03303443||Elderly|over 60 years old patients
89537001|NCT03303365|Experimental|Treatment based on SPACE MRI sequence|Cyberknife SRS of all suspect intracranial lesions visible in SPACE up to 10 simultaneous lesions
88923842|NCT01691963|No Intervention|Control group|"In the control group, anaesthesia will be induced in the same way as mentioned above for the intervention group. Also in this group, intubation will be achieved using a C-MAC® videolaryngoscope (Karl Storz, Tuttlingen, Germany) with a size 3 Macintosh blade.~The best possible view of the glottic inlet will be scored with the blade tip positioned in the vallecula. The glottic view will be scored in this position using the Cormack and Lehane classification system. If correct laryngoscope positioning cannot be achieved with a size 3 blade, a size 4 blade will be used. Hereafter, the patient's trachea will be intubated once the optimal view of the larynx had been obtained. Intubation attempts will be scored in the same way as mentioned above for the intervention group."
88923843|NCT01691963|Experimental|Epiglottic downfolding|"Endotracheal intubation will be achieved using a C-MAC® videolaryngoscope (Karl Storz, Tuttlingen, Germany) with a size 3 Macintosh blade.~The best possible view of the glottic inlet will be scored with the blade tip positioned in the vallecula.~Next, the view of the glottic inlet will be scored with the blade advanced further into the vallecula, until the epiglottis flips infero-posteriorly and becomes downfolded into the trachea.~The glottic view will be scored in both positions using the Cormack and Lehane classification system.~After successful intubation, the blade will slowly be withdrawn into the vallecula to elevate the epiglottis back to its normal position."
88923844|NCT01691976|No Intervention|Controls|Age-matched male patients with benign prostatic hyperplasia, otherwise healthy, as controls
88923845|NCT01691976|Active Comparator|LHRHa|Prostate cancer patients receiving androgen deprivation therapy by luteinising hormone releasing-hormone agonists (LHRHa)
88923846|NCT01691976|Experimental|Oestrogen|Prostate cancer patients recruited from the Prostate Adenocarcinoma TransCutaneous Hormones (PATCH) Trial, randomised to receive ADT via transdermal oestrogen patches.
88923847|NCT01691989|Experimental|aleglitazar|
88923848|NCT01691989|Experimental|placebo|
88923849|NCT01692002|Placebo Comparator|Sodium chloride pill|Study 1: pharmacokinetics Study2: Oral glucose tolerance test Study 3: intravenous glucose tolerance test
88923850|NCT01692002|Experimental|Sodium propionate pill|Study 1: pharmacokinetics Study2: Oral glucose tolerance test Study 3: intravenous glucose tolerance test
88923853|NCT01692041|Active Comparator|Ivy leave|active therapy arm with Ivy leave 5 ml twice daily p.o. for four weeks
88923854|NCT01692041|Placebo Comparator|Placebo|Ivy leave placebo 5 ml twice daily p.o. for four weeks
88923855|NCT01692054||Alcohol intoxicated adolescents|Adolescents who were hospitalized due to acute alcohol intoxication
88923856|NCT01692054||Control group|adolescents who were hospitalized due to other medical conditions but not alcohol intoxication
88923857|NCT01692067||D0|Not deployed
89537002|NCT03303365|Active Comparator|Treatment based on MPRAGE|Cyberknife SRS of all suspect intracranial lesions visible in MPRAGE up to 10 simultaneous lesions
88923858|NCT01692067||D1|Deployed to combat-related regions once
88923859|NCT01692067||D2|Deployed to combat related regions more than once
88923860|NCT01692067||D3|Deployed outside of the continental US but not to combat related regions
88923861|NCT01692080||Asthma Screenings and Camps|Children, ages 5-17 years who participate in one of the asthma screenings or camps are eligible to participate in this study.
88923862|NCT01692093|Experimental|KM110329|Participants will receive KM110329 for eight weeks. Participants will take 2 tablets by mouth with water two times a day after meals.
88923863|NCT01692093|Placebo Comparator|Control|Participants will receive placebo drug for eight weeks. Participants will take 2 tablets by mouth with water two times a day after meals.
88923864|NCT01692106|Experimental|peroral endoscopic myotomy (POEM)|The Procedure: per oral endoscopic myotomy (POEM)will be performed on all patients in this single arm study.
88923865|NCT01692132||Prucalopride|
88923866|NCT01692145|Experimental|KCT-0809 ophtalmic solution|
88923867|NCT01692145|Placebo Comparator|Placebo|
88923868|NCT01692184|Experimental|50 mg of AVL-292 and Placebo|50 mg AVL-292 (2 x 25 mg AVL-292 capsules and 6 placebo capsules) once daily for 7 days administered orally under fasted condition
88923869|NCT01692184|Experimental|100 mg of AVL-292 and Placebo|100 mg AVL-292 (4 x 25 mg AVL-292 capsules and 4 placebo capsules) once daily for 7 days administered orally under fasted condition
89537003|NCT04490681|Experimental|Ertugliflozin|Ertugliflozin 5mg
89537004|NCT04490681|Placebo Comparator|placebo|Placebo
89537005|NCT04491305||Women with pathohistological confirmation|Women aged between 18 and 50 with surgically proven endometriosis.
89537006|NCT03303287|Experimental|intervention|School health education program in Pakistan(SHEPP): The health education program will be directed towards children, parents and teachers
89439163|NCT03871894|Experimental|Intervention arm|This is the group of critically ill cirrhotic patients on mechanical ventilator support who would receive the nutritional therapy based on indirect calorimetry measurements till the period admitted in ICU(Intensive care unit); 1.5g protein per kg per day.
89439164|NCT01511328|Experimental|HPV testing|Women randomised to this arm get primary HPV testing
89439165|NCT01511328|No Intervention|cytology|women included follow the standard procedure with primary cytology
89439166|NCT02253927|Experimental|BILR 355 (dose escalation) + Ritonavir|escalating dose groups, for food effect evaluation lowest dose group (D1) with high fat meal breakfast after wash-out period
89439167|NCT05571657|Experimental|Intervention|Reminder/recall
89439168|NCT05571657|No Intervention|Usual Care|No Reminder/Recall
88923870|NCT01692184|Experimental|200 mg AVL-292|8 x 25 mg AVL-292 capsules orally once daily for 7 days under fasted condition
88923871|NCT01692184|Experimental|350 mg of AVL-292|350 mg AVL-292 (14 x 25 mg AVL-292 capsules) once daily for 7 days administered orally under fasted condition
88923872|NCT01692184|Placebo Comparator|Placebo - 8 capsules|8 placebo capsules once daily for 7 days administered orally under fasted condition
88923873|NCT01692184|Placebo Comparator|Placebo - 14 capsules|14 placebo capsules once daily for 7 days administered orally under fasted condition
88923874|NCT01692210||Blood Draw Pre and Post Surgery|Patients within the UT MD Anderson Cancer Center who are scheduled for breast cancer surgery.
88923875|NCT01692223||Unaffected Relatives|We will use a prospective, observational cohort design, we will invite a sample of individuals who have indicated willingness to be re-contacted for future studies (from existing protocols involving cancer survivors and their unaffected relatives employing mixed methods -qualitative interviews coupled with validated measures - to assess: the proportion of participants experiencing psychological distress from Whole genome/exome sequencing (WGS/WES) results.
88923876|NCT01692223||Pts with history of cancer|We will use a prospective, observational cohort design, we will invite a sample of individuals who have indicated willingness to be re-contacted for future studies (from existing protocols involving cancer survivors and their unaffected relatives employing mixed methods -qualitative interviews coupled with validated measures - to assess: the proportion of participants experiencing psychological distress from Whole genome/exome sequencing (WGS/WES) results.
88923877|NCT01692223||Participants whose genomes/exomes are not sequenced|We will also recruit an additional group of participants from the general public (with or without a cancer history) who have not had their genomes or exomes sequenced to participate in focus groups to inform us about their perceptions of the hypothetical utility of learning of incidental results from their genome or exomes. For our sampling purposes, this group of participants is referred to as the 'focus group participants (sample #3-hypothetical group)
88923878|NCT01692249|Experimental|immediate spa therapy|group (A) received immediate spa treatment, with 18 days of therapy over 3 weeks; The standardized shoulder therapy program was designed by experienced spa therapy physicians. Spa mineral water and treatments are approved and controlled by the French authorities. Spa treatment included: bubble buses at 36°C for 15 minutes, applications of mineral matured mud at 45°C to the shoulder for 20 minutes, mineral hydrojet sessions at 39°C for 7 minutes and general mobilization in a collective mineral water pool at 35°C for 20 minutes supervised by a registered physiotherapist.
88923879|NCT01692249|No Intervention|control group|in group (B), spa therapy was delayed for 6 months (control group).
88923880|NCT01692262|Experimental|Part A Group 1 Intermittent|Recruitment suspended and will not be re-opened. See intervention description below.
88923881|NCT01692262|Experimental|Part A Group 2 Intermittent|Recruitment complete. See intervention description below.
88923882|NCT01692262|Experimental|Part B|This part of the study will not be conducted following a review of data from Part A. See intervention description below.
88923883|NCT01692288|Experimental|Offered First Born® Program services|Family and first-born child are selected to be offered First Born® Program home visiting services.
88923884|NCT01692288|No Intervention|Not offered First Born® Program services|Family and first-born child are not selected to be offered First Born® Program home visiting services.
89439169|NCT02253693||Patients with haemophilia|Adult patients with haemophilia A presenting joint disease.
89439170|NCT05697016|Experimental|the Sivelestat group|The patients in this group will receive sivelestat sodium via continuous intravenous infusion (0.2mg/kg/h) over a 24-hour period for 7 days
88923885|NCT01692314|Experimental|Obese adolescents is being compared to control ones|Patients underwent to resistance training, three times a week, during three months.
88923886|NCT01692327|Other|Obese Group|Obese group with fat overload intake.
88923887|NCT01692327|Other|Control Group|Control Group + fat overload intake
88923888|NCT01692327|Other|Glucose Intolerance|glucose intolerance + fat overload intake
89439171|NCT05697016|Placebo Comparator|The Placebo group|The patients in this group will receive the placebo via continuous intravenous infusion (0.2mg/kg/h) over a 24-hour period for 7 days
89012181|NCT02960724|Experimental|68Ga-NOTA-AE105 PET/CT|One injection of 68Ga-NOTA-AE105 followed by positron emission tomography/computed tomography (PET/CT scan) will be performed before surgery and compared with the histological findings to evaluate uPAR PET/CT in staging of oral cancer and oropharyngeal cancer.
89439172|NCT02253771|Experimental|shockwave therapy|shockwave therapy
89439173|NCT02253771|Placebo Comparator|Placebo treatment|sham shockwave therapy by an identically looking device without any function
89012182|NCT00286299|Experimental|Aerobic interval training (AIT)|AIT is 4x4 minutes interval training on a treadmill at 85 to 95 % HRpeak interspersed with 3 min of active resting periods at a work load corresponding to 70 % HRpeak between each interval. Patients performed the intervals walking or running with a minimum of 5 % inclination.
89012183|NCT00286299|Active Comparator|Computer game training (CG)|36 minutes playing supervised computer games, Tetris, Xbox
89206089|NCT00626028|Experimental|Oxygen First, Nitric Oxide Last|10 minute dose of 100% Oxygen, then 10 minute dose of NO plus Oxygen, then 10 minute washout, then 10 minute dose of NO at 80 ppm on Day 1.
89439174|NCT05538442|Other|group|Healthy trailer
89439175|NCT04664907|Experimental|Patients suffering from post traumatic stress disorder|
89439176|NCT05696860|Experimental|Monitorization with Capnography|Patients followed with capnography and standard monitorization
89439177|NCT05696860|No Intervention|Monitorization Without Capnography|Patients followed with standard monitorization
89439178|NCT04425772|Experimental|Experimental Group|FNC+Standard of Care
89439179|NCT04425772|Placebo Comparator|Control Group|FNC dummy tablet+ Standard of Care
89439180|NCT05698342||Melasma mMASI 7|Female patients with melasma mMASI at least 7
89439181|NCT03327376||Characteristic and regularity of CRT|The patients who have a central venous catheterization conduct the daily ultrasound-screening for CVC-related Thrombosis (DUCT).
89439182|NCT01567995|Experimental|Clobetasone Butyrate 0.05% Cream|Clobetasone Butyrate 0.05% Cream
89439183|NCT01567995|Other|Vehicle (base cream)|Vehicle (base cream)
89439184|NCT05277909|Experimental|The expert assessment of shoulder impairments and individualised treatment plan|Participants randomised to the Intervention group will be referred to an expert assessment of their shoulder impairments at the Shoulder Sector, Vejle Hospital - Orthopaedic Department. The expert assessment will be performed by experienced specialists (e.g. physician and physiotherapist) who are specialised in shoulder diagnostics using x-ray, ultrasound, anamnesis/history and standard clinical tests such as Neers, Hawkins, Jobe´s Empty Can, Painful Arc and Resisted External Rotation. The participant's diagnosis based on the history, symptoms and clinical findings will be used to guide the individualised treatment plan. The individualised treatment plan will typically contain a referral to physiotherapeutic treatment at the municipality or private practice, receive specialised physiotherapeutic rehabilitation at Vejle Hospital, get an ultrasound guided corticosteroid injection in the shoulder or offer surgery.
89439185|NCT05277909|Active Comparator|A minimal physiotherapeutic rehabilitation program delivered in a pamphlet|Participants randomised to the Control comparator group will receive a pamphlet from the secretary and perform the exercises at home. This pamphlet contains a program with minimal exercise recommendations for the shoulder consisting of mobility, stretching, strength exercises and tissue treatment. The purpose is to stimulate circulation, improve shoulder function (mobility), increase muscle strength and reduce shoulder pain. The program consists of three warm-up exercises (arm swing, shoulder rolling and scapula-back pocket exercise) followed by three stretching exercises for the breast and shoulder area. Furthermore the pamphlet includes a tissue treatment and four strength exercises for the shoulder (external rotation, extension and flexion of the shoulder and diagonal pull apart). Mobility (with 5-10 repetitions), stretching exercises (in 30 seconds) and tissue treatments will be performed twice a day, while the strength exercises will be performed once a day with 3x12 repetitions.
89439186|NCT04627389|Experimental|study arm|20 patients with a unilateral cleft lip will be repaired with orbicularis oris muscle Z-plasty modification of modified Millard technique
89439187|NCT04627389|Active Comparator|controlled arm|20 patients with a unilateral cleft lip will be repaired with modified Millard technique
89439188|NCT03547557|Experimental|ExAblate MRgFUS|
89439189|NCT03547479|No Intervention|Control|Participants receive current standard of care (DOTS)
89439190|NCT03547479|Experimental|VDOT only|Participants receive daily DOTS treatment with video-enabled mobile monitoring, but also maintain regular supervisory checks
89439191|NCT03547479|Experimental|VDOT + mobile money incentives|Participants receive daily DOTS treatment with video-enabled mobile monitoring supplemented with mobile money incentives, but also maintain regular supervisory checks
88923889|NCT01692353||Exclusive cigarette smokers (SMK)|Subject's usual brand (UB) of cigarettes
88923890|NCT01692353||Exclusive moist snuff consumers (MSC)|Subject's usual brand (UB) of moist snuff
88923891|NCT01692353||Non-tobacco consumers (NTC)|No use of tobacco or nicotine-containing products of any kind
88923892|NCT01692366|Experimental|SAR302503 300mg|SAR302503 will be self-administered, orally, once daily, as a single agent, in consecutive, 28-day cycles at the dose level of 300mg. SAR302503 will be taken on an empty stomach at approximately the same time each day
88923893|NCT01692366|Experimental|SAR302503 400 mg|SAR302503 will be self-administered, orally, once daily, as a single agent, in consecutive, 28-day cycles at the dose level of 400 mg. SAR302503 will be taken on an empty stomach at approximately the same time each day
89439192|NCT05567523|Experimental|Group D0.25, Group D0.5, Group D0.75|Dexmedetomidine will be administered at different initial loading doses (0.25/0.5/0.75 μg/kg within 15min) following same maintained dosage ( 0.5μg/kg/h) in Group D0.25/D0.5/D0.75.
89439193|NCT05567523|Placebo Comparator|Group NS, Group MD|In Group NS, patients will be pumped 0.1ml/kg of normal saline for 15min before anesthesia induction, following continuous infusion at the rate of 0.125ml/kg/h until the end of operation. In Group MD, patients will be administrated with midazolam 0.03mg/kg at the beginning of anesthesia induction.
89537007|NCT03303287|No Intervention|control|usual
88923894|NCT01692366|Experimental|SAR302503 500 mg|SAR302503 will be self-administered, orally, once daily, as a single agent, in consecutive, 28-day cycles at the dose level of 500 mg. SAR302503 will be taken on an empty stomach at approximately the same time each day
88923895|NCT01692379|Experimental|Endovascular treatment|Mechanical embolectomy with Solitaire FR device
88923896|NCT01692379|Active Comparator|Medical treatment|Medical treatment (standard of care in acute ischemic stroke)including intravenous thrombolysis
88923897|NCT01692392||Pectus carinatum|Patients who have undergone surgical repair of pectus carinatum.
88923898|NCT01692405|No Intervention|Standard method|Standard method- shaking the biopsy needle into a formalin container.
88923899|NCT01692405|Active Comparator|Download onto a biopsy sponge pad|Samples will be downloaded by moving the needle notch on a biopsy sponge pad.
88923900|NCT01692405|Experimental|Dowloading the biopsy cores using NavigoBx system|Downloading the biopsy cores using NavigoBx™ system. The NaviGoBx™ device is intended for the retention of a biopsy specimen and for preservation of the specimen's in-needle location and orientation.
88923901|NCT01692418|Experimental|Ferric carboxymaltose|1000mg of ferric carboxymaltose will be administered as an i.v. infusion (100ml normal saline) over a minimum of 15 minutes
88923902|NCT01692418|Placebo Comparator|Placebo|Normal saline will be administered as an i.v. infusion (100ml normal saline) over a minimum of 15 minutes
88923903|NCT01692431|Experimental|DHA|High fat meal containing DHA rich oil.
88923904|NCT01692431|Experimental|EPA|High fat meal containing EPA.
88923905|NCT01692431|Placebo Comparator|Control|High fat meal with no/negligable omega-3 fatty acid content.
88923906|NCT01692457||Golimumab|Patients will be taking golimumab as per the dosing regimen given on product insert approved in Philippines.
88923907|NCT01692470||rilpivirine hydrochloride|Patients will be taking 1 tablet of 25 mg rilpivirine hydrochloride is administered once daily orally in combination with other anti-retroviral (ARV) medications.
88923908|NCT01692483||Abiraterone acetate plus prednisone|
88923909|NCT01692509||Patients requiring NIV|Patients requiring NIV because of acute respiratory failure
88923910|NCT01692522|Experimental|Ambu Aura-i|intubation
88923911|NCT01692522|Active Comparator|AirQ|intubation
88923912|NCT01692535|Experimental|GlideScope|intubation
88923913|NCT01692535|Experimental|Airtraq|intubation
88923914|NCT01692535|Experimental|McGrath MAC|intubation
88923915|NCT01692535|Experimental|King Vision|intubation
88923916|NCT01692535|Experimental|A.P. Advance|intubation
88923917|NCT01692535|Experimental|C-MAC|intubation
88923918|NCT01692548|Experimental|Neurofeedback|Neurofeedback: two sessions per week, 30 sessions total.
88923919|NCT01692548|No Intervention|Control|
88923920|NCT01692561||normaL|Healthy subjects without symptoms of dysautonomia.
88923921|NCT01692561||Neurocardiogenic syncope|Fainting due to sudden drop in blood pressure.
88923922|NCT01692561||Orthostatic hypotension|Sudden decrease in blood pressure while standing.
88923923|NCT01692561||Postural Orthostatic Tachycardic Syndrome|Increased heart rate when standing.
88923924|NCT01692574|Experimental|Combined|Group cognitive-behavior therapy for depression combined with behavior modification for weight loss
88923925|NCT01692574|Active Comparator|GCBT-ND|Group cognitive-behavior therapy for depression combined with an alternative approach to weight loss
88923926|NCT01692574|Active Comparator|DSE|Behavior modification for weight loss combined with depression support and education.
88923927|NCT01692587|No Intervention|Control|No changes in dietary group
88923928|NCT01692587|Experimental|Protein restrictive diet|reduced protein diet
88923929|NCT01692600||healthy volunteers|Age-matched with the patient group, with no oral pathologies and comorbidities
88923930|NCT01692600||Late oral radiation toxicity patients|Head-and-neck cancer patients who had undergone radiation therapy and developed late radiation side ffects
88923931|NCT01692652|Experimental|Lotemax with warm compress group|topical loteprednol etabonate (lotemax 0.5%) qid and warm compress & ocular massage (a minimum of four times, once or twice a daily) for 2months
88923932|NCT01692652|Active Comparator|warm compress only group|warm compress only group
88923933|NCT01692665||stage 3 or stage 4 meibomiang gland dysfunction patients|stage 3 or stage 4 meibomiang gland dysfunction patients
88923934|NCT01692678|Experimental|Trabectedin (Part 1 and Part 2)|Trabectedin will be administered at a dose of 1.5, 1.2 or 1.0 mg/m2 as a 24-hour intravenous infusion on Day 1 of each 21-day treatment cycle (ie, each treatment cycle being at least 21 days apart).
88923935|NCT01692678|Active Comparator|Dacarbazine (Part 2)|Dacarbazine will be administered at a dose of 1 g/m2 as a longer than 30-minute intravenous infusion on Day 1 of each 21-day treatment cycle (ie, each treatment cycle being at least 21 days apart).
88923936|NCT01692704|Experimental|HAI with FUDR & systemic cisplatin and gemcitabin|FUDR: 0.2mg/kg/day continuously i.a. for 14 days Cisplatin: 25mg/m2 i.v. Gemcitabin: different doses according to dose level 600, 800, or 1000 mg/m2 i.v.
88923937|NCT01692769|Active Comparator|Normal Saline|Patients will receive intravenous normal saline for all resuscitation and maintenance fluid for a period of 24 hours commencing on presentation to hospital.
88923938|NCT01692769|Active Comparator|Ringer's Lactate|Patients will receive intravenous Ringer's Lactate for all resuscitation and maintenance fluid for a period of 24 hours commencing on presentation to hospital.
88923939|NCT01692795||MI patients|
88923940|NCT01692808|No Intervention|Exclusive Enteral Nutrition|This group is one of the non interventional group. As enteral nutrition is one of the usual therapy of Crohn disease at diagnosis.
88923941|NCT01692808|Experimental|EEN + Vitamin D3 3000 UI daily|Exclusive Enteral Nutrition + Vitamin D3 3000 UI daily for one month This arm will be one of the two experimental arms.
88923942|NCT01692808|No Intervention|Corticosteroïd|Corticosteroids (1mg/kg/day) associated with usual vitamin and calcium supplementation: vitamin D 800 IU of vitamin D3 + 1000 mg calcium per day) for one month
88923943|NCT01692808|Experimental|Corticosteroids + Vitamin D3 4000 UI|Corticosteroids (1mg/kg/day) associated with vitamin D3 4000 UI daily and calcium 1000 mg daily for one month
89206090|NCT00777257|Experimental|Study Group A|Tdap vaccine + placebo concomitantly on Day 0; Menactra® vaccine 28 days later
89439194|NCT02584504|Experimental|Alirocumab 150 mg Q4W|Double-blind treatment period(DBTP):participants received Alirocumab 150 mg subcutaneous injection every 4 week(Q4W) alternating with placebo(for alirocumab)Q4W added to lowest-strength statin therapy(atorvastatin 5 mg daily),stable non-statin LMT/diet therapy alone for 12weeks. Participants completed DBTP,entered open-label treatment period(OLTP),received alirocumab 150 mg Q4W up to additional 52 weeks. Alirocumab dose up-titrated to 150 mg every 2 weeks(Q2W) at Week 24(OLTP:Week 12),when targeted LDL-C level at Week 20 not achieved as Japan Atherosclerosis Society Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2012:1) ≥100 mg/dL(2.59 mmol/L) in heterozygous familial hypercholesterolemia (heFH) participants/non-familial hypercholesterolemia (non-FH)participants with history of documented coronary heart disease;2) ≥120 mg/dL(3.10 mmol/L)in non-FH participants with history of documented diseases/other risk factors as categorized in primary prevention category III)
88923944|NCT01692808|Experimental|Vitamin D3 4000 UI|Vitamin D3 4000 UI /day . This arm is intended for those children in remission with or without immunosuppressant. Vitamin D will be administered in adjunction to usual therapy.
88923945|NCT01692821|Experimental|100% oxygen breathing|
89439195|NCT02584504|Experimental|Alirocumab 150 mg Q2W|In DBTP, participants received Alirocumab 150 mg subcutaneous (SC) injection Q2W added to lowest-strength statin therapy (atorvastatin 5 mg daily), stable non-statin LMT or diet therapy alone for 12 weeks. Participants who completed DBTP were entered in OLTP and received alirocumab 150 mg Q4W up to additional 52 weeks. Alirocumab dose up-titrated to 150 mg Q2W at Week 24 (Week 12 of OLTP), when targeted LDL-C levels at Week 20 were not achieved i.e. LDL-C ≥100 mg/dL (2.59 mmol/L) or ≥120 mg/dL (3.10 mmol/L) according to Japan Atherosclerosis Society(JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2012.
89439196|NCT02584504|Placebo Comparator|Placebo Q2W|In DBTP, participants received Placebo (for alirocumab) SC injection Q2W added to lowest-strength statin therapy (atorvastatin 5 mg), stable non-statin LMT or diet therapy alone for 12 weeks. Participants who completed DBTP were entered in OLTP and received alirocumab 150 mg Q4W up to additional 52 weeks. Alirocumab dose up-titrated to 150 mg Q2W at Week 24 (Week 12 of OLTP), when targeted LDL-C levels at Week 20 were not achieved i.e. LDL-C ≥100 mg/dL (2.59 mmol/L) or ≥120 mg/dL (3.10 mmol/L) according to JAS Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2012.
89439197|NCT04607889||Part 1 - Attribute development|An elicitation phase to develop the list of attributes and levels based on literature review and telephone interviews with patients.
89439198|NCT04607889||Part 2 - Pilot study|A pilot phase consisting of a self-administered, online survey, to be completed by patients and physicians, followed by telephone interviews with a subsample of participants.
88923946|NCT01692821|Experimental|15% oxygen in N2 breathing|
88923947|NCT01692821|Experimental|12% oxygen in N2 breathing|
88923948|NCT01691144||recently treated patients|
88923949|NCT01691144||2-3 years after treatment|
88923950|NCT01692834|Active Comparator|Cyclosporine in Cremophor EL®|Dosing 5 mg/kg infused at a constant rate over 4 h with a syringe pump.
88923951|NCT01692834|Active Comparator|Cyclosporine in lipid emulsion|Dosing 5 mg/kg infused at a constant rate over 4 h with a syringe pump.
88923952|NCT01692847||RRT calls prior to IGS use|Patients who triggered ACT/RRT calls prior to the installation of the IGS (Intellivue Guardian System)
88923953|NCT01692847||RRT calls during IGS use|Patients who triggered ACT/RRT calls after the installation of IGS. All patients on the study ward receive the same care in both groups. The only difference is the system used to collect vital signs and to inform the staff about patient deteriorations. In Group 2, the IGS (FDA approved and CE marked) is the vital signs collection and information system.
88923954|NCT01692860|Experimental|High protein consumption|Intervention, energy restriction. This arm has a dietary protein intake of 1.5g/kg/d
88923955|NCT01692860|Placebo Comparator|Normal protein consumption|Intervention, energy restriction. This arm has a dietary protein intake of .8g/kg/d
88923956|NCT01692873|Experimental|suspected pancreatic tumor|Realization of pancreatic tumor biopsy and blood samples
88923957|NCT01692886|Active Comparator|7vPnC (3-, 4-, 5-, 12-Month)|
89206091|NCT00777257|Experimental|Study Group B|Tdap vaccine + Menactra® vaccine concomitantly on Day 0; placebo 28 days later
89439199|NCT04607889||Part 3 - Main study|The main study, with a self-administered, online survey, to be completed by cancer patients and physicians.
89439200|NCT04599777|Experimental|TACE-Sor-Tis|TACE combined with sorafenib and tislelizumab.
89439201|NCT05696002||Advanced pelvic oncological resection|Complex resection
88923958|NCT01692886|Experimental|13vPnC (3-, 4-, 5-, 12-Month)|
88923959|NCT01692886|Experimental|13vPnC (2-, 4-, 6-, 12-Month)|
88923960|NCT01692886|Experimental|13vPnC (3-, 5-, 12-Month)|
88923961|NCT01692899||Etanercept|Etanercept: administered as first line biotherapy in RA during the period of the study
88923962|NCT01692899||Adalimumab|Adalimumab: administered as first line biotherpy in RA during the period of the study
88923963|NCT01692899||Infliximab|Infliximab: administered as first line biotherpy in RA during the period of the study
88923964|NCT01692912|Active Comparator|Intensive Care (IC)|Rheumatologists treating to target of DAS28<2.6
88923965|NCT01692912|No Intervention|Routine Care (RC)|Participants treated in the routine manner by their rheumatologist (not treated to the target of DAS28<2.6)
88923966|NCT01692925|Experimental|Lot A|Each subject will receive two single doses of turocotocog alfa from two lots of trial product on two separate days.
88923967|NCT01692925|Experimental|Lot B|Each subject will receive two single doses of turocotocog alfa from two lots of trial product on two separate days.
88923968|NCT01692925|Experimental|Lot C|Each subject will receive two single doses of turocotocog alfa from two lots of trial product on two separate days.
88923969|NCT01692925|Experimental|Lot D|Each subject will receive two single doses of turocotocog alfa from two lots of trial product on two separate days.
88923970|NCT01692977|Experimental|Alzheimer disease patients|Alzheimer disease patients
88923971|NCT01692977|Active Comparator|control|healthy control subjects.
89439202|NCT02253615|Active Comparator|Machine resistance training (MRT)|The machine resistance training will consist of four exercises for lower limbs and four exercises for upper limbs which will be alternately performed with a one-minute interval between them during familiarization and training periods. Lower limb exercises will consist of: hip extension and abduction, and knee flexion and extension. Upper limb exercises will consist of: bench press, rowing, triceps and high pulley exercise.
89439203|NCT02253615|Experimental|Elastic resistance training (ERT)|The elastic resistance training will consist of four exercises for lower limbs and four exercises for upper limbs which will be alternately performed with a one-minute interval between them during familiarization and training periods. Lower limb exercises will consist of: hip extension and abduction, and knee flexion and extension. Upper limb exercises will consist of: bench press, rowing, triceps and high pulley exercise.
89439204|NCT05698264|Experimental|NSCLC patients with EGFR mutation|"The cohort A will focus on the clonal evolution in EGFR mutated lung cancer patients by using circulating tumor DNA (ctDNA) analysis of paired baseline and end-of-treatment (EOT) plasma samples. This cohort will be compared to matched EGFR patients previously analyzed by our group.~Analysis of paired samples from this study will allow a dissection of events acquired through therapy, specifically which component of the combination therapy may be driving selection of the mutations in comparison with the control group without TTFields."
89537008|NCT03305237|Experimental|big breakfast (BB) to big dinner (BD)|Phase 1: no intervention, habitual diet for 4 days and then 4day maintenance diet Phase 2: consumption of BB energy restriction diets for 4 weeks Phase 3: washout for 1 week, controlled maintenance diet Phase 4: consumption of BD energy restriction diets for 4 weeks
88923972|NCT01692990|Experimental|Fish oil|5 g/d in 10 capsules, providing 3.5 g of long-chain n-3 fatty acids
88923973|NCT01692990|Placebo Comparator|Soy bean oil|5 g/d in 10 capsules
88923974|NCT01693003|Experimental|Indacaterol first|"Indacaterol 150 µg d.o. during the first 3-week period followed by other 3-week period of tiotropium bromide 5 µg d.o. separated by a wash-out phase of at least 5 to 14 days between each treatment period"
88923975|NCT01693003|Experimental|Tiotropium first|"Tiotropium bromide 5 µg d.o. during the first 3-week period followed by other 3-week period of Indacaterol 150 µg d.o. separated by a wash-out phase of at least 5 to 14 days between each treatment period"
88923976|NCT01693016|Other|inhalation group|20 children Taking blood samples and SpHb-measurement was made under inhalational anesthesia
88923977|NCT01693016|Other|non-inhalational|40 children Taking blood samples and SpHb measurements in awake and spontaneous breathing children.
88923978|NCT01693042|Active Comparator|Single intracoronary cell application|Single intracoronary application of autologous bone marrow derived mononuclear cells
88923979|NCT01693042|Active Comparator|repeated (2 times) intracoronary cell application|2 times (interval 4 months) intracoronary application of autologous bone marrow derived mononuclear cells
88923980|NCT01693055|Experimental|UltheraTM|UltheraTM 100 shots (infraorbital region 30shots, lateral orbital region 40shots, upper eyelid 30 shots) on the Rt, and Lt periorbital area, respectively using 1.5mm and 3.0mm probe
88923981|NCT01693081|Active Comparator|VR040/Aspirair® inhaler|VR040 was administered as an inhaled dry powder, in a dosage of 1.5, 2.3, 3.0 and 4.0mg, single dose given at each dose level.
88923982|NCT01693081|Placebo Comparator|Placebo|Placebo was administered as an inhaled dry powder, matching to active comparator at dosages of 1.5, 2.3, 3.0 and 4.0mg, single dose given at each dose level.
88923983|NCT01693107||Operator Blinded to Contact Force|Physicians performing the ablation will be blinded to the contact force data
88923984|NCT01693133|Other|Control|Standard of Care: Moist Wound Therapy and Offloading
88923985|NCT01693133|Experimental|EpiFix plus Standard of Care|Weekly application of EpiFix (up to 12 week) and standard of care (moist wound therapy and offloading)
88923986|NCT01693146|Active Comparator|Nasal insufflation of oxygen|Nasal insufflation of oxygen starting at at flow of 0.5 L/min.
88923987|NCT01693146|Active Comparator|Nasal oxygen insufflation with a TNI® 20 oxy device|Device: TNI®20 oxy Nasal insufflation at a constant high flow of 15 L/min with oxygen addition starting at 0.5 L/min
88923988|NCT01693159|Experimental|ECA: Ethyl-2-cyanoacrate|Application of ethyl-2-cyanoacrylate (ECA) for painful cetuximab-induced rhagades
88923989|NCT01693159|Active Comparator|Standard treatment of the institution|Standard treatment of the institution to treat painful cetuximab-induced rhagades
88923990|NCT01693172|Active Comparator|early postoperative mobilization|Early postoperative supervised aerobic exercise, resistance and flexibility training
88923991|NCT01693172|No Intervention|Standard|Standard rehabilitation care
88923992|NCT01693211|Experimental|Group A|Capsulorhexis and pre-fragmentation of the nucleus are performed by the femtosecond laser.
88923993|NCT01693211|Active Comparator|Group B|The Capulorhexis and nuclear fragmentation are performed manually.
88923994|NCT01693237|Active Comparator|Group psychotherapy|20 sessions of systemic and narrative group psychotherapy
88923995|NCT01693237|Experimental|Group psychotherapy with feedback|20 sessions of systemic and narrative group psychotherapy with session-to-session feedback to patient and therapist.
88923996|NCT01693276|Experimental|Gemzar/Abraxane and Radiation Therapy|Patients will receive 2 cycles of gemcitabine and abraxane prior to the start of chemoradiation. Chemoradiation will commence 2 week after the completion of second cycle of gemcitabine/abraxane. Patients will receive an additional 2 cycles of gemcitabine and abraxane to start 2-4 weeks after the completion of chemoradiation. After the last two cycles of chemotherapy, if well tolerated with continued tumor response additional cycles of chemotherapy may be given.
88923997|NCT01693289|Experimental|Metformin plus letrozole|metformin :850mg tablets twice daily for 6 months letrozole :5mg tablets twice daily form day 3to7 of cycle
88923998|NCT01693289|Experimental|ovarian drilling|bilateral diathermy ovarian drilling, four drills each ovary
88923999|NCT01693302|Experimental|-20 minute insulin|Insulin for the meal is given 20 minutes prior to starting the meal.
88924000|NCT01693302|Experimental|0 minute insulin|Insulin for the meal is given immediately before starting to eat.
88924001|NCT01693302|Experimental|+20 minute insulin|Insulin is given 20 minutes after the start of the meal.
88924002|NCT01693315|Experimental|Cohort 1 - AMA0076 Dose A (or vehicle)|Consecutive, eligible subjects who meet the inclusion/exclusion criteria in each cohort will be randomized to active or placebo (vehicle) in a 4:1 allocation ratio (12 active : 3 placebo).
89537009|NCT03305237|Experimental|big dinner (BD) to big breakfast (BB)|Phase 1: no intervention, habitual diet for 4 days and then 4day maintenance diet Phase 2: consumption of BD energy restriction diets for 4 weeks Phase 3: washout for 1 week, controlled maintenance diet Phase 4: consumption of BB energy restriction diets for 4 weeks
89537010|NCT03305003|Active Comparator|Communication modality: spiral notebook|
89537011|NCT03305003|Experimental|Communication modality: mobile application|
88924003|NCT01693315|Experimental|Cohort 2: AMA0076 Dose B (or vehicle)|Consecutive, eligible subjects who meet the inclusion/exclusion criteria in each cohort will be randomized to active or placebo (vehicle) in a 4:1 allocation ratio (12 active : 3 placebo).
88924004|NCT01693315|Experimental|Cohort 3: AMA0076 Dose C (or vehicle)|Consecutive, eligible subjects who meet the inclusion/exclusion criteria in each cohort will be randomized to active or placebo (vehicle) in a 4:1 allocation ratio (20 active : 5 placebo).
88924005|NCT01693315|Experimental|Cohort 4: AMA0076 Dose D (or vehicle)|Consecutive, eligible subjects who meet the inclusion/exclusion criteria in each cohort will be randomized to active or placebo (vehicle) in a 4:1 allocation ratio (20 active : 5 placebo).
88924006|NCT01693328||PecFent®|
88924007|NCT01693341|Active Comparator|Care-giver mediated training|Each patient and the caregiver of the intervention group received weekly home training and exercise counseling by a physical therapist about the caregiver mediated home exercise skill for stroke patient. The training program were progress weekly based on the patient's need.
88924008|NCT01693341|No Intervention|Standard-care|Maintain the inherent standard-care
88924009|NCT01693354|Active Comparator|HF dialysis|HF (high-flux) dialysis is standard hemodialysis treatment performed by using a high permeability dialyzer instead of a low permeability one.
88924010|NCT01693354|Experimental|Mid-dilution HDF|Mid-dilution is a newly developed hemodiafiltration therapy able to allow a simultaneous pre- and post-dilution infusion.
88924011|NCT01693393|Other|Cyclosporine A|All patients will receive Cyclosporine A in a dose of 2mg/kg/BW daily for 16 weeks
88924012|NCT01693406||Normal Weight|Normal weight and normoglycemic women: Pre-pregnancy BMI between 18.5 - 24.9 kg/m2.
88924013|NCT01693406||Overweight/Obese|Overweight and normoglycemic women: Pre-pregnancy BMI between > 25 kg/m2.
88924014|NCT01693406||Gestational Diabetes|Women who develop gestational diabetes and return to normal glucose control after delivery.
88924015|NCT01693406||Type 2 Diabetes|Women who are overweight and have Type 2 Diabetes that was diagnosed before pregnancy: Pre-pregnancy BMI > 25 kg/m2.
88924016|NCT01693419|Experimental|GES (Gemcitabine, Erlotinib, S-1)|"Treatment will be delivered as a 3-week cycle.~Gemcitabine 1000 mg/m² IV on day 1, 8~Erlotinib 100 mg/day PO on day 1~S-1 60 mg/m²/day PO on day 1-14"
88924017|NCT01693432|Experimental|DS (docetaxel+S-1)|"Treatment will be delivered as a 3-week cycle.~Docetaxel 60 mg/m²IV on day 1~S-1 80 mg/m2/day PO on day 1-14"
88924018|NCT01693445|Experimental|OIS (Oxaliplatin, Irinotecan, S-1)|"Dose level 1 treatment will be delivered as a 2-week cycle as bellows;~Oxaliplatin 85 mg/m²IV on day 1~Irinotecan 120 mg/m² IV on day 1~S-1 60 mg/m2/day PO on day 1-7 Dose escalation will be continued until more than one-third of the patients in a given cohort show dose limiting toxicities (DLT) during treatment cycle 1. If at least 2 patients are observed to have DLT, this dose level is defined as the maximum tolerated dose (MTD). If exactly 1 of the 3 patients treated show DLT, 3 additional patients are treated at the current dose level."
88924019|NCT01693458|Experimental|Lifestyle counseling|Appreciative Inquiry Change Agents (CA) Program (NAMWEZA)
88924020|NCT01693458|Placebo Comparator|Control group|Since the design is a stepped-wedge randomized trial, those in the control group will eventually receive the intervention later in the study.
88924021|NCT01693471||SEARCH Study Group|
88924022|NCT01693497|Experimental|Dialogical exposure therapy|Psychotherapy based on a manual integrating Gestalt principles with cognitive-behavioral techniques.
88924023|NCT01693497|Active Comparator|Cognitive Processing Therapy|Cognitive Processing Therapy, a cognitive behavioral psychotherapy for PTSD patients. Based on a German manual adapted from Resick and Schnicke, 1993.
88924024|NCT01693510|Experimental|Exercise and Nutrition Intervention|Nutrition intervention: The proposed nutrition plan is a high protein (25% energy) diet providing low fat dairy foods and individualized to energy needs. Dairy foods are accepted by women during pregnancy as a healthy choice (from pilot study) and in our recent birth cohort study, women consumed an average of 3 or more servings of dairy per day. Exercise intervention: Most previous studies and published guidance focus on aerobic exercise such as walking as it is the easiest physical activity to implement in pregnancy in terms of setting goals of steps and monitoring of adherence using accelerometer-type devices. Walking is also the most practical since women reduced moderate and vigorous physical activity during pregnancy but levels of walking were maintained.
88924025|NCT01693510|No Intervention|Usual Prenatal Care|Mothers in the Control Group will be followed by their primary care provider and have usual access to public health. In addition, women will have the opportunity to attend one focus group session exploring women's experiences with nutrition, exercise, and weight gain in pregnancy.
89537012|NCT03303131||Period A|Children discharged as recovered from September 2007 to March 2009 with at least 15% of their weight at admission
89537013|NCT03303131||Period B|Children discharged as recovered from April 2009 to December 2011 with Children discharged as recovered from September 2007-March 2009 with MUAC ≥ 124 mm
89537014|NCT03303053|Experimental|Group1:Cholestyramine+standard treatment|Cholestyramine powder 4g twice daily, Tablet Carbimazole 30 mg daily, Tablet propanolol 40 mg twice daily for 4 weeks
89537015|NCT03303053|Experimental|Group2:Prednisolone+standard treatment|Tablet prednisolone 30 mg daily for week 1, 20 mg daily for week 2, 10 mg daily for week 3 and 5 mg daily for week 4, Tablet carbimazole 30 mg daily, Tablet propanolol 40 mg twice daily for 4 weeks
89439205|NCT05698264|Experimental|NSCLC patients planned to receive PD-1 inhibitors|The cohort B will study the impact of TTField on the profile, activity, and proliferation of peripheral lymphocytes in NSCLC patients receiving PD-1 inhibitors concomitant to TTFields treatment. Lymphocytes will be purified from whole blood samples for the profile, proliferation, and activity analyzed by FACS.
89439206|NCT05061160|Experimental|Interval Aerobic Exercise training Group|Interval Aerobic Exercise for 4 weeks
89439207|NCT05061160|Active Comparator|Continuous Aerobic Exercise training Group|Continuous aerobic exercise for 4 weeks
89439208|NCT05007262|Experimental|Tangningtongluo tablets|Tangningtongluo tablets, 4 tablets one time,tid,po, taken after meals.The patients will receive drugs for 24 weeks continuously. After 24 weeks, the researchers will decide whether to continue depend on the patient condition and willingness. The maximum medication time is up to 48 weeks.Basic treatment: According to the comprehensive objectives of China Type 2 Diabetes Guidelines (2020 Edition) .The Angiotensin-Converting Enzyme（ACEI） and Angiotensin Receptor Blocker（ARB） drugs will be continued to use as the original treatment protocol.
89439209|NCT05007262|Active Comparator|Calcium dobesilate capsules|Calcium dobesilate capsules, 1 capsule at a time, tid,po.(morning, midday, and evening), used on an empty stomach.After 24 weeks, the researchers will decide whether to continue depend on the patient condition and willingness. The maximum medication time is up to 48 weeks.Basic treatment: According to the comprehensive objectives of China Type 2 Diabetes Guidelines (2020 Edition) .The Angiotensin-Converting Enzyme（ACEI ）and Angiotensin Receptor Blocker （ARB） drugs will be continued to use as the original treatment protocol.
89439210|NCT05150613|Other|Group A|No Mask
88924026|NCT01693536|Experimental|Lifestyle counselling|"Three dietician visits focussed on education to find food with sodium less than 120mg/100gms.~Two physiotherapist visits focussed on teaching personalised sustainable practical exercise."
88924027|NCT01693536|No Intervention|Control|Control group was offered free skin cancer check and wait listed for the same lifestyle counselling after the six months of the study.
88924028|NCT01693549|Experimental|Cabazitaxel|Cabazitaxel(XRP6258) will be administered on day 1 of each cycle, every 21 days, at a dose of 25 mg/m² by i.v. route in 1 hour. Treatment can be continued until patient's consent withdrawal, intolerable toxicity or documented disease progression.
88924029|NCT01693575|Experimental|Pupil expansion with APX 100 device|Use of APX 100 device during standard phacoemulsification cataract extraction surgery in patients with small pupil diameter (<4.5 mm) or with documented intraoperative floppy iris syndrome in previous eye.
88924030|NCT01693588|Experimental|Pain Management Bundle|The Pain Management Bundle will be implemented for all postoperative neurosurgical patients admitted to nursing units at the University of Florida.
88924031|NCT01693627|Active Comparator|Pinnacle/Corail with collar|Uncemented THA using Pinnacle-100/Marathon XLPE(Depuy, Warsaw, IN) acetabular component and Corail(Depuy,Warsaw,IN)collared femoral stem with 32mm Alumina Biolox Forte(Depuy,Warsaw,IN). Tantalum beads will be inserted into periprosthetic bone.
88924032|NCT01693627|Active Comparator|Marathon/Corail with collar|Reversed hybrid THA using cemented Marathon XLPE(Depuy,Warsaw,IN) acetabular component and an uncemented Corail(Depuy,Warsaw,IN)collared femoral component with 32 mm Alumina Biolox Forte(Depuy,Warsaw,IN)head. Tantalum beads will be inserted into periprosthetic bone.
88924033|NCT01693627|Active Comparator|Pinnacle/Corail without collar|Uncemented THA using Pinnacle-100/Marathon XLPE(Depuy, Warsaw, IN) acetabular component and Corail(Depuy,Warsaw,IN)collarless femoral stem with 32mm Alumina Biolox Forte(Depuy,Warsaw,IN). Tantalum beads will be inserted into periprosthetic bone.
88924034|NCT01693627|Active Comparator|Marathon/Corail without collar|Reversed hybrid total hip arthroplasty using cemented Marathon XLPE(Depuy,Warsaw,IN) acetabular component and an uncemented Corail(Depuy,Warsaw,IN)collarless femoral component with 32 mm Alumina Biolox Forte(Depuy,Warsaw,IN)head. Tantalum beads will be inserted into periprosthetic bone.
88924035|NCT01693640|Experimental|abatacept|
88924036|NCT01693666|Experimental|Lifestyle intervention group|The LIFE program emphasizes improved nutritional quality, moderate physical activity, and weight maintenance (±10 lb) in obese pregnant women using a contingency management (CM) approach to reinforce behavior change. Participants will meet with the study dietitian and exercise physiologist every 2-4 weeks to develop and maintain individualized nutrition and physical activity plans, reinforced by CM. When the subject meets with the interventionists at their regular appointments, they will review the diet and exercise requirements, and provide vouchers earned as reinforcement from the previous study period. Diet requirements include at least 5 days of food logs each week. Exercise requirements include objective verification of up to 5 exercise sessions per week (as prescribed).
88924037|NCT01693666|No Intervention|Routine care group|Participants in the Routine Care (RC) control group will receive no additional intervention beyond standard of care.
89206092|NCT00777257|Experimental|Study Group C|Menactra® vaccine + placebo concomitantly on Day 0; Tdap vaccine 28 days later
89206093|NCT00820716|Experimental|CA|Exercise training with alternate load
89439211|NCT05150613|Other|Group B|Surgical Mask
89439212|NCT05150613|Other|Group C|N95 Mask
89439213|NCT03546153|Experimental|Aerobic exercise program|Participants will complete 12 week exercise program.
89439214|NCT04549857|Experimental|intervention group|The experimental group used the base oil (sweet almond oil) to add Atlantic cedar, sweet marjoram and sweet orange essential oils. The essential oils were blended into 5% massage oil at a ratio of 3:1:1.
89439215|NCT04549857|Placebo Comparator|Placebo group|The placebo group only used base oil (sweet almond oil).
89439216|NCT04549857|No Intervention|Control group|No intervention
89439217|NCT03547089|Experimental|Viveve treatment|Group of women who receive Viveve treatment
89439218|NCT03546075|Experimental|500 mg Resveratrol|
89439219|NCT03546075|Experimental|250 mg Resveratrol|
88924038|NCT01693679|Experimental|antiviral drug|Telbivudine team,Telbivudine,600mg/d,oral,60 patients. non-Tebivudine team,Lamivudine,100mg/d,oral,20 patients.Adefovir,10mg/d,oral,20 patients.Enecavir,0.5mg/d,oral,20 patients.
88924039|NCT01693705||Tracheostomy Patients|Critical care patients with respiratory failure who were mechanically ventilated and who underwent tracheostomy
88924040|NCT01693705||Non-Tracheostomy Patients|Critical care patients with respiratory failure who were mechanically ventilated but did not undergo tracheostomy
88924041|NCT01693731||Aromatase Inhibitor|Postmenopausal women with breast cancer taking Arimidex, Aromasin, or Femara
88924042|NCT01693731||No Treatment|Healthy volunteer postmenopausal women not taking Aromatase Inhibitors
88924043|NCT01693744||Dialysis patients|Patients with stage 5 chronic kidney disease undergoing haemodialysis
88924044|NCT01693744||Chronic kidney disease patients|Stage 1-4 Chronic kidney disease patients
88924045|NCT01693744||Control group|Patients with normal renal functions
88924046|NCT01693757||BPTB group|Bone-patellar tendon-bone
88924047|NCT01693757||STG group|Semitendinosus and gracilis tendon
88924048|NCT01693757||Control|Healthy
88924049|NCT01693770|Other|MRgFUS|High intensity focused ultrasound energy, delivered under the guidance of the MR images (MgFUS) allows for a predefined amount of energy to be delivered in the desired target (Metastasis). Bone readily absorbs focused ultrasound energy resulting in a thermo-related neurolysis of the periostium with consequent pain palliation. The amount of energy delivered can be modulated with the objective to penetrate cortical space and obtain necrosis of the metastasis thus preventing local recurrence.
88924050|NCT01693809|Experimental|Caffeine|Caffeine 420mg, one time
88924051|NCT01693835||Patients|Patients with metastatic colorectal cancer
88924052|NCT01693835||Healthy subjects|Age and sec-matched healthy subjects
88924053|NCT01693848||Patients|Patients with metastatic colorectal cancer scheduled for metastatic surgery
88924054|NCT01693848||Control patients|Patients with metastatic colorectal cancer scheduled for general anesthesia without metastatic surgery
88924055|NCT01693861||Patients|Patients with metastatic colorectal cancer treated with chemotherapy
88924056|NCT01693874|Experimental|Mindfulness Based Stress Reduction|All participants in this arm receive Mindfulness Based Stress Reduction (MBSR).
88924057|NCT01693874|Active Comparator|control|All participants in this arm receive an attention control
88924058|NCT01693887||empirical therapy|immediate initiation of antifungal therapy; Itraconazole :1-14day,iv；(400mg/day bid 1-2day, 200mg/day q.d 3-14day) 15-28day,p.o(400mg/day bid)
88924059|NCT01693887||preemptive therapy|Dynamic monitoring of fungal infection, initiation antifungal therapy when clinical diagnosis ( microbial + experiment +, G/GM, CT typical change ) approveled in two weeks Itraconazole :1-14day,iv；(400mg/day bid 1-2day, 200mg/day q.d 3-14day) 15-28day,p.o(400mg/day bid) If within two weeks without obtaining positive results, researchers determine whether initiation of antifungal therapy。
88924060|NCT01693913|Experimental|Cognitive-behavioral|Those participating in a cognitive behaviorally supported exercise and nutrition treatment will receive a cognitive behavioral exercise and nutrition over 50 weeks
88924061|NCT01693913|Active Comparator|Nurtition education|This arm will participate in nutrition and exercise education
88924062|NCT01693926|Experimental|Acute physical activity intervention|25 min of moderate physical activity
88924063|NCT01693926|Placebo Comparator|Placebo|25 min of reading (instead of physical activity)
88924064|NCT01693939|Other|FS200 Femtosecond Laser|The LASIK flap will be created using the FS200 Femtosecond Laser
88924065|NCT01693952|Experimental|blood samples|
88924066|NCT01693978|Experimental|Reinforced Prolonged Exposure (RPE)|All participants will be scheduled to attend a weekly Prolonged Exposure therapy session for 12 consecutive weeks, and followed for 12 additional weeks. RPE participants will receive voucher-based reinforcement contingent on attendance to scheduled Prolonged Exposure therapy sessions.
88924067|NCT01693978|Active Comparator|Standard Prolonged Exposure (SPE)|All participants will be scheduled to attend a weekly Prolonged Exposure therapy session for 12 consecutive weeks, and followed for 12 additional weeks.
88924068|NCT01693991|Experimental|Meaning-Making intervention (MMi)|Patients in this arm will be receiving the Meaning-Making intervention (MMi) as per intervention manual (Lee, 2006).
88924069|NCT01693991|Placebo Comparator|Empathic visitor|This person will provide the basic ingredients fostering a good therapeutic relationship (i.e., trust, warmth, empathy, neutrality and authenticity) without further intervention or probing. The empathic visitor will be specifically instructed to avoid initiating discussions about meaning (e.g., how the patient interprets his feelings and thoughts, understands his/her illness and meaning in life), and focus discussions on what is currently happening (rather than on the interface between past and present).
88924070|NCT01693991|No Intervention|Control Group|Patients in this group will only be receiving treatment as usual.
88924071|NCT01694017|Active Comparator|Zidovudine|zidovudine 300 mg + lamivudine 150 mg + nevirapine 200 mg , once daily, for a year
88924072|NCT01694017|Active Comparator|Tenofovir|tenofovir 300 mg+ emtricitabine 200 mg + efavirenz 600 mg, once daily, for one year
88924073|NCT01694030|Experimental|Neutral Condition|Participants in the neutral (control) condition of the attachment security priming experiment will be asked to spend time visualising neutral events (e.g., supermarket shopping)for 3-10 minutes at a time.
88924074|NCT01694030|Experimental|Secure condition|Participants in the attachment security priming condition will be asked to complete visualisation tasks where they think about a secure attachment figure for between 3 - 10 minutes.
88924075|NCT01694043|Experimental|Non-Food Related Commercials|Participants will watch a 30-minute Saturday Night Live television show with non-food related commercials embedded.
88924076|NCT01694043|Experimental|Healthy Food Commercials|Participants will watch a 30-minute Saturday Night Live television show with healthy food commercials embedded.
88924077|NCT01694043|Experimental|Unhealthy Food Commericlas|Participants will watch a 30-minute Saturday Night Live television show with unhealthy food commercials imbedded.
88924078|NCT01694056|Experimental|Soy protein diet|High mixed protein diet (20 en%) with 25gr of soy protein per day
88924079|NCT01694056|Active Comparator|Control diet|High mixed protein diet (20 en%)
89439220|NCT03546075|Placebo Comparator|Placebo|
89439221|NCT04535895|Experimental|Simultaneous integrated boost arm|
89439222|NCT05515107|Active Comparator|Blade will placed on vallecula|Active Comparator: Children will be intubated by the C-MAC VL size 1 Miller blade will placed on the base of the tongue (vallecula)
89439223|NCT05515107|Placebo Comparator|Blade will placed under the epiglottis|Placebo Comparator: Children will be intubated by the C-MAC VL size 1 Miller blade will placed under the epiglottis
89439224|NCT03547011|Active Comparator|US guided Quadratus Lumborum block|Patients will receive ultrasound guided quadratus lumborum block with 0.3 ml /kg bupivacaine 0.25% on each side with catheter insertion for maintenance doses 0.1ml/kg/hr on each side.
89439225|NCT03547011|Active Comparator|US guided Paravertebral block.|Patients will receive ultrasound guided thoracic paravertebral block with 0.3 ml/kg bupivacaine 0.25 % on each side with catheter insertion for maintenance doses 0.1 ml/kg/hr on each side.
89439226|NCT05537584|Experimental|MDD with SERT+ Response Marker|Participants with MDD who have been classified as high sertraline responders based on behavioral and brain data.
88924080|NCT01694082|Experimental|THRIVE replication|Participants in this condition receive THRIVE with a full list of direct and indirect protective behavioral strategies to reduce alcohol consumption.
88924081|NCT01694082|Experimental|THRIVE direct strategies|Participants in this condition receive THRIVE including a subset of protective behavioral strategies that are directly related to alcohol drinking.
88924082|NCT01694082|Experimental|THRIVE indirect strategies|Participants in this condition receive THRIVE including a subset of protective behavioral strategies that are indirectly related to alcohol drinking.
88924083|NCT01694082|Sham Comparator|Brief brochure and assessment control|Participants will answer the same survey questions as participants in the THRIVE conditions, but will receive a brief alcohol-related brochure with only didactic content rather than the intervention components received by participants randomized to THRIVE conditions.
88924084|NCT01694095||Patients with geographic atrophy|
88924085|NCT05289726|Experimental|Traditional chinese medicine TDX105|"Experimental group Traditional chinese medicine TDX105 (Dissolve in warm water and then dilute to 600ml and soak hands and feet for 30 minutes each time, once in the morning and evening every day, until the end of the first 8 weeks of treatment with regorafenib)~Basic care was the same in both groups, including routine care such as topical use of urea ointment"
88924086|NCT05289726|Placebo Comparator|placebo|"The control group received placebo granules mixed with dextrin and food coloring (Dissolve in warm water and then dilute to 600ml and soak hands and feet for 30 minutes each time, once in the morning and evening every day, until the end of the first 8 weeks of treatment with regorafenib)~- Basic care was the same in both groups, including routine care such as topical use of urea ointment"
88924087|NCT05289700|Experimental|HBOT intervention group (2 ATA, 95 min, FIO2=1)|Hyperbaric Oxygen Therapy (HBOT) is the administration of oxygen at a pressure higher than atmospheric pressure (2 ATA). By breathing pure oxygen at twice the atmospheric pressure, its concentration in the blood is multiplied by nearly ten times. This allows a greater oxygen concentration in poorly vascularised areas of the body.
88924088|NCT05289700|Placebo Comparator|placebo group (1.3 ATA, 95 min, FIO2=0.21)|Hyperbaric chamber is the same chamber used for HBOT, but with a limited hyperpressure (1.3 ATA) and using ambient air (FIO2=0.21), with illusion of treatment in healthy volunteers.
88924089|NCT05289609||Prospective Cohort|Liver Transplant Recipients from High-volume centers (i.e., performing >= 65 LTs per year)
88924090|NCT05289609||Retrospective Cohort|Liver Transplant Recipients from Low-to-medium volume centers (i.e., performing <65 LTs per year) and High-volume centers
88924091|NCT05289531||Rectal resection patients|Four Turkish centers participated in data collection in 2016. The inclusion criteria were rectal adenocarcinoma within 15 cm from the anal verge and LAR with either PME or TME. All patients had bowel continuity restored for at least 18 months when invited for the study. Exclusion criteria included failed R0 surgery, recurrence or dissemination, having intestinal stoma, previous cancer (except minor skin cancers) dementia and inability to speak Turkish (i.e., the need for a translator during treatment). A research assistant at each center identified the consecutive series of eligible patients for each participating consultant surgeon
88924092|NCT05289531||52 patients re-questioned to answer the same questionaire as control group|"The test-retest reliability of the LARS score was evaluated by asking 52 randomly selected subgroup of eligible patients to repeat the assessment of the LARS score 2 to 4 weeks after their initial response. Agreement between tests for the LARS score category and for each of the five LARS score items is presented as proportions with 95% confidence intervals. We considered it a perfect agreement if the patient ticked the exact same response category at both tests, a moderate agreement if responses differed by one category, while 'no agreement' was applied to patients whose responses differed by two or more categories.~The intraclass correlation coefficient was used to evaluate the agreement between the initial test and the retest. The limit of agreements was calculated by using the Bland-Altman method. An ICC between 0.61 and 0.80 is considered strong agreement. A p value less than 0.05 was considered significant."
88924093|NCT05289518|Experimental|Intervention group|Subjects in the intervention group will recieve remote ischemic conditioning (RIC) treatment twice a day for 3 months.
89206094|NCT00820716|Active Comparator|CC|Exercise training with constant load
89439227|NCT05537584|Experimental|MDD with BUP+ Response Marker|Participants with MDD who have been classified as high bupropion responders based on behavioral and brain data.
89439228|NCT03546933||Chest pain patients presenting to the ED|All patients that present to the emergency department with chest pain and potentially other symptoms consistent with ACS and meet all eligibility criteria will undergo VitalScan Magnetocardiograph.
89439229|NCT05537506|Active Comparator|Bracket slot 0.018|
89439230|NCT05537506|Active Comparator|Bracket slot 0.022|
89439231|NCT04459377|Placebo Comparator|Placebo|Sodium Chloride solution (9mg / ml) 0.2ml / kg slow intravenous injection (2ml / min).
89439232|NCT04459377|Active Comparator|K1|S-Ketamine (0.125 mg / kg body weight). (0.625mg / ml x 0.2ml / kg) slow intravenous injection (2ml / min).
89439233|NCT04459377|Active Comparator|K2|S-Ketamine (0.25 mg / kg body weight). (1.25mg / ml x 0.2ml / kg) slow intravenous injection (2ml / min).
89439234|NCT00748618|Other|1|Standard vitamin treatment
89439235|NCT00748618|Active Comparator|2|50,000 I.U. of vitamin D3
89439236|NCT04450563|Active Comparator|Placebo + closed-loop insulin system|
89439237|NCT04450563|Experimental|Empagliflozin 2.5 mg + closed-loop insulin system|
89439238|NCT04450563|Experimental|Empagliflozin 5 mg + closed-loop insulin system|
89439239|NCT04425694||F3B ward staff|The e-EWS system will be implemented in a selected surgical ward (F3B ward) in Tuen Mun Hospital. All F3B ward staff will use the system and evaluate its effectiveness.
89439240|NCT03757065||Systemic Lupus Erythematosus|
89439241|NCT03757065||Sjogren's Syndrome|
89439242|NCT03757065||Multiple Sclerosis|
88924094|NCT05289518|Sham Comparator|Sham control group|Subject in the sham control group will recieve sham remote ischemic conditioning (Sham-RIC) treatment twice a day for 3 months.
88924095|NCT05289466|Other|Single-arm|Intraoperative Radiotherapy (Xoft, 20 Gy single dose)
89439243|NCT03757065||Systemic Sclerosis|
89439244|NCT03757065||Crohn's Disease|
89439245|NCT03757065||Ulcerative Colitis|
89439246|NCT03757065||Inflammatory Myositis|
89439247|NCT05537350|Experimental|Lumenato|1 Lumenato soft gel once a day
89439248|NCT05537350|Placebo Comparator|Placebo|1 Soft gels without active ingredients once a day
89439249|NCT05698186|Experimental|Part 1: Anti-HER2 targeted therapy containing regimen + Thero2-01S22|Patients will receive Thero2-01S22 at the recommended dose and induction therapy according to local practice with a taxane (docetaxel, paclitaxel, or nab-paclitaxel) or vinorelbine for 4 to 6 cycles in combination with pertuzumab and trastuzumab
89439250|NCT05698186|Placebo Comparator|Part 1: Anti-HER2 targeted therapy containing regimen + Placebo|Patients will receive placebo and induction therapy according to local practice with a taxane (docetaxel, paclitaxel, or nab-paclitaxel) or vinorelbine for 4 to 6 cycles in combination with pertuzumab and trastuzumab
89439251|NCT05698186|Experimental|Part 2: Anti-HER2 targeted therapy containing regimen + Thero2-01S22|Patients will receive Thero2-01S22 at the confirmed dose and induction therapy according to local practice with a taxane (docetaxel, paclitaxel, or nab-paclitaxel) or vinorelbine for 4 to 6 cycles in combination with pertuzumab and trastuzumab
89439252|NCT05698186|Placebo Comparator|Part 2: Anti-HER2 targeted therapy containing regimen + Placebo|Patients will receive placebo and induction therapy according to local practice with a taxane (docetaxel, paclitaxel, or nab-paclitaxel) or vinorelbine for 4 to 6 cycles in combination with pertuzumab and trastuzumab
89439253|NCT03546855|Experimental|treatment group|apatinib 500mg/d po.28d as one cycle
89439254|NCT04675606|Active Comparator|Low fiber diet|Patients in this arm will receive low fiber diet starting postoperative day 1. This is currently the standard protocol at our institution.
89439255|NCT04675606|Experimental|Regular diet|Patients in this arm will receive regular diet starting postoperative day 1. This will be the experimental arm.
89439256|NCT05679310|Experimental|Supplement|The supplement capsules were given to 12 healthy subjects, aged 26-52, once a day for 8 weeks
89439257|NCT05537272|Active Comparator|Tadalafil|
89439258|NCT05537272|Active Comparator|Tamsulosin|
89439259|NCT05537272|Placebo Comparator|Placebo|
89439260|NCT03756909||adenoidectomy group|Operations of adenoidectomy
88924096|NCT05289453|Experimental|study group|patients wit acute congestive glaucoma and treated bt lens extraction by phacoemulsification after IOP control
88924097|NCT05289401|Active Comparator|ESPB|Unilateral erector spinae block will be performed in the lateral position . 0.5 mL/Kg of bupivacaine 0.125% will be injected taking care not to exceed the maximum recommended dose (2 mg/kg of bupivacaine)
88924098|NCT05289401|Active Comparator|CB|caudal block performed in lateral position . bolus of 1.2 ml/Kg bupivacaine 0.125% .
88924099|NCT05289336|Experimental|Transoral Laser Microsurgery|Transoral Laser Microsurgery
89206095|NCT00826644|Experimental|Belotecan plus Cisplatin|
89206096|NCT00826644|Active Comparator|Etoposide plus Cisplatin|
89439261|NCT03756909||adenotonsillectomy group|Operations of adenotonsillectomy
89439262|NCT04634110|Experimental|Patients with ALK+ NSCLC and brain metastases|Including patients with brain metastases from ALK (anaplastic lymphoma kinase) positive NSCLC (non-small cell lung cancer), who are either neurologically asymptomatic or who have only mild neurologic symptoms (RTOG [Radiation therapy Oncology Group] acute neurologic morbidity score 0-2) from their brain metastases, who are TKI (tyrosine kinase inhibitor) naïve or who have had prior exposure to crizotinib, but who are naïve to brigatinib and other ALK TKIs including alectinib, lorlatinib, and ceritinib.
89439263|NCT05059353|Experimental|Patients with MCI|
88924100|NCT05289219|Experimental|Intervention Group|The duration of the program is 16-weeks, 3-times a week, for up to 50 minutes per session, starting 1 month after surgery, based on the recommendations of the WHO and the ACSM, because the guidelines for morbidly obese patients undergoing bariatric surgery are not defined. Information on exercises for morbidly obese adults is limited, so the exercise programs will follow the guidelines for adults aged 18 to 65 years healthy, with chronic diseases or disabilities
88924101|NCT05289219|No Intervention|Control Group|
88924102|NCT05289128|Experimental|Experimental Group/ Active HD-tDCS|Patients randomly enrolled in this group will receive 10 sessions of anodal HD-tDCS stimulation on cortical representation zone of left diaphragmatic motor cortex associated to respiratory training; for 20 minutes (each session) with a 2mA intensity. The electrical current will be delivered with a ramp-up time of 30 s, held at 3mA for 20 min, and then ramped down over 30 s.
88924103|NCT05289128|Sham Comparator|Control Group / Sham Group|Patients enrolled in this group condition will receive 10 sessions of anodal stimulation on cortical representation zone of left diaphragmatic motor cortex using HD-tDCS associated to respiratory training; for 20 minutes (each session) with a 2mA intensity. In the sham condition, the device will provide a 30-second ramp-up followed immediately by a 30-second ramp down.
88924104|NCT05289115|Experimental|Experimental Group/ Active HD-tDCS|Patients who will be randomly enrolled in this group. They will receive 10 sessions of anodal stimulation on cortical representation zone of left diaphragmatic motor cortex using HD-tDCS associated to respiratory training; for 20 minutes (each session) with a 3mA intensity. The electrical current will be delivered with a ramp-up time of 30 s, held at 3mA for 20 min, and then ramped down over 30 s.
88924105|NCT05289115|Sham Comparator|Control Group / Sham Group|Patients enrolled in this group condition will receive 10 sessions of anodal stimulation on cortical representation zone of left diaphragmatic motor cortex using HD-tDCS associated to respiratory training; for 20 minutes (each session) with a 3mA intensity. In the sham condition, the device will provide a 30-second ramp-up followed immediately by a 30-second ramp down.
88924106|NCT05289102|Experimental|Two postpartum visits.|Group 1 serves as an intervention group (experimental). All enrolled women in the intervention group were in connection with the inclusion given two pre-booked postpartum care visits. One early at 3 weeks postpartum, and one later at 7 weeks postpartum.
88924107|NCT05289102|Active Comparator|One postpartum visit.|Group 2 serves as a control group (active comparator). All enrolled women in the control group were in connection with the inclusion given one pre-booked postpartum care visit at 7 weeks postpartum according to the traditional postpartum care.
88924108|NCT05289011||Patients with spondyloarthritis without Inflammatory bowel disease|
88924109|NCT05288959|Experimental|Healthy participants|"All participants participate in five core sessions. Session 1 consists of MRI scans (T1-weighted, T2-weighted, diffusion MRI, resting-state fMRI). Thereafter, there are four TMS-EEG sessions. Session 2 delivers uni-focal spTMS to various cortical targets while EEG is recorded to determine inter-regional conduction delays. Thereafter, Sessions 3 - 5 deliver bi-focal TMS (PAS), each session using a different asynchrony (shorter, equal to, or longer than the conduction delay). The three PAS sessions are at least one week apart. Each of the PAS sessions have three segments: (a) TMS-EEG-behavioral recordings before PAS, (b) the PAS modulation, and (c) TMS-EEG-behavioral recordings after PAS.~In addition to these core sessions, some participants may be invited for additional sessions for parameter optimization and for assessing test-retest repeatability."
88924110|NCT05288881|Experimental|ANX105|
88924111|NCT05288881|Placebo Comparator|Placebo|
88924112|NCT05288738|Active Comparator|Group D1|PCA morphine 1mg/ml
88924113|NCT05288738|Active Comparator|Group D2|PCA morphine 1mg/ml
88924114|NCT05288725|Experimental|Intra-articular injection with Bone Marrow Derived Mesenchymal Stem Cells (MSCs)|Participants will undergo a bone marrow aspirate procedure. Participants will receive a single intra-articular injection of NGRM-001 on treatment day.
88924115|NCT05288725|Experimental|Subchondral injection with Bone Marrow Derived MSCs|Participants will undergo a bone marrow aspirate procedure. Participants will receive a single subchondral injection of NGRM-001 on treatment day.
88924116|NCT05288725|Experimental|Combined Intra-articular and Subchondral injection with Bone Marrow Derived MSCs|Participants will undergo a bone marrow aspirate procedure. Participants will receive a single combined intra-articular and subchondral injection of NGRM-001 on treatment day.
89439264|NCT05059353|Experimental|Cognitively Normal Subjects|
88924117|NCT05288725|Active Comparator|Corticosteroid injection|Subjects in the corticosteroid group will undergo a mock bone marrow aspirate procedure. Participants will receive a single intra-articular injection of corticosteroid on treatment day.
88924118|NCT05288465|Experimental|Hair repigmentation during Cerebrolysin treatment for neurological diseases|Patients prescribed for Cerebrolysin treatment due neurological diseases.
88924119|NCT05288426||participant post first BNT162b2 vaccination|Patients which developed myocarditis after the first dose of BNT162b2 vaccination
88924120|NCT05288426||participant post second BNT162b2 vaccination|Patients which developed myocarditis after the second dose of BNT162b2 vaccination
88924121|NCT05288426||participant post third BNT162b2 vaccination|Patients which developed myocarditis after the third dose of BNT162b2 vaccination diagnosed with MIS
88924122|NCT05288426||participant post COVID-19|Patients which developed myocarditis after COVID-19 infection
89439265|NCT05059353|No Intervention|Caregivers of Patients with MCI|
89439266|NCT05537194||Patients with hypoxia|
89439267|NCT05537194||Patients without hypoxia|
88924123|NCT05288270|Experimental|Aramis Group|Consecutive patients, admitted to Sant' Anna Institute with diagnosis of stroke after hospital discharge that need motor and cognitive treatment and rehabilitation of neurological diseases.
88924124|NCT05288270|Active Comparator|Conventional Group therapy|Consecutive patients, admitted to Sant' Anna Institute with diagnosis of stroke after hospital discharge that need motor and cognitive treatment and rehabilitation of neurological diseases.
88924125|NCT05288244|Experimental|foot bath|"It will be applied to the patients in group A (foot bath) every evening between 21.00-21.20 for 14 days. The steps of the procedure are as follows:~To be used in the footbath, a footbath tub, water at 38-40°C, a thermometer to measure the temperature of the water, foot towels, clean socks, gloves are prepared.~With the water temperature adjustment button in the foot bath tub, wait until the temperature of the water reaches 38-40 °C~Between 21:00 and 21:20, the feet are kept in water with a constant temperature of 38-40 °C for 20 minutes. (While the process is in progress, the water temperature is checked intermittently with a laser thermometer.)"
89439268|NCT05696704|Experimental|Mindfulness Based Cognitive Therapy|Mindfulness-Based Cognitive Therapy (MBCT) combines the ideas of cognitive therapy with meditative practices and attitudes based on the cultivation of mindfulness. The heart of this work lies in becoming acquainted with the modes of mind that often characterize mood disorders while simultaneously learning to develop a new relationship to them.
89439269|NCT05696704|Experimental|Behavior Activation|BA Increase reinforcing behaviors in order to influence emotions and cognitions.
89439270|NCT03956355|Experimental|Tapinarof (DMVT-505)|Tapinarof (DMVT-505) Cream Group
89439271|NCT03956355|Placebo Comparator|Vehicle Cream|Vehicle Cream Group
89439272|NCT03931161|Placebo Comparator|Placebo|Matching Placebo.
89439273|NCT03931161|Active Comparator|Evolocumab|Evolocumab Auto-Injector [Repatha]
89439274|NCT05037123|Active Comparator|Arm 1 Continuous ketamine infusion group|Continuous ketamine infusion (0.35 mg/kg after induction, followed by 0.25 mg/kg/hr until 2 hours after surgery) plus saline IV dose in post-anesthesia care unit
89439275|NCT05037123|Active Comparator|Arm 2 Ketamine + Saline group|Saline dose and infusion intraoperatively, then single-dose IV ketamine (0.60 mg/kg) in post-anesthesia care unit plus 2 hours of saline administration after surgery
88924126|NCT05288244|Experimental|lavender oil snuff|"The L group (lavender oil sniffing) will be applied, the lavender oil sniffing process will be applied every evening between 21.00-21.05 for 14 days, and the process steps will be as follows;~Essential lavender oil to be used for the enterprise is obtained from a company that has business registration and TS EN ISO 9001: 2008 quality certificates with the number G06-3231 from the Ministry of Food, Agriculture and Livestock.~3 drops of the obtained lavender oil are dripped onto the cotton pad.~The prepared cotton pad is fixed on the patient's clothing in the upper chest and shoulder area with a locked needle and the patient is asked to sniff for 5 minutes (Özkaraman et al., 2018)."
88924127|NCT05288244|Experimental|foot bath and lavender oil snuff|AL group (both foot bath and lavender oil sniffing),for 14 days, every evening between 21.00-21.20, foot bath and lavender oil sniffing between 21.00-21.05 will be applied together.
88924128|NCT05288192|Active Comparator|Suprachoroidal triamcinolone injection|Eyes treated with suprachoroidal injection of triamcinolone acetonide.
88924129|NCT05288192|No Intervention|Non-treated eyes|Eyes that are receiving no interventions during the study period.
88924130|NCT05288179|Experimental|Pirfenidone group|Patient takes pirfenidone 3 times a day，Week 1, 2 capsules/time; Week 2, 4 capsules/time; Week 3-52, 6 capsules/time
88924131|NCT05288179|Placebo Comparator|placebo group|Patients take a placebo 3 times a day，Week 1, 2 capsules/time; Week 2, 4 capsules/time; Week 3-52, 6 capsules/time
88924132|NCT05288127|Experimental|Talazoparib Single Agent|"The study will have 1 treatment group. Patients will receive a single oral dose of talazoparib (Talzenna®) 1mg/day daily for 28-day cycles until progressive disease, limiting toxicities, intercurrent medical issues, patient withdrawal of consent, death, or end of trial whichever occurs first. Treatment will be administered on an outpatient basis. Talazoparib should be taken orally once daily (i.e., continuous daily dosing) at approximately the same time each day (preferably in the morning). Talazoparib will be swallowed whole and may be taken with or without food. If a subject vomits a dose, the subject should not take a second dose that calendar day. The subject should resume daily dosing the next day.~Daily dosing of talazoparib can be interrupted for recovery from toxicity for up to 28 days. For interruptions longer than 28 days, treatment at the same or a reduced dose can be considered if the evidence of response or clinical benefit to talazoparib is noted."
88924133|NCT05291585|Experimental|the dedicated venous sinus thrombectomy stent|Patients diagnosed with acute or subacute venous sinus thrombosis within 28days from the onset of symptoms to endovascular treatment, regardless of whether anticoagulation has been performed. The dedicated venous sinus thrombectomy stent can be used to remove the thrombus to restore sinus blood flow.
88924134|NCT05291585|Active Comparator|balloon catheter thrombectomy|Intracranial thrombectomy was balloon catheter in conjunction with aspiration performed with a control product
89439276|NCT05037123|Placebo Comparator|Arm 3 Placebo group|Placebo, Saline dose and infusion intraoperatively, then saline IV dose in post-anesthesia care unit plus 2 hours of saline administration after surgery
89439277|NCT05536648|Experimental|Group 1 Single head toothbrush|Cerebral palsy children were given single head tooth brush along with fluoridated toothpaste for brushing.
89439278|NCT05536648|Experimental|Group 2 Triple head toothbrush|Cerebral palsy children were given triple head tooth brush along with fluoridated toothpaste for brushing.
89439279|NCT03892005||MOTIVATION HIP Total Hip System|All study subjects have undergone routine preoperative clinical evaluations prior to their THA, and implanted MOTIVATION HIPTM Total Hip System in accordance to indications and intended use, and appropriate surgical technique(s) will be invited to participate in the study at their first year of postoperative follow up visit, and sign ICF.
89439280|NCT05695612|Experimental|Novaloc Attachment|
89439281|NCT05695612|Active Comparator|Locator attachment|
89439282|NCT04366167||Cardiac surgery patients - lockdown 1|Cohort 1 (lockdown 1): Patients undergoing adult cardiac surgery during the Covid-19 pandemic
89439283|NCT04366167||Cardiac surgery patients - lockdown 2|Cohort 2 (lockdown 2): Patients undergoing adult cardiac surgery during the Covid-19 pandemic
89439284|NCT04366167||Cardiac surgery patients - lockdown 3|Cohort 3 (lockdown 3): Patients undergoing adult cardiac surgery during the Covid-19 pandemic
89439285|NCT05695534|No Intervention|Standard education|Patients will be educated about the procedure in a standard way by a docture and a nurse
89439286|NCT05695534|Experimental|VR Education|Patients will be educated with the use of virtual reality
89439287|NCT04365075|Experimental|Excimer Laser Combined with DCB|Using excimer laser combined with drug-coated baloons to treat infrapopliteal lesions in patients with critical limb ischemia.
89439288|NCT04365075|Active Comparator|Angioplasty Alone|Using angioplasty alone to treat infrapopliteal lesions in patients with critical limb ischemia.
88924135|NCT05291572|Active Comparator|Group A|will be treated by speech therapy only (fluency shaping).
88924136|NCT05291572|Active Comparator|Group B|will be treated by speech therapy (fluency shaping) plus Hyperbaric oxygen therapy.
88924137|NCT05291572|Active Comparator|Group C|will be treated by speech therapy (fluency shaping) plus medical treatment (brain stimulant).
88924138|NCT05291455|Experimental|Lacosamide|Lacosamide will be given.
88924139|NCT05291455|Active Comparator|Phenobarbitone|Phenobarbital will be given
88924140|NCT05291429|Active Comparator|VR - coaching arm|30 individuals to be enrolled in the intervention arm that also includes coaching sessions to support and encourage VR use (VR+coaching arm).
88924141|NCT05291429|Active Comparator|VR only - no coaching|30 individuals to be enrolled in the intervention arm without coaching (VR arm)
88924142|NCT05291429|No Intervention|No intervention - control arm|30 individuals to be enrolled in the control arm with no active intervention (comparator 2; control arm)
88924143|NCT05291416||1|healthy children aged between 4-16 years
88924144|NCT05291416||2|children aged between 4-16 years, suffering from juvenile idiopathic arthritis
88924145|NCT05291312|Other|endoscopic assisted coblation|
88924146|NCT05291312|Other|conventional curettage|
88924147|NCT05291195|Experimental|Laser-devices group|Mechanico-chemical root canal preparation and root canal disinfection were be performed by means of mechanic-chemical methods including hand instruments followed by 1.5% sodium hypochlorite. Afterwards, depending on allocations, in the laser devices group, adjuvant treatment approaches were be performed by means of laser devices either photodynamic therapy (HELBO, Photodynamic Systems GmbH), or high power diode laser (940nm, Biolase).
88924148|NCT05291195|Experimental|Sodium hypochlorite|Mechanico-chemical root canal preparation and root canal disinfection were be performed by means of mechanic-chemical methods including hand instruments followed by 1.5% sodium hypochlorite (pH 12), at room temperature (21 degrees Celsius).
88924149|NCT05291195|Experimental|Essential oil|"Mechanico-chemical root canal preparation and root canal disinfection were be performed by means of mechanic-chemical methods including hand instruments followed by 1.5% sodium hypochlorite (pH 12), at room temperature (21 degrees Celsius).~Depending on allocations, in the essential oil group, the canals were be treated with adjuvant essential oil of Cymbopogon martinii and Thymus vulgaris (Herba oils, Herba doo, Belgrade, Serbia)"
88924150|NCT05291104|No Intervention|Placebo|Interventions are not received any treatments.
88924151|NCT05291104|Experimental|Intervention|Interventions are received folic acid or choline
88924152|NCT05291052|Experimental|TIS combined therapy|All patients will be treated with the combination of tisleizumab , lenvatinib and XELOX regimen (oxaliplatin combined with capecitabine) until disease progression , unacceptable toxicity, death or the patient meets any other discontinuation criteria described in the protocol, whichever occurs first. Subjects can receive up to 8 cycles of the XELOX regimen. For subjects who are intolerant to XELOX regimen or have stable disease or objective response after complete 8 cycles of XELOX regimen, treatment with tisleizumab and lenvatinib will be continued until tumor progression or for a maximum of 2 years.
88924153|NCT05291013|Experimental|Gastric bypass with T2DM|
88924154|NCT05291013|Experimental|Gastric bypass without T2DM|
88924155|NCT05291013|No Intervention|Control group|
89012184|NCT00286299|Experimental|Maximal strength training (MST)|MST is performed in a leg press machine. The weight is lowered in a controlled manner in the eccentric phase until the patient reached 90 degrees in the knee joint. Then the patients has a short stop (~0.5 second) before the weight is moved as rapidly as possible to complete extension. The training volume is 4 sets of 4RM (i.e. 85-90 % 1RM). The training load is increased with 2.5-5 kg each time patients managed to perform 4 sets with the determined load or each training session.
89439289|NCT05678920||Pregnant and postpartum patients|Pregnant patients older than 28th gestational week and patients up to postpartum 6th week who were hospitalized in the obstetrics department
89439290|NCT04354155|Experimental|Thromboprophylaxis|Twice-daily low-dose enoxaparin thromboprophylaxis (starting dose, 0.5 mg/kg subcutaneously q12 hours, adjusted to achieve a 4 hour post-dose anti-factor Xa level of 0.20-0.49 anti-Xa U/mL)
89439291|NCT05032833|Experimental|5-MeO-DMT arm|
89439292|NCT05032833|Placebo Comparator|Placebo arm|
89439293|NCT04450654|Experimental|Gamunex-C IVIG|Gamunex-C IVIG dosed at 2g/kg will be given on week 0 and week 4.
89439294|NCT04450654|Placebo Comparator|Placebo|Albumin in a 1% solution at an equivalent volume to the corresponding Gamunex-C IVIG dose will be given at week 0 and week 4.
89439295|NCT05001165|Experimental|Intervention|Patients with perceived gaps in performance measures for guideline-directed medical therapies for heart failure with reduced ejection fraction will be chart-reviewed and called impromptu to receive point of care medication titration or reintegration into routine heart failure clinic. Patients lost to follow-up may be better identified using the HFrEF panel management tools.
89439296|NCT05001165|No Intervention|Usual Care|A control group of patients with HFrEF will receive routine primary and cardiology care as currently indicated in routine scheduled clinic grids. Patients are at the discretion of their primary care and cardiology clinicians regarding whether further HFrEF optimization is warranted. While panel management data is available to all clinicians, clinical workflows and responsibilities do not encourage the use of panel data or response to performance measurement for HFrEF.
89439297|NCT04376008|Experimental|PI-RADS 1-2|Standard prostate biopsy
89439298|NCT04376008|Experimental|PI-RADS 3-5|Targeted and standard prostate biopsy
89439299|NCT05678764||Conversational Information Collection Tool Referrals|These are patients who refer to talk therapy using the novel information collection tool.
89439300|NCT05678764||Other Referrals|These are patients who refer to talk therapy using other referral methods.
89439301|NCT03877965||Children with single ventricle congenital heart disease|Receiving digoxin per standard of care during the interstage period
89439302|NCT02586064|Experimental|Interpersonal Psychotherapy for PTSD|Relationally-focused intervention addressing PTSD symptoms and relationship dysfunctions, 12 weekly sessions
89439303|NCT02586064|Active Comparator|Prolonged Exposure|Exposure based intervention including exposure to memories and avoided places and activities
89439304|NCT02253849|Experimental|CBZ - TPB/r+CBZ|"Days 1-14: carbamazepine (CBZ) twice daily~Days 15-22: CBZ twice daily plus TPV/r twice daily"
89439305|NCT04981197|Experimental|Baduanjin exercise group|The Baduanjin exercise group received a 12-week Baduanjin exercise programme.
89439306|NCT04981197|No Intervention|Control group|Patients in this group maintain their daily life activities, and there is no intervention given.
89439307|NCT04233489|Experimental|Family Nurture Intervention (FNI)|This arm contains the combined GDM+FNI and control+FNI cohort.
89439308|NCT04233489|No Intervention|Non-FNI|This arm contains the combined GDM+no FNI and control+no FNI cohort.
89439309|NCT03545997|Experimental|Montelukast|Drug :Montelukast, capsule, 10mg, one per day in the evening, one hour before or 2 hours post meal, length of treatment 3 months
89012185|NCT02960880||Rivaroxaban|NVAF patients who were newly initiated on Rivaroxaban for stroke prevention
89439310|NCT03545997|Placebo Comparator|Placebo|Drug: Mannitol, capsule, 350mg, one per day in the evening, one hour before or 2 hours post meal, length of treatment 3 months
89439311|NCT05678608|Experimental|spinal cord tumors group|
89439312|NCT05536024||glioma patients|This study includes the glioma patients aged over 18 years, receiving surgical resection or needle biopsy for the first time, and without any radiotherapy and/or chemotherapy prior to preoperative MRI scan. All included glioma patients were redefined or newly diagnosed according to the 2021 WHO of CNS classification.
89439313|NCT05678530||Healthy|
89439314|NCT05678530||Standard of Care|
89439315|NCT03810729|Active Comparator|Modified Allen's Test|The Modified Allen's Test (MAT) will be performed in a well-lit room on the participant's hand. This technique will involve compression of both the radial and ulnar arteries by the investigator to assess patency of the contralateral artery. The participant will then be asked to clench and open their hand several times. The participant will then be asked to maintain their hand in an open position. The investigator will then release the compression over the ulnar artery and observe for palmar blush. The length of time to achieve maximal palmar blush will be recorded. This technique will then be repeated by maintaining compression over the ulnar artery and releasing of the compression over the radial artery.
89439316|NCT03810729|Active Comparator|Smartphone assessment|The smartphone app (Heart Rate, Azumio software) will be used to assess radial and ulnar artery patency. Briefly, the iPhone camera will be placed over the participant's index finger and patency assessed before and immediately following isolated contralateral artery compression for a maximum of two minutes.
89439317|NCT03810495|Experimental|OLANI (naltrexone implant)|2 OLANI containing 60% naltrexone (1.8 g total) administered one time subcutaneously
89439318|NCT04980885|Experimental|AK117+Azacitidine|"Phase Ib: Subjects will receive different doses of A117 in combination with azacitidine 75 mg/m2 subcutaneous daily for 7 days of a 28 day cycle;~Phase II: Subjects will receive AK117 at the recommended Phase 2 dose in combination with azacitidine 75 mg/m2 subcutaneous daily for 7 days of a 28-day cycle."
89439319|NCT03545685|Experimental|SMART|The subjects in SMART training group will receive add-on SMART intervention for 3 months. Subjects will play cognitive games for 1 hour per day, five days per week. SMART will track game time, resource use, and text messaging information on a daily basis, which allows researchers/clinicians to monitor subjects' daily SMART activities. Daily end-of-day RedPocket incentives will be delivered to subjects' designated account based on their resource use and game time. Top 5 APS subjects who play the game for the most time in a week will be rewarded
89012186|NCT02960880||Phenprocoumon|NVAF patients who were newly initiated on Phenprocoumon for stroke prevention
89439320|NCT03545685|Other|Control group|Participants in this group will serve as control group
89012187|NCT02961686||Patients with prostate cancer|Patients affected by prostate cancer and treated with a multidisciplinary approach that comprise exclusive radiotherapy, psychological and andrologic evaluation.
89012188|NCT00250640||Group 1|
89012189|NCT00250796|Active Comparator|Arm 1|Thalidomide+alpha interferon
89012190|NCT00250796|Experimental|Arm 2|Thalidomide+interferon+Octreotide
89439321|NCT03545841|Experimental|HIT training|6 weeks of high-intensity interval training (HIT)
89439322|NCT03545841|Experimental|Moderate intensity training|6 weeks of moderate-intensity continuous training (MICT)
89439323|NCT04184505|Active Comparator|Standard clinical treatment|"If BM-blasts >= 10%: Conventional chemotherapy: induction one cycle (3+7 protocol) and one optional consolidation cycle, followed by HSCT if a suitable sibling or unrelated donor is available versus~If BM blasts are <10%: HSCT upfront"
89439324|NCT04184505|Experimental|Experimental treatment|"If BM-blasts >= 10%: Azacitidine (AZA) 75mg/sqm/day subcutaneously for 7 days every 28 days (1 cycle of 28 days) for at least 4 cycles, followed by HSCT if a suitable sibling or unrelated donor is available~If BM blasts are <10%: Azacitidine (AZA) 75mg/sqm/day subcutaneously for 7 days every 28 days (1 cycle of 28 days) for at least 4 cycles, followed by HSCT if a suitable sibling or unrelated donor is available"
89439325|NCT03546543|Experimental|Supine|
89439326|NCT03546543|Experimental|Prone|
89439327|NCT02782923|Experimental|s-ACDFwith STISIM|Single-level anterior cervical discectomy fusion
89439328|NCT02782923|Experimental|m-ACDF with STISIM|Multi-level anterior cervical discectomy and fusion
89439329|NCT02782923|Experimental|CDR with STISIM|Cervical disc replacement
89439330|NCT02782923|Experimental|PCLF with STISIM|Posterior laminectomy and fusion
89439331|NCT02782923|Experimental|PCD with STISIM|Posterior cervical decompression procedure
89439332|NCT02782923|Sham Comparator|Control Group with STISIM|
89439333|NCT03546465|Experimental|Cohorts 1C (Caucasian subjects)|ropeginterferon alfa-2b: single dose of 100 μg
89439334|NCT03546465|Experimental|Cohorts 1J (Japanese subjects)|ropeginterferon alfa-2b: single dose of 100 μg
89439335|NCT03546465|Experimental|Cohorts 2C (Caucasian subjects)|ropeginterferon alfa-2b: single dose of 200 μg
89439336|NCT03546465|Experimental|Cohorts 2J (Japanese subjects)|ropeginterferon alfa-2b: single dose of 200 μg
89439337|NCT03546465|Experimental|Cohorts 3C (Caucasian subjects)|ropeginterferon alfa-2b: single dose of 300 μg
89439338|NCT03546465|Experimental|Cohorts 3J (Japanese subjects)|ropeginterferon alfa-2b: single dose of 300 μg
89439339|NCT03546465|Experimental|Cohorts 4C (Caucasian subjects)|ropeginterferon alfa-2b: single dose of 450 μg
88924156|NCT05291000|Experimental|RoT-ReWiH|First, pre-tests were applied to the patients in the training and reminder by watch group at first home visit.Second home visits were conducted participants 12th weeks after the first home visit.One of the researchers presented the education program to individuals with hypertensive.The education program included issues related to hypertension, measurament of pressure blood, lifestyle changes and adherence to treatment. The program using face-to-face communication technique and lasted about 45 minutes.For the patients in this group, the alarm time was set according to the time when blood pressure medication was taken, the cord was adjusted according to the arm, and then information was given about the use of the watch. At the end of the interview, the blood pressure of the experimental groups was measured and the measurement value was recorded on the blood pressure follow-up card.
88924157|NCT05291000|Experimental|Training group|First, pre-tests were applied to the patients in the training group at first home visit.The education program included issues related to hypertension, measurament of pressure blood, lifestyle changes and adherence to treatment. The program using face-to-face communication technique and lasted about 45 minutes. In addition, other drugs used by individuals at home (such as painkillers, antibiotics) were also evaluated during the home visit, and a red label was made on the antihypertensive drug box to distinguish antihypertensive drugs from other drugs. At the end of the interview, the blood pressure of the experimental groups was measured and the measurement value was recorded on the blood pressure follow-up card.
89439340|NCT03546465|Experimental|Cohorts 4J (Japanese subjects)|ropeginterferon alfa-2b: single dose of 450 μg
89439341|NCT03760458|Experimental|Weight Band #1 (6 to less than 10 kg at study entry)|Children weighing 6 to less than 10 kg at study entry. These children received 3 dispersible tablets of ABC/DTG/3TC daily while weighing 6-<10 kg; as their weight increased, they received higher doses consistent with their new weight band.
89439342|NCT03760458|Experimental|Weight Band #2 (10 to less than 14 kg at study entry)|Children weighing 10 to less than 14 kg at study entry. These children received 4 dispersible tablets of ABC/DTG/3TC daily while weighing 10-<14 kg; as their weight increased, they received higher doses consistent with their new weight band.
88924158|NCT05291000|No Intervention|Control group|Pre-tests was applied to the patients in the control group.No intervention was be applied to the patients in this group and second home visit 12th weeks after the first home visit and were readministered the post-tests.
88924159|NCT05290948|Active Comparator|investigate of the effect of intravitreal injection of bevacizumab with acetazolamide tablets|
88924160|NCT05290948|Active Comparator|Investigate the effect of intravitreal injection of bevacizumab alone|
88924161|NCT05290935|Experimental|Study group|The patients in the study group would accept the treatment of a combination of anti-PD-1 antibody camrelizumab and albumin-bound paclitaxel.
89439343|NCT03760458|Experimental|Weight Band #3 (14 to less than 20 kg at study entry)|Children weighing 14 to less than 20 kg at study entry. These children received 5 dispersible tablets of ABC/DTG/3TC daily while weighing 14-<20 kg; as their weight increased, they received higher doses consistent with their new weight band.
89439344|NCT03760458|Experimental|Weight Band #4 (20 to less than 25 kg at study entry)|Children weighing 20 to less than 25 kg at study entry. These children received 6 dispersible tablets of ABC/DTG/3TC daily while weighing 20-<25 kg; as their weight increased, they received higher doses consistent with their new weight band.
88924162|NCT05290909|Experimental|The protocol of blended and problem-based learning|The experimental group will accept the protocol of blended and problem-based learning in the professional ethics course, 2 hours /per week, for 18 weeks
89439345|NCT03760458|Experimental|Weight Band #5 (25 kg or greater at study entry)|Children weighing 25 kg or greater at study entry. These children received 1 immediate release tablet of ABC/DTG/3TC daily.
89439346|NCT02066415|Placebo Comparator|Placebo|Participants received placebo on day 1 and at weeks 4 and 8 by subcutaneous injection.
89439347|NCT02066415|Experimental|Erenumab 70 mg|Participants received 70 mg erenumab on day 1 and at weeks 4 and 8 by subcutaneous injection.
89439348|NCT02066415|Placebo Comparator|Erenumab 140 mg|Participants received 140 mg erenumab on day 1 and at weeks 4 and 8 by subcutaneous injection.
89439349|NCT02583256|Experimental|aQIV/aQIV|Subjects previously vaccinated with aQIV followed one year later by aQIV
89439350|NCT02583256|Experimental|aQIV/QIV|Subjects previously vaccinated with aQIV followed one year later by QIV
88924163|NCT05290909|Active Comparator|The traditional problem-oriented teaching model|The control group will accept the traditional problem-oriented teaching model in the professional ethics course, 2 hours /per week, for 18 weeks
88924164|NCT05290896|Other|Lens star biometry|Biometry done prior to phacoemulsification
88924165|NCT05290831|Experimental|Main study group|
88924166|NCT05290636|Experimental|single arm trial|A single-arm trial was designed. (Two-hour sessions per week for 18 weeks). The value of classroom learning and practical experience for the study subjects is emphasized in this intervention course. The case analysis teaching technique will be used extensively in the classroom, and the school's digital action learning platform will support instructional activities relevant to senior nursing and elderly nursing practice. In each section of the course, combine classroom instruction with case analysis (2 hours each, 20-30 minutes for topic teaching, 70-80 minutes for case discussion and feedback)
88924167|NCT05290571|Experimental|Intervention Group|Intervention Group will be asked to follow the actions in the provided video. It lasts for approximately 30 minutes, with 5-minute warm-up and cool-down exercises respectively, a 4-minute song repeating for 4 times and a 1-minute rest in between each repetition. Videos, in the form of a YouTube link, will be distributed for the Intervention Group, as well as the leaflets.
88924168|NCT05290571|Active Comparator|Control Group|Control Group will receive a leaflet on 10 actions extracted from mOEP, 2 actions from conventional OEP and 1 action from Mini-BESTest. The participants will perform 8-16 repetitions for each action, with 3-5 seconds of rest between actions.
88924169|NCT05290545|Experimental|Haplo-PBSC+Cord group|The third party UCB will be infused the day after infusion of PBSCs from HID.
88924170|NCT05290545|Active Comparator|Haplo-PBSC+BM group|The BMSCs from the same HID will be infused the day after infusion of PBSCs.
88924171|NCT05290532|Other|Individualized exercise training|Exercise training. Individual program training 2 days per week during 4 week, after one week of discharge
88924172|NCT05290532|No Intervention|No Intervention: Control|Usual care including rehabilitation when necessary
88924173|NCT05290519|Experimental|Group A|plant protein for 4 weeks than animal protein for 4 weeks
88924174|NCT05290519|Experimental|Group B|animal protein for 4 weeks than plant protein for 4 weeks
88924175|NCT05290506|Active Comparator|Prediabetes Low GLP-1|prediabetes patients were divided into high GLP-1 and low GLP-1 groups based on the median of fasting GLP-1 level. linagliptin 5mg once daily was administered.
88924176|NCT05290506|Active Comparator|Prediabetes High GLP-1|prediabetes patients were divided into high GLP-1 and low GLP-1 groups based on the median of fasting GLP-1 level. linagliptin 5mg once daily was administered.
88924177|NCT05290506|Active Comparator|Diabetes Low GLP-1|type 2 diabetes mellitus patients were divided into high GLP-1 and low GLP-1 groups based on the median of fasting GLP-1 level. linagliptin 5mg once daily was administered.
88924178|NCT05290506|Active Comparator|Diabetes High GLP-1|type 2 diabetes mellitus patients were divided into high GLP-1 and low GLP-1 groups based on the median of fasting GLP-1 level. linagliptin 5mg once daily was administered.
88924179|NCT05290480|Experimental|Expiratory muscle training|participant performed expiratory muscle training with threshold device
88924180|NCT05290480|Experimental|Insentive spirometry|participant performed deep breathing exercise with insentive spirometry device
88924181|NCT05290441|Active Comparator|None involement|In the pathological examination, the group of patients without EGFR involvement in the biopsy material.
88924182|NCT05290441|Active Comparator|Mild|In the pathological examination, the group of patients mild EGFR involvement in the biopsy material.
88924183|NCT05290441|Active Comparator|Moderate|In the pathological examination, the group of patients moderate EGFR involvement in the biopsy material.
88924184|NCT05290441|Active Comparator|Severe|In the pathological examination, the group of patients severe EGFR involvement in the biopsy material
88924185|NCT05290428||Retrospective part|This part will enroll at least 120 cases in previously preserved samples.
88924186|NCT05290428||Prospective part|This part will enroll at least 339 cases.
88924187|NCT05290376|Active Comparator|Control group|Group I (control): patients who would be delivered mandibular implant overdenture retained by two RTx locator attachments using conventional loading protocol
88924188|NCT05290376|Active Comparator|Study group|Group II (study): patients who would be delivered mandibular overdenture retained by two RTx locator attachments using early loading protocol.
88924189|NCT05290337|Experimental|ZR-CHOP|
88924190|NCT05290324|Experimental|MIdazolam Group|Following surgery Immediately after shifting in ICU, midazolam infusion were administered as 0.25 mg/kg/min.
88924191|NCT05290324|No Intervention|Propofol Group|Following surgery after Immediately shifting in ICU propofol infusion was started at 10µg/kg/min.
88924192|NCT05290311||COMB|The 'combined' or 'COMB' group received cognitive behavioural therapy next to pharmacotherapy for ADHD in the past. Patients chose themselves whether or not they wanted to receive cognitive behavioural therapy.
88924193|NCT05290311||PHA|The 'pharmacotherapy' group or 'PHA' received pharmacotherapy for ADHD only in the past. Patients chose themselves whether or not they wanted to receive cognitive behavioural therapy.
88924194|NCT05290298|Experimental|NITRATE|Multi-component nutritional formula (containing 1200 mg of potassium nitrate, 200 mg of magnesium, 50 mg of zinc, and 1000 mg of citric acid)
88924195|NCT05290298|Placebo Comparator|PLACEBO|Placebo (2.5 grams of inulin)
88924196|NCT05290272|Experimental|ViFIVE Digital Care Program|AI based digital care program that is individually tailored for each user depending on need. ViFive DCP includes illustration, voice guidance, and pose correction features of AI coach. Participants will required to complete the program.
88924197|NCT05290051|Experimental|Patients referred for cytogenetic analysis|Analysis of patient DNA with Optical Genome Mapping (Bionano®) and long read Sequencing (Nanopore®) in search for chromosome abnormalities (aneuploidies and SV)
88924198|NCT05290012|Experimental|Dark Chocolate|Participants consumed 18 grams of dark chocolate (36 g/day, 400 mg/day of flavanols) twice daily.
88924199|NCT05290012|No Intervention|Control|No intervention was made
88924200|NCT05289921|Experimental|HU-014 Inj|HU-014 Inj was given an injection to 5 Upper limb muscle(Total 360U/, IM)
88924201|NCT05289921|Active Comparator|Clostridium botulinum type A|Clostridium botulinum type A Inj was given an injection to 5 Upper limb muscle(Total 360U/, IM)
88924202|NCT05289895||1|Sequence I (Retrospective study: proteomic analysis of pathological specimens and information collection of previous patients with pancreatic cancer)
88924203|NCT05289895||2|Sequence 2 (Non-interventional prospective study, sample and information collection in patients with pancreatic cancer)
88924204|NCT05289895||3|Sequence 3 (Non-intervention study, healthy subjects sample and information collection)
88924205|NCT05289843|Experimental|Experimental|Rosmarinus officinals will be used as root canal irrigant in treating aysymptomatic mandibular premolars.
88924206|NCT05289843|No Intervention|Control Group|Sodium Hypochlorite used as control in root canal irrigations in treating a asymptomatic mandibular premoalrs.
89199411|NCT05631171|Experimental|Solution group|The study sample will consist of 60 patients, 30 of whom will be randomly assigned to a control group and 30 to the experimental group. Validated questionnaires will be administered to the participants of both groups, at the beginning of the study, at 1 month and 3 months by Microsoft Forms. In addition, the experimental group will be given a smartwatch to each person which will collect real-time data on activity, training and sleep in a completely anonymous way. Also, through a mobile application, the patient of the experimental group will answer questionnaires about health status perception. The application has also been trained to provide educational content and motivational messages to support the patient's self-management. The data provided by patients in both groups of the study will be coded, in order to maintain the confidentiality of the individual.
88924207|NCT05293028|Experimental|Drug:F527|F527 is dose-escalated sequentially by accelerated titration and i3+3 design.
88924208|NCT05293015|Experimental|NP-Supported Multidisciplinary Diabetes Management|NP establishes files to evaluate and manage patients before hospital and visits patients after hospitalization. Then set blood glucose control goals with endocrinology and orthopedic doctors together, initiates consultation with endocrinologists for patients with postoperative hyperglycemia, and is responsible for post-hospital follow-up.
88924209|NCT05293015|No Intervention|Regular diabetes management|The patient would go to the endocrinology outpatient clinic before hospitalization to regulate blood glucose, and be managed by by orthopedic medical staff through hospitalization. If necessary, the endocrinologist is consulted. And after the hospital, patients would be followed up by orthopedic medical staff.
88924210|NCT05292924|Experimental|Early SSC|Cesarean delivery and SSC within the first 30 minutes of birth
88924211|NCT05292924|No Intervention|Control|Cesarean delivery and SSC one hour after birth
88924212|NCT05292768||Patients with AID|
88924213|NCT05292768||Control patients with mastocytosis|
88924214|NCT05292768||Control patients with normal digestive biopsy|
88924215|NCT05292768||Control patients with renal biopsy|
88924216|NCT05292768||Control patients with inflammatory disease|
88924217|NCT05292768||Healthy control from healthcare workers|
88924218|NCT05292742|Experimental|A|Pyrotinib: 400 mg/day (once daily, orally at the same time every day), every 3 weeks for one year Capecitabine: 1000 mg/m2 orally twice daily every 3 weeks for 6 cycles Trastuzumab: Initial loading dose of 8 mg/kg followed by 6 mg/kg every 3 weeks. One year of trastuzumab treatment (including: neoadjuvant phase and adjuvant phase)
88924219|NCT05292742|Active Comparator|B|Patients in the control group will continue neoadjuvant targeted therapy, trastuzumab or trastuzumab in combination with pertuzumab. In case of neoadjuvant trastuzumab monotherapy, trastuzumab combined with pertuzumab targeted therapy is allowed in the adjuvant phase.
88924220|NCT05292677|Experimental|Intervention (Steroid/Anesthetic Mixture)|The steroid/anesthetic mixture will be injected via a 27-gauge needle once at the baseline or during the 6-week crossover timepoint.
88924221|NCT05292677|Placebo Comparator|Placebo (Normal Saline)|The placebo (Normal Saline) will be injected via a 27-gauge needle once at the baseline or during the 6-week crossover timepoint.
88924222|NCT05292573|Experimental|metformin group|"During the intervention period, metformin is given 500 mg tablet b.i.d.~We will deliver education for exercise and weight control to all eligible participants"
88924223|NCT05292573|No Intervention|Observation group|only exercise and weight control to all eligible participants
88924224|NCT05292495|Experimental|Cohort one: mild renal insufficiency|
88924225|NCT05292495|Experimental|Cohort two: moderate renal insufficiency|
88924226|NCT05292495|Experimental|Cohort three: severe renal insufficiency|
88924227|NCT05292495|Experimental|Cohort four: end-stage renal disease|
88924228|NCT05292495|Experimental|Cohort five: normal renal function|
88924229|NCT05292430||Biobank|Specimens are to be collected from subjects who are having or have had a surgical or medical procedure (such as fluid or tissue removed, a biopsy or a blood or bone marrow draw). Any subject in which the primary diagnosis of disease was made within the DHR Health System and Any subject choosing to give consent for participation will be included.
88924230|NCT05292170|Experimental|Males|10 consecutive day heat acclimation in males
89199412|NCT05631171|No Intervention|Control group|The study sample will consist of 60 patients, 30 of whom will be randomly assigned to a control group and 30 to the experimental group. Validated questionnaires will be administered to the participants of both groups, at the beginning of the study, at 1 month and 3 months by Microsoft Forms.
89206097|NCT04095533||Sepsis|"Starting at admission to ICU, patients admitted to a mixed medical-surgical ICU will be assessed every second day to determine their muscle size as measured by ultrasound, and their muscle strength as measured clinically using the Medical Research Council strength assessment at the bedside.~One-time Measures:~Illness severity as measured by the SOFA score within the first 24 hours of admission.~duration of mechanical ventilation~duration of stay in the ICU~duration of stay in the hospital"
88924231|NCT05292170|Experimental|Females + high hormones|10 consecutive day heat acclimation in females with high hormonal dose
88924232|NCT05292170|Experimental|Females + low hormones|10 consecutive day heat acclimation in females with low hormonal dose
89439351|NCT02583256|Experimental|QIV/aQIV|Subjects previously vaccinated with QIV followed one year later by aQIV
89439352|NCT02583256|Experimental|QIV/QIV|Subjects previously vaccinated with QIV followed one year later by QIV
89439353|NCT03745794|Active Comparator|Arm I (QL block, standard of care)|Patients undergo QL block before surgery and receive standard of care multimodal pain control after surgery.
89537016|NCT03303053|Active Comparator|Group 3: Standard treatment alone|Carbimazole 30 mg daily and propanolol 40 mg twice daily for 4 weeks
89439354|NCT03745794|Experimental|Arm II (second QL block)|Patients undergo QL block before surgery and receive multimodal pain control. Patients then undergo a second QL block on day 4 after surgery and continue to receive standard of care.
88924233|NCT05292157||Reverse total shoulder arthroplasty|Patients who have received a reverse total shoulder arthroplasty with more than 2 years of follow-up in a temporal frame going from 2016 to 2022.
88924234|NCT05292027|Experimental|low-dose radiotherapy group|Neoadjuvant chemotherapy combined with low-dose radiotherapy sequential concurrent chemoradiotherapy
88924235|NCT05292027|No Intervention|control group|Neoadjuvant chemotherapy sequential concurrent chemoradiotherapy
88924236|NCT05291910|Experimental|Inetetamab+ Toripalimab+ Albumin-Bound Paclitaxel|Drug: Inetetamab Initial dose of 8 mg/kg over 90 minutes IV infusion, then 6 mg/kg over 30 to 90 minutes IV infusion every three weeks Drug: Toripalimab 240mg intravenously every 3 weeks Drug: Albumin-Bound Paclitaxel 130mg/m2, IV , D1, D8, q3w
88924237|NCT05291793|No Intervention|NSAID group|Group 1, patients only received non-steroid anti-inflammatory oral and topical treatment for 3 weeks. (ibuprofen 2x800 mg (1600 mg daily), 1% nimesulide + 5%Lidocain (3 times a day))
88924238|NCT05291793|Active Comparator|Tenoxicam|Group 2, patients received intraarticular tenoxicam ( 20 mg) once.
88924239|NCT05291793|Active Comparator|Methylprednisolone|Group 3, patients received intraarticular methylprednisolone once(40mg).
88924240|NCT05291793|Sham Comparator|Saline|Group 4, patients received an intraarticular sterile saline injection(4ml).
88924241|NCT05291780|Experimental|SABR in unresectable LA-NSCLC|Patients fit for chemotherapy will be enrolled to sequential chemotherapy-stereotactic ablative radiotherapy (SABR), while patients unfit for chemotherapy will be enrolled to exclusive stereotactic ablative radiotherapy (SABR).
88924242|NCT05291702|Other|Multitract PCNL patients|Assessment of the multitract PCNL procedure in removal of large renal stones using pneumatic or laser lithotripsy.
88924243|NCT05295134|Placebo Comparator|Placebo|Maltodextrin
88924244|NCT05295134|Active Comparator|Lipase: Low-Dose|Candida cylindracea lipase (75,000 FIP per serving)
88924245|NCT05295134|Active Comparator|Lipase: Medium-Dose|Candida cylindracea lipase (150,000 FIP per serving)
88924246|NCT05295134|Active Comparator|Lipase: High-Dose|Candida cylindracea lipase (225,000 FIP per serving)
88924247|NCT05295069|Experimental|The intervention group|To reduce postpartum depression among the primiparous puerperal women in the intervention group, and a nursing care program was implemented under the guidance of Levine's model. This program was applied with 7 home visits between the 8th and 80th postpartum days. Face-to-face training and training booklets were provided in home visits. As of the fourth home visit, Pilates exercises were performed.
88924248|NCT05295069|No Intervention|The control group|In the control group women received routine postpartum care. No interventions were conducted other than routine postpartum care.
88924249|NCT05294926|Active Comparator|deep neuromuscular blockade|
88924250|NCT05294926|Active Comparator|moderate neuromuscular blockade|
88924251|NCT05294913|Experimental|Intervention group|
88924252|NCT05294913|Placebo Comparator|Placebo control group|
89206098|NCT04018560|Experimental|Intervention|
89439355|NCT04467918|Experimental|Cannabidiol (CBD)|50 cases in the CBD group plus pharmacological and clinical measures. Patients in the investigational treatment group will receive CBD within 24 hours after randomization, with a daily dose of 300mg / day (two 150mg doses; 1mL of the formulation) for 14 days.
89439356|NCT04467918|Placebo Comparator|Placebo (PLB)|50 in the placebo group plus pharmacological and clinical measures. Patients in the placebo group will also receive, within 24 hours after randomization, 1mL of the same investigational medication vehicle (medium / coconut chain triglyceride oil - MCT) for 14 days
89439357|NCT03133104||antenatal corticosteroids|Women who received a rescue dose of steroids
89439358|NCT03133104||No antenatal corticosteroids|Women who did not received a rescue dose of steroids
89439359|NCT03522090||No neck CT|Cohort of patients with suspected lung cancer where the lower neck is not routinely included in CT
89439360|NCT03522090||Neck CT|Cohort of patients with suspected lung cancer where the lower neck is routinely included in CT
89439361|NCT03522012|Experimental|LusiNex|4 mg/kg, single-dose IV infusion (Mycenax tocilizumab)
89439362|NCT03522012|Active Comparator|RoActemra|4 mg/kg, single-dose IV infusion (RoActemra; tocilizumab marketed in EU )
89439363|NCT03522012|Active Comparator|Actemra|4 mg/kg, single-dose IV infusion (Actemra; tocilizumab marketed in US)
89199413|NCT05629221|Experimental|TreC Diabete App users|"Sixty individuals allocated to the intervention group are prescribed with the TreC Diabete App for 12 months, one of the App created within the so-called TreC platform, which enables citizens from PAT to access, manage and share information about their health and wellbeing in the context of telemedicine. The use of the App is additional to the standard care, based on the integrated preventive and diagnostic care pathway (called Percorsi Preventivi Diagnostici Terapeutici Assistenziali - PPDTA in Italian).An appointment with the outpatient diabetes clinic staff is scheduled at 6 and 12 month from the first visit (taking place within 30 days of the study entry), either through telemedicine (remote visit) or face-to-face."
89199414|NCT05629221|No Intervention|non-App users|"Sixty individuals are allocated to the control group. These participants will receive standard care, which is the best care for T2DM in line with the integrated preventive and diagnostic care pathway (called Percorsi Preventivi Diagnostici Terapeutici Assistenziali - PPDTA in Italian).An appointment with the outpatient diabetes clinic staff is scheduled at 6 and 12 month from the first visit (taking place within 30 days of the study entry), either through telemedicine (remote visit) or face-to-face. Participants are asked to register their data as per routine (e.g. paper diary)."
89199415|NCT05625295||Patients with non-face-to-face consultation|A sample of 500 patients who have undergone non-face-to-face consultation with dermatology
89199416|NCT05625295||Patients with face-to-face consultation|A sample of 500 patients who have undergone face-to-face consultation with dermatology
88924253|NCT05294887|Experimental|bisoprolol first, diltiazem second|Crossover Design: bisoprolol first, diltiazem second, placebo third
88924254|NCT05294887|Experimental|bisoprolol first, placebo second|Crossover Design: bisoprolol first, placebo second, diltiazem third
88924255|NCT05294887|Experimental|diltiazem first, bisoprolol second|Crossover Design: diltiazem first, bisoprolol second, placebo third
88924256|NCT05294887|Experimental|diltiazem first, placebo second|Crossover Design: diltiazem first, placebo second, bisoprolol third
88924257|NCT05294887|Experimental|placebo first, bisoprolol second|Crossover Design: placebo first, bisoprolol second, diltiazem third
88924258|NCT05294887|Experimental|placebo first, diltiazem second|Crossover Design: placebo first, diltiazem second, bisoprolol third
88924259|NCT05294874|Active Comparator|classical gait training|physical therapy exercises including classical gait training
88924260|NCT05294874|Active Comparator|classical gait training using ankle weight|physical therapy exercises including classical gait training while using ankle weight
88924261|NCT05294874|Experimental|gait training using ankle weight after botulinum toxin injection|physical therapy exercises including classical gait training while using ankle weight and with BOTOX injection
88924262|NCT05294861|Experimental|YesMdiet|After one week baseline, the participants will be assigned to YesMdiet, consuming milk and dairy products for 14 days
88924263|NCT05294861|Active Comparator|NoMdiet|After one week baseline, the participants will be assigned to NoMdiet, consuming another source of protein and without milk or dairy products for 14 days
88924264|NCT05294822|Experimental|Autologous regenerative islet transplantation for insulin-dependent diabetes mellitus|
88924265|NCT05294783||ACL injured patients|All the ACL injured patients recruited underwent ACL reconstruction with the same group of surgeons lead by the same chief surgeon.
88924266|NCT05294744|Active Comparator|Corticosteroids|Corticosteroids following Standard Clinical Practice
88924267|NCT05294744|Experimental|Corticosteroids + N-acetylcysteine|Corticosteroids following Standard Clinical Practice plus N-acetylcisteine
88924268|NCT05294666|Experimental|cyclosporine group|The chronic ocular GVHD patients in cyclosporine group received local 0.05% cyclosporine 4 times/day for 3 months, and then changed to 0.05% cyclosporine for 2 times/day for 3 months
88924269|NCT05294666|Experimental|tacrolimus group|The chronic ocular GVHD patients in tacrolimus group received local 0.05% tacrolimus 2 times/day for 3 months, and then changed to 0.05% cyclosporine for 2 times/day for 3 months
88924270|NCT05294601|Active Comparator|HIIG Group|General nutritional recommendations will be suggested in an initial consultation with weekly telephone follow-up. The high intensity children's games program for 12 weeks, . In this group the activities will include 3 weekly sessions. . The games last 6 minutes with a 2 minute break, four games per session; which is the one established for children of these ages according to the cited authors. The session is divided into 5 minutes of warm-up, 36 minutes of intervention and 8 minutes of cool-down. The intensity varies between 85-95% of HR max. According to the equation of Tanka et., Al. HR max = 208-0.7 x age
88924271|NCT05294601|Active Comparator|MIIG Group|: The interventions will be carried out by a graduate in physical education, recreation and / or sports and the main researcher. General nutritional recommendations will be suggested in an initial consultation with weekly telephone follow-up. The medium intensity physical activity program for 12 weeks (28). Medium intensity activities are very similar to those taught in physical education class. In this group the activities will include 3 weekly sessions, with six episodes of 10 min at 65% to 85% of maximum heart rate (HRmax) separated by 5 min of recovery.
89439364|NCT05698108|Active Comparator|Conventional Physcial Therapy Group|All participants received treatment 2 times a week for 4 weeks. Pre-treatment included a Moist hot pack for 10 minutes and traditional physical therapy included Cyriax Deep Friction Massage (DFM), Ultrasound therapy as well as strengthening and stretching exercises
89439365|NCT05698108|Experimental|IASTM Group|Participants received Instrument Assisted Soft Tissue Mobilization Treatment 2 times a week for 4 weeks using Ergon IASTM tools.
89439366|NCT05695456|Active Comparator|CLE positive patients real/sham|In this arm, participants who reacted to one or two nutrients during CLE will follow a personalized exclusion diet consistent of the nutrient to which they reacted, after which they will follow a sham diet in a blinded cross-over fashion.
89439367|NCT05695456|Sham Comparator|CLE positive patients sham/real|In this arm, participants who reacted to one or two nutrients during CLE will follow a sham diet for 6 weeks, and than a personalized exclusion diet consistent of the nutrient to which they reacted, in a blinded cross-over fashion.
89439368|NCT05695456|Sham Comparator|CLE negative patients|In this arm, participants who did not react to one of the nutrients during CLE will follow a control diet consistent of milk exclusion for 6 weeks, after which they will follow a gluten exclusion diet for 6 weeks, or the other way around.
88924272|NCT05294601|No Intervention|Control Group|In this group, measurements will be made before, during and after the study. Neither medium nor high intensity interventions will be carried out in order to generate comparisons, control biases and confounding and interaction variables. However, the interventions that have been most beneficial in the intervention groups. It could be implemented in this study once the analysis between groups has been completed, according to the recommendations and follow-up by the ethics committee.
88924273|NCT05294575||OHCA in the general population|All Out-of-Hospital Cardiac Arrests
89439369|NCT05535868|Experimental|SPN3.|Inoculation with SPN3 at D0 visit. 0.1ml of pneumococcus is given
88924274|NCT05294575||Traumatic OHCA|OHCA related to Trauma
88924275|NCT05294536|Experimental|Liraglutide injection (RD12014)+ Victoza|Subjects receive liraglutide injection(RD12014) in the first cycle and Victoza in the second cycle.
88924276|NCT05294536|Experimental|Victoza + Liraglutide injection (RD12014)|Subjects receive Victoza in the first cycle and liraglutide injection(RD12014) in the second cycle.
88924277|NCT05294497|Experimental|Product usage order A B N C E D|Subjects will use each of the 6 products sequentially (A B N C E D) during an evaluation period, followed by a 4 hour Test Session.
88924278|NCT05294497|Experimental|Product usage order B C A D N E|Subjects will use each of the 6 products sequentially (B C A D N E) during an evaluation period, followed by a 4 hour Test Session.
88924279|NCT05294497|Experimental|Product usage order C D B E A N|Subjects will use each of the 6 products sequentially (C D B E A N) during an evaluation period, followed by a 4 hour Test Session.
88924280|NCT05294497|Experimental|Product usage order D E C N B A|Subjects will use each of the 6 products sequentially (D E C N B A) during an evaluation period, followed by a 4 hour Test Session.
89439370|NCT05535868|Experimental|SPN3 booster|inoculation booster at day 14 This visit will only occur for participants who have tested negative for SPN3 at days 2 and 7. 0.1ml of pneumococcus is given
88924281|NCT05294497|Experimental|Product usage order E N D A C B|Subjects will use each of the 6 products sequentially (E N D A C B) during an evaluation period, followed by a 4 hour Test Session.
89439371|NCT04720612|Experimental|Omalizumab|Participants in this arm will receive the study drug, omalizumab.
88924282|NCT05294497|Experimental|Product usage order N A E B D C|Subjects will use each of the 6 products sequentially (N A E B D C) during an evaluation period, followed by a 4 hour Test Session.
89439372|NCT04720612|Placebo Comparator|Placebo|Participants in this arm will receive a placebo treatment.
88924283|NCT05294484|Active Comparator|Fasting group|Following an overnight fast of at least 10 hours, subjects should be administered single dose of indapamide 1.5 mg SR with 240 mL (8 fluid ounces) of water. No food should be allowed for at least 4 hours post-dose. Water can be allowed as desired except for one hour before and after drug administration. Subjects should receive standardized meals scheduled at the same time in each period of the study.
88924284|NCT05294484|Active Comparator|Fed group|"Following an overnight fast of at least 10 hours, subjects should start the recommended meal 30 minutes prior to administration of the drug. Study subjects should eat this meal in 30 minutes or less; however, indapamide 1.5 mg SR should be administered 30 minutes after start of the meal. The drug should be administered with 240 mL (8 fluid ounces) of water. No food should be allowed for at least 4 hours post-dose. Water can be allowed as desired except for one hour before and after drug administration. Subjects should receive standardized meals scheduled at the same time in each period of the study.~All subjects should abstain from the consumption of fruit juices during the study period. All the subjects are to be under complete medical supervision."
88924285|NCT05294445|Active Comparator|Group1: Cryo-AF-Ablation|Patients randomized in the Cryo-AF-Ablation group should receive the cryo AF ablation within 21 days from baseline.
88924286|NCT05294445|No Intervention|Group 2: Usual care|Patients randomized in the usual care group should start or maintain on AAD therapy within 21 days from baseline, based on decision of the investigator according to current ESC Guidelines.
89439373|NCT02584660|Experimental|Rivaroxaban|Participants will receive Rivaroxaban 15 milligram (mg) orally twice daily with food for the first 21 days followed by 20 mg orally once daily with food, for approximately 69 days for a total treatment duration of 90 days.
88924287|NCT05294432||Single Group|Patients of Wilderman Medical Clinic diagnosed with symptomatic Osteoarthritis of the Knee who were prescribed with at least one intra-articular corticosteroid injection.
88924288|NCT05294393|Placebo Comparator|N/S 0.9%|Wound infiltration with 12 ml of N/S 0.9% at the end of surgery before wound closure
88924289|NCT05294393|Active Comparator|Ropivacaine 10%|Wound infiltration with 12 ml solution of 100mg ropivacaine at the end of surgery before wound closure
88924290|NCT05294393|Experimental|Ropivacaine 10% magnesium sulphate 10mg/kg|Wound infiltration with 12 ml solution of 100mg ropivacaine plus magnesium sulphate 10mg/kg at the end of surgery before wound closure
88924291|NCT05294380||oncologic|"Be between the ages of 2-18 years Being under pediatric oncology outpatient/clinical follow-up Being able to stand unaided without using a cane/walker Exclusion criteria; Having any of the diagnoses of hypertension, any cardiac arrhythmia-conduction disorders, coronary artery disease, heart failure, diabetes mellitus, hyperlipidemia, cardiovascular diseases, COPD, pulmonary infection, active infection.~Depression Illness that causes balance problems Peripheral vascular disease Presence of disease that prevents standing up with support Presence of diseases that may cause muscle mass loss (cerebral palsy, neuromuscular disease, congenital metabolic disorder, brain damage) mental retardation Children with a severe emotional disorder, adjustment disorder Physical disability to prevent safe and appropriate testing Having used anti-flu medicine in the last 1 week Failure to obtain consent"
88924292|NCT05294380||control|"Be between the ages of 2-18 years Exclusion criteria; Having any of the diagnoses of hypertension, any cardiac arrhythmia-conduction disorders, coronary artery disease, heart failure, diabetes mellitus, hyperlipidemia, cardiovascular diseases, COPD, pulmonary infection, active infection.~Depression Illness that causes balance problems Peripheral vascular disease Presence of disease that prevents standing up with support Presence of diseases that may cause muscle mass loss (cerebral palsy, neuromuscular disease, congenital metabolic disorder, brain damage) mental retardation Children with a severe emotional disorder, adjustment disorder Physical disability to prevent safe and appropriate testing Having used anti-flu medicine in the last 1 week Failure to obtain consent"
88924293|NCT05294315|Active Comparator|Single level block arm - Control|Single level erector spinae block at 4th transverse process
88924294|NCT05294315|Experimental|Bi-level block arm - Intervention|Bi-level erector spinae block at 4th and 6th transverse process
88924295|NCT05294198|Experimental|Beet protocol|Beta vulgaris L. extract (600mg)
88924296|NCT05294198|Placebo Comparator|Placebo protocol|Starch (600mg)
88924297|NCT05294094|Experimental|intervention group|blended learning
88924298|NCT05294094|Active Comparator|control group|Teaching format as usual
88924299|NCT05293990|Other|Contrast-enhanced fluid attenuated inversion recovery|Confirmation of the difference between FLAIR contrast enhancement and T1 contrast enhancement patterns-->PACS monitor shows the maximum dimension of FLAIR and T1 contrast enhancement by two neurology radiologists on FLAIR and T1 contrast enhancement images. In addition, the maximum diameter of the T2 high-signal lesion around the tumor is obtained using FLAIR images before contrast in the same plane. (Dt2)
88924300|NCT05293977|Active Comparator|Control|Patients in the control group received routine care by the dispensing pharmacist and seen by research assistant for data collection only
88924301|NCT05293977|Experimental|Intervention|Patient in the intervention group was verbally provided with pharmaceutical education/counseling about his/her prescribed antibiotic.
88924302|NCT05293873|Experimental|Treatment (BM-MNC trasnplatation)|Autologous bone marrow-derived mononuclear cell will transplant at baseline, and the second transplantation will be performed 6 months after the first transplantation and combination with rehabilitation therapy
88924303|NCT05293873|Other|Control group|rehabilitation therapy
88924304|NCT05293795|Active Comparator|3d printed model|Mother r is given 3D printed model of fetus' face
88924305|NCT05293795|Placebo Comparator|Placebo|Mother is given printed picture of 3D ultrasound of fetus
88924306|NCT05293795|No Intervention|Control|Standard of Care
88924307|NCT05293652|Experimental|Iontophosresis group|
88924308|NCT05293652|Experimental|Phonophoresis group|
88924309|NCT05293652|Experimental|Traditional group|
88924310|NCT05293574|Experimental|norethisterone acetate group|". In the norethisterone acetate group, the women will receive of norethisterone acetate 5 mg twice daily and are counseled about how to take norethisterone acetate and informed of possible side effects. They also receive a diary card for recording norethisterone acetate intake to be returned to the physician on the day of the next visit. An appointment for the women in both groups was scheduled at one month of treatment for the second ultrasonography.~If there is no remission occurred another month of Norethisterone acetate will be given ."
89199417|NCT05603819||Bipolar disorder|Patients with depression suffering from bipolar disorder.
89199418|NCT05603819||Major depressive disorder|Patients with depression suffering from major depressive disorder.
89206099|NCT04018560|No Intervention|Usual care|
89206100|NCT00824148|Experimental|Real-time glucose monitoring|Use of Guardian REAL-Time Continuous Glucose Monitoring System, (Medtronic Minimed, Northridge, CA) for 1 month, followed by observation for 2 months.
89206101|NCT00824148|Active Comparator|Self-monitoring of plasma glucose|Conventional self-monitoring of plasma glucose by finger-prick sampling for 1 month, followed by 1 month observation.
89206102|NCT04925050|Active Comparator|Drug VB0004|Experimental, Single Ascending dose , Multiple Ascending dose in healthy subjects and naive patients with mild or moderate hypertension with low cardiovascular risk
89206103|NCT04925050|Placebo Comparator|Placebo|Matching Placebo for VB0004
89439374|NCT02584660|Experimental|local Standard-of-care|Participants will receive local Standard-of-care as per local protocol and defined by the medical team caring for the participant.
88924311|NCT05293574|No Intervention|expectant managment group|
88924312|NCT05293483||COVID-19|
88924313|NCT05293483||non-COVID-19|
88924314|NCT05293301|Experimental|Periodontal Endosccope|One randomly assigned side of the mouth received deep cleaning treatment with the operator using a periodontal endoscope or Perioscopy® for magnification
89012191|NCT00279825|Other|Sequence 1|Subjects take 1 tablet of IPX054 200 mg, 1 tablet of IPX054 250 mg Placebo, 2 tablets of CD-LD IR Placebo and 1 tablet of CD-LD CR Placebo. In Second treatment, subjects take 1 tablet of IPX054 200 mg Placebo, 1 tablet of IPX054 250 mg, 2 tablets of CD-LD IR Placebo and 1 tablet of CD-LD CR Placebo. In Third treatment, subjects take 1 tablet of IPX054 200 mg Placebo, 1 tablet of IPX054 250 mg Placebo, 2 tablets of CD-LD IR and 1 tablet of CD-LD CR Placebo. In Fourth treatment, subjects take 1 tablet of IPX054 200 mg Placebo, 1 tablet of IPX054 250 mg Placebo, 2 tablets of CD-LD IR Placebo and 1 tablet of CD-LD CR.
89439375|NCT04862286|Experimental|Risankizumab|Participants will receive risankizumab subcutaneous (SC) injection every 12 weeks for 204 weeks.
89012192|NCT00279825|Other|Sequence 2|Subjects take 1 tablet of IPX054 200 mg Placebo, 1 tablet of IPX054 250 mg, 2 tablets of CD-LD IR Placebo and 1 tablet of CD-LD CR Placebo. In Second treatment, subjects take 1 tablet of IPX054 200 mg, 1 tablet of IPX054 250 mg Placebo, 2 tablets of CD-LD IR Placebo and 1 tablet of CD-LD CR Placebo. In Third treatment, subjects take 1 tablet of IPX054 200 mg Placebo, 1 tablet of IPX054 250 mg Placebo, 2 tablets of CD-LD IR Placebo and 1 tablet of CD-LD CR. In Fourth treatment, subjects take 1 tablet of IPX054 200 mg Placebo, 1 tablet of IPX054 250 mg Placebo, 2 tablets of CD-LD IR and 1 tablet of CD-LD CR Placebo.
89206104|NCT02549586|Experimental|Autologous HSCT|Eligible participants will undergo an Autologous Hematopoietic Stem Cell Transplant (HSCT) as a two-step intervention.
89439376|NCT02254083|Experimental|BIBT 986 BS - low|
89439377|NCT02254083|Experimental|BIBT 986 BS - high|
89439378|NCT02254083|Placebo Comparator|Placebo|
88924315|NCT05293301|Active Comparator|Traditional Loupes|One randomly assigned side of the mouth received deep cleaning treatment with the operator using traditional loupe magnification
88924316|NCT05293275|Active Comparator|Virtual Reality Group|patients will use the virtual reality device over two days
89439379|NCT03576573||Primary Total Hip Arthroplasty|Single arm study of subjects previously implanted with any MicroPort Orthopedics or Wright Medical Technology femoral stems and PROCOTYL® C Acetabular Components
88924317|NCT05293275|No Intervention|Standard of care|patients will receive standard of care only
89439380|NCT04467138||Inflammatory bowel disease|Patients with either Crohn's disease (CD, n=22), and Ulcerative colitis (UC, n=19).
89439381|NCT04467138||Chronic intestinal failure|Patients with intestinal failure (CIF, n=20)
89439382|NCT05535790|Experimental|Intervention group|Exposure to 24-hour LED naturalistic lighting
89439383|NCT05535790|Sham Comparator|Control group|Exposure to standard/traditional lighting setting with fluorescent tubes
88924318|NCT05293262||Patients who underwent endourological surgery for urolithiasis during COVID19|Endourological surgery (including ureteral stent insertion, ureteroscopy, retrograde intrarenal surgery)
88924319|NCT05293119|Experimental|Tofacitinib|In this group, study participants will be treated with per oral tofacitinib citrate (5 mg/twice daily)
88924320|NCT05293119|Active Comparator|Topical corticosteroid|In this group, patients will apply topical Mometasone furoate 0.1% once daily
88924321|NCT05297006||Breastfeeding group|The mother can breastfeed exclusively until the infants is at least 4 months old, after which complementary foods are added scientifically according to the baby's condition.
88924322|NCT05297006||Formula group containing new compound functional ingredients|Only use formula milk powder containing oligosaccharides, sialic acid and other ingredients feed the infants for at least 4 months, and then complementary food is added scientifically according to the infant's condition.
88924323|NCT05297006||Formula group without new compound functional ingredients|Only use formula milk powder without oligosaccharides, sialic acid and other ingredients feed the infants for at least 4 months, and then complementary food is added scientifically according to the infant's condition.
88924324|NCT05296967|Experimental|Chewing gum|POI patients are asked to chew 20 minutes x2/ day
88924325|NCT05296967|No Intervention|No chewing|POI patients receive no intervention
88924326|NCT05296863|Experimental|Non-concentrated ADSC-CM|2 ml intradermal injection of non-concentrated ADSC-CM + 1 ml of 5% topical Minoxidil daily
88924327|NCT05296863|Experimental|Concentrated ADSC-CM|2 ml intradermal injection of concentrated ADSC-CM + 1 ml of 5% topical Minoxidil daily
88924328|NCT05296824||Pulmonary vein isolation (PVI) only|Patients with symptomatic paroxysmal atrial fibrillation who received cryoballoon pulmonary vein isolation (PVI) only
88924329|NCT05296824||Pulmonary vein isolation (PVI) with posterior wall isolation (PWI)|Patients with symptomatic paroxysmal atrial fibrillation who received cryoballoon pulmonary vein isolation (PVI) with posterior wall isolation (PWI)
88924330|NCT05296499||Venous outflow obstruction extending to inferior vena cava, symptomatic with dyspnoea|Baseline assessments Post-operative assessments if applicable
88924331|NCT05296499||Venous outflow obstruction extending to inferior vena cava, not symptomatic with dyspnoea|Baseline assessments Post-operative assessments if applicable
88924332|NCT05296499||Unilateral iliac venous outflow obstruction|Baseline assessments Post-operative assessments if applicable
88924333|NCT05296499||Age and sex matched controls|Baseline assessments
88924334|NCT05296486|Experimental|phacovitrectomy surgery with silicone oil tamponade|patients who had phacovitrectomy surgery with silicone oil tamponade.The patients diagnosed cataract The patients' ages are over 50.
88924335|NCT05296486|Experimental|phacovitrectomy surgery with gas tamponade|patients who had phacovitrectomy surgery with gas tamponade.The patients diagnosed cataract The patients' ages are over 50.
89439384|NCT02143323|Active Comparator|Glutathione S-Transferase Theta1(GSTT1)/Mu1(GSTM1) wild/wild|Augmentin tablet
89439385|NCT02143323|Active Comparator|GSTT1/GSTM1 wild/null type|Augmentin tablet
89439386|NCT02143323|Active Comparator|GSTT1/GSTM1 null/wild type|Augmentin tablet
89439387|NCT02143323|Active Comparator|GSTT1/GSTM1 null/null type|Augmentin tablet
89439388|NCT04467216|Experimental|Intervention group|This arm will undertake VR simultaneous motor-cognitive training in 30 minutes session, twice a week for 8 weeks
89439389|NCT04467216|No Intervention|Control Group|This arm will be doing existing forms of motor-cognitive training in 30 minutes session, twice a week for 8 weeks
89439390|NCT04043650|Experimental|HeartSteps Intervention|For activity suggestions, at each available decision time, each participant is randomly assigned to either receive an activity suggestion or not.
89439391|NCT04466826|Experimental|Minors with chronic migraines|
89439392|NCT05678452|Active Comparator|LP-HoLEP|2J/25Hz setting
88924336|NCT05296486|Experimental|phacovitrectomy surgery with balanced saline solution tamponade|patients who had phacovitrectomy surgery with balanced saline solution tamponade.The patients diagnosed cataract The patients' ages are over 50.
88924337|NCT05296486|Experimental|phacoemulsifacation surgery without vitrectomy|patients who had phacoemulsifacation surgery without vitrectomy.The patients diagnosed cataract The patients' ages are over 50.
88924338|NCT05296434||Control Group|Healthy volunteers undergoing MRI exam, ICG test and blood biochemical tests
88924339|NCT05296434||Child-Pugh A Group|Composed of patients with liver function of Child-Pugh A grade undergoing MRI exam, ICG test and blood biochemical tests
88924340|NCT05296434||Child-Pugh B Group|Composed of patients with liver function of Child-Pugh B grade undergoing MRI exam,ICG test and blood biochemical tests
88924341|NCT05296434||Child-Pugh C Group|Composed of patients with liver function of Child-Pugh C grade undergoing MRI exam
88924342|NCT05296369|Experimental|Experimental|Folic acid intervention
89439393|NCT05678452|Active Comparator|HP-HoLEP.|2J/50Hz setting
89537017|NCT03302897|Experimental|2 μg LEP-F1 + 5 μg GLA-SE|Three intramuscular injections of LEP-F1 + GLA-SE at Days 0, 28, and 56. Low dose of antigen.
88924343|NCT05296369|No Intervention|Routine|Routine treatment intervention
88924344|NCT05296343||Adolescents and young adults|Boys and girls from 15 to 25 years old admitted to an Emergency Department (ED) following a suicidal act or considered as such by the medical team
89439394|NCT04841616|Experimental|Contrast-enhanced EUS (CH-EUS) Arm|After initial evaluation, 2.5ml of second-generation contrast media, SonoVue (Bracco, Ceriano Laghetto, Italy), will be injected. After infusion, the point of puncture will be determined when the parenchyma of the pancreas was enhanced. The contrast-enhanced area was identified and then the biopsy was directed toward that area, while avoiding unenhanced (i.e. necrotic) areas and not changing the target lesion. Rest of the procedure is identical with that in conventional EUS arm.
89439395|NCT04841616|Active Comparator|Conventional EUS Arm|Patients will undergo EUS FNB with the 22-gauge FNB needle (Acquire®, Boston Scientific Natick, MA). After each pass, the needle is removed and the stylet will be introduced into the needle to extrude any aspirated material on a glass slide for inspection of the presence of a macroscopic visible core (MVC). The total length of the MVC will be measured before placement into a formalin bottle. EUS-FNB is completed if the obtained MVC is longer than 4mm and deemed adequate by endoscopist. If the obtained MVC is < 4mm, the procedure is repeated until a MVC of ≥ 4mm is obtained and deemed adequate by endoscopist. A maximum of 7 passes is allowed
89439396|NCT04466904|Experimental|IBI362 low dose cohort|Participants receive low dose level of IBI362, matched placebo or Dulaglutide administrated by multiple subcutaneous injection.
89439397|NCT04466904|Experimental|IBI362 medium dose cohort|Participants receive medium dose level of IBI362, matched placebo or Dulaglutide administrated by multiple subcutaneous injection
89439398|NCT04466904|Experimental|IBI362 high dose cohort|Participants receive high dose level of IBI362, matched placebo or Dulaglutide administrated by multiple subcutaneous injection
89439399|NCT03524274|Experimental|cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
89439400|NCT03524274|Active Comparator|Cryotherapy & Activated CIK and bispecific antibody|the maximum tumor length≥2cm, use cryotherapy. the maximum tumor length<2 cm,Biological/Vaccine:Activated CIK and bispecific antibody CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
89439401|NCT03524274|No Intervention|Conventional therapy|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
89439402|NCT02143479||1:early conversion from Prograf® to Advagraf®|patients converted from Prograf® to Advagraf® in the first 3 months after transplantation
89439403|NCT02143479||2:late conversion from Prograf® to Advagraf®|patients converted from Prograf® to Advagraf® between 3 months and one year after transplantation
88924345|NCT05296343||Parents|One or the two parents of the included adolescents and young adults
88924346|NCT05296343||Healthcare professionals|Professionals working in one emergency departments of the inclusion centers and who usually take care of suicidal adolescents and young adults
88924347|NCT05296291|Active Comparator|High-translucent monolithic zirconia,|
88924348|NCT05296291|Active Comparator|Zirconia ceramic with porcelain|
88924349|NCT05296291|Active Comparator|Metal ceramics.|
88924350|NCT05296200||Observacional group|Subjects must remain to the exposure of gravity (1G) after 4h of hyperbuoyancy floatation(spine unloading)
88924351|NCT05296174|Experimental|cognitive-oriented intervention program|"The intervention group received a 40 mins social support intervention program once a week lasting for 6 weeks.~All participants were assessed by questionnaires before and after the intervention."
88924352|NCT05296174|Active Comparator|received health education program|"The control group received health education activities with the same frequency as the intervention group.~All participants were assessed by questionnaires before and after the intervention."
88924353|NCT05296044|Experimental|JT-003|Drug: JT-003
88924354|NCT05296044|Placebo Comparator|JT-003 Placebo|Drug: JT-003 Placebo
89537018|NCT03302897|Experimental|10 μg LEP-F1 + 5 μg GLA-SE|Three intramuscular injections of LEP-F1 + GLA-SE at Days 0, 28, and 56. Higher dose of antigen.
88924355|NCT05296005|Experimental|Treatment (chemotherapy, chemoradiation, surgery)|"NEOADJUVANT CHEMOTHERAPY: Patients receive FLOT chemotherapy consisting of docetaxel intravenously (IV) , oxaliplatin IV, leucovorin IV, and fluorouracil IV over 24 hours on day 1 or FOLFOX chemotherapy consisting of oxaliplatin IV and leucovorin IV, and fluorouracil IV continuously over 24 hours on days 1 and 2. Treatment repeats every 2 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity.~NEOADJUVANT CHEMORADIATION: Within 4 weeks after completing neoadjuvant chemotherapy, patients undergo radiation therapy in 25 fractions over 5 weeks. Patients also receive either fluorouracil IV continuously for 24 hours on days 1-5 or capecitabine orally (PO) twice daily (BID) on days 1-5. Cycles repeat weekly for 5 weeks in the absence of disease progression or unacceptable toxicity.~SURGERY: Within 4-8 weeks after neoadjuvant chemoradiation, patients undergo surgical resection according to tumor location and per surgeon expertise."
88924356|NCT05295836|No Intervention|CONTROL|In this phase of the study, the rectangular test will be performed in conditions of 16°C and 25-30% humidity, intaking 26 mL/kg/body weight of water one and a half hours before the test.
88924357|NCT05295836|Placebo Comparator|PLACEBO (PLA)|In this intervention, subjects will perform the rectangular test at 28°C and 25-30% humidity, ingesting 26 mL/kg/body weight of water and placebo one and a half hours before the test.
88924358|NCT05295836|Experimental|GLYCEROL (GLY)|In this intervention, subjects will perform the rectangular test at 28°C and 25-30% humidity, ingesting 1.2 g + 26 mL/kg/body weight of water one and a half hours before the test.
88924359|NCT05295745|Experimental|Cognitive remediation therapy and multidisciplinary intervention|The participants (obese adults) in the experimental group will receive treatment with cognitive remediation therapy, nutritional and physical activity instruction through 18 weekly sessions of intervention.
88924360|NCT05295745|No Intervention|Control|The control group participants will not receive the treatment until the experimental group participants complete the intervention and carry out the measurements
89439404|NCT03524196|Experimental|MYLO|"Manage Your Life Online (MYLO) is accessed online using a username and password. Client's type into the MYLO conversation box about a problem they are currently experiencing. MYLO operates by analysing the client's input of text for key terms and themes. It responds with questions about the problem aimed at encouraging higher level awareness.~Participants will decide how often to use the MYLO programme over a two week period. This is likely to be a reasonable length of time to allow at least one use of the programme with no upper limit on usage."
89206105|NCT00820794|Experimental|Cohort 1a|Subjects are treated with single dose lithium first. Then after at least 7 day washout, the subjects start PD 0332334 treatment from day 1 to day 9. At day 4 of PD 0332334 treatment, single dose lithium is given to subjects.
89206106|NCT00820794|Experimental|Cohort 1b|Subjects are treated with PD 0332334 from day 1 to 9 and a single dose of lithium is given at day 4. After at least 7 day washout, the subjects are treated with single dose of lithium.
88924361|NCT05295719|Placebo Comparator|Placebo & Flexibility Training (Control)|Subjects will take placebo (safflower oil, AlaskOmega®) for an initial supplementation period of 8 weeks. Participants will continue supplementation and will also engage in low-intensity flexibility training (control group) for 30 minutes 3 times/week for 6 weeks, a time-matched session of stretching and mobility exercises. All exercise sessions will be performed on an exercise mat and conducted under investigator supervision. Participants will cease supplementation and flexibility training for a 2 week follow-up period.
89439405|NCT03521778|Experimental|Fascial Distortion Model group|Patients will receive manual treatment complies with Fascial Distortion Model method.
89439406|NCT03521778|Experimental|Mulligan Concept group|Patients will receive manual treatment complies with Mulligan Concept method.
89439407|NCT03521778|Experimental|Traditional physiotherapy group|Patients will receive traditional physiotherapy.
89439408|NCT02143557|Experimental|Fat-Modified Breast Milk|Infants in this arm of the study were fed their own mother's breast milk where the fat layer was removed by centrifugation. Prior to feeding, extra energy and nutrients were added to the defatted breast milk.
89439409|NCT02143557|Active Comparator|MCT-formula group|Infants in this arm of the study were fed a MCT-containing medical food which is the current standard of care.
89439410|NCT02254239|Experimental|Treatment (everolimus, brentuximab vedotin)|"Patients receive brentuximab vedotin IV over 30 minutes on day 1 and everolimus PO QD or QOD on days 1-21. Treatment repeats every 21 days for up to 15 courses in the absence of disease progression or unacceptable toxicity. Patients then receive brentuximab vedotin IV over 30 minutes on day 1 and everolimus PO QD or every other day on days 1-84 for 1 course.~MAINTENANCE THERAPY: Beginning on course 17, patients receive everolimus PO QD, QOD, twice weekly, or thrice weekly on days 1-84. Courses repeat every 84 days in the absence of disease progression and unacceptable toxicity."
89012193|NCT00279825|Other|Sequence 3|Subjects take 1 tablet of IPX054 200 mg Placebo, 1 tablet of IPX054 250 mg Placebo, 2 tablets of CD-LD IR and 1 tablet of CD-LD CR Placebo. In Second treatment, subjects take 1 tablet of IPX054 200 mg Placebo, 1 tablet of IPX054 250 mg Placebo, 2 tablets of CD-LD IR Placebo and 1 tablet of CD-LD CR. In Third treatment, subjects take 1 tablet of IPX054 200 mg, 1 tablet of IPX054 250 mg Placebo, 2 tablets of CD-LD IR Placebo and 1 tablet of CD-LD CR Placebo. In Fourth treatment, subjects take 1 tablet of IPX054 200 mg Placebo, 1 tablet of IPX054 250 mg, 2 tablets of CD-LD IR Placebo and 1 tablet of CD-LD CR Placebo.
89012194|NCT00279825|Other|Sequence 4|Subjects take 1 tablet of IPX054 200 mg Placebo, 1 tablet of IPX054 250 mg Placebo, 2 tablets of CD-LD IR Placebo and 1 tablet of CD-LD CR. In Second treatment, subjects take 1 tablet of IPX054 200 mg Placebo, 1 tablet of IPX054 250 mg Placebo, 2 tablets of CD-LD IR and 1 tablet of CD-LD CR Placebo. In Third treatment, subjects take 1 tablet of IPX054 200 mg Placebo, 1 tablet of IPX054 250 mg, 2 tablets of CD-LD IR Placebo and 1 tablet of CD-LD CR Placebo. In Fourth treatment, subjects take 1 tablet of IPX054 200 mg, 1 tablet of IPX054 250 mg Placebo, 2 tablets of CD-LD IR Placebo and 1 tablet of CD-LD CR Placebo.
89439411|NCT05581732||Study|"32 patients in the study group received supplemental nutritional support with ONS Nutrinidrink with Dietary Fiber in a pre-calculated amount daily throughout the study for 14-16 weeks. During the hospital stay, additional nutritional support was added to the patient's standard hospital diet (ATC table). On an outpatient basis, the patient received the required amount of ONS at his disposal and add it as a supplement to his/her usual and habitual diet between main meals."
89439412|NCT05581732||Control|24 patients in the control group adhered to the standard hospital diet (ATC table), and at discharge - the usual habitual diet
89439413|NCT02254317|Placebo Comparator|0 mg placebo|Not containing GSE (Placebo)
89439414|NCT02254317|Active Comparator|300 mg GSE|Containing 300 mg of GSE
89439415|NCT02254317|Active Comparator|600 mg GSE|Containing 600 mg of GSE
89439416|NCT02254317|Active Comparator|900 mg GSE|Containing 900 mg of GSE
89439417|NCT01193088||CMT1A|Families/people with genetically defined CMT1A
89439418|NCT01193088||Genetically undefined CMT|Families/people with genetically undefined CMT with common causes ruled out.
89439419|NCT05088369|Experimental|SAD Cohorts 1 to 4: Participants receiving HM201|Each SAD cohort participant will be randomized to receive 1 of 4 escalating doses (0.01 mg/kg (2 nmol/kg); 0.03 mg/kg (5 nmol/kg); 0.06 mg/kg (10 nmol/kg); 0.12 mg/kg (20 nmol/kg).
89439420|NCT05088369|Placebo Comparator|SAD Cohorts 1 to 4: Participants Receiving Placebo|Each SAD cohort participant will be randomized to receive placebo.
88924362|NCT05295719|Active Comparator|Placebo & High-Intensity Interval Training|Subjects will take placebo (safflower oil, AlaskOmega®) for an initial supplementation period of 8 weeks. Participants will continue supplementation and will also engage in a 4 x 4 high-intensity interval training (HIIT) exercise program 3 days/week for 6 weeks. This will include a 3 min warm up at 15% watt max followed by 4 intervals for 4 min at 65% watt max with 3 min active recovery at 15% watt max . All exercise sessions will be performed on a stationary bike and conducted under investigator supervision. Participants will cease supplementation and HIIT training for a 2 week follow-up period.
89012195|NCT00286611||Amifostine|Those individuals enrolled who have received amifostine as part of standard care.
89012196|NCT04719962|Experimental|Disseminated Lyme infection|Only patients presenting with disseminated Lyme borreliosis will be part of the study.
89012197|NCT01640002|Active Comparator|Propantheline|
89439421|NCT05088369|Experimental|MAD Cohorts 1 to 4: Participants Receiving HM201|Each MAD cohort participant will be randomized to receive a once a week dose of 1 of 4 escalating doses (0.01 mg/kg (2 nmol/kg); 0.03 mg/kg (5 nmol/kg); 0.06 mg/kg (10 nmol/kg), 0.12 mg/kg (20 nmol/kg) for 4 weeks.
89439422|NCT05088369|Placebo Comparator|MAD Cohorts 1 to 4: Participants Receiving Placebo|Each MAD cohort participant will be randomized to receive placebo once a week for 4 weeks.
89439423|NCT02143635|Experimental|Arm A|
89439424|NCT02143635|Experimental|Arm B|
89439425|NCT02143635|Experimental|Arm C|
89439426|NCT02143635|Experimental|Arm D|
89439427|NCT05262582|Experimental|Thymectomy performed with sigle port RATS|The incision is performed in the 5-6th intercostal space under the breast folds without violating the mammalian tissue. This port is used for the camera and both arms simultaneously.
89439428|NCT05262582|Active Comparator|Thymectomy performed with two ports RATS|The incision is performed in the 4th intercostal space along anterior axillary fossa, for the camera and left arm. The other incision is subxiphoid longitudinal incision about 4cm for the right arm.
89439429|NCT05678062|Other|Lung- and cardiac ultrasound, as well as optic nerve sheath diameter.|Maternal ultrasound examinations will be performed after normal obstetric treatment protocols have been completed, i.e., the conduction of the study will contribute no delay in routine or emergency patient management. Ultrasound examination will be repeated after 72-96 hours, subject to the same conditions. An ultrasound examination (approximately 35-40 minutes in duration) will be performed. The ultrasound examination will consist of evaluation of lung- and cardiac ultrasound, as well as optic nerve sheath diameter.
89439430|NCT04467528|Experimental|Electroacupuncture combined with conventional drug therapy|"Conventional drug therapy:~All participants receive intravenous infusion of metoclopramide(10mg) every 12 hours in the trial~For participants with abdominal distension:~Electroacupuncture will be applied to the acupoints (LI4, PC6, ST36, SP6) 30min~For participants with post-operative ileus:~Electroacupuncture will be applied to the acupoints (LI4, SJ6, ST36, ST37) 30min~32# acupuncture needle used and twice daily for three days"
89439431|NCT04467528|Active Comparator|Conventional drug therapy|"Conventional drug therapy:~All participants receive intravenous infusion of metoclopramide(10mg) every 12 hours in the trial"
89439432|NCT02143791||Burst stimulation|At permanent implant with the Prodigy system, patients will be programmed with Burst stimulation
89439433|NCT04770324|Experimental|Interposition supraciliary implant|Any patients corresponding to inclusion / exclusion criteria
89439434|NCT04311970|Other|EoE patients|Patients will all be administered the EsoCheck device as a diagnostic test
89439435|NCT03545139|Experimental|NeoMTA (intervention group)|Revascularization with NeoMTA as coronal plug.
89439436|NCT03545139|Active Comparator|White MTA (Control group)|Revascularization with Conventional white mineral trioxide aggregate (White MTA) as coronal plug.
89439437|NCT03521700|Experimental|Intensive lipid lowering group|10 mg/d rosuvastatin was initially prescribed and target LDL-C was < 1.8mmol/L
89439438|NCT03521700|Other|Conventional lipid lowering group|5 mg/d rosuvastatin was initially prescribed and target LDL-C was ≥1.8mmol/L, <3.3mmol/L
89439439|NCT02144025|Experimental|Topical cyclosporine|This is a single arm study of patients who have received allogeneic bone marrow transplants performed with a reduced intensity conditioning regimen. In this arm, patients who are candidates to this trial, will receive topical cyclosporine twice a day for 12 months to prevent ocular graft versus host disease.
89439440|NCT03524040|Experimental|Acne patients|Application of gold microparticles to 2-3 facial areas
89439441|NCT03524040|Experimental|Heatlhy volunteers|Application of gold microparticles to 2 facial areas
89439442|NCT04748094||Free-breathing versus Compression|This cohort of volunteers and patients will undergo imaging on the MR-Linac investigating free-breathing motion, and comparing it to motion using an abdominal compression device.
89439443|NCT04748094||Free-breathing versus Breath-holding|This cohort of volunteers and patients will undergo imaging on the MRSim investigating free-breathing motion and comparing it to visually-guided breath-hold motion (and reproducibility).
89439444|NCT03523884|Experimental|Exercise Program plus Education.|Rotator cuff stretching and strengthening exercises outlined in the American Academy of Orthopedic Surgeons (AAOS) guidelines on management of rotator cuff problems.
89439445|NCT03523884|Active Comparator|Educational Program (EP).|An information sheet form AAOS, outlining the anatomy, description, causes, symptoms, examination and imaging tests performed on individuals with shoulder conditions
89439446|NCT01099761|Experimental|ACE-031 0.5 mg/kg q4wk|
89439447|NCT01099761|Experimental|ACE-031 1.0 mg/kg q2wk|
89439448|NCT01099761|Placebo Comparator|Placebo|
89012198|NCT01640002|Placebo Comparator|Placebo|
89012199|NCT01640041|Experimental|Implanted|All participants.
89012200|NCT00279903|Active Comparator|Cortisone|
89439449|NCT05566444|Experimental|Experimental heat pain|For each participant, we will collect TMS-EEG responses in 4 conditions: 1) Baseline, 2) Heat pain; 3) warm sensation; 4) post-pain.
89439450|NCT03523650|Experimental|Group 1: Propranolol Group|Group 1: Propranolol - group of randomized patients will receive one propranolol pill tid for 36 months.
89439451|NCT03523650|Placebo Comparator|Group 2: Placebo Group|Group 2: Placebo - group of randomized patients will receive one placebo pill tid for 36 months.
89439452|NCT05677750||newly diagnosed aplastic anemia, ITP, AIHA, Evan syndrome|"40 patients with newly diagnosed aplastic anemia, ITP, AIHA, Evan syndrome. aged one year and older attending Pediatric Hematology Unit at Children University Hospital in Assiut Univesity will undergo the following:~History& Physical Examination:~History and physical findings will be recorded on a standard data collection sheet.~Bone marrow aspirate and biopsy:~CD 55, CD 59 Flowcytometric markers:~PCR for COVID-19& Antibody for COVID-19~Biologic (Lab) tests:~Venous blood samples were obtained for:~CBC with reticulocytic count and differential~Platelet lymphocyte ratio&neutrophil lymphocyte ratio~Coagulation profile with PT, PC, INR, PTT~Inflammatory markers(ESR,CRP)~Serum ferritin, fibrinogin, D-dimer,."
89439453|NCT02582632|Experimental|Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir|Ombitasvir/Paritaprevir/Ritonavir(25 mg/150 mg/100 mg once daily) and Dasabuvir (250 mg twice daily) administered for 8 weeks
89439454|NCT02144103|Experimental|ADRC injection|Subjects will undergo liposuction under local anesthesia. Lipoaspirate will be processed to isolate and concentrate adipose-derived regenerative cells (ADRC). After ADRC isolation autologous cells suspension will be injected into subtenon space of patient's eye.
89439455|NCT05677672|Experimental|Human TH-SC01 cell injection|Human TH-SC01 Cell Injection is a human expanded umbilical cord mesenchymal stem cells suspension
89439456|NCT05677672|Placebo Comparator|Placebo-control group|Saline solution
89439457|NCT05399836|Experimental|Larger portions|the main meal component (lunch/dinner) served to participants in the laboratory, reflecting 100% portion. All other foods are identical across conditions (e.g. sides, seconds, dessert, snacks).
89439458|NCT05399836|Experimental|Smaller portions|the main meal component (lunch/dinner) served to participants in the laboratory, reflecting 66% portion (i.e. reduced portion size). All other foods are identical across conditions (e.g. sides, seconds, dessert, snacks).
89012201|NCT00279903|Experimental|Low Dose Btx-A|
89012202|NCT00279903|Experimental|High Dose Btx-A|
89012203|NCT02961452||Peanut allergic children|
89439459|NCT00307476|Active Comparator|rectal trumpet|"Patients meeting all study criteria will be randomized to either the rectal trumpet group or the standard treatment.~For placement of rectal trumpet (Rusch nasopharyngeal airway-32FR):"
89439460|NCT00307476|Other|standard treatment|Patients meeting all study criteria will be randomized to either the rectal trumpet group or the standard treatment. The Numeric Pain Intensity Scale (0-10) or staff observation of physiological indicators (e.g., restlessness, sweating, tachycardia, lacrimation, pupil dilatation, poor ventilator synchrony) for disoriented or unresponsive patients will be used prior to and immediately after placement of either device in order to assess patient comfort. Comfort will be assessed every 8 hours on all oriented patients using the Numeric Pain Intensity Scale.
89439461|NCT04683354|Experimental|Dose Escalation|There are 3 cohorts for the dose escalation study. Six subjects each cohort will receive oral administration of HL-085 capsules at three daily dose levels (12 mg, 18 mg and 24 mg). Three subjects of each cohort will receive TID and 3 subjects will receive BID dose regimen. Dose escalation can occur after 6 patients have completed 28 days of treatment and no or 1 DLT is identified.
89439462|NCT02178722|Experimental|Phase 1: MK-3475 + INCB024360|Phase 1: MK-3475 + INCB024360 25 mg twice a day (BID) as starting dose, followed by dose escalations (Phase 1) until recommended phase 2 dose of INCB024360 is determined
89439463|NCT02178722|Experimental|Phase 2: MK-3475 + INCB024360|(recommended phase 2 dose)
89439464|NCT03523572|Experimental|Dose Escalation|"Part 1 will enroll participants meeting the eligibility criteria set up for any of the 4 cohorts of Part 2 specified below using a 3 + 3 + 3 design. Escalating/de-escalating doses of trastuzumab deruxtecan in combination with a flat dose of nivolumab will be administered on Day 1 of each 21-day cycle.~The recommended dose for expansion (RDE) will be calculated using data collected from this population in the first two cycles. These participants may continue to receive study treatment in subsequent cycles."
89439465|NCT03523572|Experimental|Dose Expansion - Cohort 1|"Cohort 1 (n=30): Participants with pathologically documented advanced/metastatic breast cancer that has centrally-determined positive HER2 expression (IHC 3+ or IHC 2+/ISH+) [as defined by American Society of Clinical Oncology/College of American Pathologists (ASCO-CAP) guidelines]. These participants have received prior ado-trastuzumab emtansine (T-DM1).~Participants will receive the RDE of trastuzumab deruxtecan and the flat dose of nivolumab."
89439466|NCT03523572|Experimental|Dose Expansion - Cohort 2|"Cohort 2 (n=15): Participants with pathologically documented advanced/metastatic breast cancer that has centrally-determined low HER2 expression (IHC 1+ or IHC 2+/ISH-), who have exhausted treatments that can confer any clinically meaningful benefit (eg, other therapies such as hormonal therapy for patients who are hormone receptor positive).~Participants will receive the RDE of trastuzumab deruxtecan and the flat dose of nivolumab."
89439467|NCT03523572|Experimental|Dose Expansion - Cohort 3|"Cohort 3 (n=30): Participants with pathologically documented advanced/metastatic urothelial carcinoma that has centrally-determined HER2 expression of IHC 2+ or 3+, who received prior platinum-based therapy with documented progression.~Participants will receive the RDE of trastuzumab deruxtecan and the flat dose of nivolumab."
88924363|NCT05295719|Active Comparator|n-3 PUFA & Flexibility Training (Control)|Subjects will take 4 grams n-3 PUFA (AlaskOmega®) per day (3000 mg EPA and 1000 mg DHA) for an initial supplementation period of 8 weeks. Participants will continue supplementation and will also engage in low-intensity flexibility training (control group) for 30 minutes 3 times/week for 6 weeks, a time-matched session of stretching and mobility exercises. All exercise sessions will be performed on an exercise mat and conducted under investigator supervision. Participants will cease supplementation and flexibility training for a 2 week follow-up period. During this time, participants will consume 8 oz per week or consuming fish twice weekly, including one serving of oily fish.
88924364|NCT05295719|Experimental|n-3 PUFA & High-Intensity Interval Training|Subjects will take 4 grams n-3 PUFA (AlaskOmega®) per day (3000 mg EPA and 1000 mg DHA) for an initial supplementation period of 8 weeks. Participants will continue supplementation and will also engage in a 4 x 4 high-intensity interval training (HIIT) exercise program 3 days/week for 6 weeks. This will include a 3 min warm up at 15% watt max followed by 4 intervals for 4 min at 65% watt max with 3 min active recovery at 15% watt max . All exercise sessions will be performed on a stationary bike and conducted under investigator supervision. Participants will cease supplementation and HIIT training for a 2 week follow-up period. During this time, participants will consume 8 oz per week or consuming fish twice weekly, including one serving of oily fish.
88924365|NCT05295680|Experimental|Hymecromone|Participants will receive Hymecromone for six months + Standard Of Care (SOC), and will be followed for an additional nine months.
88924366|NCT05295680|No Intervention|Standard Of Care (SOC)|Participants will receive Standard Of Care (SOC), and will be followed for 15 months.
88924367|NCT05295667||Fetal Growth Retardation Group|
88924368|NCT05295576||chronic periodontitis|scaling and root planing
88924369|NCT05295576||Periodontally healthy individuals|no treatment
88924370|NCT05295381|Experimental|abdominal weight training with cough machine (CM)|abdominal weight exercise training (sandbag) is maintained for 30 minutes; the starting weight is 1kg to 2kg, and the previous day's weight is maintained each day as well as adding 0.5kg daily. Cough machine training is based on the cough assist machine Comfort Cough II (CC20), in which the inhalation and exhalation times are adjusted to 1-3 seconds, and the positive and negative pressure of the lower pressure 10-15 cmH2O is gradually increased to 30-40 cmH2O for the first time, 4-6 cycles/time, repeated 4-6 times, twice a day, five days a week, until the subject is weaned off the ventilator or transferred out of the ward. A modified Borg scale was used as an indicator of perceived dyspnea.
88924371|NCT05295381|Experimental|abdominal weight training (AWT) without cough machine (CM)|abdominal weight exercise training (sandbag) is maintained for 30 minutes; the starting weight is 1kg to 2kg, and the previous day's weight is maintained each day as well as adding 0.5kg daily.
88924372|NCT05295381|No Intervention|control|no abdominal weight training and no cough machine
88924373|NCT05295329|Experimental|Test group|Take compound salvia miltiorrhiza dropping pills
88924374|NCT05295329|Placebo Comparator|placebo group|Take a placebo
89439468|NCT03523572|Experimental|Dose Expansion - Cohort 4|"Cohort 4 (n=15): Participants with pathologically documented advanced/metastatic urothelial carcinoma that has centrally-determined HER2 expression of IHC 1+, who received prior platinum-based therapy with documented progression.~Participants will receive the RDE of trastuzumab deruxtecan and the flat dose of nivolumab."
89439469|NCT00972309|Experimental|Cohort 1: T-cell receptor alternate reading frame protein (TARP)|TARP peptides
89439470|NCT00972309|Experimental|Cohort: 2 -T-cell receptor alternate reading frame protein (TARP)|TARP dendritic cells
89439471|NCT03133026|Active Comparator|Sludge group|If Single operator cholangioscopy reveals only sludge then sludge will be cleared using conventional technique during ERCP.
89439472|NCT03133026|Active Comparator|Ingrowth / Overgrowth|If Single operator cholangioscopy reveals tumour ingrowth or overgrowth then to evaluate the role of biliary RFA for occluded stent due to tumour ingrowth or overgrowth
89439473|NCT03523494||Normal limb|Normal
89439474|NCT03523494||Abnormal limb|Lymph Edema
88924375|NCT05295316||Fibromyalgia|FM group was recruited at AMaR (rheumatic patients association of Piedmont) and the diagnosis of primary fibromyalgia was confirmed by the referring rheumatologist of the AMaR association.
88924376|NCT05295316||Control|The control group was recruited in the same geographic area as the FM participant. The general practitioner of each individual patient certified the subject's state of good health.
88924377|NCT05295303|Experimental|Interventional group|Subjects will be provided with a home-based remote integrated post-MI management system and will be instructed to perform daily routine measurements. Site investigators will review the physiological parameters of patients randomized to the Intervention group daily and treatment can be initiated or modified accordingly through instant communication (electronic communication and/or phone).
88924378|NCT05295303|Placebo Comparator|Control group|Subjects will be provided with a home-based remote integrated post-MI management system and will be instructed to perform daily routine measurements. Site investigators will review individual patient physiological parameters and risk factors only during the clinic visits
88924379|NCT05294900|Experimental|paclitaxel/carboplatin|paclitaxel+carboplatin
88924380|NCT05286398|Placebo Comparator|Control group|
88924381|NCT05286398|Experimental|Bradach group|
88924382|NCT05286398|Experimental|AEP group|
88924383|NCT05281679|Experimental|Low-intensity resistance exercise with blood flow restriction group (L-BFR).|All the participants in the low-intensity resistance exercise with blood flow restriction group (L-BFR) will receive 3 sessions of low-intensity resistance training with blood flow restriction for a total of 5 weeks.
88924384|NCT05281679|Active Comparator|High-intensity resistance exercise without blood flow restriction group (H-BFR).|All the participants in the high-intensity resistance exercise without blood flow restriction group (H-BFR) will receive 3 sessions of high-intensity resistance training without blood flow restriction for a total of 5 weeks.
88924385|NCT05276154|Active Comparator|thermoviscous bulk fill resin composite|
88924386|NCT05276154|Active Comparator|conventional bulk fill resin composite|
88924387|NCT05275647|Experimental|Treatment group : BoNT-A 100 U in Normal saline|BOTOX 100U in normal saline (BoNT-A/NS) 30ml in single intravesical instillation
88924388|NCT05275647|Placebo Comparator|Placebo group : Normal saline|Normal saline (N/S) 30ml in single intravesical instillation
88924389|NCT05274126|Experimental|Patient group (single group)|300 Patients involved in the recovery process.
89439475|NCT03526224||Aubagio|Individuals diagnosed with multiple sclerosis (MS) who have been treated with teriflunomide (Aubagio).
89439476|NCT03526224||Tecfidera|Individuals diagnosed with multiple sclerosis (MS) who have been treated with dimethyl fumarate (Tecfidera) and matched with the teriflunomide (Aubagio) patients on age, sex, disease duration, and disability level
89439477|NCT03639246|Experimental|Phase 1b: AVB-S6-500+PLD|
89439478|NCT03639246|Experimental|Phase 1b: AVB-S6-500+Pac|
89439479|NCT03639246|Experimental|Phase 2: AVB-S6-500+PLD|
89439480|NCT03639246|Experimental|Phase 2: AVB-S6-500+Pac|
89439481|NCT03639246|Active Comparator|Phase 2: Placebo+PLD|
89439482|NCT03639246|Active Comparator|Phase 2: Placebo+Pac|
89439483|NCT00594620|Experimental|1|Subjects receive supplement
89439484|NCT00594620|Placebo Comparator|2|Subjects will receive placebo
88924390|NCT05274035||Perampanel|Epilepsy patients who had failed clinical treatment with 1-3 anti-epileptic drugs (AEDs) with the optimal dose and course of treatment and needed perampanel additional treatment.
88924391|NCT05273242|Experimental|Artesunate|Please refer to the WHO solidarity Trial Plus Protocol ISRCTN18066414
88924392|NCT05273242|Experimental|Imatinib|Please refer to the WHO solidarity Trial Plus Protocol ISRCTN18066414
88924393|NCT05273242|Experimental|Infliximab|Please refer to the WHO solidarity Trial Plus Protocol ISRCTN18066414
88924394|NCT05273242|No Intervention|Local Standard of Care|No other Intervention Given except the local standard of care
89439485|NCT03544515|Sham Comparator|Scaling and use of inactive Er,Cr:YSGG|Scaling and debridement with hand scalers and ultrasonic unit together with the application of the Er,Cr:YSGG laser in an inactive fashion
89439486|NCT03544515|Experimental|Scaling and use of active Er,Cr:YSGG|Scaling and debridement with hand scalers and ultrasonic unit together with the application of the Er,Cr:YSGG laser in an active fashion
89439487|NCT03550170|Active Comparator|Teleconference|Teleconference Intervention arm
89439488|NCT03550170|Active Comparator|Internet|Internet Intervention arm
89439489|NCT03550170|Active Comparator|I-to-1, in-person|1-to-1, in-person intervention arm
89439490|NCT02582242|Experimental|BIAsp 30 TID|
89439491|NCT02582242|Active Comparator|BIAsp 30 BID|
89439492|NCT04467684|Experimental|Cohort 1|Cohort 1: 100 mg CB-0406 (n=6)
89439493|NCT04467684|Experimental|Cohort 2|Cohort 2: 200 mg CB-0406 (n=6). Dose initiated following review of all safety data from Cohort 1 by a Safety Review Committee
89439494|NCT04467684|Experimental|Cohort 3|Cohort 3: 400 mg CB-0406 (n=6). Dose initiated following review of all safety data and PK data from Cohort 2 by a Safety Review Committee.
88924395|NCT05272800|Experimental|BIS Group|Dry weight is evaluated monthly by clinical examination and biannually BIS-guided.
88924396|NCT05272800|Active Comparator|CE Group|Dry weight is evaluated monthly by clinical examination alone.
88924397|NCT05271825|Experimental|Broadband amplification|broadband amplification: (125 Hz to 10 kHz)
88924398|NCT05271825|Placebo Comparator|Band-limited amplification|band-limited amplification (125 Hz to 3-4 kHz)
88924399|NCT05271097|Experimental|MyLink2Care app|Participants in the MyLink2Care group will be provided with full app access and will be encouraged to use all features of the app.
88924400|NCT05271097|Active Comparator|treatment-as-usual (TAU)|Participants in the TAU group will receive the MyLink2Care app with major intervention features inactivated.
88924401|NCT05270850|Active Comparator|Control group|Conventional treatment for benign airway stenosis Including, but is not limited to laser, high-frequency electric knife, argon plasma coagulation (APC), cryotherapy, balloon dilation, and metal stent placement
88924402|NCT05270850|Experimental|SVF group|SVF treatment following the conventional treatment for benign airway stenosis and respiratory tract fistula.
88924403|NCT05270317|Active Comparator|Early-Stage Group|6 patients will be allocated randomly to participate in the clinical trial with cultivation duration of 6 weeks
89199419|NCT05601115|Experimental|Robot Assisted Therapy Group|In addition to the conventional treatment for 60 minutes in the Robot asisted therapy (RAT) group, it was planned to perform robotic rehabilitation with a hand-finger robot [Amadeo (Tyromotion, Graz, Austria)] for 30 minutes, accompanied by a physiotherapist who is trained in the field of robotic rehabilitation and has at least 5 years of experience. For the purpose of conventional therapy, an exercise program consisting of 45 minutes of range of motion exercises, strengthening exercises, balance exercises and neurophysiological exercises (Brunstroom exercises) accompanied by a physiotherapist experienced in stroke rehabilitation for at least 5 years, and neuromuscular therapy for the upper and lower extremities for 15 minutes.Electrical stimulation (NMES) application was planned. It was planned to apply a total of 60 sessions of treatment 5 days a week to both groups. They will be advised to continue the medical treatment they have been using during the treatment program.
88924404|NCT05270317|Active Comparator|Medium -Stage Group|6 patients will be allocated randomly to participate in the clinical trial with cultivation duration of 8 weeks
88924405|NCT05270317|Active Comparator|Late -Stage Group|6 patients will be allocated randomly to participate in the clinical trial with cultivation duration of 10 weeks
89439495|NCT04467684|Experimental|800 mg|Cohort 4: 800 mg CB-0406 (n=6). Dose initiated following review of all safety data and PK data from Cohort 3 by a Safety Review Committee.
89439496|NCT04467684|Experimental|1000 mg|Cohort 5: 1000 mg CB-0406 (n=6). Dose initiated following review of all safety data and PK data from Cohort 4 by a Safety Review Committee
89439497|NCT04467684|Placebo Comparator|Matched placebo|Two subjects in each Cohort (1, 2, 3, 4, 5) are randomized to matched placebo
89439498|NCT05004038|Active Comparator|Early Group|We will conduct a randomized, double-blind trial using a stepped-wedge design and involving a total of 60 patients with stable treated HIV and suppressed viral load who will all receive the BCG vaccine during the course of the study. Patients will be divided into two groups of equal size (early and late groups regarding administration of the BCG verum). The trial will be placebo-controlled and double-blind. Patients in the early group will receive the BCG verum at the beginning of Treatment Phase 1, and then the placebo at the beginning of Treatment Phase 2.
89439499|NCT05004038|Active Comparator|Late Group|Patients in the late group will receive placebo at the beginning of Treatment Phase 1 and then the BCG verum at the beginning of Treatment Phase 2.
89439500|NCT00663351|Active Comparator|Reflection Ceramic-Ceramic Hip System (IP)|Investigational: Reflection Ceramic-Ceramic Hip System. Ceramic femoral head component and the ceramic acetabular cup insert are composed of Biolox forte aluminum oxide material.
89439501|NCT00663351|Active Comparator|Reflection FSO V (5 hole) (Control)|Control: Reflection FSO V (5 hole). Acetabular shell with a ultra high molecular weight polyethylene insert and an alumina ceramic femoral head with a Synergy or Spectron EF femoral stem. The Synergy femoral stem are composed of implant grade titanium while the Spectron EF stem is composed of implant grade cobalt chrome.
88924406|NCT05269797|Experimental|Health-coaching Intervention|A nurse-lead health coaching intervention to support heart failure self-care management is employed by the nurses. This is a pre-post single group design - there is only one arm.
88924407|NCT05269602||L5 Radiculopathy|Patients who have Lumbar 5 root compression with the Magnetic Resonance İmaging
88924408|NCT05269602||S1 Radiculopathy|Patients who have Sacral 1 root compression with the Magnetic Resonance İmaging
89439502|NCT02288988|Other|GERD patients with Short Esophagus|Patients with True Short Esophagus diagnosed intra-operatively: The length of the intra-abdominal portion of the esophagus < 2.5 cm measured intra-operatively using a combined endoscopic-laparoscopic method. Minimally invasive antireflux surgery was performed (Collis gastroplasty + Nissen fundoplication).
89439503|NCT04976270|Experimental|GLPG3667 SD|Participants will receive a single dose of GLPG3667
89439504|NCT04976270|Placebo Comparator|Placebo SD|Participants will receive a single dose of matching placebo
89439505|NCT04976270|Experimental|GLPG3667 MD|Participants will receive repeated doses of GLPG3667 for 13 days.
89439506|NCT04976270|Placebo Comparator|Placebo MD|Participants will receive repeated doses of matching placebo for 13 days.
89439507|NCT03526146|Experimental|PLIE|PLIE is an integrative exercise program that focuses on training procedural memory for the ability to perform the movements that are most needed for daily function (e.g., transitioning safely from sitting to standing) while increasing mindful body awareness and encouraging social connection. It combines elements from a wide range of Eastern and Western exercise modalities, including occupational therapy, physical therapy, yoga, tai chi, Feldenkrais, Rosen Method, dance movement therapy and mindfulness meditation.
89439508|NCT03526146|No Intervention|Usua Care|Study participants who are randomized to the Usual Care (UC) control group will continue to participate in usual activities at the senior center, which include a combination of daily physical, mental and social activities.
89439509|NCT05677516||Group 1|Patients undergoing cryoablation of pulmonary veins with paroxysmal or persistent AF with ongoing AF during ablation.
89439510|NCT05677516||Group 2|Patients undergoing cryoablation of pulmonary veins with paroxysmal AF, in sinus rhythm during the procedure.
89439511|NCT05677516||Group 3|Patients undergoing pulmonary veins isolation with PFA with paroxysmal AF, in sinus rhythm during the procedure.
89439512|NCT05677516||Group 4|Patients undergoing RF ablation of the pulmonary veins using an electroanatomical system with paroxysmal AF, in sinus rhythm during the procedure.
89439513|NCT04971512|Experimental|EDP-721 HV SAD Cohorts|EDP-721 Dose 1, Dose 2, Dose 3 and Dose 4, in one single administration
89439514|NCT04971512|Experimental|EDP-721 HV MAD Cohorts|EDP-721 Dose 1, Dose 2 and Dose 3, once daily for 14 days
89439515|NCT04971512|Placebo Comparator|EDP-721 HV SAD Placebo Cohort|Matching placebo, in one single administration
89439516|NCT04971512|Placebo Comparator|EDP-721 HV MAD Placebo Cohort|Matching placebo, once daily for 14 days
89439517|NCT04971512|Experimental|EDP-721+ EDP-514 HBV MAD Cohorts|EDP-721 once daily for 14 days followed by EDP-721+EDP-514 once daily for 28 days
89439518|NCT04971512|Placebo Comparator|EDP-721+ EDP-514 HBV MAD Placebo Cohorts|Matching placebo once daily for 42 days
89439519|NCT03523260|Active Comparator|Tunneled dialysis Split-tip catheter|High-flow tunneled Split-tip catheter for hemodialysis will be inserted by standard interventional technique
89439520|NCT03523260|Active Comparator|Tunneled dialysis Step-tip catheter|High-flow tunneled Step-tip catheter for hemodialysis will be inserted by standard interventional technique
89439521|NCT03523260|Active Comparator|Tunneled dialysis Symmetric tip catheter|High-flow tunneled Symmetric tip catheter for hemodialysis will be inserted by standard interventional technique
89439522|NCT03526068|Experimental|SafeZoneUVC|Patients were subjected to 90s UV light therapy of 540 mW/cm2 sessions 2 times a week for 2 weeks for a total of 4 sessions. Pre and post UV light therapy swabs were taken after standard wound irrigation
89012204|NCT01640275|Active Comparator|Propofol based intravenous anesthesia|patients will receive propofol based intravenous anesthesia
89012205|NCT01640275|Experimental|Isoflurane Based Inhaled Anesthesia|patients will receive isoflurane based inhaled anesthesia
89439523|NCT04217356||Hematopoietic stem cell transplant (HCT)|Standard of care hematopoietic stem cell transplant with a matched donor.
89439524|NCT04217356||Best available non-transplant therapies (BAT)|Standard of care treatment with a janus kinase (JAK) inhibitor drug called ruxolitinib or treatment with an antimetabolite drug called hydroxyurea.
89439525|NCT03389126|Experimental|Avelumab|Avelumab 10 mg/kg every 2 wks until disease progression or unacceptable toxicity
89439526|NCT04446104|Experimental|Hydroxychloroquine|Participants will receive hydroxychloroquine tablet 400mg loading dose, followed by 200mg daily for 42 days
89439527|NCT04446104|Experimental|Ivermectin|Participants will receive ivermectin tablet 12mg single dose
89439528|NCT04446104|Experimental|Zinc/ Vitamin C|Participants will receive zinc tablet 80 mg/vitamin C 500mg daily for 42 days
89439529|NCT04446104|Experimental|Povidone-iodine throat spray|Participants will receive povidone-iodine throat spray (3 times daily) for 42 days
89439530|NCT04446104|Active Comparator|Vitamin C|Participants will receive vitamin C tablet 500mg daily for 42 days
89439531|NCT03385070||Salt-sensitive group|"Patients (n:163)with HT who presented at the emergency service at least once with a minimum increase in their systolic and diastolic blood pressure of 10% after consuming salty foods were included in the SSH group.~Biomicroscopic lens examination,urine analysis for salt intake estimation,blood pressure measurements"
89439532|NCT03385070||Salt resistance group|"Patients(n:142) who did not exhibit this increase were included in the SRH group~Biomicroscopic lens examination,urine analysis for salt intake estimation,blood pressure measurements"
89439533|NCT03385070||Control group|"Sex- and age-matched patients(n:124) without a HT diagnosis were included in the control group.~Biomicroscopic lens examination,urine analysis for salt intake estimation,blood pressure measurements"
89439534|NCT05346718|Experimental|Sequence A: Exposure to no pollen (placebo), then to first pollen concentration|Participants are first exposed to no pollen, then challenged with the first pollen concentration, and finally all following concentrations.
89439535|NCT05346718|Experimental|Sequence B: Exposure to first pollen concentration, then to no pollen (placebo)|Participants are first challenged with the first pollen concentration, then with no pollen, and finally with all following concentrations.
89439536|NCT03389048|Experimental|degenerative lumbar spine disease|patients who suffer from unilateral degenerative lumbar spine disease, undergo SLR test while being recorded by PMD-200
89439537|NCT03388970|Experimental|research group|normal saline 100ml+ vitamin K1 20mg ivgtt qd day0 and day1。
89439538|NCT03388970|Placebo Comparator|placebo group|normal saline100ml + normal saline 2 ml ivgtt qd day0 and day1
89439539|NCT04799210|Experimental|Human Factors Actual Use|Confirm device use safety and effectiveness of the Eximis CS (Contained Segmentation) System in actual use
89439540|NCT04735094|Experimental|Endobronchial biopsy with the use of a balloon attached to the echo-bronchoscope|
88924409|NCT05269576|Experimental|Single arm that receive two different interventions (clinical practice and clinical simulation).|"An analysis is carried out to the entire group prior to intervention. A second analysis is carried out to the entire group after one of the two interventions. Finally, a last analysis is carried out to the entire group after complete both types of interventions.~We apply the study in a group of medicine students of 3rth course of the degree. We examine their competencies at the beginning of the course. Re-examination is done after they do a period of clinical practice or a period of clinical simulation. At the end of the course, all the students done both interventions (clinical practice and clinical simulation), moment when we do the last examination of their competencies."
89439541|NCT04735094|No Intervention|Endobronchial biopsy without the use of a balloon attached to the echo-bronchoscope|
89439542|NCT00616941|Experimental|Cohort 1|Subjects received 4 synthetic peptides coded by the NY-ESO-1 gene (ie, NY-ESO-1 OLP4) once every 3 weeks for a total of 5 vaccinations.
88924410|NCT05269264||patients with unilateral or bilateral, primary or secundary lower limb lymphedema (LLL)|patients with unilateral or bilateral, primary or secundary LLL who visit the center for lymphedema at UH Leuven
88924411|NCT05269264||healthy controls|age, BMI and gender matched to the patients with LLL
88924412|NCT05269264||subgroup (n=40)|a subgroup of subjects (patients & healthy controls) will be evaluated again 2 weeks later
88924413|NCT05269095|Experimental|spinal anesthesia only|Patients will receive spinal anesthesia only
89439543|NCT00616941|Experimental|Cohort 2|Subjects received 4 synthetic peptides coded by the NY-ESO-1 gene (ie, NY-ESO-1 OLP4) in combination with Montanide ISA-51 vegetable grade (VG) once every 3 weeks for a total of 5 vaccinations.
88924414|NCT05269095|Experimental|spinal anesthesia and ultrasound-guided Genicular nerves block|Patients will receive spinal anesthesia and ultrasound-guided Genicular nerves block
88924415|NCT05269095|Experimental|Spinal anesthesia and US guided Adductor canal nerve block plus infiltration of the interspace|Patients will receive spinal anesthesia and ultrasound-guided Adductor canal nerve block plus infiltration of the interspace between the popliteal artery and the capsule of the posterior knee (PACK) block.
89439544|NCT00616941|Experimental|Cohort 3|Subjects received 4 synthetic peptides coded by the NY-ESO-1 gene (ie, NY-ESO-1 OLP4) in combination with Montanide ISA-51 VG and poly-ICLC once every 3 weeks for a total of 5 vaccinations.
89439545|NCT00105560|Experimental|Radiation therapy|This is a single arm study of radiation therapy with protons to standard doses.
89439546|NCT05695066|Experimental|4H group|Patients parents instructed to stop enteral feeding 4 hours before predicted anesthesia induction
89439547|NCT05695066|Active Comparator|6H group|Patients parents instructed to stop enteral feeding 6 hours before predicted anesthesia induction
89439548|NCT03393104|Experimental|Motor Control Exercise and Patient Education|"Participants will receive a total of 16 sessions (2 sessions per week) of motor control exercise and 4 sessions (1 session per week) of patient education program as described in respective protocol.~In addition, they will also perform segmental stretching exercises and instructed to perform continuous overground walk as indicated in the control group."
88924416|NCT05268783|Experimental|NEN patients|EORTC QLQ-C30, EORTC QLQ-GI.NET21 and satisfaction survey
88924417|NCT05267938|Experimental|Microneedles|Microneedles is with 750μm of height in order to prepare the palatal mucosa to receive the topical anesthetic
89439549|NCT03393104|Experimental|Motor Control Exercise|"Participants will receive a total of 16 sessions (2 sessions per week) of motor control exercise aiming at improving function of specific muscles of the lumbopelvic region and the control of posture and movement.~They will also perform segmental stretching exercises and instructed to perform continuous overground walk as indicated in the control group."
88924418|NCT05267938|Sham Comparator|patch flat|The same device as the microneedles but without microneedles
88924419|NCT05267431||RA patients recieved biological therapy|RA patients recieved different biological therapy
88924420|NCT05267431||RA patients recieved different DMARDS|RA patients recieved different DMARDS
89439550|NCT03393104|Experimental|Patient Education|"Participants will receive patient education session once a week at interval of 1-week over 8-weeks (4 sessions). The program will be aiming to provide non-threatening information to enable patients to better understand their pain, change any unhelpful beliefs about LBP, decrease fear avoidance behavior and catastrophic thought, promote positive attitude, self-management, and active coping strategies.~They will also perform segmental stretching exercises and instructed to perform continuous overground walk as indicated in the control group."
89439551|NCT03388892|Experimental|Drug-Eluting Balloon|PTA with DEB at venous anastomotic stenosis of AVG
89439552|NCT03388892|Active Comparator|Plain Balloon|PTA with PCB at venous anastomotic stenosis of AVG
89439553|NCT02577718|Experimental|Nitroglycerin-Citrate-Ethanol (NiCE)|Antimicrobial Nitroglycerin-Citrate-Ethanol catheter lock solution was administered for 2 hours then flushed
89439554|NCT00520533|Experimental|On Study|"Treatment (cycle 1):~cG250 10mg/m² IV weekly x 5 doses (1st & 5th doses trace-labelled with 124I)~Sunitinib 50 mg/day orally x 4 weeks commencing day 8~Followed by two-week break~Treatment (cycle 2 - investigator discretion):~cG250 10mg/m² IV weekly x4 doses~Sunitinib 50 mg/day orally x 4 weeks (commencing concurrently)~Followed by two-week break"
89439555|NCT03388814|Active Comparator|Bupivacaine Group|Those patients randomized to surgeon infiltration will have a skin wheal performed with lidocaine at the site where an actual pectoralis nerve block would be performed as visualized using ultrasound. Surgeons performing infiltration techniques will be blinded to the contents of the injectate and those patients randomized to surgeon infiltration will receive pharmacy study drug labeled bupivacaine injected in the same fashion and volume as the saline group for oncologic and plastic surgery.
89439556|NCT03388814|Experimental|Pectoralis Nerve block Group|Those patients who are randomized to pectoralis nerve block will have randomization immediately preoperatively and will undergo the nerve block procedure using local anesthetic in the standard fashion. Those patients randomized to pectoralis block will have a standard volume of normal saline injected for oncologic and plastic surgery.
89439557|NCT04680988|Experimental|Doublet Arm|SHR-1210+SHR-1020
88924421|NCT05266248|Experimental|Fed state|Standardized high fat breakfast before dosing
89439558|NCT04680988|Experimental|Single Arm|SHR-1210
89439559|NCT04680988|Active Comparator|Physician's choice chemotherapy|Albumin-bound paclitaxel injection or Pemetrexed disodium for injection or Gemcitabine for injection
89439560|NCT02289144|Experimental|Ceritinib|
89439561|NCT03388736|No Intervention|No lavender|No mist will be diffused into the environment.
89439562|NCT03388736|Active Comparator|0,1 lavender|0,1 ml lavender oil diluted in 120 ml water will be diffused into the environment with (17-33 ml mist output per hour).
89439563|NCT03388736|Active Comparator|0,3 lavender|0,3 ml lavender oil diluted in 120 ml water will be diffused into the environment with (17-33 ml mist output per hour).
89439564|NCT03544983|Experimental|Proactive Outreach + Web Counseling|Web + Streamlined Telephone Genetic Counseling
89439565|NCT03544983|No Intervention|Usual Care|Participants in the usual care arm will not be provided with access to the web-based intervention nor will they have access to streamlined genetic counseling. They can pursue clinical genetic counseling on their own.
89439566|NCT05340244|Experimental|Arm 1: Experimental|
89439567|NCT03393026|Experimental|Lurasidone 40-160 mg|Lurasidone 40-160 mg
89439568|NCT03384992|Experimental|Group 1|Participants were exposed to the following conditions: general health for week 1, diet-general information for week 2, and diet-BCSS information (breast cancer survivor-specific) for week 3. Telephone coaching was given.
89439569|NCT03384992|Experimental|Group 2|Participants were exposed to the one of the following usual care conditions: general health for week 1, diet-general information for week 2, and diet-BCSS information (breast cancer survivor-specific) for week 3.
89439570|NCT03384992|Experimental|Group 3|Participants were exposed to the following conditions: cognitive restructuring for week 1, general health for week 2, and diet-general information and diet-BCSS information (breast cancer survivor-specific) for week 3. Telephone coaching was given.
89439571|NCT03384992|Experimental|Group 4|Participants were exposed to the following conditions: cognitive restructuring for week 1, general health for week 2, and diet-general information and diet-BCSS information (breast cancer survivor-specific) for week 3.
89439572|NCT03384992|Experimental|Group 5|Participants were exposed to the following conditions: scheduled worry practice for week 1, general health for week 2, and diet-general information and diet-BCSS information (breast cancer survivor-specific) for week 3. Telephone coaching was given.
89439573|NCT03384992|Experimental|Group 6|Participants were exposed to the following conditions: scheduled worry practice for week 1, general health for week 2, and diet-general information and diet-BCSS information (breast cancer survivor-specific) for week 3.
88924422|NCT05266248|Experimental|Fasted state|Remain fasted for 4 hours post-dose
88924423|NCT05266131||OSA0HT0|without OSA or hypertension (OSA0HT0)
88924424|NCT05266131||OSA1HT0|OSA without hypertension (OSA1HT0)
89439574|NCT03384992|Experimental|Group 7|Participants were exposed to the following conditions: cognitive restructuring for week 1, worry practice for week 2, and General Health and Diet (General and BCSS) for week 3. Telephone coaching was given.
89439575|NCT03384992|Experimental|Group 8|Participants were exposed to the following conditions: cognitive restructuring for week 1, scheduled worry practice for week 2, and General Health and Diet (General and BCSS) for week 3.
89439576|NCT03384992|Experimental|Group 9|Participants were exposed to the following conditions: Diaphragmatic breathing and relaxation for week 1, general health for week 2, and Diet - General and BCSS for week 3. Telephone coaching was given.
89439577|NCT03384992|Experimental|Group 10|Participants were exposed to the following conditions: Diaphragmatic breathing and relaxation for week 1, general health for week 2, and Diet - General and BCSS for week 3.
89439578|NCT03384992|Experimental|Group 11|Participants were exposed to the following conditions: Diaphragmatic breathing and relaxation for week 1, cognitive restructuring for week 2, and General health and Diet (General and BCSS) for week 3. Telephone coaching was given.
89439579|NCT03384992|Experimental|Group 12|Participants were exposed to the following conditions: Diaphragmatic breathing and relaxation for week 1, cognitive restructuring for week 2, and General health and Diet (General and BCSS) for week 3.
88924425|NCT05266131||OSA0HT1|hypertension without OSA (OSA0HT1)
89439580|NCT03384992|Experimental|Group 13|Participants were exposed to the following conditions: Diaphragmatic breathing and relaxation for week 1, worry practice for week 2, and General health and Diet (General and BCSS) for week 3. Telephone coaching was given.
89439581|NCT03384992|Experimental|Group 14|Participants were exposed to the following conditions: Diaphragmatic breathing and relaxation for week 1, scheduled worry practice for week 2, and General health and Diet (General and BCSS) for week 3.
89439582|NCT03384992|Experimental|Group 15|Participants were exposed to the following conditions: Diaphragmatic breathing and relaxation for week 1, worry practice for week 2, and cognitive restructuring for week 3. Telephone coaching was given.
88924426|NCT05266131||OSA1HT1|with OSA and hypertension (OSA1HT1)
88924427|NCT05265585||Echocardiography group|
88924428|NCT05264584|Other|control arm|This arm is consisted of 60 patients.They will receive IV hydration and N-acetylcysteine (control arm).
88924429|NCT05264584|Experimental|Febuxostat arm|This arm is consisted of 60 patients.They will receive IV hydration, N-acetylcysteine and Febuxostat .
88924430|NCT05264155|Placebo Comparator|Control: one-size-fits-all|"The study was designed as a 2-arm randomized intervention trial. The experimental setup was centered around setting the complexity parameters (ie, the X values) of the 3 dynamic tasks. In particular, the parameters to determine were as follows: (1) the minimum distance of a longer walk, (2) the minimum distance of a longer bike ride, and (3) the maximum number of rewarded sports sessions (and consequently the number of rewarded points per sports session).~For the control group, the parameter values of the dynamic tasks were based on national guidelines."
88924431|NCT05264155|Active Comparator|Treatment: personalized|"The study was designed as a 2-arm randomized intervention trial. The experimental setup was centered around setting the complexity parameters (ie, the X values) of the 3 dynamic tasks. In particular, the parameters to determine were as follows: (1) the minimum distance of a longer walk, (2) the minimum distance of a longer bike ride, and (3) the maximum number of rewarded sports sessions (and consequently the number of rewarded points per sports session).~For the treatment group, these parameters were tailored to the users' self-reported capabilities and health goals."
88924432|NCT05263687|Experimental|Exercise Test|maximal and anaerobic threshold cardiopulmonary parameters
88924433|NCT05263167|Experimental|sodium aescinate group|Trial treatment is administered as sodium Aescinate 10mg in 250ml sodium chloride 0.9% infusion bag intravenously once daily for 10 days.
88924434|NCT05263167|Placebo Comparator|placebo group|Trial treatment is administered as 250ml sodium chloride 0.9% infusion bag intravenously once daily for 10 days.
88924435|NCT05262959|Experimental|Donafenib|Donafenib: 0.1g po. BID. And it will be taken on the first day of the study. PD-1: 200mg ivgtt. Q3W. It will be used at the same time as Donafenib. TACE: The first treatment will be carried out 2-3 weeks after taking Donafenib.
88924436|NCT05262686|Experimental|belimumab plus low dose IL-2|"10mg/kg belimumab was intravenously injected to patients with systemic lupus erythematosus every month for 24 weeks.~Interleukine-2 was first added to the original treatment for systemic lupus erythematosus with 1 million IU qod for 12 weeks, injected subcutaneously at the outer side of upper arm, abdomen and thigh, then the same dose of IL-2 was injected once a week for 12 weeks subcutaneously."
88924437|NCT05262686|Active Comparator|belimumab|10mg/kg belimumab was administrated to patients with systemic lupus erythematosus for at least 24 weeks, intravenously injected every month.
88924438|NCT05262686|Active Comparator|low dose IL-2|The first stage: interleukine-2 was added to the original treatment for systemic lupus erythematosus with 1 million IU qod for 12 weeks, injected subcutaneously at the outer side of upper arm, abdomen and thigh; The second stage: 1 million IU IL-2 was injected once a week for 12 weeks subcutaneously.
88924439|NCT05261334|Active Comparator|socket shield technique|immediate implant placement with socket shield technique
88924440|NCT05261334|Active Comparator|contour augmentation|early implant placement with contour bone augmentation
88924441|NCT05259540|Experimental|compound kushen injection combined with pabolizumab|compound kushen injection 20ml/day and pabolizumab 200mg/21 days
88924442|NCT05258968|Experimental|Educational Session on the Injeti Self Esteem Model|The participant will participate in a 1 hour educational session on the Injeti Self Esteem model.
88924443|NCT05254028|Active Comparator|Auricular points acupuncture|"The subject of this study is healthcare workers with tension-type headache symptoms who work at Dr. Cipto Mangunkusumo Hospital. The subject of this group will be treated with filiform needles, 30-minute needle retention, 3 times a week for 2 weeks (total of 6 therapy sessions). The Huanqiu needles with a size 0.20mm x 13mm are inserted at the auricular acupuncture points shenmen (TF4), thalamus (AT4), and occiput (AT3) bilateral."
89439583|NCT03384992|Experimental|Group 16|Participants were exposed to the following conditions: Diaphragmatic breathing and relaxation for week 1, scheduled worry practice for week 2, and cognitive restructuring for week 3.
89439584|NCT02144415|Experimental|EB-1020 400 mg|EB-1020 400 mg, administered as four 100-mg IR capsules and 4 matching placebo capsules
89439585|NCT02144415|Experimental|EB-1020 800 mg|EB-1020 800 mg, administered as eight 100-mg IR capsules
89439586|NCT02144415|Active Comparator|lisdexamfetamine 150 mg|lisdexamfetamine 150 mg, administered as 3 capsules, each containing 1 lisdexamfetamine 50-mg capsule, and 5 matching placebo capsules
88924444|NCT05254028|Active Comparator|Body points acupuncture|"The subject of this study is healthcare workers with tension-type headache symptoms who work at Dr. Cipto Mangunkusumo Hospital. The subject of this group will be treated with filiform needles, 30-minute needle retention, 3 times a week for 2 weeks (total of 6 therapy sessions). The Huanqiu needles with a size 0.25mm x 25mm are inserted at the acupuncture points LI4 Hegu, LR3 Taichong, dan GB20 Fengchi bilateral."
89439587|NCT02144415|Active Comparator|d-amphetamine 40 mg|d-amphetamine 40 mg, administered as 4 capsules, each containing two 5-mg d-amphetamine tablets and 4 matching placebo capsules
89439588|NCT02144415|Placebo Comparator|Placebo|Placebo, administered as 8 matching placebo capsules
89439589|NCT01664104||RA Participants|Participants with moderate or severe RA who are under tocilizumab treatment in routine clinical practice (in accordance with the local label) will be observed for 6 months from the start of treatment.
89439590|NCT03392870|Experimental|TAVA-ACTIVE|Integrative interventional programme. It involves high-frequency multidisciplinary intervention: nursing, psychology, psychiatry and social services. A psychotherapeutic group would be offered to those patients with an intelligence quotient>70, verbal communication and no behavioural alterations.
88924445|NCT05238870||Clinicians (interviewees) from Ghent University Hospital, Belgium|Semi-structured interviews with clinicians
89439591|NCT03392870|Active Comparator|CONTROL|As usual
89439592|NCT02739984|Placebo Comparator|Placebo|Participants received placebo subcutaneous injection once every month (QM) for 12 weeks.
89439593|NCT02739984|Experimental|Evolocumab|Participants received 420 mg evolocumab subcutaneous injection once every month (QM) for 12 weeks.
89439594|NCT03545529|Experimental|Innovative supported|In addition to usual care, patients benefit from connected tools (telealarm, numeric communication diary...) and from a strong accompaniment with a referent person who help better the patient.
89439595|NCT03545529|No Intervention|conventional supported|Patients benefit from usual care
89439596|NCT02254161|Experimental|BI 1181181 healthy young|Medium doses as tablets q.d. for 10 days
89439597|NCT02254161|Experimental|BI 1181181 healthy elderly|Medium doses as tablets q.d. for 10 days
89439598|NCT02254161|Placebo Comparator|Matching placebo in healthy young|Matching placebo for 10 days
89439599|NCT02254161|Placebo Comparator|Matching placebo in healthy elderly|Matching placebo for 10 days
89439600|NCT02140671||Patients with an asthma diagnosis|
89439601|NCT02140671||Patients where there is diagnostic doubt|
89439602|NCT02140749|Experimental|sc-FOS 2g/day|Placebo (4 weeks) Short-chain fructooligosaccharide 2 g/day (4 weeks)
89439603|NCT02140749|Experimental|sc-FOS 4g/day|Placebo (4 weeks) Short-chain fructooligosaccharide 4 g/day (4 weeks)
89439604|NCT02140749|Experimental|sc-FOS 8g/day|Placebo (4 weeks) Short-chain fructooligosaccharide 8 g/day (4 weeks)
89439605|NCT00496730|Experimental|Vytorin®|simvastatin (+) ezetimibe 10/20 mg (Vytorin®) ; tablet, once daily, 8 Weeks
89439606|NCT00496730|Active Comparator|atorvastatin|atorvastatin 10 mg; tablet, once daily, 8 Weeks
89439607|NCT02140827|Experimental|IMP education|patients in this group are educated about bowel preparation by instant messaging program and meanwhile a booklet was also sent to them.
89439608|NCT02140827|No Intervention|normal education|patients in this group are educated about bowel preparation on the day of reservation by nurse for about 15 minutes and meanwhile a booklet was also sent to them.
89439609|NCT04467372|Experimental|Tart cherry juice concentrate|tart cherry juice
89439610|NCT04467372|Experimental|Freeze dried tart cherry powder|tart cherry capsules
89439611|NCT04467372|Experimental|Juice placebo|kool-aid
89439612|NCT04467372|Experimental|Capsule placebo|maltodextrin
89439613|NCT02140905||Patients undergoing hemodialysis.|Subjects participating in the study
89439614|NCT02140983|Active Comparator|Liraglutide|90 days of liraglutide treatment at adjusting dose, up to 1.8mg/day
89439615|NCT02140983|Placebo Comparator|Placebo|90 days of placebo pen, up to 1.8mg/day.
89439616|NCT05174234||People living with HIV|a group of PLWHIV (n=392): women and men PLWHIV aged 18 to 60 years old from Haiti followed at the Cayenne Hospital, the Kourou Hospital or the West Guyanese Hospital (Saint Laurent du Maroni)
89439617|NCT05174234||People not living with HIV|a group of immigrants from Haiti not known to be infected with HIV (n=392): women and men aged 18 to 60 years from Haiti
89439618|NCT02141061|Experimental|Telapristone Acetate, Proellex Formulation A (Treatment A)|Subjects who meet the eligibility criteria will be randomized to receive either 12 mg Treatment A or 12 mg Treatment B as their first assigned treatment. After a 7-day washout period subjects will receive the alternative treatment.
89439619|NCT02141061|Experimental|Telapristone Acetate, Proellex Formulation B (Treatment B)|Subjects who meet the eligibility criteria will be randomized to receive either 12 mg Treatment A or 12 mg Treatment B as their first assigned treatment. After a 7-day washout period subjects will receive the alternative treatment.
89439620|NCT02144493||Patients with recurrent CBD stone|
89439621|NCT02144493||Patients without recurrent CBD stone|
89439622|NCT03392792|Active Comparator|tissue plasmnogen activator|
89439623|NCT03392792|Active Comparator|thrombectoy|
89439624|NCT02739828||Patients with Hidradenitis Suppurativa|Patients with moderate or severe HS treated prescribed adalimumab according to the Swedish Summary of Product Characteristics and treated as per routine clinical practice.
88924446|NCT05238870||Clinicians (interviewees) from Brussels University Hospital, Belgium|Semi-structured interviews with clinicians
88924447|NCT05238870||Clinicians (interviewees) from Orebro University Hospital, Sweden|Semi-structured interviews with clinicians
89012206|NCT01640392|Experimental|HIV prevention groups|Participants randomly assigned to the MyLife Intervention arm receive three 1.5-hour HIV behavioral risk-reduction group sessions over a 1-3 week period.
89439625|NCT02141139|No Intervention|Control arm|no medication or acetaminophen
89439626|NCT02141139|Experimental|NSAIDS (ketorolac intravenous, ibuprofen)|ketorolac IV (just before surgery) and ibuprofen for 1 weeks
89439627|NCT03392714|Experimental|R-B(O)AD|Intravenous R-B(O)AD every 4 weeks for up to 4 cycles
88924448|NCT05236608|Experimental|Nivolumab and ADG106|"Eligible patients will receive nivolumab and ADG106 by IV infusion according to the study phases below.~Phase 1b:~3 evaluable patients will be treated at the starting dose, and assessed for tolerability over the first cycle. Treatment related dose-limiting toxicities (DLT) will determine the next dose level to be studied. Dose escalation will follow the 3 + 3 study dose titration design.~Phase 2:~The dose of ADG106 given together with nivolumab will be the recommended dose in combination with nivolumab determined in phase 1b."
88924449|NCT05225402||Septic Shock|Adult patients with septic shock, admitted to ICUs at Hvidovre and Bispebjerg Hospital, respectively. Sedated and mechanically ventilated adult patients (>18 years).
88924450|NCT05224232|Experimental|Access Socket|Patients will be fitted with the access socket
88924451|NCT05224232|Active Comparator|Rigid socket|Patients will be fitted with their usual rigid socket
88924452|NCT05223517|Experimental|Acupucnture|
88924453|NCT05223517|Sham Comparator|Sham Acupuncture|
88924454|NCT05220826|No Intervention|Surgical drainaje (the standar of care)|Surgery will consist of performing a craniotomy (burr hole or drill) and evacuation of the hematoma. Depending on the operator, the surgical procedure may incorporate the use of subdural space drainage devices (e.g. Jackson Pratt drainage) connected to a soft suction reservoir. If used, these devices should be removed within 48 hours of installation.
88924455|NCT05220826|Experimental|Surgical drainaje plus early embolization of middle meningeal artery|The endovascular procedure will be performed until 72 hours after surgical evacuation of chronic subdural hematoma. Embolization will be performed with non-adhesive embolizing fluids such as Onix®, Phil®, Squid® or Libro®.
88924456|NCT05217251||exposed group|Parturient women will be identified with frontal alpha asymmetry based on EEG monitoring of uterine contractions in the first stage of labor and will then be allocated to vaginal delivery with alpha asymmetry group in hospital.
88924457|NCT05217251||control group|Parturient women will be identified without frontal alpha asymmetry based on EEG monitoring of uterine contractions in the first stage of labor and will then be allocated to vaginal delivery without alpha asymmetry group in hospital.
88924458|NCT05213871|Experimental|IASTM group|Group (A) will receive IASTM on the right upper trapezius and levator scapulae twice a week for four weeks in addition to a postural correction program.
88924459|NCT05213871|Experimental|myofascial release group|Group (B) will receive a myofascial release on the right upper trapezius and levator scapulae twice a week for four weeks in addition to the postural correction program.
88924460|NCT05210413|Experimental|Pediatric cohort|Multicentre, open-label, non-randomized, phase I clinical study, with dose-finding and expansion phases.
88924461|NCT05210413|Experimental|Adult cohort|Multicenter phase II single-arm open-label clinical trial, with a pre-screening phase to identify patients with mature tertiary lymphoid structure (TLS).
88924462|NCT05208073|Experimental|Intervention group|The experimental group received 6-week cosmetic therapy.
88924463|NCT05208073|No Intervention|Control group|The control group maintains the institution's original daily routine care.
88924464|NCT05208060|Experimental|MV130|Suspension of 6 inactivated whole bacteria concentrates, that contains 90% of Gram positive bacteria (V104 S. pneumoniae 60%, V102 S. aureus 15%, V101 S. epidermidis 15%) and 10% of Gram negative bacteria (V113 K. pneumoniae 4%, V105 M. catarrhalis 3%, V103 H. influenzae 3%), at a concentration of 300 FTU/mL, equivalent to ~ 10^9 bacteria/mL.
88924465|NCT05208060|Placebo Comparator|Placebo|Sodium chloride 9 mg/mL and water for injection s.q. f 1 mL.
88924466|NCT05205629||Donafenib + TACE|
88924467|NCT05204784|Experimental|Arm 1|2 Rheopheresis treatments per week x 2, followed by 8 weeks without treatment, 8 overall treatments
88924468|NCT05204784|Experimental|Arm 2|2 Rheopheresis treatments in week 1, followed by 1 treatment every 2 weeks, 8 overall treatments
88924469|NCT05204784|Active Comparator|Control Group|Standard of care treatment with intravenous iloprost
88924470|NCT05203705|Experimental|Treatment group 1|SHR2285 tablet; dose 1
88924471|NCT05203705|Experimental|Treatment group 2|SHR2285 tablet; dose 2
88924472|NCT05203705|Experimental|Treatment group 3|SHR2285 tablet; dose 3
88924473|NCT05203705|Experimental|Treatment group 4|SHR2285 tablet; dose 4
88924474|NCT05203705|Active Comparator|Treatment group 5|Enoxaparin
88924475|NCT05202561|Experimental|Arm A|Drug: RNA tumor vaccine Administration: intramuscular injection Dose: 600 ng/ time Dosing cycle: Day 1, day 4, day 7, and day 14.
89439628|NCT02144571|Experimental|Lifestyle|Diet and physical activity intervention group. Measurements taken at baseline, 12 weeks and 1 year.
89439629|NCT02144571|No Intervention|Wait-list control|No-treatment control group. Measurements taken at baseline, 12 weeks and 1 year. People in the control condition can elect to take the intervention after 1 year.
89439630|NCT05673538|Experimental|TT-00973-MS Tablets|TT-00973-MS tablets will be administered at the starting dose of 2mg. Subsequently, patients will be enrolled according to the standard 3+3 dose escalation design.
89439631|NCT03392636|Experimental|Group A|Mitchell Banks Herniotomy
89439632|NCT03392636|Experimental|Group B|Fergusson Gross Herniotomy
89439633|NCT03384758|Active Comparator|mild to moderate PAD|
89439634|NCT03384758|Active Comparator|Diabetes mellitus|
89439635|NCT03384758|Placebo Comparator|Healthy volunteers|
89439636|NCT02289300|Experimental|DCB-BO1202|
89439637|NCT02289300|Experimental|DCB-BO1202+Placebo|
89439638|NCT02289300|Placebo Comparator|Placebo|
89439639|NCT02144649|No Intervention|Group I (control, no juice)|Patients consume no tomato juice.
89439640|NCT02144649|Experimental|Group II (tangerine tomato juice)|Patients will consume two 5.5 oz. cans of tangerine tomato juice every day until their scheduled surgery. (approximately 4 weeks)
89439641|NCT02144649|Experimental|Group III (red tomato juice)|Patients consume two cans of red tomato juice daily until their scheduled surgery (approximately 4 weeks).
89439642|NCT05297032|Experimental|Quercetin Phytosome|All participants will receive Quercetin Phytosome
89439643|NCT03388580||BAL|patients undergoing elective bronchoalveolar lavage
89439644|NCT03525912|Experimental|Ketamine infusion|postoperative pain in adult population after abdominal, thoracic and orthopedic surgery that received adjuvant analgesia with ketamine 0.1mg/kg/h during 24 to 48 hours in postoperative period.
89439645|NCT03388502|Experimental|Text Messaging (SMS) Bot|Patients undergoing total joint (hip & knee) arthroplasty will be enrolled in their physician's automated 'Text Messaging (SMS) Bot' in addition to receiving the routine perioperative education and instructions.
89439646|NCT03388502|Active Comparator|Routine Perioperative Instructions|Patients undergoing total joint (hip & knee) arthroplasty will receive only their 'Routine Perioperative Instructions'.
89439647|NCT02289378|Experimental|Docetaxel, Oxaliplatin and 5-Fu|Docetaxel 50mg/m2 Oxaliplatin 85mg/m2 5-Fu 2800mg/m2 Repeated every two weeks
89439648|NCT03392558|Experimental|Nature-Based Sensitive Skin Regimen|"Burt's Bees Skin Care Regimen (Nature Based Sensitive Skin Regimen, NBSSR):~Burt's Bees Sensitive Facial Cleanser (to be used day and night)~Burt's Bees Sensitive Daily Moisturizing Cream (to be used in the day)~Burt's Bees Sensitive Night Cream (to be used at night)"
89439649|NCT03392558|Active Comparator|Control Regimen|"Control Skin Care Regimen (Control Regimen, CR):~Cetaphil Gentle Skin Cleanser (to be used day and night)~Cetaphil Moisturizing Lotion (to be used day and night)"
89439650|NCT03133416|Active Comparator|PRP preparation|PRP will be prepared by taking 10ml venous blood which is then mixed with 2ml of thrombin and centrifuged in a specially designed tube at 3400 rotations per minute (rpm) for 15 minutes. Then about 2ml PRP will be extracted, and will be infiltrated to the lesion site under ultrasound guidance. The injection technique is similar to that described by Kesikburun .21 Patients in group 1 or group 3 will receive 2 injections of PRP, with 1 month interval.
89439651|NCT03133416|Active Comparator|Physiotherapy|Physiotherapy includes hot pack, electric therapy and therapeutic exercise, which will be supervised by a senior physical therapist. The therapeutic exercise consists of active and passive stretch, and strengthening exercise of the rotator cuff, the shoulder girdle, and the pectoral muscles, 3 times a week, and will continue for 1.5 months. After 1.5 months' supervised training, home program exercise follows and will be continued for another 1.5 months.
89439652|NCT03133416|Active Comparator|PRP and physiotherapy|PRP will be prepared by taking 10ml venous blood which is then mixed with 2ml of thrombin and centrifuged in a specially designed tube at 3400 rotations per minute (rpm) for 15 minutes. Then about 2ml PRP will be extracted, and will be infiltrated to the lesion site under ultrasound guidance. The injection technique is similar to that described by Kesikburun .21 Patients in group 1 or group 3 will receive 2 injections of PRP, with 1 month interval;Physiotherapy includes hot pack, electric therapy and therapeutic exercise, which will be supervised by a senior physical therapist. The therapeutic exercise consists of active and passive stretch, and strengthening exercise of the rotator cuff, the shoulder girdle, and the pectoral muscles, 3 times a week, and will continue for 1.5 months. After 1.5 months' supervised training, home program exercise follows and will be continued for another 1.5 months.
89439653|NCT04565600|Experimental|Etoricoxib|Prophylactic etoricoxib (60 mg) was administered orally at each course of docetaxel-containing chemotherapy, which started from the day of chemotherapy and was performed once per day for 8 days (day 1-8).
89439654|NCT04565600|No Intervention|Control|No prophylactic regimen was given.
89439655|NCT04486898|Experimental|Music group|Music group will be receiving music intervention 3 times a day for 30 minutes per session for the duration of five (5) weeks period.
89439656|NCT04486898|No Intervention|Usual care|Those who will be in this group will be ask to continue doing their actual activities and not to partake in any kind of music listening or therapy for the 5 week period.
89439657|NCT03523182|Experimental|Spirulina (SP)|Children in the SP group (n=251) received a soya-maize-based porridge for 12 months with the addition of spirulina.
89439658|NCT03523182|Active Comparator|Control (CON)|Children in the CON group (n=250) received a soya-maize-based porridge for 12 months.
89439659|NCT04435808|Experimental|Hydroxychloroquine Arm|Group A: up to 275 health care workers who choose to take hydroxychloroquine. Will receive a 600 mg loading dose, followed by 200 mg daily (tablets).
89439660|NCT04435808|No Intervention|No Intervention Arm|Group B: Up to 75 health care workers who choose not to take hydroxychloroquine.
89439661|NCT04674748|Experimental|Dose Escalation of INCB086550|In this study 3 dose levels will be evaluated to determine the MTD or RP2D (Decided by SMC according to the safety and PK data)
89439662|NCT02290080|Experimental|Oxygen|"For patients randomized to oxygen therapy:~6 L/min of oxygen delivered by oxymask® started immediately after inclusion of the ambulance service or in the emergency department given continuously for 6-12 hours (at least 6 hours)~all patients receive standard acute coronary syndrome treatment including reperfusion strategies"
89439663|NCT02290080|No Intervention|No oxygen|"For patients randomized to withholding oxygen treatment~no oxygen is administered at any time as long as the oxygen saturation is ≥90% on pulse oximeter (repetitive checks are performed)~all patients receive standard acute coronary syndrome treatment including reperfusion strategies~observation duration 12 hours"
89439664|NCT03388424||Control|Healthy people of both sex
88924476|NCT05202561|Experimental|Arm B|"Drug: RNA tumor vaccine+Navuliumab Administration: intravenous injection Dose: 3 mg/kg Timing of administration: Administration was initiated 14 days after the first intramuscular injection of the RNA tumor vaccine.~Duration of administration: once every 2 weeks."
88924477|NCT05196009|Experimental|Mental Health and Substance Use support|Pilot Mental health and substance use peer navigation, ecological momentary assessments and virtual support group
88924478|NCT05193825|Active Comparator|Group A|Patients in Group A (active comparator) will have their internal pulse generator (IPG) adjusted by conventional procedures, i.e. by regular visits at their caregivers hospital.
88924479|NCT05193825|Experimental|Group B|Patients in Group B (experimental) will have their internal pulse generator (IPG) adjusted by using a novel software (Abbot NeurosphereTM Virtual Clinics) that allows for remote IPG programming and with the aid of a visual analogue scale (VAS).
88924480|NCT05192733||Clinical Specialty|"We will compare responses across the following clinical specialties :~Neuroanesthesiologists~Neurosurgeons~Neurocritical care specialists NB: Some participants may have a double clinical specialty."
88924481|NCT05192733||Clinical Setting|"We will compare responses across the following clinical settings:~Cities~Countries~Number of cases per year"
88924482|NCT05192629|Active Comparator|Group Midazolam|"Administration of oral midazolam (0.25 mg/kg) as premedication before propofol-based sedation.~The patient receives an oral premedication containing 0.125mL/kg of midazolam (which corresponds to a dosage of 0.25mg/kg of Ozalin® 2mg/ml, with a maximum of 20 mg). He/she also receives an intranasal spray containing matching placebo of dexmedetomidine (NaCl 0.9%). The volume administered corresponds to 0.02 mL/kg (which corresponds to a dosage of 2 mcg/kg of pure dexmedetomidine 100 mcg/mL in group D)."
88924483|NCT05192629|Experimental|Group Dexmedetomidine|"Administration of intranasal dexmedetomidine as premedication before propofol-based sedation.~The patient receives an intranasal premedication containing 2 mcg/kg of dexmedetomidine. He/she also receives an oral solution containing matching placebo of midazolam (flavored-water prepared by the pharmacy). The volume administered corresponds to 0.125 mL/kg (which corresponds to a dosage of 0.25mg/kg of Ozalin® 2mg/mL, with a maximum of 20 mg or 10mL)."
89439665|NCT03388424||quantification of microbiota in Brain|Patients of both sex with neural disorders and diseases
89439666|NCT03388424||quantification of microbiota in GI|Patients of both sex with gastrointestinal diseases
88924484|NCT05191550|Experimental|Neurosurgeons, fellows, residents and medical students|Neurosurgeons (14), neurosurgical fellows and neurosurgical residents (24) from Montreal Neurological Institute and Hospital along with medical students (12) who are enrolled in first to fourth year of McGill medical school.
88924485|NCT05191121|Active Comparator|FTP Alone|Functional Task Practice Alone - Participants allocated to this group will complete 40 minutes of training focused on improving functional tasks followed by 10 minutes of functional training/carryover in a relevant environment without functional electrical stimulation (FES).
88924486|NCT05191121|Active Comparator|FTP+Con-FES|Functional Task Practice + Conventional Functional Electrical Stimulation - Participants allocated to this group will complete 40 minutes of training focused on improving functional tasks supplemented with conventional parameter (200µs; 40Hz) functional electrical stimulation (FES). followed by 10 minutes of functional training/carryover in a relevant environment.
88924487|NCT05191121|Active Comparator|FTP+WPHF-FES|Functional Task Practice + Wide Pulse, High Frequency Functional Electrical Stimulation - Participants allocated to this group will complete 40 minutes of training focused on improving functional tasks supplemented with wide pulse, high frequency (1000µs; 100 Hz) functional electrical stimulation (FES) followed by 10 minutes of functional training/carryover in a relevant environment.
88924488|NCT05189444|Experimental|Vonoprazan group|Vonoprazan + Amoxicillin + Bismuth potassium citrate Drug: Vonoprazan 20mg bid Other Names: no Drug: Amoxicillin 0.75g tid Other Names: no Drug: Bismuth potassium citrate 0.22g bid Other Names: no
88924489|NCT05189444|Active Comparator|control group: quadruple therapy|Drug: Esomeprazole 20mg bid Other Names: no Drug: Amoxicillin 1.0g bid Other Names: no Drug: Clarithromycin 0.5g bid Other Names:no Drug: Bismuth potassium citrate 0.22g bid Other Names:no
88924490|NCT05186662||WeChat group|
88924491|NCT05186662||Control group|
88924492|NCT05185011|Experimental|mild hepatic impairment|Subjects with mild hepatic impairment
89439667|NCT03388424||quantification of microbiota in Lung|Patients of both sex with Respiratory diseases
89439668|NCT03388424||quantification of microbiota Metabolic|Patients of both sex with Metabolic Diseases
89439669|NCT03388424||quantification of microbiota in UG|Patients of both sex with Uro-genital Diseases
88924493|NCT05185011|Experimental|moderate hepatic impairment|Subjects with mild moderate impairment
88924494|NCT05185011|Experimental|healthy volunteers|Subjects with normal hepatic function
88924495|NCT05175274|Experimental|Intervention Group|colchicine 0.5mg every 24 hours for 3 years
88924496|NCT05175274|Placebo Comparator|Control Group|1 placebo tablet every 24 hours for 3 years
88924497|NCT05165199|Experimental|Elobixibat|10mg Elobixibat administration for 4 weeks
89439670|NCT02289612|Placebo Comparator|Tapioca Starch - Low-Fibre|Tapoica starch pudding without added fibre
89439671|NCT02289612|Placebo Comparator|High Maltose Corn Syrup - Low-Fibre|High maltose corn syrup pudding without added fibre
89439672|NCT02289612|Placebo Comparator|Trutol Glucose Beverage (#1)|Trutol Glucose Beverage containing 50 g of glucose without added fibre. Consumed at first treatment study visit.
89439673|NCT02289612|Placebo Comparator|Trutol Glucose Beverage (#2)|Trutol Glucose Beverage containing 50 g of glucose without added fibre. Consumed at final treatment study visit.
89199420|NCT05601115|Active Comparator|Conventional Therapy Group|45 minutes of range of motion exercises, strengthening exercises, balance exercises and neurophysiological studies were performed in the presence of a physiotherapist experienced in stroke rehabilitation for at least 5 years.An exercise program consisting of exercises (Brunstroom exercises) and 15 minutes of NMES were planned. It was planned to apply a total of 60 sessions of treatment 5 days a week to both groups. They will be advised to continue the medical treatment they have been using during the treatment program.
89439674|NCT02289612|Active Comparator|Yellow Mustard Gum Fibre - Tapioca Starch|Yellow mustard gum fibre pudding containing tapioca starch. Fibre-enriched treatment product.
89439675|NCT02289612|Active Comparator|Yellow Mustard Gum Fibre - High Maltose Corn Syrup|Yellow mustard gum fibre pudding containing high maltose corn syrup. Fibre-enriched treatment product.
89439676|NCT02289612|Active Comparator|Soluble Flaxseed Gum Fibre - Tapioca Starch|Soluble flaxseed gum fibre pudding containing tapioca starch. Fibre-enriched treatment product.
89439677|NCT02289612|Active Comparator|Soluble Flaxseed Gum Fibre - High Maltose Corn Syrup|Soluble flaxseed gum fibre pudding containing high maltose corn syrup. Fibre-enriched treatment product.
89439678|NCT02289612|Active Comparator|Fenugreek Gum Fibre - Tapioca Starch|Fenugreek gum fibre pudding containing tapioca starch. Fibre-enriched treatment product.
89439679|NCT02289612|Active Comparator|Fenugreek Gum Fibre - High Maltose Corn Syrup|Fenugreek gum fibre pudding containing high maltose corn syrup. Fibre-enriched treatment product.
89439680|NCT05646004|Experimental|621|
89439681|NCT03521544|Experimental|Plantar Fascia|Self-myofascial release in the plantar fascia.
88924498|NCT05163015||with oncogeriatric consultation|"with oncogeriatric consultation group: patients aged 75 and more with cancer with oncogeriatric consultation"
88924499|NCT05163015||without oncogeriatric consultation|"without oncogeriatric consultation group: patients aged 75 and more with cancer without oncogeriatric consultation"
88924500|NCT05160194|Other|GROW Intervention|Every participant received the GROW Intervention, chose not to participate in the GROW intervention, or dropped out before completing the GROW Intervention.
88924501|NCT05157555||"with laryngectomy group"|"with laryngectomy group: patients with laryngectomy for any type of cancer"
88924502|NCT05153278||Control group|Patients that received standard treatment (packed red blood cells) for iron deficiency anemia
88924503|NCT05153278||Experimental group|Patients that received intravenous iron instead of standard treatment (packed red blood cells) for iron deficiency anemia
88924504|NCT05150548||Entire Cohort|"Patients undergoing elective colectomy with data that has been collected in the NSQIP® Procedure Targeted Colectomy dataset from 2014-2019 with American Society of Anesthesiologists (ASA) Physical Status I-IV.~Patients will not be included in this cohort with urgent or emergency colectomy or indication for colectomy consisting of Acute diverticulitis, Enterocolitis (e.g. C. Difficile), and Volvulus, patients with disseminated cancer, wound infection, systemic sepsis or ventilator-dependence preoperatively."
88924505|NCT05129137|Experimental|FDC nefopam hydrochloride 30mg / paracetamol 500mg|Single dose: 2 tablets
88924506|NCT05129137|Active Comparator|nefopam hydrochloride 30mg|Single dose: 2 tablets
88924507|NCT05129137|Active Comparator|paracetamol 500mg|Single dose: 2 tablets
88924508|NCT05129137|Active Comparator|nefopam hydrochloride 30mg and paracetamol 500mg|Single dose: 2 tablets
88924509|NCT05126251|Experimental|Tangningtongluo group|"Tangningtongluo tablet will be used in this arm. Patients should take medicine with warm water about 30min after meal. (1.6g/time, twice a day) According to the above usage and dosage, take 12 weeks continuously. After 12 weeks, the researcher decided whether the subjects entered the extended trial according to the wishes of the subjects, and continued to use the drug until 24 weeks.~Lifestyle intervention"
88924510|NCT05126251|Placebo Comparator|Placebo group|"Placebo of Tangningtongluo tablet will be used in this arm. Patients should take medicine with warm water about 30min after meal. (2.0g/time, twice a day) According to the above usage and dosage, take 12 weeks continuously. After 12 weeks, the researcher decided whether the subjects entered the extended trial according to the wishes of the subjects, and continued to use the drug until 24 weeks.~2） Lifestyle intervention"
88924511|NCT05121740|Experimental|Arm A: Experimental 1|In the APLICOV-PC study, patients of arm A received 1.5 mg of plitidepsin / day for 3 consecutive days (total dose 4.5 mg).
88924512|NCT05121740|Experimental|Arm B: Experimental 2|In the APLICOV-PC study, patients of arm B received 2.0 mg of plitidepsin / day for 3 consecutive days (total dose 6.0 mg).
89199421|NCT05598047|Experimental|Executive Functioning Training|BrainHQ (POSIT Science Inc.) computerized cognitive training modules will be used as in our other studies; but these will focus on executive functioning training. These programs have gaming components that encourage adherence. BrainHQ cognitive training products are tested and endorsed by the scientific community. A meta-analysis of computerized cognitive training in older adults found optimal therapeutic effects occurred when training sessions last at most 60 minutes and are administered 1-3 times per week - dosage parameters already incorporated in our study. This self-administered program uses touch-screen technology with tablets which allows computer novices to engage with the training exercises.
89199422|NCT05598047|No Intervention|No-Contact Control Group|These participants will not receive any intervention.
88924513|NCT05121740|Experimental|Arm C: Experimental 3|In the APLICOV-PC study, patients of arm C received 2.5 mg of plitidepsin / day for 3 consecutive days (total dose 7.5 mg).
88924514|NCT05114473|Experimental|Workshops|This group will attend face-to-face workshops were the educational program will be developed. These workshops will be available in several sites, and specific care providers will be assigned for each of these sites.
88924515|NCT05114473|Experimental|Online-accessed material|This group will be granted online access to a platform were the educational program will be uploaded. They will be given autonomy regarding when to enter the platform and view the content.
88924516|NCT05114473|No Intervention|Control group|This group will initially no recieve an intervention and will serve as a control group.
88924517|NCT05110898|Experimental|Fixed-dose Olmesartan 20mg/40 mg + Indapamide 1,5 mg|
88924518|NCT05110898|Active Comparator|Isolated drugs Olmesartan (20 mg or 40 mg) and Indapamide (1,5 mg)|
88924519|NCT05101590|Experimental|Monitored with HDA|Participants undergoing elective major surgery and have an arterial line as part of their standard care with HDA included as part of their care
88924520|NCT05098730|Experimental|Stroke survivors with pets|Stroke survivors with pets will receive strategy training for 10-15 sessions, 45 minutes each session, delivered by a trained occupational therapist in the home.
88924521|NCT05098730|Active Comparator|Stroke survivors without pets|Stroke survivors without pets will receive strategy training for 10-15 sessions, 45 minutes each session, delivered by a trained occupational therapist in the home.
88924522|NCT05096780|Active Comparator|Beverage 1|Free caffeine 160 mg
88924523|NCT05096780|Experimental|Beverage 2|Encapsulated caffeine 160 mg
88924524|NCT05096780|Active Comparator|Beverage 3|Free caffeine 250 mg
88924525|NCT05096780|Experimental|Beverage 4|Encapsulated caffeine 250 mg
88924526|NCT05096325||Study pump|Subjects receive a CE-certified mylife™ YpsoPump® insulin pump system that allows detailed logging of pressure data.
88924527|NCT05096065|Experimental|Treatment A: Leuprolide Oral Tablet, 120 mg QD|Leuprolide Oral Tablet (Ovarest), 120 mg (2 x 60 mg tablets), administered once daily (QD), for up to 35 consecutive days with food-intake restrictions.
89439682|NCT03521544|Experimental|Tricep surae fascia|Self-myofascial release in the triceps surae fascia.
89439683|NCT03521544|Experimental|Hamstrings fascia|Self-myofascial release in the hamstrings fascia.
89439684|NCT03521544|Experimental|Spine erectors and lumbar fascia|Self-myofascial release in the spine erectors and lumbar fascia.
89439685|NCT03521544|Experimental|Occipital and suboccipital fascia|Self-myofascial release in the occipital and suboccipital fascia.
89439686|NCT03521544|No Intervention|Control group|Lay on a stretcher.
89439687|NCT03388112|No Intervention|antibiotics|the patients in this arm will not receive probiotics.
89439688|NCT03388112|Experimental|probiotics concurrent with antibiotic|the patients in this arm will receive probiotics blend of Bifidobacterium longum, Lactobacillus acidophilus, Enterococcus faecalis for 2 weeks concurrent with antibiotic.
89439689|NCT03388112|Experimental|probiotics after antibiotic|the patients in this arm will receive probiotics blend of Bifidobacterium longum, Lactobacillus acidophilus, Enterococcus faecalis for 2 weeks after antibiotic.
89439690|NCT05631730|Experimental|Flecainide and Metoprolol|"Participants will receive flecainide 50 mg twice daily (BID), with a dosage target of 100 mg BID. The maximum daily dose of flecainide will not exceed 300 mg. The first dose of flecainide will be initiated in-hospital with a 12-lead electrocardiogram (ECG) taken after 3 hours. If the ECG is considered normal after flecainide treatment, the participant will continue with 50 mg BID from the next day. Participants will receive a dosage of Metoprolol taking into consideration prior beta-blocker use and concomitant medications. The maximum daily dose of metoprolol will not exceed 200 mg. Within the run-in period, the dosage of both Flecainide and Metoprolol will be increased to the maximum tolerable dose.~The Study Team can change the immediate-release formulation of Flecainide to controlled release at the same daily dose of flecainide. Whether metoprolol sustained release will be dosed once daily (QD) or BID, will be up to the investigator and patient preference."
89012207|NCT01640392|No Intervention|Wait-list control|Participants randomly assigned to the Wait-list Control arm receive the MyLife MyStyle group sessions once they have completed a 6-month follow-up assessment.
89012208|NCT01640470|Experimental|Assistive technology|The home based AT Provision, Updating and Tune-Up (ATPUT) Intervention will include recommendations for assistive technology, possibly entailing financial assistance to repair or to acquire new AT, and training. New equipment will likely include devices such as bathroom grab bars, raised toilet seats, walkers, and bath chairs.
89012209|NCT01640470|Active Comparator|Customary care|Participants in this arm will receive customary care.
89012210|NCT01640509|Experimental|synchrotron radiation|treated by synchrotron radiation
89012211|NCT04719923||Subjects with autism spectrum disorders|Children affected by autism spectrum disorders
89012212|NCT04719923||Healthy controls|Healthy children
89012213|NCT04529356|Sham Comparator|Simple acetaminophen treatment|Acetaminophen will be taken when patients suffered from headache during the study. No specific dosage and frequency was required for this group as long as the participants record the exact drug usage.
89012214|NCT04529356|Active Comparator|Simple acetaminophen combined with low-frequency rTMS|Apart from acetaminophen usage, low frequency TMS (1HZ) will be used in patients three times a month for 6 months.
89012215|NCT04529356|Experimental|Simple acetaminophen combined with high-frequency rTMS|Apart from acetaminophen usage, high frequency TMS (10HZ) will be used in patients three times a month for 6 months.
89012216|NCT04529083|Experimental|Intervention|Mixed Reality System for virtual mirror therapy
89012217|NCT01640626|Active Comparator|Health Education|Deworming will be conducted in both schools. A health education package will be introduced to schoolchildren in the intervention school (School A) only. Both schools will be followed up for 6 months.
89012218|NCT01640626|No Intervention|Control|Schoolchildren in school B will serve as a control group. No intervention (Health education package) will be given after complete deworming at baseline.
89012219|NCT00279942|Active Comparator|Soy|A shake that contained 20 g of soy protein and 160 mg of soy isoflavone.
89012220|NCT00279942|Placebo Comparator|Placebo|A shake that contained 20 g of milk-based protein (casein) and no isoflavone.
89012221|NCT01640665|Experimental|Sorafenib and Capecitabine|One cycle will consist of 4 weeks of treatment. The dose of Sorafenib will be 600 mg administered orally daily in divided doses. Capecitabine will be given at a fixed dose of 2000 mg orally BID x 7 days every 14 days
89439691|NCT05631730|Active Comparator|Metoprolol Alone|Participants will receive a dosage of Metoprolol taking into consideration prior beta-blocker use and concomitant medications. Within the run-in period, the dosage will be increased to the maximum tolerable dose. Whether metoprolol sustained release will be dosed QD or BID, will be up to the investigator and patient preference. The maximum daily dose of metoprolol will not exceed 200 mg.
89439692|NCT03521388|Experimental|Intervention group|"The intervention consists of an Internet-based program. The program will last 3 months, with subsequent monthly reinforcement sessions for other 3 months.~The program is stepped, so that the more depressive symptomatology the more intensive program and consists of more components.~The students will interact with the program via a monitoring and feedback e-mail with 3 questions of the PHQ--9- adolescent version (1st, 2nd & 9th question) that they will receive every 2 weeks and a Website that will allow them to access to psycho-educational videos and information. There will also in the Website sections that will provide emergency information, the possibility of a contact via e-mail, and group chats. Adolescents with more depressive symptoms or suicidal risk will be invited to participate in an online counselling appointment or a face to face assessment with a mental health professional of the program."
89439693|NCT03521388|Other|Control group|The comparison group will receive general psychoeducation of depression in adolescents and will be on the waiting list to receive the intervention in the event that its efficacy is demonstrated.
89012222|NCT01640782|Experimental|Sequential regimen|Sequential treatment with CPT-11 plus Fluorouracil (FU), folinic acid (LV) and Docetaxel (TXT) plus Cisplatin (CDDP)
89012223|NCT01640782|Active Comparator|De Gramont regimen|Fluorouracil (5-FU), folinic acid (LV)
89012224|NCT00251147|Active Comparator|Open Repair|
89012225|NCT00251147|Active Comparator|Mini-open Repair|
89012226|NCT01640821|Experimental|Intervention group (CdM?)|This group will be composed of women that are seeking help for weight-related problems that have been referred to the CdM? program.
89012227|NCT01640821|No Intervention|Control group|This group will be composed of women that are seeking help for weight-related problems but that are actually on the waiting list for participating to the CdM? program.
89012228|NCT01640977||Open PLIF|The PLIF procedure achieves access to the degenerated disc from the back of the spine, and is performed through a single midline posterior incision that is typically expanded bilaterally past the facet joints to expose bony landmarks for pedicle screw fixation, which are traditionally placed in a trajectory from lateral to medial, requiring a more lateral starting point.
89012229|NCT01640977||MAS PLIF|The MAS PLIF technique is a minimally invasive variant of the traditional PLIF procedure. It is similarly performed through a single midline posterior incision but is conducted through a more medialized posterior approach, avoiding the far lateral exposure typical of the traditional PLIF.
89012230|NCT01641172|Active Comparator|Patients|Patients with disseminated testicular cancer
89012231|NCT01641172|Placebo Comparator|Healthy volunteers|Healthy men, age 18-50 years old
89012232|NCT00286845||II|
89012233|NCT00286845||1|
89012234|NCT01641211|Experimental|Video intervention|Group that will watch the Meducation inhaler device technique videos.
89439694|NCT02289768|Experimental|5-fluorouracil/salicylic acid|Actikerall® solution (5-fluorouracil 0.5%, salicylic acid 10.0%) applied to the affected area once-daily for 12 weeks
89439695|NCT02289768|Placebo Comparator|Vehicle|Vehicle solution applied to the affected area once-daily for 12 weeks
89439696|NCT03125876|Experimental|CT053PTSA|60mg-100mg
89439697|NCT03712514|Other|Rugby players|Destabilization of the upper cervical spine with Cervistab
89439698|NCT03712514|Other|Healthy non rugby players|Destabilization of the upper cervical spine with Cervistab
89439699|NCT03523026|Experimental|NMES and Peripheral Muscle Training|"Neuromuscular Electrical Stimulation (NMES) and Peripheral Muscle Training~NMES frequency will be 30 Hertz and the application time will be 30 minutes.Treatment will be programmed for 3 days per week.~Peripheral Muscle Training will be applied by elastic band and Proprioceptive Neuromuscular Facilitation 3 times per week.The program will continue for 6 weeks."
89439700|NCT03523026|Experimental|IMT and Peripheral Muscle Training|"Inspirator Muscle Training (IMT) and Peripheral Muscle Training~IMT will be applied 7 days per week, twice a day for 15 minutes.~Peripheral Muscle Training will be applied by elastic band and Proprioceptive Neuromuscular Facilitation 3 times per week. The program will continue for 6 weeks."
89439701|NCT03523026|Experimental|Peripheral Muscle Training|"Peripheral Muscle Training~Peripheral Muscle Training will be applied by elastic band and Proprioceptive Neuromuscular Facilitation 3 times per week.The program will continue for 6 weeks."
89439702|NCT04330430|Experimental|T-VEC + Nivolumab|Patients will receive pre-surgically 4 courses T-VEC (up to 4ml; first dose 10^6 PFU per mL, subsequent doses at 10^8 PFU per mL). Patients will also receive a flatdose of 240mg Nivolumab every 2 weeks after the first T-VEC injections (starting at 2nd T-VEC course at week 3, followed by the next doses at week 5 and 7).
89439703|NCT03284658||Observation|Patients with a Tyrosinemia type 1 or high-grade suspi-cion for Tyrosinemia type 1
89439704|NCT03387956|Active Comparator|Atropine group|Atropine group (A): Patients received intrathecal heavy Marcaine, 2 ml, 0.5% plus 300 µg morphine and 100 µg atropine (0.5ml), and intravenous injection of 2ml normal saline.
89012235|NCT01641211|Other|Control|This group will watch a nutrition video.
89012236|NCT01641250|Experimental|Part A: RO5429083|
89012237|NCT01641250|Experimental|Part B: RO5429083 + cytarabine|
89012238|NCT00251264|Active Comparator|Open|
89012239|NCT00251264|Active Comparator|Arthroscopic|
89012240|NCT01641289|Experimental|Paracetamol|">50kg: Paracetamol 1gm PO/NG q6hourly for 72 hours and febrile for 24 hours (maximum total dose 4g/24 hours) plus intravenous Artesunate~<50kg: Paracetamol 12.5-15mg/kg/dose q6hourly for 72 hours and febrile for 24 hours (maximum total dose 5 doses/24hours;75mg/kg) plus intravenous Artesunate"
89012241|NCT01641289|Active Comparator|No Paracetamol|"No paracetamol + Intravenous Artesunate~If temperature > 40°C, ibuprofen PO/PR will be administered in the absence of renal impairment and dehydration; 500mg paracetamol PO/PR will be administered in the presence of renal impairment or dehydration. Dengue testing will be done prior to the administration of ibuprofen."
89012242|NCT01641328|Active Comparator|Waitlist Control / Home-based training|This group will serve as a waitlist control group while the active group is performing training. Following assessment at the end of the active group period, this group will begin home-based training and will be assessed at the end of that 10 week period.
89012243|NCT01641328|Experimental|Cognitive Activation Group|This group will attend the 3/week group intervention meetings over 10 weeks.
89012244|NCT00280020|Experimental|CBT|
89012245|NCT00280020|Experimental|TCC|
89012246|NCT00280020|Active Comparator|SS|
89012247|NCT01641406|Experimental|ER- (Triple Neg. and ER- PR+ Her 2 -)|Experimental chemotherapy using neoadjuvant approach
89012248|NCT01641406|Experimental|Her 2 +|Experimental chemotherapy using neoadjuvant approach
89012249|NCT01641406|Experimental|ER + (ER+ PR+ Her 2- / ER+ PR- Her 2 -)|Experimental chemotherapy using neoadjuvant approach
89012250|NCT01641484|Experimental|local control 19.8Gy|local control at 19.8 Gy, at Day 14
89012251|NCT01641523||Hydroxyapatite Cranioplasty|patient underwent to cranioplasty reconstruction with customized hydroxyapatite prosthesis
89012252|NCT01641523||polymethylmethacrylate|patient underwent to cranioplasty reconstruction with polymethylmethacrylate prosthesis
89439705|NCT03387956|Active Comparator|Dexamethasone group|Dexamethasone group (D): Patients received intrathecal heavy Marcaine 2 ml, 0.5% plus 300 µg morphine (0.5ml), and intravenous 8 mg dexamethasone (2ml).
88924528|NCT05096065|Experimental|Treatment B: Leuprolide Oral Tablet, 80 mg QD|Leuprolide Oral Tablet (Ovarest), 80 mg (2 x 40 mg tablets), administered once daily (QD) for up to 35 consecutive days with food-intake restrictions.
88924529|NCT05096065|Experimental|Treatment C: Leuprolide Oral Tablet, 60 mg QD|Leuprolide Oral Tablet (Ovarest), 60 mg, administered once daily (QD) for up to 29 consecutive days with food-intake restrictions.
88924530|NCT05096065|Experimental|Treatment D: Leuprolide Oral Tablet, 60 mg BID|Leuprolide Oral Tablet (Ovarest), 60 mg, administered twice daily (BID), 12 hours apart for up to 35 consecutive days with food-intake restrictions.
88924531|NCT05096065|Experimental|Treatment E:Leuprolide Oral Tablet (Ovarest), 40 mg BID|Leuprolide Oral Tablet (Ovarest), 40 mg, administered twice daily (BID), 12 hours apart for up to 29 consecutive days with food-intake restrictions.
88924532|NCT05094544|Experimental|Non-ablative SBRT|Non-ablative SBRT (800 cGy X 3 fractions) given 5-7 days preoperatively in selected patients with stage I-II NSCLC
88924533|NCT05092789|Experimental|Kinesio taping group|"Participants in this group will receive treatment through standardized therapeutic Kinesio taping along with conventional therapy.~Tape will be water proof, porous, adhesive,with width of 5cm and thickness of 0.5 mm."
89439706|NCT03387956|Active Comparator|Dexamethasone and Atropine group|Dexamethasone and Atropine group (DA): Patients received intrathecally as group A, plus intravenous injection of 2 ml, dexamethasone 8 mg. Postoperative follow-up of both nausea and vomiting was done over 24 hours postoperative.
89439707|NCT03817606|Experimental|Tritanium Posterior Lumbar Cage|Surgical placement of the Tritanium Posterior Lumbar Cage
88924534|NCT05092789|Experimental|Cervical thrust manipulation group|"Participants in this group will receive treatment via cervical thrust manipulation along with conventional therapy.~Manipulation will be directed on mid cervical spine."
88924535|NCT05092789|Active Comparator|Conventional therapy group|.Participants of this group will receive only conventional therapy which will include: Hot pack for 10 minutes Stretching Exercises
88924536|NCT05087836||Patient undergoing cardiac surgery|Each patient will has 2 sets of sensors attached at forehead and temporal area.
88924537|NCT05083572|Experimental|Group A (Lavage and Vivomixx)|Colonic lavage, followed by Vivomixx treatment
88924538|NCT05083572|Experimental|Group B (Lavage and Placebo)|Colonic lavage, followed by Placebo treatment
88924539|NCT05083572|Experimental|Group C (Vivomixx)|No colonic lavage, only Vivomixx treatment
88924540|NCT05083572|Experimental|Group D (Rifaximin and Vivomixx)|Rifaximin, followed by Vivomixx treatment
88924541|NCT05076435|Experimental|Restrictive fluid administration|"No IV fluids unless one of the extenuating circumstances occur;~In case of severe hypoperfusion or severe circulatory impairment defined by either: 1) Lactate≥4 mmol/L, 2) Hypotension (systolic BP < 90 mmHg), 3) Mottling beyond the kneecap (mottling score >2) OR 4) Urinary output<0.1 mL/kg bodyweight/h (only in the first 4hrs after randomization) then a bolus of 250 ml of IV crystalloid solution may be given followed by re-evaluation~In case of overt fluid losses (e.g. vomiting, large aspirates,) IV fluid may be given to correct for the loss, but not above the volume lost.~In case the oral/enteral route for water or electrolyte solutions is contraindicated or has failed, IV fluids may be given to:~Correct dehydration or electrolyte deficiencies Ensure a total fluid input of 1 L in 24hrs~IV fluids may be given as carrier for medication, but with lowest possible volume"
89012253|NCT01641523||autologous bone|patients underwent to cranioplasty reconstruction by autologous bone repositioning
89012254|NCT01641562||TAXANES|patients with early breast cancer, scheduled to receive taxanes, with doses according to the stage of the disease
89012255|NCT00417339||hemodialysis, 4h, twice weekly|hemodialysis, four hours, twice weekly
89012256|NCT00417339||hemodialysis, 8h, twice weekly|hemodialysis, eight hours, twice weekly
89439708|NCT03817606|Active Comparator|AVS PEEK UniLIF|Surgical placement of the AVS PEEK UniLIF Posterior Lumbar Cage
89012257|NCT00417339||hemodialysis, 8h, every other day|hemodialysis, eight hours, every other day
89012258|NCT00417339||hemodialysis, 8h, six days per week|hemodialysis, eight hours, six days per week
89439709|NCT02290158|Active Comparator|Orthodontic finishing|Patients receiving a complete orthodontic finishing protocol according to the ABO-OGS
89439710|NCT02290158|No Intervention|No orthodontic finishing|Patients receiving orthodontic treatment without the finishing protocol according to the ABO-OGS
89439711|NCT04465656||[PCR-COVID 19-Pos] group|Having a microbiological diagnosis confirming COVID-19 infection (ie positive RT-PCR on nasopharyngeal swab) and/or clinical/CT signs
89439712|NCT04465656||[PCR-COVID 19-Neg] group|Having a microbiological diagnosis confirming the absence of COVID-19 infection (ie negative RT-PCR on nasopharyngeal swab) and absence of clinical /CT signs
89439713|NCT04465656||[PCR-COVID 19-Neg & Sero-COVID 19-Pos] group|"Having a microbiological diagnosis confirming the absence of COVID-19 infection (ie negative RT-PCR on nasopharyngeal swab) and absence of clinical /CT signs~Having been tested positive in a serological test for COVID-19 at M3"
89439714|NCT04465656||[PCR-COVID 19-Neg & Sero-COVID 19-Neg] group|"Having a microbiological diagnosis confirming the absence of COVID-19 infection (ie negative RT-PCR on nasopharyngeal swab) and absence of clinical /CT signs~Having been tested negative in a serological test for COVID-19 at M3"
89439715|NCT03384524|Active Comparator|Combination regiment|A combination regiment of Bromocriptine (2.5 mg/day), Metoprolol (25 mg/day) and Tamsulosin (0.4 mg/day)
89439716|NCT03384524|Placebo Comparator|Placebo|Three placebo pills, matching the external appearance of active drugs
89439717|NCT05194228|Experimental|Group 1|$1 Payment per EMA 2 EMAs per day 15 questions per EMA Fixed schedule Slider first
89439718|NCT05194228|Experimental|Group 2|$1 Payment per EMA 2 EMAs per day 15 questions per EMA Fixed schedule Likert first
89439719|NCT05194228|Experimental|Group 3|$1 Payment per EMA 2 EMAs per day 15 questions per EMA Random schedule Slider first
89439720|NCT05194228|Experimental|Group 4|$1 Payment per EMA 2 EMAs per day 15 questions per EMA Random schedule Likert first
89439721|NCT05194228|Experimental|Group 5|$1 Payment per EMA 2 EMAs per day 25 questions per EMA Fixed schedule Slider first
89439722|NCT05194228|Experimental|Group 6|$1 Payment per EMA 2 EMAs per day 25 questions per EMA Fixed schedule Likert first
89439723|NCT05194228|Experimental|Group 7|$1 Payment per EMA 2 EMAs per day 25 questions per EMA Random schedule Slider first
89439724|NCT05194228|Experimental|Group 8|$1 Payment per EMA 2 EMAs per day 25 questions per EMA Random schedule Likert first
89439725|NCT05194228|Experimental|Group 9|$1 Payment per EMA 4 EMAs per day 15 questions per EMA Fixed schedule Slider first
89439726|NCT05194228|Experimental|Group 10|$1 Payment per EMA 4 EMAs per day 15 questions per EMA Fixed schedule Likert first
89439727|NCT05194228|Experimental|Group 11|$1 Payment per EMA 4 EMAs per day 15 questions per EMA Random schedule Slider first
89439728|NCT05194228|Experimental|Group 12|$1 Payment per EMA 4 EMAs per day 15 questions per EMA Random schedule Likert first
89439729|NCT05194228|Experimental|Group 13|$1 Payment per EMA 4 EMAs per day 25 questions per EMA Fixed schedule Slider first
89439730|NCT05194228|Experimental|Group 14|$1 Payment per EMA 4 EMAs per day 25 questions per EMA Fixed schedule Likert first
89439731|NCT05194228|Experimental|Group 15|$1 Payment per EMA 4 EMAs per day 25 questions per EMA Random schedule Slider first
89439732|NCT05194228|Experimental|Group 16|$1 Payment per EMA 4 EMAs per day 25 questions per EMA Random schedule Likert first
89439733|NCT05194228|Experimental|Group 17|Payment by % EMAs 2 EMAs per day 15 questions per EMA Fixed schedule Slider first
89439734|NCT05194228|Experimental|Group 18|Payment by % EMAs 2 EMAs per day 15 questions per EMA Fixed schedule Likert first
89439735|NCT05194228|Experimental|Group 19|Payment by % EMAs 2 EMAs per day 15 questions per EMA Random schedule Slider first
89439736|NCT05194228|Experimental|Group 20|Payment by % EMAs 2 EMAs per day 15 questions per EMA Random schedule Likert first
89012259|NCT01641679||Suspected recurrent DTC|100 patients with biochemically suspected recurrent DTC
89012260|NCT00280098|Experimental|single group|
89012261|NCT01681147|No Intervention|Standard Care|Standard postpartum care after a pregnancy with gestational diabetes
89012262|NCT01681147|Experimental|Standard Care+Education Classes|"Standard postpartum care after a pregnancy with gestational diabetes~2 online nutrition and exercise education classes"
89012263|NCT01681147|Experimental|Standard Care+Education Classes+Glucose Monitoring|"Standard postpartum care after a pregnancy with gestational diabetes~2 online nutrition and exercise education classes~Self monitoring of blood glucose levels"
89012264|NCT01580137||healthy conscripts|non allergic subjects who have not a history of recurrent rhinosinusitis
89012265|NCT01580137||subjects with recurrent rhinosinusitis|subjects who have experienced recurrent rhinosinusitis episodes (3 during the previous 3 years)
89012266|NCT01685827|Active Comparator|NECT (Nifurtimox Eflornithine Combination Therapy)|"Nifurtimox tablets will be given orally three times a day, at the daily dose of 15 mg/kg/day, for 10 days.~Eflornithine (400 mg/kg/day) will be given twice daily for 7 days, as a 2-hour IV infusion."
89439737|NCT05194228|Experimental|Group 21|Payment by % EMAs 2 EMAs per day 25 questions per EMA Fixed schedule Slider first
89439738|NCT05194228|Experimental|Group 22|Payment by % EMAs 2 EMAs per day 25 questions per EMA Fixed schedule Likert first
89439739|NCT05194228|Experimental|Group 23|Payment by % EMAs 2 EMAs per day 25 questions per EMA Random schedule Slider first
89439740|NCT05194228|Experimental|Group 24|Payment by % EMAs 2 EMAs per day 25 questions per EMA Random schedule Likert first
89439741|NCT05194228|Experimental|Group 25|Payment by % EMAs 4 EMAs per day 15 questions per EMA Fixed schedule Slider first
89439742|NCT05194228|Experimental|Group 26|Payment by % EMAs 4 EMAs per day 15 questions per EMA Fixed schedule Likert first
88924542|NCT05076435|Active Comparator|Usual care (standard care)|"There will be no upper limit for the use of either IV or oral/enteral fluids~IV fluids should be given in the case of hypoperfusion or circulatory impairment and should be continued as long as hemodynamic variables improve including static or dynamic variable(s) as chosen by the clinicians. These criteria are based on the Surviving Sepsis Campaign guideline.~IV fluids should be given as maintenance if the ICU has a protocol recommending maintenance fluid~IV fluids should be given to substitute expected or observed loss, dehydration or electrolyte derangements"
88924543|NCT05075772|Experimental|BI 765080 - Administration mode 1 (T)|Subcutaneous (SC) injection (Test, T)
88924544|NCT05075772|Experimental|BI 765080 - Administration mode 2 (R)|Intravenous (IV) infusion (Reference, R)
88924545|NCT05074615|Experimental|Cranio-Cervical Flexion Training Group|"Participants of this group will receive conventional training along with cranio-cervical flexion training and home plan.~Cranio-cervical flexion training will be given with the help of pressure biofeedback unit. the cuff will be inflated at a specific pressure level and patient will be asked to maintain that pressure and gradually increase it."
88924546|NCT05074615|Active Comparator|Conventional Therapy Group|Participants of this group will receive only conventional therapy and home plan will be given which includes; hot pack, TENS, neck isometrics and passive stretching of neck musculature. Home plan will include self-stretches and neck isometrics.
88924547|NCT05070312|Experimental|MEDI3506 dose 1|MEDI3506 dose1
88924548|NCT05070312|Experimental|MEDI3506 dose 2|MEDI3506 dose 2
88924549|NCT05070312|Placebo Comparator|Placebo|Placebo 2 mL and 4 mL
88924550|NCT05058794|Experimental|Resistance exercise group|"During each exercise, only blood flow in the involved leg was restricted using an aneroid sphygmomanometer. Prior to exercise the cuff was placed on the most proximal portion of the limb and LOP was calculated in the body position that the blood flow restriction (BFR) stimulus would be applied. BFR pressure was set at 50% occlusion.Resistance applied for 1 minute (60 sec) with 30 % load of 1 repetition maximum. Subjects will receive treatment bilaterally.Participants will perform exercises 2 sets with 15 repetitions through 0 to 90 degrees.~Secondly, Rest between sets (1 min) Therapist will help these positions to maintain Knee extension and Wall Squatting.~The study includes interventional protocol of 6 weeks. Total sessions will be 12 and in each week there will 2 sessions with alternative days and follow up."
88924551|NCT05058794|Active Comparator|Conventional Therapy Group|Patients in this group will receive treatment via Knee extension,Wall squatting Each training session includes 3 minutes warm-up.First, participants will perform 2 sets with 15 repetitions in (0 to 90 degree.) Secondly, Rest between sets (1 min) Resistance applied for 1 minute (60 sec) with 30 % load of 1 repetition maximum. Subjects will receive treatment bilaterally. The study includes interventional protocol of 6 weeks. The sessions will be given on 2 alternate days making it a total of 12 sessions and then follow up.
88924552|NCT05058547|Experimental|SWEPPE|Participants will receive the smartphone application SWEPPE.
88924553|NCT05058547|No Intervention|Control|Participants randomized to the control group will not receive any active intervention for return to work after completing an Interdisciplinary Pain Rehabilitation Program .
88924554|NCT05037955||ILIT from trial NCT00470457|Patients who received ILIT in the original trial in 2005
88924555|NCT05037955||SCIT from trial NCT00470457|Patients who received SCIT in the original trial in 2005
88924556|NCT05037955||SCIT outpatient control|Patients who visited the allergy unit at the University Hospital Zurich and completed SCIT in the last 5 years
88924557|NCT05034068|No Intervention|control|the patients will be treated by using oral care only and evaluation will be done before cancer treatment and weekly till the treatment completed. In each weekly visit, oral sites will be examined, and a score was given to each site based on the degree of mucositis.
88924558|NCT05034068|Active Comparator|bezaydamine hydrochloride.|All patients were advised to rinse 15 mL of the solution benzydamine for 2 min, four to eight times daily before and during, and for 2 weeks after completion of cancer therapy. In case of any problem (e.g. burning or stinging), patients will be allowed to dilute the solution with water in the ratio 1:1 or 1:2. Study evaluations will be conducted before cancer treatment and weekly thereafter until 2 weeks after completion of the therapy .In each weekly visit, oral sites were examined and a score was given to each site based on the degree of mucositis.
88924559|NCT05034068|Active Comparator|low-level laser therapy|the patients will be treated by using a low-level laser therapy, the irradiations will be done three times a week using low power laser with a wavelength of 870 nm. The irradiation mode will be punctual and in contact, perpendicular to the oral mucosa. The power will be 60 mW, energy density of 6 J/cm2. Irradiation time will be 6 seconds per point based on the laser beam spot size of 0.55cm2. The irradiations will be done intra-orally avoiding the tumor site, oral examinations will be recorded at each irradiation session and the degree of mucositis will be recorded.
88924560|NCT05031195||1st tertile|
88924561|NCT05031195||2nd tertile|
88924562|NCT05031195||3rd tertile|
88924563|NCT05030870|Experimental|Capnographic monitoring group|In this group, in addition to the standard monitoring including observation, pulse oxygen saturation, non-invasive blood pressure, electrocardiogram in selected patients, the capnographic is also monitored. The capnographic data of the patients are available for additional noninvasive assessment of ventilation.
88924564|NCT05030870|Active Comparator|Standard monitoring group|In this group, standard monitoring including observation, pulse oxygen saturation, non-invasive blood pressure, electrocardiogram in selected patients. Capnographic data are not visible by closing the CO2 sampling line till the endoscopy end.
88924565|NCT05030025|Experimental|Group 1|single-dose pharmacokinetics will be characterized in twenty-four (24) healthy, adult males and females not of childbearing potential under fasting conditions.
88924566|NCT05030025|Experimental|Group 2|single-dose pharmacokinetics will be characterized in twenty-four (24) healthy, adult males and females not of childbearing potential under fed conditions.
88924567|NCT05019924|Active Comparator|Intervention arm|Dietary supplement
88924568|NCT05019924|No Intervention|Control arm|No intervention given
89439743|NCT05194228|Experimental|Group 27|Payment by % EMAs 4 EMAs per day 15 questions per EMA Random schedule Slider first
89439744|NCT05194228|Experimental|Group 28|Payment by % EMAs 4 EMAs per day 15 questions per EMA Random schedule Likert first
89439745|NCT05194228|Experimental|Group 29|Payment by % EMAs 4 EMAs per day 25 questions per EMA Fixed schedule Slider first
89439746|NCT05194228|Experimental|Group 30|Payment by % EMAs 4 EMAs per day 25 questions per EMA Fixed schedule Likert first
89439747|NCT05194228|Experimental|Group 31|Payment by % EMAs 4 EMAs per day 25 questions per EMA Random schedule Slider first
89439748|NCT05194228|Experimental|Group 32|Payment by % EMAs 4 EMAs per day 25 questions per EMA Random schedule Likert first
89439749|NCT03387800|Experimental|WeChat interactive peer support group|Participants will be grouped together by the researcher to form closed online peer support groups (with group names they choose). Activities on the WeChat groups serve two functions: i) It enhances social support among peer members toward smoking cessation. ii) The online support group also enhances the participants' positive affect.
89439750|NCT03387800|Active Comparator|Basic health education messages|Members of the control group will receive health education messages that will also be sent to the intervention group through WeChat. The messages include topics on physical and psychological aspects of perceived severity of smoking and perceived benefits of smoking cessation, and tips/skills on resisting situational temptations that may lead to relapse.
89439751|NCT02294136|Experimental|Prep-C|Four session nurse administered behavioral intervention.
89439752|NCT02294136|Active Comparator|Educational Control|Attention Control
89439753|NCT04465578|Active Comparator|Sling tension adjustment by classic technique|We will adjust the tension of the sling by using the classic technique (2 fingers between the fascia and the knot)
89439754|NCT04465578|Active Comparator|Sling tension adjustment by height of 4 cm|We will adjust the tension of the sling by using the height between the fascia and the knot of 4cm
89439755|NCT05599282|Experimental|Amino Acid Supplement|"Participants will be instructed to take four (4) capsules of Amino Acid Supplement with a full glass of water daily for up to 90 days, starting on day 1. No substance other than water (i.e., food, drink other than water, and/or medication, supplement, vitamin, and/or mineral) can be consumed two hours before or after taking the Investigational Product (IP). The IP must be consistently consumed immediately before nighttime sleep throughout the study.~If a dose is missed participants are instructed to record the missed dose in their study journal. Missed doses will not be taken at a later time or date. If any substance other than water is consumed two hours before or after taking the IP, that IP use will be counted as a missed dose. Participants will be advised not to exceed four (4) capsules daily."
89502043|NCT05495672|Experimental|Cohort 1-Arm A: the largest pulmonary nodule is less than or equal to 1 cm, ctDNA positive|ctDNA is detected before curative treatment. Subjects with ctDNA positive before treatment will receive curative treatments for pulmonary nodules such as surgery, radio frequency ablation or stereotactic body radiotherapy. ctDNA will be detected after curative treatment and then every three months until progression or 2 years. At the same time, routine post treatment follow-up will be performed.
88924569|NCT05018026|No Intervention|Arm 1 (Control Arm)|A default NUSMart that mirrors a conventional web-grocery store in Singapore where some healthier products are displayed with Singapore's Healthier Choice Symbol (HCS) logos (Control).
88924570|NCT05018026|Experimental|Arm 2 (Nutri-Grade Arm)|Similar to Arm 1 except that beverages will be displayed with a color-coded and graded Nutri-Grade label.
88924571|NCT05016687|Experimental|Experimental Part I Cohort 1-5: CUR-N399|Healthy subjects 18-55 years will receive single ascending doses of CUR-N399. Planned doses for respective Cohorts: Cohort 1: 2.5 mg, Cohort 2: 7.5 mg, Cohort 3: 17.5 mg, Cohort 4: 35 mg, Cohort 5: 50 mg.
88924572|NCT05016687|Placebo Comparator|Experimental Part I Cohort 1-5: Placebo|Healthy subjects will receive Placebo to match treatment of CUR-N399.
88924573|NCT05016687|Experimental|Experimental Part IIa Cohort 1-3: CUR-N399|Healthy subjects 18-55 years will receive multiple ascending doses of CUR-N399 during a 7-day period. Planned doses for respective Cohorts: Cohort 1: 10 mg/day, Cohort 2: 25 mg/day, Cohort 3: 50 mg/day.
88924574|NCT05016687|Placebo Comparator|Experimental Part IIa Cohort 1-3: Placebo|Healthy subjects 18-55 years will receive Placebo to match CUR-N399 treatment during a 7-day period.
88924575|NCT05016687|Experimental|Experimental Part IIb: CUR-N399|Healthy subjects >/= 65 years will receive multiple ascending doses of CUR-N399 during a 7-day period. The dose to be administered will determined based on safety results in Part IIa.
88924576|NCT05016687|Placebo Comparator|Experimental Part IIb: Placebo|Healthy subjects >/= 65 years will receive Placebo to match CUR-N399 treatment during a 7-day period.
88924577|NCT05013567|Experimental|Ibuprofen gel 5%|
88924578|NCT05013567|Placebo Comparator|Placebo|
88924579|NCT05011409||Newly diagnosed breast cancer patients|Newly diagnosed breast cancer patients referred to Kazakh Institute of Oncology and Radiology or Almaty Oncology Center will be assessed on the prevalence of depression and anxiety symptoms.
88924580|NCT05010408|Placebo Comparator|Control beverage for Habitual full-calorie CSD cohort|Full sweetness (sugar) for 6 months
88924581|NCT05010408|Placebo Comparator|Control beverage for Habitual low-calorie CSD cohort|Full sweetness low calorie sweetener (LCS) with sweetness level matched to the full sweetness sugar control for 6 months
88924582|NCT05010408|Active Comparator|Test beverage 1 for Habitual full-calorie CSD cohort|Reduced sweetness (moderate sugar level) for 6 months
88924583|NCT05010408|Active Comparator|Test beverage 1 for Habitual low-calorie CSD cohort|Reduced sweetness low calorie sweetener (LCS) with sweetness level matched to the moderate sugar sweetness level for 6 months
88924584|NCT05010408|Active Comparator|Test beverage 2 for Habitual full-calorie CSD cohort|Step-wise sweetness reduction over 6 months. Month 1 is the full sweetness sugar control, followed by monthly sweetness reduction. Remains at the reduced sweetness level (moderate sugar level) from months 4-6.
89439756|NCT05599282|Placebo Comparator|Placebo|"Participants will be instructed to take four (4) capsules of Placebo with a full glass of water daily for up to 90 days, starting on day 1. No substance other than water (i.e., food, drink other than water, and/or medication, supplement, vitamin, and/or mineral) can be consumed two hours before or after taking the placebo. The placebo must be consistently consumed immediately before nighttime sleep throughout the study.~If a dose is missed participants are instructed to record the missed dose in their study journal. Missed doses will not be taken at a later time or date. If any substance other than water is consumed two hours before or after taking the placebo, that placebo use will be counted as a missed dose. Participants will be advised not to exceed four (4) capsules daily."
89439757|NCT03387644|Active Comparator|Pregabalin (PG)|Patients received 150 mg pregabalin one hour before the procedure.
89439758|NCT03387644|Placebo Comparator|Control placebo (C)|Patients received placebo tablet one hour before surgery.
89439759|NCT02290002|Active Comparator|group A|In group A, (Calcium Dobesilate group), 1 cap / 8 hs Calcium Dobesilate ( 500mg) will be given from at day of HCG injection and for 21 days.
89439760|NCT02290002|Active Comparator|group B|In group B, coasting (withholding gonadotrophins while maintaining pituitary suppression) for 3 days then either giving triggering or cycle cancellation is done
89439761|NCT05172830||Group/Cohort|Ovation Alto™ Abdominal Stent Graft System Eligible patients must meet all of the inclusion criteria and none of the exclusion criteria.
89439762|NCT02294214|Placebo Comparator|Placebo|Placebo Repellent product with no active ingredient
89439763|NCT02294214|Active Comparator|Intervention|Spatial Repellent product with active ingredient
89439764|NCT03654092|Experimental|Exercise intervention|Home-based, minimal equipment exercise training program.
89439765|NCT03654092|No Intervention|Control|Usual care (study participation does not have any impact on regular treatment decisions, including participation in other exercise training programs).
89439766|NCT04132804|Experimental|Tai Chi Treatment|All patients in the trial will receive 1-hour Tai Chi lessons once per week for a total of 8 weeks.
89439767|NCT02294292|Experimental|Carvedilol + Ivabradine|"Carvedilol started to achieve target HR (heart rate) reduction to 60/min, to a lowest permissible 50-55/ min ; provided Systolic Blood Pressure> 90 mmHg.~if carvedilol is not tolerated,Ivabradine is added in a dose starting 2.5 mg BD to a maximum of 15 mg/day to ensure targeted heart rate reduction"
89439768|NCT02294292|Active Comparator|Endoscopic Variceal Ligation (EVL)|
89439769|NCT03387566|Experimental|HB002.1M 0.3mg|Participants received a 0.3mg dose of HB002.1M via intravitreal (IVT) injection.
88924585|NCT05010408|Active Comparator|Test beverage 2 for Habitual low-calorie CSD cohort|Step-wise sweetness reduction over 6 months. Month 1 is the low calorie sweetener (LCS) sweetness equivalent of the full sweetness sugar control, followed by monthly LCS sweetness reduction (reductions equivalent to the corresponding sugar reduction arm sweetness levels). Remains at the reduced sweetness level (LCS equivalent of moderate sugar sweetness level) from months 4-6.
88924586|NCT05006014||Patient with non restorable teeth|Patient with non restorable teeth located in smile line needs extraction with immediate implantation and immediate provisionalization to improve psychiatric effect of tooth loss
88924587|NCT04998708|Experimental|Intervention|The intervention group performed two types of relaxation techniques, that have shown their positive effects on immune functions, including progressive muscle relaxation exercise (PMRs)16 and cognitive-behavioral stress management (CBSM). We used two types of relaxation techniques to produce maximum effects of relaxation techniques within the limited period of COVID-19 quarantine (2 weeks). the control groups did not receive any treatment during the study; however, they were treated afterwards.
88924588|NCT04998708|No Intervention|Control|
89012267|NCT01685827|Experimental|Fexinidazole|"Fexinidazole, 600 mg tablets given by oral route, after the main daily meal (within 30 minutes from the start of the meal), at the daily dose of:~1 800 mg (3 tablets) once a day for 4 days,~Followed by 1 200 mg (2 tablets) once a day for 6 days. Total duration of treatment will be 10 days."
89199423|NCT05595122|Experimental|Intervention|EUS-CDS using FCSEMS through LAMS
89199424|NCT05577065|Experimental|Active|Arm receiving investigational product (probiotic)
89439770|NCT03387566|Experimental|HB002.1M 0.5mg|Participants received a 0.5mg dose of HB002.1M via intravitreal (IVT) injection.
89439771|NCT03387566|Experimental|HB002.1M 1.0mg|Participants received a 1.0mg dose of HB002.1M via intravitreal (IVT) injection.
89439772|NCT03387566|Experimental|HB002.1M 2.0mg|Participants received a 2.0mg dose of HB002.1M via intravitreal (IVT) injection.
89439773|NCT03387566|Experimental|HB002.1M 3.0mg|Participants received a 3.0mg dose of HB002.1M via intravitreal (IVT) injection.
89439774|NCT02294370||subjects at the early stages of diabetes|Subjects at the early stages of diabetes, individuals with impaired glucose tolerance (IGT, 2h plasma glucose during oral glucose tolerance test >7.8-11.1 mmol/l (n=50) or with type 2 diabetes (fasting plasma glucose > 7.0 mmol/l and/or 2h plasma glucose > 11.1 mmol/l on two occasions, or both criteria fulfilled in same oral glucose tolerance test while not pregnant, n=50) with short duration (<3 years)
89439775|NCT03387488|Experimental|Treatment|StingrayTM, Medtronic®
89439776|NCT02290314|Other|minimally invasive MID-line Lumbar Fusion (MIDLF)|MIDLF surgery involves a minimally invasive midline laminectomy posterior approach to the lumbar spine. An incision that is smaller than the standard incision is made in the midline of the low back directly over the spinal levels. Afterward the pressure on the compressed nerves is released, and the disc between the affected vertebrae is completely removed. A metal cage filled with bone graft is placed as described in the PLIF procedure.
89439777|NCT02290314|Other|posterior lumbar interbody fusion (PLIF)|PLIF surgery involves a standard incision in the midline of the low back directly over the involved spinal levels. Afterward the pressure on the compressed nerves is released, and the disc between the affected vertebrae is completely removed. A metal cage filled with bone graft is placed in between the vertebral bodies where the disc usually lies. This will allow bone fusion (healing) to occur from one vertebral body to the other.
89439778|NCT03391856|Experimental|intervention arm|NAC 400mg p.o tid from day 60 to day 90 post transplant
89439779|NCT03391856|Other|controlled arm|Supportive therapy including platelet infusion:prophylactic platelet transfusion was given when platelet count <20000/ul
89439780|NCT03514758|Experimental|normal hearing participants|normal hearing participants with and without hearing aids
88924589|NCT04989621|Experimental|Orelabrutinib plus Rituximab followed by Maintenance with Orelabrutinib|"Induction therapy: Patients receive Orelabrutinib at a dose of 25 mg once daily on days 1-28 and rituximab at a dose of 375mg/m2 on day 1. Treatment cycles repeat every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.~If patients achieve CR or PR or SD, they will be treated with maintenance therapy Maintenance therapy: Patients receive Orelabrutinib every day at a dose of 150mg for up to two years in the absence of disease progression or unacceptable toxicity."
88924590|NCT04989049|Active Comparator|intervention group or case group|topical folic acid on oral ulcers will be applied for 7 days and patients will be asked to visit after 7 days for follow up
88924591|NCT04989049|Placebo Comparator|control group|placebo drug for oral ulcers
88924592|NCT04984044|Active Comparator|Experimental|This arm includes 36 Diabetic Peripheral Neuropathy patients receiving the antidiabetic medications
88924593|NCT04984044|Placebo Comparator|Control|This arm includes 36 Diabetic Peripheral Neuropathy patients receiving the antidiabetic medications
88924594|NCT04984031||Generalized grade C periodontitis|generalized aggressive periodontitis ( generalized Grade C ,as in new classification) patients characterized with Bone loss/age index more than 1 and extent more 30 %
88924595|NCT04984031||Molar-incisor grade C periodontitis|localized aggressive periodontitis ( Molar-incisor pattern Grade C ,as in new classification) patients characterized with limited affection on molars and incisors and their Bone loss/age index more than 1.
88924596|NCT04983979|Experimental|SZC|3 month treatment using Sodium zirconium cyclocilicate. Doses of 5 or 10g once daily will be used. The dose will be titrated according to potassium levels performed at clinic visits
88924597|NCT04983979|Placebo Comparator|Placebo|3 month treatment using matched placebo. Doses of 5 or 10g once daily will be used. The dose will be titrated according to potassium levels performed at clinic visits
88924598|NCT04977635||600-cohort|"Patients with long-term (> 5 years) type 1 diabetes aged 16 years and older~As this is an observational study there is no intervention."
88924599|NCT04976244|Active Comparator|Brolucizumab|Arm B
88924600|NCT04976244|Active Comparator|Aflibercept|Arm A
88924601|NCT04976166|Active Comparator|Conventional group|Videos and leaflets will be provided. Patients will have education using leaflets for 5 minutes in each hospital at months 0 and 2, respectively.
88924602|NCT04976166|Experimental|Extensive Informed Decision Making group|Videos, leaflets, and intensive learning materials will be provided. Patients in the EIDM group will receive more informed and detailed education than those in the conventional group. Patients will have education for more than 10 minutes at months 0 and 2, respectively.
88924603|NCT04976166|Experimental|Shared Decision Making group|Videos, leaflets, and intensive learning materials will be provided. Patients will check self-assessment items, and then have education according to the patients' preference using a self-developed counseling calendar. Patients will have education for more than 10 minutes at months 0 and 2, respectively.
88924604|NCT04975802|Placebo Comparator|0 mg coffeeberry beverage|Appearance-matched to the other products
88924605|NCT04975802|Experimental|100 mg coffeeberry beverage|Appearance-matched to the other products
88924606|NCT04975802|Experimental|300 mg coffeeberry beverage|Appearance-matched to the other products
88924607|NCT04975802|Active Comparator|75 mg caffeine beverage|Appearance-matched to the other products
89199425|NCT05577065|Placebo Comparator|Placebo|Arm receiving placebo
89199426|NCT05571969|Experimental|2X-121 Monotherapy and Dovitinib in Combination with 2X-121 in Patients with Advanced Solid Tumors|Determine the maximum tolerated dose (MTD) of 2X-121 monotherapy given twice daily (BID) and determine the MTD of dovitinib given in combination with 2X-121 (MTD) in patients with advanced solid tumors.
89439781|NCT04176614|Experimental|cereal-legume snack|Certain amount of cereal-legume snack daily for 12 weeks
89439782|NCT04176614|Active Comparator|cereal snack|Certain amount of cereal snack daily for 12 weeks
89439783|NCT01664494||Capecitabine|Participants will receive capecitabine according to the label text as monotherapy (1250 mg/m^2 twice daily) or combination therapy (800 to 1000 mg/m^2 or 1250 mg/m^2 twice daily) for 14 consecutive days followed by a treatment break of 7 days.
89439784|NCT02290470|Experimental|olanzapine Days 1-3|"Olanzapine + Chemotherapy + Antiemetic treatment~Patients will receive the chemotherapy drugs carboplatin and paclitaxel as well as the following anti-nausea/vomiting drugs:~Palonosetron (0.25 mg intravenously) on the day of chemotherapy, plus~Dexamethasone (16 mg intravenously on the day of chemotherapy), plus~Olanzapine (10 mg orally on the day of chemotherapy and 10 mg orally on days 2, 3 post chemotherapy)"
89439785|NCT02290470|Experimental|olanzapine+Dexamethasone d 1-3|"Olanzapine + Chemotherapy + Antiemetic treatment~Patients will receive the chemotherapy drugs carboplatin and paclitaxel as well as the following anti-nausea/vomiting drugs:~Palonosetron (0.25 mg intravenously) on the day of chemotherapy, plus~Dexamethasone (16 mg intravenously on the day of chemotherapy and 4 mg orally days 2, 3 post chemotherapy), plus~Olanzapine (10 mg orally on the day of chemotherapy and 10 mg orally on days 2, 3 post chemotherapy)"
89439786|NCT02290470|Active Comparator|dexamethasone days 1-3|"Dexamethasone + Chemotherapy + Antiemetic treatment~Patients will receive the chemotherapy drugs carboplatin and paclitaxel as well as usual anti-nausea/vomiting drugs:~Palonosetron (0.25 mg intravenously) on the day of chemotherapy, plus~Dexamethasone 16 mg intravenously on the day of chemotherapy (day 1), plus~Dexamethasone 8 mg orally on days 2 and 3 post chemotherapy"
89439787|NCT03387410|Experimental|Intravenous IRDye 800BK|Patients undergoing laparoscopic bowel resection & laparoscopic donor nephrectomy
89439788|NCT04314388|Experimental|Intervention: Outdoor walking Rehabilitation Programme|Participants in the intervention will be provided with an exercise diary. This will include walking routes for the instructor led 3-month outdoor-walking rehabilitation programme. The exercise diary will also include home exercises for the participants to complete twice-per-week that will be explained in detail, using coaching points and images to support. As these exercises will be completed at home. Each exercise has four progressions ranging from easy to hard.
88924608|NCT04972747|Experimental|Suggest skin care with sunflower oil for preterm babies|"Before each application, preterm babies will be given skin care in the service routine and sunflower oil will be applied twice a day for 14 days.~Absorption of sunflower oil for preterm babies will be provided by using a baby massage application.~Before the massage, 3-4 ml of sunflower oil will be applied to the whole body surface except the genital area and scalp..~12 hours after each application, the skin of the newborn will be evaluated using the Neonatal Skin Condition Assessment Scale (Appendix-2), and the measurement will be made with a DMM brand skin moisture meter and recorded in the follow-up form."
88924609|NCT04972747|Experimental|Suggest skin care with cocunut oil for preterm babies|"Before each application, preterm babies will be given skin care in the service routine and coconut oil will be applied twice a day for 14 days.~Absorption of coconut oil for preterm babies will be provided by using a baby massage application.~Before the massage, 3-4 ml of coconut oil will be applied to the whole body surface except the genital area and scalp.~12 hours after each application, the skin of the newborn will be evaluated using the Neonatal Skin Condition Assessment Scale (Appendix-2), and the measurement will be made with a DMM brand skin moisture meter and recorded in the follow-up form."
88924610|NCT04971811|Experimental|Lower-energy-dense Snack|Test snack with lower-energy-dense snack food
88924611|NCT04971811|Experimental|Higher-energy-dense Snack|Test snack with higher-energy-dense snack food
88924612|NCT04971395|Experimental|Single IV infusion of 2 mg/kg of XTMAB-16 or placebo|"Sentinel group: Each cohort will have a sentinel group of 2 participants (1:1 XTMAB-16 and placebo, respectively). dosed at least 48 hours before the remaining participants in the same cohort. (Up to 99 days)~After safety is confirmed, the remaining patients within the same cohort will be dosed.~Remaining group: Each cohort will then enroll 10 participants (8:2 XTMAB-16 and placebo, respectively) (Up to 99 days)"
89439789|NCT04314388|Other|Control: The light Stretches Programme|The control group intervention will be a non-exercise intervention to avoid training effects. The control group will be asked to keep to their normal activities of daily living and given ten targeted active stretches for the upper and lower body three times per week at home. Participants in the control group will each be provided a booklet for the given stretches.
89439790|NCT05172518|Active Comparator|Arm A|Taxane plus Intermittent Capecitabine
89439791|NCT05172518|Experimental|Arm B|Utidelone plus Intermittent Capecitabine
89439792|NCT05172518|Active Comparator|Arm C|Taxane plus Metronomic Capecitabine
89439793|NCT05172518|Experimental|Arm D|Utidelone plus Metronomic Capecitabine
89439794|NCT02298270|Experimental|Relaxation Response Resiliency Program|Participants will receive an 8-week behavioral intervention which teaches stress management and psychological resiliency-enhancing skills.
89439795|NCT02298270|Placebo Comparator|Health Education|Participants will receive and 8-week general stress and health education program, with none of the active relaxation and resiliency-based components being tested in the experimental condition.
89439796|NCT03724084|Experimental|Treatment (pinometostat)|"Patients receive pinometostat IV continuously on days 1-35, daunorubicin hydrochloride IV over 10-30 minutes on days 8-10 and cytarabine IV continuously on days 8-14 in the absence of disease progression or unacceptable toxicity.~Patients who do not achieve CR/CRi after treatment receive pinometostat IV continuously on days 1-28, daunorubicin hydrochloride IV over 10-30 minutes on days 1 and 2 and cytarabine IV continuously on days 1-5 in the absence of disease progression or unacceptable toxicity."
89439797|NCT03621488|Experimental|Efficacy of Behavioral Self-Activation with virtual reality|"10 individual sessions of the Brief Behavioral Activation Treatment for Depression (BATD) program, lasting one hour, at the start of treatment, then half an hour thereafter, once a week~+ virtual reality activities of the session 4 to 9 lasting half an hour."
89439798|NCT03621488|Sham Comparator|Efficacy of Behavioral Self-Activation without virtual reality|10 individual sessions of the Brief Behavioral Activation Treatment for Depression (BATD) program, lasting one hour, at the start of treatment, then half an hour thereafter, once a week.
89439799|NCT03133182||Polypharmacy|People taking >=5 unique prescription drugs in the 3 months prior to surgery
89012268|NCT05108584|Experimental|Group 1 - Level 3 PPE and video laryngoscope|Pre-anesthesia visit aims to assess the participant's physical status based on the American Society of Anesthesiologists score and assessment of the airway. Researcher then explained about the study and plan for anesthesia using an endotracheal tube and personal protective equipment according to the group. While in the operating room, the intubation operator was assisted by an assistant who already used appropriate PPE. Coveralls or hazmat suits and surgical gowns used must match the size. The intubation operator was resident of Anesthesiology and Intensive Therapy study program (stage II) and accompanied by an independent resident (stage III) and an anesthesiologist on duty. The operator used level 3 PPE (coverall jumpsuit, face shield, goggles, N95 mask, surgical mask, boot, scrub, and two layered gloves) and video laryngoscope for intubation of the participants. Researcher was in charge for recording time and event during the intubation process according to the study form.
89012269|NCT05108584|Experimental|Group 2 - Level 3 PPE and direct laryngoscope|Pre-anesthesia visit aims to assess the participant's physical status based on the American Society of Anesthesiologists score and assessment of the airway. Researcher then explained about the study and plan for anesthesia using an endotracheal tube and personal protective equipment according to the group. While in the operating room, the intubation operator was assisted by an assistant who already used appropriate PPE. Coveralls or hazmat suits and surgical gowns used must match the size. The intubation operator was resident of Anesthesiology and Intensive Therapy study program (stage II) and accompanied by an independent resident (stage III) and an anesthesiologist on duty. The operator used level 3 PPE (coverall jumpsuit, face shield, goggles, N95 mask, surgical mask, boot, scrub, and two layered gloves) and direct laryngoscope for intubation of the participants. Researcher was in charge for recording time and event during the intubation process according to the study form.
89012270|NCT05108584|Experimental|Group 3 - Level 2 PPE and direct laryngoscope|Pre-anesthesia visit aims to assess the participant's physical status based on the American Society of Anesthesiologists score and assessment of the airway. Researcher then explained about the study and plan for anesthesia using an endotracheal tube and personal protective equipment according to the group. While in the operating room, the intubation operator was assisted by an assistant who already used appropriate PPE. Coveralls or hazmat suits and surgical gowns used must match the size. The intubation operator was resident of Anesthesiology and Intensive Therapy study program (stage II) and accompanied by an independent resident (stage III) and an anesthesiologist on duty. The operator used level 2 PPE (surgical gown/apron, face shield, goggles, N95 mask, surgical mask, boot, scrub, and two layered gloves) and video laryngoscope for intubation of the participants. Researcher was in charge for recording time and event during the intubation process according to the study form.
89012271|NCT01686841|Experimental|Fat Reduction|
89012272|NCT00417378|Active Comparator|1|Intraaortic balloon counterpulsation (IABP)
89012273|NCT00417378|Experimental|2|Left Ventricular Assist Device (Impella LP2.5)
89199427|NCT05556590||QFR-Low Group|Based on preoperative CAG, QFR analysis will be conducted for vessels bypassed with RA grafts. The RA-grafted vessels with QFR below the best cut-off value (0.50-0.55 assumed) will be allocated to QFR-Low group.
89439800|NCT03133182||No polypharmacy|People taking <5 unique prescription drugs in the 3 months prior to surgery
89439801|NCT02290548|Experimental|high flow nasal cannula|High flow nasal cannula immediately use after extubation
89439802|NCT02290548|Placebo Comparator|stanrd oxygen therapy|Oxygen cannula or mask after extubation
89199428|NCT05556590||QFR-High Group|Based on preoperative CAG, QFR analysis will be conducted for vessels bypassed with RA grafts. The RA-grafted vessels with QFR over the best cut-off value (0.50-0.55 assumed) will be allocated to QFR-High group.
88924613|NCT04971395|Experimental|Single IV infusion of 4 mg/kg of XTMAB-16 or placebo|"Sentinel group: Each cohort will have a sentinel group of 2 participants (1:1 XTMAB-16 and placebo, respectively). dosed at least 48 hours before the remaining participants in the same cohort. (Up to 99 days)~After safety is confirmed, the remaining patients within the same cohort will be dosed.~Remaining group: Each cohort will then enroll 10 participants (8:2 XTMAB-16 and placebo, respectively) (Up to 99 days)"
89199429|NCT05534191|Experimental|Intervention|This group will use a functional training system developed specifically for football players to improve their physical strength and movement abilities on the field.
89199430|NCT05534191|Active Comparator|Positive control|This group will use general strength exercises with the purpose of improving physical strength.
89199431|NCT05534191|No Intervention|Negative control|Control group A group that is not treated
89199432|NCT05533970|Experimental|0.375% ropivacaine+0.5ug/kg Dexmedetomidine 30 ml|H-FICB under ultrasound guidance before general anesthesia, given 0.375% ropivacaine+0.5ug/kg Dexmedetomidine 30 ml
89199433|NCT05533970|Experimental|0.375% ropivacaine+1ug/kg Dexmedetomidine 30 ml|H-FICB under ultrasound guidance before general anesthesia, given 0.375% ropivacaine+1ug/kg Dexmedetomidine 30 ml
88924614|NCT04969562|Experimental|experiment|Individuals with multiple sclerosis in the experimental group will be included in six sessions of EFT at seven-day intervals, in which one session lasts 30-45 minutes. SUDS will be applied before and after each EFT session. At the same time, resting heart rate and blood pressure will be measured in the EFT group before and after each session.
89199434|NCT05533970|Experimental|0.375% ropivacaine+0.25ug/kg Dexmedetomidine 30 ml|H-FICB under ultrasound guidance before general anesthesia, given 0.375% ropivacaine+0.25ug/kg Dexmedetomidine 30 ml
89199435|NCT05520333|Experimental|Intervention arm|Families receive text messages for three months.
88924615|NCT04969562|No Intervention|control|They will continue their routine treatment.
88924616|NCT04968782||Patients with acute appendicitis|
88924617|NCT04961372||Healthcare Workers|All healthcare professionals working at Gümüşhane Şiran Government Hospital
88924618|NCT04961372||Non-Healthcare Workers|Twice the number of health workers included in the study, non-health worker volunteers
88924619|NCT04960683|Experimental|Robotic -assisted gait training group using Lokomat device|"5 sessions of 40 minutes of conventional therapy and~5 sessions of 40 minutes on Lokomat per week"
88924620|NCT04960683|Active Comparator|Traditional therapy group|• 5 sessions of 40 minutes of conventional therapy
88924621|NCT04956172|Active Comparator|Tone A|Tone A uses an 80dB standard tone
89199436|NCT05520333|No Intervention|Waitlist-control arm|Families are randomized into a control group for three months and begin receiving text messages for three months.
89199437|NCT05515614|Active Comparator|Standard Fortification|Mother's breast milk will be fortified using Enfamil Liquid Human Milk Fortifier (LHMF) as per standard feeding protocol defined by LLUCH NICU.
88924622|NCT04956172|Experimental|Tone B|Tone B uses a 93dB standard tone
89199438|NCT05515614|Experimental|Targeted Fortification|Mother's breast milk will be fortified with modular additives, namely Amino Acid powder, PolyCal, and safflower oil to meet the individual nutritional needs.
89199439|NCT05512481|Experimental|Neoadjuvant/adjuvant therapy|"Drug: Camrelizumab~Drug: Apatinib mesylate~Drug: Temozolomide Injection"
89199440|NCT05493293|Experimental|NBI-921352 Treatment|Treatment for up to 107 weeks.
89199441|NCT05492110|Active Comparator|CS Reducer implantation|
89199442|NCT05492110|Sham Comparator|Sham procedure|
89199443|NCT05482412|Experimental|T3 Subgroup|"Two T3 Subgroups:~Paraphilia with androphilic or gynephilic Tanner 3 SI Marker (Sexual Incitation) note: incitation/stimulation"
88924623|NCT04950868|Experimental|Quetiapine|They will initially be given 25 mg of quetiapine per day. The dose may be increased by 25-50 mg per week, to a maximum dose of 150 mg per day by week 6 of the study.
88924624|NCT04947137|Experimental|Subjects Free of Inflammatory Disease|The first arm will be comprised of HCs who are deemed to be clinically free of inflammatory diseases, arthropathies, and/or arthroplasties and clinically free of joint pain for at least 28 days prior to the consent date.
88924625|NCT04947137|Experimental|Healthy Controls and RA Subjects on Stable Therapy|The second arm is comprised of [1] disease-free HCs and [2] clinically diagnosed RA subjects on stable treatment.
89199444|NCT05482412|Experimental|T5 (Young Adult) Subgroup|"Two T5 Subgroups Age-Play Subgroup (APSI):~Paraphilia with androphilic or gynephilic Tanner 5 SI Marker (Sexual Incitation)"
89199445|NCT05482412|Sham Comparator|Sham Comparator|Medical Device Sham Comparator taVGN (Cranial Ten - Vagus Nerve) Selection of Random Participants In Any Subgroup Class Androphilic or gynephilic SI Marker (Sexual Incitation)
89199446|NCT05482412|Experimental|T2 Subgroup|"Two T2 Subgroups:~Paraphilia with androphilic or gynephilic Tanner 2 SI Marker (Sexual Incitation)"
89199447|NCT05482412|Experimental|T4 Subgroup|"Two T4 Subgroups:~Paraphilia with androphilic or gynephilic Tanner 4 SI Marker (Sexual Incitation)"
89199448|NCT05481424|Experimental|Biodynamic Condition followed by an Active Placebo Condition.|Each lighting condition will last for two weeks (Weeks 2-3 or 4-5), be limited to the 10 workdays, and be active for 8 hours per day. The order of conditions will be randomized.
89199449|NCT05481424|Experimental|Active Placebo Condition followed by Biodynamic Condition|Each lighting condition will last for two weeks (Weeks 2-3 or 4-5), be limited to the 10 workdays, and be active for 8 hours per day. The order of conditions will be randomized.
89199450|NCT05473273||Natural Cycle Protocol|"Ultrasound monitoring to monitor follicular and endometrial growth. Serial measurements of serum Lutenizing Hormone (LH), estradiol (E2), and progesterone (P4) to identify ovulation.~Minimal endometrial thickness of 7 mm is required. No progesterone supplementation. Embryo transfer (ET) will be scheduled 5 days after the day of ovulation (120 hours of P4 exposure).~Blood samples will be drawn to measure PIBF, IL-17, IFγ, IL-10, IL-4 and TGF-ß1 on day of ovulation (P4 rise), on the day before ET, on the day of ET and 3 and 10 days later, between 9 and 12 am.~A blood test to measure beta human chorionic gonadotropin (ß-hCG) will be performed 3 and 10 days after ET and at 5 weeks +/- 3 days in case of pregnancy, between 9 and 12 am.~In case of pregnancy, a blood test to measure PIBF, IL-17, IFγ, IL-10, IL-4 and TGF-ß1 will be performed at 5 weeks +/- 3 days between 9 and 12 am.."
89199451|NCT05473273||Hormone Replacement Therapy Protocol|"Ultrasound monitoring of endometrial growth and exclude growing follicle~Oral Estradiol Valerate (Progyluton) 4 mg on cycle day 2 at 7 pm for 2 days. On 3rd day, increase dose to 6 mg. The dose may be increased based on endometrial thickness.~Once endometrial thickness is at least 7 mm and trilaminar, after 10-15 days of Estradiol Valerate administration, start Endometrin 100 mg at 1 pm and 9 pm. From 2nd day onwards increase to 3 times daily. Continue Progyluton & Endometrin until 12 weeks of pregnancy~ET on the 5th full day of Endometrin administration~Blood test to measure PIBF, IL-17, IFγ, IL-4, IL-10 and TGF-ß1 on the 1st day of Endometrin supplementation (before 1st administration), on the 4th day of Endometrin administration, on the day of ET and 3 and10 days after, 4 to 7 hours after the morning administration.~Blood test to measure beta human chorionic gonadotropin (ß-hCG) will be performed 3 and 10 days after ET and at 5 weeks +/- 3 days if pregnancy."
89199452|NCT05472831|Experimental|BAILAMOS dance program plus MIND diet|BAILAMOS dance program plus MIND diet: Includes a 6-month, twice a week x 60 minutes/session, virtually delivered Latin dance program plus a 60 minute MIND diet session per week.
89199453|NCT05472831|Experimental|BAILAMOS dance program plus Health Education|BAILAMOS dance program plus Health Education: Includes a 6-month, twice a week x 60 minutes/session, virtually delivered Latin dance program plus a 60 minute health education session per week.
89199454|NCT05467163|Active Comparator|Biventricular pacing + AV node ablation|Implantation of biventricular pacemaker with or without defibrillator lead placement followed by AV node ablation. Optimal guidelines-based heart failure treatment.
89199455|NCT05467163|Experimental|Conduction system pacing + AV node ablation|Implantation of permanent pacemaker with conduction system pacing (preferably left bundle branch) with or without defibrillator lead placement followed by AV node ablation. Optimal guidelines-based heart failure treatment.
89199456|NCT05464680|Experimental|Patients positive to SARS-CoV 2|Patients admitted to the ICU and placed on VM following SARS-CoV-2 pneumonia
89199457|NCT05464680|Sham Comparator|Patients negative to SARS-CoV 2|Patients admitted to the ICU and placed on VM outside of SARS-CoV-2 pneumonia
89199458|NCT05463068|Experimental|Lot 1|1 intramuscular (IM) injection of NVX-CoV2373 of 0.5 mL injection volume on Day 1.
89199459|NCT05463068|Experimental|Lot 2|1 intramuscular (IM) injection of NVX-CoV2373 of 0.5 mL injection volume on Day 1.
89199460|NCT05463068|Experimental|Lot 3|1 intramuscular (IM) injection of NVX-CoV2373 of 0.5 mL injection volume on Day 1.
89199461|NCT05453513|Other|PLWH|All participants will undergo neuroimaging and behavioral tests.
89199462|NCT05453175|Experimental|Interrupting sitting|Participants will engage in low intensity physical activity every thirty minutes up to 120 minutes
89199463|NCT05453175|No Intervention|Control|Participants will remain seated for the entire 120 minutes
89199464|NCT05441033|Experimental|Group-FHB|"Written and verbal consent will be obtained by explaining the purpose of the study at the first interview with the couples in the pregnant outpatient clinic. Then, from the couples, Personal Information Form-Female (PIF-F), Personal Information Form-Male (PIF-M), Antenatal Mother Attachment Scale (PAAS), Antenatal Father Attachment Scale (PABB), Pre-test data will be obtained through the Richard Campbell Sleep Quality Scale (RCAS) and State Anxiety Inventory (DQS). After the attempt to imagine the baby by listening to the fetal heart beats for 5 consecutive nights, the measurement tools will be obtained at the end of the 5th night by re-measurements. A total of 2 measurements, one pre-test and one post-intervention post-test, will be performed, and it is planned to take approximately 15 minutes for each couple to apply the measurement tools."
89439803|NCT03387332|Experimental|APG-1252|The starting dose for this study was 40 mg and 1 patient would be enrolled at this dose level. The dose escalation will convert to a standard 3+3 design following the occurrence of DLT or two ≥ Grade 2 adverse event or at doses 80 mg.
89439804|NCT02290626|Experimental|Elemental diet|"Study 1: Elemental diet (300 kcal/300 ml) containing a contrast medium (5 ml) is administered within 15 min using the PEG.~Study 2: Elemental diet (200 kcal/200 mL) labeled with 100 mg [13C]sodium acetate is administered within 15 min using the PEG."
89439805|NCT02290626|Active Comparator|Semi-solid diet|"Study 1: Semi-solid diet (300 kcal/300 ml) containing a contrast medium (5 ml) is administered within 15 min using the PEG.~Study 2: Semi-solid diet (200 kcal/200 mL) labeled with 100 mg [13C]sodium acetate is administered within 15 min using the PEG."
89439806|NCT02294448|Experimental|cohort 1|Qishe Pill（Shanghai Sundise Traditional Chinese Medicine Co., Ltd, China） in low dosage(3.75mg)
89439807|NCT02294448|Experimental|cohort 2|Qishe Pill（Shanghai Sundise Traditional Chinese Medicine Co., Ltd, China) in medial dosage(7.5mg)
89012274|NCT05140096|Experimental|Treatment AB|Participants will receive a single oral dose 100 mg acalabrutinib capsule on Day 1 of Period 1 (Treatment A) and later will receive single oral loading dose of 400 mg fluconazole tablets on Day 1, one hour prior to a single oral dose of 100 mg acalabrutinib in Period 2 (Treatment B).
89012275|NCT05140096|Experimental|Treatment AC|Participants will receive a single oral dose 100 mg acalabrutinib capsule on Day 1 of Period 1 (Treatment A), and later will receive oral dose of 200 mg iscavuconazole capsules three times daily (approximately every 8 hours apart) on Day 1, followed by 200 mg iscavuconazole capsule once daily from Day 2 to Day 5 with a single oral dose of 100 mg acalabrutinib capsule coadministered on Day 5 in Period 2 (Treatment C).
89012276|NCT04823065|No Intervention|Control group|4FMFES injection is performed as usual, no supplemental medication is used.
89012277|NCT04823065|Experimental|Loperamide|Patients will receive 4 mg loperamide per os 15 minutes prior injection of the 4FMFES radiotracer dose. As a peristalsis inhibitor, it is expected that this medication will slow down the intestinal progression of the radio-metabolite bolus and thus spare the lower abdomen (where the assessed organs of interest are) of overwhelming background that could impair diagnosis.
89012278|NCT04823065|Experimental|Hyoscine-N-butylbromide|In a similar fashion that what is used for some gastro-intestinal radiological examinations, repeated intravenous injection of 20 mg hyoscine-N-butylbromide will be applied at 0, 20 and 40 minutes following 4FMFES injection. As a peristalsis inhibitor, it is expected that this medication will slow down the intestinal progression of the radio-metabolite bolus and thus spare the lower abdomen (where the assessed organs of interest are) of overwhelming background that could impair diagnosis.
89012279|NCT02961179|Experimental|Increased dairy product|Subjects will be asked to consume a total of 3 to 5 servings per day.They will be instructed on options and variations for incorporating the dairy foods into their routine dietary pattern.
89012280|NCT02961179|Placebo Comparator|Dietary counselling|Subjects will review the standard dietary recommendation(http://www.diabetes.ca/diabetes-and-you/nutrition/meal-planning-guide/) by a registered dietitian.
89012281|NCT04829305|Experimental|Low dose of SHR2285|The subjects will receive a single dose of SHR2285 (cohort 1).
89012282|NCT04829305|Experimental|Medium dose of SHR2285|The subjects will receive a single dose of SHR2285 (cohort 2).
89012283|NCT04829305|Experimental|High dose of SHR2285|The subjects will receive a single dose of SHR2285 (cohort 3).
89012284|NCT00280215|Active Comparator|1|Patients will be randomized to a combination of Angiotensin Converting Enzyme Inhibitor and Angiotensin Receptor Blocker. Patients will be randomized to a combination of ARB(losartan 50 mg daily in adult patients, 0.7 mg/kg/day in patients < 40 kg) ACE-I (lisinopril 10 mg daily in adult patients, 0.15 mg/kg/day in pediatric patients < 40 kg) to be taken for 24 months.
89199465|NCT05441033|Experimental|Group-GIT|"Written and verbal consent will be obtained by explaining the purpose of the study at the first interview with the couples in the pregnant outpatient clinic. Then, from the couples, Personal Information Form-Female (PIF-F), Personal Information Form-Male (PIF-M), Antenatal Mother Attachment Scale (PAAS), Antenatal Father Attachment Scale (PABB), Pre-test data will be obtained through the Richard Campbell Sleep Quality Scale (RCAS) and State Anxiety Inventory (DQS). After the attempt to imagine the baby with the guided imagery technique performed for 5 consecutive nights with the measurement tools, the data will be obtained by re-measurements at the end of the 5th night. A total of 2 measurements, one pre-test and one post-intervention post-test, will be performed, and it is planned to take approximately 15 minutes for each couple to apply the measurement tools."
89439808|NCT02294448|Experimental|cohort 3|Qishe Pill（Shanghai Sundise Traditional Chinese Medicine Co., Ltd, China）in high dosage(15mg)
89439809|NCT04446572|Experimental|Repetitive Abortion (RA) group|Starting at day 0, women of the RA (n=21) group consumed (oral route) a daily sachet with ~50 mg of freeze-dried probiotic (~9 log10 CFU of L. salivarius CECT5713) for 6 months or until a diagnosis of pregnancy (whatever happened first).
89439810|NCT04446572|Experimental|Infertility (INF) group|Starting at day 0, women of the INF group (n=23) consumed (oral route) a daily sachet with ~50 mg of freeze-dried probiotic (~9 log10 CFU of L. salivarius CECT5713) for 6 months or until a diagnosis of pregnancy (whatever happened first).
89012285|NCT00280215|Placebo Comparator|2|Patients will take placebo for 24 months.
89012286|NCT04826029|Other|Standard arm|
89012287|NCT04826029|Experimental|Interventional arm|
89012288|NCT00417456|Active Comparator|1|Office Visits
89012289|NCT00417456|Experimental|2|Evisit
89012290|NCT02275351|Experimental|Active Arm 1|Topical SM04554 0.15% solution, applied once a day for 90 days
89012291|NCT02275351|Experimental|Active Arm 2|Topical SM04554 0.25% solution, applied once a day for 90 days
89012292|NCT02275351|Placebo Comparator|Vehicle Arm|Topical vehicle solution, applied once a day for 90 days
89012293|NCT04720040|Experimental|YMS-201B|transcranial Direct Current Stimulation (tDCS) application 5 ~7 days a week for 6 weeks (total of 30~42 applications)
89012294|NCT05140057|Experimental|Protocol 1|1L of Moviprep® solution the night before the procedure
89012295|NCT05140057|Experimental|Protocol 2|1L of Moviprep® solution up to 2h before the procedure
89439811|NCT04446572|No Intervention|Control group|The control group (n = 14) included fertile women having at least two children after uncomplicated term pregnancies.
89439812|NCT02290704||controls|People without eye disease
89439813|NCT02290704||GO patients|patients with Graves' ophthalmopathy
89439814|NCT03384368|Placebo Comparator|Screw-Distraction (SD) group|six pedicle screws were implanted firstly, then distraction was achieved.
89439815|NCT03384368|Experimental|Distraction-Screw (DS) group|four pedicle screws were implanted firstly, then distraction was achieved, two additional screws were introduced at the fracture level at last.
89439816|NCT02294526|Experimental|Sardine diet|Subjects follow general dietary recommendations for diabetes including a fixed amount of sardine in daily meals (100g per day, 5 days a week) as part of their usual diet.
89439817|NCT02294526|No Intervention|Control diet|Subjects only follow general dietary recommendations for diabetes.
89439818|NCT05172440|Experimental|therapy group|Subjects received axitinib 5 mg bid, 12 weeks, and tislelizumab 200 mg on the first day of the first week, 4th week, 7th week, and 10th week, and intravenous infusion. With 21 days as a treatment cycle, 4 cycles of treatment, namely 12 weeks. Axitinib was discontinued for 12 weeks after the completion of treatment, and surgery was performed 7 days later.
89439819|NCT02290860|Other|Intervention|Type 2 diabetes diagnosis test.
89439820|NCT02298426|Experimental|health management and product|"We provide large scales of weight management information included recipes according to people's constitution. Information is provide through both face to face meeting and telephones. Materials are also given to participants.~Meanwhile, we use dietary supplement products of SCHSANDRA PLUS, YI RUI CAPSULE, Gest Aid Plus: INFINITUS® to help balance the constitution of participants."
89439821|NCT02298426|Experimental|general management and product|"We provide general information about health. Information is provided through telephones and materials.~Meanwhile, we use dietary supplement products of SCHSANDRA PLUS, YI RUI CAPSULE, Gest Aid Plus: INFINITUS® to help balance the constitution of participants."
89439822|NCT02298426|Experimental|health management and placebo|"We provide large scales of weight management information included recipes according to people's constitution. Information is provide through both face to face meeting and telephones. Materials are also given to participants.~Meanwhile, we use placebo to replace the dietary supplement products."
89439823|NCT02298426|Placebo Comparator|general management and placebo|"We provide general information about health. Information is provided through telephones and materials.~Meanwhile, we use placebo to replace the dietary supplement products."
89439824|NCT02298582|Experimental|Intranasal fentanyl|
89439825|NCT05690854||Case|"The study will include patients aged ≥ 18 years with the diagnosis of L-TGA and D-TGA, who:~are admitted to IRCCS Policlinico San Donato, the Adult Congenital Heart Unit or~are scheduled for a Cardiovascular Magnetic Resonance examination in this Institution"
89439826|NCT05690854||Control|The study will include subjects aged ≥ 18 years who will invited for a Cardiovascular Magnetic Resonance examination in our Institution. This group of control will include n=15 of adult healthy subjects. A further inclusion criteria for the control subjects are age and male proportion comparable to those of the TGA group.
89439827|NCT02298660|Experimental|BOTOX|BOTOX® Total dose per patient: 200U Number of cycles:1 cycle Treatments will be conducted according to established protocol, 200 BOTOX® units with intradetrusor injections under cystoscopic guided injections into 20 sites, trigone sparing. One month later, urodynamics with continuous arterial blood pressure and electrocardiogram measurements will be repeated, as well as 24 hour ambulatory blood pressure monitoring. AD- HR QoL and I-QOL questionnaires will be administered to evaluate the effect of Botox on AD HR-QoL and bladder-related QoL.
89439828|NCT05575414|Experimental|Didactic Sessions|Women will receive online nutrition education by a registered dietitian, in addition to the same standard patient education tool as the other arm.
89439829|NCT05575414|Experimental|Education Tool|Women will receive a standard patient education tool in the form of a leaflet.
89439830|NCT03387254|Experimental|VR + active brain stimulation|Exposure to a virtual reality world with active transcranial electric stimulation
88924626|NCT04945850||Covid negative|"20 patients undergoing ocular surgery who are COVID negative will be included as control patients and undergo the same procedures.~All patients will get a vitreous tap from operative eye 0.1-0.2 ml fluid. This fresh sample will be tubed to the lab using a unique marked label. This will be performed after the trocar is placed~At the end of surgery, the BSS bag will be tubed to the lab using the same label."
89199466|NCT05441033|No Intervention|Control group|"It is planned to conduct two interviews in total with the couples included in the control group. Written and verbal consent will be obtained by explaining the purpose of the research at the first interview to be held in the pregnant outpatient clinics with the couples to be included in the control group. Later on, Personal Information Form-Female (PIF-F), Personal Information Form-Male (PIF-M), Antenatal Mother Attachment Scale (PAPAS), Antenatal Father Attachment Scale BABI, Richard Campbell Sleep Scale Pre-test data will be obtained by means of the State Anxiety Scale and the State Anxiety Scale. Measurement tools will be repeated at the end of the 5th night in parallel with the experimental groups and a total of 2 measurements will be obtained together with the pre-test measurements. It is planned that the application of the measurement tools will take approximately 15 minutes for each couple."
89439831|NCT03387254|Sham Comparator|VR + sham brain stimulation|Exposure to a virtual reality world with sham transcranial electric stimulation
89012296|NCT05140057|Experimental|Protocol 3|0.5L of Moviprep® solution up to 2h before the procedure plus 0.5L of Moviprep® solution after the capsule had reached the duodenum
89012297|NCT05140057|Experimental|Protocol 4|1L of Moviprep® solution after the capsule had reached the duodenum
89199467|NCT05440604|Experimental|Fortified milk group|2 daily servings of the investigational fortified milk for 16 weeks
89439832|NCT03517878||Comprehensive CHW Cohort|Pregnant women who become mothers and their infants living in areas served by the comprehensive CHW program. These are areas around two primary health care clinics and matched to the Control Cohort clinic areas.
89012298|NCT04829812||Prospective cohort|Prospective cohort with inclusion of consecutive or pseudo-consecutive patients by vascular specialist at their place of practice. Patient follow-up to assess wound progression and compression tolerance
89012299|NCT02271334|Experimental|Treatment T1|One inhalation of 110 mcg A006 DPI. Total 110 mcg
89199468|NCT05440604|No Intervention|Observational group|will be asked to consume beverages in accordance with their habitual pattern of intake
89199469|NCT05438004|Experimental|Ambulatory nice birth|Discharge from the maternity ward from the 2nd hour and before the 24th hour following an uncomplicated delivery
89199470|NCT05433246|No Intervention|Control Group|The patients received routine care.
89538444|NCT03266549|Active Comparator|conventional surgery group|unilateral recess-resect procedure, bilateral rectus muscle recession, or 3 horizontal rectus muscle surgery according to the type of strabismus and the presence or absence of deep amblyopia.The standard correction tables will be used as a guide for the amount of muscle recession and, or resection
89199471|NCT05433246|Experimental|Massage therapy group|The patients in the massage group were given classical massage for 2 consecutive days in each chemotherapy cycle (with an interval of two weeks). Massage therapy was performed with a classical massage technique using effleurage, petrissage, and superficial friction techniques for a total of 40 minutes on the areas below the elbow-forearm-hand (20 minutes), and below the knee-lower leg-foot (20 minutes). The patients in the massage group received 16 sessions of classical massage performed by the research nurse, who had classical massage training and certification.
89199472|NCT05425290|Experimental|Intervention Arm|
89538445|NCT03266861||Patients undergoing exercise oximetry|Patients with PAD referred for treadmill testing and exercise oximetry
89199473|NCT05425238|Experimental|Blood flow restriction|Resistance training protocol but with Blood flow restriction technique Standard BFR Application: a standard pressure (used for all patients) for e.g. 180 mmHg; a pressure relative to the patient's systolic blood pressure, for e.g. 1.2 - or 1.5-fold greater than systolic blood pressure.
89199474|NCT05425238|Active Comparator|Conventional physical therapy|Resistance training to stimulate skeletal muscle hypertrophy and strength adaptations in Duration of 6 weeks
89199475|NCT05420090|Experimental|eating banana for 6 weeks before bedtime|Participants will consume 1 portion of banana (gross 80-85 g) given to them for 6 weeks, approximately 45 minutes-1 hour before bedtime.
89199476|NCT05420090|Experimental|drinking milk for 6 weeks before bedtime|Participants will consume 200 ml of whole milk given to them for 6 weeks, approximately 45 minutes-1 hour before bedtime.
89199477|NCT05420090|Experimental|Control|Not making any changes in diet
89199478|NCT05411692|Experimental|Functional electrical stimulations and motor priming exercise|Functional electrical stimulations and motor priming exercise • Palmar Grasp (holding a ball) of Lateral Grasp (holding a tray),Tripod grip (thumb, index, and middle finger: holding a pen), Two finger opposition (thumb and index finger: holding a peg, Lateral Pinch (thumb and index finger: holding a credit card), lateral pinch, two fingers (index and middle finger: smoker's grip
89199479|NCT05411692|Active Comparator|Functional electrical stimulations|Stimulation parameters are (1) balanced, biphasic, current-regulated electrical pulses; (2) pulse amplitude from 8 to 50 mA (typical values 17- 26 mA); (3) pulse width 250 ms; and (4) pulse frequency from 20 to 70 Hz (18). Trancutaneous stimulation will be delivered bilaterally with surface electrodes placed on the volar aspect of each wrist targeting the distribution of the median nerve
89199480|NCT05411692|Placebo Comparator|Convetional phyusical therapy|The prescription of resistance load for strength training will be performed with fine motor exercise , based on sub maximal repetitions
89199481|NCT05409430|Experimental|Patients with Acute Ischemic Stroke (AIS)|Patients with Acute Ischemic Stroke (AIS), indicated for treatment with ANA 5F device in combination with Solitaire stent retriever, whose stroke is attributable to an occlusion of a large artery in the neurovasculature.
89199482|NCT05402137|Experimental|Experimental (Weight Stigma) Arm|"Participants undergoing the experimental (Weight Stigma) arm are exposed to an interaction partner (a trained confederate) who endorses anti-fat attitudes. Prior to their interaction, participants exchange a Getting to Know You Questionnaire with the confederate, where the confederate endorses anti-fat attitudes. During their interaction with the confederate, participants are told they will be completing consumer rating tasks with another participant in the study. During the ostensible consumer rating task, participants in the experimental condition rate items such as a diet magazine, body sunscreen, running shoes, and a size small T-shirt labeled as size large to bolster the weight stigma manipulation."
89199483|NCT05402137|No Intervention|Control Arm|"Participants undergoing the control arm are also exposed to an interaction partner (a trained confederate) who does not endorse anti-fat attitudes. Prior to their interaction, participants exchange a Getting to Know You Questionnaire with the confederate; however, the confederate does not endorse anti-fat attitudes. During their interaction with the confederate, participants are told they will be completing consumer rating tasks with another participant in the study. During the ostensible consumer rating task, participants in the control condition rate items such as an interior design magazine, face sunscreen, regular (non-running) shoes, and a size large T-shirt correctly labeled as size large to avoid weight stigma."
89199484|NCT05396391|Experimental|Phase Ia - Dose escalation|The goal of the Dose Escalation Phase (Part A) is to initially characterize the safety and tolerability of IAP0971, and more specifically to describe the DLTs for each dose level studied and to define the MTD based on the frequency of the occurrence of DLTs in each cohort during the DLT evaluation period.
89199485|NCT05396391|Experimental|Phase Ib - Dose extension|During the Dose Expansion Phase , patients will be enrolled to receive IAP0971 at the MTD established from the Dose Escalation Phase of the study.
89199486|NCT05396391|Experimental|Phase IIa - Clinical Exploratory Stage|After finishing Phase 1, invesigators will discuss with the sponsor about how to carry out the Phase IIa due to the results acheived from Phase I.
89199487|NCT05396352|Experimental|Right cerebellum|Participants (neurotypical, autistic) in this arm will receive tDCS targeting the right posterolateral cerebellum (lobule VII). All participants will receive anodal, cathodal and sham tDCS.
89199488|NCT05396352|Experimental|Posterior vermis|Participants (neurotypical, autistic) in this arm will receive tDCS targeting the posterior cerebellar vermis. All participants will receive anodal, cathodal and sham tDCS.
89199489|NCT05389813|Active Comparator|Oxycodone|20 mg oxycodone hydrochloride and 10 mg naloxone hydrochloride given as 1 tablet only once, 30 minutes preoperatively.
89199490|NCT05389813|Active Comparator|Pregabalin|150 mg Pregabalin given as 1 tablet only once, 30 minutes preoperatively.
89199491|NCT05389813|Placebo Comparator|Multivitamin|Abecedin Multivitamins&Minerals given as 1 tablet only once, 30 minutes preoperatively.
89538446|NCT05065775|Experimental|Dexmedetomidine|Single intranasal 100 µg bolus dose of dexmedetomidine
89439833|NCT03517878||Control Cohort|Pregnant women who become mothers and their infants living in areas that are not served by the comprehensive CHW program. These are areas around two primary health care clinics and matched to the Comprehensive CHW Cohort clinic areas.
89439834|NCT03387176||zonulin ≤17.5 ng/ml|Pediatric patients with difficult-to-manage nephrotic syndrome will be stratified based on the plasma zonulin concentration into two groups
89439835|NCT03387176||zonulin >17.5 ng/ml|Pediatric patients with difficult-to-manage nephrotic syndrome will be stratified based on the plasma zonulin concentration into two groups
89439836|NCT03384290|Placebo Comparator|Placebo|
89439837|NCT03384290|Experimental|PRS-060|
89439838|NCT02290938|Active Comparator|Community Wellness Gatherings|All youth will attend a CWG, which is a monthly gathering focused on making healthy choices and learning about Native American culture
89439839|NCT02290938|Experimental|MICUNAY|MICUNAY is a three session workshop focused on discussions about how to make healthy choices using motivational interviewing, and providing a cultural activity.
89439840|NCT03571334|Experimental|IncobotulinumtoxinA|"IncobotulinumtoxinA (Xeomin®, Merz) (INA) will be reconstituted with preservative-free normal saline to a dilution of 5mL:100 units.~Study participants in this arm will receive 50u INA (total volume 2.5mL) injected into each limb, max 2 limbs per subject (either bilateral hands or bilateral feet.)~Hands: INA will be injected across the palmar surface of the digits in a grid like pattern covering a total of 25 sites per limb (0.1mL/site).~Feet: INA will be injected across the dorsal surface of the feet also in a grid like pattern covering a total of 25 sites per limb (0.1mL/site)."
89439841|NCT03571334|Placebo Comparator|saline control|"Study participants in this arm will 2.5mL normal saline injected into each limb, max 2 limbs per subject (either bilateral hands or bilateral feet.)~Hands: saline will be injected across the palmar surface of the digits in a grid like pattern covering a total of 25 sites per limb (0.1mL/site).~Feet: Saline will be injected across the dorsal surface of the feet also in a grid like pattern covering a total of 25 sites per limb (0.1mL/site)."
89439842|NCT02298738||New onset Atrial fibrillation|New-onset AF was defined as patients with hypertension and atrial fibrillation which was identified for the first time by an electrocardiogram or ambulatory holter monitoring.
89439843|NCT02298738||control|Hypertensive patients without atrial fibrillation.
89439844|NCT02291094|Active Comparator|Lidocaine group|Patients in lidocaine group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous lidocaine infusion of 3 mg/kg/hr.
89439845|NCT02291094|Active Comparator|Remifentanil group|Patients in remifentanil group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous remifentanil infusion of 0,1 mcg/kg/min.
89439846|NCT03384056||Self Pressurized Airway Device with Blocker|
89439847|NCT03384056||Proseal Laryngeal Mask Airway|
89439848|NCT03387098|Experimental|NANT Pancreatic Cancer Vaccine|A combination of agents will be administered to subjects in this study: Aldoxorubicin HCl, ALT-803, ETBX-011, GI-4000, haNK, avelumab, bevacizumab, capecitabine, cyclophosphamide, fluorouracil, leucovorin, nab-paclitaxel, omega-3-acid ehtyl esters, oxaliplatin, SBRT.
89439849|NCT02298972|No Intervention|Comparison group|The comparison group will receive standard care.
89439850|NCT02298972|Active Comparator|Intervention group|After completion of the comparison group, new patients starting chemotherapy treatment will be offered this study. Study participants will receive the nurse support and selfmanagement intervention.
89439851|NCT02577016|Experimental|Sitagliptin + Ipragliflozin|Sitagliptin, oral, once daily for 24 weeks plus ipragliflozin (base therapy), in addition to diet and exercise.
89439852|NCT02577016|Active Comparator|Placebo + Ipragliflozin|Placebo to sitagliptin, oral, once daily for 24 weeks plus ipragliflozin (base therapy), in addition to diet and exercise.
89439853|NCT03520010|Active Comparator|Internally-driven implementation|
89439854|NCT03520010|Experimental|Externally-facilitated implementation|
89439855|NCT04465110|Experimental|GSE group|Subjects took a single dose of 600 mg GSE in capsule form through ingestion 7 days
88924627|NCT04945850||Covid positive|"60 patients undergoing ocular surgery with previous COVID infection will be stratified into three groups by time since diagnoses: 3, 6, 12 months ~ 20 patients per group.~All patients will get a vitreous tap from operative eye 0.1-0.2 ml fluid. This fresh sample will be tubed to the lab using a unique marked label. This will be performed after the trocar is placed~At the end of surgery, the BSS bag will be tubed to the lab using the same label."
88924628|NCT04944667|Other|TAVR standard|TAVR planning evaluated without VR and TAVR planning after VR analysis
88924629|NCT04941989|Experimental|Part 1 Single Ascending Dose|Eight subjects in up to 7 cohorts will be dosed. One or more subcutaneous injections of HTL0022562 will be administered. In each cohort, 6 subjects will receive HTL0022562 and 2 subjects will receive placebo.
88924630|NCT04941989|Experimental|Part 2 Multiple Ascending Dose|Eight subjects in up to 4 cohorts will be dosed, following safety, tolerability and PK review of completed dose of Single Ascending Dose Cohort 5. In each cohort, 6 subjects will receive HTL0022562 and 2 subjects will receive placebo.
88924631|NCT04939116|Experimental|200 mg QD|200 mg of ANG-3070 will be taken once daily for 12 weeks.
88924632|NCT04939116|Experimental|400 mg QD|400 mg of ANG-3070 will be taken once daily for 12 weeks
88924633|NCT04939116|Experimental|300 mg BID|300 mg of ANG-3070 will be taken twice a day for 12 weeks.
88924634|NCT04939116|Placebo Comparator|Placebo|Placebo capsules will be taken once or twice daily for 12 weeks.
88924635|NCT04938804|Experimental|Screening group|
89439856|NCT04465110|Placebo Comparator|Placebo group|Subjects took a single dose of 600 mg starch in capsule form through ingestion 7 days
89439857|NCT03391700|Active Comparator|Moderate muscle relaxation|Rocuronium is administered to maintain moderate relaxation during operation. This is conventional muscle relaxation level of this institute.
89439858|NCT03391700|Experimental|Deep muscle relaxation|Rocuronium is administered to maintain deep relaxation during operation.
89538447|NCT05016323|Experimental|HR19042 Capsules|
89538448|NCT05016323|Placebo Comparator|Placebo|
88924636|NCT04935593|Experimental|Renew Intervention Group|Participants in the group will receive training to help children strengthen social, emotional and behavioral knowledge and resilience.
88924637|NCT04935593|No Intervention|Parallel Control Group|Participants in the group will receive the usual bible lessons and activities
88924638|NCT04929405|Experimental|Intervention group|This group has access to the intervention (website for bereaved parents)
88924639|NCT04928144|Experimental|0.025% SHJ002|0.025% SHJ002 Sterile Ophthalmic Solution
88924640|NCT04928144|Experimental|0.080% SHJ002|0.080% SHJ002 Sterile Ophthalmic Solution
88924641|NCT04928144|Experimental|0.25% SHJ002|0.25% SHJ002 Sterile Ophthalmic Solution
88924642|NCT04928144|Experimental|SHJ002 - Maximum tolerated concentration|Maximum tolerated concentration of SHJ002
88924643|NCT04927793|Experimental|Single arm EDP-938|
88924644|NCT04926701|Experimental|Single ascending dose|Single dose of inhaled ETD001/placebo on one occasion
88924645|NCT04926701|Experimental|Multiple ascending dose (7 days)|Daily doses of ETD001/placebo for 7 consecutive days
88924646|NCT04926701|Experimental|Multiple ascending dose (14 days)|Daily doses of ETD001/placebo for 14 consecutive days
88924647|NCT04919239|Experimental|RUTI® arm|A dose of 25 μg of of RUTI vaccine will be given at week 1 (Cohort A-DS TB Patients) or month 1 (Cohort B-MDR TB Patients) after starting standard TB treatment.
88924648|NCT04919239|Placebo Comparator|Placebo arm|Placebo will be given at week 1 (Cohort A-DS TB Patients) or month 1 (Cohort B-MDR TB Patients) after starting standard TB treatment.
88924649|NCT04917367||Conventional surgery group|Conventional surgery with Preoperative foreign body localization
88924650|NCT04917367||New surgery group|new surgery with Intraoperative localization of foreign body
88924651|NCT04916743|Experimental|Exercise group|The patients will participate in intradialytic exercise 3 times a week for 24 weeks.
88924652|NCT04916743|No Intervention|Control group|The patients will receive regular care and treatment in every dialysis sessions without any intradialytic exercise.
88924653|NCT04914377|Experimental|Active Drug|Capsules containing TQ Formula
88924654|NCT04914377|Placebo Comparator|Placebo|Capsules containing corn oil
88924655|NCT04911439|Active Comparator|Low Arousal|This group will see 25 affective images of the International Affective Picture System with low arousal level during 8-12 randomly seconds each one at time and with randomly rest of 8-12 seconds between images.
88924656|NCT04911439|Active Comparator|Medium Arousal|This group will see 25 affective images of the International Affective Picture System with medium arousal level during 8-12 randomly seconds each one at time and with randomly rest of 8-12 seconds between images.
89538449|NCT02458703|Experimental|Patients with pulmonary AVMs and no airflow obstruction|30 patients with pulmonary AVMs and no airflow obstruction will undergo cardiopulmonary exercise testing
88924657|NCT04911439|Active Comparator|High Arousal|This group will see 25 affective images of the International Affective Picture System with high arousal level during 8-12 randomly seconds each one at time and with randomly rest of 8-12 seconds between images.
88924658|NCT04911257||Degenerate Disc Disease|Subjects who will undergo spinal fusion surgery utilizing Stryker Interbody Systems.
88924659|NCT04904172||Acute ischemic stroke who undergo intravenous thrombolytic and / or endovascular thrombectomy|Patients with acute ischemic stroke who applied to Ege University Emergency Service and decided to undergo intravenous thrombolytic and / or endovascular thrombectomy treatment or treatments by a Neurology Specialist.
88924660|NCT04903821|Experimental|Group A (Child- Pugh A)|Participants with mild impaired hepatic function (Child-Pugh A), including at least 2 female participants.
88924661|NCT04903821|Experimental|Group B (Child-Pugh B)|Participants with moderate impaired hepatic function (Child-Pugh B), including at least 2 female participants
88924662|NCT04903821|Experimental|Control A match controls for group A|Matched control participants for Group A with normal hepatic function.
88924663|NCT04903821|Experimental|Control B match controls for group B|Matched control participants for Group B with normal hepatic function
88924664|NCT04902235|Experimental|CRH administration|Experimental: CRH administration
88924665|NCT04902235|Placebo Comparator|Placebo administration|Control: Placebo administration
88924666|NCT04900480|No Intervention|Public subsidy to physiotherapy continue as usual|This control arm consists of all physiotherapy clinics with registered provider numbers in two municipalities, where the access and public subsidy to physiotherapy continue as usual.
88924667|NCT04900480|Experimental|Direct access to publicly subsidized physiotherapy|This intervention arm consists of all physiotherapy clinics with registered provider numbers in two municipalities, introducing temporary exemption on the legal required general practitioner referral for public subsidy for treatment in general physiotherapy.
88924668|NCT04899843|Active Comparator|Experimental|This arm includes 61 acne vulgaris patients receiving topical retinoids
88924669|NCT04899843|Placebo Comparator|Control|This arm includes 61 acne vulgaris patients receiving topical retinoids
88924670|NCT04897802|Experimental|Experimental: GLP1-RA administration|A single dose of 10 mcg of GLP1-RA (exenatide) will be injected subcutaneously and samples will be collected over 2 hours (15 (T15), 30 (T30), 45 (T45), 60 (T60'), 90 (T90) and 120 (T120) minutes) after GLP1-RA:placebo administration to assess OT secretory patterns
88924671|NCT04897802|Placebo Comparator|Control: Placebo administration|Sodium Chloride 0.9% will be administered subcutaneously at equivalent volume than GLP1-RA (exenatide) administration
88924672|NCT04892628|Other|Aerobic training group|"The control group will be administered a standard physical therapy intervention program which will consist of active muscle stretching and aerobic exercises.~Exercises will include:~Flexion, extension and abduction at the shoulder joint for anterior, middle and posterior fibers of deltoid~Flexion and extension at the elbow for biceps and triceps trachii~Flexion and extension at the knee joint for quadriceps and hamstring muscles~Plantar flexion at the ankle joint for gastrocnemius and soleus~Three sets of ten repetitions of each exercise will be done."
89012300|NCT02271334|Experimental|Treatment T2|One inhalation of 220 mcg A006 DPI. Total 220 mcg.
89012301|NCT02271334|Active Comparator|Treatment R1|One inhalation of 90 mcg Proventil® MDI. Total 90 mcg.
89012302|NCT02271334|Active Comparator|Treatment R2|Two inhalations of 90 mcg Proventil® MDI. Total 180 mcg
89012303|NCT00280332||A|colonic adenoma
89012304|NCT00280332||B|colonic without adenoma
89439859|NCT02294760|Active Comparator|Subsensory, OFF, subsensory|The stimulator is set subsensory for the first 4 weeks (90% of sensory threshold), then turned OFF for the next 4 weeks and finally set subsensory for the last 4 weeks.
89439860|NCT02294760|Active Comparator|Subsensory, subsensory, OFF|The stimulator is set subsensory for the first 4 weeks (90% of sensory threshold), then set subsensory for another 4 weeks and finally turned OFF for the last 4 weeks.
89439861|NCT02294838|Experimental|MRI with parotid gland stimulation|All participants will have MRI imaging of the parotid gland with IV Gadovist pre and post parotid stimulation with lemon juice. 0.05 ml/kg of Gadovist (at 4 ml/s) and 20 ml of saline flush (also at 4 ml/s) will be administered. Approximately three minutes after scan commencement, the salivary glands will be stimulated by orally administering a small portion (≈5 ml) of Citric acid.
89439862|NCT03391544|Experimental|V4c toric ICL implantation Group|V4c toric ICL implantation Group
89439863|NCT03383822|Experimental|Intranasal insulin|40 IU of intranasal insulin
88924673|NCT04892628|Experimental|Resistance training group|"The intervention group will undergo a progressive resistance training program consisting of active muscle stretching and resistance training. Exercise for intervention group will consist of:~Resisted flexion, extension and abduction at the shoulder joint for anterior, middle and posterior deltoid, using dumbbells~Resisted flexion and extension at the elbow for biceps and triceps trachii, using dumbbells~Resisted flexion and extension of knee joint for quadriceps and hamstring muscles, using therabands~Resisted dorsiflexion and plantar flexion of gastrocnemius and soleus, using therabands~Resistance will be increased on basis of progressive overload principle. Three sets of ten repetitions will be performed per muscle group. Initial weight of the dumbbells will be 1kg and will be increased by 0.5kg per week."
88924674|NCT04891523|Other|Placebo-Probiotic|First receive placebo, then active probiotics.
88924675|NCT04891523|Other|Probiotic-Placebo|First receive active probiotics, then placebo.
88924676|NCT04889807||Patients who need fluid perfusion|
88924677|NCT04883086||diabetic group ( Case)|Total of 91 participants diagnosed with diabetes type 2
88924678|NCT04883086||Non diabetic group (control)|Total of 91 participants healthy and not diagnosed with diabetes Mellitus
88924679|NCT04882384|Experimental|Peripheral Nerve Block (PENG)|Patients will receive the Pericapsular Nerve Group Block.
88924680|NCT04882332||metformin usage index and vitamin B12 level|Samples for correlation between metformin usage index and vitamin B1 level will be withdrawn from 108 type 2 diabetes patients
88924681|NCT04882189||Capsulorhexis|Capsulotomies conducted by Capsulorhexis
88924682|NCT04882189||ZEPTO Precision Capsulotomy Device|Capsulotomies conducted by ZEPTO Precision Capsulotomy Device
88924683|NCT04880460|Active Comparator|Experimental|45 MDD patients were included in this arm who were received SSRIs and Magnesium tablets
88924684|NCT04880460|Placebo Comparator|Control|45 MDD patients were included in this arm who were received SSRIs and placebo tablets
88924685|NCT04878913||C21|Subject treated with C21 in the VP-C21-006 trial
88924686|NCT04878913||Placebo|Subject treated with placebo in the VP-C21-006 trial
88924687|NCT04876924|Experimental|BBP-711 for SAD|A single dose of BBP-711 will be administered orally.
88924688|NCT04876924|Placebo Comparator|Placebo for SAD|A single dose of matching placebo will be administered orally.
88924689|NCT04876924|Experimental|BBP-711 for MAD|A dose of BBP-711 will be administered orally for multiple days.
88924690|NCT04876924|Placebo Comparator|Placebo for MAD|A dose of matching placebo will be administered orally for multiple days.
88924691|NCT04876924|Experimental|BBP-711 for SAD Food Effect|A single dose of BBP-711 will be administered orally.
88924692|NCT04876924|Placebo Comparator|Placebo for SAD Food Effect|A single dose of matching placebo will be administered orally.
88924693|NCT04871425|Experimental|Ketamine|Participant will receive 2mg IV midazolam and 0.2-0.5mg/kg IV ketamine over 2 minutes, which can be repeated q5 minutes until appropriate analgesia is achieved.
88924694|NCT04871425|Active Comparator|Fentanyl|Participant will receive 2mg IV midazolam and 0.5-1mcg/kg IV fentanyl over 2 minutes, which can be repeated q5m until appropriate analgesia is achieved.
88924695|NCT04871217|Experimental|Acute ST-elevation myocardial infarction or chronic coronary artery occlusion|68-Ga-NODAGA-RGD PET after acute ST-elevation myocardial infarction or before and after re-opening of a chronic coronary artery occlusion
88924696|NCT04858750|Other|Cook D-J stent group|"Patients randomized to this group received Cook (Limerick, Ireland, USI-626-R) D-J stent.~Note: USI is an unexpandable acronym."
88924697|NCT04858750|Other|KYB anti-reflux D-J stent group|Patients randomized to this group received KYB (Shenzhen, China, 3201162) anti-reflux D-J stent.
88924698|NCT04858750|Other|Urovision trigonal D-J stent group|"Patients randomized to this group received Urovision (Bad Aibling, Germany, ST-230726) trigonal D-J stent.~Note: ST is an unexpandable acronym. Aibling is a German region name."
88924699|NCT04855045|Experimental|Group 1 - open label|
88924700|NCT04855045|Experimental|Group 2 - open label|
88924701|NCT04855045|Experimental|Group 3: open label|
88924702|NCT04855045|Experimental|Group 4: double-masked, randomized to one of 2 dose cohorts|
88924703|NCT04838197||Caregiver|If the caregiver agrees and consents to participating in the study, basic demographic and social data will be collected at baseline. The caregiver will also complete the caregiver burden questionnaire via telephone call at five different time points: pre-operatively, and post-operative 48 hours, 1 week, 2 weeks, and 1 month.
89012305|NCT02276755|Active Comparator|Intervention: 1|Dietary Supplement: Cholecalciferol (vitamin D3)
89439864|NCT03383822|Placebo Comparator|Intranasal placebo|Placebo comparator to intranasal insulin
89439865|NCT02294916|Experimental|Child ETI withoutchest compressions|Endotracheal intubation of pediatric mannikin during resuscitation without chest compressions.
89439866|NCT02294916|Experimental|Child ETI with chest compressions|Endotracheal intubation of mannikin during resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
89439867|NCT05101252|Active Comparator|TEST Lens|Eligible subjects who are habitual soft contact lens wearers will be randomized to the TEST Lens sequence for the duration of the study.
89439868|NCT05101252|Experimental|CONTROL Lens|Eligible subjects who are habitual soft contact lens wearers will be randomized to the CONTROL Lens sequence for the duration of the study.
89439869|NCT03391310|Experimental|Honey dressing group|In this group, the wound will be cleaned with normal saline and then honey (medicated ) will be applied to cover the wound surface. The dressing will be changed once soiled (alternate day in most cases). The dressing will be applied for a maximum period upto 8 weeks (in cases of stage IV ulcers) or till healthy granulation tissue appears, whichever is earlier.
89439870|NCT03391310|No Intervention|Standard treatment group|In this group, the wound will be first cleaned with 'povidone iodine' and then covered with hydrocolloid dressing changed alternate day for maximum period upto 8 weeks (in cases of stage IV ulcers) or till healthy granulation tissue appears, whichever is earlier.
89439871|NCT02291172|Experimental|Intervention JEP|A blend of JASP-EMT using SGDs with parent training intervention with the addition of individualized DTT to teach receptive language, imitation, and joint attention when children lack these skills at entry. The comprehensive communication intervention: (a) teaches foundational social communicative behaviors, (b) related skills that predict long term language outcomes, (c) a range of communicative functions, (d) spoken language skills, (e) provides children with an immediate mode of communication, (f) incorporates instructional methods, contexts, and partners that increase both the critical skills for spoken language and social use of language. Because parents are essential partners for young children with ASD who are learning to communicate, we (g) include parents
89439872|NCT02291172|No Intervention|Business as Usual Control Group|All children, regardless of group assignment will participate in all assessments. Children randomized to the control group will not receive intervention, but will complete all other research procedures. Other treatments that all children receive in the community will be recorded with bi-monthly surveys.
89439873|NCT03514524|Experimental|healthy ageing|
89439874|NCT03514524|Experimental|TBI|
89439875|NCT03514524|Experimental|CTE|
89439876|NCT03514524|Experimental|Ischemic stroke|
89439877|NCT03514524|Experimental|aMCI and MBI|
89439878|NCT03514446|Experimental|Antibiotic therapy duration for 7 days|
89439879|NCT03514446|No Intervention|Antibiotic therapy duration for 14 days|
88924704|NCT04835584|Experimental|Part 1, KRT-232 combined with TKI (Dasatinib or Nilotinib) in patients with CML-CP|KRT-232 will be administered orally, once daily (QD) on Days 1-7 in a 28-day cycle. TKI (dasatinib or nilotinib) will be administered orally, per locally prescribed dose and schedule.
88924705|NCT04835584|Experimental|Part 2, Arm A (KRT-232 combined with Dasatinib in patients with CML-CP)|KRT-232 will be administered orally, once daily (QD) on Days 1-7 in a 28-day cycle. Dasastinib will be administered orally, per locally prescribed dose and schedule.
88924706|NCT04835584|Experimental|Part 2, Arm B (KRT-232 combined with Nilotinib in patients with CML-CP)|KRT-232 will be administered orally, once daily (QD) on Days 1-7 in a 28-day cycle. Nilotinib will be administered orally, per locally prescribed dose and schedule.
88924707|NCT04835584|Experimental|Part 2, Arm C (KRT-232 combined with Dasatinib or Nilotinib in patients with CML-AP)|KRT-232 will be administered orally, once daily (QD) on Days 1-7 in a 28-day cycle. Dasatinib or Nilotinib will be administered orally, per locally prescribed dose and schedule.
88924708|NCT04831502|Experimental|Sequence 1: TAK 906 50 mg (Treatment A+Treatment B+Treatment A+Treatment B+Treatment C)|Participants will receive TAK-906 50 milligram (mg) as Treatment A (TAK-906 capsule) and Treatment B (TAK-906 tablet) under fasted conditions and Treatment C (TAK-906 tablet) under fed conditions, orally, once on Day 1 of Periods 1 to 5. A washout interval of at least 3 days will be maintained between each Treatment Period.
88924709|NCT04831502|Experimental|Sequence 2: TAK-906 50 mg (Treatment B+Treatment A+Treatment B+Treatment A+Treatment C)|Participants will receive TAK-906 50 mg as Treatment B (TAK-906 tablet) and Treatment A (TAK-906 capsule) under fasted conditions and Treatment C (TAK-906 tablet) under fed conditions, orally, once on Day 1 of Periods 1 to 5. A washout interval of at least 3 days will be maintained between each Treatment Period.
89439880|NCT03386786|Experimental|Intervention (Health Partner)|The mobile health (mHealth) product, Health Partner for Knees and Hips (Health Partner), is a combination of a mobile application (app) and a web-based portal.
89439881|NCT03386786|Other|Control|Patients randomized to Control will receive pre-printed brochures that outline the steps of the care plan for unilateral TKA and THA, as per standard care provided to any unilateral TJA patient receiving care at Princeton Healthcare System (PHCS).
89439882|NCT03383744|Experimental|Vitamin A supplementation 1|Vitamin A status assessed at Baseline and one month after the administration of 200,000 IU of vitamin A
89439883|NCT03383744|Experimental|Vitamin A supplementation 3|Vitamin A status assessed at Baseline and three months after the administration of 200,000 IU of vitamin A
89439884|NCT02291250|Experimental|Sugar matched water with polycal OGTT|"Control: sugar matched (matched to currant sugar content) water with polycal~Blackcurrants (200grams) with polycal~Blackcurrants (200grams) with glucose~Greencurrants (200grams) with polycal Sixteen overweight/obese volunteers from the Aberdeen area will be recruited into a randomised controlled study. Volunteers will be randomised into four groups matched for BMI and age and given 200 grams of blackcurrants (which contain anthocyanins) or greencurrants (which naturally contain no anthocyanins), followed by an OGTT.~The OGTT will be carried out with glucose as a simple carbohydrate load or polycal as a complex carbohydrate load.~Volunteers will be randomised into four groups (n=4 per group). One week wash out between treatments"
89199492|NCT05387512||Camrelizumab treatment group|The primary treatment is Camrelizumab combined with Pemetrexed and Platinum, secondary treatment with standard chemotherapy after progression. Reference regimen of Camrelizumab 200mg/3 weeks; Carboplatin reference regimen was AUC = 5 mg/mL/min; Cisplatin reference regimen was 75 mg/m2; Pemetrexed reference regimen was 500 mg/m2; paclitaxel liposome reference regimen is 135-175 mg/m2.
89439885|NCT02291250|Experimental|Blackcurrants with polycal OGTT|"Blackcurrants (200grams) with polycal~Blackcurrants (200grams) with glucose~Greencurrants ( 200grams) with polycal~Control: sugar matched (matched to currant sugar content) water with polycal~Sixteen overweight/obese volunteers from the Aberdeen area will be recruited into a randomised controlled study. Volunteers will be randomised into four groups matched for BMI and age and given 200 grams of blackcurrants (which contain anthocyanins) or greencurrants (which naturally contain no anthocyanins), followed by an OGTT.~The OGTT will be carried out with glucose as a simple carbohydrate load or polycal as a complex carbohydrate load as decribed above.~Volunteers will be randomised into four groups (n=4 per group). One week wash out between treatments"
88924710|NCT04828434|Experimental|Virtual Individual Cognitive Stimulation Therapy|"Virtual Cognitive Stimulation Therapy (V-iCST), a psychosocial intervention, is a modified version of CST for people with mild to moderate dementia. Like the original CST, each of the 14 sessions will begin with a warm-up activity, which includes an orientation task and discussion of current affairs, followed by a main activity.~V-iCST will be prescribed to participants twice a week, for 7 weeks and each session is approx. 45 minutes. The intervention will be delivered by trained professionals, such as research staff, psychologists, and trainee clinical psychologists. All facilitators will have experience in dementia care and will have completed the CST training."
88924711|NCT04828434|No Intervention|Treatment as usual|Standard care.
88924712|NCT04819854|Experimental|EP395|EP395 in ascending doses. Orally, once daily.
88924713|NCT04819854|Placebo Comparator|Placebo|Placebo, weight matched in ascending doses. Orally, once daily.
88924714|NCT04819815||Type 1 diabetes mellitus|"Patients~Maximal exercise capacity (Incremental shuttle walk test), respiratory functions (spirometer), respiratory muscle strength (mouth pressure measurement), peripheral muscle strength (dynamometer), respiratory muscle endurance ( incremental threshold loading test), physical activity level (multi sensor activity monitor), quality of life (World Health Organization (WHO) well-being index), fatigue (fatigue severity scale), shortness of breath (Modified Medical Research Council MMRC) will be evaluated."
88924715|NCT04819815||Healthy Controls|Maximal exercise capacity (Incremental shuttle walk test), respiratory functions (spirometer), respiratory muscle strength (mouth pressure measurement), peripheral muscle strength (dynamometer), respiratory muscle endurance ( incremental threshold loading test), physical activity level (multi sensor activity monitor), quality of life (World Health Organization (WHO) well-being index), fatigue ( fatigue severity scale), shortness of breath (Modified Medical Research Council MMRC) will be evaluated.
88924716|NCT04816747|Experimental|Autologous PRP|Participants with diagnosed lumbar DDD are planned to be managed via intradiscal injection of 0.5-1 ml autologous PRP, whereas participants with FJS will be injected with 0.5 ml of respective solution. All procedures will be performed in surgical theatre under constant fluoroscopic guidance.
88924717|NCT04809012|Experimental|STI-3031|20 mg/kg STI-3031 administered intravenously Q2W
88924718|NCT04807985||Ambulatory CHF patients|Patients visiting an outpatient CHF clinic
89439886|NCT02291250|Experimental|Blackcurrants with glucose OGTT|"Blackcurrants (200grams) with glucose~Greencurrants (200grams) with polycal~Control: sugar matched (matched to currant sugar content) water with polycal~Blackcurrants (200grams) with polycal~Sixteen overweight/obese volunteers from the Aberdeen area will be recruited into a randomised controlled study. Volunteers will be randomised into four groups matched for BMI and age and given 200 grams of blackcurrants (which contain anthocyanins) or greencurrants (which naturally contain no anthocyanins), followed by an OGTT.~The OGTT will be carried out with glucose as a simple carbohydrate load or polycal as a complex carbohydrate load as decribed above~Volunteers will be randomised into four groups (n=4 per group). One week wash out between treatments"
89439887|NCT02291250|Experimental|Greencurrants with polycal OGTT|"Greencurrants (200grams) with polycal~Control: sugar matched (matched to currant sugar content) water with polycal~Blackcurrants (200grams) with polycal~Blackcurrants (200grams) with glucose~Sixteen overweight/obese volunteers from the Aberdeen area will be recruited into a randomised controlled study. Volunteers will be randomised into four groups matched for BMI and age and given 200 grams of blackcurrants (which contain anthocyanins) or greencurrants (which naturally contain no anthocyanins), followed by an OGTT.~The OGTT will be carried out with glucose as a simple carbohydrate load or polycal as a complex carbohydrate load as decribed above.~Volunteers will be randomised into four groups (n=4 per group). One week wash out between treatments."
89199493|NCT05387512||Control treatment group|The primary treatment is Pemetrexed and Platinum plus anti-angiogenic drugs, Secondary treatment is standard chemotherapy regimens after progression. Reference regimen of Carilizumab 200mg/3 weeks; Carboplatin reference regimen was AUC = 5 mg/mL/min; Cisplatin reference regimen was 75 mg/m2; Pemetrexed reference regimen was 500 mg/m2; paclitaxel liposome reference regimen is 135-175 mg/m2.
89439888|NCT05662358|Experimental|Denosumab|1 ml (60 mg) of denosumab (Prolia; Amgen, Inc) subcutaneous injection plus intravenous placebo every 6 months
89439889|NCT05662358|Active Comparator|alendronate|oral 70 mg alendronate sodium weekly.
89439890|NCT02299128|Sham Comparator|Minimally Therapeutic Treatment|Non-differential, prescriptive protocol of physical therapy treatment with minimal to no therapeutic benefit.
89439891|NCT02299128|Experimental|Skilled Treatment|Differential treatment based on the results from the assessment. Physical Therapy treatment in this arm will be pragmatically designed and modified by the treating therapist. Treatments will include manual therapy to the cervical spine, neuromotor retraining (position sense and movement sense), habituation and adaptation exercises.
89439892|NCT03383510|Experimental|Climate friendly group|The climate friendly group will receive instructions to eat according to a climate friendly diet, i.e., to replace the majority of their intake of animal based products with plant based food.
89439893|NCT03383510|Experimental|Organic group|The organic group will receive instructions to eat an organic diet, i.e., to replace at least 50% of their normally consumed food with organic equivalents.
88924719|NCT04807725||Peri-implant health|Includes patients with peri implant mucosa without inflammatory signs and absence of peri-implant bone loss.
88924720|NCT04807725||Peri-implantitis|Includes patients with bleeding and / or suppuration on probing, probing depth equal or greater than 6mm and bone loss equal to or greater than 3mm.
88924721|NCT04803643||Patients|"Upper extremity exercise capacity will be assessed using six minute pegboard ring test, functional exercise capacity using six minute walk test, muscle oxygenation using Moxy monitor, balance using Biodex Balance System® and Y balance test, physical activity using multi-sensor activity monitor, pulmonary function using spirometry, respiratory muscle strength using mouth pressure device, peripheral muscle strength using hand held dynamometer, respiratory muscle endurance using incremental threshold loading test, life quality using The Revised Cystic Fibrosis Questionnaire (CFQ-R) (Turkish version)."
88924722|NCT04803643||Healthy controls|"Upper extremity exercise capacity will be assessed using six minute pegboard ring test, functional exercise capacity using six minute walk test, muscle oxygenation using Moxy monitor, balance using Biodex Balance System® and Y balance test, physical activity using multi-sensor activity monitor, pulmonary function using spirometry, respiratory muscle strength using mouth pressure device, peripheral muscle strength using hand held dynamometer, respiratory muscle endurance using incremental threshold loading test, life quality using The Revised Cystic Fibrosis Questionnaire (CFQ-R) (Turkish version)."
88924723|NCT04801459|Experimental|Antiperistaltic direction of gastrointestinal anastomosis in Roux-en-Y reconstruction group|The isoperistaltic anastomosis represents the peristalsis direction of remnant stomach and jejunal efferent loop was consistent.
88924724|NCT04801459|Active Comparator|Isoperistaltic direction of gastrointestinal anastomosis in Roux-en-Y reconstruction group|The antiperistaltic anastomosis represents the peristalsis direction of remnant stomach and jejunal efferent loop was opposite.
88924725|NCT04799405|Experimental|tDCS MDD|"A group of 5 participants with major depressive disorder (MDD).~tDCS, as a relatively simple and portable technology, is particularly well suited for remotely-supervised, home-based treatment, which would facilitate longer periods of treatment as well as offer a suitable therapeutic option at the present time as the investigators aim to deal with the COVID-19 pandemic."
88924726|NCT04798131|Experimental|Active|The visual feedback will correspond to instructions, adapted to the current hallucinatory state and decoded online from the fMRI signal.
88924727|NCT04798131|Sham Comparator|Sham|The visual feedback will correspond to random instructions independently of the fMRI signal.
88924728|NCT04794036|Experimental|Experimental Group|Telerehabilitation asynchronous programme at home
88924729|NCT04794036|Active Comparator|Control Group|Rehabilitation programme with an explanatory booklet at home
88924730|NCT04792957||Pyoderma Gangrenosum|Skin biopsies obtained from patients with pyoderma gangrenosum will be studied to evaluate JAK/STAT pathway by using immunohistochemical methods.
89439894|NCT03383510|Experimental|Climate friendly and organic group|The climate friendly and organic group will receive instructions to consume a climate friendly and organic diet, i.e, to replace the majority of their intake of animal based products with plant based food AND to consume at least 50% organic food products.
89439895|NCT03383510|Placebo Comparator|Control group|The control group will receive instructions to eat according to the Nordic Nutrition Recommendations.
88924731|NCT04792957||Hidradenitis Suppurativa|Skin biopsies obtained from patients with hidradenitis suppurativa, will be studied to evaluate JAK/STAT pathway by using immunohistochemical methods
88924732|NCT04792957||Psoriasis|Skin biopsies obtained from patients with psoriasis, will be studied to evaluate JAK/STAT pathway by using immunohistochemical methods
88924733|NCT04792957||Healthy Subjects|Skin biopsies obtained from patients with healthy subjects, will be used to control group.
88924734|NCT04790773|No Intervention|Standard of care|Patient's will receive standard education on Xarelto and Eliquis per usual process without use of Alexa based voice recording.
88924735|NCT04790773|Active Comparator|Alexa Education|Patient's will opt in to receive initial education via Alexa based voice recording on Xarelto and Eliquis.
88924736|NCT04788329|Experimental|Relaxation Group|This program teaches patients how to feel calmer before surgery. Patients are taught relaxation techniques by phone or in person by trained NYU personnel.
89012306|NCT02276755|Placebo Comparator|Placebo Comparator: 2|Dietary Supplement: Placebo
89199494|NCT05384600||Patients with Incisional Hernia|Patients who have undergone elective or emergency colonic resection between 2017 and 2020 at Cardiff and Vale UHB, who have subsequently received a diagnosis of Incisional Hernia. One-off self-completed patient questionnaire upon enrolment. Sub-set will be invited to participant in qualitative interview.
89439896|NCT02291328|Experimental|High Brassica|Participants will be asked to consume 3x 84g portions of frozen broccoli, 3x 84g portions of frozen cauliflower, and 3x 300g portions of frozen broccoli and sweet potato soups a week for a total of 2 weeks.
89439897|NCT02291328|Experimental|Low Brassica|Participants will be asked to consume 1x 84g portion of either frozen broccoli or frozen cauliflower in week one, and the remaining 84g portion of Brassica in week two.
89439898|NCT03391154|Active Comparator|levothyroxine|100 pregnant female with TSH of> 2.5 mU/L but less than 4 mU/L after biochemical diagnosis of pregnancy will receive 50 ug of levothyroxine (eltroxin 50) aspen,Egypt throughout the pregnancy
89439899|NCT03391154|No Intervention|control|100 pregnant female with TSH of> 2.5 mU/L but less than 4 mU/L after biochemical diagnosis of pregnancy will not receive any drug throughout the pregnancy
89439900|NCT03391076|Experimental|FilmArray group|Patients in this group will use FilmArray Respiratory Panel to test potential viral pathogens.
89439901|NCT03391076|No Intervention|Routine test group|Patients in this group will use clinical routine methods to test potential viral pathogens.
89439902|NCT02294994|Experimental|half dose tirofiban|Tirofiban was administered once the wire had crossed the lesion during PCI with a bolus dose of 25 µg/kg of bodyweight, followed by an infusion of 0.075 µg per kilogram per minute for 24 to 36 hours.UFH heparin was administered as a bolus of 100 U/kg before PCI.
89439903|NCT02294994|Active Comparator|recommended-dose Tirofiban|Tirofiban was administered once the wire had crossed the lesion during PCI with a bolus dose of 25 µg/kg of bodyweight, followed by an infusion of 0.15 µg per kilogram per minute for 18 to 24 hours. UFH heparin was administered as a bolus of 100 U/kg before PCI.
89439904|NCT02294994|Placebo Comparator|none tirofiban|Tirofiban was not administered ,UFH heparin was administered as a bolus of 100 U/kg before PCI.
89439905|NCT03386630|Experimental|Hyperbaric bupivacaine+Sufentanil|To evaluate in spinal anesthesia for elective cesarean section what association of hyperbaric bupivacaine 0.5% (0.06 mg Cm-1 in height) plus opioid: sufentanil (5 mcg)
89439906|NCT03386630|Experimental|Hyperbaric bupivacaine+morphine|To evaluate in spinal anesthesia for elective cesarean section what association of hyperbaric bupivacaine 0.5% (0.06 mg Cm-1 in height) plus opioid: morphine (0,01 mg)
89439907|NCT03514290|Placebo Comparator|GPLACEBO|the laser tip was positioned without the emission of light (placebo effect) + tooth bleaching with 35% hydrogen peroxide (HP).
89439908|NCT03514290|Experimental|GLASER|treated with Low-lever laser + tooth bleaching with 35% hydrogen peroxide (HP).
89199495|NCT05384600||Patients without Incisional Hernia|Patients who have undergone elective or emergency colonic resection between 2017 and 2020 at Cardiff and Vale UHB, who have not subsequently been diagnosed with (or suspected of having) incisional hernia. One-off self-completed patient questionnaire upon enrolment. Sub-set will be invited to participant in qualitative interview.
89439909|NCT03386552|Experimental|Isifera+|Subjects are pertubated with Isifer+ solution containing lidocaine 0.5 mg/ml
89439910|NCT03386552|Placebo Comparator|Buffer|Subjects are pertubated with a buffer solution without lidocaine
89439911|NCT02291406|Active Comparator|Robot assisted laparoscopic hysterectomy|Robot assisted laparoscopic total hysterectomy
89439912|NCT02291406|Active Comparator|Abdominal hysterectomy|Standard extrafascial abdominal total hysterectomy through a low transverse abdominal wall incision.
89439913|NCT03383432|Other|Trans-abdominal ultrasound intrauterine device group.|Those will be subjected to intrauterine device insertion under trans-abdominal ultrasound guidance. In this method the participant will be asked to have a full bladder. Full bladder helps to displace the bowel out of the pelvis and acts as an acoustic window for high frequency sound waves and to straighten the angle between the uterine body and cervix in anteverted uterus, performing the function of the tenaculum. Then, then ultrasound will be done and the intrauterine device will be introduced vaginally under ultrasound vision.
89439914|NCT03383432|Other|Uterine Sounding Sparing intrauterine device group|The sonographer performs ultrasound using transvaginal probe to evaluate the uterine position and the endometrial length in the sagittal view of the uterus. The intrauterine device was inserted directly into the uterine cavity without using uterine sounding.
89439915|NCT03132714|Active Comparator|PD + (AMX + MET)|periodontal pockets that will receive full-mouth ultrasonic debridement associated with systemic Amoxicillin 500 mg + Metronidazole 400 mg
89439916|NCT03132714|Active Comparator|PD + CLM|periodontal pockets that will receive full-mouth ultrasonic debridement associated with systemic clarithromycin 500 mg
89439917|NCT03132714|Active Comparator|PD + (AMX + MET) + sPDT|periodontal pockets that will receive full-mouth ultrasonic debridement associated with systemic Amoxicillin 500 mg + Metronidazole 400 mg and single application of PDT
89439918|NCT03132714|Active Comparator|PD + CLM + sPDT|periodontal pockets that will receive full-mouth ultrasonic debridement associated with systemic Clarithromycin 500 mg and single application of PDT
89439919|NCT03132714|Active Comparator|PD + (AMX + MET) + rPDT|periodontal pockets that will receive full-mouth ultrasonic debridement associated with systemic Amoxicillin 500 mg + Metronidazole 400 mg and repeated application of PDT
89439920|NCT03132714|Active Comparator|PD + CLM + rPDT|periodontal pockets that will receive full-mouth ultrasonic debridement associated with systemic Clarithromycin 500 mg and repeated application of PDT
89439921|NCT03386318||day surgery patients|20 patients female 30-60 years of age
89439922|NCT03514212|Experimental|ProActiveS|As this was a feasibility study, all participants received the intervention.
89439923|NCT03339284|Active Comparator|QLB with dexamethasone|Single sided US-guided QLB using ropivacaine 3,75 mg/ml 20 ml and dexamethasone 5 mg/ml 0,4 ml
89439924|NCT03339284|Active Comparator|QLB without dexamethasone|Single sided US-guided QLB using ropivacaine 3,75 mg/ml 20 ml and isotonic natriumchloride solution (NaCl 0,9%) 0,4 ml
89439925|NCT03339284|Placebo Comparator|Placebo|Single sided US-guided QLB using isotonic natriumchloride solution (NaCl 0,9%) 20,4 ml
89439926|NCT02295072|No Intervention|Control group|2 Usual Physical Education sessions/week
89439927|NCT02295072|Experimental|Intervention Group|A 5-months physical exercise-based program (3-5 Physical Education after school sessions/week + 2 Usual Physical Education sessions/week)
89439928|NCT03517644|Experimental|Deceptive Placebo (DP)|After pretreatment heat pain assessment, participants are informed that they are about to receive an effective analgesic cream. In fact, they receive a placebo cream. Next, the posttreatment pain assessment is conducted.
88924737|NCT04788329|Experimental|Meditation Group|"This treatment group will be enrolled in Wim Hof Method, a meditation program. Patients in this group will take the online The Fundamentals Course provided by the Wim Hof Method. The patients will be introduced to the online course preoperatively"
88924738|NCT04788329|No Intervention|Standard Care Group|The control group will get the standard of care therapy after surgery.
88924739|NCT04787653|Active Comparator|Otoband efficacy on Tinnitus|"Participants will wear the Otoband on the flat part of the right mastoid bone, about an inch behind the pinna and level with the ear canal. Each participant will select his/her preferred stimulation level. The OtoBand will be programmed to operate at one of three power levels that are thought to be effective. The OtoBand will record what power level is selected and how long it was operating at that power level as well as the date and time a usage started. The use log will be downloaded at Otolith's lab once the device is received. The participant will wear the device for 30 minutes and record their Tinnitus level in a Google Form."
88924740|NCT04787653|Placebo Comparator|Placebo device efficacy on Tinnitus|"The placebo device will use the same case, headband and battery as the OtoBand. The transducer in the OtoBand will be rotated 90 degrees, so that the placebo device will vibrate in a direction ineffectual at providing bone conducted vibrations. The vibrations will be in the horizontal plane, parallel to the skull, and will not have their energy penetrating the skull all the way to the vestibular system. Each participant will select his/her preferred stimulation level. The placebo devices will be made to vibrate at one of three power levels, none of which are thought to be effective. The placebo will record what power level is selected and how long it was operating at that power level as well as the date and time a usage started. The use log will be downloaded at Otolith's lab once the device is received. The participant will wear the device for 30 minutes and record their Tinnitus level in a Google Form."
89439929|NCT03517644|Experimental|OLP with Hope (OLP Hope)|After pretreatment heat pain assessment, participants are informed that they are about to receive an placebo cream. They are told that the cream has no active pharmacological ingredient. However, using verbal instructions, the investigator aims to induce hope among the participants that the cream could have a positive effect. Next, the posttreatment pain assessment is conducted.
89538450|NCT02458703|Experimental|Patients with pulmonary AVMs and airflow obstruction|30 patients with pulmonary AVMs and airflow obstruction will undergo cardiopulmonary exercise testing
89199496|NCT05384600||Patients due to undergo surgery|Patients who are due to undergo elective colonic surgery within Cardiff and Vale UHB, who have an unknown risk of- , and may or may not go on to develop-, incisional hernia. One-off self-completed patient questionnaire upon enrolment. Sub-set will be invited to participant in qualitative interview.
89199497|NCT05371106||breastfeeding mothers|pregnant women after week 37 intending to nurse or nursing mothers of infants aged 1-12 months
89199498|NCT05365997|No Intervention|Control|Clinicians will receive no further interventions beyond usual practice.
89199499|NCT05365997|Experimental|Intervention|Clinicians receive a nudge consisting of an electronic health record in-basket message indicating a patient has a default pended order for palliative care.
89199500|NCT05363943|Active Comparator|Fixation|open reduction and internal fixation by using lateral and medial plates.
89199501|NCT05363943|Experimental|Replacement|excision of the distal part of femur and replacement with distal femoral prosthesis
89012307|NCT02278198|Experimental|Differentiated Thyroid Cancer|"All patients will receive one extra imaging scan with I-123 in addition to their routine care as described above. This research portion of their care will be similar to the scan that they undergo for the I-123 planning scan that is already a part of their routine care. The research study, which will be performed in the middle of the patient's normal standard of care treatment, will take 4 days.~On days 1 and 2, all patients will receive a intramuscular injection of rhTSH (Thyrogen).~On day 3, all patients will be given 3 mCi of I-123 in the form of a pill to take by mouth.~On day 4, all patients will receive a I-123 Whole Body Imaging Scan and a thyroid camera scan of the neck and thigh."
89012308|NCT02279290|Experimental|Healthy Mind Intervention (HMI)|This intervention will focus on teaching individuals a way to manage acute and chronic stressors more effectively.
89439930|NCT03517644|Experimental|OLP with Expectations (OLP Expectation)|After pretreatment heat pain assessment, participants are informed that they are about to receive an placebo cream. They are told that the cream has no active pharmacological ingredient. However, using verbal instructions, the investigator aims to raise expectations among the participants that the cream will have a positive effect. Next, the posttreatment pain assessment is conducted.
89439931|NCT03517644|Experimental|Control|After pretreatment heat pain assessment, this group does not receive an intervention targeting pain sensation prior to the posttreatment pain assessment.
89439932|NCT02291484|Experimental|Comprehensive cardiac CT|"Tiered cardiac CT protocol:~CT calcium scan~CT angiography (if calcium scan positive or high pre-test probability)~CT perfusion (if >50% stenosis on CTA, or cannot be ruled out)"
89439933|NCT02291484|No Intervention|Standard care|Standard diagnostic management of suspected CAD, using stress testing
89439934|NCT02291562|Experimental|Tetrahydrocannabinol|10 mg of Tetrahydrocannabinol as capsule (once)
89439935|NCT02291562|Experimental|Cannabidiol|600 mg Cannabidiol capsule (once)
89439936|NCT02291562|Placebo Comparator|placebo|placebo capsule (once)
89439937|NCT03514056||1|group Behcet
89439938|NCT03514056||2|group fibromyalgia
89439939|NCT03316586|Experimental|Nivolumab + Cabozantinib|"Nivolumab was administered every 28 days at a dose of 480mg given intravenously over 30 minutes (+/- 10 minutes) using a volumetric pump with 0.2 to 1.2 micron pore size, low protein binding polyethersulfone membrane in-line filter~Cabozantinib was administered orally, once daily for 28 days at a dose of 40 mg."
89439940|NCT02291640|Experimental|Child ETI with chest compressions|endotracheal intubation (ETI) during child mannikin resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
89439941|NCT02291640|Experimental|Child ETI without chest compressions|Endotracheal intubation of child mannikin during resuscitation without chest compressions.
89012309|NCT02279290|Active Comparator|Healthy Body Intervention (HBI)|This intervention will focus on important health-related topics.
89012310|NCT04824430||SLH 3M|Second look hysteroscopy (SLH) performed 3 months post-ablation
89439942|NCT03390998||Peripartum SCAD|Female patients who experienced any SCAD event that occurred during pregnancy or up to 1 year post-delivery
89439943|NCT03390998||Non-peripartum SCAD|Female patients who experienced any SCAD with event onset outside of the pregnancy period
89439944|NCT03513978|Experimental|IAI Protocol|A progressive exercises with transference to sport protocol, oriented to improve the proprioception.
89439945|NCT03513978|Active Comparator|FIFA 11+ Protocol|A typical exercises protocol to soccer
89439946|NCT03390920|Experimental|Umbilical Allograft|The study is nonrandomized with one arm. Depending on the body area being treated, the amount of the product utilized will be either 1.0cc's or 2cc's.
89439947|NCT03513900||cirrhosis|In this cross-sectional study , we will collect all patients with cirrhosis who meet the inclusion and exclusion criteria criteria coming to The Second Affiliated Hospital, Xi'an Jiaotong University since March 2018 to December 2018.
89012311|NCT04824430||SLH 6M|Second look hysteroscopy (SLH) performed 6 months post-ablation
89012312|NCT04824430||SLH 12M|Second look hysteroscopy (SLH) performed 12 months post-ablation
89012313|NCT04826419|Active Comparator|Non-invazive ozone therapy in a group|ozone therapy
89012314|NCT04826419|No Intervention|Control group|control groups do not take ozone therapy
89012315|NCT04822480||DPP Patients|UMMC Patients with prediabetes or risk for diabetes based on risk parameters referred to and enrolled in the DPP.
89439948|NCT03383276|Experimental|IL-1Ra|
89439949|NCT02295150|Experimental|Nadroparin|patients above 140 kg will receive a dose of 2850 IU nadroparine pre-operatively, anti-Xa factor will be determined 3 days after nadroparin use. After surgery patients receive 5700 IU nadroparin (our standard treatment). Three days after surgery and 4 weeks after surgery anti-Xa factor will be measured again.
89439950|NCT03517410||Smart phone Use Experimental group|Patients with CLBP
89439951|NCT03386084|Experimental|direct application of microwave diathermy and motor control|
89439952|NCT03386084|Placebo Comparator|application of microwave diathermy without therapeutic effects|
89439953|NCT03390608||Women with T1ab breast cancer.|
89012316|NCT04822480||Non-DPP Patients|Control matched UMMC patients with prediabetes or risk for diabetes based on risk parameters not enrolled in the DPP.
89012317|NCT04826926|Experimental|Non-surgical periodontal treatment NSPT|"Conventional staging debridement (CSD) according to the severity of periodontal disease in 2 to 4 appointments at day 0, 7, 14 and 21.~Supra and subgingival scaling and polishing will be performed by the use of manual and ultrasonic instruments and oral hygiene instructions will be given. Patients will be instructed to use interdental brushes with appropriate size interdental brushes or dental floss when interdental embrasures will not allow for interdental brushing."
89012318|NCT04826536||Cohort 1|Participants with psoriasis
89199502|NCT05363293|Experimental|Multiple Ascending Doses of AL001 vs. Placebo - Cohort 1|"Participants will be randomized to receive AL001. When adequate safety data are available, a review will be done for all participants to make a dose-escalation or dose and/or regimen modification decision. This will be repeated for each cohort.~A total of 9 cohorts will receive 5 different dose levels of AL001 in multiple ascending doses under fasted conditions up to tolerability/safety limits.~Cohort 1 will include 8 AD subjects. In this cohort, 6 active and 2 placebo AD subjects (as per randomization code) will receive the following treatment or placebo:~• Cohort 1: 60% of 450 mg lithium carbonate equivalent of AL001 (1890 mg AL001 daily ×14 days, given as 3 × 210 mg AL001 capsules TID)"
89199503|NCT05363293|Experimental|Multiple Ascending Doses of AL001 vs. Placebo - Cohort 2|"The data from the previous cohort must be deemed safe before the next sequential cohort may be enrolled and dosing initiated.~Cohort 2 will be sub-divided into 2 cohorts: Cohort 2a (8 healthy subjects - 4 non-elderly adults and 4 elderly adults) and Cohort 2b (8 AD subjects). Per randomization, there will be 6 active and 2 placebo subjects in each cohort:~• Cohort 2a and 2b: 100% 450 mg lithium carbonate equivalent of AL001 (3150 mg AL001 daily × 14 days, given as 5 × 210 mg AL001 capsules TID)."
89199504|NCT05363293|Experimental|Multiple Ascending Doses of AL001 vs. Placebo - Cohort 3|"The data from the previous cohort must be deemed safe before the next sequential cohort may be enrolled and dosing initiated.~Cohort 3 will be sub-divided into 2 cohorts: Cohort 3a (8 healthy subjects - 4 non-elderly adults and 4 elderly adults) and Cohort 3b (8 AD subjects). Per randomization, there will be 6 active and 2 placebo subjects in each cohort:~• Cohort 3a and 3b: 140% of 450 mg lithium carbonate equivalent of AL001 (4410 mg AL001 daily × 14 days, given as 7 × 210 mg AL001 capsules TID)"
89199505|NCT05363293|Experimental|Multiple Ascending Doses of AL001 vs. Placebo - Cohort 4|"The data from the previous cohort must be deemed safe before the next sequential cohort may be enrolled and dosing initiated.~Cohort 4 will be sub-divided into 2 cohorts: Cohort 4a (8 healthy subjects - 4 non-elderly adults and 4 elderly adults) and Cohort 4b (8 AD subjects). Per randomization, there will be 6 active and 2 placebo subjects in each cohort:~• Cohort 4a and 4b: 160% of 450 mg lithium carbonate equivalent of AL001 (5040 mg AL001 daily × 14 days, given as 8 × 210 mg AL001 capsules TID)"
89199506|NCT05363293|Experimental|Multiple Ascending Doses of AL001 vs. Placebo - Cohort 5|"The data from the previous cohort must be deemed safe before the next sequential cohort may be enrolled and dosing initiated.~Cohort 5 will be sub-divided into 2 cohorts: Cohort 5a (8 healthy subjects - 4 non-elderly adults and 4 elderly adults) and Cohort 5b (8 AD subjects). Per randomization, there will be 6 active and 2 placebo subjects in each cohort:~• Cohort 5a and 5b: 200% of 450 mg lithium carbonate equivalent of AL001 (6300 mg AL001 daily × 14 days - lithium dose equivalent to that used for bipolar/affective disorders, given as 10 × 210 mg AL001 capsules TID)"
89199507|NCT05358236|Other|training + written and illustrated training brochure|"Postpartum first day was given wound care and genital hygiene training (one hour).~At the end of the training, the mothers were given a written and illustrated training brochure."
89199508|NCT05358236|No Intervention|Standard of care (Control group)|Standard of care (Control group) Left to the usual care of the hospital
89199509|NCT05345743||Positive AIR-test|Patients with a positive intraoperative AIR-test result
89199510|NCT05345743||Negative AIR-test|Patients with a negative intraoperative AIR-test result
89199511|NCT05341167|Active Comparator|Intervention group:|The HPI algorithm will be used in order to prevent hypotensive episodes. When the HPI is greater than 85%, the anesthesiologist will have to intervene within the next 2 minutes taking the hemodynamic parameters available into consideration, as well as the treatment protocol that has been designed according to current literature
89199512|NCT05341167|Other|Control group:|Hypotensive episodes will be treated with vasoactive agents and fluids according to the standard clinical practice. The HPI algorithm recordings will be blinded and will not be available to the anesthesiologist for the duration of the operation.
89199513|NCT05339555|Other|IUD Self-Removal|
89199514|NCT05325047|Experimental|Speech rehabilitation|
89199515|NCT05319054|No Intervention|Cohort|Patients who have undergone colonic resection for colorectal cancer in the last 10 years. Patient reported outcome measures collected at 3-monthly intervals.
89199516|NCT05319054|Active Comparator|Optimised Conservative Management|Cohort participants who are identified as having 'major LARS' at any point are treated with Optimised Conservative Managements, consisting of medication, dietary advice, lifestyle advice and physiotherapy.
89199517|NCT05319054|Active Comparator|Trans-Anal Irrigation|Cohort participants who are identified as having 'major LARS' at any point are treated with Trans-anal irrigation, in additional to receiving optimised conservative management. Transanal irrigation system will be decided upon with the participant and procured locally.
89199518|NCT05319054|Active Comparator|Sacral NeuroModulation|Cohort participants who are identified as having 'major LARS' at any point are treated with Sacral Neuromodulation system, in addition to receiving optimised conservative management. Medtronic Interstim system will be used.
89199519|NCT05301751|Experimental|Cohort 1|A single intravitreal (IVT) dose of 0.5 mg AG-73305
89199520|NCT05301751|Experimental|Cohort 2|A single IVT dose of 1 mg AG-73305
89199521|NCT05301751|Experimental|Cohort 3|A single IVT dose of 2 mg AG-73305
89199522|NCT05301751|Experimental|Cohort 4|A single IVT dose of 3 mg AG-73305
89199523|NCT05293132|Experimental|Montelukast group|30 patients will receive montelukast sodium 10 mg/day film coated tablets (Singulair®; Merck & Co Inc) or (Clear air®; Amoun Pharmaceutical Company S.A.E., Egypt) in addition to the standard sepsis treatment starting from the onset of the diagnosis of sepsis till discharge from ICU, or death.
89199524|NCT05293132|Experimental|Co Enzyme Q10 group|30 patients will receive co enzyme Q10 capsule 210 mg / day (MEPACO Pharmaceutical Company (Egypt) in addition to the standard sepsis treatment starting from the onset of the diagnosis of sepsis till discharge from ICU, or death.
89199525|NCT05293132|Active Comparator|Control group|30 patients will receive the standard treatment of sepsis from the onset of the diagnosis of sepsis till discharge from ICU, or death.
89199526|NCT05281627||Emergency Laparotomy Patients|All adult patients (18+) who have undergone Emergency Laparotomy surgery, are recovering well (no illness which is expected to limit life to <6m post op) and have sufficient English-language and cognitive skills to complete the study questionnaires.
89439954|NCT02295228||Adults undergoing total hip arthroplasty|No intervention will be administered, this is an observational trial. The study population includes adults 50+ who are undergoing elective total hip arthroplasty for osteoarthritis.
89439955|NCT03521076|Experimental|Virtual Reality for distraction|The application of VR during the putative painful treatment (botulinum toxin injections) will provide a) active and engaging distraction during the procedure, and will b) block the view and auditory noise related to the procedure.
89439956|NCT03521076|No Intervention|Standard of Care|Patients will receive the standard of care for the putative painful treatment (botulinum toxin injections).
89439957|NCT05171582|Active Comparator|Surgery 1 (Test group)|In the test group (T), bone defects will be full-filled with bovine bone substitute with HA (Cerabone plus, Botiss, Germany)
89439958|NCT05171582|Active Comparator|Surgery 2 (Control group)|In the control group (C), bone defects will be full-filled with xenograft bovine bone substitute without HA (Cerabone, Botiss, Germany).
89439959|NCT02141373|Experimental|Glubran 2|Glubran 2 will be used at end of surgery
89439960|NCT02141373|No Intervention|Standard Surgery|
89439961|NCT02144727|Active Comparator|D2 distal subtotal gastrectomy|D2 distal subtotal gastrectomy D2 includes Nos.1.3,4sb,4d,5,6,7,8a,9,11p,and 12a nodes in Japanese classification. Systemic en bloc lymph node dissection is mandatory. Resection margin should be negative for malignancy with intraoperative frozen biopsy
89439962|NCT02144727|Experimental|D1+ distal subtotal gastrectomy|D1+ distal subtotal gastrectomy D1+ includes Nos.1,3,4sb,4d,5,6,7,8a,and 9 nodes in Japanese classification. Systemic en bloc lymph node dissection is mandatory. Resection margin should be negative for malignancy with intraoperative frozen biopsy
89439963|NCT03296696|Experimental|Dose exploration|Dose exploration of the intervention, AMG 596 alone or in combination with AMG 404
89439964|NCT03296696|Experimental|Dose expansion|Dose expansion of the intervention, AMG 596 alone or in combination with AMG 404
89439965|NCT03517332||Cohort 1|"Have a diagnosis of a malignancy in clinical stage 0 to IV including but not limited to: colon or rectal cancer, pancreatic and gastric cancer, hepatocellular carcinoma, non-small cell lung cancer, bladder cancer, melanoma~Subjects of cohort 1 must not:~• Have been treated for above diagnosed malignancy"
89439966|NCT03517332||Cohort 2|"Negative cohort with subjects that have not been diagnosed with a malignancy (cohort 2).~Subjects of cohort 2 must:~• Meet the listed matching criteria~Subjects of cohort 2 must not:~• Have been diagnosed/treated for a malignancy previously"
89439967|NCT03513822|Active Comparator|Chronic neuropathic pain and bedsore Ketamine group|"Spinal cord injury population with central neuropathic pain at the lesional or sub-lesion level, chronically (for more than three months).~Patients medullary wounded with chronic pain and ulcer pressure (inflammation factor).~Midazolam 1mg before infusion. KETAMINE INFUSION IVSE 1mg/kg during 2 hours (0,5mg/kg/h). Preparation of 100mg in fifty cc, syringe with 2mg/ml. Rate of administration: Speed = Patient weight divided by four.~Maximum 100mg. One and only perfusion."
89439968|NCT03513822|Placebo Comparator|Chronic neuropathic pain and bedsore Placebo group|"Spinal cord injury population with central neuropathic pain at the lesional or sub-lesion level, chronically (for more than three months).~Patients medullary wounded with chronic pain and ulcer pressure (inflammation factor).~Midazolam 1mg before infusion. Sodium chloride infusion IVSE during 2 hours. Rate of administration : Speed = patient weight divided by four.~One and only perfusion."
89439969|NCT03513822|Active Comparator|Chronic neuropathic pain without bedsore Ketamine group|"Spinal cord injury population with central neuropathic pain at the lesional or sub-lesion level, chronically (for more than three months).~Patients medullary wounded with chronic pain and no ulcer pressure (no inflammation factor).~Midazolam 1mg before infusion. KETAMINE INFUSION IVSE 1mg/kg during 2 hours (0,5mg/kg/h). Preparation of 100mg in fifty cc, syringe with 2mg/ml. Rate of administration: Speed = Patient weight divided by four.~Maximum 100mg. One and only perfusion."
89439970|NCT03513822|Placebo Comparator|Chronic neuropathic pain without bedsore Placebo group|"Spinal cord injury population with central neuropathic pain at the lesional or sub-lesion level, chronically (for more than three months).~Patients medullary wounded with chronic pain and no ulcer pressure (no inflammation factor).~Midazolam 1mg before infusion. Sodium chloride infusion IVSE during 2 hours. Rate of administration : Speed = patient weight divided by four.~One and only perfusion."
89012319|NCT04900246|Experimental|Visual Inspection + BWX Radiographic Assessment + Assessment of the iTero Element 5D scan|In this group, the evaluations will follow this order. First the visual inspection, then the bitewing X-ray assessment and, lastly, the iTero assessment.
89439971|NCT05171504||I , Infertile males with varicocele|Lactoferrin , iron in seminal plasma and semen analysis from Infertile patients with varicocele
89012320|NCT04900246|Experimental|Visual Inspection + Assessment of the iTero Element 5D scan + BWX Radiographic Evaluation|In this group, the evaluations will follow this order. First the visual inspection, then the iTero assessment and, lastly, the bitewing X-ray assessment.
89439972|NCT05171504||II , infertile males due to other causes than varicocele|Lactoferrin , iron in seminal plasma and semen analysis from infertile patients due to other causes than varicocele
89439973|NCT05171504||III , fertile males|Lactoferrin , iron in seminal plasma and semen analysis from fertile males with history of childbirth within the previous year
89439974|NCT02990091|Experimental|1,000mg/day n-3 HUFA|Subjects will take one capsule daily starting at study enrollment (within 24 hours of injury) for 14 consecutive days.
89439975|NCT02990091|Experimental|4,000 mg/day n-3 HUFA|Subjects will take 2 capsules twice daily starting at enrollment (within 24 hours of injury) for 14 consecutive days.
89012321|NCT04822168|Active Comparator|Standard Care|Standard Care through detox-based opioid treatment with B/N and weekly urine toxicology screening
89012322|NCT04822168|Experimental|MySafeRx™ Intervention|The MySafeRx™ platform is a combination of several key components, including daily videoconferencing check-ins with motivational interviewing-based recovery coaching, text-messaging reminders, secure storage of B/N medication within a secure medication storage device, and a standardized protocol for supervising self-administration of medication via videoconferencing.
89012323|NCT00251732|Active Comparator|Standard dose (PPI) plus low dose TCA|Standard dose Rabeprazole(PPI) plus low dose tricyclic antidepressant(TCA)
89012324|NCT00251732|Active Comparator|Double dose PPI|Double dose proton pump inhibitor plus placebo
89012325|NCT00251732|Placebo Comparator|Standard dose PPI plus placebo x 2|Standard dose 20 mg. once daily plus Placebo before dinner and placebo before bedtime
89012326|NCT04088539|Experimental|Group A|"CSD participants will receive a combined intervention:~Brief intervention using AWARD advice at baseline,~Video-based health education"
89012327|NCT04042792||ADA for ≥12 weeks and concomitant MTX therapy|PiRD patients with ADA for ≥12 weeks and concomitant MTX therapy (oral or subcutaneous)
89012328|NCT04042792||ADA for ≥ 12 weeks without MTX|PiRD patients with ADA for ≥ 12 weeks without MTX ≥ 12 weeks (or never exposed to MTX)
89012329|NCT00286962|Experimental|CIPII|Intraperitoneal insulin infusion by means of an implanted insulin pump
89012330|NCT00286962|Active Comparator|CSII/ MDI|Optimized subcutaneous insulin infusion by means of continuous subcutaneous insulin infusion (CSII) or by multiple daily injections (MDI)
89012331|NCT04011826|Experimental|Experimental: Experimental trial nasal mask|Experimental trial nasal mask: Participants will be placed on this arm for a total of 14±3 days from Visit 2. Participants will be using the trial nasal mask during this treatment arm. Participants on the extension will use this trial mask for a further six months after Visit 3.
89012332|NCT04006756|Experimental|Online cognitive training 1|Eight-week, three times a week during 45 minutes cognitive training
89012333|NCT04006756|Active Comparator|Online cognitive training 2|Eight-week, three times a week during 45 minutes cognitive activities
89012334|NCT00251771|Experimental|I|
89012335|NCT00251771|No Intervention|II|
89012336|NCT03946462|Experimental|NO Group|
89012337|NCT03946462|Placebo Comparator|Placebo Group|
89012338|NCT00280488|Active Comparator|1) MI with SO|Motivational Interviewing (MI), a brief, directive, non-confrontational intervention, with inclusion of a significant other (SO) in prolonged, intensive alcohol treatment.
89012339|NCT00280488|Active Comparator|2) MI with patient only|Motivational Interviewing (MI), a brief, directive, non-confrontational intervention, with the individual patient
89012340|NCT00280488|Active Comparator|3) Assessment only|In the assessment-only condition, patients will receive only assessment of their drinking at baseline.
89012341|NCT00251810||general anaesthesia|
89012342|NCT03531580|Experimental|Healthy volunteers|six healthy volunteers: 3 male (age 20-40; 40-60 and 60+) and 3 female (age 20-40; 40-60 and 60+)
89012343|NCT00287001|Other|1|1= cool air cooling
89012344|NCT03439930|Active Comparator|Uni-axial|Subjects in this group perform exercises on an uni-axial balance board
89012345|NCT03439930|Active Comparator|Multidirectional|Subjects in this group perform exercises on a multidirectional balance board
89012346|NCT04719650|Experimental|zoledronic acid 1mg|Add 20 mL of Zoledronic acid injection (100mL : 5mg) with 80 mL of normal saline to 100 mL. Infusion 20 minutes with constant speed. Administration only once.
89012347|NCT04719650|Experimental|zoledronic acid 2.5mg|Add 50 mL of Zoledronic acid injection (100mL : 5mg) with 50 mL of normal saline to 100 mL. Infusion 20 minutes with constant speed. Administration only once.
89012348|NCT04719650|Experimental|zoledronic acid 5mg|Infusion 100 mL of Zoledronic acid injection (100mL : 5mg) with constant speed in 20 minutes. Administration only once.
89012349|NCT04719650|Placebo Comparator|placebo|Infusion 100 mL of normal saline with constant speed in 20 minutes. Administration only once.
89012350|NCT03406312||Gastric Bypass Surgery population|liquid mixed meal tolerance test, solid mixed meal tolerance test, continuous glucose monitoring
89012351|NCT03406312||Control population|liquid mixed meal tolerance test, solid mixed meal tolerance test, continuous glucose monitoring
89012352|NCT03218605|Experimental|healthy active participants|
89199527|NCT05281627||Family Caregivers|Adult (18+) family members, close friend or caregivers of the individual who has received EmLap treatment have sufficient English-language and cognitive skills to complete the study questionnaires.
89199528|NCT05265949|Experimental|diet+physical activity|diet+physical activity
89012353|NCT03189862|Experimental|CHAMP|CHAMP, is a mastery climate motor skills interventions, that provides children the opportunity to establish behaviors that reinforces decision-making while participating in a variety of challenging movement & physical activity tasks. Duration of CHAMP is 30 min/day 4 days/week for 30 weeks. CHAMP consist of a) a 2-3 min of motor skill introductory activity that includes a group motor activity, the teaches the lesson, includes a demonstration, and understanding of developmentally appropriate learning clues b) 25 min of motor skill instruction & practice where preschoolers engage in 3-4 motor activity stations that align with the TARGET structures c) & 2-3 min motor skill closure activity that involves a review of the lesson & critical elements.
89012354|NCT03189862|No Intervention|Control - Free Play|The control/free play condition will be the preschools typical activity programs (i.e., outdoor/indoor recess) and will be implemented according to the existing procedures within the preschool centers. The centers outdoor program consist of outdoor free-play activity on a large playground area with a variety of play structures (swings, slides, ladders) that promote gross movement and activity in preschoolers. For the control condition, there will be no planned instruction nor activities provided by the classroom teachers.
89012355|NCT02960802|Active Comparator|kidney transplant patient|kidney transplantation is intervention
89012356|NCT02960802|No Intervention|healthy control|no intervention
89199529|NCT05265949|Experimental|diet|diet
89199530|NCT05265949|Experimental|physical activity|physical activity
89199531|NCT05265949|No Intervention|control|control
89199532|NCT05259774|Experimental|Relizema cream|Relizema cream, topically applied twice a day in all the affected areas for three cycles of 13 (±2) consecutive days.
88924741|NCT04787380|Experimental|LOVE-HF Arm A (Full data analysis mode of Heartfelt + weight + symptoms reporting)|Participants in LOVE-HF Arm A (Full data analysis mode of Heartfelt + weight + symptoms reporting) will not know if they are assigned to LOVE-HF Arm A or LOVE-HF Arm B. The Heartfelt device will be in 'full data analysis' mode and participants will follow standard care recommendations for weighing themselves and reporting their symptoms. 'Full data analysis' mode means that the device will be fully operational and will be detecting and reporting changes in foot volume over time. The device will have been allocated to the 'full data analysis' mode prior to shipping. Participants will be provided with electronic, internet connected weighing scales that can transmit weight data. These weighing scales will be used as per usual advice given to patients, thus taking part in the study should not change their behaviour.
88924742|NCT04787380|No Intervention|LOVE-HF Arm B (Technical checks only mode of Heartfelt + weight + symptoms reporting)|Participants in LOVE-HF Arm B (Technical checks mode of Heartfelt + weight + Symptoms reporting) will not know if they are assigned to LOVE-HF Arm A or LOVE-HF Arm B. The Heartfelt device will be in 'technical checks only' mode where the data analysis pipeline is blocked and changes in foot volume over time will not be processed or reported. However, technical checks on device functioning and image quality (e.g. camera being blocked) will be made as usual. The device will have been allocated to the 'technical checks only' mode prior to shipping. Participants will follow standard care recommendations for weighing themselves and reporting their symptoms. Participants will be provided with electronic, internet connected weighing scales that can transmit weight data. These weighing scales will be used as per usual advice given to patients, thus taking part in the study should not change their behaviour.
88924743|NCT04785781|Other|no mask|individuals perform cardiopulmonary test via cycle ergometer without mask till voluntary exhaustion
88924744|NCT04785781|Other|surgical mask|individuals perform cardiopulmonary test via cycle ergometer with surgical mask till voluntary exhaustion
88924745|NCT04785781|Other|N95/fpp2|individuals perform cardiopulmonary test via cycle ergometer with N95 mask till voluntary exhaustion
88924746|NCT04780763|Active Comparator|Arm 1, Test: Fermented milk product containing probiotics L. rhamnosus CNCM I-3690|
88924747|NCT04780763|Placebo Comparator|Arm 2, Control: Milk-based non-fermented dairy product|
88924748|NCT04777279|Experimental|Individual physical exercise group|a 12-weeks physical exercise program (60 minutes/ three times weekly)
88924749|NCT04777279|Experimental|Individual Branched-Chain Amino Acids supplements group|a 12-weeks Branched-Chain Amino Acids supplements (5 g Branched-Chain Amino Acids every day)
88924750|NCT04777279|Experimental|Combination of physical exercise and Branched-Chain Amino Acids supplements group|a 12-weeks physical exercise program (60 minutes/ three times weekly) and a 12-weeks Branched-Chain Amino Acids supplements (5 g Branched-Chain Amino Acids every day)
88924751|NCT04777279|No Intervention|Control group|no intervention
88924752|NCT04776382|Experimental|Study Group|Trainees of this group will watch an EMME (Eye Movement Modeling Examples) pre-recorded video, on where to focus their gaze while performing the epidural procedure in accordance with expert eye-tracking
88924753|NCT04776382|No Intervention|Control Group|Trainees of this group will not watch the pre-recorded video
89199533|NCT05259774|No Intervention|Vehicle|Cream, topically applied twice a day in all the affected areas for three cycles of 13 (±2) consecutive days.
88924754|NCT04775966||The study population|Patients meeting eligibility criteria (see appropriate section).
88924755|NCT04775537||OssiMend™ Bioactive Moldable|Patients undergoing Lumber Spine Fusion
88924756|NCT04774315|Experimental|Omalizumab|
88924757|NCT04769479|Experimental|acoramidis|
88924758|NCT04768361|Experimental|Behavioral Activation without Mindfulness|Program with 8 face to face sessions (115 minutes/session) in groups of 15-18 people. This program was adapted from BA proponents and excludes terms and interventions from Third Generation Therapies.
88924759|NCT04768361|Experimental|Behavioral Activation with Mindfulness|Program with 8 face to face sessions (115 minutes/session) in groups of 15-18 people. This program was adapted from BA proponents and include mindfulness practices.
88924760|NCT04768335|Active Comparator|Patient group with schizophrenia|The schizophrenic subjects will undertake a 3 hour session of cognitive experiments. Tasks will include a battery of psychoacoustic tests, a source monitoring task, an externalization task, a pitch discrimination task and a speech-in-speech task.
88924761|NCT04768335|Active Comparator|Healthy control subjects|Healthy control subjects will undertake a 3 hour session of cognitive experiments. Tasks will include a battery of psychoacoustic tests, a source monitoring task, an externalization task, a pitch discrimination task and a speech-in-speech task.
88924762|NCT04767503|Active Comparator|Propofol|Maintence of anesthesia during the operation using target control infusion with propofol 1mg/ml with bispetral index(BIS) in the range 40-60.
88924763|NCT04767503|Sham Comparator|Desflurane|Maintence of anesthesia during the operation using inhalational agent desflurane with 0.5 to 1.5 minimal alveolar concentration (MAC) with bispetral index(BIS) in the range 40-60.
88924764|NCT04761263|Active Comparator|Selected Physical Therapy group|will receive a selected physical therapy program for 90 minutes, 3 times/week for 3 successive months.
88924765|NCT04761263|Experimental|Task-oriented circuit training group|Children allocated to the study group will receive the same selected physical therapy program given to the control group for 45 minutes in addition to 45 minutes task-oriented circuit training program. The frequency of the whole program will be three times per week, for three months.
88924766|NCT04759898|Active Comparator|Stimulation (noninvasive recording)|Patients with Parkinson's disease or chronic stroke will be assigned to undergo EEG recording and transcranial direct current stimulation.
88924767|NCT04759898|Sham Comparator|Sham (noninvasive recording)|Patients with Parkinson's disease or chronic stroke will be assigned to undergo EEG recording and sham transcranial direct current stimulation.
88924768|NCT04759898|Experimental|Stimulation (invasive recording)|Patients with Parkinson's disease undergoing surgery for deep brain stimulation will be studied using electrocorticography combined with transcranial direct current stimulation
88924769|NCT04754477|Experimental|Active Osseointegrated Steady-State Implant System (OSI)|
88924770|NCT04749186|Active Comparator|Structured Didactic Model Group|A standardized video lessons (anatomy and technique), construction of a 3D epidural plastic module, practical training by using an epidural simulator with the CompuFlo Trainer instrument, and practical training with the eye-tracking assisted technique.
88924771|NCT04749186|No Intervention|Standard Training Model|The standard local institutional teaching program
88924772|NCT04748497|Other|Parasportives of various disciplines|
88924773|NCT04748458||Congenital hip pathologies|Conical tapered stem for osteoarthritis due to congenital hip pathologies
88924774|NCT04739956||Patient: point of care (POC) result not shared|Patients in this phase of the study will not be provided with the POC BhCG result. They will await the laboratory result. Simultaneously we will ascertain reliability of POC in clinical practice during this time.
88924775|NCT04739956||Partner: point of care (POC) result not shared|Partners in this phase of the study will not be informed of the POC BhCG result. They will await the laboratory result to be provided to the patient. Simultaneously we will ascertain reliability of POC in clinical practice during this time.
88924776|NCT04739956||Patient: point of care (POC) result shared|Patients in this phase will be informed of the POC test result, which will reduce the time to which they receive the result. Prior to transfer to this phase, correlation between POC and laboratory BhCG levels will be calculated in order to confirm its reliability by creating a correlation curve using the data.
88924777|NCT04739956||Partner: point of care (POC) result shared|Partners in this phase will be informed of the POC test result with the patient, which will reduce the time to which they receive the result. Prior to transfer to this phase, correlation between POC and laboratory BhCG levels will be calculated in order to confirm its reliability by creating a correlation curve using the data.
88924778|NCT04736875||Dialysis|Patients with hemodialysis-dependent end-stage renal disease and a newly created native arteriovenous fistula
88924779|NCT04735315||Born preterm|"Inclusion :~Born preterm ≤29 weeks Aged 18-40 years Participants with type-2 diabetes~Exclusion :~Currently pregnant due to administration of radionucleotides and impact on GFR Severe neurosensory deficit preventing test completion History of characterized kidney disease independent of preterm birth, including type-1 diabetes, glomerulopathies (e.g. nephrotic syndrome, glomerulonephritis), polycystic kidney disease, polycystosis, severe uropathy (Grade 4 or 5 RVU, severe hydronephrosis (SFU IV and V), posterior valve history), history of nephrectomy, exposure to radiotherapy or chemotherapy - given that we are interested in isolating the effects of preterm birth and that prevalence of these conditions is not increased in individuals born preterm In case of contra-indication to MRI scanning (which should be rare in the young population studied), the participant will still be given the opportunity to complete the other examinations."
88924780|NCT04735315||Born term|"Inclusion :~Born full-term at 37-41 weeks Birthweight ˃2500g Aged 18-40 years Participants with type-2 diabetes~Exclusion :~Currently pregnant due to administration of radionucleotides and impact on GFR Severe neurosensory deficit preventing test completion History of characterized kidney disease independent of preterm birth, including type-1 diabetes, glomerulopathies (e.g. nephrotic syndrome, glomerulonephritis), polycystic kidney disease, polycystosis, severe uropathy (Grade 4 or 5 RVU, severe hydronephrosis (SFU IV and V), posterior valve history), history of nephrectomy, exposure to radiotherapy or chemotherapy - given that we are interested in isolating the effects of preterm birth and that prevalence of these conditions is not increased in individuals born preterm In case of contra-indication to MRI scanning (which should be rare in the young population studied), the participant will still be given the opportunity to complete the other examinations."
88924781|NCT04734444|Experimental|SonoClear acoustic coupling fluid (ACF) mimicking brain tissue|SonoClear
88924782|NCT04726124|Experimental|treatment group|Microwave Ablation Therapeutic Apparatus. Patients with primary lower extremity varicose veins were treated with endovenous microwave therapy using Microwave Ablation Therapy Apparatus. Ultrasound examination and questionnaire survey（AVVQ and VCSS) were performed at 1 week, 3 months, 6 months,12 months after treatment,drug use and adverse events were recorded to assess complications and target lesion closure rate.
89439976|NCT02990091|Placebo Comparator|1 capsule safflower seed oil|Subjects will take 1 capsule daily starting at enrollment (within 24 hours of injury) for 14 consecutive days.
89439977|NCT02990091|Placebo Comparator|4 capsules safflower seed oil|Subjects will take 2 capsules twice daily starting at enrollment (within 24 hours of injury) for 14 consecutive days.
89439978|NCT02299284|Experimental|Hand-Arm Bimanual Intensive Therapy (HABIT)|HABIT, bimanual training, bilateral training, restraint therapy, PT, OT, rehab
89439979|NCT02299284|Experimental|Intensive Functional Lower-Limb Training|lower-limb function, strength training, balance, PT, OT, rehab
89439980|NCT03383120|Experimental|Laser|Mechanical debridement of the implant surface using an ultra-sonic device with saline irrigation and plastic curettes, followed by soft tissue curettage using a metallic curette. Adjunctive sub-mucosal diode laser application according to the instructions of the manufacturer (settings: 810 nm, 2.5 W, 50 Hz, 10 ms), 3x for 30 seconds, using a 400-µm thick fiber (Doctor Smile Wiser diode laser, Orcos Medical AG, Küsnacht, Switzerland), will be performed three times at one week intervals (days 0, 7, and 14).
89439981|NCT03383120|Active Comparator|Surgery|Active control includes mechanical debridement of the implant surface using an ultra-sonic device with saline irrigation and plastic curettes, followed by soft tissue curettage using a metallic curette at day 1. An open flap debridement procedure is performed at day 14 using normal saline for implant decontamination. Adjunctive systemic antimicrobials will be prescribed; Amoxi-mepha 500mg 3x/day and Metronidazole 500mg 3x/day, for 1 week. A chlorhexidine 0.2% mouth rinse will also be prescribed 2x/day for one week. Suture removal and prophylaxis are performed 7-10 days post-operatively.
89439982|NCT03545451|Experimental|Neurofeedback rehabilitation with videogames|Neurofeedback rehabilitation with videogames
89439983|NCT03175328|Experimental|early group|In the early group, continuous renal replacement therapies was started within 8 hours after randomization.
89439984|NCT03175328|Experimental|delayed group|In the delayed group, continuous renal replacement therapies was initiated if at least one of the following criteria was met: KDIGO 3, severe hyperkalemia, pulmonary edema, blood urea nitrogen level higher than 112 mg per deciliter after randomization.
89439985|NCT02144805|Active Comparator|Suturing in a single layer|The technique used for single layer to close the uterine incision following cesarean sectio
89439986|NCT02144805|Active Comparator|Suturing in two layer|The technique used for two layer technie to close the uterine incision following cesarean sectio
89439987|NCT02915445|Experimental|EpCAM CAR-T cells|Autologous T cells from patient are engineered to expressing a special chimeric antigen receptor to recognizing EpCAM by lentiviral vector. The engineered T cells were then endowed cytotoxicity to the tumor cells and hold the potential to inhibit the advance of tumors.
89439988|NCT02144883|Active Comparator|Materials|Self-help materials mailed to subjects home.
89439989|NCT02144883|Experimental|Telephone Counseling and Materials|Subjects received up to 9 telephone counseling calls plus self-help quit kit and 5 additional mailings
89439990|NCT02144961||Ultrasound|Breast ultrasound in female patients who are post-mastectomy pursuing autologous tissue breast reconstruction surgery.
89439991|NCT02141529|Active Comparator|Unipolar PRF|Unipolar pulsed radiofrequency thermocoagulation, intraarticularly in knee joint, 42oC of temperature during ten minutes
89439992|NCT02141529|Experimental|Bipolar PRF|Bipolar pulsed radiofrequency thermocoagulation, intraarticularly in knee joint, 42oC of temperature during ten minutes
89439993|NCT03513432|Experimental|Beer with 5.20 % alcohol|330 ml beer (5.20 % alcohol)/day
89439994|NCT03513432|Experimental|Non-alcoholic beer with 0.45 % alcohol|330 ml non-alcoholic beer (0.45 % alcohol)/day
89439995|NCT03513432|Experimental|Non-alcoholic beer with 0.00 % alcohol|330 ml non-alcoholic beer (0.00 % alcohol)/day
89439996|NCT02145117|Other|MBSR Training|Mindfulness Based Stress Reduction (MBSR) Training
89439997|NCT03513354|No Intervention|Control group|The control group did not perform any of the interventions.
89439998|NCT03513354|Experimental|Soil group|(2) Stretching from the lateral flexors of the cervical spine, elbow flexors and extensors, trunk lateral flexors, flexors and extensors of hip with support of 30 seconds (1x30), (3) aerobic workout through front and lateral gait walking for 20 minutes, (4) resisted exercise for upper limbs (anterior, middle and posterior deltoid, biceps, triceps) and to the lower limbs (abductors, flexors and extensors of hip and flexors and extensors knee, calf), using dumbbells and shin guards for the resistance (20 minutes), (5) balance and proprioception training through front and backward walking on mattresses, march in a straight line with one foot in front of the other, one-feet support orthostatism, touching some points marked on the ground with the toe (15 minutes)
89439999|NCT03513354|Experimental|Pool group|(2) Stretching from the lateral flexors of the cervical spine, elbow flexors and extensors, trunk lateral flexors, flexors and extensors of hip with support of 30 seconds (1x30), (3) aerobic workout through front and lateral gait walking for 20 minutes, (4) resisted exercise for upper limbs (anterior, middle and posterior deltoid, biceps, triceps) and to the lower limbs (abductors, flexors and extensors of hip and flexors and extensors knee, calf), using dumbbells and shin guards for the resistance (20 minutes), (5) balance and proprioception training through front and backward walking on mattresses, march in a straight line with one foot in front of the other, one-feet support orthostatism, touching some points marked on the ground with the toe (15 minutes)
89440000|NCT02141607||Hemorrhagic Shock|"Hypovolemic shock characterized by:~Hypotension: systolic blood pressure < 90 mm Hg or a drop of > 40 mm Hg from baseline or mean arterial pressure < 70 mm Hg persisting despite adequate fluid resuscitation.~Rapid loss of significant amount of blood~Lactate levels ≥ 2 mmol/L"
89440001|NCT02141607||Cardiogenic shock|"State of inadequate circulation of blood because of ventricular failure due to acute cardiac conditions, concomitant presence of:~Hypotension: systolic blood pressure < 90 mm Hg or a drop of > 40 mm Hg from baseline or mean arterial pressure < 70 mm Hg persisting despite adequate fluid resuscitation.~Need for a continuous infusion of inotropic drugs~Cardiac Index <2.2 L/min/m2 or use of inotropic drugs (dobutamine/isoprenaline/phosphodiesterase inhibitors or levosimendan)~Signs of reduced heart function~Cardiac overload or altered left/right ventricular function"
89440002|NCT02141607||Septic shock|"Septic shock is defined as sepsis-induced hypotension, defined as systolic blood pressure < 90 mm Hg or a drop of > 40 mm Hg from baseline or mean arterial pressure < 70 mm Hg persisting despite adequate fluid resuscitation.~Only community medical acquired sepsis with a sepsis onset within 48 hours from hospital admission (i.e. different from nosocomial infection).~Lactate levels ≥ 2mmol/L."
89440003|NCT02141607||control group|"The control group will consist on:~5 healthy blood donors: serving only for the purposes of obtaining reference values for proteomics analysis~a cohort of 20 patients hospitalized for sepsis OR cardiac syndromes not developing shock: will be recruited from patients admitted to the hospital during the study period. The clinical status of the patients will be assessed during hospitalization to ascertain shock and AHF development. Shock development will be an exclusion criteria."
89440004|NCT02299440|Experimental|Ketamine|"Patients randomized to this group will be treated via Ketamine infusion.~Intervention: Baseline evaluation Intervention: 1st perfusion of ketamine Intervention: Follow-up between perfusions Intervention: 2nd perfusion of ketamine Intervention: Follow-up after perfusions"
88924783|NCT04726124|Experimental|control group|Semiconductor Laser Treatment Apparatus. Patients with primary lower extremity varicose veins were treated with endovenous laser treatment using Semiconductor Laser Treatment Apparatus. Ultrasound examination and questionnaire survey（AVVQ and VCSS) were performed at 1 week, 3 months, 6 months, 12 months after treatment,drug use and adverse events were recorded to assess complications and target lesion closure rate.
88924784|NCT04725539|Experimental|Intermittent hypoxia (IH) pre-conditioning|"The IH pre-conditioning program will be performed in a sitting position by inhaling a gas mixture with reduced O2 content via face masks.The program will include five sessions per week for 3 weeks. Each session consists of three to five hypoxic (14-10% inspired fraction of oxygen) periods, each lasting 3-5 min with 3-min normoxic intervals.~The control setting includes breathing room air via face mask."
88924785|NCT04725539|Experimental|Hypoxia pre-adaptation|The hypoxia pre-adaptation program consists of sleeping 1 night at 1900m. The control setting includes sleeping 1 night close to sea level.
88924786|NCT04722744|Experimental|screwmented metal frameworks based on virtual implant position.|this group will receive a CAD CAM restoration based on virtually planned implant position.
88924787|NCT04722744|Active Comparator|screw-retained metal frameworks based on actual implant position.|this group will receive screw retained CAD CAM restoration based on actual implant position using conventional open tray impression.
88924788|NCT04722679||Patient|Elderly (defined as the ≥75 years old) patients with NVAF that are treated with a NOAC.
88924789|NCT04722679||Physician|Geriatricians (hospital or office-based).
88924790|NCT04721730|Experimental|PLH-YC|"The Parents will receive the optimised version of the Parenting for Lifelong Health for Young Children from 2-9 y. (PLH-YC) identified in Phase 2.~The groups will be conducted with 12 parents per group (with 2 facilitators). If local restrictions due to COVID-19 restrictions do not allow-in person meetings of this size, we will reduce the sample size (6 parents per group, and facilitator) and or conduct the groups online (e.g., using an online video software).~For each session, parents will receive a snack (or food voucher of same amount), childcare, transportation support (if needed), and a certificate at the end. Also, parents participating in at least four out of five PLH sessions will get a small gift. If the groups need be conducted online because of the COVID-19 pandemic, the parents will receive pre-paid data or another voucher of the same amount."
88924791|NCT04721730|Active Comparator|Lecture|"Parents will receive a lecture called Raising Healthy Children.~The lecture will be conducted with 12 parents per group (with one facilitator). If local restrictions due to COVID-19 pandemic will not allow in-person meetings, the groups will be online (e.g., using a video meeting software).~During the lecture, parents will receive a snack (or a food voucher of the same amount), childcare, transportation support (if needed), and a certificate at the end. If the lecture needs be conducted online because of the COVID-19 pandemic and associated restrictions, the parents will receive pre-paid data or another voucher of the same amount (instead of childcare, transport voucher and the snack)."
88924792|NCT04709042|Experimental|Chordal tension measurement and cardiac Magnetic Resonance Imaging|All patient candidates for NeoChord implantation according to the standard of care will be considered for inclusion in this clinical study. Chordal tension measurement will be performed during Neochord implantation. Moreover, all patients will undergo cardiac Magnetic Resonance Imaging (MRI) exam before the surgery, as well as at 3 months follow-up.
88924793|NCT04703010|Experimental|All participants|All participants undergo the same measurements (longitudinal design)
88924794|NCT04698096||metabolic syndrome|Patients with metabolic syndrome
88924795|NCT04698096||Healthy volunteers|Healthy volunteers
88924796|NCT04696380|Experimental|High nicotine, preferred flavor|Participants will sample their preferred flavored JUUL e-cigarette at 5% nicotine strength.
88924797|NCT04696380|Experimental|High nicotine, non-preferred flavor|Participants will sample their non-preferred flavored JUUL e-cigarette at 5% nicotine strength.
88924798|NCT04696380|Experimental|Low nicotine, preferred flavor|Participants will sample their preferred flavored JUUL e-cigarette at 3% nicotine strength.
88924799|NCT04696380|Experimental|Low nicotine, non-preferred flavor|Participants will sample their non-preferred flavored JUUL e-cigarette at 3% nicotine strength.
88924800|NCT04694196|Experimental|Locate occlusal plane|Use anatomical landmark to locate OP in dentulous subjects.
88924801|NCT04681859|Active Comparator|High Flow Nasal Oxygen (HFNO) treatment|
88924802|NCT04681859|Experimental|Continuous positive airway pressure (CPAP) therapy using OxyJet|
88924803|NCT04677517|Experimental|Implanted patients|All the participants are patients with post-lingual deafness and fitted with cochlear implants
88924804|NCT04677348|Experimental|PENG group|pericapsular nerve group (PENG) block before surgery
88924805|NCT04677348|Active Comparator|FICB group|suprainguinal fascia iliaca compartment block (FICB) before surgery
88924806|NCT04672772||Recurrent and/or metastatic SCCHN|Patients who received at least one dose of both paclitaxel 80 mg/m2 as a starting dose with weekly cetuximab, that could have been switched to biweekly during the maintenance phase, as a first line regimen in recurrent and/or metastatic disease.
88924807|NCT04671082|Experimental|Tolperisone 50 mg|Tolperisone 50 mg
88924808|NCT04671082|Experimental|Tolpersione 100 mg|Tolperisone 100 mg
89440005|NCT02299440|Placebo Comparator|Placebo/Control|"Patients randomized to this group will be treated via saline solution infusion.~Intervention: Baseline evaluation Intervention: 1st perfusion of saline Intervention: Follow-up between perfusions Intervention: 2nd perfusion of saline Intervention: Follow-up after perfusions"
89199534|NCT05237908||TSPACE 3D|the 3D printed cage (TSPACE 3D) is defined as investigational product
89199535|NCT05237908||TSPACE XP|the titanium coated PEEK cage (TSPACE XP) is defined as reference product.
89199536|NCT05234892||EVAR group|All consecutive eligible patients submitted to EVAR by Alto Endovascular AAA implantation will be included in analysis. Patients will be submitted to EVAR procedures on the basis of their own preferences, anatomical features, and operators experience.
89440006|NCT02141685||IVF patients undergoing aCGH Testing|Women undergoing fresh IVF treatment and array-comparative genomic hybridization testing (aCGH), as recommended based on medical need by the clinical site reproductive endocrinologist.
88924809|NCT04671082|Experimental|Tolperisone 200 mg|Tolperisone 200 mg
88924810|NCT04671082|Placebo Comparator|Placebo|Placebo
88924811|NCT04669587|Experimental|Part A: Dose Escalation of ZB716 monotherapy (with Food Effect Cohort)|Cohorts will follow a 3+3 study design. Approx. 3 to 6 subjects will be enrolled in each dose cohort (6 subjects in Cohort A6; food-effect evaluation). (Dose levels: 50, 100, 200, 300, 400 mg, orally QD in a 28 day cycle) The overall DLT observation period of ZB716 monotherapy will be 4 weeks following the initial dose of study drug on Cycle 1 Day 1. There will be 2 ~ 6 days between dose escalations to allow sufficient time for an adequate safety review. The max. dose may be lower than 400 mg. In the first dosing group of Part A (Cohort A1), subject dosing will be staggered such that administration of the first dose is separated by at least 7 days between the first 2 subjects. In each of Cohorts A1 to A5, 3 to 6 subjects will receive ZB716 doses according to the assigned dose level in the fasted state. For Cohort A6, Period 1, doses will be administered in the fasted state in Treatment Period 1 and 2, doses will be given 30 min. after starting a standard high fat breakfast.
88924812|NCT04669587|Experimental|Part B: Dose Expansion of ZB716 monotherapy|"Potential subjects will be screened to assess their eligibility to enter the study within 28 days prior to the first dose administration. Subjects will come to the clinical site before the first dose of study drug to confirm eligibility. Cohorts will be enrolled sequentially based on an optional Simon 2-stage study design.~Approx. 29 subjects may be enrolled in the dose expansion cohorts of Part B. For Part B, doses will be administered (self-administered by subjects at home or administered by subjects under observation of clinical staff during clinic visits) at the determined monotherapy RD of ZB716 (based on Part A) QD in a 28-day cycle. Doses will be administered in the dietary status for dosing as determined from Part A fed/fasted comparison."
88924813|NCT04669587|Experimental|Part C: Dose Escalation of ZB716 in combination with palbociclib|Cohorts will follow a 3+3 study design. Approx. 6 to 12 subjects will be enrolled in the dose escalation phase of ZB716 in combination with Palbociclib. For Part C, doses will be administered at escalating doses starting with 1 dose level below the monotherapy RD (determined in Part A) and Palbociclib will be dosed at the fixed standard dose of 125 mg QD. ZB716 will be administered on a 28 day cycle and Palbociclib will be administered for 21 days in the cycle with 7 days off treatment. Administration of the higher dose level (at monotherapy RD) of ZB716 (with the standard dose of Palbociclib) to subsequent subjects will be based on the occurrence of DLTs during the DLT observation period (Cycle 1), until MAD of ZB716 with combination of Palbociclib is reached. Doses will be administered in the dietary status for dosing as determined from Part A fed/fasted comparison.
88924814|NCT04669587|Experimental|Part D: Dose Expansion of ZB716 in combination with palbociclib|"Potential subjects will be screened to assess their eligibility to enter the study within 28 days prior to the first dose administration. Subjects will come to the clinical site before the first dose of study drug to confirm eligibility. Cohorts will be enrolled sequentially based on an optional Simon 2-stage study design.~Approx. 29 subjects may be enrolled in the dose expansion cohorts of Part D. For Part D, doses will be administered (self-administered by subjects at home or administered by subjects under observation of clinical staff during clinic visits) at the determined RD of ZB716 QD for 28 days from Part C in combination with the standard dose of Palbociclib (125 mg QD for 21 days with 7 days off treatment). Doses will be administered in the dietary status for dosing as determined from Part A fed/fasted comparison."
89199537|NCT05231980|Experimental|Pentoxifylline (PTX) group|30 patients
89199538|NCT05231980|Experimental|Alpha lipoic acid (ALA) group|30 patients
89199539|NCT05231980|Experimental|Combined PTX and ALA group|30 patients
89199540|NCT05231980|Active Comparator|control group|clomiphene
89199541|NCT05225467||Main group|All participants taking part in this study are subsequently categorized in this group
89199542|NCT05223166|Experimental|Pitolisant|Histamine H3 receptor H3R antagonist/ inverse agonist
89199543|NCT05223166|Placebo Comparator|Placebo|Placebo
89199544|NCT05205980|Experimental|Training group|This arm will receive a single-session perturbation training treatment on a treadmill under the protection of a safety harness.
89440007|NCT02254395|Experimental|Deep Brain Stimulation|Stimulation is on.
89440008|NCT02254395|Sham Comparator|Placebo|Sham Stimulation: Stimulation is off.
89440009|NCT02141763|Experimental|240/160/160 mg of UCB4940|240 mg loading dose + 160 mg maintenance dose every 3 weeks on 2 occasions (total 3 doses)
89440010|NCT02141763|Experimental|160/80/80 mg of UCB4940|160 mg loading dose + 80 mg maintenance dose every 3 weeks on 2 occasions (total 3 doses)
89440011|NCT02141763|Experimental|80/40/40 mg of UCB4940|80 mg loading dose + 40 mg maintenance dose every 3 weeks on 2 occasions (total 3 doses)
89440012|NCT02141763|Experimental|560/320/320 mg of UCB4940|560 mg loading dose + 320 mg maintenance dose every 3 weeks on 2 occasions (total 3 doses)
89440013|NCT02141763|Placebo Comparator|Placebo|0.9% sodium chloride aqueous solution (physiological saline, preservative free) of pharmacopoeia (USP/Ph.Eur) quality in a 10 mL glass vial
88924815|NCT04668092|Experimental|Functional dry needling|Functional dry needling for shortened hamstring muscle
89440014|NCT02295384||Audit Group|"Patients attending HHMP in Darlinghurst, Sydney, New South Wales with documented HIV-1 infection from 1st January 2005 to 31st July 2014, who were considered linked to care (Attendance during the study period for at least 2 visits >3 months and <12 months apart with measured laboratory virological or immunological markers (either on-site or at a co-management site))."
89440015|NCT02145195|Experimental|Vitamin D (10 microgram/day)|Tablets with 10 microgram vitamin D3 (cholecalciferol) daily for 20 weeks.
89440016|NCT02145195|Experimental|Vitamin D (20 microgram/day)|Tablets with 20 microgram vitamin D3 (cholecalciferol) daily for 20 weeks.
89440017|NCT02145195|Placebo Comparator|Placebo control|Tablets with 0 microgram vitamin D daily for 20 weeks.
89440018|NCT03517020|Experimental|Test|Torrent's Nebivolol Tablets 20 mg
89440019|NCT03517020|Active Comparator|Reference|Forest Pharmaceuticals Inc.'s Bystolic® Tablets 20 mg
89440020|NCT02145273|Experimental|Intervention|Subjects screen positive for depression and are offered a group Therapy intervention for depression: Interpersonal Psychotherapy for Depression Group.
89440021|NCT02145273|No Intervention|Control|Subjects screen positive for depression and are offered Treatment as usual: External referral.
89440022|NCT02145273|No Intervention|comparison|Subjects screen negative for depression: no referral or intervention.
88924816|NCT04661592|Experimental|Control|Neurologically healthy individuals will be recruited for the longitudinal study
88924817|NCT04659941|Experimental|BCG vaccine|0.1 ml of the reconstituted vaccine to be administered intradermally in the lower insertion of the deltoid muscle, preferably on the right side, in only one occasion
88924818|NCT04659941|Placebo Comparator|0.9% sodium chloride (NaCl) saline solution|0.1 ml of 0.9% NaCl saline solution to be administered intradermally in the lower insertion of the deltoid muscle, preferably on the right side, in only one occasion
89440023|NCT02295462|Experimental|Person-centered Care|Medication Review + Person-centered Care
88924819|NCT04658953|Experimental|Ultrasound-guided infiltration|The patient is positioned in the prone position with a block under his stomach. After disinfection of the lumbosacral region with alcoholic chlorhexidine 0.5%, the investigators position the convex probe of the ultrasound machine in the transverse plane. Once the spine has been located, the investigators look for the spinous processes of the lower lumbar vertebrae L4 and L5 with the mark on the cranial side and the side opposite the mark on the side of the sacrum. The latter is visualized as a continuous hyperechoic line. Then, the probe is tilted 90 ° to be in a transverse plane. A 22G needle is introduced in a transverse axis starting from the laterality by inserting it in the direction of the median bone contacts of the lower lumbar vertebrae L3, L4 and L5. An infiltration will be unilaterally performed at three levels (L3-L4, L4-L5 and L5-S1 levels).
88924820|NCT04658953|Experimental|Fluoroscopy-guided infiltration|"The patient is positioned in the prone position with a block under his stomach. The lumbosacral region is disinfected with alcoholic chlorhexidine 0.5%.~The C-shaped arm of a X-ray fluoroscopy is positioned around the patient in an antero-posterior view tilted ¾ in order to free the classic view called scotty dogs . The puncture point is determined by the positioning of the needle in so-called tunnel vision. The needle is thus brought to the bone contact corresponding to the eye of the scotty dog in tunnel vision, an area corresponding to the passage of the lumbar median branch. An infiltration will be unilaterally performed at three levels (L3-L4, L4-L5 and L5-S1 levels)."
88924821|NCT04658823|Experimental|HOV-12020|Palm tocotrienols complex Oral softgel capsule (containing 285mg mixed tocotrienols and tocopherol)
88924822|NCT04658823|Placebo Comparator|PLACEBO|Placebo Oral Softgel capsule (each capsule containing vitamin E stripped soybean oil)
89199545|NCT05205980|Sham Comparator|Control group|This arm will not receive perturbation training but will go through harnessed walking on the same treadmill for the same time as the other group.
89440024|NCT02295462|Active Comparator|Optimised Treatment|Medication Review
89440025|NCT02254629|Experimental|laxative-probiotic sequential|laxative：2000 ml. Probiotic：2 tablets/ times, 3 times / day for the first 2 weeks，immediately after colonoscopy
89440026|NCT02254629|Active Comparator|probiotic|Probiotic：2 tablets/ times, 3 times / day for the first 2 weeks.
89440027|NCT02254629|Active Comparator|Laxative followed by Probiotic 2 weeks later|laxative：2000 ml. Probiotic：2 tablets/ times, 3 times / day for the last 2 weeks with two weeks interval after colonoscopy.
89440028|NCT02145585||Robotic pharmacological system|Robotic pharmacological system/Automated anesthesia delivery system
89440029|NCT02291796|Experimental|Bezafibrate group|Patients with acute coronary syndrome with ST elevation and fibrinogen receiving a dose of 400 mg every 24 hours of Bezafibrate in addition to conventional anti-ischemic treatment
89440030|NCT02291796|No Intervention|Control group|Patients with acute coronary syndrome with ST elevation and hyperfibrinogenemia who received only conventional anti-ischemic treatment
89440031|NCT03544827|Experimental|Atropine 0.01% then atropine 0.1%|Participants will be on topical atropine 0.01% ophthalmic solution QD OU for 1 week (7 days) and then topical atropine 0.1% ophthalmic solution QD OU for 1 week (7 days) with a washout period of 4 weeks in between each intervention
89440032|NCT03544827|Experimental|Atropine 0.1% then atropine 0.01%|Participants will be on topical atropine 0.1% ophthalmic solution QD OU for 1 week (7 days) and then topical atropine 0.01% ophthalmic solution QD OU for 1 week (7 days) with a washout period of 4 weeks in between each intervention
89502044|NCT05495672|No Intervention|Cohort 1-Arm B: the largest pulmonary nodule is less than or equal to 1 cm, ctDNA negative|Subjects with ctDNA negative will undergo routine follow-up. ctDNA will be detected every three months until progression or 2 years.
89440033|NCT02295618|Experimental|ETI with chest compressions|endotracheal intubation (ETI) during child mannikin resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
89199546|NCT05202938||Septic shock with SIMD: SIMD+|8 patients in septic shock (Sepsis-3-) with SIMD: ejection fraction (LVEF) < 45% in the first 48 hours of admission into the intensive care unit. No prior cardiac ultrasound or normal cardiac ultrasound values less than 2 years ago , or an ino-vasotropic infusion (milrinone, dobutamine, norepinephrine or epinephrine) required to obtain a LVEF ≥ 45%, or a drop of ≥ 20% compared to the LVEF value record ed less than 2 years ago.
89440034|NCT02295618|Experimental|ETI without chest compressions|Endotracheal intubation of child mannikin during resuscitation without chest compressions.
89440035|NCT00107991|Experimental|Treatment arm|Open-label treatment with etanercept 50 mg/week subcutaneous injection
89440036|NCT02299674||Persons with unilateral transfemoral amputation|
89440037|NCT03513276|Experimental|Multimodal analgesia + Local Infiltration Anesthesia|100cc of 2% ropivacaine + Adrenaline 10mcg/ml + 20cc saline solution
89440038|NCT03513276|Active Comparator|Multimodal analgesia + saline solution|120cc of saline solution
89440039|NCT02299752|Experimental|Catheterization|Blood vessel Catheterization during resuscitation with single and double - gloving system. Catheterization was performed using simulation mannikin
89440040|NCT02291874|Experimental|Ipragliflozin group|Ipragliflozin treatment
89440041|NCT02145819|Placebo Comparator|A: spontaneous LH peak|In group A, embryos are thawed 4 days after LH surge, with a re-evaluation and transfer 5 days after LH surge.
89440042|NCT02145819|Active Comparator|B: hCG|In group B, embryos are thawed 5 days after hCG administration, with a re-evaluation and transfer 6 days after hCG.
89440043|NCT02299830|Experimental|cryotherapy|give the cases whose central airway stricture were caused by soft neoplasm tissues cryotherapy
89440044|NCT02299830|Experimental|argon plasma coagulation|give the cases whose central airway stricture were caused by hard neoplasm tissues argon plasma coagulation
89440045|NCT02299830|Experimental|stent|give the cases whose central airway stricture were caused by neoplasm compression stent placement
89440046|NCT02299830|Experimental|snare|give the cases whose central airway stricture were caused by polypoid neoplasm tissues snare
89440047|NCT02291952|Experimental|Experimental|During Forced Desynchrony sleep and wake will occur at different circadian phases, while meals are restricted to the biological day.
89440048|NCT02291952|Other|Control|During Forced Desynchrony sleep and wake, as well as meals, will occur at different circadian phases.
89440049|NCT02145897|Experimental|Autologous Stromal Vascular Fraction|single dose of autologous adipose derived Stromal Vascular Fraction (SVF) SVF divided in two fraction and infused intravenously and intramuscularly
89440050|NCT02145897|Experimental|Autologous Adipose Derived MSCs|One dose of 1 million per kg body weight adipose tissue derived Ex-vivo expanded Mesenchymal stem cells (MSC) intravenously and one dose of 1 million per kg body weight adipose tissue derived Ex-vivo expanded Mesenchymal stem cells (MSC) intramuscularly
89440051|NCT02145897|Active Comparator|Control|
89440052|NCT03516630|Experimental|TRZ 20|Product is administered as single dose in the morning, under fasting conditions. 10 drops for the dose of 20 mg is suspended in 120 mL of still mineral water. A wash-out interval of at least 7 days is required before the administration of the other doses foreseen in the study.
89440053|NCT03516630|Experimental|TRZ 60|Product is administered as single dose in the morning, under fasting conditions. 30 drops for the dose of 60 mg is suspended in 120 mL of still mineral water. A wash-out interval of at least 7 days is required before the administration of the other doses foreseen in the study.
89440054|NCT03516630|Experimental|TRZ 140|Product is administered as single dose in the morning, under fasting conditions. 70 drops for the dose of 140 mg is suspended in 120 mL of still mineral water. A wash-out interval of at least 7 days is required before the administration of the other doses foreseen in the study.
89440055|NCT03516630|Placebo Comparator|Placebo|Product is administered as single dose in the morning, under fasting conditions. Trazodone-matching placebo corresponding to 70 drops is suspended in 120 mL of still mineral water. A wash-out interval of at least 7 days is required before the administration of the other doses foreseen in the study.
89440056|NCT03516630|Active Comparator|Moxifloxacin|Product is administered as single dose in the morning, under fasting conditions. One 400 mg tablet is swallowed (without chewing) with 240 mL of still mineral water. A wash-out interval of at least 7 days is required before the administration of the other doses foreseen in the study.
89440057|NCT02142075|Experimental|Daptomycin, IV|"Patients with creatinine clearance ≥30 ml/min will receive 10 mg/kg of daptomycin (Cubicin®) once daily,~Patients with creatinine clearance <30 ml/min will receive the same daptomycin dose (10 mg/kg) but less frequently, every 48h instead of every day"
89440058|NCT03544749|Experimental|Ambu® AuraGain™ group|
89440059|NCT03544749|Active Comparator|I-gel group|
89199547|NCT05202938||Septic shock without SIMD: SIMD-|8 patients in septic shock (Sepsis-3) without SIMD. Ejection fraction (LVEF) ≥ 45% with or without ino-vasotropic infusion (milrinone, dobutamine, norepinephrine or epinephrine), or similar to the LVEF recorded less than 2 years ago.
89440060|NCT02292030||cardioversion+HTEA|Heart failure patients accompanied by atrial fibrillation receive the treatment of cardioversion+HTEA.
89199548|NCT05202938||Acute Heart Failure with reduced Ejection Fraction: HFrEF|8 patients with acutely reduced ejection fraction (LVEF) < 50%. with or without ino-vasotropic infusion (milrinone, dobutamine, norepinephrine or epinephrine) No prior cardiac ultrasound, or normal cardiac ultrasound values less than 2 years ago, or a drop of ≥ 20% compared to the LVEF recorded less than 2 years ago. No evidence of sepsis or septic shock.
89440061|NCT02292030||only cardioversion|Heart failure patients accompanied by atrial fibrillation receive the treatment of cardioversion, but not with HTEA.
89538451|NCT03266159|Experimental|Part 1: Subjects receiving GSK525762 + trametinib|Eligible subjects will receive doses of GSK525762 with a starting dose of 40 milligrams (mg), or 60 mg in combination with trametinib with a starting dose of 1 mg or 1.5 mg or 2 mg, administered orally once daily. Dose escalation will continue until the maximally-tolerated dose combination (MTC) is reached. Once the MTC is reached, subjects will be enrolled in expansion cohort and will receive a fixed dose combination.
89440062|NCT02145975|Experimental|Fentanyl|"Procedure: Fentanyl for rescue of acute postoperative pain in the postanesthesia care unit~Intervention:~The nurse will administer 1 ug per kg during 5 seconds when the patient complain of pain (visual analog scale, VAS, ≥7). Immediately with the onset of drug administration a timer started; every 5 minutes the researcher assess the EVA and the drug will be administered if VAS > 3, until the patient manifests as a lower pain VAS ≤ 3 (mild). The nurse in charge in the PACU will manage the drug and will take 100 ug of fentanyl which is diluted in 10 mL of normal saline leaving a 10μg per ml concentration, are not labeled and for the physical and chemical characteristics of both drugs (colorless) risks of unblinded is minimized."
89538452|NCT03266159|Experimental|Part 2: Subjects with SCLC receiving GSK525762+ trametinib|Eligible subjects with small cell lung cancer (SCLC) will receive their Part 2 dose as the dose combination of GSK525762 with trametinib selected at the end of Part 1.
89012357|NCT04823221||Rezūm system|The basic principle of the Rezūm System is to deliver a controlled amount of sterile water vapor directly into the hyperplastic tissue in the transition zone of the prostate using a transurethral approach .The stored thermal energy in the vapor is transferred directly onto the cell membranes as the vapor condenses and releases the heat of condensation, causing cell death. Inaddition, this thermal energy transfer collapses the vasculature within the treatment zone, resulting in a bloodless procedure. During procedure the water vapor is created by a heating element in the Rezūm Delivery Device,Saline flush during vapor delivery protects and preserves the urethra.
89012358|NCT01600027|Placebo Comparator|Group B|received 1 ml/kg bupivacaine 0.25%.
89012359|NCT01600027|Active Comparator|group BD|received 1 ml/kg bupivacaine 0.25% with dexmedetomidine 2 μg/kg
89012360|NCT03147508||Neck pain patients|
89012361|NCT02699086|Experimental|Low dose + Low dose|1 PDC-1421 Capsule, trice daily, p.o. after meal for 28 + 28 days
89538453|NCT03266159|Experimental|Part 2: Subjects with RMCRC receiving GSK525762+ trametini|Eligible subjects with Ras-mutated colorectal cancer (RMCRC) will receive their Part 2 dose as the dose combination of GSK525762 with trametinib selected at the end of Part 1.
89012362|NCT02699086|Experimental|Low dose + High dose|1 PDC-1421 Capsule for 28 days + 2 PDC-1421 Capsules for 28 days, trice daily, p.o. after meals
89012363|NCT01805284|Experimental|Linezolid|
89012364|NCT01337128|Experimental|Carotid endarterectomy (CEA)|Patients with carotid stenosis who are randomly assigned to a carotid endarterectomy.
89012365|NCT01337128|Experimental|Carotid Stenting (CAS)|Patients with carotid stenosis who are randomly assigned to a carotid stenting.
89012366|NCT01337128|No Intervention|matched control group|Matched control group.
89012367|NCT04719884|No Intervention|Control group|Standard perioperative anesthesia management
89502045|NCT05495672|Experimental|Cohort 2-Arm C: the largest pulmonary nodule is between 1 cm to 2 cm, ctDNA positive|"ctDNA is detected before curative treatment. Subjects with ctDNA positive before treatment will receive curative treatments for pulmonary nodules such as surgery, radio frequency ablation or stereotactic body radiotherapy.~ctDNA is rechecked following treatment. Subjects with ctDNA positive after treatment will receive chemotherapy. Subjects with ctDNA negative after curative treatment will undergo routine follow-up.~After treatment, ctDNA will be detected every three months until progression or 2 years. At the same time, routine post treatment follow-up will be performed."
88924823|NCT04657380|Active Comparator|Usual case management practices|The first-episode psychosis services participating in the study offer case-management, which will correspond to the treatment as usual in the control group. All the centers are part of the National Transition Network (https://idpsy.org/reseau-transition/centres/). Involvement in this network ensures homogeneity of the usual practices which correspond to the internationally standards. Care delivery is based on intensive treatment during the critical period of psychosis, relying on a wide network of caring and non-caregiving professionals, working together with a view to the successful recovery of the patient. The patient and his or her family are at the center of care and receive proposals for psychoeducation and support throughout the different phases of the illness. This is concomitant with a regular evaluation of patients in order to update the care offer according to their clinical needs.
88924824|NCT04657380|Experimental|Mobile case-management application|"The intervention tested will be a mobile application used during consultations involving the patient and the case manager to define care objectives. The mobile application to be evaluated will result from the process of a co-design phase based on the iterative user-centered design approach, involving representatives of carers, patients and caregivers. These stakeholders will define the content and form of the smartphone application during co-building workshops.~The main purpose of the final application will be to assist in the definition of patients' goals using an approach rooted in recovery theory, with the monitoring of goal achievement in three phases : 1) defining priorities for the patients, through a recovery oriented discussion with the patient and the case manager 2) Setting the concrete objectives and list concrete actions tho achieve them 3) evaluating the achievements."
88924825|NCT04655885|Experimental|Optimization of cardiac flow by base water-electrolyte supply|Optimization of cardiac flow by base water-electrolyte supply of 1 ml / kg / h by Ringer Lactate® and faced with any decrease of more than 10% of the VES compared to the reference VES, achievement of an optimization of the preload by administration of 250 ml of Ringer Lactate® with renewal until correction of the VES.
88924826|NCT04655885|Other|Control arm|Increase basic hydro-electrolyte supply of 6 ml / kg / h by Ringer Lactate® and 1: 1 blood loss compensation by crystalloids of the same nature.
88924827|NCT04649515|Experimental|TY027 1,500 mg|1,500 mg of TY027 will be administered via IV infusion over a period of 30 minutes.
88924828|NCT04649515|Experimental|TY027 2,000 mg|2,000 mg of TY027 will be administered via IV infusion over a period of 30 minutes.
88924829|NCT04649515|Placebo Comparator|Placebo|Placebo will be administered via IV infusion over a period of 30 minutes.
88924830|NCT04640818||CLAD-GROUP|Patients with cladribine therapy
88924831|NCT04640818||CD20-GROUP|Patients with anti CD20 therapy (ocrelizumab or rituximab)
88924832|NCT04635449|Active Comparator|Intervention|age-specific information, complemented by a follow-up targeted telephone call
88924833|NCT04635449|No Intervention|Treatment as usual|usual information given at PICU discharge
88924834|NCT04625777|No Intervention|Waitlist control|In this waitlist control condition, participants will not receive any programming intervention. They will know that they have access to stress reduction programming after a certain date. They will also provide survey data at 3 time points and heart rate variability data at 2 time points while waiting. The survey questions will include a wide variety of stress items.
88924835|NCT04625777|Experimental|One of three stress reduction interventions|There are three stress reduction interventions: Mindfulness Based Stress Reduction, Daily Examen, and stress inoculation.
88924836|NCT04624087|Experimental|High Dose|Participants will perform the food-specific computerized go/no-go training four times per week for 4 weeks.
88924837|NCT04624087|Experimental|Low Dose|Participants will perform the food-specific computerized go/no-go training one time per week for 4 weeks.
89440063|NCT02145975|Active Comparator|Morphine|"Procedure: Morphine for rescue of acute postoperative pain in the postanesthesia care unit~Intervention:~The nurse will administer 0,1 mg per kg during 5 seconds when the patient complain of pain (visual analog scale, VAS, ≥7). Immediately with the onset of drug administration a timer started; every 5 minutes the researcher assess the EVA and the drug will be administered if VAS > 3, until the patient manifests as a lower pain VAS ≤ 3 (mild). The nurse in charge in the PACU will manage the drug and will take 10 mg of morphine which is diluted in 10 mL of normal saline leaving a 1 mg per ml concentration, are not labeled and for the physical and chemical characteristics of both drugs (colorless) risks of unblinded is minimized."
88924838|NCT04624087|Active Comparator|Active Control|Participants will perform the generalized, nonfood-specific computerized go/no-go training one time per week for 4 weeks.
88924839|NCT04622332|Experimental|SIR1-365|SIR1-365 dose 1 daily for 14 days
88924840|NCT04622332|Placebo Comparator|Matching placebo|Matching placebo dose 1 daily for 14 days
88924841|NCT04616027|Experimental|Healthy participants with normal renal function|This arm includes participants with normal renal function who will receive an oral dose of PF-06882961 20 milligrams (mg) on Day 1
88924842|NCT04616027|Experimental|Participants with T2DM with normal renal function|This arm includes participants with Type 2 Diabetes Mellitus (T2DM) with normal renal function who will receive an oral dose of PF-06882961 20 mg on Day 1
88924843|NCT04616027|Experimental|Participants with T2DM with mild renal impairment|This arm includes participants with Type 2 Diabetes Mellitus (T2DM) with mild renal impairment who will receive an oral dose of PF-06882961 20 mg on Day 1
88924844|NCT04616027|Experimental|Participants with T2DM with moderate renal impairment|This arm includes participants with Type 2 Diabetes Mellitus (T2DM) with moderate renal impairment who will receive an oral dose of PF-06882961 20 mg on Day 1
89440064|NCT02295696|Experimental|Intervention group|Intervention arm : EMMA consultations
88924845|NCT04616027|Experimental|Participants with T2DM with severe renal impairment|This arm includes participants with Type 2 Diabetes Mellitus (T2DM) with severe renal impairment who will receive an oral dose of PF-06882961 20 mg on Day 1
88924846|NCT04614506||Subject with DS|Participants will complete two visits spaced out by 4 - 8 weeks to undergo neurophysiological assessments (Electroencephalogram [EEG], and Transcranial magnetic stimulation [TMS]).
88924847|NCT04611100|No Intervention|Conventional|Patient receive endoscopic placement of metallic biliary stent for obstructive jaundice
88924848|NCT04611100|Experimental|Radiofrequency ablation|Patient receive endoscopic intraductal radiofrequency ablation before placement of biliary stent for obstructive jaundice
88924849|NCT04609657|Placebo Comparator|Control beverage for Habitual full-calorie CSD cohort, n=28|Full sweetness (sugar) for 6 months
88924850|NCT04609657|Placebo Comparator|Control beverage for Habitual low-calorie CSD cohort, n=28|Full sweetness low calorie sweetener (LCS) with sweetness level matched to the full sweetness sugar control for 6 months
88924851|NCT04609657|Active Comparator|Test beverage 1 for Habitual full-calorie CSD cohort, n=28|Reduced sweetness (moderate sugar level) for 6 months
89440065|NCT02295696|No Intervention|Control group|Control arm: Usual care/consultations
89440066|NCT02146053|Active Comparator|Ferrous sulfate|ferrous sulfate taken at mealtimes twice daily during 1 week of the treatment period.
89440067|NCT02146053|Placebo Comparator|Placebo|placebo taken at mealtimes twice daily during 1 week of the treatment period.
89440068|NCT02295852|Experimental|Group A: LOW-SODIUM LOW LIPID CALCIUM RICH DIET|Experimental Group A: patients will change their diet in a diet similar for total daily calories, sodium and macronutrients but enriched in calcium (1200 mg/daily) and will be followed up to 1 year with an intermediate control after the first 3 months;
89440069|NCT02295852|Active Comparator|Group B: LOW-SODIUM LOW LIPID DIET|Experimental Group B: patients will continue the low-lipid, low-sodium diet up to 1 year with an intermediate control after the first 3 months.
88924852|NCT04609657|Active Comparator|Test beverage 1 for Habitual low-calorie CSD cohort, n=28|Reduced sweetness low calorie sweetener (LCS) with sweetness level matched to the moderate sugar sweetness level for 6 months
88924853|NCT04609657|Active Comparator|Test beverage 2 for Habitual full-calorie CSD cohort, n=28|Step-wise sweetness reduction over 6 months. Month 1 is the full sweetness sugar control, followed by monthly sweetness reduction. Remains at the reduced sweetness level (moderate sugar level) from months 4-6.
88924854|NCT04609657|Active Comparator|Test beverage 2 for Habitual low-calorie CSD cohort, n=28|Step-wise sweetness reduction over 6 months. Month 1 is the low calorie sweetener (LCS) sweetness equivalent of the full sweetness sugar control, followed by monthly LCS sweetness reduction (reductions equivalent to the corresponding sugar reduction arm sweetness levels). Remains at the reduced sweetness level (LCS equivalent of moderate sugar sweetness level) from months 4-6.
88924855|NCT04608916|Active Comparator|Scalpel incision group|This group of patients will receive skin incision made with use of a scalpel blade.
88924856|NCT04608916|Experimental|Electrocautery incision group|This group of patients will receive skin incision made with use of electrocautery.
88924857|NCT04607876|Active Comparator|Standard of Care|The FAR Control Arm will involve risk factor assessment in first degree relative subjects and implementation of an education program for the randomized participants and their primary care provider.
88924858|NCT04607876|Other|Enhanced Intervention|"This intervention will involve risk factor assessment and web based risk factor management.~Technological facilitators including a population health care management portal which will be used to facilitate risk factor management to monitor risk factor control, and to facilitate new symptom and complications management;~Telemedicine to allow FAR Coordinator and providers capability for evaluation and management in home/facility, which facilitates real time communication and collaboration and virtual evaluation of the subject when higher level of intervention is required~Educational portal provides a common educational platform for professional and subject education around stroke symptoms, complications, recovery and risk factor management, and lifestyle changes.~FAR EI teams will be coordinated at FAR Central where a centralized group of specialists initiate and monitor risk factor mitigation strategies tailored to the individual participant."
88924859|NCT04606784|Experimental|Ampion|Ampion
88924860|NCT04606784|Other|Standard of Care|Standard of Care
89440070|NCT02295930|Experimental|folfoxiri+cetuximab+surgery+cetuximab|"Induction FOLFOXIRI plus cetuximab will consist of:~CETUXIMAB 500 mg/sqm IV over 1-h* , day 1 followed by~IRINOTECAN 130 mg/sqm IV over 1-h, day 1 followed by~OXALIPLATIN 85 mg/sqm IV over 2-h, day 1 concomitantly with~l-LV 200 mg/sqm IV over 2-h, day 1 followed by~5-FLUOROURACIL 2400 mg/sqm IV 48-h continuous infusion, starting on day 1 repeated every 2 weeks for 8 cycles.~Surgical revaluation will be performed after the induction phase (8 cycles).~Patients deemed unsuitable for surgery will received maintenance treatment as follows:~•CETUXIMAB 500 mg/sqm IV over 60-min, day 1 repeated every 2 weeks until PD, patient's refusal, unacceptable toxicity or consent withdrawal."
89440071|NCT02295930|Experimental|folfoxiri+cetuximab+surgery+bevacizumab|"Induction FOLFOXIRI plus cetuximab will consist of:~CETUXIMAB 500 mg/sqm IV over 1-h* , day 1 followed by~IRINOTECAN 130 mg/sqm IV over 1-h, day 1 followed by~OXALIPLATIN 85 mg/sqm IV over 2-h, day 1 concomitantly with~l-LV 200 mg/sqm IV over 2-h, day 1 followed by~5-FLUOROURACIL 2400 mg/sqm IV 48-h continuous infusion, starting on day 1 repeated every 2 weeks for 8 cycles.~Surgical revaluation will be performed after the induction phase (8 cycles).~Patients deemed unsuitable for surgery will received maintenance treatment as follows:~•BEVACIZUMAB 5 mg/kg IV over 30-min, day 1 repeated every 2 weeks until PD, patient's refusal, unacceptable toxicity or consent withdrawal."
89440072|NCT02142231|Placebo Comparator|Laser Acupuncture|Subjects and Therapists are blinded. Instead of a real Laser Acupuncture device (able to elicit physiologic responses) them is given a sham-laser device only radiating non-energetic red LED-light. Without palpation, therapists treat the acupoint Heart 7, on both wrists, each for 1 minute, with additional 18 minutes of resting time after.
89537019|NCT05727995|Experimental|Experimental group|The dressing is a polyurethane film with acrylic adhesive that adheres the dressing to the skin surrounding the incision and a polyurethane shell that encapsulates the foam bolster and interface layer, providing a closed system. The PICO pump maintains negative pressure wound therapy (NPWT) at 80mmHg (nominal) +/- 20mmHg to the wound surface. Exudate is managed by the dressing through a combination of absorption and evaporation of moisture through the outer film. PICO is intended for use in wound sizes (surface area x depth) up to 400 cm3, which are considered to be low to moderately exuding. The kit is intended to be used for 7 days on low-exuding wounds and 6 days on moderately exuding wounds. The therapy duration of the kit may be less than indicated if a clinical practice or other factors, such as wound type, wound size, rate or volume of exudate, orientation of the dressing or environmental conditions, result in more frequent dressing changes.
89537020|NCT05727995|Sham Comparator|Control group|Patients in the control arm will receive a usual care dressing using absorbent cotton pads placed in contact with the wound. Dressings will be applied directly to the wound surface to protect the wound surface environment and the wound bed. Dressing chances are scheduled every 48h.
89537021|NCT02467907|Experimental|Bevacizumab in Combination with Carboplatin and Paclitaxel|Administration of bevacizumab, carboplatin and paclitaxel once every 3 weeks, for at least 6 cycles, until disease progression (as assessed by the investigator), unacceptable toxicity, physician or participant decision or withdrawal of consent. If either chemotherapy or bevacizumab is discontinued, the participant may continue to receive the other ongoing therapy.
89537022|NCT02467283||Patients with Chronic Periodontitis|"All subjects were free of systemic diseases and to be included, individuals had to be older than 18 years of age.~Chronic periodontitis was diagnosed according to American Academy of Periodontology 1999 Consensus Report."
89537023|NCT02467283||Control Patients|"Control subjects had no radiographic evidence of bone loss or any sign of past and present periodontitis.~All subjects were free of systemic diseases and to be included, individuals had to be older than 18 years of age."
89537024|NCT02467127|No Intervention|control group|Patients without headache. No drugs will be administered
89537025|NCT02467127|Experimental|Chronic Headache|Patients with headache > 6 months. Vitamin D supplementation (from 400 iU/day up to 1600 IU/day) will be administered.
89012368|NCT04719884|Active Comparator|Study group|Perioperative extended haemodynamic monitoring of fluid loading, cardiac output and changes of peripheral vascular resistance by analysing the arterial curve was provided by non-invasive haemodynamic monitoring (LIDCO Rapid, Lidco Ltd., United Kingdom).In SG fluid optimisation was performed before pneumoperitoneum and after abdominal desuflation with actions to achieved CI, MAP and SI within 80% of baseline values.
89440073|NCT02142231|Active Comparator|Acupuncture|Acupuncture at the acupoint Heart 7, on both wrists, each for 1 minute, eliciting a deqi-response, additional stimulation and total needle-in time of 20 minutes (2 minutes treatment and 18 minutes of resting time)
89440074|NCT03516552||Hemoglobin content on blood loss|Hemoglobin content on blood loss, to assess ratio hemoglobin/volume.
89440075|NCT02142309|Experimental|Glimepiride|up to 4 mg/day
89440076|NCT02142309|Experimental|Vildagliptin|50 mg bid
89440077|NCT02142309|Experimental|Pioglitazone|up to 30 mg/day
88924861|NCT04606160|Experimental|Single Session Problem-Solving Intervention|Participants will receive a single session problem-solving intervention during visit 2 of the 4 visit research study. During visit 3, participants will receive a review of the intervention from visit 2. During visits 1, 3, and 4, participants will complete measures.
88924862|NCT04606160|No Intervention|Control - Non Single Session Problem-Solving Intervention|These participants will complete measures at visits 1,2,3, and 4. They will also receive a visit during visit 2 of the 4 visit study, where they will only complete measures.
88924863|NCT04603690|Experimental|Complementary therapy group|This arm will receive a daily supplementation of 168 mg curcumin, 260 mg quercetin and 9 mcg/360 IU of vitamin D3 (cholecalciferol) as add-on to the standard of care for 14-days
88924864|NCT04603690|Active Comparator|Control group|This arm will receive standard care alone
88924865|NCT04598360|Experimental|Experimental: Erythrocyte Fatty-Acid Status|Erythrocyte Fatty-Acid Status Profiling of cardiac surgery patients are studied before and during heart-lung-machine procedure using LC-MS / MS
88924866|NCT04590651|Experimental|Standard PHACO cataract surgery|In this group normal phacoemulsification cataract surgery will be preformed.
89440078|NCT02142309|Experimental|Canagliflozin|300 mg/day
89440079|NCT03516474||St. Michael's Hospital|"St. Michael's Hospital is an Acute care centre for the diabetic lower extremity.~n=100"
89440080|NCT03516474||South Riverdale Community Health Centre|South Riverdale is a Community Health Centre focused on prevention. n=100
89440081|NCT03516474||Westpark|Westpark is a rehabilitation site focused on post-operative/amputation care and preservation of the opposite limb. n=100
89440082|NCT03516474||Women's College Hospital|Women's College Hospital is an outpatient wound clinic focused on the management of DFUs. n=100
89440083|NCT02146209|Experimental|Test Product Formula A|Metronidazole benzoate
89440084|NCT02146209|Active Comparator|Reference Product Formula B|Flagyl 125 mg/5 ml oral suspension
89440085|NCT02146209|Active Comparator|Reference Product Formula C|Flagyl 400 mg Tablets
89440086|NCT02299908|Experimental|TAP block with Bupivacaine at 0.25%|Intervention: Injection of local anesthetics in the transverses abdominal plane
89440087|NCT02299908|Placebo Comparator|Placebo saline solution|Placebo: Injection of saline solution in the transverses abdominal plane
89440088|NCT02142543|Placebo Comparator|placebo|placebo powder containing zinc oxide, karaya gum, and yellow dye, which was added to imitate the color of the original powder, applied twice a day until the ulcer had resolved, an expected average of 3-5 days
89440089|NCT02142543|Experimental|2-DeNT powder|2-DeNT powder containing dexamethasone, diphenhydramine, tetracycline, metronidazole, nystatin, zinc oxide, and karaya gum, applied twice a day until the ulcer had resolved, applied twice a day until the ulcer had resolved, in an expected average of 3 to 5 days
89440090|NCT02299986||Single arm Ultrasound measurement|Ultrasound measurement
89440091|NCT02142621|Active Comparator|transpyloric tube feeds|Continuous transpyloric tube feeds administered through an oral/nasal feeding tube.
88924867|NCT04590651|Experimental|PHACO + extra aspiration|In this group an extra one minute anterior chamber angle aspiration will be preformed at the end of a standard cataract operation.
88924868|NCT04588857|Experimental|Active drug|dexamethasone 24 mg i.v., single dose
88924869|NCT04588857|Placebo Comparator|Placebo|saline i.v., single dose
88924870|NCT04580212|Experimental|Intervention arm|This arm received the poultry hygiene intervention.
88924871|NCT04580212|No Intervention|Control arm|This arm received no intervention.
88924876|NCT04569448|Experimental|Patient|Individuals diagnosed with Bipolar Disorder Type I or Type II and suffering a major depressive episode who will receive an adjunctive and variable dose of Brexpiprazole treatment
88924877|NCT04568733|No Intervention|Resting|
88924878|NCT04568733|Experimental|Pilates exercise session|
88924879|NCT04568733|Active Comparator|Treadmill walking at 3.2 kph|
88924880|NCT04568733|Active Comparator|Treadmill walking at 4.8 kph|
89440092|NCT02142621|Active Comparator|gastric tube feeds|Continuous gastric tube feeds administered through an oral/nasal feeding tube.
89440093|NCT03120806|Active Comparator|continous subcuticular|skin closed with continous subcuticular mattress suture using non-absorbable polypropylene
89440094|NCT03120806|Active Comparator|Interrupted subcuticular|skin closed with interrupted subcuticular mattress suture using non-absorbable polypropylene
89440095|NCT02142699|Active Comparator|Heme arginate 1mg/kg|"This is the lower of the 2 doses of Heme arginate (HA). This will be given as a single dose of 1mg/kg on the first study visit.~This is given over 1 hour intravenously."
89440096|NCT02142699|Active Comparator|Heme arginate 3mg/kg|"This is the larger dose, Heme arginate 3mg/kg (up to a maximum dose of 250mg)~This will be given intravenously, as a single dose on the first study visit, over one hour."
89502046|NCT05495672|No Intervention|Cohort 2-Arm D: the largest pulmonary nodule is between 1 cm to 2 cm, ctDNA negative|Subjects with ctDNA negative will undergo routine follow-up. ctDNA will be detected every three months until progression or 2 years.
89440097|NCT03390452|Experimental|Intervention|"The parents will receive Mobile phone messages about oral hygiene and healthy dieting of their children through teachers.~The message format will be text and images, depending upon the education/ literacy level of the parents. Parents will be reminded and information reinforced, at frequent intervals for a period of six months.~Oral hygiene of School children will be assessed before intervention, after 6 months interval"
89440098|NCT03390452|No Intervention|Control|The primary school children in the control group will not receive any intervention via their parents or teachers (in-active controls) but will be observed on selected outcome measures for baseline data, then at six month interval to compare for differences (if any) with intervention group.
89440099|NCT03390374|Experimental|Nystatin group|Nystatin oral 1 mL (0.5 mL coated in oral cavity and the rest was given through orogastric tube) three times a day
89440100|NCT03390374|No Intervention|Control group|Sterile water 1 mL three times a day for oral hygiene
89440101|NCT03545373|Experimental|Azithromycin|Azithromycin 500mg, oral, once daily for 3 days commencing on randomization day.
89440102|NCT03545373|Experimental|Amoxicillin|Amoxicillin 1g, oral, 3 times daily for 5 days commencing on randomization day.
89440103|NCT03545373|No Intervention|Standard of care|The standard of care in current national guidelines for patients presenting with cough and without danger signs (No treatment, re-evaluate with sputum results)
89440104|NCT00492856|Experimental|Post-consolidation therapy arm I|Patients receive oral tretinoin twice daily on days 1-7, oral mercaptopurine once daily on days 1-14, and oral methotrexate on day 1. Treatment repeats every 2 weeks for up to 1 year.
89440105|NCT00492856|No Intervention|Post-consolidation therapy arm II|Patients receive no further chemotherapy. Patients are followed every 3 months for 1 year. (Randomization and observation arm closed as of 8/15/10)
89440106|NCT02146287|Active Comparator|Early Cycled Light|Infants received day night cycling of light on a 12-hour on and 12-hour off basis beginning at 28 weeks PMA
89440107|NCT02146287|Active Comparator|Late Cycled Light|Infants received day night cycling of light on a 12-hour on and 12-hour off basis beginning at 36 weeks PMA
89440108|NCT05152550||Group A|Cases diagnosed as Non-severe pre-eclampsia after exclusion of severity features
89440109|NCT03545295|Experimental|QLB 2 10ml|The cadaver will receive an ultrasound- guided Quadratus Lumborum Block type 2 with 10 ml coloring solution
89440110|NCT03545295|Experimental|QLB 2 20ml|The cadaver will receive an ultrasound- guided Quadratus Lumborum Block type 2 with 20 ml coloring solution
89440111|NCT03545295|Experimental|QLB 2 30ml|The cadaver will receive an ultrasound- guided Quadratus Lumborum Block type 2 with 30 ml coloring solution
89440112|NCT03545295|Experimental|QLB 3 10ml|The cadaver will receive an ultrasound- guided Quadratus Lumborum Block type 3 with 10 ml coloring solution
89440113|NCT03545295|Experimental|QLB 3 20ml|The cadaver will receive an ultrasound- guided Quadratus Lumborum Block type 3 with 20 ml coloring solution
89440114|NCT03545295|Experimental|QLB 3 30ml|The cadaver will receive an ultrasound- guided Quadratus Lumborum Block type 3 with 30 ml coloring solution
89440115|NCT04446026|Experimental|teneligliptin|
88924881|NCT04544930|Experimental|therapist-guided|Therapist-guided Internet treatment based on cognitive behavior therapy (ICBT).
88924882|NCT04543760|Other|[PP sequence 1] - Wash-out - [SP sequence 2]|
88924883|NCT04543760|Other|[SP sequence 1] - Wash-out - [PP sequence 2]|
88924884|NCT04542980||SARS-CoV2 Positive|"Tear Samples: Tear samples will be collected from 100 patients who have tested positive for the SARS-CoV2 virus.~A total of 100 Blood samples will be drawn using standard phlebotomy techniques for venipuncture from patients who have tested positive for the SARS-CoV2 virus."
88924885|NCT04542980||Control|Control tear and serum samples will be selected from Namida Lab's own biorepository.
88924886|NCT04537559||pre-COVID-19 period|Patients hospitalized between 1.3.2019 and 28.02.2020
88924887|NCT04537559||per-COVID-19 period|Patients hospitalized between 1.3.2020 and 28.02.2022
88924888|NCT04537559||post-COVID-19 period|Patients hospitalized between 1.3.2022 and 28.02.2023
88924889|NCT04532619|Experimental|Intervention|6 weeks of Fathering Through Change videos and 3 individual coaching calls.
88924890|NCT04532619|No Intervention|Control|Links to parenting websites
88924891|NCT04531085|Active Comparator|RCT operative|Procedure of preference is open reduction and internal fixation (ORIF) with cannulated non-resolvable 4.0mm screw with or without washer. If the fracture fragment is too small or fragmented for screw fixation 1.6mm - 1.8mm Kirshner-wires and/or bone anchor are used. Long arm cast for 4 weeks.
88924892|NCT04531085|Active Comparator|RCT Non-operative|Non-operative treatment means upper limb immobilization with forearm in neutral pro-supination with a long arm cast for 4 weeks.
88924893|NCT04531085|Other|Patient preference operative|Procedure of preference is open reduction and internal fixation (ORIF) with cannulated non-resolvable 4.0mm screw with or without washer. If the fracture fragment is too small or fragmented for screw fixation 1.6mm - 1.8mm Kirshner-wires and/or bone anchor are used. Long arm cast for 4 weeks.
89440116|NCT04446026|Placebo Comparator|placebo|
89440117|NCT03383042|Experimental|Cohort 1|Single-ascending cohort 1
89440118|NCT03383042|Experimental|Cohort 2|Single-ascending cohort 2
89440119|NCT03383042|Experimental|Cohort 3|Single-ascending cohort 3
89440120|NCT03383042|Experimental|Cohort 4|Single-ascending cohort 4
89440121|NCT03383042|Experimental|Cohort 5|Single-ascending cohort 5
89440122|NCT03383042|Experimental|Cohort 6|Multiple-ascending cohort 1
89440123|NCT03383042|Experimental|Cohort 7|Multiple-ascending cohort 2
89440124|NCT03383042|Experimental|Cohort 8|Multiple-ascending cohort 3
89440125|NCT03383042|Experimental|Cohort 9|Multiple-ascending cohort 4
89440126|NCT02142777|Experimental|Investigational|All study subjects will take a 10mg pill by mouth twice daily over a 6 week period. Subjects will receive either placebo or S -Equol. They will not know which they are receiving.
89440127|NCT02142855|No Intervention|Old Control|Older individuals (65-75 y) with no exercise intervention
89440128|NCT02142855|Experimental|Old Concentric|Older individuals (65-75 y) studied before and after 8 weeks concentric exercise training
89440129|NCT02142855|Experimental|Old Eccentric|Older individuals (65-75 y) studied before and after 8 weeks eccentric exercise training
89440130|NCT02142855|No Intervention|Young Control|Young individuals (18-30 y) with no exercise intervention
89440131|NCT02142855|Experimental|Young Concentric|Young individuals (18-30 y) studied before and after 8 weeks concentric exercise training
89440132|NCT02142855|Experimental|Young Eccentric|Young individuals (18-30 y) studied before and after 8 weeks eccentric exercise training
89440133|NCT03390218|Experimental|TAO (Therapy Assisted Online)|TAO participants will attend a once weekly group in a computer lab. Each participant will complete an interactive educational module using an evidence based protocoled treatment for anxiety and/or depression, and have a brief session with the group leader to discuss application of the content. Participants will have access to a companion app they may use between sessions to practice skills and reinforce learning.
89440134|NCT03390218|Active Comparator|Treatment as usual|After the completion of a psychosocial assessment, and development of a treatment plan, clients are offered individual and group therapy sessions, case management services, and medication management services depending on the diagnoses. Individual and group therapy is often generic in nature as well, although some structured, evidence-based treatments are offered such as Psycho-Education Multi-Family Group and Illness Management Recovery.
89440135|NCT02146443|Active Comparator|Baseline|Completion of the star shaped manual dexterity test, five rounds clockwise and five rounds counter clockwise without any intervention. Time and number of errors are recorded. Measurement of static arm strength with the stretched arm test. test subject is asked to hold a 2.5 kg weight in stretched arm for as long as possible. Maximum endurance time is recorded.
89440136|NCT02146443|Active Comparator|Fatigue|Prior to completion of the star shaped manual dexterity test, the test subject is asked to stand up still and hold a 2.5-kg weight with the dominant arm fully extended as long as possible without moving. Maximum endurance time is recorded. After this, the test subject completes the the star shaped manual dexterity test and time and number of errors are recorded.
88924894|NCT04531085|Other|Patient preference non-operative|Non-operative treatment means upper limb immobilization with forearm in neutral pro-supination with a long arm cast for 4 weeks.
88924895|NCT04530435|Experimental|Treatment group|"The participants will be handed three airway resistances equivalent to a resistance of 10-20 cm H2O alongside one PEP flute. Two videos will guide the participants in use of the PEP flute; one with instructions of the rationale and how to use the flute, including how to choose the suitable resistance and one video, which gives instructions of hygienic maintenance.~Participants in the intervention group will be advised to continue use of their PEP flute in the active intervention period of 30 days or at least if they still have respiratory symptoms. They will receive daily text-messages to prompt their reporting and to use the PEP flute according to instructions."
89440137|NCT02146443|Active Comparator|Stress|During completion of the star shaped manual dexterity test, the test subject is asked to identify cards from a regular deck of playing card by naming the suit and rank of the card. They will be asked to identify one random card during each of the 10 rounds in the completion of the test. Completion time and number of errors are recorded.
89502047|NCT02233075|Experimental|REP 2139-Ca + Pegasys (TM)|REP 2139-Ca 500 mg QW for 15 weeks followed by REP 2139-Ca 250mg QW + Pegasys(TM) 180ug QW for 15 weeks followed by Pegasys(TM) 180ug QW for 33 weeks.
89012369|NCT01191073|Experimental|CAD/CAM fabricated dentures|group receiving Computer-Aided Design/Computer-Aided Manufacturing (CAD/CAM)fabricated removable partial dentures (double blind)
89502048|NCT02583919|Experimental|ISIS-GCGRRx - Dose Level 1|ISIS-GCGRRx - Dose Level 1
89502049|NCT02583919|Experimental|ISIS-GCGRRx - Dose Level 2|ISIS-GCGRRx - Dose Level 2
89502050|NCT02583919|Placebo Comparator|Placebo|Placebo
89502051|NCT02581657|Experimental|PE0139 Injection|PE0139 Subcutaneous Injection - 6 weekly doses
89502052|NCT02581657|Placebo Comparator|Placebo Injection|Placebo Subcutaneous Injection - 6 weekly doses
89502053|NCT04300244|Experimental|Arm A|Ipilimumab and nivolumab + UV1
89502054|NCT04300244|Active Comparator|Arm B|Ipilimumab and nivolumab
89502055|NCT02578771|Experimental|ZuraPrep with 70% Isopropyl alcohol|Test Article ZuraPrep with 70% isopropyl alcohol (IPA) will be compared with reference positive control Chloraprep
89502056|NCT02578771|Experimental|ZuraPrep without 70% IPA|Vehicle test article ZuraPrep without isopropyl alcohol will be compared with normal saline
89012370|NCT01191073|Active Comparator|traditional fabricated dentures|group receiving traditional fabricated dentures (double blind)
89440138|NCT02146443|Active Comparator|Fatigue and Stress|The test subject will be fatigued prior to the test (as detailed in the fatigue arm), and asked to identify cards during completion of the star shaped manual dexterity test (as detailed in the stress arm). Completion time and number of errors are recorded.
89502057|NCT02578771|Active Comparator|ChloraPrep Teal Tint|Test Article ZuraPrep with 70% isopropyl alcohol will be compared with reference positive control ChloraPrep [Chlorhexidine gluconate(CHG)/IPA] Teal Tint
89502058|NCT02578771|Placebo Comparator|Normal Saline 0.85%|Vehicle test article ZuraPrep without isopropyl alcohol will be compared with normal saline 0.85%
88924896|NCT04530435|No Intervention|Control group|The participants in the control group will receive daily text-messages to prompt their reporting of CAT-scores. To avoid attrition of the trial due to early recovery of symptoms, the project manager will call the participants by phone at day 15 to ask them about their present condition (i.e. CAT-score) and address potential concerns of continued participation of the trial. Otherwise, they will only receive usual care.
88924897|NCT04530279||Referring hospital|Burn assessments performed in referring hospitals
88924898|NCT04530279||Burn centre|Burn assessments performed in the national burn centre
89440139|NCT02782377||Pelvic Floor Dysfunction|"Observational study where patients with pelvic floor dysfunction undergo three AAR measurements. One at baseline, one with the catheter alongside and a third with the rectal balloon inflated. No intervention is performed~Note, that initial inclusion of Squeeze parameters was detailed in error, these were not compared in this study and were compared in previous study"
89440140|NCT05152082||patients with colorectal advanced adenomas|
89440141|NCT05152082||patients without colorectal advanced adenomas|
89440142|NCT02142933|Other|rectal swab and vagino-perineal swab|single-arm
89440143|NCT02143011|Other|orange juice|no sugar
89440144|NCT02143011|Other|sugar beverage|no sugar
89440145|NCT02143089|Active Comparator|Group 1|Use of urinary catheterization in Cesarean section
89440146|NCT02143089|No Intervention|Group 2|NO urinary catheterization during Cesarean section
89440147|NCT02143167|Experimental|SR-fampridine/placebo|24 weeks of SR-fampridine followed by four weeks of inactive placebo.
89440148|NCT02143167|Experimental|Placebo/SR-fampridine|24 weeks of inactive placebo followed by four weeks of SR-fampridine
89440149|NCT05150132|Experimental|Oral-B Genius® 8000 power toothbrush with Cross Action brush head with smartphone app for 8 weeks|Interactive PTB with Bluetooth® 4.0 connectivity smartphone app with Cross Action brush head using visually position detection feature. A triple pressure control system stops vibration, gives a visual warning, and reduces rotation speed in Daily Cleaning Mode-1.
89440150|NCT05150132|Active Comparator|Oral-B Genius® 8000 power toothbrush with CrossAction brush head without smartphone app for 8 weeks|PTB without Bluetooth® 4.0 connectivity without smartphone app with Cross Action brush head without using visually position detection feature triple pressure control system stops vibration, provides visual warning and reduces rotation speed. The group was asked to use PTB with daily cleaning mode 1 and brush head, but without using the Bluetooth app (without using the position detection system).
89440151|NCT05150132|Active Comparator|Manual toothbrush: Oral B ClinicLine Pro-FlexSoft (Procter&Gamble,Ohio, USA) for 8 weeks|They were instructed to brush according to the Modified Bass technique.
89440152|NCT03544671|Experimental|400 IU/d vitamin D2|Children received 1mililiter (dosage applicator) containing 400 IU of vitamin D2 per day. This suplement also contained: iron, vitamin A, C, and E, folic acid, niacin and vitamins B1, B2, B6 y B12. Vitamin D2, dosage form (1 mililiter), frequency (daily) and duration 16 weeks
89440153|NCT03544671|Experimental|800 IU7d vitmin D2|Children received 2 mililiter (dosage applicator) containing 800 IU of vitamin D2 per day. This suplement also contained: iron, vitamin A, C, and E, folic acid, niacin and vitamins B1, B2, B6 y B12. Vitamin D2, dosage form (1 mililiter), frequency (daily) and duration 16 weeks
89440154|NCT03544671|Experimental|1000 IU vitamina D3|Children received 1drop (dosage applicator) containing 1000 IU of vitamin D3 per day. dosage form (1 drop), frequency (daily) and duration 16 weeks
89440155|NCT03544671|Placebo Comparator|Multiple vitamin|Children received 1 mililiter of a supplement with multiple vitamins (dosage applicator) frequency (daily) and duration 16 weeks
89440156|NCT03382964|Active Comparator|VLA1553 low dose|VLA1553 with 3.2x10^3 TCID50/ 100 µL (microliter). Re-vaccination at Month 12 with VLA1553 with 3.2x10^5 TCID50/ 1 mL (milliliter)
89440157|NCT03382964|Active Comparator|VLA1553 medium dose|VLA1553 with 3.2x10^4 TCID50/ 1 mL Re-vaccination at Month 12 with VLA1553 with 3.2x10^5 TCID50/ 1 mL
89440158|NCT03382964|Active Comparator|VLA1553 high dose|VLA1553 with 3.2x10^5 TCID50/ 1 mL Re-vaccination at Month 6 or Month 12 with VLA1553 with 3.2x10^5 TCID50/ 1 mL
89440159|NCT05081037|Experimental|Wearable Care Group|This group will receive both a continous glucose monitoring sensor and an exercise tracker to be worn for at least 2 weeks at each study visit timepoint.
89440160|NCT05081037|No Intervention|Scheduled Care Group|This group will receive standard medical care with dietary and nutritional advice alone.
89440161|NCT02877836|Other|Segmentary dystonia|to identify movement-related functional magnetic resonance imaging (fMRI) activation patterns
89440162|NCT02877836|Other|Hemidystonia|to identify movement-related functional magnetic resonance imaging (fMRI) activation patterns
89440163|NCT02877836|Other|Generalized dystonia|to identify movement-related functional magnetic resonance imaging (fMRI) activation patterns
89440164|NCT02877836|Other|Healthy control subjects|to identify movement-related functional magnetic resonance imaging (fMRI) activation patterns
89012371|NCT01134601|Experimental|Selumetinib (AZD6244): 50 mg & Capecitabine: 825 mg/m^2|LEVEL 1 - Cycle = 49 days: AZD6244: 50 mg by mouth (PO) everyday (QD) Capecitabine: 825 mg/m^2 by mouth (PO)
89440165|NCT03545217|Experimental|intervention group|
89440166|NCT03545217|No Intervention|control group|
89440167|NCT02430987|Active Comparator|Metabolic syndrome|"The MetS diagnosis was determined by following the guidelines defined by the Adult Treatment Panel (ATP III) (8): (1) Abdominal circumference (AC) ?88cm; (2) HDL-cholesterol < 50mg/dL; (3) triglycerides > 150mg/dL; (4) arterial blood pressure (SAH) > 130/85mmHg; and (5) fasting glucose > 110mg/dL. The women considered as carrying MetS were those with at least three of the components described.~Sexual function was assessed by completion of the Female Sexual Function Index (FSFI), a questionnaire validated for Brazilian Portuguese"
89440168|NCT02430987|Placebo Comparator|Obesity|women were stratified into 3 groups by body mass index (BMI): Group 1: BMI of 18.5 to 24.9kg/m2 (Normal BMI Group), Group 2: BMI of 25 to 29.9kg/m2 (Overweight Group); Group 3: BMI of 30kg/m2 to 34.5kg/m2 or higher) (Obese Group Sexual function was assessed by completion of the Female Sexual Function Index (FSFI), a questionnaire validated for Brazilian Portuguese
89440169|NCT03385850|Experimental|early enteral nutrition|
89440170|NCT03385850|Active Comparator|delayed enteral nutrition|
89440171|NCT03390062|Experimental|apatinib|apatinib 500 mg orally daily until the untolerabale toxicities、desease progress or death
89502059|NCT05498246|Active Comparator|group (A) included 30 cases in which we used bipolar coagulation for hemostasis|group (A) included 30 cases in which we used bipolar coagulation for hemostasis
88924899|NCT04529499|Experimental|favipiravir + supportive care|Frequency: Twice daily (morning and evening) Dosage Form: Tablets. Tablet Strength 200 mg. Dosage: 1,800 mg BID on Day 1 + 800 mg BID for next 9 days (maximum). On Day 1, the second dose will be administered with at least a 4-hour interval from administration of the first dose.
89440172|NCT02410629|Experimental|Music Glove|Music Glove is a glove with sensors attached to the tips of all 5 fingers. The glove is connected to a software musical program like guitar hero. Participants will follow the rhythm or musical notes of the songs and move their fingers accordingly. Participants are reinforced with biofeedback that includes visual and auditory cues when the correct sequences are achieved.
89440173|NCT02410629|Active Comparator|Conventional Hand Exercise Program|Conventional Hand Exercise Program includes range of motion exercises, strengthening exercises, coordinating exercises of the hand and fingers. This exercise program is designed by an occupational therapist and is a general exercise program that a stroke patient will receive when he/she is being discharged from the hospital.
89440174|NCT03382886|Experimental|Nivolumab and bevacizumab, all patients|
89440175|NCT03389984|Experimental|Adalimumab|
89440176|NCT02146521||patients undergoing CT|Emergency department's patients undergoing CT scanning for evaluation of acute abdominal pain and tenderness
89440177|NCT02855918|Other|Blood sample for genetic purpose|"All the participants performed the same evaluations and blood analysis.~The study is composed of 3 groups :~depressed patients with an history of suicide attempt~depressed patients without any history of suicide attempt~healthy controls without any history of psychopathology"
89440178|NCT03382808|Experimental|SEE Training|The training sequence comprises four weekly sessions using a modified dote-probe paradigm (fearful vs. neutral expression).
89440179|NCT03382808|Active Comparator|GAZE Training|The GAZE training sequence comprises four weekly sessions using a modified dote-probe paradigm (averted vs. directed gaze).
89440180|NCT02853812|Other|single sided tinnitus|patients with single sided tinnitus on which functional brain MRI is assessed
89440181|NCT03389906|Experimental|Gold|Approximately 72000, 20-40 my-meter diameter, sterilised gold particles (=20 mg) will be provided in vials (The Berlock® Gold Implants).
89440182|NCT04927208|Experimental|Improved skeletal muscle function due to protein supplementation|Experimental: Intervention group Improved skeletal muscle function due to protein supplementation
89440183|NCT02252211|Experimental|DS-8895a|Patients received infusions with DS-8895a on Days 1, 8, 22, and 36. Infusions on Days 1 and 36 were trace labelled with ^89Zr (^89Zr-Df-DS-8895a). The Day 1 dose was 0.2 mg/kg, followed by subsequent doses calculated based on individual patient body weight and dosing cohort assignment.
89440184|NCT02173353||Pancreas cancer|Develope a stand, cradle or robotic arm to hold the ultrasound probe, to obtain an ultrasound just before a standard radiation therapy treatment is given.
89440185|NCT02146677|Other|Sham|newborns will be osteopathically evaluated and softly touched
89440186|NCT02146677|Other|Usual care|newborns will be undergone usual routine neonatology care
89440187|NCT02146677|Other|OMT|newborns will receive osteopathic evaluation and treatment according to international guidelines. Osteopathic treatment use will be indirect techniques.
89440188|NCT02147847|Experimental|Video game based training 1|Video Game play with training strategy 1
89440189|NCT02147847|Experimental|Video game based training 2|Video Game play with training strategy 2
89440190|NCT02147925|Active Comparator|Liraglutide|Liraglutide combined with metformin
89440191|NCT02147925|Active Comparator|Insulin glargine|Insulin glargine combined with metformin
89440192|NCT02147925|Active Comparator|Sitagliptin|Sitagliptin combined with metformin
89440193|NCT03544047|Experimental|Experimental arm|Patient was first treated with paclitaxel (PTX) chemotherapy 3 cycles (2 weeks regimen) and Herceptin was treated in HER2 amplification patients. After 3 cycles. If the tumor continues to reduce in the first 3 cycles, continue paclitaxel chemotherapy for 3 cycles (6 weeks) and Herceptin was treated in HER2 amplification patients. If the evaluation of the curative effect is SD or PD, according to the result of drug sensitivity of the class organ, combined with the clinical practice, the doctor chooses the most sensitive treatment plan, and continues the 2 cycle treatment (6 weeks).
89440194|NCT03544125|Experimental|Treatment (olaparib, durvalumab)|Participants receive olaparib PO twice a day BID for 28 days in the absence of disease progression or unacceptable toxicity. Participants then receive olaparib PO BID on days 1-28 and durvalumab IV over 1 hour on day 1. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. Participants may continue on therapy beyond disease progression at the discretion of the investigator.
89440195|NCT02148081||Critically ill children|
89440196|NCT02151357|Experimental|DCBCI0901|DCBCI0901 7.5mg/m2, iv infusion for day 1-day 5 and day 15-day 20
88924900|NCT04529499|Placebo Comparator|Placebo with Standard of Care|Frequency: Twice daily (morning and evening) Dosage Form: Tablets Dosage: 9 tablets for BID on Day 1 + 4 tablets BID for next 9 days (maximum). On Day 1, the second dose will be administered with at least a 4-hour interval from administration of the first dose.
89440197|NCT02151435||Patients with IPF|Observation of longitudinal biomarkers in IPF patients
89440198|NCT02146911|Experimental|Bupropion|Bupropion hydrochloride SR, Sandoz Canada, Boucherville, Quebec. Dispense for 12 weeks. One tablet (150mg) once daily for first three days, then twice daily for the remainder of 12 weeks.
89440199|NCT02146911|Experimental|Varenicline|Varenicline tartrate (Champix®), Pfizer Canada Inc., Kirkland, Quebec. Dispense for 12 weeks. One tablet (0.5mg) once daily for first three days, then one tablet (0.5 mg) twice daily for next four days, then 1 mg (one 1mg tablet or two 0.5mg tablets) twice daily for the remainder of 12 weeks.
89502060|NCT05498246|Active Comparator|group (B) included 30 cases in which we used suture renorrhaphy|group (B) included 30 cases in which we used suture renorrhaphy
88924901|NCT04528433|Experimental|Medical-education-community Collaborated Intervention|
88924902|NCT04528433|Active Comparator|routine clinical care|
88924903|NCT04523428|Experimental|Venetoclax/Acalabrutinib|All patients will receive a lead-in with 2 cycles of acalabrutinib 100 mg bid. Hereafter patients will continue with ramp-up of venetoclax followed by daily 400 mg venetoclax in combination with acalabrutinib for 24 cycles. Patients will be treated until they have received a total of 26 cycles or until progression, whichever comes first.
89012372|NCT00287040|No Intervention|1 - Usual Care|This arm looks at mammogram adherence in those individuals who at this time are not receiving booster mammogram interventions.
89012373|NCT00287040|Experimental|2. DVD Intervention|This arm will receive the initial information provided in usual care and will also receive booster mammography interventions via DVD.
89012374|NCT00287040|Experimental|3. Telephone Counseling|This arm will receive the initial information provided in usual care and receive boosters through tailored telephone counseling.
89012375|NCT00252122|Experimental|1|Patients receiving ketamine are those patients, arm 1, that are sill experiencing pain after Morphine has been given.
89012376|NCT00252161|Active Comparator|1|Procedure/Surgery: Gastrectomy with more than D2 dissection
89012377|NCT00252161|Experimental|2|Drug: Neoadjuvant chemotherapy(TS-1+CDDP) followed by gastrectomy
89012378|NCT00287196|Active Comparator|Post-operative RADIOTHERAPY|Immediate post-operative RADIOTHERAPY
89012379|NCT00287196|Experimental|Delayed Radiotherapy|OBSERVATION with delayed radiotherapy for relapse
89012380|NCT00252317|Active Comparator|1|Captopril test dose and Trandolapril
89440200|NCT02148159|Experimental|Cachexia Acupuncture-A|"Acupuncture-A group will receive acupuncture in a pre-determined set of the acupuncture points that are selected based on the potential mechanisms of cachexia. Intervention will be done by a licensed acupuncturist who has over 5 years of experience as an independent clinician and has experience particularly in the management of cancer related symptoms. Acupuncture treatment will consist of 8 sessions over 8 week period.~Acupuncture needles: Single-use, sterile stainless steel and disposable [acupuncture needles-Peace Classic Needles®, Acu-Market] Other name: Mechanism based acupuncture"
89440201|NCT02148159|Sham Comparator|General Acupuncture-B|"General Acupuncture-B group will receive acupuncture in a pre-determined set of the acupuncture points. These points are the real acupuncture points; however, these points are not specific to cachexia management. Participants will receive the acupuncture treatment over 8 weeks (total of 8 sessions) in the same manner as the experimental group; the only difference will be the place(type) and number of points targeted.~Acupuncture needles: single-use, sterile stainless steel and disposable needles [Peace Classic Needles®, Acu-Market] Other name: General acupuncture"
89440202|NCT02146989||Cerebral Palsy|Children and adolescents with spastic unilateral Cerebral Palsy (with perinatal acquired hypoxic ischemic incidents), aged 7 to 18 years, MACS levels I-III.
89440203|NCT02146989||Healthy controls|Children and adolescents without Cerebral Palsy
89440204|NCT02148315|Experimental|garden intervention|garden kit and access to garden-based lessons
89440205|NCT02148315|No Intervention|no garden|control - receives garden and lessons at end of study
89440206|NCT02776683|Experimental|All patients|
89440207|NCT02731742|Experimental|Dose A MK-1966 + Dose A SD-101|Participants received a combination of MK-1966 (Days 1 and 21) and SD-101 (Days 1, 8, 15 and Day 22) in Part A of the study (approximately 21 days). Participants were to continue in one of two expansion cohorts (Part B or C) and receive up to 8 cycles of treatment (approximately 24 weeks). Each cycle was 21 days.
89012381|NCT00252317|Placebo Comparator|2|
89012382|NCT01118026|Experimental|ABVD +/- BEACOPP + radiation|"Patients receive ABVD administered by intravenous (IV) infusion on days 1 and 15 of each cycle. A cycle is considered 28 days. Patients receive a total of two cycles.~Patients undergo a PET scan following two cycles of ABVD. If the PET scan is negative, then the patient will receive four more cycles of ABVD (a total of 6 cycles of ABVD). If the PET scan is positive, then the patient receives four cycles of escalated BEACOPP for 21 days (a total of 4 cycles).~3-6 weeks after BEACOPP therapy, patients receive radiation therapy for 5 days per week (a total of 3.5 weeks).~All patients will be followed for a maximum of ten years."
89012383|NCT00280800|Active Comparator|1|constant CPAP
89440208|NCT02731742|Experimental|Dose A MK-1966 + Dose B SD-101|Participants received a combination of MK-1966 (Days 1 and 21) and SD-101 (Days 1, 8, 15 and Day 22) in Part A of the study (approximately 21 days). Participants were to continue in one of two expansion cohorts (Part B or C) and receive up to 8 cycles of treatment (approximately 24 weeks). Each cycle was 21 days.
89440209|NCT02731742|Experimental|Dose B MK-1966 + Dose B SD-101|Participants received a combination of MK-1966 (Days 1 and 21) and SD-101 (Days 1, 8, 15 and Day 22) in Part A of the study (approximately 21 days). Participants were to continue in one of two expansion cohorts (Part B or C) and receive up to 8 cycles of treatment (approximately 24 weeks). Each cycle was 21 days.
89012384|NCT00280800|Experimental|2|automatic CPAP
89012385|NCT01648153|Active Comparator|GSK1070806 0.25mg/kg|TwoIV administrations of 0.25mg/kg GSK1070806 4weeks apart
89012386|NCT01648153|Active Comparator|GSK1070806 5mg/kg|Two IV administrations of 5mg/kg of GSK1070806 4 weeks apart
89012387|NCT01648153|Placebo Comparator|Placebo (Saline)|Two IV administrations of saline 4 weeks apart
89012388|NCT02753998|Experimental|Conventional angioplasty + paclitaxel-coated balloon|Treatment of stenosis of AVF by conventional angioplasty + 1 minute additional angioplasty with paclitaxel-coated balloon
89012389|NCT02753998|Placebo Comparator|Conventional angioplasty + placebo balloon|Treatment of stenosis of AVF by conventional angioplasty + 1 minute additional angioplasty with placebo balloon.
89012390|NCT02279836|Other|Single arm post-marketing Study|SC20 Colonoscope and Colonoscopy System For Colonoscopy
89012391|NCT00287235|Experimental|Group 1: Standard Medical Therapy + MARS|Patients who were randomized to Group 1 received daily MARS treatments in addition to Standard Medical Therapy for 5 consecutive days.
89012392|NCT00287235|Active Comparator|Group 2: Standard Medical Therapy Only|Patients who were randomized to Group 2 received standard medical treatment only.
89012393|NCT02753452|Active Comparator|Residential Immersive Life Skills group|Youth will take part in a residential life skills program of between one and three weeks, consisting of formal workshops, peer learning, outings in the community, one-on-one coaching and daily living tasks carried out with peers (e.g. cooking, laundry, grocery shopping).
89012394|NCT02753452|Active Comparator|Non-residential life skills program|Youth will take part in programs focusing on increasing specific life skills, but taking place only during the day (i.e. non- residential).
89012395|NCT02753452|No Intervention|Deferred RILS applicants|Youth who applied to a Residential Immersive Life Skills program but are deferred to a subsequent year. These youth are included as a comparator group to match the motivation level required to apply to a RILS program.
89012396|NCT02753452|No Intervention|No life skills program|Youth who did not apply or take part in any group life skills program. These youth provide a diagnosis and age matched comparator group.
89440210|NCT02731742|Experimental|Dose C MK-1966 + Dose B SD-101|Participants received a combination of MK-1966 (Days 1 and 21) and SD-101 (Days 1, 8, 15 and Day 22) in Part A of the study (approximately 21 days). Participants were to continue in one of two expansion cohorts (Part B or C) and receive up to 8 cycles of treatment (approximately 24 weeks). Each cycle was 21 days.
89440211|NCT02731742|Experimental|Part B Expansion Cohort|Participants were to receive the MTD/MAD of MK-1966 and SD-101 established in Part A for up to 7 additional treatment cycles with MK-1966 and up to 6 additional treatment cycles with SD-101. Each cycle was to be 21 days.
89440212|NCT02731742|Experimental|Part C Expansion Cohort|Participants were to receive the MTD/MAD of MK-1966 and SD-101 established in Part A for up to 7 additional treatment cycles with MK-1966 and 6 additional treatment cycles with SD-101. Each cycle was to be 21 days.
89440213|NCT02254707|Experimental|BILB 1941 ZW|Escalating Doses
89440214|NCT02254707|Placebo Comparator|Placebo|
89440215|NCT03543891||Control group|50 healthy volunteers were included in the healthy control group
89440216|NCT03543891||Thyroid cancer group|50 patients of thyroid cancer were included
89440217|NCT02963714|Experimental|60 µg dose hepatitis B vaccine|60 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6
89440218|NCT02963714|Experimental|20 µg dose hepatitis B vaccine|20 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6
89012397|NCT02754154||Patients using Warfarin|Patients 18 years of age and older with Non-Valvular Atrial Fibrillation (NVAF) using Warfarin
89012398|NCT02754154||Patients using Apixaban|Patients 18 years of age and older with Non-Valvular Atrial Fibrillation (NVAF) using Apixaban
89440219|NCT02147145||Observation Cohort|
89440220|NCT02148393|Active Comparator|Control|In the control group, following oocyte retrieval, intensified luteal phase support for fresh embryo transfer (with Pregnyl®, Utrogestan® and Progynova®) will be performed. Fresh ET in the uterine cavity will be performed on the 5th day of embryo development at blastocyst stage under ultrasound guidance whenever possible.
89440221|NCT02148393|Experimental|Intervention|"Elective vitrification with subsequent-cycle embryo thawing/transfer (CryoBioSystem®) will be performed. Hence, no luteal phase support will be provided immediately after oocyte retrieval. Instead, patients will wait for a subsequent cycle before starting exogenous hormone therapy for endometrial preparation.~On the day of embryo transfer, blastocyst(s) will be warmed one by one until one or two blastocysts are suitable for transfer. ET to the uterine cavity will be performed under ultrasound guidance whenever possible."
89012399|NCT02754154||Patients using Dabigatran|Patients 18 years of age and older with Non-Valvular Atrial Fibrillation (NVAF) using Dabigatran
89199549|NCT05202938||Acute Heart Failure with preserved Ejection Fraction: HFpEF|8 patients with acute heart failure and a preserved ejection fraction (ejection fraction (LVEF ≥ 50% or similar to normal cardiac ultrasound values recorded less than 2 years ago). No evidence of septic shock.
89440222|NCT03385694||Assessment|All the patients operated on Van Nes Rotationplasty for bone tumors at IOR and long term surviving
89440223|NCT03125252|Experimental|Bundle|Specific action plan : ABCDE, complemented with care related to the nursing and paramedical role concerning the patient's environmental factors
89440224|NCT03125252|Other|Control|Standard paramedical and medical practices
89440225|NCT02416154||Follicular phase|Normally cycling women in the follicular phase of menses
89440226|NCT02416154||Luteal phase|Normally cycling women in the luteal phase of menses
89440227|NCT03382184|Experimental|Fraxel DUAL 1550 nm|The Fraxel DUAL 1550 nm laser will be used at 7 mJ, 8 pulses, 120 spots/cm2, treatment level 3 (9% coverage) for hair regrowth. 25 patients with alopecia will be part of this group.
89440228|NCT03382184|Experimental|Halo Hybrid Laser 1550 nm|The Halo laser will be used per protocol due to the dynamic thermal optimization technology for hair regrowth. 25 patients with alopecia will be part of this group.
89440229|NCT02324816|Experimental|Lateral Thigh Treatment Group|CoolSculpting treatment in the lateral thighs for non-invasive subcutaneous fat reduction.
89440230|NCT03385616|Experimental|Treatment with GATS|Gala Airway Treatment System (GATS)
89440231|NCT00104871|Experimental|Bortezomib|Bortezomib 1.3 mg/m^2 intravenous (IV) at over 3-5 seconds on days 1, 4, 8, and 11. Treatment repeats every 21 days for at least 4 courses.
89440232|NCT03385538|Experimental|Clopidogrel non-responders|Increasing doses og Clopidogrel depending on PRU values measured on VerifyNow
89440233|NCT03385460|Experimental|ESWL BOTOX|Each patient will be subjected to Low Energy Shock Waves.The target dose of low energy shock waves will be 3000 shock delivered into SP region in 3 horizontal points at SP transverse crease . all patients will be catheterized using nylaton catheter 16 ch, the study group will be injected with 100 IU botulinium toxin A. vial will be dissolved in saline half of the estimated bladder capacity. All patients will be kept for 2 hours without micturation giving a chance of BOTOX absorption .
89440234|NCT03543033|Experimental|Treatment|Patients will receive a corticosteroid epidural injection within 2 weeks of their scheduled lumbar surgery
89440235|NCT03543033|No Intervention|Control|Patients will not receive a corticosteroid injection within 2 weeks of their scheduled lumbar surgery.
89440236|NCT03380702|Active Comparator|whitening photoactivation gel|exposure to hydrogen gel and photoactivation for teeth whitening
89440237|NCT03380702|Placebo Comparator|placebo|exposure to gel without active whitening substance and the same photoactivation source as active comparator
89440238|NCT02148471||Healthy controls|Healthy living liver donors with healthy liver on imaging and/or liver histology
89440239|NCT02148471||Simple steatosis|Patients with non-alcoholic fatty liver disease confirmed by liver biopsy with a diagnosis of simple steatosis
89440240|NCT02148471||Nonalcoholic steatohepatitis|Patients with non-alcoholic fatty liver disease confirmed by liver biopsy with a diagnosis of steatohepatitis
89440241|NCT02148471||Minimal findings|Patients undergoing liver biopsy because of suspected fatty liver but nonspecific findings on liver histology. This group was initially used as a control group. Later in the study, this group was replaced by healthy donors as true healthy controls.
89440242|NCT04723160||Test Group|ophthalmologists read images applying the assistant software
89440243|NCT04723160||Control Group|ophthalmologists read images independently
89440244|NCT02147223|Active Comparator|Flavanol rich product A|250 mg flavanols
88924904|NCT04508504|Experimental|Preop PENG Block|Patients will receive a preoperative ultrasound-guided pericapsular nerve group block with 20 mL 0.5% ropivacaine in a manner consistent with Girón-Arango et al 2018 (PMID:30063657). Using appropriate sterile precautions, and procedural sedation with up to 2 mg IV midazolam, an ultrasound (SonoSite S-Nerve or Export) equipped with either a linear 15-6 megahertz (MHz), or a curvilinear 5-2 MHz transducer (habitus-dependent) is used to identify the anterior inferior iliac spine, iliopubic eminence, and psoas muscle. After skin localization with 1-2 mL 1% lidocaine, a 22g 80 mm echogenic block needle (Pajunk SonoBlock II Facet) is advanced lateral to medial, in plane with the ultrasound beam, beneath the psoas tendon to the iliopubic eminence. 20 mL 0.5% ropivacaine is injected beneath the psoas tendon and above the iliopubic eminence, in 5 mL increments with periodic aspiration to prevent intravascular injection. The needle is withdrawn, and the needle entry site wiped clean.
88924905|NCT04508504|Placebo Comparator|Placebo|Patients in the placebo group will receive a subcutaneous injection of 5 mL 0.9% normal saline. Using appropriate sterile precautions, and procedural sedation with up to 2 mg IV midazolam, an ultrasound (SonoSite S-Nerve or Export) equipped with either a linear 15-6 megahertz (MHz), or a curvilinear 5-2 MHz transducer (habitus-dependent) is used to identify the anterior inferior iliac spine, iliopubic eminence, and psoas muscle. After skin localization with 1-2 mL 1% lidocaine, a 22g 80 mm echogenic block needle (Pajunk SonoBlock II Facet) is advanced lateral to medial, in plane with the ultrasound beam, 1-2 cm beneath the skin, remaining in the subcutaneous tissue. 5 mL of 0.9% normal saline is injected, with periodic aspiration to prevent intravascular injection. The needle is withdrawn, and the needle entry site wiped clean.
88924906|NCT04507633|Experimental|ROMA therapy|ROMA therapy combines four elements including reminiscence, reality orientation, music, and art in the intervention.
89440245|NCT02147223|Active Comparator|Flavanol rich product B|500 mg flavanols
89440246|NCT02147223|Active Comparator|Flavanol rich product C|750 mg flavanols
89440247|NCT02147223|Placebo Comparator|Flavanol free product|flavanol free
89440248|NCT02147379|Experimental|Lurasidone|Lurasidone 20 - 80 mg / day added to current treatment for 6 weeks.
89440249|NCT02147379|No Intervention|Treatment as usual|Patients randomized to this arm will continue their usual treatment.
89440250|NCT02148549|Experimental|Optimal chemotherapy courses|Neoadjuvant chemotherapy 4 courses of FIRINOX early 5 patients, and 8 courses of FIRINOX subsequent 5 patients
89440251|NCT04690400|Experimental|Active care group|Participants will practice stretching exercises twice a week, at a distance and under the supervision of a professional, for 12 weeks. In addition, the experimental group will receive the same written guide and video of the comparator group.
88924907|NCT04507633|No Intervention|control group|usual care
88924908|NCT04503382|Experimental|Kindness media|Short videos of kindness media. As part of a program entitled EnSpire®, this media consists of short videos that display acts of kindness and compassion that are edited together into a single reel.
89502061|NCT03128827|Experimental|Test Subjects|All test subjects were pediatric patients following general anesthesia who received the RAM sensor which measures respiration rate.
89440252|NCT04690400|Active Comparator|Self-care group|Participants will receive stretching advice by written guide and video with stretching exercises, to be performed individually, without distance supervision, for 12 weeks. Participants will be able to resolve questions about the protocol at any time, via telephone.
89440253|NCT03375476||Vascular surgical patients|Patients undergoing elective vascular non-cardiac surgery in general anesthesia
89440254|NCT02147457||ELBW (CASES)|Extremely low birth weights, born in 2000-2005, birth weight below 1000 grams, who were initially admitted (2000-2005) at the Neonatal Intensive Care Unit, UZ Leuven Belgium and have been well characterized and documented in the postnatal period.
89440255|NCT02147457||CONTROLS|Survivors (CASES) (n = 140) will be matched with two healthy controls. One control will be matched to sex, birth year and residential area and will be suggested by the index patient (e.g. school friend, neighbor), the second control will be age and sex matched from the area of the field.
89440256|NCT03375398|Experimental|3 tablets Sugardown™|Repeated-measures, open cross-over design: 10 subjects consumed three different test meals comprising of white rice consumed with 3 tablets Sugardown™
89440257|NCT03375398|Placebo Comparator|Rice only|Repeated-measures, open cross-over design: 10 subjects consumed three different test meals comprising of white rice
89440258|NCT03375398|Experimental|6 tablets Sugardown™|Repeated-measures, open cross-over design: 10 subjects consumed three different test meals comprising of white rice consumed with 6 tablets Sugardown™
89440259|NCT04868942|Experimental|Participant assisting to the event|Attending to musical event protected by established protection measures (protection kit, distancing, flow management, health mediation).
89440260|NCT04868942|No Intervention|Participant with no other constraints than national recommendations|A group control participant will not attend to the event
89440261|NCT02147535|Experimental|Methylphenidate|
89440262|NCT02148627|Experimental|LY3041658 (IV)|Single dose of LY3041658, administered as a slow intravenous (IV) infusion in escalating dose cohorts.
89440263|NCT02148627|Experimental|LY3041658 (SC)|Single dose of LY3041658 administered subcutaneously (SC).
89440264|NCT02148627|Placebo Comparator|Placebo|Single dose of placebo (0.9% sodium chloride injection) administered as a slow IV infusion.
89440265|NCT03487796|Experimental|MySTYLE|MySTYLE is online, brief and encourages parent-adolescent communication about sex and HIV prevention. Participants (non-heterosexual Black adolescent males and parents/caregivers) will receive two texts per week (for eight weeks) with links to intervention content that includes video, games and graphics to improve knowledge, motivation and skills for HIV prevention. Topics include assertive communication, sexual safety, goal setting, and resilience.
88924909|NCT04503382|Active Comparator|Standard television|Children's commercial programming--as the control condition, participants watched commercial children's programming such as Disney, Nickelodeon, etc.
88924910|NCT04501094|Experimental|1/Arm 1-Treatment with Bintrafusp alfa (M7824)|Treatment with Bintrafusp alfa (M7824)
88924911|NCT04495907||Group I|Group I- Asymptomatic patients with SARS-CoV-2 Infection
89440266|NCT03487796|Other|Waitlist Control|Participants randomized to the waitlist control will be eligible to receive the eight-week MySTYLE intervention after the completion of the 4-month follow-up assessment. During their first four months of participation, waitlist control participants will not receive any intervention materials.
89440267|NCT02151747||Sanger|BRCA 1/2 test results by Sanger sequencing
89440268|NCT02151747||NGS|BRCA 1/2 test results by NGS
89440269|NCT02151825|Experimental|Synbiotic|3 capsules per day containing 4 billion CFU of Bifidobacterium lactis BB-12, Lactobacillus acidophilus LA-5, Lactobacillus casei 431 and Saccharomyces boulardii in combination with prebiotics Inulin (1 g) and Galactooligosaccharides (100 mg)
89440270|NCT02151825|Placebo Comparator|Placebo|3 capsules of Maltodextrin per day
89440271|NCT02155569|Active Comparator|Transperitoneal Cesarean|
89440272|NCT02155569|Active Comparator|Extraperitoneal Cesarean|
89440273|NCT02148705|Experimental|NexoBrid Gel|NexoBrid Gel is applied to the burn wound at a dose of 2 g NexoBrid sterile powder mixed with 20g sterile Gel Vehicle per 1% of TBSA (~ surface of an adult palm) for four hours.
89440274|NCT02148705|Placebo Comparator|Gel Vehicle|Gel Vehicle is applied to the burn wound at a dose of 20 g sterile Gel per 1% of TBSA (~ surface of an adult palm) for four hours.
89440275|NCT02148705|Active Comparator|Standard of Care (SOC)|Subjects in the SOC group may be treated with a combination of surgical and non-surgical eschar removal procedures, according to the investigator's judgment.
88924912|NCT04495907||Group II|Group II-Symptomatic patients with SARS-CoV-2 Infection
88924913|NCT04490707|Experimental|Azacitidine plus Lenalidomide (AZA+LEN)|"Arm 1(AZA+LEN): Elderly or unfit for intensive therapy AML patients who had achieved CR after remission-induction and consolidation chemotherapy enter maintenance therapy with AZA combined with LEN: AZA 50mg/m² per day for days 1-5 and LEN 10mg per day orally for days 6-26 , every 28 days for up to 12 cycles or progression.~AZA -Azacitidine, LEN- Lenalidomide"
88924914|NCT04490707|Experimental|Azacitidine(AZA)|"Arm 2 (AZA): Elderly or unfit for intensive therapy AML patients who had achieved CR after remission-induction and consolidation chemotherapy enter maintenance therapy with AZA 50mg/m² per day for days 1-5, every 28 days for up to 12 cycles or progression.~AZA -Azacitidine"
88924915|NCT04490707|No Intervention|Observation|Arm 3(Observation): Elderly or unfit for intensive therapy AML patients who had achieved CR after remission-induction and consolidation chemotherapy enter observation.
88924916|NCT04489485||Primary Care Providers (PCP)|20 PCP who provide well child care to teens 12-18. After randomization, 10 PCPs in the enhanced care group will use the Teen Depression Module for care.
88924917|NCT04489485||Standard care teens|All teens coming for routine well child care to the control group PCPs will have routine depression screening and Youth Health Questionnaire without goals to inform treatment as usual. They will be offered a goals text messaging conversation. Suicide screening will be at the discretion of the PCP.
89440276|NCT02254785|Experimental|Cabazitaxel|
89440277|NCT02254785|Active Comparator|Abiraterone or enzalutamide|
89502062|NCT02259595|Experimental|HPN-07 500 mg / Placebo|Single dose of 500mg HPN-07 plus placebo in oral capsules.
89502063|NCT02259595|Experimental|HPN-07 1000 mg / Placebo|Single dose of 1,000mg HPN-07 plus placebo in oral capsules
89502064|NCT02259595|Experimental|HPN-07 1500 mg / Placebo|Single dose of 1,500mg HPN-07 plus placebo in oral capsules
89440278|NCT02148783|Experimental|methylphenidate administration|All participants will receive oral methylphenidate 60 mg before the second TMS study. The participants will receive oral methylphenidate 60 mg before the second PET scan. Subjects will then be treated with oral methylphenidate, using a forced titration. Dose titration will be incremental within 6 days (dose-escalation phase) , starting at 5 mg orally twice daily for 3 days, and 10 mg twice daily for the next 3 days. Then the dose will be increased to 30 mg twice daily starting from day 7 given twice daily for additional 3 weeks.
89440279|NCT02155803|Experimental|Sarcoidosis related Calcium Dysregulation|Subjects with Sarcoidosis associated calcium dysregulation will be administered 80 units of Acthar Gel (adrenocorticotropic hormone) twice a week for 12 weeks. Clinical visits will be scheduled for -30 days, day of 1st dose and 4,8,12 and 16 week after 1st dose to monitor the health of subjects.
89440280|NCT02148861|Experimental|Insulin 287 + placebo|Subjects will receive one of two treatment combinations: either insulin 287 + placebo or insulin degludec + placebo. Dose escalation design (4 dose levels).
89440281|NCT02148861|Active Comparator|Insulin degludec + placebo|Subjects will receive one of two treatment combinations: either insulin 287 + placebo or insulin degludec + placebo. Dose escalation design (4 dose levels).
89440282|NCT02149017|Experimental|SNUBH-NM-333(18F), Safety, Efficacy|10 young controls, 10 cognitively normal elderly, and 10 Alzheimer's disease patients
89440283|NCT02152059|Experimental|BIBF1120|BIBF1120 200 mg twice daily continuously
89440284|NCT03124316|No Intervention|Email #1: FULLY TURNED OFF|No behavioural change techniques (BCTs) 'turned on' in the email. The email would contain only standardized content.
89440285|NCT03124316|Experimental|Email #2: ANTICIPATED REGRET|Anticipated regret content + standardized content
89012400|NCT02754154||Patients using Rivaroxaban|Patients 18 years of age and older with Non-Valvular Atrial Fibrillation (NVAF) using Rivaroxaban
89012401|NCT00280839|Active Comparator|topiramate|
89012402|NCT00280839|Placebo Comparator|placebo|
89199550|NCT05186233|Active Comparator|Non-personalized light condition|Participants will receive light exposure recommendations from the SHIFT mobile application based on their habitual sleep schedule. Participants will follow these recommendations over the course of two weeks.
89199551|NCT05186233|Experimental|Personalized light condition|Participants will receive light exposure recommendations from the SHIFT mobile application based on their activity levels. Participants will follow these recommendations over the course of two weeks.
89199552|NCT05182632|Experimental|Group pelvic floor tele-rehabilitation|12 weekly treatment online sessions + daily home exercise program
89199553|NCT05182476|Placebo Comparator|Placebo|Placebo daily
89199554|NCT05182476|Experimental|Luvadaxistat treatment schedule 1|Luvadaxistat daily
89440286|NCT03124316|Experimental|Email #3: MATERIAL INCENTIVE|Material incentive content + standardized content
89440287|NCT03124316|Experimental|Email #4: PROBLEM SOLVING|Problem solving content + standardized content
89440288|NCT03124316|Experimental|Email #5: REGRET + INCENTIVE|Anticipated regret content + Material incentive content + standardized content
89440289|NCT03124316|Experimental|Email #6: REGRET + PROBLEM SOLVING|Anticipated regret content + Problem solving content + standardized content
89012403|NCT04719728||pre lingual|aided response, speech perception threshold impedance telemetry electrically evoked action potential p1n1 cortical evoked potential
89012404|NCT04719728||post lingual|aided response, speech perception threshold speech in noise impedance telemetry electrically evoked action potential p1n1 cortical evoked potential
89440290|NCT03124316|Experimental|Email #7: INCENTIVE + PROBLEM SOLVING|Material incentive content + Problem solving content + standardized content
89440291|NCT03124316|Experimental|Email #8: ALL BCTs|Anticipated regret content + Material incentive content + Problem solving content + standardized content
89440292|NCT02149095|Experimental|TransCon PEG treprostinil|Dosing will begin at 0.116 mg/kg TransCon PEG treprostinil subcutaneous injection and the dose escalated in subsequent cohorts to MTD.
89440293|NCT03124394||CRS and intraoperative chemotherapy|Patients receiving cytoreductive surgery and intraoperative chemotherapy (HIPEC/PIPAC)
89440294|NCT04925739||OSA patients treated with CPAP|"OSA patient, not previously treated with CPAP, are treated with a ResMed Airsense 10 CPAP and an Air Liquide Medical Systems NINA mask during 30 days, monitored by the home care provider AGIRADOM.~After 30 days of CPAP treatment, 4 self-questionnaires are completed by the patient and parameters of the CPAP treatment (compliance, estimated unintentional leakage and therapeutic pressures) are collected."
89440295|NCT02520050|Active Comparator|Traditional MNT|Will be instructed to follow a MNT plan as recommended by the ADA through consultation with a RD.
89440296|NCT02520050|Active Comparator|Structured MNT|Will be instructed to follow a MNT plan as applied in the Why WAIT™ program, which includes structured dietary plan, dietary modification and use of diabetes-specific meal replacement (Ultra Glucose Control®; Metagenics Inc.) three times per day.
89440297|NCT02520050|Active Comparator|Structured MNT plus Weekly Support|Will be instructed to follow a MNT plan as applied in the Why WAIT™ program, which includes structured dietary plan, dietary modification and use of diabetes-specific meal-replacement (Ultra Glucose Control®; Metagenics Inc.) three times per day plus weekly coaching.
89440298|NCT02149251||Pre-genetic diagnosis|Women in this group had ICSI and PGD to exclude genetically affected children or for sex selection
89440299|NCT02149251||Control group|This group will include women who had IVF without PGD
89440300|NCT02149329|Experimental|Short treatment|Discontinuation of imipenem-cilastatin or meropenem after 3x24 hours irrespective of presence of fever.
89440301|NCT02149329|No Intervention|Extended treatment|Extended treatment with imipenem-cilastatin or meropenem for at least 6 more days. The treatment with a carbapenem will be continued until patients have been treated for at least 9x24 hours and have been afebrile (tympanic membrane temperature <38.0°C) for at least five consecutive days or until resolution of neutropenia (ANC > 0,5 x10^9/L), whichever comes first.
89012405|NCT00414869|Experimental|NCX-1000|Experimental drug under evaluation
89440302|NCT03255512|Experimental|Vericiguat + isosorbite mononitrate|"Subjects received Isosorbide mononitrate (ISMN) up-titration with 30 mg / 60 mg, about 7 days each,prior to start of vericiguat administration.~Then subjects received 2.5 mg vericiguat for about 14 days, followed by 5 mg vericiguat for about 14 days, followed by 10 mg vericiguat for about 14 days together 60 mg ISMN od on each day of vericiguat administration, taken 1 hour prior to vericiguat (in-house days) or together with vericiguat (out-patient days)."
89012406|NCT00414869|Placebo Comparator|Placebo|Placebo powder
89440303|NCT03255512|Placebo Comparator|Placebo + isosorbite mononitrate|"Subjects received Isosorbide mononitrate (ISMN) up-titration with 30 mg / 60 mg, about 7 days each, prior to start of placebo administration.~Then subjects received placebo matching 2.5 mg vericiguat for about 14 days, followed by placebo matching 5 mg vericiguat for about 14 days, followed by placebo matching 10 mg vericiguat for about 14 days together 60 mg ISMN od on each day of placebo administration, taken 1 hour prior to placebo (in-house days) or together with placebo (out-patient days)."
89440304|NCT02149407|Active Comparator|Glycerin group (GG)|"Glycerin group GG will receive the 0.5 suppository (700 mg) twice daily for 48 hours. We will use the rounded part and discard the other part then will hold baby's buttocks for 2 minutes to ensure its delivery."
89440305|NCT02149407|Active Comparator|Rectal stimulation group (SG)|"Rectal stimulation SG by soft cotton swab inserted to around 3 cm. The stick will press against the rectal wall in all direction for 2 minutes twice daily for 48 hours. Ky gel will be used to lubricate the stick and minimize direct friction to rectal wall."
89012407|NCT01680055||AA-ATG|Acquired Aplastic Anemia Patients Treated with Antithymocyte Globulin plus Cyclosporine
89012408|NCT01680133||NGT|Normal glycaemic healthy control men, age between 45-65, BMI 25-35 kg/m2
89440306|NCT02149407|Sham Comparator|Control group (CG)|"Control group CG will receive routine NICU medical care without any specific intervention for the infant. The research nurse will do shame placebo twice daily by opening his diaper to blind the team for 2 minutes."
89440307|NCT03543657|Experimental|Molidustat group|Subjects in the molidustat group will receive molidustat and darbepoetin alfa placebo.
89440308|NCT03543657|Active Comparator|Darbepoetin alfa group|Subjects in the darbepoetin alfa group will receive molidustat placebo and darbepoetin alfa.
89440309|NCT04404998|Experimental|Lower Energy Density & Lower Satiation|Test meal with lower energy density and lower satiation information
89012409|NCT01680133||T2D|Type 2 diabetic men, age 45-65 yrs, BMI 25-35, diagnosed >5yrs and Hba1c 7-9%
89012410|NCT01680211|Experimental|Salacia bark extract (SR-B-01) and TLC|Capsules containing 250mg of salacia bark extract,two times a day along with Therapeutic Lifestyle Change (TLC)
89012411|NCT01680211|Experimental|Sesame seeds extract (SI-S-01) and TLC|Capsules containing 250mg of sesame seed extract,two times a day along with Therapeutic Lifestyle Change (TLC)
89012412|NCT01680211|Experimental|Salacia leaf extract (SR-L-01) and TLC|Capsules containing 250mg of salacia leaf extract,two times a day along with Therapeutic Lifestyle Change (TLC)
89012413|NCT01680211|Placebo Comparator|Placebo and TLC|Capsules containing 250mg of placebo,two times a day along with Therapeutic Lifestyle Change (TLC)
89012414|NCT01680250|Experimental|Sirolimus|Sirolimus administration group starting dose: 2mg/day target trough level: 4-10 ng/dL
89440310|NCT04404998|Experimental|Lower Energy Density & Higher Satiation|Test meal with lower energy density and higher satiation information
89440311|NCT04404998|Experimental|Higher Energy Density & Lower Satiation|Test meal with higher energy density and lower satiation information
89440312|NCT04404998|Experimental|Higher Energy Density & Higher Satiation|Test meal with higher energy density and higher satiation information
89440313|NCT03380234|Experimental|Intervention|8 worksheets and around 15 online quizzes and 30 WhatsApp messages.
89440314|NCT03380234|Other|Control|Control students will receive the following minimal intervention to reduce their intention to smoke and SHS - a leaflet on smoking and SHS published by the Department of Health.
89440315|NCT02152215|Active Comparator|Acellular dermal matrix membrane|An acellular dermal matrix membrane will be used as a barrier between the osseous graft and the soft tissue flap.
88924918|NCT04489485||Enhanced care teens|All teens coming for routine well child care to the enhanced group PCPs will have depression screening with strengths and goals and a depression screen with follow up suggestions for activities to help any depression symptoms, as well as Youth Health Questionnaire with goals and then they will receive treatment guided by the Teen Depression Module and offered a depression text messaging conversation. Suicide screening will be conducted.
88924919|NCT04489485||Standard care- caregivers|All caregivers of teens <18 years old coming for routine well child care to the control group PCPs will complete a Pediatric Symptom Checklist and Short Moods and Feelings Questionnaire, plus a Youth Health Questionnaire- Parent version to inform treatment as usual. If the internalizing subscale is positive the caregiver will also complete the Short Moods and Feelings Questionnaire and 3, 6 and 11.5 month follow up report of Intervention received (Parent Intervention Questionnaire)
88924920|NCT04489485||Enhanced care- caregivers|All caregivers of teens <18 years old coming for routine well child care to the enhanced group PCPs will complete a Pediatric Symptom Checklist plus a Youth Health Questionnaire- Parent version to inform treatment as usual. If the internalizing subscale is positive the caregiver will also complete the Short Moods and Feelings Questionnaire and 3, 6 and 11.5 month follow up report of Intervention received (Parent Intervention Questionnaire)
89440316|NCT02152215|Experimental|Polylactic acid membrane|A polylactic acid membrane will be used as a barrier between the osseous graft and the soft tissue flap.
89440317|NCT03380156|Experimental|Interventional|Active TVS will be performed by use of a Tragus stimulator device with electrodes attached to the tragus of the ear. Stimulator will be applied continuously for 1 hour.
89440318|NCT03380156|Placebo Comparator|Control|Sham TVS will be performed by use of a Tragus stimulator device with electrodes attached to the ear lobule. Stimulator will be applied continuously for 1 hour.
89440319|NCT02155959||one group|one group receiving a toric intraocular lens during cataract surgery.
88924921|NCT04488913|Other|Standard of Care Treatment|Exposure to traditional evaluation for suspected acute coronary syndrome (ACS) with ECG, 0- and 3-hour troponin testing using the 99th percentile as the upper reference limit, and application of the History, EKG, Age, Risk factors, and troponin (HEART) score.
88924922|NCT04488913|Active Comparator|RACE-IT pathway|Exposure to new protocol for suspected ACS, which includes the use of 0- and 1-hour ECG and high-sensitivity troponin testing and application of the HEAR score (a modification of the HEART score)
89440320|NCT02730728|Active Comparator|Single shot adductor canal block|adductor canal block group will receive single shot adductor canal block with 20ml bolus of 0.5% ropivicaine for analgesia after TKA
89440321|NCT02730728|Active Comparator|24 hour continuous adductor canal block|adductor canal block group will receive 24 hour continuous adductor canal block (0.2% Ropivicaine at 8 milliliter/hour) with initial 5ml bolus of 0.5% Ropivicaine for analgesia after TKA
89440322|NCT02730728|Active Comparator|48 hour continuous adductor canal block|adductor canal block group will receive 48 hour continuous adductor canal block (0.2% Ropivicaine at 8 milliliter/hour) with initial 5ml bolus of 0.5% Ropivicaine for analgesia after TKA
89440323|NCT02156037|Experimental|dashboard team care intervention|Dashboard team
89440324|NCT02156037|Active Comparator|usual diabetes team control|usual clinical diabetes team with no access to the diabetes dashboard
89440325|NCT03379922|Experimental|Stress balls|The first arm will be given stress balls to squeeze during their treatment and will also receive standard care (the offer of oral analgesia)
89012415|NCT02279875|Experimental|Linezolid 300 mg once per day|Half of a 600mg (scored) tablet
89012416|NCT02279875|Experimental|Linezolid 300 mg twice per day|Half of a 600mg (scored) tablet
89012417|NCT02279875|Experimental|Linezolid 600 mg once per day (A)|600mg (scored) tablet
89012418|NCT02279875|Experimental|Linezolid 600 mg once per day (B)|600mg (scored) tablet
89012419|NCT02279875|Experimental|Linezolid 600 mg twice per day|600mg (scored) tablet
89012420|NCT02279875|Experimental|Linezolid 1200 mg once per day|Two 600mg (scored) tablets
89012421|NCT02279875|Experimental|Linezolid 1200 mg 3 times per week|Linezolid 1200 mg administered as a single oral dose three times per week (1200 mg: Day 1, 3, 5, 8, 10, and 12)
89012422|NCT02279875|Active Comparator|HRZE once per day|"Treatment will be administered orally once daily for 14 days per the~Subject's weight as follows:~30-37 kg: 2 tablets;~38-54 kg: 3 tablets;~55-70 kg: 4 tablets;~71 kg and over: 5 tablets."
89012423|NCT04824508|Active Comparator|Conventional position (head position)|Leaderposition at the patient's head
89012424|NCT04824508|Active Comparator|Remote position|Leaderposition remote from patient and hands-off
89012425|NCT00252551|Experimental|1|osteosynthesis
89012426|NCT00252551|Active Comparator|2|Simple surgery
89012427|NCT00280995|Experimental|Cohort A|Loading doses followed by weekly maintenance doses
89012428|NCT00280995|Experimental|Cohort B|Loading doses followed by weekly maintenance doses
89012429|NCT00280995|Experimental|Cohort C|Loading doses followed by weekly maintenance doses
89012430|NCT00280995|Experimental|Cohort D|Loading doses followed by extended weekly maintenance doses
89012431|NCT04822675|Experimental|Percutaneous mitral repair|Percutaneous mitral repair +/- coronary artery bypass grafting within 14 days of mitral repair.
89012432|NCT04822675|Active Comparator|Mitral valve surgery|Surgical mitral valve surgery +/- coronary artery bypass grafting
89012433|NCT05139667|Experimental|tacrolimus/corticosteroid|topical steroids ( triamcinolone acetonide 0.1 %), tacrolimus paste and tacrolimus patch
89012434|NCT05139667|Active Comparator|corticosteroids|topical corticosteroid
89012435|NCT05139667|Active Comparator|tacrolimus|topical tacrolimus patch and tacrolimus paste
89012436|NCT02271061|Experimental|Kinesio Tape|Taping method will be performed in supine position .The taping technique will be started at tibial tuberosity to medial and lateral epicondyles of the femur. The tape will be cut in I shape with 30 cm. The back paper of tape will be removed from the center of tape and both end of the back paper will be placed at each end of tape. Center of the tape will be placed on the tibial tuberosity with no tension. Participants' knee will be bend approximately 20 - 30 degrees. The tape will be pulled at 1/3 of each end with 75% of available tension along the medial and lateral collateral ligaments and the tibia will be pushed to the back. The end of the tape will be placed with no tension toward the medial and lateral aspects of the thigh .
89012437|NCT02271061|Sham Comparator|Control tape|Apply tape in same technique without tension.
89012438|NCT00287352|Placebo Comparator|Double-Blind Treatment|Olanzapine continuing with placebo
89012439|NCT00287352|Active Comparator|Olanzapine, Amantadine|Standard combine with Amantadine
89012440|NCT04823962|Experimental|GM-CSF|rhGM-CSF (molgramostim) + hydrogel
89012441|NCT04823962|Placebo Comparator|Placebo|Hydrogel
89012442|NCT02271997|Active Comparator|Ferrous fumarate|40 patients receive ferrous fumarate 3 times a day 200mg
89440326|NCT03379922|Experimental|Headphones|The second arm will be given headphones to listen to music during their treatment and will also receive standard care.
89012443|NCT02271997|Active Comparator|Ferrous gluconate|40 patients receive ferrous gluconate 2 times a day 695 mg
89012444|NCT02271997|Active Comparator|Iron(III)carboxymaltose|40 patients receive a single intravenous shot of ferinject
89012445|NCT04821076|Active Comparator|Energy balance|
89012446|NCT04821076|Experimental|Energy restriction|
89012447|NCT04821076|Active Comparator|Energy balance + exercise|
89012448|NCT04821076|Experimental|Energy restriction + exercise|
89012449|NCT00281034||OASIS Study Group|
89012450|NCT05139082|Other|CDK4/6 inhibitor (TQB3616) + PD-L1 monoclonal antibody (TQB2450)|TQB3616 capsules (120/150/180mg p.o. qd, d1-d21) combined with TQB2450 injection (1200mg ivgtt, d1)
89012451|NCT04719767|Experimental|visual|In the visual group, a visual laryngeal mask was placed and endotracheal intubation was guided under visual conditions. The endotracheal tube was removed 10 minutes before the end of the operation, and the laryngeal mask was retained.
89012452|NCT04719767|No Intervention|Non-visual|In the non-visual group, laryngeal mask airway was inserted. After clinical judgment of good counterpoint, endotracheal intubation was inserted blindly through LMA. Endotracheal intubation was removed 10 minutes before the end of the operation, and the laryngeal mask airway was retained.
89012453|NCT05138926|Experimental|Cervical manipulation group|high speed, low amplitude cervical manipulation
89012454|NCT05138926|Sham Comparator|Control group|placebo mobilization without manipulation
89012455|NCT04473352||Single Group|Patients with suspected acute viral status for COVID 19 will be invited to participate in the identification of the first symptoms. The diagnosis of COVID-19 will be confirmed according to the determinations of the MS through the reaction of qRT-PCR in the nasopharynx swab. Patients will undergo multiple collections of biological material including blood, saliva, semen, and urine. Each patient will be subjected to serial sample collections. The samples will be processed and analyzed for the presence of viral RNA. Patients with 2 consecutive negative samples did not need to perform subsequent collections.
89012456|NCT01680367|Experimental|Arm I (control)|Patients receive transparent film dressing (otolaryngology service) or Xeroform petroleum gel impregnated gauze dressing (surgical oncology service) after surgery.
89440327|NCT03379922|No Intervention|Control|The control group will receive standard care (the offer of oral analgesia)
89440328|NCT03381794||Patients with corneal transplantation|Aim is to include all patients in Germany treated with the different types of corneal transplantation with an interim-assessment of the period between 2001 and 2016.
89440329|NCT02156193|Experimental|Prophylactic clip|Before conventional snare polypectomy, hemoclips will be applied on the base of stalk.
89440330|NCT02156193|Active Comparator|No prophylactic management|Conventional snare polypectomy will be performed without any preventive management.
89440331|NCT03379766|Experimental|Successor of Phonak Audéo B-Direct|The successor of Phonak Audéo B-Direct will be fitted to the participants individual hearing loss.
89440332|NCT03379766|Active Comparator|Phonak Audéo B-Direct|The Phonak Audéo B-Direct will be fitted to the participants individual hearing loss.
89440333|NCT02149563|Active Comparator|Treatment|One hundred participants will receive home treatment with oxygen-enriched air (40% O2) through a nasal tube during the night (7 hours) for one month.
89440334|NCT02149563|Placebo Comparator|Placebo|100 participants will receive regular air treatment (21% O2) through a nasal tube (identical to the procedure providing 40% O2) for one month
89440335|NCT03381716||male|Drug:Beta-blocker,Angiotensin II receptor blocker,Angiotensin-converting enzyme,Calcium-channel blocker,Aspirin,Statin
89440336|NCT03381716||female|Drug:Beta-blocker,Angiotensin II receptor blocker,Angiotensin-converting enzyme,Calcium-channel blocker,Aspirin,Statin
89440337|NCT02149641||Nasopharyngeal cancers|Intensitiy modulated radiotherapy with chemotherapy
89440338|NCT03543579||Multiple myeloma patients|Patients with multiple myeloma and an indication to receive carfilzomib
89440339|NCT04319822|Experimental|blood samples, muscular biopsy, and quality of life|quality of life, blood samples, quadriceps biopsy in intensive care unit (before and after the ICU hospitalization and one at M6
89440340|NCT02152449|No Intervention|Control group|"Control group: systematic advice on swallowing, plus:~If no weight loss compared to usual weight: no intervention~if weight loss <5%: advice on a fat- and protein-enriched diet~if weight loss ≥5%: advice on a fat- and protein-enriched diet + 1 unit of ONS/day per os"
89440341|NCT02152449|Experimental|oral nutritional supplementation|"Experimental ONS Group: systematic advice on swallowing + systematic advice on a fat- and protein-enriched diet, plus:~if no weight loss compared to usual weight: 1 ONS/day per os~if weight loss <5% compared to usual weight: 2 ONS/day per os~if weight loss ≥5% compared to usual weight: 3 ONS/day per os"
89012457|NCT01680367|Experimental|Arm II (native collagen wound dressing)|Patients receive native collagen wound dressing after surgery.
89012458|NCT00281073|Active Comparator|TEE and ICE|Serial use of TEE and ICE for comparative analysis
89440342|NCT02520128|Other|Cohort 1 (closed to recruitment)|"Cohort 1: Patients with Limb/limb girdle soft tissue sarcoma (STS) receiving (neo)-adjuvant radiotherapy (Intensity Modulated Radiotherapy)~Dose schedules for Cohort 1:~Pre-operative RT - 50 Gy in 25 daily fractions over 5 weeks~Post-operative RT - 60 Gy in 30 daily fractions to the high dose planning target volume (PTV) and 52.2 Gy in 30 daily fractions to the low dose PTV treated concurrently over 6 weeks~Post-operative RT (positive resection margins) - 66 Gy in 33 daily fractions to the high dose PTV, and 53.46Gy in 33 fractions to the low dose PTV treated concurrently over 6 ½ weeks."
89440343|NCT02520128|Other|Cohort 2|"Cohort 2: Patients with Ewing sarcoma of the spine/pelvis receiving definitive radical or (neo)-adjuvant radiotherapy (Intensity Modulated Radiotherapy)~Dose schedules for Cohort 2:~Pre-operative RT - 50.4 Gy in 28 daily fractions over 5½ weeks~Post-operative RT - 54 Gy in 30 daily fractions over 6 weeks~Primary RT - 54 Gy in 30 daily fractions over 6 weeks."
89440344|NCT02520128|Other|Cohort 3|"Cohort 3: Patients with non-Ewing primary bone sarcomas of the spine/pelvis receiving definitive radical or adjuvant Radiotherapy (Intensity Modulated Radiotherapy)~Dose schedule for Cohort 3:~Primary RT - 70 Gy in 35 daily fractions over 7 week~Post-operative RT (non-chordoma) - primary bone sarcoma 60 Gy in 30 daily fractions over 6 weeks~Post-operative RT (chordoma) - 70 Gy in 35 daily fractions over 7 weeks."
89440345|NCT03542955|Active Comparator|ActiPatch Group|Subjects in this group will receive an active pulsed shortwave therapy device to wear 24 hours a day for 4 weeks.
89440346|NCT03542955|Placebo Comparator|Control Group|Subjects in this group will take Etoricoxib 60mg, once daily for 4 weeks.
89440347|NCT03542331|Other|Control group|The control group wille have a mock catheter introduction between day 6 and 8 of the cycle without any Lipiodol flush
89440348|NCT03542331|Experimental|Intervention group|The intervention group will undergo endometrial flushing with Lipiodol between day 6 and 8 of the cycle
89012459|NCT00281073|Active Comparator|ICE or TEE|
89012460|NCT01680406|Active Comparator|Artemether-lumefantrine|Weight-based dose to be administered as fixed-dose combination twice daily for three days.
89199555|NCT05182476|Experimental|Luvadaxistat treatment schedule 2|Luvadaxistat daily
89199556|NCT05180227|Placebo Comparator|Without Stimulation|Participant will complete an orthostatic challenge without transcutaneous stimulation.
88924923|NCT04486170|No Intervention|Control group: Current hospital education practices|The control group will receive standard of care postpartum educational materials provided by the nursing and resident physician staff. The will be asked to complete a brief questionnaire to determine if they would be interested in receiving education in a video formal.
88924924|NCT04486170|Experimental|Intervention group: Standardized video and pamphlet|The subjects enrolled in the invention group will be shown a 5 minute educational video on hypertension in the postpartum period. The patients will be shown the video on the ipad while they are in the comfort of their room. They will also be provided with a pamphlet with similar information that was discussed in the video. They will also be asked to complete a brief, anonymous survey to assess patient satisfaction with the video shown, no patient identifiers will be collected.
88924925|NCT04482738||Lean subjects|24 hours before the study visit, participants will be asked to refrain from alcohol and strenuous exercise. Patients will be asked to remain fasted 10 hours before the study visit takes place. On the day of the study visit, patients will be admitted to the hospital and, after intake of the study meal, blood samples will be taken.
88924926|NCT04482738||Obese subjects|24 hours before the study visit, participants will be asked to refrain from alcohol and strenuous exercise. Patients will be asked to remain fasted 10 hours before the study visit takes place. On the day of the study visit, patients will be admitted to the hospital and, after intake of the study meal, blood samples will be taken.
88924927|NCT04472468|Experimental|Treatment (pericardiotomy)|"Patient in this arm will receive balloon pericardiotomy before insertion of pericardiocentesis.~An 20mm over-the-wire ultra-non-compliant Percutaneous Transluminal Angioplasty Balloon is used to dilate the pericardium.~Success of balloon pericardiotomy is confirmed by full inflation of the balloon which is confirmed on two orthogonal projections.~Standard pericardiocentesis with prolonged drainage is performed afterwards.~Pericardial drain is removed when output is less than 100cc/day"
88924928|NCT04472468|No Intervention|Control (standard pericardiocentesis)|"Standard pericardiocentesis procedure is performed using standard pigtail pericardial drain. - Pericardial fluid is then tapped until dry on table.~Pericardial drain is removed when output is less than 100cc/day"
88924929|NCT04464577|Experimental|Arm A: BMS-986235+Fluconazole|
88924930|NCT04464577|Experimental|Arm B: BMS-986235+ Bupropion|
88924931|NCT04464577|Experimental|Arm C: BMS-986235+ Itraconazole|
89537026|NCT02467127|Experimental|Chronic headache with drug overuse|Patients with headache > 6 months related to drug treatment, i.e. non steroidal antinflammatory drugs. Vitamin D supplementation (from 400 iU/day up to 1600 IU/day) will be administered.
89537027|NCT02467127|Experimental|Acute Headache|Patients without chronic headache but with an history of headache < 6 months. Vitamin D supplementation (from 400 iU/day up to 1600 IU/day) will be administered.
89537028|NCT03302819|Experimental|Breast cancer accuracy|Patients with a known or suspected (and subsequently proven) breast cancer
89537029|NCT03302819|Experimental|Imaging characteristics and performance|Patients attending the symptomatic clinic
89537030|NCT03302819|Experimental|Tumour response in neoadjuvant treatment|Patients who are being treated with neoadjuvant chemotherapy or endocrine treatment
89537031|NCT02466893|Other|ADAPT Technique/Standard SR Group|
89537032|NCT05727917|Experimental|hetrombopag group (Experimental group)|After hematopoietic stem cell reinfusion, the patients begin to take hetrombopag orally 7.5mg/d, until the patients reach complete platelet response (CR, platelet count ≥50×109/L for 3 consecutive days without platelet transfusions for 7 consecutive days). The treatment will stop when patients accept 21 consecutive days of treatment or reach the discontinuation criteria.
89537033|NCT05727917|Placebo Comparator|Control group|After hematopoietic stem cell transfusion, the patients will be only observed, and the observation during the treatment period will be ended after 30 days.
89537034|NCT03302585|Experimental|High-Dose Vitamin D Treatment Group|"Patients in this arm will receive:~-5 days of high-dose oral vitamin D3 (50,000 IU daily x 5), followed by 85 days of moderate dose oral vitamin D3 (10,000 IU daily x 85 days)"
89440349|NCT03381638||Normal Volunteer|Volunteers who report to have never had a concussion and are not at high risk of getting a concussion are scanned to obtain a baseline of all ages, sex, race, etc. All patients will be scanned with the Blink Reflexometer.
89440350|NCT03381638||Concussion Protocol|Athletes who had a potential concussion and will go through any stage of the approved protocol, are scanned by the Blink Reflexometer device. Results are then analyzed prior to unblinding the clinical diagnosis from an Athletic Trainer and/or Neurologist.
89440351|NCT02152527||Trimetazidine|Patients for coronary artery bypass grafting surgery who had preoperative trimetazidine usage in standard ischemic coronary disease therapy.
89440352|NCT02152527||Control|Patients for coronary artery bypass grafting surgery who had standard therapy for ischemic coronary disease without trimetazidine.
89440353|NCT03543501|Experimental|Real-time ultrasound imaging group|See intervention
89440354|NCT03543501|Experimental|PBU group|See intervention
89440355|NCT02149797|Active Comparator|Four port laparoscopic cholecystectomy|This group of patients undergone classical four port laparoscopic cholecystectomy
89440356|NCT02149797|Active Comparator|SILC-Pick'n roll-Beginning (group I)|"This group of patients undergone single-incision laparoscopic cholecystectomy using our new technique called Pick'n roll, this group was designed new intervention's beginning arm."
89440357|NCT02149797|Active Comparator|SILC-Pick'n roll-Experienced (group II)|"This group of patients undergone single-incision laparoscopic cholecystectomy using our new technique called Pick'n roll, this group was designed new intervention's experienced arm."
89440358|NCT03744585||Cohort 1|Subjects who received at least one dose of cabozantinib during the Authorization for Use (ATU) period (12/09/2016 to 09/12/2016) for the treatment of advanced Renal Cell Carcinoma (RCC).
89440359|NCT03744585||Cohort 2|Subjects who received at least one dose of cabozantinib during the first six months after the ATU period (10/12/2016 to 16/02/2018).
89440360|NCT03744507||Uterine Fibroids|Premenopausal women with uterine fibroids confirmed by an ultrasound.
89440361|NCT03744507||Endometriosis|Premenopausal women with endometriosis diagnosed or confirmed by surgical or direct visualization, or histopathology within 10 years of the Screening visit.
89440362|NCT05431426|Experimental|Mild renal impaired subjects|Administration of a single dose of CH6001 800 µg in mild renal impaired subjects.
89440363|NCT05431426|Experimental|Moderate renal impaired subjects|Administration of a single dose of CH6001 800 µg in moderate renal impaired subjects.
89440364|NCT05431426|Experimental|Severe renal impaired subjects|Administration of a single dose of CH6001 800 µg in severe renal impaired subjects.
89440365|NCT05431426|Experimental|Healthy volunteers|Administration of a single dose of CH6001 800 µg in healthy volunteers.
89012461|NCT01680406|Experimental|Artemether-lumefantrine and primaquine|"Artemether-lumefantrine will be given in a weight-based dose to be administered as fixed-dose combination twice daily for three days.~Primaquine will be given beginning on day 2 of artemether-lumefantrine to patients with a normal G6PD test; dose is weight-based to be administered once daily for 14 days."
89012462|NCT01680406|Active Comparator|Chloroquine|Chloroquine will be given in a weight-based dose to be administered once daily for three days.
89440366|NCT03379220||Subdural ECoG (Group 1)|For patients who require craniotomy to treat TBI, a subdural electrode strip will be placed intraoperatively following evacuation of a hematoma or contusion, as required. Electrode strips will be used for subsequent electrocorticography (ECoG) during intensive care. Patients will also undergo continuous scalp EEG monitoring.
89440367|NCT03379220||Burr Hole ECoG (Group 2)|For patients who do not require surgery but do require invasive monitoring, an intraparenchymal ECoG electrode array will be placed through a cranial burr hole. Depending on other monitoring needs, the location of injuries, and other clinical considerations, the burr hole may be the same as used for placement of other probes or may be separate. In cases of focal injury, the burr hole will be placed to allow electrode targeting to a lobe with significant primary lesion(s). Patients will also undergo continuous scalp EEG monitoring.
89440368|NCT03379220||EEG (Groups 1-3)|Continuous EEG recordings will be made using Ag/AgCl electrodes placed on or beneath the scalp (subdermal wire) according to standard practice. The default montage will employ eight lead electrodes for each hemisphere following the 10/20 system (Right: Fp2, F4, C4, P4, O2, F8, T4, T6; left: Fp1, F3, C3, P3, O1, F7, T3, T5). Other montages with more dense placement of electrodes in the region of ECoG monitoring may also be used.
89440369|NCT00104637|Active Comparator|Sildenafil / Placebo|Sildenafil first, followed by washout, followed by placebo
89440370|NCT00104637|Placebo Comparator|Placebo / Sildenafil|Placebo first, followed by washout, followed by Sildenafil
89440371|NCT03379142|Other|Behavioral: Faith-Based messages|We will send faith-based messages one week prior to Ramadan and twice a day during Ramadan.
89440372|NCT05534776||First Scoring Session|Participants whose de-identified photos will be printed in the first booklet for the first scoring session.
89440373|NCT05534776||Second Scoring Session|Participants whose de-identified photos will be printed in the second booklet for the second scoring session.
89440374|NCT04810208|Experimental|NZ-DTX Depot|
89440375|NCT05428774|Experimental|Test Product 1|Participants will consume test product 1 during one experimental visit.
89440376|NCT05428774|Experimental|Test Product 2|Participants will consume test product 2 during one experimental visit.
89440377|NCT05428774|Placebo Comparator|Placebo|Participants will consume placebo during one experimental visit.
89440378|NCT02156349|Other|Control Group|Patients treated by usual customary medical practice (Usual Care) in the out-patient facility i.e. Diabetes specialized medical practice, Medical Care Center or hospital outpatient clinic.
89440379|NCT02156349|Other|Intervention group|"Patients are treated according to the concept Integrated personalized diabetes management."
89502065|NCT02259595|Experimental|HPN-07 MTD plus NAC 1200mg|Single dose of maximum tolerated dose of HPN-07 plus 1,200 mg NAC in oral capsules. Dose selection will be determined from safety data of previous cohorts by Data Assessment Committee (DAC).
89502066|NCT02259673|Experimental|Fun exercise|effect of fun physical exercise on sarcopenia
89502067|NCT02259673|Experimental|fun exercise|effect of fun physical exercise on interest in exercise
89537035|NCT03302585|Placebo Comparator|Placebo/Standard Vitamin D3 Group|"Patients in this arm will receive Placebo/Standard of Care Vitamin D3:~-5 days of placebo, followed by 85 days of standard of care dose of oral vitamin D3 (4,000 IU daily x 85 days)"
89440380|NCT03125330|Experimental|One-to-One Coaching|"Participants randomized to One-to-One Coaching meet for an initial 2-hour coaching session, followed by seven 1-hour coaching sessions every 3-weeks. These eight sessions take place over the course of 6 months.~Additional requirements for One-to-One Coaching:~Complete a 30-minute online assessment of goal attainment, well-being, burnout, and leadership strengths (a) at study enrollment, (b) at 6-months after study enrollment, and (c) 12-months following study enrollment.~Complete a 15-minute VIA Character Strengths Test online prior to One-to-One Coaching.~Following the completion of the final coaching session, participants are interviewed by a con-investigator by phone call to assess the experience of coaching.~Each coaching session will be recorded, transcribed, anonymized, and analyzed to identify common themes."
89440381|NCT03125330|Active Comparator|Group Coaching|"Participants meet for 90-minutes each month for 6 months for facilitated professional coaching with a group of colleagues.~Additional requirements:~Complete a 30-minute online assessment of goal attainment, well-being, burnout, and leadership strengths (a) at study enrollment, (b) at 6-months after study enrollment, and (c) 12-months following study enrollment.~Complete a 15-minute VIA Character Strengths Test online prior to Group Coaching.~Prior to your initial group coaching session, participate in a 75-minute private phone interview with the primary investigator to discuss the how you make decisions and make sense of the world.~Following the completion of the final coaching session, participants are interviewed by a con-investigator by phone call to assess the experience of coaching.~Each coaching session will be recorded, transcribed, anonymized, and analyzed to identify common themes."
89440382|NCT03125330|No Intervention|Group Coaching Waitlist|"Participants are offered group coaching at the completion of the 12-month study period. Six 90-minute group coaching sessions will occur over the course of six months.~Additional requirements:~• Complete a 30-minute online assessment of goal attainment, well-being, burnout, and leadership strengths (a) at study enrollment (b) and at 6-months after study enrollment."
89440383|NCT04445636|Experimental|Dexmedetomidine group|A group which will receive dexamedetomidine as an adjunct to bupivacaine used in caudal anesthesia.
89440384|NCT04445636|Experimental|Morphine group|A group which will receive morphine as an adjunct to bupivacaine used in caudal anesthesia.
89440385|NCT03542253||Age|
89440386|NCT03542253||Sex|
89440387|NCT03542253||triglyceride|
89440388|NCT03542253||Lipoprotein|
89440389|NCT03542253||CT|Target Reconstruction
89440390|NCT03542253||micorRNA-A Plasma exocrine|
89440391|NCT03542253||micorRNA-A Paracancerous tiusse|
89440392|NCT03542253||pathologic diagnosis|
89440393|NCT03542253||hemolysis|
89440394|NCT03542253||ct-DNA|
89440395|NCT03542253||micorRNA-A in plasma|
89440396|NCT03542253||Sample quality control|
89440397|NCT03542253||positive|
89440398|NCT03542253||negative|
89440399|NCT03542253||micorRNA-R in plasma|
89440400|NCT03542253||micorRNA-R in Plasma exocrine|
89440401|NCT03542253||Surgery|
89440402|NCT04445480|Experimental|Popliteal block group|
89440403|NCT04445480|Active Comparator|Control group|
89440404|NCT05649124|Experimental|Acupressure group|"Participants in this group will be interviewed at postpartum 3rd and 5th hours. The application will be explained and a voluntary consent form will be signed.~Participant Information Form will be filled in by the researcher by face-to-face interview.~The VAS and McGill Pain Questionnaire, which will be applied to evaluate perineal pain at the 3rd and 5th hours of the postpartum period, will be filled in by the participant.~In a total application where SP6, ST36 and LI4 points will be applied for 2 minutes, the total time will be 12 minutes.~After the application, the VAS and McGill Pain Questionnaire Evaluating Perineal Pain will be filled in by the participant.~The participant will be informed that the study has been completed."
89440405|NCT05649124|No Intervention|Control group|"Participants in this group will be interviewed at postpartum 3rd and 5th hours. The application will be explained and a voluntary consent form will be signed.~Participant Information Form will be filled in by the researcher by face-to-face interview.~3. VAS (Visual analog scale) and McGill Pain Questionnaire for Evaluating Perineal Pain will be required at 5th and 5th hours.~No application will be made other than routine applications."
89440406|NCT02768103|Experimental|SCI transfer + training|Individuals with tetraplegia and brachioradialis to flexor pollicis longus transfer will participate in 10 week home training program to improve surgical outcome (pinch strength)
89440407|NCT02152839|Experimental|Old Unilateral Exercise|Old individuals (65-75y) studied before and after 6 weeks of unilateral resistance exercise training
89440408|NCT02152839|Experimental|Young Unilateral Exercise|Young Individuals (18-30y) studied before and after 6 weeks unilateral resistance exercise training
89440409|NCT03375086|Experimental|Single arm|Patients will receive APX3330 orally, twice per day until disease progression
89440410|NCT02152917|Active Comparator|Tranexamic acid|A dose of tranexamic acid (10mg/Kg) will be administered 20 minutes before inflating the pneumatic tourniquet and another dose 15 minutes after the tourniquet release.
89440411|NCT02152917|Active Comparator|Floseal®|Floseal® will be applied in regions of potential bleeding before the release of the pneumatic tourniquet.
89440412|NCT02152917|No Intervention|Control group|
89440413|NCT03111212|Active Comparator|Iloprost|
89440414|NCT03111212|Placebo Comparator|control|
89440415|NCT02156427|Experimental|VITICELL|In this arm, lesions will be treated by autologous epidermal cells suspension (containing hyaluronic acid) obtained after VITICELL kit's use, a class III medical device.
89440416|NCT02156427|Placebo Comparator|PLACEBO|In this arm, lesions will be treated by a suspension of hyaluronic acid without epidermal cells.
89440417|NCT02156505|Experimental|DoubleBare stent|Placement of double bare stent
89440418|NCT03543423|Experimental|Oral glucose tolerance test|Intervention: oral glucose tolerance test (75 gram glucose supplemented with 5g 3-OMG and 1g paracetamol) ingested over 2 min.
89440419|NCT03543423|Experimental|Liquid mixed meal test|Intervention: Standardised liquid mixed meal (supplemented with 1g paracetamol) ingested over 2min
89440420|NCT03375008|Experimental|Imaging diagnostic and biopsy|47 subjects who are suspected NASH from June 2016 to December 2017.
89440421|NCT02149953|Experimental|Glycine intake|Dietary supplement: Glycine intake
89440422|NCT03380936|Active Comparator|Arm 1 - conversion to Envarsus XR|Optimize: conversion to Envarsus XR (Tacrolimus Extended Release Oral Tablet [Envarsus]) with goal trough tac level > 8 ng/ml, MPA at 720 mg bid unless medically contraindicated, prednisone at current dose (5mg) or continue taper to 5mg per center standard of care protocol
89440423|NCT03380936|Active Comparator|Arm 2 - plasma exchange and IVIG|Treat clinical AMR: Plasma exchange x 5 treatments, each followed by IVIG 200 mg/kg except last dose of 1 gm/kg. Rituximab 375 mg/m2 following final plasma exchange treatment.
89440424|NCT02150031|Other|Control|"Blood extraction using the intravenous access 18-22 gauge angiocath catheter (Becton Dickinson, Sparks, MD, USA) (at baseline, 30 seconds and 15 minutes after tooth extraction).~No prophylactic Chlorhexidine regimen.~Local anesthesia with lidocaine plus adrenaline (1:100,000).~Tooth extraction."
89440425|NCT02150031|Active Comparator|CHX-Mouthwash|"Blood extraction using the intravenous access 18-22 gauge angiocath catheter (Becton Dickinson, Sparks, MD, USA)(at baseline, 30 seconds and 15 minutes after tooth extraction).~Mouthwash with 0.2% Chlorhexidine (10 ml for 1 minute) (Oraldine Perio®, Johnson and Johnson, Barcelona, Spain).~Local anesthesia with lidocaine plus adrenaline (1:100,000).~Tooth extraction."
89440426|NCT02150031|Active Comparator|CHX-MW/SUB_IR|"Blood extraction using the intravenous access 18-22 gauge angiocath catheter (Becton Dickinson, Sparks, MD, USA) (at baseline, 30 seconds and 15 minutes after tooth extraction).~Mouthwash with 0.2% Chlorhexidine (10 ml for 1 minute) (Oraldine Perio®) and subgingival irrigation with 1% Chlorhexidine on the tooth to be extracted; the irrigation will be done with the Heraeus Citojet Intraligamental Syringe (Kulzer Heraeus S.A., Madrid, Spain) at six points on each tooth (3 points on the vestibular surface and 3 on the palatine surface).~Local anesthesia with lidocaine plus adrenaline (1:100,000).~Tooth extraction."
89440427|NCT02150031|Active Comparator|CHX-MW/SUPRA_IR|"Blood extraction using the intravenous access 18-22 gauge angiocath catheter (Becton Dickinson, Sparks, MD, USA)(at baseline, 30 seconds and 15 minutes after tooth extraction).~Mouthwash with 0.2% Chlorhexidine (10 ml for 1 minute) (Oraldine Perio®) and then supragingival irrigation with 1% Chlorhexidine on the tooth to be extracted; the irrigation will be done continuously around the tooth to be extracted by a conventional syringe.~Local anesthesia with lidocaine plus adrenaline (1:100,000).~Tooth extraction."
89440428|NCT03374852|Experimental|CPI-613 + mFOLFIRNOX|"CPI-613: 500 mg/m2, IV infusion at a rate of 4 mL/min via a central venous port mFOLFIRNOX (given immediately after CPI-613 administration): Oxaliplatin (Eloxatin) at 65 mg/m2 given as a 2-hr IV infusion via a central venous port~Folinic acid at 400 mg/m2 given as a 90-min infusion immediately after oxaliplatin, and concurrently with irinotecan (Camptosar).~Irniotecan at 140 mg/m2 given as a 90-min IV infusion via a central venous port via a Yconnector.~Flurouracil (5FU) at 400 mg/m2 as bolus followed by a 46-hr infusion at 2400 mg/m2, starting immediately after completion of folinic acid and irinotecan"
89440429|NCT04655170|Experimental|Group 1: Revefenacin (YUPELRI) & Formoterol (Perforomist)|Revefenacin 175 μg once per day and Formoterol 20 μg twice per day via jet nebulizer for 7 days or until discharge if prior to day 7.
89440430|NCT04655170|Active Comparator|Group 2: Ipratropium Bromide (Atrovent) & Albuterol (Ventolin) as Standard of Care|Albuterol and Ipratropium every 6 hours nebulized over the 7-day treatment period or until discharge if prior to day 7.
89440431|NCT03378986||Unilateral THA|Patients who underwent to unilateral total hip arthroplasty
89440432|NCT03378986||Bilateral THA|Patients who underwent to simultaneous bilateral total hip arthroplasty
89440433|NCT02156583||Older, left ventricular assist device|Older heart failure patients undergoing left ventricular assist device implantation
89440434|NCT03125174||control|healthy individuals with no history of lung disease
89440435|NCT03125174||bronchiectasis patients|individuals with a diagnoses of bronchiectasis
89440436|NCT02156661|Active Comparator|Oxytocin|"Oxytocin: Syntocinon-Spray, Novartis~intranasal administration, 24 IU oxytocin; ; 3 puffs per nostril, each with 4 IU OXT"
89440437|NCT02156661|Placebo Comparator|Placebo|Placebo nasal spray
89440438|NCT04797026|Experimental|Penpal Program to Alleviate Loneliness|A social program connecting patients in residential care facilities with high school students through monthly letter writing would positively impact quality of life for both, reducing quantitative and qualitative measures of loneliness
89440439|NCT02150187|Experimental|HCap Formula|Pill of HCap Formula every other day for 6 month during the treatment phase; Follow up phase: nothing.
89440440|NCT02150187|Placebo Comparator|Placebo|Same as treatment with placebo pills
89440441|NCT03374774||Participants with Type 2 Diabetes Mellitus|Participants will be prescribed and treated with commercially available BIAsp 30 according to routine clinical practice at the discretion of the treating physician, independent of this study. The study will gather data over the course of routine treatment on willingness to pay for BIAsp 30 in FlexPen® or Penfill®.
89440442|NCT02156817||Late Preterm Infants (LPT)|34 weeks and 0-6 days gestational age
89440443|NCT02156817||Moderate preterm infants (MPT)|32 weeks and 0-6 days gestational age
89537036|NCT02898233|Active Comparator|Deprexis and active LLLT|Participants will have access to Deprexis and will receive active low-level light therapy (4 days X 8 minutes of active LLLT)
89537037|NCT02898233|Sham Comparator|Deprexis and sham LLLT|Participants will have access to Deprexis and will receive sham low-level light therapy (4 days X 5 seconds of active LLLT and 55 seconds of sham LLLT)
89440444|NCT03374696|Experimental|Intervention group|The intervention SAFETY was performed in school facilities by professional actors and staff from the municipality's youth guidance center within the county. The actors first enacted a play portraying youths and problems with condom use. Next, a value exercise was held by the youth guidance center staff. The class continued with chlamydia games held by the youth guidance center staff, providing information on symptoms, protection, how to get tested, treatment and consequences. The youth guidance center staff and the actors, playing students, then held a condom school. Lastly, the students came up with new endings to the play. All replays were enacted and the students gave feedback on the new endings. The class ended with condoms being handed out.
89440445|NCT03374696|Active Comparator|Control group|The intervention in the control group contained standard education from school staff, based on the sex education guidelines of the Swedish National Agency for Education. Students got education on human sexuality, reproduction, menstruation, love, sex, pregnancy and how STIs and unwanted pregnancy are prevented.
89440446|NCT02150265|No Intervention|Waiting list control group|6 week waiting list
89440447|NCT02150265|Experimental|Individual cognitive behavioral therapy with SMART|SMART manual cognitive behavioral therapy individual weekly sessions for 6 weeks
89440448|NCT02150421||e-book|study the course materials by using e-book
89440449|NCT03124472|Active Comparator|uterine artery ligation|"Pfannenstiel incision of skin and opening of the anterior abdominal wall in layers.~The loose peritoneum of the lower uterine segment is dissected downwards to mobilize the urinary bladder and expose the lower uterine segment.~Uterine artery ligation was performed by grasping the broad ligament with thumb anterior and the index finger lifting the base below the site uterine incision; the uterine artery was singly ligated with No. 1 vicryl suture. Myometrium was included so that uterine vessels are not damaged.~Cresenteric lower uterine segment incision was performed as usual. Higher incisions were performed in cases where the traditional incision was expected to be directly through the placenta."
89440450|NCT03124472|Active Comparator|Traditional lower segment Cesarean section|"Pfannenstiel incision of skin and opening of the anterior abdominal wall in layers.~The loose peritoneum of the lower uterine segment is dissected downwards to mobilize the urinary bladder and expose the lower uterine segment.~Cresenteric lower uterine segment incision was performed as usual. Higher incisions were performed in cases where the traditional incision was expected to be directly through the placenta."
89440451|NCT03125408||chronic HCV Infected patients|chronic HCV patients who will undergo standard of care FDA approved antiviral therapy to treat genotype 1,2, or 3 infections and will have blood drawn at various time points and tested using the DxN HCV Assay. Study is observational and results will not be used to manage patient care.
89440452|NCT04852666||IBD Partners cohort|IBD Partners is an internet-based cohort study of patients with Crohn's disease (CD) and ulcerative colitis (UC). It is coordinated by the University of North Carolina School of Medicine in conjunction with the Crohn's & Colitis Foundation. There is no intervention for this study.
89440453|NCT04852666||SPARC-IBD cohort|SPARC-IBD is a multi-center cohort study of patients with Crohn's disease (CD) and ulcerative colitis (UC). It is coordinated by the Crohn's & Colitis Foundation. There is no intervention for this study.
89440454|NCT03374618|Experimental|systemic lupus erythematosus|adult with systemic lupus erythematosus
89440455|NCT03374618|Experimental|systemic sclerosis|adult with systemic sclerosis
89012463|NCT01680406|Experimental|Chloroquine and primaquine|"Chloroquine will be given in a weight-based dose to be administered once daily for three days.~Primaquine will be given beginning on day 2 of chloroquine to patients with a normal G6PD test; dose is weight-based to be administered once daily for 14 days."
89012464|NCT00252746|Experimental|ZD6474 100mg|Daily dose
89012465|NCT00252746|Experimental|ZD6474 200mg|daily dose
89012466|NCT00252746|Experimental|ZD6474 300mg|daily dose
89012467|NCT01680484|Active Comparator|Bitter chocolate|50 grams Ülker Golden %70 bitter chocolate, İstanbul, Turkey
89012468|NCT01680484|Active Comparator|Orange juice|Ülker İçim Orange Juice 250 cc, İstanbul, Turkey
89012469|NCT01680484|No Intervention|Control|Sit and rest
89012470|NCT01680523|Experimental|RH group|Radical hysterectomy followed by tailored adjuvant therapy
89012471|NCT01680523|Active Comparator|CCRT group|Primary concurrent chemoradiation therapy
89012472|NCT01680562||skin cancer|Skin cancer patients with scheduled tumor excision and subsequent histopathological analysis of the tumor.
89440456|NCT03374618|Other|healthy volunteers|healthy volunteer (adult)
89440457|NCT02767323|Experimental|Active or Sham rTMS over the DLPFC (Aim1a)|excitatory rTMS applied over the DLPFC (fMRI-guided). Active and Sham rTMS will be tested in a within subject design
89440458|NCT02767323|Experimental|Active or Sham rTMS over the Parietal cortex (Aim1b)|excitatory rTMS applied over the parietal cortex (fMRI-guided). Active and Sham rTMS will be tested in a within subject design
89012473|NCT04528147|Experimental|Yi Jin Jing Tiger Roaring Speech Rehabilitation|Yi Jin Jing tiger roaring speech rehabilitation with real-time feedback technique Duration: Each time requires an hour of training; Frequency: three times a week, 4 weeks in total.
89012474|NCT04528147|Experimental|Conventional Speech Rehabilitation|"Patients will receive speech rehabilitation recommended by The Parkinson's Foundation.~Duration: Each time requires an hour of training; Frequency: three times a week, 4 weeks in total."
89012475|NCT01680601|Experimental|RIPC group|Patients assigned to this arm will go through a remote ischaemic preconditioning (RIPC)protocol
89012476|NCT01680601|Placebo Comparator|Control|Patients assigned to this arm will not receive the intervention, however the protocol will be applied to a wooden block in order to maintain blinding to relatives and investigators.
89012477|NCT01680679|Experimental|Inactivated Trivalent Influenza Vaccine|Inactivated trivalent influenza vaccine (TIV), split virion
89012478|NCT01680679|Placebo Comparator|Inactivated Polio Vaccine|Inactivated poliovirus vaccine (IPV), trivalent
89012479|NCT01680679|No Intervention|Surveillance arm|Those ineligible for vaccination will be enrolled for febrile acute respiratory illness (FARI) surveillance to assess indirect effects of vaccination in household members.
89440459|NCT02767323|Experimental|Active or Sham rTMS over the DLPFC and the Parietal cortex (Aim1c)|excitatory rTMS applied over the DLPFC and the parietal cortex (fMRI-guided). Active and Sham rTMS will be tested in a within subject design
89440460|NCT03370094||patients with suspected stroke|patients with suspected stroke due to paramedic's initial evaluation of face, arm, and speech function will be diagnosed with audio-video-streaming of suspected stroke symptoms and signs
89440461|NCT05534698|Active Comparator|PCI|Revascularization by PCI
89440462|NCT05534698|Active Comparator|CABG|Revascularization based on CABG.
89440463|NCT03743493||Prevalence numerator|An opioid prescribed or dispensed in the query period (1/1/2010-12/31/2017)
89440464|NCT03743493||Prevalence denominator|Any diagnosis on record in the query period (1/1/2010-12/31/2017)
89440465|NCT03743493||Guideline A numerator|An opioid prescribed or dispensed in the query period (1/1/2010-12/31/2017) AND NO cancer diagnosis in the year prior to the index event
89440466|NCT03743493||Guideline A denominator|Any diagnosis on record in the query period (1/1/2010-12/31/2017) AND NO cancer diagnosis in the year prior to the index event
89440467|NCT03743493||Guideline B numerator|An opioid prescribed or dispensed in the query period (1/1/2010-12/31/2017) AND NO inpatient cancer diagnosis OR cancer procedure in the year prior to the index event
89440468|NCT03743493||Guideline B denominator|Any diagnosis on record in the query period (1/1/2010-12/31/2017) AND NO in-patient cancer diagnosis OR cancer procedure in the year prior to the index event
89440469|NCT03374540||Rivaroxaban|Patients who initiated Oral anticoagulant (OAC) treatment with rivaroxaban
89440470|NCT03374540||Vitamin K antagonist (VKA)|Patients who initiated OAC treatment with VKA
89440471|NCT04304950|Experimental|Morning|Participants with Ulcerative Colitis or Crohn's Disease taking 6-Mercatopurine or Azathioprine orally once a day in the evening were assigned to the morning group. Instead of taking their medication at their usual PM time, they were instructed to take their medications in the morning for the duration of the study-10 weeks. The dosage amount is per clinical care and not defined by the study protocol.
89440472|NCT04304950|Experimental|Evening|Participants with Ulcerative Colitis or Crohn's Disease taking 6-Mercatopurine or Azathioprine orally once a day in the morning were assigned to the evening group. Instead of taking their medication at their usual AM time, they were instructed to take their medications in the evening for the duration of the study-10 weeks. The dosage amount is per clinical care and not defined by the study protocol.
89440473|NCT03374462|Experimental|Telemedicine Intervention|All participants will receive the study intervention, which consists of home-based telemedicine visits with a diabetes specialist, at a frequency determined by the patient's degree of glycemic control (every 4, 6, or 8 weeks).
89440474|NCT02780115|Experimental|Cohort 1: Vehicle Control|Vehicle dosed in both eyes administered once daily during office visits 1 through 5.
89440475|NCT02780115|Experimental|Cohort 2: AGN-199201 Dose A and AGN-190584 Dose A|Fixed combinations of AGN-199201 Dose A and AGN-190584 Dose A dosed in both eyes administered once daily during office visits 1 through 5.
89440476|NCT02780115|Experimental|Cohort 3: AGN-199201 Dose B and AGN-190584 Dose B|Fixed combinations of AGN-199201 Dose B and AGN-190584 Dose B dosed in both eyes administered once daily during office visits 1 through 5.
89440477|NCT02780115|Experimental|Cohort 4: AGN-199201 Dose C and AGN-190584 Dose C|Fixed combinations of AGN-199201 Dose C and AGN-190584 Dose C dosed in both eyes administered once daily during office visits 1 through 5.
89440478|NCT02780115|Experimental|Cohort 5: Vehicle, AGN-199201 Dose C and AGN-190584 Dose C|Dominant eye dosed with Vehicle. Fixed combinations of AGN-199201 Dose C and AGN-190584 Dose C dosed in nondominant eye. Treatment administered once daily during office visits 1 through 5.
89440479|NCT03378752||Atelectasis formation using HFJV|Computed tomography scans are performed every 15 minute during the first 45 minutes during general anaesthesia using high frequency jet ventilation.
89440480|NCT02808208|Experimental|Single dose AMSC treatment in Radiocephalic (RCF)or brachiocepahlic (BCF) arteriovenous fistula|Subjects who receive a radiocephalic (RCF)or brachiocepahlic (BCF) arteriovenous fistula through standard of care procedure for dialysis, will receive a single dose of Autologous Adipose Derived Mesenchymal Stem Cells (AMSC)
89440481|NCT02808208|No Intervention|No Treatment in Radiocephalic (RCF)or brachiocepahlic (BCF) arteriovenous fistula|Patients receive standard of care.
89440482|NCT02808208|Experimental|Single dose AMSC treatment at first stage of brachiobasilic arteriovenous fistula|Subjects who receive a brachiobasilic arteriovenous fistula (BBF) through standard of care procedure for dialysis, will receive a single dose of Autologous Adipose Derived Mesenchymal Stem Cells (AMSC) at time of first stage of BBF
89440483|NCT02808208|Experimental|AMSC treatment at first and second stage of brachiobasilic arteriovenous fistula|Subjects who receive a brachiobasilic arteriovenous fistula (BBF) through standard of care procedure for dialysis, will receive Autologous Adipose Derived Mesenchymal Stem Cells (AMSC) at first and second stage of BBF
89537038|NCT02898233|Other|Deprexis only|Participants will have access to Deprexis but will not receive real or sham LLLT
89012480|NCT01680718|Experimental|Intranasal oxytocin|Participants will self-administer 24 IU oxytocin (Syntocinon, Novartis Pharmaceuticals). 5 puffs per nostril (1 puff = 2.4 IU oxytocin).
89012481|NCT01680718|Experimental|Intranasal vasopressin|Participants will self-administer 20 IU vasopressin (American Regent Pharmaceuticals). 5 puffs per nostril (1 puff = 2 IU vasopressin).
89012482|NCT01680718|Placebo Comparator|Intranasal placebo|2 mls Glycerine and 3 mls purified water (methylparaben and propylparaben mixed according to purified water formula) for a total of 5 ml, which will be filtered with a 5mu filter (used previously; Bartz et al., 2010). Participants will self-administer 5 puffs per nostril.
89012483|NCT01680757|Experimental|LAA exclusion with LARIAT & Accessories|Permanent exclusion of the LAA using the LARIAT Suture Delivery Device and Accessories
89012484|NCT01680796|Experimental|Active Treatment|"Dovitinib will be given at up to four different dose levels beginning with dose level 1 on a 5 days on/2 days off dosing schedule of each 21-day cycle.~Bortezomib will be given at two different dose levels intravenously on Days 1 and 8 of each 21-day cycle.~Dexamethasone will be given orally on Days 1, 2, 8, and 9 of each 21-day cycle."
89012485|NCT01680874|Experimental|Probiotic|"This arm will receive a probiotic combination which will consist of equal amounts of Lactobacillus acidophilus NCFM® (ATCC 700396), Lactobacillus paracasei Lpc-37 (ATCC SD5275), Bifidobacterium lactis Bi-07 (ATCC SC5220), and Bifidobacterium lactis Bl-04 (ATCC SD5219).~The probiotic will be taken orally, once a week, for 4 weeks."
89012486|NCT01680874|Placebo Comparator|Placebo|A placebo will be taken orally, once a day, for 4 weeks.
89012487|NCT01680913|Experimental|Spinal with ultrasound guidance|The intervention group's interspaces will be determined using the curved linear probe on a Zonare ultrasound using two views.
89012488|NCT01680913|Active Comparator|Spinal by palpation of Tuffier's line|Current clinical practice. Standard of care would have the attending anesthetist palpate the Tuffier's line to pinpoint the appropriate location for the spinal.
89012489|NCT01680952|Active Comparator|A) TEST|
89012490|NCT01680952|Experimental|B) CONTROL|
89012491|NCT01681108|Other|Lifestyle counseling|Individualized meal planning and exercise regimen sessions will be developed for each participant
89012492|NCT01681303|Experimental|AST-120 group|Administration of AST-120
89012493|NCT01681303|No Intervention|2|
89012494|NCT04528420|Experimental|Optimised arm|Patients will be taken care of early and optimally way.
89012495|NCT04528420|No Intervention|Standard arm|Patients will be monitored as in standard practice
89012496|NCT01681381|Active Comparator|Firebird2® DES|Device:Firebird2® DES The Firebird2® rapamycin-eluting stent (Firebird2® DES) is an open cell balloon expandable cobalt chromium stent coated with a biocompatible durable styrene-butylenes-styrene (SBS) polymer containing rapamycin at a dose of 9 micrograms per millimeter of stent length.
89012497|NCT01681381|Experimental|Tivoli® DES|Device:Tivoli® DES The Tivoli® DES is an open cell balloon expandable cobalt chromium stent coated with a bio-gradable polymer (PLGA) containing rapamycin at a dose of 8 micrograms per millimeter of stent length.
89012498|NCT01681420|Experimental|Approved Intervention Counseling|Approved blood donors randomized to intervention and choosing HIV counseling option with no donation.
89012499|NCT01681420|Experimental|Approved Intervention Donation|Approved blood donors randomized to intervention and choosing donation with no HIV counseling.
89012500|NCT01681420|Experimental|Deferred Intervention|Deferred blood donors randomized to intervention with HIV counseling.
89012501|NCT00281190||Healthy smokers|Smokers with normal pulmonary function
89012502|NCT00281190||COPD patients|COPD patients
89012503|NCT01681498||Pregnancy|
89012504|NCT01681537|Experimental|Treatment Arm|Lenalidomide and re-induction chemotherapy
89012505|NCT00287625|Active Comparator|1|PRP
89440484|NCT02808208|Placebo Comparator|Placebo treatment in brachiobasilic arteriovenous fistula|Subjects will receive placebo at first and second stage of BBF
89012506|NCT00287625|No Intervention|2|control
89012507|NCT01681654|Experimental|Immediate Lifestyle Intervention - Maintenance Program|Patients will receive a 12-week lifestyle program during treatment. Patients will also receive maintenance support following the 12-week program.
89012508|NCT01681654|Experimental|Immediate Lifestyle Intervention - No Maintenance Program|Patients will begin the 12-week lifestyle intervention during treatment. Patients will not receive a maintenance support following the 12-week intervention.
89012509|NCT01681654|Experimental|Delayed Lifestyle Intervention - Maintenance Program|Patients will receive a 12-week lifestyle intervention program following treatment (12 weeks after diagnosis). Patients will then receive maintenance support following the 12-week program.
89012510|NCT01681654|Experimental|Delayed Lifestyle Intervention - No Maintenance Program|Patients will receive a 12-week lifestyle intervention program following treatment completion (12 weeks following diagnosis). Patients will not receive maintenance support following the 12-week program.
89012511|NCT01681693|Experimental|Metformin|Subjects will be given an oral dose of metformin once per day for two days.
89012512|NCT01681732|Experimental|Personalized Care Plan|A personalized plan based on baseline clinic visit data
89012513|NCT01681732|Active Comparator|Control|This arm will be standard care
89012514|NCT01681888|Experimental|Surface EMG Biofeedback|
89012515|NCT04528264|Experimental|Ultrasound guided|Intraoperative high frequency ultrasound used to guide the reduction of depressed zygomatic arch.
89012516|NCT04528264|Other|Conventional blind reduction technique|Conventional blind reduction of zygomatic arch fracture will be conducted without any intraoperative imaging.
89440485|NCT04736446|Experimental|I-gel® group|Continuous chest compressions from the start of the CPR with early i-gel® device insertion and asynchronous ventilations
89440486|NCT04736446|Other|Standard group|Basic (standard) management by using a ratio of 30 compressions and 2 face mask ventilations
88924932|NCT04453384|Experimental|Treatment arm|"Administrations of XAV-19~Phase 2a: XAV-19 at 0.5 mg/kg at D1 and D5(Group 1) or at 2 mg/kg at D1 and D5 (Group 2), or at 2 mg/kg at D1 (groupe 3)~Phase 2b: Selected dose from Phase 2a : one administration at 2 mg/kg on day1"
88924933|NCT04453384|Placebo Comparator|Placebo arm|"same administration as treatment arm~Phase 2a: two administrations of placebo (day 1 and day 5) for Group 1 and 2, one administration of placebo on day 1 for Group 3~Phase 2b: one administration of placebo on day 1"
88924934|NCT04440774|Experimental|CHIK low dose|Volunteers will receive a single dose of 5x10^9 vp ChAdOx1 Chik delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator
88924935|NCT04440774|Experimental|CHIK mid dose|Volunteers will receive a single dose of 2.5x10^10 vp ChAdOx1 Chik delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator
88924936|NCT04440774|Experimental|CHIK high dose|Volunteers will receive a single dose of 5x10^10 vp ChAdOx1 Chik delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator
88924937|NCT04440774|Experimental|ZIKA low dose|Volunteers will receive a single dose of 5x10^9 vp ChAdOx1 Zika delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator
88924938|NCT04440774|Experimental|ZIKA mid dose|Volunteers will receive a single dose of 2.5x10^10 vp ChAdOx1 Zika delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator
88924939|NCT04440774|Experimental|ZIKA high dose|Volunteers will receive a single dose of 5x10^10 vp ChAdOx1 Zika delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator
88924940|NCT04440774|Experimental|CHIK ZIKA low dose|Volunteers will receive a single dose of 5x10^9 vp ChAdOx1 Chik and 5x10^9 vp ChAdOx1 Zika delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator
88924941|NCT04440774|Experimental|CHIK ZIKA mid dose|Volunteers will receive a single dose of 2.5x10^10 vp ChAdOx1 Chik and 2.5x10^10 vp ChAdOx1 Zika delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator
88924942|NCT04440774|Experimental|CHIK ZIKA high dose|Volunteers will receive a single dose of 5x10^10 vp ChAdOx1 Chik and 5x10^10 vp ChAdOx1 Zika delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator
88924943|NCT04440774|Placebo Comparator|Placebo|Volunteers will receive a single dose of isotonic saline solution (0.9%) delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator
88924944|NCT04427397|Experimental|Sulcular Bristle Tip Technique (SBTT)|This test group will receive formal instruction on the Sulcular Bristle Tip Technique (SBTT).
88924945|NCT04427397|No Intervention|User manual of the electric toothbrush (DFU)|This control group will be asked to read and use the instructions found in the user manual of the electric toothbrush (DFU). No formal instruction will be provided. The DFU accompany the electric toothbrush regardless of the subject's participation in the research.
88924946|NCT04418362|Experimental|Neurofeedback training|Neurofeedback training: self-administered at home 4-6 times per week for 8 weeks. Each session consists of 6 blocks of 5 minute training with a one minute rest period between each block.
88924947|NCT04416867|Active Comparator|group-1 splint and home exercise|Patients in group 1 will be treated with splinting of the affected hand at night and a home exercise program. A wrist orthosis which held the wrist in the neutral position will be used for splinting at night time for a minimum of eight hours. Each patient will be given a home exercise program of wrist range of motion, wrist stretch, wrist isometric strengthening and median nerve glide exercises to be performed daily for the duration of the study
89440487|NCT03369938|Experimental|exercise training intervention|
89440488|NCT03369938|No Intervention|usual care|
89440489|NCT02156973|No Intervention|Group One Usual care|Patients attending for CT coronary angiography all receive an information leaflet with their appointment letter, and a brief verbal description of the scan by the radiographer immediately before it is undertaken, as standard care. All patients attending will be offered the opportunity to complete a short questionnaire (until all patients are recruited - anticipated to be 4 weeks). The Speilberger State-Trait Anxiety Index has been abbreviated and validated for use in outpatient settings to gauge levels of pre-procedural anxiety. This will be undertaken on arrival and repeated immediately before the scan, to see if patients feel better prepared after the standard interaction with staff.
89440490|NCT02156973|Experimental|Group Two Video information|The patient video will be introduced to Group Two once Group One has been completed. In addition to the information sheet these patients (again, for four weeks or until recruitment is complete) will be sent an internet hyperlink to its presence on YouTube (video-sharing website) and the Hospital website with their appointment letter. Patients who do not have internet access will be offered the opportunity to see the video in the preparation room while waiting for their scan. Questionnaires will be administered as before, again done twice to examine any late impact of the information on patient anxiety, and the patient will undergo their test.
89440491|NCT03378674|Experimental|Group A|remifentanil infusion of 0,15 mcg/Kg/min
89440492|NCT03378674|Active Comparator|Group B|remifentanil infusion of 0,3 mcg/Kg/min
89440493|NCT02157207|Placebo Comparator|Placebo|Placebo will be ingested in front of laboratory personnel in two doses, separated by 30 minutes to increase absorption, consumed 90 and 60 minutes before the testing protocol. Placebo microcrystalline cellulose capsules will be of similar taste, color and appearance.
89440494|NCT02157207|Experimental|Antioxidant|"Supplementation will be ingested in front of laboratory personnel in two doses, separated by 30 minutes to increase absorption, consumed 90 and 60 minutes before the testing protocol. The first dose will consist of 300 mg of α-lipoic acid, 500 mg of vitamin C, and 200 IU of vitamin E, and the second dose will be 300 mg of α-lipoic acid, 500 mg of vitamin C, and 400 IU.~of vitamin E."
89440495|NCT04178408||Cases|Cases of inflammatory bowel disease
89440496|NCT04178408||Controls|Two controls per case. 1. Sibling or other second degree relative of similar age. 2. neighbourhood control matched for age
89440497|NCT02261103|Active Comparator|Pramipexole IR, fasted|Pramipexole immediate release (IR) tablets
89440498|NCT02261103|Experimental|Pramipexole ER, fasted|Pramipexole extended release (ER) tablets
89440499|NCT02261103|Experimental|Pramipexole ER, fed|Pramipexole extended release tablets with a high-fat meal 30 min before drug administration
89440500|NCT03378596|Experimental|L-citrulline & L-arginine|L-citrulline (6 grams) L-arginine (8 grams)
89440501|NCT03378596|Active Comparator|L-citrulline & Placebo|L-citrulline (6 grams) Placebo (6 grams)
89012517|NCT01681927||1.4kg wt gain 8AM -10 PM|Complete a questionnaire. Measure and record weight in AM and PM.Record for one week,number of times urinated after bedtime and before waking up.
89440502|NCT03378596|Active Comparator|L-arginine & Placebo|L-arginine (8 grams) Placebo (6 grams)
89440503|NCT03378596|Active Comparator|Placebo|Placebo (6 grams)
89440504|NCT05643274||Participants|Patients with neurodevelopmental disease and their both parents
89440505|NCT02153151||In vitro effect of AMP-514|Patients undergo blood sample collection at baseline, during the second week of RT, at the end of RT, and at 1 month after the end of RT
89440506|NCT04525742|Other|Parents who have a disabled child or children|Parents having disabled child or children will be included in the research and it will be wanted to complete the survey questionary
89440507|NCT04833465||JIA|Patients ages 5-21 with a diagnosis of JIA.
89440508|NCT04833465||SLE|Patients ages 5-21 with a diagnosis of SLE.
89440509|NCT04833465||FM|Patients ages 5-21 with a diagnosis of FM.
89440510|NCT05475340|Experimental|Experimental|Participants will undergo ten to thirty minutes of transcranial ultrasound treatment. The sanitation device will be aimed at the hypothalamus. Targeting will include reference to scalp fiducials based on the obtained MRI; confirmation of target accuracy will either be obtained by Doppler waveform confirmation or optical tracking technology which co-registers patient neuroimaging with real space.
89440511|NCT03369860|Experimental|Healthy Subjects|Healthy Subjects take part in the experimental manipulation
89440512|NCT02766777|Experimental|Lubiprostone|Participants received lubiprostone twice daily (BID). Participants received either lubiprostone 12 mcg BID, lubiprostone 24 mcg BID (dose based on participant's weight) up to 24 weeks.
89440513|NCT05534308|Active Comparator|Control Group|The control group (CG) will be composed of patients undergoing the same surgical procedure, and standard treatment consisting only of compression compression by elastic stockings.
89440514|NCT05534308|Experimental|Intervention Group|The intervention group (IG) will be composed of patients undergoing phleboextraction with saphenectomy and intervention with contensive taping, in the period intraoperative associated with compression with elastic stockings.
89440515|NCT03374306|Experimental|Atropine 0.01%|Group receiving atropine treatment for 18 months
89440516|NCT03374306|Placebo Comparator|Artifical tear|Group receiving placebo for 18 months
89440517|NCT05534230|Placebo Comparator|Control Group|Intravenous normal saline at a standard dose of 0.5mcg/kg/hr continued to postop until extubation.
89440518|NCT05534230|Active Comparator|Dexmedotimidine Group|Intravenous dexmedetomidine infusion started after induction at a standard dose of 0.5mcg/kg/hr and continued until extubation.
89440519|NCT03369782|Placebo Comparator|Placebo|Placebo alternative for rocuronium and for sugammadex
89440520|NCT03369782|Active Comparator|Rocuronium|Rocuronium as bolus and in syringe pump Sugammadex just before reduction of the joint
89440521|NCT00157014|Experimental|Tacrolimus - Adult|Adults: 0.05 - 0.10 mg/ kg/ day in 2 divided doses starting within 10 days of transplant
89440522|NCT00157014|Active Comparator|Cyclosporine - Adult|Adults: 3-5 mg/ kg/ day in 2 divided doses starting within 10 days of transplant
89440523|NCT00157014|Experimental|Tacrolimus - Pediatric|Pediatrics: 0.05 - 0.30 mg/ kg/ day in 2-3 divided doses starting within 10 days of transplant
89440524|NCT00157014|Active Comparator|Cyclosporine - Pediatric|Pediatrics: 6 - 10 mg/ kg/ day in 2-3 divided doses starting within 10 days of transplant
89440525|NCT03374228|Experimental|BMS-986205|Single oral dose of BMS-986205 tablet on the morning of Day 1 followed by a 15-minute infusion of [13C]BMS-986205 solution for intravenous administration starting 01:45 hours after the oral dose administration
89440526|NCT02778867|Active Comparator|1-Food Elimination Diet (1FED)|Participants eliminate milk from the diet in Phase 1
89440527|NCT02778867|Active Comparator|6-Food Elimination Diet (6FED)|Participants eliminate milk, egg, wheat, soy, nuts, fish from the diet in Phase 1
89440528|NCT02778867|Other|1FED Non-Responders (6FED)|Participants that fail to respond to 1FED in Phase 1 eliminate milk, egg, wheat, soy, nuts, fish from the diet in Phase 2
89440529|NCT02778867|Other|6FED Non-responders (SGC)|Participants that fail to respond to 6FED in Phase 1 administer swallowed glucocorticoids (SGC) (Flovent HFA) 880 mcg twice daily in Phase 2
89440530|NCT03374150|Experimental|high protein|High protein (HP) group were given counseling about weight loss program by applying low calorie-high protein diet with diet menu composition of 22-30% protein, along with instructions for allowed cooking method.
89440531|NCT03374150|Active Comparator|standard protein|Active comparator receiving standard protein (SP) proportion were counseled about weight loss program by means of low calorie-balanced composition diet with menu comprised of 12-20% protein.
89440532|NCT04232072|Active Comparator|Group ESPB = Erector spinae plane block group|ESPB will be performed 30 min before induction of general anesthesia, with patients in the sitting position by using US. Under aseptic conditions, the high frequency linear probe will be covered with a sterile sheath and a 22G, 50 mm block needle will be used. Local anesthetic infiltration with 2% of lidocaine will be applied under the skin. US probe will be placed longitudinally 2-3 cm lateral to the T7 transvers process. The block needle will be inserted cranio caudal direction and then for correction of the needle 5 ml saline will be enjected deep into the erector spina muscle fascia. Following confirmation of the correct position of the needle 20 ml %0.25 bupivacaine will be administered for block. The same procedure will be performed for the opposite site.
89440533|NCT04232072|Active Comparator|Group Ibuprofen = Ibuprofen|In Group Ibuprofen, a dose of 800 mg ibuprofen IV will be administrated 30 min before induction of general anesthesia.
89440534|NCT04232072|No Intervention|Group C = Control group|A dose of 100 mg tramadol intravenously will be performed to all patients 30 min before the end of the surgery for postoperative analgesia. At the end of the surgery, local anesthetic infiltration will be perfomed around the port entrance sites by the surgical team to the all patients. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit at the postoperative period.
89440535|NCT02157285|No Intervention|Routine Counseling|Subjects randomized to receive routine counseling before selecting a method of contraception
89440536|NCT02157285|Experimental|Peer Mentor counseling|Subjects randomized to receive peer counseling before selecting a method of contraception
89440537|NCT03369626|Other|FareWell Program|All participants receive the FareWell Program intervention in this evaluation study
89440538|NCT02300064|Experimental|Healthy volunteers|Healthy volunteers will undergo one or more exercise interventions: knee-extensor exercise test; exercise test with restricting/releasing blood flow; exercise test with variable oxygen concentration and MRI; or exercise test with oral antioxidant or placebo cocktail.
89440539|NCT02300064|Experimental|COPD patients|Patients with Chronic Obstructive Pulmonary Disease (COPD) will undergo one or more exercise interventions: knee-extensor exercise test; exercise test with restricting/releasing blood flow; exercise test with variable oxygen concentration and MRI; or exercise test with oral antioxidant or placebo cocktail.
89440540|NCT05473390|Active Comparator|study group|20 patient with hemiplegia
89440541|NCT05473390|Active Comparator|control group|20 patient with hemiplegia
89440542|NCT02778555||Sample 1|In Sample 1 (N=186), our 14-item Daily PCS was administered daily for 14 days to replicate the 3-factor structure at the daily level, and to select the ideal 5 items for a brief Daily PCS.
89440543|NCT02778555||Sample 2|In Sample 2 (N=209), the 5-item Daily PCS was administered daily for 14 days with short forms for PROMIS Pain Intensity, Depression, Anger, and Anxiety included on days 1, 7, and 14.
89440544|NCT02778555||Sample 3|In Sample 3 (N=318), the 5-item Daily PCS was administered daily for 14 days with short forms for PROMIS Pain Intensity, Depression, Anger, and Anxiety included on days 1, 7, and 14. In addition, assessments of pain, mood, activity, sleep, energy level, and positive affect were administered daily for the 14-day period.
89440545|NCT03513198||Non-resectable pancreatic cancer|"All patients with a suspicion of pancreatic masses will undergo EUS (including EUS-FNA for confirmation of diagnosis). A positive cytological diagnosis will be taken as a final proof of malignancy of the pancreas mass. The diagnoses obtained by EUS-FNA will be further verified during a clinical follow-up of at least 6 months.~Both pancreatic adenocarcinomas and pancreatic neuroendocrine tumors will be included.~Endoscopic ultrasound (including fine needle aspiration for confirmation of diagnosis) with sequential contrast-enhanced endoscopic ultrasound and elastography endoscopic ultrasound and contrast-enhanced computed tomography will be performed before and 2 months after the first course of treatment"
89440546|NCT03369548|Experimental|Apple/ Polyphenol|Participants will be asked to consume 2 Renetta Canada apples (with skin) and 2 placebo capsules every day for 8 weeks.
89440547|NCT03369548|Experimental|Oats / Prebiotic|Participants will be asked to consume 40g jumbo rolled oats with semi-skimmed milk and 2 placebo capsules every day for 8 weeks.
89440548|NCT03369548|Experimental|Lactobacillus reuteri NCIMB 30242 / Probiotic|Participants will be asked to consume 2 probiotic capsules and 40g cornflakes with semi-skimmed milk every day for 8 weeks.
89440549|NCT03369548|Placebo Comparator|Placebo / cornflakes|Participants will be asked to consume 40g cornflakes with semi-skimmed milk and 2 placebo capsules every day for 8 weeks.
89440550|NCT02150577|Experimental|Implementation|Evidence Based Quality Improvement
89440551|NCT02150577|No Intervention|Control|Usual Quality Improvement
89440552|NCT03373994||18F-FDG PET/CT initial-time imaging|PET/CT imaging was underwent 5min after 18F-FDG injection.
89440553|NCT03373994||18F-FDG PET/CT balanced-time imaging|PET/CT imaging was underwent 60min after 18F-FDG injection.
89440554|NCT03520764|Experimental|New infant formula with synbiotics|pHP infant formula with synbiotics (test product)
89440555|NCT03520764|Active Comparator|Standard infant formula with prebiotics|Standard (commercial) infant formula with prebiotics (control product)
89440556|NCT03520764|No Intervention|human milk|Full breastfeeding for at least 17 weeks
89440557|NCT03369470|Experimental|App Dexterity|
89440558|NCT03369470|Active Comparator|Theraband|
89440559|NCT02296008|Other|surgery for Hirschsprung's disease|children after surgery for Hirschsprung's disease will undergo 3D high resolution anorectal manometry procedure
89440560|NCT02296008|Other|surgery for anorectal malformation|children after surgery for anorectal malformation will undergo 3D high resolution anorectal manometry procedure
89440561|NCT02296008|Other|surgery for other disorders|children after surgery for other disorders will undergo 3D high resolution anorectal manometry procedure
89012518|NCT01681927||>1.4kg wt gain 8AM - 10PM no nocturia.|Complete a questionnaire. Measure and record weight in AM and PM.Record for one week,number of times urinated after bedtime and before waking up.
89440562|NCT03378284|Experimental|Tegoprazan(Test drug)|Tegoprazan drug QD for 7 days
89440563|NCT03378284|Active Comparator|Active comparator drug|Active comparator drug QD for 7 days
89440564|NCT03516396|Experimental|Training Plus|"Intervention: Community Development~Training plus enhanced community development activities"
89440565|NCT03516396|Active Comparator|Control|No inputs
89440566|NCT03516396|Experimental|Training Only|"Intervention: Training~Training Only (livestock management and child nutrition)"
89440567|NCT03369392|Experimental|Feasibility Cycle 1|Participants use the initial PANDA application.
89440568|NCT03369392|Experimental|Feasibility Cycle 2|Participants use the PANDA application after modifications are made based on suggestions from participants in cycle 1.
89440569|NCT03369392|Experimental|Feasibility Cycle 3|Participants use the PANDA application after modifications are made based on suggestions from participants in cycle 1 and 2.
89440570|NCT02296086||Group I|"Study sites in which patients perform early mobilization as per local standard of care, which is as follows:~2 days (at the latest) after surgery: Transfer from the bed to a sitting chair for the first time~4 (± 2) days after surgery: Stand up and put both feet on the ground for the first time (walking aids allowed)~5 (± 2) days after surgery: Walking (at least partial weight bearing, walking aids allowed)~The patients are instructed by the investigator at the hospital about a standardized mobilization program to be followed at home"
89440571|NCT02296086||Group II|Study sites in which patients start walking (i.e. partial weight bearing, walking aids allowed) more than 7 days after surgery as per local standard of care
89440572|NCT02617550|Experimental|Vericiguat + Nitroglycerin|Co-administration of vericiguat and nitroglycerin
89440573|NCT02617550|Placebo Comparator|Placebo + Nitroglycerin|Aministration of matching placebo and nitroglycerin.
89012519|NCT01681927||> 1.4 kg wt gain 8AM -10PM with nocturia|Complete a questionnaire. Measure and record weight in AM and PM. Record the number of times and collect all urine passed overnight in separate containers for one week.Collection of blood and interstitial fluid samples, fluorescein dye angiography, and bioimpedance study.
89012520|NCT01681966|Experimental|Application of PRF110- oily solution|Post operative application of new extended release PRF110- oily solution (Ropivacaine)
89012521|NCT01682122||Newborns|Healthy newborns in Regular and Observation nurseries who are between 0-72 hrs of age. Infants with gestational age > or = 35weeks and birth weight > 2500g, who are hemodynamically stable, have no cardiorespiratory abnormalities and have no evidence of sepsis. If a blood culture was drawn due to the presence of maternal risk factors (e.g. maternal fever, prolonged rupture of membranes), patients will be included only if the blood culture result is negative and in case of intrapartum antibiotic treatment, ancillary blood tests (CBC with differential, CRP) are also within the normal range
89012522|NCT01682161|Experimental|Group 1 (Immediate switch)|Paliperidone palmitate will be administered immediately after randomization and will be continued throughout the treatment phase.
89012523|NCT01682161|Experimental|Group 2 (Delayed switch)|Current oral antipsychotics will be continued until Week 8, and later on paliperidone palmitate will be administered.
89440574|NCT03512886|Active Comparator|Single task training|The exercise program consisting of 10 different motor tasks will be implemented in a single task training group.
89440575|NCT03512886|Experimental|Multi-task training|In the multitasking training group, a second motor task in the first two weeks, a cognitive task in the third and fourth week, both motor and cognitive tasks in the last two weeks will be added to these 10 different motor tasks.
89440576|NCT03512886|No Intervention|Control group|The control group will be taught relaxation exercises and will be asked to perform the exercises at home.
89440577|NCT03369314||Patients Receiving octaplasLG®|The data will be collected in all patients who have received at least one infusion of octaplasLG®
89440578|NCT05533840||Age under 18|Participants under the age of 18
88924948|NCT04416867|Active Comparator|group 2 RESWT|Patients in group 2 will be treated with splinting of the affected wrist at night, a home exercise program similar to that of group one and a total of 3 sessions of RESWT at a frequency of one session per week using the Masterpuls ® mp200 radial shock wave therapy system (Elite-Storz Medical AG, Kreuzlingen, Switzerland). RESWT at a pressure of 4 bars, a frequency of 5Hz and 2000 hits in total will be applied 2cm proximal to the median nerve, with the probe directed towards the palm, diffusely over the pisiform.
88924949|NCT04416867|Active Comparator|group 3 physical therapy|Patients in group 3 will be treated with splinting of the affected wrist at night, a home exercise program similar to that of group one and two and 20 minutes of liquid paraffin treatment of the hand, 1.5watt/cm2 therapeutic ultrasound applied to the volar surface of the wrist for 5 minutes and 20 minutes of transcutaneous electrical nerve stimulation (TENS) on five consecutive days of the week for a total of fifteen sessions over 3 weeks.
88924950|NCT04414618|Active Comparator|opaganib|Study participants will receive opaganib 2 x 250 mg capsules (500 mg) plus standard of care every 12 hours
88924951|NCT04414618|Placebo Comparator|placebo|Study participants will receive placebo 2 x 250 mg capsules (500 mg) plus standard of care every 12 hours
88924952|NCT04412824|Active Comparator|Alcohol Beverage Cues|Participants will complete an MRI with alcohol beverage visual cues and oral alcohol session.
88924953|NCT04412824|Placebo Comparator|Non-Alcoholic Beverage Cues|Participants will complete an MRI with non-alcoholic beverage cues and oral alcohol session.
88924954|NCT04412057|Experimental|CERC-002|
88924955|NCT04412057|Placebo Comparator|Placebo|
88924956|NCT04408807|Experimental|Study Group|ROPEE screening with speculum-free fundoscopy
88924957|NCT04408807|Active Comparator|Control Group|ROPEE screening with speculum fundoscopy
88924958|NCT04402658|Experimental|Physical performance test|After performing measurements of lung function by spirometry, participants will inhale either salbutamol or placebo. After 15 minutes of rest, a second spirometry will be performed before the participants warm-up by 10 minutes cycling. The exercise protocol will consist of 60 minutes of cycling at 70% of maximal oxygen consumption (VO2max) on the cycle ergometer followed by an all-out sprint. Several times during the exercise test, 30-second Wingate tests will be conducted. Participants will be blinded to feedback such as power (W), distance covered, and heart rate. Strong verbal encouragement will be given to each participant for them to perform their best. Measurements of lung function (spirometry), heart rate, arterial oxygen saturation and Borg ratings of perceived exercising will be recorded throughout the trials, as well as capillary blood sampled for analysis of [La-] and [Glucose].
88924959|NCT04402060|Experimental|180 mg APL-9 IV plus SOC|
88924960|NCT04402060|Placebo Comparator|Isotonic saline plus SOC|
88924961|NCT04393766|Experimental|normal saline|
88924962|NCT04393766|Placebo Comparator|non normal saline|
89440579|NCT05533840||Age 18-30|Participants aged 18-30
89440580|NCT05533840||Age 31-40|Participants aged 31-40
88924963|NCT04391179|Experimental|Dipyridamole 100 Milligram(mg)|100 milligrams (mg) by mouth (PO) four times a day (QID)
88924964|NCT04391179|Placebo Comparator|Placebo|Placebo given by mouth four times a day
88924965|NCT04388228|Experimental|Extended audit and feedback|"The intervention consists of an extended electronically delivered feedback with multiple components which will be delivered 4 times electronically into general practices over 12 months.~This extended feedback report consists of:~Benchmarking of the results of the audit versus peers, versus guidelines and versus disease specific laboratory results.~A low cognitive load of the feedback where the results will be presented with the help of graphs.~Action plans to improve the quality of registration~A push system to minimize the effort the GP must make to consult the feedback."
88924966|NCT04388228|Active Comparator|Basic feedback|In the past, all GPs received basic feedback on the level of registration in the EHR and this form of feedback will still be provided in the control group. By providing all GPs a basic level of feedback, we do not change the former protocol and all GPs will receive the opportunity to improve their registration performance. Only the way of receiving feedback is more straightforward, the GP needs to login to HealthStat.be.
88924967|NCT04386304|Experimental|Dose escalation of (+)-epicatechin|Subjects will receive escalating doses of (+)-epicatechin starting at 75 mg/day and progressing to 150 mg/day and 225 mg/day with 2 months treatment duration for each dose. Subjects will continue treatment on the individual's maximum tolerated dose for another 6 months.
88924968|NCT04386096|Experimental|Mehealth for ADHD software with medication continuity tools|
88924969|NCT04386096|Active Comparator|Mehealth for ADHD software with no medication continuity tools|
88924970|NCT04381169|Experimental|Aggressive fluid resuscitation|"Lactated Ringer Solution 20 ml/kg bolus (administered over 2 hours) followed by an infusion of 3 ml/kg/h.~At 12(±4) hours:~A) Hypovolemia: same bolus and infusion B) No hypovolemia: infusion of lactated Ringer Solution 1.5 ml/kg/h C) Fluid overload: infusion rate of lactated Ringer Solution will be decreased or stopped~Similar adjustments are repeated at 24(±4), 48(±4) and 72(±4) hours~Fluid resuscitation is maintained at least 48h, and then it can be stopped in case of tolerating oral feeding for at least 8 hours"
89012524|NCT01682200|Experimental|ProOxy, Effects and Side Effects in treating acne|Patients are instructed to clean the face with ProOxy facial cleanser and then spray on the face wet enough but not dripping twice daily (upon waking up and before bedtime) for 3 months.
89440581|NCT05533840||Age 41-50|Participants aged 41-50
89440582|NCT05533840||Age 51-60|Participants aged 51-60
89440583|NCT05533840||Age ≥61|Participants aged ≥61
89012525|NCT01682395|Active Comparator|G-SV Resection and colostomy|Gangrenous sigmoid volvulus patients randomized to undergo resection with colostomy and delayed anastomosis
89012526|NCT01682395|Experimental|G-SV Resection and anastomosis|Gangrenous sigmoid volvulus subjects randomized to undergo resection and anastomosis
89012527|NCT01682395|Active Comparator|NG-SV resection and anastomosis|Nongangrenous sigmoid volvulus subjects randomized to undergo resection and anastomosis
89440584|NCT03520530|Experimental|Mouth Guard|Patients will push in the second stage of labor without use of mouth guard
89440585|NCT03520530|No Intervention|Control|Patients will push in the second stage of labor without use of mouth guard
89440586|NCT02547740||Early Glaucomatous Damage|Patients with early functional glaucomatous damage.
89440587|NCT02547740||Ophthalmologically Healthy|Healthy subjects that are ophthalmologically normal
89012528|NCT01682395|Experimental|NG-SV mesosigmoidopexy|Nongangrenous sigmoid volvulus subjects randomized to undergo mesosigmoidopexy
89012529|NCT01682434|Active Comparator|Wavefront-guided LASIK|One eye will be randomized to wavefront-guided treatment. The other receives conventional LASIK.
89012530|NCT01682434|Active Comparator|Conventional LASIK|One eye will receive wavefront-guided LASIK. The other eye receives conventional treatment.
89440588|NCT03378206|Experimental|Hinged 8-figure plate|Hinged 8-figure plate is a novel devise that has modifications in order to improve the treatment effect of conventional 8-figure plate. This arm will be used to verify the effectiveness and feasibility of the modification.
89440589|NCT03378206|Active Comparator|conventional 8-figure plate|Conventional 8-figure plate is widespread method to treat genu varum and valgus. This arm, as a comparator, will be the control group to verify the feasibility of the novel hinged 8-figure plate.
89440590|NCT03512808|Experimental|Ursodiol 500mg tablets|Ursodiol 500mg tablets followed by Urso Forte 500mg tablets
89440591|NCT03512808|Active Comparator|Urso Forte 500mg tablets|Urso forte 500mg tablets followed by Ursodiol 500mg tablets
89440592|NCT05533762|Active Comparator|arch insole|"Half of the subjects are randomly assigned to assess balance capacity with arch insole first.~Three day wash out, the subjects are assess balance capacity with sham insole."
89440593|NCT05533762|Sham Comparator|sham insole|"Half of the subjects are randomly assigned to assess balance capacity with sham insole first.~Three day wash out, the subjects are assess balance capacity with arch insole."
89440594|NCT03520452|Placebo Comparator|Placebo|Placebo
89440595|NCT03520452|Experimental|302 mg green coffee extract|Green coffee extract
89440596|NCT03520452|Experimental|604 mg green coffee extract|Green coffee extract
89012531|NCT01682473|Experimental|Arm 1: 5/2 Dosing|Subjects will receive oral ZSTK474 at a fixed once daily dose administered in 4-week (28-day) cycles of 5 days on drug and 2 days off drug.
89012532|NCT01682473|Experimental|Arm 2: 21/7 Dosing|Subjects will receive oral ZSTK474 at a fixed once daily dose administered in 4-week (28-day) cycles of 21 days on drug and 7 days off drug.
89440597|NCT03520452|Experimental|906 mg green coffee extract|Green coffee extract
89440598|NCT02519582|Experimental|Niclosamid|Patients receive 2 g niclosamide orally per day until progression or toxicity
89440599|NCT03512730|Experimental|Titanium brush, H2O2 3%, plastic curettes|
89440600|NCT03512730|Active Comparator|H2O2 3%, plastic curettes|
89012533|NCT01682551|Experimental|Chinese Medicine|"The participators in this arm will take 2g (powder in capsule) of Wu Zhu Yu Tang or placebo orally three times in the first day and one time in the second day."
89012534|NCT01682551|Placebo Comparator|Acetazolamide|"If the participators have the history of AMS, he/she will be randomized to take Wu Zhu Yu Tang plus placebo of Acetalozamide or Acetalozamide plus placebo of Wu Zhu Yu Tang."
89012535|NCT02279914|Experimental|400 mcg|receives 400 mcg of misoprostol 3 hours prior to the procedure
89012536|NCT02279914|Experimental|600 mcg|receives 600 mcg of misoprostol 90 minutes prior to the procedure
89012537|NCT01682590|Experimental|Early initiation of RRT|Start of RRT within a maximum of 12 hours after randomisation.
89440601|NCT03378050|Experimental|Intervention group|"The intervention group will receive a multi-component individualized support intervention HEART, which will consist of 12 sessions in four stages."
89440602|NCT03378050|Active Comparator|Control group|"Participants is the control group will be placed on a waiting list for 12 weeks. They will receive the intervention, after they complete the 12-week follow-up assessment. Caregivers in the control group will receive 12 week follow-up as usual (FU) including two brief check-in calls and an outcome measures call during the study period."
89440603|NCT03377972||WHO diagnostic standard|
89012538|NCT01682590|Active Comparator|Deferred RRT|Start of RRT between 48 and 60 hours after randomisation.
89012539|NCT01682629|No Intervention|Non-Scripted Debriefing, Low Realism Simulation|A debriefing script was designed for novice instructors to facilitate a 20-minute debriefing session. In this arm, novice instructors were provided the scenario learning objectives but NO SCRIPT, and asked to observe the simulation and conduct a 20 minute debriefing. The simulation scenario itself was conducted with an infant simulator. The low realism group had the simulator with the compressor turned off, thus eliminating the functionality of physical findings.
89440604|NCT03377972||Japan diagnostic standard|
89440605|NCT03516318|Experimental|SMART Connections|"The intervention components include:~Informational messages that reflect the content of the structured group counseling curriculum and are posted to the Facebook group wall on a regular basis for approximately 4 to 5 months~Moderated, closed group chats in a secret Facebook group where YLHIV can interact with their peers and with a trained support group facilitator~Access to a trained facilitator via Facebook Messenger for the duration of the intervention who will be able to provide information or basic counseling on ART/HIV care related issues, with referral to health care services as needed"
89440606|NCT03516318|No Intervention|Control|All study participants, in both study arms, will receive standard services currently available to YLHIV in these facilities and communities. The services currently include: routine clinical care for HIV treatment including laboratory testing (CD4, viral load tests); active case management by community volunteers with intensive adherence support during the first 4 weeks of ART; adherence support through phone calls and SMS (short messaging service) reminders; and enhanced adherence counseling for patients with unsuppressed viral loads.
89440607|NCT05467462|Experimental|Carbetocin|100-mg carbetocin was intravenously administered immediately after birth of the baby
89440608|NCT05467462|Experimental|Oxytocin Group|The oxytocin infusion consisting of 20 IU dissolved in 500 mL of normal 0.9 % sodium chloride solution and infused at a rate of 125 mL/h was administered immediately after clamping the umbilical cord
89440609|NCT05467462|Experimental|Carbetocin and Tranexamic acid Group|100-mg carbetocin was intravenously administered immediately after birth of the baby and tranexamic acid infusion consisting of 1gr dissolved in 100 mL of normal 0.9 % sodium chloride solution was administered immediately after clamping the umbilical cord
89440610|NCT05467462|Experimental|Oxytocin and Tranexamic acid Group|The oxytocin infusion consisting of 20 IU dissolved in 500 mL of normal 0.9 % sodium chloride solution and infused at a rate of 125 mL/h was administered and tranexamic acid infusion consisting of 1gr dissolved in 100 mL of normal 0.9 % sodium chloride solution was administered immediately after clamping the umbilical cord
89440611|NCT03373838||Census|Epidemiological study. Sociodemographic and medical survey.
89440612|NCT03373838||Qualitative interview|Individual qualitative interview.
89440613|NCT03516240|Experimental|Experimental|Participants receive the topical analgesic, Biofreeze.
89440614|NCT03516240|Placebo Comparator|Placebo|Participants receive a placebo cream.
89440615|NCT03516162||Patients With Brain Tumors/AVMs|"Patients with a brain tumour/AVM scheduled for maximum safe resection via craniotomy.~Participants fulfilling all of the following inclusion criteria are eligible for the study:~Consent of the patient~Age: ≥18~Fluent language skills in German~Patient is capable to use a smartphone (based on the Google Android system) and uses a smartphone since at least 3 months~Preoperative smartphone-assessed day-to-day behaviour can be recorded for at least 1 week (7 days)"
89440616|NCT03516162||Patients With Hydrocephalus|"Patients with hydrocephalus scheduled for VP-shunting~Participants fulfilling all of the following inclusion criteria are eligible for the study:~Consent of the patient~Age: ≥18~Fluent language skills in German~Patient is capable to use a smartphone (based on the Google Android system) and uses a smartphone since at least 3 months~Preoperative smartphone-assessed day-to-day behaviour can be recorded for at least 1 week (7 days)"
89440617|NCT03369002|Experimental|Normal|"Child-Pugh Score: N/A~Subjects will receive a single 10 mg oral dose of seladelpar"
89440618|NCT03369002|Experimental|Mild Impairment|"Child-Pugh Score: A (5 to 6 points)~Subjects will receive a single 10 mg oral dose of seladelpar"
89440619|NCT03369002|Experimental|Moderate Impairment|"Child-Pugh Score: B (7 to 9 points)~Subjects will receive a single 10 mg oral dose of seladelpar"
89440620|NCT03369002|Experimental|Severe Impairment|"Child-Pugh Score: C (10 to 15 points)~Subjects will receive a single 10 mg oral dose of seladelpar"
89440621|NCT03520296||Patients hospitalized in the cardiology unit|
89440622|NCT03520296||Patients hospitalized in the orthopedic surgery unit|
89440623|NCT03520296||Patients hospitalized in the endocrinology unit|
89440624|NCT05451316||Upadacitinib|Adolescents and adults with moderate to severe prurigo-type AD, who are prescribed UPA according to the label and practice in Japan.
89440625|NCT03373526|Active Comparator|Aerobic Physical Training|Aerobic Training
89440626|NCT03373526|Experimental|Combined Physical Training|Inspiratory Muscle Training Aerobic Training
89440627|NCT02778399|Experimental|OBE2109 50 mg|
89440628|NCT02778399|Experimental|OBE2109 75mg fixed dose (FD)|
89440629|NCT02778399|Experimental|OBE2109 75mg titrated dose (TD)|
89440630|NCT02778399|Experimental|OBE2109 100mg|
89440631|NCT02778399|Experimental|OBE2109 200 mg|
89440632|NCT02778399|Placebo Comparator|Placebo / OBE2109 100mg|Participants received placebo for the first 12 weeks and were then crossed-over to active treatment with OBE2109 100mg for a further 12 weeks.
89440633|NCT03520218|Experimental|Performance of R-PEM|"5miCi of F-18 FDG will be injected and patients will wait for uptake of FDG before proceeding with first set of R-PEM scans. Additional optional R-PEM scans may be performed 4 hours after injection, and then possibly 7 hours after injection.~These R-PEM images will be compared to standard diagnostic breast work-up using DBT and MRI"
89440634|NCT03377894|Active Comparator|• Group (A) blunt incision|"100 primigravidas at term who underwent elective transverse lower segment Cesarean section for the first time among the age group of 20 - 37 years with a singleton pregnancy.~undergoing blunt uterine incision expansion"
89537039|NCT03302507|Experimental|BESS, biportal endoscopic spine surgery|Biportal endoscopic decompression surgery for lumbar spinal stenosis
88924971|NCT04381169|Experimental|Moderate fluid resuscitation|"At recruitment:~A) Hypovolemia: Lactated Ringer Solution 10 ml/kg bolus (administered over 2 hours) followed by an infusion of 1.5 ml/kg/h.~B) No hypovolemia: infusion of lactated Ringer Solution of 1.5 ml/kg/h (no bolus).~At 12(±4) hours:~A) Hypovolemia: same bolus and infusion B) No hypovolemia: infusion of lactated Ringer Solution 1.5 ml/kg/h C) Fluid overload: infusion rate of lactated Ringer Solution will be decreased or stopped~Similar adjustments are repeated at 24(±4), 48(±4) and 72(±4) hours~Fluid resuscitation can be stopped before the first 48h in case of tolerating oral feeding for at least 8 hours"
88924972|NCT04376684|Experimental|Part 1: Participants receiving otilimab|Participants (age >=18 years and <=79 years) will receive a single dose of otilimab administered as an IV infusion in addition to standard of care in Part 1.
88924973|NCT04376684|Placebo Comparator|Part 1: Participants receiving placebo 1|Participants (age >=18 years and <=79 years) will receive a single dose of matching placebo administered as an IV infusion in addition to standard of care in Part 1.
88924974|NCT04376684|Experimental|Part 2: Participants receiving otilimab|Participants (age 70 years or above) will receive a single dose of otilimab administered as an IV infusion in addition to standard of care in Part 2.
88924975|NCT04376684|Placebo Comparator|Part 2: Participants receiving placebo 2|Participants (age 70 years or above) will receive a single dose of matching placebo administered as an IV infusion in addition to standard of care in Part 2.
88924976|NCT04375683|Experimental|Ph-positive ALLs|Subjects aged 60 years or older are received flumatinib and dose-adjusted VDCP or prednisone regimen. Subjects younger than 60 years are received flumatinib and hyper-CVAD regimen
88924977|NCT04368832||Experimental group|During prenatal monitoring, at least one consultation by remote consultation (phone or teleconsultation)
88924978|NCT04368832||Control group|"Prenatal monitoring by face-to-face consultations adapted to confinement (absence of clinical signs or notion of travel, occupation, contact, clustering (TOCC), no attendant, limited movements inside the hospital and precautions of droplet and contact type)"
89440635|NCT03377894|Active Comparator|• Group (B) sharp incision|100 primigravidas, at term who underwent elective transverse lower segment Cesarean section for the first time among the age group of 20 - 37 years with a singleton pregnancy undergoing sharp uterine incision expansion
89440636|NCT03516084|Experimental|ZL-2306(nirapairb)|
89440637|NCT03516084|Placebo Comparator|Placebo|
89440638|NCT03368924|Other|SCA patients (SS genotype)|"To compare the level of anti band 3 antibodies in steady state and during vaso-occlusive crises in SCA patients.~To assess the relationship between level of biomarkers of oxidation of SS RBCs, altered hemorheological parameters, biomarkers of cellular activation (microparticles) and anti band 3 antibodies rate, taking into account the alpha-globin genes status.~To study the relationship between level of anti band 3 antibodies and severity of these VOC using an index of clinical severity (IS2) calculated at the end of SCA patients hospitalization for VOC.~To study early clinical (including the activity of the autonomic nervous system activity) and biological items to evaluate the relationship between these items and severity of VOC."
89440639|NCT05366452|Experimental|IMPELLA CP GROUP|patients will receive IMPELLA CP before PCI on top of conventional therapy based on the same protocol as the control group and emergent culprit PCI
89012540|NCT01682629|Experimental|Scripted debriefing, Low Realism|In this arm, novice instructors were provided the scenario learning objectives WITH A DEBRIEFING SCRIPT, and asked to observe the simulation and conduct a 20 minute debriefing USING THE SCRIPT. The lo realism group had the simulator with the compressor turned on, thus eliminating the functionality of physical findings.
89440640|NCT05366452|Active Comparator|CONTROL GROUP|patients will receive IV inotropes associated or not with vasopressors according to the attached protocol and based on the current guidelines (annex 1) (2, 4) in addition to emergent culprit lesion PCI
89440641|NCT03377738|No Intervention|anti-smoking therapy|All patients will be given only an intervention for tobacco cessation which will depend on the individual's cessation phase
89440642|NCT03377738|Experimental|anti-smoking therapy + spirometry|All patients will be given an intervention for tobacco cessation which will depend on the individual's cessation phase. In addition, in this group will be given a spirometry test as a motivational element for dishabituation.
89440643|NCT02300376|Experimental|Calcium edetate de sodium versus inulin|The designing a Bayesian model of the plasma clearance of Calcium edetate de sodium is compared to the renal clearance of Inulin.
89440644|NCT02300454|Active Comparator|Non-slip element balloon (NSE)|Lacrosse® NSE dilatation before use of SeQuent® Please drug coated balloon (DCB)
89440645|NCT02300454|Placebo Comparator|Balloon|Non-compliant balloon dilatation before use of SeQuent® Please drug coated balloon (DCB)
89440646|NCT02157363|Active Comparator|Repositioning Group|The patient is placed on a vacuum mattress in supine position for the abdominal part using a midline laparotomy. After completion of the abdominal part, the abdomen is closed and dressed in standard fashion and the patient is repositioned under full anesthesia is a left-lateral decubitus (LLD) position. After the thorax is sterile prepped and draped, a right dorso-lateral thoracotomy in the 4th to 6th intercostal space under preservation of body of the serratus muscle is performed.
89440647|NCT02157363|Experimental|Single positioning|The patient is placed on a vacuum mattress and in a left-screwed supine position for the entire operative procedure. The pelvis and the lower extremities are placed at 0° rotation, whereas the torso is rotated leftwards to an angle of 45° (Fig. 1). The patient is prepped and draped from the shoulders to the inguinal region. A midline laparotomy is done for the abdominal part and the abdomen closed afterwards. For the thoracic part, the operating table is tilted about 30° to the left, and a right anterolateral thoracotomy is performed in the 4th to 6th intercostal space.
89440648|NCT03368846|Experimental|[14C]-Varlitinib|
89440649|NCT05533450|Experimental|Multi-focal rigid scleral contact lens|During the study period, subjects will wear a multi-focal rigid scleral contact lens daily.
89440650|NCT05533450|Active Comparator|Rigid gas permeable contact lens|During the study period, the subjects will wear rigid contact lenses daily
89440651|NCT02153385|Experimental|Yoga group|Two yoga sessions per week for 8 weeks
89440652|NCT02153385|No Intervention|Control group|Usual level of physical activity; no involvement in any yoga practice during the course of the study
89012541|NCT01682629|Experimental|non-Scripted Debriefing, High Realism Simulation|In this arm, novice instructors were provided the scenario learning objectives WITHOUT A DEBRIEFING SCRIPT, and asked to observe the simulation and conduct a 20 minute debriefing WITHOUT USING THE SCRIPT. The hi realism group had the simulator with the compressor turned on, thus activating the functionality of physical findings.
89012542|NCT01682629|Experimental|Scripted Debriefing, High Realism Simulation|In this arm, novice instructors were provided the scenario learning objectives WITH A DEBRIEFING SCRIPT, and asked to observe the simulation and conduct a 20 minute debriefing USING THE SCRIPT. The hi realism group had the simulator with the compressor turned on, thus activating the functionality of physical findings.
89440653|NCT04525040|Experimental|Intervention arm|Children in this arm were given ProbioKid®; one capsule daily, for 6 weeks.
89440654|NCT04525040|Other|Pragmatic arm|Children in this arm received standard of care as usual without a preventive intervention
89440655|NCT03377582|Active Comparator|Conventional therapy|Exercise-based cardiac rehabilitation
89440656|NCT03377582|Experimental|Virtual reality based therapy|Exercise-based virtual reality
89440657|NCT03377504|Experimental|mirror group|Routine physical therapy and exercise program will be applied to all patients for a total of 4 weeks, 5 days a week, 1 hour/day. Mirror therapy will be applied to the mirror group for 30 minutes per day in addition to this routine treatment.
89440658|NCT03377504|Active Comparator|control group|Routine physical therapy and exercise program will be applied to all patients for a total of 4 weeks, 5 days a week, 1 hour/day. A total of 20 sessions of treatment will be given to each patient.
89537040|NCT03302507|Active Comparator|ULBD, unilateral laminotomy bilateral decompression|Minimally invasive ULBD for lumbar spinal stenosis
89440659|NCT02157441|Experimental|all patients|intervention is lower uterine compression sutures (involved bilateral uterine artery ligation and compression of the lower uterine segment at the same time with one circular stitch) as a conservative treatment for the treatment of postpartum hemorrhage in women with placenta previa complete centralis.
89440660|NCT05361460||patients undergoing major elective joint replacement surgery|patients ≥60 years that are undergoing major elective joint replacement surgery Exclusion criteria: a score on the mini-mental state examination (MMSE) at screening of ≤ 22 i.e. suspected dementia; < 60 years of age; suffering from a nervous system disease; taking tranquillisers or antidepressants; underwent a surgical procedure in the previous six months; or inability to read and speak Swedish; suffering from a severe visual or auditory disorder, alcoholism or drug dependence
89440661|NCT02296398||Romidepsin therapy|Patients who received romidepsin per standard of care practice or included in other clinical trials (when receiving romidepsin therapy).
89440662|NCT02153463|Experimental|Activity Counselling|Physical Activity Counselling weekly for 8 weeks
89440663|NCT02153463|No Intervention|Standard Care|Standard care with no change in medications for 8 weeks
89440664|NCT03377426|Experimental|LYS228|IV infusion
89440665|NCT03377426|Active Comparator|Standard of care|IV infusion of standard of care antibiotics for at least 5 days
89440666|NCT03520062|Experimental|GLP-1 Receptor Agonist (Liraglutide)|3.0mg daily dose
89440667|NCT02150655|Experimental|Probiotic|Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 oral capsules
89440668|NCT02150655|Placebo Comparator|Placebo|Sugar pill
89440669|NCT03373292|Experimental|Venous stenting (Group-1)|Patients in this group will undergo venous stenting treatment at once after enrollment.
89440670|NCT03373292|Experimental|Stenting one-month after routine medical treatment (Group-2)|Patients in this group will undergo routine medical treatment for one month, followed by venous stenting intervention.
89440671|NCT03516006|Experimental|UCMSC|infusion of aUCMSC and Ursodeoxycholic acid therapy
89440672|NCT03516006|Active Comparator|UDCA|Ursodeoxycholic acid therapy 15mg/kg/d
89440673|NCT02150733|Experimental|Group 1 - Normal hepatic function|Subjects with normal hepatic function
89440674|NCT02150733|Experimental|Group 2 - Mild hepatic impairment|Subjects with mild hepatic impairment by Child-Pugh classification scores
89440675|NCT02150733|Experimental|Group 3 - Moderate hepatic impairment|Subjects with moderate hepatic impairment by Child-Pugh classification scores
89440676|NCT02150733|Experimental|Group 4 - Severe hepatic impairment|Subjects with severe hepatic impairment by Child-Pugh classification scores
89440677|NCT03512652|Other|Patello|
89440678|NCT02157597|Active Comparator|Control Arm|"The control patients will have open display of the NIRS monitor in the OR, but recording without display in the CICU, along with a request to the surgical and intensive teams to react to the data in their usual way. The disparity between the OR and CICU reflect the current opinions of the clinicians in these different environments regarding the necessity of NIRS monitoring within their sphere of practice.~In this way, continuous recording of cerebral and somatic oximetry will be made in all patients. However for control patients the monitor display will be switched off in the CICU using a pre-programmed research mode, which permits both ongoing recording and also the display of technical error messages (such as inadvertent disconnections or probe displacement)."
89440679|NCT02157597|Experimental|NIRS based management|The trial interventions of NIRS based management consists of provision to the cardiac surgical and intensive care teams of a protocol to guide their interpretation of cerebral and somatic NIRS monitoring and interventions to try in the event of monitored desaturation during the pre- and post-bypass periods (when the circulation is perfused by the beating of the native heart). The investigators believe that there is insufficient data to inform an evidence-based protocol for the bypass phase of surgery, particularly regarding the interpretation of NIRS data under conditions of hypothermia.
89440680|NCT02300532||Cohort 1|Patients with diagnosed malignant glioma treated by surgery, implanted Gliadel wafers 7.7mg
89440681|NCT03373214|Experimental|30 µg Na-GST-1 + CPG 10104|
89440682|NCT03373214|Experimental|100 µg Na-GST-1 + CPG 10104|
89440683|NCT03373214|Experimental|100 µg Na-GST-1|
89440684|NCT02157675|Experimental|Polyherbal capsule|Subjects take 1 capsule with breakfast and 1 capsule with lunch. Subjects should take capsules immediately prior to meals and not with carbonated beverages.
89440685|NCT02157675|Placebo Comparator|Placebo capsule|Subjects take 1 capsule with breakfast and 1 capsule with lunch. Subjects should take capsules immediately prior to meals and not with carbonated beverages.
89440686|NCT03512574|Experimental|Group PD|combination of pregabalin and dexmedetomidine
89440687|NCT03512574|Active Comparator|Group P|pregabalin +placebo
89440688|NCT03512574|Active Comparator|Group D|placebo + dexmedetomidine
89440689|NCT03512574|Placebo Comparator|Group C|placebo + placebo
89440690|NCT02150811||Hunner's ulcer|
89440691|NCT03373136|Experimental|Cold snaring|Polypectomy will be done without electrocautery
89440692|NCT03373136|Active Comparator|Hot snaring|Polypectomy will be performed with electrocautery
89440693|NCT01994980|Active Comparator|Default 4 days antibiotic therapy|Default 4 days antibiotic therapy
89440694|NCT01994980|No Intervention|Default 8 days antibiotic therapy|Default 8 days antibiotic therapy
89440695|NCT02292264||Surgical treatment of ventral hernia|Adult patients who underwent a ventral hernia Repair at Zealand University hospital
89537041|NCT03302429|Experimental|PRF/ BCP|"Biphasic calcium phosphate (BCP)bioceramic bone substitute combined with platelet rich fibrin PRF"
89537042|NCT03302429|Active Comparator|autogenous bone graft|Autogenous bone graft involving utilizing bone obtained from the same individual receiving the graft
89537043|NCT03302351|Experimental|Dexmedetomidine|1st group will include 30 patients will receive intravenous dexmedetomidine 1 mcg/kg.
88924979|NCT04367987||Patients undergoing colorectal surgery|
88924980|NCT04363905|Placebo Comparator|Placebo|100 mg lactose capsule
88924981|NCT04363905|Experimental|Ferrous sulfate|20 mg ferrous sulfate and lactose capsule
88924982|NCT04362891|Experimental|Juvéderm®|Cross-linked hyaluronic acid dermal filler product brand A (1,0 mL at baseline and 0,2 mL touch-up at 2-week follow-up).
88924983|NCT04362891|Experimental|Restylane®|Cross-linked hyaluronic acid dermal filler product brand B (1,0 mL at baseline and 0,2 mL touch-up at 2-week follow-up).
89012543|NCT01682746|Experimental|Treatment|Photofrin (porfimer sodium) photodynamic therapy.
89012544|NCT04527601||ELGAN admissions during peak three months of COVID-19 pandemic|
89012545|NCT04527601||ELGAN admissions in the three corresponding months of 2019|
89440696|NCT03368768||Contact group email of Mahidol-Oxford Research Unit (MORU)|The investigator aims to have at least 100 adult people who could provide information for the total of one year. This expects that at least 20 of those 100 people would have common cold or diarrhea at least one time over one year period. This should provide more than 80% power to detect whether the proportion of having antibiotics when they have common cold or diarrhea was lower than 50% or not. The hypothesized proportion was 20% as stated by the national strategy against AMR in Thailand
89440697|NCT02296554|Experimental|SLAP Repair|Patient will receive SLAP repair for their SLAP tear.
89012546|NCT01682902|Experimental|Formulation 1|
89012547|NCT01682902|Experimental|Formulation 2|
89012548|NCT01682902|Active Comparator|Insulin aspart (NovoLog®)|
89012549|NCT01683097|No Intervention|Control|Questionnaire
89012550|NCT01683097|Experimental|Intervention|Standardized explanation followed by questionnaire
89012551|NCT01683136|Experimental|Deep TMS treatment|
89012552|NCT01683136|Sham Comparator|inactive stimulation|
89012553|NCT01683175|Experimental|Arm 1|Erlotinib 150mg daily oral up to 2 years
89012554|NCT01683175|Active Comparator|Arm 2|NP Chemotherapy for 4 cycles
89012555|NCT00281346|Experimental|transthoracic Doppler echocardiography|
89440698|NCT02296554|Experimental|Biceps Tenodesis Repair|Patient will receive biceps tenodesis repair for their SLAP tear.
89440699|NCT02153697|Experimental|Pigmanorm Cream, Q-switched Ruby laser,solar lentigines|Solar lentigines on the left back of the hand side are treated with Pigmanorm Cream once a day for 7 weeks. Solar lentigines on the right back of the hand side are treated with a Q-switched Ruby laser at Baseline and if required at day 28.
89440700|NCT03373058|Experimental|Experimental group|"Cytoreductive surgery~Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with Docetaxel 75 mg/m^2 and cisplatin 75 mg/m^2 intraperitoneally in succession~6 cycles of adjuvant chemotherapy: paclitaxel 175 mg/m^2 IV>3 hour(Docetaxel 75 mg/m^2, if paclitaxel is not available.)+ carboplatin AUC = 5-6 IV>1 hour, every 3 weeks."
89440701|NCT03373058|Active Comparator|Control group|"Cytoreductive surgery~6 cycles of adjuvant chemotherapy: paclitaxel 175 mg/m^2 IV>3 hour(Docetaxel 75 mg/m^2, if paclitaxel is not available)+ carboplatin AUC = 5-6 IV>1 hour, every 3 weeks."
89012556|NCT01683253|Experimental|Levodopa/Carbidopa(200mg/50mg)|
89012557|NCT01683253|Experimental|Control A (dopaminergic agonist )|Parkinson patients treated with anti-Parkinson drug over 6 months.
89012558|NCT01683253|No Intervention|Control B (no drug)|Parkinson diseased patients not treated.
89012559|NCT01683292|Experimental|Inhaled VR040|Inhaled apomorphine, dry powder, VR040 at fine particle doses (FPD) of 0.2mg, 0.5mg and 0.8mg. A single dose, followed by a second dose at 12 minutes if efficacy end point was not attained.
89199557|NCT05180227|Active Comparator|With Stimulation|Participant will complete an orthostatic challenge with transcutaneous stimulation.
89440702|NCT02292342|Active Comparator|0.1 mg/ kg BW pure (-)-epicatechin|0.1 mg/ kg BW pure (-)-epicatechin (according to volunteer) dissolved in 3 ml/kg BW of water.
89440703|NCT02292342|Active Comparator|0.5 mg/ kg BW pure (-)-epicatechin|0.5 mg/ kg BW pure (-)-epicatechin (according to volunteer) dissolved in 3 ml/kg BW of water.
89012560|NCT01683292|Placebo Comparator|Placebo|Inhaled dry powder. A single dose, followed by a second dose at 12 minutes if efficacy end point was not attained.
89012561|NCT01683370||Patients|Pediatric patients with cancer, receiving standard chemotherapy, and receiving standard supportive therapy in case of fever in neutropenia (FN) (No intervention for study purposes)
89012562|NCT01683682|Experimental|BIBF 1120, Vinorelbine, Carboplatin|"To determine the 'Maximum Toleraetd Dose', dose escalation for BIBF 1120 will be conducted following the 3 + 3 design. A cohort of three patients will be treated at the starting dose level 150mg bid and observed until the end of the first cycle.~Under certain conditions the dose level will be escalated to 200mg bid in a second cohort."
89012563|NCT00287703|Experimental|1|Active Pulsating Electro Magnetic Fields (PEMF) treatment
89012564|NCT00287703|Sham Comparator|2|5 days a week for 5 weeks for 30 minutes Sham PEMF
89012565|NCT00253097|No Intervention|Control|Patients in the control group had the usual care provided at the stroke unit, that is counselling on avoiding risky health behavior, compliance with preventive medication, measurement of blood pressure and a 3 months' visit in the outpatient clinic
89012566|NCT00253097|Experimental|Intervention|Patienta allocated to the intervention group have 4 visits by a study nurse. She will measure patient's blood pressure (BP) by standardized meathods, inform the patient about the target BP, stress the importance of lowering the BP and in case of elevated BP she advices the patient to go the the GP for further control. She advises about smoking cessation, reduction of alcohol consumption, loss of excess body weigt and stresses the importance of physical activity as appropriate
89012567|NCT01683721||Winx|
89012568|NCT01683799|Experimental|Insomnia treatment|Cognitive Behavioral Therapy for Insomnia
89012569|NCT01683799|No Intervention|Control|
89012570|NCT04527640|Experimental|Synbiotic Arm|Patients receiving synbiotics: Lactobacillus acidophilus & Bifidobacterium longum 5x10^9 Colony Forming Unit (CFU) and Fructooligosaccharides (FOS) 60 mg, 2 capsules/day for 60 days
89012571|NCT04527640|Placebo Comparator|Placebo Arm|Patients receiving placebo capsules containing saccharum lactis (2 capsules/day for 60 days)
89012572|NCT04527562|Active Comparator|TRAETMENT GROUP|Participants in the colchicine treatment group will be given a starting dose of 1.2 mg of Colchicine (2 tablets of 0.6 mg )single or 12 hourly divided dose. After that, they will take colchicine 0.6mg daily for 13 days. If they develop gastro intestinal side effects e.g abdominal pain, burning, vomiting, diarrhea, omeprazole and antiemetic will be prescribed.
89440704|NCT02292342|Active Comparator|1.0 mg/ kg BW pure (-)-epicatechin|1.0 mg/ kg BW pure (-)-epicatechin (according to volunteer) dissolved in 3 ml/kg BW of water.
89440705|NCT02292342|Placebo Comparator|0.0 mg/ kg BW pure (-)-epicatechin|Water only (3 ml/kg BW)
89440706|NCT02151045|Active Comparator|Non target epidural infiltration at L3-L4 stage|"In this control arm, there are patients with a non target posterior epidural space infiltration of corticoids done at L3-L4 stage on scan control.~These patients must have a discal hernia confirmed by scanner or RMI"
89440707|NCT02151045|Experimental|Epidural infiltration on contact of disco radicular conflict|"In this experimental arm, there are patients with an epidural infiltration of corticoids done in lateral on contact of disco radicular conflict on scan control.~These patients must have a discal hernia confirmed by scanner or RMI"
89440708|NCT03377348|Other|subconjunctival injection of triamcinolone acetonide|intraoperative subconjunctival injection of triamcinolone acetonide and limited peritomy during bare scleral pterygium excision
89440709|NCT02157831|Experimental|Subjects from UPCC 10903|
89440710|NCT02296710|Experimental|Echocardiographic and sleep apnea test|Echocardiographic Evaluation of systolic and diastolic function of both ventricles and evaluation of apnea-hypopnea index and type of apnea
89440711|NCT02153775|Experimental|Progressive muscle relaxation|Progressive muscle relaxation: single 20-minutes session
89440712|NCT02153775|No Intervention|Reading newspaper of the day|Reading newspaper of the day : single 20-minutes session
89440713|NCT03368690|Experimental|Oligopin®|"Dietary supplement, Polyphenolic extract from pine bark. This group receives a nutritional supplement for a period of 10 weeks.~Children and adolescent 20-50 kg body weight: 25 mg Oligopin®/day; > 50 kg body weight: 50 mg Oligopin®/day Adults 40-60 kg body weight: 100 mg Oligopin®/day; > 60 kg body weight: 150 mg Oligopin®/day"
89440714|NCT03368690|Placebo Comparator|Placebo|Placebo treatment ( identical capsules containing maltodextrin and magnesium stearate )
89440715|NCT02151123||Diagnosed colon cancer patients|Patients undergoing colectomy for colonic adenocarcinoma.
89440716|NCT03515928|Active Comparator|Noise Exposed Group|
89440717|NCT03515928|Placebo Comparator|Control Group|
89440718|NCT02255253|Experimental|Telmisartan|capsule,40mg per day,2 months
89440719|NCT02255253|Experimental|Hydrochlorothiazide|tablet, 25mg per day, 2 months
89440720|NCT02296788|No Intervention|No Exercise Control|Healthy Living Control Group
89440721|NCT02296788|Experimental|Aerobic Exercise Group|8 kcal/kg of body weight/week (KKW) (~900 kcal/wk)
89440722|NCT02296788|Experimental|Aerobic Exercise Group 2|20 KKW (~2250 kcal/wk)
89440723|NCT03372824||Pregnant women|Primiparas above 25 years of age, singleton pregnancy
89440724|NCT02300688|Experimental|Arm 1|Period 1 (Treatment A) - Wash out - Period 2 (Treatment B)
89012573|NCT04527562|Placebo Comparator|CONTROL /PLACEBO GROUP|"COVID-19 Patients in this arm will receive standard COVID-19 treatment according to national guidelines of Bangladesh and will receive placebo.~Standard care of enrolled study patients will consist:~Isolation facility~Symptomatic treatment with Paracetamol, Fexofenadine~Steam inhalation/Gurgle of Lukewarm water.~Ensuring of hand wash (20 seconds each time) and ideally wearing mask.~Monitoring by the attending nurses."
89012574|NCT00281424|No Intervention|control|no pedometer
89440725|NCT02300688|Experimental|Arm 2|Period 1 (Treatment B) - Wash out - Period 2 (Treatment A)
89440726|NCT02151201|Experimental|Influenza vaccination video education|Influenza vaccination video education
89440727|NCT02151201|Placebo Comparator|Hand Washing video education|Hand Washing vaccination video education
89440728|NCT03368378|Experimental|Group 1|During robot-assisted radical prostatectomy after the posterior isolation of seminal vesicles, the Retzius space will be accessed and the endopelvic fascia will be incised. The DVC will be identified and incised. The DVC will be then selectively ligated using a V-lok 3/0 barbed suture. After the early DVC isolation, incision and ligation, the bladder neck will be incised and preserved when possible. A posterior nerve sparing approach will be then performed. During apical dissection, the urethral sphincter will be identified and carefully preserved. Posterior reconstruction and anastomosis will be then performed.
89440729|NCT03368378|Active Comparator|Group 2|After the posterior isolation of seminal vesicles, the Retzius space will be accessed and the endopelvic fascia will be incised. The bladder neck will be then incised and preserved when possible. An inter-fascial or intra-fascial nerve-sparing technique will be then performed and the posterolateral aspect of the neurovascular bundles will be preserved. The DVC will be then isolated and selectively ligated using a V-lok 3/0 barbed suture. The anterolateral fibers of the neurovascular bundles will be then identified and preserved when possible. During apical dissection, the urethral sphincter will be identified and carefully preserved. Posterior reconstruction and anastomosis will be then performed.
89440730|NCT02153853||Rectal cancer|Patients undergoing laparoscopic surgery for rectal cancer at the Department of Gastrointestinal Surgery, Hvidovre Hospital, Copenhagen, Denmark.
89440731|NCT03372746||1|Participants across multiple sites with AMD from the original cohort of study participants enrolled in the AREDS2
89440732|NCT03541863||Endocrine therapy|use endocrine therapy (ET) after Fulvestrant, include but not limited to: tamoxifen, anastrozole, letrozole, exemestane, exemestane + everolimus
89440733|NCT03541863||Chemotherapy|use Chemotherapy (CT) after Fulvestrant, include but not limited to: capecitabine, docetaxel-based, vinorelbine, paclitaxel-based
89440734|NCT03896984||Cohort_2LX|Patients with mCRPC who received NAH monotherapy (Abiraterone or Enzalutamide) as first liine (1L) after diagnosis of mCRPC who then received Ra-223 monotherapy as second line (2L) treatment
89537044|NCT03302351|Experimental|Ketamine|2nd group will include 31 patients will receive intravenous ketamine 0.4 mg/kg.
89199558|NCT05171062|Experimental|Cohort 1|Study patients will receive 0.1-1 mg/kg bexmarilimab (FP-1350) given in combination with Pembrolizumab 200mg IV once every three weeks. The first subject will be started on 0.1mg to establish toleration, for one dose, and then the dose will be escalated to 1mg. This subject will be included in Cohort 1 data.
88924984|NCT04362891|Experimental|Belotero®|Cross-linked hyaluronic acid dermal filler product brand C (1,0 mL at baseline and 0,2 mL touch-up at 2-week follow-up).
88924985|NCT04362891|Experimental|Stylage®|Cross-linked hyaluronic acid dermal filler product brand D (1,0 mL at baseline and 0,2 mL touch-up at 2-week follow-up).
88924986|NCT04356742|Experimental|Dapagliflozin 10mg + Evogliptin 5mg + Metformin|
88924987|NCT04356742|Placebo Comparator|Dapagliflozin Placebo + Evogliptin 5mg + Metformin|
88924988|NCT04353284|Experimental|Camostat mesylate|Camostat mesylate 200mg taken 7 days.
88924989|NCT04353284|Placebo Comparator|Placebo|Placebo taken for 7 days.
88924993|NCT04348864|Experimental|Positive-Antigen swab test for SARS-COV-2|Subjects who have tested positive for the presence of SARS-COV-2 viral antigen using a rapid test or LAMP/PCR-based molecular test from nasal pharyngeal self-swab or a swab administered in a clinical setting at the point of care by a trained clinician. Parallel PCR-based testing occurs in an advanced laboratory to obtain Ct values for positive test results.
88924994|NCT04348864|Sham Comparator|Negative-Antigen swab test for SARS-COV-2|Subjects who have tested negative for the presence of SARS-COV-2 viral antigen using a rapid test or LAMP/PCR-based molecular nasal pharyngeal self-swab or a swab administered in a clinical setting by a trained clinician. PCR-based testing occurs in an advanced laboratory.
88924995|NCT04338100||Chest Ultrasound|Only one arm, all included patients having chest ultrasonography.
88924996|NCT04330807|Other|Patient with chronic kidney disease|Patients will perform a Handgrip fatigability test with their dominant hand and will complete two questionnaires of assessment of subjective fatigue.
88924997|NCT04330807|Other|CONTROL GROUP|Patients will perform a Handgrip fatigability test with their dominant hand and will complete two questionnaires of assessment of subjective fatigue.
88924998|NCT04328012|Experimental|Losartan|losartan 25 mg po QD X 14 days
88924999|NCT04328012|Placebo Comparator|Placebo|placebo QD X 14 days
88925000|NCT04322058||Fathers or paternal caregivers to a child 0-18 years of age|Parenting and Healthy Relationship Education (10 Core 24/7 workshops covering- 15 hours of education), financial and economic mobility programming, comprehensive case management, and supplemental workshops utilizing the Within My Reach curriculum.
88925001|NCT04310150|Experimental|Treatment arm label- Collastat®|
88925002|NCT04310150|Active Comparator|Control arm label- Floseal®|an marketed product is Floseal
88925003|NCT04307498|Other|Intensive Outpatient Program - Prolonged Exposure|Participants will complete fifteen weekday 90-minute Prolonged Exposure therapy sessions over three consecutive weeks plus seven augmentations designed to maximize treatment outcomes. If necessary, the treatment window may be extended for another week.
88925004|NCT04306848|Experimental|Pilot|Eligible subjects who have consented to the study, and have had the baseline data gathered as part of their participation in the Lifestyle Medicine Clinic, an intensive therapeutic lifestyle medicine program, will be given a CGMs device and supplies, and instructed in how to utilize these. They will set up the app on their smart phone to provide them with feedback on their glucose level to correlate with their lifestyle activities.
88925005|NCT04303897||XEN Glaucoma Stent|
88925006|NCT04303663|Active Comparator|Fibular Plate|Open reduction and internal fixation of the fibular fracture Fixation of the fibular will be performed with a fibular plate +/- lag screws as judged intraoperatively
88925007|NCT04303663|Experimental|Fibular Nail|Percutaneous or mini-open reduction of the fibular fracture and fixation with a fibular nail.
89440735|NCT03896984||Cohort_2LH|Patients with mCRPC who received NAH monotherapy (Abiraterone or Enzalutamide) as 1L after diagnosis of mCRPC who then received another NAH monotherapy (i.e., Abiraterone to Enzalutamide or Enzalutamide to Abiraterone) as 2L treatment. None of the patients had ever received Radium-223 dichloride
89440736|NCT02292498|Experimental|FLIR ONE thermal camera|Thermal camera (FLIR ONE)
89440737|NCT02151279|Placebo Comparator|control group|Chitosan as wine fining agent
88925008|NCT04299061|Experimental|Study Group|
89440738|NCT02151279|Active Comparator|Shrimp allergic patients|Chitosan as wine fining agent
89440739|NCT03519828||Patients with post-stroke cognitive impairment|
89012575|NCT00281424|Experimental|pedometer|given pedometer
89440740|NCT03519828||Patients without post-stroke cognitive impairment|
89440741|NCT02157987|Experimental|bevacizumab|bevacizumab spray
89440742|NCT03861728|Experimental|Viral Conjunctivitis Treatment|Patients with viral conjunctivitis as defined by a + AdenoPlus test and clinical symptoms and signs of viral conjunctivitis who will be treated with 0.01% Hypochlorous acid
89440743|NCT03861728|Placebo Comparator|Viral Conjunctivitis Placebo|Patients with viral conjunctivitis as defined by a + AdenoPlus test and clinical symptoms and signs of viral conjunctivitis who will be treated with Basic Sterile Saline
89440744|NCT02159313|Experimental|BAY63-2521 with Non sparkling water|Single dose of a whole 2.5 mg riociguat tablet (fasted) with 240 mL of non-sparkling water at room temperature
89440745|NCT02159313|Experimental|BAY63-2521 with applesauce|Single dose of a crushed 2.5 mg riociguat tablet suspended in 50 mL applesauce, to be eaten with a spoon (fasted)
89440746|NCT02159313|Experimental|BAY63-2521 with water|Single dose of a crushed 2.5 mg riociguat tablet suspended in a glass with 25 mL water, to be drunk and flushed twice with 25 mL water in the same glass (fasted)
89440747|NCT02159313|Experimental|BAY63-2521 after breakfast|Single dose of a whole 2.5 mg riociguat tablet taken within 5 minutes after the last bite of a continental breakfast (fed) with 240 mL of non-sparkling water at room temperature
89440748|NCT03377114|Active Comparator|Neutral|When inserting a tracheal tube to oral cavity via nostril before use of laryngoscope in nasotracheal intubation, clinicians advance the tube with patient' head and neck in neutral position.
89440749|NCT03377114|Experimental|Head tilting|When inserting a tracheal tube to oral cavity via nostril before use of laryngoscope in nasotracheal intubation, clinicians advance the tube with patient' head in head-tilting position.
89440750|NCT02153931||Volunteers|Parents of children with NF1
89440751|NCT03515772||Amlodipine with Dolutegravir|"This is the control group regarding HIV drug interaction potential on amlodipine"
89440752|NCT03515772||Amlodipine with Darunavir|"This is the case group regarding HIV drug interaction potential on amlodipine"
89440753|NCT03515772||Atorvastatin with Dolutegravir|"This is the control group regarding HIV drug interaction potential on atorvastatin"
89440754|NCT03515772||Atorvastatin with Darunavir|"This is the case group regarding HIV drug interaction potential on atorvastatin"
89440755|NCT03515772||Rosuvastatin with Dolutegravir|"This is the control group regarding HIV drug interaction potential on rosuvastatin"
89440756|NCT03515772||Rosuvastatin with Darunavir|"This is the case group regarding HIV drug interaction potential on rosuvastatin"
89440757|NCT02158065|No Intervention|Usual care|Patients will receive information (leaflet) and guidance on the benefits associated with increased physical activity in COPD patients and their health status
89440758|NCT02158065|Experimental|Coaching program|In addition to usual care, patients will receive the coaching program
89440759|NCT02296944||Children aged under 7 years old when tympanoplatie|Collection of anatomical and functional results in the appearance of the tympanic membrane after surgery
89440760|NCT02296944||Children aged 7 to 10 years at the tympanoplatie|Collection of anatomical and functional results in the appearance of the tympanic membrane after surgery
89440761|NCT02296944||Children aged 11 to 14 years at the tympanoplatie|Collection of anatomical and functional results in the appearance of the tympanic membrane after surgery
89440762|NCT02296944||Children aged over 14 years at the tympanoplatie|Collection of anatomical and functional results in the appearance of the tympanic membrane after surgery
88925009|NCT04294914|Active Comparator|Fibromyalgia|Individuals with fibromyalgia.
88925010|NCT04294914|Experimental|Healthy controls|Healthy, pain-free individuals
88925011|NCT04294147|Experimental|Galcanezumab|Participants received a single subcutaneous (SC) dose of 240 milligram (mg) Galcanezumab.
88925012|NCT04294147|Active Comparator|Erenumab|Participants received a single SC dose of 140 mg Erenumab.
88925013|NCT04289454|Other|Effect of flavor modifiers|Intervention in the study: Subjects will taste model KE drinks with (control condition) and without (experimental condition) added flavors. Design is within-subjects (subjects will taste both the experimental and control drinks), with order counter-balanced across subjects.
88925014|NCT04269707|Other|IV Iron|The primary objective in this study is to allow participants who were randomized to receive oral iron in the 1VIT17044 trial and who had an unsatisfactory response to oral iron or those that required a concomitant intervention, (defined as, blood transfusion, use of IV or oral iron outside of protocol, increase in erythropoietin for any reason [Day 0 thru Day 35 of study protocol 1VIT17044], change in IBD treatment) to receive one course of FCM. This course of FCM will consist of two doses of FCM at 15 mg/kg (maximum single dose of 750 mg), separated by seven days.
88925015|NCT04265573||Children under-five|Uncomplicated malaria case in this group will be managed using Pyronaridine-Artesunate at health facility level. This drug is registered in Burkina Faso for routine medical care for uncomplicated malaria case.
88925016|NCT04265573||Individuals five years of age and above|Uncomplicated malaria case in this group will be managed using Dihydoartemisinin-Piperaquine health facility level. This drug is registered in Burkina Faso for routine medical care for uncomplicated malaria case.
88925017|NCT04265573||Pregnant women|Uncomplicated malaria case in this group will be managed using Artemether-Lumefantrin health facility level. This drug is registered in Burkina Faso for routine medical care for uncomplicated malaria case.
88925018|NCT04264637|Experimental|Azelastine hydrochloride 0.15% + Placebo|Each participant will receive a single dose (two sprays per nostril) of study intervention Azelastine hydrochloride 0.15% and Placebo at treatment period 1 and 2 respectively.
88925019|NCT04264637|Experimental|Placebo + Azelastine hydrochloride 0.15%|Each participant will receive a single dose (two sprays per nostril) of study intervention Placebo and Azelastine hydrochloride 0.15% at treatment period 1 and 2 respectively.
88925020|NCT04264234|Experimental|Placenta Previa|Placenta previa cases will be evaluated at 32nd week by vaginal ultrasonography and MRI.
88925021|NCT04263649||All subjects|patients who require a PICC
88925022|NCT04263246|Experimental|PhytoDyNAmic|Six capsules per day b.i.d.
88925023|NCT04263246|Placebo Comparator|Inulin|Six capsules per day b.i.d.
88925024|NCT04245306|Experimental|Children with Autism Spectrum Disorders|A group of 25 children with autism spectrum disorders (ASD)
89440763|NCT03368300|Other|Patients|Parkinson's patient
89012576|NCT01684072|Experimental|vaccine without gelatin|use the upper arm flank deltoid muscle adheres to stick cohere place the skin after 75% ethyl alcohol disinfection the hypodermic injection
89012577|NCT01684072|Active Comparator|vaccine with gelatin|use the upper arm flank deltoid muscle adheres to stick cohere place the skin after 75% ethyl alcohol disinfection the hypodermic injection
89012578|NCT01684111|Experimental|BIBF 1120, Vinorelbine|"To determine the 'Maximum Tolerated Dose', dose escalation for BIBF 1120 will be conducted following the 3 + 3 design. A cohort of three patients will be treated at the starting dose level 150mg bid and observed until the end of the first cycle.~Under certain conditions the dose level will be escalated to 200mg bid in a second cohort."
89012579|NCT01684189||Patient registry|Patients with newly diagnosed malignant hematological diseases will be enrolled into this registry
89012580|NCT02960529||extra-peritoneal high ligation of hernia|the 150 patients were subjected trans-umbilical single-port laparoscopic extra-peritoneal approach repair for inguinal hernia
89012581|NCT02960529||intraabdominal high ligation of hernia|the 150 patients were subjected trans-umbilical single-port laparoscopic intraabdominal approach repair for inguinal hernia
89012582|NCT01684267|Experimental|Healthy|Healthy individuals
89012583|NCT01684267|Experimental|Post-stroke|Chronic stroke survivors
89012584|NCT01684306|Experimental|Placebo|Study subjects received, in a double blind fashion, a placebo pill identical to the drug.
89012585|NCT01684306|Experimental|Modafinil|"Modafinil (Provigil), a drug on the market since 1997, is employed for the treatment of narcolepsy and other sleep disorders. In recent years, modafinil has also been used off-label to treat cognitive dysfunction in psychiatric disorders such as schizophrenia and Attention Deficit/Hyperactivity Disorder (ADHD).~Study subjects received, in a double blind fashion, either a single dose (100 mg) of modafinil."
89012586|NCT01684345|Placebo Comparator|Placebo|
89012587|NCT01684345|Experimental|Dose 1 gevokizumab|
89012588|NCT01684345|Experimental|Dose 2 gevokizumab|
89012589|NCT01684384|Experimental|No treatment|CT-scans will be taken in the study. The EC of the University hospital antwerp considers this as an intervention.
89012590|NCT01684462|Experimental|Human Serum Albumin 20|Human Serum Albumin 20% 100cc intravenously infused over 4~8h
89012591|NCT01684462|Placebo Comparator|0.9 % Normal saline|Treatment with same volume of normal saline
89012592|NCT01684501||Amputees|Adults with history of traumatic unilateral transtibial amputation
89012593|NCT01684579|Experimental|Exercise and psychosocial counseling|Patients will participate in a psychosocial counseling session, 1 day/week for 20 weeks. Patients will be invited to participate in a progressive aerobic and resistance exercise program designed to achieve moderate and then vigorous levels of exercise, 5 days/week for 20 weeks.
89012594|NCT01684618|Experimental|Cerebral NIRS oximetry + CPAP|Cerebral NIRS oximetry, using the INVOS Cerebral/Somatic Oximeter, and changes in regional cerebral oxygen saturation, rSO2, during induced changes in CPAP flow pressure
89012595|NCT02961413||cohort 1|Compound glycyrrhizin tablets / injection
89199559|NCT05171062|Experimental|Cohort 2|Study participants will receive 3mg/kg Bexmarilimab given in combination with Pembrolizumab 200mg IV once every three weeks. 3 participants will need to complete this level before the next cohort dosing begins.
89199560|NCT05171062|Experimental|Cohort 3|Study participants will receive 10 mg/kg Bexmarilimab plus pembrolizumab 200mg IV once every 3 weeks. 3 participants will need to complete this level before the next cohort dosing begins.
89440764|NCT03368300|Other|witnesses: without parkinson's disease|Subjects without parkinson's disease
89440765|NCT02154009||Healthy Volunteers|Volunteers will be studied for Fellows to practice and gain normative values for pupillometric function.
89440766|NCT02154009||Patients|Referred patients with known or suspected abnormalities of one or more components of the autonomic nervous system
89440767|NCT02300844|Experimental|NNC0174-0833 10 mg/mL|
89440768|NCT02300844|Placebo Comparator|Placebo|
89440769|NCT03124628|Experimental|Flywheel resistance exercise|During 8 weeks, all the subjects will follow a standard resistance exercise training program within the Stockholm Habilitation Center system. In addition, patients in this arm will perform flywheel leg press resistance exercise twice per week.
89440770|NCT03124628|Active Comparator|Weight-stack resistance exercise|During 8 weeks, all the subjects will follow a standard resistance exercise training program within the Stockholm Habilitation Center system. In addition, patients in this arm will perform conventional, weight-stack leg press resistance exercise twice per week.
89012596|NCT02961413||cohort 2|Isoglycyrrhizinate magnesium injection / diammonium glycyrrhizinate enteric-coated capsules
89012597|NCT02961413||cohort 3|Bicyclol
89012598|NCT02961413||cohort 4|Silibinin capsules
89012599|NCT02961413||cohort 5|Ursodeoxycholic acid capsules
89012600|NCT02961413||cohort 6|N- acetylcysteine
89012601|NCT01684657|Placebo Comparator|Placebo|This is the comparator. Placebo will be matched to color, taste, size, and smell.
89012602|NCT01684657|Experimental|Asenapine|This is an atypical antipsychotic that blocks dopamine and increases serotonin. The dosage will be from 2.5 to 10mg daily throughout the study.
89012603|NCT00416910|Active Comparator|FCM|Fludarabine i.v. (25 mg/m2/d, d1-3) Cyclophosphamide i.v. (200 mg/m2/d, d1-3) Mitoxantrone i.v. (8 mg/m2, d1) q28d, max. 6 cycles
89012604|NCT00416910|Experimental|FCM + G-CSF|Fludarabine i.v. (25 mg/m2/d, d1-3) Cyclophosphamide i.v. (200 mg/m2/d, d1-3) Mitoxantrone i.v. (8 mg/m2, d1) Filgrastim (G-CSF) s.c. (5 µg/kg/d beginning on day +6 until neutrophil recovery above 1500/µl.) q28d, max. 6 cycles
89012605|NCT01684696|Experimental|mHealth TLC|"The mhealth TLC group will meet with a nurse before each of 4 clinician visits and use the mHealth TLC on an iPad with an interactive 3-dimensional intervention that allows individuals to experience virtual visits with their clinicians. Key aspects of mHealthTLC include informational videos about lung cancer and LCS. Blame and self-blame will be addressed, information about the role of addiction, social/cultural factors, and tobacco industry influence on smoking behaviors will be highlighted. Patients will experience practiced interaction in ever increasing complex situations with avatars (i.e., receptionist, medical assistant, and clinician). A virtual coach will accompany the patient through the virtual visit and will provide information and coaching (as needed)."
89199561|NCT05171062|Experimental|Cohort 4|Study participants will receive 30 mg/kg Bexmarilimab plus pembrolizumab 200mg IV once every 3 weeks.
89440771|NCT03519750|Active Comparator|Intravenous melatonin|Intravenous administration, making it possible to calculate bioavailability for other routes of administration
88925025|NCT04245306|Active Comparator|Typically Developing children|A larger group of 150 typically developing children (TD)
88925026|NCT04245306|Experimental|Children with Developmental Language Disorders|A group of 25 children with developmental language disorders (DLD)
88925027|NCT04244240||Sickle cell disease patient|Adults with sickle cell disease (homozygous SS or heterozygous SC, Sβ0 or Sβ+) with cognitive complaint.
88925028|NCT04240197|Sham Comparator|Standard Pressure Transducer|Epidural pressure waveforms will be measured by using a standard invasive monitor pressure transducer
88925029|NCT04240197|Active Comparator|CompuFlo|Epidural pressure waveforms will be measured by using the CompuFlo Instrument
88925030|NCT04239976|Experimental|Supportive Care (scrambler therapy, sensory test, gait test)|Patients undergo scrambler therapy over 30-45 minutes QD Monday-Friday for 2 weeks. Patients also undergo a quantitative sensory test and a gait assessment test using a FitBit before receiving scrambler therapy, at the end of the first and second weeks of scrambler therapy, and 1 month after the last day of scrambler therapy.
88925031|NCT04239079||PD and Controls|50% of the participants will be healthy controls and 50% will be patients diagnosed with Parkinson's disease
88925032|NCT04239079||AD/aMCI and Controls|50% of the participants will be healthy controls and 50% will be patients diagnosed with Alzheimer's disease or Amnestic Mild Cognitive Impairment (aMCI)
88925033|NCT04238091|Active Comparator|Antibiotics prior to FMT|Participants will take a standardized regimen of antibiotics for three days prior to fecal transplant.
88925034|NCT04238091|Active Comparator|No Antibiotics prior to FMT|Participants will not take antibiotics before the transplant.
88925035|NCT04237155|Other|Healthy controls involved in step 1|30 healthy individuals will complete a verbal material scoring questionnaire
88925036|NCT04237155|Other|Patients with schizophrenia involved in step 1|30 patients with schizophrenia will complete a verbal material scoring questionnaire
88925037|NCT04237155|Other|Healthy controls involved in step 2|30 healthy individuals will complete the source-monitoring task which will be created from step 1 as well as the task of reference
88925038|NCT04237155|Other|Patients with schizophrenia involved in step 2|30 patients with schizophrenia will complete the source-monitoring task which will be created from step 1 as well as the task of reference
88925039|NCT04236531|Experimental|individuals at ultra-high risk for psychosis (UHR)|"30 individuals meeting the UHR criteria according to the Comprehensive Assessment of at-risk mental state (CAARMS) will be recruited and will complete cognitive task and MRI scan"
88925040|NCT04236531|Experimental|patients with first episode psychosis (FEP)|30 patients with first episode psychosis (FEP) will be recruited and will complete cognitive task and MRI scan
88925041|NCT04236531|Sham Comparator|healthy controls|30 healthy individuals will be recruited and will complete cognitive task and MRI scan
88925042|NCT04231825|Experimental|Verum Stimulation|This group will receive 6-Hz tACS
88925043|NCT04231825|Active Comparator|Frequency Control|This group will receive 1-Hz tACS
88925044|NCT04223479|Experimental|Probiotic Formula Capsule|In this intervention arm, the patients will receive oral viable capsules of probiotic contain (1*10 10 colony-forming unit (CFU)/g) of lactobacillus (Lactobacillus rhamnosus , Lactobacillus acidophilus, Lactobacillus reuteri, Lactobacillus paracasei, Lactobacillus casei, Lactobacillus gasseri, Lactobacillus plantarum) and bifidobacteria (Bifidobacterium lactis, Bifidobacterium breve, Bifidobacterium bifidum, Bifidobacterium longum, Bifidobacterium infantis) species three times a per day
88925045|NCT04223479|Placebo Comparator|Placebos|In this intervention arm Placebo arm received three oral viable capsules daily, containing polysaccharides, without any viable probiotics matching the probiotic capsules in appearance, smell, and taste.
88925046|NCT04186793|Experimental|Guided Grocery Shopping|Participants in this study arm will receive a guided grocery shopping intervention for four weeks.
89012606|NCT01684696|Active Comparator|Attention Control|Attention control group (ACG) - Patients assigned to the ACG will meet with a nurse and receive only the informational videos on an iPad before 4 clinician visits with assessments after each clinician visit. An effort will be made to match the intervention condition on salience, credibility, and contact time.
89012607|NCT01684774||I. USG|Patients receiving Ultrasound-guided Ankle Block
89012608|NCT01684774||II. ALG|Patients receiving Anatomic Landmark-guided Ankle Block
89012609|NCT02279992|Experimental|Vardenafil + Carboplatin|Vardenafil (Levitra®) 20 mg oral administered 1 hour prior to start of craniotomy + Carboplatin (Paraplatin®) 100 mg IV administered over 30 minutes at the start of craniotomy
89012610|NCT02279992|Active Comparator|Carboplatin Alone|Carboplatin (Paraplatin®) 100 mg IV administered over 30 minutes at the start of craniotomy
89012611|NCT00287820|Active Comparator|1|olanzapine
89012612|NCT00287820|Active Comparator|2|risperidone
89012613|NCT02272348|Experimental|Education to functional insulin therapy immediately|Immediately after inclusion, patients will follow a functional insulin therapy training course during 2.5 days.
89012614|NCT02272348|Other|No education to functional insulin therapy immediately|After inclusion in the study, patients go on usual diabetes management. At the end of study, they will receive education to functional insulin therapy.
89012615|NCT02279095|Experimental|Palovarotene dose level 1 (completed)|Participants received 10 mg palovarotene for 14 days, followed by 5 mg palovarotene for 28 days (or weight-based equivalent) for eligible flare-ups (Part A).
89012616|NCT02279095|Experimental|Palovarotene dose level 2|Participants with at least 90% skeletal maturity received 5 mg palovarotene for up to 24 months and 20 mg palovarotene for 28 days, followed by 10 mg for 56 days for eligible flare-ups (Part B).
89012617|NCT02279095|Experimental|Palovarotene dose level 3|Participants with less than 90% skeletal maturity received weight-adjusted doses of 20 mg palovarotene for 28 days, followed by 10 mg for 56 days for eligible flare-ups (Part B).
89440772|NCT03519750|Experimental|Rectal melatonin|Rectal administration of melatonin
89440773|NCT03519750|Experimental|Intravesical melatonin|Intravesical administration of melatonin
89440774|NCT03519750|Experimental|Vaginal melatonin|Vaginal administration of melatonin
89440775|NCT03519750|Experimental|Transdermal melatonin|Transdermal administration of melatonin
89440776|NCT02159391|No Intervention|Usual Intervention|A standard intervention will be performed by nursing staff during hospital admission. Written information about the consequences of driving under the influence of alcohol and/or drugs will be provided. No psychological intervention.
89440777|NCT02159391|Experimental|Brief Motivational Interview|A Brief Motivational Interviewing will be performed during hospital admission by a psychologist experienced with this intervention.
89440778|NCT03372668|Other|All Participants|Each study participant will progress through the three, 4-week study periods in the ABA withdrawal design in the same, designated order. The first and third 4-week study periods (or the A periods) have no intervention and only consist of twice weekly data collection. The second 4-week study period (or the B period) will include the twice weekly delivered massage therapy combined with components of mirror therapy intervention.
89012618|NCT02279095|Experimental|Palovarotene dose level 4|All participants will receive 5 mg palovarotene for up to 48 months and 20 mg palovarotene for 28 days, followed by 10 mg for 56 days for eligible flare-ups (Part C). Skeletally immature participants will receive weight-adjusted doses.
89012619|NCT00287859|Experimental|Escalating Cohorts|"Patients receive topotecan intravenously (IV) over 30 minutes on days 1, 8, 15, 22, and 29. Treatment repeats every 42 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of topotecan until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. A total of 6 patients will be treated at the MTD."
89012620|NCT01684891|Experimental|RG1662|
89012621|NCT01684969|Active Comparator|intravenous haloperidol|intravenous haloperidol pharmacokinetics
89012622|NCT01684969|Placebo Comparator|Placebo|
89012623|NCT01685086||Patients with severe chronic kidney disease|
89012624|NCT01685086||Patient with peritoneal dialysis|
89012625|NCT01685086||Patients with hemodialysis|
89012626|NCT01685125|Active Comparator|Arm A (abiraterone acetate, prednisone)|Abiraterone acetate 1000 mg PO QD and Prednisone 5 mg PO BID on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
89012627|NCT01685125|Experimental|Arm B (abiraterone acetate, prednisone, dasatinib)|Abiraterone acetate 1000 mg PO QD, Prednisone 5 mg PO BID, and dasatinib 100 mg PO QD on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
89012628|NCT04527679|Experimental|GC combined Lenvatinib|"GC chemotherapy D1 Cisplatin 25mg/m2+ gemcitabine 1g/m2, D8 gemcitabine 1g/m2 Three weeks is a course of treatment, a total of 8 courses.~Lenvatinib (<60kg: 8mg /d; ≥60kg, 12mg)."
89012629|NCT01685164||LNG-IUS|Nulliparous women
89012630|NCT01685164||Cu-IUD|Nulliparous women
89012631|NCT01685281|Active Comparator|Metadoxine (MG01CI) 1400 mg|single dose of Metadoxine (MG01CI) 1400 mg
89012632|NCT01685281|Active Comparator|Metadoxine (MG01CI) 700 mg|Single dose of Metadoxine (MG01CI) 700 mg
89012633|NCT01685281|Placebo Comparator|Placebo|Single dose of Placebo
89012634|NCT04527952|Experimental|Time-restricted feeding (TRF)|Participants will eat the majority of their calories in the day. More specifically participants will consume 70% of their total calories before 5 pm and the remaining 30% after 5 pm.
89440779|NCT03512340|Experimental|Part A|Part A will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of SRF231 as a monotherapy in patients with advanced solid tumors and lymphoma/Chronic lymphocytic leukemia.
89537045|NCT03302351|Experimental|Dexmetedomidine-Ketamine combination|3rd group will include 33 patients will receive combination between intravenous dexmedetomidine 0.5mcg/kg and low dose ketamine 0.25mg/kg.
89012635|NCT04527952|Active Comparator|Intermittent fasting (IF)|This involves eating all of one's meals within a specific time (e.g. 8 hours) frame and fasting for the remaining hours (16 hours) in a day.
89012636|NCT04527952|Active Comparator|Alternate day fasting (ADF)|This involves complete fasting (i.e. no food or caloric containing beverages, only water consumption) for roughly an entire 36-hour period, followed by an ad libitum feeding day.
89012637|NCT01682005||Complete RV vaccination|Subjects had received 2 doses of Rotarix or 3 doses of Rotateq/mixed within the vaccination window and the observation time is from the end of the vaccination window (8 months old) to end of observation.
89012638|NCT01682005||Incomplete RV vaccination|Subjects received at least one vaccination but less than complete vaccination has been received within the vaccination window and the observation time from 8 months old (if still observed) to end of observation.
89012639|NCT01682005||Any RV vaccination before 8 months|Subjects received any vaccination within the vaccination window and the observation time from 6 weeks old to earliest of end of observation or 8 months old.
89012640|NCT01682005||Historical unvaccinated on/before 8 months old|Subjects did not receive any RV vaccination within the vaccination window and the observation time is from 6 weeks old (if still observed and on/before 12/31/06) to earliest of: 12/31/2006, end of observation, or 8 months old.
89012641|NCT01682005||Historical unvaccinated after 8 months old|Subjects did not receive any RV vaccination within the vaccination window and observation time is from 8 months old (if still observed and on/before 12/31/2006) to earliest of: 12/31/2006 or end of observation.
89012642|NCT01682005||Contemporary unvaccinated on/before 8 months old|Subjects did not receive any RV vaccination within the vaccination window and observation time is from 6 weeks old (if on/after 01/01/2007) to earliest of: end of observation, or 8 months old.
89012643|NCT01682005||Contemporary unvaccinated after 8 months old|Subjects did not receive any RV vaccination within the vaccination window observation time is from 8 months old (if on/after 01/01/2007) to end of observation.
89012644|NCT01685398|Placebo Comparator|normal saline|normal saline 1-2 drops put on the hemangioma lesion 4 times a day and rub over the entire lesion with a finger
89012645|NCT01685398|Experimental|0.5% timolol maleate eye drop|0.5% timolol maleate solution 1-2 drops put on the hemangioma lesion 4 times a day and rub over the entire lesion with a finger
89440780|NCT03512340|Experimental|Part B Cohort 1|Depending upon the results from Part A of the study and the decision from the Safety Review Committee, 1 or 2 doses or dosing frequencies of SRF231 in select advanced solid and hematologic malignancies.
89440781|NCT02158143|Experimental|vitamin D3|
89440782|NCT03372590|Experimental|NICU-based rehabilitation bundle|Patients identified to be at high risk for cerebral palsy will be enrolled after parental consent is obtained to the NICU rehabilitation program. This program consists of maternal-driven evidence based intervention that include: vocal soothing, scent exchange, comforting touch, kangaroo care, and infant massage. These intervention will be provided at GA-appropriate intervals.
89440783|NCT03372590|Other|Standard of care|Infants not participating in the intervention study will be provided with standard or care. Interventions include kangaroo care, physical therapy and infant massage provided by NICU staff.
89440784|NCT02158221|Active Comparator|Migraine patients with high genetic load|PACAP intravenous infusion 1.5 microgram/min for 20 min
89440785|NCT02158221|Active Comparator|Migraine patients with low genetic load|PACAP intravenous infusion 1.5 microgram/min for 20 min
89440786|NCT02292576|Experimental|Acute dose/Chronic dose|Acute dose/Chronic dose.
89440787|NCT02292576|Experimental|Chronic dose/Acute dose|Chronic dose/Acute dose.
89012646|NCT01685476|Other|Intracranial pressure|
89012647|NCT01685515|Experimental|Oral Decitabine and Tetrahydrouridine|Oral Decitabine and Tetrahydrouridine
89012648|NCT01685515|Placebo Comparator|Placebo|Placebo
89012649|NCT04527250|Experimental|Experimental:1mg|ASC41 one tablet (1mg) single oral dose at Day 1 and once daily for 14 days from Day 14 to Day 27.
89012650|NCT04527250|Experimental|Experimental:2mg|ASC41 two tablets (2mg) single oral dose at Day 1 and two tablets daily for 14 days from Day 14 to Day 27.
89440788|NCT03367832||Paediatric surgical patients|All patients < 16 years, admitted to participating centres during the study period who undergo elective and non-elective surgery
89440789|NCT02158299|Experimental|Avitene,Drainaging,reexamine|
89012651|NCT04527250|Experimental|Experimental:5mg|ASC41 one tablet (5mg) single oral dose at Day 1 and once daily for 14 days from Day 14 to Day 27.
89012652|NCT04527250|Experimental|Experimental:10mg|ASC41 two tablets (10mg) single oral dose at Day 1.
89012653|NCT04527250|Experimental|Experimental:20mg|ASC41 four tablets (20mg) single oral dose at Day 1.
89012654|NCT04527250|Placebo Comparator|Placebo:1mg|ASC41 placebo one tablet (1mg) single oral dose at Day 1 and once daily for 14 days from Day 14 to Day 27.
89012655|NCT04527250|Placebo Comparator|Placebo:2mg|ASC41 placebo two tablets (2mg) single oral dose at Day 1 and two tablets daily for 14 days from Day 14 to Day 27.
89012656|NCT04527250|Placebo Comparator|Placebo:5mg|ASC41 placebo one tablet (5mg) single oral dose at Day 1 and once daily for 14 days from Day 14 to Day 27.
89012657|NCT04527250|Placebo Comparator|Placebo:10mg|ASC41 placebo two tablets (10mg) single oral dose at Day 1.
89012658|NCT04527250|Placebo Comparator|Placebo:20mg|ASC41 placebo four tablets (20mg) single oral dose at Day 1.
89012659|NCT04527484|Active Comparator|Group A|SHR-1314 Vial
89012660|NCT04527484|Active Comparator|Group B|SHR-1314 PFS
89440790|NCT02158299|Experimental|Sapylin,Drainaging,reexamine|
89440791|NCT02158299|Active Comparator|Drainaging,reexamine|
89440792|NCT03512106|Experimental|Acupuncture group|Chinese traditional acupuncture
89440793|NCT03512106|Placebo Comparator|Sham group|Sham
89440794|NCT02519816|Experimental|Intervention|Open-label phase II study. After signing informed consent, patients will undergo 6 times an apheresis during the 6-month treatment period. These cells will be manufactured into the Rhitol and frozen in aliquots. Then re-infused.
89440795|NCT02297022|Experimental|Deep Brain Stimulation|Patients with Prader-Willi syndrome to receive DBS.
89440796|NCT02519894|Experimental|Intervention group|Intensive low sodium education and immediate sodium intake feedback by dietary scanning calculator
89440797|NCT02519894|Placebo Comparator|Controlled group|Standard education
89440798|NCT03372512||Fluid overload (Liters) ≥ median|
89440799|NCT03372512||Fluid overload (Liters) < median|
89440800|NCT02301000|Experimental|Intestinal microbiota therapy|The patients allocated to this group will receive 60 ml of the anaerobically cultivated human intestinal microbiota through a rectal catheter.
89440801|NCT02301000|Active Comparator|Metronidazole|The patients allocated to this group will receive metronidazole 400 mg t.i.d. for 10 days
89440802|NCT02154165|Active Comparator|Blue light wavelenght 460 nm|
89440803|NCT02154165|Active Comparator|Turquoise light wavelength 499 nm|
89440804|NCT03372356||Neuroendocrine tumors|Patients with neuroendocrine tumors will be given access to an application that monitors distress, anxiety, depression, self-perceived burden, and resilience at regular intervals for 3 months lasting for 24 months.
89440805|NCT02158455|Experimental|NT SVG grafts|NT SVG randomized for revascularization of left or right coronary territory
89440806|NCT02158455|Active Comparator|RA grafts|RA grafts randomized for revascularization of left or right coronary territory
89440807|NCT02292732|Experimental|Trametinib/ ORTHO-NOVUM® tablet|Subjects in treatment period 1will take one active tablet from the ORTHO-NOVUM® tablet 1/35 dial-pack once daily at approximately the same time each day for 21 days (Days 1 through 21), followed by one placebo tablet once daily at approximately the same time each day for 7 days (Days 22 through 28). In addition, subjects will take trametinib 2 mg (1 tablet) once daily at approximately the same time each day for a total of 17 days (Days 12 through 28). Subjects in treatment period 2 will take one active tablet from the ORTHO-NOVUM® tablet 1/35 dial-pack once daily at approximately the same time each day for 11 days (Days 1 through 11). In addition, subjects will take trametinib 2 mg (1 tablet) once daily at approximately the same time each day for 11 days (Days 1 through 11).
89440808|NCT03376958|Experimental|Apatinib|Apatinib 500mg once daily makes an initial dose and 28 days made one treatment cycle. All patients took the drug continuously until disease progression, intolerable toxicities, and patient-requested withdrawal. Appropriate supportive care were given.
89440809|NCT02159625|Experimental|Abdominal Compression Elastic Support|To compress the abdomen at 15 mmHg for 3 hours during the course of hemodialysis treatment.
89440810|NCT02297178||Cystoscopy Alone|Patients who received cystoscopy only for treatment of OAB and voiding dysfunction.
89199562|NCT05164471|Experimental|FLT180a|A single dose of FLT180a will be administered. Dose will be determined by enrollment cohort. The first 3 patients will receive 7.7 x 10e11 vg/kg. The dose in subsequent cohorts will be determined by the DMC based on review of data from the prior cohort(s).
89440811|NCT02297178||Cystoscopy & Urethral Dilatation|Patients who received urethral dilatation and cystoscopy for treatment of OAB and voiding dysfunction.
89440812|NCT03376802|Experimental|SAR425899|Repeated once daily subcutaneous (SC) doses of SAR425899 administered over 19 days
89440813|NCT03376802|Placebo Comparator|Placebo|Repeated once daily SC doses of placebo administered over 19 days
89440814|NCT03515694|Placebo Comparator|Dose of 0mg/kg TOF1|
89440815|NCT03515694|Placebo Comparator|Dose of 0mg/kg TOF2|
89440816|NCT03515694|Experimental|Dose of 0 ,5mg/kg TOF1|
89440817|NCT03515694|Active Comparator|Dose of 0,5mg/kg TOF2|
89440818|NCT03515694|Experimental|Dose of 1mg/kg TOF1|
89440819|NCT03515694|Active Comparator|Dose of 1mg/kg TOF2|
89440820|NCT03515694|Experimental|Dose of 2mg/kg TOF1|
89440821|NCT03515694|Active Comparator|Dose of 2mg/kg TOF2|
89440822|NCT03376724|Experimental|Functional exercise|
89440823|NCT03376724|Active Comparator|Control Group|
89440824|NCT03541707|Active Comparator|Active Therapy|
89440825|NCT03541707|Sham Comparator|"As if Stimulation"|
89440826|NCT03367676|Experimental|Experimental Arm|12 weeks adjuvant docetaxel plus trastuzumab
89440827|NCT02158611|Other|Lifestyle counseling|
89440828|NCT03367598||Normal weight|nondiabetic and nonobese individuals (18.5 kg/m2 ≤ BMI < 25 kg/m2, n=349)
89440829|NCT03367598||Overweight|nondiabetic and nonobese individuals (25 kg/m2 ≤ BMI < 30 kg/m2, n=154)
89440830|NCT02292810|Experimental|Inspiratory muscle exercise|Patients will exercise the inspiratory muscle using a load of 60% of maximum inspiratory mouth pressure (MIP 60%).
89440831|NCT02292810|Placebo Comparator|Inspiratory muscle exercise placebo|Patients will exercise the inspiratory muscle using a load of 2% of maximum inspiratory mouth pressure (MIP 2%).
89440832|NCT02255019||IBD, CD, UC|All patients should either have a known IBD diagnose or suspect of having IBD.
89440833|NCT03376568||Narcolepsy with RBD & Control|Narcolepsy with REM sleep disorder lable(20) and Control subjects lable(20)
89440834|NCT03376568||Narcolepsy with /without RBD|Narcolepsy with REM sleep disorder lable(20) and Narcolepsy without REM sleep disorderlable (20)
89440835|NCT03515538|Experimental|RRx-001 Pre-Treatment plus SOC|Two infusions of RRx-001 will be given each week during the two weeks prior to the start of RT/cisplatin SOC (four doses total). No additional RRx-001 will be given during the course of RT/cisplatin
89537046|NCT04862351|Experimental|TecHCR|12 weeks Hybrid between supervised exercise training and video call sessions Educational videos Dietary and exercise log
89537047|NCT04862351|Other|Centre-based|12 weeks usual care provided by the centre-based, outpatient cardiac rehabilitation clinic Dietary and exercise log
89537048|NCT05727683|Experimental|JWCAR029 Treatment|"A lymphodepletion conditioning with cyclophosphamide and fludarabine will be conducted before JWCAR029 infusion.~Potential JWCAR029 doses:~Dose level 1: 0.10×10^6 CAR+ T cells/kg Dose level 2: 0.30×10^6 CAR+ T cells/kg Dose level 3: 0.75×10^6 CAR+ T cells/kg Dose level 4: 1.0×10^6 CAR+ T cells/kg"
89537049|NCT02881307|Experimental|Dietary Supplement|
89537050|NCT02881307|Active Comparator|Dietary Counseling|
89440836|NCT03515538|Experimental|RRx-001 Pre-Treatment, 2 Concurrent Doses plus SOC|Two infusions of RRx-001 will be given each week during the two weeks prior to the start of RT/cisplatin SOC. In addition, one dose of RRx-001 will be given on the last radiation day in each of weeks 2 and 5 during RT/cisplatin administration
89440837|NCT03515538|Experimental|RRx-001 Pre-Treatment, 6 Concurrent Doses plus SOC|Two infusions of RRx-001 will be given each week during the two weeks prior to the start of RT/cisplatin SOC. In addition, one dose of RRx-001 will be given on the last radiation day of each of the first 6 weeks during RT/cisplatin administration
89537051|NCT03302039|Experimental|Single shot|Spinal anesthesia will be performed using intrathecal bupivacaine. Then, a single shot phenylephrine (1.5 ug/Kg) will be administered.
89440838|NCT03515538|Active Comparator|Standard of Care|No doses of RRx-001 will be administered. Patients assigned to this arm will receive only standard of care in the form of a 7-week course of fractionated radiation therapy concurrent with a high-dose cisplatin regimen (100 mg/m2 dose in each of RT weeks 1, 4, and 7).
89440839|NCT02158689|Active Comparator|human menopausal gonadotropin (hMG)|hMG at a dose of 300 IU/day will be initiated on the second or third day of spontaneous menstruation and continued until the day of ovulation triggering. Ovulation triggering will be performed with the administration of 10000 IU of human chorionic gonadotropin (hCG) as soon as two-three follicles of 17 mm diameter will be observed by transvaginal ultrasound.
89440840|NCT02158689|Active Comparator|Letrozole|Letrozole (Femara; Novartis, East Hanover, NJ) at a dose of 5 mg/day will be initiated on the second or third day of spontaneous menstruation and continued for 5 days. Again on the second or third day of spontaneous menstruation, 150 IU of hMG will be started until the day of ovulation triggering. Ovulation triggering will be performed with the administration of 10000 IU of hCG as soon as two-three follicles of 17 mm diameter will be observed by transvaginal ultrasound.
89440841|NCT03372200|Experimental|FYU-981|
89440842|NCT03372200|Active Comparator|Febuxostat|
89440843|NCT02159781|Experimental|periodontal treatmnent|
89440844|NCT03372122|Active Comparator|SAGE Chlorhexidine Gluconate Cloth|Ready to use disinfectant cloth
89440845|NCT03372122|Active Comparator|HUBS with Hibiclens|Dry cloths to be used with water and disinfectant
89440846|NCT02292888|Active Comparator|patients with LVEF >40%|Correlation between hemodynamic variable : SV and echocardiographic variable : Doppler VTI will be compared before and after Passive Leg Raising (PLR) test.
89440847|NCT02292888|Active Comparator|patients with LVEF < or equal to 40%|Correlation between hemodynamic variable : SV and echocardiographic variable : Doppler VTI will be compared before and after Passive Leg Raising (PLR) test.
89440848|NCT02158845|Active Comparator|LNG-IUS|LNG-IUS: levonorgestrel intrauterine system
89440849|NCT02158845|Active Comparator|GnRHa|GnRHa: leuprolide
89440850|NCT03372044|Experimental|PF-06865571|Treatment
89440851|NCT02301078||Percutaneous Needle Aponeurotomy|Patients who choose to undergo percutaneous needle aponeurotomy (PNA) for primary treatment of Dupuytren's disease
89440852|NCT02301078||Xiaflex|Patients who choose to receive Collagenase clostridium histolyticum injection (drug name Xiaflex) for primary treatment of Dupuytren's disease.
89440853|NCT04786977||VIPN Patients|
89440854|NCT04786977||Healthy Volunteers|
89440855|NCT03367520|Experimental|StayQuit|StayQuit offers 3 meetings during hospitalization and up 13 telephone calls. StayQuit begins in the hospital with an assessment of motivation to remain quit after discharge and a brief intervention to develop discrepancy between values and behaviors and generate change talk. Participants are also encouraged to try nicotine replacement therapy during the hospitalization and after discharge. Telephone counseling is brief and focused on managing withdrawal from nicotine, coping with cravings, and supporting use of NRT. The investigators will work with hospital staff as needed to ensure that nicotine replacement therapy is offered to participants during the inpatient stay and prescribed at discharge.
89440856|NCT02292966|Experimental|Hepatitis C treatment|12 weeks of DCV/ASV/BCV therapy.
89440857|NCT02159937||Patients with metastatic cancer|Blood sampling by vena punction.
89440858|NCT03519672||Participants with cTTP - adolescents|Adolescents aged 12 to 17 years
89440859|NCT03519672||Participants with cTTP - adults|Adults aged ≥18 years
89012661|NCT04527835||patients suspected for viral myocarditis|All patients admitted with unexplained heart failure in the last 3 months will be investigated for viral myocarditis by the use of 12 lead ECG, echocardiography, Cardiac MRI , coronary angiography, Endomyocardial biopsy ( optional ), serological tests including ELIZA,Extraction of nucleic acid, Determination of viral genome by using PCR., Quantitative real-time PCR to assess viral load, Immunohistochemistry analysis of EMB.
89012662|NCT01685554|Active Comparator|normothermic CPB|cardiopulmonary bypass with maintenance of normal body temperature
89440860|NCT02519660|Experimental|Lidocaine/Tetracaine patch (Ralydan)|Ralydan patch is a drug delivery system designed to release local anaesthetics (lidocaine and tetracaine) through the skin. It is applied in the site of venipuncture 30 minutes before needle procedure
89440861|NCT02519660|Active Comparator|Lidocaine/Prilocaine cream (EMLA)|EMLA cream is an eutectic mixture of local anaesthetic (lidocaine, prilocaine). It is applied in the site of venipuncture 60 minutes before needle procedure
89440862|NCT03511872|Experimental|Peers' group|"36 Medical students are allocated randomly to Peers' group where they are trained on BLS skills by senior students.~Four students from the latest three years of study in medical schools in Syria (4th, 5th, and 6th) are randomly selected and enrolled to be instructors for basic life support training course to transfer the resuscitation skills to medical students from pre-clinical years."
89440863|NCT03511872|Experimental|Professionals' group|36 students are allocated randomly to professionals' group where they are trained on BLS skills by professional trainers in emergency. Four professionals (2 emergency doctors, cardiologist and anesthesiologist) are leading training to the control group to deliver the basic life support training course with the same duration and content as the intervention group.
89440864|NCT02297334|Active Comparator|With CytoSorb device|Patients randomised to this arm are treated with the CytoSorb device during bypass.
89012663|NCT01685554|Active Comparator|hypothermic CPB|cardiopulmonary bypass using mild hypothermia
89012664|NCT01685593|Sham Comparator|regular bandage|no abdominal binder
89012665|NCT01685593|Experimental|abdominal binder|binder
89012666|NCT01685632|Active Comparator|Surgery with IPCH|Patients having an IPCH (Intra Peritoneal Chemo Hyperthermia) during the surgery time
89012667|NCT01685632|Sham Comparator|patients without IPCH|Patients recused for the surgery due to intraoperative contraindication
89440865|NCT02297334|No Intervention|Withouot device|Patients randomised to this arm are treated without the CytoSorb device during bypass.
89440866|NCT03376412|Experimental|Single Arm Treatment.|All patients will be unilaterally implanted in the non-dominant eye with the Raindrop Near Vision Inlay for the compensation of presbyopia.
89440867|NCT03371966|Active Comparator|High Nitrate Beetroot Juice|Beetroot juice high in nitrate will contain approximately 10.0 mmole nitrate per 120 ml.
89440868|NCT03371966|Placebo Comparator|Low Nitrate Beetroot Juice|Beetroot juice low in nitrate will contain approximately 0.5 mmole nitrate per 120 ml.
89440869|NCT03519594||Embolization group|The group that underwent embolization after pelvic injury.
89440870|NCT03519594||Non-embolization group|The observed group of pelvic injuries without embolization
89440871|NCT03541473|Active Comparator|Peptamen® 1.5 Vanilla|
89440872|NCT03541473|Placebo Comparator|Boost Plus® Vanilla|
89440873|NCT03371888|Experimental|PRP injections|Intramuscular injection of Platelet-Rich Plasma into the masseter and temporalis muscle
89440874|NCT03371888|Placebo Comparator|0,9% NaCl injections|Intramuscular injection of 0,9% NaCl into the masseter and temporalis muscle
89440875|NCT02154321||Attention Deficit Hyperactivity Disorder|This study aims to recruit 100 adult participants: 50 of which are adults diagnosed with Attention Deficit Hyperactivity Disorder and 50 healthy controls. All participants will perform a total of two tasks while connected to electroencephalogram (EEG) sensors; the first task is a resting state task and after that a cognitive challenge task (attention control). Study activity is performed in a single visit which lasts two hours. Participants will also be asked to complete some behavioral questionnaires.
89440876|NCT02154321||Healthy Control|This study aims to recruit 100 adult participants: 50 of which are adults diagnosed with Attention Deficit Hyperactivity Disorder and 50 healthy controls. All participants will perform a total of two tasks while connected to electroencephalogram (EEG) sensors; the first task is a resting state task and after that a cognitive challenge task (attention control). Study activity is performed in a single visit which lasts two hours. Participants will also be asked to complete some behavioral questionnaires.
89440877|NCT02297490|Placebo Comparator|Placebo|Placebo treatment is identical to the active treatment schedule. The placebo-preparation used is identical to the active solution but without any allergen substance in it.
89440878|NCT02297490|Experimental|Allergovit 6-grasses immunotherapy|Immunotherapy will be performed for approx. 5 months. 7 injections will be administered at weekly intervals to reach the maintenance dose. However, dosing must be individualised.
89440879|NCT03371810|Experimental|Bright light therapy|"Mobile therapeutic light (10.000 LUX), daily (except Sunday) for 30 min in the morning or evening for 10 weeks in total.~Additional treatment as usual comprising pharmacotherapy, group based or individual cognitive behavioural therapy (not including elements of bright light therapy or exercise) is allowed."
89440880|NCT03371810|Experimental|Physical exercise|"Aerobic exercise of moderate-to-vigorous intensity three days a week plus muscle-strengthening exercises two days a week during 10 weeks in total.~Additional treatment as usual comprising pharmacotherapy, group based or individual cognitive behavioural therapy (not including elements of bright light therapy or exercise) is allowed."
89440881|NCT03371810|No Intervention|Treatment as usual|Stable treatment as usual comprising pharmacotherapy, group based or individual cognitive behavioural therapy (not including elements of bright light therapy or exercise).
89440882|NCT02154399|Experimental|Treatment (EF5)|Patients receive EF5 IV over 1-2.5 hours. Beginning 24-55 hours later, patients undergo tumor hypoxia measurement using a polarographic needle electrode and intraoperative tumor measurement before undergoing surgical biopsy or resection.
89440883|NCT02519192|Experimental|VAC Arm, Vac sponge irrigations|For patients who fall under the VAC arm, a physician will do the initial placement of the wound VAC (V.A.C.Ulta™ Negative Pressure Wound Therapy System) at the patient's bedside. An information sheet will be provided to the patient, and the patient will be taught how to irrigate the sponge system independently. While inpatient, nursing will perform VAC sponge irrigation.
89440884|NCT02519192|Active Comparator|NonVac, ostomy bag, wet to dry dressings|For patients who fall under the non-VAC arm, a physician or wound care nurse will perform the initial application of the ostomy bag or wet to dry dressing change. An information sheet will be provided to the patient. While inpatient, members from the nursing or physician team will perform ostomy bag application and ostomy dressing changes.
89440885|NCT02293200|Experimental|Traditional learning|chest compression group learning without CPR feedback device. After a month of quality control of chest compressions is made also without the device.
89440886|NCT02293200|Experimental|Experimental learning|Training is done using TrueCPR feedback device. After a month of quality control of chest compressions is made without the device. To do this will be indicated on the impact of the use of feedback devices for improving the effectiveness of training in CPR.
89012668|NCT01685671|Active Comparator|NESP 60μg|Prefilled syringe filled with Darbepoetin alfa 60μg
89012669|NCT01685671|Experimental|CKD-11101 60μg|Prefilled syringe filled with Darbepoetin alfa 60μg
89012670|NCT01685710|Experimental|GTN patch|GTN patch 5mg, in situ 24hrs
89012671|NCT01685710|Placebo Comparator|Placebo patch|Placebo patch, in situ for 24hrs
89440887|NCT03542799|Experimental|3|anti-tumor response of EGFR IL12 CART
89440888|NCT02519972|Experimental|Low dose computed tomography|All the Low dose computed tomography of lung was performed with 64 slices multidetectors CT in single hold breath covering entire lung. The protocol of scanning parameters (120KVp, 40-80 mA, 1.25 mm or less in thickness) was standardized. The raw data would be reconstructed to axial images (3 mm thickness and interval) and coronal images (3 mm thickness and interval). The scan should be finished in a single breath (15-20 second) from the thoracic inlet to adrenal glands.
89440889|NCT02297568|Active Comparator|Calciferol,1800 IU/d supplement|The lactating mothers and their breastfed infants with maternal 25 Hydroxy-vitamin D (25OHD) levels of 10-30 ng/ml in third trimester were randomly assigned to 1,800 IU/d .
89440890|NCT02297568|Placebo Comparator|Placebo|The lactating mothers and their breastfed infants with maternal 25 Hydroxy-vitamin D (25OHD) levels of 10-30 ng/ml in third trimester were randomly assigned to receive placebo.
89440891|NCT02154555|No Intervention|no debridement|The postoperative clinical visits will occur at one week, one month, and three months following surgery. During all three postoperative visits, no debridement will be performed.
89012672|NCT01685749||Enrolled participants|The targeted study population will include all people at Seal Beach who have been identified by the Seal Beach Lifeguards to have been stung by a jellyfish over the course of one year who are adults or children whose parent or guardian is present at the time of the injury. Children and pregnant women are included in the group.
89012673|NCT01685788||study participants|
89012674|NCT00281619||Mycophenolic Acid (CellCept)|purpose of this study is to determine how fast children, who have had a recent kidney transplant, absorb, breakdown and eliminate mycophenolic acid (CellCept) following their prescribed dose
89012675|NCT04527211|Experimental|Ivermectin|Oral administration of ivermectin 200 mcg/kg every week for seven weeks
89012676|NCT04527211|Placebo Comparator|Placebo|Oral administration of placebo of similar characteristics every week for seven weeks
89012677|NCT01685866|Other|Vein-Viewer Vision|A medical device called Vein-Viewer Vision
89012678|NCT01685866|No Intervention|no medical device|in the second arm, we use no medical device
89012679|NCT01685944|Placebo Comparator|Placebo|
89012680|NCT01685944|Experimental|Live Pediococcus pentosaceus LP28|
89012681|NCT01685944|Experimental|Heat-killed Pediococcus pentosaceus LP28|
89012682|NCT01686022||Pollen Allergy|Pollen allergy and control will have the same intervention, ie. Skin prick test and collect serum samples.Then measure the specificIgE, immunoblot, and ELISA inhibition
89012683|NCT01686217|Experimental|Dose Group 1 Treatment A|Lowest per tablet dose of ASP015K Extended Release (ER) tablets under fasted conditions
89012684|NCT01686217|Active Comparator|Dose Group 1 Treatment B|Medium per tablet dose ASP015K Immediate Release (IR) tablets under fasted conditions for comparison to lowest dose ER fasted conditions
89012685|NCT01686217|Experimental|Dose Group 1 Treatment C|Lowest per tablet dose of ASP015K ER tablets under fed conditions
89012686|NCT01686217|Experimental|Dose Group 2 Treatment D|Medium per tablet dose of ASP015K ER tablets under fasted conditions
89440892|NCT02154555|Experimental|debridement|The postoperative clinical visits will occur at one week, one month, and three months following surgery. During the one week postoperative visit, the randomized unilateral debridement will be performed. Debridement includes removing any crust or mucous in the nose. During the one month and three month visit, the PI will only examine the nose.
89440893|NCT03376334|Experimental|Motor Imagery (MI)|Those meeting the inclusion criteria were selected (n=22). Each participant was necessary to complete the Movement Imagery Questionnaire in a quiet room. Finally, each participant assigned a score by using a 7-point scale regarding the ease/difficulty associated with representing each movement mentally. Next their baseline balance measurement was performed using the SEBT. Later this group had 9 motor imagery sessions, each session for 15 minutes, 3 sessions (alternate days) per week for a total of 3 weeks. Reassessment of balance was done after every 3 sessions.
89440894|NCT03376334|No Intervention|Control (C)|Those meeting the inclusion criteria were selected (n=10). Baseline measurement of SEBT was done on day 1, end of week 1, end of week 2 and end of week 3.
89440895|NCT03515382|Experimental|Treatment A|single dose GLPG1690.
89440896|NCT03515382|Experimental|Treatment B|Single dose itraconazole + single dose GLPG1690.
89440897|NCT03515382|Experimental|Treatment C|Single dose voriconazole + single dose GLPG1690.
89440898|NCT02154633|Experimental|Family Gene Toolkit|Psychosocial educational presentations over the Internet (Webinars) Two Webinars lasting 1 hour each One follow-up phone call lasting 20 minutes
89440899|NCT02154633|Active Comparator|Delayed Family Gene Toolkit|Psychosocial educational presentations over the Internet (Webinars) Two Webinars lasting 1 hour each One follow-up phone call lasting 20 minutes
89012687|NCT01686217|Active Comparator|Dose Group 2 Treatment E|Medium per tablet dose of ASP015K IR tablets under fasted conditions for comparison to medium dose ER fasted conditions
89012688|NCT01686217|Experimental|Dose Group 2 Treatment F|Medium per tablet dose of ASP015K ER tablets under fed conditions
89199563|NCT05148962|Experimental|Cohort 1: 1 or 2 Doses of 10 mcg GRT-R910 after AstraZeneca Standard of Care|Healthy adults ≥60 years of age receive up to 2 doses of 10 mcg GRT-R910 homologous prime-boost
89440900|NCT02297646|Experimental|Carbohydrates|50 grams of carbohydrates 4 times a week for each training session
89440901|NCT02297646|Placebo Comparator|Control|no carbohydrate intake
89440902|NCT02519426||Cumulative complexity score <9|Mandibular third molar surgery patients with Juodzbalys and Daugela impacted mandibular third molars surgical extraction complexity index cumulative score lower than 9.
89440903|NCT02519426||Cumulative complexity score y≥9|Mandibular third molar surgery patients with Juodzbalys and Daugela impacted mandibular third molars surgical extraction complexity index cumulative score higher than 9.
89440904|NCT02519426||Pell Gregory index <Class 2B|Mandibular third molar surgery patients with Pell Gregory index Class 1A, Class 1B, Class 1C, or Class 2A
89440905|NCT02519426||Pell Gregory index ≥Class 2B|Mandibular third molar surgery patients with Pell Gregory index Class 2B, Class 2C, Class 3A, Class 3B, or Class 3C
89440906|NCT02519426||Winter index <Horizontal impaction|Mandibular third molar surgery patients with Winter predicted index of Mesio-Angular, Disto-Angular or Vertical impaction
89440907|NCT02519426||Winter index ≥Horizontal impaction|Mandibular third molar surgery patients with Winter predicted index of Horizontal, Buccal / Lingual Obliquity, Transverse, Inverse impaction
89440908|NCT03519360|Experimental|Restricted ultrafiltration rate (UFR)|UFR ≤10 ml/kg/hr
89440909|NCT03519360|Experimental|Standard of Care/ Unrestricted UFR|UFR as needed
89440910|NCT02158923|Experimental|Individualized ventilation|Intraoperatively ventilated patients with a tidal volume (VT) of 8 ml / kg of ideal body weight, and a FiO2 of 0.8. After intubation, all patients were conduct an alveolar recruitment maneuver (MRA) and PEEP level individualized spanned (see Calculation of optimal PEEP). Every 40 minutes will be assessed the need to adjust the level of PEEP by evaluating the dynamic compliance of the respiratory system (Crs). Faced with a decline in Crs> 10% a new MRA and optimal PEEP setting will be assessed.
89440911|NCT02158923|Experimental|Individualized vent. + postop. CPAP|Intraoperatively ventilated patients with a tidal volume of 8 ml / kg of ideal body weight, and a FiO2 of 0.8. After intubation, all patients were conduct an alveolar recruitment maneuver (MRA) and PEEP level individualized spanned (see Calculation of optimal PEEP). Every 40 minutes will be assessed the need to adjust the level of PEEP by evaluating the dynamic compliance of the respiratory system (Crs). Faced with a decline in Crs> 10% a new MRA and optimal PEEP setting will be assessed. Postoperatively a CPAP of 5 cmH2O (or 10 cmH2O if BMI> 30) with a FiO2 of 0.5 will be applied.
89012689|NCT01686217|Experimental|Dose Group 3 Treatment G|Highest per tablet dose of ASP015K ER tablets under fasted conditions
89440912|NCT02158923|No Intervention|Standard ventilation|Intraoperatively ventilated patients with a tidal volume of 8 ml / kg of ideal body weight, PEEP 6 cmH2O and FiO2 0.8. In these groups no recruitment maneuvers or optimal PEEP setting will be performed.
89440913|NCT02158923|Active Comparator|Standard vent. + postoperative CPAP|Intraoperatively ventilated patients with a tidal volume of 8 ml / kg of ideal body weight, PEEP 6 cmH2O and FiO2 0.8. In these groups no recruitment maneuvers or optimal PEEP setting will be performed. Postoperatively, a CPAP of 5 cmH2O (or 10 cmH2O if BMI> 30) with a FiO2 of 0.5 will be applied.
89440914|NCT03690518|No Intervention|Control|Controls will have a regular follow-up without any intervention (no rehabilitation program)
89440915|NCT03690518|Active Comparator|Rehabilitaiton|Cardiac rehabilitation: Rehabilitation will have a regular follow-up with intervention (rehabilitation program)
89440916|NCT02159001|Active Comparator|ECT treatment right after recruitment|This group receives electroconvulsive therapy treatment right after they are recruited.
89440917|NCT02159001|Placebo Comparator|ECT after 4 weeks period.|This group receives electroconvulsive therapy treatment after 4 weeks waiting period.
89440918|NCT03511560|Active Comparator|Tacrolimus, Immediate release|Tacrolimus (immediate-release) will be administered twice daily per clinical judgment of supervising physician (dosing and monitoring in accordance with center protocol) to a minimum whole blood tacrolimus concentration of at least 8 ng/mL.
89440919|NCT03511560|Experimental|Envarsus XR|Envarsus XR (Tacrolimus Extended Release Oral Tablet) will be administered once daily at initial weight-based dose of 0.12 mg/kg. Dosing and monitoring thereafter predicated on clinical judgment to a minimum whole blood tacrolimus concentration of at least 8 ng/mL. When possible, patients will receive their daily dose of Envarsus using the fewest number of pills possible.
89199564|NCT05148962|Experimental|Cohort 2: 1 or 2 Doses of 30 mcg GRT-R910 after AstraZeneca Standard of Care|Healthy adults ≥60 years of age receive up to 2 doses of 30 mcg GRT-R910 homologous prime-boost
89440920|NCT02160171||Term neonates|Term neonates who are undergoing continuous video amplified Electroencephalogram (aEEG)/Electroencephalogram (EEG) monitoring for clinical purposes (e.g. because seizures were suspected, or the neonate is being treated with therapeutic hypothermia). EEGs will be analysed off line by 'Algorithm for Neonatal Seizure Recognition'
89440921|NCT03519126|Experimental|vaginal|Group of volunteers who will be treated with vaginal electrostimulation
89199565|NCT05148962|Experimental|Cohort 3: 2 Doses 10 mcg GRT-R910 after Adenovirus-Based Vector Vaccine Standard of Care|Healthy adults ≥60 years of age receive 2 doses of 10 mcg GRT-R910 homologous prime-boost
89440922|NCT03519126|Experimental|posterior tibial nerve|Group treated with transcutaneous electrostimulation of the posterior tibial nerve
89440923|NCT03519126|No Intervention|control|Group of volunteers who will not be treated
89440924|NCT03688802|Active Comparator|OC-01 (varenicline) nasal spray, 1.2 mg/mL|OC-01 (varenicline) nasal spray, 1.2 mg/mL, one time dosing
89440925|NCT03688802|Placebo Comparator|Placebo (vehicle control) nasal spray|Placebo (vehicle control) nasal spray, one time dosing
89440926|NCT02159157|No Intervention|Arm A|"Physical Therapy consult for post op care and general physical activity recommendation 1-4 weeks prior to starting chemotherapy.~Phone calls designed to support the patient to maintain current activity level."
89440927|NCT02159157|Placebo Comparator|Arm B|"Physical Therapy consult for post-op care 1-4 weeks prior to starting chemotherapy.~Exercise prescription aimed at increasing physical activity by a minimum of 10 MET hours/week.~Motivational phone calls aimed at encouraging the patient to adhere to their exercise prescription."
89440928|NCT03511482|Experimental|MyAsthma Application and Lloyds Pharmacy Online Doctor|Web based applications to support people with Asthma management
89440929|NCT03511482|Experimental|MyAsthma Application and Usual care|Web based application to support people with Asthma Management
89440930|NCT03511482|No Intervention|Usual care only (control)|Usual care of asthma management
89440931|NCT02160249|Experimental|Community-based rehabilitation and facility based care|"Community-based rehabilitation is delivered to participants and their caregivers at their home by a specialist CBR worker. It comprises psychoeducation, adherence support, rehabilitation (including self-care and social skills), family support groups and accessing existing community organisations. It also involves community awareness raising and education and mobilisation of community leaders.~Facility based care (usual care) consists of anti-psychotic medication prescribed by a nurse or clinical officer in a health centre and basic psycho-education."
89440932|NCT02160249|Active Comparator|Facility-based care|Facility based care (usual care) consists of anti-psychotic medication prescribed by a nurse or clinical officer in a health centre and basic psycho-education.
89440933|NCT03518970|Experimental|Nursing intervention|The experimental group will receive the Nursing intervention to reduce uncertainty in illness and increase quality of life in family caregivers of patients with cancer in palliative care
89440934|NCT03518970|No Intervention|Conventional care|The control group will receive the nursing care conventionally given in the health care institution
89440935|NCT02154711||Mitochondrial Disease|Individuals with genetic diagnoses (nuclear or mitochondrial) of mitochondrial disease
89440936|NCT02154711||Unaffected|Healthy individuals, without mitochondrial disease
89440937|NCT03511404|Experimental|Chronical LBP|Patients with chronic low back pain to be measured with Numeric Pain Rating Scale (NPRS).
89440938|NCT02159235||AIHD-patients (ICD-10 I21)|Patients suffering from acute ischemic heart disease according to ICD-10 I21
89440939|NCT02159235||CIHD-patients (ICD-10 I25)|patients suffering from chronic ischemic heart disease according to ICD-10 I25
89440940|NCT03656744|Experimental|500mg HTD1801, bid|
89440941|NCT03656744|Experimental|1000mg HTD1801, bid|
89440942|NCT03656744|Placebo Comparator|placebo, bid|
89440943|NCT02297880|Experimental|Beverage containing low calorie sweeteners|Beverage containing low calorie sweeteners (flavour)
89440944|NCT02297880|Active Comparator|Still water|Still water (no flavour)
89199566|NCT05148962|Experimental|Cohort 4: 2 Doses 10 mcg GRT-R910 after mRNA Vaccine Standard of Care|Healthy adults ≥60 years of age receive 2 doses of 10 mcg GRT-R910 homologous prime-boost
89440945|NCT02298036|Experimental|Remote Therapy Offered|Participants randomised to this arm receive 6-10 sessions of remote CBT
89440946|NCT02298036|No Intervention|Treatment as Usual|Participants do not receive remote therapy and remain in usual care
89440947|NCT02293356|Experimental|Nimotuzumab Injection|200mg,Once a week，Intravenous infusion over 60 minutes
89440948|NCT03518892||Spinal Cord Injury Group|Body Composition, Resting Metabolic Rate, and dietary assessment
89440949|NCT03518892||Healthy Controls|Body Composition, Resting Metabolic Rate, and dietary assessment
89440950|NCT03515148|Experimental|Cryotherapy and eccentric exercise|12 weeks, 5 days/week, once a day, 2 exercise, 3 sets/execise, 15 repetition/set of eccentric exercise of foot plantar flexors First exercise with knee in extension, second exercise with knee in flexion. Previously subjects should cold their leg in ice water during sexteen minutes at a temperature of 8ºC (+/-2ºC)
89440951|NCT03515148|Experimental|Vibration and eccentric exercise|12 weeks, 5 days/week, once a day, 2 exercise, 3 sets/execise, 15 repetition/set of eccentric exercise of foot plantar flexors First exercise with knee in extension, second exercise with knee in flexion.During the exercise subjects will be subjected to vibration. Vibrations parameters: Frequency: 35Hz, Amplitude: 4 milimeters, Force: 3,9G
89440952|NCT03371576||2 different torical intraocular lenses|
89537052|NCT03302039|Active Comparator|Fixed infusion|Spinal anesthesia will be performed using intrathecal bupivacaine. Then, fixed infusion phenylephrine will be administered at a dose of (0.75 mcg/Kg/min). the infusion will stop if reactive hypertension occurred.
89199567|NCT05148962|Experimental|Cohort 6: 2 Doses 10 mcg GRT-R910 after mRNA Vaccine Standard of Care|Healthy adults ≥18 to ≤59 years of age receive 2 doses of 10 mcg GRT-R910 homologous prime-boost
89440953|NCT03511170|Experimental|alternative regiment|The first stage:XELOX chemotherapy and XELIRI chemotherapy (alternation of every two cycles) until one of the schemes appears imaging progress or intolerance.And then enter the second stage. The second stage: continue to apply another plan until there is progress or intolerance.
89440954|NCT03511170|Placebo Comparator|classical regiment|Use the XELOX chemotherapy until appears imaging progress or intolerance.And then change to the XELIRI chemotherapy until there is progress or intolerance.
89440955|NCT03518814||Multimetastatic melanoma in remission|Questionnaires
89440956|NCT02301312|Experimental|POSS-PCU graft|POSS-PCU vascular graft will be used to create vascular access for dialysis.
89440957|NCT03376178|Experimental|six-hole group|lidocaine and ropivacaine injection through catheters
89440958|NCT03376178|Active Comparator|end-hole group|lidocaine and ropivacaine injection through catheters
89440959|NCT02293434||All Children (1 month to 18 years)|All children (1 month to 18 years) admitted to all PICUs in France during three one-week periods (February, June, October) in the course of a year
89440960|NCT02298114|Experimental|neuromuscular electrical stimulation|Neuromuscular electrical stimulation will be applied Functional Electrical Stimulation (FES) machine. The electrodes will be placed over the motor points of the following muscles: pectoral muscles (fibres of the pectoralis major muscle) and rectus abdominis muscles (bilaterally) The first training session will have a duration of 30 minutes , which will then be extended by 1 minute for every 2 days of administration. The intensity will be increased until muscle contraction is visible or palpable or, intensity will be adjusted according to tolerance associated conventional physiotherapy. Neuromuscular electrical stimulation will be applied held until extubation end conventional respiratory and motor physiotherapy until discharge from the ICU.
89440961|NCT02298114|Sham Comparator|Conventional physiotherapy|Conventional physiotherapy will be administered by professionals from the physiotherapy department twice a day, for 30 minutes. The protocol will include upper and lower extremity functional diagonals from the proprioceptive neuromuscular facilitation method (two series of 10 repetitions for each bilateral diagonal), manual bronchial hygiene exercises, such as thoracic vibrocompression, manoeuvres with a manual resuscitator (bag squeezing) and aspiration of secretions where necessary. Associated will receive placebo electrical stimulation, in this case the procedure is the same, but intensity is set to a sensory level, not high enough to provoke either visible or palpable muscle contractions.
89440962|NCT03514836|Experimental|DCVac and ONCOS-102|ONCOS-102 is given intra-tumor up to 4 times, cyclophosphamide is given prior to the first dose of ONCOS-102 and at the fifth week of treatment DCVac is given sc every 21-28 days for up to 10 doses
89440963|NCT03511014|Experimental|microcurrent|
88925047|NCT04186793|Experimental|Diet Provision Group|"Participants in this study arm will be provided with a diet low in free sugars. This intervention replaces the habitual diet with a low free sugars diet (goal of <3% of total calories)."
88925048|NCT04182841|Other|RheOx Treatment|RheOx is a CE-marked device-based, energy delivery system that delivers energy to ablate soft tissue such as the airway epithelium and sub-mucosal tissue layers. The energy is delivered via a proprietary catheter through the bronchoscope.
88925049|NCT04181619|Experimental|Coffeeberry beverage|300 mg Coffeeberry extract in 300 ml beverage
88925050|NCT04181619|Placebo Comparator|Color and flavor matched beverage|0 mg Coffeeberry extract in 300 ml flavor and color-matched beverage
88925051|NCT04179565|Active Comparator|Immediate intervention|The immediate education (IE) group will receive the intervention, Healthy Children, Healthy Families: Parents Making a Difference! in period 1. In period 2, IE will receive no education and will be followed longitudinally for periods 2 and 3.
88925052|NCT04179565|Active Comparator|Delayed intervention|The delayed education (DE) group will serve as controls in period 1, receiving no intervention. In period 2, the treatments will cross over, so DE will receive the Healthy Children, Healthy Families: Parents Making a Difference! intervention.
88925053|NCT04178772|Experimental|JJVC Marketed Contact Lens|Eligible subjects that have no experience with soft multifocal lenses for more than 2 years will be assigned to a single study lens type worn in both eyes daily for at least 6 hours per day, everyday for approximately 12 weeks.
88925054|NCT04226976|Experimental|Otoband efficacy on AUV|Participants will wear the Otoband during the single site visit against the skin, on the flat part of the right mastoid bone, about an inch behind the pinna and level with the ear canal. Half the participants will be given the Otoband at power level 96db and half will be given the Otoband at power level 98db (all bone conduction levels re:1dyne). This will be randomized and neither the participant nor the investigator will know what power level the Otoband is set at. The participants will be fitted with the Otoband and will undergo the vestibular battery test. The investigator will record the outcome measurements.
88925055|NCT04226976|Placebo Comparator|Placebo device efficacy on AUV|Participants will wear the placebo device during the single site visit against the skin, on the flat part of the right mastoid bone, about an inch behind the pinna and level with the ear canal. The placebo device will be set at a power level of 90db (bone conduction level re:1dyne). Neither the participant nor the investigator will know that this device is the placebo device. The participants will be fitted with the placebo device and will undergo the vestibular battery test. The investigator will record the outcome measurements.
88925056|NCT04178187|Active Comparator|Lactolevure|Patients will receive quadruple eradication therapy for Helicobacter Pylori infection with Amoxicillin, Clarithromycin, Metronidazole, Omeprazole and Probiotics
88925057|NCT04178187|Placebo Comparator|Placebo|Patients will receive quadruple eradication therapy for Helicobacter Pylori infection with Amoxicillin, Clarithromycin, Metronidazole, Omeprazole and Placebo
88925058|NCT04169490|Experimental|FS2 Emulsion Moisturizer|The FS2 Emulsion Moisturizer Arm is comprised of three (3) topical treatments including: Placebo Cream Base Emulsion Moisturizer, FS2 Emulsion Moisturizer and Active Comparator Onion Skin Extract Gel (Mederma). The topical treatments are applied b.d. for 120 days.
88925059|NCT04169490|Experimental|Active Comparator + FS2 Emulsion Moisturizer|The Active Comparator + FS2 Emulsion Moisturizer Arm is comprised of two (2) topical treatments including: Active Comparator Silicone Gel (Kelo-Cote), and Active Comparator Silicone Gel (Kelo-Cote) + FS2 Emulsion Moisturizer. The topical treatments are applied b.d. for 120 days.
89440964|NCT03511014|Sham Comparator|control|
88925060|NCT04169451|Experimental|letrozole group|Women will be given IUI treatment with ovarian stimulation with letrozole 5mg/day starting from day 3 of menstrual cycle for 5 days.
88925061|NCT04169451|No Intervention|natural cycle group|Women will be given IUI treatment without ovarian stimulation.
88925062|NCT04169438|Placebo Comparator|Vehicle Cream Base Emulsion Moisturizer + Petrolatum|Vehicle Cream Base Emulsion Moisturizer + Petrolatum
88925063|NCT04169438|Experimental|FS2 Emulsion Moisturizer + Petrolatum|FS2 Emulsion Moisturizer + Petrolatum
89012690|NCT01686217|Active Comparator|Dose Group 3 Treatment H|Medium per tablet dose of ASP015K IR tablets under fasted conditions for comparison to highest dose ER under fasted conditions
89012691|NCT01686217|Experimental|Dose Group 3 Treatment I|Highest dose of ASP015K ER tablets under fed conditions
89012692|NCT04719572|Other|Basic treatment group|elemental calcium 600mg/ day + vitamin D 1000IU/day
89440965|NCT03376100|Active Comparator|Control Group|Patients with distal forearm fractures randomized to Hematoma Block.
89440966|NCT03376100|Active Comparator|Intervention Group|Patients with distal forearm fractures randomized to Ultrasound guided nerve block
89440967|NCT03371342|Experimental|MEDITOXIN|
89440968|NCT03371342|Active Comparator|BOTOX|
89440969|NCT02302326|Experimental|Metformin|PCOS women began treatment with ER 500 mg metformin per day, and the dose was increased to 1000 mg after 2 weeks, and to 1700 mg/d after a further 2 weeks, and was maintained at this dose for a total of 12 weeks.
89440970|NCT02302326|Experimental|Myo-inositol + folic acid|PCOS women received a dietary supplement (Ovusitol® : 4 g myo-inositol plus 400 micrograms of folic acid) for 12 weeks
89440971|NCT02302326|No Intervention|Healthy women|Healthy untreated women adjusted for age and body mass index
89440972|NCT03371264||Cohort R1 and Cohort T1|Cohort R1 (patients on the waiting list between 2009 and 2013) and Cohort T1 (transplanted patients between 2009 and 2013)
89440973|NCT03371264||Cohort R2 and Cohort T2|Cohort R2 (patients on the waiting list in 2014) and Cohort T2 (transplanted patients in 2014)
89440974|NCT03367130|Experimental|Intervention|HIV-positive individuals will receive the standard HIV care following the national ART guidelines. In addition, the intervention group will receive mobile phone calls. A mobile phone reminder will be made two days prior to their scheduled appointment for pills pick up. Trained research assistants will remind them of their scheduled clinic appointment of pills pick up. If the first call is missed, the second call will be made within the same day, if the second call is also missed, the final call will be made next day. The intervention will be delivered over the period of six months. Outcome assessors will not be involved in the phone calls.
89440975|NCT03367130|Placebo Comparator|Control|Control group will also receive the standard HIV care following the national ART guidelines and phone calls educating them on healthy living. Phone calls will be made once a month.
89502068|NCT05490524|No Intervention|Control group|"The Control group will receive standard health care with no technical support, where the intervention groups will receive platform and device services provided to each user. In that respect, Intervention Group 1 will receive no real-time feedback, where Intervention Group 2 will unhand with real data and notifications.~A control group is defined as a group of clinical trial participants who will not be provided any digital devices as part of the trial and will receive care as usual by PASYKAF and AMEN."
88925064|NCT04161040|Experimental|Relapse (experimental) Group|Opportunities for sedentary leisure and physical activities will be continuously available throughout all phases. Each phase will last 20 minutes. The first phase will mimic pre-intervention conditions; there will be a variety of activities available. No incentives for engaging in physical activity will be provided, although such activities will be available. For the Relapse (experimental) Group, the second phase will mimic an incentive-based intervention in which participants can earn monetary incentives for engaging in physical activity. Then, during the third phase, the incentives will be discontinued.
88925065|NCT04161040|Experimental|Fatigue Control Group|Opportunities for sedentary leisure and physical activities will be continuously available throughout all phases. Each phase will last 20 minutes. The first phase will mimic pre-intervention conditions; there will be a variety of activities available. No incentives for engaging in physical activity will be provided, although such activities will be available. The second phase will mimic an incentive-based intervention in which participants can earn monetary incentives for engaging in physical activity. Participants in this arm will continue to earn incentives during Phase 3 to control reductions in physical activity due to fatigue.
88925066|NCT04161040|No Intervention|No-Incentive Control Group|Opportunities for sedentary leisure and physical activities will be continuously available throughout all phases. Each phase will last 20 minutes. Participants in this arm will not earn incentives during any of the three phases to control for the possibility that participants will engage in some physical activity in the absence of incentives.
88925067|NCT04159818|Experimental|Control group|no induction treatment, nivolumab 240 mg flat-dose, every 2 weeks
88925068|NCT04159818|Experimental|Cisplatin induction|Cisplatin 40mg/m2, weekly for two weeks, after 2 weeks followed by nivolumab 240 mg flat-dose, every 2 weeks
88925069|NCT04159818|Experimental|Low dose doxorubicin induction|Low dose doxorubicin 15mg flat dose, weekly for 8 weeks, after 2 weeks followed by nivolumab 240 mg flat-dose, every 2 weeks
88925070|NCT04157881|Other|APO-Dabigatran|Single dose 150mg APO-Dabigatran given with 24 hours of Pharmacokinetic (PK) testing post dose
88925071|NCT04157881|Other|APO-Dabigatran and Rabeprazole|4-7 doses of rabeprazole followed by single dose 150mg APO-Dabigatran given with 24 hours of Pharmacokinetic (PK) testing post dose
88925072|NCT04148651|Experimental|CO2RE® Treatment|All eligible subjects will undergo up to 5 treatments at 4±1-week intervals to the vulva with a fractional CO2 laser.
88925073|NCT04142736|Experimental|Prone position|Patients with acute hypoxemic respiratory failure from any cause
88925074|NCT04142736|No Intervention|Supine position|Patients with acute hypoxemic respiratory failure from any cause
88925075|NCT04136990|Active Comparator|Isolated ACL reconstruction|Isolated ACL reconstruction only.
88925076|NCT04136990|Experimental|ACL + LEAT|ACL reconstruction combined with Lateral Extra-Articular Tenodesis (LEAT).
88925077|NCT04136262|Experimental|Tripterygium wilfordii Hook F (TwHF) plus methotrexate (MTX)|Oral Tripterygium wilfordii Hook F 20mg thrice daily for 24 weeks. Oral methotrexate 10 mg per week for 24 weeks.
88925078|NCT04136262|Placebo Comparator|TwHF (dummy) plus MTX|Oral dummy Tripterygium wilfordii Hook F 20mg thrice daily for 24 weeks. Oral methotrexate 10 mg per week for 24 weeks.
89440976|NCT02293590|Experimental|intensive, adapted treatment strategy|"Experimental: intensive, adapted treatment strategy Certolizumab pegol (CZP, Cimzia (R)): 200mg every 2 weeks after loading d 400mg at Weeks 0, 2 and 4~DMARD:~Patients without sufficient treatment response will be taken to the next step according to the therapeutic algorithm or next drug, for example: 15=>25mg Metoject (R)/week => Leflunomide Gebro (R)20mg/d => Salazopyrine EN(R) 2000mg/d~Glucocorticoids:~At Week, 0 patients will be initiated on Spiricort (R) 20mg/d and tapered every 5 days~Joint injections:~Starting at Week 0 up to 5 joint injections may be conducted into synovitic joints at every visit of the study.~The maximum cumulative Lederlon (R) dose is 100mg/visit. Joints are to be infiltrated with the following doses of triamcinolone and lidocaine"
89440977|NCT02293590|Active Comparator|fixed-dosed program|"Intervention:~Certolizumab pegol (Cimzia (R), CZP) CZP of 400mg at Weeks 0, 2 and 4, followed by 200mg injections from Week 6, every 2 weeks until Week 24.~DMARD:~Patients are to continue to receive their stable weekly dose of DMARD as noted at study entry for the duration of the study (24 weeks)~Glucocorticoids:~Prednisolone (Spiricort (R)) daily dose of ≤ 10 mg~Joint injections:~None"
89440978|NCT02302404|Experimental|Cohort 1: GSK2982772 Single Ascending Dose (Part A) (0.1-10mg)|Eight subjects will be randomized equally (1:1:1:1) to one of the 4 placebo-controlled dose sequences with 2 subjects in each sequence and each subject having four dose periods (3 active dose of GSK2982772 + 1 placebo dose). The subjects will fast overnight from Day -1 to Day 1 of the treatment period. Two of the 8 subjects will be randomized to the dosing on Day 1 as sentinel dosing. Assuming adequate safety in the judgment of the Principal Investigator (e.g., vital signs, ECGs, and adverse events) through approximately 24 hours; the remaining 6 subjects may be randomized to dosing on the following day. Subjects will receive single planned doses of GSK2982772 as 0.1, 0.5, 2.5, and 10mg. A sequential design will be used including approximately weekly dose escalations while allowing for a sufficient washout period. The proposed doses may be adjusted based on emerging safety and PK
89502069|NCT05490524|Experimental|Intervention group 1 (limited technology)|Intervention Group 1 - platform/devices (no real feedback provided (limited technology group) A limited technology group is defined as a group of clinical trial participants who receive the digital devices but not the automated interventions through the devices (prompts, messages).
88925079|NCT04133922|Active Comparator|GLP-1|GLP-1 infusion 1.2 pmol/kg/min for 150 min
88925080|NCT04133922|Active Comparator|GLP-1 + Insulin clamp|GLP-1 infusion 1.2 pmol/kg/min for 150 min and insulin 1 mU/kg/min + Dextrose 20% at variable rate to maintain euglycemia for 120 min
88925081|NCT04133922|Active Comparator|Saline + Insulin clamp|Saline infusion at 30 ml/hr for 150 min and insulin 1 mU/kg/min + Dextrose 20% at variable rate to maintain euglycemia for 120 min.
88925082|NCT04118049|Experimental|Vaginal Probiotic Arm|"BiopHreshTM vaginal probiotic supplement (Good Clean Love, Inc. Eugene, OR) is offered over the counter. It contains a total of 5 billion lactobacilli: L. crispatus, L. gasseri, L. jensenii, and L. rhamnosus.~RestoreTM gel: moisturizing personal lubricant.~We will recommend to participants to use the probiotic supplement and vaginal lubricant as a vaginal suppository three times weekly at night for 3 months."
88925083|NCT04118049|Other|Standard Care Arm|Women will perform standard care which includes follow up at 3 months for pessary removal/care.
88925084|NCT04117516|Active Comparator|Open surgery|30 patients will be operated with an open carpal tunnel release.
88925085|NCT04117516|Experimental|Percutaneous surgery|30 patients will be operated with a percutaneous carpal tunnel release.
88925086|NCT04115761|Other|Investigational Group|ADCV01 is autologous dendritic cells (DCs) stimulated by the patients' own tumor antigens. The total 10 doses (1 mL/dose; 2±0.5 × 10^7 cell/dose) of ADCV01 will be administered to patients assigned to the investigational group. The ADCV01 will be administered to the bilateral subaxillary subcutaneous regional lymph nodes (half of volume about 0.5 mL of ADCV01) once weekly for the first 4 doses, and the following 2 treatments will be administered bi-weekly. The last 4 treatments will be administered every 4 weeks.
88925087|NCT04115761|Other|Control Group|the conventional treatment (RT and chemotherapy) will be given after tumor resection, followed by subsequent evaluations by an approximately 8-week interval.
88925088|NCT04104828||Grass/tree AIT with Allergovit|Collection of blood and data from patients that receive allergen-immunotherapy (AIT) with Allergovit, an aluminium-containing AIT preparations.
89199568|NCT05140941|Experimental|Sofosbuvir/Velpatasvir|Sofosbuvir/Velpatasvir 400 MG-100 MG Oral Tablet, one tablet taken once daily for 84 days
88925089|NCT04104828||Grass/tree AIT with Polvac|Collection of blood and data from Patients that receive AIT with Polvac, an MCT-containing AIT preparation.
88925090|NCT04104828||Grass/tree AIT with Pollinex Quattro|Collection of blood and data from patients that receive AIT with Pollinex Quattro, an MCT-MPLA containing AIT preparation.
88925091|NCT04098198||Participants with an Inborn Error of Metabolism|Participants diagnosed with an Inborn Error of Metabolism aged between 2 months to 50 years
88925092|NCT04085042|No Intervention|Usual Care|Usual care during peripheral venous catheterization. Nurses will continue with the normal routine practice, by preparing all needed material individually.
88925093|NCT04085042|Experimental|PIVC pack|Nurses will use a sterile pack that includes all needed devices for peripheral intravenous catheterization according to the latest evidence (eg, cannula, swabs, disposable tourniquet, antiseptic).
89501630|NCT02155517|Experimental|Propofol Infusion|"Propofol will be administered using a commercially available target-controlled infusion with an incorporated pharmacokinetic model developed by Schnider and Cortinez (arcomed ag, Medical System, Switzerland )..~The study will make in two stages:~STAGE I: All volunteers will receive propofol infusion with the first model randomly chosen (Schnider or Cortinez) using TCI device, and the initial effect-site target concentration of propofol will be 3 ug/ml for 20 minutes.~STAGE II: 72 hours after stage I . All volunteers will receive propofol infusion with the first model randomly chosen (Schnider or Cortinez) using TCI devices, and the initial effect-site target concentration of propofol will be 3 ug/ml for 20 minutes."
89501631|NCT02229643||Traumatic brain injury|Patients delivered within 4 h whose highest abbreviated injury score (AIS) was 3 or less (other than head injury) were considered to be isolated traumatic brain injury cases and were included in this study.
89501632|NCT03115125|Other|Adult patients with severe sepsis|
88925094|NCT04082676|Experimental|Height and weight based group|"Patients in Height and weight based group will receive intrathecal hyperbaric bupivacaine based on patients height and weight according to Harten chart with 10 μg of fentanyl (0.1 ml)"
88925095|NCT04082676|Active Comparator|Height based group|"Patients in Height based group will receive intrathecal hyperbaric bupivacaine based on patients height i.e. (0.06mg/cm) with 10 μg of fentanyl (0.1 ml)"
88925096|NCT04073667|Experimental|Early Rehabilitation Group|The first six weeks (1st-6th) will be followed as an exercise group and the second six weeks (7th-12th) will be followed as a control group without any intervention.
88925097|NCT04073667|Experimental|Late Rehabilitation Group|The first six weeks (1st-6th) will be followed as a control group without any intervention and the second six weeks (7th-12th) will be followed by exercise.
88925098|NCT04070131|No Intervention|Control Group|Regular follow ups.
89501633|NCT02155595||500 with BP treatment|patients will undergo lab tests, X-ray, bone scan or MRI, as needed (90 of these individuals can opt for iliac crest bone biopsy)
88925099|NCT04070131|Experimental|Intervention Group|One weekly session (1 hour) of Horse-Assisted Rehabilitation, 24 weeks.
88925100|NCT04053569|Experimental|Diet with table grape|Table grape (5g/Kg) administered for four weeks with dietary recommendations. A strict restriction of fruits and the limitation of other foods containing polyphenols will be necessary.
88925101|NCT04053569|No Intervention|Specific dietary advice|Dietary recommendations (such as limitation of alcohol, caffeine), and low consumption of fruits.
88925102|NCT04048642|Experimental|DASH diet; plant-based diet; DASH diet|Food is provided: 7 days of an ad libitum DASH diet, followed immediately by 7 days of an ad libitum whole food, plant based diet, followed immediately by 7 days of an ad libitum DASH diet again.
89440979|NCT02302404|Experimental|Cohort 2: GSK2982772 Single Ascending Dose (Part A) (40-240mg)|Eight subjects will be randomized equally to one of the 4 placebo-controlled dose sequences with 2 subjects in each sequence and each subject having 4 dose periods (3 active dose of GSK2982772 +1 placebo dose). The subjects will fast overnight from Day -1 to Day 1 of the treatment period. Two of the 8 subjects will be randomized to the dosing on Day 1 as sentinel dosing. Assuming adequate safety in the judgment of the Principal Investigator (e.g., vital signs, ECGs, and adverse events) through 24 hours; the remaining 6 subjects may be randomized to dosing on the following day. Subjects will receive single planned doses of GSK2982772 as 40, 100, 180, and 240 mg. A sequential design with weekly dose escalations and sufficient washout period will be used. The proposed doses may be adjusted based on emerging safety and PK. After the completion of the fasted treatment periods, subjects will receive a high fat meal within 30 minutes of dosing with GSK2982772 during a final treatment period.
89440980|NCT02302404|Experimental|Cohort 3: GSK2982772 Repeat Dose (Part B)|Twelve subjects will be randomized to repeat doses of GSK2982772 or placebo in a 3:1 ratio. The subjects will fast overnight from Day -1 to Day 1 and overnight from Day 13 to Day 14. The selection of appropriate daily doses will be performed upon consideration of available safety and tolerability and PK data from Part A. Once-daily dosing is planned, but twice-daily dosing may be considered based upon the exposure observed in the Part A data
89440981|NCT02302404|Experimental|Cohort 4: GSK2982772 Repeat Dose (Part B)|Twelve subjects will be randomized to repeat doses of GSK2982772 or placebo in a 3:1 ratio. The subjects will fast overnight from Day -1 to Day 1 and overnight from Day 13 to Day 14. The selection of appropriate daily doses will be performed upon consideration of available safety and tolerability and PK data from Part A and/or any preceding repeat dose cohorts in Part B. Once-daily dosing is planned, but twice-daily dosing may be considered based upon the exposure observed in Part A or any preceding repeat dose cohorts in Part B
89440982|NCT02302404|Experimental|Cohort 5: GSK2982772 Repeat Dose (Part B)|Twelve subjects will be randomized to repeat doses of GSK2982772 or placebo in a 3:1 ratio. The subjects will fast overnight from Day -1 to Day 1 and overnight from Day 13 to Day 14. The selection of appropriate daily doses will be performed upon consideration of available safety and tolerability and PK data from Part A and/or any preceding repeat dose cohorts in Part B. Once-daily dosing is planned, but twice-daily dosing may be considered based upon the exposure observed in the Part A or any preceding repeat dose cohorts in Part B.
89440983|NCT02302404|Experimental|Cohort 6: GSK2982772 Single Ascending Dose (Part A)|This additional cohort in Part A of the study will only be conducted to allow for evaluation of additional dose levels or repeated evaluation of a dose level already studied. Doses will be selected based on the safety, tolerability, and PK data from Part A and/or previous Part B cohorts. Eight subjects will be randomized equally (1:1:1:1) to one of the 4 placebo-controlled dose sequences with 2 subjects in each sequence and each subject having four dose periods (3 active dose of GSK2982772 + 1 placebo dose). The selection of appropriate daily doses will be performed upon consideration of available safety and tolerability and PK data from Part A and/or any preceding repeat dose cohorts in Part B.
89440984|NCT02302404|Experimental|Cohort 7: GSK2982772 Repeat Dose (Part B)|This additional cohort in Part B of the study will only be conducted to allow for evaluation of additional dose levels or repeated evaluation of a dose level already studied Doses will be selected based on the safety, tolerability, and PK data from Part A and/or previous Part B cohorts. Twelve subjects will be randomized to repeat doses of GSK2982772 or placebo in a 3:1 ratio. The selection of appropriate daily doses will be performed upon consideration of available safety and tolerability and PK data from Part A and/or any preceding repeat dose cohorts in Part B.
89440985|NCT03124082|Active Comparator|opioid|remifentanil 0,15-0,25 mcg/kg/h
89440986|NCT03124082|Experimental|opioid free|ketamine bolus 0,5 mg/kg + infusion 0,25 mg/kg/h lidocaine bolus 1 mg/kg + infusion 1 mg/kg/h clonidine 4 mcg/kg
89440987|NCT02301702|Experimental|Tdap Vaccine|Combination Tetnus Toxoid, Reduced Diptheria Toxoid and Acellular Pertusis (Tdap)
89440988|NCT02301702|Active Comparator|Td Vaccine|Tetanus toxoid and reduced diphtheria toxoid vaccine (Td)
89440989|NCT03552224|Experimental|Subjects with no hearing loss|Subjects referred for cerebellopontine angle surgery with no hearing loss with recording of auditory nerve activity by contact electrode
89440990|NCT03552224|Experimental|Subjects with hearing loss|Subjects referred for cerebellopontine angle surgery with hearing loss with recording of auditory nerve activity by contact electrode
89440991|NCT03518502|Active Comparator|Sorafenib monotherapy arm|The sorafenib monotherapy group receives sorafenib immediately after randomization.
89440992|NCT03518502|Experimental|TACE-sorafenib sequential therapy arm|TACE(transarterial chemoembolization )-sorafenib group receives 2~4 times of TACE before starting sorafenib.
89440993|NCT02301780|Placebo Comparator|Control Group|Placebo
88925103|NCT04036994|Active Comparator|Experimental: Treatment group|
89440994|NCT02301780|Active Comparator|Intervention Group|Aspirin
89440995|NCT03124004||Direct Oral Anticoagulants|assuming Pradaxa or Eliquis or Apixaban or Xarelto; undergoing periodontal debridement
88925104|NCT04036994|No Intervention|Control group (no intervention)|
88925105|NCT04032782|Experimental|HM15136|
88925106|NCT04032782|Placebo Comparator|Placebo of HM15136|
89440996|NCT03124004||oral anticoagulant therapy|assuming Coumadin or Sintrom; undergoing periodontal debridement
89440997|NCT02302482|Experimental|Functional autonomy level collection|Collection of the Functional autonomy level every 6 - 12 months by phone
89199569|NCT05130840|Experimental|Stage IV HER2+ breast cancer|Once enrolled on study, patients will undergo screening MRI Brain (unless already done as standard of care within 2 months on enrollment to evaluate for CNS disease) as well as lumbar puncture to evaluate for CNS disease. Once on study, patients will undergo LP and MRI Brain at 2 timepoints 6 months apart (+/- 8 weeks). LP will be performed to analyze cerebrospinal fluid for: cytology, circulating tumor cells and cell-free DNA. 6-month intervals for investigations have been based on feedback from patient advocates as well as clinical determination.
89199570|NCT05130840|Experimental|Stage II-III HER2+ breast cancer|Once enrolled on study, patients will undergo screening MRI Brain (unless already done as standard of care within 2 months on enrollment to evaluate for CNS disease) as well as lumbar puncture to evaluate for CNS disease. Once on study, patients will undergo LP and MRI Brain at 2 timepoints 6 months apart (+/- 8 weeks). LP will be performed to analyze cerebrospinal fluid for: cytology, circulating tumor cells and cell-free DNA. 6-month intervals for investigations have been based on feedback from patient advocates as well as clinical determination.
89440998|NCT03124238|Experimental|Massage|Massage therapy of the lumbar muscles in a prone position during 30 minutes
89440999|NCT03124238|No Intervention|Control|Rest during 5 minutes in a prone position
89441000|NCT02302560||Patients with elective hip surgery|Patients with elective hip surgery (implementation or replacement of hip joint endoprotheses).
89441001|NCT04527068|Experimental|Bevacizumab +Tripleitriumab|Participants receive bevacizumab 7.5mg/kg and tripleitriumab 240mg in day 1 intravenously every 3week until disease progression or unacceptable toxicity
89441002|NCT02302638|Active Comparator|Sage 1-step|"Embryo culture in different single-step media:~Half of each patient's oocytes will be randomly allocated to be cultured in Sage 1-step medium for up to six days following oocyte retrieval."
89441003|NCT02302638|Active Comparator|CSCM|"Embryo culture in different single-step media:~Half of each patient's oocytes will be randomly allocated to be cultured in CSC medium for up to six days following oocyte retrieval."
89441004|NCT04526756|Experimental|Intervention group|patients in this group will receive mechanical thrombectomy and standardized drug treatment of acute ischemic stroke
89441005|NCT04526756|No Intervention|control group|patients in this group will receive standardized drug treatment of acute ischemic stroke
89441006|NCT02739360|Experimental|Idelalisib|Participants will receive idelalisib until unacceptable toxicity, disease progression, study discontinuation, or death occurs.
89441007|NCT03510936|No Intervention|blue light phototherapy|the patients in this arm will not receive probiotics.
89441008|NCT03510936|Experimental|probiotics concurrent with phototherapy|the patients in this arm will receive probiotics blend of Bifidobacterium longum, Lactobacillus acidophilus, Enterococcus faecalis for 2 weeks
88925107|NCT04030520|Experimental|intervention|participants will receive a behavioral intervention including counseling and offer of HIV oral fluid self test and PrEP
88925108|NCT04030520|Active Comparator|comparison|participants will be not be offered HIV oral fluid self test but receive counseling, condoms and offered PrEP
88925109|NCT04012177|No Intervention|Control Arm|Arm-A: Standard antenatal care (ANC) counseling, service provision and nutrition counseling (World Health Organization (WHO) standard)
88925110|NCT04012177|Experimental|Nutrition only Arm|Arm-B:Balanced-energy protein (BEP), ready-to-use utrition supplement for at least 6 months + Standard ANC counseling, service provision and nutrition counseling (WHO standard)
88925111|NCT04012177|Experimental|Nutrition plus Azithromycin Arm|Arm-C:Balanced-energy protein (BEP), ready-to-use nutrition supplement for at least 6 months + 2000 mg of Azithromycin at week 20 and 28 of pregnancy + Standard ANC counseling, service provision and nutrition counseling (WHO standard).
89199571|NCT05119842|Experimental|Treatment|Treatment with the VOIS Implant
88925112|NCT04012177|Experimental|Nutrition plus Choline and Nicotinamide Arm|Arm-D: Balanced-energy protein (BEP), ready-to-use nutrition supplement for at least 6 months + Choline 450 and Nicotinamide 100 mg (1 each once daily orally starting from week 20 until birth outcome) + Standard ANC counseling, service provision and nutrition counseling (WHO standard).
88925113|NCT04011995|Experimental|Intermittent caloric restriction|
88925114|NCT04011995|Active Comparator|Low carbohydrate diet|
89199572|NCT05108441|Other|Echo|Ultrasound and magnetic resonance imaging measurements of quadriceps femoris
89441009|NCT03375944|No Intervention|control group|Cardiac supervision
89441010|NCT03375944|Other|study group|Cardiac supervision and rehabilitation
89441011|NCT03123770|Experimental|DC Follow T|Participants receive pegylated liposomal doxorubicin plus cyclophosphamide followed by docetaxel before surgery.
89441012|NCT03123770|Active Comparator|EC Follow T|Participants receive epirubicin plus cyclophosphamide followed by docetaxel before surgery.
89441013|NCT04464642|Experimental|group A|"group A is a control arm who will get conventional drug (methotrexate). 25 mg subcutaneous weekly . at 3 months if DAS-28 not fall by at least 1.2, drug is to be changed and regarded as therapy failure. if at least 1.2 improvement of DAS-28 occur,then therapy is continued for 6 monyhs"
89441014|NCT04464642|Experimental|group B|"group B will get tofacitinib 10 mg weekly. if DAS-28 not improved at least 1.2 at 3 months, it is regarded as therapy failure. if improved at least 1.2, then therapy continued for 6 months"
89441015|NCT02293668|Active Comparator|Combined 450|Recombinant FSH 225IU/day and human menopausal gonadotropin (hMG) 225IU/day will be initiated on the second or third day of spontaneous menstruation and continued until the day of ovulation triggering. Ovulation triggering will be performed with the administration of 10000IU of human chorionic gonadotropin (hCG) as soon as two-three follicles of 17 mm diameter will be observed by transvaginal ultrasound.
89199573|NCT05101902||Overall Study|Participants will undergo antibody and genetic screen, initial pre-screening, eligibility monitoring and eligibility confirmation for potential transition to the treatment trial center once a treatment assignment in the study CAH-301 becomes available. Participation in Study CAH-300 is permitted to continue until treatment assignment is available in the treatment trial or unless, during eligibility monitoring or eligibility
89441016|NCT02293668|Active Comparator|Combined 300|Recombinant FSH 150IU/day and human menopausal gonadotropin (hMG) 150IU/day will be initiated on the second or third day of spontaneous menstruation and continued until the day of ovulation triggering. Ovulation triggering will be performed with the administration of 10000IU of human chorionic gonadotropin (hCG) as soon as two-three follicles of 17 mm diameter will be observed by transvaginal ultrasound.
89441017|NCT02293668|Active Comparator|Letrozole and hMG|Letrozole (Femara; Novartis, East Hanover, NJ) at a dose of 5 mg/day and human menopausal gonadotropin (hMG) 150IU/day will be initiated on the second or third day of spontaneous menstruation and continued until the day of ovulation triggering. Ovulation triggering will be performed with the administration of 10000 IU of human chorionic gonadotropin (hCG) as soon as two-three follicles of 17 mm diameter will be observed by transvaginal ultrasound.
89441018|NCT04526678|Experimental|Iron supplements|The intervention group will ingest 27 mg iron supplement per day for three months while the control group will not ingest iron supplements.
89441019|NCT04526678|No Intervention|Control group|The control group will not ingest iron supplements.
89501634|NCT02155595||500 without BP treatment|patients will undergo lab tests, X-ray, bone scan or MRI, as needed
88925115|NCT04004910|Experimental|Immunopheresis® - Arm 1|All patients will receive up to 16 weeks of initial treatment as per study arm assignment, which will include up to 48 LW-02 column-based Immunopheresis® treatments over a 4-month period (up to 3 procedures per week) though treatment can be extended based on certain protocol-specfied conditions. Each patient assigned to the treatment with LW-02 column-based Immunopheresis® will require central vascular access for the procedure. This part is alrady completed.
88925116|NCT04004910|Experimental|Immunopheresis® combined with low dose chemotherapy - Arm 2|All patients will receive up to 16 weeks of treatment as per study arm assignment, which will include up to 48 LW-02 column-based Immunopheresis® treatments over a 4-month period (up to 3 procedures per week) though treatment can be extended based on certain protocol-specfied conditions. Each patient will require central vascular access for the procedure. Patients also will receive a low dose chemotherapy regimen administered iv or oraly. Patients treated with combination will be administered their chemotherapy following the first LW-02 column-based Immunopheresis® procedure of each week starting from week 2, assuming first week of study treatment serves as a run-in period confirming good tolerance of Immunopheresis® alone.
88925117|NCT04004910|Active Comparator|Chemotherapy - Arm 3|Patients who are assigned chemotherapy arm of the study will be treated with low dose chemotherapy alone. The chemotherapy will be administered intravenously or oraly depending on the regimen used.
88925118|NCT04000334|Experimental|Cerebral hypoperfusion (group A)|Cerebral hypoperfusion will be defined by an abnormal TCD at inclusion (t0) when two of the three measured values are abnormal using the following thresholds: Vm < 30 cm/s, Vd < 20 cm/s, PI > 1.4.
88925119|NCT04000334|Active Comparator|Normal cerebral perfusion (group B)|Normal cerebral perfusion will be defined by a normal TCD at inclusion (t0) when two of the three measured values are normal using the following thresholds: Vm > 30 cm/s, Vd > 20 cm/s, PI < 1.4.
88925120|NCT03993249|Other|Chemoradiotherapy|standard of care chemo-radiotherapy
89199574|NCT05094882||RUL|patients who recieved the resection of right upper lobe (RUL)
89199575|NCT05094882||RML|patients who recieved the resection of right middle lobe ()
89199576|NCT05094882||RLL|patients who recieved the resection of right lower lobe (RML)
89199577|NCT05094882||LUL|patients who recieved the resection of left upper lobe (LUL)
89199578|NCT05094882||LLL|patients who recieved the resection of left lower lobe (LLL)
88925121|NCT03993249|Experimental|Combination|standard of care chemo-radiotherapy + Nivolumab
89199579|NCT05072574|Experimental|Experimental: nutritional education program|Specific dietary treatment and follow-up using coaching techniques, supported by new technologies, and will attend a nutritional education program
89441020|NCT02302014|Experimental|Palliative Care Intervention|Baseline interview with trial cardiologist and trial nurse lasting for up to 1 hour Creation of a Future Care Plan (FCP) document following this baseline interview Sharing of FCP document with primary care and unscheduled care organisations 6 week interview with trial nurse lasting for up to 1 hour to review FCP 12 week interview with trial nurse lasting for up to 1 hour to review FCP Continuous access to trial nurse by mobile telephone 9am - 5pm Monday-Friday for 12 weeks Trial nurse will - ensure FCP is appropriately shared with primary and secondary care, patient is registered on primary care palliative care register and will liaise with specialist PC services and the general practitioner as needed.
89441021|NCT02302014|No Intervention|Usual Care|Usual Care
89441022|NCT03123692|Experimental|Treatment|14 days treatment with NBMI 300 mg/day
89441023|NCT03123692|Placebo Comparator|Placebo|14 days treatment with Placebo
89441024|NCT03367052|Experimental|Two level Prodisc-C vivo|Two level Prodisc-C vivo cervical artificial disc replacement.
89441025|NCT03367052|Active Comparator|Hybrid|This group of patients will be treated with hybrid construct, i.e., one level of Prodisc-C vivo and one level of anterior cervical discectomy fusion (ACDF).
88925122|NCT03991611|Experimental|IPREA3 program|Application of the IPREA 3 program (multicomponent intervention to reduce perceived discomforts in critically ill patients) for at least 5 months
88925123|NCT03991611|Other|Intermediate group|Application of the IPREA 3 program (multicomponent intervention to reduce perceived discomforts in critically ill patients) for less than 5 months
88925124|NCT03991611|Active Comparator|Standard care|Standard care
88925125|NCT03991611|Other|PTSD-REA_COVID cohort|ICU admission between March 1, 2020 and April 30, 2020.
88925126|NCT03990883|Other|Treatment of device 1 on left side|Treatment of nasolabial folds (NLF) with both Investigational Device and Comparator; Princess Filler Lidocaine is assigned to left NLF, Comparator is assigned to right NLF
88925127|NCT03990883|Other|Treatment of device 1 on right side|Treatment of nasolabial folds (NLF) with both Investigational Device and Comparator; Princess Filler Lidocaine is assigned to right NLF, Comparator is assigned to left NLF
88925128|NCT03984890|Experimental|Vitamin D Group|Vitamin D3 Supplementation plus traditional treatment of CGD and TB
88925129|NCT03984890|Other|Control Group|Traditional treatment of CGD and TB without Vitamin D Supplementation
89199580|NCT05072574|No Intervention|Control Group|Dietary and general lifestyle recommendations
89199581|NCT05070988||Rare diseases|Children and adult patients with rare diseases and followed at the Necker Enfant Malades Hospital, Paris
89199582|NCT05068440|Experimental|Zanubrutinib|administered orally
89441026|NCT03510858|Experimental|Intervention group|
89441027|NCT03510858|Other|Control group with crossover|Participants in the control group will receive the intervention after 12 months, cross-over design
89441028|NCT04465032|Active Comparator|Autologous gut microbiome transplantation|Three autologous (own) fecal transplantations (at baseline, 3 and 6 weeks)
89441029|NCT04465032|Experimental|Allogenic gut microbiome transplantation|Three allogenic (lean donor) fecal transplantations (at baseline, 3 and 6 weeks)
89441030|NCT03375632|Experimental|Uric acid-overproduction Type|
89441031|NCT03375632|Experimental|Uric acid-underexcretion Type|
89441032|NCT02302170|Experimental|H. pylori vaccine in children|H. pylori vaccine (15mg/dose) in children between 6-15 years of age
89441033|NCT02302170|Placebo Comparator|placebo in children|placebo (0mg/dose) in children between 6-15 years of age
89441034|NCT02302794|Active Comparator|open surgery|Conventional procedure
88925130|NCT03982459|Experimental|Decision support tool|Patients in this single-arm study all receive training in use of a decision support tool by a trained coordinator.
88925131|NCT03980834|Active Comparator|Professional Learning, Program Training and Coaching|
88925132|NCT03980834|Active Comparator|Program for Parents of Pre-K Students|
88925133|NCT03980834|Active Comparator|Program for Pre-K Students|
88925134|NCT03978780|Placebo Comparator|Control Group|Patients randomised to the Control group will then receive a sham subcutaneous injection of 0.5ml normal saline injected at the same site as the ESP block (see above) under ultrasound guidance to stimulate a real block procedure.
88925135|NCT03978780|Experimental|Erector spinae plane (ESP) block group|Local anaesthetic infiltration utilising 1% lidocaine will occur, and an 80mm 22G block needle will be inserted using an in-plane cranial to caudad approach, the needle will be advanced to target the interfascial plane deep to the erector spinae muscle at the T2 transverse process. Once the needle tip is in the correct position, 20 ml of the local anaesthetic (ropivacaine 0.5% with 1:400,000 epinephrine) will be administered slowly in 5 ml aliquots under frequent aspiration and correct spread in the interfascial plane will be observed.
88925136|NCT03978104|Experimental|Okara biscuits|Subjects will consume their habitual diet with daily okara biscuit consumption accounting to 20 grams/ day of dry okara powder for 21 days.
88925137|NCT03978104|Experimental|Bio-okara biscuits|Subjects will consume their habitual diet with daily bio-okara biscuit consumption accounting to 20 grams/ day of dry bio-okara powder for 21 days.
88925138|NCT03978104|Experimental|Control biscuits|Subjects will consume their habitual diet with daily control biscuit consumption for 21 days.
88925139|NCT03973528|Experimental|traditional Chinese medicine|The experimental group use traditional Chinese medicine
88925140|NCT03973528|No Intervention|non- traditional Chinese medicine|The no intervention group no use traditional Chinese medicine.
88925141|NCT03968081|Experimental|Social exclusion|Participating at the cyberball game in exclusion condition in wich they will receive 2 time the ball in the 10 first throw then none of them in the last 20 throw.
89441035|NCT02302794|Experimental|laparoscopic surgery|Minimum invasive procedure
89441036|NCT03366896|Experimental|Delirium|Diagnosis of delirium according to 5th Edition of The Diagnostic and Statistical Manual of Mental Disorders (DSM-5) by Psychiatrist.
89441037|NCT02302872|Experimental|ARTO system|
89441038|NCT03371186|Experimental|Bundled RMNCH Intervention|Stepped wedge, cluster-controlled implementation science trial of 5 bundled intervention components (1. Community Health Worker, 2, Continuous Surveillance, 3. CB-Integrated Management of Newborn and Childhood Illness, 4. Group Antenatal and Postnatal Care, and 5. Balanced Post-Partum Contraceptive Counseling) implemented across 40 village clusters in Achham District, Nepal and 40 village clusters in Dolakha District, Nepal (covering a total population of approximately 300,000) in coordination with district authorities and study staff. The investigators anticipate the experimental arm will enroll approximately 12,000 women and their children over the 18mo enrollment period.
89441039|NCT02302248|Experimental|Crowdsourced Reappraisal|Participants received the web-based crowdsourcing reappraisal intervention.
89441040|NCT02302248|Active Comparator|Expressive Writing|Participants received the web-based expressive writing intervention.
89441041|NCT03366818|Experimental|thrombectomy|thrombectomy by Versi system
89441042|NCT02302950||women that picked up raltegravir 2013|minority women that picked up raltegravir at Thomas street Health Center 2013
89441043|NCT02293746|Other|Inspire® UAS System|This is a single-arm study; all participants will be implanted with the Inspire® Upper Airway Stimulation (UAS) System.
89441044|NCT03366740|Experimental|GB mixed full strength rice suji|"On day 4 (3 days after milk suji) after diagnosis of PD, if PD doesn't resolve, the child will be enrolled in the study and after randomization will get the GB mixed full strength rice suji.~The allocated diet will be continued for 7 days and a child will be followed. If there is deterioration of diarrhea (either increased frequency or watery consistency) for 3 days or condition remains static up to 7 days the child will be declared as treatment failure."
89441045|NCT03366740|Experimental|Full strength rice suji alone|On day 4 (3 days after milk suji) after diagnosis of PD, if PD doesn't resolve, the child will be enrolled in the study and after randomization will get full strength rice suji alone.
89441046|NCT03366740|Active Comparator|3/4th strength rice suji|On day 4 (3 days after milk suji) after diagnosis of PD, if PD doesn't resolve, the child will be enrolled in the study and after randomization will get 3/4th strength rice suji.
89441047|NCT03510780|Active Comparator|EMD treated patients|"Periodontal surgery with Enamel Matrix Derivative is performed, after local anaesthesia, mucoperiosteal SPPFs will be raised. Autogenous corticocancellous BG material will be collected using bone scrapers EMD will be applied to the entire root surfaces ; then, ABG will be applied alternatively with EMD into the IBD according to the sandwich technique until the IBD will be completely filled. Finally the flap will be repositionated and sutures completed by interrupted sutures."
89441048|NCT03510780|Experimental|PRF treated patients|Periodontal surgery with Platelet Rich Fibrin is performed, after local anaesthesia, mucoperiosteal SPPFs will be raised. Autogenous corticocancellous BG material will be collected using bone scrapers , the PRF membrane cut into small pieces and mixed with the ABG will be placed within the IBDs until they will be completely filled. Then the other two PRF membranes in each patient will be adapted over the grafted defect Finally horizontal mattress and interrupted sutures will be carried out.
89441049|NCT03363620|Experimental|self ligation brackets damon ormco®|the self ligation bracket (damon system) in the orthodontic treatment, was used in the experimental group with the recommended protocol damon arches sequence.
89199583|NCT05059938|Experimental|MyFitnessPal user|Patients will be shown how to download and use MyFitnessPal onto the patient's smartphone. The patient will be asked to use the application to aid in the patient's weight loss plan over up to six months.
89441050|NCT03363620|Active Comparator|conventional brackets orthos ormco®|the conventional bracket (orthos system) in the orthodontic treatment, was used in the active comparator group with the recommended protocol damon arches sequence as used in the experimental group.
89199584|NCT05059938|No Intervention|Traditional Weight Loss Counseling|Patients will be given traditional weight loss counseling from the physician and monitored over up to six months.
89441051|NCT02293824||Premature infants|Premature infants <29 weeks birth gestational age receiving caffeine per standard of care for the prevention or treatment of apnea of prematurity.
89441052|NCT03510702||Periodontal patients.|Taking gingival Crevicular fluid.
89441053|NCT03510702||Periodontally healthy patients.|Taking gingival Crevicular fluid.
89441054|NCT03363542|Active Comparator|Fruits and vegetables rich diet|dietary education to increase fruits and vegetable consumption
89441055|NCT03363542|Active Comparator|Whole grain fiber rich diet|dietary education to increase whole grain fiber consumption
89441056|NCT03363542|Active Comparator|Fruits and vegetables and whole grain fiber rich diet|dietary education to increase fruits and vegetable and whole grain fiber consumption
89441057|NCT03363542|No Intervention|Control group|Routine care
89441058|NCT04464330||Anterior Cruciate Ligament injury and reconstruction group|According to the previous clinical diagnosis, patients who has suffered the Anterior Cruciate Ligament injury.
89441059|NCT04464330||normal control group|According to the previous clinical diagnosis, volunteers who has never suffered the lower extremity sports injuries.
89441060|NCT03370796|Experimental|Reminiscence Therapy|The Reminiscence program will consist of a set of sessions thematically sequenced topics that address the life course of the participant. Each session will integrate a group of activities that will be developed in group and will have a didactic character, privileging subjective interests and interpersonal communication.
89441061|NCT03370796|No Intervention|Control Group|The control group shall participate in the institutional care provided by the professionals of each RSE.
89441062|NCT03510624|Experimental|First rebaudioside A and then placebo|
89441063|NCT03510624|Experimental|First placebo and then rebaudioside A|
89441064|NCT03366584|Experimental|Intervention|"beta carotene 25,000 IU~vitamin D3 50,000 IU~zinc 50 mg~dexamethasone 6 mg"
89441065|NCT03366584|Active Comparator|Control|dexamethasone 6 mg
89441066|NCT03507972|Other|Ankle ultrasound & ankle MRI|Ankle ultrasound performed on the day of emergency consultation member MRI (without injection of contrast products) performed within 7 days following the trauma
89441067|NCT04445012||Aortic Valve Stenosis (Adults)|30 patients with mild, 30 with moderate, and 30 with severe mitral regurgitation, using the BSE gradings [Wharton 2014].
89441068|NCT04445012||Mitral Valve Regurgitation (Adults)|30 patients with mild, 30 with moderate, and 30 with severe mitral regurgitation, using the BSE gradings [Wharton 2014].
89441069|NCT04445012||Aortic Regurgitation (Adults)|30 patients with mild, 30 with moderate, and 30 with severe aortic regurgitation, using the BSE gradings [Wharton 2014].
88925142|NCT03968081|Active Comparator|Social inclusion|Participating at the cyberball game in inclusion condition in wich they will receive 33% of the throw : 10 in a total of 30
89441070|NCT04445012||Mitral Stenosis (Adults)|30 patients with mild, 30 with moderate, and 30 with severe mitral stenosis, using the BSE gradings [Wharton 2014].
89441071|NCT04445012||Mixed Valve Disease (Adults)|30 patients with mild, 30 with moderate, and 30 with severe mixed valve disease. Overall classification based on the most severe disease using the BSE gradings [Wharton 2014].
89441072|NCT04445012||Ventricular Septal Defects (Paediatric Patients)|36 paediatric patients with mild, 37 with moderate, and 36 with severe ventricular septal defects, using gradings from [Samaan 1970].
89441073|NCT04445012||Aortic Stenosis (Paediatric Patients)|36 paediatric patients with mild, 37 with moderate, and 36 with severe aortic stenosis
89441074|NCT04445012||Pulmonary Stenosis (Paediatric Patients)|36 paediatric patients with mild, 37 with moderate, and 36 with severe pulmonary stenosis.
89441075|NCT04445012||Patent Ductus Arteriosus (Paediatric Patients)|36 paediatric patients with mild, 37 with moderate, and 36 with severe patent ductus arteriosus, graded using ductal size [Arlettaz 2017].
89441076|NCT04445012||No Disease (Paediatric Patients)|264 paediatric patients with no heart disease. Note that we are only taking recordings from those who have been referred for an echocardiogram with a suspected heart condition but are subsequently found to have no heart disease.
89441077|NCT02306460||left atrial catheter ablation|
89441078|NCT02306460||left atrial appendix closure|
89441079|NCT02306460||paroxysmal atrial fibrillation control group|
88925143|NCT03966742|Experimental|Treatment|Doxorubin-eluting particle embolization for treatment of Desmoid Fibromatosis.
89441080|NCT02306460||persistent atrial fibrillation control group|
89441081|NCT03366506||ALS patients|"ALS patients ( suspected, possible, probable or definite per El-Escorial criteria).~Observation"
89441082|NCT02293278|Experimental|Physical Activity Intervention|"The intervention consists of 2, 3-hour workshops conducted by a master trainer with experience in promoting PA in preschoolers. Each provider in the intervention group is given the Healthy Opportunities for Preschoolers resource training manual, suggested implementation, and a starter kit of equipment. Master Trainers facilitated biweekly PA sessions throughout the intervention.~During the 6 month intervention, Preschoolers Activity Trial staff will visit the day care facilities to conduct baseline, 3 month, and 6 month measurements."
88925144|NCT03966638||Patients receiving platelet rich plasma|The group is composed of patients receiving an intra-meniscal injection of platelet-rich plasma, under echographic control, for isolated meniscal lesion.
88925145|NCT03965260||Bacteria-infected cirrhotic patients|All kind of etiologies for cirrhosis and all kind of bacterial infections (spontaneous bacterial peritonitis, urinary tract infections, pneumonia, skin and soft tissue infections and spontaneous bacteremia)
88925146|NCT03956498|Other|Patients with cervix or vaginal cancer|
89441083|NCT02293278|No Intervention|Control Group|"Day cares randomly assigned to the control group will continue with their existing programming. Day care providers will receive the PA intervention upon completion of their involvement in the 6 month trial, including: 2 three hour educational workshops, Healthy Opportunities for Preschoolers manual and program outlining the ideal implementation of activities from the manual.~During the 6 month intervention, Preschoolers Activity Trial staff will visit the day care facilities to conduct baseline, 3 month, and 6 month measurements."
89441084|NCT03363386|Experimental|Proprioceptive Exercise Group (PG)|Aerobic Exercise Proprioceptive Exercises
89441085|NCT03363386|Active Comparator|Resistive Exercise Group (RG)|Aerobic Exercise Resistive Exercises
89206107|NCT04044378|Experimental|Arm A: famitinib and camrelizumab|"In the dose-defining phase I portion, camrelizumab was given at a fixed dose of 200mg Q2W, while the de-escalated 3+3 design was used to detect the recommended dose of famitinib from an initial level of 15mg orally taken daily. Recommended phase 2 dose (RP2D) was defined as the highest dose at which no more than 30% patients experience a DLT in the first two courses.~In the phase II portion, famitinib will be orally taken daily with RP2D together with camrelizumab intravenous infusion at a dose of 200 mg over 30 minutes, once every two weeks (Q2W), 4 weeks (28 days) as one treatment cycle."
89441086|NCT03518346|Experimental|Virtual Reality Group|Participants may be randomized to the virtual reality, VR, group or the standard of care group. For the VR group, we are using the Samsung VR Go (VR head set), Samsung S7 (phone) and programmed distraction (Spaceburgers, Pebbles the Penguin, and/or Happy Place). Spaceburgers and Pebbles the Penguin were designed by the Department of Anesthesiology at Lucile Packard Children's Hospital Stanford through the Stanford Chariot Program (Childhood Anxiety Reduction Through Innovation and Technology). Happy Place is a nongame immersive experience that will be offered to children uninterested in the previously mentioned game. Happy Place was designed by a Swedish Pharmacy Chain, Apotek Hjartat, aimed to distract patients from their pain with a peaceful, interactive environment. Each of the video games runs for the length of time needed to complete the venipuncture.
89441087|NCT03518346|Active Comparator|Standard of Care Group|Participants may be randomized to the virtual reality, VR, group or the standard of care group. The standard of care group will use various distractions. Distraction tools include books and movies using a wall mounted TV as standard practice.
89441088|NCT03363308|Experimental|Phase 1|training for health care workers supplemented by QI teams
89441089|NCT03363308|No Intervention|Phase 2|
89441090|NCT03518268|Active Comparator|Dietary supplement Vivomixx|Vivomixx sachets contains a mixture of 450 billion viable lyophilized bacteria from 8 strains: Lactobacillus paracasei DSM 24733, Lactobacillus plantarum DSM 24730, Lactobacillus acidophilus DSM 24735, Lactobacillus delbrueckii subspecies bulgaricus DSM 24734, Bifidobacterium longum DSM 3 24736, Bifidobacterium infantis DSM 24737, Bifidobacterium breve DSM 24732, and Streptococcus thermophilus DSM 24731
89441091|NCT03518268|Placebo Comparator|Placebo|The placebo sachets contain the inactive ingredients maltose and silicon dioxides
89441092|NCT03366350|Experimental|Consolidative allo-HSCT following CAR-T therapy|Patients who had achieved MRD-negative complete remissions through CAR-T therapy (NCT02965092) will, on their own accord, receive allo-HSCT if there are no previous HSCT, contraindications, and other restrictions.
89441093|NCT03363230|Experimental|Mindfulness skills|
89441094|NCT03363230|Active Comparator|Interpersonal effectiveness skills|
89441095|NCT02519114|Experimental|Bone MarrowTransplantation|KIR-mismatched haploidentical bone marrow transplantation
89441096|NCT03370562|Active Comparator|Dexmedetomidine|Patient will receive 10 mcg of dexmedetomidine in 5 ml of normal saline, administered by slow intravenous injection
89441097|NCT03370562|Placebo Comparator|Placebo|Patient will receive 5 ml of normal saline, administered by slow intravenous injection
89441098|NCT03370484|Placebo Comparator|Control|Water with artificial sweetener
89441099|NCT03370484|Experimental|Milk mineral supplement|Milk Minerals containing 1000 mg calcium with artificial sweetener and water
89441100|NCT03507738|Experimental|Adult MT-5625 middle dose|Adult receiving intramuscular injection with either middle dose of MT-5625 or placebo
89441101|NCT03507738|Experimental|Adult MT-5625 high dose|Adult receiving intramuscular injection with either high dose of MT-5625 or placebo
88925147|NCT03956394|Other|Active Takayasu disease|UltraFast ultrasound will be performed in the usual health care, with the evaluation of carotid artery disease by Doppler ultrasound in patients hospitalized for Takayasu Arteritis Assessment.
88925148|NCT03956394|Other|Non-active Takayasu disease|UltraFast ultrasound will be performed in the usual health care, with the evaluation of carotid artery disease by Doppler ultrasound in patients hospitalized for Takayasu Arteritis Assessment.
89441102|NCT03507738|Experimental|Toddler MT-5625 middle dose|Toddler receiving intramuscular injection with either middle dose of MT-5625 or placebo
89441103|NCT03507738|Experimental|Toddler MT-5625 high dose|Toddler receiving intramuscular injection with either high dose of MT-5625 or placebo
89441104|NCT03507738|Experimental|Infant MT-5625 low dose|Infant receiving intramuscular injection with either low dose of MT-5625 or placebo
89441105|NCT03507738|Experimental|Infant MT-5625 middle dose|Infant receiving intramuscular injection with either middle dose of MT-5625 or placebo
89441106|NCT03507738|Experimental|Infant MT-5625 high dose|Infant receiving intramuscular injection with either high dose of MT-5625 or placebo
89441107|NCT03507738|Active Comparator|Rotarix|Infant receiving oral administration with Rotarix
89441108|NCT04524806|Active Comparator|2 mm-thick splint group (2 mm-TSG)|The group which applied the 2 mm thick stabilization splint
89199585|NCT05050305|Experimental|Marizomib plus pomalidomide and dexamethasone|"A safety run-in using a modified 3+3 dose de-escalation design with relapsed/refractory multiple myeloma (RRMM) cohort, expanded to a total of 16 participants once recommended phase 2 does (RP2D) has been identified.~Marizomib (MRZ) at a pre-determined dose on Days 1, 8, 15, 22 of a 28 day study cycle~Pomalidomide (POM) at a daily predetermined dose on Days 1-21 of a 28 day study cycle~Dexamethasone (DEX) at a daily predetermined dose on Days 1, 2, 8, 9, 15, 16, 22, 23 of a 28 day study cycle~Simultaneously, relapsed/refractory multiple myeloma (RRMM) with central nervous system (CNS) involvement cohort will receive an identical modified 3+3 dose de-escalation design and expanded to an efficacy-evaluable total of 30 patients once recommended phase 2 does (RP2D has been identified"
89012693|NCT04719572|Active Comparator|Basic treatment+ anti-osteoporosis drug group|alendronate(70mg/week), zoledronate(5mg 1/ year), tripopeptide(20ug 1/day), denosumab(120mg/month), activated vitamin D(0.25ug 1/day), menatetrenone(15mg tid) according to the patient's condition
89199586|NCT05048667|Experimental|SWT plus PRP Group|Participants will receive weekly Shockwave Therapy (SWT) and Platelet Rich Plasma (PRP) for 5 weeks. SWT will be administered weekly on Weeks 1, 2, 3, 4, and 5. PRP will be administered on Week 1 and Week 5.
89199587|NCT05048667|Placebo Comparator|Sham SWT plus Placebo Saline Group|Participants will receive weekly Sham Shockwave Therapy (SWT) and Placebo Saline Intracavernosal Injection (ICI) for 5 weeks. Sham SWT will be administered weekly on Weeks 1, 2, 3, 4, and 5. Placebo Saline ICI will be administered on Week 1 and Week 5.
89199588|NCT05047354||1|Subjects with Smith-Lemli-Opitz syndrome
89012694|NCT04719572|Other|Basic treatment + non-drug treatment group|diet, exercise, rehabilitation therapy
89441109|NCT04524806|Active Comparator|4 mm-thick splint group (4 mm-TSG)|The group which applied the 4 mm thick stabilization splint
89441110|NCT03507660|Experimental|verbal instruction|"The participants will be verbal instructed to contract the pelvic floor muscle with the following sentences:~squeeze the pelvic floor muscles.~squeeze and lift the pelvic floor muscles as if stopping the flow of urine~Take a moderate breath in, let the breath out, draw in and lift your pelvic floor.~squeeze the anus~shorten the penis~elevate the scrotum"
89441111|NCT03370328|Experimental|Peppermint oil|post-op surgical patients
89441112|NCT03370328|Experimental|Ginger oil|post-op surgical patients
89441113|NCT03370328|Experimental|Peppermint and ginger oil|post-op surgical patients
89441114|NCT03507582|Active Comparator|Virtual Reality Distraction|This intervention consists of a disposable virtual reality headset which will enable the use of virtual reality in clinic through the commodity hardware iPod Touch. An additional piece of software on an iPad will allow clinical staff to act as an orchestrator and trigger events that occur for the patient's benefit in the virtual reality environment. The mechanism for the dashboard will be dashboard software running on an iPad tablet that will wirelessly communicate to the iPod Touch the patient is wearing. A study timer will be incorporated into the orchestration dashboard. The VAS/FACES scale will be incorporated into the iPad used for orchestration.
89199589|NCT05047354||2|Subjects with Disorders of cholesterol synthesis and metabolism
89199590|NCT05044104|Experimental|Wearable technology in endoscopic gastrointestinal procedures with sedation|Subjects undergoing a endoscopic gastrointestinal procedure with sedation as part of standard of care will wear a consumer-facing wearable smart watch for the duration of the procedure.
89199591|NCT05036616||Separation technique|
89501635|NCT05497934|Experimental|Treatment arm|Subjects will be imaged with OCT and endoscopy before treatment of the tympanic membrane with topical glycerol, after treatment of the tympanic membrane with topical glycerol and after rinsing the tympanic membrane with saline
88925149|NCT03952182|Active Comparator|Spinal Orthosis (LSO, TLSO, etc)|Patient's in this arm will be given an orthosis for the treatment of their injury (TLSO for thoracic or upper lumbar injury, LSO for lumbar injury)
89441115|NCT03507582|Active Comparator|Standard of Care Distraction|This intervention consists of a two dimensional distraction (ie TV/tablet) as well as verbal distraction (ie singing/talking/music) will be allowed by caregivers, nurses and phlebotomy staff but will not qualified or quantified. IV procedures will proceed in Groups A and B. At the completion of the IV procedure the nurse orchestrator will stop the procedure timer. The Subject, Guardian and Nurse orchestrator will complete the Final VAS/FACES assessment on the iPad.
89441116|NCT02303106|Active Comparator|lamotrigine|lamotrigine alone
89441117|NCT02303106|Experimental|Lamotrigine + paracetamol|Lamotrigine + paracetamol
89441118|NCT04525664|Experimental|Participants who test positive for Helicobacter pylori|Participants who test positive for Helicobacter pylori by fecal antigen testing will be offered treatment with triple therapy (clarithromycin 500 mg per os twice daily, amoxicillin 1 g per os twice daily, omeprazole 40 mg per os twice daily) for 14 consecutive days. Two to four weeks following the completion of treatment, participants will repeat fecal antigen testing to confirm whether they eradicated the Helicobacter pylori.
89441119|NCT04525664|Experimental|Patients with dyspepsia and negative for Helicobacter pylori|Participants who report chronic dyspepsia but are negative for Helicobacter pylori by fecal antigen testing will receive daily omeprazole (20 mg per os) for one month. Their symptoms will be reassessed after completion of the month treatment.
88925150|NCT03952182|Experimental|No Spinal Orthosis|the patient's in this arm will not be given an orthotic. They will be given a bending restriction and otherwise remain activities as tolerated.
88925151|NCT03929588|Experimental|Refraction with a Hand-held Device Supported by Mobile App.|BCVA with handheld device with app.
88925152|NCT03929588|Active Comparator|Manual Refraction|BCVA with phoropter
88925153|NCT03929588|Active Comparator|Automated Refraction|BCVA with autorefractoer
88925154|NCT03928678|Active Comparator|thefast track (FTS group)|
88925155|NCT03928678|Placebo Comparator|Thecontrolgroup|
88925156|NCT03924700|Experimental|Biportal endoscopic discectomy|Biportal endoscopic discectomy for lumbar herniated intervertebral disc
88925157|NCT03924700|Active Comparator|Microdiscectomy|Microdiscectomy for lumbar herniated intervertebral disc
88925158|NCT03924427|Experimental|BMS-986165|Given daily
88925159|NCT03922451||Pediatric patients supported on ECMO|
88925160|NCT03908073|Active Comparator|Active transcutaneous vagal nerve stimulation|The participant will be taught how to use the device and administer doses in our laboratory and independently at home over a period of 24 hours.
88925161|NCT03908073|Placebo Comparator|Sham transcutaneous vagal nerve stimulation|The participant will be taught how to use the device and administer doses in our laboratory and independently at home over a period of 24 hours.
88925166|NCT03907332|Experimental|Intervention Arm|"Study group 1 - Home visits by a team made up of a CHW and CHN in addition to all existing usual care practices (see below).~Standardized educational Messages will be given during these scheduled home visits by the CHW-CHN including:~One visit during the second trimester of the pregnancy~Two visits during the third trimester of pregnancy"
88925167|NCT03907332|No Intervention|Control Arm|Study group 2 (Control) - Existing usual care practices. Usual Care includes at least four antenatal visits and care package which includes education on pregnancy, labour and delivery given at the health facility or at community settings to individuals and/or groups of pregnant women.
88925168|NCT05802667||STEMI|A total of 300 STEMI patients admitted to the Department of Cardiology, Peking University Third Hospital from April 1, 2023 to March 31, 2024 were enrolled.
89199592|NCT05036616||Integration technique|
89012695|NCT01686295|Experimental|iRestore Hair Rejuvenation System|Seventy six (76) subjects will be enrolled in the 24-week study; of which 38 will be male and 38 will be female using the iRestore hair growth device
89012696|NCT01686295|Sham Comparator|Sham Device Arm|This study arm will use a sham device consistent with the experimental device with 12 men and 12 women with androgenetic alopecia 3 times a week for 30 minutes on non-consecutive days
89012697|NCT04528030|Other|Treatment starting with an on ON cycle|The treatment will start ON cycle for 6 hours, followed by OFF cycle for 6 hours, followed by OFF cycle for 6 hours and finished with ON cycle for 6 hours.
89012698|NCT04528030|Other|Treatment starting with an on OFF cycle|The treatment will start OFF cycle for 6 hours, followed by ON cycle for 6 hours, followed by OFF cycle for 6 hours and finished with ON cycle for 6 hours.
89012699|NCT01686412|Active Comparator|Healthy patients|
89012700|NCT01686412|Active Comparator|Oncology patients|
89441120|NCT03510546|Experimental|Active|"De-novo: Each capsule contains 60 mg. pyridostigmine. 1 capsule is administered twice within 4 hours.~Chronic: Each capsule contains 60 mg. pyridostigmine. Number of administered capsules per dosage depend on the patient's usual dosage. Study drug is administered twice within 4 hours.~Patients are examined/rated before 1st dose, 1 hour after 1st dose, 1 hour after 2nd dose (Visit 1). After cross-over (Visit 2), patients will be rated open-label at 1 month (Visit 3) and 3 months (Visit 4)."
89012701|NCT01686490|Other|D.|The focus is evaluation of LifeSkills Video/Workbook for patients about to receive an AICD. Patients who now have received their AICD were given a video/workbook pre-implantation as an intervention to reduce their concerns/distress. After implantation, they will be asked what was and was not helpful about the materials they received.
89441121|NCT03510546|Placebo Comparator|Placebo|"Same as Active, however capsules contain placebo."
89441122|NCT03505008|Experimental|MTX-Monotherapy Group|Participants will receive Methotrexate (MTX) at a starting dose of 6 to 8 mg/week, which will be promptly escalated to the maximum tolerated dose (MTD) of ≤25 mg/week up to Week 12, and maintained until Week 24. If the dosage of MTX is maintained ≥ 10 mg/week and simple disease activity index (SDAI) remission is achieved at Week 24, the MTX therapy will continue until Week 48.
89441123|NCT03505008|Experimental|ADA/MTX-Maximum Tolerated Dose Group|Participants will receive Methotrexate (MTX) at a starting dose of 6 to 8 mg/week, which will be promptly escalated to the MTD of ≤25 mg/week up to Week 12, and maintained until Week 24. If the dosage of MTX is maintained ≥ 10 mg/week and SDAI remission is not achieved at Week 24, Adalimumab (ADA) 40 mg will be administered subcutaneously every other week in addition to the MTX therapy until Week 48.
89012702|NCT00281736|Experimental|Arm I|Patients receive HPPH IV over 1 hour on day 1. Approximately 24 hours later, the lesion is exposed to laser light endoscopically.
89012703|NCT00281736|Experimental|Arm II|Patients receive HPPH as in arm I, but at a higher dose, followed by laser light exposure.
89012704|NCT01686529|Experimental|One subconjunctival injection|Autoconjunctival grafting and one subconjuntival bevacizumab injection (2.5mg/0.1ml) was applied after surgery
89441124|NCT03505008|Experimental|ADA/MTX-Reduced Dose Group|Participants will receive Methotrexate (MTX) at a starting dose of 6 to 8 mg/week, which will be promptly escalated to the MTD of ≤25 mg/week up to Week 12, and maintained until Week 24. If the dosage of MTX is maintained ≥ 10 mg/week and SDAI remission is not achieved at Week 24, Adalimumab (ADA) 40 mg will be administered subcutaneously every other week in addition to low-dose MTX (6 to 8 mg/week) treatment until Week 48.
89441125|NCT03363074|Experimental|Orthotic Insole|Device: Orthotic Insole 8-week follow-up with Orthotic Insole
89441126|NCT03363074|Experimental|Low-level Laser Therapy|Low-Level Laser 5-week follow-up
89441127|NCT03362996|Experimental|Experimental Group|"50 patients Freshly-Pressed Extra Virgin Olive Oil Aluminum bottle with 500 ml of freshly-pressed extra virgin olive oil 1 bottle per 10 days.~Dietary Supplement: Freshly-Pressed Extra Virgin Olive Oil dietary intake of the content of 50 mL (3 tablespoons from the bottle containing the product)"
89441128|NCT03362996|Placebo Comparator|Control group 1|50 patients Extra Virgin Olive Oil Aluminum bottle with 500 ml of freshly-pressed extra virgin olive oil 1 bottle per 10 days. Extra Virgin Olive Oil dietary intake of the content of 50 mL (3 tablespoons from the bottle containing the product)
89441129|NCT03362996|Other|Control Group 2|50 patients that will have the same dietary habits and a Mediterranean dietary protocol
89012705|NCT01686529|Experimental|Two subconjuctival injections|Autoconjunctival grafting and subconjuntival bevacizumab injection (2.5mg/0.1ml) was applied after surgery, with another injection 15 days after surgery
89012706|NCT01686529|Active Comparator|Conventional treatment|Autoconjunctival grafting without subconjuntival bevacizumab injection
89012707|NCT01686607||1) parenteral micafungin users|patients who had been treated with parenteral micafungin
89012708|NCT01686607||2) other parenteral antifungal users|patients who had been treated with a parenteral antifungal agent (not micafungin)
89012709|NCT05140720|Experimental|6 weeks - 6 months of age|Group 1: Age group from 6 weeks - 6 months
89012710|NCT05140720|Experimental|7 - 11 months of age|Group 2: Age group from 7 - 11 months
89199593|NCT05036044||With moderate or severe carotid-cerebral artery disease|moderate (stenosis 50-69%) or severe (stenosis 70-100%) carotid-cerebral artery disease
89199594|NCT05036044||Without moderate or severe carotid-cerebral artery disease|mild (stenosis 30-49%) or no (stenosis 0-29%) carotid-cerebral artery disease
89199595|NCT05034276|Experimental|MORE-VR|Mindfulness-Oriented Recovery Enhancement deployed over virtual reality.
89199596|NCT05029154|Experimental|Exercise|Patients in the exercise group will perform interval training 3 days per week.
89441130|NCT03507504||care pathway with SCU-B|250 patients with dementia and behavioural and psychological symptoms of dementia (BPSD) followed up by six clinical centres with a Special Care Unit for BPSD (SCU-B)
89441131|NCT03507504||care pathway without SCU-B|250 patients with dementia and BPSD followed up by six clinical centres without SCU-B
89441132|NCT03366038||Modified Pancreaticojejunostomy|Shark Mouth Modified Pancreaticojejunostomy is performed following pancreaticoduodenectomy.
89441133|NCT02311452||Acute Osteomyelitis|
89441134|NCT02311452||Complicated Pneumonia|
89441135|NCT02311452||Complicated Appendicitis|
89441136|NCT03507426|Active Comparator|Retrobulbar group|Retrobulbar block
89441137|NCT03507426|Active Comparator|Ketamine group|Intravenous analgesia
89441138|NCT03507426|No Intervention|Control group|General anesthesia alone
88925169|NCT05802641||single fraction of SBRT（30Gy/1f）|Participants with early lung cancer receive single fraction of SBRT（30Gy/1f).
88925170|NCT05802641||Multiple fractions of SBRT（36Gy/3f）|Participants with early lung cancer receive multiple fractions of SBRT（36Gy/3f).
88925171|NCT05802537|Experimental|Home-based exergame program|The home-based exergame program was conducted at the participants' homes for 50 min, three times a week, for eight weeks.
88925172|NCT05802537|Active Comparator|Online education|Online education on fall prevention and musculoskeletal health management was provided once a week for 50 minutes, one day a week, for 8 weeks.
88925173|NCT05802511|Experimental|Exablate treatment|Exablate treatment on Neuropathic Pain
88925174|NCT05802498|No Intervention|control GROUP|This group will perform 8 continuous weeks of treatment, 5 days a week, for a total of 180 minutes, including muscle stretching, joint range increase with passive and active assisted mobilization sessions of the scapulohumeral and pelvic girdles. Motor coordination exercises. Postural exercises with exercises for trunk control in sitting and standing positions with feedback and feed-forward techniques. gait training; gait training; proprioceptive exercises and exercises to maintain static and dynamic balance in monopodalica; strengthening of trunk muscles; postural exercises, muscle relaxation/stretching, release of the tracks; re-education in postural passages and transfers with fall prevention strategies.
88925175|NCT05802498|Experimental|irma group|This group will perform 8 continuous weeks of treatment, 5 days a week, for a total of 180 minutes, including muscle stretching, increasing joint range with assisted passive and active mobilisation sessions of the scapulohumeral and pelvic girdles. Motor coordination exercises. Postural exercises with exercises for trunk control in sitting and standing with feedback and feed-forward technique. Gait training; gait training; proprioceptive exercises and static and dynamic balance maintenance in monopodalics; trunk muscle strengthening; postural exercises, muscle relaxation/relaxation, caterpillar release; re-education in postural transitions and transfers with fall prevention strategies. Prior to neuromotor rehabilitation treatment, the subjects will undergo rehabilitation training using the NIRVANA augmentative reality system.
88925176|NCT05802485|Other|collection of blood and tumor samples|
88925177|NCT05802472|Experimental|Polyphenolic beverage|Thirty subjects were randomly assigned (Visit 1), and weight and height will be evaluated, as body composition and blood sampling to assess glucose, liver, and kidney function. During Visit 2, and before the administration (1.2 mg/kg of weight) of a single infusion of the polyphenolic extract, glucose in the blood will be quantified (basal; with 12 hours of fasting); later, administer a load of 75 g of oral sucrose and after 30 minutes, the blood sample will begin at different intervals: 20, 40, 60, 90 and 120 minutes. The participant solves the food consumption frequency questionnaires during this procedure. A second blood sample will be taken 48 hours later (Visit 3). Finally, a urine sample will be taken to rule out acute kidney damage through the sensitive kidney damage biomarker (KIM-1). In addition, the participant will be interviewed to answer the adverse effects questionnaire.
88925178|NCT05802472|Placebo Comparator|Water|Thirty subjects were randomly assigned (Visit 1), and weight and height will be evaluated, as body composition, and blood sampling to assess glucose, liver, and kidney function. During Visit 2, and before the administration of a single water as placebo, glucose in the blood will be quantified (basal; with 12 hours of fasting); later, administer a load of 75 g of oral sucrose and after 30 minutes, the blood sample will begin at different intervals: 20, 40, 60, 90 and 120 minutes. The participant solves the food consumption frequency questionnaires during this procedure. A second blood sample will be taken 48 hours later (Visit 3). Finally, a urine sample will be taken to rule out acute kidney damage through the sensitive kidney damage biomarker (KIM-1). In addition, the participant will be interviewed to answer the adverse effects questionnaire.
88925179|NCT05802459||Patients undergoing complex esophageal reconstruction|All the patients who are candidates for complex esophageal reconstruction performed by the Complex Esophageal Reconstruction Functional Unit of the Bellvitge University Hospital (UREC-HUB), during the study period.
88925180|NCT05802446|Experimental|Active feedback|"Group receiving real neurofeedback (NFB) (activity of the emotional brain network)"
88925181|NCT05802446|Sham Comparator|Sham feedback|"Group receiving sham NFB (activity from brain regions not implicated in emotion processing) to control for a potential placebo effect."
89441139|NCT03362918|No Intervention|Control Group|"Participants randomized to the control group will continue with their usual level of physical activity. They will track their menstrual cycles and perform daily ovulation tests.~Once all post-intervention assessments are complete, they will have the option to begin an exercise program with three supervised sessions of either high-intensity interval training or continuous aerobic exercise training free of charge. They will be given a Polar heart rate (HR) monitor as a gift for their participation in the study."
89441140|NCT03362918|Experimental|High-Intensity Interval Training|Participants randomized to this group will complete three high intensity interval training sessions per week, two of which will be supervised. They will exercise for a total of 30 minutes per session. Each session will begin with a five-minute warm-up and end with a five-minute cool-down.
89441141|NCT03362918|Experimental|Continuous Aerobic Exercise Training|Participants randomized to this group will complete three continuous aerobic training sessions per week, two of which will be supervised. They will exercise for a total of 50 minutes per session. Each session will begin with a five-minute warm-up and end with a five-minute cool down.
89441142|NCT02311530|Experimental|Test|Felodipine Extended Release Tablets USP 10 mg
89441143|NCT02311530|Active Comparator|Reference|Plendil® Extended release tablets 10 mg
89441144|NCT04522466|Experimental|Patients infected by SARS-CoV-2 treated by Hydroxychloroquine|Blood sample on patients infected by SARS-CoV-2 treated by Hydroxychloroquine
89012711|NCT05140720|Experimental|12 - 24 months of age|Group 3: Age group from 12 - 24 months
89441145|NCT02306772|Experimental|Formulation A|TP05 Coating A
89441146|NCT02306772|Experimental|Formulation B|TP05 Coating B
89441147|NCT03358394|Experimental|Intervention group|The intervention group will be asked to complete the outcomes measures anxiety, depression and mindfulness questionnaires at baseline, a week before the start of the intervention and at the end of the intervention time period(i.e., after five weeks).
89441148|NCT03358394|Experimental|Control group|"The control group will be asked to complete the outcomes measures anxiety, depression and mindfulness questionnaires at baseline, a week before the start of the intervention and at the end of the intervention after six weeks.~At the end of the pilot trial, control group will receive the full intervention. They would be sent the materials week by week as same as the intervention group."
89441149|NCT03132558||CTA|Patients with AIS only receieved cerebral CTA exam.
89441150|NCT03132558||CTA+DSA|Patients with AIS receieved cerebral CTA, followed by endovascular treatment with the guidence of digital substration angiography (DSA).
89441151|NCT04463472|Experimental|Low-dose group|
89441152|NCT04463472|Experimental|High-dose group|
89441153|NCT04524650||stage 0|without liver function injury or splenomegaly
89441154|NCT04524650||stage 1|occurrence of liver function injury (ALT or AST > 2 ULN (upper limit of normal)
89441155|NCT04524650||stage 2|occurrence of splenomegaly or reduced platelet count (<150 X10^9/L)
89441156|NCT04524650||stage 3|occurrence of portal hypertension and/or gastroesophageal varices
89441157|NCT03507348|Other|Desensitization with Tocilizumab and rituximab (MFI >15000)|
89441158|NCT03507348|Other|Desensitization with Rituximab only (MFI<15000)|
89441159|NCT03362840|Experimental|Early Start Denver Model (ESDM) group|The ESDM is a manualized comprehensive treatment model for young children (12-48 months). In the preschool based ESDM, learning objectives are guided by the ESDM curriculum checklist, which includes developmental skills in language, play, motor skills, personal independence, imitation and cognition.
89441160|NCT03362840|Active Comparator|Eclectic preschool intervention group|The eclectic approach consists of a combination of methods from several treatment-models. Individualized educational plans are based on multi-disciplinary assessment, and include objectives in several domains - communication, social-skills, play, emotional adjustment, adaptive daily skills, motor skills and cognition. They are presented to parents at the beginning of the year and are reviewed by the staff three times a year.
89441161|NCT03450252|Experimental|Active pacing|Active ventricular pacing. The pacemaker is set-up with a short atrio-ventricular delay to allow for appropriate pacing capture of the ventricle.
89441162|NCT03450252|Sham Comparator|Back-up pacing|Back-up pacing. The pacemaker is set-up to sense and pace only in the right atrium (AAI) without any pacing capacity in the ventricle.
89441163|NCT03365960|Active Comparator|Active1|watermelon rind
89441164|NCT03365960|Active Comparator|Active2|watermelon flesh
89441165|NCT03365960|Active Comparator|Active3|watermelon seeds
89012712|NCT00253682||1|HIV-uninfected infants born to HIV-infected women with in-utero exposure to HIghly Active Ani-Retroviral Therapy (HAART) who were enrolled in the Women and Infants Transmission Study (WITS).
89012713|NCT00253682||2|Historical cohort of HIV-uninfected infants born to HIV-infected women from the Pediatric Pulmonary and Cardiovascular Complications of HIV Study (P2C2 HIV) who were not exposed to HAART.
89012714|NCT01686724|Other|Business as Usual (BAU)|This group receives services as usual in their schools. They will receive the intervention after follow-up measures are gathered.
89441166|NCT03365960|Placebo Comparator|Control Comparator|placebo
89441167|NCT03510312||Long-term follow up, observational|This cohort does not involve interventions, just follow up of prognosis of ischemic stroke/transient ischemic attack patients.
89441168|NCT02518802|Experimental|Synchronous therapy|'Gefitinib and Pemetrexed' Synchronous use of Gefitinib for 2 years during or after chemotherapy with Pemetrexed plus Cisplatin regimen. Gefitinb, 250mg per day,take orally for 2 years. Pemetrexed, 500mg/m2, day 1; Cisplatin 75mg/m2, day 1. Three weeks as a cycle. Four cycles in total.
89441169|NCT02518802|Active Comparator|Chemotherapy|Pemetrexed: Pemetrexed, 500mg/m2, day 1; Cisplatin 75mg/m2, day 1. Three weeks as a cycle. Four cycles in total.
89441170|NCT02303340||Study Group|Any patient who enrolled and signed informed consent will be sent to bone mineral density DEXA Scan, and for blood testing for PTH, Phosphor, Calcium ,Vitamin D and Creatinine levels. Density measurements will be done in specific sites on the CBCT's of the jaws.
89441171|NCT04524026|Experimental|Intervention|recFSH and co-treatment with letrozole 5 mg/day from stimulation day 1 on cycle day 2 or 3 until the day before gonadotrophin releasing hormone(GnRH) agonist administration to trigger final oocyte maturation. GnRH antagonist 0.25 mg/day from stimulation day 5 until day of GnRH agonist administration. No luteal phase support.
89441172|NCT04524026|No Intervention|Control group|recFSH from stimulation day 1 on cycle day 2 or 3 until the day before GnRH agonist administration to trigger final oocyte maturation. GnRH antagonist 0.25 mg/day from stimulation day 5 until day of GnRH agonist administration. No luteal phase support.
89441173|NCT04523948||Cohort One|Subjects will be invited to participate in brief weekly in person or telehealth behavioral support with the objective of reducing their rate of combustible tobacco use. Subjects will also be offered the choice of various conventional nicotine replacement aids, snus, electronic cigarette, varenicline or bupropion.
89441174|NCT04523948||Cohort Two|Subjects will be invited to participate in brief weekly in person or telehealth behavioral support with the objective of reducing their rate of combustible tobacco use. Subjects will also be offered the choice of various conventional nicotine replacement aids, snus, electronic cigarette, varenicline or bupropion.
89441175|NCT04523948||Cohort Three|Subjects will be invited to participate in brief weekly in person or telehealth behavioral support with the objective of reducing their rate of combustible tobacco use. Subjects will also be offered the choice of various conventional nicotine replacement aids, snus, electronic cigarette, varenicline or bupropion.
89441176|NCT04523948||Cohort Four|Subjects will be invited to participate in brief weekly in person or telehealth behavioral support with the objective of reducing their rate of combustible tobacco use. Subjects will also be offered the choice of various conventional nicotine replacement aids, snus, electronic cigarette, varenicline or bupropion.
89441177|NCT04523948||Cohort Five|Subjects will be invited to participate in brief weekly in person or telehealth behavioral support with the objective of reducing their rate of combustible tobacco use. Subjects will also be offered the choice of various conventional nicotine replacement aids, snus, electronic cigarette, varenicline or bupropion.
89441178|NCT02311608||High Dose Somatostatin/Octreotide|continuous IV infusion of 500μg/h of Somatostatin or continuous IV infusion of 50μg/h of Octreotide when usual somatostatin or Octreotide dose fails to achieve hemostasis of acute variceal bleeding patients
89441179|NCT02311608||Terlipressin as salvage|an initial injection of 2mg of Terlipressin followed by an injection of 1mg of Terlipressin per 6h when usual somatostatin or Octreotide dose fails to achieve hemostasis of acute variceal bleeding patients
89441180|NCT02311608||Terlipr+usual dose somato/Octreo|an initial injection of 2mg of Terlipressin followed by an injection of 1mg of Terlipressin per 6h together with continuous IV infusion of 250μg/h of Somatostatin or continuous IV infusion of 25μg/h of Octreotide when usual somatostatin or Octreotide dose fails to achieve hemostasis of acute variceal bleeding patients
89441181|NCT02311608||Control:Usual Dose Somato/Octreo|Hemostasis achieved by continuous IV infusion of 250μg/h of Somatostatin or continuous IV infusion of 25μg/h of Octreotide
89441182|NCT02311608||Control: Initial Terlipressin|Hemostasis achieved by an initial injection of 2mg of Terlipressin followed by an injection of 1mg of Terlipressin per 6h
89441183|NCT03358316||cuff tear patients|Patients with cuff tear
89441184|NCT02307006|Experimental|Ceftaroline|Experimental comparator for surgical peri-operative prophylaxis for procedures at increased risk if MRSA infection
89441185|NCT02307006|Active Comparator|Cefazolin / Vancomycin|Standard of care comparator for surgical peri-operative prophylaxis for procedures at increased risk if MRSA infection
89441186|NCT02307084|Experimental|Pre-operative ultrasound imaging|Subjects that are randomly allocated to this group will have ultrasound imaging assessment of the long saphenous vein in both legs. This will allow assessment of the suitability of the long saphenous vein and marking of the distribution prior to heart bypass surgery to allow targeted harvesting of a bypass conduit.
89441187|NCT02307084|No Intervention|Current protocol|This group will not undergo pre-operative ultrasound imaging of the long saphenous vein in accordance with current Trust protocols.
89441188|NCT03362684|Experimental|FOLFOX-4 plus Cetuximab|
89441189|NCT03362684|Active Comparator|FOLFOX-4|
89441190|NCT02311686|Experimental|10 g ethanol|Subjects will be required to drink a dilution of 31 mL of vodka in 369 mL of lemon-flavored water in 15 minutes.
89441191|NCT02311686|Experimental|20 g ethanol|Subjects will be required to drink a dilution of 63 mL of vodka in 337 mL of lemon-flavored water in 15 minutes.
89441192|NCT02311686|Experimental|40 g ethanol|Subjects will be required to drink a dilution of 125 mL of vodka in 275 mL of lemon-flavored water in 15 minutes.
89441193|NCT02311686|Experimental|60 g ethanol|Subjects will be required to drink a dilution of 188 mL of vodka in 212 mL of lemon-flavored water in 15 minutes.
89441194|NCT02311686|Experimental|80 g ethanol|Subjects will be required to drink a dilution of 250 mL of vodka in 150 mL of lemon-flavored water in 15 minutes.
89441195|NCT03362606|Experimental|OC-CTLs|Autologous ovarian cancer specific cytotoxic lymphocytes
89441196|NCT02311764|Experimental|Carboplatin|Carboplatin will be administered weekly
88925182|NCT05802433|Experimental|Control (Low risk genotype)|Participants with no genetic variation in their VDR, GC and CYP2R1 genes that would increase their risk of vitamin D deficiency. Participants will be given 10µg vitamin D supplements for 90 days. This group is a control against the medium and high-risk intervention groups.
89441197|NCT03365726|Experimental|DST (dobutamine-stress-test)|dobutamine stress echocardiography performed to patients undergoing major surgery
89441198|NCT03365726|No Intervention|NDST (no-dobutamine-stress-test)|patients refused the dobutamine stress test and transesophageal echocardiography measured the troponin level in first 24 hours after surgery
89441199|NCT02307162|Placebo Comparator|Dummy solution|Nebulised suspension to be administered as either a single dose (Part A) or 11 doses over 6 days (Parts B anc C)
89441200|NCT02307162|Experimental|RPL554 suspension|"Nebulised suspension to be administered as either a single dose (Part A) or 11 doses over 6 days (Parts B anc C).~Starting dose in Part A to be 1.5mg/mL with planned up to 2 fold increments. Doses in Part B will be selected from Part A. Doses in Part C to be selected from Part B"
89441201|NCT03358160||TKA|Orthopaedic patients who underwent surgical operation for total knee arthroprothesis.
89441202|NCT03358160||Rizoarthrosis|Orthopaedic patients who underwent surgical operation to treat chronic arthrosis of the thumb.
89441203|NCT03358160||Healthy Controls|Healthy age-matched controls.
89441204|NCT02303418|Active Comparator|Carbetocin|100 µgm of Carbetocin will be diluted in 10ml saline and will be given by the anesthesist slowly intravenously after delivery of the baby. The uterine tone and amount of bleeding will be noted and the need for further uterotonic agents will be determined 2 minutes after giving the drug.
89441205|NCT02303418|Active Comparator|Oxytocin|5 mg of oxytocin will be diluted in 10ml saline and will be given by the anesthesist slowly intravenously after delivery of the baby. The uterine tone and amount of bleeding will be noted and the need for further uterotonic agents will be determined 2 minutes after giving the drug.
89441206|NCT03365648|Experimental|Lertal® + standard therapy|Lertal® double-layer tablets (1 tab/day for 4 weeks) plus standard therapy (antihistamine)
89441207|NCT03365648|Placebo Comparator|Placebo + standard therapy|Placebo tablets (1 tab/day for 4 weeks) plus standard therapy (antihistamine)
89441208|NCT03362528|Experimental|Short term collection of IMD data|Subjects will collect spectral raman data on WM3.4NR four times a day for 30 days distributed over a time period of 60 days. Each timepoints are conducted in duplicate. Spectral data will be compared to standard BG measurements.
89441209|NCT03362528|Experimental|Long term collection of IMD data|Subjects will collect spectral raman data on WM3.4NR four times a day for the initial 30 days, distributed over a time period of 60 days. Subjects will for the remaining 60 days of measurements, distributed over 120 days collect spectral data twice a day. Each timepoints are conducted in duplicate. Spectral data will be compared to standard BG measurements.
88925183|NCT05802433|Experimental|Intervention (Medium risk genotype)|Participants with genetic variation in their VDR, GC and CYP2R1 genes that moderately increase their risk of vitamin D deficiency. Participants will be given 10µg vitamin D supplements for 90 days. This group will be compared against the low-risk control group to determine the effect of genetic variations on vitamin D status.
88925184|NCT05802433|Experimental|Intervention (High risk genotype)|Participants with genetic variation in their VDR, GC and CYP2R1 genes that increase their risk of vitamin D deficiency. Participants will be given 10µg vitamin D supplements for 90 days. This group will be compared against the low-risk control group to determine the effect of genetic variations on vitamin D status.
88925185|NCT05802381|Experimental|protein supplements|This group will receive dietary guidance and protein supplements for 3 months
89199597|NCT05029154|Placebo Comparator|Attention Control|Physical activity education and physical activity monitoring.
88925186|NCT05802381|Other|dietary guidance|this group will receive dietary guidance for 3 months
88925187|NCT05802368|Experimental|study group|a 30-minute VR-based training session utilizing Kinect Xbox after the session of traditional physical therapy.
88925188|NCT05802368|Experimental|control group|Traditional physical therapy, 30-minutes physical therapy exercise program each week with 48-hour intervals at least
89199598|NCT05026554||CHE|Adults with moderate to severe chronic hand eczema
89199599|NCT05026554||Healthy Volunteers|Healthy adults
89441210|NCT03510000|Experimental|Main arm|Single arm open-label cross-over study with random order of SGLT-2 inhibitor intervention (Empagliflozin 25mg po qd), in which each cross-over phase includes different meal strategies (carbohydrate counting, meal announcement, no meal announcement) on separate days in the setting of single hormone artificial pancreas
89441211|NCT03504930||Impact of biotherapy on postoperative morbidity|Impact of biotherapy on postoperative morbidity in ulcerative colitis
89441212|NCT03362450||Pregnant patients seen for second or third trimester|Foetus with diagnosis of prenatal volvulus based on post-natal findings and prenatal imaging findings
89441213|NCT03365492|Experimental|Treatment Arm|Patients with CAD who receive the BioFreedom™ Biolimus A9™ stent.
89441214|NCT03507270|Other|FABP group|Coronary angiography and PCI (according to indications).
89441215|NCT03358082|Active Comparator|Tacrolimus group|Tacrolimus 0.03% ointment twice daily for 6 months
89199600|NCT05026554||Atopic Dermatitis|subjects with moderate to severe AD
88925189|NCT05802355|Experimental|Manual Diaphragm Release|received 3sessions/ week for 12 consecutive weeks.
89441216|NCT03358082|Active Comparator|Hydrocortisone group|hydrocortisone acetate 1% ointment twice daily for 6 months
89441217|NCT03358004|Experimental|ARM A|Vinorelbine 50 mg, thrice a week
89441218|NCT03358004|Experimental|ARM B|Vinorelbine 40 mg thrice a week + capecitabine 500 mg thrice a day
89441219|NCT03507192|No Intervention|Arm 1|30 subjects In arm 1, no intervention is performed.
89441220|NCT03507192|Active Comparator|Arm 2|30 patients In arm 2 , active comparators, Muscle relaxation using full body massage machine is performed every morning and evening for 30 minutes.
89441221|NCT03509922|Experimental|Anplag Tab. 100mg bid|sarpogrelate hydrochloride 100mg bid for 24 weeks
89441222|NCT03509922|Experimental|Anplag Tab. 100mg tid|sarpogrelate hydrochloride 100mg tid for 24 weeks
89441223|NCT03365336|Experimental|Intervention Group|Each Flu Care capsule consists of combination of seven polyherbal formulation (350 mg). Participant will be instructed to take one capsule thrice daily at a fixed time in the day for the study duration of 7 days along with 75 mg of Oseltamivir.
89441224|NCT03365336|Active Comparator|Standard Care Group|Standard of care consist of 75 mg of Oseltamivir for five days and any other required provision of care. These will be determined on case by case basis by research clinician.
89441225|NCT03509844|Experimental|Prolonged Exposure|Psychotherapy: 10 weeks, Prolonged Exposure (individual sessions) according to the manual developed by Foa et al., adapted for a residential care setting
89441226|NCT03509844|Experimental|STAIR|Psychotherapy: 10 weeks, Skills Training in Affect and Interpersonal Regulation (STAIR) (group sessions), according to the manual developed by Cloitre et al., adapted for a residential care setting
88925190|NCT05802355|Experimental|control group|received 3sessions/ week for 12 consecutive weeks.
88925191|NCT05802342|Experimental|A|GM1 (100 mg) + albumin paclitaxel
88925192|NCT05802342|Experimental|B|GM1 (400 mg) + albumin paclitaxel
88925193|NCT05802342|Placebo Comparator|C|placebo + albumin paclitaxel
88925194|NCT05802329|Experimental|Cohort 1 (Low Dose)|3+3 participants will receive intravitreal injection of OCU200 low dose concentration.
88925195|NCT05802329|Experimental|Cohort 2 (Medium Dose)|3+3 participants will receive intravitreal injection of OCU200 medium dose concentration.
88925196|NCT05802329|Experimental|Cohort 3 (High Dose)|3+3 participants will receive intravitreal injection of OCU200 high dose concentration.
89199601|NCT05020327|Experimental|Low Risk Patients|This is the group of patients who will undergo the graded oral amoxicillin challenge testing. Total dose of the amoxicillin will be 45 mg/kg (maximum of 1000 mg). 10 % of this dose will be given first followed by 90 % of the dose 30 minutes after. Each dose will be given only once.
89441227|NCT03509844|Experimental|STAIR/NT|Psychotherapy: 16 weeks, 10 weeks Skills Training in Affect and Interpersonal Regulation (STAIR) (group sessions), followed by 6 weeks of Narrative Therapy (NT) (individual sessions), according to the manual developed by Cloitre et al., adapted for a residential care setting.
89441228|NCT03362216|Experimental|experimental group|Treated with Compound Methyl Salicylate Liniment group
89441229|NCT03362216|Active Comparator|Control group|Treated with Diclofenac Sodium Liniment group
89441230|NCT03365258|Other|High Nutritional Risk|modified NUTRIC score ≥ 5
89441231|NCT03365258|Other|Low Nutritional Risk|modified NUTRIC score < 5
89441232|NCT02303496|Experimental|PRP Cream Application|Application of Cream Containing Platelet Rich Plasma and Oleaginous Base
89441233|NCT02303496|Active Comparator|SW Cream Application - Placebo|Application of Cream Containing Sterile Water and Oleaginous Base
89441234|NCT03362138||Dermoscopy|Dermoscopic imaging of a lesion decided to be biopsied
89441235|NCT03507114|Experimental|Rumination-Focused CBT (RFCBT)|RFCBT seeks to change the process of thinking as opposed to the content of thoughts as in standard CBT. The underlying idea is that shifting individuals repetitive negative thinking into the concrete mode will reduce unconstructive ruminations and worries.
89441236|NCT03507114|No Intervention|Wait List Control Group|This arm represents the wait-list comparison group.
89441237|NCT03357848||Study group|Surgical patients receiving nutritional support (enteral and/or parenteral nutrition) pre and/or after surgery
89441238|NCT03357848||Control group|Surgical patients without nutritional support during the perioperative period
89441239|NCT03123536||Point-of-care ultrasound group|High risk patients received point-of-care ultrasound assessment perioperatively, treatment was oriented by the findings of point-of-care ultrasound.
89441240|NCT03123536||Control group|High risk patients received management by the experience of the clinical team.
89441241|NCT03504696||Patients with Advanced Melanoma|RIC-Mel patients with advanced (unresectable or metastatic) melanoma treated with nivolumab in the context of nivolumab ATU program (occurred from 12-Sep-2014 to 31-Aug-2015)
89441242|NCT03357770|Experimental|low dose of mesenchymal stem cells|Three groups of patients were enrolled in this study. Every group includes three patients. The three groups of patients were treated with high, medium and low dose of cytokine.The low-dose is 1 × 10^7cells / 3mL
89441243|NCT03357770|Experimental|medium dose of mesenchymal stem cells|the medium-dose is 5 × 10^7cells / 3mL
89441244|NCT03357770|Experimental|high dose of mesenchymal stem cells|the high dose is 1 × 10^8cells / 3mL
89441245|NCT02307240|Experimental|CUDC-907 - five days on/two days off|60 mg/day CUDC-907, oral administration, five days on/two days off until disease progression or other discontinuation criteria are met.
89441246|NCT03365180|Experimental|The Starter Kit Algorithm|Basal insulin initiation and titration using the Starter Kit Algorithm at two weeks, followed by standard of care titration during the following the next 10 weeks (maximum), or until optimal daily dose is considered identified.
89441247|NCT02307396|Experimental|Intervention|"Intervention group: guided discontinuation or dose-reduction of the current antipsychotic medication. The antipsychotic drug used before study start will be discontinued gradually under medical surveillance. The process of discontinuation depends on the physicians judgement und should be guided be the participants needs and clinical status. This approach was already used before in another study (gradual discontinuation, Wunderink et al., 2007). We assume that the dose can be reduced by approximately 1/6 of the starting dose every two weeks. If long acting antipsychotics are applied, there is no need for a gradual discontinuation due to their long half life."
89441248|NCT02307396|Active Comparator|Control|The participants receive the same antipsychotic drugs, they have received before the start of the study, without changing the dose or the application form. Study medication is, with exception of Clozapin, every oral or depot neuroleptic drug approved for the treatment of schizophrenia in Germany.
89441249|NCT03357692|Experimental|maxillary total edentulism|all on four implant rehabilitation with trans-sinusal implants
89441250|NCT04523636|Active Comparator|Custom Splint|Custom Splint- Thermoplastic device fabricated by occupational therapist
89441251|NCT04523636|Active Comparator|Prefabricated Splint|Prefabricated Splint- Commercially available from Restorative Care of America, Inc (RCAI)
89441252|NCT03509688|Experimental|entecavir|drug:entecavir 0.5mg/day, one time/day,144weeks
89441253|NCT03509688|Experimental|entecavir+resveratrol|entecavir 0.5mg/day, 144weeks intervention:resveratrol 1000mg/day, 48weeks
89441254|NCT03509688|Experimental|entecavir+thymosin α1|entecavir 0.5mg/day, 144weeks thymosin α1 2 times/week, 24weeks
89441255|NCT03365024|Experimental|Computerized Intervention 1|A web-based program will deliver components of CBT-I on a time and event-based schedule. Pre and Post-Intervention assessments will be administered to determine the efficacy of the intervention.
89441256|NCT03365024|Active Comparator|Computerized Intervention 2|A web-based program will deliver components of sleep education via an Internet platform. Pre and Post-Intervention assessments will be administered to determine the efficacy of the intervention.
88925197|NCT05802329|Experimental|Cohort 4 (High Dose/MTD + Lucentis)|3 + 3 additional participants will be enrolled to receive OCU200 (High Dose or MTD) + Lucentis (in a sequential manner on dosing dates).
88925198|NCT05802316||awake|awake tracheal intubation
88925199|NCT05802316||asleep|standard intubation videolaryngoscopy (VL) and direct laryngoscopy (DL)
89441257|NCT02307474|Experimental|Treatment (Stereotactic Radiosurgery, pazopanib hydrochloride)|Patients receive pazopanib hydrochloride PO daily for up to 60 days. Patients then continue to receive pazopanib hydrochloride PO daily and undergo stereotactic radiosurgery (SBRT) every other day over days 60-65.
89441258|NCT02518880|Other|Plasma volume measurements|
89441259|NCT03504618||Metastatic colon cancer patients|Colon cancer patients with metastase at the diagnostic time, impossibility of radical resection, adenocarcinoma, treated by at least 3 cycles of FOLFOXIRI in the first-line in the Oncology and Palliative Care Department
89441260|NCT02518412|Experimental|Active tDCS|Participants receive active tDCS stimulation. Half of the participants receive active tDCS stimulation, i.e 30 minutes active stimulation of the temporal cortex.
89441261|NCT02518412|Placebo Comparator|Placebo tDCS|Participants receive placebo tDCS stimulation. Half of the participants receive placebo tDCS stimulation, i.e 30 minutes inactive stimulation of the temporal cortex.
89441262|NCT03357458|Experimental|Family Integrated Care|Study participants receive FICare, a dynamic psycho-educational intervention, while their infant(s) was/were admitted to a Level II NICU.
89441263|NCT03357458|No Intervention|FICare Control Group|Study participants received standard care while their infant(s) was/were admitted to a Level II NICU.
88925202|NCT05802290|Experimental|nivolumab|nivolumab monotherapy at 240mg flat dose as a 30-minute IV infusion on Day 1 of a treatment cycle every 2 weeks (14 days) until confirmed progression of disease, unacceptable toxicity, death or withdrawal of consent
88925203|NCT05802212|Experimental|Metformin intervention for 12 weeks|Metformin intervention for 12 weeks
88925204|NCT05802160|Experimental|Good Start Matters Parenting intervention|The intervention group will receive immediate access to the app where the Good Start Matters - Parenting intervention will be delivered over a 2-months period.
88925205|NCT05802160|No Intervention|Control|The control group will not receive access to the intervention until they complete the follow-up measures (after 10 weeks).
88925206|NCT05802147|Experimental|Early Skin to Skin Contact Group|Women who met the criteria for inclusion in the study and accepted the study (n:180) were told how to apply skin-to-skin contact. Skin-to-skin contact was initiated within the first minutes of normal delivery and skin-to-skin contact was applied to the mothers for a minimum of 15 minutes (due to the high number and frequency of births in the TDL service and hospital conditions). Routine newborn care procedures (eye drops, vaccination, footprints, etc.) performed in the delivery room were performed during skin-to-skin contact. After the skin-to-skin contact between the mother and the newborn was terminated at the end of delivery, 2 hours later, mothers were asked to fill in a personal questionnaire and a traumatic birth scale. The maternal attachment scale was completed 1 month after birth by telephone interview.
89441264|NCT02303730|Experimental|Exenatide|Exenatide 5 ug twice daily 1 hour before meal subcutaneously for 4 weeks, then add to 10 ug twice daily 1 hour before meal subcutaneously for another 20 weeks
89441265|NCT02303730|Active Comparator|Insulin glargine|Insulin glargine subcutaneously, once daily, for 24 weeks
89441266|NCT04524728||Cohort A|Patients that received palbociclib combined with letrozole 2.5 mg
89441267|NCT04524728||Cohort B|Patients that received palbociclib combined with fulvestrant 500 mg
89441268|NCT04523792|Experimental|Opioid withdrawal patients|Subjects with opioid use disorder seeking treatment and/or experiencing symptoms of opioid withdrawal receive acute administration of SUBOXONE sublingual film followed by SUBLOCADE administration in the 1) ED, 2) Clinical Decision Unit or 3) Inpatient unit combined with 6 months of treatment with SUBLOCADE in the outpatient treatment clinic.
88925207|NCT05802147|No Intervention|Control Group|Standard midwifery practices and labor follow-up were applied to women who met the inclusion criteria in the hospital (during the delivery room) (n: 187), agreed to participate in the study, and were in the control group. Neonatal routine care procedures (vaccine, footprint, eye drop application, etc.) of the postpartum hospital were performed. Then, after 2 hours postpartum, mothers were asked to fill in a personal questionnaire and a traumatic birth scale. The maternal attachment scale was completed 1 month after birth by telephone interview.
88925209|NCT05802121|Experimental|Apple Cider Vinegar|Webbers Natural apple cider vinegar pills (NPN: 80021269), enteric coated. Each patient will be instructed to take 6 enteric slow-release acetate capsules (equivalent of 500 mg/ capsule containing 25 mg acetate x 6 capsules) per day for 3 months.
88925210|NCT05802121|Placebo Comparator|Placebo|Placebo pills will be provided by our hospital pharmacy, and patients will be given the same instructions as in the treatment arm.
88925211|NCT05802108|Experimental|Experimental Group|evolocumab combined with statins
88925212|NCT05802108|Other|Control Group|statins only
88925213|NCT05802082||Group P: n: 32patients|Group P: Patients administered iv 10mg/kg paracetamol 30 minutes before surgery
88925214|NCT05802082||Group K:n:32 patients|Group K: Patients administered iv 10mg/kg paracetamol 15 minutes before the end of surgery
88925215|NCT05802043|Experimental|Cognitive Stimulating Interventions|The study interventions will be developed by the researchers based on review of the related literature and with reference to the CST manual (Spector, et al., 2006), and review on Cognitive Stimulation (Woods et al., 2012). The study subjects of group 1, the study group, will receive the proposed interventions, the cognitive stimulation interventions through small groups of study subjects receiving 12 sessions of group activities (2 sessions/week, approximately 45- 60 minutes/session). A group size of 6 to 8 will be conducted. The interventions group will be conducted in activity rooms within the elderl club. The study subjects group 2, the control group, will receive the routine activities of the elderly club. The researchers will provide the control group with written materials related the essential cognitive stimulation interventions after ending the implementation of the proposed interventions for the study group.
88925216|NCT05802043|Active Comparator|Routine Club care|The study subjects group 2, the control group, will receive the routine activities of the elderly club.The researchers will provide the control group with written materials related the essential cognitive stimulation interventions after ending the implementation of the proposed interventions for the study group,
88925217|NCT05802017|Experimental|Allergen-specific substitute diet|Participants follow a 4-month allergen-specific diet according to their immunology results.
89441269|NCT02303808|No Intervention|USUAL CARE|Patients will perform the inhalation of the 7% hypertonic saline (following the gold standard recomendation) during 15 minutes. Right after, patients will perform independently their usual session of autogenic drainage during 30 minutes.
88925218|NCT05802017|No Intervention|Healthy diet|Participants follow a 4-month standard healthy diet.
88925219|NCT05801991|Experimental|Neurolens Treatment|Participants will receive Neurolens lenses (measured with the Neurolens device while wearing their habitual contact lenses) in their study spectacles
88925220|NCT05801991|Placebo Comparator|Placebo Lens|Participants will receive plano (no power) lenses in their study spectacles
89012715|NCT01686724|Experimental|Collaborative Life Skills Intervention (CLS)|CLS is a 12-week program and includes school, parent, and student components which are integrated via joint teacher, parent, and student meetings and use of integrated behavioral programs in the classroom, on the playground, and at home.
89441270|NCT02303808|Active Comparator|INHALATION WITH PEP DEVICE|Patients will perform the inhalation of the 7% hypertonic saline (following the gold standard recomendation) combined with a PEP device (Acapella Duet) during 15 minutes. Right after, patients will perform independently their usual session of autogenic drainage during 30 minutes.
89441271|NCT03364946||High Nasal Flow Therapy|Every patient in the ICU that requires High Nasal Flow Therapy
89441272|NCT02312232|Experimental|Levodopa formulation A|Levodopa formulation A together with ODM-104 100 mg and carbidopa
89441273|NCT02312232|Experimental|levodopa formulation B|levodopa formulation B together with ODM-104 100 mg and carbidopa
89012716|NCT01686763||subarachnoid hemorrhage disease|subarachnoid hemorrhage patients
89441274|NCT02312232|Experimental|levodopa formulation C|levodopa formulation C together with ODM-104 100 mg and carbidopa
89441275|NCT02312232|Active Comparator|Sinemet IR 100/25 mg|Sinemet IR 100/25 mg together with ODM-104 100 mg
89199602|NCT05020327|Other|No Risk Patients|Patients in the group will be de-labeled in the electronic medical record for No Risk for allergic reaction to amoxicillin based on screening questionnaire.
89441276|NCT02312232|Active Comparator|Half Sinemet CR 100/25 mg|Half Sinemet CR 100/25 mg together with ODM-104 100 mg
89441277|NCT04524884|Experimental|Cohort A|Surufatinib 250mg will be taken orally once daily continuously through a 21-day cycle of study treatment. Toripalimab 240mg will be intravenously administered on Day 1 of each cycle. After neoadjuvant Toripalimab and Surufatinib treatment, the patients will receive operation treatment if the tumor is evaluated as resectable cases by clinical examination.
89441278|NCT04524884|Experimental|Cohort B|Surufatinib 250mg will be taken orally once daily continuously through a 21-day cycle of study treatment. Toripalimab 240mg will be intravenously administered on Day 1 of each cycle. After neoadjuvant Toripalimab and Surufatinib treatment, the patients will receive further drug reatment, if the tumor is evaluated as unresectable cases and patients have potential benefits by clinical examination.
89441279|NCT04524884|Experimental|Cohort C|Surufatinib 250mg will be taken orally once daily continuously through a 21-day cycle of study treatment. Toripalimab 240mg will be intravenously administered on Day 1 of each cycle. After neoadjuvant Toripalimab and Surufatinib treatment, the patients will be removed from the study, if the tumor is evaluated as unresectable cases and patients have no potential benefits by clinical examination.
89441280|NCT03509610|Active Comparator|CONTROL|Diet consisting of 50% carbohydrate (20% sugar), 15% protein, 35% fat
89441281|NCT03509610|Experimental|LOW SUG|Diet consisting of 50% carbohydrate (<5% sugar), 15% protein, 35% fat
89441282|NCT03509610|Experimental|LOW CHO|Diet consisting of <8% carbohydrate (<5% sugar), 15% protein, >77% fat
89441283|NCT02307708|Experimental|8° incline shoe|"The shoe is inclined from front to back and from top to bottom of 8 °. This causes a controlled and an eccentric contraction during the passage.~During the walk we will have:~In support tardigrade : an ankle dorsiflexion with a stretching the Achilles tendon (eccentric contractions).~In support digitigrade: plantar flexion of ankle with a muscle contraction of triceps surae (concentric contraction)."
89441284|NCT02307708|Active Comparator|kinesitherapy|The patient performs its home therapy and consults his physiotherapist once a week according to the protocol Stanish
89441285|NCT04521530|Experimental|immediate functional loading with temporary crowns|patients were rehabilitated with immediate functionally loaded implants.
89441286|NCT04521530|Experimental|immediate non functional loading with temporary crowns|patients were rehabilitated with immediate non-functionally loaded implants.
89441287|NCT03506958||General Practice|Hundred patients with an X-ray confirmed diagnosis of a non-complex fracture or dislocation and planned to be treated in the general practice Zorgplein Lemmer.
89441288|NCT03506958||Hospital|Hundred patients with an X-ray confirmed diagnosis of a non-complex fracture or dislocation and planned to be treated in the Antonius Hospital Sneek.
89441289|NCT04521452|Experimental|Evogliptin Group|evogliptin 5mg daily
89441290|NCT04521452|No Intervention|Non-evogliptin Group|DM medications except evogliptin and other DPP-4 inhibitors
89441291|NCT03504540||Case (with pseudo-drusen-like deposits)|"Patients with lupus, treated or not with antimalarial drugs, with pseudo-drusen-like deposits"
89441292|NCT03504540||Control (without pseudo-drusen-like deposits)|"Patients with lupus, treated or not with antimalarial drugs, without pseudo-drusen-like deposits"
89441293|NCT03361670||Specimens that meet inclusion criteria|
89441294|NCT03364790|Experimental|group1|participant with posterior lumbar interbody fusion(PLIF or PLF)
89441295|NCT03364790|Experimental|group2|participant with total knee arthroplasty (TKA)
89441296|NCT03364790|Experimental|group3|participant with PLIF and TKA on one stage
89441297|NCT03364790|No Intervention|group4|participant without operation
89441298|NCT03504462|Experimental|Distal tibial nerve block|Patient receiving a specific block of medial and lateral plantar nerves in order to preserve the calcaneal nerve
89441299|NCT02303886|Active Comparator|A Methylene blue 10 mg/ml 2mg/kg|ten patients that recieved MB1 methylene blue 2 mg/kg infusion under 60 min
89441300|NCT02303886|Placebo Comparator|B Methylene blue 10 mg/ml 0.02 mg/kg|Same patients received MB2 Methylene blue 0.02 mg/kg infusion under 60 min
89441301|NCT02518958|Experimental|RRx-001 + Nivolumab|Patients enrolled in this trial will receive study drug (RRx-001) on Day 1 as a single agent. Nivolumab (3 mg/kg) will be administered on Day 2 or Day 3 as a single agent.
89441302|NCT03506802|Experimental|Treatment (Genetically engineered PBMC and PBSC)|Refer to outline
89441303|NCT02518724|Active Comparator|RIPC intervention group|"The experiment protocol consist 2 series (with a month between them), both series include the described 3 days:~Day 1 - anthropometry measurements and VO2max test (BRUCE protocol). Day 2 - steps test (heled protocol). Day 3 - anaerobic test (wingate protocol), 1 hour rest and time to exhaustion test (heled protocol).~the second series will be performed after RIPC intervention exposure at the beginning of every meeting."
89441304|NCT02518724|Placebo Comparator|false exopsure group|"The experiment protocol consist 2 series (with a month between them), both series include the described 3 days:~Day 1 - anthropometry measurements and VO2max test (BRUCE protocol). Day 2 - steps test (heled protocol). Day 3 - anaerobic test (wingate protocol), 1 hour rest and time to exhaustion test (heled protocol).~the second series will be performed after placebo intervention exposure at the beginning of every meeting."
89441305|NCT03364712||pregnant|Pregnant women receiving routine medical care, including venipuncture.
89441306|NCT03364712||non-pregnant|Women not pregnant receiving routine medical care, including venipuncture.
89441307|NCT02307786||Beta-Thalassemiall -Transplantation|
89441308|NCT02307786||Beta-Thalassemia Supportive Care|
89441309|NCT03509454||Type 1 DM, Normo albuminuric|Type 1 diabetics with no history of albumnuria (UACR < 30 mg/g in 2 out of 3 consecutive samples)
89441310|NCT03509454||Type 1 DM, Micro albuminuric|Type 1 diabetics with history of micro albumnuria (UACR 30-299 mg/g in 2 out of 3 consecutive samples)
89441311|NCT03509454||Type 1 DM, Macro albuminuric|Type 1 diabetics with history of macro albumnuria (UACR 30-299 mg/g in 2 out of 3 consecutive samples)
88925221|NCT05801952|Experimental|Aerobika OPEP Therapy|Bronchial drainage session with the Aerobika OPEP device consist of breathing through the device for 15 breaths in one cycle, and taking a few (3-5) relaxed exhalations in accordance with the forced exhalation technique. This cycle is repeated at least three times. The maximum number of cycles is five considering the need. The size of the applied expiratory resistance is selected individually. The pressure is 5 - 20 cm H2O and the oscillation frequency is up to about 15 Hz. Duration of the session: 10 - 20 min. Duration of the program: 4 days. Frequency: twice a day.
88925222|NCT05801952|Experimental|Flutter O-PEP Therapy|Bronchial drainage session with the Flutter O-PEP device consist of breathing through the device for 15 breaths in one cycle, and taking a few (3-5) relaxed exhalations in accordance with the forced exhalation technique. This cycle is repeated at least three times. The maximum number of cycles is five considering the need. The size of the applied expiratory resistance is selected individually. The pressure is 5 - 20 cm H2O and the oscillation frequency is up to about 15 Hz. Duration of the session: 10 - 20 min. Duration of the program: 4 days. Frequency: twice a day.
89199603|NCT05020327|Other|High Risk|Patients in this group are deemed high risk for allergic reaction to penicillin based on screening questionnaire and will remain labeled with allergy in the electronic medical record. They will be referred as outpatient to allergy-immunology for further evaluation.
89441312|NCT03509454||Healthy subjects|Subjects with no history of diabetes, other diseases or intake of medicine which in the judgement of the investigator could affect the results, specifically renal, cardiovascular or inflammatory/infectious diseases should be considered for exclusion.
89441313|NCT03361592|Experimental|Spinal Manipulative Therapy|The participants assigned to the intervention group received the procedure Lumbar (SMT) was performed after baseline measurements, using Diversified techniques, aiming to correct vertebral dysfunctional segments after clinical assessment. Participants were asked to lay down prone on, to perform spinal motion palpation analysis was performed in order to evaluate the presence of dysfunction in vertebral segments of lumbar spine.
89441314|NCT03361592|Sham Comparator|Sham pre-load positioning SMT|"The participants assigned to the control group received the procedure Sham (pre-load positioning MVT). The Sham (SMT) was performed with participant body positioning in the lateral position, as the SMT intervention. The doctor followed the participant through the same position of (SMT) intervention, using the maintenance of set-up position, but no manipulative thrust was delivered. The therapist applied minimal pressure and slid their hands across the skin to mimic the manipulative trust. The position was maintained for approximately 1 minute in total, 30 seconds on each side, and none of force or researcher body weight were putted in this procedure, only minimal pressure common to stabilize the set up position of (SMT)."
89441315|NCT03361514|Active Comparator|Supported Protocolized Discontinuation|Supported Protocolized Discontinuation (SPD) Patients will receive guidance of their GP and can have supportive meetings with the mental health assistant.
89441316|NCT03361514|Experimental|SPD + Mindfulness (MBCT)|In addition to the SPD (as mentioned above) patients are offered Mindfulness Based Cognitive Therapy (MBCT)
89441317|NCT02307864|Experimental|Treatment Sequence 1|Participants will receive treatment A (2*50 milligram [mg] tramadol hydrochloride [HCl] immediate release [IR] tablet + 1 tramadol HCl placebo every 6 hours on Days 1, 2, and 3, along with single dose of 2*50 mg tramadol HCl IR tablet + 1 tramadol HCl placebo + 1 moxifloxacin placebo on Day 4); treatment B (3*50 mg tramadol HCl IR tablet every 6 hours on Days 1, 2, and 3, along with single dose of 3*50 mg tramadol HCl IR tablet + 1 moxifloxacin placebo on Day 4); treatment C (3 tramadol HCl placebo every 6 hours on Days 1, 2, and 3, along with single dose of 3 tramadol HCl placebo + 1 moxifloxacin placebo on Day 4); and treatment D (3 tramadol HCl placebo every 6 hours on Days 1, 2, and 3, along with single dose of 3 tramadol HCl placebo + 1 moxifloxacin placebo on Day 4) in 4 treatment periods as per protocol defined sequence. A washout period of 7 to 15 days will be maintained between each treatment period.
89441318|NCT02307864|Experimental|Treatment Sequence 2|Participants will receive treatment A; treatment B; treatment C; and treatment D in 4 treatment periods as per protocol defined sequence. A washout period of 7 to 15 days will be maintained between each treatment period.
89441319|NCT02307864|Experimental|Treatment Sequence 3|Participants will receive treatment A; treatment B; treatment C; and treatment D in 4 treatment periods as per protocol defined sequence. A washout period of 7 to 15 days will be maintained between each treatment period.
89441320|NCT02307864|Experimental|Treatment Sequence 4|Participants will receive treatment A; treatment B; treatment C; and treatment D in 4 treatment periods as per protocol defined sequence. A washout period of 7 to 15 days will be maintained between each treatment period.
89441321|NCT03509376|Experimental|Suture repair|Diastasis recti is repaired using nylon suture for the plication
89441322|NCT03509376|Experimental|Rolled mesh repair|Diastasis recti is repaired with self gripping mesh to reinforce the suture line
89441323|NCT04444778|Active Comparator|Continuous positive airway pressure|Diet and general life style recommendations plus continuous positive airway pressure (CPAP).
89441324|NCT04444778|No Intervention|Conservative treatment|Diet and general life style recommendations.
89441325|NCT03504150|Experimental|SPHERE|It is an online self-guided comprehensive cognitive-behavioural therapy program that offers a headache diary, learning modules that teach a variety of cognitive and behavioural skills to cope better with their headaches, and a discussion forum where users may interact.
89441326|NCT03504150|Experimental|PRISM|It is an online self-guided brief cognitive-behavioural therapy program that offers a headache diary and helps users discover their headache triggers and non-triggers. Then the program provides the users with a few personalized recommendations to help them to cope with their triggers.
89441327|NCT03504150|No Intervention|Usual care|
89441328|NCT03364478|Experimental|DML group|The group underwent laparoscopic right hemicolectomy with dorsal and medial hybrid approach. In DML group, the dissecting based on CME is performed with dorsal approach and medial approach hybridized.
89441329|NCT03364478|Active Comparator|MLA group|The group underwent laparoscopic right hemicolectomy with traditional medial-to-lateral approach. In MLA group,the dissecting based on CME is performed with meidial-to-lateral approach.
88925223|NCT05801952|Experimental|PEP Therapy|Bronchial drainage session with the PEP device consist of breathing through the device for 15 breaths in one cycle, and taking a few (3-5) relaxed exhalations in accordance with the forced exhalation technique. This cycle is repeated at least three times. The maximum number of cycles is five considering the need. The size of the applied expiratory resistance is selected individually. The pressure is 10-20 cmH2O during exhalation. Duration of the session: 10 - 20 min. Duration of the program: 4 days. Frequency: twice a day.
88925224|NCT05801926|Experimental|Immediate assignment|Within this block, half are assigned to receive the sensor right away.
88925225|NCT05801926|Active Comparator|Delayed assignment|Within this block, half are assigned to receive the sensor after a delay of 3 to 4 weeks
88925226|NCT05801900|Active Comparator|Ketorolac group|ketorolac 30 mg (diluted in 200 mL normal saline) intravenously over 5 minutes
88925227|NCT05801900|Active Comparator|Ibuprofen group|ibuprofen 800 mg intravenously (Diluted in 200 mL of normal saline) over 5 minutes
88925228|NCT05801887|Experimental|Shockwave treated group|The osteoblast like cells are treated with shockwaves
88925229|NCT05801887|Placebo Comparator|No shockwave group|The osteoblast like cells are not exposed to shockwaves
88925230|NCT05801874||Hemiparetic patients|Hemiparetic patients assessed during gait and stance performance by means of different instrumental tools (smart and portable device vs 3D laboratory gait analysis) in order to evidence gait pattern; kinematics, kinetics and spatio-temporal data.
88925231|NCT05801874||Healthy age matched subjects|Healthy age matched subjects assessed during gait and stance performance by means of different instrumental tools (smart and portable device vs 3D laboratory gait analysis) in order to evidence gait pattern; kinematics, kinetics and spatio-temporal data.
88925232|NCT05801848||Chronic lower back pain patients|Patients with chronic lower back pain where the source could not be identified on MRI scans
88925233|NCT05801848||Age matched healthy controls|Healthy individuals without any previously known pain or intervention on lower back
88925234|NCT05801783|Experimental|R130 Treatment Group|Every 7-14 days,1-4 ml R130 （concentration of 1x10^6-1x10^8 plaque-forming Units/mL,PFU/mL）will be injected intratumoral or Intraperitioneal in patients with relapsed/refractory ovarian cancer.
88925235|NCT05801744|Experimental|Reciprocal inhibition up conditioning|Each participant completes 6 baseline sessions and 30 up conditioning sessions. In the 30 conditioning sessions, the magnitude of reciprocal inhibition in the paretic leg of participants post-stroke will be up conditioned.
88925236|NCT05801731|Experimental|Experimental|Low-GI snack, administered at 10.00 and 16.00 during the test days
88925237|NCT05801731|Active Comparator|Control|Normal GI snack, administered at 10.00 and 16.00 during the test days
89441330|NCT02303964|Active Comparator|Type A Thawed Plasma|"Eligible subjects with polytrauma (PT) and major hemorrhage (MH) will be randomized to receive 2 units of thawed Type A plasma in the pre-hospital setting administered by EMS first responders.~An exception from informed consent under 21CFR 50.24 is required since enrollment will occur (for the majority of subjects) before consent can be obtained."
89441331|NCT02303964|Placebo Comparator|Normal saline|Eligible subjects with polytrauma (PT) and major hemorrhage (MH) will be randomized to receive normal saline in the pre-hospital setting administered by EMS first responders. Normal saline is standard of care
89441332|NCT04520984|Experimental|Arm 1|Intervention
89441333|NCT04520984|Other|Arm 2|Standard Care
89441334|NCT02304042|Active Comparator|Carbetocin|125 women will receive carbetocin after delivery of the anterior shoulder. The drug will be diluted in 10ml saline and will be given by the slowly intravenously after delivery of the anterior shoulder
89441335|NCT02304042|Active Comparator|Oxytocin|125 women will receive carbetocin oxytocin after delivery of the anterior shoulder. The drug will be diluted in 10ml saline and will be given by the slowly intravenously after delivery of the anterior shoulder
88925238|NCT05801718||chronic cardiac patients|patients with chronic cardiac diseases affecting their groth parameters & body mass index
88925239|NCT05801718||chronic renal patients|patients with chronic renal diseases affecting their growth parameters & body mass index
88925240|NCT05801718||chronic respiratory diseases|patients with chronic respiratory diseases affecting their growth parameters & body mass index
88925241|NCT05801718||chronic metabolic diseases|patients with chronic metabolic diseases affecting their growth parameters & body mass index
88925242|NCT05801718||chronic neurological diseases|patients with chronic neurological diseases affecting their growth parameters & body mass index
88925243|NCT05801718||chronic haematological diseases|patients with chronic haematological diseases affecting their growth parameters & body mass index
88925244|NCT05801718||chronic gastro-intestinal diseases|patients with chronic gastro-intestinal diseases affecting their growth parameters & body mass index
89199604|NCT04994704|Experimental|Propofol group|Propofol based total intravenous anesthesia
89441336|NCT04521218|Experimental|Thrust joint Manipulation|Thrust joint Manipulation, heat application, Strengthening exercise and home plan
89441337|NCT04521218|Active Comparator|Reverse Sustained Natural apophyseal glides|Reverse Sustained Natural apophyseal glides (SNAG), heat application, Strengthening exercise and home plan.
88925245|NCT05801640|Experimental|Faciliated tucking position|Experiment group will receive faciliated tucking position throughout the OG inserting. The faciliated tucking position will be applied 3 minutes before the orogastric (OG) tube is inserted. This intervention will be applied throughout the OG inserting process. The application will continue for 3 more minutes after the OG is inserted.
88925246|NCT05801640|Experimental|Reiki|Experiment group will receive reiki throughout the OG inserting. This group will be take reiki 3 minutes before the orogastric (OG) tube is inserted. This intervention will be applied throughout the OG inserting process. The intervention will continue for 3 more minutes after the OG is inserted.
88925247|NCT05801640|No Intervention|Control Group|The routine OG insertion procedure of the clinic will be performed for the control group infants without any intervention. The group will received no further intervention.
88925248|NCT05801627|Experimental|SAL067|SAL067 12mg once daily
88925249|NCT05801627|Placebo Comparator|Placebo|placebo once daily
88925250|NCT05801588|Experimental|T'ai Chi and Qigong Rehabilitation|T'ai chi/Qigong is a multidimensional (mind, body, and spirit integrative) and multimodal (strength, flexibility, balance, posture, and light to moderate aerobic) form of exercise that is safe for persons of all ages and physical abilities. The 12-week, twice-per-week t'ai chi and qigong gentle movement and meditation program proposed to be studied is adapted from the WaQi program, a curriculum developed by Master Yang Yang, PhD. The practice is gentle yet powerful, aiming to relieve and prevent back, neck, and hip pain. It has an online teaching module and is uniquely suited for our study population. The program requires no difficult movement transitions, but still contains all essential parts including meditation. The WaQi program has less psychological stress and physical challenge than other exercise activities because it can be performed either sitting, standing, and lying down.
88925251|NCT05801588|Active Comparator|Usual care|The control arm will receive the same 12-week, twice-per-week t'ai chi and qigong gentle movement and meditation, online live T'ai Chi and Qigong teaching module from Jan. 26, 2023 to April 17, 2023.
88925252|NCT05801575|Experimental|Chinese Herbal Medicine (CHM) teabag, Cluster 1|Intervention Cluster 1 is the first intervention arm designed to examine the efficacy and safety of CHM teabag in decreasing stroke risk by machine-learning-based retinal image analysis in elderly population. It will receive 16 weeks of the intervention.
89199605|NCT04994704|Active Comparator|Remimazolam group|Remimazolam based total intravenous anesthesia
89441338|NCT02307942|Experimental|SURGERY|Patient will be operated for a gastric banding disposal
89441339|NCT02307942|No Intervention|STANDARD|Standard of care for obesity
89441340|NCT03364322||Dry eye syndrome|
89441341|NCT02308098|Experimental|Budesonide/formoterol Easyhaler 320/9 ug/inhalation 4 inh|Budesonide/formoterol Easyhaler 320/9 ug/inhalation 4 inh Placebo Symbicort Turbuhaler 320/9 ug/inhalation 4 inh
89441342|NCT02308098|Experimental|Budesonide/formoterol Easyhaler 320/9 ug/inhalation 1 inh|Budesonide/formoterol Easyhaler 320/9 ug/inhalation 1 inh Placebo Symbicort Turbuhaler 320/9 ug/inhalation 1 inh
89441343|NCT02308098|Experimental|Symbicort Turbuhaler 320/9 ug/inhalation 4 inh|Symbicort Turbuhaler 320/9 ug/inhalation 4 inh Placebo Budesonide/formoterol Easyhaler 320/9 ug/inhalation 4 inh
89441344|NCT02308098|Experimental|Symbicort Turbuhaler 320/9 ug/inhalation 1 inh|Symbicort Turbuhaler 320/9 ug/inhalation 1 inh Placebo Budesonide/formoterol Easyhaler 320/9 ug/inhalation 1 inh
88925253|NCT05801575|Experimental|CHM teabag, Cluster 2|Intervention Cluster 2 is the second intervention arm designed to examine the efficacy and safety of CHM teabag in decreasing stroke risk by machine-learning-based retinal image analysis in elderly population. It will receive 12 weeks of the intervention.
88925254|NCT05801575|Experimental|CHM teabag, Cluster 3|Intervention Cluster 3 is the third intervention arm designed to examine the efficacy and safety of CHM teabag in decreasing stroke risk by machine-learning-based retinal image analysis in elderly population. It will receive 8 weeks of the intervention.
88925255|NCT05801575|Experimental|CHM teabag, Cluster 4|Intervention Cluster 4 is the fourth intervention arm designed to examine the efficacy and safety of CHM teabag in decreasing stroke risk by machine-learning-based retinal image analysis in elderly population. It will receive 4 weeks of the intervention.
88925256|NCT05801536|Experimental|Upper limb task practice with or without cervical transcutaneous electrical stimulation|Task specific practice will be combined with cervical transcutaneous electrical stimulation.
88925257|NCT05801523|Active Comparator|laparoscopic ethanol sclerotherapy|
88925258|NCT05801523|Active Comparator|laparoscopic cystectomy|
88925259|NCT05801497||Balneotherapy Group|Patients will receive a cycle of BT or a cycle of mud-bath therapy once daily for 12 days for a total duration of two weeks, in addition to their usual treatments for fibromyalgia. The bath can be performed both in a bathube or in a pool for 10 minutes, at a 37-38°C. The application of mud will follow the standard procedure with a duration of 15-20 minutes at 40-45°C. After the treatment, patients will relax for 20-30°C minutes. To be included in the study, thermal interventions must be carried out with sulfourous, solfate, bicarbonate, saline or sodium chloride and arsenical-ferruginous mineral waters, according to the classification by Marotta and Sica.
88925260|NCT05801497||Control Group|This group will include patients who will refuse the thermal treatment for personal reasons. Patients will continue their established routinary care for FS. The treatment must be stable for at least 3 months; some variations in analgesic consumption will be possible and will be collected in the clinical chart.
88925261|NCT05801484|Experimental|Linezolid continuous infusion|In the intervention arm, Linezolid is administered 600 mg as loading dose as an infusion lasting one hour (flow rate 300 ml/h), followed by continuous infusion of 1200 mg linezolid over 24 hours (flow rate 25 ml/h) which is immediately initiated. The continuous infusion is administered until the end of the treatment.
88925262|NCT05801484|Active Comparator|Linezolid Intermittent administration|In the comparator arm, 600 mg dose of Linezolid is administered as one-hour infusion (flow rate 300 ml/h). Two doses at 12-h intervals are infused until the end of the treatment.
88925263|NCT05801458|Experimental|Modeling Resin Insertion Technique|Resin Composite (Tetric® N-Ceram Nano-hybrid incremental composite) / Wetting Agent (Modeling Resin, Bisco)
88925264|NCT05801458|Placebo Comparator|Conventional Resin Composite Incremental Placement Technique|Conventional resin composite incremental placement technique (Tetric® N-Ceram Nano-hybrid incremental composite)
88925265|NCT05801380||Alzheimer's disease patients with AChE inhibitor monotherapy|This cohort includes those with the disease and given AChE inhibitor monotherapy only
88925266|NCT05801380||Alzheimer's disease patients given AChE inhibitor and NMDA receptor anatgonist combination therapy|This cohort includes those with the disease, given AChE inhibitor and NMDA receptor antagonist combination therapy
88925267|NCT05801367|Active Comparator|Formocresol (Control-Gold standard-Group A)|Premade Formocresol (Tricresol & Formalin) will be used in this research. Composition was Tricresol 35%, Formaldehyde (40%) 19%, excipient additive 100% (PD, Switzerland, ISO9001/ISO9001_2000/ ISO13485/CE_MARK), (Universal Dental Pvt, Ltd)
88925268|NCT05801367|Experimental|Allium sativum oil (Experimental-Group B)|Premade Allium sativum oil (Garlic oil) (Mohammad and Baroudi, 2015b) will be used in this research (SAC group of companies-9001:2015 certified; Registration # PAK17.1724-U; NTN # 0299739-8, Karachi, Pakistan
88925269|NCT05801354|Active Comparator|Formocresol (Control-Gold standard-Group A)|Premade Formocresol (Tricresol & Formalin) was used composed of Tricresol 35%, Formaldehyde (40%) 19%, excipient additive 100% (PD, Switzerland, ISO9001/ISO9001_2000/ ISO13485/CE_MARK), (Universal Dental Pvt, Ltd).
88925270|NCT05801354|Experimental|Turmeric gel (Experimental-Group B)|Turmeric gel will be self-prepared at the Institute of Microbiology and Molecular Genetics, Punjab University, Lahore. 2kgs of Turmeric rhizomes were purchased from a local market in Lahore and verified by a taxonomist, Botany Department, Government College University, Lahore (voucher number: GC.Herb.Bot.3693). Approximately 170g powder along with 550ml distilled water will be taken in a Soxhlet extractor for 96 hours and then filtered repeatedly through Whatman No.1 filter paper. The obtained filtrate will then be mixed with 6% Sodium Carboxy-Methyl Cellulose (NaCMC) (Genevex Chem, Hyderabad, India) to form gel. Four Vitamin C grounded tablets (Wilson's Vitamin C, Wilson's Healthcare, Islamabad, Pakistan) and twelve Vitamin E capsules (Evion, Martin Dow pharmaceuticals, Ltd. Karachi, Pak) will then be added in 100g of gel as antioxidants.
88925271|NCT05801328|Experimental|Occlusal ending of wires|The wires will be bent occlusally for the interventional side
89012717|NCT01686802|Active Comparator|ibuprofen|ibuprofen 10 mg/kg (max 600 mg) every 6 hours as needed for pain (maximum 8 doses) from the time the patient is discharged from hospital as deemed by the physician to a maximum of 48 hours.
89012718|NCT01686802|Active Comparator|oral morphine|oral morphine 0.5 mg/kg (max 20 mg) every 6 hours as needed for pain (maximum 8 doses) from the time the patient is discharged from hospital as deemed by the physician to a maximum of 48 hours.
89012719|NCT01686880|Experimental|Preoperative aTARE|The patients in this arm will receive Sirsphere trans-arterial radioembolization before surgery
89012720|NCT00253721|Experimental|All subjects|
89012721|NCT01686919|Experimental|milk-free|morbidly obese patients with irritable bowel syndrome (IBS) eligible for gastric bypass surgery
89012722|NCT01686997|Active Comparator|Primairy long biliopancreatic limb RYGB|Roux limb 75 cm and Biliopancreatic Limb 150 cm
89012723|NCT01686997|Active Comparator|Redo Long biliopancreatic limb RYGB|Roux limb 75 cm and Biliopancreatic limb 150 cm
89012724|NCT01686997|Active Comparator|Primairy standard RYGB|Roux limb 150 cm and Biliopancreatic limb 75 cm
89441345|NCT03123302||Group 1|Epileptic patients who are sedated with a total dose of propofol 2 mg/kg and midazolam 0.1 mg/kg.
89441346|NCT03123302||Group 2|Epileptic patients who are sedated with a total dose of pentothal 4 mg/kg and midazolam 0.1 mg/kg.
89012725|NCT01686997|Active Comparator|Redo standard RYGB|Roux limb 150 cm and Biliopancreatic limb 75 cm
89012726|NCT01687075|Experimental|CR8|a drug eluting coronary device, made of Cobalt-Chromium alloy and integrally coated with i-Carbofilm™, loaded with formulated Sirolimus
89012727|NCT00281892|Experimental|Fludarabine plus Darbopoetin|Group 1 - Patients with an initial Hb-value of less than 12 g/dl receive fludarabine (30 mg/m² intravenously on day 1, 3, 5; repeated every 28 days for 6 cycles and 500 mcg of darbepoetin alfa subcutaneously every 3 weeks
89012728|NCT00281892|Active Comparator|fludarabine mono|"Group 1 - Patients with an initial Hb-value of less than 12 g/dl receive fludarabine (30 mg/m² intravenously on day 1, 3, 5; repeated every 28 days for 6 cycles with no additional growth factor support.~Group 2 - Patients with an initial Hb-value more than 12 g/dl start to receive fludarabine (30 mg/m² intravenously on day 1, 3, 5; repeated every 28 days for 6 cycles . Patients of group 2 will be eventually randomized at later timepoints, if the Hb-value drops below 12 g/dl. Randomized patients will receive either 500 mcg darbepoetin alfa subcutaneously every 3 weeks or continue therapy with fludarabine without additional administration of darbepoetin alfa."
89441347|NCT03123302||Group 3|Non-epileptic patients who are sedated with a total dose of propofol 1 mg/kg and ketamine 1 mg/kg.
89012729|NCT02274571|Experimental|Drug|TSEC (Duavee™, combination of CE and BZA)
89012730|NCT02274571|Placebo Comparator|Placebo|Non active comparator
89012731|NCT01687231|No Intervention|Neutropenic Diet|This arm is the control and subjects will receive the standard of care neutropenic diet.
89012732|NCT01687231|Experimental|Non-neutropenic Diet|This arm is interventional and subjects will receive a non-neutropenic diet without restriction.
89012733|NCT01687309|Other|Cohort A fed session|GSK2586184 800mg single dose with food
89012734|NCT01687309|Other|Cohort A fasted session|GSK2586184 single dose without food
89012735|NCT01687309|Active Comparator|Cohort B active study medication|GSK2586184 800mg single and twice daily dose for 13 days
89012736|NCT01687309|Placebo Comparator|Cohort B placebo|Placebo-to-match single and twice daily dose for 13 days
89012737|NCT01687348|Experimental|lidocaine|lidocaine traitment
89012738|NCT01687426|Active Comparator|Brimonidine Tartrate 0.025%|
89012739|NCT01687426|Placebo Comparator|Vehicle|
89012740|NCT04719689|Experimental|Dry needling|Dry needling, hot pack, stretching exercises.
89012741|NCT04719689|Experimental|Dry Cupping|Dry cupping, hot pack, stretching exercises.
89012742|NCT01687543|Experimental|Probiotics|Patients will be given a mixture of maltodextrin ( a starch product often used i alimentary products) and two strains of probiotic bacteria ( L. plantarum 299 and L. plantarum 299v ) dissolved in water through a nasogastric tube. Patients randomized 1:1 between groups
89012743|NCT01687543|Placebo Comparator|Control|Patients will be given only the dissolved maltodextrin in water through the nasogastric tube. Patients randomized 1:1 between groups
89012744|NCT00287898|Experimental|Telephone Genetic Counseling|Participants randomized to this arm will receive all genetic counseling via telephone.
89012745|NCT00287898|Active Comparator|Usual Care|Participants randomized to usual care will receive standard in-person genetic counseling.
89012746|NCT01687582|Experimental|GLP-1 analog|Liraglutide, 0.6 to 1.8 mg per day or Exenatide, 5 to 10 µg twice a day.
89012747|NCT01687621||Neonates, 1 to 10 days old|Neonates between day 1-10 of life presenting to hospitals and community health centers in Southern Province, Zambia, with no prior diagnosis of omphalitis, whose guardian, aged 15 and above, is willing to allow their newborn to participate in the study.
89012748|NCT01687660|Experimental|acupoint-meridian group|Apply traditional acupuncture to prevent the migraine attack according to TCM theory
89012749|NCT01687660|Other|sham-acupoint group|sham-acupoint will be penetrated for migraine prophylaxis.
89012750|NCT01687660|No Intervention|waiting list|No acupuncture nor other methods will be conducted in this group.
89012751|NCT01687699|Experimental|spironolactone|
89199606|NCT04990817|Experimental|Average American Diet With SoFAS Replaced With Avocado|Average American diet with foods that provide the equivalent of 1 medium to large avocado per day. It is anticipated that energy from avocado would replace 12-15% of daily energy, roughly half from solid fats and half from added sugars (SoFAS).
89441348|NCT03123302||Group 4|Non-epileptic patients who are sedated with a total dose of midazolame 0.1 mg/kg and ketamine 1 mg/kg.
89441349|NCT02308176|Experimental|intervention group|health advice and app installation in patient's mobile
89441350|NCT02308176|Placebo Comparator|control group|health advice
89441351|NCT03364166|Active Comparator|buccinator muscle excision with skin|surgical excision of the buccinator muscle with the skin in buccal squamous cell carcinoma and neck dissection also done
89537053|NCT03302039|Active Comparator|Variable infusion|Spinal anesthesia will be performed using intrathecal bupivacaine. Then, variable infusion phenylephrine will be administered at a starting dose of (0.75 mcg/Kg/min). the infusion will be titrated according to blood pressure.
89537054|NCT02467205|Other|Intervention|pedometer supported walking and education A ;pedometer will be given to each person in the intervention group at the first education session. Participants will be encouraged to use the pedometer for a 6 month period Educational component; participants will attend six weekly sessions in small groups of up to six people; the content of the sessions will be based on educational cognitive behavioural programme development, In addition, participants will receive education material in the first education session. The intervention group will receive two booster sessions, after 3 and 6 months.
89537055|NCT02467205|No Intervention|Control|participants randomly allocated to the comparison group will receive one education session (visit 2) regarding the importance of exercise and healthy diet and will be given education material similar to intervention group and encouraged to read it.
88925272|NCT05801328|No Intervention|Apical ending of wires|The wires will be bent apically for the control side.
88925273|NCT05801302|Experimental|Foam rolling (longer volume)|Participants will perform a single session with a longer foam rolling volume. The protocol will be 3 sets of 60 seconds, with between-sets intervals of 30 seconds and a standardized command to the participant to perform the highest pressure possible. The speed will be controlled through metronome (30 bpm). The foam rolling will be performed with the foam roller placed under the plantar flexors and Achilles tendon in a sitting position, with hands supported to the ground, keeping the body out of contact with the ground, with the unassessed leg crossed above the leg of interest. A standard device (smooth foam roller) with dimensions of 30 cm x 15 cm will be used.
88925274|NCT05801302|Active Comparator|Foam rolling (shorter volume)|Participants will perform a single session with a shorter foam rolling volume. The protocol will be 3 sets of 30 seconds, with between-sets intervals of 30 seconds and a standardized command to the participant to perform the highest pressure possible. The speed will be controlled through metronome (30 bpm). The foam rolling will be performed with the foam roller placed under the plantar flexors and Achilles tendon in a sitting position, with hands supported to the ground, keeping the body out of contact with the ground, with the unassessed leg crossed above the leg of interest. A standard device (smooth foam roller) with dimensions of 30 cm x 15 cm will be used.
88925275|NCT05801302|No Intervention|Control condition|Participants will remain in the intervention position (in a sitting position, with hands supported to the ground, with the unassessed leg crossed above the leg of interest) for 180 seconds (longer volume time), without the application of any intervention
88925276|NCT05801289|Active Comparator|Group Q|will receive 25 mg quetiapine at night of surgery and 25 mg daily for 7 days postoperative
88925277|NCT05801289|No Intervention|Group C|will receive placebo alone
88925278|NCT05801250|Experimental|AI platform|"All the patients in these group were asked to scan a QR code using smartphone to follow the WeChat public account.The WeChat public account can automatically push clear written instructions for bowel preparation. Including dietary advice ，how to consume the laxatives and remind patients to upload pictures.Patients will receive a reminder to upload stool images from the WeChat public account. After uploading their images, the patients received an evaluation result of pass or not pass .~For patients who received results of not pass, the system displayed tips instructing the patients to drink more water, or walk to improve the bowel preparation quality."
88925279|NCT05801250|No Intervention|Manual guidance|A leaflet with clear written instructions on how to consume the laxatives was given to patients in these group.
88925280|NCT05801185|Experimental|Unilateral lower limb suspension|Participants will perform a 5-day unloading intervention using the ULLS model. Short-length crutches, aided by handgrip and forearm support distal to the elbow will be used to assist in any upright or ambulatory activity. One foot (randomized in a counterbalance manner) will be equipped with a shoe having a 10-cm thick sole, which permits the unloaded limb to move passively about the hip joint while adopting a near straight position.
88925281|NCT05801107|Experimental|WX0593|60 mg of WX-0593 tablets, once daily for 7 days, followed by 180 mg of WX-0593 tablets, once daily in a 21-days cycle.
88925282|NCT05801094|Experimental|QL1604|
88925283|NCT05801068|Experimental|Periprocedural management of FXa-inhibitor group|Hold and resume factor Xa inhibitor during perioperative/periprocedural period according to predefined protocol.
88925284|NCT05801055|Experimental|Arm 1|Arm which will be randomised to get the combination drink prior to the diagnostic endoscopy
88925285|NCT05801055|No Intervention|Arm 2|Comparator arm where endoscopy will be done without any drink
88925286|NCT05801016|Other|Anorexia nervosa|Female anorexia nervosa patients
88925287|NCT05801016|Other|Healthy controls|Healthy female control participants
88925288|NCT05800977|Experimental|Prizloncabtagene Autoleucel|Prizlon-cel will be intravenously administered as a single infusion after lymphodepletion.
88925289|NCT05800912|Experimental|Narrative photography group|Students in the NP group performed training activities on empathy and care for patients undergoing heart transplantation.
89537056|NCT03301727|Active Comparator|In-person CBT-I Treatment|Participants receive 6 in-person weekly 1.5-hour sessions of cognitive-behavioural therapy for insomnia (CBT-I) for pregnant women, supervised by a registered, licensed clinical psychologist.
88925290|NCT05800912|Active Comparator|Traditional learning group|Students in the TL group performed a conventional intervention without real patients.
88925291|NCT05800899|Active Comparator|Brief Motivational Interviewing|
88925292|NCT05800899|Experimental|Culturally Adaptation Brief Motivational Interviewing|
88925293|NCT05800886|Experimental|Tea Group|At the 4th hour postoperatively, the patients in the tea group were first mobilized after drinking 200 ml of tea within 15 minutes. Patients were supported by the investigator for early mobilization from the 4th hour after surgery.
88925294|NCT05800886|Experimental|Coffee Group|At the 4th hour postoperatively, the patients in the tea group were first mobilized after drinking 200 ml of coffee within 15 minutes. Patients were supported by the investigator for early mobilization from the 4th hour after surgery.
88925295|NCT05800886|Experimental|Warm Water Group|At the 4th hour postoperatively, the patients in the tea group were first mobilized after drinking 200 ml of warm water within 15 minutes. Patients were supported by the investigator for early mobilization from the 4th hour after surgery.
88925296|NCT05800886|Active Comparator|Control Group|The first mobilization and oral intake of the patients in the control group started at the 8th hour. Control group didn't receive any intervention. Participants received usual care from health professionals.
88925297|NCT05800847|Placebo Comparator|Control|Patients in this arm will be receiving 100 mg placebo q8h for 2 days followed by 300 mg placebo q8h for 12 days. Patients will also receive 30 pills of hydrocodone-acetaminophen 5-325 mg q4-6h as needed.
88925298|NCT05800847|Experimental|Gabapentin|Patients in this arm will be receiving 100 mg gabapentin q8h for 2 days followed by 300 mg gabapentin q8h for 12 days. Patients will also receive 30 pills of hydrocodone-acetaminophen 5-325 mg q4-6h as needed.
88925299|NCT05800808|Experimental|High Intensity Exercise|Vigorous cycling
88925300|NCT05800808|Active Comparator|Continuous Moderate Exercise|Leisurely cycling
88925301|NCT05800795|Active Comparator|laser group|Healing abutments have been treated by Er:YAG laser. The laser-machine (with a wavelength of 2.940 nm) was used with settings of 100 mJ/pulse (12.7 J/cm₂) and 10 Hz. The healing abutments' surface was thoroughly decontaminated by the fiber tip in a semicircular contact mode with copious water irrigation.
88925302|NCT05800795|Active Comparator|plasma group|"Healing abutments have been sprayed with an atmospheric pressure plasma device (Piezobrush® PZ2)~, by using active gas, low-temperature plasma treatment under irradiation at 0.2 MPa for a total of 80 seconds at 10 mm (20 seconds per each surface)"
88925303|NCT05800795|No Intervention|control group|Healing abutments were installed as they came from industry and received no further treatment.
89441352|NCT03364166|Active Comparator|buccinator muscle excision without skin|surgical excision the buccinator muscle without the skin in buccal squamous cell carcinoma and neck dissection also done.
89441353|NCT03504072|Active Comparator|Tofacitinib 5mg|tofacitinib 5 mg 12 hourly daily for 9 months. Evaluation schedule will be baseline, 1st month, 3rd months and 3 monthly for 9 months. relevant investigations will be done at each visit. occurrence of tuberculosis and infections will be recorded at follow up visits.
89441354|NCT03504072|Active Comparator|Etanercept 50 mg|Etanercept 50 mg subcutaneously every 7 days interval for 1st month then, Etanercept 50 mg in 15 days interval for 2nd month then 50 mg every 21 days interval for 9 months. Occurrence of tuberculosis and infections will be recorded at follow up visits.
89441355|NCT03361280|Experimental|Atenolol|Atenolol (50 mg) administered 3 hours prior to a hemodialysis session. Blood samples are collected a multiple times during dialysis and spent dialysate is collected at the end of the dialysis session.
88925304|NCT05800756|Experimental|cohort 1|patients with stage II-III HR+/HER2+ breast cancer
88925305|NCT05800197||premenopausal women|premenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer T4 Nany or Tany N2-3
88925306|NCT05800197||postmenopausal women|postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer T4 Nany or Tany N2-3
88925307|NCT05798962||Acute muscle strain|Subjects with an acute muscle strain (within 14 days post injury) in either the hamstrings or the calf muscles
88925308|NCT05798962||Chronic muscle strain|Subjects with a chronic muscle strain more than 6 months prior to inclusion in either the hamstrings or the calf muscles
88925309|NCT05798962||Achilles tendon rupture|Subjects with a full Achilles tendon rupture more than 12 months prior to inclusion
88925310|NCT05798741|Experimental|Hardware removal|hardware removal
88925311|NCT05798741|No Intervention|hardware retaining|Patients that retain their hardware
88925312|NCT05798637||Group A|Elderly subjects diagnosed with coronary syndrome ascertained by coronary angiography
88925313|NCT05798637||Group B|Frail elderly
88925314|NCT05798637||Group C|Elderly subjects with type 2 diabetes mellitus
88925315|NCT05798637||Group D|Elderly subjects with alzheimer's disease
88925316|NCT05798637||Group E|Not frail elderly subjects
88925317|NCT05797857|Experimental|Intervention arm|
88925318|NCT05797597|Experimental|Aspirin|Acard 300 mg (Acidum acetylsalicylicum). 1 tablet (300 mg) twice a day
88925319|NCT05797597|Placebo Comparator|Placebo|Placebo 1 tablet twice a day
88925320|NCT05797324|Experimental|Luminette|Patients without ocular contraindications undergo a Luminotherapy protocol (intermittent blue-enriched light therapy with Luminette 10000 lux equivalent) with morning or evening timing, depending on the circadian phase.
88925321|NCT05797324|Sham Comparator|Sham|Control group (white light <100 lux equivalent).
88925322|NCT05796102|Experimental|PET-MRI|PET-MRI in esophagogastric cancers
88925323|NCT05795335||Patients have received or plan to receive CDK4/6 inhibitors for advanced disease.|
88925324|NCT05794776|Experimental|BurstDR stimulation|BurstDR spinal cord stimulation during hyperglycemic clamp
88925325|NCT05794776|Experimental|Tonic stimulation|Tonic spinal cord stimulation during hyperglycemic clamp
88925326|NCT05794776|Placebo Comparator|No stimulation|No spinal cord stimulation during hyperglycemic clamp
88925327|NCT05794750|Experimental|AK104 injection++chemotherapy|Local CRC with short-course radiotherapy followed by sequential chemotherapy and AK104
88925328|NCT05794750|Experimental|TME surgery|Local CRC with short-course radiotherapy followed by sequential chemotherapy and AK104
88925329|NCT05794750|Experimental|chemotherapy|Local CRC with short-course radiotherapy followed by sequential chemotherapy and AK104
89441356|NCT03361280|Experimental|Bisoprolol|Bisoprolol (5 mg) administered 3 hours prior to a hemodialysis session. Blood samples are collected a multiple times during dialysis and spent dialysate is collected at the end of the dialysis session.
89441357|NCT03361280|Experimental|Metoprolol|Metoprolol (50 mg) administered 3 hours prior to a hemodialysis session. Blood samples are collected a multiple times during dialysis and spent dialysate is collected at the end of the dialysis session.
89441358|NCT03361280|Experimental|Carvedilol|Carvedilol (6.25 mg) administered 3 hours prior to a hemodialysis session. Blood samples are collected a multiple times during dialysis and spent dialysate is collected at the end of the dialysis session.
89441359|NCT02308254|Active Comparator|Lixisenatide|Lixisenatide: 10 mcg, one subcutaneous injection dose
89441360|NCT02308254|Placebo Comparator|Placebo|Matching placebo: one subcutaneous injection dose
89441361|NCT03361202||Atrial fibrillation group|blood sampling
89441362|NCT03361202||control group|blood sampling
89441363|NCT03357146||CRA|Patients with chronic retinal artery occlusion
89441364|NCT03357146||Control|Healthy
89441365|NCT02304120|Experimental|Sensorimotor|"The experimental group will receive added PPT to the conventional physiotherapy. PPT will be applied by means of a neuro-orthopaedic medical device (Posturomed®, see section 3.2). The Posturomed allows adaptive oscillation in the horizontal plane. Therapy instructions advise seven stages of difficulty. In all stages the patient is asked to provoke oscillation by stepping on site. After three steps, the patient must stand still on one leg for 2 seconds before he or she repeats the steps. Difficulty is increased by a) decreasing the damping through release of the breaks and b) through added juggling of a ball during the motor task (dual-task and divided attention). The next stage is reached once stabilisation in the previous stage is secured."
89441366|NCT02304120|Active Comparator|Low-intensity activity|Added to conventional therapy, as administered to all participants, the control group will do added treadmill walking. The control intervention will consist of 10 minutes of walking at comfortable pace. The patient will be instructed in treadmill functions and asked to set the speed between 2 and 4 km/h. The speed should be adjusted to the level where the patient would still be able to talk comfortably.
88925330|NCT05792293|Experimental|Study Group|Fifty female patients diagnosed with breast cancer receiving Anthracycline based chemotherapy
88925331|NCT05792293|Placebo Comparator|Control Group|Fifty female patients diagnosed with breast cancer receiving Anthracycline based chemotherapy
88925332|NCT05792059||patients with HFpEF|
88925333|NCT05792059||patients without HFpEF|
88925334|NCT05788263|Experimental|Craniovertebral angle assesment|Craniovertebral angle is the most widely used measurement to assess Forward head posture. Craniovertebral angle is described as the acute angle formed between a horizontal line passing through the spinous process of the seventh cervical vertebra (C7) and the line connecting the midpoint of the tragus to the spinous process of C7.
88925335|NCT05788263|Experimental|Spatio-temporal gait analyz (LEGSystm)|The gait performance of the cases was evaluated with a spatio-temporal gait analysis device named LEGSystm developed by BioSensicstm. The device consists of two sensors. The sensors are placed 3-5 cm above the ankle of the subject to be tested with the help of velcro. The device is controlled from the computer with its own software and instantly sends the raw data it collects to the computer via Bluetooth. The software analyzes the raw data it receives from the device and turns it into results.The Modified Get Up and Go Test (MKYT), which is also supported by the legsyst, was used for assesment. The test was repeated 2 times and the average time was recorded. Legsystm provides information on double stride length, duration and speed of walking, as well as standing, turning, sitting times and total time
89441367|NCT03361124|Placebo Comparator|Control|Patient will receive standard post-partum Oxytocin (20 mU in 1 L LR) and 1 L LR over 8 hours following delivery.
89441368|NCT03361124|Experimental|Treatment|Patient will receive standard post-partum Oxytocin(20 mU in 1 L LR) an additional 20 mU Oxytocin in 1 L LR over 8 hours following delivery.
89441369|NCT02312388|Experimental|Catheter-over-the-needle technique|to use the 22G angiocatheter for central venous catheterization
89441370|NCT02312388|Experimental|Thin-wall needle technique|to use the sharp hollow 23G needle for central venous catheterization
89441371|NCT03364088|Active Comparator|Spinal anesthesia with tourniquet|"This group will be operated under spinal anesthesia (15 mg of bupivacaine) and in continuous light propofol sedation. Surgical tourniquet (with the pressure of 250 mmHg or > 100 mmHg higher than systolic blood pressure) is used during the operation.~Local infiltration analgesia (LIA) will be administered during the operation. Patients receive 1 g of intravenous tranexamic acid approximately 5 - 10 minutes before the removal of the tourniquet.~Postoperatively patient-controlled analgesia (PCA) with intravenous oxycodone will be used for 24 hours."
89441372|NCT03364088|Active Comparator|Spinal anesthesia without tourniquet|"This group will be operated under spinal anesthesia (15 mg of bupivacaine) and in continuous light propofol sedation. Surgical tourniquet is not used during the operation.~Patients receive 1 g of intravenous tranexamic acid approximately 5 - 10 minutes before the surgical incision. Local infiltration analgesia (LIA) will be administered during the operation.~Postoperatively patient-controlled analgesia (PCA) with intravenous oxycodone will be used for 24 hours."
88925336|NCT05788263|Experimental|Neck Disabilty Index|It is a questionnaire created to determine the level of disability caused by chronic neck pain in daily life.
88925337|NCT05785689|Experimental|DEX: Bolus dexmedetomidine 0,5 mcg/kg|Intravenous infusion during first 10 minutes of anesthesia
89441373|NCT03364088|Active Comparator|General anesthesia with tourniquet|"This group will be operated under general anesthesia (propofol and remifentanil are used with target-controlled infusion (TCI) mode) and surgical tourniquet (with the pressure of 250 mmHg or > 100 mmHg higher than systolic blood pressure) is used during the operation.~Local infiltration analgesia (LIA) will be administered during the operation. Patients receive 1 g of intravenous tranexamic acid approximately 5 - 10 minutes before the removal of tourniquet. Intravenous bolus of oxycodone 0.1 mg/kg (ideal body weight) is given when the closure of surgical wound begins.~Postoperatively patient-controlled analgesia (PCA) with intravenous oxycodone will be used for 24 hours."
89441374|NCT03364088|Active Comparator|General anesthesia without tourniquet|"This group will be operated under general anesthesia (propofol and remifentanil are used with target-controlled infusion (TCI) mode) without the use of surgical tourniquet.~Patients receive 1 g of intravenous tranexamic acid approximately 5 - 10 minutes before the surgical incision. Local infiltration analgesia (LIA) will be administered during the operation. Intravenous bolus of oxycodone 0.1 mg/kg (ideal body weight) is given when the closure of surgical wound begins.~Postoperatively patient-controlled analgesia (PCA) with intravenous oxycodone will be used for 24 hours."
89441375|NCT02304198|Experimental|Udenafil|Udenafil 50mg tablet by mouth, every 12 hours for 1-year(48-weeks)
89441376|NCT02304276|Active Comparator|1 (Explanted valves)|"10 subjects who are due to undergo repeat aortic valve replacement surgery~Investigations:~Baseline 18F-Fluoride PET-CT scan~Retrieval of explanted bioprosthetic aortic valve at time of surgery for analysis"
89441377|NCT02304276|Experimental|2 (AVR)|"70 subjects with surgical bioprosthetic AVR, to include 10 subjects who have had a valve replacement < 1 month; 20 at 2 years; 20 at 5 years and 20 at >10 years.~Investigations:~Baseline 18F-Fluoride PET-CT scan~Repeat CT calcium score of aortic valve at 2 years~Annual clinical follow-up for 5 years (history, examination, blood tests, ECG and echocardiogram)"
89441378|NCT02304276|Experimental|3 (TAVI)|"50 subjects who have undergone TAVI with the COREVALVE and 50 subjects with the SAPIEN valve. In each group this will include 10 subjects who have had TAVI < 1 month; 20 at 2 years and 20 at 5 years.~Investigations:~Baseline 18F-Fluoride PET-CT scan~Repeat CT calcium score of aortic valve at 2 years~Annual clinical follow-up for 5 years (history, examination, blood tests, ECG and echocardiogram)"
89441379|NCT04524260|Active Comparator|Painting art therapy|Intervention group
89441380|NCT04524260|Sham Comparator|Usual Care|Control group
89441381|NCT02308332|Active Comparator|Intervention|patients switching from Atripla to Eviplera
89441382|NCT02308332|No Intervention|Control|patients remaining on Atripla
88925338|NCT05785689|Placebo Comparator|Placebo (PCB): Bolus isotonic saline|Intravenous infusion during first 10 minutes of anesthesia
88925339|NCT05784025|Experimental|AlterG|Traditional rehabilitation program plus robotic rehabilitation making use of the antigravity AlterG device
88925340|NCT05784025|No Intervention|Control|Standard rehabilitation program
88925341|NCT05772117|Experimental|Intervention|Participants receive Chatbot-delivered interventions tailored to their stage of change regarding PV uptake in a conversational way at Month 0, 1, 2, and 3.
88925342|NCT05772117|Active Comparator|Control|Participants receive Chatbot-delivered general information related to PV at Month 0, 1, 2, and 3.
88925343|NCT05765864||Patients|The Enrollment Kit and Time1 Kit will be administered at enrollment, Time2 Kit will be administered before discharge and Time 3 kit after 6 and 18 months post hospitalization (see Detailed description and Study Protocol). The interventions will be Treatment as usual.
88925344|NCT05765864||Controls|The Enrollment Kit and the Time Kit1 will be administered (see Detailed description and Study Protocol).
88925345|NCT05758909||Patients receiving transfemoral (TF) TAVI|TF TAVI
89441383|NCT03361046||Transcatheter Aortic Valve-in-Valve Implantation Cohort|
89441384|NCT02308410||Tourniquet group|This group received a pneumatic tourniquet during total knee arthroplasty.
89441385|NCT02308410||Non-tourniquet group|This group received no tourniquet during total knee arthroplasty.
89441386|NCT02312466||School aged children|
89441387|NCT02312466||Pregnant women|
88925346|NCT05753644|Experimental|SGB group|The subjects will accept ultrasound guided SGB in the right side of the neck in a supine position. The drug is 5 ml of 0.5% ropivacaine.
88925347|NCT05753644|Placebo Comparator|control group|The subjects will accept sham block in the right side of the neck in a supine position. A sham block is performed by subcutaneous infiltration (1 mL1% lidocaine) on the site.
88925348|NCT05735314|Experimental|Step 1 (3 clinics) - 6 months control followed by 24 months of intervention|
88925349|NCT05735314|Experimental|Step 2 (3 clinics) - 12 months control followed by 18 months of intervention|
88925350|NCT05735314|Experimental|Step 3 (3 clinics) - 18 months control followed by 12 months of intervention|
88925351|NCT05735314|Experimental|Step 4 (4 clinics) - 24 months control followed by 6 months of intervention|
88925352|NCT05733663||Adult patients diagnosed with coeliac disease|A group of paediatric or adult patients diagnosed with CD and started on a strict GFD, with baseline and a follow-up intestinal biopsy to assess histological and intraepithelial lymphogram at least 1-year after starting the GFD, and with increased γδ+ T-cells at baseline.
89441388|NCT02312466||Women of reproductive age|
89441389|NCT03360968|Experimental|Treatment A-B|Patient is treated with 1 hour SPN-CPAP/PS followed by 1 hour of Variable-PS ventilation mode
89441390|NCT03360968|Experimental|Treatment B-A|Patient is treated with 1 hour Variable-PS followed by 1 hour of SPN-CPAP/PS ventilation mode
89441391|NCT01822522|Experimental|Stratum A Treatment (cabozantinib s-malate): 20 mg/day|"Patients receive cabozantinib s-malate 20 mg PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.~This arm includes patients who are on ritonavir-boosted or cobicistat-boosted antiretroviral regimens"
88925353|NCT05729243|Experimental|Cytisine|"Cytisine will be given as 1.5 mg tablet formulations for 25 days.~The following treatment schedule will be followed:~Days 1 to 3: 1.5 mg taken every 2 hours (6 pills (9 mg)/day)~Days 4 to 12: 1.5 mg taken every 2.5 hours (5 pills (7.5 mg)/day)~Days 13 to 16: 1.5 mg taken every 3 hours (4 pills (6 mg)/day)~Days 17 to 20: Taper down to 1 tablet every 5 hours (3 pills (4.5 mg)/day)~Days 21 to 25: Taper down to 1-2 tablets daily (1.5-3 mg/day)"
88925354|NCT05729243|Placebo Comparator|Placebo|Placebo will be given following the same schedule as the Cytisine Arm.
88925355|NCT05722132|Active Comparator|One cycle-no monetary incentive|
88925356|NCT05722132|Active Comparator|One cycle-fixed amount of incentive|
88925357|NCT05722132|Active Comparator|One cycle-raffle as incentive|
88925358|NCT05722132|Active Comparator|4 cycles- no monetary incentive|
88925359|NCT05722132|Active Comparator|4 cycles- fixed amount of incentive|
88925360|NCT05722132|Active Comparator|4 cycles- raffle as incentive|
88925361|NCT05756504|Experimental|NSAIDs|Patients in this arm will be given ketorolac injection 30 mg IV x TDS for pain management of mild to moderate acute pancreatitis
88925362|NCT05756504|Experimental|Opioids|Patients in this arm will be given injection tramadol IV x TDS for pain management of mild to moderate acute pancreatitis
88925363|NCT05697510|Experimental|SILTUXIMAB|
88925364|NCT05686980|Experimental|Arm 1: Healthy Japanese Participants|Participants will receive ABBV-552 once a week for 21 Days.
88925365|NCT05686980|Experimental|Arm 2: Healthy Han Chinese Participants|Participants will receive ABBV-552 once a week for 7 Days.
88925366|NCT05685095|Experimental|Treadmill walking|The training program will last 12 weeks and consist of treadmill walking. The duration of the walking bouts (and pauses), and the speed of the belt will be adjusted as needed following the patients' progress. Music will be added as suited to boost motivation and support regular cadence. All training sessions will be supervised.
88925367|NCT05685095|Experimental|Nordic walking|The training program will last 12 weeks and consist of Nordic walking, taught and supervised by an adapted physical activity teacher. The session will be carried out outside, weather permitting. When possible, training will gather 2 to 4 patients for group emulation. The duration of the walking bouts (and pauses) will be adjusted to follow the patients' progress.
88925368|NCT05674266|Experimental|AN Active tDCS|"Treatment as usual plus experimental treatment"
88925369|NCT05674266|Sham Comparator|AN Sham tDCS|"Treatment as usual plus placebo treatment"
88925370|NCT05660187|Experimental|Telehealth care|Telehealth visits will be performed using institutionally-approved, secure, web-based teleconferencing. The standard neurology visits will occur every 6 months with their established neurology clinician via telehealth. The comprehensive care will be offered via telehealth or within the patient's local community. The comprehensive care visits will be adapted for the individual participants' needs and symptoms, consistent with standard clinical care.
88925371|NCT05660187|Active Comparator|In-Clinic care|Standard neurology visits will be conducted in-clinic visits every 6 months with their established neurology clinician. The comprehensive MS care visits will be conducted in-clinic. The comprehensive care visits will be adapted for the individual participants' needs and symptoms, consistent with standard clinical care.
88925372|NCT05657925|Active Comparator|Ondansetron|ondansetron 8 mg prn sublingually when awakening with nausea. as per the FDA label for ondansetron.
88925373|NCT05657925|Placebo Comparator|Placebo|Matching placebo will be identical in appearance to the active treatment pill.
89199607|NCT04990817|Placebo Comparator|Average American Diet|Average American diet based on macronutrient analyses from the most recent Nutrition and Health Examination Survey.
89441392|NCT01822522|Experimental|Stratum A Treatment (cabozantinib s-malate): 40 mg/day|"Patients receive cabozantinib s-malate 40 mg PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.~This arm includes patients who are on ritonavir-boosted or cobicistat-boosted antiretroviral regimens"
88925374|NCT05656495|Experimental|Ambervin intramuscularly|Arm 1 (n=104) receives the study drug Ambervin for intramuscularly administration 1 mg 1 time per day. The course of treatment is 10 days.
88925375|NCT05656495|Experimental|Ambervin inhaled|Arm 2 (n=105) receives the study drug Ambervin for inhalation administration 10 mg 1 time per day. The course of treatment is 10 days.
88925376|NCT05656495|Active Comparator|Standard of care|Arm 3 (n=104) patients receive standard therapy prescribed in accordance with the recommended treatment regimens included in the InterimGuidelines for the prevention, diagnosis and treatment of new coronavirus infection (COVID-19) approved by the Russian Ministry of Health by decision of the investigator and taking into account the availability of drugs at the study site
89199608|NCT04988451|Experimental|ASL Services - Adult ASL Development|Presence (or absence, across 6-week periods) of ASL services designed to support improvement in ASL fluency
89441393|NCT01822522|Experimental|Stratum A Treatment (cabozantinib s-malate): 60 mg/day|"Patients receive cabozantinib s-malate 60 mg PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.~This arm includes patients who are on ritonavir-boosted or cobicistat-boosted antiretroviral regimens"
89441394|NCT01822522|Experimental|Stratum B Treatment (cabozantinib s-malate): 60 mg/day|"Patients receive cabozantinib s-malate 60 mg PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.~This arm includes patients who are on efavirenz or etravirine-based antiretroviral regimens"
89441395|NCT01822522|Experimental|Stratum B Treatment (cabozantinib s-malate): 100 mg/day|"Patients receive cabozantinib s-malate 100 mg PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.~This arm includes patients who are on efavirenz or etravirine-based antiretroviral regimens"
89441396|NCT01822522|Experimental|Stratum C Treatment (cabozantinib s-malate): 60 mg/day|"Patients receive cabozantinib s-malate 60 mg PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.~This arm includes patients who are on antiretroviral regimens that do not include the agents specified on stratum A or B, or who are not on antiretroviral therapy"
89441397|NCT03509298|Experimental|Cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
89441398|NCT03509298|Active Comparator|Cryotherapy & Activated CIK and bispecific antibody|the maximum tumor length≥2cm, use cryotherapy. the maximum tumor length<2 cm,Biological/Vaccine:Activated CIK and bispecific antibody CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
89441399|NCT03509298|No Intervention|Conventional therapy|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
89441400|NCT03360812|Experimental|Intervention group|The intervention is an online training resource to improve the recognition of imminent death in palliative care patients. The intervention should take approximately 15 minutes to complete. During this time, the participants who are in the intervention arm will be shown the results of a previous study which identified how expert palliative care doctors recognise imminently dying palliative care patients. The intervention will be implemented via the website, immediately after participants have completed the first set of vignettes.
89441401|NCT03360812|No Intervention|Control group|The participants assigned to the control group will not receive this additional information and will simply be informed that they are approximately half way through the task and will be asked to continue on to the next set of vignettes.
88925377|NCT05653388||Enrolled Subjects|Once enrolled subjects will provide Archival Tissue, Optional Fresh tumor from a biopsy and blood collections at baseline, day 8 of cycle 1, day 1 of cycles 2-6, and at progression.
88925378|NCT05651893|Experimental|Second forward view examination group|After successful intubation of the cecum, the colonoscope is withdrawn to the splenic curvature with the colonic mucosa carefully inspected. Then the left colon, including the splenic curvature to the anus, is examined twice in the forward view.
89441402|NCT03503994|Other|Drug|"Patients receiving inhaled beclomethasone diproprionate in four escalating doses:~200 mcg bid~400 mcg bid~600 mcg bid~800 mcg bid"
89441403|NCT04520828|Experimental|Postural repositioning|
89441404|NCT03509220|Experimental|PBK-1701TC|2-Day Split-Dosing Regimen
89441405|NCT03509220|Active Comparator|Standard oral preparation|2-Day Split-Dosing Regimen
89441406|NCT04524494||RAS- active medication|Patients taking RAS- active medication (ACE- Inhibitor, Angiotensin II AT1 Antagonist (Sartan)) on a daily Basis for at least 6 months for medical reasons
89441407|NCT04524494||no RAS- active medication|Patients not taking RAS- active medication
89441408|NCT01796002|Experimental|Experimental: Romidepsin plus CHOP|"Patients in experimental arm receive romidepsin plus CHOP (Ro-CHOP) administered in 3 week cycles for 6 cycles.~Romidepsin is administered at a dose of 12 mg/m² IV on day 1 and day 8 every 3 weeks."
89441409|NCT01796002|Active Comparator|Standard: CHOP|Patients in control Arm receive cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) administered in 3 week cycles for 6 cycles.
89441410|NCT04524338|Experimental|At Home tDCS Users|Participants conducting tDCS at home
89199609|NCT04988451|Experimental|ASL Services - Child Language Development|Presence (or absence, across 6-week periods) of ASL services designed to support improvement in ASL fluency
89441411|NCT03509142|Experimental|IBS implantation|Implantation of IBS in patients with coronary artery lesions. All the subjects will be assigned to cohort 1 (n=30) and cohort 2 (n=15).
89441412|NCT04520360|Experimental|Types of Carisbamate|"A single 300 mg oral dose of the Oral Suspension Type 1 under fasting conditions~A single 300 mg oral dose of Oral Suspension Type 2 under fasting conditions~A single 300 mg oral dose of Oral Suspension Type 2 under fed conditions~A single oral dose of the 300 mg Oral Tablet under fasting conditions~A single oral dose of the 300 mg Oral Tablet under fed conditions"
89441413|NCT03132480|Experimental|hypovolemia|
89441414|NCT03356912|Active Comparator|Cabazitaxel plus prednisone|Cabazitaxel 25 mg/m² intravenously (Day 1) every 3 weeks, plus prednisone 10 mg orally given daily. Premedication must be administered according to Cabazitaxel Package Insert.
89441415|NCT03356912|Experimental|Cabazitaxel|Cabazitaxel 25 mg/m² intravenously (Day 1) every 3 weeks. Premedication must be administered according to Cabazitaxel Package Insert.
89441416|NCT02308566|Active Comparator|Conventional Extracorporeal Circulation Technique|Conventional Extracorporeal Circulation Technique
89441417|NCT02308566|Experimental|Minimized Extracorporeal Circulation Technique|Minimized Extracorporeal Circulation Technique
89441418|NCT00102687|Experimental|Aza-5|Azacitidine administered subcutaneously at 75mg/m^2 for 5 days on a 28 day cycle.
89441419|NCT00102687|Experimental|Aza-5-2-2|Azacitidine administered subcutaneously at 75mg/m^2 for 5days with 2 days off, then for an additional 2 days, on a 28 day cycle.
89441420|NCT00102687|Experimental|Aza-5-2-5|Azacitidine administered subcutaneously at 50mg/m^2 for 5 days with 2 days off, then for an additional 5 days, on a 28 day cycle.
89199610|NCT04981951|Experimental|Dexmedetomidine and Bupivacaine|Patients will be given Dexemtomidine ( the intervention) added to the Bupivacaine
89199611|NCT04981951|No Intervention|Bupivacaine alone|patients will be given Bupivacaine alone
89441421|NCT00102687|Experimental|Maintenance Aza 5 days q 4 weeks|Azacitidine administered subcutaneously at 75mg/m^2 for 5 days every 4 weeks.
89441422|NCT00102687|Experimental|Maintenance Aza 5 days q 6 weeks|Azacitidine administered subcutaneously at 75mg/m^2 for 5 days every 6 weeks.
89441423|NCT04509440|Experimental|Neural prolotherapy|Neural prolotherapy using isotonic dextrose 5% in water solution (about 3 ml). The injection was done using Lyftgot technique. The subcutaneous injections were done at sensory nerves fascial penetration points and tender areas around the anserine bursa anatomical region.
89441424|NCT04509440|Active Comparator|Corticosteroid group|Corticosteroid with local anaesthetics (40 mg of triamcinolone acetonide (40 mg/ml) with 1.5 ml mepivacaine HCl 3% ) (local anesthetic). They were given as a single local soft tissue injection at the point of maximal tenderness on the lower medial aspect of the knee region.
89441425|NCT02312544|Active Comparator|OTX-TP treatment|OTX-TP (sustained release travoprost, 0.36 mg) to be used in this trial with placebo drops administered separately
89441426|NCT02312544|Active Comparator|Timolol control|Timolol Maleate Ophthalmic Solution, 0.5% dosed twice daily (BID) in the presence of a placebo vehicle punctum plug (PV).
89502070|NCT05490524|Experimental|Intervention group 2 (full technology)|Intervention Group 2 -platform/devices (with real feedback provided) (full technology group) A full technology group is defined as a group of clinical trial participants who receive the digital devices as part of the trial and healthcare professionals receive the patients' data.
89441427|NCT03360734|Experimental|Combination|"First part: Combination of Gatipotuzumab (GAT) and Tomuzotuximab (TOM) Treatment: 5 weeks monotherapy with TOM (Day 1: 60mg, Day 2: 660mg, Week 2: 1200mg, Week 4: 1200mg). Then combination of 1200mg TOM with 1400mg of GAT every two weeks until disease progression, as long as patient does not meet any other discontinuation criterion such as unacceptable toxicity.~Second part: Combination of GAT and TOM or an approved anti-EGFR antibody, i.e. Cetuximab, Panitumumab, or Necitumumab Treatment: One week monotherapy with TOM (Week 1, Day 1: 60mg, Day 2: 660mg). Then 1200mg TOM in combination with 1400mg of GAT every two weeks until disease progression, as long as patient does not meet any other discontinuation criterion such as unacceptable toxicity or commercial anti-EGFR antibody (dosage according to local practices) in combination with 1400mg of GAT every two weeks until disease progression or until unacceptable toxicity"
89441428|NCT02308644|Experimental|Bevacizumab|Group 1 - 21 eyes treated with intravitreal bevacizumab injection (1.25mg) at the weeks 0, 6,12 and 18 plus standard metabolic control with glycated hemoglobin measured at baseline, week 12 and 18. All patients were followed by expert (endocrinologist)
89441429|NCT02308644|Sham Comparator|Sham|Group 2 - 20 eyes treated with sham injection at weeks 0 and 6; and intravitreal bevacizumab injection(1.25mg) in the weeks 12 and 18 plus standard metabolic control with glycated hemoglobin measured at baseline, week 12 and 18. All patients were followed by expert (endocrinologist)
89502071|NCT02571907|Experimental|Zenith® Branch Endovascular Graft-Iliac Bifurcation|Zenith® Branch Endovascular Graft-Iliac Bifurcation in combination with the Atrium iCAST™ and the Zenith® Flex AAA Endovascular Graft
88925379|NCT05651893|Experimental|Extended withdrawal time group|After successful intubation of the cecum, the colonoscope is withdrawn to the splenic curvature with the colonic mucosa carefully inspected. The colonoscope was withdrawn to the anus directly with withdrawal time extended to the double routine withdrawal time of the left colon.
88925380|NCT05650060||Secukinumab|all patients with psoriasis who received secukinumab
88925381|NCT05649904|Experimental|IRRAflow with Active Fluid Exchange System (IRRAflow)|Subjects may be randomized to receive the IRRAflow with Active Fluid Exchange System (intervention) for intracranial pressure monitoring and for externally draining intracranial fluid as a means of reducing intracranial pressure.
88925382|NCT05649904|Active Comparator|External Ventricular Drainage (EVD)|Subjects may be randomized to receive an External Ventricular Drain (control) for intracranial pressure monitoring and for externally draining intracranial fluid as a means of reducing intracranial pressure.
88925383|NCT05634733||Patients with Sepsis|These are patients who present to the emergency department with sepsis. They will have a MAPSE at the time of enrollment and then after initial treatment.
88925384|NCT05625321|Active Comparator|Educational Group Weight Loss Classes|Participants will participate in a 12-month weight loss program, taught by lay health educators, and designed to promote and encourage healthy weight loss, dietary changes, and increased physical activity. Participants will attend 90-minute sessions weekly for 6 months, bi-weekly for 3 months, and monthly for 3 months.
88925385|NCT05625321|Experimental|Educational Group Weight Loss Classes PLUS Home Gardening Intervention|Participants will receive the educational group weight loss classes PLUS a home gardening intervention. The gardening intervention will be led by local Master Gardeners (MGs) who will help guide participants in setting-up and maintaining their garden.
88925386|NCT05622604|No Intervention|no intervention condition|no intervention
88925387|NCT05622604|Experimental|autonomous use condition|Participants will be given a free subscription to the Pray.com app and will be directed to use the app five days per week.
88925388|NCT05622604|Experimental|meditative prayer condition|Participants will be given a free subscription to the Pray.com app and will be directed to listen to a meditation prayer five days per week.
88925389|NCT05616637||Pes Planus|Participants with unilateral pes planus aged 18-40 years will be included in the study.
88925390|NCT05611229||Population 1: BRAF+ melanoma patients treated with either TT or IO in the adjuvant setting|Included patients were aged more than or equal to 18 years, were required to have a diagnosis of melanoma (ICD-9 172.x & ICD-10 C43.x or D03.x), pathologic stage III disease, evidence of resection, adjuvant treatment with IO (e.g., nivo or pembro) or TT (e.g., dab+tram) on or after January 1, 2014, and prior to August 30,2020 (data cut-off), and any evidence of a BRAF+ result.
89012752|NCT00287937|Experimental|Treatment (vorinostat, paclitaxel, carboplatin)|Patients receive oral SAHA once or twice daily on days 1-14* and paclitaxel IV over 3 hours followed by carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who have stable disease after the completion of 6 courses may receive single-agent SAHA at the discretion of the treating physician.
89012753|NCT01687816||No interventions to be administered|Only a nasal swab is collected, no therapeutic interventions
89012754|NCT01687855||OSAHS group|Subjects that underwent night Ultrafast Magnetic Resonance Imaging with obtaining a series of midline sagittal images of the upper airway .
89012755|NCT01687855||normal group|Subjects that underwent night Ultrafast Magnetic Resonance Imaging with obtaining a series of midline sagittal images of the upper airway .
89012756|NCT00253838|Active Comparator|Restoration HA Stem|The Restoration hip stem, is made from titanium alloy, a different type of metal that has a roughened surfacing and allows for a hydroxylapatite (HA) coating
89012757|NCT00253838|Sham Comparator|Solution stem|The Solution stem is made from Cobalt Chrome, a type of metal, and does not have a hydroxylapatite (HA) coating.
89012758|NCT01687894||Vasopressins & propofol|Administer vasopressin 0.05 or 0.07 IU/kg before sitting position during propofol anesthesia.
89012759|NCT01687894||Placebo & propofol|Administer saline 10 ml (placebo) 2 min before beach chair position during propofol anesthesia
89012760|NCT01687894||Vasopressins & sevoflurane|Administer vasopressin 0.05 or 0.07 IU/kg 2 min before beach chair position during sevoflurane anesthesia
89012761|NCT01687894||Placebo & sevoflurane|Placebo (saline 10 ml) for vasopressin is administered 2 min before beach chair position during sevoflurane anesthesia
89012762|NCT01687933|Experimental|three-dimensional glasses (Virtual Reality glasses)|Women in case group used the glasses for 30 minutes
89012763|NCT01687933|Experimental|usual care|Women in control group did not use the glasses.
89441430|NCT04510636|Experimental|Pembrolizumab and Bendamustine|"The study drugs will be given in 3 week periods called cycles.~Pembrolizumab is available in powder form or as a liquid for infusion. Pembrolizumab at a dose of 200 mg will be given over 30 minutes, once every cycle for up to 35 cycles (approximately 24 months).~Bendamustine is available in powder form for injection. Bendamustine at a dose of 90 mg/m2 will be given over 60 minutes, on Days 1 and 2 of every cycle for up to 6 cycles."
89441431|NCT05618626|Experimental|Physical exercise and dietary intervention for NAFLD|The exercise program will consist of muscular strength and aerobic exercises; additionally, each session will start and end with low intensity warm-up and cool down periods. The program will be divided in months. Months 1-2, twice a week directly-supervised exercises group sessions, and 1 telehealth session. Months 3-6, once a week directly-supervised group session and twice a week home-based telehealth. Months 7-12, Monthly telephone support. Months 12, 24 and 36, All participants (control and intervention arms) will receive a full evaluation. In the dietary intervention, investigators proposed a diet rich in anti-inflammatory components, legumes and in dietary fiber. The baseline evaluation of nutritional condition includes: anthropometry, bioimpedance analysis, hepatobiliary ultrasound, Fibroscan,blood lipids, and a battery of metabolic markers and a diet survey, Automated Self-Administered 24-hour Dietary Assessment Tool (ASA24). Both interventions are performed in parallel.
89502072|NCT05486000|Experimental|treatment group|This group contains patients with chronic left heart failure who are undergoing intervention in the atrial shunt implant system
89502073|NCT02259751|Experimental|KUC 7483 CL|
89012764|NCT01688089|Experimental|ODM-103|Oral capsules dosage 10-800mg once daily for one day or three times daily for 7 days
89012765|NCT01688089|Placebo Comparator|Placebo|Oral capsules given once daily for one day or three times daily for 7 days
89012766|NCT01688089|Active Comparator|entacapone + levodopa/carbidopa|entacapone: oral tablet 200mg given four times daily for one day; levodopa/carbidopa: oral tablet 100/25mg given four times daily for one day
89012767|NCT00253877|Active Comparator|Conserve Plus Hip Resurfacing|Conserve Plus Hip Resurfacing group. Complication rate will be compared between groups.
89012768|NCT00253877|Other|Total Hip Replacement|Historical Total Hip Replacement control group of recently published conventional total hip replacement results (Williams, 2002). Complication rate will be compared between groups.
89012769|NCT01688128|Experimental|Intervention_Control group|Phase I: U-SMART for 4 weeks (2 session/week); Washout: for 2 weeks; Phase II: No intervention for 4 weeks
89012770|NCT01688128|Experimental|Control_Intervention group|Phase I: No intervention for 4 weeks; Washout: for 2 weeks; Phase II: U-SMART for 4 weeks (2 session/week)
89012771|NCT01688206|Experimental|Vanucizumab|Participants will receive escalating doses of vanucizumab and fixed dose of vanucizumab, intravenously every 2 weeks.
89012772|NCT01688206|Experimental|Vanucizumab + Atezolizumab|Participants will receive fixed dose of vanucizumab along with atezolizumab, intravenously every 2 weeks.
89012773|NCT01688245|No Intervention|Control|No SMS dialog
89502074|NCT02259751|Placebo Comparator|Placebo|
89502075|NCT05495516||active group|The study group consisted of 86 patients with signs of CHF above class 2 (NYHA) 30 days after myocardial infarction.
89502076|NCT05495516||comparison group|This group consisted of 100 patients without signs of CHF or with CHF class 1 (NYHA) 30 days after myocardial infarction.
89012774|NCT01688245|Active Comparator|SMS Assessments|Weekly post-weekend drinking outcome assessments
89502077|NCT02804035|Experimental|sc2Wear Furosemide Combination Product|Drug-device combination product of buffered furosemide injection, (Furosemide Injection Solution), 8 mg/mL, and patch pump (sc2Wear Furosemide Pump) for subcutaneous administration of 80 mg dose delivered over 5 hours.
89502078|NCT00345943||Adolescents with Bulimia Nervosa or subclinical BN|Adolescents with Bulimia Nervosa or subclinical Bulimia Nervosa
89502079|NCT00345943||Healthy control adolescents|Healthy control adolescents
89502080|NCT02262793|Experimental|telmisartan and ASA/ER-DP (concomitant)|
89502081|NCT02262793|Active Comparator|ASA/ER-DP alone|
89012775|NCT01688245|Experimental|SMS Assessments & Feedback|Weekly pre-weekend drinking intention & post-weekend drinking outcome assessments with personalized feedback and harm-reduction support
89012776|NCT01688284|Active Comparator|No treatment|patients with recurrent miscarriages
89012777|NCT01688284|Active Comparator|OFFICE HYSTEROSCOPY|Office hysteroscopic endometrial biopsy at the luteal phase of the menestrual cycle
89012778|NCT01688323||Elderly Chemorads|Elderly patients with Head and Neck Cancer who are Undergoing Chemotherapy
89012779|NCT00288093|Experimental|Treatment (triapine, radiation therapy)|Patients undergo radiotherapy once daily, 5 days a week, for approximately 5.5 weeks (a total of 28 fractions). Patients also receive 3-AP (Triapine) IV over 2 hours 3 days a week every other week for 5.5 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of 3-AP (Triapine) until the maximum tolerated dose (MTD) is determined.
89441432|NCT05618626|No Intervention|Standard of care|Participants in the control arm first have a baseline evaluation of the nutritional condition, with anthropometry evaluation, bioimpedance analysis, hepatobiliary ultrasound, Fibroscan, blood lipids, a battery of metabolic markers, and a diet survey, Automated Self-Administered 24-hour Dietary Assessment Tool (ASA24). After the evaluation period, participants received one counseling session, including written material, with advice to follow a healthy diet rich in fruits and vegetables, whole-grain foods, low in salt and sugars, and recommendations for an exercise plan of at least 30 minutes of aerobic exercise three times a week.
89441433|NCT02308722|Experimental|5-fraction stereotactic body radiation therapy|See intervention
89441434|NCT03540849|Experimental|BV after allogeneic hematopoietic stem cell transplantation|
89441435|NCT02160405|Experimental|Normal diet|
89441436|NCT03509064||1: Patients with small fiber neuropathy|patients with Sjogren syndrome have a definite small fiber neuropathy
89441437|NCT03509064||2: Patients without peripheral neuropathy|patients with Sjogren syndrome without signs of peripheral neuropathy (small or large fiber)
89441438|NCT02160483|Experimental|Magnetic resonance imaging|Functional magnetic resonance imaging using arterial spin labelling, functional connectivity, diffusion tensor imaging, magnetic resonance spectroscopy to evaluate women with chronic pelvic pain and/ or endometriosis
89441439|NCT03503760|Experimental|true-sham|"Patients first received the true LIMFA Therapy® treatment for 3 weeks followed by 3 weeks of washout and then six sham sessions for 3 weeks more."
89441440|NCT03503760|Experimental|sham-true|"Patients first received the sham treatment for 3 weeks followed by 3 weeks of washout and then six true LIMFA Therapy® sessions for 3 weeks more."
89441441|NCT04509206|Experimental|Intervention|Subjects will undergo four nutritional educational classes, lasting 1 hour long, conducted over a two month period. These classes will occur on zoom and subjects will be located in their home.
88925391|NCT05611229||Population 2: BRAF+ melanoma patients with LTB treated with TT or IO in the metastatic setting|Included patients were aged more than or equal to 18 years, and were required to have a diagnosis of melanoma (ICD-9 172.x & ICD-10 C43 or D03x), a pathologic stage IV diagnosis, treatment with IO (e.g. ipi, nivo, pembro, ipi+nivo) or TT (dab+tram, vem+cobi, enco+bini) on or after January 1, 2014 and prior to May 31, 2020 (data cut-off), and evidence of a BRAF+ result after therapy initiation. Patients were required to be classified as LTB at the time of stage IV diagnosis. LTB was defined as having normal LDH and <3 metastatic sites at the time of stage IV diagnosis.
88925392|NCT05611216||Third-line (3L) Cohort|patients with Chronic Myeloid Leukemia - Chronic Phase (CML-CP) who initiated 3L for CML-CP
88925393|NCT05611216||T315I Cohort|patients with CML-CP with T315I mutation
88925394|NCT05599035|Active Comparator|1st group received active rTMS,|Active rTMS was applied using a figure-of-8 coil (7-cm diameter loop) positioned over the parietal area for ten sessions (10 trains, with frequency of stimulation 20-Hz, each lasting for 10 seconds with an inter-train interval of 30 seconds. The intensity of stimulation was set at 80% of the RMT for the first dorsal interosseous (FDI) of the contralateral hand with a total 2000 pulses for each hemisphere). Each patient received five sessions /week for two consecutive weeks with ten total sessions over the parietal area. The parietal region was determined according to the 10-20 system for electroencephalographic electrode positioning at P3 and P4, respectively.
88925395|NCT05599035|Sham Comparator|2nd group was the sham group|rTMS was applied using the same parameters, but with the coil edge was applied perpendicular to the scalp in the sagittal plane jut to reproduce the noise of the stimulation
88925396|NCT05580705|Active Comparator|ROUTINE PHYSICAL THERAPY GROUP|This group will receive routine physical therapy including strength training intervention. This protocol will be given for two weeks (6 sessions on alternate days, 3 sessions per week), outcomes will be measured at baseline, at the end of 1st week and 2nd week.
88925397|NCT05580705|Experimental|VIBRATION THERAPY|This group will receive routine physical therapy and vibration therapy. This protocol will be given for two weeks (6 sessions on alternate days, 3 sessions per week), outcomes will be measured at baseline, at the end of 1st week and 2nd week.
88925398|NCT05574816|Active Comparator|Patient without breast lump|No breast lump identified during mammography (ACR 1 et 2 Birads classification)
88925399|NCT05574816|Experimental|Patient with breast lump|Suspicious breast lump identified during mammography (ACR 4b, c ou ACR 5 Birads classification)
89441442|NCT05532826|Experimental|EBV-CTL infusion patients|Given donor EBV-CTL infusion after allo HSCT
89441443|NCT02160561|Experimental|Intervention Arm|Experimental - Intervention Arm patients who are in critical illness with acute respiratory failure and are mechanically ventilated will be placed in an upright reverse trendelenburg position
89441444|NCT02304354|Experimental|Rituximab|two intravenous infusions of 1000 mg with a two-week interval between them
89441445|NCT05615350|Experimental|Meals served during breakfast|Twice a week for six weeks (in total twelve times) participants will consume meals ad libitum during breakfast.
89441446|NCT05615350|Experimental|Meals served during lunch|Twice a week for six weeks (in total twelve times) participants will consume meals ad libitum during lunch. They will receive a standardized breakfast meal.
89441447|NCT03356600|Experimental|Apatinib plus radiotherapy|"Apatinib:~Within 1 week before radiotherapy, the dose of Apatinib were 500mg/daily .During radiotherapy,the dose of Apatinib were 250mg/daily.~After radiotherapy, if the subject did not have a level 3 or above adverse reaction, investigators consider increasing doses to 500mg.~Radiotherapy:~The subjects with 1 to 4 metastases receive stereotactic radiosurgery or stereotactic radiation therapy ,and the subjects with more than 4 metastases receive stereotactic radiosurgery plus whole-brain radiation therapy."
88925400|NCT05566665||ECMO requiring ARDS patients|"The study population for the Aim 1 study will comprise adult patients admitted to the participating ICUs suffering from ARDS (as defined by the Berlin criteria) and treated with ECMO.~The study population for the Aim 2 study will comprise the subgroup of patients as per Aim 1, whose clinical course is complicated by VAP necessitating antibiotic treatment with ceftazidime/avibactam, meropenem/vaborbactam, ceftolozane/tazobactam, or cefiderocol."
89502082|NCT02262793|Experimental|telmisartan and ASA/ER-DP (consecutively)|
89502083|NCT02262793|Active Comparator|telmisartan|
89012780|NCT00288132|Active Comparator|Usual Care|
89012781|NCT00288132|Experimental|Intervention|
89441448|NCT04464018|Experimental|Working group|Working group (hybrid simulation method) after the theoretical lecture, the application with hybrid simulation method is made by videotaping. Repeat the same practice after 1 Week
89441449|NCT04464018|No Intervention|Control group|Control group (Low reality simulation method) after the theoretical lecture, the application with low reality simulation method is made. Repeat the same practice after 1 Week Control group received only general care
89441450|NCT00102531|Experimental|Cisplatin liposomal 24 mg/m2|Inhaled liposomal cisplatin was administered over 1 day in a 14-day treatment cycle by inhalation for a maximum of 6 cycles.
89441451|NCT00102531|Experimental|Cisplatin liposomal 36 mg/m2|The study allowed for a dose escalation of liposomal cisplatin to 36 mg/m2 if no adverse events of Grade 3 or higher occurred after at least 3 cycles of drug administration at 24 mg/m2
89441452|NCT03360266|Active Comparator|Profluorid group|5% Sodium Fluoride varnish (Profluorid varnish) applied over white spot lesions on maxillary anterior teeth
89441453|NCT03360266|Experimental|Enamel Pro|Sodium Fluoride with ACP varnish (Enamel Pro varnish) applied over white spot lesions on maxillary anterior teeth
89441454|NCT03360266|Experimental|MI varnish|Sodium Fluoride with CPP-ACP varnish (MI varnish) applied over white spot lesions on maxillary anterior teeth
89441455|NCT02154789|Experimental|polidocanol|
89441456|NCT02154789|Active Comparator|cryotherapy|
89441457|NCT02154789|Active Comparator|infra-red coagulation|
89441458|NCT05532748|Experimental|"Modified Pachon's incentive, then Branded incentive Triflo II®"|The first measurement with the tomograph will be made using the modified Pachon's incentive, and a week later the measurement will be made using the branded incentive
89441459|NCT05532748|Active Comparator|"Branded incentive Triflo II®, then modified Pachon's incentive"|The first measurement with the tomograph will be made using the branded incentive, and a week later the measurement will be made using the modified Pachon's incentive.
89441460|NCT03506490|Experimental|Experimental|The participants of this study were 33 subjects of both genders (M = 68 years old; SD = 4.2 years old) and were divided in two groups: a control group (N = 15; M = 67, 6 years old; SD = 4.1 years old) and an experimental group (N = 18; M = 67, 4 years old; SD = 4.4 years old). The participants performed a Soda Pop test before the aerobic training session (Baseline). The training session lasted 45 minutes and was composed of running exercises. After the training session, the motor memory consolidation was held in three different stages: Training; 1 hour after training; 24 hours after training.
89441461|NCT03503682|Active Comparator|standard treatment|Patients in this group are treated with 3000 cGy in 10 daily fractions
89441462|NCT03503682|Experimental|short course treatment|Patients in this group are treated with 2000 cGy in 4 fractions administered twice a day (at least 6-8 hours interval)
89441463|NCT05532592||no hesitancy group (NHG)|Participants who got vaccine after transplantation or were willing to be vaccinated.
88925401|NCT05566665||Antibiotic treated ECMO requiring ARDS patients.|The study population for the Aim 2 study will comprise the subgroup of patients as per Aim 1, whose clinical course is complicated by VAP necessitating antibiotic treatment with ceftazidime/avibactam, meropenem/vaborbactam, ceftolozane/tazobactam, or cefiderocol.
88925402|NCT05550454|Experimental|Automatic Mechanical Ventilation|Automatic Mechanical Ventilation during ACLS
88925403|NCT05550454|Active Comparator|Manual Ventilation|Standard care with manual ventilation, Ambu-bagging, during ACLS
88925404|NCT05529160||Study Population|Up to 20 subjects will be recruited from the patient population at the Principal Investigator's clinic. Subject recruitment will end once 15 evaluable subjects have completed the study.
88925405|NCT05521984|Experimental|Dapagliflozin + Standard of Care carmustine chemotherapy (Ages 6-10)|"Dapagliflozin will be initiated by mouth once daily at the same time as standard of care carmustine chemotherapy.~Dapagliflozin 5 mg by mouth once daily on days 1-84 (duration of study)~All patients will stop taking dapagliflozin after 12 weeks of treatment, corresponding to 2 cycles of carmustine.~Carmustine chemotherapy dose adjustments will be made per oncologist's judgement."
88925406|NCT05521984|Experimental|Dapagliflozin + Standard of Care carmustine chemotherapy (Ages 11-21)|"Dapagliflozin will be initiated by mouth once daily at the same time as standard of care carmustine chemotherapy.~Dapagliflozin will be initiated at 5 mg by mouth once caily, days 1-4 (2 weeks)~Dapagliflozin will be escalated to 10 mg by mouth once daily for the remaining 10 weeks~Dose adjustment will need to be approved by endocrinologist Dr. Sprague/or another attending MD diabetologist at SLCH/WUSM on the HRPO-approved study team. This dose is reflective of current clinical practice for diabetes and heart failure.~All patients will stop taking dapagliflozin after 12 weeks of treatment, corresponding to 2 cycles of carmustine.~Carmustine chemotherapy dose adjustments will be made per oncologist's judgment."
88925407|NCT05503823|Experimental|Participants|Each participant will have their resting and active motor threshold measured using the transcranial magnetic stimulation (TMS) device. Participants will receive tACS for 10 minutes in the first session and tRNS in the second session.
89012782|NCT00253916|No Intervention|Control Arm|No exercise measured
89012783|NCT00253916|Experimental|Aerobic cardiovascular exercise program|Aerobic cardiovascular exercise program
89441464|NCT05532592||hesitancy group (HG)|Participants who were uncertain or refused to be vaccinated.
89441465|NCT02771145|Experimental|FID 120947A|FID 120947A contact lens disinfecting solution used with soft contact lenses (study lenses) on a daily basis for 180 days. SCL preservative solution used standard-of-care.
89441466|NCT02308800|Active Comparator|Quantum™ Therapy/NPWT with Prontosan|Quantum™ Negative Pressure Wound Therapy with Prontosan irrigant.
89441467|NCT02308800|Active Comparator|Quantum™ Therapy|Quantum™ Negative Pressure Wound Therapy without irrigant.
89441468|NCT04444414|Experimental|Manual Therapy group|Bilateral manipulation lumbosacral, hip joint gapping, stretching the hip rotators with hip and knee flexion, femorotibial gapping, decompression of connective tissue of the patellofemoral region, internal and external joint line opening in laterality, mobilization of the base of the fibula, tibiofibular-talus gapping, and muscle strengthening.
89441469|NCT04444414|Other|Control group|They received no treatment, they just went to the evaluations.
89502084|NCT02559206|Experimental|30 μg linaclotide DR1 and placebo|
89502085|NCT02559206|Experimental|100 μg linaclotide DR1 and placebo|
89502086|NCT02559206|Experimental|300 μg linaclotide DR1 and placebo|
89502087|NCT02559206|Experimental|30 μg linaclotide DR2 and placebo|
89441470|NCT03506256|Experimental|Norofloxacin|The recommended dosage of norfloxacin for urinary-tract infections in adults is 400 mg orally every 12 hours; the drug should be given for 7 to 10 days in uncomplicated infections and for 10 to 21 days in complicated ones. Adverse drug effects were mild and included disturbances of the gastrointestinal tract and the central nervous system. The study shall be completed in accordance with the ICH topic E6 (R1)(CPMP/ICH/one hundred thirty five/95) guiding principle for top medical practice and the ideas enunciated within the announcement of Helsinki and the approval by way of an Institutional Ethics Committee.
89441471|NCT04508660|Experimental|Subjects with facial redness|Topical application twice daily for 4 weeks
89441472|NCT02308956|Experimental|Integrated mental health in primary care|Participants in the new intervention arm will receive a task sharing model of locally-delivered mental health care integrated into primary healthcare. General health workers (health officers, nurses and community-based health extension workers) will be given brief training using the WHO's mental health Gap Action Programme and ongoing supervision in order to deliver mental health care to people with severe mental disorders.
89441473|NCT02308956|Active Comparator|Psychiatric nurse-led specialist care|Participants in the active control arm will receive an established model of centralised, specialist mental health care delivered by psychiatric nurses at an out-patient clinic within Butajira general hospital and supported by outreach from project workers.
89441474|NCT03356444|Experimental|Abiraterone group|Abiraterone acetate is administered in this arm.
89441475|NCT03356444|Active Comparator|Docetaxel group|Docetaxel is administered in this arm.
89441476|NCT05597176|Experimental|Spinal Cord Injury Exercise Group|Participants will exercise at home 3-5 times per week under supervision via teleconference. Participants will be part of this group for 18-20 weeks.
89441477|NCT04520438|Experimental|NSPT + L-PRF|Scaling and root planing associated to Leucocyte and Platelet rich Fibrin Membrane and irrigation with exudate of L-PRF.
89441478|NCT04520438|Other|NSPT alone|Only Scaling and root planing
89441479|NCT02304510||females|females aged between 18 and 50 years old living in Beijing
88925408|NCT05503485|Experimental|Existential group treatment|Participants who are randomized to the experimental condition will participate in an existential group treatment together with 3 to 6 other participants in seven group sessions of 90-120 minutes each for seven weeks.
89441480|NCT03360032||All participants|All patients will be asked to undertake an incremental shuttle walk test and a cardiopulmonary exercise test and the results will be compared.
88925409|NCT05503485|Active Comparator|Supportive telephone calls|Participants who are randomized to the control condition will receive brief supportive telephone calls once a week for 7 weeks.
88925410|NCT05497323|Experimental|Combination Cream Group|Group 2 will use Adapalene 0.1% cream intermittently every two nights and the combination cream every morning. Group 3 will use Adapalene 0.1% cream every night and the combination cream every morning. Subjects were evaluated on day 28 and day 56.
88925411|NCT05497323|Other|Adapalene 0,1% cream|The control group (Group 1) will use Adapalene 0.1% cream only every night. Subjects were evaluated on day 28 and day 56.
88925412|NCT05495087|Experimental|IHT Treatment|Exposures to hypoxic air (10% O2) up to 5 min intermittent with up to 5 min recovery (breathing room air) per session, 3 sessions/week, up to 12 weeks.
88925413|NCT05495087|Placebo Comparator|Sham-IHT control|Exposures to normoxic air (21% O2) up to 5 min intermittent with up to 5 min recovery (breathing room air) per session, 3 sessions/week, up to 12 weeks.
88925414|NCT05494450|Other|ExufiberAG+02|using ExufiberAG as the primary dressing on medium to high exuding chronic wounds.
88925415|NCT05490563|Experimental|SLS-005 0.75 g/kg Dose|"SLS-005 (trehalose injection, 90.5 mg/mL for intravenous infusion). SLS-005 will be administered as a weight-based dose of 0.75 g/kg by IV infusion once a week.~For 52 weeks"
88925416|NCT05490563|Experimental|SLS-005 0.50 g/kg Dose|"SLS-005 (trehalose injection, 90.5 mg/mL for intravenous infusion). SLS-005 will be administered as a weight-based dose of 0.50 g/kg by IV infusion once a week.~For 52 weeks"
88925417|NCT05490563|Placebo Comparator|Placebo volume equivalent to a SLS-005 0.75 g/kg dose calculation|"Placebo (sodium chloride injection, 0.9, USP) will be administered by IV infusion once a week as a weight-based volume equivalent to a SLS-005 0.75 g/kg dose.~For 52 weeks"
88925418|NCT05490563|Placebo Comparator|Placebo volume equivalent to a SLS-005 0.50 g/kg dose calculation|"Placebo (sodium chloride injection, 0.9, USP) will be administered by IV infusion once a week as a weight-based volume equivalent to a SLS-005 0.50 g/kg dose.~For 52 weeks"
88925419|NCT05460130|Other|Study Participants|Persons infected with the hepatitis C virus who meet the study inclusion criteria and do not meet one or more of the exclusion criteria.
88925420|NCT05460026|Active Comparator|Group A|Routine physical therapy will be given to the participants of group A
88925421|NCT05460026|Experimental|Group B|Powerball exercises with routine physical therapy will be given to the participants of group B
88925422|NCT05446207|Active Comparator|Group A|This group will receive routine physiotherapy with task oriented training. This protocol will be given for 3 alternative days per week. Each session will be of 45 minutes. Data will be collected at baseline, at 4th week and at 8th week.
88925423|NCT05446207|Experimental|Group B|This group will receive passive music therapy and routine physiotherapy with task oriented training. This protocol will be given for 3 alternative days per week. Each session will be of 60 minutes. Data will be collected at baseline, at 4th week and at 8th week.
88925424|NCT05431972|Experimental|Cardea SOLO|for 7 day holter monitor (patch type)
88925425|NCT05431972|Active Comparator|12 Lead EKG|(traditional EKG for under 2 minutes)
88925426|NCT05419310|Experimental|Group A1|Rehabilitation based on core strengthening exercises associated with the application of REAL elastic taping
88925427|NCT05419310|Sham Comparator|Group A2|Rehabilitation based on core strengthening exercises, associated with the application of SHAM elastic taping - sham comparator to group A1
88925428|NCT05419310|Experimental|Group A3|rehabilitation based on exercises for core strengthening
89012784|NCT00253916|Experimental|Resistance Exercise Program|Resistance Exercise Program
89441481|NCT03503604|Experimental|group 1|hPV19 mAb plus FOLFOX(5-Fluorouracil,Oxaliplatin,Leucovorin)
89441482|NCT03503604|Experimental|group 2|hPV19 mAb plus paclitaxel/carboplatin
89441483|NCT03503604|Experimental|group 3|hPV19 mAb plus gemcitabine/carboplatin
89441484|NCT03503604|Experimental|group 4|hPV19 mAb plus FOLFIRI(5-Fluorouracil,Irinotecan, Leucovorin)
89441485|NCT05334706|Experimental|Vaccination|Single arm, vaccination with 9vHPV in a 3-dose regimen (Day 1, Month 2, Month 6).
89441486|NCT03356288||Asthma|20 Participants with moderate to severe asthma, as defined by British Thoracic Society (BTS) guidelines
89441487|NCT03356288||Chronic heart failure|10 Participants with a diagnosis of chronic heart failure
89441488|NCT03356288||Breathing Pattern Disorder|10 Participants with a diagnosis of Breathing Pattern Disorder
89441489|NCT03356288||Pneumonia|10 participants with a radiologically confirmed diagnosis of pneumonia
89441490|NCT03356288||Motor Neurone Disease|10 participants with a diagnosis of motor neurone disease with known hypercapnic failure.
89441491|NCT03356288||Healthy|10 Participants who have no known lung, cardiac or neuromuscular condition.
89441492|NCT02154867|Experimental|Fecal transplantation|Fecal transplantation of freshly prepared feces from healthy donor. Application by colonoscope in proximal half of colon.
89441493|NCT02154867|Placebo Comparator|Placebo fecal transplantation|Sham transplant subject's own feces. Application by colonoscope in proximal part of colon.
89441494|NCT04508816|Experimental|Anti-EGFR arm|In the induction chemotherapy phase, TP regimen (Docetaxel 75mg/m2, D1 + DDP 25mg/m2, D1-3, repeat every 3 weeks) or GP regimen (Gemcitabine 1.0g/m2, D1, 8 + DDP 25mg/m2 , D1-3, repeat every 3 weeks) will be used. Cetuximab 400mg/m2 will be used one week before radiotherapy and 250mg/m2/week during IMRT, or nimotuzumab 200mg/week; meanwhile, cisplatin 80mg/m2 will be used every 3 weeks.
89441495|NCT03503526|Experimental|Music therapy treatment|"An intervention consisting of 12 weekly sessions of trauma-focused treatment in form of group music and imagery therapy.~Receptive music therapy."
89441496|NCT03503526|No Intervention|Wait List Control|No treatment for approximately 12 weeks.
89441497|NCT03356210|No Intervention|Treatment as usual (TAU)|This control group will receive treatment as usual; conventional counseling
89441498|NCT03356210|Experimental|Neurofeedback + TAU|20 sessions of symptom-based NF training in conjunction with traditional therapy
89441499|NCT02304588|Experimental|Mesenchymal stem cells|Maximal amount of MSC cells injected: 10-20*10^6 cells (up to volume of 20mL, depending on the wound size & patient weight).
89441500|NCT02160639|No Intervention|usual care|usual care includes diabetes self management education
89441501|NCT02160639|Active Comparator|diabetes self management support|diabetes self management support in addition to usual care, which includes diabetes self management education
89441502|NCT03359876||Rivaroxaban|NVAF patients with renal dysfunction newly initiated on rivaroxaban 15 mg for stroke prevention
89441503|NCT03359876||Warfarin|NVAF patients with renal dysfunction newly initiated on vitamin K antagonist (warfarin) for stroke prevention
89441504|NCT02309034|Experimental|Jump exercise|rebound exercises.
89441505|NCT02309034|Experimental|Aquatic exercise|Hydrogimnastic.
89441506|NCT02309034|Active Comparator|Nutritional guidance|Nutritional counseling classes.
89441507|NCT02160717||Turner Syndrome|Female with Turner Syndrome
89441508|NCT02160717||Healthy Controls|Healthy Female
89441509|NCT03541395|Other|Testosterone|A Gonadotropin releasing hormone agonist (GnRH-agonist) is administered to lower the testosterone to castration levels. After four weeks testosterone undecanoate is administered to increase the testosterone to normal levels.
88925429|NCT05419310|Active Comparator|Group B|The intervention group B will perform rehabilitation treatment with a structured protocol based on rehabilitation pilates. Comparator to Group A3
88925430|NCT05404217|Active Comparator|LN-OS-22|2 capsules orally once a day for 56 days
88925431|NCT05404217|Placebo Comparator|Maltodextrin|2 capsules orally once a day for 56 days
88925432|NCT05375968|Other|Splanchnic venous capacitance(SVC).|Splanchnic venous capacitance(SVC), the comparison between participants with POTS (Postural Tachycardia Syndrome) and Healthy Control group.
88925433|NCT05370378|Experimental|Group A|This group of participants will receive Hold Relax with Agonist Contraction (HR-AC) technique with routine physical therapy. The protocol will be given to the participants for two weeks (6 sessions on alternate days, 3 session per week). Each session will be of 60 minutes. The data will be collected before applying intervention, at first week and at 2nd week.
88925434|NCT05370378|Active Comparator|Group B|This group of participants will receive Active Release Therapy, a kind of soft tissue mobilization along with routine physical therapy. The protocol will be given to the participants for two weeks (6 sessions on alternate days, 3 session per week). Each session will be of 60 minutes. The data will be collected before applying intervention, at first week and at 2nd week.
88925435|NCT05345782|Active Comparator|Laparoscopic Hypo gastric Neural Plexus Block|laparoscopy for diagnosis of the causes of chronic pelvic pain then injecting 5 ml normal saline for hydro dissection of the retroperitoneal space at the level of the sacral promontory then30 ml (14 ml Marcaine +14 ml normal saline+2ml betamethasone) are injected.
89441510|NCT03503448|Other|space between 11/21|Osteotomy between the maxillary central incisors
89441511|NCT03503448|Other|space between 12/13 and 22/23|Osteotomy between the maxillary lateral incisors and canines
89012785|NCT00288171|Experimental|Allopurinal|Hypertensive renal transplant recipients with elevated uric acid will the treated with allopurinol and placebo in an randomized cross over fashion. Subjects will serve as their own controls.
89012786|NCT00288171|Placebo Comparator|Placebo|
89441512|NCT05236582|Experimental|50 subjects with chemotherapy-induced thrombocytopenia|50 enrolled subjects will be picked up to take Herombopag at the indicated dose.
89441513|NCT03354650||complete blood count|blood sample is collected from infant to detect presence of sepsis
89441514|NCT03354650||c reactive protein|measuring c reactive protein in blood sample to determine neonatal sepsis
89441515|NCT02160951|Experimental|LGH447|LGH447, QD
89441516|NCT02304666|Experimental|Crohn disease's Patients|Patients with Crohn disease or presenting an ulcerative colitis
89441517|NCT02304666|Other|Control patient|Patients with programmed colonoscopy screening for familial colon cancer history, polyps or for irritbale bowel syndrome
89441518|NCT05226832|Experimental|Injection Group|
89441519|NCT03354572|Active Comparator|NAC|receive 150 mg/kg acetylcysteïne in 200 ml saline (NaCl0,9%) prior to surgery
89441520|NCT03354572|Placebo Comparator|placebo|receive only NaCl 0.9% prior to surgery (volume identical to active comparator)
89441521|NCT03508674|Experimental|Intervention|Levita Magnetic Surgical System
89441522|NCT02161029|Active Comparator|New drill biopsy instrument|To take biopsies from gastric submucosal tumors with a new drill biopsy instrument used with flexible endoscopes.
89441523|NCT02161029|Active Comparator|Conventional biopsy instrument|To take biopsies from gastric submucosal tumors with conventional biopsy forceps used with flexible endoscopes
89441524|NCT03359798|Experimental|Narcotic counseling script|Study participants will be read a script regarding post-cesarean section narcotic use.
89441525|NCT03359798|Sham Comparator|Post-partum depression counseling script|Study participants will be read a script of the same length, and much of the same wording as the experimental script. However, this script's content is focused on post-partum depression.
89441526|NCT02309346|Experimental|clindamycin once a day|Clindamycin 2700mg+gentamicin 240mg+ 250ml sterile saline solution i.v. once a day until clinical improvement
89441527|NCT02309346|Active Comparator|clindamycin thrice a day|Gentamcin 240mg i.v once a day, plus clindamycin 900mg i.v. 8/8 h diluted in 250ml of sterile saline solution
89441528|NCT03541239|Active Comparator|non-ischemic preconditioning|The participants will have the cuff attached to the arm, however not be inflated for the 4 cycles of remote ischemic conditioning: 1 cycle is 5 minutes of inflation followed by 5 minutes of deflation. The ischemic reperfusion injury was induced by cuff inflation by the Single Cuff Tourniquet 8000 to 200 mmHg in the arm for 20 minutes followed by reperfusion for 15 minutes.
89441529|NCT03541239|Experimental|ischemic preconditioning|The blood supply to the distal part of the arm will be occluded by inflation of a single cuff to 200mmHg, by the help of the Single Cuff Tourniquet 8000, for 5 minutes separated from 5 minutes of deflation, a cycle that happens 4 times in total. The ischemic reperfusion injury was induced by cuff inflation to 200 mmHg in the arm for 20 minutes followed by reperfusion for 15 minutes.
89441530|NCT03356054|Experimental|Brentuximab vedotin-R-DHAP|Brentuximab vedotin added to R-DHAP
89441531|NCT02161107|Experimental|Grass-SPIRE 1|Grass-SPIRE regimen 1 given 2 weeks apart
89441532|NCT02161107|Experimental|Grass-SPIRE 2|Grass-SPIRE regimen 2 given 2 weeks apart
88925436|NCT05345782|Active Comparator|Laparoscopic Combined Hypo gastric Neural Plexus Block and Uterosacral Nerve Block|laparoscopy for diagnosis and conventional surgical treatment of the causes of pelvic pain then injecting 5 ml normal saline for hydro dissection of the retroperitoneal space at the level of the promontory followed by 30 ml (14 ml Marcaine +14 ml normal saline+2ml betamethasone) then injecting 5 ml ( 2.5 marcaine+1ml betamethasone +1.5 ml normal saline) 2 cm away from the cervix at the uterosacral ligament on each sides.
89441533|NCT02161107|Placebo Comparator|Placebo|Placebo given 2 weeks apart
89441534|NCT03508596|Experimental|Intervention|"Intervention group (IG)~An educational intervention for the supervisors"
89441535|NCT03508596|No Intervention|Control|control group (CG)
89441536|NCT03508596|No Intervention|Non-Intervention|group without intervention (GWI)
89441537|NCT03354494||DSG-CTP|
89441538|NCT02312700|Experimental|Interactive empowerment (IEm) group|Intervention: Patients fill in the questionnaire online and their profile (obtained from their answers) is immediately sent to the physician
89441539|NCT02312700|Sham Comparator|Control|Intervention: Patients fill in the questionnaire online, but their profile (obtained from their answers) is not sent to the physician
89441540|NCT02518568|Experimental|Drug|
89441541|NCT03359720||guyane|
89441542|NCT03359720||martinique|
89441543|NCT03359720||guadeloupe|
89441544|NCT05532514||GROUP A|exposure in 5x5 fov at 90 voxel size
89441545|NCT05532514||GROUP B|exposure in 5x5 fov at 200 voxel size
89441546|NCT03354338|Experimental|Experimental Group|Intensive Periodontal treatment and pre-medication with 2 gr of oral amoxicilline 1 hour before treatment
89441547|NCT03354338|Placebo Comparator|PLACEBO|Intensive Periodontal treatment with 2 gr of Placebo 1 hour before treatment
89441548|NCT02304822|Active Comparator|Multiple-dose of ciprofloxacin prophylaxis|Multiple-dose prophylactic antibiotic of 200mg intravenous ciprofloxacin, 30 minutes before surgery and within 12 hours after surgery additionally
89441549|NCT02304822|Experimental|Single-dose of ciprofloxacin prophylaxis|Single-dose prophylactic antibiotic of 200mg intravenous ciprofloxacin, 30 minutes before surgery only
89502088|NCT02559206|Experimental|100 μg linaclotide DR2 and placebo|
89502089|NCT02559206|Experimental|300 μg linaclotide DR2 and placebo|
89441550|NCT02304822|Experimental|Zero-dose of ciprofloxacin prophylaxis|Zero-dose of ciprofloxacin prophylaxis with none intravenous ciprofloxacin either preoperatively or postoperatively
89441551|NCT05532436|Experimental|Grup 1|One day before the operation, the participants in the experimental group were given breathing exercise training, and they were applied 5 times a day for 10 repetitions until the 30th day after the operation. Introductory Information Form, State-Trait Anxiety Scale, Visual Comparative Sleep Scale and Recovery Quality-40 Questionnaire were used to collect data 1 day before surgery, on the day of surgery, on the 1st day, 15th and 30th days after surgery.
89441552|NCT05532436|No Intervention|Grup 2|Each data collection tool was collected as in the experimental group patients, but without breathing exercises. Only routine nursing care was given to the patients in the control group. The patients in the control group were given a breathing exercise brochure/booklet when they came to the control after the postoperative 30th day, and they were shown how the breathing exercises would be done correctly.
89441553|NCT03359564||micro endoscopic discectomy|the patients with lumbar disc herniation
89441554|NCT02309424|Active Comparator|Vinegar|0,50mmol vinegar (6% acetic acid)
89441555|NCT02309424|Placebo Comparator|Placebo|50 ml water
89441556|NCT03359486|Experimental|Group problem management plus|Five sessions of group low intensity psychological intervention
89441557|NCT03359486|Active Comparator|Enhanced treatment as usual|Referral to primary health care workers trained in mental health Gap Action Programme.
89441558|NCT03506178|Experimental|Obstructive sleep apnea patients|
89441559|NCT03506178|Other|Healthy controls|
89441560|NCT04519034||Audit 1|All vitamin D results performed since January 2020 (N= ~15000) together with age, weight and height if available, ethnicity and other relevant laboratory markers (Ca, adjusted calcium, PTH, Mg, phosphate, liver and renal profile, Covid-19 screening, CRP, Haematinics, FBC)
89441561|NCT04519034||Audit 2|All Covid-19 screening results together with vitamin D, ethnicity, age, weight, height, length of stay in hospital including ICU (if applicable), type of illness, recovered or not, associated health conditions, CRP, Ferritin, Haematinics, vitamin A and E, procalcitonin, LDH, INR, fibrinogen, FBC, D-dimers, CK, Troponin-T, cytokines, renal function and electrolytes from patients tested at GSTT NHS Trust.
89441562|NCT02312778|Experimental|HVLA Manipulation|Intervention Group who receives a high velocity and low amplitude (HVLA) lumbar manipulation. A manual procedure also known as high velocity and low amplitude lumbar spinal manipulation is delivered to the subjects in the side lying position. The more restricted lumbar segment (mobility restriction) will be the target region for the manipulative procedure.
89441563|NCT02312778|No Intervention|Sham Manipulation|Control Group who receives a simulated manipulation.
89441564|NCT03354260|Experimental|intervention|Optimized personalized oral nutrition in ICU and nutritional follow up with therapeutic educational after exit of ICU
89441565|NCT03354260|No Intervention|Control|
89441566|NCT02304900|Experimental|Group 1 : white implant|Randomization will determine the color of the implant to be used for each patient for interventions in both eyes, white or yellow to know.
89441567|NCT02304900|Experimental|Group 2 : yellow implant|Randomization will determine the color of the implant to be used for each patient for interventions in both eyes, white or yellow to know.
89441568|NCT04517006|No Intervention|Track activities|For three weeks research subjects will be keeping track of the things they do without altering their routine in any way.
89441569|NCT04517006|Experimental|Self-focused acts|"For three weeks research subjects will be treating themselves by doing things that they enjoy. These acts don't have to be large or costly, but they should be over and above what they typically do. They are asked to do one (or more) things they enjoy each day for the first three days of each week and report them."
89441570|NCT04517006|Experimental|Prosocial acts|For three weeks research subjects are asked to perform acts of kindness, meaning behaviors that benefit someone else and are over and above what they typically do (i.e., they are not expected of them). These acts should also involve some sacrifice by them (e.g., in effort, energy, time, or money) and be completed for the first three days of each week.
89441571|NCT03503214||Septic patients|Patients with sepsis or septic shock according to the SEPSIS-III (Singer M Jama 2016) admitted to the general Intensive Care Unit
89012787|NCT04519255||Screening of clinically cured patients with severe COVID-19|①Patients with severe COVID-19 cure were determined based on nucleic acid tests, CT examinations, and clinical criteria; ②Age > 18 years, age < 85 years, no gender restriction; ③ All had received COVID-19 drug therapy; ④ ECOG of general condition score: 0-2; No dysfunction of main viscera; Oxygen partial pressure ≥10.64kPa; White blood cells ≥4×109/L; Blood routine hemoglobin ≥9.5g/dL; The absolute count of neutrophils ≥1.5×109/L; Platelet count ≥100×109/L; Total bilirubin ≤1.5 times the upper limit of normal value; Creatinine ≤1.25 times the upper limit of normal value; The creatinine clearance rate was ≥60ml/min; ⑤ Can obtain complete follow-up information, understand the situation of this study and sign informed consent.
89012788|NCT04519255||Screening of clinically cured patients with mild COVID-19|①Patients with mild COVID-19 cure were determined based on nucleic acid tests, CT examinations, and clinical criteria; ②Age > 18 years, age < 85 years, no gender restriction; ③ All had received COVID-19 drug therapy; ④ ECOG of general condition score: 0-2; No dysfunction of main viscera; Oxygen partial pressure ≥10.64kPa; White blood cells ≥4×109/L; Blood routine hemoglobin ≥9.5g/dL; The absolute count of neutrophils ≥1.5×109/L; Platelet count ≥100×109/L; Total bilirubin ≤1.5 times the upper limit of normal value; Creatinine ≤1.25 times the upper limit of normal value; The creatinine clearance rate was ≥60ml/min; ⑤ Can obtain complete follow-up information, understand the situation of this study and sign informed consent.
89199612|NCT04977063|Other|SmartPill and Atmo capsule|The SmartPill and Atmo gas capsule will be tested simultaneously. This will allow the ability of the Atmo gas capsule to measure gastrointestinal transit time to be compared to the SmartPill. The order of swallowing will be randomised using a computer-generated list. The two capsules will be swallowed within 5 minutes of each other
89441572|NCT03503214||Healthy volunteers|Subjects without known respiratory, cardiovascular, hepatic, renal or hematologic diseases.
89441573|NCT02578186|Experimental|Diphenhydramine Hydrochloride|Diphenhydramine (50 mg) elixir taken when subjects had trouble falling asleep
89441574|NCT02578186|Placebo Comparator|Placebo|Placebo elixir taken when subjects had trouble falling asleep
89441575|NCT02304978|Experimental|Group CRC|patient with a colorectal cancer
89441576|NCT02304978|Experimental|Group control|Control - volunteers
89441577|NCT03123458|Experimental|Single arm, cfMSC to treat immune disorders|cfMSCs treatment
89441578|NCT05530876|Experimental|Experimental Group|Women with breast cancer who will undergo the intervention with virtual game.
89441579|NCT05530876|Active Comparator|Control Group|Healthy women who will undergo the intervention with virtual game.
89441580|NCT03123224|Experimental|Combined Aerobic and Resistance Exercise|Participants will work with study staff to develop an individualized physical training program based on their level of functioning at study entry. Exercises will focus on increasing the heart rate to a point at which participants will breathe more heavily and may sweat.
89441581|NCT03123224|Active Comparator|Balance and Flexibility|Participants will work with study staff to develop an individualized physical training program based on their level of functioning at study entry.
89441582|NCT02305056|Experimental|C13 N15 Valine|Intervention C13 N15 Valine
89441583|NCT03506100|Other|water walking in spirometric values|Experimental: practice swimming complemented with water walking
89441584|NCT03123146|Experimental|Fb-Cognitive Behavioral Therapy|Functional Behavior-Based Cognitive Behavioral Therapy: Group activities, individual work in parent-child dyads, group parent training, and social skills exercises.
89441585|NCT03123146|No Intervention|Treatment as Usual (TAU)|"Children assigned to this condition received usual care, meaning that they could continue with any services. This group acted as a control group whereby access to intervention was patient-directed."
89441586|NCT02309502|Experimental|Green Pascal|Single-session Barely Visible Pascal 532nm 3,000 burns 20ms
89441587|NCT02309502|Experimental|Yellow Pascal|Single-session P-RPhS; Pascal 577nm 3000 burns 20ms Endpoint Management:70%
89441588|NCT02309502|No Intervention|Observation|Observation
89441589|NCT04128436|Other|Progesterone levels|Patients will be divided into groups according to quartiles (25/50/75) of progesterone levels. Optimal range of progesterone levels for ongoing pregnancy rate will be calculated.
89441590|NCT03354182|Active Comparator|Control group|Open flap surgery on mandibular type II furcations treated with Bio-oss collagen + Bio-gide
89441591|NCT03354182|Active Comparator|Test group|Open flap surgery on mandibular type II furcations treated with Bio-oss collagen alone
89441592|NCT02313012|Experimental|Dose Level 1 CC-90003|CC-90003 by mouth (PO) daily on days 1 -21 of every 28 day cycle; Cycle 1, Days 1 to 28 will constitute the dose limiting toxicity (DLT) assessment period for purposes of non-tolerated dose (NTD) and Maximum Tolerated Dose determination.
89441593|NCT03359330||Degradable conduit small gap tublization|patients with fresh peripheral nerve injury in the upper extremities,repaired with degradable conduit small gap tublization
89441594|NCT03506022|Other|patients with type 1 mellitus diabetes|All participants were admitted in sleep laboratory and screened for one night of 8 hours employing standard polysomnography (Brainnet System - Medatec) parameters
89441595|NCT02309658|Experimental|Interventional|Treatment consisted of gemcitabine at a dose of 1000 mg/m2, followed by cisplatin 35 mg/m2 administered on day 1 and 8, for two cycles. After that, weekly cisplatin 40mg/m2 is administered concomitant with radiotherapy (45-55Gy) in 1,8-2,0 daily fractions and a 10Gy boost when there was parametrial involvement. Low-dose rate brachytherapy, in 4 fractions of 7Gy, in a total of 28Gy will complete the protocol.
89441596|NCT04508738|Experimental|ERP Intervention|Combination of different methods to improve recovery.
89441597|NCT04508738|No Intervention|Control|Passive recovery by sitting on a chair
88925437|NCT05335473|Experimental|Eribulin plus Tucidinostat|phase 1b： 3+3 trial design will be used for Tucidinostat dose escalation cohorts phase 2: Eribulin+Tucidinostat
88925438|NCT05327920||Participants Receiving Upadacitinib|Participants receiving upadacitinib for Rheumatoid Arthritis
88925439|NCT05300984|Experimental|Group 1|
88925440|NCT05300984|Experimental|Group 2|
88925441|NCT05300542|Experimental|Skin UVB irradiated 1.25MED|
88925442|NCT05300542|Experimental|Skin UVB irradiated 1.6MED|
88925443|NCT05300542|No Intervention|Untreated Skin|
88925445|NCT05286879|Other|Patient Navigator|Navigators will assist linking study participants to appropriate community service providers
88925446|NCT05286879|Other|Mobile Health Unit|Study participants will be linked to a MHU within their community
88925447|NCT05270980|Experimental|Intervention Group (Cohorting)|
89441598|NCT04508738|Placebo Comparator|Placebo|A combination of methods similar to the ERP intervention but at an intensity / mixture supposed to be ineffective at improving recovery.
89441599|NCT05532280|Experimental|Test Product (T)|subjects were administered a single tablet of 90 mg Etoricoxib with approximately 240 ml water after an overnight fast of 10 hours
89441600|NCT05532280|Active Comparator|Reference Product (R)|subjects were administered a single tablet of 90 mg Etoricoxib with approximately 240 ml water after an overnight fast of 10 hours
88925448|NCT05270980|No Intervention|Control Group (No Cohorting)|
88925449|NCT05268588|Experimental|Intervention Arm|The mHealth education and social support intervention includes tailored weekly educational content via interactive voice recognition and an android application, a phone-based provider-moderated group discussion, a provider-moderated group text chat, and referral to care as needed. Individuals are enrolled into groups of 20, have two intervention sessions prenatally and then have weekly meetings through six months postpartum for a total of 26 sessions.
88925450|NCT05268588|No Intervention|Control Arm|Standard postnatal care.
88925451|NCT05265767|Experimental|Autologous HSCT CD68-ET3-LV gene therapy|Autologous gene modified peripheral blood stem cell transplantation for patients with severe hemophilia A (FVIII <1%).
89441601|NCT04508426|Experimental|Mass Balance|
89441602|NCT04508114|No Intervention|control group|Participants in the control group will not receive the ATP testing result (pretest) immediately until finished the research.
89441603|NCT04508114|Experimental|experimental group|Participants in the experimental group will be informed the ATP testing result (pretest) and receive the explanation by research assistant.
89441604|NCT02305134|Active Comparator|Tipepidine Hibenzate|Tipepidine is taken orally at 30 mg/day (10 mg after breakfast, 10 mg after supper, and 10 mg before bedtime), for 4 weeks.
89441605|NCT02305134|Placebo Comparator|Placebo|Placebo is taken orally after breakfast, after supper, and before for 4 weeks.
89502090|NCT02559206|Experimental|290 μg linaclotide IR and placebo|
89502091|NCT02559206|Placebo Comparator|Placebo|
89441606|NCT05532202|Experimental|NICU Mom and Baby Net|12-session mobile internet intervention with remote video based coaching targeting maternal mood, sensitive and responsive parenting interactional practices with their infants to facilitate infant social engagement with their mothers. Each session included (1) a web-based self-directed learning program through video-based teaching with check-in questions and provision of immediate corrective feedback, (2) an action plan outlining daily activity practice (homework) based on session content, (3) parent-recorded video and secure upload of session skill practice during interaction with her infant, and (4) a video-based coach call to co-view the parent-recorded video of interaction with her infant.
89441607|NCT05532202|Active Comparator|NICU Developmental Awareness System|Identical to NICU Mom and Baby Net in terms of number of sessions and session structure to serve as an equivalent attention control. 12-session mobile internet intervention with remote coaching of mother awareness of infant developmental milestones. Each session included (1) web-based self-directed learning program through video-based teaching with check-in questions and provision of immediate corrective feedback, (2) an action plan outlining daily activity practice (homework) based on session content, (3) parent-recorded video and secure upload of session skill practice during interaction with her infant, and (4) a video-based coach call to co-view the parent-recorded video of interaction with her infant.
89441608|NCT00103311|Experimental|Arm I|Patients receive SB-715992 IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89441609|NCT00103311|Experimental|Arm II|Patients receive SB-715992 IV over 1 hour on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89441610|NCT04517162|Active Comparator|Active comparator or polymerized type I collagen|1.5 mL of polymerized type I collagen every 12 h for 3 days and then every 24 h for 4 days (in total 10 injections in 7 days)
89441611|NCT04517162|Placebo Comparator|Placebo comparator o placebo|1.5 mL of placebo, every 12 h for 3 days and then every 24 h for 4 days (in total 10 injections in 7 days)
89441612|NCT02305212|Experimental|Cogmed|Cogmed is a cognitive rehabilitation protocol designed to improve working memory. The Cogmed sessions are on a computer at home for 30-40 min per day, 5 days per week for 5 weeks.
89441613|NCT02305212|No Intervention|Wait list|
89441614|NCT02155023|Experimental|Insulin dosing and glucose sensors|To test the glucose sensors different levels of glycemia are needed. To provoke different glycemic levels the following intervention will be performed: Lunch (with fast glucose absorption characteristics) will be served. Up to 30 minutes after the usual insulin dosing time, the subjects will take his/her lunch dose of insulin adjusted to the chosen lunch plus additional approximately 25% (in the range of 0-50% according to the discretion of the Investigator) of insulin - in order to provoke moderate postprandial hypoglycaemia with glucose values < 70 mg/dl.
89441615|NCT04444232|Experimental|Health services research (educational video, survey)|Participants view an educational video on cancer and cancer screening options over 12 minutes. Participants also complete a phone survey over 10-15 minutes before attending the video session and 2 months after the video session.
89441616|NCT03542721|Placebo Comparator|Placebo of DA-5515 Capsule|Placebo of DA-5515 (three times a day)
89441617|NCT03542721|Experimental|DA-5515 Capsule|Garlic oil, Gingko biloba ex.,Crataegus berry ex.,Melissa officinalis ex., (three times a day)
89441618|NCT02305368||Oncogramme|Taking a fragment of colon tumors taken from a specimen. Cells fragment are cultured for 7 days. The effects of chemotherapy are studied on these cells through chimio-oncogramme.
89441619|NCT05530564|Experimental|Low-pressure pneumoperitoneum|Participants undergone laparoscopic cholecystectomy by creation of a low-pressure pneumoperitoneum, set at 8-10 mm Hg
89441620|NCT05530564|Active Comparator|Standard-pressure pneumoperitoneum|Participants undergone laparoscopic cholecystectomy by creation of a standard-pressure pneumoperitoneum, set at 12-14 mm Hg
89441621|NCT04507958||Electronic auscultation|
89441622|NCT04507958||Conventional ausculatation|
89441623|NCT03541161||Early rehabilitation group|Breast cancer patients who underwent reconstructive surgery in samsung medical center from Jan 2017 to August 2017. Following early rehabilitation protocol, patients were educated to undergo a self-exercise program after short-term immobilization of 2 weeks.
89441624|NCT03541161||Conventional protocol group|Breast cancer patients who underwent reconstructive surgery in samsung medical center from May 2016 to Dec 2016. Following conventional protocol, patients were asked to immobilize their shoulder for more than 4 weeks and then undergo self-exercise program.
89441625|NCT04444388|Experimental|Cocoa group|5 g/day of flavonoid-rich defatted cocoa for 10 weeks
89441626|NCT04444388|Placebo Comparator|Placebo group|5 g/day of maltodextrin for 10 weeks
89441627|NCT02163213|Other|Serum Bovine Immunoglobulin|"Serum-Derived Bovine Immunoglobulin (SBI) 5.0 g by mouth twice daily;~Effects of SBI will be compared with observations and measurements performed at baseline PRIOR to starting the SBI treatment"
89441628|NCT02305602|Experimental|Post Myocardial Infarction|VentriGel will be injected via a MyoStar catheter after NOGA mapping in the 60 day to 3 year window since the first STEMI myocardial infarction
89441629|NCT04443920|Active Comparator|Tranexamic acid (TXA)|"All patients will receive 15 mg/kg Tranexamic acid (TXA) IV prior to skin incision. This arm will receive a second intravenous dose of 15 mg/kg of Tranexamic acid (TXA) before the release of the tourniquet. The medication is delivered from the pharmacy in a masked syringe labeled as study medication."
89441630|NCT04443920|Placebo Comparator|Placebo Normal Saline (NS)|"All patients will receive 15 mg/kg Tranexamic acid (TXA) IV prior to skin incision. This arm will receive a second intravenous dose of placebo (Normal Saline) in the volume calculated to be equal to the volume of 15 mg/kg of TXA. The medication is delivered from the pharmacy in a masked syringe labeled as study medication."
89441631|NCT02309814|Experimental|eyelid motion sensor device|all volunteers will wear the monitor eyelid sensor device (including the tiny magnets on the upper eyelid). a 10 minutes movie will be screened on 40 inch television screen in a 3 meters distance.
89441632|NCT03542643|Active Comparator|N-3 polyunsaturated fatty acids|n-3 polyunsaturated fatty acids dosage of 1g of Eicosapentaenoic acid(EPA)
88925452|NCT05259904|Experimental|L-citrulline|L-citrulline with a dose of 15 g/day will be administered in powder form that is mixed with water and taken orally, continuously and daily for at least 7 weeks. Dispensed at Visits 0a/1. Washout period of 4 to 6 weeks and then enter crossover phase of an additional 7 weeks. Drug will be dispensed at Visit 4.
88925453|NCT05259904|Placebo Comparator|Matching Placebo|Administered in powder form that is mixed with water and taken orally, continuously, and daily for at least 7 weeks. Dispensed at Visits 0a/. Washout period of 4 to 6 weeks and then enter crossover phase of an additional 7 weeks. Drug will be dispensed at Visit 4.
88925454|NCT05256927||All Participants|
88925455|NCT05254015|Experimental|Cognitive Rehabilitation and Exposure/Sorting Therapy (CREST)|"Compensatory Cognitive Training (CCT) Modules (7 sessions). Compensatory Cognitive Training is a manualized, low-tech, cognitive training intervention designed to target cognitive impairments common in people with psychiatric illnesses. The CCT modules specifically selected for CREST map onto known areas of HD neurocognitive impairments and include training in prospective memory, prioritizing, problem solving, planning, and cognitive flexibility.~Exposure to Discarding and Acquiring Modules (19 sessions). Symptoms of acquiring and saving are themselves avoidance behaviors to avoid internal distress related to negative thoughts and emotions. ET utilizes in vivo exposure exercises taking place in the home to enhance generalization of their new skills. Fear hierarchies typically start with a space that has low clutter volume or there is less of an urge to save a particular type of item in that environment."
88925456|NCT05254015|Active Comparator|Case Management (CM)|Case Management (CM). CM consists of a set of well-established strategies commonly used in community service settings to address serious and complex problems in particularly vulnerable and often marginalized populations such as those with HD.
88925457|NCT05252130|Experimental|Auscultation with a newly developed electronic stethoscope: NoaScope|Identification of abnormal heart and lung sounds in study participants
88925458|NCT05242302|Experimental|reverse end to side nerve transfer|
88925459|NCT05242302|Active Comparator|end to end nerve transfer|
88925460|NCT05242302|Active Comparator|nerve decompression|
88925461|NCT05232773||Experimental group|"Enrolled patients will undergo supervised rehabilitation treatment for rotator cuff repair according to a standardized protocol (5 days/week) and will undergo clinical, kinematic and shoulder muscle strength assessments to collect data useful to define objective criteria for progression between rehabilitation phases. Assessment will be performed at four different times.~The clinical evaluation of the shoulder is carried out through the Constant-Murley Score (CMS).~Pain will be assessed through the visual analogical scale (VAS). Kinematic assessment (shoulder ROM, scapula-humeral rhythm, movement smoothness, movement speed) will be assessed through magneto-inertial measurements units (M-IMU).~The maximal voluntary isometric contraction (MVIC) of shoulder flexor, abductor and rotator cuff muscles of the affected limb will be measured by the Chronojump Boscosystem® Force Sensor Kit"
88925462|NCT05232773||Healthy subjects|Healthy subjects will undergo evaluations with the same timing as patients in the Experimental group.
88925463|NCT05227339|Experimental|Interventional (RAE + Usual Care)|Subjects will receive usual care through an outpatient substance use disorder treatment facility, will be provided with a wearable sensor and the RAE mobile application. Participants will be instructed to use the RAE app for a minimum of 30 days.
88925464|NCT05227339|No Intervention|Control (Usual care)|Subjects will receive usual care through an outpatient substance use disorder treatment facility and will be provided with a wearable sensor (fitness tracker). They will not be given access to the RAE mobile app.
88925465|NCT05224505|Experimental|GNT0006 - Stage 1|6 patients treated with GNT0006 in Stage 1 (open label) 2 dose cohorts : Cohort 1: single intravenous injection 9.0E+12 vg/Kg Cohort 2: single intravenous injection 2.7E+13 vg/Kg
88925466|NCT05224505|Experimental|GNT0006 - Stage 2|"22 patients randomized in single intravenous GNT0006 arm at selected dose in Stage 2 (double blind).~The patients will receive placebo one year after to maintain the blind"
88925467|NCT05224505|Placebo Comparator|Placebo - Stage 2|11 patients randomized in placebo arm in Stage 2 (double blind). The patients will receive single intravenous GNT0006 at selected dose one year after to maintain the blind
88925468|NCT05215951|Experimental|Osimertinib plus standard chemotherapy|single-arm
88925469|NCT05205538|Experimental|Females|Female participant group
88925470|NCT05205538|Experimental|Males|Male participant group
88925471|NCT05182294|Active Comparator|Conventional symmetric nasal cannula|The patient's breathing pattern will be assessed by inductive plethysmography while using the cannula and receive HFNT for 2 hours during the first session. Patients will then be randomized to use of the conventional symmetric nasal cannula or the new asymmetric nasal cannula. At the end of the first session questionnaire data will be collected and ABGs will be repeated followed by a 30-minute rest period without any device. Patients will then crossover to receive HFNT via the other cannula type for another 2 hours during the second session. Inductive plethysmography will again be worn and ABGs will be obtained, and questionnaires will again be administered
88925472|NCT05182294|Active Comparator|AIRVO 2; new asymmetric nasal cannula|The patient's breathing pattern will be assessed by inductive plethysmography while using the cannula and receive HFNT for 2 hours during the first session. Patients will then be randomized to use of the conventional symmetric nasal cannula or the new asymmetric nasal cannula. At the end of the first session questionnaire data will be collected and ABGs will be repeated followed by a 30-minute rest period without any device. Patients will then crossover to receive HFNT via the other cannula type for another 2 hours during the second session. Inductive plethysmography will again be worn and ABGs will be obtained, and questionnaires will again be administered
88925473|NCT05161468|Active Comparator|Lidocaine|50 Subjects will be randomized to this group and will receive a lidocaine injection in their ACJ.
88925474|NCT05161468|Active Comparator|Corticosteroid|50 Subjects will be randomized to this group and will receive a corticosteroid injection in their ACJ.
88925475|NCT05161468|Active Comparator|Platelet Rich Plasma (PRP)|50 Subjects will be randomized to this group and will receive a PRP injection in their ACJ.
89012789|NCT04519255||Healthy people who are not infected with COVID-19|① Volunteers who are not infected with COVID-19; ②Age > 18 years, age < 85 years, no gender restriction; ③ ECOG of general condition score: 0-2; No dysfunction of main viscera; Oxygen partial pressure ≥10.64kPa; White blood cells ≥4×109/L; Blood routine hemoglobin ≥9.5g/dL; The absolute count of neutrophils ≥1.5×109/L; Platelet count ≥100×109/L; Total bilirubin ≤1.5 times the upper limit of normal value; Creatinine ≤1.25 times the upper limit of normal value; The creatinine clearance rate was ≥60ml/min; ④ Can obtain complete follow-up information, understand the situation of this study and sign informed consent.
89012790|NCT04518592||Severe Major Depressive Disorder|
89012791|NCT04518592||control , healthy|
89012792|NCT00253955|Experimental|1|
89012793|NCT00253955|Active Comparator|2|
89012794|NCT04472533||CTEPH|Patients diagnosed with chronic thromboembolic pulmonary hypertension
89012795|NCT04472533||CTED|Patients diagnosed with chronic thromboembolic disease but no evidence of pulmonary hypertension
89012796|NCT04472533||Control|Healthy control subjects
89012797|NCT04471051||COVID19 Convalescent Plasma Treatment|Hospitalized COVID19 patients who receive COVID19 Convalescent Plasma under Expanded Access protocol NCT04372368.
89012798|NCT04470700||subjects with greater than 3years delay|Subjects with delay in treatment of Urinary incontinence greater than three years
89012799|NCT04470700||subjects with less than three years delay|Subjects with delay in treatment of Urinary incontinence lesser than three years
89012800|NCT00288249|Experimental|Arm 2|Each subject was scheduled to receive one infusion of ZK 219477 every 3 weeks in one of the respective arms (16 mg/m2 in Arm 1, 12 mg/m2 in Arm 2, 22 mg/m2 [30-minute infusion] in Arm 3 and 22 mg/m2 [3-hour infusion] in Arm 4)
89441633|NCT03542643|Placebo Comparator|Placebo|olive oil ethyl esters
89441634|NCT02313090|Experimental|Welltang|patients using Welltang
89441635|NCT02313090|No Intervention|usual standard care|patients under usual standard of diabetic care
89441636|NCT03359018|Experimental|apatinib plus anti-PD1 therapy arm|Every patients will received apatinib 250mg or 500mg orally daily and SHR-1210 3mg/kg (no more than 200mg) iv every 2 weeks until disease progression or intolerance to side effects.
89441637|NCT05530252|Experimental|AMP Group|scaling and root planning and subgingival application of antimicrobial peptide gel
89441638|NCT05530252|Active Comparator|Perio Group|scaling and root planning and subgingival application of minocycline hydrochloride ointment
89012801|NCT00288249|Experimental|Arm 3|Each subject was scheduled to receive one infusion of ZK 219477 every 3 weeks in one of the respective arms (16 mg/m2 in Arm 1, 12 mg/m2 in Arm 2, 22 mg/m2 [30-minute infusion] in Arm 3 and 22 mg/m2 [3-hour infusion] in Arm 4)
89012802|NCT00288249|Experimental|Arm 4|Each subject was scheduled to receive one infusion of ZK 219477 every 3 weeks in one of the respective arms (16 mg/m2 in Arm 1, 12 mg/m2 in Arm 2, 22 mg/m2 [30-minute infusion] in Arm 3 and 22 mg/m2 [3-hour infusion] in Arm 4)
89012803|NCT00288249|Experimental|Arm 1|Each subject was scheduled to receive one infusion of ZK 219477 every 3 weeks in one of the respective arms (16 mg/m2 in Arm 1, 12 mg/m2 in Arm 2, 22 mg/m2 [30-minute infusion] in Arm 3 and 22 mg/m2 [3-hour infusion] in Arm 4)
89012804|NCT01600573|Experimental|pazopanib plus weekly topotecan|pazopanib in combination with weekly topotecan
89012805|NCT01600612|Active Comparator|Oxytocin|30 IU of oxytocin will be given intravenously to patients with atonic postpartum hemorrhage
89012806|NCT01600612|Active Comparator|carbetocin|10 ug of carbetocin will be given intravenously to patients with atonic postpartum hemorrhage
89012807|NCT01600612|Active Comparator|misopristol|600 ug of misopristol sublingually will be given intravenously to patients with atonic postpartum hemorrhage
89012808|NCT01600651|Sham Comparator|Recruitment maneuver (RM) sham group|when recruitment maneuver sequence precedes a sham evaluation period
89012809|NCT01600651|Sham Comparator|Sham Recruitment (RM) maneuver group|a group in which patients receive a sham sequence before the RM sequence
89199613|NCT04947527|Experimental|Test Varnish|Anti-Caries Varnish. The active ingredients are 10% (w/v) Povidone-Iodine and 5% (w/v) Sodium Fluoride CAS.
89199614|NCT04947527|Active Comparator|Control Varnish|Control Varnish. 5% (w/v) Sodium Fluoride .
89441639|NCT05530252|Other|SRP Group|scaling and root planning
89441640|NCT03505866|Other|Mutual support groups of HIV|HIV-positive people who did not enroll in a community home-based care intervention and receiving regular HIV services and support from mutual support groups of HIV
89441641|NCT02305524|Experimental|ETI with chest compressions|endotracheal intubation (ETI) during child mannikin resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
89012810|NCT00288288||1|Epicardial left ventricular lead placement during a clinically indicated open chest surgery
89012811|NCT00288288||2|Transvenous left ventricular lead implant during a clinically indicated CRT system implant
89012812|NCT01600690|No Intervention|Continue statin regimen|Patients randomized to this arm will continue their usual statin regimen and dose, without any intervention.
89012813|NCT01600690|Experimental|Statin withdrawal|Patients randomized to this arm will stop statin treatment for 5 days.
89012814|NCT01600768|Active Comparator|intermittent infusion|
89012815|NCT01600768|Experimental|extended infusion|
89012816|NCT00288327|Experimental|1|Enhanced New Leaf Intervention
89012817|NCT00288327|Other|2|Minimum Intervention
89012818|NCT00414986|Experimental|1|Practice in this arm will receive the Chronic Care Improvement intervention
89012819|NCT00414986|Experimental|2|Practices in this arm will receive the standard CQI intervention. An in-practice CQI coordinator will assist the practices in implement a chronic disease registry.
89441642|NCT02305524|Experimental|ETI without chest compressions|Endotracheal intubation of child mannikin during resuscitation without chest compressions.
89441643|NCT02163291|Experimental|paclitaxel liposome|S-1 plus paclitaxel liposome
89441644|NCT03358940|Other|patient with miscarriage complications or not|The day of inclusion, for patient with miscarriage complications or not, or threatened miscarriage there will be a urine collection. In case of hospitalization, another urine collection will be done between 12 and 18 hours after the inclusion. For patient coming for voluntary termination of pregnancy using misoprostol, a urine collection will be done the day of the inclusion and another ones 1, 4, 12 and 24 hours after the inclusion.
89441645|NCT05532124|Experimental|Part A: LAENNEC 4ml|Dosing twice a week for 2 weeks
89441646|NCT05532124|Experimental|Part A: LAENNEC 6ml|Dosing twice a week for 2 weeks
89441647|NCT05532124|Experimental|Part A: LAENNEC 10ml|Dosing twice a week for 2 weeks
89441648|NCT05532124|Active Comparator|Part A: Normal Saline|Dosing twice a week for 2 weeks
89441649|NCT05532124|Experimental|Part B: LAENNEC 1|It is administered twice a week or placebo, and administered until it is normalized for up to 6 weeks or ALT.
89441650|NCT05532124|Experimental|Part B: LAENNEC 2|It is administered twice a week or placebo, and administered until it is normalized for up to 6 weeks or ALT.
89441651|NCT05532124|Active Comparator|Part B: Normal Saline|It is administered twice a week or placebo, and administered until it is normalized for up to 6 weeks or ALT.
89441652|NCT03358862||Myopes|Children, adolescents and young adults with existing progressive myopia equal to or exceeding -0.50 D in the year prior to beginning the use of the NaturalVue contact lens.
89441653|NCT02313168||1|preoperative FRONT score
89441654|NCT02313168||2|intraoperative FRONT score
89501636|NCT02229721|Active Comparator|Syntocinon Nasalspray 32 IU|"Over 8 weeks, intranasal oxytocin (32 IE) or placebo will be self-administered by women prior to sexual intercourse. Following a washout period of 2 weeks, a cross-over will take place and patients switched to the alternate group for another 8 weeks.~The recommended dose is four puffs per nostril, containing 32 IU of synthetic oxytocin, administered up to 50 minutes prior to sexual activity. The maximal dose should not exceed four puffs per nostril per day; the minimum dose was twice weekly."
88925476|NCT05153382|Experimental|Youth with and/or at familial risk for bipolar disorder|60 youth aged 13 to 23 with and/or at familial risk for bipolar disorder will be enrolled in the dialectical behavioral therapy intervention.
89199615|NCT04909827|Experimental|group A|3D printed microfilled hybrid composite Endocrowns
89537057|NCT03301727|Active Comparator|Online CBT-I Treatment|Participants receive 6 online weekly 1.5-hour sessions of cognitive-behavioural therapy for insomnia (CBT-I) for pregnant women, supervised by a registered, licensed clinical psychologist.
89537058|NCT03301727|Other|Wait-list Control|Participants are placed on a wait-list for 6 weeks before receiving either in-person or online 6 weekly 1.5-hour sessions of cognitive-behavioural therapy for insomnia (CBT-I) for pregnant women, supervised by a registered, licensed clinical psychologist.
89537059|NCT02721875|Experimental|Volasertib monotherapy|
89537060|NCT02721875|Experimental|Volasertib + azacitidine combination|
89537061|NCT03301571|Other|All patients|"All patients will receive the treatment (CABG) and postoperatively three different interventions:~Change in preload and afterload~Change in inspired oxygen~Change in pacemaker modes"
89537062|NCT02466503|Experimental|Synflutide HFA MDI, 250/25 mcg/dose|Synflutide HFA MDI(Fluticasone propionate/ Salmeterol, 250/25mcg), Single dose, 4 puffs
89537063|NCT02466503|Active Comparator|SeretideTM EvohalerTM, 250/25 mcg/dose|SeretideTM EvohalerTM (Fluticasone propionate/ Salmeterol, 250/25mcg), Single dose, 4 puffs
89537064|NCT03301259|Experimental|wave -one reciprocating system|"The reciprocating single file systems WaveOne (Maillefer, Ballaigues, Switzerland) provide more flexibility of the M-wire Ni-Ti alloy, greater resistance to cyclic fatigue and better handling of narrow and curved canals than the traditional Ni-Ti instruments Root canal preparation will be done with theWaveOne System with strict adherence to the manufacturer's instructions. After coronal preflaring with File ISO 21 taper 8% instrument with 2.5% sodium hypochlorite as the irrigant, working length was determined and a glide path will created.~The Red file R 25 taper 8% will be used for preparing the mesial canal; and the Black ISO 40 taper 8% file will be used for preparing the distal canals where there is only a single canal."
89537065|NCT03301259|Experimental|OneShape|OneShape (MICRO-MEGA) rotary nickel-titanium use roation movement and available in two sizes N°30 - .06 rotary files. , N°25 - .06
88925480|NCT05133544|Active Comparator|Endocuff- AI assisted colonoscopy|Endocuff (Olympus, Hong Kong) and AI assisted colonoscopy will be used
88925481|NCT05133544|Active Comparator|AI-assisted colonoscopy|AI assisted colonoscopy will be used
88925482|NCT05133544|No Intervention|Conventional colonoscopy|Conventional colonoscopy will be used without AI or Endocuff.
88925483|NCT05120947|Experimental|42 Gray (Gy) Radiation|42 gy of radiation therapy will be administered in 10 fractions.
88925484|NCT05120947|Experimental|39 Gray (Gy) Radiation|39 gy of radiation therapy will be administered in 8 fractions.
88925485|NCT05120947|Experimental|32.5 Gray (Gy) Radiation|32.5 gy of radiation therapy will be administered in 5 fractions.
88925486|NCT05108389||Pregnant women with kidney disease|Pregnant women with kidney disease. No intervention.
88925487|NCT05104762|Active Comparator|Arm 1 plasmapheresis|Arm 1 (plasmapheresis): This study will be conducted at Assiut University at Neurology and psychiatry department as Group 1 of patients presented with Guillian Barrie syndrome (54 patients) will be subjected to plasmapheresis after assessment of clinical state and scales including MRC, Erasmus Guillain-Barre respiratory insufficiency score and Overall neuropathy limitation scale and Neurophysiological studies. Each patient was evaluated at baseline and at Follow up assessment points (one month and 3 months, one year follow up)
88925488|NCT05104762|Active Comparator|Arm 2: Intravenous injection of immunoglobulin|This study will be conducted at Assiut University at Neurology and psychiatry department as Group 2 of patients presented with Guillian Barrie syndrome (27 patients) will be subjected to intravenous injection of immunoglobulin after assessment of clinical state and scales including MRC, Erasmus Guillain-Barre respiratory insufficiency score, and Overall neuropathy limitation scale and Neurophysiological studies. Each patient was evaluated at baseline and at Follow up assessment points (one month and 3 months, one year follow up).
88925489|NCT05098665|Active Comparator|Arm A - RCT telemonitoring|160 ATTR-CM patients assigned to receive telemonitoring intervention
88925490|NCT05098665|No Intervention|Arm B - RCT usual care|Control group of 160 ATTR-CM patients assigned to receive usual care
88925491|NCT05094297|Experimental|Investigate the effects of an exercise intervention on U.S. Veterans.|A total of 25 U.S. Veterans (≥ 18 years of age), who suffer from pain, fatigue, low energy levels or are unable to physically do things they were once able to do, will be enrolled.
88925492|NCT05084339||pregnant group with bariatric surgery|pregnant women with a history of gastric bypass or sleeve gastrectomy
88925493|NCT05084339||matched pregnant group without history of bariatric surgery|age-and BMI matched pregnant women without history of bariatric surgery
88925494|NCT05075941||Shelters Paris/93|
88925495|NCT05075941||Workers' hostels Paris/93|
88925496|NCT05075941||travelling community IDF(77/93/95)|
88925497|NCT05075941||Street/Camps Paris/93|
88925498|NCT05075941||Covid Homeless and migrants Marseille|
88925499|NCT05075941||Hostel Paris/93|
88925500|NCT05052112|Active Comparator|E-PR-01 200mg|Oral administration : One capsule to be taken after breakfast and one capsule before dinner for around 5 to 7 days
88925501|NCT05052112|Placebo Comparator|E-PR-02 200mg|Oral administration : One capsule to be taken after breakfast and one capsule before dinner for around 5 to7 days
88925502|NCT05051618|Experimental|POWER-MS|The POWER-MS condition will deliver the Guidelines for Exercise in MS (GEMS) program with a remotely coached/guided, home-based setting using telerehabilitation. GEMS recommends 30 minutes of moderate intensity aerobic activity, 3x/week AND strength training exercises for major muscle groups, 3x/week.
88925503|NCT05051618|Active Comparator|FLEX-MS|The FLEX-MS condition will primarily focus on flexibility as the applicable exercise modality. As such, the program will emphasize that flexibility is an important component of fitness. The goal would be for each participant to enhance their flexibility by engaging in a titrated exercise prescription where the number of sets and time to hold per set will increase throughout the 16-week program.
89501637|NCT02229721|Placebo Comparator|Placebo Nasalspray|"Over 8 weeks, intranasal oxytocin (32 IE) or placebo will be self-administered by women prior to sexual intercourse. Following a washout period of 2 weeks, a cross-over will take place and patients switched to the alternate group for another 8 weeks.~The recommended dose is four puffs per nostril, administered up to 50 minutes prior to sexual activity. The maximal dose should not exceed four puffs per nostril per day; the minimum dose was twice weekly."
88925504|NCT05049070|Experimental|GoEyes|GoEyes Self administered refraction test + Standard of care refraction test
88925505|NCT05044455|Experimental|Arm 1: Experimental, intervention|The immediate intervention group will receive an online 9 week CBT intervention led by trained peers who have themselves recovered from postpartum depression. The CBT group will be two hours long, weekly and involves teaching and practice of core CBT skills. Core cognitive skills including thought records and cognitive restructuring are introduced and practiced from week 1. Behavioural techniques are introduced at week 2 and continue throughout the group, including behavioural activation, relaxation techniques, sleep strategies, exercise and goal setting. Each participant will receive a professionally design CBT manual to facilitate learning. Participants in the intervention group may also receive typical care or treatment as usual for new mothers.
88925506|NCT05044455|No Intervention|Arm 2: Control Group|The control group will receive treatment as usual (TAU) or typical care available for postpartum depression in participant's home communities, via participant's family doctor, mental health services, midwifery services, etc. Subjects in the control group will receive a list of resources where participants may seek treatment and will receive a monthly email encouraging them to seek treatment if symptoms worsen, including thoughts of self harm or harm to participant's child. Participants will also receive a copy of the Canadian Practice Guidelines for the treatment of PPD.
88925507|NCT05037708|Experimental|Group 1|Group 1 receives treatment A for 4 weeks. Afterwards, a period of washing or bleaching should be allowed in order to be sure that the effects of the intervention have disappeared. This period will last 2 months during which the usual treatment for LGA patients will be carried out, which consists of 2 monthly physiotherapy sessions, in this way it is intended that the subjects are in the initial state (as before the start of the first intervention). After this washout period, treatment B was applied to group 1.
88925508|NCT05037708|Active Comparator|Group 2|Group 2 receives treatment B for 4 weeks. Afterwards, a period of washing or bleaching should be allowed in order to be sure that the effects of the intervention have disappeared. This period will last 2 months during which the usual treatment for LGA patients will be carried out, which consists of 2 monthly physiotherapy sessions, in this way it is intended that the subjects are in the initial state (as before the start of the first intervention). After this washout period, treatment A was applied to group 2 .
88925509|NCT05032092|Experimental|Adult patients with locally advanced and/or metastasized carcinoma|"Liquid biopsies of all 200 study patients will be analysed with FoundationOne®Liquid CDx.~Tissue biopsies from all study patients for whom a tissue biopsy is available will be analysed with FoundationOne® CDx and IHC (approximately 50% of the enrolled patients).~Biomarker Monitoring of study patients receiving matched therapy with AVENIO ctDNA Surveillance Kit."
88925510|NCT05027425|Experimental|Durvalumab + Tremelimumab + Liver Transplant|Patients will be treated with the immunotherapy combination for up to 4 months. After a minimum 28 day washout, they will undergo locoregional therapy per institutional standards. Eventually, after a minimum 72-day washout from the end of immunotherapy, they will undergo liver transplant.
88925511|NCT05025826|Experimental|Phycocare|PHYCOCARE during 12 cycles of 14 days from day -3 before oxaliplatin based chemotherapy until cycle 3 months after the last dose of oxaliplatin (18 cycles, about 9 months) From D-3 to D14 before cycle 1 chemotherapy: patient will take Phycocare From D1 to D14 of cycle 2 chemotherapy and further chemotherapy cycles : patient will take Phycocare On days of chemotherapy the patient does not take Phycocare
88925512|NCT05025826|Placebo Comparator|Placebo|"Placebo during 12 cycles of 13 days from day -3 before cycle 1 of oxaliplatin based chemotherapy until 3 months after the last dose of oxaliplatin (9 months).~From D-3 to D13 before cycle 1 chemotherapy: patient will take Placebo From D1 to D13 of cycle 2 chemotherapy and further chemotherapy cycles : patient will take Placebo.~On days of chemotherapy the patient does not take Placebo"
88925513|NCT05012020|Experimental|mHealth Remote Monitoring|Use of the Clinic Portal by Healthcare professionals and use of the Mobile App by patients/caregivers
88925514|NCT05003648|Placebo Comparator|Placebo|Participants will be on the placebo arm for 2 months and will then cross over to the pramipexole arm for 2 months
88925515|NCT05003648|Active Comparator|Pramipexole|Participants will be on the pramipexole arm for 2 months and will then cross over to the placebo arm for 2 months
88925516|NCT04996849||Observational (data collection)|Patients undergo data collection every 6 months for up to 15 years.
89012820|NCT00414986|Active Comparator|3|Practice in this arm will have access to all chronic care tools, but will not have an in-practice change agent.
89012821|NCT00288444|Active Comparator|Docetaxel 36 mg/ m2 IV weekly and Lonafarnib 150 mg|Docetaxel 36 mg/ m^2 Intravenously weekly and Lonafarnib 150 mg by mouth twice a day daily.
89012822|NCT00288444|Active Comparator|Docetaxel 30 mg/ m2and Lonafarnib 150 mg|Docetaxel 30 mg/ m^2 Intravenously weekly and Lonafarnib 150 mg by mouth twice a day daily.
89501638|NCT04927403||Chronic gastroenterological diseases - inpatient stay and day clinic|Irritable Bowel Syndrome, Crohn's disease, Ulcerative colitis
89441655|NCT03354104|Experimental|Recession coverage with connective tissue graft + Emdogain®|A modified microsurgical tunnel technique by Zuhr et al. (2007). Initial sulcular incisions with a microsurgical blade are followed by a split-thickness buccal flap preparations using the tunneling knives. The preparation is extended into the mucosal tissue to gain sufficient flap mobility. The papillary regions are detached in their buccal aspects with the periosteum. The root surfaces are applied with 24% EDTA (PrefGel®, Straumann, Basel, Switzerland) for 2 minutes and then washed with saline. Subsequently, EMD (Emdogain®, Straumann, Basel, Switzerland) is applied on root surfaces. The graft is inserted into the tunnel and stabilized with absorbable suspensory sutures. The buccal flap is advanced coronally and stabilized with non-absorbable suspensory sutures.
89441656|NCT03354104|Active Comparator|Recession coverage with connective tissue graft|Procedure: A modified microsurgical tunnel technique by Zuhr et al. (2007). Initial sulcular incisions with a microsurgical blade are followed by a split-thickness buccal flap preparations using the tunneling knives. The preparation is extended into the mucosal tissue to gain sufficient flap mobility. The papillary regions are detached in their buccal aspects with the periosteum. The graft is inserted into the tunnel and stabilized with absorbable suspensory sutures. The buccal flap is advanced coronally and stabilized with non-absorbable suspensory sutures.
89441657|NCT05531968|Experimental|BMI2006 100Units|Patients were intramuscularly injected (IM) with a total of 20U of BMI2006 in 5 places of 0.1 mL (4 U/0.1 mL) each on the glabellar line.
89441658|NCT05531968|Active Comparator|Botox®|Patients were intramuscularly injected (IM) with a total of 20U of Botox® in 5 places of 0.1 mL (4 U/0.1 mL) each on the glabellar line.
89441659|NCT03354026|Experimental|Experimental: AICH-PXZY|Removing Blood Stasis medicine with folium sennae , Polygonum cuspidatum and so on, 8 herbals, Tong-fu-xing-shen. The intervention in this group includes po AICH-PXZY bid and the routine treatment of Western Medicine.Torn the medicine bag and take it after mixing with 50-80ml warm water（Or take by nasal feeding).
89441660|NCT03354026|Experimental|Experimental: AICH-without PXZY|Removing Blood Stasis medicine without folium sennae and Snakegourd seed, 6 herbals, without the effect of Poxuezhuyu. The intervention in this group includes po AICH-without PXZY bid and the routine treatment of Western Medicine.Torn the medicine bag and take it after mixing with 50-80ml warm water（Or take by nasal feeding).
89441661|NCT03354026|Placebo Comparator|Placebo: AICH-placebo|The placebo is made up of Starch, bitter taste and cyclodextrin. The intervention in this group includes po AICH-placebo bid and the routine treatment of Western Medicine.Torn the medicine bag and take it after mixing with 50-80ml warm water（Or take by nasal feeding).
89441662|NCT02309892|Experimental|Pemetrexed and Carboplatin plus L-DOS47|Patients will be recruited into cohorts of L DOS47 escalating doses, with a minimum of 3 and a maximum of 6 patients per cohort. The starting dose of L DOS47 will be 0.59 µg/kg; further possible dose levels that may be assessed are 0.78, 1.04, 1.38 and 1.84 µg/kg. The standard of care doses of pemetrexed [500 mg/m2] and carboplatin [AUC6], respectively, to be administered in combination with L-DOS47, will remain constant across cohorts.
89441663|NCT02163369|Experimental|Peppermint and Lavender Essential Oils|
89441664|NCT03122834||Cohort A|Newly diagnosed Heart Failure patients who will be treated with beta blockers (BB) and Angiotensin converting enzyme inhibitors (ACEIs)/or Angiotensin receptor blockers (ARBs) for the first time.
89441665|NCT03122834||Cohort B|Heart Failure patients who are candidate for add-on treatment with Spironolactone / Eplerenone.
89441666|NCT03505788|Placebo Comparator|high-dose loop diuretics+placebo|"At the moment of randomization (day 1), oral loop diuretics are stopped and the patient receives IV loop diuretics at a dose equal to the double of his oral daily maintenance dose + 500 mg IV bolus of placebo.~If the patient still have signs of volume overload the next mornings (day 2 and day 3), the patient will receive IV loop diuretics at a dose equal to the oral daily maintenance dose + 500 mg IV bolus of placebo. It the patient has no sign of volume overload at these time points, the study treatment will be stopped."
89441667|NCT03505788|Experimental|high-dose loop diuretics+acetazolamide|"At the moment of randomization (day 1), oral loop diuretics are stopped and the patient receives IV loop diuretics at a dose equal to the double of his oral daily maintenance dose + 500 mg IV bolus of acetazolamide.~If the patient still have signs of volume overload the next mornings (day 2 and day 3), the patient will receive IV loop diuretics at a dose equal to the oral daily maintenance dose + 500 mg IV bolus of acetazolamide. It the patient has no sign of volume overload at these time points, the study treatment will be stopped."
89441668|NCT03358784||PHILOS Plate|three or four-part fractures of proximal humerus treated with internal fixation
89441669|NCT03358784||Hemi-shoulder arthroplasty|three or four-part fractures of proximal humerus treated with hemi-shoulder arthroplasty
89501639|NCT04927403||Chronic Pain patients - inpatient stay and day clinic|Chronic pain syndrome, Rheumatism, Fibromyalgia
89501640|NCT04927403||Oncological diseases - day clinic|all kinds of oncological diseases
89199616|NCT04909827|Experimental|group B|prefabricated zirconia crowns
89501641|NCT04927403||post Covid syndrome - inpatient stay and day clinic|post Covid sydrome
89501642|NCT04927403||other diseases - day clinic|e.g. patients with cardiovascular diseases, chron. Pulmonary diseases, metabolic disorders and skin diseases, etc.
89199617|NCT04908722|Experimental|Group 1: Ad26.COV2.S Dose Level 1|Participants in the main study and sub study will receive intramuscular (IM) injections of Ad26.COV2.S as a 2-dose vaccination regimen at dose level 1 on Days 1 and 57.
89199618|NCT04908722|Experimental|Group 2: Ad26.COV2.S Dose Level 2|Participants will receive IM injections of Ad26.COV2.S as a 2-dose vaccination regimen at dose level 2 on Days 1 and 57 in the main study.
89441670|NCT04967313|Experimental|Behavioral Change Techniques to Increase Walking|Individuals will receive daily text messages with the goal of increasing daily walking by 2,000 more steps five days per week. Participants will be enrolled for a baseline period lasting two weeks where their average daily activity level will be assessed using a Fitbit device to generate an average daily step counts. Following completion of baseline, participants will receive daily text messages of behavior change techniques (BCTs) for eight weeks. The four BCTs utilized in this study are: goal setting, action planning, self-monitoring of behavior, and feedback on behavior. Each BCT will be delivered to participants daily for a two-week block. Four blocks (one BCT per block) will be delivered to the participant. The order in which the BCT interventions are presented to participants will be randomized by the study statistician. The goal of the BCT text messages will be to encourage walking behavior.
89441671|NCT02309970||Conservative|patient will get treatment with Antiplatelets or Anticoagulant depending on their clinical status/etiology
89441672|NCT02309970||IV tPA|patient will receive intravenous thrombolysis treatment
89441673|NCT02309970||Endovascular treatment|patient who will receive endovascular treatment
89441674|NCT03353948|Active Comparator|Metfrormin group (MET)|Drug: Metformin
89441675|NCT03353948|Active Comparator|COMBI group (COMBI)|Drug: liraglutide
89441676|NCT02161653|No Intervention|Prednisone|Prednisone 40 mg daily by mouth during 30 days.
89441677|NCT02161653|No Intervention|Pentoxifylline|Pentoxifylline 400 mg thrice in day by mouth during 30 days
89441678|NCT02161653|Experimental|Prednisone plus metadoxine|Prednisone 40 mg daily by mouth plus Metadoxine 500 mg thrice in day by mouth during 30 days.
89441679|NCT02161653|Experimental|Pentoxifylline plus metadoxine|Pentoxifylline 400 mg thrice in day by mouth plus Metadoxine 500 mg thrice in day by mouth during 30 days.
89441680|NCT03386526|Experimental|APG-1387 for Injection|APG-1387 will be explored sequentially using a standard 3+3 escalation scheme at the dose escalation phase and up to 20 patient per group at the dose expansion phase.
89441681|NCT02576938|Experimental|Baricitinib|"Administered once daily in multiple oral dose cohorts for 16 weeks~(Triamcinolone 0.1% topical also permitted)"
89441682|NCT02576938|Placebo Comparator|Placebo|"Administered orally once daily, for 16 weeks~(Triamcinolone 0.1% topical also permitted)"
89441683|NCT03358628||Osteosarcoma|Osteosarcoma patients with metastatic relapsed or unresectable progressive disease (total n= up to 20) following resection of the primary lesion and adjuvant chemotherapy.
89441684|NCT02163603||Pelvic osteotomy|
89441685|NCT03505632|Experimental|Recruitment with low PEEP|Recruitment maneuver ( RM) will carried out during 2 minutes with increasing PEEP in stepwise manner.PEEP increase from 5 to 10 cmH2O (3 breaths),then to 15 cm H2O (3 breaths), PEEP to 20 cmH2O (10 breaths).Then decrease by 5 cmH2O every 3 breaths till back to preset PEEP 5 cmH2O .Recruitment carried out at the following times: post intubation(T1) , after insuflation(T2) ,after desuflation (T3) and before extubation(T4) . The peak airway pressure should not exceed 40cmH2O .
89441686|NCT03505632|Active Comparator|High PEEP without RM|"Patients will receive from the start during anesthesia high PEEP (15 cmH2O) with maintaining the peak airway pressure below 40 cm H2O.~Monitoring times: after intubation(T1), post-insufflation(T2), after desuflation (T3) and before extubation(T4)."
89441687|NCT03355586||Suspected lung cancer|"Patients referred as part of a first diagnostic evaluation of newly detected pulmonary lesion(s) or when an indication for an invasive diagnostic procedure is found during follow-up of earlier detected pulmonary lesion.~Patients identified during per protocol CT imaging follow-up of known lesions when growth of the lesion is found and an indication for biopsy is determined by the treating physician and/or multidisciplinary board.~Patients identified when referred for surgical biopsy in case of nodule location inaccessible for CT-guided TTNA.~These will be subjected to a combined approach of modalities with the main intervention being electromagnetic navigation."
89441688|NCT03542487|No Intervention|1: Control|A randomly selected half of primary care practices in the study sample at Inova Health Care Services will not receive any intervention and patients/physicians located at these practices will continue with business as usual.
89501643|NCT05497700|Active Comparator|Ephedrine group|In this group, any hypotension less than 65 mm Hg will be corrected by bolus injection of 6 mg ephedrine. Bolus injection will be repeated every 3 minutes, as needed, to keep mean arterial pressure above 65 mm Hg.
89501644|NCT05497700|Experimental|Norepinephrine group|In this group, any hypotension less than 65 mm Hg will be corrected by bolus injection of 6 mcg norepinephrine. Bolus injection will be repeated every 3 minutes, as needed, to keep mean arterial pressure above 65 mm Hg.
89501645|NCT04866433|Experimental|Binaural group|Play realtime binaural sound applied music through headphones
88925517|NCT04958460|Experimental|Probiotics group|"Probiotics~Candidates conditions excluded:~Patients with major mental or neurological diseases such as intellectual disability, autism group disorders, schizophrenia, severe depression, bipolar disorder, epilepsy, brain injury, etc.~Those who have serious gastrointestinal diseases, physiological diseases or genetic diseases that will affect the results of intestinal microflora assessment~Have received ADHD-related drug treatment (containing Methylphenidate or Atomoxetine) in the past month.~Have used antibiotics or edible probiotic-related products (including drops, tablets, capsules, bacterial powder) in the past month.~Participated in other clinical research in the past month.~Vegetarians or those currently undergoing special diet therapy.~Evaluation by the host is not suitable for entering the test."
88925518|NCT04958460|Placebo Comparator|Control group|"Placebo~Candidates conditions excluded:~Patients with major mental or neurological diseases such as intellectual disability, autism group disorders, schizophrenia, severe depression, bipolar disorder, epilepsy, brain injury, etc.~Those who have serious gastrointestinal diseases, physiological diseases or genetic diseases that will affect the results of intestinal microflora assessment~Have received ADHD-related drug treatment (containing Methylphenidate or Atomoxetine) in the past month.~Have used antibiotics or edible probiotic-related products (including drops, tablets, capsules, bacterial powder) in the past month.~Participated in other clinical research in the past month.~Vegetarians or those currently undergoing special diet therapy.~Evaluation by the host is not suitable for entering the test."
88925519|NCT04952623|Experimental|E-learning Group|Participants will enroll in a 4-week e-learning program immediately after completing the pre-intervention assessment measures.
89501646|NCT04866433|Active Comparator|Audio group|Play music through headphones.
89199619|NCT04908722|Experimental|Group 3: Ad26.COV2.S Dose Level 3|Participants in the main study and sub study will receive IM injections of Ad26.COV2.S as a 2-dose vaccination regimen at dose level 3 on Days 1 and 57.
89199620|NCT04908722|Experimental|Group 4: Ad26.COV2.S Dose Level 4|Participants will receive IM injections of Ad26.COV2.S as a 2-dose vaccination regimen at dose level 4 on Days 1 and 57 in the main study.
89501647|NCT04866433|Sham Comparator|Control group|Wear headphones that do not produce sound.
89501648|NCT02155673|Experimental|Low Dose GCS-100|Low dose of GCS-100
88925520|NCT04952623|Active Comparator|Wait-list Control Group|Participants will enroll in a 4-week e-learning program, 4-5 weeks after completion of the pre-intervention assessment measures.
88925521|NCT04943172|Experimental|VenoValve|Subjects who receive VenoValve implant
88925522|NCT04913168|Experimental|Control Group|Control Group; no intervention
88925523|NCT04913168|Experimental|Intervention Group|Intervention Group; receives 13 month intervention
88925524|NCT04898816|Experimental|Group A|Application of cyanoacrylate tissue adhesive over the surgical wound
88925525|NCT04898816|Active Comparator|Group B|Suturing the surgical wound using braided black silk
88925526|NCT04880278|Active Comparator|Nabilone|In a randomized, double-blind, placebo-controlled design, we will administer a one-time oral dose of nabilone (1mg) or placebo approximately two hours prior to fMRI scanning and task performance in 60 adults with OCD.
88925527|NCT04880278|Placebo Comparator|Placebo|In a randomized, double-blind, placebo-controlled design, we will administer a one-time oral dose of nabilone (1mg) or placebo approximately two hours prior to fMRI scanning and task performance in 60 adults with OCD.
88925528|NCT04858425|Experimental|Niclosamide|Niclosamide tablets 400 mg 3 times daily for 14 days
88925529|NCT04858425|Placebo Comparator|Placebo|Matching placebo tablets 3 times daily for 14 days
88925530|NCT04824820|Experimental|Vibrator|Participants will be using commercially available genital vibrator for at least 5 minutes and/or reaching an orgasm three times a week for 3-4 months.
88925531|NCT04801771|Experimental|Subjects implanted with Inspire UAS System|Subjects who meet eligibility criteria will be implanted with the Inspire Upper Airway Stimulation (UAS) System.
88925532|NCT04762758|Experimental|PXT3003|Liquid oral solution, 10 mL twice a day, morning and evening with food
88925533|NCT04762758|Placebo Comparator|Placebo|Liquid oral solution, 10 mL twice a day, morning and evening with food
88925534|NCT04717908|Experimental|PZA sensitivity guided all oral regimen|"This regimen consists of two periods of 24-36 weeks. During the first 4-8 weeks(waiting for pyrazinamide drug sensitivity test), the regimen consists of bedaquiline, linezolid, cycloserine, clofazimine and pyrazinamide. Then based on molecular PZA drug sensitivity results, patients will be divided into three sub-groups.~The regimen for PZA-S patients, consisting of bedaquiline, linezolid, cycloserine and pyrazinamide, are given until the 24th week (prolonged to 28 or 32 weeks if no smear conversion by end of 16th and 20th week).~PZA-R sub-group regimen, consisting of bedaquiline, linezolid, cycloserine and clofazimine ,are given until 36th week (prolonged to 40 or 44 weeks if no smear conversion by end of 16th and 20th week) .~PZA-U sub-group continue the previous regimen, consisting of bedaquiline, linezolid, cycloserine , clofazimine and pyrazinamide ,until 36th week (prolonged to 40 or 44 weeks if no smear conversion by end of 16th and 20th week) ."
88925535|NCT04712656||OSA Subjects Treated with CPAP|Patients with moderate to severe OSA (ODI4>15/h) who accept CPAP therapy.
88925536|NCT04711850||Imlifidase treatment in feeder Study 16-HMedIdeS-12|No treatment is given in this long-term follow-up study. In the feeder study (16-HMedIdeS-12) the patients in this group were treated with imlifidase.
89501649|NCT02155673|Experimental|High Dose GCS-100|GCS-100 High dose
89441689|NCT03542487|Experimental|2a: Practice Orientation- No Reminder|In the other randomly selected half of primary care practices in the study sample at Inova Health Care Services, practices will be encouraged to batch order blood glucose flowsheets for all patients with diabetes with active MyChart accounts. The research team will contact physicians and practice managers with an explanation of the initiative and instructions for completing batch orders and viewing entries through the system. Additionally, providers will be given a template for a secure smart-text message to send to all patients receiving the flowsheets, instructing them to enter data for the study period. The secure message will also provide them with information on how to enter data, and on the benefits of tracking blood glucose. Of this group of practices, patients will be divided at the individual level into 4 reminder groups. Arm 2a will receive no additional reminder messaging to enter glucose measurements in the electronic flowsheets.
88925537|NCT04711850||Plasma exchange (PE) treatment in feeder Study 16-HMedIdeS-12|No treatment is given in this long-term follow-up study. In the feeder study (16-HMedIdeS-12) the patients in this group were treated with PE.
88925538|NCT04665895|Experimental|Test Product|Fluticasone propionate 100 mcg/blister oral inhalation powder/Respirent Pharmaceuticals
88925539|NCT04665895|Active Comparator|Reference Product|FLOVENT DISKUS® 100 mcg/blister oral inhalation powder/GSK
88925540|NCT04665895|Placebo Comparator|Placebo|Placebo
88925541|NCT04643145|Active Comparator|Ureteral catheter|This group will receive ureteral catheter for 2 days after the procedure
88925542|NCT04643145|Active Comparator|Indwelling double J stent|This group will receive indwelling double J stent for 2-4 weeks after the procedure
88925543|NCT04617912|Experimental|PennPET Explorer|"All subjects will be scanned in the CT scanner and then the scanner bed will be moved into position in the PennPET Explorer for initiation of the PET scan. For all PET scans a radioactive imaging drug is used.~The radiotracer injection may be performed according to one of the following scenarios:~As part of a clinical standard-of-care (SOC) PET/CT or PET/MRI scan (using an FDA-approved radiotracer; the PennPET Explorer cannot yet accommodate a study that requires a commercially available 510(k)-approved instrument for clinical results, subjects in this group will be scanned on both a commercial instrument (PET/CT or PET.MRI) and the PennPET Explorer),~As part of another research study (using either an FDA-approved radiotracer or an investigational radiotracer),~As a research injection designed specifically to utilize the PennPET Explorer (using an FDA-approved radiotracer)."
88925544|NCT04607941||Cases|Subjects diagnosed as positive for SARS-CoV-2 infection
88925545|NCT04607941||Close Subjects|"Subjects living within the same household as cases:~close cases if tested positive for SARS-CoV-2 following contact tracing recommendations~close controls if tested negative for SARS-CoV-2 following contact tracing recommendations"
88925546|NCT04607941||Control Subjects|Controls selected within the population to allow for an age, gender and location of residence-matched analysis with cases
88925547|NCT04604743|Experimental|Intervention|2 Clinics
88925548|NCT04604743|No Intervention|Control|2 Clinics
88925549|NCT04600479|Experimental|prevalence and follow-up of HCV positive patients|"Cross-sectional assessment of prevalence : evaluation of the prevalence of HCV, HBV and HIV viral infections~Cohort follow-up of HCV positive patients : evaluation of care pathway and barriers to care for hepatitis C"
88925550|NCT04545554|Experimental|Romosozumab|
88925551|NCT04523519|Experimental|Video directly observed therapy with contingency management|Video directly observed therapy with contingency management, in addition to Integrated Next-Step Counseling.
88925552|NCT04523519|Placebo Comparator|Integrated Next-Step Counseling|
88925553|NCT04518657|Experimental|Behavioral Intervention for Physical Activity in MS (BIPAMS)|The current behavioral intervention consists of two primary components; an internet website and oneonone video chats with a behavioral coach.The internet website involves content delivered through interactive video courses.The interactive video courses are based on elements of social cognitive theory.Each course consists of an introduction,the primary content,and a take home message.The interactive courses include embedded,supplementary options such as videos on content and worksheets related to the topic.A pedometer is provided for tracking steps,and these steps will be entered into the website so progress can be monitored.The chats support adherence to the intervention,discussion of website material,supportive accountability,and reporting of adverse events/injuries.The chats are conducted facetoface through an online videoconferencing platform.The chats occur 7 times during the first 2 months,4 times during the second 2 months,and twice during the final 2 months of the intervention.
89012823|NCT00288444|Active Comparator|Docetaxel 36 mg/ m2 and Lonafarnib 100 mg|Docetaxel 36 mg/ m^2 Intravenously weekly and Lonafarnib 100 mg by mouth twice a day daily
89012824|NCT00288444|Active Comparator|Docetaxel 30 mg/m2 and Lonafarnib 100 mg|Docetaxel30 mg/m^2 Intravenously weekly and Lonafarnib 100 mg by mouth twice a day daily.
89012825|NCT00415103|Experimental|1|Aprepitant: 125 mg oral day 1, follows by 80 mg oral every 24 hours in next days Palonosetrón: 0.25 mg iv every 48 horas starting day 1
89012826|NCT00415103|Active Comparator|2|Granisetrón : 3 mg iv day, all days the patient will be treated with chemotherapy, and Aprepitant placebo 125 mg oral, day 1, and 80 mg next days in chemotherapy treatment.
89441690|NCT03542487|Experimental|2b: Practice Orientation- Standard Reminder|Practices will be encouraged to batch order blood glucose flowsheets for all patients with diabetes with active MyChart accounts. The research team will contact physicians and practice managers with an explanation of the initiative and instructions for completing batch orders and viewing entries through the system. Additionally, providers will be given a template for a secure smart-text message to send to all patients receiving the flowsheets, instructing them to enter data for the study period. The secure message will also provide them with information on how to enter data, and on the benefits of tracking blood glucose. Of this group of practices, patients will be divided at the individual level into 4 reminder groups. Arm 2b will receive generic biweekly reminders, addressed from Inova Medical Group, to enter glucose measurements in the electronic flowsheets.
89501650|NCT02691741|Experimental|TFNT00|AcrySof® IQ PanOptix™ Presbyopia-Correcting IOL, bilateral implantation
88925554|NCT04518657|Sham Comparator|Wellness for MS (WellMS)|Provides an internet website and oneonone video chats that discuss materials about self-managing multiple sclerosis (MS) consequences and health indicators through methods other than physical activity.The materials are transformations of brochures provided by the National MS Society,including Gait or Walking Problems:The Basic Facts;MS and Your Emotions;Pain:The Basic Facts; Solving Cognitive Problems;Taming Stress in MS;Food for Thought:MS and Nutrition;and Vitamins,Minerals,and Herbs:An Introduction.The delivery of the internet materials and chat sessions will occur on the same time schedule and frequency as the intervention condition,and will have a comparable time commitment. The control condition will not involve tracking steps and a pedometer with not be provided.
88925555|NCT04500574|Experimental|Latanoprost contact lens|The L-CL arm will have the drug-eluting latanoprost contact lens (L-CL) and a sham drop.
88925556|NCT04500574|Placebo Comparator|Topical Latanoprost|The placebo arm will have a commercial contact lens with no drug with a nightly 0.005% latanoprost drop.
88925557|NCT04487457||Cancer|Patients receiving chemotherapy alone after immunotherapy for NSCLC or bladder cancer or ENT cancer
88925558|NCT04416282|Experimental|Terlipressin + Albumin|Injection terlipressin 2 mg/24 hours infusion + i/v albumin 1g/Kg/day
88925559|NCT04416282|Active Comparator|Albumin|i/v albumin 1g/Kg/day for next 36 hours f/b inj terlipressin 2mg/24 hours
88925560|NCT04383886||Emergency department staff|
88925561|NCT04375150||Patients with advanced renal cell carcinoma (RCC)|
88925562|NCT04321291|Experimental|Nurse information|The patient will receive a generic information leaflet plus an Individual information by nurse on biosimilars
88925563|NCT04321291|Other|Information Leaflet|The patient will receive a generic information leaflet only
88925564|NCT04231513|Experimental|SAD, Cohort 1: E2814 or E2814-matched Placebo|Participants will receive either E2814 or E2814-matched placebo as an intravenous infusion, once, on Day 1.
88925565|NCT04231513|Experimental|SAD, Cohort 2: E2814 or E2814-matched Placebo|Participants will receive either E2814 or E2814-matched placebo as an intravenous infusion, once, on Day 1.
88925566|NCT04231513|Experimental|SAD, Cohort 3: E2814 or E2814-matched Placebo|Participants will receive either E2814 or E2814-matched placebo as an intravenous infusion, once, on Day 1.
88925567|NCT04231513|Experimental|SAD, Cohort 4: E2814 or E2814-matched Placebo|Participants will receive either E2814 or E2814-matched placebo as an intravenous infusion, once, on Day 1.
88925568|NCT04231513|Experimental|SAD, Cohort 5: E2814 or E2814-matched Placebo|Participants will receive either E2814 or E2814-matched placebo as an intravenous infusion, once, on Day 1.
88925569|NCT04231513|Experimental|MAD, Cohort 1: E2814 or E2814-matched Placebo|Participants will receive E2814 or E2814-matched placebo as an intravenous infusion Q4W on 3 occasions up to Day 57 of the Treatment Period.
88925570|NCT04231513|Experimental|MAD, Cohort 2: E2814 or E2814-matched Placebo|Participants will receive E2814 or E2814-matched placebo as an intravenous infusion Q4W on 3 occasions up to Day 57 of the Treatment Period.
88925571|NCT04231513|Experimental|MAD, Cohort 3: E2814 or E2814-matched Placebo|Participants will receive E2814 or E2814-matched placebo as an intravenous infusion Q4W on 3 occasions up to Day 57 of the Treatment Period.
89501651|NCT02691741|Active Comparator|839MP|AT LISA® tri IOL, bilateral implantation
88925572|NCT04231513|Experimental|MAD, Cohort 4: E2814 or E2814-matched Placebo|Participants will receive E2814 or E2814-matched placebo as an intravenous infusion Q4W on 3 occasions up to Day 57 of the Treatment Period.
88925573|NCT04231032|Active Comparator|Active ventricular pacing|Asynchronous dual chamber pacing (DOO mode) at a heart rate just higher than that expected to be achieved with adenosine infusion (same rate in each arm)
88925574|NCT04231032|Placebo Comparator|Back-up ventricular pacing|Asynchronous atrial pacing with intrinsic ventricular activation (AOO mode) at a heart rate just higher than that expected to be achieved with adenosine infusion (same rate in each arm)
88925575|NCT04191538|Experimental|Conditioning electrical stimulation|Patients will receive percutaneous electrical stimulation one week prior to carpal tunnel release. They will receive sham stimulation immediately after surgery to ensure blinding.
88925576|NCT04191538|Active Comparator|Postoperative electrical stimulation|Patients will receive electrical stimulation immediately following carpal tunnel release, per out previous studies. They will receive sham stimulation 1 week prior to surgery to ensure blinding.
88925577|NCT04191538|Sham Comparator|No electrical stimulation|Patients will not receive electrical stimulation. They will receive electrical stimulation before and after surgery to ensure blinding.
88925578|NCT04152551|Experimental|Adult Treatment Arm|Intervention treatment arm. Adults (18+ years) with type 1 OI. Must have at least mild hearing loss. Will receive Risedronate (35mg, 0-2x/week as clinically indicated) for duration of study. Changes in hearing, quality of life, and bone density will be monitored.
89537066|NCT04839029|Experimental|Bipolar En bloc TURBT|patient subjected to bipolar Needlescopic En bloc resection of NMIBC
88821733|NCT02192398|Active Comparator|Guanfacine (2mg)|"Subjects will be randomized into 1 of the following 3 treatment groups:~guanfacine (2mg)~guanfacine (1mg)~placebo~Subjects will be instructed to take one capsule in the evening for 4 weeks."
88821734|NCT02192398|Active Comparator|Guanfacine (1mg)|"Subjects will be randomized into 1 of the following 3 treatment groups:~guanfacine (2mg)~guanfacine (1mg)~placebo~Subjects will be instructed to take one capsule in the evening for 4 weeks."
88821735|NCT02192398|Placebo Comparator|Placebo|"Subjects will be randomized into 1 of the following 3 treatment groups:~guanfacine (2mg)~guanfacine (1mg)~placebo~Subjects will be instructed to take one capsule in the evening for 4 weeks."
88821736|NCT02141646|Experimental|Motivational interviewing|
88821737|NCT02141646|Experimental|Behavioral skills training|
88821738|NCT02069730|Experimental|Unmatched Treatment (Selinexor)|"Selinexor, 30mg/m2, by mouth, twice weekly, every 28 day cycles.~If patients have a druggable aberration but there is no access to the relevant agent, then patients will receive selinexor"
88821739|NCT02069730|Experimental|Matched Therapy|"EGFR or HER2 Inhibitor,FGFR Inhibitor,C-KIT Inhibitor, Anti-androgen ,NOTCH Inhibitor,MEK or PI3K Inhibitor .~If the matched therapy is given through a clinical trial, the dosing schedule will be determined by that particular trial protocol. For matched treatments administered outside of a clinical trial, the dosing schedule will be the recommended dose by the expertise of the treating investigator."
88821740|NCT02043691|Experimental|Cook Custom Aortic Endograft|Participants will receive the following: Clinical Exam, Blood Tests, CT Scans (with and without contrast) or Ultrasound, Abdominal Device X-ray, and Angiography. These tests will aid in the design of the Cook Custom Aortic Endograft. The Cook Custom Aortic Endograft has a variable design such that seal and fixation may be obtained proximal and distal to pathology in the juxtarenal aorta, suprarenal or thoracoabdominal aorta. Grafts may include a combination of up to 5 fenestrations and branches.
88821741|NCT02043691|Experimental|Zenith t-Branch Endovascular Graft|Participants will receive the following: Clinical Exam, Blood Tests, CT Scans (with and without contrast) or Ultrasound, Abdominal Device X-ray, and Angiography. These tests will aid in the sizing of the the Zenith t-Branch Endovascular Graft. The Zenith t-Branch Endovascular Graft is a tubular graft with four branches and a covered stent at the proximal end that contains barbs for proximal fixation of the device. The graft is designed to be connected with celiac, superior mesenteric and two renal arteries via self-expanding covered bridging stents.
88821742|NCT02043691|Experimental|Surgeon-Modified Endograft|Participants will receive the following: Clinical Exam, Blood Tests, CT Scans (with and without contrast) or Ultrasound, Abdominal Device X-ray, and Angiography. These tests will aid in the design of the Surgeon-Modified Endografts. These will be created in the operating room by modifying a commercially-available Cook Alpha Thoracic Endograft or Cook Zenith Infrarenal Aortic Device such that seal and fixation may be obtained proximal and distal to pathology in the juxtarenal aorta, suprarenal or thoracoabdominal aorta. Grafts may include a combination of up to 5 fenestrations and branches.
88821743|NCT02041845|Active Comparator|A|3D conformal thoracic radiotherapy at a total dose of 45 Gy in 30 fractions, 2 fractions per day, 5 days a week
88821744|NCT02041845|Experimental|B|3D conformal thoracic radiotherapy at a total dose of 60 Gy in 40 fractions, 2 fractions per day, 5 days a week
88821745|NCT02041416||Group 1|REDCap and paper pencil
88821746|NCT02041416||Group 2|REDCap twice
88821747|NCT02041416||Group 3|Support Screen and paper pencil
88821748|NCT02041416||Group 4|Support Screen twice
88821749|NCT02037048|Active Comparator|Positive Pathologic Response|Patients with ≤50% viable tumor cells remaining in the surgical specimen will receive postoperative chemo-radiotherapy with the mFOLFOX6 regimen
88821750|NCT02037048|Experimental|Negative Pathologic Response|Patients with >50% viable tumor cells remaining in the surgical specimen, will receive postoperative chemo-radiotherapy with weekly carboplatin and paclitaxel.
88821751|NCT02018354|Active Comparator|ACL Reconstruction|Standard ACL reconstruction only.
88821752|NCT02018354|Experimental|ACL + LET|Anatomic ACL reconstruction following the same procedure as the active comparator group with an added lateral extra-articular tenodesis (LET).
88821753|NCT01979367|Experimental|Anodyne|To evaluate the efficacy treatment of lower extremity pathologies from neurological ischemia disorders using the Monochromatic Infrared Photo Energy (MIRE)
88821754|NCT01940185||LINX device|Patients implanted with the LINX® Reflux Management System.
89012827|NCT00417690|Experimental|A|Oral granules administered as one 4 g packet three times daily for two weeks followed by one 4 g packet two times daily for two weeks
89537067|NCT04839029|Active Comparator|Monopolar En bloc TURBT|patient subjected to Monopolar Needlescopic En bloc resection of NMIBC
89537068|NCT03301181|Experimental|Arm A|Approximately 20 subjects to receive BGB-3111 and rifampin
89537069|NCT03301181|Experimental|Arm B|Approximately 20 subjects to receive BGB-3111 and itraconazole
88821755|NCT01836003|Experimental|Tokafatso programmatic intervention|Antenatal clinic receives the Tokafatso programmatic intervention, including educational session, SMS-based facilitation of CD4 result delivery, and patient tracing support.
88821756|NCT01836003|No Intervention|Usual Care|Has not yet received Tokafatso combination programmatic intervention
89441691|NCT03542487|Experimental|2c: Practice Orientation- Gift Card Reminder|Practices will be encouraged to batch order blood glucose flowsheets for all patients with diabetes with active MyChart accounts. The research team will contact physicians and practice managers with an explanation of the initiative and instructions for completing batch orders and viewing entries through the system. Additionally, providers will be given a template for a secure smart-text message to send to all patients receiving the flowsheets, instructing them to enter data for the study period. The secure message will also provide them with information on how to enter data, and on the benefits of tracking blood glucose. Of this group of practices, patients will be divided at the individual level into 4 reminder groups. Arm 2c will receive generic biweekly reminders to enter data, addressed from Inova Medical Group, that will also notify that the patient will be entered to win a $50 gift card for each day entering data.
89441692|NCT03542487|Experimental|2d: Practice Orientation- Physician Reminder|Practices will be encouraged to batch order blood glucose flowsheets for all patients with diabetes with active MyChart accounts. The research team will contact physicians and practice managers with an explanation of the initiative and instructions for completing batch orders and viewing entries through the system. Additionally, providers will be given a template for a secure smart-text message to send to all patients receiving the flowsheets, instructing them to enter data for the study period. The secure message will also provide them with information on how to enter data, and on the benefits of tracking blood glucose. Of this group of practices, patients will be divided at the individual level into 4 reminder groups. Arm 2d will receive biweekly reminders, addressed from their physician, encouraging them to enter glucose measurements in the electronic flowsheets (Note that though messages will be addressed from physician, they will be sent by Inova IT).
89441693|NCT03355508|Other|puncture bevel up|
89441694|NCT03355508|Other|puncture bevel domn|
88925579|NCT04152551|No Intervention|Child (Bisphosphonate Arm)|Observational (no investigational intervention) arm. Children (6-17 years) with any type of OI who are already receiving bisphosphonate treatment as standard of care treatment for orthopedic symptoms. Changes in hearing, quality of life, and bone density will be observed for the duration of the study.
89441695|NCT02313246|Experimental|Group Cognitive Behaviour Therapy|Patients will complete an 11-session group cognitive behaviour therapy for IBS that will be led by two clinicians, one of whom will be a registered clinical psychologist, at the Digestive Diseases Clinic at McMaster University Medical Centre. The group cognitive behaviour therapy will include weekly 2-hour sessions for 11 weeks. Sessions will cover the following topics: psychoeducation about IBS and the role of stress in exacerbating IBS symptoms, progressive muscle relaxation, stress management, problem solving, identifying and modifying maladaptive thinking patterns, decreasing behavioural avoidance, and exposure to feared physical sensations.
89441696|NCT05524636|Experimental|Experimental|Exercise with peripheral magnetic stimulation of the abdominal wall muscles
89441697|NCT05524636|Active Comparator|Control|Exercise without peripheral magnetic stimulation of the abdominal wall muscles
89441698|NCT02310048|Experimental|MT-1303-FormA|MT-1303, Capsule Formulation A
89441699|NCT02310048|Experimental|MT-1303-FormB|MT-1303, Capsule Formulation B
89441700|NCT03355430||moderate keratoconus group|moderate keratoconus group underwent combined corneal wavefront-guided transepithelial photorefractive keratectomy (tPRK) and accelerated corneal collagen cross-linking (CXL) after intracorneal ring segment (ICRS) implantation
88925580|NCT04152551|No Intervention|Child (Control Arm)|Observational arm. Children (6-17 years) with any type of OI who are not receiving bisphosphonate treatment. Changes in hearing, quality of life, and bone density will be observed for the duration of the study.
88925581|NCT04152551|No Intervention|Adult Control Arm|Observational arm. Adults (18+ years) with type 1 OI. Changes in hearing, quality of life, and bone density will be monitored.
88925582|NCT04126161|Active Comparator|CT|Patients have standard of care CT prior to primary hip replacement
88925583|NCT04126161|Experimental|Ultrasound|Patients have ultrasound scans together with standard of care CT prior to primary hip replacement
88925584|NCT04112498|Experimental|nivolumab + relatlimab + rHuPH20|
88925585|NCT04069533|Experimental|RP-L102|RP-L102 is CD34+ enriched cells from subjects with Fanconi anemia subtype A transduced ex vivo with lentiviral vector carrying the FANCA gene
88925586|NCT04064749|No Intervention|Control|Participants will receive screening (i.e. services as usual) provided by a national credit counseling program.
88925587|NCT04064749|Experimental|Intervention|Participants will receive screening services provided by the credit counseling program plus added brief intervention services by University of Maryland School of Social Work (UMSSW). Added intervention services include: 1) feedback about the individual's gambling, and 2) text messages to support the individual.
88925588|NCT04057339|Placebo Comparator|SOC (Standard of Care)|Everyone in this arm will receive standard of care nutritional behavioral counseling and will be required to log their caloric intake through the use of a smartphone app.
88925589|NCT04057339|Experimental|TRE + SOC|Everyone in this arm will receive standard of care nutritional behavioral counseling and will implement a daily 8-10-hour window within which they must consume their calories. They will also be required to log their caloric intake through the use of a smartphone app.
88925590|NCT04042051|Other|Single Arm|This study is a phase Ib open label, single arm, adaptive multi-centre trial. Patients with unresectable locally advanced or metastatic HER2-positive breast cancer who previously received trastuzumab and a taxane, separately or in combination, will be treated with copanlisib (as assigned at registration according to the dose escalation scheme) plus trastuzumab emtansine 3.6mg/kg IV on day 1 of a 21-day cycle.
88925591|NCT04033991||Patients with advanced RCC|Patients with a diagnosis of kidney cancer (renal cell carcinoma, advanced or metastatic)
88925592|NCT04004741|Experimental|Osteopathic Manipulative Treatment|Group A will receive osteopathic treatment by NMM/OMM board certified attending physicians. The protocol for the OMT intervention group is based on the guidelines set forth previously in textbooks. The protocol will last 25 minutes total, with 10 minutes for the evaluation and 15 minutes for treatment. The protocol will start in ribs so as to not exacerbate any tachyarrhythmias with rib raising, thoracic myofascial release, and a pectoralis lift. The investigator will then proceed with opening the thoracic inlet, cervical myofascial release, suboccipital release, and then end by checking for and treating Chapman's points. The physician will submit their osteopathic evaluation and fill out a form in order to determine if certain arrhythmias have an associated trigger point.
89441701|NCT02305836|Experimental|Electroacupuncture combined with donepezil|Every session will last for 30 minuets and will be given every other day. There are 36 sessions for each participant in all (3 session per week, 12 weeks).
89441702|NCT02305836|Active Comparator|donepezil|Donepezil will be given once daily before bed-time for the first 4-6 weeks. Based on the treatment effect, the dosage may be increased to 10 mg once daily before bed-time for the next 6-8 weeks. Donepezil will be taken for continuous 24 weeks. The full course of treatment is 36 weeks.
89441703|NCT02155179||Good prognosis|Sperm samples >15mill/ml >30% progresive sperms
89441704|NCT02155179||bad prognosis|Sperm samples <5mill/ml <5% progresive sperms
89441705|NCT04522934|Experimental|Pain Neuroscience Education|Patients received 24 sessions, in a 8-week period, of multimodal physiotherapy along with four sessions of pain neuroscience education.
89441706|NCT04522934|Active Comparator|Biomedical Education|Patients received 24 sessions, in an 8-week period, of multimodal physiotherapy along with four sessions of biomedical education.
89441707|NCT02305914||follow-up visit|Patients who come for follow-up visit will fill in the questionnaire and undergo regular laboratory examination such as liver function test and CRP,faecal elastase-1 as well as CT scanning.Additionally,blood sample of every patient will be collected and sent to the Lab for storage and further experimented.
89441708|NCT02161809|Experimental|Physical Activity Intervention|This arm (10 summer day camps) will receive the Physical Activity intervention the first year and both healthy eating and physical activity the second and thrid years.
89441709|NCT02161809|Other|Healthy EAting Intervention|This arm (10 summer day camps) will receive the Healthy Eating intervention the first year and both healthy eating and physical activity the second and thrid years.
89441710|NCT03353714|Placebo Comparator|Pudendal block with saline|Pudendal block with normal saline
89441711|NCT03353714|Active Comparator|Pudendal block with bupivacaine|Pudendal block with bupivacaine
89441712|NCT02576860|Experimental|Treatment|CLS001 (Omignan) gel applied once daily
89441713|NCT02576860|Placebo Comparator|Vehicle Gel|Vehicle gel applied once daily
89441714|NCT03503136|Experimental|A (TPF+P-RT)|Induction docetaxel, cisplatin, and fluorouracil plus concurrent chemoradiotherapy with cisplatin
89441715|NCT03503136|Experimental|B (TNF+N-RT)|Induction docetaxel, nedaplatin, and fluorouracil plus concurrent chemoradiotherapy with nedaplatin
89441716|NCT03503136|Experimental|C (TPX+P-RT)|Induction docetaxel, cisplatin, and capecitabine plus concurrent chemoradiotherapy with cisplatin
89441717|NCT03503136|Experimental|D (TNX+N-RT)|Induction docetaxel, nedaplatin, and capecitabine plus concurrent chemoradiotherapy with nedaplatin
88925593|NCT04004741|Sham Comparator|Light Touch Treatment|Group B will receive a light touch treatment, based on previous research done studying heart rate variability and OMM, where sham treatment was utilized. The protocol consisted of contacting the right ankle, left knee, right hip, diaphragm, right shoulder, neck, and cranium for precisely two minutes each, with the goal of preventing placebo autonomic nervous system stimulation. The protocol is 25 minutes long, with 10 minutes for the evaluation and 15 minutes for treatment.
88925594|NCT03961360|Experimental|162 mg/day Aspirin|
88925595|NCT03961360|Active Comparator|81 mg/day Aspirin|
89441718|NCT04445168|No Intervention|Usual Care|Participants assigned to usual care may receive advice from their primary care physician to increase their physical activity. They will receive handouts about every 6 weeks on general health topics.
89441719|NCT04445168|Experimental|Intervention|Participants assigned to the intervention arm will receive telephone-based motivational interviews with trained interventionists to encourage increases in physical activity.
88925596|NCT03941769|Experimental|Supportive care (recombinant interleukin-7)|Within 60-180 days after CBT, patients receive recombinant interleukin-7 IM or SC once per week for 3 weeks.
89441720|NCT02305992|Experimental|Axillary Block with 0.5% Ropivicaine|Patients will receive an axillary block using an ultrasound-guided technique. After skin infiltration with 1 mL of 2% lidocaine, a 22-gauge insulated needle is advanced in-plane from the cephalic aspect of the transducer toward the posterior aspect of the axillary artery. Prior to injection, the syringe is aspirated to confirm extra-vascular placement of the needle. 20 mL solution of 0.5% ropivicaine is then injected slowly, with syringe aspiration after every 5 mL injection to confirm extravascular placement.
89441721|NCT02305992|Experimental|Stellate Ganglion Block with 0.2% Ropivicaine|Patients will receive stellate ganglion block and local anesthetic using an ultrasound-guided technique.After skin infiltration with 1 mL of 2% lidocaine, a 22-gauge insulated needle is advanced in-plane from the lateral position toward the anterior aspect of longus colli muscle just posterior to the internal jugular vein. Prior to injection, the syringe is aspirated to confirm extra-vascular placement of the needle. 10 mL of 0.2% ropivicaine is then injected slowly, with syringe aspiration after every 5 mL injection to confirm extravascular placement.
89441722|NCT02305992|Active Comparator|Local anesthetic infiltration with 0.25% Bupivicaine|Patients will receive local anesthetic infiltration of 0.25% Bupivicaine at the surgical site which will last approximately 6 hours.
89441723|NCT03355352||Patients treated with conventional i.v. PCA|
89441724|NCT03355352||Patients treated with Zalviso|
89441725|NCT05529940|Experimental|Neoadjuvant FOLFIRINOX|6 cycles of neoadjuvant mFOLFIRINOX followed by surgical resection and 6 cycles of adjuvant mFOLFIRINOX
89441726|NCT05529940|Active Comparator|Upfront Surgery|surgical resection followed by 12 cycles of adjuvant mFOLFIRINOX
89441727|NCT02313324|Experimental|ESWT group|The patients were randomly assigned to the extracorporeal shock wave therapy (ESWT) group.
89537070|NCT02721251|Experimental|Exercise|16 week intervention, building up to 30-45 minutes of aerobic exercise 4 days per week, and 15 min of resistance exercise 2 days per week
89441728|NCT02313324|Active Comparator|SWD combined IFC group|The patients were randomly assigned to the SIT group. The patients received combined therapy with shortwave diathermy (SWD) and interferential current (IFC) performed by the same physiotherapist at each treatment session.
89441729|NCT03353636|Experimental|Natural Calm Magnesium|150mg elemental magnesium in a single oral dose
89441730|NCT03353636|Active Comparator|Magnesium Bis-glycinate|150mg elemental magnesium in a single oral dose
89441731|NCT03353636|Active Comparator|MAGSmart|150mg elemental magnesium in a single oral dose
89441732|NCT03353636|Active Comparator|Magnesium citrate|150mg elemental magnesium in a single oral dose
88925597|NCT03924401|Experimental|Participants Receiving Abatacept|Pediatric participants who are undergoing URD HSCT for serious NMHD will receive 8 doses of abatacept in addition to conventional GVHD prophylaxis.
88925598|NCT03922386|Other|JX model|Subjects implanted with an RA XFINE lead (JX model)
88925599|NCT03922386|Other|TX model|Subjects implanted with an RV XFINE lead (TX model)
88925600|NCT03893188||People asking for PrEP|All individuals aged >18 years asking for PrEP prescription at one of the participating centers will be asked to participate to the SwissPrEPared Study(consecutive ongoing recruitment). Only HIV negative individuals will be deemed eligible.
89441733|NCT03353636|Placebo Comparator|Placebo|
88925601|NCT03865342|Experimental|Noom Coach DPP|Individuals will receive special instructions on how to use the app and will self-monitor their weight, exercise and receive daily DPP core content through the app over 16 weeks plus guidance from a coach, and will thereafter receive post-core DPP content up to 52 weeks.
88925602|NCT03865342|No Intervention|Usual Care|"The control group will be a usual care condition in which participants are free to seek any assistance for their medical care during the study period plus a paper version of the DPP curriculum."
88925603|NCT03853915|Experimental|FDG PET Scan|[F-18] - FDG PET Scan and blood sample to measure HPV DNA
88925604|NCT03849820|Active Comparator|Robotic-assisted partial nephrectomy|da Vinci surgical robotic assisted partial nephrectomy
88925605|NCT03849820|Active Comparator|Open partial nephrectomy|Open partial nephrectomy surgery
88925606|NCT03838510|Experimental|Brief Counseling Intervention|
88925607|NCT03838510|No Intervention|Control Group|
88925608|NCT03813355|Experimental|Active stimulation|Brain stimulation by Transcranial Direct Current Stimulation (tDCS) with active stimulations
88925609|NCT03813355|Sham Comparator|Sham stimulation|Brain stimulation by Transcranial Direct Current Stimulation (tDCS) with inactive stimulations
89441734|NCT04463160|Experimental|"prevention program for prediabetes Say No to Diabetes"|
89441735|NCT04463160|No Intervention|No prevention program|
89441736|NCT04523402|Experimental|Neoadjuvant chemotherapy following liver section|"1. GEMOX chemotherapy:~It is performed within one week after the identification of ICC;~Day1 Oxaliplatin 85mg/m2 + gemcitabine 1g/m2, Day 8 gemcitabine 1g/m2;~Three weeks is a course of treatment;~A total of 3 courses.~2. Liver resection: It is performed 1 month after chemotherapy"
89441737|NCT04523402|No Intervention|Liver resection|"Liver resection:~It is performed within one week after the identification of ICC."
89441738|NCT04463784|Experimental|Efavirenz 400MG Oral Tablet|Recruited treatment-naive HIV infected patients will be given Lamivudin 300mg per day, tenofovir 300mg per day and efavirenz 400mg per day as antiretroviral treatment.
89441739|NCT04463784|Active Comparator|Efavirenz 600MG Oral Tablet|Recruited treatment-naive HIV infected patients will be given Lamivudin 300mg per day, tenofovir 300mg per day and efavirenz 600mg per day, per standard dose.
89441740|NCT04507880|Experimental|RTSA group|Participants with a complex proximal humerus fracture given a RTSA
89441741|NCT04507880|Active Comparator|Hemiarthroplasty group|Historical cohort of participants, operated with a hemiarthroplasty of the shoulder
88925610|NCT03769285|Experimental|Nicotinamide|
88925611|NCT03769285|Placebo Comparator|Placebo|
89441742|NCT02310282||Telemedicine|In-hospital telemedicine by a stroke expert aiming to assess stroke severity using the Unassisted TeleStroke Scale.
89441743|NCT03355196|Experimental|LRX712|LRX712 given intra-articularly
89441744|NCT03355196|Placebo Comparator|Placebo|Placebo given intra-articularly
89441745|NCT03502902|Experimental|HEC68498|administered once on first day in each Treatment Period， HEC68498 VS placebo 3:1 ratio
89441746|NCT03502902|Placebo Comparator|placebo|administered once on first day in each Treatment Period
89441747|NCT04507802|Experimental|Non invasive ventilation via helmet|Patients who require noninvasive ventilation via Face mask for more than 8 hours will continue using noninvasive ventilation via facemask.
89441748|NCT04507802|No Intervention|Non invasive ventilation via facemask|Patients assigned to the conventional ventilation group will continue noninvasive ventilation via facemask
89441749|NCT02310360||Healthy volunteers|
89441750|NCT03353558||Study Group (CML group)|"This group will be CML patients. In this group each participant will be asked to wear a watch Actigraph for one week.~He will be asked to fill the appropriate questionnaires, and a daily sleep diary."
88925612|NCT03743051|Experimental|100mg Anamorelin HCl|
88925613|NCT03743051|Placebo Comparator|placebo|
88925614|NCT03710902|Experimental|Intervention|
89441751|NCT03353558||Control Group|"The control group will be non-CML patients, also without any known malignancy or known sleep disturbances.~They will be asked to wear the watch Actigraph for one week, and to fill the appropriate questionnaires and a daily sleep diary."
89441752|NCT02310438|Experimental|Early intervention music therapy|"music therapy:~6 stroke patients with hemiparesis begin music therapy treatment in their home as soon as they have completed statutory NHS community rehabilitation."
89441753|NCT02310438|Active Comparator|Delayed intervention music therapy|"music therapy:~6 stroke patients with hemiparesis begin music therapy treatment in their home 9 weeks after they have been randomised into the wait list group."
89441754|NCT05524324|Other|CRT ON (biventricular pacing) / CRT OFF (inactive or univentricular pacing)|"Patients with heart failure and SRV and who have a dispositif CRT will be screened for eligibility. If they are eligible and accept to participate (signed informed consent), the order of activation or inactivation of the CRT will be assigned by randomization.Patients randomized into this arm will start the study in CRT ON then CRT OFF mode."
89441755|NCT05524324|Other|CRT OFF (inactive or univentricular pacing) / CRT ON (biventricular pacing)|"Patients with heart failure and SRV and who have a dispositif CRT will be screened for eligibility. If they are eligible and accept to participate (signed informed consent), the order of activation or inactivation of the CRT will be assigned by randomization.Patients randomized into this arm will start the study in CRT OFF then CRT ON mode."
89441756|NCT02310516|Experimental|Patient with preoperative device|patients undergoing brain awake surgery with adequate explanations which are provided preoperatively. Preoperative device corresponds to a pre/ perioperative coaching involving the provision of a comprehensive information support on the awake surgery (short video and information brochure) and an interview with an operating room nurse
89441757|NCT02310516|Active Comparator|Patient with standard procedure|patients undergoing brain awake surgery with standard procedure (without adequate explanations)
89441758|NCT03353480|Other|Reference|250mg Azithromycin tablet manufactured at Pfizer Barceloneta, Puerto Rico, US
89441759|NCT03353480|Experimental|Experimental|250mg Azithromycin tablet manufactured at Pfizer Dalian, China
89441760|NCT02306070|Experimental|Metformin + lifestyle modification|Metformin + lifestyle modification pre, during and post HCV antiviral therapy
88925615|NCT03710902|No Intervention|Control|Standard diagnostic work-up, follow-up, and treatment of hypertension.
88925616|NCT03707236|Experimental|Treatment arm|Patients in the treatment arm will have monthly office visits for weeks 0-4 and then have monthly teledermatology visits during weeks 8-20 with a final office visit at week 24. Standardized baseline photographs including 3 facial images (front, left, and right) as well as 2 truncal images of the chest and back (if affected) will be taken in the office at treatment week 0 and 24 for all patients. All patients will be required to take photos in front of a white wall to facilitate blinding.
88925617|NCT03707236|No Intervention|Control arm|Patients in the control arm will have the same series of photographs taken at each monthly visit. These patients will also be required to fill out a monthly survey assessing acne severity, quality of life, cost of attending appointment, time missed from school/work, satisfaction with treatment (only to be reviewed by study staff) and will be screened for adverse events by their provider. Every patient will be counseled about isotretinoin and contraception (if applicable) by their provider in order to adhere with iPledge requirements. All photographs will be uploaded into the patient's medical record. The physician will be required to document a progress note in the electronic medical record after each visit as per standard hospital protocol.
88925618|NCT03698201||Cohort 1 / High grade Glioma|"Cohort 1:~Histologically confirmed high grade glioma (grade III) or glioblastoma (GBM, astrocytoma grade IV)~Planned treatment (RT alone or Chemotherapy alone or a combination of RT/Chemotherapy)"
89441761|NCT02306070|Placebo Comparator|No Metformin + Lifestyle modification|No metformin + lifestyle modification pre, during and post HCV antiviral therapy.
88925619|NCT03698201||Cohort 2 / Low grade Glioma|"Cohort 2:~Histologically confirmed low grade (grade II) glioma~Planned treatment either~expectant monitoring or~RT alone or~Chemotherapy alone or~a combination of RT/Chemotherapy"
88925620|NCT03642132|Experimental|chemotherapy, avelumab and talazoparib|Platinum-based chemotherapy + avelumab followed by avelumab + talazoparib maintenance
89441762|NCT04513886|Active Comparator|Suture Group|After harvesting a subepithelial connective tissue graft using the single incision technique collagen haemostatic sponge placement and subsequent compression with gauze soaked in saline for 5 minutes, a cross- mattress suture and interrupted single sutures were performed using nylon 5-0 when appropriate.
89441763|NCT04513886|Experimental|no Suture Group|After harvesting a subepithelial connective tissue graft using the single incision technique, collagen haemostatic sponge placement and subsequent compression with gauze soaked in saline for 5 minutes no suture was performed.
89441764|NCT05304130|Experimental|Healthy Japanese participants receiving otilimab|
89441765|NCT02306148|Placebo Comparator|Control Group|Group will practice 15 seconds isometric lower limb stretching protocol and must continue practicing running as usual.
89441766|NCT02306148|Experimental|Foot and ankle strengthening|Group will be trained during 2 months by a physiotherapist for foot and ankle strengthening and must continue to exercise at home with a training software supervision. Must continue practicing running as usual.
89441767|NCT04512326||Total or subtotal colectomy|Total or subtotal colectomy with ileorectal or ileosigmoid anastomosis
89441768|NCT03502824|Active Comparator|PuraPly® AM plus Standard of Care|
89441769|NCT03502824|Active Comparator|Standard of Care (SOC) for Pressure Ulcers|
89441770|NCT05524090||Implementation cohort|"Inclusion criteria:~Age ≥18 years;~Pathology confirmed LAPC*;~CT-based non-progressive disease in accordance with the RECIST criteria after at least 4 months of systemic chemotherapy ([m]FOLFIRINOX or gemcitabine-nab-paclitaxel).~Exclusion criteria:~(1) Metastatic pancreatic cancer prior to induction chemotherapy.~*According to the Dutch Pancreatic Cancer Group (DPCG) definition: >90 degrees arterial tumor involvement (i.e. superior mesenteric artery, celiac axis, and/or hepatic artery) and/or portovenous involvement of either >270 degrees or occlusion."
89441771|NCT03358550|Experimental|Accommodation in scotopic luminance|
88925621|NCT03642132|Experimental|chemotherapy, and talazoparib|Platinum-based chemotherapy followed by talazoparib maintenance
88925622|NCT03642132|Active Comparator|chemotherapy and bevacizumab|Platinum-based chemotherapy + bevacizumab followed by bevacizumab maintenance
88925623|NCT03632330||Dexmedetomidine|Dexmedetomidine group
88925624|NCT03632330||Midazolam|Midazolam group
88925625|NCT03632330||propofol|propofol group
88925626|NCT03632330||Midazolam/Propofol|Midazolam and Propofol group
89441772|NCT05529550||Patients|67 children in the age group of 2-18 years with confirmed diagnosis of Beta thalassemia major.
89441773|NCT05529550||Healthy control|35 healthy children
88925627|NCT03585946||Cyclosporine|
88925628|NCT03585946||Intravenous Immunoglobulin|
88925629|NCT03585946||Etanercept|
88925630|NCT03585946||Steroids|
88925631|NCT03575949|Experimental|Diagnostic (FDG PET/CT)|Patients receive fludeoxyglucose F-18 IV over 1 minute and undergo PET/CT at 70 and 180 minutes after injection at 12-14 weeks following standard CRT completion.
89441774|NCT04445324|Experimental|Transitional Online Peer Support Group (n=20)|Trained Peer Support Workers (PSWs) from the Quebec Association of PSWs will organize and facilitate two series (one per condition) of 10 co-learning recovery workshops in a manner to simulate a typical peer support group. The difference of these transitional peer support groups to real community-based peer support groups is that (A) they will be facilitated by trained PSW, (B) they will have a personal-civic recovery focus, and (C) they will have a fixed, predetermined duration (10 weekly 60 to 90-minute online workshops). Typical Peer support groups bring together people who have similar concerns so they can explore solutions to overcome shared challenges and feel supported by others with similar experiences and who may better understand each other's situation. Peer support groups should ideally be independent from mental health and social services, although some services may facilitate and encourage the creation of (transitional) peer support groups, as is the case here. (WHO)
88925632|NCT03572764|Experimental|CPX-351|"CPX-351 will be given according to the assigned dose level over a minimum of a 90-minutes via IV infusion on Days 1, 3, and 5 of the first induction~If the treating physician elects to perform a day 14 bone marrow biopsy then, a second induction may be considered for patients in the absence of a chemoablated, hypocellular marrow on the Day 14 bone marrow assessment, if the patient has failed to achieve a marrow CR, and it is deemed safe to administer by the treating physician. The second induction uses a modified schedule in which CPX-351 will be given according to the assigned dose level on Days 1 and 3~In the absence of disease progression or unacceptable toxicity, the patient may continue to consolidation at the discretion of the treating physician or the patient may proceed to alloHCT after induction at the discretion of the treating physician"
88925633|NCT03568045|Active Comparator|Usual care, standard light|"Patients will be enrolled within 30 hours of noon on enrollment day (e.g. at or after 6am on the prior calendar day). Enrollment will occur before noon, and the day of enrollment is termed study day 1.~Patients will undergo monitoring (light levels, circadian alignment), but otherwise have usual care."
88925634|NCT03568045|Experimental|10,000 lux bright light, 4 hours|"Patients will be enrolled within 30 hours of noon on enrollment day (e.g. at or after 6am on the prior calendar day). Enrollment will occur before noon, and the day of enrollment is termed study day 1.~Patients will undergo monitoring (light levels, circadian alignment), starting on study day 1. Patients will be exposed to bright light from 8am to noon starting on study day 2 and continuing through study day 5. Bright light exposure will occur in the Intensive Care Unit (ICU) and on the floor if the patient is transferred.~Feasibility metrics will be collected."
88925635|NCT03568045|Experimental|10,000 lux bright light, 8 hours|"Patients will be enrolled within 30 hours of noon on enrollment day (e.g. at or after 6am on the prior calendar day). Enrollment will occur before noon, and the day of enrollment is termed study day 1.~Patients will undergo monitoring (light levels, circadian alignment), starting on study day 1. Patients will be exposed to bright light from 8am to 4pm starting on study day 2 and continuing through study day 5. Bright light exposure will occur in the Intensive Care Unit (ICU) and on the floor if the patient is transferred.~Feasibility metrics will be collected."
88925636|NCT03558048||Men with Inflammatory Bowel Disease|Men with a confirmed diagnosis of IBD between the ages of 40-69 years old. These subjects will have their prostate specific antigen checked via a blood draw during clinic visits over the course of the study period.
89441775|NCT04445324|Active Comparator|Control Group (pharmacotherapy and/or psychotherapy N=10)|When individuals show up at the Emergency Department (T1) of the Montreal Mental Health University Institute, they are evaluated by the Evaluation and Liaison Module during their hospital stay when they are hospitalized. A diagnostic is established or confirmed by psychiatrists on the ward, and coded according to the World Health Organisation International Classification of Disease (ICD-10). According to these diagnoses, after discharge (T2) they are referred to a specialized outpatient clinic for an appointment (T3). Whether for (a) psychotic disorders or for (b) anxiety and mood disorders, pharmacotherapy or psychotherapy, or a combination of both, are then offered in accordance with guidelines of the Royal College of Physicians and Surgeons of Canada.
89441776|NCT02306304|Other|Israeli Arab men|Single arm study. The arm includes all enrolled patients screened by duplex ultra sound for abdominal aortic aneurysms.
89441777|NCT04299802|Active Comparator|Leukocyte-Rich Platelet-Rich Plasma (LR-PRP)|LR-PRP will be administered via usual protocol with venous blood draw and concentration via centrifugation. The LR-PRP will be injected under ultrasound guidance into the gluteus minimus and gluteus medius tendons, enthesis and surrounding bursae.
89441778|NCT04299802|Active Comparator|Percutaneous Ultrasonic Tenotomy|Percutaneous Ultrasonic Tenotomy will be administered via usual protocol within an outpatient surgical setting or in-office procedure. Patient will be anesthetized with local anesthetic and a <5mm incision will be made along the lateral hip with an #11 scalpel. A 14-G angiocath will be introduced through the defective area of the tendon down to the enthesis. Multiple passes will be made and then the percutaneous ultrasonic tenotomy device will be introduced to the defective area. No more than 5 minutes of energy cutting time will be used to address the defective area down to the enthesis, which will debride abnormal tissue but leave normal healthy tissue intact.
89441779|NCT03353402|Experimental|Fecal Microbiota Transplant (FMT)|FMT includes a colonoscopy conducted by a gastroenterologist followed by stool capsules which will be swallowed by the patient.
89441780|NCT03508362|Experimental|Drug user|Regular use of cocaine
89441781|NCT03508362|Active Comparator|Healthy volunteers|non-drug user
89441782|NCT04444934||Patients with not-surely pathologic diaphragmatic peritoneum|The definition of not-surely pathologic diaphragmatic peritoneum was given in association with the presence of flat dyschromic areas.
89441783|NCT04444934||Patients with certainly pathologic diaphragmatic peritoneum|The definition of certainly pathological diaphragmatic peritoneum was given when isolated or confluent thick nodules were visualized at the intra-operative inspection.
89441784|NCT02310828|Experimental|Acetium|Patient will administer Acetium capsules (100mg l-cysteine) twice a day for one month
89441785|NCT02310828|Placebo Comparator|Placebo|Patient will administer placebo capsules twice a day for one month
89441786|NCT03353324|Active Comparator|intravitreal injection of bevacizumab|
89441787|NCT03353324|Active Comparator|intravitreal injection of bevacizumab+ targeted laser|Intervention intravitreal bevacizumab injection + targeted laser photocoagulation of retinal non perfused areas
88925639|NCT03486821|Experimental|Hypofrac Radiation Therapy|"All patients on this study will receive the same type of therapy, 2 treatment hypofractionated radiation therapy.~Radiation treatment will start approximately 1-2 weeks after the simulation scan. Prior to each treatment, you will be asked to have a full bladder and empty rectum. You will be asked to take a liquid diet starting the afternoon prior to each treatment, and a laxative (such as Miralax) in the evening prior to each treatment. You will also be asked to take a Fleet's enema about 1 hours prior to the treatment time to ensure that the rectum is empty. To ensure full bladder, you will be asked to drink about 32 oz of water after the enema. This is the same procedure as above for the prep before the simulation scan.~Each treatment should take about 10-20 minutes."
88925640|NCT03453619|Experimental|APL-2|Open Label, Study Drug, APL-2
88925641|NCT03452930|Experimental|Stage 1 (tinostamustine)|Patients who have completed TMZ and RT receive tinostamustine IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
89441788|NCT02313402|Experimental|EOL (Eye On Line)|training program allowing a gradual acquisition of the eye-writing
89441789|NCT04298944||BeHealthY Cohort|Children from BeHealthY cohort who are obese/overweight but do not have mood disorders are eligible for this study. The children will be given additional questionnaires to assess emotional/behavioral well being.
89441790|NCT04298944||CHAMPION trial Cohort|"Children who are overweight/obese and have severe mental illness, and who have agreed to be contacted for future research.~Tests will be done on all participants which includes cardiovascular assessments, actigraphy, laboratory assessments and emotional/behavioral assessments."
89441791|NCT04298944||Pediatric Medical Psychiatric (PMP) Clinic Cohort|Children from the PMP Clinic who have severe mental illness but healthy weight. Tests will be done on all participants which includes cardiovascular assessments, actigraphy, laboratory assessments and emotional/behavioral assessments.
89441792|NCT03508284||Patients with Multiple Sclerosis|MS patients (EDSS: 0-5,5)
89441793|NCT03508284||Healthy group|Healthy individuals without chronic disease
88925642|NCT03452930|Experimental|Stage 2 (RT, tinostamustine)|Patients who have received no treatment other than surgery undergo RT 5 days a week for up to 6 weeks in the absence of disease progression or unacceptable toxicity. Patients also receive tinostamustine over 60 minutes IV on day 1. Treatment repeats every 21 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
88925643|NCT03396653|Active Comparator|Peer-Delivered Weight Maintenance|Contingent upon participants losing 5% of body weight or more in Phase I (weight loss) of this trial, participants will receive an 18-month patient-delivered behavioral weight maintenance intervention. Specifically, group sessions will be delivered by a mentor (i.e., successful weight loser) and weekly coaching will be delivered by a peer (other member of their weight maintenance group).
89012828|NCT00417690|Placebo Comparator|P|One packet of oral granules administered three times daily for 2 weeks followed by one packet two times daily for two weeks
88925644|NCT03396653|Active Comparator|Professionally-Delivered Weight Maintenance|Contingent upon participants losing 5% of body weight or more in Phase I (weight loss) of this trial, participants will receive an 18-month reduced intensity behavioral weight maintenance intervention, delivered by a professional. The intervention will consist of 24 group sessions.
88925645|NCT03339908|Experimental|patients with Multiple Sclerosis|Patients will benefit from unilateral thalamotomy by Gamma Knife radiosurgery
88925646|NCT03227705|Active Comparator|Intravaginal progesterone|Once the participant agrees and signs the consent form, the use of prophylactic progesterone will begin (PROMETRIUM, 200 mg in total of progesterone, 2 vaginal capsules per day at bedtime up to 36 6/7 weeks of gestation, Merck Canada Inc.)
88925647|NCT03227705|Experimental|Intravaginal progesterone and pessary|Once the participant agrees and signs the consent form, the use of prophylactic progesterone will begin (PROMETRIUM, 200 mg in total of progesterone, 2 vaginal capsules per day at bedtime, Merck Canada Inc.). Also, a perforated pessary (Dr. Arabin, cerclage pessary perforated) will be inserted. The pessary will be removed and the progesterone treatment will be stopped at 36 6/7 weeks of gestation.
88925648|NCT03178032|Experimental|single arm treatment DNX-2401|Single arm receiving virus DNX-2401 infusion after tumor biopsy
88925649|NCT03167307|Experimental|Omega-3 fatty acid oil|A daily dose of 500mg EPA/ 250mg DHA in the 8 to <13 year olds, and 1000mg EPA / 500mg DHA in the 13 to <18 years olds, respectively, will be added to standardized treatment according to the German S3 Guidelines for the treatment of depression in children and adolescents
88925650|NCT03167307|Placebo Comparator|Placebo oil|Placebo capsules will contain mostly medium chain triglycerides (MCT) and also a small amount of fish oil to mimic the fishy flavour and taste. Placebo will be added to standardized treatment according to the German S3 Guidelines for the treatment of depression in children and adolescents
88925651|NCT03162003||Cohort 1|Patient with visceral disease and/or bone lesions (excluding patients who only have nodal disease), who have commenced or are about to commence ADT and whose disease has not shown any evidence of castration resistance.
88925652|NCT03162003||Cohort 2|Patient with castrate-resistant disease at time of treatment change
88925653|NCT03150004|Experimental|CLAG-M regimen|Subject's treatment cycle is 30 days.
88925654|NCT03150004|Experimental|CLLDAC regimen|Subject's treatment cycle is 30 days. Subject may be treated on an outpatient basis (CLLDAC arm only). In addition, subjects who fail to achieve a CR/CRi after the first 30-day cycle may receive a second cycle of CLLDAC, per the discretion of the treating physician. Subjects who receive this second cycle should begin cycle 2 no later than 49 days after cycle 1.
88925655|NCT03082534|Experimental|Cohort 1|"PD-1/PD-L1 inhibitor-naïve, cetuximab-naïve~Pembrolizumab (Keytruda®):~Pembrolizumab is administered on an outpatient basis. 200 mg pembrolizumab will be administered as a 30 minute (-5 min/+10 min) intravenous (IV) infusion every 3 weeks.~Cetuximab (Erbitux®):~The initial cetuximab dose of 400mg/m2 is administered on Cycle 1, Day 1 as a 120-minute IV infusion (maximum infusion rate 10mg/min).1 Subsequent weekly cetuximab doses of 250mg/m2 are administered as 60-minute IV infusions (maximum infusion rate 10mg/min)."
89012829|NCT04451512||CSP|
89012830|NCT04451512||HSP|
89012831|NCT00417729|Active Comparator|acarbose, glibenclamide|acarbose vs. glibenclamide (background metformin therapy)
89012832|NCT04448626||Healthy subject|Healthy subject
89012833|NCT04448626||Stable COPD patients|Stable COPD patients
89441794|NCT04444856||NovoSeven|Women with severe postpartum haemorrhage treated with NovoSeven
89441795|NCT04444856||Standard of care|Women with severe postpartum haemorrhage treated with standard of care
89441796|NCT03508206|Experimental|SBRP arm|Food supplement in hard gelatin capsule form containing a Standardized botanical blend rich in polyphenols (SBRP)
89441797|NCT03508206|Placebo Comparator|Placebo arm|Hard gelatin capsule form containing maltodextrin, with the same appearance as SBRP capsules
89441798|NCT03354962|Active Comparator|ARM A|
89441799|NCT03354962|Experimental|ARM B|
89441800|NCT03502590|Experimental|IGEL arm|
89441801|NCT04463550||Patients GFAP-IgG positive in serum and/or CSF|Patients developing clinical autoimmune encephalitis or meningoencephalomyelitis with anti-GFAP antibodies, managed by the National Reference Center for Paraneoplastic Syndromes and Autoimmune Encephalitis or the National Reference Center for Centre de référence for Neuro-inflammatory diseases of the brain and the spinal cord at the Neurological Hospital of Bron.
89441802|NCT05531500|Other|Injection|Injection of local anesthetic and steroid to the diseased nerve
89441803|NCT05531500|Other|Radiofrequency|Application of radiofrequency to the diseased nerve
88925656|NCT03082534|Experimental|Cohort 2|"PD-1/PD-L1 inhibitor-refractory, cetuximab-naïve~Pembrolizumab (Keytruda®):~Pembrolizumab is administered on an outpatient basis. 200 mg pembrolizumab will be administered as a 30 minute (-5 min/+10 min) intravenous (IV) infusion every 3 weeks.~Cetuximab (Erbitux®):~The initial cetuximab dose of 400mg/m2 is administered on Cycle 1, Day 1 as a 120-minute IV infusion (maximum infusion rate 10mg/min).1 Subsequent weekly cetuximab doses of 250mg/m2 are administered as 60-minute IV infusions (maximum infusion rate 10mg/min)."
88925657|NCT03082534|Experimental|Cohort 3|"PD-1/PD-L1 inhibitor-refractory, cetuximab-refractory~Pembrolizumab (Keytruda®):~Pembrolizumab is administered on an outpatient basis. 200 mg pembrolizumab will be administered as a 30 minute (-5 min/+10 min) intravenous (IV) infusion every 3 weeks.~Cetuximab (Erbitux®):~The initial cetuximab dose of 400mg/m2 is administered on Cycle 1, Day 1 as a 120-minute IV infusion (maximum infusion rate 10mg/min).1 Subsequent weekly cetuximab doses of 250mg/m2 are administered as 60-minute IV infusions (maximum infusion rate 10mg/min)."
88925658|NCT03082534|Experimental|Cohort 4|"cutaneous HNSCC~Pembrolizumab (Keytruda®):~Pembrolizumab is administered on an outpatient basis. 200 mg pembrolizumab will be administered as a 30 minute (-5 min/+10 min) intravenous (IV) infusion every 3 weeks.~Cetuximab (Erbitux®):~The initial cetuximab dose of 400mg/m2 is administered on Cycle 1, Day 1 as a 120-minute IV infusion (maximum infusion rate 10mg/min).1 Subsequent weekly cetuximab doses of 250mg/m2 are administered as 60-minute IV infusions (maximum infusion rate 10mg/min)."
88925659|NCT03081663|Experimental|Quads-Sparing Approach with Tourniquet|Participants will have a navigated total knee arthroplasty with a quadriceps-sparing mid-vastus approach and a tourniquet.
88925660|NCT03081663|Active Comparator|Medial Para-Patellar with Tourniquet|Participants will undergo total knee arthroplasty with a medial para-patellar approach and a tourniquet. An intramedullary femoral guide and extramedullary tibial guide will be used during the surgery.
88925661|NCT03081663|Active Comparator|Quads-Sparing Approach w/o Tourniquet|Participants will have a navigated total knee arthroplasty with a quadriceps-sparing mid-vastus approach and no tourniquet.
88925662|NCT03081663|Active Comparator|Medial Para-Patellar w/o Tourniquet|Participants will undergo total knee arthroplasty with a medial para-patellar approach and no tourniquet. An intramedullary femoral guide and extramedullary tibial guide will be used during the surgery.
88925663|NCT03056339|Experimental|Fludarabine + Cyclophosphamide + CAR-NK Cells|"On Days -5, -4, and -3, participants receive Fludarabine and Cyclophosphamide. Participants also receive Mesna before and after the cyclophosphamide dose.~On Day 0, participants receive genetically modified NK cells as a cell infusion.~If participant has graft-versus-host disease (GvHD) or cytokine release syndrome after the NK cell infusion, they receive AP1903 by vein and possibly steroids by mouth or by vein."
88925664|NCT03008122|Experimental|Group 1|5 mcg ZPIV administered IM in a homologous prime-boost regimen on Day 1 and Day 29 , n=45 (2 sentinels, 43 non-sentinels) or placebo, n=5
88925665|NCT03008122|Experimental|Group 2|2.5 mcg ZPIV administered IM in a homologous prime-boost regimen on Day 1 and Day 29, n=35 or placebo, n=5
88925666|NCT02977884|Experimental|The Complete Health Improvement Program|Participants in The Complete Health Improvement Program
88925667|NCT02912897|Experimental|Cellular therapy with EBV specific autologous CTL infusion|
89441804|NCT04511468|Experimental|Experimental Group|A combination of Zinc, Chromium, Vitamin C, and Copper (ZCC supplement) with standard healthy lifestyle intervention
89012834|NCT04448626||Exacerbation COPD patients|Exacerbation COPD patients
89012835|NCT01600807|Experimental|Gemcitabine, Erlotinib, OSI-906|Experimental treatment arm
89441805|NCT04511468|Placebo Comparator|Control group|Placebo with standard healthy lifestyle intervention
89441806|NCT02313480|Active Comparator|non-massage group|received exercise, manual therapy and advice over the 30 minute intervention period, in conjunction with an exercise program to perform at home.
89441807|NCT02313480|Experimental|massage group|Received massage, exercise, manual therapy and advice over the 30 minute intervention period, in conjunction with an exercise program to perform at home.
89441808|NCT05531422|Placebo Comparator|placebo|Participants were randomized to 6 BTP episodes, in which 2 BTP episodes were treated with placebo (0 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×0µg) in a random sequence
89441809|NCT05531422|Experimental|Inhaled fentanyl aerosol|Participants were randomized to 6 BTP episodes, in which 2 BTP episodes were treated with placebo (0 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×0µg) in a random sequence
89441810|NCT03354884|Experimental|Cabozantinib|All subjects will receive open label Cabozantinib 60 mg orally once daily
89441811|NCT03354806|Experimental|Continuous peripheral nerve blocks|Ropivacaine-continous treatment using catheters for continous sciatic nerve blocks
89441812|NCT03354806|Active Comparator|Analgesic treatment|Pharmacological pain management in accordance with WHO's pain relief ladder
89441813|NCT03508128||Micra subjects|Surgical procedure
89441814|NCT04443998|Experimental|Bone reduction forceps|
89441815|NCT03350438||PTSD Patients|patients ranging 18-60, diagnosed with PTSD following a trauma that occured over one year before the current study and do not have other health problems that may affect their everyday participation.
89441816|NCT03350438||healthy adults|healthy adults, ranging 18-60, without any health problems that may affect their everyday participation.
89441817|NCT03122912|Experimental|Fish Oil|Capsules contain omega-3 fatty acids (fish oil). Dosage of 3180 mg of omega-3 fatty acids will be taken orally daily up to 16 weeks.
89441818|NCT03122912|Active Comparator|Soybean Oil|Dosage will be 3000 mg of soybean oil taken orally daily for up to 16 weeks.
89441819|NCT02313714|Experimental|Neuromuscular stimulation|The patients will receive electric muscular stimulation with a Russian current protocol twice a week for 7 weeks.
89441820|NCT02313714|Placebo Comparator|Sham Group|The patients will receive very low electric muscular stimulation with a no biological or clinical effects
89441821|NCT04504058||UFACH|Unsaturated Fatty Acid in Clinical High-risk
89441822|NCT05529082||Opioid Attitudes and Beliefs survey|Participants will complete a questionnaire about your feelings/beliefs on prescription pain medication and your experience with opioids/pain medication. Demographic information about you (such as your age, gender, race, ethnicity, and so on) will also be collected.
89441823|NCT03350360|Experimental|Attention Control Training Clinic|"Attention Control Training Clinic will consist of:~6 sessions in the clinic lasting approximately 10 minutes each.~Each session will consist of 128 presentations of pairs of neutral and threatening stimuli, followed by the presentation of a response cue (right or left arrow to be clicked on a computer keyboard)."
89441824|NCT03350360|Experimental|Attention Control Training Web-delivery|"Attention Control Training Web-delivery will consist of:~6 sessions lasting approximately 10 minutes each logged into via the internet from the participants' home.~Each session will consist of 128 presentations of pairs of neutral and threatening stimuli, followed by the presentation of a response cue (right or left arrow to be clicked on a computer keyboard).~Ideally participants will complete 2 sessions per week, allowing them to complete the trial in less than one month's time"
89441825|NCT03350360|Placebo Comparator|Comparison Task Clinic|"6 sessions in the clinic of a presumably inactive neutral-neutral stimuli intervention lasting approximately 10 minutes each.~Each session will consist of 128 presentations of pairs of faces, followed by the presentation of a response cue (right or left arrow to be clicked on a computer keyboard).~(Note that those receiving this arm, are invited to repeat the attention control training web-delivery arm at the end of their participation)."
88925668|NCT02847130||Observational (chart review, focus group, interviews)|"AIM 1 (CHART REVIEW): Patients are separated for each CPG evaluated (fever and neutropenia [FN], chemotherapy induced nausea and vomiting [CINV], fertility preservation [FP]) and are randomly selected for medical chart review. Patients with eligible episodes of FN, CINV or FP within the health records are selected and have the data from their records abstracted and reviewed by COG for adherence to COG endorsed CPGs.~AIM 2 (FOCUS GROUPS): Health care providers who provide direct care to pediatric oncology patients are identified and separated to participate in three types of focus groups: physician-only, non-physician, and mixed.~AIM 3 (INTERVIEWS): Health care providers undergo one-on-one interviews consisting of think aloud technique (TAL) of cognitive interviewing."
89012836|NCT01600807|Active Comparator|Gemcitabine, Erlotinib|Standard treatment arm
89012837|NCT01600963|Experimental|Arm A|
89441826|NCT05529004|Experimental|Preoperative pregabalin to prevent postoperative nausea & vomiting in laparoscopic surgery.|participants receive pregapalin 75mg cap orally 30 min before surgery
89441827|NCT05529004|No Intervention|placebo|participants hasn't receive pregapalin capsule
89441828|NCT03350282|Experimental|Mixture GAA-creatine|Mixture of guanidinoacetic acid and creatine monohydrate
89441829|NCT03350282|Active Comparator|Creatine|Creatine monohydrate
89441830|NCT02316210|Experimental|Digitimer stimulation|
89441831|NCT03350204|Experimental|Meniscus Injured|These participants will come in pre and post operation
89441832|NCT03350204|Experimental|Healthy|These participants will be used as a standardised comparison for the patient group
89441833|NCT02316288|Experimental|Therapy|Mindfulness and Acceptance Therapy
89441834|NCT02316288|Active Comparator|Education|Health Education
89441835|NCT02313792|Active Comparator|Palifermin|The patients belong to this arm will be given palifermin, keratinocyte growth factor, in addition to the conventional supportive care for oral mucositis. Palifermin will be given at a dose of 60 mcg/kg for 3 days before commencement of the preparative regimen and for 3 days after stem cell infusion
89441836|NCT02313792|Placebo Comparator|Normal saline|The patients belong to this arm will be given normal saline as placebo plus conventional supportive care for oral mucositis. Normal saline will be given at the same volume and schedule with the study drug.
89537071|NCT02721251|Experimental|Weight Loss|16 week intervention with a goal weight loss of 10%, accomplished with caloric and fat restriction, weekly sessions with a nutritionist, and some meal replacement
89012838|NCT01600963|Placebo Comparator|Arm B|
89012839|NCT01606969|Experimental|Dex group|dexmedetomidine-lidocaine solution,
89199621|NCT04908722|Experimental|Group 5: Ad26.COV2.S Dose Level 5|Participants in the main study and sub study will receive IM injections of Ad26.COV2.S as a 2-dose vaccination regimen at dose level 5 on Days 1 and 57.
89199622|NCT04908722|Experimental|Group 6: Ad26.COV2.S Dose Level 6|Participants in the main study and sub study will receive IM injections of Ad26.COV2.S as a 2-dose vaccination regimen at dose level 6 on Days 1 and 57.
89199623|NCT04907214|Experimental|Empagliflozin|Individuals receive empagliflozin 25mg/day orally for 12 weeks
89199624|NCT04907032|Experimental|Posterior Tibial Nerve Stimulation with Mirabegron|One arm of the study will receive PTNS combined with mirabegron. In the PTNS with mirabegron arm, the patient will take a 50 mg dose daily for 12 weeks of the trial. This arm of the study will have 27 patients randomized to this arm of the study. The percutaneous approach entails insertion of a 36-gauge needle electrode at a 60 degree angle approximately 5 cm or 3 finger breadths cephalad to the medial malleolus and posterior to the tibia. A portable electrical stimulator delivers an adjustable current in the range of 0.5-9 mA. The generators commonly are set for a pulse frequency of 20 Hz with a goal of creating a motor and/or sensory response in the foot. The stimulation sessions last for 30 min once per week for 12 continuous weeks.
89199625|NCT04907032|Placebo Comparator|Posterior Tibial Nerve Stimulation Plus Placebo|The other arm of the study will receive PTNS with placebo. In the PTNS with placebo arm, the patient will receive a placebo daily during the 12-week trial. PTNS will be performed as described: The percutaneous approach entails insertion of a 36-gauge needle electrode at a 60 degree angle approximately 5 cm or 3 finger breadths cephalad to the medial malleolus and posterior to the tibia. A portable electrical stimulator delivers an adjustable current in the range of 0.5-9 mA. The generators commonly are set for a pulse frequency of 20 Hz with a goal of creating a motor and/or sensory response in the foot. The stimulation sessions last for 30 min once per week for 12 continuous weeks.
89199626|NCT04904809|Experimental|All Registered Patients|All registered patients will have multiple access sites in a single vein closed utilizing the Perclose ProGlide SMC System and/or Perclose ProStyle SMCR System.
89199627|NCT04897633|Experimental|Patients ON|Patients will performed Simon's task with tDCS active or sham when treatment is OFF (for standard care procedure)
89199628|NCT04897633|Experimental|Patients OFF|Patients will performed Simon's task with tDCS active or sham when treatment is ON (for standard care procedure)
89199629|NCT04897633|Experimental|Healthy volunteers|Healthy volunteers will performed Simon's task with tDCS active or sham
89199630|NCT04883918|Experimental|ASC930|Experimental Arm
89199631|NCT04882917|Experimental|Experimental: Dose Escalation Cohort (Part 1A): M4076 Monotherapy|Participants will receive M4076 film coated tablet at escalated doses orally, once daily under fasting condition until disease progression, death, Adverse events (AEs) leading to discontinuation of study intervention(s), or withdrawal of consent, whichever occurs first.
89199632|NCT04882917|Experimental|Experimental: Preliminary Food Effect Assessment Cohort (Part 1B): M4076|Participants in food effect assessment will receive M4076 at the dose and schedule determined as recommended dose for expansion (RDE) in Part 1A. A single dose of M4076 will be administered on Day -7 under a fed or fasted condition, followed by a 1-week washout period.
89199633|NCT04866563|Experimental|AX-8 to Placebo|AX-8 BID, taken for 2 weeks, followed by a 1-week washout period and then Placebo BID, taken for 2 weeks.
89199634|NCT04866563|Experimental|Placebo to AX-8|Placebo BID, taken for 2 weeks, followed by a 1-week washout period and then AX-8 BID, taken for 2 weeks.
89199635|NCT04864418|Experimental|Cohort group of AST-021p for dose-escalation|"4 cohort groups for AST- 021p administration:~Group 1) 1.2mg AST-021p, Montanide ISA 51 VG and rhuGM-CSF~Group 2) 2.4mg AST-021p, Montanide ISA 51 VG and rhuGM-CSF~Group 3) 3.6mg AST-021p, Montanide ISA 51 VG and rhuGM-CSF~Group 4) 4.8mg AST- 021p, Montanide ISA 51 VG and rhuGM-CSF"
89199636|NCT04861051|Other|Ketamine|Study participants will receive 0.5mg/kg of ketamine - one single infusion
89199637|NCT04846127||CanGaroo Envelope|Participants who receive a CanGaroo envelope during their CIED implant.
89199638|NCT04846127||No Envelope|Participants who do not receive an envelope of any kind during their CIED implant.
89199639|NCT04839575|Active Comparator|Latiglutenase|IMGX003
89199640|NCT04839575|Placebo Comparator|Placebo|Placebo
89537072|NCT02721251|Experimental|Exercise + Weight Loss|Combined components of the exercise and weight loss treatments
89537073|NCT03301103|Placebo Comparator|Placebo|"The placebo will consist of low-lactose isonitrogenous soy product, and will be matched in appearance and flavour to PTM202.~After an overnight fast, subjects will be orally infected with a live, but attenuated, diarrheagenic E. coli (strain E1392-75-2A; collection NIZO food research; dose 1E10 CFU (at study day 14)."
88925669|NCT02764086|Other|Trial Cohort Description|"Escalated dose of min 65Gy to the iGTV, with 60Gy to PTV delivered to successive cohorts of patients(pts) until the MTD oesophageal dose is determined. Toxicity will be analysed 2 months post 6pts treated in a cohort.~If: ≤2pts have ≥G3 toxicity, next cohort will be enrolled & receive escalated dose (an additional +5Gy at each escalation upto max 75Gy)/3 of 6pts have ≥G3 toxicity, a further 6pts will be recruited into that dose level/≥4pts have ≥G3 toxicity, the MTD is fixed at dose level of previous cohort~Cohort is extended to 12pts:~If: ≤4pts have ≥G3 toxicity, next cohort will be enrolled & receive escalated dose/5 of 12pts have ≥G3 toxicity, the MTD is fixed at that dose level & recruitment continues up to 24pts/≥6pts have ≥G3 toxicity, the MTD is fixed at the dose level of previous cohort.~Once the max dose cohort is established, recruiting will continue at that dose until 24pts. Concurrent & neo-adjuvant/no chemotherapy arms will be escalated independently of each other"
88925670|NCT02759094|Experimental|Treatment with RefluxStop device|All enrolled subjects will receive treatment for their GERD using the RefluxStop device intervention
88925671|NCT02758054|No Intervention|Usual Care|Participants will experience standard practice for lung cancer early detection.
88925672|NCT02758054|Experimental|Usual Care + Patient Navigation|Participants will experience standard practice for lung cancer early detection plus the intervention.
89441837|NCT05285878|Placebo Comparator|Placebo|Participants will take a placebo capsule daily for 3 months. Placebo will be methylcellulose encapsulated into an opaque closed gelatin capsule for blinding. Capsules will be placed in a labeled bottle, with the contents only identifiable by a code on the package label and only the compounding pharmacy and the unblinded pharmacist at Houston Methodist Investigational Drug Service will know the code definition.
89441838|NCT05285878|Active Comparator|Fingolimod|Participants will take a 0.5 mg fingolimod capsule each day for 3 months. The fingolimod capsule will be placed inside an opaque closed gelatin capsule without transformation of the manufacteror's fingolimod capsule. The fingolimod blinded product and the placebo capsule will be identical in size, color, appearance, and weight.
89441839|NCT02314182|Experimental|A Primary tumor resection + chemotherapy|PT resection + systemic chemotherapy +/- target therapy
89441840|NCT02314182|Other|B Oxaliplatin/irinotecan + capecitabine, 5-FUI ± bevacizumab|Chemotherapy (+/- target therapy)
89441841|NCT04503980|Experimental|CAR T cells therapy|The safety and efficacy of αPD1-MSLN-CAR T cells will be assessed in a standard 3+3 dose escalation approach. Four doses of CAR T cells will be evaluated in this study: 1×10^5 CAR+ T cells/kg, 3×10^5 CAR+ T cells/kg, 1×10^6 CAR+ T cells/kg, and 3×10^6 CAR+ T cells/kg.
89441842|NCT02316444|Other|HAART exposed|Participants in both arms will receive the Hepatitis B vaccine as summarized in the study description
89441843|NCT02316444|Other|HAART naive|Participants in both arms will receive the Hepatitis B vaccine as summarized in the study description
89441844|NCT05267860|Experimental|Patients with a prophylactic drain after cholecystectomy|
89441845|NCT05267860|No Intervention|Patients without using any prophylactic Drainage after cholecystectomy|
89441846|NCT02316600|No Intervention|Control|30 frail volunteers of the control group in the second phase won't be equipped with the smart insole.
89441847|NCT02316600|Experimental|Intervention|30 frail volunteers of the intervention group in the second phase will be equipped with the smart insole for 3 months, to encourage the frail elderly person's physical activity and to monitor key parameters of frailty
89441848|NCT03350048||Training Set|"First 500 participants recruited for the Training Set:~Blood collection for optimization and validation (vs ELISA) of TransDot point-of-care test at LUMC and later for lab-based TransDot at local site laboratory~Blood, sputum, saliva and urine collection for secondary objectives and repository"
89441849|NCT03350048||Test Set|"Subsequent 300 participants to be used for the Test Set:~Fingerprick TransDot point-of-care test performed at field site after symptom screen and clinical evaluation and before CXR~Blood, sputum, saliva and urine collection for secondary objectives and repository"
89441850|NCT05531344|Experimental|Composite Steep-pulse Treatment Device|Composite Steep-pulse(High-frequency irreversible electroporation) Treatment Device
89441851|NCT05531344|Active Comparator|Tamsulosin|Tamsulosin Hydrochloride Sustained Release Capsules, 0.2mg, once a day,3 months
89441852|NCT02311140||Cystic Fibrosis patients with G551D mutation|Cohort Description Ten participants (6 Jena/4 Innsbruck) were included, of whom 6 were female and 4 were male. At the start of the study, patients were aged 7-45 years (mean age: 16.55 ± 13.42 years). Results of sweat tests and lung function FEV1 were available only from 8 patients. Lung function at baseline, as obtained from those patients, ranged from 0.96 to 4.07 L (mean FEV1: 99.7 ± 20.3% predicted, median: 103.6% predicted, IQR=20.4% predicted).
89501652|NCT02155751|Experimental|Full NELIP group|"These women (n=10) will receive the full NELIP intervention and will be introduced to both the dietary program and the exercise program as described above under detailed description."
88925673|NCT02757911|Experimental|open label|X vivo gene therapy
88925674|NCT02732275|Experimental|DS-3201b|
88925675|NCT02671305|Experimental|placental circulation intact|preterm newborns assisted bedside with placental circulation intact
88925676|NCT02671305|Active Comparator|cord milking|preterm newborns who receive cord milking before assistance performed in a routine setting
88925677|NCT02639754|Experimental|Social Network Leader Endorsement|Leaders of social networks randomized to this arm will be trained to endorse frequent HIV testing, compliance with medical guidelines, and effective ways to communicate these concepts to social network members.
88925678|NCT02639754|Active Comparator|Routine Counseling|Members of social networks randomized to this arm will receive HIV counseling at baseline sessions.
88925679|NCT02553733|Active Comparator|Beetroot juice (Beet-It Organic Shot)|Subjects will consume 70 ml of beetroot juice (Beet-It Organic Shot) twice per day (morning, afternoon) for 5 to 7 days to assess the short term effects of this nitrate supplement on graded treadmill walking responses (day 4) and vasodilator/vasoconstrictor responses in the coronary and lower leg circulations (day 5 or 6 or 7). On both study visits, subjects will consume their morning dose 1 hour 45 min before experiments begin.
89012840|NCT01606969|Active Comparator|Control group|epinephrine-lidocaine solution
89012841|NCT00254267|Experimental|Arm One|AMG 706 125mg, oral, once a day
89441853|NCT04504292|Experimental|Oral sulfate solution (SuPREP arm)|"Per the package insert: The dose for colon cleansing requires administration of two bottles of SUPREP Bowel Prep Kit. Each bottle is administered as 16 oz of diluted SUPREP solution with an additional 1quart of water taken orally. The total volume of liquid required for colon cleansing (using two bottles) is 3 quarts (approximately 2.8 L) taken orally prior to the colonoscopy outlined below under frequency.~Two 6 oz bottles of oral solution: Each 6 oz bottle contains: sodium sulfate 17.5 g, potassium sulfate 3.13 g, magnesium sulfate 1.6 g."
89441854|NCT04504292|Active Comparator|Polyethelene Glycol (GoLytely arm)|Polyethylene Glycol Bowel Prep Kit
89441855|NCT03505242|Experimental|BB|
89441856|NCT03505242|Experimental|DLT|
89441857|NCT03349970||TEE vs PAC|we will compare the SV measurements obtained by PAC thermodilution technique to those obtained by different TEE methods in 60 patients undergoing coronary artery bypass grafting (CABG) and/or aortic valve (AV) or aortic surgery with cardiopulmonary bypass (CPB) in 2 different cardiac centres. The LV cardiac deformation, expressed as global longitudinal strain (GLS) will be calculated off-line from the acquired images. We will also determine the intra and inter-observer reproducibility of each TEE method.
89441858|NCT02311218|Active Comparator|Test group with L. reuteri|Subjects in the test group take one Lactobacillus reuteri DSM 17938 and PTA 5289 containing lozenge in the morning and one in the evening.
89441859|NCT02311218|Placebo Comparator|Placebo group without L. reuteri|Subjects in the placebo group take one placebo lozenges with same look, taste and smell as the test lozenge but lacking the Lactobacillii the morning and one in the evening.
89441860|NCT05531266|Experimental|hUC-MSCs combined with glucocorticoids group.|91 patients will be involved in this group
89441861|NCT05531266|Active Comparator|glucocorticoids group|91 patients will be involved in this group
89441862|NCT04504214|Experimental|Experimental group (EG)|An Experimental Group (EG) of post-stroke subjects having vibration stimulation sessions in addition to traditional rehabilitation
89441863|NCT04504214|Sham Comparator|Control Group (CG)|A Control Group (WG) of post-stroke subjects having placebo/sham vibration sessions (same vibrators used but without the eccentric mass), in addition to traditional rehabilitation
89441864|NCT03502512|Experimental|Arm I (REVOLVE technique)|Patients undergo reconstructive surgery with REVOLVE technique.
89441865|NCT03502512|Experimental|Arm II (PureGraft technique)|Patients undergo reconstructive surgery with PureGraft technique.
89441866|NCT05523544|Other|schematherapy|all (8) participant wil recieve the same treatment, schematherpay which is treatment as usual for personality disorders in forensic psychiatric care. They will be asked however to fill in extra questionnaires to study the effect of the treatment.
89441867|NCT05523466|Experimental|Active-Sham group|will start with 5 sessions (1 per week) of active acupuncture combined with HRV evaluation for 20 min. After a 2-week washout, this group will be reallocated to another 5 sessions (1 per week) of sham acupuncture for 20 min combined with HRV evaluation.
89441868|NCT05523466|Experimental|Sham-Active group|will start an allocated 5 sessions (1 per week) of sham acupuncture combined with HRV evaluation, and after a 1-week washout period will be reallocated to 5 sessions (1 per week) of active acupuncture combined with HRV evaluation.
89441869|NCT04507490|Experimental|Whole body vibration 6 Hz|application of whole body vibration in the following parameters:frequency 6 Hz, amplitude 4 mm, five cycles lasting 1 minutes and interval between cycles of 1 minute
89441870|NCT04507490|Experimental|Whole body vibration 25 Hz|application of whole body vibration in the following parameters: 25 Hz frequency, 4 mm amplitude, five cycles lasting 1 minute and interval between 1 minute cycles
89441871|NCT04507490|Sham Comparator|Whole body vibration sham|application of whole body vibration in the following parameters: The sham vibration will be performed with the platform disconnected. A sound device will be connected producing a noise similar to that of the connected platform for a time equivalent to that of the treatment protocol.
88925680|NCT02553733|Placebo Comparator|Beetroot juice placebo (Beet-It Organic Placebo)|Subjects will consume 70 ml of beetroot juice placebo (Beet-It Organic Placebo) twice per day (morning, afternoon) for 5 to 7 days to assess the short term effects of this nitrate supplement on graded treadmill walking responses (day 4) and vasodilator/vasoconstrictor responses in the coronary and lower leg circulations (day 5 or 6 or 7). On both study visits, subjects will consume their morning dose 1 hour 45 min before experiments begin.
88925681|NCT02552394|Experimental|HuJ591 Administration|6 subjects will be treated at 300 mg dose. The decision about treating subjects at the lower dose will depend upon their response. If ≥4 of 6 subjects respond at the 300 mg level, then 6 more subjects will be recruited at the 200 mg level. If ≥4 of 6 subjects respond at the 200 mg level than 6 more subjects will be recruited at the next dose level of 100 mg. If ≥ 4/6 subjects respond at this level, then 6 subjects will be recruited at the last dose level of 50 mg. At any level, if the first four consecutive subjects respond, the next two subjects will be enrolled in the same dose-level cohort and further subjects will be recruited at the next dose level. Response at every dose level is defined by conversion from an unfavorable CTC count at baseline to a favorable CTC count.
88925682|NCT02462187|Experimental|NVN1000 8% Gel twice daily|NVN1000 8% Gel twice daily
88925683|NCT02462187|Experimental|NVN1000 8% Gel once daily|NVN1000 8% Gel once daily
88925684|NCT02462187|Experimental|NVN1000 16% Once daily|NVN1000 16% Gel once daily
88925685|NCT02462187|Placebo Comparator|Vehicle Gel|Vehicle Gel at frequency to match active
88925686|NCT02462187|Experimental|NVN1000 24% once daily|NVN1000 24% once daily
88925687|NCT02351869|Active Comparator|Nitrous oxide|N2O-condition participants will inhale an initial mixture of 10% N2O in oxygen (O2) for 5 minutes, followed by 25% N2O in O2 for 20 minutes. N2O-condition participants will also receive 5ml intravenous saline concomitantly with 10% N2O, and again with 25% N2O.
89441872|NCT03501732|Experimental|Values Affirmation plus Risk Feedback|Values Affirmation with Risk Feedback in substance use and HIV domains of risk
88925688|NCT02351869|Placebo Comparator|Midazolam|Inhaled room air plus intravenous midazolam bolus (total 2mg). Midazolam-condition participants will receive intravenous infusions of 0.5mg midazolam in 5ml saline (start of 1st inhalation epoch), followed by 1.5mg midazolam in 5ml saline (start of 2nd inhalation epoch).
88925689|NCT02342535|Other|Physical activity intervention|"Participants will attend bi weekly exercise classes for a total of 16 weeks, led by certified, and trained instructors.~The participant's children between the ages of 6 and 14 years will participate in the martial arts class with the mothers."
89441873|NCT03501732|Active Comparator|Risk Feedback|Sham Values Affirmation with Risk Feedback in substance use and HIV domains of risk
89441874|NCT03501732|No Intervention|Sleep Control|Description of sleep habits in lieu of values affirmation/sham values affirmation. No risk feedback
89441875|NCT03349814||Appendicitis group|"Patients, who undergo a diagnostic laparoscopy, which because of the operative findings leads to an appendectomy, and the appendix is found to be inflamed in the pathology report.~A diagnostic laparoscopy where the appendix seems inflamed, and therefore is removed."
89012842|NCT01601002|Experimental|Mirtazapine|Mirtazapine in dosage of 7.5 mg to 45 mg/day
89012843|NCT00254306||1|"ex-ecstasy users"
89441876|NCT03349814||Normal appendix group|"Patients, who undergo a diagnostic laparoscopy, that either because of the operative findings (mesenteric lymphadenitis or normal diagnostic laparoscopy) does not lead to appendectomy, or leads to appendectomy, but the appendix is not found to be inflamed in the pathology report.~A diagnostic laparoscopy where the appendix is not found to be inflamed, and therefore is not removed.~OR~A diagnostic laparoscopy where the appendix seems inflamed, and therefore is removed, but is not found to be inflamed in the pathology report."
89012844|NCT00254306||2|control subjects
89012845|NCT01607086|Experimental|Group 1|To receive the sequence of investigational products in the order of AB where A is cherry lamotrigine ODT and B is cherry placebo.
89012846|NCT01607086|Experimental|Group 2|To receive the sequence of investigational products in the order of BA where A is cherry lamotrigine ODT and B is cherry placebo.
89012847|NCT01607125|Experimental|Vortioxetine|
89012848|NCT01607125|Placebo Comparator|Placebo|
89441877|NCT05528536|Experimental|Acceptance and Commitment Therapy (ACT) and Exercise|This group receives eight weeks' Acceptance and Commitment Therapy (ACT) and exercise intervention.
89441878|NCT05528536|Sham Comparator|Art and Exercise|This group receives eight weeks' art workshops (skill-based) and exercise intervention.
89441879|NCT05528536|Active Comparator|Treatment as usual|This group receives treatment as usual in the local community setting.
89441880|NCT03501654|Experimental|TecnisSymfony intraocular lens insertion group|
89501653|NCT02155751|Experimental|Exercise program only/ELIP|These women (n=10) will only be given the exercise component (ELIP) of NELIP, as outlined below in interventions. Once dietary intake has been assessed, this group will not be given any dietary intervention but will be encouraged to eat a healthy, balanced diet. Access to the nutritionist in the clinic is available and encouraged.
89012849|NCT01607164|Experimental|Online self-help mood management|"Healthy Mood Project Website~Online self-help automated mood management course available in Spanish and English via a website.~Intervention consisted of 8 cognitive-behavioral mood management lessons."
89012850|NCT01601041||urinary tract infection|urinary tract infection in male patients with neurogenic bladder dysfunction due to spinal cord injury managed by intermittent catheterization
89012851|NCT01601041||control group|less than three urinary tract infections / year
89012852|NCT00254618|Experimental|30 mg|30 mg/kg/day mesalamine
89012853|NCT00254618|Experimental|60 mg|60 mg/kg/day mesalamine
89012854|NCT00254618|Experimental|90 mg|90 mg/kg/day mesalamine
89012855|NCT01601119||Rebif cohort|Subject will receive Rebif as the treatment medication as per the standard or current practices or as directed by the healthcare professional. Allocation of subjects to a specific cohort was based on the first DMT they will be prescribed regardless of any subsequent treatment switches.
89012856|NCT01601119||Other DMT cohort|Subjects will receive DMT other than Rebif as per the standard or current practices or as directed by the healthcare professional. Allocation of subjects to a specific cohort was based on the first DMT they will be prescribed regardless of any subsequent treatment switches.
89012857|NCT01601158|Experimental|Umbilical Cord Blood and Rehabilitation|Allogeneic Umbilical Cord Blood infusion and Active Rehabilitation
89012858|NCT01601197|Experimental|Tactile stimulation|Ipsilateral limb will be rubbed immediately before, during and after immunization injection(s)
89012859|NCT01601197|No Intervention|No tactile stimulation|There will be no tactile stimulation of ipsilateral limb before, during and after immunization injection(s)
89012860|NCT01601314|Experimental|magnesium sulphate|The patients who are going to receive Magnesium Sulphate
89012861|NCT01601314|Placebo Comparator|Control|Patients who are going to receive Sodium Chloride 0.9%
89012862|NCT00254657|Placebo Comparator|Placebo|
89012863|NCT00254657|Experimental|Levetiracetam|
89012864|NCT01607515|Other|suspected PH|Patients who undergo right heart catheterization for PH diagnosis undergo impedance cardiography
89012865|NCT02482753|Experimental|Chidamide + exemestane, open-label|Patients receive 30 mg Chidamide per week and 25 mg exemestane QD. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
89199641|NCT04834375|No Intervention|Standard dexamethasone dose|Dexamethasone 6 mg IV daily for 10 days
89441881|NCT03349736|Other|Pelvic Floor Muscle Training|"Women visiting antenatal (up to16 weeks of gestation) will be enrolled for the study. The women will be follow up 4 times during the antenatal visit until 37 weeks of gestation. Questionnaire data and clinical measurements(strength of PFM by Electromyograph biofeedback) will be registered at baseline and and follow-up at week 37 of pregnancy.~The treatment program will include~1) Information, educational material (leaflets, posters, and video) and individual/group exercise on PFM exercise on the 1st day of the visit. Counseling about the importance of performing PFM exercise will be provided. Women are advised to perform home PFM exercise and record in the exercise diary."
89441882|NCT05531110|Active Comparator|Control arm|Bilateral Alcon SN60WF IOL insertion
89441883|NCT05531110|Experimental|Intervention arm|Bilateral Eyhance ICB00 IOL
89441884|NCT02314338|Experimental|Pulmonary rehabilitation|Multi-disciplinary pulmonary rehabilitation
89441885|NCT03349658|Active Comparator|general anesthesia|Patients in this group were randomized to receive general anesthesia.
89441886|NCT03349658|Active Comparator|spinal anesthesia|Patients in this group were randomized to receive spinal anesthesia.
89441887|NCT02314416|Active Comparator|Standard Treatment|Patients in the Control Arm will receive collagen matrix for wound coverage and standard wound care that will include chemical/surgical debridement (using a topical paste to clean the wound or removing bad tissue using a scalpel or scissors) and dressing care. In addition, they may also have imaging studies (such as x-ray, CAT scan, ultrasound) performed if determined to be necessary by the physician.
89441888|NCT02314416|Experimental|Amniotic Stem Cells and Collagen Matrix|Patients will receive amniotic stem cells(NuCel) embedded in collagen matrix for wound coverage, and standard wound care that will include chemical/surgical debridement (using a topical paste to clean the wound or removing bad tissue using a scalpel or scissors) and dressing care. In addition, they may also have imaging studies (such as x-ray, CAT scan, ultrasound) performed if determined to be necessary by the physician.
89441889|NCT03353012|Experimental|Levonorgestrel immediate post-partum|Breast-feeding postpartum woman who receive Levonorgestrel drug implant (75 mg) between 48-72 hr after child delivery
89441890|NCT03353012|Experimental|Etonogestrel immediate post-partum|Breast-feeding postpartum woman who receive Etonogestrel drug implant (68 mg) between 48-72 hr after child delivery
89441891|NCT03353012|Active Comparator|Levonorgestrel delayed post-partum|Breast-feeding postpartum woman who receive Levonorgestrel drug implant (75 mg) between 5-7 weeks after child delivery
89441892|NCT03353012|Active Comparator|Etonogestrel delayed post-partum|Breast-feeding postpartum woman who receive Etonogestrel drug implant (68 mg) between 5-7 weeks after child delivery
89441893|NCT02316756|Experimental|Single Ascending Doses Cohort 1|subjects receive 3 active doses and one placebo
89441894|NCT02316756|Experimental|Single Ascending Doses Cohort 2|subjects receive 3 doses and one placebo
89441895|NCT02316756|Experimental|Cohort 3|optional cohort
89441896|NCT03352856|Active Comparator|Active|Highly purified barley starch packed in sachets; Increasing doses given at clinic as follows: 0.6 g, 2 g, 6 g and 18 g. If required, continued at home with 2 x 18 g daily for 5 days.
89441897|NCT03352856|Placebo Comparator|Placebo|Maize starch packed in sachets; Increasing doses given at clinic as follows: 0.6 g, 2 g, 6 g and 18 g. If required, continued at home with 2 x 18 g daily for 5 days.
89441898|NCT05523232|Experimental|42 Hz group|Vibration training with 42 Hz was given to participants.
89441899|NCT05523232|Active Comparator|63 Hz group|Vibration training with 63 Hz was given to participants.
89441900|NCT04462614|Experimental|single-arm study|Chronic hemodialysis patients for at least 3 months at Reims University Hospital, treated by long-term anticoagulation with VKA and dialysed with the HeprAN ™ membrane
88925690|NCT02330289|Experimental|Report card arm|The intervention arm will receive an email report card describing their lab use compared to their peers as well as a link to a website visually tracking the team's daily ordering of common lab tests compared to the peer teams.
88925691|NCT02330289|No Intervention|Control arm|Physicians in the control arm will not receive the email or website link.
88925692|NCT02311582|Experimental|Phase I: MK-3475 + MLA|-In the phase I portion of this study, MK-3475 will be given every 3 weeks starting no more than 1 week after MLA until progression or unacceptable toxicity.
89012866|NCT02482753|Experimental|Chidamide + exemestane, double-blinded|Patients receive 30 mg Chidamide twice per week and 25 mg exemestane QD. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
89012867|NCT02482753|Placebo Comparator|placebo + exemestane, double-blinded|Patients receive placebo twice per week and 25 mg exemestane PO QD. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
89012868|NCT00288795|No Intervention|1|Standard Care
89441901|NCT03349580|Experimental|The training group|The training group performed rehabilitation program twice per week over 9 weeks. The group commenced rehabilitation 3 weeks after the surgery. During the phase one training (week 1 to week 5), the isometric exercises were preformed on the trunk extension, flexion and lateral flexion muscles. During the phase 2 (week 6 to week 9), the exercises were performed on the strength machines and duration of the exercises were maintained and prolonged to 30 seconds. The leg adduction and hip extension exercises were added. The patients were instructed to perform abdominal bracing (IAP) and maintain the neutral position of their lumbar spine before and during the exercises.
89441902|NCT03349580|No Intervention|The control group|The control group followed the hospital's standard protocol. These do not include exercises or physiotherapy before 3 months after surgery.
89441903|NCT05518552|Experimental|manual Lumbar Traction|The subjects consist of 25 patients with chronic low back pain. They underwent a manual lumbar traction with Physiotherapist pulling the patients while lying prone on a couch
89012869|NCT00288795|Other|2|Massage Treatment
89012870|NCT00288795|Other|3|Polarity Treatment
89012871|NCT01607632|Experimental|loving-kindness meditation|
89441904|NCT05518552|Experimental|Prone traction|This group consist of patients with non specific chronic low back pain that were put on prone traction.
89441905|NCT02314494||Infants at risk|Infants identified as at risk of obesity using the ProAsk intervention
89441906|NCT02314494||Infants not at risk|Infants identified as not at risk of obesity using the ProAsk intervention.
89441907|NCT02316912|Active Comparator|Single dose level 1 active|Six subjects ATX2417 I mg tablet once.
89012872|NCT01607710||Generalized Anxiety Disorder|The group of participants diagnosed with generalized anxiety disorder.
89441908|NCT02316912|Active Comparator|Single dose level 2 active|Six subjects ATX2417 2x1 mg tablet once.
89441909|NCT02316912|Active Comparator|Single dose level 3 active|Six subjects ATX2417 5 mg tablet once.
89441910|NCT02316912|Active Comparator|Single dose level 4 active|Six subjects ATX2417 4x5 mg tablets once.
89441911|NCT02316912|Active Comparator|Single dose level 5 active|Six subjects ATX2417 to be determined.
89441912|NCT02316912|Active Comparator|Multiple dose level 1 active|Six subjects ATX2417 dose to be determined once daily for 8 days.
89441913|NCT02316912|Active Comparator|Multiple dose level 2 active|Six subjects ATX2417 dose to be determined once daily for 8 days.
89441914|NCT02316912|Placebo Comparator|Single dose level 1 placebo|Two subjects one placebo tablet once.
89441915|NCT02316912|Placebo Comparator|Single dose level 2 placebo|Two subjects one placebo tablet x2 once.
89441916|NCT02316912|Placebo Comparator|Single dose level 3 placebo|Two subjects one placebo tablet once.
89441917|NCT02316912|Placebo Comparator|Single dose level 4 placebo|Two subjects two placebo tablets once.
89441918|NCT02316912|Placebo Comparator|Single dose level 5 placebo|Two subjects four placebo tablets once.
89441919|NCT02316912|Placebo Comparator|Multiple dose level 1 placebo|Two subjects matching placebo(s) once daily for 8 days
89441920|NCT02316912|Placebo Comparator|Multiple dose level 2 placebo|Two subjects matching placebo(s) once daily for 8 days.
89012873|NCT01607710||Nonclinical Control Group|The comparison group of participants with no psychiatric diagnoses.
89012874|NCT01607827|Active Comparator|Polyp removal upon insertion and withdrawal|
89012875|NCT01607827|No Intervention|Polyp removal upon withdrawal only|
89199642|NCT04834375|Experimental|Weight-based dexamethasone dose|Dexamethasone 0.2 mg/kg/day IV (maximum 20 mg daily) for 10 days
89199643|NCT04812964|Active Comparator|Standard Diet|Standard protein diet group as control based on 0.5 gram protein per pound of lean body mass with same calories: 15% protein and 55% carbohydrate.
89199644|NCT04812964|Active Comparator|High Protein Diet|High protein diet group based on 1 gram of protein per pound of lean body mass: 30% protein and 40% carbohydrate.
89199645|NCT04788745|Experimental|Experimental|Trimetazidine 35mg
89199646|NCT04774549||Patients with inflammatory cardiomyopathy|Patients referred to CMR for suspected/known inflammatory cardiomyopathy and/or diagnosed inflammatory cardiomyopathy from CMR findings
89199647|NCT04761666||static verticalization device|children with severe cerebral palsy (GMFCS IV & V) with static verticalization device
89441921|NCT02316912|Active Comparator|Single dose level 6 active|Six subjects ATX2417 to be determined.
89441922|NCT02316912|Active Comparator|Single dose level 7 active|Six subjects ATX2417 to be determined.
89441923|NCT02316912|Placebo Comparator|Single dose level 6 placebo|Six subjects placeboto be determined.
89441924|NCT02316912|Placebo Comparator|Single dose level 7 placebo|Six subjects placebo to be determined.
89441925|NCT03349424|Experimental|Stilamin group|Patients in the Stilamin group will be continuous intravenous infusion with the somatostatin in addition to postoperative conventional treatment.
89441926|NCT03349424|No Intervention|Control group|Patients in the control group will receive the postoperative conventional treatment, without addition of any new medicines.
89441927|NCT02314572|Other|Single-arm|
89441928|NCT04506710||Patients with low-risk prostate cancer|Histologically confirmed low-risk prostate cancer (PSA up to 10 ng / ml; Gleason (3 + 3) = 6 (ISUP 1); tumor stage T2a (low- risk according to the D'Amico scale))
89441929|NCT02572570|Experimental|Posterior Composite Resin Restoration|Participants will receive two commercially available tooth-colored restorative materials used for direct restoration as per manufacturer's instructions.
89441930|NCT02316990||patients ≥18 ,Neurosurgical departments and whose GCS≤10[4]|"The subject population that will be included in the NIS are the consecutive discharged patients ≥18 years old who were hospitalized to Neurosurgical departments and whose GCS≤10[4] within 24 hours of lesion/admission.(GCS: Glasgow Coma Scale NIS: Non-Interventional Study~)"
89441931|NCT03122990|Experimental|Full mouth scaling and root planing|FM-SRP No surgical periodontal treatment will be performed in all dentition within 24 hours
89012876|NCT01607866|Experimental|Quadrant parotidectomy|Patients in this arm will receive excision of the parotid gland quadrant harboring the tumor
89441932|NCT03122990|Active Comparator|Quadrant Scaling and Root Planing|"Q-SRP No surgical periodontal treatment will be performed in all dentition subdivided in four appointments. Each appointment will be performed in one week interval. In each appointment only a quadrant of the dentition will be instrumented."
89441933|NCT03349346|Experimental|Cohort 1- Participants 12 to less than 18 years of age|"Participants will receive idelalisib monotherapy (from day 1 to day 21), followed by combination therapy with RICE. Upon enrollment, participants will be assigned to one of the 3 dose levels during idelalisib monotherapy (Dose level 1 = 55 mg/m^2 twice daily (BID), Dose level 2 = 85 mg/m^2 BID, Dose level 3 = 125 mg/m^2 BID) administered as 50 mg, 100 mg or 150 mg tablets as appropriate, or as 10 mg dispersible tablets for oral suspension for participants who cannot swallow tablets.~Day 1: single dose of idelalisib~Day 2 up to Day 21: initiate and continue idelalisib BID dosing~Day 22 for up to 12 months: idelalisib twice per day in combination with RICE. Cycles of RICE will be administered over 5 days every 3 weeks (Day 1: rituximab; Day 3: rituximab, ifosfamide, carboplatin, etoposide; Days 4 and 5: ifosfamide, etoposide) starting day 22 (or earlier if there is evidence of clinical progression while on idelalisib monotherapy) for up to 12 months."
89441934|NCT03349346|Experimental|Cohort 2- Participants 1 to less than 12 years of age|"Participants will receive one of the 3 doses of idelalisib monotherapy (from day 1 to day 21) followed by combination therapy with RICE. Idelalisib will be administered as as 50 mg, 100 mg or 150 mg tablets as appropriate, or as 10 mg dispersible tablets for oral suspension for participants who cannot swallow tablets. Participants will will be enrolled at dose level 1 once tolerability is demonstrated in the older cohort (Cohort 1). Thereafter, both age cohorts will be dose escalated independently.~Day 1: single dose of idelalisib~Day 2 up to Day 21: initiate and continue idelalisib BID~Day 22 for up to 12 months: idelalisib twice per day in combination with RICE. Cycles of RICE will be administered over 5 days every 3 weeks (Day 1: rituximab; Day 3: rituximab, ifosfamide, carboplatin, etoposide; Days 4 and 5: ifosfamide, etoposide) starting day 22 (or earlier if there is evidence of clinical progression while on idelalisib monotherapy) for up to 12 months."
89441935|NCT03502434|Experimental|90 mg/mL SM04755 in water|90 mg/mL SM04755 in water applied via patches
89441936|NCT03502434|Experimental|90 mg/mL SM04755 in aqueous Vehicle|90 mg/mL SM04755 in aqueous Vehicle applied via patches
89441937|NCT03502434|Experimental|90 mg/mL SM04755 in aqueous Vehicle (without Benzyl Alcohol)|90 mg/mL SM04755 in aqueous Vehicle (without Benzyl Alcohol) applied via patches
89441938|NCT03502434|Other|Vehicle|Aqueous Vehicle applied via patches
89441939|NCT03502434|Other|White petrolatum|White petrolatum (Negative control) applied via patches
89441940|NCT03502434|Other|Sodium lauryl sulfate|Sodium lauryl sulfate (SLS 0.5%) (Positive control) applied via patches
89441941|NCT04302142|Experimental|Intervention group|
89441942|NCT04302142|Placebo Comparator|Control Group|
89441943|NCT02317068|Experimental|High Atrial Base Rate Pacing|The base rate of pacemaker will be determined 75-100 beats/minute in condition that during first step of follow-up, his/her atrial pacing will be more than 80% of atrial high rate/automatic mode switch
89441944|NCT02317068|Active Comparator|Device Default|The base rate of pacemaker will be determined 60 beats/minute
89441945|NCT03352700|Placebo Comparator|3L PEG|only used 3L PEG
89441946|NCT03352700|Experimental|3L PEG+Dyclonine Hydrochloride Mucilage|used 3L PEG+Dyclonine Hydrochloride Mucilage
89441947|NCT05522998|Experimental|Ciprofol Group|Experimental drug: Ciprofol; Dosage form: injection; Specification: 20ml: 50mg; Frequency and duration: intravenous infusion with micropump, anesthesia induction dose 0.4-0.5mg/kg, Administration for 30s (± 5S)
89012877|NCT01607866|Active Comparator|Superficial parotidectomy|Patients in this group will receive superficial parotidectomy
89012878|NCT01607944||Normal Glucose Tolerance|
89441948|NCT05522998|Active Comparator|Propofol Group|Experimental drug: Propofol; Dosage form: injection; Specification: 20ml: 200mg; Frequency and duration: intravenous infusion with micropump, anesthesia induction dose 2-2.5mg/kg, Administration for 30s (± 5S)
89441949|NCT05528224|Experimental|stepped-care Internet-based cognitive behavioral therapy(SC-ICBT) combined with medication|"In the main study, after individualized assessment（0 week and 3 week separately）, OCD patients will be provided with self-guided ICBT or therapist-guided ICBT through the severity of their symptoms flexibly while they will continue with the medications they already have.~In the pilot study, 23 OCD patients will be assigned to SC-ICBT group based on their autonomous will. They will begin with self-guided ICBT, followed by an assessment of their treatment outcomes at week 3, with non-responders being escalated to a higher intensity of treatment, and additional therapist-guided ICBT in the following three weeks. During the 6-week treatment they will continue with the medications they already have."
89441950|NCT05528224|Active Comparator|Cognitive Behavioral Group Therapy (CBGT) combined with medication|"In the main study, OCD patients will be provided with therapist-guided offline Cognitive Behavioral Group Therapy while they will continue with the medications they already have.~In the pilot study, 23 OCD patients will be assigned to CBGT group based on their autonomous will. They will receive the same CBGT intervention as in the main study while they will continue with the medications they already have."
89441951|NCT05528224|Active Comparator|conventional medical treatment (TAU)|"In the main study, OCD patients will be treated as usual. Namely, they will continue with the medications they already have.~This group is not present in the pilot study, as both SC-ICBT group and CBGT group combines medications. We suppose that the mere use of SC-ICBT group compared to CBGT group (a commonly used psychotherapy in Chinese clinical practice) is sufficient to draw conclusions about the feasibility of SC-ICBT in in adults with OCD in China.~However, in order to further validate the economic benefits of SC-ICBT, we chose to set TAU group in the main study."
89441952|NCT03498534|Active Comparator|Patients with a -TST|In all patients with a negative TST test, Isoniazid 300 mg per day will be administered for 6 months
89012879|NCT01607944||Type 2 Diabetes|
89012880|NCT01608022|Experimental|PF804|
89199648|NCT04761666||non verticalization device|children with severe cerebral palsy (GMFCS IV & V) without static verticalization device
89441953|NCT03498534|Active Comparator|Patients with a +TST|In patients with a +TST test researchers will test for HIV, hepatic function and we will take a chest x-ray. Isoniazid 300 mg per day will be administered for 6 months
89012881|NCT04719494|Experimental|Training Group|During the 12-training day sessions, subjects will walk on the treadmill for a total of 30 minutes. Participants will walk at a comfortable pace while we perform controlled movements to the treadmill system. Subjects will be fitted with a fall-arrest harness and assisted onto the treadmill system. In the dynamic balance training group, we will move the motion base as participants walk in order to challenge their balance.
89199649|NCT04752579|Experimental|Pilates exercise program|Participants allocated to this group will receive a 10-week Pilates exercise program with each session having a duration of 45'.
89441954|NCT03498534|Active Comparator|HIV positive patients|The researchers will test hepatic function and take a chest x-ray. Isoniazid 300 mg per day will be administered for 6 months
89199650|NCT04752579|Placebo Comparator|Control|Participants allocated to this group received general consulting instructions and a home-based general exercise sheet
89199651|NCT04741672|Experimental|Intervention group|Providing guidance and calling after discharge routine procedure.
89441955|NCT02518178|Active Comparator|NFC Sticker|Participants will receive an NFC (Near Field Communication) sticker, placed on their existing immunization (MAMTA) card. This will serve as a comparator to the NFC necklace while still allowing for patient data to be digitized and utilized by the health service provider, Seva Mandir.
89441956|NCT02518178|Experimental|NFC Necklace|Participants will receive a necklace with an NFC pendant, which interfaces with the Khushi Baby mobile application to digitize the data. This arm will allow for the assessment of peer influence effects of the necklace as a social symbol.
89441957|NCT02518178|Experimental|NFC Necklace + Voice Reminder|In addition to the NFC necklace, mothers of the participants in this arm will receive dialect-specific voice call reminders, informing them about the next camp and the importance of vaccinations.
89199652|NCT04741672|Experimental|Control group|Discharge routine procedure.
89199653|NCT04739709|Experimental|APP13007 0.05% BID|1 drop APP13007 0.05% twice daily for 14 days to study (operated) eye
89199654|NCT04739709|Placebo Comparator|Matching Vehicle Placebo|1 drop matching vehicle place twice daily for 14 days to study (operated) eye
89012882|NCT04719494|No Intervention|Control Group|Subjects who are in the control group will also walk on the treadmill, but the motion base will remain stationary. They will complete 12-training day sessions.
89199655|NCT04717479|Other|Intervention|Participants will be paired with an English language learner and engage in 8 weeks, 1 hour videoconferencing sessions.
89441958|NCT03502356|Active Comparator|Control Group|This group will include 200women undergoing elective cs. In this group, patients will receive standard antibiotic prophylaxis CEFAZOLIN (at a dose of 1 g) and azithromycin (at a dose of 1g) 2 hours preoperative.
89441959|NCT03502356|No Intervention|Study Group|This group will include 200women undergoing elective cs. In this group, patients will receive only standard prophylaxis antibiotic(CEFAZOLIN)
89441960|NCT05518318|Experimental|GLS-010|GLS-010 therapy
89441961|NCT05518318|Active Comparator|chemotherapy|chemotherapy
89441962|NCT04509518|Experimental|Study group|Participants in the study group received exercise therapy program plus additional TENS therapy
89441963|NCT04509518|Other|Control group|Participants in the study group received exercise therapy program plus sham TENS
89441964|NCT05522920|Experimental|Therapy|Conventional physical therapy will be used with and without spinal cord stimulation to investigate improvement of upper limb function.
89441965|NCT03498456|Experimental|Tegoprazan/Amoxicillin/Clarithromycin|Tegoprazan 50 mg / Amoxicillin 1000 mg / Clarithromycin 500 mg
89441966|NCT03498456|Active Comparator|Lansoprazole/Amoxicillin/Clarithromycin|Lansoprazole 30 mg / Amoxicillin 1000 mg / Clarithromycin 500 mg
89441967|NCT03352622|Active Comparator|CASES|Patients with RA with methotrexate therapy and inhibitors of tumor necrosis factor alpha (TNFα) infliximab, etanercept, adalimumab; That present problems of effectiveness
89441968|NCT03352622|Active Comparator|CONTROLS|Patients with RA with methotrexate therapy inhibitors of tumor necrosis factor alpha (TNFα) infliximab, etanercept, adalimumab; No problems of effectiveness
89441969|NCT05518240||Acute ischemic stroke (AIS)|Patients who experienced acute ischemic stroke (AIS), eligible for restoration of blood flow using a Solitaire or Embotrap device to remove thrombus from the neurovasculature
89441970|NCT02317146|Experimental|Six Hours Postpartum|The woman received magnesium sulfate for 6 hours after delivery as prophylaxis to eclampsia.
89441971|NCT02317146|Active Comparator|Twenty-four hours Postpartum|The woman received magnesium sulfate for 24 hours after delivery as prophylaxis to eclampsia.
89441972|NCT04463238|Experimental|Cartilage membrane surgery|"The test group applied the guidance provided by Shaanxi Baiao Regenerative Medicine Co., Ltd.~Cartilage regeneration membrane combined with microfracture surgery."
89441973|NCT04463238|Other|Microfracture|The control group was treated with microfractures widely recognized at home and abroad.
89441974|NCT04509830|Experimental|hip strengthening|resistance training for hip abductor, hip extensor, and hip external rotator will be performed.cuff weights will be used with 80% of 1 repetition maximum at 3 sets of 8 repetitions with 10-15 second rest between repetitions and 1-2 minute rest between sets.
89441975|NCT04509830|Active Comparator|quadriceps strengthening, stretch for hamstring,cuff muscles|"quadriceps strengthening: multi-angle isometric exercise from sitting position will be performed. cuff weights will be used with 3 sets of 12 repetitions at 40% of 1 reprtition maximum.~self stretch for hamstring and cuff muscles from supine position. the procedure will be repeated 4 times."
89441976|NCT05528146|Experimental|A|In a single-blind crossover trial (male or female), these groups will receive 3.5 g/day or 7 g/day of psyllium for 4 weeks. The trial will stop 1 week after the first phase and post-test. The two groups will then swap doses for 4 weeks. Post-tests will be recorded upon completion of this Phase 2 trial. After completing the trial, determine the dose effect.
89441977|NCT05528146|Experimental|B|In a single-blind crossover trial (male or female), these groups will receive 3.5 g/day or 7 g/day of psyllium for 4 weeks. The trial will stop 1 week after the first phase and post-test. The two groups will then swap doses for 4 weeks. Post-tests will be recorded upon completion of this Phase 2 trial. After completing the trial, determine the dose effect.
89441978|NCT02317224|Experimental|"3-Hole subxiphorid and subcostal approach"|The patient were in the supine position with legs apart at about 45°, made a 2.0 cm incision below xiphoid process as the observation hole. Then made two 0.5cm operation holes along bilateral rib arch at midclavicular line, two trocars were inserted into the two holes under the guidance of B-ultrasound.After that, carbon dioxide was pumped into the anterior mediastinum, the pressure was maintained at 8 mmH2O, ultrasound scalpel and a grasping forceps were inserted through the operating ports respectively. Retrosternal space including bilateral lower poles of thymus, internal mammary arteries and phrenic nerves were exposed by both blunt and sharp dissection. Then ultrasound scalpel were used to separate the thymus and its surrounding fat tissue, cut off thymic veins by ultrasound scalpel.For patients with myasthenia gravis, bilateral mediastinal pleurae and the affected adipose tissues had been thoroughly removed.
89441979|NCT02317224|Experimental|Trans sternal approach|
89441980|NCT02317224|Experimental|VATS approach|
89441981|NCT05528068|Placebo Comparator|control group|standard care, physiological monitoring by wearable devices and healthy lifestyle education
89441982|NCT05528068|Experimental|supervised lifestyle intervention group|standard care, physiological monitoring by wearable devices and personalized and supervised lifestyle intervention including dietary and physical activity modification
89441983|NCT02518334|Experimental|Alcohol consumption|Alcohol consumption and wine consumption
89441984|NCT02317302|Experimental|FDG-PET/CT or FDG-PET/MR|"Standard of care FDG-PET/CT or FDG-PET/MR at baseline~FDG-PET/CT or FDG-PET/MR after the 2nd but before the 3rd brachytherapy treatment~Standard of care 3 month post treatment FDG-PET/CT or FDG-PET/MR~We will perform the research-related FDG-PET on the PET/MR rather than the PET/CT if the patient is safe to undergo MR and agrees to undergo MR.~The standard of care imaging may be performed on the PET/CT scanner or the PET/MR scanner."
89441985|NCT05518084|Experimental|Liponovo tissue product|4,5mlLiponovo tissue product, single injection
89441986|NCT05518084|Sham Comparator|Plasebo|4,5ml Ringer, single injection
89441987|NCT04503824||Group IIa: 13 papular OLP|
89441988|NCT04503824||Group IIb: 13 atrophic OLP|
89441989|NCT04503824||Group IIc: 13 erosive OLP|
88925693|NCT02311582|Experimental|Phase II: MK-3475 Only (Arm B)|"In the phase II portion of this study, MK-3475 will be given every 3 weeks beginning 3 weeks after surgical debulking or no more than 1 week after biopsy (if no debulking)~The phase II dose was determined during the Phase I portion of the study. Patients enrolling in phase II will need to have tissue available for diagnostic purpose and for immunological monitoring.~Surgical resection/debulking is per standard of care and optional for the purpose of this study and the performing neurosurgeon will determine whether each patient will undergo surgery.~For those not undergoing surgical resection/debulking, a biopsy for tissue diagnosis and immune monitoring will only be performed when clinically warranted."
89012883|NCT01608139|Experimental|Curcumin + Sorafenib + Vorinostat|"Participant assigned to a dose level of the study drug combination based on when joined this study. Up to 9 dose levels of the study drug combination will be tested. Three (3) to 6 participants will be enrolled at each dose level of the study drug combination. During first cycle only, Curcumin initiated on Day 1, Vorinostat on Day 3 and Sorafenib on Day 5. Beginning with Cycle 1 Day 5, all agents administered continuously. Cycle of therapy is 28 days.~Starting dose of Curcumin: 4 grams by mouth per day on Day 1. Starting dose of Sorafenib: 200 mg by mouth daily beginning on Day 5. Starting dose of Vorinostat: 100 mg by mouth daily beginning on Day 3."
89441990|NCT04503824||Group I: 13 healthy individuals|
89441991|NCT05522686|Experimental|Patients in the Brochure Education Group|Patients in the Brochure Education Group were given information about urodynamics in a room reserved for education, and the education brochure was introduced. Patients reviewed the brochure and at the end of the education, it was given to them.
89441992|NCT05522686|Experimental|Patients in the Video Education Group|Patients in the Video Education Group were informed about urodynamics in a room reserved for education. Patients watched the educational video on a computer. The urodynamics patient education video was shown to patients once during the session. They did not request to watch it again.
89441993|NCT05522686|Experimental|Patients in the Brochure-Supported Video Education Group|Patients in the Brochure-Supported Video Education Group were given information about urodynamics in a room reserved for education, and the education brochure was introduced. They examined the brochure and watched the educational video on a computer.
89012884|NCT01607671|Experimental|Timolol|This group will receive ophthalmic Timolol maleate 0.5%, 1 drop to the effected eye twice daily for 4 weeks.
89012885|NCT01607671|No Intervention|Standard Care|This group will be treated with current standard care. This does not include Timolol or other medications to reduce intraocular pressure.
89012886|NCT01608256||mild cognitive impairment|men and women, aged 50 to 70. The inclusion criteria are:diagnosis of MCI (given by a neurologist), valid driver's license and driving experience of at least a year. the exclusion criteria are: people diagnosed with other neurological damage such as: dementia, CVA and head injury, people with sensory or motor impairment.
89012887|NCT01608256||Healthy people|Men and women, ages 50-70. the inclusion criteria are: healthy people with out neurological disease or psychiatric illness, have valid driver's license and driving experience of at least a year.
89441994|NCT05522686|Other|Control Group|Patients in this group were given routine clinical information by the healthcare professional that would perform the urodynamics procedure. After patients were given verbal information, a written text containing the necessary preparations for urodynamics was given to them. The routine patient information text included adjustment to the appointment day and time, nutrition, mechanical bowel preparation, and medications necessary for the procedure.
89441995|NCT03352544|Experimental|Exercise|Exercise training for 12 weeks (aerobic and resistance training trice a week).
89012888|NCT01608334|Experimental|group A|Fentanyl
89012889|NCT01608334|Active Comparator|Group B|Sufentanil
89012890|NCT01608373|Active Comparator|Intravenous lidocaine injection group|Patients in Group I (intravenous lidocaine injection group) received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous lidocaine infusion of 2 mg/kg/hr.
89441996|NCT03352544|No Intervention|Usual treatment|Usual treatment during 12 weeks, coinciding with exercise intervention time frame.
89012891|NCT01608373|Active Comparator|Intraperitoneal lidocaine irrigation group|Patients in Group P(intraperitoneal lidocaine irrigation group) receive a peritoneal lidocaine irrigation with 3.5mg/kg lidocaine and normal saline 100cc.
89012892|NCT01608373|Placebo Comparator|Intravenous normal saline group|The patients in Group C (placebo control group) received normal saline intravenous injection
89012893|NCT01608412|Active Comparator|Tacrolimus|"The subjects included in the study will be clinically followed up for at least 12 months. The patients will be selected at 3 months post-transplant according to inclusion and exclusion criteria and randomized in a 1:1 ratio for conversion to everolimus or maintenance of tacrolimus therapy.~Intervention arm: Tacrolimus"
89012894|NCT01608412|Active Comparator|Everolimus|"The subjects included in the study will be clinically followed up for at least 12 months. The patients will be selected at 3 months post-transplant according to inclusion and exclusion criteria and randomized in a 1:1 ratio for conversion to everolimus or maintenance of tacrolimus therapy.~Intervention arm: Everolimus"
89012895|NCT01608529|Experimental|Cyclist group|
89441997|NCT02317458|Experimental|Active arm|One arm with standard of care and C3BS-CQR-1 injection (treatment group) using intramyocardial catheter injection.
89441998|NCT02317458|Sham Comparator|Control arm|One arm with standard of care undergoing a sham procedure (control group)using intramyocardial catheter injection. .
89441999|NCT05518006|Experimental|PreMama Balance|"Each day, the participants will take 1 packet of Premama Balance, dissolved in one glass (8oz+) of water. Premama Balance may be taken with or without food. Should participants present themselves with a sensitive stomach, it is recommended to take the drink with or after a meal to avoid an upset stomach. Participants will repeat this process daily for 6 months/24 weeks (study period) until the study is complete.~At week 12 and in week 24, the participants will take a survey and a hormone test to track progress. In total there will be 3 surveys and 3 hormone tests. Additionally, participants will fill out a weekly consumption survey to track compliance."
89501654|NCT02155751|Experimental|Nutrition program only/NLIP|These women (n=10) will only be given the nutrition program (NLIP) of NELIP as outlined below in intervention. They will be encouraged to be more active but will not be given an exercise intervention.
89501655|NCT02155751|No Intervention|Control|A control group (n=30) of obese pregnant women will also be recruited and will be matched by pre-pregnancy BMI, maternal age and parity, with no intervention, but will attend the clinic for standard obstetric care and follow-up.
89501656|NCT02155907||Rtest, Atrial fibrillation|Patients with ischemic stroke or TIA within the last week. Sinus rhythm on the surface ECG. Age ≥ 60 years. Given written informed consent
89501657|NCT03993223|Experimental|MTrP group|Healthy overhead athletes with upper trapezius myofascial trigger point
89501658|NCT03993223|Sham Comparator|Control group|Healthy overhead athletes without upper trapezius myofascial trigger point
89501659|NCT02156063|Experimental|NT100|NT100 Dose 1
89501660|NCT02156063|Placebo Comparator|Placebo|Placebo
89501661|NCT03106389|Active Comparator|Misoprostol|This group will receive 400 micrograms of misoprostol administered vaginally for the first dose, followed after 6 hours by 400 micrograms administered orally, repeated every 6 hours.
89442000|NCT05518006|Placebo Comparator|Placebo Drink|"Each day, the participants will take 1 packet of Placebo Drink, dissolved in one glass (8oz+) of water. Placebo Drink may be taken with or without food. Should participants present themselves with a sensitive stomach, it is recommended to take the drink with or after a meal to avoid an upset stomach. Participants will repeat this process daily for 6 months/24 weeks (study period) until the study is complete.~At week 12 and in week 24, the participants will take a survey and a hormone test to track progress. In total there will be 3 surveys and 3 hormone tests. Additionally, participants will fill out a weekly consumption survey to track compliance."
89442001|NCT03349112|Active Comparator|Anesthetized|A study team member will apply 1 mL of 2% viscous lidocaine to each nares prior to the passage of the catheter, Participants in this group will additionally receive .8 mL of a 4% Lidocaine spray to both nares prior to HRPM.
89442002|NCT03349112|Placebo Comparator|Non-Anesthetized|A study team member will apply 1 mL of 2% viscous lidocaine to each nares prior to the passage of the catheter. Randomized participants in this group will not receive .8 mL of a 4% Lidocaine spray prior to HRPM .
89442003|NCT03501420||Physicians|A sample of 230 to 325 rheumatologists actively involved in management and treatment decisions of pSS subjects in France, Italy, Spain, Germany and the United States will be included in the survey.
89442004|NCT03501420||Subjects with pSS|Subjects with a confirmed diagnosis of pSS under consultation of the rheumatologists enrolled in the study will be included.
89442005|NCT02320890|Experimental|YBand (YDT-201N)|transcranial Direct Current Stimulation (tDCS) application 3 days a week for 12 weeks (total of 36 applications)
89442006|NCT02320890|Sham Comparator|sham-Yband (YDT-201N)|sham-tDCS application 3 days a week for 12 weeks (total of 36 applications)
89442007|NCT03352466|Experimental|NasoShield very low dose|Single intranasal spray (Part A)
89442008|NCT03352466|Experimental|NasoShield low dose|Single intranasal spray (Part A)
89442009|NCT03352466|Experimental|NasoShield medium dose|Single intranasal spray (Part A)
89442010|NCT03352466|Experimental|NasoShield high dose|Single intranasal spray (Part A) or two intranasal sprays 21 days apart (Part B)
89442011|NCT03352466|Placebo Comparator|Placebo|Normal saline, single intranasal spray (Part A) or two intranasal sprays 21 days apart (Part B)
89442012|NCT03352466|Active Comparator|BioThrax|Three intramuscular injections 15 days apart (Part A)
89442013|NCT02320968|Experimental|Patients with nocturnal extraesophageal reflux|This is a non-randomized study to evaluate the effectiveness of the MedclineTM Sleep Assist Device on patients who experience nocturnal extraesophageal reflux. All patients will receive the device. Participants will serve as their own controls while undergoing 96-hour pH monitoring. Participants will follow their regular sleep position patterns on Days 1 and 2 of the study and will use the sleep assist device on Days 3 and 4. pH data and patient report of symptoms will be evaluated during the initial 96 hours of the study to capture physiologic results. All participants will use the sleep assist device for the remainder of the study to determine if a reduction in overall reflux symptom index (RSI) is achieved.
89442014|NCT05522608||patients with postoperative pain|Patients with postoperative pain after transabdominal preperitoneal hernia repair
89442015|NCT05522608||patients without postoperative pain|Patients without postoperative pain after transabdominal preperitoneal hernia repair
88925694|NCT02311582|Experimental|Phase II: MK-3475 + MLA (Arm A)|"In the phase II portion of this study, MK-3475 will be given every 3 weeks no more than 1 week after MLA, or no more than 1 week after biopsy (if no debulking).~The phase II dose will be determined during the phase I portion of this study and is 200 mg. Patients enrolling in phase II will need to have tissue available for diagnostic purpose and for immunological monitoring.~Surgical resection/debulking is per standard of care and optional for the purpose of this study and the performing neurosurgeon will determine whether each patient will undergo surgery.~--For those not undergoing surgical resection/debulking, a biopsy for tissue diagnosis and immune monitoring will be performed during MLA~MLA will take place at least 3 weeks but not more than 6 weeks after surgical resection/debulking or if no surgical resection/debulking will start on day 1"
89012896|NCT04718454||Equator attachment|Implant installation over epoxy resin model at the canine area on both sides following the surgical protocol of the implant placement,Equator Attachment fabrication is firmly screwed to the fixture on both sides at the canine region
89442016|NCT03498222|Experimental|Dose Level -1|Atezolizumab 1200mg Pemetrexed 500mg/m2 Carboplatin AUC5 ADI PEG20 9mg/m2
89442017|NCT03498222|Experimental|Dose Level 1|Atezolizumab 1200mg Pemetrexed 500mg/m2 Carboplatin AUC5 ADI PEG20 18mg/m2
89012897|NCT04718454||ball attachment|Implant installation over epoxy resin model at the canine area on both sides following the surgical protocol of the implant placement,ball Attachment fabrication is firmly screwed to the fixture on both sides at the canine region
89442018|NCT03498222|Experimental|Dose Level 2|Atezolizumab 1200mg Pemetrexed 500mg/m2 Carboplatin AUC5 ADI PEG20 36mg/m2
89442019|NCT02518022|Experimental|Intervention|For carbohydrates in beer, subjects will get covering by Insulin (1/2 of calculated amount). As well Insulin basal rate will set to half for 12 hours
89442020|NCT02518022|No Intervention|Standard|No Insulin Treatment of carbohydrates in beer.
89442021|NCT03352388|Experimental|Snack|Dairy- and berry-based snacks
89442022|NCT03352388|No Intervention|Reference|No snacks
89442023|NCT03498144||Patients with acquired punctal stenosis|Patients with acquired punctal stenosis with epiphora
89442024|NCT03498144||Control subjects|normal subjects, without evidence of any punctal abnormalities.
89442025|NCT03497988|Experimental|Syntocinon (=Oxytocin), then Placebo|"Single-Dose Intranasal Oxytocin~Single-Dose Placebo"
89442026|NCT03497988|Experimental|Placebo, then Syntocinon (=Oxytocin)|"Single-Dose Placebo~Single-Dose Intranasal Oxytocin"
89442027|NCT04610476|No Intervention|Control group|Individual previous stable glucocorticoid/DMARD therapy is continued
89442028|NCT04610476|Experimental|Reduction group|Individual previous stable dosage of glucocorticoids/DMARDs will be stepwise reduced according to a predefined algorithm
89442029|NCT03348800|Experimental|Test Side|The side in which computer controlled anesthetic delivery system will be used as dental anesthesia before dental surgery
89442030|NCT03348800|Active Comparator|Control Side|The side in which conventional syringe will be used as dental anesthesia before dental surgery
89442031|NCT03501342|Experimental|Virtual reality group|In virtual reality group, 30 minutes of Pilates training, 10 minutes of rest and then 20 minutes of virtual reality will be applied.
89442032|NCT03501342|Active Comparator|Dynamic Balance Training|"In the Dynamic Balance Training group, 20 minutes of dynamic balance exercises will be applied after Pilates training."
89442033|NCT03501342|No Intervention|Control group|The control group will be taught relaxation exercises and will be asked to perform the exercises at home.
89442034|NCT03352310|Experimental|Study Group|autologous UCB transfusion
89442035|NCT03352310|Other|Control Group|standard care
89442036|NCT02314806|Experimental|Irrigation with Gentamicin solution|The surgical bed is irrigated with a gentamicin solution
89442037|NCT02314806|Experimental|Irrigation with Clindamycin solution|The surgical bed is irrigated with a clindamycin solution
89442038|NCT02314806|Placebo Comparator|Irrigation with Normal saline|The surgical bed is irrigated with normal saline
89442039|NCT04502654||Pilot group|As a pilot Group for observating variable rehabilitation under individual baselines.
89442040|NCT03501186|Experimental|Group 1|forward walking on leveled surface
89442041|NCT03501186|Active Comparator|Group 2|forward walking on sand.
88925695|NCT02311582|Experimental|Phase II (after amendment #12): MK-3475 + MLA|"After amendment 12, all patients will be enrolled in this arm~MK-3475 will be given every 3 weeks no more than 1 week after MLA~The phase II dose will be determined during the phase I portion of this study and is 200 mg. Patients enrolling in phase II will need to have tissue available for diagnostic purpose and for immunological monitoring.~Surgical resection/debulking is per standard of care and optional for the purpose of this study and the performing neurosurgeon will determine whether each patient will undergo surgery.~For those not undergoing surgical resection/debulking, a biopsy for tissue diagnosis and immune monitoring will be performed during MLA~MLA will take place at least 3 weeks but not more than 6 weeks after surgical resection/debulking or if no surgical resection/debulking will start on day 1"
88925696|NCT02237820|Experimental|Dexamethasone|
88925697|NCT02237820|Active Comparator|Prednisone|
88925698|NCT02225704|Experimental|Radium-223 and enzalutamide|Radium-223 50kBq/kg by intravenous injection on day 1 of every 4 week cycle for maximum of 6 cycles Enzalutamide 160mg orally daily
88925699|NCT02186678|Experimental|assesment by 68Ga-DOTATATE PET-CT|
88925700|NCT02160353|Experimental|Combined hormonal therapy|Abiraterone acetate: 1000mg/day (four 250g tablets, orally once a day) for 126 days Prednisolone; 5mg/day (1 tablet orally once a day, concomitant to abiraterone acetate) for 126 days GnRh agonist for 4 injections (at 28 day intervals)
88925701|NCT02152358|Active Comparator|Ganciclovir|Patients with a positive CMV PCR
88925702|NCT02152358|Placebo Comparator|Ganciclovir placebo|Patients with a positive CMV PCR
88925703|NCT02152358|Active Comparator|Aciclovir|Patients with a PCR positive for HSV
88925704|NCT02152358|Placebo Comparator|Aciclovir placebo|Patients with a positive PCR for HSV
88925705|NCT02151019|Experimental|Experimental Arm|50.4 Gy / 28# external beam pelvic radiotherapy delivered using IMRT
88925706|NCT02151019|No Intervention|Control Arm|50.4 Gy / 28# external beam pelvic radiotherapy delivered using a 3-Dimensional (3-D) planned technique
88925707|NCT02150408|Experimental|assesment by 68Ga-DOTATATE PET-CT|
88925708|NCT02120040|Other|Hemangioblastoma (HB) of the Central nervous system (CNS)|
88925709|NCT02050997||B|Unresectable or metastatic PDAC patients who will receive standard treatment of CT +/- radiotherapy
88925710|NCT02050997||A|Resectable PDAC patients who will receive standard treatment of CT +/- radiotherapy
88925711|NCT02050750||TAILORx ICORG 06-31|Patients must have participated in TAILORx ICORG 06-31, participated in trial arms, and have adequate tumour tissue available
88925712|NCT02050737||A - due for adjuvant chemotherapy|Stage II/III colorectal cancer resectable disease due for adjuvant chemotherapy
88925713|NCT02050737||B - for observation only|Stage II colorectal cancer with resectable disease for observation only
89442042|NCT03501186|Experimental|Group 3|Backward walking on leveled surface
89442043|NCT03501186|Active Comparator|Group 4|Backward walking on sand.
89442044|NCT04506476|Experimental|Activity tracker with weekly goals|"Patients receive a fitness tracker, a booklet Physical training, exercise and cancer and an in-person briefing on physical activity during cancer therapy. We suggest a daily step-count which should improve the patients physical activity during radiotherapy of breast cancer. Patients receive weekly feedback and a new goal with the aim to reach a total of 6000 daily steps, which should be then maintained during radiotherapy."
89442045|NCT04506476|Experimental|Activity tracker without Weekly goals|"Patients receive a fitness tracker, a booklet Physical training, exercise and cancer and an in-person briefing on physical activity during cancer therapy.~The patients self-document their daily step count during radiotherapy, there will be no recommendation for the daily count of steps."
89442046|NCT04506476|No Intervention|Control arm with no activity tracker|"Patients receive a booklet Physical training, exercise and cancer and an in-person briefing on physical activity during cancer therapy. A fitness tracker will not be provided."
89442047|NCT03497754|Experimental|Cardiac output measurements|Cardiac output will be measured using TTE with and without the use of Probefix so not 2 arms but 2 consecutive measurements in the same patient
89442048|NCT02321124|Active Comparator|intervention|we will apply connective tissue manipulation and life style advice.
89442049|NCT02321124|Other|control group|We will apply only life style advice.
89442050|NCT02321202|Active Comparator|Control group|For postoperative parenteral nutrition, only Structolipid applied for 5 consecutive days.
89442051|NCT02321202|Experimental|Trial group|For postoperative parenteral nutrition, Omega-3 Fatty Acid-Based Parenteral Nutrition (20% Structolipid and 10% Omegaven) were applied for 5 consecutive days.
89442052|NCT00709202|Active Comparator|1|Subjects assigned to this arm will receive Betahistine.
89442053|NCT00709202|Placebo Comparator|2|Subjects in this group will received placebo.
89442054|NCT02314884|Experimental|Cafusertib Hydrochloride|Cafusertib Hydrochloride d1q3w
89442055|NCT05517538|Experimental|Palpation-guided|injected with the Palpation Method of neurotoxin adminstration
89442056|NCT05517538|Experimental|EMG-guided|injected with the EMG-guided Method of neurotoxin adminstration
89442057|NCT02321280|Experimental|Single arm single dose of denosumab|Open label = Single dose administration of single dose Denosumab 120 mg subcutaneously
88925714|NCT01855685|Experimental|Open label|X vivo gene therapy
88925715|NCT01840293||Primary Breast Cancer|
88925716|NCT01840293||Recurrent/Metastatic Breast Cancer|
88925717|NCT01822444||Intent-to-treat population with aCRC or mCRC|Advanced Colorectal Cancer with planned treatment with a aCRC or mCRC and who fulfil all inclusion and exclusion criteria
88925718|NCT01819064|Experimental|Infants and children less than 15Kg.|This group consists of children who are ASA physical status I and II, less than 2 years of age and scheduled for elective surgical procedure and weigh less than 15Kg will receive atropine 5 mcg/kg IV during sevoflurane anesthesia.
88925719|NCT01817751|Experimental|Treatment (sorafenib tosylate, valproic acid, sildenafil)|"Sorafenib 400 mg orally twice a day;~Valproic acid (to levels ≥ Lower Level of Normal (LLN) orally twice a day;~Sildenafil 50 mg orally twice a day~A cycle consists of 4 weeks.~*The first 6 patients evaluable for qualifying toxicity assessment will be treated as a safety lead-in; enrollment will be gated (the first 3 evaluable patients must complete 4 weeks of the combination therapy before the next 3 patients start combination treatment on protocol)"
88925720|NCT01810861||Serotype distribution (this is a non-interventional study)|Serotype distribution both in pediatrics and adults (this is a non interventional study)
88925721|NCT02744053|Experimental|Diagnostic (DCE-MRI, MBI)|Patients undergo DCE-MRI over 45-60 minutes. Patients receive technetium Tc-99m sestamibi via injection, and after 5 minutes patients undergo MBI scan over 1 hour. Both DCE-MRI and MBI are performed at the time of enrollment, at the end of anthracycline therapy, and at the conclusion of NAC before surgery. All patients also undergo standard of care imaging with DM and US (at the same time points if the treating doctor chooses to do so).
88925722|NCT01726309||Stage IV CRC|
88925723|NCT01726309||Stage IV NSCLC|
88925724|NCT01725633|Other|Progressive Stretching Group|
88925725|NCT01725633|Experimental|Nonlinear Aerobic Training|
88925726|NCT01722851||Cohort 1|All newly diagnosed breast cancer patients who are scheduled to undergo neoadjuvant chemotherapy
88925727|NCT01722851||Cohort 2|All breast cancer patients who present with metastatic disease, disease recurrence or progression, who are commencing up-front chemotherapy ± hormonal therapy
88925728|NCT01722851||Cohort 3|All breast cancer patient who present with metastatic disease who are commencing hormonal therapy only.
88925729|NCT01706913|No Intervention|No consult|Those who are in the control group will follow internal medicine hospitalist recommendations alone which will include when and what type of post-discharge follow-up appointments the patient will have. We would like to emphasize that as part of the standard of care, patients in the control arm may still receive a dermatology consult if it is deemed necessary and/or requested. We will not prevent patients or the patient's team of caregivers from requesting a dermatology consultation during the course of hospitalization. A follow-up phone call will be performed two weeks after discharge for patients in the control group in order to confirm the patient's outcome. There will also be a medical record review one month after the patient's initial discharge from the hospital to assess for readmission
88925730|NCT01706913|Active Comparator|Dermatology Consult|The patients randomized to the treatment group will obtain a dermatology evaluation within 24 hours of being admitted to MGH for their cellulitis. The skin and lymph node exam performed by the dermatologist on patients in the treatment group will be documented in the LMR for the subjects' medical records. Patients who are readmitted for cellulitis within one month of being discharged from the hospital will be considered treatment failures. Patients in the treatment group will have a follow-up visit in dermatology clinic within two weeks after being discharged. There will also be a medical record review performed one month after the patient's initial discharge from the hospital to assess for readmission.
88925731|NCT01604122||Patients|Patients with TTR-FAP or TTR-CM. No drug will be administered; this is a non-interventional observational study.
88925732|NCT01604122||Caregivers|Caregivers who are taking care of patients with TTR-FAP or TTR-CM. No drug will be administered; this is a non-interventional observational study.
88925733|NCT01588483||giant cell arteritis|patients with biopsy and/or scintigraphy proven GCA
88925734|NCT01564056|Other|Arm A: ENDOCRINE TREATMENT|HORMONOTHERAPY (Tamoxifen, aromatase inhibitor or sequential hormonotherapy) is left to the investigator judgement in both groups (I and II).
88925735|NCT01564056|Experimental|Arm B: CHEMOTHERAPY + ENDOCRINE TREATMENT|"HORMONOTHERAPY (Tamoxifen, aromatase inhibitor or sequential hormonotherapy) is left to the investigator judgement in both groups (I and II).~CHEMOTHERAPY regimen will be chosen amongst the following ones:~TC (docetaxel + cyclophosphamide)~AC (doxorubicin + cyclophosphamide)~MC (liposomal non pegylated doxorubicin [Myocet®]+ cyclophosphamide)"
88925736|NCT01549730|Experimental|PET FAZA imaging|PET FAZA imaging of tumor hypoxia in patients with cervix cancer
88925737|NCT01349322|Active Comparator|Whole breast irradiation + sequential boost|Standard fractionation whole breast irradiation (WBI) with sequential boost.
88925738|NCT01349322|Experimental|Hypofractionated whole breast irradiation + concurrent boost|Hypofractionated whole breast (H-WBI) irradiation with a concurrent boost
88925739|NCT01326832||Primoris|50 patients included in RSA cohort of total of 350 anticipated Primoris cases
88925740|NCT01284829|Experimental|adrenal tumors|adrenal tumors
88925741|NCT01222390|Experimental|Contour Profile Tissue Exander|Patients undergoing breast reconstruction using a Contour Profile Tissue Expander (CPX3).
89442058|NCT03501108|No Intervention|Control|Patients in the control arm receive usual pharmaceutical care in hospital i.e. daily medication review by the attending physicians and ward-assigned pharmacist.
89442059|NCT03501108|Experimental|Intervention|Patients in the intervention arm receive usual pharmaceutical care as per the control group plus application of STOPPFrail deprescribing criteria advice points on their medication list at a single time point i.e. within 24 hours of randomization. The bespoke STOPPFrail advice report is presented to the patient's attending physician who then adjusts the patient's prescriptions according to the STOPPFrail advice points. The attending physician can implement as few or as many STOPPFrail advice points as he/she sees appropriate.
89442060|NCT03348644|Experimental|Phosphate tablets.|800 mg oral phosphor supplement distributed over five times a day independently of any prior treatment dose.
89442061|NCT03348644|Active Comparator|High cheese intake.|Cheese with an estimated phosphate content of 800 mg distributed over 5 meals.
89442062|NCT03348644|Active Comparator|High milk intake.|800 ml of milk daily corresponding to approximately 800 mg phosphor per day.
89442063|NCT03501030|Experimental|Activity restriction|Women in the intervention group will be recommended activity restriction. Activity restriction is defined as the following forms of activity restriction: pelvic rest and prohibition of sexual activity, reduction of work and/or non work activity. Bed rest will not recommended.
89442064|NCT03501030|No Intervention|No activity restriction|Women in the control group will not receive any reccomandation regarding activity restriction. Bed rest and abstain from sexual intercourse will also not recommended.
89442065|NCT02317536|Experimental|Carnipure Product 1|Carnitine-based product 1, subjects will take one dose once daily for 56 days.
89442066|NCT02317536|Experimental|Carnipure Product 2|Carnitine-based product 2, subjects will take one dose once daily for 56 days.
89442067|NCT02317536|Placebo Comparator|Placebo|Placebo, subjects will take one dose once daily for 56 days.
89442068|NCT03352154|Experimental|patients with unilateral cochlear implants submitted to P300|Patients with unilateral cochlear implants, using the speech processor at least 6 months, submitted to P300 exam before CI surgery, on speech processor activation and after 06 months.
89442069|NCT02321358|Experimental|Two-time implementation intention|Group will receive physical activity materials along with the implementation intention intervention and a booster again six weeks following.
89442070|NCT02321358|Active Comparator|One-time implementation intention|Group will receive physical activity materials along with the implementation intention intervention.
89199656|NCT04717479|Other|Wait-list Control|Participants will wait 8 weeks and then they will be paired with an English language learner and engage in 8 weeks, 1 hour videoconferencing sessions.
89199657|NCT04712903|Experimental|Durvalumab in Combination with Platinum-Etoposide|Durvalumab 1500 mg via IV infusion will be concurrently administered with first-line chemotherapy (EP) on an every 3 week (q3w) schedule for 4 to 6 cycles, and will continue to be administered post-chemotherapy on an every 4 week (q4w) schedule until confirmed progressive disease (PD) or unacceptable toxicity.
89199658|NCT04710927|Active Comparator|High Viscosity GIC (HVGIC)|Group 1
89012898|NCT01608568|Active Comparator|Interrupted suture|interrupted technique using 0 non-barbed delayed absorbable suture (PDS II™, Ethicon, Somerville, NJ, USA)
89012899|NCT01608568|Active Comparator|Quill suture|self-anchoring 1 barbed delayed absorbable suture (Quill™ SRS, Angiotech Pharmaceuticals, Inc. Vancouver, Canada)
89012900|NCT01608646|No Intervention|S-1 plus oxaliplatin|S-1 40 mg/m2 administered orally BID after breakfast and evening meal from Day 1 through Day 14 with a single dose of oxaliplatin 130 mg/m2 will be administered as an 2-hour IV infusion following the morning dose of S-1 on Day 1. The combination therapy will be repeated every 3 weeks.
89012901|NCT01608685||Renal transplant recipients|Inclusion criteria: All renal transplant recipients followed by the Division of Nephrology aged above 18 years, and having accepted study protocol after informed consent
89442071|NCT02321358|Sham Comparator|Sham Comparator Group|Group will receive Canada's Food Guide which contains a small amount of physical activity information.
89442072|NCT05527366|Experimental|Control Group|Conservative treatment
89442073|NCT05527366|Experimental|Vagus Stimulation Group|Vagus Stimulation Group
89442074|NCT04502342|Active Comparator|Hydroxychloroquine/Azythromycin|Patients received Hydroxychloroquine 200 mg tablet orally 3 times daily for 10 days and Azythromycine 250 mg orally at the rate of 2 tablets the first day, then one tablet for 5 days.
89442075|NCT04502342|Experimental|Cospherunate/Azithromycine|Patients received Cospherunate (50 mg Artésunate/125 mg Amodiaquine) at the rate of 2 tablets orally twice daily for 6 days and Azythromycine 250 mg orally at the rate of 2 tablets the first day, then one tablet for 5 days.
89442076|NCT04502342|Experimental|Cospherunate/Phytomedicine/Azithromycine|Patients received Cospherunate (50 mg Artésunate/125 mg Amodiaquine) at the rate of 2 tablets orally twice daily for 6 days and Phytomedicine tablet 350 mg at the rate of 2 tablets orally twice daily for 6 days, and Azythromycine 250 mg orally at the rate of 2 tablets the first day, then one tablet for 5 days.
89012902|NCT00254852|Active Comparator|O|This treatment arm includes autograft harvested from local bone and / or the iliac crest, supplemented with a demineralized bone matrix (DBM) autograft extender, Optecure.
89012903|NCT00254852|Active Comparator|A|This treatment arm includes autograft harvested from local bone and / or the iliac crest.
89012904|NCT01608763|Experimental|Full personalized feedback|Participant provided with the full CYD personalized feedback summary.
89012905|NCT01608763|Experimental|Only normative feedback|Participant provided with just the normative feedback component of the CYD personalized feedback summary.
89012906|NCT01608763|Experimental|Just other personalized feedback|Participant provided with all the other personalized feedback components of the CYD intervention (i.e., no normative feedback).
89012907|NCT01608763|No Intervention|No intervention control|Participant provided with a list describing the components of the CYD intervention but not provided any personalized feedback.
89012908|NCT00288990||1|subjects who are NAb positive
89012909|NCT00288990||2|Subjects who are antibody negative
89442077|NCT02315040|Active Comparator|IUI|standard intrauterine insemination method
89442078|NCT02315040|Experimental|EVIE|Slow release insemination method (SRI)
89442079|NCT04462848|Experimental|anti-SARS-CoV-2 human convalescent plasma|single transfusion of human convalescent plasma
89012910|NCT00288990||3|subjects who are BAb positive
89012911|NCT01608802|Active Comparator|Standard care|Standard care will be provided to the control group, i.e. existing HIV outpatient multiprofessional care, ART monitoring and adherence support.
89012912|NCT01608802|Experimental|Palliative care|Palliative care delivered by an existing nurse who has been provided with palliative care training, palliative care patient management planning records, and clinical supervision
89442080|NCT00709124|Experimental|NMES|60 minute daily NMES sessions every day for the duration of subject's ICU stay.
89442081|NCT00709124|Sham Comparator|Sham|60 minute sham sessions every day for the duration of subjects ICU stay. No voltage will be applied to those receiving sham sessions.
89442082|NCT03500952|Experimental|Patient Decision Aid|Birth Control After Pregnancy patient decision aid and supporting document
89442083|NCT03500952|Active Comparator|Patient Information Leaflet|Postpartum Birth Control patient information leaflet
89012913|NCT01608841|No Intervention|Gemcitabine|
89012914|NCT01608841|Experimental|Gemcitabine plus erlotinib|
89012915|NCT01608919|No Intervention|diagnostic blood tests|We are using 2 standard approved blood tests that may be useful in predicting who may develop a venous thromboembolism after cancer surgery.
89012916|NCT01609036||Cohort|
89012917|NCT00254969|Experimental|1|
89012918|NCT01609075||Cohort|
89012919|NCT02273440|Experimental|BIIL 284 BS with theophylline|
89012920|NCT02273440|Placebo Comparator|Placebo with theophylline|
89199659|NCT04710927|Experimental|Silver Diamine Fluoride (SDF) + HVGIC|Group 2
89199660|NCT04710927|Experimental|Papain based gel + SDF + HVGIC|Group 3
89199661|NCT04694976||Sickle cell disease children from Lyon, France|Sickle cell disease children, followed in IHOPe (Institut d'Hématologie et d'Oncologie Pédiatrique) center, consulting their referring haematologist doctor or in emergency ward, with prescribed blood sample.
89442084|NCT02315118|Experimental|T-cell therapy + Rituximab + IL-2|"Patients will undergo apheresis procedure and T cell expansion will be done in the laboratory. All patients will receive Rituximab on day -2 and IL-2 three times per week for one week starting on day -1 (dose 1 of 3). IL-2 dosing will be continued 3 times per week for one week (3 doses total).~On Day 0, T cell modification in the laboratory and T cell infusion in the patient will be done.~A disease status evaluation will be conducted approximately 4 weeks post-T cell infusion."
89442085|NCT03500796|Other|Corneal perforation patients|"Patients who had/impeding corneal perforation due to melting of the cornea after infection with a corneal pathogen (bacterial or viral), with no previous surgical intervention.~Patients will undergo:~Platelet rich plasma clot implantation Wound closure with amniotic membrane"
89442086|NCT05527288|Experimental|Non-cognitively impaired subjects or mild to moderate Alzheimer disease subjects|Visually and quantitatively assess PET images obtained after single application of 300 MBq [18F]florbetaben and PET scanning of patients with healthy subjects and non-cognitively impaired subjects or mild to moderate Alzheimer disease subjects.
89442087|NCT03122600||vascular surgery group|Elderly patients undergoing vascular surgery in the lower half of the body
88925742|NCT01182415|Experimental|High-dose chemotherapy with autologous stem cell transplant|
88925743|NCT01164150|Experimental|Arm B|Radiation: 45 Gy / 25 fractions pelvic radiotherapy using intensity modulated radiotherapy (IMRT) followed by 11 Gy / 2 fractions vaginal vault brachytherapy
88925744|NCT01164150|Other|Arm A Control|Radiation: 45 Gy/25 fraction external beam pelvic radiotherapy delivered using a 3-dimensional planned technique followed by 11 Gy / 2 fractions vaginal vault brachytherapy
88925745|NCT01030523|Experimental|Short Implants|ASTRA TECH Implant System, OsseoSpeed™ 4.0 S (length: 6 mm)
88925746|NCT01030523|Active Comparator|Long Implants in combination with bone grafting|ASTRA TECH Implants System, OsseoSpeed™ implants (lengths: 11, 13, 15 mm) in combination with bone grafting
88925747|NCT00951535|Other|Arm A|Treatment will be delivered in 1.8 Gy fractions; dose escalation will be in 1.8 Gy increments from 75.6 Gy to a maximum 81 Gy.
88925748|NCT00812669|Experimental|Fludarabine, Cylophosphamide and Rituximab|
88925749|NCT00802711|Experimental|Arm I|Patients undergo accelerated partial breast irradiation (APBI) using 3-dimensional conformal radiation therapy twice daily over 5-10 days (total of 10 fractions) in the absence of disease progression or unacceptable toxicity.
88925750|NCT00802711|Experimental|Arm II|Patients undergo APBI using multi-catheter interstitial brachytherapy twice daily over 5-10 days (total of 10 fractions) in the absence of disease progression or unacceptable toxicity.
88925751|NCT00160979|Experimental|hypoxia and RT in prostate cancer|
88925752|NCT03903315||medical treatment alone|Patients with central malignant airway obstructions undergoing medical treatment alone
88925753|NCT03903315||endoscopic + medical treatment|Patients with central malignant airway obstructions undergoing medical and endoscopic treatment
88925754|NCT03893253|Experimental|Early Booster Teaching|The early booster group will receive a booster teaching session at 3 weeks post-training followed by feedback.
88925755|NCT03893253|Active Comparator|Late Booster Teaching|The late booster group will receive a booster teaching session at 2 months post-training followed by feedback.
88925756|NCT03893253|No Intervention|Control group|The control group will receive no booster teaching at all.
88925757|NCT03889314|Experimental|Rosuvastatin 20mg|Each participant will receive a 3 month randomly allocated supply of this medication preceded by a 7 day wash-out period.
89442088|NCT03497598|Experimental|mannose|"2g d-mannose (white) powder (Hänseler AG, Herisau, Switzerland) daily (sachet) for 6 months.The powder is dispensed in neutral sticks and ready to be dissolved in 100ml of water for oral Ingestion.~rUTI diary"
89442089|NCT03497598|Placebo Comparator|placebo|"2g Hänseler lactose (white) powder (Hänseler AG, Herisau, Switzerland) daily (sachet) for 6 months. The powder is dispensed in neutral sticks and ready to be dissolved in 100ml of water for oral Ingestion.~rUTI diary"
88925758|NCT03889314|Placebo Comparator|Placebo|
89442090|NCT05521750||Age|Patient age
89442091|NCT05521750||Gender|Patient's gender
89442092|NCT05521750||Surgical Time|Duration of surgery, begin from incision until skin closure
89442093|NCT05521750||Intraoperative Blood loss|Total blood loss during operation
89442094|NCT05521750||Length of Stay|Duration of hospitalization
88925759|NCT03889314|No Intervention|No Treatment|7 day wash-out period between months
88925760|NCT03884166||stroke|
88925761|NCT03884166||control|
88925762|NCT03884153|Experimental|CRP apheresis|"CRP apheresis by means of selective apheresis using the PentraSorb-CRP adsorber"
88925763|NCT03884023||AD group|Alzheimer's disease
88925764|NCT03884023||aMCI group|Amnestic Mild Cognitive(MCI) impairment due to Alzheimer's disease
88925765|NCT03884023||NC group|Normal Control
88925766|NCT03877211|Experimental|Cochlear implant users|Adult cochlear implanted patients wearing an Oticon Medical/Neurelec device will have speech audiometry test in noise, psychophysical tuning curves in forward masking and Electrically-evoked Auditory Brainstem Response (EABR) measurement
88925767|NCT03877211|Active Comparator|Normal-hearing subjects|Normal-hearing subjects will have speech audiometry test in noise, psychophysical tuning curves in forward masking, auditory canal examination and tonal audiometry
88925768|NCT03874312||Calibration group|Patients with systolic chronic heart failure who undergo right heart catheterization (RHC) for heart transplant/left ventricular assist device workup.
88925769|NCT03874312||Validation group|Patients with systolic chronic heart failure who undergo RHC for heart transplant/left ventricular assist device workup.
88925770|NCT03873792|Other|Allergy pregnant women|
88925771|NCT03873792|Other|Health pregnant women|
88925772|NCT03873194|Experimental|Meditation group|Patients who are going to practice meditation and will receive only the usual outpatient care, with the aim of observing reduction of systemic blood pressure in this period.
88925773|NCT03873194|Other|conventional treatment|Patients that will receive only the usual outpatient care, with the aim of observing the systemic blood pressure in this period.
88925774|NCT03870880|Experimental|Risperidone ISM 75 mg|"Patients assigned to this arm will receive 75 mg of Risperidone ISM during the open label extensión (OLE).~Patients enter the study as rollover patients from the study NCT03160521, along with newly enrolled de novo patients."
88925775|NCT03870880|Experimental|Risperidone ISM 100 mg|"Patients assigned to this arm will receive 100 mg of Risperidone ISM during the open label extensión (OLE).~Patients enter the study as rollover patients from the study NCT03160521, along with newly enrolled de novo patients."
88925776|NCT03863782||Sarcoid uveitis|The cohort is composed by patients diagnosed or treated for sarcoid uveitis in the departement for Internal Medicine, Croix Rousse Hospital, Lyon, France.
88925777|NCT03862261|No Intervention|Standard-of-Care|Pediatric TB services based on current routine approach (national standard of care)
88925778|NCT03862261|Experimental|Intervention|Integrated pediatric TB services
88925779|NCT03861377|Active Comparator|Remifentanil R2|Low dose Remifentanil induction dose (R2)
88925780|NCT03861377|Active Comparator|Remifentanil R4|Medium dose Remifentanil induction dose (R4)
88925781|NCT03861377|Active Comparator|Remifentanil R8|Medium dose Remifentanil induction dose (R8)
88925782|NCT03858816|Experimental|Mixture probiotics|The probiotic contain 1 ×10^9 CFU/1 capsule of mixture probiotics, taking 1 probiotic capsule for up to 4 months after birth.
88925783|NCT03858816|Placebo Comparator|Placebo|Taking 1 placebo capsule for up to 4 months after birth.
88925784|NCT03857893|Active Comparator|Control Group : pH-Cream|Control Group will be only treated with a fixed amount (1g) of pH-cream (Cetomacrogol cream) to self-administered with a vaginal applicator for 12 weeks (one dose every three days and if deem necessary, additional doses can be applied and notified in the calendar provided).
89199662|NCT04694313|Experimental|OPM|Two types of measurement will be compared (SQUID and OPM) with the reference that constitutes the in-depth recordings (Stereotactic-EEG or SEEG) used to precisely define the region of the brain to be resected in order to cure epileptic patients of their seizures.
89199663|NCT04692701|Experimental|Pulvinar stimulation|Medial pulvinar deep brain stimulation
89442095|NCT05521750||VAS Pre-op|Pain scale measured with visual analog scale (VAS) prior to the operation
89442096|NCT05521750||1 Month VAS|Pain scale measured with visual analog scale (VAS) 1 month after the operation
89442097|NCT05521750||3 Month VAS|Pain scale measured with visual analog scale (VAS) 3 month after the operation
89442098|NCT05521750||Decrease VAS 1 month|Difference of VAS score within 1 month of evaluation
89442099|NCT05521750||Decrease VAS 3 month|Difference of VAS score within 3 month of evaluation
89442100|NCT05521750||Disc weight|Estimation of total disc weight
89442101|NCT05521750||Removed disc weight|weight of removed disc measured after operation
89442102|NCT05521750||Percentage of Removed Disc|Percentage of removed disc as seen on the axial MRI
89442103|NCT03122756|Experimental|Group (D)|will include 50 women who will receive intravenous dexamethasone.
89442104|NCT03122756|Placebo Comparator|Group (C)|will include 50 women who will receive intravenous normal saline (0.9 %).
89442105|NCT03500718|Experimental|Pediatric patients with bilateral sensorineural hearing loss|One group will be studied: Patients undergoing cochlear implantation surgery between age 1 and 6 years who meet the above inclusion and exclusion criteria seen in JIPMER during the study period.
89442106|NCT05517070||Hemophilia Group|Hemophilia adult patients
89442107|NCT05517070||Control Group|Healthy adult subjects
89442108|NCT03122678|Experimental|Thiamine Supplementation Group|Patients will receive 200mg thiamine in 50mL of 5% dextrose once daily for 7 days or until discharge from the intensive care unit.
89442109|NCT03122678|Placebo Comparator|Placebo Group|Patients will receive placebo (50mL 5% dextrose) once daily for 7 days or until discharge from the intensive care unit.
89442110|NCT05521594|Experimental|FNAC|
89442111|NCT05521594|Experimental|post operative hitopathology|
89442112|NCT04506398||Retrospective cohort|20 HCC patients experienced post-transplant HCC
89442113|NCT04506398||Perspective cohort|20 HCC patients who underwent liver transplant, the patients would be recruited if recurrence would be diagnosed >6 months after liver transplant
89442114|NCT03348488|No Intervention|Standard ultrafiltration|standard ultrafiltration (fluid removal from the body by dialysis at the prescribed volume and rate) during a conventional treatment
89442115|NCT03348488|Active Comparator|High dose ultrafiltration|Intervention= Fixed rate high dose ultrafiltration (fluid removed from the body by dialysis) of 1 litre per hour over 1 hr instaed of standard ultrafiltration rate and volume.
89442116|NCT03502122|Experimental|VR rehabilitation|Virtual Reality based rehabilitation therapy for motor function, 1 hour a time at an intensity of three times per week over 8 weeks (total, 24 sessions).
89442117|NCT03502122|Active Comparator|control- conventional rehabilitation|conventional rehabilitation therapy for motor function, 1 hour a time at an intensity of three times per week over 8 weeks (total, 24 sessions).
89442118|NCT02315274|Experimental|Single arm, remote contact.|Between visit remote contact.
89442119|NCT02317770|Active Comparator|Lidocaine Spray|20 puffs of 10% Lidocaine spray
89442120|NCT02317770|Active Comparator|Nebulized Lidocaine|2.5 mL of 10% Lidocaine
89442121|NCT03348410|Experimental|Intervention|Motivational interviewing
89442122|NCT03348410|No Intervention|Control|Control group
89442123|NCT02317848|Other|patients with acute heart failure|polygraphy, echocardiography, ECG during hospitalisation for acute heart failure
89442124|NCT04506242|Experimental|apatinib+ Neoadjuvant/Adjuvant camrelizumab|"Neoadjuvant: Prior to surgery, participants receive 3 cycles (cycle length: 2 weeks) of camrelizumab [200 mg, intravenous (IV); given on cycle day 1] in combination with apatinib ,5 days on 2days off].~Adjuvant: 4-8 weeks following surgery, participants receive up to 12 cycles (cycle length: 2 weeks) of camrelizumab [200 mg, IV; given on cycle day 1]. Participants who can not able to benefit from immunotherapy will not receive camrelizumab adjuvant therapy."
89199664|NCT04691596|Active Comparator|Control Group|One fourth of participants were assigned to the Control Group, and received a basic training with the StepUp app and were asked to contact the study team with any problems or questions they encountered during the eight-week study period. No other intervention tools or app reminders were provided to the Control Group.
89442125|NCT05526898|Experimental|SyntrFuge System|Adipose tissue microsized via the SyntrFuge System
89442126|NCT05526898|Other|Standard of Care|Steroid Injection
89442127|NCT02317926|Active Comparator|Levothyroxine Plus Liothyronine Group|Levothyroxine Plus Liothyronine Group
89442128|NCT02317926|Active Comparator|Levothyroxine Group|Levothyroxine Group
89442129|NCT02317926|Active Comparator|Desiccated Thyroid Extract Group|Desiccated Thyroid Extract Group
89199665|NCT04691596|Experimental|Treatment Group 1|Additionally eligible to receive weekly $5 Amazon gift cards over the first four weeks of the study for performing a ≥10-minute walk (i.e. non-cue-contingent incentives)
89442130|NCT05526820|Experimental|The combined immunization group|225 participants received one dose of live attenuated varicella vaccine and the first dose inactivated hepatitis A vaccine on day 0 and the second dose of inactivated hepatitis A vaccine on day 180.
89442131|NCT05526820|Active Comparator|The Non-combined immunization group|225 participants received one dose of live attenuated varicella vaccine on day 0,the first dose of inactivated hepatitis A vaccine on day 42 and the second dose of inactivated hepatitis A vaccine on day 222.
89442132|NCT02321592|Active Comparator|Arm A|"AFM13 is administered three times a week (e.g. monday-wednesday-friday) for 8 consecutive weeks.~Arm A ist closed."
89442133|NCT02321592|Active Comparator|Arm B|"AFM13 is administered three times a week (e.g. monday-wednesday-friday) for 2 consecutive weeks followed by a weekly appication 6 consecutive weeks.~Arm B is closed."
89442134|NCT02321592|Active Comparator|Arm C|AFM13 is administered for five consecutive days a week as continuous infusion for 8 consecutive weeks
89442135|NCT03352076|Active Comparator|Oral Danatrol|200 mg orally TDS (600 mg daily) for 5-7 days
89442136|NCT03352076|Experimental|Vaginal Danazol|100 mg of Danazol Cream to be applied vaginally for 5-7 days on a single daily dose
89442137|NCT02321670|Active Comparator|End-to-end|Excision of the stricture and end-to-end anastomosis of the urethra.
89442138|NCT02321670|Active Comparator|Graft|Incision of the stricture and grafting procedure with buccal mucosa where the corpus spongiosum is not divided.
89442139|NCT05521282|Experimental|Treatment group|"Based on the basic treatment, Qianglidingxuan Tablets were given 6 tablets/time, 3 times a day, and warm water was given for 12 weeks.~Qianglidingxuan Tablets:~Specifications: 60 tablets per bottle; Storage: airtight, moisture-proof; Active ingredients:Gastrodia elata, Eucommia ulmoides, wild chrysanthemum, Eucommia ulmoides leaves, Chuanxiong; Manufacturer: Shaanxi Hanwang Pharmaceutical Co., LTD."
89442140|NCT05521282|Placebo Comparator|Control group|"Based on basic treatment, Qianglidingxuan Tablets mimetics were given 6 tablets/time, 3 times a day, and warm water was given for 12 weeks.~Qianglidingxuan Tablets mimetics:~Specifications: 60 tablets per bottle; Storage: airtight, moisture-proof; Active ingredients:NA; Manufacturer: Shaanxi Hanwang Pharmaceutical Co., LTD."
89442141|NCT05311124|Experimental|Single-arm prospective|Single-arm prospective pilot study. All patients receive Integra dermal regeneration template (IDRT) that sign an inform consent.
89442142|NCT03502044|Active Comparator|Arm 1, active KOS treatment|Patients in arm 1 receive active KOS treatment throughout study, which means 16 active KOS treatments. Patients receive KOS treatments twice a week during 8 consecutive weeks.
89442143|NCT03502044|Placebo Comparator|Arm 2, 8 inactive KOS treatments then 8 active KOS treatments|Patients in arm 2 receive inactive KOS treatment during the first 8 KOS treatments of the study. Thereafter patients in arm 2 receive 8 active KOS treatments. Patients receive KOS treatments twice a week during 8 consecutive weeks.
89442144|NCT02517944||Familial hypercholesterolemia patients|"clinical data~biological data~cardiac and aortic RMI with gadolinium"
89442145|NCT02517944||Control group|"clinical data~biological data~cardiac and aortic RMI with gadolinium"
89442146|NCT03497442|Experimental|Treatment Arm|This is a randomized vehicle controlled, double blinded, interventional study. Patients of East Asian descent with a history of Asian Flushing Syndrome will be asked to apply a thin layer of brimonidine 0.33% gel to one half of their face thirty minutes before consuming alcohol (1.5 oz vodka for women, 3.0 oz vodka for men). The Photos will be taken 30 minutes, one hour, and 1.5 hours after consumption of alcohol. Erythema will be assessed at each time point by both the patient and study investigator using a 5- point erythema assesment score. Patient blood alcohol content (BAC) will be measured noninvasively at each time point.
89442147|NCT03497442|Placebo Comparator|Placebo Arm|This is a randomized vehicle controlled, double blinded, interventional study. Patients of East Asian descent with a history of Asian Flushing Syndrome will be asked to apply a thin layer of vehicle gel to one half of their face thirty minutes before consuming alcohol (1.5 oz vodka for women, 3.0 oz vodka for men). The Photos will be taken 30 minutes, one hour, and 1.5 hours after consumption of alcohol. Erythema will be assessed at each time point by both the patient and study investigator using a 5- point erythema assesment score. Patient blood alcohol content (BAC) will be measured noninvasively at each time point.
89442148|NCT05516602|Experimental|Peer Support|Standard health worker counselling during clinic visits plus peer support over the weekends.
89442149|NCT05516602|No Intervention|Standard|Standard health worker counselling during clinic visits.
88925785|NCT03857893|Experimental|Dynamic Quadripolar Radio-Frequency treatment|"Experimental Group will be treated with Dynamic Quadripolar Radio-Frequency (DQRF) (with Eva™ Device) for 8 weeks (+ 4 weeks). The Dynamic Quadripolar Radio-frequency sessions will involve -5 sessions (one every 14-21 days), if necessary External treatment (vulvar - will be applied before internal treatment for more comfort) : 10 minutes (5 minutes left side, 5 minutes right side), and Internal treatment (VVA, Vaginal Laxity, Mild-Stress Urinary Incontinence (SUI)): 20 minutes.~In parallel, patients can also apply pH-cream (Cetomacrogol cream) (one dose of 1g) if they judge necessary but they are not allowed to use it during the seven days before radiofrequency session. If they use pH-cream, they must notify it in the calendar provided."
88925786|NCT03854461|Active Comparator|Educational material|Participants will be given written educational material to encourage dietary change towards a better quality diet. Educational material will be adapted from resources used in previous dietary intervention studies.
88925787|NCT03854461|Experimental|Personalised dietary advice and educational material|Participants will also be given the educational material, but will be encouraged to make dietary change using individualized recommendations incorporating food markers of specific components of a high quality diet. Food markers of diet quality will be used to develop an algorithm to deliver personalized dietary advice. Based on biomarker data, a system of categorization of biomarker status will be developed, alongside dietary advice related to this biomarker categorization, and decision trees created, as previously described in the Food4Me study, to ensure standardized delivery of advice within this intervention arm.
88925788|NCT03844100|Experimental|Patients with Refractory Functional Dyspepsia|"Patients with FD diagnosed by the Rome IV criteria, patients with Refractory Functional Dyspepsia~Person who have had early satiation and bothersome postprandial fullness for minimum 3 days a week and epigastric pain and epigastric soreness for minimum 1 day a week~Person with above symptoms that started at least 6 months before and continused for minimum 3 months~Person having no possible causes of above symptoms including organic disease, structural modification, systemic disease, and endocrinology-metabolic disease~Person who do not respond to at least 2 general treatments for FD~Dyspepsia symptoms that can disrupt daily life (global overall symptom scale score =>5)"
88925789|NCT03836144||Cystinuria|10 patients with cystinuria. Experimental. Urine collected before treatment initiation and 3 months after. Treatment: Usual alkalizing treatment using oral potassium citrate. The initial dosage will be 4 g/day divided into 3 to 4 oral daily doses. If the objective of urinary pH is not reached after the first two weeks of treatment, the dose will be increased by 2 grams (6 grams total). If the urinary pH remains below 7.5 after 2 weeks with 6 grams of potassium citrate per day, the alkalizing treatment will then be supplemented with oral sodium bicarbonate in the form of Vichy water or officinal preparation. This treatment is the usual treatment recommended for cystinuria .
88925790|NCT03836144||Non cystinuria nephrolithiasis|20 patients with a nephrolithiasis not due to cystinuria. Control group. Urine collected once to study biomarkers of inflammation No intervention.
88925791|NCT03836144||Inflammatory nephropathy|"10 patients with an inflammatory nephropathy of glomerular or tubulo interstitial origin (confirmed by renal biopsy).~Control group. Urine collected once to study biomarkers of inflammation. No intervention."
89206108|NCT04044378|Active Comparator|Arm B: famitinib alone|Only phase II portion (Phase I have been completed): famitinib will be 20mg orally taken daily, 4 weeks (28 days) as one treatment cycle.
89012921|NCT01588678|Experimental|DS-3078a|"Part 1 - Dose escalation of DS-3078a to determine the maximum tolerated dose (MTD) will be guided by the modified continuous reassessment method (mCRM) using a Bayesian logistic regression model (BLRM) following escalation with overdose control (EWOC) principle.~Before starting mCRM, initial dose escalation will proceed following an accelerated titration in which single subjects will be enrolled into sequential dose levels with a dose increment of up to 100% from the previous dose.~Upon completion of Part 1 with established MTD and tentative recommended phase 2 dose (RP2D), the Dose Expansion (Part 2) will begin with the intention of further assessing the safety and tolerability of DS-3078a, confirming the RP2D, determining the Pharmacodynamic response in tumor samples, and evaluating preliminary efficacy of DS-3078a in subjects."
89012922|NCT04719455|Experimental|Intervention treatment experienced patients|AIMS
89012923|NCT04719455|Experimental|Intervention starting patients|AIMS
89012924|NCT04719455|Other|Control group treatment experienced patients|Regular care
89012925|NCT04719455|Other|Control group starting patients|Regular care
89012926|NCT01588717|Experimental|glycopyrrolate|glycopyrrolate 2 to 6 mg/day
89012927|NCT01588756|Experimental|AcSDKP-NH2 inuline|AcSDKP-NH2 inuline, Once intravenous administration of 100 µg or less
89012928|NCT01588756|Experimental|AcSDKP-NH2 Cr-EDTA|AcSDKP-NH2 Cr-EDTA, Once intravenous administration of 100 µg or less
89012929|NCT04719104|Experimental|Participating group of neonates|Participating group: Neonates that have had both a serum bilirubin measurement and transcutaneous measurement post phototherapy. This is a single arm study as we are only targeting one group of individuals with the intervention (transcutaneous bilirubin measurement). However, we will compare the serum bilirubin measurement to the transcutaneous measurement from the same neonate to determine if there is a clinically significant difference between the two measurements.
89012930|NCT01588795|Experimental|Denervation + TMNS|Patients are treated with the renal denervation procedure after randomization and are maintained on standardized anti-proteinuric medications
89012931|NCT01588795|Active Comparator|TMNS|Patients are maintained on standardized anti-proteinuric medications
89012932|NCT00107614|Experimental|DT PACE/auto transplant/maint therapy|
89012933|NCT04718532||patients|patients with retinal diseases
89442150|NCT02738580|Active Comparator|rFSH|Controlled ovarian hyperstimulation with GnRH antagonists and rFSH in women with normal ovarian function.
88925792|NCT03817892|No Intervention|Unguided 2 minutes (U2)|"The External Chest Compression are performed without guidance of the CPRmeter device (according to the current guidelines).~The duration or rhythm of a relay during which a rescuer performs External Chest Compression before being relayed by another rescuer is 2 minutes according to the current guidelines."
88925793|NCT03817892|Experimental|Unguided 4 minutes (U4)|"The External Chest Compression are performed without guidance of the CPRmeter device (according to the current guidelines).~The duration or rhythm of a relay during which a rescuer performs External Chest Compression before being relayed by another rescuer is 4 minutes. (Rhythm of a relay 4 minutes)"
89012934|NCT00107380|Experimental|R-CHOP x 8 with I-131 Tositumomab|"Cyclophosphamide 750 mg/m2 IV Day 1 Doxorubicin 50 mg/m2 IV Day 1 Vincristine 1.4 mg/m2 IV Day 1 Prednisone 100 mg PO Days 1-5 Rituximab 375 mg/m2 IV Day 1 Q 21 Days x 6 cycles~Unlabeled Anti-B1 Antibody 450 mg IV Day 170 Dosimetric dose 35 mg IV Day 170~Unlabeled Anti-B1 Antibody 450 mg IV Day 177 Therapeutic dose 35 mg IV Day 177"
89012935|NCT00270153|Placebo Comparator|enalapril|
89012936|NCT00270153|Placebo Comparator|Placebo|
89012937|NCT00289224|Experimental|1|Cholera Vaccine
89012938|NCT00289224|Placebo Comparator|2|Placebo
89012939|NCT04054843||Gestational diabetes mellitus|First trimester pregnancies with gestational diabetes mellitus
89012940|NCT04054843||Control|First trimester healthy pregnancies
89199666|NCT04691596|Experimental|Treatment Group 2|Received an instructional video on the benefits of contextual-cue-dependent habits and instructions on how to identify an optimal personalized cue that would consistently trigger their ≥10-minute walking habit, then they were similarly eligible weekly for $5 Amazon gift cards over the first four weeks conditional on completing a ≥10-minute walk at any time of day (i.e. non-cue-contingent incentives)
89442151|NCT02738580|Active Comparator|HP-HMG|Controlled ovarian hyperstimulation with GnRH antagonists and HP-HMG with normal ovarian function.
89442152|NCT03348332|No Intervention|Sedentary pregnant women|Pregnant women who do not exercise regularly during pregnancy
89442153|NCT03348332|Experimental|Exercise pregnant women|Pregnant women who participate in a supervised exercise program
89442154|NCT02318004|Experimental|Home monitoring|Home monitoring via the EarlySense non-invasive nocturnal monitoring system. Movement, heart rate and respiratory rates will be monitored while subject is in his bed. The trends of monitored values will be daily reported to a central repository. No intervention will be attempted and care will be coordinated by the family physician and treating cardiologist as usual.
89442155|NCT04505696|Other|Speech-Language Pathology Introduction and scope|Demographic Information Section on Knowledge & Awareness Section on Practices
88925794|NCT03817892|Experimental|Guided 2 minutes (G2)|The External Chest Compression are performed with guidance of the CPRmeter device. (Guidance of the External Chest Compression) The duration or rhythm of a relay during which a rescuer performs External Chest Compression before being relayed by another rescuer is 2 minutes according to the current guidelines.
88925795|NCT03817892|Experimental|Guided 4 minutes (G4)|The External Chest Compression are performed with guidance of the CPRmeter device. (Guidance of the External Chest Compression) The duration or rhythm of a relay during which a rescuer performs External Chest Compression before being relayed by another rescuer is 4 minutes. (Rhythm of a relay 4 minutes)
88925796|NCT03811574|Experimental|Semaglutide 2.4 mg|Participants will receive semaglutide injections once-weekly for 68 weeks. Participants will be initiated at a once-weekly dose of 0.25 mg and follow a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0, 1.7 and 2.4 mg/week), until the target dose (2.4 mg) is reached after 16 weeks. Participants will continue semaglutide 2.4 mg until week 68.
88925797|NCT03811574|Placebo Comparator|Placebo (semaglutide 2.4 mg)|Participants will receive placebo (semaglutide) injections once-weekly for 68 weeks. Participants will be initiated at a once-weekly dose of 0.25 mg and follow a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0, 1.7 and 2.4 mg/week), until the target dose (2.4 mg) is reached after 16 weeks. Participants will continue placebo (semaglutide 2.4 mg) until week 68.
88925798|NCT03811574|Experimental|Semaglutide 1.7 mg|Participants will receive semaglutide injections once-weekly for 68 weeks. Participants will be initiated at a once-weekly dose of 0.25 mg and follow a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0 and 1.7 mg/week), until the target dose (1.7 mg) is reached after 12 weeks. Participants will continue semaglutide 1.7 mg until week 68.
88925799|NCT03811574|Placebo Comparator|Placebo (semaglutide 1.7 mg)|Participants will receive placebo (semaglutide) injections once-weekly for 68 weeks. Participants will be initiated at a once-weekly dose of 0.25 mg and follow a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0 and 1.7 mg/week), until the target dose (1.7 mg) is reached after 12 weeks. Participants will continue placebo (semaglutide 1.7) until week 68.
88925800|NCT03796416|Active Comparator|misoprostol|"Induction using misoprostol:~Insert misoprostol 25 micrograms in the posterior fornix of the vagina digitally Repeat cervical exam every 4 hours"
88925801|NCT03796416|Experimental|Misoprostol and foley bulb|"Induction using Foley balloon combined with misoprostol:~A 26 French intracervical Foley balloon will be inserted above the internal os at the start of induction, inflated using 80cc of sterile water.~If a Foley balloon is not able to be inserted at the time of starting induction of labor, misoprostol 25microgram can be inserted in the posterior fornix of the vagina and the misoprostol protocol followed."
88925802|NCT03796221|Active Comparator|Control Group|Will receive standard pediatric obesity treatment
88925803|NCT03796221|Experimental|Intervention Group|Will receive standard pediatric obesity treatment and parenting videos
88925804|NCT03795558|Experimental|Etelcalcetide 2.5 mg|Etelcalcetide, starting dose of 2.5mg thrice weekly, dose will be escalated every 4 weeks in 2.5mg/dialysis session increments to a maximum dose of 15mg thrice weekly
88925805|NCT03795558|Experimental|Etelcalcetide 5 mg|Etelcalcetide, starting dose of 2.5mg thrice weekly, dose will be escalated every 4 weeks in 2.5mg/dialysis session increments to a maximum dose of 15mg thrice weekly
88925806|NCT03795558|Experimental|Etelcalcetide 7,5 mg|Etelcalcetide, starting dose of 2.5mg thrice weekly, dose will be escalated every 4 weeks in 2.5mg/dialysis session increments to a maximum dose of 15mg thrice weekly
88925807|NCT03795558|Experimental|Etelcalcetide 10 mg|Etelcalcetide, starting dose of 2.5mg thrice weekly, dose will be escalated every 4 weeks in 2.5mg/dialysis session increments to a maximum dose of 15mg thrice weekly
88925808|NCT03795558|Experimental|Etelcalcetide 12,5 mg|Etelcalcetide, starting dose of 2.5mg thrice weekly, dose will be escalated every 4 weeks in 2.5mg/dialysis session increments to a maximum dose of 15mg thrice weekly
88925809|NCT03795558|Experimental|Etelcalcetide 15 mg|Etelcalcetide, starting dose of 2.5mg thrice weekly, dose will be escalated every 4 weeks in 2.5mg/dialysis session increments to a maximum dose of 15mg thrice weekly
89442156|NCT05521204|Experimental|Treatment Group|
89442157|NCT03497364|Experimental|Bupivacaine group|Pregnant women received combined spinal-epidural anesthesia by injecting bupivacaine. The dose of bupivacaine depended on height of subjects.
89442158|NCT03497364|Experimental|Ropivacaine group|Pregnant women received combined spinal-epidural anesthesia by injecting ropivacaine. The dose of ropivacaine depended on height of subjects).
89442159|NCT03497364|No Intervention|Control group|Pregnant women received combined spinal-epidural anesthesia by injecting bupivacaine. 2ml bupivacaine (0.75% bupivacaine (2 ml) + cerebrospinal fluid (1 ml)) was injection for all subjects.
89199667|NCT04691596|Experimental|Treatment Group 3|Received an instructional video on the benefits of contextual-cue-dependent habits and instructions on how to identify an optimal personalized cue that would consistently trigger their ≥10-minute walking habit, then they were eligible weekly for $5 Amazon gift cards over the first four weeks conditional on completing a ≥10-minute walk at any the pre-specified time of their chosen contextual cue (i.e. cue-contingent incentives)
89442160|NCT03348254||1|Group one will consist of patients receiving a single shot antibiotic prophylaxis preoperatively before primary arthroplasty of hip or knee
89442161|NCT03348254||2|Group two will consist of patients receiving multiple shot antibiotic prophylaxis perioperatively before and after primary arthroplasty of hip or knee
89442162|NCT03348176|Experimental|Vegetable exposure|Repeated exposure to a variety of vegetables from the start of complementary feeding
89442163|NCT03348176|Experimental|VIPP-Feeding Infants|Promotion of responsive feeding practices from the start of complementary feeding
89442164|NCT03348176|Experimental|Exposure + VIPP-FI|Combination of repeated exposure to vegetables and promotion of responsive feeding practices
89442165|NCT03348176|Sham Comparator|Control|Phone calls on development child with no information on complementary feeding
88925810|NCT03790098|Experimental|Yoga Class Participants|Group 1 participants will meet twice per week for one hour to practice restorative-flow yoga with a certified yoga instructor. There will be a total of 24 classes. Group 1 participants will also receive an at-home supplemental booklet, a yoga video led by the class instructor, and encouragement to practice two additional days each week at home. They will be asked to fill out a form to record their at-home practice.
88925811|NCT03790098|No Intervention|No Classes|Group 2 participants will not attend yoga classes as part of the study and will be asked not to begin yoga classes outside the study. After the 24 classes, they will be given the 'at-home' supplemental materials.
88925812|NCT03785457|Experimental|Repetitive Trunk Extension|Participants with low back pain will be asked to perform standing repetitive trunk extension at a rate of 10 per 45 seconds, repeated five times with 15-second rest breaks
88925813|NCT03785457|Experimental|Sustained Trunk Extension|Participants with low back pain will be asked to perform standing sustained trunk extension for 5 x 45 seconds with 15-second rest breaks
88925814|NCT03782142||Group A NRTI + NNRTI|Based on current regimens that are commonly used (2017-2018 ART guidelines), our groups will include NRTI such as TAF (tenofovir alafenamide) or TDF (tenofovir disoproxil fumarate) and an NNRTI (Non-nucleoside reverse transcriptase inhibitor, Rilpivirine
88925815|NCT03782142||Group B NRTI + boosted PI|NRTI such as TAF (tenofovir alafenamide) or TDF (tenofovir disoproxil fumarate) and a boosted Protease Inhibitor: Prezcobix- [darunavir+cobicistat combination]
88925816|NCT03782142||Group C NRTI + II|NRTI such as TAF (tenofovir alafenamide) or TDF (tenofovir disoproxil fumarate) and an Integrase inhibitor (dolutegravir)
88925817|NCT03776695|Experimental|2 mg/kg|Subject will be administered with 2 mg/kg of Tyzivumab via IV infusion over a period of 30 minutes.
88925818|NCT03776695|Placebo Comparator|2 mg/kg - Placebo|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes.
88925819|NCT03776695|Experimental|5 mg/kg|Subject will be administered with 5 mg/kg of Tyzivumab via IV infusion over a period of 30 minutes.
88925820|NCT03776695|Placebo Comparator|5 mg/kg - Placebo|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes.
88925821|NCT03776695|Experimental|10 mg/kg|Subject will be administered with 10 mg/kg of Tyzivumab via IV infusion over a period of 30 minutes.
88925822|NCT03776695|Placebo Comparator|10 mg/kg - Placebo|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes.
88925823|NCT03776695|Experimental|20 mg/kg|Subject will be administered with 20 mg/kg of Tyzivumab via IV infusion over a period of 30 minutes.
88925824|NCT03776695|Placebo Comparator|20 mg/kg - Placebo|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes.
88925825|NCT03770299|Experimental|Arm A|Nivolumab + SOC (chemotherapy in eligible participants or observation)
88925826|NCT03770299|Active Comparator|Arm B|SOC (chemotherapy in eligible participants or observation)
88925827|NCT03760835|Experimental|Dual-release hydrocortisone|
88925828|NCT03760835|Active Comparator|Conventional glucocorticoids|
88925829|NCT03759496|Experimental|Durvalumab treated patients|Subjects will receive up to 1000mg durvalumab (MEDI4736) via weekly intravesical administration, for up to a maximum of 6 weeks or until confirmed progression, unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met.
88925830|NCT03759184|Experimental|Arm 1 -DOSE ESCALATION|DOSE ESCALATION: Interleukin-15 (IL-15) by continuous intravenous (civ) infusion at escalating doses of 0.5, 1, and 2 mcg/kg/day on days 1-5 of each 4-week cycle (max 6 cycles), with Obinutuzumab by IV infusion at a dose of 100 mg on day 4, 900 mg on day 5, 1,000 mg on day 11, and 1,000 mg on day 18 of the first cycle; then 1,000 mg on day 4 of each subsequent cycle, to determine the maximum tolerated dose (MTD)
88925831|NCT03759184|Experimental|Arm 2 - DOSE EXPANSION|DOSE EXPANSION: 3 to 6 patients to receive interleukin-15 (IL-15) by continuous intravenous (civ) infusion at the maximum tolerated dose (MTD) on days 1-5 of cycles 1-6 with Obinutuzumab by IV infusion at a dose of 100 mg on day 4, 900 mg on day 5, 1,000 mg on day 11, and 1,000 mg on day 18 of the first cycle; then 1,000 mg on day 4 of each subsequent cycle (Total 9 patients at MTD)
88925832|NCT03747640|Experimental|tDCS with mindfulness-based meditation|Self Transcranial Direct Current Stimulation (tDCS) with Mindfulness-Based Meditation
88925833|NCT03747640|Sham Comparator|sham tDCS with sham meditation|Sham self Transcranial Direct Current Stimulation (tDCS) with sham Meditation
88925834|NCT03736876|Experimental|Treatment group|These students will receive About Us, an innovative, healthy relationship intervention. The program includes 10 lessons that blend group-based activities with online activities implemented in school-based health centers.
88925835|NCT03736876|No Intervention|Delayed intervention (control group)|These students will receive the business-as--usual condition (e.g., the standard health education that is provided by the school during the study period), and will receive the intervention once the study period has concluded.
88925836|NCT03736603|Experimental|Pathway Intervention 1|Hospitals randomized to group 1 receive PIPA Intervention Bundle 1.
89199668|NCT04691011|Other|Muscle|
89199669|NCT04691011|Other|Spinal cord|
89199670|NCT04691011|Other|Brain|
88925837|NCT03736603|Experimental|Pathway Intervention 2|Hospitals randomized to group 2 receive PIPA Intervention Bundle 2, which adds a mobile app.
88925838|NCT03736603|No Intervention|Control|Hospitals are in the control arm (usual care) after January 2017 until active implementation begins, which includes 3-6 months of implementation preparation (identifying local multidisciplinary champions, educational sessions/webinars for local champions, one teleconference with an external practice facilitator).
88925839|NCT03727750|Experimental|Gemtuzumab Ozogamicin (GO)|Patients will receive three doses of Gemtuzumab Ozogamicin (GO) 3 mg/m2 (up to one vial) as a 2 hour intravenous infusion on Cycle 1 Days 1, 4, and 7. A second cycle of GO 3mg/m² (up to one vial) on Cycle 2 Days 1, 4, and 7 will be allowed at the investigator's discretion for patients who meet the criteria
88925840|NCT03719417|Active Comparator|Unicompartmental Biologic Arthroplasty|Subject will be receiving a unicompartmental biologic arthroplasty only
88925841|NCT03719417|Active Comparator|Extensive Biologic Arthroplasty|Subject will be receiving a unicompartmental biologic arthroplasty with at least one additional surface in another compartment being replaced concurrently.
88925842|NCT03719170|Experimental|De-prescribing Program|Veterans Integrated Service Networks (VISNs) randomly assigned to the PPI de-prescribing program. VISNs are the 19 geographical regions that make up the VHA.
88925843|NCT03719170|No Intervention|No De-prescribing Program|Veterans Integrated Service Networks (VISNs) randomly assigned to usual care and will not receive the national de-prescribing program. VISNs are the 19 geographical regions that make up the VHA.
88925844|NCT03718052|Experimental|Early valve surgery (EVS)|Cardiac surgery as soon as possible within 72 hours of randomization
88925845|NCT03718052|Active Comparator|Conventional care|Conventional care according to the 2015 European guidelines.
88925846|NCT03717428|Experimental|Daily Weighing Group|This group will be weighed and height measured in our metabolic unit at the beginning and end of the two year experimental period. In addition, the intervention in Daily Weighing Group is that they will be given an internet based scale and asked to weigh themselves immediately after rising from bed every morning for the duration of the two year experimental period.
88925847|NCT03717428|Active Comparator|Control Group|The only intervention for the control group is that they will be weighed and height measured at the beginning and end of the experimental period in our metabolic unit.
88925848|NCT03715829|Experimental|Cohort 1|Induction dose 1 given once a day(QD) for 4 weeks followed by maintenance dose A given QD for 20 weeks
89442166|NCT02315508|Experimental|AUT00063|4 capsules of 200 mg of the new medicine, AUT00063, to take orally with food for 4 weeks.
89442167|NCT02315508|Placebo Comparator|Placebo|4 capsules of placebo, to take orally with food for 4 weeks.
88925849|NCT03715829|Experimental|Cohort 2|Induction dose 2 given QD for 4 weeks followed by maintenance dose A given QD for 20 weeks
89501662|NCT03106389|Experimental|Misoprostol/Transcervical catheter|This group will receive the same regimen, but will have in addition a transcervical balloon (Foleys') catheter that is inflated with 30 ml. of fluid; with weighted traction using a 1000 ml fluid-filled bag applying continuous pressure to the cervix
88925850|NCT03715829|Experimental|Cohort 3|Maintenance dose A given QD for 24 weeks
88925851|NCT03715829|Experimental|Cohort 4|Maintenance dose B given QD for 24 weeks
88925852|NCT03715829|Experimental|Cohort 5|Maintenance dose C given QD for 24 weeks
88925853|NCT03715829|Placebo Comparator|Cohort 6|Placebo given QD for 24 weeks
88925854|NCT03715829|Experimental|Extension Cohort 1|4 week drug holiday (no drug given) followed by PF-06700841 oral tablet QD for 20 weeks
88925855|NCT03715829|Experimental|Extension Cohort 2|Induction dose 1 given QD for 4 weeks followed by maintenance dose A given QD for 20 weeks in conjunction with narrow band UVB phototherapy
88925856|NCT03715829|Experimental|Extension Cohort 3|Induction dose 1 given QD for 4 weeks followed by maintenance dose A given QD for 20 weeks
88925857|NCT03715829|Experimental|Extension Cohort 4|Maintenance dose A given QD for 24 weeks
88925858|NCT03715829|Experimental|Extension Cohort 5|Maintenance dose B given QD for 24 weeks
88925859|NCT03715829|No Intervention|Extension Cohort 6|Observation period for 24 weeks
88925860|NCT03712176||Cohort 1 : chemotherapy and radiotherapy|50 women aged between 18 and 65 with first non-metastatic breast cancer treated by surgery and adjuvant therapy (chemotherapy and radiotherapy)
88925861|NCT03712176||Cohort 2 : radiotherapy only|150 women aged between 18 and 65 with first non-metastatic breast cancer treated with surgery and adjuvant therapy (radiotherapy only).
88925862|NCT03711175|Other|Group A|The subscapularis is repaired. Receives device
88925863|NCT03711175|Other|Group B|The subscapularis is not repaired. Receives device
88925864|NCT03704441|Other|bupivacaine 6mg|bupivacaine 6mg
88925865|NCT03704441|Other|bupivacaine 7mg|bupivacaine 7mg
88925866|NCT03704441|Other|bupivacaine 8mg|bupivacaine 8mg
88925867|NCT03704441|Other|bupivacaine 9mg|bupivacaine 9mg
88925868|NCT03704441|Other|bupivacaine 10mg|bupivacaine 10mg
88925869|NCT03704441|Other|bupivacaine 11mg|bupivacaine 11mg
88925870|NCT03704441|Other|bupivacaine 12mg|bupivacaine 12mg
88925871|NCT03703947||Watchful-waiting group|The prospective, longitudinal part of the study will include an arm with 120 AAA watchful waiting patients, with a 24-month follow-up period. Clinical data collection, and blood sampling will be conducted at baseline, and at 6, 12, 18 and 24 months for all patients. CT will be conducted at baseline and 12 and 24 months. Quality of life and depression questionnaires will be performed at baseline, at 12 and 24 months of follow-up in all patients.
88925872|NCT03703947||EVAR group|The prospective, longitudinal part of the study will include an arm with 120 AAA patients undergoing endovascular aneurysm repair (EVAR), with a 24-month follow-up period. Clinical data collection, and blood sampling will be conducted at baseline, at 1 month after EVAR and at 6, 12, 18 and 24 months after EVAR. CT will be conducted at baseline, at 1 month after EVAR and at 12 and 24 months after EVAR patients. Quality of life and depression questionnaires will be performed at baseline, at 1 month, at 12 and 24 months of follow-up after EVAR.
89199671|NCT04690998|Other|Without treatment for SMA|Patient that will not take treatment for SMA during the two years of the study.
88925873|NCT03703947||Cross-sectional group (after EVAR)|A cross-sectional study will be performed in 200 patients treated for AAA with EVAR in the past years. In these patients, clinical data collection, blood sampling, ultrasound and CT will be performed at their next regular outpatient clinic visit.
88925874|NCT03678259|Experimental|124I-p5+14 Injection|A single-injection dose of 124I-p5+14 adequate for imaging amyloid deposits by using PET/CT imaging in subjects with confirmed systemic amyloidosis of several sub-types.
88925875|NCT03676153|Experimental|Nurse-guided arm|Nurse-provided guidance following an integrative medicine treatment program, for patient implementation of self-administered manual therapies, relaxation, lifestyle changes and traditional medicine.
88925876|NCT03676153|Active Comparator|Non nurse-guided arm|Integrative medicine treatment program, with no nurse-provided guidance on patient implementation of self-administered manual therapies, relaxation, lifestyle changes and traditional medicine.
88925877|NCT03660839|Experimental|Ferroquine 400 milligram (mg)|On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition.
88925878|NCT03660839|Experimental|Ferroquine 400 mg + Artefenomel 300 mg|On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 300 mg oral suspension.
88925879|NCT03660839|Experimental|Ferroquine 400 mg + Artefenomel 600 mg|On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 600 mg oral suspension.
88925880|NCT03660839|Experimental|Ferroquine 400 mg + Artefenomel 1000 mg|On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 1000 mg oral suspension.
88925881|NCT03660241|Experimental|PF-04965842|PF 04965842 is an oral selevtive janus kinase (JAK) 1 inhibitor
88925882|NCT03651102|Experimental|Thalidomide in combination with hydroxyurea|All the study patients refractory to hydroxyurea will be given thalidomide at an average dose of 2mg/kg/day (range 1-4mg/kg/day). Participants will also be continued on hydroxyurea at a dose of 10-20 mg/kg/day.
88925883|NCT03649802|Placebo Comparator|Low dose Vitamin D-800 IU|Intervention includes low dose arm-800 IU given daily
88925884|NCT03649802|Active Comparator|High dose Vitamin D-5000 IU|Intervention includes high dose arm-5000 IU given daily
88925885|NCT03635385|Active Comparator|Plasma exchange (PE) technic patient group|
88925886|NCT03635385|Active Comparator|Immunoadsorption technic patient group|
88925887|NCT03634943||Patients with Nutritional Support|Patients expected to be admitted >72h at the Intensive Care Unit with the need of artificial Nutritional Support
88925888|NCT03626792|Other|Hypertensive group|The Mat Pilates session was held lasting 50 minutes of exercises with the first 5 minutes heating and in each exercise performing 10 repetitions with 45 seconds of rest between one exercise and another. For practice, are used only mats, and alternative devices such as the Swiss ball and the flexible ring, as well as body weight and the force of gravity as resistance factors and Borg's subjective perception of effort scale for intensity parameters. The 20 exercises were chosen through the classic exercises thus classified by the creator of the Joseph Pilates method.During the sessions, volunteers were instructed on correct breathing without performing the valsalva maneuver.
88925889|NCT03626792|Other|Normotensive group|The Mat Pilates session was held lasting 50 minutes of exercises with the first 5 minutes heating and in each exercise performing 10 repetitions with 45 seconds of rest between one exercise and another. For practice, are used only mats, and alternative devices such as the Swiss ball and the flexible ring, as well as body weight and the force of gravity as resistance factors and Borg's subjective perception of effort scale for intensity parameters. The 20 exercises were chosen through the classic exercises thus classified by the creator of the Joseph Pilates method.During the sessions, volunteers were instructed on correct breathing without performing the valsalva maneuver.
88925890|NCT03616041||Colon capsule endoscopy|Participant who meet the eligible criteria undergo an evaluation for severe hematochezia with a second-generation colon capsule endoscopy system in addition to standard diagnostic tests including tagged RBC scan, and/or computerized tomographic angiography (CTA), and/or conventional angiography.
88925891|NCT03607318|Experimental|iASIST|iASIST, involves 1) an individual intervention with the adolescent in which motivational enhancement techniques are used to explore alcohol use as a risk factor for continued suicide-related thoughts and behaviors and to create a change plan, 2) a subsequent family intervention using motivational enhancement techniques to align the parent with the adolescent to strengthen the adolescent's self-efficacy and commitment to the change plan as well as the parent's ability to support the adolescent in their plan to reduce or stop drinking, and 3) a post-discharge mHealth booster to adolescents focused on strengthening their commitment to the change plan, and to parents focused on their commitment, confidence, and ability related to supporting the adolescent in reducing or stopping drinking.
88925892|NCT03607318|Active Comparator|Attention-Matched Comparison|The attention-matched comparison condition involves one psychoeducation session focused on the role of a healthy lifestyle in mental health and an additional family intervention, in which the adolescent will review handouts from the session with the parent, facilitated by the interventionist. In addition, adolescents and parents assigned to the comparison will receive a post-discharge mHealth control about the maintenance of a healthy lifestyle with the same frequency and type of interaction as the iASIST mHealth booster.
88925893|NCT03600116||Study Visit|After consent and enrollment, subjects with type 1 diabetes will arrive to the study visit having fasted the night before. Subjects will be given a meal, and will be given an insulin injection for this meal, calculated based on their prescribed meal to carbohydrate ratio as well as a correction bolus to correct their current plasma glucose value down to 40 mg/dL based on their prescribed insulin sensitivity factor. Following the insulin injection, subjects will eat breakfast and be observed in the clinic setting. Blood, breath, and sweat samples will be collected throughout the study visit with increased frequency of collection during hypoglycemia. After subjects reach the hypoglycemia threshold, they will be allowed to eat and drink and their blood sugar will be monitored for stability prior to discharge.
89199672|NCT04690998|Other|Under treatment for SMA|Patient that will take treatment for SMA during the two years of the study
89206109|NCT04044378|Experimental|Arm C: Famitinib and Ifofamide|Only phase II protion (Phase I have been completed): famitinib will be 20mg orally taken daily, 4 weeks (28 days) as one treatment cycle together with ifofamide 1800 mg/m^2/day intravenous infusion will be administered on Days 1 to 3 and 15-17 of each 28-day cycle for a total of 5 cycles.
89442168|NCT05516446|Experimental|DEB for de Novo Lesions|"Preparation of the lesion by pre-dilation or another technique using a balloon undersized by 0.5 mm compared to the reference diameter of the artery and, if necessary, by a second balloon with a balloon/artery ratio of 0.8-1 inflated to 16-18 atm for best results.~when obtaining a stent-like result and in the absence of a major dissection less than grade C, a flow TIMI less than 3 and a residual stenosis of more than 30%, an angioplasty by a drug eluting balloon will be performed for an inflation of 30 seconds at 8-10 atm.~Otherwise, an angioplasty using a drug eluting stent will be proceeded.~Before removing the intracoronary guide, the operator will evaluate by Quantitative Coronary Arteriography (QCA)~The post-procedural TIMI flow.~the minimal post-procedural luminal diameter in mm."
89442169|NCT05516446|Active Comparator|DES for de Novo Lesions|"The preparation of the lesion and the post dilation will be left to the discretion of the operator.~Angioplasty with Drug eluting balloon after pre dilatation will be performed.~Before removing the intracoronary guide, the operator will evaluate by Quantitative Coronary Arteriography (QCA)~The post-procedural TIMI flow.~the minimal post-procedural luminal diameter in mm."
89442170|NCT02318082|Experimental|Interleukin-2 (IL-2)|Interleukin-2: Each participant will receive daily subcutaneous IL-2 for self-administration per cycle. Each participant will start at Dose Level A. In the abscence of DLTs or severe non-DLT adverse events, participants will have daily SC IL-2 dose-escalated at Week 2 (to dose level B) and at Week 4 (to Dose Level C), and continue on their maximum tolerated dose (MTD) IL-2 for 4 weeks total.
89442171|NCT04994470|Experimental|Web-based intervention group|Two-week web-based intervention
89442172|NCT04994470|Sham Comparator|Web-based control group|Two-week web-based sham comparator
89442173|NCT02518100|Experimental|VSP 3-Lead Study Participants|"Intervention: Vital Signs Patch (VSP) System 3-Lead (NEHB) Configuration The participants of this arm will have the following vital signs taken and recorded by the VSP System in the 3-lead (NEHB) configuration:~Arterial blood oxygen Saturation (SpO2) ECG Heart Rate Surface Temperature Respiration"
89442174|NCT02518100|Experimental|VSP 1-Lead Study Participants|"Intervention: Vital Signs Patch (VSP) System 1-Lead (PAL) Configuration. The participants of this arm will have the following vital signs taken and recorded by the VSP System in the 1-lead (PAL) configuration:~Arterial blood oxygen Saturation (SpO2) ECG Heart Rate Surface Temperature Respiration"
89442175|NCT04301674||Occupational Asthma|Patients refered for assesment of occupational asthma
89442176|NCT04301674||Respiratory Healthy Control|Employees at Oslo University Hospital
89442177|NCT03501888|Active Comparator|Cognitive Behavior Therapy (CBT)|CBT: individually, ca 18 weeks.
89442178|NCT03501888|Active Comparator|Acceptance and Commitment Therapy (ACT)|ACT: given in a group setting: ca 18 weeks.
89442179|NCT03347006|Placebo Comparator|Placebo|Placebo control
89442180|NCT03347006|Experimental|Dose 1|1.5 g of omega-3 supplement
89442181|NCT03347006|Experimental|Dose 2|3.0 g of omega-3 supplement
89442182|NCT03347006|Experimental|Dose 3|4.5 g of omega-3 supplement
89442183|NCT03497286|Experimental|Treatment|Participants in the treatment condition will be enrolled in the text-based mentorship program and will be able to engage with their assigned mentor as much or as little as they choose.
89442184|NCT03497286|Active Comparator|Control|Participants in the control condition will receive periodic informational texts related to the growth and development of their new baby.
89442185|NCT03348098|Experimental|single arm|Apatinib Combined With Paclitaxel in Neoadjuvant Therapy of Locally Advanced Exploratory Research on Single-arm of TNBC
89442186|NCT02315742|Experimental|Let's Move Program|Patients will take part in a 12-week exercise program.
89442187|NCT02321826|Experimental|Music|Listening to music for 45 minutes at bedtime
88925894|NCT03579628|Experimental|AsiDNA|"Part A: AsiDNA as a single agent:~The study will follow a dose escalation 3 + 3 cohort design (with 6 dose levels).~All patients will receive a loading dose of AsiDNA for 3 consecutive days as iv infusion at Day 1 (D1), Day 2 (D2) and Day 3 (D3), followed by iv infusion once a week (at D8 and D15 of a 21 days treatment period (1 cycle = 21 days). Each subsequent cycle will be administered on a weekly basis (D1, D8, D15) of a 21 days treatment period.~Part B: AsiDNA combination with Carboplatin with or without Paclitaxel (Background treatments):~Part B1: Combination cohort of AsiDNA at DL3 (600mg) with Carboplatin AUC 5.~Part B2: Combination cohort of AsiDNA at DL3 (600mg) with Carboplatin AUC 5 and weekly Paclitaxel: 80 mg/m2 (full dose)."
88925895|NCT03575104|Experimental|Daridorexant 10 mg|
88925896|NCT03575104|Experimental|Daridorexant 25 mg|
88925897|NCT03575104|Placebo Comparator|Placebo|
89442188|NCT02321826|Active Comparator|Audiobook|Listening to audiobook for 45 minutes at bedtime
89442189|NCT02321826|No Intervention|Control|No intervention control group
89442190|NCT05526274||General population aged ≥9 to ≤16 years.|
89442191|NCT02318238|Active Comparator|6 minute walking test|walking during 6 minutes
89442192|NCT02318238|Experimental|6 minute step test|stepping during 6 minutes
89442193|NCT02318238|Experimental|4 meter gait speed|walking as fast as possible on 4 meters
89442194|NCT04503356|Active Comparator|OMNI as a standalone procedure|
89442195|NCT04503356|Active Comparator|OMNI combined with cataract surgery|
89442196|NCT02318316||EBC level|Exhaled breath condensate level of allogeneic stem cell transplantation patients
89442197|NCT02318394|Experimental|Monotherapy Arm|MEDI0562 monotherapy
89442198|NCT05516368|Experimental|TF-CBT|16 sessions of trauma-focused CBT adapted to victims of terrorism with long-term PTSD, major depressive disorder and/or anxiety disorders
89442199|NCT05516368|No Intervention|Waiting list control|4 months of waiting list condition
89442200|NCT03351842|Active Comparator|Arm I|Undergo surgery, followed by observation. Patients receive no further therapy
88925898|NCT03573557|Active Comparator|Pink Pad|The Pink Pad will be used with subjects undergoing laparoscopic surgery or vaginal surgery while in to Trendelenburg to determine how much slipping is happening during the procedure.
88925899|NCT03573557|Active Comparator|Bean Bag|The Bean Bag will be used with subjects undergoing laparoscopic surgery or vaginal surgery while in to Trendelenburg to determine how much slipping is happening during the procedure.
89199673|NCT04689997|Experimental|computerized Substance Brief Intervention cSBI|Enhanced care PCPs will address the serious morbidity of teen substance use during routine check-up visits using cSBI and follow up care using a new Module of CHADIS that facilitates guideline-based care. The CHADIS c-SBI Module will include pre-visit screening tools and embedded education that cover substance use and strengths and goals. It will also include reminders to the patient about their goals and commitments for change and teleprompted interview hints for the PCP. These hints will be aimed at enhancing a patient focused discussion of individual strengths and barriers related to the teens' goals in a motivational interviewing style.
89199674|NCT04689997|No Intervention|Standard care|Standard care PCPs will screen using a standard SU tool and carry out their usual health supervision visits without additional decision support.
89199675|NCT04689035|Experimental|Cohort 1|AVLX-144_dose1
89199676|NCT04689035|Experimental|Cohort 2|AVLX-144_dose2
89199677|NCT04689035|Experimental|Cohort 3|AVLX-144_dose3
89199678|NCT04689035|Experimental|Cohort 4|AVLX-144_dose4
89199679|NCT04689035|Experimental|Cohort 5|AVLX-144_dose5
89199680|NCT04689035|Experimental|Cohort 6|AVLX-144_elderly
89199681|NCT04684862|Experimental|Hepatic Artery Infusion (HAI) Therapy|Eligible patients will be implanted with a device that combines components of two commercially available drug delivery pumps to administer regional chemotherapy (FUDR) to the liver. Specifically, a Medtronic pump is being used with an Intera tapered catheter, instead of the Medtronic catheter.
89199682|NCT04683627|Experimental|HP-5000 Treatment|HP-5000 Topical Patch will be evaluated against placebo topical patches.
89199683|NCT04683627|Placebo Comparator|Placebo Treatment|Placebo patches without diclofenac sodium will be used.
89199684|NCT04657666|Experimental|Nabiximols|"Nabiximols is a complex botanical medicine formulated from extracts of the cannabis plant that contains the principal cannabinoids delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) and also contains minor constituents, including other cannabinoid and non-cannabinoid plant components, such as terpenes, sterols, and triglycerides. Each spray delivers 100 microliters (μL) of nabiximols.~Nabiximols will be self-administered by participants as an oromucosal spray in the morning and evening, up to a maximum of 12 sprays per day for 12 weeks."
89199685|NCT04657666|Placebo Comparator|Placebo|"Placebo to match nabiximols will be presented as an oromucosal spray containing the excipients ethanol and propylene glycol (50% v/v) with colorings and flavored with peppermint oil (0.05% v/v). Each spray will deliver 100 μL containing no active ingredients.~Placebo will be self-administered by participants as an oromucosal spray in the morning and evening, up to a maximum of 12 sprays per day for 12 weeks."
89199686|NCT04652687||VIA Disc NP|Patients meeting study criteria receiving Vivex VIA Disc NP injection as treatment
89199687|NCT04646967|Active Comparator|No ketorolac|15 mg/kg oral dose of acetaminophen is administered prior to surgery. General anesthesia will be induced with sevoflurane via facemask. After establishing venous access, a laryngeal mask will be inserted, and anesthesia maintained with 1 minimum alveolar anesthetic concentration (MAC) of sevoflurane in oxygen/air 50/50 mixture. The DPNB nerve block is done using a 23 GA needle inserted below the Buck fascia. Once the needle tip is positioned appropriately and after a negative aspiration test, 0.2mL/kg (maximum 10mL) of 0.25% bupivacaine is injected in small aliquots, with intermittent aspiration throughout. In all patients, skin incision is performed at least 5 min after placement of the nerve block. Patients will be advised to take ibuprofen and acetaminophen postoperatively as needed.
89199688|NCT04646967|Experimental|Peri-operative ketorolac|Exactly same as the no ketorolac group except at the beginning of the circumcision, once the patient is asleep, patients in the perioperative ketorolac group will also receive a 0.5 mg/kg intravenous dose of ketorolac.
88925900|NCT03573557|Active Comparator|Gel Pad|The Gel Pad will be used with subjects undergoing laparoscopic surgery or vaginal surgery while in to Trendelenburg determine how much slipping is happening during the procedure.
89199689|NCT04633512|Experimental|ActivSight Group|Patients undergoing intestinal anastomoses (colorectal and bariatric) with ActivSight (n=52) Patients undergoing cholecystectomy with ActivSight (n=28)
89442201|NCT03351842|Experimental|Arm II|Undergo surgery, followed by chemotherapy (cis Platinum/Carboplatin, Pemetrexed Disodium). Patients receive chemotherapy comprising cisplatin 75mg/m2 or Carboplatin AUC=5mg/ml/min, and pemetrexed 500mg/m2 in day 1. Treatment continues every 3 weeks for 4 courses.
89199690|NCT04614324|Experimental|RhinAer ARC Stylus Treatment|The RhinAer procedure will be performed in the study clinic using the RhinAer Stylus and Aerin Console. The RhinAer Stylus is a disposable handheld device capable of delivering bipolar radiofrequency energy to tissue when connected to the Aerin Console radiofrequency generating device. Participants will have both nostrils treated in the portion of the nasal cavity mucosa overlying the region of the posterior nasal nerve.
89199691|NCT04606355||PDI Check & Conventional|Autostereoscopic, dynamic forced choice game (ie on Nintendo 3DS) and Rosenbaum or HOTV near card, Ishihara color plates, Innova Rabin color test, Titmus Stereo test
89199692|NCT04589286|Experimental|Pack Health's Digital Life Coaching (DLC)|Participants will receive 16 weeks of access to a trained human life coach employed by Pack Health. Coaches will communicate via phone calls, text messages, emails, and links to web-based Pack Health resources plus the addition of generic wellness-related electronic handouts at the time of each email reminder for participant-reported outcome (PRO) assessments
89199693|NCT04589286|Active Comparator|Quasi-usual care control arm|Participants will receive usual supportive care for stem cell transplantation plus the addition of generic wellness-related electronic handouts at the time of each email reminder for participant-reported outcome (PRO) assessments
89199694|NCT04563754|Experimental|mHRME|"5-10 ml of proflavine hemisulfate (0.01%) will be applied on the anal epithelium. The mHRME will then be inserted and imaging of abnormal tissues will be performed.~This is a single-arm study where all subjects will receive both standard of care HRA (High resolution anoscopy) and experimental mHRME imaging."
89199695|NCT04539249|Experimental|Magnesium sulphate|Combination of intravenous magnesium sulphate, intravenous paracetamol and rectal diclofenac
89199696|NCT04539249|Active Comparator|Pentazocine|Combination of intramuscular pentazocine, intravenous paracetamol and rectal diclofenac
88925901|NCT03573115|Experimental|Acne patients|
88925902|NCT03569982|No Intervention|Control|Patients receiving best supportive care
88925903|NCT03569982|Experimental|Intervention|Patients receiving integrative care (including acupuncture) in addition to best supportive care
88925904|NCT03569475|Experimental|Levomilnacipran ER 40-80 mg/day|Levomilnacipran extended release (ER) capsules, orally, 10 milligram per day (mg/day) on Days 1 to 3, 20 mg/day on Days 4 to 7, and 40 mg/day from Week 2 through Week 8 of the Double-blind Treatment Period followed by levomilnacipran ER 40 mg/day on Days 1 and 2, and then 20 mg/day from Day 3 through Day 7 in the Down-taper Period. Based on therapeutic response and tolerability, an additional dose increase to 80 mg/day was permitted at Week 3 of the Double-blind Treatment Period.
89199697|NCT04513002|Other|Group 1: Triheptanoin and no Placebo|"Parallel group, placebo-controlled, dose-escalation each 2 months for 12 months. Dose based on percent (%) of calculated caloric intake.~Thirty participants will be randomised in blocks on a 1:1:1 ratio into one of three groups.~Group 1: 10%, 20%, 35%, 35%, 35% (no placebo). Group 2: placebo, 10%, 20%, 35%, 35% Group 3: placebo, placebo, 10%, 20%, 35%"
89199698|NCT04513002|Other|Group 2: Placebo and Triheptanoin|"Parallel group, placebo-controlled, dose-escalation each 2 months for 12 months. Dose based on percent (%) of calculated caloric intake.~Thirty participants will be randomised in blocks on a 1:1:1 ratio into one of three groups.~Group 1: 10%, 20%, 35%, 35%, 35% (no placebo). Group 2: placebo, 10%, 20%, 35%, 35% Group 3: placebo, placebo, 10%, 20%, 35%"
89199699|NCT04513002|Other|Group 3: Placebo, Placebo and Triheptanoin|"Parallel group, placebo-controlled, dose-escalation each 2 months for 12 months. Dose based on percent (%) of calculated caloric intake.~Thirty participants will be randomised in blocks on a 1:1:1 ratio into one of three groups.~Group 1: 10%, 20%, 35%, 35%, 35% (no placebo). Group 2: placebo, 10%, 20%, 35%, 35% Group 3: placebo, placebo, 10%, 20%, 35%"
89199700|NCT04495829||Phorcides|Both eyes of subjects eligible for Contoura(R) topography-guided ablation with the Wavelight excimer laser, with surgery planned using Phorcides software.
89199701|NCT04492891|Experimental|Arm A Cyclosporine|Neoral, N=50 Patients 2.5 mg/kg PO BID 7 days
89199702|NCT04492891|Other|Arm B Standard of Care|Standard of Care Treatment, N= 25 Patients 7 days
89199703|NCT04449198|Experimental|Individuals with type 1 diabetes|Individuals with type 1 diabetes will be randomly assigned to 1 of the 2 interventions (Resveratrol or placebo)
89199704|NCT04449198|No Intervention|Healthy Controls|Healthy individuals who participate will receive no intervention and serve as controls.
89199705|NCT04446559|Experimental|Sitting in a chair position|For patients randomized in the chair group, we will perform the transfer to the chair immediately after the morning arterial blood gas. The chair position will be maintained for 3 hours, if the patient shows no clinical signs of discomfort or intolerance.
88925905|NCT03569475|Active Comparator|Fluoxetine 20 mg/day|Fluoxetine capsule, orally, 10 mg/day at Week 1, and 20 mg/day from Week 2 through Week 8 of the Double-blind Treatment Period followed by fluoxetine 10 mg/day from Day 1 through Day 7 of the Down-taper Period.
89199706|NCT04446559|No Intervention|Semi-recumbent in bed position|The patient will benefit from conventional positioning techniques in the ICU bed. With the help of the medical monitoring software present in the wards, we will note the different nursing care given to the patient during the 3 hours following the morning arterial gasometry.
89199707|NCT04432337|Experimental|Type 2 diabetes patients|The variation in the plasma concentration of the two pro-inflammatory cytokines IL-1β and IL18, between a baseline level measured the day before the operating room (D-1) and 24 hours (D1) for TD2 patients after cardiac surgery with extracorporeal circulation .
89199708|NCT04432337|Active Comparator|Non-diabetic type 2 patients|The variation in the plasma concentration of the two pro-inflammatory cytokines IL-1β and IL18, between a baseline level measured the day before the operating room (D-1) and 24 hours (D1) for non-diabetic type 2 patients after cardiac surgery with extracorporeal circulation
89199709|NCT04426539||Amyloid PET-Positive|Those for whom a beta amyloid PET scan is consistent with underlying AD as causing or contributing to cognitive impairment
89199710|NCT04426539||Amyloid PET-Negative|Those for whom a beta amyloid PET scan has ruled out AD (i.e. not consistent with underlying AD as causing or contributing to cognitive impairment)
89199711|NCT04417595|Experimental|Fish Oil|Participants allocated to n-3 LCPUFA supplementation will be instructed to take four 1000 mg n-3 LCPUFA capsules (Metagenics™) daily. This will provide a total daily dose of 4000 mg n-3 LCPUFAs (2840 EPA and 1160 DHA).
88925906|NCT03569475|Placebo Comparator|Placebo|Matching placebo capsules once daily through 8 weeks in the Double-blind Treatment Period and Days 1 through 7 in the Down-taper Period.
88925907|NCT03565380|Experimental|Patients with intervention|12-week community-based Tai Chi rehabilitation program starting at 12 weeks after TKA
88925908|NCT03565380|Experimental|Patients without intervention|usual post-operative care
89199712|NCT04417595|Placebo Comparator|Olive Oil|Oleic acid (olive oil) capsules have a similar texture, size, color, and consistency to EPA capsules. Participant will be instructed to take four 100mg olive oil capsules
89199713|NCT04385082|Placebo Comparator|Placebo|Smoked Cannabis (~0% THC)
89199714|NCT04385082|Experimental|Low strength cannabis|Smoked Cannabis (~4% THC)
89501663|NCT02258893|Experimental|NO2 Scrubber, then HEPA filter, then Control|Participants will have 3 periods of 4 weeks with each filter with a 1 week washout between phases in the order of NO2 Scrubber, then HEPA filter, then Control.
89199715|NCT04385082|Experimental|Higher strength cannabis|Smoked Cannabis (~10% THC)
89199716|NCT04353960||anticholinergic|Patients who receive anticholinergic medication before strabismus surgery
89199717|NCT04353960||non-anticholinergic|Patients who do not received anticholinergic medication before strabismus surgery
88925909|NCT03565380|Experimental|Asymptomatic controls|untreated asymptomatic controls
88925910|NCT03550144|Experimental|Awe Walk Condition|Participants were instructed to take at least one (~15 minute) walk per week for 8 consecutive weeks. Participants were told to seek the experience of feeling awe. Participants were told to keep a fairly light to moderate pace and were encouraged to walk alone and without interruption from a mobile device.
89199718|NCT04312945|Experimental|Primary Parent|Participants will be randomly assigned to one of 4 conditions that differ by who is with them in the MRI scanner room: Primary Parent, Close Friend, Experimenter, No Social Partner.
88925911|NCT03550144|Active Comparator|Control Walk Condition|Participants were instructed to take at least one (~15 minute) walk per week for 8 consecutive weeks. Participants were told to keep a fairly light to moderate pace and were encouraged to walk alone and without interruption from a mobile device.
89199719|NCT04312945|Experimental|Close Friend|Participants will be randomly assigned to one of 4 conditions that differ by who is with them in the MRI scanner room: Primary Parent, Close Friend, Experimenter, No Social Partner.
88925912|NCT03546556|Experimental|Allogeneic|A total of 12 patients who have undergone allogenic bone marrow transplantation will undergo Fluorothymidine FLT-PET-MRI imaging on two separate occasions.
88925913|NCT03546556|Experimental|Autologous|3 patients undergoing autologous stem cell transplant will also undergo Fluorothymidine FLT-PET-MRI imaging the same two time points in order to determine how much of the FLT signal observed after allogeneic transplant is unique to that population and the result of allo-antigen driven T cell expansion.
88925914|NCT03545191|Experimental|Daridorexant 25 mg|
89442202|NCT02321904||Diabetic cases|Children with Type 1 Diabetes 8 to 18 years old followed at the Alberta Children's Hospital Diabetes Clinic with duration of diabetes for at least 5 years will undergo Corneal Confocal Microscopy, Nerve Conduction Studies, Quantitative sensory testing, Neuropathy Symptom Scoring and Clinical nerve examinations.
89442203|NCT02321904||Normal controls|Healthy children aged 8 to 18 years will undergo Corneal Confocal Microscopy, Nerve Conduction Studies, Quantitative sensory testing, Neuropathy Symptom Scoring and Clinical nerve examinations.
89442204|NCT05520970|Experimental|2 doses of AdCLD-CoV19-1|Group 1 will receive 2 doses of AdCLD-CoV19-1
89442205|NCT05520970|Experimental|1 dose of AdCLD-CoV19-1|Group 2 will receive 1 doses of AdCLD-CoV19-1 followed by 1 dose of placebo
89442206|NCT05520970|Placebo Comparator|Placebo|Group 2 will receive 1 doses of placebo followed by 1 dose of AdCLD-CoV19-1 after an interim analysis
89442207|NCT02315820|Experimental|Induction of Labor (IOL)|Group I, Induction of Labor group (IOL). Women will be admitted for induction at 38-40+3 weeks when estimated fetal weight 3800-4500 gram.
89442208|NCT02315820|No Intervention|Expectant|Group II. Will be expectantly managed until 40+6 weeks, or an induction indication will appear.
89442209|NCT04505306|Active Comparator|Subthreshold Laser 30%|Patients in the SPCW group were treated with grid pattern laser with 20ms pulse PASCAL laser 532nm (TopCon Medical Laser Systems, Tokyo, Japan) with 30% EndPoint algorithm.
89442210|NCT04505306|Active Comparator|Subtreshold Laser 50%|Patients in the SPCW group were treated with grid pattern laser with 20ms pulse PASCAL laser 532nm (TopCon Medical Laser Systems, Tokyo, Japan) with 50% EndPoint algorithm.
88925915|NCT03545191|Experimental|Daridorexant 50 mg|
89442211|NCT04505306|Active Comparator|Micropulse Laser|Patients in the STMP group were treated with the 810-nm diode micropulse scanning laser TxCell™ (IRIDEX Corporation, Mountain View, CA, USA) at 15% duty cycle.
88925916|NCT03545191|Placebo Comparator|Placebo|
88925917|NCT03543514||PREHABILITATION GROUP|Patients affected on Cold-rectal cancer who needs surgery. We made trimodal prehabilitation
89442212|NCT02571244|Experimental|Motivational Interview plus text message|Inside the hospital: All participants have received the written materials. Patients with high tobacco dependence (Fagerstrom screening test score 5 or higher) have received also Nicotine Replacement Therapy (NRT). The written materials provided information on benefits of quitting and strategies for a successful quit plan, including information on relapse prevention. Post discharge extended treatment: Participants in this arm have received a telephone counseling session using a motivational interviewing approach and fifteen or eight days of text messages. The timing, duration, and content of the counseling session were consistent with guideline-based recommendations.
89442213|NCT02571244|No Intervention|Control Arm|Inside the hospital: All participants have receive the written materials. Patients with high tobacco dependence (Fagerstrom screening test score 5 or higher) have received also Nicotine Replacement Therapy (NRT). The written materials provided information on benefits of quitting and strategies for a successful quit plan, including information on relapse prevention. Post discharge extended care: None
88925918|NCT03537365|Experimental|Bovine Colostrum / intervention group|Preterm infants are supplemented with bovine colostrum (BC) as a fortifier to human milk. BC is the first milk from cows after parturition and is a rich source of protein (80-150 g/L) and bioactive components, including lactoferrin, lysozyme, lactoperoxidase, immunoglobulins, and growth factors. The product is supplied in a sterile, powdered form and consists of unmodified, intact BC.
89199720|NCT04312945|Experimental|Experimenter|Participants will be randomly assigned to one of 4 conditions that differ by who is with them in the MRI scanner room: Primary Parent, Close Friend, Experimenter, No Social Partner.
89199721|NCT04312945|Experimental|No Social Partner|Participants will be randomly assigned to one of 4 conditions that differ by who is with them in the MRI scanner room: Primary Parent, Close Friend, Experimenter, No Social Partner.
89442214|NCT03497208|Experimental|Microneedling+cell susp+phototherapy|Experiment is about the use of abrasion technic with dermaroller, equipped with a 0,25mm needle, applied on a vitiligo lesion. After that, a transplant with non cultured cell suspension (melanocytes and keratinocytes) will be applied to pacient 's skin scalp.
89442215|NCT03497208|Active Comparator|Microneedling and phototherapy|Technique involves only the abrasion with dermaroller equipped with 0,25mm on the lesion of vitiligo.
89442216|NCT02447406|Experimental|AZD6094 (Volitinib) in combination with docetaxel|"Phase Ib:Volitinib should be administered at least 200mg orally once a day in 21 days for achieving appropriate antitumor activity.~Phase II: Subjects will receive Volitinib once daily ( at the MTD determined from Phase Ib) for 21 days as one cycle.~Docetaxel 60 mg/m2 will be administered via intravenous access once every 3 weeks."
89442217|NCT03500562||HCV participant population in China|
89442218|NCT05584982|Experimental|AtbFinder-1|persons with cystic fibrosis to whom AtbFinder was used to formulate an individualized antibiotic regimen
89442219|NCT02315976|Experimental|Propatyl nitrate|Patients treated with propatyl nitrate 10mg thrice daily
89442220|NCT03122210|Other|Control group|In this group, the nursing staff administed oxygen supply if necessary with the usual pratice in care unit for 24 hours after myocard infarction. In this group the SpO2 was recorded any time with FreeO2 device - recording mode.
89442221|NCT03122210|Other|FreeO2 with SpO2 target = 92%|In this group oxygen flow was automatically adjusted with the FreeO2 device (automatic titration of oxygen flow) to achived SpO2 target set by clinicial for 24 hours after myocard infarction. In this group, the SpO2 target was set at 92%.
89442222|NCT03122210|Other|FreeO2 with SpO2 target =97%|In this group oxygen flow was automatically adjusted with the FreeO2 device (automatic titration of oxygen flow) to achived SpO2 target set by clinicial for 24 hours after myocard infarction. In this group, the SpO2 target was set at 97%.
88925919|NCT03537365|Active Comparator|FM85 / control group|Preterm infants are supplemented with PreNAN FM85 as fortifier to human milk. PreNAN FM85 contains partially hydrolyzed protein and maltodextrin including vitamins and minerals. The product is supplied in a powdered form.
88925920|NCT03533712|Experimental|Fortified BEP supplement|Intervention: Dietary Supplement: Fortified balanced energy-protein (BEP) supplement + iron and folic acid supplement.
88925921|NCT03533712|Active Comparator|Fe and folic acid|Dietary Supplement: Fe and folic acid supplement.
88925922|NCT03529838|Placebo Comparator|No medication|Group of pre-hypertensive women with no medication who practiced 12 weeks of training with Combined Exercise Training, non-obese, nonsmokers and with no characteristics that prevented them from performing the activities. In addition this group could not modify the dose or type of the medicine and should be using the same medicine and dose for at least 6 months
88925923|NCT03529838|Active Comparator|Angiotensin receptor blockers|Group of hypertensive women taking Angiotensin receptor blockers who practiced 12 weeks of training with Combined Exercise Training, non-obese, nonsmokers and with no characteristics that prevented them from performing the activities. In addition this group could not modify the dose or type of the medicine and should be using the same medicine and dose for at least 6 months
88925924|NCT03529838|Active Comparator|Beta blockers|Group of hypertensive women taking Beta blockers who practiced 12 weeks of training with Combined Exercise Training, non-obese, nonsmokers and with no characteristics that prevented them from performing the activities. In addition this group could not modify the dose or type of the medicine and should be using the same medicine and dose for at least 6 months
89442223|NCT02321982|No Intervention|Separate-day preoperative consultation|Patients referred for Mohs surgery for non-melanoma skin cancer will have a preoperative consultation in advance of the day of the procedure.
89442224|NCT02321982|Experimental|Same-day preoperative consultation|Patients referred for Mohs surgery for non-melanoma skin cancer will have a preoperative consultation on the day same day as the procedure.
89442225|NCT04505150|Experimental|Monitoring of lifestyle change activities|The intervention arm will involve (i) the delivery of a blended learning education program and (ii) weekly phone calls to participants. The lectures will be delivered to 10 teams, comprised of about 15 participants in each team and lead by a volunteer team leader using the ORCD's laptop, overhead projector and the sound system in local clubs, school premises or participants' houses. The ORCD investigator including the physician and an information technology person will facilitate the education programs. The interpretations or additional explanations will be made by the physician following WHO guidelines and recommendations[36]. The investigator will maintain a folder for each team and will communicate at least with the team leaders by phone calls once every week to remind them to adhere to lifestyle modification intervention program. The weekly monitoring program will continue until the study ends.
89442226|NCT04505150|No Intervention|lifestyle change activities: non-monitoring|The control group will only receive the printed materials, no active monitoring
89442227|NCT02322060||Primary ovarian insufficiency|"Primary ovarian insufficiency (POI; also known as premature ovarian failure/dysfunction/insufficiency or premature menopause) is characterised by amenorrhoea, sex hormone (oestrogen, progesterone and testosterone) deficiency and elevated gonadotrophins levels in a woman aged more than two standard deviations below the mean age of menopause estimated for her reference population. POI is defined as a disorder in ovarian function in any woman before the age of 40 years, irrespective of the cause.~In our study, we mainly recruit POI patients who also desire to have a baby of their own."
89442228|NCT02322060||Ovarian resistance syndrome|We currently also include patients diagnosed with Ovarian resistance syndrome, which means that follicles exist, but do not response to FSH.
89442229|NCT04505228|Experimental|Research group|The patients receiving Atropine and the extra Chinese herb formulas treatment
89442230|NCT04505228|Active Comparator|Control group|The patients receiving the basic treatment of atropine
89442231|NCT02316054||diabetes and MPHI|myocardial perfusion heterogeneity imaging
89442232|NCT02322138|Experimental|Experimental 1 Infant Formula|Milk-based infant formula without prebiotics
89442233|NCT02322138|Experimental|Experimental 2 Infant Formula|Milk-based infant formula with prebiotics
89442234|NCT02322138|Other|Human Milk-Fed Reference Group|Breast fed infants
89442235|NCT05584826|Experimental|MDMA-Assisted Therapy|Participants will receive two doses of MDMA, administered during the Treatment Period with manualized therapy. This 8-week Treatment Period includes two Preparatory Sessions and four Integrative Sessions of non-drug therapy.
89442236|NCT02324400|Active Comparator|Treatment|
89442237|NCT02324400|Sham Comparator|Control|
89442238|NCT02573350|Experimental|Delamanid 100 mg BID + OBR|Participants received Delamanid 100 milligrams (mg) (2x50 mg tablets), orally, twice daily (BID) along with at least 4 additional anti-TB medications per optimized background regimen (OBR) from Week 0 to Week 26. Participants were administered OBR as directed by the given investigator based on WHO guidelines and clinical judgment.
89442239|NCT02573350|Experimental|Delamanid 200 mg BID + OBR|Participants received Delamanid 200 mg (4x50 mg tablets), orally, BID along with at least 4 additional anti-TB medications per OBR up to Week 26. Participants were administered OBR as directed by the given investigator based on WHO guidelines and clinical judgment. A participant might have been titrated to Delamanid 200 mg BID after an initial hospitalization of 2 weeks. Participants were grouped according to the longest duration of Delamanid dose administered during the study.
89442240|NCT02322294|Experimental|Glucodia™|
89442241|NCT02322294|Placebo Comparator|Placebo|
89442242|NCT02322372|Active Comparator|Group F|"Ultrasound-guided femoral blockade with 15 mL of bupivacaine 0.5% diluted in 15 mL saline was performed in supine position. Then the patient was turned to lateral decubitus position with the operated extremity on dependant position and intrathecal injection of heavy bupivacaine 1 mL (5 mg) was administered from L3-L4 intervertebral space at a rate of 1 mL/20 second.~."
89442243|NCT02322372|Active Comparator|Group S|The patient was turned to lateral decubitus position with the operated extremity on dependant position and intrathecal injection of heavy bupivacaine 2 mL (10 mg) was administered from L3-L4 intervertebral space at a rate of 1 mL/20 second.
89442244|NCT01376804|Experimental|Valganciclovir|Participants received a once daily oral dose (solution or tablets) of valganciclovir starting within 10 days of kidney transplant for up to 200 days post-transplant. Dose (in milligrams) was calculated using the algorithm [7 * Body Surface Area * Creatinine Clearance].
89442245|NCT02322450|Experimental|A: P1-QGC001 - Washout-placebo - P2-placebo|The first period (P1) will correspond either to QGC001 or placebo, the second period (P2) will correspond either to QGC001 or placebo.
89442246|NCT02322450|Experimental|B: P1-placebo - Washout-placebo - P2-QGC001|The first period (P1) will correspond either to QGC001 or placebo, the second period (P2) will correspond either to QGC001 or placebo.
89442247|NCT03500250||Nurses|Nurses working on the neurological wards of three hospitals (one university hospital and two general hospitals)
89442248|NCT05526118||AHORA group|All 50 prospective subjects are enrolled into a single cohort, all subjects must meet inclusion/exclusion criteria
89442249|NCT03122132||Spanish cohort with HCV treated with DAA|Spanish cohort with HCV treated in real practice with ombitasvir/paritaprevir/ritonavir 8 weeks and dasabuvir 8 weeks
89442250|NCT04461912|Experimental|Cataract|Participants with diverse types and severities of cataract, that should realize phacoemulsification surgery
89442251|NCT04461912|Placebo Comparator|Control|Participants on which the presence of cataract have been excluded
89442252|NCT03351686|Experimental|tranexamic acid group|
89442253|NCT03351686|No Intervention|non tranexamic (control) group|
89442254|NCT02324556||Laparoscopic total mesorectal excision|Patients operated with laparoscopic total mesorectal surgery for rectal cancer
89442255|NCT02324556||transanal total mesorectal excision|Patients operated with a combined transanal and laparosocopic total mesorectal surgery for rectal cancer
89442256|NCT03347942|Experimental|Intervention|During a period of 30 days the research participant in the intervention group will be instructed to wait at least 20 minutes after finishing the first portion of meals previously considered sufficient by the individual before being served again if he or she feels the need.
89442257|NCT03347942|Other|Control|The control group will also serve the dish the same way, but you can serve additional portion without waiting.
89442258|NCT04461990||Luminal|"Luminal A：ER+ and/or PR+,HER2- Luminal B：ER+ and/or PR+,HER2+~* ER:estrogen receptor PR:progesterone receptor HER2:human epidermalgrowth factor receptor-2"
88925925|NCT03524911|Experimental|CHFFF nutrition education|Expanded Food and Nutrition Education (EFNEP) participants in 5 NY counties in 2015
89442259|NCT04461990||HER2 overexpression|"ER- PR-,HER2+~* ER:estrogen receptor PR:progesterone receptor HER2:human epidermalgrowth factor receptor-2"
89442260|NCT04461990||Triple negative|"ER- PR-,HER2-~* ER:estrogen receptor PR:progesterone receptor HER2:human epidermalgrowth factor receptor-2"
89442261|NCT03351530||Pre-diabetes|
88925926|NCT03523520|Active Comparator|Methylnaltrexone oral tablets|"Methylnaltrexone oral tablets (total 450 mg) + subcutaneous water injection~Eligible patients with complaint of opioid-induced constipation will receive this treatment after study enrollment. Time to bowel movement will be recorded until 3 hours in the emergency department, and patient will be contacted after 24 hours if bowel movement was not achieved after the 3 hours."
88925927|NCT03523520|Active Comparator|Methylnaltrexone subcutaneous injection|"Methylnaltrexone 12mg subcutaneous injection + sugar placebo tablet~Eligible patients with complaint of opioid-induced constipation will receive this treatment after study enrollment. Time to bowel movement will be recorded until 3 hours in the emergency department, and patient will be contacted after 24 hours if bowel movement was not achieved after the 3 hours."
89442262|NCT03351530||Diabetes|
89442263|NCT03351530||Diabetes with periodontal disease|
89442264|NCT03351530||Periodontal patient|
89442265|NCT03351530||Healthy person|
89442266|NCT02318862|Other|GERD|Those who have abnormal pH and abnormal esophageal mucosa and those who have abnormal pH and normal esophageal mucosa and are scheduled for standard of care esophagogastroduodenoscopy (EGD) with mucosal impedance testing
89442267|NCT02318862|Other|non-GERD|Those who have normal pH and normal esophageal mucosa and are scheduled for standard of care esophagogastroduodenoscopy (EGD) with mucosal impedance testing
89442268|NCT03347864|Experimental|68Ga-NOTA-RM26 PET/CT|The patients were injected with 1.85 MBq per kilogram body weight of 68Ga-NOTA-RM26 in one dose intravenously and underwent PET/CT scan 30-45 min later
89442269|NCT03494400|Experimental|Presential Aerobic Training with Hormone Therapy|A group of women with breast cancer who use Tamoxifen or Aromatase Inhibitor and will perform presential aerobic training.
89442270|NCT03494400|Active Comparator|Presential Aerobic Training without Breast Cancer|A group of women without breast cancer who use Aromatase Inhibitor and will perform presential aerobic training.
89442271|NCT03494400|Experimental|Home-based Aerobic Training with Hormone Therapy|A group of women with breast cancer who use Tamoxifen or Aromatase Inhibitor and will perform home-based aerobic training.
89442272|NCT03494400|Active Comparator|Home-based Aerobic Training without Breast Cancer|A group of women without breast cancer who use Aromatase Inhibitor and will perform aerobic training home-based.
89442273|NCT04503200|Active Comparator|Double guidewire|
89442274|NCT04503200|Active Comparator|Transpancreatic precut|
89442275|NCT02319018|Experimental|Treatment (alisertib, mFOLFOX)|Patients receive alisertib PO BID on days 1-3 and mFOLFOX regimen comprising oxaliplatin IV over 2 hours on day 2, leucovorin calcium IV over 2 hours on day 2, and fluorouracil IV continuously over 46 hours on days 2-4. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
89442276|NCT05584748|Experimental|Simulation group|During anodal stimulation, the participants will receive 1.5 mA of constant current over the site for 20 min, with a 15-second ramp up and scale down at the beginning and the end of the procedure.
89442277|NCT05584748|Sham Comparator|Sham group|In the sham stimulation condition, the current will only be administered during the first 30 seconds and last 30 seconds of the 20-minute window.
89442278|NCT02574520|Placebo Comparator|Part 1|SABER-Bupivacaine and Saline Placebo
89442279|NCT02574520|Active Comparator|Part 2|SABER-Bupivacaine and Bupivacaine HCl
89442280|NCT04425226|Experimental|Pembrolizumab plus Lenvatinib|Participants receive intravenous (IV) pembrolizumab at 200 mg on Day 1 of each 21-day cycle. Number of cycles: until >42 days before liver transplantation or unacceptable toxicity develops. Patients receive Lenvatinib 8-12mg(basing on weight), once a day, oral at least 38 days of each 6 weeks cycle until >7 days before liver transplantation.
89442281|NCT04425226|No Intervention|Comparator|Participants are advised to stay as healthy as possible and wait regularly
89442282|NCT03497052||Group 1|Oocytes and embryos will be cultured in GEMS single step medium (in vitro culture in medium 1)
89442283|NCT03497052||Group 2|Oocytes and embryos will be cultured in IRVINE single step medium (in vitro culture in medium 2)
89442284|NCT03351452|Experimental|Real tDCS|20 min of 2 mA real anodal transcranial direct current stimulation applied via 5x7 cm rubber electrode over the VLPFC (current density: 0.057 mA/cm2) and cathodal 10x10 rubber electrode over supraorbital region (current density: 0.02 mA/cm2). Additional ramp-up and ramp-down phase of 15 s at the beginning and the end of stimulation.
89442285|NCT03351452|Experimental|Real tACS|20 min of 2 mA real transcranial alternating current stimulation in theta frequency applied via 5x7 cm and 10x10 cm rubber electrodes over the VLPFC (current density: 0.057 mA/cm2) and supraorbital region (current density: 0.02 mA/cm2). Additional ramp-up and ramp-down phase of 15 s at the beginning and the end of stimulation.
89442286|NCT03351452|Sham Comparator|Sham tES|30 s of 2 mA sham transcranial electric current stimulation applied via 5x7 cm and 10x10 cm rubber electrodes over the VLPFC (current density: 0.057 mA/cm2) and supraorbital region (current density: 0.02 mA/cm2). Additional ramp-up and ramp-down phase at beginning and end of stimulation lasting for 15 s. Electrodes remain attached to the participant's head for the duration of the encoding phase of the memory task.
89442287|NCT05520658|Active Comparator|group A|patients will receive intralesional combined digoxin and furosemide , one session every 2 weeks for maximum 6 sessions
89442288|NCT05520658|Active Comparator|group B|patients will receive intralesional 5 fluorouracil mixed with 1ml of 2% lignocaine and epinephrine one session every 2 weeks for maximum 6 sessions .
89442289|NCT02324634|Experimental|ES intervention|Electrical stimulation (ES) twice a day, 5 days a week, for 3 months
89442290|NCT02324634|No Intervention|Control|Usual care only
89442291|NCT02322606|Other|Cohort 1: TAK-137 5 mg, TAK-137 placebo|Single-dose administration in a fasting state
89442292|NCT02322606|Other|Cohort 2: TAK-137 10 mg, TAK-137 placebo tablet|Single-dose administration in a fasting state
89442293|NCT02322606|Other|Cohort 3: TAK-137 20 mg or TAK-137 2 mg + TAK-137 placebo|Single-dose administration in a fasting state
89442294|NCT02322606|Other|Cohort 4: TAK-137 5mg, TAK-137 placebo|Once daily for 7 days in a fasting state
89442295|NCT02322606|Other|Cohort 5: TAK-137 10 mg, TAK-137 placebo|Once daily for 7 days in a fasting state
89442296|NCT02322606|Other|Cohort 6: TAK-137 15 mg, TAK-137 placebo|Once daily for 7 days in a fasting state
89442297|NCT05526040|Experimental|Intervention|Standard medical nutrition therapy with Immunonutrition
89442298|NCT05526040|Active Comparator|Control|Standard medical nutrition therapy
89442299|NCT03351374||Temple Physicians Incorporated|A community-based provider, operating 32 primary care sites
89199722|NCT04271189|Experimental|POLYCHEM|Metformin (extended release), Pioglitazone, Sitagliptin and Empaglifozin.
89442300|NCT03351374||WhiteBark|For profit entity created by the Indiana Rural Health Association
89442301|NCT03351374||Drexel Family Intervention Science|Academic center that developed and deployed Attachment Based Family Therapy (ABFT) assessment, treatment, and prevention models with an interest in adolescents struggling with substance abuse, depression, trauma, and suicidality.
89442302|NCT03351374||Bon Secours Health System|A primary care clinic in Baltimore that provides care services to a population in a lower socioeconomic status in downtown Baltimore.
89199723|NCT04271189|Active Comparator|STANDARD CARE|Standard of care according to the local health service.
89442303|NCT03351374||Howard University Hospital CARES|A project provides free outpatient medical, dental, mental health, nutrition and social services for HIV positive uninsured and underinsured residents of the District of Columbia.
89442304|NCT05520580|No Intervention|Conventional Group|Received a classic CS without intervention (Control group)
89442305|NCT05520580|Experimental|Assisted group|after uterotomy during CS, the mother was instructed and motivated to push for the delivery of the head and the shoulders of the baby. Simultaneously, the surgical assistant applied fundal pressure to support the mothers pushing if necessary.
89442306|NCT04462926|Experimental|[68Ga]Ga-PSMA-11 PET/CT|1.8-2.2 MBq (0.049-0.060 mCi) per kilogram bodyweight will be injected intravenously prior to perform the PET/CT
89442307|NCT02319096|Experimental|Patients with stress incontinence|Patients who present to urogynaecology clinic with proven stress urinary incontinence who will be offered Whole body vibration therapy.
88925928|NCT03523520|Active Comparator|Naloxegol oral tablets|"Naloxegol oral tablets (total 25 mg) + subcutaneous water injection~Eligible patients with complaint of opioid-induced constipation will receive this treatment after study enrollment. Time to bowel movement will be recorded until 3 hours in the emergency department, and patient will be contacted after 24 hours if bowel movement was not achieved after the 3 hours."
88925929|NCT03518242|Experimental|Treatment (Specimen collection, chemotherapy)|"SPECIMEN COLLECTION: Patients undergo collection of tumor tissue and peripheral blood samples for analysis via next generation sequencing to identify novel pathways in the pathogenesis of breast cancer.~TREATMENT: Patients are invited to participate in a treatment study. Patients receive cyclophosphamide PO daily on days 1-21, methotrexate PO QD on days 1, 8, and 15, and capecitabine PO BID on days 1-14. Treatment repeats every 21 days for 8 cycles in the absence of disease progression or unacceptable toxicity."
88925930|NCT03501719||Triple ART|Patients who remain in triple ART during the follow-up.
88925931|NCT03501719||Dual ART|Patients switched to dual ART during the follow-up.
88925932|NCT03501719||Monotherapy|Patients switched to monotherapy during the follow-up.
88925933|NCT03500549|Experimental|Pegcetacoplan|1080 mg pegcetacoplan administered subcutaneously twice-weekly or every three days.
88925934|NCT03500549|Active Comparator|Eculizumab|Complement (C5) Inhibitor.
89442308|NCT03494244||ADM|Patients having undergone direct-to-implant breast reconstruction using acellular dermal matrix.
89442309|NCT03494244||Non-ADM (Vicryl)|Patients having undergone direct-to-implant breast reconstruction using non-acellular dermal matrix mesh (Vicryl mesh).
88925935|NCT03495557|Sham Comparator|Control|Simple closure
88925936|NCT03495557|Experimental|Experimental|Simple closure + mesh
88925937|NCT03481608|Active Comparator|Olive Oil Shake|"Intervention: No Lauric Acid~A breakfast shake made from a complete meal shake will be prepared with water and supplemented with 2 tablespoons of olive oil."
89199724|NCT04243551|Active Comparator|Latiglutenase|IMGX003
89442310|NCT05584592|Experimental|Intergrate early palliatuve care + Conventional chemotherapy|
89442311|NCT05584592|Active Comparator|Conventional chemotherapy|
89442312|NCT02322684|Active Comparator|Group Q|Blind endotracheal intubation will be performed through the air-Q
89442313|NCT02322684|Active Comparator|Group B|Blind endotracheal intubation will be performed through the air-Q with bougie assisted
89442314|NCT05516056|Experimental|ERAS group|First 50 patients included in the ERAS pathway for cholecystectomy in CHUK, Rwanda
89442315|NCT02324712|Active Comparator|Acupuncture|Acupuncture treatment for TMD
89442316|NCT02324712|Sham Comparator|Sham Acupuncture|Acupuncture treatment for TMD using the non-penetrating Park Sham Acupuncture Device
89442317|NCT04503044||CT Lung Cancer Screening Patients|All CT Lung Cancer Screening patients at LHMC from January 1st, 2012 to September 30th, 2014 with an in-network PCP that had baseline CT scans will be scored. A subset of these patients with T4 screening scans will be scored for progression.
89442318|NCT02322918||Participants admitted to BCPP|Blood or saliva samples will be collected from participants for whole genomic/transcriptomic sequencing
88925938|NCT03481608|Experimental|Coconut Oil Shake|"Intervention: Lauric Acid~A breakfast shake made from a complete meal shake will be prepared with water and supplemented with 2 tablespoons of coconut oil."
88925939|NCT03480217|Experimental|Multifaceted Implementation Strategy|Patients will be screened for hypertension by primary care providers, registered nurses, medical assistants, and front desk staff from clinics randomized to receive the intervention, Multifaceted Implementation Strategy.
88925940|NCT03480217|No Intervention|Usual Care|Patients will be screened for hypertension by primary care providers, nurses, medical assistants, and front desk staff of clinics randomized to the usual care group that do not intentionally receive any parts of the multifaceted implementation strategy.
88925941|NCT03463018|Experimental|Echinacea angustifolia|20 mg tablet of Echinacea angustifolia root extract standardized for a specific alkamide profile, two tablets twice daily (total daily dose of 80 mg) for two weeks
88925942|NCT03463018|Placebo Comparator|Placebo|Identical excipients as in the experimental arm, without the active ingredient
88925943|NCT03441776|Other|Randomized GVRT|Randomized Generalized Vestibular Rehabilitation Treatment (8 treatments) as part of standard of care (not research visits)
88925944|NCT03441776|Other|Randomized IVRT|Randomized Individualized Vestibular Rehabilitation Treatment (3 treatments) as part of standard of care (not research visits)
88925945|NCT03438838|Active Comparator|Laparoscopic Heller's Myotomy (LHM)alone|A minimum 10 patients undergo Laparoscopic Heller's myotomy alone
88925946|NCT03438838|Active Comparator|LHM with Anterior Fundoplication|A Minimum 10 patients undergo Laparoscopic Heller's myotomy along with fundoplication
88925947|NCT03435185|Active Comparator|Blockade Group|Lidocaine injections. Procedure. Grater occipital nerve and supraorbital nerve were blocked with %2 lidocaine. These injections were repeated weekly for three weeks. After treatment was completed, patients were followed up for 2 months at the polyclinic to assess the clinical response.
89199725|NCT04243551|Placebo Comparator|Placebo|Placebo
89442319|NCT03351140||Subjects with breast cancer|Approximately 30 subjects who have confirmed diagnosis of breast cancer will be included in the study
89442320|NCT03351140||Subjects with prostate cancer|Approximately 30 subjects who have confirmed diagnosis of prostate cancer will be included in the study
89442321|NCT03351140||Subjects with NSCLC|Approximately 30 subjects who have confirmed diagnosis of NSCLC will be included in the study
89442322|NCT03351140||Subjects with multiple myeloma|Approximately 30 subjects who have confirmed diagnosis of multiple myeloma excluding smoldering/asymptomatic multiple myeloma will be included in the study
89442323|NCT03351140||Subjects with DLBCL or follicular lymphoma|Approximately 30 subjects who have confirmed diagnosis of DLBCL or follicular lymphoma will be included in the study
89442324|NCT02319252|Active Comparator|Gastric tube|A gastric tube is used
89442325|NCT02319252|Active Comparator|Jejunal tube|A jejunal tube is used
89442326|NCT05520424|Experimental|The Daily Supplement|Participants will use test product daily, and complete Biomarker assessments (at 1st dose, Day 7, Day 31), as well as surveys (at 1st dose, Day 7, Day 31), and Cognitive battery Assessments (at 1st dose, Day 7, Day 31).
89442327|NCT02319330|Experimental|Phone counseling intervention|Treatment as usual (TAU) plus a nurse-delivered mobile phone counseling intervention delivered at weeks 1 to 12, 14, and 16 post-randomization.
89442328|NCT02319330|Active Comparator|Treatment as Usual|Routine HIV clinic-based counseling
89442329|NCT05081362|Other|COVID-severe|patient recovered from severe COVID desease
89442330|NCT05081362|Other|COVID-moderate|patient recovered from moderate COVID desease
89442331|NCT05081362|Other|COVID-mild|patient recovered from mild COVID desease
89442332|NCT05584436||oocytes obtained without flushing|First accessible follicle larger than 12 mm
89442333|NCT05584436||oocytes obtained after flushing|Oocytes obtained after a total of 6 cc flushing of follicles that oocyte cumulus complex could not be obtained after the first aspiration
89442334|NCT02324790|Experimental|Treatment|Treated with iNAP® Sleep Therapy System on the treatment PSG night.
89442335|NCT03351062|Active Comparator|Tamoxifen treatment group|Patients in this group will receive tamoxifen treatment.
89442336|NCT03351062|Active Comparator|Toremifene treatment group|Patients in this group will receive Toremifene treatment.
89442337|NCT03496818||Crohn's Disease|Participants age 18-80 years old, diagnosed with Crohn's disease with active disease based on MR enterography or CT enterography confirmed within the prior 90 days.
89442338|NCT03496818||Healthy controls|Participants age 18-80 years old, with no diagnosis of inflammatory bowel disease.
89442339|NCT02324868|Experimental|Shower patch IV catheter protection|Newly developed waterproof catheter dressing may be used for bathing activities
89442340|NCT02324868|Other|Conventional IV catheter protection|No specific dressing will be provided to the patient to protect the catheter entry site during bathing activities.
89442341|NCT05515900|Experimental|Sodium active, HMB active|The subjects in this group will take sodium pills of 2,000 mg/day from baseline to week 8, and take HMB pills of 3 g/day from week 5 to week 8 while on reduced-sodium diet.
89442342|NCT05515900|Experimental|Sodium active, HMB placebo|The subjects in this group will take sodium pills of 2,000 mg/day from baseline to week 8, and take placebo pills of 3 g/day from week 5 to week 8 while on reduced-sodium diet.
89442343|NCT05515900|Experimental|Sodium placebo, HMB active|The subjects in this group will take placebo pills from baseline to week 8, and take HMB pills of 3 g/day from week 5 to week 8 while on reduced-sodium diet.
89442344|NCT05515900|Placebo Comparator|Sodium placebo, HMB placebo|The subjects in this group will take placebo pills from baseline to week 8 while on reduced-sodium diet.
89442345|NCT03496740|Active Comparator|Penile Block|"Ultrasound guided dorsal penile nerve block will be administered after general anesthesia.~0,25% Bupivacaine 0,5ml/kg (max. 20ml) will be used for the blocks"
89442346|NCT03496740|Active Comparator|Pudendal Block|Nerve stimulator-guided pudendal block. 0,25% Bupivacaine 0,5ml/kg (max. 20ml) will be used for the blocks
89442347|NCT04888676|Experimental|Self- Adhesive Bulk fill Resin Composite ( Surefil one™ ,Dentsupply Sirona)|New Surefil one™ restorative Self-adhesive: no etching, bonding or cavity conditioning inserted in increments of up to 4 mm in thickness.
89442348|NCT04888676|Active Comparator|Bulkfill Resin Composite. (Tetric N-Ceram Bulk Fill )|after selective etching of enamel and bonding, the bulk-fill composite resins are inserted in increments of up to 4 mm in thickness.
89442349|NCT04504760|Experimental|ONO-2910 (Part A and B)|
89442350|NCT04504760|Placebo Comparator|Placebo (Part A)|
89442351|NCT04504760|Experimental|ONO-2910 (Part C and D)|
89442352|NCT04504760|Placebo Comparator|Placebo (Part C and D)|
89442353|NCT05525884||MAFLD and Non-MAFLD|
89442354|NCT05525884||Steatosis and Non-Steatosis|
89442355|NCT05525884||Fibrosis and Non-Fibrosis|
89442356|NCT02324946||Study Group|Mass Screening
89442357|NCT05520268|Experimental|Conventional music therapy (CMT)|Participants receive 10 weeks of CMT and standard care.
89442358|NCT05520268|Experimental|Digital music rehabilitation (DMR)|Participants receive 10 weeks of DMR and standard care.
88925948|NCT03435185|Placebo Comparator|Placebo Group|Saline injections. Procedure. Grater occipital nerve and supraorbital nerve were injected with saline.These injections were repeated weekly for three weeks. After treatment was completed, patients were followed up for 2 months at the polyclinic to assess the clinical response.
88925949|NCT03423069|Experimental|Diet low in FODMAPs|Diet low in FODMAPs (diet A) during 12 weeks (with intermediate nutritional checks every 4 weeks) before returning to the final study visit.
89442359|NCT05520268|No Intervention|Standard care|Participants receive only standard care. Standard care comprises normal care services received by the PWDs in the Finnish health care system.
89442360|NCT02443896|Experimental|Sealant applied to molars|"All 'sealable' permanent molars will be sealed: Occlusal fissures and where appropriate, buccal pits (on lower molars) and palatal pits (on upper molars) will be sealed.~If patient compliance is adequate, a resin based sealant will be used as the first choice material. The tooth is thoroughly cleaned, prepared with a special solution, and dried. The liquid sealant is then applied and allowed to set hard."
89442361|NCT02443896|Sham Comparator|No sealant applied to molars.|No molars will be sealed.
89442362|NCT05515822|Active Comparator|Dezocine group|Dezocine (1ml: 5mg) was administered 30 minutes before the end of surgery (0.15mg/kg i.v.) and during patient controlled intravenous analgesia (Dezocine 30mg+ Tropisetron 10mg+Saline, total 200ml)
89442363|NCT05515822|Experimental|Oxycodone group|Oxycodone (1ml: 10mg) was administered 30 minutes before the end of surgery (0.15mg/kg i.v.) and during patient controlled intravenous analgesia (Oxycodone 30mg+ Tropisetron 10mg+Saline, total 200ml)
89442364|NCT05515822|Experimental|Esketamine+Oxycodone group|Esketamine (2ml: 50mg) was administered 5 minutes before incision (0.15mg/kg i.v.), while Oxycodone was administered 30 minutes before the end of surgery (0.15mg/kg i.v.) and during patient controlled intravenous analgesia (Oxycodone 30mg+ Tropisetron 10mg+Saline, total 200ml)
89442365|NCT05520112|Experimental|Patients with Recurrent Pregnancy Loss receiving standard treatment and autologous MSC|Experimental: Patients with Recurrent Pregnancy Loss receiving standard treatment and autologous MSC
89442366|NCT05520112|Active Comparator|Standard treatment according to the clinical protocols|Standard treatment of Recurrent Pregnancy Loss according to the clinical protocols
89442367|NCT03496584|Active Comparator|Pomegranate Juice|Postprandial high fat meal will be administered with pomegranate juice with the first dose of the intervention, Pomegranate Juice , followed by 12 weeks of pomegranate juice consumption.
89442368|NCT03496584|Placebo Comparator|Placebo Juice|Postprandial high fat meal will be administered with pomegranate juice with the first dose of the intervention, Placebo Juice , followed by 12 weeks of pomegranate juice consumption.
89442369|NCT02322996||open label|After the surgery and the onset of moderate-severe pain, QST and PROMIS questionnaires will be repeated. Throughout these procedures, patients will rate their pain perception using a numeric rating scale. Approximately 2-3 hours after surgery at the onset of moderate pain, the rescue analgesic (toradol) will be administered via intramuscular injection. Again, QST and PROMIS protocols will be repeated after the drug is given and when patients report pain relief. A standard naproxen dose of 500 mg will be given to patients upon leaving the clinic and they will be instructed to take one pill orally each day before returning for evaluation after 48 hours.
89442370|NCT04294654|Experimental|Vortioxetine|5 - 20 mg/day tablets
89442371|NCT04772144|Experimental|Intervention group|
89442372|NCT04772144|No Intervention|Control group|
89442373|NCT05525728|Other|patient|One cohort of patients
89442374|NCT03496506|Experimental|Sequential treatment arm|Subjects receive 1 tablet of selexipag twice daily from Day 1 to Day 9 and 1 tablet in the morning of Day 10. In the morning of Day 4 and 1 hour before the administration of selexipag, they receive 4 tablets of clopidogrel. Then from Day 5 to Day 10, 1 hour before the morning administration of selexipag, they receive 1 tablet of clopidogrel .
89442375|NCT02325024|Experimental|Renally Impaired Subjects|"Treatment group consists of subjects with severe renal impairment or ESRD and in accordance with the following criteria;~Clinically significantly abnormal creatinine and creatinine clearance (CLcr <30 mL/min) and not requiring dialysis.~Onset of renal impairment must have been documented at least 3 months prior to study start."
89501664|NCT02258893|Experimental|NO2 Scrubber, then Control, then HEPA filter|Participants will have 3 periods of 4 weeks with each filter with a 1 week washout between phases in the order of NO2 Scrubber, then Control, then HEPA filter
88925950|NCT03423069|Active Comparator|Specific dietary advice for IBS|Dietary advice for IBS (diet B) during 12 weeks (with intermediate nutritional checks every 4 weeks) before returning to the final study visit.
89442376|NCT02325024|Experimental|Matched subjects with Normal Renal Function|Group consists of healthy subjects (as determined by medical history, physical examination, biochemistry, hematology, urinalysis, hepatitis B and C, and HIV testing) who demonstrate normal renal function (CLcr > 80 mL/min) and are individually matched to renally impaired subjects with respect to age (within the decile or five years, whichever is less), gender, and Body Mass Index (BMI) (+/- 10% BMI).
89442377|NCT05525650|Experimental|1Arm A|As the maintenance UNIT, 200 PAU
89442378|NCT05525650|Placebo Comparator|1Arm B|Placebo arm of 1Arm A.
89442379|NCT05525650|Experimental|2Arm C|As the maintenance UNIT, 400 PAU
88925951|NCT03417349||Aspiration thrombectomy|Patients with acute ischemic stroke of the anterior circulation whom the treating physician deemed eligible to be treated with SOFIA™/ SOFIA™ as a first line treatment technique
88925952|NCT03411889|Experimental|functional lacrimal delay|Participants shown to have functional delay on DSG will be included. The intervention will be an MRI scan during tear drainage
88925953|NCT03410342|Placebo Comparator|Low Fruits and Vegetables (LFV)|"1 portion of fruits plus 1 portion of vegetables, of commonly consumed types per day.~Intakes are at 25th percentile of UK consumption (NDNS) and will exclude citrus fruits, cruciferous and allium vegetables."
88925954|NCT03410342|Experimental|High Fruits and Vegetables (HFV)|4 portions of fruits plus 4 portions of vegetables, of commonly consumed types per day excluding citrus fruits, cruciferous and allium vegetables.
88925955|NCT03410342|Experimental|High Citrus fruits and Cruciferous vegetables (CC)|4 portions of citrus fruits plus 4 portions of cruciferous vegetables per day excluding any other types of fruits and vegetables including allium vegetables.
88925956|NCT03383380|Experimental|Rapamycin|Treatment for patients with activated phosphoinositide 3-kinase δ syndrome
88925957|NCT03373097|Experimental|GD2-CART01|After a lymphodepleting regimen the patients will receive 1.0 to 10.0 x 10⁶/kg GD2 Chimeric Antigen Receptor (CAR) positive T cells.
88925958|NCT03366792|Experimental|MRI Targeted Biopsy|
88925959|NCT03350997|Experimental|Trial 1|Subjects will have two CGM devices placed on either side of the abdomen, near the belly button. Trial 1 Exercise - subjects will use a mouthpiece and nose clip (which will allow all of their expired air to pass through the metabolic cart for analysis of oxygen consumption and carbon dioxide production) for ~5 min at the beginning, middle and toward the end of exercise to verify they are exercising at 65% of VO2peak. This will allow us to accurately measure energy expenditure (kcal) during exercise. One hour after the exercise session, participants will eat a standardized dinner which includes the energy expended from their exercise session (+ 350 kcal).
88925960|NCT03350997|Experimental|Trial 2|Subjects will have one CGM device placed on one side of the abdomen. Trial 2 Exercise - subjects will exercise at 65% of VO2peak. One hour after the exercise session, participants will eat a standardized dinner which will NOT include the energy expended from their exercise session (- 350 kcal).
88925961|NCT03348020|Experimental|Baseline Clinical Trial|Before blood donation, subjects will participate in a baseline clinical trial where the research team will perform a series of metabolic tests as described in the detailed study description.
88925962|NCT03348020|Experimental|Post-Blood Donation Clinical Trial|1 month after blood donation, subjects will participate in post-blood donation clinical trial where the research team will perform a series of metabolic tests as described in the detailed study description.
88925963|NCT03342053|Experimental|RO7234292 Monthly|RO7234292 is administered every 28 days intrathecally for 14 months.
88925964|NCT03342053|Experimental|RO7234292 Bimonthly|RO7234292 is administered every 56 days intrathecally for 14 months following 2 monthly doses to serve as a loading dose.
88925965|NCT03325777|Experimental|Approach Bias Retraining Group|Individuals in this condition will receive seven sessions of ABR training in which they are instructed to approach (pull the joystick) images tilted to the right and avoid (push the joystick) images tilted to the left. They will be told that the training may weaken automatic cigarette-approach and strengthen automatic cigarette-avoidance. Furthermore, they will be told that the opposite effect will be true for the stimuli not related to cigarettes (i.e., the positive stimuli).
88925966|NCT03325777|Sham Comparator|Control Group|Individuals in this condition will receive seven sessions of SHAM training in which they are instructed to approach (pull the joystick) images tilted to the right and avoid (push the joystick) images tilted to the left. They will be told that the purpose of the training is to improve control over these automatic tendencies and that following the training sessions, they will easily be able to push or pull the stimuli regardless of content.
88925967|NCT03314506|Experimental|Trial|Subjects will need to come to the Substrate Metabolism Laboratory in the morning around 7:00 AM. After about a 15-30 minute rest, the study team will collect a blood sample from the subject's hand or forearm. The study team will also obtain a small sample of fat tissue from the area just underneath the skin near the belly button. Next, subjects will exercise on a treadmill at a moderate intensity for about 1 hour. Immediately after exercising the study team will collect a blood sample. The subject will remain resting in the laboratory for 3 hours after exercise, and then the study team will collect another blood and fat tissue sample. Upon completion, the subject will be provided a snack before leaving the laboratory.
88925968|NCT03302520|Experimental|Novomax|Novomax(R) ceramic glass spacer for interbody fusion
88925969|NCT03302520|Active Comparator|PEEK cage|PEEK cage for interbody fusion
88925970|NCT03297476||high-risk group|"Selected by High-risk subtype detection panels"
88925971|NCT03297476||non high-risk group|"Selected by High-risk subtype detection panels"
89442380|NCT05525650|Placebo Comparator|2Arm D|Placebo arm of 2Arm C.
89442381|NCT05525650|Experimental|3Arm E|As the maintenance UNIT, 800 PAU
89442382|NCT05525650|Placebo Comparator|3Arm F|Placebo arm of 3Arm E.
89442383|NCT03132324|Experimental|INCB059872 0.5 mg|INCB059872 0.5 mg tablet administered orally every other day (QOD) for 28 days on an empty stomach. If dose was well tolerated, once daily (QD) administration was evaluated independently and in parallel with QOD administration.
89442384|NCT03132324|Experimental|INCB059872 1 mg|INCB059872 1 mg tablet administered orally QOD for 28 days on an empty stomach. If dose was well tolerated, QD administration was evaluated independently and in parallel with QOD administration.
89442385|NCT03132324|Experimental|INCB059872 2 mg|INCB059872 2 mg tablet administered orally QOD for 28 days on an empty stomach. If dose was well tolerated, QD administration was evaluated independently and in parallel with QOD administration.
89442386|NCT05519956|Active Comparator|level Ib-covering IMRT|Patients who had level II involvement with extracapsular extension (ECE), and/or had a maximum nodal axial diameter (MAD) of greater than 2cm in level II.
89442387|NCT05519956|Experimental|level Ib-sparing IMRT|Patients who had level II involvement with extracapsular extension (ECE), and/or had a maximum nodal axial diameter (MAD) of greater than 2cm in level II
89442388|NCT03346616|Experimental|Texting Group|"The texting group received a daily text message containing a board style multiple choice question. If the participant wanted immediate feedback, the message contained a link to a website containing the answer to the question along with an explanation, the source material, and a more complete clinical vignette. One hour after the initial text message was sent, a follow up answer text message was delivered. Text messages were sent 6 days per week (Monday through Saturday) at 2 pm and 3 pm."
89442389|NCT03346616|Active Comparator|Non Texting Group|The non-texting group received access to the journal articles from which the text message content was derived, but did not receive any text messages or any of the online material or question stems.
89442390|NCT02319564|Active Comparator|beclomethasone|"beclomethasone dipropionate 250mcg per puff per puff (Chiesi metered dose inhaler) via a masked spacer (Aerochamber Max®, Plattsburgh, NY, USA). One puff BID for 14 days.~Non-identifiable MDI prepared by Chiesi Farmaceutici Inc."
89442391|NCT02319564|Active Comparator|beclomethasone and salbutamol|"beclomethasone diprionate 250mcg and salbutamol 100mcg per puff (Chiesi metered dose inhaler) via a masked spacer (Aerochamber Max®, Plattsburgh, NY, USA). One puff BID for 14 days.~Non-identifiable MDI prepared by Chiesi Farmaceutici Inc."
89442392|NCT02319564|Placebo Comparator|Placebo|"placebo (Chiesi metered dose inhaler) via a masked spacer (Aerochamber Max®, Plattsburgh, NY, USA). One puff BID for 14 days.~Non-identifiable MDI prepared by Chiesi Farmaceutici Inc."
89442393|NCT03122054|Other|Group L (n:88)|patients treated surgically with laparoscopic cholecystectomy immediately
89442394|NCT03122054|Other|Group D (n:88)|patients first treated medically and than treated surgically with delayed (4-8 weeks later) laparoscopic cholecystectomy
89442395|NCT05515510|Active Comparator|Control|"Oral health prevention recommendations (frequency of brushing, technique, diet counselling, fluoride use, etc.) will be provided as usual by the dentist (verbal/oral) according to the current German Ratgeber 2020 (KZBV,2029), which are implemented as standard oral health recommendation at the Department of Preventive and Pediatric Dentistry of Greifswald University.~Parents in the control group will be ask after the intervention, and at the recalls (between 2 and 12 weeks and 3 months), to answer a questionnaire in order to determine their knowledge, behaviour, attitudes and related oral health practices."
89199726|NCT04221945|Experimental|chemoradiotherapy + pembrolizumab|Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 3-week cycle (Q3W) for 5 cycles followed by pembrolizumab 400 mg IV on Day 1 of each 6-week cycle (Q6W) for an additional 15 cycles. During the Q3W dosing period of pembrolizumab, participants receive concurrent chemoradiotherapy. The standard of care chemoradiotherapy regimen includes cisplatin 40 mg/m^2 IV once per week (QW) for 5 or 6 weeks plus external beam radiotherapy (EBRT) followed by brachytherapy with minimum total radiotherapy dose of 80 Gray Units (Gy) for volume-directed and 75 Gy for point-directed given with the total duration of radiation treatment not to exceed 50 days (with an extension to a maximum of 56 days for unforeseen delays).
89442396|NCT05515510|Experimental|Test|"Oral health recommendations will be provided according to the current German Ratgeber 2020 (KZBV,2029), which are implemented as standard at the Department of Preventive and Pediatric Dentistry of Greifswald University. Test arm receives this information with a digital application (FU-APP) in addition to the established oral health recommendation/instruction according to the current German Ratgeber 2020 (KZBV,2020). After the intervention and at the recalls (between 2 and 12 weeks and 3 months), parents will be asked to answer two questionnaires in order to determine their FU-APP acceptance, knowledge, behaviour, attitudes and related practices."
89442397|NCT02325180|Experimental|DHA-PQ|One tablet of dihydroartemisinin-piperaquine consists of 40 mg of dihydroartemisinin and 320 mg of piperaquine. DHA-PQ is administered once daily for 3 days (at enrolment, hour 24 and you 48). Dosing should be given based on body weight. Daily dose for dihydroartemisinin is 2.25 mg/kg (total 6.75 mg/kg) and for piperaquine is 18 mg/kg (total 54 mg/kg).
89442398|NCT02325180|Active Comparator|AL|Half a tablet of artemether-lumefantrine consists of 20 mg of artemether and 120 mg of lumefantrine is given per 5 kg body weight. AL is administered as 6-dose regimens given twice daily for 3 days (at enrolment, hour 8, hour 24, hour 36, hour 48 and hour 60).
89442399|NCT05052658|Active Comparator|Palpation Group|
89442400|NCT05052658|Experimental|Ultrasound Group|
89442401|NCT03499626|Experimental|ASLAN001|A 3+3 study de-escalating dose design will be employed for dose determination. Subjects will receive treatment in 21-day cycles until disease progression, intolerable toxicities or withdrawal of consent.
89501665|NCT02258893|Experimental|HEPA filter, then NO2 scrubber, then Control|Participants will have 3 periods of 4 weeks with each filter with a 1 week washout between phases in the order of HEPA filter, then NO2 scrubber, then Control
89012941|NCT04055038|Experimental|Platinum-based chemotherapy|"This is an experimental arm of this study. Allowed therapeutic options:~Paclitaxel 60-80 mg/m2 + carboplatin area under curve (AUC) 2-2.7 d 1, 8, 15 every 3 or 4 weeks (Q3W or Q4W);~Gemcitabine 1000 mg/m2 d 1, 8 + cisplatin 75 mg/m2 1 every 3 weeks;~Doxorubicin 40-50 mg/m2 d 1 + carboplatin AUC5 or cisplatin 60-75 mg/m2 d 1 every 3 weeks;~Topotecan 0.75 mg/m2 d 1-3 + cisplatin 60-75 mg/m2 or carboplatin AUC 4-5 d 1 every 3 weeks;~Etoposide 100 mg once daily orally d 1-7 + cisplatin 60-75 mg/m2 d1 every 3 weeks.~Up to 6 cycles of chemotherapy will be administered to study participants allocated to this arm."
89012942|NCT04055038|Active Comparator|Non-platinum monochemotherapy|"This is a control arm of this study. Allowed therapeutic options:~Paclitaxel 60-80 mg/m2 weekly (or day 1, 8, 15 every 4 weeks schedule);~Gemcitabine 1000 mg/m2 d 1, 8, 15 every 4 weeks;~Doxorubicin 50-60 mg/m2 d 1 every 3 weeks;~Topotecan 1,2-1,5 mg/m2 d 1-5 every 3 weeks;~Etoposide 100 mg once daily orally d 1-10 every 3 weeks.~Up to 6 cycles of chemotherapy will be administered to study participants allocated to this arm."
89501666|NCT02258893|Experimental|HEPA filter, then Control, then NO2 scrubber|Participants will have 3 periods of 4 weeks with each filter with a 1 week washout between phases in the order of HEPA filter, then Control, then NO2 scrubber
89012943|NCT04054609|Other|FAZA PET/MRI scan|PET/MRI scan using radiotracer 18F-Fluoroazomycin Arabinoside
89012944|NCT04054531|Experimental|KN046 + carboplatin/paclitaxel|KN046 5 mg/kg IV every three weeks (Q3W) +Carboplatin AUC5 IV Q3W x 4 cycles + Paclitaxel 500 mg/m2 IV Q3W x 4 cycles
89012945|NCT04054531|Experimental|KN046 + carboplatin/pemetrexed|KN046 5 mg/kg IV Q3W +Carboplatin AUC5 IV Q3W x 4 cycles + Pemetrexed 500 mg/m2 IV Q3W x 4 cycles
89012946|NCT04054336|Experimental|Inhibition group|The inhibition group gets the instructions to respond to pictures containing soft drinks by swiping/pulling them towards themselves, whereas pictures with alcoholic content shall be ignored. Up on pulling the pictures successively enlarge, whereas they shrink when ignored and slowly fade out.
89012947|NCT04054336|Experimental|Classical AAT group|The classical AAT group is provided with a tablet on which an explicit AAT training is installed. Thus, just as participants in the inhibition group, participants are instructed to react upon soft drinks by swiping/pulling towards themselves the picture. Pictures containing alcoholic content shall be pushed away. Up on pulling pictures enlarge and up on pushing they shrink until they fade out.
89012948|NCT04054336|Sham Comparator|Control group|This type of active control group receives the instructions to swipe alcohol pictures to the left and soft drink pictures to the right (or vice versa depending on the sequential counterbalancing procedure).
89501667|NCT02258893|Experimental|Control, then HEPA filter, then NO2 scrubber|Participants will have 3 periods of 4 weeks with each filter with a 1 week washout between phases in the order of Control, then HEPA filter, then NO2 scrubber
89012949|NCT04517305||Pyrotinib plus vinorelbine|Patients used pyrotinib plus vinorelbine as treatment for metastatic breast cancer.
89012950|NCT00255515|Experimental|1|quetiapine fumarate
89012951|NCT00255515|Active Comparator|2|Conventional treatment for schizophrenia
89012952|NCT00255515|Experimental|3|quetiapine fumarate + Cognitive Remediation Therapy
89012953|NCT04508101||drainage group|Patients satisfying inclusion criteria who underwent either total as well as unicompartmental knee arthroplasty with suction drainage positioning
89012954|NCT04508101||non-drainage group|Patients satisfying inclusion criteria who underwent either total as well as unicompartmental knee arthroplasty without suction drainage positioning
89012955|NCT00289419|Active Comparator|A|
89012956|NCT00289419|Experimental|B|
89012957|NCT04505176||1|20 patients being in the HHHNFC. In this study, it was aimed to monitor continuous oxygen saturation, PI, PVI, transcutaneous PO2 and PCO2 measurements just before, during and after the surfactant application and to compare the results of babies who received nCPAP and HHHFNC support.
89012958|NCT04505176||2|20 patients in the CPAP group. In this study, it was aimed to monitor continuous oxygen saturation, PI, PVI, transcutaneous PO2 and PCO2 measurements just before, during and after the surfactant application and to compare the results of babies who received nCPAP and HHHFNC support.
89012959|NCT01600144||data collection|
89012960|NCT04504162||outpatient|Patients visiting a psychiatric hospital
89012961|NCT00270387|Experimental|001|Natrecor (nesiritide)
89012962|NCT04491721||Rituximab Biosimilar HLX01 in Combination With CHOP|Rituximab Biosimilar HLX01 in Combination With CHOP,in Previously Untreated Subjects With CD20+ DLBCL.
89012963|NCT04491721||MabThera in Combination With CHOP|MabThera in Combination With CHOP，in Previously Untreated Subjects With CD20+ DLBCL.
89012964|NCT00255749|Experimental|early intervention epoietin alfa|Patients receive epoetin alfa subcutaneously on day 1. Treatment repeats every 21 days for up to 5 courses.
89442402|NCT00709592|Experimental|ATG 1.7 mg/kg, TBI, transplant|(Rabbit-ATG;Thymoglobulin,Genzyme) ATG 5.1 mg/kg in three divided doses (1.7 mg/kg/d) given over three days (day -9 to -7) followed by 450 cGy TBI and tacrolimus plus MMF GVHD prophylaxis. Patients receive lower dose anti-thymocyte globulin IV on days -9 to -7. Patients undergo total-body radiation (TBI) twice daily (BID) on day -1 and once daily (QD) on day 0. Patients then undergo peripheral blood stem cells or bone marrow transplant on day 0. GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS: patients receive tacrolimus orally (PO) on days -2 to 90-120 with taper for 2 months, and mycophenolate mofetil (MMF) PO BID on days 0-30.
89442403|NCT00709592|Experimental|ATG 2.5 mg/kg/d, TBI, transplant|(Rabbit-ATG;Thymoglobulin,Genzyme) ATG 7.5 mg/kg in three divided doses (2.5 mg/kg/d) given over three days (day -9 to -7) followed by 450 cGy TBI and tacrolimus plus MMF GVHD prophylaxis. Patients receive higher dose anti-thymocyte globulin intravenously (IV) on days -9 to -7. Patients undergo total-body radiation (TBI) twice daily (BID) on day -1 and once daily (QD) on day 0. Patients then undergo peripheral blood stem cells or bone marrow transplant on day 0. GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS: patients receive tacrolimus orally (PO) on days -2 to 90-120 with taper for 2 months, and mycophenolate mofetil (MMF) PO BID on days 0-30.
89442404|NCT02325258|Experimental|Telephone call|Telephone call to physicians in charge of patients who have just had blood cultures drawn. Diagnostic and therapeutic recommendations to physicians in charge.
89442405|NCT02325258|No Intervention|No telephone call|control arm: no intervention
88925972|NCT03285139|Experimental|Immediate Intervention|Group CBT for PPD. Women in the treatment group will attend a 9-week group Cognitive Behavioural Therapy intervention for PPD. This intervention was developed at the Women's Health Concerns Clinic (WHCC) at St. Joseph's Healthcare Hamilton and designed to be brief, simple, and applicable to women in community settings. It consists of 9 weekly 2-hour sessions where core CBT skills are learned and practiced, and a new psychoeducational topic is introduced and discussed by women each week. The CBT intervention will be delivered by lay-peers.
88925973|NCT03285139|Experimental|Wait List Controls|Group CBT for PPD 9 weeks after enrollment. The women in this arm of the study will receive the same Cognitive Behavioural Therapy intervention as in the immediate intervention arm, however they will begin the CBT group 9 weeks after enrolling in the study.
88925974|NCT03285139|No Intervention|Healthy Controls|No treatment. The participants in this arm of the study will not be suffering from postpartum depression and will not receive the Cognitive Behavioural Therapy treatment. Healthy controls will complete study measures upon enrollment in the study, 9 weeks later as well as 6 months later.
88925975|NCT03283241|Active Comparator|Zolidd One ExHex|Coated titanium implant
88925976|NCT03283241|Sham Comparator|One ExHex|Uncoated titanium implant
88925977|NCT03262909|Experimental|GelrinC prospective treatment arm|Patients will undergo GelrinC implantation.
88925978|NCT03262909|Other|Microfracture historical control arm|Microfracture historical control arm
88925979|NCT03261817|Experimental|APA in patients|patients receiving physical activity (APA) by web during 16 weeks with 2 sessions a week
88925980|NCT03261817|Sham Comparator|HE in patients|patients receiving Health education program (HE) by web during 16 weeks with 2 sessions a week
88925981|NCT03261817|Active Comparator|APA in healthy volunteer controls|Healthy volunteers receiving physical activity (APA) by web during 16 weeks with 2 sessions a week
88925982|NCT03261817|Sham Comparator|HE in healthy volunteer controls|Healthy volunteers receiving Health education program (HE) by web during 16 weeks with 2 sessions a week
88925983|NCT03259581|Experimental|Transarterial chemoembolization|Transarterial chemoembolization
88925984|NCT03242772|Active Comparator|ESDM informed parent coaching + Amphetamine|Amphetamine regimen (11 weeks total duration) will begin 2 weeks prior to initiation of ESDM informed parent coaching (8 weekly sessions) and continue through the week 11 endpoint assessment. The drug is an orally dissolvable, extended-release form of d- and l-amphetamine.
88925985|NCT03242772|Placebo Comparator|ESDM informed parent coaching + Placebo Oral Tablet|Placebo regimen (11 weeks total duration) will begin 2 weeks prior to initiation of ESDM informed parent coaching (8 weekly sessions) and continue through the week 11 endpoint assessment. The placebo contains no active drug and appears identical to the amphetamine (active drug).
88925986|NCT03236311|Placebo Comparator|Placebo|Matching placebo for 4 weeks.
88925987|NCT03236311|Experimental|SAR407899|SAR407899 with dose titration over 4 weeks administration (3 week titration phase + 1 week maintenance phase).
88925988|NCT03234686|Experimental|Deferiprone|Patients will orally receive the equivalent 15 mg/kg of 600mg delayed release Deferiprone tablets twice daily.
88925989|NCT03234686|Placebo Comparator|Placebo|Patients will receive matching placebo tablets designed to mimic the experimental treatment, twice daily
88925990|NCT03229629|Experimental|Maternal BCC only|Mothers with child under 20 months or pregnant will receive Behavior Change Communication (BCC)
88925991|NCT03229629|Experimental|Maternal BCC & Paternal BCC|"Mothers with child under 20 months or pregnant will receive BCC~Husband/partner of the enrolled mother will receive BCC *BCC: Behavior Change Communication"
88925992|NCT03229629|Experimental|Food voucher|"Mothers or fathers with child under 20 months or pregnant will receive monthly food voucher worth 200 birr(~$10)~Within household, recipient of voucher (mother or father) will be randomly selected.~Food voucher"
88925993|NCT03229629|Experimental|Maternal BCC & Food Voucher|"Mothers with child under 20 months or pregnant will receive BCC~Mothers or fathers with child under 20 months or pregnant will receive monthly food voucher worth 200 birr(~$10)~Within household, recipient of voucher (mother or father) will be randomly selected.~BCC: Behavior Change Communication"
89012965|NCT00255749|Other|standard intervention epoietin alfa|Patients receive epoetin alfa as in arm I once their hemoglobin level is ≤ 10.5 g/dL.
89012966|NCT04490122||Inhalational|will receive inhalational anesthesia
89442406|NCT05515354|Experimental|Mid-Follicular Phase Target Quit Date|Participants will start their quit attempts during the mid-follicular phase of their MC (6-8 days post-onset of menses). Each participant will be provided with a range of appropriate dates based on the information about their menstrual cycle, and they will select a target quit date from the range. Participants will be receiving NRT and will have access to behavioral support for the following 6 weeks.
89501668|NCT02258893|Experimental|Control, then NO2 scrubber, then HEPA filter|Participants will have 3 periods of 4 weeks with each filter with a 1 week washout between phases in the order of Control, then NO2 scrubber, then HEPA filter
88925994|NCT03229629|Experimental|Maternal BCC&Paternal BCC &Food Voucher|"Mothers with child under 20 months or pregnant will receive BCC~Husband/partner of the enrolled mother will receive BCC~Enrolled participants will receive monthly voucher worth 200 birr(~$10)~Within household, recipient of voucher (mother or father) will be randomly selected.~BCC: Behavior Change Communication"
88925995|NCT03229629|No Intervention|Control|Control group
88925996|NCT03226795|Experimental|interventional arm|
88925997|NCT03223974|Experimental|Paclitaxel DCB for MB and/or SB|Balloon/vessel diameter ratio 0.8-1.0, 8-10 ATM(atmosphere), lasting for >30 seconds
88925998|NCT03223974|Active Comparator|DES in MB|with regular techniques
88925999|NCT03208153|Experimental|Invasive|In-hospital routine coronary angiogram and revascularization if anatomically feasible
88926000|NCT03208153|Active Comparator|Conservative|In-hospital coronary angiogram only if poor clinical course
88926001|NCT03192046|Experimental|Carbon Fiber Ankle Foot Orthosis (AFO)|For the bracing group, the participants will wear custom fabricated carbon fiber braces in addition to participating in a daily walking program and 7 visits of PT.
88926002|NCT03192046|Active Comparator|Control Group, Walking Program Only|The participants in this group will be prescribed a daily home walking walking program and 7 visits of PT.
88926003|NCT03191253|Experimental|Intervention|The intervention consists of comprehensive, medically-appropriate food support (meals and groceries), individual nutritional counseling, and group-based nutritional education.
88926004|NCT03191253|No Intervention|Control|The control group will continue to receive their regular Project Open Hand services (standard of care) which includes 1-2 food services/day.
88926005|NCT03190369|Placebo Comparator|Placebo|Participants received a single IA injection of phosphate buffered saline on Day 1 and were observed for 26 weeks.
88926006|NCT03190369|Experimental|Hylan G-F 20|Participants received a single IA injection of 6 mL Hylan G-F 20 (Synvisc-One) on Day 1 and were observed for 26 weeks.
88926007|NCT05438342|Experimental|synchronized hyperthermia autologous progenitor expansion -T (SHAPE-T)|Besides NCCN guideline recommended systemic anti-cancer treatment( chemotherapy /anti-PD-1 immmunotherapy/targeted therapy), combined with autoimmune cell therapy combined and noninvasive electromagnetic wave hyperthermia
88926008|NCT05438342|Active Comparator|systemic anti-cancer treatment plus Hyperthermia|BesidesNCCN guideline recommended systemic anti-cancer treatment( chemotherapy /anti-PD-1 immmunotherapy/targeted therapy), combined with noninvasive electromagnetic wave hyperthermia
88926009|NCT05438342|Active Comparator|systemic anti-cancer treatment|Only apply NCCN guideline recommended systemic anti-cancer treatment ( chemotherapy /anti-PD-1 immmunotherapy/targeted therapy)
88926010|NCT05438108|Experimental|SBRT sequential chemotherapy, bevacizumab and sitilimab|
88926011|NCT05437952|Experimental|Taurine and Exercise (Tau+Ex)|Participants who will receive 3g of taurine supplementation associated with physical training in the period of 16 weeks.
88926012|NCT05437952|Experimental|Placebo and Exercise (PL+Ex)|Participants who will receive 3g of placebo supplementation associated with physical training in the period of 16 weeks.
88926013|NCT05437952|Experimental|Taurine (Tau)|Participants who will receive 3g of taurine supplementation in the period of 16 weeks.
88926014|NCT05437952|Placebo Comparator|Placebo (PL)|Participants who will receive 3g of placebo supplementation in the period of 16 weeks.
88926015|NCT05437913|Other|Self compassion intervention|4 weeks group and online format self compassion intervention
88926016|NCT05437874|Placebo Comparator|Natural Water|"355 ml of water should be drunk.~Salivary pH will be determined at 0, 5, 10, 15, 30, 45 and 60 minutes later~Dental biofilm pH will be determined at 0, 5, 10, 15, 30, 45 and 60 minutes later~Streptococcus mutans dental biofilm formation ( Colony Forming Units) will be conducted at 0 and 120 minutes later"
88926017|NCT05437874|Active Comparator|Carbonated water|"355 ml of carbonated water should be drunk~Salivary pH will be determined at 0, 5, 10, 15, 30, 45 and 60 minutes later~Dental biofilm pH will be determined at 0, 5, 10, 15, 30, 45 and 60 minutes later~Streptococcus mutans dental biofilm formation ( Colony Forming Units) will be conducted at 0 and 120 minutes later"
88926018|NCT05437874|Experimental|Aspartame/acesulfame K|"355 ml of drink of diet coke should be drunk.~Salivary pH will be determined at 0, 5, 10, 15, 30, 45 and 60 minutes later~Dental biofilm pH will be determined at 0, 5, 10, 15, 30, 45 and 60 minutes later~Streptococcus mutans dental biofilm formation ( Colony Forming Units) will be conducted at 0 and 120 minutes later"
88926019|NCT05437874|Experimental|Saccharose|"355 ml of drink of regular coke should be drunk~Salivary pH will be determined at 0, 5, 10, 15, 30, 45 and 60 minutes later~Dental biofilm pH will be determined at 0, 5, 10, 15, 30, 45 and 60 minutes later~Streptococcus mutans dental biofilm formation ( Colony Forming Units) will be conducted at 0 and 120 minutes later"
88926020|NCT05437861|No Intervention|Treatment as usual|
88926021|NCT05437861|Experimental|Brief Intervention|
88926022|NCT05437783|Active Comparator|Healthy Bangladeshi Bangalee volunteers|Bangladeshi bangalee participants will be fasting overnight for 10 h, all subjects will receive a single oral dose of 500mg of azithromycin with 250 ml of water. Drug intake will be ensured by direct supervision. Standardized meals will be served 4 and 10 h after dosing. Venous blood sample will be collected at multiple timepoints beginning before drug administration (0h) and containing at timepoints 1.0,2.0,3.0,4.0,6.0,8.0,12.0,24.0,48.0 and 72.0h post dosing. Two ml peripheral blood will be collected from each subject for genetic study.
88926023|NCT05437783|Active Comparator|Healthy Bangladeshi minor ethnics volunteers|Bangladeshi minor ethnics participants will be fasting overnight for 10 h, all subjects will receive a single oral dose of 500mg of azithromycin with 250 ml of water. Drug intake will be ensured by direct supervision. Standardized meals will be served 4 and 10 h after dosing. Venous blood sample will be collected at multiple timepoints beginning before drug administration (0h) and containing at timepoints 1.0,2.0,3.0,4.0,6.0,8.0,12.0,24.0,48.0 and 72.0h post dosing. Two ml peripheral blood will be collected from each subject for genetic study.
88926024|NCT05437744|Experimental|Study group|
88926025|NCT05437744|Active Comparator|Control group|
88926026|NCT05437731|Experimental|Study group|
88926027|NCT05437731|Active Comparator|Control group|
88926028|NCT05437718|Other|Group NB (thoracic paravertebral block Group)|Thoracic paravertebral block(TPVB) is performed 20 minutes before the ablation surgery began,30 mL of 0.375% ropivacaine was totally injected in T3-4 and T5-6 spinal segment（the block segment can be adjusted according to the tumor site) under the ultrasound guidance.
89442407|NCT05515354|Experimental|Mid-Luteal Phase Target Quit Date|Participants will start their quit attempts during the mid-luteal phase of their MC (6-8 days pre-onset of menses). Each participant will be provided with a range of appropriate dates based on the information about their menstrual cycle, and they will select a target quit date from the range. Participants will be receiving NRT and will have access to behavioral support for the following 6 weeks.
89442408|NCT05515354|Active Comparator|Randomly Selected Target Quit Date (Usual Care)|Participants will start their quit attempts within 30 days of their enrollment into the study. They will select their target quit dates without regard for their MC. Participants will be receiving NRT and will have access to behavioral support for the following 6 weeks.
88926029|NCT05437666|Experimental|Education group|The education program was given both an educational presentation and a booklet related to the pelvic floor health
88926030|NCT05437666|Other|Control group|The control group will be given a booklet related to the pelvic floor health
88926031|NCT05437653|Active Comparator|Control group|Healthy weight group ( same age and sex)
88926032|NCT05437653|Active Comparator|Obese group|Obese group
89012967|NCT04490122||Total intravenous|will receive total intravenous anesthesia with propofol infusion(100-150 mcg/kg/min) and dexmedetomedine 0.3mcg/kg/h.
89012968|NCT01600183|Active Comparator|casting|subjects with MTA will be treated with cast for 20 weeks. casting is replaced during every study visit.
88926033|NCT05437627||Study Group:|Study Group: This will be consisted of sixty (60) stuttering patients. They will be divided into 2 subgroups; children group 30 patients with age ranges from (10-18y) and adult group 30 patients with age ranges from (19-30y)
88926034|NCT05437627||Control Group|Control Group: This will be consisted of sixty (60) subjects who have normal fluency. They will be selected from the relative of the patients attending to the outpatient clinic and will be matched for age, sex and socioeconomic state with the patients group.
88926035|NCT05437614|Active Comparator|Treatment of refractory glaucoma using Micropulse diode laser cyclophotocoagulation|
88926036|NCT05437614|Active Comparator|Treatment of refractory glaucoma using cyclocryoablation|
88926037|NCT05437549|Other|PVI|
88926038|NCT05437523|Experimental|Study group participants received a constipation action plan (USCAP)|"Received a personalized, pictographic, constipation action plan which detailed the subjects medications to manage functional constipation. The action plan was downloaded from:~https://wrnmmc.libguides.com/pediatrics/USAP~Watched a study group, specific, education video. Followed up in 4 months."
88926039|NCT05437523|Active Comparator|Control|Received medications to treat functional constipation Did not receive a written action plan. Watched a control group, specific, education video. Followed up in 4 months.
88926040|NCT05437497|Experimental|Remimazolam group|"Background oxycodone injection: Slowly inject oxycodone(0.05mg/kg) intravenously. Three minutes (± 1min) after the end of oxycodone injection , begin sedation induction as follows.~Sedation induction before EUS-FNA/FNB: the initial dose of remimazolam is 0.15-0.2 mg/kg, and the intravenous injection time is about 1 minute. If the subject's MOAA/S score is 1 point or below after the initial dose, EUS-FNA/FNB can be started; if the degree of sedation is insufficient, additional remimazolam(0.05 mg/kg each time) is allowed. The injection time of additional remimazolam is not less than 15 seconds, and the time interval between each additional administration is ≥ 2 minutes.~Maintenance of sedation: In order to maintain the MOAA/S≤1, the investigator can decide to add remimazolam 0.05mg/kg each time, and the intravenous injection time should not be less than 15 seconds, with an additional administration interval of ≥ 2 minutes."
88926041|NCT05437497|Active Comparator|Propofol group|"Background oxycodone injection: Slowly inject oxycodone(0.05mg/kg) intravenously. Three minutes (± 1min) after the end of oxycodone injection , begin sedation induction as follows.~Sedation induction before EUS-FNA/FNB: the initial dose of propofol is 1.5-2.0 mg/kg, and the intravenous injection time is about 1 minute. If the subject's MOAA/S score is 1 point or below after the initial dose, EUS-FNA/FNB can be started; if the degree of sedation is insufficient, additional propofol(0.5 mg/kg each time) is allowed. The injection time of additional propofol is not less than 15 seconds, and the time interval between each additional administration is ≥ 2 minutes.~Maintenance of sedation: In order to maintain the MOAA/S≤1, the investigator can decide to add propofol 0.5mg/kg each time, and the intravenous injection time should not be less than 15 seconds, with an additional administration interval of ≥ 2 minutes."
89012969|NCT01600183|Experimental|UNFO-s|subjects with MTA will be treated with the UNFO-s device for 12 weeks - will be worn day and night during first 6 weeks and only at night during next 6 weeks
89012970|NCT04487665||positive COVID-19|patient diagnosed by nasopharyngeal positive COVID-19
89012971|NCT01600261||eye exam|
89012972|NCT04486027||Healthy|Healthy individuals not smoking, not using Disease-Modifying Anti-Rheumatic Drugs (DMARD) and/or anti-inflammatory drugs other than cortisol and methotrexate, not receiving chemotherapy, not being hypothyroidic
89442409|NCT03499548|Experimental|Intervention|10 hours of intensive CBT for suicide will be delivered to male prisoners who are having thoughts of ending their lives. This will be delivered in 2 hours sessions, 5 times across 2 weeks.
89442410|NCT05052190|Active Comparator|Text Message R/R with Direct Appointment Schedule Link|Participants in this arm will receive up to 3 R/R messages by text. R/R message will be sent with a Direct Appointment Scheduling link and instructions to make a flu vaccine appointment.
89442411|NCT05052190|Active Comparator|Text Message R/R without Direct Appointment Schedule Link|Participants in this arm will receive up to 3 R/R messages by text with no link to schedule an appointment.
89442412|NCT05052190|Active Comparator|Text Message R/R with Direct Appointment Schedule Link + text Pre-Appointment Reminder|Participants in this arm will receive up to 3 R/R messages by text. R/R message will be sent with a Direct Appointment Scheduling link and instructions to make a flu vaccine appointment. Participants will receive a Pre-Appointment Reminder via text when they schedule a visit during the study period.
89442413|NCT05052190|Active Comparator|Text Message R/R without Direct Appointment Schedule Link + Text Pre-Appointment Reminder|Participants in this arm will receive up to 3 R/R messages by text. R/R message will be sent without a Direct Appointment Scheduling link and instructions to make a flu vaccine appointment. Participants will receive a Pre-Appointment Reminder via text when they schedule a visit during the study period.
89442414|NCT05052190|Active Comparator|Portal Message R/R with Direct Appointment Schedule Link|Participants in this arm will receive up to 3 R/R messages by portal. R/R message will be sent with a Direct Appointment Scheduling link and instructions to make a flu vaccine appointment.
89442415|NCT05052190|Active Comparator|Portal Message R/R without Direct Appointment Schedule Link|Participants in this arm will receive up to 3 R/R messages by portal. R/R message will be sent without a Direct Appointment Scheduling link and instructions to make a flu vaccine appointment.
89442416|NCT05052190|Active Comparator|Portal Message R/R with Direct Appointment Schedule Link + Portal Pre-Appointment Reminder|Participants in this arm will receive up to 3 R/R messages by portal. R/R message will be sent with a Direct Appointment Scheduling link and instructions to make a flu vaccine appointment. Participants will receive a Pre-Appointment Reminder advising them to ask their doctor for the flu vaccine at their upcoming appointment via portal when they schedule a visit during the study period.
89442417|NCT05052190|Active Comparator|Portal Message R/R without Direct Appointment Schedule Link + Portal Pre-Appointment Reminder|Participants in this arm will receive up to 3 R/R messages by portal. R/R message will be sent without a Direct Appointment Scheduling link and instructions to make a flu vaccine appointment. Participants will receive a Pre-Appointment Reminder advising them to ask their doctor for the flu vaccine at their upcoming appointment via portal when they schedule a visit during the study period.
89442418|NCT05052190|No Intervention|No R/R Message or Pre-Appointment Reminder|Participants do not receive any flu vaccine R/R message or Pre-Appointment Reminder advising them to ask their doctor for the flu vaccine at their upcoming appointment during the specified flu season.
89012973|NCT04486027||Active Rheumatoid Arthritis|Active Rheumatoid Arthritis meeting American College of Rheumatology (ACR) RA remission criteria
89012974|NCT04486027||Rheumatoid Arthritis in remission|Rheumatoid Arthritis in remission meeting American College of Rheumatology (ACR) RA remission criteria
89012975|NCT04482205||precovid group|those who were operated from fJanuary first to March 15
89442419|NCT03496350|Experimental|Internet CBT|Internet-based cognitive behavioural therapy in Arabic with therapeutic guidance through email.
89442420|NCT03496350|No Intervention|Wait-list|Wait-list control
89442421|NCT05525182|Experimental|Phase II|ES16001: 480 mg/day ES16001: 720 mg/day ES16001: 960 mg/day Placebo
89442422|NCT05525182|Experimental|Phase III|ES16001 Placebo
89442423|NCT02325336|Experimental|bar-code-assisted administration|during administration rounds, nurses will use the BCMA system to help preventing administration errors
89012976|NCT04482205||covid|those operated from March 16, to May 31, 2020
89012977|NCT00255983|Experimental|1|faropenem medoxomil
89012978|NCT00255983|Placebo Comparator|2|
89012979|NCT04477174||Group A|Twelve health professionals randomised assign to as equally count. The participants match between the images with scale scores. After 2 weeks, the participants match again.
89012980|NCT04477174||Group B|Twelve health professionals randomised assign to as equally count. The participants match between the images with scale scores.
89012981|NCT00415259|Experimental|Laterally wedged shoe insoles|Full-length 5 degree lateral wedged insoles worn inside the shoes daily for 12 months
89012982|NCT00415259|Other|Flat control insoles|
89012983|NCT00270621|Experimental|Treatment|FHP Night time Enuresis intervention
89012984|NCT00270621|No Intervention|Control|To receive standard/usual care for Nocturnal Enuresis- No FHP Night time Enuresis INtervention
89012985|NCT04475263||Carbon monoxide exposure|Confirmed exposure to carbon monoxide
89012986|NCT01600300|Placebo Comparator|Sham|Treatment with inactivate Tesmac device
89442424|NCT02325336|No Intervention|control|during administration rounds, nurses will administer drugs as usual
89442425|NCT03499470|Active Comparator|Intervention|"The intervention mainly consists of a developed protocol for education about the disease and medications AND an education of the equipment and how to use it to have the best benefit.~Actions in structured discharge and follow up protocol:~Patient education for disease severity and medications~Education of family/relatives about medications and types of equipment~Detailed education for LTOT and/or NIV (how to use, duration of use, solutions for possible common problems)~Preparation of home environment for patients needs~Regular telephone visits on day 7 and day 14 after discharge and telephone visits in emergency situations and early referral to the hospital when needed~Outpatient control for the first month"
89442426|NCT03499470|No Intervention|Control|Control patients will receive usual care
89012987|NCT01600300|Active Comparator|Tesmac|Treatment with active Tesmac device
89012988|NCT01600339|Experimental|CABAZITAXEL|cabazitaxel at a starting dose of 25 mg/m
89012989|NCT00256022|Active Comparator|Lactobacillus Acidophilus Arm|The probiotic will be given to the patient 2 a dy for between 2-7 days preoperatively. Participation in this study requires 6 separate blood tests commencing at the start of surgery and continuing for 24 hours immediately post operatively.
89012990|NCT00256022|Active Comparator|Lactobacillus Fermentum Arm|The probiotic will be given to the patient 2 a dy for between 2-7 days preoperatively. Participation in this study requires 6 separate blood tests commencing at the start of surgery and continuing for 24 hours immediately post operatively.
89012991|NCT00256022|Active Comparator|Lactobacillus Fermentum and Lactobacillus Acidophilus|The probiotic will be given to the patient 2 a dy for between 2-7 days preoperatively. Participation in this study requires 6 separate blood tests commencing at the start of surgery and continuing for 24 hours immediately post operatively.
89012992|NCT00256022|Placebo Comparator|Placebo|The placebo will be given to the patient 2 a day for between 2-7 days preoperatively. Participation in this study requires 6 separate blood tests commencing at the start of surgery and continuing for 24 hours immediately post operatively.
89442427|NCT05051878|Experimental|articulating paper occlusal adjustment|occlusal adjustments of implant supported prosthesis according to articulating paper occlusal analysis
89442428|NCT05051878|Experimental|T-scan occlusal analysis|occlusal adjustments of implant supported prosthesis according to T-scan occlusal analysis
89442429|NCT05519722|Experimental|Intervention group|
89442430|NCT05519722|No Intervention|Control group|
89442431|NCT02325492|Experimental|Aramchol 400 mg|• One tablet of Aramchol 400 mg and one tablet of Placebo
89442432|NCT02325492|Experimental|Aramchol 600 mg|• One tablet of Aramchol 400 mg and one tablet of Aramchol 200 mg.
89442433|NCT02325492|Placebo Comparator|Placebo|• Two tablet of Aramchol matching placebo.
89442434|NCT04745468|Experimental|Apheresis Group|"20 patients receive 2 apheresis treatments at intervals of 24 ± 12 h (additionally to the standard therapy after bypass surgery). The first treatment starts within 24 h postoperatively. If the CRP concentration increases to at least 30 mg/L 6-18 h after the end of the second treatment, a third treatment is performed.~For each treatment the 1 - 2.5-fold plasma void is processed. The duration of each treatment is 4-6 h."
89442435|NCT04745468|No Intervention|Control group|17 patients of the control group receive the standard therapy after bypass surgery.
89012993|NCT01600417||clinical suspicion of lumbar instability|
89012994|NCT01600456|Active Comparator|Choice: Prolonged exposure (PE)|"Participants randomized to choice who choose prolonged exposure (PE)."
89012995|NCT01600456|Active Comparator|Choice: PE plus sertraline|"Participants randomized to choice who choose PE plus sertraline."
89012996|NCT01600456|Active Comparator|No choice: Prolonged exposure (PE)|"Participants randomized to no choice who are then randomized to PE."
89012997|NCT01600456|Active Comparator|No Choice: PE plus sertraline|"Participants randomized to no choice who are then randomized to PE plus sertraline."
89012998|NCT00256100|Active Comparator|One|Enoxaparin Sodium (Clexane ) is to be used in the control arm of the study
89012999|NCT00256100|Active Comparator|Two|Fondaparinux will be used as the anticoagulant in the sencond arm of the study
89013000|NCT01600534|Experimental|Lifestyle counseling|Participants obtain access to an internet-based educational intervention.
89013001|NCT01600534|Other|Usual Care Lifestyle counseling|Self directed educational intervention
89013002|NCT00289926|Experimental|dehydroepiandrosterone|50.0mg dehydroepiandrosterone capsule, by mouth, daily for 12 months
89013003|NCT00289926|Placebo Comparator|Placebo|Placebo capsule consists of 298.5 mg /capsule Microcrystalline Cellulose, NF 1.5 mg /capsule Magnesium Stearate, NF manufactured to mimic dehydroepiandrosterone capsule
89013004|NCT01609114||control groups|chemotherapy (C/T) is applied in the morning. After 4-6 hrs, RT is delivered (according to the clinical practice).
89013005|NCT01609114||experimental groups|RT is delivered in the morning. After 4-6 hrs, C/T is applied.
89442436|NCT03499392|Other|psychological investigation|
89442437|NCT02437370|Experimental|Arm A (pembrolizumab, docetaxel)|pembrolizumab IV over 30 minutes on day 1 and docetaxel IV over 60 minutes on day 1.
89442438|NCT02437370|Experimental|Arm B (pembrolizumab, gemcitabine hydrochloride)|pembrolizumab IV as in Arm A and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8.
89442439|NCT05515120|Active Comparator|Rivaroxaban plus Aspirin|"Drug: Rivaroxaban 15 mg Rivaroxaban 15 mg BID~Other Names:~Xarelto 15 mg Rivaroxabana 15 mg Drug: Aspirin 300 mg"
89442440|NCT05515120|Placebo Comparator|Acenocoumarol|Drug: Acenocoumarol Other Name: Vitamin K antagonist
89442441|NCT02323074|Experimental|fBCI-robot|focalized BCI-robot hand training
89442442|NCT02323074|Experimental|gBCI-robot|generalized BCI-robot hand training
89442443|NCT02323074|Sham Comparator|sham-BCI|Sham BCI
89442444|NCT03496116|Experimental|ECIG Session: 0.5 Ohms, 3 mg|Heating coil resistance 0.5 Ohms Liquid nicotine concentration 3 mg
89442445|NCT03496116|Experimental|ECIG Session 0.5 Ohms, 8 mg|Heating coil resistance 0.5 Ohms Liquid nicotine concentration 8 mg
89013006|NCT01609192|Experimental|hydroxyurea|
89013007|NCT01609270||CardioRoot|All subjects receive the CardioRoot graft at baseline implant procedure.
89013008|NCT00270699|Experimental|1|One subcutaneous vaccination with rDEN4delta30-200,201 vaccine (10^5 PFU dose) into the deltoid region of either arm.
89013009|NCT00270699|Experimental|2|One subcutaneous vaccination with rDEN4delta30-200,201 vaccine (10^3 PFU dose) into the deltoid region of either arm. This arm will enroll after Arm 1.
89442446|NCT03496116|Experimental|ECIG Session 1.5 Ohms, 3 mg|Heating coil resistance 1.5 Ohms Liquid nicotine concentration 3 mg
89442447|NCT03496116|Experimental|ECIG Session 1.5 Ohms, 8 mg|Heating coil resistance 1.5 Ohms Liquid nicotine concentration 8 mg
89501669|NCT03106311|Active Comparator|Rupture of membranes group|Pregnant women with definite rupture of membranes will undergo speculum examination. Vaginal washing will be done. The washing fluid will be taken for quantitative and qualitative assessment of beta subunit of human chorionic gonadotropin.
89442448|NCT05515042|Active Comparator|Ad26.COV2.S (VAC31518, JNJ-78436735) Vaccine|"Description: The Ad26.COV2.Sis a recombinant, replication-defective adenovirus type 26 (Ad26) vector vaccine encoding the SARS-CoV-2 spike (S) glycoprotein.~Dose: The Ad26.COV2.S drug product (DP) is supplied as a single-dose or multi-dose suspension (target DP titer is 1×1011 virus particles [vp]/mL or 2×1011 vp/mL) for intramuscular (IM) injection.~Dosage Form: Sterile liquid suspension for injection Colourless to slightly yellow, clear to very opalescent suspension (pH 6-6.4).~Packaging: The vaccine will be provided as a multi-dose vial with 5 doses per vial with a total volume of 2.5ml.~Administration: Vaccination (5x10^10 vp dose) is given as a 0.5mL intramuscular injection into the deltoid muscle in the upper arm."
89442449|NCT05515042|Active Comparator|SARS-CoV-2 rS (CovovaxTM)|"Description - SARS-CoV-2 rS (CovovaxTM): is a recombinant protein nanoparticle vaccine constructed from the SARS-CoV-2 full-length spike (S) glycoprotein co-formulated with Matrix-M1 adjuvant.~Dose: Each 0.5ml of SARS-CoV-2 rS consists of 5μg of a recombinant nanoparticle spike protein plus 50 μg of Matrix-M1 adjuvant.~Dosage Form: Suspension for injection COVOVAX™ is colourless to slightly yellow, clear to mildly opalescent, free to practically free from visible particles.~Packaging: The vaccine will be supplied as a multi-dose vial containing 10 doses per vial Administration: Vaccinations are given as a 0.5mL intramuscular injection into the deltoid muscle in the upper arm"
89442450|NCT05515042|Active Comparator|BNT162b2 (Pfizer) (Comirnaty)|"Description: is a nucleoside-modified messenger RNA encoding the viral spike (S) glycoprotein of SARS-CoV-2. Vaccinations 30mcg (0.3mL) will be given as an intramuscular injection into the deltoid muscle in the upper arm.~Dose: Each dose (0.3 mL) contains 30 micrograms of COVID-19 mRNA Vaccine. Dosage Form: White to off-white frozen suspension for Intramuscular (IM) injection Packaging: This vaccine will be supplied as a multidose vial and must be diluted with 0.9% Sodium Chloride USP before use. Each vial (0.45 mL) contains 6 doses of 0.3 mL after dilution.~Administration: Comirnaty should be administered intramuscularly after dilution. Each dose must contain 0.3 mL of vaccine. The preferred site is the deltoid muscle of the upper arm"
89442451|NCT04664270|Experimental|e-Psychotherapy|Group will receive 8-week online program including CBT in combination with mindfulness and problem-based therapy in addition to treatment as usual. The content will reflect challenges cancer and palliative patients face through the course of treatment and developed into interactive and engaging therapy modules. All online sessions and interactions will occur through a secure online platform. Pre-designed therapy modules are assigned to the patients, accessible to them at any time throughout the week. Each module consists of approximately 30 slides, which take 45-50 minutes to complete. Each module highlights a different topic and includes general information, an overview of skills, and homework that is to be completed within that week. This homework can be directly submitted through the platform to the clinician who will then provide personalized feed-back to the patient. The average time spent per week by a clinician with a particular patient is about 15 minutes.
89442452|NCT04664270|No Intervention|Treatment as Usual|The control group will receive treatment as usual in the first 8 weeks; if still significantly symptomatic (less than 50% response to treatment from baseline), they will then be offered the 8-week e-psychotherapy program. They will be instructed to continue with any lifestyle activities (i.e., diet, exercise, medication, etc.)
89442453|NCT02323152|Experimental|psychoeducation|Usual treatment + psychoteraphy focused on problem solving (6 sessions). The psychoeducational programme consists of 6 sessions of 60 minutes, one per week.
89442454|NCT02323152|Active Comparator|Control group|Puerperal control with their doctor. This group will also be interviewed with the same frecuency of the experimental group but will not receive a psichologycal treatment.
89442455|NCT04502108||Employees|Employees of the Department of Health Professions, Bern University of Applied Sciences
89442456|NCT04502108||Students|Students of the Department of Health Professions, Bern University of Applied Sciences
89442457|NCT02323230|Experimental|DPX-Survivac + low dose cyclophosphamide|
89442458|NCT02323308||vaccination|Anti-HBV vaccine injection
89442459|NCT02319720|Experimental|BMA/Cultured Bone Marrow Cells|The subjects in this arm will have fresh bone marrow aspirate administered to the wound at the time the bone marrow is taken. Part of the aspirate will be cultured. Up to three applications of cultured cells will be applied to the wound following the bone marrow biopsy. A single treatment cycle will consist of one application of a freshly obtained bone marrow aspirate and up to three applications of cultured cells derived from that aspirate. If the wound has not healed, up to three additional treatment cycles may be performed. Each bone marrow biopsy will be followed by direct application of fresh bone marrow to the wound and up to three applications of cultured cells (prepared from the most recent bone marrow biopsy).
89501670|NCT03106311|Active Comparator|Intact membranes group|Pregnant women with intact membranes will undergo speculum examination. Vaginal washing will be done. The washing fluid will be taken for quantitative and qualitative assessment of beta subunit of human chorionic gonadotropin.
89501671|NCT02255045|Experimental|Dose 1 of meloxicam in vaginal ring|2.4 g of meloxicam in a vaginal ring
89501672|NCT02255045|Experimental|Dose 2 of meloxicam in vaginal ring|3.0 g of meloxicam in a vaginal ring
89013010|NCT00270699|Experimental|3|One subcutaneous vaccination with rDEN4delta30-200,201 vaccine (10^1 PFU dose) into the deltoid region of either arm. This arm will enroll after Arms 1 and 2.
89013011|NCT00270699|Placebo Comparator|4|One subcutaneous vaccination with placebo into the deltoid region of either arm.
89013012|NCT01609387|Experimental|Gastric Banding new vitamins|Randomization between optimal multivitamins for bariatric surgery and normal over the counter multivitamins (in Gastric Band patients)
89013013|NCT01609387|Active Comparator|Gastric Banding current vitamins|Randomization between optimal multivitamins for bariatric surgery and normal over the counter multivitamins (in Gastric Band patients)
89013014|NCT01609387|Experimental|RYGB new vitamins|Randomization between optimal multivitamins for bariatric surgery and normal over the counter multivitamins (in RYGB patients
88926042|NCT05437484|Experimental|Intervention group: peer-led BASICS session|Participants randomized to the intervention group received a peer-led BASICS session.
88926043|NCT05437484|No Intervention|Control group|Participants randomized to the control group did not receive any specific intervention.
89442460|NCT02319720|Experimental|Cultured Bone Marrow Cells|In this group, the bone marrow aspirate will be sent to the laboratory to be grown in tissue culture. Once the cell cultures have matured (within 8 weeks) they will be checked for sterility and frozen until applied to the subject's wound. Up to three applications of cultured cells will be applied to the wound following the bone marrow biopsy. A single treatment cycle will consist of up to three applications of cultured cells derived from a single bone marrow aspiration. If the wound has not healed, up to three additional treatment cycles may be performed. Each bone marrow biopsy will be followed by up to three applications of cultured cells (prepared from the most recent bone marrow biopsy).
89442461|NCT02319720|Experimental|Bone Marrow Aspirate|The subjects in this group will have fresh bone marrow aspirate administered to the wound at the time the bone marrow is taken. A single treatment cycle will consist of one application of a freshly obtained bone marrow aspirate. If the wound has not healed, up to three additional bone marrow biopsies may be performed. If the wound heals at any point during this protocol, no additional bone marrow biopsy procedures will be performed and no additional cells will be applied.
89442462|NCT02319720|Active Comparator|Control|In this arm, subjects will receive currently approved treatments for their wound. These treatments will include debridement and dressing changes. Wound dressings allowed will include gauze, foam dressings, occlusive films, and non-stick pads. More advanced dressing materials such as Hydrocolloids, alginates, silver containing dressing and biomaterials can also be used. Compression will be utilized for lower extremity wounds.
89442463|NCT04610060|Experimental|Power walking group|"Exercise in the form of Power walking at hospital for 10-20 minutes on treadmill with various exercise intensities. Weekly Steps at home 30 minutes walking with target to reach 1000 steps daily.~Standardised Outpatient Cardiac Rehabilitation based on ACSM Guidelines where provided for four weeks. The program consisted of warm up, aerobics, strengthening and cool down exercises based on ACSM Guidelines described in Table 1 (Deborah, Jonathan, Gary & Meir, 2018)."
88926044|NCT05437471|Active Comparator|Group A (GnRH analogue with Aromatase Inhibitor|This group of candidates will be administered a single dose of 11.25mg GNRH analoge (Lucrin) followed by Letroloze 10mg OD for 3 months
88926045|NCT05437471|Active Comparator|Group B (GnRH analogue with Progesterone|This group of candidates will be administered a single dose of 11.25mg GNRH analoge (Lucrin) followed Duphaston 10mg BD by for 3 months
88926046|NCT05437471|Placebo Comparator|Group C (GnRH analogue alone)|This is a control group. The candidates will be administered a single dose of 11.25mg GNRH analoge (Lucrin) only.
88926047|NCT05437432|Experimental|Vita ambria onlay restoration|onlays constructed from zirconia-reinforced lithium disilicate glass ceramic press system
88926048|NCT05437432|Active Comparator|e.max onlay restoration|onlays constructed from lithium disilicate glass ceramic press system
88926049|NCT05437367|Other|posture correction exercises group 1|Group A (Control group 1): Participants using smartphones more than 4 hours per day will receive posture correction exercises only.
88926050|NCT05437367|Experimental|scapular stabilization and postural correction exercises group 1|Group B (Experimental group 1): Participants using smartphones more than 4 hours per day will receive scapular stabilization and postural correction exercises.
88926051|NCT05437367|Other|posture correction exercises group 2|Group C (Control group 2): Participants using smartphones less than 4 hours per day will receive posture correction exercises only.
88926052|NCT05437367|Experimental|scapular stabilization and postural correction exercises group 2|Group D (Experimental group 2): Participants using smartphones less than 4 hours per day will receive scapular stabilization and postural correction exercises.
88926053|NCT05437341|Experimental|bi-4SCAR-PSMA/CD70 T Cell Therapy for CD70 and/or PSMA positive cancer|
88926054|NCT05437328|Experimental|bi-4SCAR-GD2/CD56 T Cell Therapy for GD2 and/or CD56 positive tumor|
88926055|NCT05437315|Experimental|bi-4SCAR-GD2/PSMA T Cell Therapy for GD2 and PSMA positive tumor|
88926056|NCT05437302|Experimental|interventional|prism spectacles prescribed
88926057|NCT05437302|Active Comparator|non interventional|presbyopia glasses prescribed
88926058|NCT05437237|Experimental|Dry electrode cap EEG|All patients that are included in the study will undergo a dry electrode electroencephalography (EEG).
88926059|NCT05437224|Experimental|ambrisentan|Open Label
88926060|NCT05437185|Active Comparator|Active group|The investigators aimed for six sessions of anodal stimulation over the right DLPFC (F4 in 10-20 EEG system) with cathode above the left DLPFC (F3) using HDCstim by Newronika S.r.l., Italy. The therapy was administered over two weeks (Mon, Wed, Fri) to ensure a washout period of 48 to 72 hours between applications. The current of 1.5 mA was delivered via silicone electrodes inserted into saline (0.9%) filled cellulose sponges, both 5x5cm (Current Density of 0.6 A/m2), for 20 minutes with 20 seconds of both ramp-up and ramp-down. An International 10-20 EEG system was used to determine the stimulation location, and dedicated EEG caps were used to ensure consistency between applications.
89442464|NCT04610060|Active Comparator|Standardised outpatient cardiac rehabilitation group|Standardised Outpatient Cardiac Rehabilitation based on ACSM Guidelines where provided for four weeks. The program consisted of warm up, aerobics, strengthening and cool down exercises based on ACSM Guidelines described in Table 1 (Deborah, Jonathan, Gary & Meir, 2018).
89442465|NCT02319798|Active Comparator|face-to-face consultations|Those randomized to face-to-face follow up will attend their appointments in hospital as usual.
89442466|NCT02319798|Experimental|telephone consultations|Those randomized to telephone consultation will be told to expect a call from the gastroenterology doctor at the time of their appointment.
89442467|NCT05512468|Other|Experimental: Tattooing of biopsied node|Prior to NST, suspicious axillary lymph nodes were biopsied by core needle or fne needle aspiration. The largest and/or biopsy-confrmed metastastic node was then injected with highly purifed carbon suspension either at the time of biopsy or at a separate session.
89442468|NCT05583734|Experimental|Portomar(TM) Device|"Portomar(TM) Device for bone marrow biopsy~Subjects are self-controlled with one side having conventional biopsy and the other having the Portomar(TM) biopsy."
89442469|NCT04461756|Experimental|inhaled THC/CBD (PPP001)|
89442470|NCT04297306|Active Comparator|Exercise prescription|"This group will be provided with a prescript exercise program, taken from UK National Guidance.~The advice will be directed to be undertaken for 6 weeks immediately prior to surgery."
89442471|NCT04297306|Experimental|Exercise prescription and Virtual Reality Exercise Gaming|"This group will be provided with a prescript exercise program as in Arm 1. However, this group of patients will also be presented with a Virtual Reality Headset, pre-programmed with Exercise promoted games which will be provided to support and encourage their exercise regimen.~Again this advice and support will be directed to be undertaken for 6 weeks immediately prior to surgery."
89442472|NCT05583656||Edwards Inspiris Resilia Valve|
89442473|NCT02325570|Experimental|KLOX BioPhotonic OraLum Gel + SRP|Split-mouth design:the half-mouth randomly selected will be treated with KLOX BioPhotonic OraLum gel (with a LED curing lamp) as an adjunct to SRP.
89442474|NCT02325570|Other|Scaling and Root Planing (SRP)|The second half-mouth will be treated with SRP alone.
89442475|NCT01977638|Experimental|CXD101|Dose escalation study of CXD101 administered orally twice daily for 5 consecutive days in every 21 day cycle. Starting dose 1mg twice daily (2mg/day).
89442476|NCT03495804|Active Comparator|mannitol|Participants are given a minimum of 1500 mL of a preparation of mannitol as oral contrast agent over an hour prior to the examination.
89442477|NCT03495804|Experimental|polyethylene glycol|Participants are given a minimum of 1500 mL of a preparation of polyethylene glycol as oral contrast agent over an hour prior to the examination.
88926061|NCT05437185|Placebo Comparator|Sham group|The sham (placebo) was administered using the same devices with a preprogrammed sham protocol (using HDCprog by Newronika S.r.l., Italy) of 20 minutes to be virtually indistinguishable from the active stimulation.
89442478|NCT05580926|Experimental|Watch your Weight During Holidays Program|
88926062|NCT05437081|Experimental|EMERGE program|Participants were randomly assigned to one of two conditions: intervention or control. Intervention participants engaged in a 4 session program named the EMERGE program focused on identity development (emerging adults) or support for emerging adults (parents). Control participants received referrals to community agencies for behavioral and mental health support as needed.
88926063|NCT05437081|No Intervention|Referral services as needed|Participants were randomly assigned to one of two conditions: intervention or control. Control participants received services as usual.
88926064|NCT05436990|Experimental|vactosertib in combination with pembrolizumab|Participants will be treated for up to 35 cycles (approximately 2 years) after initiation of treatment with intravenous 200mg of pembrolizumab every 3 weeks in combination with vactosertib. Vactosertib will be given orally for 200mg, bid for 5 days (from Mon. to Fri.) per week.
88926065|NCT05436938|Experimental|Psoriasis patients with mild severity, treatment group|with Jing Si herbal tea liquid packets use
88926066|NCT05436938|Placebo Comparator|Psoriasis patients with mild severity, placebo group|without Jing Si herbal tea liquid packets use
88926067|NCT05436938|Experimental|Psoriasis patients with moderate to severe severity, treatment goup|with Jing Si herbal tea liquid packets use
88926068|NCT05436938|Placebo Comparator|Psoriasis patients with moderate to severe severity, placebo group|without Jing Si herbal tea liquid packets use
88926069|NCT05436847|Experimental|Group A|NDT- age appropriate Transitions (age appropriate) Milestones training (age appropriate) Proprioceptive Input- age appropriate (Pushups Static quadruped, squat sitting, trampoline, hopping etc. With weights and splints for joint to joint approximation)
89442479|NCT05580926|Placebo Comparator|Control group (minimal intervention)|
89442480|NCT03499158||1|affected arms of patients who had gone to electrodiagnostic study and diagnosed as carpal tunnel syndrome
89442481|NCT03499158||2|healthy arms of patients who had gone to electrodiagnostic study and diagnosed as carpal tunnel syndrome in the other arms
89501673|NCT02255045|Active Comparator|Oral non-steroidal anti-inflammatory drug|Diclofenac potassium
89501674|NCT02255045|Placebo Comparator|Placebo vaginal ring and oral pill|Placebo vaginal ring and placebo oral pill
89501675|NCT02258971|Experimental|BEA 2180 BR oral|
89501676|NCT02258971|Active Comparator|BEA 2180 BR infusion|
89442482|NCT04968496|No Intervention|Food Insecure Group|Children randomized to the naturally-occurring Food Insecure group will receive a weekly newsletter with information on available area-specific food programs. The weekly newsletter will be sent in two ways: 1) a paper copy will be mailed and 2) a link to an electronic version will be sent via Ilumivu to families to remove any barriers to engagement with the information. In the absence of school meal programs, children from low-income households are at increased risk for food insecurity during the summer.37-39 Given low engagement in summer food programs, it is not expected that this newsletter will impact food security in this group.
89442483|NCT04968496|Experimental|Food Secure Group|Children randomized to the Food Secure group will receive breakfast and lunch meals for eight weeks throughout the summer. Weekly meals will be delivered to each participant's home by Yumble, a company that prepares meals for children ages 3 to 12 years and ships them fresh in insulated, food safe packaging to the home. The meals have similar nutrition standards to those offered via the National School Lunch Program and include fruits, vegetables, whole grains, and lean/ vegetarian proteins. To accommodate cultural preferences or dietary constraints, Yumble offers 20 different breakfast, lunch and dinner meals each week. Families will choose their weekly menus to improve adherence. Participants who have siblings in their home will be provided a family meal kit, which provides 24 meals each week. Additional meals will help to prevent household food insecurity and ensure that the child enrolled in the study consumes the meals each week.
89442484|NCT05580848|Experimental|Examined group|28 patients with indication for distal radius fracture (DRF) osteosynthesis : 14 patients with extraarticular DRF and 14 patients with intraarticular DRF with associated wrist arthroscopy
89442485|NCT05580848|No Intervention|Control group|28 patients with indication for distal radius fracture (DRF) osteosynthesis : 14 patients with extraarticular DRF and 14 patients with intraarticular DRF without associated wrist arthroscopy.
89442486|NCT02325648||HIPEC cytoreductive surgery|
89442487|NCT05519410|Experimental|Sintilimab Combined With Lenvatinib|Pre-operation: 2-3 cycles;
89442488|NCT05519410|Active Comparator|HAIC|Pre-operation: HAIC-FOLFOX 2-3 cycles;
88926070|NCT05436847|Active Comparator|Group B|NDT- age appropriate Transitions (age appropriate) Milestones training (age appropriate)
88926071|NCT05436821|Experimental|Vagus nerve stimulation|"Auricular Vagus Nerve Stimulation (AVNS) was applied to the experimental group. AVNS application was applied to both ears simultaneously for 20 minutes, with waveform biphasic asymmetric, pulse duration 300 microseconds and frequency 25 hertz. AVNS application was made with Vagustim brand device.~The acute effect of the application was evaluated in both groups by isometric quadriceps strength measurement, heart rate variability measurement, grip strength measurement and modified star balance test measurement performed before and after the single session AVNS."
88926072|NCT05436821|Sham Comparator|Control group|"Sham Auricular Vagus Nerve Stimulation (AVNS) was applied to the experimental group. AVNS application was applied to both ears simultaneously for 20 minutes, with no pulse. AVNS application was made with Vagustim brand device.~Before and after sham AVNS isometric quadriceps strength measurement, heart rate variability measurement, grip strength measurement and modified star balance test measurement performed."
88926073|NCT05436782|Active Comparator|Group A|• Group A (control group) will receive routine physical therapy involving muscle strengthening exercises, range of motion exercises, and stretching exercises up to the patient's tolerance. Other exercises will be pelvic bridging, rolling, sitting and standing exercises, walking practice and balancing in parallel bars, and wobble board exercises. Each session will be of 60 minutes 5 times weekly for 6 weeks
88926074|NCT05436782|Experimental|Group B|Group B (experimental group) will receive routine physical therapy for 20 minutes and additionally PNF technique (rhythmic initiation, and then agonistic reversals will be performed in lower extremity in D1 flexion pattern and D1 extension pattern up to patient's tolerance and core strengthening for 20 minutes 5 times weekly for 6 weeks. The outcome measure will be measured at and 6th week interval
88926075|NCT05436743|Experimental|K-Y jelly soaked packs|K-Y jelly soaked packs inserted for pretension of postoperative sore throat
88926076|NCT05436743|Active Comparator|Water soaked packs|Water soaked packs inserted for pretension of postoperative sore throat
88926077|NCT05436730||"Escape Phenomenon of the Antihypertensive Therapy Efficacy"|Men and women aged 18-90 years with arterial hypertension grade 1-3, stage I-II and initially achieved target BP levels while taking 2-3-component AHT.
88926078|NCT05436704||EUS-FNB|
88926079|NCT05436574|Other|Before/after study|Before/after study to measure the effects of the implementation of a dance therapy activity on the quality of life of the elderly population
88926080|NCT05436509|Experimental|bi-4SCAR-CD19/79b T Cell Therapy for CD19 and/or CD79b positive B cell malignancies|
88926081|NCT05436496|Experimental|bi-4SCAR-CD19/70 T Cell Therapy for CD19 and/or CD70 positive B cell malignancies|
88926082|NCT05436405|Experimental|transpedal access|Trans-pedal Access for Endovascular Revascularization in patients with failed antegrade access forComplex Infra-popliteal Lesions in Critically Ischemic Limb
88926083|NCT05431738|Active Comparator|STENT WITH ANTI-MIGRATION DEVICE|Placement of a gastroesophageal stent with anti-migration device : Ella®, Leufen, Novatech
88926084|NCT05431738|Active Comparator|STENT WITHOUT ANTI-MIGRATION DEVICE|Placement of a gastroesophageal stent without anti-migration device : Hanarostent® ECW, Life Partners Europe
88926085|NCT05429229|Experimental|Q10 coenzyme, vitamin E and cross-linked hyaluronic acid|This arm will administer eye drops with a combination of cross-linked hyaluronic acid, Q10 coenzyme and vitamin E, it will consist of 26 patients with diabetic retinopathy and mild to moderate dry eye syndrome. One drop will be instilled in each eye every 4 hours for a month.
89013015|NCT01609387|Active Comparator|RYGB current vitamins|Randomization between optimal multivitamins for bariatric surgery and normal over the counter multivitamins (in RYGB patients)
89013016|NCT01609387|Experimental|Gastric sleeve new vitamins|Randomization between optimal multivitamins for bariatric surgery and normal over the counter multivitamins (in Gastric Sleeve patients)
89013017|NCT01609387|Active Comparator|Gastric sleeve current vitamins|Randomization between optimal multivitamins for bariatric surgery and normal over the counter multivitamins (in Gastric Sleeve patients)
89442489|NCT05578586|Experimental|Experimental vs Control|The patients who are randomized to receive meropenem 1 gram 6 times daily in 15 minutes infusions.
89442490|NCT05578586|Active Comparator|Controls|The patients who are randomized to receive meropenem 2 gram 3 times daily in 3 hours infusions.
89442491|NCT03082638||Control|served in Gulf War during 1990 - 1991 and have no symptoms of Gulf War Illness based on criteria
89442492|NCT03082638||Case|Served in Gulf War during 1990 -1991 and have Gulf War Illness
89442493|NCT03121976|Experimental|Ultrasound|Femoral catheters inserted using ultrasound only
89013018|NCT01609426||children with idiopathic nephrotic syndrome|children below 16 years of age with a steroid dependent nephrotic syndrome
89013019|NCT01609465||Stable angina|
89013020|NCT00256178|Experimental|Lapaquistat Acetate 50 mg QD + Simvastatin|
89013021|NCT00256178|Experimental|Lapaquistat Acetate 100 mg QD + Simvastatin|
89013022|NCT00256178|Active Comparator|Simvastatin|
89013023|NCT00270738|Experimental|1|TrA training group
89013024|NCT00270738|Active Comparator|2|PFMT group
89442494|NCT03121976|Active Comparator|Ultrasound + Nerve Stimulation|Femoral catheters inserted using ultrasound with nerve stimulation
89442495|NCT02319876||Severe sepsis|Patients with severe sepsis
89013025|NCT00270738|Active Comparator|3|control group (PFM exercise at home)
89442496|NCT02319876||SIRS patient|Patients after elective surgeries presented with SIRS but without sepsis
89442497|NCT02319876||Volunteer|Volunteers
89442498|NCT02570152|Experimental|AFI Group|Population living in randomly selected households in geographically-defined communities. Households including at least one member aged less than 18 years will be considered eligible if at least one adult (aged no more than 50 years) and one child (aged less than 18 years) consent (and assent if applicable) to participate in the study.
89442499|NCT03495726|Experimental|Headspace app|Participants randomized to use the mindfulness app for 6 weeks.
89442500|NCT03495726|No Intervention|Waitlist control group|This group will receive treatment as usual for 6 weeks. After the completing the 6-week surveys, the waitlist group will receive a subscription to the Headspace app.
89442501|NCT02323386|Experimental|ATTUNE knee system|The patients will undergo primary Total Knee Arthroplasty (ATTUNE knee system)
89442502|NCT02325726||Renal Resistive Index/Nephrocheck test|Patients undergoing elective cardiac surgery with extracorporeal circulation and who are at risk to develop postoperative Acute Kidney Injury.
89442503|NCT03494088||Children with Autism with gastrointestinal (GI) symtpoms|
89013026|NCT01609504|Experimental|Transanal Endoscopic Microsurgery|Patients were treated by TEM as follows: mucosal incision included all the tatoo spots performed at admission staging, in order to excise a minimum of 1 cm of normal mucosa around the tumor, according to its diameter before NT (ELRR- Endo Luminal Loco Regional Resection)
89013027|NCT01609504|Active Comparator|Total Mesorectal Excision|
89013028|NCT01609621||Retrograde access|
89013029|NCT02488408|Experimental|Part A|To identify the maximum tolerated dose (MTD) of bemcentinib (BGB324) in participants with relapsed or refractory AML following treatment with cytotoxic chemotherapy or a targeted or biologic agent, or in participants with high risk MDS (Norway only).- This Arm of the study has completed recruitment
89013030|NCT02488408|Experimental|Part B|"To identify the safety and tolerability of bemcentinib:~as a single agent in participants with AML who are unsuitable for intensive chemotherapy~in a combination with cytarabine in participants with AML who are unsuitable for intensive chemotherapy~in a combination with decitabine in participants with AML who are unsuitable for intensive chemotherapy~as a single agent in participants with previously treated MDS"
89013031|NCT01580176|Experimental|GlucoseMonitor|
89013032|NCT01609660|No Intervention|Control group|No intervention at all
89013033|NCT01609660|Experimental|Study group|Use of Saccharomyces boulardii, 100mg for at least seven days before surgery
89013034|NCT01609699|Experimental|Group A - will undergo 3 successive treatments, 1 week apart|The Contour I - Y System is a non-invasive focused ultrasound, for body contouring purposes, designed to selectively disrupt sub-dermal fat cells at a designated focus employing focused ultrasound. All other types of tissue, such as blood vessels, muscles and peripheral nerves remain intact. There are no thermal effects. Fat cell destruction is achieved by ultrasound-induced mechanical effects during a very short exposure time.
89013035|NCT01609699|Experimental|Group B - will undergo 3 successive treatments, 2 weeks apart|The Contour I - Y System is a non-invasive focused ultrasound, for body contouring purposes, designed to selectively disrupt sub-dermal fat cells at a designated focus employing focused ultrasound. All other types of tissue, such as blood vessels, muscles and peripheral nerves remain intact. There are no thermal effects. Fat cell destruction is achieved by ultrasound-induced mechanical effects during a very short exposure time.
89013036|NCT00289965|Active Comparator|1|in-person brief motivational intervention
89013037|NCT00289965|Active Comparator|2|Alcohol 101plus
89013038|NCT00289965|Active Comparator|3|AlcoholEdu (a Web-based tutorial).
89013039|NCT01609738||Sinus node dysfunction|Patients with sinus node dysfunction and structurally normal hearts
89013040|NCT01609738||CRT indication|Patients with an indication for CRT (heart failure with an LVEF <35% and LBBB)
89013041|NCT00256334|Experimental|Resveratrol|GM-CSF administration to all subjects in addition to chemotherapy treatment.
89013042|NCT01609777|Other|Handover with SBAR|Handover with handover tool.
89013043|NCT01609855|Experimental|HBB- Hioscine Butyl Bromide|
89013044|NCT01609855|Placebo Comparator|Placebo arm|
89013045|NCT00270816|Experimental|interferon beta cyclical administration|Interferon ß-1b Treatment by Cyclical Administration
89013046|NCT00270816|Active Comparator|Interferon ß-1b Treatment|Interferon ß-1b Treatment
89013047|NCT01609972|Experimental|Test|Subjects randomized to this arm will be trialed and implanted with the Nevro Senza System
89013048|NCT01609972|Active Comparator|Control|Subjects randomized to this arm will be trialed and implanted with a commercially available SCS system.
89013049|NCT00256412|Placebo Comparator|1|
89013050|NCT00256412|Active Comparator|2|Low Dose
89013051|NCT00256412|Active Comparator|3|High Dose
89013052|NCT01602367|Experimental|Arm 1: BMS-823778 (2mg)|
89013053|NCT01602367|Experimental|Arm2: BMS-823778 (6mg)|
89013054|NCT01602367|Experimental|Arm 3: BMS-823778 (15mg)|
89442504|NCT03494088||Children with Autism without gastrointestinal (GI) symtpoms|
89442505|NCT03494088||Healthy Children|
89442506|NCT03495570||A|HIV-infected (chronic or acute infection) with a HIV viral load of >1000 copies/mL in the 6 months prior to study entry and not (yet) in receipt of combination antiretroviral therapy (cART) at study entry.
89013055|NCT01602367|Experimental|Arm4: Placebo|
89013056|NCT01606891|Experimental|parent-targeted intervention|experimental
89013057|NCT01606891|No Intervention|Primary Care|Standard primary care
89013058|NCT01609816|Experimental|Dasatinib|This is a phase 1 dose escalation study, using a standard 3+3 design. Dasatinib is administered orally once daily in the outpatient setting. The starting dose of dasatinib is 20 mg daily. The increment of dose escalation is 20 mg per dose level. Thus, there will be 5 dose levels (20 mg, 40 mg, 60 mg, 80 mg and 100 mg, respectively) with 3 patients in each cohort. Patients will continue on dasatinib for 6 months
89013059|NCT01602094||Adequate antimeales antibody levels|ELISA test OD > 0.1
89013060|NCT01602094||Inadequate measles antibody levels|ELISA test OD < 0.1
89013061|NCT00256529||I|All subjects presenting in with dysphagia will be in this cohort.
89013062|NCT01606930|No Intervention|Usual Care Group|"Group will see their physician without receiving the activation instrument."
89442507|NCT03495570||B|HIV-infected on cART with HIV viral load <50 copies/mL within the 6 months prior to study entry, at least one measure of HCV (chronic or acute infection) showing a detectable HCV viral load and not in receipt of HCV treatment at study entry.
89442508|NCT03495570||C|HCV mono-infected (chronic or acute infection) with detectable HCV viral load (>lower limit of quantification) in the prior 6 months and not in receipt of HCV treatment at study entry.
89442509|NCT03495570||D|HBV mono-infected (chronic or acute infection) patients with detectable HBV viral load in the prior 6 months and not in receipt of HBV treatment at study entry.
89442510|NCT03494010||prospective cohort|Patients will be followed to determine the impact of the hybrid closed-loop (HCL) system that was prescribed at part of clinical care.
89442511|NCT03494010||historical controls|Medical record data of these patients, who did not use the HCL system, will be compared with patients in the HCL cohort.
89442512|NCT03495492|Experimental|Participants|Group receiving dermal chelation and nutritional therapy
89442513|NCT03495336|Experimental|Washout period|Coffee abstention phase for 2 weeks.
89442514|NCT03495336|Experimental|Light roast coffee (LR)|Participants will follow LR Coffee consumption procedure and consume at least 3 cups of Light (LR) roast Turkish coffee brews per day for 4 weeks after a washout period (WO) of 2 weeks.
89442515|NCT03495336|Experimental|Second washout period|coffee abstention phase for 2 weeks
89442516|NCT03495336|Experimental|Dark roast coffee (DR)|Participants will follow DR Coffee consumption procedure and consume at least 3 cups of Dark (DR) roast Turkish coffee brews per day for 4 weeks after a washout period (WO) of 2 weeks.
89442517|NCT02570074|Experimental|Fosfomycin - 3 doses QoD/7 doses QD|Fosfomycin given as a 3 gm dose, every other day for 3 doses, followed by 3 gm dose, once a day for 7 doses.
89442518|NCT02570074|Experimental|Fosfomycin - 7 doses QD/3 doses QoD|Fosfomycin given as a 3 gm dose, once a day for 7 doses, followed by 3 gm dose, every other day for 3 doses.
89442519|NCT03499002|Experimental|Simulation Lab|
89442520|NCT03499002|Experimental|ER in situ Simulation|
89442521|NCT03498924||CASES|Patients with endometrial cancer
89442522|NCT03498924||CONTROLS|Matched controls without neoplasm disease
89442523|NCT02569996|Experimental|Rituximab|Participants will receive rituximab 375 milligrams per meter square (mg/m^2) every 8 weeks for 24 months or until progression, relapse, death, or institution of a new anti-lymphoma treatment.
88926086|NCT05429229|Active Comparator|Sodium hyaluronate|This arm will administer eye drops with sodium hyaluronate, it will consist of 26 patients with diabetic retinopathy and mild to moderate dry eye syndrome. One drop will be instilled in each eye every 4 hours for a month.
88926087|NCT05429229|Active Comparator|Sodium hyaluronate and chondroitin sulfate|This arm will administer eye drops with a combination of sodium hyaluronate and chondroitin sulfate, it will consist of 26 patients with diabetic retinopathy and mild to moderate dry eye syndrome. One drop will be instilled in each eye every 4 hours for a month.
88926088|NCT05427643|Experimental|study group|"patients need dental implants with narrow alveolar ridge of less than 6 mm horizontal width .~they will receive dental implants with I_PRF mixed with synthetic bone graft."
89442524|NCT03498846|Experimental|Modified EA and AMLK|Modified corneal epithelial autograft (EA) combined with allogeneic middle lamellar keratoplasty (AMLK) is used for the treatment of patients with severe corneal burn.
89442525|NCT03498846|Active Comparator|LA and AMLK|Limbal autograft (LA) combined with AMLK is used for the treatment of patients with severe corneal burn.
89442526|NCT02325882|Active Comparator|Conventional fentanyl-based epidural PCA|
89442527|NCT02325882|Experimental|dexmedetomidine to fentanyl-based intravenous PCA|
89442528|NCT02325882|Active Comparator|Conventional fentanyl-based intravenous PCA|
89442529|NCT05519332|Experimental|PVDP group|Patients underwent percutaneous vertebral-disc plasty
89442530|NCT05519332|No Intervention|PVP group|Patients underwent conventional percutaneous vertebroplasty
89442531|NCT03498768||Inpatients with lung nodules|All inpatients in our department are invited to finish the questionnaire at inpatient education on the first day of hospitalization as the baseline date, then they are followed up by phone call to reevaluate their psychosocial status at 6 months and 1 year after the surgery.
89442532|NCT03498690|Active Comparator|Integrative|
89442533|NCT03498690|Active Comparator|Role Specific|
89442534|NCT03498690|Active Comparator|Consecutive|
89442535|NCT04424836||H GROUP|patients get the oxygen supply with high flow nasal cannula . In group H, HFNC device settings the initial flow rate was 30 L/min and could be increased to 60. The Fio2 was adjusted to maintain oxygen saturation as indicated by a pulse oximetry reading of grater than or equal to %90.
89442536|NCT04424836||C GROUP|patients get the oxygen supply with conventional methods. In group C 6-15 L/min oxygen delivered to patients by conventional methods and targeted to maintain the oxygen saturation %90 or over.
88926089|NCT05427643|Experimental|control group|patients need dental implant with adequate horizontal bone with of more than 6 mm.
88926090|NCT05426811|Experimental|Regorafenib combined with Raltitrexed|"Regorafenib:~120mg/d，Po，qd,d1-d21，Every 4 weeks~Raltitrexed:~3mg/㎡，ivgtt，d1，Every 3 weeks"
88926091|NCT05426369|Experimental|Dose Escalation|For single dose escalation, the dose level will be 2µg/kg -15 µg/kg.
89442537|NCT02323542|Experimental|High-SDS biscuit|Biscuit with high Slowly Digestible Starch content
89442538|NCT02323542|Active Comparator|Low-SDS cereal product|Cereal product with low Slowly Digestible Starch content
89442539|NCT04424758|Experimental|Intervention group|Receives information about mammography screening through a video. The video was developed with the goal of informing about mammography screening in a societal perspective using best available evidence.
89442540|NCT04424758|Placebo Comparator|Control group|Receives information about energy systems through a video. The video does not contain any information related to mammography screening.
89442541|NCT05144646|Experimental|HEALTHY SUBJECTS|With healthy subjects in a randomised, open experimental design, in an intrasubject control group (application of HFA / EVOO on one heel, using the contralateral heel as a control and evaluating oxygenation and tissue perfusion in both cases). This intervention would correspond to phase 1
89501677|NCT01257763|Experimental|Study device|The study device is a transdermal microneedle array designed to introduce microscopic channels into the skin. The study device arm will receive application of this device.
89013063|NCT01606930|Active Comparator|"Activated Group"|"Group will be given an activation instrument to complete before their appointment and instructed to refer to and use the instrument during their clinical encounter."
89013064|NCT00256568||Primary Care Practices|One hundred and three prescribers, managers, nurses and office staff at seven primary care practices in Vermont
89013065|NCT02270047|Active Comparator|A|Orange nectar with NAXUS fibre, 5g/100mL
89013066|NCT02270047|Placebo Comparator|B|Orange nectar
89013067|NCT02960607|Experimental|Icotinib|250mg, tid until disease progression or unacceptable toxicities occurred
89013068|NCT02270086||Sarcoma patient|Patient diagnosed with soft tissue sarcoma and receiving preoperative radiotherapy.
89013069|NCT02270125||Adult patients with chronic rhino sinusitis|Group of adult patients indicated for mucotomy due to chronic hypertrophic rhinosinusitis, with or without polyposis
89013070|NCT02270125||Stillborn children|Control group of stillborn children whose nasal mucosa was not exposed to airborne particles
89013071|NCT02270164|Experimental|Artichoke Leaf Extract|Pycrinil® 100 mg/flaxseed oil 380 mg liquid filled hard plant based capsules (Licaps®) twice daily with food
89013072|NCT02270164|Placebo Comparator|Placebo|Placebo/flaxseed oil 380 mg liquid filled hard plant based capsules (Licaps®) twice daily with food
89013073|NCT00256607||coronary artery calcium (CAC)|Cohort from the VADT study, had baseline coronary atherosclerosis assessed by coronary artery calcium (CAC) measured by computed tomography. Participants were followed over the 7.5-year study for development of cardiovascular endpoints.
89013074|NCT00290082|Active Comparator|loxapine|agitated patients were randomly assigned either to loxapine, either to midazolam group
89013075|NCT00290082|Active Comparator|midazolam|midazolam is compared to loxapine in terms of efficacy and tolerance
89013076|NCT02270320|No Intervention|Control|Control group will receive a telephone consultation once every two weeks for 12 weeks.
89013077|NCT02270320|Active Comparator|Physical activity|Experimental group will receive a 60-minute 24 forms Yang-style Tai Chi Chuan exercise program, three times per week for 12 weeks.
89013078|NCT02270398|Experimental|Dual-task training group|Participants in this group will receive dual-task balance and gait training for half hour and relaxation exercise for another half hour in each session. There will be 3 sessions per week for 8 weeks.
89013079|NCT02270398|Active Comparator|Single-task training group|This group of subjects will participate in single-task gait and balance activities for half hour and single-task cognitive training in sitting position for another half hour in each session. There will be 3 sessions per week for 8 weeks.
89013080|NCT02270398|Active Comparator|Flexibility and strength training group|The subjects in this group will engage in flexibility exercises and upper limb strengthening exercises for one hour in each session. There will be 3 sessions per week for 8 weeks.
89013081|NCT00256646||Group 1|"Patients who are enrolled in the ongoing randomized clinical trial AGlycemic Control and Complications in Diabetes Mellitus Type 2."
89013082|NCT02270437|Experimental|cocktail analgesia|The local infiltration mixture of ropivacaine, fentanyl, adrenaline is used intra-articularly during operation. The patients in the cocktail analgesia group received an injection of 200mg ropivacaine, 100ug fentanyl, and 0.25mg adrenaline into knee collateral ligaments, posterior aspect of the capsule, quadriceps tendon, patellar tendon, fat pad, periosteum, and synovium, along with PCIA morphine postoperatively.
89013083|NCT02270437|No Intervention|no cocktail injection|The patients in the no cocktail injection group received PCIA morphine postoperatively.
89013084|NCT02270554|Experimental|Reinforced staple|Endo GIA Reinforced Reload with Tri-Staple technology
89013085|NCT02270593||Placenta previa|first; maternal serum, fetal membranes (placenta) and maternal myometrial samples will be investigated for ADAMTS, Proteoglycans and oxidative/antioxidative enzyme status levels in patients with placental invasion anomalies Placenta Previa totalis by ELISA, western blot, immunohystochemistry and PCR (polymerase chain reaction).
88926092|NCT05426369|Experimental|Dose Expansion - Group A|For dose expansion, the dose level is recommended to be the bioeffective dose obtained from dose escalation and administered once weekly (group A) for a treatment cycle(21 days).
88926093|NCT05426369|Experimental|Dose Expansion - Group B|For dose expansion, the dose level is recommended to be the bioeffective dose obtained from dose escalation and administered once weekly ( group B )for a treatment cycle(21 days).
88926094|NCT05426369|Experimental|Dose Expansion - Group C|For dose expansion, the dose level is recommended to be the bioeffective dose obtained from dose escalation and administered twice weekly (C group) for a treatment cycle(21 days).
88926095|NCT05426148|Experimental|Bivalent HPV Vaccine Consistency Lot 1|Biological/Vaccine: Participants would receive 2 doses of Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli) intramuscularly at 0, 6 month.
88926096|NCT05426148|Experimental|Bivalent HPV Vaccine Consistency Lot 2|Biological/Vaccine: Participants would receive 2 doses of Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli) intramuscularly at 0, 6 month.
88926097|NCT05426148|Experimental|Bivalent HPV Vaccine Consistency Lot 3|Biological/Vaccine: Participants would receive 2 doses of Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli) intramuscularly at 0, 6 month.
88926098|NCT05422651||patients with fever|All subjects will receive the currently recognized routine test of fever according to their disease and corresponding etiological treatment if needed and no additional intervention and treatment will be added for subjects
88926099|NCT05422352|Experimental|intervention Group|Patients who will receive carnosine supplementation + Vitamin B complex two tablets per day
88926100|NCT05422352|No Intervention|Control group|Patients will receive only Vitamin B Complex two tablets per day
88926101|NCT05419765||non-cirrhotic NAFLD, carriers of the PNPLA3 I148M variant|Italian Caucasians, aged> 18 and <70 years, with non-cirrhotic NAFLD and carriers of the PNPLA3 I148M variant
88926102|NCT05419765||non-cirrhotic NAFLD, carriers of the wild type allele|Italian Caucasian subjects, aged> 18 and <70 years, with non-cirrhotic NAFLD and carriers of the wild type allele
88926103|NCT05400304||Training dataset|No interventions
88926104|NCT05400304||External validation1|No interventions
88926105|NCT05400304||External validation2|No interventions
88926106|NCT05393089|Experimental|AGN-190584|Participants will receive one drop of AGN-190584 instilled in each eye once daily for 14 days.
88926107|NCT05393089|Placebo Comparator|Vehicle|Participants will receive one drop of vehicle instilled in each eye once daily for 14 days.
88926108|NCT05360524|Active Comparator|Laminectomy alone in patients with traumatic cervical spinal cord injury without instability|laminectomy only with expected less operative time, blood loss and restriction of neck motion (compared to laminectomy with fusion). Instrumented fusions also entail the risks of screw misplacement, pseudoarthrosis, distal junction kyphosis, and adjacent segment pathology.
88926109|NCT05360524|Active Comparator|Laminectomy and fusion in patients with traumatic cervical spinal cord injury without instability|Multi-level laminectomy compromises the posterior tension band and increases the mobility of the neck, resulting in post laminectomy kyphosis and potential dynamic injury to the spinal cord . In contrast, spinal instrumentation and fusion helps to eliminate movement at the treated levels and reduce spinal cord tension with less incidence of kyphosis.
88926110|NCT05304182|Experimental|Pre-Op|The experimental intervention is non-invasive optical imaging, in particular digital photography and optical coherence tomography, conducted with the investigational and comparator device, for the purpose of measuring dimensions of the eye.
88926111|NCT05304182|Active Comparator|Post-Op|The experimental intervention is non-invasive optical imaging, in particular digital photography and optical coherence tomography, conducted with the investigational and comparator device, for the purpose of measuring dimensions of the eye.
88926112|NCT05195099|Active Comparator|control group|
88926113|NCT05195099|Experimental|respiratory treatment|
88926114|NCT05019482|Experimental|University-based 8-weeks intervention to promote Physical Activity (PA)|Experimental group: 8-weeks program of Physical Activity constructed by users during a design-based innovative workshops before the beginning of the interventions .
88926115|NCT05019482|No Intervention|Control Group|Control group: No intervention, only two measurement times
88926116|NCT04970381|Experimental|Rivaroxaban|
88926117|NCT04932226|Other|All participants|Each participant is his/her own control. Each will have all four interventions in random order.
88926118|NCT04915560|Experimental|ORTEC Employee|ORTEC professional employees performing an industrial cleaning task.
88926119|NCT04895046|Experimental|Investigational Group|"Cycle 1-4 (cycle length 4 weeks): Niraparib 300 mg taken orally on days 1-21 and Dostarlimab 500 mg intravenously on day 1~Cycle 5 and above (cycle length 3 weeks): Niraparib 300 mg taken orally on days 1-21 and 1000 mg intravenously on day 1 of every other cycle"
88926120|NCT04837105|Active Comparator|Control group|"Classic rehab (physio including strength rehab, fitness, motor activity...) + treadmill gait training 3*/week/4weeks:~5 minutes of warm-up with gradual increase in treadmill speed, max 20 minutes of walking at 80% of maximum speed, 5 minutes of active recovery with gradual decrease in treadmill speed.~(protocol from Grecco et al.)"
88926121|NCT04837105|Experimental|Test group|"Classic rehab - same as control group - (physio including strength rehab, fitness, motor activity...) + overground ARROW CP gait training 3*/week/4weeks:~walking sprint session at maximal speed with gradual increase in number of repetitions over the weeks.~(protocol from Verschuren et al.)"
88926122|NCT04805398|Experimental|CM310|CM310 300mg is given subcutaneously (SC) every two weeks for 16-week treatment
88926123|NCT04805398|Placebo Comparator|Placebo|Placebo is given subcutaneously (SC) every two weeks for 16-week treatment.
88926124|NCT04721444||Arm A - Cohort A1|Training set: Pneumonitis in the context of IO therapy and negative for infectious pneumonia (including COVID-19)
88926125|NCT04721444||Arms A and B - Cohort B1|Training set B1: IO and RT naive and pneumonia (without COVID-19)
89442542|NCT05144646|Experimental|PATIENTS|With hospitalised patients and patients from social and health centers an experimental, randomised, open design, also with an intrasubject control group (application of HFA / EVOO on one heel, using the contralateral heel as a control and evaluating oxygenation and tissue perfusion in both cases). This intervention would correspond to phase 2.
88926126|NCT04721444||Arms A and B - Cohort B2|Training set B2: IO and RT naive and confirmed COVID-19 positive with pneumonia
89442543|NCT02323620|No Intervention|Standard care|Optimal standard care after myocardial infarction.
89442544|NCT02323620|Experimental|Intracoronary infusion of BM-MC|Bone marrow-derived progenitor autologous cells aspiration and intracoronary infusion of the cells.
89442545|NCT02572882|Other|Single arm|This is a sequential study in which participants are observed (no intervention) for 8 weeks (pre-treatment), then participants self-administer p-inulin 8g orally twice daily for 12 weeks (treatment phase), and then observed for a final 8 weeks during which no treatment was administered (post-treatment).
89442546|NCT02319954|Active Comparator|Compression|Each patient will be randomized to receive compression of their nose on either the left or right for 5 continuous minutes after performing a lateral rhinotomy.
89442547|NCT02319954|No Intervention|No compression|Each patient will serve as their own control with the other side not receiving any compression after a lateral rhinotomy.
89442548|NCT00708500|Placebo Comparator|Placebo+PEG2b+RBV, x 44 weeks|Participants in Arm 1 (control) received pegylated interferon alfa 2b (PegIntron, PEG2b) + Ribavirin (RBV) (weight-based dosing [WBD]) for 4 weeks followed by boceprevir placebo + PEG2b + RBV (WBD) for 44 weeks with 24 weeks post-treatment follow-up.
89442549|NCT00708500|Experimental|Boceprevir+PEG2b+RBV, Response Guided Therapy|"Participants in Arm 2 (experimental) were assigned either a 36-week or 48-week course of therapy based on their HCV-RNA status at Treatment Week 8.~PEG2b + RBV (WBD) for 4 weeks followed by boceprevir + PEG2b + RBV (WBD) for 32 weeks, then:~36-week regimen: Participants who have undetectable HCV-RNA at Treatment Week 8 discontinue treatment and enter 36 weeks of post treatment follow-up.~48-week regimen: Participants who have detectable HCV-RNA at Treatment Week 8 are assigned an additional 12 weeks of therapy, followed by 24 weeks of post treatment follow-up. Placebo replaces boceprevir for the remaining 12 weeks of therapy, and this switch will occur in a blinded fashion."
89442550|NCT00708500|Experimental|Boceprevir+PEG2b+RBV, x 44 weeks|Participants in Arm 3 (experimental) received PEG2b + RBV (WBD) for 4 weeks followed by boceprevir + PEG2b + RBV (WBD) for 44 weeks with 24 weeks post-treatment follow-up.
89501678|NCT01257763|Sham Comparator|Sham device|The sham device will be very similar in appearance to the study device. The sham device arm will receive application of this device.
88926127|NCT04721444||Arm B - Cohort A2|Training set: Pneumonitis in the context of thoracic RT and negative for infectious pneumonia (including COVID-19)
88926128|NCT04721444||Arm A - Test Cohort (Cohort C1)|Test set C1: Patients on IO and with possible toxicity versus COVID-19 or other infective pneumonitis
88926129|NCT04721444||Arm B - Test Cohort (Cohort C2)|Test set C2: Patients with pneumonitis in context of thoracic RT with possible toxicity versus COVID-19 or other infective pneumonitis.
88926130|NCT04721444||Arm C|Patients with radiotherapy planning CT scans and post-treatment surveillance CT scans at 3, 6 and 12-months post treatment
88926131|NCT04704011|Experimental|Arm 1: Basic Needs Assessment|-Patients will receive a phone call from a research team member 2-4 weeks before their colposcopy appointment. The team member will remind the patient of the date and time of their appointment and conduct a basic needs assessment. Those who have at least one unmet basic need or are unsure of their current needs will be referred to the 24-hr assistance hotline, 2-1-1 United Healthy Way Missouri. After the date of their appointment, patients will be contacted to ask whether they contacted 2-1-1 and used any recommended services.
88926132|NCT04704011|Active Comparator|Arm 2: Usual Care Cohort|-Patients will receive an automated phone call two weeks before their colposcopy appointment to remind them of the date and time of their visit.
88926133|NCT04677829|Experimental|PNT001 1000mg|PNT001 diluted in 5% dextrose for infusion
88926134|NCT04677829|Experimental|PNT001 4000mg|PNT001 diluted in 5% dextrose for infusion
88926135|NCT04677829|Placebo Comparator|Placebo|5% dextrose for infusion
88926136|NCT04672551|No Intervention|Waitlist control group|The intervention group consists of 30 patients diagnosed with PTSD induced by ACS. No intervention or any other procedure will be conducted during the study period of 36 weeks. Afterwards these subjects will be offered an EMDR therapy as provided in the intervention.
88926137|NCT04672551|Experimental|Intervention group|The intervention group consists of 30 patients diagnosed with PTSD induced by ACS. Eight individual EMDR sessions lasting for 1 hours will be provided over 8 weeks by licensed EMDR therapists from the German-speaking part of Switzerland. Each EMDR session follows a standardized 8-phase protocol.
88926138|NCT04657198|Experimental|Group High Dose_Adjuvanted|Participants in one of the high dose adjuvanted groups in part B of the parent study RSV OA=ADJ-002: Group High Dose Adjuvanted will receive one revaccination dose of the RSVPreF3 OA investigational vaccine in the current study by intramuscular (IM) injection in the non-dominant arm.
89013086|NCT02270710||Healthy Subjects|Overall in good health Provide informed consent Male and females, age 18 years and older Nonsmokers
88926139|NCT04657198|Experimental|Group Medium Dose_Adjuvanted|Participants in one of the medium dose adjuvanted groups in part B of the parent study RSV OA=ADJ-002: Group Medium Dose Adjuvanted will receive one revaccination dose of the RSVPreF3 OA investigational vaccine in the current study by IM injection in the non-dominant arm.
88926140|NCT04657198|Experimental|Group Low Dose_Adjuvanted|Participants in one of the low dose adjuvanted groups in part B of the parent study RSV OA=ADJ-002: Group Low Dose Adjuvanted will receive one revaccination dose of the RSVPreF3 OA investigational vaccine in the current study by IM injection in the non-dominant arm.
88926141|NCT04645836|Experimental|Intervention Group|"New management mode intervention: Pharmaceutical care A more recent strategy is pharmaceutical care, where a hospital provides timely patient education, monitoring and management of adverse drug reactions, identifying other drug-related problems, and an evaluation of treatment adherence by a clinical pharmacist. At the first visit, the clinical pharmacist provides a mobile phone number and encourages patients to contact them anytime if they need any consultation on the TB treatment.~Short Message Service and Phone calls daily use of the mobile phone for a TB treatment will support pharmaceutical care. TB patients or family members will receive phone calls every evening (except Sunday) during the whole ambulatory TB treatment phase to assure that the patient takes the medication prescribed and provided by the TB physician and to collect information on treatment adherence and possible side effects."
88926142|NCT04645836|No Intervention|No Intervention Group.|Treatment Group included in the control arm will receive traditional - clinical Directly Observed Therapy (DOT) as recommended by World Health Organization and routine treatment group (6 months treatment regimen); Routine health education provided by health care professionals.
88926143|NCT04590586|Experimental|Apremilast + Standard of Care|Participants will be randomized to receive 30 mg apremilast orally twice a day (BID) in addition to standard of care treatment for 14 days or until hospital discharge, death, or discontinuation of investigational product, whichever occurred first.
89442551|NCT05144100|Experimental|Arm 1 - Surgery +/- Neck Dissection|Patients would undergo appropriate surgery via open, endoscopic, TLM, TORS or a combination. The primary and the neck would be addressed. For N0 neck, clearance of levels II-IV will be required, with levels I and/or V electively dissected at the discretion of the operating surgeon and based on extension of nodal disease. For N+ neck and tumors approaching to within 1cm of the midline, we recommend a contralateral neck dissection be performed as well of levels II-IV but to be done as per operating team's discretion. For lateralized lesions of the BOT and tonsil, ipsilateral neck dissection will be performed. A minimum of 18 lymph nodes per dissected side of the neck is required and will be subject to quality assurance review
88926144|NCT04590586|Placebo Comparator|Apremilast Placebo + Standard of Care|Participants will be randomized to receive matching placebo to apremilast orally twice a day in addition to standard of care treatment for 14 days or until hospital discharge, death, or discontinuation of investigational product, whichever occurred first.
88926145|NCT04590586|Experimental|Lanadelumab + Standard of Care|Participants will be randomized to receive lanadelumab 300 mg by intravenous infusion on Day 1, and a second dose administered on Day 4 in addition to standard of care.
88926146|NCT04590586|Placebo Comparator|Lanadelumab Placebo + Standard of Care|Participants will be randomized to receive placebo to lanadelumab by intravenous infusion on Day 1, and a second dose administered on Day 4 in addition to standard of care.
88926147|NCT04590586|Experimental|Zilucoplan + Standard of Care|Participants will be randomized to receive 32.4 mg zilucoplan by subcutaneous injection every day for 14 days, or until discharge if discharge was before 14 days of treatment in addition to standard of care.
88926148|NCT04590586|Placebo Comparator|Zilucoplan Placebo + Standard of Care|Participants will be randomized to receive placebo to zilucoplan by subcutaneous injection every day for 14 days, or until discharge if discharge was before 14 days of treatment in addition to standard of care.
88926149|NCT04588012|Experimental|Online self-help the OurRelationship.dk program|Couples in the intervention condition will receive the full OurRelationship program including the three modules, the Observe, the Understand, and the Respond module. The program takes 6-8 hours to complete the program after the randomization. The second coach call will take place after the Observe phase. The third coach call will take place after the Understand phase. The fourth coach call will take place after the Respond phase.
88926150|NCT04588012|Active Comparator|"Off line self-help the book Pas på Parforholdet"|"Couples in the active control group receive two copies of the book Pas på parforholdet, når kærligheden er kommet for at blive [Take care of your relationship when love is here to stay] by Mattias Stølen Due (2016). This book includes general research based knowledge on maintaining a healthy relationship as well as questions and exercises for couples to do on their own. To support couples in an activate self-help approach, a sheet with guidelines on using the book will help couples plan their reading and couple conversations. Regular questionnaires will be sent to couples in the control group (matched timely to the questionnaires received by the intervention group). As such, the active control condition will mirror the benefit that couples are likely to get from using well-chosen, solid literature with the addition of any benefit that the research participation (filling in questionnaire) will generate."
88926151|NCT04564209|Experimental|Treatment|The treatment group will be exposed to the infographic intervention when they present for clinic/study visits. During their visit with the provider, the provider offer health education while using infographics.
88926152|NCT04564209|No Intervention|Control|The control groups will receive standard health education.
88926153|NCT04477707||Treatment group|Patients received treatment in phase 3 clinical trials FIDELIO or FIGARO.
88926154|NCT04477707||Placebo group|Patients received placebo in phase 3 clinical trials FIDELIO or FIGARO.
88926155|NCT04312009|Experimental|Losartan|Participants in this arm will receive the study drug, Losartan.
88926156|NCT04312009|Placebo Comparator|Placebo|Participants in this arm will receive a placebo treatment.
89501679|NCT03106233||LTP flap breast reconstruction|All consecutive patients who underwent LTP flap breast reconstructions (unilateral, bilateral or stacked unilateral) between September 2012 and November 2016 at three centers in Maastricht, the Netherlands, and New York and New Orleans, the United States, were included. Autologous breast reconstruction was performed by using the upper lateral thigh region as a donor site.
89501680|NCT02229799||Stroke patients|
89501681|NCT02150447|Active Comparator|Intervention group|Proton pump inhibitor (lansoprazole) therapy for the prevention of gastric cancer bleeding
89501682|NCT02150447|Placebo Comparator|Placebo group|Placebo for the prevention of gastric cancer bleeding
88926157|NCT04100096|Experimental|Brexpiprazole 2-3 Milligrams Per Day|Participants received brexpiprazole, 2-3 milligrams per day (mg/day) tablets, orally, up to Week 12 during the treatment phase.
88926158|NCT04100096|Placebo Comparator|Placebo|Participants received brexpiprazole-matching placebo tablets, orally, up to Week 12 during the treatment phase.
88926159|NCT03964337|Experimental|Cabozantinib Followed by Prostatectomy (Arm A)|Experimental group will received cabozantinib for 4 weeks, followed by a 2 week drug washout before a prostatectomy.
88926160|NCT03964337|Active Comparator|Immediate Prostatectomy (Arm B)|Control group will receive an immediate prostatectomy.
88926161|NCT03957226|Experimental|Trasnhumeral e-OPRA Implant|This arm includes patients with transhumeral amputation that will receive the e-OPRA implant system.
89501683|NCT03934099|Experimental|LC350189 50mg|LC350189 50mg, Once a day (QD)
88926162|NCT03937466|Experimental|Experimental Cooling Mattress Pad|Subjects will use a cooling mattress pad nightly for approximately 8 weeks
88926163|NCT03863639||Pre-Eclampsia|15 English-speaking women with severe pre-eclampsia
88926164|NCT03863639||Control|15 English-speaking pregnant controls with uncomplicated pregnancy matched by age and gestational age
88926165|NCT03850483|Placebo Comparator|Vehicle cream QD|Vehicle cream applied once daily (QD)
88926166|NCT03850483|Experimental|PF-06700841 0.1% cream QD|PF-06700841 0.1% cream applied once daily (QD)
88926167|NCT03850483|Experimental|PF-06700841 0.3% cream QD|PF-06700841 0.3% cream applied once daily (QD)
89501684|NCT03934099|Experimental|LC350189 100mg|LC350189 100mg, QD
89501685|NCT03934099|Experimental|LC350189 200mg|LC350189 200mg, QD
88926168|NCT03850483|Experimental|PF-06700841 1% cream QD|PF-06700841 1% cream applied once daily (QD)
88926169|NCT03850483|Experimental|PF-06700841 3% cream QD|PF-06700841 3% cream applied once daily (QD)
88926170|NCT03850483|Experimental|PF-06700841 0.3% cream BID|PF-06700841 0.3% cream applied twice daily (BID)
88926171|NCT03850483|Experimental|PF-06700841 1% cream BID|PF-06700841 1% cream applied twice daily (BID)
88926172|NCT03850483|Placebo Comparator|Vehicle cream BID|Vehicle cream applied twice daily (BID)
88926173|NCT03850483|Experimental|PF-06700841 3% cream BID|PF-06700841 3% cream applied twice daily (BID)
88926174|NCT03612479|Experimental|KIDFIT Healthy|
88926175|NCT03612479|Active Comparator|KIDFIT Safe|
88926176|NCT03563742|Experimental|Treatment: Rilpivirine+Combination Therapy (TDF/3TC)|The participants will receive antiretroviral treatment of rilpivirine 25 milligram (mg) tablet orally once daily from Day 1 for 48 weeks with a meal to improve absorption. The participants will also receive background combination therapy of 1 tablet orally once daily containing 300 mg tenofovir disoproxil fumarate (TDF) and 300 mg lamivudine (3TC).
88926177|NCT03529799|Experimental|Injured Participants|Participants with mild traumatic brain injury (mTBI) tested using the I-PAS goggles
89501686|NCT03934099|Placebo Comparator|Placebo|Placebo, QD
89501687|NCT02254889|Active Comparator|pre-ESD group|All subjects were randomly assigned to treatment with intravenous proton pump inhibitor (PPI) before ESD.
88926178|NCT03529799|Active Comparator|Uninjured Participants|Participants with no mild traumatic brain injury (mTBI) tested using the I-PAS goggles
88926179|NCT03513237|Experimental|Cervical dilation group|the surgeon will perform the cervical dilatation by inserting the double-gloved index ﬁnger into the cervical canal after extraction of placenta and membranes and will remove the outer gloves after digital dilatation of the cervix.
88926180|NCT03513237|No Intervention|no cervical dilation group|No cervical dilation will be done.
88926181|NCT03473925|Experimental|Navarixin 30 mg + Pembrolizumab 200 mg|Participants received 30 mg navarixin via oral capsules once daily, plus 200 mg pembrolizumab via IV infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years
88926182|NCT03473925|Experimental|Navarixin 100 mg + Pembrolizumab 200 mg|Participants received 100 mg navarixin via oral capsules once daily, plus 200 mg pembrolizumab via IV infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years).
88926183|NCT03424122|Experimental|Treatment A|Parsaclisib + Rituximab
88926184|NCT03424122|Experimental|Treatment B|Parsaclisib + Bendamustine + Rituximab
88926185|NCT03424122|Experimental|Treatment C|Parsaclisib + Ibrutinib
89013087|NCT02270710||SLE Subjects|Enrolled by Hospital for Special Surgery Diagnosed with Systemic Lupus Erythematosus
89013088|NCT02270749|Active Comparator|hydroxocobalamin injection|25 patients receive the standard treatment of a vitamin B12 deficiency: hydroxocobalamin injection
89013089|NCT02270749|Active Comparator|FitForMe vitamin B12 tablets|25 patients receive a daily dose vitamine B12 tablets
89013090|NCT02270788|Experimental|Study Participants|"All participants who consent and are enrolled on the study.~Interventions: Crenolanib, sorafenib, triple intrathecal chemotherapy (methotrexate, hydrocortisone and cytarabine with leucovorin)."
89013091|NCT02270866|Experimental|TNM(trademark) - thermoneuromodulation|TNM (thermoneuromodulation device). A standardized active thermal neuromodulation waveform will be used for all patients. The device is noninvasive and does not use electrical stimulation.
89013092|NCT00290121|Active Comparator|Olanzapine|
89013093|NCT02270905|Experimental|dCELL® Meniscus|
89013094|NCT04709744||SLE patients|SLE patients were presented to chest outpatient clinic and emergency hospital, Mansoura University with manifestation suggesting COVID-19 infection. Vit D was measured in serum by ELISA. Vit D was added to anti COVID-19.
89013095|NCT02271022||Cohort 1|"Patients (≥18 years of age) with a working diagnosis of NSTEMI and treatment with an OAP agent (ticagrelor, clopidogrel, or prasugrel) either in the ED, or in any case within the timeframe that emergency physicians consider to be upstream-within the first 72 hours of care and at least 4 hours before diagnostic angiography. In addition, only those patients who undergo a diagnostic coronary angiography within 72 hours of ED arrival will be eligible for UPSTREAM."
89013096|NCT02271100|Placebo Comparator|palpation guidance|placement of spinal or combined spinal epidural needle using palpation to guide entry position
89013097|NCT02271100|Active Comparator|ultrasound guidance|placement of spinal or combined spinal epidural using ultrasound to guide entry position
89013098|NCT02271178|Experimental|Combined capsule|Combined capsule containing ramipril (5 to 10 mg), atenolol (50 to 100 mg), 100 mg aspirin, 40 mg simvastatin. In follow-up visits doses of atenolol and ramipril capsules may be adjusted according to blood pressure and heart rate.
89013099|NCT02271178|Other|Conventional treatment|Usual therapy
89013100|NCT02271295|Experimental|Enoxaparine|69 Child Pugh B7-C10, cirrhotic patients receiving anticoagulation treatment (daily subcutaneous injection of enoxaparin 4000UI/day) during 24 months
89013101|NCT02271295|No Intervention|Control|69 Child Pugh B7-C10, cirrhotic patients not receiving anticoagulation treatment
89013102|NCT02271373|Experimental|intervention group|The intervention group undertook interventions by increasing time spent outdoors. The interventions composed of performing two additional recess program lasting 30 minutes outside the classroom that encouraged children to go outside for outdoor activities during recess in both the morning and afternoon during school days within a intervention period of 1 school year.
89013103|NCT02271373|No Intervention|control group|The control school did not have any interventions.
89013104|NCT02271412|Experimental|LY03005|LY03005 40, 80, 120, or 160 mg
89013105|NCT02271412|Placebo Comparator|Placebo|Placebo at 40, 80, 120, or 160 mg
89013106|NCT00271050|Experimental|1|
89013107|NCT02271568||Obese patients|15 Obese patients (BMI>30) having one of comorbidity (type 2 diabetes, dyslipidemia, or hypertension) and morbid obese patients (BMI>35) accepted for bariatric surgery.
89442552|NCT05144100|Experimental|Arm 2 - Chemoradiation|"Patients will receive IMRT with normal tissue sparing techniques (70Gy/35# or 66Gy/ 30#) along with concurrent weekly cisplatin. Weekly cisplatin will be administered during IMRT at a dose of 40 mg/m2 IV on days 1, 8, 15, 22, 29, 36, and 43 for a total of up to 7 weekly doses, administered during the course of IMRT.~For patients with T1-2 lateralized tonsil tumors with <1 cm invasion into the soft palate, no invasion of BOT, and N1 neck involvement, unilateral neck will be irradiated. The contralateral neck will be addressed for some BOT tumors<1cm or at the midline and may be considered in patients with N2 and N3status. For patients with residual neck disease after CCRT, a formal neck dissection will be performed. For patients with residual primary disease after CCRT, surgery for the primary will be performed if feasible."
89013108|NCT02271568||Control patients|15 matched controls receiving Intensive medical therapy
89013109|NCT02271607|Experimental|moxibustion|A series of moxibustion sessions within four weeks from the baseline followed by observation period of four weeks.
89013110|NCT02271607|No Intervention|waiting|Waiting period of four weeks followed by moxibustion therapy sessions on the same way with moxibustion group.
89013111|NCT02271646|Experimental|0.5% marcaine 20ml|3 levels ultrasound guided thoracic paravertebral blocks at T5-6, T7-8 and T9-10 (total 0.5% marcaine 20ml)
89013112|NCT02271685|Experimental|Overestimate Parkinson's|People are told that overestimates on the sound estimation task are associated with being healthy and having a low risk of Parkinson's disease, whereas those who are accurate are more likely to develop the disease later in life.
89013113|NCT02271685|Experimental|Overestimate Alzheimers|People are told that overestimates on the sound estimation task are associated with being healthy and having a low risk of Alzheimers disease, whereas those who are accurate are more likely to develop the disease later in life.
89013114|NCT02271685|Experimental|Underestimate Parkinson's|People are told that underestimates on the sound estimation task are associated with being healthy and having a low risk of Parkinson's disease, whereas those who are accurate are more likely to develop the disease later in life.
89013115|NCT02271685|Experimental|Underestimate Alzheimers|People are told that underestimates on the sound estimation task are associated with being healthy and having a low risk of Alzheimers disease, whereas those who are accurate are more likely to develop the disease later in life.
89013116|NCT02271763|Active Comparator|Palpating neck|Subjects will have their neck palpated by an anesthesiologist to locate their cricothyroid membrane
89013117|NCT02271763|Experimental|Ultrasound neck|Subjects will have their neck scanned with ultrasound by an anesthesiologist to locate their cricothyroid membrane
89013118|NCT02271802|Experimental|Butyrate|Enema containing sodium butyrate
89013119|NCT02271802|Placebo Comparator|Placebo|Enema containing NaCl
89013120|NCT02271841||Before introduction of PVI|Physicians' practices
89013121|NCT02271841||After introduction of PVI|Physicians' practices
89013122|NCT02271958|Experimental|Group 1|Oral administration of 2,5 mg of mifepristone daily for 6 months
89013123|NCT02271958|Experimental|Group 2|Oral administration of 5 mg of mifepristone daily for 6 months
89199727|NCT04221945|Experimental|chemoradiotherapy + placebo for pembrolizumab|Participants receive placebo for pembrolizumab IV on Day 1 of each 3-week cycle (Q3W) for 5 cycles followed by placebo IV on Day 1 of each 6-week cycle (Q6W) for an additional 15 cycles. During the Q3W dosing period of placebo, participants receive concurrent chemoradiotherapy. The standard of care chemoradiotherapy regimen includes cisplatin 40 mg/m^2 IV once per week (QW) for 5 or 6 weeks plus external beam radiotherapy (EBRT) followed by brachytherapy with minimum total radiotherapy dose of 80 Gray Units (Gy) for volume-directed and 75 Gy for point-directed given with the total duration of radiation treatment not to exceed 50 days (with an extension to a maximum of 56 days for unforeseen delays).
89199728|NCT04206501|Experimental|ICM guided Medical Management Group|A pre-specified management regimen based on standard clinical practice will be provided to the study team in which medical management including medication dosing (focusing on beta-blockers and diuretics) will be monitored and modified using Cardiac Implantable Electronic Devices (CIED) and OptiVol Monitor data. Based on CIED and patient engagement data, the study team will adjust medications and dosages, and optimize activity/exercise steps.
89199729|NCT04206501|No Intervention|Conventional Management Control Group|Non-study physicians will receive CIED/OptiVol data (as in usual care) and its use and the management strategy will be left to his/her discretion. To control for patient contact, patients in the conventional management group will have the same study visits as the interventional group and will include in-person device interrogation, and documentation of any medications changes.
89199730|NCT04199325|Experimental|Intervention group|
89199731|NCT04199325|Placebo Comparator|Control group|
89199732|NCT04189133|Experimental|Study group|The study group will receive the daily administration sc of Luveris with increasing dosages two weeks (Treatment phase) as follows: Rec-LH 75 IU daily for 2 weeks; Rec-LH 150 IU daily for 2 weeks; Rec-LH 300 IU daily for 2 weeks; Rec-LH 600 IU daily for 2 weeks.
89199733|NCT04189133|Active Comparator|Control group|"The control group will receive the administration im of Gonasi HP as follows:~hCG 500 IU two times weekly, for 2 weeks; hCG 1000 IU two times weekly, for 2 weeks; hCG 1500 IU two times weekly, for 2 weeks; hCG 2000 IU two times weekly, for 2 weeks."
89199734|NCT04158804|Experimental|Procalcitonin algorithm+stewardship team|antibiotic prescription guided by PCT values
89199735|NCT04158804|No Intervention|standard group|standard of care guided by current guidelines
89199736|NCT04157725|Experimental|Group A (mild stimulation protocol)|
89199737|NCT04157725|Active Comparator|Group B (conventional stimulation protocol)|
89199738|NCT04145518|Active Comparator|Naproxen/Placebo Crossover|"Participants will be randomized to take either a placebo pill or a single 550 mg naproxen sodium pill. Randomization with a block size only known by the statistician, will be programmed to be allocated out of REDcap.~Our clinical research pharmacy will provide naproxen and an identical looking placebo in containers with codes only known to the statistician to provide a double-blinded experimental design.~On a subsequent episode of menstrual pain (1-2 months later), participants will receive the opposite treatment and undergo the exact same assessments."
89199739|NCT04145518|Placebo Comparator|Placebo/Naproxen Crossover|Participants will receive placebo first in this arm.
89199740|NCT04140903|Experimental|Oral antibiotics|Patients will be randomised to oral antibiotics after two weeks of appropriate antibiotic therapy for bacterial brain abscess since definitive aspiration/excision of brain abscess or, in case of no planned diagnostic neurosurgical procedure, since initiation of guideline recommended antibiotics for bacterial brain abscess
89199741|NCT04140903|Active Comparator|Standard treatment|Patients will be randomised to continuation of standard intravenous antibiotics after two weeks of appropriate antibiotic therapy for bacterial brain abscess since definitive aspiration/excision of brain abscess or, in case of no planned diagnostic neurosurgical procedure, since initiation of guideline recommended antibiotics for bacterial brain abscess
89199742|NCT04130126|No Intervention|Warm showers|Participants in the warm showers condition are instructed to continue their normal warm showers throughout the study
89199743|NCT04130126|Experimental|Cold showers|Participants in the cold showers condition will be asked to take cold showers over a time period of 3 months
89199744|NCT04118998|Experimental|Abduction Loading|The intervention for the experimental group entails practicing reaching with abduction loading.
89199745|NCT04118998|Active Comparator|Supported Reaching|The intervention for the active comparator entails practicing reaching while supported.
89199746|NCT04101721|Experimental|Aflibercept Group|Patients will receive a single intravitreal (IVT) injection per eligible eye at baseline.
89199747|NCT04101721|Experimental|Laser Group|Patients will undergo laser treatment in each eligible eye at baseline.
89199748|NCT04066062||Retrospective|A total of 700 vessel from 700 patients clinically indicated CCTA and IVUS or OCT performed within 3 months.
89199749|NCT04066062||Prospective|A total of 1,000 subjects will be enrolled in this Registry. This number of subject is expected to provide a maximum of 1,300 vessels. All CCTA and IVUS/OCT will be performed within 3 months
89199750|NCT04057872|Active Comparator|TPE in Septic Shock|The patients in this arm will receive TPE
89199751|NCT04057872|No Intervention|Reference Population|The patients will receive the standard of care for septic shock treatment
89199752|NCT03995368|Experimental|People with Schizophrenia|People who have been diagnosed with schizophrenia and meet the investigators' research criteria for symptoms indicative of schizophrenia within their lifetime.
89013124|NCT02271958|Experimental|Group 3|Oral administration of 10 mg of mifepristone daily for 6 months
89199753|NCT03995368|Experimental|People with TBI|People who have been diagnosed with a mild or moderate traumatic brain injury (TBI) and meet research criteria indicative of TBI within their lifetime.
89199754|NCT03995368|Experimental|Healthy Controls|People without a history of psychiatric illness or TBI and who do not meet research criteria for a psychiatric illness or TBI.
89199755|NCT03977129|Experimental|QFR group|
89199756|NCT03977129|Active Comparator|CAG group|
89199757|NCT03968640|Active Comparator|CoQ10 group|The patients assigned to the CoQ10 group will receive the loading dose of CoQ10 (1,800 mg/day) for 4 weeks followed by the maintenance dose of CoQ10 (600 mg/day) for 8 weeks or until hospital discharge, whichever comes first.
89199758|NCT03968640|Placebo Comparator|Placebo|Allocation-concealed placebo will be used as an appropriate control.
89442553|NCT02320032|Experimental|Aripiprazole Lauroxil - A|Intramuscular (IM) injection Dose and Dosing Sequence A
89013125|NCT02271958|Experimental|Group 4|Oral administration of mifepristone placebo daily for 3 months
89013126|NCT02272036|Active Comparator|SMS receiving|Study participants of the SMS group receive in total 14 short messages (SMS) containing time adjusted information on colonoscopy preparation starting 4 days before colonoscopy appointment on their mobile phones.
89013127|NCT02272036|Active Comparator|Non-SMS receiving|Study participants of the Non-SMS-Group do not receive any SMS before colonoscopy. Preparation is done according to regular written information given to the patient.
89013128|NCT02272153|Active Comparator|Egg refined grain|Eggs with white toast
89013129|NCT02272153|Active Comparator|Egg whole grain|Eggs with whole grain toast
89013130|NCT02272153|Active Comparator|Cereal Refined grain|rice cereal with white toast
89013131|NCT02272192|Experimental|ESDM15 hr/week|Children receive 15 hours a week of 1:1 intervention at home plus parent coaching using the Early Start Denver Model and following its manual
89199759|NCT03962504|Experimental|written exposure therapy|The WET condition consists of 5-7 weekly treatment sessions, with the first session lasting 1 hour and each subsequent session lasting approximately 40 minutes. The first session consists of education about common trauma reactions and the WET rationale. The participant is then given general instructions for completing the trauma narratives and specific instructions for completing the first 30-minute narrative writing session. All WET sessions begin with the therapist reading the specific writing instructions, clarifying any questions the person has, and leaving the instructions with the participant during the 30-minute writing session. Writing instructions begin with a focus on the details of the trauma and then shift to the meaning of the trauma event. After 30 minutes of writing, the therapist stops the writing and conducts a 5-10 minute check-in regarding how the writing session went for the participant.
89199760|NCT03962504|Active Comparator|Prolonged Exposure|Prolonged Exposure (PE) is a 8-15, 90 minute trauma-focused treatment which consists of imaginal and in vivo exposures
89199761|NCT03951792||Colorectal Cancer Subjects|Subjects under going colorectal resection with colorectal cancer will have tissue and stool collected
89199762|NCT03951792||Benign Colon Resection Subjects|Subjects under going colorectal resection without colorectal cancer will have tissue and stool collected
89199763|NCT03948074|Experimental|High THC/Low CBD Cannabis Oil|THC+THCa = 573 mg CBD+CBDA = 0 mg Total cannabinoids = 573 mg (0.95mg/drop) Dried marijuana equivalent = 5g
89199764|NCT03948074|Experimental|Low THC/High CBD Cannabis Oil|THC+THCa = 37mg CBD+CBDA = 784mg Total cannabinoids = 821mg (1.37mg/drop) Dried marijuana equivalent = 6g
89199765|NCT03948074|Experimental|Equal amounts of THC/CBD Cannabis Oil|THC+THCa = 516mg CBD+CBDA = 456mg Total cannabinoids = 972mg (1.62mg/drop) Dried marijuana equivalent = 6g
89199766|NCT03948074|Placebo Comparator|Placebo Oil|Medium Chain Triglyceride (MCT) oil
89199767|NCT03932318|Experimental|Phase I and Phase II|"Lintuzumab-Ac225 will be administered on Day 8 of each cycle for four cycles (unless in the 0.5 μCi/kg or 0.25 μCi/kg cohorts, where there is a potential for an additional four cycles, pending PI and Medical Monitor review).~Venetoclax will be taken on Days 1-21 of each cycle for up to 12 cycles.~Azacitidine will be administered on Days 1-7 of each cycle for up to 12 cycles.~Each cycle is 28 days, with a potential to expand to 42 days to allow for full hematologic recovery."
89199768|NCT03926949|Active Comparator|Intervention group|Participants will receive parenteral nutrition (Olimel 7.6% E 1000 ml), infused over 4-5 hours at outpatient infusion clinic for 5-10 days within 14 days prior to surgery.
89199769|NCT03926949|Other|Control group|Participants will receive nutrition therapy by registered dietitians within 14 days prior to surgery. Patients with SGA B and SGA C will receive advanced nutrition care and specialized nutrition care, respectively
89199770|NCT03918603|Experimental|ultra-protective multimodal ventilation group|Patient will be diposed on ventral decubitus: one session at least more than 12 hours between inclusion and H48
89199771|NCT03918603|No Intervention|protective ventilation group|Patient will received usual care
89199772|NCT03912155||Patients|20 patients per presumed location of the epileptogenic zone (see experimental plan) for a total of 120 patients, including 30 minors. For patients, a MEG-EEG-SEEG examination during the SEEG exploration period.
89199773|NCT03912155||Controles|For the control population, 120 control subjects, including 30 minors, that is to say as many as patients. For control subjects, a MEG-EEG exam.
89199774|NCT03896347||ViBone®|One product will be used on each level. At the time of surgery, implantation of ViBone®, DBM, and BMP will be randomized between the three treated levels.
89199775|NCT03896347||Demineralized Bone Matrix|One product will be used on each level. At the time of surgery, implantation of ViBone®, DBM, and BMP will be randomized between the three treated levels.
89199776|NCT03896347||Bone Morphogenetic Protein|One product will be used on each level. At the time of surgery, implantation of ViBone®, DBM, and BMP will be randomized between the three treated levels.
89199777|NCT03864926|Active Comparator|Standard of Care|Standard of Care Tacrolimus
89013132|NCT02272192|Experimental|ESDM 25 hr/week|Children receive 25 hours a week of 1:1 intervention at home plus parent coaching using the Early Start Denver Model and following its manual
89199778|NCT03864926|Experimental|Experimental|Envarsus XR
89199779|NCT03855735|Experimental|TeamBaby Online Training Intervention Group Phase 2 (IG1)|Those who give birth and relatives who have been arbitrarily assigned to the intervention group receive an interactive online training on different communication models and competencies (Phase 2).
89199780|NCT03855735|No Intervention|No Intervention|Those who give birth and relatives who have been arbitrarily assigned to the control group do not receive any training on different communication models competencies and will not gain access to the digital app prior to giving birth.
89199781|NCT03855735|Experimental|TeamBaby App Training Intervention Group Phase 3 (IG2)|Those who give birth and relatives who have been arbitrarily assigned to the intervention group will gain access to the digital app and receive a communication training via the app (Phase 3).
89199782|NCT03853434|Experimental|Embolization|After angiography all metastases with poor/moderate vascularization will be embolized with acrylic glue in the treatment group.
89199783|NCT03853434|No Intervention|No embolization|After angiography all metastasis with poor/moderate vascularization will not be embolized with acrylic glue in the control group
89442554|NCT02320032|Experimental|Aripiprazole Lauroxil - B|Intramuscular (IM) injection Dose and Dosing Sequence B
88926186|NCT03230097|Experimental|BI 409306|Patients meeting Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) diagnostic criteria for attenuated psychosis syndrome (APS) per the Structured Interview for Psychosis-Risk Syndromes (SIPS) took 50 milligrams BI 409306, as a film-coated tablet, orally twice a day at approximately the same time every day in the morning and in the evening (approximately 12 hours apart) with or without food for 52 weeks.
88926187|NCT03230097|Placebo Comparator|Placebo|Patients meeting Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) diagnostic criteria for attenuated psychosis syndrome (APS) per the Structured Interview for Psychosis-Risk Syndromes (SIPS) took placebo matching 50 milligrams BI 409306, as a film-coated tablet, orally twice a day at approximately the same time every day in the morning and in the evening (approximately 12 hours apart) with or without food for 52 weeks.
88926188|NCT03226067|Experimental|GKT137831 400mg twice daily|"GKT137831 400mg twice daily~Patients will self-administer 4 capsules in the morning and 4 capsules in the evening."
88926189|NCT03226067|Experimental|GKT137831 400mg once daily|"GKT137831 400mg once daily~Patients will self-administer 4 capsules in the morning and 4 capsules in the evening. The capsules in the evening will be placebos."
88926190|NCT03226067|Placebo Comparator|Placebo Arm|Patients will self-administer 4 capsules in the morning and 4 capsules in the evening. All capsules will be placebos.
88926191|NCT03190525||Multiple Myeloma patients|
88926192|NCT02993211|Active Comparator|Standard resection|For patients undergoing bipolar transurethral standard resection, bladder tumour is resected in a piecemeal manner.
88926193|NCT02993211|Experimental|En bloc resection|For patients undergoing bipolar transurethral en bloc resection, bladder tumour is resected and removed in one piece.
88926194|NCT02968940|Experimental|Avelumab and hypofractionated radiation therapy(HFRT)|"Avelumab 10 mg/kg intravenously (IV) every 2 weeks.~Hypofractionated radiation therapy to a total dose of 30 Gy, delivered in 6 Gy per fraction for 5 consecutive daily fractions"
88926195|NCT02846350|Active Comparator|Experimental condition|The proposed intervention training utilizes a structured, sustainable MI training and supervision program designed to improve retention, adherence and persistence in challenging patients.
88926196|NCT02846350|No Intervention|Standard of Care (SOC)|Physicians providing SOC will attend 3 time-matched video presentations over 2 years on research on optimizing entry into and retention in care and adherence, from materials available at the International Association for Providers of AIDS Care
88926197|NCT02803593|Active Comparator|Control|Asian American breast cancer survivors who do not use the TICAA, but use the information on breast cancer by the American Cancer Society (ACS). Participants are asked to use the online ACS resources for 3 months.
88926198|NCT02803593|Experimental|TICAA Intervention|Asian American breast cancer survivors who use the TICAA intervention and the information by the ACS. The intervention is a technology-based information and coaching/support program to enhance survivorship experience of Asian American breast cancer survivors. Participants are asked to use the TICAA program for 3 months.
88926199|NCT02772068|Active Comparator|Healthy Senior Control|Fifteen healthy senior subjects will perform light exercise at a fixed heart rate of 100 beats per minute. Subjects will then be given either placebo infusion (normal saline) or Istaroxime infusion for one hour. Subjects will be blinded to which infusion they are receiving. Subjects will then repeat light exercise at a fixed heart rate of 100 beats per minute. Primary outcome is changes in cardiac filling pressures during exercise.
88926200|NCT02772068|Experimental|Heart failure patients|Fifteen HFpEF subjects will perform light exercise at a fixed heart rate of 100 beats per minute. Subjects will then be given either placebo infusion (normal saline) or Istaroxime infusion for one hour. Subjects will be blinded to which infusion they are receiving. Subjects will then repeat light exercise at a fixed heart rate of 100 beats per minute. Primary outcome is changes in cardiac filling pressures during exercise.
88926201|NCT02755948|Experimental|RSV A Memphis 37|Half the participants will be inoculated with RSV Memphis 37 10(4) plaque forming units (PFU) in 1 milliliter (mL) 25% sucrose/Dulbecco's Modification of Eagle's Medium (DMEM) delivered by intranasal drops. They will then be monitored as in-patients for 10 days with daily clinical assessment and blood and respiratory tract sampling. Following discharge, they will be followed up for up to 6 months post-inoculation.
88926202|NCT02755948|Experimental|Influenza A/California/04/2009|Half the participants will be inoculated with Influenza A/California/04/09 3.5x10(4) tissue culture infective dose 50% (TCID50) in 1 mL in Dulbecco's phosphate buffered saline (DPBS) delivered by intranasal drops. They will then be monitored as in-patients for 10 days with daily clinical assessment and blood and respiratory tract sampling. Following discharge, they will be followed up for up to 6 months post-inoculation.
88926203|NCT02663908|Experimental|Degarelix|
88926204|NCT02663908|Active Comparator|Leuprolide|
89199784|NCT03809533|Experimental|HCV seropositive non-viremic (HCV Ab+/NAT-) donor|"Kidney recipients will be monitored for HCV for one year following transplant. When HCV RNA is detected, the transmission-triggered treatment phase will be initiated.~Recipients will be treated with 12-week oral course of sofosbuvir/velpatasvir (Epclusa®), a fixed-dose combination of a nucleotide analogue HCV NS5B polymerase inhibitor (sofosbuvir - 400mg) and a NS5A inhibitor (velpatasvir - 100mg)."
89199785|NCT03809533|Experimental|HCV seropositive viremic (HCV Ab+/NAT+) donor|Starting post-operative day 1, kidney recipients will be treated with 12-week oral course of sofosbuvir/velpatasvir (Epclusa®), a fixed-dose combination of a nucleotide analogue HCV NS5B polymerase inhibitor (sofosbuvir - 400mg) and a NS5A inhibitor (velpatasvir - 100mg).
88926205|NCT02650284|Other|Bicompartmental Knee Replacement (BKR)|Receiving Restoris MCK Multicompartmental Knee System for Bicompartmental Knee Replacement (BKR). Surgery performed using Stryker's robotic-arm assisted surgery system Mako
88926206|NCT02650284|Other|Total Knee Replacement (TKR)|Receiving Stryker Triathlon Primary Total Knee System for Total Knee Replacement. Surgery performed using Stryker's robotic-arm assisted surgery system Mako
88926207|NCT02554487|Experimental|sSDB ASV+|sSDB ASV+: Patients with an AHI > 20/h assessed during the first night of stroke that are randomized to ASV treatment (AirCurveTM10 CS PACEWAVE Adaptive-Servo-Ventilator (ResMed Ldt., Australia)).
88926208|NCT02554487|No Intervention|sSDB ASV-|sSDB ASV-: Patients with an AHI > 20 no ASV treatment.
88926209|NCT02554487|No Intervention|no SDB|no SDB: Stroke patients without SDB (AHI < 5 / h) serve as a control group to observe the evolution of the lesion volume and stroke outcome without the additional burden of SDB.
88926210|NCT02333292||IFN|HCV-infected patients, pre-treated or treatment-naïve, who start a regimen containing pegylated interferon in combination with any DAA
88926211|NCT02333292||IFN-free|HCV-infected patients, pre-treated or treatment-naïve, who start a regimen containing one or more DAA
88926212|NCT02203773|Experimental|ABT-199 + Azacitidine|Treatment Naive Acute Myelogenous Leukemia
88926213|NCT02203773|Experimental|ABT-199 + Decitabine|Treatment Naive Acute Myelogenous Leukemia
88926214|NCT02203773|Experimental|ABT-199+Decitabine+Posaconazole|Treatment Naive Acute Myelogenous Leukemia
88926215|NCT02175030|Active Comparator|Copper T380 IUD|Randomized to copper T380 IUD for EC (emergency contraception)
88926216|NCT02175030|Active Comparator|LNG20 IUD|Randomized to LNG20 IUD for EC (emergency contraception)
88926217|NCT01555541|Experimental|Single-arm study|
88926218|NCT01398852|Experimental|CXL Treatment|All eyes to be treated with riboflavin and UV light
88926219|NCT01398839|Sham Comparator|Sham Control|
88926220|NCT01398839|Experimental|CXL Treatment|
88926221|NCT00501176|Active Comparator|plastic stent|Stent insertion
88926222|NCT00501176|Active Comparator|metalic stent|Stent inserttion
88926223|NCT00496795|Other|epirubicin/docetaxel sequential|Epirubicin/docetaxel sequential, i.e. one arm study with Epirubicin 4 cycles 60 mg/m2 q2w, followed by docetaxel 4 cycles, 100 mg/m2 q2w. Each course with pegfilgrastim.
88926224|NCT03178786|Experimental|Parkinson's Disease|
88926225|NCT03178786|Sham Comparator|Healthy Control Subjects|
88926226|NCT03174379|Placebo Comparator|Control Group|Standard of Care (SOC) treatment will be based upon Traditional Chinese Medicine (TCM) interpretation of 4 phases of MS.
88926227|NCT03174379|Active Comparator|Treatment Group|60-minute treatment session twice a week for three weeks
88926228|NCT03164889|Experimental|ETV+GM-CSF|Entecavir (ETV) plus Granulocyte Macrophage-colony Stimulating Factor (GM-CSF). ETV was given 0.5mg/d, oral; GM-CSF was given 100ug, the 3th, 4th, 5th day at week1, 4, 12, 24, 48, subcutaneous injection.
88926229|NCT03164889|Active Comparator|ETV monotherapy|As standard antiviral therapy, Entecavir was given 0.5mg/d, oral.
88926230|NCT03161444|Other|Elective patient|Patient who has patricipated to the study CHIKVIH (NCT02553369) will have a blood collection during a follow up visit for HIV infection.
88926231|NCT03141190|Experimental|Mental Training for Surgeons|Mindfulness-Based Stress Reduction (MBSR, as published elsewhere extensively) slightly modified by shortening the eight weekly classes to 2 hours each and the home practice requirement to 20 minutes. Taught by a veteran MBSR teacher with greater than 10,000 hours of personal practice and nearly 10 years of formal MBSR teaching experience.
88926232|NCT03141190|Active Comparator|The Mind of a Surgeon|8 weekly classes of 2 hours each with group reading and discussion of selected articles and stories about the ethos and experience of becoming a surgeon. Designed and administered by a surgical faculty member with extensive experience in surgical education and scholarly work in the area of the 'surgical personality'.
88926233|NCT03133260||Non cardiac surgery|Determine perioperative troponin to diagnose perioperative MINS. In case of MINS acetylsalicylic acid and statins will be started if no contraindication. We will follow-up these patients for a year (including cardiologic evaluation after discharge)
88926234|NCT03097146|Other|comprehensive multidisciplinary stroke care|
88926235|NCT03096834|Placebo Comparator|Placebo DB|Matching placebo subcutaneous injections administered every 4 weeks during Double-Blind Epoch
88926236|NCT03096834|Experimental|AMG334 140 mg DB|AMG334 70 mg subcutaneous injections (2) administered every 4 weeks during Double-Blind Epoch
88926237|NCT03096834|Experimental|AMG334 140 mg DB cont on AMG334 140 mg|AMG334 70 mg subcutaneous injections (2) during DB continued on AMG334 140 mg in Open-Label Epoch
88926238|NCT03096834|Experimental|Placebo in DB to AMG334 140 mg|Placebo in Double-Blind Epoch (DB) switched to AMG334 140 mg in Open-Label Epoch
88926239|NCT03065465|Other|Standard endoscopic treatment|For those assigned to the standard endoscopy group, endoscopic hemostasis is performed using usual CURE hemostasis therapy for the focal GI lesions: injection of dilute (e.g. 1: 20,000) epinephrine (in 1-2 cc aliquots in 4 quadrants next to the SRH) of active bleeding or adherent clots (prior to snaring them off); coaptive coagulation with multipolar electrocautery (MPEC) probe and/or standard through the endoscope hemoclips along the course of the underlying artery as detected by DEP. Hemostasis is performed until active bleeding stops and/or the SRH is obliterated. Residual blood flow after visually guided hemostasis is recorded, but not used as a guide for additional hemostasis in this study.
88926240|NCT03065465|Experimental|Over-the-scope hemoclipping device|For those assigned OTSC, prior to use of the OTSC in UGI lesions with active bleeding or adherent clots, dilute epinephrine (1: 20,000) is injected around the SRH in 1-2 cc aliquots and the clots are cold guillotined off, as previously described (2, 4, 17). As a brief additional description, after initial diagnosis and preparation of the lesion and SRH (as described for standard hemostasis), the therapeutic sized endoscope is removed and this or a diagnostic panendoscope will be affixed with the OTSC of appropriate size for the endoscope and the target lesion. The endoscope is re-introduced and passed to the bleeding site. The SRH is centered in the field of view and within the cap of the OTSC device. Using high suctioning and firm pressure to center the SRH, the lesion and SRH is captured into the cap and the OTSC is deployed by rotating the handle and thereby compressing the bleeding lesion and surrounding tissue with mechanical hemostasis.
88926241|NCT03065192|Experimental|VY-AADC01 Single Dose|9.4 x 10^12 vector genomes of VY-AADC01
88926242|NCT03056014|Active Comparator|N-acetylcysteine 600 mg|
89199786|NCT03808922|Experimental|Cohort 1 and Cohort 2 Treatment|DAS181 4.5mg qd x 7 OR 10 days
88926243|NCT03056014|Active Comparator|N-acetylcysteine 1200 mg|
88926244|NCT03056014|Placebo Comparator|placebo|
88926245|NCT03056014|Active Comparator|PUFA 1000 mg|
88926246|NCT03056014|Active Comparator|PUFA 2000 mg|
88926247|NCT03056014|Placebo Comparator|Placebo|
88926248|NCT03126812|Experimental|Carboplatin, paclitaxel, pembrolizumab|Carboplatin AUC= 6 paclitaxel 80 mg/m2 Pembrolizumab 200 mg starting cycle 2
88926249|NCT03026972|Experimental|Population I|Population I has 25 subjects,and it is considered as Tuberculin purified protein derivative(TB-PPD) skin test and specific gamma-interferon (γ-IFN) detection result all negative.Population I are coxal muscle injection of placebo or low dose adjuvant or low dose vaccine.
88926250|NCT03026972|Experimental|Population II|Population II is considered as Tuberculin purified protein derivative(TB-PPD) skin test , ESAT6-CFP10 skin test and specific gamma-interferon (γ-IFN) detection result all negative.It has 30 subjects.Population II are coxal muscle injection of placebo or high dose adjuvant or high dose vaccine.
88926251|NCT03026972|Experimental|Population III|Population III is considered as ESAT6-CFP10 skin test and specific gamma-interferon (γ-IFN) detection result negive,but Tuberculin purified protein derivative(TB-PPD) skin test positive.Population IV is needed 30 subjects.These subjects are coxal muscle injection of placebo or high dose adjuvant or high dose vaccine.This arm is uninfected TB PPD positve population.
88926252|NCT03026972|Experimental|Population IV|Population IV is considered as Tuberculin purified protein derivative(TB-PPD) skin test and ESAT6-CFP10 skin test and specific gamma-interferon (γ-IFN) detection result all positive.We are called latent infection population,and need to screen 50 subjects through these three selection method.Population III are coxal muscle injection of placebo or adjuvant( including low dose adjuvant or high dose adjuvant) or vaccine(including low dose vaccine high dose vaccine).
88926253|NCT03012815|Experimental|Gabapentin|Patients will receive gabapentin taper over 9 days with the option to add divalproex for patients who have a history of seizures or severe withdrawal. Will still undergo CIWA-Ar scoring but will not be administered a benzodiazepine.
88926254|NCT03012815|Active Comparator|Benzodiazepine|Patients will receive a benzodiazepine if scoring greater than 9 on the CIWA-Ar scale.
88926255|NCT03001011|Placebo Comparator|Placebo|Participants received placebo (for Renvela) orally 3 times per day (TID) for up to 8 weeks. One to five tablets were taken with meals, as directed by physician and were titrated (up to a maximum of 15 tablets per day) to reach a target goal of serum phosphorus less than or equal to (<=) 4.6 mg/dL (<=1.49 mmol/L).
88926256|NCT03001011|Experimental|Renvela|Participants received Renvela orally TID for up to 8 weeks. One to five tablets were taken with meals, as directed by physician and were titrated (up to a maximum of 15 tablets per day) to reach a target goal of serum phosphorus <=4.6 mg/dL (<=1.49 mmol/L).
88926257|NCT02993757|Experimental|CYD Dengue Vaccine + Gardasil (Concomitant Administration)|Dengue immune participants received 3 doses of CYD dengue vaccine 0.5 milliliter (mL) subcutaneously (SC) at Day 0, Month 6, and Month 12; whereas dengue non-immune participants received only 2 doses of CYD vaccine at Day 0 and Month 6. Both immune and non-immune participants received 2 doses of Gardasil vaccine 0.5 mL Intramuscular (IM), concomitantly with the first 2 doses of CYD dengue vaccine.
88926258|NCT02993757|Experimental|CYD Dengue Vaccine + Gardasil (Sequential Administration)|Dengue immune participants received 3 doses of CYD dengue vaccine 0.5 mL SC at Month 1, Month 7, and Month 13; whereas dengue non-immune participants received only 2 doses of CYD vaccine at Month 1 and Month 7. Both immune and non-immune participants received 2 doses of Gardasil vaccine 0.5 mL IM at Day 0 and Month 6 sequentially (i.e., one month before) to each of the first 2 doses of CYD dengue vaccine.
89442555|NCT02320032|Experimental|Aripiprazole Lauroxil - C|Intramuscular (IM) injection Dose and Dosing Sequence C
88926259|NCT02980068|Experimental|15N Nitrate|single 1,000mg dose of 15N nitrate with 3g of conjugated linoleic acid (CLA).
88926260|NCT02980068|Experimental|14N Sodium Nitrate|single 1,000mg dose of 14N sodium nitrate with 3g of conjugated linoleic acid (CLA)
88926261|NCT02979535|Experimental|CYD Dengue Vaccine + Cervarix (Concomitant Administration)|Participants received 3 doses of CYD dengue vaccine 0.5 milliliter (mL) subcutaneously (SC) at Day 0, Month 6, and Month 12 and 2 doses of Cervarix vaccine 0.5 mL Intramuscularly (IM) concomitantly with the 2 first doses of CYD dengue vaccine.
88926262|NCT02979535|Experimental|CYD Dengue Vaccine + Cervarix (Sequential Administration)|Participants received 3 doses of CYD dengue vaccine 0.5 mL SC at Month 1, Month 7, and Month 13 along with the 2 doses of Cervarix vaccine 0.5 mL IM at Day 0 and Month 6 sequentially (i.e., one month before) to each of the 2 first doses of CYD dengue vaccine.
88926263|NCT02978716|Experimental|Group 1: Gemcitabine/Carboplatin (Days 1 and 8)|Participants received Intravenous (IV) infusion of standard GC chemotherapy (gemcitabine 1000 milligrams per meter square [mg/m^2] and carboplatin area under the curve [AUC] 2) on Days 1 and 8 of 21-day cycle. The carboplatin dose was calculated using the Calvert formula, with a target AUC 2 (maximum 300 mg).
88926264|NCT02978716|Experimental|Group 2: Trilaciclib + Gemcitabine/ Carboplatin (Days 1 and 8)|Participants received IV infusion of trilaciclib 240 mg/m^2 plus GC chemotherapy (gemcitabine 1000 mg/m^2 and carboplatin AUC 2) IV infusion on Days 1 and 8 of 21-day cycle. Trilaciclib was administered prior to chemotherapy.
88926265|NCT02978716|Experimental|Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9)|Participants received IV infusion of trilaciclib 240 mg/m^2 on Days 1, 2, 8, and 9 plus GC chemotherapy (gemcitabine 1000 mg/m^2 and carboplatin AUC 2) IV infusion on Day 2 and 9 of 21-day Cycle. Trilaciclib was administered prior to chemotherapy.
88926266|NCT02976220|Experimental|Digital Education|1 month digital education program
89442556|NCT02320032|Experimental|Aripiprazole Lauroxil - D|Intramuscular (IM) injection Dose and Dosing Sequence D
89501688|NCT02254889|Placebo Comparator|post-ESD group|All subjects were randomly assigned to treatment with intravenous proton pump inhibitor (PPI) after ESD.
89013133|NCT02272192|Experimental|EIBI 15 hr/week|"Children receive 15 hours per week of 1:1 intervention at home plus parent training using Early Intensive Behavioral Intervention (EIBI) and following the Manual A Work in Progress"
89013134|NCT02272192|Experimental|EIBI 25 hr/week|"Children receive 25 hours per week of 1:1 intervention at home plus parent training using EIBI and following the Manual A Work in Progress"
89013135|NCT02272270|Experimental|Treatment with Study Agent Combination|"Radiation Therapy 2.0GyX30fx, 5 days per week for a total of 60 Gy Temozolomide 75mg/m2 daily throughout radiation Minocycline begins one week prior to chemoradiation, and continues twice a day throughout radiation Arm -2:100mg PO BID Arm -1:150mgPO BID Arm 0: 200mg PO BID Arm 1: 400mg PO BID Arm 1a: 300mg PO BID~Followed by 28 day break followed by~Temozolomide 150-200mg/m2 on days 1-5 out of 28 for up to12 cycles~Minocycline taken twice a day throughout each 28 day cycle for up to 12 cycles:~Arm -2:100mg PO BID Arm -1:150mgPO BID Arm 0: 200mg PO BID Arm 1: 400mg PO BID Arm 1a: 300mg PO BID"
89013136|NCT02272387|Active Comparator|Vitamin D3 (cholecalciferol) treatment|50,000 IU vitamin D3 (cholecalciferol) tablet weekly x 8 weeks plus prenatal vitamin (400 IU vitamin D)
89013137|NCT02272387|Placebo Comparator|Vitamin D placebo|Placebo tablet (appearance same as active vitamin D) plus prenatal vitamin (400IU vitamin D)
89013138|NCT02272426|Experimental|CARET + CTI|Combined Aerobic and Resistance Exercise Training (CARET) plus Cognitive Training Intervention (CTI)
89013139|NCT02272426|Sham Comparator|Sham CARET + Sham CTI|Control group Sham Combined Aerobic and Resistance Exercise Training (CARET) plus Sham Cognitive Training Intervention (CTI)
89013140|NCT02272465||Received blood products during transport|There is no intervention as this is an observational study. The first group will be the patients that received blood products during the helicopter transport from the scene of the injury per standard of care guidelines at the participating institutions.
89013141|NCT02272465||Received crystalloid during transport|There is no study intervention. The second group will be the patients that did not receive blood products during the helicopter transport because blood products are not available or part of the standard of care during flight.
89013142|NCT02272504||Standard of care arm|Chronic liver disease patients who are under going standard of care surveillance for the development of HCC as defined by AASLD guidelines.
89013143|NCT02272504||Biomarker Arm|Chronic liver disease patients who are under going standard of care surveillance for the development of HCC as defined by AASLD guidelines plus the addition of biomarker assays (AFP, AFP-L3 and DCP) every 6 months.
89013144|NCT00271206|Active Comparator|Progesterone|200 mg to 400mg of progesterone
89013145|NCT00271206|Placebo Comparator|Sugar Pill|Will mirror active medication
89013146|NCT02272543|Active Comparator|Fish surimi peptide powder|Fish surimi peptide powder
89013147|NCT02272543|Placebo Comparator|Placebo|Placebo
89013148|NCT02272582|Experimental|SOMVC001 Vascular Conduit Solution|Each patient will serve as his/her own control because each patient will have two graft segments with one segment immersed in SOMVC001 and the other in heparin dosed saline (Standard solution). Patients will be randomized using a simple random sample allocation scheme. At the time of randomization, patients will be assigned an allocation number. Each randomized patient will be implanted with two SVGs, alternating Target Region A (Circumflex or Diagonal) and Target Region B (Right Coronary System or Diagonal) and alternating (proximal vs. distal) segments of the harvested SV. A randomization schedule will be developed to ensure appropriate randomization allocation of the harvested vein segment being grafted to the targeted regions.
89199787|NCT03808922|Placebo Comparator|Cohort 1 and Cohort 2 Placebo|Placebo qd x 7 OR 10 days
89199788|NCT03808922|Experimental|Cohort 3|DAS181 4.5mg qd x 7 OR 10 days (≥ 40 kg) DAS181 2.5mg qd x 7 OR 10 days (< 40kg)
89199789|NCT03808922|Experimental|Cohort 4|DAS181 4.5mg qd x 7 OR 10 days
89199790|NCT03808922|Experimental|DAS181 COVID-19 Treatment|DAS181 4.5mg q12h x 7 OR 10 days
89199791|NCT03808922|Placebo Comparator|DAS181 COVID-19 Placebo|Placebo q12h x 7 OR 10 days
89199792|NCT03796793|Experimental|Wound Edge Debridement Group|Participants in this group will receive wound edge debridement in addition to standard of care (SOC) treatment for up to 4 weeks.
89199793|NCT03796793|Active Comparator|Standard care group|Participants in this group will receive only the standard care of treatment for up to 4 weeks.
89199794|NCT03763864|Other|Inherited disorders|
89199795|NCT03760016|Active Comparator|Moderate-Intensity Aerobic Training|
89199796|NCT03760016|Experimental|High-Intensity Interval Training|
89199797|NCT03756870|Experimental|CTO PCI|Patients will receive optimal medical therapy, with percutaneous coronary intervention of the chronic total occlusion.
89199798|NCT03756870|No Intervention|OMT|Patients will receive optimal medical therapy, without percutaneous coronary intervention of the chronic total occlusion.
89199799|NCT03718234|Experimental|Subcutaneous Hydrocortisone via Infusion Pump|Patients will receive a subcutaneous injection of hydrocortisone (HC). Each patient's total daily dose (TDD) of oral tablet hydrocortisone to determine the doses to be delivered of the study drug. The 24-hr schedule and percentage of the TDD of HC will be as follows: approximately 60% of the TDD of HC will be delivered in 3 equal pulses at 0300, 0600 and 0900. Another 35% will be delivered in 3 equal pulses at 1200, 1500 and 1800 and the remaining 5% at 2100 and 2400.
89199800|NCT03718234|Active Comparator|Standard glucocorticoid therapy|Subjects in this arm will continue on standard oral hydrocortisone therapy
89501689|NCT02150525|Experimental|Arm I (oral omega-3 fatty acid)|Patients received 3.5g oral omega-3 fatty acid daily for 6 months. Questionnaire administration, pills counts, and medication diaries were collected at monthly intervals.
89199801|NCT03717519||s-CRLM|Patients with synchronous colorectal liver metastases who underwent surgical resection
89199802|NCT03708276|Experimental|My MS Toolkit|20 Participants asked to use My MS Toolkit.
89199803|NCT03643107|Experimental|Irofulven + Prednisolone 10mg|"Irofulven will be administered as an intravenous dose of 0.45 mg/kg, over a 30-minute infusion period by venous access at day 1 and 8 of a three week cycle.~Irofulven will be administered in combination with a daily dose of 10 mg orally administered prednisolone."
89199804|NCT03641703|Experimental|FLT180a|Participants who have received gene therapy vector (FLT180a)
89199805|NCT03623243|Experimental|Siponimod|"Participants will receive titrated doses of siponimod tablets, orally, once daily of 0.25 mg on Day 2, 0.5 mg on Day 3, 0.75 mg on Day 4, 1.25 mg on Day 5, and maintenance dose of siponimod 2.0 mg tablets, orally, once daily from Day 6 up to 6 months.~As of protocol amendment 3, participants entering the trial converting from fingolimod will start directly with 2 mg dose of siponimod."
89199806|NCT03619707|Experimental|Oral Dydrogesterone|Oral dydrogesterone (Duphaston 10 mg) will be given orally four times daily : will be continued till the pregnancy test, and till at least 12 weeks of gestation in case of a positive pregnancy test.
89199807|NCT03619707|Experimental|Vaginal microprogesterone|Vaginal progesterone (Utrogestan 200 mg) will be given vaginally four times daily: will be continued till the pregnancy test, and till at least 12 weeks of gestation in case of a positive pregnancy test
89199808|NCT03611673|Experimental|Group A: 15 Scents|Participants will be asked to inhale 15 different scents two times a day.
89199809|NCT03611673|Active Comparator|Group B: 4 Scents|Participants will be asked to inhale 4 different scents two times a day.
89199810|NCT03603717|Experimental|CBT-I|Four individual sessions that will last approximately 15-30 minutes each across a 6-week time period, with the option to deliver sessions over the telephone as necessary.
89199811|NCT03603717|Active Comparator|SH|Four individual sessions that will last 15-30 minutes each across a 6-week time period, with the option to deliver sessions over the telephone as necessary.
89199812|NCT03597568|Experimental|Resveratrol|Patients will receive resveratrol 400 mg PO per day in divided doses of 200 mg in the morning and 200 mg in the evening
89199813|NCT03597568|Placebo Comparator|Placebo|Patients will receive placebo pill identical in appearance and taste to the supplement
89199814|NCT03593408||Pediatric Patients on ECMO Support|
89199815|NCT03591445|Experimental|Experimental：Bronchoscopy|Patients with ground glass opacity featured lung cancer who are candidates for surgeyr received the bronchoscopy examination before surgery.
89199816|NCT03572582|Experimental|TACE in combination with nivolumab|Treatment will be divided into 4-week cycles from the starting date of TACE. The second TACE will be repeated on day 1 (± 4 days) of cycle 3 (after 8 weeks ± 4 days). Nivolumab will be initiated on day 2-3 after the first TACE session. Nivolumab will be administered every two weeks (240mg fixed dose IV) until disease progression for up to two years.
89199817|NCT03567603||opioid exposed neonates|prenatal opioid exposure
89199818|NCT03567603||non-opioid exposed neonates|no prenatal opioid exposure
89199819|NCT03562832|Experimental|PARP inhibitor 2X-121|600 mg PARP inhibitor 2X-121 as single daily oral agent in mBC patients
89199820|NCT03505892||Participants receiving adalimumab|Participants with AS receiving adalimumab
89199821|NCT03492164|Other|[18F]FluorThanatrace ([18F]FTT)|1-(4-(2-Fluoroethoxy)phenyl)-8,9-dihiydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one also known as [18F]FluorThanatrace or [18F]FTT is a positron emitting radiopharmaceutical that has been studied in animals for selective measurement of the in vivo inhibition of the PARP-1 nuclear enzyme with positron emission tomography (PET/CT).
89199822|NCT03432871|Experimental|Nicotinamide Riboside|"This is an open-label experimental medicine study.~All subjects will receive the same dosage of the supplement Nicotinamide Riboside."
89199823|NCT03399942|Experimental|DBS-ACC ON|Start of stimulation of the DBS-ACC: On the first period, between M4 and M7, the DBS-ACC is ON and the second period, between M7 and M10 is OFF
89199824|NCT03399942|Experimental|DBS-ACC OFF|Start of stimulation of the DBS-ACC: On the first period, between M4 and M7, the DBS-ACC is OFF and the second period, between M7 and M10 is ON
89199825|NCT03389139|Active Comparator|spinal anesthesia|Patients in this group were randomized to receive spinal anesthesia. (Near infrared spectroscopy (spinal anesthesia))
89199826|NCT03389139|Active Comparator|general anesthesia|Patients in this group were randomized to receive general anesthesia. (Near infrared spectroscopy (general anesthesia)).
89199827|NCT03382938|Active Comparator|Dexmedetomidine|Drug: dexmedetomidine (Dexmed) 20 mL solution of dexmedetomidine used for wound infiltration
89199828|NCT03382938|Active Comparator|Ropivacaine|Drug: ropivacaine 20 mL solution of ropivacaine 0.375% used for wound infiltration
89199829|NCT03382938|Active Comparator|Dexmedetomidine - Ropivacaine|Drug: dexmedetomidine (Dexmed) combined with Drug: ropivacaine 20 mL solution of dexmedetomidine 1γ/kg within ropivacaine 0.375% used for wound infiltration
89199830|NCT03382938|Placebo Comparator|0.9 % saline|Drug:0.9 % saline solution (Normal saline). 20 ml with 0.9 % saline solution used for wound infiltration
89199831|NCT03380468|Experimental|Cisplatin plus pemetrexed|Drug: cisplatin 75mg/m2 iv Drug: pemetrexed 500mg/m2 iv
89199832|NCT03380468|No Intervention|Observation|Observation and follow up only
89199833|NCT03356366|Experimental|Principal study|Patients pathological process will be assessed using MRI 3T
89199834|NCT03356366|Experimental|Ancillary study 1|Patients pathological process will be assessed using MRI 1,5T
89199835|NCT03356366|Experimental|Ancillary study 2|Patients pathological process will be assessed using MRI 7T
89501690|NCT02150525|Placebo Comparator|Arm II (placebo)|Patients received equivalent, matched oral placebo (seven capsules) daily for 6 months. Questionnaire administration, pills counts, and medication diaries were collected at monthly intervals.
89501691|NCT02229955|Experimental|T-sporin eye drop|Cyclosporine 0.05% : 1 drop twice a day for 12 weeks to both eyes
89442557|NCT05514652|Experimental|First group|Multimodal low-opioid protocol provided for induction of anesthesia with intravenous (iv) propofol administration using the dosage of 1.5-2 mg/kg at 40 mg in interval of 10-15 seconds, iv fentanyl dosage 1-1.5 μg/kg and iv pipecuronium bromide dosage of 0.1 mg/kg. Before intubation of the trachea, a lidocaine 1 mg / kg bolus was added intravenously, with the simultaneous establishment of a continuous infusion at a dose of 1.5-2 mg/kg/h. All patients were administered a bolus of ketamine (0.5 mg/kg) and were started continuous infusion dexmedetomidine at a dose 0.7 μg/kg/h. If indicated fentanyl was used as additional analgesic during surgery by bolus injection. Depth of anesthesia was monitored with bispectral index; the dosage of sevoflurane from 1,5vol% to 2,5vol% was titrated to maintain BIS values from 40 to 60.
89442558|NCT05514652|Active Comparator|Second group|Routine opioid protocol of anesthesia provided for induction of anesthesia with the iv administration of propofol dosage of 1.5-2 mg/kg at 40 mg in interval of 15-20 seconds, iv fentanyl at a dose of 1-1.5 μg/kg and iv pipecuronium bromide dosage of 0.1 mg/kg. For analgesia, bolus injections of fentanyl were used at a dose of 8-10 μg/kg for the entire duration of the operation, muscle relaxation - pipecuronium bromide at a dose of 0.1 mg/kg. Depth of anesthesia was monitored with bispectral index; the dosage of sevoflurane from 1,5vol% to 2,5vol% was titrated to maintain BIS values from 40 to 60.
89442559|NCT05573282||Sequential therapy of Regorafenib combined with ICIs|"Sequential therapy of Regorafenib combined with one kind of ICIs after standard HAIC treatment in advanced hepatocellular carcinoma (HCC).~ICIs: atezolizumab, pembrolizumab, nivolumab, camrelizumab, tislelizumab, sintilimab or other ICIs."
89442560|NCT03495258|Experimental|Clarion Evolve Laser Vaporization System|Clarion Evolve Laser Vaporization System
89442561|NCT03495258|Experimental|Olympus TURis Plasma Vaporization|Olympus TURis Plasma Vaporization
89442562|NCT05143398|Active Comparator|Diet Arm|low-calorie diet normoproteic with an energy deficit of 15% compared to what emerged from the calorimetric value (basal REE)
89442563|NCT05143398|Active Comparator|Protein Arm|low-calorie diet normoproteic + an integration of 8.72 g of protein in the form of a nutritional supplement (18-20% protein)
89442564|NCT05143398|Active Comparator|EAA Arm|low-calorie diet normoproteic + amino acid supplement (2 sachet/daily; 1 sachet contains protein 0 gr, carbohydrates 6.69 gr , lipids 0 gr, i-leucine 1,2 gr, i-isoleucine 0,6 gr, i-valine 0,6 gr).
89442565|NCT05143398|Active Comparator|EAA + TCA|low-calorie diet normoproteic + an amino acid supplement (2 stick/daily; 1 stick pack contains protein 0 gr, carbohydrates 1,046 gr, lipids 0.074 gr, i-leucine 1.2 gr, i-isoleucine 0.6 gr, i-valine 0.6 gr, citric acid, succinic acid and malic acid)
89442566|NCT00673244|Experimental|1|
89442567|NCT05568992|Experimental|AI assisted group|AI assisted endoscopist' optical detection of advanced adenomas among 100 images of polyps
89442568|NCT05568992|No Intervention|non-AI assisted group|Endoscopist' optical detection of advanced adenomas among 100 images of polyps using their experience of colonoscopy
89442569|NCT04424680|No Intervention|Control|"Patients will be followed in heart failure outpatients units according to the usual established protocol. In the first visit, patients from both control and intervention groups will complete the questionnaires with the help of researchers. After one year of follow-up, the questionnaires will be submitted again to all patients and three new questionnaires will be proposed.~Treatment for heart failure will be the same in both groups."
89442570|NCT04424680|Experimental|Intervention|"Patients will participate in the Advanced Care Planning Program. In the first visit, patients from both control and intervention groups will complete the questionnaires with the help of researchers. After one year of follow-up, the questionnaires will be submitted again to all patients and three new questionnaires will be proposed.~Treatment for heart failure will be the same in both groups."
89442571|NCT04501016|Experimental|Tailored Intervention|Tailored behavioral counseling combined with tobacco cessation pharmacotherapy.
89442572|NCT02320188|Experimental|Eccentric exercise|Thirty sessions of Eccentric training in twelve weeks. Average of two sessions per week without spacing higher than eight days between two sessions.
89442573|NCT02320188|Experimental|Concentric exercise|Thirty sessions of Concentric training in twelve weeks. Average of three sessions per week without spacing higher than eight days between two sessions.
89442574|NCT02320188|No Intervention|No training (control)|Usual activities. No further training during the observation period
88926267|NCT02973321|Placebo Comparator|Placebo|Placebo (for SAR425899) subcutaneous (SC) injection once daily (QD) from Week 1 to Week 26, matching 3 SAR425899 dose levels of 0.12 mg, 0.16 mg and 0.20 mg.
89442575|NCT05519176||Cases|Varicose veins of lower extremities inpatients with venous ulceration from The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital.
89442576|NCT05519176||Controls|Varicose veins of lower extremities inpatients without venous ulceration from The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital.
89442577|NCT05519020||Ivacaftor/Tezacaftor/Elexacaftor eligible|People with cystic fibrosis who are eligible for and taking Ivacaftor/Tezacaftor/Elexacaftor
88926268|NCT02973321|Experimental|SAR425899 0.12 mg|SAR425899 SC injection QD at maintenance dose of 0.12 mg for 25 weeks (Week 2 to Week 26) following 1 week dose increase step (0.06 mg at Week 1).
88926269|NCT02973321|Experimental|SAR425899 0.16 mg|SAR425899 SC injection QD at maintenance dose of 0.16 mg for 24 weeks (Week 3 to Week 26) following 2 weeks dose increase step (0.06 mg at Week 1 and 0.12 mg at Week 2).
88926270|NCT02973321|Experimental|SAR425899 0.20 mg|SAR425899 SC injection QD at maintenance dose of 0.20 mg for 23 weeks (Week 4 to Week 26) following 3 weeks dose increase step (0.06 mg at Week 1, 0.12 mg at Week 2 and 0.16 mg at Week 3).
88926271|NCT02973321|Active Comparator|Liraglutide|Liraglutide SC injection QD at maintenance dose of 1.8 mg for 24 weeks (Week 3 to Week 26) following 2 weeks dose increase steps (0.6 mg daily at Week 1 and by 1.2 mg daily at Week 2).
88926272|NCT02967250|Experimental|Ursodeoxycholic acid treatment|Each subject will receive UDCA intervention for six weeks.
89442578|NCT05519020||Ivacaftor/Tezacaftor/Elexacaftor ineligible|People with cystic fibrosis who are not taking Ivacaftor/Tezacaftor/Elexacaftor for any reason
89442579|NCT05143242|Active Comparator|Guided bone regeneration: Control|Deproteinized bovine derived xenograft (Geistlich Bio-Oss® 0.25 - 1 mm, Geistlich Pharma AG, Wolhusen, Switzerland)
89442580|NCT05143242|Active Comparator|Connective tissue graft: Test|Connective tissue graft harvested from the palate
88926273|NCT02963844|Experimental|Inspiratory Muscle Training|The components of this group held the IMT load equivalent to 75% of the Pimáx. (measured weekly) for eight weeks.
88926274|NCT02963844|Sham Comparator|Inspiratory Muscle Training Sham|This group simulate the training, conducted the training without charge for the same period the intervention group.
88926275|NCT02944188|Experimental|LRH plus ERAS|patients undergo Laparoscopic right hemicolectomy plus ERAS
88926276|NCT02944188|Active Comparator|ORH plus ERAS|patients undergo open right hemicolectomy plus ERAS
88926277|NCT02943785|Experimental|Edoxaban-based Regimen|Edoxaban-based regimen 60 mg and 30 mg film coated tablet for once-daily oral use, and 15 mg film coated tablet in case of transitioning at the end of treatment. Dosing must follow the locally approved label.
88926278|NCT02943785|Active Comparator|VKA-based Regimen|VKA-based regimen oral VKA tablets as selected and provided by the site and used in accordance with the local label. The Investigator will monitor the patient and adjust the VKA dose to maintain the dose within target.
88926279|NCT02938143|Experimental|4-stage criteria-based exercise protocol|a progressive 4-stage criteria-based exercise protocol within the limits of pain
88926280|NCT02938143|Active Comparator|Heavy-load eccentric exercise protocol|a 12-week painful heavy-load eccentric exercise protocol
88926281|NCT02936947|Experimental|tomotherapy (HFPV vs free breathing)|Tomotherapy: locally advanced lung cancer (Stage III) or left breast cancer. High Frequency Percussive Ventilation will be coupled to tomotherapy treatment. The alternative procedure is free breathing.
88926282|NCT02936947|Experimental|linear accelerator (HFPV vs ABC)|"Linear accelerator: breast cancer or pulmonary cancers (Stage I/II) requiring a stereotaxic radiotherapy.~High Frequency Percussive Ventilation will be coupled to linear accelerator. The alternative procedure is Active Breathing Control (ABC)."
88926283|NCT02932345||Long-term survivors group (case)|EGFR M+ aNSCLC patients who continuously received gefitinib for at least 3 years
88926284|NCT02932345||Rapid PD group (control)|EGFR M+ aNSCLC patients who had undergone PD after gefitinib treatment≤3 months
88926285|NCT02927990||Study group|Percutaneous coronary interventions with additional imaging provided by the new software package
88926286|NCT02927990||Control group|Percutaneous coronary interventions without the new software package
88926287|NCT02923674|Other|Weight loss + sitless|"All participants will undergo a dietary WL intervention designed to elicit behavioral changes leading to decreased caloric intake sufficient to yield a ~10% loss of initial body mass.~Participants will be encouraged and taught to reduce sedentary behavior (SB) during waking hours. The SitLess treatment targets increases in postural shifts and light, spontaneous physical activity (SPA) (MET level <3)."
88926288|NCT02923674|Other|Weight loss + exercise|"All participants will undergo a dietary WL intervention designed to elicit behavioral changes leading to decreased caloric intake sufficient to yield a ~10% loss of initial body mass.~Participants will be asked to perform structured aerobic exercise (mostly treadmill walking) of moderate-intensity for 4-5 days/week, progressing to a duration of 200 min/week."
88926289|NCT02923674|Other|Weight loss + exercise + sitless|"All participants will undergo a dietary WL intervention designed to elicit behavioral changes leading to decreased caloric intake sufficient to yield a ~10% loss of initial body mass.~Participants will be encouraged and taught to reduce sedentary behavior (SB) during waking hours. The SitLess treatment targets increases in postural shifts and light, spontaneous physical activity (SPA) (MET level <3).~Participants will be asked to perform structured aerobic exercise (mostly treadmill walking) of moderate-intensity for 4-5 days/week, progressing to a duration of 200 min/week."
88926290|NCT02921971|Placebo Comparator|Placebo|Placebo (for SAR156597), single subcutaneous (SC) injection once in a week (QW) up to Week 24.
88926291|NCT02921971|Experimental|SAR156597|SAR156597 200 milligram (mg), single SC injection QW up to Week 24.
88926292|NCT02908334|No Intervention|Standard of Care|standard of care treatment for disseminated or meningeal coccidioidomycosis
88926293|NCT02908334|Experimental|Standard of Care + Sertraline|Standard of care treatment with the addition of sertraline for the treatment of disseminated or meningeal coccidioidomycosis
89442581|NCT05561348|Experimental|active transcutaneous auricular vagus nerve stimulation|For Experimental Arm, active transcutaneous auricular vagus nerve stimulation, Patients underwent seven consecutive daily sessions of taVNS.
88926294|NCT02906397|Experimental|Experimental: Galunisertib/SBRT|Galunisertib (LY2157299) 150mg by mouth twice a day on days 1-14 of 28 day cycles SBRT 18Gy, delivered in one fraction between Cycle 1 D15 and D28
88926295|NCT02905669|Experimental|EndoFLIP|Esophago-gastric junction distensibility will be assessed in patients thanks to impedance planimetry using EndoFLIP device.
89442582|NCT05561348|Sham Comparator|sham transcutaneous auricular vagus nerve stimulation|For sham transcutaneous auricular vagus nerve stimulation arm, Sham Comparator, patients underwent seven consecutive daily sessions of sham-taVNS (the electrodes were fixed at the same position without releasing current).
89442583|NCT05512078|Experimental|intervention|patient specific surgical positioning guide
89442584|NCT05512078|Active Comparator|control|onlay bone graft
89442585|NCT02517788|Experimental|Part A: Interferon beta-1a in HSA-free solution|Twelve subjects will participate in 3 periods of part A, receiving 18 MIU biosimilar interferon beta-1a without albumin as i.v. bolus into a distal port under constant saline infusion as 3 treatments.
89442586|NCT02517788|Experimental|Part A: Interferon beta-1a combined with HSA+ solution|Twelve subjects will participate in 3 periods of part A, receiving 18 MIU biosimilar interferon beta-1a with albumin as i.v. bolus into a distal port under constant saline infusion as 3 treatments.
89442587|NCT02517788|Active Comparator|Part A: Interferon beta-1a in marketed HSA+ solution|Twelve subjects will participate in 3 periods of part A, receiving 18 MIU original interferon beta-1a with albumin as i.v. bolus into a distal port under constant saline infusion as 3 treatments.
89442588|NCT02517788|Experimental|Part B: Interferon beta-1a in HSA-free solution|Twelve additional volunteers will participate in part B, receiving 4 x 18 MIU biosimilar interferon beta-1a with albumin as s.c. doses at 48 hours intervals as 3 pre-filled syringes (3 sites 1 cm apart in abdominal wall on each dosing day, alternating right side for odd dose [i.e. dose 1 and 3] and left side for even dose [i.e. dose 2 and 4]).
89442589|NCT02517788|Active Comparator|Part B: Interferon beta-1a in marketed HSA+ solution|Part B: Twelve additional volunteers will participate in part B, receiving 4 x 18 MIU original interferon beta-1a with albumin as s.c. doses at 48 hours intervals as 3 pre-filled syringes (3 sites 1 cm apart in abdominal wall on each dosing day, alternating right side for odd dose [i.e. dose 1 and 3] and left side for even dose [i.e. dose 2 and 4]).
89442590|NCT05143086|Placebo Comparator|Placebo|Mouthwash without fluoride.
89442591|NCT05143086|Active Comparator|Mouthwash standard|Mouthwash with 225ppm sodium fluoride (NaF). Positive control.
89442592|NCT05143086|Experimental|Mouthwash 50% Nano-F|Mouthwash experimental with Fluoride being half of fluoride Nanoencapsulated and other half freeform of NaF.
89442593|NCT05143086|Experimental|Mouthwash 100% Nano-F|Mouthwash experimental with fluoride 100% Nanoencapsulated.
89442594|NCT03347630|Other|oesophagus cancer MRI|Diagnostic test
89442595|NCT04293406||Established Prostate Cancer Group|Established Prostate Cancer Group will consist of a qualitative study of 12 semi-structured interviews with self-identified AA patient undergoing prostate treatment (stages I-III) (N-12 patients) and 12 semi-structured interviews with H/L patient undergoing prostate treatment (stages I-III) (N=12 patients) at NYPH Queens and NYPH-BM. Interview content will focus on psycho-social and socio-cultural factors associated with prostate cancer decision making, social support, and physician-patient communication.
89442596|NCT04293406||At Risk of Prostate Cancer Group|"At Risk of Prostate Cancer Group will recruit 58 self-identified AA or H/L men at risk of prostate cancer (stages I-III) receiving care at NYPH-Queens and NYPHQ (29 at each hospital) to participate in the evaluation of the tailored DNI intervention. Men who consent to participate in the study will complete a baseline survey. After biopsy appointment, participants with a negative Prostate Cancer biopsy will receive a study closure phone call, ending study participation.~Participants with positive Prostate Cancer biopsy will proceed with study procedures and be randomly assigned to decision navigation intervention (DNI) or standard of care (SOC). Participants with a positive Prostate Cancer biopsy will be followed for 6 months and complete assessments at 2 weeks, 1 month, and 6 months (close of the study)."
89442597|NCT02320344|Experimental|Partners in Care|
89442598|NCT03347552|Experimental|Active Treatment|Participants in the active arm will be enrolled in the HOME Program.
89442599|NCT03347552|No Intervention|E-CARE|"Receiving enhanced care as usual. Participants at these sites are described as receiving enhanced care as usual or E-CARE because they will be recruited, enrolled and complete baseline and follow-up assessments in addition to care as usual."
89442600|NCT05128266||Endodontical Retreatment|non-surgical retreatment of teeth with broken file instrument into the canal using ultrasounds, microscope and a modified spinal needle
89442601|NCT05514262|Experimental|The stress ball group|With this group, a yellow stress ball will be used which is 6cm in diameter, of medium hardness and made of high quality silicone, and which returns to its original shape after being squeezed. The researcher will explain to the individuals in the group how they should use the stress ball five minutes before beginning the vaccination and during the procedure. The individuals will be taught to take the stress ball in their right hand, the side on which the vaccination will not be given, and, counting from one to three, to squeeze and release the ball, continuing until the procedure is finished. It will be explained that during the procedure, they should give their attention to the stress ball and focus on squeezing it.
89442602|NCT05514262|Experimental|The Buzzy® group|Individuals in this group will use the Buzzy® device. Before the vaccination procedure, the researcher will place the Buzzy® device, which will be at room temperature, on the vaccination site, and it will vibrate in a non-discomforting way for one minute. After this, the Buzzy® device will be removed from the site, and the nurse will perform the vaccination. Because Buzzy® is a device which can be re-used, it will be disinfected after each vaccination procedure, and re-used with other individuals. The Buzzy® device also has ice wings which will not be used in this study, and only the body of the device will be used to provide vibration.
89442603|NCT05514262|No Intervention|The control group|Individuals included in the control group will receive no intervention before the vaccination procedure, and the routine Covid-19 vaccination procedure will be used.
89442604|NCT02320422|Experimental|Behavioral Telehealth|
89442605|NCT03493776|Active Comparator|Pre-Transplant Group|VZV Subunit vaccine will be administered
89442606|NCT03493776|Experimental|Post-Transplant Group|VZV Subunit vaccine will be administered
89442607|NCT04599790|Experimental|TACE-Len-Sin|TACE combined with lenvatinib and sintilimab.
89442608|NCT02517632|Experimental|Exercise group|This arm will be submitted to a exercise session and counseling from pharmaceutical and nutritional professionals.
88926296|NCT02903615|Experimental|Novel type 1 diet|Experimental diet to be examined: altered macronutrient composition: lower carbohydrate, Mediterranean-style, prebiotic fibre focus.
89442609|NCT02517632|Other|Control group|This arm will have only the counseling from pharmaceutical and nutritional professionals.
89442610|NCT03132168|Other|Subjects undergoing radical cystectomy|Subjects involved in the study will be evaluated with various non-invasive assessments including the Richmond Agitation-Sedation Scale, pain assessments on a Numeric Rating Scale (NRS-11), and CAM-ICU scale. Blood draws will also take place in order to perform microRNA testing in all subjects participating in the trial. Standardized anesthetic care as described by the approved protocol will be followed for each subject included in this trial.
89442611|NCT04937062|Experimental|SLC6A1 and STXBP1|"Each participant will be enrolled for 14 weeks (4 weeks baseline, 8 weeks of drug exposure, and 2 weeks follow-up). After clinical assessment by the investigator if deemed safe and appropriate, and requested by the caregiver, participants may continue to receive the study medication (extended use), up to December 2025. Participants who remain on phenylbutyrate therapy will be followed quarterly through video visits, and yearly in-person visit. Participants who do not opt to remain on phenylbutyrate therapy will be weaned off the medication during the 2 week follow-up period."
88926297|NCT02903615|Placebo Comparator|Standard therapy|Standard dietary therapy, as promulgated by Australian standards
88926298|NCT02895906|Experimental|NFC-1|Doses of NFC-1 will be administered as 50, 100, 200, or 400 mg twice daily as capsules for oral administration.
88926299|NCT02887651|No Intervention|observation|patients in the observation arm receive no adjuvant local radiation therapy after complete surgical resection of a cerebral metastasis
88926300|NCT02887651|Active Comparator|cavity boost radiation therapy|patients in the intervention arm receive an adjuvant local radiation therapy (cavity boost radiation therapy: 10 x 3 Gy ad 30 Gy; clinical target volume (CTV): resection cavity plus surrounding 5 mm; planning target volume (PTV): CTV + 1mm)
88926301|NCT02886286|Experimental|Bupivacaine + Opioid|Intrathecal solution has bupivacaine with an opioid (hydromorphone, fentanyl or morphine). Patients will administer PTM bolus of bupivacaine with opioid. The bolus will be administered over 2 minutes and will have a variable frequency depending on patient's need but the number of boluses should be >2 and <10. The bupivacaine dosage would range between 0.4 and 1.5 mg per bolus. The opioid dose will vary depending on the concentration of the opioid in the solution.
88926302|NCT02886286|Active Comparator|Opioid|Intrathecal solution has only an opioid (hydromorphone, fentanyl or morphine) and no bupivacaine. Patients will administer PTM bolus of opioid without bupivacaine. This opioid bolus dose would be the same as they would have received prior to enrolling in the study (with bupivacaine). The bolus will be administered over 2 minutes and will have a variable frequency depending on patient's need but the number of boluses should be >2 and <10.
88926303|NCT02865187|Experimental|Vitamin D + hormonal contraception|600IU/day Vitamin D + hormonal contraception
88926304|NCT02865187|Active Comparator|Vit D + non-hormonal contraception|600IU/day Vitamin D
88926305|NCT02861885||Lesion SSL|Patient cohort referred by colonoscopy screening indication, digestive syndrome or monitoring, with ascendant colon macroscopic SSL suspicion throughout white light during colonoscopy
88926306|NCT02826707|Experimental|SPPAC intervention|Smartphone-delivered peer-led physical activity counselling
89442612|NCT04937062|Experimental|Monogenetic Epileptic Encephalopathy|"Each participant will be enrolled for 20 weeks (5 weeks baseline, 12 weeks of drug exposure, and 2 weeks follow-up) . After clinical assessment by the investigator if deemed safe and appropriate, and requested by the caregiver, participants may continue to receive the study medication (extended use), up to December 2025. Participants who remain on phenylbutyrate therapy will be followed quarterly through video visits, and yearly in-person visit. Participants who do not opt to remain on phenylbutyrate therapy will be weaned off the medication during the 2 week follow-up period."
89442613|NCT04256408|Experimental|Treatment group|Treatment group
88926307|NCT02826707|No Intervention|Control group|Pragmatic no-contact control group
88926308|NCT02824198|Experimental|CYD Dengue Vaccine booster Group|Participants who received 3 doses of the tetravalent dengue vaccine in a previous CYD dengue vaccine study (CYD28), received a booster injection of CYD dengue vaccine at Day 0 in this study (CYD63).
88926309|NCT02824198|Placebo Comparator|Placebo Group|Participants who received 3 doses of the tetravalent dengue vaccine in a previous CYD dengue vaccine study (CYD28), received an injection of a placebo at Day 0 in this study (CYD63).
88926310|NCT02817126|Experimental|Robot-assisted surgery|Patients undergo robot-assisted resections.
88926311|NCT02817126|Active Comparator|Laparoscopic surgery|Patients undergo laparoscopic resections.
88926312|NCT02817074|Active Comparator|MIND Diet +Weight loss|3-year intervention of dietary counseling to adhere to the MIND diet plus reduce calorie intake by 250 kcal /day for mild weight loss
88926313|NCT02817074|Placebo Comparator|Usual Diet + Weight Loss|3-year intervention of usual diet + counseling to reduce calorie intake by 250 kcal/day for mild weight loss
88926314|NCT02801045|Experimental|art therapy|Individual 30-60 minutes art therapy sessions, twice a week, offering visual arts materials.
88926315|NCT02789098|Other|STEMI|All patients included in this study (1 arm)
88926316|NCT02787551|Experimental|Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC)|"Core period: FRC injected subcutaneously once daily (QD) for 26 weeks on top of oral anti-diabetic drug (OAD) therapy. Dose individually adjusted.~Single arm extension period: Participants who completed core treatment period and met eligibility criteria entered in extension treatment period and received same treatment (FRC injected subcutaneously QD on top of OAD therapy) for 26 weeks (up to Week 52). Dose individually adjusted."
88926317|NCT02787551|Active Comparator|GLP-1 Receptor Agonist|Core period: GLP-1 RA receptor agonist (liraglutide QD, exenatide twice daily [BID], exenatide extended-release QW, albiglutide QW, or dulaglutide QW) injected subcutaneously for 26 weeks on top of OAD therapy. GLP-1 RAs were administered as per local labeling at the same dose schedule as prior to randomization.
88926318|NCT02782871|No Intervention|Control|Manual ventilation with Mapleson C-circuit
88926319|NCT02782871|Experimental|Intervention|Pneupac VR1 portable ventilator
88926320|NCT02770742||Patients for outpatient colonoscopy|The cohort consists of subsequent patients who present for routine colonoscopy. There is no active Intervention. However, groups who choose to perform colonoscopy with or without sedation will be compared.
88926321|NCT02763228|Experimental|Group 1: Exercise Program|"The exercise in this study will consist of two types of exercise training: resistance training and aerobic exercise. Resistance training is like weight lifting to improve strength and function. Participants will complete resistance training by using resistance machines and free weights. Aerobic exercise is exercise that intends to improve the cardiopulmonary or oxygen/lung and heart systems. It is often referred to as cardio exercise. Treadmill walking, stationary cycling sessions, and/or other exercises will be used for aerobic exercise.~Participants will be instructed in the exercise routine by physical fitness experts and trainers."
88926322|NCT02763228|Active Comparator|Group 2: Support Group|"First 20 Weeks: Participants will take part in a structured Health Education and Support Group sessions once a week.~Last 32 weeks: Participants will be encouraged to take part in any of the Support Group sessions offered regularly on their own schedule."
88926323|NCT02747121|Other|Control before intervention|External inspection of health services. The intervention is external inspection of sepsis detection and treatment. The intervention is delivered on the organizational Level. Patient are not assigned to the intervention. The intervention is rolled out sequentially to 24 hospitals. We collect data at base line, before the inspections and 8 and 14 month after the inspections. The first arm is the Control period before the inspections.
88926324|NCT02747121|Experimental|Intervention|External inspection of health services. We compare the effect measures before and after the inspection. The intervention arm is data after the hospitals have received the inspection.
88926325|NCT02736136|Experimental|Intervention|Joint observation and video feedback plus usual care in the neonatology (plus completion of self-report questionnaires and 15 min filmed mother-infant interaction)
88926326|NCT02736136|No Intervention|Control|Usual care in the neonatology (plus completion of self-report questionnaires and 15 min filmed mother-infant interaction)
88926327|NCT02735044|Experimental|HOE901-U300|HOE901-U300 (Insulin glargine 300 Units/milliliter [U/mL]) Subcutaneous(SC) injection once daily for 12 months.
88926328|NCT02735044|Active Comparator|Lantus|Lantus (Insulin glargine 100 U/mL) SC injection once daily for 12 months.
88926329|NCT02720744|Experimental|Sodium Oxybate|Patients will undergo a screening period and will then be titrated to the following once-nightly doses: 4.5 g sodium oxybate, 6.0 g sodium oxybate, 7.5 g sodium oxybate, and 9.0 g sodium oxybate.
88926330|NCT02720744|Placebo Comparator|Placebo|Patients will undergo a screening period and will then be titrated to the following once-nightly doses: 4.5 g placebo, 6.0 g placebo, 7.5 g placebo, and 9.0 g placebo.
88926331|NCT02699515|Experimental|MSB0011359C (M7824)|
89442614|NCT02320500|Active Comparator|standard physiotherapy|Standard of care physiotherapy for knee osteoarthritis (OA) patients who have been diagnosed with knee OA and may be candidates for total knee replacement (TKA)
88926332|NCT02695160|Experimental|Cohort 1|SB-FIX: Low Dose
88926333|NCT02695160|Experimental|Cohort 2|SB-FIX: Medium Dose
88926334|NCT02695160|Experimental|Cohort 3|SB-FIX: High Dose
88926335|NCT02692651|Active Comparator|Fidaxomicin|Fidaxomicin 200 mg PO BID for 10 days or until the end of the duration of concomitant antibiotic exposure, whichever is longer.
88926336|NCT02692651|Active Comparator|Vancomycin|Vancomycin 125 mg PO QID for 10 days or until the end of the duration of concomitant antibiotic exposure, whichever is longer.
88926337|NCT02690246||patients with HHT|patients with Hereditary Haemorrhagic Telangiectasia
88926338|NCT02690246||control cohort|indirectly only as a control cohort in questionnaire of affected persons
88926339|NCT02688855|Experimental|Investigational Group|Standard Rigid Fixation + Active OL1000 device
88926340|NCT02688855|Sham Comparator|Control Group|Standard Rigid Fixation + Sham OL1000 device
88926341|NCT02677688|Experimental|Autologous EBV specific CTL infusion|
88926342|NCT02675699|Experimental|Optimisation + HENRY|
88926343|NCT02675699|Active Comparator|HENRY as standard|
88926344|NCT02674061|Experimental|Cohort A: Pembrolizumab|Participants in Cohort A received 0-2 prior lines of treatment for recurrent ovarian cancer (ROC; 1-3 total prior lines including front-line treatment) and will be administered pembrolizumab at a dose of 200 mg via intravenous (IV) infusion on Day 1 of each 21-day cycle for up to 35 cycles (up to ~2 years). Qualified participants who complete 35 administrations of pembrolizumab but progress after discontinuation can initiate a second course of pembrolizumab 200 mg for up to 17 cycles (up to ~1 additional year).
89442615|NCT02320500|Experimental|Myofascial-specific therapy|Patient undergo myofascial pain-specific therapy which includes trigger point injections at the same time points as the comparator (1 session every 2 weeks for 8 weeks)
88926345|NCT02674061|Experimental|Cohort B: Pembrolizumab|Participants in Cohort B received 3-5 prior lines of treatment for ROC (4-6 total prior lines including front-line treatment) and will be administered pembrolizumab at a dose of 200 mg via IV infusion on Day 1 of each 21-day cycle for up to 35 cycles (up to ~2 years). Qualified participants who complete 35 administrations of pembrolizumab but progress after discontinuation can initiate a second course of pembrolizumab 200 mg for up to 17 cycles (up to ~1 additional year)
88926346|NCT02672982|Experimental|new combined NUTPSY treatment|2-month combined nutrition and psychosocial intervention
88926347|NCT02672982|Active Comparator|standard NUT treatment|2-month of standard nutritional treatment only
88926348|NCT02659124|Other|Standard of Care plus AmnioFix|All patients will receive the standard of care alone on half of their face, and AmnioFix in addition to the standard of care on the other half of their face.
88926349|NCT02654314|Experimental|Melatonin|5 mg Melatonin nightly, beginning within 24 hours of admission
88926350|NCT02654314|Placebo Comparator|Cellulose Microcrystylline|Blue capsule matching the melatonin arm
88926351|NCT02652611|Experimental|Screw Removal|Patients enrolled in the SI screw removal treatment group will undergo the surgery 5-9 months after the initial SI screw stabilization surgery. The surgeon will remove all screws that he/she is able and feels is appropriate for the patient. The patient will mobilize as per the surgeon's instructions and x-rays will be taken at follow-up clinic appointments as per standard of care to determine if the injury continues healing properly. If additional surgery is required or other complications arise, this will be recorded within the study follow-up forms.
88926352|NCT02652611|Experimental|Non-screw Removal|Patients enrolled in the Non-SI screw removal treatment group will not undergo surgical intervention to for removal of their SI screws. remove all screws that he/she is able and feels is appropriate for the patient. The patient will mobilize as per the surgeon's instructions and x-rays will be taken at follow-up clinic appointments as per standard of care to determine if the injury continues healing properly. If complications arise and/or the patient requires screw removal surgery, crossover will be allowed and recorded within study follow0up forms.
88926353|NCT02634905|Experimental|Individual session therapeutic education|The children included in the active arm will undergo, along with their parents (by child's age and wish), a structured individual TPE session between W0 and W2. This session will be conducted by the nurse trained in TPE. The session will be one hour long.
88926354|NCT02634905|No Intervention|Control|
88926355|NCT02628444|Experimental|STAGE-I Group 1: CYD Dengue Vaccine|Participants received 3 doses of CYD dengue vaccine 0.5 milliliters (mL) subcutaneously (SC) at Day 0 (Vaccination 1), Month 6 (Vaccination 2), and Month 12 (Vaccination 3).
88926356|NCT02628444|Experimental|STAGE-I Group 2: Placebo + CYD Dengue Vaccine (Months 6,12)|Participants received a dose of placebo at Day 0 (Vaccination 1) along with 2 doses of CYD dengue vaccine 0.5 mL SC at Month 6 (Vaccination 2) and Month 12 (Vaccination 3).
88926357|NCT02628444|Experimental|STAGE-I Group 3: Placebo + CYD Dengue Vaccine (Month 12)|Participants received 2 doses of placebo at Day 0 (Vaccination 1) and Month 6 (Vaccination 2) along with a dose of CYD dengue vaccine 0.5 mL SC at Month 12 (Vaccination 3).
88926358|NCT02628444|Experimental|STAGE-II Group 1a: CYD Vaccine + CYD Booster Vaccine (1 Year)|Participants from Group 1 who received vaccination in STAGE-I; and were seropositive at Baseline received a booster dose of CYD dengue vaccine in STAGE-II at 1 year post last dose in STAGE-I (i.e., at Month 24).
88926359|NCT02628444|Experimental|STAGE-II Group 2a: Placebo + CYD + CYD Booster (1 Year)|Participants from Group 2 who received vaccination in STAGE-I and were seropositive at baseline received a booster injection of CYD dengue vaccine in STAGE-II at 1 year post last dose in STAGE-I (i.e., at Month 24).
88926360|NCT02628444|Experimental|STAGE-II Group 3a: Placebo + CYD + CYD Booster (1 Year)|Participants from Group 3 who received vaccination in STAGE-I and were seropositive at Baseline received a booster injection of CYD dengue vaccine in STAGE-II at 1 year post last dose in STAGE-I (i.e., at Month 24).
88926361|NCT02628444|Experimental|STAGE-II Group 1b: CYD Vaccine + CYD Booster Vaccine (2 Years)|Participants from Group 1 who received vaccination in STAGE-I and were seropositive at Baseline received a booster injection of CYD dengue vaccine in STAGE-II at 2 years post last dose in STAGE-I (i.e., at Month 36).
89442616|NCT00708734|Experimental|Arm 1|functional exercise training
89501692|NCT02229955|Active Comparator|Restasis eye drop|Cyclosporine 0.05% : 1 drop twice a day for 12 weeks to both eyes
89501693|NCT03922165||DS peds eligible for Adenotonsillectomy|Dyads of caregivers and children with DS aged 3-13 years diagnosed with SDB and referred for treatment with adenotonsillectomy.
89501694|NCT02392143|Active Comparator|Printed Education Material|Participants received printed education materials (PEM) sent by first class mail.
88926362|NCT02628444|Experimental|STAGE-II Group 2b: Placebo + CYD + CYD Booster (2 Years)|Participants from Group 2 who received vaccination in STAGE-I and were seropositive at Baseline received a booster injection of CYD dengue vaccine in STAGE-II at 2 years post last dose in STAGE-I (i.e., at Month 36).
88926363|NCT02628444|Experimental|STAGE-II Group 3b: Placebo + CYD + CYD Booster (2 Years)|Participants from Group 3 who received vaccination in STAGE-I and were seropositive at baseline received a booster injection of CYD dengue vaccine in STAGE-II at 2 years post last dose in STAGE-I (i.e., at Month 36).
88926364|NCT02626962|Experimental|Nivolumab and Ipilimumab|Nivolumab and Ipilimumab every 3 weeks for a total of four doses (Cycles 1 and 2) followed by Nivolumab every 2 weeks
88926365|NCT02623998|Experimental|Intervention|Drug: insulin glargine - sc injection Drug: sitagliptin/metformin - oral administration Behavioral: lifestyle therapy
88926366|NCT02623998|No Intervention|Standard Care|Standard glycemic care as informed by the current clinical practice guidelines
88926367|NCT02623725|Experimental|CYD Dengue Vaccine Booster Group|Participants who received 3 doses of the tetravalent dengue vaccine in previous CYD dengue vaccine studies (CYD13 or CYD30), received a booster injection of CYD dengue vaccine at Day 0 in this study (CYD64).
88926368|NCT02623725|Experimental|Placebo Group|Participants who received 3 doses of the tetravalent dengue vaccine in previous CYD dengue vaccine studies (CYD13 or CYD30), received an injection of placebo at Day 0 in this study (CYD64).
88926369|NCT02608684|Experimental|Cisplatin+Gemcitabine+Pembrolizumab|"2 cycles of 750mg gemcitabine and 30mg cisplatin chemotherapy (standard of care) followed by 4 cycles of gemcitabine and cisplatin combined with pembrolizumab in 21-day treatment cycles followed by single-agent pembrolizumab maintenance therapy for up to 2 years of treatment (6 cycles combination treatment + 28 cycles maintenance).~Gemcitabine 750 mg/m2 every 3 weeks (Q3W) x 6 cycles IV infusion~-Day 1 and Day 8 of each 3 week cycle Standard of care~Cisplatin 30 mg/m2 Q3W x 6 cycles IV infusion~-Day 1 and Day 8 of each 3 week cycle after gemcitabine Standard of care~Pembrolizumab 200 mg Q3W starting with cycle 3 IV infusion~-Day 1 of each 3 week cycle after gemcitabine and cisplatin Experimental"
88926370|NCT02587520|Experimental|Adolescents: SP0173 Formulation 1|Healthy participants aged 10-18 years received a single dose of the SP0173 Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed (Tdap) vaccine.
88926371|NCT02587520|Experimental|Adolescents: SP0173 Formulation 2|Healthy participants aged 10-18 years received a single dose of the SP0173 Tdap vaccine.
88926372|NCT02587520|Experimental|Adolescents: SP0173 Formulation 3|Healthy participants aged 10-18 years received a single dose of the SP0173 Tdap vaccine.
88926373|NCT02587520|Experimental|Adolescents: SP0173 Formulation 4|Healthy participants aged 10-18 years received a single dose of the SP0173 Tdap vaccine.
88926374|NCT02587520|Active Comparator|Adolescents: Adacel®|Healthy participants aged 10-18 years received Adacel®.
88926375|NCT02587520|Active Comparator|Adolescents: Boostrix®|Healthy participants aged 10-18 years received Boostrix®.
88926376|NCT02587520|Experimental|Adults: SP0173 Formulation 1|Healthy participants aged 19-64 years received a single dose of the SP0173 Tdap vaccine.
88926377|NCT02587520|Experimental|Adults: SP0173 Formulation 2|Healthy participants aged 19-64 years received a single dose of the SP0173 Tdap vaccine.
88926378|NCT02587520|Experimental|Adults: SP0173 Formulation 3|Healthy participants aged 19-64 years received a single dose of the SP0173 Tdap vaccine.
88926379|NCT02587520|Experimental|Adults: SP0173 Formulation 4|Healthy participants aged 19-64 years received a single dose of the SP0173 Tdap vaccine.
88926380|NCT02587520|Active Comparator|Adults: Adacel®|Healthy participants aged 19-64 years received Adacel®.
88926381|NCT02587520|Active Comparator|Adults: Boostrix®|Healthy participants aged 19-64 years received Boostrix®.
88926382|NCT02587520|Experimental|Older Adults: SP0173 Formulation 1|Healthy participants aged greater than equal to (>=65) years received a single dose of the SP0173 Tdap vaccine.
88926383|NCT02587520|Experimental|Older Adults: SP0173 Formulation 2|Healthy participants aged >=65 years received a single dose of the SP0173 Tdap vaccine.
88926384|NCT02587520|Experimental|Older Adults: SP0173 Formulation 3|Healthy participants aged >=65 years received a single dose of the SP0173 Tdap vaccine.
88926385|NCT02587520|Experimental|Older Adults: SP0173 Formulation 4|Healthy participants aged >= 65 years received a single dose of the SP0173 Tdap vaccine.
88926386|NCT02587520|Active Comparator|Older Adults: Adacel®|Healthy participants aged >=65 years received Adacel®.
88926387|NCT02587520|Active Comparator|Older Adults: Boostrix®|Healthy participants aged >=65 years received Boostrix®.
88926388|NCT02584829|Experimental|Group 1 (avelumab and MHC class I up-regulation)|Patients who do not have a HLA type for which T cells can be generated or for whom T cells cannot be generated for technical issues receive avelumab intravenously (IV) over 1 hour every 2 weeks for 12 months. Within 7-10 days after completion of 1-3 doses of avelumab, patients receive MHC class I up-regulation intervention comprising either localized radiation therapy or recombinant interferon beta via intra-tumor injection.
89501695|NCT02392143|Active Comparator|Academic Detailing|Participants' primary care physicians (PCPs) received academic detailing (AD) to improve colorectal cancer screening referral and follow-up practices.
88926389|NCT02584829|Experimental|Group 2 (avelumab, MHC class I up-regulation, T cells)|Patients who have an HLA type for which T cells can be generated receive avelumab IV over 1 hour every 2 weeks for 12 months. Patients also receive MHC class I up-regulation intervention as in Group 1 between 7-10 days after the first infusion of avelumab and 2-5 days before the first infusion of MCPyV TAg-specific polyclonal autologous CD8+ T cells. Patients receive two infusions of MCPyV TAg-specific polyclonal autologous CD8+ T cells IV over 60-120 minutes.
88926390|NCT02581306|Other|Exercise session|All subjects will exercise for 1 hour at a moderate intensity. There are no different arms in this study
88926391|NCT02570308|Experimental|Dose escalation|Dose escalation cohorts of the intra-patient escalation regimen.
88926392|NCT02570308|Experimental|Dose expansion|Dose expansion cohort with the recommended phase 2 dose of the intra-patient dose escalation regimen.
88926393|NCT02540200|Active Comparator|Standard treatment|The patients undergo standard bone marrow stimulation technique (i.e. microfracture) for the treatment of their chondral lesions of the hip. This is currently the standard treatment for this condition.
88926394|NCT02540200|Experimental|BST-CarGel|In addition to undergoing the standard intervention with microfracture, BST-CarGel (the device of interest for the study) is applied during the intervention.
88926395|NCT02536898|Experimental|Fracture liaison service|"Information, assessment & lifestyle advice~refer to DXA scan, except patients with dementia, difficulties laying on the back or short life exp.~Blood samples~Sufficient intake of Vitamin D & calcium, combined with physical activity will be recommended with lifestyle advice (smoking & alcohol intake)~Patients With Hip, Vertebral or two or more low-trauma fractures are recommended treated with anti-osteoporosis drug~Other fractures, treatment recommended if FRAX score≥20% for major fracture & T-score≤-1.5~Fracture patients with reduced kidney function will be treated with anti-RANKL~Anti-osteoporosis drug prescribed by hospital physician~Follow-up phone call after 3 months and visit to talk with coordinating nurse after 1 year~Patients with spine or femoral neck T-scores≤-3.5, >2 severe vertebral fractures & those who suffer a second fracture while using anti-osteoporosis drug, will be referred for further examination and teriparatide treatment will be considered"
89442617|NCT02320578|Experimental|3D Laparoscopy|"Laparoscopic radical hysterectomy with pelvic lymphadenectomy are performed with 3D Laparoscopic technology.~A 10 mm port is inserted at the umbilicus for the telescope. Once pneumoperitoneum (12 mmHg) is achieved, intra-abdominal visualization will be obtained with a 0° high-definition 3D telescope. Two additional 5 mm ports are placed under direct visualization. One more 5- mm trocar is inserted in the right mid abdomen at the level of the umbilicus. The instruments used include bipolar grasper, monopolar scissors, monopolar hook, various graspers and a suction irrigation system."
88926396|NCT02536898|Other|Current treatment|Treatment as offered before intervention.
88926397|NCT02512172|Experimental|Oral CC-486 & MK-3475|Oral CC-486 300 mg days 1-14 or 21 every 28 days + IV MK-3475 200 mg days 1 and 15 every 28 days
88926398|NCT02512172|Experimental|Romidepsin & MK-3475|Romidepsin 14 mg/m2 days 1, 8 and 15 + IV MK-3475 200 mg days 1 and 15 every 28 days
88926399|NCT02512172|Experimental|Oral CC-486 & Romidepsin & MK-3475|Oral CC-486 300 mg days 1-14 or 21 + romidepsin 7 mg/m2 (days 1, 8 and 15) + IV MK-3475 200 mg days 1 and 15 every 28 days.
88926400|NCT02510703|Other|Type 2 diabetes group|Type 2 diabetes group
88926401|NCT02510703|Other|no diabetes|no diabetes
88926402|NCT02502396||Chart Review - Patterns of Rivaroxaban Usage|Retrospective chart review study to evaluate Rivaroxaban's utilization in cancer patients for venous-thromboembolism (VTE) or non-valvular atrial fibrillation (NVAF).
88926403|NCT02499367|Active Comparator|Radiation therapy|Radiotherapy on metastatic lesion
88926404|NCT02499367|Active Comparator|Low dose doxorubicin|15mg flat dose, once weekly for 2 weeks
88926405|NCT02499367|Active Comparator|Cyclophosphamide|metronomic schedule, 50mg daily orally for 2 weeks
88926406|NCT02499367|Active Comparator|Cisplatin|40mg/m2, weekly for 2 weeks
88926407|NCT02499367|Active Comparator|No induction treatment|
89442618|NCT02320578|Active Comparator|Standard Laparoscopy|Laparoscopic radical hysterectomy with pelvic lymphadenectomy are performed with standard laparoscopy technology. A 10 mm port is inserted at the umbilicus for the telescope. Once pneumoperitoneum (12 mmHg) is achieved, intra-abdominal visualization will be obtained with a 0° high-definition telescope. Two additional 5 mm ports are placed under direct visualization. One more 5 mm trocar is inserted in the right mid abdomen at the level of the umbilicus. The instruments used include bipolar grasper, monopolar scissors, monopolar hook, various graspers and a suction irrigation system.
88926408|NCT02497612|Experimental|Ferroquine (up to 400 mg) + Artefenomel (up to 800 mg)|On Day 0, based on the body weight (BW), participants received orally a single dose of ferroquine (FQ) capsules or oral suspension (along with matching placebo, as applicable to maintain blinding) and a single dose of artefenomel (OZ439) (maximum dose up to 800 milligrams [mg]) oral suspension as follows: BW greater than or equal to (>=) 35 kilograms (kg): FQ 400 mg + OZ439 800 mg; BW >=24 kg to less than (<) 35 kg: FQ 300 mg + OZ439 600 mg; BW >=15 kg to <24 kg: FQ 200 mg + OZ439 400 mg; BW >=10 kg to <15 kg: FQ 150 mg + OZ439 300 mg; BW >=7 kg to <10 kg: FQ 100 mg + OZ439 200 mg; >=5 kg to <7kg: FQ 75 mg + OZ439 150 mg.
88926409|NCT02497612|Experimental|Ferroquine (up to 600 mg) + Artefenomel (up to 800 mg)|On Day 0, based on the BW, participants received orally a single dose of FQ capsules or oral suspension (along with matching placebo, as applicable to maintain blinding) and a single dose of OZ439 (maximum dose up to 800 mg) oral suspension as follows: BW >= 35 kg: FQ 600 mg + OZ439 800 mg; BW >=24 kg to <35 kg: FQ 450 mg + OZ439 600 mg; BW >=15 kg to <24 kg: FQ 300 mg + OZ439 400 mg; BW >=10 kg to <15 kg: FQ 225 mg + OZ439 300 mg; BW >=7 kg to <10 kg: FQ 150 mg + OZ439 200 mg; >=5 kg to <7kg: FQ 115 mg + OZ439 150 mg.
88926410|NCT02497612|Experimental|Ferroquine (up to 900 mg) + Artefenomel (up to 800 mg)|On Day 0, based on the BW, participants received orally a single dose of FQ capsules or oral suspension (along with matching placebo, as applicable to maintain blinding) and a single dose of OZ439 (maximum dose up to 800 mg) oral suspension as follows: BW >= 35 kg: FQ 900 mg + OZ439 800 mg; BW >=24 kg to <35 kg: FQ 675 mg + OZ439 600 mg; BW >=15 kg to <24 kg: FQ 450 mg + OZ439 400 mg; BW >=10 kg to <15 kg: FQ 335 mg + OZ439 300 mg; BW >=7 kg to <10 kg: FQ 225 mg + OZ439 200 mg; >=5 kg to <7kg: FQ 170 mg + OZ439 150 mg.
89442619|NCT03347474|Experimental|Bilateral surgical implantation of DBS system to NAc|
89501696|NCT02392143|Active Comparator|Academic Detailing+Telephone Education|Participants' primary care physicians (PCPs) received academic detailing (AD) to improve colorectal cancer screening referral and follow-up practices and participants received tailored telephone education (TTE).
89502092|NCT04478539||COVID-19 patients admitted to the ICU|"COVID-19 patients will be treated with the Prismaflex® oXiris® system in the ICU.~Treatment will be initiated within 4 - 12 hours after admission upon establishing control of the haemostasis, ACT = Activated Coagulation Time of 180 seconds"
89199836|NCT03322774|Sham Comparator|Attention Control|This group receives sleep hygiene education, which serves as a credible control intervention to digital cognitive behavioral therapy for insomnia (dCBT-I). This intervention mimics the web-based patient contact inherent in dCBT-I but is inert with respect to sleep outcomes.
89199837|NCT03322774|Experimental|Stepped Care Model|"This group receives digital Cognitive Behavioral Therapy for Insomnia (dCBT-I) through the third party program, Sleepio. Following initial treatment with dCBT-I, individuals who do not experience remission of their insomnia will begin treatment with face-to-face Cognitive Behavioral Therapy for Insomnia with a trained staff member in behavioral sleep medicine."
89199838|NCT03322774|Sham Comparator|Stepped Care Model Control|"This group receives digital Cognitive Behavioral Therapy for Insomnia (dCBT-I) through the third party program, Sleepio. Following initial treatment with dCBT-I, individuals who do not experience remission of their insomnia will receive sleep hygiene education, serving as a credible control intervention for comparison to the Stepped Care Model."
89199839|NCT03322774|Experimental|digital CBT-I|"This group receives digital Cognitive Behavioral Therapy for Insomnia (dCBT-I) through the third party program, Sleepio. Treatment includes weekly sessions of CBT-I administered over the internet in hour-long video sessions. Daily sleep diaries are recorded online for individual tailoring of treatment."
89199840|NCT03304483|Experimental|Athletes|246-km running
89199841|NCT03284892|Experimental|SOC group|Received SOC program addition to usual care
89199842|NCT03284892|No Intervention|Control group|Received usual care only
89199843|NCT03279952|Other|medication arm|CNS Stimulant
89199844|NCT03271242||Implementation support|Units and their patients where the unit according to pairwise randomization is offered systematic implementation support for 18 months for the specific practice.
89199845|NCT03271242||No implementation support|Units and their patients where the unit according to pairwise randomization is not offered systematic implementation support for 18 months for the specific practice.
89199846|NCT03258853|Active Comparator|Usual Care|Usual Care diabetes management: Patients will manage their diabetes using standard of care for diabetes as per their typical regimen including use of an insulin pump or injectable insulin. Usual care arm for 14 days. Patients will wear a continuous glucose monitor (CGM) during this arm
89199847|NCT03258853|Experimental|Insulin only bionic pancreas|Insulin Only Bionic Pancreas diabetes management, a wearable bionic pancreas system that automatically delivers insulin using a continuous glucose monitoring (CGM) device, for 14 days.
89199848|NCT03236155|Active Comparator|1 prescription|Receives 90 pills in single prescription at discharge from hospital
89199849|NCT03236155|Active Comparator|3 prescriptions|Receives 30 pill prescription at discharge from hospital. Two refills available if requested.
89199850|NCT03216551||The assumed selective lymph node dissection group|Patients with consolidation tumor ratios ≤ 0.5 tumors will be considered to have negative mediastinal metastasis. Patients with intraoperative lepidic predominant adenocarcinoma diagnosis will be considered to have negative mediastinal metastasis. Patients with an apical tumor will be considered to have negative inferior mediastinal lymph node metastasis. If both N1 nodes and visceral pleural invasion are negative, patients with peripheral non-apical-segment upper lobe tumors will be considered to have negative inferior medistinal lymph node metastasis. If N1 nodes are negative, patients with left superior segment tumors will be considered to have negative 4L lymph node metasis, and patients with left basal segment tumors will be considered to have negative superior mediastinal lymph node metastasis.
89199851|NCT03192202|Experimental|Cohort 1|1.5 mg/kg of AFM13 once weekly for weeks 1-8.
89199852|NCT03192202|Experimental|Cohort 2|7 mg/kg of AFM13 once weekly for weeks 1-8.
89199853|NCT03192202|Experimental|Cohort 3|7mg/kg CIVI for weeks 1-8.
89199854|NCT03192202|Experimental|Cohort 4|200mg flat dose once weekly for 8 weeks.
89199855|NCT03177122|Experimental|Myo-Inositol|1g Myo-inositol per day, in combination with alpha- lipoic acid and cysteine, (Celine Tablets; Surveal Pharmaceuticals; Belgium) + 400 ug of Folic acid
89199856|NCT03177122|No Intervention|No intervention|Standard care: 400 ug of Folic acid
89199857|NCT03169166|Experimental|"Repeated 3-dose GnRHa  Triptorelin"|Triptorelin pre-filled syringes (Gonapeptyl 0.1mg; Ferring GmbH, Germany) will be administered subcutaneously in three repeated doses 12 hours apart (0.3/0.2/0.2mg) when at least three follicles 18 mm in diameter have been observed by ultrasound examination.
88926411|NCT02497612|Experimental|Ferroquine (up to 1200 mg) + Artefenomel (up to 800 mg)|On Day 0, based on the BW, participants received orally a single dose of FQ capsules or oral suspension (along with matching placebo, as applicable to maintain blinding) and a single dose of OZ439 (maximum dose up to 800 mg) oral suspension as follows: BW >= 35 kg: FQ 1200 mg + OZ439 800 mg; BW >=24 kg to <35 kg: FQ 900 mg + OZ439 600 mg; BW >=15 kg to <24 kg: FQ 600 mg + OZ439 400 mg; BW >=10 kg to <15 kg: FQ 450 mg + OZ439 300 mg; BW >=7 kg to <10 kg: FQ 300 mg + OZ439 200 mg; >=5 kg to <7kg: FQ 225 mg + OZ439 150 mg.
88926412|NCT02497131|Experimental|Brentuximab Vedotin 16 cycles|Subjects will receive 1.8 mg/kg of brentuximab vedotin as an iv infusion administered on Day 1 of each 21-day cycle for a maximum of 16 cycles.
88926413|NCT02491333|Experimental|true acupuncture + placebo metformin|"True acupuncture and placebo metformin will be started 2 days after the baseline visit including OGTT. All subjects will be asked to use a barrier method for contraception.~True acupuncture treatment will be given three times per week. Each treatment session lasts for 30 minutes and can be separated by an interval of 1-3 days, with a maximum of 48 treatment sessions during 4 month.~Placebo metformin will be given at 0.5g/times, 3 times one day and for 4 month."
88926414|NCT02491333|Sham Comparator|sham acupuncture + placebo metformin|"Sham acupuncture and placebo metformin will be started 2 days after the baseline visit including OGTT. All subjects will be asked to use a barrier method for contraception.~Sham acupuncture treatment will be given three times per week. Each treatment session lasts for 30 minutes and can be separated by an interval of 1-3 days, with a maximum of 48 treatment sessions during 4 month. Placement of needles is unlikely to affect ovulation and IR in women with PCOS.~Placebo metformin will be given at 0.5g/times, 3 times one day and for 4 month."
88926415|NCT02491333|Active Comparator|sham acupuncture + metformin|"Sham acupuncture and metformin will be started 2 days after the baseline visit including OGTT. All subjects will be asked to use a barrier method for contraception.~Sham acupuncture treatment will be given three times per week. Each treatment session lasts for 30 minutes and can be separated by an interval of 1-3 days, with a maximum of 48 treatment sessions during 4 month.Placement of needles is unlikely to affect ovulation and IR in women with PCOS.~Metformin will be given at 0.5g/times, 3 times one day and for 4 month."
88926416|NCT02490943|Active Comparator|Warm Compress Pre-Injection|Group A, N = 10, will receive warm compress before injection for three treatments, followed by cold compress after injection for three treatments.
88926417|NCT02490943|Active Comparator|Cold Compress Post-Injection|Group B, N= 10, will receive cold compress after injection for three treatments followed by warm compress before injection for three treatments.
88926418|NCT02490943|No Intervention|No Intervention Pre/Post-Injection|Group C, N= 8, will receive no treatment for six injections following screening.
88926419|NCT02470286|Experimental|Cohort 1 (SA001 60mg or Placebo)|6 subjects receiving a single dose of 60mg SA001 and 2 subjects receiving placebo
88926420|NCT02470286|Experimental|Cohort 2 (SA001 120mg or Placebo)|6 subjects receiving a single dose of 120mg SA001 and 2 subjects receiving placebo
88926421|NCT02470286|Experimental|Cohort 3 (SA001 180mg or Placebo)|6 subjects receiving a single dose of 180mg SA001 and 2 subjects receiving placebo
88926422|NCT02470286|Experimental|Cohort 4 (SA001 240mg or Placebo)|6 subjects receiving a single dose of 240mg SA001 and 2 subjects receiving placebo
88926423|NCT02470286|Experimental|Cohort 5 (SA001 300mg or Placebo)|6 subjects receiving a single dose of 300mg SA001 and 2 subjects receiving placebo
88926424|NCT02469987|Experimental|MYL-1402O|MYL-1402O (bevacizumab), single 1mg/kg i.v. infusion over 90 minutes.
88926425|NCT02469987|Active Comparator|US Marketed Avastin (R)|US Marketed Avastin(R) (bevacizumab), single 1mg/kg i.v. infusion over 90 minutes.
88926426|NCT02469987|Active Comparator|EU Marketed Avastin(R)|EU Marketed Avastin(R) (bevacizumab), single 1mg/kg i.v. infusion over 90 minutes.
89501697|NCT05033327|Other|Nutrition and Exercise App|The exercise and nutrition app intervention will be provided to study participants. The app offers self-directed and supervised (virtual) programming to support nutrition and exercise self-management. Each participant follows a program that has been tailored to their overall health, physical function, and needs.
88926427|NCT02460458||Type 3 Von Willebrand's Disease (VWD3)|Patients with diagnosis of Type 3 Von Willebrand's Disease
88926428|NCT02457559|Experimental|Tirabrutinib 40 mg once daily (CLL)|Participants with relapsed/refractory chronic lymphocytic leukemia (CLL) received tirabrutinib 40 mg once daily for up to 96 months from first dose in the parent study.
88926429|NCT02457559|Experimental|Tirabrutinib 80 mg once daily (CLL)|Participants with relapsed/refractory CLL received tirabrutinib 80 mg once daily for up to 96 months from first dose in the parent study.
88926430|NCT02457559|Experimental|Tirabrutinib 160 mg once daily (CLL)|Participants with relapsed/refractory CLL received tirabrutinib 160 mg once daily for up to 96 months from first dose in the parent study.
88926431|NCT02457559|Experimental|Tirabrutinib 320 mg once daily (CLL)|Participants with relapsed/refractory CLL received tirabrutinib 320 mg once daily for up to 96 months from first dose in the parent study.
88926432|NCT02457559|Experimental|Tirabrutinib 400 mg once daily (CLL)|Participants with relapsed/refractory CLL received tirabrutinib 400 mg once daily for up to 96 months from first dose in the parent study.
88926433|NCT02457559|Experimental|Tirabrutinib 500 mg once daily (CLL)|Participants with relapsed/refractory CLL received tirabrutinib 500 mg once daily for up to 96 months from first dose in the parent study.
88926434|NCT02457559|Experimental|Tirabrutinib 600 mg once daily (CLL)|Participants with relapsed/refractory CLL received tirabrutinib 600 mg once daily for up to 96 months from first dose in the parent study.
88926435|NCT02457559|Experimental|Tirabrutinib 300 mg twice daily (CLL)|Participants with relapsed/refractory CLL received tirabrutinib 300 mg twice daily for up to 96 months from first dose in the parent study.
88926436|NCT02457559|Experimental|Tirabrutinib 160 mg once daily (NHL)|Participants with relapsed/refractory non-Hodgkin's lymphoma (NHL) received tirabrutinib 160 mg once daily for up to 96 months from first dose in the parent study.
88926437|NCT02457559|Experimental|Tirabrutinib 320 mg once daily (NHL)|Participants with relapsed/refractory NHL received tirabrutinib 320 mg once daily for up to 96 months from first dose in the parent study.
89199858|NCT03169166|No Intervention|"Conventional 1-dose GnRHa  Triptorelin"|Triptorelin pre-filled syringes will be administered subcutaneously in a single dose (0.3 mg) when at least three follicles 18 mm in diameter have been observed by ultrasound examination.
88926438|NCT02457559|Experimental|Tirabrutinib 480 mg once daily (NHL)|Participants with relapsed/refractory NHL received tirabrutinib 480 mg once daily for up to 96 months from first dose in the parent study.
88926439|NCT02457559|Experimental|Tirabrutinib 600 mg once daily (NHL)|Participants with relapsed/refractory NHL received tirabrutinib 600 mg once daily for up to 96 months from first dose in the parent study.
88926440|NCT02439307|Active Comparator|Rifaximin|Patients will receive per day 1200 mg of rifaximin
88926441|NCT02439307|Placebo Comparator|Placebo|Patients will receive a placebo of rifaximin
88926442|NCT02437175|Placebo Comparator|Placebo|Placebo: 1 sequence of 10 tablets on the morning and 1 sequence of 10 tablets at the evening, daily, during 120 days.
88926443|NCT02437175|Experimental|Trace elements|NUTRI ENDO 1 (1 sequence of 10 tablets on the morning) and NUTRI ENDO 2 ( sequence of 10 tablets at the evening), daily, during 120 days.
88926444|NCT02424409|Active Comparator|1: Control|
88926445|NCT02424409|Experimental|2: Intervention|
88926446|NCT02418039|Placebo Comparator|MHE and normal protein diet|Normal protein content (0.8 g/kg/day)
88926447|NCT02418039|Experimental|MHE and high protein diet|Patients with minimal hepatic encephalopathy will received a high protein diet (1.5 g/kg/day)
88926448|NCT02417974|Experimental|Fecal Microbiota Transplant (FMT)|Fecal Microbiota Transplant (FMT) via colonoscopy
88926449|NCT02417974|No Intervention|Control|No Fecal Microbiota Transplant (FMT) via colonoscopy
88926450|NCT02385786|Experimental|Mindfulness-Based Cognitive Therapy|Adult Participants with Major Depressive Disorder who Enroll in an open clinical trial of MBCT as Mono-therapy
88926451|NCT02381652|Experimental|Cingal/Cingal|Subjects who had received an injection of Cingal in the 13-01 study will receive a single 4 milliliter (mL) intra-articular injection of Cingal (88 milligrams Hyaluronic Acid plus 18 milligramsTriamcinolone Hexacetonide) in the index knee in the 13-02 study.
88926452|NCT02381652|Experimental|Cingal/Monovisc|Subjects who had received an injection of Monovisc in the 13-01 study will receive a single 4 milliliter (mL) intra-articular injection of Cingal (88 milligrams Hyaluronic Acid plus 18 milligramsTriamcinolone Hexacetonide) in the index knee in the 13-02 study.
88926453|NCT02381652|Experimental|Cingal/Saline|Subjects who had received an injection of Saline in the 13-01 study will receive a single 4 milliliter (mL) intra-articular injection of Cingal (88 milligrams Hyaluronic Acid plus 18 milligramsTriamcinolone Hexacetonide) in the index knee in the 13-02 study.
88926454|NCT02378259|Experimental|Bariatric surgery|Roux-en-Y gastric bypass surgery
88926455|NCT02378259|Active Comparator|Intense conservative treatment|Intense conservative treatment. 8 week LCD followed by outpatient visits 1/ month
88926456|NCT02367794|Experimental|Arm A: Atezolizumab + Paclitaxel + Carboplatin|The induction phase of the study will consist of four or six cycles; atezolizumab, paclitaxel, and carboplatin will be administered on Day 1 of each 21-day cycle. The Day 1 order of drug administration is as follows: atezolizumab, then paclitaxel, then carboplatin. Participants who experience no further clinical benefit at any time during the induction phase will discontinue all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants will begin maintenance therapy with atezolizumab. Atezolizumab will be continued as long as there is a clinical benefit to the participant.
89199859|NCT03140735|Other|Control group of 150 heart disease-free individuals|
89199860|NCT03140735|Other|Patients with aortic sclerosis|
89199861|NCT03140735|Other|Patients with moderate aortic stenting (RA)|
88926457|NCT02367794|Experimental|Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin|The induction phase of the study will consist of four or six cycles; atezolizumab and carboplatin will be administered on Day 1 of each 21-day cycle. Nab-Paclitaxel will be administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration is as follows: atezolizumab, then nab-paclitaxel, then carboplatin. Participants who experience no further clinical benefit at any time during the induction phase will discontinue all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants will begin maintenance therapy with atezolizumab. Atezolizumab will be continued as long as there is a clinical benefit to the participant.
89199862|NCT03140735|Other|Patients with Serious Aortic Retention|
89199863|NCT03068780|Experimental|Oleogel-S10|
89199864|NCT03068780|Placebo Comparator|Control Gel|
89199865|NCT03027310||Healthy Volunteers|adult healthy volunteers
89199866|NCT03027310||tremor patients|adult patients with tremor
89199867|NCT03006848|Experimental|Avelumab|"All participants with recurrent/refractory osteosarcoma who consent to the study.~Interventions: Avelumab and quality of life questionnaires."
89199868|NCT02981069|Active Comparator|Byetta / Bydureon|"Exenatide:~4 weeks Byetta, 5 to 10ug sc (daily) 12 weeks Bydureon 2mg sc"
88926458|NCT02367794|Active Comparator|Arm C: Nab-Paclitaxel + Carboplatin|The induction phase of the study will consist of four or six cycles; carboplatin will be administered on Day 1 of each 21-day cycle, nab-paclitaxel will be administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration is as follows: nab-paclitaxel, then carboplatin. Participants who experience disease progression at any time during the induction phase will discontinue all study treatment. In the maintenance phase, participants will receive best supportive care.
89442620|NCT02323932|Active Comparator|Bilateral Cochlear implant users|The perception of intonation will be assessed through the use of 2 tests. In the first test, listeners will have to identify statements and yes/no questions that will be presented by male and female talkers in the background of four- talkers-babble noise comprised of two females and two males. In the second test, listeners will be presented with gradual changes in the fundamental frequency of a sentence. They will be required to identify the sentence with each of the changes as a statement or a question. Each of the 2 tests will be presented in three listening conditions: each of the CI alone and bilateral (CI/CI) conditions.
89199869|NCT02981069|Active Comparator|Dapagliflozin|4 weeks Dapagliflozin, Farxiga, 10mg 12 weeks Dapagliflozin, Farxiga, 10mg
89199870|NCT02981069|Active Comparator|Byetta/Bydureon plus Dapagliflozin|"Exenatide:~4 weeks Byetta, 5 to 10ug sc (daily) 12 weeks Bydureon 2mg sc PLUS~Dapagliflozin:~4 weeks Dapagliflozin, Farxiga, 10mg 12 weeks Dapagliflozin, Farxiga, 10mg"
89199871|NCT02981069|Placebo Comparator|Placebo|Placebo group (4 weeks and 12 weeks)
89199872|NCT02980991|Experimental|Neoadjuvant chemotherapy group|Two cycles of pemetrexed and cisplatin given to patients before surgery
89199873|NCT02958462|Other|Potential Premyeloid Cancer or Bone Marrow Failure Patients|Follow up provided for patients tested using Next Generation Sequencing (NGS) and other relevant functional studies
89199874|NCT02923128|Active Comparator|Dexmedetomidine+routine PCIA|PCIA pump was provided after surgery, which consisted of 3 ug/kg sufentanil and 3 ug/kg dexmedetomidine, total amount 150ml, 2 mL bolus dose with a lock-out of 10 minutes and background infu-sion rate 2 mL/h.
89199875|NCT02923128|Sham Comparator|Routine PCIA|3 ug/kg sufentanil without dexmedetomidine, total amount 150ml, 2 mL bolus dose with a lock-out of 10 minutes and background infu-sion rate 2 mL/h.
89199876|NCT02839642|Active Comparator|Rivastigmine|"Subject will receive a treatment of Rivastigmine twice daily during 24 weeks of treatment.~Study drug will be administered orally. Sufficient test drug will be dispensed to subjects or their caregivers at each study visit to allow twice daily dosing until the next scheduled study visit"
89199877|NCT02839642|Placebo Comparator|Placebo|Subject will receive a placebo twice daily during 24 weeks of treatment. Study drug will be administered orally. Sufficient test drug will be dispensed to subjects or their caregivers at each study visit to allow twice daily dosing until the next scheduled study visit
89199878|NCT02810444|Experimental|BT595|Subjects received BT595 (100 mg/mL human normal immunoglobulin) at doses between 0.2 and 0.8 g per kg body weight (bw) (2 to 8 mL/kg bw), either at a Q3W or Q4W schedule, The initial doses and dosage interval had to be consistent with the subject's prestudy IVIg treatment.
89199879|NCT02672748|Experimental|Gardening|Receiving two years of technical, labor and financial support in starting, growing, and harvesting from a home food garden.
89199880|NCT02672748|No Intervention|Control|The control families receive a garden as a delayed intervention after two years.
88926459|NCT02364323|Experimental|Personalized risk counselling|Intervention includes risk counseling to patients with diabetes on future risk of diabetic complications based on an established genetic counseling framework for common polygenic disorders which will be delivered to patient in a counselling sesssion 6 weeks after genetic testing
88926460|NCT02364323|Placebo Comparator|Normal usual care|Intervention includes normal usual care. General education on diabetes and diabetic complications
88926461|NCT02363998|Other|Open Label Lofexidine|During this open-label study, subjects will be given the option to receive lofexidine tablets for 7 days and up to 14 days if requested.
88926462|NCT02353832|Other|No Arm|Study did not have Arm(s)
88926463|NCT02353728|Experimental|All Patients|Nilotinib at a dose of 300 mg P.O. twice a day (BID) daily
88926464|NCT02351583||preclampsia|10 with diagnosis of preeclampsia will be examined with both NIRS and cytocam to obtain data
88926465|NCT02351583||normal pregnancy|10 with normal pregnancy will be examined with both NIRS and cytocam to obtain data
88926466|NCT02345070|Placebo Comparator|Placebo qw|Participants received one injection of placebo (matched to SAR156597) subcutaneously once every week (qw) for 52 weeks.
88926467|NCT02345070|Experimental|SAR156597 200 mg q2w|Participants received one injection of SAR156597 200 mg subcutaneously once every 2 weeks (q2w) alternating with placebo (matched to SAR156597) for 52 weeks.
88926468|NCT02345070|Experimental|SAR156597 200 mg qw|Participants received one injection of SAR156597 200 mg subcutaneously qw for 52 weeks.
88926469|NCT02325466|Placebo Comparator|Aspirin/Ticagrelor placebo|aspirin 81 mg daily and ticagrelor placebo twice daily
88926470|NCT02325466|Active Comparator|Aspirin/Ticagrelor|aspirin 81 mg daily and ticagrelor 90 mg twice daily
88926471|NCT02325466|Active Comparator|Aspirin Placebo/Ticagrelor|aspirin placebo daily and ticagrelor 90 mg twice daily
88926472|NCT02323100|Active Comparator|Ravicti low dose|Low dose Ravicti® oral liquid at 6ml (6.6 gm) by mouth or gastrostomy tube at 8 am, 5.5 ml (6.05gm) at 4pm and midnight for 7 days.
88926473|NCT02323100|Active Comparator|Ravicti high dose|Ravicti® oral liquid at 9ml (9.9 gm)at 8 am and 8.25ml (9.08 gm) at 4pm and midnight for 7 days.
88926474|NCT02323100|Placebo Comparator|Placebo|Matching placebo taken at 8am, 4pm and midnight for 7 days.
88926475|NCT02322710|Active Comparator|TulleGras M.S.|Sterile dressing that consists of viscose tissue coated with mineral vaseline
88926476|NCT02322710|Active Comparator|Urgotul|Sterile, hydrocolloid dressing, that consists of a polyester fabric coated with hydrocolloid particles and vaseline
88926477|NCT02303548|Experimental|1 (Sodium bicarbonate)|Sodium bicarbonate 50cc (50mEq) intravenous injection over 2 min
88926478|NCT02303548|Placebo Comparator|2 (Normal saline)|Normal saline 50cc intravenous injection over 2 min
88926479|NCT02300493|Experimental|Experimental|weigh themselves daily
88926480|NCT02300493|Active Comparator|Control|Weigh themselves every six months
89199881|NCT02612311|Experimental|Ublituximab + TGR-1202|"Ublituximab: IV infusion dose on Days 1, 8 and 15 followed by maintenance infusions~TGR-1202: Fixed oral daily dose"
89501698|NCT02230033|Experimental|Treatment A|Single oral dose of JNJ-56021927 240 milligram (mg) capsule will be administered on Day 1.
88926481|NCT02292654|Experimental|Olipudase alfa|Participants received intravenous (IV) infusion of olipudase alfa once every 2 weeks (Q2W) for 64 weeks. Each participant underwent a dose escalation according to the following paradigm: 0.03, 0.1, 0.3, 0.3, 0.6, 0.6, 1.0, 2.0, 3.0 milligram per kilogram (mg/kg). Three (3) mg/kg was the target maintenance dose, which was maintained for the remaining duration of 64 treatment weeks.
88926482|NCT02257749|Experimental|Active Rehabilitation|Active Rehabilitation Intervention and Comprehensive Education Intervention (Standard Care)
88926483|NCT02257749|Active Comparator|Comprehensive Education Intervention|Comprehensive Education Intervention (Standard Care) only
88926484|NCT02243033||Visualase|MR-guided laser focal therapy
88926485|NCT02239354|Experimental|Cohort 1|2 VC-01™ Combination Product implants
88926486|NCT02239354|Experimental|Cohort 2|4 or 6 VC-01™ Combination Product implants
88926487|NCT02234310|Experimental|Recombinant Coagulation Factor IX Fc Fusion Protein (rFIXFc)|Participants received rFIXFc intravenous (IV) injection as follows: Prophylactic treatment regimen: started with rFIXFc 50 International Units per kilogram (IU/kg) weekly until a participant reached at least 50 exposure days (ED=24-hour period in which greater than or equal to (>=1) injection/dose of rFIXFc was given) to rFIXFc, withdrawal from study or end of study. Adjustments to dose and dosing interval was based on incremental recovery, subsequent Factor IX (FIX) levels, physical activity, bleeding pattern, in accordance with local standards of care for prophylactic regimen (PR). Treatment with episodic (on demand) regimen can be initiated before PR at investigators discretion. Episodic (On demand; optional): rFIXFc at individual doses based on participant's clinical condition, type and severity of bleeding event until PR.
88926488|NCT02194816||Parkinson's Disease Patients|Any individuals who has a diagnosis of Parkinson's disease (PD), parkinsonism, or a parkinson's plus syndrome will be allowed to participate.
88926489|NCT02162563|Experimental|Arm B: FOLFOXIRI & bevacizumab (inclusion completed)|"Patients with RAS or BRAF mutated and/or right-sided tumors will receive 5FU, irinotecan, oxaliplatin (FOLFOXIRI) and bevacizumab.~Intervention: FOLFOXIRI with bevacizumab"
88926490|NCT02162563|Active Comparator|Arm A: FOLFOX/FOLFIRI & bevacizumab (inclusion completed)|"Patients with RAS or BRAF mutated and/or right-sided tumors will receive doublet fluoropyrimidine-containing chemotherapy (FOLFOX or FOLFIRI), plus bevacizumab.~Intervention: FOLFOX/FOLFIRI with bevacizumab"
88926491|NCT02162563|Experimental|Arm D: FOLFOX/FOLFIRI & panitumumab|"Patients with RAS and BRAF wildtype and left-sided tumors will receive doublet fluoropyrimidine-containing chemotherapy (FOLFOX or FOLFIRI), plus panitumumab.~Intervention: FOLFOX/FOLFIRI with panitumumab"
88926492|NCT02162563|Active Comparator|Arm C: FOLFOX/ FOLFIRI & bevacizumab|"Patients with RAS and BRAF wildtype and left-sided tumors will receive doublet fluoropyrimidine-containing chemotherapy (FOLFOX or FOLFIRI), plus bevacizumab.~Intervention: FOLFOX/FOLFIRI with bevacizumab"
89199882|NCT02612311|Active Comparator|Obinutuzumab + Chlorambucil|"Obinutuzumab: IV infusion dose on Days 1, 8 and 15 in Cycle 1 followed by Day 1 infusion in Cycles 2 - 6~Chlorambucil: Oral dose on Days 1 and 15 of Cycles 1 - 6"
89199883|NCT02612311|Experimental|Ublituximab|- Ublituximab: IV infusion dose on Days 1, 8 and 15 followed by maintenance infusions
88926493|NCT02158403|Other|Clinical Management Recommendations|Clinical management recommendations for reducing pump thrombosis
88926494|NCT02154568|Experimental|Hyperpolarized helium MRI of the chest|
88926495|NCT02139436|Experimental|FES-row-training|Subjects will perform 6 months of FES-row-training.
88926496|NCT02139436|Other|Wait-list time control|Subjects perform 6 months of their standard of care
88926497|NCT02139436|Active Comparator|Arms-only-row-training|Subjects will perform 6 months of arms-only row training
88926498|NCT02127086|Experimental|Intervention Group|The study design is a non-randomized quasi-experimental cohort design with two cohorts who will be sequentially studied. In phase 1, patients will comprise the usual care group (UCG), or control cohort, defined as receiving pain assessment and management practices that nurses are currently performing on the study units. In phase 2 the PAIN Algorithm coupled with analgesic order sets will be introduced to nurses and physicians on all participating units as the intervention. Patients enrolled in this phase will be considered the intervention group (IG), also called the experimental cohort. Nurses will be enrolled from the participating inpatient units to provide data on the clinical utility of the PAIN Algorithm.
88926499|NCT02127086|No Intervention|Usual Care Group|The study design is a non-randomized quasi-experimental cohort design with two cohorts who will be sequentially studied. In phase 1, patients will comprise the usual care group (UCG), or control cohort, defined as receiving pain assessment and management practices that nurses are currently performing on the study units. In phase 2 the PAIN Algorithm coupled with analgesic order sets will be introduced to nurses and physicians on all participating units as the intervention. Patients enrolled in this phase will be considered the intervention group (IG), also called the experimental cohort. Nurses will be enrolled from the participating inpatient units to provide data on the clinical utility of the PAIN Algorithm
88926500|NCT02120079|Active Comparator|Lotemax|Lotemax (loteprednol etabonate) 0.5% is a prescription-only, preserved ophthalmic suspension supplied by Bausch & Lomb, Inc. Lotemax (loteprednol etabonate) 0.5% has been approved by the FDA for treatment of ocular inflammation with a maximum dosing frequency of 24 drops per eye per day. It is a C-20 ester-based corticosteroid, with a potent anti-inflammatory efficacy, but decreased impact on intraocular pressure (IOP) compared to other corticosteroids, which may increase IOP. The medication will be applied topically to both eyes for 6 weeks with the following regimen: four times a day for 2 weeks, twice daily for 2 weeks, and once daily for 2 weeks.
88926501|NCT02120079|Active Comparator|Soothe Tired Eyes Lubricant Eye Drop (Artificial Tears)|Soothe Tired Eyes Lubricant Eye Drop (Bausch & Lomb Inc.) is a preserved artificial tear which is used to relieve the dryness of the eye and to prevent further irritation. Its active ingredient is glycerin 1%. The artificial tear will be applied topically to both eyes for 6 weeks with the following regimen: four times a day for 2 weeks, twice daily for 2 weeks, and once daily for 2 weeks.
88926502|NCT02106195|Experimental|Belumosudil 200 mg|Belumosudil 200 mg (two 100 mg capsules) orally once daily for 28 days
88926503|NCT02104180|Active Comparator|TulleGras M.S.|
88926504|NCT02104180|Active Comparator|Urgotul|
88926505|NCT02097550|Experimental|eHealth Intervention|Patients randomized to this arm will receive eHealth materials every 2-4 weeks over the 12-month intervention. However, the exact nature of timing, dose, and delivery channel will be informed by the formative research.
88926506|NCT02097550|No Intervention|Standard of care|These patients will receive the standard of care from their physician.
88926507|NCT02059681|Experimental|Autologous bone marrow derived-CD133+ cells|CD133+ cells (1-12x10^6) suspended in 10 ml physiological saline supplemented with 5% human albumin solution will be injected into the myocardium via the endocardial route; the whole 10 ml solution will be divided into 15-20 injections.
89199884|NCT02612311|Experimental|TGR-1202|- TGR-1202: Fixed oral daily dose
89199885|NCT02607319|Experimental|Low molecular weight heparin|Bemiparin sodium 3,500 IU anti Xa/0.2 ml solution (Hibor; Laboratories Rovi Pharmaceuticals) for injection in pre-filled syringes.
89199886|NCT02607319|No Intervention|No intervention group|Control group receiving standard care.
89199887|NCT02596191|Experimental|patients with mild CMT 1A disease|Charcot-Marie-Tooth Neuropathy Score between 1 and 10
89199888|NCT02596191|Experimental|patients with moderate CMT 1A disease|Charcot-Marie-Tooth Neuropathy Score between 11 and 20
89501699|NCT02230033|Experimental|Treatment B|Itraconazole 200 mg (2 capsules of 100 mg) will be administered once daily orally from Day 1 until Day 32, along with single oral dose of JNJ-56021927 240 mg capsule on Day 4.
89199889|NCT02596191|Experimental|patients with severe CMT 1A disease|Charcot-Marie-Tooth Neuropathy Score ≥21
89501700|NCT02230033|Experimental|Treatment C|Gemfibrozil 600 mg oral tablet will be administered twice daily from Day 1 until Day 32, along with single oral dose of JNJ-56021927 240 mg capsule on Day 4.
89013149|NCT02272582|Active Comparator|Standard of Care Heparin-dosed saline|Each patient will serve as his/her own control because each patient will have two graft segments with one segment immersed in SOMVC001 and the other in heparin dosed saline (Standard solution). Patients will be randomized using a simple random sample allocation scheme. At the time of randomization, patients will be assigned an allocation number. Each randomized patient will be implanted with two SVGs, alternating Target Region A (Circumflex or Diagonal) and Target Region B (Right Coronary System or Diagonal) and alternating (proximal vs. distal) segments of the harvested SV. A randomization schedule will be developed to ensure appropriate randomization allocation of the harvested vein segment being grafted to the targeted regions.
89013150|NCT02272621|Experimental|Partial upper hemisternotomy aortic valve replacement|Partial upper hemisternotomy AVR will be performed according to current standard of care practices.
89013151|NCT02272621|Experimental|Full sternotomy aortic valve replacement|Full sternotomy AVR through a standard median sternotomy will be performed according to current standard of care practices.
89013152|NCT02272660|Experimental|Parecoxib sodium|The patients in the parecoxib group received a single 40mg dose of parecoxib sodium 30 minutes before incision.
89013153|NCT02272660|Placebo Comparator|Normal saline injection|The control group received 2 mL normal saline injection at the same time point.
89013154|NCT02272699|Experimental|Nimotuzumab with Chemotherapy|"Patients will receive neoadjuvant chemotherapy of paclitaxel and cisplatin with concurrent nimotuzumab.~Paclitaxel 175mg per square metre on day 1 and cisplatin 30mg per square metre on day 1 and day 2 every 3 weeks for 2 cycles. Nimotuzumab 200mg per week for 6 weeks.~After neoadjuvant treatment, patients will be evaluated by a multidisciplinary teams (MDTs) and esophagectomy will be given for patients with resectable disease."
89013155|NCT02272699|Experimental|Nimotuzumab with radiotherapy|"Patients will receive neoadjuvant radiotherapy with concurrent nimotuzumab. Intensity-modulated radiation therapy(IMRT) of primary tumor and local lymph nodes with 95% planning target volume (PTV) of 41.4 Gy/23f. Nimotuzumab 200mg per week for 6 weeks.~After neoadjuvant treatment, patients will be evaluated by a multidisciplinary teams (MDTs) and esophagectomy will be given for patients with resectable disease."
89013156|NCT02272699|Active Comparator|Surgery alone|Patients in this group will be given esophagectomy without any neoadjuvant treatment. Adjuvant radiotherapy is permit for patients with positive lymph nodes metastasis.
89013157|NCT02272738|Experimental|Gemcitabine, Nab-Paclitaxel|"A conformal phase I study using 3 plus 3 method.~Chemoradiotherapy while Gemcitabine, Nab-Paclitaxel are administered.~Both Gemcitabine and Nab-Paclitaxel are an interventional agents in this arm.~Gemcitabine is administered with 30 min intravenous infusion on day 1,8 and 15 every 4 weeks.~Nab-Paclitaxel is administered with 30 min intravenous infusion on day 1,8 and 15 every 4 weeks.~Radiotherapy (a total dose of 50.4Gy) was delivered in 28 fractions."
89013158|NCT00271245|Experimental|1|200 µg selenium as selenate
89013159|NCT00271245|Experimental|2|400 µg selenium as selenate
89013160|NCT00271245|Experimental|3|200 µg selenium as selenomethionine
89013161|NCT00271245|Placebo Comparator|4|placebo
89013162|NCT02272855|Experimental|HF10 plus ipilimumab|
89013163|NCT02272894||Group A|D2 Radical Gastrectomy Adding Dissection of the Superior Mesenteric Vein Lymph Node
89013164|NCT02272894||Group B|D2 Radical Gastrectomy
89013165|NCT02272933|Experimental|Wireless Body-Worn Sensors|Elderly patients will wear sensors (Smart Slippers and a belt-clip sensor) as they go about their daily life in a geriatric care center.
89013166|NCT02273011||single shot spinal anesthesia|single shot spinal anesthesia for caesarean section was executed for anesthesia, oral analgesic medication was applicated for postoperative analgesia.
89013167|NCT02273011||combuned spinal epidural anesthesia|combined spinal epidural anesthesia for caesarean section was executed for anesthesia, epidural and oral analgesic medication was applicated for postoperative analgesia.
89013168|NCT02273089||OSA w/o EDS|Males with moderate to severe obstructive sleep apnea without excessive daytime sleepiness will be proposed nocturnal CPAP (ResMed S9 AutoSet) for three months
89013169|NCT02273089||OSA w EDS|Males with moderate to severe obstructive sleep apnea with excessive daytime sleepiness will be proposed nocturnal CPAP (ResMed S9 AutoSet) for three months
89013170|NCT01580215||Main cohort|"Patients of both genders of at least 18 years of age~Who understand and voluntarily sign an informed consent form~FEV1 > 15% predicted and < 45% predicted~RV >180% predicted~Diagnosis of emphysema with CT evidence of hyperinflation~Absence of collateral ventilation according to Chartis Assessment System~Treated with Zephyr Endobronchial Valve (EBV)"
89013171|NCT02273128||CTR Gene in Osteoporosis and Periodontitis|Patients aged between 35 - 60 yrs with Osteoporosis (BMD>-2.5) and Chronic Periodontitis (>3mm Pocket Probing Depth)
89013172|NCT00290550|Other|1|MK-0457
89013173|NCT02273245||thoracic aortgram CTs|A retrospective cohort assessment of thoracic aortogram CTs of male and female adult (age>18) patients presenting with symptoms of AAS.
89501701|NCT02150603||Adults with congenital heart disease|
89013174|NCT02273401|Experimental|BI 11054 CL|
89013175|NCT02273401|Placebo Comparator|Placebo|
89013176|NCT01601353|Experimental|Treatment|Injection of adipose derived cells into penis
89013177|NCT01601353|No Intervention|Control|No intervention through 9 months
89013178|NCT01601392|Experimental|Anodal tDCS|
89013179|NCT01601392|Active Comparator|Cathodal tDCS|
89013180|NCT01601392|Sham Comparator|Sham|
89013181|NCT01601509|Active Comparator|nasal spray with tramazoline and dexamethazone|
89013182|NCT01601509|Placebo Comparator|Placebo|
89013183|NCT00257465|Experimental|A|'Autologous, DNP-modified vaccine (M-Vax)'
89013184|NCT00257465|Experimental|B|Autologous, DNP-Modified Vaccine (MVax)
89013185|NCT00257465|Experimental|C|Autologous, DNP-Modified Vaccine (MVax)
89013186|NCT00257465|Placebo Comparator|D|0 cells
89013187|NCT01601548|Experimental|Intervention Arm|Subjects are randomized to the Mindfulness Based Cancer Recovery (MBSR) intervention. Participants are presented with mindfulness medication techniques and share their experiences related to these meditation practices. There is a home practice component with an expectation of regular home meditation practice of 45 minutes per day. A full day silent retreat will occur in the second half of the course, providing an opportunity for class participants to gain experience with mindfulness techniques.
88926508|NCT02050919|Experimental|Treatment (sorafenib, chemotherapy, radiation, surgery)|Patients receive sorafenib tosylate PO QD on days 1-71 and 85-155, epirubicin hydrochloride IV over 3-5 minutes, and ifosfamide IV over 90 minutes on days 15-17, 36-38 (ifosfamide only), 57-59, 99-101, 120-122, and 141-143. Patients undergo EBRT on days 36-45 and surgical resection on day 78. Patients with positive margins, undergo EBRT boost on days 91-98.
88926509|NCT02001142|Experimental|Exercise|
88926510|NCT02001142|No Intervention|Sedentary Control|
88926511|NCT01997463|No Intervention|Regular Therapy|Regular Asthma Therapy
88926512|NCT01997463|Experimental|Supervised Therapy|Supervised asthma therapy in schools
88926513|NCT01976754|Other|dexmedetomidine,sepsis,ED50|Intervention Name: dexmedetomidine dosage form: intravenous injection dosage：0.2-0.7μg/kg/h frequency: 1 duration:12 hours
88926514|NCT01943825|Experimental|CYD Dengue Vaccine: Group 1|Participants received 3 doses of CYD dengue vaccine, one each at 0, 2 and 6 months, respectively.
88926515|NCT01943825|Experimental|CYD Dengue Vaccine: Group 2|Participants received 3 doses of CYD dengue vaccine, one each at 0, 6 and 12 months, respectively.
88926516|NCT01943825|Experimental|CYD Dengue and JE Vaccine: Group 3|Participants received 3 doses of CYD dengue vaccine, one each at 0, 2 and 6 months, and 2 doses of JE (IXIARO) vaccine at 0 and 1 months, respectively.
88926517|NCT01943825|Experimental|CYD Dengue and JE Vaccine: Group 4|Participants received 2 doses of JE (IXIARO) vaccine at 0 and 1 months; and 3 doses of CYD dengue vaccine at 7, 9 and 13 months, respectively.
88926518|NCT01913457||Adults w/ PH|Subjects above 18y scheduled to undergo RHC for Doppler ultrasound external right chest wall tests
88926519|NCT01913457||Children w/ PH|Children 0-18y old scheduled to RHC
88926520|NCT01913457||Children control|Children 0-18y old w/o PH for Lung Doppler tests as controls
88926521|NCT01863186|Active Comparator|Lofexidine HCl (2.4mg dose)|225 subjects will be randomized to receive 2.4 mg total daily dose of lofexidine HCl during the double-blind period of the study. Subjects will take 4 tablets QID for a total daily dose of 2.4 mg (one tablet in each dose will be a placebo tablet to maintain the blind) for up to 7 days.
88926522|NCT01863186|Active Comparator|Lofexidine HCl (3.2mg dose)|225 subjects will be randomized to receive 3.2 mg total daily dose of lofexidine HCl during the double-blind period of the study. Subjects will take 4 tablets QID for a total daily dose of 3.2 mg for up to 7 days.
88926523|NCT01863186|Placebo Comparator|Placebo|150 subjects will be randomized to receive placebo during the double-blind period of the study. Subjects will take 4 tablets QID for up to 7 days.
88926524|NCT01863186|Other|Open Label Lofexidine HCl|During the open-label portion of the study, subjects will be given the option to receive lofexidine HCl tablets for up to 7 days. Dosing regimens are at the discretion of the Investigator.
88926525|NCT01828840|Active Comparator|morphine, epidural|Epidurally administrated morphine
88926526|NCT01828840|Active Comparator|fentanyl, epidural|epidurally administrated fentanyl
88926527|NCT01828840|Active Comparator|methadone, epidural|epidurally administrated methadone
88926528|NCT01828840|Active Comparator|morphine, intervenous|intravenously administrated morphine
88926529|NCT01822834||Non-CF Bronchiectasis Patients with or without NTM|Patients over the age of 18 with non-CF Bronchiectasis with or without Nontuberculosis Mycobacteria (NTM).
88926530|NCT01822834||Nontuberculosis Mycobacteria (NTM)|Patients over the age of 18 with Nontuberculosis Mycobacteria (NTM)
88926531|NCT01817426|Active Comparator|infliximab|Patients in this arm are randomized to continue IFX therapy at an unchanged dosage and frequency.
88926532|NCT01817426|Placebo Comparator|Placebo|Patients in this arm are randomized to receive matching placebo.
88926533|NCT01741103|Experimental|Sitagliptin|
88926534|NCT01741103|Placebo Comparator|Placebo|
88926535|NCT01722331|Experimental|Tildrakizumab 200 mg|Tildrakizumab 200 mg administered subcutaneously (SC) once a week at Weeks 0 and 4 and then every 12 weeks.
88926536|NCT01722331|Experimental|Tildrakizumab 100 mg|Tildrakizumab 100 mg administered SC once a week at Weeks 0 and 4 and then every 12 weeks.
88926537|NCT01722331|Placebo Comparator|Placebo|Matching placebo administered SC once a week at Weeks 0 and 4.
88926538|NCT01630590|Experimental|Cabozantinib + Androgen Ablation Therapy|Patients receive Cabozantinib at starting dose of 60 mg by mouth every day. Study cycles 3 weeks in duration. Patients stay on treatment as long as they are benefitting. Patients receive androgen ablation therapy, either by means of luteinizing hormone-releasing hormone super-agonist (of any formulation), LHRH antagonist, or surgical castration. Study doctor will decide what hormone therapy patient will receive.
88926539|NCT01619085|Experimental|All subjects|patient to receive a capsule containing Nintedanib twice a day
88926540|NCT01612663|Active Comparator|deep needle non-site specific|
88926541|NCT01612663|Active Comparator|contralateral elbow to the knee pain|
88926542|NCT01612663|Active Comparator|Energy of Living Systems Needling|
88926543|NCT01612663|Placebo Comparator|Sham acupuncture|
89199890|NCT02596191|Other|control group|Healthy volunteers
88926544|NCT01499095|Experimental|HOE901-U300|
88926545|NCT01499095|Active Comparator|Lantus|
88926546|NCT01499082|Experimental|HOE901-U300|
88926547|NCT01499082|Active Comparator|Lantus|
88926548|NCT01488890|Experimental|CYD Dengue vaccine: Group 1|Participants received 3 doses of CYD dengue vaccine; one each at 0, 6 and 12 months.
88926549|NCT01488890|Experimental|CYD Dengue vaccine: Group 2|Participants received 3 doses of CYD dengue vaccine; one each at 0, 2 and 6 months.
88926550|NCT01488890|Experimental|CYD Dengue and Yellow Fever vaccine: Group 3|Participants received 3 doses of CYD dengue vaccine; one each at 0, 2 and 6 months, and single dose of YF vaccine at Day 0.
88926551|NCT01488890|Active Comparator|Yellow Fever vaccine: Group 4|Participants received single dose of YF vaccine at Day 0.
88926552|NCT01436396|Experimental|CYD Dengue Vaccine Group|Participants received the Stamaril® and the CYD dengue vaccine (Injection 1) at enrolment (Month [M] 0) at age 12 to 13 months; measles, mumps and rubella vaccine, pneumococcal conjugated vaccine, hepatitis A vaccine at M1 (age 13 to 14 months); CYD dengue vaccine (Injection 2) at M6 (age 18 to 19 months); diphtheria, tetanus, acellular pertussis, inactivated polio and Haemophilus influenza type b (DTaP-IPV/Hib) vaccine at M7 (age 19 to 20 months); and CYD dengue vaccine (Injection 3) at M12 (age 24 to 25 months); and hepatitis A vaccine at M13 (age 25 to 26 months).
89442621|NCT02323932|Active Comparator|Bimodal Cochlear implant users|The perception of intonation will be assessed through the use of 2 tests. In the first test, listeners will have to identify statements and yes/no questions that will be presented by male and female talkers in the background of four- talkers-babble noise comprised of two females and two males. In the second test, listeners will be presented with gradual changes in the fundamental frequency of a sentence. They will be required to identify the sentence with each of the changes as a statement or a question. Each of the 2 tests will be presented in three listening conditions: CI alone, HA alone and bimodal (CI/HA) conditions.
89442622|NCT04502498||60 patients with local advanced bladder cancer|Local advanced bladder cancer patients candidate for radical cystectomy
89442623|NCT02324010|Experimental|Sitaglipltin (100mg)|Active drug (sitagliptin)
88926553|NCT01436396|Experimental|Placebo Group|Participants received the Stamaril® vaccine and placebo matched to CYD vaccine (Injection 1) at enrolment (M0) (age 12 to 13 months); measles, mumps, and rubella vaccine, pneumococcal conjugate vaccine and hepatitis A vaccine at M1 (age 13 to 14 months); CYD dengue vaccine (Injection 2) at M6 (age 18 to 19 months); DTaP IPV/Hib vaccine at M7 (age19 to 20 months); and CYD dengue vaccine (Injection 3) at M12 (age 24 to 25 months); and hepatitis A vaccine at M13 (age 25 to 26 months).
88926554|NCT01414777|Experimental|ondansetron|ondansetron 8 mg IV will be administered prior to placement of the spinal anesthesia
88926555|NCT01414777|Placebo Comparator|Placebo|Ondansetron 8 mg IV or Placebo will be administered prior to placement of the spinal anesthestic
88926556|NCT01411241|Experimental|CYD Dengue Vaccine Group 1|Participants received the first injection of CYD dengue vaccine at Month 0 (9 to 12 months of age), a measles, mumps, rubella (MMR) vaccine and pneumococcal conjugate vaccine at Month 1 (10 to 13 months of age), a booster dose of Pentaxim vaccine was administered concomitantly with the second injection of CYD dengue vaccine at Month 6 (15 to 18 months of age), placebo at Month 7 (16 to 19 months of age) to maintain the blind, and the third injection of CYD dengue vaccine at Month 12 (21 to 24 months).
89013188|NCT01601548|No Intervention|Control Arm|No intervention is administered. Health-related quality of life questionnaires will be completed.
89442624|NCT02324010|Placebo Comparator|Placebo (sugar pill)|Inactive drug (placebo)
89442625|NCT05513794|Experimental|Patient group|Patient with parkinson disease
89442626|NCT05513794|Experimental|Healthy volunteer group|Healthy volunteer
89442627|NCT02517710|Placebo Comparator|Control|Group of patients receiving standard hysterotomy closure with synthetic braided suture
89442628|NCT02517710|Experimental|Stratfix|group of patients having the hysterotomy incision closed with barbed synthetic suture. Time to closure, blood loss, and postoperative pain
89501702|NCT02230111|Experimental|Energy restriction plus CDR group|Subjects will receive a reduced-calorie low energy density diet which will provide 85% of their energy needs for a period of 4 weeks. They will be told that they are on a low-calorie diet and strategies to increase CDR will be used.
89537074|NCT03301103|Experimental|PTM202|"PTM202 is a dry powder for reconstitution, comprised of a proprietary mixture of dried bovine colostrum and dried whole egg.~After an overnight fast, subjects will be orally infected with a live, but attenuated, diarrheagenic E. coli (strain E1392-75-2A; collection NIZO food research; dose 1E10 CFU (at study day 14)."
89537075|NCT00702221|Experimental|ATV with CoVaccine HT™|Angiotensin Therapeutic Vaccine with CoVaccine HT™ adjuvant (an ingredient that may improve the immune response of the vaccine)
89013189|NCT01601665||Toric High Cylinder Power IOL|Toric high cylinder power intraocular lens implanted during cataract surgery in the first operative eye, with the second operative eye implanted within 30 days of the first implantation.
89537076|NCT00702221|Placebo Comparator|CoVaccine HT™ adjuvant alone|CoVaccine HT™ adjuvant alone
89538454|NCT03266159|Experimental|Part 2: Subjects with RMNSCLC receiving GSK525762+ trametinib|Eligible subjects with Ras-mutated non small cell lung cancer (RMNSCLC) will receive their Part 2 dose as the dose combination of GSK525762 with trametinib selected at the end of Part 1.
89538455|NCT03266159|Experimental|Part 2: Subjects with RMPAC receiving GSK525762+ trametinib|Eligible subjects with Ras-mutated pancreatic adenocarcinoma (RMPAC) will receive their Part 2 dose as the dose combination of GSK525762 with trametinib selected at the end of Part 1.
89442629|NCT02517476|Experimental|Nutritional support|For the purpose of this study, we have developed nutritional guidelines by consensus and adapted to current guidelines (e.g., ESPEN, ASPEN). These guidelines specify a reinforced nutritional therapy strategy to cover nutritional requirements, focusing on nutritional targets based on the specific nutritional diagnoses defined by the IDNT. The nutritional guidelines may vary according to important medical diagnoses (i.e. renal failure). They specify not only nutritional targets, but also escalation of the route (i.e. food fortification, oral, enteral, parenteral) if targets cannot be achieved (≤75%) every 5 hours. Nutritional goals are being assessed daily in patients in the intervention group.
89442630|NCT02517476|No Intervention|"Usual care (appetite-guided) controls"|"In control patients, we will use conventional nutrition according to the ability and desire of the patient to eat, using standard care food provided by the hospital kitchen (appetite-guided)."
89442631|NCT02320656|Experimental|Acute leukemia/myelodysplastic or myeloproliferative disease|
89442632|NCT03346304|Experimental|PDT treatment (Intervention Arm)|Patients randomised to the PDT treatment (Intervention Arm) will have two courses of PDT treatment in total (for each lung treated). Follow-up is the same as for Control Arm patients: an AFB at 6, 12, 24, and at 36 months post-randomisation; with further AFB visits at 18 and/or at 30 months post-randomisation (dependent on lesion appearance).
89442633|NCT03346304|No Intervention|Surveillance (Control Arm)|Patients randomised to the surveillance (Control Arm) will have: an AFB at 6, 12, 24, and at 36 months post-randomisation; with further AFB visits at 18 and/or at 30 months post-randomisation (dependent on lesion appearance).
89013190|NCT01601665||Monofocal IOL|Monofocal intraocular lens implanted during cataract surgery in the first operative eye, with the second operative eye implanted within 30 days of the first implantation.
89013191|NCT00416364||1|
89013192|NCT00416364||2|
89013193|NCT00416364||3|
89013194|NCT00416364||4|
89013195|NCT01601743|Active Comparator|Sitting|Sitting for the same period of time and duration (30 minutes per session, 3 times per week, over 4 consecutive weeks).
89013196|NCT01601743|Active Comparator|Running|Exercise (running) for 30 minutes per session, 3 times per week, over 4 consecutive weeks.
89013197|NCT01601743|Active Comparator|Walking|Exercise (walking) for 30 minutes per session, 3 times per week, over 4 consecutive weeks.
89013198|NCT01601899|Active Comparator|ARM A|Stavudine (d4T) 30 mg po BD if wt < 60kg, or 40 mg po BD if wt > 60kg PLUS Lamivudine (3TC) 150mg po BD PLUS Efavirenz 600mg po nocte
89013199|NCT01601899|Active Comparator|ARM B|Stavudine (d4T) 20 mg po BD if wt < 60kg, or 30 mg po BD if wt > 60kg PLUS Lamivudine (3TC) 150mg po BD PLUS Efavirenz 600mg po nocte
89013200|NCT01601899|Active Comparator|ARM C|TDF 300 mg po QD PLUS Lamivudine (3TC) 150mg po BD PLUS Efavirenz 600mg po nocte
89013201|NCT01601938|Experimental|Selenium|500 mcg of selenium (10mL) daily for 7 days
89013202|NCT01601938|Placebo Comparator|Placebo|Placebo 10 mL (delivered from biosyn) for 7 days
89013203|NCT01602055|Experimental|Azivol|
89013204|NCT01602055|Active Comparator|Zithromax|
89013205|NCT00257543|Experimental|single arm study|this is a single arm study
89013206|NCT01602133|Experimental|one intervention arm|
89013207|NCT00416403|Experimental|Arm I|Patients receive oral fluvastatin sodium once daily for 3-6 weeks in the absence of disease progression or unacceptable toxicity.
89013208|NCT00416403|Experimental|Arm II|Patients receive oral fluvastatin sodium as in arm I at a higher dose.
89502093|NCT02262871|Experimental|CF patients HFN|CF patients who meet the eligibility criteria will be randomized to receive HFN and then crossover to other device.
89013209|NCT00416403|Experimental|Arm III|Patients do not receive fluvastatin sodium. breast Cancer surgery only
89013210|NCT01602211|Experimental|Arm I (INSPIRE internet full program access)|Participants receive full access to the INSPIRE internet site comprising an individually tailored program with a greeting home page with links to each target area, a 'My Health Action Plan' health care guideline for transplant survivors, self-care tips and tool pages for each complication and major issues for HCT survivors, a section for each complication (mood, energy, heart health, strengthening bones, second cancers), resource pages, opportunities to send secure messages with questions or comments on any topic, opportunities to request additional assistance or information, mobile texting options, and social media links (Twitter/Facebook/Pinterest) maintained and monitored by the Social Media Specialist.
89538456|NCT03266159|Experimental|Part 2: Subjects with RAST receiving GSK525762+ trametinib|Eligible subjects with Ras-pathway activated solid tumors (RAST) will receive their Part 2 dose as the dose combination of GSK525762 with trametinib selected at the end of Part 1.
88926557|NCT01411241|Experimental|CYD Dengue Vaccine Group 2|Participants received the first injection of CYD dengue vaccine at Month 0 (9 to 12 months of age), a MMR vaccine and pneumococcal conjugate vaccine at Month 1 (10 to 13 months of age), the Pentaxim vaccine was administered concomitantly with placebo at Month 6 (15 to 18 months of age) to maintain the blind, a second injection of CYD dengue vaccine at Month 7 (16 to 19 months of age), and the third injection of CYD dengue vaccine at Month 12 (21 to 24 months).
88926558|NCT01380938|No Intervention|Arm C. Standard duration|"Patients will be randomly assigned in 3:3:1 ratio to three treatment arms. In the standard treatment group (Arm C), patients will be treated for 24 weeks independently of the HCV RNA status at week 4 with Peginterferon alpha-2a at a dose of 180 mcg weekly in combination with oral ribavirin administered at a dosage of 800 mg/day.~Patients enrolled in Arm C will be treated for standard 24 weeks duration of treatment."
88926559|NCT01380938|Experimental|Arm A|"Patients enrolled in Arm A will receive Peginterferon alpha-2a at a dosage of 180 mcg weekly in combination with oral ribavirin administered at a dosage of 1000 mg/day for patients with a body weight < 75 kg or 1200 mg/day for those with a body weight > 75 kg.~Patients with week 4 viral clearance (labelled as rapid virological responders, RVR) will be allocated to 12 week treatment duration (Arm A), whereas those without RVR will be treated for 24 weeks (Arm A)"
88926560|NCT01380938|Experimental|Arm B|"Patients enrolled in Arm B will receive Peginterferon alpha-2a at a dosage of 180 mcg weekly in combination with oral ribavirin administered at a dosage of 800 mg/day.~Patients with week 4 viral clearance (labelled as rapid virological responders, RVR) will be allocated to 12 week treatment duration (Arm B), whereas those without RVR will be treated for 48 weeks (Arm B)"
88926561|NCT01374516|Experimental|CYD Dengue Vaccine Group|Participants were to receive 3 doses of CYD dengue vaccine; one each at 0, 6, and 12 months.
88926562|NCT01374516|Placebo Comparator|Placebo Group|Participants were to receive a placebo vaccine at 0, 6, and 12 months.
89538457|NCT04800887|Active Comparator|Extended depth of focus intraocular lens|Eyes of patients implanted with extended depth of focus lens Tecnis Eyhance
88926563|NCT01373281|Experimental|Dengue Vaccine Group|Participants were to receive CYD dengue vaccine at 0, 6, and 12 months.
88926564|NCT01373281|Placebo Comparator|Control Group|Participants were to receive a placebo vaccine at 0, 6, and 12 months.
88926565|NCT01340105|Experimental|Microwave|Hepatocellular carcinoma treated with microwave ablation
88926566|NCT01340105|Active Comparator|Radiofrequency|Hepatocellular carcinoma treated with radiofrequency ablation
88926567|NCT01254422|Experimental|CYD Dengue vaccine group|Participants received 3 injections of the CYD dengue vaccine, 1 injection each at 0, 6, and 12 months.
88926568|NCT01254422|Placebo Comparator|Placebo Group|Participants received 3 injections of placebo, 1 injection each at 0, 6, and 12 months.
88926569|NCT01204242|Placebo Comparator|Placebo|"ALL subjects will receive lidocaine up to 1.5mg/kg IV (in the vein) as a rapid injection.~Then the continuous IV infusion of the study medication (containing lidocaine 8 mg/ml or placebo) will be started and will continue for up to two hours in the recovery room."
88926570|NCT01204242|Experimental|Lidocaine|"ALL subjects will receive lidocaine up to 1.5mg/kg IV (in the vein) as a rapid injection.~Then the continuous IV infusion of the study medication (containing lidocaine 8 mg/ml or placebo) will be started and will continue for up to two hours in the recovery room."
88926571|NCT01187433|Experimental|Dengue Vaccine Group|Participants will receive Live, attenuated, recombinant dengue serotype 1 , 2, 3 , and 4 virus vaccine
88926572|NCT01187433|Placebo Comparator|Control Group|Participants will receive a placebo, NaCl 0.9%.
88926573|NCT01150045|Active Comparator|Arm A - FOLFOX and placebo (12 treatments)|Patients receive FOLFOX every 2 weeks plus placebo every day for 12 treatments (24 weeks). Each 2-week period is called a cycle. FOLFOX includes oxaliplatin, leucovorin and 5-FU.Then, patients receive placebo alone every day for 3 years total.
88926574|NCT01150045|Experimental|Arm B - FOLFOX and celecoxib (12 treatments)|Patients receive FOLFOX every 2 weeks plus celecoxib every day for 12 treatments (24 weeks). Each 2-week period is called a cycle. FOLFOX includes oxaliplatin, leucovorin and 5-FU.Then, patients receive celecoxib alone every day for 3 years total.
88926575|NCT01150045|Active Comparator|Arm C - FOLFOX and placebo (6 treatments)|Patients receive FOLFOX every 2 weeks plus placebo every day for 6 treatments (12 weeks). Each 2-week period is called a cycle. FOLFOX includes oxaliplatin, leucovorin and 5-FU.Then, patients receive placebo alone every day for 3 years total.
88926576|NCT01150045|Experimental|Arm D - FOLFOX and celecoxib (6 treatments)|Patients receive FOLFOX every 2 weeks plus celecoxib every day for 6 treatments (12 weeks). Each 2-week period is called a cycle. FOLFOX includes oxaliplatin, leucovorin and 5-FU.Then, patients receive celecoxib alone every day for 3 years total.
88926577|NCT01098032|Active Comparator|Systemic alone therapy group|Systemic alone therapy group will be treated by intravenous sodium bicarbonate plus NAC administration. Patients allocated to the Systemic alone therapy group will receive 154 mEq/l of sodium bicarbonate in dextrose and H2O, according to the protocol reported by Merten et al. (9) The initial i.v. bolus was 3 ml/kg per hour for 1 hour immediately before contrast injection. Following this, patients will receive the same fluid at a rate of 1 ml/kg per hour during contrast exposure and for 6 hours after the procedure. All patients will receive NAC (Fluimucil, Zambon Group SpA, Milan, Italy) orally at a dose of 1200 mg twice daily on the day before and on the day of administration of the contrast agent (total of 2 days. Additional NAC dose (1.2 g) will be administered i.v. during the procedure.
89013211|NCT01602211|Experimental|Arm II (delayed program access control)|Participants receive annotated website links to existing transplant and cancer survivor sites, followed by delayed access to the INSPIRE internet program after 1 year.
89013212|NCT01602250|Placebo Comparator|levobupivacaine placebo|levobupivacaine placebo
89013213|NCT01602250|Experimental|levobupivacaine Intralipid®|levobupivacaine Intralipid®
89013214|NCT01602250|Experimental|ropivacaine Intralipid®|ropivacaine Intralipid®
89013215|NCT01602250|Placebo Comparator|ropivacaine placebo|ropivacaine placebo
88926578|NCT01098032|Experimental|RenalGuard System group|Prophylactic controlled hydration with saline (0.9%) plus N-acetylcystein (NAC; 6 g in total). In the RenalGuard group, an initial bolus (priming) of 250 ml will be administered. In case of left ventricular dysfunction (ejection fraction ≤30%) and/or unstable hemodynamic conditions the bolus will be reduced to 150 ml. Following the initial bolus, furosemide (0.25 mg/kg) will be administered in order to achieve the optimal urine flow (≥300 ml/h). The hydration will be continued throughout the duration of the procedure and will last 4 hours following the procedure. Additional doses of furosemide are allowed in case of decrease of urine flow <300 ml/h.
88926579|NCT01034306|Experimental|CF101 1 mg|piclidenoson (CF101) 1 mg tablet oral, Q12h for 12 weeks
88926580|NCT01034306|Placebo Comparator|Placebo|placebo tablet to match the active, oral dosage, Q12h for 12 weeks
88926581|NCT01013857|Active Comparator|Health coaching|Phone patients every week to discuss medication adherence
88926582|NCT01013857|Experimental|Health coaching plus home-titration|Health coaches call patients every week to discuss medication adherence and to intensify medications if appropriate according to physician-created algorithm
88926583|NCT00993447|Experimental|CYD Dengue Vaccine Group|Sanofi pasteur's CYD Dengue vaccine group (Dengvaxia®)
88926584|NCT00993447|Sham Comparator|Control Vaccine Group|
88926585|NCT00945009|Experimental|Arm 1 (Bilateral Wilms Tumors)|Patients start with three drug chemotherapy (Regimen VAD; vincristine, dactinomycin and doxorubicin) and are evaluated and six and 12 weeks for feasibility of undergoing a partial nephrectomy/renal sparing surgery. At week 12 definitive surgery takes place followed by chemotherapy and radiation therapy based on histology and stage. Treatment continues for 25 or 31 weeks depending on histology. Patients are followed for up to 10 years following end of therapy.
88926586|NCT00945009|Experimental|Arm 2 (Unilateral High Risk tumors bilaterally predisposed)|Patients start with either 2 drug or three drug chemotherapy (Regimen VA, VAD) and are evaluated a 6 and 12 weeks for feasibility of undergoing a partial nephrectomy. At week 12 definitive surgery takes place followed by chemotherapy.
88926587|NCT00945009|Experimental|Arm 3 (DHPLN)|Patients with this rare disease are diagnosed based on cross-sectional imaging characteristics and undergo 2 drug chemotherapy (Regimen;VA). Patients are reassessed at 6 weeks and 12 weeks. If disease has responded or stayed stable chemotherapy is completed for 19 weeks (Regimen EE4A). If disease has progress a biopsy is performed to assess histology and adjust therapy based on the biopsy. This therapy may include, nephrectomy, chemotherapy or radiation therapy.
88926588|NCT00896389|Other|Salt-loading and thiazide diuretic (HCTZ)|Salt loading:2 L of 0.9% NaCl. HCTZ:12.5/ 25 mg of HCTZ for 1 week
88926589|NCT00880893|Experimental|CYD Dengue Vaccine Group|Participant's received the CYD Dengue Vaccine at 0, 6, and 12 months as first, second, and third vaccinations, respectively.
88926590|NCT00880893|Sham Comparator|Placebo Group|All participants received a placebo at first vaccination (Month 0). Participants <12 years received hepatitis A at second (Month 6) and third (Month 12) vaccinations. Participants >= 12 years received influenza vaccine of Northern and Southern hemisphere formulations at second (Month 6) and third (Month 12) vaccinations.
88926591|NCT00875901|Experimental|Peripherally located lung tumor|12 cobalt gray equivalent per fraction to a total of 48 cobalt gray equivalent
88926592|NCT00875901|Experimental|Centrally located lung tumor|6 cobalt gray equivalent per fraction to a total of 60 cobalt gray equivalent
88926593|NCT00845390||ICD Patients|ICD patients
88926594|NCT00779961|Experimental|Group A|Early Cleft Palate Repair (Age group 6-10 months)
88926595|NCT00779961|Active Comparator|Group B|Sick Kids Routine cleft palate repair (age group 10-14 months)
88926596|NCT00770380|Experimental|Hypnosis for relapse prevention|The hypnosis intervention was conducted in two face-to-face visits with hypnosis recorded for home practice. Learning, practicing, and employing hypnotic skills in resisting the urge to smoke are core components of this intervention.
88926597|NCT00770380|Active Comparator|Behavioral relapse prevention counseling|In the behavioral relapse prevention counseling, participants were taught coping strategies for resisting the urge to smoke. This intervention focused on relapse prevention (i.e., maintenance stage of change) and was based on the theoretical concepts and treatment procedures advocated by Marlatt and Gordon and recent smoking relapse data.
88926598|NCT00587301|Experimental|Lap-Band|Lap-band surgery in treatment of morbidly obese adolescents
88926599|NCT00579527|Experimental|Cultured Thymus Tissue Implantation (CTTI) w/immunosuppression|Patients with complete DiGeorge Anomaly (cDGA) undergo cultured thymus tissue implantation (previously described as transplantation) with tailored immunosuppression based on the subject's pre-implantation T cell numbers and function.
88926600|NCT00579527|Experimental|CTTI with Parathyroid Transplantation w/immunosuppression|Patients with complete DiGeorge Anomaly (cDGA) undergoes cultured thymus tissue thymus implantation (previously described as transplantation) with tailored immunosuppression based on the subject's pre-implantation T cell numbers and function. If the patient has hypoparathyroidism, and is eligible, the patient may also receive a parathyroid transplant.
88926601|NCT01904123|Experimental|Treatment (STAT3 inhibitor WP1066)|Patients receive STAT3 inhibitor WP1066 PO BID on Monday, Wednesday, and Friday of weeks 1 and 2. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88926602|NCT00576836|Experimental|Cultured Thymus Tissue Implantation w Parathyroid Transplant|"Cultured Thymus Tissue Implantation With Parathyroid Tissue Transplantation. Subjects who were enrolled in this arm underwent cultured thymus tissue implantation with parathyroid transplantation, if eligible.~No specific dose was assigned. The thymus tissue dose was the number of grams of cultured thymus tissue divided by the weight of the recipient in kg or per square meter of body surface area of the recipient.~There was a one time administration of the cultured thymus tissue and parathyroid tissue."
89502094|NCT02262871|Experimental|CF patients NIV|CF patients who meet the eligibility criteria will be randomized to receive NIV and then crossover to other device.
89502095|NCT02235181|No Intervention|Standard Treatment|Women will be allocated to standard treatment, currently this is no treatment.
89502096|NCT02235181|Active Comparator|Arabin pessary|The Arabin cervical pessary will be inserted between 18 and 20+6 days gestation and removed between 35 and 36+6 weeks gestation unless Labour occurs sooner.
89502097|NCT02233153||Pre-Elder Friendly Surgical Intervention Group|Elder Acute Care and Emergency Surgery patients
89502098|NCT02233153||Post-Elder Friendly Surgical Intervention Group|Elder Acute Care and Emergency Surgery patients
89442634|NCT03493308|Experimental|Pain neuroscience and exercise|Participants will received an 8 week intervention consisting of pain neuroscience education and exercise. Pain neuroscience education will be conducted in line with international guidelines, covering the neurophysiology of pain, transition from from acute to chronic pain and the nervous system ability to modulate the pain experience. exercise will include general exercise and dance.
89442635|NCT02320734|Active Comparator|deep neuromuscular relaxation|continuous infusion of rocuronium 0.6 mg/kg/hr (group 1). On demand bolus rocuronium can be given if demanded by anesthesiologist or surgeon
89442636|NCT02320734|No Intervention|on demand neuromuscular relaxation|continuous infusion of NaCl 0.9% 0.06 ml/kg/hr (group 2) On demand bolus of Rocuronium will be given when demanded by anesthesiologist or surgeon.
89442637|NCT03346226|Experimental|Dexmedetomidine Hydrochloride|Dex Group: 0.5 μg/kg of Dex is given 10 minutes before operation through injection pump during 15 minutes. After the operation starts, the initial pumping ratio of Dex is 0.5ug/kg/h and adjusted under BIS surveillance to keep BIS between 70-80 until 30 minutes before the end of surgery. Meanwhile, OAA/S grade is evaluated every 15 minutes to maintain OAA/S at grade 4. If discrepancy occurs, OAA/S prevails.
89442638|NCT03346226|Active Comparator|Propofol|Prop Group: Propofol is given with an initial ratio of 2-10mg/kg/h, when the operation starts. Under BIS surveillance, dripping rate is adjusted to keep BIS between 70-80 until 5 minutes before the end of surgery. Meanwhile, OAA/S grade is evaluated every 15 minutes to maintain OAA/S at grade 4. If discrepancy occurs, OAA/S prevails.
89442639|NCT03347240|Active Comparator|Brain lesioning group|Stereotactic lesioning of the thalamus or gloves pallidus
89442640|NCT03347240|Active Comparator|Combined rhizotomy group|Combined anterior and posterior lumbosacral rhizotomy
89442641|NCT03347240|Active Comparator|Deep brain stimulation group|Bilateral globus pallidus internus deep brain stimulation
89442642|NCT03347240|Active Comparator|Intra-thecal Baclofen infusion therapy|Intra-thecal infusion pump
89442643|NCT02324088|Active Comparator|Arm A|4 cycles of high-dose EC (E150 mg/m² and C 4000 mg/m² every 3 weeks) then mastectomy with axillary lymph node dissection and radiotherapy
89442644|NCT02324088|Experimental|Arm B|4 cycles of high-dose EC (E150 mg/m² and C 4000 mg/m² every 3 weeks) then mastectomy with axillary lymph node dissection and radiotherapy followed by 4 cycles of D-5FU (D 85 mg/m², day 1 and 5FU 2500 mg/m²/day continuous infusion, days 1-5 every 3 weeks)
89013216|NCT01602289|Experimental|LY2875358|Part A. LY2875358 will be administered intravenously (IV) at escalating doses (700 mg up to 2000 mg) on Day 1 and Day 15 of a 28-day cycle, until any discontinuation criterion is met.
89442645|NCT02324166|Active Comparator|Cefazolin|For the control group, cefazolin will be drawn into a 1 mL syringe and 0.5 mL will be injected with a 30-gauge needle into the subconjunctival space. This will be performed at the end of the retinal surgery.
89442646|NCT02324166|Active Comparator|Cefazolin + Lidocaine|For the comparator group, the cefazolin and 0.2 mL lidocaine 2% will be mixed together in the same 1 mL syringe and 0.5 mL of the mixed solution injected with a 30-gauge needle into the subconjunctival space. This will be performed at the end of the retinal surgery surgery.
89442647|NCT05518942|Experimental|sensorimotor rhythm neurofeedback training|Sensory motor rhythm neurofeedback: The subjects will perform 60 minutes per week for 10 weeks, with a total training time of 600 minutes. The intervention in this trial lasts for 10 weeks (1 time/week), with the goal of improving sensory motor rhythm. Since this training uses visual and auditory feedback, if patients are assigned to this group, they will be ask to wear an EEG cap with 19 electrodes. They can take a relaxed sitting posture and choose animations (e.g., puzzles, mazes, and other feedback content), and then focus on computer screen animation for training, each training time is approximately 60 minutes.
89442648|NCT05518942|No Intervention|control group|Patient should maintain their usual activity and treatment. Research assistants will weekly contact them to confirm their compliance.
89442649|NCT03346538|Experimental|Continuous infusion high-dose group (Group H)|High-dose MCI-186 will be administered as a bolus, and then as a continuous infusion. In addition, a placebo will be administered as an intravenous infusion twice a day over 30 minutes.
89442650|NCT03346538|Experimental|Continuous infusion low-dose group (Group L)|Low-dose MCI-186 will be administered as a bolus, and then as a continuous infusion. In addition, a placebo will be administered as an intravenous infusion twice a day over 30 minutes.
89442651|NCT03346538|Experimental|Approved dosing regimen group (control group)|A placebo will be administered as a bolus, and then as a continuous infusion. In addition, MCI-186 30 mg will be administered as an intravenous infusion twice a day over 30 minutes.
89442652|NCT05513170|Active Comparator|Closed sinus lift using Densah bur|Closed sinus lifting will be performed using densah burs and then dental implants will be placed.
89442653|NCT05513170|Active Comparator|Conventional closed sinus lift using osteotomes|Sinus lifting will be performed using osteotomes and then dental implants will be placed.
89442654|NCT02513342|Experimental|Endostar+Docetaxel+Cisplatin|Patients in this group will be given conventional chemotherapy medicine: Docetaxel+Cisplatin chemotherapy recommended by treatment guidelines for Advanced Non-small Cell Lung Squamous Carcinoma , and the Endostar-Recombinant human endostatin injection is injected by 30mg continuous intravenous injection pump,d1-d7.
89442655|NCT02513342|Active Comparator|Docetaxel+Cisplatin|Patients in this group will be given conventional chemotherapy medicine: Docetaxel+Cisplatin chemotherapy recommended by treatment guidelines for Advanced Non-small Cell Lung Squamous Carcinoma.
89442656|NCT02517320|Experimental|MT-3995 Low|
89442657|NCT02517320|Experimental|MT-3995 Middle|
89442658|NCT02517320|Experimental|MT-3995 High|
89442659|NCT02517320|Placebo Comparator|Placebo|
89442660|NCT03491826||ROM before 34 weeks (A)|premature rupture of membrane before 34 weeks
89442661|NCT03491826||ROM after 34 weeks (B)|premature rupture of membrane after 34 weeks
89442662|NCT04589962||Percutaneous Group|
89199891|NCT02582021||Women|Women undergoing clinically-ordered coronary angiography for signs and symptoms of ischemia who have no obstructive coronary artery disease (CAD)
89199892|NCT02582021||Women or men|Women and men hospitalized for signs and symptoms of ischemia and evidence of Heart Failure with preserved ejection fraction (HFpEF) who have not undergone a clinically-ordered coronary angiography
88926603|NCT00576836|Experimental|Cultured Thymus Tissue Implantation|"Cultured Thymus Tissue Implantation. Subjects who were enrolled in this arm underwent cultured thymus tissue implantation (CTTI) only.~No specific dose was assigned. The thymus tissue dose was the number of grams of cultured thymus tissue divided by the weight of the recipient in kg or per square meter of body surface area of the recipient.~There was a one time administration of the cultured thymus tissue.~."
89442663|NCT04589962||Surgical Group|
89442664|NCT02512952|Active Comparator|Group 1|SRP with Open flap debridement (OFD) alone for treating periodontal pocket
89442665|NCT02512952|Active Comparator|Group 2|SRP with Open flap debridement (OFD) with Platelet rich fibrin (PRF) placement into bone defect
89442666|NCT02512952|Active Comparator|Group 3|SRP with Open flap debridement (OFD) with Titanium Platelet rich fibrin (TPRF) placement into bone defect
89442667|NCT03493230|Experimental|Patient with malignant melanoma|Patient with advanced or metastatic malignant melanoma (stage IIIB inoperable or IIIC or stage IV) will have a first blood test before any treatment, then at day 15 or 30 after initiation of therapy, and every two months until recurrence or progression for a maximum of 22 months.
89442668|NCT02513108|Active Comparator|same day discharge|patients discharged same day after uncomplicated PCI
89442669|NCT02513108|No Intervention|standard care|standard care where patients are discharged the day after procedure after adequate observation
89442670|NCT03495024|Other|Smoking cessation with varenicline|FDA-approved indication of varenicline for smoking cessation
89442671|NCT02513030||Replacement of defibrillator|
89199893|NCT02581085|Placebo Comparator|Placebo Vehicle|Subjects will take 2 placebo capsules following AM meal, 2 placebo capsules following PM capsules
89442672|NCT02324244||immunocompetent patients underwent heart surgery|
89442673|NCT02512796||Transplant patients, MRI with Gadolinium contrast dye|Patients with kidney, pancreas or liver transplant and exposed to gadolinium contrast agents.
89442674|NCT02512796||Non-transplant patients, MRI with Gadolinium contrast dye|Non-transplant patients exposed to gadolinium contrast.
89442675|NCT02512796||Healthy controls, no transplant no Gadolinium contrast dye|Age- and sex-matched healthy controls not exposed to gadolinium contrast.
89442676|NCT05040048||Parkinson's disease Group|Blood, cerebrospinal fluid (CSF) and skin biopsy samples. Neuropsychological assessment. Motor and non motor assessments for Parkinson's disease group only.
89442677|NCT05040048||Alzheimer's disease Group|Blood, cerebrospinal fluid (CSF) and skin biopsy samples. Neuropsychological assessment. Brain MRI for Alzheimer's disease group only.
89442678|NCT04772014||e-cigarette users|daily e-cigarette use (additional smoking of traditional tobacco cigarettes is not an exclusion criterion)
89442679|NCT04772014||nicotine-naïve|lifetime consumption of less than 20 cigarettes or e-cigarettes
89502099|NCT02233153||Pre-Elder Friendly Surgical Control Group|Elder Acute Care and Emergency Surgery patients
89442680|NCT04188314|Experimental|Desflurane Interventional Group|"The intervention group will receive desflurane for maintenance of anaesthesia. Standard protocols for induction and maintenance of anaesthesia will be followed, as discussed with Prof. F. Puehringer, an international expert in the field of desflurane use. A detailed leaflet describing the protocol has been developed, which will be handed to the treating anaesthetist on the day of surgery.~After induction of anaesthesia and after the airway is secured, fresh gas flow is reduced to 2 l/min and the desflurane vaporiser is opened to 12%. This is maintained until 1MAC is reached. The fresh gas flow will then be turned down to 0.2-0.5 l/min (taking into consideration the machine leak) and the vaporiser adjusted to maintain 1MAC. The use of basal to minimal fresh gas flow is intentional, to minimise the amount of anaesthetic vapour used. When basal flow is used, 100% oxygen is required to meet oxygen demand."
88926604|NCT00576407|Experimental|Cultured Thymus Tissue Implantation in Complete DiGeorge|"Participants with Complete DiGeorge Syndrome, who were eligible, received cultured thymus tissue implantation (CTTI).~No specific dose was assigned. There was a one time administration of the cultured thymus tissue."
89442681|NCT04188314|Active Comparator|Isoflurane Control Group|The control group will receive Isoflurane for maintenance of anesthesia. After induction of anaesthesia and after the airway is secured, fresh gas flow is reduced to 2 l/min and the Isoflurane vaporiser is opened and adjusted to attain 1MAC. Once 1MAC is attained, the fresh gas flow will be reduced to 0.2-0.5 l/min (taking into consideration the machine leak) and the vaporiser will be adjusted to maintain 1MAC. The use of basal to minimal fresh gas flow is intentional, to minimise the amount of anaesthetic vapour used. When basal flow is used, 100% oxygen is required to meet oxygen demand.
89442682|NCT05512780|Experimental|Dalpiciclib+ letrozole|"Dalpiciclib combined with Letrozole,28 days as one cycle.~Dalpiciclib: 150 mg (p.o.) was given once daily for 3 weeks, followed by 1 week off in each 4-week cycle.~Letrozole: 2.5mg, p.o., once a day, continuous administration."
89442683|NCT04501172||Study group|People who use social networks, with permanent residence in Greece, aged above 18 years old and adequate literacy of Greek language
89442684|NCT02324322|Experimental|Exoskeleton training|"To examine the effectiveness of robotic exoskeleton-assisted over ground walking (5 hrs. p/wk, 100 sessions, 20 wks = 100 hrs) to induce positive changes in muscle volume and structure of the lower limbs for non-ambulatory persons with SCI. Combined with our current training protocol where people step 1500-2000/session we predict that the 2,000 lower extremity muscle contractions will be sufficient in our proposed exoskeletal study.~MRI's will be performed to accurately assess muscle CSA of each lower limb to determine individual's muscle thigh and shank volume.~Muscle Biopsies for the quadricep muscle will be performed to determine changes in BMD and bone structure due to intensive exoskeleton assisted walking."
89442685|NCT02517242|Experimental|Pens Device|All patients will receive pens device, insulin, blood glucose monitor, lancet tapes, capillary blood glucose tests (3 tests/day). All will be evaluated monthly for six months
89442686|NCT02517242|Active Comparator|Syringe|All patients will receive syringe to insulin, insulin, blood glucose monitor, lancet tapes, capillary blood glucose tests (3 tests/day). All will be evaluated monthly for six months
89442687|NCT03494712|Experimental|S 95010|Increasing single doses of S 95010 to 5 subjects.
89442688|NCT03494712|Placebo Comparator|Placebo|Increasing single doses of Placebo to 2 subjects.
89442689|NCT02517164||Fallers|patients aged 50 years and over who already fell
89442690|NCT02517164||At risk of falls|patients aged 50 years and over at risk of falls
89442691|NCT05511376|Active Comparator|DIET|Personal nutrition programs were prepared according to ideal body weight, with protein intake as 30% of total daily calories or 1-1.2 g/kg.
89442692|NCT05511376|Active Comparator|EXERCISE|"A pre-exercise breathing exercise study was planned.~Exercise:~It was planned to apply the Moderate Resistant Exercise Protocol (3 days a week for 60 minutes) and as aerobic exercise, walking 5 days a week (150 minutes / week) as 30 minutes / day."
89442693|NCT05511376|Active Comparator|AURICULAR VAGUS NERVE STIMULATION|"The Vagustim device was applied in Biphasic, Frequency 10 Hz, Modulation mode, with a pulse width of 300 μs, for 30 minutes /3 days/week by keeping the current intensity constant where the participants felt comfortable.~It will be applied as bilateral VSS from the tragus and turbinate parts of the ear."
89502100|NCT02233153||Post-Elder Friendly Surgical Control Group|
88926605|NCT00543348|Active Comparator|1|CUTTING BALLOON ANGIOPLASTY
88926606|NCT00543348|Placebo Comparator|2|Balloon angioplasty with a high pressure balloon
88926607|NCT00531232|Experimental|Clofarabine 55 mg/day|Participants received Clofarabine 55 mg/day orally for 5 consecutive days of each 28-day treatment cycle until disease progression or death, whichever comes first (maximum study duration: up to 4 years).
88926608|NCT00531232|Experimental|Clofarabine 35 mg/day|Participants received Clofarabine 35 mg/day orally for 5 consecutive days of each 28-day treatment cycle until disease progression or death, whichever comes first (maximum study duration: up to 4 years).
88926609|NCT00531232|Experimental|Clofarabine 25 mg/day|Participants received Clofarabine 25 mg/day orally for 5 consecutive days of each 28-day treatment cycle until disease progression or death, whichever comes first (maximum study duration: up to 4 years).
88926610|NCT00467103||Chronic Stroke patients with Nonfluent Aphasia|patients with left hemisphere (LH) stroke who have chronic nonfluent aphasia
88926611|NCT00389844|No Intervention|1|Routine care
88926612|NCT00389844|Active Comparator|2|Exercise only
88926613|NCT00389844|Active Comparator|3|Motivation only
88926614|NCT00389844|Experimental|4|Exercise plus motivation
88926615|NCT00365326|Experimental|Treatment with autologous bone marrow (BM)-derived CD133+ stem cell therapy|The Phase I single arm clinical study, was designed to assess the safety and feasibility of a dose escalating intracoronary infusion of autologous bone marrow (BM)-derived CD133+ stem cell therapy to the patients with chronic total occlusion (CTO) and ischemia.
88926616|NCT00265525|Experimental|Cardio fit|
88926617|NCT00265525|No Intervention|Usual Care|
88926618|NCT00066950|No Intervention|Counseling Only|Oral Health Counseling Only
88926619|NCT00066950|Experimental|CHX+Counseling (caregiver) + FV (child)|Oral Health Counseling plus Chlorhexidine for caregiver plus fluoride varnish every 6 months from 12mo to 30mo of age for child
88926620|NCT01694134|Active Comparator|Corticoids|A group of patients will receive an intradiscal injection of Hydrocortancyl.
88926621|NCT01694134|Sham Comparator|Local anaesthetic|A group of patients will receive an intradiscal injection of Lidocaine.
88926622|NCT01694147||patients with sepsis related ALI/ARDS.|Consecutive septic patients with ALI/ARDS in medical intensive care units (ICUs) will be enrolled. EVLWI will be measured by PiCCO monitoring system.
88926623|NCT01694160|Experimental|Paricalcitol|Paricalcitol 2 ug/daily for 48 weeks
88926624|NCT01694160|No Intervention|no intervention|
88926625|NCT01694173|Experimental|Stem cell therapy - SPD artery|Stem cells will be infused into the superior pancreaticoduodenal artery.
88926626|NCT01694173|Active Comparator|Stem cell therapy - splenic artery|Stem cells will be infused into the splenic artery.
88926627|NCT01694173|Active Comparator|Stem cell therapy-intravenous|Stem cells will be given intravenously.
88926628|NCT01694173|Placebo Comparator|Normal saline placebo -sham procedure|Sham procedure with infusion of normal saline.
88926629|NCT01694212|Experimental|Diclofenac|Patients with diabetic retinopathy having preoperative treatment with diclofenac
88926630|NCT01694212|Placebo Comparator|Placebo|Control group having placebo treatment
88926631|NCT01694225|Experimental|bubble package for monthly prescription|use of bubble packaging for monthly prescription
88926632|NCT01694238|Active Comparator|Cruciate incision|Cruciate incision in the abdominal wall fascia
88926633|NCT01694238|Experimental|Circular incision|Circular incision in the fascia
88926634|NCT01694238|Experimental|Mesh enforced cruciate incision|Mesh enforcement and then cruciate incision in the abdominal wall fascia
88926635|NCT01694264|Experimental|Experimental Group|Entecavir (Baraclude (Bristol-Myers Squibb) 0.5mg.) will be taken orally on an empty stomach (2 hours after a meal or at least 2 hours before the next meal), once daily from 1 week before starting anti-TNFα and continue 72 weeks after anti-TNFα is administered.
88926636|NCT01694264|Placebo Comparator|Control Group|Placebo of Entecavir (prepared by Bristol-Myers Squibb) will be taken orally on an empty stomach (2 hours after a meal or at least 2 hours before the next meal), once daily from 1 week before starting anti-TNFα and continue 72 weeks after anti-TNFα is administered.
88926637|NCT01694290|Experimental|Chemical Ice packs to neck, groin, axillae|Chemical ice packs will be changed out every 9 minutes
88926638|NCT01694290|Experimental|Chemical Ice Packs to cheeks, palms, soles|Chemical Ice packs will be changed out every 9 minutes
88926639|NCT01694290|No Intervention|no chemical ice packs|
88926640|NCT01694303|Active Comparator|Engaging computerized tasks|Participants will log into a personalized website and engage in computerized tasks online.
88926641|NCT01694303|Experimental|Neurobehavioral computerized tasks|Participants will log into a personalized website and engage in computerized tasks online.
88926642|NCT01694316|Active Comparator|Engaging in Computerized tasks|Participants will log into a personalized website and engage in computerized tasks online.
89199894|NCT02581085|Active Comparator|Tocotrienol supplement|Subjects will take (2) 200 mg TCT capsules following AM meal, (2) 200 mg TCT following PM meal
88926643|NCT01694316|Experimental|Neurobehavioral computerized tasks|Participants will log into a personalized website and engage in computerized tasks online.
88926644|NCT01694329||2006-2010 cohort|cohort of children born between 2006 and 2010, and living in Nunavik
88926645|NCT01694355|Experimental|Vitamin D treatment|We assume that among postmenopausal women, Vitamin D treatment will improve bone mineralization and will cause a rapid increase in BMD.
88926646|NCT01694381|Experimental|mutant pro-urokinase (M5) alone|In the first study part subjects in cohorts of 4 will receive ascending doses of either M5 (3 subjects) or M5-placebo (1 subject) without C1-inhibitor.
89013217|NCT01602289|Experimental|LY2875358+Erlotinib|Part B1. Erlotinib will be administered orally at 150 mg dose level each day. LY2875358 will be administered intravenously (IV) at recommended dose level in Part A on Day 1 and Day 15 of a 28-day cycle. (Part B1 was added per protocol amendment in January, 2013.)
89442694|NCT03346460|Experimental|Tongue scraper group (Group 1)|Fifteen patients will be included in this group. Tongue scraping will be performed by the same operator in all patients. Posterior-anterior movements will be performed with the scraper over the lingual dorsum, followed by cleaning the scraper with a gauze. This procedure will be performed ten times in each patient, in order to standardize the mechanical removal of the tongue coating.
89442695|NCT03346460|Experimental|aPDT group (Group 2)|Fifteen patients will be included in this group. One session of aPDT will be performed with the photosensitizer (PS) urucum manipulated at a concentration of 20% (Fórmula e Ação®) in spray, to be applied in sufficient quantity to cover the middle third and back of the tongue (5 sprinkles) for 5 minutes for incubation. The excess will be removed with a sucker in order to keep the surface wet with the PS itself, without using water. Six points with a distance of 1 cm between them will be irradiated, considering the halo of light scattering and effectiveness of aPDT. The apparatus shall be precalibrated at wavelength 440-480nm for 60 seconds per point, irradiance of 450mW/cm and the light shall be irradiated so that a halo of 2cm diameter is formed per point.
89442696|NCT03346460|Experimental|Tongue scraper and aPDT (Group 3)|Tongue scraping will be performed by the same operator in all patients. Posterior-anterior movements will be performed with the scraper over the lingual dorsum, followed by cleaning the scraper with a gauze. This procedure will be performed ten times in each patient, in order to standardize the mechanical removal of the tongue coating. After, one session of aPDT will be performed with the photosensitizer (PS) urucum manipulated at a concentration of 20% (Fórmula e Ação®) in spray, to be applied in sufficient quantity to cover the middle third and back of the tongue (5 sprinkles) for 5 minutes for incubation. Six points with a distance of 1 cm between them will be irradiated, considering the halo of light scattering and effectiveness of aPDT. The apparatus shall be precalibrated at wavelength 440-480nm for 60 seconds per point, irradiance of 450mW/cm and the light shall be irradiated so that a halo of 2cm diameter is formed per point.
89442697|NCT04834362|Experimental|Analog insulin arm|Patients treated with insulin analog regimen will receive 50% of total daily dose as basal insulin glargine at the same time of day and 50% as insulin aspart given in 3 equally divided doses at 6 am, 12 pm and 6 pm.
89442698|NCT04834362|Active Comparator|Human insulin arm|Patients treated with human insulin regimen will receive 50% of total daily dose as NPH insulin at around 6 am and 6 pm, while the rest 50% regular human insulin three times a day in 3 equally divided doses at around 6 am, 12 pm and 6 pm
89442699|NCT05507710|Active Comparator|Interventional study arm|Surgery will be performed according to local protocol. Flap viability during adequate hemodynamic conditions is evaluated a standard of care. Then after anastomosis of the flap but before the inset, the second intervention is performed. Intervention: evaluation of the perfusion of the skin and fat with fluorescence imaging using ICG. The flap is marked according to the fluorescence imaging evaluation, and parts without perfusion are resected. The remaining flap is inset to the remaining breast skin.
89442700|NCT05507710|No Intervention|Control arm|Surgery will be performed according to local protocol.Flap viability during adequate hemodynamic conditions is evaluated as standard of care. Then after anastomosis of the flap but before the inset, the surgeon will leave the room, the researcher will make a recording of the flap and this will have no consequences for the procedure.
89442701|NCT03121274|Active Comparator|Early pushing during vaginal delivery|patients are allowed to push within one hour after full cervical dilatation whether the vertex was visible or not
89442702|NCT03121274|Active Comparator|Delayed pushingduring vaginal delivery|patients here are asked not to push for maximum of 3 hours or start pushing when the vertex was visible
89442703|NCT05512702||Thrombolytic Treatment Group|These are the patients with intermediate-high riskPE and consulted by EGEPET. They received reduced dose thrombolytic treatment.
89442704|NCT05512702||Anticoagulation Treatment Group|This group includes patients who diagnosed wit PE before the establishment of EGEPET. And these patients are classed into intermediate-high risk based on early mortality and received anticoagulation treatment, not thrombolytic treatment.
89442705|NCT02516930|Other|Crowdsourced video|One-minute crowd-sourced video promoting condom use among men who have sex with men and transgender individuals.
89442706|NCT02516930|Other|Social marketing video|One-minute social marketing video promoting condom use among men who have sex with men and transgender individuals
88926647|NCT01694381|Experimental|Mutant pro-urokinase (M5) and its inhibitor, C1 inhibitor|"In the second study part subjects in cohorts of 5 will receive ascending doses of either M5 or M5-placebo, preceded by a single intravenous dose of C1-inhibitor or C1-inhibitor-placebo. Each subject will randomly be allocated to one of the following treatment arms within one cohort:~C1-inhibitor followed by M5 (3 subjects);~C1-inhibitor followed by M5-placebo (1 subject);~C1-inhibitor-placebo followed by M5-placebo (1 subject).~Dose levels of both M5 and C1-inhibitor within each cohort will be chosen based on the available safety, pharmacokinetic and pharmacodynamic data of the preceding cohorts."
88926648|NCT01694394||Cohort|Single arm cohort will receive a St. Jude Medical Implantable Cardiac Monitor (Confirm ICM model 2102) for continuous monitoring over the study follow-up period to determine incidence of sub-clinical atrial fibrillation.
88926649|NCT01694407|Active Comparator|TFV Alone Vaginal Tablet|
88926650|NCT01694407|Active Comparator|Emtricitabine (FTC) Alone Vaginal Tablet|
88926651|NCT01694407|Active Comparator|TFV Combined with FTC Vaginal Tablet|
88926652|NCT01694407|Placebo Comparator|Placebo Vaginal Tablet|
88926653|NCT01694446|Experimental|Intraduodenal glucose or fructose|
88926654|NCT01694459|Active Comparator|Standard dose heparin|Bolus of 100 UI/Kg of heparin. Activated clotting time (ACT) > 300 sec. during the procedure
88926655|NCT01694459|Experimental|Low-dose heparin|Bolus of 50 UI/Kg heparin with a target ACT during the procedure of >200 sec.
88926656|NCT01694472|Experimental|MAGE-A4 TCR Gene-Modified T Cells|
89442707|NCT03494634|Experimental|Chidamide|
89442708|NCT05507632|Experimental|single-arm|All patients treatment with Donafenib plus Sintilimab in combination with TACE
89442709|NCT05512546||Aspirin Group|patients were prescribed 75 mg/day of either aspirin for 6 months
89442710|NCT05512546||Clopidogrel Group|75mg/day prescribed for 6 months
89442711|NCT02517086|Active Comparator|therapeutic exercises|The applied therapeutic exercises involve shoulder movements including flexion, extension, abduction, adduction, internal and external rotation in isolated or combined movements, with ten repetitions of each movement, associated with the music, and stretching movements finalizing the sequence of movements.
89442712|NCT02517086|Active Comparator|elastic compression|exercises for upper limb will be performed for an hour associated with the use of elastic compression. Elastic compression will be effected through a clamp brand compression of 30-40 mmHg according to the measures of voluntary member.
89442713|NCT02517086|Active Comparator|functional compressive bandaging|exercises for upper limb will be performed for an hour associated with the use of functional compressive bandaging. The functional compressive bandaging will be held with the volunteer sitting with ipsilateral upper limb resting on the support surgery. After hydration member a cotton mesh is used to prevent friction density 1cm strip of foam on the member to be wrapped. Elastic bandages of cotton will be involved 5 cm, 10 cm, 15 cm from the fingers to the axillary region multilayered
89442714|NCT04879498|Experimental|Monolithic zirconia|Monolithic zirconia posterior 3-unit fixed partial dentures
89442715|NCT04879498|Active Comparator|Veneered zirconia|Veneered zirconia posterior 3-unit fixed partial dentures
89442716|NCT04879498|Active Comparator|Metal-ceramic|Metal-ceramic posterior 3-unit fixed partial dentures
89442717|NCT05511220|Experimental|PRIMeR|Virtual parent coaching in use of a novel intervention consisting of Social Routines and Reciprocal Imitation Training strategies
88926657|NCT01694498|Active Comparator|A. Desmopressin 25 µg|1 orally disintegrating tablet every night during study period
89442718|NCT05511220|Active Comparator|PRT|Virtual parent coaching in use of Pivotal Response Treatment strategies
89442719|NCT03345134|Experimental|MK-3475 and BCG|Single treatment group of high risk superficial upper urinary tract transitional cell carcinoma; combination treatment with MK-3475 and BCG
89442720|NCT02512562|Active Comparator|Group 1: AL-335, Simeprevir and ACH-3102|AL-335, ACH-3102, and Simeprevir dosed in healthy human volunteers once daily for 24 days.
89442721|NCT02512562|Active Comparator|Group 2: AL-335, Simeprevir and ACH-3102|AL-335, ACH-3102, and Simeprevir dosed in healthy human volunteers once daily for 24 days.
88926658|NCT01694498|Active Comparator|B. Desmopressin 50 µg|1 orally disintegrating tablet every night during study period
88926659|NCT01694498|Placebo Comparator|C. Placebo|1 orally disintegrating tablet every night during study period
88926660|NCT01694511|Active Comparator|Introductory conventional endoscopy|Conventional endoscopy followed by HRME+CVC after 30 days.
88926661|NCT01694511|Active Comparator|Introductory HRME+CVC|HRME+CVC followed by conventional endoscopy after 30 days.
88926662|NCT01694537|Placebo Comparator|placebo|The comparison drug is placebo, which is made with same size and shape with study drug. DLBS1033 and placebo is produced by PT Dexa Medica. Placebo will taken 3 times 1 tablet per day for 7 days. Wash out period before enter another arm is 7 days.
88926663|NCT01694537|Experimental|DLBS1033|The study drug is enteric coated DLBS1033, which contain 490 mg bioactive protein fraction. The drug will taken 3 times 490 mg per day for 7 days. Wash out period before enter another arm is 7 days.
89442722|NCT03489096|Experimental|Cryoballoon Ablation|Cryoballoon Ablation: PVI + substrate modification. Left atrial fibrosis ablation in addition to standard pulmonary vein isolation in patients with paroxysmal and persistent atrial fibrillation. Ablation will be performed utilizing the Medtronic Arctic Front Advance Cryoballoon catheter.
89442723|NCT05511142|Experimental|Classic Peyton's Four-Step Approach|Students followed offline training session of endotracheal intubation and mask ventilation procedural skills
89442724|NCT05511142|Experimental|Modified Peyton's Four-Step Approach|Students followed online training session of endotracheal intubation and mask ventilation procedural skills
89442725|NCT02516774|Experimental|Dose escalation|Adalimumab will be administrated subcutaneously 1h prior to chemotherapy at D1W1, D1W3, D1W5, D1W7, and D1W9, starting with the chemotherapy for a total duration of 9 weeks (5 injections in total)
89442726|NCT05510986|Active Comparator|Fentanyl group|Drugs
89442727|NCT05510986|Experimental|Oxycodone Hydrochloride group|Drugs
89442728|NCT04856358|Experimental|GLPG3121 SAD|Single doses of GLPG3121 at up to 3 dose levels in ascending order
89442729|NCT04856358|Placebo Comparator|Placebo SAD|Single doses of placebo
89442730|NCT04856358|Experimental|GLPG3121 MAD|Multiple doses of GLPG3121 at up to 3 dose levels in ascending order
89442731|NCT04856358|Placebo Comparator|Placebo MAD|Multiple doses of placebo
89442732|NCT04856358|Experimental|GLPG3121 FE fed|Single dose of GLPG3121 in fed state
88926664|NCT01694550||Pacemaker mode programming|High grade AV-block
88926665|NCT01694576|Experimental|Adjuvant chemotherapy with paclitaxel and nedaplatin|Patients will receive 3 cycles of adjuvant chemotherapy consisting of paclitaxel and platinum after concurrent chemoradiation
88926666|NCT01694576|No Intervention|Observation|Patients will be followed up without adjuvant chemotherapy after concurrent chemoradiation
88926667|NCT01694589|Experimental|LDE-225|LDE-225: dose - 800 mg, taken by mouth once daily for 2 weeks.
88926668|NCT01694602||Newly Diagnosed NSCLC patients|In this study, newly diagnosed NSCLC patients who are not candidates for curative resection, will receive a (non-radioactive) oral dose of deuterated 3-methylhistidine (D-3MH).
88926669|NCT01694615|Active Comparator|Cryoprobe biopsy|All patients enrolled will undergo standard forceps biopsies followed by cryoprobe biopsies and results will be compared
88926670|NCT01694615|Active Comparator|Forceps Biopsy|All patients enrolled will undergo standard forceps biopsies followed by cryoprobe biopsies and results will be compared
89442733|NCT04856358|Experimental|GLPG3121 FE fasted|Single dose of GLPG3121 in fasted state
89442734|NCT02512640|Active Comparator|Volume-controlled ventilation|Volume-controlled ventilation throughout the surgery
89442735|NCT02512640|Active Comparator|Pressure-controlled ventilation|Pressure-controlled ventilation throughout the surgery
89442736|NCT02512406||Patients with Tourette Syndrome|Questionnaires including the Sensory Profile or the Adult/Adolescent Sensory profile and Children's Yale-Brown Obsessive Compulsive Scale or Yale Global Tic Severity Scale will be administered. When time permits, the Children's Yale-Brown Obsessive Compulsive Scale or Yale-Brown Obsessive Compulsive Scale will also be administered. Demographic data will also be collected for each study patient.
89442737|NCT00101907|Experimental|Panitumumab + Gem/Cis|Panitumumab 9 mg/kg intravenously on Day 1 + gemcitabine (gem) 1250 mg/m^2 on Day 1 and Day 8, and cisplatin (cis) 75 mg/m^2 on Day 1 of each 3-week cycle.
89442738|NCT00101907|Experimental|50 mg QD AMG 706 + panitumumab + Gem/Cis|AMG 706 50 mg administered orally once daily (QD) + panitumumab 9 mg/kg intravenously on Day 1 + gemcitabine (gem) 1250 mg/m^2 on Day 1 and Day 8, and cisplatin (cis) 75 mg/m^2 on Day 1 of each 3-week cycle.
89442739|NCT00101907|Experimental|75 mg QD AMG 706 + panitumumab + Gem/Cis|AMG 706 75 mg administered orally once daily (QD) + panitumumab 9 mg/kg intravenously on Day 1 + gemcitabine (gem) 1250 mg/m^2 on Day 1 and Day 8, and cisplatin (cis) 75 mg/m^2 on Day 1 of each 3-week cycle.
89442740|NCT00101907|Experimental|100 mg QD AMG 706 + panitumumab + Gem/Cis|AMG 706 100 mg administered orally once daily (QD) + panitumumab 9 mg/kg intravenously on Day 1 + gemcitabine (gem) 1250 mg/m^2 on Day 1 and Day 8, and cisplatin (cis) 75 mg/m^2 on Day 1 of each 3-week cycle.
89442741|NCT00101907|Experimental|125 mg QD AMG 706 + panitumumab + Gem/Cis|AMG 706 125 mg administered orally once daily (QD) + panitumumab 9 mg/kg intravenously on Day 1 + gemcitabine (gem) 1250 mg/m^2 on Day 1 and Day 8, and cisplatin (cis) 75 mg/m^2 on Day 1 of each 3-week cycle.
89442742|NCT00101907|Experimental|75 mg BID AMG 706 + panitumumab + Gem/Cis|AMG 706 75 mg administered orally twice daily (BID) + panitumumab 9 mg/kg intravenously on Day 1 + gemcitabine (gem) 1250 mg/m^2 on Day 1 and Day 8, and cisplatin (cis) 75 mg/m^2 on Day 1 of each 3-week cycle.
89442743|NCT02512484||high risk TB individuals attending A&E Departments|Assessment against inclusion/exclusion criteria in terms of risk of TB. If eligible, assessment and testing as appropriate for active or latent TB
89442744|NCT03491748|Experimental|Part A (SAD): Cohort 1, 100 mg ETX0282/Placebo|Part A of the study will explore the safety, tolerability, and pharmacokinetics (PK) of a single ascending dose (SAD) of oral ETX0282. Participants will be treated with a single oral dose of 100 milligrams (mg) ETX0282 or placebo in a fasted state. They will be confined to the Study Unit from Day -1 and discharged following collection of the 72-hour postdose assessments (Day 4).
89442745|NCT03491748|Experimental|Part A (SAD): Cohort 2, 200 mg ETX0282/Placebo|Part A of the study will explore the safety, tolerability, and PK of a SAD of oral ETX0282. Participants will be treated with a single oral dose of 200 mg ETX0282 or placebo in a fasted state. They will be confined to the Study Unit from Day -1 and discharged following collection of the 72-hour postdose assessments (Day 4).
89442746|NCT03491748|Experimental|Part A (SAD): Cohort 3, 400 mg ETX0282/Placebo|Part A of the study will explore the safety, tolerability, and PK of a SAD of oral ETX0282. Participants will be treated with a single oral dose of 400 mg ETX0282 or placebo in a fasted state. They will be confined to the Study Unit from Day -1 and discharged following collection of the 72-hour postdose assessments (Day 4).
89442747|NCT03491748|Experimental|Part A (SAD): Cohort 4, 800 mg ETX0282/Placebo|Part A of the study will explore the safety, tolerability, and PK of a SAD of oral ETX0282. Participants will be treated with a single oral dose of 800 mg ETX0282 or placebo in a fasted state. They will be confined to the Study Unit from Day -1 and discharged following collection of the 72-hour postdose assessments (Day 4).
89442748|NCT03491748|Experimental|Part A (SAD): Cohort 5, 600 mg ETX0282/Placebo|Part A of the study will explore the safety, tolerability, and PK of a SAD of oral ETX0282. Participants will be treated with a single oral dose of 600 mg ETX0282 or placebo in a fasted state. They will be confined to the Study Unit from Day -1 and discharged following collection of the 72-hour postdose assessments (Day 4).
89442749|NCT03491748|Experimental|Part A (SAD): Cohort 6 (Elderly), 300 mg ETX0282/Placebo|Part A of the study will explore the safety, tolerability, and PK of a SAD of oral ETX0282. Elderly participants (aged 65 years or older) will be treated with a single oral dose of 300 mg ETX0282 or placebo in a fasted state. They will be confined to the Study Unit from Day -1 and discharged following collection of the 72-hour postdose assessments (Day 4).
89442750|NCT03491748|Experimental|Part B (Food Effect): Cohort 7, 100 mg ETX0282/Placebo|Part B of the study will explore the effect of food on oral ETX0282. Participants will be treated with a single oral dose of 100 mg ETX0282 or placebo (Day 1) while fasted and with a single oral dose of 100 mg ETX0282 or placebo (Day 4) with a high-fat meal. They will be confined to the Study Unit from Day -1 and discharged following collection of the 72-hour post fed state dose assessments (Day 7).
89538458|NCT04800887|Active Comparator|Monofocal intraocular lens|Eyes of patients implanted with monofocal lens Tecnis ZCB00
88926671|NCT01694628|Experimental|CLIMB (COPD Lifestyle, Mood, and Behavior)|Counseling sessions for COPD and depression
88926672|NCT01694628|No Intervention|Control|Usual Care
88926673|NCT01694680|Active Comparator|Lutein-enriched-egg beverage|Powder in sachets is provided and dissolved to prepare Lutein-enriched-egg beverage
88926674|NCT01694680|Placebo Comparator|Placebo|Powder in sachet to prepare beverage
88926675|NCT01694693||RA patients treated by Orencia|RA patients treated by Orencia according to usual practice from June 1st 2007
88926676|NCT01694719|Experimental|Behavioral Activation + Cognitive Control Training|Participants will receive 5 sessions of behavioral activation therapy concurrent with 4 sessions of cognitive control training, a computerized intervention which targets cognitive control processes such as working memory and attention.
88926677|NCT01694719|Active Comparator|Behavioral Activation Therapy plus Control Task|Participants will receive 5 sessions of behavioral activation therapy and 4 sessions of a non-active, computerized control task.
88926678|NCT01694732|Experimental|varenicline with counselling|Active varenicline associated with intensive smoking cessation counselling
88926679|NCT01694732|Placebo Comparator|Placebo with counselling|Placebo of varenicline associated with intensive smoking cessation counselling
89442751|NCT03491748|Experimental|Part C (MAD): Cohort 9, 200 mg ETX0282/Placebo|Part C of the study will explore the safety, tolerability, and PK of MAD of oral ETX0282. Part C will be administered in a fed state. Participants will be treated with a single oral dose of 200 mg ETX0282 or placebo on the morning of Day 1, and will then be dosed three times a day (TID) beginning on the morning of Day 2 (i.e., 24 hours after the Day 1 dose) through Day 7. Participants will be treated with a single oral dose of 200 mg ETX0282 or placebo on the morning of Day 8. They will be confined to the Study Unit from Day -1 and discharged following collection of the 72-hour post Day 8 dose assessments (Day 11).
89442752|NCT03491748|Experimental|Part C (MAD): Cohort 10, 200 mg ETX0282/Placebo|Part C of the study will explore the safety, tolerability, and PK of MAD of oral ETX0282. Part C will be administered in a fed state. Participants will be treated with a single oral dose of 200 mg ETX0282 or placebo on the morning of Day 1, and will then be dosed TID beginning on the morning of Day 2 (i.e., 24 hours after the Day 1 dose) through Day 7. Participants will be treated with a single oral dose of 200 mg ETX0282 or placebo on the morning of Day 8. They will be confined to the Study Unit from Day -1 and discharged following collection of the 72-hour post Day 8 dose assessments (Day 11).
89442753|NCT03491748|Experimental|Part D: Cohort 12, ETX0282/Placebo plus Cefpodoxime Proxetil|Part D of the study will explore the safety, tolerability, and PK of oral ETX0282 when administered as a single oral dose in combination with cefpodoxime proxetil tablets to healthy participants in a fed state. Participants will be treated with a single oral dose of 600 mg ETX0282 or placebo in a fed state on Day 1, with a single oral dose of 400 mg cefpodoxime proxetil in a fed state on Day 4, and with a single oral dose of 600 mg ETX0282 or placebo plus a single oral dose of 400 mg cefpodoxime proxetil dosed at the same time in a fed state on Day 7. They will be confined to the Study Unit from Day -1 and discharged following collection of the 72-hour post Day 7 dose assessments (Day 10).
89442754|NCT03491748|Experimental|Part B (Food Effect): Cohort 14, 300 mg ETX0282/Placebo|Part B of the study will explore the effect of food on oral ETX0282. Participants will be treated with a single oral dose of 300 mg ETX0282 or placebo (Day 1) while fasted and with a single oral dose of 300 mg ETX0282 or placebo (Day 4) with a high-fat meal. They will be confined to the Study Unit from Day -1 and discharged following collection of the 72-hour post fed state dose assessments (Day 7).
89442755|NCT03491748|Experimental|Part G: Cohort 17, 300 mg ETX0282/Placebo|Part G of the study will explore the tolerability and PK profile of oral ETX0282 when administered either as a single dose (i.e., 300 mg as a single dose) or in 4 equal, divided doses over a 6 hour period (i.e., 75 mg every 2 hours for 4 doses [a 300 mg total dose]) when administered in a fasted state. Participants will receive the 2 treatments in a cross-over design according to one of 2 randomized sequences: AB or BA. Treatment A: 0 hours, 4 × 75 mg ETX0282/placebo; 2, 4, and 6 hours, 1 × 75 mg placebo. Treatment B: 0 hours, 1 × 75 mg ETX0282/placebo and 3 × 75 mg placebo; 2, 4, and 6 hours, 1 × 75 mg ETX0282/placebo. Participants will be confined to the Study Unit from Day -1 and discharged following collection of the 24 hours post Day 4 dose assessments (Day 5).
89442756|NCT04769206|Experimental|Galantamine|"Galantamine 16mg/day~- titrating: 4mg once a day for 2 weeks, titrate to 8mg once a day for 2 weeks, then 8mg twice a day for 8 more weeks"
89442757|NCT04769206|Placebo Comparator|Placebo|"placebo (micro crystalline cellulose)~- 1 pill once daily for 4 weeks, then 2 pills daily for 8 weeks"
88926680|NCT01694758||Patients with diabetes type 2|
88926681|NCT01694784|Experimental|Quantitative|In the quantitative arm, we will present harms as absolute risks in the Quantitative Information Sheet. Compared with other risk formats, absolute risks have been shown to improve understanding relative to other common risk formats.
88926682|NCT01694784|Active Comparator|Qualitative|In the qualitative arm, we will describe harms using verbal descriptors (such as rare, uncommon, fairly common, and common) in the Qualitative Information Sheet.
88926683|NCT01694784|Experimental|Narrative|In the narrative arm, we will present harms using patient narratives (i.e. descriptions in which patients describe their experience with decision making about potentially harmful screening services)in the Narrative Information Sheet. To address concerns in the literature that characteristics of the narrator independently influence narrative effect, we will present narratives in paper format with a banner of culturally diverse age-appropriate pictures shown at the top.
88926684|NCT01694784|Experimental|Framed|In the framed arm, we will frame not screening with potentially harmful services as beneficial (i.e. use a gain frame). In the Framed Information Sheet, we will highlight the harms that could be avoided by not getting screened.
88926685|NCT01694797|Experimental|Metoprolol Succinate ER Tablets, 50 mg|Metoprolol Succinate ER Tablets, 50 mg of Dr.Reddy's Laboratories Ltd
88926686|NCT01694797|Active Comparator|TOPROL-XL ER Tablets 50 mg|TOPROL-XL ER Tablets 50 mg of AstraZeneca
88926687|NCT01694810|Experimental|2% NVN1000 Topical Gel|2% NVN1000 Topical Gel once daily for 4 weeks
88926688|NCT01694810|Experimental|4% NVN1000 Topical Gel|4% NVN1000 4% Topical Gel once daily for 4 weeks
88926689|NCT01694810|Placebo Comparator|Vehicle Topical Gel|Vehicle Topical Gel once daily for 4 weeks
88926690|NCT01694810|Experimental|8% NVN1000 Topical Gel|8% NVN1000 8% Topical Gel applied once daily for 4 weeks
88926691|NCT01694823|Experimental|CS-ACI|"Group/Cohort Label： pretherapy post-treatment~Group/Cohort Description ：The CS-ACI is used to prepare cell sheet and implant to the Cartilage defects.The arm of safety and efficacy are compared preoperative observation with postoperative observation."
89442758|NCT03791840||Ultrasound evaluation|Eligible patients undergo lymph node biopsy or lymph node dissection. Before surgery, the status of axillary lymph node status was evaluated using ultrasound. After surgery, all lymph node specimens would be collected and be assessed using ultrasound in a special evaluation system in vitro.
89442759|NCT02517008|Experimental|Mama kits intervention|"Health facilities randomized to this arm provided mama kits - packages of childcare materials including a cloth (chitenge), baby blanket, and diaper - to all mothers who delivered at these facilities between June 1, 2013 - Aug 31, 2013."
89442760|NCT02517008|No Intervention|No intervention|Health facilities randomized to this arm provided obstetric services as normal.
89442761|NCT02161887||Complementary Medicine Group|Patients receiving chiropractic care, acupuncture, or meditation for chronic pain
89442762|NCT02161887||Conventional Medicine Group|Patients receiving conventional medicine care (physical therapy, medication management) for chronic pain.
89442763|NCT03492996|Experimental|LCB01-0371 dose with a [14C]-LCB01-0371-tracer|A mass balance study to investigate the absorption, metabolism, excretion of LCB01-0371 after a single oral LCB01-0371 dose with a [14C]-LCB01-0371-tracer dose in healthy male subjects
89442764|NCT02161965|Experimental|Rivaroxaban|"Rivaroxaban (oral tablet) for patients with atrial fibrillation:~20 mg once daily for patients with GFR > 49 ml per minute and 15 mg rivaroxaban once daily for patients with GFR of 15 to 49 ml.~Rivaroxaban (oral tablet) for patients with pulmonary embolism: 2 x a day 15 mg at day 1-21 and 1x 20 mg from day 22 ongoing"
89442765|NCT02161965|Active Comparator|vitamin K antagonists|Adjusted dose of warfarin or fluindione (oral tablet) titrated according to target international normalized ratio with a target range 2.0 to 3.0.
89442766|NCT02565784|Experimental|Intradermal injection|Restylane and/or Perlane
89442767|NCT02050308|Experimental|Internet-All Nations Breath of Life (I-ANBL)|"The culturally-tailored program includes 9 individual Internet-based sessions across a 12 week period and an additional individual Internet-based session at 6 months. Web sessions will last about half-an-hour (30 minutes) and will discuss topics that are important to quitting smoking (like: preparing to quit, dealing with cravings, and support systems, etc.) and topics relevant to American Indian culture (like traditional use of tobacco).~We plan to give participants in our cessation program a choice of varenicline, bupropion, nicotine replacement therapy or no pharmacotherapy. We choose to give our participants a choice because our experience shows that we would be unlikely to recruit AI participants into a trial that requires pharmacotherapy use."
88926692|NCT01694836|Experimental|Depigoid Birch 5.000 DPP/ml|"Suspension for s.c. injection. Treatment schedule:~Build-up phase (1 day: 0,2 ml+0,3 ml at interval of 30 minutes)~Maintenance phase (3 years: 0,5 ml at intervals of 4-6 weeks)"
88926693|NCT01694836|Placebo Comparator|Placebo|"Suspension for s.c. injection. Treatment schedule:~Build-up phase (1 day: 0,2 ml+0,3 ml at interval of 30 minutes)~Maintenance phase (3 years: 0,5 ml at intervals of 4-6 weeks)"
88926694|NCT01694862|Experimental|Integrated FP /PNC service delivery|Clinic or district identified as 'intervention' in which FP and PNC services are (theoretically) being provided together with HIV services (counselling, testing, treatment etc.) and in which the procedural intervention has been applied.
89442768|NCT02050308|Active Comparator|Honoring the Gift of Heart Health|"The culturally-tailored program includes 9 individual Internet-based sessions across a 12 week period and an additional individual Internet-based session at 6 months. Web sessions will last about half-an-hour (30 minutes) and will discuss topics that are important to heart health (like: Assessing risk for heart disease, increasing fruit and vegetable consumption, physical activity, etc.).~We plan to give participants in our cessation program a choice of varenicline, bupropion, nicotine replacement therapy or no pharmacotherapy. We choose to give our participants a choice because our experience shows that we would be unlikely to recruit AI participants into a trial that requires pharmacotherapy use."
89442769|NCT02164071||Multiple Myeloma (MM)|Patients with Myltiple Myeloma, symptomatic or asymptomatic
89442770|NCT02164071||Myelodysplastic Syndromes or Acute Myeloid Leukemia|Patients with Myelodysplastic Syndromes (MDS), any International Prognostic Scoring System (IPSS) risk, or Acute Myeloid Leukemia (AML)
89442771|NCT02164071||Chronic Lymphocytic Leukemia (CLL)|Patients with Chronic Lymphocytic Leukemia
88926695|NCT01694862|No Intervention|Non-integrated FP/PNC service delivery|Clinic or district where FP and PNC services are not (theoretically) being provided together with HIV services, and in which no procedural intervention has been applied.
88926696|NCT01694875||No Treatment|
88926697|NCT01694888|Experimental|midwifery students|all midwifery students studying at last term (except one who was absent) (27) in Mashhad school of nursing and midwifery in April 2011
88926698|NCT01694901||SmartPilot® system|50 patients scheduled for elective surgery (general/abdominal surgery; traumatological/orthopedic surgery, gynecology, urology) in general anesthesia using the SmartPilot® system
88926699|NCT01694901||Standard arm|50 patients scheduled for elective surgery (general/abdominal surgery; traumatological/orthopedic surgery, gynecology, urology) in general anesthesia according to the standard operating procedures of the department, i.e. manually controlled clinical anesthesia and EEG-derived parameters of anesthetic depth
89442772|NCT03345056|Other|included cases|vitrectomy done with planned foveal separation and followed for the result
89442773|NCT02164149||Quality of colon cancer surgery|Patients with primary colon cancer
89442774|NCT04790916|Experimental|RO7049665 3.5 mg|Participants will receive RO7049665 3.5 mg, administered as subcutaneous (SC) injection, every 2 weeks (Q2W) until participants experience relapse or the study is closed.
89442775|NCT04790916|Experimental|RO7049665 7.5 mg|Participants will receive RO7049665 7.5 mg, administered as SC injection, Q2W until participants experience relapse or the study is closed.
89442776|NCT04790916|Placebo Comparator|Placebo|Participants will receive RO7049665-matching placebo, administered as SC injection, Q2W until participants experience relapse or the study is closed.
89442777|NCT02516852|Experimental|Intervention|
89442778|NCT02516852|No Intervention|Control|
89442779|NCT05510830|Experimental|Patients|The patients who meet the inclusion criteria will receive diagnostic cervical conization for pathological examinations. Then they will be followed up for at least two years with every six months' return to our clinics to test HPV and colposcopy if necessary.
89442780|NCT02162043||Usability assessment|Patients without any experience with visual field testing will be recruited and tested with different versions of the developed self-test. This will help identify usability features that will make the test user-friendly.
89442781|NCT02162043||Hospital-based clinical trial|The new test will be evaluated on patients attending Manchester Royal Eye Hospital to provide an estimate of its diagnostic performance.
89442782|NCT02162043||Community-based trial|Patients attending Manchester Royal Eye Hospital's outpatient clinics will be recruited to trial the new test on their friends and family in order to evaluate the uptake and performance of the new test in a home environment without any researchers/clinicians presence.
89442783|NCT02516618|Experimental|Cohort 1|Participants in this cohort will receive dose 1 of Fasinumab or placebo
89442784|NCT02516618|Experimental|Cohort 2|Participants in this cohort will receive dose 2 of Fasinumab or placebo
89442785|NCT02516618|Experimental|Cohort 3|Participants in this cohort will receive dose 3 of Fasinumab or placebo
89442786|NCT02516618|Experimental|Cohort 4|Participants in this cohort will receive dose 4 of Fasinumab or placebo
88926700|NCT01694914|Experimental|Animal Compound Free Medium|Patients in this arm receive a corneal graft stored in organ culture in a animal compound free medium
88926701|NCT01694914|Active Comparator|organ culture medium containing 2% of fœtal calf serum|Patients in this arm receive a corneal graft stored in organ culture in a commercial organ culture medium containing 2% of fœtal calf serum
88926702|NCT01694927|Experimental|Mesenchymal Stem cells|
88926703|NCT01694979||Single group: pelvic floor and breathing|This is a single group with repeated measures during variable breathing effort
88926704|NCT01694992|Experimental|Early mobilization|The Intervention Group - Early Mobilization - will follow the early physiotherapy program within the first 24 - 48 hours after stroke, five times per week for 30 plus a time spent out of bed (sitting).
88926705|NCT01694992|No Intervention|Control|The Control Group will follow within the routines of the hospital as is usually done.
89442787|NCT02516618|Experimental|Cohort 5|Participants in this cohort will receive dose 5 of Fasinumab or placebo
89442788|NCT05507554|Active Comparator|Opioid Group|This group comprises of patients with ureter stones stones who undergo ureteroscopy procedure. They will be randomized to intravenous injection Tramadol 50 mg. They will also be discharged on Tramadol oral capsule 50 mg for postoperative pain after the ureteroscopy procedure with stent placement
89442789|NCT05507554|Active Comparator|Paracetamol (Acetaminophen) Group|This group comprises of patients with ureter stones stones who undergo ureteroscopy procedure. They will be randomized to intravenous injection Paracetamol 1 Gram. They will also be discharged on oral Tablet Paracetamol 1 Gram for postoperative pain after the ureteroscopy procedure with stent placement
89442790|NCT05507554|Active Comparator|Diclofenac Sodium Group|This group comprises of patients with ureter stones stones who undergo ureteroscopy procedure. They will be randomized to intra muscular injection Diclofenac Sodium 50 mg. They will also be discharged on oral Tablet Diclofenac Sodium 50 mg for postoperative pain after the ureteroscopy procedure with stent placement.
89442791|NCT01460862||Omalizumab Cohort|
89442792|NCT02512328|No Intervention|Regular colonoscopy preparation|Comparison group. Regular colonoscopy preparation
89442793|NCT02512328|Experimental|APP supported colonoscopy preparation|APP as additional device for colonoscopy preparation
89442794|NCT02155491||Prospective cohort 1|In order to observe temporal trends in management of VTE a first cohort of 5000 consecutive unselected patients treated for acute VTE will be recruited. This cohort will take approximately 9 months to recruit. Potential patients must be assessed for eligibility within 30 days of their acute VTE diagnosis. They will be followed prospectively for 36 months.
89538459|NCT03266237|Experimental|Healthy Adult|Healthy adult participants aged 21-40 years will be vaccinated with Vaxigrip® influenza vaccine
89013218|NCT01602289|Experimental|LY2875358+Gefitinib|Part B2. Gefitinib will be administered orally at 250 mg dose level each day. LY2875358 will be administered intravenously (IV) at recommended dose level in Part A on Day 1 and Day 15 of a 28-day cycle. (Part B2 was added per protocol amendment in January, 2013.)
89442795|NCT02155491||Prospective cohort 2|In order to observe temporal trends in management of VTE a second cohort of 5000 consecutive unselected patients treated for acute VTE will be recruited. Recruitment into the second cohort will commence when recruitment is completed in the first cohort. This cohort will take approximately 9 months to recruit. Potential patients must be assessed for eligibility within 30 days of their acute VTE diagnosis. They will be followed prospectively for 36 months.
89442796|NCT05502640|Other|sponge group|Control group
89442797|NCT05502640|Experimental|Chicken group|
89442798|NCT02516384|Experimental|Fecal Microbiota Transplantation|Individuals with Ulcerative Colitis will undergo a fecal microbiota transplantation.
89442799|NCT04110366|Experimental|Live attenuated influenza vaccine|Participants receiving live attenuated influenza vaccine (LAIV)
89442800|NCT04110366|Experimental|Mucosal immune stability cohort|Participants receiving a vehicle control nasal challenge
89442801|NCT02512016|Other|Nulliparous Women in Third Trimester|Study Procedures
89442802|NCT00995202|Other|Standard Monitoring CEA/ Standard Imagery|No specific follow-up of CEA and Standard imagery
89442803|NCT00995202|Other|Intensive monitoring CEA/ Standard Imagery|Intensive follow-up CEA and Standard imagery .
89013219|NCT01602328|Active Comparator|AC607|Treatment with AC607
89013220|NCT01602328|Placebo Comparator|Placebo|Treatment with Placebo
89013221|NCT01602406|Experimental|LJM716 in combination with trastuzumab|
89013222|NCT01602445||Cancer patients|All cancer patients with a diagnosed acute symptomatic VTE episode.
89442804|NCT00995202|Other|Intensive Monitoring CEA / Intensive Monitoring Imagery|Intensive follow-up CEA and Intensive imagery
89442805|NCT00995202|Other|Standard Monitoring CEA/ Intensive Monitoring Imagery|No specific follow-up of CEA and Intensive Imagery
89442806|NCT02516462|Experimental|IVM|Immature oocytes recovered from each subject will be placed into IVM media for maturation.
89442807|NCT02516072|No Intervention|Control|Patients will receive iv hydration prior to procedure dependent on classification of risk as per eGFR.
89442808|NCT02516072|Experimental|Remote Ischaemic preconditioning (RIPC)|Patients will receive iv hydration prior to procedure dependent on classification of risk as per eGFR. Additionally, patients will receive RIPC; a blood pressure cuff will be placed around one arm of the patient, it will then be inflated to a pressure of 250mmHg for 5 minutes. The cuff will then be deflated and the arm allowed to reperfuse for 5 minutes. This will be repeated so that each patient receives a total of 3 ischaemia-reperfusion cycles immediately prior to the procedure.
89013223|NCT01602523|Active Comparator|budesonide/formoterol|budesonide/formoterol 160/4.5 mcg (Symbicort)
89013224|NCT01602523|Placebo Comparator|Placebo|Symbicort placebo
89013225|NCT01602601||Cohort 1|Patients will have a single blood draw for the analysis of antibodies induced by idursulfase. Samples will be used to further evaluate whether the antibodies induced by idursulfase bind to GSK2788723 molecules in vitro and if these antibodies neutralize the bioactivity of GSK2788723 in vitro.
89199895|NCT02575963|Experimental|Phase 1 (Completed)|"Cytarabine + Lintuzumab-Ac225 Cytarabine days 1 to 10 of each cycle. Doses were divided into 2 equal fractions with the first fraction given approx. 4-7 days after 1 cycle of low dose cytarabine and the second fraction given 4-7 days after the first fraction, followed by up to 11 more cycles. Furosemide (Phase 1 only) and Spironolactone were administered after Lintuzumab-Ac225.~Experimental: Phase 2~Experimental: Lintuzumab-Ac225 The Phase II dose determined during the Phase I dose escalation was 4.0 μCi/Kg Lintuzumab-Ac225 and 25 μg/Kg unlabeled HuM195 divided into 2 equal fractions with the first fraction given on Day 1 and the second fraction given on Day 5-8. Spironolactone is administered after Lintuzumab-Ac225."
89442809|NCT04650204|Experimental|Arm A (perampanel)|Patients receive perampanel PO QD for 40 weeks in the absence of disease progression or unacceptable toxicity.
89442810|NCT04650204|Active Comparator|Arm B (ASD)|Patients receive ASD per standard of care for 40 weeks in the absence of disease progression or unacceptable toxicity.
89442811|NCT04501250|Experimental|Rinsulin® NPH|Single subcutaneous administration of Insulin at a dose 0.4 IU / kg
89442812|NCT04501250|Active Comparator|Humulin® NPH|Single subcutaneous administration of Insulin at a dose 0.4 IU / kg
89442813|NCT02761629|Experimental|Peg-IFN-Alpha-2A+Ribavirin - 48 Weeks|Participants will receive Peg-IFN-Alpha-2A and ribavirin for 48 weeks.
89442814|NCT02761629|Active Comparator|Peg-IFN-Alpha-2A+Ribavirin - 72 Weeks|Participants will receive Peg-IFN-Alpha-2A and ribavirin for 72 weeks.
89442815|NCT03345992|Placebo Comparator|Placebo|After enrollment, the placebo arm will receive water for injection at a volume of 20ml diluted to a final volume of 250 ml dextrose in water 5%, infused once daily through intravenous route, within 1 hour, for a duration of four consecutive days.
89013226|NCT01602640|Experimental|Morphine|
89013227|NCT01602640|Active Comparator|Fentanyl and Midazolam|Control
89013228|NCT00290667|Active Comparator|Interventional: CHOP-14 + 8 x 2-weekly rituximab|Arm I (2-weekly rituximab): Patients receive rituximab IV 375 mg/m^2 (females) and 500 mg/m^2 (males) over 4 hours on days 0, 14, 28, 42, 56, 70, 84, and 98. Patients also receive pegfilgrastim subcutaneously on day 4 of each course.
89442816|NCT03345992|Active Comparator|Clarithromycin|After enrollment, the active drug arm will receive 1g of clarithromycin (500 mg powder for concentrate for solution for infusion per vial), dissolved into 20 ml water for injection and then diluted to a final volume of 250 ml dextrose in water 5%. This will be infused through intravenous route, once daily within 1 hour, for a duration of four consecutive days.
89442817|NCT03488940|Active Comparator|24-hours group|"The septic patients randomized to 24-hours group will be received enteral nutrition preparation by 24 hours of continuously pumping through stomach tube every day.~Feeding will be started within 24 hours in admission of ICU. The time of therapy is 7 days."
89442818|NCT03488940|Experimental|16-hours group|"The septic patients randomized to 16-hours group will be received enteral nutrition preparation by 16 hours of continuously pumping through stomach tube every day.~Feeding will be started within 24 hours in admission of ICU. The time of therapy is 7 days."
89442819|NCT03488940|Experimental|intermittent group|"The septic patients randomized to intermittent group will be received enteral nutrition preparations by four meals every day(08:00,12:00 18:00,22:00), each meal are pumped within 60mins through stomach tube.~Feeding will be started within 24 hours in admission of ICU. The time of therapy is 7 days."
89442820|NCT02511860|Placebo Comparator|Placebo|Patients will consume a placebo pill containing methylcellulose.
89442821|NCT02511860|Active Comparator|Active|Patients will consume 850 mg of burdock twice per day.
89442822|NCT02162121|Experimental|Stimulating catheter|"After Spinal Anesthesia (Levobupivacaine 0,5% 15mg) all patients in the arm will receive continuous lumbar plexus block with stimulating catheter (Stimolong, Pajunk, Germany). Mepivacaine 1% 15 ml will be administrated. As post-operative analgesia Ropivacaine 0,2% will be continuous administrated."
89442823|NCT02162121|Active Comparator|Non-stimulating catheter|"After Spinal Anesthesia (levobupivacaine 0,5% 15mg) all patients in the arm will receive continuous lumbar plexus block with non-stimulating catheter (Stimolong, Pajunk, Germany). Mepivacaine 1% 15ml will be administrated. As post-operative analgesia Ropivacaine 0,2% will be continuous administrated."
89442824|NCT02511938|Experimental|Menu Only intervention|Restaurants will receive a new healthy kids' menu
89442825|NCT02511938|Experimental|Menu Plus Intervention|Restaurants will receive a new healthy kids' menu, supporting marketing materials, and brief trainings for customer service staff and kitchen staff to support and promote the new menu items.
89442826|NCT02164227|Experimental|respiratory pattern|Deep and slow inspiration is used in the initial and active stages, at which time the contractions vary from uncomfortable to strong, lumbosacral pain and cervical dilation may occur between 3 and 8 cm in this case the mother is driven to inspire slowly and the level of inspiratory reserve volume followed by slow exhalation to functional residual capacity; Sigh with post-expiratory pause that corresponds to a small spontaneous exhalation to relax occurs in tidal volume; Expiratory delay that corresponds to a prolonged propelled with the lips during the lull and expiration in the expiration time that corresponds to a slow inspiration followed by two or three puffs with the short lips will be used propelled.
89442827|NCT02164227|No Intervention|Control|Follows the service routine
89442828|NCT02511548|Experimental|Intervention|Financial incentive
89442829|NCT02511548|No Intervention|Control|No financial incentive
89442830|NCT02164305|Experimental|Strengthening group|4-week exercise training, 3 times a week, 30 minutes per visit.
89442831|NCT02164305|Experimental|Neuromuscular group|4-week exercise training, 3 times a week, 30 minutes per visit
89442832|NCT02164305|Sham Comparator|Control|Only have 2 assessments.
89442833|NCT03345758||ECMO mode,outcome|ECMO mode includes VV-ECMO and VA-ECMO, outcome includes survive condition , physical and mental health, cognitive function and social adaptation
89442834|NCT02507492|Experimental|RM-493 Once Daily|Dose once daily in the morning
89442835|NCT02162199|Experimental|Debio 1450|Debio 1450 40 mg, capsules, orally, once in the morning under fasted conditions
89442836|NCT02162199|Placebo Comparator|Placebo|Placebo 0 mg, matching capsules, orally, once in the morning under fasted conditions
88926706|NCT01695005|Experimental|LY3039478 - Dose Escalation|Part A: LY3039478 administered orally three times per week (TIW) at escalating doses (2.5 milligrams [mg] to 100 mg) for two 28 day cycles. Participants receiving benefit may continue until disease progression
88926707|NCT01695005|Experimental|LY3039478 - Cohort Expansion|Part B, C, D and E: LY3039478 administered orally three times per week (TIW) at a fixed dose determined in Part A for two 28 day cycles. Participants receiving benefit may continue until disease progression.
88926708|NCT01695005|Experimental|Dose 1 LY3039478 + Prednisone|Part F1: LY3039478 administered orally TIW for 28 day cycles. Prednisone will be co-administered with LY3039478 for the first 2 weeks in cycle 1 only (28 day cycles). Participants receiving benefit may continue until disease progression.
88926709|NCT01695005|Experimental|Dose 2 LY3039478 + Prednisone|Part F2: LY3039478 administered orally TIW (twice a week in cycle 1) for 28 day cycles. Prednisone will be co-administered with LY3039478 for the first 2 weeks in cycle 1 only. Participants receiving benefit may continue until disease progression.
89199896|NCT02541305|Active Comparator|Cotrol|No propioceptive program.
89442837|NCT02507414|Experimental|Group 1|"Patients under going Whipple's procedure, gastric resection and liver resection (n=75).~Interventions:~Blood samples obtained pre-, intra-, and one day postoperatively (n=15).~Measurements of microcirculation using LSCI from procedure start and up to 60 min during surgery.~Head down tilt of 20 degrees at three time points."
89442838|NCT03540693||RYGB-longitudinal|Longitudinal group of subjects studied before and after Roux-n-Y gastric bypass surgery
89442839|NCT03540693||SG_longitudinal|Longitudinal group of subjects studied before and after sleeve gastrectomy surgery
89442840|NCT03540693||LAGB_longitudinal|Longitudinal group of subjects studied before and after laparoscopic gastric banding surgery
89442841|NCT03540693||Weight-loss success|Subjects who lost ≥40% body weight by 2-5 years post-surgery
89442842|NCT03540693||Weight-loss failure|Subjects who lost <25% body weight (or lost more but then regain weight so that now are at <25%) by 2-5 years post-surgery
89442843|NCT02511470|Other|CPR with metronome on|Participants will perform two minutes of uninterrupted chest compressions on a pediatric manikin with the metronome on. Data for compression rate and depth will be collected during this time interval.
89538460|NCT03266237|Experimental|Healthy Elderly|Healthy Elderly participants aged 65-90 years will be vaccinated with Vaxigrip® influenza vaccine.
89442844|NCT02511470|Other|CPR with metronome off|Participants will perform two minutes of uninterrupted chest compressions on a pediatric manikin with the metronome off. Data for compression rate and depth will be collected during this time interval.
89442845|NCT02760927|Experimental|Endotracheal Tube Fastener|The intervention administered is a revised commercially available endotracheal tube holder with a tract to accommodate a subglottic suction lumen of an oral endotracheal tube.
89442846|NCT04500782||Patients|Group of patients with CP aged 4 to 10 years.
89442847|NCT02511704|Experimental|Electronic cigarette|"Multiple dose~Nicotine 0.8 mg, administrated by electronic cigarette (10 puffs) + Nicotine 0.8 mg, administrated by electronic cigarette (10 puffs) separated by 60 minutes"
89442848|NCT02511704|Active Comparator|Cigarette|"Multiple dose~Nicotine 0.8 mg, administrated by cigarette (10 puffs) + Nicotine 0.8 mg, administrated by cigarette (10 puffs) separated by 60 minutes"
89442849|NCT02164461|Experimental|ADXS11-001|
89442850|NCT02511392|Active Comparator|Group 1: Real rTMS-1 Hz|Included 15 patients, they received 1 Hz rTMS with intensity of 100% of the RMT continuous with total 2000 applied in 200 trains, each of 10 pulses, with 5 seconds intertrain interval
89442851|NCT02511392|Active Comparator|Group 2: Real rTMS-10 Hz|Included 15 patients, they received 10 Hz rTMS with intensity of 100% of the RMT applied in 10 trains, each of them 200 pulses, with 20 seconds intertrain interval
89442852|NCT02511392|Sham Comparator|Group 3: Sham rTMS|Included 15 patients; they received the same number of pulses 2000 pulse applied in 200 trains, each of 10 pulses, with 5 seconds intertrain interval, but coil was placed over the same area but perpendicular to the scalp.
89442853|NCT02162277||Osteoporosis diagnostic kit|
89442854|NCT04500704|Active Comparator|Almonertinib 110mg PO once daily|Almonertinib 110mg PO once daily.
88926710|NCT01695018||p16 methylation positive|48 patients with mild or moderate oral epithelial dysplasia containing methylated p16.
89442855|NCT04500704|Experimental|Almonertinib plus carboplatin and pemetrexed|Almonertinib 110mg PO once daily in combination with pemetrexed (500 mg/m2) plus carboplatin (AUC=5) on Day 1 of 21day cycles (every 3 weeks) for 4-6 cycles, followed by Almonertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.
89442856|NCT02164617|Experimental|Wheelchair-bound Senior Elastic Band|Wheelchair-bound Senior Elastic Band (WSEB) exercise program has three phases: 1) warm-up: 6 movements to loosen up the body and elevate the energy for a safe transition to the next phase, 2) aerobic motions: 6 low-to-medium speed exercises to enhance the cardiovascular-respiratory workout, and 3) static stretching: 6 low-speed, gentle stretching exercises to build up muscle power/endurance and increase range of motion and flexibility. It is conducted three times per week, 40 minutes per practice.
89442857|NCT02164617|No Intervention|control|routine care
89442858|NCT02507180||Pregnant women with suspected DVT|Pregnant women presenting with suspected DVT will have the LEFt clinical decision rule applied by the attending physician and will have a clinical D-dimer test done.
88926711|NCT01695018||p16 methylation negative|104 patients with p16 mild or moderate oral epithelial dysplasia NOT containing methylated p16.
88926712|NCT01695031|Experimental|Tailored asthma management program|Teens randomized to the experimental arm will receive 4 sessions of web-based, tailored asthma management
88926713|NCT01695031|Active Comparator|Generic web-based education|Teens in the control group will receive generic, web-based asthma education.
88926714|NCT01695057|Experimental|Treatment (vorinostat and surgery)|Patients receive vorinostat 400 mg daily PO on days 1-21 followed by surgery within 14 days.
88926715|NCT01695070|Experimental|Melatonin|Women with IUGR will take 4mg prolonged release melatonin oral tablets twice daily. Treatment will occur as soon as the diagnosis of intrauterine growth restriction is made and the patient has been enrolled to this study until birth. The overall duration of treatment will vary due to the nature of intrauterine growth restriction.
89442859|NCT02166567|Experimental|YoPro and FACS|Spermatozoa to be used for ICSI will be stained with the YoPro Dye and then be sorted with FACS to select non-YoPro stained spermatozoa, known to have significantly less fragmented DNA.
89442860|NCT02166567|Active Comparator|Swim-up|Spermatozoa will be processed using the conventional swim-up me
89442861|NCT04500314|Experimental|Whole body vibration plus routine physical therapy|
89442862|NCT04500314|Active Comparator|Routine physical therapy|
89442863|NCT02166645|Experimental|Prone position|Prone position per 48 hours after extubation
89442864|NCT02166645|Active Comparator|Supine position|Supine position per 48 hours after extubation
89442865|NCT02507258||PROFEMUR® Am Femoral Stem|Single study group previously implanted with a primary PROFEMUR® Am Femoral Stem and PROCOTYL® O HA Coated Acetabular Component
89442866|NCT02164773|Active Comparator|magnesium sulfate|magnesium sulfate 50mg caudal 1ml(5%) prepared after addition of 9ml of 0.9%normal saline to 1ml of 500mg(50%)of magnesium sulfate to be added to 1ml/kg of 0.25%of bupivacaine in caudal block in children undergoing lower abdominal surgery under sevoflurane anesthesia to prevent emergence agitation.
89442867|NCT02164773|Placebo Comparator|o.9%normal saline|0.9% of normal saline added to the conventional 0.25% bupivacaine in caudal block.
89442868|NCT02507024||Intervention|The online questionnaire includes questions about how ANCA-associated vasculitis effects patients quality of life.
89442869|NCT02166723||CRYOABLATION|Cryoballoon ablation will be applied to all patients with persistent atrial fibrillation. It consists on applying the Arctic Front Cryoballoon to the pulmonary veins and freezing the antrum. In addition debulking of the atrial roof will be performed by a single application of the cryoballoon to the left and right roof, the septal wall and the lateral ridge wall.
89501703|NCT02230111|Experimental|Energy restriction without CDR group|Subjects will receive a reduced-calorie low energy density diet which will provide 85% of their energy needs for a period of 4 weeks. To have a condition of energy restriction without CDR, they will not be told that they are on a low-calorie diet and non-restrictive messages will be used.
88926716|NCT01695096|Experimental|The Embryos will be cultured on a humidity free incubator|We will set the humidity level to 0.0% in the IVF incubator that will be used for culturing the Human embryos after ICSI procedure and we will monitor the outcome embryologically and clinically and record the results.
89199897|NCT02541305|Experimental|Experimental|Propioceptive program
89199898|NCT02507284|Experimental|SRX246 120mg BID|SRX246 capsules, administered orally, in divided doses twice daily
89442870|NCT02511314|Experimental|Intervention|"Tena Identifi is an integrated electronic monitoring system based upon a wearable continence pad which allows registration of resident's micturition patterns over a 72 hour period, allowing caregivers to construct an individualised continence care plan, including use of appropriate products.~To create a voiding report, a resident wears the Identifi Sensor Wear with an attached Identifi Logger for three consecutive days (72 hours). The logger continuously logs the moisture status of the brief. The resulting data is sent to a server via 3 G signal where it is mapped onto a graph indicating voiding times and volumes."
89442871|NCT02511314|No Intervention|Control Intervention|"The control portion of the study is usual care, defined as the routine practices and procedures, including continence assessment approach, prescribed in the nursing home unit or facility."
89442872|NCT00101439|Experimental|Ezetimibe→Placebo|After a 2-week single- blind placebo run-in, participants will receive ezetimibe 10 mg once daily for 4 weeks and then receive placebo once daily for 4 weeks.
89442873|NCT00101439|Experimental|Placebo→ Ezetimibe|After a 2-week single- blind placebo run-in, participants will receive placebo once daily for 4 weeks and then receive ezetimibe10 mg once daily for 4 weeks.
89442874|NCT02507102|Experimental|Investigational Voyager Therapy|Investigational treatment with Voyager Therapy
89442875|NCT03344900||Phase I|It is estimated that 100 participants with SCD will be enrolled for the Phase I portion which will identify barriers to hydroxyurea utilization.
89442876|NCT03344900||Phase II|It is estimated that 72 participants with SCD will be enrolled for the Phase II portion of the study which will evaluate the degree of feasibility and acceptance of mHealth intervention on hydroxyurea adherence.
89442877|NCT02166801|Active Comparator|Early intervention for infants|A 30w intensive intervention according to the small step program, with daily practice sections conducted by parents at home, with weekly support by therapists.
89442878|NCT02166801|Active Comparator|Usual care|Usual care means that the Children in this arm of the study participate in the established follow up program that is established at the Astrid Lindgrens Children's Hospital and offered to all Children that displays a delayed early gross and fine motor development.
89442879|NCT03345680|No Intervention|Control Group|Children will be screened, both parents and children will be informed of any abnormalities in the mouth.
89442880|NCT03345680|Experimental|Interventional Group|Interventional (Dental Screening) Children will be screened for dental caries and referred to a specific hospital for treatment, namely King Saud University Dental College, treatment will be provided free of charge to the referred participants.
89442881|NCT02166879||Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS)|Chart review from patients undergoing elective surgery.
89442882|NCT03344822|Experimental|68Ga-PSMA PET-CT|
89442883|NCT02166957||Long disruption > 5cm +/- loss of SES|
89442884|NCT02166957||Short disruption < 5cm|
89442885|NCT02506712|Experimental|spinal cord injury|use a wheelchair with and without a assisting device to power manuel wheelchair
89442886|NCT02506712|Other|volunteer|push a wheelchair with and without a assisting device to power manuel wheelchair
89442887|NCT02162355|Experimental|GLPG0634 in Japanese subjects|Per panel, 6 Japanese healthy subjects will receive one of the three doses (50 mg, 100 mg or 200 mg) of GLPG0634 as tablets once daily for 10 days
88926717|NCT01695096|Placebo Comparator|The Embryos will be cultured on a >95% humidity incubator|We will set the humidity level to > 95% in the IVF incubator that will be used for culturing the Human embryos after ICSI procedure and we will monitor the outcome embryologically and clinically and record the results.
88926718|NCT01695109|Placebo Comparator|Placebo|
88926719|NCT01695109|Active Comparator|Liraglutide|
88926720|NCT01695122|Experimental|valproic acid|
88926721|NCT01695148|Active Comparator|White Maize Flour|Children will receive 2 meals a day (~200 g of white maize flour), 6 days a week for 6 months.
88926722|NCT01695148|Experimental|β-Carotene Biofortified Maize|Children will receive 2 meals a day (~200 g of beta-carotene biofortified maize flour), 6 days a week for 6 months.
89442888|NCT02162355|Placebo Comparator|Placebo in Japanese healthy subjects|Per panel, 2 or 4 (last panel only) Japanese healthy subjects will receive placebo as tablets once daily for 10 days
89442889|NCT02162355|Experimental|GLPG0634 in Caucasian subjects|In the last panel, 6 Caucasian healthy subjects will receive one dose of GLPG0634 (200 mg) as tablets once daily for 10 days
89442890|NCT02162355|Placebo Comparator|Placebo in Caucasian healthy subjects|In the last panel, 4 Caucasian healthy subjects will receive receive placebo as tablets once daily for 10 days
89442891|NCT02515838|Placebo Comparator|Placebo|Placebo infusion
89442892|NCT02515838|Experimental|Sevuparin|Sevuparin infusion
89442893|NCT04033068|Experimental|Two MV-ZIKA-RSP vaccinations (high dose)|14 Participants will receive MV-ZIKA-RSP 1 x10E5/dose on day 0 and day 28
89442894|NCT04033068|Experimental|Two MV-ZIKA-RSP vaccination (low dose)|14 Participants will receive MV-ZIKA-RSP 2,5 x10E4 /dose on day 0 and day 28
89442895|NCT04033068|Experimental|One MV-ZIKA-RSP vaccination (high dose) and one placebo|12 Participants will receive MV-ZIKA-RSP 1 x10E5/dose on day 0 and placebo on day 28
89442896|NCT04033068|Placebo Comparator|Two placebo injection|8 Participants will receive placebo on day 0 and placebo on day 28
89442897|NCT02162589||POEM for Achalasia|Any patient who has undergone clinically indicated and/or standard of care POEM for the treatment of Achalasia.
89442898|NCT02162745|Experimental|Isotonic solution (NaCl 0.9%)|Single nasal irrigation with 1 ml of isotonic solution (NaCl 0.9%) per each nostril
89442899|NCT02162745|Experimental|Hypertonic solution (NaCl 3%)|Single nasal irrigation with 1 ml of hypertonic solution (NaCl 3%) per each nostril
89442900|NCT02162745|No Intervention|Supportive care|Wiping the nose, positioning the child, changing a wet diaper, feeding.
89442901|NCT02506790|Experimental|Toremifene and metformin|Toremifene 60 mg daily with metformin 850 mg BID
89442902|NCT02506790|Experimental|Toremifene and melatonin|Toremifene 60 mg daily with melatonin 3 mg before sleep daily
88926723|NCT01695148|No Intervention|Non-Intervened|Children will receive no food for the duration of the study, but families in this group will receive an equivalent ration of food items at the end of the trial.
88926724|NCT01695161||mucopolysaccharidosis|mucopolysaccharidosis
88926725|NCT01695161||Fabry disease|Fabry disease
89442903|NCT02506790|Active Comparator|Toremifene|Toremifene 60 mg daily
88926726|NCT01695161||healthy controls|healthy controls
89442904|NCT02162901|Experimental|Choice-Class with IVR Calls|Participants enrolled in this arm of the study will have chosen to attend one 2-hour class to be introduced to the educational intervention, and will then receive follow-up/support IVR calls for a period of 12 months.
89442905|NCT02162901|Experimental|Choice-DVD with IVR calls|Participants enrolled in this arm of the study will have chosen to watch a DVD at home to be introduced to the educational intervention, and will then receive follow-up/support IVR calls for a period of 12 months
89442906|NCT02162901|Experimental|Random-Class with IVR calls|Participants randomized to this arm of the study will be randomized a second time into one of three groups. Participants in this group will attend one 2-hour class to be introduced to the educational intervention, and will then receive follow-up/support IVR calls for a period of 12 months
89442907|NCT02162901|Experimental|Random-DVD with IVR calls|Participants randomized to this arm of the study will be randomized a second time into one of three groups. Participants in this group will be given a DVD to watch at home to be introduced to the educational intervention, and will then receive follow-up/support IVR calls for a period of 12 months
89442908|NCT02162901|Active Comparator|Random-Class only|Participants randomized to this arm of the study will be randomized a second time into one of three groups. Participants in this group will attend one 2-hour class to be introduced to the intervention and will receive a workbook to use at home.
88926727|NCT01695174|Experimental|Xifaxan|Xifaxan 550 mg two times per day for three months
88926728|NCT01695187|Experimental|NB-001 (0.3%)|NB-001 is an oil-in-water emulsion composed of nanometer-sized, positively charged droplets (average particle size = 180nm). NB-001 is composed of highly refined soybean oil, purified water, ethanol, edetate disodium dihydrate (EDTA) and two surfactants: polysorbate (Tween) 20 and cetylpyridinium chloride (CPC).
88926729|NCT01695187|Placebo Comparator|Vehicle|NB-001 is an oil-in-water emulsion composed of nanometer-sized, positively charged droplets (average particle size = 180nm). NB-001 is composed of highly refined soybean oil, purified water, ethanol, edetate disodium dihydrate (EDTA) and one surfactant: polysorbate (Tween) 20.
88926730|NCT01695200|Experimental|Omega-3 Fatty Acids|15ml omega-3 liquid form, twice a day for 12 weeks (Total daily dosage:840mg DHA and 192mg EPA)
88926731|NCT01695213|Active Comparator|HA-Omnifit|Patients who receive a HA-Omnifit uncemented hip stem
88926732|NCT01695213|Active Comparator|Symax hip stem|Patients with the Symax uncemented hip stem
88926733|NCT01695226|Placebo Comparator|placebo|pre-operative placebo twice daily for two to three weeks
88926734|NCT01695226|Experimental|celecoxib|pre-operative celecoxib (400 mg) twice daily for two to three weeks
88926735|NCT01695252|No Intervention|S-Sup|Standard supervision
88926736|NCT01695252|Experimental|MEMOS|Patient informed clinical outcomes supervision
88926737|NCT01695265|Experimental|Exercie oronasal breathing (ONB)|Exercise protocol was walking on a treadmill for 10 minutes at a constant rate at 50% of VO2peak with oronasal breathing (ONB) (Without FeelBreathe device)
88926738|NCT01695265|Experimental|Exercie nasal breathing through the FB|Exercise protocol was walking on a treadmill for 10 minutes at a constant rate at 50% of VO2peak with nasal restriction using FeelBreathe device.
88926739|NCT01695278|Active Comparator|Standard Care|Participants will receive standard care from physicians for monitoring and treating their diabetes. They are placed on a wait list to receive the intervention.
88926740|NCT01695278|Experimental|Telephone Counseling|Weekly telephone counseling intervention for 16 weeks, used to identify and overcome barriers to diabetes control and set goals for positive behavioral changes supplemented by monthly group classes on skill development.
89199899|NCT02507284|Experimental|SRX246 160mg BID|SRX246 capsules, administered orally, in divided doses twice daily
88926741|NCT01695343|Experimental|KB001-A|KB001-A administered up to 5x intravenously (IV) at 10 mg/kg up to a maximum dose of 800 mg per dose.
88926742|NCT01695343|Placebo Comparator|Placebo Comparator|Placebo administered up to 5x intravenously
88926743|NCT01695356|Active Comparator|290-400 nm sunscreen|"Sunscreen containing Mexoryl SX, Mexoryl XL, Titanium Dioxide, Octocrylene, Tinosorb S, Avobenzone, and Ethylhexyl triazone.~Fluid vehicle administered daily, from 8AM to 5PM every 3 hr, for 12 weeks."
88926744|NCT01695356|Experimental|290-800 nm sunscreen|"Sunscreen containing Benzophenone-3, Octinoxate, Octocrylene, Titanium Dioxide, Zinc Oxide, and iron oxide.~Fluid vehicle administered daily, from 8AM to 5PM every 3 hr, for 12 weeks."
88926745|NCT01695382|Experimental|Navigation|Participants randomized to the control arm of the study will receive a packet of written materials that are appropriate linguistically and written for individuals with low health literacy. In addition they will have 5 navigator initiated home visits to review the educational materials and help patients and families address barriers to palliative care through education, advocacy, and activation.
88926746|NCT01695382|No Intervention|Control|Participants randomized to the control arm of the study will receive a packet of written materials that are appropriate linguistically and written for individuals with low health literacy.
88926747|NCT01695395||Intellectual disabled adults without a mental disorder|
88926748|NCT01695395||Intellectual disabled adults with a mental disorder|
88926749|NCT01695421|Experimental|Functional electrical stimulation|Burst modulated alternating rectified current with a 10 Hz carrier frequency, 400 microsecond pulse duration and 50 Hz bursts
88926750|NCT01695421|Experimental|Medium-frequency alternating current|Burst modulated alternating current with a 2500 Hz carrier frequency, 400 microsecond pulse duration and 50 Hz bursts
88926751|NCT01695421|Experimental|Burst-modulated alternating current|Burst modulated alternating current with a 4000 Hz carrier frequency, 400 microsecond pulse duration and 50 Hz bursts.
89442909|NCT02511080|Active Comparator|Spot-on group|Use active measures against intraoperative hypothermia
89442910|NCT02511080|No Intervention|control|standard measures against intraoperative hipothermia
88926752|NCT01695421|Placebo Comparator|Placebo|Training with the intensity of 5 mA.
88926753|NCT01695434||Copaxone MRI|Patients with relapsing-remitting multiple sclerosis who take Copaxone will have a MRI.
88926754|NCT01695434||Healthy Controls MRI|Subjects who are otherwise healthy, without neurological disorders, will have a MRI.
89199900|NCT02507284|Placebo Comparator|Placebo|Placebo capsules, administered orally, in divided doses twice daily
89442911|NCT04649736|Experimental|Home-based Respiratory Physiotherapy and Telephone-Based Psychological Support|"Participants in the intervention arm will receive the conventional care given by the hospital that consists of discharged recommendations and a follow-up plan through telephone calls to verify treatment compliance. Discharged recommendations include performing respiratory exercises at home and medication. There is no plan for diagnosing mental illness or a strategy for respiratory o psychological rehabilitation at the hospital.~Additionally, these participants will receive the intervention program that involves home-based respiratory physiotherapy and telephone-based psychological support for 6 weeks."
89442912|NCT04649736|No Intervention|Control|Participants in the control arm will only receive the conventional care given by the hospital that consists of discharged recommendations and a follow-up plan through telephone calls to verify treatment compliance. Discharged recommendations include performing respiratory exercises at home and medication. There is no plan for diagnosing mental illness or a strategy for respiratory o psychological rehabilitation at the hospital.
89442913|NCT03540615|Experimental|BAY1830839|Single Dose escalations
89442914|NCT03540615|Placebo Comparator|Placebo|Matching Placebo
89442915|NCT04500002|Experimental|INH|3 tablets of isonicotinic acid hydrazide 300 mg will be given as single daily doses, 5 mg per day for two days at home and the third dose will be given on admission to hospital on day 3 and will be followed by vaginal misoprostol 800 mcg every three hours up to maximum three doses.
89442916|NCT04500002|Active Comparator|Misoprostol|Misoprostol Alone 800 mcg every three hours up to maximum three doses
89442917|NCT05149716|Experimental|Taurine supplementation|Taurine supplementation composed of capsules of taurine powder. Dosage: 1.5 gram/day Frequency: 1 time/day Duration: 16 weeks
89442918|NCT05149716|Placebo Comparator|Placebo supplementation|Placebo supplementation composed of capsules of starch powder. Dosage: 1.5 gram/day Frequency: 1 time/day Duration: 16 weeks
89442919|NCT03345524|Experimental|Peer-buddy system|Will meet with peer-buddy who will help with them with CPAP usage. Also will receive standard of care CPAP educational training
89442920|NCT03345524|Active Comparator|Usual Care|Will receive educational material at the same frequency that those in the experimental arm. Will also receive standard of care CPAP educational training.
89442921|NCT02515682|Active Comparator|High equol|High equol group will be given natural S-equol supplementation 20mg per day for 24 week.
89442922|NCT02515682|Active Comparator|Low equol|Low equol group will be given natural S-equol supplementation 10mg/d (+10mg starch) for 24 weeks
89442923|NCT02515682|Placebo Comparator|Placebo|Placebo group will be given placebo control (made from starch) 20 mg per day for 24 weeks.
89442924|NCT02510924|Active Comparator|Tracheal intubation with Airtraq sp|Tracheal intubation with Airtraq sp.
89442925|NCT02510924|Experimental|Tracheal intubation with Airtraq Mobile|Tracheal intubation with Airtraq Mobile
89442926|NCT02510846|Experimental|Intensive educative program|5 hours a week
89442927|NCT02510846|Active Comparator|Usual practice of educative program|1 hour a week
88926755|NCT01695447|Experimental|duct-to-mucosa|duct-to-mucosa technique is used for pancreaticojejunostomy after pancreaticoduodenectomy
89442928|NCT03488706||Gray Zone Group|The gray zone group PSA between 4.00 to 10.99 ng/ml.
89442929|NCT02510768|Experimental|ELAPR002f|ELAPR002f A tropoelastin polymer cross-linked with hyaluronic acid.
89442930|NCT02510768|Experimental|ELAPR002g|ELAPR002g A tropoelastin polymer cross-linked with hyaluronic acid.
89442931|NCT02510768|Placebo Comparator|Saline|Saline
89442932|NCT02515604|Active Comparator|Single dose group|
89442933|NCT02515604|Active Comparator|Repeated dose group|
89442934|NCT02510534|Active Comparator|Control|This arm receives Menopur 150 international units x 1 dose
89442935|NCT02510534|Active Comparator|Treatment|This arm receives Menopur 150 international units x 1 dose and Endometrin 100mg twice a day x 14 days
89442936|NCT03799146|Experimental|Intervention group|Participants will receive the e- and mHealth intervention 'MyPlan 2.0'.
89442937|NCT03799146|Experimental|Waiting List control group|Participants will not receive the e- and mHealth intervention 'MyPlan 2.0', but will be given access to the intervention after all testing phases.
89442938|NCT02510612|Experimental|Dexmedetomidine|Patients in group D will be given dexmedetomidine during anesthesia induction and maintenance phase respectively.In induction phase infuse 1μg/Kg of dexmedetomidine in 10 minutes， the speed in maintenance phase is 0.4μg/Kg.h
89442939|NCT02510612|Placebo Comparator|placebo|Patients in group P will be given normal saline during anesthesia induction and maintenance phase
89442940|NCT03749616|Active Comparator|Non-operative Acetaminophen|Acetaminophen will be given to participants for pain control following their injury.
89442941|NCT03749616|Active Comparator|Operative Acetaminophen|Acetaminophen will be given to participants for pain control following their surgery for arm fracture.
89442942|NCT03749616|Experimental|Non-operative NSAID|Ibuprofen will be given to participants for pain control following their injury.
88926756|NCT01695447|Active Comparator|invagination|invagination technique is used for pancreaticojejunostomy after pancreaticoduodenectomy
88926757|NCT01695460|Active Comparator|Vitamin D|"The active treatment consists of vitamin D and is given in tablets of the brand D3 Vitamin ®, supplied by D3 Pharmacy Ltd., Bispensgade 22, 9000 Aalborg.~The tablets contain the vitamin D in the form of vitamin D3, also known as cholecalciferol.~D3 Vitamin ® consists of small white tablets, which are easy to swallow.~D3 Vitamin ® contains 25 micrograms vitamin D3 (colecalciferol) per tablet, equivalent to 1000 IU (International Units).~Tablet Excipients: Cellulose, dicalcium phosphate, magnesium stearate, silicon dioxide and talc. Vitamin D3 ® contains no gluten, soy, gelatin or other animal products."
88926758|NCT01695460|Placebo Comparator|Placebo|Placebo tablets to match D3 Vitamin ®, were produced. They are identical to the D3 Vitamin ® in appearance, ie small white tablets. These tablets do not have a therapeutic effect. Placebo tablets produced and delivered by D3 Pharmacy Ltd., Bispensgade 22, 9000 Aalborg.
88926759|NCT01695499||Immunosuppressed ICU Patients with lung infiltrates|Immunosuppressed ICU Patients with lung infiltrates
88926760|NCT01695499||Control Group|BAL and blood aliquots of 20 immunocompetent pts (suffering from lung diseases) will be collected and tested identically as a control population.
88926761|NCT01695512||Immunocompromised Patients|Patients with acute leukemia undergoing induction chemotherapy or undergoing allogeneic stem cell transplantation
89442943|NCT03749616|Experimental|Operative NSAID|Ibuprofen will be given to participants following their surgery for arm fracture.
89442944|NCT03491514|Experimental|Test Granola|51 g of Test Granola
89442945|NCT03491514|Placebo Comparator|Control Granola|54.1 Control Granola
89442946|NCT04499222|Experimental|Portex|usage of PORTEX POLAR [Smiths Medical International, Hythe, United Kingdom] nasotracheal tube
89442947|NCT04499222|Active Comparator|Mallinckrodt|usage of Mallinckrodt TaperGuard [Covidien, Ireland] nasotracheal tube
89442948|NCT04532502||Study group|All female assistants in anesthesia
89442949|NCT02506478||ED patients|All ED patients who are able to drink water/juice, and be able to communicate juice preference.
88926762|NCT01695512||Control Group|Patients underdoing bronchoscopy and diagnostic BAL without immunosuppression and without signs of infection (Sarcoidosis, Lung Cancer)
89199901|NCT02501096|Experimental|Lenvatinib + Pembrolizumab|Participants with one of the tumors: non-small cell lung cancer, renal cell carcinoma, endometrial cancer, urothelial cancer, squamous cell carcinoma of the head and neck, melanoma or leiomyosarcoma.
89199902|NCT02455622|Experimental|Enrolled Patients|Patients who are receiving treatment with Elaprase in this study (SHP-ELA-401), who are <6 years of age, and were previously treatment-naïve. Patients who are not enrolled in this study (SHP-ELA-401) but are enrolled in the Hunter Outcome Survey (HOS) patient registry and were < 6 years of age at start of Elaprase treatment. While not enrolled in the present Study SHP-ELA-401, their height and weight data from HOS will be utilized in the Primary Growth Analysis for this study.
89199903|NCT02432248|Experimental|Dehydroepiandrosterone|DHEA is considered as health supplement and is available over the counter. Side effects are minimal at present dosage (25mg or 50mg tds).
89442950|NCT03703128||Informants of suicide victims|Partners, children, parents, siblings, other relatives, peers or other informants of adults (aged 45-60 years) who received a definitive verdict of suicide in the Dutch-speaking part of Belgium (Flanders). The suicide should have taken place more than 3 months ago and less than 5 years ago.
89442951|NCT03703128||Control group|Informants i.e., partners, children, parents, siblings, other relatives, peers or other informants of adults (aged 45-60 years) who have mental health problems.
89442952|NCT02506166|No Intervention|No or Mild Sleep Apnea Group (Group 1)|"ICM patients with no or mild sleep apnea enrolled in this arm will continue with standard therapy (ICD/CRT-D implant + maximal medical therapy), but will receive no active Positive Airway Pressure (PAP) therapy for sleep apnea treatment. See Part: Study Population for more details.~In all ICM patients enrolled into ESCAPE-SCD Study, the ICD/CRT-D devices will be implanted based on current ESC Guidelines for primary prevention of sudden cardiac death (see Section: References)"
89442953|NCT02506166|No Intervention|Obstructive Sleep Apnea - Control Group (Group 2)|"ICM patients with predominant obstructive sleep apnea randomised to this arm will receive standard therapy (ICD/CRT-D implant + maximal medical therapy), but no PAP therapy for sleep apnea treatment. See Part: Study Population for more details."
89442954|NCT02506166|Active Comparator|Obstructive Sleep Apnea - Active Group (Group 3)|"ICM patients with predominant obstructive sleep apnea randomised to this arm will receive standard therapy (ICD/CRT-D implant + maximal medical therapy), plus as intervention, all patinets in this group will receive sleep apnea treatment by using PAP device. See Part: Study Population for more details."
88926763|NCT01695525|Experimental|Yoga|Participants will be asked to practice Yoga 3 times per week at a minimum, and daily at a maximum. Participants will receive training in different Yoga techniques including breathing exercises, postures and meditation. Participants will be asked to practice 1 hour Yoga sessions comprised of breathing exercises, postures and meditation.
89442955|NCT02506166|No Intervention|Central Sleep Apnea Group (Group 4)|"ICM patients with predominant central sleep apnea enrolled in this group will receive standard therapy (ICD/CRT-D implant + maximal medical therapy). Because the SERVE-HF Trial demonstrated a negative effect of predominantly central sleep apnea treatment on cardiovascular mortality in patients with HFrEF by using adaptive servo-ventilation therapy, patients in Group 4 will not receive any PAP therapy for treatment of sleep disordered breathing. See Part: Study Population for more details."
89442956|NCT03728517||Subjects who undergo gynecologic surgery|Subjects who will undergo gynecologic surgery via vaginally, laparoscopic , or robotic who require observation or inpatient stay overnight. This group will receive pain medication in the hospital and will also be discharged home with pain medication.
88926764|NCT01695538|Experimental|Yoga|Participants will be asked to practice yoga 3 days per week, at a minimum and encouraged to practice 7 days per week, for 1 year.
89442957|NCT03491436|Experimental|Remote monitoring group|Women (at risk of) GDM will be included in this study. They receive a iHealth Align (a glucose monitor) and associated glycemiestrips. The app of iHealth will be downloaded on the pregnant women's Smartphone to collect the data and to send them to the researcher in the hospital.
89442958|NCT02762565|Experimental|breast scanner|
88926765|NCT01695551||Ventricular Tachycardia|Participants in cohort will have implantable defibrillators in-situ and are undergoing ablation procedure for ventricular tachycardia.
88926766|NCT01695564||WATCHMAN|Patients that had the WATCHMAN device implanted
88926767|NCT01695564||LARIAT LAA Device|patients that had LARIAT LAA device implanted
88926768|NCT01695577|Experimental|Multidisciplinary evaluation and VR|Vestibular rehabilitation and balance training. Twice a week for eight weeks.Outcome measures and tests at baseline, after 8 weeks and 6 months after the injury.
88926769|NCT01695577|Active Comparator|Multidisciplinary evaluation and no VR|Multidisciplinary evaluation. Outcome measures and tests at baseline, after 8 weeks and 6 months after the injury.
88926770|NCT01695590|Experimental|PRLX 93936|PRLX 93936 administered IV 3 days a week (Monday, Wednesday and Friday) for 3 weeks followed by a 9 day rest period = 1 cycle
88926771|NCT01695603|No Intervention|Standard mode of controlled ventilation|Each brain injured patient will be ventilated during two hours with a standard mode of controlled ventilation.
88926772|NCT01695603|Experimental|Intellivent arm|Each brain injured patient will be ventilated during two hours with an automated mode of ventilation, the Intellivent mode.
88926773|NCT01695616|Placebo Comparator|Placebo|Patients enrolled in this arm will take a tablet twice a day
88926774|NCT01695616|Active Comparator|Passiflora incarnata and isoflavona combination|Patients enrolled in this arm will take a tablet twice a day
88926775|NCT01695629||None to Mild|Subjects with Diabetes with none to mild peripheral neuropathy
89442959|NCT03488550|Experimental|ANX007-GLA-01|
89538461|NCT03266237|Experimental|Healthy Elderly Pre-Frail|Healthy Elderly participants aged 65-90 years will be vaccinated with Vaxigrip® influenza vaccine.
89538462|NCT03266237|Experimental|Healthy Elderly Frail|Healthy Elderly participants aged 65-90 years will be vaccinated with Vaxigrip® influenza vaccine.
88926776|NCT01695629||Severe|Subjects with diabetes with severe neuropathy
88926777|NCT01695642||Microkeratome|mechanical microkeratome
88926778|NCT01695642||Intralase|femtosecond laser
88926779|NCT01695655||PKP|Subjects undergoing penetrating keratoplasty
88926780|NCT01695681|Other|Dietary instruction|Gluten-free diet
88926781|NCT01695694|Active Comparator|community support group|
88926782|NCT01695694|Experimental|supporting positive and healthy relationships|
88926783|NCT01695707|Placebo Comparator|Placebo|"Subjects randomized to placebo will receive opaque size 00 gelatin capsules containing 240mg lactose. As with the intervention group, 1 capsule will be taken by each day throughout the treatment period."
88926784|NCT01695707|Experimental|Pioglitazone|"Subjects randomized to pioglitazone will receive opaque size 00 gelatin capsules containing pioglitazone. For the first 3 weeks, capsules will contain 30 mg pioglitazone. For the remaining 9 weeks of the treatment period, capsules will contain 45 mg pioglitazone unless subjects are unable to tolerate this increased dose.~One capsule will be taken by each day throughout the treatment period."
88926785|NCT01695720|Experimental|VisionScope Imaging (VSI) Exam|A VisionScope Imaging (VSI) Exam is diagnostic arthroscopic procedure. Through a natural or surgical opening, an endoscope is inserted through a cannula to illuminate and visualize the interior cavity of a joint.
88926786|NCT01695733|Experimental|Schedule A|Influenza vaccination on the first day of chemotherapy
88926787|NCT01695733|Experimental|Schedule B|Influenza vaccination 1 week (+/- 1 day) prior to chemotherapy
88926788|NCT01695759|Experimental|Epoetin alpha|Participants assigned to this arm will receive two subcutaneous administrations per week of 50 UI/kg of Epoetin alpha (Eritromax), totaling 100 UI/kg/week. After the first four weeks of treatment, once a month throughout the study the medication dose can be adjusted by the study Investigator according to the laboratory results.
88926789|NCT01695759|Active Comparator|Eprex|Participants assigned to this arm will receive two subcutaneous administrations per week of 50 UI/kg of Epoetin alpha (Eprex), totaling 100 UI/kg/week. After the first four weeks of treatment, once a month throughout the study the medication dose can be adjusted by the study Investigator according to the laboratory results.
88926790|NCT01695785||Healthy weight|greater than or equal to the 5th to less than the 85th BMI percentile
88926791|NCT01695785||Obese|greater than or equal to the 95th BMI percentile
88926792|NCT01695798|No Intervention|Chronic malnourished bOPV|This arm will receive only bOPV
88926793|NCT01695798|Experimental|Malnourished IPV+bOPV|This arm will receive IPV and bOPV
88926794|NCT01695798|No Intervention|Normally nourished bOPV|This arm will receive only bOPV
88926795|NCT01695798|Experimental|Normally nourished IPV+bOPV|This arm will receive both IPV and bOPV
88926796|NCT01695811||FLAK|FLAK
88926797|NCT01695811||PKP|Retrospective
88926798|NCT01695824|Active Comparator|LAA occluder|
88926799|NCT01695824|Active Comparator|Warfarin|
88926800|NCT01695837|Experimental|Group A-dietary counseling month 0-6|"Group A Visit #1 - Weight, height, blood pressure and pulse were measured at the beginning of the visit. During a focused office visit the primary care physician (PCP) reviewed the results of the fasting lipid panel and diet test with the patient; the PCP provide the patient with written educational materials and access to the counseling website. Weekly automatic emails sent to patient reminding to visit the counseling website~Visit #2 - Same as visit #1. Weekly automatic emails sent to patient reminding to visit the counseling website.~Visit #3 - Weight, blood pressure and pulse were measured at the beginning of the visit. During a focused office visit the PCP reviewed the results of the new fasting lipid panel and diet test with the patient."
88926801|NCT01695837|Other|Group B- Dietary counseling month 3-6|"Group B Visit #1: Weight, height, blood pressure and pulse were measured at the beginning of the visit. Follow up visit and lab order were scheduled for 3 months. No blood test or diet test results were reviewed with the patient.~Visit #2 - Weight, blood pressure and pulse were measured at the beginning of the visit. During a focused office visit the PCP reviewed the results of the two fasting lipid panels ; the PCP provide the patient with written educational materials and access to the counseling website. Weekly automatic emails sent to patient reminding to visit the counseling website~Visit #3 - Weight, blood pressure and pulse were measured at the beginning of the visit. During a focused office visit the PCP reviewed the results of the new fasting lipid panel and diet test with the patient."
88926802|NCT01695850|Experimental|MZRW|MZRW is composed of Fructus Cannabis (HuoMaRen), Radix et Rhizoma Rhei (DaHuang), Radix Paeoniae Alba (BaiShao), Semen Armeniacae Amarum (KuXingRen), Fructus Aurantii Immaturus (ZhiShi) and Cortex Magnoliae Officinalis (HouPo).
88926803|NCT01695850|Active Comparator|Senna|Senna is a stimulant laxative which facilitates the passage of stools by altering intestinal electrolyte transport and increasing intestinal motor activity.
88926804|NCT01695850|Placebo Comparator|Placebo|Placebo MZRW and Placebo Senna
88926805|NCT01695876|Experimental|AMG 357|AMG 357 is a small molecule for treatment of inflammatory disease
88926806|NCT01695876|Placebo Comparator|Placebo|Matching placebo to AMG 357 containing no active drug
88926807|NCT01695902|Experimental|Levosert-20|Levosert is a LNG-releasing Intrauterine Delivery System (IUS) containing 52 mg of LNG in a cylindrical-shaped reservoir. The reservoir is mounted on the vertical arm of a T-shaped plastic frame and is covered with a release rate controlling membrane.
88926808|NCT01695902|Active Comparator|Mirena®|Mirena® IUS, Bayer-Schering, a LNG-releasing Intrauterine Delivery System (IUS) containing 52 mg of LNG.
88926809|NCT01695915||Healthy|Transabdominal ultrasound
88926810|NCT01695915||Constipated|Transabdominal ultrasound
88926811|NCT01695928|Active Comparator|Extracorporeal shockwave therapy (ESWT)|Active treatment
88926812|NCT01695928|Placebo Comparator|ESWT Placebo|No extracoporeal shockwave therapy
89442960|NCT02506322|Experimental|SEKT Cognitive-Behavioral-Emotional|Specific psychotherapy (SEKT - 4 modules) for typical problems of Bipolar patients to maintain remission and to prevent relapse. Including classical elements of self observation, psychoeducation, cognitive and behavioral interventions, social rhythm but also emotion regulation and meta-cognitive techniques. Delivered in a group setting in 4 one day treatment workshops, each one month apart. Homework assignment and electronical monitoring during time between sessions.
89442961|NCT02506322|Active Comparator|FEST Clinical Supportive Educational|This supportive, active control psychotherapy (FEST) is using general principals and non-specific interventions such as positive attitude, optimism, support, empathy, focus on emotion, self-help, strengthening and eliciting own resources, time and room for discussion of personal experiences. Psychoeducation about illness and drug treatment (mood stabilizer) to facilitate compliance.
89442962|NCT02167113||study population|
89442963|NCT03488394|Experimental|Treatment|Gene therapy (autologous, CD34+ cell enriched cells fraction containing HSCs, transduced with the IDUA LV encoding for the human IDUA gene and cryopreserved in cryoformulation medium)
89442964|NCT02515526|Active Comparator|Reference|A cocktail of six different test substances to be administered orally followed by an I.V. dose of midzolam
89442965|NCT02515526|Experimental|Test|A cocktail of six different test substances to be administered orally followed by an I.V. dose of midzolam. In addition, ethanol will be administered at six different time points with of reaching a blood alcohol concentration of 1 per mille to see its effect on the activity of major cytochrome P450 enzymes, NAT-2 and P-glycoprotein.
89442966|NCT03492450|No Intervention|Control Group|All subjects continue participating in their normal daily and physical activities.
89442967|NCT03492450|Experimental|Treadmill training Group|16 sessions (2 sessions/week for 8 weeks) of treadmill training as recommended in a review on this subject (Langeskov-Christensen, 2015) aimed at the reduction/stabilization of gait and balance disturbances.
89442968|NCT04497662|Experimental|KPL-404 (IV Administration)|
89442969|NCT04497662|Experimental|KPL-404 (SC Administration)|
89442970|NCT05135130||ON101 Cream|Patients Who Had Participated in the ON101CLCT02 Diabetic Foot Ulcer Trial and assigned to ON101 Cream arm
89442971|NCT05135130||Aquacel® Hydrofiber® dressing|Patients Who Had Participated in the ON101CLCT02 Diabetic Foot Ulcer Trial and assigned to Aquacel® Hydrofiber® dressing arm
89442972|NCT02505932||Arthroscopic Latarjet procedure|arthroscopic approach (set Depuy-Mitek, Raynham, MA)
88926813|NCT01695967|Experimental|Turbinate Cauterization|Turbinate Cauterization will be completed.
88926814|NCT01695967|No Intervention|control|no turbinate cauterization
88926815|NCT01696019|Experimental|Fast walking|Participants assigned to this group met with two group leaders three times per week in the morning in Jing An Park and were encouraged to walk quickly around a 400 meter circular route. Each session consisted of 10 minutes of warm-up stretching, 30 minutes of brisk walking, and 10 minutes of cool-down exercises. Prior to the first session, each participant was given a pedometer with their name on it. They were asked to take 100 steps and the sensitivity and positioning of the pedometer was adjusted to assure accurate measurement. At the termination of each session, the pedometers were collected and the number of steps taken by each participant at that session recorded. A record of the number of steps taken for every participant at each session over the 40 week period was maintained.
89442973|NCT02505932||Mini-open Latarjet procedure|mini-open approach (set Arthrex, Naples, FL)
89442974|NCT04460976|Experimental|Experimental group|Experiment group that receives the psychoeducation direct after the baseline measurement.
89442975|NCT04460976|Other|Control group|Standard care / treatment as usual. Comparison group alos receives Prisma psychoeducation after the three-month follow-up time period.
89442976|NCT02167191|Experimental|HIT|High intensity interval training sessions on an cycle ergometer
89442977|NCT02515448|Experimental|Gentamicine injectable(day 1+2)and then gentamicine inhalation|
89442978|NCT02506088|Experimental|Your Voice Your View|Participants in schools assigned to the treatment group will engage in a four session intervention aimed at prevention of sexual violence. Your Voice Your View is grounded in social norms theory and bystander intervention training. The intervention also includes a social norms marketing campaign.
89442979|NCT02506088|No Intervention|Wait List Control Group|Participants in schools assigned to the wait list control group will complete survey assessments at the same schedule as schools assigned to the treatment group. Schools will have the option to implement Your Voice Your View following completion of the 6-month survey.
89442980|NCT02170857|No Intervention|Open Curettage Only|patients will be treated by the conventional surgical method, i.e. open curettage without injecting any material.
89442981|NCT02170857|Experimental|Open Curettage with Hyaluronic Acid|Hyaluronic Acid injection will be employed in conjunction with the ordinary surgical procedure.
89442982|NCT04460820|Experimental|Doxorubicin Hydrochloride Liposome Injection|50mg/m2 ,IV on Day 1 of each cycle
89442983|NCT04460820|Active Comparator|Doxorubicin Hydrochloride Liposome Injection(Caelyx®)|50mg/m2 ,IV on Day 1 of each cycle
89199904|NCT02432248|Placebo Comparator|Placebo|Medical starch is considered as medicine components. Side effects are minimal at present dosage.
89442984|NCT02510378|Experimental|Short course radiotherapy|"Patients with rectal cancer and resectable liver metastases receive 25 Gy in 5 fractions of 5 Gy over 5 days to the pelvis and XELOX consolidating chemotherapy (with or without target therapy) al least 4 cycles after 2 weeks.~After evaluation, patients with resectable rectal cancer and liver metastasis will undergo surgery. Those patients with unresectable lesions will receive chemotherapy."
89442985|NCT02170935|Experimental|BIBR 1048 capsule|
89442986|NCT03345368|Experimental|rTMS treated group|A Magstim Rapid2 Stimulator equipped with a double 70mm alpha coil P/N 3191-00 (Magstim, Wales, UK) will be used to stimulate the motor cortex. Transcranial magnetic stimulation will be applied through a coil at 10 Hz, a field intensity of 90% of the motor threshold. Stimuli will be provided in 10 trains of 100 pulses, followed by a 28 s rest period.
89442987|NCT03345368|Sham Comparator|sham rTMS group|Sham rTMS will be administered with the coil held in contact with the head but a 180 degrees from scalp, and the power parameter will be reduced by half to avoid stimulation.b
89442988|NCT03488316|Active Comparator|Calcium Hydroxide temporary filling material|Temporary filling with Ca(OH)2
89442989|NCT03488316|Active Comparator|MTA temporary filling material|Temporary filling with MTA
88926816|NCT01696019|Active Comparator|Tai Chi|Participants assigned to this group met with a Tai Chi master and assistant three times per week in the morning in Jing An Park or at a nearby gymnasium depending on weather conditions. Each session included 20 min of warm-up exercises (lower back and hamstring stretching, gentle calisthenics, and balance training), 20 min of Tai Chi practice, and 10 min of cool-down exercises.
89442990|NCT03540537|Other|PCA for Open Hepatectomy|Patient-controlled intravenous analgesia in Open hepatectomy (PCA solution: 2 μg/kg weight sufentanil and 8.96 mg tropisetron mesylate diluted in 100 ml normal saline；PCA parameters: loading dose: 2 ml, background infusion: 2ml/h, bolus: 0.5ml, lockout-time: 15min; PCA duration: 48 hours from the end of suturing)
88926817|NCT01696019|Active Comparator|Intellectual stimulation|Participants assigned to this group met with a group leader and an assistant for one hour three times a week in the morning at the neighborhood community center. Although direction was initially given regarding subjects for discussion, the participants decided on their own to organize and select topics themselves.
89442991|NCT03540537|Experimental|QLB for Open Hepatectomy|Bilateral quadratus lumborum block with 20 ml 0.375% ropivacaine each side(maximum total dose 3 mg/kg) combine Patient-controlled intravenous analgesia (same as PCA for Open hepatectomy Arm)
89442992|NCT03540537|Experimental|TPVB for Open hepatectomy|T6+T8 of thoracic paravertebral block with 15 ml 0.375% ropivacaine each segment (maximum total dose 3 mg/kg) combine Patient-controlled intravenous analgesia (same as PCA for Open hepatectomy Arm)
89442993|NCT03540537|Other|PCA for Laparoscopic Hepatectomy|Patient-controlled intravenous analgesia in Laparoscopic hepatectomy (same as PCA for Open hepatectomy Arm)
88926818|NCT01696019|Placebo Comparator|Contact and testing only|The fourth group received no intervention. Contact was maintained by phone during the intervention period to reduce dropout. Participants were called four times during the 40 weeks intervention period by the study coordinator.
88926819|NCT01696097|Other|Dietary Counseling|Pork vs. Chicken/Fish in a DASH Diet on Blood Pressure
88926820|NCT01696110|Experimental|Bivalirudin|Bivalirudin will be started in the cath lab, 0.75 mg/kg intravenous bolus followed by 1.75 mg/kg per h infusion; if ACT<225s 5min after bolus, an additional dose of 0.3mg/kg bolus should be given. After procedure, a prolonged infusion (1.75mg/kg per h) will be given for at least 30 min (totally no more than 4 h) followed by a reduced dose infusion (0.2mg/kg per h) up to 20 h.
88926821|NCT01696110|Active Comparator|Heparin monotherapy|100 IU/kg intravenous bolus. If ACT <225s 5 min after bolus injection, additional dose of heparin (20U/kg) will be given.
88926822|NCT01696110|Active Comparator|heparin plus tirofiban|heparin 60 IU/kg intravenous bolus and Tirofiban: 10μg/kg intravenous bolus followed by 0.15μg/kg per min infusion for up to 36h.
88926823|NCT01696123|Experimental|MLC601|MLC601 (NeuroAid, Moleac Pte. Ltd, Singapore) (0.4 g per capsule) was prescribed as one capsule three times daily without an escalation dose.
88926824|NCT01696136|Active Comparator|AF-Ablation with Multi-electrode catheter|Regular AF-ablation with a multi-electrode ablation catheter
88926825|NCT01696136|Active Comparator|AF-Ablation with single-tip electrode|Regular AF-ablation with a regular single-tip ablation catheter
88926826|NCT01696149|Experimental|electrical nerve stimulation|All subjects participated, randomly, in a 4 Hz transcutaneous electrical nerve stimulation session, a 110 Hz transcutaneous electrical nerve stimulation session, and a control (off-transcutaneous electrical nerve stimulation) session. Each session consisted of a 20- minute stimulation period and a 10-minute follow up period
88926827|NCT01696162|Active Comparator|PDF exercise sheets|Participants in this arm will receive a PDF sheet of 6 exercises that are commonly administered for the treatment of anterior knee pain. They will be asked to perform the exercises three times a week for 6 weeks. A questionnaire will be administered at the three, six and twelve week mark to evaluate efficacy, compliance and safety.
88926828|NCT01696162|Active Comparator|Limited Exercise Videos|"Participants in this arm will receive the same six exercises as provided in the PDF sheet in arm 1 in a video format. They will be asked to perform the exercises three times per week for 6 weeks.~A questionnaire will be administered at the three, six and twelve week mark to evaluate efficacy, compliance and safety."
88926829|NCT01696162|Experimental|Algorithm based Exercise Videos|Participants in this arm will be provided a 6 week regimen of exercise videos for their anterior knee pain. Following each exercise session, the participant will be asked for their input concerning each exercise. The algorithm will adjust the exercise regimen for the next session based on the participants input. A questionnaire will be administered at the three, six and twelve week mark to evaluate efficacy, compliance and safety.
89442994|NCT03540537|Experimental|QLB for Laparoscopic Hepatectomy|Bilateral quadratus lumborum block 20 ml 0.375% ropivacaine each side(maximum total dose 3 mg/kg) combine Patient-controlled intravenous analgesia (same as PCA for Open hepatectomy Arm)
89442995|NCT03540537|Experimental|TPVB for Laparoscopic Hepatectomy|T6+T8 of thoracic paravertebral block with 15 ml 0.375% ropivacaine each segment (maximum total dose 3 mg/kg) combine Patient-controlled intravenous analgesia (same as PCA for Open hepatectomy Arm)
89442996|NCT02510222|Experimental|Oral Magnesium sulfate|Magnesium sulphate 4% concentration orally ( 65 mg per day for children one to three years of age; 110 mg per day for children four to eight years of age; 350 mg per day for children older than eight years) for 1 month
89442997|NCT02510222|Placebo Comparator|Control|Fifty children with cerebral palsy will be treated with conventional therapy as physiotherapy. They will receive placebo.
89442998|NCT02444910|Experimental|KDT501|Experimental drug, KDT501, is administered at 600mg for 10 consecutive days. On days 11 and 21 (+/- 1 day), based on the KDT501 drug exposure level, the subject will be provided instructions on dose adjustment of KDT501. Dose adjustments will be administered at 800mg for 10 consecutive days, determined at day 11; followed by 1,000mg for 8 consecutive days if determined at day 21.
89442999|NCT04497818||Netizens|Netizens of Al Qassim province of Saudi Arabia were the target population for this cross sectional study. Sample size is (n=385) estimated based on the population size in Al Qassim province (Confidence Interval 95%, Design effect 1 & hypothesized % frequency of outcome factor of 50%). Assessment of Fear of COVID-19 was estimated using FEAR OF COVID-19, a 5 item Likert Scale. Assessment of Dental Anxiety was estimated using Modified Dental Anxiety 5 item Likert Scale. An online Survey form (Arabic 7 English) was developed using Google form application. The Google form link was shared to the netizens of Al Qassim province, across all relevant Social media platforms. Statistical analysis is done using SPSS 22.00 software program.
89443000|NCT02167269|Active Comparator|Baby EAR-JR|The subjects receive Baby EAR circuit from the start until primary and secondary outcomes are achieved. Then the fresh gas flow will be increased to 500 ml/kg/min for 10 minutes before switching to Jackson-Rees (JR) circuit and the procedure will be repeated.
89443001|NCT02167269|Active Comparator|JR-Baby EAR|The subjects receive Jackson-Rees (JR) circuit from the start until primary and secondary outcomes are achieved. Then the fresh gas flow will be increased to 500 ml/kg/min for 10 minutes before switching to Baby EAR circuit and the procedure will be repeated.
89443002|NCT02165085||Vascular-Ehlers Danlos syndrome|N=50 patients with vascular Ehlers-Danlos syndrome
89443003|NCT02165085||Spontaneous arterial dissection(s)|N=50 patients
89443004|NCT02165085||Healthy volunteers|n=100 Healthy volunteers
89443005|NCT03491358|Active Comparator|Wright jet nebulizer|Will employ the Wright jet nebulizer for use in an allergen challenge triad
89443006|NCT03491358|Experimental|Solo vibrating mesh nebulizer|Will employ the Aerogen Solo vibrating mesh device for use in an allergen challenge triad
89443007|NCT02515292||IUGR: newborn with intrauterine growth restriction|"Inclusion criteria:~newborn infants with symmetrical (both weight and height lower than 10th percentile) or asymmetrical (birth weight is lower than 10th percentile but height and age-appropriated height) intrauterine growth restriction~agreement of the parents that their child to be included in the study"
89443008|NCT02515292||control: newborn without intrauterine growth restriction|"Inclusion criteria:~- matches newborn without intrauterine growth restriction in terms of gender and gestational age as IUGR group"
89443009|NCT02167347|Experimental|Family Intervention|Culturally Adapted Family intervention for Psychosis Sessions will be offered weekly basis
89443010|NCT02167347|No Intervention|Control|"Caregiver ' s Patients who will be randomized to the treatment as usual arm will receive routine care"
89443011|NCT03491202||atrial fibrillation|Patients with a diagnosis of atrial fibrillation will be eligible for enrollment
89443012|NCT02505776||GLASH VISTA™|Patients with eyelash hypotrichosis prescribed bimatoprost cutaneous solution 0.03% (GLASH VISTA™) as per local standard of care in clinical practice.
88926830|NCT01696175||PICU admittance|Children equipped with an arterial and a central venous catheter within 12 hours after admittance to a Dutch PICU
89443013|NCT03540381||Identified neoatherosclerosis group|From the patients treated with coronary stents, the investigators functionally evaluated their HDL by measuring the CUC. the investigators also performed follow-up OCT to evaluate the presence of neoatherosclerosis. Consecutive patients were divided into two groups. The patients with neoatherosclerosis were identified neoatherosclerosis group and the remaining were not-identified neoatherosclerosis group. After that, clinical follow-up was performed to assess TLR and the investigators examined the relation between CUC, neoatherosclerosis and TLR.
89443014|NCT03540381||Not-identified neoatherosclerosis group|
88926831|NCT01696201|No Intervention|Control group|Sedentary pregnant women
88926832|NCT01696201|Experimental|Exercise group|Exercise program
88926833|NCT01696227||Nissle 1917|In vitro, Nissle 1917's ability to adversely affect the growth of uropathogens associated with urinary catheters and those with a known GI resevoir will be measured.
88926834|NCT01696240|Placebo Comparator|Placebo|Capsule that is identically appearing with udenafil will be administered to patients in placebo group. For the first 4 weeks, patients will receive 50 mg of placebo drug two times a day, and then the dosage will be doubled to 100 mg two times a day for next 8 weeks.
88926835|NCT01696240|Active Comparator|Udenafil|Patients will receive 50 mg of udenafil two times a day, and then the dosage will be doubled to 100 mg two times a day for next 8 weeks.
88926836|NCT01696253||Subjects at risk for Alport sydrome|
88926837|NCT01696253||Newly identified subjects with Alport syndrome|
88926838|NCT01696266||Insulin-treated patients with diabetes|
88926839|NCT01696305|Experimental|Hyalobarrier|ACP200 (Auto-crosslinked polysaccharide:inner ester of hyaluronic acid) 30mg/ml*10ml/syringe and 5cm-cannula
88926840|NCT01696305|Active Comparator|Guardix-SG|Poloxamer/sodium alginate mixture 6g/syringe
88926841|NCT01696318|No Intervention|Educational program|Educational Program with Professional Physical Education, Pharmacist and Nutritionist
88926842|NCT01696318|Experimental|Educational program and individual care|Educational program and individual care with professional Physical Education; Pharmacist and Nutritionist
88926843|NCT01696331|Experimental|Text Message Reminder|
88926844|NCT01696344||Cohort 1|No additional ablation after AF termination(PVAI only)
88926845|NCT01696344||Cohort 2|Additional ablation of extra-PV triggers before and after isoproterenol-challenge after AF termination (PVAI + ablation of extra-PV triggers)
88926846|NCT01696370|Active Comparator|Trimetazidine|
88926847|NCT01696370|Placebo Comparator|Placebo capsule|
88926848|NCT01696383|Experimental|DuoTrav|One drop self-administered topically to the study eye(s) once daily every evening at 8:00 pm for 12 weeks
88926849|NCT01696409||Arm A|400 IU vitamin D3 once a day for 2 months
88926850|NCT01696409||Arm B|2000 IU Vitamin D3 once/day for 2 months
88926851|NCT01696422|Experimental|Step A: dengue lyophilized vaccine|Dengue 1,2,3,4 (attenuated) vaccine Two doses with a six-months interval, SC
88926852|NCT01696422|Active Comparator|Step A:dengue liquid vaccine|TetraVax-DV Vaccine - Admixture TV003 Two doses with a six-months interval, SC
89443015|NCT03491124|Sham Comparator|Sham Treatment|Participants will continue to receive usual care from their primary care provider, which can include medications, physical therapy, biofeedback, and education according to DoD/VA guidelines for LBP management. Participants randomized to this arm will also receive a sham intervention, pointing a laser pointer to the ear without turning the laser on.
89443016|NCT03491124|Experimental|Auricular Acupuncture|Participants will continue to receive usual care from their primary care provider, which can include medications, physical therapy, biofeedback, and education according to DoD/VA guidelines for LBP management. Participants randomized to this arm will receive up to five ASP needles per ear placed in the predetermined BFA pattern. Needles are placed until the participant states pain is reduced 1/10.
89443017|NCT02505854|Active Comparator|Probiotic|Hypocaloric diet associated with capsule containing 1billion UFC Bifidobacterium lactis and sache with 5 g of maltodextrin
89443018|NCT02505854|Active Comparator|Symbiotic|Hypocaloric diet associated with capsule containing 1billion UFC Bifidobacterium lactis and sache with 5 g of fructooligosaccharide
89443019|NCT02505854|Placebo Comparator|Placebo|Hypocaloric diet associated with capsule containing 50g of gelatin and sache with 5 g of maltodextrin
89443020|NCT02171013|Experimental|Dabigatran etexilate batch A|
89443021|NCT02171013|Experimental|Dabigatran etexilate batch B|
88926853|NCT01696422|Placebo Comparator|Step A: Placebo|Placebo comparator Two doses with a six-months interval, SC
88926854|NCT01696422|Experimental|Step B: dengue lyophilized vaccine|Dengue 1,2,3,4 (attenuated) vaccine Single dose, SC
88926855|NCT01696422|Placebo Comparator|Step B: Placebo|Placebo comparator Single dose, SC
88926856|NCT01696448|Experimental|Experimental Group|CAR-191: Berberine 200mg, Alpha-lipoic Acid 150mg, Picrorhiza 100mg each in a separate capsule, to be taken 3 times a day, 30 minutes before breakfast, lunch and dinner. Total 9 capsules per day.
88926857|NCT01696448|Placebo Comparator|Control Group|3 placebo capsules, to be taken 3 times a day, 30 minutes before breakfast, lunch and dinner. Total 9 capsules per day.
88926858|NCT01696474|Experimental|Bortezomib therapy|A single course of Bortezomib will be given at the dose of 1,3 mg/sqm iv on days 1, 4, 8, 11. Prophylaxis of HZ reactivation will be given with oral acyclovir at the dosage of 400 mg twice daily for one month after the end of Bortezomib.
88926859|NCT01696487|Experimental|Healthy Volunteers|Volunteers will be challenged with oral 150g Fructose per day for 28 days.
88926860|NCT01696487|No Intervention|NAFLD|Patients with confirmed fatty liver (imaging positive) will be compared at baseline with other arms.
88926861|NCT01696487|No Intervention|NASH|Patients with confirmed non-alcoholic steatohepatitis (biopsy proven) will be compared at baseline with other arms.
88926862|NCT01696487|No Intervention|Hepatitis C genotype 1 (HCV-GT1)|Patients with confirmed hepatitis C genotype 1 will be compared at baseline with other arms and act as different liver disease control group
88926863|NCT01696500|Experimental|NPB-01|
88926864|NCT01696526|Experimental|vitamin D fortified fish|Human volunteers receiving vitamin D fortified fish, 4 weeks
89443022|NCT03490890|Experimental|Microwave ablation in the GGO|Patients with GGO were treated with microwave ablation.
89443023|NCT02261181|Experimental|XONRID|"Patients will be treated with XONRID + standard of care (SOC) preemptive treatment adopted during radiation treatment for head and neck cancer patients.~Patients will be instructed to apply the study cream (XONRID) on the irradiated area two times daily, the first application 1-2 h after the morning radiotherapy session, the second in the evening, starting on the first day of irradiation and continuing until 2 weeks after the completion of the radiation treatments or the development of Grade 3 or 4 skin toxicity. When G3 toxicity will occur the patient will be discontinued from the study medication and the skin toxicity will be managed according to internal guidelines. The use of other topical medications for the treatment of dermatitis will be not permitted during the study."
88926865|NCT01696526|Placebo Comparator|conventional fish|consumption of conventional fish , 4 weeks
88926866|NCT01696539|Experimental|Walking Intervention|Participants are provided with the current standard of prostate cancer care, and are additionally encouraged to walk 10,000 steps per day, as measured by pedometers provided at start of intervention. Once a week, participants will take part in a group walk with 7-8 other participants and a research nurse. Participants are also encouraged to keep a walking journal, in which they record the number of steps they walk each day. This journal is submitted to investigators at the end of the intervention period.
88926867|NCT01696539|Active Comparator|Standard of Care|Participants are provided with the current standard of prostate cancer care, but are not assigned to a physical activity intervention.
88926868|NCT01696552|Active Comparator|TKR with Positioning Guides (PSPG)|Use of PSPG (Signature, Materialise) in TKR (Vanguard Total Knee System, Biomet)
88926869|NCT01696552|Active Comparator|TKR with Conventional Technique|TKR (Vanguard Total Knee System, Biomet), Conventional Technique
88926870|NCT01696578|Experimental|BF-CBT and group physiotherapy|Multivitamin+10 sessions of biofeedback supported cognitive behavioral therapy (BF-CBT) and 10 sessions of group physiotherapy
88926871|NCT01696578|Active Comparator|Waiting list|The waiting list group receives only multivitamin pills while being waiting and will receive the same intervention 3 months later
89199905|NCT02418143||Implantable electronic device placement|CorMatrix CanGaroo ECM envelope for an implantable electronic device placement following a battery change out or upgrade.
89013229|NCT00290667|Active Comparator|Interventional: CHOP-14 + 8 x dose-dense rituximab|Arm II (pharmacokinetic-based dose-dense rituximab): Patients receive rituximab IV 375 mg/m^2 (females) and 500 mg/m^2 (males) over 4 hours on days -1, 0, 3, 7, 14, 21, 28, and 42. Patients also receive pegfilgrastim subcutaneously on day 4 of each course.
89199906|NCT02370797|Experimental|Single Fraction IOeRT|A single dose of 21 Gy calculated such that the 90% isodose line encompasses the posterior of the tumor bed will be administered.
89199907|NCT02364089|Experimental|Surgery followed by intensive medical care|Laparoscopic surgical removal of the adrenal tumor
89199908|NCT02364089|Active Comparator|Intensive medical treatment only|Standardized medical treatment of hypertension by SAHR.
89443024|NCT02509832|Other|Cooling + PCI|The subjects will be considered to be enrolled in the Test Arm of the trial when all inclusion and exclusion criteria have been met, the informed consent form has been signed, and randomization to the Test Arm of the trial to allow cooling with the Proteus IVTM System before and after PCI.
88926872|NCT01696591||NEUROSTEM®-AD|"A single administration of human umbilical cord blood-derived mesenchymal stem cells through a brain surgery~DOSE A - 250,000 cells per entry site, 3 million cells per brain; DOSE B - 500,000 cells per entry site, 6 million cells per brain"
88926873|NCT01696591||Control Group|"A group of subjects with comparable demographics (age and gender) and disease characteristics [Clinical Dementia Rating Scale Sum of Boxes (CDR-SOB)] as the NEUROSTEM®-AD-treated group, but did not receive the treatment with NEUROSTEM®-AD and were continued on conventional therapy. Restrictions in the concurrent use of drug therapy are as follows:~Patients are, in principle, permitted to continue the drug therapy they were on prior to the enrollment, for the treatment of concurrent illnesses other than Dementia, such as hypertension, diabetes mellitus, or hyperlipidemia.~For drugs used in the treatment of dementia, behavior-modifying drugs can be added to the pharmacological regimen of a subject during the course of the study. However, adding a new cognitive enhancer, such as donepezil, memantine, galantamine, rivastigmine, is not permitted while dose adjustment is permitted given that the drug had been in use prior to the initiation of the study."
88926874|NCT01696604|Experimental|Part A: Cohort 1-GSK2849466|The subjects will receive single planned dose of GSK284946 in ascending order (0.01, 0.03, 0.1, and 0.3 mg) in ratio of 3:1.with placebo within each of 4 treatment periods. The dose will not be allowed to exceed 30 mg over a 24-hour period.
88926875|NCT01696604|Experimental|Part A: Cohort 1-Placebo|The subjects will receive single dose of matching placebo in one of the 4 treatment periods.
88926876|NCT01696604|Experimental|Part A: Cohort 2-GSK2849466|The subjects will receive single planned dose of GSK284946 in ascending order (0.3, 1, 3, and 10 mg) in ratio of 3:1.with placebo within each of 4 treatment periods. The dose will not be allowed to exceed 30 mg over a 24-hour period in one of the 4 treatment periods.
88926877|NCT01696604|Experimental|Part A: Cohort 2-Placebo|The subjects will receive single dose of matching placebo in one of the 4 treatment periods.
88926878|NCT01696604|Experimental|Part B: Cohort 3-GSK2849466 (Repeat dose 1)|The selection of appropriate doses for Part B will be performed upon consideration of available safety and tolerability and PK data from Part A and/or any preceding repeat dose cohorts. The subjects will receive GSK2849466 in ratio of 3:1.with placebo.
89443025|NCT02509832|Other|PCI only|The subjects will be considered to be enrolled in the Control Arm of the trial when all inclusion and exclusion criteria have been met, the informed consent form has been signed, and randomization to the Control Arm of the trial to allow PCI only.
89443026|NCT02165163|Experimental|Balance Training|"Balance training will be conducted individually two times per week for 4 weeks. Each training session will include virtual reality tasks such as ankle reaching and obstacle crossing using a virtual obstacle shown on a computer screen. Each session will last 30 - 45 minutes."
89443027|NCT02165163|No Intervention|Control|The control group will keep their normal activity without receiving any intervention.
89199909|NCT02347995|Placebo Comparator|Resistive Training|Participants will drink a placebo beverage after each resistance training session.
89199910|NCT02347995|Experimental|Resistive Training + Protein|Participants will drink 30 grams of whey protein after each resistance training session.
88926879|NCT01696604|Experimental|Part B: Cohort 3-Placebo (Repeat dose 1)|The subjects will receive repeat dose of matching placebo.
88926880|NCT01696604|Experimental|Part B: Cohort 4-GSK2849466 (Repeat dose 2)|The selection of appropriate doses for Part B will be performed upon consideration of available safety and tolerability and PK data from Part A and/or any preceding repeat dose cohorts. The subjects will receive GSK2849466 in ratio of 3:1.with placebo. In Cohort 4 subjects will be dosed in the fasted state on Days 1 and 14 and in the fed state on Day 7.
88926881|NCT01696604|Experimental|Part B: Cohort 4-Placebo (Repeat dose 2)|The subjects will receive repeat doses of matching placebo.
88926882|NCT01696604|Experimental|Part B: Cohort 5-GSK2849466 (Repeat dose 3)|The selection of appropriate doses for Part B will be performed upon consideration of available safety and tolerability and PK data from Part A and/or any preceding repeat dose cohorts. The subjects will receive GSK2849466 in ratio of 3:1.with placebo
88926883|NCT01696604|Experimental|Part B: Cohort 5-Placebo (Repeat dose 3)|The subjects will receive repeat doses of matching placebo.
88926884|NCT01696617|Experimental|Aripiprazole 8-week group|Adjunctive aripiprazole 8-week treatment
88926885|NCT01696617|Active Comparator|Aripiprazole 6-week group|Adjunctive aripiprazole 6-week treatment
88926886|NCT01696630|Active Comparator|Desflurane|Desflurane 6.5% (+/-0.5%) in association with a thoracic epidural analgesia in maintenance phase
88926887|NCT01696630|Experimental|Xenon|Xenon 60% (+/-5%) in association with a thoracic epidural analgesia in maintenance phase
88926888|NCT01696656||Intestinal insufficiency|Patients with variable categories of major intestinal resection due to benign diseases,suffering from intestinal insufficiency and maintained with home nutritional support. Only clinically stable and nonhospitalized subjects will be recruited.
88926889|NCT01696669|Experimental|Chemotherapy + Surgery + Radiotherapy|"Standard risk patients: MP6 Treatment:~CHEMOTHERAPY: 2 cycles of vincristine-doxorubicin + dexrazoxane-cyclophosphamide, 1 cycle of ifosfamide-etoposide. SURGERY: Ideally within 21 days after chemotherapy.~CHEMOTHERAPY: 1 cycle of vincristine-doxorubicin + dexrazoxane-cyclophosphamide, 1 cycle of ifosfamide-etoposide.~RADIOTHERAPY: On the primary tumor bed in case of unresectable tumors, resected tumors with inadequate margins, or those with histologic response <90%.~High risk patients:~CHEMOTHERAPY: Window phase with 2 cycles of gemcitabine + docetaxel. MP6 TREATMENT. CHEMOTHERAPY: Maintenance therapy for 1 year with gemcitabine + docetaxel."
88926890|NCT01696682|Experimental|Narrow Gastric Conduit|The group in which narrowed gastric conduit will be performed during minimally invasive esophagectomy
88926891|NCT01696682|Experimental|Wide Gastric Conduit|The group in which widened gastric conduit will be performed during minimally invasive esophagectomy
88926892|NCT01696708|Other|Patients|31-Phosphorus RMN Spectroscopy
88926893|NCT01696708|Other|Volunteers|31-Phosphorus RMN Spectroscopy
88926894|NCT01696786|Experimental|Oocyte cryopreservation|
88926895|NCT01696799|Experimental|Econazole Nitrate Foam|Investigational Drug Product
88926896|NCT01696799|Placebo Comparator|Vehicle Foam|Vehicle Foam Comparator
88926897|NCT01696799|Active Comparator|Econazole Nitrate Cream|Active comparator cream product
88926898|NCT01696812|Experimental|electrode position, STN DBS, Parkinson' disease|To determine the electrode positions with the relationship of the STN from the fused images of the preoperative MRI and the postoperative CT via web-site.
88926899|NCT01696825|Experimental|Diazepam Tablet, 5 mg, Vaginal|
88926900|NCT01696825|Experimental|Diazepam Suppository, 5 mg, Vaginal|
88926901|NCT01696825|Experimental|Diazepam Cream, 5 mg, Vaginal|
88926902|NCT01696825|Active Comparator|Diazepam Tablet, 5 Mg, Oral|
88926903|NCT01696838|Experimental|EA group|Electroacupuncture group
88926904|NCT01696838|Experimental|MOX group|Herbs-partitioned moxibustion group
88926905|NCT01696851||wheelchair rugby players with tetraplegia|
88926906|NCT01696851||other routine sport participants with tetraplegia|
88926907|NCT01696864|Experimental|stroke patients - hand|stroke patients with the ability to move their hand
88926908|NCT01696864|Experimental|stroke patient - arm|stroke patients with the ability to move their arms
88926909|NCT01696890|Active Comparator|integrated care|telemonitoring-assisted follow-up with intensive collaboration between general practitioner and specialized Heart failure clinic.
88926910|NCT01696890|Active Comparator|standard care|telemonitoring- assisted follow-up with usual care by general practitioner, without supervision of heart failure clinic
88926911|NCT01696903|No Intervention|Conventional anastomosis|"Conventional anastomosis: The pancreaticojejunostomy is carried out in a traditional way according to Cattell's duct-to-mucosa technique."
88926912|NCT01696903|Active Comparator|Novel anastomosis|Novel anastomosis: This the active comparator to the conventional anastomosis. A new pancreaticojejunostomy technique is used for the reconstruction. The pancreas is intubated into the jejunum.
88926913|NCT01696916|Experimental|exercise testing|6-minute walking test with pCO2 and pO2 measurement
88926914|NCT01697007|Experimental|2 injections of DNA administered by Zetajet|This arm will receive 600 micrograms of HIVIS DNA given as 2 injections using the Zetajet device each injection will comprise of 0.1 ml at a concentration of 3mg/ml
88926915|NCT01697007|Experimental|2 injections DNA by Zetajet and electroporation|This arm will receive 600 micrograms of HIVIS DNA given as 2 injections using the Zetajet device each injection will comprise of 0.1 ml at a concentration of 3mg/ml followed by electroporation using the Derma Vax device.
88926916|NCT01697007|Experimental|1 injection DNA by Zetajet and electroporation|This arm will receive 600 micrograms of HIVIS DNA given in 1 injection using the Zetajet device the injection will comprise of 0.1 ml at a concentration of 6mg/ml followed by electroporation using the Derma Vax device.
88926917|NCT01697020|Experimental|Arm 1|Mercaptopurine 20mg/ml Oral Suspension
89443028|NCT04166214|Experimental|Dental Providers|The tele-mentoring intervention involves training dental faculty members and residents to use intraoral cameras to take photographs of oral lesions and place them in the Dentrix electronic health record (EHR), along with descriptions of the lesions.
89443029|NCT04166214|Experimental|Dental Patients|The tele-mentoring intervention involves training dental faculty members and residents to use intraoral cameras to take photographs of oral lesions and place them in the Dentrix electronic health record (EHR), along with descriptions of the lesions.
89443030|NCT02510066|Experimental|Acupuncture|Acupuncture participants would receive electroacupuncture on Jiaji (Ex-B2) points for 3 times in a week.
89443031|NCT02510066|Placebo Comparator|Placebo acupuncture|Placebo acupuncture participants would receive placebo acupuncture on non-point points for the same period.
88926918|NCT01697020|Active Comparator|Arm 2|Mercaptopurine 50mg tablets
88926919|NCT01697046|Experimental|Isentress+Truvada|All participants will receive the intervention
89443032|NCT02757963|Other|BPE/BPO screening and IPSS screening tool|Subjects presenting to a GP with a primary complaint other than LUTS will be screened for probable BPH using BPE/BPO screening tool and the IPSS screening tool. Subjects testing positive on the BPE/BPO screening tool or on the IPSS will be enrolled and offered a prostate specific antigen (PSA) test and urinalysis to establish a diagnosis of probable benign prostatic hyperplasia (BPH) (Part I - Visit 1). If the GP determines that the subject has probable BPH (IPSS >=8 and/or BPE/BPO questionnaire >=3 with a PSA >=2 ng per ml), the subject will proceed to Part II and will be scheduled for an urologist assessment and diagnostic tests to confirm or refute a BPH diagnosis and to assess risk of progression of BPH.
89443033|NCT02509910||Standard therapy|intraoperative standard fluid therapy for major abdominal surgery
89443034|NCT02509910||Goal directed therapy|intraoperative goal directed fluid therapy based on an angorithm lead by SVV/CI for major abdominal surgery patients
89443035|NCT02509754|Experimental|Atrial fibrillation catheter ablation|Atrial fibrillation (AF) catheter ablation is performed following each Center's common practice. Activated clotting time (ACT) is maintained above 350 seconds. The left atrium (LA) is accessed by transseptal puncture or through a patent foramen ovale. A multipolar catheter and an irrigated-tip ablation catheter are inserted into the LA and a 3-dimensional reconstruction of the LA and pulmonary veins (PVs) ostia is performed. The mainstay is to obtain a complete antral PVs isolation, defined by complete elimination of PVs potentials. PVs isolation may be accompanied by the creation of linear lesions (roof line, left isthmus) or ablation of complex fractioned atrial electrograms. Patients are discharged on oral anticoagulation and optimal medical therapy. Each center will evaluate patients for ICD implantation; a loop recorder may be implanted if within routine clinical practice.
89443036|NCT02509754|Experimental|Rate control arm|Patients randomized to rate control only arm will undergo ICD implantation and optimization of the rate control therapy. In case of uncontrolled ventricular rate at 24-h ECG Holter, defined as a mean resting heart rate higher than 90 bpm, patients will receive atrioventricular (AV) node ablation and resyncronization therapy (CRT-D) implantation, performed following common practice at each Center. In case of failure or technical difficulties of the transvenous approach, epicardial screw-in or steroid-eluting passive lead is implanted via a limited thoracotomy. Transcatheter AV node ablation is performed as follows: a non-irrigated tip ablation catheter is introduced on the right side of the interatrial septum and ablation performed on the fast pathway region or the smallest His bundle signal. The goal of the procedure is AV modulation below 30 bpm or complete AV block.
89443037|NCT02167425||Late Post-IMAT Cohort|Enrollment into the Late Post-IMAT Cohort will occur over a 9-month period in beginning in the second year of the intervention and will be followed by a 3-month period of follow-up after the close of enrollment.
89443038|NCT02167425||Early Post-IMAT Cohort|Enrollment into the Early Post-IMAT Cohort will occur over a 9-month period immediately following the intervention and will be followed by a 3-month period of follow-up after the close of enrollment.
89443039|NCT02167425||Late Pre-IMAT Cohort|Enrollment into the Late Pre-IMAT Cohort will begin one year prior to implementation of the intervention. Enrollment will occur over a 9-month period and will be followed by a 3-month period of follow-up after the close of enrollment.
89199911|NCT02186418|Experimental|ARU-1801|Autologous CD34+ hematopoietic stem cells transduced ex-vivo with gamma-globin lentiviral vector. Administered via IV infusion.
88926920|NCT01697059|Experimental|Piperacillin + Amoxicillin|Piperacillin/Tazobactam (Zosyn®) 100 mg/kg, up to adult dose of 3 g, i.v. q 6 hours x 2 doses, followed by Ampicillin/Clavulanate (Augmentin®) 50 mg/kg/d p.o. in 3 divided doses for 1 week.
88926921|NCT01697085|Experimental|Sea buckthorn oil|3 g (6 capsules)/day for three months
88926922|NCT01697085|Placebo Comparator|Placebo oil|3 g (6 capsules)/day for three months
88926923|NCT01697098|Experimental|12 hours Dexamethasone|Those patient will be given 12 hours dexamethasone after randomization
88926924|NCT01697098|Experimental|24 hours Dexamethasone|Those patient will be give 24 hours dexamethasone after randomization
89199912|NCT02121873||Women with and without breast cancer|Nipple aspirator, ductal lavage microcatheter, blood draw
89443040|NCT02167425||Early Pre-IMAT Cohort|Enrollment into the Early Pre-IMAT Cohort will begin two years prior to implementation of the intervention. Enrollment will occur over a 9-month period and will be followed by a 3-month period of follow-up after the close of enrollment.
89443041|NCT02509676|Experimental|dynamic stretching exercise|This group will perform dynamic stretching exercise to their left side gastrocnemius muscles for 5 weeks (5 days a week, 3 sets of exercise a day, each set including 5 repetitions of dynamic stretching lasting 45 seconds)
89443042|NCT02509676|No Intervention|control|this group will not perform any stretching exercises for 5 weeks
89443043|NCT03111732|Experimental|1/Arm 1|Pembrolizumab plus Oxaliplatin plus Capecitabine
89443044|NCT01663714|Experimental|open-label, single arm|cycolophosphamide, vacristine, and pednisone (CVP) x6 cycles followed by tositumomab and iodine I 131 tositumomab. CVP will be repeated every 21 days for a total of six cycles. tositumomab and iodine I 131 tositumomab will begin within 56 days following the first day of the sixth cycle of CVP. Patient will undergo two dosing phase for the tositumomab and iodine I 131 tositumomab therapy.
89199913|NCT02115724|Experimental|Antioxidant Cocktail|Following an overnight fast, blood samples, flow-mediated dilation, and nitroglycerin mediated dilation (NMD; 0.4mg sub-lingual nitroglycerin spray) will be performed at baseline and 2 hours following either a single dose oral antioxidant cocktail (1000 mg Vitamin C, 600 IU vitamin E, 600 mg Alpha Lipoic Acid) or placebo on two days separated by at least 72 hours.
88926925|NCT01697111|Experimental|Arm 1|
88926926|NCT01697111|Experimental|Arm 2|
89199914|NCT02115724|Other|Biopsy|Following an overnight fast, a subcutaneous gluteal/hip fat biopsy sample will be obtained from each subject under local anesthesia, with adipose tissue (~2x1.5x1.5cm) to be harvested and placed immediately in physiological saline solution (PSS): Small arteries, 100 to 150 um in diameter, will be dissected from the fat under a dissecting microscope, transferred to an arteriographic bath chamber, and cannulated for pressurized myography.
89199915|NCT02060565||Chronic liver disease|all patients with chronic liver disease followed using non-invasive methods
89199916|NCT02036372|Experimental|BR (bolus regimen)|"Day before surgery: half evening dose long acting insulin~Day of surgery:~patients using mealtime and longacting insulin/NPH: withhold mealtime morning dose, stop glucose lowering tablets~patients using only long acting insulin/NPH: half dose of long-acting or NPH insulin, stop glucose lowering tablets~Measure blood glucose every 60 minutes, start 30 min prior to surgery~Give bolus of insulin according to treatment algorithm"
88926927|NCT01697111|Active Comparator|Arm 3|
88926928|NCT01697124|Experimental|SPARK-EC|SPARK-EC curriculum for preschoolers offered instruction and practice in a comprehensive program designed to promote motor development through increased physical activity.
88926929|NCT01697137|No Intervention|Usual Care|Following enrollment, participants will visit with their primary care provider per usual.
88926930|NCT01697137|Experimental|Participant Video and Provider Cueing|Participants will watch a video prior to meeting with their provider. Participants will then cue their providers to discuss organ donation with them.
88926931|NCT01697150|Experimental|Control to Range Testing|Subjects will spend two nights in a non hospital setting while the DiAs Diabetes Assistant Wearable Artificial Pancreas Platform is remotely monitored from an adjacent room. DiAs Diabetes Assistant Wearable Artificial Pancreas Platform is composed of an Android-based cell phone platform operating with a DexCom sensor, OmniPod Insulin Management System and an Insulet iDex remote controller. Communication runs on a tablet. The Control to Range software will be capable of transmitting patient state data to a remote monitoring device. The subject will be trained on the open loop features of the cell phone platform user interface: DexCom displays, Insulin injection history display, bolus function. The subject may use the study pump per his/her usual home regimen and may make adjustments to his/her insulin based on symptoms or SMBG readings.
88926932|NCT01697163||Iressa|Lung cancer patients with EGFR mutation
88926933|NCT01697189|Experimental|Fatigue management training|Experimental group subjects participated in a single half-day fatigue management training session.
88926934|NCT01697189|No Intervention|No fatigue management training|The control group subjects did not participate in the fatigue management training.
88926935|NCT01697202||no intervention|
88926936|NCT01697215||Oral or nasal endotracheal intubation|Oral or nasal endotracheal intubation, anticipated to last at least 48 hours Adults that require ETT internal diameter sizes of 6.5 - 9.0 mm Subject must be at least 18 years old (no upper age limitation) English speaking patients/decision makers.
88926937|NCT01697228|Other|Immediate treatment group|This group will receive vitamin D supplementation for the first 6 months, then will be monitored off vitamin D for the next 6 months.
88926938|NCT01697228|Other|Delayed treatment group|This group will be monitored for the first 6 months, and then will be given vitamin D for the next 6 months.
89199917|NCT02036372|Experimental|LG (Liraglutide)|"Day before surgery: half dose of long acting and mealtime insulin from start liraglutide~Day of surgery: withhold own insulin, stop oral glucose lowering tablets~Start with 0.6 mg liraglutide subcutaneously (s.c.) the day prior to surgery at 17.00hr.~In case of nausea graded higher than minimal, the patient will be excluded from the study~Otherwise, treatment will be continued with 1.2 mg liraglutide s.c. per day on the day of surgery at 07.00hr.~Measure glucose every 60 minutes, start 30 min prior to surgery~Adjust according to bolus algorithm of BR group"
89199918|NCT02036372|Active Comparator|GIK (glucose -insulin - potassium) infusion|"Day before surgery: half evening dose long acting insulin~Day of surgery: stop oral glucose lowering tablets and withhold own insulin.~GIK infusion: 500 cc glucose 5% with insulin and 10 mmol KCL per 500 cc. Start at 83 ml/hr.~Calculate the insulin amount in the GIK infusion according to the formula:~I= (PG-7)/(200/W)+8 I=Insulin amount, PG=glucose 30 minutes preoperative, W= body weight in kg~Measure blood glucose every 60 minutes, start 30 min prior to surgery~Adjust glucose > 8 mmol/l according to treatment algorithm"
89199919|NCT01965249|Active Comparator|Long stitch group|Long stitch suture technique Stitch interval = 10 mm; Lateral = 10 mm
89199920|NCT01965249|Experimental|Short stitch group|Short stitch technique for AWC stitch interval = 5 mm; Lateral 5 - 8 mm
89443045|NCT02165319|Active Comparator|Barrel|Endotracheal tube with barrel-shaped cuff will be used during general anesthesia.
89443046|NCT02165319|Active Comparator|Tapered|Endotracheal tube with tapered-shaped cuff will be used during general anesthesia.
89443047|NCT02505308|Experimental|DIVA-1 CCND2|Individuals carrying a genetic change in the CCND2 gene and controls matched for gender, age and BMI. Participants will undergo the Glucose-Potentiated Arginine-Induced Insulin Secretion (GPAIS) test plus optional faecal elastase measurement. Case/control status will be unblinded at analysis.
89443048|NCT02505308|Experimental|DIVA-2 Low Risk of Diabetes|Individuals carrying the fewest genetic risk alleles for diabetes and controls carrying the average number of genetic risk alleles, matched for gender, age and BMI. Participants will undergo the Glucose-Potentiated Arginine-Induced Insulin Secretion (GPAIS) test plus optional faecal elastase measurement. Case/control status will be unblinded at analysis.
89443049|NCT02167581||epithelial odontogenic tumours|
89443050|NCT02941146|Experimental|Zeltiq Dual Sculpting Treatment Group|All subjects treated with CoolSculpting System using the CoolAdvantage and CoolAdvantage Plus applicators simultaneously on the abdomen.
89013230|NCT01602757|Experimental|Synera|"Subjects received 4 Synera® patches for 2 hours in Session 1 and 4 patches for 12 hours in Session 4. During Study Session 2, subjects were randomly assigned to 4-hour applications of either 4 Synera® patches or 4 lidocaine/tetracaine patches without heat (no heat patches) and were crossed over during Study Session 3."
89199921|NCT01953016||immunodeficiency|Individuals of all ages, gender, and races with an immunodeficiency disorder from NIH studies, will be accepted for registration.
89443051|NCT02171091||study arm|One tracheal sample will be obtained using sterile (5 ml) sterile saline solution using irrigation and wall suction from each patient every day for 72 hours, total sampling time is approximately 10 seconds per specimen. Lung samples or fiberoptic obtained samples will be collected at same time intervals as the tracheal samples when possible and if they are done as standard of care. Samples will not be collected for research only and the time for this procedure will not be extended to collect extra tissue. A blood sample (10ml) will be collected simultaneously with the airway samples and also will be used for baseline control measurements.
89443052|NCT02515136|Experimental|Parkinson's disease|Parkinson's disease patients
89443053|NCT02515136|Other|Controls|Healthy volunteers paired with Parkinson's disease patients on sex and age group, whose data will be extracted from a CNRS existing database
89443054|NCT02514902|Experimental|Lateral Flow Device|Determine the feasibility of testing whole blood samples from patients with acute stroke (both ischemic and hemorrhagic) and traumatic brain injury being evaluated in the Emergency Department and Inpatient Services at University of Kentucky. No diagnostic or treatment decisions will be based on the results for any patient and the patient will not be told of the results.
89443055|NCT05510752|Active Comparator|Psychoeducation Group|Psychoeducation is the most commonly offered non-pharmacological treatment for perinatal distress, with the assumption that an understanding of perinatal distress, self-care and infant milestones will improve mental health outcomes. Psychoeducation has been shown to be effective in reducing the severity of perinatal anxiety and depression.
89443056|NCT05510752|Experimental|Cognitive Behavioural Group Therapy|Cognitive Behavioural Group Therapy (CBGT) is a well-established psychological treatment for anxiety and other mental health disorders. CBGT treatment for perinatal anxiety has shown significant reductions in anxiety (primary outcome), worry and depression from pre- to post-treatment when compared to a waitlist control condition. However, to be considered well-established, a treatment must be at least as effective as other active interventions. As such, the present study will compare CBGT to what is most commonly offered to perinatal women with a principal anxiety disorder (i.e., psychoeducation).
89443057|NCT03490578|Experimental|Robot-assisted gait training|Robot-assisted gait training using an exoskeletal robot (Walkbot_S; P&S Mechanics Co. Ltd., Seoul, Korea)
89443058|NCT03490578|Active Comparator|Intensive treadmill training|Intensive treadmill training using an usual treadmill
89443059|NCT02255487|Experimental|IrriSept System|IrriSept device used for surgical irrigation in subjects with abdominal trauma or acute surgical abdomen
89443060|NCT02255487|Active Comparator|Standard of Care (SoC) only|Institution will provide routine Standard of Care (SoC) surgical preparation for subjects with abdominal trauma or acute surgical abdomen.
89443061|NCT02505386|Active Comparator|Ertapenem IV|IV administration of ertapenem
89443062|NCT02505386|Experimental|Ertapenem SC|SC administration of ertapenem
89443063|NCT03488160|Experimental|Single arm|The Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T) Dosage form：injection Dosage:100ml/time Frequency:the first day,the second day Duration:total two times
89443064|NCT02509364||AE-IPF|"Diagnosis criteria for AE-IPF:~Diagnosed IPF patient experiences unexplained dyspnea within 1 month~With objective evidence of hypoxia and new onset of pulmonary infiltration based on imaging examination~With other diagnosis like pulmonary embolism, pneumothorax or heart failure excluded."
89013231|NCT02961101|Experimental|Anti-PD-1 antibody+decitabine|Decitabine will be administrated at 10mg/d on day1 to 5, followed by Anti-PD-1 antibody 200mg on day8 IV Q3 weeks until progression.
89443065|NCT02509364||Stable-IPF|"Diagnosis criteria for Stable-IPF:~Exclusion of other known causes of ILDs~Presence of a usual interstitial pneumonitis (UIP) pattern on high-resolution computed tomography (HRCT)~Specific combinations of HRCT and surgical lung biopsy pattern in patients subjected to surgical lung biopsy."
89443066|NCT02509364||Health control|Healthy volunteer
89443067|NCT02171169||Transsacral lumbar interbody fusion|
89443068|NCT02171169||Transforaminal lumbar interbody fusion|
89443069|NCT02514980|Active Comparator|Bupivacaine group|Infraorbital nerve block using bupivacaine 0.25% on each side.
89443070|NCT02514980|Active Comparator|Bupivacaine-Ketamine group.|Infraorbital nerve block using bupivacaine 0.25% combined with 0.5mg/kg ketamine on each side.
89443071|NCT03344588|Active Comparator|artery preserving varicocelectomy|In all patients, sub-inguinal varicocelectomy will be carried out under spinal anesthesia, by a single surgeon (KS), using surgical microscope. A 2-3 cm pre-pubic incision will be performed. The cord will be grasped with a Babcock clamp and isolated over a vessel tape. Any external cremastric veins will be identified and ligated using vicryl 3/0. After opening the spermatic fascia, the vassal compartment including the vasal, cremasteric arteries and lymphatics will be separated from the pampiniform plexus compartment and preserved. In group A (APV), testicular arteries will be spared with aid of by intraoperative Doppler US (VTI intraoperative Doppler system 20 MHz). The arteries will be carefully dissected by a micro-dissector, separated over a vessel loupe, and then the remaining veins will be ligated using vicryl 3/0.
89013232|NCT02961101|Experimental|Anti-PD-1 antibody|Anti-PD-1 antibody 200mg IV Q3 weeks until progression.
89443072|NCT03344588|Active Comparator|artery ligation varicocelectomy|In all patients, sub-inguinal varicocelectomy will be carried out under spinal anesthesia, by a single surgeon (KS), using surgical microscope. A 2-3 cm pre-pubic incision will be performed. The cord will be grasped with a Babcock clamp and isolated over a vessel tape. Any external cremastric veins will be identified and ligated using vicryl 3/0. After opening the spermatic fascia, the vassal compartment including the vasal, cremasteric arteries and lymphatics will be separated from the pampiniform plexus compartment and preserved. In group B (ALV), all vascular channels will be ligated without identifying or sparing the internal spermatic arteries
89443073|NCT04412044|Experimental|Asthmatics|Patients receive anti-IL5 treatment as part of their prescribed routine. Immunological and clinical parameters will be evaluated at the start of the treatment and after 6 months of treatment
89443074|NCT02165475|Experimental|Biofeedback|
89443075|NCT02165475|Experimental|medical treatment|
89443076|NCT02165475|Experimental|combination of the two treatments|
89199922|NCT01807936|Experimental|Three-field lymphadenectomy|Cervical-thoracic-upper abdominal three-field lymphadenectomy
88926939|NCT01697241|Experimental|Supervised exercise and patient education|The entire duration of the intervention is 12 weeks, and consists of 24 sessions each lasting 60-70 minutes. Patients will receive two types of exercises, delivered on separate days. One type of exercise is individualized, goal-based neuromuscular training (NEMEX) in groups with progression guided by the patient's neuromuscular function (12 sessions). The other type of exercise is individualized, intensive resistance training (RT) in groups with each exercise progression guided by load (12 sessions).
88926940|NCT01697241|Other|Patient Education|The patient education program is designed to educate the patients about hip OA during 3 sessions of 90 min. duration
88926941|NCT01697280|Experimental|Educational messages only|EPI vaccinators/volunteers will educate mothers/care-providers of infants less than 12 months old months about the benefits of routine immunization
88926942|NCT01697280|Experimental|Immunization status verification only|EPI vaccinators/volunteers will identify and record details of un/under-vaccinated children less than 12 months old in households they visit during an NID, and update immunization registries maintained at the local EPI centers so these children can be reached in subsequent outreach activity.
88926943|NCT01697280|Experimental|Education and vaccine verification|EPI vaccinators/volunteers will educate mothers/care-providers of infants less than 12 months old months about the benefits of routine immunization, identify and record details of un/under-vaccinated children in households they visit during an NID, and update immunization registries maintained at the local EPI centers so these children can be reached in subsequent outreach activity.
88926944|NCT01697280|No Intervention|Status quo|No interventional activity will take place in this group. Therefore, the status quo (routine services) will be maintained during Polio NID
88926945|NCT01697293|Experimental|Treatment (chemotherapy, surgery)|"COURSES A 1-12 (PHASE I & II): Patients receive triciribine phosphate IV over 60 minutes on days 1, 8, and 15, 29, 36, 43, 57, 64, and 71 and paclitaxel IV over 1 hour on days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 79. Treatment repeats every 14 days for 4 courses in the absence of disease progression or unacceptable toxicity.~COURSES B 1-4 (PHASE II): Patients receive doxorubicin hydrochloride IV over 5-10 minutes and cyclophosphamide IV over 30-60 minutes on day 1. Treatment repeats every 2 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.~SURGERY (PHASE II): Eligible patients undergo modified radical mastectomy, radical mastectomy, segmental mastectomy or lumpectomy with an axillary lymph node dissection or biopsy."
88926946|NCT01697306|Active Comparator|Gemcitabine-arm|7-15 days after TUR patients received six weekly instillations of gemcitabine (Gemzar, Eli Lilly SpA), 2.000 mg diluted in 50 cc of saline. Maintenance consisted in monthly instillations up to 1 year
88926947|NCT01697306|Active Comparator|BCG-arm|7-15 days after TUR patients received an induction cycle of six weekly instillations of Connaught strain Bacillus Calmette-Guerin (BCG Immucyst) 1/3 dose (27 mg) diluted in 50 cc of saline. Maintenance consisted of 3 weekly instillations at 3, 6 and 12 months
88926948|NCT01697410|Experimental|terlipressin|
88926949|NCT01697410|Active Comparator|norepinephrine|
88926950|NCT01697423|Experimental|platelet-rich plasma|
88926951|NCT01697423|Active Comparator|durolane|
88926952|NCT01697436|Experimental|Crossover Period 1|
88926953|NCT01697436|Experimental|Crossover Period 2|
88926954|NCT01697436|Experimental|Crossover Period 3|
88926955|NCT01697436|Experimental|Crossover Period 4|
88926956|NCT01697475|Experimental|Intervention Group|Motivational text messaging
88926957|NCT01697475|No Intervention|Control Group|Step count
88926958|NCT01697488||Cohort|Overall sample
88926959|NCT01697488||Subgroup|Patients aged >/= 70 years
88926960|NCT01697514|Experimental|Part A: LY2940680 (Dose Escalation)|LY2940680 administered orally once daily at escalating doses (92.5 milligrams per square meter [mg/m^2] up to 370 mg/m^2) for two 28 day cycles. Lower dose levels (23 mg/m^2 and 46 mg/m^2) may also be explored, if necessary. Participants receiving benefit may continue until disease progression, unacceptable toxicity, or discontinuation.
88926961|NCT01697514|Experimental|Part B: LY2940680 (Dose Confirmation)|LY2940680 administered orally once daily for two 28 day cycles. Dose based on Part A. Participants receiving benefit may continue until disease progression, unacceptable toxicity, or discontinuation.
88926962|NCT01697553|Experimental|Home automation pack coupled to teleassistance service|
88926963|NCT01697553|Active Comparator|Home without automation pack coupled to teleassistance service|
88926964|NCT01697605|Experimental|BGJ398|Eligible participants received oral BGJ398 once daily or twice daily. Patients may continue treatment with BGJ398 until the patient experiences unacceptable toxicity or progressive disease.
88926965|NCT01697618|Experimental|BIAsp 30|
88926966|NCT01697618|Active Comparator|BHI 30|
88926967|NCT01697631|Experimental|BIAsp|
88926968|NCT01697631|Experimental|Insulin aspart|
88926969|NCT01697644|Experimental|Low dose|
88926970|NCT01697644|Experimental|High dose|
88926971|NCT01697657|Experimental|Detemir|
88926972|NCT01697657|Active Comparator|NPH|
89443077|NCT03345212|No Intervention|Control group|Patients in this group continue their sedentary life-style throughout the study period. Patients will be advised to perform no specific exercise training during the trial. After 15 weeks, the patients are offered to take part in the training program as well.
89443078|NCT03345212|Experimental|Training group|"Standard rehabilitation therapy includes dietary measures, massages and relaxation techniques. Additionally, patients perform exercise and respiratory therapy and mental gait training.~Patients will be informed about group allocation."
89443079|NCT04862338|Experimental|Nicotinamide mononucleotide (NMN-C)|Nicotinamide mononucleotide (NMN-C) at 400 mg/day for 28 days in total
89443080|NCT02171325|Experimental|irinotecan|irinotecan； 60 mg/m2、65mg/m2、70mg/m2、75mg/m2、80mg/m2、85mg/m2、90mg/m2、95mg/m2、100mg/m2
89443081|NCT03344432||With intraocular pressure high|Intracranial pressure equal or more than 20 mmHg
88926973|NCT01697670|Experimental|Photodynamic therapy with Gliolan|Intervention: Laser light illumination with a cylindrical light diffuser (Model RD, Medlight SA) is performed 3 hours after administration of 15 mg/kg 5-aminolevulinic acid (5-ALA, Gliolan)
88926974|NCT01697683|Active Comparator|Probiotic Rhamnosus Lactobacilli|
88926975|NCT01697683|Placebo Comparator|Sugar pill|
88926976|NCT01697722||Step-up as FDC ICS/LABA|ICS asthma patients who increased therapy as FDC ICS/LABA (no increase in daily ICS dose).
88926977|NCT01697722||Step up as separate therapies|ICS asthma patients who increased therapy as ICS / LABA via separate pMDI and / or BAI inhalers (no increase in daily ICS dose).
88926978|NCT01697722||Qvar step-up|ICS asthma patients who increased therpy as extra-fine hydrofluoroalkane-beclometasone dipropionate
88926979|NCT01697735|Experimental|Berberine;Atorvastatin or Rosuvastatin|Follow the previous administration program，participants will continue to receive 20mg Atorvastatin daily or 10mg Rosuvastatin daily; Besides taking statins, Participants will receive 500mg berberine twice a day for 8 weeks.
88926980|NCT01697735|Active Comparator|Atorvastatin or Rosuvastatin|Due to the different clinical prescriptions by different doctors and similar Efficacy in lowering lipids.Usually,Participants receive 20mg Atorvastatin daily or 10mg Rosuvastatin to treat hyperlipidemia.
88926981|NCT01697761|Experimental|Treatment Group|treat by moxibustion and acupuncture
88926982|NCT01697761|Experimental|Control Group|treat by Sham acupuncture and moxibustion
88926983|NCT01697787|Other|Amodiaquine-Artesunate|ASAQ is produced by Sanofi-Aventis as CoarsucamTM and as artesunate-amodiaquine Winthrop®
88926984|NCT01697787|Other|Artemether-Lumefantrine|AL (tablets containing 20 mg of artemether and 120 mg of lumefantrine) is produced by Novartis
88926985|NCT01697826|Active Comparator|ClinSupV3 -soft gelatin capsule|Soft gelatin capsule containing 100mg Clindamycin and 200mg clotrimazole administered per vaginally for 3 consecutive days
89443082|NCT03344432||Without intraocular pressure high|Intracranial pressure smaller than 20 mmHg
89443083|NCT01663636||SMS Vaccine|Mothers will be sent an SMS message reminding them to come for their scheduled vaccines 1 week prior to the date of 2nd and 3rd doses
89443084|NCT01663636||Usual care|Mothers under usual care will serve as a control
89443085|NCT02171403||Lactose intolerance|Patients with a positive lactose-breath test and complaints during the test
89443086|NCT02171403||Lactose malabsorption|Patients with a positive lactose-breath test and no complaints during the test
89443087|NCT02171403||Healthy controls|Subjects with a negative lactose-breath test
89443088|NCT02509286|Experimental|Perioperative Chemotherapy (FLOT):|"The FLOT Arm consists of the FLOT protocol, which consists of 5-Fluorouracil, Leucovorin, Oxaliplatin and Docetaxel. Repetition every 2 weeks (d15, q2w). Four neoadjuvant cycles (8 weeks) prior to surgery and four adjuvant cycles (8 weeks) postoperatively are given.~Surgery is carried out by transthoracic subtotal esophagectomy or by transabdominal distal esophageal resection plus gastrectomy depending on tumor localization."
89443089|NCT02509286|Active Comparator|Neoadjuvant Chemoradiation (CROSS):|"The CROSS Arm consists of the CROSS protocol, which consists of neoadjuvant radiation therapy (41.4Gy / 23fractions) and concurrent chemotherapy with Carboplatin and Paclitaxel (5 weeks) prior to surgery.~Surgery is carried out by transthoracic subtotal esophagectomy or by transabdominal distal esophageal resection plus gastrectomy depending on tumor localization."
89443090|NCT02165553|Experimental|Hibiscus sabdariffa calyces extract as a cold drink|Subjects are asked to consume 250 ml of Hibiscus calyces drink after a high fat breakfast
89443091|NCT02165553|Placebo Comparator|Water|Subjects are asked to consume 250 ml of water after a high fat breakfast
88926986|NCT01697826|Active Comparator|ClinSupV3ER- Extended release tablet|ER tablets containing 100mg clindamycin and 200mg clotrimazole administered per vaginally for 3 consecutive days.
88926987|NCT01697852|Experimental|LLIN plus IRS|LLIN by universal coverage campaign 2 rounds of indoor residual spraying with bendiocarb insecticide
88926988|NCT01697852|Active Comparator|LLIN only|LLIN by universal coverage campaign
88926989|NCT01697865|Active Comparator|Transfer group|The first surgical technique includes a concomitant latissimus and teres major transfer (transfer group).
88926990|NCT01697865|Active Comparator|Control group|The second technique does not include a concomitant latissimus and teres major transfer (control group).
88926991|NCT01697878|Experimental|Randomization Group 1|CPAP first followed by standard of care
88926992|NCT01697878|Active Comparator|Randomization group 2|Standard of care followed by CPAP
88926993|NCT01697891|Experimental|ALTENS|Patients in this arm will be treated with Acupuncture-like Transcutaneous Electrical Nerve Stimulation using Codetron (Codetron ALTENS)
88926994|NCT01697904|Experimental|Low Oxygen Strategy|"Resuscitation was initiated with room air (21% O2) for LOX infants. Supplemental oxygen was given if 1) the heart rate (HR) was less than 100 bpm after 30 seconds of effective ventilation, 2) the lower limits of goal saturations were not met. Targeted goal Pre-ductal saturations after birth were derived by approximation of the interquartile values for healthy term infants as reported by Kamlin et al and Dawson et al.FiO2 was increased or decreased by 10% in 30 second intervals as needed. If HR < 60 bpm after 30 seconds of effective ventilation , FiO2 was increased to 100% until the heart rate was stabilized.~Targeted Pre-ductal SpO2 After birth~min 60%-65%~min 65%-70%~min 70%-75%~min 75%-80%~min 80%-85%~10 min 85%-94%"
89199923|NCT01807936|No Intervention|Two -field lymphadenectomy|Thoracic-upper abdominal two -field lymphadenectomy
89443092|NCT03065244|Active Comparator|IVIG|Patient will be randomly assigned to receive a second IVIG infusion: 2 g/kg IV over 8-10 hours single infusion
89443093|NCT03065244|Active Comparator|Infliximab|Patient will be randomly assigned to receive Infliximab 10 mg/kg IV over 2 hours
89443094|NCT05502484|Experimental|4 weeks baseline followed by Integrative DBT|Integrative Dialectical Behavioural Therapy (DBT) consisting of 8 weeks outpatient pretreatment DBT, 40 weeks inpatient DBT, 24 weeks follow-up including 12 weeks after care DBT and 12 weeks no DBT.
88926995|NCT01697904|Active Comparator|Traditional Oxygen strategy ( TOX)|Resuscitation for TOX infants was started with 100% O2 and adjusted every 30 seconds by 10% to meet the target oxygen saturation range of 85-94%
88926996|NCT01697917|Other|Total Gastrectomy or Proximal Gastrectomy|
88926997|NCT01697943|Experimental|Roux-En-Y Pouch Reconstruction or Roux-En-Y Reconstruction|
88926998|NCT01697982|Experimental|Living with Hope Program|"Participants will receive the Living with Hope Program (LWHP). The LWHP involves viewing a short film and choose to begin one of three hope activities: a) Write or ask someone to help you write one or more letters to someone begin to write a letter to someone, b) Begin a Hope Collection or c) begin an About Me Collection."
88926999|NCT01697982|Experimental|LWH Film|Participants will viewing a short film entitled Living with Hope (LWH), which is based on the research team's grounded theory study, and shows cases of terminally ill persons and their family members talking about how they maintain their hope
88927000|NCT01697982|No Intervention|Usual Care|Participants in the usual care group will not receive an intervention. Data collection for outcome variables will be the same as the participants in the other arms.
88927001|NCT01697995||Lexiscan-Echo echo subjects|No Intervention: Observational study
88927002|NCT01697995||Lexiscan-Echo control subjects|No intervention: observational study
88927003|NCT01698034|Experimental|Volunteering|Weekly volunteering with elementary school children in after school programs
88927004|NCT01698034|No Intervention|Control|Wait-list control
88927005|NCT01698047|Experimental|Resiliency Class|"Resiliency Classes (study group) Study participant randomized to the Resiliency classes will be offered and assigned a time and date to attend the classes. Each class will have up to 10 participants. Classes will be 90-120 minutes in duration and will be held weekly for six weeks. At the classes, participants will be offered a copy of the Resiliency Class Manual. And at each class, light snacks and refreshments will be offered.~The Resiliency Class manual covers the following topics:~Session 1 - What Affects Your Mood and Resilience; Session 2 - Pleasant Activities Can Help Improve Your Mood and Make You Resilient; Session 3 - What Gets In The Way of Pleasant Activities: Harmful Thoughts and How to Change Them; Session 4 - How to Increase Your Resilience Through Support from Others; Session 5 - My Personal Resiliency Plan: Goal Setting; Session 6 - Celebrate Your Resiliency: Graduation"
88927006|NCT01698047|Active Comparator|Case Management|Case management phone calls (control group) Study participants randomized to the case management phone calls will be told that they will receive two calls over two months by study staff to offer them referrals based on their perceived need for services to local health care, mental health, substance use, social services, child welfare, housing, and food. In addition, study participants in this arm of the study will be told that if the study determines that the resiliency classes are better at improving mood than the case management calls, they will receive a call to invite them to participate in resiliency classes for free at the B-RICH partner agencies.
88927007|NCT01698060|Experimental|Intestinal Delivery|ND1.1
88927008|NCT01698073|Experimental|mCOL|mCircle of Life is a culturally-based HIV-prevention intervention designed for American Indian and Alaska Native 10-12 year-olds. It includes both online and facilitated material.
88927009|NCT01698073|Active Comparator|AS+|After-School Science Plus is a curriculum designed for youth to teach science and literacy using everyday materials. It helps youth see how science is a part of everyday life and provides role models of scientists who come from different backgrounds and ethnicities.
88927010|NCT01698086|Experimental|Experimental group|Participants who are randomized to the Experimental group will perform 1-hour supervised intervention sessions 2x/wk for 6-wks, then 1x/wk for 8-weeks, for a total of 20 supervised sessions (Figure 1). The intervention is a progressive vestibular rehabilitation program comprised of balance and eye movement exercises as detailed in our preliminary study report.
88927011|NCT01698086|No Intervention|Wait-listed Control group|The Wait-listed Control group will not receive treatment; however, participants in the Wait-listed Control group will undergo the same outcome measurement plan as the Experimental group. If interested, participants from this group will be placed on a wait-list and will have the opportunity to receive instructions in how to perform the vestibular rehabilitation program following their completion of the study.
88927012|NCT01698112|Experimental|Flaxseed High Dose|
88927013|NCT01698112|Experimental|Flaxseed Low Dose|
89443095|NCT05502484|Experimental|6 weeks baseline followed by Integrative DBT|Integrative Dialectical Behavioural Therapy (DBT) consisting of 8 weeks outpatient pretreatment DBT, 40 weeks inpatient DBT, 24 weeks follow-up including 12 weeks after care DBT and 12 weeks no DBT.
88927014|NCT01698112|No Intervention|Flaxseed control|
88927015|NCT01698125||Abdominal surgery|Patients 65 years or older scheduled for abdominal surgery at Oslo University Hospital
89443096|NCT05502484|Experimental|8 weeks baseline followed by Integrative DBT|Integrative Dialectical Behavioural Therapy (DBT) consisting of 8 weeks outpatient pretreatment DBT, 40 weeks inpatient DBT, 24 weeks follow-up including 12 weeks after care DBT and 12 weeks no DBT.
89443097|NCT02171481|Experimental|Dabigatran etexilate polymorph II|
89443098|NCT02171481|Active Comparator|Dabigatran etexilate polymorph I|
89443099|NCT02165631||Group A-Simbinza|Patients in Group A will receive Simbrinza (brinzolamide) 1%/0.2%, with instruction for three times daily (every 8hours) administration of the medication in both eyes for a minimum of 4 weeks and a maximum of 8 weeks of medication therapy.
89443100|NCT02165631||Group B-Timolol|Patients in Group B will receive Timolol 0.5%, with instructions for twice daily administration (every 12 hours) of the medication in both eyes for a minimum of 4 weeks and a maximum of 8 weeks of medication therapy.
89443101|NCT02171559|Experimental|Dabigatran etexilate capsules after enoxaparin ampoules|
89443102|NCT02171559|Active Comparator|Dabigatran etexilate capsules without enoxaparin|
89013233|NCT02961101|Experimental|Anti-PD-1 antibody+chemotherapy|Chemotherapy will be given depends on the cancer type and treatment regimen before enrollment. Chemotherapy was administrated on day1 , followed by Anti-PD-1 antibody 200mg on day2 IV Q3 weeks until progression.
89013234|NCT01602913||Patients with diagnosis of Type II Diabetes|Patients indicating T2DM after the index date (ICD-9-CM 250.x), or 1 diagnostic code and 1 prescription of oral anti-diabetic medications or insulin (or Byetta and Victoza) after the index date
89013235|NCT01602913||Patients without diagnosis of Type II Diabetes|Patients not indicating T2DM
89013236|NCT01602952|Experimental|Radotinib|"Phase 1 : 200mg/kg or 1200mg/m^2~Phase 2 : 400mg Bid"
89013237|NCT00257699|Placebo Comparator|I|Ciprofloxacin placebo and Metronidazole placebo
89443103|NCT02165709|Experimental|Salpingectomy|Participants will be offered a risk-reducing salpingectomy, and if they choose this options the surgeon will proceed with a salpingectomy.
89443104|NCT02165709|Active Comparator|Traditional sterilization|Participants will be offered a risk-reducing salpingectomy, and those that choose a traditional sterilization will be in this treatment arm.
89443105|NCT02964780||Gastric Bypass Surgery|Solid mixed meal tolerance test, MRI, CT, anthropometrics, liver biopsies, fat biopsies, muscle biopsies
89443106|NCT02964780||Conservative weight loss|Solid mixed meal tolerance test, MRI, CT, anthropometrics, liver biopsies, fat biopsies, muscle biopsies
89443107|NCT04901754|Experimental|Camrelizumab Plus Apatinib|camrelizumab 200 mg administered intravenously (IV) on Day 1 of each 21-day cycle plus Apatinib capsules 250 mg given orally
89443108|NCT03343730|Experimental|Non-mydriatic color fundus photography|All participants will receive Non-mydriatic color fundus photography with the RetinaVue camera at an already scheduled annual physical exam or follow up clinic visit with their primary care provider (PCP).
89443109|NCT03343730|Active Comparator|Standard of Care (Control)|All patients will also receive a referral for a dilated eye exam with an eye care professional. A yearly dilated exam as referred by the PCP.
89443110|NCT04499378||SARS-CoV-2|Patients with a positive SARS-CoV-2 PCR test upon admission to the emergency department.
89013238|NCT00257699|Experimental|II|Ciprofloxacin 500 mg bid po Metronidazole - total daily dose dependent on body weight
89013239|NCT01603030|Experimental|moxifloxacin/prednisolone combination|1 gtt, 4x/day, 15 days
89013240|NCT01603030|Active Comparator|moxifloxacin 0,5% + Prednisolone 1%|1 drop of each bottle, BID, 15 days
89013241|NCT01603069|Active Comparator|AZD3241, 300 mg|AZD3241 300 mg BID
89013242|NCT01603069|Active Comparator|AZD3241, 600 mg|AZD3241 600 mg BID
89443111|NCT04499378||H1N1 influenza|Patients with a positive Influenza H1N1 PCR test upon admission to the emergency department.
89443112|NCT02514590|Experimental|Freedom SCS System - 1500 HZ|Epidural Space covering vertebrae level T8-T11 determined by paresthesia mapping for painful area.
89443113|NCT02509208|Experimental|SurgiClot|All qualified subjects will be treated with the SurgiClot haemostatic dressing
89443114|NCT02505620||Surgical|Surgical correction of OSAS disease
89013243|NCT01603069|Placebo Comparator|Placebo|Placebo to AZD3241
89013244|NCT00257738|Experimental|MAGE -A3 vaccine|for those individuals in which tumor tests positive for MAGE-A3
89013245|NCT00257738|Experimental|HPV 16 vaccine|for patients with HPV 16 positive tumor
89013246|NCT01603108|Experimental|Rifaximin Arm|Rifaximin will be initiated post-LT, once the subject is able to tolerate oral medications/diet. Rifaximin will be dosed at 550mg twice daily for 90 days (+/- 10 days) post-LT.
89013247|NCT01603108|Placebo Comparator|Placebo Control Arm|Rifaximin placebo will be initiated post-LT, once the subject is able to tolerate oral medications/diet. Rifaximin placebo will be taken twice daily for 90 days (+/- 10 days) post-LT.
89013248|NCT00290823|Experimental|1|Participants will receive 6 mg dexamethasone daily for 10 days Participants will also receive albendazole and omeprazole.
89443115|NCT02505620||Conservative|Conservative treatment of OSAS disease
89443116|NCT02505152|Experimental|Shunt|Perform percutaneous transhepatic intrahepatic portosystemic shunt
89443117|NCT02514356|Active Comparator|Own adherence|Participants in this group receive a weekly message by SMS. They receive the intervention 'Behavioral: Own Adherence'.
89443118|NCT02514356|Active Comparator|Own and group level adherence|Participants in this group receive a weekly message by SMS. They receive the intervention 'Behavioral: Own and Group Adherence'.
89443119|NCT02504996|Active Comparator|Paracetamol|1 g intravenous paracetamol (Perfalga, Bristol Myers) in 100 ml saline with a rapid infusion.
89443120|NCT02504996|Active Comparator|morphine|0.1 mg/kg morphine in 100 ml saline with a rapid infusion.
89443121|NCT02504996|Placebo Comparator|placebo|100 ml saline
89443122|NCT02509130||Patients who attended RAAC/SAAC.|Patients who have previously attended the Rapid Access Asthma Clinic (RAAC) will be approached for the quantitative study. Patients who went onto the attend the Severe Asthma Assessment Clinics (SAAC) will also be approached for the quantitative and qualitive parts of the study.
89443123|NCT02509130||Patients eligible for RAAC, but DNA'd|Patients identified by the GP search, who did not attend the previous MISSION clinics will be approached to participate in the quantitative part of the study.
89443124|NCT02509130||Asthma Outpatients|Patients who are attending outpatient clinics as new referrals will be approached to participate in the quantitative part of the study.
89443125|NCT02509130||Healthcare Professionals|Healthcare professionals who performed the MISSION RAAC or SAAC will be approached for qualitative interview part of the study only.
89013249|NCT00290823|Experimental|2|Participants will receive 6 mg dexamethasone daily for 10 days, then 8 mg dexamethasone daily for 4 weeks with a 2-week taper. Participants will also receive albendazole and omeprazole.
89013250|NCT01603186|Experimental|Quetiapine Fumarate Tablets 25 mg|Quetiapine Fumarate Tablets 25 mg of M/s Ipca Laboratories Limited, India
89013251|NCT01603186|Active Comparator|Seroquel®|Seroquel® (Quetiapine Fumarate) Tablets 25 mg of M/s AstraZeneca Pharmaceuticals LP, USA
89013252|NCT02484937|Active Comparator|Group 1 (PMS Treatment)|Subjects will be treated monthly for 6 months by Pain Medicine Specialist (PMS) per standard protocol. The PCP will not be involved in the treatment.
89443126|NCT02508818|Other|Cardiovascular measurements|
89443127|NCT02508896|Experimental|AFFITOPE® AT04A+adjuvant|3 injections of 15µg AFFITOPE® AT04A+adjuvant once every 4 weeks and 1 boost immunization at a dose of 75μg, which will be applied one year after the 3rd immunization
89443128|NCT02508896|Experimental|AFFITOPE® AT06A+adjuvant|3 injections of 15µg AFFITOPE® AT06A+adjuvant once every 4 weeks and 1 boost immunization at a dose of 75μg, which will be applied one year after the 3rd immunization
89443129|NCT02508896|Placebo Comparator|Adjuvant without active component|3 injections of Placebo once every 4 weeks and 1 boost immunization which will be applied one year after the 3rd immunization
89443130|NCT02514434|Experimental|Ultrasonography|Subjects will be regularly screened for HCC by ultrasonography with serum AFP(alpha fetoprotein).
89443131|NCT02514434|Experimental|Non-contrast MRI|Subjects will be regularly screened for HCC by non-contrast magnetic resonance imaging(MRI) with serum AFP(alpha fetoprotein).
89443132|NCT02504606|Experimental|Besylsartan|amlodipine besylate 6.944mg+losartan K 100mg
89443133|NCT02504606|Active Comparator|Amosartan|amlodipine besylate 7.841mg+losartan K 100mg
89199924|NCT01633541|Experimental|platinum/docetaxel + AT-101|"platinum/docetaxel + AT-101 The platinum will either be cisplatin or carboplatin as deemed best by the medical oncologist.~(Both Arms) Day #1: Patients will undergo induction chemotherapy with (TP) docetaxel (Taxotere) 75 mg/m2 and cisplatin 100 mg/m2 (or Carboplatin AUC 6).~(AT-101 Arm) Days #1-3: Patients will receive AT-101 40 mg orally twice daily On Day 23 (+/- 3 days), there will be a direct laryngoscopy (DL) with tumor biopsy and blood draw, repeat CT scan of the neck with perfusion within a week biopsy."
89443134|NCT00708422|Experimental|Travoprost|One drop self-administered in the study eye(s) once daily at night for 12 weeks
89443135|NCT00708422|Active Comparator|Latanoprost|One drop self-administered in the study eye(s) once daily at night for 12 weeks
89443136|NCT02165865|Experimental|upper extremity/ hand transplantation|hand transplant on unilateral dominant hand or bilateral upper extremity amputees
89443137|NCT02514200|Experimental|Topography-based CXL (KXL2)|Individualized pulsed topography-based corneal crosslinking; 1 second on, 1 second off; 7.2J/cm2 - 15.0J/cm2; arcuate treatment zone. The Avedro KXL II™ System is used for the crosslinking after epithelial debridement in topical anesthesia and application of topical riboflavin every 3 minutes for 10 minutes.
88927016|NCT01698164|Active Comparator|estradiol plus MPA|"1 mg estradiol valerate, once a day, for 28 days, since the 17th day of taking estradiol valerate adding 4mg medroxyprogesterone acetate, once a day, for 12 days. 28 days forms one cycle. The anticipated duration is 24cycles.~estradiol valerate, 1mg*21/box medroxyprogesterone acetate, 2mg*100/bottle"
88927017|NCT01698164|Experimental|estradiol plus progesterone|"1 mg estradiol valerate, once a day, for 28 days, since the 17th day of taking estradiol valerate adding 200mg progesterone capsule, once a day, for 12 days. 28 days forms one cycle. The anticipated duration is 24cycles.~estradiol valerate, 1mg*21/box progesterone capsule, 100mg*6/box"
88927018|NCT01698164|Experimental|Ximingting tablet|1 tablet of cimicifuga rhizoma extract, tid 100mg*15*2/box The anticipated duration is 2 years.
88927019|NCT01698177|Active Comparator|Group A|This group will receive the influenza vaccine preoperatively.
88927020|NCT01698177|Active Comparator|Group B|Group B will receive the influenza vaccine postoperatively, prior to hospital discharge.
88927021|NCT01698177|No Intervention|Group C|Group C subjects have already received the seasonal flu vaccine.
88927022|NCT01698177|Placebo Comparator|Group D|Group D subjects have refused the vaccine, but agree to have serum titers drawn.
88927023|NCT01698190|Active Comparator|Fine needle aspiration (FNA)|Endoscopic ultrasound guided needle tissue acquisition: Tissue acquisition using a standard FNA needle
88927024|NCT01698190|Active Comparator|Fine needle biopsy (FNB)|Endoscopic ultrasound guided needle tissue acquisition: Tissue acquisition using a new Core needle (Procore; Fine Needle Biopsy).
88927025|NCT01698203|Experimental|ropivacaine|
88927026|NCT01698203|Placebo Comparator|placebo|
88927027|NCT01698216||Consta Sustenna switching|The patients group who switched to paliperidone palmitate from risperidone long acting injection
88927028|NCT01698229||Group 1|Study cohort is comprised of healthy children, ages 2yrs - 8yrs, who are already undergoing a lumbar puncture procedure at New York Presbyterian Hospital for clinical or diagnostic purposes.
88927029|NCT01698242|Experimental|Enhanced Training|The Enhanced Training intervention follows a multi-level strategy in which both the patient and their PCP are intervened upon concurrently. Randomization occurs at the PCP-level, that is, patients are assigned to the Enhanced Training group only if their PCP has been enrolled and randomized to this group. Descriptions of the intervention on the PCP-level and patient-level are provided in the intervention section.
88927030|NCT01698242|Active Comparator|Enhanced Education|The Enhanced Education intervention follows a multi-level strategy in which both the patient and their PCP are intervened upon concurrently. The intervention strategy revolves around providing nominal information through the mail. Randomization occurs at the PCP-level; that is, patients are assigned to the Enhanced Education group only if their PCP already has been enrolled and randomized to this group. Description of the intervention on the PCP-level and patient-level is provided in the intervention section.
89443138|NCT02514200|Active Comparator|Conventional pulsed CXL (pCXL)|Conventional pulsed corneal crosslinking; 1 second on, 1 second off; 5.4 J/cm2; 8 mm central treatment zone. The Avedro KXL II™ System is used for the crosslinking after epithelial debridement in topical anesthesia and application of topical riboflavin every 3 minutes for 10 minutes.
89443139|NCT04645797|Experimental|APR003 Dose Escalation|This portion of the study will evaluate the safety and pharmacokinetics of a range of APR003 doses administered once a week for 21 days in subjects with advance colorectal cancer (CRC) with metastases to the liver and to determine the RP2D.
89443140|NCT02165943||Vitoss Bone Graft with BMA|Patients with a benign bone lesion of the extremity or pelvis for which surgical curettage age was recommended and who received Vitoss bone graft with BMA to fill the cavity.
89199925|NCT01633541|Active Comparator|Active Comparator arm|"(Both Arms) Day #1: Patients will undergo induction chemotherapy with (TP) docetaxel (Taxotere) 75 mg/m2 and cisplatin 100 mg/m2 (or Carboplatin AUC 6).~Day #23 (+/- 3 days): Patients will undergo a direct laryngoscopy (DL) with biopsy. Patients will also undergo a repeat CT scan of the neck with perfusion within a week (+/-) of their perspective biopsies."
89199926|NCT01399372|Active Comparator|Chemotherapy|Rituximab, methotrexate, procarbazine for four 28-day cycles with vincristine for the first two cycles, followed 3-5 weeks later by two 28-day cycles of cytarabine.
89199927|NCT01399372|Experimental|Chemotherapy + Low-Dose WBRT|Rituximab, methotrexate, procarbazine for four 28-day cycles with vincristine for the first two cycles, followed 2-5 weeks later by 3 weeks of low-dose whole-brain radiotherapy (WBRT), followed 3-5 weeks later by two 28-day cycles of cytarabine.
89199928|NCT01267604|Active Comparator|Recombinant FSH|225IU rFSH
89199929|NCT01267604|Experimental|Recombinant FSH Inositol Melatonin|225IU rFSH, 4g Inositol and 3mg Melatonin
89199930|NCT01241227||Chronic liver disease|All patients with chronic liver disease followed using FibroScan and non-invasive markers
89443141|NCT02165943||Vitoss bone graft|Patients with a benign bone lesion of the extremity or pelvis for which surgical curettage was recommended and who received Vitoss bone graft to fill the cavity.
89443142|NCT02508740|Experimental|normal renal function|Healthy subjects with normal renal function (Stage 1, >90 mL/min) will receive a single oral dose of 0.25 mg bevenopran.
89443143|NCT02508740|Experimental|mild renal impairment|Patients with mild renal impairment (Stage 2, 60-89 mL/min) will receive a single oral dose of 0.25 mg bevenopran.
89443144|NCT02508740|Experimental|moderate renal impairment|Patients with moderate renal impairment (Stage 3, 30-59 mL/min) will receive a single oral dose of 0.25 mg bevenopran.
89443145|NCT02508740|Experimental|severe renal impairment|Patients with severe renal impairment (Stage 4, <30 mL/min) will receive a single oral dose of 0.25 mg bevenopran.
88927031|NCT01698255|Experimental|ENGAGE|"ENGAGE is a stepped care psychotherapy based on what is known about how older adults respond to depression interventions. Stepped care is a model of treatment that starts with the minimum effective therapeutic techniques first, and then based on how well people respond to treatment, additional therapeutic techniques are added until people are recovered from their depression. The steps of ENGAGE are:~basic social and physical engagement, which has been found to be a very effective depression strategy for most older adults;~the addition of strategies to address clinical features of depression interfering with treatment engagement, namely affect regulation, pessimism, and disorganization."
88927032|NCT01698255|Active Comparator|Standard of Care Psychotherapy|The comparison group for this study will be the current standard of care psychotherapy offered by Westchester Jewish Community Services (WJCS) therapists. This type of psychotherapy is often supportive or eclectic in nature. Therapists will focus on helping the subject to express feelings and focus on strengths and abilities in working through current difficulties and transitions. Therapists assigned to provide standard psychotherapy to eligible participants will receive training and supervision from WJCS staff consistent with agency practice.
88927033|NCT01698346|No Intervention|control|50 unvaccinated pregnant women
88927034|NCT01698346|Active Comparator|Pertussis vaccine (Boostrix®, GSK Biologicals, Rixensart)|50 pregnant women vaccinated with pertussis vaccine
88927035|NCT01698372|Experimental|Prevena device (Group A)|Group A will have the VAC Prevena portable device applied to the saphenous vein harvest site after standard wound closure following coronary artery bypass surgery.
88927036|NCT01698372|No Intervention|Conventional dressing (Group B)|Group B will have conventional dry dressing applied to the saphenous vein harvest site after standard wound closure following coronary artery bypass surgery.
88927037|NCT01698385|Active Comparator|Lifestyle counseling|
88927038|NCT01698385|No Intervention|Control, just measurements|
88927039|NCT01698398|Experimental|CF-LVAD pumpspeed.|Optimal pumpspeed setting of CF-LVAD during exercise on ergometric bicycle.
88927040|NCT01698437|Other|Transcranial MR-Guided Focused Ultrasound for Brain Tumors|
88927041|NCT01698450|Other|Focused Ultrasound for Movement Disorders|
88927042|NCT01698476|Active Comparator|vitamin D (cholecalciferol) and PBA (sodium phenylbutyrate)|Dose of interventions: 5,000 IU of vitamin D (cholecalciferol tablets) once daily and 500 mg PBA (sodium phenylbutyrate tablets) twice daily for 16 weeks.
88927043|NCT01698476|Placebo Comparator|Placebo tablets|Placebo tablets for vitamin D once daily and placebo tablets for PBA (phenylbutyrate) twice daily for 16 weeks.
88927044|NCT01698515||Anti-TNF subgroup|"anti - TNF subgroup~20 subjects with RA, who are starting TNF inhibitors based on the decision of their treating rheumatologist, will be recruited from the clinic. Patients will be starting commercially available anti-TNF agents that have already been authorized for insurance coverage. We are not requesting anti-TNFs or other drugs specifically for patients enrolled in this study from any pharmaceutical company. Patients will also continue on their background MTX and corticosteroids if they are taking these agents, and MTX will be required for patients taking Infliximab or Golimumab as per approved indication. No medications will be supplied through the study.~--------------------------------------------------------------------------------"
88927045|NCT01698541|Experimental|Tacni|Tacrolimus administered as generic formulation Tacni in accordance with standard protocol at the transplant center
88927046|NCT01698541|Active Comparator|Prograf|Tacrolimus administered as Prograf in according to standard protocol at the transplant center
89199931|NCT01087125||Pregnant RA patients with abatacept exposure during pregnancy|
89199932|NCT01063517|Experimental|1|Olaparib + paclitaxel
89199933|NCT01063517|Active Comparator|2|paclitaxel + placebo
89199934|NCT01047111|Active Comparator|Ivor-Lewis Procedure|Arm A: Esophagectomy was conducted through right side thoracotomy plus midline laparotomy approach:Ivor-Lewis Procedure.
89199935|NCT01047111|Active Comparator|Sweet Procedure|Arm B: Esophagectomy was conducted through left side thoracotomy or thoracoabdominal incision: Sweet Procedure
89199936|NCT00920621|Experimental|Vitamin D treatment|vitamin D treatment plus prenatal multivitamins
89199937|NCT00920621|Placebo Comparator|placebo|placebo plus prenatal multivitamins
89199938|NCT00903591||1|All women will be interviewed by telephone using the a similar questionnaire as used in the parent study. DNA samples will be obtained either via blood samples drawn during a home or clinic visits, or an Oragene Saliva DNA Self-Collection Kit sent to the participant's home.
89199939|NCT00820430||Control--Non-Osteoporotic Knee|Kellgren-Lawrence (KL) scale score of 0, Age: 18-35 years
89443146|NCT02508740|Experimental|End Stage Renal Disease (ESRD)|Patients with End Stage Renal Disease (ESRD) receiving dialysis for at least 3 months preceding the initial dose in this study (Stage 5) will participate in 2 treatment periods and will receive a single oral dose of 0.25 mg bevenopran at 3 hours after completion of the last hemodialysis session of the week in Period 1 and a single oral dose of 0.25 mg bevenopran at 3 hours before initiation of the last hemodialysis session of the week in Period 2
89199940|NCT00820430||Minimal Osteoarthritis, Knee|Kellgren-Lawrence (KL) scale score of 1 or 2, Age: Older than 18; no upper limit
89199941|NCT00820430||Moderate Osteoarthritis, Knee|Kellgren-Lawrence (KL) scale score of 3, Age: Older than 18; no upper limit
89443147|NCT02167659|Experimental|BIS Assessment|"Patients will undergo measurements by trained staff. Measurements will be performed pre-op and at 3, 6, 12, 15*, 18, 21*, 24, and 36 months post-op. Measures include L-Dex, skin assessment and self-report forms. Patients with < 6.5 L-Dex units change will continue follow-up for 36 months. Patients with an L-Dex value change ≥ 6.5 will undergo circumference measurement and begin treatment for 4 weeks with a 23-32 mmHg compression sleeve with gauntlet. At the end of 4 weeks patients will have their arms measured. Those demonstrating improvement will continue with follow up. Those not demonstrating improvement will be removed from the study and their medical oncologist or surgeon will be notified.~*At discretion of the site PI or attending physicians."
89443148|NCT02167659|Active Comparator|Tape Measure|"Patients will undergo measurements by trained staff. Measurements will be performed pre-op and at 3, 6, 12, 15*, 18, 21*, 24, and 36 months post-op. Measures include arm volume (tape measure), skin assessment and self-report forms. Patients with no volume increase will continue follow-up for 36 months. Patients with a volume change of between ≥ 5% and < 10% in the at-risk limb will undergo L-Dex testing and begin treatment for 4 weeks with a 23-32 mmHg compression sleeve with gauntlet. At the end of 4 weeks patients will have their arms measured. Those demonstrating improvement will continue with follow up. Those not demonstrating improvement will be removed from the study and their medical oncologist or surgeon will be notified.~*At discretion of the site PI or attending physicians."
89443149|NCT02504684|Active Comparator|1470-nm|Endovenous 1470-nm diode laser
89443150|NCT02504684|Experimental|1920-nm Group|Endovenous 1920-nm diode laser
89443151|NCT03540303|Experimental|CAR19 T cells carrying cytoplasmic activated PD-1|patients with refractory/relapsed B-NHL receive a preconditioning before infusion of CAR T cells.
89443152|NCT05142579|Experimental|ENDOTRACHEAL TUBE HOLDER|Endotracheal tube holder was used for endotracheal tube detection of patients in this group.
89443153|NCT05142579|Active Comparator|BANDAGE|The bandage was used for endotracheal tube detection of patients in this group.
89443154|NCT02504762|Experimental|Treatment: HCR|Participants will be randomized into the treatment or control group. In the treatment group, participants will be treated with PCI and MICS CABG. In the control group, participants will be treated with conventional CABG for their multivessel CAD.
89443155|NCT02504762|Active Comparator|Control: Conventional CABG|Participants will be randomized into the treatment or control group. In the treatment group, participants will be treated with PCI and MICS CABG. In the control group, participants will be treated with conventional CABG for their multivessel CAD.
89443156|NCT02171637|Experimental|BIBW 2992|
89443157|NCT02166021|Experimental|IT- Treated|Injection to IT (Group 1). After 6 months, 8 patients (group 1A) will be treated with MSC once again in IT, and 8 additional patients (group 1B) will receive a placebo.
89443158|NCT02166021|Experimental|IV - Treated|Injection to IV (Group 2). After 6 months, 8 patients (group 2A) will be treated with MSC once again in IV, and 8 additional patients (group 2B) will receive a placebo.
89443159|NCT02166021|Placebo Comparator|Placebo|Placebo at the first injection (group 3). After 6 months, 8 patients (group 3A) will be treated with MSC in IT, and 8 additional patients (group 3B) will be treated with MSC in IV.
89443160|NCT02504528|Experimental|allergic asthma|asthma patients that sensitive to house dust mites.
89443161|NCT02504528|Experimental|normal controls|normal controls with or without sensitive to house dust mites.
89443162|NCT02171715|Experimental|BIBW 2992 MA2, final formulation|
89443163|NCT02171715|Experimental|BIBW 2992 MA2, trial formulation II|
89443164|NCT02171715|Active Comparator|BIBW 2992 MA 2 drinking solution|
89443165|NCT02760069|Active Comparator|Inhaled ISO + oral ondansetron|Inhaled isopropyl alcohol pads as needed for nausea (up to q30 minutes) and drink oral elixir comprising ondansetron (4 mg).
89443166|NCT02760069|Experimental|Inhaled ISO + oral placebo|Inhaled isopropyl alcohol pads as needed for nausea (up to q30 minutes) and drink oral placebo elixir.
88927047|NCT01698567|Active Comparator|Antithrombin III|"Product- Antithrombin III is derived from pooled human plasma~ATIII will be dosed using the formula recommended by the manufacturer:~(goal activity - baseline activity) x weight (kg) x .714 (Assume: start with 35% activity [7], goal 120% activity[18], so dose = 120-35 x wt (kg) x .714, e.g. 5 kg infant: 85 x 5 x .714 = 303 units)~a."
88927048|NCT01698567|Placebo Comparator|Placebo|placebo (normal saline)
88927049|NCT01698580|Active Comparator|usual care|The control group will receive a baseline assessment to identify risk factors for falls and will be referred to their clinicians with a report of individual modifiable risk factors to be managed without any specific guidance: referral to routine services, treatments or any specific orientation will be at the discretion of their primary clinicians. So, further management of each participant in the control group will be individualized, with no specific protocol. Interventions will be recorded. Participants will receive a leaflet with basic orientations for fall prevention.
88927050|NCT01698580|Experimental|Multifactorial Falls Prevention Program|12 week intervention for 10 to 12 participants with sessions once a week, lasting for 2 hours, consisting of: On-site exercises (progressive body balance exercise program),Home-based exercise program, Educational and Behavioural sessions and management of modifiable risk factors.
88927051|NCT01698593|Active Comparator|Ring Finger Nerve Block|
88927052|NCT01698606|Active Comparator|Secondary lifestyle intervention arm|6-month wait list group. Second arm to receive multidisciplinary, family-centered lifestyle intervention with behavioral counseling, following of completion of main 6-month intervention for arm 1.
88927053|NCT01698606|Experimental|Primary lifestyle intervention arm|First arm to receive multidisciplinary, family-centered lifestyle intervention with behavioral counseling
88927054|NCT01698619||Climbers on Mount Aconcagua|The Cohort consists of volunteers climbing Mount Aconcagua.
88927055|NCT01698632||benign-looking adnexal masses|
88927056|NCT01698645||PecFent®|
88927057|NCT01698671|Other|InterGard Synergy Vascular Graft|
88927058|NCT01698697|Active Comparator|U100|
88927059|NCT01698697|Experimental|U200|
88927060|NCT01698723|Active Comparator|Ribavirin|1000 mg (5 capsules)
88927061|NCT01698723|Placebo Comparator|Placebo|5 capsules of placebo
88927062|NCT01698736|Active Comparator|Semiselective IA|Semiselective immunoadsorption (GAM peptide adsorber)
88927063|NCT01698736|Experimental|Semiselective IA + membrane filtration|Semiselective immunoadsorption (GAM peptide adsorber) in combination with membrane filtration
88927064|NCT01698749|Experimental|Ozurdex in diabetic macular edema|Intravitreal ozurdex given in patients with diabetic macular edema and patients followed up for change in central macular thickness and visual acuity over period of 6 months
88927065|NCT01698762||Osteoarthritis (OA)|"One OA group will watch a DVD - Multimedia Patient Decision Aids (MM-PtDAs) of information about their disease type.~One OA group will read a booklet - Comparative Effectiveness Research Summary Guide (CERSG) about their disease type.~Questionnaires completed at baseline, 3, and at 6 months."
88927066|NCT01698762||Osteoporosis (OP)|"One OP group will watch a DVD - Multimedia Patient Decision Aids (MM-PtDAs) of information about their disease type.~One OP group will read a booklet - Comparative Effectiveness Research Summary Guide (CERSG) about their disease type.~Questionnaires completed at baseline, 3, and at 6 months."
88927067|NCT01698762||Rheumatoid Arthritis (RA)|"One RA group will watch a DVD - Multimedia Patient Decision Aids (MM-PtDAs) of information about their disease type.~One RA group will read a booklet - Comparative Effectiveness Research Summary Guide (CERSG) about their disease type.~Questionnaires completed at baseline, 3, and at 6 months."
88927068|NCT01698788|Experimental|TPHM removal without ozurdex|Comparison of taut posterior hyaloid removal with (Group B)and without intraoperative ozurdex(Group A)
88927069|NCT01698788|Experimental|TPHM removal with ozurdex|Comparison of TPHM removal with (Group B) and without (Group A)Ozurdex
88927070|NCT01698827||Kangaroo|"20 patients managed by Kangaroo gastrostomy tubes. Patients will be submitted to initial screening and tube replacement, followed tube assessment visits every two months, till 6 months."
88927071|NCT01698827||Cook|"20 patients receiving Wilson Cook gastrostomy tubes.Patients will be submitted to initial screening and tube replacement, followed tube assessment visits every two months, till 6 months."
88927072|NCT01698827||Silmag|"20 patients managed by Silmag gastrostomy tubes.Patients will be submitted to initial screening and tube replacement, followed tube assessment visits every two months, till 6 months."
88927073|NCT01698827||Freka|"20 patients carrying Freka gastrostomy tubes.Patients will be submitted to initial screening and tube replacement, followed tube assessment visits every two months, till 6 months."
88927074|NCT01698827||Bard|"20 patients using the Bard gastrostomy tube. Patients will be submitted to initial screening and tube replacement, followed tube assessment visits every two months, till 6 months."
88927075|NCT01698866|Experimental|vaccin GenHevac B Pasteur|vaccin GenHevac B Pasteur (Suspension for injection in pre-filled syringe / 20 μg microgram(s)Per day). In total, 3 injections at M0, M1 and M6
88927076|NCT01698931|Experimental|Treatment period 1|
88927077|NCT01698931|Active Comparator|Treatment period 2|
88927078|NCT01698931|Placebo Comparator|Treatment period 3|
89443167|NCT02760069|Active Comparator|Inhaled placebo + oral ondansetron|Inhaled normal saline pads as needed for nausea (up to q30 minutes) and drink oral placebo elixir.
89443168|NCT02504138|Experimental|Desflurane balanced anesthesia group|
89443169|NCT02504138|Active Comparator|Propofol total intravenous anesthesia group|
89443170|NCT04499144|Experimental|modified buccal flap and subepithelial connective palatal flap|
89199942|NCT00311324|Experimental|Special Intervention|One individual counseling visit, twelve group sessions, three postcards, and twelve telephone calls.
89443171|NCT02166099||SpyGlass Choledochoscopy procedure|Any patient who has undergone SpyGlass Choledochoscopy procedures for diagnosis and/or treatment of a pancreatico-biliary disorder
89443172|NCT02508584|Experimental|Intervention|This is a single patient treatment IND
89443173|NCT02166177|Experimental|Autologous Regulatory T cell therapy|Autologous regulatory T cell therapy infused intravenously (2 dose groups: low dose and high dose)
89443174|NCT02508662||Advanced Cancer (Refractory) with Genomic Mutation|Participants with advanced cancer who have exhausted standard treatment option and have no potential clinical trial available, and who have potentially actionable alterations on genomic profiling.
89443175|NCT02171793|Experimental|BI 1744 CL|
89443176|NCT02171793|Placebo Comparator|Placebo|
89443177|NCT02508506|Experimental|ALKS 5461|Sublingual tablet
89443178|NCT02171871|Experimental|CONTROL GROUP|"Healthy non-smoking volunteers (18-40 years old) will be subject, after giving their brief medical history, to IOS and to the nitrogen washout test. The IOS will be conducted in four positions (standing, sitting, right and left lateral decubitus), whereas the nitrogen washout test in two (sitting and decubitus).~Then the subjects will be exposed to a smoking environment for 20 minutes."
89443179|NCT02513810|Experimental|Short-term DAPT after Biofreedom|
89443180|NCT02513810|Active Comparator|Long-term DAPT after BioMatrix or Ultimaster|
89443181|NCT02167737|Experimental|Bedside Decision Aid Group|This arm will include study participants who are randomized to the group utilizing the bedside decision aid, which has hospital staff arrange fall-risk reduction interventions (e.g., home safety checks, exercise programs, vision checks, etc.).
89443182|NCT02167737|Active Comparator|Control Arm|"Participants in the control/comparator arm will experience the same study procedures with the exception of not using the Bedside Decision Aid and instead being given the Centers for Disease Control (CDC) brochure, What You Can Do to Prevent Falls, and arranging for their own fall prevention strategies."
89443183|NCT03121742|Placebo Comparator|Treatment as usual [TAU] plus assessment|Patients will receive standard care plus assessment.
89443184|NCT03121742|Experimental|Treatment as usual [TAU] plus intervention|Patients will receive standard care plus an ecological momentary intervention.
89443185|NCT02166255|Experimental|Treatment (APN401)|Patients receive autologous siRNA-transfected peripheral blood mononuclear cells APN401 IV over 30 minutes.
89443186|NCT02508272||Trauma patients|age ≥18 y ISS ≥ 17 points admission < 6 h.
89443187|NCT02166411|Experimental|myomectomy using barbed sutures|.Myoma bed is sutured with barbed sutures
89443188|NCT02166411|Active Comparator|myomectomy using conventional sutures|Myoma bed is sutured with conventional sutures
89443189|NCT02508350|Experimental|daptomycin|Daptomycin for injection 10-12mg/kg/day,determination of plasma concentration
89443190|NCT02171949|No Intervention|Control group|
89443191|NCT02171949|Active Comparator|Bone marrow mononuclear cell therapy|
89443192|NCT02503826|Experimental|1.5 SF|Sufentanil,1.5mcg/kg
89443193|NCT02503826|Experimental|2.0 SF|Sufentanil, 2.0mcg/kg
89443194|NCT02503826|Experimental|2.5 SF|Sufentanil, 2.5mcg/kg
89443195|NCT02172027||Lung Cancer, Pleural effusion|
88927079|NCT01698944|Experimental|Somatropin|
88927080|NCT01698957||UA Doppler Velocimetry|Any patient eligible for an Ultrasound greater than or equal to 18 weeks gestation without a fetal or uterine anomaly.
88927081|NCT01698970|Experimental|1 = Tested product|
88927082|NCT01698970|Placebo Comparator|2 = Control product|
88927083|NCT01698996|Active Comparator|No Packing|No Packing
88927084|NCT01698996|Experimental|Packing|Packing
88927085|NCT01699009|Experimental|Vegan diet|The diet group will be asked to follow a low-fat, vegan diet for 16 weeks.
88927086|NCT01699009|Placebo Comparator|Supplement group|The supplement group will follow an unrestricted diet, but will be given a pill containing a small, clinically insignificant amount of omega- 3 oils and vitamin E, which will serve as a placebo.
88927087|NCT01699035||stroke survivors|stroke survivors who have either returned to work, have thought about returning to work, or have tried to return to work
89443196|NCT02166489|Experimental|mesenchymal stem cell transplantation|Intravenous injection of mesenchymal stem cell in patients with PKD
89443197|NCT03121664|Experimental|Cohort 1|
89443198|NCT02503904|Active Comparator|TAD+IVAD|
89443199|NCT02503904|Active Comparator|IVAD|
89443200|NCT02172105|Experimental|BI 1744 CL|
89443201|NCT02172105|Placebo Comparator|Placebo|
89443202|NCT05142423|Experimental|AK109+AK104|AK104: 10mg/kg (d1, q3w); AK109: 10mg/kg or 15mg/kg(d1, q3w)
89443203|NCT04498676|Experimental|Test product|
89443204|NCT02261259|Experimental|Immediate treatment|This arm receives osteopathic manipulative treatment shortly after enrollment
89443205|NCT02261259|Experimental|Delayed treatment|This arm receives osteopathic manipulative treatment approximately 4 weeks after enrollment
89443206|NCT02261259|No Intervention|Healthy control (no neck pain)|In this arm, healthy controls are tested at baseline.
89443207|NCT02513654|Experimental|Lamotrigine dispersible tablets 25mg, 50mg, 100mg|Each subjects will start dosing with lamotrigine 25mg dispersible tablet once daily at Day 1 and remain at this dose level for 2 weeks (Days1-14), then will be titrated to 50 mg once daily at Day 15 and last for weeks 3-4 (Days 15-28), and then titrated to 100 mg once daily at Day 29 during weeks 5-6 (Days 29-42).
89443208|NCT02504060|Placebo Comparator|Starch capsule|During the 12- weeks treatment phase of the study, the daily dose of 3 tablets will be taken 30 minutes after breakfast, lunch and supper.
89443209|NCT02504060|Experimental|N-acetyl-D-glucosamine|During the 12- weeks treatment phase of the study, the daily dose of 100mg*3 (3 tablets) will be taken 30 minutes after breakfast, lunch and supper.
89443210|NCT03538977|Active Comparator|Conventional physiotherapy (GP)|The sample will be evaluated once a day in the morning until they complete at least 11 intervention sessions of conventional physiotherapy in five moments: immediately before therapy, immediately after, 15, 30 and 60 minutes after the intervention.While they are in need of intensive care and hospitalized in the NICU, infants will receive conventional physiotherapy care three times a day. After discharge to the intermediate care unit (ICU), patients will receive care only once a day. Evaluations and interventions will be carried out five days a week (Monday to Friday), according to the logistics of the unit.
89443211|NCT03538977|Experimental|GP + hydrotherapy (GH)|The sample will be evaluated once a day in the morning until they complete at least 11 intervention sessions of hydrotherapy in five moments: immediately before therapy, immediately after, 15, 30 and 60 minutes after the intervention. While they are in need of intensive care and hospitalized in the NICU, infants allocated to GH, hydrotherapy will be performed once a day, associated with two sessions of conventional physiotherapy. After discharge to the intermediate care unit (ICU), patients will receive care only once a day, both conventional physiotherapy and hydrotherapy. Evaluations and interventions will be carried out five days a week (Monday to Friday), according to the logistics of the unit.
89443212|NCT02503748|Experimental|Intervention|Online Tutorial
89443213|NCT02167971|Experimental|Active Coil|The patients assigned to this group will undergo repetitive Transcranial Magnetic Stimulation over 10 sessions (each one with 2,000 pulses) on left dorsolateral prefrontal cortex.
89443214|NCT02167971|Sham Comparator|Sham|The patients assigned to this group will undergo 10 sessions of rTMS but with an inactive coil, which will not generate electromagnetic pulses.
89443215|NCT02513888|Experimental|Vitamin D + diet and lifestyle|subjects will be given vitamin D supplement will be given along with diet nd lifestyle modification
89443216|NCT02513888|Placebo Comparator|placebo + diet and lifestyle|Subjects will be given placebo with diet and lifestyle
89443217|NCT00101595|Experimental|1|
89443218|NCT02513576|Experimental|Physiotherapy exercises|Two strategies of abdominal exercises with and without movement of the upper limbs applied in patients with sternal instability as randomization.
89443219|NCT02503592|Active Comparator|Cochlear Implant group - Vestibular testing|Adult patients who have been implanted with a Med-El Cochlear implant device within the last 3 months who completed pre-op vestibular testing as standard of care. These subjects will undergo a series of post-op vestibular testing, at the 3 month and 12 month follow up visits
89199943|NCT00311324|Experimental|Delayed Intervention|"Direct mailing of two American Dietary Association pamphlets (Healthy Eating and Staying Alive) and three bimonthly newsletters providing general health information and study updates."
89199944|NCT00964600|Experimental|TAP blockade|bilateral TAP blockade at the end of cesarean delivery
89443220|NCT02503592|No Intervention|Control Group - existing historical vestibular data|This group will consist of existing historical vestibular testing data only. No subjects will be enrolled on this arm.
89443221|NCT02174757|Experimental|Inersan|Inersan - 2 Lozenges daily (one lozenge in morning and one lozenge in night) for 2 weeks. Each lozenge contains at least 1 billion CFU of Lactobacillus brevis CD2.
89443222|NCT02174757|Experimental|Inersan and Doxycycline together|"Doxycycline: 1 Tablet once daily (in afternoon) for 2 weeks. Each tablet contains 100 mg Doxycycline.~Inersan - 2 Lozenges daily (one lozenge in morning and one lozenge in night) for 2 weeks. Each lozenge contains at least 1 billion CFU of Lactobacillus brevis CD2."
89443223|NCT02174757|Active Comparator|Doxycycline|Doxycycline: 1 Tablet once daily (in afternoon) for 2 weeks. Each tablet contains 100 mg Doxycycline.
89443224|NCT03121196||deprived women|Two groups of women will be compared deprived women and non-deprived women
88927088|NCT01699048|Other|Hybrid group|Hybrid approach (Minimally invasive off-pump revascularization of the left anterior descending artery (LAD) with the left internal mammary artery (LIMA) bypass followed by consecutive percutaneous coronary intervention (PCI) in the rest of the arteries with drug eluting stents (DES) (Hybrid group, n=50)
88927089|NCT01699048|Other|PCI|Multi-vessel PCI with DES (MV-PCI group, n=50)
88927090|NCT01699048|Other|CABG|Coronary artery bypass graft (CABG) treatment (CABG group, n=50)
88927091|NCT01699061|Placebo Comparator|Placebo|Placebo tablet administered with a meal twice a day on Day 1
88927092|NCT01699061|Experimental|Tivantinib|3 tivantinib tablets 120 mg administered twice daily with a meal starting on Day 2
88927093|NCT01699074|Experimental|1 gram of White Korean Ginseng|1 gram of White Korean Ginseng
89443225|NCT03121196||non-deprived women|Two groups of women will be compared deprived women and non-deprived women
89443226|NCT03121508|Other|TODAY Project|All participants will attend individualized self-management sessions led by an occupational therapist. The classes will focus on promoting modifying daily activities, habits, roles, and routines to promote healthy lifestyles for individuals with type 2 diabetes.
89443227|NCT02168127|Experimental|Active drug group|PRC-063 - Active methylphenidate hydrochloride extended-release capsules drug group
89443228|NCT02513420|Experimental|Perineal muscle training|This group will recibe a training of a combination of perineal massage and pelvic floor muscle excersice that will start after 33 weeks of gestation. Every week until the childbith, They will be evaluated with a diary.
89443229|NCT02513420|No Intervention|Usual prental care|Usually pregnant women have not a training focused in pelvic floor muscle, so this group won't receive any indication of pelvic floor training except if They complains of urinary incontinence.
88927094|NCT01699074|Experimental|3 grams of White Korean Ginseng|3 grams of White Korean Ginseng
88927095|NCT01699074|Experimental|6 grams of White Korean Ginseng|6 grams of White Korean Ginseng
89013253|NCT02484937|Experimental|Group 2 (PCP Treatment)|Subjects will be treated monthly for 6 months by the Primary Care Provider (PCP).The PCP will be involved and a multimodal therapeutic strategy will be communicated to the PCP by the PMS. The PCP will make dosage based on an algorithm provided by the PMS on how to adjust drug doses over time. It is not intended that the PCP may have ongoing engagement with the PMS. A direct line of communication will be set up between the PCP and the data integration clinical coordinator to handle serious medical concerns.
89013254|NCT00271284|Experimental|I|
89013255|NCT00271284|Active Comparator|II|
89013256|NCT02480257|Experimental|TARA Intervention group|TARA is comprised of 12 weekly classes delivered in a group format by two trained facilitators with approximately 8-15 participants. The 90 minute sessions are designed to promote skills for autonomic regulation, attention modulation, emotion regulation and cognitive control.
89013257|NCT02487043|Experimental|Dental health coaches|Telephone-based case-management intervention. Contact with families every 2 weeks during one year. Including motivational interviewing, support for dental preventive measures at home, answer questions, care coordination) + conventional protocol (Fluoride prevention program)
89013258|NCT02487043|No Intervention|Control group|Conventional protocol (Fluoride prevention program) and follow-up as usual
89013259|NCT00257816|Experimental|Topotecan|Adding weekly topotecan to cisplatin in patients with primary, locally advanced carcinoma of the cervix receiving pelvic irradiation.
89013260|NCT01603303|Other|Usual Care + Education Materials|Completion of 8 or 9 brief questionnaires at start of study and 6 and 12 months afterwards. Questionnaires should take about 45 to 50 minutes to fill out each time. Participants receive written handout about ways to keep bones stronger during treatment with Aromatase Inhibitors (AIs) and ways to prevent AI side effects such as muscle aches, stiffness, sexual problems, and hot flashes. Water-based vaginal lubricant used during sexual activity.
89013261|NCT01603303|Experimental|Luvena Group|Luvena used vaginally 2 or 3 times a week. Completion of 8 or 9 brief questionnaires at start of study and 6 and 12 months afterwards. Questionnaires should take about 45 to 50 minutes to fill out each time. Participants receive written handout about ways to keep bones stronger during treatment with Aromatase Inhibitors (AIs) and ways to prevent AI side effects such as muscle aches, stiffness, sexual problems, and hot flashes. Participants use an interactive, internet-based website called Tendrils: Sexual Renewal after Cancer before, during and after treatment with AIs. Telephone counseling for up to 30 minutes in weeks 2, 4, 6, 8, 10, 12, 16, 20, and 24. The counselor will follow a manualized program and some sessions will be recorded.
89013262|NCT01603303|Experimental|Hyalo-Gyn Group|Hyalo-Gyn used vaginally 2 - 3 times a week. Completion of 8 or 9 brief questionnaires at start of study and 6 and 12 months afterwards. Questionnaires should take about 45 to 50 minutes to fill out each time. Participants receive written handout about ways to keep bones stronger during treatment with Aromatase Inhibitors (AIs) and ways to prevent AI side effects such as muscle aches, stiffness, sexual problems, and hot flashes. Participants use an interactive, internet-based website called Tendrils: Sexual Renewal after Cancer before, during and after treatment with AIs. Telephone counseling for up to 30 minutes in weeks 2, 4, 6, 8, 10, 12, 16, 20, and 24. The counselor will follow a manualized program and some sessions will be recorded.
89013263|NCT00271323|Experimental|1|Induction chemotherapy followed by concurrent chemoradiotherapy
89013264|NCT00271323|Active Comparator|2|Concurrent chemo-radiotherapy followed by consolidation chemotherapy
89013265|NCT01603342|Experimental|clopidogrel|
89013266|NCT01603342|Placebo Comparator|Placebo|
89013267|NCT01603381|Experimental|CBT-I|Cognitive Behavioral Therapy for Insomnia
89013268|NCT01603381|No Intervention|Monitor Only (M.O.)|
89013269|NCT00290862|Experimental|CORTOSS|Patients prospectively randomized to be treated with Cortoss constitute treatment group.
89013270|NCT00290862|Active Comparator|PMMA|Patients prospectively randomized to be treated with PMMA constitute active control group.
89013271|NCT01603498|Experimental|Dexamethasone 8mg|
89013272|NCT01603498|Experimental|Methylprednisolone|Methylprednisolone 40mg
89013273|NCT01603576|Experimental|Suprachoroidal retinal prosthesis|
89013274|NCT01603654|Experimental|sodium picosulphate/magnesium citrate|
89013275|NCT01603654|Active Comparator|low-volume PEG -ascorbic acid|
89013276|NCT06302569|Experimental|Pembrolizumab + Enfortumab Vedotin|"Patients will be treated with Pembrolizumab q21 plus Enfortumab Vedotin 1,8q21 for 3 cycles (3 infusion of Pembrolizumab and 6 infusion of Enfortumab Vedotin) then radiological imaging will be repeated and patients with SD, PR or CR will continue pembrolizumab until disease progression, or unacceptable toxicities or completion of treatment (17 cycles). Patients with progressive disease after 3 cycles of study intervention will be treated as per clinical practice.~Patients who will experience progressive disease during pembrolizumab monotherapy treatment could restart Enfortumab Vedotin."
89013277|NCT06302556||Lung re-transplant cohort|This cohort includes consecutive participants who underwent lung re-transplantation for chronic lung allograft dysfunction from 2010 to 2020; the immune checkpoints analyses will be conducted on stored specimens from lungs explanted during re-transplantation.
89537077|NCT05726981|Experimental|Patients with nodules treated by thermal ablation|"The study population is a monocentric cohort of patients who underwent thermoablation treatment for benign thyroid nodules 3 years ago. These patients aged >18 years-old were carriers of a benign but troublesome thyroid nodule before thermal ablation, either unique or dominant, i.e. associated with one or more other non-significant nodules (<20 mm) that were subjected to simple ultrasound surveillance. Patients refused, after clear and fair information, surgical management of their nodule. On average, 2 patients have been treated for TA per week in the Thyroid Disease and Endocrine Tumor Department since 2016. Patients systematically benefit from annual clinical and ultrasound monitoring as part of their follow-up in our Department."
89537078|NCT03301025|Active Comparator|Pregabalin group|(n=53):
89013278|NCT06302556||Previous lung transplant cohort|This cohort includes participants who received first bilateral lung transplantation from 2017 to 2020. The immune checkpoints analyses will be conducted on stored specimens from postoperative transbronchial biopsy performed for clinical suspicious of rejection.
89199945|NCT00964600|No Intervention|No TAP|These patients would have usual analgesic drugs after cesarean
89199946|NCT00964756|Experimental|Gene therapy|
89199947|NCT00964834|Experimental|Doxycycline and Valortim|Randomized such that sixteen volunteer subjects to be renadomized to receive Doxycycline and Valortim
89443230|NCT02172183|Experimental|CBT group|This group consist on a combined intervention: CBT group + psychopharmacological treatment. The group program was based on cognitive-behavioral principles and also motivational interviewing techniques to facilitate skills implementation. The treatment comprised 12 manualized sessions with an inattention module and an impulsivity module.
89443231|NCT02172183|Active Comparator|Psychopharmacological treatment|Participants were only visited to monitor their adherence and continuation on medications for ADHD (methylphenidate or atomoxetine) as prescribed by their psychiatrist.
89443232|NCT02174835|Experimental|Cohort A - Period 1|Twice daily dosing orally for 7 days
89443233|NCT02174835|Active Comparator|Cohort A - Period 2|Twice daily dosing orally for 7 days
89443234|NCT02174835|Experimental|Cohort A - Period 3|Twice daily dosing orally for 7 days
89443235|NCT02174835|Experimental|Cohort B - Period 1|Twice daily dosing orally for 7 days
89443236|NCT02174835|Active Comparator|Cohort B - Period 2|Twice daily dosing orally for 7 days
89443237|NCT02174835|Experimental|Cohort B - Period 3|Twice daily dosing orally for 7 days
89443238|NCT02255877|Active Comparator|Zip Surgical Skin Closure|Subjects randomized to receive one knee (left or right) closed with ZipSurgical Skin Closure and the other knee closed with standard staples
89443239|NCT02255877|Active Comparator|Steel Staples|Subjects randomized to receive one knee (left or right) closed with Staples and the other knee closed with ZipSurgical Skin Closure
89443240|NCT02174991|Experimental|0.5% Rho-Kinase Inhibitor|AR-12286 is a novel Rho-kinase inhibitor developed by Aerie Pharmaceuticals, Inc., Bridgewater, NJ. It is a potent Rho-kinase inhibitor with single-digit nanomolar inhibitory activity against Rho-kinase in enzymatic inhibition assays (deLong MA, et al. IOVS 2009; 50: ARVO E-abstract 4058). Mechanism-of action studies in monkeys demonstrate that AR-12286 lowers IOP primarily by increasing aqueous humor outflow through the trabecular meshwork (Wang RF, et al. IOVS 2009; 50:ARVO E-abstract 1465). Rho-kinase AR-12286 is well tolerated and produces clinically and statistically significant ocular hypotensive efficacy in patients with ocular hypertension and glaucoma. It is well tolerated by most of patients and the only side effect was ocular hyperemia in a minority of subjects (Williams, Novack, Van Haarlem, & Kopczynski, 2011). It is currently in phase II testing.
89443241|NCT02174991|Experimental|0.7% Rho-Kinase Inhibitor|AR-12286 is a novel Rho-kinase inhibitor developed by Aerie Pharmaceuticals, Inc., Bridgewater, NJ. It is a potent Rho-kinase inhibitor with single-digit nanomolar inhibitory activity against Rho-kinase in enzymatic inhibition assays (deLong MA, et al. IOVS 2009; 50: ARVO E-abstract 4058). Mechanism-of action studies in monkeys demonstrate that AR-12286 lowers IOP primarily by increasing aqueous humor outflow through the trabecular meshwork (Wang RF, et al. IOVS 2009; 50:ARVO E-abstract 1465). Rho-kinase AR-12286 is well tolerated and produces clinically and statistically significant ocular hypotensive efficacy in patients with ocular hypertension and glaucoma. It is well tolerated by most of patients and the only side effect was ocular hyperemia in a minority of subjects (Williams, Novack, Van Haarlem, & Kopczynski, 2011). It is currently in phase II testing.
89537079|NCT03301025|Placebo Comparator|placebo group|(n=53):
88927096|NCT01699074|Placebo Comparator|3 grams of Wheat Bran Control|3 grams of Wheat Bran Control
88927097|NCT01699074|Active Comparator|500mg of Korean Red Ginseng|500mg of Korean Red Ginseng
88927098|NCT01699100|Experimental|device|In-shoe plantar pressure measurements were performed in 26 patients with diabetic neuropathic feet at baseline condition, and 52 regions of interest (ROIs, with mean peak pressure > 200kPa or with the highest mean peak pressure in the forefoot area) were identified as suitable areas for removal of pegs. Data of in-shoe plantar pressures of the three insole conditions (pre-peg removal, post-peg removal, and post-peg removal plus arch support) were collected. Mean peak pressure (MPP) and pressure-time integral (PTI) were recorded for analysis.
88927099|NCT01699126|Experimental|CPAP, Hypertension|evaluate the effect on FMD, blood pressure and inflammation after CPAP on OSA
88927100|NCT01699126|Active Comparator|CPAP and statin, Hypertension|evaluate the effect on FMD, blood pressure and inflammation after CPAP plus statin on OSA patients
88927101|NCT01699126|Active Comparator|OSA, statin, Hypertension|evaluate the effect on FMD, blood pressure and inflammation after statin treatment on OSA
88927102|NCT01699126|No Intervention|Placebo|We will also measure the FMD, blood pressure and inflammation on patients with only life style modification as in all other patients
88927103|NCT01699139|Active Comparator|positional device|
88927104|NCT01699139|Sham Comparator|lumbar corset|
88927105|NCT01699152|Experimental|TG02 citrate|TG02 citrate capsules given orally.
88927106|NCT01699165|Sham Comparator|Placebo Nasal filter|Placebo treatment
88927107|NCT01699165|Active Comparator|Nasal Filter|Active treatment
88927108|NCT01699191|Active Comparator|Probiotic Mixture|Probiotic mixture
88927109|NCT01699191|Placebo Comparator|Placebo|Placebo
88927110|NCT01699204|Placebo Comparator|Filtered air with placebo|Exposure for 2 hours to filtered air and placebo tablets 3 times daily for 6 days
88927111|NCT01699204|Active Comparator|Diesel exhaust with placebo|Exposure for 2 hours to diesel exhaust and placebo tablets 3 times daily for 6 days
88927112|NCT01699204|Experimental|Diesel exhaust with N-acetylcysteine|Exposure for 2 hours to diesel exhaust and N-acetylcysteine tablets (600 mg) 3 times daily for 6 days
88927113|NCT01699230|Experimental|Omega 3 supplemented patients|To show the existence of a atrial cardiomyocytes membranes modification in omega-3 supplemented patients with coronary atherosclerosis
88927114|NCT01699230|No Intervention|Control group|
88927115|NCT01699256|Experimental|Enhanced strategy|Enhanced implementation strategy
88927116|NCT01699256|Active Comparator|Strategy as usual|Normal implementation strategy
88927117|NCT01699269|Other|brain tumor|
88927118|NCT01699282|Experimental|Group thorough VKA (antivitamin K)education|
88927119|NCT01699282|Active Comparator|control group|
88927120|NCT01699295|Experimental|A+PAAC|Lessons delivered using A+PAAC
89013279|NCT06302556||Prospective lung transplant cohort|This cohort includes participants who will have their first bilateral lung transplant from April 2024 to April 2025. Immunopathological characterization of bronchoalveolar leukocytes and analysis of immuno checkpoints will be performed on leftover material of bronchoalveolar lavage and transbronchial lung biopsy samples performed for clinical suspicious of rejection.
89013280|NCT06302543|Experimental|bone marrow|autologous bone marrow derived mononuclear cells injected 1cc per ovary for 2 ovaries under general anesthesia under ultrasound guide
89013281|NCT06302530|Experimental|Group A (Strayer):|This group will consist of patients with isolated gastrocnemius contracture who will be operated with the Strayer technique. This consists of ultrasound-guided surgical recession of the gastrocnemius tendon distally.
89013282|NCT06302530|Experimental|Group B (Plantar transection):|This group will include patients with mild contracture of the triceps suralis who will undergo surgery by ultrasound-guided transection of the plantar tendon on the medial aspect of the gastrocnemius.
89013283|NCT06302517|No Intervention|non-BIS-guided group (group C)|The depth of anesthesia was not monitored in the non-BIS-guided group (group C).
89013284|NCT06302517|Experimental|BIS-guided group (group B)|The BIS-guided group (group B) underwent intraoperative monitoring of BIS anesthesia depth
89013285|NCT06302504|Experimental|Nature-based mindfulness program|The program will include mindfulness exercises, including body scan, mindful stretching, mindful sitting, and befriending exercise. At least one of the four sessions will be conducted in retreat center in nature area.
89013286|NCT06302491|Experimental|AND017 capsules 8 mg|
89013287|NCT06302491|Experimental|AND017 capsules 12 mg|
89013288|NCT06302491|Experimental|AND017 capsules 16 mg|
89013289|NCT06302491|Placebo Comparator|AND017 Placebo capsules|
89443242|NCT02255955|Experimental|550 mg naproxen sodium and 30mg codeine|Preoperatively patients received oral naproxen sodium codeine, postop contramal infused by PCA, and postoperative contramal consumption, side effects pain intensity measured by VAS.
89537080|NCT05726903|Experimental|Depo SC Home|Participants will be given instructions on home administration of DMPA SC and be provided with all necessary supplies.
89013292|NCT06302452|No Intervention|No Intervention: Standard Care|All trauma patients will receive standard routine care which may include some screening and counseling on gun safety.
89013293|NCT06302452|Experimental|ACTFAST Intervention|During the implementation and maintenance periods, all trauma patients will receive study activities including firearm access screening, counseling on safe storage practices, and referral to safe storage and other community resources as appropriate.
89013294|NCT06302426|Experimental|INI-4001 Monotherapy Dose Escalation - INI-4001 Dose Level 1|For dose-level 1, INI-4001 will be administered intravenously once per week on Days 1, 8 and 15 of a 21-day cycle. A complementary therapy may be introduced in combination with INI-4001.
89013295|NCT06302426|Experimental|INI-4001 Monotherapy Dose Escalation - INI-4001 Dose Level 2|For dose-level 2, INI-4001 will be administered intravenously once per week on Days 1, 8 and 15 of a 21-day cycle. A complementary therapy may be introduced in combination with INI-4001.
89013296|NCT06302426|Experimental|INI-4001 Monotherapy Dose Escalation - INI-4001 Dose Level 3|For dose-level 3, INI-4001 will be administered intravenously once per week on Days 1, 8 and 15 of a 21-day cycle. A complementary therapy may be introduced in combination with INI-4001.
89013297|NCT06302426|Experimental|INI-4001 Monotherapy Dose Escalation - INI-4001 Dose Level 4|For dose-level 4, INI-4001 will be administered intravenously once per week on Days 1, 8 and 15 of a 21-day cycle. A complementary therapy may be introduced in combination with INI-4001.
89013298|NCT06302426|Experimental|INI-4001 Monotherapy Dose Escalation - INI-4001 Dose Level 5|For dose-level 5, INI-4001 will be administered intravenously once per week on Days 1, 8 and 15 of a 21-day cycle. A complementary therapy may be introduced in combination with INI-4001.
89013299|NCT06302426|Experimental|INI-4001 Monotherapy Dose Escalation - INI-4001 Dose Level 6|For dose-level 6, INI-4001 will be administered intravenously once per week on Days 1, 8 and 15 of a 21-day cycle. A complementary therapy may be introduced in combination with INI-4001.
89013300|NCT06302413|Experimental|Virtual Reality|"Participants in this arm will receive the following interventions:~Virtual Reality Park Virtual Reality Avatar"
89013301|NCT06302413|Placebo Comparator|Treatment As Usual|"Participants in this arm will receive the following interventions:~Virtual Reality Park"
89443243|NCT02255955|Active Comparator|300 mg paracetamol and 30 mg codeine|Preoperatively patients received oral paracetamol codeine, postop contramal infused by PCA, and postoperative contramal consumption, side effects pain intensity measured by VAS.
89013302|NCT06302400|Experimental|Radioembolisation with 166Holmium microspheres|
89013303|NCT06302387|Experimental|Acellular Dermal Matrix|This group received vertical soft tissue thickness augmentation using an acellular dermal matrix.
89013304|NCT06302387|Experimental|Soft Tissue Expansion using Tenting Technique|This group underwent soft tissue expansion using a tenting technique with a submerged healing abutment.
89013305|NCT06302374|Experimental|Cohort 1 GR2001 0.01mg/kg/placebo|Four subjects will be randomly assigned to receive either GR2001 or placebo at a 3:1 ratio (i.e. 3 subjects receive GR2001 and 1 with placebo).
89443244|NCT02255955|Placebo Comparator|Placebo|Preoperatively patients received oral placebo tablet, postop contramal infused by PCA, and postoperative contramal consumption, side effects pain intensity measured by VAS.
89443245|NCT02172261|Experimental|Sequence ABC|"Treatment A: BI 10773 once daily from day 1 to 5~Treatment B: BI 10773 and glimepiride once on day 1~Treatment C: Glimepiride once on day 1"
89013306|NCT06302374|Experimental|Cohort 2 GR2001 0.02mg/kg/placebo|Ten subjects will be randomly assigned to receive either GR2001 or placebo at a 4:1 ratio (i.e. 8 subjects receive GR2001 and 2 with placebo).
89013307|NCT06302374|Experimental|Cohort 3 GR2001 0.05mg/kg/placebo/HTIG|24 subjects will be randomly assigned to receive GR2001 or placebo or HTIG(250IU) at a 1:1:1 ratio (i.e. 8 subjects receive GR2001, 8 with placebo and 8 with HTIG).
89013308|NCT06302374|Experimental|Cohort 4 GR2001 0.1mg/kg/placebo|Ten subjects will be randomly assigned to receive either GR2001 or placebo at a 4:1 ratio (i.e. 8 subjects receive GR2001 and 2 with placebo).
89013309|NCT06302374|Experimental|Cohort 5 GR2001 0.2mg/kg/placebo|Ten subjects will be randomly assigned to receive either GR2001 or placebo at a 4:1 ratio (i.e. 8 subjects receive GR2001 and 2 with placebo).
88927121|NCT01699295|Active Comparator|CON|Regular sedentary lessons
89443246|NCT02172261|Experimental|Sequence CAB|"Treatment C: Glimepiride once on day 1~Treatment A: BI 10773 once daily from day 1 to 5~Treatment B: BI 10773 and glimepiride once on day 1"
89443247|NCT02501564|Experimental|Naproxen Sodium Codeine|One tablet twice a day
89443248|NCT02501564|Placebo Comparator|Placebo|One tablet twice a day
89443249|NCT02172339|Experimental|Tiotropium|group comparison (healthy, renal impairment)
89443250|NCT02503670|Other|HealthyDads.ca web-based program|An on-line self-help psychoeducational website tailored to new dads. Psychoeducational learning modules and tools, including a 6 week physical activity challenge..
89443251|NCT02503670|Other|Control group|No access to the intervention. Will complete the same questionnaires as the Healthydads.ca group over the study period.
89443252|NCT02172417|Experimental|Cimetidine + Tiotropium followed by Tiotropium|
89443253|NCT02172417|Experimental|Ranitidine + Tiotropium followed by Tiotropium|
89443254|NCT02501486|Other|ACTH stimulation test|this is a single arm study. An ACTH-stimulation test will be done
88927122|NCT01699308|Experimental|Genotropin|10 persons with TBI and GHD will receive daily rhGH injections titrated to bring their GH levels into the normal range for one year. Treatment is initiated using Genotropin (rhGH) at an initial daily dose of 200mcg/day subcutaneously with a titration schedule calling for an increase in daily dosage by 200 mcg every two months until the target daily dose, 600 mcg/day, is achieved. The 10 GHD subjects will be assessed at baseline with EEG, fMRI and DTI and neuropsychological measures, again at 6 months, and a third time at 12 months.
88927123|NCT01699308|No Intervention|Control|5 demographically-matched TBI with normal GH subjects will be assessed at baseline (with EEG, fMRI and DTI, and neuropsychological measures) and at 12 months.
88927124|NCT01699321|Experimental|Your Move (physical activity)|The Your Move intervention is a multi-level, theory and evidence-based intervention that will include the following components: monthly handbills with community resources, newsletters, contests (shop and customer level), tailored health feedback report, and monthly phone calls from the research team.
88927125|NCT01699321|Other|Your Money (financial empowerment)|The Your Money program is an attention control intervention. Owners and barbers will receive 3 workshops that focus on financial health. Customers will receive monthly handbills and newsletters about different financial health topics.
88927126|NCT01699334|Experimental|Psychoeducational video|
88927127|NCT01699334|Active Comparator|Relaxation video|
88927128|NCT01699347|Experimental|OK432|Intracystic injection of OK432 under US guiding
88927129|NCT01699360|Experimental|Cyclosporine A, Tacrolimus, Sirolimus|"Cyclosporine A：soft capsule,2-6mg/kg/d, the same twice daily dose at least five days.~Tacrolimus:capsule,0.15-0.3mg/kg/d, the same twice daily dose at least five days.~Sirolimus:tablet,2mg/d, once a day."
88927130|NCT01699386|Active Comparator|Control Study Formula|protein hydrolysate formula
88927131|NCT01699386|Experimental|Experimental Study Formula|free-amino acid-based medical food
88927132|NCT01699399|Experimental|water immersion|infuse water during insertion phase of colonoscopy instead of air insufflation; remove the water during withdrawal phase.
88927133|NCT01699399|Experimental|water exchange|infuse and remove water during the insertion phase of colonoscopy. Air insufflation is used only in the withdrawal phase
89443255|NCT02255643|Experimental|-10% of effective PMT|Patients are set to a voltage 10% less than their original PMT at start of study, Changes in PMT settings
89443256|NCT02255643|Active Comparator|former setting (+/- 0% of PMT)|Patients are set to their original PMT at start of study, Changes in PMT settings
89443257|NCT02255643|Experimental|+10% of effective PMT|Patients are set to a voltage 10% more than their original PMT at start of study, Changes in PMT settings
89443258|NCT03343340|Experimental|Early CRRT|Early Continous Renal Replacement Therapy within 6 hours + Standard Medical Therapy
89443259|NCT03343340|Active Comparator|Late CRRT|Late Continous Renal Replacement Therapy + Standard Medical Therapy
89443260|NCT02168205|Experimental|4 mg Pomalidomide - Fed|On Day 1, participants will receive a single oral dose of 4 mg pomalidomide under fed conditions.
89443261|NCT02168205|Experimental|4 mg Pomalidomide - Fasted|On Day 1, participants will receive a single oral dose of 4 mg pomalidomide under fasted conditions
89443262|NCT02168205|Experimental|4 mg Pomalidomide + caffeine - Non-smoking|Participants will remain in the clinical site for a total of 10 days. They will receive orally a 200-mg caffeine capsule on Day 6, and on Day 8, participants will receive a single oral dose of 4 mg pomalidomide.
89443263|NCT02168205|Experimental|4 mg Pomalidomide + caffeine - Smoking|Participants will be required to smoke approximately 20 cigarettes a day for 10 days. They will receive orally a 200-mg caffeine capsule on Day 6, and on Day 8, participants will receive a single oral dose of 4 mg pomalidomide.
89443264|NCT04496570|Active Comparator|Periodontitis patients|gingival crevicular fluid and saliva collection were taken before and after nonsurgical periodontal treatment
89443265|NCT04496570|No Intervention|Healthy individuals|gingival crevicular fluid and saliva collection were taken at baseline after oral hygiene instructions
89443266|NCT02168283|Experimental|treatment arm|active fluid management includes 3 components: dietary counseling, diuretics, and intensive dialysis regimen
88927134|NCT01699399|Active Comparator|air insufflation|standard colonoscopy using traditional air insufflation during insertion
88927135|NCT01699412|Experimental|Dexamethasone|Patients under topical treatment with solution of dexamethasone 0.1 mg/mL associated to nystatin 100,000 UI/mL
88927136|NCT01699412|Experimental|Clobetasol|Patients under topical treatment with solution of clobetasol 0.05% associated with nystatin 100,000 UI/mL
88927137|NCT01699425|Experimental|Ajust|Experimental group: surgery to treat stress urinary incontinence with the sling Ajust®
89443267|NCT02168283|Active Comparator|control arm|dietary counseling alone
89443268|NCT03343652|Experimental|NB|Nivolumab 3 mg/kg IV infusion on day 1,14 + Bendamustine hydrochloride 90 mg/kg IV infusion on day 1,2 up to 3 cycles. Duration of cycle 28 days
89443269|NCT02175069|Experimental|Interscalene Nerve Block - 5ml|"ultrasound guided interscalene plexus block (UISB)~Ropivacaine 0.75%, 20ml Gadopentetate-Dimeglumine 0.05 mmol Shoulder Surgery"
89443270|NCT02175069|Active Comparator|Interscalene Nerve Block - 20ml|"ultrasound guided interscalene plexus block (UISB)~Ropivacaine 0.75%, 5ml Gadopentetate-Dimeglumine 0.0125 mmol Shoulder Surgery"
88927138|NCT01699425|Active Comparator|Classical transobturator tape|Control group: surgery to treat stress urinary incontinence with the Align® sling.
89443271|NCT02503280|Experimental|Group A - Autologous hMSCs|Autologous hMSCs: 40 million cells/ml delivered in 0.5 ml injection volumes times 10 injections for a total of 2 x 10^8 (200 million) hMSCs. The Biosense Webster MyoStar NOGA Injection Catheter System will be used in the delivery of the study drug.
89443272|NCT02503280|Experimental|Group B - Autologous Human C-Kit CSCs II|Autologous hMSCs PLUS autologous C-Kit hCSCs: Mixture of 39.8 million hMSCs and 0.2 million C-Kit hCSCs/ml delivered in 0.5 ml injection volumes times 10 injections for a total of 1.99 x 10^8 (199 million) hMSCs and 1 million C-Kit hCSCs.The Biosense Webster MyoStar NOGA Injection Catheter System will be used in the delivery of the study drug.
89443273|NCT02503280|Placebo Comparator|Placebo|Placebo (ten 0.5 ml injections of phosphate-buffered saline [PBS] and 1% human serum albumin [HSA]).The Biosense Webster MyoStar NOGA Injection Catheter System will be used in the delivery of the study drug.
89443274|NCT02503046||Arthritis with Periodontitis|"Patients aged between 30-65 years with 6 positive diagnostic criteria for Rhematoid Arthritis. Patients should have Clinical attachment loss >6mm, and Probing pocket depth>5mm in more than 6 teeth to satisfy criteria for periodontitis.~5ml of blood to be collected from each patient, centrifuged and plasma extracted used for estimation of Pentraxin3(Quantikine ELISA) Pooled plaque sample taken,DNA extracted by PCR for estimation of P.Gingivalis levels."
89443275|NCT02503046||Periodontitis group|"Patients aged between 30-65 years with Periodontal findings being presence of atleast 20 teeth in the mouth .More than 6 teeth with Clinical attachment loss >6mm and Probing pocket depth>5mm to satisfy criteria for periodontitis. 5ml of blood to be collected from each patient, centrifuged and plasma extracted used for estimation of Pentraxin3(Quantikine ELISA).~Pooled plaque sample taken,DNA extracted by PCR for estimation of P.Gingivalis levels.."
89443276|NCT02503046||Healthy Subjects|"Subjects aged between 30-65 years with no systemic diseases and periodontitis. 5ml of blood to be collected from each patient, centrifuged and plasma extracted used for estimation of Pentraxin3(Quantikine ELISA).~Pooled plaque sample taken,DNA extracted by PCR for estimation of P.Gingivalis levels.."
89443277|NCT02168517||Group I|Overweight osteoarthritis patients
89443278|NCT02168517||Group II|Normal weight osteoarthritis patients.
89443279|NCT02168517||Group III|Overweight healthy men.
89443280|NCT02168517||Group IV|Normal weight healthy men.
89443281|NCT04498520|Experimental|Treatment (abexinostat tosylate, palbociclib, fulvestrant)|Patients receive abexinostat PO BID on days 1-4, 8-11, and 15-18, palbociclib PO QD on days 1-21, and fulvestrant IM on days 1 and 15 of cycle 1 and day 1 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88927139|NCT01699438|Experimental|Mesalazine|
88927140|NCT01699438|Placebo Comparator|Placebo|
89443282|NCT02168595|Experimental|Cohort 1|2 mg/kg GMI-1271 or matching placebo
89443283|NCT02168595|Experimental|Cohort 2|5 mg/kg GMI-1271 or matching placebo
88927141|NCT01699477|Other|Trancranial MRg Focused Ultrasound for Neuropatic Pain|
88927142|NCT01699490|Experimental|Fluoxetine + Valsartan|"The initial dose of fluoxetine was 20 mg once daily, which could be increased by 20 mg in divided doses to a maximal daily dose of 60 mg.~Add-on treatment to 40 mg per day of valsartan"
88927143|NCT01699490|Active Comparator|Fluoxetine + Placebo|"The initial dose of fluoxetine was 20 mg once daily, which could be increased by 20 mg in divided doses to a maximal daily dose of 60 mg.~Add-on treatment to placebo"
88927144|NCT01699516||Intestinal graft vs host disease|Patients with biopsy-proven intestinal acute GVHD in the setting of an allogenic transplant
88927145|NCT01699516||Control group|In the setting of an allogenic bone marrow transplant: patients with biopsy-proven stomach GVHD without intestinal symptoms and patients with neutropenic enterocolitis. Normal volunteers.
88927146|NCT01699529|Experimental|Renal Denervation|
89199948|NCT00964834|Experimental|Placebo Antibiotic and Valortim|Randomized such that four volunteer subjects to receive Placebo Antibiotic and Valortim.
89443284|NCT02168595|Experimental|Cohort 3|10 mg/kg GMI-1271 or matching placebo
89443285|NCT03344276|Active Comparator|Control Group|Patients, as outlined by NASCET criteria, will have between 50 symptomatic stenosis or 70% asymptomatic stenosis of the carotid artery. Patients, undergoing carotid artery stenting for carotid stenosis, will undergo cognitive testing at 2 time points before intervention (1 months, and 2 months). The two preoperative time points will serve as the control group.
88927147|NCT01699555|Experimental|GNbAC1|Single dose intravenous (IV) GNbAC1 of 0.0025mg/kg, 0.025mg/kg, 0.15mg/kg, 0.60mg/kg, 2.00mg/kg or 6.00mg/kg
88927148|NCT01699555|Placebo Comparator|GNbAC1 placebo|Single dose intravenous (IV) GNbAC1 placebo
88927149|NCT01699568|Experimental|Vulcano Actives|Implants 4mm x 10mm Vulcano Actives (anodized surface)(AR Torque Vulcano actives), Conexão Sistemas de Prótese, Arujá, Brasil)will be placed on edentulous area in maxilla
88927150|NCT01699568|Active Comparator|Porous|Implants 4mm x 10mm Porous (dual acid-etched surface treatment)(AR Torque Porous, Conexão Sistemas de Prótese, Arujá, Brasil)will be placed on edentulous area in maxilla
88927151|NCT01699581|Experimental|Nestle Impact Advanced Recovery|"Nestle Impact Advanced Recovery~1 dose of Nestle Impact Advanced Recovery orally three times a day"
88927152|NCT01699594|Experimental|Mannitol|This arm will assess the allergen induced change in airway responsiveness to mannitol bronchoprovocation.
88927153|NCT01699594|Active Comparator|Methacholine Chloride|This arm will assess the allergen induced change in airway responsiveness to methacholine bronchoprovocation.
88927154|NCT01699620|Experimental|Dermatome|BAHA implant insertion with Dermatome technique
88927155|NCT01699620|Experimental|Linear incision|BAHA implant insertion with linear incision
88927156|NCT01699646|Active Comparator|CTG + FBS|intrapartum surveillance with CTG+FBS
88927157|NCT01699646|Active Comparator|Neoventa S 21 ST-ANalysis of fetal heart|intrapartum surveillance with CTG + STAN
88927158|NCT01699672|Experimental|Group and Individual information|The patients will receive two 1.5-2 hour standardized validated group information sessions in addition to regular information from their doctors and nurses.
88927159|NCT01699672|No Intervention|Individual information|Standard information about disease and treatment from doctor and nurse given at 2 occasions.
89443286|NCT03344276|Experimental|Intervention Group|Patients, as outlined by NASCET criteria, will have between 50 symptomatic stenosis or 70% asymptomatic stenosis of the carotid artery. Patients, undergoing carotid artery stenting for carotid stenosis, will undergo cognitive testing at 2 time points after invention (1 month and 2 months). The two postoperative time points will serve as the intervention group.
89443287|NCT02172495||Symptoms of COPD|Patients with symptoms of COPD receiving Tiotropium bromide 18 micrograms
89443288|NCT02172573|Experimental|Pramipexole|
89443289|NCT02172573|Experimental|Bromocriptine|
89443290|NCT02172573|Placebo Comparator|Placebo|
89443291|NCT02175303|Experimental|Decidual stromal cell therapy for toxicity and inflammation|Patients with toxicity, inflammation or hemorrhages will receive decidual stromal cells at approximately 1x10^6 cells/kg at one or more occasions at weekly intervals dependent on clinical response.
88927160|NCT01699711|Active Comparator|Dietary Supplement: Epigallocatechin-3-gallate (EGCG)|EGCG normally works as a dietary supplement. EGCG administration in Down syndrome patients will result in an improvement of their cognitive performance. A daily oral dose containing 9 mg/kg (range 6.9-12.7) of EGCG is given during twelve months.
88927161|NCT01699711|Placebo Comparator|Placebo|No active treatment is given.
88927162|NCT01699724|Active Comparator|JZoloft|Oral tablet of sertraline hydrochloride (Japanese commercial tablet: JZoloft ® tablet) 50 mg as a single oral dose under fasted conditions
88927163|NCT01699724|Experimental|ODT without water|sertraline ODT 50 mg without water as a single oral dose under fasted conditions
88927164|NCT01699724|Experimental|ODT with water|sertraline ODT 50 mg with water as a single oral dose under fasted conditions
88927165|NCT01699776|Active Comparator|Ivabradine|Ivabradine, 7,5 mg b.id. by mouth for 14-16 weeks.
88927166|NCT01699776|Active Comparator|Digoxin|Digoxin 0.125 mg once a day, 5 times per week, for 12-14 weeks by mouth.
88927167|NCT01699802|Experimental|Inhaled anaesthetic agent|The group where the investigators adds inhaled anaesthetic agent when using the anaesthetic gas reflector (AnaConda).
88927168|NCT01699828|Experimental|Buspirone 120 mg|Buspirone 120 mg (encapsulated).
88927169|NCT01699828|Experimental|Buspirone 60 mg|Buspirone 60 mg (encapsulated)
88927170|NCT01699828|Placebo Comparator|Placebo|Placebo (encapsulated)
88927171|NCT01699828|Experimental|Buspirone 30 mg|Buspirone 30 mg (encapsulated).
88927172|NCT01699841||HIV+ and HIV- mothers and their infants|
88927173|NCT01699854|Active Comparator|capsaicin patch|
88927174|NCT01699854|Placebo Comparator|placebo patch|
88927175|NCT01699880||conventional high FiO2 bag reservoir facemask|this group of patients is intubated according to our current practice that requires the use of a high FiO2 nonrebreathing with bag reservoir facemask to ensure preoxygenation in patients requiring tracheal intubation. a small nasal catheter is inserted just before laryngoscopy to ensure a low oxygen flow to allow oxygenation during laryngoscopy.
88927176|NCT01699880||high flow nasal cannula oxygen|we wish to change our standard practice of preoxygenation and expand our use of high flow nasal cannula oxygen therapy to the tracheal intubation setting. Currently, used of high flow oxygen nasal cannula oxygen therapy to ensure oxygenation during intubation is limited to the patients already under high flow nasal cannula oxygen. the change of practice consists in the systematic use of high flow nasal cannula oxygen therapy in all patients requiring tracheal intubation in the ICU.
88927177|NCT01699893|Experimental|unique arm|"At V0: 1500 will be screened~At V1: 1000 subjects will be performed following samples: blood, nasal swab,stool. 500 subjects among 1000 will be performed one additional sample (Skin Biopsy)~At V2: only the 500 subjects having performing the skin biopsy at V1 will come at V2 to perform blood, nasal swab and stool samples"
88927178|NCT01699906|Experimental|Dietary intervention|Diet regimen to induce weight loss
88927179|NCT01699919|Active Comparator|intravenous lignocaine|Intravenous lignocaine will be given as a bolus of 1.5mg/kg at the time of intubation followed by an infusion at a rate of 1.5mg/kg/hr throughout surgery and till one hour post surgery.
88927180|NCT01699919|Placebo Comparator|normal saline|Normal saline will be given as a bolus at the time of intubation and saline infusion given to patients in the control group during the surgery and till one hour post surgery.
89443292|NCT03344120|Active Comparator|suture stent|suture stent positioning after ureteroscopy. Intervention: administration of USSQ questionnaire.
89443293|NCT03344120|Active Comparator|conventional double-J stent|conventional double-J stent positioning after ureteroscopy. Intervention: administration of USSQ questionnaire.
89443294|NCT02507882|Experimental|HCC|This group will include patients with chronic hepatitis C (no. =135)
89443295|NCT02507882|Experimental|HCC with Cirrhosis|This group will include patients with chronic hepatitis C (no. =135) with cirrhosis (F4).
89443296|NCT02507882|Experimental|HCV related HCC patients|This group will include patients with HCV related HCC (no. =135) This is confirmed by presence of focal lesion detected by Imaging (computed tomography (CT) and ultrasound), and elevated serum AFP.
89443297|NCT02175381|Experimental|Carbo/GEM|
89443298|NCT03540225|Experimental|Early Low-dose Arm|Start from 11-14 week: 200 mg self-administered vaginal progesterone daily
89443299|NCT03540225|Experimental|Early High-dose Arm|Start from 11-14 week: 400 mg self-administered vaginal progesterone daily
89443300|NCT03540225|Experimental|Late Low-dose Arm|Start from 20-24 week: 200 mg self-administered vaginal progesterone daily
89443301|NCT03540225|Experimental|Late High-dose Arm|Start from 20-24 week: 400 mg self-administered vaginal progesterone daily
88927181|NCT01699932|Experimental|Arm 1|24-week treatment period: starting dose will be of 2/1000 mg or 4/2000 mg of glimepiride/metformin fixed combination (Amaryl M® ) depending on the previous treatment and dose. The Interventional medicinal product's dose will be increased every 2 weeks up to the maximum tolerated dose of 8/2000 mg of Amaryl M® , and adjusted throughout the 24-week treatment period according to fasting Self Monitored Plasma Glucose (SMPG) values in the objective to obtain fasting SMPG values ≤ 130mg/dL (7.2mmol/L) and > 70 mg/dL (3.9mmol/L) without symptomatic hypoglycemia.
88927182|NCT01699945||Verbal Autopsies|The study involves filling of verbal autopsies for still births and deaths in women of reproductive age group.
88927183|NCT01699958|Experimental|Problem-solving intervention|2 individual sessions teaching problem-solving skills with the use of videos, handouts, and worksheets.
88927184|NCT01699958|No Intervention|Control: Standard Care|Control arm participants will receive standard of care from their primary care provider.
88927185|NCT01699971|Active Comparator|Lichtenstein|Hernia repair with lichtenstein propylene mesh
88927186|NCT01699984||Hospitalized patients|All patients hospitalized in 4 inpatient facilities in Northern Italy during 4 index-months.
88927187|NCT01699997|Experimental|Oxytocin|Each treatment will consist of 10 insufflations (5/nostril alternating between nostrils) of OXT Spray, which contains approximately 40 international units (IU) of OXT
88927188|NCT01699997|Placebo Comparator|Placebo vial|Each treatment will consist of 10 insufflations (5/nostril alternating between nostrils) of placebo Spray, which contains all OXT Spray ingredients except for oxytocin.
88927189|NCT01700010|Experimental|Lapatinib and Paclitaxel|"Lapatinib comes in tablet form and is taken by mouth at a dose of 1,000 mg every day. Paclitaxel will be given through the vein (IV) at a dose of 80 mg/m2 on days 1, 8, and 15 at each 28 day cycle. If cancer does not progress and study treatment can be tolerated after 6 cycles of paclitaxel and lapatinib, paclitaxel will be stopped and lapatinib will continue until disease progression, side effects cannot be tolerated, participant is removed from or withdraws from study, or for other reasons.~Subjects with locally advanced disease who respond to treatment and are felt to be appropriate for local therapy may proceed to receive local therapy as deemed appropriate by the managing physician after a minimum of 6 cycles or upon achieving complete remission followed by an additional 2 cycles. Subjects who proceed to receive local therapy will be removed from protocol therapy. Subjects who elect not to receive or are not candidates for local therapy may continue treatment on protocol."
88927190|NCT01700023||patients with leg-edema|patients with decompensated heart failure presenting with leg-edema
88927191|NCT01700062|Experimental|Medium calorie|
88927192|NCT01700062|Experimental|standard calorie|
88927193|NCT01700075|Active Comparator|Conventional treatment|"Lipidlowering: Atorvastatin (Liprimar) - 40mg per day. Antihypertensive: Diroton (Lisinopril, Gedeon Richter Ltd) - 10mg twice per day and Ditiazem (calcium bloker from the benthodiazepines, Lannacher, Austria) - 90mg per day.~Antihyperglycemic drugs: biguanides Metformin - 0.5 g two or tree times per day, or Exenatide - 5-10 µg per day.~Anti-inflammatory: TromboACC (acetylsalicylate acid) up to 2 g per day and/or Clopidogrel (thienopyridine class antiplatelet agent) - 75mg per day."
88927194|NCT01700075|Experimental|Weight loss treatment|Weight loss treatment by administering a healthy very low-calorie, low-fat vegetables and salt diet and includes an adjustment and modify eating behavior and increased physical activity.
88927195|NCT01700088||Oxygen cannular|After lung resection surgery,every patient will received supplementary oxygen 5 L/minutes via oxygen cannular for 120 minutes
88927196|NCT01700127|Other|Breastfeeding|Breastfeeding Encouraged
88927197|NCT01700127|Active Comparator|Breastfeeding Withheld|Breastfeeding Withheld
88927198|NCT01700153|Experimental|Experimental: Robotic-assisted therapy|All patients will receive a similar classical rehabilitation as a basis. the 10 patients of this group will receive a supplement of robotic-assisted therapy.
88927199|NCT01700153|Active Comparator|Classical therapy|All patients will receive a similar classical rehabilitation as a basis. the 10 patients of this group will receive a supplement of classical rehabilitation.
89443302|NCT02501252|Experimental|CORN Based at health post|Trained CORN based at health post will provide SBA and other RH services on demand at health post or household levels on an outreach bases.
89443303|NCT02501252|Active Comparator|CORN Based at health center|Trained CORN based at health center, but working in the community in an outreach basis will provide SBA and other RH services
89443304|NCT02501252|No Intervention|Control|will be composed of a randomly selected comparable controls clusters. Control clusters (arm) will be similar with the other two arms (groups) except for the intervention.
89443305|NCT02507648|Experimental|A Test|Test drug (Oseltamivir) 1 tablet contains 75 mg Oseltamivir
89443306|NCT02507648|Active Comparator|B Reference|Reference drug (Tamiflu®) 1 tablet contains 75 mg Oseltamivir
89443307|NCT02172729|Experimental|ACB with lidocaine 5 mg/ml|Adductor canal block (ACB) with 20 ml lidocaine 5 mg/ml, single bolus
89443308|NCT02172729|Experimental|ACB with lidocaine 15 mg/ml|Adductor canal block with 20 ml lidocaine 15 mg/ml, single bolus
89443309|NCT02503124|Experimental|Chronobiological intervention|Single night's wake therapy followed by bright light therapy for a week as add-on treatment to treatment as usual.
89443310|NCT02503124|Active Comparator|Control|Treatment as usual including a private educational meeting in sleep hygiene.
89443311|NCT02172807|Experimental|Tiotropium low & Placebo|Tiotropium 18 µg inhalation capsule and Placebo MDI
89443312|NCT02172807|Experimental|Tiotropium high & Placebo|Tiotropium 36 µg inhalation capsule and Placebo MDI
89443313|NCT02172807|Active Comparator|Oxitropium & Placebo|Oxitropium MDI (100 µg/puff) and Placebo inhalation capsules
89443314|NCT03343262|Experimental|"ta-VNS yidan-pi"|"Device:ta-VNS & Electro-acupuncture(yidan-pi auricular acupoints):2 times per day,2 days per week for 12 weeks"
89443315|NCT03343262|Placebo Comparator|"ta-VNS jian"|"Device:ta-VNS & Electro-acupuncture(jian auricular acupoints):2 times per day,2 days per week for 12 weeks"
89443316|NCT04568421||Treated with immunomodulatory and/or -suppressive drugs|Patients with rheumatic diseases treated with immunomodulatory and/or immunosuppressive drugs and with diagnosis of SARS-CoV-2 infection (past or present) with positive test for the virus SARS-CoV-2 from analysis of nasopharyngeal or oropharyngeal swab specimens (reverse transcriptase-polymerase- chain-reaction assay) or by serology, independently of symptoms.
89443317|NCT04568421||Not treated with immunomodulatory and/or -suppressive drugs|Patients with rheumatic diseases not treated with immunomodulatory and/or immunosuppressive drugs and with diagnosis of SARS-CoV-2 infection (past or present) with positive test for the virus SARS-CoV-2 from analysis of nasopharyngeal or oropharyngeal swab specimens (reverse transcriptase-polymerase- chain-reaction assay) or by serology, independently of symptoms.
89443318|NCT02502968|Experimental|Cytarabine & BL8040|"Subjects ≥60 years: cytarabine 1g/m2 intravenously twice a day over 3 hours on day 1, 3 and 5 on 2 cycles and BL-8040 (1.25 mg/kg) subcutaneously on days 1 to 5 of each cycle~Subjects <60 years: cytarabine 3g/m2 intravenously twice a day over 3 hours on day 1, 3 and 5 on 3 cycles and BL-8040 (1.25 mg/kg) subcutaneously on days 1 to 5 of each cycle"
89443319|NCT02502968|Active Comparator|Cytarabine & Placebo|"Subjects ≥60 years: cytarabine 1g/m2 intravenously twice a day over 3 hours on day 1, 3 and 5 on 2 cycles and Placebo (for BL-8040) subcutaneously on days 1 to 5 of each cycle~Subjects <60 years: cytarabine 3g/m2 intravenously twice a day over 3 hours on day 1, 3 and 5 on 3 cycles and Placebo (for BL-8040) subcutaneously on days 1 to 5 of each cycle"
88927200|NCT01700218|Other|telemonitoring|patients in the telemonitoring arm will record vital parameters (blood pressure, heart rate, body weight) and transmit these parameters together with wellbeing and daily dose of heart failure medication
89443320|NCT04496648|Active Comparator|Percutaneous Coronary Intervention|Conventional PCI and optimal medical therapy
89443321|NCT04496648|Placebo Comparator|Sham-percutaneous coronary intervention|Sham-PCI and optimal medical therapy
89443322|NCT02172963|Experimental|Decidual Stromal Cell therapy for Hemorrhagic Cystitis|
89443323|NCT02168673||Group 1|Healthy non-smokers
89443324|NCT02168673||Group 2|Healthy non-smokers
89443325|NCT02502578|Experimental|CNT-01|Patients will receive CNT-01 500 mg orally three times daily for 14 days. On Day 15, patients will take CNT-01 500 mg only once after blood drawing.
89443326|NCT02502812|Experimental|Treatment Sequence A (Innovator) - B (Clop F1) - C (Clop F2)|Subjects will receive a single 75 mg tablet of reference clopidogrel (Treatment A) in treatment period 1, 75 mg tablet Clop F1 (Treatment B) in treatment period 2, and 75 mg tablet Clop F2 (Treatment C) in treatment period 3 under fasting conditions. Each treatment period will be separated by 7-14 days of washout Period.
89443327|NCT02502812|Experimental|Treatment Sequence A(Innovator) -C(Clop F2)-B (Clop F1)|Subjects will receive a single 75 mg tablet of reference clopidogrel (Treatment A) in treatment period 1, 75 mg tablet Clop F2 (Treatment C) in treatment period 2, and 75 mg tablet Clop F1 (Treatment B) in treatment period 3 under fasting conditions. Each treatment period will be separated by 7-14 days of washout Period.
89443328|NCT02502812|Experimental|Treatment Sequence B (Clop F1) - A (Innovator) - C (Clop F2)|Subjects will receive a single 75 mg tablet Clop F1 (Treatment B) in treatment period 1, 75 mg tablet of reference clopidogrel (Treatment A) in treatment period 2, and 75 mg tablet Clop F2 (Treatment C) in treatment period 3 under fasting conditions. Each treatment period will be separated by 7-14 days of washout Period.
88927201|NCT01700218|Other|control|patients in the control arm will not record any vital parameter
88927202|NCT01700231||Liver resection ,Liver Dysfunction|100 patients will be monitored perioperatively, in a subset of 40 patients hepatic venous pressure gradient will be monitored
88927203|NCT01700244|Experimental|Pacemaker|
89443329|NCT02502812|Experimental|Treatment Sequence B (Clop F1) - C (Clop F2) - A (Innovator)|Subjects will receive a single 75 mg tablet Clop F1 (Treatment B) in treatment period 1, 75 mg tablet Clop F2 (Treatment C) in treatment period 2, and 75 mg tablet of reference clopidogrel (Treatment A) in treatment period 3 under fasting conditions. Each treatment period will be separated by 7-14 days of washout Period.
88927204|NCT01700257|Other|CT scan & Early CDT Lung test|Every study participant receives a CT scan & Early CDT-Lung test (biomarker blood test) for lung cancer screening purposes.
88927205|NCT01700270|Experimental|dovitinib (TKI258)|dovitinib, 5 days on / 2 days off dose schedule
88927206|NCT01700283|Experimental|exercise education and walking program|
88927207|NCT01700283|No Intervention|maintain their daily activity|
88927208|NCT01700296|No Intervention|Standard Care|"Standard Care: finishing treatment for AECOPD in hospital and after hospital discharge to further control by the GP. In case of severe symptoms and / or airway obstruction (measured by FEV1) refer patients for follow-up in lung clinic. The subjects are recorded with the same subjective, clinical, paraclinical and invasive parameters as the Best care group"
89199949|NCT00964834|Experimental|Placebo Antibiotic and Placebo Valortim|Randomized such that four volunteer subjects to receive Placebo Antibiotic and Placebo Valortim.
89443330|NCT02502812|Experimental|Treatment Sequence C (Clop F2) - A (Innovator) - B (Clop F1)|Subjects will receive a single 75 mg tablet Clop F2 (Treatment C) in treatment period 1, 75 mg tablet of reference clopidogrel (Treatment A) in treatment period 2, and 75 mg tablet Clop F1 (Treatment B) in treatment period 3 under fasting conditions. Each treatment period will be separated by 7-14 days of washout Period.
89443331|NCT02502812|Experimental|Treatment Sequence C (Clop F2) - B (Clop F1) - A (Innovator)|Subjects will receive a single 75 mg tablet Clop F2 (Treatment C) in treatment period 1, 75 mg tablet Clop F1 (Treatment B) in treatment period 2, and 75 mg tablet of reference clopidogrel (Treatment A) in treatment period 3 under fasting conditions. Each treatment period will be separated by 7-14 days of washout Period.
89443332|NCT02175537|Experimental|Microclinic social induction training|BMI of 30 and over; or BMI of 25 and over and self-reported pre-diabetes or type II diabetes will receive the Microclinic Social Induction Diabetes and Obesity Program. The intervention is a training on diabetes self-management, disease monitoring, diabetes prevention, prevention of complications, health behavior change, and social network supports in order to improve chronic disease risk factors.
89443333|NCT02175537|No Intervention|Controls|Receiving no intervention but parallel primary and secondary outcome measures as intervention study arm
89443334|NCT02168751|Active Comparator|propofol|propofol doses to maintain hypnoses between 40-60 bis(Bispectral Index Scale)during the lung resection surgery
89443335|NCT02168751|Experimental|sevoflurane|Sevoflurane doses to maintain hypnoses between 40-60 bis(Bispectral Index Scale)during the lung resection surgery
89443336|NCT02507726|Experimental|Flexima Active Soft convexe|Flexima Active soft convexe (1 to 3 appliances per day)
88927209|NCT01700296|Experimental|Best care|"Best Care: subjects are randomly assigned to the Best care regardless MRC class and severity of symptoms through:~10 weeks of rehabilitation (2 hours, 2 times a week) by Region Zealand's instructions on sundhed.dk. COPD rehabilitation includes physical exercise, smoking cessation, medication, nutrition education and psychosocial support and patient education. Rehabilitation provided by a multidisciplinary effort with lung nurse, dietician and physiotherapist according to national and international guidelines (1.5) (6) (24) (25)~Outpatient follow-up every 3 months, a total of 5 visits, and during these visits various subjective, clinical, paraclinical and invasive parameters."
88927210|NCT01700309|No Intervention|Control group|Treatment as usual
88927211|NCT01700309|Experimental|Young and Active|This arm will recieve web-based health counselling through the web-site Young and Active.
88927212|NCT01700322|Active Comparator|Ticagrelor|Ticagrelor 180mg oral loading dose and 90mg b.i.d for 30 days following coronary artery stenting
88927213|NCT01700322|Active Comparator|Clopidogrel|Clopidogrel 600mg loading dose + 75 mg once a day for 30 days following coronary artery stenting.
88927214|NCT01700322|Active Comparator|Prasugrel|Prasugrel 60mg oral loading dose followed by 10mg once a day for 30 days following coronary artery stenting
88927215|NCT01700361||No treatment|This is an observational study. Women in this study are not receiving any treatments.
89443337|NCT02173041|Other|Standard Usual Care|Community program which follows with referral services
89443338|NCT02173041|Experimental|Prevention Awareness Groups (PAG)|Prevention Awareness Groups (PAG) is a community based integrated substance abuse prevention program targeting vulnerable populations. It comprises of community programs, physician led counseling followed by treatment follow up in community based clinic.
88927216|NCT01700400|Experimental|Experimental Phase I Dose Escalation|"Pemetrexed: intravenous; 500 mg/m² for Dose Levels 1, 2 and 3~Carboplatin: intravenous; 5 AUC for Dose Level 1; 6 AUC for Dose Levels 2 and 3~Bevacizumab: intravenous; 15 mg/kg for Dose Levels 1, 2, and 3~Everolimus: oral, 2.5 mg/day for Dose Levels 1 and 2; 5.0 mg/day for Dose Level 3"
88927217|NCT01700413|Experimental|Idarubicin|Cohort 1: Idarubicin 14 mg/m2 (day 1-3), Cytarabine 200 mg/m2 (Days 1-7), G-CSF 150 mcg/m2/day Cohort 2: Idarubicin 16 mg/m2 (day 1-3), Cytarabine 200 mg/m2 (Days 1-7), G-CSF 150 mcg/m2/day Cohort 3: Idarubicin 18 mg/m2 (day 1-3), Cytarabine 200 mg/m2 (Days 1-7), G-CSF 150 mcg/m2/day
89013310|NCT06302374|Experimental|Cohort 6 GR2001 0.1mg/kg/placebo|Eighteen subjects will be randomly assigned to receive either GR2001 or placebo at a 2:1 ratio (i.e. 12 subjects receive GR2001 and 6 with placebo) followed by a dose of Tetanus Toxoid（TT） on Day0.
89199950|NCT00612105|Experimental|1|Retigabine
89199951|NCT00612105|Placebo Comparator|2|Placebo
89443339|NCT02507570|Experimental|Open label|Single arm study to evaluate safety and tolerability of Enzalutamide with concurrent administration of Radium ra 223 dichloride in subjects with symptomatic metastatic prostate cancer.
89443340|NCT02175693||E2014|
88927218|NCT01700426|Active Comparator|iron|"Sixty-eight subjects found to have ID or IDA will be consented and randomized to one of the two treatment regimens (34 subjects per group). Liquid supplement preparations of iron (both groups), Vitamin E (test) and placebo (control) will be distributed by the research pharmacy at Children's Hospital Colorado.~A commercial ferrous sulfate solution (Fer-In-Sol, 15 mg elemental Fe/mL; Mead Johnson, Inc, Evansville, IN) will be distributed to all qualifying participants for the study by the research pharmacy at Children's Hospital Colorado. The volume of the suspension will be individualized by the pharmacy to the infant's weight, to maintain consistent iron dosing at 6 mg/kg/day."
89199952|NCT04017741|Active Comparator|Active group|The active group will be administered 2 mls of 2% lidocaine and 80mg methylprednisolone.
89443341|NCT03344042|Active Comparator|Fentanyl|100mcg Fentanyl administered into epidural space during regular contractions before cervical dilation
89443342|NCT03344042|Active Comparator|Sufentanyl|10mcg sufentanyl administered into the epidural space during regular contractions before cervical dilation
89443343|NCT03344042|No Intervention|Control|No epidural analgesia
89443344|NCT02173119||HCC patients having MRI post-TACE|HCC patients who have undergone conventional lipiodol based chemoembolization.
89443345|NCT03343964||Children with moderate to severe TBI|
89443346|NCT02175849||Drug resistant TB patients|Patients with rifampicin resistant TB or MDR-TB newly confirmed by drug susceptibility tests (DST)
89443347|NCT02175849||Contacts|Contacts of patients with newly detected rifampicin resistant TB or MDR-TB in households, schools, workplaces and other locations.
89443348|NCT04495322|Experimental|10 mg TG-1000|Eligible subjects will receive single oral dose of study drug (2 x 5-mg TG-1000 capsules)on Day 1 under fasted condition.
89443349|NCT04495322|Experimental|20 mg TG-1000 or Placebo|Eligible subjects will receive single oral dose of study drug (20 mg TG-1000 capsule or Placebo capsule) on Day 1 under fasted condition.
89443350|NCT04495322|Experimental|40 mg TG-1000 or Placebo|Eligible subjects will receive single oral dose of study drug (2 x 20 mg TG-1000 capsules or Placebo capsules) on Day 1 under fasted condition.
89443351|NCT04495322|Experimental|80 mg TG-1000 or Placebo|Eligible subjects will receive single oral dose of study drug (4 x 20 mg TG-1000 capsules or Placebo capsules) on Day 1 under fasted condition.
89443352|NCT04495322|Experimental|120 mg TG-1000 or Placebo|Eligible subjects will receive single oral dose of study drug (6 x 20 mg TG-1000 capsules or Placebo capsules) on Day 1 under fasted condition.
89443353|NCT04495322|Experimental|160 mg TG-1000 or Placebo|Eligible subjects will receive single oral dose of study drug (8 x 20 mg TG-1000 capsules or Placebo capsules) on Day 1 under fasted condition.
89443354|NCT04495322|Experimental|X mg TG-1000 (fasted)+wash-out+X mg TG-1000 (fed)|Based on the preliminary results, one optimal dose (X mg) of TG-1000 will be selected. Subject will receive a single oral dose of TG-1000 under fasted condition. After washout period, subject will receive a single oral dose of TG-1000 under fed condition.
89443355|NCT04495322|Experimental|X mg TG-1000 (fed)+wash-out+X mg TG-1000 (fasted)|Based on the preliminary results, one optimal dose (X mg) of TG-1000 will be selected. Subject will receive a single oral dose of TG-1000 under fed condition. After washout period, subject will receive a single oral dose of TG-1000 under fasted condition.
89443356|NCT02175927|Experimental|High Dose Amoxicillin|High dose amoxicillin/metronidazole-based quadruple therapy for 14 days: Lansoprazole 30mg bid, Bismuth Potassium Citrate 220mg bid, Amoxicillin 1000mg tid, Metronidazole 400mg qid
89443357|NCT02175927|Active Comparator|Tetracycline|Classical quadruple therapy for 14 days: Lansoprazole 30mg bid, Bismuth Potassium Citrate 220mg bid, Tetracycline 500mg qid, Metronidazole 400mg qid
89443358|NCT00707486|Experimental|Hemcon Dental Dressing|The HemCon® Bandage is an FDA-cleared chitosan-based flat bandage that controls severe arterial bleeding from traumatic injuries. In comparison to traditional bandages, the HemCon® Bandage provides superior control of bleeding, wound site adhesiveness, multiple injury site usage, biocompatibility and provides a barrier to infective agents.
89443359|NCT00707486|Active Comparator|Gauze with pressure and/or Gelfoam|Post operative care for oral surgery subjects consists of the subject biting on sterile cotton gauze to provide pressure to the extraction site. A common alternative practice involves the placement of Gelfoam (with or without antibiotic/steroid medication) into the extraction socket prior to application of the sterile gauze pressure dressing. This treatment was chosen as the study control to compare the HemCon Dental Dressing to the standard of care for oral surgery subjects, including the use of cotton gauze and/or Gelfoam to control post operative bleeding.
89443360|NCT03539991|Experimental|Supportive care (online course, virtual meeting)|Participants complete an online course focusing on different aspects of tobacco prevention and cessation over 1 hour each per week for 4 weeks. They also engage in 6 virtual meetings over 1 hour about tobacco use once per month.
89443361|NCT05460884|Sham Comparator|Control|Participants will consume 109 g of white bread
89443362|NCT05460884|Experimental|Experimental 1: Seaweed extract at lower dose (LD) and white bread|Participants will consume 109 g of white bread with 0.5g of seaweed extract
89443363|NCT05460884|Experimental|Experimental 2: Seaweed extract at higher dose (HD) and white bread|Participants will consume 109 g of white bread with 1g of seaweed extract
89443364|NCT05452460|Experimental|Mindfulness training group|Participants in the mindfulness training (MT) group will engage in a 60-min session of mindfulness program per week for 8 weeks.
88927219|NCT01700426|Active Comparator|iron 2|"Sixty-eight subjects found to have ID or IDA will be consented and randomized to one of the two treatment regimens (34 subjects per group). Liquid supplement preparations of iron (both groups), Vitamin E (test) and placebo (control) will be distributed by the research pharmacy at Children's Hospital Colorado.~A commercial ferrous sulfate solution (Fer-In-Sol, 15 mg elemental Fe/mL; Mead Johnson, Inc, Evansville, IN) will be distributed to all qualifying participants for the study by the research pharmacy at Children's Hospital Colorado. The volume of the suspension will be individualized by the pharmacy to the infant's weight, to maintain consistent iron dosing at 6 mg/kg/day."
89443365|NCT05452460|No Intervention|Waitlist control group|Participants in the waitlist control group will be required to maintain regular life and routine training. Once the participants in control group finished the whole experiment, they will be invited to participate in the MBPP program for eight weeks.
89443366|NCT02759055|Experimental|Clinical Decision Support (CV Wizard)|In the Intervention arm, primary care providers will be provided with an EHR-linked, Web-based clinical decision support system that identifies patients with prediabetes and provides patients and their primary care providers personalized, evidence-based CDS and follow up to reduce risk of heart attacks or stroke, optimizing management and follow up of pre-diabetes patients with uncontrolled CV risk factors.
89443367|NCT02759055|No Intervention|Usual Care|In the No Intervention arm, patients receive usual care from their primary care clinic and care providers.
89443368|NCT03343106|Experimental|ACT plus ERP|Sessions 1 and 2 involved information-gathering, discussion of the ACT model of OCD and ERP, and introduction to self-monitoring of rituals. Session 3 involved the development of an exposure hierarchy and response prevention plan, and further explanation of the ACT-based approach to ERP which focuses on learning flexible responding in the presence of obsessions, anxiety, and urges to ritualize. Exposure practices (sessions 4-16) were procedurally similar to the ERP condition, but focused on the facilitation of ACT processes rather than on fear extinction. Homework exposure practice was linked to the participant's goals and values. Session 16 included an ACT model of relapse prevention focusing on following one's values in the presence of obsessive thoughts and compulsive urges.
89501704|NCT02223949|Experimental|Cook double balloon catheter|Insertion of the Cook double balloon catheter to the cervix until both balloons are properly located in the cervical canal. After properly located it is inflated with 20 ml of saline. Then both balloons are additionally inflated to a total of 80 ml each balloon. Twelve hours later the balloons are deflated and the device is removed.
89537081|NCT03300791||Admitted|We will include patients who had beeb admitted by an acute heart failure in hospitalization ward
88927220|NCT01700452||patients suspected of having lung cancer|Subjects presenting with 0.8 - 3 cm solitary pulmonary nodules with high probability for malignance. The subject must be scheduled for a lung biopsy procedure to determine clinical diagnosis.
88927221|NCT01700465||Hemodialysis|Patients undergoing hemodialysis
88927222|NCT01700478|Experimental|Misoprostol + vasopressin, Vasopressin|Misoprostol 400ug given rectally one hour before surgery.
88927223|NCT01700491|Active Comparator|Epidural Catheter 0.2% ropivacaine|Patients will receive an infusion of 0.2% ropivacaine at a range of 0-10 mL/hr through an epidural catheter. They will also receive an infusion of saline at a rate of 0-10 mL/hr through a paravertebral catheter.
88927224|NCT01700491|Active Comparator|Paravertebral Catheter 0.4% ropivacaine|Patients will receive an infusion of 0.4% ropivacaine at a range of 0-10mL/hr through a paravertebral catheter. They will also receive an infusion of saline at a range of 0-10mL/hr through an epidural catheter.
88927225|NCT01700504|Experimental|Gentamicin lavage|Patients undergoing an axillary lavage with 500ml of normal saline followed by 500ml gentamicin solution
88927226|NCT01700504|Active Comparator|Normal saline lavage|Patients undergoing 2 axillary lavages with 500ml of normal saline
88927227|NCT01700556|Active Comparator|Usual Care|"150 patient-caregivers will receive a light support in the form of paper brochures and 3 preventive home visits by a nurse"
88927228|NCT01700556|Experimental|UP Protocol|150 patient-caregivers provided with the systematic and comprehensive support of a case manager social worker and receiving 3 preventive home visits by a nurse
88927229|NCT01700556|Experimental|UP-TECH Protocol|150 patient-caregivers provided with the systematic and comprehensive support of a case manager social worker, receiving an intervention based on assistive technologies and 3 preventive home visits by a nurse
88927230|NCT01700595|Experimental|new technical intervention|''new technical intervention'' represents the surgical procedure which is applied for the patients assigned to this group because of their certain characteristics. Namely, pediatric patients with broad axillary, anterior chest wall, mammary and neck scars are treated with this surgical approach.
88927231|NCT01700608||plerixafor treated patients|lymphoma and myeloma patients
88927232|NCT01700634||OA patients with HIGH central sensitization|Central sensitization will be defined by the presence of both spreading sensitization and temporal summation to repeated pressure pain stimulation (Arendt-Nielsen et al. 2010, Graven-Nielsen et al. 2010, Woolf 2010, Imamura et al. 2008, Nijs et al. 2010).
88927233|NCT01700634||OA patients with LOW central sensitization|
88927234|NCT01700634||Control subjects|
88927235|NCT01700647||smoking controls|patients referred for bronchoscopy who have detailed axamination and do not have any dysplasia proven by bronchoscopy and laryngoscopy Breath test- sampling using ENose
88927236|NCT01700647||In Situ carcinoma larynx|Biopsy proven in situ carcinoma larynx proven by laryngoscopy and bronchoscopy Breath test- sampling using ENose
88927237|NCT01700647||Advanced Larynx Cancer|Biopsy proven stage 3/4 larynx cancer proven by laryngoscopy and bronchoscopy Breath test- sampling using ENose
88927238|NCT01700660||VIO|Patients operated under VIO.
89443369|NCT03343106|Experimental|ERP alone|ERP followed Kozak and Foa's treatment manual. Sessions 1 and 2 included information-gathering, psychoeducation about the cognitive-behavioral model of OCD and rationale for ERP, and introduction to self-monitoring of rituals. Session 3 was dedicated to developing the treatment plan (exposure hierarchy, response prevention plan). Sessions 4-16 included in-session prolonged and repeated gradual exposure therapy (in vivo and imaginal as needed), the assignment of daily exposure practices for between-sessions, and instructions to refrain from rituals (response prevention in session and between sessions), along with self monitoring of any rituals that were performed. Session 16 also addressed discontinuation and relapse prevention.
89443370|NCT02176239||Gammaplex® IVIg|
89443371|NCT03725475||Stage III|stage III Non-small Cell Lung Cancer (NSCLC )
89443372|NCT02496182|Placebo Comparator|Placebo|Conventional treatment (Prednisone 0.5 mg/kg/day for 4 weeks, then 0.25 mg/Kg/day for 8 weeks and maintenance dosage of 0.125 mg/Kg/day plus Azathioprine 2-3 mg/kg/day with a maximal dosage of 150 mg/day starting with 25-50 mg/day increasing gradually until day 14 with maximal dosage) plus Placebo tablet 2 times at day.
89443373|NCT02496182|Experimental|Pirfenidone 1800 mg|Conventional treatment (0.5 mg/kg/day for 4 weeks, then 0.25 mg/Kg/day for 8 weeks and maintenance dosage of 0.125 mg/Kg/day plus Azathioprine 2-3 mg/kg/day with a maximal dosage of 150 mg/day starting with 25-50 mg/day increasing gradually until day 14 with maximal dosage) plus Pirfenidone long release tablet 900 mg 2 times at day, starting with 600 mg at day
89443374|NCT02496182|Experimental|Pirfenidone 1200 mg|Conventional treatment (0.5 mg/kg/day for 4 weeks, then 0.25 mg/Kg/day for 8 weeks and maintenance dosage of 0.125 mg/Kg/day plus Azathioprine 2-3 mg/kg/day with a maximal dosage of 150 mg/day starting with 25-50 mg/day increasing gradually until day 14 with maximal dosage) plus Pirfenidone long release tablet 600 mg 2 times at day starting with 600 mg at day
89443375|NCT02496026|Experimental|tDCS plus wrist robot therapy|In addition to standard rehabilitation treatment Group A will perform daily sessions of wrist robot-assisted treatment in combination with tDCS (30 minutes). During first 20 min of each session the patient receives a direct current stimulation through surface sponge electrodes (35 cm2), 2 milliampere intensity: the anodal electrode is placed on presumed lesional area, the cathodal electrode is placed on the controlateral orbital bone.
89443376|NCT02496026|Sham Comparator|Sham tDCS plus wrist robot therapy|Group B is treated as Group A, but tDCS, even if the cap is applied on the patient head, is not activated and no current is delivered.
89443377|NCT02168907|Experimental|Treatment (CPI-613, bendamustine hydrochloride, rituximab)|Patients receive 6,8-bis(benzylthio)octanoic acid intravenously IV over 2 hours on days 1-4 (week 1) and days 1 and 4 (weeks 2 and 3). Patients also receive bendamustine hydrochloride IV over 30 minutes on days 4 and 5 and rituximab on day 5 of week 1. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
89443378|NCT03343028||Psychotherapy|The investigators will assess and acquire data on these Veterans across the course of the project prior to and after receiving Prolonged Exposure (PE) or Cognitive Processing Theory (CPT) treatment at VA Palo Alto (VAPAHCS) and the Albuquerque VA. They will acquire fMRI, behavioral, EEG, TMS/EEG, and saliva at baseline on these Veterans and again 3 months after treatment to assess prediction and durability of the clinical and brain/behavioral metrics. All study assessments will take place at Stanford University/VAPAHCS. Subjects will be recruited through VAPAHCS and Albuquerque VA. Subjects will complete a clinical assessment including: neuroimaging, self-report questionnaires completed via computer or paper-and-pencil, cognitive testing, saliva, and TMS and EEG assessments.
89443379|NCT03343028||Healthy Controls|The investigators will assess and acquire data on these Veterans who do not have history of PTSD and have no history of any Axis I psychiatric disorder, are taking psychotropic medication, or use illicit drugs. They will acquire fMRI, behavioral, EEG, TMS/EEG, and saliva once. All study assessments will take place at Stanford University. Subjects will be recruited through public flying, online ads and VAPAHCS. Subjects will complete a clinical assessment including: neuroimaging, self-report questionnaires completed via computer or paper-and-pencil, cognitive testing, saliva, and TMS and EEG assessments.
89443380|NCT02173197||OT arm|"Through the initial evaluation of the complex patients' needs, the OT will propose a targeted intervention to the needs emerged and decide which approach will use to achieve the goal (i.e. compensatory or restorative).~We will describe the characteristics of the population included and identify common needs and problems of the complex patients through the COPM.~The needs and problems identified will be grouped into macro-areas, and the OT will propose the appropriate treatment on the basis of the area identified, the patient's needs and the available resources regardless of the origin of the disease."
89443381|NCT02500784|Active Comparator|Formoterol A|12 months, formoterol, 20microgram/2ml, inhaler, BID
89443382|NCT02500784|Placebo Comparator|Formoterol B|12 months, normal saline, 2ml, inhaler, BID
89443383|NCT02176317|Experimental|Autologous Umbilical Cord Blood (UCB)|All participants will receive a single intravenous (into the vein) infusion of autologous umbilical cord blood cells.
89443384|NCT03538353|Other|Pain Education Video|Participants will watch a pain education video and then answer several questions.
89443385|NCT02495870|Experimental|Pork, 58°C, 72 minutes|Pork muscle (semitendinosus) sous-vide cooked at 58°C for 72 minutes
88927239|NCT01700660||Control|Patients operated without VIO.
88927240|NCT01700686||Obese subjects|Meal test and dexa scan
88927241|NCT01700699||Sorafenib|Assessment of percentage of BRAFV600E in tissue specimens of MRR-DTC patients treated with Sorafenib
88927242|NCT01700699||Axitinib|Assessment of percentage of BRAFV600E in tissue specimens of MRR-DTC patients treated with Axitinib
88927243|NCT01700699||Pazopanib|Assessment of percentage of BRAFV600E in tissue specimens of MRR-DTC patients treated with Pazopanib
88927244|NCT01700699||TKI|Assessment of percentage of BRAFV600E in tissue specimens of MRR-DTC patients treated with different type of tyrosine kinase inhibitor
88927245|NCT01700699||Motesanib|Assessment of percentage of BRAFV600E in tissue specimens of MRR-DTC patients treated with Motesanib
89199953|NCT04017741|Placebo Comparator|Placebo group|The placebo group will be administered 4mls of 0.9% saline.
89199954|NCT00546052|Experimental|1|Losartan (MK0954) / Losartan + HCTZ (MK0954A)
88927246|NCT01700699||Sunitinib|Assessment of percentage of BRAFV600E in tissue specimens of MRR-DTC patients treated with Sunitinib
89199955|NCT00887601|Experimental|Part I|Subjects will receive placebo, MK3134, and donepezil in one of four treatment sequences.
89443386|NCT02495870|Experimental|Pork, 58°C, 17 hours|Pork muscle (semitendinosus) sous-vide cooked at 58°C for 17 hours
89443387|NCT02495870|Experimental|Meat balls, 58°C, 17 hours|Meat balls made from pork Semitendinosus. Sous-vide cooked at 58°C for 17 hours
89443388|NCT02495870|Active Comparator|Pork, 160°C (until 58°C in core)|Pork muscle (semitendinosus) oven cooked at 160°C until 58° in core.
89443389|NCT02168985|Experimental|Attend TFH Program|Couples attend the three-day Faithful House Training program immediately
89443390|NCT02168985|No Intervention|Wait-listed for TFH Program|Couples attend The Faithful House program three-months after the initial group
89443391|NCT02495792|No Intervention|Control group|Group does not receive the biofeedback sensor
88927247|NCT01700712|Active Comparator|L. reuteri (DSM 17938 and ATCC PTA 5289; 1x108 CFU|2 tablets a day for 2 weeks
89443392|NCT02495792|Experimental|Biofeedback group|Group does receive the biofeedback sensor
89443393|NCT02176395|Experimental|Danhong injection|Based on the standard medical care, 40ml of Danhong injection, added into 250ml of 0.9% saline, given by continuous IV infusion at 2.5ml/min within 2 hours.
89443394|NCT02176395|Placebo Comparator|placebo|Based on the standard medical care, 40ml of 0.9% saline as the placebo, added into 250ml of 0.9% saline, given by continuous IV infusion at 2.5ml/min within 2 hours.
89443395|NCT02176395|No Intervention|healthy volunteer|
89443396|NCT02500940|Experimental|Control group|Neoadjuvant chemotherapy with tri-weekly cisplatin plus fluorouracil × 3 cycles (cisplatin 100 mg/m2, day 1, followed by fluorouracil 1000 mg/m2/d, days 1-4 continuous iv infusion, repeated every 3 weeks) + Intensity-Modulated Radiation Therapy ≧ 70 Gy/35 fractions
89443397|NCT02500940|Active Comparator|Test group|Neoadjuvant chemotherapy with weekly cisplatin, fluorouracil and leucovorin × 10 weeks (cisplatin 60 mg/m2 at days 1, 15, 29, 43, 57; alternatively with fluorouracil 2500 mg/m2 + leucovorin 250 mg/m2 at days 8, 22, 36, 50, 64) + Intensity-Modulated Radiation Therapy ≧ 70 Gy/35 fractions
89443398|NCT02176473|Experimental|Computerized Cognitive Behavioral Therapy|A computerized version of CBT has been developed in an effort to more widely disseminate the powerful effects of this psychotherapy modality, with studies showing efficacy comparable to that of traditional CBT.8 The present study aims to further investigate the feasibility of combining ECT and computerized CBT (c-CBT).
88927248|NCT01700712|Placebo Comparator|Sugar pill|2 tablets a day for 2 weeks
88927249|NCT01700738|Experimental|gastric ring surgery|in this group a gastric ring will be put by surgery.
88927250|NCT01700738|Active Comparator|nutritional help|the usual treatment of obesity in France with nutritional care will be dispensed for this arm
88927251|NCT01700751|Experimental|Dose Level 0 (starting dose)|brentuximab vedotin 0.3mg/kg, given IV on Days 7, 28, 49 & 70
88927252|NCT01700751|Experimental|Dose Level 1|brentuximab vedotin 0.6mg/kg, given IV on Days 7, 28, 49 & 70
89443399|NCT02500472|Experimental|Kava Supplement|See intervention description.
89443400|NCT02173275||derivation cohort|n = 309
89443401|NCT02173275||validation cohort|n = 309
89443402|NCT02495636|Experimental|Safety Run Up Group|The first 12 patients to be enrolled will initiate therapy with CDX-1401 alone, with the addition of MPDL3280A the day of their 4th CDX-1401 vaccination (week 7). These patients will undergo a tumor biopsy prior to initiation of trial therapy, after their 3rd CDX-1401 vaccination (during week 6) and after their 3rd MPDL3280A infusion (during week 14 or 15, if there are no dose delays). Although we don't expect significant synergistic toxicities of combination therapy based on mechanism of action/ formulation/ administration/ distribution of CDX-1401 and past vaccine/ immune checkpoint trials, these first 12 patients will constitute a safety run in group.
89443403|NCT02495636|Experimental|Expanded Trial Group|If there are no unexpected toxicities (no more than 3 of 12 patients with grade 3+ treatment related events as defined in 4.1.1), an additional 28 patients will be enrolled. Unlike the first 12 patients, these additional 28 patients will initiate both CDX-1401 and MPDL3280A on the same day, and will undergo tumor biopsies before starting trial therapy and after their 3rd CDX-1401 vaccination (during week 6).
89443404|NCT02176551|Experimental|Product 0405|Topical active investigational Product 0405
89443405|NCT02176551|Placebo Comparator|Placebo for Product 0405|Topical Placebo for Product 0405
89443406|NCT02495714|Experimental|Intervention schools|Active Learning; One hour each schoolday of physical Activity as part of academic learning Dietary councelling; teaching children and parents about a healty diet
89443407|NCT02495714|No Intervention|Control schools|No intervention
88927253|NCT01700751|Experimental|Dose Level 2|brentuximab vedotin 1.2mg/kg, given IV on Days 7, 28, 49 & 70
89443408|NCT02169063|Experimental|Diagnostic (11C-acetate, 18F-fluoride, PET)|Patients receive carbon-11 acetate IV and fluorine F 18 sodium fluoride IV over 1 minute and undergo PET at baseline and at 6-12 weeks after systemic therapy starts.
89443409|NCT02495558|Experimental|Patients with Tracheostomy|Assessment of reflex cough Assessment of the deccanultation outcome (follow-up)
89443410|NCT02173431||BMI 20 to 24.99|30 patients
88927254|NCT01700751|Experimental|Dose Level 3|brentuximab vedotin 1.8mg/kg, given IV on Days 7, 28, 49 & 70
88927255|NCT01700751|No Intervention|Control Dose Level|The first 3 patients will not receive brentuximab vedotin.
88927256|NCT01700777|Experimental|Intensive rehab group|"A group of children will beneficiate of HABIT-ILE treatment in an intensive way (camp) for 90h."
88927257|NCT01700777|Active Comparator|Regular treatment group|A group of children with hemiplegic cerebral palsy will beneficiate from conventional training at a regular frequency (1 to 6 hours / week) for 90hours.
88927258|NCT01700790|Experimental|Lopinavir/ritonavir and ritonavir|Two tablets of twice daily of Lopinavir/ritonavir 200 mg/50mg with 3 tablets of ritonavir 100 mg of twice daily given with rifampin 600 mg daily.
88927259|NCT01700803|Experimental|Povidone Iodine 10%|Using Povidone Iodine 10% hand scrub before caesarian section
88927260|NCT01700803|Experimental|Povidone Iodine 7.5% hand scrub|Using Povidone Iodine 7.5% hand scrub before caesarian section
88927261|NCT01700855|Experimental|Electroacupuncture|Patients received electroacupuncture stimulation
88927262|NCT01700855|Sham Comparator|Non-electroacupuncture|Patients received sham electroacupuncture
88927263|NCT01700868|Experimental|Vegan Group|Participants in the intervention group will follow a low-fat, vegan diet for 20 weeks, and will attend nutrition classes in the form of a weekly support group.
88927264|NCT01700868|Active Comparator|American Diabetes Association guidelines|Participants will follow ADA diet according to ADA regulations. This group will also receive weekly nutrition classes.
88927265|NCT01700881|Experimental|Plant-based diet|The diet group will be asked to follow a low-fat, vegan diet for 16 weeks
88927266|NCT01700881|Placebo Comparator|Supplement|The supplement group will follow an unrestricted diet, but will be given a pill containing a small, clinically insignificant amount of omega- 3 oils and vitamin E, which will serve as a placebo.
88927267|NCT01700894|Experimental|Walking Program + motivational interviewing calls|"The Women's Walking Program (WWP) core included a lifestyle PA prescription with an accelerometer for self-feedback and monitoring and 6 group visits (1 every week for 5 weeks in the 1st 24 weeks and 1 3 months later) targeted to increase lifestyle PA in AA women.~Participant in the WWP plus motivational interviewing telephone call arm receives 11 motivational interviewing telephone calls from an interventionist, with two calls in between each of the group-visits. Motivational interviewing calls are tailored to the individual and intended to sustain intervention effects between group-visits"
88927268|NCT01700894|Experimental|Walking Program + automated calls|"The Women's Walking Program (WWP) core, including a lifestyle physical activity prescription with an accelerometer for self-feedback and monitoring and 6 group visits (1 every 5 weeks during the first 24 weeks and 1 3 months later) targeted to increase lifestyle physical activity in African American women.~Participants in the WWP plus automated telephone call arm receive 11 automated calls with two calls sent between each group-visit. The automated calls are intended to supplement and sustain the intervention effects of the group-visits."
89443411|NCT02173431||BMI 25 to 29.99|30 patients
89443412|NCT02173431||BMI 30 to 34.99|30 patients
89443413|NCT02173431||BMI 35 to 39.99|30 patients
89443414|NCT02173431||BMI 40 to 44.99|30 patients
89443415|NCT02173431||BMI 45 to 49.99|30 patients
89443416|NCT02173431||BMI more than 50|30 patients
89443417|NCT04496882|Experimental|Switching therapy cohort|single arm, open label Patients will receive Vemlidy (tenofovir alafenamide, TAF) 25mg, daily for 48 weeks
89443418|NCT04496882|No Intervention|Historical continuing therapy cohort|By retrospectively review medical records, The patients continued the original regimen (ETV, TDF) for retreatment (within 3 months of clinical relapse)
89443419|NCT02176629|Experimental|Condition virtual reality (VR)|The subject is placed in front of a Barcotm screen capable of displaying high quality images.
89443420|NCT02176629|Active Comparator|Condition classic cognitive stimulation (CSC)|It is proposed about using the test dam Zazzo suitable for elderly. This classic test measures sustained attention.
89443421|NCT02502500|Active Comparator|Celecoxib|Celecoxib
89443422|NCT02502500|Experimental|AKB-6548 and Celecoxib|AKB-6548; celecoxib
89443423|NCT02500394|Placebo Comparator|standard care|Patients in the standard care population receive - if biomarkers are elevated -treatment of AKI in accordance with KDIGO 2012 guidelines
89443424|NCT02500394|Active Comparator|interventional care|Patients in the interventional population receive - if biomarkers are elevated - individualized treatment/volume substitution (balanced electrolyte solution = Ionosteril; 1,25-5 ml/kg/bw/6 hours) ) on the basis of predefined criteria
89443425|NCT02502422|Other|Classic laryngeal mask airway|single arm
89443426|NCT02173587|Experimental|Mussel oil capsules|Four mussel oil capsules (containing 800mg mussel oil and 800mg corn oil) per day for first two months and two mussel oil capsules (containing 400mg mussel oil and 400mg corn oil) per day thereafter for four months.
89443427|NCT02173587|Placebo Comparator|Corn oil capsuels|Four corn oil capsules (containing 1600mg corn oil) for first two months and two mussel oil capsules (containing 800mg corn oil) per day thereafter for four months.
89013311|NCT06302374|Experimental|Cohort 7 GR2001 0.2mg/kg/placebo|Eighteen subjects will be randomly assigned to receive either GR2001 or placebo at a 2:1 ratio (i.e. 12 subjects receive GR2001 and 6 with placebo) followed by a dose of Tetanus Toxoid（TT） on Day0.
89013312|NCT06302374|Experimental|Cohort 8 GR2001 0.1mg/kg/ GR2001 0.2mg/kg/ HTIG|"Thirty six subjects will be randomly assigned to receive GR2001(0.1mg/kg) or GR2001(0.2mg/kg) or HTIG(250IU) at a 1:1:1 ratio (i.e. 12 subjects receive GR2001(0.1mg/kg), 12 with GR2001(0.2mg/kg) and 12 with HTIG).~Seventy two subjects will be randomly assigned to receive GR2001(0.1mg/kg) or GR2001(0.2mg/kg) or HTIG(250IU) at a 1:1:1 ratio (i.e. 24 subjects receive GR2001(0.1mg/kg), 24 with GR2001(0.2mg/kg) and 24 with HTIG) followed by one dose of Tetanus Toxoid（TT） on Day0 and Day28."
89013313|NCT06302361|Experimental|Lymphovenous anastomosis (LVA)|Intervention with lymphovenous anastomosis (LVA) surgery of the affected arm.
89013314|NCT06302348|Experimental|Sepiapterin|Participants ≥1 month of age with average screening blood Phe ≥360 micromoles (μmol)/liter (L) will receive age- and weight-adjusted doses of sepiapterin orally once daily for 4 weeks in Part 1. Participants ≥1 month of age with average screening blood Phe <360 μmol/L will receive an age- and weight-adjusted dose of sepiapterin on Day 1 of Part 1 after protein/Phe load. Participants <1 month of age at screening will receive a single oral dose of sepiapterin on Day 1 of Part 1. Participants who are responsive to sepiapterin in Part 1 will progress to Part 2 and will continue to receive sepiapterin orally once daily for up to 6 years.
89013315|NCT06302335|Experimental|Povidone-iodine arm|Patients submitted to colorectal resections using Povidone-iodine in the surgical wound.
89013316|NCT06302335|Active Comparator|Saline solution arm.|Patients submitted to colorectal resections using saline solution in the surgical wound.
89013317|NCT06302322|Experimental|Natural Thin Gums|
89013318|NCT06302322|Experimental|Natural Thick Gums|
89013319|NCT06302322|Experimental|Surgically augmented Thin Gums|
89013320|NCT06302309|Experimental|Intervention|The intervention group will receive 4 sessions of the 'managing the mental state' intervention immediately after randomization.
89013321|NCT06302309|Experimental|Waitlist|The control group will enter a waiting period of 4 weeks and receive the same 4-week intervention thereafter.
89013322|NCT06302296|Experimental|injectable form of PRF|A group of patients in which participants will be undergo to orthodontic treatment will be received a 0.9 ml injection of PRF after 1st premolar extraction.
89013323|NCT06302296|Experimental|traditional orthodontic treatment|A group of patients in which participants will be undergo to traditional orthodontic treatment will be received a Placebo injection after 1st premolar extraction.
89013324|NCT06302283||Family Members or Informal Caregivers|family members or informal caregivers that have cared for a patient with Covid-19 or of a patient who has died in the first phase of the pandemic (March to December 2021)
89013325|NCT06302270||mother-infant dyads|
89199956|NCT00887601|Experimental|Part II|Subjects will receive placebo and three different doses of MK3134 (1 mg, 5 mg, and 25 mg) in one of four treatment sequences.
89443428|NCT02495480|Experimental|sheathed group|The sterilized disposable sheath covered the outer surface of the colonoscope, then colonoscope will be performed in conventional way;a new sheath will be placed on the endoscope in sheathed group as a intervention
89013326|NCT06302231|Experimental|Time-Restricted Eating and Aerobic Exercise Performed in Fasted State|"Participants will be prescribed a diet plan to promote weight loss, but no food will be provided to them.~Diets will be formulated to contain 50% energy as carbohydrate, 20% as protein, and 30 % as fat.~Participants will be instructed to divide their daily energy intake between three meals each day (lunch, afternoon snack, and dinner).~Participants will be instructed to eat from 12.00 until 20.00 (8-hour window). Aerobic exercise sessions will be carried out during the morning shift with participants in a fasted state."
89199957|NCT00964912|Active Comparator|BMS-820836 (Part 1, Panel 1)|
89199958|NCT00964912|Active Comparator|BMS-820836 (Part 1, Panel 2)|
89443429|NCT02495480|No Intervention|conventional group|Colonoscopy will be performed with air insufflation during insertion
89443430|NCT02173665|Experimental|BI 1356 BS - Powder in bottle (PIB)|
89443431|NCT02173665|Experimental|BI 1356 BS - Tablet|
89443432|NCT02173665|Active Comparator|Placebo|
89443433|NCT02495324|Experimental|Fimasartan|Placebo daily for 2 weeks and Fimasartan 60mg daily for 2 weeks and 120mg daily for 4 weeks
89443434|NCT02495324|Active Comparator|Valsartan|Placebo daily for 2 weeks and Valsartan 80mg daily for 2 weeks and 160mg daily for 4 weeks
89443435|NCT02495324|Other|Olmesartan medoxomil|Reference group. Placebo daily for 2 weeks and Olmesartan 10mg daily for 2 weeks and 20mg daily for 4 weeks
89443436|NCT02173743|Experimental|PRP group|PRP during barbotage
89199959|NCT00964912|Active Comparator|BMS-820836 (Part 1, Panel 3)|
89199960|NCT00964912|Active Comparator|BMS-820836 (Part 1, Panel 4)|
89199961|NCT00964912|Active Comparator|BMS-820836 (Part 1, Panel 5)|
89199962|NCT00964912|Active Comparator|BMS-820836 (Part 1, Panel 6)|
89199963|NCT00964912|Active Comparator|BMS-820836 (Part 1, Panel 7)|
89199964|NCT00964912|Active Comparator|BMS-820836 (Part 1, Panel 8)|
89199965|NCT00964912|Active Comparator|BMS-820836 (Part 1, Panel 9)|
89443437|NCT02173743|Other|Control group|Regular barbotage
89443438|NCT02500238||Control|This group will provide 2 breath carbon monoxide (reading of ≤ 6 parts per million) and a saliva sample, urine sample, and toe nail clippings will be taken from this group.
89443439|NCT02500238||Smoking|This group will provide 1 breath carbon monoxide test (reading of ≤ 6 parts per million) and a saliva sample, urine sample, and toe nail clippings.
89443440|NCT02500238||Vaping|This group will provide 2 breath carbon monoxide test (reading of ≤ 6 parts per million) and a saliva sample, urine sample, and toe nail clippings.
89443441|NCT02495246|Active Comparator|Group 1|ChAd3-EBO-Z (1x10^11 vp) and Ad26.ZEBOV (5x10^10 vp) 28 days later.
88927269|NCT01700894|Experimental|Walking Program|"The Women's Walking Program (WWP) core, including a lifestyle physical activity prescription with an accelerometer for self-feedback and monitoring and 6 group visits (1 every 5 weeks during the first 24 weeks and 1 3 months later) targeted to increase lifestyle physical activity in African American women.~Participants in the WWP receive no telephone calls."
89199966|NCT00964912|Active Comparator|BMS-820836 (Part 2, Panel A)|
89199967|NCT00964912|Active Comparator|BMS-820836 (Part 2, Panel B)|
89443442|NCT02495246|Active Comparator|Group 2|Ad26.ZEBOV (5x10^10 vp) and ChAd3-EBO-Z (1x10^11 vp) 28 days later.
89443443|NCT02495246|Active Comparator|Group 3|ChAd3-EBO-Z (1x10^11 vp) and Ad26.ZEBOV (5x10^10 vp) 56 days later.
89443444|NCT02495246|Active Comparator|Group 4|Ad26.ZEBOV (5x10^10 vp) and ChAd3-EBO-Z (1x10^11 vp) 56 days later.
89443445|NCT02495402|No Intervention|No Intervention: Control|No Intervention
89443446|NCT02495402|Experimental|Motivational Interviewing|A brief interview intervention for substance abuse
89443447|NCT02256033|Experimental|Istradefylline|One 40-mg tablet of istradefylline administered on Day 1.
89443448|NCT02502110|Experimental|rosuvastatin 20mg/day|To receive oral rosuvastatin 20mg/day and regular therapy from 7 days before ablation and last for 3 months.
89013327|NCT06302231|Active Comparator|Time-Restricted Eating and Aerobic Exercise Performed in Fed State|"Participants will be prescribed a diet plan to promote weight loss, but no food will be provided to them.~Diets will be formulated to contain 50% energy as carbohydrate, 20% as protein, and 30 % as fat.~Participants will be instructed to divide their daily energy intake between three meals each day (lunch, afternoon snack, and dinner).~Participants will be instructed to eat from 12.00 until 20.00 (8-hour window). Aerobic exercise sessions will be carried out during the afternoon shift with participants in a fed state."
89013328|NCT06302231|Other|Time-Restricted Eating|"Participants will be prescribed a diet plan to promote weight loss, but no food will be provided to them.~Diets will be formulated to contain 50% energy as carbohydrate, 20% as protein, and 30 % as fat.~Participants will be instructed to divide their daily energy intake between three meals each day (lunch, afternoon snack, and dinner).~Participants will be instructed to eat from 12.00 until 20.00 (8-hour window). Participants in this arm will not perform aerobic exercise training."
89013329|NCT06302218|Active Comparator|iPACK + ACB|"spinal anesthesia~+ ultrasound guided iPACK (20ml 0,2% ropivacaine) with ACB (10ml 0.5% ropivacaine)"
89013330|NCT06302218|Active Comparator|Erectro Spinae Plane Block|"spinal anesthesia~+ ultrasound guided ESPBk - 20ml 0,2% ropivacaine"
89013331|NCT06302218|Placebo Comparator|Control group|Only spinal anesthesia - No peripheral nerve block
89013332|NCT06302205|Sham Comparator|Sham Group|Home-based low-intensity exercise training without subsequent physical activity intervention.
89013333|NCT06302205|Experimental|Moderate-intensity (MIT)|Home-based moderate-intensity exercise training with subsequent physical activity intervention.
89013334|NCT06302205|Experimental|Combined moderate and high-intensity (MHIT)|Home-based moderate- and high-intensity exercise training with subsequent physical activity intervention.
89013335|NCT06302166|Active Comparator|High Intensity circuit training (HICT)|"For the group allocated with exercise, high intensity circuit training (HICT) of three supervised sessions per week for 20-30 mins will be given. HICT commenced after 10 mins low to moderate intensity warm up and after completing session ended with 10 mins cool down. Intensity of exercise will be measured on borg rating of perceived exertion (RPE). Perceived exertion is how hard you feel like your body is working. Although this is a subjective measure your exertion rating based on a 0 to 10 modified borg rating scale may provide a fairly good estimate of your actual heart rate during physical activity. 0 perceiving no exertion at all to 10 perceiving a maximal exertion of effort. A moderate intensity activity will be at 3-5 perceiving somewhat hard, similarly 6-10 will be perceived as high intensity activity."
89013336|NCT06302166|Active Comparator|Intermittent fasting (IF)|For the group allocated with intermittent fasting, a time restricted feeding (TRF) methodology will be administered. The Fasting protocol will begin with a 12-hour eating window (12:12) and will gradually go down to 8 hours eating window over a period of 8 weeks (16:8).
89013337|NCT06302166|Active Comparator|Combination of HICT and IF|The group allocated with both exercise and intermittent fasting will be provided with both HICT for three sessions per week and 8 hours' time restricted eating.
89013338|NCT06302153|Experimental|progressive loading exercises|"progressive loading exercises Progressive loading exercises & stretching protocol will be given. The exercises included are as follows~Standing calf raise double leg~Standing calf raise single leg 4 sets with 8 repetitions will be given. Session will be given thrice a week for 40 minutes.~Soleus wall sits double leg~Toe taps~Toe walks forward hops double"
89013339|NCT06302153|Experimental|Conditioning Exercises|"conditioning exercises Conditioning exercises & stretching protocol will be given. (31)~Standing calf raise~Seated calf raise~Calf press hold~Loaded plant walk~Single leg step hops up 4 sets with 8 repetitions will be given. Session will be given thrice a week for 40 minutes."
89013340|NCT06302127|No Intervention|Control|During the study, control participant will be provided with existing essential public health service including quarterly follow-ups and annual physical examination, and be advised to see their usual provider for care, as appropriate.
89013341|NCT06302127|Experimental|Intervention|Intervention group will receive the risk-stratified integrated CVD management (RISIMA) model consisting of 5 core elements provided as a package: (1) Team-based care; (2) Risk-stratified care pathway; (3) Strengthened health education; (4) Financial incentives for integration of care; (5) Supporting health information system.
89013342|NCT06302101|Experimental|İntervention|chair-based exercises and cognitive exercises
89013343|NCT06302101|Active Comparator|Control group|chair-based exercises
89013344|NCT06302062|Experimental|Cohort A|Three patients were planned to be enrolled, and each subject received one to two cell transfusions.
89013345|NCT06302062|Experimental|Cohort B|14 to 20 patients were enrolled, and each subject received one to two cell transfusions. In this group, Tumor Associated Lymph node T cells were combined with Serplulimab Injection.
89013346|NCT06302049|Experimental|esomeprazole group|patients in this arm will receive esomeprazole 20 mg once daily
89013347|NCT06302049|Placebo Comparator|Placebo group|patients in this arm will receive placebo once daily
89013348|NCT06302036|No Intervention|control group|No application will be performed on the participants in the control group, and as in the intervention group, pre-tests (PSI and STAI) will be carried out immediately after the depression risk determination is made (after the BDI application), and post-tests will be carried out after the interviews are completed. All students in the control group will be reminded of their high scores on the depression scale and will be advised to seek medical help.
89013349|NCT06302036|Experimental|experimental group|For applications and information, a computer-assisted zoom program or other online programs that can provide meetings (Google meet, teams program or WhatsApp video call) will be used. The students in the intervention group will be informed about the function and application of EFT, it will be explained practically, and the application steps will be taken. This stage is planned to take approximately 15 minutes.
89443449|NCT02502110|No Intervention|blank control|Regular therapy from 7 days before ablation and last for 3 months. Regular medicines used for AF includes warfarin, metoprolol sustained release tablet, amiodarone, perindopril and irbesartan.
89443450|NCT02173899|Experimental|varicella-1|The second varicella vaccine and 1 year of the interval time between 2 doses
89013350|NCT06302023|Experimental|DHA supplement|DHA supplement 1000mg per day
89013351|NCT06302023|No Intervention|no DHA supplement|no DHA supplement
89013352|NCT06302010|No Intervention|Control Group|Pregnant women in the control group will not receive any intervention other than routine hospital care during the NST procedure.
89013353|NCT06302010|Experimental|Intervention Group|Pregnant women in the intervention group will be explained how to use the stress ball before NST. Pregnant women will be asked to demonstrate using a stress ball, and it will be verified that they can use it correctly. Pregnant women will be told to squeeze the ball once and release it after counting to three, to inhale each time they press the ball, to exhale when they relax their grip, and to focus only on the ball. Pregnant women will be instructed to continue this practice throughout the NST procedure (approximately 20 minutes). In addition, stress balls used in the hospital environment to minimize contamination will be disinfected with disposable asepsis wipes before being given to pregnant women.
89443451|NCT02173899|Experimental|varicella-3|The second varicella vaccine and 3 years of the interval time between 2 doses
89443452|NCT02173899|Experimental|varicella-5|The second varicella vaccine and 5 years of the interval time between 2 doses
89443453|NCT02173977|Active Comparator|ARM A- Agonist/Antagonist protocol|The Ultrashort GnRH Agonist/antagonist method entails pre-treatment with oral contraceptive pills before the combination of GnRH ultrashort agonist and antagonist protocol
89443454|NCT02173977|Active Comparator|ARM B- Antagonist protocol|The standard IVF method entails Flexible Multidose GnRH Antagonist protocol during COH
89443455|NCT02502344|Experimental|medical intervention group|subjects in this group will accept healthy lifestyle changes such as food control and intensive exercise for 3 months first. Then their insulin resistance will be evaluated again . If their insulin resistance didn't improve, then they will take metformin 0.5g qd to reduce insulin resistance. If their insulin resistance improved, they will continued healthy lifestyle changes.
89443456|NCT02502344|No Intervention|clinical observeral group|subjects in this group will not accept medical interventions
89443457|NCT04496180|Experimental|PREVENA (CiPNT)|"Target population is every patient undergoing a laparotomic procedure and responding to inclusion criteria marked in paragraph 3.8 (see forward) A member of the medical surgery team should apply all parts just after the surgical procedure.~A medical member (nurse specialist in wound care) of the surgical team removes the dressing. All other manipulations of the therapy unit, the connector and the cartridge can be carried out by any nurse practitioner in hospital or extra hospital environment but must warn the investigators.~The aspiration will be stopped 24 hours before and the dressing is removed by a nurse at home or in the hospital.~The specialized nurse who will take a photo and assess the condition of the wound in the treatment room.~One of the investigators, non-operators, who will also assess the condition of the wound by photo."
89443458|NCT04496180|Active Comparator|Simple dressing|Simple dressing; standard, waterproof dressing applied to wound
89443459|NCT02174133||patients after HTX|
89443460|NCT02174133||patients after LVAD implantation|
89443461|NCT02174133||patients with coronary heart disease|
89443462|NCT02174133||healthy volunteers|
89443463|NCT02174211|Active Comparator|Arm A: Ranibizumab (Lucentis)|Previous Vitrectomy
88927270|NCT01700920|Experimental|Mesenchymal Stem Cell|"Cell suspension mesenchymal stem cells (MSCs) obtained from bone marrow aspirate from the patient and expanded in vitro in a specific medium enriched with platelet lysate without addition of animal products.~They employ a minimum dose of 0.5 x 106 MSC / kg and a maximum of 1, 0x106 CSM / kg of patient weight.~Pharmaceutical form: Suspension cell Route of administration: local implant intraosseous injection with trocar in the femoral head."
88927271|NCT01700933|Active Comparator|High-dosage-group|
88927272|NCT01700933|Active Comparator|Low-dosage-group|
88927273|NCT01700972|Experimental|Imaging at 10-minute vs. 30-45-minutes|The radionuclide Myoview will be administered once for the rest and stress myocardial perfusion imaging. The subsequent rest and stress imaging will be performed twice each - at 10 minutes and 30-45 minutes after radiotracer injection.
88927274|NCT01700998|Placebo Comparator|Placebo|250 ml saline 0.9% for 24 hours in an infusion rate solution of 10.4 ml / hr for 3 days repeated during ICU stay if hypomagnesemia occurs.
88927275|NCT01700998|Experimental|Magnesium|48 mEq Magnesium diluted in 250 ml saline 0.9% for 24 hours in an infusion rate solution of 10.4 ml / hr. Therapy is continued for 3 days and repeated if hypomagnesemia occurs during ICU stay
88927276|NCT01701050||Blood collection|Female patients 18 years or older with estrogen receptor (ER) positive, HER2 negative, progressive metastatic breast cancer after one or more lines of endocrine therapy (ET) who are initiating a new ET will be enrolled into the study. Patients must have immunohistochemistry (IHC) proven ER positive disease, IHC and/or fluorescence in-situ hybridization (FISH) proven HER2 negative disease, and an ECOG performance status of 0-2. Patients with brain metastases only or those who are progressing on fulvestrant are not eligible for the study.
88927277|NCT01701076|Experimental|Bendamustine|All patients are treated with bendamustine in combination with lenalidomide and dexamethasone for a maximum of 6 cycles.
88927278|NCT01701089|Experimental|RO4602522 Group 1|
88927279|NCT01701089|Experimental|RO4602522 Group 2|
88927280|NCT01701128|Experimental|Speed TT|Walk on treadmill with progressive increases in speed
88927281|NCT01701128|Experimental|Mixed TT|Walk on treadmill with progressive increases in speed and incline
88927282|NCT01701128|Active Comparator|Control|Light-intensity exercise group, work flexibility and coordination
88927283|NCT01701141||Individuals with MDD|Individuals with current MDD as determined by structured clinical interview for DSM-IV (SCID) at time of enrollment.
88927284|NCT01701141||Healthy Controls|Individuals with no psychiatric diagnosis as determined by structured clinical interview for DSM-IV (SCID) at time of enrollment
88927285|NCT01701180|Experimental|Oxytocin|24 IU Oxytocin, intranasal application 45 min prior to the experiment
88927286|NCT01701180|Placebo Comparator|Placebo|Intranasal application, sodium chloride solution, 3 puffs per nostril
88927287|NCT01701206|Experimental|HIV intervention Group|Experimental arm receives peer-led HIV information on social media
88927288|NCT01701206|No Intervention|Control arm|
89199968|NCT00887757|Experimental|gemcitabine +ABT-263|
89443464|NCT02174211|Active Comparator|Arm B: Ranibizumab (Lucentis)|Non-vitrectomised, PVD / no PVD
89443465|NCT02174211|Active Comparator|Arm C: Aflibercept (Eylea)|Non-vitrectomised, PVD / no PVD
89443466|NCT02500160|Experimental|patient specific instrumentation (MRI)|MRI based patient-specific instrumentation
89443467|NCT02500160|Active Comparator|patient specific instrumentation (CT)|CT based patient-specific instrumentation
89443468|NCT02169141||PK of Levofloxacin-Capreomycin|Pharmacokinetics (PK) in M/XDR-TB patients receiving at least Levofloxacin and Capreomycin as part of their WHO treatment for M/XDR-TB
89443469|NCT02495012|Placebo Comparator|control|5IU/60 kg bolus and 0.002 IU/kg/h continuous infusion for 48 hours
89443470|NCT02495012|Active Comparator|treatment|5IU/60 kg bolus and 0.002 IU/kg/h continuous infusion for 48 hours
89443471|NCT02169297|Experimental|Ultrasound-Guided Sub-Paraspinal Block|Patients allocated to the treatment group received bilateral ultrasound-guided placement of multi-perforated soaker catheter at sub-paraspinal location and an intravenous PCA post-operatively
89013354|NCT06301997|Experimental|Topical ZAX.1400.P03|ZAX.1400.P03, applied topically twice daily for 3 weeks after enrolment
89013355|NCT06301997|Placebo Comparator|Placebo|Placebo, applied topically twice daily for 3 weeks after enrolment
89013356|NCT06301984|Experimental|Experimental|In the initial assessment, data regarding the general health status will be collected and imaging exams (panoramic X-ray of the anteroposterior, lateral and traction spine, and X-ray of the right and left hands) and laboratory tests (blood count, coagulogram, dosage of sodium and potassium, urea and creatinine levels, AST and ALT, PCR, ESR, type I urine and urine culture) will be requested. During the preoperative consultation, measurements of the study variables will be obtained from the imaging exams), in addition to obtaining photographs of the patients. To install the Insight GS system, the surgical approach will be carried out according to the manufacturer's instructions for use, briefly described below. A posterior midline skin incision is made from the upper to the lower instrumented level. Subfascial exposure of the spine is performed, ensuring that the facet joint capsules are spared. Pedicle screws are inserted bilaterally at the cranial and caudal ends of the instrumentati
89013357|NCT06301971|Experimental|Emraclidine 30 mg|Participants will receive a single oral dose of 30 milligrams (mg) (approximately 75 microcurie [μCi]) [14C]-emraclidine on Day 1.
89013358|NCT06301958|Experimental|Dextrose prolotherapy|A subject received a single intra-articular injection of 25% hypertonic glucose solution 10 mL (1:1 of 50% dextrose and normal saline) into one knee with arthritis after aspiration of all synovial fluid.
89443472|NCT02169297|Placebo Comparator|PCA only|Patients allocated to the control group had two sham multi-perforated soaker catheters taped to their back and received intravenous PCA post-operatively
89443473|NCT02494934|Experimental|Cognitive-behavioural therapy|Eight sessions of psychotherapy incorporating cognitive-behavioural and sex therapy interventions.
89443474|NCT02494934|Experimental|physical therapy|Eight sessions of physical therapy targeting the pelvic floor muscles.
89443475|NCT02169375|Experimental|Mu Rhythm with adaptation|
89443476|NCT02169375|Experimental|Mu Rhythm without adaptation|
89443477|NCT04496492|Experimental|Tocotrienol|Subjects receiveTocotrienol 200 mg/twice daily before surgery
89443478|NCT02500004|Active Comparator|Cachectic pancreatic cancer|"Cachectic patients with pancreatic cancer~BAT activity: 18F-FDG PET-MRI-imaging. Body composition: DXA scanning, D2O and MRI. Inflammatory and metabolic profile of adipose tissue: abdominal subcutaneous adipose tissue biopsy.~Systemic inflammatory profile: blood sampling. Resting metabolic rate: indirect calorimetry. Physical activity level: accelerometry. Total daily energy expenditure: double-labeled water."
89443479|NCT02500004|Active Comparator|Cachectic NSCLC|"Cachectic patients with non-small cell lung cancer~BAT activity: 18F-FDG PET-MRI-imaging. Body composition: DXA scanning, D2O and MRI. Inflammatory and metabolic profile of adipose tissue: abdominal subcutaneous adipose tissue biopsy.~Systemic inflammatory profile: blood sampling. Resting metabolic rate: indirect calorimetry. Physical activity level: accelerometry. Total daily energy expenditure: double-labeled water."
89013359|NCT06301906||Group 1|
89013360|NCT06301880|Placebo Comparator|Group 1: Normal saline|Patients in this group were randomly assigned to receive the topical application of normal saline (0.9% sodium chloride solution) on the LIMA graft as control
89013361|NCT06301880|Active Comparator|Group 2: Nitroglycerin|Patients were randomly assigned to receive the topical application of nitroglycerin (Caspian Tamin Pharmaceutical, Guilan, Iran) 10 mg in 20 ml of normal saline on the LIMA graft.
89013362|NCT06301880|Active Comparator|Group 3: milrinone|Patients were randomly assigned to receive the topical application of milrinone (Baxter Pharmaceuticals, Ahmedabad, India) on the LIMA graft
89013363|NCT06301854|Experimental|TPN171H group|The recommended dosage is 5 mg/ time, as needed, it is recommended to take warm water within 0.5 to 4 hours before sexual activity. In the first month of the treatment period, the dose is 5 mg, and depending on the efficacy and tolerance of the subjects, the dose can be increased to 10 mg or reduced to 2.5 mg, which can be taken no more than once a day.
89013364|NCT06301841|No Intervention|control|"Conventional microbiological investigations are performed as soon as possible after ICU admission including blood cultures, non-invasive or invasive respiratory tract sample, urine antigen assays and viral PCR.~Antibiotics have to be started as soon as possible after ICU admission and during at less 3 days"
89013365|NCT06301841|Experimental|Intervention|"In addition to conventional microbiological investigations, a non-invasive or invasive respiratory tract sample is collected as soon as possible and tested with the respiratory broad-panel mPCR (Biofire FilmArray Pneumonia plus Panel de Biomérieux). This test detects 18 bacteria, 9 viruses and 7 antibiotic resistance markers. In addition a procalcitonin assay is performed on day-3 of ICU admission.~Antibiotics have to be started as soon as possible after ICU admission and during at less 3 days.~At day 3, clinicians have to consider all the early microbiological results (including the respiratory broad-panel mPCR (Biofire FilmArray Pneumonia plus Panel de Biomérieux) and procalcitonin, and subsequently to apply an algorithm of early antibiotics discontinuation or de-escalation."
89013366|NCT06301828|Experimental|Experimental group|Enrolled patients were treated with endostar combined with stereotactic body radiation therapy and Envafolimab.
89013367|NCT06301789|Placebo Comparator|Control Group|receive pre-emptive ultrasound-guided quadratus lumborum block with 25 mL of 0.25% bupivacaine on each side of the abdominal wall before induction of GA.
89443480|NCT02500004|Active Comparator|Cachectic COPD|"Cachectic COPD patients.~BAT activity: 18F-FDG PET-MRI-imaging. Body composition: DXA scanning, D2O and MRI. Inflammatory and metabolic profile of adipose tissue: abdominal subcutaneous adipose tissue biopsy.~Systemic inflammatory profile: blood sampling. Resting metabolic rate: indirect calorimetry. Physical activity level: accelerometry. Total daily energy expenditure: double-labeled water."
89443481|NCT02500004|Active Comparator|Non-cachectic COPD|"Non-cachectic COPD patients.~BAT activity: 18F-FDG PET-MRI-imaging. Body composition: DXA scanning, D2O and MRI. Inflammatory and metabolic profile of adipose tissue: abdominal subcutaneous adipose tissue biopsy.~Systemic inflammatory profile: blood sampling. Resting metabolic rate: indirect calorimetry. Physical activity level: accelerometry. Total daily energy expenditure: double-labeled water."
89537082|NCT03300635|Other|Fibromyalgia patients|All study subjects, both patients and healthy controls, will attend all three interventions: Mental distress and relaxation test, Glucose tolerance test, and Exercise test
89443482|NCT02500004|Other|Healthy individuals|"BAT activity: 18F-FDG PET-MRI-imaging. Body composition: DXA scanning, D2O and MRI. Inflammatory and metabolic profile of adipose tissue: abdominal subcutaneous adipose tissue biopsy.~Systemic inflammatory profile: blood sampling. Resting metabolic rate: indirect calorimetry. Physical activity level: accelerometry. Total daily energy expenditure: double-labeled water."
89443483|NCT02499848|Experimental|Intraprostatic administration|PRX302
89443484|NCT02502188|Experimental|Part 1 - CC-90005 and Placebo|CC-90005 or Placebo will be administered orally from low to high dose
89443485|NCT02502188|Experimental|Part 2 - CC-90005 and Placebo|CC-90005 or Placebo will be administered orally from low to high dose
88927289|NCT01701219|Other|Cohort A|S. aureus on at least 1 blood culture within 72 hours of beginning study drug
89443486|NCT02502032|Experimental|Cisatracurium 0.005 mg/kg|The group received pretreatment of cisatracurium 0.005 mg/kg.
88927290|NCT01701219|Other|Cohort B|MRSA on a baseline blood culture and on at least 1 additional blood culture after at least 72 hours of vancomycin and/or daptomycin treatment
88927291|NCT01701232|Active Comparator|MabThera|Reference rituximab at a dose of 375 mg/m2 intravenously once a week for four weeks (on days 1, 8, 15 and 22)
88927292|NCT01701232|Experimental|BCD-020|Proposed rituximab biosimilar at a dose of 375 mg/m2 intravenously once a week for four weeks (on days 1, 8, 15 and 22)
88927293|NCT01701297|Active Comparator|Co-trimoxazole|Co-trimoxazole 960mg daily po
88927294|NCT01701297|Experimental|VSL#3 active|VSL#3 active 2 sachets/daily
88927295|NCT01701297|Placebo Comparator|VSL#3 placebo|VSL#3 placebo 2 sachets/daily
88927296|NCT01701310|Experimental|Ferric carboxymaltose|
88927297|NCT01701310|Active Comparator|Ferrous Sulphate|
88927298|NCT01701323|Experimental|Treatment (Ex-vivo expanded cord blood progenitors)|Patients receive filgrastim SC or IV on days 1-7, fludarabine phosphate IV QD over 30 minutes on days 2-6, cytarabine IV QD over 4 hours on days 2-6, and ex-vivo expanded cord blood progenitor cells IV over 30 minutes on day 8.
88927299|NCT01701336|Experimental|Unique Arm|"Ad6NSmut~MVA-NSmut~15 subjects receiving 2 doses Ad6NSmut at week 0 and 4, then 2 doses of MVA-NSmut at weeks 8 and 12. PEG-IFN/RBV therapy starts at week 10 after first vaccination"
88927300|NCT01701349|Active Comparator|Fosbretabulin + paclitaxel + carboplatin|"Six 21 day cycles of:~Fosbretabulin (60 mg/m2) IV on Day 1, 8, 15 Paclitaxel (200 mg/m2) IV on Day 2 Carboplatin (AUC 6) IV on Day 2"
88927301|NCT01701349|Placebo Comparator|Placebo + paclitaxel + carboplatin|"Six 21-day cycles of:~Placebo (formulated and packages to match fosbretabulin)on Day 1, 8, 15 Paclitaxel (200 mg/m2) IV on Day 2 Carboplatin (AUC6) IV on Day 2"
88927302|NCT01701427||1|1. Healthy, un-operated, groin-hernia free, pain-free and medicinal free males
88927303|NCT01701453|Experimental|6 months group|6 months duration of P2Y12 inhibitor (clopidogrel, ticagrelor, prasugrel) treatment
88927304|NCT01701453|Experimental|12 months or longer group|12 months or longer duration of P2Y12 inhibitor (clopidogrel, ticagrelor, prasugrel) treatment
88927305|NCT01701466|Experimental|Arm B: standard of care plus NeoVIDERM cream|Patients will apply NeoVIDERM cream to the treatment area everyday one week before starting radiotherapy, throughout treatment and for two weeks post treatment. Patients will also perform standard of care skin treatment.
88927306|NCT01701466|Active Comparator|Arm A: standard skin care|Patients will be asked to apply Aveeno cream twice a day starting the day of their treatment until two weeks after the end of their treatments. If they develop dry desquamation, they will be asked to apply Flamazine twice a day until dermatitis resolves.
88927307|NCT01701479|Experimental|Experimental arm|"Subcutaneous aldesleukin (IL-2) will be given at a dose of 6 x 106 IU/m2/day in two 5 day blocks (days 1-5 and 8-12).~A continuous infusion of ch14.18/CHO is started on day 8. The duration of the infusion is dependent on the assigned infusion schedule. The duration will range from 10 to 21 days. Three dose levels will be considered with respect to daily dose (7 mg/m2, 10 mg/m2, 15 mg/m2), which relates to total doses of 100 mg/m2,150 mg/m2 and 210 mg/m2.~Patients will receive isotretinoin (13-cis-RA) 160 mg/m²/day divided into two equal doses given orally twice a day for 14 days after the completion of the ch14.18/CHO infusion. The starting day is dependent on the duration of ch14.18/CHO infusion and may be either day 19, 23, 24 or 30."
88927308|NCT01701479|Active Comparator|Comparator arm|"A continuous infusion of ch14.18/CHO is started on day 8. The duration of the infusion is dependent on the assigned infusion schedule. The duration will range from 10 to 21 days. Three dose levels will be considered with respect to daily dose (7 mg/m2, 10 mg/m2, 15 mg/m2), which relates to total doses of 100 mg/m2,150 mg/m2 and 210 mg/m2.~Patients will receive isotretinoin (13-cis-RA) 160 mg/m²/day divided into two equal doses given orally twice a day for 14 days after the completion of the ch14.18/CHO infusion. The starting day is dependent on the duration of ch14.18/CHO infusion and may be either day 19, 23, 24 or 30."
88927309|NCT01701492||Stem Cell Transplant Survivors|All participants enrolled on this study will complete a questionnaire and undergo neurocognitive evaluation.
88927310|NCT01701492||Normal control participants|Control participants in the community without a history of serious illness, matched on age, gender, race/ethnicity and socioeconomic status. They will complete a questionnaire and undergo neurocognitive evaluation.
88927311|NCT01701518|Other|Ozurdex|Intra-operative Ozurdex (biodegradable 0.7mg dexamethasone implant) post-vitrectomy for epiretinal membrane
88927312|NCT01701531|Experimental|RBCPF|Treatment intervention arm
88927313|NCT01701544|Sham Comparator|NBM DBS Off|NBM DBS switched off
88927314|NCT01701544|Active Comparator|NBM DBS On|NBM DBS Switched On
89443487|NCT02502032|Experimental|Cisatracurium 0.01 mg/kg|The group received pretreatment of cisatracurium 0.01 mg/kg.
89443488|NCT02502032|Experimental|Cisatracurium 0.02 mg/kg|The group received pretreatment of cisatracurium 0.02 mg/kg.
88927315|NCT01701557|Active Comparator|slow fluid rate|bolus 10 ml/kg of NS followed by 1.25 times maintenance rate
88927316|NCT01701557|Active Comparator|Fast fluid rate|bolus 20 ml/kg of NS followed by 1.5 times maintenance rate
88927317|NCT01701583|Experimental|Omalizumab|Patients will receive omalizumab 300mg subcutaneously every 4 weeks for 12 weeks at the study center.
88927318|NCT01701596|Experimental|Rotational atherectomy (RA)|Immediate rotational atherectomy (RA) in the treatment with nondilatable calcified lesion complicated by coronary dissection
88927319|NCT01701596|Active Comparator|Delayed rotational atherectomy (RA)|Delayed RA in the treatment with nondilatable calcified lesion complicated by coronary dissection
88927320|NCT01701609|Experimental|Cognitive Remediation Therapy|CRT: Frontal/Executive Program. The program has a duration of 40 sessions, with two session for week. Is is carried out individually and utilizes paper and pencil tasks. The main technique utilized is the scaffolding in a context of learning without errors.
89537083|NCT03300635|Other|Healthy controls|All study subjects, both patients and healthy controls, will attend all three interventions: Mental distress and relaxation test, Glucose tolerance test, and Exercise test
88927321|NCT01701635|Experimental|Disclosure intervention|In the disclosure intervention plus usual care arm the adherence and disclosure specialist will meet with caregiver at each clinic visit and provide information, education, disclosure skills, and support till disclosure occurs.
88927322|NCT01701635|Active Comparator|Usual care|"In the enhanced usual care (control) arm the disclosure specialist will meet with caregiver at each clinic visit and provide them will general health education and no mention or effort will be made to improve disclosure skills of caregiver."
88927323|NCT01701648|Active Comparator|1|
88927324|NCT01701661|Active Comparator|conservative treatment|Compression stockings class II
88927325|NCT01701661|Active Comparator|Operative treatment|stripping of main trunk or if previously removed, removal or ligating the refloating trunk
88927326|NCT01701687||Decompensated Alcoholic Cirrhosis|Recruited patients will have diagnosed liver cirrhosis (histological, radiological or accepted clinical parameters)admitted with an episode of decompensation. Patients must still be drinking hazardous alcohol quantities (>14 units for women, >21 units for men) at study enrollment
89443489|NCT04495244||Investigational Population|"Suspected Invasive Breast Cancer (any size) or DCIS (pre-invasive) are of particular interest. Women with abnormal screening mammograms (R3-5) recalled for further investigation.~Inclusion criteria~Women with suspected Invasive Breast Cancer (tumours of any size and/or DCIS).~Individuals with an abnormal or suspicious screening mammogram recalled for further evaluation.~Suspected Invasive Breast Cancer (tumours of any size and/or DCIS).~Willing to give written Informed Consent and provide whole blood samples~Age 30-75 years~Exclusion criteria~Breast surgery within the previous 12 months (for any reason) or recent breast biopsy (including needle core biopsy)~Inoperable (T4 category) or inflammatory breast cancer~Previous history of cancer previously at any site~Previous history of breast cancer~Concomitant or other concurrent anti-cancer therapy~Male~No histopathological diagnosis"
89443490|NCT04495244||Borderline (Atypica and LCIS) Population|"Women with borderline pathological B3 lesions (suspected atypia Ductal or Lobular and benign proliferative disease without DCIS or invasion) Inclusion criteria~Abnormal screening mammogram with suspected benign breast disease or proliferative changes~Willing to give Written Informed Consent and provide whole blood samples~Aged 30-75 years~Exclusion criteria~Existing cancer diagnosis~Male~Breast surgery within the previous 12 months (for any reason) or recent breast biopsy (including needle core biopsy)~Previous history of any cancer~Previous history of breast cancer~Concomitant or other concurrent anti-cancer therapy"
88927327|NCT01701700|Experimental|portable electronic magnifier|Use of a prescribed electronic magnifier plus existing optical aids for a period of 2 months
88927328|NCT01701700|Active Comparator|optical aids|Use of existing optical aids for 2 months
88927329|NCT01701713|Experimental|TDCS - DKI ED2011|TDCS with DKI ED2011 session is followed by a behavioral naming therapy with different cues
88927330|NCT01701713|Sham Comparator|Sham-TDCS|Sham-TDCS session is followed by a behavioral naming therapy with different cues
88927331|NCT01701726|Experimental|Acupuncture|Two types of acupuncture are given, one is acupuncture at affected meridian points, the other is at non-affected. For the first type, We select the acupoints from the affected meridians.Patients in this group are divided into two subgroups according meridian syndrome differentiation(jue-yin style,yang-ming style).Patients pertaining to Jue-yin-style are treated with taichong (LR3), renying(ST9), taixi(KI3), neiguan(PC6) .Patients pertaining to Yang-ming-style: taichong(LR3), renying(ST9), zusanli(ST36), quchi(LI11). For the second,We select the acupoints from the non-affected meridians.Patients assigned into the non-affected meridian acupuncture group will be treated with Fengchi (GB20), waiguan(SJ5), yinlingquan(SP9), xuehai (SP10).
88927332|NCT01701726|Sham Comparator|Sham acupuncture|"we use sham acupoints:~The edge of the tibia (1-2cm lateral and horizontal to the zusanli (ST36))~Half way between the tip of the elbow and the axilla~On the ulnar side of the arm, half way between the epicondylus medialis of the humerus and the ulnar side of the wrist.~2cm superior to fu tu(LI18)"
88927333|NCT01701726|No Intervention|Waiting list|Participants who will be randomized into the waiting-list group will not receive any acupuncture treatment throughout 13-week observation period. At the end of trial, if the participant would like to be treated with acupuncture, it will be provided three times weekly for 6 weeks.
88927334|NCT01701739|Experimental|aleglitazar / digoxin|
88927335|NCT01701752|Active Comparator|Group 1|Day 1: FP-01.1 + Placebo ; Day 29: FP-01.1
88927336|NCT01701752|Active Comparator|Group 2|Day 1: FP-01.1 + TIV ; Day 29: FP-01.1
88927337|NCT01701752|Active Comparator|Group 3|Day 1: FP-01.1-Adjuvant + Placebo ; Day 29: FP-01.1-Adjuvant
88927338|NCT01701752|Active Comparator|Group 4|Day 1: FP-01.1-Adjuvant + TIV ; Day 29: FP-01.1-Adjuvant
88927339|NCT01701752|Active Comparator|Group 5|Day 1: Adjuvant + TIV ; Day 29: Placebo
88927340|NCT01701752|Active Comparator|Group 6|Day 1: Placebo + TIV ; Day 29: Placebo
88927341|NCT01701765||Patients in residential facilities|All patients staying in September 2010 in 23 medium-long term RFs of the St John of God Order in Northern Italy with a primary psychiatric diagnosis and younger than 65 years recruited.
88927342|NCT01701778|Experimental|Caudal Dexmedetomidine|"Caudal: Levobupivacaine 0.25% 1ml/kg and dexmedetomidine 1µg/kg~Intravenous: 10 ml normal saline~Anesthesia was induced and maintained with sevoflurane"
88927343|NCT01701778|Experimental|Intravenous Dexmedetomidine|"Caudal: Levobupivacaine 0.25% 1ml/kg~Intravenous: dexmedetomidine 1µg/kg~Anesthesia was induced and maintained with sevoflurane"
88927344|NCT01701778|Placebo Comparator|Placebo|"Caudal: Levobupivacaine 0.25% 1ml/kg~Intravenous: 10 ml normal saline~Anesthesia was induced and maintained with sevoflurane"
88927345|NCT01701791|Experimental|Computerized Decision Support System (CDSS)|GPs will use a CDSS with treatment algorithms, supervision from a consultant psychiatrist, and despatch to patients of reminders via mobile texting or automatic mobile (or landline) phone calls to improve adherence to the treatment prescribed.
88927346|NCT01701791|No Intervention|Treatment as usual|GPs will provide TAU, will make their own decisions and will therefore not use the CDSS. Patients will not receive any reminders.
88927347|NCT01701804||integrative treatment|
88927348|NCT01701817||Patients with Atrial Fibrillation (AF)|(1) patients with new onset/first detected Atrial Fibrillation (AF) diagnosed within the 6 months preceding the baseline visit; or (2) patients with AF who had initiation or transition to a FXa (Factor Xa) inhibitor or a direct thrombin inhibitor within the preceding 3 months.
88927349|NCT01701830||Case Group|Patients with chronic kidney disease of stage 3-4.
88927350|NCT01701830||Control group|30 healthy subject
88927351|NCT01701843|Other|Placebo (left) / Cromoglicate (right)|Placebo (on a lesion left bodyside), Cromoglicate (on a lesion on right bodyside)
88927352|NCT01701843|Other|Placebo (right) / Cromoglicate (left)|Placebo (on a lesion right bodyside), Cromoglicate (on a lesion on left bodyside)
88927353|NCT01701856|Experimental|Interferon beta-1b|Interferon beta-1b 250 mcg s.c. every other day
88927354|NCT01701869||NTHi positive|No intervention, this is an observational study
88927355|NCT01701869||NTHi negative|No intervention, this is an observational study
88927356|NCT01701869||Healthy Control|No intervention, this is an observational study
88927357|NCT01701882|Experimental|tenofovir/emtricitabine/rilpivirine|A one pill fixed dose combination of tenofovir 245mg, emtricitabine 200mg and rilpivirine 25mg once daily.
88927358|NCT01701921|Experimental|Pregabalin 75|Pregabalin 75mg by mouth one hour before surgery
89443491|NCT04495244||Control Population|"Healthy Controls Inclusion criteria~Normal breast examination - No cancer detected/suspected by physical exam, diagnostic radiology or screening mammography~Willing to give Written Informed Consent and provide whole blood samples~Aged 30-75 years~Exclusion criteria~Cancer diagnosis~Male~Breast surgery within the previous 12 months (for any reason) or recent breast biopsy (including needle core biopsy)~Previous history of any cancer~Concomitant or other concurrent anti-cancer therapy"
89443492|NCT02494856|Experimental|Surgery with Naproxen|Fifty healthy volunteers underwent removal of symmetrically positioned lower third molars, will be treated to control pain, swelling and trismus with naproxen 500mg.
89443493|NCT02494856|Experimental|Surgery with Naproxen and Esomeprazole|Fifty healthy volunteers underwent removal of symmetrically positioned lower third molars, will be treated to control pain, swelling and trismus with naproxen 500mg and esomeprazole 20mg.
89443494|NCT04495010|Experimental|Neoadjuvant treatment + Adjuvant treatment|
89443495|NCT04495010|Experimental|Adjuvant treatment|
89443496|NCT04495010|Experimental|Neo treat with patho response-driven Adju treat or observation|Neoadjuvant treatment with pathologic response-driven Adjuvant treatment or observation
89443497|NCT02169531|Experimental|ex vivo activated immune cells|Up to 20 patients diagnosed with type 2 diabetes mellitus and hyperglycemia will be enrolled and assigned to a single treatment group. Patients will give a small amount of peripheral blood and the blood will be processed and cultured in our laboratory. The ex vivo activated autologous blood cells will be infused intravenously back to patients. The treatment will be done twice a week for consecutive 4 weeks. The metabolic parameters of patients before and after the therapy will be compared to determine if the therapy is safe and effective.
89443498|NCT03539913|Active Comparator|Saccharomyces boulardii|Floratil, 250 mg sachets, twice daily (1 in the morning and 1 in the evening) during 5 consecutive days.
89443499|NCT03539913|Active Comparator|Bacillus clausii|Enterogermina, 5 ml vials, twice daily (1 in the morning and 1 in the evening) during 5 consecutive days.
89443500|NCT03539835|Experimental|Resistance training|
89443501|NCT03539835|Active Comparator|Cognitively-based compassion training|
89443502|NCT03343418|Active Comparator|desmopressin|Patients randomized to this group receive desmopressin 0,3 microgram.kg-1 as an intravenous infusion given during 20 min.
89443503|NCT03343418|Placebo Comparator|Placebo|Patients randomized to the control group will receive the infusion of 100 mL 0.9% saline (SF0,9%).
89443504|NCT02499926|Experimental|Dietary supplement: Arginine|Graded arginine excess intake
89443505|NCT03539679|Experimental|Encouraging physical activity|Encouraging physical activity by using motion sensor and feedback.
89443506|NCT03539679|No Intervention|CONTROL GROUP|No intervention.
89443507|NCT03725319||Epinephrin injection|Diluted Epinephrin (1:100) in small amounts from 1 to 5 ml is injected into apex of the papilla to stop post sphincterotomy-bleeding
88927359|NCT01701921|Active Comparator|Pregabalin 150|Pregabalin 150mg by mouth one hour before surgery
88927360|NCT01701921|Placebo Comparator|Sugar pill|Placebo : Sugar pill manufactured to mimic pregabalin capsule by mouth one hour before surgery
88927361|NCT01701934|Experimental|Roflumilast|Roflumilast 500 mcg, once daily for 6 months
88927362|NCT01701934|Placebo Comparator|Placebo pill|Placebo pill, once daily for 6 months
88927363|NCT01701960||Group 1|This cohort will be injected with 1% lidocaine with 1:100,000 of epinephrine into the nasal mucosa at the time of nasal surgery
88927364|NCT01701960||Group 2|This group will be injected with 1% lidocaine with 1:200,000 of epinephrine into the nasal mucosa at the start of nasal surgery.
88927365|NCT01702012|Experimental|Almased Meal Replacement Powder|Participants assigned to this arm will receive the Almased meal replacement powder and will be asked to replace one meal per day during the first 6 months of participation. During the second 6 months, participants will be allowed to choose whether to continue using the product to replace a meal or to use the product as a supplement prior to meals.
88927366|NCT01702012|Active Comparator|Lifestyle Intervention|Participants randomized to this group will receive 5 group sessions in the first two months of participation and 5 additional group sessions in the last two months. These group sessions will focus on lifestyle behavior changes for weight loss and management including goal-setting, calorie balance, general nutrition, and physical activity.
88927367|NCT01702038|Experimental|Rituximab|Participants will receive an intravenous infusion of rituximab on Days 0 and 14
88927368|NCT01702064|Experimental|Nilotinib with Ruxolitinib|"The starting dose of ruxolitinib will be 5mg by mouth (PO) twice a day (BID) and will increase by 5 mg increments in each cohort, to a maximum dose of 15 mg PO BID. Nilotinib will be given at a dose ranging from 300 mg PO BID to 400 mg PO BID, depending on the participant's dose prior to enrollment on the trial.~Dose Level 1: Ruxolitinib 5 mg twice a day (BID); Nilotinib 300 mg or 400 mg BID.~Dose Level 2: Ruxolitinib 10 mg BID; Nilotinib 300 mg or 400 mg BID.~Dose Level 3: Ruxolitinib 15 mg BID; Nilotinib 300 mg or 400 mg BID."
88927369|NCT01702077|Experimental|Neurofeedback first|Neurofeedback then sham feedback
88927370|NCT01702077|Experimental|Sham first|Sham feedback then neurofeedback
88927371|NCT01702090|Experimental|TMC114/ritonavir|
88927372|NCT01702103|Experimental|Mometasone|Mometasone, nasal spray for 8 weeks, 2 actuations each nostril in the morning.
88927373|NCT01702103|Active Comparator|Nasonex®|Nasonex nasal spray for 8 weeks 2 actuations each nostril in the morning.
88927374|NCT01702129|Experimental|anti-EGFR Immunoliposomes|anti-EGFR immunoliposomes loaded with doxorubicin. Dose escalating study. 3 patients per dose level. Dose levels: 5, 10, 20, 30, 40, 50 and 60 mg doxorubicin/m2.
89443508|NCT03725319||Plastic stent insertion|A plastic stent (diameter: 8-11,5F and length of 50 -100mm) is inserted into the common bile duct to stop post sphincterotomy-bleeding
89443509|NCT05504096|Other|Single-Arm: Healthy Participants|All participants will be administered with the In-Ear and Wearable devices concurrently for 8 minutes while the application records the readings from the devices. Participants with the first glucometer reading of less than 11.1 mmol/L will be required to return one-hour post sugary drink consumption for a second reading with both devices.
89443510|NCT02176707||Idiopathic pulmonary fibrosis sufferers|
89443511|NCT02174289|Active Comparator|Active Bi-ventricular Pacing|
89443512|NCT02174289|Placebo Comparator|No Biventricular pacing|
89443513|NCT03341624|Experimental|cataract surgery cataract extraction and intraocular implanta|
89013368|NCT06301789|Experimental|InterventionalGroup|received pre-emptive ultrasound-guided quadratus lumborum block with 25 mL of 0.25% bupivacaine plus 2 ml of magnesium sulfate 10 % on each side of the abdominal wall before induction of GA.
89013369|NCT06301776|Experimental|Experimental group|3 Months DAPT+9 months ticagrelor monotherapy after Bridge(MicroPort NeuroTech, Shanghai, China) implantation
89013370|NCT06301776|Active Comparator|Control group|6 Months DAPT+6 months ticagrelor monotherapy after Bridge(MicroPort NeuroTech, Shanghai, China) implantation
89013371|NCT06301659|Experimental|modified mirror therapy+routine rehabilitation therapy|The study lasted 30 days for each participant. The patients enrolled were randomly divided into the experimental group and the control group, all under routine rehabilitation therapy. Additionally, the patients in the experimental group were given modified mirror therapy.
89013372|NCT06301659|Active Comparator|routine rehabilitation therapy|The study lasted 30 days for each participant. The patients enrolled were randomly divided into the experimental group and the control group, all under routine rehabilitation therapy.
89013373|NCT06301646|Experimental|comprehensive rehabilitation therapy+Intermittent Oro-esophageal Tube Feeding|Study lasts 15 days for each patient. The patients were given comprehensive rehabilitation therapy. The experimental group was provided the support of enteral nutrition by Intermittent Oro-esophageal Tube Feeding.
89013374|NCT06301646|Active Comparator|comprehensive rehabilitation therapy+Nasogastric Tube Feeding|Study lasts 15 days for each patient. The patients were given comprehensive rehabilitation. The control group was provided the support of enteral nutrition by Nasogastric Tube Feeding.
89013375|NCT06301581||Group 1|HiRes Ultra or HiRes Ultra 3D Version V2 newly implanted on this side
89013376|NCT06301581||Group 2|HiRes Ultra or HiRes Ultra 3D Version V2 implanted following an Ultra Version V1 device failure on the same ear
89013377|NCT06301555|No Intervention|Blank Control|No intervention
89013378|NCT06301555|Experimental|RL Algorithm Intervention|
89013379|NCT06301555|Active Comparator|No Algorithm Active Control|
89013380|NCT06301542||In-laboratory|Patients will be brought to the laboratory for functional electrical stimulation mobility assessment.
89013381|NCT06301542||In-home|Patients will undergo functional electrical stimulation mobility assessment in their home.
89013382|NCT06301529|Active Comparator|100mg|Participants assigned to this arm will be taking 100mg daily, up to 7 times, for study duration.
89013383|NCT06301529|Experimental|150mg|Participants assigned to this arm will be taking 150mg, every other day, up to 4 times, for study duration.
89013384|NCT06301516|Experimental|Experimental: Impact VR|Participants enrolled into Impact VR will be complete the first of four sessions. The four 20-minute sessions will be completed over 4 weeks (one session per week) either in the lab, at the participant's home, school or a mutual private meeting place
89013385|NCT06301516|Other|Comparative Control|Participants enrolled into the comparative control group will complete a one-time PowerPoint presentation that provides an overview of emotion expressions and instructions on how to recognize emotions in others
89013386|NCT06301490|No Intervention|control group|18 participants will have strengthening exercises, rang of motion exercises and ice application for 10 mins
89013387|NCT06301490|Experimental|experimental group|18 participants will have strengthening exercises, rang of motion exercises and ice application for 10 mins, with adding Myofascial Release
89013388|NCT06301464||Patients with gastric neoplasms|Patients with gastric neoplasms
89013389|NCT06301464||Normal control|Normal control without gastric neoplasms
89013390|NCT06301451|Experimental|General dietary guidance and hydrogen water group|Trial group is treated with general dietary guidance and hydrogen water prepared by portable hydrogen rich water machine.
89013391|NCT06301451|No Intervention|General dietary guidance group|Control group is treated with general dietary guidance.
89013392|NCT06301438||dalpiciclib|dalpiciclib oral day 1-21, every 28 days
89443514|NCT02176785|Sham Comparator|Sham tDCS|tDCS will be applied, but then turned off after 30 seconds.
89013393|NCT06301425|Experimental|Intervention group|According to the MFC MRD status after the first consolidation (MRDcon1), the MRDcon1 positive patients were categorized into high-risk group (i.e., risk stratification). All the patients in high-risk group who fulfilled all inclusion/exclusion criteria were randomly assigned in a 1:1 ratio to receive a second consolidation therapy (intervention group) or receive allo-HSCT directly (control group).
89013394|NCT06301425|Active Comparator|Control group|According to the MFC MRD status after the first consolidation (MRDcon1), the MRDcon1 positive patients were categorized into high-risk group (i.e., risk stratification). All the patients in high-risk group who fulfilled all inclusion/exclusion criteria were randomly assigned in a 1:1 ratio to receive a second consolidation therapy (intervention group) or receive allo-HSCT directly (control group).
89443515|NCT02176785|Experimental|Anodal tDCS 2mA 10 Minutes|Anodal tDCS will be applied bi-frontally for 10 minutes at 2mA
89443516|NCT02176785|Experimental|Cathodal tDCS 2mA 10 Minutes|Cathodal tDCS will be applied Bi-Frontally for 10 minutes at 2mA
89443517|NCT02501798|Experimental|Drug: Methylphenidate|Drug: Methylphenidate 7 days dosage as (prior to study) clinically titrated long acting Equasym (brand)
89443518|NCT02501798|Active Comparator|Drug: Placebo|Drug: Placebo 7 days Empty green-yellow capsule
89443519|NCT02501720|Active Comparator|Tourniquet Group|Post burn flexion contractures will be released under tourniquet control
89443520|NCT02501720|Experimental|Tumescent technique group|Post burn flexion contractures will be released using Tumescent solution
89443521|NCT02174367||Psoriasis|Patients with moderate to sever psoriasis attending a tertiary referral center. patients will be evaluated with a questionnaire, measurement of height,weight, waist circumference, fasting bloods, abdominal ultrasound and transient elastography.
89013395|NCT06301412|No Intervention|EVT group|standard endovascular treatment (EVT) for large vessel occlusion (LVO) without hypothermia
89013396|NCT06301412|Active Comparator|EVT group plus hypothermia group|standard endovascular treatment (EVT) for large vessel occlusion (LVO) combined with hypothermia
89199969|NCT02542527|Experimental|Pumping with a fluid filled breast pump|Participants pump (each breast 25 min) with the new fluid filled breast pump
89199970|NCT00965224|Experimental|standard therapy + vaccination|
89199971|NCT00965224|No Intervention|standard therapy|
89199972|NCT00887835|Experimental|PERPOS™ PLS|Minimally invasive transfacet fixation with PERPOS™ PLS as an aid to fusion
89013397|NCT06301399|Experimental|Rituximab+PD-1 or PD-L1 inhibitors+targeted therapy|"Rituximab: Dissolve 375mg/m2 in 0.9% sodium chloride injection, dilute to a concentration of 1 mg/mL of rituximab, intravenous infusion every 3 weeks until tumor progression or intolerable toxic reactions occur. The recommended initial infusion rate is 50mg/h; After the initial 60 minutes, an increase of 50mg/h can be made every 30 minutes until the maximum speed is 400mg/h. The starting rate of rituximab infusion in the future can be 100mg/h, increasing by 100mg/h every 30 minutes until the maximum rate is 400mg/h.~PD-1 (or PD-L1) inhibitors and targeted drugs: Select first-line PD-1 (or PD-L1) inhibitors and VEGFR targeted drugs according to clinical routine treatment, and administer according to the original first-line combination therapy dosage until progression or intolerable toxic reactions occur."
89013398|NCT06301386|Experimental|Everolimus in combination with PD-1|Patients will be treated with Everolimus and PD-1
89013399|NCT06301373|Experimental|Methotrexate Combined With Tofacitinib|Methotrexate 10-15mg orally once a week, tofacitinib 5mg orally twice a day
89013400|NCT06301373|Active Comparator|Methotrexate|Methotrexate 10-15mg orally once a week
89013401|NCT06301347|Experimental|Learning through Play Plus|"The proposed intervention is a combination of two interventions:~Learning through Play The 'Learning through Play' programme is intended to stimulate early child development. The central feature of the program is a pictorial calendar devised for parents, depicting eight successive stages of child development from birth to 3 years, with illustrations of parent-child play and other activities that promote parental involvement, learning, and attachment.~Culturally Adapted Cognitive Behavioral Therapy for Psychosis (CaCBTp) The CaCBTp interventions will follow the treatment manual developed by David Kingdom and David Tarkington and culturally adapted by Farooq Naeem. In CBT the general approach will be a collaborative understanding of the development of symptoms and further work toward reducing distress and disability in participants."
89013402|NCT06301347|No Intervention|Treatment-as-Usual|This group of patients will not be provided any intervention. They will be taking only treament as usual (which in Pakistan means attending the outpatient clinic at regular intervals and taking prescribed medication) and we will compare this group with LTP Plus group after three months.
89013403|NCT06301334|Active Comparator|Group CTB|n=30): patients included in this group will receive unilateral US-guided CTB after general anesthesia. The CTB will be performed by using 20 ml bupivacaine 0.25%
89013404|NCT06301334|Active Comparator|Group ESPB|patients included in this group will receive unilateral US-guided ESPB after general anesthesia. The ESB will be performed by using 20 ml bupivacaine 0.25%
89013405|NCT06301308|Sham Comparator|Intraurethral lidocaine gel alone|Participants received 10 ml of intraurethral lidocaine gel at a concentration of 2%
89013406|NCT06301308|Experimental|Intraurethral lidocaine gel + lidocaine 2% injection|Participants received 10 ml of intraurethral lidocaine gel at a concentration of 2% and using the injection of lidocaine 2% to irrigate the urethra using a 20 ml syringe.
89013407|NCT06301308|Experimental|intraurethral lidocaine gel + liquid paraffinl|Liquid paraffin were used to lubricate hte cystoscopy tube AND participants received 10 ml of intraurethral lidocaine gel at a concentration of 2%
89443522|NCT05503004|Experimental|Intervention group|comprehensive prehabilitation program including supervised exercise., mindfulness and nutrition assessment.
89443523|NCT05503004|Active Comparator|Standard care|Standard care before surgery
89443524|NCT02169609|Experimental|Dinutuximab. Immunotherapy|"Dinutuximab will be administered at 17.5 mg/m2/day for 4 days up to 5 courses. Each dose should be infused IV over approximately 10 hours.~Immunotherapy (sargramostim + isotretinoin + interleukin2) Sargramostim will be administered at 250 micrograms/m2/d by subcutaneous (SC) injection daily from Day 0 through 13 (daily with the infusion of Dinutuximab and for 3 days before and 7 days afterward).~Isotretinoin (13-cis-retinoic acid, or RA) (160mg/m2/day or 5.33mg/kg/day if < 12kg) PO divided into 2 doses daily x 14 days.~Interleukin-2 (IL-2) 3 MIU/m2/day will be given by continuous infusion for 4 days during the first week of each course 2 and 4 given on Days 0 - 3"
89501705|NCT02223949|Active Comparator|PGE1 tablet insertion|Insertion of 25 mg PGE1 (Prostaglandin E1) tablet is inserted in the posterior fornix. The patient woll the be instructed to stay in bed for the next 60 minutes. After six hours a repeated dose will be administered. Total of 4 PGE1 doses within 24 hours.
89013408|NCT06301295|Experimental|Ultrathin bronchoscopy with intratumoral washing|Each subject suspected of early-stage lung cancer will undergo bronchooscopic procedure for generic alteration with Next Generation Sequencing.
89443525|NCT02499614|Experimental|Patients with MET amplification or MET exon 14 mutation|Pretreated NSCLC patients with MET amplification or MET exon 14 mutation with locally advanced or metastatic NSCLC and with at least one measurable tumor lesion will be considered eligible for the trial and they will receive crizotinib 250 mg BID p.o until disease progression, unacceptable toxicity or patient refusal.
89443526|NCT02499614|Experimental|Patients with ROS1 translocation|Pretreated NSCLC patients with ROS1 translocation with locally advanced or metastatic NSCLC and with at least one measurable tumor lesion will be considered eligible for the trial and they will receive crizotinib 250 mg BID p.o until disease progression, unacceptable toxicity or patient refusal.
89443527|NCT02176941||ATHEROMA group|"ATHEROMA group will include patients undergoing cardiovascular surgery or have pacemaker/defibrillator implantation and have a clinically significant atherosclerotic disease"
89443528|NCT02176941||Control Surgery group|"Control Surgery group will include patients undergoing other surgery or pacemaker/defibrillator implantation without evidence of clinical CV disease or history of previous CV disease."
89013409|NCT06301243|Experimental|Inactive|Subjects will be asked to be sedentary prior to an acute exercise bout (<5,000 steps as measured by a physical activity monitor).
89443529|NCT02169687|Experimental|Hifu|
89013410|NCT06301243|Placebo Comparator|Normal activity|Subjects will be asked to have normal activity prior to an acute exercise bout (>8,500 steps as measured by a physical activity monitor).
89013411|NCT06301230|Active Comparator|Hospital-based surgical training group|This group represents the surgical residents who trained with PLET at the hospital.
89013412|NCT06301230|Experimental|Home-based surgical training group|This group represents the surgical residents who trained with PLET at home.
89013413|NCT06301204|Placebo Comparator|control group|control group patient give no drug administration during bimaxillary orthognathic surgery.
89013414|NCT06301204|Active Comparator|group 1(intravenous administration of 250 mg tranexamic acid)|group 1 (TRANEXEL 250 mg/5 mL) patients administered 250 mg tnx acid during the whole bimaxillary orthognathic surgery
89013415|NCT06301204|Active Comparator|group 2 (intravenous administration of 500 mg tranexamic acid)|group 2 (TRANEXEL 250 mg/5 mL) patients administered 500 mg tnx acid during the whole surgery.
89013416|NCT06301191||Semaglutide group|25 patients treated with semaglutide. Pulse wave velocity, aumentation index, SBPao and PPao with Arteriograph, Mobilograph and Complior, and perfused boundary region (PBR) of sublingual vessels using a high-resolution camera with Sideview Darkfield Imaging technique (Microscan, Glucockeck) will be evaluated. PBR consists the cell-free space which is formed from the separation of red blood cells from plasma at the surface of the endothelial glycocalyx.Liver steatosis and stiffness will be measured using Fibroscan® Mini+ 430 (Echosens, Paris, Île-de-France). CAP score will be used as an index of liver fat content, with normal values being < 238 dB/m. E score will be used as an index of liver fibrosis, with normal values being 2- 6 kPa. Blood glucose, glycosylated hemoglobin (HbA1c) and a full lipidemic profile will be measured before and at 4 and 12 months of treatment.
89013417|NCT06301191||D-PP4 group|25 patients treated with D-PP4 inhibitors. Pulse wave velocity, augmentation index, SBPao and PPao with Arteriograph, Mobilograph and Complior, and perfused boundary region (PBR) of sublingual vessels using a high-resolution camera with Sideview Darkfield Imaging technique (Microscan, Glucockeck) will be evaluated. PBR consists the cell-free space which is formed from the separation of red blood cells from plasma at the surface of the endothelial glycocalyx.Liver steatosis and stiffness will be measured using Fibroscan® Mini+ 430 (Echosens, Paris, Île-de-France). CAP score will be used as an index of liver fat content, with normal values being < 238 dB/m. E score will be used as an index of liver fibrosis, with normal values being 2- 6 kPa. Blood glucose, glycosylated hemoglobin (HbA1c) and a full lipidemic profile will be measured before and at 4 and 12 months of treatment
89013418|NCT06301165|Experimental|TPC induction chemotherapy + CCRT|TPC induction chemotherapy regimen followed by concurrent chemoraditherapy (cisplatin 100 mg/m2, every 3 weeks for 3 cycles) and IMRT (PTVnx 70Gy/33f; PTVnd 70Gy/33f; PTV1 60Gy/33f; PTV2 54Gy/33f)
89443530|NCT02501876||T2D-MCI|110 MCI subjects with type 2 diabetes. There is a retrospectiv observational study. No intervention will be performed.
89443531|NCT02501876||nonT2D-MCI|110 MCI subjects without diabetes. There is a retrospectiv observational study. No intervention will be performed.
89443532|NCT02169765|Active Comparator|Hepatic resection|Indications for HR were the presence of appropriate residual liver volume determined by volumetric computed tomography and lack of hepatic encephalopathy.
89443533|NCT02169765|Experimental|Radiofrequency ablation|Radiofrequency ablation is performed in less than one week after clinical diagnosis.
89443534|NCT03341468|Experimental|Urethral catheter immobilization|Subjects randomized to the intervention group will undergo radical prostatectomy with placement of the urethral catheter per the standard of care. The urethral catheter immobilization device will be applied in the operating room prior to the patient being transported to the recovery room. Subjects will be informed on safe use of the device and must demonstrate competency in removing and replacing the device prior to discharge. Subjects will also be given an elastic leg strap, which they may use concurrently with the device. Subjects will attend routine follow up appointments with their surgeon for removal of the urethral catheter and void trial per standard of care, at which the device will no longer be needed.
89443535|NCT03341468|No Intervention|No urethral catheter immobilization|Subjects randomized to the control group will undergo radical prostatectomy with placement and securing of the urethral catheter per the standard of care. The catheter will be secured to the leg using cloth tape. Subjects will also be given an elastic leg strap that they may use following discharge, as is routine. Subjects will attend routine follow up appointments with their surgeon for removal of the urethral catheter and void trial per standard of care.
89443536|NCT02169843|Experimental|Sevoflurane & Dexmedetomidine|inhale Sevoflurane + intravenous pumping Remifentanil 0.1µg/kg/min + intravenous inject cisatracurium besilate 0.08mg/kg in fixed time interval + finally add sufentanil 0.15µg/kg,and intravenous pumping Dexmedetomidine 0.2µg/kg/h.
89537084|NCT05726513|Other|Low support, high Positive end-expiratory pressure|Low support, high Positive end-expiratory pressure
89443537|NCT02169843|Active Comparator|Sevoflurane & Placebo|inhale Sevoflurane + intravenous pumping Remifentanil 0.1µg/kg/min + intravenous inject cisatracurium besilate 0.08mg/kg in fixed time interval + finally add sufentanil 0.15µg/kg,and intravenous pumping Placebo(for Dexmedetomidine )0.05ml/kg/h.
89443538|NCT03341390|Active Comparator|Aspirin|325 mg tablet, once daily for 5 days (Day -5 to -1)
89443539|NCT03341390|Experimental|BMS-986177 plus aspirin|200 mg BMS-986177 twice daily and 325 mg tablet aspirin once daily (Day 1-7)
89443540|NCT03341390|Placebo Comparator|Placebo plus aspirin|200 mg Placebo twice daily and 325 mg tablet aspirin once daily (Day 1-7)
89443541|NCT02169921|Experimental|TurboHawk|This study is designed as a single arm study. For angioplasty, the Atherectomy Catheter, TurboHawk is used in this arm. Spider FX, the Distal Embolus Protection Device, can concomitantly be used with TurboHawk
89443542|NCT02499536|Experimental|Study participants|After general anesthesia development of the atelectasis will be investigated by the lung ultrasound
89443543|NCT02174445|Experimental|Imatinib|Imatinib 400-800mg, daily, maximum 6 years
89443544|NCT02174445|Active Comparator|Nilotinib|Nilotinib, 300mg, twice daily, maximum 6 years
89443545|NCT02501408|Experimental|Propriofoot prosthesis|New propriofoot prosthesis is worn instead of usual prosthesis foer 1 month
88927375|NCT01702142||NIATx Only|NIATx (Network for the Improvement of Addiction Treatment) organization change model only
88927376|NCT01702142||NIATx and Advancing Recovery|Organizational and system changes
88927377|NCT01702155|Experimental|DFP-10917|"7-day continuous infusion (in the vein): Starting dose 4 mg/m^2~14-day continuous infusion (in the vein): Starting dose 10 mg/m^2~Phase II Only: 6 mg/m^2 for the 14-day continuous infusion (in the vein)"
88927378|NCT01702168||CBT Training|
88927379|NCT01702181|Placebo Comparator|Placebo|Matching placebo.
88927380|NCT01702181|Active Comparator|Tacrolimus|Tacrolimus 0.1% ointment twice daily for 28 days.
88927381|NCT01702181|Experimental|OPA-15406|
88927382|NCT01702194|Experimental|TD-1211 IV [C14]|TD-1211 IV [C14]
88927383|NCT01702194|Experimental|TD-1211 PO [C14]|TD-1211 PO [C14]
88927384|NCT01702207|Active Comparator|Once Daily Tacrolimus|Treatment Arm - Subjects are switched from the tacrolimus twice daily (Prograf®) to the once daily formulation (Advagraf®) to maintain a trough tacrolimus level of 5-8.
88927385|NCT01702207|Active Comparator|Twice Daily Tacrolimus|Control Arm - Subjects are kept on Prograf® which is the Twice Daily Tacrolimus
88927386|NCT01702220|Experimental|CBT|
88927387|NCT01702220|Active Comparator|Enhanced Community Care (ECC)|
88927388|NCT01702272||Dengue Virus|
88927389|NCT01702285|Experimental|CUDC-101|200-500 mg CUDC-101, orally administered, twice daily, in continuous 21 day cycles until disease progression or other discontinuation criteria are met.
88927390|NCT01702324|Experimental|DD-25|A concentration of 0.025% of topical DD-25 cream.
88927391|NCT01702337||HPV-1 Group|Hypothetical group of women vaccinated with HPV-1 vaccine in Taiwan.
88927392|NCT01702337||HPV-2 Group|Hypothetical group of women vaccinated with HPV-2 vaccine in Taiwan.
88927393|NCT01702350|Experimental|Study Drug Formulation A|Enterric Coated Tablet Formulation of GSK2251052
88927394|NCT01702350|Experimental|Study Drug Formulation B|Modified Release Table Formulation of GSK2251052
88927395|NCT01702350|Experimental|Study Drug Formulation C|Enterric Coated Powder for Oral Suspension Formulation of GSK2251052
88927396|NCT01702350|Experimental|Study Drug Formulation D|Immidiate Release Table Formulation of GSK2251052
88927397|NCT01702350|Experimental|Study Drug Formulation E|Oral Solution Formulation of GSk2251052
89443546|NCT02501408|No Intervention|Control|Usual prosthesis is worn for 1 month
89443547|NCT02174601||colonoscopy group|
89443548|NCT00708032|Other|spectacles|habitual spectacles worn daily for 12 months
89443549|NCT00708032|Experimental|narafilcon A soft contact lenses|narafilcon A soft contact lenses worn as daily disposable for 12 months
89443550|NCT02178267|Experimental|Lactobacillus reuteri|The study was performed by two groups. And these groups were constituted from the newborn preterm infants who are received probiotics (Lactobacillus reuteri) and no probiotics.
89443551|NCT00707174|Active Comparator|1|"Topical imiquimod group:~treat the LM site two centimeters beyond the perimeter margin with topical imiquimod 5% cream Monday thru Friday of each week for a total of twelve weeks. After three months of topical treatment, a one-month wash out period will be observed to allow for resolution of inflammation that can obscure the pathologist's ability to evaluate the excised tumor/treatment site."
89443552|NCT00707174|Experimental|2|"Topical imiquimod and topical tazarotene 0.1% cream group:~Patients randomized to this group will undergo an identical treatment protocol as the topical imiquimod group with the addition of topical tazarotene 0.1% cream on Saturday and Sunday of each week."
89443553|NCT02177019|Experimental|Development of personal health plan|Personal Health Plan
89443554|NCT03341234|Active Comparator|Group SPB|Ultrasound guided serratus plane block with 30 ml %0,25 bupivacaine
89443555|NCT03341234|Active Comparator|Group Control|Ultrasound guided sham block with 2 ml saline subcutaneously
88927398|NCT01702376|Experimental|Retosiban 100 mg|Each subject will be randomized to single dose of retosiban 100 mg in one of the four treatment sequences.
88927399|NCT01702376|Experimental|Retosiban 800 mg|Each subject will be randomized to single dose of retosiban 800 mg in one of the four treatment sequences
88927400|NCT01702376|Placebo Comparator|Placebo|Each subject will be randomized to single dose of matching placebo in one of the four treatment sequences
89443556|NCT02178423|Experimental|Ultrasound|Ultrasound for diagnosis of CVC position in children
89537085|NCT05726513|Other|Low support, zero positive end-expiratory pressure|Low support, zero positive end-expiratory pressure
88927401|NCT01702376|Active Comparator|Moxifloxacin 400 mg|Each subject will be randomized to single dose of moxifloxacin 400 mg in one of the four treatment sequences
88927402|NCT01702389|Experimental|Remifentanil|The study has only one arm. Same group of volunteers will receive remifentanil infusion with abrupt withdrawal, remifentanil infusion with gradual dose reduction and saline infusion at three separate trials.
88927403|NCT01702402|Experimental|Intervention Arm|Intervention activities will include behaviour change communications on healthy timing and spacing of pregnancy, couples counselling, social networking and expansion of contraceptive options for postpartum women, including provision of oral contraceptive pills and condoms in the home.
88927404|NCT01702402|Other|Comparison|A comparison area received standard government health services.
88927405|NCT01702415|Placebo Comparator|Placebo|Placebo
88927406|NCT01702415|Experimental|Zoledronic acid|Active IMP
88927407|NCT01702467|Experimental|GSK2647544|The starting dose of GSK2647544 is 0.5 mg. The escalating doses to be administered will be determined based on study results from previous dose (s).
88927408|NCT01702467|Placebo Comparator|Placebo|Matching placebo
88927409|NCT01702480|Experimental|Part 1: GSK2981710 10 gram (g)|Eight subjects will receive single dose of GSK2981710 in the form of 10 g medium-chain triglycerides (MCT) powder daily for 14 days.
88927410|NCT01702480|Experimental|Part 1: GSK2981710 20 g|Eight subjects will receive single dose of GSK2981710 in the form of 20 g MCT powder daily for 14 days.
88927411|NCT01702480|Experimental|Part 1: GSK2981710 30 g|Eight subjects will receive single dose of GSK2981710 in the form of 30 g MCT powder daily for 14 days.
88927412|NCT01702480|Experimental|Part 1: GSK2981710 40 g|Eight subjects will receive single dose of GSK2981710 in the form of 40 g MCT powder daily for 14 days.
88927413|NCT01702480|Placebo Comparator|Part 1: Placebo|Eight subjects will receive single dose of matching placebo daily for 14 days.
88927414|NCT01702480|Experimental|Part 2: GSK2981710 (dose to be decided from Part 1)|The subjects will receive single dose of GSK2981710 in the form of MCT powder (dose to be decided from Part 1) daily for 14 days.
88927415|NCT01702480|Placebo Comparator|Part 2: Placebo|The subjects will receive single dose of matching placebo daily for 14 days..
88927416|NCT01702493|Active Comparator|Part 1: Cap SRT2104|500 mg SRT2104 (in the form of two, 250 mg capsules) will be administered as a single oral dose in the fasting state
88927417|NCT01702493|Experimental|Part 1: Tab SRT2104 (slow release)|500 mg SRT2104 (in the form of two, 250 mg slow release tablets) will be administered as a single oral dose in the fasting state.
88927418|NCT01702493|Experimental|Part 1: Tab SRT2104 (intermediate release)|500 mg SRT2104 (in the form of two, 250 mg intermediate release tablets) will be administered as a single oral dose in the fasting state.
88927419|NCT01702493|Experimental|Part 1: Tab SRT2104 (fast release)|500 mg SRT2104 (in the form of two, 250 mg fast release tablets) will be administered as a single oral dose in the fasting state.
88927420|NCT01702493|Experimental|Part 2A: SRT2104 500 mg single-dose|500 mg SRT2104 (formulation selected from Part 1) will be administered as a single oral dose in the fed state.
88927421|NCT01702493|Experimental|Part 2B: SRT2104 single alternative dose|An alternative dose (other than 500 mg, but not to exceed 2000 mg) of SRT2104 (formulation selected from Part 1) will be administered as a single oral dose.
88927422|NCT01702493|Experimental|Part 2C: SRT2104 500 mg daily for 7 days|500 mg SRT2104 (formulation selected from Part 1) will be administered daily for 7 days.
88927423|NCT01702506|Experimental|Fasted|Dacomitinib administered under fasted conditions
88927424|NCT01702506|Experimental|Fed|Dacomitinib administered under fed conditions
88927425|NCT01702506|Experimental|Antacid|Dacomitinib administered under antacid treatment
88927426|NCT01702584||stent assisted embolization|stent assisted embolization of intracranial aneurysm
88927427|NCT01702597|Experimental|WBV|Patients will receive supervised physical therapy using a whole body vibration device (Galileo® Med M Plus, Novotec, Pforzheim, Germany) twice a week, 30 minutes per session, for 6 weeks.
88927428|NCT01702597|Active Comparator|Physiotherapy|Patient will receive the current gold standard treatment protocol: supervised physical therapy, twice a week, 30 minutes per session, for 6 weeks.
89199973|NCT00887991||Electric Pump 1 (ISIS Duo iQ Electric Breast Pump)|This is a parallel trial where subjects (mother of preterm infants) will be allocated to use one of two electric breast pumps to express milk. The use of electric breast pumps is routine practice on neonatal units in the UK.
88927429|NCT01702610|Experimental|Temozolomide, Accelerated Hypofractionated RT|Patient will receive two weeks of neo-adjuvant Temozolomide followed by Accelerated Hypofractionated RT for a total of 20 fractions for a total of 60Gy followed by Temozolomide for 12 cycles.
88927430|NCT01702623|Active Comparator|Oxcarbazepine first, then Trileptal|Single dose of oxcarbazepine suspension, 600 mg, then single dose of trileptal suspension, 600 mg (after washout period)
89013419|NCT06301165|Active Comparator|GP induction chemotherapy + CCRT|GP induction chemotherapy regimen followed by concurrent chemoraditherapy (cisplatin 100 mg/m2, every 3 weeks for 3 cycles) and IMRT (PTVnx 70Gy/33f; PTVnd 70Gy/33f; PTV1 60Gy/33f; PTV2 54Gy/33f)
89013420|NCT06301152|Experimental|high intensive laser|high-intensity laser was applied 3 times in a week, for three weeks, total of 9 sessions
89013421|NCT06301152|Experimental|extracorporeal shock wave therapy|extracorporeal shock wave therapy was applied once a week, for three weeks total of 3 sessions
89013422|NCT06301139|Experimental|Goat milk-based formula|goat milk-based infant formula (GMF)
89013423|NCT06301139|Placebo Comparator|Cow's milk-based formula|cow's milk-based infant formula supplemented with probiotics (CMFp)
89013424|NCT06301113|Experimental|300 Nano mg CBD Candy|
89013425|NCT06301113|Placebo Comparator|Sugar free raspberry flavor candy|
89013426|NCT06301074|Experimental|HS-10509 in healthy adults|In SAD, participants in each dose-escalation cohort will orally receive a single dose of HS-10509 or a matching placebo on Day 1
89013427|NCT06301074|Placebo Comparator|Placebo in healthy adults|In SAD, participants in each dose-escalation cohort will orally receive a single dose of HS-10509 or a matching placebo on Day 1
89013428|NCT06301074|Experimental|HS-10509 in patients|In MAD, patient with schizophrenia in each dose-escalation cohort will orally receive HS-10509 or a matching placebo once daily for 28 days.
89013429|NCT06301074|Placebo Comparator|Placebo in patients|In MAD, patient with schizophrenia in each dose-escalation cohort will orally receive HS-10509 or a matching placebo once daily for 28 days.
89013430|NCT06301061|Experimental|Patients treated with Focal Microvibration|Patients will be treated with focal microvibration through the application on the skin of four devices for 6 hours/day every day except thursady and Sunday.
89013431|NCT06301061|Sham Comparator|Patients treated with a Sham device|Patients will be treated with four sham device which will be attached on the skin for 6 hours/day every day except thursady and Sunday.
89013432|NCT06301061|Active Comparator|Patients treated with standard pharmacological approach|Patients will be treated with standard pharmacological therapy
89013433|NCT06301048||Pancreatic Stenting Group|performed pancreatic duct stent placement after endoscopic papillectomy
89013434|NCT06301048||Non-Pancreatic Stenting Group|have not performed pancreatic duct stent placement after endoscopic papillectomy
89013435|NCT06301048||Biliary Stenting Group|performed common bile duct stent placement after endoscopic papillectomy
89013436|NCT06301048||Non-Biliary Stenting Group|have not performed common bile duct stent placement after endoscopic papillectomy
89013437|NCT06301035|Experimental|Asymmetric HFNC|Asymmetric HFNC
89013438|NCT06301035|Active Comparator|Standard HFNC|Standard HFNC
89013439|NCT06301009|Experimental|AI-CAC arm|All patients included in the study and undergoing AI-CAC calculation on a chest x-ray
89013440|NCT06300983|Active Comparator|Experimental group|The intervention consisted of 5 sessions, with each lasting 100 minutes and delivered on a weekly basis.
89013441|NCT06300983|Placebo Comparator|Control group|The control group, which do not receive any psychoeducative intervention
89013442|NCT06300970|Active Comparator|Artesunate+Amodiaquine (ASAQ)|"Amodiaquine-artesunate (ASAQ) dose based on weight, given once daily for three days.~ASAQ has three formulations, with the dose depending on the weight of the child according to the following.~4.5-8.9 kg = 1 tablet 25 mg AS/67.5 mg AQ 9-17.9kg = 1 tablet 50 mg AS/135 mg AQ 18.0-35.9kg = 1 tablet 100 mg AS/270 mg AQ~≥36.0kg = 2 tablets 100 mg AS/270 mg AQ"
89013443|NCT06300970|Active Comparator|Artemether+Lumefantrine (AL)|"Artemether+Lumefantrine (AL) dose is based on weight and given twice daily for three days. AL has one formulation, with pills containing 20 mg artemether and 120 mg lumefantrine. The number of tablets per dose depends on the weight of the child according to the following:~5 -14.9 kg = 1 tablet per dose 15 -24.9 kg = 2 tablets per dose 25 -34.9 kg = 3 tablets per dose~≥35 kg = 4 tablets per dose~1 tablet contains 20 mg artemether and 120 mg lumefantrine"
89013444|NCT06300957|Experimental|Intervention|"Participants will be randomly assigned 2:1 to Experimental or Waitlist Control conditions. Experimental group will immediately access Help Wanted, a secondary prevention program for adults who self-identify as having sexual attraction to children. Help Wanted is an online self-help curriculum to prevent Child Sexual Abuse (CSA) and reduce the psychosocial stressors of help-seekers. Content is designed to increase knowledge about CSA, counter distorted attitudes and cognitions, cope with sexual thoughts and urges about children, support development of a healthy sexuality, counter stigma and shame, build a positive self-image, and encourage safe disclosure practices. Harm and risks are clearly identified within an overall positive messaging framework. Help Wanted incorporates testimonials from survivors and from positive role models, avoids the collection of personal identifiers or reportable information, and adheres to other best practices of prevention programming."
89013445|NCT06300957|Other|Waitlist Control|Participants randomized to the Waitlist Control group will be barred from accessing the Help Wanted program for a period of one month.
89013446|NCT06300944|Active Comparator|Group C(Control Group)|At the beginning of the operation, intravenous infusion of reifentanil 0.1~0.2 μg/kg·min, propofol 2~4mg/kg·h, rocuronium 0.3mg/kg·h intermittently, inhalation of 1%~2% sevoflurane were maintained, the fluctuation of blood pressure was not more than 20% of the basic level, and the heart rate was 50~100 times /min. Pump proper amount of normal saline.The postoperative PCIA regimen was Sufentanil 2ug/kg, ondansetron 16mg, diluted with appropriate normal saline, a total of 100ml
89013447|NCT06300944|Experimental|Group K(Esketamine Group)|Intraoperatively, remifentanil 0.1-0.2 μg/kg·min, propofol 2-4 mg/kg·h, intermittent rocuronium 0.3 mg/kg·h, inhalation of 1%-2% sevoflurane were given by continuous intravenous infusion, to maintain blood pressure fluctuation within 20% of the baseline level and heart rate within 50-100 beats/min. Esketamine 0.2mg/kg·h was pumped at the beginning of the procedure.The postoperative PCIA regimen was Sufentanil 2ug/kg, ondanseetron 16mg, esketamine 0.75mg/kg, diluted with appropriate normal saline, a total of 100ml.
89013448|NCT06300931||Intern dentists|Group of interns to take KAP survey followed by a lecture and then another KAP survey
89013449|NCT06300905|Experimental|Group I|Brushing twice daily in the morning and evening with 2 minutes each time
89443557|NCT02499224|Experimental|YYB101|Dose-escalation cohort: YYB101 of each dose level (0.3mg/kg to 5mg/kg), IV infusion on Day 1, Day 29, and followed by every 2 weeks Dose-expansion cohort: YYB101 of MTD (or RP2D), IV infusion every 2 weeks
89199974|NCT00887991||Electric Pump 2 (Medela Symphony Electric Breast Pump)|This is a parallel trial where subjects (mother of preterm infants) will be allocated to use one of two electric breast pumps to express milk. The use of electric breast pumps is routine practice on neonatal units in the UK.
89443558|NCT02169999|Experimental|Personalized Diabetes Care Website|Subjects are exposed to Personalized Diabetes Care website.
89443559|NCT02169999|No Intervention|No Exposure To Website|Subjects are not exposed to Personalized Diabetes Care website
89443560|NCT03120416|Experimental|Resistance exercise training program|Eight exercises will be used to include large upper and lower body muscle groups. The baseline 1 repetition maximum (RM) will be used to set initial training loads. All exercise sessions will be performed under the supervision of an exercise physiologist. Vital signs and body weight will be recorded before each session. The workload during training will be adjusted to reflect 80% of the most recent 1 RM (approximately 8-12 RM set). In addition, patients' workloads will be progressively increased if the patients can lift the weight more than 12 repetitions. Participants will perform three sets of 8-12 repetitions on each machine per session.
89443561|NCT03120416|No Intervention|Control|Participants randomized to the control group will be offered an educational brochure regarding exercise published by the NKF.
89443562|NCT02177097||40 patients (uTHA)|Patients undergoing primary uncemented total hip arthroplasty surgery.
89443563|NCT02177097||40 patients (hTHA)|40 patients undergoing primary hybrid total hip replacement surgery.
89443564|NCT02177097||40 patients (TKA)|40 patients undergoing total knee replacement surgery.
89443565|NCT02178501|Experimental|Omega-3 PUFA|OMEGA-3 PUFA 2000 mg once daily (1000 mg EPA and 1000 mg DHA)
89443566|NCT02178501|Placebo Comparator|Placebo|Placebo once daily
89443567|NCT04496102|Active Comparator|Cemented TKA|Cemented TKA (Triathlon, Stryker) include patellar resurfacing
89443568|NCT04496102|Experimental|Cementless TKA|Cementless TKA (Triathlon Tritanium, Stryker) include patellar resurfacing
89443569|NCT02178579||Multiple Myeloma (MM) treatment with bortezomib|No intervention planned.
89443570|NCT02178579||Multiple Myeloma (MM) treatment with carfilzomib|No intervention planned.
89443571|NCT02499068|Experimental|COPD, Telehealth|Patients randomized to this arm would be followed by home telehealth devices and monitored on a daily bases for early detection of exacerbations and prompt clinical intervention.
89443572|NCT02499068|No Intervention|COPD, Normal clinical practice|Patients would do the usual clinical practice.
89443573|NCT03337022|Experimental|CC-90006; Dose level 1|CC-90006 will be administered subcutaneously (SC) on days 1, 15, and 29.
89443574|NCT03337022|Experimental|CC-90006; Dose level 2|CC-90006 will be administered subcutaneously (SC) on days 1, 15, and 29.
89443575|NCT03337022|Experimental|CC-90006; Dose level 3|CC-90006 will be administered subcutaneously (SC) on days 1, 15, and 29.
89443576|NCT03337022|Experimental|CC-90006; Dose level 4|CC-90006 will be administered subcutaneously (SC) on days 1, 15, and 29.
89443577|NCT03337022|Placebo Comparator|Placebo|Placebo (saline) will be administered subcutaneously (SC) on days 1, 15, and 29.
89443578|NCT02178735|Experimental|Anterior compartment prolapse|Woman with cystocele who underwent anterior vaginal tailored mesh surgery
89443579|NCT02178735|Experimental|Posterior compartment prolapse|Woman with rectocele, enterocele, uterine prolapse, vaginal stump prolpase who underwent posterior vaginal tailored mesh surgery
89443580|NCT02178735|Experimental|anterior and posterior prolapse|Woman with cystocele and rectocele/uterine prolapse/vaginal vault prolapse/enterocele who underwent anterior and posterior vaginal tailored mesh surgery
89443581|NCT03120494|Experimental|Subjects at risk of HIV|25 high risk MSM and 50 negative partners in a sero-discordant couple will be recruited and emtricitabine and tenofovir (Truvada) for PrEP will be provided, per guidelines, for one year
89443582|NCT03537573|Active Comparator|Usual Care/Guideline|The Usual Care group (also known as the Guideline group) follows the recent Center for Disease Control (CDC) guidelines and, when triggered by an opioid prescription during a qualifying visit, will be delivered real-time in a short checklist of recommendations to: 1) check the state-specific Prescription Drug Monitoring Program; 2) assess risk factors for opioid-related harms (e.g., history of substance use disorder, history of mental health problems, benzodiazepine use); 3) avoid extended-release or long-acting opioids; 4) use a low dose of immediate-release opioid for short period of time (3-7 days); and 5) consider non-opioid management such as acetaminophen, non-steroidal anti-inflammatory agents (NSAIDS), and physical therapy. Epic EHR order sets will be linked to enable easing ordering of non-opioid therapy.
89443583|NCT03537573|Experimental|Guideline + Opioid Justification (OJ)|Providers will be required asked to enter a free text justification for their decision to prescribe an opioid analgesic for the acute pain condition. The provider will be notified that the justification provided will be visible in the Epic EHR. The provider has the option of entering a justification or not. If no justification is entered, nothing will be entered into the record (i.e., the Opioid Justification area in the encounter record will be left blank). The provider does not need to enter a justification if they choose to cancel the opioid prescription.
89199975|NCT04392921|Experimental|Intervention Arm|Patients randomized to amiodarone treatment
89199976|NCT04392921|Placebo Comparator|Control Arm|Patients randomized to placebo treatment
89199977|NCT00959530|Experimental|lingualized|complete denture fabricated by lingualized occlusion scheme
89199978|NCT00959530|Placebo Comparator|Full Bilaterally Balanced Articulation|complete denture fabricated by Full Bilaterally Balanced Articulation scheme
89443584|NCT03537573|Experimental|Guideline + Provider Comparison (PC)|Providers will receive monthly feedback via e-mail on their status in regards to initial opioid prescriptions for acute pain, adherence to safe opioid prescribing guidelines, and proportion of patients started on opioids f or acute pain who transition to chronic opioid therapy (> 3 months). Providers in the lowest decile overall for proportion of patients with initial opioid prescriptions , unsafe opioid prescribing, and transition to chronic opioid therapy (> 3 months) will be given positive feedback for providing high quality, evidence-based care to their patients with acute pain. Providers outside the lowest decile will be notified they are outside the high quality, evidence-based care range and will be provided with their proportions compared to the high performers.
89443585|NCT03537573|Experimental|Guideline + OJ + PC|This arm will include the guideline, opioid justification, and provider comparison described above.
89443586|NCT03120962|Experimental|oxycodone|Oxycodone 20mg/day, for 4 weeks and famciclovir 500mg three-times daily for 7 days.
89443587|NCT03120962|Active Comparator|standard treatment|Gabapentin 900mg/day, titrated up to max tolerated dose or 1800mg/day (whichever is lower), for 4-12 weeks and famciclovir 500mg three-times daily for 7 days.
89443588|NCT02178813|Experimental|Administration of minocycline|"All patients in the study will receive minocycline periprocedurally with the following schedule:~Day prior to procedure: 800mg p.o., 700mg p.o.~Day of procedure: 600mg i.v., 500mg p.o.~Day after procedure: 400mg p.o., 400mg p.o."
89443589|NCT03341000|Experimental|DISCSS Device|This pilot feasibility study will explore and help determine optimal settings and configuration of the DISCSS™ System with patients that have completed a percutaneous trial with a commercially available SCS trial system.
89443590|NCT02170233||Sepsis|This group will contain patients meeting criteria for sepsis for enrollment in the study (target population).
89443591|NCT02170233||Normals|This group will be healthy patients who will have data points recorded for controls for the study to assess the reliability of these measures on healthy patients.
89443592|NCT03340922|Experimental|Automatic annotation of LAT (WF-method)|The annotation of LAT in each acquired point will be automatically performed using the LAT annotation tool integrated into CARTO navigation system, called Wavefront (WF). Automatic annotation of LAT performed by the CARTO system uses the maximum negative slope of the distal U-EGM to set the timing of the mapping annotation, displayed on the corresponding B-EGM. Additionally, the automatic annotation of LAT will be aided by an ECG recognition pattern algorithm (included in the last version of CARTO), which is intended to avoid wrong annotation of ventricular complexes other than the clinical PVC.
89443593|NCT03340922|Active Comparator|Manual annotation of LAT (M-method)|A detailed electrocardiogram (ECG)-gated activation map of the chamber of interest will be acquired using the CARTO navigation system. An experienced electrophysiologist will perform the annotation of LAT in each acquired point. The LAT will be measured from the onset of B-EGM (earliest positive or negative deflection) of the distal dipole of the mapping catheter to the defined reference. The use of the U-EGM as a guidance to identify the real onset of B-EGM will be decided under electrophysiologist criteria.
89443594|NCT02170311|Experimental|Z-213 100mg|Group/Cohort Label: 100 mg iron Z-213 will be administered by intravenous infusion.
89443595|NCT02170311|Experimental|Z-213 500mg|Group/Cohort Label: 500 mg iron Z-213 will be administered by intravenous infusion.
89443596|NCT02170311|Experimental|Z-213 800mg|Group/Cohort Label: 800 mg iron Z-213 will be administered by intravenous infusion.
89443597|NCT02170311|Experimental|Z-213 1000mg|Group/Cohort Label: 1000 mg iron Z-213 will be administered by intravenous infusion.
89443598|NCT03121040|Experimental|Subjects ingested VAAM® for 10 weeks|Ten young athletes ingested Vespa amino acid mixture (VAAM®) for 10 weeks, divided into different meter race including 1500-, 800- and 400-meter races.
89443599|NCT03121040|Experimental|Subjects ingested VAAM® for 6 weeks|Ten young athletes ingested Vespa amino acid mixture (VAAM®) for 6 weeks, divided into different meter race including 1500-, 800- and 400-meter races.
89443600|NCT03121040|No Intervention|Subjects ingested nothing|Ten young athletes before ingesting Vespa amino acid mixture (VAAM®) , divided into different meter race including 1500-, 800- and 400-meter races.
89443601|NCT02177253|Experimental|Ipratropium bromide / Salbutamol Inhalation solution|
89443602|NCT02177253|Placebo Comparator|Placebo Inhalation solution|
89443603|NCT02177253|Experimental|Ipratropium bromide Inhalation solution|
89443604|NCT02177253|Active Comparator|COMBIVENT Inhalation Aerosol (ipratropium bromide/salbutamol)|
89443605|NCT02177253|Placebo Comparator|Placebo Inhalation Aerosol|
89443606|NCT03121118||Scan opportunity|40 dyads comprised of individuals with Mild Cognitive Impairment and a study partner who is either a family member or kin-like friend.
89443607|NCT03121118||Comparison group|40 dyads comprised of individuals with Mild Cognitive Impairment and a study partner who is either a family member or kin-like friend.
89443608|NCT02170467|Experimental|Control|Assessment of intestinal permeability in small intestine (Lactulose/ Mannitol ratio) in controls and camparison with pateints with anorexia nervosa.
89443609|NCT02170467|Experimental|patients with anorexia nervosa|Assessment of intestinal permeability in small intestine (Lactulose/ Mannitol ratio) in patients with anorexia nervosa before and after re-feeding.
89443610|NCT02178891|Other|short implants|
89443611|NCT03120884|Experimental|IVF|embryos are cultured using conventional in vitro fertilization.A maximum of 2 embryos will be transferred for each treatment cycle.
89443612|NCT03120884|Experimental|ICSI|embryos are fertilized using ICSI.A maximum of 2 embryos will be transferred for each treatment cycle.
89443613|NCT02498990|Experimental|Weight reduction|
89443614|NCT02177331|Experimental|Lacidipine|
89443615|NCT03336788|Placebo Comparator|TMS|
89443616|NCT03336788|Active Comparator|TMS with virtual reali|
89443617|NCT02170545||Multi-Part Proximal Humerus Fracture|All participants that meet the entry criteria will be included in the study cohort.
89443618|NCT03336710||Primary sample|Community sample of adults (18-65) from the greater Buffalo, NY region, oversampling people who are seeking mental health treatment.
89443619|NCT05233046|Experimental|Impact of Nourish Carolina - Control Group|Group A - nutrition (one time/week) and mental health counseling (biweekly) for 12 weeks
89443620|NCT05233046|Experimental|Impact of Nourish Carolina - Study Group|Group B - nutrition ( one time/week) and mental health counseling (biweekly)with Nourish Carolina for 12 weeks
89443621|NCT02179125|Experimental|Bronchoscopic LVR-coil treatment|Bronchoscopic lung volume reduction with coil treatment
89443622|NCT03340688|Active Comparator|Cervical cerclage + vaginal progesterone|Cervical cerclage in twin pregnancy with transvaginal cervical length ≤15mm and Daily vaginal progesterone 400mg from diagnosis of short cervix to 36 weeks
89443623|NCT03340688|No Intervention|Vaginal progesterone|Daily vaginal progesterone 400mg from diagnosis of short cervix to 36 weeks
89443624|NCT02177409|Experimental|Telmisartan|4-week placebo run-in, 8-week fixed dose period
89443625|NCT02177409|Active Comparator|Amlodipine|4-week placebo run-in, 8-week fixed dose period
89013450|NCT06300905|Active Comparator|Group II|Brushing twice daily in the morning and evening with 2 minutes each time
89013451|NCT06300892||Patients undergoing open GI surgery|Patients with SSI
89443626|NCT02494388||Serous cystadenoma|Serous cystadenoma patients. Endoscopic ultrasound guided needle based confocal endomicroscopy will be applied in all patients.
89443627|NCT02494388||Mucinous cystic neoplasms|Mucinous cystic neoplasms patients. Endoscopic ultrasound guided needle based confocal endomicroscopy will be applied in all patients.
89443628|NCT02494388||Intraductal papillary mucinous neoplasms (IPMN)|IPMN patients. Endoscopic ultrasound guided needle based confocal endomicroscopy will be applied in all patients.
89443629|NCT02494388||Mucinous cystdenocarcinoma|Mucinous cystadenocarcinoma patients. Endoscopic ultrasound guided needle based confocal endomicroscopy will be applied in all patients.
89443630|NCT02494388||Other cystic lesions|Other cystic lesions patients (cystic neuroendocrine tumors, solid pseudopapillary neoplasms, cystic lymphangioma, etc.) Endoscopic ultrasound guided needle based confocal endomicroscopy will be applied in all patients..
89443631|NCT02170623|Experimental|Period 1: BIBR 1048 MS with Pantoprazole|"Three treatments of different formulations of 50 mg BIBR 1048 MS (bid for 3 days) with 40 mg Pantoprazole (bid). Randomised sequence.~BIBR 1048 MS Capsule I with pantoprazole (bid for 3 days);~BIBR 1048 MS Capsule K with pantoprazole (bid for 3 days);~BIBR 1048 MS Drinking solution with Pantoprazole (bid for 3 days)"
89443632|NCT02170623|Experimental|Period 2: BIBR 1048 MS|"Three treatments of different formulations of 50 mg BIBR 1048 MS (bid for 3 days) without Pantoprazole. Fixed sequence.~BIBR 1048 MS Capsule K (bid for 3 days);~BIBR 1048 MS Drinking solution (bid for 3 days)"
89443633|NCT02494544|Active Comparator|ConforMIS iTotal Knee replacement|iTotal patient-specific knee replacement system
89443634|NCT02494544|Active Comparator|DePuy total knee replacement|Off the shelf knee replacement system
89443635|NCT02494544|Active Comparator|Zimmer total knee replacement|Off the shelf knee replacement system
89443636|NCT02494544|Active Comparator|Biomet total knee replacement|Off the shelf knee replacement system
89443637|NCT02494544|Active Comparator|Smith & Nephew total knee replacement|Off the shelf knee replacement system
89443638|NCT02494544|Active Comparator|Stryker total knee replacement|Off the shelf knee replacement system
89443639|NCT02170701|Experimental|BIBR 1048|Ascending doses (in mg) given twice daily
89443640|NCT02498756|Experimental|IP plus CIK|Patients receive ipilimumab and CIK.
89443641|NCT02498756|Active Comparator|IP alone|Patients receive ipilimumab alone.
89443642|NCT02255721|Experimental|SHIP Intervention|SHIP is a health behavior change intervention to give parents the knowledge, motivation, and skills necessary to set goals, problem-solve, and improve their child's sleep.
89443643|NCT02255721|Active Comparator|SHIP Control Arm|The active control arm uses the same strategies as the SHIP intervention arm, but for child health topics unrelated to sleep or outcome measures.
89443644|NCT03336632|Experimental|Chidamide|Chidamide, tablets, 5 mg/tablet, 20 mg orally twice weekly from D-7~+14 Cyclophosphamide: 50 mg/Kg intravenously D+3, +4 Cyclosporine A: intravenously then orally 3 mg/Kg D+5~D+100
89443645|NCT02498288|Experimental|Isotretinoin Arm|All subjects in this study will be randomized to receive all the 3 distinct medications of isotretinoin in a sequential manner. Subjects will receive a single dosage of two capsules x 20 mg (40 mg) orally, for three periods, six sequences, with a wash-out period of two weeks to eliminate the first dosage.
89443646|NCT02756403|Active Comparator|Azithromycin|500 mg of Azithromycin
89443647|NCT02756403|Active Comparator|Doxycycline|200 mg of Doxycycline
89443648|NCT02756403|Active Comparator|Metronidazole|500 mg of Metronidazole
89443649|NCT02756403|Placebo Comparator|Placebo|Inactive Ingredient
89443650|NCT03336554||observation group|One group of participants are under observation. This trial has two phase. Phase I: 40 participants will be enrolled. Only if epigenetic cfDNA library has been built, investigators would move on to Phase II. Another 60 participants will be enrolled for further analysis.
89443651|NCT03336476|Experimental|Videolaryngoscopy|Videolaryngoscopy the trachea will be intubated using a videolaringoscope
89443652|NCT03336476|Active Comparator|Direct laryngoscopy|Direct laringoscopy the trachea will be intubated using a laringoscope
89013452|NCT06300892||Control group|age-, sex-, diagnosis-, and wound class-matched control patients without SSI
89199979|NCT00959608|Active Comparator|Basic|Basic program participants receive 10-15 minute PCP weight management counseling at approximately four month intervals for up to 24 months and weight management materials.
89443653|NCT03539289|Other|MUFA Diet|Monounsaturated Fatty Acids Diet
89443654|NCT03539289|Other|SFA Diet|Saturated Fatty Acids Diet
89443655|NCT02493296||Observational|The cohort will have their central aortic pressure, and carotid-femoral and brachio-femoral pulse-wave velocities measured. These measurements will take place pre-operatively, within a week of surgery, 6-weeks and 1-year post-operatively also. The surgery will be abdominal aortic aneurysm repair.
89443656|NCT02179281|Experimental|Suspend Before Low feature turned ON|"MiniMed™ 640G system with the Suspend Before Low feature turned ON; continuously set on at 3,6 mmol/L (65 mg/dL). Suspend On Low Alert and Resume Basal Alert for the SmartGuard group should be set OFF.~Administered intervention: Medtronic MiniMed™ 640G system"
89443657|NCT02179281|Active Comparator|Suspend Before Low feature turned OFF|"MiniMed™ 640G system with the Suspend Before Low and Suspend On Low features are both turned OFF; Alert On Low is set at 65 mg/dL (3,6 mmol/L). Resume Basal Alert should be set OFF as well.~Administered intervention: Medtronic MiniMed™ 640G system"
89443658|NCT03336320|Experimental|Multidomain Intervention Group|Home-based multidomain intervention composed of nutritional counselling, exercise (balance, gait, , and cognitive training provided using ICT solutions. A web platform, containing information, questionnaires, videos, games, and tests related to each one of the three components of the multidomain intervention will be made available to participants in this group.
89013453|NCT06300879|Experimental|Experimental group|Performing totally laparoscopic proximal gastrectomy with esophagogastrostomy by fissure technique
89013454|NCT06300866|Experimental|Group I|toothpaste brushing 2x daily morning & evening for 2 minutes
89013455|NCT06300866|Active Comparator|Group II|toothpaste brushing 2x daily morning & evening for 2 minutes
89443659|NCT03336320|Active Comparator|Control Group|"Participants from CG will also be equipped with wrist worn accelerometers (that will record daily activity data continuously) but contrary to MIG, participants won't have access to the password encrypted application, and therefore, to the multidomain intervention. However, they will be able to access the study website with overall information on the eMIND study and links to the website of health authorities (such as http://www.mangerbouger.fr/PNNS or the World Health Organization http://www.who.int/topics/ageing/fr/) regarding healthy ageing topics. Plus, in order to control for the social aspect of MIG, participants in CG will receive monthly phone calls from the research team."
89443660|NCT02494310|Experimental|HRME - Prevention Mobile Unit|Procedures to be done in the mobile unit (van): Visual inspection will be performed with 5% acetic acid (VIA) applied to the cervix followed by standard colposcopy. Proflavine (0.01%) will then be applied topically. Lugol's solution will then be applied and colposcopy performed and abnormal lesions noted. HRME images will be acquired from any areas that are abnormal by VIA and/or colposcopy. VIA, colposcopy and HRME observations will recorded by quadrant. Any abnormal areas by VIA and/or colposcopy will be biopsied. If no abnormal areas are noted, one cervical biopsy will be obtained from a normal appearing area with a HRME image of this area obtained.
89443661|NCT02494310|Experimental|HRME - Barretos Cancer Hospital|Procedures to be done at Barretos Cancer Hospital: Visual inspection will be performed with 5% acetic acid (VIA) applied to the cervix followed by standard colposcopy. Proflavine (0.01%) will then be applied topically. Lugol's solution will then be applied and colposcopy performed and abnormal lesions noted. HRME images will be acquired from any areas that are abnormal by VIA and/or colposcopy. VIA, colposcopy and HRME observations will recorded by quadrant. Any abnormal areas by VIA and/or colposcopy will be biopsied. If no abnormal areas are noted, one cervical biopsy will be obtained from a normal appearing area with a HRME image of this area obtained.
89443662|NCT03537417||Tension pneumothorax group|Patients undergoing intentional pneumothorax for thoracoscopic ablation of cervical sympathetic chain as a treatment for hyperhidrosis
89443663|NCT02494466|Active Comparator|Group E (n=10)|Patients with high Ig E levels
89443664|NCT02494466|Active Comparator|Group C (n=10)|Patients with normal Ig E levels
89443665|NCT02494466|Active Comparator|Group M (n=10)|Patients who would be administered with 4mg PO MS 10 days before surgery because of high IgE
89443666|NCT02179593|Other|2-Segment SARPE|Maxilla expansion using one sagittal section of the maxilla.
89443667|NCT02179593|Other|3-Segment SARPE|Maxilla Expansion using two parasagittal section of the maxilla.
89443668|NCT03537339||Observation|Record general information of patients' sex, age, previous history, family history, electrocardiogram, echocardiography, cardiac biomarkers TnT, BNP, biochemical examination, and clinical treatment and so on
89443669|NCT02177487|Experimental|Telmisartan + Hydrochlorothiazide|
88927431|NCT01702623|Active Comparator|Trileptal first, then Oxcarbazepine|Single dose of oxcarbazepine suspension, 600 mg, then single dose of trileptal suspension, 600 mg (after washout period
88927432|NCT01702636|Active Comparator|Tranexamic Acid|Intravenous tranexamic acid 1000 mg in 100 mL 0.9% NaCl over 10 minutes followed by 1000 mg in 500 mL 0.9% NaCl infusion over 8 hours.
88927433|NCT01702636|Placebo Comparator|Placebo|Intravenous placebo in 100 mL 0.9% NaCl over 10 minutes followed by 500 mL 0.9% NaCl infusion over 8 hours.
88927434|NCT01702649|Experimental|RPX2003 (Biapenem)|Single and multiple dose of RPX2003 (Biapenem).
88927435|NCT01702649|Placebo Comparator|Normal Saline|Single and multiple doses of normal saline.
88927436|NCT01702662|Experimental|Photopill treatment|Photopill treatment, 2 minutes per cm rectal mucosa (3cm) 10 times
88927437|NCT01702675|Experimental|ACH15 - 50mg capsule|ACH15 50mg capsule by mouth single dose (Group 1)
88927438|NCT01702675|Experimental|ACH15 - 250 mg capsule|ACH15 250mg capsule by mouth as single dose(Group 2)
88927439|NCT01702675|Experimental|ACH15 - 500mg capsule|ACH15 500mg capsule by mouth in a single dose(Group 3)
88927440|NCT01702675|Experimental|ACH15 - 1000 mg (two 500mg capsule)|ACH15 500mg capsule by mouth, two 500 mg capsules once as a single dose(Group 4)
88927441|NCT01702675|Experimental|ACH15 - 2000 mg (four 500 mg capsule)|ACH15 500mg capsule by mouth, four 500 mg capsules once as a single dose(Group 5)
88927442|NCT01702675|Experimental|ACH15 - 500 mg (twice a day for 7 days)|ACH15 500mg capsule by mouth twice a day for seven days (Group 6)
88927443|NCT01702675|Placebo Comparator|Placebo - 250 mg capsule|Placebo 250mg capsule by mouth single dose (Group 2)
88927444|NCT01702675|Placebo Comparator|Placebo - 500 mg capsule|Placebo 500mg capsule by mouth in a single dose(Group 3)
88927445|NCT01702675|Placebo Comparator|Placebo - 1000 mg (two 500mg capsule)|Placebo 500mg capsule by mouth, two 500 mg capsules once as a single dose(Group 4)
88927446|NCT01702675|Placebo Comparator|Placebo 2000 mg (four 500mg capsule)|Placebo 500mg capsule by mouth, four 500 mg capsules once as a single dose(Group 5)
88927447|NCT01702675|Placebo Comparator|Placebo - 500 mg (twice a day for 7 days)|Placebo 500mg capsule by mouth twice a day for seven days (Group 7)
88927448|NCT01702701|Active Comparator|Montelukast|patients will receive 10 mg po montelukast daily for 12 weeks.
88927449|NCT01702701|Active Comparator|Fluticasone|patients will receive 440mcg fluticasone po bid for 12 weeks
89443670|NCT02177565|Experimental|carrier plus BMSCs|carrier plus in vitro expanded autologous BMSCs
89443671|NCT02177565|Placebo Comparator|carrier alone (control).|Carrier alone
89443672|NCT03342872|Experimental|Core Training|
89443673|NCT03342872|Experimental|Core Training & Facilitation|
89443674|NCT03342872|No Intervention|Control|
89443675|NCT02177643|Active Comparator|Diacerein|Diacerein 50 mg immediate release capsule, once daily for the starting 28 days and Diacerein 50 mg immediate release capsule twice a day for the remains of the study.
88927450|NCT01702714|Experimental|RO5083945 + carboplatin + paclitaxel|
88927451|NCT01702714|Experimental|RO5083945 + cisplatin +gemcitabine|
88927452|NCT01702727|Experimental|I-BiTTM game|30 minutes intervention weekly for 6 weeks.
88927453|NCT01702727|Active Comparator|Non-I-BiTTM game|30 minutes intervention weekly for 6 weeks.
88927454|NCT01702727|Experimental|I-BiTTM DVD|30 minutes intervention weekly for 6 weeks.
88927455|NCT01702740|Experimental|Part A, 1 mg/kg CNTO 136|
88927456|NCT01702740|Experimental|Part A, 4 mg/kg CNTO 136|
88927457|NCT01702740|Experimental|Part A, 10 mg/kg CNTO 136|
89013456|NCT06300853|Other|Cancer patients|Adult patients with a solid tumor diagnosis [I, II, III, IV stage,] and active anti-cancer treatment or treatment discontinued for less than 6 months, followed at IRCCS Sacro Cuore - Don Calabria, Negrar (Verona), Italy will be prospectively recruited at the moment of the future booster doses administration of SARS-CoV-2 vaccine.
89013457|NCT06300853|Other|Elderly subjects|Subjects over 70 years of age who live in the nursing home in the social area at the IRCCS Sacro Cuore - Don Calabria Hospital will be prospectively recruited at the moment of the future booster doses administration of SARS-CoV-2 vaccine.
89013458|NCT06300840|No Intervention|Baseline|Wearing no Balancebelt.
89013459|NCT06300840|Sham Comparator|Sham condition|Wearing the BalanceBelt while it is switched off
89013460|NCT06300840|Experimental|Intervention|Wearing the BalanceBelt while it is switched on
89013461|NCT06300827|Experimental|Experimental Group|Experimental Group: Structured digital-based training will be implemented.
89443676|NCT02177643|Placebo Comparator|Placebo|Placebo capsules once a day for the starting 28 days and two times daily for the remainder of the study.
89443677|NCT03340376|Experimental|atezolizumab monotherapy|A fixed dose of 1200 mg atezolizumab will be administered intravenously on Day 1 of each 21-day cycle until progressive disease
89443678|NCT03340376|Experimental|atezolizumab combined with doxorubicin|A fixed dose of 1200 mg atezolizumab will be administered intravenously on Day 1 of each 21-day cycle. Doxorubicin will be administered on Day 1 of each 21-day cycle at a dose of 75mg/m² for a total of 6 cycles or until progressive disease
89013462|NCT06300827|No Intervention|Control Group|"Control Group: The nursing student will be expected to continue their daily life.~Nursing students who meet the inclusion criteria will be randomly assigned to the experimental group by a statistician."
89013463|NCT06300814|Experimental|Progressive relaxation exercise group|15 children aged 9-16 years who met the inclusion and exclusion criteria.
89013464|NCT06300814|Experimental|Music recital group|15 children aged 9-16 years who met the inclusion and exclusion criteria.
89013465|NCT06300814|No Intervention|Control group|15 children aged 9-16 years who met the inclusion and exclusion criteria.
89013466|NCT06300788|Experimental|CKD group|Patient with chronic kidney disease
89443679|NCT03340376|Active Comparator|doxorubicin monotherapy|Doxorubicin will be administered on Day 1 of each 21-day cycle at a dose of 75mg/m² for a total of 6 cycles or until progressive disease
89443680|NCT02030223|Active Comparator|Transversus abdominis plane block with 20 ml ropivacaine 0,75%|Transversus abdominis plane block with 20 ml ropivacaine 0,75%
89443681|NCT02030223|Placebo Comparator|Transversus abdominis plane block with 20 ml saline|Transversus abdominis plane block with 20 ml saline
89443682|NCT03340298|Experimental|grain|25 gram fiber from whole grain products and 10 gram fiber from fruits and vegetables
89443683|NCT03340298|Experimental|fruits and vegetables|25 gram fiber from fruits and vegetables as main supplier and the remaining 10 grams from whole grain sources
89443684|NCT03340298|Experimental|grain-fruits and vegetables|17.5 gram fiber from whole grain and 17.5 gram fiber from fruits and vegetables
89443685|NCT03537105|Experimental|Sclerodermic patients|Sclerodermic patients presenting cutaneous fibrosis
89013467|NCT06300788|Experimental|Dialysis group|Dialysis patients (hemodialysis or peritoneal dialysis)
89013468|NCT06300788|Experimental|kidney transplant group|Kidney transplant patients
89443686|NCT02182167|Experimental|IV NAC|"Participants will receive IV N-acetylcysteine or placebo. The dosing regimen is based on the regimens used in paracetamol poisoning .~Initial dose: 150 mg/kg body mass of N-acetylcysteine/WFI infused in 200 mL of 5% dextrose intravenously over 60 minutes, followed by continuous infusion: 50 mg/kg body mass in 500 mL of 5% dextrose over next 4 hours, followed by 100 mg/kg body mass in 1 litre of 5% dextrose over 16 hours."
89443687|NCT02182167|Placebo Comparator|Placebo|Water
89443688|NCT03537885|Experimental|TMS, EEG, and tDCS Group|"Participants will wear a cap fitted with Electroencephalography (EEG) electrodes to detect the brain's activity during the task. Transcranial Magnetic Stimulation will be used to evaluate the brain's responsiveness to Transcranial Direct Current Stimulation.~All study participants will receive the same study procedures - TMS, tDCS, and EEG."
89443689|NCT03336086|Other|experimental|This group underwent a weight loss program
89443690|NCT03336086|No Intervention|control|This group underwent adlibitum diet + physical activity
89537086|NCT05726513|Other|Zero support, zero positive end-expiratory pressure|Zero support, zero positive end-expiratory pressure
89013469|NCT06300788|Active Comparator|Control group|Control group of patients with normal renal function
89013470|NCT06300775|Active Comparator|Modified Hyrax|Appliance used for rapid maxillary expansion
89013471|NCT06300775|Active Comparator|Quad Helix|Appliance used for slow maxillary expansion
89013472|NCT06300762|Experimental|Cutimed Sorbion products|Within this arm the Cutimed Sorbion (Cutimed® Sorbion® Sachet/Sana/Border) products will be used for exudate managment.
89013473|NCT06300762|Active Comparator|Zetuvit (RespoSorb) products|Within this arm the comperator products Zetuvit® Plus/(RespoSorb® Super), Zetuvit® Plus Silicone/(RespoSorb® Silicone) and Zetuvit® Plus Silicone Border/(RespoSorb® Silicone Border) will be used for exudate management.
89013474|NCT06300749|Experimental|Chiropractic Cervical Manipulation Group (CCMG)|Patients in both groups were placed in supine position and manipulation was applied to patients in the chiropractic cervical manipulation group.
89013475|NCT06300749|Sham Comparator|Control Group (CG)|Patients in both groups were placed in supine position and manipulation was applied to patients in the chiropractic cervical manipulation group.
89013476|NCT06300697|Other|Control group Adult|Participation will be approximately 14 days after enrollment.
89013477|NCT06300697|Other|Food allergy-only group|Participation will be approximately 14 days after enrollment.
89013478|NCT06300697|Other|Food allergy plus atopic dermatitis group|Participation will be approximately 14 days after enrollment.
89013479|NCT06300697|Other|Atopic dermatitis without food allergy group|Participation will be approximately 14 days after enrollment.
89013480|NCT06300697|Other|Control Group less than 18 years old|Participation will be approximately 14 days after enrollment.
89443691|NCT02030145|Active Comparator|Classic Thoracic Lymphatic Pump|Subjects begin with Classic Thoracic Lymphatic Pump, then crossover to Compressive Thoracic Lymphatic Pump after 4-week washout period.
89443692|NCT02030145|Experimental|Compressive Thoracic Lymphatic Pump|Subjects begin with Compressive Thoracic Lymphatic Pump, then crossover to Classic Thoracic Lymphatic Pump after 4-week washout period.
89443693|NCT02498366|Experimental|experimental protocol|50 healthy, male, trained and aged 18-30 will be recruited and asked to undergo a series of physical tests.
89443694|NCT02182245|Experimental|Combination Therapy|
89443695|NCT02182245|Experimental|Monotherapy|
88927458|NCT01702740|Experimental|Part B, 10 mg/kg CNTO 136/placebo|
89443696|NCT05233124|Active Comparator|Dual antiplatelet therapy|Acetyl salicylic acid, 100mg once a day + clopidogrel 75mg, once a day.
89443697|NCT05233124|Experimental|Antiplatelet monotherapy + low dose anticoagulant|Clopidogrel 75mg + Rivaroxaban 75mg
89443698|NCT04494620|No Intervention|Control Arm|Standard of Care
89443699|NCT04494620|Active Comparator|Intervention Arm|Visual Inspection of Oral Cavity for Precancers and Cancer
89443700|NCT03342794|Other|preexisting posterior capsule defects|congenital cataracts with a preexisting posterior capsule defect
89443701|NCT03335930|Experimental|Morning exercise|To exercise at morning (08:00-10:00)
89443702|NCT03335930|Active Comparator|Afternoon exercise|To exercise at afternoon (14:00-16:00)
89443703|NCT03335930|Active Comparator|Evening exercise|To exercise at evening (18:00-20:00)
89443704|NCT02493218|Experimental|Mindfulness Instruction|Instruction on mindfulness concepts and practices. Classes are 45-90 minutes each and held weekly for 12 weeks.
89443705|NCT02493218|Active Comparator|Health Education Instruction|Instruction on general health and wellness. Classes are 45-90 minutes each and held weekly for 12 weeks.
89443706|NCT03340142|Experimental|Single Arm|All patients will undergo standard of care ablation procedures. VIVO™ results will be compared to that of standard of care results, but will not be used in diagnosis or treatment.
89443707|NCT03339986|Experimental|Reduction|Participants will be instructed to reduce all high energy dense snacks that they serve to thier children by 50%
89443708|NCT03339986|Experimental|Replacement|Participants will be instructed to replace all high energy dense snacks with fresh fruit and vegetables
89443709|NCT02498054|Experimental|Education with new meter feature.|Subjects experience a computer stimulation of a new meter feature ( colour range indicator) to help subjects interpret whether blood glucose results are low, in-range or high based on accepted guidance.
89443710|NCT02753595|Experimental|Eribulin mesylate plus PEGPH20 (Phase 1b)|"Recommended Phase 2 dose (RP2D) will be determined from the below dose levels:~Dose level 1: PEGPH20 (3.0 microgram per kilogram (mcg/kg)) followed by eribulin mesylate (1.4 milligrams per square meter (mg/m^2)) or~Dose level 0: PEGPH20 (1.6 mcg/kg) followed by eribulin mesylate (1.4 mg/m^2) or~Dose level -1: PEGPH20 (1.6 mcg/kg) followed by eribulin mesylate (1.1 mg/m^2)~Dose level 1 can be selected as the RP2D if no more than 1 out of 6 participants has a DLT; DLT was only observed from the first treatment cycle; otherwise, Dose level 0 will be assessed in a second cohort of 6 subjects and will be selected as the RP2D if no more than 1 subject has a DLT. Otherwise, Dose level - 1 will be assessed in a third cohort of 6 subjects. Upon determination of the RP2D, study Phase 1b Expansion Part will proceed to confirm the RP2D, and thereafter Phase 2 part will proceed."
88927459|NCT01702753|Active Comparator|Bifidobacterium animalis subsp. lactis|
88927460|NCT01702753|Placebo Comparator|Placebo|
88927461|NCT01702766|Active Comparator|Bifidobacterium animalis subsp. lactis|
88927462|NCT01702766|Placebo Comparator|Placebo|
88927463|NCT01702779|Other|optiflow|
88927464|NCT01702779|Other|O2|
88927465|NCT01702792|Experimental|Tumor Vaccine|1 x 107 TCE tumor lysate in 0.5 ml Lactated Ringers Solution (approximately 1 mg of tumor lysate protein) and equivalent volume of adjuvant will be injected 2 weeks and 3 weeks (2 vaccinations) after surgery in the intradermal skin of the upper thigh. There will be 2 vaccine administrations and patients will be followed for 2 months after inguinal node removal for any possible vaccine/study-related toxicity.
88927466|NCT01702818||HSDD group|Women with a diagnosis of Hypoactive Sexual Desire Disorder (HSDD).
88927467|NCT01702818||Control Group|Women without a diagnosis of Hypoactive Sexual Desire Disorder (HSDD).
88927468|NCT01702857|Experimental|TDENV-PIV alum4|4 µg TDENV-PIV with Alum adjuvant; 0.5 mL intramuscular injection at 0 and 28 days
88927469|NCT01702857|Experimental|TDENV-PIV AS03B|1 µg TDENV-PIV with AS03B adjuvant; 0.5 mL intramuscular injection at 0 and 28 days
88927470|NCT01702857|Placebo Comparator|Placebo|Phosphate buffered saline; 0.5 mL intramuscular injection at 0 and 28 days
88927471|NCT01702857|Experimental|TDENV-PIV alum1|1 µg TDENV-PIV with Alum adjuvant; 0.5 mL intramuscular injection at 0 and 28 days
88927472|NCT01702857|Experimental|TDENV-PIV AS01E|1 µg TDENV-PIV with AS01E adjuvant; 0.5 mL intramuscular injection at 0 and 28 days
88927473|NCT01702870||Suspected myositis|Participants with suspected myositis based on clinical criteria (Bohan and Peters criteria) referred for Magnetic resonance imaging
88927474|NCT01702870||Controls|Normal volunteers without myositis, who will undergo MR imaging to establish normal ranges of MR signal in health muscle
88927475|NCT01702974|Active Comparator|Vitamin D (cholecalciferol) and PBA (sodium phenylbutyrate)|Dose of interventions: 5,000 IU of vitamin D (cholecalciferol tablets) once daily and 500 mg PBA (sodium phenylbutyrate tablets) twice daily for 16 weeks.
88927476|NCT01702974|Placebo Comparator|Placebo tablets|Placebo tablets for vitamin D once daily and placebo tablets for PBA (phenylbutyrate) twice daily for 16 weeks.
88927477|NCT01703052|Experimental|CHF 6001 SD or placebo|Single administration of CHF 6001 dose levels 1 to 7 or placebo
88927478|NCT01703052|Experimental|CHF 6001 MD or placebo|Multiple administration of CHF 6001 dose levels 1 to 5 or placebo
88927479|NCT01703078|Active Comparator|Ingenol mebutate gel 0.05%|once daily for two consecutive days
88927480|NCT01703078|Experimental|Ingenol derivative concentration 1|once daily for two consecutive days
88927481|NCT01703078|Experimental|Ingenol derivative concentration 2|once daily for two consecutive days
88927482|NCT01703078|Experimental|Ingenol derivative concentration 3|once daily for two consecutive days
88927483|NCT01702116|Experimental|extralevator APR|"This is a modified and more extensive procedure that is used to remove the levator muscle en bloc with the anal canal and the mesorectum, creating a more cylindrical specimen, so that the amount of tissue removed around the tumor will be larger, thereby reducing the probability that the CRM will be positive."
88927484|NCT01702116|Active Comparator|standard APR|conventional abdominoperineal resection (APR)
88927485|NCT01703104|Active Comparator|Paludrine + Folic Acid|This arm uses routine drugs, Paludrine + Folic Acid
88927486|NCT01703104|Active Comparator|Paludrine + Folic Acid + Jobelyn|This group uses Paludrine + Folic Acid + Jobelyn
88927487|NCT01703130|Experimental|Local Anesthestic Dose|
88927488|NCT01703143|Experimental|Laser Ablation|Laser ablation of focal lesions in patients with medically refractory partial epilepsy.
88927489|NCT01703156|Experimental|Non-Stress Group|Medical therapy will be implemented and will include the following: aspirin, clopidogrel, b-blockers, and statins. The dosages of aspirin, b-blocker and statin will be left to the discretion of the treating physician. Statins will be initiated irrespective of LDL unless contraindicated. Clopidogrel will be taken for at least one month and ideally up to one year. Sublingual nitroglycerin will be provided to all patients. Other anti-ischemic medications including long-acting nitrates, calcium channel blockers, and ranolazine may be provided at the treating physicians' discretion. If a patient has contraindications to any medications, they will not be administered. If a statin contraindication exists, other cholesterol-lowering medications may be administered. Appendix 4 shows the detailed management of low risk ACS patients randomized to the non-stress group.
88927490|NCT01703156|Active Comparator|Stress Group|Medical therapy will be implemented and will include the following: aspirin, clopidogrel, b-blockers, and statins. Statins will be initiated irrespective of LDL unless contraindicated. Clopidogrel will be taken for at least one month and ideally up to one year. Sublingual nitroglycerin will be provided to all patients. Other anti-ischemic medications including long-acting nitrates, calcium channel blockers, and ranolazine may be provided at the treating physicians' discretion. If a statin contraindication exists, other cholesterol-lowering medications may be administered. All patients will undergo noninvasive stress testing. Results of individual stress tests will be reviewed by a cardiologist. Based on the myocardium deemed at risk and patient symptoms, further testing with angiography and revascularization using percutaneous techniques and/or coronary artery bypass grafting may be considered. Likewise, medical treatment may be adjusted.
89443711|NCT02753595|Experimental|Eribulin mesylate plus PEGPH20 (Phase 2)|Participants will receive eribulin mesylate and PEGPH20 at the established RP2D level achieved in the Phase 1b.
89443712|NCT02753595|Experimental|Eribulin mesylate (Phase 2)|Participants will receive eribulin mesylate at 1.4 mg/m^2.
89443713|NCT03335852|Experimental|Abicipar pegol|Abicipar pegol 2 mg administered to the study eye by intravitreal injection
89443714|NCT02177721|Experimental|Raxibacumab arm|"This is an open-label, single arm study. The study will be implemented for subjects who receive FDA-approved raxibacumab as part of medical treatment of anthrax or for post-exposure prophylaxis.~Intervention: Sampling of subjects or use of subjects salvaged standard of care samples may be considered for the following assessments (if available/applicable): pregnancy test, pharmacokinetics (PK) sampling, protective antigen, toxin neutralizing antibody (TNA), anti-raxibacumab antibodies."
89443715|NCT02179905||Irritable bowel syndrome, Control|
89443716|NCT02177799||gastroenteritis|
89443717|NCT03335618|Experimental|Active Coaching and Monitoring|
89443718|NCT03335618|Sham Comparator|Passive Monitoring|
89443719|NCT04494464||Patients with LDL cholesterol ≥250 mg/dL|Patients older than 18 years old and have a serum LDL-C≥250 mg/dL between January 2010 and December 2016. Patients with a serum TSH≥10 mIU/mL, patients with glomerulonephritis or nephrotic syndrome, patients with ALT or AST higher than 3 times of normal limits and patients with serum triglyceride >400 mg/dL were excluded.
89443720|NCT02179983|No Intervention|Standard care|Standard care for exacerbation and follow-up without rehabilitation
89443721|NCT02179983|Experimental|Pulmonary rehabilitation|6 weeks of exercise and patient education after exacerbation (pulmonary rehabilitation)
89443722|NCT03342482|Placebo Comparator|Placebo|5 g of placebo (sugar and salt) will be administered in veggie capsules
89443723|NCT03342482|Experimental|MSG|5 grams of MSG will be administered in veggie capsules
89443724|NCT02180139|Experimental|Primary motor cortex (M1) stimulation|Treatment by transcranial direct current stimulation will be targeted to the motor cortex for all treatment sessions with Bilateral M1 with cathode to contralateral M1 and anode to ipsilateral M1, 15 minutes (Goal: decrease contralateral M1 excitability)
89443725|NCT02180139|Experimental|Cerebellum stimulation|Treatment with transcranial direct current stimulation will be targeted to the cerebellum at every session with anode to ipsilateral cerebellum with cathode to ipsilateral side of face, 15 minutes (Goal: increase ipsilateral cerebellum activation which exerts inhibitory effect on motor circuits)
89443726|NCT02180139|Experimental|Combined M1 and Cerebellum stimulation|Treatment with transcranial direct current stimulation will be placed with M1 anode contralateral + cerebellum anode. M1 will first be 'primed' with anode on contralateral M1, cathode on face, for 10 min, followed immediately by 15 min of cerebellar stimulation as in #2. (Goal: prime the contralateral M1 with increased excitability to engage a potentially larger effect from the following ipsilateral cerebellar stimulation that will be excited to exert inhibitory effect on the motor circuits including M1)
89443727|NCT02180139|Placebo Comparator|Sham stimulation|transcranial direct current stimulation will be given in placebo form. Sham stimulation: electrode placement will be same as M1. Sham tDCS will be applied by ramping down current intensity to 0 after 30 seconds following standard practice for sham tDCS.
89443728|NCT02493140|Active Comparator|Cashew apple extract (Cashewin)|
89443729|NCT02493140|Placebo Comparator|Placebo|
89443730|NCT03339674|Experimental|Intervention|Psychoeducational Group Intervention on Alcohol Drinking Related to Stress: Psychological group intervention with 3 sessions of 60 min (Odenwald & Semrau, 2012). Contains psychoeducation on alcohol drinking related to stress and PTSD.
89443731|NCT03339674|Active Comparator|Control|Cognitive Training: Psychological group intervention with 3 sessions of 60 min. The content is paper-and-pencil based cognitive training of memory and attention functions.
89443732|NCT02494232||minor blunt thoracic trauma patient|demographic data, physical examination findings
89443733|NCT00707954|Experimental|TA-7284|
89443734|NCT00707954|Placebo Comparator|Placebo of TA-7284|
89443735|NCT03339518|Experimental|BRIM3 Educational intervention|Individuals will receive a booklet and counseling about risk.
89443736|NCT03339518|Other|Wait list Control|At the completion of the study, individuals in the wait list condition will receive a booklet.
88927491|NCT01703182||leg amputation|Patients undergoing below-knee and above ankle amputation for vascular reasons will receive transcutaneous oximetry and transcutaneous carbon dioxide measurement
88927492|NCT01703195|Other|Diffusion Weighted Magnetic Resonance Imaging (DWMR)|Patients receive Magnetic Resonance Imaging (MRI) and Diffusion Weighted Magnetic Resonance Imaging (DWMR) imaging pre-treatment and 4-6 weeks post-treatment.
88927493|NCT01703234|Experimental|Ramipril|
88927494|NCT01703247|Active Comparator|PVI+LL|Circumferential PVI was accomplished and then additional ablation lines were created by connecting the left inferior PV to the mitral annulus (mitral isthmus) and the LA between the two superior PVs (roof). Finally, patients underwent cavo-tricuspid isthmus ablation in the right atrium.
88927495|NCT01703247|Active Comparator|PVI+GP|To accomplish ganglionated plexi ablation, LA target sites were identified as the anatomic locations where vagal reflexes were evoked by transcatheter high-frequency stimulation (HFS). Rectangular electrical stimuli were delivered at a frequency of 20-50 Hz, output amplitude 15 V and pulse duration of 10 ms, for 5 sec (Stimulator B-53, Biotok Inc, Russia).
88927496|NCT01703273|Experimental|low key intervention|
88927497|NCT01703273|Active Comparator|routine care|
88927498|NCT01703312|Experimental|QGE031|During the 10-week treatment period, participants will receive a dose of study drug subcutaneously once every two weeks (total of six doses). Three dose levels of QGE031 will be offered during the study: low, medium, and high. Participants will be randomized to receive one of these dose levels for all dosing visits.
88927499|NCT01703312|Active Comparator|omalizumab|During the 10-week treatment period, participants will receive a dose of study drug subcutaneously once every two weeks (total of six doses) or once every four weeks (total of three doses). The dose that a participant receives will depend upon the participant's body weight and IgE level; dosage will be determined based upon local omalizumab dosing charts.
88927500|NCT01703312|Placebo Comparator|placebo|During the 10-week treatment period, participants will receive a dose of study drug subcutaneously once every two weeks (total of six doses).
88927501|NCT01703325|Active Comparator|triamcinolone injection (10 mg/ml)|"Three finger nails are chosen from the equally average Targeted NAPSI scores which are evaluated by two independent dermatologists. Block randomization are performed to arrange such fingers into group A, B or C~Group A: Triamcinolone injection (10 mg/ml) on 4 sites for the pathology from both nail matrix (B) and nail bed (A) or 2 sites for the pathology from either nail matrix(B) or nail bed (A) as shown in picture, the EMLA was applied before injection"
88927502|NCT01703325|Active Comparator|Topical 0.05% clobetasol ointment|Three finger nails are chosen from the equally average Targeted NAPSI scores which are evaluated by two independent dermatologists. Block randomization are performed to arrange such fingers into group A, B or C Apply Topical 0.05% clobetasol propionate ointment on the nail fold twice daily for 6 months
88927503|NCT01703325|No Intervention|Controlled group|Three finger nails are chosen from the equally average Targeted NAPSI scores which are evaluated by two independent dermatologists. Block randomization are performed to arrange such fingers into group A, B or C Controlled group
88927504|NCT01703338||Lumbar spinal surgery|The study included participants who were diagnosed by a neurological surgeon and received lumbar surgery according to relevant imaging findings
88927505|NCT01703351|Experimental|Drug: 0.5% ropivacaine|
89443737|NCT03339362|Active Comparator|Active Procedure|"All patients will receive 6 X-ray guided peri-articular injections via a spinal needle at 2 bilateral lumbar levels using 0.5ml of 1% Lidocaine. This a test procedure to identify the patient has a 50% pain reduction from baseline pain numerical score. If patients pass this test injection, they will be randomised to the active or sham procedure.~4 X-ray guided intra-articular facet-joint injections via a spinal needle at 2 bilateral lumbar levels, using 0.5ml 0.5% bupivacaine + 20mg methylprednisolone per joint"
89443738|NCT03339362|Sham Comparator|Sham procedure|"All patients will receive 6 X-ray guided peri-articular injections via a spinal needle at 2 bilateral lumbar levels using 0.5ml of 1% Lidocaine. This a test procedure to identify the patient has a 50% pain reduction from baseline pain numerical score. If patients pass this test injection, they will be randomised to the active or sham procedure.~4 X-ray guided peri-articular injections via a spinal needle at 2 bilateral lumbar levels using 0.5ml normal saline per injection"
89443739|NCT03339050|Experimental|Health for Hearts United|Health for Hearts United (HHU) is a 18-month church-based intervention to reduce CVD risk in mid-life and older African Americans.
89443740|NCT02492828||Patients for filled prescriptions for apixaban|
89443741|NCT02492828||Patients for filled prescriptions for warfarin|
89443742|NCT03335462|Experimental|Paravertebral injections|Lumbar paravertebral injections containing contrast will be performed. The needles are kept in their position and afterwards followed by CT scan.
89443743|NCT03335384|Experimental|Measurement of Pdi|Two small balloons, which are attached to small, flexible tubes, will be put into the esophagus (food tube) and stomach through the nose. Each balloon is about 2 inches long (deflated) and about the width of a pencil tip. A gastric balloon will be inserted into subject's stomach while an esophageal balloon will be inserted into the subject's esophagus. To reduce any discomfort with this procedure, lidocaine gel or spray will be put into the subject's nose and administered to the back of the throat before the balloon. In addition, swallowing water during the procedure will help to reduce any gagging sensation and will assure that the balloon goes into the esophagus.
88927506|NCT01703351|Active Comparator|Fentanyl 500mcg + acupan 160mg + nasea 0.6mg|
88927507|NCT01703364|Experimental|Lenalidomide/Fludarabine/Rituximab|"Lenalidomide: day 8-21 of cycle 1 and day 1-21 of cycles 2-6; Starting Dose: 5 mg (first 5 patients) and 10 mg (further 5 patients) increase Lenalidomide dose via dose levels (10)/15/20/25 mg/d every 28 days if no limiting toxicity occurs~Fludarabine: 25 mg/m2 iv d1-3 or 40 mg/m2 po d1-3; repeat every 28 days~Rituximab: 375 mg/m2 iv day 4 on cycle 1 and 500 mg/m2 iv day 1 on cycles 2-6; repeat every 28 days"
88927508|NCT01703390|Experimental|ERCC-1 low|modifiedFOLFOX6 + Cetuximab oxaliplatin 85 mg/m2 on day 1, 15 q d29 for 6 cycles folinic acid (FA) 400 mg/m2 on days 1 and 15 and q d29 for 6 cycles fluorouracil (5-FU) 400 mg/m2 bolus day 1 + 2400 mg/m2 46-hour infusion on days 1, 2 and 15, 16 and q d29 for 6 cycles or until unacceptable toxicity Cetuximab will be administered as a 120- minute intravenous infusion at 500 mg/m2 on day 1 then 500 mg/m2 bi-weekly
88927509|NCT01703390|Experimental|ERCC-1 high|FOLFIRI + Cetuximab irinotecan 180 mg/m² on day 1, 15 q d29 for 6 cycles folinic acid (FA)400 mg/m2 on days 1 and 15 and q d29 for 6 cycles fluorouracil (5-FU) 400 mg/m2 bolus + 2400 mg/m2 46-hour infusion on days 1, 2 and 15, 16 and q d29 for 6 cycles or until unacceptable toxicity Cetuximab will be administered as a 120- minute intravenous infusion at 500 mg/m2 on day 1 then 500 mg/m2 bi-weekly
88927510|NCT01703416||1|
88927511|NCT01703429||Individuals with MS|
89501706|NCT02151617|Experimental|Cohort 1-PF-06743649 or placebo|Subjects will be randomized to receive PF-06743649 or placebo as 2 single doses in periods 1 and 2 either in the fed or fasted state followed by once daily dosing for 14 days in period 3
89501707|NCT02151617|Experimental|Cohort 2-PF-06743649 or placebo|
89501708|NCT02151617|Experimental|Cohort 3-PF-06743649 or placebo|
89443744|NCT03335384|Experimental|Measurement of SNIPs|While the gastric and esophageal balloon catheters are in place, the subject will be asked to perform a maximal sniff maneuver (SNIP) while one nostril is occluded with a plug containing a nasal pressure transducer to measure airway pressure during maximal inspiration. The distal end of the pressure catheter will be connected to a hand held pressure meter to display peak pressure and to provide you visual feedback. This maneuver will be performed 10 times.
89443745|NCT02497898|No Intervention|regular chemotherapy|Patients after chemotherapy are just followed up.
89443746|NCT02497898|Experimental|CIK regimen|Patients after chemotherapy will receive at least 3 cycles of Cytokine-induced killer cells (CIK) treatment every 3 months.
89443747|NCT03335306||Healthy subjects in Hong Kong|
89443748|NCT03120338|Experimental|The Development and Wellbeing Assessment|"The Development and Wellbeing Assessment (DAWBA: http://www.dawba.com/) is a computerised structured instrument for gathering diagnostic data from parents or guardians, teachers and young people themselves.~The DAWBA will be administered in addition to care as usual."
89443749|NCT03120338|No Intervention|Care as Usual|Care as usual
89443750|NCT02494154|Active Comparator|Conventional flow via nasal prongs|Oxygen delivery via conventional nasal interface with flow adjusted to reach a target SpO2 according to the patient's condition.
89443751|NCT02494154|Experimental|High flow nasal cannulas 20L/min|Oxygen delivery via high flow nasal cannulas (20L/min) with fraction of inspired oxygen (FiO2) adjusted to reach a target SpO2 according to the patient's condition.
89443752|NCT02494154|Experimental|High flow nasal cannulas 40L/min|Oxygen delivery via high flow nasal cannulas (40L/min) with FiO2 adjusted to reach a target SpO2 according to the patient's condition.
89443753|NCT02494154|Experimental|High flow nasal cannulas 60L/min|Oxygen delivery via high flow nasal cannulas (60L/min) with FiO2 adjusted to reach a target SpO2 according to the patient's condition.
89443754|NCT02498210|Experimental|IVF after IVM|"If the patients will not concive during the IVM cycle . results of this following IVF cycle will be compared to the initial IVF preformance~Intervention : In Vitro Maturation Procedure"
89443755|NCT02497820|Active Comparator|100 mg daily aspirin|They will receive one small tablets each day for two years in a blinded fashion
89443756|NCT02497820|Active Comparator|300 mg daily aspirin|They will receive two large enteric coated tablets each day for two years in a blinded fashion
89443757|NCT02497820|Active Comparator|600 mg daily aspirin|They will receive two large enteric coated tablets each day for two years in a blinded fashion
89443758|NCT02493920|Experimental|SLI group|In this group the preterm infants will receive sustained lung inflation (SLI) with mask in the delivery room; the parameters of respiratory mechanics will be monitored for 5 minutes by means of the forced oscillation technique.
89443759|NCT02493920|No Intervention|Control|Preterm infants will be assisted in the delivery room with a continuous positive airway pressure (CPAP) of 5 cmH2O with mask and the parameters of respiratory mechanics will be monitored for 5 minutes by means of the forced oscillation technique.
88927512|NCT01703442||Ovarian cancer patients|Perioperative primary epithelial ovarian cancer patients
88927513|NCT01703468|Active Comparator|Oxcarbazepine then Trileptal|600 mg suspension
88927514|NCT01703468|Active Comparator|Trileptal then Oxcarbazepine|600 mg suspension
88927515|NCT01703481|Experimental|Part 1|Dose Escalation, Part 1: Participants will be enrolled in sequential cohorts to determine recommended Phase 2 doses (RP2D).
89443760|NCT02492906||Osteoarthrosis group|Patients with primary severe knee osteoarthrosis or with chronic knee pain.
89443761|NCT02492906||Healthy patients|Healthy patients
88927516|NCT01703481|Experimental|Part 2|Dose Confirmation, Part 2: Tumor biopsy cohorts will confirm RP2D.
88927517|NCT01703481|Experimental|Part 3, Cohort A|First dose expansion, Part 3: Participants with squamous non-small cell lung cancer.
88927518|NCT01703481|Experimental|Part 3, Cohort B|First dose expansion, Part 3: Participants with small cell lung cancer.
88927519|NCT01703481|Experimental|Part 3, Cohort C|First dose expansion, Part 3: Participants with breast cancer.
89443762|NCT03120260|Experimental|Short Sleep|Diet+ have 5 hour sleep at night (SS)
89501709|NCT02151617|Experimental|Cohort 4-PF-06743649 or placebo|
89443763|NCT03120260|Experimental|Normal Sleep|Diet+ have 7-8 hour sleep at night (NS)
89443764|NCT03338738|Experimental|Patients with ESBL, antibiotic pressure|Patients with ESBL, antibiotic pressure will be included. On the day of inclusion, a stool culture is performed on the first stool issued after the start of antibiotic therapy in order to evaluate the initial flora and the relative initial faecal abundance of multidrug-resistant bacteria. In the absence of stool emission by the patient, a rectal swab will be performed. 72 hours after initiation of antibiotic therapy, a blood sample (5 ml) will be taken to determine plasma concentrations of antibiotics. In addition, a stool sample will be taken at 72 hours after the start of antibiotic therapy, at the end of antibiotic therapy and 60 days after this end to evaluate the change in initial flora and relative faecal abundance of ESBL-producing enterobacteria.
89443765|NCT03338660|Placebo Comparator|Control (Placebo)|Subjects will receive infusion of placebo (saline).
89443766|NCT03338660|Active Comparator|Platelet storage routine|Subjects will receive infusion of platelets stored by routine method.
89443767|NCT03338660|Experimental|Platelet storage experimental|Subjects will receive infusion of platelets stored by a novel methodology.
89443768|NCT02497742|Active Comparator|Once daily BMP|Patient in this arm will receive once daily basic metabolic panel to monitor electrolytes
89443769|NCT02497742|Active Comparator|Twice daily BMP|Patient in this arm will receive twice daily basic metabolic panel to monitor electrolytes
89443770|NCT02497586|Experimental|MRS|Magnetic resonance spectroscopy (MRS) is a type of scan which offers the possibility of assessing tumour function by measuring concentrations of chemicals (metabolites) within the abnormal tissue. This is a prospective feasibility study, aiming to recruit 15 consecutive patients with lung cancer to undergo proton MRS. The feasibility and repeatability of the technique will be assessed by analysis of the MR spectra obtained.
89443771|NCT02497508|Experimental|Nivolumab|Nivolumab will be administered 2 weekly by intravenous infusion in a dose of 3 mg/kg
89443772|NCT02493842|Experimental|Invasive nerve stimulation|"Invasive nerve stimulation using the following experimental devices~Transverse Intrafascicular Multichannel Electrode for human (TIME-4H)~The STIMEP stimulator~The EPIONE Psychophysical Testing Platform software for stimulator control~Nerve stimulation therapy is provided while providing visual guidance to the subject and without the use of hand prosthetic devices"
89443773|NCT03334994|Active Comparator|Control group: immediate implant alone|Patient will be treated with immediate implant alone.
89443774|NCT03334994|Active Comparator|(Group A) immediate implant alone|Patient will be treated with immediate implant alone.
89443775|NCT02497352|Experimental|Flaxseed|30 g milled brown flaxseed + lifestyle modification
89443776|NCT02497352|Active Comparator|control|lifestyle modification including dietary and physical activity recommendation
89443777|NCT03338426|Experimental|Experimental|Co-administration of a fixed dose combination of Fimasartan 120mg and Atorvastatin 40mg
89443778|NCT03338426|Active Comparator|Active Comparator 1|Co-administration of Fimasartan 120mg and Placebo for Atorvastatin 40mg
89443779|NCT03338426|Active Comparator|Active Comparator 2|Co-administration of Atorvastatin 40mg and Placebo for Fimasartan 120mg
88927520|NCT01703481|Experimental|Part 3, Cohort D|First dose expansion, Part 3: Participants with solid tumors (consisting of one of the following: gastric, head and neck, lung adenocarcinoma, urothelial, glioblastoma multiforme [GBM], ovarian or prostate).
88927521|NCT01703481|Experimental|Part 4, Cohort E|Second dose expansion, Part 4: Participants with non-small cell lung cancer.
88927522|NCT01703481|Experimental|Part 4, Cohort F|Second dose expansion, Part 4: Participants with solid tumors (consisting of one of the following: breast, urothelial, GBM).
88927523|NCT01703494|Active Comparator|Fecal Microbiota Transplantation|After completing at least a 10 day course of vancomycin for treatment of the most recent acute C. difficile infection, subjects will receive fecal Microbiota Transplant (FMT) with a 300 mL donor fecal suspension delivered via colonoscopy.
88927524|NCT01703494|Sham Comparator|Sham Fecal Microbiota Transplantation|After completing at least a 10 day course of vancomycin for treatment of the most recent acute severe C. difficile infection, subjects will receive a 300 mL infusion of a sham (autotransfusion) fecal solution at colonoscopy.
89443780|NCT03338348|Other|Azacitidine + Vosaroxin|"Cycle 1-8:~Azacitidine: 75 mg/m²/d subcutaneously, d 1-7; Vosaroxin: Dose Level 0: 70mg/m², Dose Level -1: 50mg/m², Dose Level -2: 40mg/m², IV over ten minutes, d 1+4 .~Patients who have completed 8 cycles of azacitidine and vosaroxin are scheduled to maintenance with single agent azacitidine at 75 mg/m²/d on days 1-7 until relapse or progression."
89443781|NCT02497274|Experimental|Roux Y gastric bypass|candidates for bariatric surgery by Roux Y gastric bypass with taste assessment and epithelium gustatory smear and biopsy
88927525|NCT01703546|Experimental|LAGB & LGCP|"All study patients will have the following surgical procedure: Laparoscopic Adjustable Gastric Banding and Gastric Plication (LAGB & LGCP).~The percent of Excess Body Weight Loss will be monitored at all post op visits."
88927526|NCT01703559|Placebo Comparator|Placebo|Administered once daily in both eyes for 15 days
88927527|NCT01703559|Experimental|Phentolamine Mesylate Ophthalmic Solution 0.5%|Administered once daily in both eyes for 15 days
89443782|NCT02497274|Experimental|Sleeve gastrectomy|candidates for bariatric surgery by sleeve gastrectomy with taste assessment and epithelium gustatory smear and biopsy
89443783|NCT03334916|Experimental|YMC026|108 subjects will be assigned in this group. They will be administered 20mL of YMC026 three times a day for 6 days.
89443784|NCT03334916|Placebo Comparator|Placebo|108 subjects will be assigned in this group. They will be administered 20mL of placebo three times a day for 6 days.
89443785|NCT02497196|Experimental|Part 1:Active tPCS, Active tDCS|12 out of the 48 total health subjects will receive active tPCS and active tDCS. This will be done for 20 minutes simultaneously.
89443786|NCT02497196|Experimental|Part 1: Active tPCS, Sham tDCS|12 out of the 48 total health subjects will receive active tPCS and sham tDCS. This will be done for 20 minutes simultaneously.
89443787|NCT02497196|Experimental|Part 1:Sham tPCS, Active tDCS|12 out of the 48 total health subjects will receive sham tPCS and active tDCS. This will be done for 20 minutes simultaneously.
89443788|NCT02497196|Sham Comparator|Part 1: Sham tDCS, Sham tDCS|12 out of the 48 total health subjects will receive sham tPCS and sham tDCS. This will be done for 20 minutes simultaneously.
89443789|NCT02497196|Experimental|Part 2: Active tPCS/Active tDCS|Part 2 will run as a four-period crossover design, where all chronic visceral pain subjects (18 total) will be receiving all (4) possible combinations of tDCS and tPCS interventions (active or sham) at the end of the experiment in a random, consecutive way. This represents the combination of receiving active tPCS and active tDCS (1/4 combinations all subjects will receive).
89443790|NCT02497196|Experimental|Part 2: Active tPCS/Sham tDCS|Part 2 will run as a four-period crossover design, where all chronic visceral pain subjects (18 total) will be receiving all (4) possible combinations of tDCS and tPCS interventions (active or sham) at the end of the experiment in a random, consecutive way. This represents the combination of receiving active tPCS and sham tDCS (1/4 combinations all subjects will receive).
89443791|NCT02497196|Experimental|Part 2: Sham tPCS/Active tDCS|Part 2 will run as a four-period crossover design, where all chronic visceral pain subjects (18 total) will be receiving all (4) possible combinations of tDCS and tPCS interventions (active or sham) at the end of the experiment in a random, consecutive way. This represents the combination of receiving sham tPCS and active tDCS (1/4 combinations all subjects will receive).
89443792|NCT02497196|Sham Comparator|2: Sham tPCS/Sham tDCS|Part 2 will run as a four-period crossover design, where all chronic visceral pain subjects (18 total) will be receiving all (4) possible combinations of tDCS and tPCS interventions (active or sham) at the end of the experiment in a random, consecutive way. This represents the combination of receiving sham tPCS and sham tDCS (1/4 combinations all subjects will receive).
89443793|NCT03334838|Experimental|GRP 1 - Assess relative bioavailability (4-way crossover)|"GROUP 1 (Treatments A, B, C, D) All treatments in Group 1 consisted of a dose of 120 mg nifurtimox (4 x 30 mg tablets).~In Treatment A, dose administration was in a fasted state.~For the other treatments, dose administration was in a fed state:~Treatment B after a low-fat breakfast; Treatment C after a breakfast consisting of dairy products (yogurt+milk); and Treatment D after a high-calorie and high-fat breakfast."
89443794|NCT03334838|Experimental|GRP 2 - Assess relative bioavailability (2-way crossover)|"All subjects in Group 2 received a single dose of nifurtimox in each of the Treatments D and E.~In Treatment D, subjects received 120 mg nifurtimox (4 x 30 mg tablets), and in Treatment E, subjects received 240 mg nifurtimox (8 x 30 mg tablets). Both treatments were administered in a fed state, after a high-calorie and high-fat breakfast."
89443795|NCT02497118|Experimental|Endostatin plus NP|drug:Endostatins Intravenous drip， 7.5mg/m^2, d1-14 drug:vinorelbine Intravenous drip 25mg/m^2,IV, d1, d8; drug:Cisplatin，75mg/m^2 Intravenous drip,divide into d1-3 for 2 cycles
89443796|NCT02497118|Active Comparator|NP neoadjuvant chemotherapy|drug:vinorelbine Intravenous drip 25mg/m^2,IV, d1, d8; drug:Cisplatin，75mg/m^2 Intravenous drip,divide into d1-3 for 2 cycles
89443797|NCT02496962|Experimental|Statin group|drug: atorvastatin (Pfizer, U.S.); the frequency: 20mg atorvastatin was taken daily; duration: Study treatment was commenced 3 days before sleep deprivation and continued for 2 days during sleep deprivation.
89443798|NCT02496962|Placebo Comparator|Control group|drug: placebo (Pfizer, U.S.); the frequency: Placebo was taken daily; duration: Study treatment was commenced 3 days before sleep deprivation and continued for 2 days during sleep deprivation.
89443799|NCT03334604|Experimental|Multispecies probiotic group|175 participants.
89443800|NCT03334604|Placebo Comparator|Control group|175 participants.
88927528|NCT01703559|Experimental|Phentolamine Mesylate Ophthalmic Solution 1.0%|Administered once daily in both eyes for 15 days
88927529|NCT01703572|Experimental|OMP-52M51|
88927530|NCT01703585||metastatic breast cancer|
88927531|NCT01703585||metastatic colorectal cancer|
88927532|NCT01703585||metastatic gynecological cancer|
88927533|NCT01703585||metastatic melanoma|
88927534|NCT01703611|Experimental|MNT according to AND EBNPG for Type 2 DM|Six or more Medical Nutrition Therapy visits(education and counseling on diet, self management, and lifestyle changes) provided over a 12 month period according to Academy of Nutrition and Dietetic Evidence Based Nutrition Practice Guidelines (EBPGN) (www.guidelines.gov)
88927535|NCT01703611|Active Comparator|Usual Nutrition Care|Visits for usual nutrition therapy (diet and lifestyle changes) provided by dietitians over a 12 month period.
88927536|NCT01703624|Experimental|glycopyrronium bromide 12.5mcg|glycopyrronium bromide 12.5mcg single dose via pressurised metered dose inhaler (pMDI)
88927537|NCT01703624|Experimental|glycopyrronium bromide 25mcg|glycopyrronium bromide 25mcg single dose via pressurised metered dose inhaler (pMDI)
88927538|NCT01703624|Experimental|glycopyrronium bromide 50mcg|glycopyrronium bromide 50mcg single dose via pressurised metered dose inhaler (pMDI)
88927539|NCT01703624|Experimental|glycopyrronium bromide 100mcg|glycopyrronium bromide 100mcg single dose via pressurised metered dose inhaler (pMDI)
88927540|NCT01703624|Placebo Comparator|placebo|placebo single dose via pressurised metered dose inhaler (pMDI)
88927541|NCT01703637|Experimental|Sitagliptin|Drug: sitagliptin sitagliptin 100mg tablet by mouth , once daily for 12 weeks
88927542|NCT01703637|Experimental|Vildagliptin|Drug: vildagliptin saxagliptin 50mg tablet by mouth , twice daily for 12 weeks
88927543|NCT01703637|Experimental|Saxagliptin|Drug: saxagliptin saxagliptin 5mg tablet by mouth , once daily for 12 weeks
88927544|NCT01703650||Resectable pancreas cancer|patients with resectable pancreas adenocarcinoma or neuroendocrine tumor underwent perfusion CT after intravenous iopromide administration
88927545|NCT01703650||Locally advanced Pancreas cancer|Patients with locally advanced pancreas cancer underwent perfusion CT after intravenous iopromide administration before and after chemotherapy.
89443801|NCT03334370||DM subjects in Hong Kong|
89443802|NCT02492594||Pediatric patients with febrile neutropenia|Peripheral blood sampling - samples from 200 pediatric patients with severe immunosuppression and neutropenic fever will be analyzed
89443803|NCT02492594||Adult patients with febrile neutropenia|Peripheral blood sampling - samples from 200 adult patients with severe immunosuppression and neutropenic fever will be analyzed
89443804|NCT02496728|Experimental|Cardiovascular Health|Participants will be given the results of their health assessment and feedback regarding their health behaviors and overall health. Recommendations for change will be given if warranted. Participants will download the study's mobile health application on their smartphone. They will then be asked to report once a week about their health behaviors on the application. Participants will also be asked to self-monitor health behaviors that are not already at ideal levels using the study application (environmental cues). Participants will be asked to join a secret Facebook group where informational materials will be posted, participants can post about study health behaviors and social interaction around health behaviors can occur (social support and environmental cues).
89443805|NCT02496728|Active Comparator|Whole Health|Participants will be given the results of their health assessment. They will then receive educational materials about sunscreen use, safe sex, hydration and vehicular safety. Participants will download the study's mobile health application on their smartphone. They will then be asked to report once a week about their health behaviors on the application. Participants will also be asked to self-monitor how much water they drink using the study application. Participants will be asked to join a secret Facebook group where informational materials will be posted, they can post about study health behaviors and social interaction around health behaviors can occur (social support and environmental cues).
89443806|NCT02496806|Experimental|Treatment|400mg capsule containing seaweed extract (treatment) Intervention: Dietary Supplement: Treatment capsule containing seaweed extract (treatment)
89443807|NCT03342326|Other|patient with Alzheimer's Disease|"Exposure to familiar songs : a) Words and Music (sing condition), b) Words only (spoken condition) and c) Music only (instrumental condition) After each song : rate the popularity of the song on a scale of 1 to 5.~Music Experience Questionnaire : questions about the past music training~Implicit tasks memory : a) Completion of trigrams : freely complete the first 3 letters of a word. b) lexical decision : judge whether an audibly presented sound sequence is a word existing in the French language or not."
89443808|NCT03342326|Other|healthy volunteer|"Exposure to familiar songs : a) Words and Music (sing condition), b) Words only (spoken condition) and c) Music only (instrumental condition) After each song : rate the popularity of the song on a scale of 1 to 5.~Music Experience Questionnaire : questions about the past music training~Implicit tasks memory : a) Completion of trigrams : freely complete the first 3 letters of a word. b) lexical decision : judge whether an audibly presented sound sequence is a word existing in the French language or not.~For volunteer over 65 years : Mini Mental State Examination, 5 words by Dubois and fluence verbal test"
89443809|NCT04494230||Attention deficit hyperactivity disorder (ADHD) only|the diagnosis of ADHD
89443810|NCT04494230||Attention deficit hyperactivity disorder (ADHD) andSpecificand|the diagnosis of ADHD and SLD
89443811|NCT04494230||ADHD and oppositional defiant disorder (ODD)|the diagnosis of ADHD and ODD
89443812|NCT04494230||ADHD and Anxiety Disorder|the diagnosis of ADHD and Ank. Dis.
89443813|NCT04494230||Typical Development Children|no mental symptoms described by their teachers or parents and showing healthy development
89443814|NCT03338114|Experimental|FLX-787-ODT (orally disintigrating tablet)|FLX-787-ODT (orally disintigrating tablet)
89443815|NCT03334136|Active Comparator|Vitamin D|25-hydroxyvitamin D 20.000 IU capsule given orally. Five capsules the first day and thereafter one capsule every week for 4 months.
88927546|NCT01703676||Patients|Klinefelter Patients
88927547|NCT01703676||Parents|Parents of Klinefelter Patients
88927548|NCT01703676||Controls M|Healthy Male Control with normal karyotype
88927549|NCT01703676||Controls F|Healthy female controls
88927550|NCT01703689|Experimental|strong intervention group (SIG)|Nursing homes that received audit and feedback information on quality indicators and benefited of cooperative work meetings with hospital geriatricians
88927551|NCT01703689|Active Comparator|intervention group (LIG)|Nursing homes that only received audit and feedback information on quality indicators
88927552|NCT01703715||Patients aged 65 years and over|All patients aged 65 years and over admitted to acutely to medical wards
88927553|NCT01703728||Highly purified menotropin (HP-hMG) treatment|Cohort of women from 18 to 36 years old treated by HP-hMG for controlled ovarian stimulation (COS) for a first or second cycle of IVF / ICSI.
88927554|NCT01703754|Experimental|Ad-RTS-hIL-12 and veledimex|Experimental study drug monotherapy arm (A)
88927555|NCT01703754|Experimental|Ad-RTS-hIL-12 and Palifosfamide|Study drug combination therapy arm (C)
88927556|NCT01703767||Gulf War 1 Veterans|Persian Gulf War 1 Veterans (GW1V) who are currently treated by a primary care physician at the VA Salt Lake City Health Care System. GW1V will assess their primary care satisfaction before and after their providers receive a Provider Education Workshop.
88927557|NCT01703780||resistant hypertension|blood pressure remaining above goal (< 140/90 mm Hg for the general population and < 130/80 mm Hg for patients with diabetes or renal disease) despite using optimal doses of 3 antihypertensive agents of different classes(including a diuretic) for half to one year.
88927558|NCT01703780||controllable hypertension|blood pressure can reach 130/80 mm Hg or less in half year by use of optimal dose of less than 3 antihypertensive agents of different classes
89013481|NCT06300671|Active Comparator|Pronation Group|Participants with a value between 6-9 according to the foot posture index-6 evaluation will be included in the pronation group.
89443816|NCT03334136|Placebo Comparator|Placebo|Placebo oral capsules. Five capsules the first day and thereafter one capsule every week for 4 months.
89443817|NCT03342248|Experimental|access to the social network|This group is made up of carers who have access to the social network via a digital platform developed during step 1. This network will offer features from step 1 (sharing experiences on a forum, monitoring health status )
89443818|NCT03342248|No Intervention|no access to the network|"This group consists of caregivers who do not have access to the social network via a digital platform developed during step 1.~Access to the social network will be offered to all carers at the end of the study, especially those assigned in the control group to limit their refusal to participate."
89443819|NCT03120728|Experimental|12-14mm leading follicle size|Placement of the etonogestrel/ethinyl estradiol contraceptive vaginal ring when leading follicle measures 12-14mm on transvaginal ultrasound.
89443820|NCT03120728|Experimental|15-17mm leading follicle size|Placement of the etonogestrel/ethinyl estradiol contraceptive vaginal ring when leading follicle measures 15-17mm on transvaginal ultrasound.
89443821|NCT03120728|Experimental|18mm or greater leading follicle size|Placement of the etonogestrel/ethinyl estradiol contraceptive vaginal ring when leading follicle measures 18mm or greater on transvaginal ultrasound.
89443822|NCT02496650|Experimental|Group D|Dexmedetomidine (DEX) infusion was started in doses 0,2-1,4 μg/kg/hr and titrated to achieve target sedation level; symptom-triggered BZD administration (diazepam 10mg bolus) were used wherever DEX infusion was not enough. Antipsychotics (haloperidol 5mg boluses) were used as a rescue medication for severe agitation or hallucinations.
89443823|NCT02496650|No Intervention|Group C|Benzodiasepine (BZD) boluses (diazepam 10mg) were used to achieve target sedation level and to control AWS symptoms (symptom-triggered administration). Antipsychotics (haloperidol 5mg boluses) were used as a rescue medication for severe agitation or hallucinations.
89443824|NCT03334058|Experimental|ARGX-113|
89443825|NCT03333902|Experimental|QLB type 2|"Ultrasound-guided, Inject at the point posterior to quadratus lumborum muscle, 0.2% ropivacaine 30mL in each side for a total of 60mL.~Subjects also receive an intravenous patient controlled analgesia (PCA) pump of 0.5 mg/mL morphine for 48 hours."
89443826|NCT03333902|Experimental|QLB type 3|"Ultrasound-guided, Inject at the point between the quadratus lumborum and the psoas major muscle, 0.2% ropivacaine 30mL in each side for a total of 60mL.~Subjects also receive an intravenous patient controlled analgesia (PCA) pump of 0.5 mg/mL morphine for 48 hours."
89443827|NCT03333902|Experimental|QLB type 2+3|"Ultrasound-guided, conduct both QLB type 2 and 3, 0.2% ropivacaine 15mL in each point of injection, for a total of 60mL.~Subjects also receive an intravenous patient controlled analgesia (PCA) pump of 0.5 mg/mL morphine for 48 hours."
88927559|NCT01703780||healthy control|"Age>50 years old~Blood pressure ≤ 120/80 mm Hg( 24-hour blood pressure monitor or home blood pressure measurement at 6-9 am and 5-8pm, twice)~No cardiovascular diseases: coronary artery disease(coronary angiography or CTA), cerebrovascular diseases(history, MRI-Lacunar brain stem), Carotid ultrasound~No peripheral angiopathy (ABI<0.9 or lower extremity vessels Doppler ultrasound)~No major cardiovascular risk factors:~Dyslipidemia~Diabetes~Smoke within one year"
88927560|NCT01703793|Placebo Comparator|Vehicle|Vehicle (placebo) treatment, twice a week for four weeks.
88927561|NCT01703793|Experimental|Test Product 10156|Product 10156 treatment, twice a week for four weeks.
88927562|NCT01703793|Experimental|Test Product 49778|Product 49778 treatment, twice a week for four weeks.
88927563|NCT01703884|Experimental|ASAQ|In the intervention area, obstetric, medical, drug-exposure histories will be collected at ANC visits. In addition, in the last trimester of the pregnancy women will be systematically evaluated with RDT for whether they have malaria parasites and treated effectively.
89443828|NCT03333902|Active Comparator|epidural anesthesia group (EA)|"Epidural catheter placement was conducted when finishing spinal anesthesia. After surgery, 30 mL saline (placebo) was Injected at the point posterior to the quadratus lumborum in each side for a total of 60mL. We used a single bolus of 0.15% ropivacaine + 2 mg morphine (diluted in 6 ml saline) via epidural cathether.~Subjects also receive an intravenous patient controlled analgesia (PCA) pump of 0.5 mg/mL morphine for 48 hours."
89443829|NCT02492438|Active Comparator|PPV23 naive, PPV23 vaccination|vaccination with PPV-23 in 40 PPV-23 naive patients
89443830|NCT02492438|Experimental|PPV23 naive, PCV13 vaccination|vaccination with PCV-13 in 40 PPV-23 naive patients
89443831|NCT02492438|Experimental|PPV23 > 4 years ago, PCV13 vaccination|vaccination with PCV-13 in 40 patients that received PPV-23 more than 4 years ago
89443832|NCT02492438|Experimental|PPV23 < 4 years, PCV13 vaccination|vaccination with PCV-13 in 40 patients that received PPV-23 less than 4 years ago
89443833|NCT03337958|No Intervention|CONTROL GROUP|Received the standard medical and pharmacological care provided by the hospital
88927564|NCT01703884|No Intervention|SP|At ANC and labor wards for women in the control area, there will be no change from routine approaches.
88927565|NCT01703897||Obese patients|
88927566|NCT01703910|Active Comparator|Arm A|Control treatment and will be treated with any of the schemes used in the study according to the discretion of the physician.
88927567|NCT01703910|Experimental|Arm B|Treatment guided by the gene expression profiles obtained from the CTC
88927568|NCT01703936|Experimental|agricultural training program|Three to four month residential agriculture and life skills training program.
88927569|NCT01703936|No Intervention|Control group|
88927570|NCT01703962||Patients with IDH1 R132H or wild type IDH1/IDH2 glioma|
88927571|NCT01703975|No Intervention|Single training|Students training alone on the simulator
88927572|NCT01703975|Experimental|Training in pairs (Dyad Training)|Students training in pairs on the simulator
88927573|NCT01704001|Experimental|Renal impairment grade 0|
88927574|NCT01704001|Experimental|Renal impairment grade 1|
88927575|NCT01704001|Experimental|Renal impairment grade 2|
88927576|NCT01704001|Experimental|Renal impairment grade 3|
88927577|NCT01704014||α1-ARA Group|All patients on α1-ARA(α1-adrenergic receptor antagonists) medication who underwent cataract surgeries.
88927578|NCT01704014||Control Group|Age and sex-matched control subjects
88927579|NCT01704027|Experimental|Radiotherapy|Patient will receive a pelvic and prostatic simultaneous integrated boost intensity-modulated arctherapy (SIB-IMAT) in combination with three years of androgen deprivation
88927580|NCT01704040|Experimental|Part 1: Healthy participants (CNTO 3157 + HRV-16)|
89443834|NCT03337958|Experimental|INTERVENTION GROUP|The group received the standard medical and pharmacological care provided by the hospital. In addition, an educational program on the use of inhalers, which included an explanation of the use of inhalers together with a ventilatory re-education program, furthermore, the technique of inhaler use was trained.
89443835|NCT03337880||Cases|newborns who were delivered with an extractor
89443836|NCT03337880||Controls|newborns who were not delivered with an extractor
89443837|NCT02496572||Short-course MDR-TB regimen patients|"Short course MDR-TB treatment regimen. New presumptively diagnosed MDR TB patients (adults and children) with Xpert® MTB/RIF or Hain MTBDR, or confirmed with Hain MTBDR plus on positive cultures if initial molecular tests negative or confirmed from MGIT culture/DST if initial molecular tests negative;~Children (<14 years old) suspected of MDR TB without bacteriological confirmation but documented as a close contact of a confirmed MDR TB patient"
89443838|NCT03342170||CIRRAL|alcoholic cirrhosis
89443839|NCT03342170||CIRVIR|Viral cirrhosis
89443840|NCT03333824|Experimental|Wee-1 kinase inhibitor AZD1775|To evaluate the effect of multiple doses of AZD1775 on the PK of substrates for CYP3A (midazolam), CYP2C19 (omeprazole), CYP1A2 (caffeine) and to evaluate the effect of multiple doses of AZD1775 on QT interval
89443841|NCT03121430|Experimental|Group A|subjects using the drug eluting peripheral vascular stent system
89443842|NCT03121430|Active Comparator|Group B|subjects using the Nitinol Stent System (Cordis Corporation)
89443843|NCT02492516|Experimental|Stem cell|The patients with diagnosis of ALS who receive adipose derived mesenchymal stem cell.
89443844|NCT03342092||Questionnaire|Questionnaires distributed to the families 15 days before child's medical consultation
89443845|NCT04494152||Critically ill patients|Adult critically ill patients hospitalised in the intensive care unit.
89443846|NCT02496338|Experimental|Intervention group|Training program about menopausal health isues
89443847|NCT02496338|No Intervention|Control group|No training program about menopausal health isues
89443848|NCT02496494|Experimental|Tacrolimus conversion group|Cyclosprine was converted to tacrolimus in kidney transplant recipients.
89443849|NCT03337412|Experimental|Patients|initial assessment of physical capacities, determination of personalized objectives on the occasion of 1 to 2 workshops during the hospital checkup. Telephone Contact by the APA educator at 6 months. One-year medical visit.
89443850|NCT03337412|Experimental|Employees|"initial assessment of physical capacities, participation in 10 to 20 physical activity workshops over 6 months on working time, then employees oriented towards autonomous activities over the following 6 months.~Evaluation by computer-filled questionnaires."
88927581|NCT01704040|Placebo Comparator|Part 1: Healthy participants (placebo + HRV-16)|
89443851|NCT03337334|Other|Non-Focused stimulation|Stimulation frequency is set similar to that of the tremor and the amplitude is set up to 2 mA peak amplitude (reduced if not uncomfortable). One 5*5 cm2 square patch electrodes are placed over the Motor cortex and the Prefrontal cortex respectively and a common return electrode of 10*10 cm2 over the ankle. Each subject follows three sessions of 12 min length each. During each session the tremor is measured while interleaving between Motor cortex stimulation, Prefrontal cortex stimulation and No stimulation. By the end of each session we get 4 min of Motor Cortex stimulation, 4 min of Prefrontal Cortex stimulation and 4 min of No stimulation.
89443852|NCT03337334|Other|Focused stimulation|Stimulation frequency is set similar to that of the tremor and the amplitude is set up to 5 mA peak amplitude (with the help of local anesthetic cream and amplitude is reduced if not uncomfortable). A set of 4*1 gel-filled cup-electrodes is placed over each of motor cortex and the occipital cortex respectively. Each subject follows three sessions of 12 min length each. During each session the tremor is measured while interleaving between Motor cortex stimulation, Occipital cortex stimulation and No stimulation. By the end of each session we get 3 min of Motor Cortex stimulation, 3 min of occipital Cortex stimulation and 6 min of No stimulation.
89443853|NCT03337256|Experimental|GI bleeding score|Early endoscopy in emergency department + other clinical parameters
89443854|NCT03337178|No Intervention|Control|Standard of care
89443855|NCT03337178|Experimental|Blinded Fitbit|Blinded Fitbit, no step goal, and no activity feedback
89443856|NCT03337178|Experimental|Fitbit|Fitbit plus step goal and activity feedback
89443857|NCT03333512|Experimental|Nap|After each night with a 5-hour sleep opportunity, participants have a daytime nap opportunity of 1.5 hours.
89443858|NCT03333512|No Intervention|No nap|After each night with a 6.5-hour sleep opportunity, participants do not have a daytime nap opportunity, but instead watch documentaries.
89443859|NCT03333434|Other|AFO - Ankle_7 group|AFO is active comparator, ANKLE7 is the experimental treatment
89443860|NCT03333434|Other|Ankle-7 - AFO group|AFO is active comparator, ANKLE7 is the experimental treatment
89443861|NCT03333278|Active Comparator|Vitamins|intravenous: Ascorbic acid (Vitamin C: 1.5g every 6 hours) Thiamine (Vitamin B1: 200mg every 12 hours) Hydrocortisone (50mg every 6 hours)
89443862|NCT03333278|Other|Control|Hydrocortisone (50mg every 6 hours)
89443863|NCT03333122||Breast Conserving Therapy|Patient who undergo breast conserving therapy or breast conserving therapy with oncoplastic therapies will complete the BREAST-Q Lumpectomy survey module.
89443864|NCT03333122||Mastectomy|Patients who undergo mastectomy will complete the BREAST-Q Mastectomy survey module.
89443865|NCT03333122||Mastectomy with Reconstruction|Patient who undergo breast reconstruction will complete the BREAST-Q Reconstruction survey module. This group will be further subdivided based on implant or autologous tissue reconstruction.
89443866|NCT04494308||exacerbated|COPD patients admitted to the hospital for an exacerbation occurred within the past 10 days.
89443867|NCT04494308||stable|COPD stable patients with no exacerbations in the past 3 months
88927582|NCT01704040|Experimental|Part 2: Asthmatic patients (CNTO 3157 + HRV-16)|
88927583|NCT01704040|Placebo Comparator|Part 2: Asthmatic patients (placebo + HRV-16)|
89443868|NCT02492204||Survivors|
89443869|NCT02492204||Non survivors|
89501710|NCT02151617|Experimental|Cohort 5-PF-06743649 or placebo|
88927584|NCT01704092||Group High-dose|Dexmedetomidine loading dose 1μg/kg Dexmedetomidine maintenance dose 0.6μg/kg/h
88927585|NCT01704092||Group Low-dose|Dexmedetomidine loading dose 0.6μg/kg Dexmedetomidine maintenance dose 0.3μg/kg/h
89443870|NCT04847596||participants with RMS treated with ofatumumab|Relapsing MS participants receiving a full course (two doses) of a COVID-19 mRNA vaccine after starting ofatumumab 20 mg subcutaneous treatment
89443871|NCT02565706|Active Comparator|WIC Fresh Start Program|Participants in this arm receive the Fresh Start program.
89443872|NCT02565706|Active Comparator|Existing Online Health Education|Participants in this arm receive existing online WIC health education.
89443873|NCT02565706|Experimental|WIC Fresh Start Program (FMNP)|Participants in this arm receive the Fresh Start program and WIC Farmers' Market Nutrition Program (FMNP) vouchers redeemable at farmers' markets.
89443874|NCT02565706|Active Comparator|Existing Online Health Education (FMNP)|Participants in this arm receive existing online WIC health education and WIC Farmers' Market Nutrition Program (FMNP) vouchers redeemable at farmers' markets.
89443875|NCT05510518||BMI >30 kg/m2|Singleton pregnant women with normal OGTT at 24-28 weeks of gestation and BMI >30 kg/m2
89443876|NCT05510518||BMI >35 kg/m2|Singleton pregnant women with normal OGTT at 24-28 weeks of gestation and BMI >35 kg/m2
89443877|NCT03339752|Active Comparator|Treatment A|Rosuvastatin Day 1
89443878|NCT03339752|Experimental|Treatment B1|ACT-541468 Day 5 to Day 7
89443879|NCT03339752|Other|Treatment B2|Rosuvastatin Day 8; ACT-541468 Day 8 to Day 12
89443880|NCT05502406|Experimental|IASTM|The participants of the respective group will receive myofascial release using a C shaped glider, by the help of gentle horizontal strokes the targeted soft tissue restrictions will be relieved over the cervicodorsal fascia
89443881|NCT05502406|Experimental|MMFR|The participants of the respective group will recieve manual soft tissue release over the cervicodorsal fascia using velvet glove technique for a period of 5 to 7 mins inorder to set free any adhesion in the underlying myofascia
89443882|NCT03332966||Participants|"The adolescent psychiatric organizations of the Helsinki University Central Hospital (serving the capital region's 1.1 million inhabitants), the Tampere University Hospital (catchment area of 500.000 inhabitants), and the Oulu University Hospital (catchment area of 500.000 inhabitants) have agreed to implement the data collection as part of routine intake assessments for patients aged 15-17. All consenting patients are enrolled; the only exclusion criterion is a previous diagnosis of psychotic disorder.~The participants fill in psychiatric self-report questionnaires, and their structured diagnostic interview data are collected with their permission."
89443883|NCT05465252|Experimental|krill oil|Subjects will take 3 capsules/1500mg of krill oil per day for 6 month
89443884|NCT05465252|Placebo Comparator|olive oil|Subjects will take 3 capsules/1500mg of olive oil per day for 6 month
89443885|NCT03331172|Experimental|High Intensity Focused Ultrasound|
89443886|NCT02491658|Experimental|Treat Psoriasis Vulgaris with UC-MSCs|Subjects in this arm will receive 6 times UC-MSCs infusions (each time 1×10^6/kg) within 8 weeks.
89443887|NCT02491580||KTx Uppsala|Patients who have received a kidney transplant in Uppsala.
88927586|NCT01704092||Group Control|Dexmedetomidine loading dose and Dexmedetomidine maintenance dose were placed with the same amount of 0.9% saline as placebo
89443888|NCT02491580||KTx Europe|Patients who have received a kidney transplant in Uppsala.
89443889|NCT05232968|Experimental|Elderly volunteers participating in the long-term exercise program|Elderly volunteers will be recruited from participants in the long-term exercise program (ongoing since 2017) at the Center of Physical Activity BMC SAS in Bratislava.
89443890|NCT05232968|No Intervention|Elderly sedentary volunteers|Control population will be recruited from the sedentary elderly, who dropped out from the exercise program ≥2 years prior entering this study and do not exercise on regular basis.
89443891|NCT05232968|Experimental|Elderly volunteers participating in the short-term exercise program|Elderly volunteers will follow 4-month of aerobic-strength training intervention and exercise induced effects on mild cognitive impairment will be determined afterwards.
89443892|NCT03332888|Experimental|Interventional Group|For this trial, HMA-CD20 will be given as an intravenous infusion of 1000 mg I.V twice in a month separating them by fourteen days starting at the baseline visit. The dose for both HMA-CD20 dosages willbe identical at the screening visit after the participant's eligibility has been established, and it will remain thesame for both infusions. The standard dose for HMA-CD20 is 1,000 mg per intravenous infusion on day 1 and day 15.
89443893|NCT03332810|Experimental|SME family based physical activity|Adults and family members will participate into one core session and one booster session
89443894|NCT03332810|Active Comparator|Gathering activity|Adults and family members will participate into two gathering activities
89443895|NCT03332732|Experimental|Part 1A|In Part 1A, subjects will receive single doses of VNRX-5133 and VNRX-5022 alone and in combination. All subjects will receive all treatments in the sequence specified by the randomization schedule..
89443896|NCT03332732|Experimental|Part 1B|In part 1B, subjects from Part 1A will receive metronidazole with or without VNRX-5133 + VNRX-5022. All subjects will receive all treatments in the sequence specified by the randomization schedule.
89199980|NCT00959608|Experimental|Basic Plus|Half of study participants are randomly assigned to Basic Plus program, where in addition to receiving the same intervention as the Basic program participants, the Basic Plus participants also receive counseling from a lifestyle coach at the primary care provider's office (monthly in year 1 and bimonthly in year 2).
89199981|NCT00673920|Placebo Comparator|Placebo|"Participants received matching placebo:~on Day 15 of Cycle 1 (Participants who were administered OCR 400 mg on Day 1 of a Cycle 1 in combination with Methotrexate)~on both Days 1 and Day 15 of Cycle 1 (Participants who were randomized to the Placebo + Methotrexate group)"
88927587|NCT01704105|Active Comparator|Water Quality|100 clusters, approximately 1,000 newborns
88927588|NCT01704105|Active Comparator|Sanitation|100 clusters, approximately 1,000 newborns
88927589|NCT01704105|Active Comparator|Handwashing|100 clusters, approximately 1,000 newborns
88927590|NCT01704105|Active Comparator|Combined Water, Sanitation, and Handwashing|100 clusters, approximately 1,000 newborns
88927591|NCT01704105|Active Comparator|Nutrition|100 clusters, approximately 1,000 newborns
88927592|NCT01704105|Active Comparator|Nutrition + Combined Water, Sanitation, and Handwashing|100 clusters, approximately 1,000 newborns
88927593|NCT01704105|No Intervention|Active control arm|200 clusters, approximately 2,000 newborns. Village-level promoter will visit household and will strictly engage in recording the child's MUAC, which will also be conducted in all active comparator arms as well.
88927594|NCT01704105|No Intervention|Passive control arm|100 clusters, approximately 1,000 newborns. No intervention.
88927595|NCT01704118|Experimental|I-gel|I-gel (Intersurgical Ltd, Wokingham, Berkshire, UK) is a disposable supraglottic airway device with a non-inflatable cuff in which part of that is fixed on glottis is made of thermoplastic elastomer, unlike other laryngeal masks
88927596|NCT01704118|Active Comparator|ProSeal Laryngeal mask|ProSeal laryngeal mask (PLMA) (LMA North America, Inc., San Diego, USA) is a modified type of LMA (larger and deeper bowl and enlarged and softer cuff) with gastric drainage tube.
89199982|NCT00673920|Experimental|Ocrelizumab 400mg|Participants received Ocrelizumab 400mg in combination with Methotrexate on Day 1, Cycle 1.
89199983|NCT00673920|Experimental|Ocrelizumab 200mg|Participants received Ocrelizumab 200 mg in combination with Methotrexate on Day 1 and Day 15, Cycle 1.
89199984|NCT00673920|Experimental|Ocrelizumab 200mg/ Ocrelizumab 200mg|Participants who received two 200 mg infusions of Ocrelizumab + Methotraxate during Cycle 1 were re-randomized (1:1 randomization ratio) to receive two infusions of 200 mg Ocrelizumab + Methotraxate during Cycle 2
89537087|NCT02467595|Experimental|R 0.15 group|"Rocuronium bromide 0.15 mg kg-1 group~Anesthesia was induced with propofol 2.5 mg kg-1 , fentanyl 2 mcg kg-1, and rocuronium bromide 0.15 mg kg-1~After mask ventilation with 5 vol% sevoflurane in 100% oxygen for 2 minutes, tracheal intubation was done.~At the end of surgery, discontinuation of sevoflurane and extubation, sending recovery room.~When poor intubating condition., added rocuronium bromide 0.3 mg kg-1 .~Drug: Rocuronium bromide Rocuronium bromide 0.15 mg kg-1 was injected at I.V. line to patients (R 0.15 group), as muscle relaxants during anesthesia for adenotonsillectomy."
88927597|NCT01704131||children > 6 months|children > 6 months of age
88927598|NCT01704131||children < 6 months|children < 6 months
88927599|NCT01704170|Experimental|Renal Denervation Using Externally Focused Ultrasound Therapy|
88927600|NCT01704222||Child in nursery|Children older than 3 months and less than 6 years kept in nurseries retained, regardless of the duration of custody of the child in the manger concerned.
88927601|NCT01704235||Primary health care providers|medical physicians and nurse practitioners
88927602|NCT01704248|Placebo Comparator|Routine self-instillation technique|The participants first use the Routine self-instillation technique for two weeks and then switch to the Eye Drop Guide technique for another two weeks.
89199985|NCT00673920|Experimental|Ocrelizumab 200mg/ Ocrelizumab 400mg|Participants who received two 200 mg infusions of Ocrelizumab + Methotraxate during Cycle 1 were re-randomized (1:1 randomization ratio) to receive a single infusion of 400 mg Ocrelizumab + Methotraxate during Cycle 2
89199986|NCT00673920|Experimental|Ocrelizumab 400mg/ Ocrelizumab 400mg|Participants who received single 400mg infusions of Ocrelizumab + Methotraxate during Cycle 1 received a infusion of 400 mg Ocrelizumab + Methotraxate during Cycle 2
89199987|NCT00673920|Experimental|Placebo/ Ocrelizumab 200mg|Participants who received placebo during Cycle 1 were re-randomized (1:1 randomization ratio) to receive two infusions of 200 mg Ocrelizumab + Methotraxate during Cycle 2
89199988|NCT00673920|Experimental|Placebo/ Ocrelizumab 400mg|Participants who received placebo during Cycle 1 were re-randomized (1:1 randomization ratio) to receive single infusion of 400 mg Ocrelizumab + Methotraxate during Cycle 2
88927603|NCT01704248|Experimental|Eye Drop Guide technique|The participants first use the Eye Drop Guide technique for two weeks and then switch to the Routine self-instillation technique for another two weeks.
88927604|NCT01704300||CALIBER Healthy Cohort|We will report findings from the CALIBER (CArdiovascular disease research using Linked BEspoke studies and Electronic Records) collaboration where we linked primary care data (from the General Practice Research Database [GPRD]) to three further sources of electronic health records: the Myocardial Ischemia National Audit Project registry (MINAP),cause specific discharge data from Hospital Episodes Statistics (HES) and cause specific mortality from the Office for National Statistics (ONS).
88927605|NCT01704313|Experimental|Interrupted|Interrupted suturing technique used around heel of anastomosis
88927606|NCT01704313|Active Comparator|Continuous|Continuous suturing technique used for the anastomosis
88927607|NCT01703299||imipenem-treated patients|imipenem-treated patients
88927608|NCT01703299||ertapenem-treated patients|ertapenem-treated patients
88927609|NCT01704339|Experimental|QUTENZA|Single treatment with QUTENZA (topical capsaicin 8%) transdermal patch
88927610|NCT01704352|Active Comparator|CBT-I|Cognitive behavioral therapy for insomnia (CBT-I) is a multicomponent treatment consisting of sleep restriction therapy, psychoeducation about sleep, stimulus control, stabilizing circadian rhythm and challenging beliefs and perception of sleep.
88927611|NCT01704352|No Intervention|Treatment as usual|Treatment as usual (TAU) consists of pharmacological and supportive psychosocial treatment according to the needs of the patient.
89443897|NCT03332732|Experimental|Part 2 - 2A|Multiple dose administration of Low Dose VNRX-5133 + VNRX-5022
89443898|NCT03332732|Experimental|Part 2 - 2B|Multiple dose administration of High Dose VNRX-5133 + VNRX-5022
89443899|NCT03332732|Placebo Comparator|Part 2 - 2C|Multiple dose administration of Placebo (matching VNRX-5133 + VNRX-5022)
89443900|NCT03324854|Experimental|mosquito net mesh|The open ventral hernia repair were carried out with rives technique, followed by the placement of the mosquito net mesh, and left active-close drainage, 30 minutes before the incisión, prophylactic antibiotic 1gm of cefalotin was administered.
89443901|NCT03324854|Active Comparator|prolene mesh|The open ventral hernia repair were carried out with rives technique, followed by the placement of the prolene mesh, and left active-close drainage, 30 minutes before the incisión, prophylactic antibiotic 1gm of cefalotin was administered.
89443902|NCT02492360||Severe Toxicity Group|Diagnosis of testicular cancer; History of any grade 3 or higher peripheral neuropathy after receiving standard dose cisplatin completed more than 1 year but within the last 5 years; Long-term persistence (> 6 months) of grade 2 or higher peripheral neuropathy after completion of a cisplatin containing regimen. Interventions: blood sample collection and report of peripheral neuropathy after cisplatin therapy.
89443903|NCT02492360||Control Group|Diagnosis of testicular cancer; No history of neurotoxicity (grade 0-1) after completion of a standard cisplatin-containing chemotherapy regimen completed more than 1 year but within the last 5 years; Matched to a specified subject with neurotoxicity based on age (within 10 years), chemotherapy regimen or total cisplatin dosage. Interventions: blood sample collection and report of peripheral neuropathy after cisplatin therapy.
89443904|NCT02492282|Experimental|Closed-Loop|This group includes patients with randomization process be assigned to closed loop intravenous anesthesia; the system evaluates, feeds and acts according to the patient's bispectral index, excluding the anesthesiologist. This system use a variable control of specific therapeutic effect; a target value for this variable (set point); an actuator control (infusion pump), a system (patient) and a control algorithm.
88927612|NCT01704378|Experimental|BIAsp|
88927613|NCT01704391||Aortic aneurysm patients|10 patients with a CT verified diagnosis of aortic aneurysm demanding open elective surgical correction with insertion of vascular prosthesis
88927614|NCT01704391||Aortic occlusive disease patients|10 patients with CT verified aortic occlusive disease demanding open elective surgical correction with insertion of vascular prosthesis
88927615|NCT01704417|Experimental|IDeg followed by IGlar|
88927616|NCT01704417|Experimental|IGlar followed by IDeg|
88927617|NCT01704430|Experimental|Glutamine|Oral/enteral glutamine 0.5 g/kg satisfactory body weight per day (divided doses every 8 hours) starting 6 hours post-operatively
88927618|NCT01704430|Placebo Comparator|Maltodextrin|Oral/enteral maltodextrin 0.5 g/kg satisfactory body weight per day (divided doses every 8 hours) starting 6 hours post-operatively
89443905|NCT02492282|Active Comparator|Open-Loop|This group includes patients with the randomization process are assigned to open loop in which the application of anesthetics is exclusively with pharmacokinetic parameters using TCI and employs mathematical models drug. For propofol used Schneider model and Minto model for remifentanil based on effective site concentration. Changes will be made by the anesthesiologist according to his criteria, trying to keep the BIS range of 40 and 60.
89443906|NCT02492126||Chronic Cough|Subjects with chronic cough will undergo cough reflex sensitivity testing to citric acid. The dose, starting at 0.03 mol/L citric acid will be administered as single breath inhalations using flow-limited calibrated pots and a dosimeter with 3 placebo inhalations of normal saline randomly interspersed. Following each inhalation, the number of coughs in the subsequent 15 seconds will be counted and recorded. The challenge will be terminated once the citric acid has induced 5 or more coughs.
89443907|NCT03331016|Other|Waitlist Control Group|Waitlist Control Group will serve as control group for 6 months, receiving no intervention during that time but completing periodic surveys to assess outcomes among controls (knowledge, attitudes, behaviors). They will also later receive the intervention (training program) and be followed for 6 more months.
89443908|NCT03331016|Experimental|Intervention Group|Intervention Group will receive the intervention (training program) right away, then will be followed for 6 months.
89443909|NCT05464862|Experimental|Group A|Popliteal Plexus Block given with 10 ml of Lidocaine Hydrochloride 10 mg/ml
89443910|NCT05464862|Experimental|Groups B|Popliteal Plexus Block given with 20 ml of Lidocaine Hydrochloride 10 mg/ml
89443911|NCT05464862|Experimental|Group C|Popliteal Plexus Block given with 30 ml of Lidocaine Hydrochloride 10 mg/ml
89443912|NCT05464862|Active Comparator|Group FNB|Femoral Nerve Block given with 20 ml of Lidocaine Hydrochloride 10 mg/ml
89443913|NCT05464862|Active Comparator|Groups SNB|Sciatic Nerve Block given with 20 ml og Lidocaine Hydrochloride 10 mg/ml
88927619|NCT01704443|Experimental|Immediate treatment|Women in the Immediate treatment arm will receive the Group Psychoeducational treatment in the next available group. There will be 8-9 womenper group and each session will be 2.25 hours in duration and there will be 4, bi-weekly sessions over the course of 2 months. Session content includes education about chronic pain, PVD, stress and sexual response, mindfulness practices, and cognitive techniques to notice thought patterns that contribute to increased pain.
88927620|NCT01704443|Experimental|Waitlist Control- delayed treatment|Women in the Waitlist Control arm will receive no treatment for a period of approximately 8 weeks. After the waitlist period they will receive the same Group Psychoeducational treatment as the participants in the immediate treatment arm of the study.
88927621|NCT01704469|Experimental|The local anesthetic injection group|
88927622|NCT01704482|Experimental|N-acetylcysteine|N-acetylcysteine bolus of 150 mg/kg in 250 mL of 5% glucose over 15 mins, followed by continuous intravenous infusion of 50 mg/kg in 250 mL of 5% glucose over 4 hrs, then 100 mg/kg in 1000 ml of 5% glucose over 20 hrs
88927623|NCT01704482|Placebo Comparator|Glucose 5%|equivalent volume over the same period.
88927624|NCT01704508|Active Comparator|Artemether-lumefantrine|6-dose regime will be used:
88927625|NCT01704508|Active Comparator|Dihydroartemisinin-piperaquine|A 3 dose regime will be used
89013482|NCT06300671|Active Comparator|Hyperpronation Group|Participants with a value between 10-12 according to the foot posture index-6 evaluation will be included in the hyperpronation group.
89013483|NCT06300671|Active Comparator|Neutral Group|Participants with a value between 0-5 according to the foot posture index-6 evaluation will be included in the neutral group.
89443914|NCT03324776|Other|Afrezza Inhalant Product|Patients will be instructed to follow a Weekly Treat-to-Target BG Testing Regimen and make Afrezza dose changes according to an Afrezza Titration Algorithm
89443915|NCT03332654||Multiple sclerosis|Prevalence and risk factor of stress urinary incontinence in women with multiple sclerosis and included in the database over 15 years from December 1999 to June 2014, who had undergone a urodynamic test
89443916|NCT02561806|Active Comparator|Ustekinumab|45 mg ustekinumab given as SC injection for participants ≤100 kilograms (kg) and 90 mg SC injection for participants >100 kg at Week 0, 4, 16, 28, and 40. Placebo for ixekizumab injections will be used for blinding.
89443917|NCT02561806|Experimental|Ixekizumab|160 milligrams (mg) ixekizumab given as two subcutaneous (SC) injections at baseline followed by 80 mg ixekizumab given as a single SC injection once every 2 weeks from week 2 through week 12. After week 12 participants will receive 80 mg ixekizumab every 4 weeks through week 52.Placebo for ustekinumab injections will be used for blinding.
89443918|NCT03324620|Experimental|pre active HSCT|"Candidates for transplantation of hematopoietic progenitors since May 12, 2012, regardless of sex and age, who agree to participate in the study and sign informed consent.~In the pre-transplantation visit with the physiotherapist: Measures of muscle mass and strength, quality of life questionnaires, program presentation, fitness assessment and lifestyle determination. The exercises will be personalized, stimulating your practice before admission and involving the family. During admission, the team will encourage the patient to remain active by adapting to the symptoms. At discharge, measures of resistance, exercise tolerance and quality of life at discharge, in the month after discharge, 3 months after discharge, 6 months after discharge and 12 months after discharge."
89443919|NCT03324620|No Intervention|control group|"Patients' candidates for transplantation of hematopoietic progenitors prior to May 12, 2012, regardless of gender and age, who meet the inclusion criteria and are collected correlatively until completing 104 subjects.~Clinical history review to calculate the days of hospitalization in the different hospitalization units during the transplant. As well as the number and type of complications and the use of health resources. Status vitae. Baseline review of functional tests and exercise tolerance."
89443920|NCT03332576|Experimental|Cohort 1|"6 Doses DPX-Survivac (2 prime q3w, 4 boost q8w)~Low dose cyclophosphamide"
89199989|NCT00959686|Experimental|Bendamustine|Bendamustine at the dose of 120 mg/m2 IV over 60 minutes on days 1 and 2 every 21 days for 6 cycles
89199990|NCT00379795|Experimental|Ranibizumad 0.5 mg|Ranibizumab 0.5 mg intravitreal injection 0.5 mg in the study eye on an as needed basis no more frequently than every 30 days (no more than 12 injections per year) for 24 months. Dosing interval was determined by the investigator, on the basis of clinical evaluations and judgment.
89443921|NCT03332576|Experimental|Cohort 2|"6 Doses DPX-Survivac (2 prime q3w, 4 boost q8w)~Low dose cyclophosphamide"
89443922|NCT03332576|Experimental|Cohort 3|"3 Doses DPX-Survivac (1 prime, 2 boost q8w)~Low dose cyclophosphamide"
89443923|NCT03332576|Experimental|Cohort 4|"5 Doses DPX-Survivac (2 prime q6w, 3 boost q6w)~Low dose cyclophosphamide"
89443924|NCT03332576|Experimental|Cohort 5|"5 Doses DPX-Survivac/DPX-Survivac(Aqueous) (2 prime q4w, 3 boost q4w)~Low dose cyclophosphamide"
89443925|NCT03330938|Experimental|CBI and Resilience|8 sessions total, once a week, 2 hours long each, consistent of 6 sessions of Cognitive-behavioral Intervention (CBI) plus 2 sessions to improve resilience strengths.
89443926|NCT03330938|Active Comparator|Cognitive-behavioral Intervention|8 sessions total, once a week, 2 hours long each. Cognitive-behavioral Intervention (CBI) without resilience strengthening.
89443927|NCT03330860|Experimental|Neuromarketing strategy|Twelve clips regarding maternal and neonatal health topics, designed with mixed 2D and 3D elements, each one about 45 seconds long (prepared based on the best available evidence and validated by clinical experts).
89443928|NCT03330860|Active Comparator|No-capsule group|Control clip with 2D elements about 45 seconds long, containing information on prenatal control and presented in conventional format (narration, static images and on screen text).
89443929|NCT03324386|Experimental|Individual Orientation|This was a prospective randomized clinical study conducted with the following 4 groups of hypertensive patients: Experimental: individual orientation: receiving individual orientation required by an embracement strategy characterized by 7 nursing visits at 20-day intervals, for 4 months);The ntervention is composed by relational strategies characterized by interpersonal relationships
89501711|NCT02691507|Active Comparator|Positive Control|Marketed - EpiCeram(R) Skin Barrier Emulsion: Apply in a thin layer to the affected skin areas 2 times per day (or as needed) and massage gently into the skin.
88927626|NCT01704534|Experimental|Ustekinumab|Ustekinumab 45 mg or 90 mg (dependent on patient's weight) administered on weeks 0-4-16-28
88927627|NCT01704560|Experimental|Coversheet to Informed Consent|Coversheet attached to Informed Consent.
89013484|NCT06300619|Active Comparator|Pilates|Standard Pilates Protocol with no hip/shoulder cuff cuing. Delivered from a seated position.
89013485|NCT06300619|Experimental|Pilates+4|Pilates protocol that involves hip and shoulder cuff activation and stabilization exercises and cues to augment the Pilates exercise.
88927628|NCT01704560|No Intervention|No Coversheet|Standard, full permission form, without the coversheet.
88927629|NCT01704573||NMR by abstinence status|"This study uses a mixed design with one between-subject factor (NMR: continuous variable) and one within-subject factor (session: 24 hours abstinent vs. smoking as usual) to examine NMR by abstinence status interactions on α4β2* nAChR availability using 2-[18F]-fluro-3-[2(S)-2-azethidinylmethoxy]-pyridine (2-[18F]FA) PET imaging.~Subjects will participate in two one-hour PET sessions: a) after smoking as usual (smoking exposure standardized) and b) the other following 24 hours of smoking abstinence.~All participants who complete both PET scans will also complete an anatomical MRI scan."
88927630|NCT01704586|Active Comparator|Radioiodine|Standard procedures using only I-131. All patients in this arm will have assigned I-131 ablation, followed by periodic I-131 diagnostic re-evaluations after 4-6 months as needed.
89501712|NCT02691507|Experimental|Experimental|Not Yet Marketed - 1% Colloidal Oatmeal Balm: Apply at least once per night or more if needed.
89443930|NCT03324386|Experimental|VLE for Distance Learning|This was a prospective randomized clinical study conducted with the following 4 groups of hypertensive patients:Experimental: a technological education strategy for distance learning (DL), using a technological education strategy (E-Care of Hypertension) for Distance Learning (DL) characterized by 7 nursing visits at 20-day intervals, for 4 months). The intervention is composed by the use of equipment-oriented techniques or audio-visual aids in educational environments remotely accessed for health education specifically for hypertensive patients
89443931|NCT03324386|Experimental|E-blended Learning|This was a prospective randomized clinical study with the patient received experimental intervention: a technological education strategy with E-blended Learning modality with E-Care of Hypertension, associated with face-to-face consultation with the health professional and making 7 nursing visits at 20-day intervals, for 4 months. The intervention is composed by the use of equipment-oriented techniques or audio-visual aids in presential educational environments intended for health education specifically for hypertensive patients
89443932|NCT03324386|No Intervention|No intervention|No type of intervention was performed making 2 nursing visits at baseline and 1 after 120 days (No intervention)
89443933|NCT02561572|Experimental|Intervention|Acupuncture at the Yintang point for 30 minutes.
89443934|NCT02561572|No Intervention|Control|No intervention for 30 minutes.
89443935|NCT03330782|Experimental|Elderly|Remifentanil was infused at predetermined effect-site concentration before propofol infusion in elderly patients.
89443936|NCT03330782|Active Comparator|Adult|Remifentanil was infused at predetermined effect-site concentration before propofol infusion in adult patients.
89443937|NCT03332342|Experimental|Daily rinse of ocular surface|Eye wash of the ocular surface with one teaspoon of saline immediately upon awakening, performed daily.
89443938|NCT03332342|Active Comparator|Weekly rinse of ocular surface|Eye wash of the ocular surface with one teaspoon of saline immediately upon awakening, performed weekly.
89443939|NCT03332342|Experimental|Occasional rinse of ocular surface|Eye wash of the ocular surface with one teaspoon of saline immediately upon awakening, performed on two separate occasions
89443940|NCT02492048|Active Comparator|Split Thickness Skin Graft Harvest|Retrospective review
89013486|NCT06300593||PCOS phenotype A|clinical and/or biochemical hyperandrogenism (HA) + ovulatory dysfunction (OD) + polycystic ovarian morphology (PCOM)
89013487|NCT06300593||PCOS phenotype B|HA + OD
89013488|NCT06300593||PCOS phenotype C|HA + PCOM
89013489|NCT06300593||PCOS phenotype D|OD + PCOM
89013490|NCT06300580|Experimental|ABBV-932|Participants will receive ABBV-932.
89443941|NCT02492048|Experimental|Cellutome Epidermal Harvesting System|Prospective patients will receive a skin graft utilizing the Cellutome Epidermal Harvesting System
89013492|NCT06300541||1) IBD conventional treatment,|Medical therapy
89013493|NCT06300541||2) Colectomy|Surgical treatment
89013494|NCT06300528|Experimental|Treatment (pemigatinib)|Patients receive pemigatinib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also under CT and PET or PET/CT and blood sample collection at screening and on study. Patients may also undergo bone marrow aspirate and biopsy during screening and on study.
89199991|NCT04588948|Experimental|Vitrectomized Eyes|The study is an exploratory investigation to evaluate the intraocular and systemic pharmacokinetics of intravitreal aflibercept. A sample size of 60 eyes was chosen to provide a sample of 30 non-vitrectomized eyes and 30 vitrectomized eyes to evaluate.
89443942|NCT05506540|Experimental|Single Ascending Dose, ENN0403 1 mg|Single oral use of ENN0403 at dose level 1 mg, in fasted state.
89443943|NCT05506540|Experimental|Single Ascending Dose, ENN0403 4 mg|Single oral use of ENN0403 at dose level 4 mg, in fasted state.
89443944|NCT05506540|Experimental|Single Ascending Dose, ENN0403 10 mg|Single oral use of ENN0403 at dose level 10 mg, in fasted state.
89443945|NCT05506540|Experimental|Single Ascending Dose, ENN0403 20 mg|Single oral use of ENN0403 at dose level 20 mg, in fasted state.
89443946|NCT05506540|Experimental|Single Ascending Dose, ENN0403 30 mg|Single oral use of ENN0403 at dose level 30 mg, in fasted state.
89443947|NCT05506540|Experimental|Single Ascending Dose, ENN0403 20 mg (Fed)|Single oral use of ENN0403 at dose level 30 mg, after high calorie and high-fat breakfast meal.
89443948|NCT05506540|Experimental|Multiple Ascending Dose, ENN0403 6 mg|ENN0403 capsules for oral administration, 6 mg QD X 14 Days
89443949|NCT05506540|Experimental|Multiple Ascending Dose, ENN0403 12 mg|ENN0403 capsules for oral administration, 12 mg QD X 14 Days
89443950|NCT05506540|Experimental|Multiple Ascending Dose, ENN0403 20 mg|ENN0403 capsules for oral administration, 20 mg QD X 14 Days
89443951|NCT05506540|Placebo Comparator|Single/Multiple Ascending Dose, placebo capsules for oral adminstration|Placebo capsules for oral administration
89443952|NCT03332186|Experimental|Mild Renal Impairment|Mild renal impairment defined as eGFR 60 to <90 mL/min/1.73 m^2
89443953|NCT03332186|Experimental|Moderate renal impairment|Moderate renal impairment defined as eGFR 30 to <60 mL/min/1.73 m^2
89443954|NCT03332186|Experimental|Severe renal impairment|Severe renal impairment defined as eGFR <30 mL/min/1.73 m^2, not requiring dialysis
89443955|NCT03332186|Experimental|Normal renal function|Normal renal function defined as eGFR ≥90 mL/min/1.73 m^2
89443956|NCT05506462|Experimental|Ketamine|50-60 minutes intravenous infusion of 60mg ketamine
89443957|NCT03330704|Active Comparator|Standard Therapy|This group will receive 3% hypertonic sodium chloride for the management of their cerebral edema. 3% Sodium Chloride is the generic name of this intravenous fluid preparation.
89443958|NCT03330704|Experimental|Balanced Therapy|This group will undergo two simultaneous infusions. 23.4% sodium chloride and 8.4% sodium bicarbonate will be infused at the same time in various ratios for management of cerebral edema with a balanced approach
89443959|NCT03330626|Active Comparator|IO group|Fluid overload will be removed in the patients who received continuous renal replacement therapy, but the amount of fluid removal are guided by the intake-output balance.
89443960|NCT03330626|Experimental|InBody group|Fluid overload will be removed in the patients who received continuous renal replacement therapy, but the amount of fluid removal are guided by the bioimpedance analysis (InBody S10).
89443961|NCT03330548|Active Comparator|TeleMOVE!|Veterans randomized to the control arm will participate in TeleMOVE!, an arm of the Management of Overweight Veterans (MOVE!) program. TeleMOVE! is telehealth treatment program within the VA designed to improve the lives of Veterans by assisting with weight management and health promotion. This program includes daily interaction with in-home messaging technologies and clinician contact as needed
89443962|NCT03330548|Experimental|Culinary Rx|Veterans randomized to the experimental arm will participate in Culinary Rx. Culinary Rx is an online instructional cooking and nutrition course that healthcare professionals can prescribe to patients who need to transition away from a Standard American Diet to a more health-supportive, whole foods, plant-based lifestyle. In partnership with The Plantrician Project, this course will focus on teaching the foundational cooking skills needed for long-term behavioral change, coupled with lifestyle education around nutrition and resources that will help users successfully face the many challenges inherent to dietary change.
89443963|NCT05501938|Experimental|Cerclage|Perform physical exam indicated cerclage between 24w0d to 25w6d
89443964|NCT05501938|No Intervention|Control|No intervention; routine monitoring in pregnancy for preterm delivery
89443965|NCT03330470|Experimental|exercise and carnosine supplementation|exercise: participants will be subjected to 3 months supervised exercise intervention carnosine supplementation: participants will be instructed to take carnosine 2 times daily
89443966|NCT03330470|Experimental|exercise and supplementation with placebo|exercise: participants will be subjected to 3 months supervised exercise intervention supplementation with placebo: participants will be instructed to take placebo 2 times daily
89443967|NCT03330470|Experimental|stretching controls and carnosine supplementation|stretching controls: participants will be subjected to 3 months supervised stretching program carnosine supplementation: participants will be instructed to take carnosine 2 times daily
89443968|NCT03330470|Experimental|stretching controls and supplementation with placebo|stretching controls: participants will be subjected to 3 months supervised stretching program supplementation with placebo: participants will be instructed to take placebo 2 times daily
89443969|NCT03332108|Experimental|Intervention|Those allocated to the intervention arm will be enrolled in the mHealth intervention (EpxBreastfeeding) for six months, and will also be asked about breastfeeding status at their six-week postpartum follow up visit (standard of care) as well as during phone interviews at three and six months postpartum.
89443970|NCT03332108|Other|Control|Those in the control arm will be asked about breastfeeding status (exclusive, supplementing, or formula only) at their six-week postpartum follow up visit (standard of care) as well as during phone interviews at three and six months postpartum.
89443971|NCT03324152|Experimental|High-intensity interval training (HIIT) - myositis|12-week, 3d/w, HIIT
89443972|NCT03324152|Active Comparator|Standard low-intensity home exercise control (CG)|12-week, 5 d/w, home exercise.
89443973|NCT03324152|Active Comparator|High-intensity interval training (HIIT) - healthy|12-week, 3d/w, HIIT.
89443974|NCT03331952||Invasive pneumococcal disease study (PCV-D)|"Prospective study of children with invasive pneumococcal disease / probable bacterial meningitis (PCV-D)~Clinical procedures~At study enrolment:~Admission clinical findings / laboratory results will be recorded.~A questionnaire will be administered to the parent / guardian or caretaker to assess the child's immunisation status, household structure, environmental exposures, and recent antimicrobial use.~Radiology procedures As part of routine clinical management at AHC, a digital chest radiograph (CXR) may be performed as part of a child's diagnostic work up. CXRs will be read and interpreted primarily by the AHC radiologists. All CXR will subsequently be re-read by two study clinicians and interpreted according to the WHO paediatric radiologic pneumonia criteria.~Laboratory procedures~• Residual routine clinical specimens further analysed as part of the study protocol:~Blood and cerebrospinal fluid culture specimens.~EDTA / serum specimens.~Urine."
89443975|NCT03331952||Pneumonia study (PCV-P)|"Prospective study of children hospitalised with clinical and/or radiologic pneumonia (PCV-P)~Clinical procedures As described for PCV-D.~Radiology procedures As part of routine clinical management at AHC, a digital chest radiograph (CXR) is performed on all children with an admission diagnosis of pneumonia. CXRs will be handled as described for PCV-D.~Laboratory procedures~Study specific specimens:~o Nasopharyngeal swab at enrolment.~Residual routine clinical specimens further analysed as part of the study protocol:~As described for PCV-D."
89443976|NCT03331952||Pneumococcal colonisation study (PCV-C)|"Cross-sectional pneumococcal colonisation surveys in children attending the AHC out-patient department (PCV-C)~Three annual surveys, enrolling 450 children each year, will be done to identify and characterise pneumococcal nasopharyngeal colonisation in AHC out-patient department (OPD) attendees.~Clinical procedures~• Subjects will be recruited from the OPD waiting area after nurse triage. A questionnaire will be administered to the parent / guardian or caretaker to assess the child's immunisation status (by review of the handheld immunisation card where possible), household structure, environmental exposures, and recent antimicrobial use.~Laboratory procedures • Study specific specimens:~o Nasopharyngeal swab at enrolment. A nasopharyngeal swab will be collected from each participant and these will be processed as described for PCV-P."
89443977|NCT05506228||Cerebral Palsy (CP) / Acquired Brain Injury (ABI)|Children and adolescents with cerebral palsy and acquired brain injury.
89443978|NCT05506228||TD (Typically Developed)|Typically developed children and adolescents.
89443979|NCT03330392|Experimental|AGP|take two tablets per day (500 mg/day) for 8 weeks.
89199992|NCT04588948|Experimental|Non-Vitrectomized Eyes|The study is an exploratory investigation to evaluate the intraocular and systemic pharmacokinetics of intravitreal aflibercept. A sample size of 60 eyes was chosen to provide a sample of 30 non-vitrectomized eyes and 30 vitrectomized eyes to evaluate.
89199993|NCT00758628|Active Comparator|1|Bromfenac
89199994|NCT00758628|Placebo Comparator|2|Blink
89443980|NCT03330392|Placebo Comparator|Placebo|take two tablets per day for 8 weeks.
88927631|NCT01704586|Active Comparator|I-124|I-124 PET/CT guided concept following ATA guideline recommendations after total thyroidectomy. Uptake outside of thyroid bed constitutes I-131 therapy for remnant ablation and metastasis therapy based on I-124 dosimetry. Remnant mass and/or metastasis mass will be estimated by a diagnostic CT scan simultaneously while doing PET at the optimum time point 2-3 days after administration of I-124. If there is no uptake outside of thyroid bed, no ablation will follow in stage I disease according to AJCC with the possibility of lymph node involvement but no distant metastasis and no microscopical residual disease (Patient age <45y: any T, any N, M0; Patient age 45y or older: T1, N0, M0). Periodic follow-up may include I-124 PET/CT when indicated to determine whether or not another I-131 therapy has to follow. Thyroglobuline increase also constitutes I-124 PET/CT imaging.
88927632|NCT01704612|Active Comparator|Diabete group|Patient with type 2 diabete received 20 mL ropivacaine
88927633|NCT01704612|Sham Comparator|Control group|no diabete reveived 20 mL ropivacaine
88927634|NCT01704625|Experimental|Osteopathic Manipulative Treatment|The osteopathic treatment group will have performed on them 3 standardized osteopathic manipulative treatments. If at any time the patient is unable to tolerate a treatment secondary to pain that particular study will be stopped. If the patient's nurse enters the room with medication, the study will be stopped and patient will not be included in the study. At no time will the patient's medical treatment in the emergency department be delayed to perform OMT
88927635|NCT01704625|Sham Comparator|Sham Osteopathic Manipulative Treatment|The sham group will receive 3 sham treatments. If at any time the patient is unable to tolerate a treatment secondary to pain that particular study will be stopped. If the patient's nurse enters the room with medication, the study will be stopped and patient will not be included in the study. At no time will the patient's medical treatment in the emergency department be delayed to perform OMT.
88927636|NCT01704638|Experimental|2677TT|Plasma kinetics of fluvoxamine and digoxin in this genotype
88927637|NCT01704638|Other|2677GG|plasma kinetics of fluvoxamine and digoxin in this genotype
88927638|NCT01704664|Active Comparator|I - Nutritional therapy only during the postoperative period.|Postoperative nutritional therapy administered in group I will not include immunomodulating factors. Early postoperative enteral nutrition, based on standard elementary diet (Peptisorb), starts 20 hours post-surgery. The initial flow rate will be 8 ml/h, which will be increased gradually, with the volume doubled every 24 hours, up to 100 ml/h. The enteral nutrition will be continued for six days. During the initial five days post-surgery, the patients will be additionally supplemented parenterally via peripheral veins (commercially available two-chamber bag for peripheral access with 480 kcal of energetic value and 5.7g of N contained in standard amino acids).
88927639|NCT01704664|Active Comparator|II - parenteral glutamine in postoperative time|The nutritional therapy of group II patients will start post-surgery. It will be based on early enteral nutrition with elementary diet (Peptisorb) with simultaneous parenteral nutrition with two-chamber bag with 480 kcal energetic value and 5.7g of N contained in standard amino acids administered via peripheral veins. Additionally, glutamine (100 ml of Dipeptiven) will be added to the two-chamber bag. The parenteral nutrition will be administered for five days.
88927640|NCT01704664|Active Comparator|III - perioperative oral immunonutrition|Preoperatively, group III patients will be given commercially available oral diet enriched with arginine (Cubitan, 1 package 3 times per day). Additionally, they will be administered commercially available two-chamber bag with 480 kcal energetic value and 5.7g of N in standard amino acids via peripheral access. The duration of pre-operative preparatory phase ranged between 5 and 10 days (8 days on average). Enteral nutrition with commercially available arginine-containing diet (Cubison) will start 20 hours post-surgery at an 8 ml/h flow rate; the rate will be increased gradually, with the volume doubled every 24 hours, up to 100 ml/h and continued for six days. Simultaneously, commercially available two-chamber bags for peripheral access with composition identical to that used preoperatively will be administered via peripheral veins for five days.
88927641|NCT01704664|Active Comparator|IV - Perioperative parenteral immunonutrition|Nutritional therapy of group IV will be based on intravenous preparations. Two-chamber bags with 480 kcal energetic value and 5.7 g of N in standard amino acids will be administered preoperatively. A solution of glutamine (Dipeptiven, 100 ml) and ω3-fatty acids (Omegaven, 100 ml) will be added to the bags. The duration of pre-operative preparatory phase ranged between 5 and 10 days (8 days on average). Enteral nutrition with elementary commercially available diet (Peptisorb) will be begun 20 hours post-surgery; it will be started at an 8 ml/h flow rate and increased gradually, with the volume doubled every 24 hours, up to 100 ml/h. The enteral nutrition will be continued for six days. During the initial five days post-surgery, the patients will be additionally supplemented parenterally via peripheral veins; similarly to the preoperative period, the content of two-chamber bag for peripheral access enriched with glutamine and ω3-fatty acids will be administered for five days.
88927642|NCT01704677|Experimental|Surgery|Replacement of the degenerative intervertebral lumbar disc with an artificial lumbar disc device (degeneration had to be restricted to the two lower levels (L4/L5 and/or L5/S1))
88927643|NCT01704677|Active Comparator|Multidiciplinary rehabilitation|
88927644|NCT01704690|Experimental|S-1 and Paclitaxel|Patients in these arm will receive combination treatment of S-1 and paclitaxel. S-1, 80-120mg po, bid, from day 1 to day 14 Paclitaxel, 175mg/m2, IV infusion on day 1 Repeated every 21 days
88927645|NCT01704690|Active Comparator|Paclitaxel and Cisplatin|"Patients in these arm will receive combination treatment of paclitaxel and cisplatin.~Paclitaxel, 175mg/m2, IV infusion on day 1 Cisplatin, 30 mg/m2, IV infusion on day 1 and day 2 Repeated every 21 days"
88927646|NCT01704690|Active Comparator|5-FU and Cisplatin|Patients in these arm will receive combination treatment of 5-FU and cisplatin. 5-FU, 2500mg/m2, continue iv infusion for 120 hours Cisplatin, 35 mg/m2, IV infusion on day 1 and day 2 Repeated every 21 days
88927647|NCT01704703|Experimental|Experimental|FOLFIRI + panitumumab
88927648|NCT01704716|Experimental|R0: COJEC plus G-CSF|Patients randomised to G-CSF during induction treatment (Rapid COJEC) received a single daily subcutaneous injection of 5 microgram/kg/day G-CSF (filgrastim) beginning 24 hours after the last chemotherapy dose.
88927649|NCT01704716|Active Comparator|R0: COJEC|Induction treatment (COJEC) without filgrastim Patients randomised to Rapid COJEC alone will receive induction Treatment without G-CSF
88927650|NCT01704716|Active Comparator|R1: BuMel MAT|"The BuMel MAT regimen consists of oral administration of busulphan and the short i.v. infusion of melphalan.~In July 2007 (amendment 3) oral busulfan was changed to i.v. Busulfan (Busilvex)"
89013495|NCT06300515|Active Comparator|Control|During the intervention phase (hospitalization for hematopoietic stem cell transplantation (HSCT) and subsequent 8-week outpatient phase following discharge), the control group will participate in a Health Counseling Program (1 time/week) on aspects related to a healthy lifestyle such as reducing sedentary lifestyle, acquiring healthy nutritional habits, the importance sleep, screen use, and how to address barriers related to clinical status. We will adapt the program to the needs and timing of the patient's treatment, providing the content in one session/week orally (e.g. using presentations) and in writing (e.g. through brochures).
89013496|NCT06300515|Experimental|Exercise|During the intervention phase (hospitalization for hematopoietic stem cell transplantation (HSCT) and subsequent 8-week outpatient phase following discharge), the intervention group will participate in exactly the same Health Counseling Program as the Control group. Additionally, this group will perform an exercise program combining aerobic and muscle strength exercises
89013497|NCT06300502|Active Comparator|Kybella Injection|Kybella is sterile 1% deoxycholic acid provided in a 2 mL single-use vial.
89013498|NCT06300502|Active Comparator|Asclera Injection|Asclera is sterile 1% polidocanol provided in a 2 mL single-use vial.
89013499|NCT06300502|Active Comparator|1064nm laser|The laser used is the GentleMax Pro laser (755/1064 nm wavelength) which targets hemoglobin.
89013500|NCT06300502|Active Comparator|755nm laser|The laser used is the GentleMax Pro laser (755/1064 nm wavelength) which targets hemoglobin.
89013501|NCT06300489|Experimental|irinotecan liposomes+capecitabine+chemoradiotherapy|There are three dose groups inciuding wild-type (GG+6/6)，unit site mutant (GG+6/7 or GA+6/6) and double sites mutant (GG+7/7 or AA+6/6 or GA+6/7)。Every group will receive irinotecan liposomes injection and capecitabine based chemoradiotherapy.
89013502|NCT06300476|Experimental|Low dose group|Subretinal injection low dose of JWK006 in one eye
89013503|NCT06300476|Experimental|Medium dose group|Subretinal injection medium dose of JWK006 in one eye
89013504|NCT06300476|Experimental|High dose group|Subretinal injection high dose of JWK006 in one eye
89443981|NCT04820218|Other|Without Try-on glasses|Subjects will be asked to measure their visual acuity without their try-on glasses
89443982|NCT02491346|Active Comparator|conventional empirical glycemic control|the patients' blood glucose is controlled by physician according to their experience through insulin subcutaneous injection or insulin continuous infusion whose dosage is determinated by the physician.
89443983|NCT02491346|Experimental|SGC directed glycemic control|the patients' blood glucose is controlled by SGC system through insulin continuous infusion whose dosage is determinated by SGC.
89013508|NCT06300450|Experimental|Alert|Alert-based CDS will consist of an on-screen electronic alert that will notify the clinician that the patient has an indication for LDL-C-lowering therapy but is not prescribed any. The clinician will have the opportunity to proceed to an order template through which appropriate lipid-lowering can be prescribed. The clinician could also elect to learn more about current evidence-based recommendations for LDL-C lowering in the PAD population. Finally, the clinician could elect to proceed without ordering oral LDL-C-lowering therapy or reading evidence-based recommendations for LDL-C lowering but would have to provide a rationale for not doing so.
89013509|NCT06300450|No Intervention|No Alert|No on-screen notification will be issued to the clinician
89501713|NCT02150681|Experimental|Mindfulness-based cognitive therapy|8 class sessions of mindfulness therapy given in a group setting, with one 2-hr session per week for 8 weeks.
89501714|NCT02259361|Active Comparator|Experimental|Intervention: Sustained-release oral dalfampridine, one 10 mg tablet, twice daily, taken 12 hours apart (one tablet in the morning and one tablet in the evening) for 14 consecutive days.
89501715|NCT02259361|Placebo Comparator|Placebo|Placebo, one 10 mg tablet, twice daily, taken 12 hours apart (one tablet in the morning and one tablet in the evening) for 14 consecutive days.
89501716|NCT02255201|Active Comparator|Beverage A|Single dose, Pre-Workout Master Performance Blend Dose 1
89199995|NCT00959998|Active Comparator|Relaxation acupressure|
88927651|NCT01704716|Experimental|R1: CEM MAT|The CEM MAT regimen uses three drugs: the dose of Carboplatin must be based on renal function with a target area under the concentration versus time curve (AUC) of 16.4 mg/ml.min, etoposide 350 mg/m2/course and melphalan 210 mg/m2/course
88927652|NCT01704716|Active Comparator|R2: ch14.18/CHO|ch14.18/CHO is given at a dose of 20 mg/m2/day over five days every four weeks for five courses
88927653|NCT01704716|Experimental|R2: ch14.18/CHO plus Aldesleukin|Patients randomised to receive ch14.18/CHO plus Aldesleukin
88927654|NCT01704716|Active Comparator|R3: COJEC Induction|"Rapid COJEC induction treatment is applied over ten weeks; three different courses are given every ten days:~Course A (given on days 0 and 40): vincristine, carboplatin, and etoposide Course B (given on days 10, 30, 50, and 70): vincristine and cisplatin Course C (given on days 20 and 60): vincristine, etoposide, and cyclophosphamide"
88927655|NCT01704716|Experimental|R3: Modified N7|The modified N7 induction is a dose intense induction chemotherapy regimen including two putatively non cross-resistent drug combinations: high-dose cyclophosphamide plus doxorubicin/vincristine (CAV) and high-dose cisplatin/etoposide (P/E).
88927656|NCT01704716|Active Comparator|R4: cnt inf ch14.18/CHO|ch14.18/CHO is given as continuous Infusion over 10 days at a cumulative dose of 100mg/m2. Patients receive 5 cycles of ch14.18/CHO
88927657|NCT01704716|Experimental|R4: cnt inf ch14.18/CHO plus Aldesleukin|"ch14.18/CHO is given as continuous Infusion over 10 days at a cumulative dose of 100mg/m2. Patients receive 5 cycles of ch14.18/CHO.~In addition, Aldesleukin is given at a dose of 3 x 10e6 on days 1 to 5 and on days 9, 11, 13, 15, and 17 during ch14.18/CHO infusion"
88927658|NCT01704729|Other|group2|Cycloplegic subjective refraction by an experienced optometrist or ophthalmologist
88927659|NCT01704729|Other|group3|"Cycloplegic subjective refraction by a vision technician trained in the Zhongshan Ophthalmic Center's Rural Refractionist Program"
88927660|NCT01704729|Other|group4|Cycloplegic subjective refraction by an experienced optometrist or ophthalmologist
88927661|NCT01704729|Other|group1|Non-cycloplegic self-refraction using First Generation, Child-Specific fluid-filled adjustable spectacles and updated self-refraction protocol
88927662|NCT01704768|Experimental|COPE/Healthy Lifestyles TEEN Program|COPE is a manualized 15-session educational and cognitive-behavioral skills building program guided by Cognitive Behavioral Theory with physical activity as a component of each session.
88927663|NCT01704768|Placebo Comparator|Healthy Teens Attention Control Program|Healthy Teens is an attention control program that controls for the time spent with the adolescents in the COPE group is essential to determining the efficacy of the experimental program.
88927664|NCT01704794|Active Comparator|Folic Acid + Paludrine +Jobelyn (500mg)|Folic acid 5mg given twice daily. Paludrine 50mg to 20mg daily. Jobelyn 500mg once daily.
88927665|NCT01704794|Active Comparator|Folic Acid + Paludrine +Jobelyn (250mg.)|Folic Acid 5mg daily Paludrine 20 - 40mg daily Jobelyn 250mg daily
88927666|NCT01704794|Active Comparator|Folic Acid + Paludrine + Jobelyn (2mg)|Folic Acid 5mg daily Paludrine 20 - 40mg daily Jobelyn 2mg daily
88927667|NCT01704807|Active Comparator|Intervention, Custom Orthotics|Wearing custom foot orthotics
88927668|NCT01704807|Sham Comparator|Sham Foot Orthotic|Wearing sham or flat shoe insoles
88927669|NCT01704820|Experimental|Retroflexion arm|Retroflexion arm: retroflexion in the cecum or proximal ascending colon and slow withdrawal to the hepatic flexure with removal of all visible colon polyps
88927670|NCT01704820|Placebo Comparator|Forward view arm|Colonoscope is slowly withdrawn from the proximal colon to the hepatic flexure and all visible colon polyps are removed.
88927671|NCT01704833|Experimental|Cognitive Behavioral Therapy|This group receives 15 weeks of Paranoia-Focused Cognitive Behavioral Therapy (PFCBT) in addition to standard care.
88927672|NCT01704833|No Intervention|Treatment as Usual|This group receives standard care only.
88927673|NCT01704872|Experimental|dose level finding ch14.18/CHO|A dose escalation design based on Phase I rules starting at 10 mg/m2/day ch14.18/CHO. This is 50% below the dose of ch14.18/SP2/0 used in a large cohort of patients. Dose escalation will be adapted to a modified Fibonacci series aiming at 10, 20 and 30 mg/m2 of ch14.18/CHO. Since this study is a bridging study aiming at a reassessment of the toxicity and determination of the pharmacokinetics of ch14.18/CHO, only a limited number of dose escalation steps (3) is implemented in the design.
88927674|NCT01704885|Sham Comparator|Active Control Group|Children in the active control group will play with puzzles, a building toy, or color. The play facilitator will praise the child and interact at a similar rate to control for interaction with a caring adult.
88927675|NCT01704885|Experimental|Play Intervention|"children in the play intervention group will be given 3 story stems that they are asked to play out with the goal of helping the main character feel better (see session scripts). The play facilitator will play with the child, modeling and praising use of positive coping skills. In the first session the play facilitator will focus on positive self-statements, in the second session the play facilitator will focus on problem-solving, and a combination of these two approaches will be used in the final session. The child will be allowed to make up a story about whatever they want before ending each session."
88927676|NCT01704898|Other|Efavirenz 600 Test-Stocrin 600 Reference|Efavirenz 600 mg will be randomly assigned.
88927677|NCT01704898|Other|Stocrin 600 Reference-Efavirenz 600 Test|Stocrin 600 mg will be randomly assigned.
88927678|NCT01704911|Experimental|Transradial Coronary Intervention|Transradial Coronary Intervention
88927679|NCT01704911|Experimental|Transfemoral Coronary Intervention|Transfemoral Coronary Intervention
88927680|NCT01704924|Active Comparator|Prevena|Incision with prevena device overlying
88927681|NCT01704924|Active Comparator|Standard of Care dressing|Prevena device is not used
89013510|NCT06300411|Experimental|SRG-514|SRG-514
89199996|NCT00959998|Experimental|High Intensity Stimulating Acupressure|
89199997|NCT00959998|Experimental|Low Intensity Stimulating Acupressure|
89199998|NCT01048411|Active Comparator|Naja-comp.|s.c. injection of naja comp (homeopathic remedy) three times a week
89443984|NCT05506072|Experimental|BFR group with standard therapy|Participants will be randomized into their assigned group of receiving standard therapy with BFR by a blinded therapist within the study. Participants will then visit the clinic for study testing at six weeks, 12 weeks, and six months after their surgery. During each of these visits, they will be asked to complete a survey, and then their shoulder strength and flexibility will be measured. Each study visit will last approximately 30 minutes. Participants will also attend 12-18 shoulder rehabilitation sessions in the clinic over six weeks from the six week to 12 week mark (about two to three sessions per week). Each rehabilitation session will last approximately 30 minutes and consist of Blood Flow Restriction Training with the standard rehabilitation exercises. Between the 12-week follow-up and 6-month follow-up, participants will receive standard post-surgical rehabilitation for their specific shoulder surgery without Blood Flow Restriction training.
89443985|NCT05506072|Active Comparator|standard therapy group|"Participants will be randomized into their assigned group of receiving standard therapy without BFR by a blinded therapist within the study using a computer generated randomization formula Participants will then visit the clinic for study testing at six weeks, 12 weeks, and six months after their surgery. During each of these visits, they will be asked to complete a survey, and then their shoulder strength and flexibility will be measured. Each study visit will last approximately 30 minutes. Participants will also attend 12-18 shoulder rehabilitation sessions in the clinic over six weeks from the six week to 12 week mark (about two to three sessions per week). Each rehabilitation session will last approximately 30 minutes and consist of standard rehabilitation exercises without BFR.~Between the 12-week follow-up and 6-month follow-up, participants will receive standard post-surgical rehabilitation for their specific shoulder surgery without Blood Flow Restriction training."
89443986|NCT03330314|Experimental|Part 1|Intravenous (IV) infusion
89443987|NCT03330314|Experimental|Part 2: Cohort A|Intravenous (IV) infusion (Dose A)
89443988|NCT03330314|Experimental|Part 2: Cohort B|Intravenous (IV) infusion (Dose B)
89443989|NCT03330314|Experimental|Part 2: Cohort C|Intravenous (IV) infusion (Dose C)
89443990|NCT05501782||Questionnaire|
89443991|NCT03331874||Basal Cell Carcinoma|Diagnosis of Basal Cell Carcinoma by Reflectance confocal microscopy
89443992|NCT05501626|Active Comparator|Active TBS arm|Patients randomized to this arm will receive active TBS 5 consecutive days of the week (Monday to Friday) in the first 3 weeks and then 2 alternate days of the week (with interval of at least 1 day between sessions) for another 3 weeks comprising 21 sections.
88927682|NCT01704937|Experimental|Colonoscopy|"Fecal microbiota transplant (stool transplant) from healthy, unrelated donor via colonoscopy"
88927683|NCT01704937|Experimental|Nasogastric Tube (NGT)|"Fecal microbiota transplant (stool transplant) from healthy, unrelated donor via NGT"
88927684|NCT01704989|Active Comparator|Laser pathway|Arm in which patients first randomised to receive SLT laser
89443993|NCT05501626|Sham Comparator|Sham TBS arm|Patients randomized to this arm will receive sham TBS 5 consecutive days of the week (Monday to Friday) in the first 3 weeks and then 2 alternate days of the week (with interval of at least 1 day between sessions) for another 3 weeks comprising 21 sections.
89443994|NCT03323996||Health Professionals|Health Professionals attending a training in therapeutic education
89443995|NCT03323996||Patients|Patients of the health Professionals recruited for the study
88927685|NCT01704989|Active Comparator|Topical therapy|Arm in which patients first selected to receive drops (Prostagladin analogue as first-line)
88927686|NCT01705002|Experimental|Cohort A: Promitil 0.5 mg/kg|Three treatment cycles, intravenous infusion of Promitil
88927687|NCT01705002|Experimental|Cohort B: Promitil 1.0 mg/kg|Three treatment cycles, intravenous infusion of Promitil
88927688|NCT01705002|Experimental|Cohort C: Promitil 1.5 mg/kg|Three treatment cycles, intravenous infusion of Promitil
88927689|NCT01705002|Experimental|Cohort D: Promitil 2.0 mg/kg|Three treatment cycles, intravenous infusion of Promitil
88927690|NCT01705002|Experimental|Cohort E: Promitil 2.5 mg/kg|Three treatment cycles, intravenous infusion of Promitil
88927691|NCT01705002|Experimental|Cohort F: Promitil 3.0 mg/kg|Three treatment cycles, intravenous infusion of Promitil
88927692|NCT01705002|Experimental|Cohort G: Promitil 3.5 mg/kg|Three treatment cycles, intravenous infusion of Promitil
88927693|NCT01705002|Experimental|Cohort H: Promitil 4.0 mg/kg|Three treatment cycles, intravenous infusion of Promitil
88927694|NCT01705002|Experimental|Expanded Cohort|"Patients treated with the selected RP2D of PROMITIL (3 mg/kg) intravenously administered on their first cycle and reduced dose of 2 mg/kg from cycle 2 and onwards.~Only for mCRC patients."
89443996|NCT05505994|Experimental|Study group|DWP16001 A mg, Dapagliflozin placebo
89443997|NCT05505994|Active Comparator|Control group|DWP16001 A mg placebo, Dapagliflozin
89443998|NCT03330080||Ecological momentary assessment (EMA)|The ecological momentary assessment (EMA) will be used for participants to complete surveys from home on two occasions each day over seven days.
89501717|NCT02255201|Active Comparator|Beverage B|Single dose, Pre-Workout Master Performance Blend Dose 2
89501718|NCT02255201|Active Comparator|Beverage C|Single dose, Pre-Workout Performance Energy Blend
89501719|NCT02255201|Active Comparator|Beverage D|Single dose, Pre-Workout Energy Blend
89501720|NCT02255201|Placebo Comparator|Beverage E|Single dose, Pre-Workout Placebo
89501721|NCT02224027|Active Comparator|i-gel|Each novice performs i-gel insertion in difficult laryngoscopy scenario.
89443999|NCT03323918|Experimental|ImPACT|Project ImPACT will be provided in 18 weekly intervention sessions, during which parents will learn how to stimulate their children's social imitation, social engagement, language and play skills. First, parents are taught techniques that promote interaction with the child (one technique per session, through demonstration and coaching). In the second half of the intervention, parents are taught direct teaching techniques, e.g., to promote language or play, again by means of demonstration and coaching. After completion of the program, families will receive guidance every 2-3 weeks for an additional 12 weeks, during which the support will generally not focus on social-communicative abilities, although ImPACT follow-up sessions might be given if necessary.
89444000|NCT03323918|Active Comparator|TAU|Treatment as usual (TAU) will be provided at the typical frequency, which is every 2-3 weeks. TAU can include targeting eating and sleeping problems, adaptive skills, or other goals. TAU will not include forms of intervention explicitly targeting social communicative skills. However, limited guidance on social communication development can be given if explicitly asked by parents.
89444001|NCT05501392|Experimental|Intervention|This group received health education, P.E. classes, child nutritional services, as well as a parent component.
89444002|NCT05501392|Active Comparator|Control|This group received their usual health education and P.E. classes.
89444003|NCT02180217|Experimental|osilodrostat (LCI699)|Consisted of a single-arm, open-label, osilodrostat dose-titration in individual patients and then osilodrostat during a double-blind, placebo controlled RW Period.
89444004|NCT02180217|Placebo Comparator|LCI699 Placebo|Consisted of a single-arm, open-label, osilodrostat dose-titration in individual patients and then placebo during a double-blind, placebo controlled RW Period.
89444005|NCT03323840|Experimental|Incentivized Care|Patients will meet with the pharmacist up to 2 times/month for blood pressure measurement. Patients will receive a $10 gift card for each measurement.
89444006|NCT05501314|Experimental|Early discharge with remote home monitoring.|"Patients are discharged early~Patients receive remote home monitoring using a wearable sensor and a smartphone app.~Patients fill in a satisfaction questionnaire"
88927695|NCT01705002|Experimental|Combination Cohort|"Patients treated with one cycle of 2.5mg/kg Promitil day 1 together with Capecitabine 1,000 mg bid po days 1-21 followed by two cycles of 2.0 mg/kg Promitil day 1 together with Capecitabine 1,000 mg bid po days 1-21, at four-week intervals.~Only for mCRC patients."
88927696|NCT01705002|Experimental|Triple combination Cohort|"Patients treated with one cycle of 2mg/kg Promitil I.v and 5 mg/kg Bevacizumab i.v on day 1 together with Capecitabine 1,000 mg bid p.o days 1-14 at four-week intervals.~Only for mCRC patients."
88927697|NCT01705002|Experimental|3 Weekly Cohort|"Patients treated with one cycle of 2mg/kg Promitil I.v and 7.5 mg/kg Bevacizumab i.v on day 1 together at three-week intervals.~Only for mCRC patients."
89013511|NCT06300372|Experimental|Group A=M-TAPA block group|M-TAPA plane block will be performed and standard postoperative pain management protocols will be applied.
89199999|NCT01048411|Placebo Comparator|Placebo|s.c. injection of placebo (NaCl-solution) three times a week
89444007|NCT03323762|Experimental|RIC|"RIC treatment arm The CellAegis auto RIC (automated blood pressure cuff) will be placed on the upper arm and inflated to 200 mmHg for 5 minutes followed by 5 minutes of deflation. The programmed cycle is repeated 4 times in total, summing up to a total treatment length of 35 minutes.~The treatment will be carried out on the morning of day 2 to day 7 by the participants themselves at their home."
89444008|NCT02491424|Experimental|Fixation of ITAP to lower limb amputees.|"Direct skeletal fixation of ITAP to lower limb amputees. 20 patients in the study will be fitted with Intraosseous Transcutaneous Amputation Prosthesis.~The device has been designed to be surgically implanted in a one stage procedure."
89444009|NCT02491268|Experimental|Cilostazol 50mg B.I.D.|"After the registration, the Site Investigators should start protocol treatment within 28 days including the day of registration.~Protocol treatment defines as follows;~Investigational Treatment:~Cilostazol 50mg B.I.D. p.o. 96 Weeks"
89444010|NCT02491268|Placebo Comparator|Placebo B.I.D.|"After the registration, the Site Investigators should start protocol treatment within 28 days including the day of registration.~Protocol treatment defines as follows;~Comparative Treatment:~Placebo B.I.D. p.o. 96 Weeks"
89444011|NCT05509504|Experimental|Intervention|
89444012|NCT05509504|No Intervention|Control|
89444013|NCT02182323|Experimental|BI 201335 in single rising doses|
89444014|NCT02182323|Placebo Comparator|Placebo|
89444015|NCT02182323|Experimental|BI 201335 NA fasted or fed|"two randomized sequences:~BI 201335 NA or placebo fasted~BI 201335 NA or placebo after high-fat breakfast"
89444016|NCT03323684|Experimental|Quadratus lumborum block Group (QL)|Quadratus lumborum block will be performed
89444017|NCT03323684|Experimental|Transversus abdominis plane Group (TAP)|Subcostal transversus abdominis plane will be performed
89444018|NCT03323684|Experimental|Control group (C)|Postoperative analgesia will be accomplished with conjunction of paracetamol and ketorolac
89444019|NCT02182401|Experimental|BI 207127 NA|fixed sequence
89444020|NCT04292080|Experimental|Group TECFIDERA™|30 patients will receive oral administration of Dimethyl Fumarate (Tecfidera™) 120 mg twice a day for the first week and then 240 mg of Tecfidera twice a day for 51 weeks following approved standard treatment scheme.
89444021|NCT04292080|Other|No comparator|30 patients will receive no specific treatment (standard of care) up to 24 months following randomization.
89444022|NCT03323606|Active Comparator|Gambling Internet Intervention|The gambling only Internet intervention (G-only) will consist of a new online version of self-change tools that have previously been translated successfully into an online form and shown to have a significant impact on gambling in three trials. A major focus of this intervention is to provide individuals with clear and concise behavioral and cognitive strategies for meeting the goal of reducing or quitting gambling.
89444023|NCT03323606|Experimental|Gambling Internet Intervention + CYD|The G+A intervention condition will consist of the G-only intervention and an online intervention for drinking. The online drinking intervention chosen is Check Your Drinking, a brief online intervention designed to provide personalized normative feedback aimed at motivating reductions in drinking
89444024|NCT02177955|Placebo Comparator|midazolan|7.5 mg midazolan 45 minutes before the surgery
89444025|NCT02177955|Placebo Comparator|diazepam|10 mg diazepam 45 minutes before the surgery
89444026|NCT04290988|Experimental|Active EEG Neurofeedback|15 sessions of active EEG neurofeedback at a frequency of 3-5 sessions per week for a duration of 3-5 weeks.
88927698|NCT01705015|Experimental|UCFit plus direct feedback about exercise|Subjects assigned to higher feedback will be encouraged to look at the summary of daily data about pedaling and will be encouraged to progress activity - more repetitions per minute (RPM range from 10-60), more frequent sessions (up to 3 times daily), longer sessions (from 5-20 minutes), and exertion against larger forces (no resistance, mild, moderate) for the legs. These subjects will also be encouraged to carry out pedaling with the upper extremities once a day, if the arms are free of lines that could be damaged. Progression of leg exercises would be within the capability and motivation of each subject, but would not exceed increments of 10% from one day to the next in any one of these parameters. Graphical displays that can be used for feedback will be available at the patient's bedside. The staff, patient and family will be able to view these bar graphs.
88927699|NCT01705015|Placebo Comparator|UCFit plus encouraged exercise|These subjects will receive a graph of the total number of minutes cycled each day and the average RPMs. The coordinator will only encourage these subjects to try to increase their total cycling time. These bar graphs will not be posted, but will be left by the bedside.
88927700|NCT01705041|Experimental|Diagnostics for All liver function test (LFT)|HIV clinic patients meeting targeted enrollment criteria will give fingerstick blood for use on investigational LFT in comparison to routine transaminase test performed at the clinic lab (gold standard)
88927701|NCT01705054||Outpatient Coronary Artery Disease Patient|CAD patients being seen in a participating cardiology office for a scheduled clinic visit who agree to take the survey.
88927702|NCT01705093|Experimental|Flavonoid-rich freeze-dried strawberry powder|50g of flavonoid-rich freeze-dried strawberry powder
88927703|NCT01705093|Placebo Comparator|macronutrient- matched control powder|50g macronutrient-matched control powder that will lack strawberry flavonoids
88927704|NCT01705171||IBS patients with fructose intolerance|analysis of biopsies
88927705|NCT01705171||Control group: no IBS or fructose intolerance|analysis of biopsies
88927706|NCT01705197|Active Comparator|Avanfil 100 or 200mg|All subjects, who are judged to be suitable to the clinical trial after 4-week free run-in period was completed, should be administered with Avanafil 100mg(study group) or placebo 100mg(control group) for the first 4 weeks after randomization. When there are no moderate to severe adverse events at the 4 weeks evaluation after administration, and when it is decided by the researcher that the effect of Avanafil or placebo 100mg against erectile dysfunction is insufficient, a dosage increase to 200mg is executed. For subjects with a sufficient improvement effect on ED at 100mg, no dosage increase is allowed, and the previous 100mg administration should be maintained until the termination of the study.
88927707|NCT01705197|Placebo Comparator|Placebo 100mg or 200mg|When there are no moderate to severe adverse events at the 4 weeks evaluation after administration, and when it is decided by the researcher that the effect of Avanafil or placebo 100mg against erectile dysfunction is insufficient, a dosage increase to 200mg is executed.
88927708|NCT01705210||Diabetes mellitus type 2 (DM2)|
88927709|NCT01705210||metabolic syndrome (MetS)|
88927710|NCT01705210||healthy controls|
88927711|NCT01705223|Experimental|group A|DNA vaccine prime at week 0,4,8 and rTV boost at week 16
88927712|NCT01705223|Experimental|group B|DNA vaccine prime at week 0,4,8 and rTV boost at week 24
88927713|NCT01705223|Experimental|group C|DNA vaccine prime at week 0,4,8 and rTV boost at week 32
88927714|NCT01705223|Experimental|group D|DNA vaccine prime with the addition of electroporation at week 0, 4, 8 and rTV boost at week 24
88927715|NCT01705249|Experimental|estradiol / norethisterone acetate|
88927716|NCT01705262||u-65 M|Male patients under 65
88927717|NCT01705262||u-65 K|Female patients under 65 years old
88927718|NCT01705262||o-65 -K|Female patients over 65 years
89444027|NCT04290988|Sham Comparator|Sham Feedback|15 sessions of sham neurofeedback at a frequency of 3-5 sessions per week for a duration of 3-5 weeks.
89501722|NCT02224027|Active Comparator|proceal laryngeal mask airway|Each novice performs proceal laryngeal mask airway insertion in difficult laryngoscopy scenario.
88927719|NCT01705262||O-65 M|Male patients over 65 years
88927720|NCT01705275|Experimental|ONO-8539 BID|ONO-8539
88927721|NCT01705275|Placebo Comparator|Placebo BID|0mg
89501723|NCT02224027|Active Comparator|tracheal tube|Each novice performs tracheal intubation in difficult laryngoscopy scenario.
89444028|NCT03323528|Active Comparator|Dorithricin|"Dorithricin throat lozenges is a fixed combination of three active substances: Benzalkonium Chloride-Benzocaine Topical plus tyrothricin. Lozenge has to be sucked slowly until it fully dissolves in the mouth and dosed up to 8 lozenges per day. Test product without mint oil.~Intervention: The initial dose is administered at the study site. Patients administer at home 1 lozenge at intervals of 2 hours (±15 minutes) up to a maximum of 8 lozenges per day."
89444029|NCT03323528|Placebo Comparator|Placebo|"Placebo Oral Tablet is taken orally. Placebo consists of a lozenge with matched appearance and the same excipients as those of the Dorithricin lozenge. The initial dose (2 lozenges simultaneously) is administered at the study site.~Intervention: Patients are instructed to administer at home 1 lozenge at intervals of 2 hours (±15 minutes) up to a maximum of 8 lozenges per day."
89444030|NCT02180295|Experimental|V212 Lot 1|Approximately 7.5 Units/0.5 mL subcutaneous injection administered in a 4-dose regimen given approximately 30 days apart
89444031|NCT02180295|Experimental|V212 Lot 2|Approximately 7.5 Units/0.5 mL subcutaneous injection administered in a 4-dose regimen given approximately 30 days apart
89444032|NCT02180295|Experimental|V212 Lot 3|Approximately 7.5 Units/0.5 mL subcutaneous injection administered in a 4-dose regimen given approximately 30 days apart
89444033|NCT05501158|Experimental|Dose adjustment of tamoxifen|Following the CPIC guidelines, those identified as Poor Metabolizers (PMs) and Intermediate Metabolizers (IMs) from our previous study are recommended to adjust their tamoxifen dosage to 40 mg per day.
89444034|NCT05501158|No Intervention|Standard dose of tamoxifen|Those identified as Normal Metabolizers (NMs) from our previous study remain on tamoxifen 20 mg per day.
89444035|NCT03329534|Experimental|Subjects with GRDs|An intervention of a change in diet, specifically a gluten free diet taught by a health care professional will be administered for one month's time.
88927722|NCT01705301||Deep Brain Stimulation|Patient's undergoing the clinical procedure of Deep Brain Stimulation will have the experimental protocol that involves, after implantation of the DBS electrodes, a single electrochemical recording electrode, from the WINCS system, implanted along the same trajectory path as the electrophysiology and the DBS electrode
88927723|NCT01704742||No treatment|
88927724|NCT01704963|Experimental|PCI-32765|Patients will receive oral doses of PCI-32765 in Cohort 1, Cohort 2 and CLL/SLL Cohort. In Cohort 1, single oral dose of PCI-32765 140 mg and 280 mg will be given before administration of daily oral doses of 420 mg per day for 35 days in Cycle 1 and for 28 days in Cycle 2 and thereafter. In Cohort 2 and CLL/SLL Cohort, PCI-32765 560 mg and 420 mg per day, respectively will be administered daily for 35 days in Cycle 1 and for 28 days in Cycle 2 and thereafter.
88927725|NCT01705314|Experimental|vitamin D supplements|children and adolescents that are randomized to the intervention will receive 7 mls of D-drops (14,000U/week of vitamin D) for eight months
88927726|NCT01705314|Placebo Comparator|vitamin D placebo|children and adolescents that are randomized to placebo will receive 7 mls of placebo drops for eight months
88927727|NCT01705327||Parkinson's Disease Subjects|
88927728|NCT01705327||Healthy Control Subjects|
88927729|NCT01705340|Experimental|Treatment (MK2206, lapatinib ditosylate, trastuzumab)|Patients receive Akt inhibitor MK2206 PO on days 1, 8, and 15; lapatinib ditosylate PO QD on days 1-21 or on days 1-3, 8-10, and 15-17; and trastuzumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
88927730|NCT01705366||Knee Arthroplasty|"Patients undergoing total knee arthroplasty. This may be Non-MAKO® Robot Assisted Total Knee Arthroplasty or MAKO® Robot Assisted Medial Knee Arthroplasty or MAKO® Robot Assisted Medial and PF Knee Arthroplasty~The Non-MAKO® Robot Assisted Total Knee Arthroplasty uses the Depuy Knee Replacement System or the Stryker® Knee Replacement System. The MAKO® Robot Assisted Arthroplasty uses the RESTORIS Multicompartmental Knee System ."
88927731|NCT01705379||MenACWY-CRM|2 years of age and older
88927732|NCT01705392|Experimental|Bevacizumab plus propranolol|Bevacizumab 10mg/kg q2w plus propranolol 80 mg x 1
88927733|NCT01705392|Experimental|Bevacizumab plus enalapril|Bevacizumab 10mg/kg q2w plus enalapril 5 mg x 1
88927734|NCT01705392|Active Comparator|Dacarbazine|Dacarbazine 1000mg/m2 q3w
88927735|NCT01705405|Experimental|medical device|medical device to acquire ultrasound and endoscopic images during surgery
88927736|NCT01705431|Experimental|Support for students with EBD|
88927737|NCT01705431|No Intervention|Control|Participants continue with services as usual
88927738|NCT01705444|Other|Foley catheter and The Spanner Insertion|Quality of life questionnaire after using the Foley catheter and the Spanner
88927739|NCT01705457|Active Comparator|with Multiple Sclerosis, vitamin A|Patients with Multiple Sclerosis confirmed Relapsing Remitting Type
89200000|NCT00765024|Active Comparator|Albendazole|Albendazole for 7 days
89444036|NCT03329534|Active Comparator|Subjects without GRDs|An intervention of a change in diet, specifically a gluten free diet taught by a health-care professional will be administered for one month's time.
89444037|NCT03323450|Experimental|High grade gliomas(WHO grade III or IV; n=15)|The two groups will follow identical study timelines. Participants will receive a 1 hour training session on CogMed® (PI or trained graduate student). Participants will complete 5 weeks of CogMed® training within their own home. It consists of 25 training sessions. Each session lasts 30-45 minutes.The study team will check in with participants once a week via phone or email. Brief neuropsychological evaluations will be conducted at 4 time points. Each assessment will take approximately 30-60 minutes. Each participant will receive a $25 gift card to the VCU medical center gift shop at two time points.
89444038|NCT03323450|Experimental|Low grade gliomas(WHO grade II; n=15)|The two groups will follow identical study timelines. Participants will receive a 1 hour training session on CogMed® (PI or trained graduate student). Participants will complete 5 weeks of CogMed® training within their own home. It consists of 25 training sessions. Each session lasts 30-45 minutes.The study team will check in with participants once a week via phone or email. Brief neuropsychological evaluations will be conducted at 4 time points. Each assessment will take approximately 30-60 minutes. Each participant will receive a $25 gift card to the VCU medical center gift shop at two time points.
89444039|NCT02182479|Experimental|Berodual® via Respimat®, high dose|
89444040|NCT02182479|Experimental|Berodual® via Respimat®, low dose|
89444041|NCT02182479|Active Comparator|Berodual® via MDI, high dose|
89444042|NCT02182479|Placebo Comparator|Placebo via Respimat®|
89444043|NCT02182479|Placebo Comparator|Placebo via MDI|
89444044|NCT02560558|Experimental|Belatacept 8-weekly|Subjects who are stable on belatacept therapy at least one year after a renal transplant will receive belatacept infusion intravenously (IV) at 5 mg/kg every 8 weeks.
89444045|NCT02560558|Active Comparator|Belatacept 4-weekly|Subjects who are stable on belatacept therapy at least one year after a renal transplant will receive belatacept infusion intravenously (IV) at 5 mg/kg every 4 weeks.
89444046|NCT03329456|Other|Ropivacaine|Single arm intervention
89444047|NCT02178033|Other|low-volume (2L) PEG|All participants will receive low-volume (2L) PEG plus ascorbic acid solution (MOVIPREP®*, Norgine, Harefield, United Kingdom); Bowel cleansing preparation is divided into two equal doses (each MOVIPREP® sachet dissolved in one liter of water, according to manufacturer's instruction). Each dose must be followed by at least 0.5 L of clear fluid at each administration, and should be taken in a maximum time of 2 hours. In this arm, both doses are taken the day before colonoscopy, starting on the evening at about 18:00. Solution intake should be completed before 22.00 h.
89444048|NCT02178033|Active Comparator|Split dose low-volume PEG solution|All participants will receive low-volume (2L) PEG plus ascorbic acid solution (MOVIPREP®*, Norgine, Harefield, United Kingdom); Bowel cleansing preparation is divided into two equal doses (each MOVIPREP® sachet dissolved in one liter of water, according to manufacturer's instruction). Each dose must be followed by at least 0.5 L of clear fluid at each administration, and should be taken in a maximum time of 2 hours. In this arm, the first dose is taken on the evening before colonoscopy (at about 20:00 h), the second one is taken early in the morning on the day of the procedure, starting about 4 h before the scheduled procedure time.
89444049|NCT02491736|Experimental|ketoprofen|2.5% ketoprofen gel
89444050|NCT02491736|Placebo Comparator|Placebo|Placebo gel
88927740|NCT01705457|Placebo Comparator|with multiple sclerosis,placebo|Patients with Multiple Sclerosis confirmed Relapsing Remitting Type
88927741|NCT01705470|Experimental|arm1|will receive 60 mg (6 ml) of intra-venous furosemide before administration of the blood transfusion (250-300 ml of packed cells).
88927742|NCT01705470|Experimental|arm2|will receive 6 ml of normal saline (NaCl 0.9%) before administration of the blood transfusion (250-300 ml of packed cells).
88927743|NCT01705483|Experimental|Part 1: ASP9853 with docetaxel|2 docetaxel dose levels and starting dose of ASP9853 followed by escalation of ASP9853 with additional dose cohorts
88927744|NCT01705483|Experimental|Part 2: ASP9853 with paclitaxel|Starting dose for ASP9853 determined as one dose level below maximum tolerated dose (MTD) determined in Part 1, 2 paclitaxel dose levels and starting dose of ASP9853 followed by escalation of ASP9853 with additional dose cohorts
88927745|NCT01705522||IBD patients|patients with ulcerative colitis or crohn's disease, in remission
88927746|NCT01705535|Experimental|Pelvic floor muscle exercises|Individual supervised pelvic floor muscle exercises. Standard information and guidance
88927747|NCT01705535|Active Comparator|Masage of the neck and back|Massage of the neck and back. Standard information and guidance
88927748|NCT01705600|Experimental|Pain Verbalization Repression Rules|This group will wear a bracelet with a set of rules which will restrict ones verbalization of pain complaints
88927749|NCT01705639|Experimental|Melatonin|melatonin 4mg od for 3 months
88927750|NCT01705665||Aspirated Coronary Thrombi During AMI|
88927751|NCT01705678|Active Comparator|Krill oil|Krill oil will be compared to fish oil as an active comparator
88927752|NCT01705678|Active Comparator|Fish oil|Fish oil 500 mg of DHA/EPA
88927753|NCT01705704||Cohort|
88927754|NCT01705743|Active Comparator|Group 1 Sevoflurane+Nitrous oxide|
88927755|NCT01705743|Active Comparator|Group 2 Sevoflurane|
88927756|NCT01705756|Placebo Comparator|Vehicle|•Patients randomized to placebo will receive syringes identical to active drug (100 mg prefilled syringes for subcutaneous injection) filled with drug vehicle
88927757|NCT01705756|Experimental|Kineret (Anakinra)|Patients randomized to active drug will receive Kineret (Anakinra), 100 mg prefilled syringes for subcutaneous injection, once a day for 4 months. The syringes will arrive relabeled from the supplier (SOBI) to Sheba Medical Center. They will be stored at the PI's store room in a temperature controlled refrigerator.
88927758|NCT01705769|Experimental|RUTF-Centrally produced|Ready to Use Therapeutic Food-Centrally produced by an Indian company
88927759|NCT01705769|Experimental|RUTF-Locally produced|Ready to Use Therapeutic Food-Locally produced by the study team at each study site
88927760|NCT01705769|Active Comparator|High energy and micronutrient rich foods|High energy and micronutrient rich foods prepared by caregivers at home using ingredients provided to them
88927761|NCT01705782|No Intervention|Saline|Only saline is given.
88927762|NCT01705782|Placebo Comparator|+ Saline|Endotoxin is given + Placebo (Saline)
88927763|NCT01705782|Active Comparator|+ amino acids|Endotoxin is given + amino acids (intravenously)
88927764|NCT01705795|Active Comparator|Mepolizumab|Mepolizumab 750 mg four times one month apart.
89444051|NCT05501080|Experimental|SAAE group|Subjects received super selective adrenal artery embolization treatment
89444052|NCT05501080|Active Comparator|Spironolactone group|Subjects received spironolactone treatment
89444053|NCT02256657|Experimental|Step 1: Toolkit Implemented in Month 4|Quality Improvement Toolkit
89444054|NCT02256657|Experimental|Step 2: Toolkit Implemented in Month 8|Quality Improvement Toolkit
89444055|NCT02256657|Experimental|Step 3: Toolkit Implemented in Month 12|Quality Improvement Toolkit
89444056|NCT02256657|Experimental|Step 4: Toolkit Implemented in Month 16|Quality Improvement Toolkit
89444057|NCT02256657|Experimental|Step 5: Toolkit Implemented in Month 20|Quality Improvement Toolkit
89444058|NCT03331406|Experimental|12-week physical activity program|"The physical activity program is of moderate intensity and consists of aerobic, strength, flexibility, and balance training with a target duration of 150 minutes per week.~At study start, participants will be provided with a pedometer to objectively monitor their aerobic activity, variable weight ankle weights and a medical journal to record physical activity.~Exercise Trainer --A exercise trainer will be assigned to design a physical activity program."
89444059|NCT04721938|Other|Intervention|Systematic weight loss intervention
88927765|NCT01705795|Placebo Comparator|Placebo|Placebo (saline) four times one month apart
88927766|NCT01705808|Experimental|Protein C concentrate|
88927767|NCT01705808|Placebo Comparator|Placebo|
88927768|NCT01705821||Skull Base Surgery Candidate|Patient with a skull base lesion will undergo use of standard surgical curette with force sensor built into shaft. 6-axis force and torque data will be collected during the surgical procedure.
88927769|NCT01705834||Arthritis patients|Patients with Rheumatoid Arthritis
88927770|NCT01705847|Experimental|GS-9820|Participants will be sequentially enrolled at progressively higher dose levels to receive GS-9820 administered twice a day. Escalation will proceed to the maximum tolerated dose (MTD), defined as the highest tested dose associated with a rate of dose-limiting toxicities (DLT) of < 33% during the first 4 weeks of therapy.
88927771|NCT01705860||Assessment|All subjects will receive same assessments.
88927772|NCT01705873||LPV/r|LPV/r based HAART
88927773|NCT01705873||Efavirenz|EFV first line based HAART
88927774|NCT01705912|Experimental|Training|Complete intervention i.e. basic intervention + individual training program.
88927775|NCT01705912|Active Comparator|Control|Basic intervention.
88927776|NCT01705938|Active Comparator|Group 1|SP-333 0.1 mg & Placebo, one tablet by mouth, single dose
88927777|NCT01705938|Active Comparator|Group 2|SP-333 0.3 mg & Placebo, 3 tablets by mouth, single dose
88927778|NCT01705938|Active Comparator|Group 3|SP-333 1 mg & Placebo, one tablet by mouth, single dose
88927779|NCT01705938|Active Comparator|Group 4|SP-333 3 mg & Placebo, 3 tablets by mouth,single dose
88927780|NCT01705938|Active Comparator|Group 5|SP-333 10 mg & Placebo, 1 tablet by mouth, single dose
88927781|NCT01705938|Active Comparator|Group 6|SP-333 30 mg & Placebo, 3 tablets by mouth, single dose
88927782|NCT01705938|Active Comparator|Group 7|SP-333 60 mg & Placebo, 6 tablets by mouth, single dose
88927783|NCT01705951|Experimental|Group 1: Resistance Training/Nicotine Replacement|
88927784|NCT01705951|Experimental|Group 2: Resistance Training only|
88927785|NCT01705951|Experimental|Group 3: Nicotine Replacement Therapy only|
88927786|NCT01705951|No Intervention|Group 4: Control; no RT and no NRT|
88927787|NCT01705990|Experimental|Group A: SeV-G(NP) followed by Ad35-GRIN|SeV-G(NP) (IN) at 2x10^7 CIU at Month 0 followed by Ad35-GRIN (IM) at 1x10^10 vp at Month 4. (Vaccine/Placebo = 12/4)
88927788|NCT01705990|Experimental|Group B: SeV-G(NP) followed by Ad35-GRIN|SeV-G(NP) (IN) at 2x10^8 CIU at Month 0 followed by Ad35-GRIN (IM) at 1x10^10 vp at Month 4. (Vaccine/Placebo = 12/4)
88927789|NCT01705990|Experimental|Group C: Ad35-GRIN followed by SeV-G(NP)|Ad35-GRIN (IM) at 1x10^10 vp at Month 0 followed by SeV-G(NP) (IN) at 2x10^8 CIU at Month 4. (Vaccine/Placebo = 12/4)
88927790|NCT01705990|Experimental|Group D: SeV-G(NP) only|SeV-G(NP) (IN) at 2x10^8 CIU at Month 0 and 4. (Vaccine/Placebo = 12/4)
88927791|NCT01706016|Experimental|Patients with breast cancer smaller than 20mm|
88927792|NCT01706042|Placebo Comparator|white bread|White bread (based on 35 g available carbohydrates)
88927793|NCT01706042|Active Comparator|Legume meal|Legumes are consumed as a late evening meal(based on 35 g available carbohydrates)
88927794|NCT01706055||Group 1|
88927795|NCT01706094|Experimental|lying flat head position|positioning the head of the bed at zero degrees during the first 48 hours from admission of patients with acute ischemic stroke Active Comparator: upright position of the head of the bed during 48 hours from admission of patients with acute ischemic stroke
88927796|NCT01706133|No Intervention|Basal phase|Integrated measurement of all variables involved impact and frequency of prior use of health services and specifically to the emergency room, service access, patient characteristics, features for the classification of frailty, cognitive impairment and depression, why consultation, triage scale level on admission to the service and to the service variables in terms of length of stay, diagnosis and medical management, and related services with internal consultants percentage of inpatients discharged or deceased, in further analysis the researchers undertake group estimating frequency of use and the identification of factors associated with the use of emergency departments and adverse events
88927797|NCT01706172|Active Comparator|Dextrose 20 % Injection|Injecting 20 % Dextrose and 0.2 % lidocaine intra-articularly into the TM Joint
88927798|NCT01706172|Active Comparator|Sterile Water Injection|Injection of Sterile water in 0.2 % lidocaine intra-articularly into the TM joint
88927799|NCT01706185||Cancer Group|
88927800|NCT01706211|Experimental|BRL 49653C|Eligible patients may enter the study at visit 1 according to the inclusion/exclusion criteria. At the screening visit, patients will enter a single blind placebo run-in period to establish baseline characteristics. Patients must have been stable on sulphonylurea therapy for at least 2 months prior to the screening visit to be included. For the duration of the run-in period, patients will receive BRL 49653C placebo in addition to their constant dose of sulphonylurea. Patients eligible to enter the double-blind phase of the study will be randomized in equal numbers at visit 2, to one of two treatment groups (BRL 49653C 2 mg bid. or placebo bid). Patients will then continue to take their study medication arid the constant dose of sulphonylurea through visits 3 to 8 (weeks 4 to 24).
88927801|NCT01706211|Placebo Comparator|placebo|Eligible patients may enter the study at visit 1 according to the inclusion/exclusion criteria. At the screening visit, patients will enter a single blind placebo run-in period to establish baseline characteristics. Patients must have been stable on sulphonylurea therapy for at least 2 months prior to the screening visit to be included. For the duration of the run-in period, patients will receive BRL 49653C placebo in addition to their constant dose of sulphonylurea. Patients eligible to enter the double-blind phase of the study will be randomized in equal numbers at visit 2, to one of two treatment groups (BRL 49653C 2 mg bid. or placebo bid). Patients will then continue to take their study medication arid the constant dose of sulphonylurea through visits 3 to 8 (weeks 4 to 24).
88927802|NCT01706224||Group A|Subjects in this group will be all physicians actively working at hospital centres in Spain.
88927803|NCT01706224||Group B|Subjects in this group will be all nurses actively working at hospital centres in Spain.
88927804|NCT01706224||Group C|Subjects in this group will be all ancillary nursing professionals actively working at hospital centres in Spain.
88927805|NCT01706224||Group D|Subjects in this group will be all midwives actively working at hospital centres in Spain.
88927806|NCT01706237|Experimental|Shield|A shield (similar to a contact lens) is placed on the eye after myopic LASIK procedure.
89013512|NCT06300372|Active Comparator|Group B = control group|Only standard postoperative pain management protocols will be applied. No plane blocks will be applied
89013513|NCT06300346|Active Comparator|propofol|30 Patients will receive propofol as equal volumes of both 1% of propofol 10mg/ml and0.9% normal saline will be drawn in a 20-ml syringe before spinal puncture.
89013514|NCT06300346|Active Comparator|pregabalin|30 Patients will receive three capsules of pregabalin 100 mg once one hour before the surgical incision.
89013515|NCT06300346|Active Comparator|ondansetron|30 Patients will receive 4 mg ondansetron in 10 ml saline intravenously 5 min before spinal puncture.
89013516|NCT06300320|Experimental|TQ05105 Tablets|TQ05105 Tablets administered twice-daily. 28 days as a treatment cycle.
89013517|NCT06300307|Experimental|ATX-01|ATX-01 is a formulation of the anti-microRNA 23b (anti-miR-23b), known as X82108, a novel type of antisense oligonucleotide
89013518|NCT06300307|Placebo Comparator|Placebo|Placebo to ATX-01
89444060|NCT02491970|Experimental|Fluticasone/Formoterol|Brand name: Flutiform Dose: 250/10μg (2 puffs/once, BID) Duration of treatment: 12 weeks Mode of administration: oral inhalation
89444061|NCT02491970|Active Comparator|Fluticasone/Salmeterol|Brand name: Seretide Dose: 250/50μg (2 puffs/once, BID) Duration of treatment: 12 weeks Mode of administration: oral inhalation
89444062|NCT02491814|Experimental|1% M.F. Milk and Breakfast Cereal|Breakfast meal: 250 ml 1% M.F. Milk, 54 g Cheerios breakfast cereal, 100 mL water
89444063|NCT02491814|Experimental|Yogurt Beverage and Breakfast Cereal|Breakfast meal: 250 ml Yogurt Beverage, 54 g Cheerios breakfast cereal, 100 mL water
89444064|NCT02491814|Experimental|Soy Beverage and Breakfast Cereal|Breakfast meal: 250 ml Soy Beverage, 54 g Cheerios breakfast cereal, 100 mL water
89444065|NCT02491814|Experimental|Almond Beverage and Breakfast Cereal|Breakfast meal: 250 ml Almond Beverage, 54 g Cheerios breakfast cereal, 100 mL water
89444066|NCT02491814|Experimental|Water (control) and Breakfast Cereal|Breakfast meal: 250 ml Water, 54 g Cheerios breakfast cereal, 100 mL water
89444067|NCT02182557|Experimental|WAL 801 CL Dry Syrup + Placebo|
89444068|NCT02182557|Active Comparator|Ketotifen Fumarate Dry Syrup + Placebo|
89444069|NCT02182635|Experimental|Ba253BINEB|
89444070|NCT02182713|Experimental|Arm 1 - CombiventTM followed by Salbutamol|
89444071|NCT02182713|Active Comparator|Arm 2 - Salbutamol followed by CombiventTM|
89444072|NCT02490644||MGB1 in valvular heart surgery|Evaluation of the high mobility group box 1 as a prognostic biomarker in patients undergoing valvular heart surgery
89444073|NCT02180373||vein graft bypass|patients who have had peripheral bypass
89444074|NCT02180373||SFA stent|Patients who have had SFA stenting
89444075|NCT03331328|Sham Comparator|Control/sham|The CO2 laser will not be activated but the same procedure of moving the probe inside the vagina in a systematic manner including depressing the foot pedal at similar frequency will be performed. The smoke evacuator will also be activated, laser eye glasses and masks worn by the laser team and the subject. However, the laser will remain in the standby mode.
89444076|NCT03331328|Active Comparator|Treated|Active arm subjects will be treated intravaginally with the fractional microablative CO2 laser system (SmartXide 2 V 2 LR, MonaLisa Touch, DEKA, Florence, Italy), using the following setting: dot power 30 watt, dwell time 1000 μs, dot spacing 1000 μm and the smart stack parameter from 1 to 3. For the vulva, the dot power will be reduced to 26 watts, dwell time 800 μs, dot spacing 800 μm and the smart stack parameter of 1.
89444077|NCT03323372|Active Comparator|control group|In group 1 (G1-control), the operator applied a desensitizing gel based on 5% potassium nitrate and 2% sodium fluoride (Desensibilize KF 2% ®, FGM , Joinville, Santa Catarina, Brazil) with the aid of a custom silicone tray, which was made from a model obtained from the patient, with a vacuum plasticizer. A small layer of the gel was placed on the surface of the tray that was in contact with the vestibular face of the upper anterior teeth of the participants. The tray remained in position in the mouth for 10 minutes, according to the manufacturer's specifications.
89444078|NCT03323372|Experimental|experimental group|In group 2 (G2-intervention group), the operator applied a desensitizing gel containing 3% potassium nitrate and 0.25% sodium fluoride (Ultra EZ®, Ultradent Products Inc, South Jordan, UT, Estados Unidos) with the help of a tray in which the material is stored on the vestibular surfaces of the upper anterior teeth of the participants. The tray remained in position in the mouth for 15 minutes, according to the manufacturer's specifications.
89444079|NCT02178111|Experimental|Never perform episiotomy|In this group the birth attendant will sought to avoid the use of episiotomy, and try not to carry out the procedure unless considered absolutely needed
89013521|NCT06300281|Experimental|Neuromuscular Exercise Group|A 12-week Neuromuscular exercise program consisting of sensorimotor system training, postural stability and control, global and local joint stabilization, balance training, muscle strength, breathing, and functional movement patterns will be created for the participants in Group 1.
89013522|NCT06300281|Experimental|Aquatic Exercise Group|Group 2 will undergo a 12-week aquatic exercise program at Alanya Alaaddin Keykubat University in a 140 cm deep pool and 32-degree water temperature.
89444080|NCT02178111|Active Comparator|Selective episiotomy|Patients will be subjected to the usual routine (selective episiotomy, ie, in the presence of indications described in the literature, according to the discretion of the physician or nurse assisting the birth)
89444081|NCT03329222|Experimental|Intervention group|An infant formula which contains specific hydrolysed proteins with a fat blend, prebiotics mixture, starch and reduced lactose
89444082|NCT03329222|Active Comparator|Control group|Standard cow's milk with prebiotics mixture
89444083|NCT05509426|Experimental|Intervention Group|This group will receive an online cognitive rehabilitation programme, offered in addition to usual clinical care, to groups of 4-6 participants weekly for 10 sessions.
89013523|NCT06300268|Other|Interventional|AdvaPro Sirolimus Eluting Coronary Stent System
89013524|NCT06300255||H.O.O.V.E.S. Healing Intensives Participants|Veterans enrolled in a H.O.O.V.E.S. healing intensives program and must have served in the military.
89013525|NCT06300242|Experimental|Message Only|Patients sent an email or SMS reminding them to get vaccinated against the flu.
89013526|NCT06300242|Experimental|Message + Financial Incentive|Patients sent an email or SMS reminding them to get vaccinated against the flu and offering them a $50 financial incentive if they are vaccinated within 1-week.
89013527|NCT06300242|Active Comparator|Active Control|Patients not sent any reminder message.
89444084|NCT05509426|No Intervention|Usual Clinical Care|This group will receive only their usual clinical care, which may include information on cognitive problems as per clinical practice but not specific cognitive rehabilitation.
89444085|NCT02180529|Experimental|Methylphenidate|On the intervention days (days 2-4) participants will undergo cognitive assessment at 9:00 in the morning, followed by the administration (at 10:30) of different doses of Ritalin (10, 20 and 30mg) every day of intervention. Two hours after taking the drug participants will be assessed cognitively by means of Mindstreams and MoCA (Montreal Cognitive Assessment).
88927807|NCT01706289||diabetic mellitus screen|
88927808|NCT01706302||Cohort Group|
88927809|NCT01706315|Experimental|Cohort 1 - GSK2140944 400 mg|Subjects will be randomized in 6:2 ratio to receive either GSK2140944 (Day 1: Single oral dose Days 3 to 16: (14 Days) BID oral doses) or placebo for approximately 15 days
88927810|NCT01706315|Placebo Comparator|Cohort 1 - Placebo|Subjects will be randomized in 6:2 ratio to receive either GSK2140944 BID or matching placebo for approximately 15 days
88927811|NCT01706315|Experimental|Cohort 2 - GSK2140944 800 mg|Subjects will be randomized in 12:4 ratio to receive either GSK2140944 (Day 1: Single oral dose Days 3 to 16: (14 Days) BID oral doses) or placebo for approximately 15 days. GSK2140944 dose in Cohort 2 will be decided based on the safety and PK data from six subjects in Cohort 1
88927812|NCT01706315|Placebo Comparator|Cohort 2 - Placebo|Subjects will be randomized in 12:4 ratio to receive either GSK2140944 BID or matching placebo for approximately 15 days
88927813|NCT01706315|Experimental|Cohort 3 - GSK2140944 1500 mg|Subjects will be randomized in 12:4 ratio to receive either GSK2140944 (Day 1: Single oral dose Days 3 to 16: (14 Days) BID oral doses) or placebo for approximately 15 days. GSK2140944 dose in Cohort 3 will be decided on the safety data and available PK data from at least 12 subjects dosed at the Cohort 2
88927814|NCT01706315|Placebo Comparator|Cohort 3 - Placebo|Subjects will be randomized in 12:4 ratio to receive either GSK2140944 bid or matching placebo for approximately 15 days
88927815|NCT01706315|Experimental|Cohort 4 - GSK2140944 2500 mg|Subjects will be randomized in 12:4 ratio to receive either GSK2140944 (Day 1: Single oral dose Days 3 to 16: (14 Days) BID oral doses) or placebo for approximately 15 days. GSK2140944 dose in Cohort 4 will be decided on the safety data and available PK data from at least 12 subjects dosed at the Cohort 3
88927816|NCT01706315|Placebo Comparator|Cohort 4 - Placebo|Subjects will be randomized in 12:4 ratio to receive either GSK2140944 bid or matching placebo for approximately 15 days
88927817|NCT01706315|Experimental|Cohort 5 - GSK2140944 TBD|Subjects will be randomized in 6:2 ratio to receive either GSK2140944 (Day 1: Single oral dose Days 3 to 16: (14 Days) TID oral doses) or placebo for approximately 15 days. GSK2140944 dose in Cohort 5 will be decided on the safety data and available PK data from at least 12 subjects dosed at the Cohort 4
88927818|NCT01706315|Placebo Comparator|Cohort 5 - Placebo|Subjects will be randomized in 6:2 ratio to receive either GSK2140944 TID or matching placebo for approximately 15 days
88927819|NCT01706315|Experimental|Cohort 6 - GSK2140944 TBD|Subjects will be randomized in 6:2 ratio to receive either GSK2140944 (Day 1: Single oral dose Days 3 to 16: (14 Days) TID oral doses) or placebo for approximately 15 days. GSK2140944 dose in Cohort 5 will be decided on the safety data and available PK data from at least 6 subjects dosed at the Cohort 5
88927820|NCT01706315|Placebo Comparator|Cohort 6 - Placebo|Subjects will be randomized in 6:2 ratio to receive either GSK2140944 TID or matching placebo for approximately 15 days
88927821|NCT01706341|Active Comparator|acetate Ringer's solution|Administering acetate Ringer's solution that contains no glucose as an initial infusion A total infusion volume of acetate Ringer's solution is 1500ml
88927822|NCT01706341|Active Comparator|acetate Ringer's solution with 1% glucose|Administering the acetate Ringer's solution that contains 1% glucose as an initial infusion A total infusion volume of the acetate Ringer's solution containing 1% glucose is 1500ml (containing 15g of glucose)
88927823|NCT01706354|Active Comparator|Local anaesthetic|Infiltration of local anaesthetic into the surgical site by the surgeon using a combination of 0.5% L-bupivicaine prior to incision and 1% lignocaine topically after the wound is opened. Maximum dose limits of 2mg/kg for bupivicaine, and 3mg/kg for lignocaine will be observed, recognising that these are additive.
88927824|NCT01706354|Experimental|Regional anaesthetic|Ultrasound guided brachial plexus block. Supraclavicular will be the block performed unless there is a contraindication in which case axillary block may be used. A 1:1 mixture of 0.5% L-bupivicaine and 1.5% lignocaine with adrenaline (1 in 200,000) will be injected, up to a volume of 40ml but using a minimum of 25ml. Maximum dose limits of 2mg for bupivicaine and 7mg/kg for lignocaine with adrenaline will be observed, recognising that these are additive.
89200001|NCT00765024|Experimental|ivermectin|ivermectin 200 mcg/kg single dose
89200002|NCT00765024|Experimental|ivermectin 2 doses|ivermectin 200 mcg/kg two doses in 2 weeks
88927825|NCT01706367|Experimental|Low dose C diff vaccine|
88927826|NCT01706367|Experimental|Low dose C diff vaccine + adjuvant|
88927827|NCT01706367|Experimental|Mid dose C diff vaccine|
88927828|NCT01706367|Experimental|Mid dose C diff vaccine + adjuvant|
88927829|NCT01706367|Experimental|High dose C diff vaccine|
88927830|NCT01706367|Experimental|High dose C diff vaccine + adjuvant|
88927831|NCT01706380|Experimental|Interactive voice response with personal feedback|Interactive voice response follows the client twice weekly for 3 months with respect to symptoms and substance use, in both arms. This intervention group also receives a personalized and automated feedback describing whether the symptom status of the patient is better, worse or equal, compared to the preceding follow-up.
88927832|NCT01706380|Active Comparator|Interactive voice response without personal feedback|This control group is also followed with identical interactive voice response follow-up, addressing symptoms and substance use, but without the personal feedback.
88927833|NCT01706393|Experimental|probiotics|"Probiotics supplementation group. Probiotics intake for 6 weeks(including 5weeks of Rtx) and it take one tablet twice a day.~Probiotics is composed of Lactobacillus acidophilus, Streptococcus thermophilus, Bifidobacterium lactis, L. rhamnosus, B. longum and B. bifidum."
88927834|NCT01706393|Placebo Comparator|placebo|"Placebo group. Placebo intake for 6 weeks(including 5weeks of Rtx) and it take one tablet twice a day.~Placebo is composed of starch.Probiotics and placebo were similar in appearance, taste."
88927835|NCT01706406|Experimental|1 treatment|"Women randomized into the treatment group will undergo pre-treatment testing (questionnaires and physiological assessment)within 14 days of beginning treatment"
88927836|NCT01706406|Other|2 waitlist|"Women randomized to the waitlist group will undergo initial testing (questionnaires and physiological testing) and receive no treatment until the next scheduled group (4 months). They will undergo pretreatment testing and treatment on the same schedule as women in the treatment group."
88927837|NCT01706419|No Intervention|no school meal|control group receiving no school meal
88927838|NCT01706419|Placebo Comparator|normal school meal|school meal without fortified rice, placebo group
88927839|NCT01706419|Experimental|cold extruded fortified rice|school meal with fortified rice using cold extrusion kernels
88927840|NCT01706419|Experimental|warm extrusion|school meal with fortified rice using warm extrusion kernels
88927841|NCT01706419|Experimental|hot extruded|school meal with fortified rice using hot extrusion kernels
88927842|NCT01706445|No Intervention|Control|
88927843|NCT01706445|Other|intervention|Exercise training
88927844|NCT01706471|Experimental|Everolimus + Low dose CsA +PD|
88927845|NCT01706471|Active Comparator|Myfortic+ Standard CsA + PD|
88927846|NCT01706484|Experimental|80 mg BNO 1016 und placebo|2 tablets (one containing 80 mg BNO 1016 and one placebo) by mouth 3 times daily
88927847|NCT01706484|Experimental|160 mg BNO 1016|2 tablets (each containing 80 mg BNO 1016) by mouth 3 times daily
88927848|NCT01706484|Placebo Comparator|placebo|2 tablets (each without BNO 1016) by mouth 3 times daily
88927849|NCT01706510|Experimental|Ticagrelor|Ticagrelor 180 mg loading dose followed by 90 mg bid for 7 days ± 2 days
88927850|NCT01706510|Active Comparator|Clopidogrel|Clopidogrel 600 mg Loading Dose followed by 75 mg Daily for 7 days ± 2 days
88927851|NCT01706523|Experimental|STX209|Active treatment with STX209
88927852|NCT01706562||Itraconazole|
88927853|NCT01706601||Hemorrhoids|Patient with hemorrhoids
88927854|NCT01706627|Placebo Comparator|Matched placebo|Matched placebo (identical formulation and delivery, without active ingredient)
88927855|NCT01706627|Active Comparator|Drug: 10 mg Melatonin|10 mg melatonin gelatin capsule
88927856|NCT01706627|Active Comparator|Drug: 20 mg Melatonin|20 mg melatonin gelatin capsule
88927857|NCT01706653|Active Comparator|Intervention 1|Polyphenol-enriched fruit-based drink - low
88927858|NCT01706653|Active Comparator|Intervention 2|Polyphenol-enriched fruit-based drink - medium
88927859|NCT01706653|Active Comparator|Intervention 3|Polyphenol-enriched fruit-based drink - high
88927860|NCT01706653|Placebo Comparator|Intervention 4|Very low polyphenol fruit based drink (control)
88927861|NCT01706679|Active Comparator|Maximum therapeutic dose of ATX-101|ATX-101 10 mg/ml
88927862|NCT01706679|Active Comparator|Supratherapeutic dose of ATX-101|ATX-101 20 mg/ml
88927863|NCT01706679|Active Comparator|Moxifloxacin|moxifloxacin (400mg)
88927864|NCT01706679|Placebo Comparator|Placebo vehicle|placebo vehicle (PBS)
88927865|NCT01706718|Placebo Comparator|Control white bread|
88927866|NCT01706718|Experimental|Beetroot bread|
88927867|NCT01706731|Active Comparator|TAU plus Cognitive-behavioral Therapy|Participants randomized to this group will receive treatment as usual plus cognitive behavioral therapy (CBT) provided by trained Buddhist monks.
88927868|NCT01706731|Sham Comparator|TAU plus routine counselling|Participants randomized into this group will receive treatment as usual (TAU) plus plus routine psychological support from non-CBT monks.
88927869|NCT01706744|Experimental|Intermediate care unit|Follow-up treatment and care in a intermediate care unit after discharge from hospital
88927870|NCT01706744|Active Comparator|Local health care 1|Discharge from hospital to usual care as provided by the local health and social care (Verdal)
88927871|NCT01706744|Active Comparator|Local health care 2|Discharge from hospital to usual care as provided by the local health and social care (Stjørdal)
88927872|NCT01706757|Experimental|with go-cart|conducts exercises with the help of a go-cart
88927873|NCT01706757|No Intervention|without go-cart|conduct exercises without go-cart
88927874|NCT01706783|Experimental|NNC0195-0092 (somapacitan)|
88927875|NCT01706783|Active Comparator|Norditropin NordiFlex®|
88927876|NCT01706796|Experimental|PF-06273340 Oral Solution Fasted|
88927877|NCT01706796|Experimental|PF-06273340 Immediate Release Tablet Fasted|
88927878|NCT01706796|Experimental|PF-06273340 Modified Release (MR1) Tablet Fasted|
88927879|NCT01706796|Experimental|PF-06273340 Modified Release (MR2) Tablet Fasted|
88927880|NCT01706796|Experimental|PF-06273340 Modified Release (MR1) Tablet Fed|
88927881|NCT01706796|Experimental|PF-06273340 Modified Release (MR2) Tablet Fed|
88927882|NCT01706809||Biomarkeres|
89200003|NCT00965536||1|Seroquel
89444086|NCT02180529|Placebo Comparator|Placebo|Participants in the control group will receive placebo. On the intervention days (days 2-4) participants will undergo cognitive assessment at 9:00 in the morning, followed by the administration (at 10:30) of Placebo every day of intervention. Two hours after taking the placebo participants will be assessed cognitively by means of Mindstreams and MoCA (Montreal Cognitive Assessment).
89444087|NCT04412122|Experimental|Kinesio Taping|Kinesio taping is thought to remove the barriers that slow the healing process, activate neurological suppression and reduce pain (El-Refayea, El Nahasa & Ghareebb, 2016; Kamali, Sinaei & Taherkhan, 2018). Kinesio tape stimulates cutaneous mechanoreceptors. Mechanoreceptors decrease sympathetic nervous system activity and increase parasympathetic activity, which can improve intestinal control (Azam, 2017; Szczegielniak, Krajczy, Bogacz, Luniewski & Sliwinski, 2007). Kinesio taping changes skin contours and accelerates blood flow. Increased blood flow brings more oxygen and nutrients to the area. This phenomenon contributes to the natural healing process (Kafa et al., 2015).
89444088|NCT04412122|Experimental|Breathing Exercise|Breathing exercise is accepted as a key to relaxation or cooling down (El-Refayea et al., 2016). It is stated that breathing exercises reduce anxiety by preventing the transmission of pain messages to the spinal cord (Rejeh et al., 2013), reducing the catecholamine response (Rakel & Herr, 2004) and muscle tension by distracting subjects (Kelle, Güzel & Sakallı, 2016).
89444089|NCT04412122|Experimental|Kinesio Taping and Breathing Exercise|According to the application protocols, two applications were made together.
89444090|NCT04412122|Other|Control Group|No intervention was performed to reduce pain in the control group.
89444091|NCT02178189|Active Comparator|Standard-calorie infant formula|Infants assigned to this arm were fed standard-calorie infant formula (20 kcal/oz) from 72 hours of life until 21 days of age.
89444092|NCT02178189|Experimental|High-calorie infant formula|Infants assigned to this arm were fed high-calorie infant formula (24 kcal/oz) from 72 hours of life until 21 days of age.
88927883|NCT01706848|Active Comparator|Celotres|Scar halves randomized to treatment with device, opposite side treated per standard of care.
89444093|NCT03323216||No diabetes|Patients without diabetes
89444094|NCT03323216||Type 2 diabetes|Patients with diagnosis of type 2 diabetes (new/established)
89444095|NCT03323216||Prediabetes|Patients with an intermediate state of hyperglycemia with glycemic parameters above normal but below the diabetes threshold.
89444096|NCT02180607||Healthy Controls|Response to social feedback, monetary incentive delay, and go/no-go tasks
89444097|NCT02180607||MDD patients|Response to social feedback, monetary incentive delay, and go/no-go tasks
89444098|NCT02182791|Experimental|Nevirapine tablets|"once a day (q.d.) Day 2-15,~twice a day (b.i.d.) Study day 16-30"
89444099|NCT02182791|Active Comparator|EE/NET tablets|Single dose on Study Day 0 and 30
89444100|NCT03329144|Experimental|Cognitive Behavioural Therapy|The women in this arm will receive a 9-week CBT-based curriculum delivered by Public Health Nurses to help build resilience and optimize mood, anxiety, and emotion regulation while attending a supported school program in Niagara Region.
88927884|NCT01706848|Active Comparator|Standard surgical wound closure|Scar halves randomized to treatment with device, opposite side treated per standard of care.
88927885|NCT01706861|Other|Celotres|Celotres following surgical removal of earlobe keloid.
89444101|NCT03329066|Experimental|MAST - Managing Asthma & Sleep in Teens|This is an eight week intervention consisting of 4 group and 4 individual tailored coaching sessions that focuses on both asthma and sleep. In this behavioral medicine intervention, teenagers learn ways to better care for their asthma and sleep hygiene. Teen sessions are delivered in school. Their caregivers will receive four educational booklets that correspond to each group session; topics mirror the objectives of each group and the booklets are sent at the time of each group.
89444102|NCT03329066|Active Comparator|ASMA - Asthma Self-Management for Adol|ASMA is an evidence-based intervention for students, caregiver education, and education for students' medical providers. The student intervention consists of 3 group sessions & 5 individual tailored coaching sessions. All sessions are held at school. The caregiver intervention includes 3 educational booklets that correspond to the timing of the student group and 4 brief telephone-counseling sessions to review the booklets, answer questions, and provide strategies to support adolescents' steps to care for their asthma. With caregiver permission, we mail students' healthcare providers a toolkit consisting of (1) a letter informing them their patient is participating in ASMA and is being directed to them for clinical evaluation and (2) summaries of key NHLBI guidelines for treating asthma.
88927886|NCT01706874||Periodontal prophylaxis|Periodontal prophylaxis (standard of care) versus control in rheumatoid arthritis patients.
88927887|NCT01706874||Control|Periodontal prophylaxis (standard of care) versus control in rheumatoid arthritis patients
88927888|NCT01706887|Experimental|Diet Amiloride|One week Low Na diet (10 mmol/d) followed by ine week high Na diet (200 mmol/d) followed by 2 weeks administration of amiloride (10 mg the 1 st week and the 20mg).
88927889|NCT01706900|Placebo Comparator|Incubator Temp 37 degree|We will set incubator Temp to 37 degree as the routine embryo culture Temp since 1978 as the placebo arm.
88927890|NCT01706900|Experimental|Incubator Temp set to 36.5 degree|We will set incubator Temp to 36.5 so we can assess the outcome and compare the results with the placebo group.
88927891|NCT01706991||Normal Controls|Structurally normal eye with equal visual acuity and normal stereopsis.
89013528|NCT06300216||Octreotide microspheres standard dose monotherapy|
89013529|NCT06300216||Octreotide microspheres standard dose combination therapy|
89013530|NCT06300216||Octreotide microspheres incremental or increased frequency therapy|
89013531|NCT06300216||Octreotide microspheres maintenance therapy after targeted or chemotherapy|
89200004|NCT00965536||2|Seroquel Prolong
88927892|NCT01706991||Referral required|"Diagnosed with amblyopia or constant strabismus, categorized based on the GSE.~Amblyopia:~VA <20/40 and 2 logMAR lines difference in normal eye~Mild amblyopia (>20/40)~Moderate amblyopia (20/40 and <20/100)~Severe amblyopia (≥20/100 or worse)~Bilateral amblyopia: >4 years age VA<20/40 OU including high hyperopia or high astigmatism.~Strabismus:~Constant: >2 PD at near and or distance.~Intermittent: strabismus that could be controlled intermittently either through fusional mechanisms or a compensatory head position.~Amblyogenic factor categorization:~'Anisometropia'- (1.5 Diopters (D) or more difference in refractive error between the two eyes.~'hypermetropia' (≥3.5 D),~'myopia' (≥-4.0 D),~'astigmatism' (≥1.5 D).~'structural abnormalities' of the eye will not be excluded, but will be considered to have vision loss if visual acuity is 20/40 or worse."
88927893|NCT01706991||Borderline|(no long-term harm to patient if referral is delayed, however the patient does have conditions that might benefit from monitoring): Equal visual acuity and no structural abnormality with any of the following: Amblyogenic factor, intermittent strabismus, structural abnormalities, refractive error, reduced stereopsis.
88927894|NCT01707017|Active Comparator|High-load strength training|
88927895|NCT01707017|Active Comparator|Low-load strength training|
88927896|NCT01707017|Active Comparator|Low-load + moderate-load strength training|
88927897|NCT01707056|Active Comparator|Black coffee|Synthroid will be administered with 12 ounces of black coffee for a period of 6 weeks.
88927898|NCT01707056|Active Comparator|Coffee with Milk|Synthroid will be administered with 12 ounces of coffee and 2 ounces of 2% milk for a period of 6 weeks.
88927899|NCT01707056|Active Comparator|Black Tea|Synthroid will be administered with 12 ounces of black Lipton tea for a period of 6 weeks.
88927900|NCT01707056|Placebo Comparator|Water|Synthroid will be administered with 12 ounces of water for a period of 6 weeks.
88927901|NCT01707069|Experimental|Group 1: 4mg CryJ2-DNA-LAMP plasmid vaccine|"Healthy male and female subjects 18 to 63 years of age, who are skin test negative to Japanese Red Cedar pollen or Mountain Cedar pollen and have no reactive Cry J 2 antibodies.~Group 1: will receive 4mg of Biological/Vaccine: CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection (considered to be the optimal DNA vaccine dose based on historical clinical data from other DNA vaccine studies). The dosing regimen for this group will be to receive three (3) additional booster doses (4 doses in total) of a 4 mg dose at 14 day intervals."
88927902|NCT01707069|Experimental|Group 2: 2mg CryJ2-DNA-LAMP plasmid vaccine|"Healthy male and female subjects 18 to 63 years of age, who have lived in Japan, are Skin test positive to Japanese Red Cedar pollen or Mountain Cedar pollen and/or have reactive Cry J 2 antibodies, and have a history of allergic rhinitis symptoms during the Japanese Red Cedar or Mountain Cedar season will receive a total of four half (2 mg) dose dosing regimen.~Group 2: will receive 2 mg Biological/Vaccine: CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection(considered ½ of the optimal plasmid vaccine dose based on historical clinical data from studies with other antigens). The dosing regimen for this group will be to receive three (3) additional 2 mg doses at 14 day intervals between doses (4 doses in total)."
88927903|NCT01707069|Experimental|Group 3: 4 mg CryJ2-DNA-LAMP plasmid vaccine|"Healthy male and female subjects 18 to 63 years of age, who have lived in Japan, are Skin test positive to Japanese Red Cedar pollen or Mountain Cedar pollen and/or have reactive Cry J 2 antibodies, and have a history of allergic rhinitis symptoms during the Japanese Red Cedar or Mountain Cedar season will receive a total of four full (4 mg) dose dosing regimen.~Group 3: will receive 4 mg Biological/Vaccine: CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection (considered the optimal plasmid vaccine dose based on historical clinical data from studies with other antigens). The dosing regimen for this group will be to receive 3 additional 4 mg doses at 14 day intervals between doses (4 doses in total)."
88927904|NCT01707082|Experimental|Part A Cohort 1|
88927905|NCT01707082|Experimental|Part A Cohort 2|
88927906|NCT01707082|Experimental|Part A Cohort 3|
88927907|NCT01707082|Experimental|Part A Cohort 4|
88927908|NCT01707082|Experimental|Part A Cohort 5|
88927909|NCT01707082|Experimental|Part B Cohort 1|
88927910|NCT01707082|Experimental|Part B Cohort 2|
88927911|NCT01707121||Surgical patients|Patients with planned surgery for breast cancer, colorectal cancer and gall bladder disease
88927912|NCT01707134|Experimental|insulin aspart|
88927913|NCT01707134|Active Comparator|human insulin|
88927914|NCT01707160|Experimental|Treatment period 1|
88927915|NCT01707160|Active Comparator|Treatment period 2|
89444103|NCT03329066|Placebo Comparator|Information & Referral Control Group|The information-and-referral control intervention is a student-only intervention that consists of 3 group sessions and 5 individual sessions. Sessions are held once a week at school, where students will receive guideline-based information about asthma and other health topics relevant to adolescents (e.g., nutrition, safety). Students will be referred to their medical providers for asthma and other health concerns; if they do not have a provider, they are given referrals in their community.
89444104|NCT03536325|Experimental|Cohort 1: Guselkumab Dose 1 or Placebo|Participants will receive Dose 1 of guselkumab or matching placebo as an intravenous (IV) infusion on Day 1.
89444105|NCT03536325|Experimental|Cohort 2: Guselkumab Dose 2 or Placebo|Participants will receive Dose 2 of guselkumab or matching placebo as an IV infusion on Day 1.
89444106|NCT03536325|Experimental|Cohort 3: Guselkumab Dose 3 or Placebo|Participants will receive Dose 3 of guselkumab or matching placebo as an IV infusion on Day 1 based on safety data results received from Cohort 1 and 2.
89444107|NCT03536637|Experimental|Study Treatment 1|DMT310 Powder mixed with Hydrogen Peroxide
89444108|NCT03536637|Experimental|Study Treatment 2|DMT310 Powder mixed with Placebo Diluent
89444109|NCT03536637|Experimental|Study Treatment 3|Placebo powder mixed with Hydrogen Peroxide
89444110|NCT03536637|Placebo Comparator|Control|Placebo powder mixed with Placebo Diluent
89444111|NCT02488538|Active Comparator|Combined oral contraceptives and Fuoxetine|Group 1 will receive COC containing drospirenone (drospirenone 3mg+Ethinylestradiol 0.03mg; Yasmin® ScheringAG, Egypt) daily for 21 days starting from the 3rd day of menstruation in addition to oral fluoxetine 20 mg daily. .
89013532|NCT06300203|Experimental|Interleukin-4 receptor responders|Interleukin-4 receptor was injected subcutaneously.
89013533|NCT06300203|Placebo Comparator|Placebo|Placebo was injected subcutaneously.
89013534|NCT06300177|Experimental|D-1553 Tablet|D-1553 Tablet，21 days as a treatment cycle.
89013535|NCT06300177|Active Comparator|Docetaxel Injection|Docetaxel Injection，21 days as a treatment cycle.
89444112|NCT02488538|Active Comparator|Combined oral contraceptives|Group 2 will receive COC containing drospirenone daily for 21 days starting from the 3rd day of menstruation in addition to a daily oral placebo similar in size, color and structure to fluoxetine
89444113|NCT02488538|Placebo Comparator|Placebo|Group 3 will receive oral placebo similar to COC daily for 21 days starting from the 3rd day of menstruation in addition to a daily oral placebo similar in size, color and structure to fluoxetine.
89444114|NCT02180685|Other|Anchor fixation|Medial fixation of the reconstruction at the medial femural condyle with suture anchors.
89444115|NCT02180685|Other|Screw fixation|Medial fixation of the reconstruction at the medial femural condyle with a screw.
89444116|NCT04492826||Infected patients|patients with bone flap surgeries
89444117|NCT02568046|Experimental|Sym004 12 mg/kg + FOLFIRI|Phase 1b, Dose-Escalation: Dose Level 1
89444118|NCT02568046|Experimental|Sym004 9 mg/kg + FOLFIRI|Phase 1b, Dose-Escalation: Dose Level -1
89444119|NCT02568046|Experimental|Sym004 (RP2D) + FOLFIRI|Phase 2a, Dose-Expansion: Sym004 in the RP2D in combination with FOLFIRI
89444120|NCT02180763|Experimental|Gammanorm® 165 mg/mL|
89444121|NCT02488460|No Intervention|Normal math|This arm serves as the control group receiving regular math lessons
89444122|NCT02488460|Experimental|Active math|This arm serves as the intervention group receiving physically active math lessons
89444123|NCT03536481|Experimental|T-R cohort under fasted state|Subjects will be administered with one single dose of ensartinib capsules (test product) under fasted state, after a wash period of 14 days,the subjects will be administered with one single dose of ensartinib capsules (reference product) under fasted state.
89444124|NCT03536481|Experimental|R-T cohort under fasted state|Subjects will be administered with one single dose of ensartinib capsules (reference product) under fasted state, after a wash period of 14 days,the subjects will be administered with one single dose of ensartinib capsules (test product) under fasted state.
89444125|NCT03536481|Experimental|T-R cohort after meal|Subjects will be administered with one single dose of ensartinib capsules (test product) after meal, after a wash period of 14 days,the subjects will be administered with one single dose of ensartinib capsules (reference product) after meal.
89200005|NCT01743391|No Intervention|Control|Standard treatment
89444126|NCT03536481|Experimental|R-T cohort after meal|Subjects will be administered with one single dose of ensartinib capsules (reference product) after meal, after a wash period of 14 days,the subjects will be administered with one single dose of ensartinib capsules (test product) after meal.
89444127|NCT02488616|Active Comparator|Sensor-augmented pump therapy|Participants will use sensor-augmented pump therapy with low-glucose suspend to regulate glucose levels. The low-glucose suspend feature available in the MiniMed® Paradigm® Veo™, Medtronic combined with the Enlite sensor® will be used. This feature allows for suspension of insulin delivery at a pre-set sensor glucose value for up to 2 hours.
89200006|NCT01743391|Experimental|Intervention|Office-hysteroscopy with endometrial biopsy before standard treatment
89444128|NCT02488616|Active Comparator|Single-hormone closed-loop strategy|Variable subcutaneous insulin infusion will be used to regulate glucose levels. Participant's usual fast-acting insulin analog will be infused using a subcutaneous infusion pump (MiniMed® Paradigm® Veo™, Medtronic). Every 10 minutes, the glucose levels as measured by the sensor (Enlite sensor®, Medtronic) will be transferred automatically to a smartphone, that harbors the algorithm, that will calculate the recommended doses and will send it wirelessly to the infusion pump.
89444129|NCT03323138|Experimental|Ex-PRESS and phacoemulsification|A treatment session of PACG coexisting cataract treated with phacoemulsification combined with P50 Ex-PRESS miniature glaucoma device (Alcon Laboratories, Fort Worth, Texas, USA).
89444130|NCT03323060||Male and/or females ≥ 22 yrs old|≥ 22 years of age requiring transanal procedures in the areas of the anus, rectum, and distal colon Transanal endoscopic surgical procedure
89444131|NCT03328910||Analgesia monitoring|After anesthesia induction, all participants received standard anesthesia monitoring, SPI monitor (GE Healthcare, Helsinki, Finland) and bispectral index (BIS). BIS was kept between 40-60, whereas no specific target was determined for SPI. At the end of surgery, anesthesia was terminated and the patients were stimulated to wake up. After the participants were able to breathe spontaneously and obey verbal commands, extubation was carefully performed, and the monitoring of SPI was stopped.
89444132|NCT02256423|Active Comparator|REFERENCE 1: Nurofen® 200 mg tablet|Single group 3-way crossover study
89444133|NCT02256423|Active Comparator|REFERENCE 2: Ibuprofen 200 mg soft gel capsule|Single group 3-way crossover study
89444134|NCT02256423|Experimental|ibuprofen 200 mg soft gel capsule|single group, 3-way cross
88927916|NCT01707173|Other|Standard Education|Control group participants will receive standard educational materials published by the CDC or American Academy of Pediatrics as an intervention along with a generic infant safety DVD
88927917|NCT01707173|Experimental|Tailored education|Parents/caregivers will receive educational materials tailored to their specific beliefs and barriers about infant supine sleep along with a DVD detailing standard guidelines along with specific solutions and facilitators to infant supine sleep as the intervention.
88927918|NCT01707186||Group 1A|Early phase, requiring change in treatment
88927919|NCT01707186||Group 2|Established phase, stable treatment
88927920|NCT01707186||Group 2A|Established phase, requiring a change in treatment
88927921|NCT01707186||Group 1|Early phase, stable treatment
88927922|NCT01707199|Experimental|Artesunate + Sulphadoxine-pyrimethamine|"AS+SP will be administered according to the patient's age, based on a dose of 4mg artesunate/kg body weight once daily for 3 days plus SP at a dose of 25mg sulphadoxine/kg body weight single dose on the first day.~One co-blister pack of Artecospe will be used per patient and obtained via WHO from Guilin Pharmaceutical Co. Ltd., Shanghai China, with appropriate expiry date."
88927923|NCT01707212|Experimental|Pain management education|Education about pain management during infant immunization
88927924|NCT01707212|Other|No pain management education|Control - general information about immunization only
88927925|NCT01707251|Experimental|Intravenous Ibuprofen|800 mg Ibuprofen IV every 6 hours starting preoperatively (5 doses).
88927926|NCT01707251|Placebo Comparator|Saline|IV saline every 6 hours starting preoperatively (5 doses).
88927927|NCT01707277|Experimental|Inspiratory muscle training|Inspiratory muscle training for improving maximum inspiratory pressure plus phrmacological treatment Pharmacological treatment (usual care)
88927928|NCT01707277|Active Comparator|Usual care|Pharmacological treatment
88927929|NCT01707303|Other|Usual Care|Usual hospital rehabilitative services
88927930|NCT01707303|Experimental|Early ICU Rehabilitation Strategy|Early ICU physical therapy will be applied in this arm
88927931|NCT01707316|Experimental|Sequence 1: Treatment A-B-C|The study consists of 3 single-dose treatment periods. Each treatment period will be 5 days in duration. Successive treatment periods will be separated by a washout period (with no medication) of 10 days.
88927932|NCT01707316|Experimental|Sequence 2: Treatment B-C-A|The study consists of 3 single-dose treatment periods. Each treatment period will be 5 days in duration. Successive treatment periods will be separated by a washout period (with no medication) of 10 days.
88927933|NCT01707316|Experimental|Sequence 3: Treatment C-A-B|The study consists of 3 single-dose treatment periods. Each treatment period will be 5 days in duration. Successive treatment periods will be separated by a washout period (with no medication) of 10 days.
88927934|NCT01707329|Active Comparator|Chemotherapy|Docetaxel 60-75mg/m2, 4 cycles; or pemetrexed 500mg/m2, 4 cycles.
88927935|NCT01707329|Experimental|Icotinib+Chemotherapy|Icotinib: 125 mg is administered orally three times per day. Chemotherapy: docetaxel 75mg/m2, 4 cycles; or pemetrexed 500mg/m2, 4 cycles.
88927936|NCT01707342|Experimental|Simeprevir (TMC435)|Treatment A: single oral dose of simeprevir (TMC435) 50 mg; and Treatment B: single oral dose of simeprevir (TMC435) 150 mg. A single 10 minute intravenous infusion of [3H]-TMC435 (100 microcurie) 100 microgram will be followed 5 hours later after administration of Treatment A and Treatment B in Period 1 and Period 2, respectively.
88927937|NCT01707355|Active Comparator|invention with poster|intervention - poster
88927938|NCT01707355|No Intervention|control|control - no poster
88927939|NCT01707394|Experimental|Group 1: Apixaban (low dose)|
88927940|NCT01707394|Experimental|Group 2A: Apixaban (low dose)|
88927941|NCT01707394|Experimental|Group 2B: Apixaban (low dose)|
88927942|NCT01707394|Experimental|Group 3: Apixaban (low dose)|
88927943|NCT01707394|Experimental|Group 4: Apixaban (low dose)|
88927944|NCT01707394|Experimental|Group 5: Apixaban (low dose)|
88927945|NCT01707394|Experimental|Group 2A (higher dose): Apixaban (low dose)|
88927946|NCT01707407|Experimental|Pomalidomide|
88927947|NCT01707407|Experimental|Pomalidomide plus Ketoconazole|
88927948|NCT01707407|Experimental|Pomalidomide plus Ketoconazole plus Fluvoxamine|
88927949|NCT01707407|Experimental|Pomalidomide plus Carbamazepine|
88927950|NCT01707433||Diagnosis of hip disease|Diagnosed with spondyloepiphyseal dysplasia or multiple epiphyseal dysplasia or bilateral Legg-Calve-Perthes disease, or bilateral proximal femoral epiphyseal dysplasia
89444135|NCT03322982|Experimental|MS Diet|34 people with MS following low-fat diet
89444136|NCT03322982|No Intervention|MS Wait-List|34 people with MS following usual diet
89444137|NCT03322982|No Intervention|Diet Healthy Control|20 controls with no diagnosis of MS, age and sex-matched to members of the MS Diet group
89444138|NCT03322982|No Intervention|Wait-List Healthy Control|20 controls with no diagnosis of MS, age and sex-matched to members of the MS Wait-List group
89444139|NCT05141097|Experimental|Treatment|Being cared for by an Integrative Medicine provider
89444140|NCT05141097|No Intervention|Control|Being cared for by conventional medicine provider
89444141|NCT02185677||MSA-P|
89444142|NCT02185677||MSA-C|
89444143|NCT05464472||Transcatheter Aortic Valve Implantation|Patients are assessed for cognitive function pre and post transcatheter aortic valve implantation.
89444144|NCT05464472||Control matched population|Control matched population are assessed for cognitive function at day 0 and at 6 month
89444145|NCT03320486|Experimental|Group 1 - dapaconazole cream 2%|Topical application of dapaconazole cream 2%, once daily, during 42 days.
88927951|NCT01707446|Active Comparator|Near-infrared reflectance spectroscopy|Bilateral NIRS (The INVOS® Cerebral/Somatic Oximeter)will be used to measure rSO2 intraoperatively and during the 24h postoperative period in the intensive care unit. In the intervention group, an alarm threshold at 75% of the baseline rSO2 value will be established.
88927952|NCT01707446|No Intervention|Blinded Near-infrared reflectance spectroscopy|In the control group, the NIRS monitor screen will be electronically blinded, however, the recording will be continuous after verification of the signal strength and baseline value by an independent observer trained in NIRS application and unaware of the study design.
88927953|NCT01707498|Experimental|Tetraplegic patients|Scanning device RoBIK Brain-Computer Interface
88927954|NCT01707498|Experimental|Healthy volunteers|RoBIK Brain-Computer Interface
88927955|NCT01707524|Experimental|Trans-radial approach|Randomized left versus right radial artery approach
88927956|NCT01707524|No Intervention|Trans-femoral approach|Observational
88927957|NCT01707537|Experimental|Euvichol|Euvichol is a homogeneous suspension of inactivated suitable strains of Vibrio cholera serogroup O1 and O139. Euvichol is Yellow to yellowish colour.
89444146|NCT03320486|Active Comparator|Group 2 - ketoconazole cream 2%|Topical application of ketoconazole cream 2%, once daily, during 42 days.
89444147|NCT02180919|No Intervention|Control period|All patients with receive standard optimal medical care according to ESC Heart Failure guidelines, NICE COPD guidelines or other best practice care pathways as relevant to their condition.
89444148|NCT02180919|Experimental|Telemonitoring|telemonitoring will be carried out in the patient's home using the conformity European (CE) marked Philips Motiva system which comprises weight scales, blood pressure and heart rate monitoring, finger pulse oximeter and provides question/answer prompts all of which is linked to the patient's television screen and can be tuned into just as like a television (TV) channel. Measurements of blood pressure, heart rate and weight will be obtained from the heart failure patients daily. In the respiratory patients heart rate and oximetry will be measured daily, and blood pressure and weight once a week.
89444149|NCT02567656|Experimental|Single arm|RP6530 administered orally twice a day.
89444150|NCT02182869|Experimental|Combivent® HFA|
89444151|NCT02182869|Active Comparator|Combivent® CFC|
88927958|NCT01707550||Cohort|
88927959|NCT01707563|Other|Marfan patients|Study participants were recruited between 11/2009 and 10/2011, among adult patients consulting in the Multidisciplinary Marfan Clinic of our University Hospital, and having a known mutation in the FBN1 gene. There, patients are evaluated by geneticists, rheumatologists, cardiologists, and ophthalmologists. Systematic slit-lamp examination, cardiac ultrasonography, and radiological investigations are also performed. A skin punch biopsy was used to establish a fibroblast cell culture. We determined mRNA levels for FBN1 and compared it to the clinical involvement.
88927960|NCT01707563|Other|control patients|Fibroblasts were obtained from non Marfan patients (cell bank). We determineed mRNA level for FBN1 for each allele.
88927961|NCT01707576|Other|screening of adolescent mental suffering. Management|screening of adolescent mental suffering consultant to emergencies. Management and later monitoring
88927962|NCT01707589|Experimental|Neonates admitted to the NICU|Neonates admitted to the NICU for a variety of medical reasons will be the cohort group. Those whose parents give informed consent will compose the subjects of the study
89444152|NCT03109106|Experimental|PCT Arm|"oAntibiotic management includes use of a validated PCT algorithm in addition to clinical judgment, other laboratory values, and microbiological pathogen identification. Subjects will be enrolled and data collected prospectively in 2017.~Patient records will be reviewed for outcomes data and the patients will receive a phone call for outcomes assessment at 30 days post discharge."
89444153|NCT03109106|No Intervention|Control Group|Patients enrolled during the control blocks will receive antibiotics for respiratory infection at the provider's discretion in keeping with current standards of care. Patient records will be reviewed for outcomes data and the patients will receive a phone call for outcomes assessment at 30 days post discharge.
89444154|NCT02185833|Experimental|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET of Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey one tablet, once
89444155|NCT02185833|Active Comparator|DYNABAC 250 MG ENTERIC COATED TABLET|DYNABAC 250 MG ENTERIC COATED TABLET of Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey, two tablets, once
89444156|NCT02488382|Experimental|Lonquek|treatment with Lonquek for autologous stem cell collection
89444157|NCT05505682|Experimental|Intervention clusters|Residential areas that receive releases of male Wolbachia-infected Aedes aegypti
88927963|NCT01707602|Experimental|Arm A|Type Vaccine Name: INTANZA® 15 T Description : transcutaneous vaccination
88927964|NCT01707602|Active Comparator|Arm B|Type: Vaccine Name: INTANZA® 15ug Description : intradermal vaccination
88927965|NCT01707602|Active Comparator|Arm C|Type : Vaccine Name: Vaxigrip® Description :Intramuscular vaccination
88927966|NCT01707615|Other|control group|In the control group, all patients were enrolled in a lifestyle intervention
88927967|NCT01707615|Active Comparator|GSPE group|GSPE 240 mg/day (120mg bid) in addition to the same lifestyle intervention.
89444158|NCT05505682|No Intervention|Non-intervention clusters|Residential areas that do not receive releases of male Wolbachia-infected Aedes aegypti
89444159|NCT02180997|Experimental|Tamsulosin 1|Volunteers will be taken Tamsulosin and solifenacin
89444160|NCT02180997|Experimental|Solifenacin 1|Volunteers will be taken Tamsulosin and solifenacin
89444161|NCT02180997|Experimental|Co-administration 1|Volunteers will be taken Tamsulosin and solifenacin
89444162|NCT02180997|Experimental|Tamsulosin 2|Volunteers will be taken Tamsulosin and solifenacin
89444163|NCT02180997|Experimental|Solifenacin 2|Volunteers will be taken Tamsulosin and solifenacin
89444164|NCT02180997|Experimental|Co-administration 2|Volunteers will be taken Tamsulosin and solifenacin
89444165|NCT03328754|Experimental|Group 1 Powerscope|Powerscope placed bilaterally for class II correction
89444166|NCT03328754|Experimental|Group 2 Forsus|Forsus placed bilaterally for class II correction
89444167|NCT02185911||Cohort 1|Patients with CKD
89444168|NCT03322826|Active Comparator|Lymphadenectomy|systematically Lymphadenectomy of the lymph-node stations ATS 2, 4, 7, 8, 9,10,11 on the right side and ATS 5, 6, 7, 8, 9,10,11 on the left side
89444169|NCT03322826|Experimental|systematic sampling of the lymph nodes|systematic sampling of the lymph-node stations ATS 2, 4, 7, 8, 9,10,11 on the right side and ATS 5, 6, 7, 8, 9,10,11 on the left side
89444170|NCT02491502|Experimental|Echopulse|Echopulse HIFU
89444171|NCT03328520|Experimental|First Year Students in Wellness FYIs|
89444172|NCT05505526|Experimental|Electroacupuncture|Participants in EA group will receive treatment at bilateral Bladder Meridian (BL) 33 [Zhongliao], BL35 [Huiyang] and Spleen Meridian (SP) 6 [Sanyinjiao]. The EA treatment will last 30mins for each session, 3 sessions a week (ideally every other day) for a succession of 8 weeks.
89444173|NCT05505526|Sham Comparator|Sham electroacupuncture|Participants in SA group will receive treatment at bilateral sham BL33 [Zhongliao], sham BL35 [Huiyang] and sham SP6 [Sanyinjiao]. The SA treatment will last 30mins for each session, 3 sessions a week (ideally every other day) for a succession of 8 weeks.
89444174|NCT02488226|Experimental|Gaze Contingent|Participants will view social videos using Gaze-contingent eye-tracking technology . If the participants looking patterns deviate from a normative pattern, they will be redirected to the normative point of regard using gaze-contingent cues.
89444175|NCT02488226|No Intervention|Control Condition|Participants will view unaltered social videos which do not change based on where the participant is looking.
89444176|NCT05509114|Experimental|Virtual Reality Glasses|The intervention introductory information formula was face-to-face by researchers from the State-Trait Anxiety Inventory (STAI-I, STAI-II), the Scale of Patient Perception of Hospital Experience with Nursing Care (PPHEN) and Visual Analog Scale for Pain (VAS) Before starting the research, a preliminary application plan is determined with 10 virtual virtual applications. It is not included in the applications made in the pre-application. Before watching the video, patients are informed about how to train, how to do it, and detailed information about the video. When the patient is removed from the service and in the left lateral position, 2 minutes before the assistant physician, the virtual is about to take place. The video was watched after about 10-15 minutes until the process was finished. After the procedure, STAI-I, STAI-II, PPHEN and VAS were reapplied by the researchers.
89444177|NCT02488304|Experimental|HRCT scans|High Resolution Computed Tomography scans will be taken
89444178|NCT03322748|Experimental|Experimental group|Usual physical therapy+ strengthening of lower limbs muscles
89444179|NCT03322748|Other|Control group|Usual physical therapy
89444180|NCT03322670||Signs of CAP and a positive chest X-Ray|Patients with at least 2 signs suggestive of CAP on presentation at general practice (one general sign of infection and one sign of pulmonary localization) and and a chest X-Ray not compatible with CAP
89444181|NCT03322670||Patients directly hospitalized|Patients with at least 2 signs suggestive of CAP on presentation at general practice (one general sign of infection and one sign of pulmonary localization) and and who are directly hospitalized before complementary examinations
88927968|NCT01707628|Active Comparator|Early group after rituximab|"Patients who received rituximab last dose 3-6 months before influenza vaccination will be the early group."
88927969|NCT01707628|Active Comparator|Late group after rituximab|"Patients who received rituximab last dose 9-12 months before influenza vaccination will be the late group."
89444182|NCT03322670||Control patients|Healthy Patients (age-matched with a radiologically confirmed CAP patient)
89444183|NCT03322670||Patients with partial participation|Patients with at least 2 signs suggestive of CAP on presentation at general practice (one general sign of infection and one sign of pulmonary localization) and who can not or do not want to perform all the complementary examinations of the study
89200007|NCT05279638||psoriasis vulgaris patients|psoriasis vulgaris patients , both sex , 18,55 years old
89444184|NCT03322670||Signs of CAP and a negative Chest X-Ray|Patients with at least 2 signs suggestive of CAP on presentation at general practice (one general sign of infection and one sign of pulmonary localization) and and a chest X-Ray not compatible with CAP
89444185|NCT02560012|Other|Personalized therapy|"Subjects will receive one of the four first-line therapy agents based on their tumor's profile. The first-line agents are sunitinib, temsirolimus, sorafenib, or pazopanib. These are all routine drugs for RCC treatment and will be given at their approved doses and dosing schedules.~Upon disease progression, subject's tumor(s) will be biopsied again to create another tumor profile. The second-line agents are everolimus or axitinib. Both of these are routine drugs for RCC treatment and will be given at their approved doses and dosing schedules."
89444186|NCT03320174|Active Comparator|Tafenoquine 200 mg (2 x 100 mg tablets)|Tafenoquine 200 mg (2 x 100 mg tablets) daily for three consecutive days, followed by study treatment (tafenoquine 200 mg or placebo) once per week for 51 weeks
88927970|NCT01707628|Active Comparator|Control group|Healthy individuals will be receive vaccination with influenza vaccine and will serve as controls.
89444187|NCT03320174|Placebo Comparator|Placebo|Placebo daily for three consecutive days, followed by study treatment (tafenoquine 200 mg or placebo) once per week for 51 weeks
89444188|NCT05500768|Experimental|hypothermic compression bandage|
89444189|NCT05500768|Active Comparator|Conventional compression bandage|
89444190|NCT03328442|Experimental|Vista technique|The vista technique with PRF membrane uses a Vestibular incision subperiosteal tunnel access in combination with Platelet rich fibrin membrane to treat gingival recession defects.
89444191|NCT03328442|Active Comparator|modified coronally advanced flap|A modified coronally advanced flap utilising Platelet rich fibrin membrane to treat gingival recession defects.
88927971|NCT01707641|Active Comparator|CD#2|patients will be asked to melt slowly in the mouth 6 lozenges per day, containing Lactobacillus brevis CD2
88927972|NCT01707641|Active Comparator|bicarbonate sodium mouthwash|patients will be asked to wash their mouth with bicarbonate several times per day
88927973|NCT01707680||Dexmedetomidine|Here, patients to be included are those being sedated with dexmedetomidine as primary sedative.
88927974|NCT01707680||Propofol|Here, patients to be included are those being sedated with propofol as primary sedative.
88927975|NCT01707680||Midazolam|Here, patients to be included are those being sedated with midazolam as primary sedative
88927976|NCT01707706|Experimental|Traditional Acupuncture|"Patients will be treated at bilateral Ear Shenmen, Sishencong EX-HN1, Anmian, Neiguan PC6, Shenmen HT7, Sanyinjiao SP6, and unilateral Yintang EX-HN3 and Baihui GV20. Acupuncture treatment will be performed by a registered Chinese medicine practitioner. De qi(an irradiating feeling considered to be indicative of effective needling) is achieved if possible. An electric-stimulator (ITO ES160, Japan) is connected to these needles to give an electric-stimulation in continuous wave, frequency of 4 Hz, 0.4 ms square wave pulses and constant current. Surgical tape or hair pin will be adhered to the needles.The needles will be left for 30 min and then removed. Acupuncture treatment will consist of three sessions per week for 3 consecutive weeks."
88927977|NCT01707706|Active Comparator|Minimal Acupuncture|"Patients will be treated superficially at points away from classic acupoints. The points include bilateral Forearm [1 inch lateral to the middle point between HE3 and HE7] , Upper arm [1 inch lateral to LU 3 ], and Lower leg [0.5 inch dorsal to GB39]; for head, the non-acupoints include bilateral Head [middle point between GB8 and ST8], Forehead [middle point between ST8 and GB14], Neck [middle point between TB16 and SI17], and Ear [the point on the helix, inferior to the apex]. The points selected have been used in previous acupuncture studies as sham control. De qi is avoided during needling. The treatment procedure, electric-stimulation, frequency, duration and number of treatment sessions will be the same for the Traditional Acupuncture group."
88927978|NCT01707706|Placebo Comparator|Placebo Acupuncture|Placebo needles designed by Streitberger (1998) will be used. The placebo needles are blunt needle that will not penetrate the skin during needle insertion. The handles of these placebo needles will slide over the needle when it is compressed, giving it the appearance of penetrating the skin. The placebo needles are inserted to the site 1 inch beside the acupoints in order to avoid the acupressure effect. The needles are held by a surgical tape or hair pin in hairy region to imitate the retention of needles. The needles are connected to an electric-stimulator with zero frequency and amplitude. The number, duration and frequency of the treatment sessions, and the intervention procedure will be the same for electro-acupuncture and placebo acupuncture.
88927979|NCT01707719||Alzheimer's disease|
88927980|NCT01707719||Non demented subjects|
88927981|NCT01707732|Active Comparator|Enoxaparin 40mg/ day|Enoxaparin administrated at the following dose : 40mg/ day
88927982|NCT01707732|Experimental|Enoxaparin 60 mg/day|Enoxaparin administrated at the following dose : 60 mg/day
88927983|NCT01707745|Other|Avastin|Bevacizumab(Avastin) 0.75mg in 0.03 ml
88927984|NCT01707758||pancreatic cancer|This study will collect blood from 36 patients with known or suspected pancreatic cancer and from 12 healthy cancer-free subjects.
88927985|NCT01707771|Active Comparator|Roux-en-Y gastric bypass|Both sexes, age between 30 and 60 years, BMI =/> 35 kg/m2
88927986|NCT01707771|Active Comparator|diet and lifestyle modifications|Both sexes, age between 30 and 60 years, BMI =/> 35 kg/m2
88927987|NCT01707784||Women with gestational diabetes|Women with gestational diabetes diagnosed by clinically routine 75 g oral glucose tolerance testing
88927988|NCT01707784||Women without gestational diabetes|Women without gestational diabetes diagnosed by clinically routine 75 g oral glucose tolerance testing
88927989|NCT01707797||Healthy children aged 9-15 months|Healthy children aged 12 months (± 3 months) at baseline stratified by Medicaid status and/or race/ethnicity to ensure a diverse representation. Each child will be paired with the primary caregiver, whom the investigators expect to most likely be the adult parent or legal guardian.
88927990|NCT01707810|Sham Comparator|Conventional method|In the conventional method IVC was clamped during the anhepatic phase and venous return was maintained by a portal femoral axillary venovenous bypass with a centrifugal pump. In these cases, IVC reconstruction was performed by end-to-end anastomosis above and below the liver.
88927991|NCT01707810|Experimental|Piggyback method|In the piggyback method IVC was not clamped in any case. Implantation method of the grafted IVC in recipient IVC was not standardized, being defined by the responsible surgeon during the procedure. In the two groups, all patients were submitted to simultaneous arterial and portal revascularization, according to the routine of the service.
88927992|NCT01707823|Experimental|Prevention (acetylsalicylic acid)|Patients receive acetylsalicylic acid PO for 7 days.
89200008|NCT05279638||healthy participants|
89200009|NCT02557932|Active Comparator|Standard triple therapy|7 day-PPI based standard triple therapy
89200010|NCT02557932|Active Comparator|Bismuth quadruple therapy|10 day-bismuth quadruple therapy
89200011|NCT00762684|Experimental|TAK-559 32 mg QD|
89444192|NCT03328364||enzalutamide (mCRPC pre-chemo)|Patients treated with enzalutamide prior to chemotherapy
89444193|NCT03328364||enzalutamide and chemotherapy (mCRPC post chemo)|Patients treated with enzalutamide who have previously undergone treatment with chemotherapy (docetaxel)
89444194|NCT05505370|Experimental|Study Arm Study device|Patients who meet all eligibility criteria were included and had a clinically indicated colonoscopy procedure performed using the study device. Immediately thereafter, patients had a colonoscopy procedure using standard colonoscope (Olympus CF 180) by a second endoscopist.
89444195|NCT05505370|Active Comparator|Study Arm - Predicate Device|Patients who meet all eligibility criteria were included and had a clinically indicated colonoscopy procedure performed using the study device. Immediately thereafter, patients had a colonoscopy procedure using standard colonoscope (Olympus CF 180) by a second endoscopist.
89444196|NCT03328286|Experimental|Weekly group meeting w/psychotherapist|All the participants fulfilling the eligibility criteria are asked to take part in an additional Intervention. The Intervention is a weekly group Meeting with a psychotherapist to discuss issues or Problems the Group members have
89444197|NCT03322592|Active Comparator|EUS-FNB with ROSE|Intervention: Rapid on-site evaluation (ROSE) In the EUS-FNB with ROSE arm, the material obtained with the first pass will be processed for ROSE using the touch imprint technique. The biopsy specimen is carefully pressed onto the slide, allowing the superficial cells to adhere, and then gently lifted with forceps thereby creating a touch imprint of the specimen on the slide. In case of inadequate sample, a second pass will be done and the touch imprint technique will be repeated up to a maximum of 3 passes. In case of adequate ROSE at the first or the second pass, the additional passes will be performed as EUS-FNB and the material obtained placed directly into formalin or other fixative for subsequent histopathological evaluation.
89444198|NCT03322592|Active Comparator|EUS-FNB without ROSE|Intervention: histologic evaluation In the FNB alone arm, 3 needle passes will be performed and the samples obtained will be placed directly in a vial containing formalin (or other fixative according to the local individual protocol). Macroscopic on-site evaluation (MOSE) of acquired sample will be then performed by the endoscopist.
88927993|NCT01707836||Family|Families with a child with Neurofibromatosis Type 1 who has been diagnosed with a brain tumor.
89444199|NCT03322436||AMI patients treated by PCI|AMI patient treated by PCI at risk to develop Heart Failure
89444200|NCT03328052|Experimental|MYnd Analytics PEER Online directed therapy|Patients in this arm will receive anti-depressants as recommended by the PEER Online algorithm as described below.
88927994|NCT01707849|Active Comparator|MMF arm|"MMF arm (n=20)~They will receive immunosuppression as stipulated by hospital protocol:~Tacrolimus (levels 8-10ng/mL) and Mycophenalate mofetil 1mg bid(levels 1-3ng/mL)."
88927995|NCT01707849|Experimental|EVL arm|"EVL arm (n=20):~Tacrolimus (levels 8-10ng/ml) + everolimus 1mg bid (levels 2-4 ng/mL)"
88927996|NCT01707875||fetal ventricle brain asymmetry|
88927997|NCT01707888||major lung resection|Patients undergo major lung resection by thoracoscopy/VATS.
88927998|NCT01707901|Experimental|ONO-8539|ONO-8539
88927999|NCT01707901|Placebo Comparator|Placebo|Placebo
88928000|NCT01707914|Experimental|Chinese bayberry juice|Consume 500 mL CBJ/d (250 mL CBJ twice daily)
88928001|NCT01707914|Placebo Comparator|Placebo|Consume 500 mL placebo/d (250 mL placebo twice daily)
88928002|NCT01707927||Trifecta|Degenerated aortic valve with indication for aortic valve replacement
89444201|NCT03328052|Sham Comparator|Conventional therapy|Patients in this arm will receive anti-depressants as chosen by the physician without guidance by the PEER Online algorithm.
89444202|NCT04514302|Placebo Comparator|Placebo|Single dose of a 150 mL saline solution administered intravenously as an infusion over 40 min.
88928003|NCT01707927||mosaic Ultra|Need a aortic valve replacement
88928004|NCT01707940|Experimental|BI 144807|subjects receive an oral single dose of BI 144807
89200012|NCT00762684|Placebo Comparator|Placebo QD|
89444203|NCT04514302|Experimental|INOSARS dose 1|Single dose of 5 mg/kg in a 150 mL saline solution administered intravenously as an infusion over 40 min.
89444204|NCT04514302|Experimental|INOSARS dose 2|Single dose of 15 mg/kg in a 150 mL saline solution administered intravenously as an infusion over 40 min.
89444205|NCT04514302|Experimental|INOSARS dose 3|Single dose of 30 mg/kg in a 150 mL saline solution administered intravenously as an infusion over 40 min.
89444206|NCT05508958|Experimental|Anterior approach|Cup revision surgery through the anterior approach
89444207|NCT05508958|Active Comparator|Posterolateral approach|Cup revision surgery through the posterolateral approach
88928005|NCT01707940|Experimental|BI 144807 plus Ketoconazole|subjects receive bid ketoconazole plus an oral single dose of BI 144807
88928006|NCT01707953|Experimental|Midodrine|Midodrine Hydrochloride (5mg) administered as capsule 5 and 23 hours after end of surgery.
88928007|NCT01707953|Placebo Comparator|Placebo|Placebo administered as capsule 5- and 23 hours after end of surgery.
88928008|NCT01707966|Experimental|Orteronel and best supportive care|Arm A: 300mg Orteronel twice daily and best supportive care until occurrence of an event.
88928009|NCT01707966|Placebo Comparator|Placebo and best supportive care|Arm B: Placebo twice daily and best supportive care until occurrence of an event.
88928010|NCT01707979||Diabetic neuropathy|Male participants, type1 diabetic with diabetic neuropathy
88928011|NCT01707979||Diabetes without neuropathy|Male participants, type1 diabetic without diabetic neuropathy
88928012|NCT01707979||Non diabetic control|Male participants, control group non diabetic
88928013|NCT01708005|Active Comparator|Intervention|80 participants start the oral intake of Lecitone®Se-Vitamin D3 the day after inclusion and during 24 weeks
88928014|NCT01708005|Placebo Comparator|Placebo|"80 participants in this arm start the oral intake of placebo the day after inclusion and during 12 weeks.~Then, they start the oral intake of Lecitone®Se-Vitamin D3 12 weeks after inclusion until the 24th week."
88928015|NCT01708018|No Intervention|Control group|Prior and post intervention period (on days 1 and 4) and final control (day 8): ultrasound examination of position of the fetus and amount of amniotic fluid. On these days plus weekly (until birth) questionnaires (QoL: SF-36, EQ-5D-5L, stress: PSS, psychological wellbeing: MDBF, current stress and pain: VAS). Survey concerning birth.
89444208|NCT03327974|Other|depressed patients|"All patients performed the same evaluation : ecological momentary assesement throught smartphone and 3 sheduled visits.~All patients are depressed patients."
88928016|NCT01708018|Experimental|Intervention group|Prior and post intervention (days 1 and 4) and final control (day 8): ultrasound examination of position of the fetus and amount of amniotic fluid. On these days plus weekly (until birth) questionnaires (QoL: SF-36, EQ-5D-5L, stress: PSS, psychological wellbeing: MDBF, current stress and pain: VAS). After the second intervention(day 4): qualitative questionnaire for intervention-group only. Survey concerning birth.
88928017|NCT01708031|Experimental|stress inducing task|Normal subjects without history medication presently will be participated. Stress induced through stress inducing task (mental arithmetic task), the physiological signals collected before and during the task simultaneously. All the subjects will be participating only once in this MAT based study. Because, the stress will not be possible to induce when the subject is more familiar with the stress inducing task.
88928018|NCT01708044|Experimental|Pramlintide 6 mcg per unit of insulin dose|The pramlintide dose will be calculated based on the subjects' individual insulin units. Dose ratio to be examined is pramlintide 6 mcg for each unit of insulin.
88928019|NCT01708044|Experimental|Pramlintide 9 mcg per unit of insulin dose|The pramlintide dose will be calculated based on the subjects' individual insulin units. Dose ratio to be examined is pramlintide 9 mcg for each unit of insulin.
88928020|NCT01708044|Experimental|Pramlintide 12 mcg per unit of insulin dose|The pramlintide dose will be calculated based on the subjects' individual insulin units. Dose ratio to be examined is pramlintide 12 mcg for each unit of insulin.
88928021|NCT01708044|Placebo Comparator|Placebo|
88928022|NCT01708070|Active Comparator|Asthma self-management experimental|The intervention will involve a self-management workbook, contracting to improve self-management behaviors, instruction in using of a peak flow meter, and follow-up discussions based on the workbook.
88928023|NCT01708070|Other|Asthma self-management control|The control state will involve a self-management workbook and contracting to improve self-management behaviors.
88928024|NCT01708083||Type 2 Diabetes and BMI>35|Patients with type 2 diabetes and body mass index 35 or more.
88928025|NCT01708083||BMI>35|Patients undergoing surgery, gastric bypass or cholecystectomy, without diabetes type 2 and body mass index 35 or more
89444209|NCT03327896||OCHIN EHR|"Patients who were established patients at OCHIN Primary Care Clinics in 2015 and had a face to face visit at the clinic in 2015.~Inclusion criteria for specific outcomes varies by criteria for demoninator specification for the metric."
88928026|NCT01708083||BMI 18-27|Patients undergoing surgery, cholecystectomy or reflux, without type 2 diabetes and body mass index between 18-27
88928027|NCT01708096|Active Comparator|Modifast|treated with VLD Modifast 1000 kcal/day in 2 weeks before gastric by-pass,
88928028|NCT01708096|Placebo Comparator|Normal diet|normal diet 2 weeks before gastric by-pass surgery
88928029|NCT01708109|Experimental|Biliary calculus remain|biliary calculus, less than or equal to 6 mm, remains
88928030|NCT01708109|Experimental|Biliary calculus removed|biliary calculus, less than or equal to 6 mm, removed
88928031|NCT01708135|Other|Smartphone Arm|This is a feasibility trial and thus all participants in the study will be provided a smartphone app to assist them in preparing for bariatric surgery.
88928032|NCT01708148|Active Comparator|Lactobacilli|30 Participants with verum
88928033|NCT01708148|Placebo Comparator|Placebo|30 Participants
89200013|NCT00960232|Experimental|Vitamin D|vitamin D 40.000 IU per weel
89200014|NCT00960232|Placebo Comparator|Placebo|Placebo
89444210|NCT03327896||OneFlorida EHR|"Patients who were established patients at OneFlorida Primary Care clinics in 2015 and had a face to fact visit at the clinic in 2015.~Inclusion criteria for specific outcomes varies by criteria for demoninator specification for the metric."
88928034|NCT01708200|Experimental|Memory Intervention|Two types of memory protocols (psychoeducational vs computerized) will be compared in a population of individuals with mental illness.
88928035|NCT01708226|Experimental|Attention Modification Program|Attention Modification Program
88928036|NCT01708239||Pregnant women|Pregnant women with suspected DVT assessed by the LEFt rule, D-dimer measurement and complete ultrasonography.
88928037|NCT01708252|Experimental|Ulthera treatment group|All subjects will receive an Ulthera System Treatment
88928038|NCT01708265|Active Comparator|Early mitral valve repair|Early mitral valve repair
88928039|NCT01708265|Active Comparator|Watchful waiting|Watchful waiting
88928040|NCT01708304|Other|RDAD|Exercise training for caregiver and care recipient. Behavior modification training for caregiver.
88928041|NCT01708330|Placebo Comparator|Placebo gel|Placebo gel applied topically to the cervix
88928042|NCT01708330|Experimental|Lidocaine gel|2% lidocaine gel applied topically to the cervix
88928043|NCT01708343|Sham Comparator|Placebo-sham|Placebo-sham twice a week during four weeks
88928044|NCT01708343|Active Comparator|Lidocaine injection|Lidocaine 0.2-0.5 mL of 1% injected each time into the trigger point. Twice a week during four weeks
88928045|NCT01708343|Experimental|DIMMST|"DIMMST include the combination of trigger point deep dry needling (TrP-DDN) is combined with paraspinal deep intramuscular stimulation (PDIMS) and needle rotation (NR).~Twice a week during four weeks"
88928046|NCT01708356|Experimental|Normal cycling|Cycling on a residential and downtown route (crossover design)
88928047|NCT01708369|Active Comparator|Oseltamivir & Placebo|Oseltamivir 150 mg orally will be administered 15 minutes after subjects consume orange juice
88928048|NCT01708369|Experimental|Oseltamivir & Ethanol|Oseltamivir 150 mg and ethanol targeted to blood alcohol concentration 0.08 g/dl
88928049|NCT01708369|Active Comparator|Aspirin & Placebo|Aspirin 650 mg orally will be administered 15 minutes after subjects consume orange juice
88928050|NCT01708369|Experimental|Aspirin & Ethanol|Aspirin 650 mg and ethanol targeted to blood alcohol concentration 0.08 g/dl
88928051|NCT01708382|Experimental|Ultherapy treatment on the elbows|All enrolled subjects will receive one Ultherapy treatment to the elbows.
88928052|NCT01708395||Cohort 1|First 50 patients
88928053|NCT01708395||Cohort 2|2nd group of 50 patients
88928054|NCT01708434|Experimental|Ulthera® treatment of the knees|Bilateral treatment of the knees using the Ulthera® System
88928055|NCT01708447|Active Comparator|Topical anesthetic - L.M.X.4.® cream|Topical anesthetic cream, L.M.X.4.® cream, applied to one side of the face and neck prior to Ulthera System treatment.
88928056|NCT01708447|Placebo Comparator|Placebo cream|A placebo cream with similar consistency and color will be applied to the other side of the face and neck prior to Ulthera System treatment.
88928057|NCT01708460|Experimental|Ulthera-treated subjects|All enrolled subjects will receive one Ultherapy treatment to one side of the body in the lateral buttock region. Following study completion, subjects may elect to receive a balancing treatment to the other side of the body.
88928058|NCT01708473|Active Comparator|Advil with Ultherapy|Subjects randomized to this study arm will receive Advil prior to an Ulthera System Treatment.
88928059|NCT01708473|Active Comparator|Lortab with Ultherapy|Subjects randomized to this study arm will receive Lortab prior to an Ulthera System Treatment.
88928060|NCT01708486||Adolescents' with asthma using inhalation devices|Asthmatic adolescents will record their opinion for their inhalation devices by replying to FSI-10 questionnaire
88928061|NCT01708499|Experimental|Study treatment|All enrolled subjects will receive one Ulthera System Treatment.
88928062|NCT01708512|Experimental|Ultherapy™ study treatment|Each subject will receive a customized, high-density, vectored Ulthera System Treatment.
88928063|NCT01708564|Experimental|Cohort 1|10 patients administered a single low dose of rhFVIIa
88928064|NCT01708564|Experimental|Cohort 2|10 patients administered a single intermediate dose of rhFVIIa
88928065|NCT01708564|Experimental|Cohort 3|10 patients administered a single high dose of rhFVIIa
88928066|NCT01708577|Experimental|IPANEMA validation without water intake|The one group is restricted to the water intake during the Indoor phase during testing the IPANEMA measurement system. The other group is not restricted to the water intake.
88928067|NCT01708577|Experimental|IPANEMA validation with water intake|The one group is restricted to the water intake during the Indoor phase, the other group is not restricted to the water intake.
88928068|NCT01708616|Placebo Comparator|Placebo + risperidone|
88928069|NCT01708616|Placebo Comparator|Placebo +placebo|
88928070|NCT01708616|Active Comparator|RO5285119 + placebo|
88928071|NCT01708616|Experimental|RO5285119 + risperidone|
88928072|NCT01708642|Experimental|Adrenaline|Intraoperative low-dose adrenaline infusion
88928073|NCT01708642|Placebo Comparator|Placebo|Placebo: Isotonic Saline
88928074|NCT01708655|Other|Sweat Evaporimeter measurement|"0.1 ml Carbachol, intraocular solution - diluted to 0.1 µg/ml in normal saline- dose 0.01 µg~0.2 ml Atropine sulphate, injection solution - diluted to 44 µg/ml in normal saline - dose 8.8 µg.~0.2 ml of the Beta cocktail injection solution diluted to 44 µg/ml atropine, 22 µg/ml isoproterenol and 4.6 mg/ml aminophylline in normal saline - dose:~4.4 µg Isoproterenol hydrochloride, injection solution~0.93 mg Aminophylline injection solution~8.8 µg Atropine, injection solution"
88928075|NCT01708668|Active Comparator|1|Epidural analgesia (EA) with continuous epidural infusion(CEI)
88928076|NCT01708668|Active Comparator|2|Combined spinal-epidural analgesia (CSEA) with continuous epidural infusion(CEI)
88928077|NCT01708668|Active Comparator|3|Epidural analgesia (EA) with intermittent epidural bolus (IEB, 2.5 mL bolused every 15 minutes)
89444211|NCT03327896||Oregon Medicaid|"Clients who were continuously insured through Oregon Medicaid in 2015 and had a claim with an Evaluation and Management Current Procedure Terminology (CPT) code indicating an office visit listing a Primary Care provider as the performing provider.~Inclusion criteria for specific outcomes varies by criteria for demoninator specification for the metric."
89444212|NCT03327896||Florida Medicaid|"Clients who were continuously insured through Florida Medicaid in 2015 and had a claim with an Evaluation and Management Current Procedure Terminology (CPT) code indicating an office visit listing a Primary Care provider as the performing provider. Florida Medicaid data is limited to clients who were 22 years or younger.~Inclusion criteria for specific outcomes varies by criteria for demoninator specification for the metric."
89444213|NCT04796038|Experimental|Rise SC|All patients will receive the Rise semi-compliant balloon catheter as per treatment.
89444214|NCT03319784|Active Comparator|Ketorolac (Toradol) Injection Group|Patients will be randomized into two patient groups: Ketorolac (Toradol) injection group (n=30) and or Steroid injection group (n=30). Patients assigned to Ketorolac group will receive a single dose of 60mg of Ketorolac (Toradol) mixed with 8mL of 1% lidocaine with epinephrine 1:100,000. Patients will be blinded to the kind of injection they receive, but the physicians who perform the injection will not be blinded for the medical record purposes. The injection will be done under ultrasound guidance to the subacromial space.
89444215|NCT03319784|Active Comparator|Steroid Injection Group|Patients will be randomized into two patient groups: Ketorolac (Toradol) injection group (n=30) and or Steroid injection group (n=30). Patients assigned to Steroid group will receive a single dose of 80mg of Triamcinolone Acetonide (Kenalog) mixed with 8mL of 1% lidocaine with epinephrine 1:100,000. Patients will be blinded to the kind of injection they receive, but the physicians who perform the injection will not be blinded for the medical record purposes. The injection will be done under ultrasound guidance to the subacromial space.
89444216|NCT03319706|Experimental|Test|Torrent's Olmesartan Medoxomil Tablets 40 mg
89444217|NCT03319706|Active Comparator|Reference|Daiichi Sankyo Inc's Benicar Tablets 40 mg
89444218|NCT05045170|Experimental|propofol group|patients with American Society of Anesthesiologists (ASA) I-II, Montreal cognitive assessment test≥26, trauma surgery under spinal anesthesia with propofol sedation
89444219|NCT05045170|Experimental|dexmedetomidine group|patients with American Society of Anesthesiologists (ASA) I-II, Montreal cognitive assessment test≥26, trauma surgery under spinal anesthesia with dexmedetomidine sedation
89444220|NCT05045170|Placebo Comparator|control group|patients with American Society of Anesthesiologists (ASA) I-II, Montreal cognitive assessment test≥26, trauma surgery under spinal anesthesia without sedation
89444221|NCT03322202|Experimental|Motivational Interviewing|Physical and Occupational Therapists will have 16 hours of training in Motivational Interviewing and use these techniques during sessions with patients.
88928078|NCT01708668|Active Comparator|4|Epidural analgesia (EA) with intermittent epidural bolus (IEB, 5ml bolused every 30 minutes)
88928079|NCT01708668|Active Comparator|5|Epidural analgesia (EA) with intermittent epidural bolus (IEB, 10ml bolused every 60 minutes)
88928080|NCT01708668|Active Comparator|6|Combined spinal-epidural analgesia (CSEA) with intermittent epidural bolus (IEB, 2.5 mL bolused every 15 minutes)
88928081|NCT01708668|Active Comparator|7|Combined spinal-epidural analgesia (CSEA) with intermittent epidural bolus (IEB, 5ml bolused every 30 minutes)
88928082|NCT01708668|Active Comparator|8|Combined spinal-epidural analgesia (CSEA) with intermittent epidural bolus (IEB, 10ml bolused every 60 minutes)
88928083|NCT01708681|Experimental|Lean seafood|Cross-over design, half of the subject will receive lean seafood in study period I and the other half in study period II
88928084|NCT01708681|Active Comparator|Meat, egg, milk|Cross-over design, half of the subject will receive meat, egg, milk in study period I and the other half in study period II
88928085|NCT01708694|Placebo Comparator|Placebo Starch|Yogurt with about 45 g/day of placebo starch (amylopectin).
88928086|NCT01708694|Experimental|Experimental Starch|Yogurt with about 45 g/day of slowly digestible starch (amylose).
88928087|NCT01708707|Active Comparator|Oral morphine sulfate|Oral morphine sulfate 0.4 mg/kg/day morphine every 3-4 hours as needed for Finnegan scores suggestive of Neonatal Abstinence Syndrome Other Name: morphine
88928088|NCT01708707|Experimental|Buprenorphine|Sublingual Buprenorphine 15.9 µg/kg per day in 3 divided doses, titrated up or escalated down based upon standardized scoring for neonatal abstinence syndrome
88928089|NCT01708720|Experimental|Sabin-IPV|Single intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 20, 32, and 64 D-antigen units respectively of Sabin-1,-2 and -3 per dose
88928090|NCT01708720|Experimental|Adjuvanted Sabin-IPV|Single intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 10, 16, and 32 D-antigen units respectively of Sabin-1,-2 and -3 per dose, adjuvanted with 0.5 mg aluminium hydroxide
88928091|NCT01708720|Active Comparator|IPV|Single intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 40, 8, and 32 D-antigen units respectively of Mahoney, MEF-1 and Saukett poliovirus per dose
88928092|NCT01708733|Placebo Comparator|KSY diluted|KSY diluted, 100mg decoction by mouth per day for 6 weeks
88928093|NCT01708733|Experimental|KSY|KSY, 100mg decoction by mouth per day for 6 weeks
88928094|NCT01708746||Enrolled subjects|
88928095|NCT01708746||Historic control|
88928096|NCT01708759||Sepsis|Forty patients developed septic complication during ICU stay (sepsis group).
89444222|NCT03322202|No Intervention|Control|Therapists will not participate in additional training.
89444223|NCT05505058|Experimental|Audio-visual material|The video for informed consent was developed by a science filmmaker (https://www.lostlikebeesinrain.comhttps://betomation.space/) for the project's purposes.
88928097|NCT01708759||SIRS|Forty patients were critically ill without evidence of infectious organism (SIRS group).
88928098|NCT01708772||Sepsis|Forty five patients developed septic complication during ICU stay (sepsis group).
88928099|NCT01708772||SIRS group|Forty five patients were critically ill without evidence of infectious organism (SIRS group).
88928100|NCT01708785|Active Comparator|Single context|Subjects will be exposed to food cues in a single context.
88928101|NCT01708785|Experimental|Multiple contexts|Subjects will be exposed to food cues in multiple contexts.
88928102|NCT01708785|Active Comparator|8 treatment sessions|Subjects receive 8 treatment sessions.
88928103|NCT01708785|Experimental|16 treatment sessions|Subjects receive 16 treatment sessions
88928104|NCT01708798|Placebo Comparator|Placebo|"One tablet by mouth daily. If serum potassium level is <5.0 mmol/L at four weeks, increase to two tablets by mouth daily.~If estimated glomerular filtration rate (eGFR) is between 30-49 ml per min per 1.73m2, initial dose is: one tablet by mouth every other day. If serum potassium level is <5.0 mmol/L at four weeks, increase to one tablet by mouth daily."
88928105|NCT01708798|Experimental|Eplerenone|"Eplerenone 25 mg tablet by mouth daily. If serum potassium level is <5.0 mmol/L at four weeks, increase to two 25 mg tablets by mouth daily.~If estimated glomerular filtration rate (eGFR) is between 30-49 ml per min per 1.73m2, initial dose is: eplerenone 25 mg tablet by mouth every other day. If serum potassium level is <5.0 mmol/L at four weeks, increase to 25 mg tablet by mouth daily."
88928106|NCT01708824|Experimental|dietary|"Dietary intervention to meet the target of~1.<5 servings of red/processed meat weekly; <2 servings would be processed meat 2.2 servings of refined grains daily"
88928107|NCT01708824|Experimental|physical activity|"Physical activity intervention with the following targets:~General health target - 30 minutes of moderate-to-vigorous physical activity (MVPA) 5 days per week (i.e. 10 MET-hours/week);~Cancer outcome target - 60 minutes of MVPA 5 days per week (i.e. 18-20 MET-hours/week)"
88928108|NCT01708824|Experimental|dietary and physical activity|Meeting both the dietary and physical activity targets
88928109|NCT01708824|No Intervention|usual care|Follow the general lifestyle advice in accordance with the recommendations of the Department of Health in Hong Kong available in the public domain
88928110|NCT01708837|Other|deep anesthesia group|Propofol infusion rate is titrated to maintain the target BIS values in 30-45
88928111|NCT01708837|Other|light anesthesia group|Propofol infusion rate is titrated to maintain the target BIS values in 45-60
88928112|NCT01708850|Other|Rivaroxaban|Rivaroxaban 15 mg po bid x 3 weeks, followed by rivaroxaban 20 mg po daily x 9 weeks. Then up to discretion of investigator to decide regarding further anticoagulation as study length is limited to 12 weeks.
88928113|NCT01708863||Children with Hypoplastic Left Heart Syndrome (HLHS)|HLHS patients requiring Stage II Glenn surgery
88928114|NCT01708876|Active Comparator|Artesunate-mefloquine|3 doses artesunate-mefloquine - daily over 3 days (dosage according to bodyweight - 4mg/kg and 8.3mg/kg respectively).
88928115|NCT01708876|Active Comparator|Chloroquine|4 doses chloroquine over 3 days - total dose 25mg/kg. 10mg/kg at 0 hours, 5mg/kg at 6-8, 24, 48 hours.
88928116|NCT01708889|Experimental|Group 1: BMS-914143 (eGFR ≥ 80 mL/min/1.73 m2)|BMS-914143 (Peginterferon Lambda-1a) single 180 µg Solution, Subcutaneous injection for subjects with normal renal function with eGFR ≥ 80 mL/min/1.73 m2
88928117|NCT01708889|Experimental|Group 2: BMS-914143 (eGFR 60 to 79 mL/min/1.73 m2)|BMS-914143 (Peginterferon Lambda-1a) single 180 µg Solution, Subcutaneous injection for subjects with mild renal dysfunction with eGFR 60 to 79 mL/min/1.73 m2
88928118|NCT01708889|Experimental|Group 3: BMS-914143 (eGFR 30 to 59 mL/min/1.73 m2)|BMS-914143 (Peginterferon Lambda-1a) single 180 µg Solution, Subcutaneous injection for subjects with moderate renal dysfunction with eGFR 30 to 59 mL/min/1.73 m2
88928119|NCT01708889|Experimental|Group 4: BMS-914143 (eGFR 15 to 29 mL/min/1.73 m2)|BMS-914143 (Peginterferon Lambda-1a) single 180 µg Solution, Subcutaneous injection for subjects with severe renal dysfunction with eGFR 15 to 29 mL/min/1.73 m2
88928120|NCT01708889|Experimental|Group 5: BMS-914143 (eGFR < 15 mL/min/1.73 m2)|BMS-914143 (Peginterferon Lambda-1a) single 180 µg Solution, Subcutaneous injection for subjects with end-stage renal dysfunction with eGFR < 15 mL/min/1.73 m2 (on hemodialysis [HD] or non-HD)
88928121|NCT01708928|Active Comparator|Group A|Subjects who have previous history of submentoplasty and or rhytidectomy
88928122|NCT01708928|Active Comparator|Group B|Subjects naïve to submentoplasty and or rhytidectomy
88928123|NCT01708980|Experimental|Six different strength training exercises|Six different strength training exercises are investigated. Four repetitions of each exercise are performed with a relative loading of 10 RM.
88928124|NCT01709006|Other|Radiation therapy|Modulated radiotherapy (IMRT) using RapidArc® or Helical Tomotherapy® at a dose of 70 Gy in 33 fractions to the PTV (GTV) and 59.4 Gy in 33 fractions
88928125|NCT01709019|Experimental|Group A|Low dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)
88928126|NCT01709019|Experimental|Group B|Low dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)
88928127|NCT01709019|Experimental|Group C|High dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)
88928128|NCT01709019|Experimental|Group D|High dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)
88928129|NCT01709019|Placebo Comparator|Group E|Placebo (Day 0 & Day 28); Seasonal TIV (Day 28)
88928130|NCT01709058|Experimental|Intramuscular/paravertebral injections of Oxygen-Ozone|"This group will be treated with Intramuscular/paravertebral injections of Oxygen-Ozone twice a week for six weeks"
88928131|NCT01709058|Other|Simulated treatment|"The Simulated intramuscular/paravertebral injections will mimic the Oxygen-Ozone injections in the area to be treated by pricking the skin with the needle without drilling. These simulated injections will be performed twice a week for six weeks."
88928132|NCT01709071|Experimental|Low dose Sabin-IPV|"Intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 5, 8, 16 D-antigen units respectively of Sabin-1,-2 and -3 per dose.~Infants receive three vaccinations with an interval of 8 weeks between doses."
89444224|NCT05505058|Active Comparator|Paper-based conventional material|The written material for informed consent was developed by the Swiss Association of Research Ethic Committees and the booklet was designed by the Clinical Research Center of the Geneva University Hospitals.
89444225|NCT02488148|Experimental|Hot yoga|3 hot yoga classes per week to be completed at local studios in Austin, TX.
88928133|NCT01709071|Experimental|Low dose adjuvanted Sabin-IPV|"Intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 2.5, 4, 8 D-antigen units respectively of Sabin-1,-2 and -3 per dose adjuvanted with 0.5 mg aluminium hydroxide.~Infants receive three vaccinations with an interval of 8 weeks between doses."
88928134|NCT01709071|Experimental|Middle dose Sabin-IPV|"Intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 10, 16, 32 D-antigen units respectively of Sabin-1,-2 and -3 per dose.~Infants receive three vaccinations with an interval of 8 weeks between doses."
88928135|NCT01709071|Experimental|Middle dose adjuvanted Sabin-IPV|"Intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 5, 8, 16 D-antigen units respectively of Sabin-1,-2 and -3 per dose adjuvanted with 0.5 mg aluminium hydroxide.~Infants receive three vaccinations with an interval of 8 weeks between doses."
88928136|NCT01709071|Experimental|High dose Sabin-IPV|"Intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 20, 32, 64 D-antigen units respectively of Sabin-1,-2 and -3 per dose.~Infants receive three vaccinations with an interval of 8 weeks between doses."
88928137|NCT01709071|Experimental|High dose adjuvanted Sabin-IPV|"Intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 10, 16, 32 D-antigen units respectively of Sabin-1,-2 and -3 per dose adjuvanted with 0.5 mg aluminium hydroxide.~Infants receive three vaccinations with an interval of 8 weeks between doses."
88928138|NCT01709071|Active Comparator|Conventional IPV|"Intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 40, 8, and 32 D-antigen units respectively of Mahoney, MEF-1 and Saukett poliovirus per dose.~Infants receive three injections with an interval of 8 weeks between doses."
88928139|NCT01709097||With Med-O-Wheel™|Kidney Transplant Recipient with Med-O-Wheel™
88928140|NCT01709097||With out Med-O-Wheel™|Kidney Transplant Recipient with out Med-O-Wheel™
88928141|NCT01709175|Experimental|Once-a-week Strength Training|After completing the introduction to strength training (two sessions in the first week), participants randomized to the once-a-week group will receive 12 additional weeks of progressive strength training. Participants will meet ONCE-A-WEEK to strength train in a supervised exercise group. The program includes nine exercises.
88928142|NCT01709175|Experimental|Twice-a-week Strength Training|After completing the introduction to strength training (two sessions in the first week), participants randomized to the twice-a-week group will receive 12 additional weeks of progressive strength training. Participants will meet TWICE-A-WEEK to strength train in a supervised exercise group. The program includes nine exercises.
88928143|NCT01709188|Experimental|Musical Dual Task Training|60 minute individual session once a week across 2 months for a total of 8 sessions.Each session will be led by a qualified music therapist. Within the Musical Dual Task Training session, participant will be asked to sing familiar songs, play simple percussive musical instruments such as paddle drums and shakers, sing while walking, and play instruments while walking.
88928144|NCT01709188|Active Comparator|Walking and Talking|60 minute individual session once a week across 2 months for a total of 8 sessions.Each session will be led by a qualified music therapist. Within the walking and talking session, participant will be asked to read a newspaper article prior to a walk and have a conversation with the music therapist based on the content of the news while walking.
88928145|NCT01709201|No Intervention|Treatment as Usual|Those in the Treatment as Usual group will not receive the brief intervention for substance use but will receive a brief health education brochure.
88928146|NCT01709201|Experimental|Brief Intervention|Those in the Brief Intervention group will receive a brief motivational intervention aimed at encouraging the participant to decrease their substance use.
88928147|NCT01709240|Experimental|BioWeld1 System|
88928148|NCT01709253|Experimental|Arm 1|27pt/60CGE/20fx/5wks to PGTV(mon, tue, thu, fri; 4/wk)
88928149|NCT01709253|Experimental|Arm 2|27pt/54CGE/15fx/5wks to PGTV (mon, wed, fri; 3/wk)
88928150|NCT01709253|Experimental|Arm 3|27pt / 47CGE/10fx/5wk to PGTV(tue, thu;2/wk)
88928151|NCT01709253|Experimental|Arm 4|27pt/ 35CGE/ 5fx/2.5wk to PGTV(the, thu; 2/wk)
88928152|NCT01709266|Experimental|Probiotics|Capsule containing 5x10E9 CFU probiotics. Twice daily for 2 weeks.
88928153|NCT01709266|Placebo Comparator|Placebo|Capsule containing carrier material powder of identical appearance. Twice daily for 2 weeks.
88928154|NCT01709279|Other|adipose tissue derived stromal cells|
88928155|NCT01709344|Experimental|PS-OT|Problem-solving Occupational Therapy
88928156|NCT01709344|Other|Usual care|Access to all supportive and rehabilitative services available at DHMC
88928157|NCT01709357|Experimental|Muscle energy technique|"In each volunteer, the therapist identified the latent trigger point on the upper trapezius. A questionnaire about general information was performed. And the maximum homolateral side flexion of the trigger point was measured.~On the following week, the blind assessor performed the pre-intervention measurements of pressure pain threshold, pressure pain perception and cervical range of motions.~Next, the therapist performed the muscle energy technique of the upper trapezius muscle.~Then, all measurements, before described, were repeated, by the assessor, after 10 minutes, 24 hours and one week."
88928158|NCT01709357|Experimental|Ischemic compression technique|"In each volunteer, the therapist identified the latent trigger point on the upper trapezius. A questionnaire about general information was performed. And the maximum homolateral side flexion of the trigger point was measured.~On the following week, the blind assessor performed the pre-intervention measurements of pressure pain threshold, pressure pain perception and cervical range of motions.~Next, the therapist performed ischemic compression technique on the latent trigger point.~Then, all measurements, before described, were repeated, by the assessor, after 10 minutes, 24 hours and one week."
89200015|NCT00765180|Active Comparator|2|The investigators evaluate beneficial effect of colonoscopy using narrow band imaging (NBI) for colorectal adenoma detection.
89013536|NCT06300164|Experimental|People with celiac disease who eat cookies with unripe carob - Experimental Group|"Individuals with celiac disease who met the inclusion criteria and participated in the study will divided into two groups by Specialist OrhN SEZGİN, and they will be asked to consume the cookies produced (in the preliminary study) produced as a standard (n=15) and with the addition of unripe carob (n=15) for eight weeks.~The individuals participating in the study will be asked not to change their eating habits, physical activity habits, and drug treatments during the study period. Each individual participating in the study will be provided with the required amount of cookie during the study and will be contacted weekly by Ecem GÜLÜŞEN, a dietitian, to verify whether they consume cookies regularly."
89013537|NCT06300164|No Intervention|No intervention - Control Group|Individuals with celiac disease will not eat unripe carob cookie
89013538|NCT06300151|Experimental|Ultrasound Real-time Guidance combined with Dural Puncture Epidural Group|Ultrasound real-time guidance combined with dural puncture epidural Can improve the clinical effect of labor analgesia.
89013539|NCT06300151|Active Comparator|Dural Puncture Epidural Group|Dural Puncture Epidural is a clinical improvement of Combined Spinal-Epidural and is widely used in Maternal. The implementation step is to complete the epidural puncture, temporarily do not place a tube, puncture the dura mater with a subarachnoid anesthesia needle, but do not directly inject drugs into the subarachnoid space, and then leave an epidural catheter for administration according to epidural block.
89444226|NCT02488148|Experimental|Non-heated yoga|3 yoga classes to be completed at local studios in Austin, TX.
89013540|NCT06300138|Experimental|Drug combined with infrared hyperthermia group|oral itraconazole (children less than 15 years old 6 mg/kg/d; adult patients: 200 mg/d) for a total course of 3-6 months, while infrared hyperthermia device for 3 consecutive days (times / day), each treatment for 30 minutes After two weeks (14 days), the lesions of the same target were treated continuously for 2 days (times per day), and then once a week for 2 consecutive times, the method was the same as before. After 7 times of treatment, the study physician decided whether to continue treatment n times after 1-2 weeks (n ≥ 0) according to the recovery of the subjects.
89200016|NCT00765180|Experimental|1|The investigators evaluate the beneficial effect of colonoscopy with a transparent retractable extension (TRE) device on colorectal adenoma detection rate.
89444227|NCT02488148|No Intervention|Control|Maintain usual activities for the 12-week duration of the study.
89444228|NCT02487992|Experimental|CIK plus S-1 and Bevacizumab|"Cytokine-Induced Killer Cells are used to treat advanced colorectal cancer patients with S-1 and Bevacizumab.~S-1, 60mg,p.o.,Bid,d2-15. Bevacizumab (Avastin),7.5mg/kg,ivgtt,d1. 3 weeks is a cycle. Continue until the disease progress.~Cytokine-induced killer cells 3 cycles,every 1 year. Continue until the disease progress."
89444229|NCT02487992|No Intervention|S-1 and Bevacizumab|"S-1 is an oral anticancer agent, is a derivative of fluorouracil. Bevacizumab (Avastin) is a recombinant human monoclonal IgG1 antibody, which plays a role in the biological activity of human vascular endothelial growth factor. Bevacizumab is mainly used in the treatment of advanced colorectal cancer.~S-1, 60mg,p.o.,Bid,d2-15. Bevacizumab (Avastin),7.5mg/kg,ivgtt,d1. 3 weeks is a cycle. Continue until the disease progress."
89444230|NCT03327818||conservative surgery group|
89444231|NCT03327818||hysterectomy group|
89444232|NCT05508802|Other|State Counselor-Coordinated Services|In this program, services are coordinated by a counselor employed by the New Jersey State Division of Vocational Rehabilitation Services (NJDVRS), a state-based agency that assists people with disabilities who are interested in pursuing employment. While the participant is in inpatient rehabilitation or soon after their discharge, a member of the research team will assist them in completing the necessary documentation to apply for services from this agency. Services for which they are eligible will be provided directly through NJDVRS.
89444233|NCT05508802|Other|Center Facilitator-Coordinated Services|In this program, services are coordinated by a facilitator who is employed by Kessler Institute for Rehabilitation and works cooperatively with NJDVRS. The facilitator will begin working with the participant during inpatient rehabilitation, or soon after discharge, depending on when they enroll in the study. Some services for which they are eligible will be provided through NJDVRS and others will be provided to them by the facilitator.
89444234|NCT03327740||Subjects on DTG based ARV with ABC|These are subjects who begin a DTG based ARV regimen that includes ABC
89444235|NCT03327740||Subjects that start DTG based ARV regimen but without ABC|These are subjects who begin a DTG-based ARV regimen that does not contain ABC
89444236|NCT03327740||Subjects on other integrase inhibitor based regimen with ABC|These are subjects who begin other integrase inhibitor based regimens (RAL and EGV) that contains ABC
89444237|NCT03327740||Subjects on other integrase inhibitor based regimen but no ABC|These are subjects that start non-ABC containing RAL or EGV based regimens
89444238|NCT03327740||Subjects that start any other DTG based ARV regimen|These are subjects who begin any other DTG based ARV regimen that will include DTG as monotherapy or two-drug regimens
89444239|NCT05508724||Critically-ill mechanically ventilated patients|Intensive Care patients receiving mechanical ventilation due to respiratory failure
89444240|NCT03327662|Experimental|Interventional|Active CTC assessment: Patients will receive first line docetaxel until progression by CTC, and/or disease progression according to treating clinician or completion of 10 cycles. CTC results will be available to the treating clinician to guide decision-making. A progressing CTC count on Day 1 will require confirmation with a second CTC count performed on Day 15 (-/+ 5 days) of that cycle. If a patient is found to have two successive CTC determinations showing progression by CTCs, the clinician will receive a recommendation to discontinue docetaxel on the following cycle.
89444241|NCT03327662|No Intervention|Control|Patients will receive first line docetaxel until disease progression according to treating clinician or completion of 10 cycles. Patients and treating clinicians will not be disclosed to the results of CTC determinations.
89444242|NCT03322124|Experimental|Octenidine Mouthwash|0.1% Octenidinedihydrochlorid Solution for oromucosal use, mouth rinse with 10 ml for 30 s, 10 applications over 5 days
89444243|NCT03322124|Placebo Comparator|Placebo|Placebo Solution for oromucosal use, mouth rinse with 10 ml for 30 s, 10 applications over 5 days
89444244|NCT02567266|Experimental|Unified Protocol for Adolescents (UP-A)|Participants will be treated with the Unified Protocol for the Treatment of Emotional Disorders in Adolescence. Their clinicians will also receive feedback using the Youth Outcomes Questionnaire feedback system.
89444245|NCT02567266|Experimental|Treatment as Usual Plus (TAU+)|Participants will be treated by clinicians who receive feedback using the Youth Outcomes Questionnaire, but who otherwise use Treatment as Usual
89444246|NCT02567266|Active Comparator|Treatment as Usual (TAU)|Participants will receive Treatment as Usual provided at the study clinics.
89444247|NCT03327584|Active Comparator|Ultrasound Guided Arthrocentesis|The patients in this group will have ultrasound guided arthrocentesis.
89444248|NCT03327584|Active Comparator|Landmark Guided Arthrocentesis|The patients in this group will have landmark guided arthrocentesis.
89444249|NCT04442984|Active Comparator|FOLFOX6|5FU 400mg/m2 iv bolus d1, 5-FU 2400 mg/m² d1-2, Leucovorin 400 mg d1, Oxaliplatin 85 mg/m² d1, every two weeks (q2w) 9 cycles
89444250|NCT04442984|Experimental|mFOLFIRINOX|Irinotecan 180mg/m2 d1, 5FU 250mg/m2 iv bolus d1, 5-FU 2200 mg/m² d1-2, Leucovorin 400 mg d1, Oxaliplatin 85 mg/m² d1, every two weeks (q2w) 9 cycles
89444251|NCT03327506|Experimental|hypnosis group|Intervention: hypnosis session the eve of the surgery
89444252|NCT03327506|Active Comparator|premedication|alprazolam 0,5 mg the eve and the morning of the surgery
88928159|NCT01709357|Experimental|Passive stretching technique|"In each volunteer, the therapist identified the latent trigger point on the upper trapezius. A questionnaire about general information was performed. And the maximum homolateral side flexion of the trigger point was measured.~On the following week, the blind assessor performed the pre-intervention measurements of pressure pain threshold, pressure pain perception and cervical range of motions.~Next, the therapist performed the passive stretching of the upper trapezius muscle.~Then, all measurements, before described, were repeated, by the assessor, after 10 minutes, 24 hours and one week."
88928160|NCT01709357|Sham Comparator|Sham technique|"In each volunteer, the therapist identified the latent trigger point on the upper trapezius. A questionnaire about general information was performed. And the maximum homolateral side flexion of the trigger point was measured.~On the following week, the blind assessor performed the pre-intervention measurements of pressure pain threshold, pressure pain perception and cervical range of motions.~Next, for the sham technique, the therapist only contacted with his hands the head and the shoulder of the subject, without executing any movement, for 30 seconds.~Then, all measurements, before described, were repeated, by the assessor, after 10 minutes, 24 hours and one week."
88928161|NCT01709357|No Intervention|No intervention group|"In each volunteer, the therapist identified the latent trigger point on the upper trapezius. A questionnaire about general information was performed. And the maximum homolateral side flexion of the trigger point was measured.~On the following week, the blind assessor performed the pre-intervention measurements of pressure pain threshold, pressure pain perception and cervical range of motions.~Next,the subject was lying for 30 seconds, without intervention.~Then, all measurements, before described, were repeated, by the assessor, after 10 minutes, 24 hours and one week."
88928162|NCT01709370|Experimental|Letrozole plus PD 0332991|Drug: Letrozole 2.5mg/d for 16 weeks before surgery plus PD 0332991 (CDK-4/6 inhibitor) 125 mg/d for 3 out of 4 weeks in repeated cycles for 16 weeks before surgery
88928163|NCT01709396|Experimental|18 cGY ED-TBI|18 cGY ED-TBI followed by an allogenic done marrow transplant
88928164|NCT01709487|Experimental|HIPEC surgery with chemotherapy|"3 courses of pre-operative chemotherapy: carboplatin AUC = 5 IV + paclitaxel 175 mg/m2 IV every 3 weeks~Debulking surgery~HIPEC with cisplatin 50 mg/m2 intraperitoneally at the end of surgery~3 courses of post-operative chemotherapy: carboplatin AUC = 5 IV + paclitaxel 175 mg/m2 IV every 3 weeks"
88928165|NCT01709526|Other|Improvement after psychiatric inpatient treatment|
88928166|NCT01709552|Experimental|Computer Intervention|Patients randomized to the computer intervention will complete the B-SAFER computer program during their emergency department visit.
88928167|NCT01709552|Sham Comparator|Control|Patients randomized to the control arm will receive a time-equivalent computer-based program unrelated to substance use or partner violence.
88928168|NCT01709565||No hepatic dysfunction|No hepatic dysfunction, total plasma bilirubin ≤ 2.0 mg/dl
88928169|NCT01709565||Hepatic dysfunction|Hepatic dysfunction, total plasma bilirubin > 2.0 mg/dl
88928170|NCT01709591|No Intervention|No Prenatal education|These subjects will be randomized to receive routine prenatal epidural class (control group).
88928171|NCT01709591|Active Comparator|Receives Prenatal Education|Subjects randomized to this group will receive educational video addressing the cultural and perceptions regarding the myths on epidural in either English or Spanish (Keeping an Open Mind: choices in Labor Anaglesia: an educational produce of the Society for Obstetric Anesthesia and perinatology)
88928172|NCT01709604||continuous venovenous hemofiltration|Continuous venovenous hemofiltration(CVVH):blood access was achieved by placing a double lumen catheter in the femoral or internal jugular vein. Continuous diffusive solute transport is achieved by infusing a dialysis fluid that runs counter-current to blood at an ultrafiltration rate of 35 ml/h/Kg.
88928173|NCT01709604||Standardized therapy regimens|The standardized therapy regimens included reduce absorption, accelerate the elimination and prevent the complications in patients with paraquat poisoning.
88928174|NCT01709617|Experimental|Glucose-glucose|Glucose ingestion
88928175|NCT01709617|Active Comparator|Glucose-Fructose|glucose-fructose ingestion
88928176|NCT01709617|Active Comparator|disaccharide|Disaccharide ingestion
89444253|NCT02567188||Cohort of CKD Participants|Pre-dialysis participants with CKD treated with MIRCERA according to the current standard of care and in line with the current local summary of product characteristics were observed for maximum of 12 months.
88928177|NCT01709630||Neonatal|Neonates born to pregnant women exposed to magnesium sulfate for preeclampsia, tocolysis, or neuroprotection.
88928178|NCT01709630||Maternal|Pregnant women exposed to magnesium sulfate for preeclampsia, tocolysis, or neuroprotection
88928179|NCT01709643|Other|High fat breakfast lean subjects|Subjects will consume a high fat breakfast, containing of sausage rolls. Energy content of the breakfast will be set to 50 % of the recommended daily calorie intake (BMR times 1.3).
88928180|NCT01709643|Other|High fat breakfast,obese subjects|Subjects will consume a high fat breakfast, containing of sausage rolls. Energy content of the breakfast will be set to 50 % of the recommended daily calorie intake (BMR times 1.3).
89200017|NCT00960310|Experimental|1|Bicalutamide 50 mg Film-Coated Tablets (Sandoz Inc., USA)
89200018|NCT00960310|Active Comparator|2|Bicalutamide 50 mg Film-Coated Tablets (Casodex) (Astrazeneca Pharmaceutical LP, USA)
89200019|NCT00610155|Placebo Comparator|1|
89200020|NCT00610155|Experimental|2|
89444254|NCT02487914|Active Comparator|lidocaine iontophoresis using interferential current|the threshold of pressure, tactile,and pain thresholds were evaluated after the iontophoresis of Lidocaine using interferential current.
89444255|NCT02487914|Active Comparator|interferential current|the threshold of pressure, tactile,and pain thresholds were evaluated after the application of interferential current.
89444256|NCT02487914|Active Comparator|lidocaine|the threshold of pressure, tactile,and pain thresholds were evaluated after the application of topical Lidocaine.
89444257|NCT02487680|Experimental|Breakfast meal|A breakfast like meal will be provided together with a drink to overnight fasted subjects
89444258|NCT02487680|Experimental|Lunch meal|A lunch like meal will be provided together with a drink to overnight fasted subjects
89444259|NCT03319550|Experimental|Casein|"LPS + 36 hour fast and bedrest + Casein (9% leucine) - 0.6 g protein/kg bodyweight, 1/3 as bolus and 2/3 as sipping."
89444260|NCT03319550|Experimental|Whey|"LPS + 36 hour fast and bedrest + Whey (11% leucine) - 0.6 g protein/kg bodyweight, 1/3 as bolus and 2/3 as sipping"
89444261|NCT03319550|Experimental|Leucine-enriched whey|"LPS + 36 hour fast and bedrest + Leucine-enriched whey (16% leucine) - 0.6 g protein/kg bodyweight, 1/3 as bolus and 2/3 as sipping"
89444262|NCT04442906|Active Comparator|group B|IGroup B received Intra-articular injection of 20 ml bupivacaine 0.25%+ 1 ml saline
89444263|NCT04442906|Active Comparator|group BD|. Group BD received Intra-articular injection of 20 ml bupivacaine 0.25%+ 1 ml dexmedetomidine (100 ug).
89444264|NCT04442906|Active Comparator|group BF|Group BF received Intra-articular injection of 20 ml bupivacaine 0.25%+ 1 fentanyl (50 ug).
89444265|NCT05500456|Experimental|Clear aligners|The patients in this group will be treated using clear aligners.
89444266|NCT05500456|Active Comparator|Fixed appliances.|The patients in this group will be treated using fixed appliances.
89444267|NCT03322046||Therapeutic Lifestyle Change (TLC) Intervention Group|TLC group received CVD risk lecture, enrolled in lifestyle program, received follow-up visits from team practitioner after each blood draw, access to food journaling portal for 12 month period, telephonic coaching
89444268|NCT03322046||Control Group|Control group received CVD risk lecture, then baseline, 3, 6, 12 month blood draws and 3 day food journals prior to each blood draw.
89444269|NCT02487602|Active Comparator|A|Up to 5 Gelesis100 and/or placebo capsules 30 minutes before a standard radiolabeled lunch.
89444270|NCT02487602|Active Comparator|B|Up to 5 Gelesis100 and/or placebo capsules 30 minutes before a standard radiolabeled lunch.
89444271|NCT02487602|Placebo Comparator|C|Placebo capsules 30 minutes before a standard radiolabeled lunch.
89444272|NCT02487602|Experimental|D|Up to 5 Gelesis100 and/or placebo capsules 30 minutes before a radiolabeled water.
89444273|NCT02487602|Experimental|E|Up to 5 Gelesis100 and/or placebo capsules 10 minutes before a radiolabeled meal.
89444274|NCT05504980|Experimental|İntervention group|Patients in the intervention group will be given 30 degrees right lateral, supine, and 30 degrees left lateral positions, 1 hour apart, respectively.
89013541|NCT06300138|Experimental|Drug group|Itraconazole (6 mg/kg/d; for children less than 15 years old, 200 mg/d for adults) was taken orally for 3-6 months. The specific course of treatment was determined by the research physician according to the recovery of the subjects.
89200021|NCT00610155|Experimental|3|
89444275|NCT05504980|No Intervention|Control group|Patients in the control group will be given 30 degrees right lateral, supine and 30 degrees left lateral positions, respectively, at 2 hour intervals according to the hospital routine practice.
89444276|NCT02487836|Other|First attempt stenting (T0 = date of the first act)|Efficacy of laying of a biliary stent for chemotherapy realization
89200022|NCT00960466|Active Comparator|Usual Care Arm|The usual care group will receive their Chemotherapy or Radiotherapy as normal.
89444277|NCT05500300|Experimental|Neo-Russian Electrical Stimulation|"Subjects will receive Neo-Russian electrical stimulation. The Maximal Elicited Induced Contraction (MEIC) will be measured.~One week later, after a washout period, a fatigue will be done with this type of current."
89444278|NCT05500300|Experimental|Aussie Electrical Stimulation|"Subjects will receive Aussie electrical stimulation. The Maximal Elicited Induced Contraction (MEIC) will be measured.~One week later, after a washout period, a fatigue will be done with this type of current."
89444279|NCT05500300|Experimental|RBS Electrical Stimulation|"Subjects will receive RBS electrical stimulation. The Maximal Elicited Induced Contraction (MEIC) will be measured.~One week later, after a washout period, a fatigue will be done with this type of current."
89444280|NCT05500300|Experimental|RBS-IPI Electrical Stimulation|"Subjects will receive RBS-IPI electrical stimulation. The Maximal Elicited Induced Contraction (MEIC) will be measured.~One week later, after a washout period, a fatigue will be done with this type of current."
89444281|NCT05500300|Experimental|HIFEM|"Subjects will receive HIFEM electrical stimulation. The Maximal Elicited Induced Contraction (MEIC) will be measured.~One week later, after a washout period, a fatigue will be done with this type of current."
89444282|NCT02487758|Experimental|Ridge preservation Flap|The flap procedure will consist of a full-thickness papilla preservation flap performed on the buccal and a full thickness flap on the palatal.
89444283|NCT02487758|Experimental|Ridge preservation Flapless|The test will be a flapless technique with tunneling and an intramucosal vertical incision on the buccal.
89444284|NCT04696354|Other|Interrogation Arm|patients will first be evaluated with MPV (limited to 3 views). The prescribed course of treatment based on the MPV results will be documented and patients will then be evaluated using IVUS. A treatment plan based on IVUS results will be compared with the MPV guided treatment plan and any differences will be documented. Any patients determined to still require venous stenting based on IVUS results will be stented accordingly using IVUS to guide stent placement.
89501724|NCT02156141|Experimental|Supervised high intensity training|"8 weeks of supervised high intensity training, 10 minutes, 3 times a week (once a week supervised) on a cycle ergometer followed by 8 weeks of unsupervised optional training.~Participants: Patients with Kennedy's disease or healthy control subjects (individually matched with patients).~Participants: Patients with Kennedys disease and healthy control subjects."
89501725|NCT02156141|Experimental|Unsupervised High intensity training|"8 week control period with no training followed by 8 weeks of unsupervised high intensity training on a cycle ergometer.~Participants: Patients with Kennedy's disease."
88928181|NCT01709643|Other|HF breakfast with protein,lean subjects|For the HFP breakfast, the subjects will consume 'Protifar' (Nutricia, Cuijk, The Netherlands) in addition to the sausage rolls. The amount of added proteins will be calculated to assure that the total energy content from proteins in the breakfast equals 20 %,
88928182|NCT01709643|Other|HF breakfast with protein,obese subjects|For the HFP breakfast, the subjects will consume 'Protifar' (Nutricia, Cuijk, The Netherlands) in addition to the sausage rolls. The amount of added proteins will be calculated to assure that the total energy content from proteins in the breakfast equals 20 %,
88928183|NCT01709656|Experimental|MSC plus NSAID|"human mesenchymal stem cells:1*10^4-6 cells /Kg , IV (in the vein) on day 1 of each 14-60 day cycle,1-6 times treatment, plus non-steroid anti-inflammatory drugs (NSAID: celecoxib, Celebrex® 0.2g Bid(twice a day),PO (Per Os).~Duration of treatment:24 weeks for follow up. collect peripheral blood (PBMCs and serums)of those patients at baseline and every 4 weeks for basic study after they signed informed consent."
88928184|NCT01709656|Experimental|NSAID|"non-steroid anti-inflammatory drugs (NSAID: celecoxib, Celebrex® 0.2g Bid(twice a day),PO (Per Os);a total of 24 weeks for follow up;collect peripheral blood (PBMCs and serums)of those patients at baseline and every 4 weeks for basic study after they signed informed consent."
88928185|NCT01709669||Enrolling by invitation|
88928186|NCT01709682|Active Comparator|AAD therapy|Recurrent episodes were pharmacologically managed by conventional AAD therapy (propafenone, flecainide, and/or sotalol as first-line drugs in patients without structural heart disease or amiodarone as a single drug or in combination in patients with structural heart disease or in case of first-line drug failure) according to AF management guidelines.
88928187|NCT01709682|Active Comparator|re-ablation procedure|"Reisolation of the PVs was performed by identifying the breakthrough site on the mapping catheter (NaviStar ThermoCool, Biosense-Webster Inc., Diamond Bar, CA). RF energy was delivered at 43°C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and was reduced to 43°C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation rate of 17 mL/min. Each lesion was ablated continuously until the local potential amplitude decreased by >80% or RF energy deliveries exceeded 40 s.~The endpoint of ablation was complete PVI; this was confirmed when Lasso catheter mapping showed the disappearance of all PV potentials or the dissociation of PV potentials from LA activity. Only in patients with induced left atrial flutter, additional RF ablation lines were created by connecting the left inferior PV to the mitral annulus (mitral isthmus) and the roof of the LA between the two superior PVs."
88928188|NCT01709760|Experimental|methotrexate & ENIA11|ENIA11 25 mg, sc twice weekly
88928189|NCT01709760|Active Comparator|methotrexate & Placebo|Placebo, sc twice weekly
88928190|NCT01709773|Experimental|Focal treatment arm|
88928191|NCT01709812|Other|1 standard care|standard care
88928192|NCT01709812|Experimental|2 individualized PSP|individualized patient support program
88928193|NCT01709825|Placebo Comparator|Sugar Pill|Sugar Pill will be taken as a capsule once daily for 6 weeks.
88928194|NCT01709825|Experimental|Probiotic- Bifidobacterium bifidum|Bifidobacterium bifidum (Supplement A) will be taken as a capsule once daily for 6 weeks.
88928195|NCT01709825|Experimental|Probiotic- Lactobacillus helveticus|Lactobacillus helveticus (Supplement B) will be taken as a capsule once daily for 6 weeks.
88928196|NCT01709825|Experimental|Probiotic- Bifidobacterium longum ss. Infantis R0033|Bifidobacterium longum ss. Infantis R0033 (Supplement C)will be taken as a capsule once daily for 6 weeks.
88928197|NCT01709851||Type 1 Diabetes - vMD and sMD|Patients will undergo vascular (vMD) and subcutaneous microdialysis (sMD) using the GMD-system (GlucoMen(R)Day-system)
88928198|NCT01709851||Type 1 diabetes - vMD|Patients will undergo vascular microdialysis (vMD) using the GMD-system (GlucoMen(R)Day-system)
88928199|NCT01709877|Active Comparator|Traditional multiport laparoscopic cholecystectomy|Standard laparoscopic cholecystectomy performed by the traditional multiport technique
88928200|NCT01709877|Experimental|Single port laparoscopic cholecystectomy|Laparoscopic cholecystectomy performed using the reusable ENDOCONE system with dedicated curved coaxial instruments
88928201|NCT01709890||Airway catheter during sedation|
88928202|NCT01709916||Glaucoma patients|Glaucoma patients treated with eye drops to lower the IOP.
88928203|NCT01709929|Experimental|Insulin detemir|
88928204|NCT01709942|Experimental|degarelix group|group of patients treated with long acting GnRH antagonist
88928205|NCT01709942|Active Comparator|Cetrorelix 0.25mg|patients treated with gonadotropin and Cetrorelix ina flexible GnRH antagonist protocol
88928206|NCT01709955|Experimental|Gucomannan|
88928207|NCT01709955|Placebo Comparator|Placebo pill|
88928208|NCT01709968|Experimental|MAGNOX 520®|MAGNOX 520® (un-organic granular magnesium complex, composed of Magnesium Oxide & Magnesium Oxide Monohydrate 865mg, Provides 520 mg of free elemental Mg ++); Oral administration once daily for 4 weeks.
88928209|NCT01709968|Placebo Comparator|Similarly looking placebo.|Similarly looking placebo. Oral administration once daily for 4 weeks.
88928210|NCT01709994|Active Comparator|aspirin|Aspirin dosage 100 mg/day
88928211|NCT01709994|No Intervention|standard medication|the patients will continue with standard medication
88928212|NCT01710059|Experimental|Experimental: Intervention Group|"Experimental: Intervention Group~1) Asthma Supervision; 2) Mobile Phone with talking, texting, and data plan; 3) Inhaled Corticosteroid Mobile Phone Application to provide virtual doctor supervision, immediate feedback, and positive reinforcement for taking inhaled corticosteroid medication as indicated; and 4) Beta2-adrenergic agonist Mobile Phone Application to monitor real time patterns of use of beta2-adrenergic agonist medication for asthma."
88928213|NCT01710072|Experimental|aspirin|aspirin 81 mg po every day
88928214|NCT01710072|No Intervention|no aspirin|
88928215|NCT01710085|Experimental|Diffusion weighted imaging, Recurrence|
88928216|NCT01710098||Degarelix|adult male patients with advanced hormone dependent prostate cancer who receive 240 mg as a start dose and then monthly 80mg Firmagon® for one year
88928217|NCT01710111|Experimental|Intervention Recipients Face Shield|Face shield and repeat hand hygiene measures
89444285|NCT04696354|Other|Deferred Interrogation Arm|"Deferred Interrogation Guidelines for this study are as follows:~Mandate:~• Continued compression therapy/stockings as prescribed.~Allow:~Periodic leg elevation.~Sclerotherapy under ulcer bed.~Recommend mechanical debridement as needed.~Wound biopsy if evidence of infection.~Systemic antibiotics if patient is diagnosed with an infection, avoid prophylactic prescription.~Pain management medication (Pentoxifylline/Trental) allowed but not recommended~Topical antimicrobial as needed.~Prohibit:~Negative pressure systems.~Artificial and/or autologous skin grafting within first 3 months after randomization and within the first 3 months for subjects that crossover from deferred interrogation to the interrogation arm."
89444286|NCT02491034|Other|Intervention|Depression Education Intervention
89444287|NCT04510012||Mild COVID-19|SARS-Cov-2 infected individuals with mild symptoms (WHO Ordinal Scale for Clinical Improvement in COVID-19: scores 1-2)
89444288|NCT04510012||Moderate COVID-19|SARS-Cov-2 infected individuals with moderate symptoms (WHO Ordinal Scale for Clinical Improvement in COVID-19: scores 3-4)
89444289|NCT04510012||Severe COVID-19|SARS-Cov-2 infected individuals with severe symptoms (WHO Ordinal Scale for Clinical Improvement in COVID-19: scores 5-8)
89444290|NCT03327350||WATCHMAN transplantation|This group will receive WATCHMAN device implantation.Device implantation included concomitant antithrombotic medication to facilitate device endothelialization: warfarin and aspirin for 45 days. To assess for device stability, peridevice leaks, and device-related thrombus, transesophageal echo (TEE) imaging was performed at 45 days, 6 months, and 12 months. When the 45-day TEE revealed minimal residual peridevice flow (jet width ≤5 mm) and no device-related thrombus, warfarin will be stopped and replaced by clopidogrel, 75 mg daily, until the 6-month visit, after which only aspirin was continued. If an adequate seal is not obtained or a thrombus is detected, patients continue taking warfarin until an adequate seal is attained or thrombus is resolved before transitioning to aspirin.
88928218|NCT01710111|No Intervention|Control Recipients|No face shield and no repeat hand hygiene measures
88928219|NCT01710124|Experimental|Incentive|Subjects in this group will receive financial incentives for using grocery coupons to purchase healthy foods.
88928220|NCT01710124|No Intervention|No incentive|Subjects in this group will receive no financial incentives.
88928221|NCT01710150|Placebo Comparator|CTI ablation only|subjects undergoing cavo-tricuspid isthmus (CTI) ablation alone for Atrial flutter
88928222|NCT01710150|Active Comparator|CTI ablation and PVI.|subjects undergoing cavo-tricuspid isthmus (CTI) ablation for Atrial flutter and pulmonary vein isolation (PVI) for Atrial Fibrillation.
88928223|NCT01710163|Experimental|Lithium|Potentiation of previous treatment (Quetiapine monotherapy) with Lithium (0.5 - 0.8 mEq/L)
88928224|NCT01710163|Experimental|Aripiprazole|Potentiation of previous treatment (Quetiapine monotherapy) with Aripiprazole (10 - 15 mg)
88928225|NCT01710189|Experimental|TicoVac immunisation - right deltoid muscle|IM immunisation right deltoid muscle
88928226|NCT01710189|Experimental|TicoVac immunisation - upper anterolateral thigh|IM: right upper anterolateral thigh
88928227|NCT01710202||Placebo|Control group who will not receive hydrocortisone. Will act as a comparison group to the hydrocortisone group.
88928228|NCT01710202||Experimental: Hydrocortisone|Group will receive 20mg oral hydrocortisone
88928229|NCT01710215|No Intervention|Usual Care|"No outreach mailed invitations.~Ordering of colonoscopy or FIT for screening at the discretion of the primary provider.~Follow up of abnormal tests and results reporting to the patient at the discretion of primary and specialty providers."
88928230|NCT01710215|Experimental|FIT Screening Strategy|"Mailed outreach invitation to complete FIT, including a test kit (1-sample FIT, simplified instructions on how to perform the test, and return mailer with prepaid postage).~Two live phone reminders from project staff 2 to 3 weeks after the invitation to encourage screening completion.~Centralized processes to promote guideline-based follow up."
88928231|NCT01710215|Experimental|Colon Screening Strategy|"Mailed outreach invitation to complete a colonoscopy, including a number to call to schedule a colonoscopy.~Two live phone call reminders from project staff 2 to 3 weeks after the mailed invitation to encourage screening completion.~Centralized processes to promote guideline-based follow up."
88928232|NCT01710228|Placebo Comparator|Methylprednisolone placebo|"subjects will be randomized 1:1 to receive either:~Methylprednisolone placebo or~Methylprednisolone"
88928233|NCT01710228|Experimental|methylprednisolone|"subjects will be randomized 1:1 to receive either:~Methylprednisolone placebo or~Methylprednisolone"
88928234|NCT01710267||Observation group|This group includes all volunteers of this observation study.
88928235|NCT01710280|Active Comparator|Native palm olein|75 g native palm olein
88928236|NCT01710280|Experimental|Interesterified palm olein|75 g interesterified palm olein
88928237|NCT01710293|Experimental|Communication of Patients Lost to Follow-up to Providers|This intervention will consist of two related, continuous steps over at least a 12-month period. In the first step, the investigators will query the VA's Corporate Data Warehouse (CDW, a repository of near real-time patient data from all VA medical centers) weekly to identify possible lost to follow-up events in a pre-specified time period and for a random sample of about half of the providers at the investigators' study sites. These identified patient charts will be reviewed by Facility Recipients/Cancer Trackers at each site who will then communicate patients truly found to be lost to follow-up to the appropriate provider/care team.
88928238|NCT01710293|No Intervention|Usual Care|In the usual care group, providers will continue to use the existing notification system to receive abnormal test results in accordance with institutional norms, policies, and procedures. There are no formal patient-tracking programs currently at our study sites for all abnormal test results. The investigators will apply our computerized surveillance tools in the usual care arm only when the investigators are ready to conduct the final chart reviews on intervention patients and identify these patients in similar time periods as in the intervention arm. If persistent delays are found, the investigators will inform the patients' primary care providers.
88928239|NCT01710319||smoker with lung cancer|patients that smoke greater than 45 pack years or have end organ damage due to cigarette smoking and have lung cancer
88928240|NCT01710319||smoker without lung cancer|patients that smoke greater than 45 pack years or have end organ damage due to cigarette smoking and do not have lung cancer
88928241|NCT01710319||nonsmoker with lung cancer|patients that have smoked less than 100 cigarettes in their lifetime and have lung cancer
88928242|NCT01710319||nonsmoker without lung cancer|patients that have smoked less than 100 cigarettes in their lifetime and do not have lung cancer
88928243|NCT01710371|Experimental|Arginine Stimulation Testing|Establish the methodology for glucose enhanced arginine stimulation testing (AST).
88928244|NCT01710371|Experimental|PET Imaging|Determine if pancreatic PET-determined binding measures of 18F-AV-133 differ in up to 60 subjects determined to be at one of four stages of the natural history of Type 2 Diabetes: Healthy Overweight/obese Volunteers (HOV), Subjects with Pre-diabetes (PD) and Type 2 Diabetes mellitus (T2DM).
88928245|NCT01710384|Experimental|betamethasoneb, 34-36 weeks, preterm labor|betamethasone 12 mg 2 injections will be given 24-hours apart.
88928246|NCT01710384|No Intervention|preterm labor, 34-37 weeks|betamethasone 12 mg 2 injections will be given 24-hours apart.
88928247|NCT01710397|No Intervention|Standard group, non-pregnant adults|Comparison group (prospective enrollment)
88928248|NCT01710397|No Intervention|Standard group, pregnant women|Comparison group (retrospective record review)
88928249|NCT01710397|Experimental|Rapid group, non-pregnant adults|Rapid ART initiation
88928250|NCT01710397|Experimental|Rapid group, pregnant women|Rapid ART initiation
88928251|NCT01710410|Experimental|DLPFC tDCS (left anode/right cathode)|Active transcranial Direct Current Stimulation (tDCS) administered to the left DLPFC. Brief (20-min) application of weak electric current (e.g., 2 mA) to the scalp.
88928252|NCT01710410|Experimental|DLPFC tDCS (left cathode/right anode)|Active transcranial Direct Current Stimulation (tDCS) administered to the right DLPFC. Brief (20-min) application of weak electric current (e.g., 2 mA) to the scalp.
88928253|NCT01710410|Sham Comparator|DLPFC tDCS|Sham transcranial Direct Current Stimulation (tDCS) delivered to the DLPFC. Brief (30-sec) application of weak electric current (e.g., 2mA) to the scalp.
88928254|NCT01710423|Experimental|Immediate Intervention|Peer mentoring intervention ('Cooking with Friends')
88928255|NCT01710423|No Intervention|Delayed Entry Control|
88928256|NCT01710436||Low dose - Wild genotype (LW)|75mg Qd > 7d Clopidogrel pre-treatment before PCI, according to the reality; CYP2C19 wild genotype
88928257|NCT01710436||Low dose - Variant genotype (LV)|75mg Qd > 7d Clopidogrel pre-treatment before PCI, according to the reality; CYP2C19 variant genotype
88928258|NCT01710436||High dose - Wild genotype (HW)|300mg Clopidogrel loading dose pre-treatment before PCI, according to the reality; CYP2C19 wild genotype
88928259|NCT01710436||High dose - Variant genotype (HV)|300mg Clopidogrel loading dose pre-treatment before PCI, according to the reality; CYP2C19 variant genotype
88928260|NCT01710449|Experimental|Normal|The subjects will receive the gas by breathing perfluorinated gas/oxygen mixture using either a disposable Mouthpiece without Bite blocks or Disposable oral-nasal (full Face) Non Invasive Ventilation with no Anti Asphyxia Vents no vent CAPA/NPPV Face mask and a standard Douglas Bag system.
88928261|NCT01710449|Experimental|Lung Disease|The subjects will receive the gas by breathing perfluorinated gas/oxygen mixture using either a disposable Mouthpiece without Bite blocks or Disposable oral-nasal (full Face) Non Invasive Ventilation with no Anti Asphyxia Vents no vent CAPA/NPPV Face mask and a standard Douglas Bag system.
88928262|NCT01710462|Experimental|Pantoprazole + Domperidone|The combination of pantoprazole and domperidone provided for the study will be the new incremental formulation produced by Eurofarma. For this study will be used doses of capsules containing 20 mg pantoprazole, 20 mg of domperidone.
88928263|NCT01710462|Active Comparator|Pantozol® (Takeda)|The Pantozol® may be presented in boxes of coated tablets of 20 mg or 40 mg. For this study will be used 20 mg tablets.
89444291|NCT03327350||Oral anticoagulant therapy|"This group will take oral anticoagulant drugs(warfarin or the new oral anticoagulant drugs like Dabigatran ).~For patients taking warfarin, international normalized ratio (INR) monitoring wil be performed at least every 2 weeks for 6 months and at least monthly thereafter, targeting an INR between 2 and 3. Follow-up visits occurred twice annually after the first year, with neurological assessments at 12 months and yearly thereafter or whenever a neurological event is suspected."
89444292|NCT03327272|Active Comparator|Local injection of methylprednisolone|Drug: methylprednisolone Injection of 80mg methylprednisolone injectable suspension at surgical site prior to incision closure
89444293|NCT03327272|Placebo Comparator|Local injection of saline|Administration of saline at surgical site prior to incision closure.
89444294|NCT00706238|Experimental|GSK1203486A Group|"Patients received 4 cycles of MAGE-A3 product as follows:~Cycle 1: 6 doses, each given at a 2-week interval,~Cycle 2: 6 doses, each given at a 3-week interval~Cycle 3: 4 doses, each given at a 6-week interval~Cycle 4: 4 doses, each given at a 3-month interval followed by 4 doses, each given at a 6-month interval.~The MAGE-A3 product was administered intramuscularly in the deltoid or lateral regions of the thighs, alternately on the right and left sides."
89444295|NCT03321968|Experimental|Quadrivalent VLP Influenza Vaccine - Lot 1|Participants received one intramuscular (IM) injection of 0.5 mL of their assigned vaccine lot of 30 μg/strain of the Quadrivalent VLP Influenza Vaccine on Day 0.
89444296|NCT03321968|Experimental|Quadrivalent VLP Influenza Vaccine - Lot 2|Participants received one IM injection of 0.5 mL of their assigned vaccine lot of 30 μg/strain of the Quadrivalent VLP Influenza Vaccine on Day 0.
88928264|NCT01710488|Active Comparator|Levofloxacin 1 tablet 500 mg once a day|Levofloxacin 1 tablet 500 mg once a day for 7-10 days. It will be used, according to a randomization list pre-ordered, centralized, in blocks of 4 patients
88928265|NCT01710488|Experimental|Prulifloxacin 1 tablet 600 mg once a day|Prulifloxacin 1 tablet 600 mg once a day for 7-10 days. It will be used, according to a randomization list pre-ordered, centralized, in blocks of 4 patients
88928266|NCT01710540|Other|Metformin GSK 850mg|open label, crossover, two period, two treatment, two sequence, single dose of Metformin 850mg
88928267|NCT01710540|Other|Glucophage 850mg|open label, crossover, two period, two treatment, two sequence, single dose
88928268|NCT01710553|Other|Metformin GSK 1000mg|open label, crossover, two period, two treatment, two sequence, single dose of Metformin 1000mg
88928269|NCT01710553|Other|Glucophage 1000mg|open label, crossover, two period, two treatment, two sequence, single dose of Glucophage 1000mg to asset bioequivalence
89444297|NCT03321968|Experimental|Quadrivalent VLP Influenza Vaccine - Lot 3|Participants received one IM injection of 0.5 mL of their assigned vaccine lot of 30 μg/strain of the Quadrivalent VLP Influenza Vaccine on Day 0.
89444298|NCT04493450||Smartphone-users|Cancer patients who use smartphones
89444299|NCT05508178|Experimental|Norovirus GI.4 / GII.4 Bivalent VLP Vaccine (100 µg)|Participants 18-40 years of age, 2-dose regimen: Norovirus bivalent GI.4 (50 μg) / GII.4 (50 μg) virus-like particle (VLP) vaccine, intramuscularly (IM), on Day 1 and Day 29
89444300|NCT05508178|Experimental|Norovirus GI.4 / GII.4 Bivalent VLP Vaccine (300 µg)|Participants 18-40 years of age, 2-dose regimen: Norovirus bivalent GI.4 (150 μg) / GII.4 (150 μg) virus-like particle (VLP) vaccine, intramuscularly (IM), on Day 1 and Day 29
89444301|NCT05508178|Placebo Comparator|Placebo|Participants 18-40 years of age, 2-dose regimen: Placebo (norovirus vaccine vehicle without antigens), intramuscularly (IM), on Day 1 and Day 29
89444302|NCT03327194|Experimental|ADHEAR Audio processor|
89444303|NCT03327116|Experimental|Methotrexate|
89444304|NCT04678960|No Intervention|Standard Reentry Practice|Youth/safe adult participants only receive assessments (baseline assessment while youth are at the facility; 3, 6, 12, 18 months follow-up assessments after youth are released from the facility).
89444305|NCT04678960|Experimental|TBRI Training only|"Youth/safe adult dyads participate in 9 TBRI caregiver modules (caregivers only), 9 youth modules (youth only), and 4 Nurture Groups (caregiver and youth joint role-play activities) prior to youth's release.~After the youth's release, they would receive phone support (only when requested by the caregiver or youth)."
89444306|NCT04678960|Experimental|TBRI Training + TBRI In-Home Structured Coaching|"Youth/safe adult dyads participate in 9 TBRI caregiver modules (caregivers only), 9 youth modules (youth only), and 4 Nurture Groups (caregiver and youth joint role-play activities) prior to youth's release.~After youth's release, trained TCU TBRI Practitioners provide coaching sessions to youth/safe adult dyads in which they meet 4 times (once monthly) over the first 4 months following release."
89444307|NCT04678960|Experimental|TBRI Training + TBRI In-Home Responsive Coaching|"Youth/safe adult dyads participate in 9 TBRI caregiver modules (caregivers only), 9 youth modules (youth only), and 4 Nurture Groups (caregiver and youth joint role-play activities) prior to youth's release.~After youth's release, trained TCU TBRI Practitioners provide coaching sessions to youth/safe adult dyads. They meet a minimum of 2 times during the first 2 months after release. Starting from Month 3, TBRI Practitioners would provide additional coaching when requested or when a research assistant (RA) identifies a need for additional coaching sessions."
89444308|NCT06036420|Experimental|1) Flashed Light Therapy, 2) Flashed Light Therapy with Cognitive Behavioral Therapy|"Treatment Phase 1 (2 weeks duration): light flashes administered for 60 minutes daily beginning 75 minutes prior to the participant's average morning wake time and ending 15 minutes before average morning wake time.~Treatment Phase 2 (4 weeks duration): will begin immediately following phase 1 and involve daily light flashes (as described above) combined with weekly 50-minute videoconference-delivered cognitive-behavioral therapy."
89444309|NCT06036407|Experimental|Participants|Participants make an appointment at a hearing aid shop in Switzerland. They get the results right after the hearing test and may take it to their respective physician if wanted.
88928270|NCT01710566|Experimental|Group 1|600 mcg oral misoprostol
88928271|NCT01710566|Experimental|Group 2|10 IU oxytocin in Uniject
88928272|NCT01710579|Other|ARM 1 Healthy Volunteers|Ano-rectal 3D high resolution manometry, ano-rectal radial endsonography, dynamic ano-rectal endosonography
88928273|NCT01710579|Other|ARM 2: Patients with fecal incontinence|Ano-rectal 3D high resolution manometry, ano-rectal radial endsonography, dynamic ano-rectal endosonography
88928274|NCT01710579|Other|ARM 3 Patients with constipation|Ano-rectal 3D high resolution manometry, ano-rectal radial endsonography, dynamic ano-rectal endosonography
89444310|NCT06036368|Experimental|Peroneal eTNM arm|All patients will receive treatment with peroneal eTNM
89444311|NCT06036355|Experimental|Orally take NMN (Vital NAD) combined with DC cell vaccine injection|The arm is a combination of two drugs. The first NMN is a precursor of NAD+, which is used orally. DC vaccine is a kind of immune cells expanded in vitro and used by injection.
89444312|NCT06036277||Experimental group|Women who wish to give birth without epidural anesthesia and have benefited of water immersion during labor
88928275|NCT01710592|Active Comparator|Epirubicin, Oxaliplatin, Capecitabine|"Epirubicin 50mg/m2 (day 1) bolus injection~Oxaliplatin 130mg/m2 (day 1) in 250mls of 5% dextrose. i.v. over 2 hours~Capecitabine 625mg/m2 (days 1-21) b.d. orally~8 x 3-weekly cycle"
88928276|NCT01710592|Active Comparator|Docetaxel, Oxaliplatin|"Docetaxel 20mg/m2 (days 1, 8 & 15)in 250mls of 5% dextrose. i.v. over 30mins (Dexamethasone 8mg i.v, Chlorpheniramine 10mg i.v,Ranitidine 50mg i.v. to be given 30 minutes prior to Docetaxel)~Oxaliplatin 85mg/m2 (days 1 & 15)in 250mls of 5% dextrose. i.v. over 2 hours~6 x 4-weekly cycle"
88928277|NCT01710605|Active Comparator|Standard|Treatment choices (hormonotherapy or chemotherapy) are done according to standard of each center based on clinical, radiological and biological information.
88928278|NCT01710605|Experimental|Circulating Tumor Cells|"Treatment choices (hormonotherapy or chemotherapy) are done according to the number of CTC / 7.5 ml of blood at baseline :~If <5 CTC : Hormonotherapy If 5 or more CTC : chemotherapy"
88928279|NCT01710631|Experimental|eszopiclone 3 mg|eszopiclone 3 mg (comprised of either two 1.5 mg tablets, or one 1 mg tablet and one 2 mg tablet).
88928280|NCT01710631|Placebo Comparator|placebo|placebo tablet
88928281|NCT01710670|Experimental|Ethanol + Brivaracetam|Treatment A: Ethanol + Brivaracetam
88928282|NCT01710670|Experimental|Ethanol Placebo + Brivaracetam|Treatment B: Ethanol Placebo + Brivaracetam
88928283|NCT01710670|Experimental|Ethanol + Brivaracetam Placebo|Treatment C: Ethanol + Brivaracetam Placebo
88928284|NCT01710683||Control group|Median age 45 years, 18-63.
88928285|NCT01710683||Intervention group|Median age 46 years, 18-62.
88928286|NCT01710696|Experimental|Individual dose|
88928287|NCT01710696|Experimental|Fixed dose|
88928288|NCT01710722|Experimental|caffeine and ephedrine|Caffeine 200 mg tablets and ephedrine HCl 25 mg tablets three times a day with placebo leptin A-200 subcutaneously once daily.
89444313|NCT06036277||Control group|Women who wish to give birth without epidural anesthesia and have not benefited of water immersion during labor
89444314|NCT06036264||Exposed subject group|Patients, starting dialysis, eligible for arteriovenous fistula (AVF) creation and/or renal transplantation who received pre-Advanced Practice Nurse (APN) intervention in their care pathway will be included Datas will be collected of medical record.
89444315|NCT06036264||Comparable unexposed subject group|"All patients starting dialysis sessions eligible for arteriovenous fistula (AVF) creation and/or renal transplantation will be included.~Datas will be collected of medical record."
89444316|NCT06036264||professional working with the pre-Advanced Practice Nurse (APN)|"professional working with the pre-Advanced Practice Nurse (APN) will be included.~Semi-structured interview will be performed."
89444317|NCT06036095|Active Comparator|Inhalational Anesthesia|Inhalational maintenance of anesthesia group using sevoflurane
89444318|NCT06036095|Active Comparator|Intravenous Anesthesia|Intravenous maintenance of anesthesia group using propofol
88928289|NCT01710722|Experimental|leptin A|Leptin A-200 20 mg subcutaneously once daily and placebo tablets of caffeine and ephedrine three times a day.
88928290|NCT01710722|Experimental|caffeine, ephedrine, and leptin A|Caffeine 200 mg tablets and ephedrine HCl tablets 25 mg three times a day with leptin A-200 20 mg subcutaneously once daily.
88928291|NCT01710735|Experimental|Dry needling (deep)|Subjects receive dry needle insertion deeper than 1,5cm below the skin of the Trapezius.
88928292|NCT01710735|Active Comparator|Dry needling (superficial)|Insertion of dry needle less than 1cm.
88928293|NCT01710748|Active Comparator|Polymer-Based Everolimus-Eluting Stent|Polymer-Based Everolimus-Eluting Stent
88928294|NCT01710748|Experimental|Polymer-Free Amphilimus-Eluting Stent|Reservoir-Based Polymer-Free Amphilimus-Eluting Stent
88928295|NCT01710774|No Intervention|Traditional follow-up|Traditional follow-up with standard consultations at the Section of Endocrinology. For some patients, this will include follow-up from nurses in the home care or general practice office related to wound care. However, this is not the standard procedure and will not take place in combination with telemedicine follow-up.
88928296|NCT01710774|Active Comparator|Telemedicine follow-up care|Telemedicine follow-up care for people with diabetes-related foot ulcers in municipal primary health care in collaboration with specialist health care
88928297|NCT01710813||pompe safety sub-registry|patients are selected from those who are enrolled in the Pompe Registry, and will be followed for safety evaluation in this sub-registry
88928298|NCT01710826|Experimental|Genz-682452|This study will include three cohorts for doses of Genz-682452: Dose 1, Dose 2, Dose 3. Each cohort will include 12 participants, 9 of whom will be administered Genz-682452 and 3 will be administered placebo.
88928299|NCT01710826|Placebo Comparator|Placebo|Placebo comparator taken by participants randomized to the placebo arm in each of the three cohorts. Each cohort will include 12 participants, 9 of whom will be administered Genz-682452 and 3 will be administered placebo.
88928300|NCT01710852|Experimental|Group A|ISIS CRP Rx followed by Placebo
88928301|NCT01710852|Experimental|Group B|Placebo followed by ISIS CRP Rx
88928302|NCT01710865|Experimental|Ultraseal Sealant|Both Ultraseal XT Hydro and Ultraseal XT Plus will be applied on patients.
88928303|NCT01710878|Other|Intergard Synergy Graft|
88928304|NCT01710917||Targinact® (oxycodon/naloxon)|
88928305|NCT01710930|Experimental|Study of predictive factors|
88928306|NCT01710943|Experimental|Web-based Cognitive Behavioral Treatment|"Participants who are randomly assigned to the treatment condition will receive the same standard care as those in the control condition and they will also receive access to the web-based CBT intervention. Participants in this condition will be asked to complete 24 CBT sessions, 2 sessions/topics per week for 12 weeks. Participants will be asked to complete the 18 core modules of the program during the first 9 weeks of the trial and then to re-visit important modules and complete optional modules of their choice during the final 3 weeks of the trial."
88928307|NCT01710943|No Intervention|Treatment as Usual|TAU consists of the usual Veterans Integrated Service Network 2 (VISN) primary care services. As we have described, all of the participants will be recruited from patients presenting for treatment typically for physical complaints in primary care clinics in VA's VISN 2 (Upstate NY). VISN 2 officially practices a co-located, collaborative care model of integrated (behavioral health and physical health) in its primary care clinics. This integrated model has been implemented widely in both VA and non-VA primary care clinics in the United States .
88928308|NCT01710956|Experimental|Arm 1(with twice-daily TRT)|
88928309|NCT01710956|Experimental|Arm 2 (with once-daily TRT)|
88928310|NCT01710969|Experimental|Individual Intervention|behavioral - children receive the Coping Power program in an individual, face-to-face format
88928311|NCT01710969|Experimental|Group Intervention|behavioral - children receive the Coping Power program in a small group format (5-6 children per group)
88928312|NCT01710982|Active Comparator|TZP-101|TZP-101
88928313|NCT01710982|Placebo Comparator|Placebo|Placebo
88928314|NCT01710995|Active Comparator|Zegerid 20mg capsule|Zegerid 20mg capsule (20mg omeprazole and 1100mg sodium carbonate
88928315|NCT01710995|Active Comparator|Zegerid 20mg powder for oral suspension|Zegerid 20mg powder for oral suspension (20mg omeprazole and 1680mg sodium bicarbonate)
88928316|NCT01710995|Active Comparator|Losec 20mg capsule|Losec 20mg capsule (20mg omeprazole)
88928317|NCT01711008|Placebo Comparator|No Breakfast|Water only
88928318|NCT01711008|Active Comparator|20g Cereal|20g Kelloggs Special K cereal with 83ml semi-skimmed milk
88928319|NCT01711008|Active Comparator|40g Cereal|40g Kelloggs Special K cereal with 166ml semi-skimmed milk
88928320|NCT01711034|Experimental|OPB-111077|"In escalation stage of study, treatment with a once daily dose of OPB-111077 during cycles 1 and 2 on day 1, followed by 2-day treatment free interval, and then resuming daily dosing on day 4 through day 28. For cycle 3 and beyond, OPB-111077 will be administered for 28 continuous days per cycle until MTD is reached.~In expansion portion of study, established dose of 250mg administered once daily for 28 consecutive days for each cycle. Patient in expansion are defined as those who meet eligibility criteria and have a diagnosed malignancy that is presumed to be susceptible to inhibition by OPB-111077"
88928321|NCT01711047|Active Comparator|PVI + Linear ablation|Arm A: patients have PVI and roof and mitral isthmus lines
88928322|NCT01711047|Active Comparator|PVI + linear ablation + CFAE|Arm B: patients have PVI + roof and mitral isthmus lines and CFAE ablation
88928323|NCT01711060|Experimental|oxytocin|
88928324|NCT01711060|Experimental|balloon catheter|Dufour 1859H18
89444319|NCT06036043||Intervention group|Patients treated with Botulinum Toxin
88928325|NCT01711073|Experimental|Mobilization with G-CSF plus Mozobil|Patients will receive G-CSF (Filgrastim) plus Mozobil (Plerixafor)
88928326|NCT01711086|Active Comparator|Inspiromatic followed by Aerolizer|volunteers will perform lung function pre and post Formoterol (a bronchodilator) inhalation. They will use either the Inspiromatic dry powder inhalers the delivery device. 3-60 days later participants will receive the same drug through the Aerolizer dry powder inhaler.
88928327|NCT01711086|Active Comparator|Aerolizer followed by Inspiromatic|volunteers will perform lung function pre and post Formoterol (a bronchodilator) inhalation. They will use either the Aerolizer dry powder inhalers the delivery device. 3-60 days later participants will receive the same drug through the Inspiromatic dry powder inhaler.
88928328|NCT01711099|Experimental|ESMR treated|
88928329|NCT01711112|Experimental|docetaxel|Days 1 & 8 Docetaxel 35 mg/m2 IV
88928330|NCT01711125|Experimental|Arm 1|Baclofen low dose
88928331|NCT01711125|Experimental|Arm 2|Baclofen high dose
88928332|NCT01711125|Placebo Comparator|Arm 3|Placebo
88928333|NCT01711151||Idiopathic Pulmonary Fibrosis|Questionnaire evaluation
88928334|NCT01711151||Non Idiopathic Pulmonary Fibrosis|Questionnaire evaluation
88928335|NCT01711151||Sarciodosis|Questionnaire evaluation
88928336|NCT01711151||Healthy Controls|Questionnaire evaluation
88928337|NCT01711164||patients|Chronic HCV patients who undergo antiviral therapy
88928338|NCT01711164||Healthy controls|healthy controls who are willing to give blood and liver tissue samples
88928339|NCT01711203|Experimental|Motor Control|"Pilates-based exercise with verbal cues to facilitate motor control Plank progression, use of feedback tool VERBAL CUES FOR MOTOR CONTROL GROUP (could also include above cues) Maintain neutral spine Not too arched, not too flexed Remember your pilates position Inhale, exhale Let me hear your breath"
88928340|NCT01711203|Active Comparator|General strengthening|"Patient group that will receive active strengthening without specific verbal cueing to recruit deeper abdominal musculature. Core strengthening and lower quarter strengthening is the focus of this group.~Verbal cuing will include:~VERBAL CUEING FOR NON-MOTOR CONTROL GROUP~Keep your back straight Don't slouch Don't arch your back Don't let your body move Nothing should move but your arms tighten up your abs suck in your stomach feet shoulder-width apart, knees bent, shoulders back, hold your stomach tight Time will be kept the same as the intervention group."
88928341|NCT01711229|Active Comparator|Group I: IV acetaminophen|Group I will receive 1 gram IV acetaminophen 15 minutes prior to going to the operating room for arthroscopic rotator cuff repair
88928342|NCT01711229|Active Comparator|group 2|Group 2 will receive 1.5grams of oral acetaminophen immediately prior to proceeding to the operation groom for arthroscopic rotator cuff surgery
88928343|NCT01711255||Multiple Sclerosis|Subjects who have been diagnosed with clinically definite or probable multiple sclerosis as defined and recorded by board certified neurologist.
88928344|NCT01711255||Healthy controls|Adults age 18 and older who have not been diagnosed with any neurological, endocrine, or other chronic health condition. They must also be free of any recent acute illness that can impact inflammation/clotting.
88928345|NCT01711281|Experimental|Intracardiac Impedance Measurement|
88928346|NCT01711307|Experimental|non-operative|cast applied within 48 hours
88928347|NCT01711307|Active Comparator|operative|cast applied within 48 hours and surgery within 14 days
88928348|NCT01711320|Placebo Comparator|Placebo|oral dose of Placebo combined with two dose of Metformin (OGTTs)
88928349|NCT01711320|Experimental|Omeprazole|oral dose of Omeprazole (80 mg) combined with two dose of Metformin (OGTTs)
88928350|NCT01711385|No Intervention|Standard practice|"Study patients are notified of their diagnostic test result within 72 hours. Those identified as potentially pre-diabetic or diabetic and randomized to the basic/control intervention, are informed that it is important to follow-up with their physician regarding their test results. They are contacted by phone once to schedule their 6-month recall visit."
88928351|NCT01711385|Experimental|Enhanced intervention|"Study patients are notified of their diagnostic test result within 72 hours. Those identified as potentially pre-diabetic or diabetic and randomized to the enhanced group, receive a tailored message about their modifiable risks and are advised to see their physician regarding their test results. They are given a letter to take to their physician and receive a call at month two and then again at month four if necessary to inquire if they have followed-up with their physician and encouragement to do so, if they have not, prior to their six month follow-up study visit."
88928352|NCT01711398|Experimental|IPP204106N|
88928353|NCT01711437|Experimental|PEG-S|polyethylene glycol 4000 solution with simethicon
88928354|NCT01711437|Experimental|PEG-CS + Bisacodyl|PEG-CS is a new sulphate-free iso-osmotic formulation of PEG-4000 with citrates and simethicone
88928355|NCT01711437|Experimental|PEG-ASC|polyethylene glycol 3350 hyper-osmotic solution with ascorbic acid
88928356|NCT01711437|Experimental|picoprep|sodium picosulphate plus magnesium oxide and citric acid
88928357|NCT01711450|Experimental|Paravertebral block|Paravertebral space will be needled and an anesthetic agent will be injected.
88928358|NCT01711450|Placebo Comparator|Control sham procedure|Paravertebral space will be needled, but only normal saline injected.
88928359|NCT01711463|Experimental|FF/VI|50/25 mcg, 100/25 mcg or 200/25 mcg
88928360|NCT01711463|Placebo Comparator|Placebo|matching placebo
88928361|NCT01711476|Active Comparator|Lifestyle counseling ARM 1|Arm 1 Breakfast Diet The arm 1 will be assigned to eat High calorie breakfast (800kcal) and reduced dinner (200 kcal) During 90 days from baseline to the end of the trial (day 90)
88928362|NCT01711476|Placebo Comparator|Lifestyle counseling ARM 2|Lean PCOS women in the Arm 2 will be assigned to do a dinner diet from day 0 to day 90 of the trial
88928363|NCT01711489|Experimental|isavuconazole and mycophenolate mofetil|Single dose of MMF on Day 1, isavuconazole three times daily (TID) on Days 9 and 10, isavuconazole once daily (QD) Days 11-16, a single dose of MMF on Day 13
88928364|NCT01711502||Female patients diagosed with metastatic breast cancer|
88928365|NCT01711515|Experimental|Treatment (cisplatin, radiation therapy, and ipilimumab)|Patients receive cisplatin IV over 1 hour on days 1, 8, 15, 22, 29, and 36, undergo extended beam radiation therapy 5 days a week for 6 weeks, and then undergo intracavitary brachytherapy for approximately 2 weeks. Within 2 weeks, patients receive ipilimumab IV over 90 minutes once every 3 weeks for 12 weeks.
88928366|NCT01711528|Experimental|Schedule I (dinaciclib, bortezomib, dexamethasone)|Patients receive dinaciclib IV over 2 hours and bortezomib SC or IV (if patients do not tolerate SC injection) on days 1, 8, and 15 and dexamethasone PO QD on days 1, 2, 8, 9, 15, and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88928367|NCT01711528|Experimental|Schedule II (dinaciclib, bortezomib, dexamethasone)|Patients receive dinaciclib IV over 2 hours on day 1; bortezomib SC on days 1 and 8; and dexamethasone PO QD on days 1, 2, 8, and 9. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
88928368|NCT01711567|Active Comparator|entecavir|standard drugs
88928369|NCT01711567|Active Comparator|tenofovir|study drugs
88928370|NCT01711580||Re-irradiation, high grade glioma|EORTC QLQ-C30 EORTC QLQ-BN20 Hopkins Verbal Learning Test-Revised (HVLT-R) Trail Making Test (TMT) Stroop color-word test Controlled oral word association test (COWA) Jamar hand dynamometer EORTC QLQ- FA13 Short Form health survey (SF-36)
88928371|NCT01711593|Experimental|Allergic Asthmatic, Non-allergic non-asthmatics(HC)|Track 1: Adult subjects who are allergic asthmatics or non-allergic non-asthmatics(Healthy Controls) will not receive segmental allergen challenge to the lung but will have their blood drawn at 1 time point. Track 2: Adult subjects who are allergic asthmatics will receive segmental allergen challenge to the lung and have their blood drawn at 2 time points.
88928372|NCT01711606||unselected Fragile-X patients|
88928373|NCT01711671|Experimental|DKN-01 300mg|DKN-01 plus lenalidomide (Revlimid)/dexamethasone
88928374|NCT01711671|Experimental|DKN-01 600mg|DKN-01 plus lenalidomide (Revlimid)/dexamethasone
88928375|NCT01711671|Active Comparator|Standard of Care|Lenalidomide (Revlimid)/dexamethasone
88928376|NCT01711684|Experimental|Diphenylcyclopropenone (DPCP)|Subjects will have DPCP in a topical gel formulation applied to their cutaneous metastatic lesions.
88928377|NCT01711697|Experimental|Treatment (radiation therapy, carboplatin, paclitaxel, SBRT)|Patients undergo radiation therapy daily and receive carboplatin and paclitaxel weekly for 4.5 weeks. Patients then undergo 2 boost SBRT treatments 2-3 days apart.
88928378|NCT01711723|Experimental|Renal Impaired Group|Subjects with renal impairment received darapladip 160 mg daily for 10 consecutive days.
88928379|NCT01711723|Experimental|Healthy Control Group|Healthy volunteers matching with renal impairment subjects for gender, age and BMI; received darapladip 160 mg daily for 10 consecutive days.
88928380|NCT01711749|Active Comparator|Sequence 1|01 tablet, single dose, of Reference Product in period 1 and 01 tablet, single dose, of Test Product in period 2.
88928381|NCT01711749|Active Comparator|Sequence 2|01 tablet of Test Product in period 1, and 01 tablet, single dose, of Reference Product in period 2.
88928382|NCT01711762|Experimental|GDC-0973 Single Arm|
88928383|NCT01711775|Experimental|Aleglitazar|
88928384|NCT01711788|Experimental|Intrabone umbilical cord blood tranplant|Intrabone infusion of umbilical cord blood stem cells
88928385|NCT01711801|Placebo Comparator|Part 1: Placebo|
88928386|NCT01711801|Experimental|Part 1: RO5545965|
88928387|NCT01711801|Experimental|Part 2: Food effect|
88928388|NCT01711814|Experimental|ASP015K|Experimental
88928389|NCT01711827|Experimental|Isavuconazole and Prednisone|Single dose of prednisone on Days 1 and 9, isavuconazole 3 times a day (TID) on Days 5-6, isavuconazole once a day (QD) on Days 7-10
88928390|NCT01711840||Symbicort|
88928391|NCT01711892|Active Comparator|Soccer Training|12 weeks of soccer training. (2 times per week for the first 8 weeks and 3 times per week in the last 4 weeks. Training will consist of 15 minutes warm-up and 2 x 15 minutes matches for the first 4 weeks and of 15 minutes warm-up and 3 x 15 minutes matches for the last 8 weeks). After 12 weeks assessments participants in the intervention group will continue bi-weekly supervised training for additional 20 weeks at the end of which tests will be repeated.
88928392|NCT01711892|No Intervention|Control group|Usual care
88928393|NCT01711905|Experimental|Vitamin D3|cholecalciferol 20 µg per day for 12 weeks
88928394|NCT01711905|No Intervention|Placebo|Placebo for 12 weeks
88928395|NCT01711931|Active Comparator|Everolimus-eluting bioresorbable vascular scaffold stents|
88928396|NCT01711931|Active Comparator|Everolimus-eluting stent|
88928397|NCT01711931|Active Comparator|Biolimus-eluting stent|
88928398|NCT01711944|Experimental|Online PSST|An online version of Problem-Solving Skills Training (PSST) will be compared to standard (face-to-face) PSST
88928399|NCT01711944|Active Comparator|Face-to-Face PSST|This is an 8-session face-to-face Problem-Solving Skills Training intervention
88928400|NCT01711957||Liver disease and liver transplantation|Patient with end stage liver disease and/or primary liver tumor undergoing liver transplantation
88928401|NCT01711970|Experimental|VB-111|
88928402|NCT01711996||UPJO|0-3 year old hydronephrosis patients without ureter dilatation who undergo pyeloplasty
88928403|NCT01711996||Hydronephrosis|0-3 year old hydronephrosis patients without ureter dilatation who does not meet the indication of pyeloplasty
88928404|NCT01711996||Normal|0-3 year old children without hydronephrosis
88928405|NCT01712022||Dry Eye|clinical diagnosis of dry eye
88928406|NCT01712022||Contact Lens|routine wear of contact lens
88928407|NCT01712022||Normal|Not having history of dry eye or contact lens wear or corneal pathology or surgery
88928408|NCT01712035||Treatment-active NVAMD|Patients with NVAMD who have received treatment with an anti-VEGF agent (Avastin, Lucentis, Macugen, or Eylea) 6 weeks prior enrollment visit
88928409|NCT01712035||Treatment-naive NVAMD|Individuals who have not received any treatment for neovascular AMD in the study eye
88928410|NCT01712048|Active Comparator|Submucosal Injection EMR|"For patients who are randomized to the submucosal injection arm polypectomy will be performed with selective saline injection to the layer of tissue underneath the polyp in order to create a safety cushion for resection."
88928411|NCT01712048|Active Comparator|Underwater EMR|"For patients who are randomized to the underwater arm polypectomy with water will be performed under full water emersion without the use of submucosal injection."
88928412|NCT01712087||MedStream System Implants|All subjects presenting for a de novo programmable pump implant or replacement of an implantable, programmable infusion pump for the treatment of severe spasticity with intrathecal Baclofen.
88928413|NCT01712100|Experimental|irbesartan|300 mg tablet
88928414|NCT01712100|Active Comparator|Avapro|300 mg tablet
88928415|NCT01712113|Experimental|irbesartan|300 mg tablet
88928416|NCT01712113|Active Comparator|Avapro|300 mg tablet
88928417|NCT01712126|Experimental|Irbesartan and Hydrochlorothiazide|300 mg and 25 mg tablet
88928418|NCT01712126|Active Comparator|Avalide|irbesartan 300 mg and hydrochlorothiazide 25 mg
88928419|NCT01712139|Active Comparator|Avalide|irbesartan 300 mg and hydrochlorothiazide 25 mg tablet
88928420|NCT01712139|Experimental|Irbesartan and Hydrochlolothiazide|300 mg irbesartan and 25 mg hydrochlorothiazide tablet
88928421|NCT01712165|Active Comparator|ANMUM Materna|75g milk powder in 400 ml water daily for 12 weeks.
88928422|NCT01712165|Placebo Comparator|Control|75g of milk powder in 400 ml water for 12 weeks.
88928423|NCT01712243|Active Comparator|Dim light|15 minutes of very dim (<1 lux) light during the night
88928424|NCT01712243|Active Comparator|Room light|15 minutes of normal room light (~100 lux) during the night
88928425|NCT01712243|Experimental|Colored light|15 minutes of colored light during the night
88928426|NCT01712269|Experimental|Weight-loss (bariatric) surgery|All subjects enrolled will undergo bariatric surgery to assist weight-loss
88928427|NCT01712282|Experimental|High dose training|2 x 30 minutes/day on a weight-bearing treadmill
88928428|NCT01712295|Experimental|17% Salicylate with Ethyl Pyruvate|Subjects with plantar wart(s) will apply the product to warts twice a day for up to 16 weeks.
88928429|NCT01712295|Active Comparator|17% salicylate|subjects will apply 17% salicylate (standard of care treatment) to plantar skin wart(s) twice a day for up to 16 weeks
88928430|NCT01712321|Experimental|Vilazodone|Vilazodone 20mg or 40mg taken once daily by mouth for up to 12 weeks
88928431|NCT01712321|Placebo Comparator|Placebo|Placebo to match Vilazodone 20mg or 40mg, taken once daily by mouth for up to 12 weeks
88928432|NCT01712347||mCRC Participants|mCRC participant will receive bevacizumab as per approved label with the approved first-line fluoropyrimidine based chemotherapy, as per physician discretion. The protocol does not specify the chemotherapy regimen to be used, the choice of chemotherapy will be at the discretion of treating physician.
88928433|NCT01712373|Active Comparator|Ginseng|Ginseng, tablet, 250 mg, twice, 3 months
88928434|NCT01712373|Placebo Comparator|Placebo|Placebo, tablet
88928435|NCT01712386|Experimental|COPD|
88928436|NCT01712425|Experimental|0-24 week prime/boost regimen (ARM A)|Start antiretroviral treatment raltegravir + tenofovir/emtricitabine. ChAdV63.HIVcons and MVA.HIVconsv HIV-1 vaccines, delivered intramuscularly, 0-24 week prime/boost regimen
88928437|NCT01712425|Experimental|0-8 week prime/boost regimen (ARM B)|Start antiretroviral treatment raltegravir + tenofovir/emtricitabine. ChAdV63.HIVcons and MVA.HIVconsv HIV-1 vaccines, delivered intramuscularly, 0-8 week prime/boost regimen
88928438|NCT01712425|No Intervention|Arm A control (ARM C)|Start antiretroviral treatment raltegravir + tenofovir/emtricitabine. Follow-up as in Arm A.
88928439|NCT01712425|No Intervention|Arm B control (ARM D)|Start antiretroviral treatment raltegravir + tenofovir/emtricitabine. Follow-up as in Arm B.
88928440|NCT01712464|Other|Cross over Oxytocin and Placebo|FMRI measurement and blood examinations after 26 IU Oxytocin (Syntocinon)or placebo on two consecutive days
88928441|NCT01712464|Other|Cross over Placebo and Oxytocin|FMRI measurement and blood examinations after 26 IU Oxytocin (Syntocinon)or placebo on two consecutive days
88928442|NCT01712477|Active Comparator|Intravenous sedation with propofol|Traumatic brain injured patient, already requiring sedation. Intervention is sedation with intravenous propofol during mechanical ventilation
88928443|NCT01712477|Active Comparator|Intravenous sedation with midazolam|Patients with traumatic brain injury requiring mechinical ventilation. Intervention is intravenous midazolam for sedation at variable doses to achieve adequite sedation levels
88928444|NCT01712503|Experimental|Toric intraocular lens|TFlex Lens (623T)
88928445|NCT01712503|Placebo Comparator|Monofocal intraocular lens|Superflex Aspheric Lens (920H)/Cflex Aspheric Lens (970C)
88928446|NCT01710761|Active Comparator|Nitrate supplement with caffeine|
88928447|NCT01710761|Placebo Comparator|Placebo|
88928448|NCT01712529|Experimental|Supervised physical exercise|Walking at speed of the ventilatory threshold-1 heart rate obtained from cardiopulmonary exercise test and monitored by frequency meter.
88928449|NCT01712529|No Intervention|No supervised physical exercise|No intervention for 16 weeks
88928450|NCT01712555|Experimental|fat grafting with PRP to anophthalmic orbits|There is only one arm to this study. People with orbital atrophy and loss of an eye are to be injected with autologous fat mixed with autologous PRP (platelet rich plasma) and observed for at least one year for evidence of retention of the injected fat
88928451|NCT01712568|Experimental|Test Product|Drug: Ropinirole Single oral dose of Ropinirole hydrochloride CR 2mg Tablets under fasting conditions
88928452|NCT01712568|Experimental|Reference Product|Drug: Ropinirole REQUIP XL Tablets (Ropinirole hydrochloride CR 2mg)commercial formulation under fasting conditions
88928453|NCT01712581|Experimental|Healthy volunters|175 Healthy volunters in the cohorte divided in 7 groups of age: 18-19 years old (ratio M/F: 1/1) 20-24 years old (ratio M/F: 1/1) 25-29 years old (ratio M/F: 1/1) 30-39 years old (ratio M/F: 1/1) 40-49 years old (ratio M/F: 1/1) 50-59 years old (ratio M/F: 1/1) 60-69 years old (ratio M/F: 1/1)
88928454|NCT01712594|Active Comparator|Closed Loop Procedure AB|Closed loop procedure with normal calibration first followed by closed loop procedure B with calibration error induced.
88928455|NCT01712594|Active Comparator|Closed loop Procedure BA|Closed loop procedure with an induced calibration error first followed by closed loop procedure with normal calibration.
88928456|NCT01712607|Experimental|Warm-Up|Surgery after warm-up task Preoperative Warm-Up training
88928457|NCT01712607|No Intervention|No Warm-up|Surgery without warm-up exercise
88928458|NCT01712698||Cervical spinal cord injury|Those patients with an acute cervical spinal cord injury evaluated with DTI MRI
88928459|NCT01712724|Active Comparator|Aerobic Training|Walking, elliptical, stationary recumbent or upright cycling will be the modes of AT prescribed depending on individual ability and access to equipment when away from the Centre. Treadmill or overground walking will be considered for those who can sustain high enough speeds and durations to achieve aerobic benefit. Cycle ergometer exercise (upright or recumbent) will be prescribed to patients in addition to walking when stroke-related deficits preclude a sufficient walking speed. The AT group will complete AT 5 d∙wk-1.
88928460|NCT01712724|Experimental|Combined Resistance and Aerobic Training|The AT+RT group will complete AT 3 d∙wk-1 + RT 2 d∙wk-1.The RT exercises will be task specific, incorporating muscle actions that are performed during daily activities. Resistance will be provided by hand-held dumbbells, exercise bands (wrist/ankle attachments), or patients' body weight. A weight load equivalent to 50-60% of 1 repetition maximum will be prescribed on the non-affected limb. On the hemiparetic limb ≥50% of 1 repetition maximum and/or a resistance rated as 13-14 on the Rating of Perceived Exertion scale on the last repetition of the set will be prescribed
88928461|NCT01712737|Experimental|Snack foods: raisins|children were given ad libitum access to raisins for 15 min
88928462|NCT01712737|Experimental|Snack foods: grapes|children were given ad libitum access to grapes for 15 min
88928463|NCT01712737|Experimental|Snack foods: a mix of almonds with raisins|children were given ad libitum access to a mix of almonds with raisins for 15 min
88928464|NCT01712737|Experimental|Water control|children were given ad libitum access to water
88928465|NCT01712750||VOT on bypass|
88928466|NCT01712802|Experimental|Denture Adhesives: Cream|Parallel arm that receives application of Cream denture adhesives.
88928467|NCT01712802|Experimental|Denture Adhesives: Powder|Parallel arm that receives application of powder denture adhesive.
88928468|NCT01712802|Placebo Comparator|control|Parallel arm that receive placebo.
88928469|NCT01712828|Experimental|Lenalidomide plus Quinidine|
88928470|NCT01712828|Experimental|Lenalidomide plusTemsirolimus and Diphenhydramine|
88928471|NCT01712841||Severe NEAMD|Presence of definite central or noncentral geographic atrophy within 3000 microns of the foveal center
88928472|NCT01712841||Moderate/Intermediate NEAMD|Presence of large drusen (>125µ) and pigmentary changes without geographic atrophy
88928473|NCT01712841||Mild/Early NEAMD|Presence of small or medium drusen without geographic atrophy
88928474|NCT01712867|Experimental|Phytosterol esters of omega-3|4 capsules/day for 12 weeks
88928475|NCT01712867|Active Comparator|Omega-3 acid ethyl esters|4 capsules/day for 12 weeks
88928476|NCT01712880|Active Comparator|open debridement with modular exchange|
88928477|NCT01712880|Active Comparator|one stage exchange|
88928478|NCT01712893|Experimental|Zoladex combined with chemotherapy|After signing informed consent, patients will be screened, eligible patients were randomly divided into 2 groups, the test group should use Zoladex 3.6mg once a month up to 2-3 years combined with chemotherapy,all patients will receive Tamoxifen after chemotherapy
88928479|NCT01712893|Active Comparator|Zoladex after chemotherapy|After signing informed consent, patients will be screened, eligible patients were randomly divided into 2 groups, the control group should use Zoladex 3.6mg once a month up to 2-3 years after chemotherapy,all patients will receive Tamoxifen after chemotherapy
88928480|NCT01712412|Experimental|IW-9179|Oral IW-9179 taken daily for two weeks
88928481|NCT01712412|Placebo Comparator|Placebo|Oral placebo taken daily for two weeks
88928482|NCT01712919|Experimental|cetuximab|Patients will be given intensity-modulated radiotherapy,2 cycles of concurrent chemotherapy with paclitaxel and nedaplatin,and weekly cetuximab during radiation therapy.
88928483|NCT01712945|Experimental|Palifermin (and Alemtuzumab)|Palifermin (Kepivance®), at the maximum identified tolerated dose will be administered by intravenous bolus on days -5, -4. -3 prior to, and on days 8, 9 and 10 after each cycle of alemtuzumab, then again on 3 consecutive days at month 1 and month 3 after each cycle of alemtuzumab. Patients will be observed for adverse reactions for at least 1 to 2 hours following each bolus dose. Initial treatment alemtuzumab will be administered as a fixed total dose of 60 mg IV over 5 consecutive days (12mg/day). For re-treatment at Month 12, alemtuzumab will be administered as a fixed total dose of 36mg IV over 3 consecutive days (12mg/day).
89444320|NCT06036030|Experimental|bitter melon fruit extract (Momordica charantia) with primaquine|For three days, a combination of 500 mg of bitter melon fruit extract (Momordica charantia) and 325 mg of bitter melon fruit content (13.50 mg/kg body weight) was administered. those with Plasmodium falciparum and Plasmodium vivax malaria received a single dosage of primaquine (0.25 mg/kg body weight) once daily, with those with Plasmodium falciparum malaria receiving it for 14 days.
89444321|NCT06036030|Active Comparator|dihydroartemisinin+piperaquine+ primaquine|DHP (fixed dosage combination tablets containing 40 mg dihydroartemisinin and 320 mg piperaquine) was administered to the group for 3 days, with primaquine being administered for 14 days to patients with Plasmodium vivax and 1 day initially to those with Plasmodium falciparum without difficulties. Body weight is taken into consideration while setting therapy parameters (age 15 years, >40-60 kg: 3 tablets; >60-80 kg: 4 tablets; 80 kg: 5 tablets).
89444322|NCT06035991|Experimental|Patients with end-stage Heart Failure|
89444323|NCT06035978|Experimental|Patients with Heart Failure with Reduced Ejection Fraction|Patients with heart failure with reduced ejection fraction, aged 18+, dispensary at the Cardiology Outpatient Clinic for Heart Failure University Hospital Ostrava, who are orally administered tablets one of the evaluated medicinal products or their combination as indicated by the attending physician (Nebivolol, Valsartan and Sacubitril, Carvedilol, Bisoprolol, Metoprolol, Spironolactone).
89444324|NCT06035952||Intervention|This study will have one cohort. This group of patients will undergo 3D scanning with a smartphone, and will also have standard of care diagnostics, such as an X-ray.
89444325|NCT06035913||Salivation group|The saliva group was instructed to take dihydroergot mesylate, one tablet twice a day, and observed the improvement of salivation after 1 week, after 1 month, after March and after 6 months.
89444326|NCT06035900|Experimental|10 normal healthy male volunteers|10 normal healthy male volunteers where each subject was given an identification code after signing the informed consent which was obtained according to APIC/PRU procedure of obtaining Consent form. The identification code consisted of the subject's initials, and a serial number.
89444327|NCT06035835||Probiotic 1|Administration Lacticaseibacillus rhamnosus (L. Rhamnosus) ATCC 53103 (109 UFC/day) in very low birth weight since start at the first enteral feed until 35 week Postmenstrual age
89444328|NCT06035835||Probiotic 2|Administration Lactobacillus acidophilus (L. acidophilus) ATCC 4356 (109 UFC/12 h)+Bifidobacterium bifidum (B. bifidum) ATCC 15696 (109 UFC/12 h) in very low birth weight since start at the first enteral feed until 35 week Postmenstrual age
89444329|NCT06035835||No probiotic|No suplementation diet with probiotic
89444330|NCT06035796||tNGS(targeted second generation sequencing)|tNGS detection of lower respiratory tract samples (BALF) from VAP patients.By means of super-multiple PCR amplification or probe hybridization capture, tNGS can enrich dozens to hundreds of known pathogenic microorganisms and their virulence and drug resistance genes in the samples to be tested, and then conduct high-throughput sequencing.
89444331|NCT06035796||non-tNGS(non-targeted second generation sequencing)|Perform routine clinical testing on lower respiratory tract samples (BALF) from VAP patients and collect patient clinical information. Clinical routine testing includes culture (necessary), microscopy, serology, PCR, etc., and drug sensitivity tests are conducted on positive culture samples as needed.
89444332|NCT06035770|Experimental|Mental Health First Aid training program|The intervention is a 12-hour face-to-face training course given in small groups. It was delivered as four 3-hour sessions over 4 consecutive weeks.
89444333|NCT06035770|No Intervention|control group|The control group received no intervention during the intervention period. However, they will participate in surveys at three time points (before the intervention, 3 months after the intervention and one year after the intervention). Once their final assessment is completed, controls will be offered the opportunity to take the MHFA training course, if they wish.
89444334|NCT06035757|Active Comparator|group neostigmine|If TOF count is 1 or less, wait until it becomes 2 and then give the patient neostigmine dose of 50mcg/kg. If TOF count shows 4 with fade, 40mcg/kg of neostigmine is administered and without fade, 20mcg/kg is administered.
89444335|NCT06035757|Active Comparator|group sugammadex|If TOF count shows 0 and PTC (posttetanic count) is 1 or more, sugamadex administered dose of 4mg/kg. If TOF count shows 1 or more, 2mg/kg is administered.
89444336|NCT06035666|Sham Comparator|Control|Control app
89444337|NCT06035666|Experimental|Intervention|Your World (vitality session + app)
89444338|NCT06035653||A|Minimum of 12 patients who required total radiotherapy replan
89444339|NCT06035653||B|Minimum of 28 patients who were reviewed in the multi-professional meeting but did not require full replan
88928484|NCT01712945|Placebo Comparator|Placebo (and Alemtuzumab)|Initial treatment alemtuzumab will be administered as a fixed total dose of 60 mg IV over 5 consecutive days (12mg/day). For re-treatment at Month 12, alemtuzumab will be administered as a fixed total dose of 36mg IV over 3 consecutive days (12mg/day).
88928485|NCT01712971||OPD|standard open pancreaticoduodenectomy
88928486|NCT01712971||LPD|laparoscopic pancreaticoduodenectomy
89444340|NCT06035627||Experimental group|The population of the study consisted of patients who were being treated in the general surgery clinic of the hospital, who met the sampling criteria, who were to undergo laparoscopic cholecystectomy, and who agreed to participate in the study. The sample size of the study was determined by the G*Power 3.1.9.7 program. In the power analysis, when α =0.05, β=0.10, and 1-β =0.90, the sample size was determined as 50 people per group and a total of 100 people.
89444341|NCT06035627||Control group|The population of the study consisted of patients who were being treated in the general surgery clinic of the hospital, who met the sampling criteria, who were to undergo laparoscopic cholecystectomy, and who agreed to participate in the study. The sample size of the study was determined by the G*Power 3.1.9.7 program. In the power analysis, when α =0.05, β=0.10, and 1-β =0.90, the sample size was determined as 50 people per group and a total of 100 people.
89444342|NCT06035614|Active Comparator|Tacrolimus + excimer light (group A)|group A, will be treated by Tacrolimus 0.1% ointment twice daily and excimer light 308nm twice weekly (exciplex®)
89444343|NCT06035614|Active Comparator|Tacrolimus (group B)|group B will start on Tacrolimus 0.1% ointment twice daily alone
89444344|NCT06035588|Active Comparator|Daily whitening|Volunteers should whiten daily with a whitening tray from 15 to 25 and 35 to 45 for 2 hours. This procedure will last 3 weeks.
89444345|NCT06035588|Experimental|Alternate whitening|Volunteers will bleach for 3 weeks with 16% carbamide peroxide, alternating one rest day for each placement day. They will wear a whitening tray from 15 to 25 and from 35 to 45 for 2 hours.
89444346|NCT06035562|Experimental|PVSET|Participants will receive a course of individual therapy through the Operational Stress Injury Clinic (OSIC) at Deer Lodge Centre. Therapy will consist of a validated treatment protocol known as Positive Valence System Enhancement Treatment for Anxiety and Depression (PVSET), which will consist of psychoeducation and positive activity interventions designed to increase positive emotions, cognitions, and behaviors. Therapy sessions will be facilitated by psychologists, licensed therapists (e.g., MSW, RPN), and/or graduate students in psychology under supervision at the OSIC. PVSET will consist of 6 sessions, each lasting one hour, and will be delivered either virtually or in-person at OSIC depending on patient preference.
89444347|NCT06035510|Experimental|whey protein supplement|Participants are given lactose-free Isolated whey protein 23 gm (containing with whey protein isolate 98.7 % ,Soya lecithin 1.3 % ) which mixed with water 350 ml at 6 p.m prior to surgery and 6.00 a.m. at first day after post surgery
89444348|NCT06035510|No Intervention|standard operative care|Participants followed standard operative care
88928487|NCT01712997|Experimental|Combination therapy|combine inhaled iloprost, 10μg, 4-6times/day with bosentan,125mg,po,bid.
88928488|NCT01712997|Active Comparator|monotherapy|Bosentan,125mg,po,bid.
88928489|NCT01713023|Experimental|Glucose solution|Solution containing 75g of glucose diluted in 200 mL of water
88928490|NCT01713023|Experimental|Fructose solution|Solution containing 75g of fructose diluted in 200 mL of water
89444349|NCT06035484|Experimental|LL & 0|Wheelchair seat height will be positioned at lower leg length and set inclination will be zero
89444350|NCT06035484|Experimental|LL + 1|Wheelchair seat height will be positioned at the participant's leg length plus one inch with an inclination of zero
89444351|NCT06035484|Experimental|LL - 1|Wheelchair seat height will be positioned at the participant's leg length minus one inch with an inclination of zero
89444352|NCT06035484|Experimental|LL - 2|Wheelchair seat height will be positioned at the participant's leg length minus two inches with an inclination of zero
89444353|NCT06035484|Experimental|LL - 3|Wheelchair seat height will be positioned at the participant's leg length minus three inches with an inclination of zero
89444354|NCT06035484|Experimental|3 degrees Inclination|Wheelchair seat height will be positioned at the participant's leg length with a forward seat inclination of 3 degrees
89444355|NCT06035484|Experimental|6 degrees Inclination|Wheelchair seat height will be positioned at the participant's leg length with a forward seat inclination of 6 degrees
89444356|NCT06035484|Experimental|9 degrees Inclination|Wheelchair seat height will be positioned at the participant's leg length with a forward seat inclination of 9 degrees
89444357|NCT06035432||Open access software 1|
89444358|NCT06035432||Open access software 2|
89444359|NCT06035432||Non open access paid software 1|
89444360|NCT06035432||Non open access paid software 2|
88928491|NCT01713049|Other|18F-FLT|18F-FLT PET for Suspicious Findings on Mammography and Breast Ultrasound.
88928492|NCT01713075||Symbicort|
88928493|NCT01713088|Experimental|Multisystemic therapy|MST is a family- and community-based intervention that establishes close contact with families to understand and deal with the factors that cause the young person's antisocial behaviour. The intervention targets the individual's adjustment, family relationships, school functioning and peer group affiliations. Therapists help caretakers develop skills to intervene and operate changes in important domains such as young person's individual adjustment, their family relationships, school functioning, and peer group affiliations.
89444361|NCT06035419|Experimental|education|A specially prepared training program for immigrant mothers was applied to the mothers in the experimental group.
89444362|NCT06035419|No Intervention|control|No interventions were made to the control group other than the routine interventions of the clinic (unstructured training practices given by the individual effort of the nurse).
89444363|NCT06035406|Experimental|Treatment group A: Retagliptin Phosphate Tablet|
89444364|NCT06035406|Experimental|Treatment group B: Retagliptin Phosphate Tablet|
89444365|NCT06035406|Experimental|Treatment group C: Retagliptin Phosphate Tablet|
89444366|NCT06035380|Experimental|rose oil|rose oil will be used
89444367|NCT06035380|Experimental|mint oil|mint oil will be used
89444368|NCT06035380|Placebo Comparator|plasebo|drinking water will be used
89444369|NCT06035367|Experimental|Wearing the non-invasive continous monitoring device during one week to record photoacoustic signal|Wearing the non-invasive continous monitoring device during one week to record photoacoustic signal
89444370|NCT06035354|Experimental|AK120 150 mg in phase Ib|subcutaneous injection once a week for 4 weeks.
89444371|NCT06035354|Experimental|AK120 300mg in phase Ib|subcutaneous injection once a week for 4 weeks.
89444372|NCT06035354|Placebo Comparator|Placebo Comparator: Placebo in phase Ib|subcutaneous injection once a week for 4 weeks.
89444373|NCT06035354|Experimental|AK120 150mg in phase II|subcutaneous injection every 2 weeks for 50 weeks.
89444374|NCT06035354|Experimental|AK120 300mg in phase II|subcutaneous injection every 2 weeks for 50 weeks.
89444375|NCT06035354|Experimental|AK120 450mg in phase II|subcutaneous injection every 2 weeks for 50 weeks.
89444376|NCT06035354|Placebo Comparator|Placebo Comparator: Placebo in phase II|subcutaneous injection every 2 weeks, then crossover to AK120 Regimen 4 and Regimen 5, subcutaneous injection at week 16, after primary endpoint evaluation.
89444377|NCT06035354|Experimental|AK120 150mg in phase II extension|subcutaneous injection every 2 weeks for 14 weeks.
89444378|NCT06035354|Experimental|AK120 300mg in phase II extension|subcutaneous injection every 2 weeks for 14 weeks.
88928494|NCT01713088|Active Comparator|YOT (usual services)|YOT intervention consisted of services currently available to young offenders in accordance with the Youth Justice Board National Standards.These services included supporting the young person to re-engage with education, with substance misuse problems and anger management; training them in social problem-solving skills; and programs to decrease vehicle-crime, violent-offending and knife crime. The treatments were delivered by professional social workers, specialist therapists or probation officers.
88928495|NCT01713101|Experimental|Early intravenous tranexamic acid administration|"Early intraveous administration of tranexamic acid~(1g IV bolus over 10 minutes followed by 1g slow infusion over 8 hours"
88928496|NCT01713101|Placebo Comparator|Placebo group|Normal saline (placebo) administration instead of tranexamic acid solution
88928497|NCT01713114|Experimental|Low carbohydrate|
88928498|NCT01713114|Experimental|Moderate carbohydrate|
88928499|NCT01713114|Experimental|Higher Carbohydrate|
88928500|NCT01713114|Placebo Comparator|Meal Skipping|
88928501|NCT01713127|Placebo Comparator|Placebo|5% dextrose infusion for 72 hours during ventilator care start within 48 hours after birth
88928502|NCT01713127|Active Comparator|remifentanil|0.1mcg/kg/min remifentanil infusion for 72 hours during ventilator care start within 48 hours after birth
88928503|NCT01713140|Experimental|1 strength training set performed until contraction failure|Knee extensions until contraction failure will be performed, using a relative loading of 10 repetition maximum (RM).
88928504|NCT01713153|Experimental|Misoprostol|600 mcg oral misoprostol administered during the third stage of labor
88928505|NCT01713153|Experimental|UnijectTM|10 IU oxytocin delivered IM with UnijectTM during he third stage of labor
88928506|NCT01713166|Active Comparator|Plasmalyte solution|Plasmalyte solution infusion to meet the fluid requirements.
88928507|NCT01713166|Experimental|Hextend|6% Hetastarch administeration instead of crystalloids until the total amount given reached 20 ml/kg, which is the maximally allowed daily dose. Afterward, plasmalyte solution infusion to meet the fluid requirements.
88928508|NCT01713179|Experimental|ambroxol|"Ambroxol hydrochloride (Mucopect®, trans-4[2-amino-3.5-dibrombenzylamino]-cyclohexanhydro-chloride, 60 mg, Boehringer Ingelheim) was administered orally to subjects in the ambroxol group immediately after initial examination (10 AM).~one dose for one day"
88928509|NCT01713179|No Intervention|control|
88928510|NCT01713192||Cardiac surgery|
88928511|NCT01713218|Experimental|Gemcitabine+Vismodegib|Neoadjuvant chemotherapy combining gemcitabine and Vismodegib during 4 weeks before surgery
88928512|NCT01713231|Active Comparator|standard-dose vitamin D|one group of 30 participants will be randomized to receive vitamin D3 at a dose of 400 international units per day ('standard-dose group').
88928513|NCT01713231|Experimental|high-dose vitamin D|One group of 30 participants will be randomized to receive vitamin D3 at a dose of 2000 international units per day ('high-dose group').
88928514|NCT01713244|Active Comparator|Hepatectomy|Using Hepatectomy for the treatment of advanced HCC
88928515|NCT01713244|Experimental|RFA assisted Hepatectomy|Ablating the liver tissue around the tumor before hepatectomy.
88928516|NCT01713257|Experimental|Immunoenhancing diet|Immunoenhancing diet feeding until Day 10 or the day of discharge if earlier than Day 10. The goal of caloric intake is 25 kcal/kg/day and protein 1.2 g/kg/day.
88928517|NCT01713257|Active Comparator|Isocaloric, isonitrogenous diet|Enteral feeding until Day 10 or the day of discharge if earlier than Day 10. The goal of caloric intake is 25 kcal/kg/day and protein 1.2 g/kg/day.
88928518|NCT01713270|Experimental|renal sympathetic denervation|Contrast renal angiography was performed to localize and assess the renal arteries. Once the anatomy was deemed acceptable, the internally irrigated radiofrequency ablation catheter was introduced into each renal artery. This was then maneuvered within the renal artery to allow energy delivery in a circumferential, longitudinally staggered manner to minimize the chance of renal artery stenosis. About four to eight ablations at 10 W for 60 seconds each were performed in both renal arteries. After renal sympathetic denervation, patients with persistent AF accepted direct-current cardioversion immediately.
88928519|NCT01713270|Active Comparator|drug therapy|Patients in the drug treatment group will be followed-up at 3, 6, 9 and 12 months after randomization. All the patients in this group will take their baseline antihypertensive medication at the original doses, without any changes except when medically required. Antiarrhythmic drugs treatment is consistent in both arms.
88928520|NCT01713296|Experimental|Pazopanib|
88928521|NCT01713309|Active Comparator|Filgrastim|Filgrastim 300 microgr/day subcutaneously for 7 days
88928522|NCT01713309|Placebo Comparator|NaCl 0.9%|Corresponding placebo once daily, subcutaneously for 7 days
88928523|NCT01713322|Experimental|Pain management education|Parents are provided with educational material on how to manage child pain during immunization.
88928524|NCT01713322|Other|No pain management education|Control - parents receive general information about childhood immunization.
88928525|NCT01713361|Experimental|ISIS-FXIRx Dose 2|Group B: ISIS-FXIRx Dose #2
88928526|NCT01713361|Experimental|ISIS-FXIRx Dose 3|Group C: ISIS-FXIRx Dose #3
88928527|NCT01713361|Active Comparator|Enoxaparin|Enoxaparin (40mg)
88928528|NCT01713374|Active Comparator|Myogenic activation|Subjects will undergo endothelial function assessment at rest and, after a 45 minutes pause, 1 minute after begin of myogenic activation
88928529|NCT01713374|Active Comparator|Cold pressure test|Subjects will undergo endothelial function assessment at rest and, after a 45 minutes pause, 1 minute after begin of cold pressure test
88928530|NCT01713374|Active Comparator|mental stress|Subjects will undergo endothelial function assessment at rest and, after a 45 minutes pause, 1 minute after begin of mental stress
88928531|NCT01713374|Active Comparator|Control|Control visit - no intervention performed - subjects will undergo endothelial function measurement twice at a distance of 45 minutes
89444379|NCT06035354|Experimental|AK120 450mg in phase II extension|subcutaneous injection every 2 weeks for 14 weeks.
88928532|NCT01713387|Experimental|gemcitabine , S-1|Level-2 Gem 800mg/msq, S-1 50mg/msq Level-1 Gem 800mg/msq, S-1 65mg/msq Level 1 Gem 1000mg/msq, S-1 65mg/msq Level 2 Gem 800mg/msq, S-1 80mg/msq
88928533|NCT01713413|Active Comparator|Oxymizer|Using first the Oxymizer and 24 h later the conventional nasal cannula.
88928534|NCT01713413|Active Comparator|nasal cannula|Using first the conventional nasal cannula and 24 h later the Oxymizer
88928535|NCT01713426|Experimental|Qutenza|Cutaneous patch
88928536|NCT01713426|Active Comparator|Pregabalin|Oral capsule
88928537|NCT01713452|Active Comparator|Purse string closure|Patients undergo a purse string closure of their old stoma site.
88928538|NCT01713452|Active Comparator|Primary closure|Patients have their stoma sites close primarily with staples.
88928539|NCT01713465|Experimental|1 CBMP|CBMP: Computer based Metabolic syndrome program
88928540|NCT01713478|Experimental|cirrhotic patients|"Study will include 50 cirrhotic patients, divided in 2 subgroups: 25 with alcoholic cirrhosis, and 25 with viral cirrhosis~Routine blood samples~Electrocardiogram (12 leads)~Specific biomarkers: proBNP, troponin, myocardial fibrosis (β cross laps and procollagen type-1 amino terminal), and markers of inflammation (PCR-hs, IL1, IL6, IL 10, TNFα); oxidative stress: carbonyl in plasmatic proteins, and the antioxidant capacity of plasma.~Comprehensive Echocardiography"
88928541|NCT01713478|Active Comparator|normal controls|50 normals subjects with the same procedures as cirrhotic patients: echocardiography, ECG, biomarkers
88928542|NCT01713491||Cognitively normal|Patients with IQCODE score of 52 or less
88928543|NCT01713491||Cognitively impaired - no dementia|IQCODE score 53 - 63
88928544|NCT01713491||Demented|IQCODE score 64 or more
88928545|NCT01713504|Experimental|Hypereosinophilic syndrome unexplained|
88928546|NCT01713504|Active Comparator|Hypereosinophilic syndrome explained|
88928547|NCT01713504|Sham Comparator|Normal rate of eosinophilic|
88928548|NCT01713517|Active Comparator|Universal coverage of Long Lasting Insecticidal Nets (LLIN)|Distribution of long lasting insecticidal nets to all community members in the study arm allowing for at least one net per 2 persons
88928549|NCT01713517|Experimental|LLIN Plus Indoor Residual Spraying|Distribution of long lasting insecticidal nets to all community members in the study arm allowing for at least one net per 2 persons plus indoor residual spraying with insecticide of interior walls of all houses twice yearly.
88928550|NCT01713543|Experimental|Intervention Group|The intervention consists of a tailored physical therapy focused on progressive strength, balance and gait training for a period of 3 months.
88928551|NCT01713543|No Intervention|Control Group|Usual care by physician.
88928552|NCT01713556|Experimental|Propranolol + reactivation|they have a script-driven mental imagery of the traumatic event white drug
88928553|NCT01713556|Placebo Comparator|Placebo + reactivation|They have a script-driven mental imagery of the traumatic event with placebo
88928554|NCT01713569|Active Comparator|Subject 1|Ulthera treatment will be administered to both pre-auricular regions using a 4 MHz, 4.5mm depth transducer at 1.2 Joules and 30 Watts on the Left side versus 0.9 Joules and 30 Watts on the Right side.
88928555|NCT01713569|Active Comparator|Subject 2|Ulthera treatment will be administered to both pre-auricular regions using a 7 MHz, 3.0mm depth transducer at 1.05 Joules and 25 Watts on the Left side versus 0.75 Joules and 25 Watts on the Right side.
88928556|NCT01713569|Active Comparator|Subject 3|Ulthera treatment will be administered to both pre-auricular regions using a 7 MHz, 3.0mm depth transducer at 0.45 Joules and 15 Watts on the Left side versus 0.35 Joules and 14 Watts on the Right side.
88928557|NCT01713569|Active Comparator|Subject 4|Ulthera treatment will be administered to both pre-auricular regions using a 10 MHz, 1.5mm depth transducer at 0.25 Joules and 5 Watts on the Left side versus 0.18 Joules and 5 Watts on the Right side.
88928558|NCT01713569|Active Comparator|Subject 5|Ulthera treatment will be administered to both pre-auricular regions using a 4 MHz, 4.5mm depth transducer at 0.9 Joules and 30 Watts on the Left side versus 7 MHz, 4.5mm 0.9 Joules and 25 Watts on the Right side.
88928559|NCT01713569|Active Comparator|Subject 6|Ulthera treatment will be administered to both pre-auricular regions using a 7 MHz, 3.0mm transducer at 0.35 and 14 Watts, and a 4 MHz, 4.5mm depth transducer at 0.9 Joules and 30 Watts on the Left side versus a 7 MHz, 3.0mm depth and 4.5mm depth transducer at 2.0 Joules and 40 Watts on the Right side.
88928560|NCT01713595|Experimental|Hypertonic Saline Aerosol|a single 5ml dose of 7% Saline aerosol
88928561|NCT01713634|Experimental|Low Apro/K Diet|Subjects consume a prescribed diet for 4 days with a low ratio of animal protein to potassium (0.3-0.6 g/mEq).
88928562|NCT01713634|Experimental|High Apro/K Diet|Subjects consume a prescribed diet that has a high ratio of animal protein to potassium (1.0-1.3 g/mEq) for 4 days.
88928563|NCT01713647|Experimental|LOSANET AM PLUS (10/100/12.5 mg) of PHARMALINE, Lebanon|"Subjects will be fasted overnight and receive one tablet by mouth in accordance with randomization table, and blood samples will be taken at specified intervals over 3 days~intervention: Drug: LOSANET AM PLUS Amlodipine/ Losartan/Hydrochlorothiazide Other Name: NA"
88928564|NCT01713647|Active Comparator|NORVASC & HYZAAR (100/12.5 mg)|"Subjects will be fasted overnight and receive one tablet of Norvasc &HYZAAR by mouth in accordance with randomization table, and blood samples will be taken over 3 days~intervention: Drug: LOSANET AM PLUS Amlodipine/ Losartan/Hydrochlorothiazide Other Name: NA"
89444380|NCT06035341|Experimental|Treatment Group|Participants in this group will be received orofacial manual therapy as treatment. The number of participants is planned to be 23.
88928565|NCT01713673|Experimental|Active Treatment|Subjects receive Ulthera System Treatments according to the pre-defined Ulthera® System energy settings.
88928566|NCT01713673|Sham Comparator|Sham Treatment|Subjects will receive Sham treatments using the Ulthera® System with the energy set to 0.00 Joules.
88928567|NCT01713699|Other|diagnostic|Using extra CSF material received by clinically indicated lumbar punctures to determine the sensitivity and specificity of CTCs in CSF (5ml CSF). Standard material of 5 ml CSF for cytology and 2 ml CSF for cell count and chemistry is being regularly used and processed.
89444381|NCT06035328|Experimental|Four per week|Case wheat allergy that on four times/week dose during one year maintenance phase of wheat OIT
89444382|NCT06035328|No Intervention|Once daily|Case wheat allergy that on once daily dose during one year maintenance phase of wheat OIT
89444383|NCT06035315|No Intervention|Control|Pregnant women examine since 8 weeks gestation are being followed until delivery; are given government micronutrients; and perform ultrasound examinations each trimester and regular laboratory examination.
89444384|NCT06035315|Active Comparator|Interventions|Pregnant women examine since 8 weeks gestation are being followed until delivery; are given additional micronutrients (Complete multi micronutrients-Calcium-Vitamin D-DHA); and perform ultrasound examinations each trimester and additional laboratory examination (Vitamin D level-Lipid profile-Zinc)
89444385|NCT06035224|Experimental|AK104 combine with lenvatinib|Patients will receive AK104 (10mg/kg ,Q3W，intravenously) plus lenvatinib(<60kg，8 mg qd；≥60kg，12mg qd, orally.
89537088|NCT02467595|Active Comparator|R 0.3 group|"Rocuronium bromide 0.3 mg kg-1 group~Anesthesia was induced with propofol 2.5 mg kg-1 , fentanyl 2 mcg kg-1, and rocuronium bromide 0.3 mg kg-1~After mask ventilation with 5 vol% sevoflurane in 100% oxygen for 2 minutes, tracheal intubation was done.~At the end of surgery, discontinuation of sevoflurane and extubation, sending recovery room.~When poor intubating condition., added rocuronium bromide 0.3 mg kg-1 .~Drug: Rocuronium bromide Rocuronium bromide 0.3 mg kg-1 was injected at I.V. line to patients (R 0.3 group), as muscle relaxants during anesthesia for adenotonsillectomy."
88928568|NCT01713712|No Intervention|Routine Obstetric Care|
88928569|NCT01713712|Experimental|Nutritional Counseling|Patients will receive an initial 90 minute nutritional consult followed by 60 minute follow up consults every 2 weeks to monitor weight gain and nutritional status.
88928570|NCT01713725|Active Comparator|Omalizumab 300 mg|"Subcutaneous route~300 mg dose (independent from total IgE, weight or high)"
88928571|NCT01713725|Placebo Comparator|Placebo|"Saline serum~Subcutaneous route~0.6 ml saline serum with same volume as an active treatment"
88928572|NCT01713738|Experimental|rituximab|
88928573|NCT01713751|Active Comparator|Interrupted suturing Group|Includes women who have their skin closed with interrupted mattress stitches using non-absorbable polypropylene [Prolene®]
88928574|NCT01713751|Active Comparator|Subcuticular suturing Group|Includes women who have their skin closed with subcuticular stitches using non-absorbable polypropylene [Prolene®].
88928575|NCT01713764|Experimental|Low Carbohydrate Diet|"Participants will be instructed to follow a low carbohydrate diet: carbohydrate intake 10-50 grams a day not including fiber. Foods permitted include: meats, poultry, fish, eggs, cheese, cream, some nuts and seeds, green leafy vegetables, and most other non-starchy vegetables. Because most individuals self-limit caloric intake, no calorie restriction will be recommended.~Participants will also be taught information about mindfulness and positive affect practices. The mindfulness-based curriculum will focus on the following elements: training on topics such as mindful meditation, mindful eating, awareness of fullness and hunger signals, and taste satiety. The positive emotion curriculum will include: training on topics such as noticing and savoring positive events, gratitude, positive reappraisal, personal strengths, attainable goals, and acts of kindness."
88928576|NCT01713764|Active Comparator|American Diabetes Association Diet|"Participants in the American Diabetes Association (ADA) diet group will receive standard ADA advice. The diet includes high-fiber foods (such as vegetables, fruits, whole grains, and legumes), low-fat dairy products, fresh fish, and foods low in saturated fat.~Participants will also be taught information about mindfulness and positive affect practices. The mindfulness-based curriculum will focus on the following elements: training on topics such as mindful meditation, mindful eating, awareness of fullness and hunger signals, and taste satiety. The positive emotion curriculum will include: training on topics such as noticing and savoring positive events, gratitude, positive reappraisal, personal strengths, attainable goals, and acts of kindness."
88928577|NCT01713777|Experimental|"Lamotrigine Generic A/Generic B"|"Crossover trial. Each arm will receive generic A for two periods and generic B for two periods."
88928578|NCT01713777|Experimental|"Lamotrigine Generic B/Generic A"|"Crossover trial. Each participant will have two periods of generic A and two periods of generic B"
88928579|NCT01713790|Experimental|Training group|T0 - Intervention program 3x/ week over 10 weeks: Stochastic resonance whole-body vibration + Exergame + leg press - T1
88928580|NCT01713803|Placebo Comparator|Sugar pill|
88928581|NCT01713803|Experimental|buprenorphine and nalaxone|
88928582|NCT01713816||Elderly control|Healthy elderly subjects age and gender matched to the AD cohort, predominantly male
88928583|NCT01713829|Experimental|Cranberry Beverage|Cranberry Beverage is provided in an 8 oz daily beverage consumed once daily for 12 weeks
88928584|NCT01713829|Placebo Comparator|Placebo Beverage|The placebo beverage looks like the active arm and is given in the same way but contains no active ingredient.
88928585|NCT01713842|Experimental|TCZ|Tocilizumab at week 0, week 4 and week 8 8mg/kg at each perfusion
88928586|NCT01713881||post-registry|"Registry Group:~Select 500 consecutive patients from the polyp registry who were found to have a tubular adenoma on a colonoscopy done between 2007-2008 from the polyp registry.~Quantify the completion rate and time between index and surveillance colonoscopy after the establishment of the polyp surveillance program (2006-2013)."
88928587|NCT01713881||pre-registry|Pre-registry Group: Select 380 consecutive patients who were found to have a tubular adenoma on a colonoscopy done between April 2004-Nov 2006.
88928588|NCT01713894|Other|Decision Aid|In this arm of the study, parents will be counseled using a decision aid.
88928589|NCT01713894|Other|Standard|In this arm of the study, parents will be counseled using current standard methods.
88928590|NCT01713907|Experimental|Ulthera® treatment|All enrolled subjects will receive one full face and neck Ulthera® treatment.
88928591|NCT01713920|Experimental|SEVIKAR|Subjects who are eligible for the inclusion and exclusion criteria will be treated with Sevikar 5/20mg for 4 weeks. If subjects fail to reach the SBP threshold of SeSBP≥ 140mmHg after 4-week treatment, they will receive Sevikar 5/40mg for 4 weeks. At the end of 4-week treatment, subjects who fail to reach SBP threshold will receive Sevikar 10/40mg for 4 weeks. Subjects who can reach SBP threshold will continue to treat with current dose until 12 weeks.
88928592|NCT01713959|Experimental|Group A - Split Body Treatment|Active treatment of one axilla with the Ulthera System Treatment; Sham treatment of one axilla.
89013542|NCT06300138|Experimental|Infrared hyperthermia group|Infrared hyperthermia device for 3 consecutive days (times / day), each treatment for 30 minutes After two weeks (14 days), the lesions of the same target were treated continuously for 2 days (times per day), and then once a week for 2 consecutive times, the method was the same as before. After 7 times of treatment, the study physician decided whether to continue treatment n times after 1-2 weeks (n ≥ 0) according to the recovery of the subjects.
89444386|NCT06035185||Group 1- One Curve Mini 25/0.4|Root canal shaping will be completed with a heat-treated nickel titanium OneCurve Mini #25/0.4 rotary file (Micro-Mega, Besancon, France) after reaching the apical region with #10 K stainless steel files (Dentsply Maillefer, Ballaigues, Switzerland). The irrigation solution will be used by adapting an ultrasonic tip (IRRI S 21/25; VDW, Munich, Germany) to an ultrasonic device (VDW Ultra; VDW, Munich, Germany). The tip will be activated a total of three times, each cycle lasting 20 s and involving the use of 1 ml of 3% NaOCl. Then 2 ml of 17% EDTA solution will be activated for 1 minute as described above. The ultrasonic tip will be placed 2 mm shorter than the working length without touching the canal walls.
89444387|NCT06035185||Group 2- One Curve Mini 35/0.4|Root canal shaping will be completed with a heat-treated nickel titanium OneCurve Mini #35/0.4 rotary file (Micro-Mega, Besancon, France) after reaching the apical region with #10 K stainless steel files (Dentsply Maillefer, Ballaigues, Switzerland). The irrigation solution will be used by adapting an ultrasonic tip (IRRI S 21/25; VDW, Munich, Germany) to an ultrasonic device (VDW Ultra; VDW, Munich, Germany). The tip will be activated a total of three times, each cycle lasting 20 s and involving the use of 1 ml of 3% NaOCl. Then 2 ml of 17% EDTA solution will be activated for 1 minute as described above. The ultrasonic tip will be placed 2 mm shorter than the working length without touching the canal walls.
89013543|NCT06300086|Experimental|Patient letters + no GP letter.|"Patients with CKD will receive digital nudge letters, but their associated GPs will not receive a digital nudge letter.~The letters will inform patients with CKD of the importance of GDMT in CKD and that updated Danish guidelines for the treatment of CKD are available."
89013544|NCT06300086|Experimental|Patient letters + GP letter.|"Patients with CKD and their associated GPs will receive digital nudge letters.~The letters will inform the recipients of the importance of GDMT in CKD and that updated Danish guidelines for the treatment of CKD are available. The letter to the GPs will also include the definition of CKD and a summary of the guidelines."
89013545|NCT06300086|Experimental|No patient letters + GP letter|"Patients with CKD will not receive digital nudge letters, but their associated GPs will receive a digital nudge letter.~The letter will inform the GPs of the importance of GDMT in CKD and that updated Danish guidelines for the treatment of CKD are available. The letter will also include the definition of CKD and a summary of the guidelines."
89013546|NCT06300086|No Intervention|No patient letters + no GP letter|Neither patients with CKD nor their associated GPs will receive digital nudge letters.
89013547|NCT06300073|Experimental|AutoBrush U-shaped power toothbrush, then Manual Toothbrush|Participants first received the AutoBrush U-shaped power toothbrush with fluoride toothpaste for a single brushing use for 30 seconds; after a 2-day washout period, participants received the ADA reference manual toothbrush for a single brushing use for 2 minutes.
89013548|NCT06300073|Experimental|Manual Toothbrush|Participants first received the ADA reference manual toothbrush for a single brushing use for 2 minutes; after a 2-day washout period, participants received the AutoBrush U-shaped power toothbrush with fluoride toothpaste for a single brushing use for 30 seconds.
89013549|NCT06300060|Experimental|Synbiotic|Participants receive the synbiotic for 6 weeks.
89013550|NCT06300060|Placebo Comparator|Placebo|Participants receive the placebo for 6 weeks.
89013551|NCT06300047|No Intervention|Usual Care Group|No intervention group used as a control leading into the intervention for comparative analysis. Patients in this arm receive care as usual with no changes and are not aware of the intervention group.
89013552|NCT06300047|Experimental|Intervention Group|Patients in this arm receive access to and support from a Transition coordinator who will meet with them prior to transition from pediatric to adult care and follow up with them every 2 months throughout the first year of their transition period utilizing phone, text, email, social media.
89013553|NCT06300021|Experimental|Sequence capsule - ready to drink - sport bar - dairy analog - gummies - probiotic drink|Subjects receive Turmipure Gold® preparations in different food matrices in the following order: capsule - ready to drink - sport bar - dairy analog - gummies - probiotic drink
89013554|NCT06300021|Experimental|Sequence dairy analog - probiotic drink - ready to drink - gummies - capsule - sport bar|Subjects receive Turmipure Gold® preparations in different food matrices in the following order: dairy analog - probiotic drink - ready to drink - gummies - capsule - sport bar
89013555|NCT06300021|Experimental|Sequence gummies - sport bar - probiotic drink - capsule - dairy analog - ready to drink|Subjects receive Turmipure Gold® preparations in different food matrices in the following order: gummies - sport bar - probiotic drink - capsule - dairy analog - ready to drink
89444388|NCT06035146|Experimental|Mechanical energy monitoring|In the study subjects randomized into this arm, the value of mechanical energy will be monitored during mechanical ventilation.
89444389|NCT06035146|Active Comparator|Conventional mechanical ventilation|Study subjects randomized into this arm will receive conventional mechanical ventilation, to the best of the physician's knowledge.
89444390|NCT06035133|Experimental|radiotherapy removal TNT plus group|Six induction chemotherapy rounds of the CapeOX regimen were administered. RAS, BRAF, and MSI were found when the first patients were examined. Patients were given CapeOX + cetuximab for RAS wild-type patients, CapeOX + bevacizumab for RAS mutant patients, and CapeOX + cetuximab for MSI-H patients. The CapeOX regimen: Oxaliplatin 130 mg/m2, intravenous injection, day 1; capecitabine 1000 mg/m2, oral, twice daily, days 1 through 14; once every 3 weeks. A surgical procedure was carried out two weeks after consolidation chemotherapy ended.
89444391|NCT06035107||Comparing radar and auscultatory blood pressure|"25 participants will be recruited from a specialist hypertension clinic. These participants will undergo the following tests:~Questionnaire: The participant will be asked to complete a clinico-demographic questionnaire. This includes their demographic data and past medical history.~Measurement of height, weight and heart rate~Measurement of blood pressure using the radar device and using a cuff (called manual auscultation)~End of visit."
89444392|NCT06035107||Comparing radar and invasive blood pressure|"Participants will be recruited from a list of patients scheduled to attend the Royal Free Hospital catheterisation laboratory for a clinically-indicated invasive angiogram that was booked by their consultant. 50 participants aged 18 and over will be recruited.~The radar blood pressure measurements taken during the angiogram will not impact on the procedure or standard clinical care which the participant will receive. The duration of the visit is determined by the duration of the coronary angiogram and that is decided by the clinical care team. Participants will have the following tests:~Collection of baseline data including past medical history, current medication, height, weight and baseline ECG~Measurement of invasive blood pressure and radar blood pressure simultaneously before the rest of the procedure~End of visit."
89444393|NCT06035107||Testing if the radar device can measure blood pressure in the MRI scanner|"First we will develop a radar blood pressure device that can be used in the MRI scanner.~When this device has been proven to be safe, we will recruit 25 participants to have the following tests:~A questionnaire. The participant will be asked to complete a clinic-demographic questionnaire including their demographic data and past medical history.~Collection of blood test to assess kidney function. Additional blood tests will also be collected for storage and future analysis.~A cardiac MRI scan. Blood pressure will be measured at 5 minute intervals during the scan using an oscillometric cuff around the right upper arm. The radar device will measure blood pressure in a contactless way at the same time.~End of visit."
89444394|NCT06035107||Testing if the radar device can measure blood pressure during exercise|"We will recruit 50 participants the have the following tests:~Questionnaire: The participant will be asked to complete a clinico-demographic questionnaire. This includes their demographic data and past medical history.~Measurement of heart rate, breathing rate and oxygen saturations.~Recording a heart tracing called an ECG~Participants will then perform 5-10 minutes of exercise, either repeated sit-to-stand movements or using a bike ergometer. Blood pressure will be measured using a cuff and the radar device at regular intervals~Participants will then have a heart scan called an echocardiogram during which time the radar blood measurements will also be collected.~End of visit."
89444395|NCT06035055|Experimental|Ceftolozane/tazobactam 9g infusion|9g ceftolozane/tazobactam in 240 millilitres 0.9% sodium chloride IV infusion given over 24 hours for 10-14 days
89444396|NCT06035029||Case group|Children with appendectomy for appendicitis
88928593|NCT01713959|Active Comparator|Group B: Ulthera System Treatment w lido|Subjects receive a bilateral Ulthera System Treatment, with one axilla receiving a subcutaneous lidocaine injection.
88928594|NCT01713972|Experimental|Treatment (dabrafenib, pazopanib hydrochloride)|Patients receive dabrafenib PO BID on days 1-28 (once daily on day 1 and BID on days 3-28 of course 1), and pazopanib hydrochloride PO QD on days 1-28 (days 2-28 of course 1). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88928595|NCT01713972|Other|Correlative Studies|"Pharmacokinetic studies: Blood draw for various time points:~Cycle 1 Days 1, 2, 3, 4 and 15; Cycle 2 Days 1, 2; and day 1 of Cycles 4, 6 and 12~Pharmacogenomic studies: Blood draw on Cycle 1 Day 1~Tumor genotyping: Archival tumor blocks or unstained slides~BRAF mutation quantification in circulating plasma DNA: Blood draw on Cycles 1-7 Day 1 and every other cycle thereafter; and at time of progression"
88928596|NCT01713985|Active Comparator|Group A|Ulthera System Treatment Right, Thermage Left
88928597|NCT01713985|Active Comparator|Group B|Ulthera System Treatment Left, Thermage Right
88928598|NCT01714011|Active Comparator|Ziprasidone|Ziprasidone is a psychotropic agent with chemical name: 5-[2-[4-(1,2-benzisothiazole-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one.Ziprasidone is a potent antagonist of both serotonin 5-HT2A and dopamine D2 receptors, although its affinity for 5-HT2A receptors is about 10 times higher than for D2 receptors.
88928599|NCT01714011|Active Comparator|Aripiprazole|Aripiprazole is a psychotropic drug that is available as tablets for oral administration. Aripiprazole is 7-[ 4-[ 4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy]-3-4-dihydrocarbostyril. Aripiprazole exhibits high affinity for dopamine D2 and D3, serotonin 5-HT1A and 5-HT2A receptors, moderate affinity for dopamine D4, serotonin 5-HT2C and 5-HT7, alpha 1-adrenergic and histamine H1 receptors and moderate affinity for serotonin reuptake site (Ki = 98nM).
88928600|NCT01714037|Experimental|Cisplatin, Pemetrexed, Debio 0932|Cisplatin, Pemetrexed, Debio 0932
88928601|NCT01714037|Experimental|Cisplatin, Gemcitabine, Debio 0932|Cisplatin, Gemcitabine, Debio 0932
88928602|NCT01714037|Experimental|Docetaxel, Debio 0932|Docetaxel, Debio 0932
88928603|NCT01714076||cohort isolation|patients with bronchiolitis are cohorted together irrespective of viral agent diagnosed, thus respiratory syncytial virus (RSV)-positive patient stay in the same room as RSV-negative patients
88928604|NCT01714089|Experimental|RNS60 125 ml|125 ml of RNS60 administered weekly by IV infusion
88928605|NCT01714089|Experimental|RNS60 250 ml|250 ml of RNS60 administered weekly by IV infusion
88928606|NCT01714089|Active Comparator|Interferon beta-1a|Weekly dose of 30 mcg Interferon beta-1a (Avonex) administered by intramuscular injection.
88928607|NCT01714102|Placebo Comparator|Placebo|Placebo for 30 days
88928608|NCT01714102|Active Comparator|Resveratrol|1000 mg PO BID for 30 days
88928609|NCT01714128|Other|Optional Diagnostic Imaging|Optional diagnostic imaging FES-PET/CT imaging
88928610|NCT01714141|Experimental|Multi-component, technology based intervention|2 tailored, computer-delivered motivational interviewing sessions targeting adherence to asthma control medications + tailored text messaged reminders to take medications between sessions.
88928611|NCT01714141|Active Comparator|Asthma education active control|Control condition consists of active control matched to intervention for delivery-method and time-- 2 sessions of computer-delivered asthma education + daily text messaged facts about asthma.
88928612|NCT01714154|Experimental|A: setrobuvir|
88928613|NCT01714154|Experimental|B: setrobuvir + DNV/r|
88928614|NCT01714167|Active Comparator|intracerebral stem cell transplantation|Intracerebral transplantation of autologous bone marrow mesenchymal stem cell, 2-4 million stem cells per patient plus conventional treatment include rehabilitation
88928615|NCT01714167|No Intervention|conventional treatment|Control group receive conventional stroke treatment that include rehabilitation
88928616|NCT01714180||Obese Patients|
88928617|NCT01714180||Non-obese Patients|
88928618|NCT01714193|Experimental|Canagliflozin + oral contraceptive|Each volunteer will receive a single dose of an oral contraceptive containing ethinyl estradiol and levonorgestrel on Day 1, followed by canagliflozin (JNJ-28431754) once daily on Days 4 through 8. On Day 9 volunteers will receive a single dose of an oral contraceptive containing ethinyl estradiol and levonorgestrel in combination with a single dose of canagliflozin.
88928619|NCT01714206|Active Comparator|Treatment A|Each volunteer will receive digoxin once daily on Days 1 through 7.
88928620|NCT01714206|Experimental|Treatment B|Each volunteer will receive digoxin once daily on Days 1 through 7 in combination with canagliflozin (JNJ-28431754) once daily on Days 1 through 7.
88928621|NCT01714219|Experimental|Posterior reconstruction|"New posterior reconstruction, which entails opposition of the median dorsal fibrous raphe solely to the posterior counterpart of the detrusor apron~Vesicourethral anastomosis using the van Velthoven method~Anterior reconstruction, which involved opposing the anterior detrusor apron to the remaining puboprostatic ligaments and dorsal vascular complex"
88928622|NCT01714219|No Intervention|No posterior reconstruction|"No posterior reconstruction~Vesicourethral anastomosis using the van Velthoven method~Anterior reconstruction, which involved opposing the anterior detrusor apron to the remaining puboprostatic ligaments and dorsal vascular complex"
88928623|NCT01714258|Experimental|non invasive cardiac output measure|non invasive cardiac output estimation based on passive induced prolonged expiration in mechanically ventilated patients 20 times, throughout a period of about 45 min
88928624|NCT01714284|Experimental|Diet and Exercise|
88928625|NCT01714284|Sham Comparator|Informative|
88928626|NCT01714297|Active Comparator|dalteparin 5000IU s.c.|5000IU dalteparin s.c. injected the evening before cemented total hip arthroplasty
88928627|NCT01714297|Placebo Comparator|saline|Syringes of Saline with the same volume as in the dalteparin injections are injected the evenings before total hip arthroplasty. Dalteparin 5000IU are injected 6 hours after surgery and the concomitant 33 days
88928628|NCT01714375|Active Comparator|QuietDose device VOLUNTARY|"This group of employees will voluntarily use the QuietDose units in place of their regular hearing protection, which may be either ear plugs or ear muffs."
88928629|NCT01714375|No Intervention|No QuietDose device|"This group of employees will not use the QuietDose units and maintain use of their regular hearing protection which may be either ear plugs or ear muffs."
88928630|NCT01714375|Active Comparator|QuietDose Device REQUIRED|"This group of employees will be required to use the QuietDose units in place of their regular hearing protection, which may be either ear plugs or ear muffs."
88928631|NCT01714388|Experimental|Remifentanil, Vagotonic response|1 microgram/kg remifentanil given iv over at least 30 sec. at the beginning of induction of general anaesthesia
88928632|NCT01714401|Active Comparator|Salbutamol 2,5 mg|25 mechanically ventilated patients to receive 2,5mg of nebulised salbtamol (Ventolin) duration of nebulisation - 20 minutes
88928633|NCT01714401|Active Comparator|Salbutamol 5mg|25 mechanically ventilated patients 5 mg of nebulised salbutamol (Ventolin) duration of nebulisation - 20 minutes
88928634|NCT01714414|Experimental|FZD 600mg twice daily|FZD 3 tablets (600mg) twice daily / 3TC 1 tablet (150mg) twice daily / EFV 1 capsule (600mg) once daily for the duration of 24 weeks
88928635|NCT01714414|Experimental|FZD 800mg once daily|FZD 4 tablets (800mg) once daily / 3TC 2 tablets (150mg) once daily / EFV 1 capsule (600mg) once daily for the duration of 24 weeks
88928636|NCT01714414|Experimental|FZD 1200mg once daily|FZD 6 tablets (1200mg) once daily / 3TC 2 tablets (150mg) once daily / EFV 1 capsule (600mg) once daily for the duration of 24 weeks
88928637|NCT01714414|Active Comparator|AZT twice daily|1 tablet Combivir(AZT 300mg/3TC 150mg) twice daily / EFV 1 capsule (600mg) once daily for the duration of 24 weeks
88928638|NCT01714427|Active Comparator|Dexamethasone|
88928639|NCT01714427|Placebo Comparator|Sterile isotonic saline|
88928640|NCT01714440||Transplant Recipients Cohort|Main Study Cohort: Kidney (or kidney-pancreas) transplant recipients. Enrollment for this cohort is closed.
88928641|NCT01714440||Transplant Donors Cohort|Main Study Cohort: The kidney donor for transplant recipients in this study. Enrollment for this cohort is closed.
88928642|NCT01714440||Activity&mRNA Expression Substudy Cohort|A subset of subjects enrolled in the main study who will receive tacrolimus, cyclosporine or mycophenolate as part of maintenance immunosuppression therapy. This group has a prospective observational cohort design. Enrollment into the Activity and messenger ribonucleic acid (mRNA) Expression Cohort, occurring concurrently with enrollment of the rest of the study, will continue until either the required sample size of 600 is achieved or the protocol team terminates enrollment. Participants in the Activity and mRNA Expression Cohort have additional blood draws up to 2 weeks prior to transplant, at week 1, Month 3 and Month 6 post-transplant.
88928643|NCT01714466|Experimental|Part A, arm 1|Evening dose of TF048. Morning dose of TF043
88928644|NCT01714466|Experimental|Part A, arm 2|Evening dose of TF043. Morning dose of TF048
88928645|NCT01714466|Experimental|Part A, arm 3|Evening dose of TF047. Morning dose of TF043
88928646|NCT01714466|Active Comparator|Part A, arm 4|MOVIPREP (Both evening and morning dose)
88928647|NCT01714466|Experimental|Part B, arm 1|IMP selected based on the optimal dosing sequence and volume identified from Part A
89444397|NCT06035029||Control group|Children with no digestive disease or medical history
88928648|NCT01714466|Experimental|Part B, arm 2|IMP as used in Part B, arm 1, with a differing amount of additional clear fluid being consumed
88928649|NCT01714466|Active Comparator|Part B, arm 3|IMP as used in Part B, arm 1, except for a reduced amount of ascorbate
88928650|NCT01714466|Experimental|Part B, arm 4|MOVIPREP used in both evening and morning dose
88928651|NCT01714479|Placebo Comparator|Load Carriage - Control|Load Carriage - with a calorie-free placebo
88928652|NCT01714479|Experimental|Load Carriage - leucine-enriched nutrition supplement|Load Carriage with leucine-enriched amino acid supplementation
88928653|NCT01714479|Placebo Comparator|Conventional Exercise - Control|Conventional Exercise with a calorie-free placebo
88928654|NCT01714479|Active Comparator|Conventional Exercise - Leucine-enriched Nutrition Supplement|Conventional Exercise with leucine-enriched Amino Acid supplementation
88928655|NCT01714518||ILD diagnosis|Patients subjected to Cryobiopsy and/or VATS for diagnosis of interstitial lung disease
88928656|NCT01714531|Experimental|Telephone-Based Goal Management Training|The GMT intervention targets cognitive deficits in executive functioning that impact a person's ability to carry out daily tasks. Participants learn how to recognize and stop absentmindedness and automatic pilot and how to reduce daily errors and 'slips' through goal setting. The telephone-based GMT condition includes 7 sessions delivered over the phone for 10 weeks.
88928657|NCT01714531|Active Comparator|Telephone-Based Attention-Control|The attention group receives an educational intervention that is matched to the GMT intervention in terms of session length and contact with the study therapist. The telephone-based attention condition includes 7 sessions delivered over 10 weeks. Sessions address education on brain function and cognitive principles of memory, attention, language, perception, and motor skills. Education on stress reduction, sleep hygiene, energy management, exercise, communication, and nutrition are also provided
88928658|NCT01714531|No Intervention|Usual Care Control|Participants in the control group will receive usual care as determined by the treating surgeon. Usual care may include referral to a physical therapist, occupational therapist, psychiatrist, and/or psychologist and utilization of health services will be recorded during follow-up assessments.
88928659|NCT01714557|No Intervention|No prophylaxis|
88928660|NCT01714557|Active Comparator|piperacillin|
88928661|NCT01714557|Experimental|piperacillin/tazobactam|
88928662|NCT01714570|Experimental|piperacillin/tazobactam|
88928663|NCT01714570|Active Comparator|imipenem/cilastatin|
88928664|NCT01714583||High PEEP|Cohort of participants with positive end-expiratory pressure (PEEP) greater than or equal to 12cm.
88928665|NCT01714583||Low PEEP|Cohort of participants with positive end-expiratory pressure (PEEP) less than 12cm.
88928666|NCT01714596|Active Comparator|Oral Antibiotic|Oral Antibiotic Arm; Participants assigned to this group will receive oral antibiotics as prescribed by their treating physician.
88928667|NCT01714596|Active Comparator|IV Antibiotic|Participants assigned to this group will receive intravenous (IV) antibiotics as prescribed by their treating physician.
89444398|NCT06035016||cohort A|Pyrotinib 400mg, qd, po, day 1-21, q3w, Capecitabine 1000mg/m2, bid po d1-14, q3w
89444399|NCT06035016||cohort B|treatment of physician's choice
89444400|NCT06034977|Placebo Comparator|Lenvatinib|Advanced HCC patients treated by Lenvatinib.
89444401|NCT06034977|Experimental|Lenvatinib + ADI-PEG20|Advanced HCC patients treated by Lenvatinib + ADI-PEG20.
89444402|NCT06034951|Other|Patients well established on tube feeds will act as their own control|These patients will switch from current to new tube feed to assess acceptability and tolerance
89444403|NCT06034938|Experimental|Single arm DOR/3TC/TDF|Doravirine 100 mg Lamivudine 300 mg Tenofovir disoproxil fumarate 245 mg Delstrigo (R): 1 pill/day for 48 weeks
89444404|NCT06034847|Active Comparator|Conservative management|Mechanical thrombectomy of large vessel occlusions with or without administration of IV thrombolytics
89444405|NCT06034847|Active Comparator|Rescue therapy|In addition to conservative management, rescue therapy in distal occlusions consisting of either mechanical thrombectomy with small stent retrievers with or without contact aspiration, or intra-arterial pharmacotherapy with tPA (tissue Plasminogen Activator), uPA (urokinase Plasminogen Activator) or tenecteplase.
89444406|NCT06034795||Patients|"32 patients with Familial mediterranenan fever will participate. In these patients we will check bone mineral density using the dexa method.~Blood tests will also be taken to assess calcium metabolism. All patients will be treated with colchicine."
89444407|NCT06034795||Control group|Healthy children will be used as control group. MEFV gene will be checked to exclude diagnosis of FMF. In these patients we will check bone mineral density using the dexa method. Blood tests will also be taken to assess calcium metabolism. The results from the two groups will be compared.
89444408|NCT06034782||patients with salivary gland tumors|patients with salivary gland tumors
89444409|NCT06034730||Lung Cancer Patients|patients undergoing surgery for histologically proven NSCLC
89444410|NCT06034730||Healthy Control Patients|patients undergoing surgery for benign extra-thoracic disease who had undergone chest X-rays/chest CT-scan, proved to be negative during preoperative evaluation.
89444411|NCT06034704|Experimental|Magnetic Fascial Ball|In the experimental group, a fascial ball made of cork containing 3 magnets of 0.15 tesla was used. The magnetic fascia ball diameter is 6 centimetres.
89444412|NCT06034704|Placebo Comparator|Non-Magnetic Fascial Ball|In the placebo group, a fascial ball made of cork without magnets. The non-magnetic fascia ball diameter is 6 centimetres.
89444413|NCT06034691|Experimental|PCSK9i group|treatment group
89444414|NCT06034691|No Intervention|control group|control group
88928668|NCT01714622||metabolic syndrome|gastric cancer patients with metabolic syndrome
88928669|NCT01714622||metabolic disease|gastric cancer patients with metabolic disease
88928670|NCT01714622||normal|gastric cancer patients without metabolic syndrome or metabolic disease
88928671|NCT01714648|Experimental|OHSS high risk patients|Triptorelin 0.2 mg
88928672|NCT01714661|Experimental|EVP-6124, low dose|low dose, Tablet, Once Daily, Day 1 through Day 182
88928673|NCT01714661|Experimental|EVP-6124, high dose|high dose, Tablet, Once Daily, Day 1 through Day 182
88928674|NCT01714661|Placebo Comparator|EVP-6124, Placebo|Placebo, Tablet, Once Daily, Day -14 through Day 182
88928675|NCT01714674|Placebo Comparator|Placebo beverage|the impact of placebo (no active substance) on exercise-induced cTnT release
88928676|NCT01714674|Active Comparator|Dietary nitrate beverage|The impact of dietary nitrate (active substance) on exercise-induced cTnT release
88928677|NCT01714700|Active Comparator|High protein diet, Resistance exercise|High protein diet, Resistance exercise total calories 2400 Kcal/day, 55% carbohydrate, 30% protein, and 15% fat
88928678|NCT01714700|Placebo Comparator|Standard diet, Resistance exercise|total calories 2400 Kcal/day, 60% carbohydrate, 15% protein, and 25% fat; ST group
88928679|NCT01714713|Experimental|EVP-6124 low dose|low dose Tablet, Once Daily, Day 1 through Day 182
88928680|NCT01714713|Experimental|EVP-6124, high dose|high dose Tablet, Once Daily, Day 1 through Day 182
88928681|NCT01714752|Experimental|exercise|Patients perform exercise and pression measure is performed
88928682|NCT01714765|Other|Dovitinib and Everolimus|No Arms
88928683|NCT01714778||e-Cigarette|Smokers attempting to quit with behavioural support and e-Cigarettes.
88928684|NCT01714791|Active Comparator|Usual care|Patients following the outpatient cardiac rehabilitation program.
88928685|NCT01714791|Experimental|Usual care and Osteopathic treatment|Patients following the outpatient cardiac rehabilitation program and receiving osteopathic treatment.
89444415|NCT06034678|Experimental|Food Allergy Mastery Program|Participants randomized to the Food Allergy Mastery Program arm will participate in 6 telehealth intervention sessions with a trained mental health provider pertaining to food allergy education, food allergy management, anxiety and stress management, social situations, and self-efficacy. One of the 6 sessions is a group session with peers.
89444416|NCT06034678|No Intervention|Usual Care|Participants will receive their usual allergy care.
89444417|NCT06034639||Group 1|No Intervention
89444418|NCT06034626|Experimental|OPL-I|Patients treated with OPL-I with the dual filter system
89444419|NCT06034626|Active Comparator|M22|Patients treated with OPL-I with the single filter system
88928686|NCT01714817|Experimental|BMS-188667 + Mycophenolate mofetil + Prednisone|BMS-188667 30 mg/kg injection by intravenous on Days 1,15, 29, and 57, followed by a weight-tiered dose approximating 10mg/kg injection by intravenous every 4 weeks, Mycophenolate mofetil 1.5 g tablet by mouth and Prednisone up to 60 mg tablet by mouth Daily for 104 weeks
88928687|NCT01714817|Placebo Comparator|Placebo + Mycophenolate mofetil + Prednisone|Placebo matching with BMS-188667 injection by intravenous on Days 1,15, 29, and 57, followed by every 4 weeks, Mycophenolate mofetil 1.5 g tablet by mouth and Prednisone up to 60 mg tablet by mouth Daily for 104 Weeks
88928688|NCT01714830|Sham Comparator|sham group|the same protocol is applied but with the probe being turned off.
89444420|NCT06034613|Experimental|mindfulness intervention group|provide standard audio instructions for mindfulness exercises, introduce the nature and law of anxiety, depression and other emotions, the source of anxiety, depression and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems.
89537089|NCT02467595|Placebo Comparator|S group|"saline~Anesthesia was induced with propofol 2.5 mg kg-1 , fentanyl 2 mcg kg-1, and saline.~After mask ventilation with 5 vol% sevoflurane in 100% oxygen for 2 minutes, tracheal intubation was done.~At the end of surgery, discontinuation of sevoflurane and extubation, sending recovery room.~When poor intubating condition., added rocuronium bromide0.3 mg kg-1 ."
88928689|NCT01714830|Sham Comparator|treatment group|patients will be treated by ESWT once a week for 4 weeks
88928690|NCT01714843|Experimental|ASP0456 lowest dose group|oral
88928691|NCT01714843|Experimental|ASP0456 low dose group|oral
88928692|NCT01714843|Experimental|ASP0456 middle dose group|oral
88928693|NCT01714843|Experimental|ASP0456 high dose group|oral
88928694|NCT01714843|Placebo Comparator|placebo group|oral
88928695|NCT01714856|Experimental|Test Product|Single oral dose of Ropinirole hydrochloride CR 2mg Tablets under fed conditions
88928696|NCT01714856|Experimental|Reference Product|Single oral dose of REQUIP XL Tablets 2mg under fed conditions
88928697|NCT01714869|Other|Swedish Massage|Swedish Massage, once per week for 8 weeks, 60 minutes per session.
88928698|NCT01714882|Experimental|Stress Management & Resiliency Training|The couples in this group will attend the SMART in-person training class at the beginning of the study and will be taught a structured relaxation program.
88928699|NCT01714882|Active Comparator|Stress Management DVD|The couples in this group will receive a Mayo Clinic Stress Management DVD.
88928700|NCT01714895|Other|High plasma insulin-Low plasma insulin|Seven out of the 14 subjects recruited in the study have been randomized to receive on the first study day a High insulin glucose clamp and on the second day a Low insulin glucose clamp (sequence 'AB')
88928701|NCT01714895|Other|Low plasma insulin-High plasma insulin|Seven out of the 14 subjects recruited in the study have been randomized to receive on the first study day a Low insulin glucose clamp and on the second day a High insulin glucose clamp (sequence 'BA')
88928702|NCT01714908|Experimental|Erlotinib w Concurrent Radiotherapy|erlotinib 150mg oral daily up to 2 years concurrent radiotherapy total dose 60-66 Gray (Gy) in 2 Gray (Gy) fractions. One fraction per day, and 5 fractions per week.
88928703|NCT01714908|Active Comparator|etoposide/cis-platin (EP) w Concurrent Radiotherapy|etoposide 50mg/m2 on D1-5 and D29-33 cis-platin 50mg/m2 on D1, D8, D29 and D36 concurrent radiotherapy total 60-66 Gray (Gy) in 2 Gray (Gy) fractions. One fraction per day, 5 fractions per week.
88928704|NCT01714934||IPF|IPF patients diagnosed according to clinical and radiological findings
88928705|NCT01714934||NON IPF|Other interstitial lung diseases such as sarcoidosis or hypersensitivity pneumonitis diagnosed as per clinical and radiological findings
88928706|NCT01714960|Experimental|Healthy volunteers low dose|MRZ-99030 eye drops (5mg/mL), 1-3 drops three times per day, duration: 16 days.
88928707|NCT01714960|Experimental|Healthy volunteers high dose|MRZ-99030 eye drops (20mg/mL), 1-3 drops three times per day, duration: 16 days.
88928708|NCT01714960|Experimental|Glaucoma patients|MRZ-99030 eye drops (20mg/mL), 1-3 drops three times per day, duration: 16 days.
88928709|NCT01714960|Placebo Comparator|Placebo|Placebo eye drops, 1-3 drops three times per day, duration: 16 days.
88928710|NCT01714973|Experimental|ST266 intact|Ten (10) patients will be randomized before the first radiation treatment to receive ST266 (4ml) and saline placebo (4ml), one to the medial segment and the other to the lateral segment. The area of the breast will be divided into two, roughly equal parts, medial and lateral. The randomization scheme will be equal in each of two cohorts. The first cohort will receive ST266 and saline placebo applied to intact skin beginning immediately following the first radiation treatment, to continue immediately following each of ten (10) consecutive radiation treatments.
88928711|NCT01714973|Experimental|ST266 inflamed|Ten (10) patients will be randomized before the first radiation treatment to receive ST266 (4ml) and saline placebo (4ml), one to the medial segment and the other to the lateral segment. The area of the breast will be divided into two, roughly equal parts, medial and lateral. The randomization scheme will be equal in each of two cohorts. The second cohort will receive ST266 and saline placebo applied to inflamed skin (after inflammation is first noted) beginning immediately following the radiation treatment, to continue immediately following each of ten (10) consecutive radiation treatments.
88928712|NCT01714986|Active Comparator|Affect School|Psychological group education intervention
88928713|NCT01714986|Active Comparator|Body Awareness Therapy|Physiotherapeutic psychosomatic intervention
88928714|NCT01714999|Experimental|Bursectomy: Vienna|At the Department of Trauma Surgery, Medical University of Vienna, bursectomy is considered the gold standard in case of traumatic laceration of the OB or PB bursa.
88928715|NCT01714999|Experimental|Bursal reconstruction: Munich|At the Department of Trauma Surgery, Medical University of Munich, the treatment regime is a primary bursa-preserving therapy.
88928716|NCT01715025|Experimental|E2/Nomac|Women with demonstrated HMB at baseline will be assigned to 3 cycles of a E2/Nomac combined pill 1 daily for 24 days followed by 1 placebo pill daily for 4 days per cycle.
89444421|NCT06034587||good response group of treated keloids|"The Vancouver Scar Scale (VSS) is the most established questionnaire used for the evaluation of pathological scarring. This scale evaluates aspects of scar vascularity, pigmentation, pliability, and height, with the scoring system ranging from 0 to 15, where 0 is the least severe and 15 is the most severe.All the keloids in the study were classified into three categories based on the VSS score: mild (0-5), moderate (6-9), and severe (10-15).~For treatment assessment, investigators further divided the treated participants into two groups: a good response group (showing an improvement of 5 or more points in the VSS score) and a poor response group (less than 5 points improvement in the VSS score)"
89537090|NCT03300401|Experimental|Diagnostic (CEUS)|Patients receive perflutren or sulfur hexafluoride lipid microspheres and undergo CEUS at baseline, 2 and 4 weeks, and 3 and 6 months. Patients also undergo PET/CT after standard of care 90Y radioembolization at baseline.
88928717|NCT01715038|Experimental|Comprehensive|"Comprehensive LNS: LNS-PLW provided daily to mothers during pregnancy and postpartum lactation (a total of at least 11 months, starting by 20 weeks gestation and ending at 6 months post-partum) and LNS developed for infants and young children (LNS-child) provided daily to their infants (beginning at 6 months of age for a period of 18 months i.e., from 6-24 months of age)."
88928718|NCT01715038|Experimental|Child-only LNS|"Child-only LNS: Daily LNS-child supplementation of the child starting at 6 months of age and ending at 24 months of age (18 months total). Women will be provided with iron and folic acid (IFA) tablets during pregnancy and for 3 months postpartum."
88928719|NCT01715038|Experimental|Child-only MNP|"Child-only MNP: Daily MNP supplementation of the child starting at 6 months of age and ending at 24 months of age (18 months total). Women will be provided with iron and folic acid (IFA) tablets during pregnancy and for 3 months postpartum."
88928720|NCT01715038|Active Comparator|Control: IFA|Control: No additional nutrient supplementation for the child will be provided through the study, but the regular nutrition education and visits provided by the program frontline staff will continue. Women will be provided with iron and folic acid (IFA) tablets during pregnancy and for 3 months postpartum.
88928721|NCT01715051|Active Comparator|D-serine|Participants randomized to D-serine will receive 500 mg tablets of D-serine based on the participant's weight in addition to weekly cognitive behavioral therapy (CBT). The number of capsules prescribed will be based on the target ~60 mg/kg per day dose. In practice, the mg/kg daily dose will range between approximately 55 mg/kg and 65 mg/kg. Dosing will be bid.
88928722|NCT01715051|Placebo Comparator|Placebo|The number of placebo capsules prescribed to a study participant per day will be based on the participant's weight and will be bid dosing to match the dosing of D-serine.
88928723|NCT01715077|Experimental|Ipilimumab|The recommended induction dose of ipilimumab is 3 mg/kg administered intravenously over a 90-minute period every 3 weeks for a total of four doses, as guided by laboratory tests and patient assessment.
88928724|NCT01715090|Experimental|Web-based insulin titration|An online web-based insulin titration algorithm to guide patients in self-titration
88928725|NCT01715090|No Intervention|Standard care|
88928726|NCT01715103|Other|Healthy women volunteers|Healthy women volunteers with vaginal swabs by washing and cytobrush
88928727|NCT01715103|Other|HIV-1 infected women|HIV-1 infected women with vaginal swabs by washing and cytobrush
88928728|NCT01715116|Experimental|Enhanced ICD programming|
88928729|NCT01715142|Experimental|Gemcitabine+Abraxane|Chemotherapy combining gemcitabine and Abraxane during 4 weeks (1 cycle) before surgery (cohort 1: resectable patients) and during at least 8 weeks (2 cycles or more in case of response of stable disease) (cohort 2: locally advanced and metastatic patients)
88928730|NCT01715168|Active Comparator|DOXIL/CAELYX or Doxorubicin Hydrochloride (Lipspome)|Current Standard of care and/or reference product in Europe (Caelyx) and US (Doxorubicin Hydrochloride (Liposome) and Doxil)
88928731|NCT01715168|Experimental|ATI-0918|Investigational drug arm which will be compared to Doxil/Caelyx and Hydrochloride Doxorubicin (Liposome) arms for bioequivalence analysis
88928732|NCT01715181|No Intervention|Usual care|Individuals will receive usual care
88928733|NCT01715181|Experimental|Volunteer visits|Volunteers will visit 3 times per week with a visit duration of 30 minutes for each visit during the study.
88928734|NCT01715194|Active Comparator|Telemedicine intervention|"In the telemedicine intervention arm, a telemetry device is instructed and attached to the CPAP. Patients are instructed to use CPAP every night. Data of the CPAP are downloaded to the internet once daily. On week days, a nurse is checking the downloaded data three times per week. The nurse contacts the patient if~CPAP was used <4h/ night for 2 consecutive night~the median leakage was above 0.4 L/sec on 2 consecutive nights The nurse informs the patient of the problem observed, asks for explanations and gives advice on possibilities to solve the problem. The common problems and the respective solutions are discussed according to the ELF facts sheet (Dry mouth/throat, nasal congestion, skin irritation, conjunctivitis, headache, loss of benefits, appendix 1). The patient is encouraged to use CPAP every night. In the case of regular use and acceptable leakage, a congratulatory message is sent to the patient via sms or e-mail (for procedural rules, see appendix 4)."
88928735|NCT01715194|No Intervention|Control (without telemedicine)|In the control arm, no device is attached to the CPAP machine, but data stored in the CPAP machine are collected at the follow-up visit after 1 month of CPAP use.
88928736|NCT01715220|Active Comparator|Sublingual nitroglycerine|Sublingual nitroglycerine followed by pain assessment and if necessary second dose of sublingual nitroglycerine
88928737|NCT01715220|Placebo Comparator|placebo|sublingual placebo followed by pain assessment and if necessary second dose of sublingual placebo
88928738|NCT01715246|Placebo Comparator|Starter infant formula without HMO|Volumes of feed depend on age, weight and appetite.
88928739|NCT01715246|Active Comparator|Starter infant formula with 2 HMOs|Volumes of feeds depend on age, weight and appetite
88928740|NCT01715246|No Intervention|Breasfed reference group|
88928741|NCT01715259|Experimental|Abiraterone acetate|
88928742|NCT01715272|Active Comparator|Fleet enema|This group will receive Fleet enema as their treatment
88928743|NCT01715272|Experimental|TF037|This group will receive TF037 as their treatment
88928744|NCT01715311|Experimental|Indacaterol|Indacaterol once daily
88928745|NCT01715311|Placebo Comparator|Placebo|Placebo for indacaterol and placebo for tiotropium once daily
88928746|NCT01715311|Active Comparator|Tiotropium|Tiotropium
88928747|NCT01715337|Other|pulmonary rehabilitation|
89013556|NCT06300021|Experimental|Sequence probiotic drink - gummies - dairy analog - sport bar - ready to drink - capsule|Subjects receive Turmipure Gold® preparations in different food matrices in the following order: probiotic drink - gummies - dairy analog - sport bar - ready to drink - capsule
89013557|NCT06300021|Experimental|Sequence ready to drink - dairy analog - capsule - probiotic drink - sport bar - gummies|Subjects receive Turmipure Gold® preparations in different food matrices in the following order: ready to drink - dairy analog - capsule - probiotic drink - sport bar - gummies
89013558|NCT06300021|Experimental|Sequence sport bar - capsule - gummies - ready to drink - probiotic drink - dairy analog|Subjects receive Turmipure Gold® preparations in different food matrices in the following order: sport bar - capsule - gummies - ready to drink - probiotic drink - dairy analog
89013559|NCT06300008|Experimental|cetylated fatty acid|Topical cetylated fatty acid, apply 2 times/day for 6 weeks after operation
89013560|NCT06300008|Placebo Comparator|Placebo|Topical placebo, apply 2 times/day for 6 weeks after operation
89013561|NCT06299982|Experimental|608 160 mg W0+80 mg Q2W|Participants will receive starting dose of 160 milligrams (mg) 608 at week 0 followed by 80mg 608 once every two weeks (Q2W) by subcutaneous injection for 12 weeks.
89013562|NCT06299982|Experimental|608 160 mg Q4W|Participants will receive 160 milligrams 608 once every four weeks (Q4W) by subcutaneous injection for 12 weeks.
89013563|NCT06299930||Neoadjuvant chemotherapy (NACT) group|Patients who administered chemotherapy before surgery
89013564|NCT06299930||Adjuvant chemotherapy (ACT) group|Patients who administered chemotherapy after surgery
89013565|NCT06299917|Experimental|WORK-ON|"The 6-months WORK-ON VR includes three parts in addition to usual care:~1: A coordinating occupational therapist (OT) (10 hours): An initial assessment and goal setting process. Support to navigate offers in the municipalities and to involve the employer.~Provides individual support in relation to the goals agreed upon. After six months, goals, the patients' progress during the intervention and future need for support are evaluated.~Follow-up consultation 12 months after baseline. Group sessions to meet with others in the same situation and exchange experiences.~Legislative offers (social worker and coordinating OT)~Acceptance of the disease in relation to work (nurse and the coordinating OT).~Coping strategies (physiotherapist and coordinating OT).~Follow-up (nurse and the coordinating OT). Up to 8 individual consultations are offered with a physiotherapist, nurse and or social worker to achieve the goals."
89013566|NCT06299917|No Intervention|Usual care|Both the intervention and the control group will receive usual care in the outpatient department. Usual care consists of planned outpatient consultations every 3-12 months depending on the patient's needs, alternating between a rheumatologist and rheumatology nurses. In addition, they have access to support from a telephone help-line to the rheumatology nurses. The planned consultations include review of blood tests, joint examinations, review of completed questionnaires in DANBIO, which is a national rheumatology quality database, adherence to the pharmacological treatment and evaluation of whether pharmacological adjustment is necessary. The nurses can provide limited occasional patient education tailored to the specific patient on management of their disease, medications and symptoms. The participants in the control group will be offered pamphlets for their employer and colleagues (Dear Employer and Dear colleague)
89013567|NCT06299904|Sham Comparator|control group|Based on receiving personalized swallowing rehabilitation training, the control group received traditional air-pulse stimulation therapy.
89013568|NCT06299904|Experimental|trial group|The trial group received modified air-pulse stimulation therapy mediated by flexible endoscopy.
89013569|NCT06299878||Group 1|Neoadjuvant
89013570|NCT06299852|Experimental|Prospective group: STR + trastuzumab emtansine 24 hours after the STR|STR + trastuzumab emtansine. Patients included in the study will will undergo SRT for up to 2 cycles, depending on the location of the irradiated focus, followed by administration of trastuzumab emtansine at a dose of 3.6 mcg/kg once every 3 weeks, up to 4 total cycles. Targeted therapy with trastuzumab emtansine should commence 24 hours after the completion of SRT.
89013571|NCT06299852|No Intervention|Retrospective group: STR + trastuzumab emtansine > 24 hours after the STR|Patients with oligometastatic HER2+ breast cancer who were treated with trastuzumab-emtansine and who had a history of SRT. Retrospectively, using CT and MRI data, the dynamics of the process will be evaluated according to the RECIST 1.1. Based on the data of the medical documentation of patients, the main statistical indicators will be calculated.
89013572|NCT06299839|Experimental|PAS-004|Sequential dose escalation: 2 mg, 4 mg, 6 mg, 9 mg, 12 mg, 15 mg, and 18 mg
89013573|NCT06299826|Experimental|Cohort A & B: AZD5462 low dose|Participants will receive low dose of AZD5462 or matching placebo as OD tablets for 24 weeks.
89013574|NCT06299826|Experimental|Cohort A & B: AZD5462 medium dose|Participants will receive medium dose of AZD5462 or matching placebo as OD tablets for 24 weeks.
89013575|NCT06299826|Experimental|Cohort A & B: AZD5462 high dose|Participants will receive high dose of AZD5462 or matching placebo as OD tablets for 24 weeks.
89013576|NCT06299826|Experimental|Cohort A & B: Placebo|Participants will receive matching placebo OD tablets for 24 weeks.
89013577|NCT06299800||Diabetes mellitus type 2 and cancer|779 patients with cancer and diagnosis of type 2 diabetes mellitus diagnosed between 1990 and 2010
89013578|NCT06299787|Active Comparator|Active Bilateral|Bilteral TBS, applied as cTBS over the right DLPFC followed by iTBS over the left DLPFC
88928748|NCT01715350|Placebo Comparator|Placebo group|"• Drug : Placebo 2 tablet~The drug will be taken with water within 30 minutes after breakfast and supper. Even if no meal is taken, dosing will not be omitted and the drug should be taken with enough amount of water."
88928749|NCT01715350|Experimental|Dose group 1|"Drug : Placebo 1 tablet + Study drug 1 tablet~Study drug(650-mg PM012 tablet)~The drug will be taken with water within 30 minutes after breakfast and supper. Even if no meal is taken, dosing will not be omitted and the drug should be taken with enough amount of water."
88928750|NCT01715350|Experimental|Dose group 2|"Drug : Study drug 2 tablet~Study drug (650-mg PM012 tablet)~The drug will be taken with water within 30 minutes after breakfast and supper. Even if no meal is taken, dosing will not be omitted and the drug should be taken with enough amount of water."
88928751|NCT01715363|Experimental|FOLFOX + surgery + FOLFOX|"Systemic chemotherapy (modified FOLFOX 4) 48 hours before surgery~resection of the colorectal tumor during surgery~Resumption of FOLFOX within the month after surgery (post operative administration of 4 course of treatment and assessment of the response)"
88928752|NCT01715376||Integrative Chinese and western medicine|Integrative Chinese and western medicine group treat with western medical therapy for CHD refering to the 'Chronic stable angina pectoris diagnosis and treatment guide'which is published by Chinese society of Cardiology, Chinese Medical Association in March, 2007, including the anti-ischemia treatment(nitric acid ester,β-blocker,calcium antagonist,ACEI), anti platelet therapy(aspirin and/or clopidogrel) and other statins.TCM should be confirmed by the physicians, according to the syndrome differentiation and the treat plan recommended in this study.
88928753|NCT01715376||Western medicine|western medical therapy for CHD can refer to the 'Chronic stable angina pectoris diagnosis and treatment guide'which is published by Chinese society of Cardiology, Chinese Medical Association in March, 2007, including the anti-ischemia treatment(nitric acid ester,β-blocker,calcium antagonist,ACEI), anti platelet therapy(aspirin and/or clopidogrel) and other statins.
88928754|NCT01715389|Experimental|Intervention|"Parents in the intervention group will use the MyAsthma Patient Portal to receive enhanced educational information on asthma and its treatment, identify concerns and goals related to asthma treatment, track progress toward goals and management of concerns monthly, and track asthma symptoms monthly.~Clinicians seeing intervention families at office visits will have access to information from the portal including concerns, goals, progress toward goals, and tracking of asthma symptoms."
88928755|NCT01715389|No Intervention|Control|The control group will be signed up for MyChart but not use the MyAsthma Patient Portal. This group will be referred to asthma educational content on the CHOP website, complete study measures and otherwise, receive standard care.
88928756|NCT01715402||operated patients|this cohort includes patients who underwent a liver surgery whatever the pathology and whatever the surgical procedure
88928757|NCT01715428||Liraglutide|administration of liraglutide at 1.2 mg/daily
88928758|NCT01715441|Active Comparator|Irinotecan monotherapy|Intravenous infusion irinotecan 180 mg/m2 over 90 minutes (D1=D15) with cross over to irinotecan and sorafenib combination at progression.
88928759|NCT01715441|Active Comparator|Sorafenib monotherapy|Oral sorafenib 400 mg twice daily (total dose 800 mg/day) with cross over to irinotecan and sorafenib combination at progression
88928760|NCT01715441|Experimental|Sorafenib and irinotecan combination|"Intravenous infusion irinotecan 120 mg/m2 over 90 minutes (D1=D15) at Cycle 1, 150 mg/m² at C2 if no diarrhea > grade 1 and no other toxicity > grade 2, and 180 mg/m² at C3 in the same conditions~Oral sorafenib 400 mg twice daily (total dose 800 mg/day) from C1. 1 cycle = 15 days and 1 course = 4 weeks."
88928761|NCT01715480|Experimental|Broccoli sprout homogenate ingestion|Subjects will ingest broccoli sprout homogenate in the form of a shake.
88928762|NCT01715493|Experimental|Lysozyme 90 mg|
88928763|NCT01715493|Placebo Comparator|Placebo|
88928764|NCT01715506|Experimental|Educational intervention|Educational intervention with two days of lecture/course for the whole staff in the selected department in each nursing home and six monthly sessions of counselling in smaller groups
88928765|NCT01715519|Experimental|Treatment (Viibryd)|10 mg/day 1 to 7; 20 mg/day 8 to 14; 40 mg/day week 3 to end week 12. Subjects will then be tapered off vilazodone as follows: 20 mg/day week 13, 10 mg/day, week 14 and no medication during week 15.
89537091|NCT02467517|Experimental|INTRAVENOUS KETAMINE|
89444422|NCT06034587||poor response group of treated keloids|"The Vancouver Scar Scale (VSS) is the most established questionnaire used for the evaluation of pathological scarring. This scale evaluates aspects of scar vascularity, pigmentation, pliability, and height, with the scoring system ranging from 0 to 15, where 0 is the least severe and 15 is the most severe. All the keloids in the study keloids were classified into three categories based on the VSS score: mild (0-5), moderate (6-9), and severe(10-15).~For treatment assessment, investigators further divided the treated participants into two groups: a good response group (showing an improvement of 5 or more points in the VSS score) and a poor response group (less than 5 points improvement in the VSS score)"
89444423|NCT06034548|Experimental|diabetes and hypertension self-management|12-week lifestyle and disease self-management
89444424|NCT06034548|No Intervention|Control|Wait-list control
89444425|NCT06034522|Experimental|Face correction with Investigational device|Subjects will be injected with the investigational device in the face.
89444426|NCT06034444||interRAI LTCF|Nursing homes in Quebec where interRAI evaluations and care plans will be introduced.
89444427|NCT06033417|Experimental|Increased lifestyle walking (intervention)|Intentional increase in daily steps: 3,000 extra steps/day, 5-days a week, 8-weeks total.
89444428|NCT06033417|Other|Health education only (control)|Health education and no intentional increase in baseline daily steps (but with the option to receive the intervention upon conclusion of the initial 8-weeks).
89444429|NCT06032676||Infants with necrotising enterocolitis reviewed by a surgeon|Infant with suspected or confirmed NEC undergoing review by surgeon, regardless of outcome of that review (i.e. surgery indicated or not)
89444430|NCT06032351|Other|conventional teaching group|conventional teaching methods
88928766|NCT01715519|Placebo Comparator|Placebo|will be compared to the treatment group (viibryd)
88928767|NCT01715532|Experimental|Huachansu + TACE|Patients in this arm will receive Huachansu tablets each 3 and 3 times a day orally, as well as transcatheter arterial chemoembolization every 4 weeks, until progression of disease or adverse effects leading to termination of treatment. Each 4-week period is one cycle of treatment.
88928768|NCT01715532|Active Comparator|TACE|Patients in this arm will receive transcatheter arterial chemoembolization every 4 weeks, until progression of disease or adverse effects leading to termination of treatment. Each 4-week period is one cycle of treatment.
88928769|NCT01715545||day-3 poor quality embryos|
88928770|NCT01715545||developmental stage|day3 poor quality embryos day4 morular day-5/6 blastocyst
88928771|NCT01715558||RYTHMIQ study group|
88928772|NCT01715558||Historical control from OPTI-MIND|
88928773|NCT01715584|Other|Angiotensin Converting Enzyme Exposed|"Sevoflurane/oxygen/air/nitrous oxide~Hypertensive patients exposed to Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)will make up this arm.~Preoperative Exposure to any of the following Angiotensin Converting Enzyme Inhibitors Enalapril (Vasotec/Renitec) Ramipril (Altace/Prilace/Ramace/Ramiwin/Triatec/Tritace) Quinapril (Accupril) Perindopril (Coversyl/Aceon) Lisinopril (Listril/Lopril/Novatec/Prinivil/Zestril) Benazepril (Lotensin) Imidapril (Tanatril) Zofenopril (Zofecard) Trandolapril (Mavik/Odrik/Gopten) Fosinopril (Fositen/Monopril)"
88928774|NCT01715584|Other|Angiotensin Receptor Blocker Exposed|"Sevoflurane/oxygen/air/nitrous oxide~Hypertensive patients exposed to Angiotensin Receptor Blocking Agents (ARBs).~Preoperative Exposure to any of the following Angiotensin II Receptor Blocking Agents Losartan(Cozaar) Candesartan (Atacand) Valsartan (Diovan) Irbesartan (Avapro) Telmisartan (Micardis) Eprosartan (Teveten) Olemisartan (Benicar) Azilsartan (Edarbi)"
88928775|NCT01715584|Other|Non ACE/ARB Exposed|"Sevoflurane/oxygen/air/nitrous oxide~Hypertensive patients not exposed to angiotensin converting enzyme inhibitors or Angiotensin receptor blocking agents will be put into this arm."
88928776|NCT01715597|Experimental|ascorbic acid|ascorbic acid 2g in normal saline 500ml IV start 2hours before the operation
89013579|NCT06299787|Sham Comparator|Sham|Sham TBS
89444431|NCT06032351|Experimental|curriculum integration Group|The curriculum integration group will receive two intervention phases, including an innovation-integrated curriculum for dementia care and an innovation-integrated curriculum for care management with Entrustable Professional Activities (EPAs) to guide learning and assessment of competency performance to equip students with dementia care management competency.
89444432|NCT06032273|Experimental|Access to investigator-designed lung transplant education website|Access to an investigator-designed web-based educational resource with information about lung transplant for three months.
89444433|NCT06032273|No Intervention|No access to lung transplant education website|No access to the investigator-designed lung transplant educational resource.
89537092|NCT03300323|Active Comparator|IV Fluid challenge administration _5|4ml/kg intravenous fluid challenge administered over 5 minutes
88928777|NCT01715597|Placebo Comparator|Control|Normal saline 500ml IV infusion for 2hour
88928778|NCT01715610|Active Comparator|Antibiotic Clavulin or Clindamycin|Patient's in this arm are randomized by random-number generator to receive antibiotics. This is for a 7 day course of antibiotics. Those that are allergic to penicillin will receive clindamycin. Randomization occurs after knowledge of the patient's allergy status.
88928779|NCT01715610|Placebo Comparator|Placebo|Patient's randomized to this arm post-drainage will receive placebo and not receive antibiotics
88928780|NCT01715623||Children with HSP|children with Purpura of Henoch-Schönlein with or without renal complication
88928781|NCT01715623||healthy volunteers|healthy volunteers without allergy
88928782|NCT01715623||subjects with allergy|subjects with peanut allergy or hymenoptera venom allergy
88928783|NCT01715623||lymphoma|lymphoma-proliferation with chromosome 14 translocation
88928784|NCT01715636|Other|Eviplera|Eviplera = emtricitabine 200mg, rilpivirine 25mg, tenofovir 245mg, one tablet, once daily, taken with food, for 28 days
88928785|NCT01715649|No Intervention|Control-usual care|Nurse care coordination in a telephonic diabetes disease management program
88928786|NCT01715649|Experimental|Intervention paired testing and remote monitoring|Telehealth remote patient monitoring, structured blood glucose and usual care Paired testing-weekly remote monitoring Data analysis Virtual visits in EHR
88928787|NCT01715662|Experimental|Wii.n.Walk|Subjects (n=12) in the experimental arm (Wii.n.Walk) will be trained using the Wii Fit for 40-minute sessions, 3 times a week for a period of 4 weeks. Subjects will stand on the Wii Fit balance board and interact with the games through weight shifting or using the Wii remote controller. The intervention protocol includes: 1) Yoga (static single and double leg exercises), 2) Balance games (lateral and poster/anterior weight shifting exercises in standing), 3) Aerobics (running on spot and step class), and 4) Strength training (dynamic single and double leg exercises). The sessions will start in the clinic with a group of 3 participants and will graduate to individualized in-home training starting from week 2. For the in-clinic training sessions, a trained research assistant will administer the intervention and will provide external cueing and correction of the pose if the participants use unsafe technique.
88928788|NCT01715662|Placebo Comparator|Control|Subjects (n=12) in the control arm will play cognitive computer games using Wii Big Brain for the same frequency and duration as the Wii.n.Walk arm. The sessions will start in the clinic with a group of 3 participants and will graduate to individualized in-home training starting from week 2. For the in-clinic sessions, a research assistant will administer the intervention and will provide supervision. Wii Big Brain is a low-cost commercially available gaming software to improve cognitive function.
88928789|NCT01715675|Active Comparator|plant stanol|
88928790|NCT01715675|Placebo Comparator|control|
88928791|NCT01715688|Active Comparator|Alkalinized lidocaine|"The endotracheal tube cuff will be pre-filled at least 90 minutes before intubation with alkalinized lidocaine. Endotracheal tube cuff will be emptied before intubation and then re-filled with the same mixture following intubation to secure the position of the endotracheal tube. (cuff will be inflated until there is no air leak around the tube).~During emergence, when the expired fraction of desflurane reaches 0.2 MAC, the patient will be asked to open his eyes every 30 seconds. Any coughing effort before 0.2 MAC will be considered as a treatment failure and the patient will be treated according to the attending anaesthesiologist."
88928792|NCT01715688|Placebo Comparator|Saline|"The endotracheal tube cuff will be pre-filled at least 90 minutes before intubation with saline. Endotracheal tube cuff will be emptied before intubation and then re-filled with the same mixture following intubation to secure the position of the endotracheal tube. (cuff will be inflated until there is no air leak around the tube).~During emergence, when the expired fraction of desflurane reaches 0.2 MAC, the patient will be asked to open his eyes every 30 seconds. Any coughing effort before 0.2 MAC will be considered as a treatment failure and the patient will be treated according to the attending anaesthesiologist."
88928793|NCT01715701|Experimental|Paravertebral nerve blockade|A multilevel thoracic paravertebral nerve block will be performed by the anaesthesiologist prior to the induction of general anesthesia. Prior to the block, the anaesthesiologist will locate and mark each level and then, infiltrate the skin with lidocaine 2% (0.5-1 mL). Subsequently, using a Tuohy needle 22G, 5 mL of ropivacaine 0.5% will be injected at each level between T4 and T8. At the end of surgery, before skin closure, a multilevel intercostal nerve block will be performed by the surgeon using 5 mL of saline at each level between T4-T8. A PCA device will be installed upon arrival in the recovery room.
88928794|NCT01715701|Active Comparator|Intercostal nerve blockade|Prior to the induction of general anaesthesia, a paravertebral block will be simulated by measuring, marking the patient's skin and applying mild pressure at each level (T4-T8). To preserve the blind, the anaesthesiologist will also infiltrate the skin with lidocaine 2% (0.5-1 mL). A multilevel intercostal nerve block will be performed by the surgeon at the end of surgery before skin closure. Five mL of ropivacaine 0.5% will be injected at each level between T4 and T8. A PCA device will be installed upon arrival in the recovery room.
88928795|NCT01715701|Active Comparator|Patient Controlled Analgesia (PCA)|Prior to the induction of general anaesthesia, a paravertebral block will be simulated by measuring, marking the patient's skin and applying mild pressure at each level (T4-T8). To preserve the blind, the anaesthesiologist will infiltrate the skin with lidocaine 2% (0.5-1 mL). At the end of surgery, before skin closure, a multilevel intercostal nerve block will be performed by the surgeon using 5 mL of saline at each level between T4-T8. A PCA device will be installed upon arrival in the recovery room.
89013580|NCT06299774|Active Comparator|Usual care|Emergency care in a brick-and-mortar emergency department.
89013581|NCT06299774|Experimental|Emergency care at home|Emergency care in the patient's home.
89444434|NCT06032260|Experimental|Enriched panettone|100 grams of panettone enriched with fiber. The added fiber is JAX Plus® (Heallo srl, Milano, Italy), a soluble fiber with Arabinoxylans from wheat and barley
89444435|NCT06032260|Active Comparator|Panettone standard|100 grams of panettone without fiber enrichment
89444436|NCT06032221|Other|device feasibility|All participants issued with Thermidas device
89444437|NCT06031779||gastric cancer|
89444438|NCT06031779||non-gastric cancer|
89444439|NCT06030713|Active Comparator|Cord clamped after antibiotic prophylaxis|Umbilical cord clamped after 1g of cephazolin
89444440|NCT06030713|Experimental|Cord clamped before antibiotic prophylaxis|Umbilical cord clamped before 1g of cephazolin
89444441|NCT06027632|Other|Remotely-supervised online cognitive stimulation intervention|
89444442|NCT06027632|Other|Open access to online home-based cognitive exercises without supervision|
89444443|NCT06023108|Experimental|Orthokeratology group|Participants in OK lenses group will wear OK lenses at least 8 hours per day for 12 months.
89444444|NCT06023108|Active Comparator|Spectacles group|Participants in spectacles group will wear per day for 12 months.
89444445|NCT06022393|Experimental|Cognitive Reappraisal|The intervention group completes CBT-training to improve their cognitive reappraisal and emotion-regulation-skills.
89444446|NCT06022393|Sham Comparator|Reflection|The control group completes tasks based on reflection about their daily lifes, which should have no impact on their emotion-regulation-skills or functional motor disorder.
89444447|NCT06021418|Experimental|DKB-119|Injecting to one side crow's feet
89444448|NCT06021418|Active Comparator|Control|Injecting to one side crow's feet
89444449|NCT06021379||AryoGen Pharmed Trastuzumab|AryoTrust is given at dosing of 6 mg/m2 after adjuvant chemotherapy completion every 3 weeks for 9 cycles.
89444450|NCT06020404|Experimental|Controls|Eligible patients will undergo the experimental protocol.
89013582|NCT06299761|Experimental|Single Agent Dose Escalation|Single agent BBI-825, administered orally, twice daily, in 28-day cycles
89444451|NCT06020404|Experimental|Patients|Eligible patients will undergo the experimental protocol.
88928796|NCT01715727||Parkinson's Disease for follow-up|"Patients should fulfill the National Institute of Neurological Disorders and Stroke in USA ( NINDS ) Diagnostic Criteria for Parkinson Disease(37) for probable PD, except for the age of onset.~Able to tolerate the disability during the drug-off state, at least for 12 hours.~Able to understand and provide signed informed consent.~Early to moderate stage defined as Hohen and Yahr stage 1-3,"
88928797|NCT01715727||"Parkinsonss Disease with severity match"|"Parkinsonss Disease with severity match: 30 subjects~Patients should fulfill the National Institute of Neurological Disorders and Stroke in USA ( NINDS ) Diagnostic Criteria for Parkinson Disease(37) for probable PD, except for the age of onset.~Able to tolerate the disability during the drug-off state, at least for 12 hours.~Able to understand and provide signed informed consent.~Severity matched with PSP (subjects = 15)/MSA (subjects= 15), the severity was judged by Hohen and Yahr stage"
89444452|NCT06019871||Decided for conservative kidney management|Patient with advanced kidney disease and decided for conservative kidney management
89444453|NCT06019871||Decided for dialysis|Patient with advanced kidney disease and decided for dialysis
89444454|NCT06008834|Experimental|Interventional group|Patients who undergo a minimal invasive colorectal surgery and are included in the first-day discharge protocol with domiciliary follow-up
89444455|NCT06007404||Normal weight|BMI ≥ 5th percentile & < 85th percentile
89444456|NCT06007404||Obese weight|BMI ≥ 95th percentile
89444457|NCT06007404||PreDiabetes|HbA1c > 5.7%
89444458|NCT06007014|Experimental|Intervention group|Metformin and insulin glargine combined with sitaglitat sodium tablets 48mg/ day group;
89444459|NCT06007014|Placebo Comparator|Placebo group|Metformin and insulin glargine combined with placebo group
89444460|NCT06003933|No Intervention|Control group|patients received general anesthesia only.
89444461|NCT06003933|Experimental|ISP group|patients received bilateral ultrasound guided inter-semispinal plane (ISP) block at the level of C5 using 10 ml of 0.25% bupivacaine and 10ml xylocaine on each side to reduce the toxicity
89444462|NCT06002256|Active Comparator|Group 1 : Mostafa Maged maneuver|The first step in the Mostafa Maged maneuveur step is placing the right hand to the posterior fornix of vaginal canal trying to put pressure on the cervix and the lower part of uterus compressing the anterior and posterior walls of the lower uterine segment. The second point is placing the left hand over the fundus of the uterus and the posterior wall of the uterus from the abdominal part of the pregnant mother (the side of the abdominal skin). The third step is trying to grasp the whole uterus by the two hands abdominally and vaginally against the symphysis pubis as if the uterus is containing or surrounding the symphysis pubis bone, and in this way, getting the anterior and posterior walls of the uterus against each other (compression achieved)
89444463|NCT06002256|Other|Group 2 : bimanual uterine compression|"Both maneuver s are performed immediately after the delivery of the placenta and foetus, with no uterotonics administered at the onset of these maneuver s. In the event of atony after hand release due to fatigue, 5 IU of oxytocin is administered intravenously as uterotonics.~the clinician places one hand on the abdomen and the other hand inside the vagina then compresses the uterus between the two hands."
89444464|NCT05999513|Experimental|AB521 - Sequence ABC|Participants will sequentially receive AB521 capsules fasted (Treatment A), followed by AB521 tablets fasted (Treatment B), followed by AB521 tablets fed (Treatment C)
89444465|NCT05999513|Experimental|AB521 - Sequence BCA|Participants will sequentially receive Treatment B, followed by Treatment C, then Treatment A
89444466|NCT05999513|Experimental|AB521 - Sequence CAB|Participants will sequentially receive Treatment C, followed by Treatment A, then Treatment B
88928798|NCT01715727||Healthy age matched controls|"Healthy age matched controls: subjects = 112~Healthy subjects without a clinically significant abnormal laboratory values, and/or clinically significant or unstable medical or psychiatric illness.~Able to understand and provide signed informed consent.~Age range and gender matched with Parkinsonss Disease for follow up."
88928799|NCT01715727||Parkinson Plus Syndrome Group M|"MSA Patients should fulfill the NINDS Consensus statement for the clinical diagnosis of probable MSA~Able to tolerate the disability during the drug-off state, at least for 12 hours.~Able to understand and provide signed informed consent"
88928800|NCT01715727||Parkinson Plus Syndrome Group P|"PSP Patients should fulfill the NINDS-SPSP and Litvan criteria(4) for probable PSP~Able to tolerate the disability during the drug-off state, at least for 12 hours.~Able to understand and provide signed informed consent."
88928801|NCT01715740|Experimental|Chinese herbal medicine (CHM)|Subject in CHM group will receive CHM capsules, 8 capsules (4 gm) four times a day, total 16 gm a day, combined with levocetiricine 1PC once a day for 1 month.
88928802|NCT01715740|Placebo Comparator|Control|Subjects in control group will receive the placebo capsules, which has the similar look, smell and taste. The dosage, frequency and duration are the same as CHM group, in which 8 placebo capsule (4gm) 4 times a day, total 16 gm a day, combined with levocetiricine 1PC once a day, for 1 month.
88928803|NCT01715753|Active Comparator|Weight Loss Control|Diet counseling and group education lessons. Subjects follow a calorie-reduction diet for a weight loss of ≥10%.
88928804|NCT01715753|Experimental|Weight Loss-High Protein|Protein supplementation. Subjects follow a calorie-reduction diet for a weight loss of ≥10%, with a high proportion of protein, including substantial amounts of supplemental protein provided as lean beef. Intakes of > 30g of high quality protein will be achieved three times a day by subjects in this group, with all or predominantly all from animal source and 60-70% of animal protein from beef.
88928805|NCT01715779||Patients who experienced a thromboembolic event|Patients who experienced a thromboembolic event during participation in the ENABLE clinical trials.
88928806|NCT01715792||Group 1|Subject defined as acceptable in the CPRD GOLD with at least one solid organ transplant rejection reported during the overall study period (01 September to 31 October 2010).
88928807|NCT01715818|Experimental|Aleglitazar|
88928808|NCT01715818|Placebo Comparator|Placebo|
88928809|NCT01715844|Active Comparator|L-citrulline|3-gr/day of L-citrulline effervescent powder mix
88928810|NCT01715844|Placebo Comparator|Placebo|3 gr of Placebo/day matching L-citrulline effervescent powder
88928811|NCT01715870||"Population of the Epidemiological study on AMD."|
88928812|NCT01715909|Experimental|Oseltamivir: Standard dose|Participants will receive standard dose of oseltamivir capsules or suspension orally for 5 to maximum of 20 days depending on weight. Infants <1 year of age will receive oseltamivir at a dose of 3 milligrams per kilogram (mg/kg).
88928813|NCT01715909|Experimental|Oseltamivir: Triple dose|Participants will receive three times the standard dose of oseltamivir capsules or suspension orally for 5 to maximum of 20 days depending on weight and age. Infants <1 year will receive standard dose at 3 mg/kg.
88928814|NCT01715922|Other|oral treatment|"Drug: Fluconazole and flucytosine~Induction treatment for 2 weeks:~Fluconazole (1600mg/j) + flucytosine (100 mg/kg/j) lumbar punctures to control intracranial pressure Consolidation treatment for 8 weeks: fluconazole (800 mg/j)"
88928815|NCT01715935|Experimental|everolimus|everolimus, 10 mg PO daily. Before nephrectomy: 6 continuous weeks of treatment and one week of rest After nephrectomy: 4 weeks courses (for metastatic patients only)
88928816|NCT01715961|Other|anthropometric measurement|"The muscle area assessed by CT scan imaging at a lumbar vertebral landmark (L3) at the time of diagnosis, at the end of treatment, at 12 and 18 months~anthropometric measures (weight, height, BMI, brachial and calf circumference) and MNA (mini nutritional assessment)~albuminemia, transthyretin, orosomucoid, CRP~functional test to attest the muscular strength: hand grip test, unipodal test, up and go test~hematological and non-hematological chemotherapy toxicities of cycle 1 and cycle 2~OS and PFS at 18 and 24 months~GCB and ABC phenotypes determined by immunohistochemistry and transcriptome analysis"
88928817|NCT01715987||Tenofovir Disoproxil Fumarate|Patients who are taking Tenofovir Disoproxil Fumarate.
88928818|NCT01715987||Entecavir|Patients who are taking Entecavir.
88928819|NCT01716000|Experimental|2 mL vaginal gel|2 mL gel inserted vaginally for completion of vaginal gel imaging and computer aided self interview.
88928820|NCT01716000|Experimental|4 mL vaginal gel|4 mL gel inserted vaginally for completion of vaginal gel imaging and computer aided self interview.
88928821|NCT01716091||saline irrigation|irrigation group:saline irrigation after uterine wall closed control group:no irrigation after uterine wall closed
88928822|NCT01716130||IM vaccine in the past 3 years|Those subjects that received the Fluzone ID influenza vaccine, and reported having received the IM influenza vaccine in the past three years.
88928823|NCT01716130||no IM vaccine in the past 3 years|Patients that received the Fluzone ID vaccine and reported not receiving the IM influenza vaccine in the past 3 years.
88928824|NCT01716130||vaccine administrators|Those experienced vaccine administrators that administered the Fluzone ID vaccine, and were then surveyed concerning safety and overall satisfaction with the ID vaccine in comparison to the IM vaccine.
88928825|NCT01716143|Other|catheter ablation|
88928826|NCT01716182||transacral lumbar interbody fusion procedure|
88928827|NCT01716182||transforaminal lumbar interbody fusion procedure (TLIF)|
89013583|NCT06299748||Retrospective Pregnancy|woman is no longer pregnant at time of study enrollment but was exposed to efgartigimod any time within 25 days prior to conception or any time during pregnancy
89537093|NCT03300323|Active Comparator|IV Fluid challenge administration 20|4ml/kg intravenous fluid challenge administered over 20 minutes
88928828|NCT01716247|Experimental|pts at risk for breast cancer|Women at increased risk for breast cancer who are being referred for screening MRI will be offered and consented for CESM at the same time. The 2 examinations will be performed on the same day when at all possible and if not we will make every attempt to perform CESM before MRI. Patients with outside MRI performed within 30 days and of adequate quality will also be eligible for CESM.
89444467|NCT05994807|Experimental|Cohort 1|Participants in Cohort 1 will receive DC-806 single dose on Day 1, and the second dose of DC-806 along with itraconazole after the wash-out period.
89444468|NCT05994807|Experimental|Cohort 2|Participants in Cohort 2 will receive DC-806 single dose on Day 1, and the second dose of DC-806 along with carbamazepine after the wash-out period.
88928829|NCT01716273|Experimental|Chronic & Acute infected wounds|Wound will be cleaned with normal saline or tap water and Granulated sugar will be applied directly to the wound and covered with an absorbent pad and held in place with a bandage and tape.
88928830|NCT01716273|Active Comparator|Chronic and Acute infected wounds|Wound will be cleaned with normal saline or tap water and an appropriate debridement dressing (Aquacel or Sorbsan) is applied to the wound and secured with a bandage and surgical tape.
88928831|NCT01716286|Experimental|yoghurt type|low fat yoghurt vs. essence yoghurt
88928832|NCT01716338|Active Comparator|Glyburide|1.5 mg (lowest dose) by mouth every day with breakfast for 7 days
88928833|NCT01716338|Placebo Comparator|Sugar Pill (Capsule)|Matching placebo capsule by mouth every day with breakfast for 7 days
88928834|NCT01716351|Experimental|Adapted Yoga Intervention Group|Patients received the Adapted Yoga Intervention for Implantable Cardioverter Defibrillator (ICD) Recipients and a call from a cardiac research nurse once monthly for five months.
88928835|NCT01716351|No Intervention|Control|Patients received usual care and a call from a cardiac research nurse once monthly for five months to control for attention.
88928836|NCT01716364|Experimental|Anti-LeY- scFv-CD28-ζ vector.|Anti-LeY- scFv-CD28-ζ vector, a non-pathogenic, replication-incompetent retroviral vector specifically designed for this study and produced by EUFETS under GMP-conditions.
88928837|NCT01716377|Placebo Comparator|Placebo|37.5mg QD 1 week 75mg QD 1 week 150mg QD 8 weeks 75mg QD 1 week 37.5mg QD 1 week
88928838|NCT01716377|Active Comparator|Venlafaxine|37.5mg QD 1 week 75mg QD 1 week 150mg QD 8 weeks 75mg QD 1 week 37.5mg QD 1 week
88928839|NCT01716390|Active Comparator|Drink that contains plant stanols|Dietary supplement: Plant stanol
88928840|NCT01716390|Placebo Comparator|Placebo drink|Dietary supplement: Placebo
88928841|NCT01716403||HCV tritherapy and anemia|HCV-genotype 1 infected patients
88928842|NCT01715155||Female patients diagnosed with metastatic breast cancer|Patients newly diagnosed with metastatic breast cancer, either De Novo or having progressed from a non-metastatic stage.
88928843|NCT01716416|Experimental|Dose Level 1|"Pazopanib 200 mg PO QD~Cetuximab 400 mg/m^2 (cycle 1 week 1 only) followed by weekly maintenance doses of 250 mg/m^2"
88928844|NCT01716416|Experimental|Dose Level 2|"Pazopanib 400 mg PO QD~Cetuximab 400 mg/m^2 (cycle 1 week 1 only) followed by weekly maintenance doses of 250 mg/m^2"
88928845|NCT01716416|Experimental|Dose Level 3|"Pazopanib 600 mg PO QD~Cetuximab 400 mg/m^2 (cycle 1 week 1 only) followed by weekly maintenance doses of 250 mg/m^2"
88928846|NCT01716416|Experimental|Dose Level 4|"Pazopanib 800 mg PO QD~Cetuximab 400 mg/m^2 (cycle 1 week 1 only) followed by weekly maintenance doses of 250 mg/m^2"
88928847|NCT01716416|Experimental|Part 2 Dose|"Pazopanib (dose to be determined in Part 1 of study) mg PO QD~Cetuximab 400 mg/m^2 (cycle 1 week 1 only) followed by weekly maintenance doses of 250 mg/m^2"
88928848|NCT01716429|Active Comparator|Low Calorie|Participants in this arm will be instructed on how to reduce their caloric intake and follow a low calorie diet
88928849|NCT01716429|Experimental|Vegan diet|Participants in this arm will follow a very low fat diet (~10% kcals from fat) and also a diet that has a low glycemic index and is free of animal products (vegan)
88928850|NCT01716442|Active Comparator|steroid-resistant|Steroid-resistant group: n=27 , enroll all for treatment
88928851|NCT01716442|Active Comparator|steroid-dependent-rituximab|steroid-responsive group: n=38
88928852|NCT01716442|Placebo Comparator|steroid-dependent-placebo|steroid-responsive group: n=23
89013584|NCT06299748||Prospective Pregnancy|woman is pregnant or breastfeeding at time of study enrollment.
89444469|NCT05993117|Experimental|G114R VNS system|
89444470|NCT05983913|Experimental|cognitive-motor training group|Participants will receive 50 minutes of cognitive-motor training twice per week for 6 weeks. The cognitive-motor training program uses a wearable sensor-based interactive system to perform cognitive tasks in a large space without the constraints of physical movement. Participants wear a wearable sensor-based device on their dominant arm or leg and use an interactive system to perform cognitive-motor tasks.
88928853|NCT01716481|Experimental|Mesenchymal stem cell treatment|
88928854|NCT01716481|No Intervention|Standard treatment|
88928855|NCT01716494||Severe Asthma|Subjects with severe asthma (SARP protocol definition)
88928856|NCT01716494||Well controlled asthma|Subjects with well controlled asthma
88928857|NCT01716494||Normal control|Subjects that are healthy normals
88928858|NCT01716507|Other|20 gauge pars plana vitrectomy|20 gauge pars plana vitrectomy for retinal detachment repair
88928859|NCT01716507|Other|23 gauge pars plana vitrectomy|23 gauge pars plana vitrectomy for retinal detachment repair
88928860|NCT01716546|Experimental|1|Panitumumab plus DCF
88928861|NCT01716572|Active Comparator|gastric lavage|gastric lavage by nasogastric tube with 1 liter saline before the endoscopy
88928862|NCT01716572|Active Comparator|erythromycin|administration of 250mgr of erythromycin before the endoscopy
88928863|NCT01716598|Experimental|Treatment|Targeted Lung Denervation Therapy (TLD Therapy)
88928864|NCT01716611|Active Comparator|Tolvaptan group|Form : Tablet, Dosage: 15 mg, 30 mg or 60 mg, Frequency: once a day. Duration: 28days
89444471|NCT05983913|Experimental|cognition training group|Participants will receive 50 minutes of cognitive training twice a week for 6 weeks. The cognitive training program will be delivered in booklet form, and participants will perform the cognitive tasks of the cognitive-motor training in a seated position with no physical movement.
89444472|NCT05976139|Experimental|inherited retinal dystrophies with macular oedema|"Laser treatment will be performed in patients with macular edema in IRD (experimental arm) who:~underwent treatment with diuretics or nutritional drainage products for 3 months and subsequent 'wash-out' of one month 17,18 and had no reduction in macular oedema, in terms of central retinal thickness, of at least 20% compared with the initial assessment~they have had an intravitreal injection of anti-VEGF or steroids, and after 3 months there is no reduction in central retinal thickness (CRT) of at least 20% compared to the initial assessment~have after 3 months a thickness reduction <10% compared to baseline assessment, following initial treatment with micropulsed laser, and may be candidates for repeating treatment;~are not eligible for diuretic therapy due to the presence of comorbidities."
89444473|NCT05975216||Diagnosed-but-untreated|Diagnosed but untreated (DBU) HCV patients through positive serology with positive or unknown HCV RNA in UZ Brussel between 2012 - 2022.
89444474|NCT05964296|Experimental|Application group|Patients randomized to the digital application arm will benefit from treatment as usual and will have access to the MAURISSE application, allowing them to communicate with the healthcare team using a messaging system, to report and follow substance use, to access a To-do list, to access personal multimedia contents helping with the treatment, to report a feeling of boredom (these moments presenting a risk of relapse) and finally to access a list of propositions in order to fight this feeling
89444475|NCT05964296|Active Comparator|Standard-of-care group|These patients will benefit from the usual care within the center (appointments with doctors; regular follow-up meetings with nurses, psychologists, social workers, therapeutic groups depending on the evaluation).
88928865|NCT01716611|Placebo Comparator|Placebo group|Form : Tablet, Dosage: 15 mg, 30 mg or 60 mg, Frequency: once a day. Duration: 28days
88928866|NCT01716624|Active Comparator|Oxybutynin|
88928867|NCT01716624|Experimental|Botulinum Toxin A injection|
88928868|NCT01716637|Active Comparator|Etanercept|25 mg administered weekly for 6 weeks
88928869|NCT01716637|Active Comparator|Nutritional Supplements|Nutritional supplements administered daily for 6 weeks in each period as well as an additional 12 weeks following visit 15.
88928870|NCT01716650||Saphenous nerve block|Data collection after saphenous nerve block placement
88928871|NCT01716676|Active Comparator|Standard CPAP follow-up|
88928872|NCT01716676|Experimental|Telemedicine CPAP follow-up|
88928873|NCT01716689|Experimental|Patients with advanced sarcoma|
88928874|NCT01716702|Experimental|Couples Prostate Cancer Support Group|"The participants in the support group will receive 6 weekly online intervention sessions with a professional facilitator. In addition participants will be asked to complete relationship-enhancement exercises and readings in between sessions.~Participants will be asked to complete questionnaires at three time points: 1)pre-intervention (baseline) 2) post-intervention (7 weeks), and 3) post intervention (13 weeks)."
88928875|NCT01716702|No Intervention|Wait-List Control|Participants will be asked to complete questionnaires at three time points: 1)week 1 2) week 7, and 3) week 13.
88928876|NCT01716728|No Intervention|Enzyme analysis|Patients invited for evaluation will undergo lysosomal acid lipase enzyme analysis
88928877|NCT01716741|Other|Enzyme analysis|Patients invited for evaluation will undergo glucocerebrosidase enzyme analysis
88928878|NCT01716767|Experimental|Menthol|Biofreeze topical gel containing 3.5% menthol
88928879|NCT01716767|Placebo Comparator|Placebo|Topical gel containing a menthol scent, but no active menthol
88928880|NCT01716780|No Intervention|Routine care|"Patients allocated to the control group will undergo their 'usual care'; they will be given pain medication when they specifically request it or when their oncology doctor/ nurse or GP considers it appropriate to prescribe it, either at the oncology clinic visit or at any time during the course of the study."
88928881|NCT01716780|Experimental|Intervention|"Patients allocated to the intervention group will be reviewed by the pain/palliative care team and will undergo prospective, proactive, integrated, structured pain treatment according to recent guidelines on cancer pain care."
88928882|NCT01716793|Other|Risk-adapted postremission treatment|Ara-C, autologous transplantation, Allogeneic HLA-identical sibling transplantation depending on risk factors (cytogenetics, courses to CR)and availability of an HLA-identical sibling, CD34+ selection.
88928883|NCT01716819|Other|Abdominal obesity|"Single arm, follow up cohort in patient with abdominal obesity. No comparator: description of interventions :~Composition of body mass by Dual x-ray absorptiometry Pulse wave velocity Electrocardiogram Urine sample Blood sample (and biological collection) Assessment of sleep apnea syndrome Glucose tolerance test Echocardiography Echotracking cardiac and abdominal magnetic resonance imaging Ambulatory blood pressure monitoring"
88928884|NCT01716832|Experimental|Mindfulness walking|
88928885|NCT01716832|No Intervention|No intervention (waiting list)|
88928886|NCT01716845||Development group 1|
88928887|NCT01716845||Development group 2|
88928888|NCT01716845||Development group 3|
88928889|NCT01716845||Validation group|
88928890|NCT01716858|Experimental|A single-arm study|
88928891|NCT01716871|Active Comparator|cryotherapy using Cold pack®|"patients with lateral ankle sprain who have been randomized in the cold packs® group.~Application of cryotherapy with Cold pack® or ice-cubes pack in the sprained ankle during 20 minutes 4 times a day, 3 days long."
88928892|NCT01716871|Active Comparator|cryotherapy using Neurocryostimulation|"Patient with lateral ankle sprain randomized in the neurocryostimulation group.~Application of neurocryostimulation with Duo-cryo® device during 1 minute on the sprained ankle, 2 times a day, 3 days long"
88928893|NCT01716897|Other|50 mg E2609 capsule formulation in fasted state|50 mg E2609 capsule formulation
88928894|NCT01716897|Other|50 mg E2609 tablet formulation in fasted state|50 mg E2609 tablet formulation in fasted state
88928895|NCT01716897|Other|50 mg tablet formulation in fed state|50 mg E2609 tablet formulation in fed state
88928896|NCT01716910|Placebo Comparator|Maltodextrin|'Combination of Lactobacillus acidophilus NCFM and cellobiose', Sachet, 5 g/day
88928897|NCT01716910|Active Comparator|Synbiotic|'Combination of Lactobacillus acidophilus NCFM and cellobiose', Sachet, 5 g/day + 10e9 CFU
88928898|NCT01716923|Experimental|S-303 Treated Red Blood Cells|Patients receive S-303 treated red blood cells (RBCs).
88928899|NCT01716923|Active Comparator|Conventional, untreated Red Blood Cells|Patients receive conventional, untreated red blood cells (RBCs).
88928900|NCT01716936||MAGEC Implant|All patients implanted with the MAGEC System will be reviewed for inclusion into this retrospective study.
88928901|NCT01716949|Experimental|HyRec|Radiotherapy, Hyperthermia, 5-Fluorouracil (may be replaced by Capecitabine), Capecitabine (may be replaced by 5-Fluorouracil), Oxaliplatin
88928902|NCT01716962||ARDS with acute circulatory failure|acute respiratory distress syndrome with acute circulatory failure with infusion of 6% tetrastarch for a total of 500ml
88928903|NCT01716975|Placebo Comparator|EVP-6124, Placebo|Placebo, Tablet, Once Daily, Day -14 through Day 182
88928904|NCT01716975|Experimental|EVP-6124, low dose|low dose, Tablet, Once Daily, Day 1 through Day 182
88928905|NCT01716975|Experimental|EVP-6124, high dose|high dose, Tablet, Once Daily, Day 1 through Day 182
88928906|NCT01716988||Micafungin|
88928907|NCT01717027|Experimental|Treatment A|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
88928908|NCT01717027|Experimental|Treatment B|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
88928909|NCT01717027|Experimental|Treatment C|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
88928910|NCT01717027|Experimental|Treatment D|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
88928911|NCT01717066|Experimental|the ginsenoside Rg3|320 HCCs,the ginsenoside Rg3 capsule,4-8 weeks after surgery, will be taken, 2 capsules, BID, 8 weeks as one cycle, continue taking it until the tumor recurs or until the end date of the study for patients without recurrence
88928912|NCT01717066|Placebo Comparator|the placebo|160 HCCs as control group with patients who don't receive any adjuvant therapy after liver resection, to compare with the treatment group
88928913|NCT01717079|Active Comparator|Effective arm|Effective coil
88928914|NCT01717079|Placebo Comparator|Placebo arm|Placebo coil
88928915|NCT01717092||Consecutive patients with acute PE|
88928916|NCT01717105||metastatic non-small cell lung cancer|Only epidermal growth factor receptor (EGFR) M+ patients will be eligible for the study assessments
88928917|NCT01717118|Active Comparator|Tetravalent Vaccine|"Month 2 visit: May be scheduled on the appropriate month +/- 3 weeks.~Month 6, 21, 60 and 61 visit (vaccination scheme 0, 2, 6): May be programmed on the appropriate month +/- 4 weeks.~Month 7 and 61 visit (vaccination scheme 0, 6, 60): The time interval between the month 6/60 visit and the month 7/61 visit must be at least 3 weeks and maximum 7 weeks from the previous vaccination"
88928918|NCT01717118|Active Comparator|Bivalent Vaccine|"Month 1 visit: May be scheduled 21 to 62 days after the Day 0 visit.~Month 6 visit: May be scheduled 161 to 216 days after the Day 0 visit.~Month 6 visit: The time interval between the month 6 visit and the month 7 visit must be at least 3 weeks and maximum 7 weeks from the previous vaccination.~Month 21, 60 and 61 visit (vaccination scheme 0, 1, 6): May be scheduled on the appropriate month +/- 4 weeks.~Month 61 (vaccination scheme 0, 6, 60) The time interval between the month 60 visit and the month 61 visit must be at least 3 weeks and maximum 7 weeks from the previous vaccination"
88928919|NCT01717144|No Intervention|traditional medical care|patients benefiting of a traditional medical care
88928920|NCT01717144|Experimental|therapeutic education program|The educational program consisted of both individual and collective educational consultations with a therapeutic education nurse
88928921|NCT01717157|Experimental|Treatment sequence 1 (AEBD)|
88928922|NCT01717157|Experimental|Treatment sequence 2 (BACE)|
88928923|NCT01717157|Experimental|Treatment sequence 3 (CBDA)|
88928924|NCT01717157|Experimental|Treatment sequence 4 (EDAC)|
88928925|NCT01717157|Experimental|Treatment sequence 5 (DECA)|
88928926|NCT01717157|Experimental|Treatment sequence 6 (EADB)|
88928927|NCT01717157|Experimental|Treatment sequence 7 (ABEC)|
88928928|NCT01717157|Experimental|Treatment sequence 8 (BCAD)|
88928929|NCT01717170|Experimental|Tocilizumab (4 mg/kg)|Tocilizumab (4 mg/kg) as an intravenous infusion over 1 hour at day 0, 30, 60, 90, 120, and 150.
88928930|NCT01717170|Experimental|Tocilizumab (8 mg/kg)|Tocilizumab (8 mg/kg) as an intravenous infusion over 1 hour at day 0, 30, 60, 90, 120, and 150.
88928931|NCT01717183|Experimental|URGO 310 3113 dressing - new|flexible, conformable, non-adhesive and non-occlusive lipido-colloid matrix that does not adhere to the wound.
88928932|NCT01717183|Placebo Comparator|URGO 310 3113 dressing|flexible, conformable, non-adhesive and non-occlusive lipido-colloid matrix that does not adhere to the wound.
88928933|NCT01717196|Experimental|DIFFERENT VOLUME ASPIRATION BIOPSY|The needle system was in all cases the 22 gauge EUS-FNA (Expect needle). After the puncture the stylet was removed, and we performed three punctures with a 22 G needle with both volume aspiration 10 and 20 cc and without syringe for each lesion. The sequence of different volume aspiration Biopsy/ FNA (10cc, 20cc, no aspiration) was randomly assigned by sealed envelope system.
88928934|NCT01717222|Active Comparator|Intraperitoneal (IP) group|Patients will receive 100 ml of 0.2% Lignocaine as intraperitoneal lignocaine irrigation in the gall bladder fossa along with a placebo of normal saline of volume equivalent to 1.5 mg/kg of intravenous lignocaine at induction and normal saline of volume equivalent to 2 mg/kg/hour of intravenous lignocaine as continuous infusion until one hour postoperatively to ensure blinding
89444476|NCT05957926|Experimental|Hyaluronic acid + Hydroxyapatite|hyaluronic acid is used for bone regeneration and it has a good potential for osteogenesis and mineralization so it can have synergistic effect when used with hydroxyapatite for bone regeneration after cyst enucleation
89444477|NCT05957926|Active Comparator|Hydroxyapatite alone|Hydroxyapatite is inorganic component of bone tissue used as bone graft, scaffolds, filler and cement for repair and regeneration of bone defect , and it stimulates bone remodeling by generating surface active moieties or cell signaling process
89444478|NCT05955872|Experimental|Sequence A: VX-147|Participants will receive VX-147 reference tablet under fasted condition in Treatment Period 1, then VX-147 test tablet under fed condition in Treatment Period 2, and VX-147 test tablet under fasted condition in Treatment Period 3. A washout period of 5 days will be maintained between 3 treatment periods.
89444479|NCT05955872|Experimental|Sequence B: VX-147|Participants will receive VX-147 test tablet under fed condition in Treatment Period 1, then VX-147 test tablet under fasted condition in Treatment Period 2, and VX-147 reference tablet under fasted condition in Treatment Period 3. A washout period of 5 days will be maintained between 3 treatment periods.
89444480|NCT05955872|Experimental|Sequence C: VX-147|Participants will receive VX-147 test tablet under fasted condition in Treatment Period 1, then VX-147 reference tablet under fasted condition in Treatment Period 2, and VX-147 test tablet under fed condition in Treatment Period 3. A washout period of 5 days will be maintained between 3 treatment periods.
89444481|NCT05954676|Experimental|CareOrbit - Patients|"Patients will be assigned a username and password to access their CareOrbit account via the internet (caregivers will use the same account information). These patients may designate up to 3 additional individuals who will be participating in the patient's postoperative care to receive the link along with a unique username and password via email. All patients will additionally receive standard pre- and post-operative instructions and care. This will include verbal education by the surgeons at their pre-operative visits.~Patient questionnaires will be distributed at the first and second post-operative visits (typically 1-2 weeks after discharge and 3 months after post-operative clinic visit). At 30 days following discharge, the patients' medical records will be reviewed by the study team to assess for the primary or secondary outcomes. Patients will be contacted by telephone to inquire about ED/UC visits outside of the BJC system."
89444482|NCT05954676|Experimental|CareOrbit - Caregivers|"Patients will be assigned a username and password to access their CareOrbit account via the internet (caregivers will use the same account information). These patients may designate up to 3 additional individuals who will be participating in the patient's postoperative care to receive the link along with a unique username and password via email. All patients will additionally receive standard pre- and post-operative instructions and care. This will include verbal education by the surgeons at their pre-operative visits.~Patient questionnaires will be distributed at the first and second post-operative visits (typically 1-2 weeks after discharge and 3 months after post-operative clinic visit). At 30 days following discharge, the patients' medical records will be reviewed by the study team to assess for the primary or secondary outcomes. Patients will be contacted by telephone to inquire about ED/UC visits outside of the BJC system."
88928935|NCT01717222|Active Comparator|Intravenous (IV) group|Patients will receive 1.5mg/kg of intravenous lignocaine as bolus dose at induction and 2mg/kg/hour as continuous infusion of intravenous lignocaine until one hour after surgery and 100 ml of saline intraperitoneally as placebo to ensure blinding.
88928936|NCT01717235|Experimental|Test Product|Drug: Ropinirole Single oral dose of Ropinirole hydrochloride CR 2mg Tablets under fasting conditions
88928937|NCT01717235|Experimental|Reference Product|REQUIP XL Tablets (containing Ropinirole hydrochloride CR 2mg Tablets)under fasting conditions
88928938|NCT01717248|Experimental|GCS-100|GCS-100 will be administered once weekly by a ten minutes injection.
88928939|NCT01717274|Experimental|Hot saline irrigation|Hot saline is prepared by first placing 2 litres of sterile normal saline (0.9%) into a basin (IntraTemp Therma BasinTM) that is wrapped in a sterile disposable drape (IntraTemp Therma Basin DrapeTM). The basin is then placed in a medical grade warmer (IntraTemp Fluid Warming SystemTM). The warmer is set to heat the saline up to a temperature of 50 degrees Celsius. An external digital thermometer is placed in the saline at all times to ensure that the temperature is between 45-50 degrees.
88928940|NCT01717274|No Intervention|Room temperature saline irrigation|Room temperature saline is prepared in the same manner as the experimental arm except that the warmer is switched off and the temperature of the saline in the basin is left to equilibrate to the temperature of the operating room.
88928941|NCT01717300|Experimental|Anacetrapib 100 mg|
88928942|NCT01717300|Experimental|Anacetrapib 25 mg|
88928943|NCT01717300|Placebo Comparator|Placebo|
88928944|NCT01717339|Other|Normal Subjects|Non-OSA (Obstructive sleep apnea) patients
88928945|NCT01717339|Other|OSA subjects|(Obstructive sleep apnea) OSA subjects
88928946|NCT01717352|Active Comparator|Weight Loss Education|Provides participants with important information about weight control and healthy eating prior to treatment to prepare participants for participation in a weight loss program and enhance outcomes.
88928947|NCT01717352|Active Comparator|Sleep and Eating Routine|Establish a consistent sleep and eating routine prior to treatment to prepare participants for participation in a weight loss program and enhance outcomes.
88928948|NCT01717365||OTs|Occupational therapists
88928949|NCT01717378||Potential research participants|UCSF Registry represents a single recruitment pool of individuals who have consented to be contacted about future studies for which they may be eligible based on self-reported health information.
88928950|NCT01717404|Experimental|Mexiletine|6-day treatment period during which the medication will be taken orally with an initial dose of: 200 mg every 8 hours for 3 doses on day 3, increasing to 300 mg every 8 hours on days 4 and 5 (6 doses), and increasing further to 400 mg every 8 hours on days 6-8 if no telemetry changes and no dose limiting side effects
88928951|NCT01717417||group 1|Patient treated with Trans Palatal Arch as anchorage for canine traction
89444483|NCT05948501||mTBI w/ Visual Impairment|Individuals 18 years or older, current patient of Gaylord Hospital Outpatient Services, within the last 6 months have been diagnosed with a mTBI/concussion with visual field loss of greater than or equal to 20% as determined by a perimetry screening
89444484|NCT05948501||mTBI w/o Visual Impairment|Individuals 18 years or older, current patient of Gaylord Hospital Outpatient Services, within the last 6 months have been diagnosed with a mTBI/concussion currently presenting with no symptoms consistent with peripheral vision loss.
89444485|NCT05948501||Healthy Control|Community dwelling adults aged 18 years or older with no diagnosis of mTBI/concussion within the last 6 months. Population will be matched to the concussion population within the age, gender, and height range of the concussion population.
89444486|NCT05947695|Experimental|Intervention|The oncology nurse-specialist-led multidisciplinary early intervention arm includes standard of care with additional coordination of services, patient education, and referral to treatment and other resources aligned with comprehensive best practice models for multidisciplinary care teams.
89444487|NCT05947695|Active Comparator|Standard of Care|The standard of care comparator arm is usual clinical care using NCCN guidelines and evidence-based practice for palliative and survivorship care for patients treated with distant metastases.
89444488|NCT05946902|Active Comparator|mirabegron|mirabegron 25 mg
89444489|NCT05946902|Active Comparator|tolterodine|tolterodine 4 mg
89444490|NCT05946902|Experimental|combined therapy|tolterodine 4 mg & mirabegron 25 mg
89444491|NCT05946889||Suture|Women with ovarian cyst who received robotic/laparoscopic ovarian cystectomy with suture
88928952|NCT01717417||Group 2|Patient treated with miniscrew as anchorage for canine traction
88928953|NCT01717430||Corticosteroid injection|Consecutive patients receiving initial or repeated sacroiliac joint or single or multi-level epidural corticosteroid injections as part of their management plan for SI joint, neck, back, or radicular pain. Injections will be performed using 0.5 mL bupivacaine 0.25% and 15 mg dexamethasone sodium phosphate.
88928954|NCT01717443||Women, renal disease, transplantation|Women with end-stage renal disease, whose eligibility for renal transplantation is assessed
88928955|NCT01717469|Active Comparator|RV Pacing|Right ventricular pacing
88928956|NCT01717469|Experimental|LV Pacing|Left ventricular pacing through coronary sinus tributaries
88928957|NCT01717495||Implantation Procedures|Patients submitted to initial pacemaker or ICD implantation
88928958|NCT01717495||Reoperation Procedures|Patients submitted to pacemaker or implantable cardioverter-defibrillator generator replacements, upgrade procedures and lead extraction
88928959|NCT01717508|Other|Cognitive Behavioral Therapy|12 weekly sessions of cognitive behavioral therapy
88928960|NCT01717508|No Intervention|Healthy Controls|
88928961|NCT01717534|Experimental|Heat-treated lactobacilli|"One sachets (1 gram of content) will be consumed once a day, and will be suspended in a provided milk powder to be reconstituted with water.~The duration of the treatment is 5 months."
89444492|NCT05946889||Human Fibrin Glue|Women with ovarian cyst who received robotic/laparoscopic ovarian cystectomy with human fibrin glue
88928962|NCT01717534|Placebo Comparator|Maltodextrin|"One sachets (1 gram of content) will be consumed once a day, and will be suspended in a provided milk powder to be reconstituted with water.~The duration of the treatment is 5 months."
88928963|NCT01717547|Experimental|Yoga|Yoga-based treatment - manualized group treatment - classes will be held twice per week for approximately 85 minutes for a period of eight weeks.
88928964|NCT01717560|Experimental|Collaborative multidisciplinary integrated care|Collaborative, multidisciplinary, integrated care for hepatitis C
89444493|NCT05929183|Active Comparator|Repetitive Transcranial magnetic stimulation|
89444494|NCT05929183|Sham Comparator|Sham Repetitive Transcranial magnetic stimulation|
89444495|NCT05906979|Experimental|Digital intervention|Participants will interact with PAHOLA the digital assistant of the Pan American Health Organization.
89444496|NCT05906979|Experimental|Digital intervention (text only)|Participants will interact with PAHOLA (text only version) the digital assistant of the Pan American Health Organization.
89444497|NCT05906979|Other|Information on alcohol use and risk|A PDF containing standard information on alcohol use and risk from the Pan American Health Organization.
89444498|NCT05905081|Experimental|Exercise Group|30-minutes moderate-intensity aerobic exercise will be performed according to ACSM guidelines
89444499|NCT05905081|No Intervention|Control Group|30-minutes video screening while sitting
89444500|NCT05901987|Experimental|Low dosing group|1.2x10^14 vg/person of GC101 delivered one-time intrathecally (n=3)
89444501|NCT05901987|Experimental|Medium dosing group|2.4x10^14 vg/person of GC101 delivered one-time intrathecally (n=3)
89444502|NCT05901987|Experimental|High dosing group|4.8x10^14 vg/person of GC101 delivered one-time intrathecally (n=3)
89444503|NCT05898763|Experimental|Treatment arm|Patients will be vaccinated with the TEIPP24 vaccine in Montanide ISA 51 every three weeks for a total of three rounds of vaccination. The total treatment duration is 9 weeks for each patient. The three dose levels tested are 20, 40 and 100 µg of peptide. Dose 1: 20 µg of peptide in Montanide ISA 51; Dose 2: 40 µg of peptide in Montanide ISA 51; Dose 3: 100 µg of peptide in Montanide ISA 51. Patients in the extension cohort will receive the highest safest dose of peptide in combination with pembrolizumab.
89444504|NCT05898737||Parturients|Parturients on labour requiring an epidural
89444505|NCT05891509|Experimental|Minimally Invasive Hematoma Evacuation|Subjects randomized to this arm will receive the intervention of minimally invasive hematoma evacuation and best medical therapy
89444506|NCT05891509|Active Comparator|Best Medical Therapy|Subjects randomized to this arm will receive best medical therapy alone
89444507|NCT05886023|Active Comparator|Active Intervention|The intervention comprises vegetable burger containing high nitrate vegetables (100g of spinach, ~1000mg/kg FW nitrate) on white bread sandwich, provided at breakfast and lunch.
89444508|NCT05886023|Placebo Comparator|Control Intervention|The intervention comprises vegetable burger containing low nitrate vegetables (200g of peas, sweet corn, < 30 mg/kg FW nitrate) on white bread sandwich, provided at breakfast and lunch.
89444509|NCT05884242|Experimental|Active Arm: Adalimumab + Lipopolysaccharide (LPS) Challenge|Healthy participants will receive adalimumab subcutaneous (SC) injections via prefilled syringe or prefilled pen on Day 1, followed by the LPS intravenous (IV) injection challenge on Day 6.
89444510|NCT05884242|Experimental|Control Arm: LPS Challenge|Participants will receive LPS IV injection on Day 6. No study interaction will be administered.
89444511|NCT05868837|Experimental|Rituximab|
89444512|NCT05868837|Placebo Comparator|Placebo|
89444513|NCT05866627|Experimental|Afimetoran, followed by famotidine + afimetoran|
89444514|NCT05866627|Experimental|Famotidine + afimetoran, followed by afimetoran|
89444515|NCT05866627|Experimental|Afimetoran|
89444516|NCT05866627|Experimental|Famotidine, followed by afimetoran|
89444517|NCT05860049|Experimental|conventional physiotherapy|They will receive conventional physical therapy (Superficial thermotherapy will be applied by an infrared lamp (250 watts), located 50cm from the patient's neck for 15 minutes. Electrotherapy will be provided in the form of TENS with a frequency of 100Hz and 250 microsecond pulses for 45 minutes using two 4x6cm electrodes placed bilaterally at the spinous process of C7 vertebra. Stretching exercises for Upper Trapezius, Levator Scapulae, Sternocleidomastoid and Scalenes muscles, each stretching exercise maintain 30 second and repeated 5 times for each side. Active range of motion exercises for neck extension, neck flexion, neck rotation, and neck lateral flexion to both directions, that includes active movement without resistance as follow: Patient sitting on the chair, therapist standing behind the patient, asking the patient to move his neck smoothly in extension, flexion, rotation, and lateral flexion to both directions for 1set 5 repetitions.
89444518|NCT05860049|Experimental|conventional physiotherapy,core stability training and istrument assisted soft tissue mobilization|"They will receive conventional physical therapy~core stability exercise and IASTM technique."
89444519|NCT05850078|Experimental|FB101|Microbial intervention using product FB101
89444520|NCT05850078|Experimental|FB101 diluted|Microbial intervention using diluted FB101
89444521|NCT05850078|Placebo Comparator|Placebo|Saline water
89444522|NCT05841667||CES1 without or without single nucleotide polymorphism (SNP)|We will determine the CES1 genotype of participants through a laboratory test. Several different types of SNPs can be identified, and analyses can be further stratified by CES1 SNP type.
89444523|NCT05838937||Investigation cohort|Cardiogenic shock patients from any cause receiving veno-arterial extracorporeal membrane oxygenation
89444524|NCT05835453|Active Comparator|Conventional tray|Two simple randomizations will be performed using a software program freely available online (www.sealedenvelop.com). For the first randomization, for each participant, the group (type of tray) will be randomized and it will always be applied to the participant's right hemiarch (n=40) according to the model: conventional tray or clear aligner. Subsequently, the second randomization will be carried out, which will define the alternate days for the use of the tray and the aligner: Monday, Wednesday and Friday or Tuesday, Thursday and Saturday.
89444525|NCT05835453|Active Comparator|Clear aligner|The patients will use the clear aligner on their right hemiarch and according to the second randomization it will be applied on Monday, Wednesday and Friday or Tuesday, Thursday and Saturday.
89444526|NCT05833711|Experimental|Froniglutide 50 mg|Froniglutide (PF1801) 50 mg will be administered subcutaneously once a week.
89444527|NCT05833711|Experimental|Froniglutide 70 mg|Froniglutide (PF1801) 70 mg will be administered subcutaneously once a week.
89444528|NCT05833711|Placebo Comparator|Placebo|Matching placebo will be administered subcutaneously once a week.
89444529|NCT05828953|Experimental|Anlotinib|Experimental: The dosage of Anlotinib is 8mg per dose, once daily, to be taken orally before breakfast.
89444530|NCT05828953|Placebo Comparator|Placebo,|control group：Placebo, take orally once daily before breakfast
89444531|NCT05825534|Experimental|EIT monitoring|
89444532|NCT05824975|Experimental|Dose escalation phase : GI-102 as a single agent|Dose escalation: GI-102, multiple ascending doses
89444533|NCT05824975|Experimental|Dose expansion phase : GI-102 as a single agent|Dose expansion: GI-102, tentative RP2D
89444534|NCT05809713|Experimental|Technology enabled Team Care|Ongoing Team-based, Pharmacist led telephonic management of uncontrolled high blood pressure involving cellular-enabled home BP monitoring, medications, diet and exercise, and referral for social problems
88928965|NCT01717573|Active Comparator|Deferred stenting|During primary PCI in STEMI, when TIMI 3 flow has been re-established with guide-wire, aspiration thrombectomy and/or balloon angioplasty, stenting is then deferred for a period of 4-16 hours following reperfusion. During this time, patients remain in the Coronary Care Unit and will receive intravenous tirofiban and subcutaneous low molecular weight heparin (enoxaparin 1 mg/kg)
88928966|NCT01717573|Sham Comparator|Conventional treatment|Conventional treatment in STEMI, with immediate stenting
88928967|NCT01717599|Experimental|Diclofenac group|
88928968|NCT01717599|Placebo Comparator|Placebo(normal saline) group|
88928969|NCT01717612|Active Comparator|Histoacryl group|the injected agents consisted of n-butyl-2-cyanoacrylate (Histoacryl; B.Braun, Melsungen AG, Germany) 0.5ml mixed with 1.5 ml Lipiodol ultra-fluide (Guerbet, Bois Cedex, France). The injection site was aimed at the bleeding varices or varices with red color signs or at the most prominent varices.
88928970|NCT01717612|Experimental|thrombin group|Among the thrombin group, the injection site was also aimed at the bleeding varices or varices with red color signs or at the most prominent varices. The injected agents consisted of lyophilized human Thrombin in calcium chloride solution containing thrombin 500IU/ml). (Floseal, Baxter Healthcare Corporation, CA, Hayward, USA)
88928971|NCT01717625|Experimental|Montelukast|"montelukast sodium~dosage~< 1000g : 0.5 mg/D QD~1000g~1500g : 1.0 mg/D QD~1500g~2000g : 1.5 mg/D QD~> 2000g : 2mg/D QD~medication period : to discharge or GA 36wks"
88928972|NCT01717625|No Intervention|Control|Standard treatment of BPD and preterm infants
88928973|NCT01717651||CPM device|a CPM (continuous passive motion) device attached to one of your legs intermittently over the next three days.
88928974|NCT01717664|Experimental|RHB-104|5 RHB-104 capsules administered orally BID
88928975|NCT01717677|Experimental|radical prostatectomy|Procedure/Surgery: radical prostatectomy
88928976|NCT01717677|Experimental|percutaneous radiation therapy|Radiation: percutaneous radiation therapy
88928977|NCT01717677|Experimental|permanent seed implantation|Radiation: permanent seed implantation
88928978|NCT01717677|Experimental|Active Surveillance|Procedure/Surgery: Active Surveillance
88928979|NCT01717690|Active Comparator|CHG antiseptic body cleanser|"One randomly selected intervention unit in Complex Continuing Care program where all patients (MRSA-positive and MRSA-negative) will be bathed daily with an antiseptic body cleanser (CHG).~Only MRSA-negative patients at enrollment will be included in the study analysis, and only their outcomes (MRSA status and time to conversion) will be analyzed.~Antiseptic body cleanser - 2% Chlorhexidine Gluconate in a non-alcohol and non-alkaline base, delivered to skin surface through the bath cloths impregnated with this antiseptic solution."
88928980|NCT01717690|No Intervention|Non-antiseptic body cleanser|"Two control units in Complex Continuing Care program where all patients (MRSA-positive and MRSA-negative) will be bathed daily with a non-antiseptic body cleanser (Comfort Bath ®).~Only MRSA-negative patients at enrollment will be included in the study analysis, and only their outcomes (MRSA status and time to conversion) will be analyzed."
88928981|NCT01717703|Experimental|Water Control|Water Control
88928982|NCT01717703|Experimental|Fruit drink|Fruit drink
88928983|NCT01717703|Experimental|Cola|Cola
88928984|NCT01717703|Experimental|1% chocolate milk|1% chocolate milk
88928985|NCT01717716|Experimental|Calorie-free control|Calorie-free control
88928986|NCT01717716|Experimental|HFCS-55 drink|HFCS-55 drink
89444535|NCT05809713|Active Comparator|Enhanced Usual Care|Home BP monitoring device provided along with BP log, basic diet and exercise instruction, and care provided by the patient's usual doctor/provider
89444536|NCT05792917|Experimental|tafolecimab (a modified manufacturing process)|450mg，SC，single dose
89444537|NCT05792917|Active Comparator|tafolecimab (a original manufacturing process)|450mg，SC，single dose
88928987|NCT01717716|Experimental|Glucose drink|Glucose drink
88928988|NCT01717716|Experimental|Sucrose drink|Sucrose drink
88928989|NCT01717729|Experimental|RFA-125I group|The combination RFA and 125I (RFA-125I) (n = 68; 42 men, 26 women; mean age, 50.7 years; age range, 29-73 years) In this group, patients were accepted not only radiofrequency ablation (RFA) but also iodine-125.
88928990|NCT01717729|Active Comparator|RFA-only group|(n = 68; 47 men, 21 women; mean age, 48.9 years; age range, 30-74 years) In tis group,the patient were just peformed radiofrequency ablation alnoe.
88928991|NCT01717755|No Intervention|Best medical management.|"Best medical management consists of the standard of care of patients with acute ischemic stroke according to existing local protocols and guidelines, and may include IV thrombolysis.~If treated with IVT as part of BMM, IVT should be started within 4.5 hours of estimated time of BAO."
88928992|NCT01717755|Experimental|Additional intra-arterial treatment.|Best medical management followed by intra-arterial treatment and best medical management
88928993|NCT01717781|Experimental|Thunderbeat|"Laparoscopic radical hysterectomy with pelvic lymphadenectomy are performed with Thunderbeat technology: using Thunderbeat technique, surgeons can avoid changing instruments during surgery since Thunderbeat combines bipolar energy for haemostasis and ultrasound for dissection and cut.~Thunderbeat is used to divide the round ligaments, to seal ovarian pedicles, to open the anterior and posteriors leaves of the broad ligaments peritoneum, to incise the bladder peritoneum, to develop the paravesical and pararectal spaces, to seal uterine arteries and uterine pedicles, to dissect the bladder and develop rectovaginal septum, to unroof the ureter, to cut parametria, and to divide the uterosacral ligaments. Monopolar hook is used in the culdotomy. Thunderbeat is also used to perform pelvic lymphadenectomy."
88928994|NCT01717781|Active Comparator|Standard|"Laparoscopic radical hysterectomy with pelvic lymphadenectomy are performed with standard bipolar electrosurgery.~A 10 mm port is inserted at the umbilicus for the telescope. Once pneumoperitoneum (12 mmHg) is achieved, intra-abdominal visualization will be obtained with a 0° high-definition telescope.~Two additional 5 mm ports are placed under direct visualization. One more 5-mm trocar is inserted in the right mid abdomen at the level of the umbilicus. The instruments used include bipolar grasper, monopolar scissors, monopolar hook, various graspers and a suction irrigation system."
88928995|NCT01716260||Chloroquine and Primaquine|Chloroquine (CQ)10mg/kg for day 1, 2 and 5mg/kg for day 3 Primaquine (PQ)0.25mg/kg/day for 14 days
88928996|NCT01716325|Experimental|Weight loss - ICT support|Weight loss - ICT support
88928997|NCT01716325|Other|Conventional|Weight loss, comparator - no ICT support; conventional live workshops for weight loss
88928998|NCT01717794|Active Comparator|Standard bipolar electrosurgery|"Laparoscopic total hysterectomy with pelvic lymphadenectomy are performed with standard bipolar electrosurgery.~A 10 mm port is inserted at the umbilicus for the telescope. Once pneumoperitoneum (12 mmHg) is achieved, intra-abdominal visualization will be obtained with a 0° high-definition telescope.~Two additional 5 mm ports are placed under direct visualization. One more 5-mm trocar is inserted in the right mid abdomen at the level of the umbilicus. The instruments used include bipolar grasper, monopolar scissors, monopolar hook, various graspers and a suction irrigation system."
88928999|NCT01717794|Experimental|Thunderbeat technology|"Laparoscopic total hysterectomy with pelvic lymphadenectomy are performed with Thunderbeat technology: using Thunderbeat technique, surgeons can avoid changing instruments during surgery since Thunderbeat combines bipolar energy for haemostasis and ultrasound for dissection and cut.~Thunderbeat is used to coagulate the fallopian tubes, to coagulate and divide the round ligaments, to seal ovarian pedicles, to open the anterior and posteriors leaves of the broad ligaments peritoneum, to develop the paravesical and pararectal spaces, to seal uterine arteries and uterine pedicles, to incise the bladder peritoneum, to dissect the bladder, to develop rectovaginal septum, to cut parametria, and to divide the uterosacral ligaments. Thunderbeat is also used to perform the pelvic lymphadenectomy and, if necessary, the para-aortic lymphadenectomy."
88929000|NCT01717807||lung cancer; advanced pancreatic cancer|
88929001|NCT01717820|Experimental|Freeze-dried whole-grape powder|Freeze-dried whole-grape powder (46g/day)will be provided to participants for 12 weeks.
88929002|NCT01717833|Experimental|NEMS group|
88929003|NCT01717833|Sham Comparator|Sham group|
88929004|NCT01717846|Experimental|Arm 1|Orencia Group is for RA patients who have not received any other biologic treatment, including abatacept previously, and whose doctor has determined that it is appropriate to treat their RA with Abatacept. If you are in Group 1, you will receive the study drug, Abatacept, given in an intravenous (IV - injected into a vein) as well as subcutaneous form. Abatacept, given in an intravenous injection is approved by the FDA for the treatment of RA.
88929005|NCT01717846|Other|Arm 2 or group 2|Arm 2 or Group 2 is for RA patients who are being treated wth non-biologic DMARDS who, with their doctor, have decided that they will not be receiving treatment with Abatacept in the next six months. These patients will not receive the study drug abatacept.
88929006|NCT01717885||HIV+children on LPV/r|HIV+ children who are stabilized on a LPV/r based ART regimen
88929007|NCT01717885||HIV+ children on nevirapine|HIV+ children who are stabilized on an nevirapine based ART regimen
88929008|NCT01717885||HIV+ children on efavirenz|HIV+ children who are stabilized on an efavirenz based ART regimen
88929009|NCT01717885||HIV+ pregnant women on LPV/r|HIV+ pregnant women who are stabilized on an LPV/r based ART regimen
88929010|NCT01717885||HIV+ pregnant women on NVP|HIV+ pregnant women who are stabilized on an nevirapine based ART regimen
88929011|NCT01717885||HIV+ pregnant women on EFV|HIV+ pregnant women stabilized on an efavirenz based ART regimen
88929012|NCT01717885||HIV negative children|HIV negative children that will serve as a control for HIV positive children on either a LPV/r, NVP or EFV based ART regimen and will be compared to HIV negative non-pregnant adults
88929013|NCT01717885||HIV negative adults|HIV negative adults that will serve as a control for comparing results to HIV negative children and HIV negative pregnant women
88929014|NCT01717885||HIV negative pregnant women|HIV negative pregnant women who will serve as a control for HIV positive pregnant women on either a LPV/r, NVP or EFV based ART regimen and will be compared to HIV negative non-pregnant adults
88929015|NCT01717911|Active Comparator|Metformin|The titration of metformin was used 500 mg for an adjust unit in splitting dose with the same target to the maximum daily dose of 2550 mg (1000 mg twice daily and then 850 mg tid).
88929016|NCT01717911|Experimental|Sitagliptin|The subjects treated with sitagliptin started with 100 mg before breakfast once daily. The dosage was fixed as 100mg per day. Decreased by 50mg if fasting blood glucose was <70mg /dl, discontinued the study if blood glucose was still <70mg/dl under sitagliptin 50mg per day.
88929017|NCT01717911|Experimental|Insulin|In the insulin therapy group (Insulin glargine), subjects were instructed in the techniques for insulin injection and home capillary glucose monitoring. Daily dose was administrated before breakfast.
88929018|NCT01717937||PVOCT|Subjects will receive fluorescein angiography (FA) as part of their normal clinical evaluation and will undergo phase variance optical coherence tomography (PV-OCT) as the study intervention. This involves having subjects undergo standard, noninvasive optical coherence tomography (OCT) scans with an FDA-approved OCT device, and the data gathered by this device will be transferred to a separate computer for processing using novel software. This software is capable of utilizing the existing data to generate phase variance OCT images.
88929019|NCT01717950|Experimental|30 µg Na-APR-1 (M74)/Alhydrogel®|
88929020|NCT01717950|Experimental|30 µg Na-APR-1 (M74)/Alhydrogel® plus 2.5 µg GLA-AF|
88929021|NCT01717950|Experimental|30 µg Na-APR-1 (M74)/Alhydrogel® plus 5.0 µg GLA-AF|
88929022|NCT01717950|Experimental|100 µg Na-APR-1 (M74)/Alhydrogel®|
88929023|NCT01717950|Experimental|100 µg Na-APR-1 (M74)/Alhydrogel® plus 2.5 µg GLA-AF|
88929024|NCT01717950|Experimental|100 µg Na-APR-1 (M74)/Alhydrogel® plus 5.0 µg GLA-AF|
88929025|NCT01717963|Experimental|Naltrexone intramuscular suspension|Extended release naltrexone injections 380mg
89444538|NCT05786066|Experimental|Perampanel + Ketamine|Participants will receive oral perampanel or placebo, in counterbalanced order, 2.5 hours before a standard, subanesthetic Ketamine infusion (0.5 mg/kg over 40 minutes). Ketamine infusions will be at least three weeks apart. Participants will refrain from caffeine and over-the-counter medication seven days before the infusion day.
88929026|NCT01717963|Active Comparator|Buprenorphine-naloxone|Flexible oral dose 4-24 mg daily
88929027|NCT01718002|Other|Educational video on oral hygiene|The patient was asked to execute the technique used daily oral hygiene that, with the sequence, movements and technical procedures for its implementation evaluated and recorded an instrument to analyze the steps of oral hygiene. Subsequently, patients watched the video prepared individually in the ward where they were interned. After this step, the patient demonstrated again the procedure for oral hygiene. At this point the researcher also observed the sequence, movements and technical procedures used to analyze the steps of oral hygiene, using the same instrument for such employee initially.
88929028|NCT01718015||Patients with diabetic polyneuropathy|
88929029|NCT01718015||Patients with diabetes without peripheral nerve disorder|
88929030|NCT01718015||Patients with polyneuropathies not due to diabetes|
88929031|NCT01718015||Patients not suffering from diabetes or nerve disease|Control subjects
88929032|NCT01718015||Patients with unspecified nerve disease|
88929033|NCT01718054|Active Comparator|vascular|In this intervention period children will receive a vascular ready-to-use supplementary food with added L-Arginine & L-Citrulline plus daily chloroquine
88929034|NCT01718054|Active Comparator|regular|In this intervention period children will receive a regular ready-to-use supplementary food plus weekly dose of chloroquine
88929035|NCT01718067|Experimental|Vakum|VAKÜM system (Free Aspire, MPR, Legnano-I) added to the conventional manual ELTGOL technique
88929036|NCT01718067|Active Comparator|Control|conventional manual ELTGOL technique
88929037|NCT01718080||Group A|Healthy lean children before puberty
89444539|NCT05786066|Placebo Comparator|Placebo + Ketamine|Participants will receive oral perampanel or placebo, in counterbalanced order, 2.5 hours before a standard, subanesthetic Ketamine infusion (0.5 mg/kg over 40 minutes). Ketamine infusions will be at least three weeks apart. Participants will refrain from caffeine and over-the-counter medication seven days before the infusion day.
89444540|NCT05782101||Bronchopulmonary Dysplasia/Retinopathy of prematurity|Preterm neonates whith Bronchopulmonary dysplasia and/or Retinopathy of prematurity
89444541|NCT05782101||No Bronchopulmonary Dysplasia/Retinopathy of prematurity|Preterm neonates without Bronchopulmonary Dysplasia and/or Retinopathy of prematurity
89444542|NCT05781087||Standard of care|Patients after ST-elevation myocardial infarction with non-culprit coronary artery disease.
89444543|NCT05776888||Early Treatment Cohort (Cohort 1)|Patients that, before initiation of Ofatumumab, were either treatment naive or have started their treatment for RMS with another disease modifying therapy (BRACE, teriflunomide or fumarates). Non-naive patients in this cohort must have started the use of Ofatumumab within 3 years after first DMT initiation.
89444544|NCT05776888||Later Treatment Cohort (Cohort 2)|Patients that have been on BRACE and/or Teriflunomide and/or fumarates for at least three years or longer before the switch to Ofatumumab has been initiated.
89444545|NCT05774587|Active Comparator|Active control|Participants will complete a 3-month cardiac rehabilitation programme supported by the onsite CR service
88929038|NCT01718080||Group B|Otherwise healthy overweight children before puberty
88929039|NCT01718080||Group C|Healthy lean adolescents in mid to late puberty
88929040|NCT01718080||Group D|Otherwise healthy overweight adolescents in mid to late puberty
88929041|NCT01718093|Active Comparator|Insulin plus sitagliptin|The subjects continued their usual insulin regimen throughout the study. Sitagliptin was started and continued at 50 mg orally twice daily
88929042|NCT01718093|Active Comparator|Insulin plus metformin|The subjects continued their usual insulin regimen throughout the study. Metformin was started at 500 mg orally daily. The dose was increased over a 2 week period up to 2,000 mg per day as tolerated.
88929043|NCT01718093|Active Comparator|Insulin plus sitagliptin and metformin|The subjects continued their usual insulin regimen throughout the study. Sitagliptin was started and continued at 50 mg orally twice daily. Metformin was started at 500 mg orally daily. The dose was increased over a 2 week period up to 2,000 mg per day as tolerated.
88929044|NCT01718106|Active Comparator|Single long bioabsorbable polymer DES|Patients with long coronary stenosis treated by a single long bioabsorbable polymer DES
88929045|NCT01718106|Active Comparator|Two bioabsorbable polymer DES in overlapping|patients with long coronary artery stenosis tretaed by 2 bioabsorbable polymer DES with minimal overlapping
88929046|NCT01718119|Experimental|DA-3803|subjects treated with DA-3803(r-hCG)
89200023|NCT00960466|Experimental|DT&PL arm|"During the second week of radiotherapy/second cycle of chemotherapy, patients in the Distress Thermometer and Problem List (DT&PL) arm of the study will complete the DT&PL (estimated 15 minutes to complete) with the trained radiographer/nurse.~The DT&PL assessment will be repeated at the end of therapy fractions/cycles. This will elicit concerns about post-therapy issues and facilitate continuity of care between the cancer team and primary care. Depending on the duration of therapy, therapists may choose to use the DT&PL at other points during patient care. A copy of the DT&PL will be stored in the medical record to track the frequency of use and to check that those assigned to usual care were not monitored with the DT&PL."
89200024|NCT00758940|Experimental|1|Acrysof ReSTOR multifocal IOL
89444546|NCT05774587|Experimental|mHealth technology assisted exercise counselling (mHealth)|Participants will complete a walking mHealth technology assisted exercise counselling intervention. All participants will have 4 exercise consultations with their exercise specialist. The intervention will be supported by 3 mHealth elements; 1) a wrist worn fitness watch, 2) a smartphone app for patients, and 3) a coaching website for the exercise specialist. The 3 elements will be synced, allowing data to be transferred between platforms.
89444547|NCT05769244|Experimental|testicular torsion|
88929047|NCT01718119|Active Comparator|Ovidrel|subjects treated with Ovidrel(r-hCG)
88929048|NCT01718132||postoperative patients|
88929049|NCT01718171||Group I, Group II, Group III, Group IV|Values and results of the Systemic Inflammatory Response and C-reactive protein to appendicitis
88929050|NCT01718184|Experimental|Sulcoflex|Sulcoflex intraocular lens implantation
88929051|NCT01718210|Experimental|GM-CSF medium|patient's embryos are incubated after fertilization with mediun supplemented with GM-CSF
88929052|NCT01718210|Placebo Comparator|CONTROL|50 women with recurrent implantation failure (at leat three previous IVF attempts failed with at least 8 good embryos transferred in uterus)that the obtained with IVF are incubated with a standard medium for IVF, and utilized as control group.
88929053|NCT01718223|Experimental|Treatment (interstitial photodynamic therapy using temoporfin)|Patients receive temoporfin IV over at least 6 minutes on day 1 and undergo interstitial photodynamic therapy on day 3. Within 4-6 weeks, patients undergo surgical resection.
88929054|NCT01718236|Experimental|Rocuronium + sugammadex|Intubation after rocuronium administration and reversal of blockade after administration of sugammadex
88929055|NCT01718236|Experimental|Succinylcholine + Neostigmine|Intubation after succinylcholine administration, neuromuscular block is than maintained by rocuronium administration and reversal of block is by neostigmine + atropine administration
88929056|NCT01718249|Other|deep brain stimulation|
88929057|NCT01718288|Experimental|iloprost + standard treat.(aspirin)|1B - patients unsuitable to surgical or endovascular vascular therapy: treatment with iloprost intravenous infusions for 10 days every 3 months, in addition to conventional treatment
88929058|NCT01718288|Active Comparator|Standard Treatment (aspirin....)|"1A - patients unsuitable to surgical or endovascular vascular therapy: conventional treatment~Conventional Treatments:correction of concomitant risk factors, physical exercise, antiplatelet, standard heparin / low molecular weight heparin, hemorheological / vasodilators such as pentoxifylline / buflomedil, propionyl-L-carnitine, Defibrotide) but not prostanoids"
88929059|NCT01718288|Experimental|Vascular surgery patients + iloprost|2B - patients suitable to vascular surgical or endovascular therapy: treatment with intravenous infusions iloprost for 10 days every 3 months, in addition to conventional treatment
88929060|NCT01718288|Active Comparator|Vasc. Surg.+ standard treat. (aspirin..)|2A - patients suitable to vascular surgical or endovascular therapy + standard treatment (aspirin...)
88929061|NCT01718301|Experimental|boceprevir + ribavirin + peginterferon|boceprevir 800 mg three times a day (v.o.) in combination with peginterferon (alfa-2b or alfa-2a) and ribavirin
88929062|NCT01718314|Experimental|Sublingual Misoprostol & Lidocaine placebo|Misoprostol 200 µg sublingually single dose and Lidocaine spray placebo
88929063|NCT01718314|Experimental|Lidocaine Pump Spray & Misoprostol placebo|Lidocaine Pump spray, 6 sprays to cervix (60 mg totally) and sublingual misoprotol placebo
88929064|NCT01718327|Experimental|open label, single arm|single arm: sunitinib until progresion or unacceptable toxicity
88929065|NCT01718340|Experimental|Metformin|The patients with PCO and hyper insulinemia will be subdivided into two groups, one group will continue metformin 500 mg three times per day from the start of induction of ovulation till the end of pregnancy, the other group will stop the drug once pregnancy test become positive
88929066|NCT01718366|Experimental|ferritin level >300ng/ml and < 1000ng/ml|"Patients will be included in 2 groups according to the ferritin level at time of inclusion.~Patients with the ferritin level >300ng/ml and < 1000ng/ml, will be included in Group 1.~Interventions: Deferasirox, Vitamin D (100000/week) and Azacitidine (75 mg/kg/day Day1 today 7)~5 patients in each cohort: Cohort 1: Deferasirox: 5mg/kg/d Cohort 2: Deferasirox: 10mg/kg/d Cohort 3: Deferasirox: 15mg/kg/d"
88929067|NCT01718366|Experimental|ferritin level > 1000ng/ml|"Patients will be included in 2 groups according to the ferritin level at time of inclusion.~Patients with the ferritin level > 1000ng/ml, will be included in Group 2. Intervention: Deferasirox, Vitamin D (100000/week) and Azacitidine (75 mg/kg/day Day1 today 7)~5 patients in each cohort: Cohort 1: Deferasirox: 10mg/kg/d Cohort 2: Deferasirox: 15mg/kg/d Cohort 3: Deferasirox: 20mg/kg/d"
88929068|NCT01718379|Experimental|Arm A|"Lenalidomide 10 mg/day for 21 days every 28 days for 4 courses.~Evaluation of response at the end of 4 months according to IWG 2006 and IWG 2000 criteria.~Maintenance: responders will continue to follow the corresponding treatment arm until relapse occurs; non responders at cycle 4 in arm A will be considered in failure of treatment and the introduction of Epoetin beta is at the discretion of the physician.~The patients will be followed every 3 months for 12 months"
88929069|NCT01718379|Experimental|Arm B|"Lenalidomide 10 mg/day for 21 days every 28 days for 4 courses combined with weekly subcutaneous injections of Epoetin beta (60,000 Units/w).~Evaluation of response at the end of 4 months according to IWG 2006 and IWG 2000 criteria.~Maintenance: responders will continue to follow the corresponding treatment arm until relapse occurs; non responders at cycle 4 in arm A will be considered in failure of treatment and the introduction of Epoetin beta is at the discretion of the physician.~The patients will be followed every 3 months for 12 months"
88929070|NCT01718392|Experimental|Training|24 weeks combined exercise programme (supervised)
88929071|NCT01718392|No Intervention|Control|sedentary/habitual lifestyle
89013585|NCT06299735|Active Comparator|Patient group using a double-lumen tube for single-lung ventilation|Group DLT: For the assessment of postoperative pulmonary complications, arterial blood gas analysis, chest X-ray, respiratory sounds, and the patient's oxygen requirement will be monitored every 6 hours for 24 hours. The parameters to be examined preoperatively are: smoking history, ARISCAT score (Age, Preoperative SpO₂, Respiratory infection in the last month, Preoperative anemia (Hgb ≤10 g/dL), Surgical incision, Duration of surgery, Emergency procedure).
89013586|NCT06299735|Active Comparator|Patient group using a endobronchial blocker for single-lung ventilation|Group BB: For the assessment of postoperative pulmonary complications, arterial blood gas analysis, chest X-ray, respiratory sounds, and the patient's oxygen requirement will be monitored every 6 hours for 24 hours. The parameters to be examined preoperatively are: smoking history, ARISCAT score (Age, Preoperative SpO₂, Respiratory infection in the last month, Preoperative anemia (Hgb ≤10 g/dL), Surgical incision, Duration of surgery, Emergency procedure).
89013587|NCT06299709|Experimental|Part A: Sequence 1|Participants will receive VNZ/TEZ/D-IVA reference fixed dose combination (FDC) tablet in dosing period 1, then VNZ/TEZ/D-IVA test FDC granules dose level 1 in dosing period 2, and finally VNZ/TEZ/D-IVA test FDC granules dose level 2 in dosing period 3. A washout period of 14 days will be maintained between 3 dosing periods.
89013588|NCT06299709|Experimental|Part A: Sequence 2|Participants will receive VNZ/TEZ/D-IVA test FDC granules dose level 1 in dosing period 1, then VNZ/TEZ/D-IVA test FDC granules dose level 2 in dosing period 2, and finally VNZ/TEZ/D-IVA reference FDC tablet in dosing period 3. A washout period of 14 days will be maintained between 3 dosing periods.
89013589|NCT06299709|Experimental|Part A: Sequence 3|Participants will receive VNZ/TEZ/D-IVA test FDC granules dose level 2 in dosing period 1, then VNZ/TEZ/D-IVA reference FDC tablet in dosing period 2, and finally VNZ/TEZ/D-IVA test FDC granules dose level 1 in dosing period 3. A washout period of 14 days will be maintained between 3 dosing periods.
89013590|NCT06299709|Experimental|Part B: Sequence 1|Participants will receive VNZ/TEZ/D-IVA test FDC granules under fasted condition in dosing period 1, then VNZ/TEZ/D-IVA test FDC granules under fed state in dosing period 2. A washout period of 18 days will be maintained between 2 dosing periods.
89013591|NCT06299709|Experimental|Part B: Sequence 2|Participants will receive VNZ/TEZ/D-IVA test FDC granules under fed state in dosing period 1, then VNZ/TEZ/D-IVA test FDC granules under fasted condition in dosing period 2. A washout period of 18 days will be maintained between 2 dosing periods.
89013592|NCT06299696|Experimental|VNZ/TEZ/D-IVA|Participants will be given VNZ/TEZ/D-IVA FDC to retain in their mouths for approximately 10 seconds and then expectorated.
89013593|NCT06299683|Experimental|Psychosocial Treatment|The psychosocial self-management intervention consists of 8 weekly 50-minute individual visits with an assigned trained therapist. Sessions follow a structured protocol that has been developed with the patient population and tested in a prior study. Treatment modules are individualized and include topics such as pain coping strategies, relaxation training, education on IC/BPS, and communication strategies.
89013594|NCT06299683|Active Comparator|Pelvic Floor Physical Therapy|The pelvic floor physical therapy condition consists of 10 weekly 45-minute individual visits with an assigned trained physical therapist. In IC/BPS, pelvic floor physical therapy (PT) uses manual manipulation to release localized muscle tension, trigger points, and correct other scars and restrictions to reduce pain and urgency symptoms. Specific techniques will include external connective tissue manipulation to the abdominal wall, back, buttocks and thighs, myofascial trigger point release, and internal transvaginal/transrectal treatment of the soft tissues of the pelvic floor with connective tissue and myofascial manipulation to pelvic floor musculature
89013595|NCT06299670|Experimental|Thalidomide|Patient getting Thalidomide
89013596|NCT06299670|Experimental|Hydroxyurea|Hydroxyurea
89013597|NCT06299670|Experimental|Combination|combination of Thalidomide & Hydroxyurea
89013598|NCT06299657|Experimental|IMPROVE|In this arm, participants will receive the IMPROVE intervention, a clinician-delivered protocol targeting anxiety and uncertainty.
89013599|NCT06299657|Active Comparator|PHET|In this arm, participants will receive a clinician-delivered protocol with a digital component, called PHET. PHET focuses on healthy living more broadly and does not include information about anxiety or uncertainty.
89013600|NCT06299644|Active Comparator|Belt and Suspenders Configuration|Endoscopic sleeve gastroplasty with the Endomina system creating proximal and distal gastric plications (belt and suspenders configuration).
89013601|NCT06299644|Active Comparator|Belt Configuration|Endoscopic sleeve gastroplasty with the Endomina system creating distal gastric plications (belt configuration).
89013602|NCT06299631||Crohn's disease patients undergoing ICR|Crohn's disease patients undergoing ICR treated with TNF inhibitors
89013603|NCT06299605|Active Comparator|14-day quadruple regimen|Vonoprazan 20mg bid + Amoxicillin 1000mg bid + Tetracycline 500mg qid + Bismuth 220mg bid for 14 days
89013604|NCT06299605|Experimental|14-day triple regimen|Vonoprazan 20mg bid + Amoxicillin 1000mg bid + Tetracycline 500mg qid for 14 days
89013605|NCT06299605|Experimental|7-day triple regimen|Vonoprazan 20mg bid + Amoxicillin 1000mg bid + Tetracycline 500mg qid for 7 days
89013606|NCT06299566||People with experience of cystic fibrosis|Adults or children with experience of CF.
89013607|NCT06299566||Health professionals|Health professionals with experience of caring for people with experience of CF.
89444548|NCT05769244|Active Comparator|other testicular pathology|
89444549|NCT05769244|Sham Comparator|healthy patients|
89444550|NCT05767372|Experimental|Coherent breathing group|The participants will receive Inspiratory muscle trainer and Coherent breathing exercise three times per week for 12 weeks.
89444551|NCT05767372|Experimental|Inspiratory muscle training group|The participants will receive Inspiratory muscle training three times per week for 12 weeks.
88929072|NCT01718405|Experimental|Exercise Group|Each individual subject will give a blood sample for genetic analysis and undertake an exercise session and a rest session as a control. Cognitive function will be tested before and after each session.
88929073|NCT01718418|Experimental|+ ind.CHO + prebiotics|test meal: intrinsic indigestible carbohydrates in combination with a combined probiotic supplement.
88929074|NCT01718418|Experimental|+ ind.CHO - prebiotics|test meal: intrinsic indigestible carbohydrates in combination with placebo probiotic supplement.
88929075|NCT01718418|Experimental|- ind.CHO - prebiotics|reference: no ind. carbohydrates and no probiotic supplement
88929076|NCT01718431|Experimental|indigestible carbohydrates|test meal: indigestible carbohydrates
88929077|NCT01718431|Experimental|reference|reference meal: no indigestible carbohydrates
88929078|NCT01718457|Experimental|Endobarrier device insertion|
88929079|NCT01718470|Active Comparator|Endotracheal tube|At the end of surgery, emerge from anesthesia with the ETT still in place
88929080|NCT01718470|Active Comparator|Laryngeal mask|At the end of surgery,emerge from anesthesia after ETT had been replaced by an LMA.
88929081|NCT01718496|Active Comparator|Morphine|Patient with advance COPD who will randomly receive single dose oral Morphine
88929082|NCT01718496|Placebo Comparator|Placebo|patient with advanced COPD who will receive Placebo
88929083|NCT01718548|Active Comparator|CS and Lingzhi|CS liquid (each dosage is a bottle of liquid containing 30 ml: comprising 75% of CS, 6% Lingzhi, 6% shitake, 5% bamboo shoot, 2% honey, 0.1% potassium sorbet and 5.9% pure water) and Lingzhi capsule (each capsule contains 620mg of: 52.42% Lingzhi, 28.23% CS, and 19.35% soy gel ) ; one quarter bottle of CS to be ingested twice a day, and the Lingzhi capsule to be taken once a day, both for a period of 28 days.
88929084|NCT01718548|Placebo Comparator|Placebo|Liquid tea ingested twice a day and flour-filled capsules ingested once a day over a period of 28 days
88929085|NCT01718561|No Intervention|Control|Usual clinical airway evaluation and usual registration in Danish Anaesthesia Database (without SARI registration)
88929086|NCT01718561|Experimental|SARI|Registration of Modified SARI score and predictors for difficult mask ventilation in Danish Anaesthesia Database
88929087|NCT01718574|Experimental|Self-help book|
88929088|NCT01718574|No Intervention|Usual Care Control|
88929089|NCT01718587|Experimental|stem cell transplantation therapy|umbilical cord mesenchyma stem cell transplantation through interventional procedures do in liver cirrhosis patients.
88929090|NCT01718587|Active Comparator|antiviral therapy|"Antiviral therapy: lamivudine, 100 mg per day (oral dose); or adefovir dipivoxil 10 mg per day (oral dose); or grace entecavir 0.5-1mg per day (oral dose); or behalftelbivudine 600 mg per day (oral dose).~Supportive therapy are allowed to use on patients not including intravenous infusions of plasma or albumin."
88929091|NCT01718613|Active Comparator|Norepinephrine|
88929092|NCT01718613|Active Comparator|Vasopressin|
88929093|NCT01718626|Active Comparator|S1+Docetaxel|
88929094|NCT01718626|Experimental|S1+Docetaxel followed by S1|
88929095|NCT01718639|Active Comparator|IQP-LH-101 tablet|4 chewable tablets to be chewed thoroughly before swallowing
88929096|NCT01718639|Active Comparator|IQP-LH-101 liquid|2 liquid sachets to be emptied into the mouth and consumed.
88929097|NCT01718639|Placebo Comparator|Placebo|1 tablet to be swallowed with water.
88929098|NCT01718652|Experimental|Canagliflozin + cyclosporine|Each volunteer will receive canagliflozin (JNJ-28431754) once daily on Days 1 through 8 with a single dose of cyclosporine on Day 7.
88929099|NCT01718678|Active Comparator|Melatonin|Melatonin, Tablet, 3 mg, once, one month
88929100|NCT01718678|Placebo Comparator|Placebo|Placebo, tablet
88929101|NCT01718704|Experimental|Viberect device|Men in this group will begin using the Viberect device 3 days after Foley catheter removal after surgery on a daily (or at least 4 times a week) basis for 7-10 minutes in a relaxed setting.
88929102|NCT01718704|No Intervention|No Viberect|Men in this group will not be provided with the Viberect device
88929103|NCT01718717|Active Comparator|6 days TEA|Postoperative analgesia for the first six postoperative days with TEA and daily monitoring for arrhythmia
88929104|NCT01718717|Active Comparator|3 days TEA and 3 days intravenous morphine|Postoperative analgesia for the first three postoperative days with TEA followed for the next three days with intravenous morphine, and daily monitoring for arrhythmia
88929105|NCT01718730||Mild depression|Subjects with mild, but clinically significant depression
88929106|NCT01718730||Moderate to Severe MDD|Subjects with moderate to severe major depressive disorder who have not yet initiated treatment with an SSRI
88929107|NCT01718730||MDD with response to SSRI|Subjects with moderate to severe major depressive disorder that has responded to an SSRI
88929108|NCT01718730||MDD without response to SSRI|Subjects with moderate to severe major depressive disorder which has not responded to treatment with an SSRI
88929109|NCT01718756|Placebo Comparator|Placebo|The placebo group received 12 hourly boluses of 0.9% saline, followed by a constant infusion for 48 hrs after surgery.
88929110|NCT01718756|Active Comparator|Scheduled|They received a 12 hourly boluses of lornoxicam followed by a constant infusion of 0.9% saline, for 48 hrs after surgery
88929111|NCT01718756|Active Comparator|Continuous infusion|They received boluses of lornoxicam 0.8 mg/mL before induction of anaesthesia followed by a 12 hourly boluses of 0.9% saline and a constant infusion at 10 mL/h of lornoxicam 0.13 mg/mL, for 48 hrs. after surgery.
88929112|NCT01718769|Active Comparator|STAMP using|100 boys and girls aged 1 to 6, attending Clalit Health Care Services Pediatric Centers, will undergo an assessment using the STAMP Tool; a questionnaire including 3 questions with a summary score, according to which the nutritional risk level shall be determined. These children shall also undergo a complete dietician assessment in order to examine the validity of the STAMP Tool.
88929113|NCT01718769|Placebo Comparator|No STAMP using|150 files shall be reviewed in the beginning of the research and after 6 months in order to estimate the change in medical staff's attention to nutritional status, by way of noting relevant diagnoses, reference to nutritional status- related tests and recording of anthropometric measurements.
88929114|NCT01718782|Active Comparator|laryngeal mask Ambu AuraOnce|laryngeal mask Ambu AuraOnce
88929115|NCT01718782|Active Comparator|laryngeal mask LMA Supreme|laryngeal mask LMA Supreme
88929116|NCT01718795|Active Comparator|Bag-valve mask ventilation|"Bag-valve mask ventilation during CPR, i.e. traditional ventilation during CPR. Airway management with bag-valve mask ventilation and efficient ventilation: yes or no?~Intervention is Bag-valve mask ventilation during CPR"
88929117|NCT01718795|Active Comparator|Laryngeal Tube|"Laryngeal Tube Ventilation during CPR, i.e. the alternative ventilation technique to be compared to the traditional technique. Airway management with laryngeal tube and efficient ventilation: yes or no?~Intervention is Ventilation through laryngeal tube during CPR"
88929118|NCT01718808|Active Comparator|Arm A: Cetuximab|Cetuximab 500 mg/m2 every 2 weeks
88929119|NCT01718808|Active Comparator|Arm B: Cetuximab and Capecitabine|"Cetuximab 500 mg/m2 every 2 weeks plus Capecitabine 1000 mg/m2 (*) bid d1-14 every 3 weeks~* 750 mg/m2 if creatinine-clearance 30-50 ml/min"
88929120|NCT01718821||Advanced upper GI cancer patients|Upper GI cancers include: esophageal cancer, gastric cancer, ampulla vater cancer, pancreatic cancer and cholangiocarcinoma.
88929121|NCT01718834|Active Comparator|prophylactic vaccine|6 monthly doses each of 648 ug of prophylactic vaccine subcutaneously injected to healthy volunteers
88929122|NCT01718834|Active Comparator|therapeutic vaccine|6 monthly doses each of 648 ug subcutaneously injected to chronic HCV patients
88929123|NCT01718847|Experimental|NOV120101 (Poziotinib)|16 mg PO once daily until disease progression or unacceptable toxicity development
88929124|NCT01718860||Postoperative Residual Paralysis|Patients with train-of-four ratio less than 0.9 measured in the postanesthesia care unit
88929125|NCT01718860||No Postoperative Residual Paralysis|Patients with train-of-four ratio greater than 0.9 measured in the postanesthesia care unit
88929126|NCT01718886||Obalon Gastric Balloon|Patients received 1-3 Obalon Gastric Balloons over a period of 12 weeks
88929127|NCT01718899|Experimental|PVX-410, .4 mg dose|Approximately 3 patients will receive 6, bi-weekly, subcutaneous injections of a .4 mg dose of PVX-410 in combination with an intramuscular injection of Hiltonol (poly ICLC). Patients will complete a 12 week treatment phase and then will be followed for safety, immunogenicity and clinical response for 12 months.
88929128|NCT01718899|Experimental|PVX-410, .8 mg dose|Approximately 10 patients will receive 6, bi-weekly, subcutaneous injections of an .8 mg dose of PVX-410 in combination with an intramuscular injection of Hiltonol (Poly ICLC). Patients will complete a 12 week treatment phase and then will be followed for safety, immunogenicity and clinical response for 12 months.
88929129|NCT01718899|Experimental|PVX-410 plus lenalidomide|Approximately 10 patients will receive 6, bi-weekly, subcutaneous injections of an .8 mg dose of PVX-410 in combination with an intramuscular injection of Hiltonol (Poly ICLC). Patients will also receive 3 cycles of lenalidomide. Patients will complete a 12 week treatment phase and then will be followed for safety, immunogenicity and clinical response for 12 months
88929130|NCT01718912|Other|Metronidazole-nystatin oral rinse, regular oral hygiene|Week 1: daily brushing with suction brush. Week two: daily brushing with a mixture of metronidazole-nystatin suspension.
88929131|NCT01718925||Inflammatory Bowel Disease|Ulcerative Colitis and Crohns's disease patients will be recruited from sqeduled outpatient follow-up
88929132|NCT01718925||Irritable Bowel Syndrome|Irritable Bowel patients will be recruited from sqeduled outpatient follow-up
88929133|NCT01718925||Rheumatoid Arthritis|Rheumatoid Arthritis patients will be recruited from sqeduled outpatient follow-up
88929134|NCT01718925||Diabetes Mellitus|Diabetes mellitus patients will be recruited from sqeduled outpatient follow-up
88929135|NCT01718951|Active Comparator|golimumab|golimumab 50mg subcutaneous every 4 weeks
88929136|NCT01718951|Active Comparator|pamidronate|Pamidronate (60mg) intravenously every 4 weeks
88929137|NCT01718964|Other|A|Cortisol 20 mg /Placebo Mannitol
88929138|NCT01718964|Other|B|Placebo Mannitol/Cortisol 20mg
88929139|NCT01718977|Experimental|Body Weight Supported Treadmill Training|BWSTT protocol will consist of training of individuals with complete SCI on a treadmill with a body weight support system. BWSTT is assisted by three individuals who participate in training. One trainer provides support at the hip, and one trainer at each leg. The participant will be fitted with a harness while seated in their wheelchair and then wheeled up a ramp to the treadmill. Cables attached to the harness will be used to hoist the participant into a standing position. Appropriate body weight support will be set according to the suggested Hocoma locomotor training protocol, in which weight is added until the participant is in dynamic support as indicated by the dynamic gauge on the treadmill. Dynamic support is usually indicated at the weight where participants do not have knee-buckling during a static standing position; however, this may not be observed in all severe, motor-complete SCI participants.
89013610|NCT06299501|Experimental|Routine group|Nurses within the routine group receive training and are assigned to inform about family violence at the home visit that takes place when the child is newborn and to by routine ask questions about family violence to mothers at the 6-8 weeks visit to CHC.
89444552|NCT05750550|Experimental|Instrument Assisted Soft Tissue Mobilization Group|With the IASTM device, application will be made over the skin to the triceps surae muscle and plantar fascia for 15 minutes. The application will be made in the prone position. Massage oil will be used to reduce tissue friction before the application.
89444553|NCT05749627|Experimental|Neoantigen peptide vaccine/neoantigen-based DC treatment|Patients assigned to the neoantigen peptide vaccine/neoantigen-based DC treatment group will receive 5-6 subcutaneous injections of neoantigen peptide vaccine or neoantigen-based DC immune preparation within a 14-week treatment period.
89444554|NCT05744843|Experimental|Smartphone-based exercise arm|Eight to twelve week smartphone delivered exercise programme
89444555|NCT05744843|Active Comparator|Stenting Arm|Deep venous stenting as standard of care
88929140|NCT01718977|Active Comparator|Arm Cycle Ergometry Training|"Arm Cycle Ergometry Training ACET will be performed on an arm-cycle ergometer against individually determined levels of resistance. Upright hand cuffs will be used so that the hand will be placed with the thumb pointing downward, and the ergometer will be positioned so that the arm never exceeded the height of the shoulder.~The end objective is for the individual to complete 30-minutes of exercise in 2, 15-minute bouts. For safety reasons, stop criteria for individual sessions will be set and participants will have a rest period of 5 minutes and afterwards asked if they want to stop exercise, or resume the session."
88929141|NCT01718990||Patients with Idiopathic Pulmonary Fibrosis (IPF)|Sixty patients with IPF will be included in this prospective cohort;15 IPF patients per year for years 1-4.
88929142|NCT01718990||Healthy Volunteers|Sixty normal controls will be recruited from volunteers.
88929143|NCT01719029|Experimental|Conventional Diet|Low carbohydrate/higher fat diet: 40% carbohydrate, 45% fat, 15% protein
88929144|NCT01719029|Experimental|Complex Carbohydrate Diet|High complex carbohydrate/lower fat diet: 60% complex carbohydrate, 25% fat, 15% protein
88929145|NCT01719042|Active Comparator|Zofran (8mg)|Participant will take Zofran (8mg) once per day before taking their antibiotic regimen
88929146|NCT01719042|Active Comparator|Ensure|Subject will drink a can of Ensure before taking their antibiotic regimen
88929147|NCT01719068||Workers exposed to asbestos|
88929148|NCT01719081|Experimental|Ultrasound Guided SIJ Injection|Needle placement will be performed under US guidance. Fluoroscopy will be used to confirm needle placement prior to medication injection.
88929149|NCT01719081|Active Comparator|Xray Guided SIJ Injection|Needle placement will be performed under fluoroscopy.
88929150|NCT01719094||Childhood Cancer Surviviors|
88929151|NCT01719094||Adolescent/young adults with no cancer history|
89444556|NCT05744843|No Intervention|Healthy Volunteers|Healthy Volunteers for baseline testing
89444557|NCT05744648|Experimental|Group A|Group A will receive composite resin restoration with Titania nanoparticle incorporated bonding agent
89444558|NCT05744648|Experimental|Group B|Group B will receive composite resin restoration without Titania nanoparticle incorporated bonding agent
89444559|NCT05738954||Second trimester|Second trimester fetal morphology Collect patient data, anonymize and label it. Written informed consent or verbal recorded consent (if the participant lacks the ability to write or sign) will be obtained before performing the MS. In the unlikely event that some of the participants will withdraw their consent after the ultrasound has been performed, the data collected will not be used in the project. Data for publications and dataset will be previously made anonymous following standard practices. The participants will sign a GDPR form.
88929152|NCT01719094||Newly diagnosed cancer patients|
88929153|NCT01719107|Active Comparator|L. reuteri DSM 17938 chewable tablets|The active study product consists of a citrus flavored 450 mg chewable tablet containing freeze-dried L. reuteri DSM 17938. The study product is a convex tablet 10.3 mm in diameter, plain on both sides and with faint spots. It is composed of freeze-dried L. reuteri, isomalt, xylitol, sucrose distearate, hydrogenated palm oil, lemon-lime flavoring and anhydrous citric acid. The total viable count of L. reuteri DSM 17938 is 1x108 live bacteria (CFU)/tablet.
89444560|NCT05726409|Experimental|Mobile application user|Each participant will be sent an email with a link to download a mobile application to access the meal planner function.
89444561|NCT05718674||ECP patient|Patients with chronic or acute GvHD after allogeneic haematopoietic stem cell transplantation undergoing extracorporeal photopheresis
88929154|NCT01719107|Placebo Comparator|Placebo chewable tablets|The placebo study product consists of an identical formulation in all respects except that the live bacteria are excluded.
88929155|NCT01719120|Experimental|Self-help CBT with tel. consultation|Self-help CBT with tel. consultation (SHTC)group will receive telephone consultation provided by the investigator in addition to self-help cognitive-behavioral therapy once per week for 6 consecutive weeks.During the consultation, the investigator will answer questions about the treatment content, monitor whether the subjects read the assigned materials and comply with the tasks and procedures, and provide encouragement and support.
88929156|NCT01719120|Experimental|Self-help CBT|The subjects will receive self-help cognitive-behavioral therapy (SH)once per week for 6 consecutive weeks.
88929157|NCT01719120|No Intervention|Waiting-list control (WL)|Subjects in this group will not receive any kind of treatment during the waiting period. They will receive the treatment identical to the self-help group within 3 months from the baseline.
88929158|NCT01719133|Other|All subjects|placebo histamine T1 T2 T3 T4 T5 T1-T2-T3 T4-T5
88929159|NCT01719159|Experimental|Rituximab|Rituximab, 25 mg, is administrated intrathecal three times one week apart
88929160|NCT01719185|Experimental|Phentermine and B12|Those in the experimental group will take 37.5 mg of phentermine daily as well as receive 1000 mg intramuscular injections of B12 weekly.
88929161|NCT01719185|Active Comparator|Phentermine|Those in the control group will take phentermine 37.5 mg daily as well as receive 1000 mg intramuscular injections of saline weekly.
88929162|NCT01719250|Experimental|Treatment (buparlisib)|Patients receive buparlisib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88929163|NCT01719263|Experimental|Treatment plus Optimal Medical Therapy|Patients will be treated with the InterVapor System and Optimal Medical Therapy
88929164|NCT01719263|Active Comparator|Optimal Medical Therapy|Patients will be treated according to Optimal Medical Therapy
88929165|NCT01719276|Active Comparator|Graded Activity|Exercise treadmill, Strengthening of the lower limbs and trunk
88929166|NCT01719276|Active Comparator|Supervised exercises|Stretching, Strengthening, Motor Control
88929167|NCT01719289|Experimental|PROGRAVIDA|All women in this arm receive a stepped-care program for depression based on psycho-education and problem solving techniques.
88929168|NCT01719289|No Intervention|Treatment as usual|Primary health care professionals in charge of prenatal care are notified by the research team about all women with depression receiving pre-natal care and included in the trial. Primary health care professionals decide how to treat these women without any interference from the research team.
88929169|NCT01719302|Experimental|cohort 1|
88929170|NCT01719315||MDD with Hypersomnia|Participants with Major Depressive Disorder and co-morbid hypersomnia
88929171|NCT01719315||MDD without hypersomnia|Participants with Major Depressive Disorder but without co-morbid hypersomnia
88929172|NCT01719315||BPAD with hypersomnia|Participants with Bipolar Affective Disorder and co-morbid hypersomnia
88929173|NCT01719315||BPAD without hypersomnia|Participants with Bipolar Affective Disorder without co-morbid hypersomnia
88929174|NCT01719315||Primary Hypersomnia|Patients with primary hypersomnia (idiopathic hypersomnia)
88929175|NCT01719315||Primary Insomnia|Patients with primary insomnia
88929176|NCT01719315||Narcolepsy|Subjects with narcolepsy
88929177|NCT01719315||Healthy Controls|healthy participants
88929178|NCT01719328|Experimental|Vinyasa yoga|Group administered 60 minute vinyasa yoga classes delivered twice weekly for 8 weeks
88929179|NCT01719354|Experimental|Community Health center|Aftercare in a community Health center
88929180|NCT01719354|Active Comparator|Control|AFtercare as usual in hospital/Mental health centers of District Psychiatric Service (DPS.
88929181|NCT01719406|Experimental|Intervention, behavioral lifestyle education|Pregnant women will participate in 20 educational sessions designed to promote daily exercise, vegetable and fruit intake, maintain a diet that is relatively lower in fat and rich in whole grains.
88929182|NCT01719406|No Intervention|Control|Standard medical care
88929183|NCT01719419|Experimental|Placebo|Fatty food intake on the day the Modified sham feeding technique with placebo compared to the day modified sham feeding with orlistat.
88929184|NCT01719419|Experimental|Orlistat|Fatty food intake on the day of the modified sham feeding technique with orlistat compared to the day with placebo.
88929185|NCT01719432||Obese patients|
88929186|NCT01719432||Non-obese patients|
88929187|NCT01719445||RFPM/Paper and Pen Method|
89444562|NCT05718063|Experimental|Full MAP for Coaches eLearning Training Course|
89444563|NCT05718063|Active Comparator|Summarized MAP for Coaches eLearning Training Course|
89444564|NCT05710341|Active Comparator|Water with added nitrate|137 mg sodium nitrate or 164 mg potassium nitrate (100mg of nitrate) in a 500 mL water bottle (200 mg/L) provided twice, one with breakfast and one with lunch. This is equivalent to 200mg nitrate in total.
89444565|NCT05710341|Placebo Comparator|Water without added nitrate|137 mg sodium chloride or 164 mg potassium chloride in a 500 mL water bottle provided twice, one with breakfast and one with lunch.
89444566|NCT05708365|Active Comparator|Standard-Lung Protective Ventilation|
89444567|NCT05708365|Active Comparator|Ultra-Lung Protective Ventilation|
89444568|NCT05708209||Group A|20 patients with a diagnosis suggestive of OSCC
88929188|NCT01719471||Smokers|Nicotine dependent individuals otherwise medically healthy
88929189|NCT01719471||Healthy|Medically healthy individuals who do not smoke
88929190|NCT01719510|Other|Positive Group B Streptococcus vaginal sample|"At time of delivery we will performed vaginal swabs in two groups: women tested positive for GBS at 35-37 weeks and women with risk of neonatal infection.~For all women included will be achieved in the delivery room:~a blood sample to the mother and a sampling of umbilical cord blood. Newborns will have a search for GBS (standard culture) in the stools and the pharynx.~For mothers, the collection of milk when breastfeeding."
88929191|NCT01719523|Experimental|EPI-743|EPI-743- Participants will receive 200mg three times a day of EPI-743 for 2 weeks and then receive 300mg of EPI-743 for an additional 2 weeks.
88929192|NCT01719536|Experimental|Icotinib|Icotinib 125mg is administered orally three times per day.
88929193|NCT01719536|Active Comparator|Chemotherapy|Patients in this arm will receive pemetrexed/cisplatin for 4 cycles, of who don't progress will receive maintenance treatment with pemetrexed.
88929194|NCT01719549|Experimental|Dovitinib|
88929195|NCT01719575|Other|Motilitone|take motilitone 30mg three times daily for the first week After 7 day wash-out period, take placebo three times daily for the second week
88929196|NCT01719575|Other|Placebo|take placebo three times daily for the first week After 7 day wash-out period, take motilitone 30mg three times daily for the second week
88929197|NCT01719588||Prolonged release tapentadol|Patients will be taking prolonged release tapentadol hydrochloride as per the product insert approved in Philippines.
88929198|NCT01719601||Immediate release tapentadol|Patients will be taking immediate release tapentadol hydrochloride as per the product insert approved in Philippines.
88929199|NCT01719614|Experimental|Rilpivirine+Metformin|All participants will receive study medications in two sessions in a fixed, sequential order as a session 1 (a single dose of metformin on Day 1) followed by washout period (period when no treatment is received) of 4 days and then session 2 (rilpivirine on Day 5 to Day 17 with a single dose of metformin on Day 15).
88929200|NCT01719627|Experimental|MVC 300 mg|MVC 300 mg in unique dose
88929201|NCT01719627|Active Comparator|TVD 300/200 QD|TVD 300/200 QD during 7 days.
88929202|NCT01719627|Experimental|Maraviroc 600mg|MVC 600mg in unique dose
88929203|NCT01719679|Experimental|School Located Vaccine (SLV) Program|A vaccine program carried out by a community vaccinator will be conducted in a limited number of participating schools. The program will be open to the students enrolled at the participating schools
88929204|NCT01719679|No Intervention|no School Located Vaccine (SLV) Program|Schools that are part of the non-intervention arm of the study will not have a school-located vaccine program.
88929205|NCT01719705|Placebo Comparator|Placebo|receive two identical placebo capsules
88929206|NCT01719705|Active Comparator|Pregabalin 150 mg group|one capsule of pregabalin 150 mg
88929207|NCT01719705|Active Comparator|Pregabalin 300 mg group|two capsules of pregabalin 150 mg
88929208|NCT01719731|Placebo Comparator|Non-Education|This group will not receive the psychosocial education.
88929209|NCT01719731|Active Comparator|Education|This group will receive the psychosocial education
88929210|NCT01719770|Active Comparator|Rocuronium|Continuous infusion of rocuronium with 0,25mg/kg (blinded) for 29 hours after initiation of mild therapeutic hypothermia
88929211|NCT01719770|Placebo Comparator|Placebo|Continuous infusion of sodium-chloride (placebo) and rocuronium bolus (0,25mg/kg)in case of shivering episode (blinded)
89444569|NCT05708209||Group B|20 age-and-sex-matched healthy individuals, as normal controls.
89444570|NCT05708053|Experimental|Metformin Group|"Patients will receive pre-treatment standard and post treatment of care to the procedure plus metformin 500 mg twice daily 7 days before and 6 months after the PCI procedure.~Metformin will be stopped on the same day of the procedure and restored 3 hours after the procedure."
89444571|NCT05708053|No Intervention|Comparator|Patients will receive pre-treatment and post treatment standard of care to the procedure
89444572|NCT05701020|Experimental|Adult women with an abnormal pap test|
89444573|NCT05699122|Active Comparator|The Control Group - Persistent erythema with intact epidermis|The Control Group - Persistent erythema with intact epidermis
89444574|NCT05699122|Experimental|The Experimental Group - Persistent erythema with intact epidermis|The Experimental Group - Persistent erythema with intact epidermis
89444575|NCT05699122|Active Comparator|The Control Group - Erythema with signs of epidermis loss|The Control Group - Erythema with signs of epidermis loss
89444576|NCT05699122|Experimental|The Experimental Group - Erythema with signs of epidermis loss|The Experimental Group - Erythema with signs of epidermis loss
89444577|NCT05678543||Mothers|Pregnant women with pre existing diabetes.
89444578|NCT05678543||Partners|Partners to pregnant women with pre existing diabetes.
89444579|NCT05678543||Offspring|Offspring born to women with pre existing diabetes
89444580|NCT05674292|Experimental|Erchonia Violet Zerona Z6|405nm violet laser light therapy.
89444581|NCT05671523|Experimental|Dry needling|The patients will receive ten sessions, twice a week, for five weeks of dry needling in addition to their conventional physical therapy program (splinting and ultrasound therapy.)
89444582|NCT05671523|Active Comparator|conventional treatment|The patients will receive conventional treatment (splinting and ultrasound therapy) for 5 weeks
89444583|NCT05661188|Experimental|atezolizumab and tiragolumab in concomitancy with standard chemoradiotherapy|"TIRANUS is a Phase II, single-arm, open-label, non-randomized, multicenter clinical trial of atezolizumab and tiragolumab in concomitance with standard chemoradiotherapy as first-line in treatment-naïve, localized squamous cell carcinoma of the anal canal who are candidates for radical chemoradiotherapy. Patients with well differentiated stage I anal margin cancer or previously treated with immunotherapy are not eligible.~All patients receive atezolizumab (1200mg) plus tiragolumab (600 mg) for 2 cycles (Q3W) in concomitance with the 6 weeks of standard scheduled chemoradiotherapy (cisplatin: 60 mg/m² on days 1 and 29; 5-FU: 1000 mg/m² per day on days 1-4 and 29-32; radiotherapy: 1.8 Gy per day / total dose 54 Gy). After the concomitant phase, patients receive atezolizumab and tiragolumab for 6 additional cycles (consolidation phase)."
88929212|NCT01719796|Experimental|Bilateral TAP catheter|Ultrasonography guided bilateral TAP catheter insertion.
88929213|NCT01719796|No Intervention|No TAP catheter|
88929214|NCT01719822|No Intervention|Usual Care|Standard 8-week pulmonary rehabilitation programme with 2 supervised sessions per week and a written home exercise plan/diary.
88929215|NCT01719822|Experimental|Intervention|Standard 8-week pulmonary rehabilitation programme with 2 supervised sessions per week. In addition they will receive a pedometer with a daily step count target set by a physiotherapist and a written home exercise plan/diary.
88929216|NCT01719835|Experimental|Chemotherapy GEM-P|Gemcitabine, Methylprednisolone, Cisplatin
88929217|NCT01719835|Active Comparator|Chemotherapy CHOP|Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone
88929218|NCT01719848||Preoperative airway examination|patients undergoing general anesthesia for any surgery
88929219|NCT01719874|Experimental|TCN-032|single-dose, administered intravenously
88929220|NCT01719874|Placebo Comparator|Placebo (saline)|single-dose, administered intravenously
88929221|NCT01719913|Active Comparator|Low gluten|Poor gluten diet: Participants consume less than 5g gluten per day (estimated to correspond to a gluten intake below the 10th percentile in the population)
88929222|NCT01719913|Placebo Comparator|High gluten|Refined grain/ gluten rich diet : Participants consume more than 25g of gluten per day (estimated to correspond to a gluten intake around the 90th percentile in the population)
88929223|NCT01719926|Experimental|Capecitabine/Oxaliplatin|Patients receiving Capecitabine/Oxaliplatin chemotherapy
88929224|NCT01719926|Experimental|Cisplatin + Xeloda(Capecitabine) or Gemcitabine|Patients receiving Cisplatin regimen
88929225|NCT01719952|Experimental|Carbetocin|Carbetocin 100 µg, given as an intravenous bolus over 30 seconds others names are: duratocin, pabal
88929226|NCT01719952|Active Comparator|Oxytocin|Other names are Pitocin, syntocinon given as an intravenous bolus over 30 seconds by the anaesthetist following clamping of the umbilical cord only in patient that has been randomized to this group.
88929227|NCT01719965||Health Workers|"Worked in SMRU for at least 6 months~Clinic assistants, medics or home visitors"
88929228|NCT01719965||Researchers|"Worked in SMRU for at least 6 months~Physician or scientist"
88929229|NCT01719965||CAB members|- Member of the CAB for at least 3 months
88929230|NCT01719965||Community members|- Lived in the border area (area served by SMRU or Mae Sot) for at least 6 months
88929231|NCT01719965||Research subjects|- Participants who are currently enrolled in an SMRU study
88929232|NCT01719978|Active Comparator|Hyaluronidase|Lower Third Molar Extraction -- 3.6mL 2% Mepivacaine with 1:100,000 epinephrine + Hyaluronidase
88929233|NCT01719978|Placebo Comparator|Placebo|Lower Third Molar Extraction -- Anesthetic: 3.6 mL of the LA 2% HCl mepivacaine with 1:100,000 epinephrine + Placebo (0.9% saline)
89200025|NCT00965770||IUD|Repeat abortion rate in women receiving IUDs immediately post-abortion
89444584|NCT05656469|Experimental|PSY-PGx Group|This is the intervention group. All patients will be treated according to a personalised medication recommendation based on the results of pharmacogenetic testing, following the prespecified dosing guideline. Prescribing physicians will prescribe one of the predefined drugs and will be unblinded for genotype and the resulting metabolisation phenotype.
89444585|NCT05656469|No Intervention|Dosing as usual (DAU) group|This is the control group. In this group, prescribing physicians will also prescribe one of the predefined drugs, but will remain blinded to their patients' genotype and resulting metabolism phenotype for the duration of their participation in the study. After the study, patients in the control group will also be given their pharmacogenetic profile, which will make it possible to personalise their medication if necessary.
89444586|NCT05649787|No Intervention|Usual care|Patients allocated to this arm will receive the usual care plus explicit recommendations for home-based aerobic and strength training.
89444587|NCT05649787|Active Comparator|Supervised aerobic training|Patients allocated to this arm will receive the usual care plus supervised aerobic training
89444588|NCT05649787|Active Comparator|Supervised aerobic plus low to moderate-intensity strenght training|Patients allocated to this arm will receive the usual care plus supervised aerobic and low to moderate-intensity strength training
88929234|NCT01719991|Experimental|Nurse case management and self-management support|The first component of the intervention is the monitoring offered under the case management process. The second component of the intervention consists of group meetings (10-12 people) for self-management support in accordance with the stanford model. A sample of patients in each of the four FMGs (n = 126) will be recruited. These patients will receive the intervention for six months.
89444589|NCT05649787|Active Comparator|Supervised aerobic plus moderate to high-intensity strenght training|Patients allocated to this arm will receive the usual care plus supervised aerobic and moderate to high-intensity strength training.
89444590|NCT05640674|Active Comparator|Opioid Pain Management|Ibuprofen (liquid, 10mg/kg/dose every 6 hours) will be the first line pain medication and Hydrocodone/Acetaminophen (liquid, 0.135mg Hydrocodone/kg/dose every 6 hours) will be used as needed for breakthrough pain.
89444591|NCT05640674|Experimental|Non-Opioid Pain Management|Ibuprofen (liquid, 10mg/kg/dose every 6 hours) will be the first line pain medication and Acetaminophen (liquid, 15mg/kg/dose every 6 hours) will be used as needed for breakthrough pain.
89444592|NCT05629689|Experimental|Part A Cohort 1 - 1 mg dose|1 mg mass dose of GEH200520 Injection with fixed dose of GEH200521 (18F) Injection administered together
89444593|NCT05629689|Experimental|Part A Cohort 2 - 2 mg dose|2 mg mass dose of GEH200520 Injection with fixed dose of GEH200521 (18F) Injection administered together
89444594|NCT05629689|Experimental|Part A Cohort 3 - 4 mg dose|4 mg mass dose of GEH200520 Injection with fixed dose of GEH200521 (18F) Injection administered together
89444595|NCT05629689|Experimental|Part A Cohort 4 - 8 mg dose|8 mg mass dose of GEH200520 Injection with fixed dose of GEH200521 (18F) Injection administered together
89444596|NCT05629689|Experimental|Part A Cohort 5 (optional) - 12 or 15 mg dose|12 or 15 mg mass dose of GEH200520 Injection with fixed dose of GEH200521 (18F) Injection administered together
88929235|NCT01719991|No Intervention|Control group|Patients in the control group (n = 121) will receive the usual care for six months and then the same intervention as the experimental group for the next five months (waiting list control group).
88929236|NCT01720199|Experimental|Intervention group|Preadolescents allocated to the Diario della Salute (DDS) intervention.
88929237|NCT01720199|No Intervention|Control group|
88929238|NCT01720459|Active Comparator|Micronized trans-resveratrol|Micronized trans-resveratrol
89444597|NCT05629689|Experimental|Part A Cohort 6 - Optimal dose|Selected (optimal) mass dose as determined from results of Cohorts 1 through 5 of GEH200520 Injection with fixed dose of GEH200521 (18F) Injection administered together
89013611|NCT06299501|Experimental|Indication group|Nurses within the indication group receive training and are assigned to inform about family violence at the home visit when the child is newborn and to pose questions about family violence on evidence based indication.
88929239|NCT01720459|Placebo Comparator|Placebo|
88929240|NCT01720537|Experimental|Cohort 1|
88929241|NCT01720537|Experimental|Cohort 2|
88929242|NCT01720537|Experimental|Cohort 3|
88929243|NCT01720537|Experimental|Cohort 4|
88929244|NCT01720537|Experimental|Cohort 5|
88929245|NCT01720537|Experimental|Cohort 6|
88929246|NCT01720719|Active Comparator|Vitamin E|Oral Vitamin E 300mg, qd, for 24 weeks
88929247|NCT01720719|Experimental|Atorvastatin|Oral atorvastatin 20mg, qd, for 24 weeks
88929248|NCT01721005|Other|pulse palpation education|The subject is educated to pulse palpation by registered cardiac nurse. The education time is limited to 10 minutes and done according preplanned education model
88929249|NCT01721187||Low disinhibition|fMRI during fed and fasted states
88929250|NCT01721187||High disinhibition|fMRI during fed and fasted states
88929251|NCT01721213||Patients using Trobalt™|Use of Trobalt™ current use or at least one prescription filled within the previous three months.
88929252|NCT01721213||Physicians prescribing AEDs|Physicians (neurologists) who prescribed AEDs at least once in the three months prior to the survey.
88929253|NCT01721213||Physicians Prescribing Trobalt™|Physicians (neurologists) who have had experience of prescribing Trobalt™ specifically, from among those who have prescribed AEDs at least once in the three months prior to the survey.
88929254|NCT01721551|Experimental|Exercise training|HD patients will receive a 9 months intradialytic exercise training program
88929255|NCT01721551|Placebo Comparator|No exercise|HD patients will not participate in any type of systematic exercise training
88929256|NCT01721785||Primary staging group I|"All patients will be treated according to standard practice of the concerning hospital.~Patients in group I are patients that will be stratified for direct surgery (TME) or a short-course of radiotherapy (5x5 Gy) followed by immediate TME.~Group I will undergo only a staging MRI, including gadofosveset-enhanced MRI."
88929257|NCT01721785||Restaging group II|"All patients will be treated according to standard practice of the concerning hospital.~Patients in group II are patients that will be stratified for a long course of chemoradiotherapy.~Group II will undergo a staging MRI, a re-staging MRI and a optional sigmoidoscopy as part of restaging. MRI includes diffusion-weighted imaging and gadofosveset-enhanced MRI."
88929258|NCT01721824|Experimental|IPS-MA|"The IPS-MA method consists of five basic services for the participants. 1)Individual mentor support, based on psychiatric knowledge. 2)Coordination by the mentor of activities, internal as well as from external providers. 3)Career counseling aimed at people with mental illnesses. 4)Impartial help to clarify private economy. 5) Contact to employers to help participants obtain jobs, and keep them.~Participants will receive the IPS-MA method in addition to treatment as usual."
88929259|NCT01721824|No Intervention|Control group|"Participants randomised to the control group will receive treatment as usual only. This means the standard support offered by the social- and health services in Denmark."
88929260|NCT01721928||ICU patients with AKI|ICU patients with AKI treated with continuous venovenous hemodialysis
88929261|NCT01721928||ICU patients without AKI|ICU patients without AKI defined as RIFLE group O and R
88929262|NCT01722214|Experimental|Group Adalimumab|A total of 53 patients with moderate to severe psoriasis will randomized in the adalimumab group. At Day 0 patients will receive adalimumab. It will be administered sub-cutaneously as described in the Canadian product monograph (80mg followed by 40mg at Week 1 and 40mg every other week). At Week 16, all patients will received two injections of placebo. As of Week 17, patients randomized to the adalimumab group will receive 40 mg adalimumab every other week until Week 51.
88929263|NCT01722214|Placebo Comparator|Placebo Group|A total of 53 patients with moderate to severe psoriasis will be randomized in the placebo group. At Day 0 these patients will receive the placebo. It will be administered sub-cutaneously as described in the Canadian product monograph of adalimumab. At Week 16, all these patients will received two injections of adalimumab. As of Week 17, patients randomized to the placebo group will receive 40 mg adalimumab every other week until Week 67.
88929264|NCT01722422|Placebo Comparator|normoxia and isotonic saline|Administration of oxygen in order to maintain SaO2 between 88% and 95%. Fluid resuscitation if needed with isotonic saline during 3 days.
88929265|NCT01722422|Active Comparator|normoxia and 3% hypertonic saline|Administration of oxygen in order to maintain SaO2 between 88% and 95%. Fluid resuscitation if needed with 3% hypertonic saline during 3 days.
88929266|NCT01722422|Active Comparator|hyperoxia and isotonic saline|"Administration of oxygen with FiO2 = 100% during the first 24 hours and after switch oxygen administration to usual care.~Fluid resuscitation if needed with isotonic saline during 3 days."
88929267|NCT01722422|Active Comparator|hyperoxia and 3% hypertonic saline|"Administration of oxygen with FiO2 = 100% during the first 24 hours and after switch oxygen administration to usual care.~Fluid resuscitation if needed with 3% hypertonic saline during 3 days."
88929268|NCT01722474|Experimental|ASI Device|Study Participants will attend the research clinic one time (one visit) for the vascular testing. Each instrument/assessment will be run sequentially starting with the Arterial Stiffness Screening Device, then followed by SphygmoCor system, which will then be followed by the CR-2000 CV Profiler, then finally the VP-1000.
88929269|NCT01722526|Experimental|Recombinant human acid sphingomyelinase|Participants will receive rhASM of an initial dose of 0.1 mg/kg, followed by several dose escalations, as tolerated, up to 3.0 mg/kg. All doses are given 2 weeks apart.
88929270|NCT01722578|Experimental|L-ornithine L-aspartate|L-ornithine L-aspartate (6 ampules, each ampule containing 5 grams of the drug in 10 ml solution) to be diluted in 440 ml of Dextrose 5% (to make a total of 500 ml of solution), as intravenous infusion at the rate of 21 ml/hour, over 24 hours, for 5 days
88929271|NCT01722578|Placebo Comparator|Placebo (sterile water)|Placebo (sterile water, 6 ampuoles of 10 ml each) diluted in 440 ml of Dextrose 5%, as intravenous infusion at the rate of 21 ml/hour, over 24 hours, for 5 days
88929272|NCT01722786||DOA|"Expected number of patients estimated by study duration~N= 90 patients treated with direct oral anticoagulants (DOA) with acute bleeding~N= 40 patients treated with direct oral anticoagulants (DOA) with urgent surgical intervention"
88929273|NCT01722786||VKA|"Expected number of patients estimated by study duration~N= 90 treated with vitamin K antagonists (VKA) with acute bleeding~N= 40 patients treated with vitamin K antagonists (VKA) with urgent surgical intervention"
88929274|NCT01723007|Experimental|Other: Apple|Women were supplemented with apples. Sixteen women were asked to ingest three apple daily between meals ( approximately 120g kcal) between meals (breakfast, lunch and dinner).
88929275|NCT01723007|Active Comparator|Other: oatmeal cookies|A another group with nineteen women were asked to ingest three oatmeal cookies a day, approximately 60g and similar caloric content to experimental group (approximately 120 kcal) between meals (breakfast, lunch and dinner).
88929276|NCT01723007|Active Comparator|Other: Pear|Women were supplemented with pear. Sixteen women were asked to ingest daily three pears (approximately 120 kcal) between meals daily (breakfast, lunch and dinner).
88929277|NCT01723280||80% oxygen group|
88929278|NCT01723280||30% oxygen group|
88929279|NCT01723423||Expander/Implant|Patients receiving expander/implant breast reconstruction procedures.
88929280|NCT01723423||Lat Dorsi|Patients receiving latissimus dorsi breast reconstructions with or without implant.
89013612|NCT06299501|Active Comparator|Treatment as usual|Nurses within the treatment as usual group do not receive training but ask questions when they suspect ongoing violence in the family.
88929281|NCT01723423||PTRAM|Patients receiving pedicle transverse rectus abdominis musculocutaneous (PTRAM)breast reconstruction.
88929282|NCT01723423||FTRAM|Patients receiving free transverse rectus abdominis musculocutaneous (FTRAM.)
88929283|NCT01723423||DIEP|Patients receiving deep inferior epigastric perforator (DIEP) breast reconstructions.
88929284|NCT01723423||SIEA|Patients receiving superficial inferior epigastric artery (SIEA)breast reconstruction.
88929285|NCT01723423||S-GAP|Patients receiving superior gluteal artery perforator breast reconstruction.
88929286|NCT01723423||I-GAP|Patients receiving inferior gluteal artery perforator breast reconstruction.
88929287|NCT01723475|Experimental|BAY2010112 (s.c.)|
88929288|NCT01723475|Experimental|BAY2010112 (c.i.v.)|
88929289|NCT01723852|Active Comparator|Vitamin D supplement|Vitamin D supplement according to national guidelines (10 ug/day) from 2 weeks to 2 years of age
88929290|NCT01723852|Active Comparator|Vitamin D supplement at 30 ug/day|Vitamin D supplement at 30 ug/day from 2 weeks to 2 years of age
88929291|NCT01724229|Other|treatment with OTC drug products|"Body Wash & Shampoo applied directly to the skin or cloth; soiled area gently wiped clean. No rinsing necessary.~Moisture Barrier Cream: Once area cleansed and dried thoroughly, a thin coat is gently applied to the area of the skin exposed to moisture twice daily for two weeks or as directed by doctor.~2-in-1 Cleanser: applied directly to the skin or a cloth and skin gently wiped clean. No rinsing necessary.~Antifungal Cream: Once reddened area cleansed and dried thoroughly a thin layer is applied over the affected area twice daily for two weeks or as directed by doctor."
88929292|NCT01724450|Active Comparator|Carvedilol|
88929293|NCT01724450|Placebo Comparator|Control|
88929294|NCT01724463||Electronically Screened Sepsis Patients|Patients between the ages 1 month and 18 years admitted to the hospital or presenting to the Emergency Department (ED) with clinical signs of Systemic Inflammatory Response Syndrome (SIRS) electronically screened for severe sepsis. Patients screened as positive will receive an evidence based goal directed severe sepsis management bundle.
88929295|NCT01724567|Experimental|Weight Loss|12 weeks of Low Calorie Diet to obtain a 10 - 15 % weight loss. Followed by 40 weeks on a weight maintenance diet and interval training 2 times a week.
88929296|NCT01724567|Experimental|Interval Training|12 weeks of interval training 3 times a week followed by 40 weeks of interval training 2 times a week.
88929297|NCT01724684|Other|Telehealth program|Telehealth program service
88929298|NCT01724684|Other|Usual care|Usual care service
88929299|NCT01724723|Experimental|Entecavir group|Study treatment for only treatment group: entecavir (BARACLUDE®) 0.5 mg per day during and within 6 months after anti-tuberculous treatment.
88929300|NCT01724723|No Intervention|Control group|Not receiving entecavir (BARACLUDE®)
88929301|NCT01724762|Experimental|Nursing orientation|Patients who received nursing orientation and read the informative manual concerning bed bath
88929302|NCT01724892|Active Comparator|Loteprednol etabonate|Topical Loteprednol etabonate eye drop 0.5%, 4 times a day, 3 weeks
88929303|NCT01724892|Active Comparator|Dexamethasone|Topical Dexamethasone eye drop 0.1%, 4 times a day, 3 weeks
88929304|NCT01725139|Experimental|Cohort 1-GSK2126458|Subjects will be randomized in 3:1 ratio to receive either GSK2126458 (0.25 mg twice daily [bid]) or placebo for approximately 8 days (7 to 10 days dosing)
88929305|NCT01725139|Placebo Comparator|Cohort 1-Placebo|Subjects will be randomized in 3:1 ratio to receive either GSK2126458 bid or matching placebo for approximately 8 days (7 to 10 days dosing)
88929306|NCT01725139|Experimental|Cohort 2-GSK2126458|Subjects will be randomized in 3:1 ratio to receive either GSK2126458 bid or placebo for approximately 8 days (7 to 10 days dosing). GSK2126458 dose will be decided from Cohort 1 and which could be escalated or deescalated or repeated from Cohort 1 dosing.
88929307|NCT01725139|Placebo Comparator|Cohort 2-Placebo|Subjects will be randomized in 3:1 ratio to receive either GSK2126458 bid or matching placebo for approximately 8 days (7 to 10 days dosing).
88929308|NCT01725139|Experimental|Cohort 3- GSK2126458|Subjects will be randomized in 3:1 ratio to receive either GSK2126458 bid or placebo for approximately 8 days (7 to 10 days dosing). GSK2126458 dose will be decided from Cohort 2 and which could be escalated or deescalated or repeated from Cohort 2 dosing.
88929309|NCT01725139|Placebo Comparator|Cohort 3-Placebo|Subjects will be randomized in 3:1 ratio to receive either GSK2126458 bid or matching placebo for approximately 8 days (7 to 10 days dosing).
88929310|NCT01725139|Experimental|Cohort 4- GSK2126458|Subjects will be randomized in 3:1 ratio to receive either GSK2126458 bid or placebo for approximately 8 days (7 to 10 days dosing). GSK2126458 dose will be decided from Cohort 3 and which could be escalated or deescalated or repeated from Cohort 3 dosing.
88929311|NCT01725139|Placebo Comparator|Cohort 4- Placebo|Subjects will be randomized in 3:1 ratio to receive either GSK2126458 bid or matching placebo for approximately 8 days (7 to 10 days dosing).
88929312|NCT01725139|Experimental|Cohort 5- GSK2126458|Subjects will be randomized in 3:1 ratio to receive either GSK2126458 bid or placebo for approximately 8 days (7 to 10 days dosing). GSK2126458 dose will be decided from Cohort 4 and which could be escalated or deescalated or repeated from Cohort 4 dosing.
88929313|NCT01725139|Placebo Comparator|Cohort 5- Placebo|Subjects will be randomized in 3:1 ratio to receive either GSK2126458 bid or matching placebo for approximately 8 days (7 to 10 days dosing).
88929314|NCT01725139|Experimental|Cohort 6- GSK2126458|Subjects will be randomized in 3:1 ratio to receive either GSK2126458 bid or placebo for approximately 8 days (7 to 10 days dosing). GSK2126458 dose will be decided from Cohort 4 and which could be escalated or deescalated or repeated from Cohort 5 dosing.
88929315|NCT01725139|Placebo Comparator|Cohort 6- Placebo|Subjects will be randomized in 3:1 ratio to receive either GSK2126458 bid or matching placebo for approximately 8 days (7 to 10 days dosing).
89444598|NCT05629689|Experimental|Part B|Selected (optimal) dose of GEH200520 Injection from Part A with fixed dose of GEH200521 (18F) Injection administered together in 3 sequential repeat imaging visits
89444599|NCT05620784|Experimental|Loop Diuretic (Furosemide)|This group of patients will receive 20mg of IV furosemide during the morcellation phase of their HoLEP.
89444600|NCT05620784|No Intervention|Control|This group of patients will not receive 20mg of IV furosemide during the morcellation phase of their HoLEP.
89444601|NCT05619471|Experimental|Subjects with Skin conditions that are candidates for biopsy|
88929316|NCT01725256|Experimental|80mg AIR001 four times daily|80mg AIR001 nebulized four times daily for 16 weeks
89444602|NCT05596760|Experimental|Jumpstart Guide|The Jumpstart Guide is developed using automated methods. It summarizes the presence/absence of POLST, advance directives and DPOA documentation. The Jumpstart Guide also provides tips for conducting discussion about goals of care.
89444603|NCT05596760|No Intervention|Usual Care|Clinicians of patients in the Usual Care arm will not receive a Jumpstart Guide.
89444604|NCT05595629|Active Comparator|Text-message based remote blood pressure monitoring|Women in this group will receive current standard of care: remote blood pressure monitoring via text message. Specifically, they will receive automatic blood pressure cuffs, instructions how to obtain their blood pressures and log them into our Electronic Medical Record, and contact information for the nurse practitioner and community health worker managing the program. The NP will respond via text message to each individual measurement with instructions as to next steps.
89444605|NCT05595629|Experimental|App-based remote blood pressure monitoring|Women in this group will receive a Bluetooth-enabled automatic blood pressure cuff that synchs automatically to a smartphone application that incorporates Artificial Intelligence to respond to each recorded measurements with recommended next steps and also document the measurement and response in a secure platform. This affiliated smartphone application will also contain education on hypertension management. Upon receipt of the blood pressure cuff, participants will be instructed to set up the program/app.
89444606|NCT05586477|Other|Intervention Order (Placebo - Diphenhydramine)|On separate days, participants will march on a treadmill for 60 minutes at a fixed rate of oxygen consumption (~1.75 liters of oxygen consumption per minute) in ~28°C and 30% relative humidity
89444607|NCT05586477|Other|Intervention Order (Diphenhydramine -Placebo)|On separate days, participants will march on a treadmill for 60 minutes at a fixed rate of oxygen consumption (~1.75 liters of oxygen consumption per minute) in ~28°C and 30% relative humidity
89444608|NCT05578651||SternaLock XP|Median sternotomy with rigid plate fixation (SternaLock XP) as the sole closure method
89444609|NCT05577338|Experimental|training group|Theory of Mind psychotherapy psychotherapy
89444610|NCT05577338|Active Comparator|active control group|receive disease-related health knowledge
88929317|NCT01725256|Experimental|46mg AIR001 four times daily|46mg AIR001 nebulized four times daily for 16 weeks
88929318|NCT01725256|Experimental|80mg AIR001 once daily|80mg AIR001 nebulized once daily for 16 weeks
88929319|NCT01725269|Experimental|80mg AIR001, nebulized four times daily|AIR001, 80 mg into nebulizer
88929320|NCT01725269|Experimental|46 mg AIR001, nebulized four times daily|AIR001, 46 mg into nebulizer
88929321|NCT01725269|Experimental|80mg AIR001, nebulized once daily|AIR001, 80 mg into nebulizer
89444611|NCT05572450|Experimental|Infectious Titre 1|Dose Arm 1 (Part A): Approximately 10^5.5 TCID50/mL (titre may be adjusted based on stock titre)
89444612|NCT05572450|Experimental|Infectious Titre 2|Dose Arm 2 (Part A): Approximately 10^4.5 TCID50/mL (titre may be adjusted based on stock titre)
89444613|NCT05572450|Experimental|Infectious Titre 3|Optional Dose Arm 3 (Part B): to be determined (TBD), depending on outcome of Part A
89444614|NCT05572450|Experimental|Infectious Titre 4|Optional Dose Arm 4 (Part B): TBD, depending on outcome of Part A
89444615|NCT05570266||Cases|"Cases are taken by recruiting women who:~have no first degree family history of breast or ovarian cancer~are or had been diagnosed with primary breast cancer or tested positive for high penetrance genes (e.g. BRCA 1/2)~menarche age >12 years old~premenopausal"
89444616|NCT05570266||Cohort|"Controls are taken from clients who visited Breast Cancer Care Alliance (BCCA) and:~have no family history of breast or ovarian cancer~premenopausal~menarche age >12 years old~asymptomatic~do not have any first-degree relationship with the cases~consented for the study and follow up"
89444617|NCT05568706|Experimental|EDP-938|EDP-938 800 mg, once daily
88929322|NCT01725438|Experimental|Pregnant women accepting an invasive prenatal diagnosis|Pregnant women accepting an invasive prenatal diagnosis and a sample blood (non invasive diagnosis)
88929323|NCT01725828|Experimental|External Palpation group|External Palpation group will consist of 109 patients, who's CTM will be marked using traditional palpation technique of identifying the Cricothyroid membrane.
88929324|NCT01725828|Experimental|Ultrasound group|"Ultrasound group will consist of 114 patients, who's CTM will be marked using, ultrasonography to identify the CTM.~The Intervention by using the Ultrasound to determine the CTM."
88929325|NCT01726660|Experimental|IMT Robotic Arm Therapy: Aim training|Alternating sessions of planar (shoulder/elbow) and wrist robotic therapy programmed for aim training, 3x/week for 12 weeks.
88929326|NCT01726660|Experimental|IMT Robotic Arm Therapy: Smoothness Training|Alternating sessions of planar (shoulder/elbow) and wrist robotic therapy programmed for smoothness training, 3x/week for 12 weeks.
88929327|NCT01726660|Experimental|IMT Robotic Arm Therapy: Impairment training|Alternating sessions of planar (shoulder/elbow) and wrist robotic therapy programmed for whole-arm, impairment training, 3x/week for 12 weeks.
89444618|NCT05568706|Placebo Comparator|Placebo|Matching placebo, once daily
89444619|NCT05547919|Experimental|Gastrointestinal tumors histologically positive for PSMA|Tumor biopsy at baseline to establish diagnosis and to identify PSMA expression in an ex-vivo setting. Patients with ex-vivo PSMA expression receive a multimodal imaging approach: This includes a PSMA-targeted PET/CT (18F-PSMA) at baseline and conventional imaging.
89444620|NCT05538871||Degenerative scoliosis|Diagnosis of degenerative (De novo) scoliosis,
89444621|NCT05538871||Adult idiopathic scoliosis|Diagnosis of idiopathic scoliosis,
88929328|NCT01726660|Experimental|IMT Robotic Arm Therapy: Functional training|Alternating sessions of planar (shoulder/elbow) and wrist robotic therapy programmed for whole arm, functional training, 3x/week for 12 weeks.
88929329|NCT01726751|Other|Early off-stimulation (group B)|Late SCS treatment. After 2 weeks without SCS, randomization to either of two study arms: Group B starting with no SCS for a period of six weeks (A) followed by a period of active SCS (on-period for 6 weeks). Thereafter, free stimulation for 12 weeks, followed by a concluding 2 sweeks of no SCS.
88929330|NCT01726751|Other|Early on-stimulation (group A)|Early SCS treatment. After 2 weeks without SCS, randomization to either of two study arms: Group A starting with SCS for a period of six weeks (A) followed by a period of no SCS (off-period for 6 weeks). Thereafter, free stimulation for 12 weeks, followed by a concluding 2 sweeks of no SCS.
88929331|NCT01727245|Other|Obese|Obese patients undergoing gastric by-pass surgery
88929332|NCT01727245|Other|Control group|Cholecystectomy and anti-reflux surgery
88929333|NCT01727362|Active Comparator|Usual care + acupuncture|
88929334|NCT01727362|Active Comparator|Usual care|
88929335|NCT01727427||Anticoagulants, aspirin|Parenteral or oral anticoagulants: heparin, fondaparinux, vitamin-K antagonists, direct thrombin inhibitors, direct factor Xa inhibitors; aspirin. Any dosage, frequency and duration
88929336|NCT01727609|Active Comparator|Slower milk feed increment|Increase milk feeds by 18 ml/kg/day until on full milk feeds (tolerating 150 ml/kg/day for 3 consecutive days)
88929337|NCT01727609|Experimental|Faster milk feed increment|Increase milk feeds by 30 ml/kg/day until on full milk feeds (tolerating 150 ml/kg/day for 3 consecutive days)
88929338|NCT01727661||type 1 diabetes mellitus|"exercise testing with near-infrared spectroscopy~lung function testing~quality of life"
88929339|NCT01727661||healthy controls|"exercise testing with near-infrared spectroscopy~lung function testing~quality of life"
88929340|NCT01727778|Experimental|Antibody treatment|Intravenous infusion of the anti-GRP78 monoclonal IgM antibody PAT-SM6 group 1: 0.3mg/kg Group 2: 1.0mg/kg Group 3: 3mg/kg Group 4: 6mg/kg
88929341|NCT01727999||TPO responder|Patients with therapeutic response to TPO
88929342|NCT01727999||TPO non-responder|Patients not responding to TPO agonists
88929343|NCT01728025|Experimental|Ranolazine|Ranolazine 500-1000 mg twice a day as tolerated
88929344|NCT01728207|Experimental|IMMU-114|IMMU-114 will be administered subcutaneously (under the skin) once or twice weekly for 3 weeks followed by one week of rest. Treatment cycles will continue until disease worsening or toxicity. Various dose levels will be studied.
88929345|NCT01728389|Experimental|Intrabone transplantation|Direct intrabone transplantation procedure of peripheral blood haematopoietic stem cells form HLA-matched sibling donors in patients with myeloid and lymphoid malignancies.
88929346|NCT01728415|Experimental|A: Exercise|High intensity interval exercise training (3 x 3 minutes of intensity abow 85% og Heart rate peak)
88929347|NCT01728415|Active Comparator|B: Execise|Moderate continuous exercise training
88929348|NCT01728415|No Intervention|C: Controll|Usual care without exercise training
88929349|NCT01728675|Experimental|Young group|Participants will underwent two isokinetic eccentric exercise sessions
88929350|NCT01728675|Experimental|Elderly group|Participants will underwent two isokinetic eccentric exercise sessions
88929351|NCT01728870|Experimental|Unique Diet+Partial Enteral Nutrition|"Unique Diet+Partial Enteral Nutrition (PEN): This group will receive as follows:~Weeks 1-6: 50% of dietary needs from PEN (Modulen, Nestle) and 50% from a limited whole food diet.~Weeks 7-12: 25% of dietary needs from PEN (Modulen, Nestle) and 75% from a limited whole food diet."
88929352|NCT01728870|Active Comparator|Exclusive Enteral Nutrition (Modulen)|"Exclusive Enteral Nutrition(EEN): This group will receive as follows:~Weeks 1-6: EEN(100% of dietary needs from Modulen) Weeks 7-12: 25% of dietary needs from Modulen and 75% from a free diet."
88929353|NCT01729195|Experimental|Single-arm|The syndesmosis injury of the patients will be fixed with a ciprofloxacin containing bioabsorbable PLGA bone screw or a stainless steel metal screw
88929354|NCT01729351||IPDI EF HFA-BDP|Patients initiating inhaled corticosteroid therapy as extra-fine HFA-BDP MDI at the index date
88929355|NCT01729351||IPDI FP|Patients initiating inhaled corticosteroid therapy as FP via pMDI at the index date
88929356|NCT01729351||IPDI NEF HFA-BDP|Patients initiating inhaled corticosteroid therapy as non-extra-fine HFA-BDP via pMDI at the index date
88929357|NCT01729351||IPDA EF HFA-BDP|Patients increasing inhaled corticosteroid therapy as extra-fine HFA-BDP MDI at the index date
88929358|NCT01729351||IPDA FP|Patients increasing inhaled corticosteroid therapy as FP MDI at the index date
88929359|NCT01729351||IPDA NEF HFA-BDP|Patients initiating inhaled corticosteroid therapy as non-extra-fine HFA-BDP via pMDI at the index date
88929360|NCT01729741|No Intervention|No drain|No drain was inserted after Thyroid surgery
88929361|NCT01729741|Experimental|Drain|A drain was inserted after thyroid surgery
88929362|NCT01729780|Sham Comparator|Sham EEG-NF|Subjects who will undergo sham EEG-NF.
88929363|NCT01729780|Active Comparator|True EEG-NF|Subjects who will undergo true EEG-NF training in order to lessen their anxiety symptoms.
88929364|NCT01729910|Experimental|Parent education / behavioral counseling|Parents of children in the intervention group will be invited to participate in four group visits and two individual visits with their primary care provider as well as four follow-up phone calls with study personnel (project coordinator or registered dietician). Providers and study personnel will be trained in the use of the NIH We Can! curriculum for group visits and brief motivational interviewing for individual visits and follow-up phone calls.
88929365|NCT01729910|Placebo Comparator|Usual Care|Parents of children in the control group will receive usual care from their primary care provider as well as a copy of the NIH We Can! Parent Handbook.
89444622|NCT05538871||Degenerative scoliosis - matched controls|Population sample matched to the degenerative scoliosis group.
88929366|NCT01729936|Experimental|Sitting time Change Intervention|"Sitting time Change Intervention: recommendation to substitute Sitting time by doing the regular activities standing or walking.~Duration: 6 month. Frequency: 1 time each 15 days during the first 4 month and 1 time each month the last 2 months."
88929367|NCT01729936|No Intervention|Active Control|Control visits to the Primary Health Care Center
88929368|NCT01730001|Active Comparator|Early Intubation|Early intubation is defined as prehospital intubation on the scene of the patient illness/injury, or where the EMS physician first meets the patient (e.g en route to hospital). Intubation includes drug assisted and/or rapid sequence intubation (RSI) with endotracheal tube.
88929369|NCT01730001|Active Comparator|Late intubation|Late intubation is defined as on-scene prehospital high-flow (> 10 L/min) supplemental oxygen by mask, assisted bag-mask-ventilation by EMS physician if required and stable recovery position during transport to hospital. Intubation should be done on arrival in the emergency department.
88929370|NCT01730014|Experimental|Trial part 1|
88929371|NCT01730014|Experimental|Trial part 2, treatment A|
88929372|NCT01730014|Experimental|Trial part 2, treatment B|
88929373|NCT01730066|Experimental|Probiotics|Patients will gurgle and swallow a mixture of probiotic bacteria preoperatively and given the same study product enterally postoperatively
88929374|NCT01730066|No Intervention|Control|No intervention.What has been the standard procedure so far
88929375|NCT01730157|Experimental|Treatment (yttrium Y 90 glass microspheres, ipilimumab)|Patients undergo radioembolization with yttrium Y 90 glass microspheres via hepatic arterial infusion on day 1. Beginning on day 29, patients also receive ipilimumab IV over 90 minutes. Treatment with ipilimumab repeats every 3 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
88929376|NCT01730183|Experimental|Bone marrow derived stem cells|Autologous Bone Marrow derived Stem Cells(BMSC) transplanted intrathecally into patients with spinal cord injury.
88929377|NCT01730196|Experimental|Fit Body and Soul|Faith-based adaptation of the Group Life Style Program
88929378|NCT01730196|Active Comparator|Wellness education|A health education program developed from the list of topics provided by the Centers for Disease Control and Prevention (CDC) Guide to Community Prevention Services
88929379|NCT01730209|Experimental|Everolimus|Everolimus once daily for 1 year, titration to trough levels of 5-10 ng/ml
88929380|NCT01730209|Placebo Comparator|Placebo|Placebo treatment for 1 year. Tablets will be identical to everolimus tablets.
88929381|NCT01730222|Experimental|PAXG regimen|cisplatin at 30 mg/m2 on days 1 and 15, nab-paclitaxel at the RP2D on days 1 and 15, capecitabine at 1250 mg/ m2 days 1-28, gemcitabine at 800 mg/ m2 on days 1 and 15 every 4 weeks
88929382|NCT01730222|Active Comparator|gemcitabine + nab-paclitaxel|gemcitabine at 1000 mg/ m2 on days 1, 8 and 15 every 4 weeks + nab-paclitaxel at 125 mg/ m2 on days 1, 8 and 15 every 4 weeks
88929383|NCT01730235||Case Group|Group receiving access to MyMediHealth web site.
88929384|NCT01730235||Control Group|Children completing baseline and week two measures, but without any additional intervention.
88929385|NCT01730248|Experimental|JAK Inhibitor Naive|Two treatment periods applicable to all patients; Treatment Period (6 cycles / 28 days per cycle) and Extension Period ( 6 or more cycles of 28 days, with visits every 28days for 6 cycles and then visits every 12 weeks) following the treatment period dependent on patient continued eligibility. Two Study Phases: Dose Escalation Phase to determine maximum tolerated dose (MTD) / Recommended Phase II dose (RPIID) & an Expansion Phase
88929386|NCT01730248|Experimental|Prior JAK Inhibitor|Two treatment periods applicable to all patients; Treatment Period (6 cycles / 28 days per cycle) and Extension Period (6 or more cycles of 28 days, with visits every 28 days for 6 cycles then visits every 12 weeks) following the treatment period dependent on patient continued eligibility. Two Study Phases: Dose Escalation Phase to determine MTD / RPIID & an Expansion Phase
88929387|NCT01730261|Experimental|Online Emotional Regulation Treatment|Participants will receive 24 treatment sessions, with baseline, post-treatment screening and follow-up screening, and bi-weekly assessments
88929388|NCT01730274||patients|children operated on a cerebellar tumor
88929389|NCT01730274||healthy subjects|healthy volunteers
88929390|NCT01730287|Experimental|Control|No lining applied in group1.
88929391|NCT01730287|Experimental|CEM cement|CEM cement applied over remained caries in group4.
88929392|NCT01730287|Experimental|Mineral Trioxide Aggregate (MTA)|MTA applied over remained caries in group3.
88929393|NCT01730287|Experimental|Calcium Hydroxide|Calcium Hydroxide applied over remained caries in group2.
88929394|NCT01730326|Experimental|Paracetamol|Paracetamol which will be given after randomization will be diluted in serum physiologic and will be given as intravenous rapid infusion.
88929395|NCT01730326|Active Comparator|Dexketoprofen|Dexketoprofen which will be given after randomization will be diluted in serum physiologic and will be given as intravenous rapid infusion.
88929396|NCT01730352|No Intervention|H. pylori no treatment|Observational group, with clinical and platelet count follow-up
88929397|NCT01730352|Experimental|H. pylori triple therapy|Triple therapy for H. pylori eradication: clarithromycin 15mg/kg, amoxicillin 50mg/kg, furazolidone 7mg/kg and/ or doxycycline 4,4mg/kg (all 2 times per day), with a proton pump inhibitor for 14 days.
88929398|NCT01730365||Histological biopsy procedures|Patients with a suspicious lesion in lung or liver or breast who are planned for a standard core biopsy procedure. And patients planned for percutaneous RFA (Radiofrequency Ablation) of colorectal liver metastasis
88929399|NCT01730391||Study cohort|Subjects visiting the hospital with suspected bacterial meningitis in The Philippines and Vietnam.
89444623|NCT05538871||Idiopathic scoliosis - matched controls|Population sample matched to the idiopathic scoliosis group.
89444624|NCT05537792|Experimental|Smart Robotic Knee/Ankle Prothesis|This study will be conducted on a sample population of individuals with transfemoral amputation (single arm). Each participant will test with each condition of the study (repeated measures).
89444625|NCT05535023|Experimental|SAR444245 plus Cemiplimab|Participants will receive SAR444245 and Cemiplimab by vein on Day 1 of Cycles 1 and 2. Each drug's infusion should take about 30 minutes.
89444626|NCT05506891|Experimental|Astragalus group|
88929400|NCT01730404|Experimental|CHF6001|CHF6001 DPI (Dry Powder Inhaler) once daily
88929401|NCT01730404|Active Comparator|Roflumilast|Roflumilast, tablet, once daily
88929402|NCT01730404|Placebo Comparator|placebo|Placebo
88929403|NCT01730417|Experimental|Radiation dosimetry|no carrier added metaiodobenzylguanidine
88929404|NCT01730430||Collection of CSF|"Those with Alzheimer's disease~Those with non-Alzheimer's disease dementia~Healthy elderly volunteers"
88929405|NCT01730443||On progesterone treatment|The group assigned to progesterone treatment.
88929406|NCT01730443||group assigned to placebo|The group that will not be receiving progesterone treatment
88929407|NCT01730456|Experimental|RoActemra/Actemra|
88929408|NCT01730469|Experimental|AT1001 150 mg|Each subject will receive a single oral dose of AT1001 150 mg administered orally with 240 mL room temperature water after at least a 4-hour fast
88929409|NCT01730482|Experimental|[14C] AT1001 Arm|Each subject will receive a single oral dose of 150 mg of [14C] AT1001 as an aqueous solution containing 1 μCi AT1001 on Study Day 1.
88929410|NCT01730495|Experimental|Etanercept|
88929411|NCT01730508||Chronic Hepatitis B Participants|Hepatitis B e antigen (HBeAg) chronic hepatitis B (CHB) participants who received treatment with pegylated interferon alfa (peginterferon alfa) according to China labeling and China standard of care and were followed up to 1 year after treatment cessation.
88929412|NCT01730521||Difference in Iron bioavailabilty exercise and resting phase|the subjects will act as their own control during the study
88929413|NCT01730560|Experimental|Arm 1:Treatment A|Treatment A (active) followed by treatment B (neutral)
88929414|NCT01730560|Experimental|Arm 2: Treatment B|Treatment B (neutral) followed by treatment A (active)
88929415|NCT01730573|Active Comparator|Interscalene block|This arm patients will receive inter scalene block which will be ultrasound and nerve stimulator guided.
88929416|NCT01730573|Active Comparator|Suprascapular and Axillary nerve block|This arm patients will receive Suprascapular and axillary nerve blocks which will be ultrasound guided and nerve stimulator guided.
89444627|NCT05506891|Active Comparator|Physical therapy group|
89444628|NCT05505500||Parent/Guardian of child with Nephrotic Syndrome (NS)|This group will help create the Observer Reported Outcome (ObsRO) tool.
89444629|NCT05505500||Person with Nephrotic Syndrome (NS)|This group will help create the Patient Reported Outcome (PRO) tool.
89444630|NCT05503316|Experimental|GRAIL group|"Participants will receive 5 weeks of training on the GRAIL device, which is focused on training balance during walking.~Therapy frequency: 2*30 minutes per week."
89444631|NCT05503316|Active Comparator|Traditional gait rehabilitation|"Participant will receiver traditional gait rehabilitation which also includes training balance during walking.~Therapy frequency in both groups is equal."
88929417|NCT01730599||PD patients|PD patients carriers of the G2019S mutation in the LRRK2 gene
88929418|NCT01726400||Interferon and ribavirin|Treatment with standard of care pegylated interferon alpha and ribavirin.
88929419|NCT01730625|Experimental|ABMT + CBT|CBT and ABMT
88929420|NCT01730625|Other|CBT Alone|CBT alone (compare/control group)
88929421|NCT01730625|Placebo Comparator|ABMT placebo + CBT|ABMT placebo training and CBT
88929422|NCT01730651|Experimental|Tomotherapy|"Tomotherapy fraction size (Gy) = 0.4 x 진단 당시의 LN short diameter (cm) + 1.6 (pilot study range, 1.5-3.0 Gy)~Total dose(summation dose with 3D-CRT) (Gy10) (EQD2, α/β=10 Gy) = 5 x 진단 당시의 LN short diameter (cm) + 56 (pilot study range, 54.6-78.0 Gy)"
88929423|NCT01730664|Experimental|ertapenem|single dose ertapenem
88929424|NCT01730677|Experimental|Lapatinib+Vinorelbine|lapatinib 1000mg, once daily vinorelbine 20mg/m2, D1 and D8, every 3 weeks
88929425|NCT01730677|No Intervention|Vinorelbine|vinorelbine 30mg/m2, D1 and D8, every 3 weeks
88929426|NCT01730703||Adults ages 65 and older|
88929427|NCT01730716|Experimental|Surgery|There will be 5 sequential cohorts (Groups A-E) with 3 subjects in each cohort. Each cohort will follow a dose escalation plan. New patients will be enrolled into each group. No control group is included. All patients will received spinal cord injections of HSSC.
88929428|NCT01730742|Experimental|Sleep deprivation|Total sleep deprivation: participants were required to stay up for the entire night before a 'Blood Sample' was taken and the 'Neuroeconomics task' and 'Portion size task' were performed
88929429|NCT01730742|Experimental|Sleep|Sleep: participants had an 8-h sleep opportunity before a 'Blood Sample' was taken and the 'Neuroeconomics task' and 'Portion size task' were performed
88929430|NCT01730794|Other|Conventional Lung Protective Ventilation|In this group, patients will be ventilated in either volume A/C, pressure A/C, pressure support, pressure regulated volume control or volume support based on the discretion of the medical team with TV 4-8 ml/kg PBW range and PP or pressure (control or support) level <30 cmH2O.
88929431|NCT01730794|Other|NAVA Ventilation Group|In the NAVA group, NAVA level will be set initially at zero, then the maximum Edi will be determined as the average level over the next 3 to 5 breaths without ventilatory support or PEEP. The actual NAVA level will then be titrated by the clinician to achieve the following: 1) an Edi equal to approximately 50% of the maximum Edi, 2) an average tidal volume of between 4 to 8 ml/kg predicted body weight (PBW), and 3) an average respiratory rate between about 15 and 40 per minute. In addition, the trigger sensitivity should be set as sensitive as possible without causing auto-triggering and the maximum pressure limit in NAVA should be set at 40 cm H2O.
89444632|NCT05500976|Experimental|mini-Med|Mediterranean-amplified habitual/Western (mini-MED) diet, containing 500 kcal/day from Mediterranean target foods (such as raspberries, avocado, red bell pepper, basil, walnuts, chickpeas, oats, salmon).
89444633|NCT05500976|Active Comparator|Western|Habitual/Western (Western) diet, containing 500 kcal/day from non-Mediterranean target foods (such as potato, beef, sour cream, refined grain bread, chocolate dessert).
89444634|NCT05487183|Experimental|Healthy Volunteers|QST devices and computer tasks are used to measure OA, OH, pain intensity, and other outcomes
89444635|NCT05485974|Experimental|Dose Escalation and Expansion|HBI-2438 will be given orally in ascending doses (escalation cohort), until the maximum tolerated dose or recommended Phase 2 dose is reached. Up to 6-8 patients will then be enrolled in the expansion cohort at the recommended dose.
89444636|NCT05484076|Experimental|breastfeeding counseling|Pregnant women will be given breastfeeding counseling, which will take place in a total of five sessions at specified intervals.
89444637|NCT05484076|No Intervention|control group|No training will be given to the control group. They will be asked to fill in the questionnaires included in our study at specified intervals.
89444638|NCT05457907|Experimental|Parameter testing|In order to test parameters, each individual will be subjected to four interventions with the ultrasound device, one sham intervention and 3 interventions with varying intensity, frequency, and duty cycle.
89444639|NCT05457907|Experimental|Anatomical targeting|In order to test anatomical targeting, each individual will be subjected to four interventions with the ultrasound device, one sham intervention and 2 interventions, varying the anatomical targets.
89444640|NCT05450679||Cervical Radiofrequency Ablation (RFA)-treated group|Only patients who have already been deemed candidates by their primary pain physician for cervical RFA will be recruited to the study. During the cervical RFA procedure, all patients will undergo sensory and motor stimulation testing prior to receiving radiofrequency lesioning, which is a standard and recommended practice.
89444641|NCT05449366|Experimental|Treatment arm|According to standard of care work-up for CRS-HIPEC, patients will undergo diagnostic laparoscopy to determine the feasibility of complete cytoreduction with HIPEC. In case CRS-HIPEC is not considered feasible, a peritoneal port-a-cath (PAC) system will be placed. Through this PAC, 8-16 weekly cycles of intraperitoneal chemotherapy will be administered.
89444642|NCT05447806|Experimental|Active Inpatient Diabetes Clinical Decision Support|"The Active arm consists of participants treated during the ON phase of the GlucAlert-CDS tool. The tool operates through an automated process of rules embedded in the EMR recognizing hypoglycemia (established or impending); recurrent hyperglycemia (in type 1 and 2 DM, or stress hyperglycemia-SH); and inappropriate insulin use (sliding scales monotherapy if recurrent hyperglycemia in type 2 DM or SH, or any time in type 1 DM). If the tool's criteria are met, an alert in the EMR will notify the provider with the clinically recommended treatment."
89444643|NCT05447806|No Intervention|Inactive Inpatient Diabetes Clinical Decision Support|"The Inactive arm consists of participants treated during the OFF phase of the GlucAlert-CDS Tool. Alerts will not be sent to provider's"
89444644|NCT05444855|Experimental|Intervention Trial Participants|"All adolescents will have access to THO+ activities and materials shared by the peer leaders.~All adolescents will be asked to complete an eligibility screening survey and baseline survey online or in-person. They will complete short surveys at 2, 4 and 6 months via Twilio text, call, or email.~Peer Leaders~Investigators will enroll up to 40 Peer Leaders. In addition to the above activities (under intervention trial participant), if a teen is a peer leader they will attend a training session in-person or online with our study team to learn about sexual and mental health information and how to share information with their friends (like text or social media). The peer leaders will answer the same surveys described above and will be asked about their Peer Leader experience and how they are sharing the study health information."
89444645|NCT05444855|No Intervention|Adult Stakeholders|Adults Involved with teens (e.g., parent of teen, member of community, works at community partner organization) that will help promote community based events and provide feedback on events.
89444646|NCT05444855|Experimental|Event Day Participants|Adolescents not already in the trial who attend demonstration and clinical care events must enroll as research participants if they want to receive study medications or testing. This again is all optional to teens. This survey will ask for contact information which is required to track study medications and provide testing results, all other survey questions will be optional.
89444647|NCT05440214|Experimental|Dialectical Behavior Therapy - Skill Training|
89444648|NCT05440214|No Intervention|Treatment As Usual|
89444649|NCT05422248|Active Comparator|Series|Standard wound care for 4 weeks followed by intervention device wound care for up to 12 weeks.
89444650|NCT05422248|Active Comparator|Paired|Intervention device wound care to a portion of wound and standard wound care to the remaining portion of the wound, for up to 12 weeks.
89444651|NCT05422157||Control|No intervention. Collection of additional blood volume (50 mL) during blood tests provided as part of the usual medical care.
89444652|NCT05422157||Hemophilia|No intervention. Collection of additional blood volume (50 mL) during blood tests provided as part of the usual medical care.
89444653|NCT05422157||FV Leiden|No intervention. Collection of additional blood volume (50 mL) during blood tests provided as part of the usual medical care.
89444654|NCT05422157||Cirrhosis|No intervention. Collection of additional blood volume (50 mL) during blood tests provided as part of the usual medical care.
89444655|NCT05422157||Anticoagulation|No intervention. Collection of additional blood volume (50 mL) during blood tests provided as part of the usual medical care.
89444656|NCT05415462|Experimental|mRNA-1010|Participants will receive a single dose of mRNA-1010 by intramuscular (IM) injection on Day 1.
89444657|NCT05415462|Active Comparator|Licensed Quadrivalent Inactivated Seasonal Influenza Vaccine|Participants will receive a single dose of licensed quadrivalent inactivated seasonal influenza vaccine by IM injection on Day 1.
88929432|NCT01730807|Experimental|IntellaTip XP MiFi|Patients with Atrial Flutter will receive ablation treatment with the IntellaTip MiFi XP catheter
89444658|NCT05413135|Experimental|ARO-APOC3|1 dose of ARO-APOC3 by subcutaneous (sc) injection every 3 or 6 months
89444659|NCT05411523||Observational (spinal cord stimulation, questionnaires)|Patients receiving spinal cord stimulation therapy complete questionnaires over 30 minutes at baseline and at 3, 6, and 12 months.
88929433|NCT01730859|Experimental|Balance exrercise and ankle taping|"Balance Exercises:Balance exercises for 6 weeks, 3 sessions per week and each session was 40 minutes for training group.~Ankle taping: Ankle joint taping was performed for 6 weeks and was renewed three times a week."
88929434|NCT01730885|Other|BGStar|Comparision
88929435|NCT01730898|Active Comparator|Control capsule|2 capsules
88929436|NCT01730898|Experimental|Experimental capsule|2 capsules
88929437|NCT01730911|No Intervention|ParaGard, paper diaries|Women who have chosen ParaGard IUDs as their contraception, and randomized to submit bleeding diaries on paper.
88929438|NCT01730911|Active Comparator|ParaGard, text message|Women who have chosen ParaGard IUDs as their contraception, and randomized to submit bleeding diaries via text message.
89444660|NCT05400161|Active Comparator|MoodGym Alone|The MoodGym program is an evidence-based online cognitive behavioral treatment program that has been shown to be effective at reducing depression symptoms in a meta-analysis of 11 trials (g=0.36, 95% CI 0.17-0.56). Moodgym contains five modules with interactive exercises, workbooks, anxiety and depression quizzes, and downloadable relaxation audio files that can be completed online without therapist interaction.
89444661|NCT05400161|Experimental|Parenting Program + MoodGym|The social media-based parenting program consists of 8 weekly sessions using a Facebook platform with the following topics: depression psychoeducation and behavioral activation, infant temperament, play, feeding, safety, sleep, parent-child interactions, and shared book reading. Participants in the experimental arm will also be enrolled in the online depression treatment program, MoodGym.
89444662|NCT05395494|Experimental|D-Cycloserine|Participants will orally ingest a capsule containing 100mg of the antibiotic d-cycloserine daily (Monday-Friday) during 4 weeks of rTMS treatment (20 sessions) 60-120 minutes prior to rTMS treatment.
89444663|NCT05395494|Placebo Comparator|Placebo|Participants will orally ingest a capsule identical to that containing the study medication, however this capsule will contain a placebo. They will ingest this capsule daily (Monday-Friday) for 4 weeks of rTMS treatment (20 sessions) 60 - 120 minutes prior to rTMS treatment.
89444664|NCT05394064|Experimental|Active Treatment|Patients treated with SBT101
89444665|NCT05394064|Sham Comparator|Imitation Procedure|Procedure that mimics treatment with SBT101, but does not infuse anything into the spinal cord
89444666|NCT05393297|Experimental|HNSCC receiving (chemo)radiotherapy|Radiation: Intra-treatment FDG-PET-CT and MRI will be used to identify tumours and patients for dose-escalation. Patients identified for dose-escalation (boost) will undergo adaptive radiotherapy replanning, with the primary tumour (GTVp) receiving 76.9Gy in 35 fractions.
89444667|NCT05389787|Experimental|TMS|
89444668|NCT05389787|Sham Comparator|Sham|
89444669|NCT05374304|Experimental|Lead-In (BC/WC-GeriOnc)|Lead-in phase oncologists will complete the BC/WC-GeriOnc communication tool training. Cancer treatment decision-making discussions will be recorded with 2 patients per oncologist and ask patients and oncologists to complete study questionnaires over one-month follow-up and one semi-structured interview about the decision-making process and communication.
89444670|NCT05374304|Experimental|Intervention (BC/WC-GeriOnc)|Intervention group oncologists will complete the BC/WC-GeriOnc communication tool training. Cancer treatment decision-making discussions will be recorded with 2 patients per oncologist to understand baseline oncologist practices and communication. Patients and oncologists will be asked to complete study questionnaires over a 2 month follow-up and 1 semi-structured interview. For each randomized oncologist, cancer treatment decision-making discussions will be recorded with 5 patients per oncologist. Both patients and oncologists will also be asked to complete study questionnaires over a 2 month follow-up and 1 semi-structured interview about the decision-making process and communication. Each patient will be given the option to select 1 caregiver to participate. Caregivers will be asked to complete study questionnaires and a semi-structured interview about their decision-making experience.
89444671|NCT05374304|No Intervention|Waitlist Control|Usual care will be provided to the patients, with optional training for the oncologists at study completion.
89444672|NCT05371873||Anatomical resection group|Anatomical resection of liver cancer tissue
89444673|NCT05371873||Non-anatomical resection group|Non-anatomical resection of liver cancer tissue
88929439|NCT01730911|No Intervention|Mirena, paper diaries|Women who have chosen Mirena IUDs as their contraception, and randomized to submit bleeding diaries on paper.
88929440|NCT01730911|Active Comparator|Mirena, text message|Women who have chosen Mirena IUDs as their contraception, and randomized to submit bleeding diaries via text message.
88929441|NCT01730924|Other|Contact force available|
88929442|NCT01730924|Other|Contact force not available|
88929443|NCT01730963||Pregnant, Preterm, In Labor|Gestation Age at or less than 36 weeks, clinically determined to be in labor
88929444|NCT01730963||Pregnant, Preterm, Nonlaboring|Gestation Age at or less than 36 weeks, clinically determined to not be in labor
88929445|NCT01730963||Pregnant, Term, Nonlaboring|Gestation Age more than 36 weeks, clinically determined to not be in labor
89444674|NCT05363046||Group A|Participants will complete the PD diary on 3 consecutive days in 1 week.
89444675|NCT05363046||Group B|Participants will complete the PD diary on 2 consecutive days in each of 2 consecutive weeks.
88929446|NCT01730976|Experimental|Vitamin D 2,000 I.U. daily|Study subjects will take 2,000 I.U. vitamin D daily for three months
88929447|NCT01730989|Experimental|Estromineral Serena Plus|"Estromineral Serena Plus is an association of soy isoflavones, Lactobacillus sporogenes, magnolia, chaste tree, Vitamin D3, calcium and magnesium.~1 tablet oad for 12 weeks"
88929448|NCT01730989|Active Comparator|Estromineral|"Estromineral is an association of soy isoflavones, Lactobacillus sporogenes, Vitamin D3, and calcium.~1 tablet oad for 12 weeks"
88929449|NCT01731015|Experimental|Normal Subject|Each subject will receive oxygen as a contrast agent to visualize the airway and alveolar spaces in their lungs using magnetic resonance imaging of inert gas/oxygen mixtures. The subjects will receive the gas by breathing room air interleaved with oxygen using a standard Douglas Bag system. No additional drug products, investigational or otherwise will be provided in this study.
89444676|NCT05341310|Experimental|ADHDCoach|Participants in the experimental group will have access to an individually-tailored Internet intervention developed for the present study. The intervention in clinician-guided and it consists of nine modules delivered for four weeks. The Internet Intervention, called ADHDCoach, is based on an existent Behavioral Parent training protocol, an intervention that was previously tested in a randomized controlled trial with Romanian children. The contents for parent modules were developed according to Rational Emotive and Behavioral Therapy.
89444677|NCT05341310|Active Comparator|Treatment as usual|Treatment as usual at the outpatient clinic
89013613|NCT06299423|Experimental|Howdy Senior® device|Patients will undergo standard perioperative management. Additionally, patients will perform three preoperative and twelve postoperative HOWDY Senior® assessments. The assessment consists of a nocturnal electrocardiogram (ECG) measure and a morning rest Heart Rate Variability (HRV) measure of five minutes.
89013614|NCT06299423|No Intervention|Standard perioperative management|Patients belonging to the historical cohort of comparison, who underwent standard perioperative management and surgical intervention between January 2021 and January 2022.
89013615|NCT06299124|Experimental|RGT-419B monotherapy|Dose escalation and dose expansion of RGT-419B monotherapy
89013616|NCT06298708|Experimental|L-HAV|Live-attenuated hepatitis A vaccine.
89013617|NCT06298708|Active Comparator|I-HAV|Inactivated hepatitis A vaccine.
89013618|NCT06298500||Histoacryl Lapfix|Histoacryl Lapfix - Cannula for laparoscopic mesh fixation in patients undergoing hernia repair surgery
89013619|NCT06298110|Experimental|PRP group|on the morning of surgery, 30 mL of venous blood will be drawn from the patient in anticoagulant-containing PRP tube for preparation of PRP solution. The drawn blood will be centrifuged at 1,200 rpm for 12 minutes to be separated into three layers: an upper layer that contains platelets and white blood cells, an intermediate thin layer (the buffy coat) that is rich in white blood cells, and a bottom layer that contains red blood cells. The upper and intermediate buffy layers will be transferred to an empty sterile tube. The plasma will be centrifuged again at 3,300 rpm for 7 minutes to help with the formation of soft pellets (erythrocytes and platelets) at the bottom of the tube. Pellets are homogenized in the lower third (5 mL) of the plasma to create the PRP. The prepared PRP solution will be transferred within sterile single use syringe (3cm) from the laboratory to the operation room, then applied and spread over the subcutaneous space before skin closure
89013620|NCT06298110|No Intervention|Control group|the patients received no topical treatment in the subcutaneous tissue or the skin before closure during surgery
89444678|NCT05341297|Experimental|ParentKIT|Transdiagnostic parent-led Internet-delivered intervention Participants in the experimental group will have access to the ParentKIT intervention. The intervention was developed based on existing Cognitive Behavioral Therapy/ Rational Emotive Behavior Therapy protocols for parents of children with internalizing problems. It consists of nine modules delivered over three weeks.
89444679|NCT05341297|No Intervention|Waitlist|Participants in the waitlist condition will have access to the program after 3 weeks.
89444680|NCT05338333|Other|LID210464, then AOHG MF|Lehfilcon A multifocal contact lenses (LID210464) worn in Period 1, with lotrafilcon B multifocal contact lenses (AOHG MF) worn in Period 2, as randomized. Each study lens type will be worn bilaterally (in both eyes) for 30 days. CLEAR CARE® will be used for nightly contact lens cleaning and disinfecting.
89444681|NCT05338333|Other|AOHG MF, then LID210464|Lotrafilcon B multifocal contact lenses (AOHG MF) worn in Period 1, with lehfilcon A multifocal contact lenses (LID210464) worn in Period 2, as randomized. Each study lens type will be worn bilaterally (in both eyes) for 30 days. CLEAR CARE® will be used for nightly contact lens cleaning and disinfecting.
89444682|NCT05337618|Experimental|SD-Guided Care|In this arm, ECoG data will be reviewed for SDs in real-time using the bedside clinical CNS monitor. As a secondary measure, recognition of SDs will be facilitated by custom software on a laptop that receives data from the CNS monitor. Data on SD occurrence will be used to guide treatment in a tier-based therapeutic escalation and de-escalation protocol with the goal of SD suppression. Therapies to be used among the tiers include adjusted targets for MAP, CPP, PaCO2, plasma glucose, temperature, as well as ketamine pharmacotherapy. Changes between tiers are determined by the success or failure of SD suppression at the given treatment level.
89013621|NCT06297889|Experimental|Core strength training interventions for 1-6 weeks|Core strength training: Experiment: Experimental Group: Core Strength Training for 1-6 Weeks.Participants undergo a one-hour training session three times a week for 1- 6 weeks, incorporating a 15-minute warm-up followed by 45 minutes of targeted core strength training.
89013622|NCT06297889|Experimental|Core strength training interventions for 7-12 weeks|Core strength training: Experiment: Experimental Group: Core Strength Training for 7-12 Weeks.Participants undergo a one-hour training session three times a week for 7-12 weeks, incorporating a 10-minute warm-up followed by 50 minutes of targeted core strength training.
89013623|NCT06297746|Active Comparator|Subvastus approach|Patients indicated for total knee arthroplasty.
89013624|NCT06297746|Active Comparator|Medial Parapatellar approach|Patients indicated for total knee arthroplasty.
89013625|NCT06297525|Experimental|Phase 1a (Part 1, Dose Escalation)|Up to 5 dose levels with STP938 administered as oral monotherapy
89013626|NCT06297525|Experimental|Phase 1b (Part 2, Safety Expansion)|Further evaluation of STP938 administered as oral monotherapy at the RP2D
89013627|NCT06297278|Experimental|Moderate Intensity Exercise|
89013628|NCT06297278|No Intervention|Control (Coloring)|
89013630|NCT06296875|Placebo Comparator|Vegetable oil|4g/day vegetable oil for 24 weeks
89013631|NCT06296875|Active Comparator|Krill oil|4/g/day krill oil for 24 weeks
89013632|NCT06296602|Experimental|ANAPreP-HPV|"A prelevement for HPV genotyping and anal cytology will be carried out in addition to the anal swabs taken quarterly to screen for other sexually transmitted infections.~A questionnaire will be completed by the doctor to record the data of interest."
89013633|NCT06296329||Cases|Participants with Anorexia Nervosa
89013634|NCT06296329||Controls|Not-hospitalized participants with a healthy weight
89013635|NCT06295887|Experimental|Test group|The test group wears an HMD (head-mounted display) and participates in a simulation program using VR. They experience both easy and difficult cases using VR. After the simulation session, a debriefing session will be provided.
89200026|NCT02541825|Experimental|the stent of diameter of 7mm|Procedure/Surgery:Jugular vein puncture and catheterization. Device:RUPS-100(COOK Company)sheath ,7mm balloon,Pigtail catheter,the stent of diameter of 7mm (Bard,Fluency) Drug(including placebo):No Biological/Vaccine:No
89200027|NCT02541825|Other|the stent of diameter of 8mm|Procedure/Surgery:Jugular vein puncture and catheterization. Device:RUPS-100(COOK Company)sheath ,8mm balloon,Pigtail catheter,the stent of diameter of 8mm (Bard,Fluency) Drug(including placebo):No Biological/Vaccine:No
88929450|NCT01731015|Experimental|Subjects with Lung/or Airway Disease|Each subject will receive oxygen as a contrast agent to visualize the airway and alveolar spaces in their lungs using magnetic resonance imaging of inert gas/oxygen mixtures. The subjects will receive the gas by breathing room air interleaved with oxygen using a standard Douglas Bag system. No additional drug products, investigational or otherwise will be provided in this study.
88929451|NCT01731028||Somatropin|Children with growth hormone deficiency treated with somatropin as Zomacton® according to the marketing authorization
88929452|NCT01731067|Active Comparator|CYP1A2, 2B6, 2C9, 2C19, 3A4 inhibitors|Oral intake of fluvoxamine (50 mg per day during 2 days) and voriconazole (400 mg) before oral intake of the cocktail probe drugs
88929453|NCT01731067|Active Comparator|CYP2D6 and P-gp inhibitor|Oral intake of quinidine (200 mg) before oral intake of the cocktail probe drugs
88929454|NCT01731067|Active Comparator|CYPs and P-gp inducer|Oral intake of rifampicin (600 mg per day during 7 days) before oral intake of the cocktail probe drugs
88929455|NCT01731067|Experimental|Probe cocktail alone|"Oral intake of the cocktail probe drugs :~bupropion 25 mg~flurbiprofen 25 mg~omeprazole 5 mg~dextromethorphan 5 mg~midazolam 1 mg~fexofenadine 25mg~Caffeine (a cup of coffee)"
88929456|NCT01731080||Pseudoxanthoma Elasticum|Patients with genetically and clincally proven PXE
88929457|NCT01731080||chronic kidney disease|Type 2 diabetic patients with mediacalcosis and matched to PXE patients for gender and age (+/- 5 yrs).
88929458|NCT01731080||Diabetes|patients with chronic kidney disease and matched to PXE patients for gender and age (+/- 5 yrs).
88929459|NCT01731093|Experimental|AT-001|AT-001
88929460|NCT01731093|Placebo Comparator|Placebo|Matching placebo.
88929461|NCT01731132||Group 1|
88929462|NCT01731145|Experimental|SNUMAP assessment|Uses SNUMAP motion sensing system to quantify tremor symptom.
88929463|NCT01731158|Other|arm A|"sequential therapy with approved drugs~Avastin in combination with Roferon-A (first-line), Afinitor (second-line) and a TKI (Sutent, Nexavar or Votrient) (third-line)"
88929464|NCT01731158|Other|arm B|"sequential therapy with approved drugs~Avastin in combination with Roferon-A (first-line), a TKI (Sutent, Nexavar or Votrient) (second-line) and Afinitor (third-line)"
88929465|NCT01731184|Experimental|Midazolam|Midazolam (Hypnovel) at 0.04 mg /kg with morphine titration (first bolus: 0.1 mg/kg then 3 mg every 5 minutes).
88929466|NCT01731184|Placebo Comparator|Placebo|Placebo at 0.04 mg /kg with morphine titration (first bolus: 0.1 mg/kg then 3 mg every 5 minutes).
88929467|NCT01731197|Experimental|Test ISP-10|10 grams of the test ISP will be consumed as a dry-blended beverage
88929468|NCT01731197|Experimental|Test ISP-20|20 grams of the test ISP will be consumed as a dry-blended beverage
88929469|NCT01731197|Active Comparator|Control ISP-10|10 grams of the control ISP will be consumed as a dry-blended beverage
88929470|NCT01731197|Active Comparator|Control ISP-20|20 grams of the control ISP will be consumed as a dry-blended beverage
88929471|NCT01731223|Experimental|Group treatment for insomnia|Group treatment for insomnia.
88929472|NCT01731223|No Intervention|No intervention|Treatment as usual
88929473|NCT01731249|Placebo Comparator|Placebo|Placebo sublingual solution
88929474|NCT01731249|Experimental|Birch pollen allergen extract|Sublingual Solution of Birch pollen allergen extract 300IR once daily 5 months per year and during 2 years
88929475|NCT01731262||RA group|expression of Shh pathway associated factors from peripheral blood mononuclear cells or synovial tissues will be detected
88929476|NCT01731262||control group|expression of Shh pathway associated factors from peripheral blood mononuclear cells or synovial tissues will be detected
88929477|NCT01731275|Experimental|E6011|
88929478|NCT01731275|Placebo Comparator|E6011 Matching Placebo|
88929479|NCT01731288||vulvodynia|Women with vulvodynia
88929480|NCT01731288||control|Women without vulvar pain
88929481|NCT01731301|Experimental|Ribavirin, peginterferon, boceprevir|The efficacy and safety of HCV treatment in patients with ESRD will be assessed with a maximal tolerated dose of ribavirin, peginterferon and boceprevir.
88929482|NCT01731327|Experimental|Experimental Treatment A|A single dose of 11 mg tofacitinib modified-release (MR) administered in a fasting state.
88929483|NCT01731327|Experimental|Experimental Treatment B|A single dose of 22 mg tofacitinib modified-release (MR) administered in a fasting state.
88929484|NCT01731340|Active Comparator|Supplemental Calcium|"750 mg Calcium Citrate per day~800 IU Vitamin D3 per day~Low Dietary Calcium (450 mg per day)"
88929485|NCT01731340|Active Comparator|Dietary Calcium|"400 IU Vitamin D3 per day~High Dietary Calcium (1200 mg per day)"
88929486|NCT01731340|No Intervention|Usual Diet|"400 IU Vitamin D3 per day~Unrestricted Dietary Calcium"
88929487|NCT01731366|Placebo Comparator|Refined grain|Refined grain diet: Participants consume less than 10 g of whole grain per day (corresponds to the whole grain intake below the 10th percentile of the population)
88929488|NCT01731366|Active Comparator|Whole grain|Whole grain diet: Participants consume more than 75g of whole grain per day (corresponds to the whole grain intake of the 90th percentile of the population)
88929489|NCT01731379||Surgical resections|Patients planned for elective inguinal, axillary or cervical lymph node dissection or parotidectomy, patients with rectal cancer undergoing rectal surgery and patients undergoing resection of a soft tissue tumour.
88929490|NCT01731392|Experimental|Milk with Bifidobacteria|duration of the treatment is 5 months
89444683|NCT05337618|No Intervention|Standard ICU Care|"Management in the Standard ICU Care arm will follow published national guidelines consisting of common ICU-based targets for physiologic intervention that are thought to mitigate the development of secondary brain injuries.~Continuous ECoG monitoring will be performed for seizure monitoring, but information on the course of SDs in these patients will not be used to guide care. To enforce blinding to SD-related ECoG data, the ECoG bedside software will be locked with password protection to prevent displays with frequency filtering and time/amplitude scales that are necessary to identify SDs."
89444684|NCT05335668|Experimental|Patients with central poststroke pain|Patients with central poststroke pain
89444685|NCT05335668|Experimental|Patients without central poststroke pain|Patients without central poststroke pain
89444686|NCT05335668|Active Comparator|healthy controls|healthy volunteers
89444687|NCT05334433|Experimental|Local anesthesia injection with the comfort in jet (Needless system)|A needle-less injection approach will be used to administer the local anesthetic solution
89444688|NCT05334433|Active Comparator|Local anesthesia injection with needle injection (conventional technique).|A conventional aspirating syringe fitted with 27-gauge long needles will be used to administer the local anesthetic solution.
89444689|NCT05327309|Active Comparator|Propranolol|propranolol with a mean dose of 2mg/kg/day in 2 divided doses for a period of 6 months
89444690|NCT05327309|Experimental|Bleomycin|Bleomycin 15mg diluted in 15 ml of Normal Saline along with a dosage of 0.5 mg/kg for a period of 6 months.
88929491|NCT01731392|Active Comparator|Milk with non replicating lactobacilli|duration of the treatment is 5 months
88929492|NCT01731392|Placebo Comparator|Semi skimmed milk|duration of the treatment is 5 months
88929493|NCT01731405||Formats A,B,C; medicines Ritalin, Morphine Sulfate, Aranesp|All patients will see all 3 different formats of the Medication Guide prototypes. They will also see information for the same drugs, in the same order - Ritalin, Morphine Sulfate, and Aranesp. All participants see all the formats, the only thing that changes by participant is which format is in each medication. There will be 6 different randomized orders - A,B,C; A,C,B; B,C,A; B,A,C; C,A,B; C,B,A. So for example, A,B,C participants would see Ritalin in format A, Morphine Sulfate in format B, and Aranesp in format C.
88929494|NCT01731405||There is not another group|
88929495|NCT01731418|Other|Treamtent-as-usual|Treatment-as-usual can be defined as the commonly used psychotherapy for abused women in Iran, such as medical therapy and/or supportive psychotherapy.
88929496|NCT01731418|Experimental|Narrative Exposure Therapy|Narrative Exposure Therapy (NET) is a standardized short-term approach based on the principles of cognitive behavioral exposure therapy and testimony therapy for the treatment of PTSD resulting from organized violence.
88929497|NCT01731431|Active Comparator|Insulin|standard protocol of insulin treatment for gestational diabetes
88929498|NCT01731431|Experimental|Glyburide|initial dose 2.5 mg per day increased if necessary until 10mg twice a day if glycemia is not controlled
88929499|NCT01731457|Experimental|Etanercept|
88929500|NCT01731457|No Intervention|Control|
88929501|NCT01731496|Experimental|Telephone reminder|Telephone message reminder to parents of adolescents whose child is due for a 2nd or 3rd dose of HPV vaccine.
88929502|NCT01731496|Experimental|Text Message reminder|Text message reminder to parents of adolescents whose child is due for a 2nd or 3rd dose of HPV vaccine.
88929503|NCT01731496|No Intervention|Control: Telephone|
88929504|NCT01731496|No Intervention|Control: Text Message|
88929505|NCT01731509|Active Comparator|Standard FETO|Group of fetus that undergo fetal endoscopic tracheal occlusion between 26 0/7 weeks and 28 6/7 weeks.
88929506|NCT01731509|Experimental|Early FETO|Group of fetus that undergo fetal endoscopic tracheal occlusion between 22 0/7 weeks and 24 6/7 weeks.
88929507|NCT01731535||Prior bisphosphonate users|Patients with record of using bisphosphonate medication
88929508|NCT01731548|Experimental|study arm|"For patients who are randomized to study arm, (i.e. to irradiate the post-chemotherapy tumor extent) the clinical target volume-tumor (CTV-T) includes the post-chemotherapy gross tumor volume-tumor (GTV-T) with a margin of 0.8 cm.~Chemotherapy includes etoposide 100mg/m2 d1-d3 combine with cisplatin 80mg/m2 d1 at 21-day interval for 4 cycles.~Radiotherapy will be administered with cycle 3 chemotherapy（1.5 Gy twice daily to 45 Gy in 30 fractions over 3 weeks）"
88929509|NCT01731548|Active Comparator|control arm|"For patients who are randomized to control arm, (i.e. to irradiate the pre-chemotherapy tumor extent) the clinical target volume-tumor (CTV-T) includes the pre-chemotherapy gross tumor volume-tumor (GTV-T) with a margin of 0.8 cm.~Chemotherapy includes etoposide 100mg/m2 d1-d3 combine with cisplatin 80mg/m2 d1 at 21-day interval for 4 cycles.~Radiotherapy will be administered with cycle 3 chemotherapy (1.5 Gy twice daily to 45 Gy in 30 fractions over 3 weeks)."
88929510|NCT01731561|Experimental|Rituximab infusion according biological parameters|Rituximab infusion based on ANCA and CD19 lymphocytes
88929511|NCT01731561|Active Comparator|Systematic rituximab infusion|Semestrial rituximab infusion until 18 months
88929512|NCT01731574|Active Comparator|Dapivirine Ring + Miconazole|Dapivirine Ring + miconazole
88929513|NCT01731574|Experimental|Dapivirine Ring|Dapivirine Ring
88929514|NCT01731587|Experimental|L-BLP25 plus Cyclophosphamide (CPA)|
88929515|NCT01731613|Active Comparator|Standard Fortification|receive human milk fortified with human milk fortifier(HMF) in the standard amount (4 packs /100 ml of HM) throughout the study
88929516|NCT01731613|Experimental|Adjustable fortification|encompasses increasing/decreasing the amount of human milk fortifier(HMF) and adding supplemental protein guided by periodic determinations of the protein concentration of human milk (PCHM), body weight, blood urea nitrogen(BUN)
88929517|NCT01731639|Experimental|MSOME|The samples will be evaluated under high magnification
88929518|NCT01731652|Experimental|TMX-101|TMX-101 0.4% (200 mg in 50 ml) instilled in the bladder once weekly for 6 weeks
89444691|NCT05325125||Children who have completed treatment for Tuberculosis|Children 19 years and below who had drug-sensitive pulmonary tuberculosis, either bacteriologically confirmed or not and who have completed treatment within the preceding 6 weeks before enrolment
89444692|NCT05318794|Experimental|Neoadjuvant systemic and peritoneal chemotherapy|Standard neoadjuvant systemic and pressurised intraperitoneal aerosol chemotherapy
89444693|NCT05312593|Experimental|Trial Group|A group of 30 patients will be randomly assigned to Hyaluronic Acid domiciliary treatment, applied into Peri-implant mucositis sites.
89444694|NCT05312593|Active Comparator|Control Group|A group of 30 patients will be randomly assigned to Chlorhexidine mouthwash domiciliary treatment, applied into Peri-implant mucositis sites.
89444695|NCT05263830||Patient with hepatocellular carcinoma|Patients with an indication for treatment with Atezolizumab / Bevacizumab for the management of an advanced disciplinary hepatocellular carcinoma in a multidisciplinary consultation meeting.
88929519|NCT01731665||The Songpa-Kangdong cohort of IBD|Incident cases of IBD in the Songpa-Kangdong district, a well-defined administrative area in Seoul, the capital of Korea, beginning in 1986, when the first patient with IBD was diagnosed, until 2017. For the prevalent cases, the inhabitants with IBD at Dec 31, 2007 in the Songpa-Kangdong district are included.
88929520|NCT01731704|Active Comparator|Stereotactic Radiosurgery (SRS)|Radiation Therapy: Radiosurgical (SRS) technique via Gamma Knife Perfexion radiosurgical system
88929521|NCT01731704|Active Comparator|Whole Brain Radiation Therapy (WBRT)|whole-brain radiation therapy 30 Gy in 10 fractions. Treatment will be delivered once daily, 5 fractions per week, over 2 to 2.5 weeks
88929522|NCT01731717|Experimental|Stepped care intervention (SCM)|"Patients within the stepped care intervention are screened by general physician using the PHQ-9 (inclusion criterion: >4 points) and diagnosed according to International Classification of Diseases (ICD-10) criteria. Patients receive differentially intensive treatment according to depression severity.~Patients with mild depression receive:~Step I: Active monitoring or Step II: II.a. Bibliotherapy or II.b. Online self-help (Deprexis®) or II+: Telephone-based psychotherapy~Patients with moderate depression receive:~Step III: III.a. Outpatient psychotherapy or III.b. Psychopharmacological treatment~Patients with severe depression receive:~Step IV: Combined psychotherapy and psychopharmacological treatment, optionally in inpatient setting."
88929523|NCT01731717|Active Comparator|Control group: treatment as usual|Patients in the control group are screened by their general physician using the PHQ-D-9 depression scale. Patients included in the study then receive treatment as usual from general physician or other health service providers.
88929524|NCT01731743|Other|implantation of a trifocal IOL (AT LISA tri 839MP)|
88929525|NCT01731756|Experimental|Palmer arsenical keratosis (study)|Leaf extract of A. indica plus salicylic acid (6%) in petroleum jelly base will be applied on palmer keratotic lesion once daily at bedtime for 12 weeks
88929526|NCT01731756|Placebo Comparator|Palmer arsenical keratosis (control)|Salicylic acid (6%) in petroleum jelly base will be applied on palmer keratotic lesion once daily at bedtime for 12 weeks
89444696|NCT05256901|Experimental|Sugammadex|The reversal agent, Sugammadex, will be administered at the start of closure.
89444697|NCT05256901|Active Comparator|Neostigmine/Glycopyrrolate|The reversal agent, Neostigmine, will be administered at the start of closure.
88929527|NCT01731769|Active Comparator|Axillary dissection|Axillary dissection is a surgical procedure that incises (opens) the armpit (axilla or axillary) to identify, examine, or remove lymph nodes (small glands, part of the lymphatic system, which filters cellular fluids).
88929528|NCT01731769|Experimental|vacuum assisted closure|Vacuum assisted closure (also called vacuum therapy, vacuum sealing or topical negative pressure therapy) is a sophisticated development of a standard surgical procedure, the use of vacuum assisted drainage to remove blood or serous fluid from a wound or operation site.
88929529|NCT01731795|No Intervention|No dexamethasone|Patients will be treated with conventional treatment
88929530|NCT01731795|Active Comparator|Dexamethasone|Conventional treatment plus dexamethasone
88929531|NCT01731808|No Intervention|Standard care|All participants received three specially-developed brochures with information regarding the diabetic foot condition. The brochures contained explanations to a) the cause and warning signs of diabetic foot ulcers, b) the precautions patients can take in their daily life, and c) helpful foot gymnastics to be practiced at home. The participants who were randomized in the control group received standard care. Standard care consisted of either physician-prescribed inpatient or outpatient wound care.
88929532|NCT01731808|Experimental|Nursing counseling|
88929533|NCT01731821|Experimental|Nonstented stump-closed anastomosis|Nonstented stump-closed anastomosis is used for pancreaticojejunostomy after pancreaticoduodenectomy.
88929534|NCT01731821|Active Comparator|Duct-to-mucosa anastomosis|Duct-to-mucosa technique is used for pancreaticojejunostomy after pancreaticoduodenectomy.
88929535|NCT01731834|Active Comparator|Aspiration of secretion|10 children are evaluated at rest, during and after aspiration technique secretion
88929536|NCT01731834|Experimental|Vibrocompression|10 children will be assessed at rest, during and after the maneuver vibrocompression
88929537|NCT01731847|Experimental|The combination group|Patients received 12 sessions of NMES for 1 hour /day, 5 days/week within a period of 2-3 weeks. FEES was done before and after NMES for evaluation and guiding therapy. All patients subsequently received 12 sessions of traditional swallowing rehabilitation (50 minutes/day, 3 days/week) for 4 weeks.
88929538|NCT01731860|Experimental|Patients receiving PET/CT|Patients already scheduled for a clinically necessary PET/CT scan.
88929539|NCT01731899||agomelatine|patients diagnosed of fibromyalgia and concomitant major depression receiving agomelatine for this later disease
88929540|NCT01731925|Experimental|Sunitinib|Sunitinib 37.5 mg daily. Lanreotide at the dose of 120 mg will be injected every 28 days as the reference treatment to control the carcinoid syndrome in both arms.
88929541|NCT01731925|Placebo Comparator|Placebo|Placebo (for sunitinib). Lanreotide at the dose of 120 mg will be injected every 28 days as the reference treatment to control the carcinoid syndrome in both arms.
88929542|NCT01731964|Experimental|WA- NG Telescope Prothesis|Implantable Miniature Telescope for end stage AMD
88929543|NCT01731977|Experimental|Strengths-based family psychoeducation|Family psychoeducation in addition to treatment as usual
88929544|NCT01731977|No Intervention|Waiting list|Treatment as usual
88929545|NCT01732003|Experimental|Omega-3 Complete|Oral ingestion of 3000 mg (5 capsules) of Omega-3 Complete (Jamieson Laboratories Ltd., Windsor, Ontario, Canada) per day for 12 weeks
88929546|NCT01732003|Placebo Comparator|Placebo Pill|Oral ingestion of 5 capsules of a placebo oil pill (Jamieson Laboratories Ltd., Windsor, Ontario, Canada) per day for 12 weeks
89013636|NCT06295887|Active Comparator|Control group|"The control group participates in simulation training using Sim-man, and the scenarios are the same in both the control and the test groups (easy cases and difficult cases).~After the simulation session, a debriefing session will be provided."
89444698|NCT05245955|Experimental|Robotic assessment of sensory hand function|This arm involves a group of persons with Parkinson's disease and an age-matched control group. Both groups undergo the assessments of kinaesthesia and haptic perception of the hand implemented on the ReHapticKnob.
88929547|NCT01732016|Other|Normobaric hypoxia chamber|Study subjects will be put into a hypoxic state by exposing them to normobaric (sea-level atmospheric pressure) hypoxia (low oxygen) by administrating an air mix containing a reduced O2 concentration. This is achieved in a hypoxia chamber where O2 concentration is gradually reduced to simulate high altitude (around 4500 m).
88929548|NCT01732029|Other|Normobaric hypoxia chamber|Study subjects will be put into a hypoxic state by exposing them to normobaric hypoxia by administrating an air mix containing a reduced O2 concentration. This is achieved in a hypoxia chamber where O2 concentration is gradually reduced to simulate high altitude (about 4500 m).
88929549|NCT01732055|Active Comparator|Partner-Assisted Interpersonal Psychotherapy|Partner-Assisted Interpersonal Psychotherapy is an 8-week series of psychotherapy sessions attended by the patient and her identified partner.
88929550|NCT01732055|Other|Treatment as Usual|Treatment prescribed for subjects by the UNC Perinatal Psychiatry clinic physicians according to the clinic algorithm.
88929551|NCT01732068|Experimental|Corifollitropin alfa+hMG|
88929552|NCT01732081||Patients with chronic hepatitis B virus infection|Patients chronically infected with hepatitis B virus (HBV), and followed in university hospital of Strasbourg, France
88929553|NCT01732094|Experimental|Corifollitropin Alfa + hMG|
88929554|NCT01732133|Experimental|Measurement of arterial pressure|
88929555|NCT01732146|Active Comparator|Erythropoietin beta|1000 to 1500 U/kg/dose X 3 every 24 hours
88929556|NCT01732146|Placebo Comparator|Placebo|0.2 ml saline solution X 3 given every 24 hours
88929557|NCT01732159|Experimental|Administration of the checklist|Patients will be contacted by phone for administration of the checklist
88929558|NCT01732159|No Intervention|No contact by phone|Patients who will not be contacted by phone
88929559|NCT01732172|Experimental|Patient Group|Patient with urethritis
88929560|NCT01732172|Other|Control group|Subjects with no urethritis and no history urogenital infection
88929561|NCT01732185|Other|Patient|congenital cystic adenomatoid malformations
88929562|NCT01732198|Experimental|NU300 and Prevnar 13|NU300 at a single dose of 0.5 mL IM
88929563|NCT01732198|Active Comparator|ActHIB and Prevnar 13|ActHIB at a dose of 0.5 ml IM
88929564|NCT01732224|Experimental|Tenofovir + Telbivudine|Tenofovir (300 mg/day) plus telbivudine (600 mg/day).
88929565|NCT01732224|Active Comparator|Tenofovir|In tenofovir arm subjects will receive tenofovir (300 mg) once daily.
88929566|NCT01732237|Experimental|JNJ-42396302|Patients will receive JNJ-42396302 100 micrograms as a single oral dose after an overnight fast of at least 10 hours.
88929567|NCT01732237|Experimental|JNJ-42692507|Patients will receive JNJ-42692507 100 micrograms as a single oral dose after an overnight fast of at least 10 hours.
88929568|NCT01732237|Experimental|JNJ-53773187|Patients will receive JNJ-53773187 100 micrograms as a single oral dose after an overnight fast of at least 10 hours.
88929569|NCT01732250|Experimental|Colistin and Meropenem|IV meropenem, 2 gram q8h, adjusted for renal function IV Colistin with loading dose of 9 mil IU units, Maintenance dose 4.5 mil IU q12h, adjusted for renal function
88929570|NCT01732250|Active Comparator|Colistin|IV Colistin with loading dose of 9 mil IU units, Maintenance dose 4.5 mil IU q12h, adjusted for renal function
88929571|NCT01732276|Experimental|gefitinib|gefitinib tablet 250mg/day by mouth until disease progression
88929572|NCT01732289|Experimental|A|
88929573|NCT01732302|Experimental|Educational intervention|Primary health care centers (PHCC) in the intervention group will be visited twice by a pharmacist within a period of three months. At the first visit, an educational intervention will focus on two properties: on the one hand, feed-back of actual patient data of the PHCC illustrating the primary-health-care-specific characteristics of inappropriate prescribing in the elderly patient will be given. Education of relevant subjects will be given in relation to detected problems. On the other hand, a clinical routine regarding the performance of drug utilization reviews will be developed in cooperation with the health care providers. At the second visit 3 months later, the developed concept will be critically reviewed and eventually developed further.
88929574|NCT01732302|No Intervention|Delayed educational intervention|Primary health care centers in the delayed intervention group will receive the same intervention as described above with 9 months delay.
88929575|NCT01732315|Experimental|Vaccination Email Reminder|This group of parents in the study will receive email notifications about due/overdue vaccines for their adolescents. Vaccination records will be reviewed to identify adolescent patients in both practices who are newly eligible for a vaccine and/or overdue for a vaccine at the start of every other month. Email notifications will then be sent to the parents of these children.
88929576|NCT01732315|No Intervention|Usual Care|This group of parents in the study will not receive email notifications about due/overdue vaccines for their adolescents.
88929577|NCT01732328|Placebo Comparator|placebo|Inactive pill (microcrystalline cellulose and corn starch) taken daily
88929578|NCT01732328|Active Comparator|Calcium plus vitamin D|600mg of calcium and 200 international units (IU) vitamin D taken daily
88929579|NCT01732341|Experimental|STENTYS self-apposing stent|Intervention to treat STEMI with the STENTYS self-apposing stent
88929580|NCT01732341|Active Comparator|VISION balloon-expandable stent|STEMI treatment with a VISION balloon-expandable stent
88929581|NCT01732367|Active Comparator|Lamivudine plus adefovir|Continue lamivudine/adefovir add on treatment (standard treatment)
88929582|NCT01732367|Experimental|Tenofovir|Switch from lamivudine/adefovir add on treatment to tenofovir monotherapy
88929583|NCT01732380|Active Comparator|Radiotherapy|Radiotherapy 2.0Gy/day, 5 times/week,6 weeks In Subjects With Inoperable esophageal cancer
89444699|NCT05243524|Experimental|MVP-S + CPA|All subjects will receive two doses of maveropepimut-S (q3w) followed by up to six doses (q8w) plus low-dose cyclophosphamide on a repeating cycle of one week on/one week off.
89444700|NCT05226455|Experimental|venetoclax + azacitidine +/- donor lymphocyte infusion|"Venetoclax + azacitidine +/- donor lymphocyte infusion (maximum 12 cycles). Venetoclax: on D1 to D14 of 28 days cycle ; Phase I: 4 dose levels: 50, 100, 200, 400 mg/d, starting dose at 100 mg ; Phase II: dose defined in the phase I.~Azacitidine 75 mg/m²/d or 50 mg/m²/d (if allohematopoietic stem cell transplantation relapse < 4 months) x 5 days (on D1 to D5 of 28 days cycle)."
89444701|NCT05223205|Experimental|Air group|Air tamponade after vitrectomy.
89444702|NCT05223205|Experimental|SF6 group|10% SF6 tamponade after vitrectomy.
88929584|NCT01732380|Experimental|Raltitrexed/Oxaliplatin Plus Radiotherapy|Raltitrexed 2.5mg/㎡ d1,Oxaliplatin 100mg/㎡ d1,q21d Plus Radiotherapy 2.0Gy/day, 5 times/week,6 weeks In Subjects With Inoperable esophageal cancer
88929585|NCT01732393|Active Comparator|oral quercetin capsules|Patients in the intervention group were administered two, 250 mg Quercetin capsules daily for 3 weeks
88929586|NCT01732393|Placebo Comparator|oral placebo capsules|Patients in the placebo group received two placebo capsules containing lactose .
88929587|NCT01732497|Experimental|Single Group miraDry Treatment|This is a single group study where each enrolled subject will receive active miraDry treatment in each axilla.
89200028|NCT00884871||Laparoscopic adjustable gastric banding|100 obese women undergoing laparoscopic adjustable gastric banding
88929589|NCT01732562|No Intervention|Control|Patient receives the standard of care.
88929590|NCT01732562|Experimental|Patient e-Learning educational tool|Patient receives the standard of care and access to patient e-Learning educational tool.
88929591|NCT01732575|Experimental|Enrichment|Enrichment with meaning-generating activities
88929592|NCT01732575|No Intervention|Rehabilitation as usual|The ongoing, normal day center program.
88929593|NCT01732601|Experimental|Intensive Outpatient CBT|Intensive CBT for both parents and adolescents as well as family sessions to increase communication.
88929594|NCT01732601|Active Comparator|Standard Care|Standard Treatment in the Community
88929595|NCT01732614|Experimental|Topcon Endpoint Management Laser|
88929596|NCT01732653|Experimental|TT+VR|The training will consist of walking on the treadmill while negotiating obstacles in a virtual reality simulation.Training will be provided3 times a week for a duration of 6 weeks (total of 18 sessions).
88929597|NCT01732653|Active Comparator|TT alone|The training will consist of walking on the treadmill 3 times a week for a duration of 6 weeks (total of 18 sessions).
88929598|NCT01732666|Placebo Comparator|group L|receives 100 ml of 0.9% saline immediately after anesthesia induction and 0.05µg/kg/min of remifentanil during anesthesia.
88929599|NCT01732666|Placebo Comparator|group H|100 ml of 0.9% saline immediately after anesthesia induction and 0.3 µg/kg/min of remifentanil during anesthesia.
88929600|NCT01732666|Experimental|group N|20mg of nefopam mixed in 100 ml of 0.9% saline immediately after anesthesia induction and 0.3 µg/kg/min of remifentanil during anesthesia.
88929601|NCT01732679||stroke patients|specialized rehabilitation in a multidisciplinary team, Sunnaas International Network
88929602|NCT01732705|Experimental|HIT (trained leg) DM|High intensity interval training for one leg (trained leg) (randomized) in patient with type 2 diabetes
88929603|NCT01732705|No Intervention|Control leg, DM|Control leg (untrained leg)in patient with type 2 diabetes
88929604|NCT01732705|Experimental|HIT (trained leg), Control subject|High intensity interval training for one leg (trained leg) (randomized) in control subject
88929605|NCT01732705|No Intervention|Control leg, Control subject|Control leg (untrained leg)in control subject
88929606|NCT01732731|Experimental|treadmill training|children will receive home-based treadmill training with supervision from a physical therapist
88929607|NCT01732731|No Intervention|no treadmill training|children will not receive treadmill training
89200029|NCT00765414|Experimental|1|
88929608|NCT01732744|Placebo Comparator|Physiological solution|"1)Negative Control: physiological solution, for 20 minutes~All the volunteers used one of the four chemical methods (interventions) in a random sequence for a period of 07 days each. Between each period of use, there was a one week wash out period during which the patient performed his/her habitual cleaning procedure, in order to avoid a carry-over effect."
88929609|NCT01732744|Active Comparator|Sodium hypochlorite|"2)active Comparator 1: Sodium hypochlorite, for 20 minutes~All the volunteers used one of the four chemical methods (interventions) in a random sequence for a period of 07 days each. Between each period of use, there was a one week wash out period during which the patient performed his/her habitual cleaning procedure, in order to avoid a carry-over effect."
88929610|NCT01732744|Active Comparator|Peroxide alkaline|"2)Active Comparator 2: Alkaline peroxide (Polident), for 5 minutes~All the volunteers used one of the four chemical methods (interventions) in a random sequence for a period of 07 days each. Between each period of use, there was a one week wash out period during which the patient performed his/her habitual cleaning procedure, in order to avoid a carry-over effect."
88929611|NCT01732744|Experimental|Castor bean solution|"3)Experimental: castor bean solution, for 20 minutes~All the volunteers used one of the four chemical methods (interventions) in a random sequence for a period of 07 days each. Between each period of use, there was a one week wash out period during which the patient performed his/her habitual cleaning procedure, in order to avoid a carry-over effect."
89444703|NCT05215418|Experimental|VI-0521 Top Dose (Phentermine 15 mg + Topiramate 92 mg)|Week 1: VI-0521 (Phentermine 3.75 mg + Topiramate 23 mg) oral capsule, once daily; Week 2: VI-0521 (Phentermine 7.5 mg + Topiramate 46 mg) oral capsule, once daily; Week 3: VI-0521 (Phentermine 11.25 mg + Topiramate 69 mg) oral capsule, once daily; Weeks 4-8: VI-0521 (Phentermine 15 mg + Topiramate 92 mg) oral capsule, once daily
89444704|NCT05215418|Active Comparator|Phentermine 30mg|Weeks 1-8: Phentermine 30mg oral capsule, once daily
89444705|NCT05215418|Placebo Comparator|Placebo|Weeks 1-8: Placebo oral capsule, once daily
89444706|NCT05211388|Experimental|arm 1: generator-controlled RFA|In up to 6 patients (arm 1: generator-controlled RFA), RFA will be performed directly following manufacturer-specified algorithms, with recording of 3D ultrasound echo decorrelation images during ablation.
89444707|NCT05211388|Experimental|arm 2: imaging-controlled RFA|In up to 6 additional patients (arm 2: imaging-controlled RFA), real-time, 3D echo decorrelation imaging during ablation will provide an additional treatment end point.
89444708|NCT05209425|Active Comparator|Regular Vitamin D3 1000IU|The first group receives regular Vitamin D3 1000IU
89444709|NCT05209425|Active Comparator|Microencapsulated Vitamin D3 1000IU|The second group receives microencapsulated Vitamin D3 1000IU
89444710|NCT05209425|Active Comparator|Regular Vitamin D3 2500IU|The third group receives regular Vitamin D3 2500IU
89444711|NCT05209425|Active Comparator|Microencapsulated Vitamin D3 2500IU|The fourth group receives microencapsulated Vitamin D3 2500IU
89444712|NCT05201040|Experimental|Mannitol-combined Hyaluronic acid|2.0mL/syringe for one treatment
89444713|NCT05201040|Placebo Comparator|Normal saline|2.0mL for one treatment
89444714|NCT05198557|Experimental|MT-0551 group|Participants will receive intravenous (IV) inebilizumab on Day 1 and Day 15 of randomized controlled period (RCP). The participants who entered open label period (OLP) will receive IV inebilizumab on Day 1 and IV placebo on Day 15 of OLP and will be followed by IV inebilizumab every 26 weeks.
89444715|NCT05198557|Placebo Comparator|Placebo group|Participants will receive IV placebo on Day 1 and Day 15 of the RCP. The participants who entered OLP will receive IV inebilizumab on both Day 1 and Day 15 in OLP and will be followed by IV inebilizumab every 26 weeks.
88929612|NCT01732848||Subjects treated with BMS-986094/INX-08189|Subjects who participated in a clinical trial in which at least 1 dose of BMS-986094/INX-08189 was administered
89444716|NCT05177601|Active Comparator|TMS+DCS|"The Transcranial Magnetic Stimulation (TMS) involves magnetic stimulation of the brain to the left medial prefrontal cortex (mPFC) daily for four weeks. The stimulation is intermittent Theta-Burst (iTBS).~Participants will orally ingest a capsule containing 100mg of the antibiotic d-cycloserine (DCS) daily (Monday-Friday) for 4 weeks of rTMS treatment (20 sessions) one hour prior to rTMS treatment."
89444717|NCT05177601|Active Comparator|TMS+Placebo|"The Transcranial Magnetic Stimulation (TMS) involves magnetic stimulation of the brain to the left medial prefrontal cortex (mPFC) daily for four weeks. The stimulation is intermittent Theta-Burst (iTBS).~Participants will orally ingest a capsule identical to that containing the study medication, however this capsule will contain a placebo. They will ingest this capsule daily (Monday-Friday) for 4 weeks of rTMS treatment (20 sessions) one hour prior to rTMS treatment."
88929613|NCT01732848||Subjects treated with Placebo matching BMS-986094/INX-08189|Subjects who participated in a clinical trial in which at least 1 dose of Placebo matching BMS-986094/INX-08189 was administered
88929614|NCT01732861|Experimental|CC-292 + Lenalidomide|
88929615|NCT01732887|Other|Immediate cognitive fitness training|"After the initial baseline evaluation, the immediate treatment group participants will receive individualized multi-domain cognitive training and standard of care. Cognitive training includes at least 1/2 hour per session, 3 days per week, throughout the 10 week interval. After 10 weeks of cognitive fitness training, participants in this group will switch to a 20 week no intervention period where they receive only standard of care treatment."
89013637|NCT06295419|Experimental|cerebral palsy|cerebral palsy will be evaluated single and dual task conditions
89013638|NCT06295419|Experimental|healthy controls|Healthy controls will be evaluated single and dual task conditions
89013639|NCT06295406||Cases|Participants with age range between 11 and 16 years, with overweight (BMI>85° ) or obesity (BMI>95°)
89444718|NCT05177601|Sham Comparator|shamTMS+DCS|"Sham rTMS treatment involves scalp stimulation with no magnetic pulse daily for four weeks (20 sessions). Sham rTMS involves only the click replicating the sound of the magnetic discharge, without any magnetic pulse being delivered to the brain.~Participants will orally ingest a capsule containing 100mg of the antibiotic d-cycloserine (DCS) daily (Monday-Friday) for 4 weeks of rTMS treatment (20 sessions) one hour prior to rTMS treatment."
89444719|NCT05177601|Placebo Comparator|shamTMS+placebo|"Sham rTMS treatment involves scalp stimulation with no magnetic pulse daily for four weeks (20 sessions). Sham rTMS involves only the click replicating the sound of the magnetic discharge, without any magnetic pulse being delivered to the brain.~Participants will orally ingest a capsule identical to that containing the study medication, however this capsule will contain a placebo. They will ingest this capsule daily (Monday-Friday) for 4 weeks of rTMS treatment (20 sessions) one hour prior to rTMS treatment."
89444720|NCT05172479||Positive qSOFA|Adult patients with suspected infection and a qSOFA score ≥ 2 at the triage in the ED who are planned for hospitalization
89444721|NCT05172479||Negative qSOFA|Adult patients with suspected infection and a qSOFA score < 2 at the triage in the ED who are planned for hospitalization
89444722|NCT05172479||Positive SIRS|Adult patients with suspected infection and a SIRS criteria ≥ 2 at the triage in the ED who are planned for hospitalization
89444723|NCT05172479||Negative SIRS|Adult patients with suspected infection and a SIRS criteria < 2 at the triage in the ED who are planned for hospitalization
89444724|NCT05172479||Positive NEWS|Adult patients with suspected infection and a NEWS ≥ 5 or red score (i.e., a score of 3 in any one parameter) at the triage in the ED who are planned for hospitalization
89444725|NCT05172479||Negative NEWS|Adult patients with suspected infection and a NEWS < 5 at the triage in the ED who are planned for hospitalization
89444726|NCT05172479||Positive NEWS2|Adult patients with suspected infection and a NEWS2 ≥ 5 or red score (i.e., a score of 3 in any one parameter) at the triage in the ED who are planned for hospitalization
89444727|NCT05172479||Negative NEWS2|Adult patients with suspected infection and a NEWS2 < 5 at the triage in the ED who are planned for hospitalization
89444728|NCT05172479||Positive MEWS|Adult patients with suspected infection and a MEWS ≥ 5 at the triage in the ED who are planned for hospitalization
89444729|NCT05172479||Negative MEWS|Adult patients with suspected infection and a MEWS < 5 at the triage in the ED who are planned for hospitalization
89444730|NCT05164991|Experimental|MR imaging|The experiment is aimed to induce a virtual rubber hand illusion, in which the individuals can potentially experience an embodiment illusion
88929616|NCT01732887|Other|Delayed cognitive fitness training|"After the initial baseline evaluation, the delayed cognitive fitness training group participants will receive only standard of care for 10 weeks (no intervention period). Starting in week 11, participants in this arm will receive individualized multi-domain cognitive training and standard of care. Cognitive training includes at least 1/2 hour per session, 3 days per week, throughout the 10 week interval. After 10 weeks of cognitive fitness training, participants will go for another 10 weeks with only standard of care treatment."
88929617|NCT01732900|Active Comparator|Morphology|Embryos selected for transfer will be based on morphology alone.
88929618|NCT01732900|Experimental|GemART assay|Embryos selected for transfer will be based upon morphology and GemART assay.
89444731|NCT05163028|Experimental|Dose Escalation and Expansion|HBI-2376 will be given orally in ascending doses (escalation cohort), until the maximum tolerated dose or recommended Phase 2 dose is reached. Up to 6 patients will then be enrolled in the expansion cohort at the recommended dose.
89444732|NCT05152914|Experimental|Intervention|
88929619|NCT01732939||AT|Docetaxel 75 mg/m2, day 1 or paclitaxel 175mg/m2 day 1 plus Epirubicin 75 mg/m2, day 1 or doxorubicine 50mg/m2 day 1 for 6-8 cycles
88929620|NCT01732939||AT-NP|docetaxel 75mg/m2,day 1 or paclitaxel 175mg/m2,day 1 plus doxorubicine 50mg/m2,day 1 or epirubicin 75mg/m2, day 1,for3-4 cycles then switch to vinorelbine 25mg/m2, day 1 and day 8 plus cisplatinum 75mg/m2, day 1 for 3-4 cycles
88929621|NCT01732952||regions,hospitals,age, gender, risk levels, comorbidity,|
88929622|NCT01732965|Placebo Comparator|NB-UVB phototherapy|NB-UVB alone
88929623|NCT01732965|Experimental|phototherapy and photochemotherapy|NB-UVB and PUVA
88929624|NCT01732978|Other|Babies|Any child born in the University Hospital of Saint Etienne (inborn) whatever its term birth, hospitalized in a neonatal unit at the time of registration (after 37 weeks of gestation for preterm infants) or maternity
89444733|NCT05149781||patients with EH|patients with endocrine hypertension
89444734|NCT05149781||patients with PH|patients with primary hypertension
89444735|NCT05136807||Observational (quality of life questionnaire)|Patients complete quality of life questionnaires over 10-15 minutes at baseline and every 6 months for patients participating in an observational study or every month for patients participating in a treatment study for up to 3 years.
89444736|NCT05134545|Experimental|Genoss® DCB|Paclitaxel Coated PTA Balloon Catheter
89444737|NCT05134545|Active Comparator|IN.PACT Admiral® DCB|Paclitaxel Coated PTA Balloon Catheter
89444738|NCT05114018|Experimental|Experimental group receiving pasteurized Akkermansia muciniphila|Experimental group receiving pasteurized Akkermansia muciniphila.
89444739|NCT05114018|Placebo Comparator|Control group|Control group receiving placebo, identical to verum regarding the form, size, taste, color and intake.
89444740|NCT05072795|Experimental|Stress Induction|
89444741|NCT05067621|Experimental|Receive treatment|Semaglutide (Wegovy) pen is a subcutaneous injection
89444742|NCT05067621|Placebo Comparator|Placebo|The placebo pen is almost exactly the same as the Wegovy subcutaneous injection except it does not contain the active ingredient, Semaglutide.
89444743|NCT05051774|Experimental|Intervention Group|In addition to usual care, the intervention group will receive the 12 weeks intervention consists of three monthly group education and center-based group exercise followed by 20 minutes of individualized telephone follow-up at weeks 3, 7, and 11.
88929625|NCT01732991|Experimental|prostatic photo-vaporization|prostatic photo-vaporization (PVP) surgery with laser Greenlight
88929626|NCT01733004|Experimental|Arm A|MM-141 monotherapy
88929627|NCT01733004|Experimental|Arm B|MM-141 and Everolimus
88929628|NCT01733004|Experimental|Arm C|MM-141 and Abraxane and Gemcitabine
88929629|NCT01733017|Experimental|sodium reduction, omega-3, lycopene|combination of dietary sodium restriction with supplementation of omega-3 capsules and lycopene containing juices or foods
88929630|NCT01733017|Placebo Comparator|Control|Limited nutritional counseling, juice without lycopene, rice oil capsules
88929631|NCT01733030||250 mg Seromycin|Healthy adults who will receeve one administration of 250 mg of Seromycin prior to the start of the study.
88929632|NCT01733030||500 mg Seromycin|Healthy adults who will recieve one administration of 500 mg of Seromycin prior to the start of the study.
88929633|NCT01733030||Placebo|Healthy adults who will receive one administration of a placebo pill prior to the start of the study.
88929634|NCT01733043|Experimental|Dexmedetomidine infusion|Dexmedetomidine 0.5 mcg/kg loading dose administered over 20 minutes, followed by 0.6 mcg/kg/hr infusion for 1 hour and 40 minutes
88929635|NCT01733043|Placebo Comparator|Placebo|Normal saline infusions will be administered over 4 hours at rates mimicking the DEX infusion rate
88929636|NCT01733095|Experimental|ambrisentan|In all patients with clinically significant PoPH, ambrisentan will be administered orally using a low ascending dose regime (see below). Duration of treatment will be 12 months.
88929637|NCT01733108|Experimental|Canagliflozin (JNJ-28431754) + glyburide|Each volunteer will receive a single dose of glyburide on Day 1, followed by canagliflozin (JNJ-28431754) once daily on Days 4 through 8. On Day 9 volunteers will receive a single dose of glyburide in combination with a single dose of canagliflozin.
88929638|NCT01733134|Experimental|Standard therapy plus Tolvaptan|Patient in the interventional group will receive tolvaptan in addition to standard therapy
88929639|NCT01733134|Placebo Comparator|Standard therapy plus placebo|
88929640|NCT01733173||mass in posterior fossa, either benign or malignant|A pilot study will be performed. We will perform fMRI and DTI in children before and after surgery for posterior fossa brain tumors. Each subject will receive the standard of care for their brain tumors in terms of surgical resection, radiation therapy and/or chemotherapy.
88929641|NCT01733199|Experimental|BA-|Patient with no secondary behavioural addiction
88929642|NCT01733199|Experimental|BA+/DDS-|Patients with secondary behavioural addiction, without dopamine dysregulation syndrome
88929643|NCT01733199|Experimental|BA+/DDS+|Patients with secondary behavioural addiction and dopamine dysregulation syndrome
88929644|NCT01733290|Experimental|Botulinum toxin A|A total of 100 units of BoNT-A will be injected deeply into the external sphincter at the 3, 6, 9 and 12 o'clock positions in approximate equal aliquot.
88929645|NCT01733290|Placebo Comparator|Control arm-Normal saline instillation|Normal saline instillation
88929646|NCT01733303|Experimental|Exercise|Participants are allocated to the exercise group will commence the personalized core training exercise with EMG biofeedback based on their testing results in muscle quality.
88929647|NCT01733342|Active Comparator|Celsite|patients received celsite chemoport implantation under local anesthesia
88929648|NCT01733342|Experimental|Humanport|patients received Humanport chemoport implantation under local anesthesia
88929649|NCT01733355|Experimental|Tau diagnostic|[F18] T807
88929650|NCT01733381||Barefoot runners|This group of individuals will run in minimally shod foot ware. For the purposes of this study we have defined this to be Vibram Five Finger shoes. Participants will be runners who consistently run in these shoes at least 20 miles per week.
88929651|NCT01733381||Shoed runners|This group of individuals will run in normal running shoes. Participants will be runners who consistently run in regular running shoes (that are not considered by industry standards to be minimal shoes) at least 20 miles per week.
88929652|NCT01733394|Experimental|Generic A - Generic B - Brand - Generic A - Brand - Generic B|Sequence 1
88929653|NCT01733394|Experimental|Generic B - Brand - Generic A - Generic B - Generic A - Brand|Sequence 2
88929654|NCT01733394|Experimental|Brand - Generic A - Generic B - Brand - Generic B- Generic A|Sequence 3
88929655|NCT01733446|No Intervention|Standard anesthesia regimen|Positive pressure ventilation will be stopped at the same time infusions of anesthetic agents and spontaneous ventilation employed until emergence from anesthesia is observed. (This is standard protocol for everyday anesthesia management of this population.)
88929656|NCT01733446|Experimental|Continuation of High Frequency Jet Ventilation ( HFJV)|In Group B after cessation of anesthetic infusions, High Frequency Jet Ventilation (HFJV) will continue through the endotracheal tube. Patient will be extubated when awake. Respiratory Inductance Plethysmography (RIP) and transcutaneous carbon dioxide (PtcCO2) measurements will continue for the duration of emergence.
89444744|NCT05051774|No Intervention|Control Group|The control group will receive the usual care provided in the study hospital included an unstructured health education conducted by a nurse on healthy lifestyle and health assessment and brief unstructured health education on their conditions, focusing on the risk factors management and stress management by the cardiologist.
89444745|NCT05051579|Experimental|12 milligram (mg) LY3502970|Participants received maintenance dose 12 mg with dose escalation starting from 3 mg,6 mg and then 12 mg LY3502970 administered orally once daily until 36 weeks.
89444746|NCT05051579|Experimental|24 mg LY3502970|Participants received maintenance dose 24 mg with dose escalation starting from 3 mg, 6 mg, 8 mg,12 mg and then 24 mg LY3502970 administered orally once daily until 36 weeks.
89444747|NCT05051579|Experimental|36 mg-1 LY3502970|Participants received maintenance dose 36 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 8 mg, 12 mg, 24 mg and then 36 mg LY3502970 administered orally once daily until 36 weeks.
89444748|NCT05051579|Experimental|36 mg-2 LY3502970|Participants received maintenance dose 36 mg with dose escalation starting from 3 mg, 6 mg,12 mg, 24 mg and then 36 mg LY3502970 administered orally once daily until 36 weeks.
88929657|NCT01733459|Experimental|Treatment I|1 DLBS3233 capsule 100 mg (once daily) and 1 placebo caplet of Metformin XR (twice daily)
88929658|NCT01733459|Active Comparator|Treatment II|1 Metformin XR caplet 750 mg (twice daily) and 1 placebo capsule of DLBS3233 (once daily)
88929659|NCT01733485|Active Comparator|Aspirin|
88929660|NCT01733485|Active Comparator|Indomethacin|
88929661|NCT01733485|No Intervention|Control|
88929662|NCT01733511||admitted to emergency department|
88929663|NCT01733511||patients admitted to surgical ward|
88929664|NCT01733524|Sham Comparator|Picture of a fish|Participants will receive a picture of a betta fish.
88929665|NCT01733524|Active Comparator|Pet fish|Participants will receive a betta fish and the supplies to care for the fish for a one year time period.
88929666|NCT01733537|Experimental|Vest and Education|Motorcycle Taxi Drivers provided with a reflective, fluorescent vest and basic education about recommended measures to increase their visibility
88929667|NCT01733537|Other|Education Alone|Motorcycle Taxi Drivers provided with basic education about recommended measures to increase their visibility
89444749|NCT05051579|Experimental|45 mg-1 LY3502970|Participants received maintenance dose 45 mg with dose escalation starting from 3 mg, 6 mg, 8 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally once daily until 36 weeks.
88929668|NCT01733550||Glaucoma patients|Intraocular pressure is measured by Home iCare performed by the study nurse, by the patient it self and by Goldmann applanation tonometry.
88929669|NCT01733563|Experimental|fructose sweetened beverage|"Soft drink consumption:~Subjects have to drink a fructose sweetened beverage (3x 200ml per day, 13.3g fructose/100ml) during 7 weeks"
88929670|NCT01733563|Experimental|glucose sweetened beverage|"Soft drink consumption:~Subjects have to drink a glucose sweetened beverage (3x 200ml per day, 13.3g glucose/100ml) during 7 weeks"
88929671|NCT01733563|Experimental|sucrose sweetened beverage|"Soft drink consumption:~Subjects have to drink a sucrose sweetened beverage (3x 200ml per day, 13.3g sucrose/100ml) during 7 weeks"
88929672|NCT01733563|Experimental|No change of eating habits|"No Soft drink consumption (no soft drink diet):~Subjects do not change their eating habits during 7 weeks"
89200030|NCT00960544|Experimental|Capecitabine|Capecitabine - Routine administration of twice daily dosing for days 1-14 of a 21-day cycle.
89444750|NCT05051579|Experimental|45 mg-2 LY3502970|Participants received maintenance dose 45 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally once daily until 36 weeks.
88929673|NCT01733576|Sham Comparator|Sham HD-tDCS|
88929674|NCT01733576|Active Comparator|Active HD-tDCS 1|
88929675|NCT01733576|Active Comparator|Active HD-tDCS 2|
88929676|NCT01733576|Active Comparator|Active HD-tDCS 3|
88929677|NCT01733589|Experimental|Recombinant Human Endostatin|All patients received recombinant human endostatin(7.5mg/m2/24h) Continued Pumping Into Vein through 5 days at week 1, 3, 5, and 7. During week 2 through 8, patients received etoposide 50mg/m2 days 1-5 and cisplatin 50mg/m2 on day 1,8, every 4 weeks for two cycles with concurrent thoracic radiation at 60~66Gy in 30~33 fractions for 6~7 weeks.
88929678|NCT01733602|Experimental|active tDCS and cognitive training|Transcranial direct current stimulation combined with cognitive training
88929679|NCT01733602|Active Comparator|sham tDCD and cognitive training|Sham transcranial direct current stimulation combined with cognitive training
88929680|NCT01733615||Mucopolysaccharidosis IVA|Patients with the condition.
88929681|NCT01733654|Active Comparator|RO4995819 5mg|RO4995819 5mgX6wks
88929682|NCT01733654|Active Comparator|RO4995819 15mg|RO4995819 15mg X 6 weeks
88929683|NCT01733654|Active Comparator|RO4995819 30mg|RO4995819 30mg X 6 weeks
88929684|NCT01733654|Placebo Comparator|Placebo|Placebo X 6 weeks
88929685|NCT01733667|Experimental|MediENT|Right or left sinus cavity where MediENT will be place after randomization.
88929686|NCT01733667|Active Comparator|MeroPack|Right or left sinus cavity where MeroPack will be placed after randomization of MediENT is assigned.
88929687|NCT01733706|Active Comparator|Standard counseling|a psychologist will provide standard counseling
88929688|NCT01733706|Experimental|No nicotine electronic cigarette|patients will receive standard counseling as well as an electronic cigarette
88929689|NCT01733719|Active Comparator|ER plus RFA|Initial Endoscopic Resection of visible neoplasia/HGD in Barrett's esophagus followed by 4 x 2 monthly interventions (either ER of residual/metachronous visible lesions or RadioFrequency Ablation of 'flat' dysplastic or non-dysplastic Barrett's esophagus)
88929690|NCT01733719|Active Comparator|ER plus APC|Initial Endoscopic Resection of visible neoplasia/HGD in Barrett's esophagus followed by 4 x 2 monthly interventions (either ER of residual/metachronous visible lesions or Argon Plasma Coagulation of 'flat' dysplastic or non-dysplastic Barrett's esophagus)
88929691|NCT01733771||CAM with standard care|Symptomatic hospitalized people referred by the medical team to CAM treatments on top of standard of care
88929692|NCT01733771||Standard care only|Symptomatic patients who are referred to CAM treatments but are not interested in such treatments
89444751|NCT05051579|Placebo Comparator|Placebo|Participants received placebo administered orally once daily until 36 weeks.
89444752|NCT05045404|Experimental|Treatment (poziotinib hydrochloride, ramucirumab)|Patients receive poziotinib hydrochloride PO BID on day 1 and ramucirumab IV over 30-60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89444753|NCT05044676||patients with hepatocellular carcinoma|Patients with an indication for treatment with Atezolizumab / Bevacizumab for the management of an advanced disciplinary hepatocellular carcinoma in a multidisciplinary consultation meeting.
89444754|NCT05044546|Experimental|Aim 1 and secondary aim 2 (focus group)|Participants participate in focus group over 60-90 minutes. Participants who completed and dropped out of postpartum treatment also participate in a focus group.
89444755|NCT05044546|Experimental|Aim 3 Group I (BA)|Participants participate in smoking cessation counseling over 15 minutes and BA counseling sessions over 45 minutes once a week for 10 weeks to pilot test delivery via smartphone videoconferencing and to conduct process evaluation of technical issues in use of smartphones.
89444756|NCT05044546|Experimental|Aim 3 Group II (HW)|Participants participate in smoking cessation counseling over 15 minutes and health and wellness education counseling sessions over 45 minutes once a week for 10 weeks to pilot test delivery via smartphone videoconferencing and to conduct process evaluation of technical issues in use of smartphones.
89444757|NCT05044546|Experimental|Aim 4 Group III (BA)|Participants participate in 8-14 smoking cessation counseling over 15 minutes and BA counseling sessions over 45 minutes every 2-3 weeks till the end of the pregnancy. Following birth, participants also participate in 4 additional sessions within the first 6 weeks, then that last 4 evenly distributed across 10 weeks.
89444758|NCT05044546|Experimental|Aim 4 Group IV (HW)|Participants participate in 8-14 smoking cessation counseling over 15 minutes and health and wellness education counseling sessions over 45 minutes every 2-3 weeks till the end of the pregnancy. Following birth, participants also participate in 4 additional sessions within the first 6 weeks, then that last 4 evenly distributed across 10 weeks.
88929693|NCT01733784|Experimental|Viscoelastic properties of the airway|
88929694|NCT01733797|Experimental|Wooden spatula|
88929695|NCT01733797|Experimental|Therabite|
88929696|NCT01733810|Experimental|Reflux Patients|Patients with reflux and a prior history of reflux esophagitis are being enrolled. The intervention is cessation of acid-suppressing medications.
88929697|NCT01733823|Experimental|Group A|Performance scale 0-1, Charlson co-morbidity score=0 Treatment: 76 Gy/ 56 fx/ 10/W with cisplatin 40 mg/m2/W and nimorazole
88929698|NCT01733823|Experimental|Group B|PS 0-1 Charlson=1 Treatment: 76 Gy/ 56 fx/ 10/W with cisplatin 40 mg/m2/W and nimorazole
88929699|NCT01733823|Experimental|Group C|PS 0-1 Charlson >=2 Will start inclusion after Group A and B Treatment: 76 Gy/ 56 fx/ 10/W with cisplatin 40 mg/m2/W and nimorazole
88929700|NCT01733823|Experimental|Group D|PS 2, Charlson: Any Will start inclusion after Group C Treatment: 76 Gy/ 56 fx/ 10/W with cisplatin 40 mg/m2/W and nimorazole
88929701|NCT01733836|Experimental|Metformin|850mg BID
88929702|NCT01733836|Placebo Comparator|Placebo|
88929703|NCT01733849||Group Bulgaria|Subjects in this group include infants/children from Bulgaria, less than five years of age with home visits by the GP/paediatrician for the treatment of AGE or brought to the GP/paediatrician for the treatment of AGE.
88929704|NCT01733849||Group Latvia|Subjects in this group include infants/children from Latvia, less than five years of age with home visits by the GP/paediatrician for the treatment of AGE or brought to the GP/paediatrician for the treatment of AGE.
88929705|NCT01733862||Group Japan|Children less than five years of age, hospitalized for RV GE or AGE and children with outpatient or emergency room visits for RV GE or AGE, between November 2007 and October 2016 (i.e., before and after the introduction of RV vaccination in Japan) in any of the selected hospitals.
88929706|NCT01733875|Experimental|CC-220 0.03 mg|
88929707|NCT01733875|Experimental|CC-220 0.1 mg|
88929708|NCT01733875|Experimental|CC-220 0.3 mg|
88929709|NCT01733875|Experimental|CC-220 1 mg|
88929710|NCT01733875|Experimental|CC-220 2 mg|
88929711|NCT01733875|Experimental|Placebo|In each arm, 6 subjects will receive a dose of CC-220 and 2 subjects will receive placebo depending on the randomization schedule.
88929712|NCT01733875|Experimental|CC-220 4 mg|
88929713|NCT01733875|Experimental|CC-220 6 mg|
88929714|NCT01733875|Experimental|CC-220 1 mg (Part 2 only)|
88929715|NCT01733901|Active Comparator|RSD+PCI+Medicine|We will recruit 300 randomised CHD patients who meet the inclusion criteria. First undergo percutaneous coronary intervention, and then perform the renal artery angiography procedure to confirm anatomy. If renal artery meet the inclusion criteria, give the renal sympathetic denervation. After renal sympathetic denervation traditional secondary prevention of coronary heart disease is recommend. Finally we will conduct a clinic follow-up every six month and a telephone follow-up every three month(Total 24 months).
88929716|NCT01733901|Placebo Comparator|PCI+Medicine|We aslo will recruit 300 randomised CHD patients who meet the inclusion criteria. There are no significant differences in age, gender, race, past medical history,personal history and so on between the two groups. In this group we will perform percutaneous coronary intervention firstly, then give traditional secondary prevention of coronary heart disease just like the RSD+PCI+Medicine group. Third we will conduct a clinic follow-up every six month and a telephone follow-up every three month(Total 24 months).
88929717|NCT01733914|Experimental|Acupuncture|Experimental group
88929718|NCT01733914|Sham Comparator|Waiting list|Control group
88929719|NCT01733927|Experimental|Rapid testing for HIV|The intervention consisted in administer an oral rapid test for HIV (OQA) to people that also had taken an ELISA test to compare their tests results. Group 1 consisted of 344 participants who did not know their HIV status; Group 2 consisted of 153 participants who were previously confirmed to be HIV positive. The participants were instructed to obtain their own oral fluid sample using the testing devices provide by the OQA rapid test kits. Project team members, certified to interpret OQA results, registered each test outcome on a data form using the same code number that the participant was assigned for the ELISA test.
88929720|NCT01733940|Experimental|"Tegaderm CHG Dressing"|This arm is receiving a clorhexidine dressing for intravascular catheters.
89444759|NCT05041998|Experimental|Unmodified Socket + 8 Socket Modifications in Random Order|The sequence of the 9 different interventions (original socket and 8 versions derived from it) is randomized for each participant. The number of participants is smaller than the number of possible permutations. Therefore the enacted ordering is randomly selected from the pool of possible orderings. Participants walk for less than 10 minutes with every socket type while data is being collected.
89444760|NCT05031494|Experimental|YH003 with Toripalimab in subjects with unresectable /metastatic melanoma|YH003 in combination with Toripalimab in subjects with unresectable /metastatic melanoma after having failed PD-1/L1 +/- CTLA-4 treatment;
89444761|NCT05031494|Experimental|YH003 with Toripalimab in subjects with PDAC|YH003 in combination with Toripalimab in subjects with unresectable/ metastatic pancreatic ductal adenocarcinoma (PDAC) as 2nd line treatment;
89444762|NCT05031494|Experimental|YH003 with Toripalimab plus standard chemotherapy|YH003 in combination with Toripalimab plus standard chemotherapy (Nab-paclitaxel + Gemcitabine) in subjects with unresectable/metastatic PDAC as 1st line treatment;
89444763|NCT05023889|Other|open label|single open arm label
89444764|NCT05022368|Experimental|Oral Safety Device|"patients on which the device LabraGuard is used."
89444765|NCT05019703|Experimental|Treatment (atezolizumab, cabozantinib)|Patients receive atezolizumab IV over 60 minutes on day 1 and cabozantinib PO QD on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89444766|NCT05019651|Experimental|Single Arm- Apollo Wearable System|Apollo Device TVS (10-200 Hz) attached to the subject's wrist or ankle via a commercially available wearable vibration technology can deliver TVS (Transcutaneous Vibratory Stimulation). The intensity will be targeted for the sensory threshold (the level at which the vibration is just noticeable) as this is where the TVS seems to be most effective from prior studies. Similar vibratory stimuli have been demonstrated to be safe in the literature.10-14 The intensity of the vibration will be adjusted to the subjects' comfort and can be controlled by the subject at any time.
88929721|NCT01733940|Active Comparator|"Tegaderm IV dressing"|Use of tegaderm iv dressings for intravascular catheters. Change each 7 days.
88929722|NCT01733966|Experimental|Secnidazol-Ciprofloxacin|2g(single dose) of Secnidazol associated with 1g(2 doses of 500mg)of Ciprofloxacin during 3 days
88929723|NCT01733966|Active Comparator|Amoxicillin-Clavulanic Acid|3g (3 doses of 1g) of Amoxicillin-Clavulanic acid during 10 days
88929724|NCT01733979|Experimental|Heme-Iron Polypeptide|
88929725|NCT01733979|Placebo Comparator|Placebo|
88929726|NCT01733979|Active Comparator|Heme-Iron|
88929727|NCT01733979|Active Comparator|Organic Iron|
88929728|NCT01733992|Active Comparator|R348 Ophthalmic Solution, 0.2%|R348 Ophthalmic Solution, 0.2%, single (1 day) and multiple ascending dose (13 days) followed by a single dose on the fourteenth day.
88929729|NCT01733992|Active Comparator|R348 Ophthalmic Solution, 0.5%|R348 Ophthalmic Solution, 0.5%, single (1 day) and multiple ascending dose (13 days) followed by a single dose on the fourteenth day.
88929730|NCT01733992|Active Comparator|R348 Ophthalmic Solution, 1.0%|R348 Ophthalmic Solution, 1.0%, single (1 day) and multiple ascending dose (13 days) followed by a single dose on the fourteenth day.
88929731|NCT01733992|Placebo Comparator|Placebo|Placebo, single (1 day) or multiple ascending dose (13 days) followed by a single dose on the fourteenth day.
88929732|NCT01734005|Experimental|Red Ginseng|
88929733|NCT01734005|Placebo Comparator|Placebo|
88929734|NCT01734018||Cohort|
88929735|NCT01734044|Experimental|combination treatment group|100 enrolled patients are randomly picked up to take rhTPO in combination with dexamethasone at the indicated dose.
88929736|NCT01734044|Active Comparator|single treatment group|100 enrolled patients are randomly picked up to take dexamethasone at the indicated dose.
88929737|NCT01734057|Experimental|combinant treatment group|120 enrolled patients are randomly picked up to take Rituximab in combination with rhTPO at the indicated dose.
89444767|NCT05010681|Experimental|Lenvatinib plus Sintilimab|
89444768|NCT05010668|Experimental|Cryoablation in combination with Sintilimab plus lenvatinib|
89444769|NCT05008874||Males with AMN|Adult males with confirmed diagnosis of ALD and symptoms of AMN.
89444770|NCT04996940|Experimental|Tobacco then Menthol|A 30-minute session with tobacco flavor then a 30-min session with menthol flavor
89444771|NCT04996940|Experimental|Menthol then tobacco|A 30-minute session with menthol flavor then a 30-min session with tobacco flavor
89444772|NCT04979377||Adult premenopausal women with type 1 diabetes mellitus|One-hundred and fifty women aged from 18 to 45 years old consecutively recruited from a type 1 diabetes clinic at a tertiary hospital of Madrid, Spain
89444773|NCT04965181|Experimental|Mindfulness-based Addiction Treatment (MBAT) + iQuit Mindfully|"Participants will receive virtual group counseling based on the Mindfulness-Based Addiction Treatment (MBAT) group protocol, iQuit Mindfully text messages, and nicotine replacement therapy (NRT). MBAT consists of 8 weekly 2-hour sessions. NRT consists of 8 weeks of generic nicotine patches and nicotine lozenges. Participants who smoke >10 cigarettes/day will receive 4 weeks of 21 mg patches, 2 weeks of 14 mg patches, and 2 weeks of 7 mg patches. Those who smoke less than 10 cigarettes/day will receive 4 weeks of 14 mg patches and 4 weeks of 7 mg patches. Participants who smoke their first cigarette within 30 minutes of waking will receive 8 weeks of 4mg mini lozenges (6-9 4mg mini lozenges per day). Those who smoke their first cigarette over 30 minutes of waking will receive 8 weeks of 2mg mini lozenges (6-9 2mg mini lozenges per day). Participants will also be given the National Cancer Institute Clearing the Air booklet and a referral to the Tobacco Cessation Quitline."
89444774|NCT04965181|Experimental|iQuit Mindfully|"Participants will receive iQuit Mindfully text messages and nicotine replacement therapy (NRT). NRT consists of 8 weeks of generic nicotine patches and nicotine lozenges. Participants who smoke >10 cigarettes/day will receive 4 weeks of 21 mg patches, 2 weeks of 14 mg patches, and 2 weeks of 7 mg patches. Those who smoke less than 10 cigarettes/day will receive 4 weeks of 14 mg patches and 4 weeks of 7 mg patches. Participants who smoke their first cigarette within 30 minutes of waking will receive 8 weeks of 4mg mini lozenges (6-9 4mg mini lozenges per day). Those who smoke their first cigarette over 30 minutes of waking will receive 8 weeks of 2mg mini lozenges (6-9 2mg mini lozenges per day). Participants will also be given the National Cancer Institute Clearing the Air booklet and a referral to the Tobacco Cessation Quitline."
88929738|NCT01734057|Active Comparator|single treatment group|120 enrolled patients are randomly picked up to take dexamethasone at the indicated dose.
88929739|NCT01734070|Experimental|Cherry consumption|Volunteers will supplement their diets with 280 grams/day of pitted Bing cherries by replacing an equivalent amount of carbohydrate calories. We will prefer that the subjects split the cherries into three equal portions and consume one with each meal; however, this will not be mandatory.
88929740|NCT01734083|Experimental|Whole body vibration exercise|The experimental group will receive 2 sessions of whole body vibration exercise training and conventional exercise per week for a period of 9 weeks. The total duration of vibration exposure per session will range from 4 to 6 minutes. The vibration frequency and amplitude used will be 30 Hz and 1 mm, respectively.
88929741|NCT01734083|Active Comparator|Conventional exercise|This group will receive 2 sessions of conventional exercise training per week for a period of 9 weeks.
88929742|NCT01734096|Active Comparator|control group|healthy volunteer
88929743|NCT01734096|Active Comparator|obesity group|Patients with BMI >30 Kg/m2
88929744|NCT01734096|Active Comparator|white coat hypertension group|Patients with office blood pressure >140/90 mmHg and ambulatory daytime blood pressure <135/85 mmHg
88929745|NCT01734096|Active Comparator|Resistant hypertension|Patients with ambulatory blood pressure > 135/85 mm Hg (day) or >120/70 mm Hg (night) with 3 antihypertensive drugs with direct observance of drug taking.
88929746|NCT01734109|Placebo Comparator|Standard of Care - Wound Care|Standard, acceptable local wound care management, consisting of topical treatments, chemical debriders, or light bedside debridement.
88929747|NCT01734109|Active Comparator|Quantum NPWT|Intervention with Quantum NPWT to Standard III/IV pressure ulcers for 12 weeks.
88929748|NCT01734109|Active Comparator|Quantum NPWT with Irrigation|NPWT with the Quantum device, with the addition of simultaneous irrigation using 0.25% acetic acid.
88929749|NCT01734135|No Intervention|Usual Care|Usual care
88929750|NCT01734135|Experimental|Clinical Reminder|A note is sent to the primary care provider using the electronic medical record indicating the high BNP result and potential benefit of measurement of the left ventricular ejection fraction. A draft order is placed for an echocardiogram for the provider to accept or delete.
88929751|NCT01734148|Experimental|Experimental group (RELAX TO SLEEP program)|
88929752|NCT01734148|No Intervention|Control group (Usual Care)|
88929753|NCT01734174||cardiac patients|Patients having elective coronary artery bypass grafting surgery, valve repair or replacement surgery, aortic repair or replacement surgery, or any combination of these surgeries will be recruited for this study to validate measurements of left ventricular volume and ejection fraction (a quantitative measure of general heart function) as assessed by 3-dimensional transesophageal echocardiography (3D TEE) as compared to 3-dimensional transthoracic echocardiography (3D TTE). Secondarily, we will also compare the 3D TEE assessment to the 2D TEE and TTE assessment, which is routinely performed simultaneously. Last, we will compare this assessment to a third method of quantification of cardiac function via a pulmonary artery catheter using thermodilution.
88929754|NCT01734187|Experimental|Fermented Cinnamon Vine Powder|
88929755|NCT01734187|Placebo Comparator|Placebo|
88929756|NCT01734200|Experimental|Eriobotyra Japonica Lindley Extract|
88929757|NCT01734200|Placebo Comparator|Placebo|
88929758|NCT01734213|Experimental|Eriobotyra Japonica Lindley Extract|
88929759|NCT01734213|Placebo Comparator|Placebo|
88929760|NCT01734226|Experimental|Prunus Mume Extract|
88929761|NCT01734226|Placebo Comparator|Placebo|
88929762|NCT01734252|No Intervention|Standard Treatment|If a Heparin resistance appears and the patient meets the inclusion and exclu-sion criteria, he/she will be enrolled. The Heparin administration will be contin-ued and, if necessary increased. Hereby the maximum heparin dose is 1.500 IU per hour.
88929763|NCT01734252|Experimental|Treatment with Argatroban|If a Heparin resistance appears and the patient meets the inclusion and exclu-sion criteria, he/she will be enrolled. The Heparin administration will be stopped and Argatroban will be given and adjusted until the target aPTT-range is achieved.
88929764|NCT01734265|Experimental|Depigoid 50% Grasses/50% Olea europaea (2000DPP/ml)|Depigoid 50%Grasses/ 50% Olea europaea (2.000 DPP/ml) The administration regimen will consist of a rush build-up regimen: 0.2 ml followed by 0.3 ml after 30 minutes if no adverse events occur a second maintenance dose of 0,5 ml 4 weeks later.
88929765|NCT01734265|Experimental|Depigoid 50% Grasses/50% Parietaria judaica (2000DPP/ml)|Depigoid 50%Grasses/ 50% Parietaria judaica(2.000 DPP/ml) The administration regimen will consist of a rush build-up regimen: 0.2 ml followed by 0.3 ml after 30 minutes if no adverse events occur a second maintenance dose of 0,5 ml 4 weeks later.
88929766|NCT01734278||Asenapine|Patients prescribed asenapine for any indication.
88929767|NCT01734291|Active Comparator|Family psychoeducation plus TAU|Family psychoeducational therapy in addition to treatment as usual for the patients.
88929768|NCT01734291|Placebo Comparator|Treatment as usual(TAU)|Treatment as usual administered by physician and counseling administered by nurse.
88929769|NCT01734304|Experimental|DC vaccination|Vaccination with TLR7/8-matured DCs electroporated with mRNA encoding WT1, PRAME, and CMVpp65
88929770|NCT01734330|Experimental|Cognitive behavior therapy|Cognitive behavior therapy for 6 weeks associated to nicotine replacement for 12 weeks
88929771|NCT01734330|Other|Nicotine replacement|Nicotine replacement for 12 weeks
88929772|NCT01734343|Other|HOYA iMics Y-60H|eyes with implanted intraocular lens HOYA iMics Y-60H
88929773|NCT01734343|Other|PhysIOL microAY|eyes with implanted intraocular lens PhysIOL microAY
88929774|NCT01734356|Other|inherited arrhythmias|6 patient with inherited arrhythmias
88929775|NCT01734356|Other|valvulopathies|6 patient with valvulopathies
88929776|NCT01734356|Other|controle|8 healthy people for these pathologies
88929777|NCT01734408|Experimental|alum-adjuvant 160U /0.5ml EV71 vaccine|A booster dose of alum-adjuvant 160U /0.5ml EV71 vaccine in 160 children whom had received two doses of alum-adjuvant 160U/0.5ml EV71 vaccines one year before.
88929778|NCT01734408|Placebo Comparator|placebo A|A 0/0.5ml placebo in 80 children whom had received two doses of alum-adjuvant 160U/0.5ml EV71 vaccines one year before.
88929779|NCT01734408|Experimental|alum-adjuvant 320U /0.5ml EV71 vaccine|A booster dose of alum-adjuvant 320U /0.5ml EV71 vaccine in 160 children whom had received two doses of alum-adjuvant 320U/0.5ml EV71 vaccines one year before.
88929780|NCT01734408|Placebo Comparator|placebo B|A 0/0.5ml placebo in 80 children whom had received two doses of alum-adjuvant 320U/0.5ml EV71 vaccines one year before.
89013640|NCT06295237|No Intervention|Standard of Care|Optimized ventilator settings to control and reduce the number of asynchronies
89200031|NCT00888147||Fiber formula|This group will receive tube feeding formula that contains fiber.
89444775|NCT04965181|Experimental|Mindfulness-based Addiction Treatment (MBAT)|"Participants will receive virtual group counseling based on the Mindfulness-Based Addiction Treatment (MBAT) group protocol and nicotine replacement therapy (NRT). MBAT consists of 8 weekly 2-hour sessions. NRT consists of 8 weeks of generic nicotine patches and nicotine lozenges. Participants who smoke >10 cigarettes/day will receive 4 weeks of 21 mg patches, 2 weeks of 14 mg patches, and 2 weeks of 7 mg patches. Those who smoke less than 10 cigarettes/day will receive 4 weeks of 14 mg patches and 4 weeks of 7 mg patches. Participants who smoke their first cigarette within 30 minutes of waking will receive 8 weeks of 4mg mini lozenges (6-9 4mg mini lozenges per day). Those who smoke their first cigarette over 30 minutes of waking will receive 8 weeks of 2mg mini lozenges (6-9 2mg mini lozenges per day). Participants will also be given the National Cancer Institute Clearing the Air booklet and a referral to the Tobacco Cessation Quitline."
89444776|NCT04965181|Active Comparator|Usual Care|"Participants in the usual care condition are provided with nicotine replacement therapy (NRT). NRT consists of 8 weeks of generic nicotine patches and nicotine lozenges. Participants who smoke >10 cigarettes/day will receive 4 weeks of 21 mg patches, 2 weeks of 14 mg patches, and 2 weeks of 7 mg patches. Those who smoke less than 10 cigarettes/day will receive 4 weeks of 14 mg patches and 4 weeks of 7 mg patches. Participants who smoke their first cigarette within 30 minutes of waking will receive 8 weeks of 4mg mini lozenges (6-9 4mg mini lozenges per day). Those who smoke their first cigarette over 30 minutes of waking will receive 8 weeks of 2mg mini lozenges (6-9 2mg mini lozenges per day). Participants will also be given the National Cancer Institute Clearing the Air booklet and a referral to the Tobacco Cessation Quitline."
89444777|NCT04964167|Placebo Comparator|Group I (Standard Root Planning)|
89444778|NCT04964167|Active Comparator|Group II (Standard Root Planning + Photodynamic Therapy)|
89444779|NCT04964167|Experimental|Group III (Standard Root Planning + Aloe Vera)|
89444780|NCT04964128|Experimental|meal gesture dosing for unannounced meals within the AHCL System|
89444781|NCT04954794|Experimental|TACE in combination with Sintilimab plus a bevacizumab biosimilar|
89444782|NCT04943341|Experimental|Eco-guided Triamcinolone-Acetonide injection|Patients affected by medial plica syndrome will be treated with an eco-guided injection of Triamcinolone-Acetonide.
89444783|NCT04931056||Facial Plating|Patients undergoing surgical procedures for facial reconstruction for whom Biomet Microfixation titanium plates (or Ti mini plates) were utilized for the repair.
89444784|NCT04931056||Mandibular Plating|Patients undergoing surgical procedures for mandibular reconstruction, including TMJ, for whom Biomet Microfixation titanium plates (or Ti mini plates) were utilized for the repair.
89200032|NCT04049136||Healthy pregnant women with BMI <30|
89200033|NCT04049136||Healthy pregnant women with BMI >=30|
89200034|NCT04037631||Patients without clinically significant age-related cataract|
89444785|NCT04931056||HTR-PEKK (midface)|Patients undergoing surgical procedures for midface reconstruction using custom-made prostheses manufactured on PEEK material.
89444786|NCT04901156|Experimental|Multi-modality aphasia therapy plus 1Hz rTMS|Chronic stroke patients, receive 10 days of 3.5hrs of multi-modality aphasia therapy (M-MAT) preceded by 20 minutes of 1Hz rTMS delivered at 100% of resting motor threshold over the right pars triangularis.
89444787|NCT04901156|Sham Comparator|Multi-modality aphasia therapy plus sham rTMS|Chronic stroke patients, receive 10 days of 3.5hrs of multi-modality aphasia therapy (M-MAT) preceded by 20 minutes of sham rTMS is achieved using a sham TMS coil which attenuates the magnetic output of the stimulator by 80%.
89444788|NCT04890067||Localized Osteosarcoma|This cohort include patients affected by localized Osteosarcoma, referred to participating Institutions.
89444789|NCT04887987|Experimental|Lumbar strengthening training combined with LED PBMT (TR+LED)|Each participant will be submitted to a 8-wk lumbar strengthening training program and will receive the LED PBMT 30 minutes before each training session.
88929781|NCT01734408|Experimental|alum-adjuvant 640U /0.5ml EV71 vaccine|A booster dose of alum-adjuvant 640U /0.5ml EV71 vaccine in 160 children whom had received two doses of alum-adjuvant 640U/0.5ml EV71 vaccines one year before.
88929782|NCT01734408|Placebo Comparator|placebo C|A 0/0.5ml placebo in 80 children whom had received two doses of alum-adjuvant 640U/0.5ml EV71 vaccines one year before.
88929783|NCT01734408|Experimental|adjuvant-free 640U /0.5ml EV71 vaccine|A booster dose of adjuvant-free 640U /0.5ml EV71 vaccine in 160 children whom had received two doses of adjuvant-free 640U/0.5ml EV71 vaccines one year before.
88929784|NCT01734408|Placebo Comparator|placebo D|A 0/0.5ml placebo in 80 children whom had received two doses of adjuvant-free 640U/0.5ml EV71 vaccines one year before.
88929785|NCT01734421|Other|Control group|Habitual deshabituation in the control group following the guidelines of the primary health care institution.
88929786|NCT01734421|Active Comparator|Cell phone Aplication for Smarth Phone|Cell phone 6-month implementation of recommendations of a Clinical Practice Guideline smoking cessation which includes mobile APPs application
88929787|NCT01734447|Experimental|1.2, continuous treatment|
88929788|NCT01734447|Experimental|1.2, non-continuous treatment|
88929789|NCT01734447|Experimental|2.4, non-continuous treatment|
88929790|NCT01734460||third trimester pregnant women|no intervention
88929791|NCT01734473|Experimental|Study day 1|Hydrolyzed casein protein. On each study day participants receive one out of 4 protein meals (interventions). The 4 interventions are given in a randomized order.
88929792|NCT01734473|Experimental|Study day 2|Hydrolyzed casein protein + carbohydrates. On each study day participants receive one out of 4 protein meals (interventions). The 4 interventions are given in a randomized order.
88929793|NCT01734473|Experimental|Study day 3|Hydrolyzed casein protein + leucine. On each study day participants receive one out of 4 protein meals (interventions). The 4 interventions are given in a randomized order.
89444790|NCT04887987|Placebo Comparator|Lumbar strengthening training combined with placebo PBMT (TR+PLA)|Each participant will be submitted to a 8-wk lumbar strengthening training program and will receive the placebo PBMT 30 minutes before each training session.
89444791|NCT04881760|Placebo Comparator|Placebo|Participants received placebo matched to LY3437943 administered as subcutaneous (SC) injection once-weekly (QW).
88929794|NCT01734473|Experimental|Study day 4|Hydrolyzed casein protein + carbohydrates + leucine. On each study day participants receive one out of 4 protein meals (interventions). The 4 interventions are given in a randomized order.
88929795|NCT01734473|Experimental|Study Day 5|4 levels of hydrolyzed casein protein + carbohydrates
88929796|NCT01734486|Experimental|Low dose|
88929797|NCT01734486|Experimental|High dose|
88929798|NCT01734499|Experimental|Coping Class|"A 4-hour structured program which will be offered once a month as the Coping Class by a certified facilitator of The Change Cycle. Quality of Life survey completed at 5 time points after informed consent."
88929799|NCT01734499|Active Comparator|Standard of Care|Standard of Care. Three components of this: (1)Surveillance Program, (2)Local support groups centered at community cancer centers, (3)Comprehensive Postoperative Rehabilitation which offers physical and occupational rehabilitation.Quality of Life surveys completed at 5 time points after informed consent.
88929800|NCT01734538|Experimental|Omega-3 Complete|Oral ingestion of 3000 mg (5 capsules) of Omega-3 Complete (Jamieson Laboratories, Ltd., Windsor, Ontario, Canada) per day for 12 weeks.
88929801|NCT01734538|Placebo Comparator|Placebo Capsule|Oral ingestion of 5 capsules of a placebo oil pill (Jamieson Laboratories Ltd., Windsor, Ontario, Canada) per day for 12 weeks
88929802|NCT01734564|Experimental|Hiltonol and autologous dendritic cells|Hiltonol and autologous dendritic cells
88929803|NCT01734564|Experimental|Hiltonol, dendritic cells and radiation|Hiltonol, dendritic cells and radiation.
88929804|NCT01734577|Active Comparator|Dry needling|Monofilament needles will be inserted into each subject's left multifidus muscle and stimulated mechanically for a local twitch response
88929805|NCT01734577|Sham Comparator|Sham needling|Monofilament tubes will be pressed into the left multifidus muscle and mechanically manipulated to give the sensation that needling is occuring.
88929806|NCT01734590|Experimental|Carbohydrate based food mix 1|Slowly digestible carbohydrate
88929807|NCT01734590|Experimental|Carbohydrate based food mix 2|Slowly digestible carbohydrate
88929808|NCT01734590|Active Comparator|Control carbohydrate based food|Rapidly digestible carbohydrate
88929809|NCT01734603|Active Comparator|conventional rehabilitation program|conventional rehabilitation program 20 patients are expected in this arm. Patients perform walking treadmill exercises with complete rest.
88929810|NCT01734603|Experimental|experimental rehabilitation program|experimental rehabilitation program 20 patients are expected in this arm. Patients perform walking treadmill exercises with active recovery (no stop walking).
88929811|NCT01734616|No Intervention|Young|Young subjects to be controlled to older individuals with interventions
88929812|NCT01734616|No Intervention|Old|Older individuals to compare to young and other older intervention groups
88929813|NCT01734616|Experimental|Old Exercise|Older individuals studied after an intervention of 20 weeks fully-supervised resistance exercise training
88929814|NCT01734616|Experimental|Old Acute Cocoa|Older individuals studied with the addition of cocoa flavanols during their acute study
88929815|NCT01734616|Experimental|Old 7 Day Cocoa|Older individuals studied after 7 day supplementation of cocoa flavanols
88929816|NCT01734629||Coronary CT Spirometry Cohort|Patients refereed to coronary CT enrolled in the study.
89444792|NCT04881760|Experimental|1 milligram (mg) LY3437943|Participants received 1 mg LY3437943 administered as SC injection QW.
89444793|NCT04881760|Experimental|4 mg LY3437943 (2 mg)|Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 administered as SC injection QW.
89444794|NCT04881760|Experimental|4 mg LY3437943|Participants received 4 mg LY3437943 administered as SC injection QW.
88929817|NCT01734642||PATIENT HOSPITALIZED|ALL THE PATIENTS HOSPITALIZED IN THE INVOLVED UNITS WHO GAVE THEIR INFORMED CONSENT. PATIENTS HOSPITALIZED DURING THE WEEK-END WILL BE ENROLLED ON the next MONDAY
88929818|NCT01734681|Experimental|Treatment with G-202|G-202 will be administered by intravenous infusion over one hour on Days 1, 2 and 3 of a 28-day treatment cycle. The G-202 dose will be 40 mg/m2 on Day 1 and 66.8 mg/m2 on Days 2 and 3.
88929819|NCT01734707|Active Comparator|Allicor|Allicor 150 mg tablet by mouth two times a day
88929820|NCT01734707|Placebo Comparator|Sugar pill|Placebo tablet 150 mg by mouth two times a day
88929821|NCT01734720||common bile duct stone|Patients undergoing cholecystectomy
88929822|NCT01734733|Experimental|NTCELL|"NTCELL 40 microcapsules (+/- 20%)~The NTCELL microcapsules are drawn up into a catheter system and introduced intracranially by stereotactic insertion into the brain under guidance by neuroimaging."
88929823|NCT01734759|Experimental|Taste Test|
88929824|NCT01734798|Experimental|Arm 1|post-operative radiotherapy will be done in locally advanced bladder cancer patients (P3b, P4a, G3 and / or LN positive patients) after radical cystectomy Dose of Radiotherapy: 45 Gray Gy/30 fractions/3 weeks
88929825|NCT01734798|Experimental|Arm 2|adjuvant chemotherapy (gemcitabine and cisplatin) in addition to post operative radiotherapy in locally advanced bladder cancer patients (P3b, P4a, G3 and / or LN positive patients) after radical cystectomy
88929826|NCT01734798|Experimental|Arm 3|Adjuvant chemotherapy alone in locally advanced bladder cancer patients (P3b, P4a, G3 and / or LN positive patients) after radical cystectomy
88929827|NCT01734824|Active Comparator|Teriparatide|daily subcutaneous injection of teriparatide 20µg for three months
88929828|NCT01734824|Placebo Comparator|Placebo Teriparatide|daily subcutaneous teriparatide placebo injection
88929829|NCT01734824|Active Comparator|Denosumab|one subcutaneous injection of denosumab
88929830|NCT01734824|Active Comparator|Placebo Denosumab|one subcutaneous injection of denosumab placebo
89013641|NCT06295237|Active Comparator|Activated automatic detection and adjustment of asynchronies|Active mode of a mechanical ventilator software automatically detecting and adjusting ventilator parameters to control or reduce the number of events.
89444795|NCT04881760|Experimental|8 mg LY3437943 (2 mg)|Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 and then 8 mg LY3437943 administered as SC injection QW.
89444796|NCT04881760|Experimental|8 mg LY3437943 (4 mg)|Participants received 4 mg LY3437943 starting dose followed by 8 mg LY3437943 administered as SC injection QW.
89444797|NCT04881760|Experimental|12 mg LY3437943 (2 mg)|Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943, 8 mg LY3437943 and then 12 mg LY3437943 administered as SC injection QW.
89444798|NCT04879797|Other|Maternal Safety Bundles Implementation|The first intervention targets obstetric hemorrhage, severe hypertension and maternal health equity by implementing three relevant AIM bundles: Obstetric Hemorrhage, Severe Hypertension in Pregnancy, and Reduction of Peripartum Racial/Ethnic Disparities. The Perinatal Neonatal Quality Improvement Network (PNQIN) will facilitate this collaborative QI project and support participating hospitals by providing guidance, education, and technical assistance to hospitals to support implementation of bundles using the QI process. Implementation strategies are based on the Institute for Healthcare Improvement (IHI) improvement model and the AIM program implementation toolkit and have previously been used by PNQIN to implement the Obstetric Care for Women with Opioid Use Disorder AIM bundle in 22 hospitals, including the five hospitals for this study.
88929831|NCT01734863|Experimental|Radiotherapy Arm|"this study arm will take External Beam radiotherapy as follows :~Radiotherapy Technique: Conformal radiotherapy, Intensity modulated radiotherapy [IMRT] is allowed.~Radiotherapy Dose: 45 Gy/25 fractions/5 weeks (1.8 Gy/fraction). , the inclusion criteria are as following:~Age < 18 years old.~Non-metastatic Ewing Sarcoma patients who will undergo surgery and show poor histologic response to neo-adjuvant chemotherapy.~Negative surgical margins.~Patients show good safety profile and acceptable performance status."
88929832|NCT01734863|No Intervention|No Radiotherapy Arm|"this arm will not take radiotherapy and their inclusion criteria as following:~Age < 18 years old.~Non-metastatic Ewing Sarcoma patients who will undergo surgery and show poor histologic response to neo-adjuvant chemotherapy.~Negative surgical margins.~Patients show good safety profile and acceptable performance status."
88929833|NCT01734876|Experimental|Tactile Touch|Tactile Touch is given to the active arm
88929834|NCT01734876|Active Comparator|Rest To Music|Rest to Music. Rest for 30-60 minutes, aroma therapy, quit music in the background, well temepered room, lying position
88929835|NCT01734915||NSCLC|Subjects with advanced NSCLC, will undergo blood draw
88929836|NCT01734941|Active Comparator|TSO 2500|2500 TSO every other week
88929837|NCT01734941|Active Comparator|7500 TSO|7500 TSO every other week
88929838|NCT01734941|Placebo Comparator|Placebo|placebo every other week.
88929839|NCT01734954|Experimental|Sciatic nerve blockade at bifurcation|Ultrasound-guided block at the bifurcation of the sciatic nerve
88929840|NCT01734954|Experimental|Sciatic block 2 cm beyond bifurcation|Ultrasound-guided block of the sciatic nerve 2 cm beyond of the bifurcation
88929841|NCT01734967|Experimental|needle based CLE & EUS-FNA|The study will prospectively include patients referred to our department for EUS and EUS-FNA of suspected pancreatic masses during a 12 months period. The indication for this investigation will be based on the patient's clinical history and previous imaging studies (abdominal ultrasound, CT scan, MRI).
88929842|NCT01734980|Experimental|Endobronchial Ultrasound|EBUS-TBNA is a procedure that allows accurate sampling of mediastinal lymph nodes and peribronchial lesions
88929843|NCT01735006|Experimental|HPV vaccine|This dosage contains 40μg HPV 16 virus-like particle antigen and 20μg HPV 18 virus-like particle antigen adsorbed in alum-adjuvant
88929844|NCT01735006|Placebo Comparator|HEV vaccine|commercialized HEV vaccine which contains 30μg HEV antigen adsorbed in alum-adjuvant
88929845|NCT01735019|Experimental|group 1|administration of remifentanil with target-controlled infusion (TCI) system at a given concentration during anesthetic emergence
88929846|NCT01735045|Experimental|Test Group myopia control|Subjects wearing contact lenses made of LSH (mangofilcon A) Soft (hydrophilic) Contact Lens for myopia control
88929847|NCT01735045|Active Comparator|Myopia Control|Subjects wearing Benz 3GX (hioxifilcon B) Soft (hydrophilic) Contact Lens for myopia control
88929848|NCT01735058|Active Comparator|Sodium hyaluronate|Ultrasound guided injection of sodium hyaluronate
88929849|NCT01735058|Placebo Comparator|Normal saline|Ultrasound guided injection of normal saline
88929850|NCT01735071|Experimental|bevacizumab and trabectedin|Arm A: bevacizumab (15 mg/kg) given as 1 hour infusion will be followed by trabectedin (1.1 mg/sqm) 3 hour iv infusion; to be repeated every 21 days until progression, unacceptable toxicity, patient or physician decision to discontinue, or death patients
88929851|NCT01735071|Experimental|bevacizumab, trabectedin and carboplatin|"Arm B: cycle 1-6, bevacizumab given as 1 hour infusion will be followed by carboplatin area under curve 4 (AUC 4) and trabectedin 3 hour iv infusion.~Cycle 7- end of treatment, bevacizumab given as 1 hour infusion will be followed by trabectedin 3 hour iv infusion.~Patient enrolled in arm B will receive (cycle 1-6): trabectedin 0.8 mg/m2 ,carboplatin AUC 4 day 1 every 28 days and bevacizumab 10 mg/kg iv on day 1 and day 15.~From cycle 7 to disease progression, unacceptable toxicity, patient or physician decision to discontinue, or death patients will receive bevacizumab 15 mg/kg iv and trabectedin 1.1 mg/m2 day 1 every 21 days"
88929852|NCT01735084|Experimental|Prevenar13|The booster dose of Prevenar13 is 0.5 mL given intramuscularly only, with care to avoid injection into or near nerves and blood vessels. The preferred sites are anterolateral aspect of the thigh (vastus lateralis muscle) in infants or the deltoid muscle of the upper arm in young children.
88929853|NCT01735084|Experimental|Synflorix|The booster vaccination schedule consists of one dose of 0.5 ml with an interval of at least 1 month between doses.
88929854|NCT01735097|Experimental|Arsenical keratosis (Study)|Vitamin E (200 mg, soft capsule) plus Nigella sativa (500 mg, soft capsule) twice daily, orally for 12 weeks
88929855|NCT01735097|Active Comparator|Arsenical keratosis (Control)|Vitamin E (200 mg, soft capsule) plus Placebo (refined oil in soft capsule with same size and color as that contains N sativa) twice daily, orally for 12 weeks
88929856|NCT01735110|Active Comparator|Femoral approach group|PCI through Femoral approach
88929857|NCT01735110|Experimental|radial approach group|PCI through radial approach
89444799|NCT04879797|Other|Doula Services|The second intervention that this study evaluates is doula services. Investigators are evaluating doula services that are offered by two doula organizations at three hospitals. Investigators will provide top-up training to these doulas in order to provide some standardization and quality assurance of the services delivered. The training is developed and delivered by an obstetrician (Meadows) and doula (Gebel) and will take place among providers (staff associated with three chosen hospitals), patient navigators, and two doula groups, Birth Sisters and Accompany Doula Care, on factors that comprise the risk profile and how to offer targeted doula services to women who fit the risk profile. All sites will use standardized data instruments to evaluate the number of factors in the risk profile being met as well as standardized language and recruitment materials for mothers.
89444800|NCT04857645|Experimental|ASTX727 treatment|
89444801|NCT04845893||Skeletal Ewing Sarcoma|This cohort include patients affected by Ewing Sarcoma of bone, referred to participating Institutions.
89444802|NCT04844099|Experimental|Intervention arm|The intervention will be oral dihydroartemisinin (20mg) and piperaquine (160 mg) and administered once weekly at approximate doses of dihydroartemisinin 2.5mg/kg/day and piperaquine 20mg/kg/day based on participants' weight categories
89444803|NCT04844099|Active Comparator|Comparator|The active control will be Sulphadoxine-Pyrimethamine (SP), the current standard of care for malaria chemoprevention for SCA in Uganda and Malawi. This will also be provided by Guilin Pharmaceutical Co. Ltd as their generic World Health Organization-approved sulphadoxine-pyrimethamine 500/25mg tablets. It will be administered as monthly single-day courses of SP at approximate doses of S=25mg/kg and P=1.25mg/kg.
89444804|NCT04837014|Experimental|Acetaminophen and naproxen only arm|Patient allocated to the intervention arm will be discharged home with a prescription for regular acetaminophen and naproxen for 48 hours, and then as needed for one week's duration.
89444805|NCT04837014|Active Comparator|Acetaminophen, naproxen and dilaudid arm|Patient allocated to the control group will be discharged home with a prescription for regular acetaminophen, naproxen, and 5 tabs of hydromorphone 1 mg, with instruction to prioritize non opioid analgesic as first line.
89444806|NCT04834349|Experimental|Cohort I (NBTXR3, SBRT, pembrolizumab)|Patients receive NBTXR3 IT on day 1. Patients then undergo SBRT QOD on days 15-29. Beginning the first day of radiation therapy, patients also receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 3 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
89444807|NCT04834349|Experimental|Cohort II (NBTXR3, IMRT/IMPT, pembrolizumab)|Patients receive NBTXR3 IT on day 1. Patients then undergo IMRT/IMPT QD on days 15-50. Beginning the first day of radiation therapy, patients also receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 3 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
89444808|NCT04815668|Experimental|Acupuncture group|
89444809|NCT04815668|Placebo Comparator|Placebo acupuncture group|
89444810|NCT04815668|Other|Rescue medication|
89444811|NCT04813042|Experimental|Working Out Dads|Fathers allocated to the Working Out Dads (WOD) arm will receive the intervention program. WOD is a 6-week manualised program. The weekly 90 minute sessions combine a one hour facilitated discussion by a male facilitator trained in delivery of WOD and a 30-minute gym workout provided by a personal trainer. The group size ranges from 6-10 fathers, with 14 groups running over the study period. The weekly sessions are provided in the evenings, in local gyms or a community setting (e.g., maternal child health centre, local council rooms, local hall, local park, Tweddle Child & Family Health Service).
89444812|NCT04813042|Active Comparator|Usual Care|Fathers allocated to the Usual Care arm will receive the clinical care typically provided to parents experiencing mental health difficulties by an Early Parenting Centre or community health service. Within 2 weeks of baseline assessment, Usual Care participants will receive a brief psychological consultation from Tweddle's Clinical Manager.
89444813|NCT04804748||Phase A|"Approximately 150 consecutive patients undergoing elective cardiac surgery (bypass and / or valve surgery)~Data regarding standard of care post-operative pacing and treatment of POAF, if applicable, will be collected from time of surgery until discharge~No use of an external bi-atrial pacing device~No use of Defipace~In-hospital data will be collected for all patients~Patients that developed POAF (n=50) will be followed-up with a phone call 30 days after surgery"
89444814|NCT04804748||Phase B|"Approximately 300 consecutive patients undergoing elective cardiac surgery (bypass and / or valve surgery) with planned TMA implantation~In-hospital data will be collected for all patients~Use of the DefiPace system for the treatment (low-energy cardioversion) and post-operative prevention (bi-atrial pacing) of POAF will be documented (n=100). These patients will be followed-up with a phone call 30 days after surgery"
89444815|NCT04794634|Experimental|Alzheimer Disease|
88929858|NCT01735123|Experimental|extensively hydrolyzed casein formula|The investigators plan to randomize 60 out of 120 infants to be weaned to an extensively hydrolyzed casein formula. Recruited mothers are encouraged to breast-feed. The dietary intervention will be applied until 9 months of age. The minimum exposure time to the study formula should be 90 days. Signs of beta-cell autoimmunity, i.e. diabetes-associated autoantibodies, will be monitored in the study participants, although the study will not have sufficient power to detect statistically significant differences in the seroconversion rate between the groups due to the limited number of infants randomized.
89444816|NCT04794634|Experimental|Lewy body disease|
89444817|NCT04794634|Active Comparator|healthy patient|
89444818|NCT04779918|Other|OviTex Reinforced Tissue Matrix|This is a single-arm study. All study subjects will receive OviTex.
89444819|NCT04776213|Experimental|Mavenclad®|
89444820|NCT04762069|Experimental|Berubicin|"Berubicin intravenously infused will be administered at a dose of 7.1 mg/m2 as free base as a 2 hour intravenous (IV) infusion once daily for 3 consecutive days followed by 18 days off study drug (each cycle = 21 days)~Each treatment cycle is 21 days. Subjects will be allowed to continue on treatment at the discretion of the Investigator if there is no evidence of disease progression and the subject is not experiencing unacceptable toxicity as well as if both the subject and Investigator agree that further therapy is in the subject's best interest."
89444821|NCT04762069|Active Comparator|Lomustine (CCNU, CeeNU®, or Gleostine®) capsules|Lomustine (CCNU, CeeNU®, or Gleostine®) capsules will be administered at the institutionally-approved dose and regimen or per the full prescribing information/summary of product characteristics.
89444822|NCT04749797|Placebo Comparator|Saline group|The surgeon will administer injectable saline as a cranial block. The supraorbital, supratrochlear, zygomaticotemporal, auriculotemporal, postauricular lesser and greater occipital nerve branches on the ipsilateral side of the operation will be blocked with 5-10 cc of solution (with a maximum of 60 cc at all sites) by needle infiltration. This process generally takes 1-2 minutes. Following this, the general anesthesia is lightened and the patient is extubated in usual fashion.
89444823|NCT04749797|Active Comparator|Bupivacaine|The surgeon will administer bupivacaine as a cranial block. The supraorbital, supratrochlear, zygomaticotemporal, auriculotemporal, postauricular lesser and greater occipital nerve branches on the ipsilateral side of the operation will be blocked with 5-10 cc of solution (with a maximum of 60 cc at all sites) by needle infiltration. This process generally takes 1-2 minutes. Following this, the general anesthesia is lightened and the patient is extubated in usual fashion.
89444824|NCT04749797|Experimental|Liposomal Bupivacaine|The surgeon will administer Exparel (liposomal bupivacine) as a cranial block. 20 mL of Exparel will be diluted with saline to constitute 60 mL total. The supraorbital, supratrochlear, zygomaticotemporal, auriculotemporal, postauricular lesser and greater occipital nerve branches on the ipsilateral side of the operation will be blocked with 5-10 cc of solution (with a maximum of 60 cc at all sites) by needle infiltration. This process generally takes 1-2 minutes. Following this, the general anesthesia is lightened and the patient is extubated in usual fashion.
89444825|NCT04748861|Experimental|Indoor Cycling (IC)|Participants will engage in high-intensity interval training (HIIT; 60-90% of heart rate reserve) in their home via the commercially available Peloton® cycling system or 2) 3x/week (minimum 90 minutes/week) for 18 months.
89444826|NCT04748861|No Intervention|Usual and Customary Care (UCC)|Participants engage in their habitual level of physical activity.
89444827|NCT04747275|Other|Liquid Stable Levothyroxine (l-T4) TirosintSOL first, then Oral Tablet Levothyroxine (L-T4)|Participants start on Liquid Tirosint®-SOL for 8 weeks using continued same daily dose of LT4. Dose adjustments are allowed as needed, based on laboratory results and clinical response. Then Participants will crossover to conventional therapy of LT4 tablets for 8 weeks. Participants total participation will be 16 weeks total.
88929859|NCT01735123|Experimental|cow's milk based infant formula|The investigators plan to randomize 60 out of 120 infants to be weaned to a cow's milk based infant formula. Recruited mothers are encouraged to breast-feed. The dietary intervention will be applied until 9 months of age. The minimum exposure time to the study formula should be 90 days. Signs of beta-cell autoimmunity, i.e. diabetes-associated autoantibodies, will be monitored in the study participants, although the study will not have sufficient power to detect statistically significant differences in the seroconversion rate between the groups due to the limited number of infants randomized.
88929860|NCT01735136|Experimental|InSan Bamboo Salt|
88929861|NCT01735136|Placebo Comparator|Placebo|
88929862|NCT01735149|Experimental|Kochujang Pills|
88929863|NCT01735149|Placebo Comparator|Placebo|
89444828|NCT04747275|Other|Oral Tablet Levothyroxine (L-T4) first, then Liquid Stable Levothyroxine (L-T4) Tirosint-SOL|Participants continue conventional therapy of LT4 tablets for 8 weeks at current dose, after 8 weeks will crossover to receive Liquid Stable Levothyroxine (L-T4) Tirosint-SOL for 8 weeks. Participants total participation will be 16 weeks total.
89444829|NCT04728724|Experimental|Group A|Anti-PD-1 monotherapy
89444830|NCT04728724|Experimental|Group B|Anti-PD-1 plus chemotherapy
89444831|NCT04699981|Experimental|Control: Patients colonized rectally with ESBL-producing enterobacteria without antibiotic pressure|Known patients colonized rectally with ESBL-producing enterobacteria and not subjected to antibiotic pressure
89444832|NCT04699981|Experimental|Case: Patients colonized rectally with ESBL-producing enterobacteriaceae, with antibiotic pressure|Known patients colonized rectally with ESBL-producing enterobacteriaceae and subjected to antibiotic pressure (antibiotic therapy predicted greater than 24 hours) with beta-lactams or dual therapy comprising a beta-lactam. The prescription of antibiotic therapy, a decision independent of the study procedures, will be carried out as part of routine care in the context of microbiologically documented infection. The choice of molecules will be left to the discretion of clinicians.
89444833|NCT04696289|Experimental|Standardized catheterization assessment|Assessment of pulmonary veins including angiography, intravascular ultrasound, pressure assessment and compliance testing.
89444834|NCT04695600|Experimental|Botulinum toxin arm|100 units of botulinum toxin (Botox, Allergan, CA) diluted in 2.5 mL of normal saline will be injected into the cricopharyngeus muscle under direct endoscopic vision using an esophago-gastro-duodenoscope (GIF 190,Olympus). The procedure will be done under general anesthesia in the endoscopy suite as the position of the endoscope is unstable at cricopharynx and the muscle needs to be relaxed during the procedure. Pre-procedure a Ryle's tube will be placed into the stomach under endoscopic guidance which will be kept a day post procedure. Cricopharyngeus muscle will be identified as the muscle at the upper esophageal sphincter located just behind the laryngeal opening. Botulinum toxin will be injected into the muscle in four aliquots into each quadrant using 23 G needle (160cm). Post procedure patient will be observed for an hour for any untoward adverse event
89444835|NCT04695600|Placebo Comparator|Placebo arm|2.5 mL of Normal saline will be injected into the cricopharyngeus muscle under direct endoscopic vision using an esophago-gastro-duodenoscope (GIF 190,Olympus). The procedure will be done under general anesthesia in the endoscopy suite as the position of the endoscope is unstable at cricopharynx and the muscle needs to be relaxed during the procedure. Pre-procedure a Ryle's tube will be placed into the stomach under endoscopic guidance which will be kept a day post procedure. Cricopharyngeus muscle will be identified as the muscle at the upper esophageal sphincter located just behind the laryngeal opening. Post procedure patient will be observed for an hour for any untoward adverse event
89444836|NCT04685577|Experimental|Nefopam|NEFOPAM 3% cream will be applied topically to healing deep dermal scratches in the lateral hip of burn patients daily (twice) for 3 weeks during the proliferative phase of wound healing.
89444837|NCT04685577|Placebo Comparator|Placebo|This will work as a placebo for the experimental drug.
89444838|NCT04669860||calcium oxalate urolithiasis group|Participants with CO urolithiasis scheduled for definitive endoscopic stone removal will be evaluated to identify bacterial and fungal microbiome in mid-stream voided urine sample, urine sample collected from the bladder, kidney stone fragment, and a renal papillae biopsy specimen.
89444839|NCT04669860||renal cell carcinoma group|Participants with RCC scheduled for definitive kidney removal surgery will be evaluated to identify bacterial and fungal microbiome in a catheterized urine specimen from the bladder, a biopsy of the tumor, and a biopsy of normal-appearing renal papillae specimen.
89444840|NCT04669860||healthy control group|The participants will provide a clean-catch voided midstream urine sample to identify bacterial and fungal microbiome.
89444841|NCT04667039|Experimental|GNR-067|Ranibizumab
89444842|NCT04667039|Active Comparator|Lucentis®|Ranibizumab
89444843|NCT04666584|Active Comparator|ScoreFlex balloon|Pre-dilatation with a ScoreFlex balloon before implantation with a Magmaris bioresorbable scaffold
88929864|NCT01735162||Very high risk|Very high risk PICU patients are on mechanical ventilation and at least one inotrope or vasopressor at time of admission
88929865|NCT01735162||High Risk|High risk PICU patients have a history of transplantation (solid organ or bone marrow)
88929866|NCT01735162||Moderate risk|Moderate risk PICU patients are all other admissions to the ICU (may have either mechanical ventilation or inotropy/vasopressor use but not both). Cannot have a history of transplant. Minimum expected stay 48 hours.
88929867|NCT01735188||Living|
88929868|NCT01735188||Deceased|
88929869|NCT01735227|Experimental|omeprazole group|omeprazole group:all patients taking clopidogrel loading dose 300mg + aspirin 300mg and the subsequent maintenance dose of clopidogrel 75mg(1 year) + aspirin 300mg(1 month)+ aspirin 100mg(long-term)and taking omeprazole 20mg/d(1 month).on the day of admission ( before medication ) , medication for 12-24 hours , medication after 72 hours , 30 days , each taken early morning fasting venous blood again , measuring AA 、ADP - induced platelet aggregation . And selected 30 days , 6 months and 12 months to record the patient's clinical adverse events ( including death , myocardial infarction , and any revascularization , stent thrombosis , recurrent angina , rehospitalization due to cardiovascular disease , bleeding events) .
88929870|NCT01735227|Experimental|pantoprazole group|pantoprazole group: all patients taking clopidogrel loading dose 300mg + aspirin 300mg and the subsequent maintenance dose of clopidogrel 75mg(1 year) + aspirin 300mg(1 month)+ aspirin 100mg(long-term),taking pantoprazole 20mg/d(1 month).
89200035|NCT00762840|Experimental|Apexum|the tooth is treated by a standard root canal treatment, supplemented by Apexum Ablator protocol, in which the periapical lesion tissue is minced and removed through the root canal, in a minimally invasive fashion.
89444844|NCT04666584|Active Comparator|Standard non-compliant balloon|Pre-dilatation with a non-compliant balloon before implantation with a Magmaris bioresorbable scaffold
89444845|NCT04643899|No Intervention|Control group|Patients benefiting only from the usual nutritional rehabilitation program G1a: diabetic patients G1b: non-diabetic patients
89444846|NCT04643899|Experimental|Electrostimulation group|Patients benefiting from the usual program AND muscle electrostimulation sessions G2a: diabetic patients G2b: non-diabetic patients
89444847|NCT04633187|Experimental|EDP-938|
89444848|NCT04633187|Placebo Comparator|Placebo|
89444849|NCT04628988|Experimental|CC-90011 in combination with Abiraterone and Prednisone|Oral administration (PO) of CC-90011 monotherapy administered once per week (QW), for 4 weeks. From cycle 2 onwards, all participants will receive 60 mg of CC-90011 PO QW, in combination with 100 mg of abiraterone PO daily, and 5 mg of prednisone PO every 12 hours (10mg QD)
89444850|NCT04621435|Experimental|68Ga-Dosimetry population (Cohort 1a)|PET imaging will begin 30 +/-10 minutes, 60 +/-15 minutes and 120 +/-20 minutes after injection of 68Ga-FAP-2286. Contrast may be administered if clinically indicated.
88929871|NCT01735240|Experimental|First AZD5069, then Ketoconazole + AZD5069|AZD5069 in first period (on 1 day) and in second period (after wash out) ketoconazole alone (on 2 days) then ketoconazole + AZD5069 (on 1 day), then again ketoconazole alone (on 2 days)
88929872|NCT01735253|Experimental|gastric bypass, duodenojejunal bypass|
88929873|NCT01735266|Active Comparator|Air colonoscopy|Air was insufflated during whole procedure of colonoscope insertion.
88929874|NCT01735266|Experimental|Whole-colon water exchange colonoscopy|The air pump was turned off before colonoscopy. During the whole procedure of the scope insertion, residual air in lumen was suctioned and 37°C (maintained with a water bath) water was infused with a peristaltic pump to obtain lumen visualization. Air was insufflated until cecum was reached or appendix opening was seen.
88929875|NCT01735266|Experimental|left-colon water exchange colonoscopy|In the left side of colon (including descending colon, sigmoid colon and rectum), water was infused instead of air to obtain lumen visualization as described above in whole-colon water exchange colonoscopy group.
88929876|NCT01735305||Antiplatelet therapy|patients with coronary artery disease receiving any antiplatelet therapy, without any intervention by the investigators.
88929877|NCT01735318|Experimental|Lisinopril Tablets 40 mg|Lisinopril Tablets 40 mg of Ipca Laboratories Limited, India
88929878|NCT01735318|Active Comparator|Zestril® (Lisinopril) 40 mg Tablets|Zestril® (Lisinopril) 40 mg Tablets of AstraZeneca Pharmaceuticals LP USA
88929879|NCT01735331||VEGF level|VEGF level in hysteroscopic endometrial biopsy of the patients with recurrent pregnancy loss.
88929880|NCT01735331||control group|Patients with Abnormal Uterine Bleeding
88929881|NCT01735344|Experimental|Lisinopril Tablets 40 mg|Lisinopril Tablets 40 mg of Ipca Laboratories Limited, India
88929882|NCT01735344|Active Comparator|Zestril® (Lisinopril) 40 mg Tablets|Zestril® (Lisinopril) 40 mg Tablets of AstraZeneca Pharmaceuticals LP USA
88929883|NCT01735357|Placebo Comparator|Olive oil (BP specification)|5g per day
88929884|NCT01735357|Experimental|DHA-rich oil|Fish oil supplement (total = 5g/day) providing 3.1g/day of DHA triacylglycerol, blended with olive oil
88929885|NCT01735357|Experimental|EPA-rich oil|Fish oil supplement (total = 5g/day) providing 2.9g/day of EPA triacylglycerol, blended with olive oil
88929886|NCT01735370|Experimental|Etodolac Tablets USP 500mg|Etodolac Tablets USP 500 mg of Ipca Laboratories Limited, India
88929887|NCT01735370|Active Comparator|Etodolac Tablets USP 500 mg|Etodolac Tablets USP 500 mg of Taro Pharmaceutical Industries Ltd., USA
88929888|NCT01735383|Experimental|Etodolac Tablets USP 500mg|Etodolac Tablets USP 500 mg of Ipca Laboratories Limited, India
88929889|NCT01735383|Active Comparator|Etodolac Tablets USP 500 mg|Etodolac Tablets USP 500 mg of Taro Pharmaceutical Industries Ltd., USA
88929890|NCT01735409|Experimental|1-day regimen|ABX 260 mg/m2 day 1 + DDP 75mg/m2 day 1
89444851|NCT04621435|Experimental|64Cu-Dosimetry population (Cohort 1b)|PET imaging will begin 60±15 minutes, 240±30 minutes after injection,and 24±2 hours after injection of 64Cu-FAP-2286. Contrast may be administered if clinically indicated.
89444852|NCT04621435|Experimental|Participants with metastatic disease (Cohort 2)|Participants with metastatic disease will have PET imaging 50-100 minutes after injection of 68Ga- or 64Cu- FAP-2286. Contrast may be administered if clinically indicated.
89444853|NCT04621435|Experimental|Participants without metastatic disease (Cohort 3)|Participants without metastatic disease will have PET imaging 50-100 minutes after injection of 68Ga- or 64Cu- FAP-2286. Contrast may be administered if if clinically indicated.
89444854|NCT04598009|Experimental|Treatment (binimetinib, imatinib)|Patients receive binimetinib PO BID on days 1-28 and imatinib PO QD on days 1-28. Cycles repeat every 28 days
89444855|NCT04596852|Experimental|Healthy children|
89444856|NCT04596852|Experimental|Children with cerebral palsy|
89444857|NCT04595188|Experimental|Sulphur amino acids in Adults > 60|"Total sulphur amino acid, as methionine only: all subjects will receive up to 7 methionine test levels, without dietary cysteine, assigned in random order.~Minimum methionine, with excess dietary cysteine: all subjects will receive up to 7 methionine test levels, in the presence of excess and constant dietary cysteine, assigned in random order."
89444858|NCT04583072||Non-Hispanic/Latino White/Caucasian men|Self-identified as White Non-Hispanic men, with age range (45.0 - 75.0 years), without prior evidence of prostate cancer
89444859|NCT04583072||African/Black men|Self-identified as African or Black men, with age range (45.0 - 75.0 years), without prior evidence of prostate cancer
89444860|NCT04583072||Hispanic/Latino White/Caucasian men|Self-identified as White Hispanic men, with age range (45.0 - 75.0 years), without prior evidence of prostate cancer
89444861|NCT04583072||Asian men|Self-identified as Asian men, with age range (45.0 - 75.0 years), without prior evidence of prostate cancer
89444862|NCT04556552|Experimental|Active non-invasive Vagal nerve stimulation (VNS)|Active non-invasive Vagal Nerve Stimulation (nVNS) with opioid cues.
88929891|NCT01735409|Experimental|2-day regimen|ABX 140 mg/m2 day 1,8 + DDP 75mg/m2 day 1
88929892|NCT01735409|Experimental|3-day regimen|ABX 100 mg/m2 day 1,8,15 + DDP 75mg/m2 day 1
88929893|NCT01735422|Experimental|r-hLH (825 International Units [IU])|
88929894|NCT01735422|Experimental|r-hLH (2750 IU)|
88929895|NCT01735422|Experimental|r-hLH (5500 IU)|
88929896|NCT01735422|Experimental|r-hLH (11000 IU)|
88929897|NCT01735422|Experimental|r-hLH (22000 IU)|
88929898|NCT01735422|Active Comparator|u-hCG (5000 IU)|
88929899|NCT01735435|No Intervention|Group 2 (Control group)|Group 2(Control group)-patients in this group received nutrition according to the standard hospital dietary regimen.
88929900|NCT01735435|Experimental|Group 1 (Indirect Calorimetry)|Group 1(Indirect Calorimetry)-The tight calorie group received calories with an energy goal determined by repeated REE measurements using indirect calorimetry.
88929901|NCT01735448||Aboriginal smoker, male, Adelaide|Focus group: Aboriginal smoker, male from Adelaide
88929902|NCT01735448||Aboriginal smoker, female, Adelaide|Focus group: Aboriginal smoker, female, from Adelaide
88929903|NCT01735448||Aboriginal ex/non-smoker, male, Adelaide|Focus group: Aboriginal ex/non-smoker, male, from Adelaide
88929904|NCT01735448||Aboriginal ex/non-smoker, female, Adelaide|Focus group: Aboriginal ex/non-smoker, female, from Adelaide
88929905|NCT01735448||Healthcare workers, Adelaide|Focus group: Healthcare workers who are based in Adelaide and work with Aboriginal patients
88929906|NCT01735448||Healthcare workers, Murray Bridge|Focus group: Healthcare workers who are based in Murray Bridge and work with Aboriginal patients
88929907|NCT01735448||Aboriginal smoker, male, Murray Bridge|Focus group: Aboriginal smoker, male, from Murray Bridge
88929908|NCT01735448||Aboriginal smoker, female, Murray Bridge|Focus group: Aboriginal smoker, female, from Murray Bridge
88929909|NCT01735448||Aboriginal ex/non-smoker, male, Murray Bridge|Focus group: Aboriginal ex/non-smoker, male, from Murray Bridge
88929910|NCT01735448||Aboriginal ex/non-smoker, female, Murray Bridge|Focus group: Aboriginal ex/non-smoker, female, from Murray Bridge
88929911|NCT01735448||Key community stakeholders|One-on-one interviews with 10 key Aboriginal community stakeholders
89444863|NCT04556552|Sham Comparator|Sham stimulation|Sham stimulation of vagus with opioid cues
89444864|NCT04553718|Experimental|experiemental group|Experimental group was the mHealth app to improved their gestational weight gain and physical activity during pregnancy.
88929912|NCT01735448||Respiratory physicians|One-on-one interviews with 10 Respiratory physicians
88929913|NCT01735448||Consultants and General Practitioners|One-on-one interviews with 10 consultants and/or GP's
88929914|NCT01735474|Placebo Comparator|Placebo|30 people are recruited in order to the inclusion criteria for the study. Placebo controlled.
88929915|NCT01735474|Active Comparator|Manual technique|30 people are recruited in order to the inclusion criteria for the study. Experimental group.
88929916|NCT01735487|Active Comparator|Own Brand cigarette|Smoke Own Brand cigarette, 15 puff of cigarette.
88929917|NCT01735487|Experimental|One High 2,4% nicotine|Smoke electronic cigarette One High 2,4% nicotine for a day, 15 puff of e-cigarette.
88929918|NCT01735487|Experimental|Original 7,4 mg nicotine|Smoke electronic cigarette Original 7,4 mg nicotine for a day. 15 puff of e-cigarette.
88929919|NCT01735487|Placebo Comparator|Nicotine Free|Smoke electronic cigarette nicotine free (15 puff)
88929920|NCT01735487|Experimental|EGO 9mg|Smoke electronic cigarette EGO for a day (15 puff)
88929921|NCT01735500||CAG without PCI|
88929922|NCT01735500||CAG with PCI|
88929923|NCT01735513|Experimental|Transaortic TAVI with EmbolX|"Subjects are randomized into this arm to receive a transaortic transcatheter aortic valve implantation with the use of the embolic protection device EmbolX"
88929924|NCT01735513|Active Comparator|Transaortic TAVI without EmbolX|"Subjects are randomized into this arm to receive a transaortic transcatheter aortic valve implantation without the use of the embolic protection device EmbolX"
88929925|NCT01735539|Experimental|Old Bolus|15g EAA bolus
88929926|NCT01735539|Experimental|Old Arginine|15g EAA Bolus supplemented with 3g Arginine
88929927|NCT01735539|Experimental|Young Bolus|15g EAA bolus
88929928|NCT01735539|Experimental|Young Pulse|4 x 3.75g Mixed EAA Pulses
88929929|NCT01735539|Experimental|Old Pulse|4 x 3.75g Mixed EAA Pulses
88929930|NCT01735552||Infants requiring PRBCs|Premature infants who require PRBCs for anemia that is not related to sepsis, surgery, NEC or immunologic abnormalities.
88929931|NCT01735565||Post bone marrow transplant|Patients who are undergoing bone marrow transplant, as well as patients who have completed a bone marrow transplant within the previous year.
88929932|NCT01735578||Premature infants with anemia|Inpatient premature infants at the University of Utah Neonatal Intensive Care Unit (NICU) with Hct < or = to 28 who are being fed and are stable.
89444865|NCT04553718|No Intervention|control group|standard prenatal care and without mHealth app
89444866|NCT04546958|Active Comparator|Nutritional counseling arm|Nutritional counseling, targeting daily protein intake 1.2 g/kg Dietitian will provide one-to-one dietary education, 30 minutes duration, on a monthly basis
89013642|NCT06295198|Experimental|Mulligan Group|Participants in the Mulligan group stood in front of the physical therapist at the end of the treatment table and placed their affected lower extremity forward and the other slightly backward. The physical therapist placed both hands on top of each other on the patient's talus to stabilize the talus. The athlete was asked to move until he reached the end of his pain-free ankle dorsiflexion range. Meanwhile, the physiotherapist gave posterior pushing with both hands. The Mulligan mobilization technique was performed 10 times by each athlete.
89013643|NCT06295198|Experimental|Maitland Group|Maitland group, III. degree talus mobilization technique was applied. In this mobilization technique, 120 seconds of application, 60 seconds of rest, and then 120 seconds of application were performed. Maitland III, which takes 5 minutes in total. For the 10-degree mobilization technique, the participant was placed on his back with the foot pointing forward, the ankle was placed in 20° plantar flexion, and the talocrural ligament was in a relaxed position. The hand stabilizing the foot was placed proximal to the malleolus to stabilize the leg. The other hand performing the mobilization grasped the anterior talus using the first web space. The talus was then shifted posteriorly downwards with force.
89013644|NCT06294561|Experimental|Itraconazole|healthy subjects will be given Itraconazole 200 mg orally with TGRX-326 60 mg
89013645|NCT06294561|Experimental|Efavirenz|healthy subjects will be given Efavirenz 600 mg orally with TGRX-326 60 mg
89013646|NCT06294509|No Intervention|No stimulation (control)|Participants will wear device but will not receive any stimulation
89013647|NCT06294509|Active Comparator|Movement-unrelated stimulation (control)|Participants will wear device and receive randomly timed stimulation
89013648|NCT06294509|Experimental|pre-movement taVNS|Stimulation will start after 500ms of being in the home position, before the onset of the movement cue.
89013649|NCT06294509|Experimental|during-movement taVNS|Stimulation will occur during the movement phase.
89013650|NCT06294509|Experimental|post-movement taVNS|Stimulation will occur immediately after a successful trial (no stimulation if the trial is failed).
89013654|NCT06294132|Experimental|Lumbar Mnaipulation|Participants will be randomly assigned to receive lumbar manipulation by an experience physical therapist.
89013655|NCT06294132|Sham Comparator|Sham Lumbar Manipulation|Participants will be randomly assigned to receive a sham lumbar manipulation by an experienced physical therapist.
89013656|NCT06293807|Experimental|Treatment group Xylocaine|Participants have been scheduled to receive an area of gum surgery to treat periodontal (gum) disease in their mouth while under intravenous (IV) conscious sedation. The study drug is administered after surgery.
89013657|NCT06293807|Experimental|Treatment group Bupivicaine|Participants have been scheduled to receive an area of gum surgery to treat periodontal (gum) disease in their mouth while under intravenous (IV) conscious sedation. The study drug is administered after surgery.
89444867|NCT04546958|Experimental|Nutritional counseling plus whey protein supplements arm|Nutritional counseling plus whey protein supplements, targeting daily protein intake 1.5 g/kg In addition to receiving nutritional counseling, participants are instructed to take an additional whey protein supplement at the dose of ~0.3 g/kg protein intake.
89013658|NCT06293807|Placebo Comparator|Placebo control group|Participants have been scheduled to receive an area of gum surgery to treat periodontal (gum) disease in their mouth while under intravenous (IV) conscious sedation. The study drug is administered after surgery.
89013659|NCT06293469|Experimental|Accelerated Flap Coverage|Accelerated flap surgery timing at a goal of within 72 hours from injury. Management of the fracture or dislocation, selection of flap, and post-injury flap management will be at the discretion of the operating surgeons and documented for both treatment groups.
88929933|NCT01735591|Experimental|Probiotic|Capsules with 3x10^9 colony forming units (Lactococcus lactis PB 411 - 50%; Lactobacillus casei PB 121 - 25%; Lactobacillus acidophilus PB 111 - 12,5%; Bifidobacterium bifidum PB 211 - 12,5%). 1 capsule a day from inclusion until liver transplantation
88929934|NCT01735591|Placebo Comparator|Placebo|Placebo, 1 capsule a day from inclusion until the date of liver transplantation
88929935|NCT01735604|Experimental|anti-CD20-CAR T cell|Arm 1 Patients receive anti-CD20-CAR lentiviral vector-transduced autologous T cells with 41BB vector for 3-5 days in the absence of disease progression or unacceptable toxicity.
88929936|NCT01735643|Experimental|interactive videogame intervention|
88929937|NCT01735643|Experimental|waiting group|
88929938|NCT01735669|Experimental|Remifentanil|External cephalic version at term under Remifentanil perfusion
88929939|NCT01735669|Active Comparator|Nitrous oxide|External cephalic version at term under Nitrous oxide inhalation
88929940|NCT01735682|Experimental|Whole body vibration|This group will receive whole body vibration and conventional exercise training (1 hour per session, 3 sessions per week, for 8 consecutive weeks).
88929941|NCT01735682|Active Comparator|Conventional exercise|This group will receive convention exercise training (1 hour per session, 3 sessions per week, for 8 consecutive weeks).
88929942|NCT01735682|Active Comparator|Control|This group will have exercise training that involve only the upper limbs (about 30 minutes per session, 3 sessions per week, for 8 consecutive weeks).
88929943|NCT01735708|Placebo Comparator|Health Education|Participants in the Health Education arm will receive 7 individual sessions, each of which will focus on a different health education topic.
88929944|NCT01735708|Active Comparator|HIVPASS Intervention|Participants in the HIVPASS intervention arm will receive 7 individual sessions with the study interventionist, the first of which is a collaborative meeting with the PCP. Sessions will focus on pain interference and depression management.
88929945|NCT01735721|Active Comparator|Open Sinus Lift with DFDBA|In each patient, one sinus was chosen at random and filled with DFDBA (Tissue Regeneration Corporation, Iran).
88929946|NCT01735721|Experimental|Open Sinus Lift with Algipore|The contra lateral sinus was filled with Algipore (Dentsply, USA).
88929947|NCT01735734||Capillary malformation|
88929948|NCT01735747|Experimental|Temozolomide, Nedaplatin, Vincristine, Radiotherapy|The newly diagnosed PCNSL patients will be given concurrent temozolomide (75mg/m2, orally) daily during WBRT. Then, the TNV regimen will be given after four weeks. TNV regimen consisted of temozolomide (200mg/m2 orally, days 1-5), nedaplatin (80mg/m2 i.v., day 1), vincristine (1.4mg/m2 i.v., day 1). Each cycle was 4 weeks and a maximum of six cycles were applied.
88929949|NCT01735760||Palpation|The group using palpation as primary attempt at localizing the cricothyroid membrane
88929950|NCT01735760||Ultrasonography|The group using ultrasound for their primary approach to localizing the cricothyroid membrane
88929951|NCT01735773||Hemodialysis group|Patients on chronic hemodialysis program
88929952|NCT01735773||Peritoneal dialysis group|Patients on chronic peritoneal dialysis program
88929953|NCT01735773||Pre-dialysis group|Patients with chronic kidney disease stage-4
88929954|NCT01735773||Control group|Healthy volunteers
88929955|NCT01735786||Treatment group|Subjects in this group will received Endoclot treatment immediately after EMR.
88929956|NCT01735786||Control group|Subjects in this group will not received any hemostasis treatment after EMR.
88929957|NCT01735851|Active Comparator|Thoracic epidural analgesia|Group 1 will receive a catheter congruent TEA. The epidural space will be identified using the loss of resistance technique. After a test dose to rule out intravascular and intrathecal placement of the catheterthe initial block will be made with 0.25% bupivacaine 5 mL followed by 3 mL aliquots administered every 5 minutes to establish a block between T8 and T12. An infusion will be started at 8 mL/hour with 0.1 % bupivacaine with 10microgram/mL of dilaudid and continued for 72 hours. Additional nurse administered boluses of 5-10mL of the standard solution will be allowed via the epidural catheter every 6hourly for poor pain control followed by an increase in the basal infusion rate up to a maximum of 14mL/hr. Patients will be allowed to self administer additional boluses of 3mL of the standard infusate every 20minutes (PCEA)
88929958|NCT01735851|Experimental|Bilateral Paravertebral block|Group 2 will have bilateral PVB catheters inserted using the ultrasound with patients prone. A high-frequency linear probe will used to visualize the transverse process, pleura and the internal intercostal membrane. A 17 guage Tuohy needle will be inserted to puncture the internal intercostal membrane. Injection of local anesthetic will push the pleura away, which will be the end point of needle position. A curved pigtail catheter will be inserted and further 5mL of local anesthetic will be injected while observing further movement of pleura. A similar procedure will be done on the contralateral side at the same level. Infusion of 0.2% ropivacaine will be continued for the next 72 hours. They will also receive IVPCA and additional nurse administered boluses of 5-10mL of ropivacaine 0.2% in the PVB every 6 hourly to the side of maximal pain.
88929959|NCT01735864|Active Comparator|Indirubin 200 μg/g|per gram of ointment contains 200 μg of indirubin
88929960|NCT01735864|Active Comparator|Indirubin 100 μg/g|per gram of ointment contains 100 μg of indirubin
88929961|NCT01735864|Active Comparator|Indirubin 50 μg/g|per gram of ointment contains 50 μg of indirubin
88929962|NCT01735864|Active Comparator|Indirubin 10 μg/g|per gram of ointment contains 10 μg of indirubin
88929963|NCT01735890|Experimental|CJ Amlodipine/Valsartan 10/160mg|
88929964|NCT01735890|Active Comparator|Novartis Exforge 10/160mg|
88929965|NCT01735968|Experimental|STI571 (imatinib mesylate) and BYL719|The study will comprise of 2 parts. A dose escalation and a dose expansion part. All patients in the dose escalation part will have a pharmacokinetic (PK) run-in period of 7 days receiving imatinib monotherapy. Patients will receive increasing doses of BYL719 (200, 300, 400 mg) in combination with 400mg imatinib daily until maximum tolerated dose (MTD) and rapid phase 2 dose (RP2D) is determined. Approximately 35 patients will enter the expansion phase.
88929966|NCT01736007|Sham Comparator|Liquid light guide tip on laser|Excimer laser treatment with 308-nm excimer laser with guide tip applied to alopecia patch twice a week.
88929967|NCT01736007|Active Comparator|308-nm excimer laser to alopecia patch|Laser treatment with 308-nm excimer laser procedure to alopecia patch twice a week with increasing fluence as tolerated.
88929968|NCT01736020|Placebo Comparator|Placebo|Placebo
88929969|NCT01736020|Experimental|Dexmedetomidine|Dexmedetomidine intravenous infusion during scan.
88929970|NCT01736020|Experimental|Propofol|Propofol intravenous infusion during scan.
88929971|NCT01736020|Experimental|Ketamine|Ketamine intravenous infusion during scan.
88929972|NCT01736020|Experimental|Nitrous Oxide|Nitrous Oxide inhalation during scan.
88929973|NCT01736033|Placebo Comparator|Tamsulosin + Placebo|Tamsulosin 0.2mg + Placebo 5 mg daily until clinical progression
88929974|NCT01736033|Active Comparator|Tamsulosin + Finasteride|Tamsulosin 0.2mg + Finasteride 5 mg daily until clinical progression
88929975|NCT01736046||Crohn's Disease patients|All patients referred for CT Enterography will be undergo both standard and low dose CT Enterography
88929976|NCT01736098|Experimental|High Energy Flux|Energy Flux Exercise Intervention: 7kcal/kg/day at 5 days/week of energy expenditure and matching energy intake
88929977|NCT01736098|Experimental|Medium Energy Flux|Energy Flux Exercise Intervention: 3.5kcal/kg/day at 5 days/week of energy expenditure and matching energy intake
88929978|NCT01736098|No Intervention|Low Energy Flux|No Intervention: maintain normal lifestyle
88929979|NCT01736111|Experimental|Personal feedback|"This arm will receive all intervention components of Active Comparator group, plus the following:~Text messages to prompt participant to reply with self-monitoring entries~Human coach uses system to send personalized text messages with feedback on self-monitoring entries"
88929980|NCT01736111|Active Comparator|One Way Text|"Printed handouts from the Aim for a Healthy Weight booklet, which is published by National Heart, Lung, and Blood Institute and is frequently included in control conditions in primary care-based weight loss studies.~Other handouts will discuss the use of prepackaged foods as well as setting goals for calorie intake, physical activity, and weight loss.~One to three text messages per week, based on topics from Aim for a Healthy Weight and other sources. The text messages will be pre-scheduled, automated, non-tailored, and one-way (no reply will be requested). The total dose of contact will be low because each text message is limited to 160 characters. The condition is comparable in intensity to control conditions in other weight loss trials in the primary care setting.~Usual medical care from the PCP.~Education on symptoms of hypoglycemia, hypotension, and cardiovascular disease, with instructions to contact their PCP in the event of those symptoms."
88929981|NCT01736137||Chronic Heart failure group|All chronic heart failure group participants will perform two walk tests at the same day, with a heart rate monitor, and answer questionnaires about their perception of quality of life. Tests will be conducted on a single day, without follow up of patients. The six minute walk test will be performed according the American Thoracic Society Statement (2002).
88929982|NCT01736137||Control Group|All control group participants will perform two walk tests at the same day, with a heart rate monitor, and answer questionnaires about their perception of quality of life. Tests will be conducted on a single day, without follow up of patients. The six minute walk test will be performed according the American Thoracic Society Statement (2002).
88929983|NCT01736150|Experimental|Sevelamer carbonate|Subjects randomized by a central randomization system to one of two treatment groups in a 2:1 (active: placebo) fashion, stratified by Visit 1a phosphorus result (>5.5 mg/dL-6.5 mg/dL versus greater than 6.5 mg/dL), and site.
88929984|NCT01736150|Placebo Comparator|Placebo|Subjects randomized by a central randomization system to one of two treatment groups in a 2:1 (active: placebo) fashion, stratified by Visit 1a phosphorus result (>5.5 mg/dL-6.5 mg/dL versus greater than 6.5 mg/dL), and site.
88929985|NCT01736163||Thyrogen and 131I|Patients were previously treated with Thyrogen in conjunction with a high ablative activity of 131I.
88929986|NCT01736163||Thyroid Hormone Withdrawal and 131I|Patients were previously treated with Thyroid hormone withdrawal (THW) in conjunction with a high ablative activity of 131I.
88929987|NCT01736228|Experimental|DIABECELL|two transplants of 10,000 IEQ/kg DIABECELL (administered at least 12 weeks apart)- total of 20,000 IEQ/kg
88929988|NCT01736280|Other|1|Standard of Care. Participants will be evaluated and treated for their particular digestive disorder or presenting symptoms.
88929989|NCT01736306||Volunteers|Volunteer milk donors
88929990|NCT01736371|Sham Comparator|Total Intravenous Anesthesia|Only propofol infusion is used for maintenance of anesthesia keeping Bispectral Index (BIS) between 45-55.
88929991|NCT01736371|Active Comparator|1% Sevoflurane|1% Sevoflurane with propofol infusion is used for maintenance. BIS is kept between 45-55 by adjusting propofol infusion.
88929992|NCT01736371|Active Comparator|Sevoflurane|Only Sevoflurane is used for maintenance keeping BIS between 45-55
88929993|NCT01736384||Obesity|Gastric bypass surgery and non-obese controls undergoing cholecystectomy
88929994|NCT01736410|Other|IHC method|
88929995|NCT01736410|Other|FISH method|
89444868|NCT04540107|Experimental|Cohort 1 (MRI, MRSI) (CLOSED TO ENROLLMENT)|Patients undergo MRI and MRSI scans over 1 hour at baseline. Patients then continue to undergo MRSI scans that follow the clinical MRI schedule set by doctors to monitor patients' care. Participants enrolled in cohort 1 may later enroll in cohort 2 of study once eligibility has been reviewed and approved by neuro-oncologist
89444869|NCT04540107|Experimental|Cohort 2 (MRI, hyperpolarized carbon C 13 pyruvate, MRSI)|Patients undergo MRI scan at baseline. Patients then receive hyperpolarized carbon C 13 pyruvate IV over less than 1 minute and undergo MRSI scan at baseline. Patients then continue to undergo MRSI scans that follow the clinical MRI schedule set by doctors to monitor patients' care.
89444870|NCT04534556|Experimental|Immediate Start Vagus Nerve Stimulation group|The Immediate Start VNS group will receive rehabilitation and active stimulation for 18 in-office sessions over the course of approximately six weeks during Phase 1. For Phase 2, all subjects will be provided with the option to participate in an open-label extension consisting of an additional 18 sessions of in-office rehabilitation with active VNS over the course of approximately six weeks. Additionally, participants may be provided with a system of rehabilitative devices to utilize at home.
89444871|NCT04534556|Placebo Comparator|Delayed Start Vagus Nerve Stimulation group|The Delayed Start VNS group will receive equivalent rehabilitation with placebo stimulation for 18 in-office sessions over the course of approximately six weeks during Phase 1. For Phase 2, all subjects will be provided with the option to participate in an open-label extension consisting of an additional 18 sessions of in-office rehabilitation with active VNS over the course of approximately six weeks. Additionally, participants may be provided with a system of rehabilitative devices to utilize at home.
89444872|NCT04529252||Spinocerebellar Ataxia and Other Nucleotide Repeat Diseases|Participants with a clinical diagnosis of spinocerebellar ataxia and other nucleotide repeat diseases (not including Huntington's Disease) with or without a genetic mutation and unaffected family members (grandparents, parents, brothers, sisters, cousins, uncles and aunts) who may or may not carry a genetic mutation for the disease.
89444873|NCT04529252||Control Group|Participants with no known medical or family history of inherited neurodegenerative forms of spinocerebellar ataxia or nucleotide repeat diseases (not including Huntington's Disease) and spouses or caregivers of patients with spinocerebellar ataxia and nucleotide repeat diseases (not including Huntington's Disease) will serve as controls in the study.
89444874|NCT04523493|Experimental|Experimental group|Toripalimab combined with Lenvatinib
89444875|NCT04523493|Placebo Comparator|Control group|Placebo combined with Lenvatinib
89444876|NCT04503551|Experimental|PDS Arm|Participants randomized to the PDS arm will receive two intravitreal ranibizumab injections and will then have the PDS implant (pre-filled with ranibizumab) surgically inserted. PDS implant refill-exchange procedures will be performed on a fixed interval every 36-weeks (Q36W) thereafter
89444877|NCT04503551|Other|Comparator Arm|Participants randomized to the comparator arm will undergo study visits every 4 weeks (Q4W) for comprehensive clinical monitoring until they receive the PDS implant (pre-filled with ranibizumab). PDS implant refill-exchange procedures will be performed on a fixed interval Q36W thereafter. Participants will be eligible to receive intravitreal ranibizumab 0.5 mg injections if treatment eligibility criteria are met.
89444878|NCT04497909|Experimental|Pre-clerkship cohort|First- and second-year medical students
89444879|NCT04497909|Experimental|Clerkship cohort|Third- and fourth-year medical students
89444880|NCT04497909|Experimental|Resident cohort|Medical residents
89444881|NCT04496167|Experimental|EN3835|EN3835 up to 1.74 mg
89444882|NCT04496167|Placebo Comparator|Placebo|Placebo
89444883|NCT04485195|Active Comparator|Vernakalant|Patients randomized to this arm will receive an initial infusion of 3 mg/kg infused over a 10-minute period by a pre-programmed IV pump.82 For patients ≤ 100 kg the infusion is prepared by adding 25 mL of BRINAVESS 20 mg/mL to 100 mL of diluent creating a total volume of 125 mL at a concentration of 4 mg/mL. For patients > 100 kg the infusion is prepared by adding 30 mL of BRINAVESS 20 mg/mL to 120 mL of diluent creating a total volume of 150 mL at a concentration of 4 mg/mL. For patients weighing ≥ 113 kg, the maximum initial dose is 339 mg (84.7 mL of 4 mg/mL solution).
88929996|NCT01736423|Experimental|Female Patients with D-IBS|
88929997|NCT01736436|Experimental|100 mg APG101 weekly over 12 weeks|Single arm open label study. Patient receive 100 mg APG101 i.v. weekly over 12 weeks with a 6 monthly follow-up phase
88929998|NCT01736449|Placebo Comparator|Pterygium Excision Alone|
88929999|NCT01736449|Experimental|Pterygium Excision with Bevacizumab Injection|
88930000|NCT01736462|Experimental|Mapracorat|Mapracorat ophthalmic suspension, 3%
88930001|NCT01736488|Experimental|Fimasartan 60mg|60mg/day of Fimasartan will be oral administered for the study period (8 weeks)
88930002|NCT01736488|Active Comparator|Atenolol 50mg|50mg/day of Atenolol will be oral administered for the study period (8 weeks)
88930003|NCT01736501|No Intervention|Baseline1-demographics|Baseline survey- demographics only
88930004|NCT01736501|Other|Baseline1 w/genetics|Genetics education, baseline interest in genome screening - 1
88930005|NCT01736501|Other|Baseline2-demographics|Baseline survey- demographics only
89444884|NCT04485195|Active Comparator|Procainamide|Patients randomized to this arm will receive a continuous infusion of IV procainamide with a dose of 15 mg/kg in 500 mL of normal saline given over 60 minutes (maximum dose 1,500 mg), by a pre-programmed pump. While the CAEP Best Practices Checklist suggests an infusion time of 30-60 minutes, we believe that a 60-minute period will avoid some adverse events.
89444885|NCT04485130|Experimental|Disulfiram|This study will provide disulfiram. Participants in Cohort 1 receiving disulfiram will take 2 capsules of disulfiram (each capsule contains 500 mg DSF plus 27.75 mg microcrystalline cellulose powder) per day for a total of 5 consecutive days. Participants in Cohort 2 receiving placebo will take 4 capsules of disulfiram (each capsule contains 500 mg DSF plus 27.75 mg microcrystalline cellulose powder) per day for a total of 5 consecutive days.
89444886|NCT04485130|Placebo Comparator|Placebo|This study will provide placebo comparator for disulfiram. Participants in Cohort 1 receiving placebo will take 2 capsules of placebo (each capsule contains only microcrystalline cellulose powder) per day for a total of 5 consecutive days. Participants in Cohort 2 receiving placebo will take 4 capsules of placebo (each capsule contains only microcrystalline cellulose powder) per day for a total of 5 consecutive days.
89444887|NCT04469491|Experimental|Inhaled IFN arm|IFN (Interferon) pulmonary (Inhalation) + routine care (+/- antibiotics; +/- dexamethasone; + appropriate O2 support)
89444888|NCT04469491|Active Comparator|Control Arm:|Aerosol (WFI water and routine care (+/- antibiotics;+/- dexamethasone; + appropriate O2 support).
89444889|NCT04460924||MSM HIV-uninfected and ART naïve|Men who have sex with men without HIV infection, not receiving ART
89444890|NCT04460924||MSM HIV-infected starting ART|Men who have sex with men with HIV infection, starting ART
89444891|NCT04460924||MSM HIV-infected on ART with >500 CD4 Tcells|Men who have sex with men with HIV infection, on ART and with >500 CD4 T cells/uL
89444892|NCT04460924||MSM HIV-infected on ART with <350 CD4 Tcells|Men who have sex with men with HIV infection, on ART and with <350 CD4 T cells/uL
89444893|NCT04460924||MSM HIV negative patients starting PEP with INST|Men who have sex with men without HIV infection, starting post-exposure prophylaxis with raltegravir
89444894|NCT04458948|Experimental|Hydroxychloroquine and Azithromycin|All subjects receive Hydroxychloroquine and Azithromycin.
88930006|NCT01736501|Other|Baseline2 w/genetics|Genetics education, baseline interest in genome screening - 2
88930007|NCT01736514|Experimental|febuxostat group|oral
88930008|NCT01736514|Active Comparator|allopurinol group|oral
88930009|NCT01736605|Active Comparator|Massage|Daily massage for 20 minutes the first 3 days following surgery.
88930010|NCT01736605|Active Comparator|Massage combined with meditation|Daily massage for 20 minutes combined with meditation the first 3 days following surgery.
88930011|NCT01736644|Placebo Comparator|Electrocautery|Use of electrocautery in tourniquet and without tourniquet total knee replacement surgery.
88930012|NCT01736644|Active Comparator|Bipolar Sealer Aquamantys|Use of bipolar sealer Aquamantys in tourniquet and tourniquetless total knee replacement surgical procedures.
88930013|NCT01736670|Experimental|Acute Steroid Responsive dermatitis|10 patients with acute steroid-responsive dermatoses
88930014|NCT01736670|Experimental|Chronic Steroid Responsive Dermatits|10 patients with chronic steroid-responsive dermatoses
89444895|NCT04386746|Experimental|Intravesical Gemcitabine/Docetaxel|Gemcitabine/Docetaxel induction is given intravesically in sequential order once a week for six consecutive weeks. One gram of gemcitabine in 50 ml of sterile water is slowly instilled into the bladder via a Foley catheter and the catheter is clamped for 60 minutes. The bladder is then drained and 40 mg of docetaxel in 50 ml of NSS is then slowly instilled via the Foley catheter into the bladder. The catheter is again clamped for 60 minutes before draining. If initial efficacy seen, patients will have monthly maintenance instillations of Gemcitabine/Docetaxel.
89444896|NCT04383119|Experimental|Arm A|Trabectedin at the dose of 1.5 mg/m2-1.3 mg/m2 with a top-dose of 2.6 total mg per cycle (according the clinical practice in pretreated patients and in all our ISG studies) will be administered via a central venous catheter as a 24-hour infusion on day 1 of 21-days treatment cycles
89444897|NCT04383119|Active Comparator|Arm B|Gemcitabine 800-1000 mg/m2 will be administered via a central venous catheter on days 1,8 every 21 days
89444898|NCT04383119|Active Comparator|Observational Cohort|Treatmen according clinical practice (not defined in advance). The patient who will refuse randomization between Arm A and B can choose to participate to the observational cohort to the study, where they will be treated according clinical practice
88930015|NCT01736670|Active Comparator|Control, Otherwise healthy|10 healthy controls
88930016|NCT01736709|Experimental|trivalent seasonal influenza vaccine|2012-2013 trivalent seasonal influenza vaccine in 60 infants with two-dose regimen, 21 days interval trivalent seasonal influenza vaccine in 60 adults and 60 old people with single-dose regimen
89444899|NCT04367779||A : High Grade Sarcoma|Pediatric and adult patients with High Grade Sarcoma treated or to be treated with Proton Beam Therapy (PBT) and not candidate to surgery before PBT.
89444900|NCT04367779||B : Brain tumors|Pediatric and adult patients with Brain Tumors treated or to be treated with Proton Beam Therapy (PBT) and not candidate to surgery before PBT.
89444901|NCT04367779||C : Meningioma|Pediatric and adult patients with Meningioma treated or to be treated with Proton Beam Therapy (PBT) and not candidate to surgery before PBT.
88930017|NCT01736722|Experimental|MRI-guided laser induced thermal therapy|The target tumor/lesion will undergo laser therapy using the MRI scan to plan the treatment and ensure proper placement of the laser within the tumor. An MRI (Magnetic Resonance Imaging) is a exam that creates pictures using magnetic rays instead of x-rays. The tumor(s) will then be heated by the laser in an attempt to eliminate their presence. The physician will be able to see and control the temperature of the laser.
88930018|NCT01736735|Experimental|CLP|CLP BID
88930019|NCT01736735|Placebo Comparator|Placebo|BID powder
88930020|NCT01736761|Experimental|Darunavir, Ritonavir, Rilpivirine|Darunavir 800 mg once daily, Ritonavir 100 mg once daily and Rilpivirine 25 mg once daily
89444902|NCT04357756|Experimental|YH001 combined with Toripalimab|All the patients will receive YH001 intravenously as single agent for 21 days followed by combination phase.
89444903|NCT04350502|Experimental|complicated pleural infection patients|Patients with a complicated pleural infection will be managed according to the French guideline with a chest tube drainage associated to a treatment with amoxicillin (2g*3 by day) and clavulanic acid (200mg*3 by day). Repeated samples of pleural fluid and serum will be taken to evaluate antibiotics' concentrations at H0; H½; H1; H2; H3; H4; H8 and H24
89444904|NCT04339101|Experimental|Treatment (itacitinib adipate, tacrolimus, sirolimus)|"RIC: Patients receive fludarabine via infusion on days -9 to -5 and melphalan on day -4 in the absence of disease progression or unacceptable toxicity.~ALLOGENEIC HSCT: Patients undergo HSCT on day 0.~GVHD PROPHYLAXIS: Patients receive itacitinib PO QD beginning on day -3 and continuing until day 100 in the absence of disease progression or unacceptable toxicity. Patients also receive tacrolimus IV or PO and sirolimus PO beginning day -3 and continuing until day 100 with a taper in the absence of disease progression or unacceptable toxicity."
89444905|NCT04305548|Experimental|Trabectedin|Trabectedin: 1.5 mg/m² - 1.3 mg/m² (at investigator's discretion, with a top-dose of 2.6 total mg per cycle), given in 24-hour continuous infusion
89444906|NCT04294134|Active Comparator|MIO-CPP|The 9 month MIO-CPP model will begin with the standard 12 weeks of MIO for each mother, with the CPP assessment and engagement phase embedded during this time. This phase will be followed by the dyadic mother-child phase, the core intervention stage of CPP. If a parent needs additional stabilization, more individual time can be added. During the core phase of dyadic CPP the Child Parent Specialists will continue to build and strengthen parents' reflective functioning by embedding aspects from MIO. The 9 month MIO-CPP model will begin with the standard 12 weeks of MIO for each mother, with the CPP assessment and engagement phase embedded during this time. This phase will be followed by the dyadic mother-child phase, the core intervention stage of CPP. If a parent needs additional stabilization, more individual time can be added.
89444907|NCT04294134|Experimental|MIO-CPP-CRS|"In Phase 2, participants will receive MIO-CPP therapy, as well as support from a CRS. The MIO-CPP model will begin with 6 sessions of MIO for each study participant, with the CPP assessment and engagement phase embedded during this time. This phase will be followed by the dyadic mother-child phase, the core intervention stage of CPP. If a parent needs additional stabilization, more individual time can be added. During the core phase of dyadic CPP the Child Parent Specialists will continue to build and strengthen parents' reflective functioning by embedding aspects from MIO.~Participant dyads will be assigned a Certified Recovery Specialists (CRSs) who will provide services to support them as they transition out of SUD treatment and back into their home communities."
89444908|NCT04293224|Experimental|DGA Mediterranean diet pattern, energy balance|Diet plan focused on energy balance (meets calorie needs), emphasizes fruits, vegetables and whole grains and limits calories from added sugars and saturated fats and reduces sodium intake per Dietary Guidelines for Americans (DGA) recommendations.
89444909|NCT04293224|Experimental|DGA Mediterranean diet pattern, negative energy balance|Negative energy balance (~25% calorie reduction compared to needs), emphasizes fruits, vegetables and whole grains and limits calories from added sugars and saturated fats and reduces sodium intake per Dietary Guidelines for Americans (DGA) recommendations.
89444910|NCT04293224|Experimental|TAD diet pattern|Typical American Diet (TAD) with negative energy balance (~25% calorie reduction compared to needs) which mimics intake of fruits, vegetables, whole grains, added sugars, saturated fats and sodium based on data from What We Eat in America (WWEIA).
89444911|NCT04288245|Experimental|Immediate Start Vagus Nerve Stimulation group|The Immediate Start VNS group will receive rehabilitation and active stimulation for 18 in-office sessions over the course of approximately 6 weeks during phase 1. For phase 2, all subjects will be provided the option to participate in an open-label extension consisting of an additional 18 sessions of in-office rehabilitation with active VNS over the course of approximately 6 weeks. Participants that elect to continue in the open-label extension will be assessed approximately 1 week after the conclusion of the additional 18 sessions of therapy.
89444912|NCT04288245|Placebo Comparator|Delayed Start Vagus Nerve Stimulation group|The Delayed Start VNS group will receive equivalent rehabilitation with placebo stimulation for 18 in-office sessions over the course of approximately 6 weeks during phase 1. For phase 2, all subjects will be provided the option to participate in an open-label extension consisting of an additional 18 sessions of in-office rehabilitation with active VNS over the course of approximately 6 weeks. Participants that elect to continue in the open-label extension will be assessed approximately 1 week after the conclusion of the additional 18 sessions of therapy.
89444913|NCT04270136|Experimental|breast cancer mastectomy|
89444914|NCT04246177|Experimental|Lenvatinib plus Pembrolizumab plus TACE|Participants will receive a combination of lenvatinib, pembrolizumab, and TACE. Lenvatinib will be administered at a dose of 12 mg (for participants with screening body weight ≥60 kg) or 8 mg (for participants with screening body weight <60 kg) orally once a day during each 21-day cycle until progressive disease or unacceptable toxicity (up to 2 years [~35 cycles] or longer with Sponsor approval). Pembrolizumab will be administered via IV infusion at a dose of 400 mg once every 6 weeks (Q6W) for up to 2 years (~17 doses). Participants will undergo TACE as a background procedure of chemotherapeutic and embolic agent(s).
89444915|NCT04246177|Active Comparator|Oral Placebo plus IV Placebo plus TACE|Participants will receive a combination of lenvatinib-matching oral placebo, pembrolizumab-matching IV placebo, and TACE. Lenvatinib-matching oral placebo will be administered once a day during each 21-day cycle for up to 2 years (~35 cycles) or longer with Sponsor approval and pembrolizumab-matching IV placebo will be administered once every 6 weeks (Q6W) for up to 2 years (~17 doses). Participants will undergo TACE as a background procedure of chemotherapeutic and embolic agent(s).
89444916|NCT04238481|Experimental|Pudexacianinium chloride - Dose Level A|Participants received single dose of pudexacianinium chloride at dose level A by intravenous (IV) bolus infusion on day 1 once the surgical area of interest is in view.
89444917|NCT04238481|Experimental|Pudexacianinium chloride - Dose Level B|Participants received single dose of pudexacianinium chloride at dose level B by IV bolus infusion on day 1 once the surgical area of interest is in view.
89444918|NCT04238481|Experimental|Pudexacianinium chloride - Dose Level C|Participants received single dose of pudexacianinium chloride at dose level C by IV bolus infusion on day 1 once the surgical area of interest is in view.
89444919|NCT04238481|Experimental|Pudexacianinium chloride - Dose Level B - Dose Expansion|Participants who were enrolled in the dose expansion group received single dose of pudexacianinium chloride at dose level B by IV bolus infusion on day 1 once the surgical area of interest is in view.
89444920|NCT04234386|Active Comparator|Dose Level 1: 21 Gy|Participants will receive radiation therapy to the partial breast using the GammaPod technology before a lumpectomy.
89444921|NCT04234386|Active Comparator|Dose Level 2: 24 Gy|Participants will receive radiation therapy to the partial breast using the GammaPod technology before a lumpectomy.
89444922|NCT04234386|Active Comparator|Dose Level 3: 27 Gy|Participants will receive radiation therapy to the partial breast using the GammaPod technology before a lumpectomy.
89444923|NCT04234386|Active Comparator|Dose Level 4: 30 Gy|Participants will receive radiation therapy to the partial breast using the GammaPod technology before a lumpectomy.
89444924|NCT04227054|Experimental|Intervention|
89444925|NCT04222010|Experimental|serratus loco-regional anesthesia|patient who underwent thoracoscopic surgery will be assigned to serratus plane bloc (Ropivacaine 2 mg/mL, 40 mL) and paravertebral placebo bloc (saline, 20 mL)
89444926|NCT04222010|Experimental|paravertebral bloc Loco-regional anesthesia|patient who underwent thoracoscopic surgery will be assigned to paravertebral bloc (Ropivacaine 4 mg/mL, 20 mL) and serratus plane placebo bloc (saline, 40 mL)
89444927|NCT04222010|Experimental|serratus and paravertebral bloc Loco-regional anesthesia|patient who underwent thoracoscopic surgery will be assigned to serratus plane bloc (Ropivacaine 1,3 mg/mL, 40 mL) and paravertebral bloc (Ropivacaine 1,3 mg/mL, 20 mL)
89444928|NCT04179526|Experimental|Transdiagnostic Internet-delivered REBT|Protocol is based on Rational Emotive Therapy (Ellis, 1962, 1994), structured in 8 modules delivered over 6 weeks (Module 1- Introduction and psychoeducation about emotions, Module 2 - Psychoeducation anxiety and depression, Module 3 - Relaxation, Module 4 - Negative patterns of thinking and cognitive restructuring, Module 5 - Problem solving, Module 6 - Exposure and Behavioral activation, Module 7 - Positive emotions and Module 8 - Gaining maintenance)
89444929|NCT04179526|No Intervention|Waitlist|Participants in the control group will complete pre-treatment and post-treatment assessments. After participants in the experimental group complete post-treatment assessment, they will receive the intervention.
89444930|NCT04179500|Experimental|Study Participants|Participants will receive bedaquiline 200 mg once daily for 8 weeks then 100 mg once daily for 18 weeks together with pretomanid 200 mg + moxifloxacin 400 mg + pyrazinamide 1500 mg once daily (BPaMZ) for 26 weeks.
89444931|NCT04166643|Active Comparator|Education only|Education
89444932|NCT04166643|Experimental|WHHIP-PLUS and Function Focused Care|"Component I: Stakeholder Group Involvement:~Component II: Environment Assessment:~Component III: Organizational Changes To Reduce Job Stress:~Component IV- Worker Health Behavior Change including function focused care interventions"
89444933|NCT04145700|Experimental|Ramucirumab + Gemcitabine + Docetaxel|Participants received intravenous (IV) infusions of ramucirumab 9 milligrams per kilogram (mg/kg), gemcitabine 900 milligrams per meter square (mg/m2) on days 1, 8, and docetaxel 75 mg/m2 on day 8 of a 21-day cycle until disease progression or a criterion for discontinuation were met.
88930021|NCT01736774|Experimental|Usual care intervention|Primary care as required including medication
88930022|NCT01736774|Experimental|Physiotherapy treatment|Exercise and manipulative therapy
88930023|NCT01736787|Experimental|Cauliflower Mushroom extract|
88930024|NCT01736787|Placebo Comparator|Placebo|
88930025|NCT01736800|Experimental|Temozolomide/Topotecan|Temozolomide pills are to be taken on an empty stomach at night and should not be chewed. Patients receive Temozolomide on days 1-5 of a 28-day schedule. Patients will receive Topotecan intravenous treatment days 2-6 of each 28-day cycle at The Mehthodist Hospital Outpatient Infusion Center.
88930026|NCT01736813||CCR5-inhibitor at 300 mg/bid|colorectal cancer patients with liver metastases (twelve patients treated with 300 mg/bid)
89444934|NCT04145700|Active Comparator|Gemcitabine + Docetaxel|Participants received intravenous infusions of gemcitabine 900 mg/m2 on days 1, 8, and docetaxel 75 mg/m2 on day 8 of a 21-day cycle until disease progression or a criterion for discontinuation were met.
89444935|NCT04140110|Experimental|Intervention group|Achieving SBP level of <120 mmHg within 1 hour after randomisation, and maintaining this level at least 72 hours.
89444936|NCT04140110|No Intervention|Control group|Maintaining SBP 140-180mmHg, and BP lowering treatment can be given only when BP level ≥150 mmHg in order to achieve the target of ≥140 mmHg, and maintaining this level at least 72 hours.
89444937|NCT04125537||Dialysis Centers - Seriously Ill patients - pre-implementation cohort|Dialysis center patients who screened positive as seriously ill in month 1 of the collaborative activities (the preimplementation period).
89444938|NCT04125537||Dialysis Centers - Seriously Ill patients - post-intervention cohort|Dialysis Center patients who screened positive as seriously ill in month 15 of the intervention (the post-implementation period).
89444939|NCT04117126|Experimental|urinary incontinence|Recruitment, 3-day voiding record, initiate a individualized prompted voiding schedule based on the client's toileting needs until discharge, 1, 3 and 6 month follow-up post-discharge.
89444940|NCT04111497|Experimental|Treatment (glasdegib)|Patients receive glasdegib PO QD on days 1-28. Cycles repeat every 28 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
89444941|NCT04108156|Experimental|PDS Arm|Participants randomized to the PDS arm will receive intravitreal ranibizumab injection every 4 weeks (loading phase) and will then have the PDS implant (pre-filled with ranibizumab) surgically inserted. PDS implant refill-exchange procedures will be performed on a fixed interval every 24-weeks (Q24W) thereafter
89444942|NCT04108156|Active Comparator|Intravitreal Arm|Participants randomized to the intravitreal arm will receive intravitreal ranibizumab injection every 4 weeks until they receive the PDS implant (pre-filled with ranibizumab). PDS implant refill-exchange procedures will be performed on a fixed interval Q24W thereafter.
89444943|NCT04079738|Experimental|Phase I:TAK-659 + Ixazomib|Phase I: TAK-659 (Days 1-15) + Ixazomib dose escalation (Days 1, 8, 15)
89444944|NCT04079738|Experimental|Phase II:TAK-659 + Ixazomib|Phase II: TAK-659 at MTD (Days 1-15) + Ixazomib at MTD (Days 1, 8, 15)
89013660|NCT06293469|Active Comparator|Standard of Care Flap Timing|The flap surgery will be performed at the standard of care timing for the institution. Management of the fracture or dislocation, selection of flap, and post-injury flap management will be at the discretion of the operating surgeons and documented for both treatment groups.
89013661|NCT06293287|Placebo Comparator|placebo|The control group will receive an injection of a placebo (0.9% saline solution) of equal volume once daily.
89013662|NCT06293287|Active Comparator|enoxaparin sodium|Subjects in the experimental group will be administered subcutaneous enoxaparin sodium injections at a dose of 4000 Axa IU once daily.
89013663|NCT06291896|Other|Single Arm|"All participants perform:~conventional breast examination path (i.e., screening mammogram, integrated with other radiological/histological output when deemed necessary by the responsible Investigator in each site) AND MammoWave exam."
89013664|NCT06291584|Experimental|Face-to-Face Exercise Group|In the face-to-face exercise group called Group 1, students will apply an exercise program of respiratory exercises and resistance exercises with the physiotherapist.
89013665|NCT06291584|Experimental|Telehealth Exercise Group|In the online (telehealth) exercise group, group 2 will be applied by the students with the help of the physiotherapist.
89444945|NCT04066504||Sonidegib|Patients with laBCC undergoing sonidegib treatment in routine clinical practice
89444946|NCT04063085|Experimental|PROTAHERE group|The PROTAHERE group received intra-pelvic PROTAHERE Absorbable Adhesion Barrier during the scheduled pelvic surgery and be followed for 24 months.
89444947|NCT04063085|Active Comparator|Hyalobarrier group|The Hyalobarrier group received intra-pelvic Hyalobarrier Gel during the scheduled pelvic surgery and be followed for 24 months.
89444948|NCT04063085|Sham Comparator|No treatment group|The no treatment group did not receive any anti-adhesion agent during the scheduled pelvic surgery and be followed for 24 months.
89444949|NCT04063085|Active Comparator|Seprafilm group|The Seprafilm group received intra-pelvic Seprafilm Adhesion Barrier during the scheduled pelvic surgery and be followed for 24 months.
88930027|NCT01736826||Group P: pregnancy w/complications|"The patient is pregnant and has complications typical of placental vascular disease (preeclampsia, eclampsia, HELLP syndrome, retro-placental hematoma, in utero fetal death) or venous thromboembolism (deep vein thrombosis, pulmonary embolism).~100 patients will be included.~Interventions to be administered: Bloodwork, baseline"
89444950|NCT04063085|Active Comparator|Interceed group|The Interceed group received intra-pelvic Gynecare Interceed (TC7) Absorbale Adhesion Barrier during the scheduled pelvic surgery and be followed for 24 months.
89444951|NCT04054635|Experimental|Regimen 1|Two applications of silver diamine fluoride (SDF) four months apart, which is the protocol frequency adopted by the Winnipeg Regional Health Authority's (WRHA) Clinical Guideline on SDF.
89444952|NCT04054635|Experimental|Regimen 2|Two applications of silver diamine fluoride (SDF) six months apart, which is the American Dental Association's recommendation for SDF.
89444953|NCT04054635|Experimental|Regimen 3|Two applications of silver diamine fluoride (SDF) one month apart, which is proposed in the American Academy of Pediatric Dentistry's clinical practice guidelines.
89444954|NCT04033510||AF/NR|Single cohort with a known or new diagnosis of atrial fibrillation, and intention attain/maintain normal rhythm. Subjects with be their own controls: Tablet-based cognitive testing to be performed while in atrial fibrillation (AF), and while they are in normal rhythm (NR). Results of both sets of cognitive testing will be compared.
88930028|NCT01736826||Group T1: Healthy volunteers|"Healthy volunteers with no history of chronic or neoplastic disease.~30 healthy volunteers will be included.~Interventions to be administered: Bloodwork, baseline"
88930029|NCT01736826||Group T2: Pregnancy, no complications|"Pregnant patients with no identifiable pregnancy complications, and no history of chronic or neoplastic disease.~50 pregnant volunteers will be included.~Interventions to be administered: Bloodwork, baseline"
88930030|NCT01736826||Group T1x: 15 Healthy volunteers|"15 Healthy volunteers selected from group T1 (the first 15). These patients will have 2 additional months of follow up.~Interventions to be administered: Blood work, Months 1 & 2"
89013666|NCT06291584|No Intervention|Control Group|In the control group called Group 3, students will not be given any exercise program.
89013667|NCT06291454||Stage III Grade B periodontitis group (Group 1)|Stage III Grade B periodontitis patients and systemically healthy
89013668|NCT06291454||Stage III Grade C periodontitis group (Group 2)|Stage III Grade C periodontitis patients and systemically healthy
89013669|NCT06291454||Control group (Group 3)|Periodontally healthy (control group) and systemically healthy patients
89013670|NCT06291142||Patient Participants|Patients with an SSc spectrum disorder, and healthy controls (objective 3)
89013671|NCT06291142||Healthcare Professional Participants|Healthcare Professionals taking part in the qualitative element of the study
89013672|NCT06290050|Experimental|Treatment A: Midazolam 2 mg|Midazolam 2 mg (1 milliliter [mL] of 2 milligram per milliliter [mg/mL]), syrup, orally, on Day 1 of Period 1.
89013673|NCT06290050|Experimental|Treatment B: Repaglinide 0.5 mg|Repaglinide 0.5 mg (1*0.5 mg), tablets, orally, on Day 2 of Period 1.
89013674|NCT06290050|Experimental|Treatment C + Treatment A: TAK-279 Dose 1 + Midazolam 2 mg|TAK-279 Dose 1, capsules, orally, on Days 1 through 15 of Period 2 followed by Midazolam 2 mg (1 mL of 2 mg/mL), syrup, orally, on Day 14 of Period 2.
89200036|NCT00762840|Active Comparator|Control|the tooth is subject to conventional endodontic procedure alone, (standard root canal treatment)
89200037|NCT00888225|Experimental|Eccentric exercise|Group exposed to eccentric exercise treatment
89200038|NCT00888225|Active Comparator|Concentric exercise|Group exposed to concentric exercise treatment
89200039|NCT00765492|Experimental|1|
89200040|NCT00765492|Placebo Comparator|2|
89444955|NCT04017247|Active Comparator|Intermittent treatment|Infusion of oxytocin for 6 hours at a time until patient delivers.
89444956|NCT04017247|Active Comparator|Continous treatment|Infusion of oxytocin continuously from patient admission for 16 hours.
89444957|NCT03953235|Experimental|Phase 1|"GRT-C903~GRT-R904~nivolumab~ipilimumab"
89444958|NCT03953235|Experimental|Phase 2|"GRT-C903~GRT-R904~nivolumab~ipilimumab~Phase 2 for some patients includes a monthly or every two month treatment schedule"
89444959|NCT03933696|Active Comparator|Active Lighting Intervention|"The TLI will provide high circadian stimulation during the day produced by light sources that provide moderate light levels of spectra that are tuned to the sensitivity of the circadian system. Combining spectrum and light level, TLI will allow us to: (a) use a light source that will stimulate the circadian system, and (b) provide the participants with options as to how the light treatment will be delivered. The investigators will deliver at least 300-400 lux at the eye of the bluish-white light during the day (CS of 0.4 or greater).~The lighting intervention will be in place for 24 weeks"
89444960|NCT03933696|Placebo Comparator|Placebo Lighting Intervention|The placebo condition light source will be a warm yellow - white (2700 - 3000 K) source providing 50 -100 lux at the eye. The lighting intervention will be in place for 24 weeks.
89444961|NCT03897998|Active Comparator|Naloxone|NARCAN® Naloxone Nasal Spray will be used to block placebo effects during the fMRI experiment. Participants will be stratified for sex and then randomized to naloxone (The dose of naloxone will be 4 mg, so 0.1 mL of 40 mg/ml naloxone solution given intranasally) or saline (0.1 mL 0.9% sodium chloride intranasally), respectively. Investigators, staff, and participants will be blinded to the treatment options.
89444962|NCT03897998|Sham Comparator|Saline|Saline will be used as a sham comparator for blocking placebo effects during the fMRI experiment. Participants will be stratified for sex and then randomized to naloxone (The dose of naloxone will be 4 mg, so 0.1 mL of 40 mg/ml naloxone solution given intranasally) or saline (0.1 mL 0.9% sodium chloride intranasally), respectively. Investigators, staff, and participants will be blinded to the treatment options.
89444963|NCT03891706|Experimental|TCR-T cell infusion|Patient will exposed to Individualized Tumor-t Cell Receptor (TCR) -Mediated T Cells therapy
89444964|NCT03885401|Experimental|Enhanced care planning|The intervention consists of two components - enhanced care planning and clinical-community linkages. The enhanced care plan is created using MOHR (https://myownhealthreport.org). MOHR screens patients for unhealthy behaviors, mental health needs, and social needs. Patients identify the needs they would like to address and create a care plan, which they update quarterly. A clinical navigator and community health worker (CHW) help patients address their care plans using clinical-community linkages, which has four components. First, clinicians and clinical navigators have a resource registry identifying community programs and support - No Wrong Door (NWD) and https://navigator.aafp.org/. Second, MOHR shares information (care plans, patient narrative, and patient progress) across clinical and community team members. Third, MOHR supports messaging and video visits for team members and patients. Finally, MOHR sends care team members quarterly patient progress updates.
89444965|NCT03885401|No Intervention|Usual medical care|"Clinicians randomized to the control condition will continue to provide usual care. This includes current non-systematic assessment of health behaviors, mental health needs, and social needs. Neither clinicians nor patients will be eligible to receive CHW support or have access to NWD. Clinicians may refer some control patients to community programs as part of their current usual care. Control clinicians will be blinded as to which patients are included in the study. At the end of the study, the investigators will share with control clinicians our lessons learned, access to MOHR, and lists of useful community resources."
89444966|NCT03862417|Experimental|Schroth exercise group|Will attend 5 1-hr long individual sessions to learn Schroth exercises and the home program. A 30-min. daily home program of 3 to 4 exercises will be progressed by the certified Schroth therapist using an algorithm. Patients will attend weekly 1-hr long group therapist-led exercise classes for 3 months. At each group class, adequate exercise performance will be assessed using the checklist. An algorithm guides the prescription of exercises intensity and progression from static to dynamic depending on the participant's ability. Prescription begins with Sitting on a Ball. If performed adequately, a more challenging exercise is attempted. The 3 most challenging exercises performed adequately as per the checklist will be prescribed with a detailed handout.
89444967|NCT03862417|No Intervention|Control group|Observation without treatment or with previously prescribed pain medication is the current standard for adults with degenerative scoliosis not planning surgery.
89444968|NCT03852992|Experimental|Safety Group|"will participate in one visit, receiving laser assisted delivery of minoxidil and PK data. The safety group treatments will follow dose escalation as follows:~Safety Participant 1: Post-laser 5mg minoxidil (0.25ml of 20mg/ml sterile solution, applied post-laser procedure)~Safety Participant 2: Post-laser 10mg minoxidil (0.5ml of 20mg/ml sterile solution, applied post-laser procedure)~Safety Participant 3: Post-laser 20mg minoxidil (1mL of 20mg/mL sterile solution, applied post-laser procedure)"
89444969|NCT03852992|Placebo Comparator|Placebo|"Laser: Fractional ablative, deep mode, 5% fractional coverage~Post-Laser Saline 0.9%: 2ml of sterile saline solution applied post-laser procedure"
89444970|NCT03852992|Experimental|Treatment A|"Laser: Fractional ablative, deep mode, 5% fractional coverage~Post-Laser Minoxidil 2%: 2ml of 20mg/ml sterile solution, applied post-laser procedure"
89444971|NCT03852992|Experimental|Treatment B|"Laser: Fractional ablative, deep mode, 5% fractional coverage~Post-Laser Minoxidil 2%: 2ml of 20mg/ml sterile solution, applied post-laser procedure~At-Home Minoxidil 5%: 2ml of 50mg/ml foam q24 h for duration of study"
89200041|NCT02541747|Active Comparator|massage|massage for 30 min, once a week for 4 weeks
89200042|NCT02541747|No Intervention|control|Rest as control
89444972|NCT03820726|Experimental|Nintedanib|Patients taking 150 milligram (mg) bid blinded trial medication (active drug or placebo) at the end of INBUILD® started treatment with nintedanib 150 mg bid in this extension trial. Patients taking 100 mg bid blinded trial medication (active drug or placebo) at the end of INBUILD® started treatment with nintedanib in this extension trial either at 100 mg bid or at an increased dose of 150 mg bid at the discretion of the investigator orally as soft gelatine capsule, twice daily (bid), together with a glass of water (~250 mL), in a dose interval of 12 hours. With an optional dose reduction to 100 mg bid temporarily or permanently to manage adverse events (AEs). The treatment had a duration of 96 weeks or until nintedanib was made available to the patients outside of the clinical trial. Treatment was stopped if any reason for withdrawal was met.
89444973|NCT03774446|Experimental|Seliciclib|80 mg each day oral seliciclib for 4 weeks
89444974|NCT03754634|Experimental|drugs|Eltrombopag and Diacerein
89444975|NCT03751618|Experimental|Capsular suture|Capsular suture at the end of hip arthroscopy
89444976|NCT03751618|Active Comparator|No capsular suture|No capsular suture at the end of hip arthroscopy
89444977|NCT03745404|Experimental|Lido-Patch (Open-label Run-in Phase)|All participants applied up to 3 Lido-Patches (lidocaine 5% medicated plaster) per day (depending on the size of PHN area). Patches were applied topically for up to 12 hours per day (patch free interval: at least 12 hours) at the site of skin affected by painful PHN.
89444978|NCT03745404|Experimental|Lido-Patch (Double-blind Phase)|Up to 3 patches (lidocaine 5% medicated plaster) per day (depending on the size of PHN area) were applied topically for up to 12 hours per day (patch free interval: at least 12 hours) at the site of skin affected by painful PHN.
89444979|NCT03745404|Placebo Comparator|Placebo Patch (Double-blind Phase)|Up to 3 placebo plasters per day (depending on the size of PHN area) were applied topically for up to 12 hours per day (patch free interval: at least 12 hours) at the site of skin affected by painful PHN.
89444980|NCT03744312|Experimental|Cognitive impairment|Alzheimer's disease (mild cognitive impairment or mild stage Alzheimer's disease dementia)
89444981|NCT03744312|Active Comparator|No cognitive impairment|Healthy Controls
89444982|NCT03737123|Experimental|Chemotherapy and Atezolizumab|Subjects that received a PD 1 or PD-L1 inhibitor with no prior platinum chemotherapy for metastatic disease will be treated with atezolizumab + carboplatin + gemcitabine on trial. Subjects that received sequential or concurrent PD1/PDL1 inhibitor and carboplatin-based regimen will be treated with atezolizumab + docetaxel on trial.
88930031|NCT01736826||Group T2x: 15 Pregnancy, no complications|"15 patients selected from group T2 (the first 15); these patients will have 7 months of follow up during pregnancy.~Interventions to be administered: Bloodwork, Months -1 to -6"
88930032|NCT01736839||CF adults colonized with Pseudomonas aeruginosa|
88930033|NCT01736878|Experimental|Sorafenib tablets|Oral administration of Sorafenib tablets, 400 mg bid, until disease progression or unacceptable toxicity
88930034|NCT01736878|Placebo Comparator|Placebo tablets|Oral administration of Placebo tablets until disease progression, afterwards continuation with Sorafenib at the discretion of the investigator
88930035|NCT01736891|Experimental|Rasagiline|Rasagiline 0.5 mg by mouth every day for 2 weeks, then 1 mg by mouth every day for 12 weeks, then switch to 0.5mg by mouth every day for remainder of the study (approximately 16 weeks total)
88930036|NCT01736891|Placebo Comparator|Placebo|placebo 0.5 mg by mouth every day for two weeks, then 1 mg by mouth every day for 12 weeks, then switch to 0.5mg by mouth every day for remainder of the study (approximately 16 weeks total)
88930037|NCT01736904|Active Comparator|FOLFIRI|FOLFIRI regimen
88930038|NCT01736904|Experimental|wXELIRI regimen|wXELIRI
88930039|NCT01736969|Experimental|RD047-023|RD-047-023
88930040|NCT01736969|Active Comparator|Predicate Device|legally marketed predicate device
88930041|NCT01736982|Active Comparator|Standard of Care|transdermal nicotine replacement [21 mg patches (4 wks), 14 mg (2 wks), 7 mg (2 wks)], breath sample monitoring, standard smoking cessation counseling
88930042|NCT01736982|Experimental|Standard of Care plus Contingency Management|Standard smoking cessation intervention plus contingency management
88930043|NCT01736995|Experimental|Motivational/Cog Beh Tx-Contingency Mgmt|The group Motivational Enhancement Tx/Cognitive Behavioral Tx (MET/CBT) treatment is a peer-focused, multi-component intervention involving 2 initial individual motivational sessions followed by 12 group sessions that includes a functional analysis of behavior to identify antecedents and consequences of drug use and skills training for coping with cravings, enhancing assertive communication, drug refusal, managing negative moods, problem-solving, decision-making, and relapse prevention. The additional inclusion of contingency management (CM) methods will provide immediate, tangible reinforcers as a consequence delivered contingently upon evidence of abstinence from substance use or other desirable behavior.
89200043|NCT04488952|Experimental|nerve block combined with general anesthesia group|Patients in this group receive nerve block combined with general anesthesia.
89444983|NCT03712813|Experimental|Macrodyne LivMD plate|
89444984|NCT03712813|No Intervention|Wait-Listed Control|
89444985|NCT03639714|Experimental|Phase 1|"GRT-C901~GRT-R902~nivolumab~ipilimumab"
89444986|NCT03639714|Experimental|Phase 2 Cohorts|"GRT-C901~GRT-R902~nivolumab~ipilimumab"
89444987|NCT03634267|Experimental|Treatment (MRI, internal radiation therapy)|Participants undergo MRI scan during internal radiation therapy applicator placement.
89444988|NCT03625102|Experimental|Antroquinonol 100 mg PO BID|Antroquinonol (Hocena) 50mg/capsule. 2 capsules antroquinonol, twice a day.
89444989|NCT03625102|Experimental|Antroquinonol 50 mg PO BID|Antroquinonol (Hocena) 50mg/capsule. 1 capsule antroquinonol and 1 capsule placebo,twice a day.
89013675|NCT06290050|Experimental|Treatment C + Treatment B: TAK-279 Dose 1 + Repaglinide 0.5 mg|TAK-279 Dose 1, capsules, orally, on Days 1 through 15 of Period 2 followed by Repaglinide 0.5 mg (1*0.5 mg), tablets, orally, on Day 15 of Period 2.
89444990|NCT03625102|Placebo Comparator|Placebo|Placebo capsule, 2 capsules placebo, twice a day
89444991|NCT03567876|Experimental|V-RBAC (RBAC followed by Venetoclax)|"Induction phase: RBAC --> up to 6 cycles for low risk (LR) patients and up to 4 cycles for high risk (HR) patients.~Patients proceeding to Venetoclax treatment will receive consolidation with single agent Venetoclax 800 mg/die x 4 28d cycles (with initial ramp-up dose) of each consolidation cycle. Consolidation will be followed by maintenance with single agent Venetoclax 400 mg/die (V maint ) for a total of 2 years (4 months consolidation+20 months maintenance)."
89444992|NCT03518801|Experimental|Prolonged Exposure + Cannabidiol|Psychotherapy plus active medication
89444993|NCT03518801|Active Comparator|Prolonged Exposure + Placebo|Psychotherapy plus placebo medication
89444994|NCT03502707|Placebo Comparator|Cohort (C)1 Group (G)1: Placebo for RSV preF Protein|Participants will receive intramuscular injection of placebo on Day 1, Day 57 and at Month 12.
89444995|NCT03502707|Experimental|C1 G2: RSV preF Protein|Participants will receive intramuscular injection of 50 microgram (mcg) RSV preF protein on Day 1, Day 57 and at Month 12.
89444996|NCT03502707|Placebo Comparator|C1 G3: Placebo for Ad26.RSV.preF/RSV preF or RSV preF Protein|Participants will receive intramuscular injection of placebo on Day 1, Day 57 and at Month 12.
89444997|NCT03502707|Experimental|C1 G4: Mixture of Ad26.RSV.preF/RSV preF Protein|Participants will receive intramuscular injection of a mixture of 5*10^10 viral particles (vp) of Ad26.RSV.preF/RSV preF 50 mcg protein on Day 1, Day 57 and at Month 12.
89444998|NCT03502707|Experimental|C1 G5: RSV preF Protein|Participants will receive intramuscular injection of 150 mcg RSV preF protein on Day 1, Day 57 and at Month 12.
89444999|NCT03502707|Placebo Comparator|C1 G6: Mixture of Placebo for Ad26.RSV.preF/RSV preF Protein|Participants will receive intramuscular injection of placebo on Day 1, Day 57 and at Month 12.
89445000|NCT03502707|Experimental|C1 G7: Mixture of Ad26.RSV.preF/RSV preF Protein|Participants will receive intramuscular injection of a mixture of 5*10^10 vp of Ad26.RSV.preF plus 150 mcg RSV preF protein on Day 1, Day 57 and at Month 12.
89445001|NCT03502707|Placebo Comparator|C1 G8: Placebo for Ad26.RSV.preF/Placebo for RSV preF Protein|Participants will receive intramuscular injection of placebo on Day 1 and at Month 12 and in only 1 arm on Day 57.
89445002|NCT03502707|Experimental|C1 G9: Mixture of Ad26.RSV.preF/RSV preF Protein and Placebo|Participants will receive intramuscular injection of a mixture of 1*10^11 vp of Ad26.RSV.preF plus 150 mcg RSV preF protein in 1 arm on Day 1 and 57 and at Month 12 and placebo in another arm on Day 1 and at Month 12.
89445003|NCT03502707|Experimental|C1 G10: Ad26.RSV.preF, RSV preF Protein and Placebo|Participants will receive separate intramuscular injections of 1*10^11 vp of Ad26.RSV.preF in 1 Arm and 150 mcg RSV preF protein in another arm on Day 1 and at Month 12 and placebo in 1 arm on Day 57.
89445004|NCT03502707|Experimental|C2 G11: Ad26.RSV.preF and Placebo|Participants will receive intramuscular injection of 1*10^11 vp of Ad26.RSV.preF in 1 arm and placebo in another arm on Day 1 and placebo in 1 arm on Day 57.
89445005|NCT03502707|Experimental|C2 G12: Mixture of Ad26.RSV.preF/RSV preF Protein and Placebo|Participants will receive intramuscular injection of a mixture of 5*10^10 vp Ad26.RSV.preF plus 50 mcg RSV preF protein in 1 arm and placebo in another arm on Day 1 and placebo in 1 arm on Day 57.
89445006|NCT03502707|Experimental|C2 G13: Mixture of Ad26.RSV.preF/RSV preF Protein and Placebo|Participants will receive intramuscular injection of a mixture of 1*10^11 vp Ad26.RSV.preF plus 50 mcg RSV preF protein in 1 arm and placebo in another arm on Day 1 and placebo in 1 arm on Day 57.
89445007|NCT03502707|Experimental|C2 G14: Mixture of Ad26.RSV.preF/RSV preF Protein and Placebo|Participants will receive intramuscular injection of a mixture of 1*10^11 vp Ad26.RSV.preF plus 150 mcg RSV preF protein in 1 arm and placebo in another arm on Day 1 and placebo in 1 arm on Day 57.
89013676|NCT06287359||Parents/carers|Parents or carers of children with severe motor disabilities complaining of spinal pain
89200044|NCT04488952|Experimental|spinal anesthesia group|Patients in this group receive spinal anesthesia.
89013677|NCT06286683||Patients admitted to intensive care|Patients admitted to intensive care for aneurysmal subarachnoid hemorrhage (SAH) and eligible for their first out-of-bed mobilization
89013678|NCT06285409|Active Comparator|Carbetocin|Dose-response testing with increasing concentrations of carbetocin in a pattern of 1 log molar increase every 10 min, from 10-5 M to 10-5 M
89013679|NCT06285409|Active Comparator|Oxytocin|Dose-response testing with increasing concentrations of oxytocin from 10-10 M to 10-5 M.
89445008|NCT03502707|Experimental|C2 G15: Mixture of Ad26.RSV.preF/RSV preF Protein and Placebo|Participants will receive intramuscular injection of a mixture of 5*10^10 vp Ad26.RSV.preF plus 150 mcg RSV preF protein in 1 arm and placebo in another arm on Day 1 and placebo in 1 arm on Day 57.
89445009|NCT03502707|Experimental|C2 G16: Ad26.RSV.preF, RSV preF Protein and Placebo|Data from C1 G10 will be pooled with those of C2 G16. Participants will receive separate intramuscular injections of 1*10^11 vp of Ad26.RSV.preF in 1 Arm and 150 mcg RSV preF protein in another arm on Day 1 and placebo in 1 arm on Day 57.
89445010|NCT03502707|Experimental|C2 G17: Mixture of Ad26.RSV.preF/RSV preF Protein and Placebo|Data from C1 G9 will be pooled with those of C2 G17. Participants will receive intramuscular injection of a mixture of 1*10^11 vp of Ad26.RSV.preF plus 150 mcg RSV preF protein in 1 arm on Day 1 and 57 and placebo in another arm on Day 1.
89445011|NCT03502707|Placebo Comparator|C2 G18: Placebo for Ad26.RSV.preF/Placebo for RSV preF Protein|Participants will receive intramuscular injection of placebo in separate arms on Day 1 and in only 1 arm on Day 57.
89445012|NCT03502707|Experimental|C3 G19: Selected Regimen (SR)|If a one-dose regimen is selected, participants in this group will receive SR on Day 1 and a booster (the SR) at Month 12 and month 24. The participants who are randomized to two-dose regimen will receive SR on Day 1 and Day 57, and a booster (the selected regimen) at Month 12.
89445013|NCT03502707|Experimental|C3 G20: SR + Placebo for SR|If a one-dose regimen is selected, participants in this group will receive SR on Day 1 and Month 24, and a placebo at Month 12. The participants who are randomized to two-dose regimen will receive selected regimen on Day 1 and Day 57, and a placebo at Month 12.
89445014|NCT03502707|Placebo Comparator|C3 G21: Placebo for SR|If a one-dose regimen is selected, participants in this group will receive placebo for SR on Day 1 and at Month 12 and Month 24. The participants who are randomized to two-dose regimen will receive placebo for SR on Day 1, Day 57, and Month 12.
89445015|NCT03480334|Experimental|Arm A|Nivolumab 240 mg i.v. at 2-weekly intervals combined with 20Gy radiotherapy (RT) to a preferably progressive and not pre-irradiated single lesion. Nivolumab will be continued for a maximum of 18 months or until disease progression or unacceptable toxicity.
89445016|NCT03473535|Active Comparator|PST Alone|Participants will receive six sessions of face-to-face PST.
89445017|NCT03473535|Experimental|Blended-Therapy|Participants with receive six sessions of face-to-face PST supplemented by the BEACON platform.
89445018|NCT03447951|Experimental|PTS100 (Para-Toluenesulfonamide): 30%TTV|Total dose = 30% total tumor volume
89445019|NCT03445559|No Intervention|Control|No intervention
89445020|NCT03445559|Experimental|Intervention|The intervention is comprised of three components: 1) Clinical Order Check, 2) Academic Detailing, and 3) Audit and Feedback.
89445021|NCT03432741|Experimental|Treatment (FDG-PET, direct tumor microinjection)|Patients undergo FDG-PET and receive saline intralesionally on day 1. Patients also receive up to five additional injections of gemcitabine hydrochloride, romidepsin, belinostat, carfilzomib, copanlisib hydrochloride, nivolumab, trastuzumab, daratumumab, obinutuzumab, pembrolizumab, or rituximab intralesionally per investigator on day 1. Beginning 5 days later, patients with nodal/extranodal mass undergo restaging FDG-PET and biopsy (if clinically feasible). Within 3-7 days, patients with cutaneous disease undergo restaging photography and biopsy.
89445022|NCT03425006|Experimental|Itacitinib and Pembrolizumab|
89445023|NCT03407157|Experimental|Intervention|Probiotic supplementation
89445024|NCT03407157|Placebo Comparator|Control|Placebo
89445025|NCT03401073|Placebo Comparator|0.9% Sodium Chloride|The study will include a total 20 individuals. Subjects will be randomized equally to treatment or placebo. The placebo will consist of 0.9% Sodium Chloride per day over 2 days. Followed by 0.9% Sodium Chloride over 1 day every 3 weeks for a total of 6 treatments. Participants who are randomized to placebo will receive the same volume as they would if they were randomized to IVIG (i.e.: as if receiving IVIG at 2gm/kg) through a peripheral IV line.
89013680|NCT06285409|Active Comparator|Ergometrine|Dose-response testing with increasing concentrations of ergometrine from 10-10 M to 10-5 M
89013681|NCT06285409|Active Comparator|Carboprost|Dose-response testing with increasing concentrations of carboprost from 10-10 M to 10-5 M
89013682|NCT06285409|Placebo Comparator|Control|No drug added to physiological salt solution (PSS).
89013683|NCT06284967||Patients|Adults aged 20 - 45 years with symptomatic isthmic spondylolysis
89013684|NCT06284967||Controls|Matched population without spondylolysis indicated for plain x-ray and CT lumbo-sacral spine. These will be recruited mainly from the Trauma Unit. This will not add any non-indicated radiation exposure to healthy individuals
89013685|NCT06284707|Other|swimming training|Participants complete 2 swimming training sessions per week. Total program time 10 weeks
89013686|NCT06284707|Experimental|swimming training and rhythmic gymnastics training|"Participants perform 2 swimming training sessions per week and 2 rhythmic gymnastics training sessions.~Total program time 10 weeks"
89013687|NCT06283108|Experimental|Virtual Reality Experimental|Standard CCLS care and distraction with Virtual Reality
89013688|NCT06283108|Active Comparator|Standard CCLS care|Standard CCLS care
89013689|NCT06281613||Case group|
89013690|NCT06281613||Control Headgear|
89013691|NCT06281314|Experimental|Parkinson'disease group|Rehabilitation takes place with individual one-hour sessions per day. The stimulation intervention is organized on 4 different themes (chosen from orientation, memory, praxis, language, executive functions, attention, problem-solving, and functional activities) for 15' each.
89013692|NCT06281314|Experimental|Multiple Sclerosis group|Rehabilitation takes place with individual one-hour sessions per day. The stimulation intervention is organized on 4 different themes (chosen from orientation, memory, praxis, language, executive functions, attention, problem-solving, and functional activities) for 15' each.
89013693|NCT06281314|Experimental|Alzheimer group|Rehabilitation takes place with individual one-hour sessions per day. The stimulation intervention is organized on 4 different themes (chosen from orientation, memory, praxis, language, executive functions, attention, problem-solving, and functional activities) for 15' each.
89013694|NCT06279416||grup-1: awake nasal fiberoptic intubation|awake nasal fiberoptic intubation
89013695|NCT06279416||grup-2: awake intubation with laryngeal mask airway-mediated aintree catheter|awake intubation with laryngeal mask airway-mediated aintree catheter
89013696|NCT06279416||grup-3: awake intubation with videolaryngoscopy|awake intubation with videolaryngoscopy
89445026|NCT03401073|Experimental|Intravenous Immunoglobulin|The study will include a total 20 individuals. Subjects will be randomized equally to treatment or placebo. Treatment will consist of IVIG administered at an initial dose of 2 grams/kg over 2 days followed by 1 gram/kg over 1 day every 3 weeks for a total of 6 treatments
89445027|NCT03359954|Experimental|Treatment (radiation therapy, surgery)|Patients undergo boost radiation therapy 6-8 days before breast surgery. After surgery, patients continue to receive standard of care radiation therapy.
89013697|NCT06279234|Experimental|Part A|Multiple doses of PF 06954522 or placebo daily for up to 8 weeks in adult participants with T2DM in up to 7 cohorts.
89013698|NCT06279234|Experimental|Part B (Optional)|Multiple doses of PF 06954522 or placebo daily for up to 8 weeks in non-diabetic adult participants with obesity in up to 3 cohorts.
89445028|NCT03285581|Other|truSculpt RF|Subjects will receive RF treatments
89445029|NCT03273374|Experimental|IORT group|Intraoperative radiation therapy of 10 Gy delivered during surgery followed by adjuvant gemcitabine chemotherapy
89013699|NCT06279234|Experimental|Part C (Optional)|An 8-period multiple-dose assessment of the effect of PF-06954522 on rosuvastatin, midazolam, and omeprazole PK in healthy adult participants for up to 14 weeks in healthy adult participants.
89013700|NCT06278259|Experimental|experimental group|The telerehabilitation program is moderately intense aerobic exercise 3 times per week and included 3 parts: warm-up, central part, and cool-down. Each session : 30 min, 3 sessions/ week for 3 months.With the Baduanjin exercise program is delivered individually, at each patient's home, through telerehabilitation, with direct remote supervision by a physiotherapist
89013701|NCT06278259|Active Comparator|control group|The control group will receive the same aerobic exercises only
89200045|NCT04488952|Placebo Comparator|control group|This group is used to obtain the learning effect.
89200046|NCT00888303|Active Comparator|A (dexamethasone)|20 minutes before total or partial thyroidectomy for benign disease a single dose of intravenous 8 mg/2mL of dexamethasone is administered
89200047|NCT00888303|Placebo Comparator|B (Control)|20 minutes before total or partial thyroidectomy for benign disease 100 mg of saline solutions are administered intravenous
89200048|NCT00967642|No Intervention|standard treatment|glycemia before meals and subcutaneous regular insulin if higher than 200 mg/dl
89200049|NCT00967642|Other|Intravenous Insulin|intravenous insulin/24h guided by glycemia (Optium, Abbott) evaluated hourly, targeting values lower than 110 mg/dl
89200050|NCT02541591|Experimental|Neuroprotect|MAP between 85-100mmHg SVO2 between 65-75%
89445030|NCT03269422|Experimental|MR Image Guided, Intensity-Modulated Radiotherapy|Patients enrolled in this study will undergo MR-based, image-guided, intensity-modulated radiotherapy using similar equipment, techniques, and treatment-planning procedures as currently practiced at MSKCC.
89445031|NCT03227419|Experimental|Tocilizumab Prefilled Syringe|"Market approval recommendations will be respected. Treatment should be started within 7 days of randomization.~The treatment protocol has no specific provision for treatment adaptation. Treatment will be managed in compliance with the marketing approval recommendations and drug labeling described below."
89445032|NCT03227419|Experimental|Abatacept Prefilled Syringe|"Market approval recommendations will be respected. Treatment should be started within 7 days of randomization.~The treatment protocol has no specific provision for treatment adaptation. Treatment will be managed in compliance with the marketing approval recommendations and drug labeling described below."
89445033|NCT03213730|Experimental|Experimental group|Standard care + 3D-MOT protocol.
89445034|NCT03213730|Active Comparator|Active control group|Standard care + visual attention task (2048 online game)
89445035|NCT03213730|No Intervention|Control group|Standard care alone
89200051|NCT02541591|Active Comparator|Control|MAP>65mmHg
89445036|NCT03183245|Experimental|Human Acellular Vessel (HAV)|The HAV is a tissue-engineered vascular conduit (6mm diameter) for hemodialysis access in patients with end-stage renal disease. It will be surgically implanted in the forearm or upper arm on Study Day 0.
89445037|NCT03183245|Active Comparator|Arteriovenous fistula (AVF)|The comparator is an autologous arteriovenous fistula created in the forearm or upper arm on Study Day 0.
89445038|NCT03181971|Experimental|Water Access and Promotion|Intervention group will receive installation of water stations in high traffic areas, schoolwide promotion, and 4th graders will receive a curricula focused on increasing intake of water.
89445039|NCT03181971|No Intervention|Control|Usual care.
88930044|NCT01736995|Experimental|Functional Family Tx- Contingency Mgmt|Functional Family Therapy (FFT) is a brief treatment for youth with problem behaviors, including substance abuse that consists of 12 to 14 weekly family sessions. The FFT treatment is applied in five distinct phases: Engagement, Motivation, Relational Assessment, Behavior Change, and Generalization and each phase has specific goals, techniques, and therapist skills. The additional inclusion of contingency management (CM) methods will provide immediate, tangible reinforcers to the family as a consequence delivered contingently upon evidence of abstinence from substance use or other desirable behavior.
89445040|NCT03146078||Primary Cohort|"Participants with baseline visual acuity ETDRS letter score of 54 or more [approximate Snellen equivalent 20/80 or better] and stable fixation and clinically determined [on Octopus 900 Pro] kinetic visual field III4e area 10° or more in the study eye (primary cohort) will be enrolled into the longitudinal natural history study"
89445041|NCT03146078||Secondary Cohort|"Participants with baseline visual acuity ETDRS letter score of 53 or less [approximate Snellen equivalent 20/100 or worse] or unstable fixation or clinically determined [on Octopus 900 Pro] kinetic visual field III4e area less than 10°in the study eye (secondary cohort) will be enrolled in the cross-sectional baseline study"
89445042|NCT03127774|Experimental|Surgery with HIPEC|Cytoreductive surgery followed by HIPEC with cisplatin and sodium thiosulfate
89445043|NCT03120325|Experimental|Idiopathic Gastroparesis|Patients with idiopathic gastroparesis and delayed gastric emptying. All patients in trial will be giving themselves vagal nerve stimulation for two minutes on each side twice a day in the morning and the night for four weeks starting at visit 3 and ending at visit 5.
89445044|NCT03120325|Experimental|Diabetic Gastroparesis|Patients with diabetic gastroparesis and delayed gastric emptying. All patients in trial will be giving themselves vagal nerve stimulation for two minutes on each side twice a day in the morning and the night for four weeks starting at visit 3 and ending at visit 5.
89445045|NCT03120325|Experimental|Functional Dyspepsia|Patients with functional dyspepsia and normal gastric emptying. All patients in trial will be giving themselves vagal nerve stimulation for two minutes on each side twice a day in the morning and the night for four weeks starting at visit 3 and ending at visit 5.
89445046|NCT03116529|Experimental|Treatment|Neoadjuvant Radiation plus Durvalumab and Tremelimumab Wide Surgical Resection Adjuvant Durvalumab
89445047|NCT03099681||Epitheloid Sarcoma patients|Patients with diagnosis of localized or advanced epitheloid sarcoma seen in the Italian reference centers for sarcoma treatment that receive treatment for Epitheloid Sarcoma
89445048|NCT03080948||History of Melanoma (cases)|Participants at high-risk for melanoma (that is, those having many nevi and morphologically atypical nevi) who either have a history of invasive melanoma (cases) or do not have a history of melanoma (controls) and will perform comprehensive total body imaging of their moles in order to identify phenotypic markers of melanoma risk that aid in melanoma risk stratification. In addition, we will investigate histopathologic and molecular features of moles that are associated with melanoma risk and with melanoma subtypes. The evaluations needed for this study protocol will be primarily performed during routine clinical care.
89445049|NCT03080948||No Melanoma History (controls)|Participants at high-risk for melanoma (that is, those having many nevi and morphologically atypical nevi) who either have a history of invasive melanoma (cases) or do not have a history of melanoma (controls) and will perform comprehensive total body imaging of their moles in order to identify phenotypic markers of melanoma risk that aid in melanoma risk stratification. In addition, we will investigate histopathologic and molecular features of moles that are associated with melanoma risk and with melanoma subtypes. The evaluations needed for this study protocol will be primarily performed during routine clinical care.
89445050|NCT03004833|Experimental|Arm A|4 Cycles of Nivolumab plus AVD followed by IF-RT (30 Gy)
89445051|NCT03004833|Experimental|Arm B|4 Cycles of Nivolumab, followed by 2 cycles of Nivolumab plus AVD, followed by 2 Cycles of AVD followed by IF-RT (30 Gy)
89445052|NCT02957981|Experimental|Web-Based Counseling|Genetic information provided via an individually tailored website.
88930045|NCT01736995|Experimental|Motivational/Cog Beh Tx|The group Motivational Enhancement Tx/Cognitive Behavioral Tx (MET/CBT) treatment is a peer-focused, multi-component intervention involving 2 initial individual motivational sessions followed by 12 group sessions that includes a functional analysis of behavior to identify antecedents and consequences of drug use and skills training for coping with cravings, enhancing assertive communication, drug refusal, managing negative moods, problem-solving, decision-making, and relapse prevention.
88930046|NCT01736995|Experimental|Functional Family Tx|Functional Family Therapy (FFT) is a brief treatment for youth with problem behaviors, including substance abuse that consists of 12 to 14 weekly family sessions. The FFT treatment is applied in five distinct phases: Engagement, Motivation, Relational Assessment, Behavior Change, and Generalization and each phase has specific goals, techniques, and therapist skills.
88930047|NCT01737008|Experimental|Dacomitinib with Radiotherapy|Dacomitinib, 15mg to 45mg orally, once daily. Radiotherapy, once daily (Monday to Friday) over six weeks.One day on weeks 2 to 6 the participants will receive treatment twice daily (bid).
88930048|NCT01737008|Experimental|Dacomitinib and Chemoradiotherapy|Dacomitinib: 15mg to 45mg orally, once daily. Radiotherapy: Once daily (Monday to Friday) over seven weeks. Twice daily (bid) treatments may be introduced to compensate for treatment days missed due to statutory holidays, or machine maintenance. Cisplatin: 100mg/m2 intravenously; weeks 1, 4, and 7.
88930049|NCT01737034|Experimental|low GI, low GI|low GI diet (semi starvation phase) followed by low GI diet in the refeeding phase
88930050|NCT01737034|Experimental|low GI, high GI|low GI diet (semi starvation phase) followed by high GI diet in the refeeding phase
88930051|NCT01737034|Experimental|high GI, low GI|high GI diet (semi starvation phase) followed by low GI diet in the refeeding phase
89445053|NCT02957981|Active Comparator|Standard Care|Participants are not provided with web-based education but can choose to pursue genetic counseling and testing.
89445054|NCT02932111|Experimental|Osteopathic session|The osteopath put fingers on abdominal projection of the junction and sinks deeply into the abdomen until it perceives the trigger zone. Once in contact with the sphincter, it performs friction in the hourly sense, vibration, inhibitions or rebounds.
89445055|NCT02932111|Placebo Comparator|Placebo manipulative session|The Osteopath will touch the patient's limbs at the same place of osteopathic manipulative treatment, but without any intention of treatment and without any known and indexed reproduction techniques to simulate an osteopathic treatment, without its benefits.
89445056|NCT02915263|Placebo Comparator|0.9% Sodium Chloride|The study will include a total 20 individuals. Subjects will be randomized equally to treatment or placebo. The placebo will consist of 0.9% Sodium Chloride per day over 5 days. Participants who are randomized to placebo will receive the same volume as they would if they were randomized to IVIG (i.e.: as if receiving IVIG at 2gm/kg) through a peripheral IV line.
89445057|NCT02915263|Experimental|IGIV-C|The study will include a total 20 individuals. Subjects will be randomized equally to treatment or placebo. The treatment will consist of IVIG administered at 2 grams/kg divided over 5 days, with a follow up treatment 3 weeks (+/-3 days) later of IVIG 1gram/kg administered over 2 day (or placebo).
89445058|NCT02845947|Experimental|Music Therapy|Music Therapy to be provided for pediatric patients undergoing extubation readiness trial
89445059|NCT02845947|No Intervention|Control|Patients undergoing standard extubation readiness trial
89445060|NCT02825160||Ventavis|Ventavis treatment group
89445061|NCT02777892||pulmonary valve replacement|SAPIEN S3 Transcatheter Heart Valve in the pulmonic position at the time of data collection
89445062|NCT02777606|Experimental|Si-Ni-Tang (a Chinese Herbal Formula)|Treatment for severe sepsis adheres to the International guidelines for management of sepsis and septic shock 2012 and the Surviving Sepsis Campaign updated bundles in response to new evidence in 2015. Besides, 150ml of Si-Ni-Tang will be given by p.o. or a nasogastric tube once per day for 3 days in the treatment group.
89445063|NCT02777606|No Intervention|Control|Treatment for severe sepsis adheres to the International guidelines for management of sepsis and septic shock 2012 and the Surviving Sepsis Campaign updated bundles in response to new evidence in 2015.
89445064|NCT02777476|Experimental|procedure with B-Lite® Light Weight Breast Implant|
89445065|NCT02737462|Experimental|CG200745 PPA|CG200745 PPA intravenously daily for first 5 consecutive days per cycle (4 weeks)
89445066|NCT02735083|Experimental|UCART19 follow-up|
89445067|NCT02631447|Experimental|Arm A: Combo Target/Combo Immuno|Combo Target (LGX818 450 mg p.o. od + MEK162 45 mg p.o. bid) until PD; then Combo Immuno (nivolumab 1 mg/kg solution IV combined with ipilimumab 3 mg/kg solution IV every 3 weeks for 4 doses then nivolumab 3 mg/kg solution IV every 2 weeks) until PD
89445068|NCT02631447|Experimental|Arm B: Como immuno/Combo Target|Combo Immuno (nivolumab 1 mg/kg solution IV combined with ipilimumab 3 mg/kg solution IV every 3 weeks for 4 doses then nivolumab 3 mg/kg solution IV every 2 weeks) until PD; then Combo Target (LGX818 450 mg p.o. od + MEK162 45 mg p.o. bid) until PD
89445069|NCT02631447|Experimental|Arm C: Sandwich|Combo Target (LGX818 450 mg p.o. od + MEK162 45 mg p.o. bid) for 8 weeks followed by Combo Immuno (nivolumab 1 mg/kg solution IV combined with ipilimumab 3 mg/kg solution IV every 3 weeks for 4 doses then nivolumab 3 mg/kg solution IV every 2 weeks) until PD; then Combo Target (LGX818 450 mg p.o. od + MEK162 45 mg p.o. bid) until PD
89445070|NCT02630615||Cohort A (one-time blood sample)|"Blood samples will be collected from eligible patients only once at baseline. These samples will be immediately processed for CTCs and CTC derived xenografts.~For Cohorts A & B: Patients can participate in both cohorts simultaneously, or only one cohort per patient preference."
89445071|NCT02630615||Cohort B (multiple blood samples)|Blood samples will be collected from eligible patients at baseline just prior to initiation of therapy. Samples will also be collected on day 1 of every cycle of therapy for 4 cycles (typical cycles are 21 days for chemotherapy, 28 days for targeted therapy and 14 days for immune therapy). At the time of initiation of the treatment break, blood samples will be collected. During the treatment break, patients will be followed every 6-12 weeks with imaging studies, and we will collect blood samples at each visit. At the time of disease progression in the event patient goes on best supportive care, the last blood draw will be at the time of this decision as there will unlikely be any further imaging studies going forward. If a patient is found to have disease progression while on active therapy, the next blood draw will be on the first day of the next therapy and time point of subsequent blood draws will depend on the type of therapy the patient receives.
89445072|NCT02463266||SUSTAIN Monitoring and Care Management|SUSTAIN program participants who complete an initial clinical assessment and, if indicated, agree to follow-up services including Monitoring and/or Care Management.
89445073|NCT02424656||1|"Patients with TBI and DOC.~Experimental measures (MRI, TMS-EEG, and clinical scales) will be performed at 4 time points: within 2 weeks of admission, 6-10 weeks after admission, at discharge, 1-year follow-up after TBI episode. FDG-PET will be performed in a subset of 25 patients at 3 time points: at admission, at discharge, and at 1-year follow-up."
89445074|NCT02424656||2|"Healthy patient-matched controls.~Experimental measures (MRI, TMS-EEG, and FDG-PET) will be performed at 2 time points: within patient admission, and within patient discharge."
89445075|NCT02415933|Experimental|Trickle Up|Economic empowerment
89445076|NCT02415933|Experimental|Trickle Up Plus|Economic empowerment + child rights sensitization
89445077|NCT02415933|No Intervention|Wait-list|Women in villages assigned to the control arm do not receive any intervention during the study period, but are placed on a wait-list to receive the intervention upon completion of the evaluation phase.
89445078|NCT02390869|Experimental|R2-MANT|A) Rituximab B) Lenalidomide
89445079|NCT02390869|Active Comparator|R-MANT|A) Rituximab
89445080|NCT02343952|Experimental|Experimental Arm|Pembrolizumab -200 mg IV 3 weeks
89445081|NCT02281513|Other|ANTLER Pilot Cohort|Pilot study participants will be provided the smartphone application, fitbit activity monitor, and coaching sessions.
88930052|NCT01737034|Experimental|high GI, high GI|high GI diet (semi starvation phase) followed by high GI diet in the refeeding phase
89445082|NCT02250937|Experimental|Arm I (busulfan days -13 and -12 before PBSCT)|"PREPARATIVE REGIMEN: Patients receive venetoclax PO QD on days -22 to -3 and busulfan IV over 3 hours on days -13 and -12. Patients then receive fludarabine phosphate IV over 1 hour, cladribine IV over 2 hours, and busulfan IV over 3 hours on days -6 to -3.~TRANSPLANT: Patients undergo allogeneic PBSCT on day 0."
88930053|NCT01737047||HIV positive over 50 years of age|"All study subjects will undergo a whole body DEXA scan (dual energy X-ray absorptiometry). at the beginning and end of the study.~Blood sample collections for the determination of the plasma concentrations of tenofovir and the third agent (i.e. a non-nucleoside reverse transcriptase, protease, entry or integrase inhibitor) in the patient's regimen will be drawn"
88930054|NCT01737047||HIV positive under the age of 50|"All study subjects will undergo a whole body DEXA scan (dual energy X-ray absorptiometry). at the beginning and end of the study.~Blood sample collections for the determination of the plasma concentrations of tenofovir and the third agent (i.e. a non-nucleoside reverse transcriptase, protease, entry or integrase inhibitor) in the patient's regimen will be drawn"
88930055|NCT01737047||HIV negative over the age of 50|All study subjects will undergo a whole body DEXA scan (dual energy X-ray absorptiometry). at the beginning and end of the study.
88930056|NCT01737073|Experimental|IVR self management|cognitive behavioral based self management training for chronic pain delivered by interactive voice response (IVR)
88930057|NCT01737073|Experimental|Opioid monitoring|monthly interactive voice response (IVR) monitoring of prescription opioid use with feedback to the prescribing physician
88930058|NCT01737073|Experimental|IVR self management plus opioid monitoring|Cognitive behavioral based self management training for chronic pain delivered by IVR plus monthly IVR monitoring of prescription opioid use with feedback to the prescribing physician
89445083|NCT02250937|Experimental|Arm II (busulfan days -20 and -13 before PBSCT)|"PREPARATIVE REGIMEN: Patients receive venetoclax PO QD on days -22 to -3 and busulfan IV over 3 hours on days -20 and -13. Patients then receive fludarabine phosphate IV over 1 hour, cladribine IV over 2 hours, and busulfan IV over 3 hours on days -6 to -3.~TRANSPLANT: Patients undergo allogeneic PBSCT on day 0."
89445084|NCT02223208|Experimental|Ro-CHOEP-21|During the Phase I It will administered Romidepsin (dose escalation) and the combination of CHOEP-21. During the Phase II It will administered Romidepsin (dose according to phase I) and the combination of CHOEP-21.
89445085|NCT01884753||Adult women with lower urinary tract symptoms|Adult women (not less than 20 year-old) with lower urinary tract symptoms
89445086|NCT01872208|Experimental|Human Acellular Vessel (HAV)|HAV implantation to study participants.
88930059|NCT01737073|Other|Enhanced usual care|Weekly automated wellness tips via IVR
88930060|NCT01737086|Experimental|ORS with probiotic and zinc|Oral rehydration solution with freeze-dried Lactobacillus reuteri DSM 17938 and zinc sulphate
88930061|NCT01737086|Placebo Comparator|Standard ORS|Standard oral rehydration solution
88930062|NCT01737099|Experimental|DHA-O|
88930063|NCT01737099|Active Comparator|Fish oil|
88930064|NCT01737099|Placebo Comparator|Placebo|
88930065|NCT01737112|Experimental|99mTc-3PRGD2 SPECT/CT scanning|Determine if 99mTc-3PRGD2 SPECT/CT is safe and effective in diagnosis and evaluation of lung cancer patients.
88930066|NCT01737138|Active Comparator|RSD+Medicine|The investigators will recruit 50 randomised CKD patients who meet the inclusion criteria. First undergo renal artery angiography procedure to confirm anatomy. If renal artery meet the inclusion criteria, give the renal sympathetic denervation. At the same time, we will use optimal medication to protect renal function. Then we will conduct a clinic follow-up and a telephone follow-up e(Total 36 months).
88930067|NCT01737138|Placebo Comparator|Medicine|The investigators aslo will recruit 50 randomised CKD patients who meet the inclusion criteria. There are no significant differences in age, gender, race, past medical history,personal history and so on between the two groups. In this group we will use optimal medication just like the RSD+Medicine group. Third we will conduct a clinic and a telephone follow-up(Total 36 months).
88930068|NCT01737151|Active Comparator|Arm I (standard stereotactic body radiation therapy (SBRT)|Patients undergo standard daily fractions of SBRT over 7-8.5 weeks
88930069|NCT01737151|Experimental|Arm II (four fraction split-course SBRT)|Patients undergo 2 fractions of SBRT in weeks 1 and 4
88930070|NCT01737164|Experimental|Aerobic Exercise - Older Subjects|Subjects aged 65 and higher will perform 16 weeks of moderate intensity exercise
88930071|NCT01737164|Experimental|Aerobic Exercise - Young Subjects|Subjects 18-30 years old will perform 16 weeks of moderate intensity exercise
88930072|NCT01737177|Experimental|Bendamustina, Lenalidomide, Rituximab|1 arm for all patients
88930073|NCT01737190|Experimental|PEEP guided by Esophageal pressure + Recruitment maneuver.|"Upon patient recruitment Esophageal balloon will be inserted and esophageal / pleural pressure will be measured. Thereafter, Inspiratory pressures and PEEP will be adjusted according to well established criteria. Inspiratory pressure and PEEP will be adjusted to achieve the best lung compliance possible while not exceeding transpulmonary end Inspiratory pressure of 25 to 30 cm H2O, and at the same time maintaining a positive transpulmonary end expiarory pressure of not more than 5 cm H2O.~A recruitment maneuver with application of 40 cm H2O for up to 40 seconds will be performed."
88930074|NCT01737203|Active Comparator|Viagra|Oral tablet of sildenafil citrate (Japanese commercial tablet: Viagra® tablet) 50 mg as a single oral dose under fasted conditions
88930075|NCT01737203|Experimental|ODT without water|Sildenafil ODT 50 mg without water as a single oral dose under fasted conditions
88930076|NCT01737203|Experimental|ODT with water|Sildenafil ODT 50 mg with water as a single oral dose under fasted conditions
88930077|NCT01737216|Experimental|Zoledronic acid plus First-line chemotherapy|
88930078|NCT01737216|Active Comparator|First-line chemotherapy|
88930079|NCT01737229|Experimental|Direct pulp capping/carious exposure|symptomatic (provoked pain) or asymptomatic mature or immature tooth that presented pulp exposure when scraping out carious lesions or performing cavity preparation.
88930080|NCT01737229|Experimental|Direct pulp capping/dental trauma|• Permanent mature or immature single-root tooth having suffered traumatic injury < 72 hours, with amelodentinal coronal fracture causing pulp exposure.
88930081|NCT01737229|Experimental|Repairing root canals/pulp chamber floor|"Iatrogenic perforation of the pulpal floor, with or without LEO.~Iatrogenic perforated root canals following post space preparation involving dentin matrix, with or without LEO.~Iatrogenic perforated root canals with stripping not involving dentin matrix, with or without LEO."
88930082|NCT01737229|Experimental|Retrograde endodontic surgery - adults|"Failure of endodontic treatment or retreatment, evidenced by recent or persistent clinical or radiological signs of LEO and/or symptoms on a tooth in which the root canal filling looks to be of sufficiently good quality, provided that a working coronal restoration is in place.~Failure of endodontic treatment evidenced by recent or persistent clinical or radiological signs of LEO and/or symptoms on a tooth in which the root canal filling is inadequate, when orthograde retreatment does not offer a more favorable risk-benefit ratio than the surgery option"
88930083|NCT01737229|Experimental|Pulpotomy in primary molars - children (3 to 12 years )|"Molar presenting deep carious lesion without irreversible pulpal disease, as the molar has to stay on the dental arch for at least 3 years.~Pulp exposure during excision of a carious lesion on a temporary molar that does not present irreversible pulp disease. The molar has to stay of the dental arch for at least 3 years."
89445087|NCT01798407|Experimental|Activa Tremor Control Sys (DBS Implant)|all subjects will receive bilateral surgical implantation of DBS system. Those who respond at 12 months will enter a randomized, staggered withdrawal phase.
88930084|NCT01737229|Experimental|Apexification - children (7 to 18 years) + adults|"Permanent immature single-root tooth having suffered periodontal or dentoalveolar injury causing pulp necrosis with or without periapical disease (LEO) in children, teenagers or adult patients.~Permanent immature single-root tooth presenting pulp necrosis with or without periapical disease (LEO) in children.~Apical Root Resorption"
89445088|NCT01798407|Experimental|Randomized, staggered withdrawal phase|For responders only: double blind discontinuation will be attempted on either the 12 or 13 month visit. Stimulation intensity will be decreased by 50% and then completely discontinued two weeks later. Subjects will be seen biweekly until 15 months post activation or escape criteria are met. These escape criteria include relapse at 2 visits, hospitalization, active suicidal ideation, or withdrawing consent. If any of these criteria are met, the blind will be broken and open treatment will be resumed.
89445089|NCT01793493|Experimental|Cognitive stimulation|
88930085|NCT01737294||Treatment with QUTENZA|Patients with Peripheral Neuropathic Pain
88930086|NCT01737307|Experimental|Fluoride Varnish|Fluoride varnish was used once in this group. Fluoride varnish(NaF 5%,Sultan,USA)
88930087|NCT01737307|Experimental|Oral hygiene|Oral hygiene followed twice daily. No F varnish or CPP-ACP applied.
88930088|NCT01737307|Experimental|CPP-ACP|CPP-ACP paste (GC Tooth Mousse,Gc,USA)was applied by patients once daily. 3gr,for 42 days.
88930089|NCT01737320|Experimental|short-course|antibiotic treatment stopped on day 7 if the patient has been afebrile for 48 hours and clinically stable. Continued hospitalization will be left to the discretion of the treating physician. Antibiotics will be restarted if fever recurs in at least 2 consecutive measurements above 38 or in cases of clinically or microbiologically documented infections.
88930090|NCT01737320|Active Comparator|accepted prolonged antibiotic treatment|"antibiotic treatment continued for 14 days according to accepted hospital local guidelines. Duration of hospital stay will also be left to the discretion of the treating physician.~Type of empiric antibiotic treatment and later, specific antibiotic treatment, will be chosen by the treating physicians in consultation with the infectious diseases unit.~The decision on timing of switch to oral antibiotic therapy will also be left to the discretion of the treating physician."
88930091|NCT01737346|Experimental|lomustine and procarbazine|1 cycle (4 weeks) includes CCNU 75mg/m2 (D1) and procarbazine 60mg/m2 (D11-D24)by mouth for up to 6 cycles
88930092|NCT01737359|Experimental|amdoxovir 300 mg bid|in combination with zidovudine 300 mg bid for 12 weeks; lopinavir/ritonavir (400 mg/100 mg) bid is added on week 3
88930093|NCT01737359|Experimental|amdoxovir 500 mg bid|in combination with zidovudine 300 mg bid for 12 weeks; lopinavir/ritonavir (400 mg/100 mg) bid is added on week 3
88930094|NCT01737359|Active Comparator|tenofovir DF 300 mg qd|in combination with zidovudine 300 mg bid for 12 weeks; lopinavir/ritonavir (400 mg/100 mg) bid is added on week 3
88930095|NCT01737372||Secondary Progressive MS (SPMS)|Secondary Progressive MS participants
88930096|NCT01737372||Clinically Isolated Syndrome (CIS)|Clinically isolated syndrome participants
88930097|NCT01737372||Healthy participants|No immunological or neurological illnesses.
89445090|NCT01793493|Active Comparator|Sanitary education|
89445091|NCT01744418|Experimental|HAVG graft|HAVG graft implantation to study participants.
88930098|NCT01737385||Type 1|One segment fracture
88930099|NCT01737385||Type 2|Two segment fracture
88930100|NCT01737385||Type 3|Three segment fracture
88930101|NCT01737385||Type 4|Four segment fracture
88930102|NCT01737411|Active Comparator|solifenacin|10 mg solifenacin per day for three months
89445092|NCT01710176|Active Comparator|standard chemotherapy with full-dose epirubicin + ifosfamide|Standard arm foresees 3 cycles of preoperative chemotherapy, each cycle will be repeated every 21 days and includes: epirubicin 60 mg/m2/day, short infusion, days 1 and 2; ifosfamide 3 g/m2/day, days 1, 2, 3
88930103|NCT01737411|Experimental|cesa/vasa|repair of USL
88930104|NCT01737424|Placebo Comparator|Placebo|Placebo
88930105|NCT01737424|Experimental|LC28-0126|LC28-0126(IV)
88930106|NCT01737437|Experimental|group L|10% Lidocaine was applied to the laryngoscope blade and 0.9% normal saline was applied to the trachea.
88930107|NCT01737437|Placebo Comparator|group C|0.9% normal saline was applied to trachea and laryngoscope blade in Group C.
88930108|NCT01737437|Experimental|group V|0.9% normal saline was applied to the laryngoscope blade and 10% Lidocaine was applied on trachea.
88930109|NCT01737437|Experimental|group LV|10% Lidocaine was applied on laryngoscope blade and trachea.
88930110|NCT01737450|Experimental|BKM120|Full dose=100 mg/day (oral route) One study cycle equals 28 days. Patients will be treated until disease progression, unacceptable toxicity, or willingness to stop.
88930111|NCT01737463|Active Comparator|Group A|"Endoscopic snare papillectomy (ESP) was performed by using diagnostic or therapeutic duodenoscope (JF-240, TJF-240, JF-260, TJF-260; Olympus Optical Co, Ltd, Tokyo, Japan).~A pancreatic duct stent was inserted immediately after the excision."
88930112|NCT01737463|Active Comparator|Group B|"Endoscopic snare papillectomy (ESP) was performed by using diagnostic or therapeutic duodenoscope (JF-240, TJF-240, JF-260, TJF-260; Olympus Optical Co, Ltd, Tokyo, Japan).~A pancreatic duct stent was not inserted immediately after the excision."
88930113|NCT01737476|Sham Comparator|control|control-sham
88930114|NCT01737476|Active Comparator|Deep TMS PFC Lt|Deep TMS PFC left
88930115|NCT01737476|Active Comparator|DEEP TMS PFC Rt|DEEP TMS PFC Rt
88930116|NCT01737476|Active Comparator|Superficial TMS PFC Lt|Superficial TMS PFC Lt
88930117|NCT01737476|Active Comparator|superficial TMS PFC Rt|superficial TMS PFC Rt
88930118|NCT01737489|Active Comparator|LACE ( Listening And Communication Enhancement )|use the commercially available auditory training program which is administered by computer as daily lessons.
88930119|NCT01737489|Active Comparator|NOOK (Electronic reader)|will use an electronic reader (NOOK device) to do speech tracking
88930120|NCT01737489|No Intervention|Control|
88930121|NCT01737515||Main group|Consecutive patients undergoing colorectal surgery for benign or malignant colorectal disease without any diversion from the standard of care
88930122|NCT01737541|Experimental|Fluoxetine|fluoxetine per os 20 mg daily
88930123|NCT01737541|Placebo Comparator|Placebo|per os daily
89445093|NCT01710176|Experimental|histotype-tailored chemotherapy according to the histotype|gemcitabine+docetaxel for undifferentiated pleomorphic sarcoma, trabectedin for myxoid liposarcoma with hypercellularity, ifosfamide for synovial sarcoma, ifosfamide+etoposide for malignant peripheral nerve sheath tumor, gemcitabine+dacarbazine for leiomyosarcoma
89445094|NCT01644357|No Intervention|Dispensing only|Non clinical pharmacists will dispense drugs to patients and usual care will be offered.
89445095|NCT01644357|Experimental|Pharmaceutical care|Patients on experimental group will receive counseling and education on the asthma condition, medication and lifestyle issues. In all visits, the inhaler technique will be reviewed, adherence to treatment and drug related problems were checked. If necessary the patient will be referred to the respiratory specialist to change the medication or to prescribe dose adjustment. Pharmacists document their initial and monthly follow up encounters using a specified form.
89445096|NCT01592370|Experimental|Nivolumab monotherapy (Dose Escalation)|"Nivolumab solution intravenously as specified~Non-randomized~Enrollment is closed for this cohort"
89445097|NCT01592370|Experimental|Nivolumab + Ipilimumab|"Nivolumab and Ipilimumab solution intravenously as specified~Non-randomized~Enrollment is closed for this cohort"
89445098|NCT01592370|Experimental|Nivolumab + Lirilumab|"Non-randomized~Nivolumab: 3 mg/kg given every 2 weeks Lirilumab: 3 mg/kg given every 4 weeks~Enrollment is closed for this cohort"
89445099|NCT01592370|Experimental|Nivo + Dara + Pom + Dexa vs. Nivo + Dara|"Randomized~Nivolumab:~Cycle 1: 240 mg Day 15 Cycle 2-6: 240 mg Days 1, 15 Cycle 7 & beyond: 480 mg Day 1~Daratumumab:~Cycle 1-2: 16 mg/kg Days 1, 8, 15, 22 Cycle 3-6: 16 mg/kg Days 1, 15 Cycle 7 & beyond: 16 mg/kg Day 1~Pomalidomide:~4 mg po (by mouth) daily on Days 1 - 21 of each 28-day cycle~Dexamethasone:~Weeks without daratumumab dosing:~40 mg po daily (Days 1, 8, 15, 22) of each 28-day cycle for participants ≤ 75 years old~20 mg po daily (Days 1, 8, 15, 22) of each 28-day cycle for participants > 75 years old~Weeks with daratumumab dosing:~20 mg iv before the daratumumab infusion and 20 mg po after the daratumumab infusion in participants ≤ 75 years old~16 mg iv before the daratumumab infusion and 4 mg po after the daratumumab infusion in participants > 75 years old~Enrollment is closed for this cohort"
89445100|NCT01592370|Experimental|Daratumumab vs. Nivolumab + Daratumumab|"Randomized~Nivolumab:~Cycle 1: 240 mg Day 15 Cycle 2 & beyond: 480 mg Day 1~Daratumumab:~Cycle 1-2: 16 mg/kg Days 1, 8, 15, 22 Cycle 3-6: 16 mg/kg Days 1, 15 Cycle 7 & beyond: 16 mg/kg Day 1"
88930124|NCT01737554||Participants|"Participants include children with cancer and hematologic disorders who, as part of their standard clinical care, have a central venous access device (CVAD) used for infusion, withdrawal of blood, or hemodynamic monitoring.~Intervention: Catheter resistance monitoring"
88930125|NCT01737580|Active Comparator|Intanza+resiquimod gel|Intanza 15mcg intradermal injection + resiquimod gel applied to the vaccination site immediately post vaccination.
88930126|NCT01737580|Placebo Comparator|Intanza + placebo gel|Intanza 15mcg intradermal injection + placebo gel applied to the vaccination site immediately post vaccination.
88930127|NCT01737606|Experimental|echography|Fast Cerebral Pulsatility Imaging
88930128|NCT01737632|Experimental|Multidimensional Family Therapy (MDFT)|MDFT is an intensive, in-home family-based drug abuse treatment for adolescent substance abusers. MDFT views family factors in their context -in terms of the network (individual, familial, peer, community) or multiplicity of influences on drug use and change.
88930129|NCT01737632|Other|Adolescent Residential Treatment|"The Adolescent Treatment Program (ATP) is a residential dual diagnosed substance abuse treatment program that is staff secure. It is based on a social learning approach which emphasizes positive reinforcement for appropriate coping behavior and social skills, and incorporates a levels system which allocates privileges and responsibilities according to the individual's behavioral capacities."
88930130|NCT01737645||obese patients|BMI (body mass index) more than or equal to 35 kg/m2 (weight in kilograms divided by the square of the height in metres)
88930131|NCT01737645||Thin patients|BMI less than or equal to 30 kg/m2
88930132|NCT01737658|Other|Exercise Program upon enrollment|Subject will receive exercise intervention immediately upon enrollment to study
88930133|NCT01737658|Other|Exercise Program 6 months after enrollment|Subject will be enrolled into study and then receive exercise intervention 6 months after enrollment.
88930134|NCT01737671|Experimental|Methotrexate Infusion|3 consecutive cycles of intraventricular methotrexate infusions into implanted fourth ventricle catheter/Ommaya reservoir following surgical catheter placement into fourth ventricle, each cycle is 4 consecutive daily doses of intraventricular methotrexate with minimum 2 weeks between cycles. If any serum methotrexate level is > 0.3 micromolar, then Leucovorin therapy administered (5 mg/square meter per dose) every 6 hours by vein or mouth.
88930135|NCT01737723||Study population|Stroke patients
88930136|NCT01737736||Patients undergoing cartoid endarterectomy surgery|
88930137|NCT01737749||Patients undergoing cardiac surgery|
88930138|NCT01737775|Experimental|Abdominal laparoscopic surgery (C group)|
88930139|NCT01737775|Experimental|Abdominal surgery by laparotomy (L group)|
88930140|NCT01737775|Experimental|Head and neck surgery (O group)|
88930141|NCT01737788|Experimental|Therapeutic Trial|Therapeutic cervical cerclage with or without cervical occlusion in women presenting with short cervix (<25mm)
88930142|NCT01737788|Experimental|Prophylactic Trial|Prophylactic cervical cerclage with or without cervical occlusion in women with a history of cervical insufficiency
88930143|NCT01737801|Experimental|Lung function test|Lung function test
88930144|NCT01737814|Experimental|MST-188|MST-188 injection administered as a continuous infusion 100 mg/kg for 1 hour followed by 30 mg/kg/hr for up to 48 hours.
88930145|NCT01737814|Placebo Comparator|Saline|Saline administered as a continuous infusion for up to 49 hours
88930146|NCT01737853||Ganfort's Group|"Ganfort® QD for patients under Krytantek®~For patients assigned to the Ganfort's group, instructions for applying one drop QD (8:00 PM ± 30 minutes)"
88930147|NCT01737853||Krytantek's Group|"Krytantek® BID for patients under Ganforti®~For patients assigned to the Krytantek's group, application schedule will be BID (8:00 AM ± 30 minutes and 8:00 PM ± 30 minutes)"
88930148|NCT01737866|Experimental|Group 1|End Stage Renal Diseas (ESRD) requiring hemodialysis
88930149|NCT01737866|Experimental|Group 2|Normal renal function (eGFR >or = 80mL/min/1.73m^2)
88930150|NCT01737866|Experimental|Group 3|Mild decrease in GFR (eGFR 60-79 mL/min/1.73m^2)
89445101|NCT01495637|Experimental|GM-CSF|GM-CSF is given in one of four treatment regimens (three days at a dose of 30, 62, or 125 mcg/m2/day, or extended dosing at 125 mcg/m2 through post-trauma day 6) to critically injured children who demonstrate severe reduction in innate immune function on post-trauma day 1, 2, or 3.
89445102|NCT01437709|Experimental|patients receiving Immunotherapy (This arm is closed)|The proposed study is a Simon 2 stage optimal study design investigating the activity of ofatumumab alone or in conjunction with Bendamustine for patients with MCL who are either not candidates for ASCT or aged 65 or older. The study design will allow for an estimation of the single agent response of ofatumumab in patients at low biologic risk for immediate disease progression.
89445103|NCT01437709|Experimental|patients receiving Chemoimmunotherapy|The proposed study is a Simon 2 stage optimal study design investigating the activity of ofatumumab alone or in conjunction with Bendamustine for patients with MCL who are either not candidates for ASCT or aged 65 or older. The combined regimen will assess the response rates of the combined chemo- immunotherapy program in patients with need for cytoreductive therapy, or high risk for disease progression. Patients with a leukemic phase only presentation of mantle cell lymphoma generally have clinically low-risk disease, regardless of mantle cell IPI calculations. Upon reciew with the principal investigator, these patients may be stratified to the immunotherapy only arm if clinically appropriate.
89445104|NCT01093183|Experimental|Treatment (lenalidomide and cyclophosphamide)|Patients receive lenalidomide PO QD on days 1-21 and cyclophosphamide PO QD on days 1-28. Treatment repeats every 28 days for at least 4 courses in the absence of disease progression or unacceptable toxicity. Treatment modifications may apply according to response.
89445105|NCT01080937||Patient with acute heart failure|Hospitalized patient, whatever the mode of initial admission with acute heart failure
89445106|NCT00848315|No Intervention|1|Usual Care that the Type 2 Diabetes Patients usually receive at the health centers.
89445107|NCT00848315|Experimental|2|Cognitive Behavioral Intervention
89445108|NCT00777036|Experimental|Cohort 1: Imatinib-resistant/intolerant CP-CML|"Dasatinib 60 mg/m² tablet every day (QD) [with a maximum dose of 100 mg QD for subjects with high BSA] for minimum of 24 months, may continue as long as deriving clinical benefit~OR~Dasatinib 72 mg/m² powder for oral suspension (PFOS) QD [with a maximum dose of 120 mg QD for subjects with high BSA] for minimum of 24 months, may continue as long as deriving clinical benefit"
89445109|NCT00777036|Experimental|Cohort 2: Ph+ALL or AP- or BP-CML|"Dasatinib 80 mg/m² tablet QD [with a maximum dose of 140 mg QD for subjects with high BSA] for minimum of 24 months, may continue as long as deriving clinical benefit~OR~Dasatinib 96 mg/m² PFOS QD [with a maximum dose of 170 mg QD for subjects with high BSA] for minimum of 24 months, may continue as long as deriving clinical benefit"
89445110|NCT00777036|Experimental|Cohort 3: Newly diagnosed, treatment naïve CP-CML|"Dasatinib 60 mg/m² tablet QD [with a maximum dose of 100 mg QD for subjects with high BSA] for minimum of 24 months, may continue as long as deriving clinical benefit~OR~Dasatinib 72 mg/m² PFOS QD [with a maximum dose of 120 mg QD for subjects with high BSA] for minimum of 24 months, may continue as long as deriving clinical benefit"
89445111|NCT00720720|Active Comparator|1|plant sterol enriched margarine
89445112|NCT00720720|Placebo Comparator|2|placebo margarine
89445113|NCT00641225|Experimental|1|SBI-087
89445114|NCT00571272||1|Infants less than 6 months old with a cholestatic liver disease who were initially enrolled into the Childhood Liver Disease Research and Education Network (ChiLDREN) Prospective Biliary Atresia Epidemiology study (PROBE study; P003)
89445115|NCT00571272||2|Participants with a cholestatic liver disease who are between birth and 25 years old who were NOT initially enrolled into the Childhood Liver Disease Research and Education Network (ChiLDREN) Prospective Biliary Atresia Epidemiology study (PROBE study; P003)
89445116|NCT00571272||3|Post-liver transplant participants with a cholestatic liver disease who are between 1 day and 25 years old. Affected parents of patients enrolled in the study are eligible for enrollment if they are 25 years old or less
89445117|NCT00571272||4|A screening group of participants, birth through 25 years old, suspected of having ALGS, PFIC (or BRIC) or BAD, who do not meet complete enrollment criteria for Group 1, 2, or 3.BRIC)
89445118|NCT00571272||5|Affected siblings (without evidence of liver disease) of Alpha-1 Antitrypsin Deficiency participants who are enrolled in LOGIC.
89445119|NCT00176644|Experimental|Transdermal estradiol|
89445120|NCT00106171|Experimental|Immediate Treatment Arm|Participants will receive immediate HAART for 1 year; then HAART will stopped until clinically indicated.
89445121|NCT00106171|No Intervention|Deferred Treatment Arm|Participants will receive no immediate HAART, but will receive HAART when HAART is clinically indicated.
89445122|NCT00045201|Experimental|Treatment (enzyme inhibitor, chemotherapy)|Patients receive oral erlotinib hydrochloride daily on days -6 to -1. Patients then receive irinotecan hydrochloride IV over 90 minutes on day 1 and oral erlotinib hydrochloride once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
88930151|NCT01737866|Experimental|Group 4|Moderate decrease in GFR (eGFR 30-59 mL/min/1.73m^2)
89445123|NCT03327038|Experimental|Psychological Intervention|Patients will be randomized to the intervention group after they have complete the study screening form. Patients randomized to the intervention group will receive a multifaceted intervention consisting of the following components (administered over an 8 week period): (1) Web-Based Cognitive Behavioral Therapy: (2) Short Questionnaires; (3) Ongoing Nurse Monitoring.
89445124|NCT03327038|Active Comparator|Control|Patients will be randomized to the control group after they have completed the study screening form. Patients randomized to the control group will receive the usual standard of care that is available to patients with moderate anxiety or depression. Additionally, control patients will completed detailed questionnaires for assessment of primary and secondary outcomes.
89445125|NCT03326960||Sevoflurane|Patients in Sevoflurane group are maintained with sevoflurane from an anesthesia machine through the laryngeal mask airway guided by Narcrotrend index monitoring.
89445126|NCT03326960||Propofol|Patients in Propofol group are maintained with propofol through intravenous administration guided by Narcrotrend index monitoring.
89445127|NCT03326960||Desflurane|Patients in Desflurane group are maintained with desflurane from an anesthesia machine through the laryngeal mask airway guided by Narcrotrend index monitoring.
89445128|NCT03319472||Benign Pleural Effusion|Patients that will be diagnosed within a month from admission with any non-malignant cause of pleural effusion, including but not limited to effusions caused by common or tuberculous or fungal infection, heart failure, etc. Documentation of the etiology will be required for inclusion in this group, including but not limited to bacteriology, virology, PCR, radiology, heart echocardiogram or catheterization, as appropriate.
89445129|NCT03319472||Malignant Pleural Effusion|Patients that will be diagnosed within a month from admission with any malignant cause of pleural effusion, including but not limited to effusions caused by lung, breast, colon, ovary, mesothelial, hematopoietic, prostate, or any other cancer. Diagnosis will be based on verification of the presence of malignant cells in the pleural fluid or tissues. Patients with cancer and an effusion without such documentation will be assigned to the benign group if an alternative diagnosis is made. In any other case, they will be excluded.
89445130|NCT03319394|Experimental|The First Twenty|TF20 group completed a structured exercise program. Once a week a trained firefighter with current CPR and First Aid certifications met with the group to assess progress and answer questions about the workouts or the program. The rest of the time, the participants completed the workouts on their own time. Workouts contained a combination of aerobic (e.g., running, rowing, jumping), body weight (e.g., air squats, pushups, situps), and weight lifting (e.g., presses, back squats, lunges) exercises with workouts designed to use equipment available in an exercise/gym facility (e.g., weight racks, benches). Sixty-minute TF20 sessions included a warm-up, workout and cool down. All sessions were able to be logged online in TF20 program.
89445131|NCT03319394|Active Comparator|Comparison|The Comparison Group followed and documented their regular workout routine for 14 weeks. Once a week, a trained firefighter with current CPR and First Aid certifications met with the group to discuss questions. Participants were able to choose when to complete their workouts.
89445132|NCT04669444|Experimental|Low Driving Pressure Protocol|The patients ventilator driving pressure will be decreased (as tolerated by the patient) for 2 hours while on extracorporeal membrane oxygenation (ECMO) support.
89445133|NCT03319238||Patient cohort|Neuropathic pain patient taking ketamine
89445134|NCT03321890|Experimental|Combination therapy regimen|Chidamide + prednisone+cyclophosphamide+etoposide+methotrexate
89445135|NCT02487368|Experimental|Needle stimulation pad|a self-administered treatment with a mechanical needle stimulation pad, a mechanical device to be used for 30 minutes daily for 14 days.
89445136|NCT05499910|Experimental|NSBAA|The Neuro Strengths-Base Approach to Autism is an approach developed from various research on how the autistic brain works, the approaches that work best to motivate autistic individuals, and how others can understand as well as support behaviors that may occur with autistic individuals.
89445137|NCT03319160||Retrospective|Patients who have already completed use of LifeVest before start of the study
89013702|NCT06277674|Experimental|cadonilimab plus pemetrexed and anlotinib|"Twenty elderly patients (age≥65 years) with advanced non-squamous NSCLC with T790M negative after EGFR-TKI resistance will be enrollrd in this study. Participants will receive 4 to 6 cycles of cardunnilumab in combination with pemetrexed and anlotinib every 3 weeks, followed by maintenance treatment with cadonilimab plus anlotinib until disease progression, intolerable toxicity, withdrawal of consent, death, or other protocol-specified causes, whichever occurs first.~Cadonilimab was administered intravenously at a dose of 10 mg/kg every 3 weeks. Pemetrexed was administered intravenously at a dose of 500 mg/m² every 3 weeks Anlotinib was taken at doses of 10mg orally once daily for two weeks on a one-week-off schedule."
89013703|NCT06276426|Experimental|Soy|The experimental group will be asked to consume 2 servings/day of soy foods for 3 months
89013704|NCT06276426|Active Comparator|Non-Soy Plant-Based Foods|The control group will be asked to consume 2 servings/day of non-soy plant-based foods for 3 months
89013705|NCT06276335|Experimental|Immediate implant placement and conventional loading (Test)|In this group, a dental implant will be placed on the same day as tooth extraction and loaded after 3 months
89445138|NCT03319160||Prospective|Patients receiving a LifeVest prescription in clinical routine
89445139|NCT05504824|Experimental|Experimental group|"Students in both experimental groups were applied the student information form and the pretest of the CRCF between May 18 and 20, 2021 before the education. The schedule of the education intervention was determined according to the convenience of the students in the experimental group. Accordingly, the experimental group was given education between June 8 and 11, 2021. After the education sessions were completed, experimental groups were applied the CRCF as a posttest on June 28, 2021. The students in the experimental group were asked to fill out the Student Satisfaction with Education Questionnaire and the Form for Views on the Education online."
89445140|NCT05504824|No Intervention|Control group|Students in control groups were applied the student information form and the pretest of the CRCF between May 18 and 20, 2021 before the education. The students in the control group continued their current standard education process. After the education sessions were completed, control groups were applied the CRCF as a posttest on June 28, 2021.
89445141|NCT04492748|Experimental|Collagen and PRP injections|Ultrasound guided injections
89445142|NCT04492748|Active Comparator|Collagen injections|Ultrasound guided injections
89445143|NCT04492748|Active Comparator|PRP injections|Ultrasound guided injections
89013706|NCT06276335|Active Comparator|Late implant placement and conventional loading (Control)|In this group, a dental implant will be placed after complete bone healing (4 - 6 months after tooth extraction) and loaded after 3 months
89013707|NCT06275659|Experimental|CT-100-004-A Psoriasis|
89013708|NCT06275659|Sham Comparator|CT-100-004-B Psoriasis|
89013709|NCT06275659|Experimental|CT-100-004-A Atopic Dermatitis|
89013710|NCT06275659|Sham Comparator|CT-100-004-B Atopic Dermatitis|
89013711|NCT06275100|Experimental|Prehabilitation arm|"Participants will be exposed to physical and psychological prehabilitation whilst waiting for surgery. The prehabilitation will not alter the surgical waiting time or any medical intervention but aims to work around patient's essential care.~Physical/ exercise component has a directly supervised component (aerobic exercise) and an unsupervised portion (Inspiratory muscle training and strength training) which is done via an app or leaflet depending on participant's preference. Participants will be given a guide number of exercises to do in their own time throughout the day.~The psychological component consist of a psychoeducation booklet, meditation audio and signposting if they require further assistance. The psychoeducation component is voluntary."
89445144|NCT05504668|Experimental|Turmeric Brainwave|Turmeric Brainwaves (now Mind Focus) is a proprietorial herbal supplement from Pukka Herbs which contains (inc. mg daily dose when 2 capsules combined); brahmi (320 mg), gotu kola leaf (144 mg), turmeric whole powder (116 mg), reishi full spectrum (116 mg), rosemary (116 mg), cardamom (88 mg), holy basil (86 mg), turmeric Wholistic™ extract (58 mg), green tea (58 mg) and seagreens (58 mg).
89445145|NCT05504668|Placebo Comparator|Placebo|Magnesium Stearate
89445146|NCT03326882|Active Comparator|Glidescope|A device for endotracheal intubation
89445147|NCT03326882|Active Comparator|Macintosh laringoscope|A device for endotracheal intubation
89445148|NCT05464394|Experimental|Tranexamic acid|1500mg Tranexamic acid
89445149|NCT05464394|Placebo Comparator|Placebo|sodium chloride
89445150|NCT05464316|Experimental|Adjustable Transobturator Male System|
89445151|NCT05464316|Active Comparator|Artificial Urinary Sphincter|
89445152|NCT05499754||pLMA(n=30)|
89445153|NCT05499754||sLMA(n=30)|
89445154|NCT05499754||I-jel(n=30)|
88930152|NCT01737866|Experimental|Group 5|Severe decrease in GFR (eGFR 15-29 mL/min/1.73m^2)
89445155|NCT03321812|Experimental|decalcification bone scaffold|Decalcification bone scaffold is a novel tissue engineered acellular matrix scaffold with the closest biomechanics and structure to normal cartilage.
89445156|NCT03321812|Active Comparator|Microfracture|Microfracture is a conventional treatment for cartilage lesions of the knee.
89445157|NCT05499598|Experimental|Modified minimally invasive surgical technique with PRF and vitamins A and C|Surgical technique (M-MIST) with the same procedures will be performed. Approximately 10 mm of fresh blood will be drawn by venipuncture of the antecubital vein and collected into a blood collection tube without anticoagulant. Ascorbic Acid will be added to the fresh blood to achieve a concentration of 250 μg/ml, Retinol will also be added to achieve a concentration of 20 μmol/L. The resultant PRF clot will be placed into the intra-osseous defect.
89445158|NCT05499598|Active Comparator|Modified minimally invasive surgical technique with PRF|Surgical technique (M-MIST) with the same procedures will be performed. Approximately 10 mm of whole blood is drawn by venipuncture of the antecubital vein and is collected into two blood collection tubes without anticoagulant for PRF preparation.The resultant PRF clot will be placed into the intra-osseous defect
89445159|NCT04476082||Initial Diagnosis|Patients with initial diagnosis of a malignant condition of the gastrointestinal tract planned to receive cytostatic treatment.
89445160|NCT04476082||Ongoing Cytostatic Treatment|Patients with a malignant condition of the gastrointestinal tract already receiving cytostatic treatment.
89445161|NCT05232656|No Intervention|Pre-intervention|"Usual care on three general medicine units.~Patients/caregivers do no have access to the discharge preparation checklist. Providers do not have access to the safety dashboard."
89445162|NCT05232656|Experimental|Post-intervention|Patients/caregivers have access to the pre-discharge preparation checklist. Providers have access to patient safety dashboard.
89445163|NCT04442750|Experimental|A (0.5%) group|patients will receive a single shot erector spinae block with 30 ml 0.5% bupivacaine followed by general anesthesia
89445164|NCT04442750|Experimental|B (0.375%) group|patients will receive a single shot erector spinae block with 30 ml 0.375% bupivacaine followed by general anesthesia
89445165|NCT04442750|Experimental|C (0.25%) group|patients will receive a single shot erector spinae block with 30 ml 0.25% bupivacaine followed by general anesthesia
89445166|NCT05499364|Active Comparator|Quit.gov program|Generic intervention based on quit.gov sessions.
89445167|NCT05499364|Experimental|TinCat|Individualized asynchronous telehealth including LGBTQ+ affirming components.
89445168|NCT03319004|Experimental|Compare bispectral index and phase lag entropy|
89445169|NCT03318848|Experimental|Video during simulation|The intervention group simulated the bed bath while watching the video, under the supervision of the tutor
89445170|NCT03318848|No Intervention|Simulation without video|The students of the control group performed the simulation of the bed bath procedure, with the aid of a tutor.
89445171|NCT05333224|Experimental|Telerehabilitation|A telerehabilitation-based exercise group where the therapist coaches the family, performs one-on-one exercises with families with a doll in his hand, and can perform the necessary interventions such as promoting good practices and preventing bad practices, and the other 2 days where the families show their exercises by sending videos to the therapist, and again provide the therapist's intervention and follow-up via videos
89445172|NCT05333224|Other|Control|The control group that will be given exercise training in 1., 4., 8., and 12. week.
89445173|NCT02490566|Experimental|Technology Arm|Tablet computer with chronic disease apps will be given to patients. This tablet will also be used for follow-up visits done via video conferencing. Intervention: Telehealth.
88930153|NCT01737866|Experimental|Group 6|Normal renal function (eGFR >or = 80mL/min/1.73m^2)
88930154|NCT01737918|Experimental|trans obturatorial tape (TOT)|placement of a sub-urethral tape
89538463|NCT02457923|Experimental|Mobile phone counselling|"The intervention will include:~An App for real time data collection of mothers by ASHAs, data transfer, and, display of counselling messages and health video during ASHAs monthly home visit.~Weekly voice and text messages from server at a prescribed time to provide targeted information on infant feeding counselling.~Server generated reminders and alerts, delivered to the mother, ASHA and ANM.~An App for field supervisor to monitor ASHAs~Women will receive fortnightly mobile phone counselling calls by an ANM at times they recommend. Need based counselling will also be provided"
88930155|NCT01737918|Active Comparator|solifenacin|10 mg per day
88930156|NCT01737957|Experimental|Low-fluence|Low-fluence pan-retinal photocoagulation in a single session for proliferative diabetic retinopathy
88930157|NCT01737957|Active Comparator|Full-fluence|Full-fluence pan-retinal photocoagulation for proliferative diabetic retinopathy
88930158|NCT01737983|Experimental|Lactobacillus reuteri (LR) ATCC55730|The tested probiotic, Lactobacillus reuteri, was administered in 5 drops per day (10^10 colony-forming units) for 6 months
88930159|NCT01737983|Placebo Comparator|placebo|The placebo was packed in identical bottles, had the same color, weight, smell, and taste of the probiotic formulation for 6 months During the test period, patients were not allowed to consume any other product that contained probiotics or prebiotics
88930160|NCT01738022|Experimental|Gas mixture administration|Subjects will breathe different gas mixtures with different densities and viscosity for brief periods in order to promote changes in peak inspiratory flow
88930161|NCT01738035|Experimental|NEFECON 8 mg/day|NEFECON 8 mg/day (2 active + 2 placebo capsules daily) for 9 months
88930162|NCT01738035|Experimental|NEFECON 16 mg/day|NEFECON 16 mg/day (4 active capsules daily) for 9 months
88930163|NCT01738035|Placebo Comparator|Placebo|Placebo (4 placebo capsules daily) for 9 months
88930164|NCT01738048||Mastectomy|Patients treated with mastectomy without reconstruction
88930165|NCT01738048||Reconstruction|Patients treated with mastectomy followed by reconstruction
88930166|NCT01738061|No Intervention|reference group|They continued their daily routine.
88930167|NCT01738061|Experimental|Multidimensional lifestyle intervention|The multidimensional lifestyle intervention program received motivational activities to improve awareness of the impact of lifestyle on chronic diseases and the importance of self-health management.
88930168|NCT01738074|Experimental|trivalent rotavirus genetic reassortment vaccine|2ml of rotavirus genetic reassortment vaccine by mouth every month for three month
88930169|NCT01738074|Placebo Comparator|Placebo|2ml of placebo by mouth every month for three month
88930170|NCT01738087|Experimental|NEXThaler 100/6 mcg DPI|Single dose (4 inhalations)of NEXThaler 100/6 mcg DPI: total dose 400/24 mcg
88930171|NCT01738087|Experimental|NEXThaler 200/6 mcg DPI|Single dose (4 inhalations)of NEXThaler 200/6 mcg DPI: total dose: 800/24 mcg
88930172|NCT01738087|Placebo Comparator|NEXThaler placebo|Single dose (4 inhalations)
88930173|NCT01738087|Experimental|NEXThaler 100/6 mcg plus CB|Single dose (4 inhalations) NEXThaler 100/6 mcg administered with activated charcoal (Charcoal Block): total dose 400/24 mcg
88930174|NCT01738087|Experimental|NEXThaler 200/6 mcg plus CB|Single dose (4 inhalations) NEXThaler 200/6 mcg administered with activated charcoal (Charcoal Block): total dose 800/24 mcg
88930175|NCT01738087|Active Comparator|Flixotide Accuhaler 500 mcg|Single dose (2 inhalations) of fluticasone propionate
88930176|NCT01738100|Experimental|Ticagrelor + Intracoronary Morphine|180 mg loading pre-PCI followed by 90 mg bid for 5 days. Intracoronary Morphine Sulfate 3 mg + Saline 3 ml mix.
88930177|NCT01738100|Experimental|Ticagrelor + Intracoronary Saline|180 mg loading pre-PCI followed by 90 mg bid for 5 days. Saline 3 ml intracoronary injection.
88930178|NCT01738100|Experimental|Clopidogrel + Intracoronary Morphine|600 mg loading pre-PCI followed by 75 mg qd for 5 days. Morphine Sulfate 3 mg + Saline 3 ml mix intracoronary injection.
88930179|NCT01738100|Active Comparator|Clopidogrel + Intracoronary Saline|600 mg loading pre-PCI followed by 75 mg qd for 5 days. Saline 3 ml intracoronary injection.
88930180|NCT01738113|Experimental|open kinetic chain exercise|Open kinetic chain exercise
88930181|NCT01738113|Experimental|Closed Kinetic chain exercise|Closed kinetic chain exercise
88930182|NCT01738152|Experimental|HLA treatment|This is a single arm prospective longitudinal clinical trial investigating the feasibility of a hyaluronic acid (HLA) vaginal gel (HyaloGYN®; Cebert Pharmaceuticals, Inc.; Birmingham, Alabama) to improve estrogen deprivation vaginal and vulvar health symptoms in post-menopausal women with a history of hormone-receptor positive cancer with estrogen deprivation symptoms of vaginal dryness and discomfort.
88930183|NCT01738178|Placebo Comparator|Control - Placebo|These participants will receive placebo tablets during the first 5 years
88930184|NCT01738178|Active Comparator|Caffeine group|This group of participants will receive caffeine tablets.
88930185|NCT01738217|Experimental|Fluobeam|
89445174|NCT05504200|Experimental|Bladder and Pelvic Floor Muscle Training|Participants randomised to the intervention group will complete an 8-week bladder and PFMT programme, both at the LSCIC and at home. They will be invited to 3 face-to-face follow up appointments over the 8-weeks, where they will meet with a physiotherapist to check their technique and monitor their progress. At home participants will receive a daily text reminder to complete their PFM training, they will also receive a weekly phone call from a member of the research team who will check how they are managing and whether they have any questions. At the end of the programme, participants will be asked to repeat the questionnaires and have their pelvic floor re-assessed. Following this, they will complete the urodynamic investigation with tSCS.
89445175|NCT05504200|No Intervention|Control|Participants randomised to the control group will continue with their usual care for 8-weeks. They will return to repeat their baseline questionnaires and have their pelvic floor re-assessed. Finally, they will complete tSCS bladder filling and emptying cycles with urodynamics.
89445176|NCT02487290|Experimental|Treatment|Aneufix ACP-T5
89445177|NCT05294458|Experimental|Cotadutide solution for injection|"Period 1, subcutaneous injection of cotadutide solution~Period 2, subcutaneous injection of cotadutide solution~Period 3, subcutaneous injection of cotadutide solution"
88930186|NCT01738243|Experimental|Unilateral Upper Eyelid Retraction|"This arm will consist of participants with unilateral upper eye lid retraction secondary to thyroid eye disease (TED).~Patients enrolled will be randomized 1:1 to Hyaluronic Acid Gel Injection or Saline injection"
88930187|NCT01738243|Experimental|Bilateral Upper Eyelid Retraction|"This arm will consist of participants with bilateral upper eye lid retraction secondary to thyroid eye disease (TED).~Patients enrolled will be randomized 1:1 to Hyaluronic Acid Gel injection or Saline injection"
88930188|NCT01738256|Experimental|Face-to-Face|Group meetings face-to-face using intervention for wellbeing with ACT principles.
88930189|NCT01738256|Experimental|Mobile|Intervention for wellbeing via mobile phone application with ACT principles.
88930190|NCT01738256|Experimental|Internet|Intervention for wellbeing via Internet (Virtual Health Check and Coaching).
88930191|NCT01738256|Experimental|Control|Control group, no intervention.
89200052|NCT00961012|Experimental|Intervention|"Experimenter A places the subject in the High Fowler's position by raising the foot of the bed to its highest position, 50 degrees, and the head of the bed to its highest position, 60 degrees. Experimenter A sets the timer for 8 minutes as per pressure mapping protocol. For more stable values, a settling time of 8 minutes is required to factor in creep of the pressure mapping sensors and mattress. Experimenter A aims the laser beam to the top of the scapulae where the subject's shoulder meets the mattress surface. Experimenter B initiates a FSA file with the subject's number, takes a pressure reading once 8 minutes is up, measures the trunk displacement, obtains spirometry readings as per protocol, and takes a measure of discomfort. Experimenter B leaves the room, Experimenter A sets the timer for 5 minutes and opens the randomization/ allocation envelope."
88930192|NCT01738269||Apparently healthy subjects|
88930193|NCT01738269||Non-malignant conditions subjects|
88930194|NCT01738269||Malignant conditions subjects|
88930195|NCT01738282|Experimental|Baclofen|Baclofen 20mg tablet. Titration:increasing dosage regimen to reach the target dosage of 180 mg (9 tablets)in 7 weeks Maintenance period with a constant dosage during 17 weeks Progressive decrease and stop of study treatment in 2 weeks
88930196|NCT01738282|Placebo Comparator|Placebo|Placebo tablet Titration:increasing dosage regimen to reach the target dosage of 9 tablets in 7 weeks Maintenance period with a constant dosage during 17 weeks Progressive decrease and stop of study treatment in 2 weeks
88930197|NCT01738295|Active Comparator|Donepezil|Donepezil administration. In this group Donepezil (Aricept pill, 5 mg) will be orally administrated 3h before each experiment (1 week intervals)
88930198|NCT01738295|Placebo Comparator|Lactose pill|Placebo administration. In this group, placebo (lactose pill) will be orally administrated 3h before each experiments (1 week intervals)
89538464|NCT02457923|No Intervention|Usual health care services|The control clusters to receive usual health care services at PHC. The existing data collection methods will be continued in these clusters. Routine IYCF counseling is provided in existing level of care and its frequency is consistent with the visit schedule described in the intervention group: at antenatal clinics; at delivery; and at immunization clinics postnatal.
88930199|NCT01738308|Experimental|Healing Touch Treatment|"Healing Touch Treatment~When enter PACU + usual standard of care.~The Healing Touch practitioner will be at the bedside when the patient is first brought to the PACU. The HT practitioner will center and then attune with the child, connecting their energy with the child and setting the intention for healing for the child's highest good. The practitioner will then place one hand on the center of the patient's chest in the high heart area. The practitioner will hold this position until they feel a deep connection and quieting within the patient's energy. When the patient is awake and parents have been called to the bedside the HT practitioner will energetically ground and release the patient,"
88930200|NCT01738308|Sham Comparator|Sham Healing Touch Treatment|Usual standard of post operative care plus a sham Heal Touch treatment upon entering the post anesthesia care unit. Treatment done by untrained study staff using same hand locations.
88930201|NCT01738308|No Intervention|Control- No treatment done|Usual standard of post operative care with no additional intervention
88930202|NCT01738334|Active Comparator|Healthy subjects|"The active control group of healthy individuals was subjected to the practice of meditation for eight weeks."
88930203|NCT01738334|No Intervention|Standby|The control group of participants (patients and healthy subjects) who was not practice anything for eight weeks.
89445178|NCT02491190|Experimental|Treatment|Empower educational module: After the patient activation measure/s are collected, for parents or patients assigned to the intervention arm, they will be given an opportunity to launch the EMPOWER video and interactive powerpoint. They will be able to pause on reviewing the educational material and come back to it, as with other assigned education, and they will be able to review it again if they would like. Discharge surveys will be assigned 24 hours prior to the estimated discharge time in Apex. Oneview will display notifications that the surveys have been assigned.
89445179|NCT02491190|No Intervention|Control|Standard care: Those who opt to participate in the study will be randomly assigned to receive standard features of the media center (control group), or standard features plus the educational module intervention. They will complete online (1) a baseline patient activation survey (for patients old enough to complete and for caregivers) at the start of their participation, and (2) an end-of-study survey pre-discharge or at the end of the study period.
89445180|NCT05564572|Experimental|Health Status Assessment|Completion of a patient-reported health status assessment preceding each clinic visit. The health status assessment consists of the Kansas City Cardiomyopathy Questionnaire-12 (KCCQ-12) along with additional select questions. The results of the assessment will be available to clinicians in the electronic health record.
89445181|NCT05564572|No Intervention|Usual Care|Patients will not complete a patient-reported health status measures.
89445182|NCT02490410|Experimental|whey protein|2 x 10g whey protein per day orally for 6 months
89445183|NCT02490410|Other|whey protein+soy protein|10g whey protein + 10g soy protein per day orally for 6 months
89445184|NCT02490410|Other|soy protein|2 x 10g soy protein per day orally for 6 months
89445185|NCT03326648|Experimental|Strength training + protein supplement|Two sessions of strength training each week in addition to daily protein supplementation for 10 weeks.
89013712|NCT06273163|Experimental|Medically tailored meals|Participants will receive 10 medically tailored meals per week (40 meals per month) for four-months.
89445186|NCT03326648|Experimental|Protein supplement|Daily protein supplementation for 10 weeks.
89445187|NCT04649164|Other|Focus group participants|"Subjects participating in focus groups will be either:~caregiver mentees in our previous peer mentoring study~peer mentors and completed 16 weeks of mentoring in our previous peer mentoring study~current family caregivers of community-dwelling LBD patients in the Chicago area.~The investigators will conduct virtual focus groups using a password-protected videoconference platform. The informed consent process will take place online prior to the focus group. Focus groups will be led by a qualified neuropsychologist using open-ended questions. The aim of these groups is to revise and improve upon our previous peer mentor program's curriculum. Participants will be presented with the previous program's curriculum and a variety of proposed educational resources for inclusion in the revised curriculum. The investigators will obtain participants' feedback. Focus groups will be recorded and transcribed."
89445188|NCT04649164|Other|Peer mentors|Mentors will attend one 6-7 hour virtual training session. Study expectations and logistics will be reviewed with each potential mentor prior to the training session via phone. Informed consent process will take place online via REDCap prior to the training session. Baseline data will be collected via online surveys. Next, mentors will receive training regarding topics including active listening, mentoring, goal-and boundary-setting, an overview of LBD, risk factors for hospitalization, impact on caregiver, practical approaches to symptom management, and caregiving issues. The study team will present the PERSEVERE curriculum and accompanying handbook. The team will solicit questions and lead roleplay conversations. Finally mentors will complete post-training assessments. Once all caregiver mentees (Arm 3) are recruited, the mentors will contact their mentees once weekly by phone for 16 weeks to deliver the PERSEVERE curriculum.
89445189|NCT04649164|Experimental|Caregiver mentees|Once Aim 2 is complete and mentors have been trained, caregiver mentees will be matched with mentors by relationship to LBD patient, then by sex and age, as much as possible. The study team will contact mentees once a match is available for them. The mentee will complete baseline primary and secondary outcome assessments online via REDCap, including: mastery and loneliness scales, Short Zarit Burden Interview, Hospital Anxiety and Depression Scale. The team will provide the mentor's contact information and send the PERSEVERE handbook. Mentoring pairs will begin the 16-week peer mentor program. Pairs will be expected to speak for >15-30 minutes weekly, and to review that week's PERSEVERE topics in the handbook before or during each call to facilitate meaningful conversations. Mentors and mentees will complete online study diaries every 2 weeks. Upon completion of the 16-week mentor program, mentors and mentees will be sent a link to complete postmentoring assessments online.
89445190|NCT02490956|Experimental|Rabies vaccination|"Verorab® (PVRV; Purified Vero Cell Vaccine) 0.5 ml intramuscular~Standard intramuscular regimen: ESSEN on days 0, 3, 7, 14, 28 and booster at 1 year later on days 360 and 363"
89445191|NCT03326570||Bronchoscopy Data Collection|Medical information collected after bronchoscopy for up to 2 years.
89445192|NCT03326414|Other|Constant PEEP - low tidal volume|PEEP is 10mbar, tidal volume is set to 4-5ml/kg IBW
89445193|NCT03326414|Other|Constant PEEP - high tidal volume|PEEP is 10mbar, tidal volume is set to 8-10ml/kg IBW
89445194|NCT03326414|Other|constant tidal volume - low PEEP|tidal volume is 8ml/kg IBW, PEEP is set to 3mbar
89445195|NCT03326414|Other|constant tidal volume - high PEEP|tidal volume is 8ml/kg IBW, PEEP is set to 12mbar
89445196|NCT03326258|Experimental|Treatment (glembatumumab vedotin, nivolumab, ipilimumab)|Patients receive glembatumumab vedotin IV over 90 minutes and nivolumab IV over 60 minutes on day 8 of course 1 and on day 1 of subsequent courses. Patients in melanoma expanded cohort also receive ipilimumab IV over 90 minutes on day 1. Treatment with ipilimumab repeats every 21 days for 4 courses in the absence of disease progression or unaccepted toxicity and courses with glembatumumab vedotin and nivolumab repeat every 21 days in the absence of disease progression or unaccepted toxicity.
89445197|NCT05564260|Experimental|The Kaleidescope Group|Kaleidoscope was watched during blood drawing
89445198|NCT05564260|Experimental|The VR Group|watching the application by wearing virtual glasses to the child during the blood drawing
89445199|NCT05564260|No Intervention|Control Group|No intervention was made.
89013713|NCT06273163|Experimental|Noom®|Participants will receive a paid Noom® subscription for four-months. Noom® is a subscription-based mobile application that provides food intake and exercise tracking and uses principles from psychology to motivate behavior change.
89445200|NCT05564182|Experimental|High intensity laser therapy + exercise|HILT will be applied to the patients five times a week for a period of three weeks and one session per day for a total of 15 sessions by a physical therapy technician who is experienced in using a laser device. (BTL-6000 high intensity laser 12 W, Stevenage, Hertfordshire, England). The laser device generates a maximum power of 12 W and emits a wavelength of 1064 nm (Nd: YAG laser). In the HILT group, it will be used in the rotator cuff muscles area in two stages, Phase I and Phase II. For analgesic effect in phase I. Phase II will also be applied for the biostimulation effect. Exercise program was applied in five sessions a week for three weeks, with a total of 15 sessions a day.
89445201|NCT05564182|Active Comparator|Exercise only|Exercise program was applied in five sessions a week for three weeks, with a total of 15 sessions a day.
89445202|NCT02487212|Active Comparator|Laser+Topical corticosteroid|Hypertrophic scars were treated with fractional Erbium: Yttrium aluminium garnet (YAG) (2,940-nm) laser, then 0.05% Clobetasol propionate ointment was immediately applied on the perforated scar on one side
89445203|NCT02487212|Placebo Comparator|Laser+Petrolatum gel|Hypertrophic scars were treated with fractional Erbium: YAG (2,940-nm) laser, then topical petrolatum gel was immediately applied on the perforated scar on the other side
89445204|NCT03318614|Experimental|Probiotics M-63 group|Participants assigned to the M-63 group were given a sachet of B. infantis M63 (Morinaga Milk Industry Co., Ltd., Japan) to consume daily in addition to advice of good hygiene and sanitation practices.
89445205|NCT03318614|Placebo Comparator|Control group|No probiotic intervention was given to the control group over three months other than advice of good hygiene and sanitation practices.
89445206|NCT03318536||No Granisetron|120 Patients prior to changes of intern standards of caesarean section. Before march 2017 no patient undergoing elective caesarean section received Granisetron as a matter of routine.
89445207|NCT03318536||With Granisetron|120 Patients after changes of intern standards of caesarean section. After march 2017 all patient undergoing elective caesarean section received Granisetron as a matter of routine.
89445208|NCT05504122|Active Comparator|Laparoscopic Totally Extraperitoneal (TEP)|Patients who underwent Laparoscopic Totally Extraperitoneal (TEP) will be included in this group.
89445209|NCT05504122|Placebo Comparator|Open tension-free mesh repair technique (Lichtenstein)|Patients with open tension-free inguinal hernia(Lichtenstein) repair will be included in this group.
89445210|NCT02181153|Other|siblings of patients with IBD|Blood and fecal samples from 100 siblings of children affected with IBD will be collected at the day of enrolment. Clinical risk factors for IBD will be also recorded in a case report form.
89445211|NCT02181153|Other|patients without family history of IBD|Blood and fecal samples of 100 healthy children without a family history of IBD will be collected at the day of enrolment. Clinical risk factors for IBD will be also recorded in a case report form
89445212|NCT04283812|Experimental|D1 Stereotactic System Assessment|Participants in the clinical study will consist of subjects approved to undergo deep brain stimulation surgery for the treatment of a neurological disorder at Mayo Clinic. Subjects will have a Key secured to their skull for attachment of an MRI-compatible localizer box or D1 stereotactic frame. 3D Euclidian distance error(s), trajectory accuracy(s), operating room time, and comfort level of the system will be assessed.
89445213|NCT03318458|Experimental|Pilates group|
89445214|NCT03318458|No Intervention|No intervention group|
89445215|NCT03537027|Experimental|Vitamin D3|2000 micrograms of vitamin D3 in two doses during one day
89445216|NCT04396041||Patients treated for Pulmonary Arteriovenous Malformation|All participants in the study will be patients who have been treated for Pulmonary Arteriovenous Malformation using Microvascular Plugs, Amplatzer Vascular Plugs or Detachable coils.
89445217|NCT04282876||Degarelix|Patients undergoing radiation therapy for bladder cancer while also being treated with Degarelix (androgen deprivation therapy)
89445218|NCT04282876||Control|Patients undergoing radiation therapy for bladder cancer with or without simultanous treatment with androgen deprivation therapy (not Degarelix)
89445219|NCT02183025|Experimental|Meloxicam 7.5 mg|
89445220|NCT02183025|Experimental|Meloxicam 15 mg|
89445221|NCT02183025|Active Comparator|Mefenamic acid 1500 mg|500 mg three times daily
89445222|NCT05464004|Active Comparator|conventional physical therapy|stretching, strengthening and balance exercises
89445223|NCT05464004|Experimental|Nintendo Wii balance board therapy|Nintendo Wii balance board therapy in combination with conventional physical therapy
89445224|NCT04282174|Experimental|Regimen A|Regimen A: Hyperfractionated Total Body Irradiation/Thiotepa/Cyclophosphamide: Hyperfractionated total body irradiation to dose of 1375cGy fractions at 4-6 hour intervals three times a day for a total of 11 or 12 doses depending on age and disease risk, followed by Thiotepa 5mg/kg/day x 2 (or 10mg/kg/day x 1) and cyclophosphamide 60mg/kg/day x 2 (or Fludarabine 25mg/m2 x 5 if cyclophosphamide is contraindicated)
89445225|NCT04282174|Experimental|Regimen B|Regimen B: Busulfan/Melphalan/Fludarabine: Busulfan 0.8mg/kg/dose every six hours x 10-12 doses (depending on disease), Melphalan 70mg/m2/day x 2 and Fludarabine 25mg/m2/day x 5.
89445226|NCT03321500|Experimental|Versacyl soft liner|Versacryl soft liner are flexible biocompatible materials with a reported predictable long term performance, durable bonding to acrylic denture bases, high fatigue endurance, excellent wear characteristics and solvent resistance with almost no free monomer in the processed material
89445227|NCT03321500|Active Comparator|Silicone-based soft liner|Resilient liners were introduced in the1950s and have been used since then as a gold standard material to increase the tolerance, retention and comfort of complete dentures. Resilient liners also known as 'soft liners' can be classified as temporary or permanent, cold-cured or heat-cured.Resilient liners can be divided into two main types: plasticized acrylic resins and silicone elastomers.
89445228|NCT02185989|Active Comparator|Electrical muscle stimulation and bicycling|Patients will undergo early electrical stimulation of the quadriceps and early leg bicycling in addition to routine care (which comprises early standard mobilization)
88930204|NCT01738334|Experimental|Meditation|A Group of Patients with ADHD was participate of the meditation practices for eight weeks.
88930205|NCT01738347|Experimental|Arm 1 - GEH120714 (18F) Injection|Intervention is to administer GEH120714 (18F) Injection (100-270 Megabecquerel (MBq), single intravenous administration).
89013714|NCT06273163|Placebo Comparator|Usual care|Participants will receive usual care from their provider.
89445229|NCT02185989|No Intervention|Standard early passive/active rehabilitation|In this control group, patients will undergo routine care that comprises standard early passive/active rehabilitation delivered by physiotherapist with the assistance of ICU nurses
89445230|NCT02186067|Experimental|Referral System|"Referral System:~Primary Level Secondary Level Tertiary Level"
89445231|NCT02186067|No Intervention|Control|Usual/routine care will be provided to the patients
89445232|NCT05503888|Experimental|Almonertinib combined with SHR-1701|
89445233|NCT05503888|Placebo Comparator|Almonertinib|
88930206|NCT01738360|Experimental|Arsenic trioxide|Thirteen patients will be successively included in this study at 6 different dose levels of arsenic trioxide (0.075, 0.10, 015, 0.20, 0.25 and 0.30 mg / kg / day).
89445234|NCT02490332|Experimental|Ventilation tube treatment|Ventilation tube insertion in the tympanic membrane
89445235|NCT02490332|No Intervention|Conservative treatment|Conventional treatment
89445236|NCT02181309|Experimental|Meloxicam low dose, fasted|
89445237|NCT02181309|Experimental|Meloxicam medium dose, fasted|
89445238|NCT02181309|Experimental|Meloxicam high dose, fed|
89445239|NCT02181309|Active Comparator|Meloxicam high dose, fasted|
89445240|NCT03326024||A|Patients with Polycystic Ovary Syndrome at reproductive age (20-35) diagnosed according to Rotterdam criteria and underwent laparoscopic ovarian drilling from more than two years.
89445241|NCT03326024||B|Patients with Polycystic Ovary Syndrome at reproductive age (20-35) diagnosed according to Rotterdam criteria and didn't undergo laparoscopic ovarian drilling
89445242|NCT02186145|Experimental|Association of metronidazole; nystatin and dexamethasone|Intravaginal cream containing metronidazole (500 mg), nystatin ( 100.000 UI) and dexamethasone (0,32 mg) once a day. Period: 10 days.
89445243|NCT02186145|Active Comparator|Flagyl|Vaginal cream of metronidazole 500 mg, nystatin 100.000 UI - once a day. Period: 10 days
88930207|NCT01738399|Experimental|Coffee|Subjects take 4 cups of coffee mix per day for 24 weeks
88930208|NCT01738399|Placebo Comparator|Placebo|Subjects take 4 cups of placebo per day for 24 weeks
88930209|NCT01738412||Study population|Stroke patients
88930210|NCT01738425|Experimental|GIC-1001 oral tablets|GIC-1001; 125 mg oral tablets; Single ascending doses (SAD) from 125 mg to 1000 mg; multiple ascending dose (MAD) from 125 mg to 500 mg TID over 7 successive days
88930211|NCT01738425|Placebo Comparator|GIC-1001 matching placebo|Matching placebo, single or multiple dosing
88930212|NCT01738451|Experimental|Part 1(Cohort 1): GSK2118436 225 mg|GSK2118436 (3 capsules of 75 mg) will be administered orally at the dose of 225 mg BID from Day 1 to 7 (and single dose on Day 8) under fasted conditions, either 1 hour before or 2 hours after a meal.
89013715|NCT06267911|Experimental|Cognitive stimulation and psychological support (RGS-ICU)|
89013716|NCT06267911|No Intervention|Treatment as usual (TAU)|
89445244|NCT03325868|Experimental|Ulipristal|Ulipristal acetate 5mg daily for 12 weeks
89445245|NCT02183103|Active Comparator|meloxicam rapid release tablet after an overnight fast|
89445246|NCT02183103|Experimental|meloxicam rapid release tablet after high fat breakfast|
89445247|NCT03325790|Placebo Comparator|Placebo|Placebo
89445248|NCT03325790|Experimental|200mg SPI-1005 twice daily (BID)|200mg SPI-1005 BID
89445249|NCT03325790|Experimental|400mg SPI-1005 BID|400mg SPI-1005 BID
89445250|NCT02181465|Experimental|Group 1|One injection of G17DT followed by up to three booster injections depending on antibody response over 16 week period
89445251|NCT02181465|Experimental|Group 2|Three injections of G17DT with option of one booster after 16 weeks
89445252|NCT02490020|Experimental|iv of BMSC to prevent rejection|Routine treatment protocol(ATG 50mg*3;MP 2.0g to Pred 30mg,then maintaining 5mg qd;MMF 1.0 bid from the first day after op,then maintaining 1-1.5g/d;Plus CNI from the third day after op)+BMSC iv(2*10^6cell/kg, 48h before op)
89445253|NCT02490020|No Intervention|routine treatment protocol to prevent rejection|Routine treatment protocol(ATG 50mg*3;MP 2.0g to Pred 30mg,then maintaining 5mg qd;MMF 1.0 bid from the first day after op,then maintaining 1-1.5g/d;Plus CNI from the third day after op)
89445254|NCT02490020|Experimental|ia and iv of MSC to prevent rejection|Routine treatment protocol(ATG 50mg*3;MP 2.0g to Pred 30mg,then maintaining 5mg qd;MMF 1.0 bid from the first day after op,then maintaining 1-1.5g/d;Plus CNI from the third day after op)+BMSC (iv 2*10^6cell/kg + ia 5*10^6cell, 48h before op)
89445255|NCT02490020|No Intervention|routine treatment to prevent rejection|Routine treatment protocol(ATG 50mg*3;MP 2.0g to Pred 30mg,then maintaining 5mg qd;MMF 1.0 bid from the first day after op,then maintaining 1-1.5g/d;Plus CNI from the third day after op)
89445256|NCT02490020|Experimental|Routine CMR treatment plus MSC to prevent CMR|Routine CMR treatment protocol(MP as first line approach, ATG as second line approach,ATG be used to treat BPAR in 1 week after op)+MSC( iv 2*10^6cell/kg at d1,d7)
89445257|NCT02490020|No Intervention|Routine CMR treatment to prevent CMR|Routine CMR treatment protocol(MP as first line approach, ATG as second line approach,ATG be used to treat BPAR in 1 week after op)
89445258|NCT02490020|Experimental|Routine AMR treatment plus MSC to prevent AMR|Routine AMR treatment protocol(plasma exchange and IVIG as first line approach, anti-CD20 monoclonal antibody as second line approach)+MSC( iv 2*10^6cell/kg at d1,d7)
89445259|NCT02490020|No Intervention|Routine AMR treatment to prevent AMR|Routine AMR treatment protocol(plasma exchange and IVIG as first line approach, anti-CD20 monoclonal antibody as second line approach)
89445260|NCT02186379|Experimental|RePace Intervention Group|"Re-Pace intervention-five weekly intervention sessions lasting about 1 hour each.~Lab Test Meal-2 test meals 6-8 weeks apart."
89445261|NCT02186379|Active Comparator|Usual Care Control Group|One 25 minute education session (week 6) 2 lab test meals 6-8 weeks apart (baseline and week 6)
89445262|NCT04493918|Experimental|MSC Group|Mesenchymal Stem Cell + NaCl 0,9% 2ml
89445263|NCT02181543|Experimental|Clonidine|Clonidine 1μg/Kg, IV, single dose, anesthesia intraoperative.
89445264|NCT02181543|No Intervention|No Clonidine|Usual care of Instituto de Medicina Integral Prof. Fernando Figueira.
89538465|NCT03265925||Epilepsy patients Right Temporal Lobe|Epilepsy patients with seizures originating from the right temporal lobe
89445265|NCT02490176|Experimental|GLP-1 group|drug: liraglutide (Novo Nordisk, Bagsværd, Denmark); the frequency: Subcutaneous liraglutide were taken daily; duration: 7 days. After admission, the patients were treated with 0.6 mg liraglutide once daily for 2 day, then 1.2 mg liraglutide for another 2 day, and then 1.8 mg liraglutide for 3 days.
89445266|NCT02490176|Placebo Comparator|Control group|drug: placebo (Novo Nordisk, Bagsværd, Denmark); the frequency: Placebo were taken daily; duration: 7 days. After admission, the patients were treated with 0.6 mg placebo once daily for 2 day, then 1.2 mg placebo for another 2 day, and then 1.8 mg placebo for 3 days.
89445267|NCT02181699|Experimental|KHK2823|single agent KHK2823 administered at selected dose levels
89445268|NCT02181777|Experimental|GRASP|GRoup trAining for Social skills in Psychosis
89445269|NCT02181777|Active Comparator|Standard care|Treatment as usual as provided by care team
89445270|NCT03321344|Experimental|Test Arm|Focused Ultrasound Thermal ablation of the Medial Nerve Branch
89445271|NCT02181855|Other|Atypical GERD syptoms treated with GERD-X|Patients treated by means of full-thickness gastroplication
89445272|NCT02183181|Experimental|Meloxicam capsule|Capsules 15 mg
89445273|NCT02183181|Active Comparator|Meloxicam tablet|Tablets 15 mg
89445274|NCT02490098|Active Comparator|Single-hormone closed-loop strategy with full boluses|Variable subcutaneous insulin infusion rates will be used to regulate postprandial glucose levels. Patient's usual fast acting insulin analog (Lispro, Aspart or Glulisine) will be infused using a subcutaneous infusion pump (MiniMed® Paradigm® Veo™, Medtronic). Every 10 minutes, the glucose levels as measured by the sensor (Enlite sensor®, Medtronic) will be transferred automatically to the Smartphone platform, that harbors the algorithm, that will calculate the recommended doses and will send it wirelessly to the infusion pump. Each subject insulin-to-carbohydrate ratio will be used to calculate the insulin bolus to be given.
89445275|NCT02490098|Active Comparator|Dual-hormone closed-loop strategy with full boluses|Variable subcutaneous insulin and glucagon infusion rates will be used to regulate postprandial glucose levels. Patient's usual fast acting insulin analog (Lispro, Aspart or Glulisine) and Glucagon (Eli Lilly) will be infused using two separate subcutaneous infusion pumps (MiniMed® Paradigm® Veo™, Medtronic). Every 10 minutes, the glucose levels as measured by the sensor (Enlite sensor®, Medtronic) will be transferred automatically to the Smartphone platform, that harbors the algorithm, that will calculate the recommended doses and will send it wirelessly to the infusion pumps. Each subject insulin-to-carbohydrate ratio will be used to calculate the insulin bolus to be given.
89445276|NCT02490098|Active Comparator|Single-hormone closed-loop strategy with partial boluses|Variable subcutaneous insulin infusion rates will be used to regulate postprandial glucose levels. Patient's usual fast acting insulin analog (Lispro, Aspart or Glulisine) will be infused using a subcutaneous infusion pump (MiniMed® Paradigm® Veo™, Medtronic). Every 10 minutes, the glucose levels as measured by the sensor (Enlite sensor®, Medtronic) will be transferred automatically to the Smartphone platform, that harbors the algorithm, that will calculate the recommended doses and will send it wirelessly to the infusion pump. The partial bolus will be based on the estimated meal size (snack-regular-large-very large). For this strategy, meal size will be defined as: snack as any meal less than 30g, regular meal as any meal between 30g and 60g CHO, large meal as any meal between 60g and 90g CHO, very large meal for anything above 90g CHO. The meal size assessment will be done by the patient.
89445277|NCT02490098|Active Comparator|Dual-hormone closed-loop strategy with partial boluses|Variable subcutaneous insulin and glucagon infusion rates will be used to regulate postprandial glucose levels. Patient's usual fast acting insulin analog (Lispro, Aspart or Guilisine) and Glucagon (Eli Lilly) will be infused using two separate subcutaneous infusion pumps (MiniMed® Paradigm® Veo™, Medtronic). Every 10 minutes, the glucose levels as measured by the sensor (Enlite sensor®, Medtronic) will be transferred automatically to the Smartphone platform, that harbors the algorithm, that will calculate the recommended doses and will send it wirelessly to the infusion pumps. The partial bolus will be based on the estimated meal size (snack-regular-large-very large). For this strategy, meal size will be defined as: snack as any meal less than 30g, regular meal as any meal between 30g and 60g CHO, large meal as any meal between 60g and 90g CHO, very large meal for anything above 90g CHO. The meal size assessment will be done by the patient.
89445278|NCT02490098|Active Comparator|Sensor-augmented pump therapy|Subjects will use sensor-augmented pump therapy and freely implement their usual basal rate and CHO-matching full prandial bolus to regulate glucose levels. Patient's usual fast acting insulin analog will be infused using a subcutaneous insulin infusion pump. Each subject insulin-to-carbohydrate ratio will be used to calculate the insulin bolus to be given.
89445279|NCT02183259|Experimental|ESR 1150 CL capsule|
89445280|NCT02183259|Experimental|ESR 1150 CL ampoule|
89445281|NCT02486822|Experimental|Labor scale|Observation Amniotomy Oxytocin Cesarean Section (CS)
89445282|NCT02486822|Active Comparator|WHO partograph|Observation Amniotomy Oxytocin Cesarean Section (CS)
89445283|NCT02186457|Experimental|Polymyxin B in Normal Saline|Polymyxin B (500,000 U) in 1 liter of 0.9% Normal Saline
89445284|NCT02186457|Placebo Comparator|Placebo: Normal Saline|0.9 % Normal Saline
89445285|NCT03321266||Patients treated for a anorectal fistula|Patients who were treated for a anorectal fistula with a Biodesign Fistula plug
89445286|NCT02256501|Experimental|Mono Nunlear Cell (MNC)|The patients with idiopathic dilated cardiomyopathy who underwent intracoronary injection of autologous bone marrow-derived mononuclear cells .
89445287|NCT02256501|No Intervention|Control|The patients with cardiomyopathy that are under observe during the study.
89445288|NCT02486900|Experimental|Neurofeedback training group|The neurofeedback group will perform 6 training sessions over a period of 4 months: 4 fortnightly sessions in the first two months will be followed by 2 monthly 'booster' sessions. Each session will include several behavioural assessments and fMRI-based neurofeedback training in an MRI scanner (1 h). The neurofeedback training phase will be be followed-up by two behavioural assessments 8 and 12 months after the first training.
88930213|NCT01738451|Experimental|Part 1(Cohort 2): GSK2118436 300 mg|GSK2118436 (4 capsules of 75 mg) will be administered orally at the dose of 300 mg BID from Day 1 to 7 (and single dose on Day 8) under fasted conditions, either 1 hour before or 2 hours after a meal. If 225 mg BID is not tolerated in Part 1 /Cohort 1, then Part 1/Cohort 2 will not be initiated and 150 mg BID will be used in Part 2.
89013717|NCT06266533|Active Comparator|Conventional Nutrition Education|Conventional nutrition education
89013718|NCT06266533|Experimental|Arts-based Nutrition Education|Arts-based nutrition education video production
89445289|NCT02486900|No Intervention|Treatment-as-usual control group|The control group will receive treatment as usual (e.g. medication, counselling) but no neurofeedback training during the study period. Patients in the control group will be invited for four behavioural assessment sessions (baseline assessment, follow-up assessments 4/8/12 months after baseline).
89445290|NCT02486978|Placebo Comparator|Control (no supplement)|Reference will be white bread to give 50 g available carbohydrates with placebo capsule
89445291|NCT02486978|Experimental|Dose 1|Test will comprise white bread to give 50 g available carbohydrates and one capsule of pomegranate/olive and one capsule placebo
89445292|NCT02486978|Experimental|Dose 2|Test will comprise white bread to give 50 g available carbohydrates and 2 capsules of pomegranate/olive.
89445293|NCT02186535|Other|Daily dosing|Daily oral capsule of Vitamin D in 4000 IU/day with daily oral capsules of 1000mg of calcium
89445294|NCT02186535|Other|weekly dosing|Oral capsule Vitamin D 50,000 IU/week with a oral capsule of 1000mg of calcium, daily
89445295|NCT03325400|Other|Non-fluoride toothpaste|Participants have used toothpaste for four months. The first two months they used non-fluoride toothpaste, after which, for the next two months, they used toothpaste containing fluoride of the same manufacturer and similar composition. The tested kinds of toothpaste were applied twice a day, in the morning and evening, for three minutes in the amount of 1 g (≈2 cm). Contemporary, participants did not use other agents for oral hygiene such as mouthwash or topical fluoridation.
89445296|NCT03325400|Active Comparator|Fluoride toothpaste|Participants have used toothpaste for four months. The first two months they used non-fluoride toothpaste, after which, for the next two months, they used toothpaste containing fluoride of the same manufacturer and similar composition. The tested kinds of toothpaste were applied twice a day, in the morning and evening, for three minutes in the amount of 1 g (≈2 cm). Contemporary, participants did not use other agents for oral hygiene such as mouthwash or topical fluoridation.
89445297|NCT02186613|Experimental|Experimental|These mothers and their babies will receive Primary Care standard care (office visits at 1, 2, 4 and 6 months) plus the telephone support
89445298|NCT02186613|No Intervention|No intervention|Standard care (office visits at 1, 2, 4 and 6 months)
89445299|NCT03325244||All participants|All participants will use a portable EEG monitor and FITBIT to monitor sleep and activity before and after night call
89445300|NCT02181933|Experimental|Nevirapine|Mother: two doses, Infant: one dose
89445301|NCT02181933|Active Comparator|Zidovudine (ZDV) + Lamivudine (3TC)|
89445302|NCT02183337|Experimental|BI 1356|"Treatment sequence AB_C or C_AB~Treatment A: 5 days BI 1356 until steady state followed by~Treatment B: combined treatment of BI 1356 with pioglitazone for 7 days~Treatment C: 7 days of treatment with Pioglitazone alone"
89445303|NCT02183337|Active Comparator|Pioglitazone|"Treatment sequence AB_C or C_AB~Treatment A: 5 days BI 1356 until steady state followed by~Treatment B: combined treatment of BI 1356 with pioglitazone for 7 days~Treatment C: 7 days of treatment with Pioglitazone alone"
89445304|NCT02489786|Active Comparator|Regimen 1|patient takes 0.25mg of digoxin daily except friday
89445305|NCT02489786|Active Comparator|Regimen 2|patient takes 0.25mg of digoxin daily except Thursday and Friday
89445306|NCT02489786|Active Comparator|Regimen 3|patient takes 0.125mg of digoxin daily
89445307|NCT02489786|Active Comparator|Regimen 4|digoxin dose is calculated using Jusko-Koup method and given daily
89013719|NCT06264635|Experimental|Platelet-Rich-Plasma (PRP)|PRP refers to a treatment where a patient's own blood is used to promote healing. Blood is drawn, processed to concentrate the platelets, and then re-injected into the injured area to stimulate tissue repair.
89445308|NCT02489864|Active Comparator|Terlipressin and albumin|"Patients in this group received terlipressin as an intravenous bolus of 0.5 mg every 6 h. If a significant reduction in serum creatinine level (≥1 mg/dL) was not observed during 3-day period, the dose of terlipressin was increased in a stepwise fashion every 3 days to a maximum of 2 mg every 6 hour.~albumin (Albumin 20 percent; Instituto Grífols, Barcelona, Spain) was given at a dose of 10 gram per day."
89445309|NCT02489864|Placebo Comparator|Albumin|Only albumin (Albumin 20 percent; Instituto Grífols, Barcelona, Spain) was given at a dose of 10 gram per day.
89445310|NCT02182011|Experimental|Tenecteplase|Single i.v. bolus followed by infusion, weight adjusted
89445311|NCT02182011|Active Comparator|Alteplase|Single i.v. bolus followed by infusion
89445312|NCT02182011|Active Comparator|Streptokinase|I.V. infusion
89445313|NCT02486744|Active Comparator|80 Units of Acthar|Subjects assigned by random assignment to receive 80 Units of Acthar Gel 2x weekly for 6 months
89445314|NCT02486744|Active Comparator|40 Units of Acthar|Subjects assigned by random assignment to receive 40 Units of Acthar Gel 2x weekly for 6 months
89445315|NCT02186769|Active Comparator|Risperdal® Consta®|25 Mg or 50 mg
89445316|NCT02186769|Experimental|L03004|25 mg or 50 mg
89445317|NCT02486432|Experimental|Single arm Levodopa/Carbidopa|The intervention is dosing with Sinemet® which is an oral tablet containing Levodopa/Carbidopa. Oral administration of 2 × 12.5 mg/50 mg Sinemet® tablet containing 13.5 mg carbidopa (equivalent to 12.5 mg anhydrous carbidopa) and 50 mg levodopa three times a day on Day -1 with 240 mL water Oral administration of 1 × 12.5 mg/50 mg Sinemet® tablets containing 13.5 mg carbidopa (equivalent to 12.5 mg of anhydrous carbidopa) and 50 mg levodopa administered with 100 mL water every hour for 16 hours on Day 1
89538466|NCT03265925||Epilepsy patients Left Temporal Lobe|Epilepsy patients with seizures originating from the left temporal lobe
89445318|NCT05182047|Experimental|Treatment Sequence AB|Participant will receive a single oral dose of butamirate citrate syrup 1.5 milligrams per milliliter (mg/mL) (Treatment A [investigational product]) on Day 1 in Treatment Period 1, followed by a single oral dose of sinecod syrup (vanilla) 1.5 mg/mL (Treatment B [Reference product]) on Day 11 in Treatment Period 2. A wash-out period of at least 10 days will be maintained between each treatment period.
89445319|NCT05182047|Experimental|Treatment Sequence BA|Participants will receive Treatment B on Day 1 in Treatment Period 1, followed by Treatment A on Day 11 in Treatment Period 2. A wash-out period of at least 10 days will be maintained between each treatment period.
89445320|NCT02489240|Experimental|Vitamin D supplementation group|drug: vitamin D3 tablets (Vigantoletten; Merck Pharma, Germany); the frequency: 2000 IU vitamin D3 tablets were taken daily; duration: study treatment was commenced 3 days before intervention and maintained for 3 days after the procedure.
89445321|NCT02489240|Placebo Comparator|Control group|drug: placebo tablets; the frequency: 2000 IU placebo tablets were taken daily; duration: study treatment was commenced 3 days before intervention and maintained for 3 days after the procedure.
89445322|NCT02183415|Experimental|BI 1356 BS, low dose|
89445323|NCT02183415|Experimental|BI 1356 BS, medium dose|
89445324|NCT02183415|Experimental|BI 1356 BS, high dose|
89445325|NCT02183415|Placebo Comparator|Placebo|
89445326|NCT02486510|No Intervention|Group 1 (Control)|"Patients receiving intensive chemotherapy with/without stable antiretroviral therapy. Patients not receiving antiretroviral therapy will start it.~Patients randomized to this group will not receive clinical trial treatment (neither Maraviroc or Placebo)"
89445327|NCT02486510|Experimental|Group 2 (Treatment)|"Patients receiving intensive chemotherapy with/without stable antiretroviral therapy and Maraviroc.~Patients not receiving antiretroviral therapy will start this theraphy together with Maraviroc."
89445328|NCT02190123||ACS patients treated with OAP|Patients with ACS who have been initiated and treated with ticagrelor and other oral antiplatelets
89445329|NCT04493840|Experimental|Shenfu Injection|
89445330|NCT04493840|Placebo Comparator|5% Glucose Injection|
89445331|NCT02186925||Bladder, Kidney and Prostate Cancer Patients|
89445332|NCT04493528|Active Comparator|Needle Infiltration anesthesia|Patients received one needle injection of infiltration anesthesia at left or right upper lateral incisors using 1 ml 2% lidocaine with 1:50,000 epinephrine (xylocaine).
89445333|NCT04493528|Experimental|Needle-free infiltration anesthesia|Patients received one NFLJI (needle-free liquid jet injection) of infiltration anesthesia at left or right upper lateral incisors using 1 ml 2% lidocaine with 1:50,000 epinephrine (xylocaine).
89445334|NCT04493528|Active Comparator|Needle mental nerve block|Patients received one needle injection of mental nerve block at left or right lower premolar region using 1 ml 2% lidocaine with 1:50,000 epinephrine (xylocaine).
89445335|NCT04493528|Experimental|Needle-free mental nerve block|Patients received one NFLJI (needle-free liquid jet injection) of mental nerve block at left or right lower premolar region using 1 ml 2% lidocaine with 1:50,000 epinephrine (xylocaine).
89445336|NCT04493528|Active Comparator|Needle mandibular nerve block|Patients received one needle injection of mandibular nerve block at left or right mandibular foramen using 2 ml 2% lidocaine with 1:50,000 epinephrine (xylocaine).
89445337|NCT04493528|Experimental|Needle-free mandibular nerve block|Patients received one NFLJI (needle-free liquid jet injection) of mandibular nerve block at left or right mandibular foramen using 2 ml 2% lidocaine with 1:50,000 epinephrine (xylocaine).
89445338|NCT04493528|Active Comparator|Needle infraorbital nerve block|Patients received one needle injection of infraorbital nerve block at left or right canine fossa using 1 ml 2% lidocaine with 1:50,000 epinephrine (xylocaine).
89445339|NCT04493528|Experimental|Needle-free infraorbital nerve block|Patients received one NFLJI (needle-free liquid jet injection) of infraorbital nerve block at left or right canine fossa using 1 ml 2% lidocaine with 1:50,000 epinephrine (xylocaine).
89445340|NCT02190201|Experimental|videolaryngoscope|DLT intubation with McGrath videolaryngoscope
89445341|NCT02190201|Active Comparator|Direct laryngoscope|DLT intubation with Macintosh laryngoscope
89445342|NCT02489474||Recipients undergoing liver transplantation|Patients undergoing liver transplantation will be included and followed up during the first 72 hours post-liver transplantation in order to confirm the development of acute kidney injury. The patients will be divided into two groups (AKI group vs. non-AKI group) according to the development of acute kidney injury.
88930214|NCT01738451|Experimental|Part 2: GSK2118436 300 mg (or highest tolerated dose)|Subjects will receive a single dose of GSK2118436/placebo (4 capsules of 75 mg/highest tolerated dose) orally on the first 2 days of the study followed by 2 doses daily for 6 days and a single dose on the 9th day. There will be 1 day when a placebo will be given. All doses will be administered under fasted conditions, either 1 hour before or 2 hours after a meal.
88930215|NCT01738490|Other|Wide diameter implant|Bone anchored hearing implant For the wide diameter arm (test group), the Ponto wide implant (diameter 4,5mm, length 4mm) and abutment 6mm developed by Oticon Medical AB (Gothenburg, Sweden) will be installed.
88930216|NCT01738490|Other|Control group|Bone anchored hearing implant For the control group, the previous generation Ponto implant (diameter 3,75mm, length 4mm) and 6mm abutment (Oticon Medical AB, Gothenburg, Sweden) will be installed.
88930217|NCT01738529|Active Comparator|CLE ileocolonoscopy on Crohn patients|Patients known with Crohn´s disease
88930218|NCT01738529|Sham Comparator|CLE ileocolonoscopy on control patients|CLE ileocolonoscopy on patients without known IBD
88930219|NCT01738542|Experimental|Antiaggregants & Statins & Antihypertensives & Bosentan|Bosentan 62.5 mg/12 hours (first four weeks) and 125 mg/12 hours (eight weeks) plus Antiaggregant therapy (AAS 100mg/d or Clopidogrel 75mg/d), Statins and Antihypertensive therapy
88930220|NCT01738542|Active Comparator|Antiaggregants & Statins & Antihypertensives|Antiaggregant therapy (AAS 100 mg/d or Clopidogrel 75 mg/d), Statins, Antihypertensive therapy
88930221|NCT01738555|Experimental|amdoxovir 300 mg bid|in combination with zidovudine 300 mg bid and lopinavir/ritonavir (400 mg/100 mg bid) for 36 weeks.
88930222|NCT01738555|Experimental|amdoxovir 500 mg bid|in combination with zidovudine 300 mg bid and lopinavir/ritonavir (400 mg/100 mg bid) for 36 weeks.
89445343|NCT02183493|Experimental|Fed administration of BI 1356|
88930223|NCT01738568|Experimental|Exercise|Aerobic exercise
88930224|NCT01738620|Experimental|psychological counseling+prevention of sleep disorders in ICU|patients will receive both psychological counseling and interventions to prevent sleep disorders during their ICU stay
88930225|NCT01738620|Experimental|psychological counseling|patients will receive psychological counseling
89445344|NCT02183493|Active Comparator|Fasted administration of BI 1356|
89445345|NCT02484872||Lung neoplasms|Lung neoplasms irrespective of stage and histology
89445346|NCT02187081|Experimental|Sorafenib+RFA|We give radiofrequency ablation plus Sorafenib for the treatment of HCC
89445347|NCT02187081|Active Comparator|RFA alone|We give Radiofrequency ablation alone for the treatment of HCC
89445348|NCT02485106|Active Comparator|Rifaximin group|Corticosteroid or Pentoxifylline for 28 days Rifaximin 400mg tid for 28 days
89445349|NCT02485106|Active Comparator|Control group|Corticosteroid or Pentoxifylline for 28 days
88930226|NCT01738620|Experimental|prevention of sleep disorders in ICU|interventions to prevent sleep disorders during their ICU stay
89445350|NCT02187237|Experimental|Laser therapy|
89445351|NCT02485028|Experimental|M→D→D+M|Mirodenafil(M) in period 1, Dapoxetine(D) in period 2, Dapoxetine+Mirodenafil(D+M) in period 3
89445352|NCT02485028|Experimental|M→D+M→D|Mirodenafil(M) in period 1, Dapoxetine+Mirodenafil(D+M) in period 2, Dapoxetine(D) in period 3
89445353|NCT02485028|Experimental|D→M→D+M|Dapoxetine(D) in period 1, Mirodenafil(M) in period 2, Dapoxetine+Mirodenafil(D+M) in period 3
89445354|NCT02485028|Experimental|D+M→M→D|Dapoxetine+Mirodenafil(D+M) in period 1, Mirodenafil(M) in period 2, Dapoxetine(D) in period 3
89445355|NCT02485028|Experimental|D+M→D→M|Dapoxetine+Mirodenafil(D+M) in period 1, Dapoxetine(D) in period 2, Mirodenafil(M) in period 3
89445356|NCT02485028|Experimental|D→D+M→M|Dapoxetine(D) in period 1, Dapoxetine+Mirodenafil(D+M) in period 2, Mirodenafil(M) in period 3
89445357|NCT02183571|Experimental|Glucophage® high dose|Part I: Treatment A + B
89445358|NCT02183571|Experimental|Glucophage® low dose|Part II: Treatment C+ D
89445359|NCT03318146|Experimental|EXP-LP punctum plug|EXP-LP is a novel and innovative drug delivery system aiming to improve patient compliance and outcomes. EXP-LP punctum plug, is a non-invasive insert that replaces eye drops and provides sustained therapy for glaucoma, dry eye and other major eye diseases. EXP-LP is a combination of an ophthalmic prostaglandin drug (Latanoprost). The prostaglandin drug works by increasing the natural outflow of fluid from inside the eye
89445360|NCT03318146|Active Comparator|XALATAN®|XALATAN® (latanoprost ophthalmic solution) is an eye drop used to treat high eye pressure/intraocular pressure in people with open-angle glaucoma or ocular hypertension. XALATAN is administrated once a day
89445361|NCT02183649|Experimental|pentoxyverine citrate vs. placebo|All subjects were allocated to receive both verum and placebo in randomised order
89445362|NCT03318068|Experimental|Yoga intervention arm|The group will receive a weekly yoga session for the duration of 10 weeks. The yoga sessions will be delivered in person for 3 weeks during the intervention, coordinated with existing clinic visits. The other 7 sessions will be delivered via skype. The participant will be asked to fill out questionnaires during each of the three in-person yoga visits asking about psychological symptoms and quality of life.
89445363|NCT02187315|Experimental|Melodie group|Induction chemotherapy followed by cisplatin chrono-chemotherapy concurrent combined with intensity-modulated radiation therapy
89445364|NCT02187315|Other|Routine-chemotherapy group|Induction chemotherapy followed by cisplatin routine-chemotherapy concurrent combined with intensity-modulated radiation therapy
89445365|NCT02489396||Grocery Customers|All customers who shop on the Rosie site during the intervention period.
89445366|NCT02489162|Experimental|MyotonPRO|Experimental: Measurement of biomechanical properties of mimic muscles on the ipsilateral palsy side with the healthy contralateral side ( case - control design)
89445367|NCT02489162|Active Comparator|Non-invasive electromyography (EMG)|Comparing experimental intervention with gold standard
89445368|NCT02256735|Experimental|Treatment A|
88930227|NCT01738620|No Intervention|standard care|patients will receive standard care
88930228|NCT01738633|Experimental|nutritional + respirology counseling|patients will receive both nutritional and respirology counseling
88930229|NCT01738633|Experimental|nutritional counseling|patients will receive nutritional counseling alone
88930230|NCT01738633|Experimental|respirology counseling|patients will receive respirology counseling alone
88930231|NCT01738633|No Intervention|standard care|patients will receive standard care
88930232|NCT01738659|Experimental|normal sodium diet (120 mmol/die)|active comparator: low sodium diet (80 mmol/die)
89445369|NCT02256735|Experimental|Treatment B|
88930233|NCT01738685|Other|Control.|Nutritional Education.
88930234|NCT01738685|Other|Behavioral Intervention|Behavioral Intervention.
88930235|NCT01738711|Active Comparator|Cognitive Behavioural Therapy|Patient in this arm receive 2-6 sessions of cognitive behavioural therapy
88930236|NCT01738711|Placebo Comparator|Written information on CBT|Patients in this arm do not receive sessions of CBT but receive written information on anxiety control as per standard practice
88930237|NCT01738724|Experimental|Dienogest|Dienogest 2mg pills daily during 6 months
88930238|NCT01738724|Experimental|Goserelin|Goserelin 10.8mg preloaded syringe subcutaneously at the start of the study and after 3 months
88930239|NCT01738724|Active Comparator|Desogestrel|Desogestrel 75mcg pills daily during six months
88930240|NCT01738763|Experimental|Low dose (2.5 g of pinitol)|Each subject completed two 1-day trials separated by a 1-week interval. The subjects were randomized by alternation method to belong to the group of low, intermediate or high dose, containing 2.5, 4.0 or 6.0 g of pinitol, respectively. Each subject was newly randomized (1:1) and cross-over into one of two groups: one that received the pinitol-enriched beverage, and the other a placebo beverage. In this way, each dose and its corresponding placebo were studied in 10 normoglycaemic subjects.
89013720|NCT06264635|Placebo Comparator|Saline|Provider will go through the same motions as injecting PRP, but will use saline instead which has no known effect.
89013721|NCT06262880|Placebo Comparator|Placebo treatment|Placebo treatment (Microcrystaline cellulose): 1 capsule/d
89445370|NCT02256735|Experimental|Treatment C|
89445371|NCT02256735|Experimental|Treatment D|
89445372|NCT02256735|Placebo Comparator|Placebo|
89445373|NCT02256735|Active Comparator|Moxifloxacin|
89445374|NCT02484794|Active Comparator|Treatment as Usual|Patients will receive standard outpatient treatment that consists of group psychotherapy, skills training, self-monitoring, nutritional counselling, and meal support.
89445375|NCT02484794|Experimental|Treatment with Smartphone App|Patients will receive the same standard outpatient treatment but will use the smartphone application instead of the paper food record. Patients in this group will receive daily feedback through the app, as opposed to weekly, but will still attend the weekly nutritional counselling group.
89445376|NCT02183805|Experimental|Metastatic triple negative breast cancer|Abraxane,Cyclophosphamide,Carboplatin
89445377|NCT03316352|Experimental|Ultrasound-assisted|Ultrasound-assisted paramedian technique spinal anesthesia will be performed. A Preprocedural ultrasound scan will be performed for skin marking of entry site of spinal needle. Spinal anesthesia will be performed via paramedian approach using the skin marking site as entry point. 0.5% heavy bupivacaine will be administered into intrathecal space.
89445378|NCT03316352|Active Comparator|Landmark-guided|In these patients, spinal anesthesia will be performed via paramedian approach using conventional landmark palpation technique. Landmark-guided paramedian technique spinal anesthesia will be performed. 0.5% heavy bupivacaine will be administered into intrathecal space.
89445379|NCT02187549|Experimental|HYMOVIS|HYADD(TM) 4 Hydrogel Intra-Articular Injection
89445380|NCT02187549|Placebo Comparator|Placebo|Saline Intra-Articular Injection
89445381|NCT02484560|Experimental|Ambulatory Patients|Ambulatory patients receiving stem cell therapy
88930241|NCT01738763|Experimental|Intermediate dose (4.0 g of pinitol)|Each subject completed two 1-day trials separated by a 1-week interval. The subjects were randomized by alternation method to belong to the group of low, intermediate or high dose, containing 2.5, 4.0 or 6.0 g of pinitol, respectively. Each subject was newly randomized (1:1) and cross-over into one of two groups: one that received the pinitol-enriched beverage, and the other a placebo beverage. In this way, each dose and its corresponding placebo were studied in 10 normoglycaemic subjects.
88930242|NCT01738763|Experimental|High dose (6.0 g of pinitol)|Each subject completed two 1-day trials separated by a 1-week interval. The subjects were randomized by alternation method to belong to the group of low, intermediate or high dose, containing 2.5, 4.0 or 6.0 g of pinitol, respectively. Each subject was newly randomized (1:1) and cross-over into one of two groups: one that received the pinitol-enriched beverage, and the other a placebo beverage. In this way, each dose and its corresponding placebo were studied in 10 normoglycaemic subjects.
88930243|NCT01738776||Cases|Hip fracture patients participating in a randomised controlled trial (RCT) of orthogeriatric care (ClinicalTrials.gov NCT01009268)
89445382|NCT02484560|Experimental|Non-Ambulatory Patients|non-ambulatory patients receiving stem cell therapy
89445383|NCT02030301|Experimental|VCL-HB01, 0.25-mL dose|VCL-HB01, 0.25-mL dose by intramuscular injection once every 28 days for 3 doses
89445384|NCT02030301|Placebo Comparator|PBS, 0.25-mL dose|PBS, 0.25-mL dose by intramuscular injection once every 28 days for 3 doses
89445385|NCT02030301|Experimental|VCL-HB01, 0.5-mL dose|VCL-HB01, 0.5-mL dose by intramuscular injection once every 28 days for 3 doses
89445386|NCT02030301|Placebo Comparator|PBS, 0.5-mL dose|PBS, 0.5-mL dose by intramuscular injection once every 28 days for 3 doses
89445387|NCT02030301|Experimental|VCL-HB01, 1-mL dose|VCL-HB01, 1-mL dose by intramuscular injection once every 28 days for 3 doses
89445388|NCT02030301|Experimental|VCL-HM01, 1-mL dose|VCL-HM01, 1-mL dose by intramuscular injection once every 28 days for 3 doses
89445389|NCT02030301|Placebo Comparator|PBS, 1-mL dose|PBS, 1-mL dose by intramuscular injection once every 28 days for 3 doses
89445390|NCT02484482|Experimental|Group 1|"CKD-519 200mg administration, subjects have a Fasting, Standard Meal, High Fat Meal by randomized group.~Fasting→Standard Meal→High Fat Meal"
89445391|NCT02484482|Experimental|Group 2|"CKD-519 200mg administration, subjects have a Fasting, Standard Meal, High Fat Meal by randomized group.~Standard Meal→High Fat Meal→Fasting"
89445392|NCT02484482|Experimental|Group 3|"CKD-519 200mg administration, subjects have a Fasting, Standard Meal, High Fat Meal by randomized group.~High Fat Meal→Fasting→Standard Meal"
89445393|NCT02484482|Experimental|Group 4|"CKD-519 200mg administration, subjects have a Fasting, Standard Meal, High Fat Meal by randomized group.~Fasting→High Fat Meal→Standard Meal"
89445394|NCT02484482|Experimental|Group 5|"CKD-519 200mg administration, subjects have a Fasting, Standard Meal, High Fat Meal by randomized group.~Standard Meal→Fasting→High Fat Meal"
89445395|NCT02484482|Experimental|Group 6|"CKD-519 200mg administration, subjects have a Fasting, Standard Meal, High Fat Meal by randomized group.~High Fat Meal→Standard Meal→Fasting"
89445396|NCT02187627|Experimental|Part 1: Tracer Selection|Participants will receive a single dose of one tracer on one occasion and a single dose of a different tracer after 7 to 14 days and will be followed for 7 to 14 days for safety. At the end of Part 1, one tracer with the best performance will be selected for further study in Part 2.
89445397|NCT02187627|Experimental|Part 2A: Test-Retest|Participants will receive a single dose of selected tracer from Part 1 on one occasion and then same tracer will be administered after 6 weeks. Participants will be followed for 7 to 14 days after last PET tracer administration for safety.
89445398|NCT02187627|Experimental|Part 2B: Dosimetry|Participants will receive a single dose of selected tracer from Part 1 and will be followed for 7 to 14 days for evaluation of radiation dosimetry.
89445399|NCT02484638|Experimental|CSL689 low-dose|"Part 1: single injection of low-dose CSL689 for PK evaluation~Part 2: up to 2 injections of low-dose CSL689 per bleeding event (bleeding events 1 to 3*)~Part 3: up to 3 injections of low-dose CSL689 per bleeding event * Note: All subjects in the low-dose arm will be treated with high-dose CSL689 for bleeding events 4-6 in Part 2"
89538467|NCT03265925||Healthy|Healthy controls
89538468|NCT03265769|Active Comparator|Transradial approach|target vessel revascularization via radial access site is labeled as transradial approach
88930244|NCT01738776||Controls|A group of voluntary elderly persons without a history of hip fracture, recruited specifically for this purpose
88930245|NCT01738802|Experimental|Anti-oxidant and micronutrient|This group will take the anti-oxidant and micronutrient supplement.
89445400|NCT02484638|Experimental|CSL689 high-dose|"Part 1: single injection of high-dose CSL689 for PK evaluation~Part 2: up to 2 injections of high-dose CSL689 per bleeding event (bleeding events 4 to 6*)~Part 3: up to 3 injections of high-dose CSL689 per bleeding event~Note: All subjects in the high-dose arm will be treated with low-dose CSL689 for bleeding events 1-3 in Part 2"
89445401|NCT02484638|Active Comparator|Eptacog alfa low-dose|Single injection of low-dose Eptacog alfa in Part 1 for PK evaluation
89445402|NCT02484638|Active Comparator|Eptacog alfa high-dose|Single injection of high-dose Eptacog alfa in Part 1 for PK evaluation
89445403|NCT02187705||Patients with normotension at baseline|
89445404|NCT02187705||Patients with essential hypertension at baseline|
89445405|NCT02187705||Patients with isolated hypertension at baseline|
89445406|NCT03317912|Active Comparator|Lidocaïne 2%|Bolus 0.075ml/kg/h, following by continuous infusion 0.1ml/kg/h during surgery and 0.066ml/kg/h during 24h
89445407|NCT03317912|Placebo Comparator|Placebo (for Lidocaïne)|Bolus 0.075ml/kg/h, following by continuous infusion 0.1ml/kg/h during surgery and 0.066ml/kg/h during 24h
89445408|NCT02183961|Experimental|Laryngopharyngeal reflux|EER was detected using three methods: oropharyngeal pH was monitored for 24 hours using the Restech system; detection of pepsin in middle ear fluid obtained during myringotomy was done using Peptest, and detection of pepsin in adenoid specimen was done immunohistochemically using antibody P3635Rb-h.
89445409|NCT03321110|Experimental|Placebo|Placebo
89445410|NCT03321110|Experimental|Q10-150|coenzyme Q10 150 mg/d.
89445411|NCT03321110|Experimental|Q10-300|coenzyme Q10 300 mg/d.
89445412|NCT02187939|Active Comparator|Summer wellness program - nutrition & physical activity|The GROOVE condition uses conventional means to address health-related activities and content within the context of a science museum summer enrichment program. The emphasis is on nutrition, physical activity, and healthy lifestyle.
89445413|NCT02187939|Experimental|Summer program plus virtual world technology|The GROOVE+ condition enhances the conventional approach to address health-related activities and content within the context of a science museum summer enrichment program by employing technology and a 3-D virtual world as a key educational strategy. The emphasis is on nutrition, physical activity, and healthy lifestyle.
89445414|NCT03317756|Experimental|Patient Variation 1|Patient Educational Intervention: Patient will receive intervention videos and will be required to complete the baseline and follow-up surveys.
89445415|NCT03317756|Experimental|Patient Variation 2|Patient Control: Patients will receive an attention control and will be required to complete the baseline and follow-up surveys.
89445416|NCT03321032|Experimental|Amphilimus-eluting stents|Polymer-free Amphilimus-eluting stents
88930246|NCT01738802|Placebo Comparator|Placebo|This group will take the placebo.
88930247|NCT01738815|Experimental|valproic acid|Patients will be administered valproic acid (Depakote ER) for up to 30 days prior to tumor resection
88930248|NCT01738828||Subjects with CAD|
88930249|NCT01738828||Subjects without CAD|
88930250|NCT01738841||Cohort Group|Children aged 12 months to 12 years will receive Priorix-Tetra as prescribed by the physician.
88930251|NCT01738854|Experimental|intra-cuff pressure 40 cmH2O|
88930252|NCT01738854|Active Comparator|intra-cuff pressure 60 cmH2O|
89445417|NCT03321032|Active Comparator|Zotarolimus-eluting stents|Biolinx Polymer-based zotarolimus-eluting stents
89445418|NCT04335279|Experimental|SPIN-CHAT: Videoconference Intervention|Participants in the SPIN-CHAT videoconference intervention group will receive a brief group videoconference intervention aimed at the management of worry and anxiety 3 times per week for 4 weeks during the COVID-19 crisis. Each group will include 8 participants and sessions will be approximately 60- to 90-minutes each. Each intervention group will be moderated by a member of the research team or by leaders who have been trained in our SPIN support group leader training program.
89445419|NCT04335279|No Intervention|Wait-list Control|Participants in the wait-list control group will not receive the training program and will have no access to the resources indicated above for the duration of the trial. Wait-list controls will be given access to the program post-trial.
89445420|NCT03320954|Experimental|Anomia treatment|Phase 2 portion of the research during which participants with acquired brain injury will perform intervention activities.
89445421|NCT02488850|Active Comparator|Surgery|An anatomical surgical resection of primary tumor
89445422|NCT02488850|Active Comparator|Radiotherapy|Stereotactic Ablative Radiotherapy (SABR), outpatient treatment that is typically delivered in between 3-8 fractions
89445423|NCT02188017|Active Comparator|80 units|80 units ACTHAR gel will be given twice a week for 22 weeks after initial loading
89445424|NCT02188017|Active Comparator|40 units|40 units of ACTHAR gel will be given twice a week for 22 weeks after loading
89445425|NCT03317600|Active Comparator|Lidocaine block|
89445426|NCT03317600|Placebo Comparator|Isotonic saline block|
89445427|NCT02184117||All patients|Entire cohort undergoes paired testing
89445428|NCT02486354|Experimental|icotinib|Patients were administered with oral icotinib (tablet form, 125 mg) three times daily within two days after enrollment until disease progression or unacceptable toxicity.
89445429|NCT02184273|Experimental|Magnesium metamizol|
89445430|NCT02184273|Placebo Comparator|Placebo|
89538469|NCT03265769|Active Comparator|Transfemoral approach|target vessel revascularization via femoral access site is labeled as transfemoral approach
89538470|NCT02458781|Placebo Comparator|Placebo|"Placebo capsule:~To be provided by BAMC Pharmacy. It will be made and stored by BAMC pharmacy. The matching placebo will be a gelatin capsule filled with methylcellulose powder only. Patient will take 2 capsules two times a day for 14 days."
88930253|NCT01738854|Active Comparator|intra-cuff pressure 80 cmH2O|
88930254|NCT01738867|Placebo Comparator|Treatment A|Subject will receive oral dose of matching placebo once daily for 5 days in one of the 3 treatment periods.
88930255|NCT01738867|Experimental|Treatment B|Subject will receive 25 mg orally once daily for the first two days and 50 mg once daily for 3 days in one of the 3 treatment periods.
88930256|NCT01738867|Experimental|Treatment C|Subject will receive 10 mg orally once daily for 5 days in one of the 3 treatment periods.
88930257|NCT01738880|Active Comparator|group C|intraoperative fluid management based on CVP
88930258|NCT01738880|Experimental|group S|intraoperative fluid management based on SVV
89013722|NCT06262880|Active Comparator|Active low dose of plant derived phenolics|Active low dose of plant derived phenolics via 1 capsule/d
89013723|NCT06262880|Active Comparator|Active high dose of plant derived phenolics|Active high dose of plant derived phenolics via 1 capsule/d
89013724|NCT06262269|Experimental|TELE-APA|The TELE-APA group will benefit from an individual, specific HIIT type program, adapted to the scoliosis of each patient, by tele-rehabilitation, supervised by a teacher in adapted physical activities during 12 weeks. Then he will benefit from an adapted physical activity program at home, based on a booklet of specific exercises identical to that of the CONTROL group, of HIIT type, adapted to the scoliosis of adapted to the scoliosis of each patient for 12 weeks.
89013725|NCT06262269|Active Comparator|CONTROL|The CONTROL group will benefit from an adapted physical activity program at home, based on a booklet of specific HIIT-type exercises, adapted to the scoliosis of each patient for 2 times 12 weeks. A new exercise booklet is given at the end of the first 12 weeks.
89013726|NCT06261645|Experimental|Early start|"According to result from the random allocation patients in Early Start will initiate their treatment within two weeks following the Baseline assessment.The intervention consists of a 16 week exercise program with specific exercises to restore total rotator cuff function individually selected during clinical physiotherapy visits and performed 2 - 4 times daily.~According to progression, a mean of 10 visits are anticipated over the 16 weeks In addition, the patient will receive education and guidance in the daily use of the arm to adjust to appropriate load on the shoulder."
89013727|NCT06261645|Experimental|Delayed start|"According to result from the random allocation patients in Delayed Start will delay the start of their treatment with 16 weeks.~Participants in Delayed Start will undergo the same Baseline assessment a second time, and initiate their treatment within 2 weeks thereafter. The intervention consists of a 16 week exercise program with specific exercises to restore total rotator cuff function individually selected during clinical physiotherapy visits and performed 2 - 4 times daily.~According to progression, a mean of 10 visits are anticipated over the 16 weeks In addition, the patient will receive education and guidance in the daily use of the arm to adjust to appropriate load on the shoulder."
89013729|NCT06253221|Experimental|Mavacamten|Participants assigned to this arm will receive mavacamten from day 1 to end of treatment at week 56.
89013730|NCT06253221|Experimental|Placebo|Participants assigned to this arm will receive mavacamten from week 28 to end of treatment at week 56.
89013731|NCT06251401|Experimental|In-person cardiac rehabilitation|Those randomized to in-person cardiac rehabilitation group
89013732|NCT06251401|Experimental|Virtual cardiac rehabilitation|Those randomized to the virtual, home-based rehabilitation group
89013733|NCT06251167|Experimental|Lateral wedge insoles (LWIs)|The LWIs will incorporate a 6 degree wedge along the lateral edge of the insole.
89013734|NCT06251167|Experimental|Lateral wedge plus custom arch support (LWAS)|The LWAS insoles will incorporate custom arch support along the medial edge as well as a 6 degree wedge along the lateral edge of the insole.
89013735|NCT06251063|Experimental|Web-based psychoeducational Resource|Eligible families will be provided with website access instructions. Parents and children will be instructed to review the materials separately. The intervention will provide each person with individualized action items to be discussed as a family. It is anticipated that reviewing all of the psychoeducational materials will take the parent/child approximately one hour, resulting in a total intervention burden of two hours for the family. Participants will be encouraged to return to the website as often as needed to review content. For the purposes of this project, they will be instructed to review all intervention materials within one month of receiving the website access instructions.
89013736|NCT06250478|Experimental|Stroke patient|
89013737|NCT06250478|Active Comparator|Healthy controls|
89013738|NCT06250452|Experimental|experimental group|"Personal Information Form, SPO2 measurement and Asthma Symptom and Treatment Need Scoring / Daily Follow-up Form will be applied to the children in the experimental group before they are taken to the salt therapy room."
89013739|NCT06250452|Experimental|Control Group|The same procedure will be applied to the children in the control group. In the study planned to be carried out for 6 weeks, it is recommended that children repeat the session for 10 minutes daily, the first 5 sessions every day and the other 5 weeks once a week.
89445431|NCT03317522||Belfast HAPO|"All pregnant women who attended the Royal Victoria Maternity Hospital, Belfast were eligible to participate unless they met one or more exclusion criteria.~All eligible women from the Belfast centre were invited to take part in a prospective observational study involving an additional fasting serum sample for lipids at 28 weeks gestation and long term follow up of their HAPO offspring. Only those women who had remained blinded to oral glucose tolerance test (OGTT) results during pregnancy were included (fasting plasma glucose ≤5·8 mmol/L and 2-hour glucose ≤11·1 mmol/L). Offspring from these pregnancies had anthropometric measurements performed within 72 hours of birth and at age 5-7 years."
89013740|NCT06249425|Experimental|The experimental group|The patients are randomly assigned to either the experimental group or the placebo group. All patients receive routine rehabilitation therapy and swallowing rehabilitation training, along with enteral nutrition support using Intermittent Oro-esophageal Tube. In addition to these interventions, patients in the experimental group receive transcranial direct current stimulation, while the instruments used for patients in the placebo group only illuminate an indicator light without any actual effect.
89445432|NCT02486198|Placebo Comparator|placebo+oxaliplatin-based chemotherapy|equal saline as placebo, one hour before chemotherapy (if with chemotherapy) with oxaliplatin-based chemotherapy (every 2 or 3 weeks), or daily use until neurotoxicity progress.
89445433|NCT02486198|Experimental|GM+oxaliplatin-based chemotherapy|monosialotetrahexosylganglioside Sodium Injection, 40mg or 60mg, one hour before chemotherapy (if with chemotherapy) with oxaliplatin-based chemotherapy (every 2 or 3 weeks), or daily use until neurotoxicity progress.
89445434|NCT03536013|Experimental|Treatment|91 patients will undergo a typical lumbar microdiscectomy with the addition of a full-thickness placental allograft after the microdiscectomy has been performed.
89445435|NCT03536013|No Intervention|Control|91 patients will undergo a typical lumbar microdiscectomy without the addition of a full-thickness placental allograft.
89445436|NCT03316040|No Intervention|Control 1|This arm represent control schools. No JIC will be implemented.
89445437|NCT03316040|Experimental|Treatment 1|This arm implements the JIC among a random subset of students within the pre-defined grade.
89013741|NCT06249425|Placebo Comparator|The placebo group|The patients are randomly assigned to either the experimental group or the placebo group. All patients receive routine rehabilitation therapy and swallowing rehabilitation training, along with enteral nutrition support using Intermittent Oro-esophageal Tube. In addition to these interventions, patients in the experimental group receive transcranial direct current stimulation, while the instruments used for patients in the placebo group only illuminate an indicator light without any actual effect.
89013742|NCT06247644|Experimental|Arm 1 - On-body Injector (OBI) - only|Adhesion of device with adhesive on left or right upper arm
89013743|NCT06247644|Experimental|Arm 2 - OBI + additional adhesive ring|Adhesion of device with adhesive on left or right upper arm + additional adhesive ring to be placed additional on the skin.
89013744|NCT06243731||All Participants With Kidney Failure|Participants aged 18 years or older treated with maribavir for a refractory CMV infection and who have comorbid ESRD or severe chronic renal disease requiring peritoneal dialysis or hemodialysis will be assessed from index date (Day 0: the day of initiation of the first maribavir treatment course during the eligibility period) until, end of treatment (treatment completion, discontinuation, or addition of another antiviral regimen for CMV) +7 days post-treatment, death, or end of data availability whichever occurs earliest.
89445438|NCT03316040|Experimental|Treatment 2|This arm implements the JIC among indegree central students within the pre-defined grade.
89445439|NCT03316040|Experimental|Treatment 3|This arm implements the JIC among edge betweeness central students within the pre-defined grade.
89013745|NCT06241872|Experimental|Dry needling group (study group)|For patients in this group, dry needling will be performed once a week for three weeks on trigger points described as pain points in the Copeman nodule, gluteus medius, gluteus maximus, and iliotibial band muscles, guided by ultrasound. Patients will be instructed to perform daily stretching exercises outlined in the home program and mark their daily use of paracetamol on the provided schedule if needed. They will refrain from using NSAIDs or steroids during this period.
89013746|NCT06241872|Sham Comparator|Sham dry needling group (control group)|For the patients in this group, dry needling will be performed once a week for three weeks on trigger points described as pain points in the Copeman nodule, gluteus medius, gluteus maximus, and iliotibial band muscles, guided by ultrasound. However, the needles will not penetrate beyond the subcutaneous fatty tissue. Patients will be instructed to perform daily stretching exercises outlined in the home program and mark their daily use of paracetamol on the provided schedule if needed. They will refrain from using NSAIDs or steroids during this period.
89013747|NCT06239467|Experimental|Phase 1a: Part A Dose Escalation|OKI-219 Monotherapy Dose Escalation in participants with advanced solid tumors with the PI3Kα1047R mutation
89013748|NCT06239467|Experimental|Phase 1b: Part B Dose Escalation|OKI-219 + Fulvestrant Dose Escalation in participants with HR+/HER2- locally advanced, unresectable or metastatic breast cancer with the PI3KαH1047R mutation
89013749|NCT06239467|Experimental|Phase 1b: Part B Dose Optimization|OKI-219 + Fulvestrant Dose Optimization in participants with HR+/HER2- locally advanced, unresectable or metastatic breast cancer with the PI3KαH1047R mutation
89013750|NCT06239467|Experimental|Phase 1b: Part C Dose Escalation|OKI-219 + Trastuzumab Dose Escalation in participants with HR±/HER2+ locally advanced, unresectable or metastatic breast cancer with the PI3KαH1047R mutation
89013751|NCT06239467|Experimental|Phase 1b: Part C Dose Optimization|OKI-219 + Trastuzumab Dose Optimization in participants with HR±/HER2+ locally advanced, unresectable or metastatic breast cancer with the PI3KαH1047R mutation
89013752|NCT06238323|Experimental|All participants|Participants will be young sexual minority men (YSMM) and providers from healthcare institutions working with YSMM.
89013753|NCT06237296|Experimental|RSV/hMPV mRNA / LNP 1 Group 1|Participants will be randomized to receive a single IM injection of RSV/hMPV mRNA / LNP vaccine 1 dose 1.
89013754|NCT06237296|Experimental|RSV/hMPV mRNA / LNP 1 Group 2|Participants will be randomized to receive a single IM injection of RSV/hMPV mRNA / LNP vaccine 1 dose 2.
89013755|NCT06237296|Experimental|RSV/hMPV mRNA / LNP 1 Group 3|Participants will be randomized to receive a single IM injection of RSV/hMPV mRNA / LNP vaccine 1 dose 3.
89013756|NCT06237296|Experimental|RSV/hMPV mRNA / LNP 2 Group 4|Participants will be randomized to receive a single IM injection of RSV/hMPV mRNA / LNP vaccine 2 dose 1.
89013757|NCT06237296|Experimental|RSV mRNA / LNP 1 Group 5|Participants will be randomized to receive a single IM injection of RSV mRNA / LNP vaccine 1 dose 1.
89013758|NCT06237296|Experimental|hMPV mRNA / LNP 1 Group 6|Participants will be randomized to receive a single IM injection of hMPV mRNA / LNP vaccine 1 dose 1.
89445440|NCT02188173||dexamethasone 700 ㎍ intravitreal implant|Patients who receive dexamethasone 700 ㎍ (OZURDEX®) intravitreal implant treatment for Diabetic Macular Edema. All decisions regarding treatment are made at the sole discretion of the treating physician in accordance with their usual practices.
89445441|NCT03535935|Active Comparator|Standard medical care|Angiotensin converting enzyme inhibitor or angiotensin receptor blocker and oral hypoglycemic agents or insulin
89445442|NCT03535935|Experimental|Add on astragalus powder|3 grams of water soluble astragalus sachets (equivalent to 15g raw herbs) administrated orally on top of standard medical care for 48 weeks.
89013759|NCT06237296|Experimental|RSV/hMPV mRNA / LNP 1 Group 7|Participants will be randomized to receive a single IM injection of RSV/hMPV mRNA / LNP vaccine 1 dose 4.
89013760|NCT06237101|Experimental|High dose|Propofol concentration which generate burst suppression at high dose of remifentanil
89013761|NCT06237101|Active Comparator|Medium dose|Propofol concentration which generate burst suppression at medium dose of remifentanil
89013762|NCT06236763||Observation and control|Two accelerometers will be applied on each patient; observation (foot) and control (hand, also the gold standard). Agreement values will be compared between these two monitors.
89013763|NCT06232408|Experimental|RP-1664|
89445443|NCT03315884|Experimental|Iliac segment recanalization and stenting Iliac segment CFA|Iliac segment recanalization and stenting Iliac segment Common Femoral Artery (CFA)
89445444|NCT03315884|Active Comparator|Iliac segment recanalization, stenting and plastic CFA patch|Iliac segment recanalization, stenting and plastic Common Femoral Artery (CFA) patch
89445445|NCT02184351|Experimental|Roxanes's clotrimazole troches|
89445446|NCT02184351|Active Comparator|Mycelex® troches|
89445447|NCT02188251|Experimental|Activamp|Capsules containing 225mg of Activamp (Gynostemma pentaphyllum extract), 1 capsule taken twice daily for 12 weeks
89538471|NCT02458781|Active Comparator|Ciprofloxacin|"Ciprofloxacin 250mg capsule:~To be provided by BAMC pharmacy. It will be made and stored by BAMC Pharmacy. Ciprofloxacin 250mg tablet will be encapsulated with a gelatin capsule filled with methylcellulose. Patient will take 2 capsules of Ciprofloxacin 250mg two times a day for 14 days."
88930259|NCT01738893|Experimental|A (test)/ B (reference)|initial administration of test and cross-over to reference
88930260|NCT01738893|Experimental|B (reference/ A (test)|initial administration of reference and cross-over to test
88930261|NCT01738906|Experimental|Alcohol placebo and MSF|175 mL orange juice with 31 g Fantomalt maltodextrin and modified sham feeding of 40 g butter cake
88930262|NCT01738906|Experimental|Alcohol and MSF|65 mL vodka with 135 mL orange juice (ca 20 g alcohol)and modified sham feeding of 40 g butter cake
88930263|NCT01738906|Experimental|Alcohol placebo and consumption|175 mL orange juice with 31 g maltodextrin and consumption of 40 g butter cake
88930264|NCT01738906|Experimental|Alcohol and consumption|65 mL vodka with 135 mL orange juice and consumption of 40 g butter cake
88930265|NCT01738906|Experimental|Alcohol placebo and control|175 mL orange juice with 31 g maltodextrin and no oral exposure to butter cake
88930266|NCT01738906|Experimental|Alcohol and control|65 mL vodka with 135 mL orange juice and no oral exposure to butter cake
88930267|NCT01738932||Patients|women with histologically verified endometriosis
88930268|NCT01738932||Controls|Healthy Danish blood donors
88930269|NCT01738945|Other|Amlodipine|Amlodipine 10 mg/day for 12 weeks
88930270|NCT01738958|Active Comparator|Probiotic lactobacilli|L. reuteri, two times a day for 6 weeks
88930271|NCT01738958|Placebo Comparator|Placebo|Placebo tablets, two times a day for 6 weeks
88930272|NCT01738997|Experimental|Group A|Dilation 10 sec
88930273|NCT01738997|Active Comparator|Group B|Dilation 2 min
88930274|NCT01739023|Experimental|Autologous Human Schwann Cells|
88930275|NCT01739036|Active Comparator|Group 4|Unvaccinated control volunteers who undergo controlled human malaria infection.
88930276|NCT01739036|Active Comparator|Group 3|Controlled human malaria infection administered at an interval of approximately 8-12 months after the initial controlled human malaria infection that the volunteers received in the VAC045 clinical trial.
88930277|NCT01739036|Active Comparator|Group 2|Intramuscular administration of a mixture of ChAd63 ME-TRAP 5 x 1010 vp and ChAd63 CS 5 x 1010 vp and ChAd63 AMA1 5 x 1010 vp followed by intramuscular administration of a mixture of MVA ME-TRAP 1.33 x 108 pfu and MVA CS 1.33 x 108 pfu and MVA AMA1 1.33 x 108 pfu eight weeks later, followed by controlled human malaria infection 17-24 days later.
88930278|NCT01739036|Active Comparator|Group 1|Intramuscular administration of a mixture of ChAd63 ME-TRAP 5 x 1010 vp and ChAd63 CS 5 x 1010 vp, followed by intramuscular administration of a mixture of MVA ME-TRAP 2 x 108 pfu and MVA CS 2 x 108 pfu eight weeks later, followed by controlled human malaria infection 17-24 days later.
88930279|NCT01739049|Experimental|Liraglutide and lifestyle counselling|"Liraglutide 0.6mg od for 1st week, then 1.2mg od for 2nd week then 1.8mg od until 12 weeks.~Diet and Exercise"
88930280|NCT01739049|Active Comparator|Lifestyle counselling|Diet and Exercise
88930281|NCT01739088|Experimental|Remote ischemic preconditioning stimulus|The remote ischemic pre-conditioning arm of the study is the experimental one. Patients in this arm will receive a remote ischemic pre-conditioning stimulus at 24-48 hours pre-operatively, and again intra-operatively before CPB.
88930282|NCT01739088|Sham Comparator|Sham Ischemic Pre-conditioning|In the control (sham-RIPC) group the cuff will be placed just underneath the upper thigh and the cuff will be inflated for 5 minutes, followed by 5 minutes of cuff deflation, done sequentially for two cycles on each side. In the operating room, after induction of anesthesia, the exact same procedure will be performed in the the control group.
88930283|NCT01739101|Experimental|Intervention group|The intervention group answered a baseline questionnaire in the waiting room and received the intervention (Reproductive Life Plan) in addition to standard care.
88930284|NCT01739101|No Intervention|Control group 1|The control group 1 answered a baseline questionnaire in the waiting room and received standard care.
88930285|NCT01739101|No Intervention|Control group 2|The control group 2 received standard care.
88930286|NCT01739114|Experimental|"SI group"|"Infants randomized into the SI group will receive two initial sustained inflations with a PIP of 20 cm H2O.~After the two initial SIs infants will receive PEEP of 5 cm H2O and then CPAP if breathing spontaneously or, if found to have apnea or laboured breathing, mask IPPV with a PIP of 20 cm H2O and PEEP of 5 cm H2O at a rate of 40 to 60 bpm until spontaneously breathing, at which time CPAP will be provided."
88930287|NCT01739114|Active Comparator|IPPV group|"Infants randomized into the IPPV group will receive mask IPPV with an initial PIP of 20 cmH2O and PEEP of 5 cm H2O, and a ventilation rate of 40-60 inflations/min until spontaneously breathing, at which time CPAP will be provided."
88930288|NCT01739127||Aripiprazole|Participants receiving treatment with at least 10mg aripiprazole per day, as prescribed to them by their psychiatrists.
88930289|NCT01739127||Risperidone/Quetiapine|Participants receiving treatment with either risperidone or quetiapine, as prescribed to them by their psychiatrists.
88930290|NCT01739127||Control|Healthy participants who are not taking any antipsychotic medications.
88930291|NCT01739140|Experimental|Yoga|Study Participants will receive: 12 weekly yoga classes, a book and a home practice audio recording.
89445448|NCT02188251|Placebo Comparator|Placebo|1 capsule taken twice daily for 12 weeks
89445449|NCT03320798||"group Bullous pemphigoid"|Patients consulting at dermatology department of Reims Teaching Hospital for bullous pemphigoid between 1997 and 2011.
89445450|NCT02184429|Experimental|Single Ascending Dose-1|Single ascending doses of PF-06669571 administered to healthy volunteers in a cross over study design
89445451|NCT02184429|Experimental|Single Ascending Dose-2|Single ascending doses of PF-06669571 administered to healthy volunteers in a cross over study design
89445452|NCT02184429|Experimental|Multiple Ascending Dose-1|Daily dose of PF-06669571 in healthy volunteers
89445453|NCT02184429|Experimental|Multiple Ascending Dose-2|Daily dose of PF-06669571 in healthy volunteers
89445454|NCT02184429|Experimental|Multiple Ascending Dose-3|Daily dose of PF-06669571 in healthy volunteers
89445455|NCT02184429|Experimental|Multiple Ascending Dose-4|Daily dose of PF-06669571 in healthy volunteers
89445456|NCT02184429|Experimental|Multiple Ascending Dose-5|Daily dose of PF-06669571 in healthy volunteers
89445457|NCT03315806|Active Comparator|Beetroot Juice|Beetroot juice containing 9 mmol of nitrate per dose
89445458|NCT03315806|Placebo Comparator|Placebo juice (nitrate depleted)|Beetroot juice nitrate-depleted
89445459|NCT02030379|Experimental|Online QPL-CT to Oncologist|Use the online QPL-CT to prioritize their questions and the prioritized list will be conveyed to their oncologist
89445460|NCT02030379|Experimental|Online QPL-CT|Use the online QPL-CT to prioritize their questions.
89445461|NCT02030379|Experimental|Pencil and Paper QPL-CT|Use pencil and paper QPL-CT to prioritize their questions
89445462|NCT03320720|Experimental|Home Treatment|Patients with acute mental illness are treated at their houses by a mobile and multiprofessional care team instead of being treated as inpatients if their medical condition permits.
89445463|NCT03320720|Active Comparator|Treatment-as-usual|Patients with acute mental illness are treated as inpatients in a psychiatric clinic.
89445464|NCT02484170|Active Comparator|mannitol in vehicle cream /vehicle cream|one week on the mannitol cream (mannitol 30% in vehicle cream), a 3 day washout period, and one week on the placebo cream (vehicle cream alone). To be applied over the painful area as needed for pain. Usual frequency is 2 to 3 times daily.
89445465|NCT02484170|Active Comparator|vehicle cream /mannitol in vehicle cream|one week on the placebo cream (vehicle cream alone), a 3 day washout period, and one week on the mannitol cream (mannitol 30% in vehicle cream).To be applied over the painful area as needed for pain. Usual frequency is unknown.
89445466|NCT02188407|Experimental|Sevoflurane|Sevoflurane group (S group)- The group anaesthesied with sevoflurane
89445467|NCT02188407|Active Comparator|Propofol|Propofol 4-6 mg/kg/h iv
89445468|NCT02188563|Experimental|Comprehensive intervention|New evidence-based comprehensive smoking cessation intervention including several elements that have proven successful in non-cancer patients but not used for cancer patients before.
89445469|NCT02188563|Active Comparator|Enhanced usual care|Intervention consistent with the U.S. Department of Health and Human Services guidelines for tobacco treatment.
89445470|NCT02184507|Experimental|Supplement pre CABG|Consumption of the supplement 7 days before surgery and placebo 30 days post surgery
89445471|NCT02184507|Experimental|Supplement post CABG|Consumption of placebo 7 days before surgery and supplement 30 days post surgery
89445472|NCT02184507|Experimental|Supplement pre and post CABG|Consumption of the supplement 7 days before and 30 days post surgery
89445473|NCT02184507|Placebo Comparator|Placebo|Consumption of placebo 7 days before and 30 days post surgery
89445474|NCT03317210|Other|iron therapy with good response|Patients with an Hb level between 9.0 and 9.9 g/dl received 200 mg iron sucrose intravenously twice weekly. The maximum total iron dose was 1,600 mg, therefore therapy was stopped if the maximal iron sucrose dose was administered, or target Hb > 10.5 g/dL was achieved.
89445475|NCT03317210|Other|iron therapy with poor response|Patients with an Hb level between 9.0 and 9.9 g/dl received 200 mg iron sucrose intravenously twice weekly. If response to therapy with iron sucrose was poor (i.e. Hb increase <0.7 g/dl after 2 weeks), patients additionally received recombinant human erythropoietin (10,000 U EPREX®, Janssen-Cilag, Baar, Switzerland).
89445476|NCT03317210|Other|iron therapy and erythropoietin|Patients with an Hb between 8.0 and 8.9 g/dl received 200mg iron sucrose and recombinant human erythropoietin intravenously twice weekly.
89445477|NCT02184585|Experimental|Cohort 1: Fasted state|Treatment will be administered orally to 42 subjects in the fasted state. Subjects will be required to fast overnight (minimum 10 hours) and for a minimum of 4 hours after each dose. Subjects will participate in 3 treatment periods and assigned to one of six treatment sequences (ABC, ACB, BAC, BCA, CAB, CBA) in accordance with the randomization schedule generated by Clinical Statistics. The three treatment periods will be separated by a minimum washout period of 28 days
89445478|NCT02184585|Experimental|Cohort 2 : Fed state|Treatment will be administered orally to 42 subjects in the fed state (high fat breakfast). Dosing will take place within 30 minutes of the start of the meal. Subjects will participate in 3 treatment periods and assigned to one of six treatment sequences (ABC, ACB, BAC, BCA, CAB, CBA) in accordance with the randomization schedule generated by Clinical Statistics. The three treatment periods will be separated by a minimum washout period of 28 days
89445479|NCT03317132|Experimental|Individual Placement and Support|One year of IPS Support
89445480|NCT03317132|No Intervention|Treatment as usual|Treatment as usual
89445481|NCT02188641|Other|Diet|Low-fat diet
89445482|NCT02188641|Other|Exercise|3-day/week exercise programme
89445483|NCT02188641|Other|Diet and exercise|healthy low fat diet and 3day/week exercise programme
89445484|NCT02188641|Other|Healthy lifestyle (Control) group|Control group was provided with health education using videotaped presentation
89445485|NCT02488772|Experimental|Treatment Group|Patients allocated to treatment group will be supplied with sleep interventions (sleep mask and ear plugs), and standardized instructions of use.
89445486|NCT02488772|Active Comparator|Control Group|Patients allocated to control group will be assessed for sleep quality, but not offered sleep mask and ear plugs. They will receive standard of care as decided by treating emergency physician.
89445487|NCT02188797|Experimental|Group MI risk reduction program|Participants receive four 1-hour group motivational interviewing sessions focused on reducing substance use and sexual risk behavior. They also receive an HIV information brochure and Community Resource Guide.
89445488|NCT02188797|No Intervention|Usual care control|Participant receive HIV information brochure and Community Resource Guide.
89445489|NCT02483780|Experimental|Storytelling intervention|"Two communes will be assigned to intervention group. Within each commune, 25 adults with HTN will be enrolled.~Patients will receive 2 DVDs with stories of patients who have successfully controlled their hypertension and Learn More section, which will be coordinated with specific patient stories and will fill in gaps not covered by the storytellers."
89445490|NCT02483780|No Intervention|Usual care|"Two communes will be assigned to usual care group. Within each commune, 25 adults with HTN will be enrolled.~Patients will receive 2 DVDs with only didactic material about common non-communicable diseases but without hypertension related stories."
89445491|NCT03536403|Experimental|healthy volunteers|EOS X-rays is done with et without a kyphosis induced corset and 8-meters walk test measured by optoelectronic Vicon system with et without a kyphosis induced corset
89445492|NCT02488694|Experimental|Arm A: Afatinib|105 patients to be treated with afatinib
89445493|NCT02488694|Active Comparator|Arm B: Pemetrexed|105 patients to be treated with pemetrexed
89445494|NCT02188875|Experimental|SMS Text Messages & Fitbit One|All study participants were provided a Fitbit One to facilitate self-monitoring of PA. Those who were randomly assigned to the intervention group were asked to indicate 3 preferred times of the day to receive text message prompts to do PA throughout the 6-week study period.
89445495|NCT02188875|Active Comparator|Fitbit One Only|An active control group was also provided the Fitbit One to facilitate self-monitoring of PA throughout the 6-week study period.
89445496|NCT02480192|Experimental|Experimental Group (CBT-Meno)|After an initial assessment, the experimental group received 12 weekly sessions (2 hours each) of group-based cognitive-behavioural therapy for menopausal symptoms (CBT-Meno) (up to n=8 per group). Symptoms that were targeted included vasomotor symptoms (hot flashes/night sweats), depressive symptoms, anxiety, poor sleep, and sexual concerns. Participants were re-assessed at 12-weeks post-baseline and at 3 months post-treatment.
89445497|NCT02480192|No Intervention|Waitlist|After an initial assessment, the waitlist comparison group did not receive any treatment for 12 weeks. They were then re-assessed at 12-weeks post-baseline and this data was used to compare this group to the experimental group to determine the effectiveness of the CBT-Meno treatment. After this re-assessment participants in the waitlist condition were offered the same CBT-Meno treatment as the experimental group: 12 weekly sessions (2 hours long) of cognitive-behavioural therapy for menopausal symptoms.
89445498|NCT02483858|Experimental|PQR309|Different dose Evaluation (continous and intermittent) 20-160mg daily
89445499|NCT03316898|Placebo Comparator|Placebo|Two placebo capsules once daily for 28 Days. All participants are on a stable dose of 10 mg donepezil and, if receiving memantine, also on a stable dose of memantine as prescribed by the physician as per standard of care.
89445500|NCT03316898|Experimental|AGN-242071 5 mg|One AGN-242071 5 mg capsule plus one placebo capsule once daily for 28 days. All participants are on a stable dose of 10 mg donepezil and, if receiving memantine, also on a stable dose of memantine as prescribed by the physician as per standard of care.
89445501|NCT03316898|Experimental|AGN-242071 15 mg|AGN-242071 starting at a dose of one 5 mg capsule plus one placebo capsule once daily for 5 days followed by AGN-242071 15 mg total dose (one 5 mg and one 10 mg capsules) once daily on Days 6 to 28. Dose can be adjusted based on safety and tolerability. All participants are on a stable dose of 10 mg donepezil and, if receiving memantine, also on a stable dose of memantine as prescribed by the physician as per standard of care.
89445502|NCT03316898|Experimental|AGN-242071 25 mg|AGN-242071 starting at a dose of one 5 mg capsule plus one placebo capsule once daily for 5 days followed by AGN-24071 15 mg total dose (one 5 mg and one 10 mg capsules) once daily on Days 6 to 10 followed by AGN-242071 25 mg total dose (one 5 mg and one 20 mg capsules) on Days 11 to 28. Dose can be adjusted based on safety and tolerability. All participants are on a stable dose of 10 mg donepezil and, if receiving memantine, also on a stable dose of memantine as prescribed by the physician as per standard of care.
89445503|NCT02188953|Experimental|ACCS100|Participants will consume 1 gram of ACCS100 at each meal (up to three times per day) for seven days. The ACCS100 will be administered by mixing a powder sachet into water.
89445504|NCT02188953|Placebo Comparator|Calcium carbonate|Participants will consume 1 gram of calcium carbonate at each meal (up to three times per day) for seven days. The calcium carbonate will be administered by mixing a powder sachet into water.
89445505|NCT02030613|Other|Single arm: etanercept|Patients treated with etanercept for JIA
89445506|NCT03316820|Experimental|Treatment A|K0706 tablet
89445507|NCT03316820|Experimental|Treatment B|K0706 tablet
89445508|NCT03316820|Experimental|Treatment C|K0706 tablet
89445509|NCT03316820|Experimental|Treatment D|K0706 capsule
88930292|NCT01739153|Experimental|CARB diet|The CARB diet will be a low-fat diet where cheese is replaced by starchy carbohydrates and lean meat. The CARB diet will have the same protein content (15 E%) and quality as the CHEESE and MEAT diet but a lower fat content (approx. 25 E%) and a correspondingly higher carbohydrate content (approx. 60 E%).
89445510|NCT02483702|Experimental|Patients under 4 months Receive Irradiated Blood|Patients under 4 months of age will receive irradiated blood products, as per hospital protocol. The patient's extracellular potassium levels will be recorded pre-transfusion, at 30 minute intervals during the transfusion, and post-transfusion. The collected data will be compared to test for correlation between extracellular potassium levels, the type of blood transfused, and the amount of calcium that is administered.
89538472|NCT02458781|Active Comparator|Metronidazole|"Metronidazole 250mg capsule:~To be provided by BAMC pharmacy. It will be made and stored by BAMC Pharmacy. Metronidazole 250mg will be encapsulated with a gelatin capsule filled with methylcellulose. Patient will take 2 capsules of metronidazole 250mg two times a day for 14 days."
89445511|NCT02483702|Experimental|Patients Over 4 Months Recieve Non-Irradiated Blood|Patients over 4 months of age will receive non-irradiated blood products. The patient's extracellular potassium levels will be recorded pre-transfusion, at 30 minute intervals during the transfusion, and post-transfusion. The collected data will be compared to test for correlation between extracellular potassium levels, the type of blood transfused, and the amount of calcium that is administered.
89445512|NCT02184819|Active Comparator|levosimendan|study drug
89445513|NCT02184819|Placebo Comparator|placebo|placebo group
89445514|NCT02189109|Experimental|Dose Escalation|NVX-108 (DDFP liquid emulsion) i.v. in conjunction with Radiation Treatment and Temozolimide. 0.05-0.35cc/kg.
89445515|NCT02189187|Experimental|Mindfulness Based Stress Reduction (MBSR) program|Mindfulness Based Stress Reduction (MBSR) is an 8-week program that consists of training in mindfulness practices, the application of mindfulness to daily life, and information about healthy living and the role played by thoughts and emotions in health.
89445516|NCT02189187|Active Comparator|Healthy Living Course (HLC)|Healthy Living Course (HLC) an 8-week psycho-educational program that consists of lectures and discussion on healthy living, stress management, time management, and unhealthy behaviors (e.g. smoking, drinking).
89445517|NCT02484014|Experimental|TSM Arm|Tarang Adolescence Education Programme + SEHER Intervention (delivered by teachers as SEHER Mitra)
89445518|NCT02484014|Experimental|SM Arm|Tarang Adolescence Education Programme + SEHER Intervention (delivered by SEHER Mitra)
89445519|NCT02484014|Other|Comparison Arm|Tarang Adolescence Education Programme
89445520|NCT02483546|Experimental|huma patient based training|Students randomized to receive simulation training .The mannequin Siman 3G laerdal® displays multiple physiologic and pharmacologic responses. Three volunteers were involved in the scenario while the others were observers through an audiovisual projection. Students participating in the scenario were given 15 minutes to evaluate and manage a 60-year-old man with a known history of coronary artery disease and diabetes who presented to the emergency department with chest pain revealing an acute ST elevation myocardial infarction complicated by ventricular fibrillation. Students were required to recognize and manage ventricular fibrillation when the patient became pulseless and unresponsive. After performing the simulation, the entire group was convened for debriefing of the case.
89445521|NCT02483546|Active Comparator|traditionally teaching|students received a traditional course using slides during 60 minutes about the management of cardio pulmonary resuscitation according to the latest recommendations of the AHA. This course is offered by the same trainer who participated in the simulation session. Students were free to ask questions as the progress of education. The same educational objectives were treated with the two groups.
89445522|NCT02256813|Experimental|BIRT 2584 XX + PK-cocktail|
89445523|NCT02479958|Experimental|Control|
89445524|NCT02479958|Experimental|APDT 1|
89445525|NCT02479958|Experimental|APDT 2|
89445526|NCT02189265||Full cohort|All singleton births in the Netherlands. Stillbirths are excluded from the denominator for all outcomes other than perinatal mortality, stillbirth and congenital anomalies.
89445527|NCT02483624|Experimental|Low Dose|10 patients 225 mg of BR-DIM. 2 capsules AM and 1 PM. 52 weeks duration.
89445528|NCT02483624|Experimental|High Dose|10 patients 375 mg of BR-DIM. 3 capsules AM and 2 PM. 52 weeks duration.
89445529|NCT02483624|Placebo Comparator|Placebo|10 patients receiving weight matched placebo. 5 for high dose and 5 for low dose. 52 weeks of weight matched pills.
89445530|NCT02184897|Active Comparator|AM group|Lenograstim is administered at 8 am and apheresis is started at 10 am on D4.
89445531|NCT02184897|Experimental|PM group|Lenograstim is administered at 6 pm and apheresis is started at 8 am on D5
89445532|NCT02483390|Experimental|Intervention group: All dyads are in the intervention arm.|
89445533|NCT03535779||Group 1|Healthy volunteers receiving Tetanus (Td/IVP) vaccine were enrolled onto the study for 1 month with no additional follow up visits.
89445534|NCT03535779||Group 2|Healthy volunteers receiving the Hepatitis B (HBsAg) vaccine were enrolled onto the study for 2 months with no additional follow up visits.
89445535|NCT02184975|Experimental|Stitches|Cold Knife Conization with stitches
89445536|NCT02184975|Active Comparator|No stitches|Cold Knife Conization without stitches
89445537|NCT02189343|Experimental|Dose Escalation Cohort|Dose Escalating Cohorts of ACY-1215 in combination with pomalidomide and dexamethasone.
89445538|NCT03535701|Active Comparator|Arm I (standard of care)|Patients receive standard of care therapy with paclitaxel.
89445539|NCT03535701|Experimental|Arm II (standard of care, ketogenic diet)|Patients receive standard of care with paclitaxel. Patients undergo a controlled feeding period ketogenic diet comprising of meals prepared in the research kitchen for 3 months. Beginning 2 weeks prior to completion of the controlled feeding period, patients also undergo free living ketogenic diet program for 3 months comprising of group format, individual sessions, and online digital content to educate patients to implement a ketogenic eating pattern into their lifestyle.
89445540|NCT02486276|Active Comparator|Sumatriptan|headache is induced with Cilostazol. This headache is treated double-blinded with 1 tablet of sumatriptan 50 mg
89445541|NCT02486276|Placebo Comparator|Placebo|headache is induced with Cilostazol. This headache is treated double-blinded with 1 tablet of placebo
89200053|NCT00961012|No Intervention|Control group|"Experimenter A reminds the subject to remain immobile.~For both intervention and control group. After the five-minute period, experimenter A calls experimenter B to return. Experimenter B takes a pressure reading, measures the trunk displacement, obtains spirometry readings, and takes a measure of discomfort."
89200054|NCT00674700|Active Comparator|300 IR|300 IR house dust mites allergen extract tablet
89445542|NCT02189421|Other|Direct peroral cholangioscopy|Direct peroral cholangioscopy by using an ultra-slim upper endoscope without assisting accessories
89445543|NCT02485886|Experimental|68Ga-BMV101 injection and PET/CT scan|The patients were intravenously injected with 68Ga-BMV101 and underwent PET/CT scan 1 h and 2.5 h after that.
89445544|NCT02480036|Experimental|Combined IORT and Kyphoplasty|IORT with Kyphoplasty IORT Device: Intrabeam®
89445545|NCT02189499|Experimental|Coronary Scaffold Implantation|AmM FORTITUDE Bioresorbable Drug-Eluting Coronary Scaffold
89445546|NCT05714228||Surgical repair|
89445547|NCT05714228||Transcatheter repair|
89445548|NCT02189577|Experimental|CHF 5259|CHF 5259
89445549|NCT02189577|Placebo Comparator|Placebo|Placebo
89445550|NCT02189655|No Intervention|Group Control|Hyperbaric bupivacaine 0.5% 2.5 mL was administered intrathecally in 30 seconds.
89445551|NCT02189655|Experimental|Group Diluting with cerebrospinal fluid|Hyperbaric bupivacaine 0.5% 2.5 mL diluting with cerebrospinal fluid was administered intrathecally in 30 seconds
89445552|NCT02485652|Experimental|HM61713|HM61713 800 mg (2 x 400 mg tablets) once daily (QD)
89445553|NCT02185287||Lower urinary tract dysfunction, female, age: 18-40 years|
89445554|NCT02185287||Healthy female subjects, age: 18-40 years|
89445555|NCT02189733|Experimental|Caplacizumab - Treatment A|Single s.c. dose of reconstituted lyophilized solution of caplacizumab followed by single s.c. dose of liquid formulation of caplacizumab
89445556|NCT02189733|Experimental|Caplacizumab - Treatment B|Single s.c. dose of liquid formulation of caplacizumab followed by single s.c. dose of reconstituted lyophilized solution of caplacizumab
89445557|NCT02185365||Developmental dysplasia of the hip (DDH)|Patients will complete 2 magnetic resonance imaging (MRI): T1-rho and dGEMRIC. The T1-rho MRI does not require the injection of a contrast agent, while the dGEMRIC MRI requires a gadolinium injection to visualize cartilage in the hip.
89445558|NCT02485808||Surgical|"Men and women presenting for clinical care for whom surgical treatment of their lower urinary symptoms is planned.~There will be no interventions, as this is an observational cohort."
88930293|NCT01739153|Experimental|CHEESE diet|The CHEESE diet will contain cheese in amounts corresponding to 120 g/day on a 10 MJ diet (approx. 1.8 MJ from cheese). A high dose of cheese is chosen to provoke effects within this short time frame. The cheese types used in this study will be Danbo (45+) and Cheddar (50+) which will be supplied in equal amounts. The CHEESE diet will have the same macronutrient composition as that of the average Danish diet (15 E% from protein, max 35 E% from fat, and max 15 E% from saturated fat).
88930294|NCT01739153|Experimental|MEAT diet|The MEAT diet will be a diet without dairy products. In this diet cheese is mainly replaced by high-fat mixed meat products to achieve saturated fat content and protein quality similar to that of the CHEESE diet. The MEAT diet will have the same macronutrient composition as that of the average Danish diet (15 E% from protein, max 35 E% from fat, and max 15 E% from saturated fat).
89445559|NCT02485808||Medical|"Men and women presenting for clinical care for whom medical treatment of their lower urinary symptoms is planned.~There will be no interventions, as this is an observational cohort."
88930295|NCT01739166|Experimental|Practice-tailored intervention - Early/Phase 1|During the 6 month Intervention Phase the Practice Facilitator works with each practice to create changes that are tailored to their individual preferences and methods of operation. Sites randomized to Early/Phase 1 start their 6 month intervention immediately after randomization.
88930296|NCT01739166|Experimental|Practice-tailored intervention - Late/Phase 2|The Phase 2 group will start the practice-tailored intervention with the study facilitator 4 months post-randomization and continue through post-randomization month 10.
88930297|NCT01739179||1|VP Shunt Surgery for laparoscopic insertion of the peritoneal catheter
89445560|NCT02485808||Controls|"Men and women who are not experiencing lower urinary tract symptoms.~This group will undergo MRI, pain and auditory sensitivity testing."
88930298|NCT01739179||2|VP Shunt Surgery for open insertion of the peritoneal catheter
88930299|NCT01739192|Placebo Comparator|Arm 1|Placebo oral daily for approximately six (6) weeks.
88930300|NCT01739192|Experimental|Arm 2|Naltrexone (25 mg) oral daily for approximately six (6) weeks.
88930301|NCT01739192|Experimental|Arm 3|Naltrexone (50 mg) oral daily for approximately six (6) weeks.
89445561|NCT02485808||Neuroimaging & Sensory Testing|"Subjects from the Medical and Surgical Cohorts who agree to additional testing in the form of neuroimaging (via fMRI) and multimodal sensory testing.~This group will undergo MRI, pain and auditory sensitivity testing."
89445562|NCT02189811|Experimental|IPV|IPV at birth, 6 weeks, 10 weeks, 14 weeks, followed by tOPV at 18 and 22 weeks
89445563|NCT02189811|Experimental|bOPV|bOPV at birth, 6, 10, and 14 weeks. followed by tOPV at 18 and 22 weeks of age
89445564|NCT02189811|Experimental|bOPV and IPV|bOPV at birth, 6, 10 weeks, and IPV+bOPV at 14 weeks, and tOPV at 18 and 22 weeks of age
89445565|NCT02189811|Experimental|bOPV and IPV and IPV2|bOPV at birth, 6, 10 weeks and bOPV+IPV at 14 weeks and tOPV+IPV2 at 18 weeks and tOPV alone at 22 weeks of age
88930302|NCT01739205|Experimental|Lifestyle counseling|"CALM-D Intervention Session Topic Weekly~I Welcome to the CALM-D Program. Getting Started Being Active, Losing Weight and Managing Stress~I Negative Thoughts and Emotions~G Where's the Fat?/Three Ways to Eat Less Fat~G Taking Your Medications/Stress and You Bi weekly~G Move Those Muscles/Being Active: A Way of Life~G Challenging and Changing Negative Thoughts~G Healthy Eating~G Problem Solving Monthly~G Four Keys to Healthy Eating Out~G Social Support/Communication~G Take Charge of What's Around You/Tip the Calorie Balance~G The Slippery Slope of Lifestyle Change~G Jump Start Your Activity Plan~G Assertiveness/Make Social Cues Work for You.~G You Can Manage Stress~G Life Goals~G Ways to Stay Motivated Abbreviations: I = Individual session; G = Group session"
89200055|NCT00674700|Active Comparator|500 IR|500 IR house dust mites allergen extract tablet
89200056|NCT00674700|Placebo Comparator|Placebo|Placebo tablet
89445566|NCT02189811|Active Comparator|tOPV|tOPV at birth, 6, 10, 14, 18 and 22 weeks of age
89445567|NCT04492592|Experimental|Workshop Only|2 session weekend face:face workshop for adolescent-mother pairs
89445568|NCT04492592|Experimental|Workshop + SMS/Texting|2 session weekend face:face workshop for adolescent-mother pairs followed by 8 weeks of supplementary text messages (NOTE: there was no 'SMS/texting-only' arm of this study)
89445569|NCT04492592|No Intervention|Control|No intervention provided.
89445570|NCT02189967|Active Comparator|conventional fractionation|radiotherapy with conventional fractionation (5 x 2Gy per week)
89445571|NCT02189967|Active Comparator|accelerated fraction|radiotherapy with accelerated fraction (7 x 2 Gy per week)
89445572|NCT03316664|Experimental|INT|Integrated Neurocognitive Therapy (INT) is a manualized psychological intervention that consists of 30 sessions administered by a therapist and a co-therapist in an open group of 6-8 patients. Sessions will take place twice a week, and each session should last 90 min.
89445573|NCT03316664|Active Comparator|IPT|Integrated Psychological Therapy (IPT) is a manualized psychological intervention that consists of 5 modules which can be completed in a variable number of sessions that will be administered by a therapist and a co-therapist in an open group of 6- 8 patients. Sessions will take place twice a week, and each session should last 60 to 90 min.
89445574|NCT03316664|Other|CoC|COGPACK is a computer-based neuropsychological cognitive training program. It will be administered by a trainer in an open group of 6- 8 patients. Sessions will take place twice a week, and each session will last 45 - 60 minutes.
89445575|NCT04633863|Experimental|MDI - 101|Artificial tear containing arabinogalactan, trehalose and hyaluronic acid
89445576|NCT03315494|Experimental|SKI-O-703 200 mg (once daily)|SKI-O-703 capsule (1 x 200 mg)
89445577|NCT03315494|Experimental|SKI-O-703 400 mg (once daily)|SKI-O-703 capsule (2 x 200 mg, once daily)
89445578|NCT03315494|Experimental|SKI-O-703 200 mg (twice daily)|SKI-O-703 capsule (1 x 200 mg twice daily)
89445579|NCT03315494|Placebo Comparator|Placebo|Placebo capsule
89445580|NCT03315416||NHS Sample|Children diagnosed with speech sound disorder aged 2-5 years
89445581|NCT02193633|Experimental|AZD2014 3 on/4 off & weekly paclitaxel|3 days on, 4 days off AZD2014 BD administered orally Days 1-3 each week in combination with paclitaxel administered via IV infusion on Day 1 each week, in 7-week cycles (6 weeks treatment followed by 1 week rest).
89445582|NCT02193633|Experimental|AZD2014 2 on/5 off & weekly paclitaxel|AZD2014 BD administered orally Days 1-2 each week in combination with paclitaxel administered via IV infusion on Day 1 each week, in 7-week cycles (6 weeks treatment followed by 1 week rest).
89445583|NCT03315338|Experimental|SAD Part 1 Active Cohort A|CORT118335, 25 mg
89445584|NCT03315338|Placebo Comparator|SAD Part 1 Placebo oral capsule Cohort A|
89445585|NCT03315338|Experimental|SAD Part 1 Active Cohort B|CORT118335, 75mg
89445586|NCT03315338|Placebo Comparator|SAD Part 1 Placebo Cohort B|
89445587|NCT03315338|Experimental|SAD Part 1 Active Cohort C|CORT118335, 225mg
89445588|NCT03315338|Placebo Comparator|SAD Part 1 Placebo Cohort C|
89445589|NCT03315338|Experimental|SAD Part 1 Active Cohort D|CORT118335, 675mg
88930303|NCT01739218|Experimental|Carboplatin + Paclitaxel + Bevacizumab|Participants will receive 4 cycles of neoadjuvant therapy prior to IDS and 22 cycles of adjuvant therapy before entering long-term follow-up. Each cycle will be 3 weeks in length. Carboplatin and paclitaxel will be administered during Cycles 1 to 8. Bevacizumab will be administered during both the neoadjuvant and the adjuvant treatment periods in Cycles 1 to 26 (no treatment in Cycles 4 and 5).
88930304|NCT01739218|Active Comparator|Carboplatin + Paclitaxel|Participants will receive 4 cycles of neoadjuvant therapy prior to IDS and 22 cycles of adjuvant therapy before entering long-term follow-up. Each cycle will be 3 weeks in length. Carboplatin and paclitaxel will be administered during Cycles 1 to 8. Bevacizumab will be administered only during the adjuvant treatment period in Cycles 6 to 26.
89445590|NCT03315338|Placebo Comparator|SAD Part 1 Placebo Cohort D|
89445591|NCT03315338|Experimental|SAD Part 2 Active Cohort A, Fasting|CORT118335, 600mg, is supplied as capsules for oral dosing given after an overnight fast
89445592|NCT03315338|Experimental|SAD Part 2 Active Cohort A, Fed|CORT118335, 600mg, is supplied as capsules for oral dosing given after a high-fat breakfast
89445593|NCT03315338|Placebo Comparator|SAD Part 2 Placebo PD Effect Cohort B|
89445594|NCT03315338|Experimental|SAD Part 2 Active PD Effect Cohort B: 630mg of CORT118335|
89445595|NCT03315338|Experimental|SAD Part 2 Active PD Effect Cohort B: 675mg of CORT118335|
89445596|NCT03315338|Experimental|MAD Part 3 Active Cohort A|CORT118335, 375mg qd for 14 days
89445597|NCT03315338|Placebo Comparator|MAD Part 3 Placebo Cohort A|Placebo qd for 14 days
89445598|NCT03315338|Experimental|SAD Part 4 Active Cohort A|CORT118335, 100mg
89445599|NCT03315338|Placebo Comparator|SAD Part 4 Placebo Cohort A|
89445600|NCT03315338|Experimental|SAD Part 4 Active Cohort B|CORT118335, 300mg
89445601|NCT03315338|Placebo Comparator|SAD Part 4 Placebo Cohort B|
89445602|NCT03315338|Experimental|SAD Part 4 Active Cohort C, Fasting|CORT118335, 900mg is supplied as suspension for oral dosing given after an overnight fast
89445603|NCT03315338|Experimental|SAD Part 4 Active Cohort C, Fed|CORT118335, 900mg is supplied as suspension for oral dosing given after a high-fat breakfast
88930305|NCT01739244|Experimental|SYL040012 eye drops dose A|Ocular topical administration of SYL040012 eye drops dose A
88930306|NCT01739244|Experimental|SYL040012 eye drops dose B|Ocular topical administration of SYL040012 eye drops dose B
88930307|NCT01739244|Experimental|SYL040012 eye drops dose C|Ocular topical administration of SYL040012 eye drops dose C
88930308|NCT01739244|Placebo Comparator|Placebo|Ocular topical administration of placebo eye drops
88930309|NCT01739257|Experimental|Theater|"1-hour dramatic reading of The Most Massive Woman Wins"
88930310|NCT01739257|Active Comparator|Lecture|1-hour lecture on the medical management of obese patients
89445604|NCT03315338|Placebo Comparator|SAD Part 4 Placebo Cohort C, Fasting|Supplied as suspension for oral dosing given after an overnight fast
89445605|NCT03315338|Placebo Comparator|SAD Part 4 Placebo Cohort C, Fed|Supplied as suspension for oral dosing given after a high-fat breakfast
89445606|NCT03315338|Experimental|SAD Part 4 Active Cohort Part D|CORT118335, 1500mg
89445607|NCT03315338|Placebo Comparator|SAD Part 4 Placebo Cohort D|
89445608|NCT03315338|Experimental|MAD Part 5 Active Cohort A|CORT118335, 150mg
89445609|NCT03315338|Placebo Comparator|MAD Part 5 Placebo Cohort A|
89445610|NCT03315338|Experimental|MAD Part 5 Active Cohort B|CORT118335, dose to be determined
89445611|NCT03315338|Placebo Comparator|MAD Part 5 Placebo Cohort B|
89445612|NCT03315338|Experimental|MAD Part 5 Active Cohort C|CORT118335, dose to be determined
89445613|NCT03315338|Placebo Comparator|MAD Part 5 Placebo Cohort C|
89445614|NCT02185599||Colposcopy with DySIS|The prospective arm will recruit patients referred for colposcopy and will be examined using DySIS.
89445615|NCT02185599||Standard colposcopy|The retrospective arm will collect historical data from colposcopy examinations performed using a standard colposcope.
89445616|NCT02193711|Experimental|Topical Arthritis Cream|1-1.5 ml applied to the skin over the knee in the morning and at bedtime over the entire study period, for a total of 2-3 ml/day.
89445617|NCT02193711|Placebo Comparator|Placebo|1-1.5 ml applied to the skin over the knee in the morning and at bedtime over the entire study period, for a total of 2-3 ml/day.
89445618|NCT02193789|Experimental|Anastomosis site stricture|anastomosis site stricture after subtotal gastrectomy with Billroth-I anastomosis
89445619|NCT02483156|Active Comparator|SOF + RBV|Sofosbuvir 400 mg once daily +RBV (1000 mg/day) for 12-24 weeks
89445620|NCT02483156|Experimental|sof + RBV + AH|Single Dose (2 tablets) once daily each tablet containing SOF 200 mg, RBV 500 mg and Natural anti-hemolytic (AH) at 200 mg for 12-24 weeks
89445621|NCT02194413|Experimental|Arm 1 (healing touch)|"Patients receive daily HT sessions comprising pain drain, chakra connection, magnetic clearing, and mind clearing over 30 minutes from day 1 until 2 days before discharge from the hospital (therapeutic touch).~Interventions: therapeutic touch, quality-of-life assessment, and questionnaire administration"
89445622|NCT02194413|Active Comparator|Arm II (usual care)|"Patients receive routine nursing care from doctors and nurses from day 1 until 2 days before discharge from the hospital.~Interventions: quality-of-life assessment, and questionnaire administration"
89445623|NCT02483234|Experimental|Psoriasis/Psoriatic arthritis|Patients with Psoriasis and inflammatory and/or structural lesions and/or erosions in the MRI/HR-qCT scan will be treated with Secukinumab. Patients with psoriatic arthritis will be treated with Secukinumab. Bone changes will be evaluated influenced by IL-17 blockade
89445624|NCT02485340|Active Comparator|Sumatriptan|headache is induced with 5-ISMN. This headache is treated double-blinded with 1 tablet of sumatriptan 50 mg
89445625|NCT02485340|Placebo Comparator|Placebo|headache is induced with 5-ISMN. This headache is treated double-blinded with 1 tablet of placebo (the tablet is similar to the active tablet)
89445626|NCT05459870|Experimental|4SCAR T Cell Therapy for autoimmune diseases|
89445627|NCT05451368||calcified group|"A calcified coronary culprit lesion was defined as readily apparent densities noted within the apparent vascular wall at the site of the stenosis. target lesions were classified as severe (radio opacities noted without cardiac motion prior to contrast injection generally involving both sides of the arterial wall),moderate (densities noted only during the cardiac cycle prior to contrast injection).Severe and moderate calcification is classified as a calcified group."
89445628|NCT05451368||non-calcified group|none/mild(lesions other than severe and moderate calcified lesions). none/mild calcification is classified as a non-calcified group.
89445629|NCT04492514|Experimental|Mavrilimumab|Mavrilimumab treatment infusion
89445630|NCT04492514|Placebo Comparator|Placebo|Placebo infusion
89445631|NCT05432726||Elderly patients|Elderly patients (aged ≥65 year's old) planned to receive first-line chemotherapy for advanced solid tumor malignancies, presenting to the clinical oncology department, Assiut University Hospitals, Assiut, Egypt.
89445632|NCT02479490|Experimental|Prednisone + Everolimus|Prednisone + Everolimus
89445633|NCT02479256|Experimental|Clomiphene citrate + placebo|Women will receive one tablet of clomiphene citrate oral tablets 50 mg (Clomid®, aventis/Egypt) twice daily 12 hours apart (total dose 100 mg daily), and one tablet of placebo of tamoxifen oral tablets twice daily 12 hours apart from the 3rd day of the menses for 5 days, for only one menstrual cycle.
89445634|NCT02479256|Experimental|Tamoxifen + placebo|Women will receive one tablet of tamoxifen oral tablets 10 mg (Tamoxifen®, amriya/Egypt) twice daily 12 hours apart (total dose 20 mg daily), and one tablet of placebo of clomiphene citrate twice daily 12 hours apart from 3rd day of the menses for 5 days, for only one menstrual cycle.
89445635|NCT02482844|Other|Pacemaker|Every patient included with a de novo LBBB, persistent that is observed beyond 24 hours after the TAVI procedure, will benefit from an endocavitary electrophysiological exploration . According to the meditative delay of conduction, we shall hold the setting-up of a pacemaker in case of delay lengthened HV (> 70 ms) or of infrahissian block, in the opposite case the implantation of an holter with remote monitoring will be made
89445636|NCT02482844|Other|holter implantable|Every patient included with a de novo LBBB, persistent that is observed beyond 24 hours after the TAVI procedure, will benefit from an endocavitary electrophysiological exploration . According to the meditative delay of conduction, we shall hold the setting-up of a pacemaker in case of delay lengthened HV (> 70 ms) or of infrahissian block, in the opposite case the implantation of an holter with remote monitoring will be made
89445637|NCT02482766|Experimental|INRECSURE|Infants in the INRECSURE arm will undergo the following approach: as soon as possible after the recruitment manoeuver (at CDP-Optimal) a dose of poractant alfa (Curosurf [Chiesi Farmaceutici, Parma, Italy]) of 200 mg/kg will be administered via a closed administration system in one-two aliquots (1-2 minutes). The tube position will be confirmed by auscultation. A temporary reduction of frequency may be necessary to increase the VT up to 2.5 ml/kg for improving the surfactant spreading.
88930311|NCT01739270|Active Comparator|dexamethasone with levobupivacaine|25ml 0.5% levobupivacaine plus 4mg Dexamethasone are given for supraclavicular brachial plexus block for upper extremity surgery
88930312|NCT01739270|Active Comparator|levobupivacaine|25ml 0.5% levobupivacaine plus 1ml 0.9% saline are given for supraclavicular brachial plexus block for upper extremity surgery
88930313|NCT01739283|Experimental|hyperglycemia|Hyperglycemic clamping
89445638|NCT02482766|Active Comparator|INSURE|Infants in the INSURE arm will undergo the following approach: after intubation, a dose of poractant alfa (Curosurf [Chiesi Farmaceutici, Parma, Italy]) of 200 mg/kg will be administered via a closed administration system in one-two aliquots (1-2 minutes). The tube position will be confirmed by auscultation. During surfactant administration, infants will be manually ventilated to facilitate surfactant distribution.
89445639|NCT04492280|Active Comparator|1. Group H|These patients will receive standard therapy for sepsis plus Hydrocortisone (Solucortef®, E.I.P.I.co. under license of Pfizer) at dose 50mg every 6 hours by Intra venous route.
88930314|NCT01739283|Experimental|hypoglycemia|Hypoglycemic clamping
89445640|NCT04492280|Active Comparator|2. Group HF|These patients will receive standard therapy for sepsis plus Hydrocortisone (Solucortef®) at dose of 50mg every 6 hours by Intra venous route and Fludrocortisone (Cortilon®, Amoun) 50 Microgram once daily by nasogastric tube for one week
89445641|NCT04492280|Placebo Comparator|3. Group C|These patients will receive standard therapy for sepsis.
89445642|NCT02724644|Experimental|EN3835 Active|EN3835 0.84 mg (Collagenase Clostridium Histolyticum). Each subject can receive up to three treatment sessions. Each treatment session will be separated by approximately 21 days.
89445643|NCT02724644|Placebo Comparator|EN3835 Placebo|Placebo
89445644|NCT02479334|Placebo Comparator|Fat challenge breakfast|200 ml control drink (non-energy flavored water) and high fat breakfast (% Energy Carbohydrate:Fat:Prot / 20:60:20), acute study / one time administration
89445645|NCT02479334|Experimental|Fat challenge breakfast+spices|200 ml spices drink (non-energy flavored water + spices extract) and high fat breakfast (% Energy Carbohydrate:Fat:Prot / 20:60:20), acute study / one time administration
89445646|NCT02479334|Placebo Comparator|Carbohydrate challenge breakfast|200 ml control drink (non-energy flavored water) and high carbohydrate breakfast (% Energy Carbohydrate:Fat:Prot / 60:20:20), acute study / one time administration
89445647|NCT02479334|Experimental|Carbohydrate challenge breakfast+spices|200 ml spices drink (non-energy flavored water + spices extract) and high carbohydrate breakfast (% Energy Carbohydrate:Fat:Prot / 60:20:20), acute study / one time administration
89445648|NCT02482922|Experimental|IET and Nutrition|3 times per week of interval exercise training Once daily meal replacement
89445649|NCT02482688|Experimental|Multisensory Acute|Multisensory intervention delivered within 2 months post-stroke.
89445650|NCT02482688|Experimental|Multisensory Chronic|Multisensory intervention delivered 6 months post-stroke.
89445651|NCT02482688|Active Comparator|Unisensory Acute|Unisensory intervention delivered within 2 months post-stroke.
89445652|NCT02482688|Active Comparator|Unisensory Chronic|Unisensory intervention delivered 6 months post-stroke.
89445653|NCT04492202||First group|Physiotherapists will be included in this group.
88930315|NCT01739296|Experimental|Wedge|Lateral wedge insole with subtalar strapping Use of lateral wedge insoles with subtalar strapping for 5 to 10 hours daily
89445654|NCT04492202||Second group|Doctors will be included in this group.
89445655|NCT04492202||Third group|Nurses will be included in this group.
88930316|NCT01739296|Sham Comparator|Neutral|Neutral insole with subtalar strapping (sham) Use of neutral insoles with subtalar strapping for 5 to 10 hours daily
89445656|NCT04492202||Fourth group|Other health professionals will be included in this group.
89445657|NCT03314870|Other|Retrospective study|Tumoral tissue of 100 patients with breast cancer treated with neoadjuvant chemotherapy.
89445658|NCT03314870|Other|Prospective study|Tumoral tissue and plasma of 120 patients with breast cancer treated with neoadjuvant chemotherapy.
89445659|NCT03314792|Active Comparator|Oxycodone|Active comparator drug administrated.
89445660|NCT03314792|Experimental|Tapentadol|Experimental drug administrated.
89445661|NCT02476604|Experimental|Electronic Messaging|Subjects randomized to the intervention arm will receive health coaching and electronic messages at the rate of up to six times per week over an 8 week period.
89445662|NCT02476604|No Intervention|Control|Subjects randomized to the control arm will undergo all of the same measurements for baseline and follow up data but will not receive the intervention of health coaching and electronic messaging.
89445663|NCT02476526|Experimental|Low Volume Contrast|Subjects in this arm will receive a single intravenous injection of low volume iso-osmolar non-ionic radio contrast medium, prior to undergoing 64-MDCT scanning. The use of low volume radio contrast medium constitutes the intervention. Both experimental and control groups receive a) acetylcysteine inhalation (Mucomyst) 1200 mg po BID x 48 hours starting the day prior to the CT scan; and b) isotonic Sodium Bicarbonate Solution 3ml/kg/hr iv for 1 hour prior to the CT scan and for 6 hours after the CT scan
89013764|NCT06229223|Experimental|PALOMA|Parents/guardians of youth who have been referred to and agree to participate in the intervention by the child's primary care provider will participate in a 2-month program consisting of 5-7 phone sessions with a community health worker focusing on safety planning, information/education, program solving and self-care. Research participants will be asked to complete a survey via phone at the beginning of the program and another at the end of the program. The participants may also be asked to participate in an additional interview about the participants experience during the study.
89013765|NCT06221852|Active Comparator|Ketogenic diet arm|Eligible participants assigned to the ketogenic diet arm will be asked to follow the ketogenic diet (KD) for 12 weeks in addition to any ongoing medications (e.g., mood stabilizers and/or second-generation antipsychotics). Participants will receive weekly and as needed diet counseling from a registered dietician. Participants will be asked to monitor and report their blood ketone levels each day via a finger-prick device provided by the study team.
89013766|NCT06221852|Active Comparator|Dietary Guidelines for Americans arm|Eligible participants assigned to the Dietary Guidelines for Americans (DGA) arm will adhere to the Dietary Guidelines for Americans in addition to any ongoing medications (e.g., mood stabilizers and/or second-generation antipsychotics). Participants will receive weekly and as needed diet counseling from a registered dietician. Participants will be asked to monitor and report their blood ketone levels each day via a finger-prick device provided by the study team.
89013767|NCT06218303|Experimental|MUC1 vaccine + adjuvant Hiltonol + Aromatase Inhibitor|MUC1 peptide vaccine with poly-ICLC adjuvant Hiltonol administered subcutaneously (SQ) Anastrozole 1 mg, letrozole 2.5 mg, or exemestane 25 mg by mouth daily
89013768|NCT06218303|Active Comparator|Aromatase Inhibitor|Anastrozole 1 mg, letrozole 2.5 mg, or exemestane 25 mg by mouth daily
89013769|NCT06211348|Experimental|Genomic Sequencing|
89013770|NCT06208878||Non Interventional|All subjects with hematological and solid malignancies who are enrolled in a parent study and were exposed to allogeneic CRISPR CAR T cellular therapy will be asked to participate in this long-term follow-up (LTFU) study.
89013771|NCT06208410|Experimental|Arm A:JS105+Fulvestrant Injection|JS105 administered orally, Fulvestrant intramuscularly
89013772|NCT06208410|Experimental|Arm B:JS105+Fulvestrant Injection+Dalpiciclib Isetionate Tablets|JS105 administered orally, Dalpiciclib administered orally, Fulvestrant intramuscularly
89013773|NCT06208410|Experimental|Arm C:JS105+Toripalimab Injection|JS105 administered orally, Toripalimab intravenous infusion
89013774|NCT06208410|Experimental|Arm D:JS105+Paclitaxel for Injection (Albumin Bound)|JS105 administered orally, Paclitaxel (Albumin Bound) intravenous infusion
89013775|NCT06208410|Experimental|Arm E:JS105+Fluzoparib Capsules|JS105 administered orally, Fluzoparib administered orally
89013776|NCT06208410|Experimental|Arm F:JS105+Pyrotinib Maleate Tablets+Capecitabine Tablets|JS105 administered orally, Pyrotinib administered orally,Capecitabine administered orally
89013777|NCT06208410|Experimental|Arm G:JS105+Toripalimab Injection+Paclitaxel for Injection (Albumin Bound)|JS105 administered orally, Toripalimab intravenous infusion, Paclitaxel (Albumin Bound) intravenous infusion
89013778|NCT06208189|Experimental|high-effort session|Participants will perform sets with as many repetitions they can each set.
89013779|NCT06208189|Experimental|low-effort session|Participants will perform sets with half of the anticipated number of repetitions of the high-effort session.
89200057|NCT00888537|Experimental|Decision Aid|Patients in this arm will discuss medications to help the heart heal after a heart attack with the clinician and the help of the acute myocardial infarction (AMI) Choice Decision Aid.
89200058|NCT00888537|Active Comparator|Usual Care|Patients and clinicians in this arm will discuss medications to help the heart heal after a heart attack in their usual manner.
89013780|NCT06208189|Sham Comparator|Control session|The control session all procedures will be identical to the high-effort session.
89013781|NCT06206473|Experimental|ICU patients with ARDS and delirium|ICU patients with ARDS and delirium will be assessed twice: in the acute phase of ICU-related delirium (V1) using an mEEG battery (electrophysiological acquisition at rest and during complex cognitive stimulation), and 6 months ± 2 weeks later (V2) using a multi-domain clinical neurocognitive and psychological assessment battery.
89013782|NCT06203561|Experimental|The observation group|"The patients were provided with 1) basic treatment including intracranial pressure reduction, anti-infection therapy, blood pressure and blood glucose control, and 2) comprehensive rehabilitation therapy including respiratory tract management, care for tracheotomy tube, comprehensive training for hemiplegic limbs, swallowing function training, pulmonary function training, and acupuncture.~For the observation group, the nasogastric tube was removed, and Intermittent oro-esophageal tube feeding was initiated for nutrition support within 4 hours after completing the admission assessment, following the standard Intermittent oro-esophageal tube feeding procedure."
89200059|NCT02542371||HIV infected with known subclinical atherosclerosis|
89200060|NCT02542371||HIV infected without known subclinical atherosclerosis|
89200061|NCT02542371||Non-HIV infected with known subclinical atherosclerosis|
89200062|NCT02542371||Non-HIV infected without known subclinical atherosclerosis|
89200063|NCT00546910|Experimental|Atomoxetine|0.5 milligram per kilogram (mg/kg) per day lead-in dose for 1 weeks followed by 7 weeks at 1.2 mg/kg per day dose.
89200064|NCT00546910|Placebo Comparator|Placebo|Placebo matched to 1 week lead-in and 7 week standard target dose of atomoxetine
89013783|NCT06203561|Active Comparator|The control group|"The patients were provided with 1) basic treatment including intracranial pressure reduction, anti-infection therapy, blood pressure and blood glucose control, and 2) comprehensive rehabilitation therapy including respiratory tract management, care for tracheotomy tube, comprehensive training for hemiplegic limbs, swallowing function training, pulmonary function training, and acupuncture.~Patients in the control group were provided with nutrition support by the indwelling nasogastric tube. The entire feeding process strictly followed the standardized procedure for nasogastric feeding."
89445664|NCT02476526|Sham Comparator|Control|Subjects in this arm will undergo 64-MDCT scanning without Radio Contrast Medium (RCM). Both experimental and control groups receive a) acetylcysteine inhalation (Mucomyst) 1200 mg po BID x 48 hours starting the day prior to the CT scan; and b) isotonic Sodium Bicarbonate Solution 3ml/kg/hr iv for 1 hour prior to the CT scan and for 6 hours after the CT scan
89445665|NCT04491812|Experimental|Kinesiotaping|kinesiotaping of the triceps muscle applied to the study group alongside the physical therapy program
89445666|NCT04491812|Placebo Comparator|physical therapy program|the control group recieved only the physical therapy program
89013784|NCT06203158||High fucosylation group|Immunohistochemistry was used to detect the fucosylation level in the intestinal tissue biopsy of patients with Crohn's disease at baseline. The fucosylation level in the baseline intestinal tissue was higher than 50% of the total.
89013785|NCT06203158||Low fucosylation group|Immunohistochemistry was used to detect the fucosylation level in the intestinal tissue biopsies of patients with Crohn's disease at baseline. The fucosylation level in the baseline intestinal tissue was less than 50% of the total.
89445667|NCT02478944|Experimental|Inflammatory bowel disease|Patients with Crohn's disease and ulcerative colitis undergoing manometry
89445668|NCT02479022|Experimental|Level 1-7 escalating doses|
89445669|NCT02478866|Experimental|BPI-9016M|Seven dose cohorts will be evaluated, including 100mg, 200mg, 300mg, 450mg, 600mg, 800mg, 1000mg. BPI-9016M will be administered orally to patients once daily for each dose cohort.
89445670|NCT02482454|Other|RFA alone|Patients undergo radiofrequency ablation alone.
89445671|NCT02482454|Experimental|RFA+CIK|Autologous cytokine-induced killer cells were transfer via venous one week after RFA
89013786|NCT06201533|Experimental|Low-intensity, combined physical-cognitive exercise|The exercise program will be prescribed at low intensity for 50 minutes/session, 3 times /week for 12 consecutive weeks.
89013787|NCT06201533|No Intervention|Control|Participants will be asked to maintain their routine lifestyle throughout the study period.
89013788|NCT06200961|Active Comparator|Transnasal Endoscopy (TNE)|Unsedated endoscopic evaluation of the esophagus and stomach through the nose with a transnasal endoscope.
89445672|NCT02476760||Treated with incretins|Current use of incretin-based drugs ((DPP-4 inhibitors [sitagliptin, vildagliptin, and saxagliptin] or GLP-1 analogs [exenatide, liraglutide]) alone or in combination with other anti-diabetic drugs (if the prescription overlaps with the index or event day with a 30-day grace period).
89445673|NCT02476760||Treated with insulin|Any use of insulins between base cohort entry and the index or event day (alone or in combination with other antidiabetic drugs) and no current use of incretin-based drugs.
89445674|NCT02476760||Treated with ≥2 oral hypoglycemic agents|Current use of 2 or more non-insulin anti-diabetic medications (biguanides, sulfonylureas, thiazolidinediones, alphaglucosidase inhibitors, meglitinides) (if the prescriptions overlap with the index or event day with a 30-day grace period), and no current use of incretin-based drugs or insulins.
89445675|NCT02476760||Treated with a single oral agent|Current use of any single non-insulin anti-diabetic medication (biguanides, sulfonylureas, thiazolidinediones, alpha-glucosidase inhibitors, meglitinides) (if the prescription overlaps with the index or event day with a 30-day grace period) and no current use of more than 2 OHAs, incretin-based drugs, or insulins from base cohort entry.
89445676|NCT02476760||Not currently exposed group|All patients not currently exposed to: incretin-based drugs, ≥2 OHAs, a single OHA and no use of insulins since base cohort entry.
89445677|NCT02478554|No Intervention|Population-based|Participants will be randomly assigned to population-based fetal growth curves
89445678|NCT02478554|Active Comparator|Customized-based|Participants will be randomly assigned to customized-based fetal growth curves (intervention)
89445679|NCT05460338|Active Comparator|Weekly Cholecalciferol Group|25 hemodialysis patients on oral cholecalciferol 50.000IU Cholecalciferol, once weekly, taken post-hemodialysis session for 3 months.
89445680|NCT05460338|Active Comparator|Monthly Cholecalciferol Group|25 hemodialysis patients on Oral 200.000IU Cholecalciferol, once monthly, for 3 months.
89445681|NCT02482220|Experimental|High intensity|in this group, the participants will follow a high intensity physical activity program (High Intensity Interval exercise from 75 to 95% VO2max)
89445682|NCT02482220|Experimental|Moderate intensity|in this group, the participants will follow a moderate intensity physical activity program (Intensity from 50 to 65% VO2max)
89445683|NCT02482142|Placebo Comparator|phosphorus alone|Effect of phosphorus (500mg) ingestion alone. No meal. Needed to determine the impact of phosphorus alone on DIT
89445684|NCT02482142|Placebo Comparator|high CHO meal alone|Ingestion of placebo tablets with the high carbohydrate meal
89445685|NCT02482142|Active Comparator|High CHO meal plus phosphorus|Effect of phosphorus (500mg) tablets ingestion of DIT of the high carbohydrate meal
89445686|NCT02482142|Active Comparator|High protein meal plus phosphorus|Effect of phosphorus (500mg) tablets ingestion of DIT of the high protein meal
89445687|NCT02482142|Placebo Comparator|High protein meal alone|Ingestion of placebo tablets with the high protein meal
89445688|NCT02482064|No Intervention|Traditional Obturators|Patients will use traditional obturators which are going to be made from ordinary heat-activated acrylic resin.
89445689|NCT02482064|Experimental|Flexible Obturators|Patients will use the new obturators made from flexible resin.
89445690|NCT02476136||Placebo group|Patients participating in one of the included randomized controlled trials, assigned to the placebo group
89445691|NCT02476136||Intervention group|Patients participating in one of the included randomized controlled trials, assigned to the investigational antidepressant (paroxetine, duloxetine or fluoxetine) or active comparator (venlafaxine) group.
89445692|NCT02476370|No Intervention|Usual care|Does not receive a specific study intervention
88930317|NCT01739322|Experimental|1|"Four concentrations of Platanus acerifolia allergen extract (10, 1, 0.1, 0.01 mg/ml)~Positive control (10 mg/ml histamine dihydrochloride)~Negative control (glycerinated phenol saline solution)"
88930318|NCT01739374|Experimental|Device - Reduced mesh implants|Patients treated with reduced mesh implants for POP reconstruction
89445693|NCT02476370|Experimental|preoperative relaxation program|preoperative relaxation program
89445694|NCT02476370|Experimental|preoperative surgery education|single education unit to understand the complete surgical procedures
89445695|NCT02476370|Experimental|preoperative relaxation program+preoperative surgery education|preoperative relaxation program AND single education unit
89445696|NCT02476214|Experimental|Intervention group|Group prenatal care- receiving prenatal care through a group
89445697|NCT02476214|No Intervention|Control group|Individual prenatal care - receiving regular individual prenatal care
89445698|NCT05437094|Other|CRD-740|CRD-740 single dose administered alone
88930319|NCT01739387||Breath actuated inhaler (BAI)|Placebo. Two to nine puffs on one day only
88930320|NCT01739387||Flutiform® pMDI|Placebo. Two to nine puffs on one day only
88930321|NCT01739413|Active Comparator|General Anesthesia|Patients will receive general anesthesia alone followed by intravenous morphine for postoperative pain control. This techniques is safe and is standard procedure for colorectal surgery.
88930322|NCT01739413|Experimental|Epidural Anesthesia|Patients will receive general anesthesia plus epidural anesthesia followed by epidural analgesia for postoperative pain control. This techniques is safe and standard procedure for colorectal surgery.
89200065|NCT00763074|Placebo Comparator|Control|Conventional education of life style intervention for type 2 diabetes
89445699|NCT05437094|Other|CRD-740 and Itraconazole|CRD-740 single dose administered with Itraconazole
89445700|NCT05413772||Temocillin received empirically|Temocillin received in probabilistic , in curative context or in preventive use (prophylaxis)
89445701|NCT05413772||Temocillin received on second line of treatment|Temocillin received second-line therapy in curative context or in preventive use (prophylaxis)
89445702|NCT03314402|Experimental|group 1|Jaktinib Dihydrochloride Monohydrate
89445703|NCT03314402|Placebo Comparator|group 2|Placebo
89445704|NCT05713292|Experimental|Pirfenidone|Pirfenidone 200mg tid for first week; subsequently, 400mg tid for 2 months
89445705|NCT05713292|Placebo Comparator|Placebo|Pirfenidone placebo 200mg tid for first week; subsequently, 400mg tid for 2 months
89445706|NCT03314324|Experimental|ODM-201|
89445707|NCT03314324|Active Comparator|Enzalutamide|
89445708|NCT02475902|Experimental|Computer guided home exercise program|"A laptop computer & MS Kinect camera will be connected to a 40 TV to deliver guided fall prevention exercises. Research staff will train the participants in the use of the computerized program and be supervised performing the exercises during the instruction period. Then participants will be instructed to exercise 3 times per week for 4 weeks. Half of the participants will begin the study with the computerized version of the home exercise program while the other half begins with the paper booklet version of the home exercise program. After one month the arms will cross over."
89445709|NCT02475902|Active Comparator|Paper guided home exercise program|A paper booklet with pictures and written instructions, and an exercise log for the home exercise program will be given to half of the participants. Participants will be carefully instructed in performing the exercises correctly and then asked to perform the exercises 3 times per week for one month. Participants who began the study with the paper exercise program will switch to the computerized version of the exercise program for the second month.
89445710|NCT02481752|Experimental|AAT Training Group|Individuals in this condition will receive four sessions of AAT training in which they are instructed to approach (pull the joystick) images tilted to the right and avoid (push the joystick) images tilted to the left. They will be told that the training may weaken automatic cigarette-approach and strengthen automatic cigarette-avoidance. Furthermore, they will be told that the opposite effect will be true for the stimuli not related to cigarettes (i.e., the positive stimuli).
89445711|NCT02481752|Sham Comparator|SHAM Training Group|Individuals in this condition will receive four sessions of SHAM training in which they are instructed to approach (pull the joystick) images tilted to the right and avoid (push the joystick) images tilted to the left. They will be told that the purpose of the training is to improve control over these automatic tendencies and that following the training sessions, they will easily be able to push or pull the stimuli regardless of content.
89445712|NCT02475824|Experimental|MMD arm|Both midazolam® (0.05 mg/kg, 30% reduction for patients if age ≥70 or ASA class III-IV; Bukwang Pharm Co., Seoul, Republic of Korea) and meperidine (50mg. 25mg for patients aged ≥70 years; pethidine HCL, Hana Pharm Co., Seoul, Republic of Korea) are given intravenously at the initiation of sedation. In addition, a continuous IV infusion of dexmedetomidine (1ug/kg/h, Precedex; Hospira, Seoul, Republic of Korea) is administered 15 min before the ERCP till complete procedure
89445713|NCT02475824|Active Comparator|BPS arm|IV bolus dose of midazolam® (0.06mg/kg, 50% reduction for patients if age ≥70 or ASA class III-IV; Bukwang Pharm Co., Seoul, Republic of Korea) and meperidine (50mg. 25mg for patients aged ≥70 years; pethidine HCL, Hana Pharm Co., Seoul, Republic of Korea). Repeated doses of 10-20 mg propofol® are titrated to achieve the target level of sedation. 0.9% NaCl 1μg/Kg•hr IV continuous infusion, initiated 15 min before the procedure (ERCP) till complete procedure
89445714|NCT02478242|Active Comparator|Nafamostat mesilate group|Nafamostat mesilate was used for maintenance anticoagulation during continuous renal replacement therapy.
89445715|NCT02478242|Placebo Comparator|No anticoagulation group|Normal saline was used for maintenance anticoagulation during continuous renal replacement therapy.
88930323|NCT01739426|Experimental|Study population|"The population is composed of patients with a confirmed Zenker's diverticulum.~Intervention: Repair w/LigaSure"
88930324|NCT01739439|Experimental|Treatment (chemoradiation and radiosurgery)|Patients receive gemcitabine hydrochloride IV over 30 minutes once weekly and undergo hyperfractionated IMRT 5 days a week in weeks 1-3. Patients then undergo a single fraction of radiosurgery boost in week 5 and then receive gemcitabine hydrochloride IV over 30 minutes once weekly in weeks 6-8. Treatment continues in the absence of disease progression or unacceptable toxicity.
88930325|NCT01739452||erythropoiesis-stimulating agents|Patients diagnosed with low-risk MDS according to IPSS (low or intermediate-1), treated with erythropoiesis-stimulating agents.
88930326|NCT01739452||Transfusion support|A control group of patients who received only transfusional support.
88930327|NCT01739465|Active Comparator|Self expanding metallic stent （SEMS ）placement only|Endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous transhepatic cholangiography (PTC) would be performed to confirm the position and length of the biliary malignant. A self expanding metallic stent (SEMS) would be placed to bypass the site of narrowing
89013789|NCT06200961|Active Comparator|Sedated Esophagogastroduodenoscopy (EGD)|Sedated endoscopic evaluation of the esophagus and stomach through the mouth with a standard upper endoscope.
89200066|NCT00763074|Active Comparator|Diet|Dietary calorie restriction
89200067|NCT00763074|Active Comparator|Exercise|Encourage to increase exercise amount: more than 60min's of exercise with moderate activity level two times per day
89200068|NCT00763074|Active Comparator|Diet and exercise|Intervention for both of exercise and diet
89200069|NCT02541513|Experimental|paliparidone|All patients will begin receiving oral paliperidone 3 mg daily for 3 days followed by an injection of Paliperidone 150 mg injection on Day 8
89200070|NCT00888693|Experimental|1|ABT-288 vs placebo capsules administered orally once daily for 14 days
89200071|NCT00888693|Experimental|2|ABT-288 vs placebo capsules administered orally once daily for 14 days
89200072|NCT00888693|Experimental|3|ABT-288 vs placebo capsules administered orally once daily for 14 days
89200073|NCT00888693|Experimental|4|ABT288 vs placebo administered orally once daily for 14 days
89200074|NCT00888693|Experimental|5|ABT-288 vs placebo administered orally once daily for 14 days
89200075|NCT00888693|Experimental|6|ABT-288 vs placebo administered orally once daily for 14 days
89200076|NCT00888693|Experimental|7|ABT-288 vs placebo administered orally once daily for 14 days
89200077|NCT00888693|Experimental|8|ABT-288 vs placebo administered orally once daily for 14 days
89200078|NCT00888693|Experimental|9|ABT-288 vs placebo administered orally once daily for 14 days
89200079|NCT02558712|Other|Face to face exam|Standard of clinical care, 8 point eye exam
89200080|NCT05278767|Experimental|application group|The mobile health application (https://play.google.com/store/apps/details?id=com.sanberk.bariatriksurgery) prepared for patients undergoing bariatric surgery was completed in 6 stages. After the mobile application has been developed, a short (20-minute) brief contains information about the mobile application in the pre-operative polyclinic for the patients who are planned for bariatric surgery. The patient was followed for three months. Data were collected from the patient every month (4 times).
89200081|NCT05278767|No Intervention|control group|Standard care and follow-up protocols were applied to the patients.The patient was followed for three months. Data were collected from the patient every month (4 times).
89200082|NCT00961168|Experimental|Lung-Protective Ventilation|Lung-Protective Ventilation comparing volume vs. pressure control
89200083|NCT00885183|Experimental|acupuncture therapy|Breast cancer patients are randomised to additional 12 acupuncture treatment sessions while undergoing standard chemotherapy
89445716|NCT02475746|Experimental|PF-06372865 treatment arm|treatment arm includes two treatment periods, a single dose of PF-06372865 (period 1) followed by 8-days itraconazole with a single dose of PF-06372865 co-administered on Day 4
89445717|NCT02475590|Experimental|Sleeve gastrectomy|Laparoscopic sleeve gastrectomy
89445718|NCT02475590|Experimental|Roux-en-Y gastric bypass|Laparoscopic Roux-en-Y gastric bypass
89445719|NCT04492046||Complex Decongestive physiotherapy|All participants included in the study were included in a treatment protocol consisting of Complex Decongestive physiotherapy.
88930328|NCT01739465|Experimental|Endoscopic radiofrequency ablation plus SEMS|Endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous transhepatic cholangiography (PTC) would be performed to confirm the position and length of the biliary malignant. The radiofrequency ablation (RFA) catheter (EMcision, London, United Kingdom) would be placed under fluoroscopic guidance across the biliary stricture. Radiofrequency energy will be delivered to the malignant site. After that,A self expanding metallic stent (SEMS) would be placed to bypass the site of narrowing
88930329|NCT01739465|Experimental|Photodynamic therapy plus SEMS|Photofrin is injected 3 days prior to laser activation of the agent.Endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous transhepatic cholangiography (PTC) will be carried out to determine the length and positon of the biliary malignant. Delivery Fiber used along with the laser system to activate the photosensitizing agent and induce tumor tissue necrosis. A self expanding metallic stent (SEMS) will be placed the site of biliary narrowing
88930330|NCT01739478|Experimental|Non-packing of abscess cavity|
88930331|NCT01739478|Other|Packing of abscess cavity|Current practice
88930332|NCT01739491||Bendamustine hydrochloride|Adult Filipino patients with chronic lymphocytic leukemia will be taking bendamustine hydrochloride as per the dosing regimen given on product insert approved in Philippines.
88930333|NCT01739504|Experimental|Autologous Adipose-derived Stromal Vascular Fraction infusion|Intervention: AD-SVF infusion directly into affected joints.
88930334|NCT01739517|Experimental|Omegaven Therapy|After baseline labs, which have been collected no earlier than seven days prior to the initiation of therapy are obtained, therapy with Omegaven will be initiated at a starting dose of 0.5 g/kg/day infused over 12 hours. If tolerated, the dose will be increased to 1 g/kg/day, the goal dose. Omegaven will be infused intravenously through either a central or peripheral catheter in conjunction with parenteral nutrition.
88930335|NCT01739530|Experimental|Repaircell|allogenic differentiated adipocyte
88930336|NCT01739543|Experimental|Investigational|Subject receives Hem-Avert Device.
88930337|NCT01739543|No Intervention|Control|Subject does not receive Hem-Avert Device.
88930338|NCT01739556|Experimental|Intervention Arm|Antiplatelet regimen modification will be guided by assessment of the on-treatment platelet reactivity. Low responders to aspirin will receive 200 mg aspirin for 30 days. Low responders to clopidogrel will receive 180 mg ticagrelor for 1 year.
88930339|NCT01739556|No Intervention|Standard Treatment|Patients enrolled in the Standard Treatment arm will receive standard antiplatelet regimen including 100 mg aspirin and 75 mg clopidogrel without assessment of on-treatment platelet reactivity.
88930340|NCT01739582|Experimental|Androxal|Androxal (enclomiphene citrate) 12.5 mg, once daily, oral capsule. Subjects will be up-titrated to 25 mg if testosterone levels remain below 450 ng/dL at visit 2.
88930341|NCT01739608|Experimental|CT Colonography (CTC)|Invitation to screening. Subject who consent to participate in the study undergo to low dose CTC examination with limited bowel preparation.
88930342|NCT01739608|Active Comparator|Sigmoidoscopy (FS)|Invitation to screening. Subjects who consent to participate in the study undergo to FS.
88930343|NCT01739621|Experimental|Proellex 12 mg|Telapristone acetate, 1 vaginally inserted capsule, once a day, for 4 months
88930344|NCT01739621|Experimental|Proellex 24 mg|Telapristone acetate, 1 vaginally inserted capsule, twice a day, for 4 months
88930345|NCT01739634|Experimental|Active Drug|After a 1 week run-in period CASAD will be administered TID for 1 week. Each dose will be 2 500mg CASAD capsules. Patients will be followed for two weeks post active drug administration.
88930346|NCT01739647|Experimental|AZD3293|Up to 11 sequential cohorts of healthy young and healthy elderly subjects are planned, with single ascending doses ranging from 1mg to a maximum of 1000mg
88930347|NCT01739647|Placebo Comparator|Placebo|Placebo given (2 subjects in each cohort)
88930348|NCT01739660|Experimental|Pegloticase|Pegloticase 8 mg single intraveneous dose
88930349|NCT01739673|Experimental|Ultraviolet-A and riboflavin|
88930350|NCT01739686|Experimental|CASA Intervention|"The CASA (Collaborative Care to Alleviate Symptoms and Adjust to Illness) intervention includes 3 components:~A nurse (RN) follows structured algorithms to help patients with symptoms, specifically breathlessness, fatigue, pain, and depression.~A social worker provides structured counseling targeting adjustment to illness and depression if present.~A collaborative care model of care delivery, in which the nurse and social worker meet weekly with a primary care provider, cardiologist and palliative care specialist. This team makes medical recommendations to the intervention subjects' providers and supervises the nurse and social worker.~Most of the nurse and social worker visits are by phone."
88930351|NCT01739686|No Intervention|Usual Care|Patients in the control group will continue to receive care at the discretion of their providers, which may include referral to cardiology, palliative care, or mental health. If patients self-report depression on baseline surveys, this information will be given to their provider, and patients will be given resources. Patients will have the same amount of interaction with research assistants as the intervention patients, completing questionnaires and participating in study visits at the same frequency.
88930352|NCT01739712|Experimental|Sleep Extension|All youth in this condition are asked to extend their sleep to 10 hours or at least one hour, whichever is longer
88930353|NCT01739712|Sham Comparator|Fixed Sleep Duration|All youth in this condition are asked to maintain their baseline sleep duration.
88930354|NCT01739725|Experimental|Helical stent insertion|Study participants will receive the helical stent
88930355|NCT01739738||no Ureteral Stent - control group|non-stented volunteers to receive ultrasound for peristalsis changes detection
88930356|NCT01739738||Ureteral stent|patients who receive stent, and to receive ultrasound for peristalsis changes detection in their stented and non-stented ureter
88930357|NCT01739751|No Intervention|Control Group|Patients without feedback of a pedometers, followed for 3 months
89445720|NCT02481362|Active Comparator|Order 1|Order for sessions: Cake, apricots
89445721|NCT02481362|Active Comparator|Order 2|Order for sessions: apricots, Cake
89445722|NCT03314246|Other|Intervention|FAST user
89445723|NCT03314246|Other|Control|Standard of care
89445724|NCT05354180|Experimental|navicular mobilization|Plantar glide combined with rotation of navicular bone against the talus The glide will be given in 20 repetitions of 3 sets, for 5 days a week
89445725|NCT05354180|Experimental|rigid tapping|"A non-elastic zinc oxide sports tape will be applied to patients. Patient will be advised to protect the tape from getting wet.~Tape will be changed on every 3rd day (48 hours) on Wednesday and Friday."
89445726|NCT05354180|Experimental|"Navicular Mobilization and Rigid Taping|"|"Plantar glide combined with rotation of navicular bone against the talus The glide will be given in 20 repetitions of 3 sets, for 5 days a week.~A non-elastic zinc oxide sports tape will be applied to patients. Patient will be advised to protect the tape from getting wet.~Tape will be changed on every 3rd day (48 hours) on Wednesday and Friday."
89445727|NCT02475512|Experimental|Wash wipes|Washing with water and soap (standard care) will be replaced with two wash wipes during 30 days: (1) daily total body wash (using 3M Cavilon Bathing and Cleansing wipes) and (2) Continence Care (using 3M Cavilon Continence Care Wipes). No other preventive barrier or hydration products will be allowed in the genital-anal region.
89445728|NCT02475512|Placebo Comparator|Standard care|Washing will be done using water and pH neutral soap. No other preventive barrier or hydration products will be allowed in the genital-anal region.
89445729|NCT05712980||DTM Cohort|Patients with Failed Back Surgery Syndrome treated with Spinal Cord Stimulation with DTM programming
89445730|NCT05712980||Conventional Cohort|Patients with Failed Back Surgery Syndrome treated with Spinal Cord Stimulation with conventional programming
89445731|NCT02481518|Experimental|Magnesium|Magnesium preloading group : Magnesium preloading for Cisplatin treatment
89445732|NCT02481518|Active Comparator|Control|Control group : Normal saline preloading for cisplatin treatment
88930358|NCT01739751|Experimental|Pedometers|With a program of physical activity enhancement using pedometers as a feedback
88930359|NCT01739777|Experimental|ucMSC|Umbilical cord derived mesenchymal are injected intravenously to Patients.
88930360|NCT01739777|Placebo Comparator|Controls|Intravenous placebo solution are administrated to Patients.
88930361|NCT01739816|No Intervention|Control group|Patients get no intervention at study start, but only at study end after seven months.
88930362|NCT01739816|Active Comparator|Intervention group|At the beginning and at the end of the study, this group receives a pharmacist's led medication review focusing on daily medicines use (= Polymedication Check).
88930363|NCT01739816|Other|Observational arm|If participants after recruitment violate inclusion criteria (e.g. change from autonomous medication management to external home care) or insists on intervention despite being randomised to control group or patient condition forces pharmacist to provide a PMC.
88930364|NCT01739829|Experimental|DIABECELL group 1|10,000 IEQ per kg body weight (Total Dose) Administered in two doses: 5,000 IEQ/kg three months apart.
88930365|NCT01739829|Experimental|DIABECELL group 2|20,000 IEQ per kg body weight (Total Dose) Administered in two doses: 10,000 IEQ/kg three months apart
88930366|NCT01739842|Active Comparator|Kudzu extract treatment|"Kudzu (2 mg) will be administered as a pretreatment 2 ½ hours before a drinking session.~During the medication week, participants will take 2 capsules three times a day for a total dose of 3 grams of kudzu."
88930367|NCT01739842|Placebo Comparator|Placebo|"Placebo will be administered as a pretreatment 2 ½ hours before a drinking session.~During the medication week, participants will take 2 capsules three times a day."
88930368|NCT01739855|Active Comparator|Calcium/Vitamin D|"All subjects will receive calcium/vitamin D supplementation after laparoscopic bariatric gastric bypass surgery as follows:~daily: 500 mg oral calcium (calcium carbonate) weekly: 16.000 IU oral vitamin D3 (calciferol)"
89013790|NCT06196723||early TIPS|transjugular intrahepatic portal shunt
89445733|NCT05712902|Experimental|Daily dose of DZD9008|
89445734|NCT05715164|Experimental|E-cigarettes device plus liquid|The 200 participants will receive e-cigarettes along with basic care counseling for 48 weeks.
89445735|NCT05715164|Experimental|Nicotine Pouches|The 200 participants will receive nicotine pouches along with basic care counseling for 48 weeks.
89445736|NCT05715164|Active Comparator|Basic care counseling about smoking cessation|The 200 participants will receive basic care counseling for 48 weeks.
89445737|NCT02481284||Laser Doppler Perfusion Imaging|20 consequetive cases undergoing breast reconstruction with Deep inferior epigastric artery perforator flap who had evaluation of the microcirculation of the abdominal skin with laser Doppler perfusion imaging
89445738|NCT02475356||Mirena|Mirena treatment group
89445739|NCT05710562||Anticoagulated population|Adult patients under oral anticoagulation therapy
89445740|NCT05708768||Acutely ill persons in the municipality|Patients recieving services from a rapid response vehicle manned with dedicated physicians from the municipality
89445741|NCT02481128|No Intervention|A (access to lymphoscintigraphy)|Axillary sentinel lymph node biopsy with preoperative access to lymphoscintigraphy findings
89445742|NCT02481128|Experimental|B (no access to lymphoscintigraphy)|Axillary sentinel lymph node biopsy without preoperative access to lymphoscintigraphy findings
88930369|NCT01739855|No Intervention|No Calcium/Vitamin D|All subjects will not receive calcium/vitamin D supplementation after laparoscopic bariatric gastric bypass surgery.
88930370|NCT01739894|Experimental|IP Paclitaxel|Paclitaxel will be administered intraperitoneally at 40mg/m2 on Days 1 and 8 in a 21-day cycle in patients receiving intravenous oxaliplatin 100mg/m2 on Day 1 and capecitabine 1000mg/m2 twice daily on Days 1-14.
88930371|NCT01739907|Experimental|Iron-fortified dairy product|Consumption of an iron-fortified flavoured skimmed milk as part of the usual diet
88930372|NCT01739907|Experimental|Iron and vitamin D dairy product|Consumption of an iron and vitamin D fortified flavoured skimmed milk as part of the usual diet
88930373|NCT01739920|Experimental|Povidone-iodine|1 drop of povidone-iodine 5% will be instilled at time zero, 20-minute and 28-minute study period.
88930374|NCT01739920|Active Comparator|Povidone-iodine and Saline Solution|1 drop of saline solution 0.9% will be instilled at time zero and 20-minute. At 28-minute will be instilled 1 drop of Povidone-iodine 5%.
88930375|NCT01739946||Implanted subject|Subjects with Interstim implanted
88930376|NCT01739946||Controls|Subjects without Interstim implanted
88930377|NCT01739959||Necrotizing fasciitis proven|Histological evidence of necrotizing fasciitis at initial surgical debridement
88930378|NCT01739959||Not necrotizing fasciitis|A composite of those with no histological tissue necrosis at initial surgical debridement, and those clinically judged not to be a necrotizing infection who therefore did not undergo surgery.
88930379|NCT01739972|Active Comparator|Levothyroxine|Levothyroxine in the capsule form, once daily, appropriate dosage to keep TSH at the normal range.
88930380|NCT01739972|Active Comparator|Desiccated thyroid extract|Desiccated thyroid extract in capsule form, once daily, appropriate dosage to keep TSH in the normal range.
88930381|NCT01739985|Active Comparator|Dexamethasone + ondansetron + Placebo|dexamethasone + ondansetron + Placebo
88930382|NCT01739985|Experimental|Dexamethasone + ondansetron + Droperidol|dexamethasone + ondansetron + Droperidol
88930383|NCT01739998|Experimental|functional oil|Treatment consisted of consuming 5 ml of functional oil [olive oil (4 ml) with omega 3 fatty acids from fish oil (1 ml: 90% omega 3: 75-80% DHA and 10-15% EPA) Orange flavour] during the day by 8 weeks.
88930384|NCT01739998|Placebo Comparator|Placebo|Treatment consisted of consuming 5 ml of olive oil during the day by 8 weeks
88930385|NCT01740011|Experimental|Group A|Laparoscopic surgery with AirSeal CO2 pressure insufflation
88930386|NCT01740011|Active Comparator|Group S|Laparoscopic surgery with standard CO2 pressure insufflation
88930387|NCT01740024|Experimental|1 (Dose-Response Skin Prick Tests)|3 different cat epithelium allergenic extracts at 3 different concentrations Positive control Negative control
88930388|NCT01740037|Experimental|Specialized AF-clinic|Management of AF patients in specialized outpatient AF Clinics according to the principles of an integrated chronic care program (ICCP) performed by a nurse practitioner/ physician assistant/ specialised cardiovascular nurse, cardiologist, supported by an ICT decision support tool based on professional guidelines (CardioConsult AF®). The use of a web-based patient centered management of patient's own medication (Medication manager TM) was optional. A standardized diagnostic, treatment and follow-up pathway was performed within the ICCP. In addition, the intervention is based on identifying risk factors and potential problems in patients, and addressing needs through dynamic use of personalized education and adjustment of treatment.
88930389|NCT01740037|Active Comparator|Usual Care|Usual care provided by cardiologists at the regular outpatient clinic.
89013791|NCT06196723||LVP+A|large volume paracenteses plus albumin
89200084|NCT00885183|Other|Usual care|Control group (usual care) receives standard chemotherapy alone
89445743|NCT02474966|Experimental|Real-Sham dTMS|This arm will be treated before with real deep Transcranial Magnetic Stimulation (dTMS) (the first day) and after with sham dTMS (the second day)
89445744|NCT02474966|Experimental|Sham-Real dTMS|This arm will be treated before with sham deep Transcranial Magnetic Stimulation (dTMS) (the first day) and after with real dTMS (the second day)
89445745|NCT02475122|Other|open-label study|open-label study
89445746|NCT02475044|No Intervention|Treatment as usual (TAU)|Participants recive Psycho-education and neuro-psycological diagnosis.
89445747|NCT02475044|Experimental|Cognitive-Behavioral Therapy (CBT)|Participants recive 16 sessions of CBT in addition to arm TAU treatment.
89445748|NCT05715008|Experimental|Kefir consumption|Kefir consumption (300ml/day) for 2 weeks in a counterbalanced manner to 16 adult subjects
89445749|NCT05715008|Placebo Comparator|Placebo (cow milk)|Placebo administration for 2 weeks in a counterbalanced manner to 16 adult subjects
89445750|NCT02480894|Experimental|Sequential Dosing|Treatment A: BMS-663068 orally twice daily (BID) on Days 1 through 4 Treatment B: Maraviroc BID on Days 7 through 11 Treatment C: BMS-663068 BID plus maraviroc BID on Days 12 through 18
89445751|NCT02478086|Experimental|use amine acids parenteral 3.5g|"Amino acids parenteral (Levamin Nomo 10% ®) Group A with an initial doses of amino acids until reaching 3.5 g/kg/day during 28 days.For the study of renal function baseline urea, creatinine and BUN were measured within 24 h after birth in order to avoid any alteration cost by mother alter kidney function, afterwards the same markers were measured at the day 7, 14, 21 and 28. These markers were measure using orto-clinical diagnostic series 50-0278 USA.~The anthropometric measurements were assessed weekly by the same person to avoid bias (cephalic perimeter and height); weight was measured weekly using the same scale (SECA model 3741321009, Germany). All anthropometric and lab results were kept in a collection sheet."
89445752|NCT02478086|Experimental|use amine acids parenteral 4g|"Group B with an initial doses of 2.5 g/kg/day with daily increments of 0.5 g/kg/day until reaching 4 g/kg/day during 34 days.Weight, urea, creatinine and blood urea nitrogen (BUN) were measured weeklyFor the study of renal function baseline urea, creatinine and BUN were measured within 24 h after birth in order to avoid any alteration cost by mother alter kidney function, afterwards the same markers were measured at the day 7, 14, 21 and 28. These markers were measure using orto-clinical diagnostic series 50-0278 USA.~The anthropometric measurements were assessed weekly by the same person to avoid bias (cephalic perimeter and height); weight was measured weekly using the same scale (SECA model 3741321009, Germany). All anthropometric and lab results were kept in a collection sheet."
89445753|NCT02480816|Experimental|Bicarbonated mineral water (BW)|Bicarbonated mineral water
89445754|NCT02480816|Active Comparator|Control mineral water (CW)|Mineral water low in mineral content (control)
89445755|NCT02480660|Experimental|Video Intervention Group|Subjects will be randomized to intervention group where participants will be asked to watch a 7 minute educational video.
89445756|NCT02480660|No Intervention|Control Group|Subjects will be randomized to control group ( no intervention) and receive standard of educational care on adolescent to adult oriented health care transitions.
88821757|NCT01831635||Myeloproliferative neoplasm case|"Patients with Polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF) will be recruited based on the WHO diagnostic criteria.~Exclusion Criteria~younger than 18 years old.~where the clinician/General Practitioner (GP) does not provide consent.~incapable of giving informed consent.~physically or cognitively incapable of completing the questionnaire.~too ill to participate.~We will assess whether a pen (branded, non-branded or none), a £10 cheque and/or a charity branded trolley token will affect uptake rates in the study."
88821758|NCT01831635||General Practice Control|"GP controls will be randomly selected and frequency matched to the distribution of cases by 5-year age band, geographic location (Belfast and Southampton) and gender.~The following patient groups will be excluded. Those:~younger than 18 years old.~where the clinician/GP does not provide consent.~incapable of giving informed consent.~physically or cognitively incapable of completing the questionnaire.~too ill to participate.~We will assess whether a pen (branded, non-branded or none), a £10 cheque (at study completion) and/or a charity branded trolley token will affect uptake rates in the study."
89013792|NCT06191185|Experimental|Best Practices Bundle (BPB), No Patient Instructions and Navigation (PIN)|"BPB: patient tracking and lists, audit and feedback, standardized documentation, standardization of care team communication.~No PIN: Patients will receive usual communication from their care team."
89013793|NCT06191185|Experimental|BPB, PIN|"BPB: patient tracking and lists, audit and feedback, standardized documentation, standardization of care team communication.~PIN: enhanced patient instructions and navigation (PIN)."
89445757|NCT02474888||Rituximab|a classical induction regimen with rituximab (decision taken before inclusion), implying an infusion of 375mg/m² per week, for 4 consecutive weeks (from week -3 until week 0) with blood specimen.
89445758|NCT02474732|Other|Usability|Determine if the subjects are able to understand and follow the directions to apply the Beactive Brace.
89445759|NCT02474654|Experimental|Arm 1: PI+FNB+IO|Bupivicaine 15mg, Fentanyl 15mcg, Epimorphine 150mcg, 0.5% Ropivicaine with 1:400,000 Epinephrine 30ml, Ropivicaine 100ml, Epinephrine 600mcg, Ketorolac 30mg
89445760|NCT02474654|Experimental|Arm 2:NS+FNB+IO|Bupivicaine 15mg, Fentanyl 15mcg, Epimorphine 150mcg, 0.5% Ropivicaine with1:400,000 Epinephrine 30ml, Normal Saline 100ml
89445761|NCT02474654|Experimental|Arm 3: PI+NS+IO|Bupivicaine 15mg, Fentanyl 15mcg, Epimorphine 150mcg, Normal Saline 30ml, Ropivicaine 100ml, Epinephrine 600mcg, Ketorolac 30mg
88821759|NCT01831635||Non-blood relative or family Control|"Recruitment of 100 non-blood relative/friend controls will be undertaken by asking cases to pass on a flyer to up to 2 or 3 non-blood relatives/friends aged 18 years or older.~We will assess whether a pen (branded, non-branded or none) and/or a £10 cheque (at study completion) will affect uptake rates in the study. Only a limited number of trolley tokens were available so not assessed in this group."
89445762|NCT02474654|Experimental|Arm 4: PI+FNB+NS|Bupivicaine 15mg, Fentanyl 15mcg, Normal Saline 0.3ml, 0.5% Ropivicaine with 1:400,000 Epinephrine 30ml, Ropivicaine 100ml, Epinephrine 600mcg, Ketorolac 30mg
89445763|NCT02474654|Active Comparator|Arm 5:NS+NS+IO|Bupivicaine 15mg, Fentanyl 15mcg, Epimorphine 150mcg, Normal Saline 30ml, Normal Saline 100ml
89445764|NCT05284604|Experimental|Group 1|Peripheral IV Infusion of 100 million MSCs at baseline and repeated at three months
89445765|NCT05284604|Experimental|Group 2|Peripheral IV Infusion of 100 million MSCs at baseline and peripheral IV infusion of placebo at three months
89445766|NCT05284604|Placebo Comparator|Group 3|Peripheral IV infusion of placebo at baseline and repeated at three months
89445767|NCT05272514||Healthy individuals|10 healthy individuals will be recruited.
89445768|NCT02478008|Experimental|CardiAQ TMVI System (Transapical DS)|
89445769|NCT02477852|Experimental|anti-tuberculosis treatment two weeks|anti-tuberculosis drugs All the patients in the groups receive anti-tuberculosis treatment with Isoniazid 0.3g po qd, Rifampicin 0.45g po qd, Ethambutol 0.75 g po qd,Pyrazinamide 0.5g po tid. for two weeks.
89445770|NCT02477852|Experimental|anti-tuberculosis treatment four weeks|anti-tuberculosis drugs All the patients in the groups receive anti-tuberculosis treatment with Isoniazid 0.3g po qd, Rifampicin 0.45g po qd, Ethambutol 0.75 g po qd,Pyrazinamide 0.5g po tid. for four weeks.
89445771|NCT02480738|Experimental|Mild cognitive impairment|Intervention: Computerized Cognitive Training Apparatus
89445772|NCT02480738|Experimental|Subjective cognitive impairment|Intervention: Computerized Cognitive Training Apparatus
89445773|NCT02480738|Active Comparator|Normal controls|Intervention: Computerized Cognitive Training Apparatus
89445774|NCT02474810|Experimental|Intensive|In the Intensive Protocol, alteplase intervention is administered to all catheters based on blood flow and/or line reversal
89445775|NCT02474810|Experimental|Standard|In the Standard Protocol, alteplase intervention is administered to all catheters based only on blood flow.
89445776|NCT02480504|Experimental|intermittent energy restriction|dietary intervention, intermittent energy restriction. Participants in the experimental group will follow av 5:2 diet and consume a very low calorie diet providing 400 (females) to 600 (males) calories of energy to days a week and for an average male participant, this will reduce energy intake approximately 22%.
89445777|NCT02480504|Active Comparator|continuous energy restriction|dietary intervention, continuous energy restrictions.Participants in the active comparator group will be asked to reduce daily energy intake by 22-23%
89445778|NCT02725268|Experimental|Paclitaxel 80 mg/m^2|Paclitaxel 80 milligrams per square meter (mg/m^2), IV, weekly on Days 1, 8, and 15 of a 28-day cycle until disease progression, unacceptable toxicity, or withdraw consent (the median exposure was up to approximately 13 weeks).
89445779|NCT02725268|Experimental|Paclitaxel 80 mg/m^2 + Sapanisertib 4 mg|Paclitaxel 80 mg/m^2, IV, weekly on Days 1, 8, and 15 of a 28-day cycle along with sapanisertib 4 milligrams (mg), capsule, orally on Days 2-4, 9-11, 16-18, and 23-25 of a 28-day cycle until disease progression, unacceptable toxicity, or withdraw consent (the median exposure was up to approximately 20 weeks).
89445780|NCT02725268|Experimental|Sapanisertib 30 mg|Sapanisertib 30 mg, capsule, orally, once weekly on Days 1, 8, 15, and 22 of a 28-day cycle until disease progression, unacceptable toxicity, or withdraw consent (the median exposure was up to approximately 6 weeks).
89445781|NCT02725268|Experimental|Sapanisertib 4 mg + MLN1117 200 mg|Sapanisertib 4 mg, capsule, orally and MLN1117 200 mg, capsule, orally on Days 1-3, 8-10, 15-17, and 22-24 of a 28-day cycle until disease progression, unacceptable toxicity, or withdraw consent (the median exposure was up to approximately 8 weeks).
89445782|NCT02480426|Experimental|CT-image guidance|Previously acquired portal venous phase of CT datasets and intra-operative CT datasets were registered on a dedicated workstation. The selected volume of interest of the CT-image showing portal vein vasculature was overlaid onto the fluoroscopic display as real-time 3D CT-image guidance during the procedure.
89445783|NCT02480426|Active Comparator|CO2 portography|two two-dimensional (2D) CO2 portograms
89445784|NCT05212142|Sham Comparator|Traditional intervention: verbal education|
88930390|NCT01740050|Active Comparator|Roux- and Y bypas surgery (RYGB)|"One subject group will lose 10% of initial body weight using RYGB. RYGB is an operation that first divides the stomach into a small upper pouch and a much larger lower remnant pouch and then re-arranges the small intestine to connect to both, in this way bypassing part of the small intestine."
89445785|NCT05212142|Experimental|New intervention: verbal education, visual aids, and motivational interviewing|
89445786|NCT02480348|Experimental|Polymer-free DES (Drug Eluting Stent)|
89445787|NCT02474576|Experimental|Percutaneous aponeurotomy|Treatment of Dupuytrens-induced finger flessum using percutaneous aponeurotomy
89445788|NCT02724956|Experimental|Ambu AuraGain|"SGAD placement using Ambu AuraGain~Lubricate airway tube of SGAD & pass the aScope through until visualization of the carina.~Standard Parker Flex Tip endotracheal tube (ETT) size 6.0, 7.0, and 8.0 mm ETT will be used as per anesthesiologist preference.~Pass ETT tube down the insertion cord of the Ambu aScope & verify placement.~Inflate cuff and remove aScope."
89445789|NCT02724956|Experimental|Teleflex LMA Protector|"SGAD placement using the Teleflex LMA Protector~Lubricate airway tube of SGAD & pass the aScope through until visualization of the carina.~Standard Parker Flex Tip ETT size 6.0 and 7.0 mm. ETT will be used as per anesthesiologist preference.~Pass ETT tube down the insertion cord of the Ambu aScope & verify placement.~Inflate cuff and remove aScope."
89445790|NCT04991246|Experimental|Students, teachers,administrative staff from the medical school of Paris-Saclay University|Students,teachers,administrative staff from the medical school of Paris-Saclay University
89445791|NCT02474342|Experimental|Autologous Adipose Tissue derived MSCs|
89445792|NCT00705536|Active Comparator|Humalog first, then Humalog + rHuPH20|"Humalog first, then Humalog + recombinant human hyaluronidase PH20 (rHuPH20)~A single subcutaneous (SC) injection of 20 units (U) Humalog on Day 1 of the study, followed by a single SC injection of 20 U Humalog + 300 U rHuPH20 after a washout period of at least 6 days"
89445793|NCT00705536|Active Comparator|Humalog + rHuPH20 first, then Humalog|"Humalog + recombinant human hyaluronidase PH20 (rHuPH20) first, then Humalog~A single subcutaneous (SC) injection of 20 units (U) Humalog + 300 U rHuPH20 on Day 1 of the study, followed by a single SC injection of 20 U Humalog after a washout period of at least 6 days"
89445794|NCT00705536|Active Comparator|Humulin-R first, then Humulin-R + rHuPH20|"Humulin-R (recombinant human insulin) first, then Humulin-R + recombinant human hyaluronidase PH20 (rHuPH20)~A single subcutaneous (SC) injection of 20 units (U) Humulin-R on Day 1 of the study, followed by a single SC injection of 20 U Humulin-R + 240 U rHuPH20 after a washout period of at least 6 days"
89013794|NCT06191185|Experimental|No BPB, PIN|"No BPB: Clinic's usual practice after a patient receives an abnormal FIT result.~PIN: enhanced patient instructions and navigation (PIN)."
88930391|NCT01740050|Active Comparator|Laparoscopic adjustable gastric banding (LAGB)|One subject group will lose 10% of initial body weight using LAGB. With LAGB an inflatable band is placed around the upper part of the stomach to create a smaller stomach pouch. This slows and limits the amount of food that can be consumed at one time giving the opportunity for the sense of satiety to be met. It does not decrease gastric emptying time.
88930392|NCT01740050|Active Comparator|Very Low Calorie Diet (VLCD)|One subject group will lose 10% of initial body weight using a VLCD. There are no risks for the subjects in consuming the VLCD (Modifast, together with the recommended fruit and vegetables) as the macronutrient composition and vitamins/minerals content meet the Dutch recommended daily allowance.
88930393|NCT01740063|Experimental|DAS181-F02 formulation|DAS181 10 mg dose for three days of the F02 formulation
89445795|NCT00705536|Active Comparator|Humulin-R + rHuPH20 first, then Humulin-R|"Humulin-R (recombinant human insulin) + recombinant human hyaluronidase PH20 (rHuPH20) first, then Humulin-R~A single subcutaneous (SC) injection of 20 units (U) Humulin-R + 240 U rHuPH20 on Day 1 of the study, followed by a single SC injection of 20 U Humulin-R after a washout period of at least 6 days"
89445796|NCT04940936|No Intervention|A - control|The patients are offered high or lower dose according to usual practice
88930394|NCT01740063|Experimental|DAS181-F04 formulation|DAS181 20 mg dose group for three days of the F04 formulation,
88930395|NCT01740063|Placebo Comparator|Placebo|placebo group
88930396|NCT01740076|Experimental|soy nuts|25 g of soy nuts provided daily to the subjects and they were counseled to replace 25 g of protein in their therapeutic lifestyle change (TLC) diet with the soy. TLC diet consisted of 30% of energy from total fat (<7% saturated fat, 12% monounsaturated fat and 11% polyunsaturated fat), 15% from protein and 55% from carbohydrate; less than 200 mg of cholesterol per day and 1200 mg of calcium and 2 fatty fish meals per week. Those ingesting suboptimal dietary calcium were given calcium carbonate supplementation.
88930397|NCT01740076|Other|Therapeutic lifestyle change diet|Counseling on therapeutic lifestyle change diet consisting of 30% of energy from total fat (<7% saturated fat, 12% monounsaturated fat and 11% polyunsaturated fat), 15% from protein and 55% from carbohydrate; less than 200 mg of cholesterol per day and 1200 mg of calcium and 2 fatty fish meals per week. Those ingesting suboptimal dietary calcium were given calcium carbonate supplementation.
88930398|NCT01740102|Experimental|RIPC|Remote ischemic preconditioning (RIPC) in the operating theatre after induction of anaesthesia and before surgery.
88930399|NCT01740102|No Intervention|No RIPC|Patients in the control group will not receive remote ischemic preconditioning before the surgery.
89445797|NCT04940936|Experimental|B - Intervention|The Patient Decision Aid is used during the consultation to aid in the decision on high or lower dose.
89445798|NCT02477540|Experimental|2-time injection group : Cellgram-CLI|Within 30 days after extracting bone marrow, autologous bone marrow-derived mesenchymal stem cells is directly injected into the lesion. Then the second cell is injected within 30 days after the first cell injection.
89445799|NCT02474264|Other|male BRCA mutations carriers|Endothelial function assessment and Cardiovascular biomarkers
89445800|NCT02474264|Other|healthy males - control group|Endothelial function assessment and Cardiovascular biomarkers
89445801|NCT02474420|Active Comparator|Deferasirox|deferasirox iron chelation therapy and standard of care by the treating physician
88930400|NCT01740141|Other|Plexus before surgery|Plexus brachialis before surgery
88930401|NCT01740141|Other|Plexus after surgery|Plexus brachialis performed after surgery
88930402|NCT01740167|Experimental|Lifestyle program|health promotion lifestyle program : individual counseling, once a month, total 3 times.
89445802|NCT02474420|Experimental|Deferasirox plus amlodipine|deferasirox iron chelation therapy with amlodipine
89445803|NCT05595980|Experimental|Probiotic|Bacillus strain spore preparation
89445804|NCT05595980|Placebo Comparator|Placebo|Placebo maltodextrin
88930403|NCT01740180||CLIPPERS patients|"The population concerned by this study consists of patients diagnosed according to CLIPPERS criteria (see inclusion and exclusion criteria).~Intervention: Data entry"
88930404|NCT01740193|Active Comparator|TAP Block|
88930405|NCT01740193|Active Comparator|Ilioinguinal/iliohypogastric blockade|
88930406|NCT01740219|Experimental|Capacity Enhancement|
88930407|NCT01740219|Active Comparator|Standard Dissemination|
88930408|NCT01740232|Active Comparator|Trephination|A 1 x 10 mm pricker are used for the trephination of the meniscus before normal meniscal repair.
88930409|NCT01740232|Placebo Comparator|Normal meniscal repair|standard operation. Normal meniscalrepair.
88930410|NCT01740245|Active Comparator|Chlorhexidine|
88930411|NCT01740245|Experimental|Polyhexamethylene biguanide|
88930412|NCT01740271|Experimental|Epirubicin|Following genetic analysis, depending on results, participants will receive either standard or increased epirubicin dosing for cycles 2 - 4.
88930413|NCT01740284|Active Comparator|Grazax + Aerius|1 tablet (oral lyophilisate ) on Day 14 and Day 28 of Grazax (Phleum Pratense grass pollen allergen extract) 75.000 SQ-T and 1 tablet (melting tablet)of Aerius (desloratidine) 2.5 mg
88930414|NCT01740284|Placebo Comparator|Grazax + Placebo|1 tablet (oral lyophilisate ) on Day 14 and Day 28 of Grazax (Phleum Pratense grass pollen allergen extract) 75.000 SQ-T and 1 tablet (melting tablet)of Aerius (Placebo)
88930415|NCT01740310|Experimental|High Elaboration Video Arm|Women randomized to this arm will be exposed to a handheld/electronic tablet device-based video with detailed vaccine-related information designed to invoke a high level of attention to the message and thought (elaboration) while processing information.
88930416|NCT01740310|Experimental|High Elaboration Interactive Tutorial Arm|Women will be exposed to a handheld/electronic tablet device-based intervention designed to invoke a high level of attention to the message and thought (elaboration) while processing information through an interactive question/answer format.
89445805|NCT02474108|Placebo Comparator|without prevention|isolated mitral valve replacement or reconstruction, implantation of cardiac monitor
89445806|NCT02474108|Active Comparator|group of prevention|"mitral valve replacement or reconstruction with surgical prevention of AF (concomitant ablation of the left atrium) and implantation of cardiac monitor.~Prophylactic surgical ablation is performed to prevent AF in patients during mitral valve surgery. Ablation is performed by radiofrequency electrode or cryoprobe."
89445807|NCT02474186|Experimental|Radiation therapy|"Patients with metastatic breast cancer and other metastatic solid tumors receiving single-agent chemotherapy will receive 3.5 Gy/fraction to a total dose of 35 Gy/10 fractions over 2 weeks with concurrent systemic therapy~Systemic agents are either capecitabine (Xeloda), paclitaxel, docitaxel or taxol"
89445808|NCT02477462||Primary Biliary Cirrhosis|Subjects meeting internationally accepted criteria for the diagnosis of primary biliary cirrhosis
89445809|NCT02477462||Control|Subjects without evidence of primary biliary cirrhosis, liver disease, or inflammatory condition who are of similar age and sex distribution to the Primary Biliary Cirrhosis group
89445810|NCT02477306|Experimental|Study group|60 subjects will receive a single oral dose of idiazole 20mg DR tabs under fasting condition in one period. And the subjects will receive a single dose of PARIET 20 mg DR tabs under fasting condition in the second period. A 7 days washout interval is in between the 2 periods
89445811|NCT04868786|Experimental|Mycophenolate Mofetil|
89445812|NCT02472548|Experimental|Group A, DPX-RSV(A) low dose (Step 1)|
89445813|NCT02472548|Experimental|Group B, RSV(A)-Alum low dose (Step 1)|
88930417|NCT01740310|Placebo Comparator|Low Elaboration / Control Arm|Women randomized to the control arm will be provided standard CDC vaccine information statements that will likely lead to low elaboration information processing.
88930418|NCT01740336|Experimental|A: Paclitaxel, GDC-0941|Participants will receive GDC-091 260 milligrams (mg) orally in repeated rounds of once daily (QD) dosing for 5 consecutive days followed by 2 consecutive days during which GDC-0941 will not be administered (5/7-day schedule). This 5/7-day schedule will be repeated weekly in each 28-day cycle until disease progression or intolerable toxicity. Participants will receive 90 milligrams per square meter (mg/m^2) intravenously (IV) weekly for 3 out of 4 weeks in every 28-day cycle.
88930419|NCT01740336|Placebo Comparator|B: Paclitaxel, Placebo|Participants will receive placebo matching to GDC-0941 on the 5/7-day schedule along with 90 mg/m^2 IV weekly for 3 out of 4 weeks in every 28-day cycle.
88930420|NCT01740349||30 children with UC|This prospective pilot study of 30 pediatric subjects, that are indicated for standard colonoscopy due to follow-up of ulcerative colitis (UC), examines the Given Diagnostic System and the PillCam Colon Capsule in comparison to standard colonoscopy.
88930421|NCT01740375|No Intervention|Arm B: observation:|No additional treatment after concurrent chemoradiotherapy. However, esophagectomy will be considered as a salvage treatment for local recurrence during observation.
88930422|NCT01740375|Experimental|Arm A: esophagectomy|Esophagectomy will be performed preferentially within 8 weeks (maximum 12 weeks) after completion of concurrent chemoradiotherapy
88930423|NCT01740453|No Intervention|Single (no catheter)|ropivacaine single injection : 5 mg/ml 15 ml
88930424|NCT01740453|Experimental|Continuous infusion|Single injection with continuous injection ropivacaine 2 mg/ml 8 ml/h
88930425|NCT01740466||Ocular diseases|Observational
88930426|NCT01740479|Active Comparator|Complete Revascularization Strategy|"Complete Revascularization Strategy (Staged Non-Culprit Lesion PCI plus Optimal Medical Therapy): Staged PCI using second generation drug eluting stents (Promus Element Plus drug-eluting stent or newer version in this series is strongly recommended) of all suitable non-culprit lesions.~All patients, regardless of randomized treatment allocation will receive optimal medical therapy consisting of risk factor modification and use of evidence-based therapies (including low dose acetylsalicylic acid (ASA) and ticagrelor)."
88930427|NCT01740479|No Intervention|Optimal Medical Therapy Alone|"Culprit lesion only Revascularization Strategy (Optimal Medical Therapy Alone): No further revascularization of non-culprit lesions.~All patients, regardless of randomized treatment allocation will receive optimal medical therapy consisting of risk factor modification and use of evidence-based therapies (including low dose ASA and ticagrelor)."
88930428|NCT01740505|Experimental|Timing and Coordination|
88930429|NCT01740505|Experimental|Aerobic Walking|
88930430|NCT01740505|Active Comparator|Stretching and Relaxation|
88930431|NCT01740518||PEG + ascorbic acid|Those who taken PEG 2L + ascorbic acid
88930432|NCT01740518||PEG 4L|Those who taken PEG 4L alone
88930433|NCT01740531|Experimental|S-303 Treated Red Blood Cells (RBC)|Patients will be randomly assigned to the sequence of administration of Test and Control RBCs; eligible patients are randomly assigned to receive Test RBCs followed by Control RBCs or Control RBCs followed by Test RBCs. Each patient will complete both treatment periods.
88930434|NCT01740531|Active Comparator|Conventional, untreated Red Blood Cells|Patients will be randomly assigned to the sequence of administration of Test and Control RBCs; eligible patients are randomly assigned to receive Test RBCs followed by Control RBCs or Control RBCs followed by Test RBCs. Each patient will complete both treatment periods.
88930435|NCT01740544|Experimental|Cathodal tDCS in young study participants|Cathodal tDCS in young study participants
89445814|NCT02472548|Experimental|Group D, DPX-RSV(A) high dose (Step 2)|
89445815|NCT02472548|Experimental|Group E, RSV(A)-Alum high dose (Step 2)|
89445816|NCT02472548|Placebo Comparator|Group C & F, Placebo control (Step 1 and 2)|
89445817|NCT02477228|Active Comparator|conventional ERCP|ERCP was done through the papilla. duration of cannulation, number of trials for cannulation, number of pancreatic cannulation, bleeding during cannulation and its management, need to convert to the other approach in cannulation.
89445818|NCT02477228|Active Comparator|Precut ERCP|ERCP was done through precut from the start duration of cannulation, number of trials for cannulation, number of pancreatic cannulation, bleeding during cannulation and its management, need to convert to the other approach in cannulation.
89445819|NCT02473796|Experimental|Home based child care|The home based child care included treatment of various various childhood illnessed by locally avialable trained village health workers, improving hygiene and nutrition among children and women throgh health education. This care was in adiition to the local health care provided by the Government's primary health care services.
89445820|NCT02473796|No Intervention|control|The control arm included population where the home based neonatal care was not implimented. The health services were provided by the Government run primary health care services. Vital statistics data was collected by VHWs.
89445821|NCT02477150|Active Comparator|SLE (vaccine)|Zostavax SC injection (0.65ml)
89445822|NCT02477150|Placebo Comparator|SLE (placebo)|Placebo SC injection (normal saline 0.65ml)
89445823|NCT02472626|Experimental|Treatment (CPI-613, cytarabine, daunorubicin hydrochloride)|"INDUCTION: Patients receive cytarabine IV continuously on days 1-7, daunorubicin hydrochloride IV on days 1-3, and 6,8-bis(benzylthio)octanoic acid IV over 2 hours on days 3-7. Patients then undergo biopsy on day 14. Patients experiencing significant residual disease receive cytarabine IV continuously on days 1-5, daunorubicin hydrochloride IV on days 1-2, and 6,8-bis(benzylthio)octanoic acid IV over 2 hours on days 1-5.~CONSOLIDATION: Beginning 42 days later, patients receive cytarabine IV continuously on days 1-16 and 6,8-bis(benzylthio)octanoic acid IV over 2 hours on days 2-6. Treatment repeats every 14 days for 3 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients not undergoing transplant after consolidation receive 6,8-bis(benzylthio)octanoic acid IV over 2 hours on days 1-5. Treatment repeats every 4 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity."
89445824|NCT02472392|Active Comparator|Treatment Plan A|Rabbit anti-thymocyte globulin (ATG) will be given only to unrelated donor transplant recipients at a dose of 3 mg/kg/day I.V. Equine ATG at a dose of 30mg/kg/day may be substituted in the event of severe allergic reaction to the rabbit ATG. Rabbit ATG is only used with recipients of unrelated donor marrow or peripheral blood transplants. Busulfan (BU) will be given at a dose of 0.8 mg/kg IV q 6 hrs. BU doses will be modified based upon pharmacokinetics data to maintain steady state levels of 600-900 ng/dl. Seizure prophylaxis with levetiracetam should begin prior to the 1st dose of BU and stoped 24 hrs after the last dose of BU. Melphalan will be given at a dose of 60 mg/m2 I.V. over 15-20 min per Pediatric SCT Standards of Practice Manual.
88930436|NCT01740544|Experimental|Cathodal tDCS in elderly study participants|Cathodal tDCS in elderly study participants
89445825|NCT02472392|Active Comparator|Treatment Plan B|Rabbit anti-thymocyte globulin (ATG) will be given only to unrelated donor transplant recipients at a dose of 3 mg/kg/day I.V. Equine ATG at a dose of 30mg/kg/day may be substituted in the event of severe allergic reaction to the rabbit ATG. Rabbit ATG is only used with recipients of unrelated donor marrow or peripheral blood transplants. Fludarabine will be given at a dose of 30 mg/m2/day IV over 30 mins for 5 doses. Cyclophosphamide will be given at a dose of 50 mg/kg/day IV over 2 hrs for 4 doses.
89445826|NCT02472158|Experimental|chlorhexidine-gel-impregnated dressing|Chlorhexidine Patients receive a chlorhexidine-gel-impregnated dressing ( 3M Tegaderm CHG IV securement dressing™ ) after insertion of central venous catheter
89445827|NCT02472158|Active Comparator|Polyurethane film dressing|Polyurethane film dressing Patients receive a transparent polyurethane film dressing (3M Tegaderm IV dressing™) after insertion of central venous catheter.
89445828|NCT02472080|Experimental|gemcitabine -oxaliplatine combination|
89445829|NCT02473562|Experimental|Varenicline|Varenicline capsule 1 mg BID
89445830|NCT02473562|Placebo Comparator|Placebo|Placebo capsule
89445831|NCT05585996|Experimental|Combination therapy of CD19 CAR-T and CD19 CAR-DC|6-18 patientsare planned to be enrolled in the dose-escalation trial (0.5×10^6/kg、1×10^6/kg、2×10^6/kg和4×10^6/kg) and 52 patients in the dose-expansion trial.
89445832|NCT02724020|Active Comparator|Arm A: Single-agent Everolimus 10 mg QD|Everolimus 10 mg capsules, orally, once daily in a 28-day treatment cycle until disease progression, consent withdrawal, death, or transfer to the Post-trial Access (PTA) program (Median duration of treatment was 15.43 weeks up to end of study).
89445833|NCT02724020|Experimental|Arm B: Single-agent MLN0128 30 mg QW|MLN0128 30 mg capsules, orally, once weekly on Days 1, 8, 15, and 22 of a 28-day treatment cycle until disease progression, unacceptable toxicity, consent withdrawal, death, or transfer to the PTA program (Median duration of treatment was 9.64 weeks up to end of study).
88930437|NCT01740544|Sham Comparator|Sham tDCS in young study participants|Sham tDCS in young study participants
88930438|NCT01740544|Sham Comparator|Sham tDCS in elderly study participants|Sham tDCS in elderly study participants
88930439|NCT01740570|Experimental|Cabazitaxel|"Cabazitaxel by vein on day 1 of each 3 week cycle.~Phase I: Up to 5 dose levels of cabazitaxel tested. Two (2) dose levels will be given over 60 minutes, and 3 will be given over 30 minutes. First group of participants receive the lowest dose level. Each new group receives a higher dose level of cabazitaxel than the group before it, if no intolerable side effects were seen.~Phase II: Cabazitaxel at the highest dose that was tolerated in Phase I."
88930440|NCT01740583|Experimental|annuloplasty|All patients will receive treatment with the Mitralign Percutaneous Annuloplasty System (MPAS).
88930441|NCT01740609|Placebo Comparator|1. Placebo|Placebo
88930442|NCT01740609|Experimental|2.0|
89013795|NCT06191185|Experimental|No BPB, No PIN|"No BPB: Clinic's usual practice after a patient receives an abnormal FIT result.~No PIN: Patients will receive usual communication from their care team."
89200085|NCT00763152||stability of Beacons in prostatic bed|Patients implanted with the Calypso transponders following radical prostatectomy for prostate cancer will be followed for observation of transponder stability.
89200086|NCT00759720|Experimental|TAK-559 16 mg QD + Glyburide QD|
89445834|NCT02724020|Experimental|Arm C: Combination of MLN0128 4 mg QD + MLN1117 200 mg QD|MLN0128 4 mg and MLN1117 200 mg capsules, orally, both once daily for 3 days per week (QD X 3) on Days 1-3, 8-10, 15-17, and 22-24 of a 28-day treatment cycle until disease progression, unacceptable toxicity, consent withdrawal, death, or transfer to the PTA program (Median duration of treatment was 9.43 weeks up to end of study).
89445835|NCT02660034|Experimental|Part A: Dose Escalation Phase|Participants received tislelizumab and pamiparib (dose escalation) until determination of the maximum tolerated dose/recommended Phase 2 dose.
89445836|NCT02660034|Experimental|Part B: Dose Expansion Phase|Participants received tislelizumab and pamiparib (dose expansion).
89445837|NCT02816736|Active Comparator|LCZ696 (Entresto) + placebo|LCZ696 50 mg, 100 mg, or 200 mg orally twice daily for 24 weeks, plus valsartan placebo (to match 40 mg, 80 mg, or 160 mg) orally twice daily for 24 weeks
89445838|NCT02816736|Active Comparator|valsartan + placebo|valsartan 40 mg, 80 mg, or 160 mg orally twice daily for 24 weeks, plus LCZ696 placebo (to match 50 mg, 100 mg, or 200 mg) orally twice daily for 24 weeks
89445839|NCT02477072|Active Comparator|Fixed heparin dose (general anesthesia)|Study subjects will be randomized to receive a fixed dose of 5000 units of heparin administered intravenously 2 minutes prior to vascular clamping and blood flow interruption. A subsequent dose of heparin will be administered if requested by the surgeon following a visual assessment of the anticoagulation in the surgical field. Anticoagulation will be monitored at different time points during surgery using ACT and TEG. Peripheral blood flow will be assessed prior and after surgery using the ankle-brachial index and toe-brachial index.
89445840|NCT02477072|Experimental|Weight-adjusted doses of heparin|Study subjects will be randomized to receive 100 units of heparin per kilogram administered intravenously 2 minutes before vascular clamping and blood flow interruption. Subsequent doses of heparin will be administered to maintain the ACT between 300 and 350 seconds at all times during vascular clamping. Anticoagulation will be monitored at different time points during surgery using ACT and TEG. Peripheral blood flow will be assessed prior and after surgery using the ankle-brachial index and toe-brachial index.
89445841|NCT02477072|Active Comparator|Fixed heparin dose (regional anesthesia)|For safety reasons, study subjects under regional anesthesia will automatically be assigned to this group and will receive a fixed dose of 5000 units of heparin administered intravenously 2 minutes prior to vascular clamping and blood flow interruption. A subsequent dose of heparin will be administered if requested by the surgeon following a visual assessment of the anticoagulation in the surgical field. Anticoagulation will be monitored at different time points during surgery using ACT and TEG.
89445842|NCT03490422|Experimental|Pulpotomy|Pulpotomy is performed in carious-exposed pulp in mature permanent teeth
89445843|NCT05103410|Active Comparator|Aripiprazole|Patients will receive Aripiprazole 30 mg tablet orally 3 h before surgery
89445844|NCT05103410|Placebo Comparator|Placebo|Patients will receive placebo tablet which is identical in appearance, size, shape, and color to aripiprazole 3 h before surgery.
89445845|NCT04704882|Experimental|omental patchwork group|
89445846|NCT04704882|No Intervention|non-omental patchwork group|
89445847|NCT02472236|Experimental|Digoxin and PEX168(200µg)|Digoxin: 0.5mg, oral Administration. PEX 168: 200µg,injected subcutaneously,once a week.
89445848|NCT03492294||patients with disorders of consciousness|patients with disorders of consciousness from several brain injury have been clinically classified into coma, unresponsive wakefulness syndrome and minimally conscious state. These patients were scaned by functional magnetic resonance imaging.
89445849|NCT02193867|Experimental|Open-Label Sebelipase Alfa|All participants initiated once weekly (qw) intravenous (IV) infusions with sebelipase alfa at a dose of 1 milligram/kilogram (mg/kg) qw. A participant who met protocol defined dose escalation criteria at a dose of 1 mg/kg qw could be considered for a dose escalation to 3 mg/kg qw. If a participant continued to meet dose escalation criteria after at least 4 infusions at a dose of 3 mg/kg qw, the participant could be considered for a further dose escalation to 5 mg/kg qw. Under country-specific provisions (United Kingdom only), participants could be considered for a further dose escalation to 7.5 mg/kg qw if a thorough case review indicated that a participant continued to have evidence of disease progression at a dose of 5 mg/kg qw. All dose escalations were contingent upon acceptable safety and tolerability of preceding infusions and were undertaken by mutual agreement of the Investigator and Sponsor and after approval by an independent safety committee.
89445850|NCT02472002|Experimental|Mesenchymal cell therapy|
89445851|NCT03108872||LAAO group|One-hundred consecutive patients who underwent left atrial appendage occlusion from October 2010 to March 2015 in 5 Korean tertiary cardiovascular centers will be retrospectively registered.
89445852|NCT03108872||NOAC group|Two-hundred age-, sex-, CHA2DS2-VASc score- and HAS-BLED score- matched control will be selected with a 1:2 ratio among all patients treated with new oral anticoagulants to prevent ischemic events from 5 centers during same periods
89445853|NCT03490266|Active Comparator|Laparoscopic Repair|The abdomen will be entered and insufflated utilizing a 5 mm optical port. Only 5 mm ports will be utilized laterally to take down all anterior abdominal wall adhesions. A mid-density polypropylene mesh with a one-sided adhesion barrier that provides at least 5 cm of overlap in all directions will be inserted through a 11 or 12 mm port placed through the defect. Excision of hernia sac and preperitoneal fat and defect closure will be performed per current practice. The mesh will be secured in four points with 0-PDS sutures and/or tacked with a double crown of tacks per our current practice.
89445854|NCT03490266|Experimental|Robotic Repair|Three lateral ports will be placed including a 12 port for the camera. Adhesions will be taken down from the anterior abdominal wall. Hernia sac and preperitoneal fat will be excised per current practice and defect will be closed using a running locking barbed suture. A mid-density polypropylene mesh with a one-sided adhesion barrier that provides at least 5 cm of overlap in all directions will be inserted through the 12 mm port. The mesh will be secured circumferentially with a running barbed suture.
89445855|NCT02194491|Experimental|[11C]AS2471907 administration (Part 1)|Up to 4 single dose IV administrations (≤ 10 mL infused over approximately 1 minute) are planned, totaling less than 100 μg.
89445856|NCT02194491|Experimental|ASP3662 administration (Part 2)|The dose levels used in part 2 will depend on the ongoing analysis of EO (enzyme occupancy) from previously dosed subjects.
89445857|NCT03108560|Experimental|Sublobar group|Patients receive sublobar resection, including wedge resection and segmentectomy.
89445858|NCT03108560|Active Comparator|Lobectomy group|Patients receive lobectomy.
89445859|NCT03487770|Experimental|Aripiprazole Oral Solution|1 mg/mL, 2 ~ 15 mg/day (2 ~ 15 mL/day), taken once daily for 8 weeks. Administrate about at the same time each day, either before or after meals;
89445860|NCT03487770|Placebo Comparator|Placebo Oral Solution|2 ~ 15 mg/day (2 ~ 15 mL/day), taken once daily for 8 weeks. Administrate about at the same time each day, either before or after meals.
89445861|NCT02194569|Experimental|High citrate group|Blood flow according to weight.Target citrate concentration is 4,5 mmol/L blood flow delivered as prismocitrate 18/0 pre-filter. After correction for filtration fraction, the required further amount of substitution fluid is given post filter to achieve a hemofiltration rate of 30 ml/kg/hr. Blood citrate concentrations are tailored to achieve an iCa of 0.8-1.1 mg/dL.
89445862|NCT02194569|Experimental|Low citrate group|Blood flow according to weight. Target citrate concentration is 2.5 mmol/L blood flow delivered as prismocitrate 18/0 pre-filter. After correction for filtration fraction, the required further amount of substitution fluid is given post filter to achieve a hemofiltration rate of 30 ml/kg/hr. Blood citrate concentrations are tailored to achieve an iCa of 1.3-1.6 mg/dL.
89445863|NCT02473328|Experimental|non comparative open study|"In patients signed an informed consent and meeting all the eligibility criteria at the time of the run-in (S-4), switch of antiretroviral therapy Atazanavir 300 mg/ritonavir 100 mg once a day to Atazanavir 200 mg/ritonavir 100 mg once a day without changing the combination of 2 NRTIs associated.~The administration will be done once a day orally for 48 weeks."
89445864|NCT02473406|Experimental|Thymosin|Thymosin alpha 1 has been shown to have immunomodulatory properties
89445865|NCT02473406|Placebo Comparator|Placebo|normal saline;
89445866|NCT02194023|Placebo Comparator|Placebo (PCB)|Placebo mouthrinse: physiological saline solution (0.9% w/w solution of NaCl in deionized water)
89445867|NCT02194023|Experimental|0.12%NF|0.12% Chlorhexidine digluconate new formulation
89445868|NCT02194023|Experimental|0.03%NF|0.03% Chlorhexidine digluconate new formulation
89445869|NCT02194023|Active Comparator|PAT (Perio-Aid Treatment)|Commercialized 0.12% Clorhexidine digluconate (Perio-Aid Treatment, Dentaid, Spain)
89445870|NCT02473172|Experimental|Pressure Support Ventilation|Assisted mechanical ventilation
89445871|NCT02473172|Experimental|Neurally Adjusted Ventilatory Assist|Assisted mechanical ventilation
89445872|NCT03490188|Experimental|Treatment Arm|Patients assigned to treatment arm will receive standard post-transplantation discharge care that includes weekly follow-up visits and 24-hour access to transplant triage call center. In addition, they will be matched with a mentor who will conduct 5 meetings with the patients (which includes one video chat meeting, 4 30-minute phone calls) and discuss the following topics related to post-discharge: Medications, Lab Work, Fluid Intake and Adherence to doctor's appointment
89445873|NCT03490188|No Intervention|Control Arm|Control arm recipient will receive standard post-transplantation discharge care that includes weekly follow-up visits and 24-hour access to transplant triage call center
89445874|NCT03534843||Surgical treatment|Patients who received liver resection or palliative surgery, such as microwave coagulation therapy, hepatic artery ligation, or suturing ligation.
88930443|NCT01740622|Experimental|Injury Intervention Group|In homes of children who are randomized to the injury intervention arm of the trial, a comprehensive survey of injury hazards in living spaces will be undertaken. In addition to quantifying hazards, the area of living spaces will be obtained to allow the determination of both the number and density (number of hazards per 100 sq.ft.) of injury hazards. If one or more injury hazards are identified, they will be removed and/or modified to reduce exposure and injury risk. The intervention is focused on areas in living spaces below 1-meter (~39 inches) in height from (the 75th percentile in height or eye-level for a 3-year old US male toddler) which might be easily reached or climbed on by children less than 4 years.
88930444|NCT01740622|No Intervention|Control Group|Participants who are assigned to the control group will have their medical claims examined related to injury in the home. Households in this control condition will also be provided with information sheets on child safety developed by the American Academy of Pediatrics, The Injury Prevention Program (TIPP). These age-based recommendations for child safety are provided as standard of care at many pediatric offices.
88930445|NCT01740635|Experimental|EPIC WheelS Training Program|The EPIC WheelS program includes a comprehensive, structured library of educational material and training activities, organized in a hierarchy from simple to complex. Experimental group subjects will attend 2 training sessions with an expert Trainer. The Trainer will individualize a structured home training program, delivered via a computer tablet, and subjects will train at home for 1 month.
89200087|NCT00759720|Experimental|TAK-559 32 mg QD + Glyburide QD|
89200088|NCT00759720|Active Comparator|Glyburide QD|
89445875|NCT03534843||Non-surgical treatment|Patients who received transcatheter arterial embolization (or transcatheter arterial chemoembolization) or conservative treatment
89445876|NCT02473016|Experimental|Treatment|All subjects will receive both Active (Carbon Dioxide Drug Delivery System) and Placebo. This is a single-blind study so subjects will not know the order. Subjects will receive 3 doses of active and 3 doses of placebo. One dose is a 60 second delivery of CO2 or placebo. At the discretion of the investigator, subjects may receive up to 3 additional doses of CO2.
89445877|NCT03131856|Experimental|Nutritional intervention programme|An individual dietary plan conducted by a clinical dietician before discharge in combination with three follow-up visits after discharge (1, 4 and 8 weeks).
89445878|NCT03131856|No Intervention|Usual care|Usual care which means no individual dietary plan and no nutrition follow-up visits after discharge.
89445879|NCT03132012|Experimental|Indoor tanning intervention|Web-based intervention modules to discourage tanning.
89445880|NCT03132012|Active Comparator|standard of care control|General information regarding UV protection measures through an online Qualtrics interface. Content will mirror information provided in brochures typically available in a dermatology office or through skin cancer prevention websites.
89445881|NCT02473094|Experimental|Neoadjuvant capecitabine and metformin|"Capecitabine 825 mg/m2 bid D1-5, q7d, for five weeks;~Metformin 2500mg/d for five weeks;~3D radiotherapy 50,4Gy divided in 25 fractions"
89445882|NCT02473094|Placebo Comparator|Neoadjuvant capecitabine and placebo|"Capecitabine 825 mg/m2 bid D1-5, q7d, for five weeks;~Placebo 2500mg/d for five weeks;~3D radiotherapy 50,4Gy divided in 25 fractions"
89445883|NCT03534765||Retrospective arm|Retrospective multicentre cohort with 1 year outcomes available following emergency surgery for NELA eligible gastrointestinal pathology. Please refer to WP1 inclusion and exclusion criteria for eligibility.
89445884|NCT03534765||Prospective, multicentre arm|10 centre prospective observational arm. Please refer to WP2 inclusion and exclusion criteria for eligibility.
89445885|NCT03492138|Experimental|Participants with relapsed/refractory multiple myeloma|ONC201, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma. Run-in phase of ONC201 and dexamethasone weekly until progression at 4 weeks, lack of response at 8 weeks, or progression followed by the addition of weekly ixazomib.
89445886|NCT02472938|Experimental|BG00012|120 mg capsule oral twice daily (BID) during the first week and 240 mg BID thereafter.
89445887|NCT02472938|Placebo Comparator|Placebo|Placebo capsules orally twice a day.
89445888|NCT03131700|Experimental|RPH-001|A single dose of RPH-001 will be administered (IV) 5 mg/kg dose .
89445889|NCT03131700|Active Comparator|EU sourced Avastin®|A single dose of Avastin® will be administered (IV) 5 mg/kg dose .
89445890|NCT02194101||Supernormal oxygen delivery goal therapy|Patients will be aged over 70 yr and weight over 35 kg, and undergoing proximal femur fracture (PFF) surgery under peripheral nerve block and laryngeal mask airway anesthesia.
88930446|NCT01740635|No Intervention|Cognitive games|To provide a comparable level of investigator attention, control group subjects will receive two 1-hour social visits. To control for Trainer bias, the experimental and control groups will have separate Trainers. During social visits, the Trainer will discuss subjects' current community activities and their experience using the wheelchair, and provide verbal information related to barriers encountered. Subjects will receive a computer tablet with cognitive stimulation games to account for activity and tablet device exposure. Participants in the extra wheeling sub-group will be instructed to perform additional, unstructured wheeling for 15 minutes, 5 days per week (total 75 minutes/week) and document these on a simple calendar-style form provided. To minimize attrition, control subjects will receive a DVD with a condensed MWC skills education program after the post-intervention data collection is complete.
88930447|NCT01740661|Experimental|Cryotherapy|The subjects will be exposed to a cold (~ 12° C) water immersion tub at the umbilical level for 20 minutes.
88930448|NCT01740661|Placebo Comparator|Control|The subjects will be exposed to a non-cold (~ 26° C) water immersion tub at the umbilical level for 20 minutes.
88930449|NCT01740674|Experimental|Electronic data collection|The group of participants who will complete questionnaires via the internet
88930450|NCT01740674|No Intervention|Paper data collection|The group of participants who will continue to complete paper based questionnaires, as has been the practice for this longitudinal study.
89445891|NCT03534999|Experimental|TENS|This is intervention Group. Patients in this group received Transcutaneous Electrical Nerve Stimulation (TENS). The VAS and Oxford hip score was administered prior to the treatment to ascertain their pain intensity and hip disability level. The site of intervention (5cm away from incision site) was cleaned properly with cotton wool soaked in methylated spirit in an outward motion. Before the self-adhesive, pre gelled electrodes was placed on the cleansed sites.The TENS unit was switched on and the parameters was adjusted to the required level. For this study, parameters used are: 100µs pulse duration, 100Hz frequency and an intensity comfortable for the patient for a duration of 15 minutes.
89445892|NCT03534999|No Intervention|Control|This was the group with no intervention. Subjects were on their normal analgesic and antibiotic medication for the period of research. The VAS and Oxford hip score were administered on the first day to ascertain pain intensity and hip disability level. The subject continued on the normal analgesics only till the third day and VAS and Oxford hip score was re-administered to assess any change in the pain intensity and hip disability level.
89445893|NCT02194803||Cohort with routine OCT monitoring|
89445894|NCT02194803||Cohort without routine OCT monitoring|
89445895|NCT03534921||People with severe mental illness (SMI)|In the study period 01/04/2000-31/03/2016, people with records on the Clinical Practice Research Datalink aged >=18 years with a record of severe mental illness so that at least one event occurs in the study period.
89445896|NCT03534921||People with SMI and type 2 diabetes|Drawn from the first cohort, this group also has a record of type two diabetes mellitus registered during the study period.
89445897|NCT03534921||People with diabetes (matched controls)|This cohort will be matched on a 4:1 ratio by age (+- 2 years), gender and general practitioner practice to the group of people with comorbid SMI and diabetes.
88930451|NCT01740700|Experimental|p-Branch®|
88930452|NCT01740739||Cardiac Risk|Patients, as part of their standard of care, who are recommended for and who complete a test resulting in a Coronary Calcium Score, lipid test, hs-CRP and MPO result.
88930453|NCT01740752|Experimental|UCAN+CBT|This condition includes 22 UCAN sessions and 22 CBT sessions, totaling 44 psychotherapy sessions. UCAN is a manualized, 22-session Cognitive Behavioral Couple Therapy (CBCT) intervention that engages the couple to target the core psychopathology of AN and address the uniquely challenging stress that AN places on intimate relationships. The CBT proposed for this study is a 22 session adaptation of the manualized intervention that has been employed successfully as an outpatient post-hospitalization therapy and in an National Institute of Mental Health multisite study of fluoxetine with elements from the CBT manual used in McIntosh et al (PubMed 15800147).
89445898|NCT02368002|Experimental|Behavioral weight loss therapy|Emphasizes 1) identifying behaviors in need of change, 2) setting goals for change, 3) monitoring progress, 4) modifying environmental cues to facilitate change, and 5) modifying consequences to motivate change.
89445899|NCT02368002|Experimental|Portion-controlled meals|Fifty percent of participants who have not lost the expected amount of weight will be re-randomized to receive portion-controlled meals in addition to standard behavioral weight loss therapy.
89445900|NCT02368002|Experimental|Acceptance-based treatment|Fifty percent of participants who have not lost the expected amount of weight will be re-randomized to receive an enhanced version of behavioral weight loss therapy teaching acceptance-based behavioral skills.
88930454|NCT01740752|Experimental|CBT|"In this condition, participants will receive a higher dose of individual CBT, with 44 total sessions. Our experience with patients in the pilot strongly suggests that a higher dose of CBT will allow for further, fruitful discussion and exploration of key individual issues and is unlikely to be experienced as diluted or a slow approach to treatment. Most of these patients have complicated histories, long-standing eating disorders, and complex comorbid conditions."
88930455|NCT01740765|Experimental|Eucaloric Feeding|Subjects will complete an initial eucaloric feeding study day. During this study day, subjects will receive 100% of their calorie requirements. 24-hour energy expenditure will be measured.
88930456|NCT01740765|Experimental|Underfeeding|Following the eucaloric feeding study day, subjects will undergo the underfeeding and overfeeding arms in random order. During the underfeeding study arm, subjects will receive 50% of their calorie requirements (as determined during the initial eucaloric study day) for 3 days. 24-hour energy expenditure will be measured.
88930457|NCT01740765|Experimental|Overfeeding|Following the eucaloric feeding study day, subjects will undergo the underfeeding and overfeeding arms in random order. During the overfeeding study arm, subjects will receive 150% of their calorie requirements (as determined during the initial eucaloric study day) for 3 days. 24-hour energy expenditure will be measured.
88930458|NCT01740778||Study Group 1|Aurora vs. Microlet 2
88930459|NCT01740778||Study Group 2|Aurora vs. SoftClix
88930460|NCT01740778||Study Group 3|Aurora vs. One Touch Comfort
88930461|NCT01740778||Study Group 4|Aurora vs. Multiclix
89445901|NCT04706936|Experimental|Anti-BCMA CAR-T (CBG-002)|All subjects were intravenous administrated with CBG-002.
89445902|NCT02257203|Experimental|Sugar Sweetened Beverage Education|Parents will receive an educational module on beverage just after the conclusion of their child's well visit in a private room adjacent to the clinic
88930462|NCT01740830|Active Comparator|Anodal tDCS|
88930463|NCT01740830|Sham Comparator|Sham tDCS|
88930464|NCT01740843|Active Comparator|Low intensity anodal tDCS|tDCS will be administered for 10 min at 1mA
88930465|NCT01740843|Experimental|High intensity anodal tDCS|tDCS will be administered for 10 min at 2.5mA
88930466|NCT01740843|Sham Comparator|Sham tDCS|Sham will be administered for 10 min at 0 mA
88930467|NCT01740856|Experimental|Rest three hours|Rest three hours
88930468|NCT01740856|Experimental|Rest five hours|Rest five hours
88930469|NCT01740869|Experimental|Experimental: Patients|Children who will receive intrathecal autologous stem cells
88930470|NCT01740869|Other|Control/Crossover|We will evaluate with IDEA and CARS scales the control group for 6 months with the possibility to change arms after that time.
88930471|NCT01740908||Hyperbaric Oxygen Treatment|Six healthy adult individuals (18-65 yrs), with no current, ongoing infection or chronic disease will be recruited for this study. Treatment study subjects will undergo a daily exposure to 2.0 ATA, 100% Oxygen for 90 minutes over 5 days.
88930472|NCT01740908||Baseline|Two healthy study subjects with no current, ongoing infection or chronic disease will be rectuited to serve as a baseline group. Study subjects will not be exposed to HBO, but will have blood drawn at the same time as the treatment group.
88930473|NCT01740921|Active Comparator|Liraglutide|Liraglutide (Victoza) daily injections
88930474|NCT01740921|Placebo Comparator|diet|reduction in calorie intake
88930475|NCT01740921|Placebo Comparator|Aspirin|Aspirin 300mg once daily
88930476|NCT01740934|Active Comparator|Anatabloc Cream|Twice daily use of active facial cream
88930477|NCT01740934|Placebo Comparator|Placebo Cream|Twice daily use of placebo facial cream
89445903|NCT02257203|Active Comparator|Reading Education|Parents will receive an educational module on the importance of reading to children with instruction in interactive reading techniques that are appropriate to the child's age
89445904|NCT02194881||Ivacaftor 1|patients with CF who are homozygous or heterozygous for the G551D mutation and treated with Ivacaftor
89445905|NCT02194959|Experimental|Peer PN|A scheduling phone call will be made to all patients within 14 days of their initial referral to the study. Following the scheduling of their appointment, each patient will be mailed an informational pamphlet with written instructions for the colonoscopy once they have scheduled the procedure. The first reminder PPN phone call will be made two weeks before a patient's scheduled colonoscopy. The second reminder PPN call will be made three days before the scheduled colonoscopy. For all calls, at least three attempts (at different times of the day and different days of the week) will be made to reach patients. All telephone calls will be audio-recorded to facilitate fidelity monitoring. All colonoscopy appointments will be made within the Division of Gastroenterology at each of the hospital sites. The Project Coordinator will be responsible for confirming completion (and no-shows) for all colonoscopy appointments.
89445906|NCT02194959|Active Comparator|Pro PN|Participants randomized to standard patient navigation received care that they would normally receive if they were not participating in the study with navigation from the GI staff, and three phone calls that involved scheduling and reminding the participant about their colonoscopy appointment.
89445907|NCT03534609|Experimental|Genius System Neck Treatment|Lutronic Genius System treatment of lines, wrinkles, and texture concerns on the neck.
88930478|NCT01740947|No Intervention|Standard treatment|Standard treatment for colorectal cancer
88930479|NCT01740947|Experimental|Selective decontamination of the digestive tract (SDD)|"Standard treatment + SDD perioperatively 4 times daily 10 ml of SDD suspension, consisting of 100mg colistin sulfate, 80mg tobramycin and 500mg of amphotericin B.~SDD treatment starts 3 days before surgery and is continued until at least 3 days postoperatively."
88930480|NCT01740960|Active Comparator|delta-9-tetrahydrocannabinol|Subjects will be randomized to receive 3 doses Namisol® (3 mg, 5 mg, 6,5 mg)
88930481|NCT01740960|Placebo Comparator|Placebo|The control product is placebo, consisting of a tablet with similar appearance and taste of the test product.
88930482|NCT01740973||SILC cholecystectomy|No intervention. 239 SILC having a prospective questionnaire and clinical follow-up, if the patient suspects an umbilical hernia.
88930483|NCT01740973||and conventional lap. cholecystectomy|no intervention.Patients are also mailed a prospective questionnaire and clinical follow-up, if the patient suspects an umbilical hernia.
88930484|NCT01740986|Experimental|SA09012 Low dose|
88930485|NCT01740986|Experimental|SA09012 High dose|
88930486|NCT01740986|Placebo Comparator|Placebo|
88930487|NCT01741025|Experimental|iFuse Implant System|Surgical placement of iFuse implants in the affected SI joint
88930488|NCT01741025|Active Comparator|conservative management|Medications, physical therapy, information
88930489|NCT01741038|Experimental|AlloStim® treatment|The treatment schedule includes: (1) the priming step with two ID AlloStim® injections (Days 0 and 3), an additional two ID injections followed by IV infusion of AlloStim® (Days 7 and 10); (2) the vaccination step with cryoablation of a single metastatic lesion followed by injection of AlloStim® into the ablated tumor and IV infusion of AlloStim® on protocol day 14, followed by IV infusion of AlloStim® on Day 17 (3) the activation step with an IV study drug infusion on Day 21 and (4) the booster step with IV booster infusions of AlloStim® on days 49 and 77. Additional booster infusions can be administered monthly at the discretion of the Investigator.
88930490|NCT01741038|Other|Physician's Choice (PC)|All subjects will be assigned Physician's Choice (PC) therapy. PC can consist of best supportive care (BSC) or any US-FDA-approved cancer drug (e.g. Cetuximab) administrated as a monotherapy at the manufacturer's recommended dose. The treatment schedule shall be prospectively determined and administered as tolerated.
88930491|NCT01741051|Experimental|HEPA Filter|HEPA filter(s) placed in the participant's home from approximately 10 weeks gestation until birth.
88930492|NCT01741051|No Intervention|Control|
88930493|NCT01741064||PTH below target iPTH in CKD|iPTH at one year post transplantation below target range of iPTH by stage of CKD (KDOQI-guidelines).
88930494|NCT01741064||iPTH within target range of iPTH in CKD|iPTH at one year post transplantation within target range of iPTH by stage of CKD (KDOQI-guidelines).
88930495|NCT01741064||iPTH above target range of iPTH in CKD|iPTH at one year post transplantation above target range of iPTH by stage of CKD (KDOQI-guidelines).
89200089|NCT04037319||Main cohort|Will undergo surgery for colorectal cancer with curative intent as planned by local cancer multidisciplinary team.
89445908|NCT02194179|Experimental|NVP XR 400 mg (KCR 25%) fasted|
89445909|NCT02194179|Experimental|NVP XR 400 mg (KCR 25%) fed|
89445910|NCT02194179|Experimental|NVP XR 400 mg (KCR 20%) fasted|
88930496|NCT01741077||pregnant women|pregnant women taking 1 mg folic acid;
88930497|NCT01741077||non-pregnant women|non-pregnant women taking 0mg folic acid;
88930498|NCT01741077||non-pregnant women 2|non-pregnant women taking 1 mg folic acid
89445911|NCT02194179|Experimental|NVP XR 400 mg (KCR 20%) fed|
89445912|NCT02194179|Experimental|NVP XR 300 mg (KCR 25%) fasted|
88930499|NCT01741077||non-pregnant women 3|non-pregnant women taking 5 mg folic acid
88930500|NCT01741090|Experimental|MSC injection|This study is designed as single interventional arm without comparative arm. MSC injection means hepatic artery catheterizations and mesenchymal stem cell injection through catheter.
88930501|NCT01741116|Experimental|TKI258, inhibitor of RTKs|"Intervention: TKI258~Investigational drug, TKI258, will be administered to all of the patients after enrollments. Treatment will initially be administered as 28-day cycles as follows:~- Daily 500mg of TKI258 will be self-administered orally by the patient for 5 days, followed by 2 days of treatment off."
88930502|NCT01741129|Active Comparator|Nasal Continuous Positive Airway Pressure (CPAP)|"After 2 hours evaluation:~Infants needed invasive MV (mechanic ventilation) or Required a fraction of inspired oxygen of >40% to maintain the targeted saturation of >88% to 92%.~Non-invasive surfactant treatment (Curosurf®) 100 mg/kg per dose"
88930503|NCT01741129|Active Comparator|Nasal Intermittent Mandatory Ventilation (IMV)|"After 2 hours evaluation:~Infants needed invasive MV or Required a fraction of inspired oxygen of >40% to maintain the targeted saturation of > 88% to 92%.~Non-invasive surfactant treatment (Curosurf®) 100 mg/kg per dose"
88930504|NCT01741142|Experimental|ABT-436|Subject receiving ABT-436
88930505|NCT01741142|Active Comparator|Escitalopram|Subject receiving escitalopram.
88930506|NCT01741142|Placebo Comparator|Placebo|Subject receiving placebo
89200090|NCT00888069|Experimental|Low Dose CTAP101 Capsules|CTAP101 Capsules, 450 mcg dose
89445913|NCT02194179|Experimental|NVP XR 300 mg (KCR 25%) fed|
89445914|NCT02194179|Experimental|NVP XR 300 mg (KCR 20%) fasted|
89445915|NCT02194179|Experimental|NVP XR 300 mg (KCR 20%) fed|
89445916|NCT02194179|Active Comparator|NVP IR 200 mg (Viramune®)|
89445917|NCT02194257|Experimental|[14C]-cyclohexane ambroxol oral solution + ambroxol lozenge|
89445918|NCT02194257|Experimental|[14C]-benzyl ambroxol oral solution + ambroxol lozenge|
89445919|NCT02195115|Active Comparator|Laparoscopic cholecystectomy|surgical removal of gallbladder
89445920|NCT02195115|Active Comparator|Non-operative treatment|Administration of amitriptyline 25mg daily, Low Fat-Low Cholesterol Diet
89445921|NCT02194335|Experimental|BIBN 4096 BS - in single rising doses|
89445922|NCT02194335|Placebo Comparator|Placebo|
89445923|NCT02031003|Other|Control|Standard infant formula
89445924|NCT02031003|Experimental|Experimental 1|Standard infant formula containing a new fat blend
89445925|NCT02031003|Experimental|Experimental 2|Standard infant formula containing a new fat blend and fiber
89445926|NCT02031003|No Intervention|Human Milk (HM)|Non-randomized Human Milk group
88930507|NCT01741168|Active Comparator|TLSO|TLSO brace 8-10 weeks
88930508|NCT01741168|Experimental|No Orthosis|No Orthosis
88930509|NCT01741181|Active Comparator|Vitamin D supplementation|Vitamin D3 tablets (cholecalciferol)
88930510|NCT01741181|Placebo Comparator|Placebo pill|Placebo pill
88930511|NCT01741207|No Intervention|control|control This group is without N-acetylcystein : just receives standard treatment
88930512|NCT01741207|Active Comparator|N-acetylcystein|receive N-acetylcystein in addition to standard treatment Ampoule 200 mg/ml
88930513|NCT01741220||anesthetists|German-speaking intensive-care providers and anesthetists
88930514|NCT01741233|Experimental|UV-B irraditation|VitDgen
88930515|NCT01741246||Control|Headache-free subjects.
88930516|NCT01741246||Episodic migraine|Patients with less that 15 headache days per month that fulfill International Classification of Headache Disorders 2R (ICHD-2nd edition Revised)- criteria for Episodic Migraine.
88930517|NCT01741246||Chronic migraine|Patients that fulfill International Classification of Headache Disorders (ICHD)-2R criteria for chronic migraine (more than 15 days per month).
88930518|NCT01741285|Active Comparator|Fluticasone|Two weeks treatment with HFA-Fluticasone 250 microgram twice daily
88930519|NCT01741285|Active Comparator|Clenil|Two weeks treatment with HFA-Clenil 200 microgram 2 inhalations twice daily.
88930520|NCT01741285|Experimental|QVAR|Two weeks treatment with QVAR 2 times 100 microgram twice daily
89445927|NCT02195973|Experimental|Paclitaxel + LDE225|Patients will receive intravenous paclitaxel on days 1, 8, and 15 every 28 days (3 weeks on followed by one week off). This constitutes one cycle. in addition to the paclitaxel oral LDE225 will be taken daily. Dosages of each drug will vary according to the study cohort and phase. The study consists of six cycles of treatment followed by clinic visits every 2-3 months for up to two years.
89445928|NCT02196129|Experimental|Sinbaro-3|1cc Harpagophytum Procumbens(freeze drying) pharmacoacupuncture adminstered to 6 acupoints at the site of pain Administered once and once only before any interventions
89445929|NCT02196129|Placebo Comparator|Hwangryun(distillation)|1cc Hwangryun(distillation) pharmaco-acupuncture administered to 6 acupoints at the site of pain Administered once and once only before any other intervention
88930521|NCT01741298|Experimental|Lifestyle counseling|CHARMS Intervention Participants (Pts) randomized to the lifestyle intervention received a yr long, 17 session intervention. Pts were asked to wear a pedometer and record their food intake for at least the week prior to each session. The first 4 sessions were delivered weekly, followed by 4 sessions delivered biweekly and finally 9 sessions delivered monthly. Each session was approximately 1-2 hrs. At the beginning of each session anthropometric, physical activity and dietary data were collected. Participants were lead in a 5 min deep breathing exercise before the didactic portion of the session began. Sessions targeted a broad range of material related to diet, physical activity, and psychosocial well-being. Participants were given homework assignments to incorporate covered material into their daily lives. Participants randomized to the intervention arm received follow-up assessments at 6 and 12 months post randomization.
88930522|NCT01741324|Experimental|Umeå, vitamin D 25 microg/d, light skin|Participants with light skin will be randomized to a milk drink providing 25 microg vitamin D3 per day.
88930523|NCT01741324|Active Comparator|Umeå, vitamin D 10 microg/d, dark skin|Participants with dark skin will be randomized to a milk drink providing 10 microg vitamin D3 per dag.
89445930|NCT02195193|No Intervention|Usual Care (UC)|"The standard interventions from Clinical Pathway for Acute Coronary Syndromes in China-Phase 3 (CPACS-3) study that are limited to in-patient ACS care (refer to Usual Care [UC]), will be implemented in the participating hospitals, and hence will be received by all patients in both intervention (IC) and control (UC) groups; standardized cardiovascular disease education also will be provided to all participants.CPACS-3 registration number is NCT01398228"
88930524|NCT01741324|Active Comparator|Umeå, vitamin D 10 microg/d, light skin|Participants with light skin will be randomized to a milk drink providing 10 microg vitamin D3 per dag.
88930525|NCT01741324|Experimental|Malmö, vitamin D 25 microg/d, dark skin|Participants with dark skin will be randomized to a milk drink providing 25 microg vitamin D3 per day.
88930526|NCT01741324|Experimental|Malmö, vitamin D 25 microg/d, light skin|Participants with light skin will be randomized to a milk drink providing 10 microg vitamin D3 per day.
88930527|NCT01741324|Active Comparator|Malmö, vitamin D 10 microg/d, dark skin|Participants with dark skin will be randomized to a milk drink providing 10 microg vitamin D3 per day.
88930528|NCT01741324|Active Comparator|Malmö, vitamin D 10 microg/d, light skin|Participants with light skin will be randomized to a milk drink providing 10 microg vitamin D3 per day.
88930529|NCT01741324|Placebo Comparator|Malmö, placebo, dark skin,|Participants with dark skin will be randomized to a milk drink without added vitamin D (placebo).
89445931|NCT02195193|Experimental|Intervention Care (IC)|Besides of the UC, an nurse-coordinated integrated care model for Acute Coronary Syndromes(ACS) and depression will be delivered to intervention group, including ACS secondary prevention therapies at and after discharge, screening and treatment of depression during hospitalization and after discharge.
88930530|NCT01741324|Placebo Comparator|Malmö, placebo, light skin|Participants with light skin will be randomized to a milk drink without added vitamin D (placebo).
88930531|NCT01741324|Experimental|Umeå, vitamin D 25 microg/d, dark skin|Participants with dark skin will be randomized to a milk drink providing 25 microg vitamin D3 per day.
88930532|NCT01741337|Experimental|Patients treated by ventilation|Adaptive servo-ventilation post-operative treatment for 6 months
88930533|NCT01741337|No Intervention|Patients not treated by ventilation|Patients not treated during 6 months by an adaptive servo-ventilation
88930534|NCT01741363|Experimental|one-day sampling with one-year interval|FIT one-day sampling with one-year interval
88930535|NCT01741363|Active Comparator|one-day sampling with two-year interval|FIT one-day sampling with two-year interval
88930536|NCT01741363|Experimental|two-day sampling with one-year interval|FIT two-day sampling with one-year interval
88930537|NCT01741363|Experimental|two-day sampling with two-year interval|FIT two-day sampling with two-year interval
89200091|NCT00888069|Experimental|High Dose CTAP101 Capsules|CTAP101 Capsules, 900 mcg dose
89445932|NCT02257281|Experimental|Active Therapeutic Ultrasound|The three inflammatory forearm spots on the same side induce by the experimentally skin model(1%, 0.5%, 0% SLS) treat with active therapeutic ultrasound .
89445933|NCT02257281|Placebo Comparator|Non-active Therapeutic Ultrasound|The contralateral three inflammatory forearm spots induce by the experimentally skin model(1%, 0.5%, 0% SLS) treat with non-active therapeutic ultrasound .
89445934|NCT02196207|Experimental|Eloctate Prophylaxis|Prevention Trial, Arm A: rFVIIIFc (Eloctate) 65 IU/kg weekly will be administered by intravenous infusion in previously untreated children with severe hemophilia A beginning before the first bleed and continued for up to 48 weeks.
89445935|NCT02196207|Experimental|Emicizumab Prophylaxis|Prevention Trial, Arm B: Emicizumab 1.5 mg/kg weekly (following 4-wk induction at 3 mg/kg weekly) will be administered by subcutaneous injection in previously untreated children with severe hemophilia A beginning before the first bleed and continued for up to 48 weeks.
89445936|NCT02196207|Experimental|Eloctate ITI plus Emicizumab|Eradication Trial, Arm A: Eloctate 100 IU/kg every other day will be administered by intravenous infusion as immune tolerance plus Emicizumab 1.5 mg/kg weekly by subcutaneous injection in previously treated children and adults with severe hemophilia A and high-titer inhibitors and continued for up to 48 weeks.
89445937|NCT02196207|Active Comparator|Eloctate ITI Alone|Eradication Trial, Arm B: Eloctate 100 IU/kg every other day will be administered by intravenous infusion as immune tolerance alone in previously treated children and adults with severe hemophilia A and high-titer inhibitors and continued for up to 48 weeks.
88930538|NCT01741363|Experimental|Hp stool antigen (HpSA)+FIT|HpSA for detection of upper gastrointestinal tract diseases and upper endoscopy for H. pylori carriers; HPSA combined with FIT
88930539|NCT01741376|Placebo Comparator|Placebo + Placebo|Two placebos are given for 84 days.
88930540|NCT01741376|Active Comparator|Progesterone + Placebo|Progesterone (200 mg twice daily) and a placebo are given
88930541|NCT01741389|Placebo Comparator|Sleep only|Placebo given at night to tetraplegic individuals before going to sleep,
88930542|NCT01741389|Active Comparator|Melatonin|Melatonin given at night to tetraplegic individuals before going to sleep.
88930543|NCT01741402|Experimental|Virtual Reality Training|The virtual reality training was done by experimental group with ten games of Nintendo Wii Fit.
88930544|NCT01741402|Active Comparator|Physical Therapy|The Control Group was trained by conventional Physical Therapy exercises.
88930545|NCT01741415|Experimental|SIDI|Skills for Improving Distress Intolerance treatment protocol: individual, manualized treatment aimed at improving distress intolerance
88930546|NCT01741415|Placebo Comparator|SC|supportive counseling; psychological placebo/talk therapy - aimed at controlling for non-specific therapeutic factors
89445938|NCT02195271|Active Comparator|Melatonin|0,25mg/Kg sl before tDCS
88930547|NCT01741428|Active Comparator|Intervention (INT1)|The participants will join a 5-days course at the Feiring Heart Clinic.
88930548|NCT01741428|No Intervention|Control (KTR1)|The participants in the Control Group will receive care as usual at their local Doctors Office
88930549|NCT01741428|Active Comparator|Subgroup Intervention (INT2)|Subgroup of 200 participants from the (INT1)where multiple, known CVD risk factors are studied: Physical Activity, Physical Condition (O2-consumption), Quality of life, Biochemical markers (fasting Glucose, Insulin, Apo Lipoprotein A (ApoA), Apo Lipoprotein B (ApoB), micro-C reactive protein (CRP), Total-, LDL- and HDL-cholesterol, Triglycerides and HbA1C.
88930550|NCT01741428|No Intervention|Subgroup control (KTR2)|Subgroup of 200 participants from the (KTR1)where multiple, known CVD risk factors are studied: Physical Activity, Physical Condition (O2-consumption), Quality of life, Biochemical markers (fasting Glucose, Insulin, Apo Lipoprotein A (ApoA), Apo Lipoprotein B (ApoB), micro-C reactive protein (CRP), Total-, LDL- and HDL-cholesterol, Triglycerides and HbA1C.
88930551|NCT01741441||WAR and MR patients|Consecutive patients with MR and WAR selected for laparoscopic total fundoplication (LTF) were included in a prospective clinical study. Gastroesophageal function was assessed by clinical validated questionnaires, upper endoscopy, esophageal manometry and 24-h impedance pH monitoring before and 12 and 60 months after LTF. Gastric scintigraphy was preoperatively performed in all patients.
88930552|NCT01741467|Experimental|RT-CGM|Patients using the RT-CGM for the intervention portion of the study.
88930553|NCT01741493|Experimental|Healthy Volunteers (ABT-494)|Multiple dosing of ABT-494 in healthy volunteers
89200092|NCT00888069|Experimental|CTAP101 Injection|IV injection, 448 mcg dose
89200093|NCT00885339||A|Patients that are indicated for colonoscopy, who are suspected or known to suffer from colonic diseases.
89445939|NCT02195271|Experimental|tDCS|Transcranial direct current stimulation once time. Dose 2 mA, 20 seconds.
89445940|NCT05124483|Experimental|Pfizer [Comirnaty]|To determine the immunogenicity 4-6 weeks after subcutaneous injection of a booster dose of 90 µg AKS-452X vaccine given at >=3 months post-initial vaccination with the registered Pfizer [Comirnaty] vaccine.
89445941|NCT05124483|Experimental|Moderna [Spikevax]|To determine the immunogenicity 4-6 weeks after subcutaneous injection of a booster dose of 90 µg AKS-452X vaccine given at >=3 months post-initial vaccination with the registered Moderna [Spikevax] vaccine.
88930554|NCT01741493|Experimental|Rheumatoid Arthritis Patients|Multiple dosing of ABT-494 in patients with rheumatoid arthritis
88930555|NCT01741493|Placebo Comparator|No treatment|Placebo administration in healthy volunteers and patients with rheumatoid arthritis
88930556|NCT01741493|Other|Healthy Volunteers (tofa)|Multiple dosing of tofacitinib in healthy volunteers
88930557|NCT01741506|Experimental|Dalteparin (Fragmin®)|Dalteparin (Fragmin®) 5000 IU (International Unit) once daily
88930558|NCT01741506|No Intervention|No treatment|No treatment
88930559|NCT01741506|Other|Open surgery arm|Dalteparin (Fragmin®) 5000 IU once daily
88930560|NCT01741519|Experimental|LDLL600|Landiolol hydrochloride, intravenous infusion of 10, 20 and 40 µg/kg/min for 2 h each followed by 18 h long-term infusion of best tolerated dose.
88930561|NCT01741519|Active Comparator|Brevibloc|Esmolol, intravenous infusion of 50, 100 and 200 µg/kg/min for 2 h each followed by 18 h long-term infusion of best tolerated dose.
88930562|NCT01741558|Experimental|Methotrexate|Established treatment associated with methotrexate
89200094|NCT00763230|Experimental|active|Full active tDCS treatment
89200095|NCT00763230|Sham Comparator|sham|Placebo tDCS will be give
89445942|NCT05124483|Experimental|Janssen [Ad26.COV2.S]|To determine the immunogenicity 4-6 weeks after subcutaneous injection of a booster dose of 90 µg AKS-452X vaccine given at >=3 months post-initial vaccination with the registered Janssen [Ad26.COV2.S] vaccine.
89445943|NCT05124483|Experimental|AstraZeneca [Vaxzevria])|To determine the immunogenicity 4-6 weeks after subcutaneous injection of a booster dose of 90 µg AKS-452X vaccine given at >=3 months post-initial vaccination with the registered AstraZeneca [Vaxzevria]) vaccine.
89445944|NCT02196285|Experimental|Double viral vaccine (MR)|Measles and rubella vaccine
88930563|NCT01741558|Placebo Comparator|Placebo (Riboflavin)|Established treatment associated with placebo (riboflavin sodium fosfate 0.1%). We use riboflavin in placebo group to remain the double-blind fashion: methotrexate has a yellow color and riboflavin in that concentration has the same color.
88930564|NCT01741571|Active Comparator|EBUS guided FNA with suction|"Device/procedure: lymph node tissue collection using fine needle aspiration with suction applied.~Four fine needle aspirations will be taken sequentially from each lymph node. Two with suction and two without suction applied."
88930565|NCT01741571|Experimental|EBUS guided FNA without suction|"Device/procedure: lymph node tissue collection using fine needle aspiration without suction applied.~Four fine needle aspirations will be taken sequentially from each lymph node. Two with suction and two without suction applied."
88930566|NCT01741584|Experimental|stationary bike exercise|6 months of exercise (60% of anaerobic threshold)
88930567|NCT01741584|Placebo Comparator|aerobic|6 months of exercise <30% anaerobic threshold
89445945|NCT02196363||Pregnant mothers|No intervention
88930568|NCT01741597|Experimental|Diagnostic (DCE-MRI, tumor-homing peptide iRGD)|Patients undergo DCE-MRI on day 1 and undergo tumor-homing peptide iRGD DCE-MRI on day 2.
88930569|NCT01741610|Placebo Comparator|No coloading (Group E)|Placebo comparator
88930570|NCT01741610|Active Comparator|Cristalloid (Lactated Ringer) Coloading|Cristalloid (Lactated Ringer's) Coloading (Group L)
88930571|NCT01741610|Active Comparator|Colloid (HES) coloading|Colloid (HES) coloading (Group C)
88930572|NCT01741623|Experimental|Bisoprolol Fumarate Tablet 10 mg|Bisoprolol Fumarate Tablet 10 mg of M/s Ipca Laboratories Limited, India
88930573|NCT01741623|Active Comparator|Zebeta®|Zebeta® (Bisoprolol Fumarate) Tablets 10 mg of Duramed Pharmaceuticals Inc., USA
88930574|NCT01741636|Experimental|Supportive care (survivorship plan)|Patients undergo Survivorship Care Planning comprising disease surveillance, management of potential long-term and late effects, psycho-social-spiritual issues, and healthy living recommendations.
88930575|NCT01741649|Experimental|Clorhexidine|Skin prior to the surgical incision will be cleaned for five minutes with Clorhexidine.
88930576|NCT01741649|Experimental|Povidone|Skin prior to surgical incision will be cleaned for five minutes with a povidine solution.
88930577|NCT01741662|Other|group psychopathological|
88930578|NCT01741675|Experimental|Monetary incentive|The intervention group will receive a postal questionnaire together with a voucher worth €15 for the largest supermarket chain in Denmark. Non-responders will after three weeks receive a reminder together with another copy of the questionnaire. In both cases the questionnaire will be sent with a cover letter and a reply paid return envelope.
88930579|NCT01741675|Other|Control|The control group will only receive a postal questionnaire. Non-responders will after three weeks receive a reminder together with another copy of the questionnaire. In both cases the questionnaire will be sent with a cover letter and a reply paid return envelope.
88930580|NCT01741714|Active Comparator|Chiropractic Spinal Manipulative Therapy|Active chiropractic spinal manipulative treatment
88930581|NCT01741714|Sham Comparator|Sham manipulation|Sham chiropractic manipulative therapy
88930582|NCT01741714|No Intervention|Control group|No intervention, follow headache diary
88930583|NCT01741727|Experimental|ABT-414|Subjects with solid tumors (Phase 1) and squamous non-small cell lung cancer (NSCLC) (Phase 2)
88930584|NCT01741740||retrospective surgical patients|consecutive elective umbilical hernia repair patients during two years from two hospitals,- retrospective id with prospective follow up
88930585|NCT01741753|Experimental|Treatment Arm|BKM120+Abiraterone+Prednisone
89445946|NCT02195505||Synvisc®|
89445947|NCT02195505||Usual treatment of knee|nonsteroidal antiinflammatory drugs, antalgics
89445948|NCT02196441|Experimental|Group 2|0.5% bupivacaine Deep topical fornix nerve block anaesthesia (DTFNB)
89445949|NCT02196441|Experimental|Group 1|2% tetracaine local anaesthetic drops
88930586|NCT01741766|Experimental|Stretching Training|Whole body stretching exercises 3 times per wk for 8 weeks
88930587|NCT01741766|No Intervention|Control|This arm involves not making any change to the subject's lifestyle at the moment of the start of the intervention and for 8 wk.
88930588|NCT01741779|Experimental|Hypocaloric diet|This arm involves 12 wk of the standard Nutrisystem foods plan complemented by fresh produce and dairy. Subjects consume breakfast, lunch, dinner, and one (women) or two (men) snacks per day.
89445950|NCT02195661|Active Comparator|Melatonin sleep EEG induced group|"All children who were referred to the neurophysiology department who were either unable to keep still for their EEG, or required a sleep EEG as part of their epilepsy work-up and whose caregivers agreed to the administering of sedation with melatonin. Melatonin by mouth (3mg for children < 15kg, 6mg for those > 15kg) 1 hour before the scheduled EEG by the unit nurse. Children who can swallow the capsules directly, those who cannot are given the contents of the powder in the capsule mixed in a few millilitres of water. If the child fails to fall asleep within one hour of administration of the melatonin then a second dose 3mg is given) ."
89538473|NCT04647383|Experimental|OSA Cohort, Sequence A: Placebo + Lemborexant 10 mg|Participants with OSA will receive one lemborexant-matched placebo tablet on the night of Day 1 through Day 8 of Treatment Period 1, followed by one lemborexant 10 mg tablet on the night of Day 1 through Day 8 of Treatment Period 2. A washout period of 14 days will be maintained between the 2 treatment periods.
89445951|NCT02195661|Other|Comparison group for children sedated using previous practice|Since the choral hydrate had been withdrawn a direct comparison group was not possible. However a study performed the previous year in the department measured a several parallel useful outcomes. This study had addressed the usefulness of electroencephalograms in a South African population. A proportion of this group screened in 2012 in our unit underwent sleep studies, sedated with chloral (n=22). These patients were drawn from the same regional pool, with the same disease demographics, and the same sleep deprivation and procedural techniques to the current group. This group was screened for several common denominators to the current study themes, and comparison will be made between these, namely the proportion of patients with successful attainment of sleep studies, the proportion of studies with excessive artifact (precluding interpretation) and the usefulness of the data attained detailing whether the studies were able to assist or alter patient management.
88930589|NCT01741779|No Intervention|Control|This arm involves not making any change to the subject's lifestyle at the moment of the start of the intervention and for 12 wk.
88930590|NCT01741779|Experimental|Whole body vibration training & diet|Lower-body exercise training on a vibration platform and diet
88930591|NCT01741779|Experimental|Whole body vibration training|Lower-body exercises 3 times per wk for 12 wk in a vibration platform
88930592|NCT01741805||Severe Asthma|Patients with severe asthma as specified under inclusion, exclusion criteria
89445952|NCT03534297|Experimental|dapansutrile capsules|"A total of 8 patients in each cohort will receive dapansutrile capsules:~Cohort 1 will receive 5x 100 mg dapansutrile capsules QD for 14 days~Cohort 2 will receive 5x 100 mg dapansutrile capsules BID for 14 days~Cohort 3 will receive 5x 100 mg dapansutrile capsules QID for 14 days"
89445953|NCT03534297|Placebo Comparator|Placebo Capsules|"A total of 2 patients in each cohort will receive placebo capsules:~Cohort 1 will receive 5 placebo capsules QD for 14 days~Cohort 2 will receive 5 placebo capsules BID for 14 days~Cohort 3 will receive 5 placebo capsules QID for 14 days"
89445954|NCT02196519|Experimental|Test|All test arm subjects received Sylys Surgical sealant around anastomotic junction after closure.
88930593|NCT01741818||Group B|CVP less than 8cmH2o
88930594|NCT01741831||Darunavir|Patients having Acquired Immune Deficiency Syndrome (AIDS) will be taking darunavir as per recommended doses.
88930595|NCT01741844||Etravirine|Patients having Acquired Immune Deficiency Syndrome (AIDS) will be taking etravirine as per recommended doses.
88930596|NCT01741857|Experimental|human umbilical cord derived MSC|human umbilical cord derived MSC transplantation for SLE
88930597|NCT01741870|Placebo Comparator|Control|No intervention was given. All subjects received routine care
88930598|NCT01741870|Active Comparator|Received nutrition supplement as needed|Subjects in this group received 50 g/day soy protein-based nutritional supplement (containing 9.5 g protein, 250 kcal energy and all essential micro-nutrients) whenever subjects BMI is below 24 and MNA score also below 24.
88930599|NCT01741883|No Intervention|Standard Medical Care and Information|Patients receive standard treatment protocol for breast cancer patients and additional oral and written information about adjuvant endocrine treatment.
88930600|NCT01741883|Experimental|Side effect prevention training (SEPT)|Patients receive standard medical care and a brief behavioral intervention that targets patients' response and coping expectations while starting with adjuvant endocrine treatment.
89445955|NCT02195739||Nicotine replacement therapy cohort|Cohort defined as patients in whom nicotine replacement therapy (in any preparation) was initiated at the index smoking cessation attempt as the first recorded smoking cessation intervention.
89445956|NCT02195739||Other smoking cessation therapy|Cohort defined as patients in whom other (non-nicotine replacement therapy) smoking cessation pharmacotherapy's were initiated at the index smoking cessation attempt (e.g. bupropion, varenicline) as the first recorded smoking cessation intervention
88930601|NCT01741883|Active Comparator|Attention Control group (ACG)|Patients receive standard medical care and a comparable amount of therapist´s attention (common and unspecific factors) to the intervention group without targeting patients´ expectations.
88930602|NCT01741896|Active Comparator|RIPC|Patients in the RIPC arm will undergo a period of upper limb ischaemic preconditioning before their contrast enhanced CT scan. The RIPC stimulus involves four cycles of ischaemia/reperfusion (5 minutes of blood pressure cuff induced upper limb ischaemia with 3 minutes reperfusion). This will start at a time of 30 - 40 minutes before the administration of contrast. The cuff is inflated to 15mmHg above systolic pressure at each inflation.
88930603|NCT01741896|No Intervention|Control arm|Patients in the control arm will undergo no extra intervention.
88930604|NCT01741909|Experimental|Before, After|The intervention is educational
88930605|NCT01741922|Experimental|ASA evening&placebo morning|Patients will receive acetylsalicylic acid (100 mg)in the evening and placebo in the morning.
88930606|NCT01741922|Active Comparator|ASA morning&placebo evening|Patients will receive acetylsalicylic acid (100 mg) in the morning and placebo in the evening
88930607|NCT01741948||First time users of hormonal contraceptive|
88930608|NCT01741961||glaucoma, surgery, Ahmed valve|Patients with uncontrolled glaucoma undergoing Ahmed glaucoma valve implantation for intraocular pressure reduction.
88930609|NCT01741974|Active Comparator|Karinat|Karinat 500 mg tablet by mouth three times a day
88930610|NCT01741974|Placebo Comparator|Sugar pill|Placebo tablet 500 mg by mouth three times a day
88930611|NCT01741987|Active Comparator|optive® eye drop|
88930612|NCT01741987|Placebo Comparator|fresh tears ® eye drop|
88930613|NCT01742000|Active Comparator|Karinat|Karinat 500 mg tablet by mouth three times a day
88930614|NCT01742000|Placebo Comparator|Sugar pill|Placebo 500 mg tablet by mouth three times a day
88930615|NCT01742013|Placebo Comparator|Placebo|NaCl 0.9%, s.c., 4ml (2ml x 2), 3 times per a week, 6 weeks
88930616|NCT01742013|Experimental|GCJBP Laennec Inj.|GCJBP Laennec Injection,s.c., 4ml(2ml x 2)/day, 3 times per a week, 6 weeks
88930617|NCT01742052|Experimental|MT-1303-Low|MT-1303-Low Dose
88930618|NCT01742052|Experimental|MT-1303-Middle|MT-1303-Middle Dose
88930619|NCT01742052|Experimental|MT-1303-High|MT-1303-High Dose
88930620|NCT01742052|Placebo Comparator|Placebo|Placebo
88930621|NCT01742130|Experimental|Sodium bicarbonate|Sodium Bicarbonate (154 mEq/L in dextrose and H2O) 3 mL/kg for 1 hour before contrast medium, followed by an infusion of 1 mL/kg/h for 12 hours after the procedure
88930622|NCT01742130|Active Comparator|Saline|Sodium Saline 3 mL/kg for 1 hour before contrast medium, followed by an infusion of 1 mL/kg/h for 12 hours after the procedure
88930623|NCT01742156||Presence of coronary disease|All patients with or without coronary disease who are followed in coronary clinics or wards
88930624|NCT01742156||coronary disease|Is coronary disease associated with tortuosity of vessels Patients seen in cardiology clinics
88930625|NCT01742169|Experimental|Outreach and Reminder Intervention|Participants randomized to this arm will receive the Outreach and Reminder intervention.
88930626|NCT01742169|No Intervention|Usual Care|Patients assigned to this arm will receive usual care.
88930627|NCT01742182|No Intervention|Control|
88930628|NCT01742182|No Intervention|PD patients without sleep problems|
88930629|NCT01742182|Active Comparator|PD patients with sleep problems|light exposure
88930630|NCT01742182|Placebo Comparator|PD patients with sleep problem|light exposure
88930631|NCT01742195|Other|Nasal EBUS insertion|Patients in this arm will undergo a linear endobronchial ultrasound with the bronchoscope inserted through the nose.
88930632|NCT01742195|Other|Oral EBUS insertion|Patients in this arm will undergo a linear endobronchial ultrasound with the bronchoscope inserted through the mouth.
88930633|NCT01742221|Experimental|HemaMax|Single subcutaneous 12 microgram dose of HemaMax
88930634|NCT01742221|Placebo Comparator|Placebo|Single subcutaneous dose
88930635|NCT01742234||Kidney Donors|People who will donate a kidney at the University of Minnesota, Mayo Clinic, or University of Alabama
88930636|NCT01742234||Lung Donors|People who will donate a lung at the Washington University School of Medicine or the University of Southern California
88930637|NCT01742247|Experimental|Physiogel, Laser therapy, Moisturizer|"Experimental: Physiogel treated & Non-treated~1 Palmitoylethanolamide, Physiogel 3 times a day for 2 weeks"
88930638|NCT01740999|Experimental|silicone arthroplasty|silicone arthroplasty
88930639|NCT01740999|Active Comparator|arthrodesis|arthrodesis
88930640|NCT01742260|Experimental|Repair of cranial defect|Repair of cranial defects by tissue engineering
88930641|NCT01742273|No Intervention|standard treatment (usual care)|standard treatment (usual care)
88930642|NCT01742273|Experimental|Vitamin K1|Vitamin K1 (phylloquinone), thrice weekly p.o. (5mg)
88930643|NCT01742312||oesophageal adenocarcinoma|DEXA scan cardio-pulmonary exercise testing (CPEX) muscle biopsy
88930644|NCT01742325|Other|Lifestyle counseling|To test an intervention program (two 20-minute sessions of walking around the nurse's station daily, five days a cycle) to reduce the symptoms of fatigue and pain and increase quality of sleep.
88930645|NCT01742338|Active Comparator|Low Dose Corticosteroids|"10 mg IV q8hrs x 3 days*, then prednisone 40 mg PO daily x 4 days, then prednisone 30 mg daily x 1 day, then prednisone 20 mg daily x 1 day, then prednisone 10 mg daily x 1 day, then stop.~*If patient unable to receive IV medications, will give prednisone 20 mg PO bid for the first 3 days."
88930646|NCT01742338|Experimental|High Dose Corticosteroids|Methylprednisolone 40 mg IV q8hrs x 3 days*, then prednisone 80 mg PO daily x 4 days, then prednisone 60 mg daily x 1 day, then prednisone 40 mg daily x 1 day, then prednisone 20 mg daily x 1 day, then stop. *If patient unable to receive IV medications, will give prednisone 40 mg PO bid for the first 3 days.
88930647|NCT01742351|Experimental|Guided internet-based cognitive behavior therapy (CBT)|
88930648|NCT01742377||Patients with GerdQ positive|Gerd Q positive was defined as score equal or more than eight.
88930649|NCT01742377||Patients with GerdQ negative|Gerd Q neegative was defined as score less than eight.
88930650|NCT01742377||Normal volunteers|Normal volunteers was defined as population without dyspeptic symptom.
88930651|NCT01742390|Experimental|Aripiprazole|Plateau switch to aripiprazole (ARI) from risperidone (RIS) or paliperidone (PALI)
88930652|NCT01742390|Active Comparator|risperidone or paliperidone|Stay on risperidone (RIS) or paliperidone (PALI)
88930653|NCT01742416|Experimental|Ultrasound|
88930654|NCT01742416|Active Comparator|Palpation Method|
88930655|NCT01742429|Experimental|Levofloxacin-bismuth therapy|14 day levoﬂoxacin and bismuth-containing therapy:PPI,bismuth, amoxicillin, levoﬂoxacin
88930656|NCT01742429|Active Comparator|classical quadruple therapy|14 day classical quadruple therapy:PPI,bismuth, metronidazole, tetracycline
88930657|NCT01742442||Older cancer patients|Older cancer patients 70 years or older referred to specialist oncology outpatient clinics
88930658|NCT01742468|Experimental|Dietary supplement: n-3 LC-PUFA|Name: microalgae oil (Schizochytrium sp., Maris DHA oil, no. 3790, IOI, Hamburg, Germany; rich in docosahexaenoic acid (DHA); Dosage: 8 g oil per day = 2.11 g DHA per day; Dosage form: 8g oil was included in 60 g sausage, 8 g tomato spread, 30 g milk powder
88930659|NCT01742468|Placebo Comparator|Dietary supplement: sunflower oil|Name: sunflower oil (PPM, Magdeburg, Germany); Dosage: 8 g per day; Dosage form: 8g oil was included in 60 g sausage, 8 g tomato spread, 30 g milk powder
88930660|NCT01742481|Experimental|Education and empowerment program|Three group sessions delivered once per week over three weeks. Education on late effects of treatment, survivorship care, how to request medical records, and role playing on how to talk to a provider about childhood cancer health risks
88930661|NCT01742481|Placebo Comparator|self-guided empowerment and education|participants have information packet but receive no individualized support or assistance
88930662|NCT01742494|Active Comparator|Water-jet POEM|POEM were performed by the use of Erbe Hybrid knife (WJ group)
89445957|NCT02195739||Smoking cessation advice cohort|Cohort (control patients) defined as patients whose first recorded smoking cessation intervention involved smoking cessation advice leading to a quit attempt unassisted by pharmacological smoking cessation aids, at the index smoking cessation attempt.
89445958|NCT02195817|Other|Selincro® 18 mg with continuous psychosocial support: Cohort A|Selincro® as-needed; tablets, orally, 12-week Treatment Period in conjunction with continuous psychosocial support
89445959|NCT02195817|Other|Initial psychosocial support: Cohort B|Initial psychosocial support followed by usual care practice, 12-week Observational Period
89445960|NCT02200770|Placebo Comparator|Placebo/Inebilizumab|Aquaporin-4-antibody (AQP4-IgG) sero positive and sero negative participants will receive IV dose of placebo matched to inebilizumab on Day 1 and Day 15 of the RCP. The participants who enter OLP will receive IV inebilizumab 300 mg on both Day 1 and Day 15, followed by a single IV dose of inebilizumab 300 mg every 6 months until maximum of 3 years after the last participant enters the OLP. Participants will have choice to enter in the SFP at any point during RCP or OLP and will be free to pursue other treatment options otherwise prohibited during the RCP and OLP. Participants will continue in the SFP for 12 months from last dose of study drug.
89445961|NCT02200770|Experimental|Inebilizumab/Inebilizumab|AQP4-IgG sero positive and sero negative participants will IV dose of inebilizumab 300 mg on Day 1 and Day 15 of RCP. The participants who enter OLP will receive IV inebilizumab 300 mg on Day 1 and matching placebo on Day 15, followed by a single IV dose of inebilizumab 300 mg every 6 months until maximum of 3 years after the last participant enters the OLP. Participants will have choice to enter in the SFP at any point during RCP or OLP and will be free to pursue other treatment options otherwise prohibited during the RCP and OLP. Participants will continue in the SFP for 12 months from last dose of study drug.
89445962|NCT03534063|Active Comparator|CYP2D6-guided opioid therapy|Participants randomized to the CYP2D6-guided arm will have their CYP2D6 genotyping completed prior to surgery (in the absence of any genotyping error) with results reported in the electronic health record (EHR). Patients will be categorized as CYP2D6 PM, IM, NM, or UM based on CYP2D6 genotype/activity score and FDA guidance on drug interactions. Strong inhibitors (e.g. bupropion, fluoxetine, paroxetine) phenoconvert patients to PMs, with moderate inhibitors (e.g. duloxetine, fluvoxamine) reducing CYP2D6 activity scores by 50%.
89445963|NCT03534063|No Intervention|Usual Care|Participants randomized to the usual care arm will have their DNA collected at the start of the study and stored at the lab until after they have completed their surgery and the 2-week follow-up, at which time, their sample was genotyped with the results reported in the EHR.
89445964|NCT02196597||resection with RCT|rectal resection in the case of rectal carcinoma with preoperative radiochemotherapy
89445965|NCT02196597||resection without RCT|patients with rectal resection without preoperative radiochemotherapy
89445966|NCT03534219|Experimental|Intervention Arm: EarPopper|"All patients in this arm will receive the EarPopper device.~Length of administration: 1 year Dose: Dosing of the EP device will be twice per day, once in the morning and once before bedtime. This is consistent with previous dosing which showed no adverse events and an excellent safety profile. 5, 6~Administration:~Hold nosepiece firmly against nostril opening creating a good, tight seal is crucial. Plug the other nostril closed.~Push button to start the airflow and swallow while the device is running.~Repeat on other nostril. After 5 minutes, repeat steps 1 - 3. This will complete one treatment.~Telephone call survey:~Will be administered monthly by study investigator. Telephone call survey is based on the OMO-22 Form."
89445967|NCT03534219|No Intervention|Control|"All patients in this arm will not receive any intervention. EarPopper device will be given to this group at the end of follow-up period (1 year)~Telephone call survey:~Will be administered monthly by study investigator. Telephone call survey is based on the OMO-22 Form."
89445968|NCT02197143|Experimental|Esomeprazole|40 mg Esomeprazole in 150 ml normal saline given as a slow intravenous infusion over 15 minutes and p.o. 10ml Hydrotalcid
88930663|NCT01742494|Active Comparator|Conventional POEM|POEM were performed by the conventional technique using injection and triangle tip knife (C group).
88930664|NCT01742507|Active Comparator|Medtronic Resolute Integrity Stent|Medtronic Resolute Integrity Stent
88930665|NCT01742507|Active Comparator|Biomatrix stent|Biomatrix stent
88930666|NCT01742520|Active Comparator|Formula or Breast Milk|Breast milk or formula prior to every painful procedure.
88930667|NCT01742520|Active Comparator|Multiple doses of sucrose|Infants in this group will be treated with Sucrose 24% 0.5-1ml on the anterior pat of the tongue 1-3min prior to every invasive procedure
88930668|NCT01742533|Experimental|Group1 : HRT plus hUCMSCs treatment:|Participants will be given HRT plus human cord mesenchymal stem cells transplantation with a 12 menstrual Cycle follow-up.
88930669|NCT01742533|Experimental|Group 2: HRT plus hCBMNCs and hUCMSCs therapy|Participants will be given HRT plus combination of hCBMNCs together with hUCMSCs transplantation with a 12 menstrual Cycle follow-up.
88930670|NCT01742533|Experimental|Group3 : HRT plus hCBMNCs treatment:|Participants will be given HRT plus human cord blood mononuclear cells transplantation with a 12 menstrual Cycle follow-up.
88930671|NCT01742533|Experimental|Group 4:Hormone Replacement Therapy|Participants will be given conventional therapy only with a 12 menstrual Cycle follow-up.
88930672|NCT01742546|Experimental|Therapeutic ultrasound combine TENS|"Use therapeutic ultrasound with simultaneous TENS for 10 minutes/session for 10 sessions/course.~The therapeutic ultrasound machine in this study was Sonopuls 492 TM (Enraf-Nonius), this device has treatment head described by the manufacturers as having surface area as 5.8 cm2, ERA (Effective Radiating Area) of 5.0 cm2 and BNR (Beam Non-uniform Ratio) as max. 5.0. For electrotherapy unit which composes of 2 channels, output characteristics are constant current (CC) or constant voltage (CV), resolution of output signal is in steps of 0.2 mA and timer is limited to 30 minutes during ultrasound and combination therapy are operated."
88930673|NCT01742546|Sham Comparator|Therapeutic ultrasound with sham TENS|Use the same therapeutic ultrasound machine and place the electrode as experimental group but turn-off electrical current during treatment period
89013796|NCT06190470|Experimental|Experimental group|The participants will receive cannabis product for 2 weeks. The participants will receive the cannabis product (THC 30mg / 1 ml) manufactured by Faculty of pharmaceutical science KhonKaen University. The participants will gradually increase using the product starting from 1 drop (1.5 mg THC) per day sublingually and can increase using not more than 1 drop per day, until pain or spasticity can be controlled.
89013797|NCT06190470|Placebo Comparator|Placebo group|The participants will receive placebo product manufactured by Faculty of Pharmaceutical Science KhonKaen University for 2 weeks. The participants will gradually increase using the product starting from 1 drop per day sublingually and can increase using not more than 1 drop per day,
89013798|NCT06189716|Experimental|Experimental|High flow oxygen through nasal cannula, oxygen and carbon dioxide measurement in the hypopharynx
89013799|NCT06186037|Experimental|Combination drug group of Ezetimibe 10 mg/Rosuvastatin 5 mg|Ezetimibe 10 mg/Rosuvastatin 5 mg, Oral administration once a day, taking it for 3 years
89013800|NCT06186037|Active Comparator|Mono drug group of Rosuvastatin 20 mg|Rosuvastatin 20 mg , Oral administration once a day, taking it for 3 years
89013801|NCT06184373||Participants|Participants will be recruited at 6-8 weeks postpartum; at that appointment, CGMs will be placed. After wearing the CGM, participants will fill out surveys regarding their experience. At 10-12 weeks postpartum, they will complete the standard of care OGTT as well as complete an interview regarding their experience. At 12 months postpartum, they will complete a blood test to check their hemoglobin A1c.
89013802|NCT06181266|Experimental|Dose Level 1 - ZH9|Part 1 will evaluate SAD of ZH9 administered as an IVI in patients with recurrent NMIBC. A standard 3+3 escalation design will be employed with the dose levels
89013803|NCT06181266|Experimental|Dose Level 2 - ZH9|Part 1 will evaluate SAD of ZH9 administered as an IVI in patients with recurrent NMIBC. A standard 3+3 escalation design will be employed with the dose levels
89013804|NCT06181266|Experimental|Dose Level 3 - ZH9|Part 1 will evaluate SAD of ZH9 administered as an IVI in patients with recurrent NMIBC. A standard 3+3 escalation design will be employed with the dose levels
89013805|NCT06181266|Experimental|Dose Level 4 - ZH9|Part 1 will evaluate SAD of ZH9 administered as an IVI in patients with recurrent NMIBC. A standard 3+3 escalation design will be employed with the dose levels
89013806|NCT06180330|Experimental|Aquatic baby class|8 weeks program of aquatic exercises for infants
89013807|NCT06180330|No Intervention|No intervention|No intervention
89445969|NCT02197143|Experimental|Ranitidine|50mg Ranitidine in 150 ml normal saline given as a slow intravenous infusion over 15 minutes and p.o. 10ml Hydrotalcid
89013808|NCT06180148|Active Comparator|Mechanical insufflator-exsufflator|Standard postoperative care plus mechanical insufflator-exsufflator during the first postoperative day.
89013809|NCT06180148|No Intervention|Standard care|Standard postoperative care without mechanical insufflator-exsufflator.
89013810|NCT06175234|Other|Catheter ablation for Paroxysmal or Persistent Atrial Fibrillation|Subjects scheduled to undergo endocardial mapping and Pulmonary Vein Isolation (PVI) in the treatment of atrial fibrillation. For patients with persistent AF, left atrial posterior wall isolation (PWI) may also be performed in addition to PVI at the discretion of the investigator
89013811|NCT06171997|Experimental|Swaddling after bath group|Newborns in this group will be swaddled safely after bath.
89013812|NCT06171997|No Intervention|No swaddling after bath group|No action will be taken after bath.
89013813|NCT06171100||First dose tolvapatan|
89013814|NCT06171100||Second dose tolvaptan|
89013815|NCT06164275|Experimental|Treatment (Pembrolizumab and AVD)|"INDUCTION: Patients receive pembrolizumab IV over 30 minutes on day 1 of each cycle. Treatment repeats repeat every 21 days for 3 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo disease assessment. Patients with a response complete 3 additional cycles of pembrolizumab, undergo disease assessment and proceed to consolidation. Patients without response or with progressive disease proceed to consolidation.~CONSOLIDATION: Patients receive doxorubicin IV, vinblastine IV and dacarbazine IV on days 1 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity for 2 to 6 cycles dependent upon response and disease type. Patients undergo echocardiography/MUGA scan, CT scan, PET scan and blood sample collection throughout the study and may undergo tumor biopsy during screening."
89013816|NCT06164119|Experimental|A1: manual treatment with osteopathic techniques and nutritional treatment in premenopausal patients|Premenopausal breast cancer patients under tamoxifen and/or LHRH analogues are treated with manual treatment with osteopathic techniques (8 once-a-week manual treatments with osteopathic techniques) and nutritional treatment (personalized Mediterranean Diet).
89013817|NCT06164119|Experimental|A2: manual treatment with osteopathic techniques in premenopausal patients|Premenopausal breast cancer patients under tamoxifen and/or LHRH analogues are treated with manual treatment with osteopathic techniques (8 once-a-week manual treatments with osteopathic techniques).
89013818|NCT06164119|Experimental|A3: nutritional treatment in premenopausal patients|Premenopausal breast cancer patients under tamoxifen and/or LHRH analogues are treated with nutritional treatment (personalized Mediterranean Diet).
89013819|NCT06164119|No Intervention|A4: control group in premenopausal patients|Premenopausal breast cancer patients under tamoxifen and/or LHRH analogues receive general counselling on healthy dietary habits and lifestyle in accordance to the World Cancer Research Fund (WCRF) guidelines.
89013820|NCT06164119|Experimental|B1: osteopathic techniques and nutritional treatment in postmenopausal patients|Postmenopausal breast cancer patients under aromatase inhibitors are treated with manual treatment (8 once-a-week manual treatments with osteopathic techniques) and nutritional treatment (personalized Mediterranean Diet).
89013821|NCT06164119|Experimental|B2: manual treatment with osteopathic techniques in postmenopausal patients|Postmenopausal breast cancer patients under aromatase inhibitors are treated with manual treatment with osteopathic techniques (8 once-a-week manual treatments with osteopathic techniques).
89445970|NCT02197143|Experimental|placebo|150 ml only normal saline given as a slow intravenous infusion over 15 minutes and p.o. 10ml Hydrotalcid
89445971|NCT02096874|Other|Bevacizumab|Each study subject will recieve Intravitreal injection of 1.25mg/0.05 cc each 5 weeks for the first 3 months then PRN for six month.
89445972|NCT03489954||Non-specific chronic neck pain group|In evaluation of participants, endurance of deep cervical flexor muscles will be measured using stabilizer pressure biofeedback unit with cranio-cervical flexion test. Neck position sense of 6-direction (flexion, extension, right-left lateral flexion and right-left rotation) will be measured by CROM device (cervical range of motion device). Body balace will be measured by Balance Master System.
88930674|NCT01742559|Experimental|Anterior middle superior alveolar|The AMSA technique was performed in the test group according to Friedman & Hochman (1997). The needle was introduced with the bevel towards the palate tissue with a 45 ° angle and axially rotated (45° clockwise/45° counterclockwise) and 0.6 ml of the anesthetic was slowly infiltrated for 1 minute. In the control group a supraperiosteal infiltration (infiltrative) at the bottom of the vestibule was performed for one minute and 1.8 ml of anesthetic solution was administrated. This amount of anesthetic was divided into doses of 0.6 ml infiltrated, respectively, in the region of the incisors, canines and premolars. After the anesthetic technique, two minutes were expected for the beginning of the periodontal procedure.
89445973|NCT03489954||Healthy group|In evaluation of participants, endurance of deep cervical flexor muscles will be measured using stabilizer pressure biofeedback unit with cranio-cervical flexion test. Neck position sense of 6-direction (flexion, extension, right-left lateral flexion and right-left rotation) will be measured by CROM device (cervical range of motion device). Body balace will be measured by Balance Master System.
88930675|NCT01742559|Active Comparator|Supraperiosteal technique|The supraperiosteal technique at the bottom of the vestibule was performed for one minute and 1.8 ml of anesthetic solution was administrated. This amount of anesthetic was divided into doses of 0.6 ml infiltrated, respectively, in the region of the incisors, canines and premolars. After the anesthetic technique, two minutes were expected for the beginning of the SRP procedure.
88930676|NCT01742572|Experimental|Vegan|A vegan diet is one that does not contain any animal products (no meat, fish, poultry, eggs, or dairy) but emphasizes plant-based foods, such as fruits, vegetables, whole grains, and legumes/beans. We will also ask you to keep foods low in fat and low in glycemic index.
89445974|NCT02197299|Experimental|Carnitine|Oral administration of 4.5 g L-carnitine L-tartrate (containing 3 g L-carnitine; Carnipure, Lonza Ltd., Switzerland) once daily for 24 weeks
89445975|NCT02197299|Placebo Comparator|Sugar pill|Oral administration of placebo sugar pill
88930677|NCT01742572|Experimental|Vegetarian|A vegetarian diet is one that does not contain meat, fish, or poultry but does contain eggs and dairy, in addition to plant-based foods, such as fruits, vegetables, whole grains, and legumes/beans. We will also ask you to keep foods low in fat and low in glycemic index.
88930678|NCT01742572|Experimental|Pesco-Vegetarian|A pesco-vegetarian diet is one that does not contain meat or poultry but does contain fish and shellfish, eggs, and dairy, in addition to plant-based foods, such as fruits, vegetables, whole grains, and legumes/beans. We will also ask you to keep foods low in fat and low in glycemic index.
88930679|NCT01742572|Experimental|Semi-Vegetarian|A semi-vegetarian diet is one that contains all foods, including meat, poultry, fish and shellfish, eggs, and dairy, in addition to plant-based foods, such as fruits, vegetables, whole grains, and legumes/beans. However, red meat is limited to one time per week and poultry is limited to 5 times per week or less. We will also ask you to keep foods low in fat and low in glycemic index.
88930680|NCT01742572|Active Comparator|Omnivorous|An omnivorous diet contains all food groups. However, as part of this study, we will ask participants in this group to keep foods low in fat and low in glycemic index. Participants in this group will not need to attend weekly meetings but will receive information via e-mail each week.
88930681|NCT01742585|Experimental|ASP1585 group|
88930682|NCT01742585|Placebo Comparator|placebo group|
88930683|NCT01742598|Experimental|Portico Implant|
88930684|NCT01742611|Experimental|ASP1585 group|
89445976|NCT02196753||CIED related infection|"All patients will undergo standard diagnostic process that will consist of: medical interview, physical examination, laboratory tests, blood cultures (3 sets, 1 hour apart, repeated after 24 hours and -if applicable - with fever peak above 38°C); imaging studies (echocardiography: transthoracic, and if there are no contraindications transesophageal, in case of negative or equivocal result repeated after 7-10 days, or in series if necessary, computed tomography scan for pulmonary embolism if indicated); if there are abnormalities in other systems, decisions concerning further diagnostics will be made by the physician in charge.~Apart from standard diagnostic procedures patients will undergo whole body PET CT scan to localize infection or inflammation.~Then the investigators team will make a decision concerning further treatment (antibiotics and complete device removal vs conservative treatment)."
88930685|NCT01742624|Experimental|Advagraf group|
88930686|NCT01742624|Active Comparator|Prograf group|
88930687|NCT01742637|Experimental|Adapalene and Benzoyl Peroxide Gel 0.1%/2.5%|Adapalene and Benzoyl Peroxide Gel 0.1%/2.5% (Taro Pharmaceuticals Inc.)
88930688|NCT01742637|Active Comparator|Epiduo® Gel|Epiduo® (Adapalene and Benzoyl Peroxide Gel 0.1%/2.5%) (Galderma Laboratories, L.P.)
88930689|NCT01742637|Placebo Comparator|Placebo|Placebo (vehicle of test product) (Taro Pharmaceuticals Inc.)
88930690|NCT01742650|Active Comparator|Screw fixation|3,5mm fully threaded cortical screw transfixation of syndesmosis
88930691|NCT01742650|Active Comparator|TightRope|TightRope transfixation of syndesmosis
89445977|NCT02196753||Non-infective|Control group consisting of 20 pts with implanted CIEDs who underwent PET CT due to non infectious indications and have no data for infectious process in follow-up
88930692|NCT01742663|Experimental|Diclofenac Sodium Gel 3%|Diclofenac Sodium Gel 3% (Taro Pharmaceuticals Inc.)
88930693|NCT01742663|Active Comparator|Solaraze® (diclofenac sodium) Gel 3%|Solaraze® (diclofenac sodium) Gel 3% (Fougera Pharms)
88930694|NCT01742663|Placebo Comparator|Vehicle Topical Gel|Vehicle Topical Gel (Taro Pharmaceuticals Inc.)
88930695|NCT01742676|Experimental|ADVAGRAF group|
88930696|NCT01742676|Active Comparator|PROGRAF group|
88930697|NCT01742689|Experimental|Desmopressin intranasal spray|Patients in this arm will receive 40 microgram desmopressin intranasal spray & 100 milligram indomethacin suppository
88930698|NCT01742689|Placebo Comparator|Placebo intranasal spray|Patients in this group will receive placebo nasal spray & 100 milligram indomethacin suppository
88930699|NCT01742702||DYNAMIC (ongoing)|Subjects with primary or secondary hypertension and normotensive control subjects. In addition haemodynamic recordings to 50 subjects suffering from chronic fatigue syndrome will be performed.
88930700|NCT01742702||AERO-DYNAMIC (recordings completed)|Subjects who had voluntarily decided to participate in a professionally coached marathon school (Varala Sports Institute, Tampere) were given the chance for haemodynamic recordings before, during and after the training protocol.
89445978|NCT01186848|Active Comparator|1550-nm erbium-doped fractionated laser|
89013822|NCT06164119|Experimental|B3: nutritional treatment in postmenopausal patients|Postmenopausal breast cancer patients under aromatase inhibitors are treated with nutritional treatment (personalized Mediterranean Diet).
89013823|NCT06164119|No Intervention|B4: control group in postmenopausal patients|Postmenopausal breast cancer patients under aromatase inhibitors receive general counselling on healthy dietary habits and lifestyle in accordance to the World Cancer Research Fund (WCRF) guidelines.
89013824|NCT06163807||Asthma patients with different severities|Asthma patients with different severities followed for 5 years. Real-life, antiasthmatic drugs selected by investigators. Clinical, analytical, biomarkers, image techniques
89013825|NCT06163807||Severe asthma patients treated with biologics|In follow-up for 3 years and new patients. Real-life, antiasthmatic drugs selected by investigators. Clinical, analytical, biomarkers, image techniques
89013826|NCT06163599|Experimental|Telenovela Arm|The UP telenovela (which is the experimental treatment arm) constitutes of nine videos depicting the main character, Esperanza, who is struggling with anxiety and depression, undergoing therapy involving the UP, and completing worksheets relating to the weekly therapy sessions.
89013827|NCT06163391|Experimental|SOT201|SOT201 will be administered intravenously once every 21 days
89013828|NCT06163157|No Intervention|Control roup|The control group will receive standard treatment (lifestyle recommendations + medical (PDE-5 inhibitors)).
89013829|NCT06163157|Experimental|CTM group|In addition to the standard treatment, connective tissue massage will be applied to the CTM group.
89013830|NCT06162663|Experimental|Suvorexant with information on sleep hygiene|Participants randomized to this arm will receive 10 mg of suvorexant daily with a dose increase to 20 mg after day 7. Medication will be administered as an oral medication. Total duration of 28 days.
89013831|NCT06162663|Placebo Comparator|Placebo with information on sleep hygiene|Participants randomized to this arm will receive 10 mg of suvorexant daily with a dose increase to 20 mg after day 7. Medication will be administered as an oral medication. Total duration of 28 days.
89013832|NCT06162455|Active Comparator|Control group|Oxygen-air mixture without NO after extubation within 5 days after surgery 2 times a day for 30 min
89013833|NCT06162455|Experimental|200 ppm|NO will be supplemented at 200-ppm concentration after extubation within 5 days after surgery 2 times a day for 30 min
89013834|NCT06161233|Experimental|CAPABLE cohort|Group that receives the CAPABLE mobile application and a smartwatch during treatment
89445979|NCT01186848|Active Comparator|Combination treatment|"micro-focused ultrasound and 1550nm-fractionated laser"
89445980|NCT02196909|Active Comparator|HIBM patient|motor function, muscle strength, NMR, 24h urine and serum collections at baseline, then annually
89445981|NCT02196909|Active Comparator|Controls|motor function, muscle strength, 24h urine and serum collections at baseline only
89445982|NCT03489876|Experimental|Synthetic Cartilage Implant|Participants receive the synthetic cartilage implant. The synthetic cartilage implant that will be used is the Cartiva implant.
89013839|NCT06159283|Experimental|IVIG administration|The patients who will meet the inclusion criteria will be administered IVIG at a dose of 1,000 mg/kg, divided over 2-3 days. After administration, the patient's condition will be thoroughly observed. In case of adverse effects from an increased administration rate, the rate will be reduced immediately or suspended until symptom improvement. Other standards of care can be continued.
89445983|NCT03489876|Active Comparator|Osteochondral Autograft Transfer|Participants receive the current standard osteochondral autograft transfer procedure.
89445984|NCT02196987||Urination, urethral catheterisation|Act of urination during urethral catheterisation in males
89445985|NCT02196987||Lie, catheterisation, urethra|Urethral catheterisation without medical professional guidance
89013840|NCT06159283|No Intervention|Standard Of Care|The same anti-viral, anti-inflammatory, and anti-coagulation treatment criteria are applied to the treatment group. If the primary endpoint will be not reached by day 14 of randomization, IVIG can be given at a dose of 1,000 mg/kg based on clinicians' discretion.
89013841|NCT06159062|Experimental|162|"The dose-escalation stage will be conducted sequentially at 3 dose cohorts, which are 50 mg in the pre-test, 75 mg and 100 mg in the formal test.~Two subjects with chronic HBV infection will be enrolled in the 50 mg dose cohort and all will be given the investigational product 162.~Four subjects with chronic HBV infection will be enrolled in the 75 mg and 100 mg dose cohorts, respectively. Subjects in each cohort will be randomized 3:1 to receive a single ascending dose of investigational product 162 or placebo."
89013842|NCT06159062|Placebo Comparator|Placebo|"The dose-escalation stage will be conducted sequentially at 3 dose cohorts, which are 50 mg in the pre-test, 75 mg and 100 mg in the formal test.~Two subjects with chronic HBV infection will be enrolled in the 50 mg dose cohort and all will be given the investigational product 162.~Four subjects with chronic HBV infection will be enrolled in the 75 mg and 100 mg dose cohorts, respectively. Subjects in each cohort will be randomized 3:1 to receive a single ascending dose of investigational product 162 or placebo."
89445986|NCT03487458|No Intervention|Control|participants receive no surgical treatment
89013844|NCT06153979||Group 1 - Actue MeV Infection|Participants have acute MeV infection.
89013845|NCT06153979||Group 2 - No Actue MeV Infection|Participants do not have acute MeV infection.
89013846|NCT06152575|Experimental|Elranatamab|Participants will receive elranatamab monotherapy
89013847|NCT06152575|Active Comparator|Investigator's Choice|Participants will receive either Elotuzumab, Pomalidomide and Dexamethasone (EPd), or Pomalidomide, Bortezomib and Dexamethasone (PVd), or Carfilzomib and Dexamethasone (Kd)
89013848|NCT06152276|Other|Standard of Care Arm|Diverting loop ileostomy following low anterior resection of colorectal cancer
89013849|NCT06152094|Experimental|BP Activate Letter|Participants in the BP Activate Letter arm will receive a BP Report letter that includes computerized algorithm recommendations for medication changes they should discuss with their clinician.
89013850|NCT06152094|Active Comparator|Control Letter|Participants in the Control Letter arm will receive a Control letter suggesting they talk to their clinician about their blood pressure (without BP history or specific medication recommendations).
89445987|NCT03487458|Experimental|Rib Fixation Surgery|participants receive surgical treatment
89445988|NCT02198547|Experimental|Ropivacaine Magnesium sulfate|"Locoregional anesthesia for valgus allux correction with ropivacaine 7,5 mg/ml and Mg 4 mg/Kg.~Sciatic block at popliteal level."
88930701|NCT01742702||Liquorice (recordings completed)|Normotensive subjects, daily liquorice ingestion (daily glycyrrhizin dose 290-370 mg) for 2 weeks, haemodynamic measurements before and after the intervention.
88930702|NCT01742702||Milk polypeptides (recordings completed)|Daily ingestion of yoghurt containing small milk casein-derived polypeptides for 12 weeks versus placebo yoghurt.
88930703|NCT01742702||Bisoprolol (recordings completed)|Hypertensive subjects, bisoprolol 5 mg once daily versus placebo in a double-blind, cross-over protocol.
88930704|NCT01742702||Aortic stenosis (ongoing)|Subjects with aortic stenosis confirmed by echocardiography
88930705|NCT01742702||Methodological (recordings completed)|35 normotensive subjects who received research drugs (nitroglycerin, salbutamol, placebo resoriblet, placebo inhalation, L-arginine infusion, saline infusion) in a placebo-controlled, double-blinded manner
88930706|NCT01742702||Participants of Ironman Triathlon|Altogether 80 athletes participating in a full length Ironman competition. Non-invasive recordingds are performed under normal conditions during the training period and after completion of a full-length Ironman competition.
88930707|NCT01742715|Experimental|PEEP by Best oxygenation|"Set Positive End Expiratory Pressure (PEEP) at 25 cmH2O with fixed driving pressure that will result in delivery of a fixed Tidal Volume (TV) of 6ml/kg Ideal Body Weight (IBW). fraction of inspired oxygen (FiO2) is set to 60%.~Then decrease PEEP in steps of 4 cmH2O every 10 min until PEEP of 5 cm H2O is reached. In each step static compliance of respiratory system and lung compliance will be measured along with arterial blood gas (ABGs), and hemodynamic parameters such as cardiac output and mixed venous O2 saturation. Best or optimal PEEP will be defined as the PEEP below which PaO2 /FIO2 falls by at least 20%. If at least 20% Partial Oxygen tension (PaO2) PaO2 /FIO2 decrement is not obtained, then PEEP that will result in the highest PaO2 will be selected."
88930708|NCT01742715|Experimental|PEEP by Best Compliance|"In this group assessment begins with measuring intrinsic PEEP by an expiratory hold. Thereafter, plateau pressures will be recorded after a 0.5-sec inspiratory pause.~Applied PEEP will be increased by steps of 4 cm H2O, after each incremental step the patient will be observed for 10 minutes to allow for lung unit recruitment and equilibration. Plateau pressure will be measured after each incremental step of PEEP. Applied PEEP will be increased sequentially by 4 cm H2O increments until peak inspiratory pressure of 50 cm H2O, or plateau pressure of 40 cm H2O reached, or hypotension or decrease of 20% in cardiac output is observed."
88930709|NCT01742715|Experimental|PEEP by Esophageal pressure|Upon patient recruitment Esophageal balloon will be inserted and esophageal / pleural pressure will be measured. Thereafter, Inspiratory pressures and PEEP will be adjusted according to well established criteria. Inspiratory pressure and PEEP will be adjusted to achieve the best lung compliance possible while not exceeding transpulmonary end Inspiratory pressure of 25 to 30 cm H2O, and at the same time maintaining a positive transpulmonary end expiratory pressure of not more than 5 cm H2O.
88930710|NCT01742728||Nagasaki|Sample collection
88930711|NCT01742728||Tokushima|Oxidative stress, cytokine
88930712|NCT01742728||Kanagawa|oxidative stress
88930713|NCT01742741|Experimental|Experimental Involving Automated CTR|Closed-Loop Control: Insulin delivery will be controlled by the Diabetes Assistant (DiAs)system running in Control to Range (CTR) or in Safety Only mode. The subject will interact with the system through its Graphic User Interface (GUI). Subjects will not be allowed to administer correction boluses between meals and snacks as the DiAs will automatically be adjusting insulin to correct the hyperglycemia. The total doses recommended by the DiAs prior to meals and snacks includes the correction dose and Insulin on Board (IOB) calculated by the system.
88930714|NCT01742741|No Intervention|CGM-Augmented Insulin Pump Treatment|Open Loop Control: Insulin delivery will be controlled by the Diabetes Assistant (DiAs) system running in open-loop mode. Subjects will interact with the system through its Graphic User Interface (GUI). Subjects will be permitted to administer correction boluses at any time during the Control Admission, whether or not they are eating a scheduled meal or snack. DiAs will be initialized with the subject's typical insulin pump settings. Subjects will be reminded that all treatment decisions should be based on fingerstick values and not on continuous glucose monitor (CGM) values.
88930715|NCT01742754|Experimental|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation by colonoscopic delivery of stool to the right colon.
88930716|NCT01742767|Active Comparator|Cis (D1) + Pem (D1)|Cisplatinum 75 mg/m2 d 1 Pemetrexed 500 mg/m2 d 1 q d 21
88930717|NCT01742767|Experimental|CIS (D1+8) + Pem (D!)|Cisplatinum 40 mg/m2 d 1 + d 8 Pemetrexed 500 mg/m2 d 1 q d 21
88930718|NCT01742780|Active Comparator|Standard Vidacare Site Identification Method|Palpate up the proximal humerus towards the anterior shoulder just above the surgical neck, to the greater tubercle of the proximal humerus. Insert the needle set perpendicular to skin with a slight downward angle at the most prominent aspect of greater tubercle to establish proximal humerus intraosseous vascular access.
88930719|NCT01742780|Active Comparator|Saussy Site Identification Method|Palpate the proximal humerus to locate the intertubercular groove; rotate the forearm medially and laterally to isolate the groove. Move one finger breadth laterally from the groove to the greater tubercle. Insert perpendicular to skin with a slight downward angle to establish proximal humerus intraosseous vascular access.
88930720|NCT01742780|Active Comparator|Campbell Site Identification Method|"With the fingers on both hands fully extended similar to a karate chop, place one hand into the anterior joint space (acromioclavicular joint) of the patient. Place the second karate chop hand along the midline of the patient's lateral shoulder; touch the pinkie fingers over the superior aspect of the patient's shoulder. Overlap the thumbs on the patient's shoulder, which will be at the most prominent aspect of the greater tubercle. Insert the needle set perpendicular to skin with a slight downward angle to establish proximal humerus intraosseous vascular access."
88930721|NCT01742780|Active Comparator|Davlantes Site Identification Method|"Using one hand, place the thumb on the acromioclavicular joint in the natural recess or pocket between the distal clavicle and the humeral head, wrapping the rest of the hand around the upper arm. The hand should be oriented such that the index finger and rest of the hand is at a 90-degree angle to the thumb. The webspace between the thumb and index finger will be approximately where the surgical neck of the humerus is; move one finger breadth (approximately 1 cm) superior. Insert perpendicular to skin with a slight downward angle to establish proximal humerus intraosseous vascular access."
89013851|NCT06152094|No Intervention|Usual Care|Participants in the Usual Care arm will not receive any letter or any other intervention.
89013852|NCT06148818|Experimental|Myofascial|Myofascial Temporomandibular Dysfunction
89445989|NCT02198547|Active Comparator|Ropivacaine|Patients undergoing allux valgus correction with locoregional anesthesia with ropivacaine 7,5 mg/ml, without MG
89445990|NCT01024608|Experimental|BDP HFA 320 µg/day|During the 2-week double-blind Treatment Period participants self-administered 4 actuations (two per nostril) of 80 µg BDP HFA once daily each morning.
89445991|NCT01024608|Placebo Comparator|Placebo|During the 2-week double-blind Treatment Period participants self-administered four actuations (two per nostril) of placebo HFA once daily each morning.
89445992|NCT02197533|Experimental|Written list|Patients in the intervention group will receive both verbal information and a written supplement (Appendix 1), produced during the discussion by CM or a fellow (not the individual who obtained consent), on treatment recommendations for OAB. They will leave clinic with this written list of recommendations and will be able to take it home with them.
89445993|NCT02197533|No Intervention|Control|Patients in the control group will receive the same verbal information on the treatment recommendations for OAB, however, these patients will not receive the written list of management strategies for their condition.
88930722|NCT01742793|Experimental|Arm L: subjects with lymphoma|"The following dosing steps will be applied to the dose-escalation, phase-I component of the study for patients with lymphoma who are eligible to enter Arm L:~Dose Level Arm L Lenalidomide dose Oral Romidepsin Dose Intravenous~2 10mg D1-7, D15-21 6mg D1, 8, 15~1 10mg D1-7, D15-21 8mg D1, 8, 15~10mg D1-21 8mg D1, 8, 15 2 15mg D1-21 8mg D1, 8, 15 3 15mg D1-21 10mg D1, 8, 15 4 15mg D1-21 12mg D1, 8, 15 5 15mg D1-21 14mg D1, 8, 15 6 25mg D1-21 14mg D1, 8, 15~The first patient in arm L will be entered into the study at dosing level one."
88930723|NCT01742793|Experimental|Arm M: subjects with myeloma|"The following dosing steps will be applied to the dose-escalation, phase-I component of the study for patients with myeloma who are eligible to enter Arm M:~Dose Level Arm M Lenalidomide dose Oral Romidepsin Dose Intravenous Dexamethasone~2 15mg D1-7, D15-21 6mg D1, 8, 15 20mg D1,8,15,22~1 15mg D1-7, D15-21 8mg D1, D8, 15 20mg D1,8,15,22~15mg D1-21 8mg D1, 8, 15 20mg D1,8,15,22 2 25mg D1-21 8mg D1, 8, 15 20mg D1,8,15,22 3 25mg D1-21 10mg D1, 8, 15 20mg D1,8,15,22 4 25mg D1-21 12mg D1, 8, 15 20mg D1,8,15,22 5 25mg D1-21 14mg D1, 8, 15 20mg D1,8,15,22~The first patient in arm M will be entered into the study at dosing level one."
88930724|NCT01742806|No Intervention|control|not to use bio-absorbable felt(NEOVEIL®)
88930725|NCT01742806|Experimental|NEOVEIL®|To use bio-absorbable felt
88930726|NCT01742845|Active Comparator|control group|landmark-based superficial cervical block is used. After insertion of the needle superficially below the skin, 20 to 30 ml of 4.75 mg/ml ropivacaine are injected fan-like in the subcutaneus plane.
88930727|NCT01742845|Experimental|echo group|ultrasound-guided intermediate cervical block was performed. The probe is placed perpendicular to the skin, in the horizontal plane at the C3-C4 level. Needle is inserted in-plane. 10 ml ropivacaine 4.75mg/ml are injected under ultrasound control, 5 ml injected when needle is withdrawn under ultrasound control, 5 ml in the subcutaneous plane.
88930728|NCT01742858||Adolescents|15-18 years old
88930729|NCT01742858||Young adults I|19-24 years old
88930730|NCT01742858||Young adults II|25-30 years old
88930731|NCT01742871||controls|Patient under anti-vitamin K with no haemorrhagic manifestations admitted for another reason to Emergency Adults
88930732|NCT01742871||kaskadil|Patient under anti-vitamin K with a serious bleeding event that required treatment in the emergency Adults. Is considered serious accident requiring the use of a reversion by PPSB (Kaskadil ®).
88930733|NCT01742884|Experimental|Thealoz|Treatment with Thealoz (Trehalose) 3% for 1 month
88930734|NCT01742884|Placebo Comparator|Treatment with Thealoz´s vehicle|Treatment with Thealoz´s vehicle for 1 month
88930735|NCT01742910|Other|Tecnis ZCB00|eyes with implantation of Tecnis ZCB00
88930736|NCT01742910|Other|Acrysof SA60AT|eyes with implantation of Acrysof SA60AT
88930737|NCT01742923|Placebo Comparator|Usual care|Usual care
88930738|NCT01742923|Experimental|Complex tailored intervention|"The interventions consists of 3 elements:~Medication review with recommendations focused on antihypertensives and statins and adherence to guidelines and patient´s adherence to medications~Consultation with a pharmacist using motivational interviewing techniques~Follow-up telephone calls one month and six months after inclusion"
88930739|NCT01742962||Radical prostatectomy for prostate cancer|Prior treatment with open or robot assisted laparoscopic prostatectomy.
88930740|NCT01742975|Experimental|Arm A: Applying Ifabond|The synthetic adhesive solution Ifabond, will be applied at the end of conventional breast cancer surgery for arm A patients.
89445994|NCT02198625|No Intervention|FiO2 80%,Nonprotective Lung Ventilation|
89445995|NCT02198625|Experimental|FiO2 30%,Nonprotective Lung Ventilation|FiO2 30%,Nonprotective Lung Ventilation
88930741|NCT01742975|No Intervention|Arm B: without Ifabond|The synthetic adhesive solution Ifabond, will not be applied at the end of conventional breast cancer surgery in arm B patients.
88930742|NCT01742988|Experimental|Fimepinostat - Continuous Once Daily|Fimepinostat 30-60 mg/day
88930743|NCT01742988|Experimental|Fimepinostat - 2x/week|Fimepinostat 60-240 mg/day
88930744|NCT01742988|Experimental|Fimepinostat - 3x/week|Fimepinostat 60-180 mg/day
88930745|NCT01742988|Experimental|Fimepinostat - 4x/week|Fimepinosta 60-180 mg/day
88930746|NCT01742988|Experimental|Fimepinostat - 5x/week|Fimepinostat 60-180 mg/day
88930747|NCT01742988|Experimental|Fimepinostat - Expansion 5x/week|Fimepinostat 60 mg on the 5 days on/2 days off
88930748|NCT01742988|Experimental|Fimepinostat - Expansion 3x/week|Fimepinostat 120 mg 3 days on/4 days off
88930749|NCT01742988|Experimental|Fimepinostat 60 mg - Combination w/ rituximab|Fimepinostat 60 mg 5 days on.2 days off plus rituximab
88930750|NCT01742988|Experimental|Fimepinostat 120 mg - Combination w/ rituximab|Fimepinostat 120 mg 3x/week plus rituximab
88930751|NCT01742988|Experimental|Fimepinostat - Biocomparability Arm|Biocomparability Arm
88930752|NCT01742988|Experimental|Fimepinostat 30 mg - Combination w/ venetoclax|Fimepinostat 30 mg 5 days on/2 days off plus venetoclax. Different combinations of dose levels for venetoclax will be explored
89445996|NCT02198625|Experimental|FiO2 80%,protective Lung Ventilation|FiO2 80% and protective Lung Ventilation
89445997|NCT02198625|Experimental|FiO2 30%,protective Lung Ventilation|FiO2 30% and protective Lung Ventilation
89445998|NCT03489798|Experimental|6 Misoprostol|Up to six doses of 25ug of misoprostol applied every 6 hours. End point is cervical Bishop score > 6.
88930753|NCT01742988|Experimental|Fimepinostat 60 mg - Combination w/ venetoclax|Fimepinostat 60 mg 5 days on/2 days off plus venetoclax. Different combinations of dose levels for venetoclax will be explored
88930754|NCT01742988|Experimental|Fimepinostat - Combination w/ venetoclax and rituximab|Fimepinostat and venetoclax dosed at dose levels determined for that combination. Rituximab dosed at 375 mg/m2 IV on Day 1 of each 21 day cycle
88930755|NCT01743014|Active Comparator|ramipril|Ramipril 10 mg tablets. Each dose will be taken orally with water once daily.
88930756|NCT01743014|Active Comparator|clopidogrel and ramipril|clopidogrel 75mg tablet and ramipril 10mg. Each drug will be taken orally with water once daily
88930757|NCT01743053|Other|Control: Standard Care|The control group will receive standard care (debridement, cleansing) and Profore® multi-layer compression therapy (replacing the wound contact layer with Telfa™ Clear).
88930758|NCT01743053|Experimental|ReCell|The ReCell group will receive ReCell in addition to standard care (debridement, cleansing) and Profore® multi-layer compression therapy (replacing the wound contact layer with Telfa Clear).
88930759|NCT01743066|Experimental|Arsenicosis patients|Vitamin E (200 IU, caplet) daily orally for 20 weeks
88930760|NCT01743066|Active Comparator|Arsenic exposed controls|vitamin E (200 IU, caplet) daily orally for 20 weeks
88930761|NCT01743066|Active Comparator|Heathy volunteers|Vitamin E (200 IU, caplet) daily orally for 20 weeks
89013853|NCT06148818|Experimental|disc displacement with reduction|Temporomandibular joint disc displacement with reduction
88930762|NCT01743079|Experimental|Telbivudine|Mother receives telbivudine 600mg per day. Infant receives standard immunoprophylaxis
89445999|NCT03489798|Active Comparator|3 misoprostol|Up to 3 doses of 25ug of misoprostol applied every 6 hours. End point is cervical Bishop score > 6.
88930763|NCT01743079|Experimental|Lamivudine|Mother receives lamivudine 100mg per day. Infant receives standard immunoprophylaxis.
88930764|NCT01743079|No Intervention|No antiviral treatment|Mother receives no antiviral treatment. Infant receives standard immunoprophylaxis
88930765|NCT01743105|Experimental|Study population|"The study population consists of patients treated for acute respiratory distress in the emergency department at the Nîmes University Hospital. See inclusion and exclusion criteria.~Interventions: Diaphragm excursion measures 1, Diaphragm excursion measures 2"
88930766|NCT01743118|Experimental|Psoriasis Plaque Test|SPS4251 Ointment, 0.01%; SPS4251 Ointment, 0.1%; SPS4251 Ointment, 1%; SPS4251 Placebo, Daivonex® ointment
88930767|NCT01743144|Active Comparator|Magnesium sulphate|Magnesium sulphate (MgSO4) 10% solution is going to be used, an initial MgSO4 bolus dose 30mg/kg (i.e. 0.3mL/kg) will be infused over 10 minutes after endotracheal intubation. This will be followed by a continuous infusion of 10 mg/kg/hr (i.e. 0.1 ml/kg/h). Infusion will continue during the entire intraoperative course and will be terminated with the discontinuation of sevoflurane
88930768|NCT01743144|Placebo Comparator|normal saline|normal saline (NaCl 9%) is going to be used, an initial normal saline bolus dose 0.3ml/kg will be infused over 10 minutes after endotracheal intubation. This will be followed by a continuous normal saline infusion of 0.1 ml/kg/h. Infusion will continue during the entire intraoperative course and will be terminated with the discontinuation of sevoflurane
89013854|NCT06148818|Experimental|disc displacement without reduction|Temporomandibular joint disc displacement without reduction
89013855|NCT06148818|Other|Myofascial2|Myofascial Temporomandibular Dysfunction
89446000|NCT02197611||Validation group|Group of patients who we will consult the characteristics of the scale designed and will be made the statistical calculations of validity, reliability and reproducibility
89446001|NCT02197689|Experimental|SMS Medication Reminder|763 patients were assigned to experimental group
89446002|NCT02197689|No Intervention|No SMS Reminder|435 patients were assigned to control group as no SMS reminder
89446003|NCT05145114|Experimental|Supine Group (SG)|
89446004|NCT05145114|Experimental|Prone Group (PG)|
89446005|NCT05145114|Experimental|Lateral Decubitus Group (LDG)|
89013856|NCT06148818|Other|disc displacement with reduction2|Temporomandibular joint disc displacement with reduction
89446006|NCT02198703|Experimental|AB-Life|1 capsule of AB-Life daily during 12 weeks consumed immediately before, after or during the breakfast. The daily dose corresponds to the intake of 1.8E+10 CFU. According to the product's stability and the duration of the experiment, all participants receive at least 1.2E+09 CFU/capsule/day by the end of the study.
89446007|NCT02198703|Placebo Comparator|Placebo|1 capsule of placebo daily during 12 weeks consumed immediately before, after or during the breakfast.
89446008|NCT05144958||Totally thoracoscopic LAAO - ATRICLIP|In this group, LAA will be sealed using the epicardial thoracoscopic approach with the ATRICLIP device.
89446009|NCT05144958||Percutaneous LAAO - WATCHMAN|In this population, LAA will be occluded using an endocardial totally-percutaneous approach with the WATCHMAN device.
89446010|NCT05144958||Hybrid- minimally invasive LAAO - LARIAT|In these patients, LAA will be closed using a hybrid, combined endo- and epicardial approach using the LARIAT system.
89446011|NCT04461522||Exposed group|
89446012|NCT04461522||Control group|
89013857|NCT06148818|Other|disc displacement without reduction2|Temporomandibular joint disc displacement without reduction
89013858|NCT06145607|Experimental|Period 1, 2 and 3 ABBV-CLS-7262|"Participants will receive ABBV-CLS-7262 administered under fasted conditions.~Participants will receive ABBV-CLS-7262 administered under fed conditions (high-fat/high-calorie breakfast).~Participants will receive ABBV-CLS-7262 administered with applesauce."
89013859|NCT06136936|Active Comparator|CT-156|Study app investigational treatment for adult patients diagnosed with schizophrenia.
89446013|NCT02031081|Experimental|Treatment Period 1|A randomized assignment of prucalopride or placebo for a period of 28 days, crossover design
89446014|NCT02031081|Experimental|Treatment Period 2|A randomized assignment of either prucalopride or placebo for a period of 28 days, crossover design. Subjects who received active drug in Treatment Arm 1 will receive placebo and vice versa.
89446015|NCT02198781||Cohort|Basic science study
89446016|NCT02031315||Resident of health areas of interest|Residents of 4 health areas will be monitored for sudden unexpected death within 72 months of follow up. Circumstances and past medical conditions will be checked.
89446017|NCT02198859|Experimental|Lithium|Oral lithium carbonate dose escalation: Level 1 of 600 mg/day, then escalating to Level 2 of 900 mg/day, then the final Level 3 of 1200 mg/day.
89446018|NCT03533907||treated|The women included were patients of the Humanitas Fertility Center; they all had a diagnosis of infertility and were trying to become pregnant. They received ≥1 month of therapy with UA 5 mg/day
88930769|NCT01743157|Experimental|Biochemo + Bevacizumab then Ipilimumab|Single arm: Biochemotherapy with 4 cycles at 3 week intervals of Temozolamide 150mg/m2 x4, cisplatin 20mg/m2 x 4, vinblastine 1.2mg/m2 x 4, bevacizumab 7.5-15 mg/kg x 1, interferon 5mg/m2 x5 and aldesleukin 36,18,9, % 9 miu/day over 4 days each cycle; then ipilimumab 3mg/kg q 21 days x 4, then q 3 months x 8 for total 3 years.
88930770|NCT01743170|No Intervention|Control group|In the control group doctors will receive information on the self-measured blood pressure as recorded at home via a diary card.
88930771|NCT01743170|Experimental|Intervention group|In the intervention group, doctors will receive weekly reports via telemonitoring of self-measured blood pressure.
88930772|NCT01743183|Experimental|threshold|Held inspiratory muscle strengthening for 5 weeks with Threshold, charging 30% of maximal inspiratory pressure, 7 days a week, one supervised and unsupervised 6.
88930773|NCT01743196||Normal weight|Women with BMI 18.5 to 24.9 kg/m2
88930774|NCT01743196||Obese|Women with BMI > 30 kg/m2
88930775|NCT01743222|Experimental|eASC|"eASC~First cohort (3 volunteers, first volunteer is not randomized to detect any acute reaction): injection of 2.5 millions of eASCs suspended in 0.25 ml of HTS per lymph node, total dose 5 millions of cells.~Second cohort (3 volunteers, first volunteer is not randomized to detect any acute reaction): injection of 5 millions of eASCs suspended in 0.5 ml of HTS per lymph node, total dose 10 millions of cells."
88930776|NCT01743222|Placebo Comparator|Placebo|"First cohort (2 volunteers): injection of 0.25 ml of Hypo Thermosol (HTS) per lymph node~Second cohort (2 volunteers): injection of 0.5 ml of Hypo Thermosol (HTS) per lymph node"
88930777|NCT01743235|Experimental|Placebo|30 subjects administered a placebo
88930778|NCT01743235|Experimental|Testosterone + Buspirone hydrochloride combination drug|30 subjects are given combination drug (0.25 mg Testosterone + 5 mg Buspirone hydrochloride)
88930779|NCT01743235|Experimental|Testosterone + Buspirone hydrochloride combinat|30 subjects are given combination drug (0.25 mg Testosterone + 10 mg Buspirone hydrochloride)
88930780|NCT01743235|Experimental|Testosterone + Buspirone Combination Drug|30 subjects are given combination drug (0.5 mg Testosterone + 5 mg Buspirone hydrochloride)
88930781|NCT01743235|Experimental|Testosterone +Buspirone Combination Drug|30 subjects are given combination drug (0.5 mg Testosterone + 10 mg Buspirone hydrochloride)
88930782|NCT01743235|Experimental|Testosterone|30 subjects are given 0.5 mg Testosterone
88930783|NCT01743235|Experimental|Buspirone|30 subjects are given 10 mg Buspirone hydrochloride
88930784|NCT01743261|Active Comparator|usual care|In this arm patients were managed according to the organization of the management model which took on the care of the patient. The organization of these models is characterized by one or two professional figures (physiatrists, neurologist), with hierarchical relationships, in spaces limited to a specific pathology; access is determined by clinical stability; the instruments of governance are guidelines and consensus and the rehabilitation programme is focused on functional and cognitive areas; the medical care process is governed by hierarchy. The technology in this model is limited to a specific specialty.
88930785|NCT01743261|Experimental|Graded intensive rehabilitation|"Instruments of governance are the diagnostic-therapeutic rehabilitation. pathways (DTRP), the Quality system and product standards.~Medical care process with result-oriented autonomy. Technology support of vital signs. Multidisciplinary intervention"
88930786|NCT01743274|No Intervention|Control Group|"Randomization will be performed after initial coronary angiography, once the operator has identified the lesion responsible for the ACS. Patients will be randomly allocated to one of two groups. In the Control Group, the angioplasty procedure will be guided by traditional fluoroscopy alone.~In both groups, fractional flow reserve (FFR) will be measured at the end of the procedure, once the operator considers the result of the angioplasty to be optimal. The average of three consecutive FFR measures will be recorded."
89013860|NCT06136936|Experimental|CT-156 + UXR|Study app investigational treatment for adult patients diagnosed with schizophrenia with up to five in-patient visits with three interviews for UXR (user experience research) arm.
89013861|NCT06136598|Experimental|MK-5684|Participants will receive MK-5684 by oral tablets twice daily plus dexamethasone and fludrocortisone by oral tablets once daily continuously until unacceptable toxicity or documented progression. Hydrocortisone will also be provided to participants for use as rescue medication.
89013862|NCT06135662|Active Comparator|CAF + CTG|This arm involves patients treated with the Coronally Advanced Flap (CAF) technique, a recognized method for treating gingival recession. As an active comparator, this arm serves to compare the effectiveness and outcomes of CAF against the alternative surgical method used in the study.
89013863|NCT06135662|Active Comparator|Tunnel Technique + CTG|Patients in this arm receive the Tunnel Technique (TT) with Connective Tissue Grafts (CTG). Also an established method for gingival recession treatment, this arm acts as an active comparator to assess and compare the effectiveness of TT+CTG against the CAF technique.
89013864|NCT06129045|Experimental|Group One, Video|One-time sleep hygiene education
89013865|NCT06129045|Experimental|Group Two, Video Plus Texts|One-time sleep hygiene education plus repeated education through automated text messaging
89013866|NCT06129045|No Intervention|Group Three,|Control group with no intervention assigned
89013867|NCT06128330|Active Comparator|Standard dose group|The standard dose group will receive a bolus of 20 mg/kg tranexamic acid after anaesthesia induction.
89013868|NCT06128330|Experimental|Low dose group|The low dose group will receive a bolus of 10 mg/kg tranexamic acid. In addition 1 mg/kg tranexamic acid will be added to the priming of the extracorporeal circuit (ECC) and a continuous infusion of 1mg/kg/h tranexamic acid will be started after the bolus infusion until the end of surgery.
89013869|NCT06128018|Other|EUS-guided gastrojejunostomy (EUS-GJ)|Patients on this arm will undergo the endoscopic procedure.
89013870|NCT06128018|Other|Surgical gastrojejunostomy (S-GJ)|Patients on this arm will undergo the surgical procedure.
89013871|NCT06126900|Experimental|Intervention Group|Reminder + text messaging
89013872|NCT06126900|No Intervention|Control Group|No reminder + no text messaging
89013873|NCT06126055|Experimental|Off PPI|No symptoms of reflux
89013874|NCT06123026|Experimental|Cabergoline|1mg oral cabergoline administered once after patient's procedure
89013875|NCT06123026|Placebo Comparator|Placebo|1 tablet encapsulated placebo by Investigational Drug Pharmacy administered once after patient's procedure
89013876|NCT06122779|Experimental|BMS-986435|
89013877|NCT06122779|Placebo Comparator|Placebo|
89013878|NCT06121960|Experimental|Interventionnal|Measure DEP, DEM25, DEM 50, DEM 75, FVC, Inspiratory capacity, SpO2, Respiratory rate before, during, or after the state of self-induced cognitive trance Evolution of the feeling of self-efficacy, assessed by questionnaire.
89013879|NCT06120491|Experimental|Arm 1: Saruparib (AZD5305) + Physician's Choice NHA|Saruparib (AZD5305) + physician's choice NHA (Abiraterone, Darolutamide, or Enzalutamide)
89013880|NCT06120491|Placebo Comparator|Arm 2: Placebo + Physician's Choice NHA|Placebo + physician's choice NHA (Abiraterone, Darolutamide, or Enzalutamide)
89013881|NCT06119633|Experimental|Immediate tissue expander and fat grafting after mastectomy|Patients underwent simple mastectomy, skin-sparing or nipple-sparing mastectomy and implant-based, two-stage breast reconstruction: contextual mastectomy and expander positioning were performed during first stage (stage I) while substitution of the expander with definitive implant occurred during second stage (stage II). Fat grafting with regenerative intent was performed during stage I or between stage I and II. Adipose tissue was harvested from the abdomen, flanks, trochanter regions, inner thigh and medial aspect of knees. Fat was injected in the subfascial plane of the pectoralis major muscle with blunt cannula in order to avoid thrombo-embolic risks. At least six months after stage I patients underwent expander substitution with definitive implant and contralateral mammoplasty when required. In case of complications that required removal of the implant, autologous reconstruction was performed.
89013882|NCT06119061|Experimental|Telavancin|Subjects receiving telavancin for pharmacokinetic sampling
89013883|NCT06113237||Retrospective Pregnancy|Participants who were exposed to at least one dose of Epidiolex/Epidyolex in routine practice during the 13 days prior to last menstrual period (LMP) or at any time during their pregnancy and is no longer pregnant at the time of study enrollment.
89013884|NCT06113237||Prospective Pregnancy|Participants who were exposed to at least one dose of Epidiolex/Epidyolex in routine practice during the 13 days prior to last menstrual period (LMP) or at any time during their pregnancy and is pregnant at the time of study enrollment.
89446019|NCT02198937||Smokers|Healthy smokers
89446020|NCT02198937||Non-Smokers|Healthy non-smokers
89446021|NCT02199093|Experimental|Functional Rehabilitation of apraxia|The participants will be randomly assigned to an experimental group, to receive intervention in upper limb apraxia at home since two approaches, a rehabilitative and another compensatory (providing adaptive strategies at home). The treatment will be performed three times a week, 30 minutes a day, during a 4-week period.
89013885|NCT06107621|Experimental|Internet-based iCBT targeting Gambling Disorder and comorbidities|An 8 module internet-based iCBT program targeting Gambling Disorder and comorbidities, administered with treatment support.
89013886|NCT06099522|Experimental|Internet-based cognitive behavioral therapy (iCBT)|"An 8-module internet-delivered cognitive behavioral therapy program. Participants receiving treatment will simultaneously use Spelpaus - a self-exclusion gambling service."
89013887|NCT06099522|No Intervention|"Spelpaus (gambling self-exclusion)"|"Spelpaus only - a self-exclusion gambling service."
89013888|NCT06095765|Experimental|Colchicine|Colchicine 0.5 mg oral once daily, in addition to SOC
89013889|NCT06095765|Placebo Comparator|Placebo|Placebo oral once daily, in addition to SOC
89013890|NCT06094153|Placebo Comparator|Placebo|
89013891|NCT06094153|Experimental|HMO 1|
89013892|NCT06094153|Experimental|HMO 2|
89013893|NCT06094062|Experimental|Intervention Group|
89013894|NCT06088654|Experimental|IPH6501 monotherapy|
89013895|NCT06085105|Experimental|CPIPE Intervention arm|1. Training: A two-day training that addresses the following topics: Stress & positive coping mechanisms; Bias awareness and mitigation; Person-centered maternity care; Dealing with difficult situations; and Teamwork and communication. 2. Peer support: Groups for healthcare providers to meet with other healthcare providers of their cadre, to debrief, discuss issues they are facing, brainstorm solutions, and provide support to one another. 3. Leadership engagement: Engagement of County leadership at the onset of the project through a community advisory board to guide and help address sources of stress. 4. Mentorship: mentor-mentee relationships that provide the opportunity to coach less experienced healthcare providers on professional development, work-life balance, clinical skills, career advancement and other topics. 5. Embedded champions: facility champions to lead in organizing and facilitating peer support groups and refreshers at their facilities and serve as role models.
89013896|NCT06085105|No Intervention|CPIPE control arm|The control group will not receive the CPIPE intervention during the 12-month data collection period but will maintain their usual facility level activities.
89013897|NCT06079411|Active Comparator|TAU|"the treatment as usual (TAU; i.e., visuospatial paper and pencil stimulation) will consist of paper and pencil exercises used in clinical routine of 8 sessions of 30/40 minutes 3 times a week."
89013898|NCT06079411|Experimental|VR non-embodied|the non-embodied spatial training will consist of egocentric and allocentric spatial memory training with passive navigation of 8 sessions of 30/40 minutes 3 times a week.
89013899|NCT06079411|Experimental|VR embodied|the embodied spatial training will consist of egocentric and allocentric spatial memory training with active navigation of 8 sessions of 30/40 minutes 3 times a week.
89013900|NCT06073301|Experimental|Treatment: Acellular Fish Skin (AFS) with Standard of Care Negative Pressure Wound Therapy (NPWT)|Eligible subjects will be randomized electronically to either the Acellular Fish Skin (AFS)arm. The subject will undergo wound bed preparation by surgical debridement. the AFS will be applied to the wound bed and secured with sutures, the size of the AFS will be determined after surgical debridement. Once the AFS is in place a Negative Pressure Wound Therapy device will be placed. the subject will be monitored weekly on scheduled intervals of +/- 4 days post AFS placement to assess the status of the wound and readiness for autografting. Once the wound is ready for autografting the subject will be monitored for autograft take, for up to 9 visits. Long term follow-up will be done at month 3, 6, 9 post autograft placement
89013901|NCT06073301|Active Comparator|Acellular Human Cadaver with Standard of Care Negative Pressure Wound Therapy (NPWT)|.Eligible subjects will be randomized electronically to standard of care arm which is Acellular Human Cadaver (AHC) The subject will undergo wound bed preparation by surgical debridement. The AHC will be applied to the wound bed and secured with sutures, the size of the AHC will be determined after surgical debridement. Once the AHC is in place a Negative Pressure Wound Therapy device will be placed. the subject will be monitored weekly on scheduled intervals of +/- 4 days post AHC placement to assess the status of the wound and readiness for autografting. Once the wound is ready for autografting the subject will be monitored for autograft take, for up to 9 visits. Long term follow-up will be done at month 3, 6, 9 post autograft placement
89013902|NCT06070207|Active Comparator|TEP Group|In 20 patients; Bilateral inguinal hernia surgery will be performed with the TEP method and the 15x12x10 cm polyprolene patch used in this surgery will be marked with small metallic clips from the lateral, superomedial and inferomedial sides. During the surgery, the mesh will not be fixed. Patients whose pain scores (VAS score) are measured on the first postoperative day and who are suitable for discharge will be discharged after a pelvis x-ray is taken. One month after the surgery and 6 months later, patients will be called to the outpatient clinic and examined, their pain scores will be measured (VAS score) and pelvic radiographs will be taken. The movement of the clips marked on the patch will be compared with previous radiographs in cm.
89013903|NCT06070207|Experimental|eTEP Group|In 20 patients; Bilateral inguinal hernia surgery will be performed with the eTEP method and the 15x12x10 cm polyprolene patch used in this surgery will be marked with small metallic clips from the lateral, superomedial and inferomedial sides. During the surgery, the mesh will not be fixed. Patients whose pain scores (VAS score) are measured on the first postoperative day and who are suitable for discharge will be discharged after a pelvis x-ray is taken. One month after the surgery and 6 months later, patients will be called to the outpatient clinic and examined, their pain scores will be measured (VAS score) and pelvic radiographs will be taken. The movement of the clips marked on the patch will be compared with previous radiographs in cm.
89446022|NCT02199093|Active Comparator|Traditional health educative protocol|Control group will receive treatment with a traditional health educative protocol to improve his functionality in activities of daily living. The treatment will be performed twice in two month.
89446023|NCT02199171|Experimental|HIPEC carboplatin|"Patients receive hyperthermic carboplatin intraperitoneally over 60 minutes during the planned surgical cytoreductive procedure.~Doses as appropriate for assigned dose level in 500 cubic centimeters (cc)"
89013904|NCT06070142|Active Comparator|TEP group|In 30 patients; Inguinal hernia surgery will be performed with the TEP method and the 15x12x10 cm polyprolene patch used in this surgery will be marked with small metallic clips from the lateral, superomedial and inferomedial sides. During the surgery, the mesh will not be fixed to the Cooper ligament. Patients whose pain scores (VAS score) are measured on the first postoperative day and who are suitable for discharge will be discharged after a pelvis x-ray is taken. One month after the surgery and 6 months later, patients will be called to the outpatient clinic and examined, their pain scores will be measured (VAS score) and pelvic radiographs will be taken. The movement of the clips marked on the patch will be compared with previous radiographs in cm.
89013905|NCT06070142|Experimental|eTEP Group|In 30 patients; Inguinal hernia surgery will be performed with the eTEP method and the 15x12x10 cm polyprolene patch used in this surgery will be marked with small metallic clips from the lateral, superomedial and inferomedial sides. During the surgery, the mesh will not be fixed to the Cooper ligament. Patients whose pain scores (VAS score) are measured on the first postoperative day and who are suitable for discharge will be discharged after a pelvis x-ray is taken. One month after the surgery and 6 months later, patients will be called to the outpatient clinic and examined, their pain scores will be measured (VAS score) and pelvic radiographs will be taken. The movement of the clips marked on the patch will be compared with previous radiographs in cm.
89013906|NCT06069544|Experimental|BNT165e|Escalating dose levels
89013907|NCT06069544|Placebo Comparator|Placebo|
89013908|NCT06064682||Group 1: local tumor|patients with localized osteosarcoma who are scheduled to undergo diagnostic biopsy and are planned for surgical excision of the primary tumor
89013909|NCT06064682||Group 2: metastatic disease|patients with metastatic osteosarcoma who are scheduled to undergo either biopsy or surgery of metastatic disease
89013910|NCT06063434|Experimental|Night Shift|Night Shift 2024 is a customized, theory-based adventure video game in which the player takes on the character of Andy Jordan, a young emergency medicine physician who moves home after the disappearance of his grandfather and takes a job at a local community hospital. The investigators will ask participants to play Night Shift for 2 hours upon enrollment (or within 2 weeks), and then come back to the game quarterly to play it again for 20 minute booster sessions. They will unlock additional game content each quarter to make the experience more enjoyable.
89446024|NCT02199249|Active Comparator|Open Reduction Tightrope fixation (OT)|Device: Following fixation of Weber C fibular fracture according to AO standards, the syndesmosis will be stabilized by open reduction followed by use of a single Tightrope (Arthrex-Knotless) device. Open Reduction Tightrope fixation (OT)
89446025|NCT02199249|Active Comparator|Open Reduction screw fixation (OS)|Device: Following fixation of Weber C fibular fracture according to AO standards, the syndesmosis will be stabilized by open reduction followed by use of two or more syndesmosis screws. Open Reduction screw fixation (OS)
89446026|NCT02257359|Experimental|Epelsiban Cohort 1|Subjects will receive 300 mg of epelsiban administered orally twice (every 12 hr) on Day 1 (total daily dose of 600 mg)
89446027|NCT02257359|Experimental|Epelsiban Cohort 2|Epelsiban dose for Cohort 2 will be determined based on data from Cohort 1, but will not exceed a total daily dose of 900 mg, administered orally in divided doses (450 mg every 12 hrs or 300 mg every 8 hrs).
89446028|NCT02257359|Experimental|Additional Cohorts TBD (to be decided)|Subjects will be enrolled if determined necessary, based on data collected in Epelsiban Cohort 1 and Cohort 2
89446029|NCT00910650|Experimental|F5 TCR transgenic cells|F5 TCR transgenic cell adoptive transfer therapy
89013911|NCT06063434|Active Comparator|Usual education|Participants will receive their usual continuing medical education, but nothing additional.
89013912|NCT06059638|Experimental|Treatment Group|AVIM therapy activated with continued stable antihypertensive drug therapy
89013913|NCT06059638|Sham Comparator|Control Group|AVIM therapy deactivated with continued stable antihypertensive drug therapy
89013914|NCT06053099|Experimental|Plasma ctDNA and FFPE blocks|
89446030|NCT02257437|Experimental|LNS + borbor|Lipid-based nutrient supplement (LNS) added to borbor
89446031|NCT02257437|Active Comparator|Corn-soy blend ++ (CSB++)|CSB++ porridge
89446032|NCT02257437|Active Comparator|Sprinkles|Sprinkles added to borbor
89446033|NCT02257437|Active Comparator|LNS snack|LNS eaten as snack
89446034|NCT04461366|Experimental|monopolar radiofrequency (MRF) group|Monopolar Radiofrequency Diathermy (LVT-250, Korea) was used at average energy160-180 W, main power 50/60 Hz, 40˚C ~ 45˚C Temperature, RF output 470 kHz, 20 mm electrode size.
89446035|NCT04461366|Active Comparator|Pulsed dye laser (PDL) group|Flash lamp pulsed dye laser; Candela SPTL-1 (Candela Corp., Wayland, Mass.) with the following parameters: (585nm wavelength, 450 msec pulse duration, 6.5 to 7.5 J/cm² energy density and 5or 7mm spot size).
89446036|NCT02199327|Active Comparator|Mitomycin C|Mitomycin C 0.04% 4 times daily for 7 days and 7 days off until resolution of neoplasia (3-6 cycles).
89446037|NCT02199327|Active Comparator|Interferon alfa 2b|Interferon alfa-2b 1 million IU/ml 4 times daily until complete resolution of the tumor
89446038|NCT00756288|Experimental|1|Topical retinoid and Light therapy with photosensitizing agent
89446039|NCT00756288|Active Comparator|2|Light therapy with photosensitizing agent
89446040|NCT02198001|Active Comparator|tooth extraction and insertion of PRF|Experimental: Atraumatic tooth extraction with antibiotics( amoxicillin clavulanate combination) .Insertion of PRF membrane in tooth-extraction site.
89446041|NCT02198001|Placebo Comparator|No PRF|Atraumatic extraction with antibiotic without PRF insertion
89446042|NCT02198079||Cystic Fibrosis|Children with Cystic Fibrosis
89446043|NCT05147688|Experimental|Treatment Group|Single intravenous infusion of 100 million cells
89446044|NCT02031393||singelton pregnancy|will be followed 11-14 weeks and 19-28 weeks of gestation and after birth
89446045|NCT02031393||twin pregnancy|will be followed 11-14 weeks and 19-28 weeks of gestation and after birth
89446046|NCT05116800|Experimental|Stratum A: Soft Tissue Sarcoma|Patients with advanced soft tissue sarcoma previously treated with 0-3 prior lines of systemic therapy will receive 9-ING-41 twice weekly with gemcitabine on days 1 and 8 and docetaxel on day 8 of a 21-day cycle until disease progression or unacceptable toxicity.
89446047|NCT05116800|Experimental|Stratum B: Bone Sarcoma|Patients with relapsed or refractory bone sarcoma previously treated with at least one line of systemic therapy will receive 9-ING-41 twice weekly with gemcitabine on days 1 and 8 and docetaxel on day 8 of a 21-day cycle until disease progression or unacceptable toxicity.
89446048|NCT02199405|Experimental|massage and Sishi Daoyin|Massage of chiropractic and adjusting cervical curvature, 10 minutes, three times one week for 4 weeks Sishi Daoyin, practicing during 9-11am, once a day for 4 weeks
89446049|NCT02199405|Active Comparator|conventional massage and cervical traction|Conventional massage , 15 minutes, three times one week for 4 weeks Cervical traction , 15 minutes, three times one week for 4 weeks
89446050|NCT02198157|Active Comparator|intermittent urinary catheterization|nullipara women with epidural anaesthesia who pose urination difficulty will receive intermittent catheterization
89446051|NCT02198157|Active Comparator|continuous urinary catheter|nullipara women with epidural anaesthesia who pose urination difficulty will receive continuous catheterization
89446052|NCT04078737|Experimental|Ticagrelor plus Aspirin Group|Ticagrelor of loading dosing of 180mg followed by 90mg bid for 3 months plus aspirin of loading dose of 75-300mg followed by 75mg daily for 21 days
89446053|NCT04078737|Active Comparator|Clopidogrel plus Aspirin Group|Clopidogrel of loading dosing of 300mg followed by 75mg daily for 3 months plus aspirin loading dose of 75-300mg followed by 75mg daily for 21 days
89446054|NCT03491904|Experimental|Auto-injector (AI)|
89446055|NCT03491904|Experimental|Prefilled syringe (PFS)|
89446056|NCT03487146|No Intervention|HD(hemodialysis) group|HD group as conventional control arm
89446057|NCT03487146|Active Comparator|HD+HP(hemodialysis+hemoperfusion) group|HD+HP as active interventional group.HP was performed 1-2 times/per 2 weeks, and each session lasted for two hours.
89013915|NCT06052878||General anesthesia|Children whose mothers underwent general anesthesia for non-obstetric surgery during pregnancy.
89446058|NCT05039112|Other|P1fA, then MyDay Toric|Verofilcon A toric contact lenses worn first, with stenfilcon A toric contact lenses worn second, as randomized. Each product will be worn bilaterally (in both eyes) for 8 (-0/+3) days in a daily disposable modality.
89446059|NCT05039112|Other|MyDay Toric, then P1fA|Stenfilcon A toric contact lenses worn first, with verofilcon A toric contact lenses worn second, as randomized. Each product will be worn bilaterally (in both eyes) for 8 (-0/+3) days in a daily disposable modality.
89446060|NCT05150808|Active Comparator|Intervention IRS|Intervention IRS insecticide will be sprayed on the walls and ceilings of 8 clusters
89446061|NCT05150808|Active Comparator|Control IRS|WHO approved IRS insecticide will be sprayed on the walls and ceilings of 8 clusters
89446062|NCT02198313|Experimental|BIIX 1 XX - D1|
89446063|NCT02198313|Experimental|BIIX 1 XX - D2|
89446064|NCT02198313|Experimental|BIIX 1 XX - D3|
89446065|NCT02198313|Placebo Comparator|Placebo|
89446066|NCT03249090|Experimental|Patient Self-Reporting of Symptoms|Patients report symptoms weekly via web or automated telephone system. Email alerts to nurses for severe/worsening symptoms; printouts for clinicians at visits. Evidence based symptom management pathways provided to patients and clinicians.
89446067|NCT03249090|Active Comparator|Usual Care Delivery|Evidence-based symptom management pathways provided to patients and clinicians
89446068|NCT02199561|Experimental|Fecal Microbiota Transplant|Open label single arm delivering fecal transplant to each participant
89446069|NCT02199639||Spain|Group of patients with hemophilia recruited in the Region of Murcia (Spain) and evaluated in the Universidad Católica San Antonio between June and July 2014.
89446070|NCT02199639||El Salvador|"Group of patients with hemophilia recruited in the city of San Salvador (El Salvador) and evaluated in the Hospital Nacional Rosales and the Hospital Nacional de niños Benjamín Bloom from San Salvador in April 2014."
89446071|NCT02199639||Bolivia|Group of patients with hemophilia recruited in the city of Santa Cruz (Bolivia) and evaluated at the Hospital Nacional de niños in Santa Cruz August 2014.
89446072|NCT03487068|Other|Patients with NAFLD|
89446073|NCT02199873|Experimental|BIIX 1 XX - single rising dose|
89446074|NCT02199873|Placebo Comparator|Placebo|
89446075|NCT04740606||Treatment Group|The patients whose chest CT images show that the pulmonary nodules are highly suspected of malignant and scheduled to be diagnosed by bronchoscopy under the guidance of the Augmented Reality Navigation System.
89446076|NCT02198391||3 x 1 tablet per day|Echinaforce Junior tablets (low dose)
88930787|NCT01743274|Experimental|Optical Coherence Tomography|"Randomization will be performed after initial coronary angiography, once the operator has identified the lesion responsible for the ACS. Patients will be randomly allocated to one of two groups.~In the OCT group, OCT will be performed to optimise the results of angioplasty. The procedure will be performed according to usual practice, with or without pre-dilation before implantation of one or more stents (drug-eluting or bare metal). In the OCT group, OCT will be performed after initial coronary angiography and at the end of the procedure and the operator will have the possibility to change procedural strategy according to the data immediately available on the OCT images, with the possibility of additional interventions (additional balloon inflations, addition stent implantation, use of GPIIb/IIIa inhibitors and/or thromboaspiration and/or rotational atherectomy)."
88930788|NCT01743287|Experimental|Imotun capsule|Imotun capsule: 300.03mg/cap, orally, 1 capsule once a day during 24 weeks
89446077|NCT02198391||5 x 1 tablet per day|Echinaforce Junior tablets (high dose)
89446078|NCT05150730|Experimental|Quality-of-Life multidisciplinary care program|Six groups (between 10 -19 participants per group) received a meeting for two hours, the first hour being devoted to physical exercise, stimulating body awareness, improving mobility and muscle strengthening, relaxation and self-care.
88930789|NCT01743287|Placebo Comparator|Imotun capsule placebo|Imotun capsule Placebo: Placebo 1 capsule once a day during 24 weeks
88930790|NCT01743300|Active Comparator|Grapefruit juice arm|The grapefruit juice will be administered 3 times per day for 1 period of 3 days in the 4th week of treatment
88930791|NCT01743300|Active Comparator|Orange juice|The orange juice will be administered 3 times per day for 1 period of 3 days in the 4th week of treatment.
88930792|NCT01743326|Experimental|RFD-group|Radio Frequency Denervation
88930793|NCT01743326|Active Comparator|Local Anesthesia-group|Local Anesthesia-group
88930794|NCT01743339|Active Comparator|Control|Control (brief check-in calls) and Cognitive Processing Therapy (12 individual weekly sessions)
88930795|NCT01743339|Experimental|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy for Insomnia (4 individual therapy sessions over 5 weeks) and Cognitive Processing Therapy (12 individual weekly sessions)
88930796|NCT01743352||Hypertension patients|Local common carotid artery pulse wave velocity is compared in patients with hypertension and healthy volunteers.
88930797|NCT01743352||Healthy Volunteers|Local common carotid artery pulse wave velocity is compared in hypertension patients and healthy volunteers
88930798|NCT01743365|Experimental|Cisplatin-5FU-Afatinib|"Cisplatin 75mg/m2 iv administered on Day 1, 5FU 750mg/m2 at 24-hour iv infusion on Days 1-4, Afatinib (BIBW-2992) 40mg per os on Days 3-5, 8-12, 15-19 of each cycle. Administration of Afatinib will start on Day 3 of each cycle with an administration interval on each weekend (Weekday on, Weekend off) for 21 days. The administration of the combination Cisplatin-5FU-Afatinib will be continued until disease progression, appearance of significant toxicity, completion of 6 cycles, or withdrawal of consent. At completion of 6 cycles of the combination, in the absence of disease progression, the administration of Afatinib as maintenance monotherapy will be continued until disease progression, appearance of significant toxicity, or withdrawal of consent at the weekday on-weekend off schedule."
88930799|NCT01743378|Experimental|TAP Block Ropivacaine 0,75 %|Bilateral Transversus Abdominis Plane Block with 2 x 20 ml Ropivacaine 0,75 %
88930800|NCT01743378|Placebo Comparator|TAP Block Saline 0,9 %|Bilateral Transversus abdominis plane block with 2 x 20 ml Saline 0,9 %
88930801|NCT01743404|Active Comparator|Inflaminat|Inflaminat 500 mg tablet by mouth three times a day
88930802|NCT01743404|Placebo Comparator|Sugar pill|Placebo 500 mg tablet by mouth three times a day
88930803|NCT01743417|Experimental|Cognitive intervention|Children in this arm will receive computerised cognitive rehabilitation training for 24 sessions lasting 45 minutes. The Captain's log brain training software is programmed to increase in difficulty as child progresses through the training levels.
88930804|NCT01743417|Active Comparator|Active control|Children in this arm will receive 24 sessions of computerised cognitive rehabilitation training. Captain's log, the brain training software will not be programmed to increase in difficulty with each successive level in this arm.
88930805|NCT01743417|No Intervention|Passive control|No computer training or games will be provided to this group
89446079|NCT02199951||Dihydroartemisinin and piperaquine|The patients will take Eurartesim® (DHA/PQP) with a dose regimen of one administration every 24 hours over a period of three days, i.e. at Day 1, then after 24 hours (Day 2) and after 48 hours (Day 3) from the first administration. The dose will be based on body weight. Two strengths of Eurartesim® will be provided for dosing in children and adults: 20/160mg and 40/320mg of DHA and PQP respectively. Body weight (kg) Daily dose (mg) Number of tablets per dose 20/160mg DHA/PQ 40/320mg DHA/PQ 5 to <7 10 mg DHA and 80 mg PQP ½ tablet 7 to <13 20 mg DHA and 160 mg PQP 1 tablet 13 to < 24 40 mg DHA and 320 mg PQP 1 tablet 24 to < 36 80 mg DHA and 640 mg PQP 2 tablets 36 to < 75 120 mg DHA and 960 mg PQP 3 tablets 75 to < 100 160 mg DHA and 1280 mg PQP 4 tablets > 100.
88930806|NCT01743430|Experimental|telerehabilitation|telerehabilitation via internet
88930807|NCT01743430|No Intervention|conventional|conventional therapy
88930808|NCT01743443|Experimental|Sensitiviy|Using the Cochet-Bonnet esthesiometer central corneal sensitivity was measured preoperatively, after 7 days, and once a month after surgery until recovery of the baseline preoperative level. Normal levels of central corneal sensitivity were considered above 40mm.
88930809|NCT01743456|No Intervention|Current practice (BIS and rSO2 blinded)|
88930810|NCT01743456|Experimental|Targeted intra-operative depth of anaesthesia|
89446080|NCT02200029|Experimental|Ademetionine IV|
89446081|NCT02200029|Experimental|Ademetionine oral|
89446082|NCT03489642|Experimental|COPD Telehealth Program|Participants will take part in a structured telehealth program for 12 weeks. Web-based educational tools will be made available to participants. Study participants will meet with a registered respiratory therapist two times per week.
89446083|NCT02200107|Experimental|self management education|self management education program delivered by family doctor in primary care clinics and during and physical therapy design
89446084|NCT02200107|No Intervention|control|Routine follow up according to standard practice
89446085|NCT01433328|Experimental|Lidocaine|
89446086|NCT01433328|Placebo Comparator|Placebo|Remodulin only
89446087|NCT02198469|Experimental|Er:YAG AFL-PDT|Eligible patients were successively randomised to receive treatment with a single session of Er:YAG AFL MAL-PDT or 2 sessions of MAL-PDT with a 1-week interval between sessions
89446088|NCT02198469|Active Comparator|MAL-PDT|Eligible patients were successively randomised to receive treatment with a single session of Er:YAG AFL MAL-PDT or 2 sessions of MAL-PDT with a 1-week interval between sessions
89446089|NCT02200185|Placebo Comparator|IV titrated morphine|"patient will receive 2 mg morphine each 5 min, associated to continuous nebulisation of saline serum (placebo).~Morphine administration is stopped when VAS becomes under 50% and treatment failure is defined as VAS > 50%, 30 minutes after the beginning of the protocol."
89446090|NCT02200185|Experimental|Low dose nebulised morphine|"patient will receive 10 mg of morphine prepared with 4 ml saline serum (SS) and nebulised with 6 l/min flow during 10 minutes.~Nebulisation will be repeated 3 times, in addition, patients receive 2 ml IV SS every 5 minutes as placebo"
89446091|NCT02200185|Experimental|High dose nebulised morphine|"patient will receive 20 mg of morphine prepared with 3 ml saline serum (SS) and nebulised with 6 l/min flow during 10 minutes.~Nebulisation will be repeated 3 times, in addition, patients receive 2 ml IV SS every 5 minutes as placebo."
89446092|NCT03485664||Study Group|Severe pain on percussion of the relevant tooth was considered as basic criteria when deciding on acute infection phase. The acutely infected teeth were labelled as the study group
89446093|NCT03485664||Control Group|The asymptomatic teeth were labelled as the control group
89446094|NCT02200263|Experimental|Lutein plus Zeaxanthin|Participants randomized to this arm will receive 20 mg of Lutein (L) plus 20 mg of Zeaxanthin (Z) per day: Two pills (10 mg L+ 10 mg Z per pill) for the duration of one year.
88930811|NCT01743482|Experimental|Pazopanib|Patients will receive pazopanib at the dose of 800 mg/day orally until disease progression or evidence of unacceptable toxicity/side effects. The study will be performed according to Simon's two-stage optimal design.
88930812|NCT01743495|Other|Functional Services|The program consists of up to 10 home-based functional services sessions over 4 months.
88930813|NCT01743508|Active Comparator|Misoprostol by physician|Misoprostol treatment by midwife
88930814|NCT01743508|Experimental|Misoprostol by midwife|Misoprostol treatment by midwife
88930815|NCT01743534||Conservation of praxies and form plates|
88930816|NCT01743547|No Intervention|No Intervention; Arm A; Control Group|24 subjects who declined yoga but agreed to data collection
88930817|NCT01743547|Active Comparator|Active Comparator; Arm B; Intervention Group|24 subjects participating in 8 weeks of Yoga and agreed to data collection
88930818|NCT01743573|Experimental|yoga training|Yoga training
88930819|NCT01743573|No Intervention|control|no yoga training
88930820|NCT01743586|No Intervention|Control|
88930821|NCT01743599||Diabetic men|
88930822|NCT01743599||Non-diabetic men|
88930823|NCT01743612|Experimental|Sclerodermic patients|patients with systemic sclerosis according to Leroy's classification
89446095|NCT02200263|Placebo Comparator|Placebo softgels|Participants randomized to this arm will receive two pills per day of placebo-gels corresponding to the active compound in look and feel for the duration of one year
89446096|NCT02201043|Active Comparator|Thalidomide 150mg|Thalidomide 25mg/qd.po.2weeks; 50mg/qd.po.2weeks;100mg/qd.po.2weeks; 150mg/qd.po.to the end
89446097|NCT02201043|Active Comparator|Thalidomide 100mg|Thalidomide 25mg/qd.po.2weeks; 50mg/qd.po.2weeks; 100mg/qd.po.to the end
89446098|NCT02201043|Placebo Comparator|Placebo|Placebo po.
89446099|NCT02200341|Experimental|Mindfulness-Based Cognitive Therapy (MBCT)|Mindfulness-Based Cognitive Therapy (MBCT) 8-week intervention
89446100|NCT02200341|Active Comparator|Progressive Relaxation Training - Psychoeducation|Progressive Relaxation Training and Psychoeducation (PRT-PsyEd) 8-week intervention
88930824|NCT01743612|Experimental|Primary Raynaud's phenomenon|without secondary disease
88930825|NCT01743612|Experimental|Healthy subjects|18 years old or more
88930826|NCT01743638|Experimental|MR-Guided Laser Ablation|
88930827|NCT01743664|Experimental|Eye Movement Desesitization Reprocessing|The EMDR protocol follows procedures and phases described by Shapiro (1996). This is a complex treatment that incorporates many different interventions in order to recall trauma-related memories and to subdue them. EMDR processing consists of attending to oscillatory stimulation presented in a visual, auditory or tactile modalities, such as moving the finger from side to side across the patient's visual field or presenting an alternating tapping on the hands alternatively. Eye movements are the most commonly used external stimulus, but if the patient has problems with this kind of stimulation, such as headaches or sensomotor deficits, the therapist chooses tapping as an alternative form of oscillatory stimulation with equivalent therapeutic efficacy.
88930828|NCT01743664|Active Comparator|relaxation|Relaxation sessions will include diaphragmatic breathing, progressive muscle relaxation, visualisation, and rapid relaxation.
88930829|NCT01743690|Active Comparator|fluocinolone, placebo|fluocinolone, placebo
88930830|NCT01743690|Experimental|fluocinolone, probiotic|fluocinolone, Probiotic lactobacilli reuteri
88930831|NCT01743690|Active Comparator|Nystatin, placebo|Nystatin, placebo
88930832|NCT01743690|Experimental|nystatin, probiotic|nystatin, Probiotic lactobacilli reuteri
88930833|NCT01743716||MDD Mothers|Adult women with a history of major depressive disorder (MDD) and a healthy adolescent daughter between the ages of 12-14
88930834|NCT01743716||Healthy Control Mothers|Adult women with no history of psychopathology and an adolescent daughter between the ages of 12-14
88930835|NCT01743716||High Risk Female Adolescents|Healthy female adolescents aged 12-14 with a mother in the MDD Mothers cohort
88930836|NCT01743716||Healthy Female Adolescents|Healthy female adolescents aged 12-14 with a mother in the Healthy Control Mothers cohort.
88930837|NCT01743755|Active Comparator|Dexamethasone|
89446101|NCT02956434|Experimental|Brief family intervention|Participants will receive the BFI in this arm of the study. The BFI is a 2-session intervention for family members of Veterans who are beginning PTSD treatment.
89446102|NCT02956434|No Intervention|No intervention|Participants will not receive the BFI in this arm of the study. They will be eligible for any usual support or programming for the families of Veterans.
89446103|NCT02201121|Experimental|phenylephrine group, dopamine group, ephedrine group|"phenylephrine group: use the phenylephrine to increase the SAP from low to high level.~dopamine group: use the dopamine to increase the SAP from low to high level. ephedrine group:use the ephedrine to increase the SAP from low to high level."
89446104|NCT03485586||Group:Traditional ultrasonic biological|The measurement of axial length was performed in 60 eyes (30 eyes for each group) with senile cataract of vitrectomised eye of diabetic retinopathy using lenstar and traditional ultrasonic biological combined with cornea curvimeter.In this group,we use traditional ultrasonic biological combined with cornea curvimeter to measure the ocular parameter.
89446105|NCT03485586||Group:Lenstar|The measurement of axial length was performed in 60 eyes (30 eyes for each group) with senile cataract of vitrectomised eye of diabetic retinopathy using lenstar and traditional ultrasonic biological combined with cornea curvimeter.In this group,we use lenstar to measure the ocular parameter.
89446106|NCT02200419|Other|Transfusion Algorithm|Hospitals will be randomized to the intervention arm of the study in a stratified manner.
89446107|NCT02200575||Patients with non-secondary, essential hypertension|
89446108|NCT03486756|Experimental|Internet-CBT|Internet-CBT for anxiety-related asthma 8 weekly modules of CBT delivered over the internet and targeting enhanced function and decreased symptoms of anxiety. Participants work independently from home with the treatment and receive support from experienced Internet-CBT Psychologists through written messages in the secure platform.
89446109|NCT02201199|Active Comparator|insulin glargine U100|1 single dose
89446110|NCT02201199|Experimental|insulin glargine U200|1 single dose
89446111|NCT02201199|Experimental|insulin glargine U500|1 single dose
89446112|NCT03486600|Other|fluid resuscitation|Patients will be evaluated and the bleeding site to be investigated and hemorrhagic shock confirmed and there is an expected delay in blood and blood products transfusion for more than 40 minutes. 6% HES 130/0.4 (Voluven®) will be administered intravenously to maintain or restore hemodynamic stability up to a maximum dose of 50 mL/kg body weight.
89446113|NCT02200653|Experimental|Low dose of MICARDIS®|
88930838|NCT01743755|Placebo Comparator|Placebo|Placebo tablet, once daily for four consecutive days
88930839|NCT01743781|Experimental|intervention group|view a 10-minute informational video about comprehensive eye examination
88930840|NCT01743781|No Intervention|control group|No intervention
88930841|NCT01743794|Experimental|ropivacaine 0.2%, wound infusion|
88930842|NCT01743794|Placebo Comparator|saline solution 0.9%, wound infusion|
88930843|NCT01743807|Experimental|Dose Level 1|GNKG168 0.25 mg/kg/day on days 1 through 5
88930844|NCT01743807|Experimental|Dose Level 2|GNKG168 0.75 mg/kg/day on days 1 through 5
89446114|NCT02200653|Experimental|High dose of MICARDIS®|
89446115|NCT02200653|Active Comparator|Low dose of COZAAR® / LORZAAR®|
89446116|NCT02200653|Active Comparator|High dose of COZAAR® / LORZAAR®|
89446117|NCT04461444|Other|Group ALMS et BBS|
88930845|NCT01743807|Experimental|Dose Level 3|GNKG168 1.5 mg/kg/day on days 1 through 5
88930846|NCT01743807|Experimental|Dose Level 0|If dose level #1 is too toxic the study will back down to dose level 0. GNKG168 0.15 mg/kg/day on days 1 through 5.
88930847|NCT01743820|Active Comparator|dihydroartemisinin-piperaquine only|dihydroartemisinin -piperaquine (DP) only
88930848|NCT01743820|Experimental|DP and 0.125 mg/kg primaquine|DP and single dose oral 0.125 mg/kg primaquine
88930849|NCT01743820|Experimental|DP and 0.5 mg/kg primaquine|DP and single dose oral 0.5 mg/kg primaquine
89446118|NCT02257593|Experimental|10 % Protein|10% Dietary protein energy
89446119|NCT02257593|Experimental|15% Protein|15% Dietary protein energy
89446120|NCT02257593|Experimental|25% Protein|25% Dietary protein energy
88930850|NCT01743820|Experimental|DP and 0.25 mg/kg primaquine|DP and a single dose oral 0.25 mg/kg primaquine
88930851|NCT01743820|Experimental|DP and 0.0625 mg/kg primaquine|DP and a single dose oral 0.0625 mg/kg primaquine
88930852|NCT01743833|Active Comparator|Thoracic HVLAMT, Postive Message|Thoracic HVLAMT with a positive message given prior to the intervention.
88930853|NCT01743833|Active Comparator|Thoracic HVLATM, Neutral Message|Thoracic HVLAMT with a neutral message given prior to the intervention.
88930854|NCT01743833|Active Comparator|Scapular HVLATM, Positive Message|Scapular HVLAMT with a positive message given prior to the intervention.
88930855|NCT01743833|Active Comparator|Scapular HVLATM, Neutral Message|Scapular HVLAMT with a neutral message given prior to the intervention.
88930856|NCT01743846||Major Surgery|Patients undergoing major surgery
88930857|NCT01743885|Active Comparator|propanolol|Propanolol (Syprol:oral solution)
88930858|NCT01743885|Active Comparator|Acebutolol|Acebutolol (Sectral:oral solution)
88930859|NCT01743898||Experimental|Patient taking FDA approved dose of rivaroxaban
88930860|NCT01743898||Control Group|Patient not taking any form of anticoagulation
88930861|NCT01743911|Placebo Comparator|sugar pill|Intervention: sugar pill
88930862|NCT01743911|Active Comparator|tadalafil|Intervention: tadalafil
88930863|NCT01743924|Experimental|Raw|Broccoli,200 grams
88930864|NCT01743924|Experimental|cooked|Microwaved, 200 grams
88930865|NCT01743937|Active Comparator|Ticagrelor|Coronary occlusion with balloon inflation
88930866|NCT01743937|Active Comparator|Clopidogrel|Coronary occlusion with balloon inflation
89446121|NCT04461132|Active Comparator|Manual Lymphatic Drainage Group|All patients were treated 3 times a week for 4 weeks. The treatment program of these patients included manual lymphatic drainage on the leg, skin care, bandaging and exercise.
89013916|NCT06052878||Locoregional anesthesia|Children whose mothers underwent regional anesthesia for non-obstetric surgery during pregnancy.
89013917|NCT06052878||Control|Children whose mothers did not undergo any surgical intervention during pregnancy.
89013918|NCT06052345||CIPN group|Breast cancer patients that developed strong CIPN symptomatology at post-treatment evaluation (4 weeks after the end of therapy)
89013919|NCT06052345||No-CIPN group|Breast cancer patients that developed mild-to-no CIPN symptomatology at post-treatment evaluation (4 weeks after the end of therapy)
89013920|NCT06048770|Experimental|Multiple Ascending Dose (MAD) Cohorts, Cohort 1: RBI-4000 0.1 mcg|Participants will receive RBI-4000 0.1 micrograms (mcg) via intramuscular injection, once on Day 1 and Day 57.
89013921|NCT06048770|Experimental|MAD Cohorts, Cohort 2: RBI-4000 1 mcg|Participants will receive RBI-4000 1 mcg via intramuscular injection, once on Day 1 and Day 57.
89013922|NCT06048770|Experimental|MAD Cohorts, Cohort 3: RBI-4000 10 mcg|Participants will receive RBI-4000 10 mcg via intramuscular injection, single dose on Day 1.
89013923|NCT06048770|Experimental|MAD Cohorts, Cohort 4: RBI-4000 10 mcg|Participants will receive RBI-4000 ,10 mcg via intramuscular injection, once on Day 1 and Day 57.
89013924|NCT06048770|Active Comparator|Cohort 5: RabAvert 1 mL|Participants will receive RabAvert 1 milliliter (mL), intramuscular injection, once on Day 1 and Day 8.
89013925|NCT06048094|Experimental|18F-Fluciclovine PET Imaging|Participants will undergo a 18F-fluciclovine PET scan at the time of their SRS planning magnetic resonance imaging (MRI). Then participants will undergo single-fraction SRS as standard of care (SOC). A second 18F-fluciclovine PET scan will be completed 8 weeks (± 2 weeks) after SRS.
89446122|NCT04461132|Sham Comparator|Shame Manual Lymphatic Drainage Group|All patients were treated 3 times a week for 4 weeks. The treatment program of these patients included shame manual lymphatic drainage on the leg, skin care, bandaging and exercise. Shame manual lymphatic drainage include light touches instead of real manual lymphatic drainage techniques
89013926|NCT06046586|Experimental|Internet-delivered psychological treatment, arm #1|Support and information + Behavioral activation
89013927|NCT06046586|Experimental|Internet-delivered psychological treatment, arm #2|Support and information + Systematic exposure with mindfulness training
89013928|NCT06046586|Experimental|Internet-delivered psychological treatment, arm #3|Support and information + Promotion of health behaviors
89013929|NCT06046586|Experimental|Internet-delivered psychological treatment, arm #4|Support and information + Behavioral activation + Systematic exposure with mindfulness training
89013930|NCT06046586|Experimental|Internet-delivered psychological treatment, arm #5|Support and information + Behavioral activation + Promotion of health behaviors
89013931|NCT06046586|Experimental|Internet-delivered psychological treatment, arm #6|Support and information + Systematic exposure with mindfulness training + Promotion of health behaviors
89013932|NCT06046586|Experimental|Internet-delivered psychological treatment, arm #7|Support and information + Behavioral activation + Systematic exposure with mindfulness training + Promotion of health behaviors
89013933|NCT06046586|Experimental|Internet-delivered psychological treatment, arm #8|Support and information
89013934|NCT06046573|Experimental|Internet-delivered psychological treatment, arm #1|Support and information + Behavioral activation
89013935|NCT06046573|Experimental|Internet-delivered psychological treatment, arm #2|Support and information + Systematic exposure with mindfulness training
89013936|NCT06046573|Experimental|Internet-delivered psychological treatment, arm #3|Support and information + Promotion of health behaviors
89013937|NCT06046573|Experimental|Internet-delivered psychological treatment, arm #4|Support and information + Behavioral activation + Systematic exposure with mindfulness training
89013938|NCT06046573|Experimental|Internet-delivered psychological treatment, arm #5|Support and information + Behavioral activation + Promotion of health behaviors
89013939|NCT06046573|Experimental|Internet-delivered psychological treatment, arm #6|Support and information + Systematic exposure with mindfulness training + Promotion of health behaviors
89013940|NCT06046573|Experimental|Internet-delivered psychological treatment, arm #7|Support and information + Behavioral activation + Systematic exposure with mindfulness training + Promotion of health behaviors
89013941|NCT06046573|Experimental|Internet-delivered psychological treatment, arm #8|Support and information
89013942|NCT06045221|Experimental|Orforglipron Dose 1|Participants will receive orforglipron orally.
89013943|NCT06045221|Experimental|Orforglipron Dose 2|Participants will receive orforglipron orally.
89013944|NCT06045221|Active Comparator|Semaglutide Dose 1|Participants will receive semaglutide orally.
89013945|NCT06045221|Active Comparator|Semaglutide Dose 2|Participants will receive semaglutide orally.
89013946|NCT06040099|Experimental|Yttrium 90 glass microspheres TARE in combination with Durvalumab and Bevacizumab|Participants will undergo Yttrium 90 glass microspheres TARE according to the dosimetry recommendation.
89013947|NCT06034301|No Intervention|MEMS Cap Only|"If the participant is randomized to the control group, they will:~receive a brief education session and be handed a flyer about the importance of medication adherence~receive a MEMS cap and be given instructions on how to use it with their blood pressure medication"
89446123|NCT02200731|Experimental|FAMOS: psychosocial family intervention|The FAMOS intervention consists of a six session manualized psychosocial intervention including videos and tools. Four sessions focus on the parents and two sessions focus on the childhood cancer survivor and its siblings. The intervention is conducted by a psychologist with Cognitive Behavioral Therapy experience.
89013948|NCT06034301|Active Comparator|Medication Reminder App + MEMS Cap|Intervention group that will be shown how to use the mobile phone medication reminder app and be given assistance downloading and setting it up on their personal phone.
89013949|NCT06031883|Experimental|1|Ketamine group recieve induction and maintenance doses of ketamine by target controlled infusion in addition of propofol-dexmedetomidine as total intravenous anesthesia for patients undergoing craniotomy
89013950|NCT06031883|Experimental|2|Fentanyl group recieve induction and maintenance doses of fentanyl by target controlled infusion in addition of propofol-dexmedetomidine as total intravenous anesthesia for patients undergoing craniotomy
88930867|NCT01744002|Experimental|Shoulder Treatment with Neck Mobilization|The experiment group will receive shoulder treatment with an emphasis on 1) range of motion activities, 2) joint mobilization, 3) rotator cuff strengthening and 4) a home exercise program that consists of shoulder strengthening exercises; and Unlateral Posterior Anterior Mobilization to the cervical spine; applied as 3 X 30 seconds, to each comparable (stiff or painful) segment.
88930868|NCT01744002|Active Comparator|Control Group|The control group will receive shoulder treatment with an emphasis on 1) range of motion activities, 2) joint mobilization, 3) rotator cuff strengthening and 4) a home exercise program that consists of shoulder strengthening exercises.
88930869|NCT01744015|Experimental|Patient Decision Making Tool|Patients will be given an opportunity to use a decision making tool to assist in decision making of their care
88930870|NCT01744015|Active Comparator|Standard of care|Control group consisting of normal care
88930871|NCT01744028|Experimental|Remote patient monitoring|Remote patient monitoring system including the Exacerbations of Chronic Pulmonary Disease Tool (EXACT) tool can use changes in daily scores over a certain threshold level to alert notification to the clinical site. The site will contact the patient in order to determine the clinical significance associated with the change in score, and to treat the patient based on clinical judgment and clinical practice.
88930872|NCT01744028|Experimental|Usual care|This group of patient will continue on their usual standard care as close to real life situation as possible.
88930873|NCT01744054|Other|PET/MR or PET/CT|"Patients must have had radioembolization, within 72 hours of the PET/MR or PET/CT~Subjects will be asked to lie still within the scanner for up to 1.5 hours while images are acquired for the liver"
88930874|NCT01744067|Active Comparator|Omega-3 fatty acids|2,7 g omega-3 fatty acids / day: Omacor 1 g 1 capsule by mouth 3 times a day for 44 weeks.
88930875|NCT01744067|Placebo Comparator|Placebo|Placebo: 1 capsule containing 1 g of olive oil by mouth 3 times a day for 44 weeks.
88930876|NCT01744080|Active Comparator|Early Surgery|
88930877|NCT01744080|Experimental|Regular Wait Time|
88930878|NCT01744106|Experimental|pseudoephedrine hydrochloride 30 mg tablets|Test product
88930879|NCT01744106|Placebo Comparator|placebo tablets|Placebo
88930880|NCT01744119||Abdominal Aortic Aneurysm|
88930881|NCT01744132|Experimental|Aim 3: Contract|Half of patients screened in the pharmacy are selected to a contract group, which encourages patients to review the results of the screen, share the results with their PCP, and schedule and attend a follow-up appointment with an ophthalmologist if the results are abnormal.
88930882|NCT01744132|No Intervention|Aim 3: Control|No contract is signed for half of the patients screened in Aim 3.
88930883|NCT01744158||Children with cerebral palsy|No intervention applicable
89446124|NCT02200731|No Intervention|Control|In Denmark, standard care after treatment does not include systematic psychosocial support. Families are able to seek support on their own or contact a support group offered by the Danish Cancer Society. However support specializing the families with childhood cancer survivors and their siblings after ending medial treatment is limited.
89446125|NCT03485352||Bariatric Surgery patients|Patients attending a private clinic specialized in the treatment of obesity and bariatric surgery. Patients to be analyzed should have a medical indication for bariatric surgery.
89446126|NCT03996876|Active Comparator|Threat ABM Training|Attention Bias Modification Training with threatening words
89446127|NCT03996876|Placebo Comparator|Neutral Attention Training|Non-active version of ABM Training
89446128|NCT02200809|Experimental|MR-guided focal laser ablation|
89446129|NCT02200887||Advanced Parkinsons Disease|Polysomnogram
89446130|NCT02200887||Parkinsons Disease with Dyskinesia|Polysomnogram
89446131|NCT02200887||De novo Parkinsons Disease|Polysomnogram
89446132|NCT02200887||Healthy Volunteers|Polysomnogram
89446133|NCT02201355|Experimental|chemoradiation|Hypofractionated, PET-directed, Intensity Modulated Radiotherapy Concurrent with Weekly Cisplatin Chemotherapy
89446134|NCT02581020||1|Participants who were treated with 2D regimen (ombitasvir/ paritaprevir/ ritonavir) and completed 48 weeks of follow up from the prior Phase 2 or 3 studies conducted in Japan.
89446135|NCT02200965|Active Comparator|Received a letter on 3 occasions|"My Diabetes, My Information, My Plan Document:~To deliver a structured, understandable, well designed, user friendly, user developed and approved document / letter to all people with diabetes that contains all information about their key care processes in diabetes to promote self-awareness, patient activation and process completion of their own diabetes outcomes.~This communication (3 mailings per patient (at 0 and 3 and 6 months) will be distributed to the 50% of the whole epidemiological base of people with diabetes (n=>16,000) with the non-interventional group (that will receive the same document once at 3 months) acting as control."
89446136|NCT02200965|Active Comparator|Received letter on 1 occasion|"My Diabetes, My Information, My Plan Document:~To deliver a structured, understandable, well designed, user friendly, user developed and approved document / letter to all people with diabetes that contains all information about their key care processes in diabetes to promote self-awareness, patient activation and process completion of their own diabetes outcomes.~This communication (3 mailings per patient (at 0 and 3 and 6 months) will be distributed to the 50% of the whole epidemiological base of people with diabetes (n=>16,000) with the non-interventional group (that will receive the same document once at 3 months) acting as control."
89446137|NCT02201433||medical staff and member of an association|"members of medical staff and member of an association of parents of premature infants.~This cohort is necessary to build protocol interview for part 2 of the study"
89446138|NCT02201433||fathers|fathers of preterm newborns
89446139|NCT02201433||fathers or médical staff|This cohort is build for data validation. We will include fathers who have experienced this situation. Caregivers of NICU who are not participating in the first part
89446140|NCT04979754||RENAL TRANSPLANT RECIPIENTS|All patients with previous renal transplantation undergoing cardiac surgery with cardiopulmonary bypass
89446141|NCT04979754||NON RENAL TRANSPLANT RECIPIENTS|All patients without previous renal transplantation undergoing cardiac surgery with cardiopulmonary bypass
89446142|NCT02206347|Other|attention focus|
89446143|NCT02201511|Experimental|Arm 1|
89446144|NCT02201511|Experimental|2|
89446145|NCT02201511|Experimental|3|
89446146|NCT02201511|Experimental|4|
89446147|NCT05261997|Experimental|Endoscopic group|The patients received intravenous analgesia (flurbiprofen and remifentanil) before the ESWL (Compact Delta II; Dornier Med Tech, Wessling, Germany). After the last ESWL session, the patients are treated with following ERCP within 48h. ERCP was performed under conscious sedation with intramuscular administration of diazepam 2.5-5.0 mg and pethidine 25-50 mg. If necessary, endoscopic sphincterotomy was performed. A dilating bougie or balloon will be used to dilate the stenosis after sphincterotomy. Standard techniques (i.e., extraction basket, extraction balloon, or both) will be used for stone removal. A pancreatic duct stent for drainage and nasopancreatic catheters will be inserted for temporary drainage if necessary. Conservative treatments similar to patients in the control group were given in endoscopic group according to patients' condition.
89446148|NCT05261997|Other|Conservative group|Patients will have pancreatic enzymes (Pancreatin Enteric-coated Capsules or Oryz-Aspergillus Enzyme and Pancreatin Table) to control symptoms of exocrine pancreatic insufficiency. The recommended initial dose for adults is (25 000-40 000) IU lipase per meal (40 000 IU for meals and 20 000 IU for snacks), which can be increased until the PEI is relieved. The maximum recommended dose is (75 000-80 000) IU lipase per meal. Actions including drugs(Acarbose Tablets, Glucophage, Glimepirde Tablets) or insulin(Biosynthetic Human Insulin Injection, Tresiba or both) would also be taken for control of diabetes according to patients' glucose levels.
88930884|NCT01744184|Active Comparator|Midazolam|"midazolam sedation combined with pharyngeal anaesthesia~Participants randomized to receive midazolam will have an intravenous cannula sited and, following the administration of xylocaine throat spray as above, will be put into the left lateral position. They will then be given up to 5mg midazolam as appropriate to achieve conscious sedation as for standard protocol in endoscopy."
88930885|NCT01744184|Experimental|Entonox|"Entonox combined with pharyngeal anaesthesia.~Pharyngeal anaesthesia, given as 8-16 sprays of xylocaine to the pharynx; 3 minutes will be given to allow the pharynx to become anaesthetized.~Participants randomized to receive Entonox will be given the 50:50 nitrous oxide:oxygen mix via a mouthpiece with a demand valve system, once in position for the procedure. Inhalations will be given for 3-5 minutes (or until the participant feels adequately sedated) measured using a stopwatch. Oxygen will be given at 2 litres per minute via nasal cannulae during the procedure, (standard care for sedated procedures). The endoscopist will then proceed to intubate the cricopharynx and perform the procedure in the standard manner."
88930886|NCT01744210||CHF|
88930887|NCT01744236|Experimental|Liraglutide (main study, long-term intervention)|This arm (n=20) will receive liraglutide 1.8mg and sitagliptin-placebo during 12 weeks
89446149|NCT02206425|Experimental|bortezomib + melphalan + prednisone|Ixazomib will be administered PO at 4 mg on Days 1, 8 and 15 of a 28-day cycle. All other agents will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed. Patients that were on a 21-day cycle schedule will follow a 28-day cycle schedule and receive ixazomib on days 1, 8 and 15. Other drugs will be administered on the same days as they were given on their prior 21-day cycle schedule, except that, in the new 28-day schedule, day 1 of other drugs will be the same as day 1 of ixazomib.
89446150|NCT02206425|Experimental|bortezomib + dexamethasone|Ixazomib will be administered PO at 4 mg on Days 1, 8 and 15 of a 28-day cycle. All other agents will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed. Patients that were on a 21-day cycle schedule will follow a 28-day cycle schedule and receive ixazomib on days 1, 8 and 15. Other drugs will be administered on the same days as they were given on their prior 21-day cycle schedule, except that, in the new 28-day schedule, day 1 of other drugs will be the same as day 1 of ixazomib.
89446151|NCT02206425|Experimental|carfilzomib + dexamethasone|Ixazomib will be administered PO at 4 mg on Days 1, 8 and 15 of a 28-day cycle. All other agents will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed. Patients that were on a 21-day cycle schedule will follow a 28-day cycle schedule and receive ixazomib on days 1, 8 and 15. Other drugs will be administered on the same days as they were given on their prior 21-day cycle schedule, except that, in the new 28-day schedule, day 1 of other drugs will be the same as day 1 of ixazomib.
89446152|NCT02206425|Experimental|bortezomib + lenalidomide + dexamethasone|Ixazomib will be administered PO at 4 mg on Days 1, 8 and 15 of a 28-day cycle. All other agents will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed. Patients that were on a 21-day cycle schedule will follow a 28-day cycle schedule and receive ixazomib on days 1, 8 and 15. Other drugs will be administered on the same days as they were given on their prior 21-day cycle schedule, except that, in the new 28-day schedule, day 1 of other drugs will be the same as day 1 of ixazomib.
89446153|NCT02206425|Experimental|carfilzomib + lenalidomide + dexamethasone|Ixazomib will be administered PO at 4 mg on Days 1, 8 and 15 of a 28-day cycle. All other agents will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed. Patients that were on a 21-day cycle schedule will follow a 28-day cycle schedule and receive ixazomib on days 1, 8 and 15. Other drugs will be administered on the same days as they were given on their prior 21-day cycle schedule, except that, in the new 28-day schedule, day 1 of other drugs will be the same as day 1 of ixazomib.
89446154|NCT02206425|Experimental|bortezomib + cyclophosphamide + dexamethasone|MTD determination. Ixazomib will be administered on Days 1, 8 and 15 of a 28-day cycle at a starting dose of 3 mg in Cycle 1, and then intra-patient dose-escalation will proceed to 4 mg in Cycle 2. All other agents will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed. Patients that were on a 21-day cycle schedule will follow a 28-day cycle schedule and receive ixazomib on days 1, 8 and 15. Other drugs will be administered on the same days as they were given on their prior 21-day cycle schedule, except that, in the new 28-day schedule, day 1 of other drugs will be the same as day 1 of ixazomib.
89537094|NCT02467673|Active Comparator|NANOPARTICULATE estradiol+ progesterone|"The Blood samples are collected from the subjects early in the morning after an overnight fast. After serum testing, the identification hormone deficiencies, was determined and then, if necessary, additional transdermal nanostructured estradiol and progesterone is prescribed.~The patients are evaluated 3 months after THRT treatment protocol. All the patients were instructed about how to use the pump for transdermal application, the first application is performed in the presence of an experienced physician, in order to guarantee standardization and correct use of the THRT. Compliance was defined as completing seventy percent or more of the transdermal applications."
89446155|NCT02206425|Experimental|bortezomib + cyclophosphamide + ascorbic acid|MTD determination. Ixazomib will be administered on Days 1, 8 and 15 of a 28-day cycle at a starting dose of 3 mg in Cycle 1, and then intra-patient dose-escalation will proceed to 4 mg in Cycle 2. All other agents will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed. Patients that were on a 21-day cycle schedule will follow a 28-day cycle schedule and receive ixazomib on days 1, 8 and 15. Other drugs will be administered on the same days as they were given on their prior 21-day cycle schedule, except that, in the new 28-day schedule, day 1 of other drugs will be the same as day 1 of ixazomib. Due to a potential drug-drug interaction between ixazomib and ascorbic acid, patients will receive ixazomib in the clinic in the morning and will be instructed to take ascorbic acid in the evening, followed by cyclophosphamide.
89446156|NCT02206425|Experimental|bortezomib + PLD + dexamethasone|MTD determination. Ixazomib will be administered on Days 1, 8 and 15 of a 28-day cycle at a starting dose of 3 mg in Cycle 1, and then intra-patient dose-escalation will proceed to 4 mg in Cycle 2. All other agents will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed. Patients that were on a 21-day cycle schedule will follow a 28-day cycle schedule and receive ixazomib on days 1, 8 and 15. Other drugs will be administered on the same days as they were given on their prior 21-day cycle schedule, except that, in the new 28-day schedule, day 1 of other drugs will be the same as day 1 of ixazomib.
89446157|NCT02206425|Experimental|bortezomib + pomalidomide + dexamethasone|Ixazomib will be administered PO at 4 mg on Days 1, 8 and 15 of a 28-day cycle. All other agents will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed. Patients that were on a 21-day cycle schedule will follow a 28-day cycle schedule and receive ixazomib on days 1, 8 and 15. Other drugs will be administered on the same days as they were given on their prior 21-day cycle schedule, except that, in the new 28-day schedule, day 1 of other drugs will be the same as day 1 of ixazomib.
89446158|NCT02206425|Experimental|carfilzomib + pomalidomide + dexamethasone|Ixazomib will be administered PO at 4 mg on Days 1, 8 and 15 of a 28-day cycle. All other agents will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed. Patients that were on a 21-day cycle schedule will follow a 28-day cycle schedule and receive ixazomib on days 1, 8 and 15. Other drugs will be administered on the same days as they were given on their prior 21-day cycle schedule, except that, in the new 28-day schedule, day 1 of other drugs will be the same as day 1 of ixazomib.
89446159|NCT02201667|Experimental|Ticagrelor group|Patients wil be given 180 mg loading dose of ticagrelor and 300mg loading dose of aspirin followed by PCI, then will receive 90 mg ticagrelor twice daily with aspirin maintenance dose to 30 days after randomization.
89446160|NCT02201667|Active Comparator|Clopidogrel group|Patients will be given clopidogrel 300mg loading dose and 300mg loading dose of aspirin followed by PCI, then will receive 75mg clopidogrel once with aspirin maintenance dose to 30 days after randomization.
89446161|NCT02206503|Experimental|Cyclophosphamide; Lenalidomide; Dexamethasone|"MM Patients who experienced biochemical progression during Rd treatment without CRAB (signs of organ damage, multiple myeloma-related, as renal impairment and/or anemia and/or new bone lesions and/or hypercalcemia), will continue:~Lenalidomide orally at the dose of 25 mg/day for 21 days every 28 days.~Dexamethasone orally at the dose of 40 mg once a week.~Adding:~· Cyclophosphamide orally at the dose of 50 mg/day on days 1-21 every 28 days. CRd combination will be continued for 9-4week cycles. Patients will not receive any maintenance therapy."
89446162|NCT02201823|Experimental|ABTL0812|ABTL0812 oral
89446163|NCT05261919|Experimental|acupuncture with manipulation group|"30 participant were recruited in this study. All the participants received acupuncture at the acupoints (HT7、HT3、SI5、SI8、BL57、BL40、KI3、KI10) and were measured by an Agilent B1500A semiconductor analyzer.~The investigator perform acupuncture with supplementation manipulation first, followed by a measurement of the electrical characteristics using Agilent B1500A. The investigator remove the acupuncture and then perform acupuncture with draining manipulation, followed by measurements. After one meridian measurements were completed, the investigator removed the needle and proceeded to the next meridian to repeat the same procedure."
88930888|NCT01744236|Experimental|Sitagliptin (main study, long-term intervention)|This arm (n=20) will receive sitagliptin 100mg and liraglutide-placebo during 12 weeks
89446164|NCT02206581||young healthy adult athletes|Hydration Monitor measurement of the ultrasound velocity and measures of hydration status including urine specific gravity, plasma and urine osmolality in male and female young adults after undergoing 3% acute dehydration and a 2-hr rehydration period
89446165|NCT02201979||Breast lift in combination with implants.|Patients undergoing breast lifts in combination with implants are studied using laser fluorescent imaging to evaluate blood supply.
89446166|NCT02206659|Experimental|Telmisartan|2-week placebo run-in period followed by 6 weeks of treatment with telmisartan
89446167|NCT02206737|Experimental|E-Cigarette|3 doses of e-cigarette to be given No nicotine Low dose nicotine High dose nicotine
89446168|NCT02202057||Parkinson's disease|Men and women with Parkinson's disease, between 45 and 85 years of age. The following will be done: Respiratory resistive load on inhalation and Fluoroscopic swallowing evaluation.
89446169|NCT02202057||Healthy adults|Men and women without Parkinson's disease, between 45 and 85 years of age. The following will be done: Respiratory resistive load on inhalation.
88930889|NCT01744236|Placebo Comparator|Placebo (main study, long-term intervention)|This arm (n=20) will receive liraglutide-placebo and sitagliptin-placebo during 12 weeks
88930890|NCT01744236|Experimental|Exenatide (main study, acute intervention)|Prior to the 12-week intervention study, a GLP-1 receptor agonist (exenatide) will be administered intravenously (n=30).
88930891|NCT01744236|Placebo Comparator|Placebo (main study, acute intervention)|Prior to the 12-week intervention study, placebo will be administered intravenously (n=30).
88930892|NCT01744236|Other|Acute MRI intervention study|In a subset of 12 patients with type 2 diabetes, a crossover trial with acute infusion of exenatide and placebo is performed. This is done prior to the 12-week intervention study.
88930893|NCT01744236|Other|Pilot-study|In 10 healthy obese subjects, a crossover trial with acute infusion of exenatide, placebo and L-NMMA is performed.
88930894|NCT01744249|Experimental|Axitinib + Sandostatin LAR|Axitinib 5 mg BID + Sandostatin LAR 30mg/28 days
88930895|NCT01744249|Placebo Comparator|Placebo + Sandostatin LAR|Placebo BID + Sandostatin LAR 30mg/28 days
88930896|NCT01744275|Placebo Comparator|Placebo|Placebo
88930897|NCT01744275|Experimental|Omega 3 fatty acids supplementation|Omega 3 fatty acids capsules
88930898|NCT01744288|Experimental|1|Ticagrelor with Platelet transfusion
88930899|NCT01744288|Experimental|2|Ticagrelor without Platelet transfusion
88930900|NCT01744288|Active Comparator|3|Clopidogrel with Platelet transfusion
88930901|NCT01744288|Active Comparator|4|Clopidogrel without Platelet transfusion
88930902|NCT01744301||All patients newly prescribed PPI|All patients newly prescribed PPI
88930903|NCT01744301||All patients newly prescribed H2RA|All patients newly prescribed H2RA
88930904|NCT01744314|Experimental|drug|The treatment arm will receive 21 days of Indomethacin and Pantoprazole (gastrointestinal protective agent). The patients will receive Indomethacin 25mg three times a day and Pantoprozole 40mg once a day.
88930905|NCT01744314|Placebo Comparator|placebo|The placebo group will receive microcrystalline cellulose powder tablets to be taken as a control. The placebo will be dosed at the same intervals and duration as the treatment arm in this study.
88930906|NCT01744327||Chronic Plaque type psoriasis|Patients with plaque type psoriasis
88930907|NCT01744366|Experimental|Degarelix|Degarelix 240/80 mg
88930908|NCT01744366|Active Comparator|Goserelin|Goserelin 3.6 mg
88930909|NCT01744379|Experimental|200 mg lesinurad|200 mg lesinurad or placebo fasted and fed
88930910|NCT01744379|Experimental|400 mg lesinurad|400 mg lesinurad or placebo fasted and fed
88930911|NCT01744379|Experimental|100 mg lesinurad|100 mg lesinurad or placebo fasted and fed
88930912|NCT01744379|Experimental|50 mg lesinurad|50 mg lesinurad or placebo fasted and fed
88930913|NCT01744379|Experimental|600 mg lesinurad|600 mg lesinurad or placebo fasted and fed
88930914|NCT01744405||Lactating Women with Chagas disease|Women with Chagas disease who fulfill clinical criteria for treatment with nifurtimox, and who are also lactating
88930915|NCT01744431||No treatment|
88930916|NCT01744444|Experimental|Memantine first|
88930917|NCT01744444|Experimental|Gabapentin first|
88930918|NCT01744457|Other|20 patients with dry eye syndrome|Patients with dry eye syndrome defined as outlined in the inclusion and exclusion criteria
88930919|NCT01744457|Other|20 healthy control subjects|age- and sex-matched controls
88930920|NCT01744470|Experimental|Group A - tacrolimus half-dose|"Immunosuppressive strategy with 50 % reduction of Advagraf® daily dose at M4 (randomization) and unchanged MMF dose. Targeted tacrolimus trough level are to be higher than 3 ng/mL . If the dose is not in adequation with the dispensable units, the prescribed dose will be the closest higher dose.~Drug: Tacrolimus targeted half-dose"
88930921|NCT01744470|Experimental|Group B - tacrolimus unchanged dose|Immunosuppressive strategy will remain identical after randomization (M4): unchanged Advagraf® and MMF doses. Targeted tacrolimus trough level are to be between 7 and 12 ng/mL Drug: Tacrolimus targeted plain dose
88930922|NCT01744509|Other|Diagnosis of CRC|All the patients enrolled received all the 3 procedures: capsule colonoscopy; CT-colonography and optical colonoscopy.
88930923|NCT01744522||Leech therapy|Patients receiving leech therapy in the outpatient clinic
88930924|NCT01744535|Active Comparator|Paper food diary|
88930925|NCT01744535|Active Comparator|Online food diary|
88930926|NCT01744535|Experimental|"My Meal Mate (smartphone application)"|"A smartphone application called My Meal Mate (MMM) designed to facilitate weight loss. The app allows system users to set a goal for weight loss and self monitor diet and activity in an electronic diary. Users can select foods from the large Weight Loss Resources food database. Instant nutritional feedback is provided along with weekly feedback by text message."
89446170|NCT03660345|Experimental|PPV/MP|Study Group: Treatment-naïve subjects with center-involved diabetic macular edema undergo pars plana vitrectomy with internal limiting membrane peeling
89446171|NCT03660345|Active Comparator|Intravitreal Injection|Control Group: Treatment-naïve subjects with center-involved diabetic macular edema undergo intravitreal ziv-aflibercept monotherapy according to a fixed treatment schedule
89446172|NCT02206893|Experimental|Mobile: Professional and peer support|A mobile app that provides both professional support and peer support
89446173|NCT02206893|Experimental|Mobile: Peer support|A mobile app that provides peer support, but not professional support
89446174|NCT02206893|Experimental|Mobile: Professional Support|A mobile app that provides professional support, but no peer support
88930927|NCT01744548|Experimental|tCBT treatment|Participants randomised to the tCBT treatment arm will receive 12 individual, 1-hour tCBT sessions based upon Barlow et al.'s (2011) Unifed Protocol for emotional disorders (UP).
88930928|NCT01744548|No Intervention|7-week delayed tCBT treatment|Participants randomised to the delayed-treatment arm will receive a brief telephone call and complete the Hospital Anxiety and Depression Scale (HADS) in order to monitor risk and symptom deterioration during the 7-week delayed treatment phase. They will also receive TAU (e.g. Community Mental Health Team appointments, case reviews, etc) during this time. At the end of 7 weeks, participants in the delayed-treatment arm will crossover into the treatment arm and receive the tCBT intervention. This arm will serve as a control condition in order to enable between-group comparisons.
88930929|NCT01744561|Experimental|Exercise Intervention|Add three hours of intense physical activities per week to baseline activities. Weekly exercise should include at least 30 minutes of strength building activities and at least two hours of aerobic activities. Exercise bouts lasting 20 min or longer will be counted with respect to total weekly training time.
88930930|NCT01744561|No Intervention|Control|Keep activity level constant
88930931|NCT01744587|Placebo Comparator|Placebo|Placebo qd (2# bid) for 3 years
88930932|NCT01744587|Experimental|Epigallocatechin Gallate (EGCG)|EGCG 600 mg qd (2# bid) for 3 years
88930933|NCT01744600|Experimental|Music Therapy|Participants in the experimental group will receive one active individual music therapy session each week for 22 weeks. Each session will last thirty minutes.
88930934|NCT01744600|No Intervention|Control|Participants in the control group will receive normal, standard daily care for the 22 week period.
88930935|NCT01744613||Group A|Will include patients with PRU values above the optimal cut-off value determined by ROC analysis
88930936|NCT01744613||Group B|Will include patients with PRU values below the optimal cut-off value determined by ROC analysis.
89446175|NCT02206893|Active Comparator|Mobile: No Support|A mobile app that provides neither peer support nor professional support
89446176|NCT02206893|Active Comparator|Web: No Support|A web app that provides neither peer support, nor professional support
89446177|NCT02206971|Active Comparator|Feedback Group|receive a Smoking Cessation Manual, the opportunity for smoking cessation counseling on the phone, and urine analyses feedback via the mail plus a phone call to discuss the information
89446178|NCT02206971|No Intervention|Standard Care|receive a Smoking Cessation Manual and the opportunity for smoking cessation counseling on the phone
89446179|NCT02202213|Experimental|Lu AF11167 hard capsules; 0.25, 0.5 and 1 mg|"Part A: Lu AF11167 monotherapy Part B: Lu AF11167 adjunctive therapy to risperidone~Three times daily oral dosing for 14 days."
89446180|NCT02202213|Placebo Comparator|Matching placebo|Daily oral dosing matching the experimental arm.
88930937|NCT01744639|Experimental|HCC under treatment with radioablation|Assessment of nutritional status by anthropometry, bioelectrical impedance, blood sampling and application of psychometric hepatic encephalopathy score and critical flicker frequency, to assess the presence of hepatic encephalopathy.
89200096|NCT00379639|Experimental|Romidepsin / Gemcitabine|Participants were to receive 7, 10 or 12 mg/m^2 of romidepsin intravenously on either Days 1, 8 and 15 (Schedule A) or Days 1 and 15 (Schedule B) of each 28-day cycle, followed by 800 or 1000 mg/m^2 of gemcitabine. Subsequent doses of both drugs were based on treatment-related toxicities. The planned duration of study therapy was 6 cycles or until disease progression occurred. Patients who responded could continue beyond 6 cycles until disease progression or until a withdrawal criterion was met.
89446181|NCT02207205|Other|Catheter vs venipuncture blood samples|Evaluation of whether there is any difference in results of whole blood clotting time in blood samples drawn from an indwelling catheter versus direct venipuncture
89446182|NCT02202291|Experimental|Patient with Raynaud's phenomenon|
89446183|NCT03533127|Experimental|LY01008+Carboplatin/Paclitaxel|Drug: LY01008 15 mg/kg IV every 3 weeks on Day 1 Drug: Carboplatin Carboplatin AUC 6 IV every 3 weeks on Day 1 for 4-6 cycles Drug: Paclitaxel Paclitaxel 175 mg/m2 IV every 3 weeks on Day 1 for 4-6 cycles
89446184|NCT03533127|Experimental|Bevacizumab + Carboplatin/Paclitaxel|Drug: Bevacizumab Bevacizumab 15 mg/kg IV every 3 weeks on Day 1 Drug: Carboplatin Carboplatin AUC 6 IV every 3 weeks on Day 1 for 4-6 cycles Drug: Paclitaxel Paclitaxel 175 mg/m2 IV every 3 weeks on Day 1 for 4-6 cycles
89446185|NCT02207361|Experimental|Paclitaxel, Carboplatin，injection|Paclitaxel: 175mg/m2, IV, d1 Carboplatin: AUC 5, IV, d1 Every 21 days to 1 course of treatment.
89446186|NCT02207361|Active Comparator|Paclitaxel, Epirubicin，injection|Paclitaxel: 175mg/m2, IV, d1 Epirubicin: 60-80mg/m2, IV, d1 Every 21 days to 1 course of treatment.
89446187|NCT03533049|Experimental|myFAMI intervention|"All participants will receive the standard discharge education from their transplant and inpatient care team.~Patients who are assigned to the myFAMI group will also have the smartphone application downloaded onto either the family member's smartphone or a study-provided smartphone. Following discharge from the hospital, participants will use the smartphone application to answer nine daily questions regarding tracking family coping, transplant symptoms, family management of child transplant symptoms, and family-management difficulty with medication and follow-up regimen daily for the first 30 days following discharge."
89446188|NCT03533049|Active Comparator|Control|Family members assigned to the control group (standard care) will receive standard post-discharge follow-up care consisting of discharge education during the transplant hospitalization and at regularly scheduled appointments instructing families to contact the research nurse with problems or questions.
89446189|NCT02207517|Experimental|Office-based verg/accomm therapy (OBVAT)|OBVAT requires a participant to undergo a specific vision therapy regimen with 16 weekly, 60-minute in-office treatment sessions. Vision Therapists (O.D., M.D., Orthoptists, or specially-trained technicians) administer the therapy in the office. OBVAT procedures are then supplemented with various home therapy procedures
88930938|NCT01744678|Experimental|Access to experimental break room|"Subjects will visit the experimental break room 4 times per Orbit 1 shift:~first, prior to the beginning of the work shift~second, during an operationally feasible 20-min break during the 1st half of the work shift~third, once during an operationally feasible 20-min break during the 2nd half of the work shift~fourth, immediately after the end of the work shift~In the break room, subjects will be passively exposed to blue-wavelength enriched ceiling lights during all four visits for each work shift.~Also in the break room, subjects will perform 10-minutes of mild exercise during the first three visits to the break room during each work shift."
88930939|NCT01744717||Critically ill uncommunicative patients|Critically ill non-communicative patients, on mechanical ventilation
88930940|NCT01744262|Active Comparator|Inhalational anesthesia group|
88930941|NCT01744262|Experimental|Total intravenous anesthesia group|
88930942|NCT01744743|Active Comparator|preconception|Participants will be included according to their first outpatient visiting time. Women with TSH≥97.5%th and/or FT4≤2.5%th will accept levothyroxine 150ug daily and follow-up every 4 weeks. Medical records include: a)maternal thyroid function at enrollment; b) Levothyroxine: length, dose, drug adverse effects; c)Early trimester of pregnancy: Down's screening; d)2nd trimester of pregnancy: fetal echocardiography; e)Whole course of pregnancy: maternal complications, maternal blood pressure at each visit, fetal growth; f)Pregnancy outcome: type of delivery, length of labor, type and timing of analgesia/anesthesia, Apgar scores, postpartum hemorrhage, fetal complications; g)Offspring cognitive assessment at 0-3 years old
88930943|NCT01744743|Active Comparator|early conception|Participants will be included according to their first outpatient visiting time before 15+6 gestational week. Women with TSH≥97.5%th and/or FT4≤2.5%th will accept levothyroxine 150ug daily and follow-up every 4 weeks. Medical records include: a)maternal thyroid function at enrollment; b) Levothyroxine: length, dose, drug adverse effects; c)Early trimester of pregnancy: Down's screening; d)2nd trimester of pregnancy: fetal echocardiography; e)Whole course of pregnancy: maternal complications, maternal blood pressure at each visit, fetal growth; f)Pregnancy outcome: type of delivery, length of labor, type and timing of analgesia/anesthesia, Apgar scores, postpartum hemorrhage, fetal complications; g)Offspring cognitive assessment at 0-3 years old
88930944|NCT01744743|Placebo Comparator|late conception|Participants will be included according to their first outpatient visiting time after 16 gestational week. Women with TSH≥97.5%th and/or FT4≤2.5%th will accept levothyroxine 150ug daily and follow-up every 4 weeks. Medical records include: a)maternal thyroid function at enrollment; b) Levothyroxine: length, dose, drug adverse effects; c)Early trimester of pregnancy: Down's screening; d)2nd trimester of pregnancy: fetal echocardiography; e)Whole course of pregnancy: maternal complications, maternal blood pressure at each visit, fetal growth; f)Pregnancy outcome: type of delivery, length of labor, type and timing of analgesia/anesthesia, Apgar scores, postpartum hemorrhage, fetal complications; g)Offspring cognitive assessment at 0-3 years old
88930945|NCT01744756|Experimental|Subconjunctival Bevacizumab|One aplication of subconjunctival Bevacizumab 0,5 ml
88930946|NCT01744769||Hypothyroidism for RAI|The group of patients who experience hypothyroidism after thyroid hormone withdrawal for radioactive iodine(RAI) therapy
88930947|NCT01744795|Experimental|induced changes in hemodynamics|Twenty-five patients are planned enrolled. After induction of anesthesia, insertion of the PAC and the CardioQ probe, the patient are placed in the following successive positions: a) supine, b) head-down tilt, c) head-up tilt, d) supine, e) supine with phenylephrine administration f) pace heart rate 80 bpm, g) pace heart rate 110 bpm. CO are measured simultaneously using the CardioQ and thermodilution technique.
88930948|NCT01744808|Active Comparator|EB-1020 SR1|Sustained release formulation
89446190|NCT02207517|Placebo Comparator|Office-based placebo therapy (OBPT)|"Office-based Placebo Therapy (OBPT) requires a participant to undergo a specific therapy regimen of 16 weekly, 60 minute, in-office treatment sessions. Vision therapists (optometrists, ophthalmologists, orthoptists, or specially-trained technicians) administer the therapy in the office. OBPT procedures are then supplemented with placebo home therapy procedures.~The procedures for OBPT are designed with the intent of not providing a beneficial training effect on vergence, accommodation, saccadic accuracy, or visual attention beyond normal activities. However, the procedures are designed to simulate real vision therapy in such a way that it will be difficult for participants and parents to know that they have been assigned to the control group and thus are not receiving bonafide OBVAT"
88930949|NCT01744808|Active Comparator|EB-1020 SR2|Sustained Release Formulation
88930950|NCT01744808|Active Comparator|EB-1020 SR3|Sustained Release Formulation
89446191|NCT02202447|Experimental|EC1169|"PART A AND B: EC0652 is in development as a radioimaging agent for PSMA-expressing tumors. All patients receive a baseline 99mTc-EC0652 SPECT/CT scan for PSMA expression prior to Cycle 1 Day 1.~PART A: EC1169 given as IV bolus QW on Weeks 1 and 2 of a 3 week cycle. Dose based on dose escalation plan starting with 0.2 mg/m2~PART B: EC1169 cohort 1 - taxane naive mCRPC patients that have progressed while receiving (or subsequent to receiving) abiraterone and/or enzalutamide but must not have previously received taxane-based systemic chemotherapy for mCRPC (previous treatment with six cycles of docetaxel for metastatic castration-sensitive prostate cancer (mCSPC) is permissible).~PART B: EC1169 cohort 2 - taxane exposed mCRPC patients who have progressed while receiving (or subsequent to receiving) abiraterone and/or enzalutamide and who have progressed subsequent to receiving > 2 cycles of a taxane-based regimen for mCRPC."
89446192|NCT02202525||Essential arterial hypertension|Patients with essential arterial hypertension needing a new antihypertensive therapy
88930951|NCT01744808|Active Comparator|EB-1020 IR|Immediate Release Formulation
88930952|NCT01744808|Placebo Comparator|Placebo|Placebo Formulation
88930953|NCT01744847|Active Comparator|DGT, Tracer Metro® Direct™ Wire Guide|Double guide wire technique was performed by Tracer Hybrid® Wire Guides and Tracer Metro® Direct™ Wire Guide
88930954|NCT01744847|Active Comparator|TPS, Tracer Hybrid® Wire Guides|trans pancreatic sphincterotomy was performed by Tracer Hybrid® Wire Guides
88930955|NCT01744873|Experimental|Bisoprolol Fumarate Tablet 10 mg|Bisoprolol Fumarate Tablet 10 mg of M/s Ipca Laboratories Limited, India
88930956|NCT01744873|Active Comparator|Zebeta®|Zebeta® (Bisoprolol Fumarate) Tablets 10 mg of Duramed Pharmaceuticals Inc., USA
89446193|NCT02202603|Active Comparator|Teriparatide group 1|Subcutaneous injection of Teriparatide
89446194|NCT02202603|Placebo Comparator|excipients|Oral pill without API
88930957|NCT01744886|Active Comparator|lung surgery|"An initial baseline arterial blood gas (ABG) will be taken before anesthesia induction while breathing room air.~A second ABG will be taken on FIO2=0.5 during double lung ventilation. Then 3 ABG's will be consecutively determined each 15 min once OLV is initiated. PaO2/FIO2 is calculated on every ABG's measurement. If necessary, measures are taken to maintain oxygenation during one lung ventilation."
88930958|NCT01744886|Active Comparator|port-access cardiac surgery|"An initial baseline arterial blood gas (ABG) will be taken before anesthesia induction while breathing room air.~A second ABG will be taken on FIO2=0.5 during double lung ventilation. Then 3 ABG's will be consecutively determined each 15 min once OLV is initiated. PaO2/FIO2 is calculated on every ABG's measurement. In the port-access group, FIO2 is maintained on 1 after the stopping of the ECC, so PaO2 will become our only indicator for oxygenation. If necessary, measures are taken to maintain oxygenation during one lung ventilation."
88930959|NCT01744899||Prolonged sitting|Includes individuals who spent an average of at least 6 hours a day sitting over the past year.
88930960|NCT01744899||Control|Includes individuals who spent 4 hours or less/day sitting over the past year.
88930961|NCT01744925|Active Comparator|Icotinib of routine dose|Icotinib: 125mg, oral administration, three times per day.
88930962|NCT01744925|Experimental|Icotinib of high dose|Icotinib: 375mg, oral administration, three times per day.
88930963|NCT01744938|No Intervention|early surgery|only receiving pancreaticoduodenectomy without preoperative biliary drainage
88930964|NCT01744938|Experimental|preoperative biliary drainage|percutaneous preoperative biliary drainage before pancreaticoduodenectomy guided by CT scan
88930965|NCT01744626|Experimental|CC-292 with Rituximab|Dose Escalation
89446195|NCT02202603|Experimental|API|Oral administration of pill with API
89446196|NCT02202603|Experimental|API optimization 1|Oral administration of pill with API, for PK optimization #1
89446197|NCT02202603|Experimental|API optimization 2|Oral administration of pill with API, for PK optimization #2
89446198|NCT02202603|Experimental|API optimization 3|Oral administration of pill with API, for PK optimization #3
88930966|NCT01744951|Experimental|ADAPT|ADAPT is a manualized intervention with eight treatment modules designed as an early intervention for children, ages 5-14, who are being adopted from foster care and their adoptive parent/s.
88930967|NCT01744951|No Intervention|Care as usual|Children, ages 5-14, and their adoptive parent/s will receive care as usual in the treatment setting.
88930968|NCT01744964|Placebo Comparator|Saline|Assessment of experimental pain models before and after treatment
88930969|NCT01744964|Active Comparator|Apomorphine|Assessment of experimental pain models before and after treatment
89446199|NCT02202603|Experimental|API optimization 4|Oral administration of pill with API, for PK optimization #4
89446200|NCT02202603|Experimental|API optimization 5|Oral administration of pill with API, for PK optimization #5
89446201|NCT02202603|Experimental|API optimization 6|Oral administration of pill with API, for PK optimization #6
89446202|NCT02202603|Experimental|API optimization 7|Oral administration of pill with API, for PK optimization #7
89446203|NCT02202603|Active Comparator|Teriparatide group 2|Subcutaneous injection of Teriparatide
88930970|NCT01744990|Other|Interventional single arm|Single group of children undergoing the same investigations and follow up
89446204|NCT02202603|Experimental|Excipients|Oral pill without API
89446205|NCT02202603|Experimental|API Optimized|expanded group size with API in optimized dosage and administration form.
89446206|NCT02207595|Experimental|UCB5857 Cohort 1|UCB5857 and Placebo: Single dose followed by multiple doses over 14 days
89446207|NCT02207595|Experimental|UCB5857 Cohort 2|UCB5857 and Placebo: Single dose followed by multiple doses over 14 days
89446208|NCT02207595|Experimental|UCB5857 Cohort 3|UCB5857 and Placebo: Single dose followed by multiple doses over 14 days
89446209|NCT02207595|Experimental|UCB5857 Cohort 4|UCB5857 and Placebo: Single dose followed by multiple doses over 14 days
89446210|NCT02207595|Experimental|UCB5857 Cohort 5|UCB5857 and Placebo: Single dose followed by multiple doses over 14 days
89446211|NCT02207673|Active Comparator|Spikes as biomarker|"In arm  spikes the resection of epileptogenic tissue is guided by epileptiform spikes in the aECoG (current standard). (Independent of the randomisation ictiform spike patterns will always be resected.)"
89446212|NCT02207673|Experimental|HFOs as biomarker|"In arm HFOs resection of epileptogenic tissue is guided by HFOs in the aECoG (new). (Independent of the randomisation ictiform spike patterns will always be resected.)"
89446213|NCT02202915|Experimental|Fidelity Checklist Arm|Therapists are receiving training using the fidelity Checklist
89446214|NCT02202993|Experimental|Mibefradil with Radiation|"Patients will receive mibefradil dihydrochloride, which will be dose escalated from 150mg/day until the maximum tolerated dose (MTD) is determined, or until a dose of 350 mg/day is reached using a standard 3 + 3 design. Mibefradil dihydrochloride will be dosed orally in 4 divided doses per day for 17 consecutive days to the MTD.~This will be given concurrently with hypofractionated radiation therapy."
89446215|NCT02190357|Experimental|rifaximin|400 mg bid,orally
89446216|NCT02190357|No Intervention|controlled group|no intervention
89446217|NCT02257671|Active Comparator|Oral contraceptive|oral dose of ethinylestradiol 0.03 mg + levonorgestrel 0.15 mg per day during 11 weeks
89446218|NCT02257671|Placebo Comparator|Placebo|Oral placebo capsule daily during 11 weeks
88930971|NCT01745003|Experimental|Fibromyalgia|Investigate biochemical, functional, and structural neuroimaging changes following non-invasive brain stimulation in patients with chronic widespread pain: fibromyalgia (FM). We will be using tDCS as intervention.
88930972|NCT01745016|Placebo Comparator|Placebo|placebo
88930973|NCT01745016|Experimental|Beta-Alanine|beta-alanine
88930974|NCT01745029||Ulcerative Colitis|
88930975|NCT01743768|Experimental|SB010|"The drug will be administered in phosphate-buffered saline solution, inhaled over 5 - 10 min, using inhalation device.~Administered dose: 10 mg hgd40 in 2 mL solution (5.0 mg/mL).~Initial dose on Day 1 (single-dose PK profile); once daily dose for 28 consecutive days (Days 1 to 28); last inhalation on Day 28 (steady state PK profile)."
88930976|NCT01743768|Placebo Comparator|Placebo|"The placebo (phosphate-buffered saline) is administered as a solution, inhaled over 5 - 10 min, using inhalation device.~Initial dose on Day 1 (single-dose PK profile); once daily dose for 28 consecutive days (Days 1 to 28); last inhalation on Day 28 (steady state PK profile)."
88930977|NCT01745042||android postmenopausal women|Clinical exams
88930978|NCT01745042||gynoid postmenopausal women|Clinical exams
88930979|NCT01745068|No Intervention|Control group|
89446219|NCT02208219|Experimental|Music-supported Therapy (n=40)|Participants in this group will receive a Music-supported Therapy training at the Hospital during 1 month in addition to the standard rehabilitation program offered by the Public Health System in the Hospital, which comprises 2 hours of treatment per day (1 session of 1 hour of Occupational Therapy and 1 session of 1 hour of Physiotherapy).
89446220|NCT02208219|Experimental|home-based Music-supported Therapy(n=40)|Participants in this group will receive a Music-supported Therapy training at home during 1 month in addition to the standard rehabilitation program offered by the Public Health System in the Hospital, which comprises 2 hours of treatment per day (1 session of 1 hour of Occupational Therapy and 1 session of 1 hour of Physiotherapy).
89446221|NCT02208219|Active Comparator|Conventional treatment (n=40)|Participants in this group will receive the standard rehabilitation program offered by the Public Health System in the Hospital, which comprises 2 hours of treatment per day (1 session of 1 hour of Occupational Therapy and 1 session of 1 hour of Physiotherapy). In order to balance the number of treatment hours between arms, this group will receive extra time of Conventional Treatment during 1 month.
89446222|NCT02208453|Experimental|InSpace implantation|InSpace device implantation
89446223|NCT02190669||exercise in individuals without diabetes|exercise in individuals without diabetes
89446224|NCT02190669||exercise in type 1 diabetes|exercise in type 1 diabetes
89446225|NCT02190669||exercise in type 2 diabetes|exercise in type 2 diabetes
88930980|NCT01745068|Experimental|Integrated program|Participants will be involved in an integrated interorganisational fragility fracture prevention program, which combines both post-fracture management as well as fall prevention strategies. The intervention will last up to 18 months.
88930981|NCT01745081|Experimental|Mannitol|Bolus mannitol 20% at skin incision
88930982|NCT01745081|Experimental|Hypertonic saline|Hypertonic saline 3% at skin incision
88930983|NCT01745107|No Intervention|surgery alone|No prophylactic postoperative radiation therapy,that is surgery alone is developed in this arm
88930984|NCT01745107|Experimental|surgery plus radiation|Prophylactic postoperative radiation therapy is developed in this arm
88930985|NCT01745159|Experimental|continued tacrolimus treatment|children with moderate/severe atopic dermatitis treated with tacrolimus ointment and continuing to apply tacrolimus ointment during disease control period.
88930986|NCT01745159|No Intervention|no additional treatment|children with moderate/severe atopic dermatitis treated with tacrolimus ointment and with no additional treatment during disease control period.
89200097|NCT03948334|Experimental|ZPL389 30mg|30mg of ZPL389 + TCS and/or TCI for patients re-randomized from the core study (received placebo/ZPL389 3mg/ 10mg in the core study) and for patients continuing in the same arm from the core study
89446226|NCT02208531|No Intervention|Control|
89446227|NCT02208531|Experimental|Psychosocial Stimulation and Nutritional Care|Psychosocial Stimulation and Nutritional Care will be provided to malnourished children and their mothers every fortnight in the Community Clinics for one year.
89446228|NCT01460160|Experimental|Arm 1: Dasatinib|
89446229|NCT02203227|Placebo Comparator|Placebo|Capsule containing 250 mg of placebo, two times a day
89446230|NCT02203227|Experimental|BioTurmin|Capsule containing 250 mg of BioTurmin (Curcuma longa rhizomes extract), two times a day
88930987|NCT01745172|Experimental|Carotid body excision|Patients undergoing the carotid body excision to test the hypothesis that carotid body excision is sufficient to attain target blood pressure.
88930988|NCT01745185||Fabry disease switch group|Subjects will include individuals with Fabry disease who are switching from agalsidase alfa to agalsidase beta
88930989|NCT01745185||Control Group|Controls will include individuals with Fabry disease who have only received agalsidase beta as treatment in their lifetime.
88930990|NCT01745198||Treatment Group|This group consists of patients diagnosed with homocysteinemia who have been treated with Cerefolin®/CerefolinNAC® in the past or are currently being treated with Cerefolin®/CerefolinNAC®.
88930991|NCT01745198||Non-Treatment Group|This group consists of patients not diagnosed with homocysteinemia who have no past or current treatment with Vitamin B12, Folate or Cerefolin®/CerefolinNAC®.
88930992|NCT01745224|Experimental|Revlite Q switched Nd:YAG laser|Revlite Q switched Nd:YAG laser 1064 nm
88930993|NCT01745224|Experimental|TriVantage Q switched Nd:YAG laser|TriVantage Q switched Nd:YAG laser 1064nm
88930994|NCT01745263|Active Comparator|VitD-Omega3-StrengthExercise|Vitamin D3 (2000 IU/d); Omega-3 fatty acids (1 g/d); Strength Home Exercise (3*30 minutes/week)
88930995|NCT01745263|Active Comparator|VitD-Omega3-FlexibilityExercise|Vitamin D3 (2000 IU/d); Omega-3 fatty acids (1 g/d); Flexibility Home Exercise (3*30 minutes/week)
88930996|NCT01745263|Active Comparator|Placebo-Omega3-StrengthExercise|Placebo Vitamin D3; Omega-3 fatty acids (1 g/d); Strength Home Exercise (3*30 minutes/week)
88930997|NCT01745263|Active Comparator|Placebo-Omega3-FlexibilityExercise|Placebo Vitamin D3; Omega-3 fatty acids (1 g/d); Flexibility Home Exercise (3*30 minutes/week)
88930998|NCT01745263|Active Comparator|VitD-Placebo-StrengthExercise|Vitamin D3 (2000 IU/d); Placebo Omega-3 fatty acids; Strength Home Exercise (3*30 minutes/week)
88930999|NCT01745263|Active Comparator|VitD-Placebo-FlexiblityExercise|Vitamin D3 (2000 IU/d); Placebo Omega-3 fatty acids; Flexibility Home Exercise (3*30 minutes/week)
88931000|NCT01745263|Active Comparator|Placebo-Placebo-StrengthExercise|Placebo Vitamin D3; Placebo Omega-3 fatty acids; Strength Home Exercise (3*30 minutes/week)
88931001|NCT01745263|Sham Comparator|Placebo-Placebo-FlexibilityExercise|Placebo Vitamin D3; Placebo Omega-3 fatty acids; Flexibility Home Exercise (3*30 minutes/week)
88931002|NCT01745276|Experimental|External pins coated by biphosfonate.|External pins coated by biphosfonate.
88931003|NCT01745276|Active Comparator|External pins coated by hydroxylapatite.|External pins coated by hydroxylapatite.
88931004|NCT01745302||TCM plus EGFR-TKIs|TCM:oral granules,YangYinFang or YiQiFang or YiQiYangYinFang,four packages,twice a day, six months; EGFR-TKIs:oral tablet,Gefitinib 250mg daily or Erlotinib 150mg daily or Icotinib 125 mg three times a day ，until progression or unacceptable toxicity;
89446231|NCT02203227|Experimental|BioTurmin-WD|Capsule containing 250 mg of BioTurmin-WD (water dispersible curcuminoids), two times a day
89446232|NCT02203227|Experimental|MaQxan|Capsule containing 10 mg of MaQxan (Tagetes erecta flower extract), two times a day
89446233|NCT02208609|Experimental|Maize Tortillas with 20% Amaranth|Children in this arm were fed maize tortillas fortified with 20% amaranth
88931005|NCT01745302||Placebo plus EGFR-TKIs|TCM Placebo:oral granules,YangYinFang or YiQiFang or YiQiYangYinFang,four packages,twice a day ,six months; EGFR-TKIs:oral tablet,Gefitinib 250mg daily or Erlotinib 150mg daily or Icotinib 125 mg three times a day until progression or unacceptable toxicity;
88931006|NCT01745315|Active Comparator|LigaSure (advanced bipolar device)|Laparoscopic hysterectomy will be done with LigaSure in 15 patients.
88931007|NCT01745315|Active Comparator|Halo PKSforceps(advanced bipolar device)|Laparoscopic hysterectomy will be done with Halo PKS cutting forceps in 15 patients.
88931008|NCT01745315|Active Comparator|EnSeal (advanced bipolar device)|Laparoscopic hysterectomy will be done with EnSeal in 15 patients.
88931009|NCT01745328|Active Comparator|LVX-AMX|subject is treated with LAV-AMX, then followed by placebo.
88931010|NCT01745328|Active Comparator|TCM treatment|subject is treated with TCM
88931011|NCT01745341||vitreoretinal surgery patients|Patients undergoing vitreoretinal surgery under monitored anesthesia care. They will be observed during surgery and no interventions will be administered.
88931012|NCT01745354|Experimental|SD-101 + Combined with Local Radiation|
88931013|NCT01745406||Doctor and nurse|
88931014|NCT01745406||Doctor without nurse|
89446234|NCT02208609|Experimental|Maize Tortillas without 20% Amaranth|Children in this arm were fed maize tortillas without amaranth
89446235|NCT02208687|Experimental|Energetic|Self management group program aimed at reconditioning and social participation
89446236|NCT02208687|Other|Control group|Usual care
89446237|NCT02203383||Pts with CSA for CRT implantation|Patients with heart failure (EF<40%) and moderate to severe CSA (>15 events per hour, >50% Central)
89446238|NCT02203383||No Sleep Apnoea for CRT implantation|Heart failure (EF < 40%) but no significant sleep apnoea (<5 events per hour).
89446239|NCT01170702|Placebo Comparator|Group 1|TAP Block utilizing 15mL of 0.9% normal saline per side
89013951|NCT06029712|Experimental|GDMT delivered in a heart failure polypill|The polypill intervention will be pharmacy-level over-encapsulation of heart failure medications (beta-blocker, SGLT2 inhibitor, mineralocorticoid receptor antagonist, and ACE/ARB/ARNI) into a single capsule. For patients on twice-daily sacubitril/valsartan, one dose will be included in the polypill and the second dose will be dispensed separately. The investigators will partner with a local community pharmacy with proficiency in over-encapsulation. For patients in the polypill arm, heart failure medications will be filled as usual, but rather than dispensing each medication separately, the pharmacy technician will hand-pack all once-daily heart failure medications into a small vegan capsule.
89013952|NCT06029712|Active Comparator|GDMT delivered as individual tablets|As described above, participants who are not already prescribed a beta blocker, SGLT2i, ACE/ARB/ARNI, and MRA will be initiated on these medications prior to randomization if no contraindications exist. Participants randomized to usual care will receive their heart failure medications as individual pills. They will have the option to receive medications by mail, clinic pick-up, or pharmacy pick-up.
89013953|NCT06028659|Experimental|Coffee|In this arm, volunteers will receive, once, 3 decaffeinated coffees (150 mL total) with sugar as a known source of (poly)phenols.
89013954|NCT06028659|Other|Control|In this arm, volunteers will receive, once, 150 mL of sugared water as control.
89013955|NCT06026241||Patients over 75 who died in geriatrics|Patients over 75 years old who died in the geriatric short-stay departments of Saint-Etienne University Hospital
89013956|NCT06025539|Experimental|Animal-assisted resilience training|12 sessions of group-based, animal-assisted resilience training.
89013957|NCT06024772|Experimental|Diagnostic (mp-MRI, Definity, mp-US, prostate biopsies)|Patients undergo mp-MRI, receive Definity IV, and undergo transrectal mp-US and prostate biopsies on study.
89013958|NCT06023927||Newly-diagnosed mild OSA - initiating CPAP treatment|Subjects with newly-diagnosed mild obstructive sleep apnea being treated with CPAP undergoing clinical observation/diagnostic evaluation for detection and tracking of NTG.
89013959|NCT06023927||Newly-diagnosed moderate OSA - initiating CPAP treatment|Subjects with newly-diagnosed moderate obstructive sleep apnea being treated with CPAP undergoing clinical observation/diagnostic evaluation for detection and tracking of NTG.
89013960|NCT06023927||Newly-diagnosed severe OSA - initiating CPAP treatment|Subjects with newly-diagnosed severe obstructive sleep apnea being treated with CPAP undergoing clinical observation/diagnostic evaluation for detection and tracking of NTG.
89013961|NCT06012695|Experimental|monotherapy in advanced solid tumors|Subjects with advanced solid tumors will be treated with NBM-BMX monotherapy at different dose levels depending on the order of their enrollment.
89013962|NCT06012695|Experimental|combination therapy in newly diagnosed glioblastoma|Subjects with newly diagnosed glioblastoma will be treated with NBM-BMX at different dose levels in combination with the standard of care treatment (concomitant RT/TMZ followed by adjuvant TMZ). In the expansion study, Subjects will be treated with NBM-BMX at the recommended Phase 2 dose (RP2D) in combination with RT/TMZ.
89013963|NCT06012240|Experimental|Study 1: Group 1 Upadacitinib Dose A|Participants will receive upadacitinib Dose A once daily for 52 weeks in Period A and Period B.
89013964|NCT06012240|Experimental|Study 1: Group 2 Upadacitinib Dose B|Participants will receive upadacitinib Dose B once daily for 52 weeks in Period A and Period B.
89013965|NCT06012240|Experimental|Study 1: Group 3 Placebo|Participants will receive matching placebo once daily for 24 weeks in Period A.
89013966|NCT06012240|Experimental|Study 1: Group 4 Upadacitinib Dose A|Participants initially randomized to placebo (Period A) with a SALT score > 20 at Week 24 will be re-randomized to receive upadacitinib Dose A once daily for 28 weeks in Period B.
89013967|NCT06012240|Experimental|Study 1: Group 5 Upadacitinib Dose B|Participants initially randomized to placebo (Period A) with a SALT score > 20 at Week 24 will be re-randomized to receive upadacitinib Dose B once daily for 28 weeks in Period B.
89013968|NCT06012240|Experimental|Study 1: Group 6 Placebo|Participants initially randomized to placebo with a SALT score ≤ 20 at Week 24 will continue on placebo through Week 52.
89013969|NCT06012240|Experimental|Study 2: Group 1 Upadacitinib Dose A|Participants will receive upadacitinib Dose A once daily for 52 weeks in Period A and Period B.
89013970|NCT06012240|Experimental|Study 2: Group 2 Upadacitinib Dose B|Participants will receive upadacitinib Dose B once daily for 52 weeks in Period A and Period B.
89013971|NCT06012240|Experimental|Study 2: Group 3 Placebo|Participants will receive matching placebo once daily for 24 weeks in Period A.
89013972|NCT06012240|Experimental|Study 2: Group 4 Upadacitinib Dose A|Participants initially randomized to placebo (Period A) with a SALT score > 20 at Week 24 will be re-randomized to receive upadacitinib Dose A once daily for 28 weeks in Period B.
89013973|NCT06012240|Experimental|Study 2: Group 5 Upadacitinib Dose B|Participants initially randomized to placebo (Period A) with a SALT score > 20 at Week 24 will be re-randomized to receive upadacitinib Dose B once daily for 28 weeks in Period B.
89013974|NCT06012240|Experimental|Study 2: Group 6 Placebo|Participants initially randomized to placebo with a SALT score ≤ 20 at Week 24 will continue on placebo through Week 52.
89013975|NCT06012240|Experimental|Study 3: Group 1 Upadacitinib Dose B (SALT > 20)|Participants receiving upadacitinib Dose A with a SALT score > 20 at Week 52 (end of Period B) of Study 1 or Study 2 will dose escalate to upadacitinib Dose B once daily for 108 weeks.
89013976|NCT06012240|Experimental|Study 3: Group 2 Upadacitinib Dose A (SALT ≤ 20)|Participants receiving upadacitinib Dose A with a SALT score ≤ 20 at Week 52 (end of Period B) of Study 1 or Study 2 will remain on upadacitinib Dose A once daily for 108 weeks.
89200098|NCT03948334|Experimental|ZPL389 50mg|50mg of ZPL389 + TCS and/or TCI for patients re-randomized from the core study (received placebo/ZPL389 3mg/ 10mg in the core study) and for patients continuing in the same arm from the core study
89446240|NCT01170702|Experimental|Group 2|TAP Block utilizing 15ml of 0.2% ropivacaine per side
89013977|NCT06012240|Experimental|Study 3: Group 3 Upadacitinib Dose B (Non-Sustained)|Participants who end Period B on upadacitinib Dose B with a with a SALT score > 20 at Week 40 or Week 52 of Study 1 or Study 2 will remain on upadacitinib Dose B once daily for 108 weeks.
89013978|NCT06012240|Experimental|Study 3: Group 4 Upadacitinib Dose B (Sustained)|Participants who end Period B on upadacitinib Dose B with a with a SALT score ≤ 20 at Week 40 and Week 52 of Study 1 or Study 2 will be re-randomized to receive upadacitinib Dose B once daily for 108 weeks.
89446241|NCT01170702|Experimental|Group 3|TAP Block utilizing 15ml of 0.5% ropivacaine per side
89446242|NCT01170702|Experimental|Group 4|TAP Block utilizing 15ml of 0.75% ropivacaine per side
89446243|NCT02258061|Experimental|DDD-80 pacing|To investigate the impact of basal pacing rates of 80-bpm (DDD-80) in CRT patients on: (i) autonomic nerve function; assessed by micro-neurography, and N-terminal pro-brain natriuretic peptide (NT-proBNP) and (ii) peak oxygen consumption (pVO2) and (iii) self-perceived quality of life (QoL).
89446244|NCT02258061|Sham Comparator|DDD-60 pacing|To investigate the impact of basal pacing rates of 60-bpm (DDD-60) in CRT patients on: (i) autonomic nerve function; assessed by micro-neurography, and N-terminal pro-brain natriuretic peptide (NT-proBNP) and (ii) peak oxygen consumption (pVO2) self-perceived quality of life (QoL).
89446245|NCT02203461|Experimental|Group I|STRIBILD® Tenofovir disaproxil fumarate/emtricitabine/elvitegravir/cobicistat
88931015|NCT01745419||COPD Frequent Exacerbators|COPD patients having experienced at least two episodes of acute exacerbations in the former 12 months. (Acute exacerbations are defined as worsening symptoms requiring treatment with systemic steroids (oral or parenteral) or antibiotics, a visit to the emergency room, and/or admission to a hospital. Events separated by at least 21 days are considered as separate events of exacerbation.)
88931016|NCT01745419||COPD non- exacerbators|COPD patients who have not experienced exacerbations in the former 24 months. (Acute exacerbations are defined as worsening symptoms requiring treatment with systemic steroids (oral or parenteral) or antibiotics, a visit to the emergency room, and/or admission to a hospital. Events separated by at least 21 days are considered as separate events of exacerbation.)
88931017|NCT01745432|Experimental|ADBLOCK +laparoscopic surgery|Adhesion Barrier System is site-specific sprayable adhesion barrier gel administered on the surgical field to reduce risk of adhesion formation.
88931018|NCT01745432|No Intervention|laparoscopic surgery|Laparoscopic surgery only without use of adhesion barrier
88931019|NCT01745445|Experimental|radiotherapy alone arm|VP-16 50 mg/m2 on day 1-5 and Carboplatin AUC = 5 on day 1 will be given by intravenous infusion for 3-4 cycles. Then a total dose of 60 Gy will be given in 30 fractions of 2 Gy, 5 fractions per week; All patients will be radiated by external beam radiation, using 3-D conformal radiation technique.
88931020|NCT01745458|Experimental|SB-659032|250 mg non-enteric coated SB-659032
88931021|NCT01745458|Placebo Comparator|Placebo|matched placebo QD for 14 days
89446246|NCT02203461|Active Comparator|Group II|Truvada®/Kaletra® Tenofovir disaproxil fumarate/emtricitabine + Lopinavir/ritonavir
88931022|NCT01745484|Experimental|Arm 1|SPECT scan will be performed at baseline. Patients will receive radiotherapy according to standard CT-based plan with conventional dose-volume histogram
88931023|NCT01745510|Experimental|DHA Group|"DHA Group will receive 75 milligrams of docosahexaenoic acid (DHA) per kilogram of their baseline weight.~They will receive one dose, administered by enteral feeding every 24 h during 14 days"
88931024|NCT01745510|Placebo Comparator|Control Group (Placebo)|"Control group will receive sunflower oil which is the excipient of the DHA in this study.~They will receive one dose every 24 h during 14 days."
88931025|NCT01745523|Experimental|Vitrified oocytes using HPC+Trehalose|Oocytes are vitrified using the synthetic macromolecule HPC and trehalose
88931026|NCT01745523|Active Comparator|Vitrified oocytes using SSS+ Sucrose|Oocytes are vitrified using the SSS containing HSA and sucrose
88931027|NCT01745536|Experimental|Vitrified oocytes using closed Cryotop®|Oocytes are vitrified/stored using a closed device
88931028|NCT01745536|Active Comparator|Vitrified oocytes using open Cryotop®|Oocytes are vitrified/stored using an open device
89446247|NCT02203461|Experimental|Group III|Truvada®/Prezista®/Norvir® Tenofovir disaproxil fumarate/emtricitabine + ritonavir-boosted darunavir
89446248|NCT04880148|Experimental|Thyme and Honey-based oral spray|Thyme and Honey-based oral spray
89446249|NCT04880148|Placebo Comparator|Placebo oral spray|Placebo oral spray
89446250|NCT02191059|Experimental|Intermittent High Dose of Icotinib|"Intermittent High Dose of Icotinib in Combination With Docetaxel:~Icotinib 625mg tablet b ymouth three times per day for day1-2, Docetaxel 75mg/m2 injection intravenous drip for day 3, 3 weeks as 1 cycle"
89446251|NCT03586596|Experimental|The Decídetext program|Participants will receive a tablet-based interactive educational session, 6 months of text-messaging based counseling, which includes prompts to access free pharmacotherapy.
89446252|NCT03586596|Active Comparator|Standard Care Control|Participants will receive an adapted version of standard printed smoking cessation educational materials from the American Cancer Society and, the National Cancer Institute, which include information about the health risks of smoking, benefits & strategies for quitting and access to free pharmacotherapy by calling a free number.
89446253|NCT02208921||T2DM patients with Chronic Kidney Disease|T2DM patients with Chronic Kidney Disease
89446254|NCT02203539|Experimental|bright light|Intervention: exposure to bright light
88931029|NCT01745549|Experimental|needle 4 mm gauge 33|Needle for insulin pen, 4 mm long and with a diameter of 33 gauge (the smaller needle)
88931030|NCT01745549|Active Comparator|needle 4 mm gauge 32|Needle for insulin pen, 4 mm long and with a diameter of 32 gauge
88931031|NCT01745562|Experimental|A(reference)/B(test)|initial administration of reference and cross-over to test
88931032|NCT01745562|Experimental|B(test)/A(reference)|initial administration of test and cross-over to reference
88931033|NCT01745575|Experimental|A(reference)/B(test)|initial administration of reference and cross-over to test
88931034|NCT01745575|Experimental|B(test)/A(reference)|initial administration of test and cross-over to reference
88931035|NCT01745601|Experimental|A(reference)/B(test)|initial administration of reference and cross-over to test
89446255|NCT02203539|Experimental|blue-enriched light|Intervention: exposure to blue-enriched light
88931036|NCT01745601|Experimental|B(test)/A(reference)|initial administration of test and cross-over to reference
88931037|NCT01745614|Experimental|A (reference)/ B (test)|initial administration of reference and cross-over to test
88931038|NCT01745614|Experimental|B (test)/ A (reference)|initial administration of test and cross-over to reference
88931039|NCT01745640|Experimental|POMALIDOMIDE and dexamethasone treatment|All patients will receive pomalidomide (4 mg/day per os) and dexamethasone (40/20 mg/wk per os) during 21 day/28 day cycle
88931040|NCT01745653|Experimental|Low level laser therapy|Low level laser (970nm) will be delivered on the mucous membrane in regard to the first molar teeth on which rings of the quadhelix have been settled.
88931041|NCT01745653|Sham Comparator|sham procedure|Same procedure than experimental arm except that the laser is not activated.
88931042|NCT01745653|No Intervention|no intervention|no intervention : Patient received the quadhelix with nothing else
88931043|NCT01745666|Experimental|patients with KCNQ1 or KCNH2 mutation|
89446256|NCT02203539|Experimental|normal light|Intervention: exposure to normal light
88931044|NCT01745666|Other|patients WITHOUT KCNQ1 or KCNH2 mutation (control group)|
88931045|NCT01745679|Experimental|Ceftriaxone treatment|ceftriaxone will be administered à high dose : > or equal to 75mg/kg/day or 4 gr/day
88931046|NCT01745692|Active Comparator|Intravenous rtPA|IV alteplase (rtPA) 0.9mg/kg (10% of dose as bolus followed by 90% as infusion over 1 hour, to a maximum dose of 90mg total) given within 4.5 hours of onset of stroke symptoms
88931047|NCT01745692|Experimental|Intravenous rtPA and Mechanical Thrombectomy|IV alteplase (rtPA) 0.9mg/kg (10% of dose as bolus followed by 90% as infusion over 1 hour, to a maximum dose of 90mg total) given within 4.5 hours of onset of stroke symptoms + additional mechanical thrombectomy procedure to commence within 90 minutes of start of IV rtPA infusion
88931048|NCT01745705|Experimental|Cervical Spine Manipulation|Subjects will lie supine on a treatment table and receive a high velocity low amplitude thrust joint manipulation to their cervical spine in rotation to each side of the neck.
88931049|NCT01745705|Sham Comparator|Manual Contact|Subjects will lie supine on a treatment table and have their suboccipital region gently cupped by the therapist for 30 seconds. No movement or force will be applied, just simple manual contact.
88931050|NCT01745718|Other|MRI and targeted biopsies|All patients receive the same level/number of diagnostic procedures. They all undergo targeted biopsies which are compared to the cytological imprints.
89200099|NCT00609765|Experimental|Protocol Specified Chemotherapy|"Protocol Specified Chemotherapy Every 28 Days: Avastin, Fluorouracil, Doxorubicin, Streptozocin.~Premedications: Dexamethasone, Ondansetron"
89200100|NCT00763308|Experimental|1|Participants will use the Web-based Heart Healthy program.
89446257|NCT04460118||screw group|coracoid bone block fixed by the screw
89446258|NCT04460118||button group|coracoid bone block fixed by the suture-button
88931051|NCT01745731|Experimental|Experimental|Patients with hepatic space occupying lesion requiring an extended hepatic resection to those who were preoperatively performed a Cell infusion intraportal mononuclear bone marrow autologous and portal embolization of the affected segments.
89200101|NCT00763308|No Intervention|2|Participants will receive treatment as usual.
89446259|NCT02203617|Experimental|educational baby books|books embedded with educational information (pediatric anticipatory guidance)
89446260|NCT02203617|Active Comparator|non-educational baby books|baby books given with same illustrations but no educational information
88931052|NCT01745731|No Intervention|Control|Patients with hepatic space occupying lesion that require an extended liver resection that were performed preoperatively portal embolization of the affected segments.
88931053|NCT01745744|Experimental|Low dose|- Infusion of mesenchymal stem cells from adipose tissue: 0.5x106 cells / kg of patient weight.
88931054|NCT01745744|Experimental|High dose|- Infusion of mesenchymal stem cells from adipose tissue: 1x106 cells / kg of patient weight.
88931055|NCT01745744|No Intervention|Control|Conventional treatment
89200102|NCT01051219|Active Comparator|Losartan, daily medication|50 milligrams Losartan to be taken orally daily
89446261|NCT02203617|No Intervention|no books|not given any baby books
89446262|NCT03489330||Northwestern Memorial Hospital data|Inpatient intravenous vancomycin use
88931056|NCT01745770|Experimental|A|
88931057|NCT01745770|Active Comparator|B|
88931058|NCT01745809||Severe Asthmatics|Subjects with a pre-existing physician diagnosis of asthma with reversible airflow obstruction of at least 12%.
88931059|NCT01745809||Healthy non-smokers|Subjects will be never smokers or former smokers for the past year and less than 10 pack years lifetime with no history of asthma or any other lung disease.
88931060|NCT01745835|Active Comparator|2L Coolprep®|
88931061|NCT01745835|Experimental|1L Coolprep® and Bisacodyl|
88931062|NCT01745861|Active Comparator|Lipidem® (BBraun)|Lipid emulsion containing medium chain triglycerides (MCT), long chain triglyceride (LCT) and Omega-3 fatty acid (fish oil)
88931063|NCT01745861|Placebo Comparator|Lipofundin® MCT/LCT 20%|Lipid emulsion containing medium and long chain triglycerides
88931064|NCT01745887|Active Comparator|EBI-005-2 5mg/ml|Administration: 3 times per day
89200103|NCT01051219|Placebo Comparator|Placebo|A matched placebo will be given for patients to take once daily
89446263|NCT03489330||Henry Ford Hospital data|Inpatient intravenous vancomycin use
89446264|NCT03489330||University of Michigan Hospital data|Inpatient intravenous vancomycin use
88931065|NCT01745887|Active Comparator|EBI-005-2 20 mg/ml|Administration: 3 times per day
88931066|NCT01745887|Placebo Comparator|EBI-005-2 Placebo|Administration: 3 times per day
88931067|NCT01745926||CPR|MECHANICAL CHEST COMPRESSION
88931068|NCT01745939|Active Comparator|Lumbar manipulation|Patients will receive thrust joint manipulation to their lumbar spine in side lying
88931069|NCT01745939|Sham Comparator|Sham manipulation|Patients will receive oscillations into slight rotation, without cavitation, in side lying
88931070|NCT01745978|Experimental|the knob-tipped knife|the knob-tipped knife using for precut papillotomy in difficult CBD cannulation
88931071|NCT01745978|Active Comparator|the needle knife|the needle knife using for precut papillotomy in difficult CBD cannulation
88931072|NCT01745991||Biliary Atresia undergoing Kasai op|Randomisation for the use of CoSeal at the time of Kasai and assessment at the time of Transplantation.
88931073|NCT01746004|Experimental|[^14C]-LY2157299|Single 150 mg oral dose of LY2157299 monohydrate containing 100 micro curies of [^14C] labeled drug
88931074|NCT01746030||Questionnaires|No treatment
88931075|NCT01746069|Placebo Comparator|health advice|clinical practice routine
88931076|NCT01746069|Experimental|Quit smoking combined cessation programme|Health advice and support sms messages to patient's mobile phone + clinical routine practice
88931077|NCT01746121||Amelogenesis Imperfecta|Salivary and blood sampling, as part of routine care. Collection of exfoliated teeth
88931078|NCT01746121||healthy family members|Salivary and blood sampling, as part of routine care. Collection of exfoliated teeth
88931079|NCT01746134||Cohort|
88931080|NCT01746147||Patients with MDS and AML prior to allogeneic SCT|
88931081|NCT01746186||21-35 years of age|200 Men and 200 women: Ages 21-27 and Ages 28-35, BMI: 20-35,living in the Columbia, SC area.
88931082|NCT01746199|Experimental|cotrimoxazole daily prophylaxis|cotrimoxazole daily prophylaxis
88931083|NCT01746199|Active Comparator|Intermittent Preventive sulphadoxine-pyrimethamine Treatment|Referent treatment given according WHO recommendations
88931084|NCT01746212||Degenerative Disc Disease|Patients diagnosed with degenerative disc disease, meeting all eligibility requirements (please refer to inclusion/exclusion criteria), will be asked to participate in this study. A one-level or two-level anterior lumbar interbody fusion surgery using InQu Bone Graft Extender and Substitute, mixed with BMAC (bone marrow aspirate concentrate) as autograft, with Synthes Spinal Instrumentation will be recommended to the patient. If patients elect to proceed with surgery using the prescribed surgical components, they will be offered enrollment into the study. If the patient opts to use a different bone graft, or other spinal instrumentation, then the patient will not meet all inclusion criteria and will not be offered the opportunity to enroll in this study.
88931085|NCT01746251|Active Comparator|Concise Afatinib|Afatinib oral daily dose for 3 months
88931086|NCT01746251|Active Comparator|Prolonged Afatinib|Afatinib oral daily dose for 2 years
88931087|NCT01746277|Other|combined group|combined group chemotherapy with docetaxel 75mg/m2 d1 or pemetrexed 500mg/m2 d1, every 3 weeks,at least 2 cycles and the maximal cycle is 6 depending on disease evaluation and patient's physical condition combined with gefitinib 250mg once per day from the start day of chemotherapy until disease progression or intolerable side effects.
88931088|NCT01746277|Other|sequenced group|sequenced group chemotherapy with docetaxel 75mg/m2 d1 or pemetrexed 500mg/m2 d1, every 3 weeks,at least 2 cycles and the maximal cycles is 6 depending on disease evaluation or patient's physical condition sequenced by gefitinib 250mg once per day until disease progression or intolerable side effects.
88931089|NCT01746290|Experimental|PulsePoint notification|Conventional Emergency Dispatch PLUS The PulsePoint notification. In the event of a potential cardiac arrest identified by 911call-takers, data will be automatically pushed to PulsePoint smartphone application users within very close proximity to the emergency. This will be done in parallel with normal emergency dispatch of paramedics and fire fighters to the scene of the emergency. The activation radius around the emergency is somewhat variable, depending on phone signal strength, climate conditions and whether the phone is inside or outside, but is approximately 200-500 meters.
88931090|NCT01746290|No Intervention|Usual Care|Patients randomized to the control arm will receive conventional emergency medical dispatching procedures but no PulsePoint notification will be sent to nearby PulsePoint users.
88931091|NCT01746303|Experimental|Omega 3 and Blueberry powder|This group will receive omega-3 fatty acid and blueberry powder supplement for 24 weeks (6 months)
88931092|NCT01746303|Experimental|Omega-3 and placebo powder|This group will receive omega-3 fatty acid and placebo powder for 24 weeks (6 months)
88931093|NCT01746303|Experimental|Placebo oil and blueberry powder|This group will receive placebo oil and blueberry powder for 24 weeks (6 months).
88931094|NCT01746303|Placebo Comparator|Placebo oil and placebo powder|This group will receive placebo oil and placebo powder for 24 weeks (6 months)
88931095|NCT01746329|Experimental|Tea|Oral intake of tea containing 75 grams of glucose
88931096|NCT01746329|Experimental|Beet root|Oral intake of beetroot juice containing 75 grams of glucose
88931097|NCT01746329|Placebo Comparator|Placebo|Oral intake of 75 grams of glucose in water
88931098|NCT01746342|Active Comparator|Effective CPAP|Continuous positive airway pressure: effective fixed level determined by polysomnographic titration
88931099|NCT01746342|Sham Comparator|Sham CPAP|Continuous positive airway pressure device modified by manufacturer to deliver minimal pressure
88931100|NCT01746355|Active Comparator|rTMS-active|patients undergoing of rTMS real
88931101|NCT01746355|Sham Comparator|rTMS-Sham|patients undergoing to placebo rTMS
88931102|NCT01746381|Experimental|IVAPS mode of non-invasive ventilation|Patients with ALS randomized to this arm will be treated with non-invasive home ventilation using the Intelligent Volume-Assured Pressure Support (IVAPS) mode
88931103|NCT01746381|Active Comparator|BIST mode of non-invasive ventilation|Patients with ALS who are randomized to this arm will receive non-invasive home ventilation with the traditional bilevel non-invasive ventilation in spontaneous/timed (BIST) mode
89446265|NCT02209077|Experimental|Healthy Volunteers|OCT performed to collect data from the back of the eye
89200104|NCT00885417|Experimental|Cravit-based sequential therapy|Cravit-based sequential therapy Eligible patients will be treated with (esomeprazole 40mg bid +amoxicillin 1gm bid) for 5 days, followed by (esomeprazole 40mg bid + levofloxacin 250mg bid + metronidazole 500mg bid ) for another 5 days
89200105|NCT00766272|Experimental|Arm 1|Body-weight supported treadmill training
89446266|NCT02209077|Experimental|Glaucoma group|OCT performed to collect data from the back of the eye
89446267|NCT03356106|Experimental|CPAP|Nocturnal administration of continuous positive airway pressure treatment (CPAP) until delivery
89446268|NCT03356106|No Intervention|Control|Usual antenatal care for high risk pregnancy
89446269|NCT02191215||Nevirapine (Viramune®)|
89446270|NCT02209155|Active Comparator|R-verapamil 75 mg tablet|375 mg/day; one in the morning, two in the afternoon and two at bedtime daily
89446271|NCT02209155|Placebo Comparator|Placebo|one in the morning, two in the afternoon and two at bedtime daily
89446272|NCT03486366|Other|Workpackage1 WP1|Non interventional trial: male or female children with a definite diagnosis of TSC (Roach 1998), aged up to 4 years, diagnosis of epilepsy established on the basis of clinical seizures or epileptiform changes on EEG within 1-7 days prior to baseline. We plan to enroll 60 TSC patients into WP1 to Epimarker in 12 months.
89446273|NCT03486366|Other|Workpackage2 WP2|Non interventional trial: male or female children with a definite diagnosis of TSC (Roach criteria: Roach 1998) and epilepsy, aged up to 16 years, seizure free, in whom a decision to withdraw antiepileptic drugs was made. We plan to enroll 60 TSC patients into WP2 to Epimarker in 12 months. The data obtained in children seizure free at the end of follow-up and patients with recurrent seizures will be compare.
89446274|NCT03485118|Experimental|HS006+Chemotherapy|"Participants received six 21-day cycles of HS006(375 mg per square meter) combined with six cycles of standard cyclophosphamide,doxorubicin,vincristine,and prednisone/prednisolone(CHOP) chemotherapy(21-day cycles).~Participants received six 21-day cycles of HS006(500 mg per square meter) combined with six cycles of standard cyclophosphamide,doxorubicin,vincristine,and prednisone(CHOP) chemotherapy(21-day cycles)."
89446275|NCT03485118|Active Comparator|Rituxan+Chemotherapy|Participants received six 21-day cycles of Rituxan combined with six cycles of standard cyclophosphamide,doxorubicin,vincristine,and prednisone(CHOP) chemotherapy(21-day cycles).
89446276|NCT02209233|No Intervention|Control|If randomized to the control group, patients will not be receiving massage therapy.
88931104|NCT01746394|Experimental|Parents as Teachers Enhanced|Participants in the Parents as Teachers Enhanced (PaTE) intervention arm will receive the enhanced diet and activity maternal, infant, and early childhood home visiting program
89200106|NCT00961246|Active Comparator|general health information group|participants received general health information
89446277|NCT02209233|Experimental|Massage Therapy|If randomized to the intervention group, patients will receive massage therapy of the hand, arm, shoulder, and neck by the licensed massage therapist on duty. The massage will be given in a manner that is congruent with standard of care practices by the Heart and Surgical Hospital and the licensed massage therapist.
89446278|NCT03015558|Experimental|patients|
89200107|NCT00961246|Experimental|individually-tailored intervention|participants received individually-tailored intervention
89200108|NCT00889083||Control|Non septic patients needing hepatic surgery
89200109|NCT00889083||Sepsis|Septic patients needing surgery for peritonitis
89446279|NCT03015558|Active Comparator|healthy subjects|
89446280|NCT02191293||Viramune®|
89446281|NCT03532815|Active Comparator|Lifestyle Modification group|
89446282|NCT03532815|No Intervention|Control group|
89446283|NCT02880540|Active Comparator|Control Group|Fentanyl 50 micrograms IV every 15 minutes up to 3 doses in postanesthesia recovery room and Morphine 2mg IV every 2 hours for 2days on hospital floor
89446284|NCT02880540|Experimental|Dexmedetomidine Treated|Dexmedetomidine IV bolus 1.5microgram/kilogram and a continuous infusion starting at 0.1 microgram/kilogram/hour during surgery
89446285|NCT02191371|Experimental|propofol|Propofol is used as a maintenance anesthetic to patients in the propofol group. Intervention: propofol infusion by target-controlled infusion for maintaining anesthesia propofol (Fresofol MCT 2%) target effect site concentration: 4~5 mcg/ml, during general anesthesia
89446286|NCT02191371|Experimental|desflurane|"Desflurane is used as a maintenance anesthetic to patients in the desflurane group.~Intervention: Desflurane administration for maintaining anesthesia desflurane (Suprane) inhalation as 6~8 vol% during general anesthesia"
89446287|NCT04460274||Model Building|Number of Covid-19 cases from December 31, 2019 to June 1, 2020 were used to build ARIMA model using Hyndman-Khandakar algorithm.
89200110|NCT01048489|Other|Lifestyle counseling|
89200111|NCT01048489|No Intervention|No counseling|
89200112|NCT00961324|Experimental|IDeg|
89200113|NCT00961324|Experimental|IGlar|
89446288|NCT04460274||Model Validation|Number of Covid-19 cases from June 2, 2020 to June 15, 2020 were used to forecast cases using the ARIMA model
89446289|NCT02209311|Experimental|Tissue engineered construction implantation|
89446290|NCT02209389||Positive OctavaPink|Following a positive OctavaPink result, an MRI is performed and any additional testing (required by the MRI).
89446291|NCT02209389||Negative OctavaPink - control|"For any sample that is identified with a positive OctavaPink result, a negative sample from the same center, as close in time as possible, and of the same age decade, will be identified and recalled for an MRI and any additional testing (required by the MRI).~MRI won't be performed to all negative OctavaPink results. Only one negative control will be assigned to each OctavaPink positive result."
89446292|NCT03532737|Experimental|Investigational Arm|"All patients will receive radical chemoradiation in addition to the investigational concomitant check point inhibitor CHEMOTHERAPY: Cisplatin: 100 mg/m2 Q21d D1, D22, D43. OR Cetuximab Loading dose 400 mg/m², one week before radiation then maintenance dose 250 mg/m² weekly, D8, D15, D22, D29, D36, D43.~PD-1 inhibitor: Pembrolizumab 200 mg administered as an intravenous infusion over 30 minutes every 3 weeks 21 days prior to radiation, then Day 1 of radiation and then every 21 days for total 6 doses~Intensity modulated radiotherapy (IMRT) techniques will be used. A total dose of 66-70 Gy/ 30-35 Fr over 6-7 weeks will be delivered to the primary site and draining lymphatics using simultaneous Integrated Boost (SIB)."
89446293|NCT05151978||(glasgow coma scale) 9 _15|No Secondary Neurological deterioration
89446294|NCT05151978||(glasgow coma scale) 9_15|Secondary Neurological deterioration
89446295|NCT02209467|No Intervention|Group balance training late start|Participants randomized to late start act as No intervention group during the study period.
89446296|NCT02209467|Experimental|Group balance training early start|Group balance training focusing on core stability exercises 2 times per week for 7 weeks and 2 home training sessions per weeks.
88931105|NCT01746394|Active Comparator|Parents as Teachers|Participants in the Parents as Teachers (PaT) control arm will receive the standard maternal, infant, and early childhood home visiting program
88931106|NCT01746433|Active Comparator|Hanging Triangle Bar|"The patients randomized to this group will use a hanging triangle bar for aid in sitting up exercises.~No particular brand of hanging bar is targeted."
88931107|NCT01746433|Experimental|Ergonome|"The patients randomized to this group will use the l'ERGONOME device for aid in sitting up exercises.~Commercial name of the device: SAM ERGONOM (TM)~Manufacturer: Medicatlantic groupe Winncare, Le Pas du Château, 85680 Saint-Paul-Mont-Penit"
89200114|NCT00766350|Active Comparator|amitriptyline|
89200115|NCT00766350|Experimental|quetiapine|
89013979|NCT06012240|Experimental|Study 3: Group 5 Upadacitinib Dose A (Sustained)|Participants who end Period B on upadacitinib Dose B with a with a SALT score ≤ 20 at Week 40 and Week 52 of Study 1 or Study 2 will be re-randomized to receive upadacitinib Dose A once daily for 108 weeks.
89013980|NCT06009107|Experimental|Participant Group|Participants with relapsed or refractory B-precursor acute lymphoblastic leukemia (r/r B-ALL) will receive conditioning chemotherapy (fludarabine 25-30 mg/m^2 intravenously [IV] over 30 minutes on Day -5, Day -4, and Day -3 and cyclophosphamide 500 mg/m^2 IV over 60 minutes on Day -5, Day -4), following a single IV infusion of chimeric antigen receptor (CAR) transduced autologous T cells(HY004).
89013981|NCT06005649|Experimental|Single dose of HY004|Patients received a single dose of anti-CD22/CD19 CAR T cells after receiving a conditioning regimen of cyclophosphamide and fludarabine.
89013982|NCT06004388|Experimental|ReMMiD-C Therapeutic Arm A|Mobile application A (ReMMiD-C Digital Therapeutic) as a software-based intervention for the preventive treatment of episodic migraine in late adolescents and adults receiving Calcitonin Gene-Related Peptide (CGRP) Inhibitor Therapy.
89013983|NCT06004388|Experimental|ReMMiD-C Therapeutic Arm B|Mobile application B as a software-based intervention for the preventive treatment of episodic migraine in late adolescents and adults receiving Calcitonin Gene-Related Peptide (CGRP) Inhibitor Therapy.
89013984|NCT06003426|Experimental|BMS-986278 Dose 1|
89013985|NCT06003426|Experimental|BMS-986278 Dose 2|
89013986|NCT06003426|Placebo Comparator|BMS-986278 Placebo|
89013987|NCT05997069|Experimental|Posterior-anterior vertebral mobilizations followed by Prone press-up exercise|In experimental group the application of posterior-anterior vertebral mobilizations (three bouts of 40 seconds oscillations will be applied at the rate of approximately 3 oscillations per second and at the highest amplitude when tolerated without the reproduction of symptoms) followed by Prone press-up exercise (Ten repetitions will be performed with 5 second hold. on successful completion of 10 repetitions without increase in discomfort, second and third sets will be performed) will given.
89013988|NCT05997069|Active Comparator|Conventional physiotherapy|In conventional physiotherapy, the application of thermotherapy on lower back region (continuous with duration of 10 minutes) by means of hot pack followed by general stretching exercises (Lower Back, Hamstring, Tensor Fasciae Latae Stretching with two sets and ten repetitions) will given.Thirty second rests will be taken every five minutes during the stretching session.
89013989|NCT05995626|Experimental|Ablative CO2 laser, and intradermal hyaluronidase, via laser-assisted drug delivery|Uncover a safe, efficacious, and tolerable alternate treatment modality for patients with scleroderma-induced microstomia. Evaluate disease severity and patient quality of life before and after alternative treatment is administered
89013990|NCT05991882|Experimental|Condition 1: Craving daily+PBS daily|EMA + Introduction Module + Craving reduction and protective behavioral strategy (PBS) messages, each delivered once daily
89013991|NCT05991882|Experimental|Condition 2: Craving daily+PBS trigger|EMA + Introduction Module + Craving reduction messages delivered once daily and PBS trigger messages
89013992|NCT05991882|Experimental|Condition 3: Craving trigger+PBS daily|EMA + Introduction Module + Craving reduction trigger messages and PBS messages delivered once daily
89013993|NCT05991882|Experimental|Condition 4: Craving trigger+PBS trigger|EMA + Introduction Module + Craving reduction trigger and PBS trigger messages
89013994|NCT05991882|Experimental|Condition 5: PBS daily+ PBS trigger|EMA + Introduction Module + PBS delivered once daily and PBS trigger messages
89013995|NCT05991882|Experimental|Condition 6: Craving daily+Craving trigger|EMA + Introduction Module + Craving reduction delivered once daily and craving reduction trigger messages
89013996|NCT05991882|Experimental|Condition 7: Craving daily+Craving trigger+PBS daily+PBS trigger|EMA + Introduction Module + Craving reduction delivered once daily, craving reduction trigger messages, PBS delivered once daily, and PBS trigger messages
89013997|NCT05991882|Other|Condition 8: No daily or trigger craving or PBS|EMA + Introduction Module + no other messages
89013998|NCT05989126|Experimental|8 mg Dose|Only 1 eye will be selected as the study eye by the investigator. Patients will receive a single dose utilizing the PFS.
89013999|NCT05987644|Experimental|Phase 1b: Experimental|600mg alectinib taken orally twice daily
89014000|NCT05987644|Experimental|Phase 2: Arm A|600mg alectinib taken orally twice daily
89014001|NCT05987644|Experimental|Phase 2: Arm B|Subjects will receive SRS prior to taking alectinib. 24 hours after, but no more than 7 days after last radiation dose, alectinib should be taken at 600mg orally twice daily
89200116|NCT03992755|Experimental|LIQ861 Inhaled Treprostinil|LIQ861 inhaled treprostinil at capsule strengths of 25 μg, 50 μg, 75 μg and 100 μg. LIQ861 will be administered using the RS00 Model 8 dry powder inhalation (DPI) device (Plastiape S.p.A.; Osnago, Italy) at dose levels of 25 μg capsule strength to 200 μg capsule strength treprostinil four times a day (QID) in individual patients. Titrating to dose levels beyond 200 μg capsule strength QID, under clinical investigator supervision, requires review and approval from the Medical Monitor.
89200117|NCT01563328|Experimental|Cohort 1|DTG x 5 days followed by BCV + DTG x 10 days
88931108|NCT01746446|Experimental|Care team|Patients are offered the support and services of the care team.
88931109|NCT01746446|No Intervention|Usual Care|Patients receive usual care.
88931110|NCT01746459|Active Comparator|Low Low|Low Intensity, Low Frequency Reminder System
88931111|NCT01746459|Active Comparator|Low, High|Low Intensity, High Frequency Reminder System
88931112|NCT01746459|Active Comparator|High, Low|High Intensity, Low Frequency Reminder System
88931113|NCT01746459|Active Comparator|High, High|High Intensity, High Frequency Reminder System
88931114|NCT01746472|Experimental|2 - B-passive|
88931115|NCT01746472|Experimental|3 - B-active|
88931116|NCT01746472|Experimental|4 - B-active, B-passive|
88931117|NCT01746472|Experimental|6 - z, B-passive|
88931118|NCT01746472|Experimental|7 - z, B-active|
88931119|NCT01746472|Experimental|8 - z, B-active, B-passive|
88931120|NCT01746472|Experimental|10 - t, B-passive|
88931121|NCT01746472|Experimental|11 - t, B-active|
88931122|NCT01746472|Experimental|12 - t, B-active, B-passive|
88931123|NCT01746472|Experimental|14 - t, z|
89446297|NCT02741388|Experimental|Selinexor + immunochemotherapy|"Selinexor will be administered orally on Day1, 3, 8 and 10 of each 3-week cycle with an immunochemotherapy, R-DHAOx (Group A: rituximab + dexamethasone + oxaliplatin + cytarabine) or R-GDP (Group B: rituximab + dexamethasone + gemcitabine + cisplatin) for 3 cycles (choice of the immunochemotherapy left at the investigator's decision before patient's inclusion).~Different dose levels of selinexor will be examined sequentially in each group: 20 mg flat (DL-1), 40 mg flat (DL1), 60 mg flat (DL2), 80 mg flat (DL3)."
89446298|NCT02191527|Experimental|Point of Care Testing|The point-of-care devices will be located in the MCH services, where a trained lay counselor will do the tests.
89446299|NCT02191527|No Intervention|Laboratory Testing - Standard of care|Samples sent to the laboratory for analysis, (standard of care)
89200118|NCT01563328|Experimental|Cohort 2|DTG x 5 days followed by TVR + DTG x 10 days
89446300|NCT03484962|Experimental|Cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
89446301|NCT03484962|Active Comparator|Cryotherapy & Activated CIK and bispecific antibody|the maximum tumor length≥2cm, use cryotherapy. the maximum tumor length<2 cm,Biological/Vaccine:Activated CIK and bispecific antibody CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
89446302|NCT03484962|No Intervention|No intervention|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
89446303|NCT03484728|Placebo Comparator|High-expectation placebo manipulation|application of nonactive body cream on forearm for 10 minutes
89446304|NCT03484728|Other|Low-expectation placebo manipulation|application of nonactive body cream on forearm for 10 minutes
89446305|NCT05261373|No Intervention|Control (CG+INACT)|Participants who do not receive neither nutritional education nor exercise program. They will be instructed to maintain their normal life habits with respect to physical activity and diet.
89446306|NCT05261373|Active Comparator|Moderate-intensity continuous training (CG+MICT)|Participants who do not receive nutritional education but are enrolled in a moderate-intensity continuous training exercise program.
88931124|NCT01746472|Experimental|15 - t, z, B-active|
88931125|NCT01746472|Experimental|16 - t, z, B-active, B-passive|
88931126|NCT01746485|Experimental|UT-15C|
88931127|NCT01746498|Active Comparator|Group 1|11 patients We Applied real anodal tDCS on the left dorsolateral prefrontal cortex (DLPFC)20 minutes every day for 10 consecutive days.
88931128|NCT01746498|Active Comparator|Group 2|11 patients we applied cathodal tDCS on left DLPFC for 20 minutes every day for 10 consecutive days.
88931129|NCT01746498|Sham Comparator|Group 3|11 patients We applied sham stimulations(anodal tDCS) on the left DLPFC for few seconds the stop stimulations 2 mA every day for 10 days.
89200119|NCT00889239|Experimental|A|ceramic crown
89200120|NCT00760032|Experimental|Active|Ciprofloxacin
89200121|NCT00760032|Placebo Comparator|Placebo|Placebo
89200122|NCT00961480|Active Comparator|Treatment A|50 mg sitagliptin and 500 mg metformin as individual tablets
89200123|NCT00961480|Experimental|Treatment B|sitagliptin/metformin 50 mg/500 mg tablet
88931130|NCT01746524||CR FB|Subjects receiving Cruciate Retaining Fixed Bearing configuration of ATTUNE Primary Knee Implant
88931131|NCT01746524||PS FB|Subjects receiving Posterior Stabilized Fixed Bearing configuration of ATTUNE Primary Knee Implant
88931132|NCT01746524||CR RP|Subjects receiving Cruciate Retaining Rotating Platform configuration of ATTUNE Primary Knee Implant
88931133|NCT01746524||PS RP|Subjects receiving Posterior Stabilized Rotating Platform configuration of ATTUNE Primary Knee Implant
88931134|NCT01746550|Experimental|MD-12-001 Stent Arm|This study includes a single arm, the MD-12-001 Stent Arm.
88931135|NCT01746563|Experimental|Ranibizumab|Ranibizumab 0,05 mg intravitreal injection
88931136|NCT01746563|Active Comparator|Laser Therapy|Laser Therapy alone
89200124|NCT00961480|Active Comparator|Treatment C|50 mg sitagliptin and 1000 mg metformin as individual tablets
89200125|NCT00961480|Experimental|Treatment D|sitagliptin/metformin 50 mg/1000 mg tablet
88931137|NCT01746576|Other|All|All subjects will undergo spontaneous ventilation through an impedance threshold device and ScvO2 will be recorded before and after
88931138|NCT01746589|Other|myopic LASIK procedure|All subjects will receive bilateral myopic LASIK procedure using the 200 kHz WaveLight® FS200 Femtosecond Laser and the WaveLight® Allegretto Wave® Eye-Q Laser
88931139|NCT01746602|Experimental|healthy subjects I|20 healthy subjects
88931140|NCT01746602|Experimental|healthy subjects II|20 healthy subjects
88931141|NCT01746602|Experimental|healthy subjects III|20 healthy subjects
88931142|NCT01746602|Experimental|healthy subjects IV|20 healthy subjects
88931143|NCT01746602|Experimental|healthy subjects V|20 healthy subjects
88931144|NCT01746602|No Intervention|healthy subjects VI|20 healthy subjects
88931145|NCT01746628|Placebo Comparator|Hysterectomy without FloSeal|Endometrial curettage Intrauterine foley balloon placement for 5 minutes Removal of intrauterine foley balloon Saline irrigation of uterine cavity Hysterectomy
88931146|NCT01746628|Active Comparator|Hysterectomy with FloSeal|Endometrial curettage FloSeal placement into uterine cavity Intrauterine foley balloon placement for 5 minutes Removal of intrauterine foley balloon Saline irrigation of uterine cavity Hysterectomy
88931147|NCT01746641|Active Comparator|Remifentanil|"Remifentanil target controlled infusion effect site with Minto's pharmacokinetic model.~Start dose: 1 ng/mL. Titration: 0.5 ng/mL according to clinical criteria."
88931148|NCT01746641|Active Comparator|Propofol|"Propofol target controlled infusion effect site with Marsh's pharmacokinetic model.~Start dose: 1 mcg/mL. Titration: 0.5 mcg/mL according to clinical criteria."
88931149|NCT01746654|Experimental|P128-0.1 mg|Three healthy adult volunteers will be enrolled to P128-0.1 mg single dose-cohort 1 (Part A) Three healthy adult volunteers will be enrolled to P128-0.1 mg multiple doses-Cohort 4 (Part B) Ten chronic kidney disease patients will be enrolled to P128-0.1 mg multiple doses (Part C) Ten patient harboring S.aureus nasally will be enrolled to P128-0.1 mg single dose (Part D)
88931150|NCT01746654|Experimental|P128-0.3 mg|Three healthy adult volunteers will be enrolled to P128-0.3 mg single dose-Cohort 2 (Part A) Three healthy adult volunteers will be enrolled to P128-0.3 mg multiple doses-Cohort 5 (Part B) Ten chronic kidney disease patients will be enrolled to P128-0.3 mg multiple doses (Part C) Ten patient harboring S.aureus nasally will be enrolled to P128-0.3 mg single dose (Part D)
88931151|NCT01746654|Experimental|P128-1.0 mg|Three healthy adult volunteers will be enrolled to P128-1.0 mg single dose-Cohort 3 (Part A) Three healthy adult volunteers will be enrolled to P128-1.0 mg multiple doses-Cohort 6 (Part B) Ten chronic kidney disease patients will be enrolled to P128 1.0 mg multiple doses (Part C) Ten patient harboring S.aureus nasally will be enrolled to P128-1.0 mg single dose (Part D)
88931152|NCT01746654|Placebo Comparator|Placebo|Three healthy adult volunteers will be enrolled to placebo single dose-Cohort 1-3 (Part A) Three healthy adult volunteers will be enrolled to placebo multiple doses-Cohort 4-6 (Part B) Ten chronic kidney disease patients will be enrolled to placebo multiple doses (Part C) Ten patient harboring S.aureus nasally will be enrolled to placebo single dose (Part D)
88931153|NCT01746667|Experimental|Exposure in vivo|This treatment will consist of 10 sessions (twice a week) of exposure therapy based on the protocol used previously in exposure therapy for social anxiety disorder by Scholing & Emmelkamp (1993).
88931154|NCT01746667|Experimental|Virtual Reality Exposure Therapy|"This treatment consists of 10 sessions (twice a week) of exposure therapy by using virtual environments.~The difference between the exposure in vivo and virtual reality exposure therapy is the exposure component, which will be delivered in vivo in one condition and through the Head Mounted Display (HMD) in the other condition."
88931155|NCT01746667|No Intervention|Wait-list|Participants on the wait-list will be offered either exposure in vivo or in virtual reality after a waiting period of five weeks.
88931156|NCT01746680|Experimental|Tacrolimus with Methotrexate|Subjects have tacrolimus per oral once daily with methotrexate for 24weeks. Tacrolimus increased dosing regimen: 1mg for 0~4 weeks, 2mg for 4 weeks~8 weeks, 3mg for 8 weeks~24 weeks
88931157|NCT01746706|Experimental|patients|
88931158|NCT01746706|Experimental|volunteers|
88931159|NCT01746719|Experimental|Etodolac Capsules USP 300 mg|Etodolac Capsules USP 300 mg of Ipca Laboratories Limited, India
89200126|NCT00961480|Active Comparator|Treatment E|50 mg sitagliptin and 850 mg metformin as individual tablets
88931160|NCT01746719|Active Comparator|Etodolac Capsules USP 300mg|Etodolac Capsules USP 300mg of Taro Pharmaceutical Industries Ltd., USA
88931161|NCT01746758|Experimental|SMS text messaging referral|The text messaging system has been designed to use codes of reproductive health conditions and their treatments. Text messages are sent by drug stores and received at the dispensaries, forwarded by a bespoke software called Snapshot, which captures data online from any computer anywhere by use of a login for confidentiality.
88931162|NCT01746758|No Intervention|Comparison arm|No intervention will be implemented in intervention arm. Data on reproductive health conditions and treatments and data on referrals from drug stores in this arm will be obtained directly from ministry of health registers filled and filed at the dispensary and health centres, plus a tailor-made form which is filled by the dispensary and health centre clinicians whenever they receive a patient in the eligible categories.
88931163|NCT01746771|Experimental|HM781-36B, Paclitaxel, Trastuzumab|HM781-36B(Poziotinib): QD*2weeks/3weeks Paclitaxel: 175mg/m2 Trastuzumab(Herceptin): 8mg/kg
88931164|NCT01746797||Women currently taking antidepressants|Women who have selected to stay on antidepressant medication while undergoing infertility treatment.
88931165|NCT01746797||Women not on antidepressants|Women who decided to discontinue their antidepressants while undergoing fertility treatments.
89200127|NCT00961480|Experimental|Treatment F|sitagliptin/metformin 50 mg/850 mg tablet
88931166|NCT01746810|Experimental|Stereotactic Body RT and IRGA|Patients undergo stereotactic body radiation therapy QD for a total of 5 fractions and then undergo IRGA (either radiofrequency ablation or microwave ablation) 1 week later.
88931167|NCT01746823||Controls, Keratoconus|Sub group of Keratoconus to be treated with anti-inflammatory agents ie Cyclosporine-A
88931168|NCT01746875|Experimental|Treatment|aflibercept intravitreal injections, 2.0 mg monthly x 3 doses, then injections as needed based on recurrence of activity on OCT. If no effect of the treatment; aflibercept intravitreal injections, 2.0 mg x 3 doses is repeated, then injections as needed based on recurrence of activity on OCT. If no effect of the treatment; verteporfin photo dynamic therapy.
89200128|NCT00760110||1 Morning hypertension and normotension|Based on HBP, subjects were divided into MH and MN patients
89200129|NCT00760110||2 Clinic hypertension and normotension|Based on CBP, subjects were divided into CH and CN patients
89200130|NCT00608829|Experimental|GORE TAG® Thoracic Endoprosthesis|Gore 45mm TAG Thoracic Endograft Implantation
89200131|NCT04049370||"Retrospective data collection of the actual state"|"Retrospective data collection of the actual state 6 months prior to August 2019."
89200132|NCT04049370||Prospective data collection|Prospective data collection after implementation of the quality assurance measure for another 6 months (SOP as clinical decision tool into the electronic database of the CPU).
88931169|NCT01746875|No Intervention|Observation|
88931170|NCT01746888||Older Adults|Adults 65 years and older who present to the Emergency Department.
88931171|NCT01746914||Lung transplantated patients|Patients undergone lung transplantation
89200133|NCT00961558|No Intervention|Observation arm|Patient will not to undergo any form of Assisted Reproductive Technologies for a period of 6 months
88931172|NCT01746927||cricoid pressure|
88931173|NCT01746966||Rheumatoid Arthritis|20 patients age of 20-60 with Rheumatoid Arthritis according to ARA 1987 revised criteria and disease activity Disease Activity Score (DAS) 3-5
88931174|NCT01746966||Healthy controls participants|Healthy controls age of 20-60 according to conclusion of preventive medicine department
88931175|NCT01746992|Experimental|pirarubicin|3 cycles of CTOP(cyclophosphamide,vincristin,pirarubicin and prednisone),3 cycles of ITE(ifosfamide, pirarubicin, etoposide)and 2 cycles of methotrexate
88931176|NCT01746992|Active Comparator|doxorubicin|8 cycles of CHOP regimen(cyclophosphamide,vincristin,doxorubicin and prednisone)
89446307|NCT05261373|Active Comparator|High-intensity interval training (CG+HIIT)|Participants who do not receive nutritional education but are enrolled in a high-intensity interval training exercise program.
89446308|NCT05261373|Active Comparator|Nutritional Education (EDU+INACT)|Participants who receive nutritional education but not an exercise program.
89446309|NCT05261373|Experimental|Nutritional Education Moderate-intensity continuous training (EDU+MICT)|Participants who receive nutritional education and are enrolled in a moderate-intensity continuous training exercise program.
89446310|NCT05261373|Experimental|Nutritional Education High-intensity interval training (EDU+HIIT)|Participants who receive nutritional education and are enrolled in a high-intensity interval training exercise program.
89446311|NCT01331616|Experimental|Bevacizumab (Avastin)|
89446312|NCT02203929||Phakic eyes|Phakic eyes will be monitored with 4 preoperative optical coherence tomography scans as these patients will undergo phacoemulsification and intraocular lens implantation prior to their macular hole surgery
89446313|NCT02203929||Pseudophakic eyes|Phakic eyes will be monitored with 2 preoperative optical coherence tomography scans as there is no surgical intervention prior to the macular hole treatment.
88931177|NCT01747005||Conventional therapy|
89446314|NCT02209623||Pregnant Women receiving TDAP|
88931178|NCT01747005||ERAS|Oral intake of solid food restriction 6 hours before surgery. Oral intake clear fluids restriction 2 hours before surgery. Intravenous 5% Dextrose-500 ml 1 hour before surgery. Intravenous dexamethasone -4mg before anesthesia. Combined spinal-epidural anesthesia. Intraoperatively 10 ml/kg intravenous of crystalloids. Paracetamol intravenous 1g. Early mobilization of patient. Oral solid food intake 4 hour postoperative. Postoperative continuous epidural analgesia.
88931179|NCT01747018|Experimental|Platelet-rich Plasma|From all the patients who participated in the clinical trial, 27 ml of blood sample was collected with a 20-G needle from an antecubital vein so that the ratio of the blood and the anti-coagulant became 10:1. The collected blood samples were transferred to a prepared separation kit (Prosys PRP, Seoul, Korea) and underwent centrifugation at the speed of 3,000 RPM for three minutes. The buffy coat layer and the plasma of the upper portion of the layer were obtained and were transferred to a concentration kit (Prosys PRP, Seoul, Korea) using a 10-ml syringe. They again underwent centrifugation at the speed of 3,300 RPM for three minutes in order to obtain concentrated PRP. The injection area was sterilized aseptically and 3-4 cc of PRP were percutaneously injected into the knee joints.
88931180|NCT01747031|Experimental|Single arm study|Single arm study.The investigators will conducte computed tomography,angiography and FFR measurement during angiography in this single arm.
88931181|NCT01747044|Active Comparator|Milnacipran|Milnacipran is an antidepressant known and used in major depressive disorder according to its marketing authorization but is also part of the molecules used in the treatment of chronic neuropathic pain and fibromyalgia according to the recommendations of the EULAR
88931182|NCT01747044|Placebo Comparator|Capsules of lactose|placebo over a period of 8 weeks to 24 weeks
88931183|NCT01747057|Experimental|Dynamic guide resuscitation|This arm follows a resuscitation protocol based on dynamic-parameters-guided fluid management.
88931184|NCT01747057|Active Comparator|Standard resuscitation|This arm follows a common resuscitation protocol based on Surviving Sepsis Campaign recommendations.
88931185|NCT01747070|Active Comparator|tDCS and EAC sham|Subjects will receive 05 sessions of tDCS. The tDCS consist of application of current of 2 mA, the anode being placed in the motor cortex (M1) and the cathode in the supraorbital region, for 30 minutes,using electrodes with saline solution. The sham DIMST consist of the use of rubber electrodes placed in the same places that active treatment. Will use the same electrical apparatus, but without pass of current to the electrodes. The unit will be in front of the patient on with their lights blinking.
88931186|NCT01747070|Placebo Comparator|tDCS sham and EAC sham|The subjects will receive 05 sessions of tDCS sham and EAC sham. The sham tDCS be performed in the same way as the active, although the Electro device is turned off 30 seconds after the beginning of treatment, the session will have the same duration of 30 minutes. The EAC sham consists of placement of rubber electrodes in the same areas of active stimulation (beside the spinous processes of L1 to S2, muscles vastus lateralis, rectus anterioris, vastus medialis, tibialis anterior, peroneus longus and insertion of the pes anserinus). The electrodes are connected to the same device electro, for 30 minutes, but without passage of electrical stimulation to the patient. The device is kept on and in front of the patient, with the lights blinking.
89446315|NCT02191683||Health of women before conception|Tanzanian women aged 18-40 years focusing on prevalence of anaemia, infections, nutritional status, and NCDs.
89446316|NCT02191683||480 women during pregnancy|"Describe how 1st and 2nd trimester anaemia compared to 3rd trimester anaemia alters foetal growth and newborns' body composition.~Evaluate anaemia's effect on villous branching in placenta, and uterine and umbilical artery blood flow.~Evaluate effect on vascular endothelial growth factor A/placental growth factor balance and insulin-like growth factor axis.~Determine which markers for foetal programming such as methylation of regulatory genes related to metabolism and haematopoiesis may be discovered early after exposure to anaemia."
89446317|NCT02191761|Experimental|SM04755|
89446318|NCT02209701|Experimental|Porfiromycin|
88931187|NCT01747070|Active Comparator|tDCS sham and EAC|Subjects will receive 05 sessions of tDCS sham and EAC.The sham tDCS be performed in the same way as the active, although the Electro device is turned off 30 seconds after the beginning of treatment, the session will have the same duration of 30 minutes. The EAC consist of electrical stimulation with a frequency of 2 Hz for 30 min. The needles are placed beside the spinous processes of L1 to S2, with a depth of 3 cm and in the muscles: vastus lateralis, rectus anterioris, vastus medialis, tibialis anterior, peroneus longus and insertion of the pes anserinus.
89200134|NCT00961558|Other|Surgery Arm|Patients will have varicocelectomy within 1 month of assessment and will not undergo any form of Assisted Reproductive Technologies for a period of 6 months after surgery
89200135|NCT00889317||healthy adults|
89200136|NCT01051297||VTE -PROSPECTIVE|Patients diagnosed with VTE
89446319|NCT02191839|Active Comparator|alpha 1 antitrypsin|patients receive 4 grams of IV alpha 1 antitrypsin preoperatively
89446320|NCT02191839|Placebo Comparator|placebo|10 patients will randomely receive placebo
89446321|NCT02191995|Experimental|body awareness yoga|body awareness yoga session prior to breakfast meal
89446322|NCT02191995|No Intervention|Control Arm|No intervention
89446323|NCT05261295||Classical LMA|Patients who received general anesthesia with classical LMA
89446324|NCT05261295||i-Gel|Patients who received general anesthesia with i-Gel
89446325|NCT03535467||Conventional Rehabilitation|
88931188|NCT01747070|Experimental|tDCS and EAC|Subjects will receive 05 sessions of transcranial direct current stimulation(tDCS) and electroacupuncture(EAC). The tDCS consist of application of current of 2 mA, the anode being placed in the motor cortex (M1) and the cathode in the supraorbital region, for 30 minutes,using electrodes with saline. The electroacupuncture consist of electrical stimulation with a frequency of 2 Hz for 30 min. The needles are placed beside the spinous processes of L1 to S2, with a depth of 3 cm and in the muscles: vastus lateralis, rectus anterioris, vastus medialis, tibialis anterior, peroneus longus and insertion of the pes anserinus.
88931189|NCT01747083|Experimental|A|FDC(gemigliptin/metformin HCl sustained release 50/1000mg(25/500mgx2tablets))under fasting condition
88931190|NCT01747083|Experimental|B|FDC(gemigliptin/metformin HCl sustained release 50/1000mg(25/500mgx2tablets))under fed condition
88931191|NCT01747109|Experimental|PREOXYFLOW|"Patients randomized in PREOXYFLOW group will received a four minutes preoxygenation period with Nasal High Flow Therapy (HFT) Optiflow ® (60 l/mn FIO2 = 1) before orotracheal intubation under laryngoscopy after crash induction"
88931192|NCT01747109|Active Comparator|STANDARD FACE MASK|"Patients randomized in STANDARD FACE MASK group will received a four minutes preoxygenation period with a standard face mask (15 l/mn) before orotracheal intubation under laryngoscopy after crash induction. No specific trademark is requested by the protocol."
88931193|NCT01747122|Experimental|Wound catheter|Wound catheter
88931194|NCT01747122|Active Comparator|Epidural|Standard epidural, pre-operative insertion, to be run for 48 hours
88931195|NCT01747135|Experimental|Open label|
88931196|NCT01747161|Experimental|botulin toxin|botulin toxin
88931197|NCT01747161|Placebo Comparator|physiological water|physiological water
88931198|NCT01747174|Experimental|Std PCI + Intra-coronary (IC) Adenosine|IC Adenosine in to IRA (following thrombus aspiration) with further dose via guide catheter following coronary stent deployment.
88931199|NCT01747174|Experimental|Std PCI + IC Sodium Nitroprusside (SNP)|IC SNP in to IRA (following thrombus aspiration) with further dose via guide catheter following coronary stent deployment.
88931200|NCT01747174|Active Comparator|Std PCI|Standard PCI only
88931201|NCT01747187||Septic shock|
88931202|NCT01747226|Placebo Comparator|Fluoride rinse|A fluoride rinse with alcohol was chosen because its similarity in color and aroma to the active rinses. This anti-cavity rinse does not contain any active components and therefore it is not expected to have any anti-malodour activity.
88931203|NCT01747226|Active Comparator|Halita|Halita is a CHX-containing benchmark product that has proven to be clinically effective against halitosis (Roldan et al, 2003)
88931204|NCT01747226|Active Comparator|Meridol Halitosis|This study aims to confirm the effect of meridol®Halitosis(AmF/SnF2 and zinc) already observed in volunteers with morning bad breath (physiological)(Wigger-Alberti et al, 2010; Wilhelm et al, 2010)in patients with oral malodor (pathological).
88931205|NCT01747226|Sham Comparator|Water|To distinguish the masking effect caused by the formulations and the one caused by the rinsing itself.Only for short term evaluation (15') to not to compromise compliance of patients.
88931206|NCT01747239|Experimental|Cabazitaxel|25 mg/m2 IV every three weeks
88931207|NCT01747252|Experimental|RGC1|RGC containing the equivalent of 50 mg resveratrol
88931208|NCT01747252|Active Comparator|Resveratrol|The equivalent of 150 mg resveratrol
89200137|NCT01051297||sleep study group -PROSPECTIVE|patients undergoing sleep study
89200138|NCT01051297||VTE-Retrospective|patients with VTE , chart review
89446326|NCT03535467||Robotic Therapy|
89446327|NCT02209779|Experimental|BIBR 796 BS, low dose|twice daily doses of 5 mg for 4 weeks
89446328|NCT02209779|Experimental|BIBR 796 BS, medium dose 1|twice daily doses of 10 mg for 4 weeks
89446329|NCT02209779|Experimental|BIBR 796 BS, medium dose 2|twice daily doses of 20 mg for 4 weeks
89446330|NCT02209779|Experimental|BIBR 796 BS, high dose|twice daily doses of 30 mg for 4 weeks
88931209|NCT01747252|Experimental|RGC2|RGC containing the equivalent of 150 mg resveratrol
88931210|NCT01747278|No Intervention|Placebo|Patients were not treated with Trimethoprim/Sulfamethoxazole (TMP/SMX).
88931211|NCT01747278|Experimental|TMP/SMX|Patients received Trimethoprim/Sulfamethoxazole (TMP/SMX) 80 mg/400 mg p.o. every day as PCP Prophylaxis.
88931212|NCT01747317|Experimental|Single arm study|Single arm study.The investigators will conduct computed tomography,angiography and FFR measurement during angiography in this single arm.
88931213|NCT01747356|Experimental|Resolute stent treatment group|"All patients will receive Resolute stent implantation to cure severe coronary atherosclerotic lesions.~RESOLUTE stent system specification (eluted zotarolimus 1.6μg/mm2):~After stent implantation, each patient will be followed up at time point of 30-day, 6-month and 12-month.~Follow-up window:~Duration of hospital stay Follow-up 1: 30days after procedure (±7 days) Follow-up 2: 6-month after procedure (±30 days) Follow-up 3: 12-month after procedure (±30 days)"
88931214|NCT01747395|No Intervention|Control Group|No exercise group (sedentary)
88931215|NCT01747395|Experimental|Aerobic Exercise Training|Group undergoing isolate aerobic exercise training 3 times/week, during 40 minutes, for 04 mouths
88931216|NCT01747395|Experimental|Inspiratory Muscle Training|Group undergoing isolate inspiratory muscle training 7 times/week, during 30 minutes, for 04 mouths
88931217|NCT01747395|Experimental|Aerobic+Inspiratory Muscle Training|Group undergoing aerobic exercise training (3 times/week during 40 minutes) associate inspiratory muscle training (7 times/week during 30 minutes) for 04 mounths
88931218|NCT01747408|Experimental|25% human albumin|Subjects will be entered into one of 4 increasing dosages of 25% human albumin sequentially. Once the first 20 subjects have been enrolled and the DSMB reviews data and approves moving to the next dosage tier patients will be entered into the following dosage tier.
88931219|NCT01747512|Active Comparator|C-PERT|45 patients with cancer
88931220|NCT01747512|Active Comparator|G-PERT|65 patients with cancer
89446331|NCT02209779|Active Comparator|Placebo|
89446332|NCT05238987|Experimental|Healthy men (before-and-after (pre-post) study)|Partcipants will undergo a 75g oral glucose tolerance test (OGTT) to document baseline insulin secretion kinetics. One week later, OGTT will be repeated after administering a single dose of ferrous sulphate (120 mg of elemental iron) 2 hours prior to the test.
89014002|NCT05975359|Experimental|Interi Manifold Drain System|Following bilateral mastectomy, stage 1 surgery for immediate implant-based breast reconstruction will be performed in each patient breast. The breast randomized to treatment with the Interi manifold (intervention arm) will have the Interi manifold placed alongside the tissue expander intra-operatively. Surgical reconstruction, closure, and post-operative management will proceed as standard. Postoperative follow-up will occur within 1 week of surgery. Weekly follow-ups with documentation of clinical data throughout recovery will also take place until removal of the Interi drain system, which typically occurs 1-3 weeks after surgery. Criteria for drain removal is defined as 2 consecutive days with drain output below 30 mL. While drains are in place, patients will be required to monitor drain output and keep a daily drain log.
89014003|NCT05975359|Active Comparator|Jackson Pratt Drain System|Following bilateral mastectomy, stage 1 surgery for immediate implant-based breast reconstruction will be performed in each patient breast. The breast randomized to treatment with the Jackson Pratt drain (active comparator arm) will have the Jackson Pratt drain placed alongside the tissue expander intra-operatively. Surgical reconstruction, closure, and post-operative management will proceed as standard. Postoperative follow-up will occur within 1 week of surgery. Weekly follow-ups with documentation of clinical data throughout recovery will also take place until removal of the Jackson Pratt drain system, which typically occurs 1-3 weeks after surgery. Criteria for drain removal is defined as 2 consecutive days with drain output below 30 mL. While drains are in place, patients will be required to monitor drain output and keep a daily drain log.
89014004|NCT05974774|Active Comparator|Arm A - continuous treatment|Arm A (cMAB): ADT (LHRH agonist or antagonist) + ARPI (abiraterone or enzalutamide or apalutamide or darolutamide) continuously until start of a new anti-cancer therapy.
89014005|NCT05974774|Experimental|Arm B - intermittent treatment|Arm B (iMAB): no further treatment, including ADT and ARPI; decision to restart ADT (LHRH agonist or antagonist) and the initial ARPI (abiraterone, enzalutamide, apalutamide or darolutamide) is left at Investigator discretion.
89014006|NCT05972551|Experimental|Romosozumab|Participants will receive romosozumab once a month (QM) for 12 months.
89014007|NCT05972551|Active Comparator|Standard of Care Bisphosphonate|Participants will receive bisphosphonates per local standard of care treatment regimens, as determined by the investigator for 12 months.
89014008|NCT05955170|Experimental|Combination of tucatinib-Oral VP16-trastuzumab|"The safety run in part will be a safety evaluation including 6 patients at dose D of Oral VP16 per day, trastuzumab 600mg SC flat dose or 6mg/kg IV every 3 weeks and tucatinib 300mg PO BID.~The evaluable population for DLT in this Part 1 is defined as patients who have completed the first 2 cycles of treatment (i.e.6 weeks) and received 100% of the planned dose of tucatinib-Oral VP16-trastuzumab.Patients treated at Dose Recommended during the safety run-in part will be considered as evaluable for the part II."
89014009|NCT05950074|Experimental|"It´s Up To You program"|"Participants will receive the prevention program It´s Up To You during the academic year in school hours."
89014010|NCT05950074|No Intervention|Control|The control group will receive the usual teaching activities regarding substance use prevention.
89014011|NCT05946811|Experimental|Macitentan arm|Participants allocated to this arm will receive Macitentan 10 mg daily for 3 months
89014012|NCT05946811|Placebo Comparator|Placebo|Participants allocated to this arm will receive placebo daily for 3 months.
89014013|NCT05937789|Placebo Comparator|Control1|Enteral supplement with 8 ampules of medium chain triglycerides for participants with serum calcifediol levels of 15-19.9 ng/mL.
89014014|NCT05937789|Placebo Comparator|Control2|Enteral supplement 10 of medium chain triglycerides for participants with serum calcifediol levels of 12-14.9 ng/mL.
89014015|NCT05937789|Placebo Comparator|Control3|Enteral supplement 12 of medium chain triglycerides for participants with serum calcifediol levels below 12 ng/mL.
89014016|NCT05937789|Experimental|Vitamin D1|Enteral supplement 8 ampules vitamin D for participants with serum calcifediol levels of 15-19.9 ng/mL.
89014017|NCT05937789|Experimental|Vitamin D2|Enteral supplement 10 ampules vitamin D for participants with serum calcifediol levels of 12-14.9 ng/mL.
89014018|NCT05937789|Experimental|Vitamin D3|Enteral supplement 12 ampules vitamin D for participants with serum calcifediol levels below 12 ng/mL.
89014019|NCT05926063|Experimental|Short treatment group|"Empirical broad-spectrum antibiotics (EBAT) as per local protocol:~Meropenem 3 x 1(/2) g IV; OR~Piperacilline-Tazobactam 4 x 4 g IV; OR~Cefepime 3 x 2 g IV; OR~Ceftazidim 3 x 2 g IV~Short treatment group: EBAT will be discontinued:~After 3x24 hours;~Irrespective of presence of fever; AND~If no clinical of microbiological infection is documented."
89014020|NCT05926063|Active Comparator|Extended treatment group|"Empirical broad-spectrum antibiotics (EBAT) as per local protocol:~Meropenem 3 x 1(/2) g IV; OR~Piperacilline-Tazobactam 4 x 4 g IV; OR~Cefepime 3 x 2 g IV; OR~Ceftazidim 3 x 2 g IV~Extended treatment arm: EBAT will be continued:~At least 5x24 hours;~Until afebrile (TMT<38.0°C) for at least 5 consecutive days; OR~Until resolution of neutropenia (ANC >0,5 x109/L); OR~Until they have been treated 10 days, whatever comes first."
89014021|NCT05916950|Experimental|Thor Treatment|Treatment with the Thor system
89014022|NCT05911763||Cohort A (Prophylactic treatment)|"All participants on efanesoctocog alfa prophylactic treatment fulfilling the overall study inclusion/exclusion criteria. The prophylactic cohort will include the following sub-cohorts:~Sub-cohort A1 (Joint imaging): Participants with severe hemophilia A and joint imaging by Hemophilia Early Arthropathy Detection with Ultrasound (HEAD-US) or Joint Tissue Activity and Damage Exam (JADE) protocol performed within 6 months of initiating treatment with efanesoctocog alfa or within 3 months after initiating treatment with efanesoctocog alfa available.~Sub-cohort A2 (Children with no prior joint damage):Participants with severe hemophilia A who have no prior joint damage"
89014023|NCT05911763||Cohort B (On-Demand treatment)|Participants receiving on-demand treatment with efanesoctocog alfa who fulfil the overall study inclusion/exclusion criteria
89014024|NCT05907707|Experimental|First gamma (40Hz) stimulation, then active control (21Hz) stimulation|After collecting sleep EEG at home for one night to acclimate to the data collection during sleep, participants first receive gamma (40Hz) tACS on Day 1 followed by a 5-9 day washout. Participants then receive active control (21Hz) stimulation.
89014025|NCT05907707|Experimental|First active control (21 Hz) stimulation, then gamma (40 Hz) stimulation|After collecting sleep EEG at home for one night to acclimate to the data collection during sleep, participants first receive active control (21Hz) tACS on Day 1 followed by a 5-9 day washout. Participants then receive gamma (40Hz) stimulation.
89446333|NCT04911075|Experimental|85% TCA Group|"Participants are subject who will undergo an elective total hysterectomy procedure for indications of gynecological organ abnormalities, whether benign, pre-cancerous, or malignant other than cervical pathology.~The 85 percent TCA solution will be applied to participants cervical tissue 24 hours before surgery."
89446334|NCT02192073|Active Comparator|Suprapectoral Biceps Tenodesis|Suprapectoral Biceps Tenodesis involves detaching the long head of biceps from it's origin and reattaching it to humerus in the superior border of the pectoralis major insertion
89446335|NCT02192073|Active Comparator|Subpectoral Biceps Tenodesis|Subpectoral Biceps Tenodesis involves detaching the long head of biceps from it's origin and reattaching it to humerus in the inferior border of the pectoralis major insertion
89446336|NCT02204163|Experimental|Eutropin|Eutropin 0.24mg/kg/week
88931221|NCT01747525||NIRS/IVUS of coronary artery|All patients will have an epicardial coronary artery stenosis of intermediate severity (>50% to <70% stenosis) (stenosis ≥20% - ≤70%) by invasive angiography in whom IVUS is planned to further clinical evaluation of lesion severity; or a severe epicardial coronary artery stenosis by invasive angiography and percutaneous coronary intervention (PCI) is planned for definitive treatment.
88931222|NCT01747538|Placebo Comparator|Placebo|
88931223|NCT01747538|Experimental|Dose 1 gevokizumab|
88931224|NCT01747538|Experimental|Dose 2 gevokizumab|
88931225|NCT01747564|Experimental|mirabegron group|
88931226|NCT01747590|Experimental|Zolpidem, Alprazolam, Caffeine, and Placebo|The 4 medications are given in a counterbalanced design.
88931227|NCT01747603|No Intervention|Current management of LPTB|The current pragmatic, but non-systematic, pattern of management of LPTB infants. Growth measurements, feeding histories/methods, illness history including emergent visits to clinicians, walk-in clinics and emergency departments and breast-feeding support clinics, and basic developmental milestones (as itemized in the Rourke Developmental screening tool) will be recorded by families and primary health care providers as itemized in the Memory Book at the assessments made at the discretion of the health care providers.
88931228|NCT01747603|Experimental|Specialized LPTB Clinic|Additional 6 specialized LPTB follow-up clinic visits attended by pediatricians and neonatologists. Detailed findings from physical examination, feeding histories/methods, illness history including emergent visits to clinicians, walk-in clinics and emergency departments and breast-feeding support clinics, basic developmental milestones (as itemized in the Rourke Developmental screening tool) and physician recommendations will be recorded at each appointment. These will be compared to those obtained from families and primary health care providers as itemized in the Memory Book.
88931229|NCT01747616|Experimental|12 subjects wearing soft contact lenses|The medical test device will be administered with the contact lenses inserted
88931230|NCT01747616|Experimental|12 subjects wearing rigid contact lenses|The medical test device will be administered with the contact lenses inserted
88931231|NCT01747616|Experimental|12 subjects with soft contact lenses|The medical test device will be administered before insertion of the contact lenses
88931232|NCT01747616|Experimental|12 subjects with rigid contact lenses|The medical test device will be administered before insertion of the contact lenses
88931233|NCT01747642|Active Comparator|Oncoxin|Syp Oncoxin 25 ml bd and Cap. Oncoxin bd orally for 180 days
89446337|NCT02204163|Active Comparator|Genotropin|Genotropin 0.24mg/kg/week
89446338|NCT05238441|Experimental|SCTV01E and SCTV01E|SCTV01E on D0 and D180
88931234|NCT01747642|Active Comparator|Oncoxin & Suranix|Tab Suranix 200 mg 2 tab bd and Syp Oncoxin 25 ml bd and Cap. Oncoxin bd orally for 180 days
88931235|NCT01747642|No Intervention|Supportive treatment|Only supportive treatment. No chemotherapy, radoiotherapy, ablation or surgical intervention will be carried out.
88931236|NCT01747668|Placebo Comparator|Control Supplement|soft-gel placebo capsules, 2 capsules from the placebo bottle per day
88931237|NCT01747668|Experimental|Experimental Supplement A|soft-gel capsules; 1 capsule from the experimental bottle and 1 capsule from the placebo bottle per day
88931238|NCT01747668|Experimental|Experimental Supplement B|soft-gel capsules; 2 capsules from the experimental bottle per day
88931239|NCT01747681||Microfracture|Microfracture of articular chondral defect
88931240|NCT01747694|Experimental|Multi-respiratory muscle training|Patients will perform multi-repiratory muscle training programe for 12 weeks
88931241|NCT01747694|No Intervention|Diaphragmatic breathing|Patients will be taught diaphragmatic breathing technique routinely. To practice at home lasting 12 weeks
88931242|NCT01747707|Experimental|docetaxel, cisplatin and S-1 (DCS)|All patients receive the combination therapy of docetaxel, cisplatin and S-1 for a maximum of 6 cycles. Docetaxel 60mg/m2 IV infusion over 1 hour on d1; Cisplatin 30mg/m2 IV infusion on d1,2; S-1 40mg orally twice a day for patients with the body surface area (BSA) less than 1.25m2, 50mg twice a day with the BSA between 1.25 and 1.5m2, 60mg twice a day with the BSA over 1.5m2.
88931243|NCT01747720|Experimental|Vitamin D3 (cholecalciferol) 1000 IU|Oral vitamin D3 (cholecalciferol) supplementation, 1000 IU daily, for 12 months
88931244|NCT01747720|Experimental|Vitamin D3 (cholecalciferol) 2000 IU|Oral vitamin D3 (cholecalciferol) supplementation, 2000 IU daily, for 12 months
88931245|NCT01747720|Experimental|Vitamin D3 (cholecalciferol) 3000 IU|Oral vitamin D3 (cholecalciferol) supplementation, 3000 IU daily, for 12 months
88931246|NCT01747720|Placebo Comparator|Placebo|daily, for 12 months
89446339|NCT05238441|Active Comparator|Comirnaty and SCTV01E|Comirnaty on D0 and SCTV01E on D180
89446340|NCT05238441|Active Comparator|Comirnaty and Comirnaty|Comirnaty on D0 and D180
89446341|NCT02190981||Ultrasound for Small Bowel Obstruction|Emergency department patients undergoing point-of-care ultrasound to evaluate for suspected small bowel obstruction
89200139|NCT01051297||OSA-retrospective|PATIENT WITH OSA -CHART REVIEW
89200140|NCT01051297||OSA group -PROSPECTIVE|patients diagnosed with OSA
89200141|NCT00973492||patients with functional insulinotherapy|There is only one group in this study. The participants will attend a functional insulinotherapy class.
89200142|NCT00973570|Experimental|"Intervention group"|"The intervention group benefits from the TABADO program"
89200143|NCT00973570|No Intervention|"Control group"|"The control group not benefit from any specific intervention other than the treatment and education usually available"
89200144|NCT00892593|Experimental|1 Fecal Immunochemical Testing-Surveillance|Fecal Immunochemical Testing performed at yearly intervals.
89200145|NCT00892593|No Intervention|2 Usual Care - Surveillance|
88931247|NCT01747733||Endoscopy patients|Patients undergoing endoscopy in the endoscopy unit in HUCH (Helsinki University Central Hospital).
88931248|NCT01747746|Active Comparator|Rivaroxaban|Anticoagulation with Rivaroxaban 20 mg daily with dinner for 30 days
88931249|NCT01747746|Other|Warfarin and Enoxaparin|Warfarin: 1-10 mg per Nomogram Enoxaparin weight based 1 mg/kg Q12 or 1.5 mg/kg/day Historic control
88931250|NCT01747759|Other|Kruskal-Wallis and qualitative parameters|The evaluations will take place at baseline, the day before surgery and 6 weeks post-surgery on knowledge and beliefs scores at each visit and on a satisfaction score on the last one. Quantitative data will be compared between groups by the Kruskal-Wallis and qualitative parameters via Fisher exact test
88931251|NCT01747759|Other|Fisher exact test|The evaluations will take place at baseline, the day before surgery and 6 weeks post-surgery on knowledge and beliefs scores at each visit and on a satisfaction score on the last one. Quantitative data will be compared between groups by the Kruskal-Wallis and qualitative parameters via Fisher exact test
88931252|NCT01747785||Healthy controls|Individuals without history of cardiovascular disease and at least 18 years of age will take a baseline (at rest) cardiopulmonary exercise test (CPX) and have a cardiac echocardiogram to measure myocardial deformation. CPX and echocardiograms will be repeated during exercise sessions at 3 visits over a 12 week period.
88931253|NCT01747785||Patients at risk of heart failure|Individuals at risk of heart failure and a preserved ejection fraction of at least 50% will take a baseline (at rest) cardiopulmonary exercise test (CPX) and have a baseline cardiac echocardiogram to measure myocardial deformation. CPX and echocardiograms will be repeated during exercise sessions at 6 visits over a 12 week period. A cardiac rehabilitation exercise program will also occur over 12 weeks.
88931254|NCT01747798|Experimental|Treatment (auranofin)|Patients receive auranofin PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88931255|NCT01747824||Agitation Group|Patients that are evaluated to have an altered mental status score greater than 1 will be enrolled in the Agitation Group.
88931256|NCT01747824||Pain Group|Patients that report severe pain secondary to a long bone fracture or dislocation and report a visual analog scale pain score greater than 7 will be enrolled in the Pain Group.
88931257|NCT01747863||Mild NE|Infants with evidence of a perinatal event and NE who do not qualify for therapeutic hypothermia.
88931258|NCT01747889|Experimental|Electronic system|patients managed with an electronic chest drainage system
88931259|NCT01747889|No Intervention|traditional system|patients managed with a traditional analogue chest drainage system
88931260|NCT01747902|Other|Biceps tenodesis|The biceps tenodesis group will have their bicep detached and then re-inserted onto the shoulder.
88931261|NCT01747902|Other|Biceps Tenotomy|The biceps tenotomy group will have their bicep treated by detaching the tendon from the shoulder.
89200146|NCT00892593|No Intervention|3 Usual Care - Screening|
88931262|NCT01747941|Experimental|Cohort 1|Single ascending oral doses in fasted conditions
88931263|NCT01747941|Experimental|Cohort 2|Single ascending oral doses in fasted conditions
88931264|NCT01747941|Experimental|Cohort 3|Single ascending oral doses in fed conditions
88931265|NCT01747954|Experimental|Bag Squeezing|"20% increase in FiO2~Inflation pressure of 30 cm H2O + 10l O2/min~0.5 ml saline 0.9%~10 Manual Hyperinflation~10 vibrocompression~Aspiration Tracheal"
88931266|NCT01747954|Active Comparator|Thoracic vibrocompression|"20% increase in FiO2~0.5 ml saline~10 vibrocompression toracica on the right and left~Aspiration Tracheal"
88931267|NCT01747967|Experimental|Meal test|Both new-onset T1D children and adults will be recruited and followed up through 4 meal tests at 0, 6, 12 , 18, 24 and 30 months.
88931268|NCT01747980|Experimental|PRX-112|250 mL of resuspended carrot cells administered orally in a vehicle
88931269|NCT01747993|Experimental|tamsulosin|Tamsulosin (0.4 mg/j) (1 tablet / day for 6 days)
88931270|NCT01747993|Placebo Comparator|placebo|1 tablet / day for 6 days
88931271|NCT01748006||Blood and urine samples|
89200147|NCT00892593|Experimental|4 Fecal Immunochemical Testing-Screening|Fecal Immunochemical Testing yearly, beginning at year 6.
89200148|NCT00965926|Experimental|Low dose group|3 way cross-over. Fasting, normal diet and high-fat diet
89200149|NCT00965926|Experimental|High dose group|3 way cross-over. Fasting, normal diet and high-fat diet
89200150|NCT00889395|No Intervention|Home visit|Patients will have monthly home visits during which health educational talks will be given
89200151|NCT02557776|Experimental|Genetic testing of BRCA1 and BRCA2|"For detailes, please see Study procedure. Women with newely diagnosed breast cancer are offered written genetic counseling and screening of mutations in BRCA1 and BRCA2."
89200152|NCT00966004|Experimental|YM178 group|oral
89200153|NCT00966004|Placebo Comparator|Placebo group|oral
89200154|NCT00966004|Active Comparator|tolterodine group|oral
89200155|NCT00892671||medical students|
89200156|NCT04048590|No Intervention|Control|Control subjects will receive care at a skilled nursing facility.
89200157|NCT04048590|Active Comparator|Intervention|Intervention subjects will go home from the hospital and receive care from a specialized care team.
88931272|NCT01748019|Experimental|ST1968|"ST1968 once a week for 2 weeks every 3 weeks (protocol amendment: once every 3 weeks~--------------------------------------------------------------------------------"
88931273|NCT01748032|Other|Alternative Uses Training|In this task, subjects are asked to produce atypical and alternative uses for common daily objects.
88931274|NCT01748032|Other|Word Association Training|In this task, subjects are asked to generate the first word that comes to their mind, and thus, encourages more general and spontaneous divergent thinking.
88931275|NCT01748058|Experimental|Active video games|Exercise based on active video gaming
88931276|NCT01748058|No Intervention|Routine care|
88931277|NCT01748084|Placebo Comparator|NaCl|NaCl 500 ml IV day 1 and day 15 plus 100 mg methylprednisolone
89200158|NCT00966082|Active Comparator|Endoscopic band ligation|Perform endoscopic band ligation (EBL) until eradication of esophageal varices, and then follow-up endoscopy with 3-6 months interval
89200159|NCT00966082|Active Comparator|endoscopic band ligation+Propranolol|Perform endoscopic band ligation (EBL) until eradication of esophageal varices, and then follow-up endoscopy with 3-6 months interval, with propranolol
89446342|NCT05263323|Experimental|Experimental Group - Education Group|"Stage 1; In the intervention group, at the first stage, the data were filled with the data collection tools of the intervention group.~Stage 2; It was made two weeks after the first visit in stage 1. Patient education according to Neuman Systems Theory was given to the patients who participated in the study, who received hemodialysis treatment in the center determined as the intervention group. This training was applied in the form of one-on-one training by going to the homes of the patients on the day they did not go to dialysis, within the topics determined according to the theory.~Stage 3. It was done one month after the 2nd stage. Patient education according to Neuman Systems Theory was repeated to the patients, and a pre-prepared education guide called Let's Learn Hemodialysis was distributed and a question-answer evaluation was made.~Stage 4; It was done one month after the 3rd stage. The data of the intervention group were collected again with data collection tools."
89446343|NCT05263323|Active Comparator|Control Group|"Data collection for individuals in the control group included two stages, one at the beginning and one at the end of the study.~The first stage was applied to the experimental group during the first stage. The data of the control group were collected with data collection tools.~The second stage was given to the experimental group during the fourth stage. In this visit, The data of the control group were collected again with data collection tools."
89446344|NCT02204397|Experimental|INGAP Peptide, Ustekinumab|INGAP Peptide, Ustekinumab subcutaneous
89446345|NCT02192229|Active Comparator|intervention group|The intervention group will be supplemented with 50.000 IU vitamin D3 every week for 12 consecutive weeks
89446346|NCT02192229|Placebo Comparator|Placebo group|The placebo group will receive placebo Tablet which will be manufactured in a pharmaceutical factory to be identical to vitamin D3 Tablet in color, shape, size, and packaging
89446347|NCT02192463|Experimental|Nevirapine (NVP) ER 300 mg (KCR 20%) Medium Release|
88931278|NCT01748084|Experimental|Rituximab|Rituximab 1G IV day 1 and day 15 plus 100 mg methylprednisolone
88931279|NCT01748097|Experimental|IV bicarbonate 4.2% 20 cc|injecting 20cc 4.2% to a newly administered IV line
88931280|NCT01748097|Placebo Comparator|IV normal saline|injecting 20 cc normal saline to a newly administered IV line
88931281|NCT01748110|No Intervention|Local Control Group|This arm is for patients in the District of Columbia (DC), (Maryland) MD, (Virginia) VA area that are able to attend all follow up visits at 3 month, 6 month, 12 month and 18 months post operative periods that have been randomized to standard recommendations for fitness/health interventions prior to surgery.
88931282|NCT01748110|Experimental|Local TRIMM Group|This arm is for patients in the DC, MD, VA area that are able to attend all follow up visits at 3 month, 6 month, 12 month and 18 months post operative periods that have been randomized to receive daily text message reminder and prompts targeted to the patient's dietary, fitness and urologic goals and needs using the Tailored Rapid Interactive Mobile Messaging (TRIMM) method. Patients will receive these text messages from 4 weeks prior to surgery until 8 week after surgery
88931283|NCT01748110|Experimental|Local Intensive Group|This arm is for patients in the DC, MD, VA area that are able to attend all follow up visits at 3 month, 6 month, 12 month and 18 months post operative periods that have been randomized to undergo intensive in-person fitness interventions according to the Look AHEAD model. This will involve attendance at weekly support group meetings and personal monthly meetings with a health care provider/
88931284|NCT01748110|No Intervention|Distant Control Group|This arm is for geographically distant patients that are unable to attend all follow up visits at 3 month, 6 month, 12 month and 18 months post operative periods that have been randomized to standard recommendations for fitness/health interventions prior to surgery.
89200160|NCT00766740|Active Comparator|1|thrombectomy
89446348|NCT02192463|Experimental|NVP ER 300 mg (KCR 25%) Medium Release|
89446349|NCT02192463|Experimental|NVP ER 300 mg (KCR 30%) Slow Release|
89446350|NCT02192463|Experimental|NVP ER 400 mg (KCR 25%) Medium Release|
88931285|NCT01748110|Experimental|Distant TRIMM Group|This arm is for geographically distant patients that are unable to attend all follow up visits at 3 month, 6 month, 12 month and 18 months post operative periods that have been randomized to receive daily text message reminder and prompts targeted to the patient's dietary, fitness and urologic goals and needs using the Tailored Rapid Interactive Mobile Messaging (TRIMM) method. Patients will receive these text messages from 4 weeks prior to surgery until 8 week after surgery
88931286|NCT01748123|Active Comparator|Chlorthalidone|25mg daily orally for 8 weeks
88931287|NCT01748123|Active Comparator|Hydrochlorothiazide|50mg daily orally for 8 weeks
88931288|NCT01748136||Single Arm|CT Scan Arm
88931289|NCT01748188|Active Comparator|Ultrasound + Exercises + Cryotherapy|Ultrasound of 1 Megahertz (MHz), intensity 2 W/cm2, 5 minutes, for 20 sessions.
89200161|NCT00766740|Active Comparator|2|Standard PCI
89200162|NCT00892749|Experimental|1. ASP1585|
89200163|NCT00763542|Experimental|I|Combined treatment: CBT for SUD plus structured writing therapy for PTSD
88931290|NCT01748188|Experimental|Phonophoresis + Exercises + Cryotherapy|Phonophoresis with 50 mg dexketoprofen (Enangel), 1 MHz, intensity 2 W/cm2, 5 minutes, for 20 sessions.
88931291|NCT01748188|Experimental|Iontophoresis + Exercices + Cryotherapy|Iontophoresis by galvanic direct current with 50 mg dexketoprofen (Enantyum), intensity 2 milliamperes (mA), 20 minutes, for 20 sessions.
88931292|NCT01748201|Experimental|Joint lavage and viscosupplementation|The joint will be washed until obtaining translucent liquid and not hemorrhagic. Then it will receive an intra-articular injection of 6ml of hyaluronic acid (Synvisc One), 1ml of triamcinolone and 2 ml of ropivacaine.
88931293|NCT01748214||Nasal CPAP|Infants received nasal CPAP as standard of care.
88931294|NCT01748214||High Flow Nasal Cannual|Infants received high flow nasal cannula as standard of care.
88931295|NCT01748253|Active Comparator|Telmisartan-amlodipine tablet administration group (morning)|
88931296|NCT01748253|Active Comparator|Telmisartan-amlodipine tablet administration group (bedtime)|
88931297|NCT01748266||microcirculatory reactivity|Patients were studied during the first 48 postoperative hours. Microcirculation of the thenar eminence was analyzed by NIRS technology, through the StO2 and the resaturation slope after an ischemic challenge.
88931298|NCT01748279|Active Comparator|Atorvastatin|40 mg of Atorvastatin once daily as add-on to Formoterol only 12 weeks therapy.
88931299|NCT01748279|Placebo Comparator|Lactose tablet|One tablet taken once a day as add-on treatment to Formoterol baseline 12 weeks therapy.
88931300|NCT01748305|Experimental|Moderate-to-vigorous intensity exercise|Moderate-to-vigorous intensity exercise three times per day for three weeks
88931301|NCT01748318|Experimental|NM Regional Honey|15 ml of NM Honey applied directly to wound
88931302|NCT01748318|Active Comparator|Bactrim DS|Standard of Care Oral Antibiotic
88931303|NCT01748331|Other|Strict fluid restriction < 1 L/day|20 patients will be randomized to strict fluid restriction < 1 L/day
88931304|NCT01748331|Other|Moderate fluid restriction < 2.5 L/day|20 patients will be randomized to moderate fluid restriction < 2.5 L/day
88931305|NCT01748344|Experimental|Experimental 1|High dose ONO-4053
88931306|NCT01748344|Active Comparator|Cetirizine|10mg Cetirizine
88931307|NCT01748344|Experimental|Experimental 2|Low dose ONO-4053
88931308|NCT01748344|Placebo Comparator|Placebo|Placebo
88931309|NCT01748357||Tuberculosis group|Patients with confirmed pulmonary infection with M. tuberculosis. At least 50% of the subjects should be tested before therapy is started. Patients with treatment for tuberculosis >1 week are excluded.
88931310|NCT01748357||Inflammation group|Patients with another inflammatory disease of the lower respiratory tract, i.e. pneumonia, sarcoid or bronchial carcinoma. This group is required to detect VOC pattern caused by pulmonary inflammation.
88931311|NCT01748357||Healthy group|Healthy subjects without lung disease. These subjects should be recruited from outside the hospital / study site to avoid confounding VOC pattern caused by continuous exposure to the hospital environment.
88931312|NCT01748370|Experimental|Vitamin D hypogonadal|Vitamin D supplementation in hypogonadal men
88931313|NCT01748370|Experimental|Vitamin D eugonadal|Vitamin D supplementation in eugonadal men
88931314|NCT01748370|Placebo Comparator|Placebo hypogonadal|Vitamin D supplementation in hypogonadal men
88931315|NCT01748370|Placebo Comparator|Placebo eugonadal|Vitamin D supplementation in eugonadal men
88931316|NCT01748383|Experimental|Transplantation of BMMCs|Autologous BMCs aspiration and transplantation of these cells
88931317|NCT01748383|Experimental|Transplantation of CD 133+ cells|Autologous CD 133+ BMCs aspiration and transplantation of CD 133+ cells
88931318|NCT01748383|Active Comparator|stenting of IRA|The only stenting of IRA
88931319|NCT01748396|Experimental|Calcitriol + CaCO3|Calcitriol 0.25mcg 1cap daily for 8 weeks, and Calcium Carbonate 500mg 1tab 3 times daily for 8 weeks
88931320|NCT01748396|Active Comparator|Calcitriol|Calcitriol 0.25mcg 1cap daily for 8 weeks
88931321|NCT01748422||Experimental: Qutenza|Single treatment with Qutenza (topical capsaicin8%) transdermal patch
88931322|NCT01748435||Qutenza|Single treatment with QUTENZA (topical capsaicin 8%) transdermal patch
88931323|NCT01748461|Active Comparator|Structured intervention|Supervised cycle ergometer program
88931324|NCT01748461|Active Comparator|Coach intervention|Non-supervised cycle ergometer program
88931325|NCT01748461|No Intervention|Control group|No cycle ergometer program
88931326|NCT01748474|Experimental|Supplemental oxygen|Supplemental oxygen will be applied via a mask during CPET
88931327|NCT01748474|Placebo Comparator|Sham room air|Room air will be applied similarly to oxygen
88931328|NCT01748487|Experimental|OZURDEX|24 patients will receive an intravitreal injection of OZURDEX at the end of cataract surgery.
88931329|NCT01748500|Experimental|Pantoprazole, Docetaxel, Prednisone|
88931330|NCT01748513||preoperative venous return optimizing|Morbidly obese patients scheduled for bariatric surgery
88931331|NCT01748526|Experimental|Treatment A|Each volunteer will receive a single 200 mg dose of canagliflozin (JNJ-28431754) on Day 1.
88931332|NCT01748526|Experimental|Treatment B|Each volunteer will receive a single 300 mg dose of canagliflozin (JNJ-28431754) on Day 1.
88931333|NCT01748539|Experimental|KHK4827 70mg SC|
88931334|NCT01748539|Experimental|KHK4827 140mg SC|
88931335|NCT01748539|Experimental|KHK4827 210mg SC|
88931336|NCT01748539|Placebo Comparator|Placebo SC|
88931337|NCT01748565||premature infants|Infants born prematurely between 23-0/7 and 27-6/7 weeks post-menstrual age with and without bronchopulmonary dysplasia
88931338|NCT01748578|Active Comparator|EBI-005-1 5mg/mL|Healthy subjects will be randomized to EBI-005 5mg/mL vs. EBI-005-1 Placebo 3x/day
89446351|NCT02192463|Experimental|NVP ER 300 mg (KCR 40%) Slow Release|
89446352|NCT02192463|Experimental|NVP ER 300 mg (ECR 20%) Fast Release|
89446353|NCT02192463|Experimental|NVP ER 400 mg (KCR 20%) Medium Release|
89446354|NCT02192463|Experimental|NVP ER 400 mg (KCR 30%) Slow Release|
89446355|NCT02192463|Experimental|NVP ER 400 mg (KCR 40%) Slow Release|
89446356|NCT02192463|Experimental|NVP ER 400 mg (ECR 20%) Fast Release|
89446357|NCT02192463|Active Comparator|Nevirapine IR 1 tablet|
89446358|NCT02192463|Active Comparator|Nevirapine IR 2 tablets|
89446359|NCT02209935|Active Comparator|Usual Care|Typically, usual care is when therapies are not initiated until the treating team places an order for each element of care (physical, occupational, speech, and emotional therapy consultation).
89446360|NCT02209935|Experimental|Early Rehabilitation Protocol|Physical, occupational, speech, and emotional evaluation and support personalized to the subject's severity of illness and developmental status.
89446361|NCT02204475|Active Comparator|BOC/PR|All participants begin treatment with a 4-week lead-in of PR followed by 24 weeks of BOC/PR. At Treatment Week (TW) 28 TN participants who have undetectable HCV RNA at TW 8 will complete BOC/PR therapy. At TW 28 TN participants who have detectable HCV RNA at TW 8, as well as prior relapsers and prior partial responders, will continue on BOC/PR for an additional 8 weeks and then continue on PR for an additional 12 weeks. At TW 28 all cirrhotics and previous null responders will continue on BOC/PR for an additional 20 weeks.
89446362|NCT02204475|Experimental|Grazoprevir/Elbasvir|Participants will undergo treatment with grazoprevir 100 mg + elbasvir 50 mg for 12 weeks.
89446363|NCT02210169|No Intervention|Intermittent infusion of vancomycin|Vancomycin will be administered intravenously over 1 hour. Doses will be given from one to four times a day according to corrected gestational age.
89446364|NCT02210169|Active Comparator|Continuous infusion of vancomycin|A loading dose of vancomycin will be given over 1 hour followed by a continuous infusion of vancomycin over a 24 hour period.
88931339|NCT01748578|Active Comparator|EBI-005-1 20 mg/mL|Healthy subjects will be randomized to EBI-005 20 mg/mL vs. EBI-005-1 Placebo 3x/day
88931340|NCT01748591||PICOPREP treatment|PICOPREP powder for oral solution according to standard clinical practice
88931341|NCT01748604|Active Comparator|Standard trimodality therapy with MLD|Manual Lymphatic Drainage (MLD) followed by intermittent pneumatic compression (IPC) and followed by multilayer, multicomponent bandages (MB) until next day.
88931342|NCT01748604|Experimental|Trimodality therapy with LPD|Pneumatic massage with Lymphapress-Plus(TM) device (LPD) followed by intermittent pneumatic compression (IPC) and followed by multilayer, multicomponent bandages (MB) until next day
88931343|NCT01748604|Experimental|Bimodality therapy without MLD|intermittent pneumatic compression (IPC) followed by multilayer, multicomponent bandages (MB) until next day.
88931344|NCT01748617|Experimental|Pomegranate Juice|Acute ingestion of pomegranate juice with high fat meal.
89446365|NCT02257047|Experimental|RYR|Patients under the treatment of red yeast rice
89446366|NCT02257047|Sham Comparator|Control|Patients under the treatment of tea
89446367|NCT02210949|Other|Erythropoietin Iron|"Erythropoietin and iron:~Administration of Erythropoietin (600 IU/kg (14.4 g/L)) twice weekly for three weeks .~Administration of Iron (Ferinject (iron(III)carboxymaltose)) intravenously 1000 mg once."
89446368|NCT01109004|Active Comparator|Tandem auto transplant|Initial autologous transplant followed by a second autologous transplant and lenalidomide maintenance
89446369|NCT01109004|Active Comparator|RVD consolidation|Initial autologous transplant followed by lenalidomide, bortezomib and dexamethasone (RVD) consolidation and lenalidomide maintenance
89446370|NCT01109004|Active Comparator|Lenalidomide maintenance|Initial autologous transplant followed by lenalidomide maintenance
89446371|NCT02211651||ObeseDYS|Obese subjects with dysfunctional vascularization and inflammation of placenta.
89446372|NCT02211651||ObeseNL|Obese subjects with normal vascularization and inflammation of placenta
89446373|NCT02211651||LeanNL|Lean subjects with normal vascularization and inflammation of placenta.
89446374|NCT02204631|Experimental|Head and Neck Educational Handbook|"Prior to starting treatment, patients will be approached for trial participation and baseline questionnaires (demographics, psychological distress, symptom burden, and illness perception).~After enrollment and baseline data collection, the participant will be given the handbook. The clinician giving out the handbook will give an overview of the handbook and flip through the important sections. The clinician will encourage the participant to bring it back and forth.~Participants will complete questionnaires at 3 weeks into treatment and 2 weeks after treatment has ended (information satisfaction, psychological distress, symptom burden, and illness perception)."
89446375|NCT02204631|No Intervention|Non Head and Neck Educational Handbook|"Prior to starting treatment, patients will be approached for trial participation and baseline questionnaires (demographics, psychological distress, symptom burden, and illness perception).~The first group of participants will not receive the handbook but will receive the current standard care in the head and neck disease center.~Participants will complete questionnaires at 3 weeks into treatment and 2 weeks after treatment has ended (information satisfaction, psychological distress, symptom burden, and illness perception).~At completion of Phase I, all 30 participants will also be given a copy of the handbook and an accompanying questionnaire."
89446376|NCT02211729|Active Comparator|Seasonal malaria chemoprevention|Sulphadoxine-Pyrimethamine Amodiaquine Placebo Azithromycin
89446377|NCT02211729|Experimental|seasonal malaria chemoprevention plus AZ|Sulphadoxine-Pyrimethamine+ Amodiaquine + Azithromycin 4 rounds during malaria transmission season
89446378|NCT02212041|Experimental|Electronic cigarettes|Free disposable electronic cigarettes will be provided during 6 weeks to smokers with serious mental illness.
88931345|NCT01748617|Placebo Comparator|Control|Acute ingestion of juice-free sweetened beverage with high fat meal.
88931346|NCT01748630|Active Comparator|Dexmedetomidine, Midazolam|dexmedetomidine (group DEX); starting dose, 0.4 μg•kg-1•h-1,with intermittent fentanyl
89446379|NCT05151510|Experimental|Trigger point with 1% Lidocaine|The physician will withdraw 1cc of 1% lidocaine in a 25g needle, sterilely prep the field with a Chloraprep applicator, use index, and middle finger to squeeze the borders of the trigger point and raise the central aspect of the trigger point, insert the needle at 90-degree angle up to 5/8' deep, inject 1cc of the 1% lidocaine after ensuring needle is not in a blood vessel, removing the needle, and then covering the insertion site with a sterile bandage.
88931347|NCT01748630|Active Comparator|Midazolam|midazolam (group MDZ); starting dose, 0.1 mg•kg-1•h-1
88931348|NCT01748656|Active Comparator|AVAPS|AVAPS mode(BIPAP-A30-PHILIPS-RESPIRONICS)1 night
88931349|NCT01748656|Active Comparator|IVAPS|IVAPS mode(STELAR 150-RESMED)1 night
88931350|NCT01748669|Experimental|Patients of palmer arsenical keratosis|One soft capsule of garlic oil (10 mg) daily for 12 weeks
88931351|NCT01748669|Active Comparator|Arsenic exposed controls|One soft capsule of garlic oil (10 mg) daily for 12 weeks
88931352|NCT01748669|Active Comparator|Heathy volunteers|One soft capsule of garlic oil (10 mg) daily for 12 weeks
89446380|NCT05151510|Active Comparator|5% Lidocaine Patch|5% lidocaine patch will be placed at the point of maximal tenderness upon palpation. Location of placement will be described and instructed by physician and placed by nursing staff.
88931353|NCT01748682|Experimental|Liquid Diet Group|The group followed a very low calorie liquid diet for two weeks
88931354|NCT01748682|Active Comparator|Control Group|The group followed a very low calorie diet of normal consistency for two weeks.
88931355|NCT01748708|Experimental|Magnetic seizure therapy|
88931356|NCT01748708|Active Comparator|Electroconvulsive therapy|
88931357|NCT01748721|Experimental|Treatment (MORAb-004)|Patients receive anti-endosialin/TEM1 monoclonal antibody MORAb-004 IV on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
88931358|NCT01748734|Experimental|Supportive care (cognitive behavioral therapy)|Cognitive behavioral therapy comprising progressive muscle relaxation training, behavioral activation, seeking information as a coping strategy, enhancing social support, cognitive reappraisal, assertive communication, changing depressive core beliefs, goal setting and planning for maintenance, and maintenance over 1 hour once weekly sessions for 12-20 weeks, biweekly sessions for 4-6 weeks, and monthly sessions for 2-3 months for a total of 16-26 sessions.
88931359|NCT01748747|Experimental|Arm I (MART-1 antigen, Gag:267-274 peptide vaccine)|Patients receive MART-1 antigen and Gag:267-274 peptide vaccine emulsified in Montanide ISA 51 VG SC on day 1.
88931360|NCT01748747|Experimental|Arm II (MART-1 antigen, resiquimod, Montanide ISA 51 VG)|Patients receive MART-1 antigen emulsified in Montanide ISA 51 VG SC followed by resiquimod applied topically on day 1.
88931361|NCT01748747|Experimental|Arm III (MART-1 antigen, Gag:267-274 peptide, resiquimod)|Patients receive MART-1 antigen and Gag:267-274 peptide vaccine peptide vaccine emulsified in Montanide ISA 51 VG SC followed by resiquimod applied topically on day 1.
88931362|NCT01748773|Experimental|Combination Therapy|Participants will receive combination therapy comprising of trastuzumab, oxaliplatin, capecitabine, and radiation.
88931363|NCT01748786|Experimental|Mindfulness Emotion Regulation|12 on-line modules targeting social and emotional regulation through mindfulness training
88931364|NCT01748786|Placebo Comparator|Placebo|12 on-line modules providing information regarding health behaviors
89200164|NCT00763542|Active Comparator|II|CBT for SUD only
89200165|NCT00889629|Experimental|Doxercalciferol|Patients are randomized using an A B C D randomization scheme in which the patient and the primary investigator are blinded but the study staff is not. Active group receives doxercalciferol (Hectorol) 1mcgwith active titration based on intact PTH plus 25-OH Vitamin D3 (cholecalciferol) 400 IU. Safety labs and end point labs are monitored as per protocol, with the opportunity to increase the dose of doxercalciferol if target PTH value is not achieved by the predetermined midpoint.
89446381|NCT02212119|Placebo Comparator|Saline|Saline injection up to 5 cc in arm with paratonia (one time injection)
89446382|NCT02212119|Active Comparator|Botulinum Toxin|Up to 300 U (5 cc) of Botulinum toxin diluted 2:1 (2 cc per 100 U of Botulinum toxin) (one time injection)
89446383|NCT02257125|Experimental|high incentive|game version including visual effects and monetary rewards
89446384|NCT02257125|Active Comparator|low incentive|game version without visual effects or monetary rewards
88931365|NCT01748838|Experimental|Part 1: CTX-4430|
88931366|NCT01748838|Placebo Comparator|Part 1: Placebo + Mannitol|
88931367|NCT01748838|Experimental|Part 2: CTX-4430|
88931368|NCT01748838|Placebo Comparator|Part 2: Placebo + Mannitol|
88931369|NCT01748851|Experimental|XELOX|Capecitabine 1000mg/m2 bid D1-D14 Oxaliplatin 130mg/m2 + 5% Dextrose water (5DW) 500ml over 2hour D1 Q 2weeks
88931370|NCT01748851|Active Comparator|FOLFOX|Oxaliplatin 85mg/m2 + 5DW 500ml over 2hr D1 Leucovorin 400mg/m2 + 5DW 500ml over 2hr D1 5-Fluorouracil (5-FU) 400mg/m2 IV PUSH D1 5-FU 1200mg/m2 + 5DW 1 Liter over 22hr D1-D2 Q 2weeks
88931371|NCT01748864|Experimental|Single Arm - Healthy Volunteers|Etarfolatide (EC20)
88931372|NCT01748877|Experimental|NXN-462|capsule, 200 mg, bi.d. 28-days
88931373|NCT01748877|Placebo Comparator|Placebo|capsule, b.i.d. 28-days
88931374|NCT01748903||Target 360°, 2D, Nano Coils|Subjects will undergo embolization using Target 360°, 2D, Nano Coils for the treatment of their intracranial aneurysm.
88931375|NCT01748929|Experimental|Albendazole|single dose 400 mg tablet of albendazole
88931376|NCT01748929|Placebo Comparator|Placebo|Placebo Manufactured by Hersil Laboratories in Lima, Peru
88931377|NCT01748968||Veterans with HIV/AIDS|Veterans with HIV/AIDS
88931378|NCT01748981|Other|Physical training|Exercise intervention.
88931379|NCT01748981|Other|As usual|Controls
88931380|NCT01749007||Veterans with HIV/AIDS|
88931381|NCT01749020|Experimental|Polyphenol-rich Dark chocolate|Dark chocolate with 500 mg of polyphenols
88931382|NCT01749020|Placebo Comparator|Placebo Dark chocolate|This chocolate contains little or no polyphenols
88931383|NCT01749046|Experimental|Remegal|Remegal 1500 mg
88931384|NCT01749046|Placebo Comparator|Placebo|Placebo
88931385|NCT01749059||Congenital Heart Defect|
88931386|NCT01749072|Other|Gefitinib|Gefitinib group Gefitinib (Iressa) 250mg once per day until progression disease or intolerant side effects
88931387|NCT01749072|Other|Vinorelbine-Ifosfamide|VI group Vinorelbine 25mg/m2 d1,d8;Ifosfamide 1.25g/m2 d1-d3(Usually Ifosfamide 2g d1-d3 with Mesna 400mg 0,4,8hours after Ifosfamide administration for 3 days);every 3 weeks;at least for 2-6 cycles depending on the progression disease or the patient's physical condition
88931388|NCT01749085|Experimental|Sequence 1|
88931389|NCT01749085|Experimental|Sequence 2|
88931390|NCT01749098|Experimental|PF-04958242|PF-04958242 and ketamine
88931391|NCT01749098|Placebo Comparator|Placebo|Placebo and ketamine
88931392|NCT01749111|Experimental|Arm A|Graft versus host disease prophylaxis will be done with cyclophosphamide 50 mg/kg on day +3 and day +4
88931393|NCT01749111|Active Comparator|Arm B|In this arm, patients will receive a combination of methotrexate and a calcineurin inhibitor as graft versus host disease prophylaxis
88931394|NCT01749124|Experimental|My Coach Connect|"To evaluate the feasibility and effectiveness of this telephone tool while engaging clients and providers in discussion groups and surveys to better understand how this tool impacts the care provided and their overall experience in healthcare. Clients will use this tool to leave voice messages and survey answers which their providers will have access to by logging in to a secure website. Providers will have access to audio recordings of the voice responses, transcribed text of the responses, as well as word clouds generated from the text. Word clouds are a method of displaying the content of text such that words that are used more frequently are displayed in a larger size than words used less frequently."
88931395|NCT01749150|Experimental|with cirrhosis|
88931396|NCT01749150|Experimental|without cirrhosis|
88931397|NCT01749163|Experimental|Control|Saline will be coninfused during the pancreatic clamp
88931398|NCT01749163|Experimental|GIP|GIP will be infused intravenously during the pancreatic clamp at 1.5 pmol/kg/min
88931399|NCT01749163|Experimental|GLP-1|GLP-1 will be infused intravenously during the pancreatic clamp at 0.5 pmol/kg/min
88931400|NCT01749176|Experimental|SMS texting intervention|Behavioral text messages will be sent at random times throughout the week reagarding Healthy nutrition tips, benefits of physical activity, benefits of medication adherence and requests to check blood sugar and send back results.
88931401|NCT01749176|Placebo Comparator|Control-Usual Care|Participants will continue to receive their usual care in their primary care home. They will return at months 3 and 6 to conduct behavioral and laboratory assessments to compare results with the intervention group.
88931402|NCT01749189|Placebo Comparator|Placebo|Placebo dry blended beverage (carbohydrate)
88931403|NCT01749189|Experimental|Blend|A dry blended beverage containing a protein blend of soy, whey and casein
88931404|NCT01749189|Active Comparator|Whey|A dry blended beverage containing Whey protein
88931405|NCT01749202|Placebo Comparator|Negative Control|
88931406|NCT01749202|Active Comparator|Positive Control|
88931407|NCT01749202|Experimental|Active|
88931408|NCT01749228|Experimental|Etodolac Capsules USP 300 mg|Etodolac Capsules USP 300 mg of Ipca Laboratories Limited, India
89014026|NCT05904171|Experimental|Tangotherapy|2 hours of group-based Tangotherapy, weekly, for 6 weeks
89014027|NCT05904171|Active Comparator|Physical Activity|2 hours of group-based physical activity, weekly, for 6 weeks
89014028|NCT05903157|Active Comparator|Control Group: Delivery of a health literacy flyer|All Control Group participants received, through e-mail, a flyer about health literacy.
89014029|NCT05903157|Experimental|Weekly group sessions for weight management|"Participants in the Experimental Group were integrated into an eHealth 8-week group intervention, based on two theoretical models - the Health Action Process Approach (HAPA), and the Health Belief Model (HBM). Several Behaviour Change Techniques (BCT) were used, to promote the behaviour change.~The experimental intervention consisted of: i) weekly group sessions (by Zoom platform), with a specific theme in each session, ii) weekly challenges, and iii) WhatsApp group interaction."
89014030|NCT05900206|Experimental|T-DXd (cycles 1-3)|Trastuzumab Deruxtecan, administered every three weeks for three courses. Further treatment is decided by the intrinsic molecular (PAM50) subtype of the tumor.
89014031|NCT05900206|Active Comparator|Standard treatment (TCHP or PCHP; cycles 1-3)|TCHP (Docetaxel, Carboplatin, Trastuzumab, Pertuzumab) or PCHP (Paclitaxel, Carboplatin, Trastuzumab, Pertuzumab), administered every three weeks for three courses. Further treatment is decided by the intrinsic molecular (PAM50) subtype of the tumor.
89014032|NCT05900206|Other|ER-positive and Luminal (cycles 4-6)|Ribociclib, letrozole, trastuzumab, pertuzumab
89200166|NCT00889629|Placebo Comparator|Cholecalciferol|Patients are randomized using an A B C D randomization scheme in which the patient and the primary investigator are blinded but the study staff is not. Group 2 receives placebo (dummy bottle with pills resembling doxercalciferol) plus 25-OH Vitamin D3 (cholecalciferol) 400IU. Safety labs and end point labs are monitored as per protocol, with the opportunity to increase the dose of doxercalciferol placebo if target PTH value is not achieved by the predetermined midpoint.
89014033|NCT05900206|Other|ER-negative and Luminal, or Basal-like, or Normal-like (cycles 4-6)|Epirubicin and Cyclophosphamide in case of no complete radiologic response after the initial three courses. In case of complete radiologic response, treatment from cycles 1-3 (T-DXd or TCHP/PCHP) will continue instead for three more courses.
89014034|NCT05900206|Other|HER2-enriched (cycles 4-6)|The same treatment with T-DXd or TCHP/PCHP administered every three weeks for three more courses will continue from cycles 1-3
89014035|NCT05893160|Experimental|Experimental Intervention|The intervention group will receive sodium nitrite SR (40 mg b.i.d. for 30 days)
89014036|NCT05893160|Placebo Comparator|Placebo|The comparison group will receive an inert placebo on the same schedule as the intervention group
89014037|NCT05890677|Experimental|Group A : Surgical Group|"According to the pragmatic study design, neither the diagnostic workup nor the surgery will be standardized in order to offer surgeons considerable leeway on how to perform lymphatic surgery, which resembles the flexibility in usual care. The key aspects of the preoperative workup and the surgery including the number of LVAs (Lymphovenous Anastomosis), harvesting of lymph nodes (donor site), time of surgery, and practical details will be registered."
89446385|NCT03484650|Placebo Comparator|Control|Patients will receive standard care plus infusion of placebo
89446386|NCT03484650|Experimental|Lidocaine|Patients will receive lidocaine infusions peri-operatively
89446387|NCT05151276|Experimental|Intervention Group|individuals with odd sequence numbers were assigned to the intervention group (n=46)
89446388|NCT05151276|No Intervention|Control Group|those with even numbers to the control group (n=47).
89446389|NCT02213601|Experimental|Yoga|8-week Gentle Vinyasa Flow yoga intervention
89446390|NCT02213601|No Intervention|Wait-list Control Group|
89446391|NCT03486288||Delirium|
89446392|NCT03486288||No Delirium|
89446393|NCT02192697|Experimental|Phase I dose-escalation group|Oral administration
89446394|NCT02192697|Experimental|Phase I EGFR-T790M mutation group|Oral administration
89446395|NCT02192697|Experimental|Phase II group|Oral administration
89446396|NCT03486210||Phase 1 Group 1|Healthy volunteers
89446397|NCT03486210||Phase 1 Group 2|Health professionals
88931409|NCT01749228|Active Comparator|Etodolac Capsules USP 300mg|Etodolac Capsules USP 300mg of Taro Pharmaceutical Industries Ltd., USA
89200167|NCT00966160|Active Comparator|PI|400 mg lopinavir and 100 mg ritonavir (Kaletra capsules, Abbott Laboratories) twice daily plus 150 mg lamivudine (Epivir tablets, GlaxoSmithKline) and 300 mg zidovudine (Retrovir tablets, GlaxoSmithKline) twice daily over a 56-week run-in and a 420-week follow-up
89446398|NCT03486210||Phase 2 Group 1|Control group : patients obese without surgery
88931410|NCT01749241|Experimental|Loteprednol etabonate ointment|This is the arm which contains loteprednol steroid
88931411|NCT01749241|Other|Vehicle Ointment|This arm contains vehicle only.
89446399|NCT03486210||Phase 2 Group 2|Patients who have underwent a sleeve gastrectomy
89446400|NCT03486210||Phase 2 Group 3|Patients who have underwent a gastric bypass
89446401|NCT03486132|Other|interrupted repair of mediolateral episiotomy|"using the interrupted suture (IT) which involves placing three layers of sutures: a continuous non-locking stitch to close the vaginal epithelium. commencing above the apex of the wound and finishing at the level of the fourchette; three or four interrupted sutures to reapproximate the deep and superficial perineal muscles; and interrupted transcutaneous technique to close the skin.~The standard suture material in the study will be EGYSORB (sterile coated synthetic polyglycolic acid absorbable braided suture) No 2/0 Mediolateral episiotomy:it is defined as an incision beginning in the midline and directed laterally and downwards away from the rectum .The incision is usually about four centimeters long. In addition to the skin and subcutaneous tissues the bulbocavernosus, transverse perineal, and puborectalis muscles will be cut"
89446402|NCT03486132|Other|continous repair of mediolateral episiotomy|continuous knotless suturing technique (CKT) which involves placing the first stitch above the apex of vaginal trauma to secure any bleeding points that might not be visible. Vaginal wound, perineal muscles (deep and superficial), and skin are reapproximated with a loose, continuous, non-locking technique. The skin sutures will be placed closely fairly deeply in the subcutaneous tissue, reversing back and finishing with a terminal knot placed in the vagina beyond the hymeneal remnants Mediolateral episiotomy:it is defined as an incision beginning in the midline and directed laterally and downwards away from the rectum .The incision is usually about four centimeters long. In addition to the skin and subcutaneous tissues the bulbocavernosus, transverse perineal, and puborectalis muscles will be cut The standard suture material in the study will be EGYSORB (sterile coated synthetic polyglycolic acid absorbable braided suture) No 2/0
89446403|NCT03486132|Other|interrupted repair of lateral episiotomy|"using the interrupted suture (IT) which involves placing three layers of sutures: a continuous non-locking stitch to close the vaginal epithelium. commencing above the apex of the wound and finishing at the level of the fourchette; three or four interrupted sutures to reapproximate the deep and superficial perineal muscles; and interrupted transcutaneous technique to close the skin.~The standard suture material in the study will be EGYSORB (sterile coated synthetic polyglycolic acid absorbable braided suture) No 2/0 And Lateral episiotomy; It begins in the vaginal introitus 1 or 2 cm lateral to the midline and is directe downwards towards the ischial tuberosity"
89446404|NCT03486132|Other|continuous repair of lateral episiotomy|continuous knotless suturing technique (CKT) which involves placing the first stitch above the apex of vaginal trauma to secure any bleeding points that might not be visible. Vaginal wound, perineal muscles (deep and superficial), and skin are reapproximated with a loose, continuous, non-locking technique. The skin sutures will be placed closely fairly deeply in the subcutaneous tissue, reversing back and finishing with a terminal knot placed in the vagina beyond the hymeneal remnants And Lateral episiotomy; It begins in the vaginal introitus 1 or 2 cm lateral to the midline and is directe downwards towards the ischial tuberosity The standard suture material in the study will be EGYSORB (sterile coated synthetic polyglycolic acid absorbable braided suture) No 2/0
89446405|NCT02030691|Experimental|nCPAP - nHFPV|Eligible patient received after randomization nCPAP or nHFPV for 15 minutes then after the 15 minutes, they received the seconde non invasive device for 15 minutes. Study end 30 minutes after randomization or before if mechanical ventilation is required.
89446406|NCT02030691|Experimental|nHFPV - nCPAP|Eligible patient received after randomization nCPAP or nHFPV for 15 minutes then after the 15 minutes, they received the seconde non invasive device for 15 minutes. Study end 30 minutes after randomization or before if mechanical ventilation is required.
89200168|NCT00966160|Active Comparator|NNRTI|600 mg efavirenz (Sustiva tablets, Bristol-Myers Squibb) once daily plus 150 mg lamivudine (Epivir tablets, GlaxoSmithKline) and 300 mg zidovudine (Retrovir tablets, GlaxoSmithKline) twice daily over a 56-week run-in and a 420-week follow-up
89446407|NCT03481452|Experimental|psychotherapy intervention group|NBO behavioral intervention would be used to improve mother-infant dyad interaction and infants' disorders of regulation of states.
89446408|NCT03481452|No Intervention|control group|No behavioral intervention would be used.
89446409|NCT02204865||Pacemaker/ICD with ApneaScan|Patients with HFREF due to receive a pacemaker or ICD with ApneaScan function
89446410|NCT03481374|Active Comparator|subjects with Type 1 Diabetes mellitus|Type 1 diabetes patients without cardiovascular disease undergo autonomic function testing
89446411|NCT03481374|Placebo Comparator|Healthy controls|healthy people without known disease undergo autonomic function testing
89446412|NCT02214303||Allergic asthma|Allergic asthma (sensibilisation to D. pteronyssinus, 5 grass mixture allergens or birch pollen allergens)
89446413|NCT02214303||Allergic rhinitis|allergic rhinitis patients (sensibilisation to D. pteronyssinus, 5 grass mixture allergens or birch pollen allergens)
89446414|NCT02214303||Control group|Healthy subjects
89446415|NCT03481218||Patients with type 1 diabetes|Young adults (male and female) between the ages of 18 and 35, who have type 1 diabetes for at least one year.
89446416|NCT03481218||Individuals without chronic diseases|Young adults (male and female) between the ages of 18 and 35, without chronic diseases.
89446417|NCT02204943|Experimental|Bone Biopsy and Circulating Tumor Cell Samples|
89446418|NCT05153928||fibroid cases|Norethisterone acetate for 5 months
89446419|NCT05153928||adenomyosis|Norethisterone acetate for 5 months
89446420|NCT02214771||1: CDI in patients treated with fidaxomicin|Diagnosed with a CDI and treated with fidaxomicin
89446421|NCT02214771||2: CDI in patients receiving treatment other than fidaxomicin|Diagnosed with a CDI, regardless of the prescribed treatment (not fidaxomicin)
89446422|NCT02192853|Experimental|Sitagliptin|Patients with Type 2 Diabetes Mellitus and healthy control subjects are given tablets of sitagliptin in either a dosage of 25, 100 or 200 mg tablet in 3 different days.
88931412|NCT01749254||Acute Coronary Syndrome|40 patients admitted with ACS (NSTEMI/STEMI) will be recruited undergo 18F NaF PET, 18F FDG and CTCA within 1 month of the event.
89200169|NCT00766818|Experimental|1|Kaletra
89200170|NCT04009252|Experimental|Intervention Group|3D model to be printed and used as teaching tool to discuss injury with patient as well as its associated long-term outcomes and potential complications. The operative plan will also be reviewed with the patient using the model as well as post-operative course (ie rehabilitation)
89446423|NCT02192853|Placebo Comparator|placebo|
89446424|NCT05151042|Experimental|Group I|Distal segments repositioning using osteotomy/plate locating bone-borne surgical guide (wafer-less approach).
89446425|NCT05151042|Active Comparator|Group II|Distal segments repositioning using preoperative and final wafers.
89446426|NCT02215317||OSA group|Patients found to have OSA based on an overnight sleep study
89446427|NCT02215317||Non-OSA group|Patients found not to have OSA based on an overnight sleep study
89446428|NCT03131778|Active Comparator|Open Liver Resection|Conventional open liver resection trough subcostal incision
89446429|NCT03131778|Experimental|Laparoscopic Liver Resection|Pure laparoscopic liver resection without hand assistance
89446430|NCT03486054|Experimental|Experimental Arm A|Whole blood treated with amustaline and glutathione, a pathogen reduction technology (PRT), ordered and administered to study patients by their treating physicians
89446431|NCT03486054|Active Comparator|Control Arm B|Standard of Care (either red blood cells or whole blood)
88931413|NCT01749254||Stable angina cohort|40 patients with previously diagnosed coronary artery disease and listed to undergo elective coronary angiogram will be recruited. VH-IVUS will be attempted in all patients. Selected patients will undergo PET scan after stent implantation.
88931414|NCT01749267|Experimental|partial caries removal|partial caries removal only at enamel dentin junction (EDJ) without carious tissue removal at the pulpal site
88931415|NCT01749280||Abdominal Aortic Aneurysms|Patients will be recruited from the outpatient AAA surveillance population at the vascular unit in the Royal Infirmary of Edinburgh.Potential participation in the study will be completely asymptomatic from their AAA.
88931416|NCT01749306|Other|ABH001|ABH001 application plus wound care dressings.
89446432|NCT02205021||All subjects|
89446433|NCT02216643|Experimental|thrombectomy|mechanical thrombectomy with stentriever Solitaire FR® and/or thromboaspiration with Penumbra System® in patients with large vessel occlusion in cerebral anterior circulation vessels
88931417|NCT01749306|Other|Control|Control wound treatment
88931418|NCT01749319|Active Comparator|Oral Baclofen|
88931419|NCT01749319|Experimental|Intervenous baclofen|Crossover study that eacg subject is given both oral and intervenous baclofen
88931420|NCT01749332|Experimental|Pts having liver or colon surgery|Blood will be obtained from patients at the time of laparotomy for hepatic resection and/or hepatic arterial infusion pump placement, or pancreatic head resection . Blood will be drawn from a peripheral vein or artery (when an arterial catheter is present), the portal vein, and suprahepatic IVC and given to a research assistant and placed on ice followed by immediate processing. Total amount of blood drawn will not exceed fifty milliliters (50ml).
88931421|NCT01749358|Experimental|High Therapy Dose|Sixty total hours of ASAP therapy--challenging, intensive and meaningful practice of tasks of your choice in a collaborative partnership with your personal trainer (therapist).
88931422|NCT01749358|Experimental|Moderate Therapy Dose|Thirty total hours of ASAP therapy--challenging, intensive and meaningful practice of tasks of your choice in a collaborative partnership with your personal trainer (therapist).
88931423|NCT01749358|Experimental|Low Therapy Dose|Fifteen total hours of ASAP therapy--challenging, intensive and meaningful practice of tasks of your choice in a collaborative partnership with your personal trainer (therapist).
88931424|NCT01749358|Other|Active Monitoring|This is an observation only group.
89200171|NCT04009252|No Intervention|Control Group|The CT image will be shown to the patients along with teaching
89200172|NCT04036383|Active Comparator|vestibüler|vestibular exercise training
89446434|NCT02216643|No Intervention|best medical treatment|best medical treatment in patients with acute ischemic stroke with anterior circulation large vessel occlusion
89446435|NCT04574154|Experimental|FIB|ultrasound guided Fascia Iliaca Block
89446436|NCT04574154|Experimental|ESPB|ultrasound guided Erector Spinae Plane Block
89446437|NCT03481140||Control|donor site DIEP flap breast reconstruction procedure with standard wound closure with drains
89446438|NCT03481140||TissuGlu Surgical Adhesive|donor site DIEP flap breast reconstruction procedure with standard wound closure with TissuGlu Surgical Adhesive and no drains
89446439|NCT02217813|Experimental|1. Tafamidis|
89446440|NCT02217813|Experimental|2. Tafamidis|
89446441|NCT03477318||Patients undergoing screening colonoscopy|Patients undergoing first-time colonoscopy using white light with at least 1 polyp resected.
89446442|NCT05232903|Experimental|Group 1 SVF dose 0.5 x 10^6/kg Intravenous infusion (IV)|Intravenous infusion of stromal vascular fraction (SVF) dose 0.5 x 10^6/kg for 5 participants within 1 month after neurosurgical intracerebral hemorrhage (ICH) evacuation.
89446443|NCT05232903|Experimental|Group 2 SVF dose 1.0 x 10^6/kg Intravenous infusion (IV)|Intravenous infusion of stromal vascular fraction (SVF) dose 1.0 x 10^6/kg for next 5 participants within 1 month after neurosurgical intracerebral hemorrhage (ICH) evacuation.
89446444|NCT05232903|Experimental|Group 3 SVF dose 1.5 x 10^6/kg Intravenous infusion (IV)|Intravenous infusion of SVF stromal vascular fraction (SVF) dose 1.5 x 10^6/kg for final 5 participants within 1 month after neurosurgical intracerebral hemorrhage (ICH) evacuation.
89446445|NCT03484416|Active Comparator|Routine calcium|Patients in the routine calcium group received oral supplements of 1,500 mg/day elemental calcium (by calcium carbonate) and 1,000 IU/day cholecalciferol for 2 weeks, beginning on the first postoperative day
89446446|NCT03484416|No Intervention|control|Patients in the control group did not receive calcium or cholecalciferol for 2 weeks
89446447|NCT02257827|Experimental|IMRT- Hypofractionated schedule 70 Gy/25 fx|The IMRT plan consisted of five - seven fields to deliver the same dose prescribed at the isodose line covering 95% of PTV.By the linear-quadratic formula, considering an α/β ratio of 1.5 Gy for prostate cancer, 70 Gy/25 fractions is equivalent to 86 Gy in 43 fractions of 2 Gy. All patients were simulated on CT simulator.
89446448|NCT02257827|Active Comparator|3DCRT-Hypofractionated schedule 70 Gy/25 fx|The 3DCRT plan consisted of six fields to deliver a total dose of 70 Gy/ 25 fractions of a single daily dose of 2.8 Gy. By the linear-quadratic formula, considering an α/β ratio of 1.5 Gy for prostate cancer, 70 Gy/25 fractions is equivalent to 86 Gy in 43 fractions of 2 Gy. All patients were simulated on CT simulator.
89446449|NCT02257905||AL Amyloidosis patients who received allo HSCT|
89446450|NCT02219295|Experimental|sweet -block|application of different sugars, artificial sweeteners and sweet-taste antagonists in a single dose in 300 ml tap water every week up to 7 times and collection of blood samples over 3 hours
89446451|NCT02219295|Experimental|bitter block|application of purified bitter tasting ingredients of vegetables and hop in 300 ml tap water , collection of blood samples for 3h (-15,0,15,30,60,120,180 min)
89446452|NCT02219295|Experimental|umami-block|"application of glutamate and glutamate +IMP~same procedure as above"
89446453|NCT02219295|Other|gastroscopy|gastroscopy with and without oral intervention with artificial sweetener saccharin to take tissue samples from the upper bowel for the investigation of taste receptor cells in the upper bowel in human beings
89446454|NCT05153616|Experimental|Diagnostic Polysomnography|
89446455|NCT03484338|Experimental|Intervention|
89446456|NCT03484338|Active Comparator|Wait list controlled|
89446457|NCT02219529|Experimental|MCE|patients were assigned to swallow MCE first, followed by the gastroscopy
89446458|NCT02219529|Active Comparator|Standard gastroscopy|patients were assigned to swallow MCE first, followed by the gastroscopy
89446459|NCT04459494|Experimental|Test group|Patients undergoing dental implant treatment without flap removal (Test Group)
89446460|NCT04459494|Active Comparator|Control group|Patients who will receive dental implants by removing conventional full thickness flaps (Control group)
89446461|NCT02220075||spontaneous group|maintain spontaneous breathing during the operation, and recording tidal volume, ET CO2, respiratory rate, peak airway pressure, SpO2
89446462|NCT02220075||controlled group|controlled ventilation(tidal volume 8ml/kg, ET CO2 35~40mmHg) during the operation, recording peak airway pressure, SpO2
89446463|NCT02205255|Experimental|Azithromycin|N = 250 From day 1 up to and including day 3: 500 mg azithromycin PO once a day From day 4 up to and including day 90: 250 mg azithromycin PO once every 2 days
89446464|NCT02205255|Placebo Comparator|Placebo|N = 250 From day 1 up to and including day 3: 500 mg placebo PO once a day From day 4 up to and including day 90: 250 mg placebo PO once every 2 days
89446465|NCT02220153|Experimental|UCB7665 Intravenous 1|Single dose calculated based on body weight for 60 minutes intravenous infusion.
89446466|NCT02220153|Experimental|UCB7665 Intravenous 2|Single dose calculated based on body weight for 60 minutes intravenous infusion.
88931425|NCT01749371|Experimental|Early Vitamin E|Vitamin E is administered from Days 1-15 after the initial excision surgery after admission.
88931426|NCT01749371|Experimental|Delayed Vitamin E|Vitamin E is administered from Days 16-30 after the initial excision surgery after admission.
89446467|NCT02220153|Experimental|UCB7665 Intravenous 3|Single dose calculated based on body weight for 60 minutes intravenous infusion.
89446468|NCT02220153|Experimental|UCB7665 Intravenous 4|Single dose calculated based on body weight for 60 minutes intravenous infusion.
88931427|NCT01749384|Experimental|Treatment (bevacizumab, tivantinib)|Patients receive bevacizumab IV over 30-90 minutes on days -15, 1, and 15 (day -15 of course 1 only) and tivantinib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88931428|NCT01749397|Experimental|Treatment (veliparib and floxuridine)|Patients receive veliparib PO BID on days 1-10 and floxuridine IP on days 3-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
88931429|NCT01749423||All participants|Previous treatment with onabotulinumtoxinA for Chronic Migraine based on retrospective review of medical records.
88931430|NCT01749436||Lung ultrasound imaging|Lung ultrasound imaging examinations performed during the perioperative period for the monitoring of atelectasis associated with laparoscopic surgery
88931431|NCT01749449|Experimental|High protein 3 meals/day|35% protein intake eaten as 3 meals per day
88931432|NCT01749449|Experimental|High carbohydrate consumed 3 meals/day|High carbohydrate 3 meals/day
88931433|NCT01749449|Experimental|High protein consumed 6 meals/day|35% protein 6 meals/day
88931434|NCT01749462||Oxis|
88931435|NCT01749475||midazolam|
88931436|NCT01749475||hypnosis|
89446469|NCT02220153|Experimental|UCB7665 Intravenous 5|Single dose calculated based on body weight for 60 minutes intravenous infusion.
89446470|NCT02220153|Experimental|UCB7665 Subcutaneous 1|Single dose calculated based on body weight for 60 minutes subcutaneous infusion.
89446471|NCT02220153|Experimental|UCB7665 Subcutaneous 2|Single dose calculated based on body weight for 60 minutes subcutaneous infusion.
89446472|NCT02220153|Placebo Comparator|Intravenous Placebo|Single dose placebo comparator for each active arm of intravenous infusion.
89446473|NCT02220153|Placebo Comparator|Subcutaneous Placebo|Single dose placebo comparator for each active arm of subcutaneous infusion.
89446474|NCT04911582|Active Comparator|Cafestol 6 mg|6 mg cafestol
89446475|NCT04911582|Active Comparator|Cafestol 12 mg|12 mg cafestol
89446476|NCT04911582|Placebo Comparator|Placebo|Placebo
89446477|NCT03535389|Experimental|Pathologic group|Patients addressed to our imaging department for the realization of a knee scanner as part of routine care and presenting clinical PFI syndrome (Patellofemoral instability diagnosis based on physical examination, history and Kujala score)
89446478|NCT03535389|Active Comparator|Control group|"Patients addressed to our imaging department for osteo-articular pathologies other than patellofemoral instability (non-fracture trauma, vascular pathologies, degenerative or soft tissues).~Does not have any clinical PFI syndrome~Matched (1: 1 ratio) to PFI patients by age (+/- 40 years) and sex"
89446479|NCT03476772|No Intervention|A|children undergoing hypospadius repair given 1 ml/kg of bupivicaine 0.25 % via caudal route to achieve post operative analgesia
89446480|NCT03476772|Active Comparator|B|children undergoing hypospadius repair given 1 ml/kg of bupivicaine 0.25 % plus 0.1 mg nalbuphine via caudal route to achieve post operative analgesia
89446481|NCT02220231|Experimental|capnothorax group|After patient positioning, the capnothorax will be created by insufflation of carbon dioxide in patients undergoing video-assisted thoracoscopic extended thymectomy.
89446482|NCT03476694|Experimental|20ml of 0.75% Ropivacine|
89446483|NCT03476694|Experimental|25ml of 0.75% Ropivacine|
89446484|NCT02220387||occupational COPD|"Consists of 2 subgroups~COPD patients with history of exposure to respirable silica dust~COPD patients with history of exposure to polycyclic aromatic hydrocarbons exhaust"
89446485|NCT02220387||smokers with COPD and healthy control|"Consists of 2 subgroups~patients with COPD, history of tobacco smoke and no history of occupational exposure~healthy subjects"
89446486|NCT04798872|Experimental|web-based educational program|Consist of 6 education session during 1 month and will be followed up by telephone counselling at 2, 4, and 6 weeks postpartum.
88931437|NCT01749488|No Intervention|Control intensive care wards|This is a randomized cluster trial. The centers randomized into this arm will serve as controls. No interventions will be implemented for these centers.
88931438|NCT01749488|Experimental|Experimental intensive care wards|"This is a randomized cluster trial. The centers randomized into this arm will designate a dietitian who will help the ward implement current recommendations for the nutrition of patients undergoing intensive care.~Intervention: Designated dietitian for the ward"
88931439|NCT01749514|Experimental|ACE-536|Subjects assigned to 1 of 7 possible dosing groups.
88931440|NCT01749527|Other|24-hour pad test|decreased activity
88931441|NCT01749540|Experimental|ACE 536|ACE-536 - 1 of 7 possible dose levels.
88931442|NCT01749553|Experimental|sleeper stretch|
88931443|NCT01749553|No Intervention|no intervention|
88931444|NCT01749566|Active Comparator|Group A (standard maraviroc dosing)|maraviroc 300mg po bid x 7 days
88931445|NCT01749566|Active Comparator|Group B (reduced maraviroc dosing)|maraviroc 300mg po daily x 7 days
88931446|NCT01749566|No Intervention|Group C (no drug)|No additional drug
88931447|NCT01749579|Experimental|Propofol|The patients will receive propofol for sedation in addition to fentanyl
88931448|NCT01749579|Active Comparator|Midazolam|The patients will receive midazolam for sedation in addition to fentanyl
88931449|NCT01749592|Experimental|Cochlear Implant|Surgical Implantation of a Cochlear Implant
88931450|NCT01749618|No Intervention|No education or feedback|Rheumatologists randomized to this treatment arm receive no additional education or feedback about their systematic assessments of patients
88931451|NCT01749618|Experimental|Education and Feedback|Rheumatologists randomized to receive education and feedback participate in six web conferences designed to improve their systematic assessments of their patients, and are given feedback about their performances
88931452|NCT01749644||CF patients with chronic pseudomonas infection|
88931453|NCT01749670||Autism|Children ages 4-17 years old with DSM-IV defined autism spectrum disorder
88931454|NCT01749670||Control|Age- and gender-matched controls with typical neuropsychological developmental patterns
88931455|NCT01749696||Patients with pelvic organ prolapse|Patients, who were operated on because of pelvic organ prolapse.
88931456|NCT01749696||Patients without pelvic organ prolapse|Patients, who had hysterectomy due to other reasons than pelvic organ prolapse.
88931457|NCT01749722|Experimental|NaviAid™ G-Eye procedure|NaviAid™ G-Eye procedure
88931458|NCT01749748|Other|proton magnetic resonance spectroscopy|proton magnetic resonance spectroscopy for asymptomatic women breasts.
88931459|NCT01749761|Placebo Comparator|Hemodialysis without biofeedback|Patients will be randomized to receive hemodialysis without biofeedback for a period of 8 weeks.
88931460|NCT01749761|Active Comparator|BioLogic RR biofeedback|Patients will receive 8 weeks of HD with BioLogic RR Blood pressure guided biofeedback.
88931461|NCT01749774|Experimental|Physical activity counseling|
88931462|NCT01749787|Experimental|1.5 mcg/kg|PRTX-100 at 1.5 mcg/kg administered via infusion once per week for 5 weeks
88931463|NCT01749787|Experimental|3.0 mcg/kg|PRTX-100 at 3.0 mcg/kg administered via infusion once per week for 5 weeks
88931464|NCT01749787|Experimental|6.0 mcg/kg|PRTX-100 at 6.0 mcg/kg administered via infusion once per week for 5 weeks
88931465|NCT01749787|Experimental|12.0 mcg/kg|PRTX-100 at 12.0 mcg/kg administered via infusion once per week for 5 weeks
88931466|NCT01749787|Experimental|240 mcg|PRTX-100 at 240 mcg/dose administered via infusion once per week for 5 weeks then once every four weeks for 16 weeks thereafter.
88931467|NCT01749787|Placebo Comparator|Placebo|Placebo administered via infusion once per week for 5 weeks
88931468|NCT01749787|Experimental|420 mcg|PRTX-100 at 420 mcg/dose administered via infusion once per week for 5 weeks then once every four weeks for 16 weeks thereafter.
88931469|NCT01749852|Experimental|Polyphenol-rich Dark chocolate|Dark chocolate with 500 mg of polyphenols
88931470|NCT01749852|Placebo Comparator|Placebo Dark chocolate|This chocolate contains little or no polyphenols
88931471|NCT01749865|Experimental|A, CIK|Biological/Vaccine: Cytokine-Induced Killer Cells
88931472|NCT01749865|No Intervention|B, CONTROL|Regular follow up with no intervention
88931473|NCT01749878|Experimental|Group A: Cohorts 1 through 6|"Group A:~Cohorts 1 through 3 will receive REGN1500 subcutaneous (SC) or placebo Cohorts 4 through 6 will receive REGN1500 intravenous (IV) or placebo"
88931474|NCT01749878|Experimental|Group B|Group B will receive REGN1500 IV or placebo
89446487|NCT04798872|No Intervention|control (usual care)|Mothers in the control group will receive standard treatment with pamphlets during the prenatal period. After delivery, standard postpartum care will be provided by the midwife, including pamphlets, rooming in and encourage mothers to breastfeed the baby.
89446488|NCT03535233|Active Comparator|Intralesional group|intralesional triamcinolone acetonide 5 mg/ml monthly
89446489|NCT03535233|Active Comparator|Topical therapy group|Minoxidil 5% topical solution applied twice daily and topical clobetasol propionate 0.05% cream applied once daily every night
89446490|NCT04712292||Study group|Patients undergoing surgery for confirmed or suspected colorectal cancer between January 2020 and December 2021
89446491|NCT04712292||Control group|Patients undergoing surgery for confirmed or suspected colorectal cancer between January 2018 and December 2019
89446492|NCT02205411|Experimental|HeartAssist 5® VAD System|Implant of the HeartAssist 5® VAD System
89446493|NCT02205411|Active Comparator|Control VAD|
89446494|NCT02205489|Experimental|GZ402673 LEMTRADA|First course: Intravenous infusion for 5 consecutive days. Second course (will occur 12 months after the first course of treatment): Intravenous infusion for 3 consecutive days.
89446495|NCT05230719||dTRA group|Investigators perform percutaneous coronary intervention by dTRA for patients
89446496|NCT05230719||TRA group|Investigators perform percutaneous coronary intervention by conventional TRA for patients
89446497|NCT02205567||Group 2|1000 mg/day of Bergamot-derived product
89446498|NCT02205567||Group 1|500 mg/day of Bergamot-derived product
89446499|NCT02220465|Experimental|PA+ Smoking Cessation (LMPA)|This intervention integrates low-to-moderate physical activity (PA) with evidence based smoking cessation programming. Over the 4-week treatment period, the intervention (1 in-person and 3 phone counseling sessions) focuses on (a) gradually increasing routine PA during the pre-quit period and maintaining PA post quit day (b) increasing daily PA (steps/day) using a weekly tailored algorithm with the goal of achieving 10,000 steps by Week 4 (quit day) and (c) training participants to use PA as a primary urge management strategy, thereby embedding PA within evidence-based smoking cessation counseling. Other components include additional smoking urge management skills, increasing motivation to quit, overcoming barriers and maintaining PA for quitting and staying smoke-free .
89446500|NCT02220465|Active Comparator|Standard Care Smoking Counseling (SCC)|The control intervention parallels the format of the LMPA intervention with focus only on behavioral and cognitive urge management strategies (avoiding/escaping high-risk situations, stimulus control) and minimizing the probability that participants in the control group would increase increase/use PA during the intervention period. Participants are provided a pedometer without any instructions or encouragement around increasing walking/steps during the 8-week intervention period.
89446501|NCT03481062||Neutral|
89446502|NCT03481062||abduction|
89446503|NCT03481062||pad|
89446504|NCT03481062||combination|
89446505|NCT02220543|Experimental|Back on Track intervention|Back on Track intervention is a biopsychosocial primary care intervention
89446506|NCT02220543|Active Comparator|Primary care as usual|Primary care as usual comprises maximally 12 individual regular physical therapy sessions for a maximum of 8 weeks.
89446507|NCT02523846|Active Comparator|Background morphine infusion to IV-PCA Morphine|Calculate based on patient's age, in mg/hour
89446508|NCT02523846|Experimental|Patient re-education to IV-PCA Morphine|Using patient information leaflet
89446509|NCT05262699|Experimental|Stimulation|During motor training participants in the stimulation arm receive vibro-tactile feedback applied to their fingers when touching an object as measured by force-sensing resistors mounted to the fingertips.
89446510|NCT05262699|Placebo Comparator|Control|The control group receives the same motor training with the same derives (force-sensing resistors, vibro-tactile stimulators) mounted to the hands but receives no stimulation.
88931475|NCT01749878|Experimental|Group C: Cohorts 1 and 2|"Group C:~Cohort 1 will receive REGN1500 SC or placebo Cohort 2 will receive REGN1500 IV or placebo"
88931476|NCT01749891|Experimental|Arm 1.5 mg ALG - 1001|Arm 1.5 mg ALG- 1001 per 50ul
88931477|NCT01749891|Experimental|Arm 2.5 mg ALG -1001|Arm 2.5 mg ALG -1001 per 50ul
89446511|NCT03480984|Active Comparator|Programmed Intermittent Bolus|6 mL 0.2% ropivacaine hourly, starting on arrival to PACU, given via an hourly programmed bolus
89446512|NCT03480984|Active Comparator|Continuous Infusion|6 mL 0.2% ropivacaine hourly, starting on arrival to PACU, given via continuous infusion
89446513|NCT03484260||Case group: Testosterone Product|Male subjects prescribed testosterone in UK
89446514|NCT03484260||Control group|Matched male subjects not prescribed testosterone in the UK
89446515|NCT03480906|Experimental|Microdose administration|Latanoprost ophthalmic solution administered as a microdose using the Eyenovia MiDD
89446516|NCT03480906|Active Comparator|Eyedrop administration|Latanoprost ophthalmic solution administered as an eyedrop
89446517|NCT04527198|Experimental|group 1|Major patients, admitted in intensive care for a SARS-CoV-2 infection and requiring mechanical ventilation and deep sedation (with or without neuromuscular blockade)
89446518|NCT05262465|Experimental|MST for unfit|"Induction chemotherapy can use azacytidine combined with low-dose cytarabine, or azacytidine combined with BCL / 2 inhibitor, and infuse modified peripheral blood hematopoietic stem cells after chemotherapy.~Consolidation chemotherapy used azacytidine combined with low-dose cytarabine. After chemotherapy, modified peripheral blood hematopoietic stem cells were infused and repeated for 3 courses."
88931478|NCT01749891|Experimental|Arm 4.0 mg ALG -1001|Arm 3 4.0 mg ALG -1001 per 50ul
89446519|NCT02205645|Experimental|FibroFix™ Meniscus scaffold|The test article for this study is the FibroFix™ Meniscus scaffold, which has been developed for repair of defects of the meniscus. It is a silk derived product developed to functionally replace the excised unstable meniscus following a meniscal tear.
89446520|NCT02193321|Experimental|Amniotic membrane patch placement|One amniotic membrane patch will be placed on the epicardial surface of the heart immediately following a CABG procedure prior to wound closure.
89446521|NCT02193321|No Intervention|Control|Amniotic membrane patch will not be placed after CABG procedure prior to wound closure.
89200173|NCT04036383|Experimental|balance training|vestibular exercise training+ balance training with computerized balance system
89200174|NCT04036383|Experimental|square-step|vestibular exercise training+ square step exercise
89446522|NCT02220621|Experimental|Treatment|After the hysteroscopic adhesiolysis, crosslinked hyaluronic acid gel is applied into the uterine cavity, then a Foleys balloon catheter is inserted into the uterine cavity.
89446523|NCT02220621|Active Comparator|Control|After hysteroscopic adhesiolysis, a Foleys balloon catheter is inserted into the unterine cavity.
89446524|NCT04370418|Other|neoadjuvant chemo-radiation|"Short-course RT: 5 fractions of 5 Gy to a total dose of 25 Gy over 5 consecutive days. IMRT plans are generated with 6 MV photons.~Dose-escalated concurrent 5-FU: The 3 doses levels of 5-FU are 100, 150, and 200 mg/m2/d. 5-FU will be given by continuous infusion for 20 hours every day starting on the morning of radiation.~mFOLFOX: will be given 2 weeks after concurrent chemoradiation for a total of 4 cycles, with each cycle being 14 days. Surgery will be omitted in patients with complete pathological response and proceed to adjuvant chemotherapy. If patient develops progressive or metastatic disease, he/she will be omitted from the investigators study.~The surgery will be considered 4-8 weeks after end of therapy. Adjuvant mFOLFOX6: 6 cycles chemotherapy will begin between 4 weeks and 8 weeks after surgery.~Toxicities assessment: be using National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0."
89446525|NCT02220777|Experimental|1. ASP8477 and placebo|Part 1: SAD in postmenopausal females and Part 2: SAD in vasectomized male
89446526|NCT02220777|Experimental|2. ASP8477 alone|Part 3, fasted or fed
89446527|NCT02220777|Experimental|3. omeprazole alone|Part 4, Drug-Drug Interaction
88931479|NCT01749917|Active Comparator|Control group|30 people are recruited in order to the inclusion criteria for the study. The study include subjects who can complete the assessment battery of tests at the beginning and end in order to perform the control intervention.
88931480|NCT01749917|Experimental|Exercise program group|30 people are recruited, diagnosed with Parkinson attending to the Parkinson Association of Granada aged between 40 and 65 years. No sex differences. The study include subjects who can complete the assessment battery of tests at the beginning and end.
88931481|NCT01749943||EDSS Score 0-3.5|21 Subjects Total : 7 with normal to mildly limited walking
88931482|NCT01749943||EDSS Score 4.0-5.5|21 Subjects total: 7 subjects with moderately limited walking ability.
88931483|NCT01749943||EDSS Score 6.0-7.5|21 Subjects total: 7 subjects with severely limited walking ability
88931484|NCT01750008|Other|Global Fibroid Ablation|Global Fibroid Ablation
88931485|NCT01750008|Other|Laparoscopic Myomectomy|Myomectomy via laparoscopy
88931486|NCT01750021|Experimental|High fat low carbohydrate diet|High fat low carbohydrate diet
88931487|NCT01750021|Experimental|Low fat high carbohydrate diet|Low fat high carbohydrate diet
88931488|NCT01750034|Active Comparator|Closed method|Burn patients randomized to closed method of burn wound care.
88931489|NCT01750034|Experimental|Open method|Burn patients randomized to the open method of burn wound care.
88931490|NCT01750060|Active Comparator|Fentanyl citrate IV infusion & Naltrexone|Fentanyl citrate (equivalent to 80 mcg fentanyl)administered over 20 minutes by IV infusion every hour through 23.33 hours. Naltrexone (50 mg) will be administered orally (PO) every 12 hours, beginning 14 hours before the start of fentanyl treatment and ending approximately 11 hours after completion of treatment regimen to antagonize the clinical opioid effects of fentanyl.
88931491|NCT01750060|Experimental|Fentanyl Study System (170 mcAmps) & Naltrexone|Two consecutive 40 mcg fentanyl doses each delivered over 10 minutes by the Study System (170 mcAmps) every hour through 23.33 hours. Naltrexone (50 mg) will be administered orally (PO) every 12 hours, beginning 14 hours before the start of fentanyl treatment and ending approximately 11 hours after completion of treatment regimen to antagonize the clinical opioid effects of fentanyl.
88931492|NCT01750060|Experimental|Fentanyl, Study System (140 mcAmp) & Naltrexone|Two consecutive 35 mcg fentanyl doses, each delivered over 10 minutes by the Study System (140 mcAmp) every hour through 23.33 hours. Naltrexone (50 mg) will be administered orally (PO) every 12 hours, beginning 14 hours before the start of fentanyl treatment and ending approximately 11 hours after completion of treatment regimen to antagonize the clinical opioid effects of fentanyl.
88931493|NCT01750060|Experimental|Fentanyl, Study System (200 mcAmp) & Naltrexone|Two consecutive 50 mcg fentanyl doses, each delivered over 10 minutes by the Study System (200 mcAmp) every hour through 23.33 hours. Naltrexone (50 mg) will be administered orally (PO) every 12 hours, beginning 14 hours before the start of fentanyl treatment and ending approximately 11 hours after completion of treatment regimen to antagonize the clinical opioid effects of fentanyl.
88931494|NCT01750060|Experimental|Fentanyl, Study System (230 mcAmp) & Naltrexone|Two consecutive 54 mcg fentanyl doses, each delivered over 10 minutes by the Study System (230 mcAmp) every hour through 23.33 hours. Naltrexone (50 mg) will be administered orally (PO) every 12 hours, beginning 14 hours before the start of fentanyl treatment and ending approximately 11 hours after completion of treatment regimen to antagonize the clinical opioid effects of fentanyl.
89200175|NCT02558556|Experimental|NIRF-LC|"This group of patients will undergo near-infrared fluorescence cholangiography assisted laparoscopic cholecystectomy by use of a Laparoscopic Fluorescence Imaging System (Karl Storz), in combination with one intravenous injection of contrast agent ICG. The ICG is given directly after induction of anesthesia in a dose of 1 ml of 2,5 mg/ml solution.~Intraoperatively every 2-5 minutes (more often if desired by surgeon) camera is switched to ICG mode for fluorescence cholangiography, until CVS is established.~Registration of time until establishment of CVS, visualization of the individual structures as described as secondary endpoints, and total operation time will be done.~The complete procedure will be recorded on video."
89446528|NCT02220777|Experimental|4. ASP8477 + omeprazole|Part 4: Drug-Drug Interaction
89446529|NCT03484104||Hypothermic circulatory arrest|Patients undergoing cardiac surgery with hypothermic circulatory arrest and selective antegrade cerebral perfusion
89446530|NCT02205723|Experimental|Smartphone Asthma Control|Smartphone Asthma Control
89446531|NCT02205723|Active Comparator|Control|Control group
89446532|NCT03484026|Experimental|BioFe Medical Food|Consumption of BioFe Medical Food in a single cohort of up to 8 female subjects with iron deficiency.
88931495|NCT01750099|Experimental|Combined spinal-epidural|After verification of being in the intrathecal space with free-flow of cerebral spinal fluid, 1 mL of 0.25% bupivicaine along with 20 mcg of fentanyl will be injected into the intrathecal space. Subsequently, a B/Braun Perifix FX closed tip multiorifice flexible epidural catheter will be threaded 4 cm into the epidural space. After obtaining a T6 dermatomal level of sensory blockade, a standard solution consisting of 0.125% bupivicaine with 2 mcg of fentanyl/mL of solution will be started at 10 mL/hour with a patient controlled epidural analgesia (PCEA) option of 8 mL every 45 minutes. If a patient requires redosing, 5-10 mL of 0.25% bupivicaine will be injected slowly through epidural catheter with a goal dermatome level of T6. No systemic opioids will be given.
88931496|NCT01750099|Placebo Comparator|Continuous lumbar epidural|After identifying the epidural space with the loss of resistance technique, a standard flexible epidural catheter will be threaded 4 cm into the epidural space. A standard test dose of 3 mL of 1.5% lidocaine with epinephrine 1:200,000 will be given through the catheter. If positive for vascular or intrathecal placement, procedure to be repeated at different interspace. If negative, catheter will be secured and slowly dosed with 5-10 mL of 0.25% bupivicaine through epidural catheter with a goal dermatome level of T6. After obtaining the dermatome level of sensory blockade, a standard solution consisting of 0.125% bupivicaine with 2 mcg of fentanyl/mL of solution will be started at 10 mL/hour with a PCEA option of 8 mL every 45 minutes. If a patient requires redosing, 5-10 mL of 0.25% bupivicaine will be injected slowly through epidural catheter with a goal dermatome level of T6. No systemic opioids will be given.
88931497|NCT01749657|Active Comparator|Off-the-shelf Device and shoe|subjects will wear an off-the-shelf orthotic device (AirLift PTTD Brace) and standard Edge shoe (Aetrex Co) for 12 weeks
88931498|NCT01749657|Experimental|Custom Device - standard and Shoe|subjects will wear a custom (standard) orthotic device (Arizona Co) and Edge shoes (Aetrex Co.) for 12 weeks.
88931499|NCT01749657|Experimental|Custom Articulated device and Shoe|subjects will wear a custom articulated device (Arizona Co) and Edge shoe (Aetrex Co)for 12 weeks
88931500|NCT01749657|Experimental|Custom Extended Device and Shoe|subjects will wear a custom extended foot plate orthotic device (Arizona Co) and Edge shoe (Aetrex Co) for 12 weeks.
89446533|NCT02258295|Experimental|Intragel|Intragel (IBSA) has an average size of 800-1200 kDaltons. Intragel will give given with a concentration of 16mg/2cc. Each injection (2cc) injection will be given at baseline, then 2 weeks and 4 weeks from the baseline.
88931501|NCT06176599|Experimental|Shenxiao Yuning decoction|"Diabetes education~control of blood glucose; ③Control blood lipids；~Control blood pressure； ⑤Other symptomatic treatment； ⑥Shenxiao Yuning decoction：Astragalus 30g, Radix Pseudostellariae 15g, Rehmannia glutinosa 15g, Rhodiola rosea 12g，Cimicifuga 15g，Cuttlebone 15g，Poria 15g，Cicada degeneration 9g，Rheum palmatum 6g.~Usage: Decoct by the Traditional Chinese Medicine Pharmacy of the First Affiliated Hospital of Shandong First Medical University. Put 14 doses of Chinese medicine into the decoction bag, then put it into the automatic decoction machine, add 8 L of water and soak for 30 minutes, follow the standard decoction process Decoct 28 bags of Chinese medicine liquid, each bag is 200ml. Take 200ml warmly half an hour after breakfast and dinner."
88931502|NCT06176599|Active Comparator|Symptomatic treatment|Diabetes education: all study participants were given dietary guidance for diabetic nephropathy, low-fat, high-quality, low-protein diet, and restricted sodium intake; maintain emotional stability, quit smoking and alcohol, and exercise appropriately; ② control of blood glucose: all study participants routinely received hypoglycaemic treatment, hypoglycaemic measures are not limited (including oral hypoglycaemic drugs or insulin injection); (iii) Control of lipids: study participants with substandard lipids routinely receive lipid-lowering treatment; (iv) Control of blood pressure: those with blood pressure &amp;gt;140/90 mmHg should be treated with antihypertensive drugs to control blood pressure, and antihypertensive measures are not limited (CCB class, ACEI or ARB class, α, β-blockers, diuretics, etc.); ⑤ Other symptomatic treatment.
89200176|NCT02558556|No Intervention|CLC|"This group will undergo conventional laparoscopic cholecystectomy as in standard practice with no other intervention.~Registration of time until establishment of CVS, visualization of the individual structures as described as secondary endpoints, and total operation time will be done.~The complete procedure will be recorded on video.~Postoperatively, as in the NIRF-LC arm, the videos will be analysed to determine whether CVS is actually established, is the transition of the cystic duct into the gallbladder visualized? Is transition of the cystic artery into the gallbladder visualized? Furthermore, cost-minimalisation will be calculated."
89446534|NCT02258295|Active Comparator|Saline|Saline injections will be given similar to the active hyaluronic injections. Each injection (2cc) will be given at baseline, then 2 weeks and 4 weeks from the baseline.
88931503|NCT06176573|Active Comparator|First arm - Pre-operative vaginal cleansing with chlorhexidine|Had vaginal cleansing with chlorhexidine prior to cesarean section and were monitored for infectious morbidity.
88931504|NCT06176573|Active Comparator|Second arm - Post-operative vaginal cleansing with chlorhexidine|Had vaginal cleansing with chlorhexidine after cesarean section and were monitored for infectious morbidity.
88931505|NCT06176560|Experimental|Mesalazine Experimental|Mesalazine oral formulation
88931506|NCT06176560|Active Comparator|Mesalazine Comparator|Mesalazine oral formulation
88931507|NCT06176534|Experimental|A|nab-paclitaxel 130mg/m2，day 1 and day 8 Capecitabine 2000mg/m2，from day1 to DAY 14 Vinorelbine 25mg/m2，day 1 and day 8
88931508|NCT06176534|Active Comparator|B|palbociclib/Dalpiciclib Letrozole/Anastrozole/fulvestrant
88931509|NCT06176521|Other|Laparoscopic Sacrohysteropexy and Sacrocolpopexy Surgeries Performed Without Mesh|
88931510|NCT06176508|Experimental|HS-10374 Dose 1|
89200177|NCT00966316|Experimental|pathway|aspirin，Chinese herbs；acupuncture；rehabilitation；health education；
89200178|NCT00889785|Active Comparator|1 (Usual Care)|Patients will continue to review usual care in the diabetes clinic. Patients will receive monthly phone calls as an active control condition.
89538474|NCT04647383|Experimental|OSA Cohort, Sequence B: Lemborexant 10 mg + Placebo|Participants with OSA will receive one lemborexant 10 mg tablet on the night of Day 1 through Day 8 of Treatment Period 1, followed by one lemborexant-matched placebo tablet on the night of Day 1 through Day 8 of Treatment Period 2. A washout period of 14 days will be maintained between the 2 treatment periods.
88931511|NCT06176508|Experimental|HS-10374 Dose 2|
88931512|NCT06176508|Placebo Comparator|Placebo|
89446535|NCT03476616|Active Comparator|Eplerenone (-based therapy) arm|"Obese pts with hypertension, starting treatment with eplerenone 25mg twice daily (BD). ABPM wil be scheduled at wks 8, 16 and 24.~At wk 8 if mean ABPM < 130/80mm Hg will continue to monotherapy with eplerenone. If not controlled (mean ABPM > 130/80mm Hg) at wk8, amlodipine 5mg OD will be added.~At wk 16 if mean ABPM < 130/80mm Hg will continue to monotherapy with eplerenone, or dual therapy with eplerenone and amlodipine. If not controlled (mean ABPM > 130/80mm Hg) at wk16, indapamide 1,5mg OD will be added. All patients will be followed up for 24 weeks."
89446536|NCT03476616|Active Comparator|Valsartan (-based therapy) arm|"Obese pts with hypertension, starting treatment with valsartan 160mg once daily (OD). ABPM wil be scheduled at wks 8, 16 and 24.~At wk 8 if mean ABPM < 130/80mm Hg will continue to monotherapy with valsartan. If not controlled (mean ABPM > 130/80mm Hg) at wk8, amlodipine 5mg OD will be added.~At wk 16 if mean ABPM < 130/80mm Hg will continue to monotherapy with valsartan, or dual therapy with valsartan and amlodipine. If not controlled (mean ABPM > 130/80mm Hg) at wk16, indapamide 1,5mg OD will be added. All patients will be followed up for 24 weeks."
89446537|NCT02220933|Experimental|MD1003|MD1003 100mg capsules, 1 capsule tid for 24 months
89446538|NCT02220933|Placebo Comparator|Placebo|Placebo capsule, 1 capsule tid for 12 months, then switch to MD1003 100mg capsule, 1 capsule tid for 12 months
89446539|NCT04248972|Experimental|Intervention|A treatment with whole body red light therapy (NovoTHOR®) will be carried out
89446540|NCT04248972|Placebo Comparator|PLACEBO INTERVENTION|A placebo whole body red light will be carried out
89446541|NCT02205879|Experimental|pregabalin|
89446542|NCT02205879|Placebo Comparator|Placebo|
89446543|NCT05007756|Experimental|Ultraviolet B (UVB) Challenge|Participants will receive UVB (various doses) for minimal erythema dose (MED) assessment at baseline following which there will be washout period. Participants will then receive a single dose of UVB challenge dermally through Lumera Phototherapy System on Day 1, twice (2*) the MED at the challenge site with no UVB exposure at the contralateral control site.
88931513|NCT06176508|Active Comparator|tofacitinib|
88931514|NCT06176482|Experimental|Patients enrolled and surgically treated|
88931515|NCT06176456|Active Comparator|10 sessions with a frequency of 1 Hz|10 sessions with a frequency of 1 Hz with an amplitude of 120% of the evoked motor response in the projection of the left Dorsolateral prefrontal cortex 1600 pulses per session with total duration of procedure ~ 20 minutes
88931516|NCT06176456|Active Comparator|10 sessions with a frequency of 20 Hz|10 sessions with a frequency of 20 Hz with an amplitude of 120% of the evoked motor response in the projection of Dorsolateral prefrontal cortex (1600 pulses per session with total duration of the procedure ~ 20 minutes)
88931517|NCT06176456|Placebo Comparator|10 placebo sessions|The coil emits sound and tactile artifacts indistinguishable from therapeutic ones, but without a magnetic pulses.
88931518|NCT06176417|Experimental|group 1|Eight implants were placed in patients of missing single tooth / teeth in posterior mandible with subsequent horizontal ridge augmentation by decompression technique.
88931519|NCT06176417|Experimental|group 2|Eight implants were placed in patients of missing single tooth / teeth in posterior mandible with subsequent horizontal ridge augmentation by ridge splitting technique using piezosurgery.
88931520|NCT06176391|Other|single|Subjects are their own control
88931521|NCT06176326|Experimental|Implementation of the Developed Ethics Education Program|The developed education program will be implemented as a 7 week-2 hour session.
88931522|NCT06176313|Experimental|mandala|
89446544|NCT02193399|Experimental|Physiotherapy exercises|Strength exercises for the muscles proximal upper limbs and lower limbs and proprioception exercises
89446545|NCT02193399|No Intervention|Control group|Patients undergoing allogeneic transplantation without treatment of physiotherapy
89446546|NCT05262309|Experimental|Pamrevlumab|
88931523|NCT06176313|Experimental|Coping with Premenstrual Symptoms Education Group|
89200179|NCT00889785|Experimental|Intervention|The intervention will include participation in a comprehensive disease management program that includes: (1) application of treatment algorithms, (2) phone assessment from a diabetes nurse practitioner and dietician to assess barriers and promote problem solving, treatment adherence and management, and (3) a behavioral Internet-administered self-management problem solving component.
89446547|NCT05262309|No Intervention|Standard of care|
89446548|NCT03483948|Experimental|HMPL-523 & Azacitidine|HMPL-523 will be taken orally once daily continuously through a 28-days Cycle of study treatment. Azacitidine will be administered subcutaneously, beginning on Day 1 through Day 7 of each Cycle.
89446549|NCT02221011|Experimental|shock wave (three times)|E-SWT, Elettronica Pagani, Italy 3.5 bars 1500 beats in FCU, FCR 3 bars 4000 beats diffuse in intrinsic muscle Once a week for 3 weeks
88931524|NCT06176313|Experimental|Control Group|
88931525|NCT06176300|Experimental|Community A|
88931526|NCT06176300|Experimental|Community B|
88931527|NCT06176300|No Intervention|Community C|
88931528|NCT06176287|Active Comparator|High insertion torque group|Fifteen patients (eight females and seven males) with a single-tooth deficiency bilaterally in the molar region of the lower jaw were included in the study. Implant placement with high insertion torque was planned on one side of the jaw. The implant drills were applied as recommended by the company. To achieve high insertion torque, the single-use final drill from the implant box was not used in the high torque group.
88931529|NCT06176287|Active Comparator|Low insertion torque group|Fifteen patients (eight females and seven males) with a single-tooth deficiency bilaterally in the molar region of the lower jaw were included in the study. Implant placement with low insertion torque was planned on the otherside of the jaw. The implant drills were applied as recommended by the company. To achieve low insertion torque, the single-use final drill was applied two times.
88931530|NCT06176274|Experimental|the experimental group|a prehabilitation program will be applied before the surgery.
89446550|NCT02221011|Sham Comparator|Sham shock wave|E-SWT, Elettronica Pagani, Italy Sham without energy, 1500 beats in FCU, FCR and 4000 beats diffuse in intrinsic muscle
89446551|NCT02221011|Experimental|Shock wave (one time)|E-SWT, Elettronica Pagani, Italy 3.5 bars 1500 beats in FCU, FCR 3 bars 4000 beats diffuse in intrinsic muscle Only one dose
89446552|NCT02221089|Experimental|Retaron|
89446553|NCT02221089|Placebo Comparator|Placebo|
89446554|NCT03483870|Placebo Comparator|Morphine sulphate & Placebo|20 parturients under intrathecal anesthesia will receive 200 ug morphine sulphate intrathecally and 2 mL of normal saline 0.9% (placebo) IV injection preoperative.
89446555|NCT03483870|Active Comparator|Morphine sulphate & Granisetron|20 parturients under intrathecal anesthesia will receive 200 ug morphine sulphate intrathecally and 2 mL of 2 mg granisetron IV injection preoperative.
89446556|NCT02221167|No Intervention|Exclusive breastfeeding|Infants in the exclusive breastfeeding group will continue to breastfeed.
89446557|NCT02221167|Active Comparator|Donor Milk|"Infants in this arm will continue to breastfeed and will be given 10 ml of donor breast milk by syringe after each breastfeeding until their mother's milk comes in. (until the onset of lactogenesis II)"
88931531|NCT06176274|No Intervention|The Control Group|he will receive standard nursing care procedure.
88931532|NCT06176222|Experimental|Precedex Group|Drug: PRECEDEX INJ★ 2ML Dosage form: 100 mcg/ml dexmedetomidine Dosage: 0.1~0.4 mcg/kg/hr intravenous infusion Frequency and Duration: intrvenous infusion 12 hours after the surgery immediately
88931533|NCT06176222|Placebo Comparator|Placebo Group|Drug: 0.9% Normal Sline Dosage: 0.1 ml/kg/hr intravenous infusion Frequency and Duration: intrvenous infusion 12 hours after the surgery immediately
88931534|NCT06176157|Active Comparator|oral vitamin D2 group|
88931535|NCT06176157|Active Comparator|oral vitamin D3 group|
88931536|NCT06176157|Active Comparator|Parenteral vitamin D2 group|
88931537|NCT06176157|Active Comparator|Parenteral vitamin D3 group|
88931538|NCT06176144|Active Comparator|Sevoflurane group|Sevoflurane will be administered by inhalation for anesthesia maintenance. The concentration of inhaled sevoflurane will be adjusted to maintain the bispectral index (BIS) value between 40 and 60. Analgesia will be supplemented with remifentanil, sufentanil. Sevoflurane inhalation will be stopped at the end of surgery.
88931539|NCT06176144|Experimental|Desflurane group|Desflurane will be administered by inhalation for anesthesia maintenance. The concentration of inhaled sevoflurane will be adjusted to maintain the BIS value between 40 and 60. Analgesia will be supplemented with remifentanil, sufentanil. Desflurane inhalation will be stopped at the end of surgery.
88931540|NCT06176118|Experimental|Unblinded Intervention|There is no control group in this study. Only intervention group due to phase of trial and study intentions.
88931541|NCT06176092||Younger Adults (ages 20-39)|The study will examine age differences in learning to trust using laboratory tasks and surveys.
89446558|NCT02205957||Training quality|Tunisian residents in anesthesiology and intensive care
89446559|NCT02523612|Experimental|Patients with atypical lesions|
88931542|NCT06176092||Older Adults (60 and older)|The study will examine age differences in learning to trust using laboratory tasks and surveys.
88931543|NCT06176079||Part 1 (Cohort A): No injection of hyperpolarized (HP) 13C|Participants who are comprised of, primarily, healthy volunteers will undergo a standard MRI scan.
89200180|NCT02558166||Patients with shock|"Critically ill patients admitted to the intensive care unit (ICU)~with shock due sepsis/SIRS, cardiac failure or hemorrhage~age > 18 years,~noradrenalin support~< 24 hours of ICU admission~Signed informed consent"
89200181|NCT02558166||Patients without shock|"Critically ill patients admitted to the intensive care unit (ICU)~without shock, without vasopressor support and without fluid dependent circulation~age > 18 years~< 24 hours of ICU admission~Signed informed consent"
89200182|NCT00967720||Barriers, Adherence, Asthma|
89200183|NCT00966394||ADHD medication|Children with ADHD and pharmacologic treatment
89446560|NCT02221245||Patients with Esophageal Cancer|Tumor Biopsy via Ultrasound Endoscopy
89446561|NCT03483792||PCOS group|
89446562|NCT03483792||Control group|
89446563|NCT05262153|No Intervention|Periodontally healthy|
89446564|NCT05262153|Active Comparator|Periodontitis III-C|The patients were subjected to quadrant-wise full-mouth subgingival scaling and root planning under local anesthesia. The entire non-surgical periodontal treatment of periodontitis groups was completed in a total of 4 sessions in two weeks.
89446565|NCT05262153|Active Comparator|Periodontitis III-C Smoking|The patients were subjected to quadrant-wise full-mouth subgingival scaling and root planning under local anesthesia. The entire non-surgical periodontal treatment of periodontitis groups was completed in a total of 4 sessions in two weeks.
89446566|NCT02221323|Experimental|Insulin lispro|
89446567|NCT03483714||Healthy Participants|Spinal manipulation
89446568|NCT03483714||Acute Low back pain participants|Spinal Manipulation
89446569|NCT03483714||Chronic low back pain participants|Spinal Manipulation
89446570|NCT02193477|No Intervention|Control|Patients were given no TEAS.
89446571|NCT02193477|Experimental|TEAS Treatment|Patients were given 30min of TEAS before general anesthesia induction, 1th day and 2nd day after surgery.
89446572|NCT02193477|Sham Comparator|Sham TEAS|Patients were given 30min of sham TEAS before general anesthesia induction,1th day and 2nd day after surgery.
89446573|NCT03480516|Experimental|SDF arm|SDF arm is application of 38% silver diamine fluoride solution (SDF) on cavitated caries in primary molar, , cavities in anterior teeth will be applied only on additional consent obtained.
89446574|NCT03480516|Experimental|Fluoride varnish arm|Fluoride varnish arm is application of 5% sodium fluoride varnish on all surface of every tooth.
88931544|NCT06176079||"Part 1 (Cohort B): Injection of hyperpolarized (HP) 13C or HP13C-pyruvate+HP13C-urea copol"|"Participants will receive HP 13C injection, and receive an MRI scan. Imaging results will be used to optimize the hyperpolarized 13C part of the imaging procedure. Participants will also have the option of undergoing repeated dose imaging studies of HP 13C-pyruvate or HP13C-pyruvate+HP13C-urea copol, (up to a total of two injections per imaging visit separated by 15-60 minutes). Participants may be asked to fast up to 6 hours prior to the scan and the initial HP 13C MRI scan may be taken while participants are in a fasted state. Participants who have fasted will be offered up to 20 ounces (oz) of an oral glucose, fructose, or other high calorie drink (i.e. Gatorade, Coca-Cola, Ensure, etc.) to increase blood glucose levels, and a second HP 13C MRI scan will be performed after caloric intake."
88931545|NCT06176079||Part 2 (Group 1): NAFLD|"Participants with diagnosed NAFLD will receive HP 13C-pyruvate or HP13C-pyruvate+HP13C-urea copol injection optimized in Part 1 of the study as well as standard liver MRI pulse sequences."
88931546|NCT06176079||Part 2 (Group 2): NASH|"Participants with diagnosed NASH will receive HP 13C-pyruvate or HP13C-pyruvate+HP13C-urea copol injection optimized in Part 1 of the study as well as standard liver MRI pulse sequences."
88931547|NCT06176079||Part 2 (Group 3): Healthy Volunteers|"Healthy volunteers without known liver disease will receive HP 13C-pyruvate or HP13C-pyruvate+HP13C-urea copol injection optimized in Part 1 of the study as well as standard liver MRI pulse sequences."
88931548|NCT06176053|Experimental|Regular statict stretching for six weeks|Twelve patients aged 18-65, diagnosed with fibromyalgia, will be recruited to participate in a six-week, supervised, home-based stretching program. Exercises are to be performed daily (6 minutes per day) for six weeks. Adherence will be supported, and weekly contact with each participant will be maintained via a mHealth application.
88931549|NCT06176040|Experimental|TAVO101: High Dose|TAVO101 IV Infusion given as loading dose, Q2M, Q3M.
89200184|NCT00966394||ADHD without medication|Children with ADHD without pharmacologic treatment
89200185|NCT00966394||healthy|Healthy children ASA1
89446575|NCT03480516|Experimental|Combination arm|Combination arm is application of 38% silver diamine fluoride solution(SDF) on cavitated caries in primary molar, , cavities in anterior teeth will be applied only on additional consent obtained and then apply of 5% sodium fluoride varnish on all surface of every tooth.
89446576|NCT03476460|Experimental|Oral sodium chloride|Patients will receive capsules of sodium chloride and free water ingestion (for each capsule of sodium chloride, patients will take 250 ml of water, assuring a minimum ingestion of 750 ml of water) in the 48 hours prior contrast injection. Patients will take capsules of sodium chloride at a dose of 100 mg/kg during 48 hours previous the injection of contrast (48, 40, 32, 24, 16, and 8 hours), at the moment of contrast injection and 12 hours after the injection of contrast.
89446577|NCT03476460|Active Comparator|Intravenous sodium chloride|Patients will receive at hospital 3 ml/Kg of sodium chloride 0.9%, one hour previous contrast injection and 2 ml/kg during the 4 hours after contrast injection.
89446578|NCT02193555|Other|Non-presbyopic group|"Non-presbyopic group: age ranging from 7 to 39 years~At each scheduled lens fitting visit, subjects will be allocated one pair of CLs to correct their refractive error. One pair of control (Acuvue 1- Day Moist, etafilcon A) or prototype (Iteration X, etafilcon A) CLs will be allocated for each lens fitting/assessment visit. Lenses will be worn for approximately 1 hour per visit.~For each fitting visit, lenses will be fitted bilaterally."
89446579|NCT02193555|Other|Presbyopic group|"Presbyopic group: age 40 and above~At each scheduled lens fitting visit, subjects will be allocated one pair of CLs to correct their refractive error. One pair of control (Acuvue Oasys for Presbyopia, senofilcon A) or prototype (Iteration X, etafilcon A) CLs will be allocated for each lens fitting/assessment visit. Lenses will be worn for approximately 1 hour per visit.~For each fitting visit, lenses will be fitted bilaterally."
88931550|NCT06176040|Experimental|TAVO101: Medium Dose|TAVO101 IV Infusion given as loading dose and Q3M.
88931551|NCT06176040|Experimental|TAVO101: Medium Low Dose|TAVO101 IV Infusion given as loading dose and Q2M.
89446580|NCT02206113|Experimental|Standing workstation - 16 weeks|This arm, Standing workstation - 16 weeks, received the intervention of a standing workstation for 16 weeks. For the first 8 weeks, the participants were instructed how long to stand per hour for an 8 hour shift. The second 8 weeks their use was monitored for sustainability.
89446581|NCT02206113|Active Comparator|Standing workstation - second 8 weeks|This arm, Standing workstation - second 8 weeks, received the intervention of a standing workstation for 8 weeks of the study. For the first 8 weeks, the worked at their normal desks without an intervention. The second 8 weeks they received a standing workstation and their use was monitored.
89446582|NCT02221401|Experimental|Treatment A (FDC)|
88931552|NCT06176040|Experimental|TAVO101: Low Dose Control|TAVO101 IV Infusion given as loading dose and Q2M.
88931553|NCT06176014|Other|(PEKK fixed hybrid prostheses|5 implants were placed in mandibular arch by surgical guide and after 3 months the prostheses was constructed by using digital workflow
88931554|NCT06176014|Other|PFM fixed hybrid prostheses|5 implants were placed in mandibular arch by surgical guide and after 3 months the prostheses was constructed by using digital workflow until making wax pattern the casting was made.
88931555|NCT06176001|Active Comparator|Psychoeducation|Participants randomized to this arm are offered group-based psychoeducation shortly thereafter.
88931556|NCT06176001|Placebo Comparator|Waiting list|Participants randomized to this arm are placed on a waiting list for approximately 4 months and then offered group-based psychoeducation thereafter.
88931557|NCT06175988||Visceral Adiposity|No intervention to be adminstrated. Participants will be considered based on their visceral adiposity (ctageorial and continous). Visceral adiposity index is computed with BMI, waist circumference, triglyceridemia, HDL-cholesterol levels, and biological sex.
88931558|NCT06175975|Experimental|Auricular position|Experimental group: We will position the auricula back and up first while taking body temperature in pediatric patients. And then we will take body temperature without positioning.
88931559|NCT06175975|No Intervention|Without auricular position|Controlled group: We will not position the auricula first while taking body temperature. And then we will position the auricula back and up.
88931560|NCT06175949|Experimental|HRS-7085|
89200186|NCT04049292|Experimental|RTS and rehabilitation tool|Six months after ACLR, athletes will commence a standardized RTS assessment. The athlete will follow a standardized, sport-specific progression protocol designed to increase athletic confidence and trust in the knee during sports. Readiness to return to full, unrestricted practice will be determined based on 7 time-based, load-based, clinical and functional criteria. If the athlete fails any of the criteria, he or she will continue to participate in restricted practice. Depending on which of the specific criteria the athlete fails, a targeted treatment plan will be developed. Standardized protocols for effusion management, knee control and strength training will be triggered if the athlete fails the criteria for knee joint effusion, hopping and muscle strength, respectively. The RTS assessment and development of the targeted treatment plan will be repeated every 2 months until the athlete is cleared to RTS, up to a maximum of 12 months after ACLR.
89446583|NCT02221401|Active Comparator|Treatment B (single agents)|
89446584|NCT03483636|Experimental|Lemborexant|Participants will be randomized to receive a 10 milligram (mg) lemborexant tablet administered with 50 milliliter (mL) water followed by a total volume of 300 mL (approximately 150 mL per aliquot) of a low-calorie beverage (e.g., cranberry beverage) after an overnight fast of at least 8 hours and a sleep period of at least 8 hours. Treatment will be administered after a light breakfast (ie, not high fat), at approximately 120 minutes after wake time in the morning.
88931561|NCT06175949|Placebo Comparator|HRS-7085 simulant|
88931562|NCT06175936|Experimental|Laughter yoga group|"Laughter yoga will be applied to the intervention group in 6 sessions (45 minutes each session). Laughter yoga consists of four parts. Firstly, it starts with warm-up exercises including hand clapping (applause), singing ho ho ha ha to relax the facial muscles of the participants and body movements. Secondly, the lungs are prepared with breathing exercises and the mind is prepared for laughter with childish games. This is followed by laughter exercises. Deep breathing exercises are performed between laughter exercises. Laughter yoga is concluded with clapping, singing and relaxation exercises."
88931563|NCT06175936|No Intervention|Control group|No laughter yoga intervention will be applied to the control group.
88931564|NCT06175910|Active Comparator|percutaneous nephrolithotomy|60 patients were undergone percutaneous nephrolithotomy, three patients were lost in follow up and one case was excluded due to stricture urethra. So, the investigators analysed 56 patients
88931565|NCT06175910|Active Comparator|retrograde intrarenal surgery|60 patients were undergone retrograde intrarenal surgery, one patient was lost in follow up and one case was aborted due to narrow ureter & DJ was applied. So, the investigators analysed 58 patients.
88931566|NCT06175897|Experimental|surgical group|Undergoing DBS
88931567|NCT06175897|Sham Comparator|control group|Undergoing non-DBS
88931568|NCT06175871|Experimental|Otago exercises|"OTAGO program - based on very specific exercises for balance, force, and muscular endurance as well as on education about the risk of falling. The program is considered as home care (exercises to be done at home) but will be done as a group and with supervision, at CIUSSS or from outdoor and nature intervention (recreactional parks). OTAGO session lasts for 30-40 minutes and will be done twice a week at sites with progression. The program is comprised of 5 muscle strengthening exercises and 12 postural balance exercises. Participants will also be invited to walk 2 times per week for 30 minutes (can be divided into shorter periods, for example 3 blocs of 10 minutes) from outdoor sites or recrative parks. According to each person's strength and mobility, exercises will be increased with the use of free weights (for example during squats) and/or by increasing the number of repetitions. Total duration of the program will be 3 months (i.e., a duration adapted to the site)."
88931569|NCT06175871|Active Comparator|Conventional physiotherapy at Hospital|This group will be for the conventional type of intervention already in place in geriatric services from La Baie Hospital. This therapy used for physiotherapists at site, including mobility exercices.
88931570|NCT06175858|Other|Population with echocardiographic or clinical red flags for cardiac amyloidosis|The study aims at including all population with the previously described red flags
89446585|NCT03483636|Experimental|Lemborexant Plus Alcohol|Participants will be randomized to receive a 10 mg lemborexant tablet administered with 50 mL water followed by alcohol (0.6 grams per kilogram [g/kg] of alcohol for females or 0.7 g/kg of alcohol for males) for a total volume of 300 mL (approximately 150 mL per aliquot) of a low-calorie beverage (e.g., cranberry beverage) after an overnight fast of at least 8 hours and a sleep period of at least 8 hours. Treatment will be administered after a light breakfast (ie, not high fat), at approximately 120 minutes after wake time in the morning.
88931571|NCT06175845|Active Comparator|Arm A: ablation arm|Systemic chemotherapy and bile duct stenting with intraductal RFA of malignant bile duct obstructions employing a CE-certified ablation catheter prior to stent placement.
88931572|NCT06175845|No Intervention|Arm B: control arm|Systemic chemotherapy and bile duct stenting without RFA.
88931573|NCT06175819|Experimental|Manuka nanoformulation group|This group will apply Manuka honey ( MgO 850, UMF+20) nanoformulation on the face lesions 2 times daily for 28 days or cure of lesions (Arm 1)
88931574|NCT06175819|Experimental|Manuka honey gel group|This group will apply Manuka honey ( MgO 850, UMF+20) gel on the face lesions 2 times daily for 28 days or cure of lesions (Arm 2)
89200187|NCT04049292|Active Comparator|Usual care|Athletes will receive usual care as determined by their treating health care professional
89200188|NCT00892827|Experimental|Single Arm Study|Rituximab
89538475|NCT04647383|Experimental|COPD Cohort, Sequence C: Placebo + Lemborexant 10 mg|Participants with COPD will receive one lemborexant-matched placebo tablet on the night of Day 1 through Day 8 of Treatment Period 1, followed by one lemborexant 10 mg tablet on the night of Day 1 through Day 8 of Treatment Period 2. A washout period of 14 days will be maintained between the 2 treatment periods.
89446586|NCT03483636|Experimental|Alcohol|Participants will be randomized to receive a 10 mg lemborexant-matched placebo tablet administered with 50 mL water followed by alcohol (0.6 g/kg of alcohol for females or 0.7 g/kg of alcohol for males) for a total volume of 300 mL (approximately 150 mL per aliquot) of a low-calorie beverage (e.g., cranberry beverage) after an overnight fast of at least 8 hours and a sleep period of at least 8 hours. Treatment will be administered after a light breakfast (ie, not high fat), at approximately 120 minutes after wake time in the morning.
89446587|NCT03483636|Placebo Comparator|Placebo|Participants will be randomized to receive a 10 mg lemborexant-matched placebo tablet administered with 50 mL water followed by alcohol for a total volume of 300 mL (approximately 150 mL per aliquot) of a low-calorie beverage (e.g., cranberry beverage) after an overnight fast of at least 8 hours and a sleep period of at least 8 hours. Treatment will be administered after a light breakfast (ie, not high fat), at approximately 120 minutes after wake time in the morning.
89446588|NCT02206191||Mothers of 6-11 year olds|
89446589|NCT03483558|Experimental|Control|Participants were fed a standardized diet (without any vegetables) in this experiment.
88931575|NCT06175819|Active Comparator|clindamycin commercial gel|This group will apply clindamycin commercial gel (Clindamycin 1%gel,European pharmaceuticals, Alex, Egypt) on the face lesions 2 times daily for 28 days or cure of lesions (Arm 3)
88931576|NCT06175806|Experimental|arm I (group A) who will receive dispersible film ondansetron|arm I (group A) who will receive dispersible film ondansetron in a dose of 4 mg for those who will weigh more than 15 Kg up to 30 kg, and 8 mg for those who will weigh more than 30 Kg. The dose will be repeated if the patient had another vomiting episode within 15 minutes of taking the medicine.
88931577|NCT06175806|Experimental|Arm II (group B) who will receive oral Granisetron|Arm II (group B) who will receive oral Granisetron in a dose of 40 microgram/kg/dose; the dose could be repeated if needed after 12 hours.
88931578|NCT06175754|Active Comparator|Laser|"to take photo of problem area in the patient's standing position in the room with artificial lighting using the Canon SX510 HS from a distance of 50 cm.~to measure the maximum diameter of telangiectasia using the Ultrasound Mindray M7 .~to treat the reticular vein by the Nd:YAG laser with a wavelength of 1064 nm, a 7 mm spot, pulse length of 50 msec and fluency 140 J/cm2"
88931579|NCT06175754|Active Comparator|Laser with Sclerotherapy|"to take photo of problem area in the patient's standing position in the room with artificial lighting using the Canon SX510 HS from a distance of 50 cm.~to measure the maximum diameter of telangiectasia using the Ultrasound Mindray M7 .~to treat the reticular vein by the Nd:YAG laser with a wavelength of 1064 nm, a 7 mm spot, pulse length of 15 msec and fluency 70 J/cm2 to inject the 0.3% foam polidocanol with a 5 ml luer-lock syringe through 30 G needle into reticular vein until the vessel disappears."
88931580|NCT06175754|Active Comparator|Sclerotherapy|"to take photo of problem area in the patient's standing position in the room with artificial lighting using the Canon SX510 HS from a distance of 50 cm.~to measure the maximum diameter of telangiectasia using the Ultrasound Mindray M7 .~to inject the 0.5% foam polidocanol with a 5 ml luer-lock syringe through 30 G needle into reticular vein until the vessel disappears."
88931581|NCT06175741|Placebo Comparator|Control group|this group will receive erector spinae plane block only(bupivicaine)
88931582|NCT06175741|Experimental|Interventional 3mg|this group will receive erector spinae plane block (bupivicaine and 3mg morphine)
88931583|NCT06175741|Experimental|Interventional 5mg|this group will receive erector spinae plane block (bupivicaine and 5mg morphine)
88931584|NCT06175728|Experimental|Use of S-Press|Use of the S-Press during in patient stay alongside usual physiotherapy sessions
88931585|NCT06175702||Complete molecular response and low risk genetics|Patients in Complete Remission and Complete Molecular Response at end Induction therapy will receive consolidation with imatinib (or dasatinib if intolerance) and chemotherapy, unless they show the IKZF1plus genotype, which will imply switch to the not complete molecular response or high-risk genetics (IKZ1plus) group.
88931586|NCT06175702||Not complete molecular response or high-risk genetics (IKZF1plus)|Patients in Complete Remission and without Complete Molecular Response at the end of Induction therapy or showing the IKZF1plus genotype, will receive consolidation treatment with ponatinib and chemotherapy followed by allogeneic stem cell transplantation and maintenance therapy.
88931587|NCT06175676|Experimental|HBCS group|Apply HBCS to the anastomosis of the nasal mucosal flap and the dacryocyst mucosal flap
88931588|NCT06175676|Experimental|HBCS+5-FU group|Inject 0.3ml of 5-FU solution (25mg/ml) into the nasal mucosa around the anastomosis, and apply HBCS to the anastomosis of the nasal mucosal flap and the dacryocyst mucosal flap
89446590|NCT03483558|Experimental|Spinach|Participants were fed a standardized diet with 200g spinach in this experiment.
89446591|NCT03483558|Experimental|Celery|Participants were fed a standardized diet with 200g celery in this experiment.
89446592|NCT03483558|Experimental|Onion|Participants were fed a standardized diet with 200g onion in this experiment.
89446593|NCT03483558|Experimental|Mixed Vegetables|Participants were fed a standardized diet with 200g of mixed vegetables (spinach, celery, and onion) in this experiment.
89446594|NCT02221479|Active Comparator|Granulocyte colony-stimulating factor (G-CSF) alone|G-CSF administered up to 8 days
89446595|NCT02221479|Experimental|G-CSF plus plerixafor|G-CSF administered up to 8 days (Day 1 to Day 8) and plerixafor administered for 4 days (Day 4 to Day 7)
89446596|NCT03476382|Experimental|Experimental Group|Participants use active Ultrasound Bone Growth Stimulator device according to Investigational Protocol.
89446597|NCT02206269||Alair System|This is a single arm study with Alair system used.
89446598|NCT03476304|Experimental|Semi-direct composite endocrown restorations|
89446599|NCT03476304|Active Comparator|Post retained direct composite restoration|
88931589|NCT06175676|Active Comparator|Gelatin Sponge group|Apply gelatin sponge sheet covered with thrombin and tobramycin and dexamethasone ophthalmic ointment to the anastomosis of nasal mucosal flap and dacryocyst mucosal flap
89446600|NCT03476304|Active Comparator|Post retained ceramic restoration|
88931590|NCT06175663||Cross-sectional study|To examine if there are cerebral abnormalities present following hypertension before MRI markers of SVD have manifested, we will do high-resolution 3T MRI in 100 young (18-40 years) hypertensive adults.
88931591|NCT06175663||Longitudinal study|In a cohort study, we will examine the effects of an increase and decrease in blood pressure on the brain. For this analysis, we will include hypertensive patients that are referred to the Radboudumc Department of Internal Medicine for a diagnostic work up on the cause(s) of their hypertension. The diagnostic procedure entails withdrawal of antihypertensives for approximately four weeks, as per the routine diagnostic protocol to allow for diagnosis of the cause of hypertension, and subsequent restart of treatment until the target blood pressure is reached (normotension). Measurements are performed just before antihypertensive medication is withdrawn (baseline), approximately four weeks after withdrawal (T=1), once patients have reached their target blood pressure and blood pressure is stable, estimated to occur within 2-4 months (T=2) and approximately 1 year after T=2 (T=3).
88931592|NCT06175650||Female|Female patients undergoing cardiac surgery
88931593|NCT06175650||Male|Male patients undergoing cardiac surgery
88931594|NCT06175624|Active Comparator|Clinical Healthy|Our study will include 25 people with clinically healthy patients.
88931595|NCT06175624|Experimental|Gingivitis|Our study will include 25 people with gingivitis patients.
88931596|NCT06175624|Experimental|Periodontitis|Our study will include 25 people with periodontitis patients.
88931597|NCT06175598||Acquire Aganglionosis (AA)|
88931598|NCT06175598||Intestinal Dysmotility (ID)|
88931599|NCT06175598||Anastomotic Complications (AC)|
89200189|NCT00766896|Active Comparator|Aspirin Sensitive|"For PFA-100 using a cartridge with C-EPI (collagen-epinephrine): occlusion time >= 150 seconds~Chrono-Log Model 700 Whole-Blood: < 1Ω with 0.75 mM of arachidonic acid~Chrono-Log Model 700 Whole-Blood: with collagen at 1 mg/L and 5 mg/L, according to the formula 1 - (Rate of aggregation with 1 mg / Rate of aggregation with 5 mg) > 0.50~Chrono-Log Model 700 Whole-Blood: with collagen at 1 mg/L < 10Ω~Plateletworks: aggregation <60% with arachidonic acid will be considered sensitive~VerifyNow Aspirin Assay (Accumetrics): < 550 aspirin reaction units (ARUs)~Impact-R (Diamed) < 3.2% platelet aggregates on the surface of the plate after incubation with arachidonic acid"
89446601|NCT02224833|Experimental|Intervention|
89446602|NCT02224833|No Intervention|Control|
89446603|NCT02221635||rTMS+Risperidone|Intensity of 120% of individually determined motor threshold; frequency : 1 Hz; 360 impulsions; on period : 1 min; off period : 30 s.5 sessions per week for 4-6 weeks,than 2 sessions per week for 2 months, repeat that for 12 months.At the same time,risperidone (2-4mg) was took orally.
89446604|NCT02221635||Risperidone|Risperidone (2-4mg) was took orally.
89446605|NCT04832334||Stroke Participants|Stroke patients with hemiplegia or chronic hemiparesis
89446606|NCT04832334||Healthy Participants|The healthy control group was matched with stroke participants in terms of age, gender, dominant side and education level.
88931600|NCT06175598||Intestinal Neurodevelopmental Impairment (INI)|
88931601|NCT06175598||Incomplete Resection of Affected Intestinal Segments (IRAIS)|
88931602|NCT06175585||traditional nursing group|
88931603|NCT06175585||narrative nursing group|
88931604|NCT06175572||NCF cohort|Normanl coronary-flow patients referred to coronary angiography and undergo assessment with single photon emission computed tomography imaging (SPECT).
88931605|NCT06175572||CSF cohort|Coronary slow-flow patients referred to coronary angiography and undergo assessment with single photon emission computed tomography imaging (SPECT).
88931606|NCT06175572||ANOCA cohort|Angina with nonobstructive coronary artery patients referred to coronary angiography and undergo assessment with single photon emission computed tomography imaging (SPECT).
88931607|NCT06175572||INOCA cohort|Ischemia with nonobstructive coronary artery patients referred to coronary angiography and undergo assessment with single photon emission computed tomography imaging (SPECT).
88931608|NCT06175559|Experimental|Healing Town: Embedded Narrative in Interactive Game Design|"The game-based medication intervention game Wanping Town in this study employed a multidisciplinary participatory design approach rooted in narrative theory and behavioral psychology models. The game consists of two perspectives: narrative decision stories and cognitive games. The investigators initially employed participatory design methods to determine the plot and elements within the game, then embedded the conclusions into the therapeutic elements of the game."
88931609|NCT06175533|Experimental|plantar fasciitis|
88931610|NCT06175520|Experimental|Preconception care (PCC) intervention|There will be 12 clusters under the PCC intervention arm. Eligible participants (newlywed women) in PCC intervention areas will be followed up prospectively. The investigators will enroll around 2,500 participants residing in the study area and with no intention to relocate in the next 2 years. Under this arm, all the relevant healthcare providers and their line managers will be provided training on preconception care. Healthcare providers will enroll the participants using their couple registrars to provide preconception care.
88931611|NCT06175520|No Intervention|Comparison area|There will be 12 clusters under the comparison arm. Eligible participants will receive services through the existing health system.
88931612|NCT06175507|Experimental|Naltrexone|Naltrexone 50mg orally once daily will give for 12 weeks
88931613|NCT06175507|Active Comparator|Baclofen|Baclofen 10mg orally thrice daily will give for 12 weeks
88931614|NCT06175481||control group|
88931615|NCT06175481||experimental group|
88931616|NCT06175468|Placebo Comparator|Placebo control group|take the placebo drug 5g/bag、three times a day, treatment for 5 days
88931617|NCT06175468|Active Comparator|Treatment group|take the Formosa 1-Breath Free (NRICM101) 5g/bag、three times a day, treatment for 5 days
89446607|NCT02224911||Laser Interstitial Thermal Therapy|This is a minimally invasive procedure for focal treatment of prostate cancer.
89446608|NCT03483480|Experimental|Non powered-NPWT|
89446609|NCT03483480|Active Comparator|Open Technique|
89446610|NCT02230917|Experimental|Sotatercept|Sotatercept 0.2 mg/kg will be administered every 21 days for 12 doses subcutaneously into the upper arm, abdomen or thigh.
89446611|NCT02230917|Placebo Comparator|Placebo|0.2 mg/kg of normal saline will be administered subcutaneously in the upper arm, abdomen or thigh for 21 days for 12 doses.
89446612|NCT02221713||Group A: perforated diverticulitis|Patients with acute diverticulitis will be recruited from the A&E department at King's, prior to commencement of antibiotics. Rectal swabs will be obtained from patients with a chief complaint of acute abdominal pain upon initial assessment, prior to initial antibiotics. All specimens will be initially frozen, but only patients specimens with an admitting diagnosis of acute diverticulitis and colonic imaging (CT imaging or visualization at surgery) will be analysed. This group will include patients with perforated diverticulitis (i.e., Hinchey III or IV).
89446613|NCT02221713||Group B: unperforated diverticulitis|Patients with acute diverticulitis will be recruited from the A&E department at King's, prior to commencement of antibiotics. Rectal swabs will be obtained from patients with a chief complaint of acute abdominal pain upon initial assessment, prior to initial antibiotics. All specimens will be initially frozen, but only patients specimens with an admitting diagnosis of acute diverticulitis and colonic imaging (CT imaging or visualization at surgery) will be analysed. This group will include patients with unperforated diverticulitis (Hinchey I or II).
89446614|NCT02221713||Group C: asymptomatic diverticulosis|Patients with asymptomatic diverticulosis will be recruited from the 2-week wait (2ww) colorectal cancer pathway. Patients presenting with a chief complaint of fresh PR bleeding, with no other complaints, will be recruited prior to diagnostic imaging, either by CT, CT colonography, or endoscopy. They will provide a stool sample or rectal swab prior to bowel cleansing, if required for their evaluation, as that may alter the microbiome. Those patient samples with diverticulosis (and or haemorrhoids, as the other most common cause of fresh PR bleeding) will be analysed.
89446615|NCT02221713||Group D: normal controls|Patients with or without haemorrhoids, and no other colonic pathology will be recruited from the 2ww colorectal cancer pathway. These will be the normal controls. Patients presenting with a chief complaint of fresh PR bleeding, with no other complaints, will be recruited prior to diagnostic imaging, either by CT, CT colonography, or endoscopy. They will provide a stool sample or rectal swab prior to bowel cleansing, if required for their evaluation, as that may alter the microbiome. Those patient samples with diverticulosis (and or haemorrhoids, as the other most common cause of fresh PR bleeding) will be analysed.
89446616|NCT02224989|Experimental|Mind-Body Bridging|An awareness training program using mindfulness-based techniques.
89446617|NCT03483402|Experimental|PEXG treated with MLT|Patients with pseudoexfoliation glaucoma (PEXG) under prostaglandine analogue monotherapy with inadequate IOP control treated with 360-degrees 532nm micropulse laser trabeculoplasty (MLT)
89446618|NCT02723864|Experimental|M6620 (VX-970)|M6620 will be administered intravenous (IV) on Days 2 and 9 of each 21-day cycle; Veliparib will be administered orally twice a day (BID) Days 1-3 and 8-10 of each cycle; Cisplatin will be administered at 40 mg/m^2 IV Day 1 (and Day 8 from dose level 3 onwards) of each cycle
89446619|NCT02221791|Active Comparator|Pure Epicatechin|Participants will consume 100mg of epicatechin (capsule) + 70g white chocolate
89446620|NCT02221791|Active Comparator|High flavan-3-ol cocoa|Participants will consume 70g high flavan-3-ol cocoa (100mg epicatechin) + placebo capsule
89446621|NCT02221791|Placebo Comparator|Placebo|Participants will consume 70g white chocolate + placebo capsules
89446622|NCT03476148|Experimental|Interactive Device Rehabilitation|
89446623|NCT03476148|Active Comparator|Inpatient Rehabilitation|
89446624|NCT03476070||AYA cancer patients|Patients (aged between 15-39) diagnosed with breast cancer, lymphoma or germ cell tumor
89446625|NCT03476070||Healthy controls|Healthy controls
89446626|NCT02231073|Experimental|Exercise: Agility Boot Camp-Cognitive|Subjects will participate in an 80-minute, group (6 per group) exercise session led by a certified exercise trainer knowledgeable in the Agility Boot Camp-Cognitive (ABC-C) program for 3x/week for 6 weeks. The exercise protocol is an adaptation of our Agility Boot Camp (ABC) exercise program for PD. The exercises are designed as a circuit to challenge movement-skills known to be impaired in PD. Stations will include: Gait training, PWR Moves ©, Agility course, Lunges, Boxing and Tai Chi. Each activity was chosen for its inherent focus on multi-directional movements, dynamic postural transitions, axial mobility, big movements and whole body motor sequencing. Each station (10-20 minutes) has 3 possible progression levels, based on: (1) divided attention with secondary cognitive tasks, (2) response inhibition, (3) limiting external sensory cues, and (4) increasing speed and resistance.
89446627|NCT02231073|Active Comparator|Education: Living with Parkinson's disease|The Education arm is a chronic disease education program to teach patients how to live better with their chronic condition. It was developed by our research team to be specific for people with Parkinson's disease. It will include content and discussion of topics such as sleep, nutrition, and medication management. Classes will consist of a group of subjects (up to 6) meeting with the trainer for 90-minute session, once a week for six weeks. In order to match dose of the education intervention with the exercise intervention, participants will be provided relaxation tapes to be used at home 5 times per week for 30 minutes for an overall education dose of 240 minutes; similar to the exercise dose.
89538476|NCT04647383|Experimental|COPD Cohort, Sequence D: Lemborexant 10 mg + Placebo|Participants with COPD will receive one lemborexant 10 mg tablet on the night of Day 1 through Day 8 of Treatment Period 1, followed by one lemborexant-matched placebo tablet on the night of Day 1 through Day 8 of Treatment Period 2. A washout period of 14 days will be maintained between the 2 treatment periods.
88931618|NCT06174051|Experimental|FF EMDR|Subjects in this group will receive two EMDR treatment sessions following the flashforward protocol.
88931619|NCT06174051|Active Comparator|FB EMDR|Subjects in this group will receive two EMDR treatment sessions following the flashback protocol.
89446628|NCT05138757|Experimental|Treatment Group|Subjects who meet inclusion criteria will be randomized 1:1. The treatment group will receive prebiotic therapy for 30 days, then subjects will start peanut oral immunotherapy (POIT) in addition to the prebiotic. Subjects will continue through a prescribed course of POIT for approximately 180 days. After completion of POIT up-dosing, subjects will continue on maintenance POIT plus prebiotic therapy for an additional 180 days at which time they will undergo a DBPCFC. Subjects will then stop prebiotic therapy and continue on maintenance POIT in extended observation for approximately 4 years.
89446629|NCT05138757|Placebo Comparator|Control Group|Subjects who meet inclusion criteria will be randomized 1:1. The control group will receive placebo therapy for 30 days, then subjects will start peanut oral immunotherapy (POIT) in addition to the placebo. Subjects will continue through a prescribed course of POIT for approximately 180 days. After completion of POIT up-dosing, subjects will continue on maintenance POIT plus placebo for an additional 180 days at which time they will undergo a DBPCFC. Subjects will then stop placebo and continue on maintenance POIT in extended observation for approximately 4 years.
89446630|NCT04659824||Healthy|
89446631|NCT03483168|Experimental|Culturally sensitive pain education|
89446632|NCT03483168|Active Comparator|Standard pain education|
89446633|NCT02231151|Experimental|Pediatric Acute Care Professionals|Individuals must work in ER or ICU setting regularly or rotate through this setting with up to date BLS/PALS/ACLS certification. The participants will be required to rate the CPR based on accuracy for each video shown. The type of CPR error(s) shown to the individuals will be randomized.
89446634|NCT05259618||Patients with elevated alanine transaminase (ALT)|patients with alanine transaminase (ALT) > 3x upper limit of normal (ULN).
89446635|NCT02231229|Experimental|PCR-based strategy|PCR-based strategy: after testing for isoniazid and rifampin resistance using a molecular testing with PCR (GenoType ®MTB DR plus), patients will receive HRZ combination therapy (INH , RIF, PZA) if no resistance is detected
89446636|NCT02231229|Active Comparator|conventional therapy|Conventional therapy: based on the standard of care in France: initiation of the standard 4 drug regimen INH, RIF, PZA, and EMB, until drug susceptibility testing (DST) results are available.
89446637|NCT02523456|Experimental|Introduce EWS and Training on EWS|The group of patients who admitted to a ward where the staff has trained on EWS and EWS has been introduced.
89446638|NCT02523456|No Intervention|EWS not introduced|The group of patients who admitted to a ward where the staff has no special training on EWS and EWS has not been introduced.
89446639|NCT02225067|Experimental|C13-CAC|
89446640|NCT00705146|Active Comparator|Comfort Cool Splint|Comfort Cool(TM) splint, a prefabricated neoprene splint, fit according to the participant's size (S, M, M+, L). Participants instructed to wear the splint when symptomatic, during manual tasks, and at night if desired. Used for 4 weeks.
88931620|NCT06174051|No Intervention|Control group|Subjects in this group will not receive any treatment until the wait list period (4 weeks) is over
88931621|NCT06171425||DPAH group|patients with diffuse parenchymal lung diseases
88931622|NCT06171425||control group|aged matched healthy patients
88931623|NCT06170840|Placebo Comparator|QY101 placebo ointment|40 subjects use QY101 placebo ointment twice daily for 12 weeks
89446641|NCT00705146|Active Comparator|Hybrid Custom-made splint|The Hybrid splint was based on Pat McKee's custom-made splint design, fabricated from neoprene and 1.6 mm Rolyan Aquaplast Watercolors (Bollingbrook, IL). Participants were instructed to wear the splint when symptomatic, during manual tasks, and at night if desired. Splint was worn for 4 weeks.
89446642|NCT03475914||Psoriasis vulgaris|Pathological conditions stable for at least 1 month before collection. One punch biopsy from each patient, was taken from a big reddish and scaly plaque and another punch biopsy from the perilesional healthy skin.
89446643|NCT03475914||Psoriasis guttate|One punch biopsy from each patient, was taken from a small reddish and scaly plaque and another punch biopsy from the perilesional healthy skin.
88931624|NCT06170840|Experimental|0.3% QY101 ointment|60 subjects use QY101 placebo ointment twice daily for 12 weeks
88931625|NCT06170840|Experimental|1.0 % QY101 ointment|60 subjects use1.0 % QY101 ointment twice daily for 12 weeks
88931626|NCT06169800|Experimental|MPFL repair with Biobrace augmentation|Patients presenting with first-time lateral patellofemoral dislocation within the previous 7 days will be offered a patellofemoral stabilization procedure, including knee arthroscopy and an MPFL repair augmented with Biobrace® synthetic ligament.
88931627|NCT06169761||Healthy adults|Healthy adults of 18 years and older will fill out the STOP-BANG Questionnaire and undergo protrusive motor skills measurements.
88931628|NCT06168617|Experimental|Pilot phase|5 patients of both 3 groups will perform the parametric studying tasks. This phase aims at determine the feasibility of the tasks according to their parameters : Guided walk, visuo-manual task and posturography.
88931629|NCT06168617|Experimental|Validation phase|20 patients of both 3 groups will perform these performance tasks. This phase is designed to evaluate the performance tests executed by patients in real-life situations.
88931630|NCT06168214|Active Comparator|Rabeprazloe+bismuth+amoxicillin+clarithromycin 14days|14D: PPI: Rabeprazole 10mg bid; B: bismuth potassium citrate240mg bid/ colloidal bismuth pectin 300mg bid/ colloidal bismuth tartrate 220mg bid; A:amoxicillin1000mg bid; C: clarithromycin 500mg bid.
88931631|NCT06168214|Experimental|Vonoprazan+amoxicillin+clarithromycin 14 days|14D: V: vonoprazan 20mg bid; A:amoxicillin1000mg bid; C: clarithromycin 500mg bid.
88931632|NCT06168214|Experimental|Vonoprazan+amoxicillin+clarithromycin 7 days|7D: V: vonoprazan 20mg bid; A:amoxicillin1000mg bid; C: clarithromycin 500mg bid.
88931633|NCT06168214|Experimental|Vonoprazan+tetracycline+furazolidone 14 days|14D: V: vonoprazan 20mg bid; T: tetracycline 500mg tid; F: furazolidone 100mg bid.
88931634|NCT06168214|Experimental|Vonoprazan+tetracycline+furazolidone 7 days|7D: V: vonoprazan 20mg bid; T: tetracycline 500mg tid; F: furazolidone 100mg bid.
89014038|NCT05890677|Active Comparator|Group B: Conservative Complex Physical Decongestion Therapy (control group)|CDT (Conservative Complex Physical Decongestion Therapy) will be performed as in usual care, following the pragmatic study design. The key aspects like frequency of lymphatic drainage, time when lymphatic drainage is performed and time and class of compressive garments are used will be documented. CDT incorporates two stages of treatment. The first treatment phase (intensive phase) entails skincare, MLD (manual lymphatic drainage), exercises aimed at improvement of mobility/range of motion in the shoulder, elbow or wrist joints, and compression therapy through bandaging. Most patients undergo this phase shortly after the diagnosis of LE. CDT in the second phase (maintenance phase) aims to maintain the achieved limb volume/ circumference reduction through compression with therapeutic elastic compression garment for the arm. Skincare, mobility exercises and MLD is continued in this phase if needed
89014039|NCT05878821|Experimental|Postural correction exercise|"All women in both groups (A&B) will receive postural correction exercises which includes:~A.mckenzie exercises:~The exercise routine consists of seven types of movements,at static maximum strength, with 15_20 repetitions, holding each repetition for seven seconds.the subjects complete one 20-minutes set per day,three times a week for four weeks B.strengthening exercise targeted the periscapular muscles (Y to W,l to W), scapular retraction.strengthening exercises will be progressively performed for 3sets, with 10 to15 repetitions C.pectoralis flexibility on a foam roller.Hold for 5seconds and repeated 10 time s"
89014040|NCT05878821|Experimental|Shockwave therapy|"All women in group (B) will receive shockwave therapy once a week for the duration of the trial (4 weeks)~The dosage used will be as the following:~Energy flux Density (EFD)=0,25 ml/mm2 Number of shocks=1000 shocks(kamel et al.,2020). Time:2-5minutes per session."
89014041|NCT05878652|Experimental|Experimental Arm|Participants will utilize a 3D printed knee extension device and an at-home prehabilitation program designed to be used with the 3D printed knee extension device.
89014042|NCT05878652|Other|Control Arm|Participants will receive the standard prehabilitation education at Sanford and provided exercises to do at home.
89014043|NCT05873842||PTA-assisted group|
89446644|NCT03475914||Healthy skin of psoriasis vulgaris|Healthy skin area of 2mm2 belonging to the left gluteus from patients affected by psoriasis vulgaris
89446645|NCT03475914||Healthy skin of psoriasis guttate|Healthy skin area of 2mm2 belonging to the left gluteus rom patients affected by psoriasis guttate
89446646|NCT03483090|Experimental|Treatment A|4000mg Swisse High Strength Deep Sea Krill Oil (Superba BOOST) (4 capsules containing 1000mg each)
89446647|NCT03483090|Placebo Comparator|Treatment B|4 capsules of matching Placebo orally daily (1000mg each of mixed vegetable Oil)
89446648|NCT02222025|Experimental|Injury Prevention Programme|see intervention prescription
89446649|NCT02222025|No Intervention|Control|The coaches of the control group will receive the instruction to regularly perform a common warm-up consisting of running and ball-based exercises (sham treatment, no neuromuscular and stability exercises).
89446650|NCT03475836|Placebo Comparator|Placebo|Vegetable oil
89446651|NCT03475836|Active Comparator|High-dose mint essential oil|100 μL Mentha piperita essential oil (in vegetable oil)
89446652|NCT03475836|Active Comparator|Low-dose mint essential oil|50 μL Mentha piperita essential oil (in vegetable oil)
89446653|NCT02225379|Experimental|Hypo-Sense (non invasive sensor)|Parallel measurements of capillary blood glucose using reference method and data generated by the non- invasive study device (Hypo Sense) during approximately 4 hours, in which a hypoglycemic event will be induced.
89446654|NCT03482934||hypertensive patients|
89446655|NCT02231307|Placebo Comparator|SUBLIVAC FIX Birch 0 AUN/ml|
89446656|NCT02231307|Experimental|SUBLIVAC FIX Birch 40,000 AUN/ml|
89014044|NCT05873842||IVL-assisted group|
89014045|NCT05869955|Experimental|Administration of CC-97540|
89446657|NCT03475758|No Intervention|chemotherapy without goserelin|these patients will receive their chemotherapy without addition of Goserelin
89446658|NCT03475758|Experimental|chemotherapy with goserelin|these patients will receive their chemotherapy with addition of Goserelin
89446659|NCT03479970|Experimental|GNPT + Social Cognition|"Experimental Group: will undertake a rehabilitation treatment integrated by a set of tasks aimed at working attention, memory and executive functions together with a computerized treatment for the rehabilitation of the Social Cognition. The treatment will be carried out through the cognitive telerehabilitation platform Guttmann, NeuroPersonalTrainer® (GNPT).~The treatment will consist of the carrying out of 24 treatment sessions"
89446660|NCT03479970|Active Comparator|GNPT (only N-SC measures)|Control Group: will only conduct a cognitive rehabilitation treatment through the cognitive telerehabilitation platform Guttmann, NeuroPersonalTrainer® (GNPT) focused on attention, memory and executive functions.
89446661|NCT02222103||Suspected obstructive sleep apnea in adults|Already scheduled in-lab sleep study
89446662|NCT03479892|Experimental|NNC0194-0499|Participants will receive increasing doses of NNC0194-0499. The treatment period from first treatment (Day 1) to end of the treatment (Day 85) will be 12 weeks.
89446663|NCT03479892|Placebo Comparator|Placebo|Participants will receive NNC0194-0499 matched placebo. The treatment period from first treatment (Day 1) to end of the treatment (Day 85) will be 12 weeks.
89446664|NCT02231385|Experimental|Acetic Acid|"Subjects in Group A (study group) will undergo a standard colonoscopy. Once the right colon has been fully examined, acetic acid 2% will be sprayed and the right colon re-examined from cecum to hepatic flexure with within a frame-time of two minutes.~Subjects in Group B (control group) will undergo a second examination of the right colon without acid acetic and within the same frame-time."
89446665|NCT02231385|No Intervention|Control Group|"Subjects in Group A (study group) will undergo a standard colonoscopy. Once the right colon has been fully examined, acetic acid 2% will be sprayed and the right colon re-examined from cecum to hepatic flexure with within a frame-time of two minutes.~Subjects in Group B (control group) will undergo a second examination of the right colon without acid acetic and within the same frame-time."
89446666|NCT02523768|Experimental|ATG-F|The ATG-Fresenius® is administered by slow infusion over four hours after antihistamine (2 bulbs Polaramine® IV) and intravenous methylprednisolone (minimum 30mg); it is started on day 0 prior to surgery at doses of 4 mg / kg, and then continued to day 1, day 2 to 4mg / kg, then day 3, day 4 at the dose of 3 mg / kg
89446667|NCT02523768|Active Comparator|Simulect|The anti CD25 (basiliximab, Simulect®) is administered intravenously before surgery of renal transplantation (Day 0 and Day + 4 (1 ampoule of 20 mg x 2 times).
89446668|NCT02225457|Experimental|Hypercaloric diet and polyphenols|"polyphenols will consist in the administration of 1 gram (5x200 mg) of the compound bid during the entire overfeeding period.~Hypercaloric diet will consist in a hypercaloric diet providing an excess of 50% KCal over daily requirements, and will last 30 days."
89446669|NCT02225457|Active Comparator|Hypercaloric diet and placebo|"Placebo will consist in the administration of a number of placebo pills matching that of polyphenols, in a similar way (bid) for the duration of the overfeeding experiment.~Overfeeding will consist in a hypercaloric diet providing an excess of 50% KCal over daily requirements, and will last 30 days."
89446670|NCT05259384|Experimental|MIPD-ROB|Patients with PCN locates HEAD and NECK of pancreas who were randomized to ROBOTIC pancreaticoduodenectomy.
89446671|NCT05259384|Active Comparator|MIPD-LAP|Patients with PCN locates HEAD and NECK of pancreas who were randomized to LAPAROSCOPIC pancreaticoduodenectomy.
88931635|NCT06168214|Experimental|Vonoprazan+amoxicillin+furazolidone 7 days|7D: V: vonoprazan 20mg bid; A:amoxicillin1000mg tid; F: furazolidone 100mg bid.
88931636|NCT06168214|Experimental|Vonoprazan+amoxicillin+tetracycline 14 days|7D: V: vonoprazan 20mg bid; A:amoxicillin1000mg tid; T: tetracycline 500mg tid.
88931637|NCT06168214|Experimental|Vonoprazan+amoxicillin 7 days|7D:V: vonoprazan 20mg bid; A:amoxicillin1000mg tid.
88931638|NCT06168214|Experimental|Vonoprazan+amoxicillin 14 days|14D:V: vonoprazan 20mg bid; A:amoxicillin1000mg tid.
88931639|NCT06167876|Experimental|Stereotactic Body Radiotherapy (SBRT) Treatment Group|This arm of the study encompasses patients who are receiving the non-invasive Stereotactic Body Radiotherapy (SBRT) as the primary treatment for Hypertrophic Obstructive Cardiomyopathy (HOCM). The group will undergo precise imaging-guided radiotherapy targeting the interventricular septum, avoiding critical cardiac structures, and delivering a single high-dose radiation treatment with the aim of alleviating the symptoms of HOCM and improving cardiac function.
88931640|NCT06167876|Sham Comparator|Sham Procedure Control Group|Participants in this arm will undergo a sham procedure, which mimics the SBRT treatment process without actual radiation delivery. This group serves as a control to assess the efficacy and safety of the SBRT treatment by providing a comparative baseline. The sham procedure involves aligning patients with the linear accelerator and replicating the treatment environment, including equipment sounds and lighting, without administering any radiation.
88931641|NCT06166914|Experimental|Treatment group|Group A received intraoperative infusion of 5-FU (200 µg/ml) and LMWH (5 IU/ml) during pars plana vitrectomy and silicone oil injection with scleral buckle in children under 14 years of age with high-risk PRRD
88931642|NCT06166914|Placebo Comparator|Control group|Group B received infusion of normal saline during pars plana vitrectomy and silicone oil injection with scleral buckle in children under 14 years of age with high-risk PRRD
88931643|NCT06166355|Experimental|Cognitive-behavioral therapy plus VR-based body exposure and Attentional Bias Modification Training.|In this group, five sessions of VRE will be added to the usual CBT, as in the other experimental group, but, in addition, at the beginning of each of the exposure sessions, the training aimed at reducing the attentional bias will be carried out. The training will be developed through the visual selection of geometric figures that fit approximately with specific parts of the body. Each of these figures can have different colors. Specifically, the patient must detect and identify the figures that will appear in different parts of the avatar's body. In half of the trials, the shape of the figure must be discriminated and in the remaining 50%, the discrimination will be based on color. Throughout the training, the geometric figures will appear on weight-related body parts in 45% of the trials, and in another 45% of the trials, it will appear on non-weight-related body parts. In the remaining trials (10%), the test will appear on one of three neutral stimuli located next to the avatar.
88931644|NCT06166355|Experimental|Cognitive-behavioral therapy for anorexia and VR-based body exposure:|Patients assigned to this group will receive the usual CBT from the clinical unit or the hospital where they are, and additionally, five sessions of VR-based body exposure intervention. In these weekly sessions patients will go through a body exposure intervention in which they will own a virtual avatar with their real measurements, that will progressively increase its BMI values throughout the following exposure sessions until a healthy BMI value is reached.
88931645|NCT06166355|Active Comparator|Cognitive behavioral therapy|Patients assigned to this group will receive the usual treatment from the center in which they are recruited for the study (CBT), and will have to complete the evaluations following the same schedule as the experimental group.
88931646|NCT06165978|Experimental|Physical activity coaching - Experimental group|The experimental group intervention consists of a 12-week physical activity coaching program informed by the literature (CRD42021253066). The intervention is conducted at participants' home or within the community, delivered remotely (mostly) and face-to-face, and encompasses several behaviour change components (mandatory: self-monitoring, goal setting/review, education, feedback, contact; optional: exercise, reports, support meeting, group activities).
88931647|NCT06165978|Other|Usual care - Control group|The control group intervention runs parallel to the experimental group for 12 weeks, conducted at participants' home or within the community, and consists of usual management (i.e., World Health Organization's recommendations for being physically active).
88931648|NCT06162637|Other|A|grup A with femoral neck fracture will be fixed by femoral neck locking plate
88931649|NCT06162637|Other|B|grup B with femoral neck fracture will be fixed by Multiple cannulated cancellous screws
88931650|NCT06162611|Active Comparator|Etonogestrel contraceptive implant with oral levonorgestrel|Patients will be randomized 1:1 to each arm and will receive the contraceptive implant with a same-day encapsulated pill with either oral levonorgestrel 1.5mg
89446672|NCT05259384|Experimental|MIDP-ROB|Patients with PCN locates BODY and TAIL of pancreas who were randomized to ROBOTIC distal pancreatectomy.
88931651|NCT06162611|Placebo Comparator|Etonogestrel contraceptive implant with placebo|Patients will be randomized 1:1 to each arm and will receive the contraceptive implant with a same-day encapsulated pill with placebo X 1 dose
88931652|NCT06161181|Experimental|Experimental Group|50 MBC patients receive the DSS for three months. Patients are instructed to use the DSS ad libitum.
88931653|NCT06161181|No Intervention|Control Group|50 MBC patients not subjected to the intervention receive standard medical advice.
88931654|NCT06157697|No Intervention|Control Group|Only educational materials focused on the benefits of exclusive breastfeeding and the current international recommendations are provided.
88931655|NCT06157697|Experimental|Intervention Group 1 - Non-Conditional Social Transfer|"Educational materials focused on the benefits of exclusive breastfeeding and the current international recommendations are provided. At the baseline visit, participants are told that at the 6-month visit, they will receive a gift of their choice - which is meant to show our appreciation and support for their efforts in breastfeeding.~Intervention: Behavioral: Social Transfer"
88931656|NCT06157697|Experimental|Intervention Group 2 - Conditional Social Transfer|"Educational materials focused on the benefits of exclusive breastfeeding and the current international recommendations are provided. At the baseline visit, participants are told that at the 6-month visit, they will receive a gift of their choice if they are still exclusively breastfeeding.~Intervention: Behavioral: Social Transfer"
88931657|NCT06156722|Active Comparator|The IMSI-only group|The IMSI-only group
88931658|NCT06156722|Active Comparator|IMSI with SpermSlow group|IMSI with SpermSlow group
88931659|NCT06156722|No Intervention|Mixed embryo group|Mixed embryo group
88931660|NCT06155656|Experimental|Pea concentrate|Participants randomized to receive a soup containing 25 g of protein from pea protein concentrate
89446673|NCT05259384|Active Comparator|MIDP-LAP|Patients with PCN locates BODY and TAIL of pancreas who were randomized to LAPAROSCOPIC distal pancreatectomy.
89446674|NCT02222259|Experimental|GA and Integrated Care Plan|Participants allocated to the intervention group will be seen in the geriatric oncology clinic where they will be assessed using a geriatric assessment. Based on the issues identified in the geriatric assessment, a care plan will be developed with the participant to address the issues.
89446675|NCT02222259|No Intervention|Standard oncology care|Participants randomized to standard oncology care will receive usual care from their oncology team.
88931661|NCT06155656|Experimental|Pea isolate|Participants randomized to receive a soup containing 25 g of protein from pea protein isolate
88931662|NCT06155656|Experimental|Pea extrudate|Participants randomized to receive a soup containing 25 g of protein from pea protein extrudate
88931663|NCT06155656|Active Comparator|Whey|Participants randomized to receive a soup containing 25 g of protein from whey protein
88931664|NCT06152172|Experimental|IIM|Participants with idiopathic inflammatory myopathy will receive will receive lymphodepleting chemotherapy of cyclophosphamide and fludarabine prior to administration of KYV-101.
88931665|NCT06152172|Experimental|DCSS|Participants with diffuse cutaneous systemic sclerosis will receive lymphodepleting chemotherapy of cyclophosphamide and fludarabine prior to administration of KYV-101.
88931666|NCT06152172|Experimental|SLE|Participants with SLE-related nephritis will receive will receive lymphodepleting chemotherapy of cyclophosphamide and fludarabine prior to administration of KYV-101.
88931667|NCT06152172|Experimental|AAV|Participants with ANCA-associated vasculitis will receive will receive lymphodepleting chemotherapy of cyclophosphamide and fludarabine prior to administration of KYV-101.
88931668|NCT06145789||standing powered wheelchair|standing powered wheelchair evaluation
88931669|NCT06144281|Experimental|Intervention|The inpatient care team, including the attending/ordering and covering providers, for participants in this group will receive a message from the research team identifying their patient as appropriate for home palliative care and will be asked to refer their patient for these services.
88931670|NCT06144281|No Intervention|Usual Care|Participants in this group will receive usual care upon discharge from the hospital. Their clinical team will not be notified that they are appropriate for home palliative care services, but they may still be referred for those services if their clinicians feel their patient will benefit.
88931671|NCT06138054|Experimental|MI-CBTech|An 8-week experimental intervention that combines two treatments, Motivational Interviewing (MI) and Cognitive Behavioral Therapy (CBT). The format of the intervention will be a combination of in-person sessions and remote elements (together called MI-CBTech) delivered via mobile phone or other smart device.
89446676|NCT02225535|Placebo Comparator|Usual Care (NP)|Rural NP with client in-person, usual care
89446677|NCT02225535|Active Comparator|PT in-person|Urban PT travels to rural area to manage patient's back pain in-person.
89446678|NCT02225535|Active Comparator|PT/NP Telehealth|Intervention: Rural NP is joined by PT via Telehealth for interprofessional videoconference with patient
89446679|NCT03482700|Other|Intervention|The intervention group will have their usual annual COPD review performed by a specialist respiratory doctor at baseline and 12 months. The patients will receive care using our local COPD guidance which has been accepted by all local commissioning groups and secondary care organisations.
89446680|NCT03482700|Other|Control|Usual standard of care
89446681|NCT03479814|Experimental|IMRT-SIB plus sequential IG-RT boost|45 Gy plus 5 Gy concomitant boost are delivered to rectum and locoregional lymphnodes (25 fractions); sequential IG-RT (imaging guided-radiotherapy) boost of 5 Gy in 2 fractions is planned with 18-FDG-PET
89446682|NCT02225613|Active Comparator|Usual protocol|2 weeks conventional rehabilitation 3 weeks conventional rehabilitation
89446683|NCT02225613|Active Comparator|Spa protocol|2 weeks conventional rehabilitation 3 weeks aquatic rehabilitation
89446684|NCT03479736||Cohort 1: Participants with Achilles Tendon Rupture (ATR)|Participants will be defined as having ATR if they receive a diagnosis for ATR as well as one of the following procedures: tenotomy or primary ruptured Achilles Tendon (AT) repair (with or without graft) within 7 days of diagnosis. Index will be based on the earlier date of diagnosis or procedure. Participants with ATR, and exposures to Fluoroquinolone (FQ) or any of the other antibiotics or febrile illness not treated with antibiotic, within a defined study period and at least 1 year of continuous enrollment prior to the event will be included. It will use data from 3 databases, which are Truven CCAE and Medicare (Supplemental) and Optum ClinFormatics (Optum).
88931672|NCT06138054|Active Comparator|Mindfulness control|An 8-week active control intervention that combines supportive therapy and mindfulness training. The format of the intervention will be a combination of in-person sessions and remote elements delivered via mobile phone or other smart device.
88931673|NCT06135714|Placebo Comparator|Arm A: Standard of care|Continuation of systemic drug therapy.
88931674|NCT06135714|Experimental|Arm B: Metastasis-directed therapy followed by Standard of care|Metastasis-directed therapy (radiation or surgery for oligometastasis) + systemic drug therapy.
88931675|NCT06127342|Experimental|Moderate Intensity Exercise|"Visit 1: Participants will complete study screening, PTSD assessments, and provide written narrative for a traumatic event and a neutral control event.~Visit 2: Participants will complete baseline structural MRI scans before completing 8 trials of imaginal exposure - 4 neutral then 4 trauma narratives - with psychophysiological and fMRI measurement. Following completion of the imaginal exposure task, the participant will perform Moderate-Intensity Exercise (30-min at 70-75% max HR with 5-min warm-up and 5-min cool-down at 40-50% max HR), on a treadmill.~Visit 3: Participants will complete the same imaginal exposure with measurement of psychophysiology, fMRI, and subjective emotional responding."
88931676|NCT06127342|Active Comparator|Low Intensity Exercise|"Visit 1: Participants will complete study screening, PTSD assessments, and provide written narrative for a traumatic event and a neutral control event.~Visit 2: Participants will complete baseline structural MRI scans before completing 8 trials of imaginal exposure - 4 neutral then 4 trauma narratives - with psychophysiological and fMRI measurement. Following completion of the imaginal exposure task, the participant will perform Low-Intensity Exercise (walking control; 40-mins at 40-50% max HR),on a treadmill.~Visit 3: Participants will complete the same imaginal exposure with measurement of psychophysiology, fMRI, and subjective emotional responding."
88931677|NCT06123988|Experimental|Prolonged Overnighting Fasting Alone (POF Alone) Group|"Participants in this group will undergo a 12-week program of prolonged overnight fasting (POF), and weekly session with a trained health coach. Sessions may be delivered in-person, by telephone or by video call. Participants will also complete health-related quality of life questionnaires, and undergo blood sample collection at designated study timepoints.~Total participant duration is about 12 months."
88931678|NCT06123988|Active Comparator|Exercise Alone (EXE Alone) Group|"Participants in this group will undergo a 12-week exercise program during three weekly sessions supervised by a trained health coach. Sessions may be delivered in-person, or virtually via telehealth. Participants will also complete health-related quality of life questionnaires, and undergo blood sample collection at designated study timepoints.~Total participant duration is about 12 months."
88931679|NCT06123988|Active Comparator|Prolonged Overnight Fasting and Exercise (POF+EXE) Group|"Participants in this group will undergo a 12-week combined program of the prolonged overnight fasting and exercise interventions as described in the POF Alone and EXE Alone arm descriptions respectively. Participants will complete health-related quality of life questionnaires, and undergo blood sample collection at designated study timepoints.~Total participation is about 12 months."
88931680|NCT06123988|Other|Attention Control (AC) Group|"Participants in this group will receive other supportive care in the form of general health education sessions with a trained health coach. These bi-weekly sessions will be administered via telephone or video call in six (6) sessions over approximately 12 weeks. Participants will also complete health-related quality of life questionnaires at designated study timepoints.~Total participation is about 12 months."
88931681|NCT06123000|Active Comparator|Modified Widman Flap (MWF)|At buccal and lingual/palatal side, a full thickness incision parallel to the long axis of the tooth will be performed. In case of buccal or lingual pockets deeper than 2 mm, this initial incision will be placed approximately 1 mm apically to the free gingival margin. All soft tissues will be removed from the bony surface of intrabony defects. In case of incomplete adaptation between the flaps and the teeth or between the buccal and lingual flaps, the flaps will be thinned, and an amount of bone removal will be performed. Only osteoplasty will be allowed, while these patients will not receive ostectomy.
88931682|NCT06123000|Experimental|Fiber Retention Osseous Resective Surgery (FibReORS)|At the buccal sites, internally beveled incisions will be positioned at intra-sulcular or extra-sulcular level based on the apico-coronal dimension of the keratinized tissue. A split thickness flap beyond the MGJ will be then elevated. Vertical releasing incisions will be used to augment surgical access as needed. At lingual site split-full-thickness flap was used positioning an extra-sulcular internally beveled primary incision, while at the palatal area, the thinned palatal flap technique will be performed
88931683|NCT06118359|Experimental|SITe training for accepting providers|UW Health (accepting) providers will participate in a training to learn how to utilize SITe intervention tools during EGS transfer calls.
89014046|NCT05853900|Experimental|Arm A|Mobile application A as a software-based intervention for the preventive treatment of episodic migraine in late adolescents and adults.
89446685|NCT03479736||Cohort 2: Participants with Retinal Detachment (RD)|Participants will be defined as having a RD if they received a diagnosis of RD and a procedure for RD, e.g.: sclera buckle, vitrectomy, retinopexy, retinal cryotherapy, silicone oil fill, air gas fluid exchange or pneumatic retinopexy, within 14 days of index. Index will be defined as the earlier date of diagnosis or procedure. Participants with RD, and exposures to FQ or any of the other antibiotics or febrile illness not treated with antibiotic, within a defined study period and at least 1 year of continuous enrollment prior to the event will be included. It will use data from 3 databases, which are Truven CCAE and Medicare (Supplemental) and Optum ClinFormatics (Optum).
89538477|NCT03266003|Other|Group 1: ipDOT followed by eDOT|Following 20 observable medication doses under an initial DOT study group assignment of in-person DOT (ipDOT), patients will be assigned (crossed-over) to electronic DOT (eDOT) to collect data on another 20 observable medication doses.
88931684|NCT06111079|Experimental|Aspirin discontinuation group|initiation of aspirin 100mg qn from 12 to 16 weeks of gestation, receiving 1:1 randomized grouping at 24-27+6 weeks of gestation, discontinuing aspirin at 28 weeks of gestation.
88931685|NCT06111079|Active Comparator|Control group|initiation of aspirin 100mg qn from 12 to 16 weeks of gestation, receiving 1:1 randomized grouping at 24-27+6 weeks of gestation, continuing aspirin until 36 weeks of gestation.
88931686|NCT06109402|Experimental|Perioperative immunotherapy|In this arm, patients will receive neoadjuvant immunochemotherapy and adjuvant immunotherapy.
88931687|NCT06109402|Experimental|Adjuvant immunotherapy|In this arm, patients will receive adjuvant immunochemothrapy and immunotherapy
88931688|NCT06108999|Experimental|Connettivia BIO Cream|All subjects will be treated with Connettivina BIO line (Cream or Gauze)
88931689|NCT06108999|Experimental|Connettivina BIO Gauze|All subjects will be treated with Connettivina BIO line (Cream or Gauze)
88931690|NCT06102486||MCI|Participants diagnosed with or suspected to have MCI
88931691|NCT06102486||Control|Participants without MCI
88931692|NCT06100432|Experimental|Treatment 1|DLBS5055 & Placebo Multivitamin
88931693|NCT06100432|Active Comparator|Treatment 2|Multivitamin (Vitamin C 1000mg + Vitamin E 200IU + Beta Carotene 20000IU) & Placebo DLBS5055
88931694|NCT06100432|Experimental|Treatment 3|DLBS5055 & Multivitamin (Vitamin C 1000mg + Vitamin E 200IU + Beta Carotene 20000IU)
89200190|NCT00766896|Active Comparator|Platelet with hyperreactivity to aspirin|"For PFA-100 using a cartridge with C-EPI (collagen-epinephrine): occlusion time < 150 s~Chrono-Log Whole-Blood: above or = 1Ω with 0.75 mM of AA~Chrono-Log Whole-Blood: with collagen at 1 mg/L and 5 mg/L, according to the formula 1 - (Rate of aggregation with 1 mg / Rate of aggregation with 5 mg) below 0.50~Chrono-Log Whole-Blood: with collagen 1 mg/L above or = 10Ω~Plateletworks: aggregation of more than 60% with arachidonic acid will be considered resistant~VerifyNow Aspirin Assay (Accumetrics): ≥ 550 aspirin reaction units (ARUs)~Impact-R (Diamed) > 3.2% platelet aggregates on the surface of the plate after incubation with arachidonic acid"
89200191|NCT00889941|Active Comparator|small|
89200192|NCT00889941|Active Comparator|medium|
88931698|NCT06093386|Experimental|Intervention|
88931699|NCT06093386|No Intervention|Control/ Usual Care|Standard of care in the control group will involve the utilization of existing tools within clinical programs which may include preparation for transitions, but there will be no systematic follow-up by a paediatric provider beyond age 18. Care will be transferred to adult providers (primary care and specialists) via a transition guide that will be offered to participants and their referring providers. This is the current model of care for virtually all CMC in Ontario.
88931700|NCT06085495|Other|Improved approach mechanical thrombectomy (PMT) group|
89446686|NCT03479736||Cohort 3: Participants with Aortic Aneurysm & Dissection (AAD)|Participants will be defined as having AAD if they received a primary diagnosis for aortic aneurysm, aortic rupture or dissection and have also received an aortic repair surgical procedure concurrently to the AAD diagnosis, in an inpatient or emergency department (ED) setting. Index will be defined as the earlier date of diagnosis or procedure. Participants with AAD, and exposures to FQ or any of the other antibiotics or febrile illness not treated with antibiotic, within a defined study period and at least 1 year of continuous enrollment prior to the event will be included. It will use data from 3 databases, which are Truven CCAE and Medicare (Supplemental) and Optum ClinFormatics (Optum).
89446687|NCT02225691|Experimental|paired testing of blood glucose|Patient will be randomly assigned to one of 2 arms, namely (i) paired testing (PT) arm; and (ii) control (CL) arm. Paired testing arm will undergo paired testing of blood glucose.
89446688|NCT02225691|No Intervention|control arm|Non-insulin patients will be randomly assigned to one of 2 arms, namely (i) paired testing (PT) arm; and (ii) control (CL) arm. Patients in the control arms will not undergo paired testing and will be managed as before.
89446689|NCT02225769|Experimental|e-POCT|Febrile children managed using the e-POCT tool. The e-POCT tool is an electronic algorithm that integrates key clinical elements with the results of malaria and host biomarkers point-of-care test results (including oximetry).
89446690|NCT02225769|Active Comparator|ALMANACH|Febrile children managed using the ALMANACH algorithm. ALMANACH is an improved Integrated Management of childhood Illness (IMCI) algorithm based on mobile phones and tablets that has already been assessed for safety and efficacy.
89446691|NCT02225769|No Intervention|Routine practice|Febrile children managed according to routine care such as provided by routine health facility health workers.
89446692|NCT03479658|Experimental|HIIT two sessions|Two sessions per week of HIIT + nutritional education (1 session/week)
88931701|NCT06085495|No Intervention|Traditional simple anticoagulant group|
88931702|NCT06083064|Active Comparator|Routine imaging|Patients will have first abdominal ultrasound, and if findings are negative or inconclusive for appendicitis abdominal CT scan is made. If ultrasound is not available, CT scan can be the first imaging study. If appendicitis is found in the imaging study patient is scheduled for urgent laparoscopic appendectomy. Other patients are discharged or treated according to possible alternative diagnosis.
88931703|NCT06083064|Experimental|Adult Appendicitis Score based selective imaging|Adult Appendicitis Score (AAS) is calculated as soon as possible. Patients with AAS 16 or higher are scheduled for urgent laparoscopic appendectomy. Patients with AAS 11- 15 will have abdominal imaging as in the group 1. If appendicitis is found in the imaging study patient is scheduled for urgent laparoscopic appendectomy. Patients with AAS 10 or less are discharged without imaging studies.
89014047|NCT05853900|Experimental|Arm B|Mobile application B is an investigational digital therapeutic that is being studied for the preventative treatment of episodic migraine.
89014048|NCT05848323|Experimental|Relaxation Training|Didactic and experiential training in one or more relaxation techniques such as diaphragmatic breathing, progressive muscle relaxation, autogenic relaxation, and guided imagery to reduce autonomic nervous system arousal.
89446693|NCT03479658|Experimental|HIIT one session|One session per week of HIIT + nutritional education (1 session/week)
89446694|NCT03479658|Active Comparator|Nutritional education|Nutritional education (1 session/week)
89538478|NCT03266003|Other|Group 2: eDOT followed by ipDOT|Following 20 observable medication doses under an initial DOT study group assignment of electronic DOT (eDOT), patients will be assigned (crossed-over) to in-person DOT (ipDOT) to collect data on another 20 observable medication doses.
89446695|NCT02225847|Active Comparator|Control|Members of this group will continue with their daily life activities and will not receive gardening intervention. The control group will be given a set of psychometric assessments for health and quality of life evaluations and undergo a Functional Magnetic Resonance Imaging (fMRI) brain scan, followed by a second round of psychometric assessments and a fMRI brain scan administered seven to eight weeks after the initial baseline psychometric assessments and fMRI brain scan.
89446696|NCT02225847|Experimental|Gardening|Members of this group will be given a set of psychometric assessments for health and quality of life evaluations and a Functional Magnetic Resonance Imaging (fMRI) brain scan prior to receiving the gardening activities intervention. The gardening intervention will consist of twice weekly group sessions lasting 60 minutes in duration that will take place in a greenhouse. The duration of the experimental intervention will be six weeks for a total of 12 individual gardening activity sessions. Following the completion of the gardening intervention, a second round of psychometric assessments and a fMRI brain scan will be administered seven to eight weeks after the initial baseline psychometric assessments and fMRI brain scan.
89446697|NCT03940092||Healthy Volunteers|Healthy volunteers will be scheduled for an 23Na-MR examination
89446698|NCT03940092||Breast cancer patients (primary surgery)|Patients scheduled for primary surgery will undergo a single MR examination, involving 23Na-imaging prior to their planned surgery.
89446699|NCT03940092||Breast cancer patients (neoadjuvant chemotherapy)|Patients undergoing neo-adjuvant therapy will undertake up to two (2) combined PET/MR examinations with FDG. Examinations will be conducted at baseline and after 3-4 cycles of chemotherapy.
89446700|NCT03203642|Experimental|Tesevatinib|Participants received tesevatinib 50 mg tablet orally once daily (QD) for up to 25.3 months.
89446701|NCT03203642|Placebo Comparator|Placebo|Participants received placebo matched to tesevatinib tablet orally QD for up to 25.3 months.
89446702|NCT03475680|Experimental|"1)  MBP and oral antibiotics  group"|"Sennosides colonic preparation Oral Gentamycin Oral Ornidazole~Sennosides colonic preparation (X-PREP) :~1 per day, on day -2 and day -1.~Gentamycin :~80 mg, 4 per day, on day -2 and day -1; Liquid forms in individual vials.~Ornidazole :~g per day (2 tablet per day), on day -2 and day -1; In tablets."
89446703|NCT03475680|Placebo Comparator|"2)  MBP alone  group"|"Sennosides colonic preparation Oral placebo Gentamycin Oral placebo Ornidazole~Sennosides colonic preparation (X-PREP) :~1 per day, on day -2 and day -1.~Placebo for oral gentamycin:~Same presentation as oral gentamycin x4 per day on day -2 and day -1. - Placebo for oral ornidazole : Same presentation as oral ornidazole~1g per day (2 tablet per day) on day -2 and day -1."
88931704|NCT06083064|Experimental|Appendicitis Severity Score based observation with selective imaging using Adult Appendicitis Score|Patients with Adult Appendicitis Score (AAS) 10 or less are discharged without imaging studies. Patients with AAS 11 or more are managed based on Appendicitis Severity Score (ASS). ASS is used to identify patients with low risk of complicated disease. Patients with high ASS (>4) are managed as patients in arm 2. Patients with low ASS (<=4) begin observation protocol where patients can leave hospital and they are re-evaluated with repeated scoring after 12-24 hours from randomization. After re-scoring patients may be discharged if AAS is below 16 and decreasing and ASS is below 5 or if AAS is below 11. If AAS is 16 or higher or increasing, patients are scheduled for urgent laparoscopic appendectomy. After observation period, patients with decreasing AAS between 11-15 and ASS higher than 4 or patients with stable AAS between 11-15 are send for imaging study.
88931705|NCT06080529|Experimental|30-SEC|Participants will execute each exercise for 30 seconds
88931706|NCT06080529|Experimental|45-SEC|Participants will execute each exercise for 45 seconds
88931707|NCT06080516|Experimental|30-SEC|Participants will execute each exercise for 30 seconds
88931708|NCT06080516|Experimental|45-SEC|Participants will execute each exercise for 45 seconds
88931709|NCT06068270|Experimental|Test group|According to randomization, test group patients will receive MOPs at the beginning of the orthodontic therapy and at every other orthodontic recall appointment.
88931710|NCT06068270|No Intervention|Control group|No MOPs performed at any stage of the orthodontic therapy
88931711|NCT06066151|Experimental|Minayo Yeast Drink Product|"Minayo Iron-rich Yeast Drink with SOD, 385 pieces, 25ml/piece, each piece contains 13mg of iron.~Main ingredients: Water, erythritol, jujube juice concentrate, Wolfberry juice concentrate, ferrous gluconate, olive powder, SOD yeast powder, yeast extract (including glutathione), artichoke, etc."
88931712|NCT06060847|Experimental|Patients affected by HCC induced by metabolic syndrome as unique risk factor|Patients aged 18 years old and older, affected by HCC with MS (metabolic syndrome) as unique risk factor who comply with the criteria for bariatric surgery, will undergo liver resection and sleeve gastrectomy with minimally-invasive technique in the same surgical procedure
88931713|NCT06060847|Active Comparator|Patients with HCC related to metabolic syndrome as unique risk factor|Patients aged 18 years old and older, affected by HCC (hepatocellular carcinoma) with MS (metabolic syndrome) as unique risk factor who will undergo liver resection only
88931714|NCT06037148|Experimental|DM-101PX low dose|10 subcutaneous doses starting from 0.05 ug of which first 8 doses are ascending. Thereafter the 8th dose is repeated twice. First 9 doses are administered at 1 week interval, and the 10th dose is administered 2 weeks after the 9th dose.
88931715|NCT06037148|Placebo Comparator|Placebo|10 subcutaneous doses.First 9 doses are administered at 1 week interval, and the 10th dose is administered 2 weeks after the 9th dose.
88931716|NCT06037148|Experimental|DM-101PX middle dose|10 subcutaneous doses starting from 0.1 ug of which first 8 doses are ascending. Thereafter the 8th dose is repeated twice. First 9 doses are administered at 1 week interval, and the 10th dose is administered 2 weeks after the 9th dose.
88931717|NCT06037148|Experimental|DM-101PX high dose|10 subcutaneous doses starting from 0.2 ug of which first 8 doses are ascending. Thereafter the 8th dose is repeated twice. First 9 doses are administered at 1 week interval, and the 10th dose is administered 2 weeks after the 9th dose.
88931718|NCT06028464|Experimental|BI 1810631 (reference) and BI 1810631 + carbamazepine (test)|
89014049|NCT05848323|Experimental|Behavioral Activation|Didactic material and practice focused on identification and reduction of avoidance behaviors (e.g., excessive rest) and increased engagement in valued and reinforcing activities (e.g., physical activity, social engagement).
89446704|NCT03475680|Experimental|"3)  Oral antibiotics alone  group"|"Oral Gentamycin Oral Ornidazole~Gentamycin :~80 mg, 4 per day, on day -2 and day -1; Liquid forms in individual vials.~Ornidazole :~g per day (2 tablet per day), on day -2 and day -1; In tablets."
89446705|NCT03475680|Placebo Comparator|"4)  No preparation  group"|"Oral placebo Gentamycin Oral placebo Ornidazole~- Placebo for oral gentamycin : Same presentation as oral gentamycin x4 per day on day -2 and day -1~- Placebo for oral ornidazole : Same presentation as oral ornidazole~1g per day (2 tablet per day) on day -2 and day -1"
89446706|NCT03475602||Cyclophosphamide|Drug: Cyclophosphamide，CTX Determination of serum concentration of anti PLA2R antibody and anti TSHD7A antibody
89446707|NCT03475602||Cyclosporin|Drug: Cyclosporin Determination of serum concentration of anti PLA2R antibody and anti TSHD7A antibody
89446708|NCT02231463||ultrasound measurement|"measuring subclavian vein Diameter in six Groups:~neutral positioning, PEEP 0 cm H2O, neutral positioning, PEEP 5cm H2O, neutral positioning, PEEP 10cm H2O, Trendelenburg positioning -20°, PEEP 0 cmH2O, Trendelenburg positioning -20°, PEEP 5 cmH2O, Trendelenburg positioning -20°, PEEP 10 cmH2O After these measurements a central venous catheter is used to measure the central venous pressure."
89446709|NCT04621136|Experimental|Ripasudil eye drops|Ripasudil eye drops
89446710|NCT03475524|Experimental|study Metformin 1000 mg|
89446711|NCT03475524|Experimental|study Metformin 500 mg|
89446712|NCT03475524|Placebo Comparator|control group|
89446713|NCT02259075|Experimental|Botulinum Toxin|The patients will be injected with 25 IU of Botulinum Toxin Type A towards both the right and left sphenopalatine ganglion, a total of 50 IU.
88931719|NCT06026540|Experimental|experimental group|"After the first measurements were made and the groups were determined; Students in the experimental group will be given pilates exercises 2 days a week for 6 months. Pilates mat, pilates circle, tiny pilates ball and pilates band will be used during the pilates exercise. The duration of the Pilates exercise is 30 minutes in total, and the peer-guided application via Zoom includes the following order:~Stretching 5 minutes, superman 1 minute, quodratus stretch 2 minutes, marble 1 minute, half plank kick 4 minutes, side kick 4 minutes, pelvic curl 2 minutes, cat pose 1 minute, spine stretch 2 minutes, one leg circle 3 minutes, side leg lift 3 minutes, single leg kick 2 minutes."
88931720|NCT06026540|No Intervention|Control group|No intervention will be applied to the control group
88931721|NCT06026306|Experimental|Problem Management Plus (PM+)|The experimental group will receive a 5-session individual PM+.
88931722|NCT06026306|No Intervention|Enhanced Care as Usual|The control (enhanced care as usual) group will receive the information about freely available psychological support options. E-CAU ranges from standard community care which may include any existing mental health support services available to earthquake survivors in container cities. The participants will be given flyers which include information about the services provided by the government and by non-governmental organizations. After completion of the post and follow-up assessment of experimental group, those in the E-CAU condition will be offered with PM+.
88931723|NCT06018272|Experimental|Mentalization-Based Treatment (MBT)|
88931724|NCT06018272|Active Comparator|Bona-Fide Treatment in Germany (BFT)|
88931725|NCT06018233||People involved with creating and operating regimes which address key societal challenges.|Qualitative semi-structured interviews to explore approaches taken to regimes, including one case study group regarding the Public Benefit and Privacy Panel in Scotland. No use of drugs and no personal health related interventions. Same approaches taken to 3 other case study groups which do not involve health.
88931726|NCT06016335|Other|Training|Data from 25-35 participants will be used to train an algorithm to generate synthetic CT images from MRI scans.
88931727|NCT06016335|Other|Testing|Data from remaining participants will be used to test the synthetic CT algorithm, by comparing true CT scans to synthetic CT scans made from MRI.
88931728|NCT06011629|Other|Arthroplasty-naïve Aquacel group|All subject's receive the same dressing, this group is comprised of patients consented to the study and will receive the Aquacel dressing but have not had previous joint replacement surgery. Therefore, we consider them the arthroplasty-naïve Aquacel group.
88931729|NCT06011629|Other|Prior Aquacel group|All subject's receive the Aquacel dressing, this group is comprised of patients who have undergone previous joint replacement surgery (hip or knee) and have had a Aquacel dressing. This also includes patients who have had prior exposure to glue/mesh dressing either as a patient or healthcare worker.
88931730|NCT06011603|Other|Prineo naive group|All subject's receive the same dressing, this group is comprised of patients consented to the study and will receive the Prineo dressing but have not had previous joint replacement surgery. Therefore, we consider them Prineo-naive.
88931731|NCT06011603|Other|Prineo-exposed group|All subject's receive the Prineo dressing, this group is comprised of patients who have undergone previous joint replacement surgery (hip or knee) and have had a prineo dressing. This also includes patients who have had prior exposure to glue/mesh dressing either as a patient or healthcare worker.
88931732|NCT06010693|Experimental|Daridorexant|Participants will receive one daridorexant 50 mg tablet,orally, once daily for about 28 consecutive night on each night approximately 30 minutes before participants intends to try to sleep.
88931733|NCT06010693|Placebo Comparator|Placebo|Participants will receive one placebo matched to daridorexant 50 mg tablet,orally, once daily for about 28 consecutive night on each night approximately 30 minutes before participants intends to try to sleep.
89200193|NCT00889941|Active Comparator|large|
89446714|NCT02471846|Experimental|Anti-PD-1/PD-L1 Relapsed Cohort I|Approximately 20 participants whose most recent anti-cancer therapy consisted of single-agent programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) blockade and achieved best response of confirmed complete or partial response, or stable disease will receive GDC-0919, at the MTD or maximum administered dose (MAD) determined during the dose-escalation stage, in combination with atezolizumab. Treatment may continue until unacceptable toxicity or disease progression with an unfavorable risk-benefit ratio.
89446715|NCT02471846|Experimental|Anti-PD-1/PD-L1 Relapsed Cohort II|Approximately 20 participants whose most recent anti-cancer therapy consisted of single-agent PD-1/PD-L1 blockade and achieved unconfirmed partial response or stable disease will receive GDC-0919, at the MTD or MAD determined during the dose-escalation stage, in combination with atezolizumab. Treatment may continue until unacceptable toxicity or disease progression with an unfavorable risk-benefit ratio.
89446716|NCT02471846|Experimental|Biopsy Cohort A|Approximately 20 participants with melanoma, HNSCC, gastric, ovarian, Merkel cell, cervical, or endometrial cancer will receive GDC-0919 during Cycle 1, followed by combination treatment with GDC-0919 and atezolizumab from Cycle 2 onwards. Serial biopsies of extrahepatic lesions will be performed. Treatment may continue until unacceptable toxicity or disease progression with an unfavorable risk-benefit ratio.
89446717|NCT02471846|Experimental|Biopsy Cohort B|Approximately 20 participants with melanoma, HNSCC, gastric, ovarian, Merkel cell, cervical, or endometrial cancer will receive atezolizumab during Cycle 1, followed by combination treatment with GDC-0919 and atezolizumab from Cycle 2 onwards. Serial biopsies of extrahepatic lesions will be performed. Treatment may continue until unacceptable toxicity or disease progression with an unfavorable risk-benefit ratio.
89446718|NCT02471846|Experimental|Dose-Escalation Cohort(s)|Approximately 6 to 65 participants will be enrolled and treated at escalating doses of GDC-0919 in combination with fixed-dose atezolizumab. Treatment may continue until unacceptable toxicity or disease progression with an unfavorable risk-benefit ratio. Successive groups of at least 3 participants will be evaluated during a 21-day window for DLTs, which will determine the enrollment and dosing for subsequent cohorts in the dose-escalation stage. The MTD or MAD, whichever is reached first, will be considered for the expansion stage.
89446719|NCT02471846|Experimental|Expansion Cohorts|Approximately 160 participants (40 per diagnosis) with NSCLC, RCC, TNBC, and UBC will receive GDC-0919, at the MTD or MAD determined during the dose-escalation stage, in combination with Atezolizumab. Treatment may continue until unacceptable toxicity or disease progression with an unfavorable risk-benefit ratio.
89446720|NCT04458714|Active Comparator|CO2 group (treatment arm)|This arm included 32 patients who were randomized for using CO2 as the contrast medium for aortoiliac angiolplasty.
89446721|NCT04458714|Active Comparator|ICM group (control arm)|This arm involved 32 patients who were randomized for using iodine contrast medium (ICM) for aortoiliac angiolplasty.
89446722|NCT02259153|Active Comparator|Lean red meat diet|Participants were given 350 g per day of lean red meat to incorporate to their usual diet for ten days.
89446723|NCT02259153|Active Comparator|Fat red meat diet|Participants were given 350 g per day of fat red meat to incorporate to their usual diet for ten days.
89446724|NCT03108716|Experimental|hamate hook removal|The patients were assigned to hamate hook removal(n=13).
89446725|NCT03108716|Experimental|microscrew internal fixation|The patients were assigned to the microscrew internal fixation after open reduction (n=11).
89446726|NCT03108716|Experimental|short-arm tube-type plaster fixation|The patients were assigned to the short-arm tube-type plaster fixation (conservative treatment) (n=4).
89446727|NCT03482622||Patients undergoing Mohs surgery|Skin samples excised during Mohs surgery will be measured by the Fast Raman device. The Fast Raman measurements will be compared to gold standard histopathology to determine measurement accuracy.
89446728|NCT02231541|Experimental|Very low frequency magnetic fields|The very low frequency magnetic fields (ELF) are magnetic fields already use for orthopedics pathology that have shown to be able to repair, to reduce pain, inflammation and edema in the damaged tissues.
89446729|NCT02231541|Placebo Comparator|Turned off very low frequency magnetic fields|The very low frequency magnetic fields (ELF) are magnetic fields already use for orthopedics pathology that have shown to be able to repair, to reduce pain, inflammation and edema in the damaged tissues.
89446730|NCT03108794||Immune tolerance phase|Immune tolerance phase is diagnosed based on the presence of high serum levels of HBV-DNA, hepatitis B e antigen (HBeAg), but normal or minimally elevated serum alanine aminotransferase (ALT), and normal liver or only minimal histological activity and scant fibrosis.
89446731|NCT03108794||HBeAg positive CHB|HBeAg positive CHB is defined as those with HBsAg positive for more 6 months, HBeAg positive, high HBV DNA, elevated serum levels of ALT and histological activity.
89200194|NCT00766974|Active Comparator|1|Anti-embolism Knee High compression stocking
89200195|NCT00766974|Active Comparator|2|20-30mmHg Knee High Jobst Compression Stocking
89446732|NCT03108794||HBeAg negative CHB|HBeAg negative CHB is defined as those with HBeAg negative, anti-HBe positive, lower serum HBV DNA levels and histological necroinflammation and fibrosis.
89446733|NCT03108794||Inactive HBsAg carriers|Inactive HBsAg carriers was defined as those with HBsAg positive than 6 months, with low HBV DNA and persistently normal ALT, without evidence of cirrhosis.
89446734|NCT03108794||Compensated cirrhosis|"Diagnosis of compensated cirrhosis can be made if one of the following criteria was met:~by liver histology: Ishak fibrosis stage 5-6 or METAVIR F4.~endoscopy-proven gastroesophageal varices, afrter excluding non-cirrhotic portal hypertension.~at least 2 features of cirrhosis:~irregular liver surface, granular or nodular liver parenchyma, with or without splenomegaly (spleen thickness > 4.0cm or > 5 rib units) on ultrasound ,CT or MRI;~PLT<100×109/L without other causes;~Serum album in<35 g/L or INR>1.3 or PT prolongs>3s;~LSM>13 kpa (ALT<5×ULN)."
89446735|NCT03108794||Decompensated cirrhosis|Decompensated cirrhosis was diagnosed based on the presence of ascites, bleeding esophageal varices and/or hepatic encephalopathy in cirrhotic patients.
89446736|NCT03108794||Hepatocellular carcinoma|Diagnosis of hepatocellular carcinoma（HCC）can be established when one of the following one of the following 2 criteria:（1）in cirrhotic patients with nodules of 1cm or larger with typical features of HCC ( arterial enhancement with washout in venous or delay phase) on 2 radiological studies or with 1 radiological study and elevation of serum AFP; or（2）histological evidence of HCC.
89446737|NCT02231619|No Intervention|Demonstration of LSUPT at baseline|This group conduct a LSUPT on their own urine sample at baseline with assistance from a fieldworker.
88931736|NCT05996133|Experimental|MCP Block|Bilateral Multifidus Cervicis plane block using 30 mL of 0.25% bupivacaine + 0.5 mL (5 mg) preservative-free dexamethasone + 0.1 mL epinephrine 1:400,000.
89200196|NCT00890019|Experimental|1A, 2A, 3A, 4A, 5A, 6A, 7A|AdCh63 ME-TRAP
89200197|NCT00890019|Experimental|1B, 2B, 3B, 4B, 6B, 7B, 7C|AdCh63 ME-TRAP; MVA ME-TRAP
89200198|NCT00973726|Other|Glucose|Subjects are given an oral glucose tolerance test.
89446738|NCT02231619|Active Comparator|Baseline verbal instruction of LSUPT|Verbal instruction on how to do LSUPT at baseline
88931737|NCT05996133|Sham Comparator|Sham Block|Bilateral sham block using 3 mL of normal saline injections subcutaneously on the neck.
88931738|NCT05993507|Experimental|Problem Management Plus (PM+)|As an open trial single group pre-post design, all participants in the study will receive PM+.
88931739|NCT05988229|Experimental|Discharge equity tools|Participants randomized into this arn will receive the toolkit of linguistically appropriate discharge teaching aids at hospital discharge.
88931740|NCT05988229|No Intervention|Standard of hospital discharge care|Participants randomized into this arm will receive the standard of care at hospital discharge.
88931741|NCT05977816|Experimental|Negative Pressure Wound Therapy|The wound is dressed using negative pressure wound therapy.
88931742|NCT05977816|Active Comparator|Standard Wound dressing|After the skin is closed, the wound is covered using sterile standard gauze dressing.
88931743|NCT05975307|Experimental|Toripalimab plus chemoradiation|This study has only single arm in which the patients will receive induction chemotherapy plus anti-PD-1 therapy (toripalimab), followed by radiotherapy plus concurrent anti-PD-1 therapy
88931744|NCT05971173|Experimental|Nutritional Supplements|Juven and Centrum Silver 50+ will be administered to this group
88931745|NCT05971173|No Intervention|Control|Standard of care procedures
88931746|NCT05970042|Experimental|GameDay Ready Program|GameDay Ready is a 12-week, group-based behavioral weight management program.
88931747|NCT05970042|Active Comparator|Walking and General Health Education Program|The walking and general health education program is a 12-week, group-based program that addresses common chronic health conditions that affect men.
88931748|NCT05966740||Pediatric patients with VTE and/or at risk for VTE|
88931749|NCT05956730|Experimental|Group 1|The proposed protocol includes a part of aerobic training and a subsequent part of strengthening exercises for large muscle groups. The total duration of each session will be approximately 30 minutes. There are 2 weekly training sessions for 3 months.
88931750|NCT05956730|Active Comparator|Group 2|The proposed protocol includes a part of aerobic training and a subsequent part of strengthening exercises for large muscle groups. The total duration of each session will be approximately 30 minutes. There are 2 weekly training sessions for 3 months.
88931751|NCT05932992|Active Comparator|Mother screening|In this arm, mothers / children dyads will be enrolled. Mothers will be trained to measure mid-upper arm circumference (MUAC) on their children weekly for 6 months. All other standard care will be provided.
88931752|NCT05932992|No Intervention|standard of care|In this arm, mothers / children dyads will be enrolled. No study intervention will be performed. all other standard of care will be provided.
88931753|NCT05924971|Experimental|Standard blood pressure control plus aspirin 81 mg|Standardized postpartum blood pressure control Aspirin 81 mg by mouth x 1 week post-delivery
88931754|NCT05924971|No Intervention|Standard blood pressure control|Standardized postpartum blood pressure control
88931755|NCT05924815|Experimental|Part A (Dose Finding Cohort 1): Aficamten 50 mg|Participants in this arm will receive a single oral dose of 50 mg aficamten.
88931756|NCT05924815|Experimental|Part A (Dose Finding Cohort 2): Aficamten 75 mg|Participants in this arm will receive a single oral dose up to 75 mg aficamten.
88931757|NCT05924815|Experimental|Part A (Dose Finding Cohort 3): Aficamten 100 mg|Participants in this arm will receive a single oral dose up to 100 mg aficamten.
88931758|NCT05924815|Experimental|Part B (TQT Study): Aficamten|Participants will receive a single oral dose of aficamten. The dose will be determined based on review of Part A PK parameters, echocardiogram parameters, safety, and tolerability for aficamten.
88931759|NCT05924815|Placebo Comparator|Part B (TQT Study): Aficamten-matching Placebo|Participants in this arm will receive a single oral dose of aficamten-matching placebo.
88931760|NCT05924815|Active Comparator|Part B (TQT Study): Moxifloxacin 400 mg|Participants will receive a single oral dose of 400 mg moxifloxacin
88931761|NCT05924412|Experimental|Parecoxib|This arm will receive intravenous parecoxib in the intraoperative period.
88931762|NCT05924412|Placebo Comparator|Placebo|This arm will receive a placebo intravenous injection containing saline solution in the same volume as the intervention group
88931763|NCT05923437|Experimental|Experimental: Interventions Group|"Breast milk will be given to the newborns in the intervention group for 3 days in line with the feeding model with a chronobiological approach, simultaneously with the mother's supply."
88931764|NCT05923437|No Intervention|Control Group|Breast milk will be given to newborns in the control group according to the clinical routine and infants will be followed up for 3 days.
88931765|NCT05921903|Experimental|RSV_IC_1 group|Immunocompromised (IC) patients receiving 1 dose of RSVPreF3 OA investigational vaccine at Visit 1 (Day 1).
88931766|NCT05921903|Experimental|RSV_IC_2 group|Immunocompromised (IC) patients receiving 2 doses of RSVPreF3 OA investigational vaccine at Visit 1 (Day 1) and Visit 3 (Visit 1 + 30-60 days).
88931767|NCT05921903|Active Comparator|RSV_HA group|Healthy participants receiving 1 dose of RSVPreF3 OA investigational vaccine at Visit 1 (Day 1).
88931768|NCT05911516|Experimental|Pennisetum purpureum group|
88931769|NCT05911516|Placebo Comparator|Placebo group|
88931770|NCT05911165|Active Comparator|Control group|Resident participants who do not receive video-based surgical coaching
88931771|NCT05911165|Experimental|Comparison group|Resident participants who do receive video-based surgical coaching
88931772|NCT05909592||Healthy CrossFit participants and athletes|No intervention. The group will be monitored for incidence data of shoulder injuries (new or aggravated pre-existing)
88931773|NCT05898724|Experimental|Blank group|Blank group: include six orthodontic patients, which have a surgical procedure to install two orthodontic titanium miniscrews in the two lateral parts of the maxilla of each patient, so this group will include 12 installed orthodontic titanium miniscrews.
89446739|NCT02222415|Placebo Comparator|Training + placebo drink|Exercise + non-caloric placebo drink
89446740|NCT02222415|Experimental|Exercise + Protein drink|exercise + Drink containing Protein, Carbohydrates and Fat
89446741|NCT02737722|Experimental|Bisphosphocin Nu-3|Dosage Form: Topical Antimicrobial, Dosage: 1mg/mL, 10 mg/mL, 20 mg/mL, 50 mg/mL, 100 mg/mL Frequency: QD for day 1, 2x daily for 7 days, Duration: 8 days
89446742|NCT02737722|Placebo Comparator|Placebo|Dosage Form: Diluent, Frequency: QD for day 1, 2x daily for 7 days, Duration: 8 days
89446743|NCT02231853|Experimental|-1|1x10e4 MVST/kg infusion
89446744|NCT02231853|Experimental|1|1x10e5 MVST/kg infusion
89446745|NCT02231853|Experimental|2|5x10e5 MVST/kg infusion
88931774|NCT05898724|Experimental|Silver hydroxyapatite group:|Silver hydroxyapatite group: include six orthodontic patients, which have a surgical procedure to install two silver hydroxyapatite nano-coated orthodontic titanium miniscrews in the two lateral parts of the maxilla of each patient, so this group will include 12 installed silver hydroxyapatite nano-coated orthodontic titanium miniscrews.
89446746|NCT02231853|Experimental|3|1x10e6 MVST/kg infusion
89446747|NCT02231853|Experimental|3B|1x10e6 MVSTr/kg infusion
89446748|NCT02231853|Experimental|4|5x10e6 MVSTr/kg infusion
89446749|NCT02472860|Experimental|Cognitive Training|Targeted Cognitive Training (TCT)
89446750|NCT02472860|Placebo Comparator|Control Condition|Youth appropriate online games
89446751|NCT02258607|Experimental|Momelotinib (MMB) dose escalation|Participants will receive momelotinib (MMB) plus trametinib. Momelotinib (MMB) dose will increase to find the MTD.
89446752|NCT02258607|Experimental|Trametinib dose escalation|Participants will receive momelotinib (MMB) plus trametinib. Trametinib dose will increase to find the MTD.
89446753|NCT02258607|Experimental|Momelotinib (MMB)+trametinib|Expansion Phase: participants will receive momelotinib (MMB) plus trametinib for the duration of the study.
89446754|NCT02472704|Active Comparator|Gluten challenge|Gluten powder (10 g every 12 hours), 24 weeks
89446755|NCT02472704|Placebo Comparator|Placebo challenge|Placebo (maltodextrin; 10 g every 12 hours), 24 weeks
89446756|NCT02258685||Cohort A1|ART-treated HIV-infected individuals with lipodystrophy
89446757|NCT02258685||Cohort A2|ART-treated HIV-infected individuals without lipodystrophy
89446758|NCT02258685||Cohort A3|HIV-1 infected individuals naïve to ART
89446759|NCT02258685||Cohort A4|HIV-1 seronegative individuals who are at a high risk for infection
89446760|NCT02258685||Cohort B1|A subset of subjects from Cohort A: ART-treated HIV-infected individuals with HIV-associated dysbiosis
89446761|NCT02258685||Cohort B2|A subset of subjects from Cohort A: ART-treated HIV-infected individuals without HIV-associated dysbiosis
89446762|NCT02222571|Active Comparator|Control|9-week parenting group focused on safety
88931775|NCT05898724|Experimental|Zinc oxide group|Zinc oxide group: include six orthodontic patients, which have a surgical procedure to install two zinc oxide nano-coated orthodontic titanium miniscrews in the two lateral parts of the maxilla of each patient, so this group will include 12 installed zinc oxide nano-coated orthodontic titanium miniscrews.
88931776|NCT05897073|Experimental|Time-restricted eating intervention|Participants will be asked to reduce their daily eating time window to a maximum of 8 hours/day. They can choose when to begin their eating window but will be advised that the last meal should be completed before or at 20:00 hours. No calorie-containing food or beverage intake will be allowed outside the 8 hours eating window.
88931777|NCT05897073|Experimental|Supervised exercise intervention|The exercise intervention will include 2 days/week of supervised moderate-high intensity resistance training (rating perceived exertion >7, circuit-training, upper and lower body exercises involving major muscle groups) and high-intensity interval training (4 sets of 4-minute intervals at >85% peak heat rate with 4-minute of active recovery at 50-65% peak heat rate, uphill treadmill walking). Moreover, participants will receive an individualized moderate-intensity goal-setting aerobic (walking) program consisting of increasing 15% daily steps per week.
89446763|NCT02222571|Experimental|Parents and Tots Together Program|Parents and Tots Together Program is a 9-week, group-based parenting intervention
89446764|NCT02472470|Experimental|Treatment|intermitten TBS (iTBS) rTMS applied to the left Dorsolateral Prefrontal Cortex (DLPFC) + continuous TBS (cTBS) rTMS applied to the right DLPFC. The order will be counterbalanced. Administration of this treatment takes roughly 10 minutes. This treatment will be applied daily, 5 days/week, for 2 weeks.
88931778|NCT05897073|No Intervention|Usual-care control group|Participants will receive standard recommendations on healthy lifestyle based on Mediterranean dietary pattern and physical activity recommendations for weight loss and health promotion.
89446765|NCT02226237|No Intervention|Control Group|in which patients received no specific treatment, only the usual general guidelines
89446766|NCT02226237|Experimental|group of pelvic floor exercises|in which patients were instructed to perform home exercises daily
89446767|NCT02226237|Experimental|anal electrostimulation group|in which patients, and are instructed to perform the exercises mentioned in the group of pelvic floor exercises, also underwent anal electrostimulation
89446768|NCT02471534|Experimental|Pediatric patients with hypovolemia|Right upper abdominal compression is performed in patients with hypovolemic signs including hypotension, decreased urine output and central venous pressure less than 5 mmHg. Changes of blood pressure during abdominal compression is continuously recorded.
89446769|NCT03096548|Experimental|Sun Safety Ink! Program|A program to (1) increase full-body sun comprehensive sun protection practices, (2) decrease sunburning and tanning and (3) decrease positive attitudes regarding tanning and tanning attractiveness of tattoo studio clients. The program is comprised of a video based communication strategy training presented by research staff to artists of tattoo studios.
89446770|NCT03096548|Active Comparator|Attention Control|The attention control group will provide standard tattoo aftercare instructions to their clients.
89446771|NCT02226315||Multiple gestations|Women with a multiple gestation who were evaluated with the MaterniT21 PLUS LDT and have passed their Estimated Date of Delivery (EDD).
89446772|NCT03792750|Experimental|Experimental Arm A|2 week BMS-986205 monotherapy lead in followed by BMS-986205 + Nivo combination therapy
89446773|NCT03311048|Experimental|Hospital|Hospital cleaning workers Nasal swab was collect to upper airways inflammation evaluation. Clinical profile and respiratory symptoms employees' evaluation were performed using specific questionnaires (European Community Respiratory Health Survey for occupational diseases evaluation (ECRHS), (adapted by Ribeiro et al, 2007) and the International Study of Asthma and Allergies in Childhood (ISAAC) - Asthma module, previously translated and validated.
89446774|NCT03311048|Experimental|University|Campus (university) cleaning workers Nasal swab was collect to upper airways inflammation evaluation. Clinical profile and respiratory symptoms employees' evaluation were performed using specific questionnaires (European Community Respiratory Health Survey for occupational diseases evaluation (ECRHS), (adapted by Ribeiro et al, 2007) and the International Study of Asthma and Allergies in Childhood (ISAAC) - Asthma module, previously translated and validated.
89446775|NCT03311048|Experimental|Housekeeper|Housemaid (cleaning workers) Nasal swab was collect to upper airways inflammation evaluation. Clinical profile and respiratory symptoms employees' evaluation were performed using specific questionnaires (European Community Respiratory Health Survey for occupational diseases evaluation (ECRHS), (adapted by Ribeiro et al, 2007) and the International Study of Asthma and Allergies in Childhood (ISAAC) - Asthma module, previously translated and validated.
89446776|NCT03311048|Experimental|Control|Office workers (no relationship to cleaning) Nasal swab was collect to upper airways inflammation evaluation. Clinical profile and respiratory symptoms employees' evaluation were performed using specific questionnaires (European Community Respiratory Health Survey for occupational diseases evaluation (ECRHS), (adapted by Ribeiro et al, 2007) and the International Study of Asthma and Allergies in Childhood (ISAAC) - Asthma module, previously translated and validated.
89446777|NCT02226393|Experimental|Prolonged exposure|See intervention description
89446778|NCT02226393|Active Comparator|Child-parent Play Therapy|see intervention description
89446779|NCT02258763|Experimental|Amoxicillin-Potassium Clavulanate|Patient will be on amoxicillin-clavulanate 22.5mg/kg/dose bd for 10 days
89446780|NCT02258763|Active Comparator|Placebo|Patient will be on amoxicillin-clavulanate 22.5mg/kg/bd for 3 days followed by another 7 days of placebo medication given at the same dose and frequency
89446781|NCT02471300||1|stable mild-moderate asthmatic subjects
89446782|NCT03479424||Training Set|n = 333
89446783|NCT03479424||Validation Set|n = 167
89446784|NCT02469974|Experimental|Ruxolitinib / INC 424|Ruxolitinib, Jakafi ®, will be given orally at standard dose daily for 16 weeks pre ASCT and up to 3 months post-ASCT for 10 patients (allowing for 2 additional screen failures). Patients will restart ruxolitinib at 100 days after the ASCT as long as their platelet count is at least 50 x103. For patients whose platelet count is below 50 x103 at day 100, ruxolitinib should be restarted once platelet count reaches 50 x103. The dose of ruxolitinib can be titrated up as per clinical guidelines. PBSC mobilization will include G-CSF 10 mcg/kg/day. HDC for ASCT will consist of IV busulfan 2.0 mg/KBW once daily x 4 for days -5 to -2.
89446785|NCT03131622|Experimental|Digital Therapeutics|Patients assigned to the digital therapeutics arm will receive Ibis and all the associate services.
89446786|NCT03131622|No Intervention|Control|
89446787|NCT03482544|Active Comparator|Pregabalin Group|We will give 150 mg pregabalin capsule orally 1 day before surgery and 1 hour before surgery (totally two times) to the pregabalin group patients.
89446788|NCT03482544|Active Comparator|Control Group|In control group, we will empty the drug material from capsules and give only empty capsules to the control group patients at the same times.
89446789|NCT02750709|Experimental|Treatment Sequence A (TP 1) - B (TP 2) - C (Reference)|Subjects will receive a single 10 mg tablet of Nitisinone 10 mg Tablet (Test Product 1) in treatment period 1, 10 mg tablet of Nitisinone 10 mg Tablet High Compritol (Test Product 2) in treatment period 2, and 10 mg hard capsule of Orfadin (Reference) in treatment period 3 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
89446790|NCT02750709|Experimental|Treatment Sequence A (TP 1) - C (Reference) - B (TP 2)|Subjects will receive a single 10 mg tablet of Nitisinone 10 mg Tablet (Test Product 2) in treatment period 1, 10 mg hard capsule of Orfadin (Reference) in treatment period 2, and 10 mg tablet of Nitisinone 10 mg Tablet High Compritol (Test Product 2) in treatment period 3 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
89446791|NCT02750709|Experimental|Treatment Sequence B (TP 2) - A (TP 1) - C (Reference)|Subjects will receive a single 10 mg tablet of Nitisinone 10 mg Tablet High Compritol (Test Product 2) in treatment period 1, 10 mg tablet of Nitisinone 10 mg Tablet (Test Product 1) in treatment period 2, and 10 mg hard capsule of Orfadin (Reference) in treatment period 3 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
89446792|NCT02750709|Experimental|Treatment Sequence B (TP 2) - C (Reference) - A (TP 1)|Subjects will receive a single 10 mg tablet of Nitisinone 10 mg Tablet High Compritol (Test Product 2) in treatment period 1, 10 mg hard capsule of Orfadin (Reference) in treatment period 2, and 10 mg tablet of Nitisinone 10 mg Tablet (Test Product 1) in treatment period 3, and under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
89446793|NCT02750709|Experimental|Treatment Sequence C (Reference) - A (TP 1) - B (TP 2)|Subjects will receive a single 10 mg hard capsule of Orfadin (Reference) in treatment period 1, 10 mg tablet of Nitisinone 10 mg Tablet (Test Product 1) in treatment period 2, and 10 mg tablet of Nitisinone 10 mg Tablet High Compritol (Test Product 2) in treatment period 3 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
89446794|NCT02750709|Experimental|Treatment Sequence C (Reference) - B (TP 2) - A (TP 1)|Subjects will receive a single 10 mg hard capsule of Orfadin (Reference) in treatment period 1, 10 mg tablet of Nitisinone 10 mg Tablet High Compritol (Test Product 2) in treatment period 2, 10 mg tablet of Nitisinone 10 mg Tablet (Test Product 1) in treatment period 3 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
89446795|NCT03131544|Experimental|FLA for BPH Active Treatment|
89446796|NCT02222649|Experimental|Vitamin D3|Group supplemented with high single dose of 200,000 IU of vitamin D3 (cholecalciferol)
89446797|NCT02222649|Placebo Comparator|placebo group|Placebo capsules with starch
89200199|NCT00892905||POC INR and APTT Hemochron|Adult patients undergoing elective on pump coronary artery bypass grafting surgery who have not received anticoagulants or clopidogrel within 5 days preoperatively.
89446798|NCT03130998|Active Comparator|Control - Group A|When a patient is screened as showing depressive symptoms, the practitioner will be prompted to intervene and refer that patient to treatment. The practitioner will receive knowledge broker support to carry out these actions in the form of one email per month for one year. The first email will provide an electronic copy of a Cochrane review (describing the link between smoking and mood) and a short description of the integration of a depression ICP in the STOP portal. The STOP YouTube channel with detailed instructions on how to use the revised portal will be made available. Subsequent communications will be based on general needs identified at baseline and content discussed in the STOP Community of Practice (teleconferences, online forum between STOP practitioners).
89446799|NCT03130998|Experimental|Intervention - Group B|When a patient is screened as showing depressive symptoms, the practitioner will be prompted to intervene and refer that patient to treatment. The practitioner will receive individualized support through a remote knowledge broker (rKB) communicating via interactive technology. The rKB will be certified in tobacco cessation counseling through CAMH's TEACH program and will have completed a specialty course on tobacco addiction treatment in those with mental illness. The rKB will have access to the CAMH network of KBs (e.g. Evidence Exchange Network ) for guidance and support, as this has been shown to be important for KB success.
89446800|NCT02859519|Experimental|MOB015B|Subjects will treat all affected fingernails and/or toenails with MOB015B for 48 weeks once daily at bedtime.
88931779|NCT05897073|Experimental|Time-restricted eating plus Supervised exercise|Participants will be asked to reduce their daily eating time window to a maximum of 8 hours/day. They can choose when to begin their eating window but will be advised that the last meal should be completed before or at 20:00 hours. No calorie-containing food or beverage intake will be allowed outside the 8 hours eating window. The exercise intervention will include 2 days/week of supervised moderate-high intensity resistance training (rating perceived exertion >7, circuit-training, upper and lower body exercises involving major muscle groups) and high-intensity interval training (4 sets of 4-minute intervals at >85% peak heat rate with 4-minute of active recovery at 50-65% peak heat rate, uphill treadmill walking). Moreover, participants will receive an individualized moderate-intensity goal-
88931780|NCT05888688||patients with Heart Failure with Preserved Ejection Fraction (HFpEF)|"Heart Failure (HF) Patients: Stage A/B HFpEF~Established clinical diagnosis of HFpEF (EF>50%)~Clinically stable for ≥ 3 months (no admissions to hospital)~Age ≥65~Willing to provide written consent for participation in the study."
88931781|NCT05888688||patients with Heart Failure with Reduced Ejection Fraction (HFrEF)|"HF Patients: Stage C/D HFpEF and HFrEF~Established clinical diagnosis of HFpEF (EF>50%) OR HFrEF (EF<40%)~Clinically stable for ≥ 3 months (no admissions to hospital)~Age ≥65~Willing to provide written consent for participation in the study."
88931782|NCT05888688||Asymptomatic T2D|"Male or female, aged ≥18 and ≤75 years.~Diagnosis of stable T2D (determined by i) formal diagnosis in primary care physician case records, ii) a record of diagnostic oral glucose tolerance test OR glycated haemoglobin level ≥6.5%)."
88931783|NCT05888688||Healthy Volunteers|"Age >18~Able to provide written informed consent"
88931784|NCT05881837|Experimental|Treatment group A|HRS9531 injection
88931785|NCT05881837|Experimental|Treatment group B|HRS9531 injection
88931786|NCT05881837|Experimental|Treatment group C|HRS9531 injection
88931787|NCT05881837|Experimental|Treatment group D|HRS9531 injection
88931788|NCT05881837|Placebo Comparator|Treatment group E|HRS9531 injection Placebo
88931789|NCT05881837|Placebo Comparator|Treatment group F|HRS9531 injection Placebo
88931790|NCT05881837|Placebo Comparator|Treatment group G|HRS9531 injection Placebo
88931791|NCT05881837|Placebo Comparator|Treatment group H|HRS9531 injection Placebo
88931792|NCT05881213|Experimental|Sequence 1|"Period 1: D745, D150, D029 - A single oral dose of 3tablets under food intake condition~Period 2: CKD-378 (low-dose) - A single oral dose of 1tablet under food intake condition"
88931793|NCT05881213|Experimental|Sequence 2|"Period 1: CKD-378 (low-dose) - A single oral dose of 1tablet under food intake condition~Period 2: D745, D150, D029 - A single oral dose of 3tablets under food intake condition"
88931794|NCT05880199||Children with functional GI disorders|
88931795|NCT05880199||Healthy controls|
88931796|NCT05854628|Experimental|0.1% red flavonoids facial cream|0.1% red flavonoids facial cream
88931797|NCT05854628|Placebo Comparator|Placebo facial cream|Placebo moisturizing facial cream
88931798|NCT05847712|Experimental|Younger adults|Adults aged 18-30 years with no pre-existing health conditions
88931799|NCT05847712|Experimental|Older adults|Adults aged 50-69 with no pre-existing health conditions
88931800|NCT05846789|Active Comparator|Black Monotherapy|
88931801|NCT05846789|Experimental|Black Combination treatment|
88931802|NCT05846789|Active Comparator|Non-Black Monotherapy|
88931803|NCT05846789|Experimental|Non-Black Combination treatment|
88931804|NCT05840900|Experimental|App-based mindfulness training|App-based daily mindfulness training Standard prenatal and pregnancy care
88931805|NCT05840900|No Intervention|Usual Care|Standard prenatal and pregnancy care
88931806|NCT05835219||REBYOTA™|
88931807|NCT05829070|Experimental|CHAT-S|CHAT-S consists of 4 bi-weekly 35-45 minute videoconferencing sessions with a patient navigator and a patient booklet on insurance, costs, and survivorship care.
88931808|NCT05829070|Placebo Comparator|Usual Care|Usual care will consist of a resource list sent by the navigator.
88931809|NCT05819047||Healthy|Healthy volunteers
88931810|NCT05814510|Experimental|School staff|School staff in a K-8 school participating in Asthma CHAMPS
88931811|NCT05814510|Experimental|Children with asthma|Aged 5-13 and enrolled in Baltimore City Public School participating in Asthma CHAMPS
88931812|NCT05814510|Experimental|Caregivers of children with asthma|Caregiver of a child with asthma that is aged 5-13 enrolled in a Baltimore City Public School participating in Asthma CHAMPS
88931813|NCT05810038|Experimental|DBT Rimegepant/OLE Rimegepant|"DBT Phase (Weeks 1 through 12): Participants will receive a single oral dose of rimegepant orally disintegrating tablet (ODT) EOD for 12 weeks.~OLE Phase (Weeks 13 through 24): Participants who continue to meet study entry criteria, will enter the OLE phase and receive a single oral dose of rimegepant ODT EOD for 12 weeks. If participants have a migraine on a day that they are not scheduled to dose with rimegepant, they can take one tablet of rimegepant ODT on that calendar day to treat a migraine (as needed [PRN] dosing)."
89446801|NCT02859519|Placebo Comparator|MOB015B Vehicle|Subjects will treat all affected fingernails and/or toenails with MOB015B Vehicle for 48 weeks once daily at bedtime.
89446802|NCT02226471||NW-NBP group|normal weight and blood pressure subjects
89446803|NCT02226471||NW-HTN group|Normal weight with hypertension subjects
88931814|NCT05810038|Placebo Comparator|DBT Placebo/OLE Rimegepant|"DBT Phase (Weeks 1 through 12): Participants will receive a single oral dose of placebo matching to rimegepant ODT EOD for 12 weeks.~OLE Phase (Weeks 13 through 24): Participants who continue to meet study entry criteria, will enter the OLE phase and receive a single oral dose of rimegepant ODT EOD for 12 weeks. If participants have a migraine on a day that they are not scheduled to dose with rimegepant, they can take one tablet of rimegepant ODT on that calendar day to treat a migraine (PRN dosing)."
88931815|NCT05806515|Experimental|Treatment (carboplatin)|Patients receive carboplatin IV on study. Patients then undergo surgery on study. Patients who experience PSA progression after surgery undergo CT or MRI of the abdomen and pelvis, CT of the chest or chest X-ray, or PSMA-PET throughout the trial. Patients also undergo collection of blood samples throughout the trial.
88931816|NCT05799313|Experimental|At home removal|
88931817|NCT05799313|Active Comparator|In office removal|
88931818|NCT05793957|Experimental|Group 1 (VR)|Patients use VR during chemotherapy infusion on study.
88931819|NCT05793957|Active Comparator|Group 2 (Smartphone)|Patients use smartphone during chemotherapy infusion on study.
88931820|NCT05781620|Experimental|Vitamin D group|
88931821|NCT05781620|Placebo Comparator|Placebo group|
88931822|NCT05769881|Active Comparator|Ultrasound guided subcostal transversus abdominis plane block|After the induction of anesthesia, before the beginning of the operation, the subcostal transversus abdominis region is going to be detected under ultrasound guidance and 25-30 ml of 0.25% bupivacaine will be administered
88931823|NCT05769881|Active Comparator|Wound site local anesthetic infiltration|After induction of anesthesia, before the beginning of the operation, a total of 20 ml of 0.25% bupivacaine is going to be infiltrated in equal doses to the four regions that will have trocar access.
88931824|NCT05760781|Experimental|lowest dose treatment group|Subjects will receive one single lowest dose of STSG-0002 Injection following protocol requirements
88931825|NCT05760781|Experimental|low dose treatment group|Subjects will receive one single low dose of STSG-0002 Injection following protocol requirements
88931826|NCT05760781|Experimental|Intermediate dose treatment group|Subjects will receive one single intermediate dose of STSG-0002 Injection following protocol requirements
88931827|NCT05760781|Experimental|A single high dose of treatment group|Subjects will receive one single high dose of STSG-0002 Injection following protocol requirements
88931828|NCT05760703|Experimental|lowest dose treatment group|Subjects will receive one single lowest dose of STSG-0002 Injection following protocol requirements
88931829|NCT05760703|Experimental|low dose treatment group|Subjects will receive one single low dose of STSG-0002 Injection following protocol requirements
88931830|NCT05760703|Experimental|Intermediate dose treatment group|Subjects will receive one single intermediate dose of STSG-0002 Injection following protocol requirements
88931831|NCT05760703|Experimental|A single high dose of treatment group|Subjects will receive one single high dose of STSG-0002 Injection following protocol requirements
88931832|NCT05758337|Experimental|A group with exposure of vibropneumostimulation|The first group is a group of subjects on whom, after implantation, a new technique was applied, including the effect of vibropneumostimulation on the pereimplant tissues.
88931833|NCT05758337|No Intervention|A group of standart therapy|The second is a group of subjects whose rehabilitation was carried out by the well-known classical method.
88931834|NCT05758194|Active Comparator|Standardized RV Management|Physicians will follow prespecified parameters for RV management (consistent with SOC)
88931835|NCT05758194|Active Comparator|Usual Care RV Management|Physicians will use their own clinical judgement with no prespecified goals for RV management parameters (consistent with SOC)
88931836|NCT05757466|Experimental|Main arm|"Patients receive 6 cycles of prolgolimab monotherapy with subsequent assessment of response by PET/CT using Lugano and LYRIC criteria. Patients with complete response continue prolgolimab therapy for up to 24 cycles. Patients are switched to combination therapy with prolgolimab and chemotherapy (bendamustine) if the complete response is not achieved after 6 cycles of therapy or in case of relapse during prolgolimab monotherapy.~Patients without complete response after 6 cycles of prolgolimab monotherapy or with relapse during monotherapy will receive 3 cycles of combination therapy with prolgolimab and bendamustine every 28 days. Collection of hematopoietic stem cells is performed at any stage of combination therapy. Response evaluation after 3 cycles of combination therapy is performed by PET/CT using Lugano and LYRIC criteria. Autologous stem cell transplantation is conducted in patients who achieve complete or partial response."
88931837|NCT05754216|Other|Surgical Procedure|Consented patients who meet eligibility will have a surgical procedure for management of head and neck cancer, with dissection and exposure of the relevant anatomic structures as part of regular clinical care.
88931838|NCT05746208|Experimental|Lenvatinib Plus Pembrolizumab|Participants will receive 20 mg once daily of lenvatinib plus 400 mg of pembrolizumab every 6 weeks for up to 18 doses. Eligible participants may also receive a Hyperpolarized 13C-pyruvate (HP 13C) magnetic resonance imaging (MRI) scan
89014050|NCT05848323|Experimental|Cognitive Therapy|Didactic material and practice focused on identifying, challenging, and modifying inaccurate and/or unhelpful patterns of thought about the self and the world (e.g., catastrophizing the meaning and consequences of fatigue) to change unwanted behavioral patterns (e.g., excessive rest).
89200200|NCT00763620|Experimental|1|Catheter for mini bronchoalveolar lavage
89200201|NCT04018131|Active Comparator|Cimetidine|
89200202|NCT04018131|Placebo Comparator|Placebo|
89446804|NCT02226471||OB-NBP group|obese-normal blood pressure subjects
89446805|NCT02226471||OB-HTN group|Obese-hypertension subjects
89446806|NCT03475446|Placebo Comparator|sham tES healthy elderly|30 s of sham transcranial electric current stimulation applied via 5x7 cm and 10x10 cm rubber electrodes over the left DLPFC and supraorbital region. Additional ramp-up and ramp-down phase at beginning and end of stimulation lasting for 15 s. Electrodes remain attached to the participant's head for 20 minutes.
89014051|NCT05848141|Experimental|Indoor Rowing|Research participants will be instructed how to use a Concept 2 RowErg and will be provided instruction on basic rowing skills for beginners. Exercise training will gradually progress to 50 min of moderate-intensity exercise, on 3 days per week, for 12 weeks.
89014052|NCT05848141|No Intervention|Usual Care|Research participants in this group will have the opportunity to complete the supervised indoor rowing program after completing their post-intervention assessments.
89014053|NCT05845866|Experimental|Modified Body Project|Participants will receive this four week intervention followed by 6 months of behavioral weight management
89014054|NCT05845866|Active Comparator|Facts about obesity, myths about weight loss|Participants will receive this four week intervention followed by 6 months of behavioral weight management
89014055|NCT05843721|Other|KOS treatment|Treatment with intranasal kinetic oscillation stimulation (KOS)
89014056|NCT05842603|Experimental|Cardiac Lifestyle Program|"Participants will complete study procedures as follows:~Baseline in-clinic visit with research team doctor for history and physical and the completion of questionnaires.~6 virtual group classes alternating with 6 in-person group classes.~Semi-structured exit interview."
89014057|NCT05839262|Experimental|Experimental group|Conventional physical rehabilitation plus Active video games (CPR+AVG)
89014058|NCT05839262|Active Comparator|Control group|Conventional physical rehabilitation alone (CPR)
89014059|NCT05828082|Experimental|Treatment (tuvusertib)|Patients receive tuvusertib PO QD on days 1-14. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo biopsy, MRI, CT, PET/MRI, PET/CT or U/S and collection of blood samples throughout the trial.
89014060|NCT05823571|Experimental|Itacitinib|Itacitinib will be given at 200 mg orally daily from day -3 to day 90. Itacitinib will be given in conjunction with one of four different regimens for immunosuppression. These 4 regimens are listed in Table 2, Section 5.2 of the protocol. Itacitinib may continue beyond day +90 if there is GVHD. NOTE: If patient develops GVHD requiring treatment after all immune suppression, including itacitinib, is stopped on day +90, the itacitinib will not be restarted and the patient will be treated per standard of care.
89014061|NCT05822141|Experimental|Fish Oil (Omega-3 Fatty Acids)|15 subjects will ingest 6 capsules of fish oil of per day for 12 weeks
89014062|NCT05822141|Placebo Comparator|Olive Oil|15 subjects will ingest 6 capsules of olive oil per day for 12 weeks
89014063|NCT05816785|Experimental|Imatinib Cetuximab Combination|Participants will receive two doses of CTX and a minimum of an 8 day (maximum 14 day) course of imatinib prior to definitive surgery or definitive radiation/chemoradiation.
89537095|NCT02467673|Active Comparator|MICRONIZED estradiol+ progesterone|"The Blood samples are collected from the subjects early in the morning after an overnight fast. After serum testing, the identification hormone deficiencies, was determined and then, if necessary, additional transdermal micronized estradiol and progesterone is prescribed.~The patients are evaluated 3 months after THRT treatment protocol. All the patients were instructed about how to use the pump for transdermal application, the first application is performed in the presence of an experienced physician, in order to guarantee standardization and correct use of the THRT. Compliance was defined as completing seventy percent or more of the transdermal applications."
89014065|NCT05815017|Experimental|Gamified Physical Therapy Exercise Software Intervention + Usual Care|Participants randomized to the intervention group will be asked each day by a volunteer whether they would like to use the gamified physical therapy exercise software while in their beds. Participants willing to exercise will have the device set up for them to participate by a volunteer and the software will begin with a tutorial video for different exercises and then ask patients to perform in sequence with prompting and motion tracking. Exercises include Frontal Bicep Curls, Arm Crosses, Press Ups, Arm Rotations, and Basketball Shots.
89014066|NCT05815017|No Intervention|Usual Care|Usual Care
89014069|NCT05807269||People with stroke|Participants with stroke or risk factors for stroke
89014070|NCT05804435|Experimental|iNod™ System|Subjects with a qualifying lung lesion will have a standard of care Transbronchial Needle Aspiration using the the iNod™ System
89200203|NCT00767052|Experimental|Active|AZD1236 tablet
89014071|NCT05797480|Experimental|Experimental: Real Dry needling|1 dry needling treatment per week for 6 consecutive weeks
89014072|NCT05797480|Sham Comparator|Sham: Non penetrating dry needling|1 non penetrating dry needling per week for 6 consecutive weeks
89014073|NCT05796167|Experimental|Pimavanserin (Nuplazid)|Pimavanserin (Nuplazid) 34 mg oral capsules once a day for 6 weeks for patients with Parkinson disease psychosis (e.g., visual hallucinations, delusions) and sleep problems
89014074|NCT05789862|Experimental|Virtual behavioral health|Participants will be assessed at 3 time points over the course the standard-of-care treatment before and after a scheduled craniotomy. At each time point, the participants will be asked to complete the questionnaires and engage in virtual counseling sessions.
89014075|NCT05779306||Carlevale|Patients who had a Carlevale lens implanted
89014076|NCT05779306||Yamane|Patients who had a lens implanted using Yamane technique
89014077|NCT05778734|Other|Treatment group|"For the R00 phase: CM-PST treatment group will receive CM-PST intervention, which will consist of 8 sessions total, delivered remotely via Zoom videoconferences in individual sessions over 12 weeks. The first 4 sessions will be delivered weekly, and the remaining 4 sessions every other week. CM-PST will teach participants problem-solving skills using a structured 5-step method. In addition, participants will receive incentives for alcohol abstinence and submission of urine samples twice/wk.~K99 phase participants will also receive CM-PST intervention."
89014078|NCT05778734|Other|Control group|For the R00 phase: Participants in CM-only control will receive incentives for alcohol abstinence and submission of urine samples twice/wk. Participant incentives will start at a $10 gift card, with a $5 increase each subsequent measurement point on which alcohol is not detected or reported, to a maximum of $25, but no gift card on days when alcohol use is detected or reported, and the gift card reinforcer value will be re-set to $10.
89200204|NCT00767052|Placebo Comparator|Placebo|Placebo tablet
89200205|NCT00767052|Other|Relative bioavailability|AZD1236 Oral suspension
89200206|NCT00767052|Other|Relative bioavailability tablet|AZD1236 tablet
89200207|NCT00973882|Experimental|Carboplatin-Etoposide|
88931839|NCT05744167|Experimental|Blood flow restriction training (BFRT)|Participants will engage in a supervised 12-week lower extremity resistance exercise program, 2 times per week. BFRT will be at an intensity of 40% of 1RM with an occlusive cuff placed at the proximal end of both lower extremities to restrict the return of blood flow. The cuff will be inflated to 50% of the limb occlusion pressure in the first week, which will be increased with 10% every week during the first 4 weeks to reach a maximum of 80% limb occlusion pressure on week 4 that will be kept for the remaining 9 weeks of the program. Each exercise will be performed for 4 sets of 12 repetitions with a 30-second rest period between sets and 3 minutes rest between exercises without occlusion.
89446807|NCT03475446|Placebo Comparator|sham tES MCI|30 s of sham transcranial electric current stimulation applied via 5x7 cm and 10x10 cm rubber electrodes over the left DLPFC and supraorbital region. Additional ramp-up and ramp-down phase at beginning and end of stimulation lasting for 15 s. Electrodes remain attached to the participant's head for 20 minutes.
89446808|NCT03475446|Placebo Comparator|sham tES AD|30 s of sham transcranial electric current stimulation applied via 5x7 cm and 10x10 cm rubber electrodes over the left DLPFC and supraorbital region. Additional ramp-up and ramp-down phase at beginning and end of stimulation lasting for 15 s. Electrodes remain attached to the participant's head for 20 minutes.
89446809|NCT03475446|Experimental|real anodal tDCS healthy elderly|20 min of 2 mA real anodal transcranial direct current stimulation applied via 5x7 cm rubber electrode over the left DLPFC and cathodal 10x10 rubber electrode over supraorbital region. Additional ramp-up and ramp-down phase of 15 s at the beginning and the end of stimulation.
89446810|NCT03475446|Experimental|real anodal tDCS MCI|20 min of 2 mA real anodal transcranial direct current stimulation applied via 5x7 cm rubber electrode over the left DLPFC and cathodal 10x10 rubber electrode over supraorbital region. Additional ramp-up and ramp-down phase of 15 s at the beginning and the end of stimulation.
89446811|NCT03475446|Experimental|real anodal tDCS AD|20 min of 2 mA real anodal transcranial direct current stimulation applied via 5x7 cm rubber electrode over the left DLPFC and cathodal 10x10 rubber electrode over supraorbital region. Additional ramp-up and ramp-down phase of 15 s at the beginning and the end of stimulation.
89446812|NCT03475446|Experimental|real tACS healthy elderly|20 min of 1 mA real transcranial alternating current stimulation in theta frequency applied via 5x7 cm rubber electrode over the left DLPFC and cathodal 10x10 rubber electrode over supraorbital region. Additional ramp-up and ramp-down phase of 15 s at the beginning and the end of stimulation.
89446813|NCT03475446|Experimental|real tACS MCI|20 min of 1 mA real transcranial alternating current stimulation in theta frequency applied via 5x7 cm rubber electrode over the left DLPFC and cathodal 10x10 rubber electrode over supraorbital region. Additional ramp-up and ramp-down phase of 15 s at the beginning and the end of stimulation.
89446814|NCT03475446|Experimental|real tACS AD|20 min of 1 mA real transcranial alternating current stimulation in theta frequency applied via 5x7 cm rubber electrode over the left DLPFC and cathodal 10x10 rubber electrode over supraorbital region. Additional ramp-up and ramp-down phase of 15 s at the beginning and the end of stimulation.
89446815|NCT02222727|Active Comparator|Donepezil|Participants in the donepezil arm will receive the drug for 21 days as specified in the protocol in addition to current best medical treatment for aSAH patients.
88931840|NCT05744167|Experimental|Muscle damaging resistance training (MDRT)|Participants will engage in a supervised 12-week lower extremity resistance exercise program, 2 times per week. MDRT will be at an intensity of 80% or 120% of 1RM. The first session will be at 120% 1RM and consist of eccentric-only exercises. The concentric phase of the movement will be supported completely by a coach. The eccentric phase of the movement will be accentuated by increasing the time under tension to six seconds. Each exercise will be performed for 4 sets of 4 repetitions with 2 minutes rest between sets and 3 minutes rest between exercises. The eccentric-only exercise session will be followed by 2 (after the first session) or 3 (after all other sessions) concentric-only exercise sessions at 80% of 1RM. Here, the eccentric phase of the movement will be supported completely by a coach. In the 12 week period, there will be a total of seven eccentric-only exercise sessions.
88931841|NCT05744167|No Intervention|Control group|Control group will be asked to maintain their usual lifestyle.
88931842|NCT05735067||Group 1|RRMS patients who received Interferon beta 1a and have normal weight
88931843|NCT05735067||Group 2|RRMS patients who received Interferon beta 1a and have are obese
88931844|NCT05724095|Sham Comparator|control|
89446816|NCT02222727|No Intervention|Control|Control group participants will not receive a placebo drug but will undergo cerebral blood flow imaging in the same manner as the donepezil patients. All other aspects of treatment will be identical to that of aSAH patients not involved in the study.
89446817|NCT03475368|Experimental|Vegetarian diet|People randomized to interventional groups will take a vegetarian diet (i.e. without animal products, except milk and eggs)
89446818|NCT03475368|Experimental|Low carbs|People randomized to interventional groups will take a low carbs diet (i.e. with a limited amount of carbohydrates).
89446819|NCT03475368|Active Comparator|Mediterranean diet|People randomized to interventional groups will take a mediterranean diet (i.e. with low glycemic index carbohydrates and vegetables).
88931845|NCT05724095|Experimental|low frequency stimulation|
88931846|NCT05724095|Experimental|high frequency stimulation|
88931847|NCT05723614|No Intervention|Control|
88931848|NCT05723614|Experimental|Intervention|The two components in the intervention arm of TRUE HAVEN are: housing support for recently incarcerated people as well as family members of currently incarcerated people, and mental wellness training for neighborhood residents to participate in trauma-informed care training sessions.
88931849|NCT05715814|Experimental|Empagliflozin|
88931850|NCT05711758||PSAM Treatment Patients|Subjects having esophagogastroduodenoscopy (EGD) with Pylorus Sparing Antral Myotomy (PSAM) with standard of care lifestyle modification therapy.
89200208|NCT02558322||Primary medical care in rural areas|People living in districts, where less than 50% of the population live in cities with more than 20,000 residents and the population density outside of the cities is below 100 people per km². Excluding people living in cities with a population of at least 100,000 residents.
89446820|NCT02723786|Experimental|GSK1070806 3 mg/kg IV|Subjects received a single dose of 3 milligram per kilogram (mg/kg) intravenous (IV) infusion of GSK1070806 administered prior to kidney allograft reperfusion. Subjects also received a combination immunosuppression comprized of basiliximab; mycophenolate mofetil (MMF) or aziothioprine; tacrolimus; and corticosteroids based on the clinical judgment of the investigator.
89446821|NCT03482466|Experimental|PTSD patients|12 PTSD patients will be recruited to undergo neurofeedback training .
89446822|NCT02222805|Other|Early cord clamping (ECC)|Early (≤30 seconds) cord clamping of the umbilical cord after delivery.
89446823|NCT02222805|Other|Delayed cord clamping (DCC)|Delayed (≤180 seconds) cord clamping of the umbilical cord after delivery.
88931851|NCT05704868|Experimental|UniVRse + TAU|UniVRse is a Virtual Reality (VR) intervention targeting social anxiety in students using cognitive behavioural therapy (CBT) techniques - specifically graded exposure. Participants will have access to UniVRse for a month post-randomisation and it is recommended they complete 6 sessions each 30-minutes long over this period. Exposure to the intervention will be reached if participants complete 2 30-minute sessions. UniVRse is a self-help intervention meaning that participants can engage in the intervention independently. Participants will be supported to progress through the UniVRse programme by a virtual mentor called Sam that will take on the role traditionally undertaken by the 'therapist'. Sam's function will be to provide psychoeducation, provide instruction on how to use the VR kit and interact with the virtual environment, and provide support and encouragement. Participants will be able to complete the intervention either on campus or at home.
88931852|NCT05704868|No Intervention|Waitlist + TAU|We will be using a wait list control group. The wait list control group will receive treatment as usual for the duration of the trial. Treatment as usual may include active monitoring, meetings with academic advisors, psychiatric medication, and/or support from an NHS mental health team. We will not withhold treatment from the control group, but prospective participants may not be eligible to take part if they have current or confirmed plans to receive a psychology therapy (see exclusion criteria). Once the trial has ended, the participants in the control arm will be the first to be offered UniVRse when it is taken up by university support services.
89446824|NCT03475290|Experimental|Self-Efficacy and Perceived Social Support|
88931853|NCT05701527|Experimental|Part A-Cohort 1|Patients will be administered Dose 1 of EBC-129 as a monotherapy.
88931854|NCT05701527|Experimental|Part A-Cohort 2|Patients will be administered Dose 2 of EBC-129 as a monotherapy.
88931855|NCT05701527|Experimental|Part A-Cohort 3|Patients will be administered Dose 3 of EBC-129 as a monotherapy.
88931856|NCT05701527|Experimental|Part A-Cohort 4|Patients will be administered Dose 4 of EBC-129 as a monotherapy.
88931857|NCT05701527|Experimental|Part A-Cohort 5|Patients will be administered Dose 5 of EBC-129 as a monotherapy.
88931858|NCT05701527|Experimental|Part B|Patients will be administered three different dose levels of EBC-129 in combination with a fixed dose of pembrolizumab.
88931859|NCT05701527|Experimental|Part C|Patients will be administered the highest dose of EBC-129 as a monotherapy at the RP2D determined in Part A of the study.
88931860|NCT05674175|Experimental|Dose Finding Arm|Phase 1 will evaluate the safety of co-administration of CART22-65s with huCART19 in patients who experienced a disease relapse after prior CAR T cell therapy. There is no planned dose escalation but a dose-deescalation will be made based on the incidence of Dose Limiting Toxicities
88931861|NCT05674175|Experimental|Expansion Arm|If at least one dose level of phase 1 is determined to be safe, the phase 2 dose expansion phase of the trial will be opened to enrollment. Subjects will receive the highest dose of CART 22-65s and huCART19 cells that were determined to be safe. 2 cohorts are planned: Cohort A (relapsed/refractory, CAR T cell naïve) & Cohort B (prior treatment with a prior CAR T cell product).
88931862|NCT05674149|Other|Multi-Spectral Camera|Multi-Spectral Camera will be used in order to capture images of different skin conditions
89200209|NCT02558322||Primary medical care in region environs|People living in districts, where 50% or more of the population live in cities with more than 20,000 residents and/or population density outside of the cities is above 100 people per km². Excluding people living in cities with a population of at least 100,000 residents.
89200210|NCT02558322||Primary medical care in in urban areas|People living in cities with a population of at least 100,000 residents.
89446825|NCT03475290|Experimental|Perceived Social Support and Self-Efficacy|
89446826|NCT03475290|Active Comparator|Self-Efficacy|
89446827|NCT03475290|Active Comparator|Perceived Social Support|
89446828|NCT02226705|Experimental|Multiple Surgeries|Patients undergoing transnasal endoscopic surgery
89446829|NCT02471456||EVH|Patients that have undergone Endoscopic Vein Harvesting (EVH)
89446830|NCT02471456||OVH|Patients that have undergone open vein harvest (OVH)
89446831|NCT03479346|Experimental|GGT group|Usage: 3g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: HANPOONG PHARM & FOODS Co. Ltd.
89446832|NCT03479346|Placebo Comparator|Placebo group|Usage: 3g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: HANPOONG PHARM & FOODS Co. Ltd.
89446833|NCT02222883||patients with primary diagnosis|patients with primary diagnosis of ovarian cancer for testing of BRCA status regarding germline and somatic mutation
89446834|NCT02222883||patients with platinum-sensitive recurrence|patients with platinum-sensitive recurrence of ovarian cancer for testing of BRCA status regarding germline and somatic mutation
89446835|NCT03310814|Experimental|Personalized nutrition intervention|Participant receives gene-test results plus personalized nutrition information from a registered dietician
89446836|NCT03310814|Placebo Comparator|Usual nutrigenomics intervention|Participant receives usual nutrigenomics intervention (direct-to-consumer)
89446837|NCT04382820||Families of rare chronically ill children|Clinical study participants for the diagnostic study are patients who have sought treatment at the University Medical Center Hamburg-Eppendorf due to a rare pediatric surgical disease. Every family receives a comprehensive psychosocial diagnostic in the form of standardized instruments.
89446838|NCT04382820||Families in the comparative control group|Participants in the healthy control sample are matched to the clinical sample in terms of age and gender. Included are families of children aged 0-21 years, who have undergone a surgical procedure in the first 3 years of life that does not cause chronic complaints; such as hernia surgery or testicular relocation.
89446839|NCT02222961|Experimental|BIIR 561 CL|
88931864|NCT05661461|Experimental|Experimental|nab-Sirolimus
88931865|NCT05656105|Experimental|Healty Volunteers|
88931866|NCT05656105|Experimental|PASC|Patients meeting the case definition criteria for PASC
88931867|NCT05651802|Active Comparator|Control arm|Patients who are randomized to control arm are those who have achieved complete remission of tumor after definitive radio-chemotherapy and will receive PCI and regular brain MRI follow-up.
88931868|NCT05651802|Experimental|Study arm|Patients who are randomized to study arm are those who have achieved complete remission of tumor after definitive radio-chemotherapy and will receive regular brain MRI follow-up alone.
88931869|NCT05651659|Experimental|Interventions municipalities|Locally adapted TIME (Targeted Interdisciplinary Model for Evaluation and Treatment of Neuropsychiatric Symptoms) intervention. Municipalities will be randomly assigned to either the intervention group or the control group. A biostatician will perform the randomisation procedure independently of the project management team and the municipalities. The project management team will provide the home care services in the municipalities with the randomisation and allocation results immediately following this procedure. The intervention will start with the educational sessions (described below) within one to two weeks after randomisation.
88931870|NCT05651659|No Intervention|Control municipalities|Care as usual
88931871|NCT05650710|Other|Surgical Procedure|Consented patients who meet eligibility will have a surgical procedure for management of head and neck cancer, with dissection and exposure of the relevant anatomic structures as part of regular clinical care.
88931872|NCT05646784|Experimental|Cerebiome for Depressive patient|Patients in a current episode of MDD admitted at Hotel-Dieu de France University Hospital, as determined by the Mini International Neuropsychiatric Interview (MINI) per DSM-IV criteria. Outpatients followed by physicians from Hotel-Dieu de France University Hospital will also be recruited
88931873|NCT05646784|Placebo Comparator|Placebo for Control group|Second group of patients in a current episode of MDD admitted at Hotel-Dieu de France University Hospital, as determined by the Mini International Neuropsychiatric Interview (MINI) per DSM-IV criteria. Outpatients followed by physicians from Hotel-Dieu de France University Hospital will also be recruited
88931874|NCT05646095|Experimental|Bolstering Sleep and Adjustment in Foster Environments (B-SAFE)|Brief, behavioral sleep intervention for children and caregivers
88931875|NCT05646095|Active Comparator|Delayed Intervention|Waitlist families will be monitored for 1 month before receiving the B-SAFE intervention
88931876|NCT05636514|Experimental|Decitabine/cedazuridine + defactinib|"Decitabine/cedazuridine taken days 1-5 of each 28 day treatment cycle, cycle 1 to 6~Defactinib taken on days 1-5 of each 28 treatment day cycle from cycle 2 to cycle 6."
88931877|NCT05630170|Experimental|AI-ECG|A novel AI-ECG model developed at the Cardiovascular Data Science (CarDS) lab will be used as Software as Medical Device (SaMD) on ECG images for detection of LVSD.The AI-ECG model will be used on all participants undergoing a 12-lead ECG.
88931878|NCT05627713|Other|Individuals coming to CMIP for MONKEYPOX disease management|"300 individuals eligible for MPXV vaccination and~30 individuals suspected of MPXV infection."
89200211|NCT03666819|Experimental|Treatment (carbon dioxide fractional laser)|Participants undergo carbon dioxide fractional laser therapy over 10-15 minutes on day 1. Treatment repeats every 28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
89446840|NCT02222961|Placebo Comparator|Placebo|
89446841|NCT03479190|Active Comparator|Platelet rich plasma|ultrasound guided injection of Platelet rich plasma
89446842|NCT03479190|Placebo Comparator|Normal saline|ultrasound guided injection of Normal saline
89446843|NCT03000998|Experimental|Web App Intervention Group|The BoyVac mobile web app will be evaluated in a pair-matched group-randomized pretest-posttest controlled design. In Year 2, 30 clinics in New Mexico will be pair-matched and one member of each pair will be randomized to the intervention (mobile web app) or a usual and customary (UC) HPV vaccine adoption procedures comparison group. Clinics will be paired based on similarities in patient demographic (ethnicity and % Medicaid patients) and location (urban and rural).
89446844|NCT03000998|Active Comparator|Usual Customary Care Group|Currently in pediatric clinics in New Mexico, the HPV vaccines are offered to parents and adolescents as part of annual well-child checkups. Typically for boys aged 11-13, parents initiate this checkup as part of a back-to-school activity. As part of the well-child checkup, clinic staff (physician, physician assistant and/or nurse) talk with parents and adolescents about the recommendation that their sons or daughters receive the HPV vaccination. Well-child pediatric visits to promote good health and development are recommended for all children from infancy through adolescence by the American Academy of Pediatrics.
89446845|NCT02226783|Experimental|Treatment A AZD1722 salt tablet (fasted)|Part A-Treatment A: morning dose of AZD1722 salt tablet 5 to 10 minutes before start of intake of breakfast; evening dose 5 to 10 minutes before start of intake of dinner
89446846|NCT02226783|Experimental|Treatment B AZD1722 salt tablet (fed)|Part A Treatment B: morning dose of AZD1722 salt tablet 30 minutes after start of intake of breakfast; evening dose 30 minutes after start of intake of dinner
89446847|NCT02226783|Experimental|Treatment C AZD1722 salt tablet (fasted)|Part A Treatment C: morning dose AZD1722 HCl tablet then breakfast served 1 hour after dosing; evening dose 3 hours after start of intake of dinner and 1 hour before the next meal consumption
89446848|NCT02226783|Experimental|Treat D AZD1722 free-base tablet (fast)|Part B Treatment D: morning dose of AZD1722 free-base tablet administered 5 to 10 minutes before the start of intake of breakfast and evening dose 5 to 10 minutes before start of intake of dinner
89446849|NCT02226783|Experimental|Treat E AZD1722 free-base+Omeprazole|Part B Treatment E: morning dose of AZD1722 free base tablet administered 5 to 10 minutes before start of intake of breakfast and evening dose 5 to 10 minutes before start of intake of dinner; omeprazole was administered twice daily from Days -5 to -1 or Days 5 to 9 (depending on assigned treatment period), 1 hour before breakfast and dinner, and from Days 1 to 4 or Days 10 to 13, 1 hour prior to the administration of AZD1722
89446850|NCT03479112|Experimental|Flashcards|Study participants in this arm of the trial received bleeding control flashcards that contain diagrams and figures to correctly identify the severity of the injury and visual instructions on the appropriate application of pressure dressing, hemostatic packing, and tourniquet.
89446851|NCT03479112|Experimental|Audio-kit|Study subjects in this arm received a commercially available audio bleeding control kit. The kit included a diagram and visual aids to identify the correct severity of the injury and determine the appropriate method of bleeding control. The kit also had buttons on it to play stepwise audio instructions on the application of compression dressing, hemostatic packing and tourniquet application in two languages (English and Spanish). The audio kits were bought at the market price and the name of the manufacturer was not mentioned in the manuscript to avoid conflict of interest.
89446852|NCT03479112|Experimental|Bleeding Control (B-Con) training|Study subjects in this arm were given the American College of Surgeons Bleeding Control Basic (B-Con) in-person training course by qualified instructors. This curriculum was developed by a collaboration between American College of Surgeons and the Hartford Consensus. The session included a multimedia presentation in a class format that included some background information about extremity hemorrhage and potential benefits of immediate first-response and hemorrhage control, steps to take in a mass casualty scenario and instructional videos on hemorrhage control modalities and their appropriate use. This was followed by hands-on training in hemorrhage control, with 1:4, instructor to trainee ratio.
89200212|NCT05278455|Experimental|Lifestyle Medicine Group|Lifestyle medicine smartphone app The lifestyle medicine app contains eight weekly modules that cover healthy eating, exercise, stress management, sleep management, lifestyle psychoeducation, and goal setting.
89446853|NCT03479112|No Intervention|Control|Study subjects in this arm of the trial received no intervention (no training or access to point-of-care prompts) to assess baseline competence in hemorrhage control.
89446854|NCT03479112|Experimental|Retention of B-Con course|Control, Audio-kit, and flashcard arms undergo B-Con training at the completion of the initial evaluation, and the B-Con arm completed training prior to testing in order that all participants obtain training and then can be evaluated at retention testing. a. 3-9 months after the trial, investigators planned to test all study subjects with a simulated mass causality scenario for retention of knowledge and skills. This test will be the same as the initial test for competence at tourniquet placement in the trial and the same evaluation form will be used to evaluate the study subjects.
89446855|NCT03310658|Experimental|Single Study Site: UANL|As the only study arm, 10 enrolled subjects received vaginal cuff closure with the Zip-Stitch Soft Tissue Closure System as part of Total Laparoscopic Hysterectomy.
89446856|NCT02223117|Experimental|Intervention|Thrombosomes
89446857|NCT02223117|Placebo Comparator|Placebo|Buffer/placebo Control
89446858|NCT04559438|Experimental|Rotary Neoniti GPS|Glide path preparation using Rotary Neoniti GPS file (Neolix, châtres-la-Forêt, France).
88931879|NCT05620186|Other|Original PROSPECT|Original, distributed PROSPECT where trainees learn at their own pace in between, before/after clinical activities
89446859|NCT04559438|Active Comparator|Stainless steel K-files|Glide path preparation using manual stainless steel K-files #10, #15 (Dentsply Maillefer, Ballaigues, Switzerland).
89446860|NCT02226861|Experimental|1|Subjects will receive CD34-selected stem cells followed by fixed dose ULG IL-2 (100,000 IU/m2) given subcutaneously for 12 weeks+Sirolimus until Day +60
89446861|NCT03482388|Experimental|Crowdsourced intervention|A multimedia component will deliver two videos and two images promoting HBV and HCV testing developed through a crowdsourcing contest in China. A participatory component will invite men to submit suggestions for how to improve crowdsourced videos and images.
89446862|NCT03482388|Other|Control|No images or videos will be viewed, and suggestions for improving hepatitis testing materials will not be collected.
89446863|NCT02226939|Experimental|BILN 2061 ZW|
89446864|NCT02226939|Placebo Comparator|Placebo|
88931880|NCT05620186|Other|Massed PROSPECT|Massed, bootcamp-style training form of PROSPECT where trainees are exempt from clinical duties
88931881|NCT05610033|Experimental|AtaCor EV Temporary Pacing Lead System|Subjects implanted with the AtaCor StealthTrac Lead Model AC-101400
89200213|NCT05278455|No Intervention|Waitlist Control Group|The waitlist control group will receive access to the lifestyle medicine app at the end of the study.
89200214|NCT02558088|Experimental|salmeterol|
89200215|NCT05279482||group treated with standard dose methyl prednisolone|patients with positive PCR and requiring oxygen therapy
88931882|NCT05604287|Experimental|SAD: ID119031166M|
88931883|NCT05604287|Experimental|MAD: ID119031166M|
88931884|NCT05604287|Placebo Comparator|SAD: Placebo|
88931885|NCT05604287|Placebo Comparator|MAD: Placebo|
88931886|NCT05602649|Placebo Comparator|Placebo Gummy|Participants will self-administer a gummy containing 0mg THC
88931887|NCT05602649|Experimental|Low Dose Gummy|Participants will self-administer a gummy containing 10mg THC
88931888|NCT05602649|Experimental|High Dose Gummy|Participants will self-administer a gummy containing 25mg THC
88931889|NCT05602649|Placebo Comparator|Placebo Chocolate|Participants will self-administer chocolate containing 0mg THC
88931890|NCT05602649|Experimental|Low Dose Chocolate|Participants will self-administer chocolate containing 10mg THC
88931891|NCT05602649|Experimental|High Dose Chocolate|Participants will self-administer chocolate containing 25mg THC
88931892|NCT05602649|Placebo Comparator|Placebo Beverage|Participants will self-administer a beverage containing 0mg THC
88931893|NCT05602649|Experimental|Low Dose Beverage|Participants will self-administer a beverage containing 10mg THC
88931894|NCT05602649|Experimental|High Dose Beverage|Participants will self-administer a beverage containing 25mg THC
88931895|NCT05601180|Active Comparator|Stadard of care|standard treatment that is prescribed by the treating physician.
88931896|NCT05601180|Experimental|Standard of care + Respicure®|standard treatment that is prescribed by the treating physician in addition to Respicure®
88931897|NCT05594992|Experimental|JR-141 2.0 mg/kg/week|
88931898|NCT05590377|Experimental|Phase 1 Dose Escalation|Modakafusp alfa 60 to 240 mg, infusion, intravenously, once every 4 weeks (Q4W) with daratumumab 1800 mg, subcutaneously (SC), once weekly (QW) in Cycles 1 and 2, twice weekly (Q2W) in Cycles 3 to 6, and Q4W thereafter in each 28-day treatment cycle until disease progression.
88931899|NCT05590377|Experimental|Phase 2a Dose Finding: Modakafusp Alfa (DL1) + Daratumumab|Modakafusp alfa at dose level 1 (DL1) [selected from Phase 1 Dose Escalation] with daratumumab SC 1800 mg, SC, QW in Cycles 1 and 2, Q2W in Cycles 3 to 6, and Q4W thereafter in each 28-day treatment cycle until disease progression.
88931900|NCT05590377|Experimental|Phase 2a Dose Finding: Modakafusp Alfa (DL2) + Daratumumab|Modakafusp alfa at dose level 2 (DL2) [selected from Phase 1 Dose Escalation] with daratumumab SC 1800 mg, SC, QW in Cycles 1 and 2, Q2W in Cycles 3 to 6, and Q4W thereafter in each 28-day treatment cycle until disease progression.
88931901|NCT05588193|Experimental|Post Visit Outreach|Outreach by trained patient navigators/educators after patients' ED visit for education, counseling, linkage to preventive/sexual health care.
88931902|NCT05588193|Experimental|Tele-Sexual Healthcare|Tele-sexual health visit with a specialist offered during the ED visit to patients.
88931903|NCT05584644||Palbociclib plus hormonal treatment - first line treatment|Patients who initiated Palbociclib + hormonal therapy in the first line treatment
88931904|NCT05584644||Palbociclib plus hormonal treatment - second line treatment|Patients who initiated palbociclib plus hormonal treatment in the second line treatment
88931905|NCT05574101|Experimental|Participants with locally advanced, unresectable cutaneous squamous cell carcinoma/CSCC|Participants have locally advanced, unresectable cutaneous squamous cell carcinoma/CSCC
88931906|NCT05563103|Experimental|AIH + Walking Training with transcutaneous spinal stimulation (WALKtSTIM)|Acute Intermittent Hypoxia will be used as a pretreatment before walking training paired with transcutaneous spinal cord stimulation.
88931907|NCT05563103|Sham Comparator|Sham + WALKtSTIM|Sham acute intermittent hypoxia will be used as a pretreatment before walking training paired with transcutaneous spinal cord stimulation.
88931908|NCT05563103|Sham Comparator|AIH + Walking Training with sham transcutaneous spinal stimulation (WALKtSHAM)|Acute Intermittent Hypoxia will be used as a pretreatment before walking training paired with sham transcutaneous spinal cord stimulation.
88931909|NCT05559853||Participants with Brain Metastases|Participants will have at least one untreated brain metastasis > 1cm
88931910|NCT05559853||Healthy participants|Participants will have no known cancer diagnosis
88931911|NCT05543382||Implanted group|This group will be participants with urinary urge incontinence (UUI) who have been previously implanted with an Axonics System and are satisfied with therapy
88931912|NCT05543382||De Novo group|This group will be participants who are newly implanted with an Axonics System.
88931913|NCT05541510|Placebo Comparator|Placebo Comparator|Participants will receive placebo (formulation buffer) on treatment days 1, 3 and 5.
88931914|NCT05541510|Experimental|Low dose treatment group|Participants will receive 20 μg of AD17002 in formulation buffer on treatment days 1, 3 and 5.
89446865|NCT02232165|Experimental|Hypotension avoidance (MAP >= 65 mmHg)|Mean arterial blood pressure is maintained >= 65 mmHg for 7 days following acute SCI.
88931915|NCT05541510|Experimental|High dose treatment group|Participants will receive 40 μg of AD17002 in formulation buffer on treatment days 1, 3 and 5.
88931916|NCT05533892|Experimental|Nocardia rubra cell wall skeleton (N-CWS) Plus HAIC, Lenvatinib and Tislelizumab|N-CWS 400μg hypodermic injected every week (Q1W) for 4 weeks, following by N-CWS 400μg hypodermic injected Q4W. Hepatic arterial infusion of oxaliplatin , fluorouracil, and leucovorin every 3 weeks. Lenvatinib 12 mg (or 8 mg) once daily (QD) oral dosing. Tislelizumab 200mg intravenously every 3 weeks.
88931917|NCT05533502|Active Comparator|Dietary Supplement: Combined Plant-Based Protein and Marine-Based Multi-Mineral Supplement|Fava-Bean Protein Concentrate and Aquamin F
88931918|NCT05533502|Placebo Comparator|Placebo Control|Placebo Control
88931919|NCT05525598|Experimental|"Internet-delivered therapist-assisted treatment: One step at the time"|"One step at the times consists of 11 internet-delivered modules delivered over 14 weeks. Each module explores a different theme, primarily including elements from Cognitive Behavioral Therapy (CBT) for FSD, and includes FSD-related psychoeducation, various interactive exercises, and video and audio material. Interactions between patients and the therapist will take place via the telephone 3 times (start, mid-term, and end-of-treatment) and embedded messaging (therapist will respond to patients) approx. 2 times a week. The participating therapists are supervised every other week by specialized psychologists."
88931920|NCT05525598|Active Comparator|"Internet-delivered non-guided treatment: Get started"|"Get started is a non-guided self-help program, developed as an active control, that includes 4 modules consisting of FSD-related psychoeducation and guidance on making lifestyle improvements. Participants will have access to the Get started program for 14 weeks."
88931921|NCT05520788||Precise medicine|All patients should accept next-generation sequencing (NGS) test before treatment.
88931922|NCT05515406|Experimental|Dose Escalation Phase (Part 1)|Up to 4 dose levels will be evaluated. Eligible patients will be assigned to a dose level cohort according to a traditional 3+3 dose escalation design.
88931923|NCT05515406|Experimental|Dose Expansion Phase (Part 2)|Eligible patients will be assigned to the recommended dose level(s) selected from Part 1.
88931924|NCT05511272|Experimental|Frozen embryo transfer cycle|Patients who will undergo a frozen embryo transfer in the modified natural cycle and in an artificially prepared cycle will be included
88931925|NCT05501665|Experimental|Option A (carboplatin, pemetrexed, pembrolizumab, radiation)|"Patients receive carboplatin, pemetrexed, and pembrolizumab on day 1 of each cycle. Treatment repeats every 21 days for 4 up to cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo radiation therapy on day 1 of each cycle over 5 treatment fractions.~MAINTENANCE THERAPY: Patients then receive pemetrexed and pembrolizumab on day 1 of each cycle. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity."
88931926|NCT05501665|Experimental|Option B (carboplatin, paclitaxel, pembrolizumab, radiation)|"Patients receive carboplatin, paclitaxel, and pembrolizumab on day 1 of each cycle. Treatment repeats every 21 days for 4 up to cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo radiation therapy on day 1 of each cycle over 5 treatment fractions.~MAINTENANCE THERAPY: Patients then receive pembrolizumab on day 1 of each cycle. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity."
88931927|NCT05501665|Experimental|Option C (pembrolizumab, radiation)|Patients receive pembrolizumab on day 1 of each cycle. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo radiation therapy on day 1 of each cycle over 5 treatment fractions.
88931928|NCT05501665|Experimental|Option D (ipilimumab, nivolumab, radiation)|Patients receive ipilimumab and nivolumab on day 1 of each cycle. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo radiation therapy on day 1 of each cycle over 5 treatment fractions.
88931929|NCT05501301||Immune tolerance cohort|"Patients that are enrolled into this cohort will receive IS minimization if virus infection or side effects of IS was found. The strategy of IS minimization will follow the Clinical guidelines for pediatric liver transplantation in China(2015). Blood test and liver biopsy will be conducted to monitor liver function and intrahepatic pathological conditions. If IS is ceased for more than one year without liver dysfunction or signs of acute rejection in liver biopsy, immune tolerance was considered reached."
88931930|NCT05501236|Experimental|Muscle stimulation|Consented participants who meet eligibility will have a drug induced sleep endoscopy (DISE) and second sleep study and the Grass S88 (or comparable) muscle stimulator.
88931931|NCT05496205|Experimental|iN1011-N17, Oral capsule, Single Ascending Dose|The IP or placebo will be orally administered in the morning on Day 1, following a 10-hour overnight fast.
88931932|NCT05496205|Experimental|iN1011-N17, Oral Suspension, Single Ascending Dose|The IP or placebo will be orally administered in the morning on Day 1, following a 10-hour overnight fast.
88931933|NCT05496205|Experimental|iN1011-N17, Nanoparticle Capsule, Single Ascending Dose|The IP or placebo will be orally administered in the morning on Day 1, following a 10-hour overnight fast.
88931934|NCT05496205|Placebo Comparator|Placebo|The IP or placebo will be orally administered in the morning on Day 1, following a 10-hour overnight fast.
88931935|NCT05480449|Experimental|Dose Escalation Arm|"The phase 1 dose escalation portion of the trial will use a standard 3+3 design to establish the recommended phase 2 dose of huCART19 cells in patients with subjects with prior treatment with CD19-directed CAR T cells. Two dose escalations of huCART19 are planned for the dose escalation phase."
88931936|NCT05480449|Experimental|Dose Expansion Arms|"If at least one dose level of the dose escalation phase is determined to be safe, the phase 2b dose expansion phase of the trial will be opened to enrollment. Subjects will receive the highest dose of huCART19 cells that were determined to be safe in the dose escalation part of the trial. 2 cohorts are planned:~Cohort A (relapsed/refractory, CAR T cell naïve)~Cohort B (prior treatment with CD19-directed CAR T cells)"
88931937|NCT05475691||Type 1 SMA (with and without use of disease-modifying treatment (DMTs))|"Participants of both sexes who presented signs and symptoms of Spinal Muscular Atrophy before six months of age and have a genetic report confirming 5q SMA.~No interventions will be performed in this study (RegistrAME is observational study (retrospective and prospective) non-randomized, international multicenter study- Registration of patients in Latin America).~Data collection aims to gather as much information as possible regarding the clinical profile of patients, interventions performed in the routine of care and clinical evolution over time (Real World Evidence-RWE).~The planned SMA registry will provide an online platform to collect longitudinal data on SMA patients across Latin America to achieve a better understanding of the clinical characteristics of SMA patients, the natural history of the disease and the use of DMTs (on participants who are using DMTs)."
89200216|NCT05279482||group treated with mega dose methyl prednisolone|patients with positive PCR and requiring oxygen therapy
89200217|NCT00890175|Experimental|Inhaled loxapine @ 0 & 10 h|Inhalation of 10 mg of loxapine at 0 and 10 hours
89200218|NCT00890175|Placebo Comparator|Inhaled placebo @ 2 & 10 hours|Inhalation of 0 mg of loxapine (placebo) at 0 and 10 hours
89200219|NCT00767130||1|receiving atorvastatin
89200220|NCT00767130||2|receiving simvastatin
88931938|NCT05475691||Type 2 SMA (with and without disease-modifying treatment (DMTs))|"Participants of both sexes who presented signs and symptoms of Spinal Muscular Atrophy starting between six and eighteen months of age and have a genetic report confirming 5q SMA.~No interventions will be performed in this study (RegistrAME is observational study (retrospective and prospective) non-randomized, international multicenter study- Registration of patients in Latin America).~Data collection aims to gather as much information as possible regarding the clinical profile of patients, interventions performed in the routine of care and clinical evolution over time (Real World Evidence-RWE).~The planned SMA registry will provide an online platform to collect longitudinal data on SMA patients across Latin America to achieve a better understanding of the clinical characteristics of SMA patients, the natural history of the disease and the use of DMTs (on participants who are using DMTs)."
88931939|NCT05475691||Type 3 SMA (with and without disease-modifying treatment (DMTs))|"Participants of both sexes who presented the first signs and symptoms of Spinal Muscular Atrophy starting after eighteen months of age and have a genetic report confirming 5q SMA.~No interventions will be performed in this study (RegistrAME is observational study (retrospective and prospective) non-randomized, international multicenter study- Registration of patients in Latin America).~Data collection aims to gather as much information as possible regarding the clinical profile of patients, interventions performed in the routine of care and clinical evolution over time (Real World Evidence-RWE).~The planned SMA registry will provide an online platform to collect longitudinal data on SMA patients across Latin America to achieve a better understanding of the clinical characteristics of SMA patients, the natural history of the disease and the use of DMTs (on participants who are using DMTs)."
88931940|NCT05475691||Type 4 SMA (with and without disease-modifying treatment (DMTs))|"Participants of both sexes and that the first symptoms of Spinal Muscular Atrophy appeared from the second or third decade of life and have a genetic report confirming 5q SMA.~No interventions will be performed in this study (RegistrAME is observational study (retrospective and prospective) non-randomized, international multicenter study- Registration of patients in Latin America).~Data collection aims to gather as much information as possible regarding the clinical profile of patients, interventions performed in the routine of care and clinical evolution over time (Real World Evidence-RWE).~The planned SMA registry will provide an online platform to collect longitudinal data on SMA patients across Latin America to achieve a better understanding of the clinical characteristics of SMA patients, the natural history of the disease and the use of DMTs (on participants who are using DMTs)."
88931941|NCT05473767|Active Comparator|Family Check Up Control|The Family Check-Up is a home visiting program that typically takes place over the course of 3-5 sessions - An initial interview, assessment, feedback session, and optional treatment sessions. The Family Check-Up is designed to support child development and improve parental well-being.
88931942|NCT05473767|Experimental|Family Check-Up Heart|Family Check-Up Heart combines the traditional Family Check-Up with a heart health component.
88931943|NCT05466448|Experimental|RZL-012 50mg/ml|small synthetic molecule for submental fat reduction
88931944|NCT05464719|Experimental|Loncastuximab Tesirine|Participants will receive Loncastuximab Tesirine (lonca) by vein.
88931945|NCT05456555|Experimental|Flapless with Enamel Matrix Derivatives (EMD)|Closed non-surgical treatment of periodontal intrabony defects with the combined use of Enamel Matrix Derivatives (EMD).
88931946|NCT05456555|Active Comparator|Flapless alone|Closed non-surgical treatment of periodontal intrabony defects without any adjunct.
88931947|NCT05453136|Experimental|5 mg|Period in which participants received repeated doses of 5 mg TS-142 prior to bedtime
88931948|NCT05453136|Experimental|10 mg|Period in which participants received repeated doses of 10 mg TS-142 prior to bedtime
88931949|NCT05453136|Placebo Comparator|Placebo|Period in which participants received repeated doses of placebo prior to bedtime
88931950|NCT05445336||Internal Champion & LTC Leadership Team #1 from Site #1|The internal champion and LTC leadership team of each LTC home will attend two virtual focus group sessions to help co-design the PREVENT Program educational material. The internal champion will receive training on how to deliver the PREVENT program to the leadership team. The internal champion/pharmacist/data analyst will receive training on how to develop an audit and feedback report on fall and fracture management. All participants will attend an educational meeting facilitated by the internal champion who will use a combination of didactic and interactive activities. After the educational meeting, the leadership team will complete an action and care planning report for each LTC resident at high risk of fracture. Lastly, all participants will attend two virtual focus group sessions to discuss the successes and challenges of implementing the PREVENT program in practice.
88931951|NCT05445336||Internal Champion & LTC Leadership Team #2 from Site #2|The internal champion and LTC leadership team of each LTC home will attend two virtual focus group sessions to help co-design the PREVENT Program educational material. The internal champion will receive training on how to deliver the PREVENT program to the leadership team. The internal champion/pharmacist/data analyst will receive training on how to develop an audit and feedback report on fall and fracture management. All participants will attend an educational meeting facilitated by the internal champion who will use a combination of didactic and interactive activities. After the educational meeting, the leadership team will complete an action and care planning report for each LTC resident at high risk of fracture. Lastly, all participants will attend two virtual focus group sessions to discuss the successes and challenges of implementing the PREVENT program in practice.
88931952|NCT05445336||Internal Champion & LTC Leadership Team #3 from Site #3|The internal champion and LTC leadership team of each LTC home will attend two virtual focus group sessions to help co-design the PREVENT Program educational material. The internal champion will receive training on how to deliver the PREVENT program to the leadership team. The internal champion/pharmacist/data analyst will receive training on how to develop an audit and feedback report on fall and fracture management. All participants will attend an educational meeting facilitated by the internal champion who will use a combination of didactic and interactive activities. After the educational meeting, the leadership team will complete an action and care planning report for each LTC resident at high risk of fracture. Lastly, all participants will attend two virtual focus group sessions to discuss the successes and challenges of implementing the PREVENT program in practice.
88931953|NCT05431699|Other|Screening population|Women eligible for HPV screening will receive both ScreenFire (experimental) and careHPV (active comparator) based on El Salvador's national guidelines.
89200221|NCT00767130||3|receiving rosuvastatin
89014079|NCT05776875|Experimental|Atezolizumab and Bevacizumab in combination with TACE|"THIS IS A SINGLE ARM PILOT/FEASABILITY STUDY. THE STUDY CONSISTS OF A SCREENING PERIOD (DAY -28 TO DAY -1), A TREATMENT PERIOD, AND A TREATMENT DISCONTINUATION VISIT.~The atezolizumab and bevacizumab combination will be given every 21 days, atezolizumab 1200 mg and bevacizumab 15 mg/kg will be administered intravenously on a Q3 week schedule.~Subjects will start the combination of bevacizumab and atezolizumab followed by TACE treatment 4 weeks ±1 week or up to 5 weeks after study drugs. Full recovery from the procedure is required prior to systemic treatment."
89014080|NCT05768854|Active Comparator|Intravenous Bisphosphonates (IV-BP) -> Setrusumab|"Participants on IV-BP will continue their existing dose/regimen per investigator discretion; for participants not on IV-BP, the dose/regimen will be determined by the investigator.~After the active-controlled period, participants will receive Setrusumab during the extension period"
89446866|NCT02232165|Active Comparator|Induced hypertension (MAP >= 85 mmHg)|Induced hypertension with mean arterial blood pressure >= 85 mmHg for 7 days following acute SCI.
89014081|NCT05768854|Experimental|Setrusumab|Participants will receive Setrusumab during the active-controlled and extension period
89014082|NCT05767021|Experimental|Mirikizumab|Participants will receive mirikizumab intravenously (IV) and mirikizumab subcutaneously (SC).
89014083|NCT05766020|Experimental|Immediate training group|Participants in this group will train immediately for 4 weeks. Afterwards, they will not train for the 8 remaining weeks.
89446867|NCT03482232||Patients visiting GP|All patients visiting GP. The frequency of some drugs and diagnosis tests include in the Do-Not-Do recommendations will be analyzed.
89446868|NCT03482232||Patient visiting pediatricians|All patients visiting pediatricians (0 to 14 years old). The frequency of some drugs and diagnosis tests include in the Do-Not-Do recommendations will be analyzed.
89446869|NCT02996864|Experimental|Healthy Detours App|Participants will be encouraged to use the Healthy Detours app daily to track food, physical activity, and sleep.
89446870|NCT02996864|Placebo Comparator|Fat Secret App|Participants will be encouraged to use the FatSecret application daily to track food and physical activity.
88931954|NCT05427383|Experimental|KN026 + Paclitaxel/ Docetaxel/ Irinotecan|IV KN026 at 30 mg/kg on D1 and IV Paclitaxel at 175 mg/m² on D1 or IV Docetaxel at 75 mg/m² on D1 or IV Irinotecan at 125 mg/m² on D1, D8, Q3W
88931955|NCT05427383|Experimental|Placebo + Paclitaxel/ Docetaxel/ Irinotecan|IV Placebo at 30 mg/kg on D1 and IV Paclitaxel at 175 mg/m² on D1 or IV Docetaxel at 75 mg/m² on D1 or IV Irinotecan at 125 mg/m² on D1, D8, Q3W
88931956|NCT05427045|Experimental|Intervention group|Adult patients < 50 years old who have multiple sclerosis and back pain who are undergoing home exercise
88931957|NCT05426252|Experimental|PTIS followed by abatacept and sirolimus|Administration of reduced-toxicity conditioning regimen combined with pre-transplant immunosuppression, followed by abatacept and sirolimus as graft-versus-host disease (GVHD) prophylaxis for allogeneic transplant with either Human Leukocyte Antigen (HLA)-matched sibling donors or haploidentical donors
88931958|NCT05412342||Patients undergoing elective operations|We will follow a prospective cohort of 558 patients, undergoing any elective surgery at Stanford Hospital. Subjects will undergo baseline and longitudinal testing via a (including NIH Patient-Reported Outcomes Measurement Information System- PROMIS measures of emotional distress). After surgery, participants will report weekly changes in opioid use, pain, and adverse events; and monthly changes in opioid misuse for 1 year.
88931959|NCT05410574|Experimental|Children: Family-based Behavioral Weight Loss Treatment (FBT)|"Traffic Light Eating Plan: All foods are assigned a color of the traffic light depending on their energy density & nutritional quality. Participants are encouraged to set dietary goals to decrease the number of RED food servings consumed daily & to increase the consumption of GREEN & YELLOW foods.~Traffic Light Activity Plan: Activities are assigned colors of the traffic light depending on intensity levels. Families are encouraged to increase time spent in GREEN activities and decreased RED activities.~Behavior Change Strategies: Behavior modification will be fostered using several different strategies~Social Facilitation: FBT emphasizes creating an ecology that supports long-term change, which includes modifying the family environment, reshaping peer networks, & ensuring that there are community resources available to maintain change."
88931960|NCT05410574|Experimental|Caregivers: Family-based Behavioral Weight Loss Treatment (FBT)|"Traffic Light Eating Plan: All foods are assigned a color of the traffic light depending on their energy density & nutritional quality. Participants are encouraged to set dietary goals to decrease the number of RED food servings consumed daily & to increase the consumption of GREEN & YELLOW foods.~Traffic Light Activity Plan: Activities are assigned colors of the traffic light depending on intensity levels. Families are encouraged to increase time spent in GREEN activities and decrease RED activities.~Behavior Change Strategies: Behavior modification will be fostered using several different strategies~Social Facilitation: FBT emphasizes creating an ecology that supports long-term change, which includes modifying the family environment, reshaping peer networks, & ensuring that there are community resources available to maintain change."
88931961|NCT05396807|Other|All subjects|mCRC subjects with WT (wild type) and RAS (matated)
88931962|NCT05393128|Other|Control group (Supine position)|"The patient will remain in the supine position for 2 hours and will be followed up with the physician and nurse.~After the patient is given one of the supine position, at any time during the 2-hour follow-up period, in case the patient's vital findings and SpO2 levels are beyond the normal findings, in case of a deterioration in the general condition related to the position or another reason, the position will be terminated with the physician's recommendation and the patient will be excluded from the sample. Or except these, in case the physician evaluates the patient and suggests that the position should be changed, the current position will be terminated, and the patient will be excluded from the sample by making a position change."
88931963|NCT05393128|Experimental|Experimental Group (Right lateral position)|"The patient will remain in the right lateral position for 2 hours and will be followed up with the physician and nurse.~After the patient is given one of the right lateral position, at any time during the 2-hour follow-up period, in case the patient's vital findings and SpO2 levels are beyond the normal findings, in case of a deterioration in the general condition related to the position or another reason, the position will be terminated with the physician's recommendation and the patient will be excluded from the sample. Or except these, in case the physician evaluates the patient and suggests that the position should be changed, the current position will be terminated, and the patient will be excluded from the sample by making a position change."
89014084|NCT05766020|Experimental|Delayed Training Group|Participants in this group will receive delayed training after 4 weeks of no training.
89014085|NCT05766020|Experimental|Active control group|Participants in this group will perform an active control for 4 weeks, followed by 4 weeks of training.
88931964|NCT05393128|Experimental|Experimental Group (Left lateral position)|"The patient will remain in the left lateral position for 2 hours and will be followed up with the physician and nurse.~After the patient is given one of the left lateral position, at any time during the 2-hour follow-up period, in case the patient's vital findings and SpO2 levels are beyond the normal findings, in case of a deterioration in the general condition related to the position or another reason, the position will be terminated with the physician's recommendation and the patient will be excluded from the sample. Or except these, in case the physician evaluates the patient and suggests that the position should be changed, the current position will be terminated, and the patient will be excluded from the sample by making a position change."
88931965|NCT05386797|Experimental|Geniculate Artery Embolization arm|
88931966|NCT05366777|Experimental|Maxigesic group|At the end of induction, the Maxigesic group will receive intravenous acetaminophen (1000 mg)/ibuprofen (300 mg) for 15 min, every 6 hours, a total of 4 times.
88931967|NCT05366777|Placebo Comparator|Control group|At the end of induction, the control group will receive intravenous normal saline with the same volume and same time points as the intervention group receives.
88931968|NCT05363605|Experimental|Phase 1|Depending on assigned cohort, [In111]-FPI-1967/[225Ac]-FPI-1966 will be administered with or without pre-dosing with vofatamab.
89446871|NCT03474978|Experimental|Upper Extremity Insertion|Peripherally Inserted Central Venous Cather (PICC) inserted in upper extremity
89446872|NCT03474978|Experimental|Lower Extremity Insertion|Peripherally Inserted Central Venous Cather (PICC) inserted in lower extremity
89446873|NCT03474900|Experimental|PLGA implant, Bioretec ltd. Finland|Treatment with biodegradable elastic stable intramedullary nail in unstable forearm shaft fracture in paediatric population
88931969|NCT05363605|Experimental|Phase 2|Depending on assigned cohort, [In111]-FPI-1967/[225Ac]-FPI-1966 will be administered either with or without pre-administration of vofatamab, depending on the RP2D/regimen as determined in the phase 1 portion of the study.
88931970|NCT05357781||MS patients with IgG deficiency (serum IgG-concentration <7g/L).|MS patients with IgG deficiency (serum IgG-concentration <7g/L).
88931971|NCT05357781||MS patients with normal IgG serum concentration (serum IgG-concentration ≥7g/L).|MS patients with normal IgG serum concentration (serum IgG-concentration ≥7g/L).
88931972|NCT05356260|Active Comparator|Care as usual|CAU will be that typically provided by GPs. Also patients will be informed about a page on thuisarts.nl regarding male LUTS. The pragmatic trial design means that care can vary depending on the preferences of patients and GPs in this group.
88931973|NCT05356260|Experimental|Online self-management intervention|"Participants in the intervention group will be given access to an online self-management program that will be personalized. This program was developed based on the results of a literature search, the opinions of expert Dutch GPs and urologists, and a pilot study in secondary care, with further preliminary testing in primary care. The program consists of nine components: information, pelvic floor exercises, bladder training, sitting voiding position, urethral milking, fluid management, caffeine avoidance, alcohol avoidance, and physical activity increase. Information is presented as text with supportive figures, plus audio (a read aloud function for all text) and video fragments to facilitate engagement by men with low literacy levels."
88931974|NCT05339477||Cohort group|Diagnosis of a type 1 myocardial infarction registered in SWEDEHEART Age 18-79 years at discharge from hospital
88931975|NCT05335915|Experimental|Original/Tobacco Flavored Pouch (low nicotine dose)|participants will use a tobacco flavored pouch (4mg nicotine dose)under both controlled (experimenter-directed) and ad libitum use conditions
89014086|NCT05765253|Active Comparator|TIPS with Scorpion Portal Vein Access Kit|Scorpion or Scorpion X access set
89446874|NCT03474900|Active Comparator|Titanium elastic stable nail|Treatment with titanium elastic stable intramedullary nail in unstable forearm shaft fracture in paediatric population
89446875|NCT02227017|Experimental|TPV/RTV capsules fed|
89446876|NCT02227017|Experimental|TPV/RTV capsules fasted|
89446877|NCT02227017|Active Comparator|TPV/RTV solutions fed|
89446878|NCT02227017|Active Comparator|TPV/RTV solutions fasted|
89446879|NCT04537832||SCN1A-positive Dravet Syndrome|Participants aged between 6 and 60 months of age who have SCN1A-positive Dravet Syndrome. Clinical, neurocognitive, laboratory, the burden of disease, and health care resource utilization will be assessed.
89446880|NCT02227095|Experimental|After-school exercise program|40 min/day vigorous aerobic games after school
89446881|NCT02227095|Active Comparator|Sedentary after-school program|Attention-control condition similar to experimental condition with the exception of exercise
89446882|NCT02223273|Experimental|Multifaceted Strategy|"Multifaceted Intervention~Simulation Based Team Training~Case Manager~Check lists~Reminders~Educational Materials"
88931976|NCT05335915|Experimental|Original/Tobacco Flavored Pouch (high nicotine dose)|participants will use a tobacco flavored pouch (8mg nicotine dose)under both controlled (experimenter-directed) and ad libitum use conditions
88931977|NCT05335915|Experimental|Mint/Menthol Flavored Pouch (low nicotine dose)|participants will use a mint/menthol flavored pouch (4mg nicotine dose)under both controlled (experimenter-directed) and ad libitum use conditions
88931978|NCT05335915|Experimental|Mint/Menthol Flavored Pouch (high nicotine dose)|participants will use a mint/menthol flavored pouch (8mg nicotine dose)under both controlled (experimenter-directed) and ad libitum use conditions
88931979|NCT05335915|Experimental|Fruit Flavored Pouch (low nicotine dose)|participants will use a fruit flavored pouch (4mg nicotine dose)under both controlled (experimenter-directed) and ad libitum use conditions
88931980|NCT05335915|Experimental|Fruit Flavored Pouch (high nicotine dose)|participants will use a fruit flavored pouch (8mg nicotine dose)under both controlled (experimenter-directed) and ad libitum use conditions
88931981|NCT05335915|Active Comparator|Own brand cigarettes|participants will smoke participants' own brand of cigarettes under both controlled (experimenter-directed) and ad libitum use conditions
88931982|NCT05328037||Acute diarrhea cases|Children with acute diarrhea defined as at least 3 loose or watery stools per day for at least 3 consecutive days and up to 10 consecutive days
88931983|NCT05328037||Chronic diarrhea cases|Children with chronic diarrhea defined as 3 or more loose or liquid stools per day for at least 4 weeks
88931984|NCT05328037||Controls|Children without fever or signs of infection or ongoing diarrhea
88931985|NCT05303883|Experimental|Pediatric constraint induced therapy|Constrained induced therapy for children with hemiplegic cerebral palsy. Three hours of therapy per day, for five days a week, for four weeks.
88931986|NCT05295784|Active Comparator|Arm 1: Low dose caffeine|Each neonate will receive a single dose of caffeine citrate in the first 24 hours of life. Arm 1 neonates will receive low dose intravenous caffeine citrate (5 mg/kg).
88931987|NCT05295784|Active Comparator|Arm 2: Medium dose caffeine|Each neonate will receive a single dose of caffeine citrate in the first 24 hours of life. Arm 2 neonates will receive medium dose intravenous caffeine citrate (15 mg/kg).
88931988|NCT05295784|Active Comparator|Arm 3: High dose caffeine|Each neonate will receive a single dose of caffeine citrate in the first 24 hours of life. Arm 3 neonates will receive high dose intravenous caffeine citrate (25 mg/kg).
88931989|NCT05289687|Experimental|Course 1|Daratumumab-hyaluronidase
88931990|NCT05284435|Experimental|iCBT-Email (iCBT-E)|Parents will receive a weekly email from a therapist over the 12 weeks of treatment.
88931991|NCT05284435|Active Comparator|iCBT-Email and Videoconferencing (iCBT-EV)|Parents will receive a weekly email and six 30-minute supportive video calls with a therapist over the 12 weeks of treatment.
88931992|NCT05282225|Experimental|MI-SP +supportive Texts + monitoring (Sequence A)|Sequencing of intervention components (Phase 1 and Phase 2) resulting in Sequence or Group A: Participants will receive the in-person MI-enhanced safety plan (MI-SP) during hospitalization followed by 4 weeks of supportive Texts and monitoring post discharge.
88931993|NCT05282225|Experimental|MI-SP + monitoring (Sequence D)|Sequencing of intervention components (Phase 1 and Phase 2) resulting in Sequence or Group D: Participants will receive the in-person MI-enhanced safety plan (MI-SP) during hospitalization followed by 4 weeks of monitoring post discharge.
88931994|NCT05282225|Experimental|MI-SP + supportive Texts + monitoring + portal follow-up for non-responders (Sequence B).|Sequencing of intervention components (Phase 1 and Phase 2) resulting in Sequence or Group B: Participants will receive the in-person MI-enhanced safety plan (MI-SP) during hospitalization followed by 4 weeks of supportive Texts and monitoring post discharge in addition to the portal follow-up for non-responders.
88931995|NCT05282225|Experimental|MI-SP + supportive Texts + monitoring + booster call for non-responders (Sequence C)|Sequencing of intervention components (Phase 1 and Phase 2) resulting in Sequence or Group C: Participants will receive the in-person MI-enhanced safety plan (MI-SP) during hospitalization followed by 4 weeks of supportive Texts and monitoring post discharge in addition to the booster call for non-responders.
88931996|NCT05282225|Experimental|MI-SP + monitoring + portal follow-up for non-responders (Sequence E)|Sequencing of intervention components (Phase 1 and Phase 2) resulting in Sequence or Group E: Participants will receive the in-person MI-enhanced safety plan (MI-SP) during hospitalization followed by 4 weeks of monitoring post discharge in addition to the portal follow-up for non-responders.
88931997|NCT05282225|Experimental|MI-SP + monitoring + booster call for non-responders (Sequence F)|Sequencing of intervention components (Phase 1 and Phase 2) resulting in Sequence or Group F: Participants will receive the in-person MI-enhanced safety plan (MI-SP) during hospitalization followed by 4 weeks of monitoring post discharge in addition to the booster call for non-responders.
88931998|NCT05278962|Active Comparator|SGLT2i|Participants will be asked to take an SGLT2i for 6 months. The SGLT2i and heart failure care will be managed according to routine care, and data will be collected from the participant's medical record.
88931999|NCT05278962|Active Comparator|No SGLT2i|Participants will not be asked to take an SGLT2i. Heart failure care will be managed according to routine care, and data will be collected from the participant's medical record.
88932000|NCT05278130|Active Comparator|Intervention Arm|The intervention-arm will have a pelvic exam performed with vaginal swab collection at their initial obstetric visit (standard of care). The women undergoing the intervention will then subsequently undergo additional vaginal swab collections in 2 week intervals starting at 16 weeks gestational age until 34 weeks gestational age. Subjects will be informed of the results of the vaginal swab. If positive for an infection, subjects will be provided with the appropriate treatment in pregnancy.
89446883|NCT02223273|No Intervention|Usual Care|Hospital Standard Treatment
89446884|NCT05259072|Other|Patients with transthyretin amyloid cardiomyopathy enrolled in CARDIO-TTRansform|Patients will undergo serial Tc-99m PYP imaging at baseline, week 61 and end of trial
89014087|NCT05765253|Active Comparator|TIPS with Cook Transjugular Liver Access Set|Ring or Rosch-Uchida access set
89014088|NCT05763407|Experimental|FIRE1 System|FIRE1 System
89014089|NCT05762354||Scoliosis Group|Adolescent Idıopathic Scoliosis
89014090|NCT05760885|Experimental|Sensory Augmentation|Participants will receive sensory augmentation in the form of non-invasive vibration, while balance training is performed as described below.
89014091|NCT05760885|Active Comparator|Control|Participants will receive balance training, without any sensory augmentation.
89014092|NCT05756985||Glioblastoma|Surgical tumor resection as standard of care and specimen collection
89014093|NCT05756166|Experimental|Cohort I (CKM, pembrolizumab)|Patients receive rintatolimod IV, celecoxib PO, interferon alpha-2b IV on days 0, 1, and 2 of week 1 and days 7, 8, and 9 of week 2 on study. Patients receive pembrolizumab IV on day 9 and then every 3 weeks after that for up to 4 doses on study. Patients also undergo CT scan or MRI at screening and follow-up and undergo blood sample collection during screening and on study.
89014094|NCT05756166|Experimental|Cohort II (CMK, early pembrolizumab)|Patients receive rintatolimod IV, celecoxib PO, and interferon alpha-2b IV on days 0, 1, and 2 of week 1 and days 7, 8, and 9 of week 2 on study. Patients receive pembrolizumab IV on day 2 of week 1 and then every 3 weeks beginning in week 4 on study. Patients also undergo CT scan or MRI at screening and follow-up, undergo blood sample collection during screening and on study, and may undergo tumor biopsy at screening and follow-up.
89014095|NCT05754281||Study Cohort|60 adult subjects with type 1 or type 2 diabetes treated with insulin. The accuracy of the 2nd Gen LabPatch Continuous Glucose Sensing will be evaluated during the study visit, comparing to YSI 2300 STAT Plus, OneTouch Verio and FreeStyle Lite.
89014096|NCT05753007|Experimental|Cannabidiol (CBD) Solution Plus Standard of Care (SOC)|Full-spectrum, hemp-derived, ultra-high CBD solution administered for 8 weeks along with standard of care treatment
89014097|NCT05753007|Placebo Comparator|Placebo|Placebo solution administered for 8 weeks along with standard of care treatment
89014098|NCT05743036|Experimental|Dose Escalation|Participants will receive different doses of ZN-c3 in combination with different doses of Encorafenib and a fixed dose of Cetuximab
89014099|NCT05743036|Experimental|Dose Expansion|Participants will receive recommended dose of ZN-c3 and encorafenib as determined in dose escalation phase in combination with cetuximab
89200222|NCT00966472|Experimental|Erlotinib + Rosuvastatin|To determine the recommended phase II dose (RP2D) of rosuvastatin that can be given in combination with standard erlotinib treatment in patients with advanced incurable squamous cell cancer and NSCLC.
89200223|NCT00767208|Experimental|type 2 diabetic subjects|
89200224|NCT00767208|Experimental|overweight healthy subjects|
89200225|NCT00892983|No Intervention|Standard well child care|Standard Well Child Care (SWCC) - 8 Core visits at 2-4 weeks, 6 weeks, 3, 5, 8-10 and 15 months, 2 and 3 years.
88932001|NCT05278130|No Intervention|Control Arm|The control arm will undergo the standard of care with vaginal swab collection at their initial obstetric visit. The control arm will not undergo additional vaginal swab collections unless otherwise indicated under standard of care (further testing for bacterial vaginosis is completed in women who describe symptoms with the diagnosis or present for preterm contractions and/or pelvic cramping). There will be no placebo for the control group.
88932002|NCT05268107|Experimental|Dupilumab|The 3 groups of patients (Asian, African American, and Caucasian) will all receive the same intervention.
88932003|NCT05259722|Experimental|Delgocitinib cream 20 mg/g|Twice-daily topical application for up to 24 weeks
88932004|NCT05259722|Active Comparator|Alitretinoin capsules 30 mg per capsule|1 capsule per day for up to 24 weeks
88932005|NCT05249959|Experimental|Consolidation with ADCT-402 (loncastuximab tesirine) after a short course of immunochemotherapy|R/R MCL after one, two, three or four lines of treatment including BTKi treatment (or BTKi intolerant), with complete response (CR) or partial response (PR) or with stable disease (SD) after salvage immunochemotherapy (R-BAC, Rituximab - Bendamustine, Ara-C x 2 cycles) will undergo consolidation with loncastuximab tesirine. A patient with CR, PR or SD after one R-BAC course, which is unable to undergo a second course due to toxicity to chemotherapy, can be considered to proceed for consolidation.
88932006|NCT05247255|Active Comparator|Intervention Group|Quadratus lumborum nerve block with 0.25% ropivacaine
88932007|NCT05247255|Placebo Comparator|Control Group|Quadratus lumborum nerve block with saline
88932008|NCT05236699|Experimental|DEB-TACE combined with Surufatinib and Camrelizumab|
88932009|NCT05231629|Experimental|Arm A|3 cycles of Dara-VRd intensification followed by 13 cycles of Dara-R maintenance in MRD negative patients
88932010|NCT05231629|Active Comparator|Arm B|AHCT intensification followed by 13 cycles of Dara-R maintenance in MRD negative patients
88932011|NCT05231629|Experimental|Arm C|AHCT intensification, 3 cycles of Dara-Tec consolidation and 13 cycles of Dara-Tec maintenance in MRD positive patients
88932012|NCT05231629|Active Comparator|Arm D|AHCT intensification, 3 cycles of Dara-R consolidation and 13 cycles of Dara-R maintenance in MRD positive patients
88932013|NCT05231629|Other|Arm M|Induction - 6 cycles of Dara-VRd in all participants
88932014|NCT05229263|Experimental|Healthy volunteers|
88932015|NCT05229263|Experimental|CKD patients|
88932016|NCT05215639||Venetoclax Participants|Participants treated with Venetoclax in accordance with approved local label.
88932017|NCT05180110|Experimental|Symptoms of inflammation, Infection, tissue injury|Venous blood draw of up to 24mL and up to 6 capillary fingersticks
88932018|NCT05173298||analytic group|advanced HCC Patients
88932019|NCT05165485|Experimental|Revefenacin|Revefenacin DoseA administered with tiotropium placebo
88932020|NCT05165485|Active Comparator|Tiotropium|Tiotropium DoseB administered with revefenacin placebo
88932021|NCT05165381||Contactless vital signs and stress measurement.|Contactless vital signs and stress measurement. Eligible participants will agree to have a 1.5-minute facial video recorded using an iPad. Video will be processed through a specialized algorithm to obtain BP, HR, RR, HRV and stress index. measurements.
88932022|NCT05163964||Control Group|Prediabetes patients aged 18-65 years old, who plan to continue healthcare services at a community clinic in Malacca, no literacy barries
88932023|NCT05159388|Experimental|PRS-344/S095012|PRS-344/S095012
88932024|NCT05150990|Experimental|Virtual Reality|Weekly activities using virtual reality (Rendever)
88932025|NCT05150990|Active Comparator|Video Chat|Weekly activities using video conference (Zoom)
88932026|NCT05148078|Experimental|General Anesthesia Decrease use : PROMISE|To decrease the total number of pediatric patients who require general anesthesia through the use of PROMISE
88932027|NCT05136027|Experimental|Intervention group|Intervention group: In the exercise session will carry out a combined training in four parts, low- intensity interval training in a bicycle, resistance circuit training, low- intensity interval training in a bicycle, and CORE exercises.
88932028|NCT05136027|No Intervention|Attention Control|Regular in-hospital treatment with occupational activity sessions with the same frequency and duration as the intervention group.
88932029|NCT05130658|Experimental|C-MILL training group|The participants will be screened for the inclusion/exclusion criteria and consented during the first session. They will participate in two data collection sessions, one before the training and one after the training. The participants will undergo 10 training sessions. Individuals in the CTG will receive gait and balance training sessions with the virtual reality and auditory cues using C-MILL (such as walking on a pathway, obstacle avoidance, lateral balance etc.) to provide task specific training. C-Mill (Motekforce Link, Amsterdam, The Netherlands) is an instrumented treadmill that uses visual (on the screen as well on the treadmill) and acoustic cues for gait and balance training. The C-Mill allows for gait and balance adaptability strategy as it can provide obstacle avoidance environments, change in speed and various walking pathways in a safe and controlled environment.
88932030|NCT05130658|Active Comparator|Treadmill training group (TTG)|The participants will be screened for the inclusion/exclusion criteria and consented during the first session. They will participate in two data collection sessions, one before the training and one after the training. The participants will undergo 10 training sessions. Individuals in TTG group will walk on the treadmill (C-MILL) or stand on the treadmill (C-MILL) with no visual or auditory cues.
88932031|NCT05130658|No Intervention|Healthy Control|HCG will participate in up to four sessions. The participants will be screened for the inclusion/exclusion criteria and consented during the first session. They will participate in two data collection sessions and one C-MILL session.
88932032|NCT05129787|Active Comparator|Surgical resection|Liver resection
88932033|NCT05129787|Experimental|Thermal ablation|Thermal ablation (Microwave or radiofrequency)
88932034|NCT05110313|Experimental|PSORIASIS TREATMENT|1 syringe containing 1 mL of 100 mg/mL tildrakizumab-asmn. 100mg delivered by subcutaneous injection at weeks 0, 4, 16 and 28. Total of 20 subjects (10 male, 10 female).
88932035|NCT05110313|No Intervention|NON-PSORIASIS|No intervention. Total of 10 subjects (5 male, 5 female).
88932036|NCT05106296|Experimental|Treatment Regimen|Patients will be treated with the 4-drug chemo-immunotherapy regimen. Cycles are a minimum of 28 days, and maximum treatment duration is 12 cycles.
89446885|NCT02227173|Experimental|Single-Sequence, A B C|"Treatment A:~Single oral dose of montelukast, flurbiprofen, and digoxin on Day 1~Treatment B:~BMS-986020 orally twice daily (BID) on Day 8 through Day 10~Treatment C:~BMS-986020 orally BID, single oral dose of montelukast, flurbiprofen, and digoxin on Day 11; BMS-986020 BID on Day 12 through Day 17"
88932037|NCT05106192|Experimental|Cutaneous T-cell lymphomas (CTCL) Participants|"The first plaque will be treated using standard of care topical bexarotene or nitrogen mustard for participants with CTCL (cutaneous T-cell lymphomas)~The second plaque will be treated using a needle-free injector system.~After the treatment, the participants will be followed for another three visits over the course of 4 months to see how the treated areas responded."
88932038|NCT05106192|Experimental|Cutaneous B-cell lymphomas (CBCL) Participants|"The first plaque will be treated using standard of care intralesional TAC (triamcinolone acetonide) using a syringe/needle with participants with CBCL (cutaneous B-cell lymphomas).~The second plaque will be treated using a needle-free injector system.~After the treatment, the participants will be followed for another three visits over the course of 4 months to see how the treated areas responded."
88932039|NCT05103007|Active Comparator|Drug-eluting bead transarterial chemoembolization（DEB-TACE)|Percutaneous drug-eluting bead transarterial chemoembolization, followed by conventional transarterial chemoembolization（cTACE) every 2 months. A total of 3 times of chemoembolization will be performed.
88932040|NCT05103007|Experimental|PVL/PVE+DEB-TACE|PVL and PVE will be performed randomly assigned according to 1:1 according to the random number table.
88932041|NCT05100966|No Intervention|Usual Care|Participants in the control arm will receive usual care which involves patient education that all participants who are scheduled for hip/knee replacement receive at the arthroplasty centre. This may include recommendations to attend fitness classes or discuss nutrition tips and smoking cessation initiatives with their family doctor or other healthcare provider before surgery.
88932042|NCT05100966|Active Comparator|FitJoints Multi-modal Intervention|
88932043|NCT05096611|Active Comparator|ABC|Attachment and Biobehavioral Catch-up, 10 weekly sessions that provide parenting support
88932044|NCT05096611|Experimental|ABC+D|Attachment and Biobehavioral Catch-up plus weekly 5-10 minute videos that additional provide support for mothers' mood, stress, and coping
88932045|NCT05094128||Participants Receiving Upadacitinib.|
88932046|NCT05092880|Active Comparator|Standard of care first-line systemic therapy|capecitabine plus anti-VEGF antibody
88932047|NCT05092880|Experimental|Radioembolization|radioembolization of liver with holmium-166 microspheres
88932048|NCT05087030|Experimental|RGB-14-P (Main period)|Randomized participants will receive subcutaneous (SC) injection of RGB-14-P, on Day 1 of Treatment periods 1 and 2.
88932049|NCT05087030|Active Comparator|Prolia® (Main period)|Randomized participants will receive SC injection of Prolia®, on Day 1 of Treatment periods 1 and 2.
88932050|NCT05087030|Experimental|RGB-14-P (Transition period)|Re-randomized participants will receive SC injection of RGB-14-P, on Day 1 of Treatment period 3.
88932051|NCT05087030|Active Comparator|Prolia® (Transition period)|Re-randomized participants will receive SC injection of Prolia®, on Day 1 of Treatment period 3.
88932052|NCT05087030|Experimental|RGB-14-P (Continued till transition period)|Randomized participants will continue to receive SC injection of RGB-14-P from the main period till Day 1 of Treatment period 3.
89200226|NCT00892983|Experimental|Food Activity Breast feeding support|FAB (Food Activity Breast feeding support) 8 extra parent contacts for augmented education and support around breast feeding, food and activity
89446886|NCT03482154||With Malglycemia|
88932053|NCT05071209|Experimental|Treatment (elimusertib)|Patients receive elimusertib PO BID on days 1-3, 8-10, 15-17, and 22-24 of each cycle. Treatment repeats every 28 days for 26 cycles in the absence of disease progression or unacceptable toxicity.
88932054|NCT05044273||Coronary Artery Disease|
88932055|NCT05042687|Experimental|Tc99m sestamibi|MBI uses an injection of a small amount of radioactive material called technetium99m (Tc99m) sestamibi
88932056|NCT05035173|Experimental|Intervention Arm|Participants will have available the services offered by the Women's Cancer Survivorship Clinic and will undertake electronic Patient Reported Outcomes at baseline, 2, 4, 6, 8, 10, 12 months (end of the study).
88932057|NCT05035173|Active Comparator|Control Arm|Participants will attend a baseline and end of the study visit (12-month time point) to the Women's Cancer Survivorship Clinic to undertake the baseline and complete end of study assessments. They will complete ePRO at baseline and at 12 months. They will have usual follow up care over the 12 month period of the study. Where participants in the control arm contact the Survivorship team for clinical or other advice, they will be referred to the usual care pathway.
88932058|NCT05031949|Experimental|Hyperbaric oxygen therapy plus Camrelizumab|Subjects receive Camrelizumab intravenous at the dose 3mg/kg on Day 1 every 3 weeks, and breath pressurized (0.25 MPa) 100% oxygen (O2) indirectly by a head hood or mask for 60 minutes in multiplace chambers at Day 1 of every week.
88932059|NCT05018806|Experimental|Rilzabrutinib|Rilzabrutinib BID or TID
88932060|NCT05018806|Placebo Comparator|Placebo|Matching placebo
88932061|NCT05003895|Experimental|1/ Arm 1|Escalating doses of CAR-T cells
88932062|NCT05003895|Experimental|2/ Arm 2|MTD of CAR-T cells
89200227|NCT00892983|Experimental|Sleep|Prevention of sleep problems in first 6 months and then active early intervention for sleep problems from 6 months to 24 months
89446887|NCT03482154||Without Malglycemia|
89446888|NCT02468726|Experimental|NER1008|Use of NER1008 enema for bowel cleansing
89446889|NCT02468726|Active Comparator|Fleet|Use of Fleet enema for bowel cleansing
89446890|NCT02872701|Experimental|Patients Receiving OTL38|All patients in this arm will receive OTL38 for injection and undergo intraoperative imaging.
89446891|NCT03479034||Group 1|"Ages 18-85~Cognitively able to understand instructions and care for themselves~Lives in the community (not institutionalised)~Owner of a smartphone and able to use Apps~On 3 or more chronic prescription medications~Has had experience with prescriptions in Australia for at least 1 year~Current patient attending Holdsworth House Medical Practice~Willing to use the ScalaMed ePrescription application"
89446892|NCT04489004|Experimental|Driver ablation+CPVI|Driver ablation plus CPVI (circumferential pulmonary vein isolation)
89446893|NCT04489004|Active Comparator|Stepwise ablation|Stepwise ablation
89446894|NCT02227407|Experimental|Energy expenditure, gait pattern, RGOs|using motion capture system and forceplates to monitor gait pattern while wearing reciprocating gait orthoses to calculate the mechanical energy cost
89446895|NCT03482076|Other|transferrin receptor concentration|Prevelance of iron deficiency in this patients
89446896|NCT02031549||SpermComet Assay|All study subjects will have their surplus sperm analyzed for DNA fragmentation with the SpermComet assay.
89446897|NCT02227563|Experimental|Active tDCS|active tDCS
89446898|NCT02227563|Sham Comparator|control|sham (placebo) tDCS condition
89446899|NCT02469740|Experimental|Ticagrelor|Patients in this group will be prescribed ticagrelor 90 mg BD for 4 weeks.
89446900|NCT02469740|Active Comparator|Clopidogrel|Patients in this group will be prescribed clopidogrel 75 mg OD for 4 weeks
89446901|NCT03474666|Active Comparator|Strict Glycemic Control Group|Intravenous insulin as described by Keegan and Cols. 2010.
89446902|NCT03474666|Active Comparator|Standard Glycemic Control Group|Subcutaneous insulin as instititional protocol.
89446903|NCT04459221|Experimental|Facilitating access to HPV vaccination|
89446904|NCT04459221|No Intervention|promotion of HPV vaccination|
89446905|NCT04432220|Experimental|Anticoagulation group(Apixaban group)|Apixaban 5mg twice daily (2.5mg twice daily if meets dose-reduction criteria) for 2 years
89446906|NCT04432220|No Intervention|Nonanticoagulation group|Standard treatment except anticoagulant for 2 years
89446907|NCT04417712||Patients with ventricular septal defect|"All patients who signed informed consent and are implanted with a KONAR-MF™ VSD Occluder device will undergo follow-up (FU) evaluations as per local hospital standard and corresponding IFU which is expected to be at the following time points post-implant:~Before discharge 1-3 months after the Procedure 6 months after the procedure 12 months after the procedure"
89446908|NCT02223507|Experimental|BIIR 561 CL|
89446909|NCT02223507|Placebo Comparator|Placebo|
89446910|NCT03478800|Experimental|High school football players and acupuncture|50 healthy high school football players without active musculoskeletal injury
89446911|NCT04405622|Experimental|Toripalimab plus gemcitabin arm|Subjects receive gemcitabine and toripalimab.
89446912|NCT02223585|Experimental|Cross-over single arm|
89446913|NCT03478722||Maintenance Hemodialysis Patients|Protein meal, stable isotope amino acid infusion
89446914|NCT03478722||Control Subjects|Protein meal, stable isotope amino acid infusion
89446915|NCT02227641|Experimental|Adoptive transfer of CMV/EBV specific T-cells|Repetitive adoptive T-cell transfer starting at day 30 after allogeneic stem cell transplantation.
89446916|NCT02227641|No Intervention|Control|Observation only.
89446917|NCT02723084|Experimental|Arm A|Co-formulated ABT-493/ABT-530 (300 mg/120 mg) administered once daily (QD) for 8 weeks in HCV genotype (GT) 2 -infected, DAA treatment-naïve participants without cirrhosis.
89446918|NCT02723084|Active Comparator|Arm B|sofosbuvir (400 mg) QD co-administered with weight based ribavirin (RBV) 600-1000 mg divided twice daily (BID) for 12 weeks in HCV GT2 -infected, DAA treatment-naïve participants without cirrhosis.
89446919|NCT02750943|Experimental|Stannous Fluoride|Participants will apply a full ribbon of dentifrice containing 0.454% w/w stannous fluoride to the study toothbrush and brush their teeth in their usual manner for one timed minute twice daily (morning and evening)
89446920|NCT02750943|Active Comparator|Sodium Monofluorophosphate|Participants will apply a full ribbon of dentifrice containing Dentifrice containing 1000ppm fluoride as sodium monofluorophosphate to the study toothbrush and brush their teeth in their usual manner for one timed minute twice daily (morning and evening)
89446921|NCT03446118|Experimental|MRI to detect inflammation and fibrosis in EoE patients|To assess through MRI the existence of an inflammatory and fibrotic component in strictures of eosinophilic esophagitis patients and to determine if this component is responsive to a therapeutic course of budesonide.
89446922|NCT02471066|Experimental|active rTMS|12 patients will be enrolled in this arm.
89446923|NCT02471066|Sham Comparator|sham rTMS|12 patients will be enrolled in this arm.
89200228|NCT00892983|Experimental|FAB + Sleep|combination of interventions used in arms 2 and 3
88932063|NCT04996966|Placebo Comparator|control|In the control group, saline containing 2% albumin (2ml/kg) were intravenously injected to the patient immediately after the surgery and at day 3 after the surgery.
88932064|NCT04996966|Experimental|MSCs injection|In the MSCs injection group, 1×10^6/kg human umbilical cord-derived mesenchymal stem cells were intravenously injected to the patient immediately after the surgery and at day 3 after the surgery.
89200229|NCT00760422||With fever|
89200230|NCT00760422||Without fever|
89200231|NCT00890253|Experimental|CNI-free Immunosuppression|Immunosuppression after OLT including basiliximab, enteric-coated mycophenolate sodium (EC-MPS), and everolimus.
89200232|NCT00760500||1|
89200233|NCT00545818|Experimental|Group-1, Implant length 6 mm|Subjects treated with OsseoSpeed™ implant, length: 6 mm
89200234|NCT00545818|Other|Group-2, Implant length 11 mm|Subjects treated with OsseoSpeed™ implant, length: 11 mm
89200235|NCT00674154|Experimental|Vitamin D group|Cholecalciferol 1400 IU, 2 tablets once daily in 52 weeks
89200236|NCT00674154|Placebo Comparator|Placebo group|Placebo, two tablets daily in 52 weeks.
89200237|NCT00974038|Experimental|CBT, SP|cognitive behavioral therapy, supportive psychotherapy
89200238|NCT04048980|No Intervention|Control Group|Patients with dementia or cognitive impairment and femur fracture receiving the traditional care in traumatology units.
89200239|NCT04048980|Experimental|Experimental Group|Patients with dementia or cognitive impairment and femur fracture receiving an intervention in traumatology units.
89200240|NCT00966628|Active Comparator|Ringer's lactate|
88932065|NCT04987957|Experimental|Experimental group|"4 music genres with expert opinion will be presented to the preference of the participants in the intervention group, these types of music; Classical Music, Turkish Classical Music, Turkish Folk Music and Sufi Music. The music is instrumental, 70 decibels and non-verbal. Participants will listen to a genre they choose and download to their mobile phones once for 5 days for 15 minutes. They will listen to the music in the environment they live in, at a time convenient for them, at the desired volume level and with headphones in accordance with the determined therapy program.~At the beginning of the research, an Introductory Questionnaire will be applied to all participants. Trait Anxiety Inventory will be administered before music therapy on the 1st day of the study and after the music therapy application on the 5th day."
89200241|NCT00966628|Experimental|Hypertonic sodium lactate|
88932066|NCT04987957|No Intervention|Control group|No application will be made to the participants in the control group, and the data collection tools will be applied with the same frequency as in the intervention group.
89200242|NCT00968110|Experimental|Xolair|All patients will receive Xolair treatment for 16 weeks.
89200243|NCT00608517|Experimental|Pediatric Myeloablative conditioning|Patients undergo total-body irradiation on days -7 to -4, and receive cyclophosphamide IV over 1 hour on days -3 and -2, methylprednisolone IV twice daily on days -3 to -1, and anti-thymocyte globulin IV over 4 hours on days -3 to -1.
89200244|NCT00608517|Experimental|Adult Myeloablative conditioning|Patients receive fludarabine phosphate IV over 30 minutes on days -6 to -4, cyclophosphamide IV over 1 hour on days -5 and -4, and undergo total-body irradiation on days -3 to -1.
89200245|NCT00608517|Experimental|Reduced-intensity conditioning|Patients receive fludarabine phosphate IV over 30 minutes on days -6 to -2 and cyclophosphamide IV over 1 hour on day -6 and undergo total-body irradiation on day -1.
89200246|NCT00966706|Experimental|Arm I|Patients receive cisplatin, gemcitabine hydrochloride, and docetaxel on days 1 and 15, and capecitabine on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
89446924|NCT03481920|Experimental|PEGPH20 + Avelumab|PEGPH20, a multi-site PEGylated enzyme generated by conjugating N-hydroxysuccinimidyl ester of methoxypoly(ethylene glycol)-butanoic acid (MSBA30K/B or PEG) and recombinant human hyaluronidase (rHuPH20). PEGPH20 has a half-life of approximately 2 days, thereby enabling systemic activity and sustained duration of action to degrade HA. In many different tumor types tested in murine xenograft models, response to PEGPH20 has been shown to be more robust for tumors characterized by higher HA expression.
89446925|NCT02227797|Experimental|Voriconazole|
89446926|NCT02470988|Active Comparator|CBASP|Cognitive Behavioural Analysis System of Psychotherapy (CBASP) is a form of therapy specifically designed to treat individuals with chronic depression. CBASP combines a number of elements, with a focus on teaching the client to become aware of their interpersonal behaviour and its consequences.
89446927|NCT02470988|Experimental|CBASP Without DPI|In this arm CBASP will be delivered without Disciplined Personal Involvement (DPI) by the therapist.
89446928|NCT05784337|Experimental|Mi-thos® Transcatheter Mitral Valve Replacement System|Transcatheter mitral valve replacement with the Mi-thos® valve and transcatheter delivery system
89446929|NCT05784324||Employees within the municipal health, care and welfare services|All employees within the municipal health, care and welfare services. No internvention. We investigate the relationship between caracteristics of their shift systems and potential outcomes.
89446930|NCT05784324||Employees within the municipal health, care and welfare services 2|Employees within the municipal health, care and welfare services, replying to a survey. Sample is drawn by representative unions. No internvention. We investigate the relationship between caracteristics of their shift systems and potential outcomes.
89446931|NCT05784324||Users of the municipal health, care and welfare services.|Users of the municipal health, care and welfare services.No internvention. We investigate the relationship between caracteristics of the shift systems worked and potential outcomes for users.
89200247|NCT00966706|Experimental|Arm II|Patients receive cisplatin, gemcitabine hydrochloride, and epirubicin hydrochloride on days 1and 15, and capecitabine on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
89446932|NCT05784259|No Intervention|Control group|
89446933|NCT05784259|Experimental|Treatment group|Transdiagnostic single-session treatment
89446934|NCT05784220|Other|DPP|The CDC Diabetes Prevention Program (DPP) curriculum for lifestyle intervention, including 21 education topics delivered via text-based education module, and follow-up telephone health coaching call for each topic.
89446935|NCT05784207||IPF/UIP_CT based|patients with an ILD and a pathological UIP pattern and a final diagnosis of IPF
89446936|NCT05784207||IPF/UIP_Biopsy based|patients with a final diagnosis of IPF but a less typical HRCT pattern( lung biopsy required for the diagnosis)
89446937|NCT05784207||ILD but not IPF and prove by biopsy not UIP|patients with an ILD and a pathological non-UIP pattern
89446938|NCT05784207||Normal|Normal healthy patients
89446939|NCT05784168|Experimental|Manual therapy|"6 weeks, 12 sessions in total, 2 times a week of manual therapy: spinal manipulation, specific mobilisations and stretches. Manual therapy treatments are carried out by a physiotherapist with more than 10 years of experience.~In addition, 6 weeks, 5 times a week, a programme of therapeutic exercises at home: muscle strengthening and stretching, balance and coordination training, spinal stabilisation exercises."
89200248|NCT00763776|Other|1|Liver transection by clamp crushing technique
89200249|NCT00763776|Other|2|Liver transection by the ultrasonic dissector
89446940|NCT05784168|Experimental|Exercise therapy|"6 weeks, 12 sessions in total, 2 times a week therapeutic exercise programme under the supervision of a physiotherapist. The exercise programme consisted of muscle strengthening and stretching, balance and coordination training, spinal stabilisation exercises.~In addition, 6 weeks, 5 times a week, a programme of therapeutic exercises at home: muscle strengthening and stretching, balance and coordination training, spinal stabilisation exercises."
89446941|NCT05784142|Experimental|CHIC single arm|Patients who have received induction immunotherapy plus chemotherapy for 2-6 cycles and met the hypoRT criteria will be enrolled into the study.
89446942|NCT05784090||AD|Alzheimer's Disease
89446943|NCT05784090||NON AD|Non Alzheimer's Disease
89446944|NCT05784090||CT|Controls
89446945|NCT05784038||Human cases of monkeypox confirmed by PCR|Laboratory-confirmed mpox infection is defined as determined by polymerase chain reaction assay (PCR), culture, or antigen test obtained from a sample collected from blood, oropharynx, anal or skin lesion within 5 days of inclusion.
89446946|NCT05783986||Testing group|375 patients of our hosipital,randomly divided.
89446947|NCT05783986||Internal validation group|125 patients of our hosipital,randomly divided.
89446948|NCT05783986||External validation group|100 patients of Sun Yat-sen University Cancer Center
89446949|NCT05783947||Suspicion of autoimmune neurological disorder|Sera and CSF of patients with a suspicion of autoimmune encephalitis or paraneoplastic neurological syndrome
89200250|NCT00893061|Experimental|Arm I|Patients receive oral tamoxifen citrate once daily for 1 year in the absence of disease progression or unacceptable toxicity.
89200251|NCT00893061|Experimental|Arm II|Patients receive an oral aromatase inhibitor (letrozole, anastrozole, or exemestane) once daily for 1 year in the absence of disease progression or unacceptable toxicity.
89200252|NCT00763932|Experimental|1|
89200253|NCT00890331|Active Comparator|Diabetes Education|
89200254|NCT00890331|Experimental|TeamWork CS Sessions|
89200255|NCT00974194|Experimental|SinglePort CCK|CCK using Triport
89446950|NCT05783934|Experimental|18F-Florbetaben PET/CT scan|All the partecipants will undergo PET/CT scan evaluation after 18F-florbetaben administration
89446951|NCT05783895||Confirmed HIT|Comprehensive collection of patients with suspected and then proven HIT postoperatively from cardiac surgery with bypass surgery during the inclusion period.
89446952|NCT05783895||Absence of HIT|Patients with suspected and unconfirmed HIT postoperatively from cardiac surgery under CEC during the inclusion period.
89446953|NCT05783882|Experimental|Arm 1|
89014100|NCT05742737||Robust|Unlike previous frailty index, mFI-5 uses a small number of variables readily available in a patient's history, including functional status (partial or complete dependence), history of diabetes, COPD, congestive heart failure, and hypertension requiring medication. 1 point is assigned to each variable. Functional status refers to needing some or all of the assistance of others in daily activities, including bathing, eating, dressing, going to the toilet, moving, traveling, and more. The mFI-5 score was calculated by increasing the number of variables per patient Patients were divided into 3 groups based on their mFI-5: frail group (mFI-5, 2-5) , prefrail group (mFI-5, 1) and robust group (mFI-5, 0). The range of the mFI-5 is from 0 to 5 with increments of 1, and increasing the mFI-5 implies increasing frailty.
89014101|NCT05742737||Prefrail|Unlike previous frailty index, mFI-5 uses a small number of variables readily available in a patient's history, including functional status (partial or complete dependence), history of diabetes, COPD, congestive heart failure, and hypertension requiring medication. 1 point is assigned to each variable. Functional status refers to needing some or all of the assistance of others in daily activities, including bathing, eating, dressing, going to the toilet, moving, traveling, and more. The mFI-5 score was calculated by increasing the number of variables per patient Patients were divided into 3 groups based on their mFI-5: frail group (mFI-5, 2-5) , prefrail group (mFI-5, 1) and robust group (mFI-5, 0). The range of the mFI-5 is from 0 to 5 with increments of 1, and increasing the mFI-5 implies increasing frailty.
89014102|NCT05742737||frail|Unlike previous frailty index, mFI-5 uses a small number of variables readily available in a patient's history, including functional status (partial or complete dependence), history of diabetes, COPD, congestive heart failure, and hypertension requiring medication. 1 point is assigned to each variable. Functional status refers to needing some or all of the assistance of others in daily activities, including bathing, eating, dressing, going to the toilet, moving, traveling, and more. The mFI-5 score was calculated by increasing the number of variables per patient Patients were divided into 3 groups based on their mFI-5: frail group (mFI-5, 2-5) , prefrail group (mFI-5, 1) and robust group (mFI-5, 0). The range of the mFI-5 is from 0 to 5 with increments of 1, and increasing the mFI-5 implies increasing frailty.
89014103|NCT05740527|Other|Testing closed-loop system in an ambulatory setting|Closed-loop system feasibility testing
89014104|NCT05739136||Exposed Cohort|Pregnant women with conditions for which relugolix combination therapy is prescribed, who are exposed to relugolix combination therapy at any time during pregnancy
89014105|NCT05739136||Unexposed Cohort|Pregnant women with conditions for which relugolix combination therapy could be prescribed, who are not exposed to relugolix combination therapy at any time during pregnancy
89014106|NCT05739123||Exposed Cohort|Pregnant women who are exposed to relugolix-containing therapy at any time during pregnancy
89014107|NCT05739123||Unexposed Cohort|Pregnant women with conditions for which relugolix-containing therapy may be prescribed for indications that are approved or under phase 3 development and who are not exposed to relugolix-containing therapy at any time during pregnancy
89014108|NCT05738083||aneurysmal subarachnoid hemorrhage|primary subarachnoid hemorrhage caused by intracranial ruputured aneurysm
89446954|NCT05783856|Placebo Comparator|Control|"Control group receives the routine treatment and uses 0.9% NaCl physiological saline.~The routine treatment regimen at the Bac Ninh Center for Disease Control depends on the type of pathogen tested using multiplex real time PCR assay on day 0, as follows:~Oral administrative medication based on the results of STIs pathogen detection test, antibiotic Clinidamycin (Withus Clinidamycin®) or/and the antifungal drug Itraconazole (Miduc®) are prescribed for 7 days to treat pathogenic bacteria or/and fungi infections, respectively.~Vaginal suppository medication: Canvey®, which contains Metronidazole and Chloramphenicol, is only prescribed for further 7 days in the event that oral treatments of Clindamycin and Itraconazole have been unsuccessful."
89014109|NCT05737615|Experimental|Participants with Pancreatic Cancer|Participants have histologically confirmed primary or metastatic pancreatic ductal adenocarcinoma
89014110|NCT05737485|Experimental|RCT1100|Drug: RCT1100 single dose
89014111|NCT05735210|Experimental|Polso™ Watch blood pressure measurement compared to a reference blood pressure measurement|Mean difference between the Polso™ Watch and reference measurement, and the associated standard deviation using data from the rest and induced change measurements following initialization
89014112|NCT05727176|Experimental|Treatment Arm A|TAS-120 (20mg) tablets, oral; 21-day cycle
89014113|NCT05727176|Experimental|Treatment Arm B|TAS-120 (16mg) tablets, oral; 21-day cycle
89014114|NCT05720988|Active Comparator|Cohort I (tagraxofusp-erzs)|Patients receive tagraxofusp-erzs IV QD over 15 minutes on days 1-5. Treatment repeats every 28-42 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.
89200256|NCT00974194|Active Comparator|LS CCK|CCK using three or four trocars
89200257|NCT00767442||1|Health volunteer
89200258|NCT00767442||2|Patient with suspected oral mucosa lesion
89200259|NCT00974272|Experimental|Exenatide|
89200260|NCT00974272|Placebo Comparator|Placebo|
89446955|NCT05783856|Experimental|X-secret|"X-secret group receives the routine treatment and uses NaCl 0.9% plus B. subtilis, B. clausii, and B. coagulans at 5 billion CFU/5 mL (LiveSpo®️ X-secret).~The routine treatment regimen at the Bac Ninh Center for Disease Control depends on the type of pathogen tested using multiplex real time PCR assay on day 0, as follows:~Oral administrative medication based on the results of STIs pathogen detection test, antibiotic Clinidamycin (Withus Clinidamycin®) or/and the antifungal drug Itraconazole (Miduc®) are prescribed for 7 days to treat pathogenic bacteria or/and fungi infections, respectively.~Vaginal suppository medication: Canvey®, which contains Metronidazole and Chloramphenicol, is only prescribed for further 7 days in the event that oral treatments of Clindamycin and Itraconazole have been unsuccessful."
89446956|NCT05783830|Experimental|ACD856|
88932067|NCT04966455|No Intervention|Control group|No intervention
88932068|NCT04966455|Experimental|Experimental group|Supplementation of 50 g daily of rainsins for 3 months
88932069|NCT04965155|Experimental|Isatuximab-Dexamethasone|Isatuximab-Dexamethasone pre and post transplant in relapsed multiple myeloma patients.
88932070|NCT04958707|Experimental|Informational support group|The participants in the intervention group will be added to a chat group in the Zalo app, created and managed by one investigator, which is named The Dementia Caregiver Support group. Weekly, the investigator will post one of the topics identified in Phase 1. Before posting the information, the investigator will ask the participants what topic they would like to read and discuss the week after by voting the answer. The posted information will be based on evidence-based resources and consulted by geriatricians, the neurologist, and the psychologist who specialize in dementia. Immediately after posting the topic, one investigator will call the participants to ensure they read and understand the post. The chat group monitor will also collect the questions or comments from the carers who are encouraged to share their feelings or experiences with relevant questions. Then the monitor will post the answers after consulting with the experts.
88932071|NCT04958707|Active Comparator|Controlled group|The participants will receive usual care, introduced to the website Alzheimer.org to search for eligible information.
88932072|NCT04957147||Group A: patients with dilated cardiomyopathy|Patients with recent-onset dilated cardiomyopathy
88932073|NCT04957147||Group B: healthy volunteers|Healthy volunteers with no known heart disease
88932074|NCT04946734|Experimental|Test Arm|Device PFO closure
88932075|NCT04946734|Other|Control Arm|Drugs only
88932076|NCT04944888|Experimental|Experimental Dose 1|"Eliglustat 84mg will be administered once daily in patients who are CYP2D6 ultra-rapid metabolizers (URMs), extensive metabolizers (EMs), intermediate metabolizers (IMs), or poor metabolizers (PMs), in the first 14 days and the following every other week until 24 weeks. For patients who still benefit from the trial, eliglustat 84mg will be daily administered every other week to 96 weeks.~Immune checkpoint inhibitor (physician decided) will be administered intravenously on day 5 or day 15 every 3 weeks. For patients who still benefit from the trial, immune checkpoint inhibitor will be administered every 3 week to 96 weeks."
88932077|NCT04944888|Experimental|Experimental Dose 2|"Eliglustat 84mg will be administered twice daily in patients who are CYP2D6 ultra-rapid metabolizers (URMs), extensive metabolizers (EMs), or intermediate metabolizers (IMs), or in the first 14 days and the following every other week until 24 weeks. For patients who still benefit from the trial, eliglustat 84mg will be administered twice daily every other week to 96 weeks.~Immune checkpoint inhibitor (physician decided) will be administered intravenously on day 5 or day 15 every 3 weeks. For patients who still benefit from the trial, immune checkpoint inhibitor will be administered every 3 week to 96 weeks."
88932078|NCT04934176||Group 1|Group 1 will have had a muscle transfer driven by the trigeminal nerve (nV).
88932079|NCT04934176||Group 2|Group 2 will have had a muscle transfer driven by a cross-face nerve graft (nVII).
88932080|NCT04934176||Group 3|Group 3 will have had a muscle transfer driven by dual innervation using both the trigeminal and cross-face nerve graft.
88932081|NCT04934176||Group 4|Group 4 will have had manipulations that involve performing direct coaptation between the trigeminal nerve and a branch to the native zygomaticus major muscle (5-7 transfer) and selective neurolysis in which several facial nerve branches that innervate muscles antagonistic to the smile animation.
89014115|NCT05720988|Experimental|Cohort II (azacitidine, tagraxofusp-erzs)|Patients receive azacitidine SC daily on days 1-5 and tagraxofusp-erzs IV QD over 15 minutes on days 8-12. Treatment repeats every 28-42 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.
89446957|NCT05783778|Experimental|Toxoplasmosis seropositive female patients with active acne vulgaris|
89446958|NCT05783778|Experimental|Toxoplasmosis seronegative in female patients with active acne vulgaris|
88932082|NCT04924101|Experimental|Pembrolizumab + MK-4830 + Chemotherapy|Participants receive pembrolizumab 200 mg IV infusion on Day 1 of each cycle (cycle length = 3 weeks) every 3 weeks (Q3W) up to 35 administrations (up to approximately 2 years) or until disease progression (PD) or discontinuation, MK-4830 800 mg IV infusion on Day 1 of each cycle Q3W, up to 35 administrations (up to approximately 2 years) or until PD or discontinuation; etoposide 100 mg/m^2 on Days 1, 2, 3 of each cycle for up to 4 cycles (up to approximately 12 weeks) and cisplatin 75 mg/m^2 or carboplatin AUC 5 mg/ml/min IV, Day 1 of each cycle Q3W up to 4 cycles (up to approximately 12 weeks) or until PD or discontinuation.
88932083|NCT04924101|Experimental|Pembrolizumab + Boserolimab + Chemotherapy|Participants receive pembrolizumab 200 mg IV infusion on Day 1 of each cycle Q3W up to 35 administrations (up to approximately 2 years) or until PD or discontinuation, boserolimab 30 mg IV infusion on Day 1 of each cycle (cycle length = 6 weeks) every 6 weeks (Q6W), up to 18 administrations (up to approximately 2 years) or until PD or discontinuation; etoposide 100 mg/m^2 on Days 1, 2, 3 of each cycle for up to 4 cycles (up to approximately 12 weeks) and cisplatin 75 mg/m^2 or carboplatin AUC 5 mg/ml/min IV, Day 1 of each cycle Q3W up to 4 cycles (up to approximately 12 weeks) or until PD or discontinuation.
89014116|NCT05720936||patients with electric storm|patients with electric storm defined as the occurrence of at least three episodes of ventricular fibrillation/tachycardia in 24 hours
89014117|NCT05720546||Outpatient treatment center|Subjects received an infusion in an outpatient infusion center.
89446959|NCT05783752|Experimental|Stair-Stepping then Control|Participants start with stair-stepping 15 minutes after meals on day 1 followed by no exercise on day 2. Sequence continues throughout the 10 days.
89446960|NCT05783752|Experimental|Control then Stair-Stepping|Participants start with no exercise on day 1 followed by stair-stepping 15 minutes after meals on day 2. Sequence continues throughout the 10 days.
89446961|NCT05783739||Tendo Achilles Lengthening (TAL), percutaneous|Percutaneous lengthening of the achilles tendon.
89446962|NCT05783739||Tendo Achilles Lengthening (TAL), open|Open surgery with lengthening of the achilles tendon.
89446963|NCT05783739||Gastrocsoleus lengthening in zone 1 and 2|Lengthening of the gasrocnemius or its aponeurosis.
89446964|NCT05783674|Experimental|BrainBreaks for people without mental health problems|BrainBreaks for people without mental health problems
89446965|NCT05783674|Experimental|BrainBreaks for people with mental health problems|BrainBreaks for people with mental health problems
89446966|NCT05783557|Experimental|Experimental Group|Experimental Group
89446967|NCT05783557|Active Comparator|Active-compared Group|Active-compared Group
89446968|NCT05783531|Experimental|Intervention|This arm will receive the VMood digital mental health intervention. This consists of bibliotherapy that is delivered via a smartphone app, with coaching support provided by social workers for a duration of three months. The skills in the workbook are grounded in principles of Cognitive Behavioural Therapy.
89446969|NCT05783531|Other|Control|This arm will receive enhanced treatment as usual, which consists of regular care as provided by primary care centres and a brief introduction video about depression via the app. The control arm will receive the intervention after the intervention arm has completed the intervention period.
89446970|NCT05783518|Experimental|propofol group|
89014118|NCT05720546||Inpatient Infusion Center|Subjects received an infusion in an inpatient infusion center.
89446971|NCT05783518|Experimental|propofol and desflurane group|
89446972|NCT05783518|Experimental|desflurane group|
89446973|NCT05783492|Experimental|Intranasal ketamine|Intranasal ketamine 10 mg/kg
89446974|NCT05783479|Active Comparator|1 (estradiol)|estradiol 0.5 mg in vaginal cream twice daily for 10 days pre-procedure
89446975|NCT05783479|Active Comparator|2 (hyaluronic acid)|hyaluronic acid 5 mg in vaginal gel twice daily for 10 days pre-procedure
89446976|NCT05783479|No Intervention|3 (control)|no preparation of the cervix - arm without medication
89446977|NCT05783440|Experimental|Intervention group|Applying a system in which patients undergoing surgery can report pain scores and other pain-related outcomes with their own smartphone, both during hospitalization and for three months after discharge. During clinical admission patient reported pain scores > 3 (NRS 0-10) in the intervention group are immediately passed on to the nurse who will receive a notification on a smartphone. In the control group the patients' pain scores are not sent to the nurse. After discharge, patients will report pain scores every two weeks for three months.
89446978|NCT05783440|No Intervention|control group|Participants in the control group report postoperative pain scores and other pain related outcomes with their own smartphone. Their reported pain-scores will not be surpassed to the nurses on the ward. All patient reported pain-scores by smartphone are stored in a database that is not accessible to medical or nursing staff from the nursing ward.
89446979|NCT05783284||Readers|5 trained GI surgeons within liver surgery (the readers) will identify pre-defined anatomical landmarks in liver CT images that have been processed by HS2
89446980|NCT05783193|Experimental|TGIR (Traditional Gastrointestinal Remedy)|TGIR (500mg/capsule), 1.0g (2 capsules)
89014119|NCT05720273|Experimental|Palicalcitol|Maintenance hemodialysis patients with secondary hyperparathyroidism (SHPT) treat with palicalcitol
89014120|NCT05720039|Experimental|Robotic NSM with da Vinci SP|Subjects randomized to this arm will undergo robotic NSM (RNSM) procedures
89014121|NCT05720039|Active Comparator|Open NSM|Subjects randomized to this arm will undergo conventional open NSM procedures
89446981|NCT05783193|Placebo Comparator|Control (Microcrystalline cellulose)|Placebo control (2 capsules)
88932084|NCT04924101|Experimental|Pembrolizumab + Lenvatinib + Chemotherapy|Participants receive pembrolizumab 200 mg IV infusion on Day 1 of each 3 week cycle (Q3W) up to 35 administrations (up to approximately 2 years) or until PD or discontinuation, lenvatinib 8 mg once daily (QD) orally up to Cycles 1-4 cycles and up to 20 mg QD orally for Cycles 5-31 or until PD or discontinuation; etoposide 100 mg/m^2 on Days 1, 2, 3 of each cycle for up to 4 cycles (up to approximately 12 weeks) and cisplatin 75 mg/m^2 or carboplatin AUC 5 mg/ml/min IV, Day 1 of each cycle Q3W up to 4 cycles (up to approximately 12 weeks) or until PD or discontinuation.
89446982|NCT05783154|No Intervention|Control Group (Group-1)|In control group: 42 patients with primary KOA will receive standard conventional care including rehabilitation for knee osteoarthritis.
89446983|NCT05783154|Experimental|Experimental Group (Group-2)|In the interventional group, another 42 patients with primary KOA will receive adipose tissue-derived mesenchymal stem cells (AT-MSCs) injection intra-articularly (Group-2). However, group-2 (Interventional group) will be subdivided into two sub-groups namely group-2a, and group-2b. A total of 21 Participants of group-2a will receive single doses of autologous adipose tissue-derived stem cell (AT-MSCs) and standard conservative care including rehabilitation for KOA. Whereas, group-2b, 21 respondents will receive two doses of autologous adipose tissue-derived stem cell (AT-MSCs) at 3 months intervals along with standard conservative care including rehabilitation for KOA.
89446984|NCT05783128||Spontaneous breathing|1) Spontaneous breathing, with no airway management, in surgeries performed under regional anesthesia
88932085|NCT04921943|Experimental|Hypertonic saline|Patients who randomize to the hypertonic saline arm will be prescribed a nebulizer device to nebulize hypertonic saline (7%) twice daily for 12 weeks. Hypertonic saline (3%) can be prescribed in the case of poor tolerability of the 7% solution.
88932086|NCT04921943|Active Comparator|Standard of Care|Patients who randomize to the standard of care arm will receive treatment for pulmonary MAC based on the approved ATS/IDSA guidelines. Changes to standard of care regimen may be made based on the investigator's discretion.
88932087|NCT04919382|Experimental|Cohort I (atezolizumab, temozolomide)|Patients receive atezolizumab IV over 30-60 minutes on day 1 and temozolomide PO QD on days 1-5. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88932088|NCT04919382|Experimental|Cohort II (atezolizumab, temozolomide)|Patients receive atezolizumab IV over 30-60 minutes on day 1. Patients also receive temozolomide PO QD on days 1-14 of cycle 1 and days 1-21 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88932089|NCT04907045|Experimental|Standard Implementation Plus Health Coaching|The clinic in this arm will implement reSET and reSET-O with a standard implementation strategy and patients at the clinic will receive support from a health coach to help them engage with reSET and reSET-O.
88932090|NCT04907045|Experimental|Standard Implementation Plus Health Coaching and Practice Facilitation|The clinic in this arm will implement reSET and reSET-O with a standard implementation strategy and patients at the clinic will receive support from a health coach to help them engage with reSET and reSET-O. Additionally, a practice facilitator will provide the clinic with support for implementation.
88932091|NCT04905290|Experimental|Single Arm|On the date of implant, subjects will undergo Conduction System Pacing Optimized Therapy (CSPOT) lead placement, then Conduction System Pacing Optimized Therapy (CSPOT) acute pacing protocol, and then device implant. During the acute pacing protocol, all subjects will undergo three types of pacing configurations (defined in the intervention descriptions), and will serve as their own control. The subject will then be implanted with the cardiac resynchronization therapy defibrillator (CRT-D) or cardiac resynchronization therapy pacemaker (CRT-P) device will be implanted. Each subject's device will be programmed to conduction system pacing optimized therapy (CSPOT) configuration. Subjects will be followed for 6 months.
88932092|NCT04891640|Active Comparator|TNFi Standard Therapy|Continue fixed standard treatment (i.e., no change from current therapy)
88932093|NCT04891640|Experimental|TNFi fixed longer dosing intervals|Fixed longer dosing intervals of TNFi (i.e., increased time between doses)
88932094|NCT04891640|Experimental|TNFi Therapy Withdrawal|Stop TNFi treatment
88932095|NCT04891237|Experimental|10,000 MG01 + 10,000 T517|10,000 TU/mL of MG01 + 10,000 TU/mL of T517 of subcutaneous immunotherapy
88932096|NCT04891237|Experimental|30,000 MG01 + 10,000 T517|30,000 TU/mL of MG01 + 10,000 TU/mL of T517 of subcutaneous immunotherapy
88932097|NCT04891237|Placebo Comparator|Placebo subcutaneous|The same solution and presentation as the active treatment, but without active ingredients.
89446985|NCT05783128||Endotracheal intubation - Macintosh laryngoscope|2) Assist control ventilation, after intubation through the mouth, with the use of a Macintosh laryngoscope
89446986|NCT05783128||Endotracheal intubation - C-MAC video-laryngoscope|3) Assist control ventilation, after intubation through the mouth, with the use of a C-MAC video-laryngoscope
89446987|NCT05783128||Supraglottic Airway Device|4) Assist control ventilation, after the insertion of an LMA (laryngeal mask airway) supreme supraglottic device
89446988|NCT05783115|Active Comparator|Tibial Transportation|Tibial Transportation
89446989|NCT05783115|Experimental|Tibial Transportation Combined With Autologous mesenchymal stem cells Local Infusion|Tibial Transportation Combined With Autologous mesenchymal stem cells Local Infusion
88932098|NCT04889716|Experimental|Cohort 1|Participants receive mosunetuzumab 60 mg for cycles 1 and 2 (although fractionated for cycle 1), and 30 mg for all subsequent cycles after standard-of-care therapy with CD19-directed CAR T-cells
88932099|NCT04889716|Experimental|Cohort 2|Participants receive obinutuzumab (1000 mg for each subject) and glofitamab after standard-of-care therapy with CD19-directed CAR T-cells. The dose of glofitamab for each subject will be 30 mg, other than for cycle 1, which will be 12.5 mg glofitamab fractionated over two weeks.
88932100|NCT04882475||MCL patients relapsed or refractory to rituximab and induction chemotherapy with curative intent|"An historical cohort of patients will be identified and selected both on a clinical base and according to the availability of Formaline-fixed paraffin-embedded (FFPE) material, frozen material or viable cryopreserved cells at Mantle Cell Lymphoma (MCL) diagnosis. Samples will be analyzed in 4 subgroups, each with different clinical specificity:~refractory to Induction Chemoimmunotherapy (CIT);~refractory to Bruton Tyrosine kinase (BTK) inhibitors (BTKi);~sensitive to Induction Chemoimmunotherapy (CIT);~sensitive to Bruton Tyrosine kinase (BTK) inhibitors (BTKi)."
88932101|NCT04874714|Experimental|MM09-MG01(30.000-30.000)|30,000 AU/mL of MM09 and 30,000 AU/mL of MG01 of subcutaneous immunotherapy once a month for 11 months
88932102|NCT04874714|Experimental|MG01(30.000)|30,000 AU/mL of MG01 of subcutaneous immunotherapy once a month for 11 months
89446990|NCT05782959|Experimental|Cohort 1|BCD-245 (anti-GD-2 monoclonal antibody), dose 1
89200261|NCT00974428|Active Comparator|Wobenzym® N and placebo|Wobenzym® N 2 tablets of the treatment and 2 placebo tablets three times per day
89446991|NCT05782959|Experimental|Cohort 2|BCD-245 (anti-GD-2 monoclonal antibody), dose 2
89446992|NCT05782959|Experimental|Cohort 3|BCD-245 (anti-GD-2 monoclonal antibody), dose 3
89446993|NCT05782959|Experimental|Cohort 4|BCD-245 (anti-GD-2 monoclonal antibody), dose 4
89446994|NCT05782933|Experimental|Rituximab|Patients received rituximab 100 and 500 mg of intravenous medication on days 1 and 2, respectively. If proteinuria was reduced from baseline by no more than 25% at 3 months, cyclosporine was administered. In addition, CD19+ B-cell count was monitored every 3 months, and another rituximab 100 and 500 mg will be administered if CD19+ B-cell count >5 cells/mL.
89446995|NCT05782933|Active Comparator|Modified Ponticelli regimen|Patients received corticosteroids at months 1, 3, and 5 (methylprednisolone 0.5 g at days 1, 2, and 3, then prednisone 0.5 mg/kg/d from day-4 to day-30). At months 2, 4, and 6, patients received cyclophosphamide adjusted for age and renal function (1.0-2.0 mg/kg/day for 30 days, maximum dose 100 mg/d).
89446996|NCT05782920|Active Comparator|PRP- treated Group A|15 female patients will receive 2 vaginal PRP injections one month apart.
89200262|NCT00974428|Active Comparator|Wobenzym® N|Wobenzym® N 4 tablets three times per day
89200263|NCT00974428|Placebo Comparator|Placebo|Placebo 4 tablets three times per day
89446997|NCT05782920|Active Comparator|PRP-HA treated Group B|15 female patients will receive 2 vaginal PRP-non-cross-linked HA injections spaced a month apart.
89446998|NCT05782920|Active Comparator|Control Group C|15 female patients will receive topical non-cross-linked hyaluronic acid gel applied every three days for 2 months as a control group
89446999|NCT05782829|Experimental|L-Tyrosine|
89447000|NCT05782829|Placebo Comparator|Placebo|
89200264|NCT00760734|Experimental|Hyperbaric oxygen therapy-TBI/PCS|Intervention: Low pressure hyperbaric oxygen therapy, 40 or 80 twice daily, 5d/week, HBOTs at 1.5 ATA/60 minutes each. One month no treatment period between the 40th and 41st HBOT
89200265|NCT00760734|Experimental|Hyperbaric Oxygen Therapy-PCS/PTSD|Intervention: Low pressure hyperbaric oxygen therapy, 40 or 80 twice daily, 5d/week, HBOTs at 1.5 ATA/60 minutes each. One month no treatment period between the 40th and 41st HBOT
89200266|NCT00974506|Active Comparator|CAM-intervention|Complex intervention containing exercise therapy, nutritional advice, homeopathic treatment, naturopathic treatment in addition to routine therapy by general practitioner
89200267|NCT00974506|Active Comparator|Routine care therapy|Routine care therapy by general practitioner
89200268|NCT00764010|No Intervention|1|No dietary counseling, placebo capsules for omega-3
89200269|NCT00764010|Active Comparator|2|Dietary counseling, placebo capsules for omega-3
89447001|NCT05782803|Experimental|Exercises Group|As stated in the literature, 20 sessions of KSF training will be given to the study group for 4 weeks.
89447002|NCT05782803|No Intervention|Control Group|Participants in the control group will not receive intervention throughout the study.
89200270|NCT00764010|Active Comparator|3|No dietary counseling, omega-3 capsules
89200271|NCT00764010|Active Comparator|4|Dietary counseling and omega-3 capsules
89200272|NCT00968188|Experimental|Active intervention|Highly interactive, motivational, culturally tailored, online HIV prevention.
89200273|NCT00968188|Active Comparator|Information only|Medically fact based online intervention.
89200274|NCT00974584|Experimental|GDC-0941+Paclitaxel+Carboplatin|Bevacizumab-ineligible non-small cell lung cancer (NSCLC) participants may receive up to 6 cycles (21-day cycle) of combination chemotherapy with paclitaxel and carboplatin along with GDC-0941
89200275|NCT00974584|Experimental|GDC-0941+Paclitaxel+Carboplatin+Bevacizumab|Bevacizumab-eligible NSCLC particpants may receive up to 6 cycles of combination chemotherapy with paclitaxel and carboplatin along with GDC-0941 and bevacizumab.
89447003|NCT05782764|Experimental|single arm|Recombinant human endostatin (CIV72h, D1-D3, 14 tubes) was administered by continuous intravenous infusion every 3 weeks. The drug was discontinued until disease progression or intolerable side effects.
89447004|NCT05782751|Experimental|(groupI)|10 recession sites treated by (GEM 21s) ® with free connective tissue graft
89447005|NCT05782751|Active Comparator|(groupII)|10 recession sites GEM 21s with collagen membrane
89200276|NCT00974584|Experimental|GDC-0941+Pemetrexed+Cisplatin|Bevacizumab-ineligible NSCLC participants may receive up to 6 cycles of combination chemotherapy with pemetrexed and cisplatin along with GDC-0941.\n
89200277|NCT00974584|Experimental|GDC-0941+Pemetrexed+Cisplatin+Bevacizumab|Bevacizumab-eligible NSCLC participants may receive up to 6 cycles of combination chemotherapy with pemetrexed and cisplatin along with GDC-0941 and bevacizumab.\n
89200278|NCT01563484||low-osmolar contrast media|Patients undergo TACE of low-osmolar contrast media on day 1.
89200279|NCT01563484||iso-osmolar contrast media|Patients undergo TACE of iso-osmolar contrast media on day 1.
89200280|NCT00608205|Active Comparator|Arm A: Radiation with concurrent Cisplatin|Patients undergo full-dose radiotherapy once or twice daily 5 days a week for up to 7 weeks and receive cisplatin IV over 1 hour on days 1, 22, and 43 of radiotherapy.
89200281|NCT00608205|Experimental|Arm B: Radiation with concurrent 5-FU and Cisplatin|Patients undergo radiotherapy as in arm I and receive fluorouracil IV and cisplatin IV continuously on days 1-4 and 22-25 of radiotherapy.
89200282|NCT00974662|Experimental|WST11|Treatment with WST11-mediated VTP
89200283|NCT00974740|Placebo Comparator|atorvastatin matching placebo|atorvastatin matching placebo
89200284|NCT00974740|Experimental|atorvastatin|40 mg atorvastatin for 4 weeks (run-in period), then 80 mg atorvastatin, total treatment period was 18 months
89200285|NCT00967096|Experimental|1|The primary clinical endpoint to be assessed in this study will be the proportion of Rifaximin doses successfully administered. Because of mucositis, compliance with oral agents, even those that are well tolerated in other settings, may be limited in the early post-transplant period. Thus, it will be important to demonstrate the feasibility of administering Rifaximin to BMT patients before embarking on larger scale studies. Secondary outcomes will include AGVHD, event-free survival, overall survival, non-relapse mortality, neutrophil and platelet engraftment.
89200286|NCT04037163||CCTA-FFR|Patients who underwent CCTA within 90 days before FFR measurement will be included in the present study.
89200287|NCT05227300|Experimental|Buffered 2% lidocaine with 1:100,000 epinephrine|Buffered local anesthetic (addition of sodium bicarbonate to make a 10% buffered solution)
88932103|NCT04874714|Experimental|MM09(30.000)|30,000 AU/mL of MM09 of subcutaneous immunotherapy once a month for 11 months
89200288|NCT05227300|Active Comparator|Unbuffered 2% lidocaine with 1:100,000 epinephrine|Standard local anesthetic
89200289|NCT00890487|Other|hyaluroni acid pill|
88932104|NCT04874714|Placebo Comparator|Placebo subcutaneous|The same solution, presentation, method of administration, frequency, and duration as the active treatment, but without active ingredients.
88932105|NCT04868656|Active Comparator|Foundational Support|Foundational Support uses the Replicating Effective Program (REP) implementation strategy and includes 5 elements that were developed and tested in our prior Function QUERI work: STRIDE Toolkit; Online shared resources (SharePoint) access for clinical program training materials; Data dashboard to assist hospitals with tracking their own data; Diffusion Networks to promote peer-to-peer sharing and implementation support; and Microsoft TEAMS Channels.
88932106|NCT04868656|Experimental|Enhanced Support|Enhanced Support begins with the same activities as Foundational Support. Hospitals that are randomized to Enhanced Support and do not meet STRIDE initial program benchmarks within 6 months will continue with Foundational support and also receive higher intensity support for a period of 4-6 months. Hospitals that have sustained their implementation will continue low-touch activities while those that have been randomized to the enhanced support arm and met the initial program benchmark at 6-months but have not sustained (did not meet the sustainment benchmark), will begin engaging in high-touch activities. The higher intensity support will consist of facilitation, a process of interactive problem solving and support that occurs in a context of a supportive interpersonal relationship. Facilitation will be provided by Function QUERI team members.
88932107|NCT04867603||Digital PET/CT using [Ga-68]PSMA|Following prostate Standard of Care MRI, eligible participants will receive a single injection of [Ga-68]PSMA followed by digital PET/CT imaging approximately 60 minutes later. PET/CT takes approximately 30-35 minutes, where the participant would lay still on a scanner table.
88932108|NCT04856826|Experimental|echo guidance|insertion of a peripheral venous catheter with ultrasound guidance and therapeutic communication
88932109|NCT04856826|No Intervention|conventional|insertion of a peripheral venous catheter conventionally
88932110|NCT04849884|Experimental|CORI TENSIONER|Subjects having a robotic TKA procedure with the CORI Surgical System, including the use of the CORI™ KNEE TENSIONER accessory.
88932111|NCT04828304|No Intervention|control group|Standard of care
88932112|NCT04828304|Experimental|treatment group|Standard of care + PLASOMA treatment
88932113|NCT04826224|Experimental|Subjects with Osteoarthritis of the shoulders|Subjects diagnosed with Osteoarthritis of the shoulders will be injected with concentrated bone marrow aspirate administration after Comprehensive Arthroscopic Management (CAM) surgical procedure.
88932114|NCT04816643|Experimental|Low/Mid-Dose, ≥5 to <12 Years|Low/Mid-Dose (10mcg), 2 doses 21 days apart
88932115|NCT04816643|Experimental|Mid-Dose, ≥5 to <12 Years|Mid-Dose, (20mcg), 2 doses 21 days apart
88932116|NCT04816643|Experimental|High-Dose, ≥5 to <12 Years|High-Dose (30mcg), 2 doses 21 days apart
88932117|NCT04816643|Experimental|Low/Mid-Dose, ≥2 to < 5 Years|Low/Mid-Dose (10mcg), 2 doses 21 days apart
88932118|NCT04816643|Experimental|Mid-Dose, ≥2 to <5 Years|Mid-Dose, (20mcg), 2 doses 21 days apart
88932119|NCT04816643|Experimental|High-Dose, ≥2 to <5 Years|High-Dose, (30mcg), 2 doses 21 days apart
88932120|NCT04816643|Experimental|Low/Mid-Dose, ≥6 Months to <2 Years|Low/Mid-Dose, (10mcg), 2 doses 21 days apart
88932121|NCT04816643|Experimental|Mid-Dose, ≥6 Months to <2 Years|Mid-Dose, (20mcg), 2 doses 21 days apart
88932122|NCT04816643|Experimental|High-Dose, ≥6 Months to <2 Years|High-Dose, (30mcg), 2 doses 21 days apart
88932123|NCT04816643|Placebo Comparator|Placebo, ≥6 Months to <2 Years|
88932124|NCT04816643|Placebo Comparator|Placebo, ≥2 to <5 Years|
88932125|NCT04816643|Placebo Comparator|Placebo, ≥5 to <12 Years|
88932126|NCT04816643|Experimental|Low-Dose, ≥6 Months to <2 Years|Low-Dose (3mcg), 2 doses 21 doses apart
88932127|NCT04816643|Experimental|Low-Dose, ≥2 to <5 Years|Low-Dose (3mcg), 2 doses 21 days apart
88932128|NCT04816643|Experimental|High-Dose, 12 to <16 Years (Troponin I Testing)|High-Dose (30mcg), 3 doses
88932129|NCT04816643|Experimental|Low/Mid-Dose, ≥5 to <12 Years (Troponin I Testing)|Low/Mid-Dose (10mcg), 3 doses
88932130|NCT04816643|Experimental|Placebo, ≥5 to <12 Years (Troponin I Testing)|
88932131|NCT04816643|Experimental|Low-Dose, ≥6 Months to <2 Years (3-dose regimen)|Low-Dose (3mcg), 3 doses
88932132|NCT04816643|Experimental|Low-Dose, ≥2 to <5 Years (3-dose regimen)|Low-Dose (3mcg), 3 doses
88932133|NCT04816643|Placebo Comparator|Placebo, ≥6 Months to <2 Years (3-dose regimen)|
88932134|NCT04816643|Placebo Comparator|Placebo, ≥2 to <5 Years (3-dose regimen)|
88932135|NCT04809467|Experimental|tafasitamab + parsaclisib|"Participants will be assigned to disease specific cohorts based on the histology of their underlying disease.~Cohort 1: R/R DLBCL Cohort 2: R/R MCL Cohort 3: R/R FL Cohort 4: R/R MZL Cohort 5: R/R CLL/SLL"
88932136|NCT04799834||CASES|Subjects who have had a severe form of COVID-19 and developed respiratory failure requiring oxygen supplementation or CPAP mechanical ventilation or intubation
88932137|NCT04799834||CONTROLS 1|Subjects, comparable in age, sex and risk factors (such as concomitant diseases) with the CASES, who contracted the virus but either did not fall ill or had mild symptoms
89447006|NCT05781074|Experimental|Cryoablation combined with Sintilimab and lenvatinib|Cryoablation treatment starts at day 0. Sintilimab will be initiated on day 14 after cryoablation. Sintilimab will be administered at 200 mg i.v. every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent. Lenvatinib will be initiated on day 14 after cryoablation. Lenvatinib will be administered (bodyweight ≥ 60 kg, 12 mg; < 60 kg, 8 mg) orally daily every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
88932138|NCT04799834||CONTROLS 2|Subjects, comparable in age, sex and risk factors (such as concomitant pathologies) with the CASES, who did not contract the virus
88932139|NCT04795999|Experimental|Project With program|Project With is a 12-lesson literary-based curriculum, delivered by Youth Advocates to youth in juvenile justice facilities and group homes in Southern California either in person or virtually, under COVID-19 contingencies. Program schedule is determined by the facility. The goals of Project With are to promote optimal health and reduce teen pregnancy and sexually transmitted infections (STIs).
88932140|NCT04795999|No Intervention|Treatment as usual|The counterfactual condition for the study is a business-as-usual condition.
88932141|NCT04786548|Experimental|Celecoxib Treatment|Patients will receive standardized pharmacotherapy with celecoxib 100mg twice daily for the first week, and will then, if well-tolerated, will be increased to 200mg twice daily for the next seven weeks. Visits with the study psychiatrist will occur weekly for the first four weeks, and biweekly thereafter until week 8, which will be conducted remotely in general, although they may be conducted in-person as clinically warranted and may be conducted in person on the days of other in-person visits. If individuals experience significant side-effects from a given dose, the treating physician may lower the medication dose according to clinical judgment; if side-effects are intolerable, we will discontinue the research procedures and advance to open clinical treatment
88932142|NCT04775914|Active Comparator|PCI standard|
88932143|NCT04775914|Experimental|PCI standard + ischemic conditioning|
88932144|NCT04775914|Experimental|Stent with ultrasound|
88932145|NCT04775914|Active Comparator|Stent without ultrasound|
88932146|NCT04757519|Experimental|DPP-GLB Standard|Participants in this group will receive the standard Diabetes Prevention Program Group Lifestyle Balance (DPP-GLP) Intervention Program.
88932147|NCT04757519|Experimental|DPP-GLB Enhanced|Participants in this group will receive the enhanced Diabetes Prevention Program Group Lifestyle Balance (DPP-GLP) Intervention Program.
88932148|NCT04755725|Active Comparator|Epidural Group|epidural catheter inserted pre induction
88932149|NCT04755725|Active Comparator|Rectus sheath catheter Group|rectus sheath catheter inserted by the surgeon at the end of surgery
88932150|NCT04733547||Donor hepatectomy|Live donors undergoing hepatectomy
88932151|NCT04725604|Experimental|pH Probe|Softcell pH monitoring system: designed to measure intramuscular pH levels in patients with fracture or crush injuries sufficiently severe to be at risk of developing ACS.
88932152|NCT04723056|No Intervention|Control Group (TAU only)|Treatment as Usual (TAU) for IBS patients are tailored to each individual's needs and may involve treatment such as: dietary modification, exercise, medication, and anti-diarrheal therapy.
88932153|NCT04723056|Experimental|Experimental (TAU plus CBT)|Subjects who are in the Experimental Group will receive 8 weeks of CBT from the Zemedy mobile application in addition to their treatment as usual (TAU).
88932154|NCT04711005|Experimental|SAD Cohort 1|(2R,6R)-Hydroxynorketamine @ 0.1 mg/kg via slow IV infusion (40 minutes)
88932155|NCT04711005|Experimental|SAD Cohort 2|(2R,6R)-Hydroxynorketamine @ 0.25 mg/kg via slow IV infusion (40 minutes)
88932156|NCT04711005|Experimental|SAD Cohort 3|(2R,6R)-Hydroxynorketamine @ 0.5 mg/kg via slow IV infusion (40 minutes)
88932157|NCT04711005|Experimental|SAD Cohort 4|(2R,6R)-Hydroxynorketamine @ 1.0 mg/kg via slow IV infusion (40 minutes)
88932158|NCT04711005|Experimental|SAD Cohort 5|(2R,6R)-Hydroxynorketamine @ 2.0 mg/kg via slow IV infusion (40 minutes)
88932159|NCT04711005|Experimental|SAD Cohort 6|(2R,6R)-Hydroxynorketamine @ 4.0 mg/kg via slow IV infusion (40 minutes)
88932160|NCT04711005|Experimental|MAD Cohort 1|(2R,6R)-Hydroxynorketamine @ 1.0 mg/kg via slow IV infusion (40 minutes) on days 1, 4, 7, 10
88932161|NCT04711005|Experimental|MAD Cohort 2|(2R,6R)-Hydroxynorketamine @ 2.0 mg/kg via slow IV infusion (40 minutes) on days 1, 4, 7, 10
88932162|NCT04711005|Placebo Comparator|Placebo|Control product (placebo) will be sterile saline also administered via slow IV infusion (40 minutes).
88932163|NCT04711005|Experimental|CSF Capture Cohort 1|(2R,6R)-Hydroxynorketamine @ 0.25 mg/kg via slow IV infusion (40 minutes)
88932164|NCT04696406||Weaning failure|Defined as the failure to pass a spontaneous breathing trial or the need for reintubation or death within 48 hours
88932165|NCT04696406||Weaning success|Defined as a successful spontaneous breathing trial and is not reintubated or dies in the first 48 hours after extubation.
88932166|NCT04659954|Experimental|Application O'DIDE|The subjects will use the application O'DIDE during 8 weeks
89200290|NCT02541357|No Intervention|Usual care|Does not receive a specific study intervention
89200291|NCT02541357|Experimental|preoperative relaxation program|preoperative relaxation program
89200292|NCT02541357|Experimental|preoperative surgery education|single education unit to understand the complete surgical procedures
88932167|NCT04646733|Experimental|High Protein Diet Group|The high protein diet (HPD) group is instructed to follow a low carbohydrate, high protein ketogenic diet.
88932168|NCT04646733|Active Comparator|No High Protein Diet Group|No high protein diet (NHPD) group received an oat beverage consisted of 55 g of oats in 250 ml of water.
88932169|NCT04636710|Experimental|Sentinal Node Identification|"Within standard of care treatment for inflammatory breast cancer, participants will undergo a series of Lymphoscintigraphies: an imaging procedure to determine where their lymphatic system drains from their breast.~Prior to neoadjuvant chemotherapy~Day before surgery~These two imaging studies will be compared and the information used during participant's surgery to perform the sentinel node biopsy procedure.~During surgery participants will have a blue dye injected to affected breast to map drainage and identify sentinal nodes. The sentinal nodes will be removed first, followed by standard of care procedure to remove all axillary lymph nodes.~After surgery, a small amount of tissue from the tumor removed during surgery will be evaluated.~Participants will complete a Lymphedema Questionnaire after each Lymphoscintigraphy then every 6 months for 2 years post surgery."
88932170|NCT04622319|Experimental|Trastuzumab deruxtecan (T-DXd)|Participants who will be randomized to receive trastuzumab deruxtecan (T-DXd) at a starting dose of 5.4 mg/kg.
89200293|NCT02541357|Experimental|preop relaxation and surgery education|preoperative relaxation program AND single education unit
89200294|NCT00890565|Experimental|Treatment A: Sancuso® patch|Treatment A: Sancuso® patch (Day 1) and placebo IV (Day 3)
89200295|NCT00890565|Experimental|Treatment B: IV Granisetron 10 mcg/kg|Treatment B: placebo patch (Day 1) and granisetron IV (Day 3)
89200296|NCT00890565|Placebo Comparator|Treatment C: Matching placebo patch|Treatment C: placebo patch (Day 1) and placebo IV (Day 3)
89200297|NCT00890565|Active Comparator|Treatment D: Oral Moxifloxacin 400 mg|Treatment D: placebo patch (Day 1) and oral moxifloxacin (Day 3).
89200298|NCT00890643|Experimental|Arm 1|Persons with PTSD
89200299|NCT00890643|Placebo Comparator|Arm 2|Persons with PTSD
89200300|NCT00893217|Active Comparator|Arm 1|
89200301|NCT00893217|Experimental|Arm 2|
89200302|NCT00767598|Active Comparator|A|Vardenafil
89014122|NCT05717998||Ancillary-correlative (CMR, PET/CT, biospecimen collection)|Within 2 weeks of starting RT, patients undergo CMR, cardiac PET/CT and blood sample collection at baseline, then between fractions 12-17 of RT and at 6 months after completion of RT.
89014123|NCT05716802|Active Comparator|dance/movement therapy (DMT), twice a week, 12 weeks,|The multiple-session DMT intervention was applied to participants twice a week as a total of 24 sessions of 60 minutes over three months. The DMT intervention protocol was developed based on the therapist's experience, the theoretical frameworks, and the DMT approach described in a previous study (Bryl and Goodill 2019).
89014124|NCT05716802|Placebo Comparator|Treatment as usual (TAU), twice a week, 12 weeks,|The TAU group sessions were conducted by the licensed professional employed at the hospital. The patients received regular daily antipsychotic medication and supportive psychotherapy once a week. They also participated in daily activities from Monday to Friday for at least two hours each day, including indoor activities (watching TV, playing games, playing poker) and outside activities (walking and doing radio gymnastics).
89014125|NCT05710237|Experimental|Risperidone 1 mg plus Psilocybin 25 mg|
89014126|NCT05710237|Experimental|Placebo plus Psilocybin 25 mg|
89014127|NCT05710237|Active Comparator|Risperidone 1 mg plus Placebo|
89014128|NCT05708326|Experimental|5:2 Method|"Participants will follow the 5:2 Method (an intermittent fasting regimen) for a 90 day duration. This entails eating ad libitum for five days per week (normal days) and limiting total calorie intake to 800kcals per day (fasting days) for the remaining two days per week. The fasting days can be sequential or dispersed throughout the week, based on patient preference."
89014129|NCT05708326|Active Comparator|16/8 Method|Participants will have already followed the 16/8 Method (an intermittent fasting regimen) for a minimum of six days per week for a 90 day duration. This entailed limiting the eating hours to an 8-hour window, then fasting for the remaining 16 hours per day, with the last time of intake being 8pm.
89014130|NCT05708300||chronic rhinosinusitis with nasal polyps with bronchial asthma|Patients with chronic rhinosinusitis with nasal polyps with bronchial asthma will be administered Mepolizumab (100 MG), subcutaneusly every 30 days
89014131|NCT05708300||chronic rhinosinusitis with nasal polyps without bronchial asthma|Patients with chronic rhinosinusitis with nasal polyps without bronchial asthma will be administered Mepolizumab (100 MG), subcutaneusly every 30 days
89014132|NCT05706272|Experimental|Intervention primary care practices|"The participants in the intervention primary care practices arm will receive a holistic CGA using the PASTEL assessment tool. An elderly team including a doctor and nurse will work around the patient. The intervention includes increased care coordination."
89014133|NCT05706272|Active Comparator|Matched control primary care practices|The participants in the matched control primary care practices arm will receive care as usual at the matched control primary care centers.
89014134|NCT05702684||People living with colorectal cancer|Patients (who are living with colorectal cancer) who have agreed to complete the eHNA intervention (within 31 days of diagnosis) and care planning consultation and clinicians who work in cancer services and provide the eHNA intervention to patients who are living with colorectal cancer
89014135|NCT05702684||People living with treatable-but-not-curable cancer|Patients who have received the ARC Holistic Needs Assessment (HNA) intervention from the ARC clinic and clinicians responsible for developing/delivering the ARC HNA intervention.
89531301|NCT02121405|Experimental|Primary surgery|The patients receive primary rectectomy including anterior resection or abdominoperineal resection by open or laparoscopy with TME. To patients with pathological confirmed positive circumferential margin (CRM), postoperative concurrent radiochemotherapy is required that starts in 3 months post operation with capecitabine. Capecitabine and Oxaliplatin (CapeOx) chemotherapy starts in 4 weeks post operation to total of 6 cycles/18 weeks. To patients with pathological confirmed negative CRM, radiotherapy is omitted. The stage III patients receive 8 cycles/6 months CapeOx chemotherapy. The stage II patients with low microsatellite instability (MSI) receive 8 cycles/6 months Capecitabine chemotherapy. The stage II patients with high MSI and stage I patients do not receive adjuvant therapy.
88932171|NCT04622319|Active Comparator|Trastuzumab ematansine (T-DM1)|Participants who will be randomized to receive trastuzumab ematansine (T-DM1) at a starting dose of 3.6 mg/kg.
88932172|NCT04621188|Experimental|Lorlatinib|100 mg once daily
88932173|NCT04579653|Experimental|Group A: Experimental|Within-subjects design with a randomization of the order of tVNS administered parameters
88932174|NCT04579653|Active Comparator|Group B: Active Comparator|Within-subjects design with a randomization of the order of tVNS administered parameters
88932175|NCT04574895|Other|VTE risk prediction scores|Patients in the intervention arm will have their VTE risk prediction scores presented to the study team daily on weekdays via an automated report, which will list patients in descending order of risk severity for review by the VTE research team each weekday. Starting with the highest risk patients, the VTE research team will review each patient and clinical situation, and then the VTE research team will directly discuss risks/benefits of prophylactic anticoagulation with the admitting team. Patients with a risk score <2.5% will not be reviewed, and the investigators anticipate most of the intervention arm patients will fall into this category (based on our previous data, the investigators anticipate >90% of all patients will score <2.5%). The VTE risk report will be re-calculated based on updated EHR data every day at midnight.
88932176|NCT04574895|No Intervention|Standard of care|Patients randomized to the control arm will continue to receive current standard of care anticoagulation practice, which is at the discretion of the admitting team. In general, nearly no pediatric patients are offered prophylactic anticoagulation unless a previous VTE has been identified. This currently is at the discretion of the provider and no risk scoring is used. VTE risk prediction scores will be calculated and stored for analysis, these will not be visible to the study team in real time.
88932177|NCT04571814|Experimental|Parent and child intervention|Both parent and child will receive a computerized intervention to reduce error sensitivity.
88932178|NCT04571814|Experimental|Parent intervention and child control|Parent will receive a computerized intervention to reduce error sensitivity and child will receive an active control (a computerized program targeting health behaviors).
88932179|NCT04571814|Experimental|Parent control and child intervention|Child will receive a computerized intervention to reduce error sensitivity and parent will receive an active control (a computerized program targeting health behaviors).
88932180|NCT04571814|Active Comparator|Parent and child control|Both parent and child will receive an active control (a computerized program targeting health behaviors).
88932181|NCT04564287||Fully Recovered Individuals|Individuals with history of Covid-19 infection who have fully recovered without residual neurological symptoms
88932182|NCT04564287||Patients with neuro-PASC|Patients with history of Covid-19 infection and persistent neurological symptoms (Post-Acute Sequelae of SARS CoV-2 Infection, neuro-PASC)
88932183|NCT04543591|Experimental|Ravulizumab|"In Stage 1, all participants will receive open-label ravulizumab plus Best Supportive Care (BSC).~In Stage 2, participants will receive blinded ravulizumab plus Best Supportive Care (BSC)."
88932184|NCT04543591|Placebo Comparator|Placebo|In Stage 2, participants randomized to the placebo arm will receive matching placebo plus BSC.
88932185|NCT04541992||Airborne Group|Participants in this group will be tested for balance and agility within a 20 minute time frame.
88932186|NCT04521712|Experimental|Postpartum GDM|Women with GDM diagnosed early (< 20 weeks gestation) or with routine 3rd trimester screening (>=24 weeks) will be enrolled in this longitudinal study. All enrolled women will complete a oral glucose tolerance test and wear a continuous glucose monitor for 10 days at the 3 designated study time points (0-4 days, 4-6 weeks, and 6 months after delivery).
88932187|NCT04518306|Experimental|Triple ¼ (GMRx2)|Telmisartan 10 mg/amlodipine 1.25 mg/indapamide 0.625 mg
88932188|NCT04518306|Active Comparator|Triple ½ (GMRx2)|Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg
88932189|NCT04518306|Placebo Comparator|Placebo|Placebo
88932190|NCT04512547|Experimental|Obese Asthmatics|Obese patients that come to Duke that have been diagnosed with Asthma will be approached.
88932191|NCT04512547|Active Comparator|Obese Non-Asthmatics|The obese non-asthmatics will be collected from an IRB pre-approved Healthy Volunteer Data Repository.
88932192|NCT04502043|Experimental|Exercise therapy|Exercise therapy consists of improving dynamic hip joint stability by means of hip-specific and functional lower limb strengthening, core stability and postural balance exercises.
89200303|NCT00767598|Active Comparator|B|Sildenafil
89200304|NCT00767598|Active Comparator|C|Udenafil
89447007|NCT05780047|Experimental|Mobile EDC reduction program|Million Marker's (MM) first-of-its-kind mobile endocrine disrupting chemical (EDC) reduction program will be tested and validated in a prospective longitudinal cohort intervention trial. 50 women in reproductive age and their partners will be recruited from the Healthy Nevada Project, an existing state-wide health monitoring effort. Using MM's services, participants' urine samples will be collected two times (at pre- and post-intervention) to measure changes in EDC levels. Changes in participants' environmental health literacy, attitudes, knowledge, and behaviors will be assessed after using MM's products and services. Validated surveys on environmental health literacy and readiness to change and analyses of participants' lifestyle behaviors and product use will be conducted at baseline (first test) and upon completion of the second test. The investigators will evaluate the MM app and platform usability to improve the user experience, using the System Usability Score (SUS) survey.
89447008|NCT05779657|Experimental|Study group (Ket-Mid)|Children receiving ketamine + midazolam
89447009|NCT05779657|Placebo Comparator|Control group (Pla-Mid)|Children receiving placebo + midazolam
89447010|NCT05777473|Experimental|Kulawa|This arm will receive the standard Kulawa intervention. Kulawa is a USAID-funded program that seeks to change FP-related behaviors among young, low parity women at scale in Niger. Kulawa, implemented by Save the Children U.S. aims to increase use of quality FP services of all WRA, including young women ages 15-24 years, in 15 districts of Niger across 3 regions (Tillaberi, Maradi, and Zinder), covering a population of 12.5 million. Kulawa will address individual, social, and health system constraints to FP use through interventions to change behavior and influence social norms that govern FP use and related gender outcomes as well as interventions to improve FP service availability and quality. Kulawa SBC programming at the community-level will include small groups for young, low parity women and girls (ages 15-24) and community dialogues.
89447011|NCT05777473|Experimental|Kulawa SN (Tipping Point)|This arm will receive the Kulawa intervention, with a social network-informed intervention (KulawaSN) layered on top. In this arm 50% of eligible women will be paired with an alter to receive the adapted intervention. The social network intervention will involve pairing up young married adolescents and women with someone identified as influential in their social networks and enrolling them in the Kulawa FP programming together.
88932193|NCT04477187|Experimental|Single Group|All subjects will undergo a single treatment for skin laxity in the submentum with a dermal handpiece.
88932194|NCT04450758||resection|Patients who present with obstruction due to colon cancer with a need for urgent intervention who are treated with acute resection.
88932195|NCT04450758||bridge to sugery|Patients who present with obstruction due to colon cancer with a need for urgent intervention who are treated with bridge to surgery i.e. either stent or stoma and resection later on.
88932196|NCT04450212|Experimental|Phase I, Buccal Swab Collection for DNA Isolation|Approximately 200 healthy volunteers recruited. They complete a brief demographic survey and a undergo one-time buccal swab for collection of cheek cells for DNA analysis.
88932197|NCT04450212|Experimental|Phase II, Vitamin K (Vitacost) Supplementation|Subjects from Phase I with a homozygous CYP4F2*1 (n=14) or CYP4F2*3 carriers (n=14) are selected to receive daily vitamin K supplementation, for 10-days. Blood and urine samples are collected sequentially, at baseline, and during the supplementation period.
88932198|NCT04447339||Open|Prophylactic NSM cases by Open approach
88932199|NCT04441307|Active Comparator|Healthy Foundations|A community-based parenting education program with individual family check ins will be implemented to all participants assigned to this arm.
88932200|NCT04441307|Experimental|Family Foundations|An adapted Family Foundations parenting program for expecting first time parents with individual family check ins will be implemented to all participants assigned to this arm.
88932201|NCT04437264|Experimental|Intermittent feed|Patients will be assigned to receive intermittent enteral feeding protocol. They will receive four equal volume feeds at 8:00, 12:00, 16:00, and 20:00 hours.
88932202|NCT04437264|Experimental|Continuous feeds|Patients will be assigned to receive continuous enteral feeding protocol. Typical goal rates are in the range of 60 to 80 mL per hour for 24 hours per day.
88932203|NCT04433182|Experimental|Single arm Copa-RB|Induction phase with Copanlisib, Rituximab and Bendamustina. Maintenance phase (for patients who reach at least SD after induction) with Copanlisib in monotherapy.
88932204|NCT04408118|Experimental|Atezolizumab + Paclitaxel + Bevacizumab (Avastin®)|"All eligible patients will be treated with atezolizumab (840 mg) intravenously on days 1 and 15, Paclitaxel (90 mg/m2) on days 1, 8 and 15 via IV infusion and Bevacizumab (Avastin® 10mg/kg) intravenously on days 1 and 15.~Treatment cycles and patient visits are organized in scheduled cycles of 28 days."
88932205|NCT04404595|Experimental|anti-claudin18.2 chimeric antigen receptor T-cell therapy|Phase 1b will include two parts, dose escalation phase (Cohort A) followed by a dose expansion phase (Cohort B). Phase 2 (Cohort C) will evaluate the chosen dose in patients with advanced gastric cancer.
88932206|NCT04385368|Experimental|Durvalumab + SoC chemotherapy|Intravenous administration of Experimental and Standard of Care Therapy
88932207|NCT04385368|Placebo Comparator|Placebo + SoC chemotherapy|Intravenous administration of Placebo and Standard of Care Therapy
88932208|NCT04380636|Experimental|pembrolizumab+chemoradiation→pembrolizumab+olaparib placebo|Participants will receive pembrolizumab 200 mg intravenously (IV) every 3 weeks (Q3W) in combination with 3 cycles of the investigator's choice of platinum doublet chemotherapy and concurrent standard thoracic radiotherapy (60 Gray (Gy) over 6 weeks) followed by pembrolizumab plus olaparib placebo twice a day (BID) for approximately 1 year.
88932209|NCT04380636|Experimental|pembrolizumab+chemoradiation→pembrolizumab+olaparib|Participants will receive pembrolizumab 200 mg IV Q3W in combination with 3 cycles of the investigator's choice of platinum doublet chemotherapy and concurrent standard thoracic radiotherapy (60 Gy over 6 weeks) followed by pembrolizumab plus olaparib 300 mg BID for approximately 1 year.
88932210|NCT04380636|Active Comparator|chemoradiation→durvalumab|Participants will receive 3 cycles of the investigator's choice of platinum doublet chemotherapy with concurrent standard thoracic radiotherapy (60 Gy over 6 weeks) followed by durvalumab 10 mg/kg every 2 weeks (Q2W) for approximately 1 year.
88932211|NCT04362826|Experimental|Novel probiotic|Investigational novel probiotic plus normal standard of care for breast cancer.
88932212|NCT04362826|Placebo Comparator|Placebo|Placebo plus normal standard of care for breast cancer.
89447012|NCT05777473|No Intervention|Control|This arm will serve as the control condition. Individuals in these villages will receive neither intervention (including any other FP-relevant SBC program)
89447013|NCT05774054|Active Comparator|A|patients received (30ml /kg) ringer's lactate solution after first presentation then norepinephrine was added when persistent mean arterial pressure (MAP)> 65 mmHg despite adequate fluid resuscitation
89447014|NCT05774054|Active Comparator|B|patients received ( 30ml /kg) ringer's lactate solution after first presentation combined with norepinephrine infusion (0.05 mic/kg/min)
88932213|NCT04341948|Active Comparator|Group 1 (Treatment)|Participants in Group 1 will have Leads placed by the nerves of the mid to upper thigh. These participants will then use the SPRINT Peripheral Nerve Stimulation (PNS) System and will receive electrical stimulation for 8 weeks.
88932214|NCT04341948|Sham Comparator|Group 2 (Control)|Participants in Group 2 will have Leads placed by the nerves of the mid to upper thigh. These participants will then use the SPRINT Peripheral Nerve Stimulation (PNS) System and receive 8 weeks of sham stimulation. Participants will then have the option to crossover and receive stimulation therapy.
88932215|NCT04325607|Experimental|Negative Pressure Wound Therapy with instillation|Patients in the treatment group will be initiated on VeraFlo instillation (NPWTi) therapy upon excision of HS
88932216|NCT04325607|Active Comparator|Negative Pressure Wound Therapy|Patient in the control group will be initiated on VAC therapy (NPWT) upon excision of HS
88932217|NCT04323280|Active Comparator|Conventional Therapy|Ibuprofen 600mg every 8 hours for one week followed by tapering of dose by 200mg every week (3 weeks of therapy), in addition to Colchicine 0.5mg daily (<70kg) or 0.5mg twice daily (>70kg) for 3 months
88932218|NCT04323280|Experimental|Dexamethasone therapy|Dexamethasone therapy 20 mg once daily per os for 4 day in addition to colchicine therapy for 3 months 0.5mg daily (<70kg) or 0.5mg twice daily (>70kg)
88932222|NCT04307134||R/R ALL|Patients diagnosed as relapsed or refractory B-cell precursor lymphoblastic leukemia (ALL)
88932223|NCT04289870|Experimental|Innoventric Trillium™ Stent Graft Single Arm|Single-arm, open label, multi-center study
88932224|NCT04281498|Experimental|Patients with MPN|Ruxolitinib and Enasidenib combination therapy
88932225|NCT04276870|Experimental|Subjects with hypodiploid B-ALL|
88932226|NCT04276870|Experimental|Subjects with t(17;19) B-ALL|
88932227|NCT04276870|Experimental|Infant subjects with very high risk KMT2A B-ALL|
88932228|NCT04276870|Experimental|Subjects with central nervous system (CNS) relapse|who did not receive cranial radiation (XRT) or bone marrow transplantation (BMT)
88932229|NCT04263025|Experimental|CLARIX CORD 1K|They will receive adjunctive CLARIX® CORD 1K (Amniox Medical, Inc., Miami, FL) during Robot-Assisted Radical Prostatectomy (RARP).
88932230|NCT04263025|Active Comparator|Controls|They will undergo RARP without adjunctive CLARIX® CORD 1K.
88932231|NCT04242667|Experimental|Actionable gene result for cancer risk|
89200305|NCT00764088||Anaysis of Full Thickness wounds|To demonstrate the effectiveness or ineffectiveness of novel treating agents or agents used for compassionate rescue, subjects and their wounds will be analyzed retrospectively and their non-identifiable information will be compiled in the form of case studies. Subjects who demonstrated characteristics of interest (e.g. healing) as determined by the PI will be chosen for case studies.
89200306|NCT00670800|No Intervention|Normal Controls|Control subjects will have 5 visits (screening, oral glucose tolerance test (OGTT), neuropsychological testing, functional magnetic resonance imaging (fMRI) and positron emission tomography (PET) as they will receive no treatment and will not have repeat studies. The baseline values obtained from the control subjects will be compared to the baseline values acquired from the PCOS affected subjects.
88932232|NCT04242667|Experimental|Actionable gene result for cardiovascular disease risk|
88932233|NCT04221438|Experimental|Treatment (18F-FLT, PET/CT, encorafenib, binimetinib, surgery)|"NEOADJUVANT TREATMENT: Patients receive 18F-FLT IV and undergo a PET/CT scan approximately 60 minutes later. Within 2 weeks, patients receive encorafenib PO QD and binimetinib PO BID on days 1-28. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive 18F-FLT IV and undergo a second PET/CT scan approximately 60 minutes later.~SURGICAL RESECTION: Within 2 weeks of completing therapy with encorafenib and binimetinib, patients undergo surgery.~ADJUVANT TREATMENT: Within 2-7 days after surgery, patients resume treatment with encorafenib PO QD and binimetinib PO BID on days 1-28. Treatment repeats every 28 days for up to 11 cycles in the absence of disease progression or unacceptable toxicity."
89200307|NCT00670800|Experimental|PCOS Affected Women-Metformin Treatment|Subjects with Polycystic Ovary Syndrome (PCOS) will be scheduled for 9 visits total: following the screening visit they will go through OGTT, neuro-psychological testing, fMRI and PET scan before and after 4 months of metformin use: 500mg tablets once daily with breakfast for 1 week, then increased to one tablet twice daily with breakfast & lunch for 1 week, then increased to one tablet three times daily with breakfast, lunch & dinner.
89200308|NCT00764166|Experimental|1|
88932236|NCT04196218|Other|Driving assessment|All subjects will undergo a driving assessment(s) following shoulder surgery.
88932237|NCT04181749|No Intervention|No treatment|Patients will not be prescribed aspirin and statin
89447015|NCT05773651||Rare tumor disease|Prospective epidemiological and clinical data collection of subjects with diagnosis of a rare solid tumor.
89447016|NCT05766761|Experimental|Intervention condition, the usual prenatal care plus the alcohol intervention|The alcohol intervention consists of (1) a self-paced computer-delivered component to enhance knowledge, norms, and motivation for alcohol reduction and (2) a nurse-delivered component to reinforce the computer-delivered content and address women's questions.
89447017|NCT05766761|No Intervention|Comparison condition, usual prenatal care only|Prenatal usual care involves clinicians assessing alcohol use and counseling women on alcohol-related risks.
89447018|NCT05751148|Active Comparator|Group 1: Hyperbaric Bupivacaine|
89447019|NCT05751148|Active Comparator|Group 2: Hyperbaric Prilocaine|
89447020|NCT05741697||Patient need NIV ventillation|Patients will be eligible for enrolment if they are diagnosed with bronchiectasis and admitted to the respiratory intensive care unit (RICU); requiring ventilator support without invasive mechanical ventilation and will need NIV
89447021|NCT05741697||patient need HFNC|Patients will be eligible for enrolment if they are diagnosed with bronchiectasis and admitted to the respiratory intensive care unit (RICU); requiring ventilator support without invasive mechanical ventilation and will need HFNC
89014136|NCT05701111|Experimental|Mindfulness Curriculum|Participants will undergo a mindfulness curriculum in the classroom for 6-8 weeks and complete surveys before the start and after completion.
89014137|NCT05701111|Experimental|Teachers|Participants will be trained in the mindfulness curriculum and implement it in the classroom for 6-8 weeks. They will complete surveys before training and after implementation.
89014138|NCT05701111|Experimental|Counselors|Participants will be trained in Cue-Centered Therapy and implement the treatment with student clients for 15-18 weeks. They will complete surveys before training and after 3 months after the start of implementation.
89200309|NCT00764166|Active Comparator|2|
88932238|NCT04181749|Active Comparator|Aspirin and Atorvastatin|Patients prescribed aspirin and atorvastatin
88932239|NCT04178551|Other|Implementation Facilitation|The foundation of CONDUIT's implementation activities are the structured interactions between external facilitation teams and internal facilitation teams. A core set of internal facilitation activities will be used across all facilitation teams, and external facilitation teams will use additional activities based on the needs of their sites or clinical settings.
88932240|NCT04178551|No Intervention|Comparison Cohort|All other sites in VA not receiving CONDUIT implementation support or participating in other dedicated MOUD implementation activities during the same time period
88932241|NCT04165317|Experimental|PF-06801591 + BCG induction and maintenance|PF-06801591 in combination with Bacillus Calmette Guerin(induction+maintenance).
88932242|NCT04165317|Experimental|PF-06801591 + BCG induction only|PF-06801591 in combination with Bacillus Calmette Guerin (induction only).
88932243|NCT04165317|Active Comparator|BCG induction and maintenance|Bacillus Calmette Guerin (induction and maintenance).
88932244|NCT04165317|Experimental|BCG Unresponsive CIS|PF-06801591
88932245|NCT04165317|Experimental|BCG Unresponsive NMIBC|PF-06801591
88932246|NCT04163289|Experimental|Fecal Microbiota Transplantation|Fecal microbiota transplantation combined with approved standard of care treatment with nivolumab and ipilimumab.
88932247|NCT04161755|Experimental|Pancreatic Cancer|Radiologically resectable primary pancreatic tumors
88932248|NCT04151563|Experimental|Arm A: cabozantinib + nivolumab + ipilimumab|
88932249|NCT04151563|Experimental|Arm B: cabozantinib + nivolumab|
88932250|NCT04151563|Experimental|Arm C: nivolumab + ramucirumab + docetaxel|
88932251|NCT04151563|Experimental|Arm D: lucitanib + nivolumab|
88932252|NCT04151563|Experimental|Arm E: nivolumab + docetaxel|
88932253|NCT04151563|Active Comparator|Arm F: docetaxel|
88932254|NCT04151368|Experimental|Robotic Nipple Sparing Mastectomy Arm|Patient cohort undergoing nipple sparing mastectomy with use of robotic dissection.
88932255|NCT04142242|Experimental|Group 1: MenACYW Conjugate Vaccine (MET 49 - Menomune-primed Participants)|Participants who received a single dose of Menomune vaccine in a previous study MET49, provided a blood sample for assessment of antibody persistence (at enrollment [Day 0]) followed by a single intramuscular (IM) dose of MenACYW Conjugate vaccine, at Day 0, during Stage I in the present study (MEQ00066).
88932256|NCT04142242|Experimental|Group 2: MenACYW Conjugate Vaccine (MET49 - MenACYW Conjugate Vaccine-primed Participants)|Participants who received a single dose of MenACYW Conjugate vaccine in a previous study MET49, provided a blood sample for assessment of antibody persistence (at enrollment [Day 0]) followed by a single IM dose of MenACYW Conjugate vaccine at Day 0, during Stage I in the present study (MEQ00066).
88932257|NCT04142242|Experimental|Group 3: MenACYW Conjugate Vaccine (MET49: Menomune-primed Participants)|Participants who received a single dose of Menomune vaccine in a previous study MET49, provided a blood sample for assessment of antibody persistence at enrollment (Day 0) during Stage I in the present study (MEQ00066), followed by receiving a single IM dose of MenACYW Conjugate vaccine at Stage II in the present study (MEQ00066).
88932258|NCT04142242|Experimental|Group 4: MenACYW Conjugate Vaccine (MET49: MenACYW-primed Participants)|Participants who received a single dose of MenACYW Conjugate vaccine in a previous study MET49, provided a blood sample for assessment of antibody persistence at enrollment (Day 0) during Stage I in the present study (MEQ00066), followed by receiving a single IM dose of MenACYW Conjugate vaccine at Stage II in the present study (MEQ00066).
88932259|NCT04142242|Other|Group 5: Menomune-primed Participants (MET44)|Participants who received a single dose of Menomune vaccine in a previous study MET44, provided a blood sample for assessment of antibody persistence at enrollment (Day 0) during Stage I in the present study (MEQ00066). These participants did not receive any vaccination in the present study (MEQ00066).
88932260|NCT04142242|Other|Group 6: MenACYW Conjugate Vaccine-primed Participants (MET44)|Participants who received a single dose of MenACYW Conjugate vaccine in a previous study MET44, provided a blood sample for assessment of antibody persistence at enrollment (Day 0) during Stage I in the present study (MEQ00066). These participants did not receive any vaccination in the present study (MEQ00066).
88932261|NCT04126018||Mitral Valve Regurgitation|Patients with moderate or severe (3+ or 4+) mitral valve regurgitation on the basis of prior known clinical history or clinical exam.
88932262|NCT04126018||Aortic Valve Regurgitation|Patients with moderate or severe (3+ or 4+) aortic valve regurgitation on the basis of prior known clinical history or clinical exam.
89200310|NCT02557542|Experimental|One Stop Vein Clinic|Patients randomised to this group will be invited to the One Stop Vein Clinic, offering same day diagnosis and treatment
89200311|NCT02557542|Active Comparator|Normal Care Pathway|Patients randomised to this group will be invited to the Normal Care Pathway
89200312|NCT00767754|Other|paroxetine cr|single arm
89200313|NCT00607893|Sham Comparator|Sham CPAP|Participants will receive sham continuous positive airway pressure (CPAP) for a 2 month period. Sham CPAP involves wearing a device that appears similar to a standard CPAP device, but administers a negligible pressure. Adherence will be tracked while the participant wears the device.
89200314|NCT00607893|Active Comparator|Treatment CPAP|Participants will receive continuous positive airway pressure for a 2 month period. The optimal treatment pressure will be identified during a titration study prior to trial enrollment. Adherence will be tracked while the participant wears the device.
89200315|NCT00571038|Experimental|Peer Led|Post provided with blood pressure cuffs, pedometers and scale. Two post members trained as peer leaders who encourage post members to take positive steps to improve BP. Peer leader training involves 20 hours of training over 12 months, telephone/email access to clinical experts and educational materials to share with post members.
89200316|NCT00571038|Active Comparator|Seminar|Post provided with blood pressure cuffs, pedometers and scale. Post members, including study participants invited to didactic sessions on cardiovascular health.
89200317|NCT00764244|Active Comparator|1|Vitrectomy
89200318|NCT00764244|Active Comparator|2|Intravitreal triamcinolone injections
89200319|NCT00764244|Active Comparator|3|Laser photocoagulation
89200320|NCT00770640|Experimental|Pioglitazone 30mg QD|(and variable insulin therapy)
89200321|NCT00770640|Placebo Comparator|Placebo QD|(and variable insulin therapy)
89200322|NCT00764400|Experimental|Errorless Naming Treatment|
89200323|NCT00764400|Experimental|Verbal+Gestural Facilitation|
89200324|NCT00770718|Experimental|Recombinant Activated Factor VII|The first five patients who meet the selection criteria will be administered an intravenous dose of rFVIIa 1mg upon arrival. INR will be drawn at 20 minutes post-rFVIIa administration. If normalized (≤1.3), then repeat INR with be drawn every 2 hours thereafter for 6 hours total, and again at 24 hours after initial administration. If at any time, the INR is >1.3, then rFVIIa 1mg will be readministered and the INR will again be checked 20 minutes after administration and every 2 hours for 6 hours total and again at 24 hours post-administration. This may be repeated until a total dose of 80mcg/kg has been given. If a maximum total of 80mcg/kg has been administered without successful correction of INR, then FFP infusions will be utilized to complete correction.
89200325|NCT00770718|Experimental|Prothrombin Complex Concentrate (PCC)|5 patients will receive PCC based on ideal body weight. Each patient will receive 30 i.u./kg ideal body weight as is rounded to the nearest dispensed vial size. Vials are dispensed as 5mL (500 i.u.), 10mL (1000 i.u.), or 10mL (1500i.u.). INR will be drawn at 20 minutes post-administration and, if normalized (≤1.3), 2 hours post-administration and every 2 hours for 6 hours total. The INR will also be checked 24 hours post-administration. If at any time, the INR is >1.3, then PCC will be readministered at the same dose and the INR will again be checked 20 minutes after administration and every 2 hours for 6 hours total and again at 24 hours post-administration. A maximum total of 60 iu/kg can be administered before FFP will be used to complete the correction.
89200326|NCT00770718|Active Comparator|Fresh Frozen Plasma (FFP)|The last five patients will receive transfusions of FFP to normalize INR. If the initial INR is between 2-4, then 2 units of FFP (Round 1) will be administered emergently. If the initial INR is >4, then 4 units of FFP will be administered (Round 1). The INR will be checked after each round of FFP infusion completed. Once INR ≤1.3, then the INR will be again checked every 2 hours after normalization for 6 hours total and then 24 hours post-initial infusion. If the INR should ever return to >1.3, then repeat infusions of FFP will begin as outlined above and the INR will be checked serially as defined above.
89200327|NCT00770796|Placebo Comparator|Placebo|placebo
89200328|NCT00770796|Active Comparator|Atorvastatin|80 mg die of Atorvastatin given at least two days before elective angiography or angioplasty and continued for two days after.
89200329|NCT00767988|Active Comparator|A|Urex-cap-5 capsules (2x10^9 cfu each of RC-14 and GR-1) 1:1 ratio
89200330|NCT00767988|Placebo Comparator|B|Capsule 1:1
89200331|NCT00545740|Experimental|SPD476 (1.2 g)|
89200332|NCT00545740|Experimental|SPD476 (2.4 g)|
89200333|NCT00545740|Experimental|SPD476 (4.8 g)|
89200334|NCT00545740|Placebo Comparator|Placebo|
89200335|NCT05208190|Experimental|Clozapine|treatment with clozapine naturalistically administered (as per clinical guideline).
89200336|NCT05208190|Active Comparator|Treatment as usual|open label naturalistic treatment as usual with any antipsychotic other than clozapine
89200337|NCT00609609|Experimental|Corticosteroids|Methylprednisolone at a dose of 2 mg/kg/day with a taper to no less than 1 mg/kg/day by day 14, and no less than 0.4 mg/kg/day by day 28.
89200338|NCT00609609|Experimental|ECP + Corticosteroids|Extracorporeal Photopheresis (ECP) 8-9 treatments weekly for days 1-14, 6 treatments weekly from days 15-28, and after that 2 treatments weekly until day 60 + Methylprednisolone at a dose of 2 mg/kg/day with a taper to no less than 1 mg/kg/day by day 14, and no less than 0.4 mg/kg/day by day 28.
89200339|NCT00968422|Experimental|Low dose ABT-384|
89200340|NCT00968422|Experimental|Mid dose ABT-384|
89200341|NCT00968422|Experimental|High dose ABT-384|
89200342|NCT00968422|Placebo Comparator|Placebo|
89200343|NCT00673452|Experimental|Duloxetine|60-120 mg, oral, every day, 12 weeks
89200344|NCT00673452|Placebo Comparator|Placebo|oral, daily, 12 weeks
89200345|NCT00890799|Experimental|occluders|Shanghai pmVSD occluder (LEPU Medical Tech-nology Co, Ltd, Beijing, China) was used in this study.
89200346|NCT00967174|Experimental|Three Treatments Applied to Lower Back|Treatments were applied on the lower back, according to treatment sequence, daily for 21 days.
89200347|NCT00890877|Experimental|1|
89200348|NCT00890877|Experimental|2|
89200349|NCT00890877|Experimental|3|
89200350|NCT00890877|Experimental|4|
89200351|NCT00967252||atorvastatin 10 mg or equivalent dose|Patients already taking atorvastatin 10 mg or equivalent dose in another statin who is undergoing high risk surgery
88932263|NCT04126018||Aortic Stenosis|Patients with moderate or severe (3+ or 4+) aortic stenosis on the basis of prior known clinical history or clinical exam.
88932264|NCT04126018||Patients referred for CRT Implantation|Patients who meet clinical guideline criteria for CRT implantation with EF < 40%
88932265|NCT04123535|Experimental|Undifferentiated Pleomorphic Sarcoma (UPS)|All enrolled participants will be scheduled to receive pre-operative MRgFUS with the ExAblate 2000/2100 MRgFUS system 1-4 weeks prior to surgical resection of their tumor or approximately 2 weeks after a pre-procedure biopsy of the metastatic tumor target depending on diagnosis at enrollment. For patients enrolled with metastatic disease, pre and post-MRgFUS biopsy samples will be obtained.
88932266|NCT04123366|Experimental|Olaparib+Pembrolizumab|Participants receive olaparib 300 mg via oral tablet 2 times each day PLUS pembrolizumab 200 mg via intravenous infusion on Day 1 of each 21-day cycle. Participants may receive olaparib+pembrolizumab for up to approximately 2 years.
88932267|NCT04109950|Experimental|SEP-363856|SEP-363856 25mg, 50mg, 75mg, 100mg flexibly dosed once daily
88932268|NCT04097158||Upper Motor Neuron predominant ALS|
88932269|NCT04097158||Lower Motor Neuron predominant ALS|
88932270|NCT04097158||Bulbar predominant ALS|
88932271|NCT04097158||Generalized ALS|
89200352|NCT00967252||atorvastatin 20 mg or equivalent dose|Patients already taking atorvastatin 20 mg or equivalent dose in another statin who is undergoing high risk surgery
89200353|NCT00967252||atorvastatin 40 mg or equivalent dose|Patients already taking atorvastatin 40 mg or equivalent dose in another statin who is undergoing high risk surgery
89200354|NCT00967252||atorvastatin 80 mg or equivalent dose|Patients already taking atorvastatin 80 mg or equivalent dose in another statin who is undergoing high risk surgery
88932272|NCT04092634|Experimental|Dual mobility|Patients in this group will receive a dual mobility hip implant
88932273|NCT04092634|Active Comparator|Single bearing, traditional hip implant|Patients in this group will receive a traditional, single-bearing hip implant.
89200355|NCT00967252||non-statin group|Patients who are not taking or cannot take a statin drug who is undergoing high risk surgery
89200356|NCT00890955|Experimental|1|"Amrubicin + Cyclophosphamide 3+3 design with the following dose levels:~Dose Level -1: Amrubicin 20mg/m2, Cyclophosphamide 500mg/m2~Dose Level 1: Amrubicin 25mg/m2, Cyclophosphamide 500mg/m2~Dose Level 2: Amrubicin 30mg/m2, Cyclophosphamide 500mg/m2~Dose Level 3: Amrubicin 35mg/m2, Cyclophosphamide 500mg/m2~Dose Level 4: Amrubicin 40mg/m2, Cyclophosphamide 500mg/m2"
89200357|NCT00974896|Experimental|AMG 479 + Sorafenib cohorts|The aim is to determine the safety, tolerability and PK of AMG 479 with sorafenib. AMG 479 will be given bi-weekly; sorafenib will be given daily.
89200358|NCT00974896|Experimental|AMG 479 + Erlotinib cohorts|The aim is to determine the safety, tolerability and PK of AMG 479 with erlotinib. AMG 479 will be given bi-weekly; erlotinib will be given daily.
89014139|NCT05701111|Experimental|CCT|Participants that report PTSD symptomatology during the mindfulness curriculum surveys will be eligible to participate in Cue-Centered Therapy treatment for 15-18 weeks. They will complete surveys before and after treatment.
89200359|NCT04008550|No Intervention|No Pulmonary Arterial Hypertension before TAVI|No intervention has been done in this group of patients.
89200360|NCT04008550|Other|Pulmonary Arterial Hypertension before TAVI|In this group, a right heart catheterization is done 3 months after TAVI in order to evaluate PAH (persistence or regression).
89200361|NCT00975052|Active Comparator|A|Sitagliptin alone
89200362|NCT00975052|Active Comparator|B|Metformin alone
89200363|NCT00975052|Experimental|C|Sitagliptin and metformin concomitantly
89200364|NCT00975052|Placebo Comparator|D|Placebo
89200365|NCT00891033|Experimental|Cohort 1|1 mg/m2 IV Bortezomib on days 1, 4, 8, and 11 of Cycles 1 and 2 and 5 mg/m2 IV Panobinostat on days 1 and 8 of Cycle 2.
89200366|NCT00891033|Experimental|Cohort 2|1 mg/m2 IV Bortezomib on days 1, 4, 8, and 11 of Cycles 1 and 2 and 10 mg/m2 IV Panobinostat on days 1 and 8 of Cycle 2.
88932274|NCT04086589||Young|Observational study without intervention
88932275|NCT04086589||Elderly|Observational study without intervention
88932276|NCT04061018||High Cholesterol Efflux|Dallas Heart Study participants who are above the sex and ethnicity specific 90th % of cholesterol efflux
88932277|NCT04061018||Low Cholesterol Efflux|Dallas Heart Study participants who are below the sex and ethnicity specific 10th % of cholesterol efflux
88932278|NCT04049669|Experimental|Core Regimen, sub-cohort A|For patients not eligible for re-irradiation; Start with Core Regimen chemo-immunotherapy (indoximod with oral temozolomide).
88932279|NCT04049669|Experimental|Core Regimen, sub-cohort B|For patients who are eligible for partial re-irradiation; Start with indoximod plus up-front re-irradiation, using a palliative low-dose or partial-field radiation plan (low-dose radiation or not all disease sites included); Followed by Core Regimen chemo-immunotherapy (indoximod with oral temozolomide).
88932280|NCT04049669|Experimental|Core Regimen, sub-cohort C|For patients who are eligible for full-dose radiation; (All newly diagnosed DIPG patients and some relapsed ependymoma patients); Start with indoximod plus up-front radiation, using a palliative full-dose radiation plan to all known sites of disease (>50 Gy to brain, >45 Gy to spine); Followed by Core Regimen chemo-immunotherapy (indoximod with oral temozolomide).
89014140|NCT05701111|Other|iSWAB-DNA|Students that give prior consent to participating in DNA buccal swabs and the mindfulness curriculum are randomly selected to give buccal swabs prior to and after the mindfulness curriculum intervention. A subset of those students that qualify for CCT will give another buccal swab after CCT completion. DNA will be sent to Dr. Urban's lab for analysis of genetic resilience markers.
89200367|NCT00891033|Experimental|Cohort 3|1 mg/m2 IV Bortezomib on days 1, 4, 8, and 11 of Cycles 1 and 2 and 15 mg/m2 IV Panobinostat on days 1 and 8 of Cycle 2.
89200368|NCT00891033|Experimental|Cohort 4|1 mg/m2 IV Bortezomib on days 1, 4, 8, and 11 of Cycles 1 and 2 and 20 mg/m2 IV Panobinostat on days 1 and 8 of Cycle 2.
89200369|NCT00770952|Experimental|Pioglitazone 30 mg to 45 mg QD + Glimepiride 2 mg to 4 mg QD|
89447022|NCT05717985|Active Comparator|de-epithelized gingival graft|A type of mucogingival surgery where a gingival graft is harvested from the palate, prepared chairside and placed on a recipient site to augment it. Dressing material and sutures is placed at the donor site.
89447023|NCT05717985|Experimental|modified combined approach|A type of mucogingival surgery where a gingival graft is harvested from the palate, prepared chairside and placed on a recipient site to augment it. A part of the prepared tissues namely the epithelial layer is replaced at the donor site and sutured.
89447024|NCT05711199|Experimental|normal weight|"Treatment phase~administration of glyceroltrinitrate (Nitroderm TTS) for 15 days.~measurement of energy expenditure before and after cold exposure~performing FDG-PET/CT and tissue biopsy (brown adipose tissue and muscle)~measurement of glucose tolerance, triglyceride levels and energy expenditure before and after a mixed meal test.~Control phase:~measurement of energy expenditure before and after cold exposure~performing FDG-PET/CT and tissue biopsy (brown adipose tissue and muscle)~measurement of glucose tolerance, triglyceride levels and energy expenditure before and after a mixed meal test."
89447025|NCT05711199|Experimental|overweight|"Treatment phase~administration of glyceroltrinitrate (Nitroderm TTS) for 15 days.~measurement of energy expenditure before and after cold exposure~performing FDG-PET/CT and tissue biopsy (brown adipose tissue and muscle)~measurement of glucose tolerance, triglyceride levels and energy expenditure before and after a mixed meal test.~Control phase:~measurement of energy expenditure before and after cold exposure~performing FDG-PET/CT and tissue biopsy (brown adipose tissue and muscle)~measurement of glucose tolerance, triglyceride levels and energy expenditure before and after a mixed meal test."
89447026|NCT05703074|Other|MBRT and NR|Psychological therapy and dietary supplement
89447027|NCT05703074|Other|MBRT and placebo|Psychological therapy and placebo dietary supplement
89447028|NCT05703074|Other|Care as usual and NR|No psychological therapy (information only) and dietary supplement
89447029|NCT05703074|Other|Care as usual and placebo|No psychological therapy (information only) and placebo dietary supplement
88932281|NCT04049669|Experimental|Salvage Regimen 1|For patients who wish to continue access to indoximod after progression on the Core Regimen; Cross-over to indoximod with oral metronomic cyclophosphamide and etoposide).
88932282|NCT04049669|Experimental|Salvage Regimen 2|For patients who wish to continue access to indoximod after progression on the Core Regimen; Cross-over to indoximod with oral lomustine and temozolomide).
88932283|NCT04041401||Children and their Caregivers|Children following discharge from PICU and their caregivers receiving a storybook intervention.
88932284|NCT04029454|Experimental|Intervention period|Intervention : birth dose vaccination against hepatitis B strategy Birth dose of vaccine against hepatitis B + routine Expended Programme on Imunisation (EPI) vaccination schedule starting at 8 weeks of life
88932285|NCT04029454|No Intervention|Control period|Routine Expended Programme on Imunisation (EPI) vaccination schedule starting at 8 weeks of life
88932286|NCT04028674|Experimental|Early Activation of Laryngeal Pacing device|Early Activation of the laryngeal pacing device (n=4) at one-month post-implantation.
88932287|NCT04028674|Sham Comparator|Delayed Activation of Laryngeal Pacing device|Delayed activation of the laryngeal pacing device (n=4) at two months post-implantation.
88932288|NCT04023331|Experimental|67Cu-SARTATE|"64Cu-SARTATE - patients will receive a bolus injection of 64Cu-SARTATE during screening, and following each 67Cu-SARTATE Therapy Cycle at a rate of 2.0 MBq/kg.~67Cu-SARTATE - In the dose escalation phase, patients will receive a single administration of 67Cu-SARTATE as an IV infusion (dose will be determined based on cohort allocation). In the expansion phase, patients will receive at least 2 administrations of 67Cu-SARTATE a the MTD level as a slow IV infusion.~Participants in either phase of the study that demonstrate therapeutic benefit following treatment with 67Cu-SARTATE at any dose may be offered additional Therapy Cycles (each participant may receive a maximum of 4 Therapy Cycles in total)."
88932289|NCT04023305|Experimental|Nonfocal ARDS|ARDS patient with nonfocal lung imaging phenotype
88932290|NCT04023305|Experimental|Focal ARDS|ARDS patient with focal lung imaging phenotype
88932291|NCT04014712|Experimental|acute BH4/Tetrahydrobiopterin treatment|Oral supplement, Pill, 10 mg/kg of body weight
88932292|NCT04014712|Placebo Comparator|Placebo|Oral supplement, Pill, Placebo pill with inert excipient
88932293|NCT03967158||Consecutive percutaneous coronary intervention|
88932294|NCT03915184|Experimental|CAR-BCMA T Cells|Phase 1b will include a dose escalation followed by an expansion cohort to determine the recommended dose for the expansion part. After recommended Phase 2 is determined, patients in Phase 2 will be treated.
89014141|NCT05696626|Experimental|Treatment|Pre- and Postmenopausal Women and Men with locally advanced or metastatic ER+/HER2- breast cancer who have disease progression on an AI in combination with either palbociclib or ribociclib as their first hormonal treatment for metastatic disease and who have an ESR1 mutation.
89014142|NCT05696626|Active Comparator|Reference Therapy|Pre- and Postmenopausal Women and Men with locally advanced or metastatic ER+/HER2- breast cancer who have disease progression on an AI in combination with either palbociclib or ribociclib as their first hormonal treatment for metastatic disease and who have an ESR1 mutation.
89014143|NCT05686408|Experimental|TNX-601 ER, 39.4 mg|1x TNX-601 ER, 39.4 mg, pill taken orally once daily for 6 weeks.
89014144|NCT05686408|Placebo Comparator|Placebo|Placebo pill taken orally once daily for 6 weeks.
89014145|NCT05676606|Experimental|monitoring group|a group of chemotherapy-naive patients with first time diagnosed various kinds of tumors, planned for the first cycle polychemotherapy treatment.
89014146|NCT05673408||Subject Group 1|Neonates, Infant, Children <3 years of age
89014147|NCT05673408||Subject Group 2|Children 3-12 years of age
89014148|NCT05673408||Subject Group 3|Adolescent/Adult >12 years of age
89447030|NCT05701865|Experimental|Alcohol Intoxication|Participant will receive alcohol, the dose of which will be administered to result in a breath alcohol concentration of .08%.
89447031|NCT05701865|Active Comparator|No-Alcohol Control|Participant will receive a no alcohol control beverage, therefore their breath alcohol concentration will be .00%.
89447032|NCT05684809|Experimental|Group A|in addition to Conventional treatment, PIR and cervical mobilization were given
89447033|NCT05684809|Active Comparator|Group B|in addition to Conventional treatment, PIR were given
89014149|NCT05671900|Experimental|All patients|All patients receive same intervention throughout the trial.
89014150|NCT05664750|Experimental|TNM002|If randomized to TNM002, participant will receive a single IM gluteal injection of TNM002
89014151|NCT05664750|Active Comparator|Human tetanus immunoglobulin (HTIG)|If randomized to HTIG, participant will receive a single IM gluteal injection of HTIG
89014152|NCT05662332|Experimental|Insulin Efsitora Alfa|Participants will receive insulin efsitora alfa subcutaneously (SC) once weekly.
89014153|NCT05662332|Active Comparator|Insulin Glargine|Participants will receive insulin glargine SC once daily.
89014154|NCT05660525|Experimental|QuitAid, 4 weeks, Patch + Lozenge|Smoking participants receive QuitAid, a medication therapy management delivered by their pharmacist and 4 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch and the nicotine lozenge.
89014155|NCT05660525|Experimental|QuitAid, 8 weeks, Patch + Lozenge|Smoking participants receive QuitAid, a medication therapy management delivered by their pharmacist and 8 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch and the nicotine lozenge.
89014156|NCT05660525|Experimental|QuitAid, 4 weeks, Patch + Lozenge, QuitLine|Smoking participants receive QuitAid, a medication therapy management delivered by their pharmacist, 4 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch and the nicotine lozenge, and a Quitline intervention
89014157|NCT05660525|Experimental|QuitAid, 8 weeks, Patch + Lozenge, QuitLine|Smoking participants receive QuitAid, a medication therapy management delivered by their pharmacist, 8 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch and the nicotine lozenge, and a Quitline intervention
89447034|NCT05680051|Experimental|Experimental group|Drug-coated Balloon (Lepu Medical Technology (Beijing) Co.,Ltd.)
89014158|NCT05660525|Experimental|QuitAid, 4 weeks, Patch|Smoking participants receive QuitAid, a medication therapy management delivered by their pharmacist and 4 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch.
89014159|NCT05660525|Experimental|QuitAid, 8 weeks, Patch|Smoking participants receive QuitAid, a medication therapy management delivered by their pharmacist and 8 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch.
89014160|NCT05660525|Experimental|QuitAid, 8 weeks, Patch, QuitLine|Smoking participants receive QuitAid, a medication therapy management delivered by their pharmacist, 8 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch, and a Quitline intervention
89014161|NCT05660525|Experimental|QuitAid, 4 weeks, Patch, QuitLine|Smoking participants receive QuitAid, a medication therapy management delivered by their pharmacist, 4 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch, and a Quitline intervention
89014162|NCT05660525|Experimental|QuitAid, 4 weeks, Patch, SmokeFree Txt|Smoking participants receive QuitAid, a medication therapy management delivered by their pharmacist, 4 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch, and a texting intervention to help quit smoking.
89200370|NCT00770952|Active Comparator|Glimepiride 4 mg to 6 mg QD|
89447035|NCT05680051|Active Comparator|Control group|Drug Eluting Stent(Microport Medical)
89447036|NCT05676255|Experimental|Cognitively-Based Compassion Training for Survivors (CBCT-S)|"CBCT-S is a secular adaptation of techniques derived from traditional Tibetan Buddhist methods for cultivating compassion known as lo-jong. CBCT-S will be administered to breast cancer survivors and will not including supportive partners.~Module 1 (Week 1): Overview and Connecting to A Moment of Nurturance~Module 2 (Week 2) Developing Stable and Clear Attention~Module 3 (Week 3): Enhancing Self Awareness~Module 4 (Week 4): Cultivating Self compassion Part 1: Accepting our Suffering~Module 5 (Week 5): Self Compassion Part 2: Finding Meaning in Suffering.~Module 6(Week 6): Expanding our Circle of Concern~Module 7 (Week 7): Deepening Gratitude and Tenderness~Module 8 (Week 8): Harnessing the Power of Compassion"
89447037|NCT05676255|Experimental|Cognitively-Based Compassion Training for Dyads (CBCT-D)|"CBCT-D is a secular adaptation of techniques derived from traditional Tibetan Buddhist methods for cultivating compassion known as lo-jong. CBCT-D will be administered to breast cancer survivors and supportive partners together.~Module 1 (Week 1): Overview and Connecting to A Moment of Nurturance~Module 2 (Week 2) Developing Stable and Clear Attention~Module 3 (Week 3): Enhancing Self Awareness~Module 4 (Week 4): Cultivating Self compassion Part 1: Accepting our Suffering~Module 5 (Week 5): Self Compassion Part 2: Finding Meaning in Suffering.~Module 6(Week 6): Expanding our Circle of Concern~Module 7 (Week 7): Deepening Gratitude and Tenderness~Module 8 (Week 8): Harnessing the Power of Compassion"
89014163|NCT05660525|Experimental|QuitAid, 8 weeks, Patch, SmokeFree Txt|Smoking participants receive QuitAid, a medication therapy management delivered by their pharmacist, 8 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch, and a texting intervention to help quit smoking.
89014164|NCT05660525|Experimental|QuitAid, 8 weeks, Patch + Lozenge, SmokeFree Txt|Smoking participants receive QuitAid, a medication therapy management delivered by their pharmacist, 8 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch and lozenge, and a texting intervention to help quit smoking.
89447038|NCT05676255|Active Comparator|Health Education|"HE focuses on topics relevant to health and cancer, but is also intended for individuals who are not cancer survivors themselves.~HE will be administered to both breast cancer survivors and supportive partners together.~Module I (Week 1): Cancer Advocacy.~Module II (Week 2): Health Through the Lifespan.~Module III (Week 3): Nutrition.~Module III (Week 4): Nutrition.~Module IV (Week 5): Physical Activity.~Module V (Week 6): Sleep.~Module VI (Week 7): Stress.~Module VII (Week 8): Mental Health and Social Support."
89447039|NCT05674721|Experimental|Advil PM Liqui-Gels Minis|Participants will be randomly assigned as per cross-over design to receive a single dose of 2 Advil PM Liqui-Gels Minis capsules orally on day 1 of period 1 and will receive single dose of 2 Advil PM Liqui-Gels capsules orally on day 1 of period 2 with at least 7 days washout period. Participants will be instructed to consume the entire amount of ambient temperature water (approximately 240 milliliters [mL]) along their investigational product.
89014165|NCT05660525|Experimental|QuitAid, 4 weeks, Patch + Lozenge, SmokeFree Txt|Smoking participants receive QuitAid, a medication therapy management delivered by their pharmacist, 4 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch and lozenge, and a texting intervention to help quit smoking.
89014166|NCT05660525|Experimental|QuitAid, 8 weeks, Patch + Lozenge, SmokeFree Txt, QuitLine|Smoking participants receive QuitAid, a medication therapy management delivered by their pharmacist, 8 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch and lozenge, a texting intervention to help quit smoking, and a Quitline Intervention.
89014167|NCT05660525|Experimental|QuitAid, 8 weeks, Patch, SmokeFree Txt, QuitLine|Smoking participants receive QuitAid, a medication therapy management delivered by their pharmacist, 8 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch, a texting intervention to help quit smoking, and a Quitline Intervention.
89014168|NCT05660525|Experimental|QuitAid, 4 weeks, Patch + Lozenge, SmokeFree Txt, QuitLine|Smoking participants receive QuitAid, a medication therapy management delivered by their pharmacist, 4 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch and lozenge, a texting intervention to help quit smoking, and a Quitline Intervention.
89014169|NCT05660525|Experimental|QuitAid, 4 weeks, Patch, SmokeFree Txt, QuitLine|Smoking participants receive QuitAid, a medication therapy management delivered by their pharmacist, 4 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch, a texting intervention to help quit smoking, and a Quitline Intervention.
89014170|NCT05660525|Experimental|8 weeks, Patch + Lozenge, SmokeFree Txt, QuitLine|Smoking participants receive 8 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch and lozenge, a texting intervention to help quit smoking, and a Quitline Intervention.
89014171|NCT05660525|Experimental|8 weeks, Patch, SmokeFree Txt, QuitLine|Smoking participants receive 8 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch, a texting intervention to help quit smoking, and a Quitline Intervention.
89014172|NCT05660525|Experimental|4 weeks, Patch + Lozenge, SmokeFree Txt, QuitLine|Smoking participants receive 4 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch and lozenge, a texting intervention to help quit smoking, and a Quitline Intervention.
89014173|NCT05660525|Experimental|4 weeks, Patch, SmokeFree Txt, QuitLine|Smoking participants receive 4 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch, a texting intervention to help quit smoking, and a Quitline Intervention.
89014174|NCT05660525|Experimental|8 weeks, Patch + Lozenge, QuitLine|Smoking participants receive 8 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch and lozenge, and a Quitline Intervention.
89014175|NCT05660525|Experimental|8 weeks, Patch, QuitLine|Smoking participants receive 8 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch, and a Quitline Intervention.
89014176|NCT05660525|Experimental|4 weeks, Patch + Lozenge, QuitLine|Smoking participants receive 4 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch and lozenge, and a Quitline Intervention.
89014177|NCT05660525|Experimental|4 weeks, Patch, QuitLine|Smoking participants receive 4 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch, and a Quitline Intervention.
89014178|NCT05660525|Experimental|8 weeks, Patch + Lozenge, SmokeFree Txt|Smoking participants receive 8 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch and lozenge and a texting intervention to help quit smoking.
89014179|NCT05660525|Experimental|8 weeks, Patch, SmokeFree Txt|Smoking participants receive 8 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch and a texting intervention to help quit smoking.
89014180|NCT05660525|Experimental|4 weeks, Patch + Lozenge, SmokeFree Txt|Smoking participants receive 4 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch and lozenge and a texting intervention to help quit smoking.
89014181|NCT05660525|Experimental|4 weeks, Patch, SmokeFree Txt|Smoking participants receive 4 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch and a texting intervention to help quit smoking.
89014182|NCT05660525|Experimental|8 weeks, Patch + Lozenge|Smoking participants receive 8 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch and lozenge.
89014183|NCT05660525|Experimental|8 weeks, Patch|Smoking participants receive 8 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch.
89014184|NCT05660525|Experimental|4 weeks, Patch + Lozenge|Smoking participants receive 4 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch and lozenge.
89014185|NCT05660525|Experimental|4 weeks, Patch|Smoking participants receive 4 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch.
89014186|NCT05659875|Experimental|ARM-program|
89200371|NCT00891111|Experimental|Direct Payment|Direct Payment: Employees receive a $25 gift card upon completion of a Health Risk Assessment
89014187|NCT05651334|Experimental|Active repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS will be delivered with a MagPro R-30 magnetic stimulator (MagVenture, Farum, Denmark) Cool-B65 A/P (Active/Placebo). Participants will receive 900 pulses of 20 Hz rTMS per session at 110% of the Motor threshold (MT) (45 20-pulse trains of 1 second duration with an inter-train interval of 20 seconds). MT will be established to determine the intensity of stimulation for each participant, as recommended by safety guidelines. MT will be defined as the amount of energy required to induce a visible twitch in contralateral hand in at least 50% of stimulations. The target stimulation site will be the left DLPFC, specifically: located 6 cm anterior of the MT site identified with assistance from the neuro-navigation system to ensure that the target is located in the middle of the frontal gyrus, in the lateral part of Brodmann Area (BA) 9, near the border of BA 46.
89014188|NCT05651334|Sham Comparator|Sham repetitive Transcranial Magnetic Stimulation (rTMS)|Sham rTMS will appear identical to active treatment, with the exception that the sham side of the coil will be used resulting in no stimulation being applied to the participant, while providing a sensation of stimulation.
89014189|NCT05648214|Experimental|Part A: ALN-PNP Dose 1 or PB|8 Participants, Randomized 6:2
89447040|NCT05674721|Active Comparator|Advil PM Liqui-Gels|Participants will be randomly assigned as per cross-over design to receive a single dose of 2 Advil PM Liqui-Gels capsules orally on day 1 of period 1 and will receive single dose of 2 Advil PM Liqui-Gels Minis capsules orally on day 1 of period 2 with at least 7 days washout period. Participants will be instructed to consume the entire amount of ambient temperature water (approximately 240 mL) along their investigational product.
89447041|NCT05668598|Other|Groupe 1 : with neurocognitive disorders|with neurocognitive disorders
89447042|NCT05668598|Other|Groupe 2 : without neurocognitive disorders|without neurocognitive disorders
89447043|NCT05667766|Other|Standard of Care|Standard of Care prescribing for period of 12 months. Participants will receive pharmacogenomic test results according to the current standard of care. The participants will be followed up for a minimum of 12 weeks, with maximal time-period being 12 months depending on time of enrolment.
89447044|NCT05667766|Experimental|Experimental Arm|Extended Pharmacogenomic prescribing for a period of 12 months. Participants will receive pharmacogenomic testing across a range of clinically relevant variants, to guide the dose and drug selection of 27 drugs commonly used in supportive care. The participants will be followed up for a minimum of 12 weeks, with maximal time-period being 12 months depending on time of enrolment.
89447045|NCT05664516|Placebo Comparator|Placebo Arm|Solution without oxytocin
89447046|NCT05664516|Experimental|TNX-1900|Solution with oxytocin
89447047|NCT05664464|Active Comparator|Standard of care|Radiotherapy 30 x 2 Gy with concomitant temozolomide followed by maintenance temozolomide
89447048|NCT05664464|Experimental|Standard of care plus glutamate signaling inhibitors|Radiotherapy 30 x 2 Gy with concomitant temozolomide followed by maintenance temozolomide plus combined daily gabapentin, sulfasalazine and memantine
89447049|NCT05657457|Experimental|TNK group|
89447050|NCT05657457|No Intervention|control group|
89014190|NCT05648214|Experimental|Part A: ALN-PNP Dose 2 or PB|8 Participants, Randomized 6:2
89014191|NCT05648214|Experimental|Part A: ALN-PNP Dose 3 or PB|8 Participants, Randomized 6:2
89014192|NCT05648214|Experimental|Part A: ALN-PNP Dose 4 or PB|8 Participants, Randomized 6:2
89014193|NCT05648214|Experimental|Part A: ALN-PNP Dose 5 or PB|8 Participants, Randomized 6:2
89014194|NCT05648214|Experimental|Part A: Optional ALN-PNP Dose 5 or PB|"8 Participants, Randomized 6:2~This is an optional cohort, if there is a need for additional dose characterization of ALN-PNP."
89447051|NCT05652647|Experimental|One group of healthy adult male participants|
89447052|NCT05641831|Experimental|ARM I (canakinumab)|Patients receive canakinumab SC on study. All patients also undergo ECHO and chest x-ray during screening, collection of blood samples during screening and follow up, and bone marrow biopsy and aspiration throughout the trial.
89447053|NCT05641831|Placebo Comparator|ARM II (placebo)|Patients receive placebo SC on study. All patients also undergo ECHO and chest x-ray during screening, collection of blood samples during screening and follow up, and bone marrow biopsy and aspiration throughout the trial.
89447054|NCT05633797|Experimental|Totally endoscopic cardiac surgery|Patients will be monitored using the FibriCheck application to detect atrial fibrillation until 30 days postoperative.
89447055|NCT05633173|Experimental|Group E|Ultrasound-guided erector spina plan block was performed for patients in group E for postoperative analgesia. The patients were placed in the lateral decubitus position and the linear ultrasound probe was placed longitudinally into the sterilized area 1-2 cm lateral to the spinous process of the L1 vertebra. After visualizing the erector spina muscle and the transverse process, the transverse process was reached by pushing forward the 22 gauge, 50 mm needle in the direction from cranial to caudal. Hydrodissection was performed with 1 ml of saline for confirmation. 0.5 mL kg-1 dose of 0.25% bupivacaine was injected under the erector spina muscle at the level of the 1st lumbar vertebra by aspiration every 2 mL.
89531302|NCT02121405|Active Comparator|Preoperative radiochemotherapy|All of the patients receive conventional concurrent radiochemotherapy with capecitabine for 5 weeks. Then all of the patients receive 2 cycles/6 weeks capecitabine ± Oxaliplatin chemotherapy. Patients receive rectectomy including anterior resection or abdominoperineal resection by open or laparoscopy with total mesorectal excision 8 weeks post radiotherapy. All of the patients receive 5 cycles/15 weeks capecitabine ± Oxaliplatin adjuvant chemotherapy. The use of Oxaliplatin depends on the doctor's decision.
89014195|NCT05648214|Experimental|Part A: JPN ALN-PNP Dose 4 or PB|8 Japanese Participants only, Randomized 6:2
89014196|NCT05648214|Experimental|Part A: JPN ALN-PNP Dose 5 or PB|8 Japanese Participants only, Randomized 6:2
89014197|NCT05648214|Placebo Comparator|Part B: Placebo|Up to 32 Participants Randomized 1:1:1:1 resulting in 8 participants per arm
89014198|NCT05648214|Experimental|Part B: ALN-PNP Dose 3|Up to 32 Participants Randomized 1:1:1:1 resulting in 8 participants per arm
89014199|NCT05648214|Experimental|Part B: ALN-PNP Dose 4|Up to 32 Participants Randomized 1:1:1:1 resulting in 8 participants per arm
89014200|NCT05648214|Experimental|Part B: ALN-PNP Dose 5|Up to 32 Participants Randomized 1:1:1:1 resulting in 8 participants per arm
89014201|NCT05647694|Experimental|V-NAV users|Users who try the V-NAV for navigation tasks.
89014202|NCT05646940||PI-OMM|25 PI fed with OMM and their mothers
89014203|NCT05646940||PI-DHM|25 PI fed with DHM and their mothers
89014204|NCT05646940||TI-OMM|25 TI fed with OMM and their mothers as control group
89014205|NCT05646901||Premenopausal women with obesity|
89447056|NCT05633173|Active Comparator|Group C|The patients in group C underwent ultrasound guided caudal block for postoperative analgesia. By placing the patients in the lateral decubitus position, the linear ultrasound probe was placed longitudinally on the sterilized area on the midline of the sacrum, and access was provided with a 2.5 cm 22 gauge needle on the dorsal skin of the sacral hiatus at a 90° position. The sacrococcygeal ligament was crossed, the needle was oriented approximately 25° and advanced approximately 2 to 3 mm to reach the sacral canal. When it was understood that the sacral hiatus had been entered, 0.5 mL kg-1 0.25% bupivacaine was injected by aspirating every 2 mL after the location was confirmed with the negative aspiration method.
89014206|NCT05646901||Postmenopausal women with obesity|
89014207|NCT05646901||Men with obesity|
89014208|NCT05646901||Premenopausal women without obesity|
89014209|NCT05646901||Postmenopausal women without obesity|
89014210|NCT05646901||Men without obesity|
89014211|NCT05645107|Experimental|XEMBIFY + Standard Medical Treatment (SMT)|"Participants will receive a loading dose of 150 milligrams per kilograms per day (mg/kg/day) (Week 1, Days 1 to 5) subcutaneously (SC) for 5 consecutive daily doses followed by weekly infusions of 150 mg/kg starting Week 2 (Day 8) through Week 53 (end of Treatment Phase).~The SMT will include the antileukemic treatments and the other supportive treatments that the participants will need during their participation."
89014212|NCT05645107|Placebo Comparator|Placebo + SMT|"Participants will receive sterile 0.9 percent Sodium Chloride Injection, United States Pharmacopeia (USP) or equivalent starting at Week 1 (Days 1 to 5) SC for 5 consecutive daily doses followed by weekly infusions starting at Week 2 (Day 8) through Week 53.~The SMT will include the antileukemic treatments and the other supportive treatments that the participants will need during their participation."
89447057|NCT05633095|Experimental|Treatment group|The patient with mild cognitive disorder and early dementia who will be treated with the medical device-Neuclare
89447058|NCT05783089|Experimental|Anti-mesothelin CAR-T cells Injection|Anti-mesothelin CAR-T cells Injection will be infused at a dose ranging from 0.1×10^6/Kg ～ 2.0×10^6/Kg after receiving lymphodepleting chemotherapy.
89447059|NCT05630989||Therapy with no MEKi|Subjects have advanced PDAC with KRAS G12R mutation. Subjects' tumors must have KRAS G12R mutation, as determined by a next generation sequencing (NGS) panel or circulating tumor DNA panel of choice of the treating physician. Subjects will receive therapy with no MEKi.
89447060|NCT05630989||Therapy with MEKi- Hydroxychloroquine (HCQ)|Subjects have advanced PDAC with KRAS G12R mutation. Subjects' tumors must have KRAS G12R mutation, as determined by a next generation sequencing (NGS) panel or circulating tumor DNA panel of choice of the treating physician. Subjects will receive therapy with MEKi and HCQ.
89447061|NCT05630989||Therapy with MEKi- Epidermal growth factor receptor inhibitor (EGFRi)|Subjects have advanced PDAC with KRAS G12R mutation. Subjects' tumors must have KRAS G12R mutation, as determined by a next generation sequencing (NGS) panel or circulating tumor DNA panel of choice of the treating physician. Subjects will receive combination therapy with MEKi and EGFRi.
89447062|NCT05630989||Therapy with MEKi-Other|Subjects have advanced PDAC with KRAS G12R mutation. Subjects' tumors must have KRAS G12R mutation, as determined by a next generation sequencing (NGS) panel or circulating tumor DNA panel of choice of the treating physician. Subjects will receive combination therapy with MEKi and a specified drug combination.
89447063|NCT05624333|Other|VO group|Vegan diet followed by Omnivorous diet
89447064|NCT05624333|Other|OV group|Omnivorous diet followed by Vegan diet
89014213|NCT05640167|Other|EMPOWER PD Clinic Participation|All participants will be assigned to the same interdisciplinary clinic and educational intervention
89014214|NCT05637112||Prospective Cohort|All patients aged ≥18 years diagnosed with SLE who initiate anifrolumab as prescribed by their healthcare provider (HCP) per the approved country-specific label and are treated at the study sites will be eligible for inclusion.
89014215|NCT05631301|Experimental|Move&Connect-Youth|"Sessions run weekly at the Bloorview Research Institute by a registered physiotherapist and occupational therapist for one hour. Participants will provide electronic consent and complete the pre-intervention measures one week before the intervention begins. Data collection will also occur on week 8 (post intervention) and at 3-month follow-up.~Weekly sessions will include an active rehabilitation component including exercises focused on cardiovascular fitness, balance, co-ordination and strength.~Weekly sessions will also include an educational component through focused discussions on topics including headache management, stress coping skills, fatigue management, advocacy skills, and goal setting.~Data collection sessions will include a series of questionnaires and surveys to acquire consent, demographic information, and assess pre-post changes in concussion symptoms, self-efficacy, quality of life, mental health and social support."
89447065|NCT05607381|Experimental|Mindfulness|A well-validated mindfulness meditation-based therapy [8 sessions] is used to teach patients to independently practice meditation to cope with pain.
89447066|NCT05607381|Experimental|Meditation|A validated meditation-based therapy [8 sessions] is used to teach patients to independently practice meditation to cope with pain.
89447067|NCT05607381|Active Comparator|Usual Care|Patients will receive usual medical care for chronic low back pain.
89023507|NCT05294302|Active Comparator|eSCCIP/eSCCIP-SP|The Electronic Surviving Cancer Competently Intervention Program (eSCCIP) is an innovative eHealth intervention that combines cognitive behavioral and family systems therapy to provide parents and caregivers of children with cancer (PCCC) with evidence-based coping skills and psychosocial support focused on the family unit. eSCCIP has three 30-minute, self-directed, online modules which feature a unique mix of original video content and interactive activities, supplemented by three telehealth follow-up sessions. A stakeholder-informed Spanish-language adaption of eSCCIP (eSCCIP-SP) has been developed and will be offered to Spanish-speaking PCCC. eSCCIP aims to reduce acute distress and symptoms of post-traumatic stress while increasing positive coping self-appraisal and use of cognitive coping skills.
89447068|NCT05601674|Placebo Comparator|Conventional group|Anesthesia induction will be performed with 2 mg/kg propofol, 1 µg/kg fentanyl and 0.6 mg/kg rocuronium as standard.After intubation, anesthesia will maintained with %40 O2 and sevoflurane at 2% volume. When the sevoflurane concentration reached 1 MAC, the fresh gas flow rate will be brought to 2 L/min. Inhalation anesthetics will be turned off 10 minutes before the end of the operation. The fresh gas flow will be increased to 6 l/min to be 100% O2. At the end of the surgery, the neuromuscular block will be antagonized with neostigmine-atropine. Sedation and agitation will be assessed immediately after extubation.
89447069|NCT05601674|Active Comparator|Low Flow Group|anesthesia induction will be performed with 2 mg/kg propofol, 1 µg/kg fentanyl and 0.6 mg/kg rocuronium as standard.After intubation, anesthesia will maintained with %40 O2 and sevoflurane at 2% volume. When the sevoflurane concentration reached 1 MAC, the fresh gas flow rate will be brought to 0.5 L/min. Inhalation anesthetics will be turned off 10 minutes before the end of the operation. The fresh gas flow will be increased to 6 l/min to be 100% O2. At the end of the surgery, the neuromuscular block will be antagonized with neostigmine-atropine. Sedation and agitation will be assessed immediately after extubation.
89447070|NCT05600855|Experimental|The group of daGOAT model prevention|"Model-predicted high-risk patients: ruxolitinib 5mg bid po until at least day 60 post-transplant and terminated after day 100. If severe hematological signs occur such as when there is severe neutropenia (<0.1×10^9/L), ruxolitinib can be used at half dose or discontinued as appropriate, and can continue to be used after hematology recovery.~Model-predicted moderate-risk patients: ruxolitinib 2.5mg bid p po until at least day 60 post-transplant and terminated after day 100. If severe hematological signs occur such as when there is severe neutropenia (<0.1×10^9/L), ruxolitinib can be used at half dose or discontinued as appropriate, and can continue to be used after hematology recovery.~Model-predicted low risk: regular aGVHD prophylactic regimens."
89447071|NCT05599724||CASE|Patients who did not carry a pregnancy to term
89447072|NCT05599724||CONTROL|patients who carried a pregnancy to term
89447073|NCT05586880|Experimental|EnXtra 300 mg/ capsule|One capsule to be taken 3±0.5 hours prior to second gaming session on Day 1 followed by 1 capsule daily after breakfast for 5 days
89447074|NCT05586880|Placebo Comparator|Microcrystalline cellulose (MCC) 300mg|One capsule to be taken 3±0.5 hours prior to second gaming session on Day 1 followed by 1 capsule daily after breakfast for 5 days
89447075|NCT05559034||Healthy adults|The study will comprise only one group of healthy adults subject to a same behavioral and cognitive intervention.
89447076|NCT05541237|No Intervention|Health|
89447077|NCT05541237|Experimental|Disease|
89023508|NCT05294302|Active Comparator|Coping Space|PCCC randomized to the patient education control condition will be given access to a website with information about psychosocial functioning, coping, and PTSS related to pediatric cancer. This website will be hosted on the same platform as the intervention, available in English and Spanish, and will consist of information modified from CopingSpace.org. CopingSpace.org is an evidence-informed website developed by Ryan's Case for Smiles, a national organization dedicated to supporting families impacted by pediatric cancer and other chronic diseases.
88932295|NCT03912259|Placebo Comparator|Placebo Q2W|Placebo matched to dupilumab 600 milligrams (mg) (loading dose), subcutaneously (SC) on Day 1 followed by placebo matched to dupilumab 300 mg once every 2 weeks (Q2W) for 16 weeks.
88932296|NCT03912259|Experimental|Dupilumab 300 mg Q2W|Dupilumab at a loading dose of 600 mg, SC on Day 1 followed by 300 mg, Q2W for 16 weeks.
88932297|NCT03871829|Active Comparator|Arm A: Carfilzomib+Dexamethasone (Kd)|Participants will receive carfilzomib 20 milligram per square meter (mg/m^2) intravenously (IV) on Day 1 of Cycle 1 and then 70 mg/m^2 on Days 8 and 15 of Cycle 1 and thereafter on Days 1, 8, 15 of Cycle 2 onwards. Participants will receive dexamethasone 20 mg on Cycle 1 Day 1, a second dose of 20 milligram (mg) will be given on Cycle 1 Day 2 and 40 mg IV or orally on Days 8, 15, 22 for Cycle 1. Patients will then receive dexamethasone 40mg on days 1, 8, 15 and 22 for cycles 2-9, then on Days 1, 8, 15 for Cycle 10 onwards, until death, intolerable toxicity, start of a new treatment for multiple myeloma, withdrawal of consent, or end of the study. The total duration of each cycle is 28 Days.
88932298|NCT03871829|Experimental|Arm B: Dara-SC in combination with Kd (DKd)|Participants will receive daratumumab subcutaneous (Dara-SC) 1800 mg by SC injection on Days 1, 8, 15, 22 for Cycle 1 and 2, Days 1 and 15 for Cycle 3-6, Day 1 for Cycle 7 onwards. Participants will receive carfilzomib 20 mg/m^2 IV on Cycle 1 Day 1 and then 70 mg/m^2 on Day 8 and 15 of Cycle 1 and Days 1, 8 and 15 of Cycle 2. Participants will receive dexamethasone 20 mg on Cycle 1 Day 1, a second dose of 20 milligram (mg) will be given on Cycle 1 Day 2 and 40 mg IV or orally on Days 8, 15, 22 for Cycle 1. Patients will then receive dexamethasone 40mg on days 1, 8, 15 and 22 for cycles 2-9, then on Days 1, 8, 15 for Cycle 10 onwards, until death, intolerable toxicity, start of a new treatment for multiple myeloma, withdrawal of consent, or end of the study. The total duration of each cycle is 28 Days.
88932299|NCT03845270|Experimental|pertuzumab + trastuzumab + docetaxel|Cycle 1 : D1 : pertuzumab 840 mg, D2 : trastuzumab 8 mg/kg + docetaxel 75 mg/m² Subsequent cycle : D1 : pertuzumab 420 mg + trastuzumab 6 mg/kg + docetaxel 75 mg/m²
88932300|NCT03833960||1-cN0/pN0|Patients with initially clinically negative axilla (cN0), submitted to neoadjuvant treatment, followed by surgical procedure within ALND or SLNB was done, and the final pathological report was ypN0.
88932301|NCT03833960||2-cN+/pN0|Patients with initially clinically involved axilla (cN1-2), submitted to neoadjuvant treatment, followed by surgical procedure within ALND or SLNB was done, and the final pathological report was complete axillary remission (ypN0).
88932302|NCT03833960||3-cN0/pN+|Patients with initially clinically negative axilla (cN0), submitted to neoadjuvant treatment, followed by surgical procedure within SLNB was done, followed by ALND because of positive pathological report of sentinel node(s).
88932303|NCT03833960||4-cN+/pN+|Patients with initially clinically positive axilla (cN1-3) submitted to neoadjuvant treatment, followed by surgical procedure within ALND was done and the final pathological report was ypN1-3.
88932304|NCT03831464|Experimental|Metformin treatment group|
88932305|NCT03831464|Placebo Comparator|Placebo control group|
88932306|NCT03799991|Experimental|Vestibular therapy|Vestibular therapy (Vestibular physical therapy) entails an 8-week course of exercises delivered by a physical therapist designed to improve vestibular function.
88932307|NCT03799991|Active Comparator|Active control|"The active control regimen consists of eye movement exercises (e.g. smooth pursuit eye movements) and also general conditioning exercises (e.g. range of motion exercises, lifting light weights with the arms and legs). This regimen is vestibular neutral in that head movements which specifically challenge the vestibular system are avoided."
88932308|NCT03783936|Other|Induction and Maintenance|"Cycles 1-9; Induction; Cycle = 14 days~mFOLFOX6~oxaliplatin 85 mg/m2 IV Day 1 and~leucovorin 400 mg/m2 IV Day 1 and~5 fluorouracil 400 mg/m2 IV bolus and 2400 mg/m2 IV over 46 hours Day 1 and~Trastuzumab 6 mg/kg IV loading dose C1D1 then Trastuzumab 4 mg/kg IV Day 1 and~Avelumab 800 mg IV Day 1~Cycles 10 and subsequent; Maintenance; Cycle = 14 days~Trastuzumab 4 mg/kg Day 1 and Avelumab 800 mg Day 1"
89200372|NCT00891111|Experimental|Regret Lottery|Regret Lottery: Employees are divided into work units of about 5 employees. Employees in the lottery-linked incentive condition will be eligible for a weekly lottery drawing only if they have already completed their health risk assessment. The lotteries will work as follows. Participants will be assigned to work units of about 10 people. Each week, one work group is drawn at random. If a participants group was drawn and that participant already completed the health risk assessment, then that person will win a $100 cash prize. If all of the members of his or her work group also filled out the health risk assessment, then the prize will be boosted.
89200373|NCT00764556|Experimental|Tight glycaemic control|Intravenous or subcutaneous insulin to control blood glucose to 4.4-6.5mM
89200374|NCT00968578|Active Comparator|Methylprednisolone|Methylprednisolone 125 mg iv pre-operatively
89200375|NCT00968578|Placebo Comparator|Saline|Saline iv pre-operatively in equivalent volume (placebo)
89200376|NCT00891189||1 Control|Healthy participants without asthma
89200377|NCT00891189||2 Non-nocturnal asthma|Participants with non-nocturnal asthma
89200378|NCT00891189||3 Nocturnal asthma|Participants with nocturnal asthma
89200379|NCT00893373|Experimental|Sorafenib|Induction, Consolidation and Maintenance plus Sorafenib 2x 400 mg/d
89200380|NCT00893373|Placebo Comparator|Placebo|Induction, Consolidation and Maintenance plus Placebo
89200381|NCT00891267|Experimental|Olmesartan medoxomil low dose|Olmesartan medoxomil tablets low dose, taken once daily for 6 weeks
89200382|NCT00891267|Experimental|Olmesartan medoxomil tablets high dose|Olmesartan medoxomil tablets high dose, taken once daily for 6 weeks
89200383|NCT00891267|Active Comparator|Amlodipine|Amlodipine taken once daily for 6 weeks
89200384|NCT04036617|Experimental|NaQuinate|Initial SAD cohorts will receive 1 dose between 10-150 mg. MAD cohorts will receive 7 days dosing between 70-150 mg
89200385|NCT04036617|Experimental|Placebo|Initial SAD cohorts will receive 1 placebo dose between 10-150 mg . MAD cohorts will receive 7 days placebo dosing between 70-150 mg
89200386|NCT02541279|Experimental|Intervention|The intervention group received 6 sessions of shoulder exercises controlled by a physiotherapist.
89200387|NCT02541279|Active Comparator|Control|The control group received a paper explaining the same exercises which were performed by the intervention group. This group made the exercises at home.
89200388|NCT00545584|Experimental|Sitagliptin with Standard of Care|Subjects received sitagliptin 100 mg once daily for 26 Weeks, and: No specific intervention (standard recommendation) on physical exercise and diet.
89200389|NCT00545584|Experimental|Sitagliptin with Diet Advice|"Subjects received sitagliptin 100 mg once daily for 26 Weeks,~and:~Intervention on diet which includes advice on diet with a leaflet and a diary"
89200390|NCT00545584|Experimental|Sitagliptin with Diet and Physical Activity Advice|"Subjects received sitagliptin 100 mg once daily for 26 Weeks,~and:~Intervention on diet + physical activity which includes advice on diet and physical activity with leaflets and diaries PLUS advice on physical activity with the utilization of a pedometer: subjects were asked to walk 10,000 steps per day 5 or more days per week."
89200391|NCT00378703|Active Comparator|Arm A (bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15.
89200392|NCT00378703|Experimental|Arm B (bevacizumab and temsirolimus)|Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22 and bevacizumab as in Arm A.
89200393|NCT00378703|Experimental|Arm C (bevacizumab and sorafenib tosylate)|Patients receive bevacizumab as in Arm A and sorafenib tosylate PO BID on days 1-5, 8-12, 15-19, and 22-26.
89200394|NCT00378703|Experimental|Arm D (sorafenib tosylate and temsirolimus)|Patients receive sorafenib tosylate PO BID on days 1-28 and temsirolimus as in Arm B.
89200395|NCT00893451|Active Comparator|A|Vitamin D3 1600 IU orally twice daily
89200396|NCT00893451|Placebo Comparator|B|Placebo orally twice daily
89200397|NCT00975364||blood sampling|Consented volunteers provide a one-off blood sample
89200398|NCT00893529|Experimental|dietary intervention 1|
89200399|NCT00893529|Experimental|dietary intervention 2|
89200400|NCT00967408|Experimental|Rehabilitation + Escitalopram|Rehabilitative treatment + Oral Escitalopram 5 mg/day for the first week, 10 mg/day from second to fourth week and 20 mg/day until 6th month.
89200401|NCT00967408|Placebo Comparator|Rehabilitation + Placebo|Rehabilitative treatment + Non active Placebo tablets for 6 months
89200402|NCT00891423|Active Comparator|Meropenem short infusion|"Meropenem 1g infused over 30 minutes~every 8 hours if calculated CrCL greater than or equal to 50 mL/min OR~every 12 hours if calculated CrCL less than 50 mL/min or hemofiltration"
89200403|NCT00891423|Experimental|Meropenem extended infusion|"Meropenem 500mg infused over 3 hours~every 8 hours if calculated CrCL greater than or equal to 50 mL/min OR~every 12 hours if calculated CrCL less than 50 mL/min or hemofiltration"
89447078|NCT05533190|Experimental|Wysa AI chatbot mental health app|Wysa is a guided self-help and triaging tool delivered to patients via an app or widget. It uses Natural Language Processing to understand individuals' written inputs but not to generate responses. Wysa makes use of a wide range of clinically underpinned modules whilst gamification, clinical outcome measures and AI promotes engagement, improving efficacy and triage and reducing the cost of scale.
89447079|NCT05533190|No Intervention|Waitlist control|The intervention will be compared against a waitlist group. This comparator was selected to compare Wysa to the current standard of care for patients waiting for standard IAPT assessment and treatment.
89447080|NCT05527314|Experimental|Remimazolam|"Induction of anesthesia Slowly inject Remimazolam 0.4-0.8 mg/kg (about 1 minute) until loss of consciousness (LoC), if the degree of sedation is insufficient, additional Remimazolam (0.05 mg/kg each time) is allowed. After the LoC, fentanyl 3-4 ug/kg and cisatracurium besilate 0.1 mg/kg are injected intravenously. After the muscles are sufficiently relaxed and blood circulation is stable, the tracheal tube is inserted under a glide scope.~Maintenance of anesthesia Remimazolam 1~2 mg/kg/h and remifentanil 0.1~0.3 ug/kg/min are injected intravenously to maintain sedation and assistant analgesia, and cisatracurium besilate 0.02 mg/kg is allowed to add as appropriate. During the operation, the dose of anesthetic drugs is adjusted so that the fluctuation of heart rate and blood pressure did not exceed 20 %."
89447081|NCT05527314|Active Comparator|Sevoflorane|"Induction of anesthesia After the sevoflurane volatilization tank is adjusted to 8 % and the fresh gas flow rate is 5 L/min, the suitable mask connects with the outlet of the loop and covers the nose of the child. After the LoC, the sevoflurane volatilization tank is set to 3 % and the fresh gas flow rate is 2 L/min to maintain autonomous respiration. At the same time, fentanyl 3-4 ug/kg and cisatracurium besilate 0.1 mg/kg are injected intravenously. After the muscles are sufficiently relaxed and blood circulation is stable, the tracheal tube is inserted under a glide scope.~Maintenance of anesthesia Continuous inhalation of sevoflurane concentration 2 %-3 % and remifentanil 0.1-0.3 ug/kg/min intravenous pump to maintain sedation and assistant analgesia, and cisatracurium besilate 0.02 mg/kg is allowed to add as appropriate. During the operation, the dose of anesthetic drugs is adjusted so that the fluctuation of heart rate and blood pressure did not exceed 20 %."
89447082|NCT05521802|Experimental|C-CAR088|Autologous C-CAR088 administered by intravenous (IV) infusion
88932309|NCT03754114|Active Comparator|ICP only|ICP guided management strategy: Care in the ICU of research participants randomized to this arm will be guided by a monitoring and treatment strategy in which doctors try to prevent high intracranial pressure (ICP) caused by a swollen brain. This strategy is one of two alternative strategies that is currently used in standard care of patients with traumatic brain injury.
88932310|NCT03754114|Active Comparator|ICP + PbtO2|ICP + PbtO2 guided management strategy: Care in the ICU of research participants randomized to this arm will be guided by a monitoring and treatment strategy in which doctors try to prevent high intracranial pressure (ICP), and also try to prevent low PbtO2 (brain tissue oxygen levels). This strategy is one of two alternative strategies that is currently used in standard care of patients with traumatic brain injury.
88932311|NCT03742986|Experimental|HER2-negative, including TNBC or HR-positive|
88932312|NCT03742986|Experimental|HER2-positive, independent of HR status|
88932313|NCT03736720|Experimental|Treatment (liposomal irinotecan, leucovorin, fluorouracil)|Patients receive liposomal irinotecan IV over 90 minutes, leucovorin IV over 30 minutes, and fluorouracil IV over 46 hours on days 1 and 15. Courses repeat every 28 days for in the absence of disease progression or unacceptable toxicity.
88932314|NCT03703167|Experimental|ibrutinib in combination with rituximab and lenalidomide|Ibrutinib will be given day 1-28; Lenalidomide will be given day 1-21; Rituximab will be given on day 1. Rituximab is given for 6 cycles; Lenalidomide is given for 12 cycles; Ibrutinib is continued until disease progression, intolerable toxicity or death.
89447083|NCT05497011|No Intervention|Control|This is the actual control group receiving conventional therapy, ie. percutaneous coronary intervention.
89447084|NCT05497011|Experimental|PiCSO|This arm will be treated with Pressure controlled intermittent Coronary Sinus Occlusion (PiCSO) in addition to conventional therapy (percutaneous coronary intervention).
89447085|NCT05494242|Experimental|single superior flap technique to secure macular hole closure.|"The patients are divided into two groups:~For the first group, the flap will be carried out under the effect of perfluorocarbon.~For the second group, the flap stabilized with methylcellulose."
89447086|NCT05494242|Active Comparator|Double flap technique to secure macular hole closure.|This arm is NCT05269563, we utilize the results as a comparator to the superior single flap technique.
89447087|NCT05484505|Experimental|Nicotine replacement therapy (NRT) Preloading|"Brief Advice (5 A's & 5 R's)- 0-day, Month- 1, 3, 6, 9, 12~a. Nicotine Replacement Therapy for > 20 cigarettes per day~Nicotine Patch: Preloading for 4 weeks + 12 weeks post quit date,21 mg: 4 weeks before and after quit date,14 mg: Next 4 weeks,7 mg: Last 4 weeks Nicotine chewing gums 4 mg for 12 weeks post quit date (12/day on week 1(Tapering dose weekly)1/day on week 12~2.b. Nicotine Replacement Therapy for < 20 cigarettes per day Nicotine Patch: Preloading for 4 weeks + 12 weeks post quit date 21 mg: 4 weeks before and after quit date 14 mg: Next 4 weeks 7 mg: Last 4 weeks~Nicotine chewing gums 2 mg for 12 weeks post quit date (12/day on week~1(Tapering dose)1/day on week 12"
89447088|NCT05484505|Active Comparator|Nicotine replacement therapy (NRT)|"Brief Advice (5 A's & 5 R's)- 0-day, Month- 1, 3, 6, 9, 12~a. Nicotine Replacement Therapy for > 20 cigarettes per day~Nicotine Patch: 12 weeks post quit date 21 mg: 4 weeks after quit date 14 mg: Next 4 weeks 7 mg: Last 4 weeks~Nicotine chewing gums 4 mg for 12 weeks post quit date (12/day on week 1(Tapering dose weekly)1/day on week 12~2.b. Nicotine Replacement Therapy for < 20 cigarettes per day~Nicotine Patch: 12 weeks post quit date 21 mg: 4 weeks after quit date 14 mg: Next 4 weeks 7 mg: Last 4 weeks~Nicotine chewing gums 2 mg for 12 weeks post quit date (12/day on week 1(Tapering dose)1/day on week 12"
89447089|NCT05478161|Experimental|treatment|TAVI in severe calcified aortic stenosis or in failed surgical aortic bioprosthesis
89447090|NCT05476822||Adults who received a full course of COVID-19 vaccine and booster|Adults at Travis Air Force Base who are Active Duty, DoD beneficiaries, and civilian employees who present with a vaccination card verifying they have received a full course of mRNA spike protein COVID vaccine (Moderna, Pfizer, or Johnson & Johnson) and booster will have antibody titers performed from blood drawn at time of enrollment, at three months, six months and nine months post vaccine booster (+/- ten days).
89447091|NCT05473364|Experimental|Acetazolamide - 62.5mg Dose|2-week treatment period with 62.5mg dose of acetazolamide taken twice daily.
89447092|NCT05473364|Experimental|Acetazolamide - 125mg Dose|2-week treatment period with 125mg dose of acetazolamide taken twice daily.
88932315|NCT03676465|Experimental|Experimental Group|"Subjects will wear their personal pump (if appropriate), use a study insulin pen (if appropriate), a study CGM and study activity tracker (i.e. Fitbit). Participants will receive a weekly CloudConnect Report based on analysis of the weekly data gathered for each participant. The report will be sent via email once a week to both the subject and their parent(s). Subjects and parents will have weekly contact with the study team. Subjects will complete questionnaires at the beginning and end of the study. These questionnaires will ask subjects about:~the communication within the family about the information shared in this report~how subjects feel when blood sugar is high or low~who takes responsibility of how diabetes care is managed"
89447093|NCT05473364|Experimental|Acetazolamide - 250mg Dose|2-week treatment period with 250mg dose of acetazolamide taken twice daily.
89023510|NCT05280093|Experimental|Hybrid sinus node sparing ablation procedure|Hybrid sinus node sparing ablation procedure using the ISOLATOR Synergy Surgical Ablation System
89023511|NCT05272852|Experimental|FARAPULSE™ Pulsed Field Ablation System Plus|Ablation using FARAPULSE™ Pulsed Field Ablation System Plus
89200404|NCT04035382|Experimental|Labor Induction|Induction of labor between 39 0/7 to 39 6/7 weeks. Cervical ripening and induction method will be left to the managing clinician. However, combination method of cervical ripening with prostaglandin or oxytocin and Foley catheter, followed by oxytocin infusion and amniotomy will be encouraged.
89200405|NCT00891501|Experimental|Single|Clinical case series
89200406|NCT00967564||001|epidemiologic study QoL assessment
89200407|NCT02541045|Placebo Comparator|Group 1: Placebo|Placebo
89200408|NCT02541045|Experimental|Group 2: Metadoxine|therapy with metadoxine
89200409|NCT05131282||PE group|Women with a confirmative diagnosis of PE
89200410|NCT05131282||Normal pregnancy group|Normal pregnant women
89200411|NCT04036149|Experimental|LUCIA|CT LUCIA 611P - Intraocular lens
89200412|NCT04036149|Active Comparator|ASPHINA|CT ASPHINA 409MP - Intraocular lens
89200413|NCT00975442|Experimental|Eccentric training|
89200414|NCT00975442|Placebo Comparator|Forearm band|
89200415|NCT00891579|Active Comparator|Alimta|Treatment of Alimta
89200416|NCT00891579|Active Comparator|IRESSA|Treatment of IRESSA
89200417|NCT00968734|Experimental|Low fat meal|
89200418|NCT00968734|Experimental|Hight fat meal|
89200419|NCT03620643|Active Comparator|Crizotinib Oral Capsule [Xalkori] monotherapy|Arm 1 - Gastric cancer cohort (n=29 participants) will be treated with monotherapy called Crizotinib Oral Capsule [Xalkori] (250 mg b.d) taken on a continuous dosing schedule. One treatment cycle for Crizotinib is 28 days long.
89200420|NCT03620643|Active Comparator|Crizotinib Oral Capsule [Xalkori] plus Fulvestrant injection|Arm 2 - Lobular Breast Cancer cohort (n=29 participants) will be treated with combination therapy. The combination therapy includes; Crizotinib Oral Capsule [Xalkori] (250mg b.d.) plus Fulvestrant 50 mg/mL Prefilled Syringe [Faslodex or generic] intramuscular (IM) injection (500 mg per 1 cycle (q28 days, plus loading dose on day 15).
89200421|NCT04008316|Experimental|colchicine 1mg/day|Colchicine per os: 1 tablet (1mg) / day during 6 months
89200422|NCT04008316|Placebo Comparator|placebo|placebo 1 tablet / day during 6 months
89200423|NCT00893607|Experimental|Intra-anal|The first 12 subjects were administered 10mg NRL001 as a slow release suppository into the anal canal.
89200424|NCT00893607|Experimental|Rectal|The second 12 subjects were administered 10mg NRL001 as a slow release rectal suppository.
89200425|NCT00969046|Experimental|Bolus|20 min bolus infusion
89200426|NCT00969046|Experimental|CIV-1d|1 day continuous infusion
89200427|NCT00969046|Experimental|CIV-5d|5 day continuous infusion
89200428|NCT05011708|Experimental|Test (I-DROP MGD)|"Part I of this study is a contralateral eye design, accordingly patient would receive either I-DROP MGD (Test) or Thealoz Duo (Control) in either eye.~Part II, patients shall receive either only I-DROP MGD"
89200429|NCT05011708|Active Comparator|Control - Thealoz Duo|"Part I of this study is a contralateral eye design, accordingly patient would receive either I-DROP MGD (Test) or Thealoz Duo (Control) in either eye.~Part II, patients shall receive either only I-DROP MGD"
89200430|NCT00893685|Experimental|Home telemonitoring|
89200431|NCT00893685|No Intervention|Usual care (control group)|
89200432|NCT05008354|Active Comparator|Pyridoxine|
89200433|NCT05008354|Placebo Comparator|Placebo|
89200434|NCT00975754|Experimental|1|Pulmicort pMDI
89200435|NCT00975754|Experimental|2|Budesonide pMDI
89200436|NCT00975754|Experimental|3|Budesonide pMDI + Aerochamber Zero-stat spacer
89200437|NCT00975754|Experimental|4|Pulmicort repulses via Spira Nebuliser
89200438|NCT00975754|Experimental|5|Pulmicort Turbohaler
89200439|NCT01045681|Experimental|BVD|Bendamustine, Velcade and Dexamethasone
89200440|NCT00868647|Other|Radiofrequency Ablation|
89200441|NCT00975832||women with polycystic ovary syndrome|
89200442|NCT00975832||women without polycystic ovary syndrome|
89200443|NCT00975832||women from 18-40 years of age|
89200444|NCT00868725||possible oral cancer|Patients reporting for oral cavity examination with the possibility or certainty of oral lesions
89200445|NCT00975910|Placebo Comparator|Saline|
89200446|NCT00975910|Active Comparator|Lidocaine|
89200447|NCT01048567|Active Comparator|Lactobacillus acidophilus/rhamnosus|
89200448|NCT01048567|Placebo Comparator|Placebo|
89200449|NCT00969202|Experimental|Stereotactic Radiosurgery using NovalisTx|Single arm study using the Novalis Tx to perform radiosurgery to treat low grade prostate cancer.
89200450|NCT01051375|Experimental|Waitlist Group|The intervention involves completion of a single workshop, provision of psychoeducational materials, and regular telephone support with a specially trained nurse-coordinator to parents of youth on our waiting list, within a month of our receiving the referral.
89200451|NCT01051375|No Intervention|Standard of Care|These patients continue to receive the standard of care while awaiting formal assessment.
89200452|NCT03617913|Experimental|Treatment (avelumab, chemotherapy, radiation therapy)|Participants receive avelumab IV over 60 minutes every 14 days for a total of 10 courses in the absence of disease progression or unacceptable toxicity. Beginning 29 days after the first dose of avelumab, participants receive either fluorouracil IV on days 1-5 and 16-20 during RT and mitomycin IV on day 1 of course 3, or cisplatin IV starting on day 1 of courses 3-5 for up to 6 weeks in the absence of disease progression or unacceptable toxicity.
89200453|NCT05073328||COVID-19 patients|COVID-19 patients discharged from all French hospitals from 01 February to 30 June 2020
89014216|NCT05631301|Experimental|Move&Connect-Youth-Virtual|"Sessions run weekly via Zoom videoconferencing by a registered physiotherapist and occupational therapist for one hour. Participants will provide electronic consent and complete the pre-intervention measures one week before the intervention begins. Data collection will also occur on week 8 (post intervention) and at 3-month follow-up.~Weekly sessions taking place over Zoom will include an active rehabilitation component including exercises focused on cardiovascular fitness, balance, co-ordination and strength.~Weekly sessions will also include an educational component through focused discussions on topics including headache management, stress coping skills, mood coping skills, fatigue management, advocacy skills, and goal setting.~Data collection sessions will include a series of questionnaires and surveys to acquire consent, demographic information, and assess pre-post changes in concussion symptoms, self-efficacy, quality of life, mental health and social support."
89014217|NCT05631301|Other|Move&Connect-Youth Waitlist control|"The control group will be recruited from the waitlist for the Persistent Concussion Clinic and the Early Care Concussion Clinic at Holland Bloorview, in addition to partnered community medical offices and organizations.~For the control group, the research assistant will schedule the participants first session to obtain consent and provide youth/caregivers with week 1 questionnaires. At this time, the participants will be able to ask any questions related to the study. After eight weeks the control group will be asked to complete the post measures in order to mimic the length of the intervention. The control group will then be given the opportunity to enroll in one of the intervention arms of the Move&Connect study. They will then follow the same approved procedures for the intervention treatment group. Youth and their caregivers will be able to participate as waitlist controls without completing the intervention, if they choose."
89014218|NCT05631301|Experimental|Move&Connect-Caregiver|"The treatment sessions run once a week at the Bloorview Research Institute and last approximately one hour. Participants will provide electronic consent and complete the pre-intervention measures one week before the intervention begins. Data collection will also occur on week 8 (post intervention) and at 3-month follow-up.~Caregivers will participate in a group-based psychoeducational support group with sessions consisting of focused discussions on topics including: the ripple effect, school advocacy, child well-being, family functioning, parenting, and stress & daily challenges. The sessions will be run by a clinical neuropsychologist and social worker.~Data collection sessions will include a series of questionnaires and surveys to acquire consent, demographic information, and assess pre-post changes in their youth's concussion symptoms, and mental health, as well as parental self-efficacy, quality of life, mental health and social support."
89014219|NCT05631301|Experimental|Move&Connect-Caregiver-Virtual|"The treatment sessions run once a week using Zoom videoconferencing and last approximately one hour. Participants will provide electronic consent and complete the pre-intervention measures one week before the intervention begins. Data collection will also occur on week 8 (post intervention) and at 3-month follow-up.~Caregivers will participate in a group-based psychoeducational support group with sessions consisting of focused discussions on topics including: the ripple effect, school advocacy, child well-being, family functioning, parenting, and stress & daily challenges. The sessions will be run by a clinical neuropsychologist and social worker.~Data collection sessions will include a series of questionnaires and surveys to acquire consent, demographic information, and assess pre-post changes in their youth's concussion symptoms, and mental health, as well as parental self-efficacy, quality of life, mental health and social support."
89023512|NCT05272618||MINOCA with CMD|MINOCA patients with CMD proven by invasive or non-invasive method
89023513|NCT05272618||MINOCA without CMD|MINOCA patients without CMD
89023514|NCT05271513|Active Comparator|real transcranial magnetic stimulation plus real transcutaneous magnetic stimulation of spinalcord|the patient will receive real rTMS 2000 pulses for each hand area 20Hz 80% of Motor threshold of the hand, 10 trains, each train 10 seconds over the hand area plus 1000 pulses 10 Hz 80% of the motor threshold of the leg 10 trains, and each train 10 seconds over the mid-cervical vertebrae for consecuative 10 days (5 days/week)
89447094|NCT05453591|Experimental|Sample collection|This is a prospective study in which urine samples will be collected from healthy volunteers and urine samples and a blood sample from cancer patients with breast cancer. The participants will be asked to provide a urine sample collected with the ColliPee® device and fill out an online questionnaire to collect usability data. Thereafter, the urine sample will be aliquoted to be used in the study to investigate the different urinary analytes.
89447095|NCT05428943|Other|OPT101 1.1 mg/kg and Placebo|9 subjects (6 investigational product:3 placebo)
89023515|NCT05271513|Active Comparator|real transcranial magnetic stimulation with sham transcutaneous magnetic stimulation of spinalcord|the patient will receive real rTMS 2000 pulses for each hand area 20Hz 80% of Motor threshold of the hand, 10 trains, each train 10 seconds plus sham stimulation 1000 pulses 10 Hz 80% of the motor threshold of the leg 10 trains, and each train 10 seconds over the mid-dorsal vertebrae for 10 consecutive days (5 sessions/week)
89023516|NCT05268679||Heart transplant recipients|Heart transplant recipients followed at Bichat Hospital and who were offered vaccination against SARS-CoV-2, regardless of whether they agreed to be vaccinated or not.
89023517|NCT05263804|Other|Cohort group|Patient over 18 with an ischemic stroke
89023518|NCT05263804|Experimental|Ancillary study group|Patient over 18 with an ischemic stroke
89023519|NCT05257759|Active Comparator|Standard support|
89447096|NCT05428943|Other|OPT101 2.8 mg/kg and Placebo|9 subjects (6 investigational product:3 placebo)
89447097|NCT05407974|Experimental|Pleural abrasion Group|Mechanical pleural abrasion will be performed by rubbing the parietal pleura with gauze or a cleaning pad.
89447098|NCT05407974|Experimental|pleurectomy group|Pleurectomy will be performed by a small piece of gauze on grasper. The aim of pleurectomy is to remove the parietal pleural especially above the areas with blebs or bullae.
89447099|NCT05382494|Experimental|Intranasal Steroids|
89447100|NCT05382494|Placebo Comparator|Intranasal Saline|
89447101|NCT05351346|Experimental|R-CHOP-X|Patients in R-CHOP-X group will receive rituximab 375 mg/m² IV on day 1, cyclophosphamide 750 mg/m² IV, doxorubicin 50 mg/m² IV, and vincristine 1.4 mg/m² IV (maximum 2 mg) on day 2, and prednisone 100 mg/day PO on days 2-6 of every 21-day cycle for the first cycle. For the remaining 5 cycles, they will receive orelabrutinib 150 mg/day PO on days 1-21, or lenalidomide 25 mg/day PO on days 2-11, or decitabine 10 mg/m² IV on days -5 to -1 followed by standard R-CHOP of every 21-day cycle.
88932316|NCT03676465|Active Comparator|Control Group|"Subjects will wear their personal pump (if appropriate), use a study insulin pen (if appropriate), a study CGM and study activity tracker (i.e. Fitbit). Participants will not receive a CloudConnect Report. Subjects and parents will have weekly contact with the study team. Subjects will complete questionnaires at the beginning and end of the study. These questionnaires will ask subjects about:~the communication within the family about the information shared in this report~how subjects feel when blood sugar is high or low~who takes responsibility of how diabetes care is managed"
89447102|NCT05351346|Active Comparator|R-CHOP|Patients in R-CHOP group will receive rituximab 375 mg/m² IV on day 1, cyclophosphamide 750 mg/m² IV, doxorubicin 50 mg/m² iv, and vincristine 1.4 mg/m² IV (maximum 2 mg) on day 2, and prednisone 100 mg/day PO on days 2-6 of every 21-day cycle for 6 cycles.
89447103|NCT05323279|Experimental|novices with AI-assisted system|The novice doctors are assisted in colonoscopy with an artificial intelligence system that can indicate abnormal lesions and the speed of withdrawal in real-time, as well as feedback on the percentage of overspeed.
89447104|NCT05323279|No Intervention|experts without AI-assisted system|The expert doctors perform routine colonoscopy without artificial intelligence assistance system and no special tips
89447105|NCT05323279|No Intervention|novice without AI-assisted system|The novice doctors perform routine colonoscopy without artificial intelligence assistance system and no special tips
88932317|NCT03674528||Control Group|Subjects with a BMI of 35 or more will be asked to undergo a single MRE imaging session.
88932318|NCT03674528||Patient Group|Adults that are candidates for weight loss surgery will be asked to participate in four study visits that include MRE imaging and 1 - 2 liver biopsy procedures.
88932321|NCT03659734|Experimental|Motivational Interviewing and Guided Opioid Tapering Support|
88932322|NCT03659734|Experimental|Enhanced Usual Care|
88932323|NCT03642028|Experimental|Suvorexant|Suvorexant is a dual orexin receptor antagonist that is FDA approved to treat insomnia.
88932324|NCT03642028|Placebo Comparator|Identical Placebo|Visibly matched, equally weighted placebo tablets. In addition to matching in appearance and weight, they will have identical packaging and labeling as randomized, blinded study medication.
88932325|NCT03639753|Experimental|Parent-Teen Intervention|Parent health coaching session and supportive materials, teen on road driver assessment with feedback.
88932326|NCT03639753|Other|Usual Practice|
88932327|NCT03636295|Experimental|Reduced INR Target|Warfarin therapy will be titrated to a target INR in the range of 1.5 to 2.5.
89023520|NCT05257759|Experimental|Standard treatment coupled with electro-stimulation sessions|
89023521|NCT05253053|Experimental|Arm A: TT-00420 Tablet Monotherapy|TT-00420 tablets will be administered once daily in 21-day cycles. Dose escalation will be guided by a 3+3 design in Phase Ib to determine the recommended phase 2 dose (RP2D).
89023522|NCT05253053|Experimental|Arm B: TT-00420 tablet in combination with Atezolizumab Injection (Tecentriq ®)|TT-00420 tablets will be administered once daily in 21-day cycles. Atezolizumab(1200 mg/20 mL) will be administered intravenously on Day 1 of each 21-day cycle. Dose escalation will be guided by a 3+3 design in Phase Ib to determine the recommended phase 2 dose (RP2D).
89023523|NCT05253053|Experimental|Arm C: TT-00420 tablet in combination with nab-paclitaxel (Abraxane®)|TT-00420 tablets will be administered once daily in 21-day cycles. Nab-paclitaxel 125 mg/m^2 will be administered intravenously on Day 1 and 8 of each 21-day cycle. Dose escalation will be guided by a 3+3 design in Phase Ib to determine the recommended phase 2 dose (RP2D).
89023524|NCT05252312||Healthy adult population aged 18 to 80 years|"After listening to acoustic stimuli, participants will be asked to judge these stimuli on relevant evaluation criteria (e.g., how distressed does this person sound?)."
89023525|NCT05248516|Other|Control|no nutritional treatment administered
89023526|NCT05248516|Experimental|Simplified treatment|children are provided with 1 sachet of RUTF until discharge
89023527|NCT05248516|Active Comparator|Standard treatment|"children are provided nutritional treatment according to their weight-for-height z-score (WHZ) and their weight:~children with a WHZ<-3 will receive 200kcal/kg/d of nutritional product until discharge~children with a WHZ between -3 and -2 are provided with 1 sachet of RUTF until discharge~children with a WHZ >= -2 will not be provided any nutritional treatment"
89023528|NCT05236673||Patients who have started at first time on Jardiance®|
89023529|NCT05230589||Patients with type 2 diabetes|once-daily oral semaglutide in a real-world adult population with type 2 diabetes
89023530|NCT05227027|Experimental|Education plus game module|Participants receive an educational intervention through the Smoke Free application with the embedded game module. Participants complete questionnaires and may undergo saliva sample collection, if they report being smoke-free on follow-up.
89023531|NCT05227027|Active Comparator|Education module only|Participants receive an educational intervention through the Smoke Free application only (core app only). Participants complete questionnaires and may undergo saliva sample collection, if they report being smoke-free on follow-up.
89023532|NCT05221294|Experimental|MDN group|will receive modified Del Nido cardioplegia solution
89023533|NCT05221294|Experimental|C group|will receive Custodiol cardioplegia
89023534|NCT05214716|Active Comparator|Intervention|Respiratory specimens from the subjects are tested by the FilmArray Pneumonia panel and the results are reported via an electronic health record system. Treating physicians may adjust empirical antibiotic regimens with assistance from the guidelines formulated by the study investigators. Other microbiologic tests, including cultures, are performed as per routine practice.
89023535|NCT05214716|No Intervention|Control|Microbiologic tests, including cultures, are performed as per routine practice. No intervention is made on the antimicrobial treatment in the control arm.
89023536|NCT05192447|Experimental|Intervention Group = Exercise Group|EG will perform complementary cognitive and physical training (120 min./5/per week during study observation)
89023537|NCT05192447|No Intervention|Control Group|CG will be provided with normal hospital care during RT and next will conduct a normal daily activity at home.
89023538|NCT05185089|Experimental|Orvepitant 30mg|Orvepitant 30mg tablet once daily for 4 weeks
89023539|NCT05185089|Experimental|Orvepitant 10mg|Orvepitant 10mg tablet once daily for 4 weeks
89023540|NCT05185089|Placebo Comparator|Placebo|Placebo tablet once daily for 4 weeks
89200454|NCT05073328||"sub group The long COVID patients"|"this cohort will include patients with at least 4 weeks of claims and specific health care use after hospital admission from the initial cohort (COVID-19 patients)~According to the Haute Autorité de Santé (HAS), the most frequent symptoms in the context of long COVID are the following :~Major fatigue~Dyspnoea, cough~Chest pain, often tightness type, palpitations~Problems with concentration and memory, lack of words~Headache, paraesthesia, burning sensation~Disorders of smell, taste, tinnitus, dizziness, odynophagia~Muscle, tendon or joint pain~Sleep disorders (especially insomnia)~Irritability, anxiety~Abdominal pain, nausea, diarrhea, decrease or loss of appetite~Pruritus, urticaria, pseudo-frostbite~Fever, chills"
89447106|NCT05323019|Other|Intranasal (esketamine) Ketamine with Addition of Almond therapy|Intranasal (esketamine) Ketamine - Dose of 56mg for a maximum of 2 weeks, followed by 56 mg or 84mg twice a week for a total of 8 doses during the 28 day study.
89447107|NCT05323019|Other|Intranasal (esketamine) Ketamine with Treatment as Usual|Intranasal (esketamine) Ketamine - Dose of 56 mg for a maximum of 2 weeks, followed by 56mg or 84mg twice a week for a total of 8 doses during the 28 day study.
89447108|NCT05319821|Active Comparator|Active Intervention|PCP participants in the practice cohort or the intervention group will receive the ECHO46 intervention via real-time, interactive videoconferencing through Zoom sessions held once weekly for 4 weeks (4 sessions total) at regularly scheduled times convenient to providers. Session topics will focus on training PCP participants to assess, advise, and refer patients to be more physically active, as well as provide evidence-based strategies they can use to supplement and sustain their communication efforts.
89447109|NCT05319821|Active Comparator|Delayed Intervention|PCP participants will be offered the intervention in year 5.
89447110|NCT05315453|Experimental|Brief Cognitive Rehabilitation|5-session Cognitive Rehabilitation intervention administered over telehealth
89447111|NCT05300100|Experimental|Activities|"The duration of the experience will last 1 hour per participant in a single session.~The proposed actions were chosen from a very large sensorimotor repertoire of activities in everyday life for a child aged 5 to 8.~The activities chosen involve either the whole body or specific parts such as the hand to grasp or perform graphic tests."
89447112|NCT05297877|Experimental|AI Machine|All study participants will undergo a full day (roughly 8 hours) training programme consisting of a pre-test MCQ, a didactic lecture, hands-on training session, a post-test MCQ, and a practical evaluation. They will be randomised to using an A.I. ultrasound machine for teaching.
88932328|NCT03636295|Active Comparator|Standard INR Target|"Warfarin therapy will be titrated to a standard of care target INR range."
88932329|NCT03630107|Experimental|WO 5101 Shampoo for Scalp and Hair|WO 5101 is used in subjects with chronically itchy scalp
88932330|NCT03609177|Experimental|Advance Care Planning|"-Survey:~A group of older patients with advanced cancer (N=450) will have a survey over the course of the 36 months of recruitment.~Participants will be provided written copies of the questions to follow along during the interviews"
88932331|NCT03609177|Experimental|Advance Care Planning-Video Declaration|"Video Declaration:~From among this group of 450 participants, the video declaration of preferences activity will be conducted with 240 patients.~For those participants that agree to the video declaration, they will proceed with recording of their video declarations~The RA will begin by reading a standardized introduction to aid the subject do the video"
88932332|NCT03609177|Other|Comprehensive Record Review of ACP|"A review of Medical orders for resuscitation preferences in the electronic health record~A review of Medical orders for Palliative care consultations preferences in the electronic health record~A review of Medical orders for Hospice use preferences in the electronic health record"
88932333|NCT03609177|Experimental|Main Study Arm|Patients with cancer being seen at the 30 oncology clinics will be exposed to clinicians who have had communication skills training (Vital Talk) and who are using video decision aids (ACP Decisions). Our main outcome is advance care planning documentation.
88932334|NCT03603210||Patients treated with DCB angioplasty|"Patient cohort is comprised of all patients who received drug coated balloon angioplasty at NNUH during the above period. Within this cohort there will be two main groups which are drug coated balloon (DCB) angioplasty for de novo coronary artery disease (CAD) and DCB angioplasty for ISR/ST. Graft cases will be reported as a small third group.~Outcomes will also be reported for three sub groups of de novo disease group, namely, dcb-only angioplasty for de novo disease, dcb-only angioplasty as primary percutaneous coronary intervention (PPCI) and dcb-only angioplasty group using a DCB with a diameter of 3mm or more in de novo disease."
88932335|NCT03589846|Experimental|Muscle stimulation|Consented participants who meet eligibility will have a drug induced sleep endoscopy (DISE) and the Grass S88 muscle stimulator.
88932336|NCT03588481||Coronary stenosis|
88932337|NCT03586102|Experimental|High protein supplementation|Infants will receive a diet that consists of mother's own milk or donor human milk and bovine-based human milk fortifier plus a fixed amount of commercially available hydrolyzed bovine protein. The study intervention will begin the day after fortification is ordered and will be continued until postnatal day 50 or 32 weeks postmenstrual age, whichever occurs first.
89200455|NCT05073328||"sub group non long COVID patients"|all other patients from the initial cohort (COVID-19 patients )
89200456|NCT00975988||TYKERB® tablets|There is only one group. This group includes patients administrated TYKERB® tablets
89200457|NCT00976066|Experimental|GSK1521498|Subjects will receive a dose of the experimental compound GSK1521498
89200458|NCT00976066|Active Comparator|Naltrexone|Subjects will receive a dose of the licensed pharmaceutical product, Naltrexone
89447113|NCT05297877|Other|Conventional Machine|All study participants will undergo a full day (roughly 8 hours) training programme consisting of a pre-test MCQ, a didactic lecture, hands-on training session, a post-test MCQ, and a practical evaluation. They will be randomised to using a conventional ultrasound machine for teaching.
89447114|NCT05284877||Male organ transplant recipients|600 men with a solid organ transplant (heart, lung, liver, kidney or pancreas)
89447115|NCT05284877||Female organ transplant recipients|600 women with a solid organ transplant (heart, lung, liver, kidney or pancreas)
89447116|NCT05284877||Female immunocompetent controls|600 immunocompetent women without organ transplant or other immunosuppressive conditions/treatments
89447117|NCT05284071|Experimental|Experimental: Single-Arm|This is a prospective, single-arm, post-market study to verify clinical performance, treatment satisfaction and adherence, and safety of Actiste 1.0 (Actiste) and the Companion app with TBL Backend when used as intended by subjects diagnosed with T1DM or T2DM.
89447118|NCT05278949|Other|The scleral pocket for the primary implanted IOL|single arm
89447119|NCT05276258|Experimental|Nerve Block Using Liposomal Bupivacaine and cryoSPHERE Ablation|The experimental group (75 participants) will undergo intercostal nerve block using liposomal bupivacaine and the cryoSPHERE ablation of intercostal nerves during robotic-assisted thoracoscopic operation at Houston Methodist Hospital.
89447120|NCT05276258|Other|Historical Controls|A total of 75 propensity score-matched historical controls will be selected from the pool of patients who had standard intercostal nerve block using liposomal bupivacaine alone at Houston Methodist Hospital from January 1, 2017 through January 1, 2022, inclusively.
89447121|NCT05275946|Other|Treatment group|
89447122|NCT06145126|Other|Start pred/End placebo|Both arms will receive both placebo and prednisone
89447123|NCT06145126|Other|Start placebo/End pred|Both arms will receive both placebo and prednisone
89447124|NCT06145113|Active Comparator|Continuous Positive Airway Pressure - 10cmH2O|This arm will consist of positive airway pressure at an FiO2 of 21% (ambient air), supplied by CPAP device set to 10cmH2O of pressure, for a total of 2 hours.
89447125|NCT06145113|Placebo Comparator|Placebo Continuous Positive Airway Pressure - 1cmH2O|This arm will consist of positive airway pressure at an FiO2 of 21% (ambient air), supplied by CPAP device set to 1cmH2O of pressure, for a total of 2 hours. This 1cmH2O is necessary to maintain blinding and will provide minimal therapeutic effect.
89447126|NCT06145113|Other|Continuous Positive Airway Pressure - 10cmH2O, with supplemental oxygen|This arm will only be enrolled into once the other two arms have been completed. Additional subjects will receive CPAP at 10cmH2O with in-line oxygen (estimated 2-4 liters per minute). This is done to determine if adding supplemental oxygen can further improve symptoms.
89447127|NCT06145100||Patients with CVID and autoimmunity and no liver involvement.|Patients with CVID and autoimmune disease, but no liver involvement (normal liver enzymes and normal abdominal ultrasound)
88932338|NCT03586102|Active Comparator|Standard protein supplementation|Infants will receive a standard diet that consists of mother's own milk or donor human milk (DHM) and bovine-based human milk fortifier. The study intervention will be continued until postnatal day 50 or 32 weeks postmenstrual age, whichever occurs first.
88932339|NCT03562793|Experimental|COOPERATE Intervention Arm|Intervention patients will focus on 1) goal clarification/prioritization; 2) communication skills. There are 6 total sessions delivered individually over 12 weeks: 4 sessions teaching skills (30 min each) and 2 booster sessions delivered once/month for the next 2 months. Intervention will be delivered by telephone.
88932340|NCT03562793|No Intervention|Attention Control Arm|Veterans randomized to the control group will receive phone calls on the same schedule as intervention Veterans. During these phone calls, study staff will ask Veterans a series of questions about their pain, self-management activities, and any changes they have experienced since the last call. These phone calls are designed to control for attention only, and Veterans will not be offered specific information or advice about their pain or its management (with the exception of suggesting a doctor visit if warranted).
89023541|NCT05184361|Experimental|Intermittent energy restriction (IER)|"Initially participants will undergo 2-weeks of neutral energy balance (EB). After this, the IER will consist of: 2-weeks of energy restriction interspersed with 1-week in neutral EB (total of 23-week period).~At the end, 8-weeks in neutral EB will be required."
89023542|NCT05184361|Active Comparator|Continuous energy restriction (CER)|Similarly to IER, CER participants will undergo 2-weeks of neutral EB. After this, the CER will consist of: 16-weeks of continuous energy restriction. At the end, 8-weeks in neutral EB will be required.
89447128|NCT06145100||Patients with CVID and liver involvement and no clinical significant portal hypertension|Patients with CVID and liver involvement (elevated liver enzymes, abnormal ultrasound and/or abnormal liver biopsy), but no clinically significant portal hypertension
89014220|NCT05631301|Other|Move&Connect-Caregiver Waitlist control|"The control group will be recruited from the waitlist for the Persistent Concussion Clinic and the Early Care Concussion Clinic at Holland Bloorview, in addition to partnered community medical offices and organizations.~For the control group, the research assistant will schedule the participants first session to obtain consent and provide youth/caregivers with week 1 questionnaires. At this time, the participants will be able to ask any questions related to the study. After eight weeks the control group will be asked to complete the post measures in order to mimic the length of the intervention. The control group will then be given the opportunity to enroll in one of the intervention arms of the Move&Connect study. They will then follow the same approved procedures for the intervention treatment group. Youth and their caregivers will be able to participate as waitlist controls without completing the intervention, if they choose."
89447129|NCT06145100||Patients with CVID and clinically significant non-cirrhotic portal hypertension|Patients with CVID and clinically significant non-cirrhotic portal hypertension (indicated by the presence of ascites or esophageal varices / portal-hypertensive gastropathy).
89447130|NCT06145087|Placebo Comparator|Placebo|The placebo is provided together with the placebo by AgeLess Sciences LLC, a Public Benefit Corporation.
89447131|NCT06145087|Experimental|"NOVOS Core supplement"|"The NOVOS Core supplement is a commercially available product and has 12 ingredients. It was developed and is provided together with the placebo by AgeLess Sciences LLC, a Public Benefit Corporation."
89447132|NCT06145061||POI patients|POI patients:1.meet the diagnostic criteria for POI:POI diagnostic criteria refer to the 2016 European Society for Reproductive Medicine POI guidelines:Age < 40 years; Oligomenorrhea or amenorrhea for at least 4 months; Two measurements (on day 2-4 of the menstrual cycle, at least 4 weeks apart)Follicle Stimulating Hormone（FSH） > 25 IU/L and meet the above three requirements.2.18 years old ≤ age < 40 years old, gender female; 3.They are conscious and able to communicate normally.4.Provide recent transvaginal ultrasound or pelvic color Doppler ultrasound examination report to determine the menstrual cycle.5.Those who understand and are willing to comply with the study protocol and sign the informed consent form.
89447133|NCT06145061||healthy subjects|Healthy subjects:1.Healthy subjects who can provide physical examination report within the past 1 year and have routine physical examination by the investigator, and confirm that they have no serious underlying diseases such as reproductive system, urinary system, blood, endocrine system and nervous system;2.Currently no symptoms of oligomenorrhea or amenorrhea;3.18 years ≤ age < 40 years, female;4.Those who understand and are willing to comply with the study protocol and sign the informed consent form.
89447134|NCT06145022|Experimental|intervention group|Once a week for 10 weeks with a circumference of 60 hours with mindfulness-based stress reduction and further process of the Mind / body medicine.
89014221|NCT05629741|Experimental|CMTX-101 2.5 mg/kg|CMTX-101 will be administered as a single IV infusion over 60 minutes.
89014222|NCT05629741|Experimental|CMTX-101 5 mg/kg|CMTX-101 will be administered as a single IV infusion over 60 minutes.
89014223|NCT05629741|Experimental|CMTX-101 15 mg/kg|CMTX-101 will be administered as a single IV infusion over 60 minutes.
89014224|NCT05629741|Experimental|CMTX-101 30 mg/kg|CMTX-101 will be administered as a single IV infusion over 60 minutes.
89014225|NCT05629741|Placebo Comparator|CMTX-101 0 mg/kg|Placebo will be administered as a single IV infusion over 60 minutes
89014227|NCT05610644|Active Comparator|TRF of RDA|A time-restricted model of consumption of the RDA of protein/day.
89014228|NCT05610644|Active Comparator|TRAD of RDA|A typical American dietary ingestion pattern of the RDA of protein/day.
89014229|NCT05610644|Experimental|TRF of 2RDA|A time-restricted model of consumption of twice the RDA of protein/day.
89447135|NCT06145022|Active Comparator|waitlist control group|A unique education unit within the scope of 1,5 hours on the influence of lifestyle factors on the disease and self-help materials for the independent training. After the follow-up measurement opportunity to participate in the program.
89447136|NCT06145009|Experimental|Time Restricted Eating|Participants will limit their eating (all food and caloric beverages) to an eating window of 10 hours per day for 4 weeks. The eating window must end by 8pm. Water and non-caloric beverages are allowed outside of the eating window. No other changes are required to the types or total amount of food eaten.
89447137|NCT06144996||Non-CF Bronchiectasis Patients with or without NTM|Patients over the age of 18 with non-CF Bronchiectasis with or without Nontuberculosis Mycobacteria (NTM).
89014230|NCT05610644|Experimental|TRAD of 2RDA|A typical American dietary ingestion pattern of twice the RDA of protein/day.
89014231|NCT05610527|Active Comparator|Hormonal contraception users|Females with inflammatory bowel disease who use hormonal contraception (combination oral contraceptives, the etonogestrel implant, or the levonorgestrel intrauterine device)
89014232|NCT05610527|Other|Naturally cycling participants|Females with inflammatory bowel disease who do not use hormonal contraception and have regular menstrual cycles (self or partner permanent contraception, copper IUD, abstinence, barrier methods, and fertility awareness methods)
89014233|NCT05609968|Experimental|Pembrolizumab + Sacituzumab Govitecan|Participants receive sacituzumab govitecan 10mg/kg intravenous (IV) infusion once weekly on Day 1 and Day 8 of a continuous 21-day cycle until progressive disease (PD) requiring discontinuation, unacceptable toxicity, withdrawal of consent, or death. Participants receive pembrolizumab 200mg IV infusion on Day 1 every 3 weeks (Q3W) for up to 35 cycles (each cycle length = 21 days).
89014234|NCT05609968|Experimental|Pembrolizumab|Participants receive pembrolizumab 200mg IV infusion on Day 1 Q3W for up to 35 cycles (each cycle length = 21 days).
89014235|NCT05608993|Experimental|High Intensity|Community-based clinics and/or urgent care centers that are assigned to the high intensity arm will receive the high intensity intervention.
89014236|NCT05608993|Experimental|Low Intensity|Community-based clinics and/or urgent care centers that are assigned to the low intensity arm will receive the low intensity intervention.
89023543|NCT05181735|Experimental|Arm A (Luspatercept alone)|Patients will receive Luspatercept 1mg/kg (every 3 weeks) with titration up to max of 1.75mg/kg, subcutaneously on day 1 of each 21 day cycle (every three weeks).
89447138|NCT06144996||Nontuberculosis Mycobacteria (NTM)|Patients over the age of 18 with Nontuberculosis Mycobacteria (NTM)
89447139|NCT06144983|Experimental|Alvogyl paste|Application of 0.2 gm of Alvogyl paste inside the extraction socket filling it entirely, and suturing the flap interrupted suture following impacted mandibular third molar surgery.
88932341|NCT03556826|Experimental|Social Value Learning|For each child, two faces, randomly selected from the pool of four faces, will be assigned the high-value (HV) status and the other two the low-value (LV) status. Value status will be randomized between the faces and children and all four faces will have the same probability of being assigned HV or LV across all participants. A gaze fixation on a HV face will always activate a dynamic display and the face will smile brightly. A gaze fixation on a LV face will always result in no change to its display. Effects of training will be tested one day (efficacy) and one month (maintenance) after training. During each of the follow-up assessments, each child will first undergo the Laboratory Selective Attention (LSA) task to assess if they retained value-face associations from the training sessions, followed by the Real-World Selective Attention (RWSA) task to evaluate generalization.
88932342|NCT03551691|Active Comparator|Treatment Arm|Subjects will take omeprazole 40mg daily for 28 days, then undergo assessments of fat absorption.
88932343|NCT03551691|Placebo Comparator|Placebo Arm|Subjects will take a placebo daily for 28 days, then undergo assessments of fat absorption.
88932344|NCT03537976|Other|Static Images and Facial Videos|2D and 3D still and video images obtained from each patient before surgery.
88932345|NCT03508518|Experimental|Shared care device in psychiatry (DSPP)|System focused on collaboration between general medicine (GP) and psychiatry, offering psychiatric assessment consultations and guidance for patient addressed by his/her GP. Referrals are made to the GP with support for care or the patient can be oriented to routine psychiatric care.
88932346|NCT03508518|Active Comparator|Care as usual|"Patient will have usual care :~Psychiatric care available in the Haute Garonne: psychiatric consultation by a liberal psychiatrist or by a psychiatrist working in public health center"
88932347|NCT03508427|Experimental|Toi Même plus treatment as usual|"One-Arm study Intervention: Toi Même self-monitoring smartphone application plus treatment as usual which includes pharmacological and/or psychological treatment.~Tool: Toi Même mobile app"
88932348|NCT03501303|Experimental|No touch|No touch technique. Patients are randomized to no touch vein harvesting. The technique is used as routine in Medical care by some hospitals.
88932349|NCT03501303|Other|Control|Control technique. Patients are randomized to Control vein harvesting. The technique is used as routine in Medical care.
88932350|NCT03494881|Experimental|Treatment Arm|This is an open-label pilot investigation and all study participants are assigned to active treatment. There is no placebo arm in this study.
88932351|NCT03493425|Active Comparator|Arm A (surgery, IMRT, cisplatin, carboplatin)|Patients undergo standard of care surgery. Beginning 4-6 weeks after surgery, patients undergo image guided IMRT QD for 5 fractions per week for 30 fractions. Patients with positive margins/positive ECS in lymph nodes undergo image guided IMRT QD for 5 fractions per week for 30 fractions and cisplatin IV over 1-2 hours or carboplatin IV over 30 minutes (for patients who are ineligible to receive cisplatin) weekly for 6 weeks in the absence of disease progression or unacceptable toxicity.
88932352|NCT03493425|Experimental|Arm B (docetaxel, cisplatin, carboplatin, surgery, IMRT)|Patients receive docetaxel IV over 1 hour and cisplatin IV over 1-2 hours on day 1. Patients who are ineligible to receive cisplatin receive carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgery no later than 6 weeks following the last dose of chemotherapy. Beginning 4-6 weeks after surgery, patients undergo image guided IMRT QD for 5 fractions per week for 30 fractions. Patients with positive margins/positive ECS in lymph nodes undergo image guided IMRT QD for 5 fractions per week for 30 fractions and cisplatin IV or carboplatin IV weekly for 6 weeks in the absence of disease progression or unacceptable toxicity.
88932353|NCT03490929|Experimental|Contrast-enhanced ultrasound arm|contrast-enhanced ultrasound
88932354|NCT03477058|Experimental|WO 3308 cosmetic product for topical use|WO 3308 is used to treat acute or chronic pruritus
88932355|NCT03468634|Experimental|Adenocarcinoma|patients diagnosed with adenocarcinoma
88932356|NCT03468634|Experimental|Squamous cell cancer|patients diagnosed with squamous cell cancer
88932357|NCT03468634|Experimental|Other|patients diagnosed with another condition
88932358|NCT03468634|Experimental|Barrett's oesophagus|patients diagnosed with Barrett's oesophagus
88932359|NCT03468634|Experimental|Low-grade dysplasia|patients diagnosed with low-grade dysplasia
88932360|NCT03468634|Experimental|High-grade dysplasia|patients diagnosed with high-grade dysplasia
89447140|NCT06144983|Experimental|Cholrhexidine gel|Application of 1 ml of Chlorhexidine gel inside the extraction socket filling it entirely, and suturing the flap interrupted suture following impacted mandibular third molar surgery.
89447141|NCT06144983|No Intervention|control|no dressing material was applied following the impacted mandibular third molar surgery.
89447142|NCT06144970|Active Comparator|Active Treatment 1|Low dose TG-C 1.5 x 10e6 cells
89447143|NCT06144970|Active Comparator|Active Treatment 2|Middle dose TG-C 5.0 x 10e6 cells
89447144|NCT06144970|Active Comparator|Active Treatment 3|High dose TG-C 1.5 x 10e7 cells
88932361|NCT03468634|Experimental|Indefinite for dysplasia|patients where the diagnosis is unclear
88932362|NCT03468634|Experimental|no dysplasia|patients not diagnosed with any cancer
88932363|NCT03451123|Experimental|FET-PET/MRI|O-(2-[F-18]FET)-L-tyrosine (FET) for brain PET/MRI
89447145|NCT06144970|Sham Comparator|Sham Control|single subcutaneous injection of normal saline
89447146|NCT06144931|No Intervention|Control Group|Patients in this group will be operated under spinal anesthesia
89447147|NCT06144931|Active Comparator|PENG Group|Patients in this group will undergo PENG block guided by ultrasound then spinal anesthesia will performed
89447148|NCT06144905||Anorexia nervosa (AN) group|Female in-patients with anorexia nervosa, age 16-50 years with BMI below 18.5 kg/m2.
89447149|NCT06144905||Heathy control (HC) group|Female healthy controls, age 16-50 with normal to mild overweight (18.5 ≤ BMI< 27 kg/m2). .
89447150|NCT06144879|Experimental|the double-rod group|posterior spinal corrective surgery with osteotomy (two rods without dual-headed screw)
89447151|NCT06144879|Experimental|the three-rod group|posterior spinal corrective surgery with osteotomy (three rods with one dual-headed screw)
89447152|NCT06144879|Experimental|the four-rod group|posterior spinal corrective surgery with osteotomy (four rods with two dual-headed screws)
89200459|NCT00969514||Robotic cystectomy|Patients undergoing robotic laparoscopic cystectomy at Beaumont Hospital-RO
89447153|NCT06144814|Experimental|Hyaluronic acid|The objective of this randomized controlled trial was to compare the effect of Hyaluronic acid and Estradiol and to determine the effect on VHI.
89447154|NCT06144814|Active Comparator|Estradiol|Secondary objective was to investigate the effect of Hyaluronic acid to VVA/GSM on symptoms.
89447155|NCT06144801|Experimental|CoolSense Group|The responsible researcher carried out the application of the CoolSense device and filled out the patient information form before the arteriovenous fistula cannulation. Meanwhile, the application of the VCS and GCS was conducted both before and after the CoolSense device's application, with the latter occurring after the arteriovenous fistula cannulation. The nephrology charge nurse was responsible for these measurements, using a single device located at the patient's bedside.
89447156|NCT06144801|No Intervention|Control Group|Patients in the control group underwent routine HD arteriovenous fistula cannulation and received HD treatment following the hospital's established protocol. Data collection tools were only administered to the participants before and after the study.
89447157|NCT06144788|Experimental|JP-2266 Low-dose|Subjects take the investigational products once a day for 12 weeks.
89447158|NCT06144788|Experimental|JP-2266 High-dose|Subjects take the investigational products once a day for 12 weeks.
89447159|NCT06144788|Experimental|placebo|Subjects take the investigational products once a day for 12 weeks.
89447160|NCT06144775||Children with autism spectrum condition|Thirty ASC children with medium-high functioning, aged 7 to 13 years, IQ > 80, in the absence of motor deficits due to another clinical condition.
89447161|NCT06144775||Children with typical development|Thirty TD children, aged 7 to 13 years, IQ > 80, in the absence of motor deficits due to clinical condition.
89447162|NCT06144736|Experimental|Low risk|"Criteria for low risk:~Absence of high risk criteria~Previous carboplatin therapy post orchiectomy~Exclusion of malignancy in the RPLND histology"
89447163|NCT06144736|Experimental|High risk|"Criteria for high risk:~Clinical stage II at initial diagnosis~Primary tumor > 4 cm~Infiltration of the rete testis in the primary tumor"
89447164|NCT06144723|Experimental|HS-20105 Phase Ia (Dose escalation)|Patients with advanced solid tumors will be enrolled and receive HS-20105 of various dose strengths until the end of the study in the absence of unacceptable toxicities and disease progression.
88932364|NCT03429582|Active Comparator|Standard C02 Cryotherapy|Standard therapy using carbon dioxide for freezing of tissue
88932365|NCT03429582|Experimental|Single Tip Thermoablation|Thermoablator outfitted with a 19mm conical tip
88932366|NCT03429582|Experimental|Multiple Tip Thermoablation|Thermoablator outfitted with detachable probes
88932367|NCT03382145||postmenopausal bleeding women|Retrospective review on outcome of One stop Postmenopausal bleeding clinic in New Territorial Eastern Cluster, Hong Kong. Single group study, no intervention.
88932368|NCT03373383|Experimental|Padsevonil dosing regimen 1|Subjects will be randomized to receive a combination of tablets of Padsevonil and Placebo (as appropriate) to maintain the blinding.
88932369|NCT03373383|Experimental|Padsevonil dosing regimen 2|Subjects will be randomized to receive a combination of tablets of Padsevonil and Placebo (as appropriate) to maintain the blinding.
88932370|NCT03373383|Experimental|Padsevonil dosing regimen 3|Subjects will be randomized to receive a combination of tablets of Padsevonil and Placebo (as appropriate) to maintain the blinding.
88932371|NCT03373383|Experimental|Padsevonil dosing regimen 4|Subjects will be randomized to receive a combination of tablets of Padsevonil and Placebo (as appropriate) to maintain the blinding.
88932372|NCT03373383|Placebo Comparator|Placebo|Subjects randomized to the placebo group will receive a combination of several Placebo tablets to maintain the blinding.
88932373|NCT03320018|Experimental|Hydrogen/Minocycline|"Hydrogen will be infused into aqueous solution (normal saline or water) at as high a concentration as possible (saturation = 1.6 ppm), and administered intravenously or orally respectively, TID for 3 days.~Similarly, Minocycline will be administered either i.v. or p.o. once daily for 5 days."
88932374|NCT03320018|Placebo Comparator|Placebo Hydrogen/Placebo Minocycline|Normal saline will be substituted for both Hydrogen and Minocycline for intravenous administration. Water will be substituted for hydrogen when administered p.o., and placebo capsules will be substituted for minocycline.
88932375|NCT03306082|Experimental|Image-guided Cochlear Implant Programming (IGCIP)|Cochlear implant programming using IGCIP.
88932376|NCT03276559|Experimental|Randomized controlled trial EMPOWER arm|"The EMPOWER arm includes six 15 minute modules delivered in a 1-on-1 format with the same interventionist, and 2 boosters (approximately 45 minutes each) conducted by phone.~Subjects who meet eligibility criteria will receive up to 4 sequential assessments before and after the EMPOWER intervention within 3 months conducted in person and by phone."
88932377|NCT03276559|Placebo Comparator|Randomized controlled trial Enhanced usual care arm|"The usual care arm indicates regular ICU support for informal caregivers (i.e. social work, chaplaincy) as recorded in the patient's medical record, a general information packet for informal caregivers, and a site-specific resource list.~Subjects who meet eligibility criteria will receive up to 4 sequential assessments before and after the usual care within 3 months conducted in person and by phone."
88932378|NCT03276559|Experimental|Open-trial phase arm|The open-trial phase arm includes 10 participants who all received EMPOWER. Data from the open trial of 10 surrogate decision-makers will identify tactical and measurement issues involved in the delivery and outcomes measurements used in EMPOWER.
88932379|NCT03276559|No Intervention|Manual refinement phase arm|This phase involves obtaining feedback about the EMPOWER intervention manual using qualitative analysis from 15 stakeholders.
88932380|NCT03276559|Experimental|Open trial COVID-19 phase arm|The COVID-19 open trial phase arm did not include randomization or control arm. All participants received the EMPOWER intervention. Assessments will occur pre-intervention, immediately post-intervention, and then 1-month and 3-months from post-intervention assessment.
88932381|NCT03271034|Experimental|Baseline Lipedema characterization|Body composition and Fat distribution, adipose tissue biology, metabolic and immune function in women with Lipedema. Participants will receive a low-calorie diet therapy in the form of low calorie meals or shakes.
88932382|NCT03255577|Experimental|Sentinel Lymph Node Biopsy (SLNB)|The patients will undergo SLNB with dual tracer mapping using technetium-99m sulfur colloid and isosulfan blue dye, as is standard practice at our institution for cN1 patients. Than the SLNB procedure will be performed
88932383|NCT03250975|Experimental|Medical Therapy|medical therapy group consisting of azithromycin 250 mg and budesonide 0.5 mg for 14 days
88932384|NCT03250975|Placebo Comparator|Placebo Control|Placebo control medication for 14 days
88932385|NCT03230318|Experimental|derazantinib|Oral administration
88932386|NCT03191162|Active Comparator|B300/60|Benznidazole 300mg/day p.o. divided in two doses for 60 days
88932387|NCT03191162|Experimental|B150/60|Benznidazole 150mg/day p.o. divided in two doses for 60 days
88932388|NCT03191162|Experimental|B400/15|Benznidazole 400mg/day p.o. divided in two doses for 15 days
88932389|NCT03169972||Previously treated patients (PTPs)|PTPs: patients who had 4 or more days to other Factor VIII (FVIII) products
88932390|NCT03169972||Previously untreated patients (PUPs)|PUPs: patients who had 3 or less previous exposure days to other products
88932391|NCT03132337||Stem Cell Transplant|Serial Blood Draws
88932392|NCT03090633|Experimental|Fetoscopy|All participants will undergo fetoscopic repair of fetal spina bifida.
88932393|NCT03085316|Experimental|Investigational Device|Patient who meets eligibility to be implanted with the St. Jude Medical Infinity™ Implantable Pulse Generator System (P140049), St. Jude Medical Infinity™ Deep Brain Stimulation (DBS) Directional Lead and Extension (P140009), Swift-Lock™ Anchor (K092371), Butterfly anchor (P140009), manufactured by St. Jude Medical, Inc.
89447165|NCT06144723|Experimental|HS-20105 Phase Ib (Dose expansion)|Depending on data obtained from the dose escalation, dose expansion may proceed with multiple cohorts in subjects with advanced solid tumors. Patients enrolled will receive HS-20105 until the end of the study in the absence of unacceptable toxicities and disease progression. The recommended doses from the dose escalation will be further explored.
89447166|NCT06144697|Experimental|Part A: Single Ascending Dose (SAD) [BMS-986465 or placebo]|
89447167|NCT06144697|Experimental|Part B: Multiple Ascending Dose (MAD) [BMS-986465 or placebo, Pegasys]|
89447168|NCT06144697|Experimental|Part C: MAD in Japanese ethnicity [BMS-986465 or placebo]|
89447169|NCT06144697|Experimental|Part D: Food/Formulation/pH Effects [BMS-986465, Famotidine]|
89447170|NCT06144658|Experimental|Augmented Reality Headset Usability|In this arm, participants tested the functionality and usability of the headset (a Microsoft Hololens 2 or a Varjor XR3)
89447171|NCT06144619||Intermediate risk group (no-surgery)|Participants diagnosed with pre-biopsy mpMRI.
89447172|NCT06144619||High-risk group (surgery)|Participants who had radical prostatectomy (RP) with (or with-out) mpMR imaging.
89447173|NCT06144580||Intervention|Community Health and Wellbeing Worker + usual care
89447174|NCT06144580||Control|Usual care
89447175|NCT06144528||Children with autism spectrum condition|Thirty Autism Spectrum Disorder (ASD) children with medium-high functioning, aged 4 to 13 years, IQ > 75, in the absence of motor deficits due to another clinical condition.
89447176|NCT06144450|Experimental|Intervention Group|The presented modules will be made accessible to mothers in the experimental group through a website. The modules will be completed in order and the necessary forms and follow-ups will be completed at the end of each module.
89447177|NCT06144450|No Intervention|Control Group|No intervention will be made in the control group.
89447178|NCT06144437||study group|All participants included will be in one study group.
89447179|NCT06144372|Other|Electroconductive Type|Sonolith i-move® shockwave lithotripter (EDAP, Lyon, France)
89447180|NCT06144372|Other|Electrohydraulic Type|Rifle lithotripter (HNT Medical, Seoul, Korea)
89447181|NCT06144359|Experimental|concussed patients|"Patients will be included :~Sports patients with concussion in sport,~Consultation with Sports Medecine within 7 days of concussion.~affiliated to a social security scheme."
89447182|NCT06144359|Experimental|Control subjects|"major case matched subjects by sex and age (± 5 years).~affiliated to a social security scheme.~written consent."
89447183|NCT06144346|Active Comparator|Standard of Care|systemic and palliative treatment according to physician discretion
89447184|NCT06144346|Experimental|Metastases Directed Therapy|SABR for all metastatic sites followed by systemic treatment for 6 months
89447185|NCT06144346|Experimental|Locoregional Treatment of the Primary|patients who respond to MDT and ST will be randomized to undergo loco-regional treatment or not
89447186|NCT06144333|Other|Observational arm|
89447187|NCT06144307||External Oblique Fascial Plan Block|
89447188|NCT06144307||Subcostal Transversus Abdominis Plan Block|
89447189|NCT06144307||Control|
88932394|NCT03080883|Experimental|Group I (lower dose apixaban)|Patients receive lower dose apixaban PO BID for 365 days.
89447190|NCT06144190||Japan|Preterm infants born at 28 to 31 gestational weeks in 2020-2021 in a Level IV NICU in Japan
89447191|NCT06144190||Finland|Preterm infants born at 28 to 31 gestational weeks in 2020-2021 in a Level III NICU in Finland
89447192|NCT06144138|Experimental|Breathing Exercises followed by Meditation|Breathing exercises and Meditation taught by Prasanna Wellness, a non-profit organization, helps dissolve stress and create a proper system in the mind. These breathing exercises include slow deep breaths and rapid breaths and are followed by meditation. Participants will receive three weekly online instructions (90 minutes each) by trained instructors in addition to standard care. Weekly 60 minutes follow-ups will include 10 minutes of breathing exercises followed by 33 minutes of guided meditation practice, and then focus on participants' experiences with breathing exercise followed by meditation during the week, additional observations, and a review of relevant knowledge to support their home practice.
89447193|NCT06144138|No Intervention|Treatment as Usual|The usual standard of care for patients with glaucoma includes starting them on first line of drugs. Participants will be initiated and maintained on appropriate dosages of such medications as part of standard of care. The usual standard of care also includes an ophthalmic examination measuring best-corrected Snellen VA and pinhole acuities and a follow-up visit once a year.
88932395|NCT03080883|Experimental|Group II (higher dose apixaban)|Patients receive higher dose apixaban PO BID for 365 days.
89447194|NCT06144125|Active Comparator|fresh frozen plasma|according to the Rotational thromboelastometry (ROTEM) test, CT-EXTEM prolongation, fresh frozen plasma transfusion (FFP) is performed
88932396|NCT03060291|Experimental|Web/ Mobile-only|Participants will complete the FCU online independently, without the help of a coach.
89447195|NCT06144125|Experimental|prothrombin complex concentrate|according to the Rotational thromboelastometry (ROTEM) test, CT-EXTEM prolongation, prothrombin complex concentrate (PCC) is administered
89447196|NCT06144112|Active Comparator|fresh frozen plasma|according to the Thromboelastography (TEG) test, CK r-time prolongation, fresh frozen plasma transfusion (FFP) is performed
89447197|NCT06144112|Experimental|prothrombin complex concentrate|according to the Thromboelastography (TEG) test, CK r-time prolongation, prothrombin complex concentrate (PCC) is administered
89447198|NCT06144073|Experimental|Intervention (Mandala art therapy) group|Students with premenstrual syndrome who were included in the mandala art therapy group by randomization method will be made to practice mandala.
89447199|NCT06144073|No Intervention|Control|Control group is the group without any intervention.
89447200|NCT06144060|Experimental|Treatment group A：HRS-8427|
89447201|NCT06144060|Experimental|Treatment group B：HRS-8427|
89447202|NCT06144060|Active Comparator|Imipenem and Cilastatin Sodium|
89447203|NCT06144047|Other|Epilepsy|33 participants with drug-resistant epilepsy will be implanted with the EEGTM SubQ device under local anaesthesia, and will collect 2-channel EEG data, as well as completing an electronic seizure diary, for 6 months
89447204|NCT06144034|Experimental|Epilepsy patients|1 and 3 quadrants got the same treatment and 2 and 4 got the same treatment. Air polishing with erythritol powder was used to remove biofilm and EMS ultrasonic scaler to remove calculus if present. also rubber cup and prophylaxis paste spearmint (Kemdent Works, Purton. Swindon, Wiltshire. SN5 4HT, UK). and EMS ultrasonic scaler to remove calculus if present.
89447205|NCT06144034|Experimental|Non-epileptic pateints|1 and 3 quadrants got the same treatment and 2 and 4 got the same treatment. Air polishing with erythritol powder was used to remove biofilm and EMS ultrasonic scaler to remove calculus if present. also rubber cup and prophylaxis paste spearmint (Kemdent Works, Purton. Swindon, Wiltshire. SN5 4HT, UK). and EMS ultrasonic scaler to remove calculus if present.
89447206|NCT06143982|Experimental|Brief Intensive Trauma Treatment|If allocated to the intervention group, participants follow the Brief Intensive Trauma Treatment (BITT).
89447207|NCT06143982|No Intervention|Waitlist control group|When allocated to the WLCG, participants receive BITT after a 3 months waiting period. The WLCG receives no care during the treatment phase (one week) of the intervention group. Besides this week the WLCG can undergo every treatment including EMDR and TF-CBT during the 3 months waiting period.
89447208|NCT06143969||EkoSonicTM Endovascular System (EKOSTM, Boston Scientific)|Patients hospitalized with acute intermediate-high risk PE treated with ultrasound-assisted, catheter-directed thrombolysis using EKOSTM.
89447209|NCT06143943||primary angle-closure glaucoma|
89447210|NCT06143943||narrow angle|
89447211|NCT06143930|Active Comparator|The control group (A) will receive therapeutic strengthening training program for lower extremities.|low intensity strengthening exercise program
89447212|NCT06143930|Active Comparator|The study group (B) will receive strengthening training with blood flow restriction|the same selected low intensity resisted exercise program as group (A) with blood flow restriction
89447213|NCT06143917|Experimental|parent-child sleep intervention|Participants in the intervention will receive both the standardized usual care and parent-child sleep education, heart rate variability biofeedback training, and counseling and support.
89447214|NCT06143917|No Intervention|Control|Participants in the control group will receive attention from the research nurse and the standardized usual care.
89447215|NCT06143904|Experimental|Treatment Period 1 -2|Single-dose Intravenous (IV) Genz-112638 Day 1 followed by single dose GenZ-112638 oral capsules Day 8
88932397|NCT03060291|Active Comparator|Web/mobile + coach|Participants will complete the FCU online and will be contacted by a family coach. The coach will conduct motivational interviewing and provide support to parents via phone. Participants in this condition will have contact with a coach at least 2 times.
89447216|NCT06143904|Experimental|Treatment Period 1-4|Single-dose Intravenous (IV) Genz-112638 Day 1; single dose GenZ-112638 oral capsules Day 8; oral capsule Genz-112638 Days 9-14; single dose [14C]-Genz-112638 oral solution Day 15
89447217|NCT06143865|Experimental|Closed aspiration group|Closed system aspiration is performed according to standard guidelines for patients.
89447218|NCT06143813|Active Comparator|Block|This group will receive standard of care + a selective nerve root block as part of the diagnostic work up.
89447219|NCT06143813|No Intervention|No-block|This group will receive standard of care.
89447220|NCT06143800|Experimental|retrieval + self-focused cognitive reappraisal|Participants in this arm will first accept a memory reactivation to open the reconsolidation window, then accept the self-focused cognitive reappraisal intervention.
89447221|NCT06143800|Experimental|retrieval + context-focused cognitive reappraisal|Participants in this arm will first accept a memory reactivation to open the reconsolidation window, then accept the context-focused cognitive reappraisal.
89447222|NCT06143800|Active Comparator|non-retrieval + self-focused cognitive reappraisal|Participants in this arm will directly accept the self-focused cognitive reappraisal intervention without memory reactivation.
89447223|NCT06143800|Active Comparator|non-retrieval + context-focused cognitive reappraisal|Participants in this arm will directly accept the context-focused cognitive reappraisal intervention without memory reactivation.
89447224|NCT06143787|Placebo Comparator|Treatment (T1)|Standard hemostatic measures + Placebo matching with Tranexamic Acid Oral Solution 5%
89447225|NCT06143787|Experimental|Treatment (T2)|Standard hemostatic measures + Tranexamic Acid Oral Solution 5%
89447226|NCT06143774|Experimental|TRX-920 Oral Gel|Dose escalation (escalation from 1, 2, 4, 8, 16, 30, 60, 90 mg TRX-920 Oral Gel)
89447227|NCT06143761||neoadjuvant chemoimmunotherapy+surgery|Patients who underwent neoadjuvant chemoimmunotherapy before surgery
89447228|NCT06143761||surgery|Patients who accepted the surgery alone
89447229|NCT06143735|Experimental|experimental group（primary prevention）|Efgbemalenograstim alfa, 20 mg, subcutaneous injection, administered 48±4 hours after the completion of each chemotherapy cycle.
89447230|NCT06143735|Active Comparator|control group（secondary prevention）|Efgbemalenograstim alfa, 20 mg, subcutaneous injection, administered 48±4 hours after the completion of the next chemotherapy cycle if ≥ Grade 3 ANC reduction occurs in the preceding chemotherapy cycle.
89447231|NCT06143722|Experimental|Simultaneous radiotherapy group|
89447232|NCT06143722|Active Comparator|Sequential radiotherapy group|
89447233|NCT06143709||Precision PCI Prospective Cohort|Patients who have undergone PCI and clinical CYP2C19 genotyping
89447234|NCT06143696|Experimental|the experimental group|Qingxin Zishen decoction, oral administration, 1 dose a day, 2 times a day. For 28 days of medication, every 28 days. Observation time for 3 courses.
89447235|NCT06143696|Active Comparator|the control group|Femoston, oral, 1 each time, once a day. For 28 days of medication, every 28 days. Observation time for 3 courses.
89447236|NCT06143631|Experimental|Letrozole|Oral letrozole 2.5mg/day
89447237|NCT06143631|Placebo Comparator|Placebo and Letrozole|Placebo capsule for 12 weeks; Oral letrozole 2.5mg/day for 12 weeks
89447238|NCT06143605||salvage treatment group|patients with salvage treatment after endoscopic resection were diagnosed as having positive resection margin status
89447239|NCT06143605||without salvage treatment group|patients without salvage treatment after endoscopic resection were diagnosed as having positive resection margin status
89447240|NCT06143579|Experimental|Treatment|FOLFOX-HAIC + Lenvatinib + Envolizumab
89447241|NCT06143553|Experimental|Paclitaxel Polymeric Micelles for Injection|300mg/m2 of Paclitaxel Polymeric Micelles for Injection is intravenously administrated for ≥ 3 hours without special infusion device. The frequency of administration is once every 3 weeks (Q3W), and 3 weeks constitutes a treatment cycle.
89447242|NCT06143553|Active Comparator|The Doctor chooses the treatment（TPC）|"Control Group：The Doctor chooses the treatment（TPC）：Eribulin Mesilate injection；Capecitabine Tablets；Gemcitabine Hydrochloride for Injection；Vinorelbine Tartrate Injection；Paclitaxel (albumin-bound).~Eribulin Mesilate injection：on days 1 and 8 of the 21-day cycle, 1.4 mg/m2 , intravenous administration; Capecitabine Tablets: On days 1 to 14 of the 21-day cycle, 1000-1250mg/m2，oral administration, twice a day (once in the morning and once in the evening; Total daily dose 2000-2500mg/m2); Gemcitabine Hydrochloride for Injection: On days 1, 8 and 15 of the 28-day cycle, 800-1200mg/m2, intravenous administration; Vinorelbine Tartrate Injection: Every first day of the week, 25mg/m2，intravenous administration; Paclitaxel (albumin-bound): On day 1 of the 21-day cycle, 260mg/m2，intravenous administration for more than 30 minutes. Three weeks constituted one course of treatment."
89447243|NCT06143527|Experimental|Treatment Group (AlloRx)|Intravenous infusion
89447244|NCT06143501||Allo-HSCT Recipients|
89447245|NCT06143501||Healthy Volunteers|
89447246|NCT06143475|Experimental|FPS group|"In the FPS group, in addition to same physical therapy ran in the control group, the patient received FPS from the apparatus Vibramoov (Techno Concept, France) on their upper limbs. The patients received in total 12 Vibramoov sessions of 30 minutes, 5 times a week."
89447247|NCT06143475|Active Comparator|Conventional therapy group|In the conventional therapy group patients received sessions of traditional physical therapy: individual therapy sessions including exercises to strengthen muscles, stretching, reflex exercises for large, medium and small muscle groups of the upper limbs (ontogeny-oriented kinesiotherapy (OOKT), PNF - proprioceptive neuro-muscle facilitation, training and practice of functional rational self-service tasks). 12 sessions in total were realized 5 times a week and lasted 40 minutes each.
89447248|NCT06143462|Active Comparator|Group A: usual care (UC)|Group A (UC) will receive conventional medications.
89447249|NCT06143462|Experimental|Group B: vestibular rehabilitation treatment (VRT)|Group B (VRT) will receive outpatient VRT in combination with home practice based on conventional treatment.
89447250|NCT06143423|Experimental|AP026 (TQA2226) for injection Single administration dose (SAD)|AP026 (TQA2226) for injection, administered once.
89447251|NCT06143423|Placebo Comparator|AP026 (TQA2226) for injection matching placebo Single administration dose (SAD)|AP026 (TQA2226) for injection matching placebo, administered once.
89447252|NCT06143423|Experimental|AP026 (TQA2226) for injection Multiple administration dose (MAD)|AP026 (TQA2226) for injection, administered 4 times.
88932398|NCT03060291|No Intervention|Wait list control|"Participants in this condition will receive middle school as usual, meaning that they will continue to receive whatever services are normally provided by the middle school during the year of their participation in the study. Once their research participation is completed (i.e., after they complete their final follow-up survey), participants in this condition will be offered the opportunity to use the FCU-Online website if they wish, without the support of a coach. No additional data will be collected."
88932399|NCT03058627|No Intervention|TAVI only|TAVI is performed according to current guidelines and the choice of valve prosthesis is at the operators' discretion.
88932400|NCT03058627|Experimental|TAVI + FFR-guided complete revascularization|TAVI is performed according to current guidelines and the choice of transcatheter heart valve is at the operators' discretion. PCI is performed in any suitable lesion with diameter stenosis > 90% or FFR ≤ 0.80 in vessels ≥ 2.5 mm in diameter .
88932401|NCT03025035|Experimental|Pembrolizumab + Olaparib|This is an open-label, single-arm pilot study of pembrolizumab (study drug) in combination with Olaparib in 20 subjects with advanced BRCA mutation or HDR-defect associated breast cancer having progressed through at least a standard first line therapy.
88932402|NCT02956291|Experimental|Newly Diagnosed Brain Tumors|Participants with newly diagnosed brain tumors will undergo Magnetic Resonance Fingerprinting (MRF) scan along with their clinical scan, followed by standard of care surgery, radiation, and chemotherapy. Follow-up MRF scans will be performed to visualize recurrence.
88932403|NCT02956291|Experimental|Treated tumors with possible recurrence|Participants with treated brain tumors with possible recurrence will undergo Magnetic Resonance Fingerprinting (MRF) scan along with their clinical scan, followed by standard of care surgery, radiation, and chemotherapy. Follow-up MRF scans will be added to the repeat MRI studies as determined appropriate by the referring physician/primary care team.
88932404|NCT02953509|Experimental|Magrolimab + Rituximab, Phase 1b Dose Escalation|Participants with B-cell non-Hodgkin's lymphoma will receive 1 mg/kg magrolimab priming dose on Day 1 of Cycle 1 followed by weekly maintenance doses of 10, 20, 30, or 45 mg/kg on Days 8, 15, 22 for Cycle 1 and Days 1, 8, 15, and 22 for each cycle to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose and schedule (RP2DS) in combination with rituxumab 375 mg/m^2. Cycle length is 28 days.
88932405|NCT02953509|Experimental|Magrolimab + Rituximab, Phase 2 Indolent Lymphoma|Participants with indolent lymphoma will receive magrolimab based on RP2DS from Phase 1b portion of the study in combination with rituxumab 375 mg/m^2.
88932406|NCT02953509|Experimental|Magrolimab + Rituximab, Phase 2 Diffuse Large B-Cell lymphoma|Participants with diffuse large B-cell lymphoma (DLBCL) will receive magrolimab based on RP2DS from Phase 1b portion of the study in combination with rituxumab 375 mg/m^2.
88932407|NCT02953509|Experimental|Magrolimab + R-GemOx, Phase 1b Safety Dose Escalation Phase|Autologous stem cell transplant (or transplantation) ineligible DLBCL participants will receive 1 mg/kg magrolimab priming dose on Day 1 for Cyle 1 followed by maintenance doses of 30 or 45 mg/kg on Days 8, 11, 15, 22, and 29 for Cycle 1, every week for Cycle 2, and every 2 weeks for each cycle to determine maximum tolerated dose (MTD) + rituxumab 375 mg/m^2 + gemcitabine 1000 mg/m^2 + oxaliplatin 100 mg/m^2. Cycle length is 28 days.
89447253|NCT06143423|Placebo Comparator|AP026 (TQA2226) for injection matching placebo Multiple administration dose (MAD)|AP026 (TQA2226) for injection matching placebo, administered 4 times.
89447254|NCT06143397|Experimental|TTNS (Transcutaneous tibial nerve stimulation)|
89447255|NCT06143397|Experimental|PNS (Parasacral nerve stimulation)|
88932408|NCT02953509|Experimental|Magrolimab + R-GemOx, Phase 1b Dose Expansion Phase|Autologous stem cell transplant (or transplantation) ineligible DLBCL participants will receive magrolimab at a dose determined from Phase 1b Safety Dose-Escalation Phase in combination with rituxumab 375 mg/m^2 + gemcitabine 1000 mg/m^2 + oxaliplatin 100 mg/m^2.
88932409|NCT02939872|Experimental|DAPT|Dual antiplatelet therapy : aspirin and clopidogrel
88932410|NCT02939872|Active Comparator|Clopidogrel only|Clopidogrel monotherapy
88932411|NCT02803190|Experimental|ICG- integrated care group|Integraded Care Group
88932412|NCT02803190|Experimental|MTG- muscle training group|Muscle Traing Group
88932413|NCT02764801|Experimental|Contrast ultrasound arm|Patients receiving contrast-enhanced ultrasound for diagnosis of chemoembolization response.
88932414|NCT02723929|Experimental|Active Electrical Stim/Active Ultrasound|Subjects will undergo active low-intensity transcranial electrical stimulation in conjunction with active transcranial ultrasound for 20 minutes.
88932415|NCT02723929|Sham Comparator|Sham Electrical Stim/Sham Ultrasound|Subjects will undergo sham (placebo) low-intensity transcranial electrical stimulation in conjunction with sham transcranial ultrasound for 20 minutes.
88932416|NCT02670447||First episode of psychosis patients|Patients with schizophrenia will be studied in this clinical trial, and that have never received anti-psychotic treatment. They will perform an MRI.
88932417|NCT02647099|Active Comparator|Aspirin|One tablet acetylsalicylic acid (ASA) 160 mg, orally once daily for three years
88932418|NCT02647099|Placebo Comparator|Placebo|One tablet placebo orally once daily for three years
88932419|NCT02626715|Active Comparator|Reduced-Intensity Conditioning|"Campath (alemtuzumab), Droxia (hydroxyurea), Fludara (fludarabine), Alkeran (melphalan), Thiotepa (triethylenethiophosphoramide)~Trade Name (generic name)"
88932420|NCT02626715|Active Comparator|Myeloablative Conditioning|"Campath (alemtuzumab), Thiotepa (triethylenethiophosphoramide) , Fludara (fludarabine), Busulfex (busulfan)~Trade Name (generic name)"
88932421|NCT02593994||Onyx Drug Eluting Stent|
88932422|NCT02585622|Experimental|Bone marrow-derived Mesenchymal Stromal Cells|
88932423|NCT02585622|Placebo Comparator|Cryostor CS10|
88932424|NCT02531854|Experimental|ADXS11-001 + Pemetrexed|
88932425|NCT02531854|Active Comparator|Pemetrexed Only|
88932426|NCT02530658||Participants|"St. Jude patients with a diagnosed solid or liquid tumor (benign or malignant) and their biological parents or legally authorized representative.~Interventions: Study Introduction Visit, Informed Consent Visit, Informed Consent Follow-Up Visit, Return of Results Conversation, two Return of Results Follow-Up Visits, Tissue Sample (when available), Blood Sample or Skin Biopsy."
88932427|NCT02524834|Experimental|Endovascular Device Implantation|Endoluminal exclusion of thoracoabdominal lesion
88932428|NCT02487966|Experimental|Active tDCS and Active Mirror Therapy|Subjects will receive 20 minutes of active tDCS, while receiving 15 minutes of active Mirror Therapy.
88932429|NCT02487966|Experimental|Active tDCS and sham Mirror Therapy|Subjects will receive 20 minutes of active tDCS, while receiving 15 minutes of sham Mirror Therapy.
88932430|NCT02487966|Experimental|Sham tDCS and active Mirror Therapy|Subjects will receive 20 minutes of sham tDCS, while receiving 15 minutes of active Mirror Therapy.
88932431|NCT02487966|Sham Comparator|Sham tDCS and sham Mirrory Therapy|Subjects will receive 20 minutes of sham tDCS, while receiving 15 minutes of sham Mirror Therapy.
88932432|NCT02471690|Active Comparator|Oritavancin|IV -Single Dose - 1200 mg Oritavancin
88932433|NCT02471690|Placebo Comparator|Placebo|250 mL Dextrose 5% in Water
88932434|NCT02470702|Experimental|Oritavancin|Subjects randomized to oritavancin will receive four doses (Cohort 1) or eight doses (Cohort 2) of 1200 mg oritavancin, infused intravenously over 3 hours
88932435|NCT02470702|Placebo Comparator|Placebo|Subjects randomized to placebo will receive four doses (Cohort 1) or eight doses (Cohort 2) of 1000 mL D5W, infused intravenously over 3 hours
88932436|NCT02417714||Body CT group|100 subjects for a body CT
88932437|NCT02417714||Chest Ct Group|100 subjects for a chest CT
88932438|NCT02407145||PVDF retropubic midurethral sling|Women with urodynamic stress urinary incontinence having a retropubic polyvinylidene fluoride midurethral sling (DynaMesh®-SIS soft).
88932439|NCT02392442|Experimental|1 - Endotoxin|6 hour lavage post endotoxin
88932440|NCT02392442|Experimental|2 - Endotoxin|24 hour lavage post endotoxin
88932441|NCT02392442|Experimental|3 - Endotoxin|48 hour lavage post endotoxin
89447256|NCT06143397|Sham Comparator|Sham stimulation|
89447257|NCT06143384||Patients using Home Mechanical Ventilation (HMV)|Patients using Home Mechanical Ventilation (HMV), and registered in the Belgian agreement for HMV at 1/ the Citadelle hospital in Liège, Belgium and 2/HUB-Erasme hospital, Brussels, Belgium.
89447258|NCT06143345|Experimental|Intervention Group|Intervention participants will perform 12 sessions (3 sessions per week on alternate days) of supervised HIIT (cycling bouts eliciting 50-85% maximal heart rate) over 4 weeks. HIIT with Spin sessions will include a 5-min warm-up, then an interval-based workout phase with steady up-tempo cadences, sprints, and climbs (interspersed with recovery periods), followed by a 5-min cool down.
89447259|NCT06143345|Active Comparator|Control Group|Control participants will receive standard exercise recommendations (≥150 min of moderate-intensity physical activity per week distributed throughout the week with a minimum frequency of thrice a week).
89447260|NCT06143332|Experimental|Moderate-intensity continuous training|~50 min of constant-power output cycling, 3 x per week at 85% of gas exchange threshold
89447261|NCT06143332|Experimental|Heavy-intensity continuous training|30 min of constant-power output cycling, 3 x per week at 70% of the difference between gas exchange threshold and respiratory compensation point
89447262|NCT06143332|Experimental|High (severe)-intensity interval training|intervals; 4 x 4 min on - 3 min off at 115% of respiratory compensation point (work) and 50-70% gas exchange threshold (recovery)
89447263|NCT06143319||Recurrent low back pain|20 non-specific recurrent LBP patients, both experiencing a period of pain remission or a pain flare at the moment of testing, will be included in the current study.
89447264|NCT06143319||Chronic low back pain|20 participants experiencing non-specific chronic LBP will be included in the current study.
89447265|NCT06143319||Healthy volunteers|20 healthy participants, matched for age and Body Mass Index (BMI) with the participants experiencing chronic/recurrent low back pain or fibromyalgia will be included in the current study.
89447266|NCT06143319||Fibromyalgia|20 participants diagnosed with fibromyalgia will be included in the current study
89447267|NCT06143267|Experimental|Infusion of NST or placebo at different blood glucose levels|In a randomized, double-blind crossover design, participants will undergo six experimental days with controlled plasma glucose levels, consisting of two euglycemic, two hyperglycemic (around 8mmol/l), and two hypoglycemic (around 2.5mmol/l) days, with each pair of similar days involving the administration of either saline (placebo) or NST.
89447268|NCT06143215|Experimental|Two weeks revision group|Patients will be clinically revised in a 2-weeks basis
89447269|NCT06143215|Active Comparator|Four weeks revision group|Patients will be clinically revised in a 4-weeks basis
89447270|NCT06143215|Experimental|Six weeks revision group|Patients will be clinically revised in a 6-weeks basis
89447271|NCT06143202||Pediatric patients with hyperglycemia|Any pediatric patient admitted to the hospital and requiring an endocrine consult for frequent glucose monitoring and hyperglycemia management
89447272|NCT06143202||Nursing staff|Nursing staff providing medical care for pediatric patients enrolled in the study.
89447273|NCT06143189|Other|Control Group (CG)|Control Group participants were exposed to the normal hosting conditions of the hospital when receiving the usual chemotherapy treatment in ambulatory hospital setting.
89447274|NCT06143189|Experimental|Experimental Group (EG)|Experimental Group participants were exposed to the Hospital Clowns intervention plus the normal hosting conditions of the hospital when receiving the usual chemotherapy treatment in ambulatory hospital setting.
89447275|NCT06143176|Experimental|Stroke patients|
89447276|NCT06143137||Control group|Subjects in this group where randomized in the control group in the ReActiF-ICE study previously
89447277|NCT06143137||Therapy Group|Subjects in this group where randomized in the therapy group in the ReActiF-ICE study previously
89447278|NCT06143124|Active Comparator|Therapeutic arm|Classical triple therapy according to the antibiotic susceptibility testing (two antibiotics+PPI)+ Bismuth subcitrate for 7 days
89447279|NCT06143124|No Intervention|Control arm|Classical triple therapy according to the antibiotic susceptibility testing (two antibiotics+PPI) for 14 days
89447280|NCT06143111|Active Comparator|Flotrac Group|In this group,an arterial catheter was inserted preoperatively. An indwelling radial artery catheter was connected to the hemodynamic monitoring system (EV1000; Edward Lifesciences Corp., Irvine, CA, USA) via FloTrac™ (Edwards Lifesciences Corp.) sensors.
89447281|NCT06143111|Experimental|BioZ Group|In this group,haemodynamic parameters were collected simultaneously by the thoracic bioimpedance (BioZ.com™) monitoring.
89447282|NCT06143085|Experimental|Generalized periodontitis|Patients diagnosed with generalized periodontitis of different severities exhibiting periodontal pockets not exceeding 6mm.
89447283|NCT06143072||Part 1 of study|Women who have sustained an obstetric-related anal sphincter injury (grade 3 and 4 perineal tears) AND who are symptomatic of anal/faecal incontinence within the first five years following a vaginal delivery are eligible to participate, provided they have capacity to consent.
89447284|NCT06143072||Part 2 of study|Obstetricians (consultants) and urogynaecologists who are involved in and/or oversee the care of OASI patients' post-partum in the UK.
89447285|NCT06143007|Experimental|BB3008 monotherapy|The study is composed of fasted dose cohorts and fed dose cohort. BB3008 will be administered orally daily alone as monotherapy in all cohorts. In the fasted dose cohorts, the subjects will receive once daily of BB3008 monotherapy fasted across approximately 6 ascending dose levels. The starting dose is 80 mg/day. In the fed dose cohort, the subjects will receive once daily of BB3008 monotherapy in a fed condition. The dose selected for fed dose cohort must be deemed safe as assessed by safety monitoring committee (SMC).
89447286|NCT06142981|Experimental|Experimental group|Patients will receive three PRP sessions, where the patients received intravenous injections at four acupuncture points (stomach 36 and GB 34 on both sides) at the 1st, 2nd, and 3rd month.
89447287|NCT06142916|Experimental|MHLS|
89447288|NCT06142916|Active Comparator|CONTROL GROUP|
89447289|NCT06142903|Placebo Comparator|7 medically-tailored meals per week|Patients will be randomized to medically tailored dinner meals delivered to their homes for four weeks.
89447290|NCT06142903|Active Comparator|21 medically-tailored meals per week|Patients will be randomized to three medically tailored dinner meals each day delivered to their homes for four weeks.
89447291|NCT06142864||"-Case patients"|"-Case patients will be patients reporting at least one fall in the last 6 months."
89447292|NCT06142864||"-Control patients"|"-Control patients will be patients reporting no fall in the last 6 months."
89447293|NCT06142851||Women with superficial dyspareunia|Adult women, having sexual activity with or without vaginal penetration, suffering from superficial dyspareunia, whether or not managed by health professionals.
89447294|NCT06142838|Experimental|Intervention arm|Community pharmacist intervention
89447295|NCT06142838|No Intervention|Control arm|Usual care
89014237|NCT05608018|Other|Control Bluetooth|Participants receive a the same app as the intervention group, but the feature that notifies the teens parent when they are driving is turned off. They will self-report their smartphone communication while driving via periodic surveys. Participants will receive a Bluetooth device to keep in their primary vehicle for the duration of the study.
89014238|NCT05608018|Other|Intervention Bluetooth|Participant received the app with all features turned on, so the parent gets a notification when the teen is driving before they go to send a text message to the teen. They will self-report their smartphone communication while driving via periodic surveys. Participants will receive a Bluetooth device to keep in their primary vehicle for the duration of the study.
89014239|NCT05608018|Other|Control non-Bluetooth|Participants receive a the same app as the intervention group, but the feature that notifies the teens parent when they are driving is turned off. They will self-report their smartphone communication while driving via periodic surveys. Participants will not receive a Bluetooth device.
89014240|NCT05608018|Other|Intervention non-Bluetooth|Participant received the app with all features turned on, so the parent gets a notification when the teen is driving before they go to send a text message to the teen. They will self-report their smartphone communication while driving via periodic surveys. Participants will not receive a Bluetooth device.
89014241|NCT05607953|Experimental|SD-101|Two doses of SD-101 given over two cycles via pancreatic retrograde venous infusion (PRVI) using the PEDD method of administration.
89014242|NCT05601206|Experimental|Stepped collaborative care intervention|The 'Stepped Collaborative Care Intervention' includes at least biweekly contact from a care coordinator by phone and face to face visits occurring approximately every 2 months, and 24 hour 7 day a week access to a website that was specifically designed during the pilot study for advanced cancer patients from socioeconomically disadvantaged backgrounds.
89014243|NCT05601206|Active Comparator|Enhanced Usual Care|Patients randomized to the 'Enhanced Usual Care' arm receive their usual care from their medical team. However, if the patient scores in the clinical range on one or more of the three symptoms s/he will receive education about the symptom and be referred to the appropriate health care provider for further treatment in their community. The care coordinator will follow up with the patient after 3 weeks to assess barriers to treatment and assist further with accessing treatment if needed.
89014244|NCT05599984|Experimental|Part 1: ABBV-706 Monotherapy Dose Escalation|Participants will receive escalating doses of ABBV-706 until doses for optimization are determined, as part of an approximately 1 year treatment period.
89014245|NCT05599984|Experimental|Part 2: ABBV-706 Monotherapy Dose Optimization and Expansion|Participants with small cell lung cancer will receive varying doses of ABBV-706 in a randomized manner until the recommended phase 2 dose (RP2D) is achieved, as part of an approximately 1 year treatment period..
89014246|NCT05599984|Experimental|Part 3a: ABBV-706 + Budigalimab|Participants will receive ABBV-706 in combination with budigalimab, as part of an approximately 1 year treatment period.
89014247|NCT05599984|Experimental|Part 3b: ABBV-706 + Platinum Chemotherapy|Participants will receive ABBV-706 in combination with carboplatin or cisplatin, as part of an approximately 1 year treatment period.
89200460|NCT00976144|Experimental|GSK573719, GW642444, GSK573719+GW642444, placebo|This is a four-way cross-over study. Subjects, healthy volunteers, will receive a single dose of GSK573719 (500ug), GW642444 (50ug), GSK573719 (500ug)+GW642444 (50ug) administered concurrently, or placebo at each of the four treatment periods. There is a minimum wash-out period of seven days between doses. On enrolment into the study, subjects will be assigned to one of four treatment sequences which are based on a Williams design in accordance with the randomization schedule generated by GSK prior to study start.
89200461|NCT00868881||1|Blood Pressure poorly controlled in the previous year and poorly controlled at the inclusion in the study
89200462|NCT00868881||2|Blood Pressure poorly controlled in the previous year and well controlled at the inclusion in the study.
89200463|NCT00868881||3|Blood Pressure well controlled in the previous year and well controlled at the inclusion in the study
89200464|NCT00868881||4|Blood Pressure well controlled in the previous year and poorly controlled at the inclusion in the study
89200465|NCT00868881||5|Blood Pressure well controlled in the previous year independently of the level of control at the inclusion.
89200466|NCT00868881||6|Blood Pressure poorly controlled in the previous year independently of the level of control at the inclusion.
89200467|NCT04008472|Experimental|Telemedecine|Patients benefiting from telemedicine
89200468|NCT04008472|No Intervention|Control|routine care without telemedecine
89200469|NCT00969592|Active Comparator|insulin glulisine, insulin aspart|insulin glulisine administration during first glucose clamp, insulin aspart administration during second glucose clamp
89200470|NCT00969592|Active Comparator|insulin aspart, insulin glulisine|insulin aspart administration during first euglycemic clamp, insulin glulisine administration during second clamp
89200471|NCT00368641|Experimental|Intervention|peritoneal dialysis
89200472|NCT00368641|No Intervention|Standard of Care|
89200473|NCT00976222|Other|1 Arm Ranibizumab|
89200474|NCT00976300|Experimental|Cyclosporine A|Cyclosporine arm (CyA group) consisted of oral cyclosporine A (CyA) 4-5mg/kg/day (given in two divided doses) for 9 months followed by gradually decreasing dose of cyclosporine (3.75-1.25 mg/kg/day) within the next 9 months.
89200475|NCT00976300|Active Comparator|Cyclophosphamide|Cyclophosphamide (CPH) therapeutic arm (CPH group) consisted of 8 boluses of intravenous cyclophosphamide (10mg/kg) given within 9 months in subsequently prolonged intervals (2x3weeks, 4x4 weeks, 2x6 weeks) followed by 4-5 oral cyclophosphamide boluses (10mg/d in 6-8 week intervals).
89200476|NCT00976378|Experimental|0.05 mg/kg NOX-A12|
89200477|NCT00976378|Experimental|0.15 mg/kg NOX-A12|
89200478|NCT00976378|Experimental|0.45 mg/kg NOX-A12|
89200479|NCT00976378|Experimental|1.35 mg/kg NOX-A12|
89200480|NCT00976378|Experimental|2.7 mg/kg NOX-A12|
89200481|NCT00976378|Experimental|5.4 mg/kg NOX-A12|
89200482|NCT00976378|Experimental|10.8 mg/kg NOX-A12|
89200483|NCT00976378|Experimental|5.4 mg/kg NOX-A12 plus apheresis|
89447296|NCT06141252|Experimental|Hypothermia|Patients admitted with out-of-hospital cardiac arrest and treated with hypothermia
89447297|NCT06141252|No Intervention|No hypothermia|Patients admitted with out-of-hospital cardiac arrest and treated without hypothermia
88932442|NCT02392442|Placebo Comparator|4 Placebo comparator|6 hour control lavage
88932443|NCT02373189|Experimental|Bright light|Participants received morning bright light.
88932444|NCT02357524|Experimental|Oritavancin|Subject will receive a single oritavancin dose of 1200 mg in 1000 mL of D5W administered as a constant rate IV infusion over 3 hours via a single dedicated peripheral venous line.
88932445|NCT02340988|Experimental|Oritavancin and Warfarin|Oritavancin 1200 mg Single-Dose IV Oritavancin Diphosphate given simultaneously with 25mg dose of Warfarin
88932446|NCT02340988|Experimental|Warfarin 24 hours post dose|25mg dose of Warfarin given 24 hours post 1200 mg Single-Dose IV Oritavancin Diphosphate.
88932447|NCT02235610|No Intervention|Standard Group|"Recipients receive standard donor lungs as per current clinical practice.~No experimental procedures will be carried out."
88932448|NCT02235610|Experimental|EVLP Group|Recipients receive reconditioned EVLP donor lungs and current standard of care for lung transplant is administered.
88932449|NCT02201589|Experimental|Endovascular repair of ascending aorta|Endovascular repair with Valiant PS-IDE Stent Graft
88932450|NCT02153437|Experimental|Arm A: BMS-919373|BMS-919373 oral Solution/tablet single dose for one day
88932451|NCT02153437|Active Comparator|Arm B: Sotalol|Sotalol oral Tablet single dose for one day
88932452|NCT02153437|Placebo Comparator|Arm C: Placebo for BMS-919373|Oral solution/tablet one single dose for one day
88932453|NCT02051088|Experimental|Revascularization with drug eluting technology|Revascularization with drug eluting technology
88932454|NCT02051088|Active Comparator|Revascularization without drug elution|Revascularization without drug elution technology
88932455|NCT01901965|Experimental|NMES|neuromuscular electrical stimulation (NMES) of the quadriceps muscle with Kneehab
88932456|NCT01901965|Experimental|eccentric training|unilateral eccentric resistance exercises
88932457|NCT01901965|Sham Comparator|sham NMES|neuromuscular electrical stimulation of the quadriceps muscle with intensity which causes no visible contraction or displacement of the leg (activation below motor threshold)
88932458|NCT01884038|Experimental|Remodulin|Remodulin initiated as a continuous IV infusion at a dose of 2.5 ng/kg/min after subjects have been assessed as hemodynamically stable in the ICU. Dose may be escalated in 1.25- to 2.5-ng/kg/min increments, up to 7.5 ng/kg/min, with a target dose of 5 ng/kg/min, based on tolerability. The dose will be maintained at the maximum tolerated dose, not to exceed 7.5 ng/kg/min for 5 days after the transplantation surgery.
88932459|NCT01884038|Placebo Comparator|Placebo|Matching placebo
88932460|NCT01801072|Active Comparator|Levetiracetam|500 mg intravenous dose during the operative case then 500 mg orally twice a day for a total of seven days.
88932461|NCT01801072|No Intervention|No levetiracetam|No levetiracetam
88932462|NCT01784536|Experimental|Oritavancin|Single-Dose IV Oritavancin Diphosphate
88932463|NCT01718743|Experimental|Treatment (ixazomib citrate, lenalidomide)|Beginning 60-180 days post-transplant, patients receive ixazomib citrate PO on days 1, 8, and 15 and lenalidomide PO on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88932464|NCT01605084|Experimental|Arm 1: ATV/RTV 300/100 mg QD + optimized NRTI backbone|
88932465|NCT01605084|Experimental|Arm 2: DRV/RTV 800/100 mg QD + optimized NRTI backbone|
88932466|NCT01514864|Experimental|Dasatinib, 140 mg (NSCLC With Inactivating B-RAF Mutation)|Participants with nonsmall-cell lung cancer (NSCLC) and an inactivating B-RAF mutation received dasatinib, 140 mg, once daily as a tablet until unacceptable toxicity or disease progression occurred
88932467|NCT01514864|Experimental|Dasatinib, 140 mg (NSCLC With DDR2 Mutation)|Participants with NSCLC and a discoidin domain receptor 2 (DDR2) mutation received dasatinib, 140 mg, once daily as a tablet until unacceptable toxicity or disease progression occurred
88932468|NCT01502917|Experimental|Radioactive iodine-labeled monoclonal antibody omburtamab|This is a therapeutic Phase I study intended to assess the safety of convection-enhanced delivery (CED) of radioimmunotherapy in the treatment of children with diffuse pontine glioma.
88932469|NCT01458366|Experimental|Bendamustine 70mg/m^2|Level 1: Bendamustine 70mg/m^2 Ofatumumab, Carboplatin, and Etoposide
88932470|NCT01458366|Experimental|Bendamustine 50mg/m^2|Level -1: Bendamustine 50mg/m^2 Ofatumumab, Carboplatin, and Etoposide
88932471|NCT01458366|Experimental|Bendamustine 90mg/m^2|Level 2: Bendamustine 90mg/m^2 Ofatumumab, Carboplatin, and Etoposide
89200484|NCT00976534|Experimental|1|
89200485|NCT00976534|Placebo Comparator|2|
89447298|NCT06140485|Experimental|NW Low-Glu®|"Patients in this arm will receive one placebo tablet plus two NW Low-Glu® capsules administered PO on empty stomach with plenty of water 2 hours after meals twice daily.~A total dose of four NW Low-Glu® capsules will be administered per day."
89447299|NCT06140485|Active Comparator|Metformin|"Patients in this arm will receive one metformin 1000 mg tablet plus two placebo capsules administered PO on an empty stomach with plenty of water 2 hours after meals twice daily.~A total dose of Metformin 2000 mg will be administered per day."
89447300|NCT06140394|Active Comparator|old age group|old age group above 60 years old
88932472|NCT01458366|Experimental|Bendamustine 120mg/m^2|Level 3: Bendamustine 120mg/m^2 Ofatumumab, Carboplatin, and Etoposide
88932473|NCT01458366|Experimental|Phase II MTD|Phase II: Bendamustine at MTD from Phase I, Ofatumumab, Carboplatin, and Etoposide
88932474|NCT01126723|Experimental|Tai Chi group|
88932475|NCT01126723|Active Comparator|Educational Control group|
88932476|NCT00968760|Experimental|CD19-specific T cell Infusion without IL-2|"Conditioning Regimen of Chemotherapy (Carmustine, Cytarabine, Etoposide, and Melphalan), Stem Cell Transplant, and Gene Transfer~Group 1 - low dose of T cells without IL-2.~Group 3 - higher dose of T cells without IL-2."
89200486|NCT00979966|Experimental|A|Temsirolimus
89200487|NCT00979966|Experimental|B|Sunitinib
89200488|NCT00969826|Experimental|GCPGC 30 μg/kg|Ten volunteers were administered GCPGC 30 μg/kg or placebo (active:placebo=8:2)
89200489|NCT00969826|Experimental|GCPGC 100 μg/kg|Ten volunteers were administered GCPGC 100 μg/kg or placebo (active:placebo=8:2)
89200490|NCT00969826|Experimental|GCPGC 300 μg/kg|Ten volunteers would be administered GCPGC 300 μg/kg or placebo (active:placebo=8:2)
89447301|NCT06140394|Placebo Comparator|young aged group|young age group below 40 years old
89447302|NCT06140004||HBPC Site 1: Northern/East California|This site implemented an evidence-based model of HBPC that consists of home visits by a trained, interdisciplinary palliative care team composed of a physician, nurse, social worker, and spiritual counselor. At this site, this core team was housed in an independent hospice agency and was also convened in-house by the ACO contract or MA plan. The insurance provider contracts with the core team, using a per member per month payment for patients enrolled in HBPC. The core team will provide pain and symptom management, psychosocial support, advanced care planning, disease management education, spiritual counseling, grief counseling, and other services in response to patient and caregiver needs. HBPC patients and their caregivers also will have access to a 24/7 helpline.
89447303|NCT06140004||HBPC Site 2: Northern/West California|This site implemented an evidence-based model of HBPC that consists of home visits by a trained, interdisciplinary palliative care team composed of a physician, nurse, social worker, and spiritual counselor. At this site, this core team was housed in an independent hospice agency and was also convened in-house by the ACO contract or MA plan. The insurance provider contracts with the core team, using a per member per month payment for patients enrolled in HBPC. The core team will provide pain and symptom management, psychosocial support, advanced care planning, disease management education, spiritual counseling, grief counseling, and other services in response to patient and caregiver needs. HBPC patients and their caregivers also will have access to a 24/7 helpline.
88932477|NCT00968760|Experimental|CD19-specific T cell Infusion with IL-2|"Conditioning Regimen of Chemotherapy (Carmustine, Cytarabine, Etoposide, and Melphalan), Stem Cell Transplant, and Gene Transfer~Group 2 - higher dose of T cells with IL-2.~Group 4 - higher dose of T cells with IL-2."
88932478|NCT00967733|Active Comparator|High ALA-Low Linoleic|
88932479|NCT00967733|Placebo Comparator|Low ALA-Low Linoleic|
88932480|NCT00967733|Active Comparator|High ALA-High Linoleic|
88932481|NCT00967733|Placebo Comparator|Low ALA-High Linoleic|
88932482|NCT00707694||Probands|Ashkenazi Jews ages 95 and older
88932483|NCT00707694||Offspring|Ashkenazi Jewish offspring of Ashkenazi Jewish parent(s) who lived to at least the age of 95
88932484|NCT00707694||Controls|Ashkenazi Jewish people with no family history of longevity
88932485|NCT00415233|Experimental|1.1Gbq with rhTSH|Patients receive 1.1GBq dose of radioactive iodine and rhTSH
88932486|NCT00415233|Experimental|3.2 GBq with rhTSH|Patients receive 3.2GBq dose of radioactive idodine and rhTSH
88932487|NCT00415233|Experimental|1.1GBq without rhTSH|Patients only receive 1.1GBq dose of radioactive iodine and no rhTSH
88932488|NCT00415233|Experimental|3.2GBq without rhTSH|Patients only receive 3.2GBq dose of radioactive iodine and no rhTSH
88932489|NCT00364286|Experimental|Dasatinib|Dasatinib 50mg Orally twice daily.
88932490|NCT00339482||American Indians|Residents of the Gila River Indian Community
88932491|NCT00328614|Experimental|Samarium-153 (0.25 mCi/kg)|Cohort 1: Patients receive 0.25 mCi/kg of Samarium-153, hormonal therapy, and radiation therapy
88932492|NCT00328614|Experimental|Samarium-153 (0.5 mCi/kg)|Cohort 2: Patients receive 0.5 mCi/kg of Samarium-153, hormonal therapy, and radiation therapy
88932493|NCT00328614|Experimental|Samarium-153 (0.75 mCi/kg)|Cohort 3: Patients receive 0.75 mCi/kg of Samarium-153, hormonal therapy, and radiation therapy
88932494|NCT00328614|Experimental|Samarium-153 (1.0 mCi/kg)|Cohort 4: Patients receive 1.0 mCi/kg of Samarium-153, hormonal therapy, and radiation therapy
88932495|NCT00328614|Experimental|Samarium-153 (1.5 mCi/kg)|Cohort 5: Patients receive 1.5 mCi/kg of Samarium-153, hormonal therapy, and radiation therapy
88932496|NCT00328614|Experimental|Samarium-153 (2.0 mCi/kg)|Cohort 6: Patients receive 2.0 mCi/kg of Samarium-153, hormonal therapy, and radiation therapy
88932497|NCT00032513||CAEBV|Patients with chronic active Epstein-Barr virus.
88932498|NCT00032513||Hydroa vaccineforme|Patients with EBV hydro vaccineforme.
88932499|NCT01750125||Healthy subjects|In these health subjects we will measure ascending aortic blood flow with pulse wave Doppler and also record the raw audio of the Doppler signal
88932500|NCT01750138|Experimental|Glutamine|Glutamine powder given preoperatively for five days
88932501|NCT01750138|Active Comparator|Placebo|dextrose powder for 5 days pre-operatively
88932502|NCT01750151|Experimental|Glucose beverage|Glucose beverage
88932503|NCT01750151|Experimental|Control beverage and video game playing|Control beverage and video game playing
88932504|NCT01750151|Experimental|Glucose beverage and video game playing|Glucose beverage and video game playing
88932505|NCT01750151|Experimental|Control beverage|Control beverage
88932506|NCT01750164||Invasive breast cancer with metastatic disease|
88932507|NCT01750177|Experimental|Television Viewing|Television viewing before mealtime
88932508|NCT01750177|Experimental|Video Game Playing|Video Game Playing before mealtime
88932509|NCT01750177|Experimental|Computer Use|Computer Use before mealtime
88932510|NCT01750177|Experimental|Sitting Quietly|Sitting Quietly before mealtime
88932511|NCT01750203||No treatment|No cohort as this study is not using a treatment or intervention only swabs are being collected.
88932512|NCT01750216||Cohort|
88932513|NCT01750307|Experimental|Fatty acid supplementation|4 capsules to be taken daily
88932514|NCT01750307|Placebo Comparator|Medium Chain Triglyceride (MCT) oil softgel|4 capsules to be taken daily
88932515|NCT01750320|Experimental|Koning Breast CT - guided Biopsy|
88932516|NCT01750333||Lean children|
88932517|NCT01750333||Overweight Children (OW)|
88932518|NCT01750333||Obese children (Ob)|
88932519|NCT01750359|Active Comparator|curcumin|
88932520|NCT01750359|Placebo Comparator|placebo|
88932521|NCT01750372||Persons with lower limb amputation|Persons with amputation below the hip and at or above the ankle
88932522|NCT01750385|Active Comparator|no antibiotic prophylaxis|These patients are in no antibiotic prophylaxis group will not be administered antibiotic prophylactically.
89200491|NCT00969826|Experimental|Neulasta 100 μg/kg|Eight volunteers were administered Neulasta 100 μg/kg
89014248|NCT05599984|Experimental|Part 4a: ABBV-706 Monotherapy Dose Expansion CNS Tumors|Participants with relapsed/refractory (R/R) central nervous system (CNS) tumors will receive ABBV-706 as a monotherapy at or below the maximum tolerated dose (MTD) maximum administered dose (MAD), as part of an approximately 1 year treatment period.
89014249|NCT05599984|Experimental|Part 4b: ABBV-706 Monotherapy Dose Expansion NECs|Participants with R/R neuroendocrine carcinomas (NECs) will receive IV Infused ABBV-706 as a monotherapy at or below the MTD/MAD, as part of an approximately 1 year treatment period.
89014250|NCT05597358|Active Comparator|High Intensity Laser Therapy (HILT)|Active high intensity laser therapy for 12 biweekly sessions (6 consecutive weeks of biweekly treatments)
89014251|NCT05597358|Sham Comparator|Sham High Intensity Laser Therapy|Sham high-intensity laser therapy for 12 biweekly sessions (6 consecutive weeks of biweekly treatments)
89014252|NCT05594836|Experimental|Training|Perception of Maternal Role, Maternal Attachment and Breastfeeding Self-Efficacy
89014253|NCT05594836|No Intervention|control|not Perception of Maternal Role, Maternal Attachment and Breastfeeding Self-Efficacy
89014254|NCT05585632|Experimental|mRNA-1010|Participants will receive a dose of mRNA-1010 by intramuscular (IM) injection on Day 1.
89014255|NCT05585632|Experimental|mRNA-1345|Participants will receive a dose of mRNA-1345 by IM injection on Day 1.
89014256|NCT05585632|Experimental|mRNA-1273.214|Participants will receive a dose of mRNA-1273.214 by IM injection on Day 1.
89014257|NCT05585632|Experimental|mRNA-1045 Dose Level A|Participants will receive mRNA-1045 at Dose Level A by IM injection on Day 1.
89014258|NCT05585632|Experimental|mRNA-1045 Dose Level B|Participants will receive mRNA-1045 at Dose Level B by IM injection on Day 1.
89014259|NCT05585632|Experimental|mRNA-1045 Dose Level C|Participants will receive mRNA-1045 at Dose Level C by IM injection on Day 1.
89014260|NCT05585632|Experimental|mRNA-1230 Dose Level A|Participants will receive mRNA-1230 at Dose Level A by IM injection on Day 1.
89014261|NCT05585632|Experimental|mRNA-1230 Dose Level B|Participants will receive mRNA-1230 at Dose Level B by IM injection on Day 1.
89014262|NCT05585632|Experimental|mRNA-1230 Dose Level C|Participants will receive mRNA-1230 at Dose Level C by IM injection on Day 1.
89014263|NCT05585203|Experimental|Contingency management|In addition to receiving usual care at the recovery house, participants assigned to this arm will receive contingency management by trained recovery house staff in addition to their usual care. Contingency management sessions will be led by a trained recovery house staff member who is also a research participant in the study. Contingency management will occur once weekly for sessions of approximately 10-15 minute duration for up to 12 weeks. Participants will plan three recovery-oriented activities with the staff member each week, and upon verification of completion of the tasks, the resident participant can earn prize draws of varying monetary amounts.
89014264|NCT05585203|Active Comparator|Usual Care|Participants in this arm will receive usual care that they would normally receive at the recovery houses. Recovery houses are safe, healthy, family-like substance-free living environments that support individuals in recovery from addiction. Although recovery residences vary considerably, this form of housing benefits individuals in recovery by reinforcing a substance-free lifestyle and providing direct connections to other peers in recovery, mutual support groups and recovery support services.
89200492|NCT04007926|No Intervention|Control Group|Participants assigned to the control arm of the study will be asked to maintain their normal dietary and exercise habits.
89200493|NCT04007926|Experimental|Aerobic exercise group|Participants randomised to the aerobic exercise intervention will undertake a 12-week aerobic exercise training programme.
89200494|NCT04007926|Experimental|Resistance exercise group|Participants randomised to the resistance exercise intervention will undertake a 12-week aerobic exercise training programme.
89200495|NCT00969904|Active Comparator|1|
89014265|NCT05570422|Experimental|dose-escalation single arm|"Dose-escalation single arm, open label study. All eligible subjects will receive external beam radiotherapy (EBRT) with cisplatin (40 mg/m2) intravenously (IV) once weekly for 5 weeks (sixth dose optional) followed by image-guided brachytherapy (BT).~KRC-01 will be dosed intratumorally within 2 hours prior to EBRT starting from second week of EBRT.~There are two cohorts (n=5 per cohort) Cohort 1: Once-a-week between Monday to Thursday (not necessarily the same day every week) Cohort 2: Twice-a-week with a 1- or 2- day interval (either Mon+Wed, Mon+Thu, or Tue+Thu)"
89200496|NCT00969904|Placebo Comparator|2|
89200497|NCT00976612||Nilotinib|Patients who receive nilotinib with failure to both imatinib and sunitinib
89200498|NCT00976690|Active Comparator|1|Azathioprine : 2mg/kg/day
89200499|NCT00976690|Active Comparator|2|Mesalazine : 4g/day
89531303|NCT03336905|Experimental|Physical Activity and Prevention|"co-construction of supervised and non-supervised physical activity sessions with a physical activity trainer~balance sheet (at diagnosis and 4 monthes+/- 2 months later) : IPAQ, QLQC30, 6-min walk test, anthropometric evaluation~meetings and phone calls after the physical activity program to assess patient perception and satisfaction, and provide information and recommendations for cancer prevention"
89531304|NCT03337997|Experimental|Study group|All patients in this pilot study are in the same group. All receive Irreversible Electroporation.
89200500|NCT00976768|Experimental|FOLFIRI arm|Patients receiving FOLFIRI
89200501|NCT00608985|Experimental|1|almorexant 200 mg
89200502|NCT00608985|Experimental|2|almorexant 100 mg
89200503|NCT00608985|Placebo Comparator|3|Placebo
89200504|NCT00608985|Active Comparator|4|zolpidem 10 mg
88932523|NCT01750385|Active Comparator|second-generation cephalosporin|These patients are in antibiotic prophylaxis group will be administered second-generation cephalosporin prophylactically.
88932524|NCT01750411||Asthma|Severe Asthma Not severe Asthma
88932525|NCT01750424|Experimental|Fat Grafted|The experimental arm of the study will be composed of 15 patients who undergo autologous fat grafting into the site of the facial reconstructive scar at 3 months post-operatively. A small amount of fat will be removed near the umbilicus through a cannula using local anesthetic and a small, 2-3mm incision just barely large enough for the cannula to pass. That fat will be injected directly under the scar site in those patients using a similar cannula, local anesthetic, and small, 2-3mm incision. No sutures will be required at either the donor or injection site. Patients will subsequently return to clinic for 3-D photographic assessment at 3, 6 and 12 months post-fat grafting. The images generated at each session will be provided to a group of assessors for evaluation. They will either use the Manchester Scar Scale or the modified Manchester Scar Scale depending on whether they are within the health care profession.
89014266|NCT05567458|Experimental|Luspatercept|
89014267|NCT05567458|Placebo Comparator|Placebo|
89200505|NCT00969982|Experimental|mifepristone+misoprostol|200 mg mifepristone followed by 800 mcg buccal misoprostol repeated every 3 hours until complete abortion or maximum of 10 doses within 48 hours (maximum 5 doses per 24 hours).
89200506|NCT00969982|Active Comparator|misoprostol|Placebo resembling mifepristone followed 24 hours later by 800 mcg buccal misoprostol repeated every 3 hours until complete abortion up to a maximum of 10 doses within 48 hours (maximum 5 doses per 24 hours).
89531305|NCT05030883|Experimental|unreliable source|In this condition participants receive a news message from an unreliable source
89531306|NCT05030883|Experimental|reliable source|In this condition participants receive a news message from an reliable source
89531307|NCT05030883|Experimental|no source|In this condition participants receive a news message without a source
88932526|NCT01750424|Placebo Comparator|Non-fat grafted|The control arm will be composed of 15 patients who undergo no intervention. These patients will be identified at 3 months post-operatively from their facial reconstruction. They will undergo no fat-grafting but will be followed up with the same frequency as the experimental group, at 3 months, 6 months, and 12 months after their initial 3 month post-surgical follow-up. 3-D images will be taken at each appointment and will be distributed to all assessors. Assessors will use either the Manchester Scar Scale or a modified Manchester Scar Scale to evaluate the appearance of the scar at each time point.
88932527|NCT01750437|Experimental|YH1885L 33.3 mg|TID, Subject takes it for 4 week.
88932528|NCT01750437|Experimental|YH1885L 50mg|BID, Subject takes it for 4 week.
88932529|NCT01750437|Experimental|YH1885L 66.6 mg|TID, Subject takes it for 4 week.
88932530|NCT01750437|Experimental|YH1885L 100mg|BID, Subject takes it for 4 week.
88932531|NCT01750437|Active Comparator|Esomeprazole 20mg|QD, Subject takes it for 4 week.
88932532|NCT01750450||Elective left heart cath|Patients undergoing elective left heart catheterization will be consented for this study
88932533|NCT01750463||Arm A|"Critically ill pediatric patients admitted to PICU requiring hemoglobin monitoring.~Patients admitted to PICU requiring hemoglobin monitoring will have a reading total hemoglobin (SpHb) assessment done with the Masimo Pronto Rad 7 Non-Invasive hemoglobin monitor,prior to standard laboratory blood draw and hemoglobin analysis."
88932534|NCT01750476||Depo-Provera|Women who choose to initiate Depo-Provera
88932535|NCT01750476||Mirena|Women who choose to initiate Mirena (intrauterine device)
88932536|NCT01750476||Oral contraception|Women who choose to initiate oral contraception
88932537|NCT01750489|No Intervention|COPD|
88932538|NCT01750489|Experimental|COPD with non-invasive ventilation (NIV)|Starting non-invasive ventilation with the patient's own device during registration of MSNA.
88932539|NCT01750489|No Intervention|Healthy control subjects|
88932540|NCT01750515|Experimental|Intervention group - acupuncture treatment|
88932541|NCT01750515|No Intervention|Control group|
88932542|NCT01750528||Ankylosing spondylitis|patients aged 18 years or more who meet the 1984 modified New York criteria
88932543|NCT01750528||Control|age- (± 3 years) and gender-matched volunteers who do not have inflammatory arthropathy.
88932544|NCT01750541|Active Comparator|Haloperidol|Haloperidol 5mg intramuscular injection
88932545|NCT01750541|Active Comparator|Valproate|Valproate single Infusion; 400 mg (weigh<60 kg), 500 mg (weight>60 Kg)
88932546|NCT01750554|Experimental|bupivacaine digital nerve block|Patients undergoing spine surgery will have a 50/50 chance of being randomized to receive a bupivacaine 0.25% (2 milliliters total) intermediate-acting digital nerve block.
88932547|NCT01750554|No Intervention|No bupivacaine digital nerve block|Patients undergoing spine surgery will have a 50/50 chance of being randomized to not receive a bupivacaine 0.25% (2 milliliters total) intermediate-acting digital nerve block.
88932548|NCT01750580|Experimental|Arm 1: Lirilumab + Ipilimumab|Lirilumab and Ipilimumab on specific days
88932549|NCT01750593|Experimental|radiofrequency ablation of thyroid nodule|Under ultrasonography the thyroid nodules will be ablated by radiofrequency ablation
88932550|NCT01750606||pre-THA|Patients who are planned but have not yet received a total hip arthroplasty. No intervention or treatment - blood draw only to be used as a surrogate baseline for metal ion exposure.
88932551|NCT01750606||Metal-on-Poly|Patients receiving a Biomet metal on poly hip implanted between January 1, 2003 and December 31, 2006.
88932552|NCT01750606||M2a Magnum hip|Patients receiving a Biomet M2a Magnum hip implanted between January 1, 2006 and January 1, 2011.
88932553|NCT01750606||M2a38 hip|Patients receiving a Biomet metal on metal M2a38 hip implanted between January 1, 2004 and December 31, 2006.
88932554|NCT01750606||M2a Ringloc hip|Patients receiving a Biomet M2a Ringloc metal on metal hip implanted between January 1, 2002 and December 31, 2004.
88932555|NCT01750606||M2a Taperloc hip|Patients receiving a Biomet M2a Taperloc metal on metal hip implanted between January 1, 2002 and December 31, 2003.
88932556|NCT01750632|Experimental|Orchiectomy|The patients undergo subcapsular orchiectomy
88932557|NCT01750645||Intervention Group|
88932558|NCT01750645||Control Group|
88932559|NCT01750658||COPD|"COPD patients admitted in any of the participating ECOS hospitals due to a COPD exacerbation.~- External factors. The episodes of COPD exacerbations are associated to exogenous factors (pollution, change of ambient temperature, humidity, infections). The prevalence of environmental contamination and infections is higher than expected.~- Endogenous factors. These factors (hyperinflation, pulmonary embolism, cardiac dysfunction, mucus hypersecretion) are present in a proportion higher than expected~- During exacerbations of COPD serum markers of inflammation and autoimmunity are high relative to baseline in COPD and decrease progressively during the follow-up, after controlling the acute episode"
88932560|NCT01750723|Active Comparator|Acetazolamide|Acetazolamide 1 g in 10 ml saline, i.v. infusion
88932561|NCT01750723|Placebo Comparator|Saline|Saline, 10 ml i.v. infusion
88932562|NCT01750736|Experimental|Augmented Exercise and Manual Therapy|Subjects will receive manual therapy according to clinical guidelines followed by instruction in a specific exercise to augment the specific manual treatment provided.
88932563|NCT01750736|Active Comparator|General Exercise and Manual Therapy|Subjects will receive manual therapy according to clinical guidelines followed by instruction in a general neck range of motion exercise.
89447304|NCT06140004||HBPC Site 3: Southern California|This site implemented an evidence-based model of HBPC that consists of home visits by a trained, interdisciplinary palliative care team composed of a physician, nurse, social worker, and spiritual counselor. At this site, this core team was housed in an independent hospice and home health agency and was also convened in-house by the ACO contract or MA plan. The insurance provider contracts with the core team, using a per member per month payment for patients enrolled in HBPC. The core team will provide pain and symptom management, psychosocial support, advanced care planning, disease management education, spiritual counseling, grief counseling, and other services in response to patient and caregiver needs. HBPC patients and their caregivers also will have access to a 24/7 helpline.
89447305|NCT06138990|Experimental|Intervention arm: Pharmacoscopy-guided clinical standard-of-care|Patients in the PCY-guided treatment arm will receive one of the clinical standard-of-care treatments suggested by their own PCY results, and confirmed by the treating physician.
89447306|NCT06138990|Active Comparator|Control arm|Patients in the control arm will be treated with clinical standard-of-care therapy for RR AML selected by the physician (physician's choice).
88932564|NCT01750749|Experimental|Autologous BMDC implantation at the venous ulcer|Autologous BMDC implantation at the venous ulcer in conjunction with SOC treatment (advanced wound management plus pressure therapy)
88932565|NCT01750762|Experimental|Lenalidomide|Dose escalation. Starting dose is 10 mg/day for 3 weeks followed by 1 week off (1 cycle). Subject will receive a total of 3 cycles.
88932566|NCT01750775|Experimental|Shensong Yangxin capsule|Shensong Yangxin capsule 4 granules t.i.d. by mouth for 8weeks
88932567|NCT01750775|Placebo Comparator|placebo Capsule|placebo Capsule 4 granules t.i.d. by mouth for 8 weeks
88932568|NCT01750788||Group 1|
88932569|NCT01750801|Active Comparator|Propolis|alcohol-free mouthwash containing 5% green propolis (MGP 5%) on the control of plaque and gingivitis.
88932570|NCT01750801|Active Comparator|chlorhexidine|chlorhexidine used on the control of plaque and gingivitis.
88932571|NCT01750814|Active Comparator|GC FLU inj.|Influneza vaccine, single-dose vial
88932572|NCT01750814|Experimental|GC3102C|Influneza vaccine, multi-dose vial
88932573|NCT01750827|Experimental|SB-659032|Single dose open label
88932574|NCT01750853|Experimental|Group 1|"Period 1: 0.1 milligrams (mg) LY3045697 administered once orally or matching placebo administered once orally.~Period 2: 1 mg LY3045697 administered once orally or matching placebo administered once orally.~Period 3: 10 mg LY3045697 administered once orally or matching placebo administered once orally."
88932575|NCT01750853|Experimental|Group 2|"Period 1: 0.3 mg LY3045697 administered once orally or matching placebo administered once orally.~Period 2: 3 mg LY3045697 administered once orally or matching placebo administered once orally.~Period 3: 30 mg LY3045697 administered once orally or matching placebo administered once orally."
88932576|NCT01750853|Experimental|Group 3|"Period 1: 100 mg of LY3045697 administered once orally or matching placebo administered once orally.~Period 2: 300 mg of LY3045697 administered once orally or matching placebo administered once orally (via split delivery over a 15-minute period)."
88932577|NCT01750866|Experimental|Cabazitaxel|Cabazitaxel 25 mg/m2 will be administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle. Treatment will continue until disease progression, intolerable side effects, or a maximum of 10 cycles of therapy.
88932578|NCT01750905|Active Comparator|CD-NP|CD-NP 5 ug/kg subcutaneous injection (SQ)
88932579|NCT01750905|Placebo Comparator|Placebo|Placebo: Vehicle (D5W) SQ
88932580|NCT01750944|Experimental|Healthy Volunteers 1|"The study population consists of adult, healthy volunteers randomized into two identical groups.~Intervention: ankle first"
88932581|NCT01750944|Experimental|Healthy Volunteers 2|"The study population consists of adult, healthy volunteers randomized into two identical groups.~Intervention: toe first"
88932582|NCT01750970|Experimental|Resection under blue light|
89200507|NCT00976846|Experimental|Baxter Xenium XPH 210|Device: Baxter Xenium XPH 210 dialyzer
89200508|NCT00976924|Experimental|Andon|Andon blood glucose test strips with test meter
89447307|NCT06138353|Experimental|Shuxuening injection treatment group|Group1: Shuxuening injection treatment group (N1=25): Shuxuening injection (specification: 10ml/branch, Lanzhi Group Wanrong Pharmaceutical Co., Ltd.), 20 ml (2 branches) + 5% dextrose injection 250 ml, intravenously, once a day, from the first day of postoperative, treatment for 1 course of treatment, a total of 10-14 days.
89447308|NCT06138353|Placebo Comparator|Placebo control group|Group2: Placebo control group (N2=25): Shuxuening injection simulant (0.9% sodium chloride injection, specification: 10 ml/cartridge, Kunming Yusi Pharmaceutical Co., Ltd.), 20 ml (2 cartridges) + 5% dextrose injection 250 ml, intravenously dripped once a day, from the first day of postoperative, treatment for 1 course of treatment, for a total of 10-14 days.
89447309|NCT06138184|Active Comparator|Standard Care|Standard Educational process
89447310|NCT06138184|Experimental|Education Intervention|New educational intervention
89447311|NCT06137755|Experimental|Group 1|Recombinant Herpes Zoster Vaccine(CVI-VZV-001) 0.37 mL per dose, Intramuscular injection at Baseline, Week 8 / total 2 doses
89447312|NCT06137755|Experimental|Group 2|Recombinant Herpes Zoster Vaccine(CVI-VZV-001) 0.50 mL per dose, Intramuscular injection at Baseline, Week 8 / total 2 doses
89447313|NCT06137755|Experimental|Group 3|Recombinant Herpes Zoster Vaccine(CVI-VZV-001) 0.75 mL per dose, Intramuscular injection at Baseline, Week 8 / total 2 doses
88932583|NCT01750970|Active Comparator|Resection under white light|
88932584|NCT01750983|Experimental|Ipilimumab + Lenalidomide|"Dose Escalation Group Ipilimumab Starting Dose: 1.5 mg by vein over 90 minutes on Day 1 of each 28 day cycle.~Dose Escalation Group Lenalidomide Starting Dose: 10 mg by mouth on Days 1-21 of each 28 day cycle.~Dose Expansion Group Starting Dose for Ipilimumab and Lenalidomide: Maximum tolerated dose (MTD) from Dose Escalation Groups."
88932585|NCT01750996|No Intervention|Usual Care control (Parenting tips)|Participants randomized to usual care will have access to a brief information website containing brief parenting tips but will not receive Strongest Families Intervention
88932586|NCT01750996|Experimental|Strongest Families|Strongest Families intervention
88932587|NCT01751009|Experimental|Vitamin A supplements|Sprinkles with Vitamin A
88932588|NCT01751009|Active Comparator|Sprinkles without Vitamin A|Made of other micronutrients without Vitamin A
88932589|NCT01751035|Placebo Comparator|Treatment as Usual (TAU)|Treatment as Usual (TAU) will be defined as it already exists within the community child advocacy centers. This could include individual and/or group therapy using a variety of treatment models.
88932590|NCT01751035|Experimental|RRFT|RRFT is an acronym for an experimental intervention named Risk Reduction through Family Therapy. Please see intervention description for more detail about the model.
88932591|NCT01751048|Experimental|Group #1|N=16 subjects receive vaccine on day 0, 28, and 168 of 0.5 ml of 20 mcg of LEISH-F3 + 5 mcg Glucopyranosyl Lipid A- Stable oil-in-water emulsion (GLA-SE)
88932592|NCT01751048|Experimental|Group #2|N=16 subjects receive vaccine on day 0, 28, and 168 of 0.5 ml of 20 mcg of LEISH-F3 + 10 mcg Monophosphoryl Lipid A-Stable oil-in-water emulsion (MPL-SE)
88932593|NCT01751048|Experimental|Group #3|N=16 subjects receive vaccine on day 0, 28, and 168 of 0.5 ml of 20 mcg LEISH-F3 + Stable oil-in-water Emulsion (SE)
88932594|NCT01751074|Experimental|Part A|All subjects will be of Caucasian descent and will receive single dose of Rosuvastatin 10 mg for 1 day (Day 1) during treatment period 1, then will receive Darapladib 160 mg once daily (QD) for 10 days (Day 5 to 14) in treatment period 2. Immediately following this, all subjects will receive the combination of Darapladib 160 mg and Rosuvastatin 10 mg for 1 day (Day 15) and continued Darapladib dosing of 160 mg QD for additional 3 days (Days 16 to 18) in treatment period 2.
88932595|NCT01751074|Experimental|Part B|The decision to initiate Part B will be made by the GSK study team based on an evaluation of data from Part A. Part B will consist of a cohort of healthy subjects of Far-East Asian descent and will be conducted similar to Part A.
89200509|NCT00976924|Active Comparator|Lifescan|Lifescan blood glucose test strips with test meter
89200510|NCT00970060|Experimental|Exercise program|Supervised moderately-intense exercise, including both aerobic and strengthening activities. Sessions are 3-4 days per week for 10 weeks.
89200511|NCT00970138|Experimental|A 850|apatinib 850 mg qd, and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
89200512|NCT00970138|Experimental|B 425|apatinib 425 mg bid, and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
89200513|NCT00970138|Placebo Comparator|C pla|placebo bid, and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
89200514|NCT00977002|Experimental|PPNIV|Patient randomized to this group will be ventilated with Positive Pressure Noninvasive Ventilation post extubation
89447314|NCT06137755|Active Comparator|Active Control|Shingrix 0.50 mL per dose, Intramuscular injection at Baseline, Week 8 / total 2 doses
89447315|NCT06137495|Experimental|Allergic Rhinitis Patients|House dust mites (HDMs) IgE in sera of allergic rhinitis patients (AR) who were monosensitized to mixed HDMs, identified by SPT, is assayed using immunoblotting, chemiluminescence, and ImmunoCAP assays to compare between the accuracy of both immunoblotting and chemiluminescence assays, and ImmunoCAP as gold standard
89447316|NCT06136546|Experimental|Infliximab|Participants in this arm will receive 5 mg/kg of infliximab via an in-dwelling catheter.
89447317|NCT06136546|Placebo Comparator|Placebo|Participants in this arm will receive saline as placebo via an in-dwelling catheter.
89447318|NCT06134973||Nodular group|nodules less than 2 cm in diameter
89447319|NCT06134973||Macronodular group|nodules between 2-3 cm in diameter
88932596|NCT01751100|Active Comparator|HIV Test Offer|Group 1 (Control) is the current standard of care in HIV testing. A trained counselor provides required information to obtain informed consent for HIV testing and provides rapid HIV testing on site.
89447320|NCT06134414|Experimental|Arm 1 MY008211A low dose|Participants will receive MY008211A at a dose of 400 mg orally b.i.d
88932597|NCT01751100|Experimental|General Health Screen Offer|In Group 2 (Intervention), a free general health screening is offered that may include a blood pressure check, blood glucose measurement, a Hepatitis C (HCV) test, and an HIV test.
88932598|NCT01751191||Training set-chronic response to propranolol|
88932599|NCT01751191||Validation set-chronic response to propranolol|
88932600|NCT01751191||Acute response to propranolol|
88932601|NCT01751204|Active Comparator|Calcium tablet|250 mg calcium/tablet
88932602|NCT01751204|Experimental|Calcium ion water (250mg)|250 mg calcium in 200 ml water
88932603|NCT01751204|Experimental|Calcium ion water (125mg)|125 mg calcium in 200 ml water
88932604|NCT01751217|Experimental|Funct Family Tx/Video Teleconf (FFT-V)|Functional Family Therapy (FFT) is a brief treatment for youth with problem behaviors, including substance abuse that consists of 12 to 14 weekly family sessions. The FFT treatment is applied in five distinct phases: Engagement, Motivation, Relational Assessment, Behavior Change, and Generalization and each phase has specific goals, techniques, and therapist skills. Adolescents and parents assigned to the FFT-V condition will receive a Verizon netbook laptop computer equipped with the Microsoft Windows 7 operating system, webcam, and VTC software for use in the family home. The VTC software is designed to stream live video between therapists and participants, to record video, and to store recorded videos as digital mpeg files. All family sessions will take place via video teleconference.
88932605|NCT01751217|Experimental|Functional Family Tx|Functional Family Therapy (FFT) is a brief treatment for youth with problem behaviors, including substance abuse that consists of 12 to 14 weekly family sessions. The FFT treatment is applied in five distinct phases: Engagement, Motivation, Relational Assessment, Behavior Change, and Generalization and each phase has specific goals, techniques, and therapist skills. Families in the FFT condition will not be provided with the laptop and internet access described above. Instead, adolescents and parents in this condition will receive the FFT intervention face-to-face from an FFT therapist who will travel to the family home for each session.
88932606|NCT01751217|Active Comparator|Services as Usual|The main CYFD service provider for adjudicated youth in both Sandoval and Valencia counties is Youth Development Incorporated (YDI) which is a private not-for-profit youth service organization serving adolescents in New Mexico . YDI provides an array of services for youth including tutoring, after-school activities, gang intervention, school drop-out prevention, family counseling services, an emergency teen shelter, parenting skills training, youth leadership development, community corrections services, GED studies, substance abuse and AIDS education, etc. The YDI juvenile corrections services include intensive supervision, educational and employment assistance, community service, victim restitution, and institutional transition services.
88932607|NCT01751243|Placebo Comparator|Group 0|Haploidentical transplantation of hematopoietic progenitors
88932608|NCT01751243|Experimental|Group 1|Allo-depleted lymphocyte infusion dose: 1x105 CD3/Kg
88932609|NCT01751243|Experimental|Group 2|Allo-depleted lymphocyte infusion dose: 3x105 CD3/Kg
88932610|NCT01751243|Experimental|Group 3|Allo-depleted lymphocyte infusion dose: 5x105 CD3/Kg
88932611|NCT01751243|Experimental|Group 4|Allo-depleted lymphocyte infusion dose: 1x106 CD3/Kg
88932612|NCT01751243|Experimental|Group 5|Allo-depleted lymphocyte infusion dose: 3x106 CD3/Kg
88932613|NCT01751256|Experimental|Continuous wound infiltration|Subfascial continuous wound infiltration with Levobupivacaine: bolus 50mg and 6.25mg/h for 48 hours through a multiperforated catheter, in addition to Celecoxib 200mg twice a day, paracetamol 1g four times a day, Nefopam 20mg four times a day, and intravenous morphine for 24 hours with Patient Controlled Analgesia pump (1.2mg by bolus, 7 minutes lockout period).
88932614|NCT01751256|No Intervention|Control|Celecoxib 200mg twice a day, paracetamol 1g four times a day, Nefopam 20mg four times a day, and intravenous morphine for 24 hours with Patient Controlled Analgesia pump (1.2mg by bolus, 7 minutes lockout period).
88932615|NCT01751269|Experimental|Ascending Single and Multiple dose of RPX7009|Ascending Single and Multiple dose of RPX7009
88932616|NCT01751269|Placebo Comparator|Normal Saline|Ascending Single and multiple dose of normal saline.
88932617|NCT01751282|Placebo Comparator|Standard therapy and control saline spray|Conventional standard therapy and control saline spray
88932618|NCT01751282|Sham Comparator|standard therapy and fibrin spray|Conventional standard therapy and fibrin spray
88932619|NCT01751282|Experimental|Conventional standard therapy and MSCs|Conventional Standard Therapy and MSCs (autologous bone marrow-derived mesenchymal stem cells) in fibrin spray.
88932620|NCT01751295|Active Comparator|atorvastatin|PCI with atorvastatin pre-treatment group
88932621|NCT01751295|No Intervention|control|PCI without atorvastatin pre-treatment group
88932622|NCT01751321|Other|sitagliptin, metformin, placebo|"group- 25 patients will take sitagliptin 50 mg and metformin 1000 mg twice in a day~group- 25 patients will take placebo 50 mg and metformin 1000 mg twice in a day"
88932623|NCT01751334|Experimental|Mobile Bearing|Mobile bearing total knee arthroplasty
88932624|NCT01751334|Active Comparator|Fixed Bearing|Fixed Bearing total knee arthroplasty
88932625|NCT01751347|Active Comparator|Lidocaine|Subjects randomized to this treatment arm will receive lidocaine during their elective hand surgery.
88932626|NCT01751347|Experimental|Bupivacaine|Subjects randomized to this treatment arm will receive bupivacaine during their elective hand surgery.
89447321|NCT06134414|Experimental|Arm 2 MY008211A high dose|Participants will receive MY008211A at a dose of 600 mg orally b.i.d
89447322|NCT06134219|Experimental|Intervention|Mental Fatigue course + Usual care in clinical care
89447323|NCT06134219|Active Comparator|Control Group|Usual care in clinical care
88932627|NCT01751373|Active Comparator|Standard Therapy|Coupling focal BoNT-A injections with a therapy program comprising of functional tasks.
89447324|NCT06133959|Active Comparator|e-Lymph Control|e-Lymph (Control). e-Lymph includes training sessions on the lymphatic system, lymphedema, lymphedema diagnosis and measurement, risk of lymphedema.
89447325|NCT06133959|Experimental|The-Optimal-Lymph Flow (TOLF) Program|TOLF includes training sessions on the lymphatic system, lymphedema, lymphedema diagnosis and measurement, risk of lymphedema, healthy diet, sleep hygiene, and daily lymphatic exercises. It has 8 avatar videos with step-by-step instructions for TOLF lymphatic exercises to promote lymph flow.
89447326|NCT06130514|Active Comparator|Ultrasound-guided stellate ganglion block (US-guided SGB)|In the case of ultrasound-guided stellate ganglion block, the patient is made to lie down and stellate ganglion block is performed by injecting 5 mL of 1% mepivacaine at the level of the 6th cervical vertebra using ultrasound.
89447327|NCT06130514|Active Comparator|Fluoroscopy-guided thoracic sympathetic ganglion block (FS-guided TSGB)|In the case of fluoroscopic device-guided thoracic sympathetic nerve block, place the patient prone and inject 3 mL of 1% mepivacaine at the level of the third thoracic vertebra to perform thoracic sympathetic nerve block.
89447328|NCT06129383|Active Comparator|Control group to which serratus anterior plane block will be applied|Control group patients, accompanied by the 38 mm 6 MHz linear probe of the ultrasound device, , the patient will be placed in the lateral decubitus position and SAP block will be applied to the serratus anterior muscle fascia using 20 ml of 0.25% bupivacaine solution.
89447329|NCT06129383|Other|serratus anterior plane block to the pecto intercostal plane block will be applied.|SAP block will be applied to the patient's serratus anterior fascia using 20 ml of 0.25% bupivacaine solution. Then, PIFB will be applied to the patient's parasternal region using 10 ml of 0.25% bupivacaine solution.
89447330|NCT06125678|Experimental|Small intestinal contrast enhanced ultrasound followed by cross sectional imaging|Patients shall be undergoing small intestinal contrast enhanced ultrasound followed by cross sectional imaging
89447331|NCT06124937|Experimental|Intervention group|The intervention group will receive a 10 mg tablet of empagliflozin once a day from 3 days before surgery until discharge from the hospital.
89447332|NCT06124937|Placebo Comparator|Comperator|The comparator group will receive a matching placebo
89447333|NCT06116838|Experimental|Carrier frequency + Waveform|Spinally Evoked Motor Potentials (sEMP) will be obtained while stimulating the spinal cord at a single site with single pulses. sEMP are the electromyograph responses of the peripheral muscles to electrical stimulation of the spinal cord. We will test various waveform combinations of biphasic and monophasic waveforms with modulation frequencies of 0-10 kHz. Participants will also ambulate while receiving continuous stimulation of the various waveform combinations to determine what stimulation intensity is comfortable for each combination. The order we complete this testing will be randomized. All participants will perform testing in a different order.
89447334|NCT06116838|Experimental|Stimulation Location|Spinally Evoked Motor Potentials (sEMP) will be obtained while stimulating the spinal cord at various stimulation locations with single pulses. sEMP are the electromyograph responses of the peripheral muscles to electrical stimulation of the spinal cord. Participants will also ambulate while receiving continuous stimulation to various stimulation locations to determine what stimulation intensity is comfortable for each location. The order we complete this testing will be randomized. All participants will perform testing in a different order.
89447335|NCT06109922|Experimental|Experimental|"Bioactive whey protein concentrate containing phospholipids.~40g pre weighed powder to be mixed with 350ml of water. Consumed once daily for 12 weeks alongside their fattiest meal of the day."
89447336|NCT06109922|Placebo Comparator|Placebo|"Placebo~Placebo powder matched for macronutrient and caloric content containing pea protein around 40g powder mixed with 350ml water consumed once daily for 12 weeks alongside fattiest meal of the day."
89447337|NCT06109454||Huaier Granule|The subjects voluntarily gave up postoperative adjuvant therapy, including chemotherapy, targeted therapy, immunotherapy, and radiation therapy, and agreed to take Huaier granules.
89447338|NCT06109454||Control|The subjects received standard platinum dual-drug chemotherapy.
89447339|NCT06107114|Experimental|Experimental group|Patients with locally advanced operable head and neck squamous cell carcinoma
89447340|NCT06104891|Placebo Comparator|Placebo Control 1|Recharge Product Form 1 - control
89447341|NCT06104891|Experimental|Active Product 1|Recharge Product Form 2 - active product 1
89447342|NCT06104891|Experimental|Active Product 2|Recharge Product Form 3 - active product 1
89447343|NCT06104891|Experimental|Active Product 3|Recharge Product Form 4 - active product 1
89447344|NCT06104514|Experimental|Lift the upper lip and improve the peri-oral rhytids|
89447345|NCT06103552|Experimental|Weight Loss Program Intervention|All study participants will be assigned to the intervention arm of this trial where they will undergo the BLOOM lifestyle program for weight loss. This program is 24 weeks in duration and includes group nutrition coaching with a dietitian, regular physician appointments and access to online support materials. Participants may also choose to pursue weight loss medication or meal replacement therapy, although this is not specifically part of the BLOOM program being studied.
89447346|NCT06103331||child|identification and management of invasive fungal pathogen
89447347|NCT06103331||adult|identification and management of invasive fungal pathogen
88932628|NCT01751373|Experimental|Optimal Muscle Activation Therapy|Coupling focal BoNT-A injections with a motor training program that focuses on developing and maintaining activation patterns in the muscle treated with BoNT-A.
89200515|NCT00977002|Active Comparator|O2I|Patient randomized to this group will be submitted to traditional oxygen therapy post extubation
89200516|NCT00869037|Active Comparator|Periarticluar Multimodal Technique|
89200517|NCT00869037|Active Comparator|CFNB plus Posterior Capsular Injection|
89447348|NCT06099444|Active Comparator|Conventional High Intensity Gait Training|Participants in the conventional high-intensity gait training group will undergo gait training on a treadmill. Each session will consist of between 30-60 minutes of walking targeted to reach a high intensity, as measured via heart rate and Borg rating of perceived exertion. This may also include inclined walking, walking with an ankle weight, backwards walking, sidestepping, and/or obstacle walking.
89447349|NCT06099444|Experimental|Standard FES to the Tibialis Anterior (TA)|Participants in the standard FES gait training group will receive FES applied to the TA muscle/peroneal nerve on his/her more affected leg. FES strategically stimulates the TA/peroneal nerve at specific phases of the gait cycle identified by internal inertial measurement units (IMUs).
89447350|NCT06099444|Experimental|Synergy-Based Multichannel FES (MFES)|Participants in the synergy-based MFES gait training group will receive FES applied to muscles of the affected lower limb. These muscles may include the TA, gastrocnemius medialis, gastrocnemius lateralis, soleus, rectus femoris, vastus medialis, vastus lateralis, semitendinosus, biceps femoris, gluteus medius, and adductor longus. FES will be applied to each muscle with an activation pattern that is derived from extracted healthy muscle synergies that are scaled to fit the patient's gait cycle.
89447351|NCT06099444|Experimental|Muscle Synergy Visual Biofeedback|Participants in the muscle synergy visual biofeedback group will wear bipolar EMG sensors on the muscles of interest. In real time, muscle synergies will be extracted and the similarity of affected synergies to healthy synergies will be displayed on a screen. Patients in this group will be instructed to try to increase the similarity score of the affected synergies and the healthy synergies. No electrical stimulation will be provided in this group.
89447352|NCT06099444|Experimental|Synergy-Based Multichannel (MFES) + Muscle Synergy Visual Biofeedback|Participants in the group will receive a combination of the synergy-based MFES and muscle synergy visual biofeedback interventions. Because EMG cannot be recorded while FES is being applied in a continuous fashion, this method will alternate between providing sensory feedback (FES) and visual feedback of the muscle synergies.
89447353|NCT06099080|Experimental|SM-020 gel 1.0%|Subjects will apply the investigational product twice daily for 4 consecutive weeks. Subjects will be followed for 12 weeks post final application for a total of approximately 16 weeks of required participation in the study.
89447354|NCT06098170|Experimental|Unguided use of the My SCI Toolkit program|
89447355|NCT06098170|Experimental|Coached My SCI Toolkit|
89200518|NCT00980356|Active Comparator|Vildagliptin, 50 mg, peroral|
89200519|NCT00980356|Placebo Comparator|Placebo pill|
89200520|NCT00869115|Experimental|1|TREATMENT 0.5 μg/kg/min
88932629|NCT01751464|Experimental|WrapAround Care|
88932630|NCT01751477||Probiotics (Infloran)|Very low birth weight Infants receiving 2 capsules/d Infloran starting in the first week of life
88932631|NCT01751477||Control|Very low birth weight Infants who did not receive Infloran (historical cohort)
88932632|NCT01751503|Active Comparator|Interosseous route of TPTT|The investigators will have two groups of patients, one who had their tendon transfer using the extra membranous route and other group which had their tendon transfer through the interosseous route. Patients will be randomized to either groups before the surgery and both the patients and the assessors will be blinded to the technique used. Both these techniques have been widely described in literature and are being extensively used in surgical management of foot drop. The selection of technique depends on surgeon choice and patient factors.
88932633|NCT01751503|Active Comparator|Extra membranous route of TPTT|Extramembranous or circumtibial route of Tibialis Posterior tendon transfer.Both these techniques have been widely described in literature and are being extensively used in surgical management of foot drop. The selection of technique depends on surgeon choice and patient factors
88932634|NCT01751529|Experimental|Contrast-enhanced Ultrasound|
88932635|NCT01751542|Experimental|Mindfulness + residential treatment|Mindfulness and Acceptance Group Therapy + residential treatment
88932636|NCT01751542|Active Comparator|Residential Treatment|Residential treatment alone
88932637|NCT01751555|Experimental|TDF/3TC/EFV Treatment HIV/HBV Co-infection|TDF+3TC+EFV treatment regimen in Adults with HIV/HBV Coinfection
88932638|NCT01751581|Active Comparator|Habitual Sleep|Women sleep 8 h/night throughout the study phase
88932639|NCT01751581|Experimental|Short Sleep|Women sleep 4 h/night throughout the study phase
88932640|NCT01751594|Active Comparator|H4L Comparison Intervention|
88932641|NCT01751594|Experimental|MOVE Intervention|
88932642|NCT01751607||genetic variants|AFib patients with or without the genetic variants
88932643|NCT01751620|Experimental|Project ACCEPT|Participants randomized to the intervention (Project ACCEPT) arm.
88932644|NCT01751620|Active Comparator|HEALTH|Participants randomized to the comparison (HEALTH) arm.
88932645|NCT01751633||Surgical treatment|"Surgical treatment according to one of the following:~Posterior open approach~Posterior minimally-invasive surgery (MIS) approach The choice of the approach will be left upon the surgeon's discretion"
88932646|NCT01751633||Conservative treatment|Conservative treatment according to hospital's standard of care
88932647|NCT01751659||Phase I|"Semi-structured face-to-face or telephone interviews of 10 ATN-affiliated clinicians.~The total duration of Phase 1 is expected to last approximately nine months, including data analysis."
88932648|NCT01751659||Phase II|"Development of a new theory-based survey instrument and cognitive interview testing of this survey with approximately five clinicians (of those who participated in Phase 1).~The total duration of Phase 2 is expected to last approximately three months, including qualitative analysis of the interviews and modification of the survey."
88932649|NCT01751659||Phase III|"Administration of the newly developed survey to approximately 60 ATN-affiliated clinicians.~The total duration of Phase 3 will last approximately six to nine months."
89200521|NCT00869115|Experimental|2|TREATMENT 1.0 μg/kg/min
89200522|NCT00869115|Experimental|3|TREATMENT 1.5 μg/kg/min
89447356|NCT06098170|No Intervention|Wait-list control|Participants will not access the My SCI Toolkit program during the 8-week study period and will be asked to continue daily life, including management of pain, as usual.
89447357|NCT06097910||Observation|
89014268|NCT05561777|No Intervention|Pharmacist-led Evaluation|Patients randomized to the pharmacist-led arm will appear in the pharmacy-penicillin electronic health care dashboard. A pharmacist may, at their discretion and in consultation with the primary care team, perform an allergy risk-stratification and oral challenge in low-risk patients using local standard of care protocol
89447358|NCT06095596|Experimental|Combination treatment group|A combination treatment of vedolizumab and upadacitinib for 8 weeks in the induction therapy, then followed by a single treatment of vedolizumab in the maintenance therapy
89447359|NCT06095596|Placebo Comparator|Single treatment group|single treatment of vedolizumab both in the induction and maintenance therapy
89447360|NCT06095557|Experimental|Sponsor MCG device|All participants will receive a scan from the Sponsor MCG device
89014269|NCT05561777|Experimental|Provider-targeted Clinical Decision Support Tool|This intervention will provide access to a best-practices alert (BPA) containing the patient's risk-stratification status and a link to the local standard of care protocol, oral amoxicillin challenge order set and written consent form (same resources as used in pharmacist -led electronic health record dashboard). If the provider opts to perform the oral challenge and it is successfully passed, a second BPA will prompt them to update the allergy status in the medical record.
89200523|NCT00869115|Placebo Comparator|4|PLACEBO
89200524|NCT00368251|Placebo Comparator|Placebo|Placebo Placebo twice a day (bid), 14 weeks (2 week Up-Titration Period + 12 week Maintenance Period)
89447361|NCT06094101|Experimental|Peptide vaccination|"Peptides will be administered subcutaneously (s.c.) together with the novel toll like receptor (TLR) 1/2 ligand XS15 emulsified in Montanide ISA 51 VG as adjuvant.~Three vaccinations will be applied every 28 days."
88932650|NCT01751698|Active Comparator|JASP-EMT|JASP-EMT (Joint Attention, Symbolic Play and Enhanced Milieu Teaching) focuses on creating a context for joint engagement within naturally occurring child-led play routines. There is evidence of the effects of these interventions with children with ASD, and pilot data showing effects with minimally verbal children.
88932651|NCT01751698|Active Comparator|DTT|CORE-DTT (discrete trial training for core features of ASD) emphasizes didactic adult-led instruction and is considered the current evidenced-based 'standard of care' for children with autism (NRC, 2001).
88932652|NCT01751737|Experimental|Prostate Cancer Imaging|"Subjects will receive multi-sequence Magnetic Resonance Imaging (MRI) of the prostate and pelvis. This scan will take approximately 90 minutes.~In addition, a 18F-Choline PET/CT(Positron emission tomography/computed tomography) scan of the abdomen and pelvis is performed. This scan will take about 30 minutes. Subjects may receive an additional 30 minute scan, if needed.~Patients participating in an active surveillance program at the University of Michigan may receive yearly imaging followed by a prostate biopsy procedure."
88932653|NCT01751750|Other|Grape|
88932654|NCT01751763||Group 1|
88932655|NCT01751789|Active Comparator|Linkage|Participants will receive Suboxone during their inpatient detoxication and be given outpatient appointments to continue Suboxone treatment after completing inpatient detoxification
88932656|NCT01751789|Placebo Comparator|Detoxification|Participants will receive Suboxone to detoxify from opioids and the standard treatment offered by the inpatient detoxification program
88932657|NCT01751815|Experimental|Acu-TENS|
88932658|NCT01751815|Sham Comparator|Placebo-TENS|
88932659|NCT01751828|Experimental|Sertraline|Open-label sertraline, 8 week trial, dosing from 50mg to 200mg daily.
88932660|NCT01751854|Experimental|SSRI|SSRI alone or with training
88932661|NCT01751854|Placebo Comparator|Placebo|Placebo alone or with training
88932662|NCT01751880|Experimental|Exercise Group|
88932663|NCT01751893|Experimental|Henna arm|Based on the treatment protocol for this study the patients will receive the henna treatment for 4 weeks (supervised treatment for first week and then unsupervised sessions twice a week). The treatment will include the application of the henna mixture (paste) (40gr natural henna and 40ml of purified water) to the affected areas (feet or/and hands) and wear socks or/and gloves. The treatment session will last for 1 hour and then the mixture will be rinsed with fresh water.
88932664|NCT01751893|Placebo Comparator|Placebo|Based on the treatment protocol for this study the patients in this arm will receive the henna placebo treatment for 4 weeks (supervised treatment for first week and then unsupervised sessions twice a week). The treatment will include the application of the henna placebo mixture (paste) (40gr placebo henna and 40ml of purified water) to the affected areas (feet or/and hands) and wear socks or/and gloves. The treatment session will last for 1 hours and then the mixture will be rinsed with fresh water.
88932665|NCT01751919|Other|Group 1 (RT)|"Period 1: Glivec film-coated tablet 100 mg, 4 tablets (Active comparator)~Period 2: Imatinib mesylate tablet 400 mg, 1 tablet (experimental)"
88932666|NCT01751919|Other|Group 2 (TR)|"Period 1: Imatinib mesylate tablet 400 mg, 1 tablet (experimental)~Period 2: Glivec film-coated tablet 100 mg, 4 tablets (Active comparator)"
88932667|NCT01751932|Experimental|CGM Monitoring|Fitting of Dexcom G4 Platinum CGM monitor and Medtronic Enlite CGM monitor
88932668|NCT01751945|Experimental|EmONC package|"The EmONC package consists of:~Maternal and neonatal health pack(clean delivery kit, emollient, chlorhexidine, sms messages) for safe motherhood and newborn wellbeing.~Enhanced trainings of community-level health care providers to provide effective maternal and neonatal health services and referral of complicated cases to health facilities and creation of linkages amongst health care providers.~Community mobilisation"
88932669|NCT01751945|No Intervention|Standard of care|Standard care as per national policy
88932670|NCT01751958|Experimental|Epidural Steroid injection|Group-Epidural Steroid injection (Intermittent)
88932671|NCT01751958|Experimental|Epidural Steroid Injection2|Group-injection under angiography (continuous)
88932672|NCT01751997|Active Comparator|Transplants from 8/8-matched unrelated|Participants will receive transplants from 8/8-matched unrelated donors using myeloablative or reduced-intensity conditioning according to age or comorbidity.
88932673|NCT01751997|Experimental|Transplants from family-mismatched/haploidentical donors|Participants will receive FMT using a reduced intensity conditioning regimens.
88932674|NCT01752010|Active Comparator|Acupuncture Treatment|Traditional Chinese acupuncture.
88932675|NCT01752010|Active Comparator|Tennant™ Biomodulator Treatment|
88932676|NCT01752010|Active Comparator|Transcutaneous electrical nerve stimulation (TENS) Treatment|
88932677|NCT01752075||REVLIMID|Taiwanese patients treated with REVLIMID
88932678|NCT01752127|Active Comparator|DM arms|comparison of two different stents(Xience prime and Resolute integrity)
88932679|NCT01752127|Active Comparator|Small vessel arms|comparison of two different stents(Xience prime and Resolute integrity)
88932680|NCT01752140|Active Comparator|10-core prostate biopsy protocol group|Ultrasound guided prostate biopsy with extraction of 10 cores
88932681|NCT01752140|Active Comparator|Vienna nomogram prostate biopsy protocol group|Ultrasound guided prostate biopsy performed according to the Vienna nomogram
88932682|NCT01752153|Experimental|Silymarin (Legalon)|Patients who were unable or unwilling to use desferrioxamine or had stopped desferrioxamine treatment for at least 6 months, were received only silymarin.
89200525|NCT00368251|Experimental|Brivaracetam 5 mg/day|Brivaracetam (BRV) 5 mg/day 5 mg twice a day (bid) using 2.5 mg tablets for 12 weeks (after 2 week Up- Titration Period)
89200526|NCT00368251|Experimental|Brivaracetam 150 mg/day|Brivaracetam (BRV) 150 mg/day 150 mg twice a day (bid) using 25 mg and 50 mg tablets for 12 weeks (after 2 week Up-Titration Period)
89447362|NCT06093113|Experimental|Intervention group|"Participants will complete a web based pre-assessment and then be given access to the app Alba for two months followed by a web based post-assessment including questions regarding their experiences of using the app, and follow-up questionnaires."
89447363|NCT06093113|Active Comparator|Control group|Participants will get access to a website containing information about grief and grief reactions.
89447364|NCT06086054|Active Comparator|Intervention|The intervention is comprised of two components to link randomized patients to our health system childcare facility: 1) navigation by the research assistant to the childcare facility and 2) placement of the facility EMR referral. Navigation will occur an eligible patient is randomized to the intervention group. Navigation will consist of the research assistant educating the patient about the childcare facility and providing information about how to access the childcare facility during the telephone contact and via mailed written materials.
89447365|NCT06086054|No Intervention|Standard Care|Patients randomized to the control group will undergo current standard of care with regards to childcare, which currently consists of passive sources of information about our childcare facility (Parkland website, signage in the hospital, or via word of mouth). Currently, there is no formalized mechanism for patients referred to gynecology from primary care to receive information about childcare aside from the above passive sources of information.
89447366|NCT06085872|Experimental|PsyPills - Experimental|Each recruited student randomized in the experimental group will receive the PsyPills app.
89447367|NCT06085872|Active Comparator|MoodWheel - Monitoring|The students randomized in the control group will complete the MoodWheel app.
88932683|NCT01752153|Experimental|Combined therapy (Deaferrioxamine+Silymarin (Legalon)|In combined therapy group, patients continued desferrioxamine (Novartis Pharma AG, Switzerland) at the dose of 40 mg/Kg/day and Legalon® tablets (Madaus Pharma, Italy) was added to desferrioxamine regimen at the dose of 140 mg, taken orally, three times a day, 7 days a week.
88932684|NCT01752166||Blood culture|Subjects have had a blood culture ordered, per routine standard of care
88932685|NCT01752179|Experimental|kinesio tape|kinesio Tape : Width 5cm ,Length 35cm Y shape
88932686|NCT01752179|No Intervention|Control group|without using Kinesio tape
88932687|NCT01752192|Experimental|Telerehabilitation programme|Telerehabilitation programme: Each patient will use a telehealth monitor and measure blood pressure, pulse and weight once or twice a week over a 3 months periods with the use of a blood pressure monitor and a weightscale connected to the monitor. The patients will also measure their steps daily by the use of a digital step-counter. The patients will be able to see their data in a personal health record on a tablet where they can share informations with healthcare professionals. The patient are also offered access to a portal called www.aktivehjerte.dk where they can find informations on rehabilitations topics in text, video and sound. The patients are randomised in block of different sizes to follow rehabilitation from hospital, healthcare center or a callcenter.
88932688|NCT01752192|No Intervention|Control group traditional rehabilitation|The control group of heart patients follow traditional rehabilitation activities for a period of 3 months.The patients are randomised in block of different sizes to follow rehabilitation from hospital, healthcare center or a callcenter.
88932689|NCT01752205|Active Comparator|Chemoradiotherapy|The patients will receive radiation therapy QD, 5 days a week and receive paclitaxel IV ，dosing schedule: 45mg/m2/w.
88932690|NCT01752205|Experimental|Erlotinib and chemoradiotherapy|The patients will receive radiation therapy QD, 5 days a week and receive paclitaxel IV (45mg/m2/w) and erlotinib PO QD.
88932691|NCT01752218|Experimental|Arcuate Incision|Study arm will consist of patients who show cataract and corneal astigmatism.
88932692|NCT01752231||DCE-MRI (dynamic contrast-enhanced MRI)|Patients undergo DCE-MRI over approximately 30-60 minutes consisting of an anatomical scout image to localize the region of interest, a set of pre-injection scans to calibrate the dynamic image set, a dynamic image set during which contrast agent will be injected, and a set of post-injection scans to calibrate the DCE-MRI database.
88932693|NCT01752244|Experimental|Alfacalcidol|Alfacalcidol
88932694|NCT01752244|Placebo Comparator|Placebo|Corn oil pearl Capsules 1 gram: were given to the intervention group once a day for 8 weeks
88932695|NCT01752257|Other|EF5 Hypoxia|EF5 administered at 21mg/kg
88932696|NCT01752270|Experimental|diane-35|Diane-35 pretreatment from the third day of menstrual cycle
88932697|NCT01752270|No Intervention|blank control|
88932698|NCT01752283|Experimental|Hypnosis and local anesthesia|video-assisted thyroidectomy under hypnosis and local anesthesia.
89200527|NCT00970372||Involuntary patients|Compulsory treated patients according to the Norwegian Social and Welfare Act of 1992. Most patients have dualdiagnosis.
89447368|NCT06085872|Experimental|REThink Life Game|Students from experimental group who do not respond to PsyPills alone will play the REThink Life Game
89200528|NCT00970372||Voluntary patients|Voluntary patients on the same wards. Most patients have dual-diagnosis.
89200529|NCT00893841|Placebo Comparator|1|Quetiapine XR 300mg + Placebo
89200530|NCT00893841|Experimental|2|Quetiapine XR 300mg + Pramipexole 0.25mg
89200531|NCT00893841|Experimental|3|Quetiapine XR 300mg + Pramipexole 0.50mg
89200532|NCT00980434||1|patients with neurological symptoms
89200533|NCT00980434||2|patients without neurological symptoms
89200534|NCT02541123||Cohort A|CT negative for acute intracranial lesion with initial blood draw within 4 hours of head injury
89200535|NCT02541123||Cohort B|CT negative for acute intracranial lesion with initial blood draw within 4-6 hours of head injury
89014270|NCT05550428|Experimental|Treatment group|Participants in the intervention group will be exposed to PEMF treatment by a PEMF device (Quantum Tx, Singapore). Alternate legs will be exposed to PEMF treatment for 10 minutes per session, and the treatment regime will run biweekly for 8 weeks, summing up 16 sessions of PEMF exposure in total. All the participants were instructed on the proper performance of the exercise regimen by a senior physiotherapist before the commencement of the intervention. Subjects were then instructed to perform the home-based exercises on their own twice a week for eight weeks. One dedicated research assistant kept a weekly record of the participants' physical activity.
89014271|NCT05550428|Sham Comparator|Sham group|Participants in the intervention group will be exposed to PEMF treatment by a PEMF device (Quantum Tx, Singapore). Alternate legs will be exposed to PEMF treatment for 10 minutes per session, and the treatment regime will run biweekly for 8 weeks, summing up 16 sessions of sham exposure in total.All the participants were instructed on the proper performance of the exercise regimen by a senior physiotherapist before the commencement of the intervention. Subjects were then instructed to perform the home-based exercises on their own twice a week for eight weeks. One dedicated research assistant kept a weekly record of the participants' physical activity.
89014272|NCT05546879|Experimental|Experimental|NP137+Atezolizumab-Bevacizumab
89014273|NCT05546853|Experimental|Experimental|NP137+ mFOLFIRINOX
89014274|NCT05546437||Subjects with Ion Endoluminal dye marking of pulmonary nodule for resection|Subjects in which a pulmonary lesion dye marking procedure was attempted or performed with the Ion Endoluminal System in anticipation of resection of the lesion
89014275|NCT05541341||Acute Lymphoblastic Leukemia (ALL)|Children/young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia who received tisagenlecleucel infusion
89014276|NCT05541341||Diffuse Large B-cell Lymphoma (DLBCL)|Adult patients with relapsed/refractory Diffuse Large B-cell Lymphoma who received tisagenlecleucel infusion
89014277|NCT05541341||Follicular Lymphoma (FL)|Patients of any gender aged 18 year or older, with relapsed/refractory Follicular Lymphoma who received tisagenlecleucel infusion.
89014278|NCT05537428|Experimental|Musical Intervention|Participants will work together in a group with other voice hearers, making music with a trained facilitator for 4 weekly sessions
89014279|NCT05535478|Other|STRIDE Intervention|Educational intervention for clinicians
89014280|NCT05524415||Patients|Patients who are hospitalized in Soroka University Medical Center (SUMC) Neurology department with a diagnosis of acute stroke
89014281|NCT05523895|Placebo Comparator|Placebo|Placebo given once daily, as one capsule matching in size and color the respective pimavanserin treatment
89014282|NCT05523895|Experimental|Pimavanserin low dose|"Patients aged 5 to 12 years: 10 mg/day pimavanserin Patients aged 13 to 17 years: 20 mg/day pimavanserin~Pimavanserin given once daily, as capsule of 10 or 20 mg dose strength, respectively, according to the patient's age"
89014283|NCT05523895|Experimental|Pimavanserin high dose|"Patients aged 5 to 12 years: 20 mg/day pimavanserin Patients aged 13 to 17 years: 34 mg/day pimavanserin~Pimavanserin given once daily, as capsule of 20 or 34 mg dose strength, respectively, according to the patient's age"
89014284|NCT05519085|Experimental|MeziVd (mezigdomide, bortezomib and dexamethasone)|
89447369|NCT06084988|Experimental|MSC Intervention Group|Participants will receive one dose (50 x 106 allogeneic bone marrow (BM)-derived MSC formulated in 4 ml infusion solution (sodium chloride supplemented with human serum albumin) to be given via ultrasound-guided intra-articular injection of human allogeneic bone marrow-derived mesenchymal stromal cell product StromaForte. All patients will be observed for at least 2 hours post-injection at the study site. Both active monitoring and spontaneous reporting will be used.
89447370|NCT06083506|Other|NOVALOC TiN|Each subject will receive 4 implants. Implants will be placed flapless using a guided surgical protocol and will be immediately loaded by means of a NOVALOC TiN retained maxillary overdenture.
89447371|NCT06080555|Experimental|Test product-Ferric carboxymaltose Injection provided by SichuanHuiyuPharma|
89447372|NCT06080555|Active Comparator|Reference product-marketed by Vifor France|
89447373|NCT06079294|Experimental|FDG PET|
89447374|NCT06076681|Experimental|Group A|TNP2198 capsules 200 mg BID + rabeprazole sodium enteric-coated tablets 20 mg BID
89447375|NCT06076681|Experimental|Group B|TNP2198 capsules 400 mg BID + rabeprazole sodium enteric-coated tablets 20 mg BID
89447376|NCT06076681|Experimental|Group C|TNP2198 capsules 600 mg BID + rabeprazole sodium enteric-coated tablets 20 mg BID
89447377|NCT06076681|Experimental|Group D|TNP2198 capsules 400 mg BID + rabeprazole sodium enteric-coated tablets 20 mg BID + amoxicillin capsules 1g BID
89447378|NCT06076083||ankylosing spondylitis patients|Ankylosing spondylitis Cohort consists of individuals aged 19 to 60 who, at the time of providing consent, have received a diagnosis of ankylosing spondylitis in accordance with the Modified New York criteria and meet the 2010 diagnosis of spondyloarthritis. These individuals have voluntarily chosen to participate in the study, having fully comprehended its details, and have agreed to adhere to the required precautions.
89447379|NCT06076083||ankylosing spondylitis patients their families|Those who are between the ages of 19 and 65 A primary immediate family member (parent/brother/sister) who is related to the patient and has never developed ankylosing spondylitis, and who lives with the patient 3) Those who, after listening to the explanation of this study and fully understanding it, voluntarily decided to participate and agreed to comply with the precautions
89447380|NCT06065631|Other|Control|An eyeglasses prescription and letter to parents, with free eyeglasses at endline.
89447381|NCT06065631|Experimental|Intervention|free ready-made or custom eyeglasses
89447382|NCT06063681|Experimental|SR-8541A Monotherapy|SR-8541A will be orally administered.
88932699|NCT01752283|Active Comparator|General anesthesia|Video-assisted thyroidectomy under general anesthesia
88932700|NCT01752309||Rheumatoid Arthritis, ultrasound, persistence disease activity|Patients diagnosed with early Rheumatoid Arthritis will be assessed three times in one year with ultrasound to evaluate the predictive value of ultrasound.
88932701|NCT01752322|Experimental|Lidocaine plaster|Topical hydrogel plaster
88932702|NCT01752322|Placebo Comparator|Placebo plaster|Topical hydrogel plaster
88932703|NCT01752335|Other|tocilizumab|"All the patients are treated with tocilizumab before inclusion. The doses, frequency and duration are in acordance with the Summary of Characteristics of the Product authorised by EMA.~Usually 8mg/kg (not minor than 480 mg), once each 4 weeks."
88932704|NCT01752348|Placebo Comparator|Placebo (isotonic saline)|Endotoxin + isotonic saline. Reference for model of acute inflammatory illness
88932705|NCT01752348|Experimental|Acipimox + Placebo (isotonic saline)|Endotoxin + Acipimox + Placebo (isotonic saline). Intervention: blockage of endogenous lipolysis.
89447383|NCT06063590|Experimental|MSC arm|The patients will be receiving allogeneic bone marrow (BM)-derived Mesenchymal Stromal Cell (MSC) formulated in infusion solution (sodium chloride supplemented with human serum albumin) in a low intravenous infusion of 100 millions MSCs within approximately 30 min
89447384|NCT06063109|Experimental|Dapagliflozin|THP-00101 (Dapagliflozin) 10mg (18 Subjects): Tx A (5 days) -> Tx B (5 days) Treatment A: THP-00101 (Dapagliflozin) 10mg/5 days Treatment B: THP-00101 (Dapagliflozin) 10mg/5 days + THP-00102 (Telmisartan) 80mg/5 days
89447385|NCT06063109|Experimental|Telmisartan|THP-00102 (Telmisartan) 80mg (32 Subjects): Tx C (5 days) -> Tx B (5 days) Treatment C: THP-00102 (Telmisartan) 80mg/5 days Treatment B: THP-00102 (Telmisartan) 80mg/5 days + THP-00101 (Dapagliflozin) 10mg/5 days
89447386|NCT06056544|Experimental|Intervention Group|C4 is a longitudinal intervention which provides individualized client-centered HIV prevention and support services designed to address health and psychosocial needs that impact the success of PrEP use and adherence (i.e., co-morbidities, substance use, mental health, housing, etc.).
89447387|NCT06056544|No Intervention|Control Group|Individuals in the control group will receive standard of care for PrEP use at each clinic. The standard of care is PrEP clinical care includes identifying and engaging patients in need of PrEP, conducting necessary exams and lab tests and prescribing PrEP for the patients, as well as ongoing patient monitoring with follow-up visits and prescriptions-for as long as the patient needs PrEP.
89447388|NCT06054971||Group A|Group A will have Live telemedicine assessments completed prior to caregiver Asynchronous Video
89447389|NCT06054971||Group B|Group B will have Caregiver Asynchronous Video first, followed by live telemedicine
89447390|NCT06054568||Patient with Mitral stenosis undergoing Percutaneous Mitral trans-luminal commissurotomy|
89447391|NCT06052046|Experimental|Total30 for Astigmatism Contact Lenses|TOTAL30 for Astigmatism Monthly Replacement Contact Lenses
89447392|NCT06042621||Participants|Participants will be selected from patients who are admitted to an intensive care unit (ICU) at the University of Wisconsin Hospital, Unity Point-Meriter Hospital, Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, or Northwestern Memorial Hospital.
88932706|NCT01752348|Experimental|Acipimox + free fatty acids|Endotoxin + Acipimox + free fatty acids. Intervention: free fatty acids
88932707|NCT01752348|Experimental|Acipimox + 3-hydroxybutyrate|Endotoxin + Acipimox + 3-hydroxybutyrate. Intervention: 3-hydroxybutyrate
88932708|NCT01752361||Ulcerative Colitis|
88932709|NCT01752374||Palonosetron group|Patient recieving Palonosetron/granisetron and ramosetron
88932710|NCT01752374||Granisetron group|
88932711|NCT01752374||Ramosetron group|
88932712|NCT01752439|Experimental|Anodal transcranial direct current stimulation|Anodal transcranial direct current stimulation
88932713|NCT01752439|Sham Comparator|Sham transcranial direct current stimulation|Sham transcranial direct current stimulation
88932714|NCT01752439|No Intervention|Control group|
88932715|NCT01752465|Active Comparator|Standard Care|Patients in the standard care group will receive standard clinical care from their attending psychiatrist, including pharmacotherapy and education. Study assessments will be done at baseline, and once a month thereafter at Months 1, 2, 3, and 6.
88932716|NCT01752465|Experimental|Health Coaching|Patients in the Health Coaching group will receive both Health Coaching, and standard care. In addition to routine clinical appointments, patients receiving Health Coaching will attend Health Coaching sessions twice a month during Months 1, 2, and 3, and once a month during Months 4, 5, and 6. Study assessments will be conducted at baseline, and once a month thereafter during Health Coaching sessions at Months 1, 2, 3, and 6.
88932717|NCT01752504|Experimental|Intervention group|Community members who become engaged in the coalitions and in the broader mobilization effort. A subset of community members..
88932718|NCT01752517||refractory SCLC|NI group vinorelbine 25mg/m2 d1,d8; Ifosfamide 1.25g/m2 d1-d3; Mesna 400mg iv 0,4,8 hours after ifosfamide administration for 3 days; every 3 weeks; up to the maximum cycles (total:6);
88932719|NCT01752530|Experimental|Computer program C8 + treatment as usual|Computer program C 8 + treatment as usual. Subjects in the intervention group will be playing a special computer program C8 for 40 min a day, 6 times a week for 8 weeks in addition to treatment as usual.
88932720|NCT01752530|Other|Treatment as usual|Treatment as usual at the clinic
88932721|NCT01752543|Active Comparator|Conivaptan|10 patients will be randomized to conivaptan treatment
88932722|NCT01752543|Placebo Comparator|Dextrose|10 patients will receive placebo treatment (dextrose)
88932723|NCT01752556|Active Comparator|Hospital diagnosis|diagnosis of Sleep Apnea and therapeutic decision will perform according to polysomnography
88932724|NCT01752556|Experimental|Home diagnosis|diagnosis of Sleep Apnea and therapeutic decision will be perform according to home respiratory polygraphy
88932725|NCT01752569|Experimental|Selumetinib treatment|Phase I is a dose-finding study to discover the maximum tolerated dose of selumetinib in combination with HAART. Phase II will consider the efficacy of selumetinib for treating Kaposi's sarcoma at the recommended phase II dose discovered in phase I.
88932726|NCT01752582|Other|BuMA stent|"This study will enroll a total of 70 patients in Fuwai Hospital.All patients will be randomly assigned two groups(in a 1:1 ratio).~BuMA stent Arm:About 35 patients will undergoing implantation of BuMA stent.All of the patients will receive 6 months dual antiplatelet therapy and they will be followed (at the outpatient clinic) for up to 2 years. The follow-up visits will be conducted at 3 months(including angiographic/OCT investigation), 6 months, 1 and 2 years post PCI,in order to observe the Primary Endpoint and Secondary Endpoints."
88932727|NCT01752582|Other|EXCEL stent|"This study will enroll a total of 70 patients in Fuwai Hospital.All patients will be randomly assigned two groups(in a 1:1 ratio).~EXCEL stent Arm:About 35 patients will undergoing implantation of EXCEL stent.All of the patients will receive 6 months dual antiplatelet therapy and they will be followed (at the outpatient clinic) for up to 2 years. The follow-up visits will be conducted at 3 months(including angiographic/OCT investigation), 6 months, 1 and 2 years post PCI,in order to observe the Primary Endpoint and Secondary Endpoints."
88932728|NCT01752595|No Intervention|Standard|Subjects randomized to this group will receive standard, usual care with no intervention.
88932729|NCT01752595|Active Comparator|Preference Based Music Intervention|Subjects randomized to this arm will receive an iPod player and an activity monitoring device. The iPod will be loaded with patient indicated music preferences that is synched to the patients pace prescription. Subjects will be asked to use their iPod player during off-site exercise periods.
88932730|NCT01752595|Active Comparator|Preference Based Rhythmic Auditory Stimulation Music|Subjects randomized to this arm will receive an iPod player and an activity monitoring device. The iPod will be loaded with patient indicated music preferences that is synched to the patients pace prescription. Subjects will be asked to use their iPod player during off-site exercise periods. Rhythmic Auditory Stimulation (accentuation of beats, frequencies) will be added to the music subliminally.
88932731|NCT01752608|Experimental|eCBT Mood|Electronic cognitive behavioral therapy application running on the iPhone and iPod Touch.
88932732|NCT01752608|No Intervention|Mood Tracker|Mood monitoring application running on the iPhone and iPod Touch
88932733|NCT01752621||acromegaly|patients with acromegaly
89447393|NCT06042621||Surrogates|Surrogate participants will be the primary surrogate for an eligible patient.
89447394|NCT06042621||ICU Team Members|ICU Team Member participants will be members of the hospital staff providing care for an eligible patient.
88932734|NCT01752621||comparison population|matched background population
88932735|NCT01752647|Experimental|Low dose computed tomography|Patients will have one baseline LDCT scan.
88932736|NCT01752660|Experimental|Endurance training|Standard care during a 4 week inpatient stay at a Danish multiple sclerosis rehabilitation center added 3 weekly sessions of endurance training for the upper extremity.
89014285|NCT05519085|Experimental|PVd (pomalidomide, bortezomib and dexamethasone)|
89447395|NCT06034327|Experimental|Test Arm 1|Single vision, impact-resistant spectacle lenses
89447396|NCT06034327|Other|Test Arm 2|Single vision, impact-resistant spectacle lenses
88932737|NCT01752660|Active Comparator|Standard care|Standard care during a 4 week inpatient stay at a Danish multiple sclerosis rehabilitation center
88932738|NCT01752673|Experimental|Visualized pulmonary embolism computer task model|This group of participants was presented and trained to use a visual representation of diagnostic pathway for pulmonary embolism. The design of this visual representation is based on Bayes theorem and cognition enhancing visual design principles.
88932739|NCT01752673|Active Comparator|Didactic review pulmonary embolism lecture|This group of participants was presented with a didactic lecture covering the diagnostic approach of pulmonary embolism.
88932740|NCT01752686|Experimental|carboplatin chemotherapy|At the time of post neo-adjuvant period, the patients will be assigned to each treatment group in a 1:1 ratio i.e. carboplatin AUC 6 group vs. observation group. Six cycles of carboplatin (AUC=6) on the first day of every 21 days.
88932741|NCT01752686|No Intervention|Observation arm|In this observation arm, patients should be follow up with regular interval without treatment.
88932742|NCT01752699|Experimental|Methadone|in this arm patients will take methadone 5mg.
88932743|NCT01752699|Experimental|Placebo|in this arm patients will take placebo pills.
88932744|NCT01752725|Experimental|BiCision Arm|Coagulation with BiCision
88932745|NCT01752725|Active Comparator|Ultracision Arm|Coagulation with Ultracision
88932746|NCT01752751||Cancer Patients Age 65 or above|Cancer patients age 65 years or above with a diagnosis of head and neck cancer or lung cancer with radiotherapy or chemoradiotherapy planned as part of curative standard treatment.
88932747|NCT01752764|Experimental|Test product|Test product: Salad with high dosage fat
88932748|NCT01752764|Other|Control product|Control product: Salad with low dosage fat
88932749|NCT01752777|Experimental|Infectiousness Risk Reduction|Behavioral counseling conducted in one office session followed by 4 cell-phone-based sessions. Counseling is based on models of behavioral self-management and cognitive decision making with the primary aim to increase antiretroviral adherence, engagement in HIV care, and reduction of sexual risk behaviors for HIV transmission.
88932750|NCT01752777|Sham Comparator|General Health Improvement|Participants in this condition receive education conducted in one office session followed by 4 cell-phone-based sessions. The education sessions focus on raising awareness of health services and health improvement strategies.
88932751|NCT01752790|Experimental|Top-down|patients randomized on top-down arm will receive an induction regimen of three consecutive i.v. infusions of infliximab (Remicade, 5 mg/kg) at weeks 0, 2, and 6 plus azathioprine (2 mg/Kg per os/day). During maintaining phase, patients will receive subsequent infusions of infliximab (5 mg/kg every 8 weeks), starting 8 weeks after the end of the induction phase (week 14). At 12 motnhs patients will stop azathioprine and continue infliximab (5 mg/kg every 8 weeks)
88932752|NCT01752790|Active Comparator|Step-up|Patients randomized on Step-up arm will receive methylprednisolone (1-2 mg/Kg/day per os. for 2 weeks then tapering of 5 mg/week then stop) plus azathioprine (2 mg/Kg/die per os/day). Disease recurrences under azathioprine will be treated with steroid courses (methylprednisolone 1-2 mg/Kg/day per os. for 2 weeks then tapering of 5 mg/week then stop).
88932753|NCT01752803|Experimental|probiotic|subjects in this arm will receive probiotic supplementation for 12 weeks.
89014286|NCT05517447|Other|Observational cohort|Proptosis responders in feeder studies will enter in a non-treatment observational study
88932754|NCT01752803|Placebo Comparator|placebo|subjects in this arm will receive placebo in identical sachets similar to probiotics which only differs in the codes mentioned on the label of sachets.
88932755|NCT01752816|Active Comparator|endurance training|40 min bicycle or treadmill training at 60% maximal oxygen uptake
88932756|NCT01752816|Experimental|Strength following endurance training|20 minutes bicycle or treadmill training at 60% maximal oxygen uptake followed by 20 minutes stength training increasing from 15RM to 10RM
88932757|NCT01752868|Experimental|supplement|
88932758|NCT01752868|No Intervention|control|
88932759|NCT01752881|Experimental|AdimFlu-S|
88932760|NCT01752894|Active Comparator|Angio guided PCI|
88932761|NCT01752894|Experimental|OCT-guided PCI|
89447397|NCT06033963|Active Comparator|RIC+CEA+Standard medical treatment|Remote ischemic conditioning (RIC) is induced by 5 cycles of 5 min of bilateral upper limbs ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mmHg. RIC will be conducted twice daily for 6 consecutive days after enrollment. Additionally, the patients will be treated with carotid endarterectomy (CEA) and standard medical treatment according to the Chinese guideline for the secondary prevention of ischemic stroke and transient ischemic attack 2022.
89447398|NCT06033963|Placebo Comparator|Sham RIC+CEA+Standard medical treatment|Remote ischemic conditioning (RIC) is induced by 5 cycles of 5 min of bilateral upper limbs ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mmHg. RIC will be conducted twice daily for 6 consecutive days after enrollment. Additionally, the patients will be treated with carotid endarterectomy (CEA) and standard medical treatment according to the Chinese guideline for the secondary prevention of ischemic stroke and transient ischemic attack 2022.
89447399|NCT06032234||Omnivorous|Participants following an omniviours diet
89447400|NCT06032234||Vegan|Participants following a vegan diet
89447401|NCT06031220|Experimental|study group|30 women with twin pregnancy during the third trimester at 27th weeks gestation will make deep breathing exercise inform of diaphragmatic and costal breathing 3times a day for 15 repetitions each exercise for 9 weeks, pulmonary function test will be applied at 27th week gestation and at 36th weeks gestation.
89447402|NCT06031220|No Intervention|control group|30 women with twin pregnancy during the third trimester at 27th weeks gestation will not receive any special treatment and will be assessed with pulmonary function test at 27th week gestation and at 36th weeks gestation.
89447403|NCT06026410|Experimental|Arm #1: RAS-altered advanced solid tumors|"Patients with advanced solid tumors and the following:~HRAS-mutant and/or amplified tumors (any solid tumor type)~HRAS overexpression (only for HNSCC tumors)~KRAS and/or NRAS and/or HRAS-mutant and/or amplified for NSCLC or CRC~KRAS-mutant and/or amplified PDAC"
89447404|NCT06026410|Experimental|Arm #2: Advanced or metastatic ccRCC|Patients who have received at least 1 prior systemic therapy with IO-based treatment for locally advanced or metastatic RCC with predominantly clear cell subtype
88932762|NCT01752894|Active Comparator|BES|
88932763|NCT01752894|Experimental|EES|
88932764|NCT01752894|Active Comparator|Keep dual antiplatelet therapy (DAPT)|Study subjects will be allocated into this arm with non-randomization method
88932765|NCT01752894|Active Comparator|Discontinue Dual antiplatelet therapy (DAPT)|Study subjects will be allocated into this arm with non-randomization method
88932766|NCT01752959|Active Comparator|Remifentanyl|Group R 0.1-0.3 mic/kg/ min remifentanil infusion other names: Ultiva
88932767|NCT01752959|Experimental|esmolol|Grup E 500 micg/kg/min lading dose after 50-500 μcg/kg/dk esmolol infusion
88932768|NCT01752972|Experimental|Palmer arsenical keratosis|Spirulina 10 g/day orally for 12 weeks
88932769|NCT01752972|Active Comparator|Arsenic exposed controls|Spirulina 10 g/day orally for 12 weeks
88932770|NCT01752972|Active Comparator|Heathy volunteers|Spirulina 10 g/day orally for 12 weeks
88932771|NCT01752998|Active Comparator|TOPPS Intervention|Individuals randomized into this arm will receive 7 individual sessions of the Treating Opioid Patients' Pain and Sadness (TOPPS) intervention, designed to reduce symptoms of pain and depression.
88932772|NCT01752998|Placebo Comparator|Health Education|Individuals randomized into this arm will receive 7 individual sessions on general health education.
88932773|NCT01753024||Sepsis-PEST|septic patients with enteral nutrition and pancreatic enzyme supplementation therapy
88932774|NCT01753024||Sepsis-NPEST|Septic patients with enteral nutrition only
88932775|NCT01753024||DM-PEST|Diabetic patients with enteral nutrition and pancreatic enzyme supplementation therapy
88932776|NCT01753024||DM-NPEST|Diabetic patients with enteral nutrition only
88932777|NCT01753024||PCAS-PEST|Patients suffering from cardiac arrest receive both enteral nutrition and pancreatic enzyme supplementation therapy
88932778|NCT01753024||PCAS-NPEST|Patients suffering from cardiac arrest receive enteral nutrition only
89447405|NCT06025344|Experimental|PanCytoVir™ 1000 mg (100 mg/mL)|PanCytoVir™ oral suspension (100 mg/mL)
88932779|NCT01753024||ARF-PEST|Patients with acute renal failure receive both enteral nutrition and pancreatic enzyme supplementation therapy
88932780|NCT01753024||ARF-NPEST|Patients with acute renal failure receive enteral nutrition only
88932781|NCT01753037|Active Comparator|DHEA Group|Oral administration of a capsule containing 130 mg of dehydroepiandrosterone (DHEA) for 5 days.
88932782|NCT01753037|Placebo Comparator|Placebo Group|Oral administration of an identical capsule containing placebo for 5 days.
88932783|NCT01753050|No Intervention|Standard care|No specific hemodynamic optimization measures
88932784|NCT01753050|Experimental|Hemodynamic optimization|Hemodynamic optimization by stroke volume monitoring
88932785|NCT01753063|Experimental|Patient Expectations|At the family's initial visit to the pediatric weight management program/clinic each parent/guardian and adolescent (if age 12 yrs. or older) will complete the survey tool. At 3 months, families will be asked to complete a follow up survey. This will be fielded at a visit for those returning to clinic or by phone/mail for those not returning.
88932786|NCT01753102|Experimental|Estradiol|Intravaginal self-administration of study medication once daily for 14 days.
88932787|NCT01753102|Active Comparator|Reference: Estradiol|Intravaginal self-administration of study medication once daily for 14 days.
88932788|NCT01753102|Placebo Comparator|Placebo|Intravaginal self-administration of study medication once daily for 14 days.
88932789|NCT01753128|Active Comparator|imipramine|
88932790|NCT01753141|Experimental|Active|Cognitive Behavioral Therapy for smoking cessation plus anxiety sensitivity reduction.
88932791|NCT01753141|Active Comparator|Control|Cognitive Behavioral Therapy for smoking cessation.
88932792|NCT01753154|Experimental|Solution B (balance PD solution)|Treatment 8 weeks with solution B (balance PD solution), next 8 weeks with solution A (conventional PD solution)
88932793|NCT01753154|Active Comparator|Solution A (conventional PD solution)|Treatment 8 weeks with solution A (conventional PD solution), next 8 weeks with solution B (balance PD solution)
88932794|NCT01753180|Experimental|collagenase|
88932795|NCT01753180|Placebo Comparator|saline|
88932796|NCT01753219|Experimental|Onstep|Participants in this group will have a inguinal hernia repair ad modum Onstep.
88932797|NCT01753219|Active Comparator|Lichtenstein|Participants in this group will receive a inguinal hernia repair ad modum Lichtenstein.
88932798|NCT01753232||DALI-adsorber, hypercholesterolemia|Patients suffering from familial hypercholesterolemia treated at least twice a month with the DALI-system
88932799|NCT01753232||MONET-Filter, hypercholesterolemia|Patients suffering from familial hypercholesterolemia treated with the MONET-Lipoprotein filter
88932800|NCT01753245||Non-Metabolic Syndrome|Patients without Metabolic Syndrome criteria (OMS).
88932801|NCT01753245||Metabolic Syndrome|Patients with Metabolic Syndrome criteria (OMS).
88932802|NCT01753258||Definite diagnosis of dyspareunia|Patients who report dyspareunia, and whose dyspareunia was evaluated prior to delivery by a caregiver experienced with sexual pain disorders, with definite diagnosis.
88932803|NCT01753258||No definite diagnosis of dyspareunia|"Patients who report dyspareunia but were not evaluated prior to delivery or were evaluated inappropriately (i.e. yeast infection without cultures, inflammation and other vague definitions)."
88932804|NCT01753258||Patients without dyspareunia|Patients without dyspareunia- those who report non painful sexual intercourse. This group of patients will be used as a control group.
88932805|NCT01753271|Experimental|Thoracic Mobilization|thoracic mobilization in addition to shoulder mobilization plus exercise
88932806|NCT01753271|Active Comparator|exercise only|shoulder mobilization plus exercise alone
88932807|NCT01753349||Idiopathic cervical dystonia|Adults subjects from Hospitals, Private Practices suffering idiopathic cervical dystonia. BoNT-A injections, 3-4 times yearly.
88932808|NCT01753375|Active Comparator|Vitamin D3|Administered orally on weekly basis
88932809|NCT01753375|Placebo Comparator|Placebo|To be administered orally on weekly basis
88932810|NCT01753388|Experimental|Treatment by the Liberty Stent|
88932811|NCT01753440|Other|Stem cells implantation|Patients with severe coronary artery disease and chronic ischemic cardiomyopathy with a LVEF ≤40% who are scheduled for elective CABG according to accepted guidelines. Additional criteria include the following: age <75 years, history of myocardial infarction (not less than 14 days before the procedure), LVEF ≤40 % assessed with echocardiography, and a distinct area of dyskinetic or akinetic left ventricular myocardium corresponding with the infarct localization.
88932812|NCT01753453|Active Comparator|G-CSF alone|Patients will receive G-CSF for 5 consecutive days
88932813|NCT01753453|Experimental|G-CSF plus plerixafor|Patients will receive G-CSF for 4 consecutive days, then receive plerixafor before the 5th dose of G-CSF
88932814|NCT01753466|Experimental|Hydration|Participants who are randomized to the hydration-intervention group will be asked to consume 1.0 to 1.5 L water per day, depending on sex and weight, in addition to usual consumed beverages, for 6 weeks
88932815|NCT01753466|No Intervention|Control|
88932816|NCT01753479|Experimental|Test subject|
88932817|NCT01753492|Experimental|Ologen implantation (single arm)|Ologen implantation as an adjunctive to trabeculectomy
88932818|NCT01753505|Experimental|MDCTA|
88932819|NCT01753531||Flu Symptoms|
88932820|NCT01753583|Experimental|10 patients with corneal abrasions|
88932821|NCT01753583|Experimental|10 patients with corneal infiltrates|
88932822|NCT01753596|Experimental|30 healthy subjects|Subjects will receive 1 drop of Genteal HA eye drops in one randomly chosen eye, the other eye will receive placebo
88932823|NCT01753596|Experimental|30 patients with dry eye syndrome|Patients will receive 1 drop of Genteal HA eye drops in one randomly chosen eye, the other eye will receive placebo
88932824|NCT01753609|Experimental|Tulip capsule|swallowing Tulip capsule for up to 29 days
88932825|NCT01753622|No Intervention|Control group|Sedentary Obese and overweight pregnant women
88932826|NCT01753622|Experimental|Exercise group|Physical exercise program
88932827|NCT01753635|Experimental|Baska mask|In this arm the Baska mask will be used as the airway management device
88932828|NCT01753635|Active Comparator|single use laryngeal mask airway device (LMA)|in this arm a single use LMA device will be used for airway management.
88932829|NCT01753661|Experimental|Project ASPIRE Treatment Condition|The Project ASPIRE Treatment condition will receive the Project ASPIRE intervention program which includes the linguistic feedback reports and the multimedia education sessions. This group will complete the same assessments as the control group.
88932830|NCT01753661|Active Comparator|EI-As-Usual Condition|As an ethical decision, eligible participants may roll over to the experimental group after satisfactory completion of this treatment.
88932831|NCT01753674|Experimental|TA-65|TA-65 will be provided to volunteers for 12 weeks, two pills per day of 8 mg each
88932832|NCT01753674|Placebo Comparator|Placebo|Placebo will be provided to volunteers for 12 weeks, 2 pills per day of 8 mg each.
88932833|NCT01753687|Other|50 patients with dry eye syndrome|
88932834|NCT01753700|Experimental|UHT treated milk|1,5 L of 1,5% UHT milk pr day for 3 weeks (21days)
88932835|NCT01753700|Placebo Comparator|Paseurised milk|1,5 L 1,5% pasteurised milk pr day for 3 weeks (21 days)
88932836|NCT01753726|Experimental|Experimental group|43 people are recruited in order to the inclusion criteria for the study. They are healthy people. A diaphragm stretching technique was employed in this experimental group.
88932837|NCT01753726|Placebo Comparator|Placebo group|37 healthy people were recruited in order to the inclusion criteria.
88932838|NCT01753752|Experimental|Chitosan-N-acetylcystein|Instillation into the study eye
88932839|NCT01753752|Placebo Comparator|Placebo|Instillation into the fellow eye
88932840|NCT01753778|Experimental|Treatment|Treatment with Cryo-Touch III Device at Day 0
88932841|NCT01753791|Experimental|Cohort 1|
88932842|NCT01753791|Experimental|Cohort 2|
88932843|NCT01753791|Experimental|Cohort 3|
88932844|NCT01753791|Experimental|Cohort 4|
88932845|NCT01753804||Study participants|All participants will follow the same protocol, including muscle strength and function testing, and blood and urine collection, for a maximum of 7 visits over 3 years.
88932846|NCT01753817||Study cohort|Cohort of patients who have previously undergone transradial catheterization with the use of a 7F vascular sheath
88932847|NCT01753843|Active Comparator|early cord clamping|cord clamping within 20 sec
88932848|NCT01753843|Experimental|brief delay in cord clamping|cord clamping delayed by 30 to 60 seconds
88932849|NCT01753869|Active Comparator|ACTs after HTS inhalation:|ACTs after HTS inhalation: Patients will take a bronchodilator (Salbutamol, 2 puffs) wait 15 minutes, and then take a single inhalation (4 mls) of 7% HTS (Nebusal™) via updraft nebulizer (Portex) (approximately 20 minutes) immediately followed by an airways clearance session of 10 supervised cycles of Active Cycle of Breathing Technique (ACBT) using the acapella® (approximately 20 minutes).
88932850|NCT01753869|Active Comparator|ACTs during HTS inhalation|ACTs during HTS inhalation: Patients take a bronchodilator (Salbutamol, 2 puffs), wait 15 minutes, and then take a single inhalation (4mls) of 7% HTS (Nebusal™) through the acapella® duet (with portex updraft nebulizer attached) device. During inhalation, an airways clearance session of 10 supervised cycles of ACBT using the acapella® will be carried out (approximately 20 minutes).
88932851|NCT01753882|Experimental|Gait Training with Lexapro|Gait training 2 weeks, gait training for 4 weeks (3X week) with Lexapro (10 mg SSRI), wash out period of 1 week, gait training for 4 weeks with placebo (10 mg). Patients will also be provided prescribed TIZ by their physician to help control of spastic motor behaviors.
88932852|NCT01753882|Active Comparator|Gait Training with Placebo|Gait training 2 weeks, gait training for 4 weeks (3X week) with Placebo (10 mg), wash out period of 1 week, gait training for 4 weeks with Lexapro(10 mg). Patients will also be provided prescribed TIZ by their physician to help control of spastic motor behaviors.
88932853|NCT01753908|Experimental|Arm I (broccoli sprout extract)|Patients receive broccoli sprout extract PO QD on days 1-14 immediately prior to surgery.
88932854|NCT01753908|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD on days 1-14 immediately prior to surgery.
88932855|NCT01753921||DKA Group|Subjects who presented in diabetic ketoacidosis.
88932856|NCT01753921||Healthy control|Control subjects without diabetes.
88932857|NCT01753947|Experimental|Deliberate Practice|Residents in the deliberate practice group received individualized feedback at the end of the initial assessment case. The staff surgeon supervising the case completed 3 previously validated technical skills assessment forms.
89014287|NCT05517447|Experimental|Treatment Cohort|Proptosis non-responders in feeder studies will be administered batoclimab of 680 milligram (mg) subcutaneous (SC) for 12 weeks followed by 340 mg SC for 12 weeks
89200536|NCT02541123||Cohort C|CT positive for acute intracranial lesion with initial blood draw within 4 hours of head injury
88932858|NCT01753947|No Intervention|Conventional Feedback|Residents in the control group received informal feedback as they performed the initial laparoscopic cholecystectomy in the operating room. This was left up to the discretion of the staff surgeon supervising the operation. This corresponds to the routine teaching and feedback practices that occur during conventional surgical residency training
88932859|NCT01753960||Control group|Anesthesiologists without access to data from a continuous noninvasive hemoglobin monitoring device during surgery.
88932860|NCT01753960||SpHb group|Anesthesiologists with access to data from a continuous noninvasive hemoglobin monitoring device during surgery.
88932861|NCT01753986|Experimental|Brief Alcohol Intervention plus Standard Batterer intervention|Brief Alcohol Intervention plus 40 hours of Standard Batterer intervention
88932862|NCT01753986|Placebo Comparator|General Health Improvement plus Standard batterer intervention|General Health Improvement Intervention plus 40 hours of Standard Batterer intervention
88932863|NCT01754012|Experimental|Dietary Intervention|This group will follow for a year the NU-AGE whole diet approach elderly-specific and will be supplemented with 10micrograms per day of Vitamin D (cholecalciferol) from MCOHealth.
88932864|NCT01754012|No Intervention|Control Group|This group will follow the habitual diet.
88932865|NCT01754038||Integrative Medicine Clinic Attendees|All patients attending a participating Integrative Medicine clinic for clinical services will be invited to participate in the PRIMIER Registry
88932866|NCT01754051||Treatment by the PC 400 coils|Patients enrolled in this study must be those treated according to the cleared indication for the PC 400 System in the Instructions for Use.
88932867|NCT01754064||Cardiac Rhythm Management device|Implanted with implantable defibrillator or pacemaker system
88932868|NCT01754077|Experimental|Thirty Million Words Project|The participants in the intervention group receive the LENA linguistic feedback reports intervention and the home visiting educational session intervention. Participants in this arm complete the same assessments as participants in the control group.
88932869|NCT01754077|Other|Control Group|The control group receives the Childhood Nutrition Education intervention. Participants in this group completed the same assessments as the treatment group. Following participation in the control group, eligible families were offered the opportunity to continue into the experimental group.
88932870|NCT01754090|Active Comparator|Usual care|"Receives two interventions:~Online screening and feedback.~Online booklet."
88932871|NCT01754090|Experimental|Extended follow-up|"Receives two interventions:~Online screening and feedback.~Online multi session follow-up."
88932872|NCT01754103|Experimental|Functional Connectivity MRI|Functional Connectivity will be measured by MRI, we will perform one T1WI run as well as three resting state bold based runs. Bold runs parameters: TE 30ms, TR 3000ms, flip angle 90º, gap 0mm, 124 time points, voxel size 3mm, duration 6min18s each, FOV 240x240x141.
88932873|NCT01754116|Experimental|Lead In Period GSK1265744 30 mg + midazolam 3mg|During the lead-in period, a group of 12 subjects will receive a midazolam probe (on Day -29 and Day -14) to examine the potential of GSK265744 to inhibit or induce cytochrome P450 (CYP)3A activity. On Day -28, subjects will begin a 14 day oral dose of GSK265744 30 mg. to be taken once daily from Day-28 to Day -14. Subjects will begin a wash out period from Day -14 to Day -1 and be randomized to GSK1265744 LAP on Day 1
88932874|NCT01754116|Experimental|Lead in Period GSK1265744 30mg|On Day -28, subjects will begin a 14 day oral dose lead-in period. Subjects will be dispensed a 14 day supply of 30mg oral GSK1265744 to be taken once daily from Day-28 to Day -15. Subjects will begin a wash out period from Day -14 to Day -1 and be randomized to GSK1265744 LAP on Day 1
88932875|NCT01754116|Experimental|Treatment A|Approximately 15 subjects will be enrolled and randomized on Day 1 to receive a single dose of 400 mg GSK1265744 (Nanomilled 200 nm) LAP intramuscular suspension injection
88932876|NCT01754116|Experimental|Treatment B|Approximately 15 subjects will be enrolled and randomized on Day 1 to receive a single dose of 400mg GSK1265744 (Nanomilled 1 micro m) LAP intramuscular suspension injection
88932877|NCT01754116|Experimental|Treatment C|Approximately 15 subjects will be enrolled and randomized on Day 1 to receive a single dose of 400 mg GSK1265744 (Dry milling and homogenization 5 micro m) LAP intramuscular suspension injection
88932878|NCT01754142||Type 2 diabetes mellitus subjects initiating Kombiglyze XR|Patients with diagnosis of type 2 diabetes mellitus initiating Kombiglyze XR treatment within the approved indications will be enrolled
88932879|NCT01754155|Other|Vitamin E Polyethylene and RSA|All subjects will have the Vitamin E polyethylene and RSA beads placed during surgery. Subjects will then have standard x-ray images and RSA images taken at specific time points up until 2 years post-operatively.
88932880|NCT01754181|Experimental|Proposed treatment by Diabeloop algorithm|the insulin dose is calculated by the algorithm based on the usual treatment of the patient, the ratio I / C, the intensity of physical activity and blood glucose sensor.
88932881|NCT01754181|No Intervention|usual treatment|
88932882|NCT01754220|Active Comparator|Montelukast|Montelukast tablets: adults - 10 mg, children - 5mg taken daily for two weeks
88932883|NCT01754233|Experimental|755nm Alexandrite Laser|755nm Alexandrite Laser
88932884|NCT01754246|Experimental|Alexandrite Laser for Skin Toning|755 nm Alexandrite Laser for Skin Toning
88932885|NCT01754246|Experimental|Alexandrite Laser for Pigmented Lesions|755nm Alexandrite Laser for Epidermal Pigmented Lesions
88932886|NCT01754272||FOLFIRI + Aflibercept|Non-interventional study. No drugs administered. In this arm 612 patients from the VELOUR trial
88932887|NCT01754272||FOLFIRI + Placebo|Non-interventional study. 614 patients from the FOLFIRI + placebo arm in the VELOUR trial.
88932888|NCT01754285|Experimental|LF-PB 10 mg|2 IM injections = placebo + 10 mg
88932889|NCT01754285|Experimental|LF-PB 20 mg|2 IM injections = placebo + 20 mg
88932890|NCT01754285|Experimental|LF-PB 30 mg|2 IM injections = 10 mg + 20 mg
88932891|NCT01754285|Placebo Comparator|Placebo|2 IM injections of placebo
88932892|NCT01754298|Active Comparator|Retro-articular drilling|Retro-articular drilling goes through the cortical margin of the affected condyle, thereby sparing the articular surface and physes.
88932893|NCT01754298|Active Comparator|Trans-articular drilling|Trans-articular drilling penetrates the articular cartilage through multiple sites to create subchondral penetrations.
88932894|NCT01754311||HTLV-1 infected patients|HAM/TSP patients and HTLV-1 Asymtomatic patients
88932895|NCT01754311||control|Blood donors
88932896|NCT01754324||Methadone|All infants requiring pharmacological treatment of their NAS symptoms are treated with a standardized protocol utilizing oral methadone. This treatment protocol has been the standard of care for infants with NAS at our institution for many years. Infants enrolled in this study will have blood samples drawn at predetermined times in order to obtain information regarding the pharmacokinetics of oral methadone in this population.
88932897|NCT01754337|Active Comparator|Single-hormone closed-loop system|In single-hormone closed-loop system, variable subcutaneous insulin infusion rate will be used to regulate glucose levels.
88932898|NCT01754337|Active Comparator|Dual-hormone closed-loop system|In dual-hormone closed-loop system, variable subcutaneous insulin and glucagon infusion rates will be used to regulate glucose levels.
88932899|NCT01754337|Active Comparator|Insulin pump therapy|Patient's conventional treatment will be implemented.
88932900|NCT01754415|No Intervention|control|Do exercise at home with video program designed by our team.
88932901|NCT01754415|Experimental|hydraulic resistance circuit training|Intervention:12 weeks resistance training
88932902|NCT01754454|Experimental|Human Umbilical Cord Derived MSC|"Human Umbilical Cord Derived MSC:~Patients who receive standard of care plus treatment with ex vivo cultured adult human Umbilical Cord Derived Mesenchymal Stem Cells"
88932903|NCT01754506|Experimental|EPA+DHA|EPA+DHA (fish oil)
88932904|NCT01754506|Placebo Comparator|Placebo|mineral oil
88932905|NCT01754532||Schizophrenia patients|
88932906|NCT01754545|Experimental|Octaplas infusion and placebo (group 1)|Active treatment with randomly assigned 400 ml octaplas intravenously 2-3 times a week and 400 ml placebo (for octaplas)intravenously 2-3 times a week over two weeks.
88932907|NCT01754545|Experimental|Octaplas infusion and placebo (group 2)|Active treatment with randomly assigned 400 ml octaplas intravenously once and 400 ml placebo (for octaplas)intravenously twice in two separate intervention weeks
88932908|NCT01754558|Experimental|Ajust sling|The sling a a new device for stress urinary incontinence. The sling is ajustable and is not penetrating the skin, i.e. is only attached to the obturator membrane
88932909|NCT01754558|Experimental|TVT/TVT-O, polypropylne slings|TVT/TVT-O system. These two systems is wellknown and used for treatment of stress urinary incontinence. The sling penetrate the skin in order to secure adjustment.
88932910|NCT01754571|Experimental|CBT treatment|
88932911|NCT01754597|Experimental|Peptide Natriurétique de type B|Peptide Natriurétique de type B
88932912|NCT01754636||Elderly patients|patients aged 65 years old or older : no intervention
88932913|NCT01754636||"Young patients"|patients aged 18-64 years (added by amendment n°3 -02/2014) : no intervention
88932914|NCT01754649|Active Comparator|misoprostol vaginal 200 mcg|The study group will receive two doses of misoprostol (200mcg each tablet) vaginal 12 and 4 hours prior insertion After 24 hours of the insertion failure the women will return to the clinic and a new attempt of insertion will be done. At this time we will evaluate if the insertion was able to do or not.
88932915|NCT01754649|Placebo Comparator|placebo|The placebo group will receive two doses of placebo vaginal 12 and 4 hours prior insertion. After 24 hours of the insertion failure the women will return to the clinic and a new attempt of insertion will be done. At this time we will evaluate if the insertion was able to do or not.
88932916|NCT01754662|Experimental|Soy protein with isoflavones and cocoa|Soy protein with isoflavones and cocoa bars. 2 bars daily for 8 weeks.
88932917|NCT01754662|Experimental|Soy protein alone with cocoa|Soy protein alone with cocoa with no isoflavones. 2 bars daily for 8 weeks.
88932918|NCT01754662|Experimental|Soy protein with soy isoflavones|Soy protein with isoflavones bar. 2 bars daily for 8 weeks.
88932919|NCT01754662|Experimental|Soy protein alone|Soy protein alone without soy isoflavone or cocoa polyphenol. 2 bars daily for 8 weeks.
88932920|NCT01754662|Placebo Comparator|Placebo|Placebo bar without soy protein, isoflavones or cocoa polyphenols. 2 bars daily for 8 weeks
88932921|NCT01754675|Experimental|Soccer|Watching the soccer match at the time that the favorite team is playing
88932922|NCT01754675|Placebo Comparator|Movie|Watching a movie at the time that the favorite team is playing
88932923|NCT01754701|Experimental|Immediate iron|Children who start 4 weeks of iron therapy on Day 0
88932924|NCT01754701|Experimental|Delayed iron|Children who start 4 weeks of iron therapy on Day 28
88932925|NCT01754740|Experimental|Study Group|19 patients whom received topical medication of urea 10%
88932926|NCT01754740|Placebo Comparator|Control Group|19 patients whom received placebo
88932927|NCT01754805|Experimental|ASP015K and methotrexate|Patients receive a single dose of methotrexate on day 1 and day 8 and ASP015K (twice daily) on days 3 through 8 plus the morning of day 9.
88932928|NCT01754818|Placebo Comparator|Placebo|Placebo, oral capsule, no active study drug, single dose
88932929|NCT01754818|Experimental|Bendavia 10mg|Bendavia, oral capsule, 10mg, single dose
88932930|NCT01754818|Experimental|Bendavia 50mg|Bendavia, oral capsule, 50mg, single dose
88932931|NCT01754818|Experimental|Bendavia 100mg|Bendavia, oral capsule, 100mg, single dose
88932932|NCT01754831|Other|Fluoride varnish|Topical fluoride
88932933|NCT01754844|Experimental|Group 1-5, single ascending dose AZD7624|Subjects will participate in 1 of 5 groups. In each group 6 subjects will receive AZD7624 and 2 subjects will receive matching placebo.
88932934|NCT01754844|Placebo Comparator|Placebo|Subjects will participate in 1 of 5 groups. In each group 6 subjects will receive AZD7624 and 2 subjects will receive matching placebo.
89014288|NCT05517421|Experimental|Batoclimab|Participants will be administered batoclimab 680 mg SC weekly for 12 weeks followed by 340 mg SC weekly for 12 weeks.
88932935|NCT01754870|Experimental|Bendamustine + Rituximab-->Rituximab and Lenalidomide|"Induction chemoimmunotherapy:~Bendamustine 70 mg/m2 IV days 1 & 2 every 28 days X 6 cycles~Rituximab 500 mg/m2 IV day 1 every 28 days X 6 cycles (375 mg/m2 IV cycle 1 only, day 1 or 2)~Maintenance phase:~Rituximab 375 mg/m2 IV on day 1 of every odd-numbered 28 day cycle for a maximum of 12 doses during the maintenance phase.~Lenalidomide 5 mg orally daily on days 1-28 of each 28-day cycle for 24 cycles (maintenance cycles 1-24); dose escalation to 10 mg orally daily will be allowed at the start of cycle 2 or at the start of any subsequent cycle in subjects with acceptable toxicities needed to escalate the dose of lenalidomide to 10 mg/day."
88932936|NCT01754883|Experimental|Lithium Augmentation|Open-label trial - active treatment
88932937|NCT01754896|Experimental|Mail-out/Mail-back|Mailing of FIT kit directly to patient. Mailing completed kits in for processing.
88932938|NCT01754896|Experimental|Mail-out/Drop-off|Mailing of FIT kit directly to patient. Dropping completed kits at lab for processing.
88932939|NCT01754896|Experimental|Pick-up/Mail-back|Mailed invitation to pick up lab requisition and then kit. Mailing completed kits in for processing.
88932940|NCT01754896|Experimental|Pick-up/Drop-off|Mailed invitation to pick up lab requisition and then kit. Dropping completed kits at lab for processing.
88932941|NCT01754961|Placebo Comparator|Placebo|Placebo will be given on Day 1 orally
88932942|NCT01754961|Active Comparator|Vitamin D|Administration of 500,000 IU Vitamin D orally on Day 1
88932943|NCT01754974|Experimental|Peginterferon Lambda-1a + Ribavirin|Peginterferon Lambda-1a 180 μg solution for subcutaneous (sc) injection once weekly and Ribavirin 1000 or 1200 mg based on weight tablet by mouth twice daily for 48 weeks
88932944|NCT01754974|Active Comparator|Peginterferon alfa-2a + Ribavirin|Peginterferon alfa-2a 180 μg solution for subcutaneous (sc) injection once weekly and Ribavirin 1000 or 1200 mg based on weight tablet by mouth twice daily for 48 weeks
88932945|NCT01755000|Other|Aim 1: Hemodynamically Healthy Patients|"Nurse 1 will perform an USCOM scan and record values of Vpk and SV on the clinical data sheet.~Nurse 2 will perform the USCOM second scan within five minutes of Nurse 1's scan and record the values of Vpk and SV on the clinical data sheet.~Nurse 1 and 2 will be blinded to each other's scans by using separate clinical data forms"
88932946|NCT01755000|Other|Aim 2: Hemodynamically Unstable Patients|"Nurse 1 will perform an USCOM scan and record values of Vpk and SV on the clinical data sheet.~Nurse 2 will also be notified of the hypotensive event, will then perform the USCOM second scan within five minutes of PI's scan and record the values of Vpk and SV on the clinical data sheet.~The two USCOM scans will be completed within 10 minutes of the hypotensive episode.~Nurse 1 and Nurse 2 will be blinded to each other's scans by using separate clinical data forms."
88932947|NCT01755000|Other|Aim 3: Hemodynamically Unstable Patients + Fluid Bolus|"At the time that an enrolled patient meets one of the following criteria; SBP drops below 95 mmHg or MAP drops below 65 mmHg the PI will be notified to PI to perform the USCOM scan and record the Vpk, SV, systolic blood pressure and mean arterial pressure on the clinical data sheet within 10 minutes of the hypotensive episode, prior to the patient receiving a fluid bolus (fluid bolus is part of standard of care).~The USCOM scan will then be repeated within 5 minutes after fluid bolus delivery.~Before the hemodynamically unstable patient receives subsequent fluid boluses (multiple boluses are common standard of care), the PI will perform an USCOM scan. Then within 5 minutes after the delivered fluid bolus, the PI will perform another USCOM scan. This will continue, until no further boluses are prescribed."
88932948|NCT01755013|Experimental|PDT Group|Subjects who receive Photodynamic therapy with plastic optic diffuser.
88932949|NCT01755039||Patients with invasive out-of-hospital ventilation|
88932950|NCT01755065||Teenager laparoscopic patients|
88932951|NCT01755078|Experimental|Sevelamer HCl|Sevelamer HCl regular treatment 1-3 tablets TID
88932952|NCT01755078|Active Comparator|Calcium-based binder|Calcium-based phosphate binder (either CaCO3 or Ca acetate) administered 1-3 tablets TID
88932953|NCT01755104|Experimental|Stablor|dietary supplement Stablor
88932954|NCT01755104|Placebo Comparator|Placebo|dietary supplement Placebo
88932955|NCT01755117|Active Comparator|TKR, sciatic, femoral, obturator|TKR surgery under ultrasound guided sciatic nerve block plus femoral nerve block plus obturator nerve block
88932956|NCT01755117|Active Comparator|TKR sciatic nerve block, posterior lumbar plexus block|TKR surgery under ultrasound guided sciatic nerve block plus posterior lumbar plexus block
88932957|NCT01755130|Experimental|Diagnostic (LOUISA 3D)|Patients undergo LOUISA 3D over approximately 30 minutes on the same day or within 7 days of any breast imaging procedure and within 7 days before biopsy.
88932958|NCT01755182|Active Comparator|Pharmacologic therapy|Patients in this arm receive systemic pharmacologic therapy alone
88932959|NCT01755182|Experimental|TAE and pharmacologic therapy|Patients in this arm receive systemic pharmacologic therapy and TAE
88932960|NCT01755221|Other|Single-center prospective evaluation of the Restech pH probe|"Restech pH probe placement at initial clinic visit; Subject returns 24 hours later for probe removal~Proton pump inhibitor (PPI) therapy; Subject starts PPI medication (omeprazole 40mg once daily) and returns for follow-up visit 8-12 weeks later~Optional second pH probe placement at follow up visit; Subject returns 24 hours later for probe removal; Subject continues PPI medication for 2 more weeks"
88932961|NCT01755247|Placebo Comparator|Topical Gel Vehicle|Once daily application of topical gel vehicle to forehead for 3 days
88932962|NCT01755247|Active Comparator|8% NVN1000 Topical Gel|Once daily application of 8% NVN1000 Topical Gel to the forehead for 3 days
88932963|NCT01755247|Active Comparator|8% NVN1000 Topical Gel and moisturizer|Once daily application of 8% NVN1000 Topical Gel to the forehead, followed 15 minutes later by application of a commercially available moisturizer
88932964|NCT01755260|No Intervention|oral intake|The patients at this arm were allowed to take food through mouth
88932965|NCT01755273|No Intervention|Standard pancreaticoduodenectomy|Cases receiving pancreaticoduodenectomy with standard enteral bypass
88932966|NCT01755286|Experimental|4 mg OTO-201|
88932967|NCT01755286|Experimental|12 mg OTO-201|
88932968|NCT01755286|Placebo Comparator|Vehicle for OTO-201|
88932969|NCT01755286|Sham Comparator|Sham|
88932970|NCT01755299|Active Comparator|Active ingredient|"Regular 5-hour Energy"
88932971|NCT01755299|Active Comparator|Active ingredient-2|"5-hour Energy Decaf"
88932972|NCT01755299|Active Comparator|Active ingredient-3|Compounded caffeine product 135 mg/2 ounces
88932973|NCT01755299|Placebo Comparator|Placebo|Flavored placebo
88932974|NCT01755312|Experimental|medication reminder|medication reminder
88932975|NCT01755312|Placebo Comparator|Placebo|Placebo
88932976|NCT01755325|Experimental|Compound realgar natural indigo Tablet|"Compound realgar natural indigo Tablet, 65mg/kg/d, from day1 to day14,every 4 weeks.~imatinib,0.4g,qd"
88932977|NCT01755325|Placebo Comparator|placebo|"placebo tablet,65mg/kg/d, from day1 to day14,every 4 weeks.~imatinib 0.4g qd"
88932978|NCT01755338|Active Comparator|Methylprednisolone|Methylprednisolone i.v. 15mg/kg x 1 intraoperative Aortic Valve Replacement
88932979|NCT01755338|Placebo Comparator|Placebo (NaCl)|Placebo i.v., x1, intraoperative Aortic Valve Replacement
88932980|NCT01755364|Experimental|AdimFlu-V|
88932981|NCT01755377||No Chagas Disease|Participants with no Chagas Disease will be evaluated as a Control Group
88932982|NCT01755377||Chagas Disease|Participants diagnosed with Chagas Disease will be followed-up as a Case Group
89200537|NCT02541123||Cohort D|CT positive for acute intracranial lesion with initial blood draw within 4-6 hours of head injury
89200538|NCT02541123||Cohort E|Uninjured control group
89200539|NCT00980512|Experimental|Parent Training|Parent Training of foster parents
89200540|NCT00980512|No Intervention|Control|Control group
89200541|NCT02534077|Experimental|1|Drug: Omegaven
89200542|NCT00977158||Throat Swab|Infants who have been diagnosed with cystic fibrosis
89200543|NCT00977236|Experimental|Orthokeratology lenses|Children wearing orthokeratology at night for partial correction and spectacles at daytime for residual refractive error will be study group
89200544|NCT00977236|Other|Single-vision spectacle lenses|Children wearing single-vision spectacles in the daytime for correcting the refractive error will serve as control group
89200545|NCT00378079|Experimental|3|
89200546|NCT00378079|Active Comparator|1|
88932983|NCT01755390|Experimental|Cabazitaxel|"IV escalation part:~XRP6258 administered as a 1-hour IV infusion on Days 1, 8, 15 and 22 of each 5-week cycle until evidence of disease progression, unacceptable toxicity or patient's withdrawal.~Oral bioavailability part:~XRP6258 administered at the dose of 8.4 mg/m² as an oral administration on Day 1 Cycle 1 and as a weekly 1-hour i.v. infusion at the subsequent weeks of treatment. Patients receiving oral administration at Day 1, Cycle 1 are to fast for 12 hours before and 4 hours after administration."
88932984|NCT01755403|Other|Benznidazole|
88932985|NCT01755442|Active Comparator|AMG 151|
88932986|NCT01755442|Placebo Comparator|Placebo|
88932987|NCT01755468|Active Comparator|Continuous metformin|After a 3-week course of intensive insulin therapy, participants will be treated with ongoing metformin monotherapy. Metformin will be initiated at 500mg twice a day for the first 2 weeks, before progressing to 1000mg twice a day for the duration of the trial (24 months).
88932988|NCT01755468|Experimental|Intermittent insulin therapy|After a 3-week course of intensive insulin therapy, participants will receive intermittent intensive insulin therapy for 2 weeks every 3 months. The 2-week course of insulin therapy will be repeated at 3-, 6-, 9-, 12-, 15-,18- and 21-months, with final outcome measurement performed at 24-months
88932989|NCT01755481|Experimental|Probiotics F19|F19 in an infant formula
88932990|NCT01755481|Experimental|Whey protein concentrate|Whey protein concentrate in an infant formula
88932991|NCT01755494|Experimental|Lower dose|co-administration of a single oral dose of a 5 mg saxagliptin tablet and a 500 mg metformin XR (Glucophage XR®) tablet vs. single FDC tablet consisting of 5 mg saxagliptin and 500 mg metformin XR (Kombiglyze XR)
89200547|NCT00378079|Experimental|2|
89200548|NCT00970450|Experimental|Paracetamol|
89200549|NCT00970450|Experimental|Paracetamol/Tropisetron|
89200550|NCT00970450|Placebo Comparator|Saline|Proband will receive Saline
89200551|NCT00970450|Active Comparator|Tropisetron|Proband will receive Tropisetron alone
89200552|NCT01580917||Diabetic Test|Diabetic individuals with a history of previous plantar ulcer and a high risk of developing a foot ulceration
89200553|NCT01580917||Healthy Controls|Non-diabetic, healthy individuals with low risk of developing a neurogenic foot ulcer
89200554|NCT00970528|Experimental|Arm 1|
89200555|NCT00970528|Active Comparator|Arm 2|
89200556|NCT03936244|Active Comparator|M-TURP|The M-TURP procedure requires the use of a resectoscope (Olympus or Storz, 26Ch), camera system and irrigation fluid (Glycine 1.5%, Baxter). The system consists of a generator unit (ForceTriadTM, Medtronic) and a stainless steel loop with an electrical current running through the loop used to cut (120W) prostate tissue and cauterize (80W). Prostate tissue is cut away in small pieces and removed at the end of the procedure using an Ellik evacuator
89200557|NCT03936244|Experimental|PK-TURP|The PK-TURP procedure requires the use of a resectoscope (Storz, 26Ch), camera system and irrigation fluid (NaCl 0.9%, Baxter). The system consists of a generator unit (PlasmaKineticTM Superpulse de Gyrus, ACMI) and a platinum-iridium superloop with an electrical current running through the loop used to cut (180W) prostate tissue and cauterize (100W). Prostate tissue is cut away in small pieces and removed at the end of the procedure using an Ellik evacuator
88932992|NCT01755494|Experimental|Higher dose|co-administration of a single oral dose of a 5 mg saxagliptin tablet and two (2) 500 mg metformin XR (Glucophage XR®) tablets vs. Single FDC tablet consisting of 5 mg saxagliptin and 1000 mg metformin XR (Kombiglyze XR)
88932993|NCT01755507|Experimental|B|norUDCA
88932994|NCT01755507|Experimental|C|norUDCA
88932995|NCT01755507|Placebo Comparator|placebo|Placebo
88932996|NCT01755507|Experimental|A|norUDCA
88932997|NCT01755520|Experimental|Ticagrelor|Intervention: Drug: Ticagrelor verum + Aspirin placebo
88932998|NCT01755520|Active Comparator|Aspirin|Intervention: Drug: Aspirin verum + Ticagrelor placebo
88932999|NCT01755533|Experimental|Rural curriculum|Receive rural version of curriculum
88933000|NCT01755533|Experimental|Classic curriculum|Receive classic version of curriculum
88933001|NCT01755533|No Intervention|Control|Continue normal prevention activities
88933002|NCT01755559|Other|Artesunate-amodiaquine|Efficacy estimates at 95%
88933003|NCT01755559|Other|Dihydroartemisinin-piperaquine|Efficacy estimates at 95%
88933004|NCT01755559|Other|Artemether-lumefantrine|Efficacy estimates at 95%
88933005|NCT01755572|Experimental|Liraglutide|Liraglutide 0.6mg for 7 days, liraglutide 1.2mg for 7 days, liraglutide 1.8mg for 7 days
88933006|NCT01755572|Placebo Comparator|Placebo|Placebo 0.6mg sc for 3 weeks, Placebo 1.2mg sc for 3 weeks, Placebo 1.8mg for 3 weeks.
88933007|NCT01755585||C/T-RT group|Chemotherapy (C/T) is applied in the morning. After 2-4 hrs, radiotherapy (RT) is delivered (according to the clinical practice)
88933008|NCT01755585||RT-C/T group|Radiotherapy (RT) is delivered in the morning. After 2-4 hrs, chemotherapy (C/T) is applied (according to the clinical practice).
88933009|NCT01755611|Experimental|A(reference)/B(test)|initial administration of reference and cross-over to test
88933010|NCT01755611|Experimental|B(test)/A(reference)|initial administration of test and cross-over to reference
88933011|NCT01755624|Experimental|NovoTTF-100A device|Patients will be treated continuously with the NovoTTF-100A device. NovoTTF-100A treatment will consist of wearing four electrically insulated electrode arrays on the head. The treatment enables the patient to maintain regular daily routine.
88933012|NCT01755624|Active Comparator|Best Standard of Care|Patients will be treated as the best known standard of care for Non-Small Cell Lung Cancer metastatic to the brain.
88933013|NCT01755663|Experimental|Ivabradine|Patients will recieved ivabradine(5) 1 tab bid pc for 3 day and the day of CT, and recieve placebo of metoprolol
88933014|NCT01755663|Active Comparator|metoprolol|Metoprolol (100) 1/2 tab bid pc for 3 day and the day of CT coronary , and placebo of ivabradine
88933015|NCT01754792|Experimental|Normal fasting glucose subjects|Before pinitol/placebo administration a four weeks run-in period of a healthy diet will be follow for all subjects. After this adaptation period, each subject will be randomized (1:1) into one of two groups: one that received the pinitol-enriched beverage (4 g/day) (n=20), and the other a placebo beverage (n=20) for 12 weeks.
88933016|NCT01754792|Experimental|Impaired fasting glucose subjects|Before pinitol/placebo administration a four weeks run-in period of a healthy diet will be follow for all subjects. After this adaptation period, each subject will be randomized (1:1) into one of two groups: one that received the pinitol-enriched beverage (4 g/day) (n=20), and the other a placebo beverage (n=20) for 12 weeks.
88933017|NCT01754792|Experimental|Diabetic subjects|Before pinitol/placebo administration a four weeks run-in period of a healthy diet will be follow for all subjects. After this adaptation period, each subject will be randomized (1:1) into one of two groups: one that received the pinitol-enriched beverage (4 g/day) (n=20), and the other a placebo beverage (n=20) for 12 weeks.
88933018|NCT01755676|Experimental|Orlistat 60 mg|
88933019|NCT01755676|Placebo Comparator|Placebo|
88933020|NCT01755689|Experimental|Nimenrix+Cervarix (1,2,7-Month) Group|Subjects in this group received 1 dose of Nimenrix vaccine at Month 0 and 3 doses of Cervarix vaccine at Month 1, Month 2 and Month 7. Both vaccines were administered intramuscularly (IM) in the deltoid region of the arm.
88933021|NCT01755689|Experimental|Nimenrix+Cervarix (0,1,6-Month) Group|Subjects in this group received 1 dose of Nimenrix vaccine at Month 0 and 3 doses of Cervarix vaccine at Month 0, Month 1 and Month 6. Both vaccines were administered intramuscularly (IM) in the deltoid region of the arm.
88933022|NCT01755689|Experimental|Cervarix Group|Subjects in this group received 3 doses of Cervarix vaccine at Month 0, Month 1 and Month 6, administered intramuscularly (IM) in the deltoid region of the arm.
88933023|NCT01755689|Experimental|Nimenrix+Cervarix+Boostrix Group|Subjects in this group received 1 dose each of Nimenrix and Boostrix vaccines at Month 0 and 3 doses of Cervarix vaccine at Month 0, Month 1 and Month 6. All vaccines were administered intramuscularly (IM) in the deltoid region of the arm.
88933024|NCT01755689|Experimental|Boostrix+Cervarix Group|Subjects in this group received 1 dose of Boostrix vaccine at Month 0 and 3 doses of Cervarix vaccine at Month 0, Month 1 and Month 6. Both vaccines were administered intramuscularly (IM) in the deltoid region of the arm.
88933025|NCT01755715|No Intervention|Control group|Insertion of IUD at 2-4 weeks after abortion.
88933026|NCT01755715|Experimental|Immediate IUD insertion|Insertion of IUD immediately (at the same day to 3 days) after expulsion of placenta.
88933027|NCT01755728|No Intervention|No known PDA|For all infants, we do echo cardiogram study only if they are suspected of having PDA, due to sings and symptoms. Hence, we do not do echo cardiogram study to most of the infants.
88933028|NCT01755728|Active Comparator|Ibuprofen|If there is a PDA, that should be treated, and the infant is less than 2 weeks of age, we use ibuprofen, as this is the gold standard in literature.
89537096|NCT02467439|Active Comparator|Notification Cards|Includes two groups of newly diagnosed HIV-infected participants (ppt): Seropositive and Acutely Infected. After consent and a full survey, blood and urine sample are collected for viral genetic testing and future STI testing. Ppts will be given notification cards for their sexual partners, social contacts. Ppts will receive contract partner notification: if the named sexual partners do not present for testing within 7-14 days, community outreach workers will contact and counsel the partners to visit the clinic. Any returning sexual partner or social contact presenting to the clinic with the notification card linking to the original index ppt will be consented (HIV testing, blood and urine specimen collected for viral genetic testing and future STI testing if HIV positive). If HIV-infected, they will be in the active arm, and will receive partner notification and social contact referral cards. If they are HIV-seronegative they will be screened for acute HIV infection.
89537097|NCT02467439|No Intervention|Base Case Arm|consist of HIV seropositive and seronegative STI clinic patrons . After a brief survey to obtain demographics and sexual behavior, seronegative ppts will have blood collected for screening for acute HIV infection. If a person has acute HIV infection, they will be contacted by a community outreach worker and brought back in for counseling, and, if consenting, enrolled in the active arm. STI clinic patrons who are seropositive at screening will be given cards and asked to refer their sexual partners for evaluation using passive referral. Sexual partners presenting to the clinic with the notification card linking to the original index ppt in the base case arm will be consented to be in study (HIV testing, blood and urine specimen collected for viral genetic testing and future STI testing if HIV positive). If they are seropositive, these participants will be in the base case arm, and will receive partner notification cards for passive referral.
88933029|NCT01755728|Active Comparator|Surgical closure of PDA|Infants with symptomatic PDA, who had to be treated, but could not be treated by ibuprofen, either due to age (> 2 weeks) or due ibuprofen contraindications (thrombocytopenia or renal failure), whose could not be treated by paracetamol (either because of parents' refuse or because they were on nothing per os protocol due to other disease), for whom surgery was the treatment of choice to close the arterial duct.
88933030|NCT01755728|Experimental|Paracetamol|Infants with symptomatic PDA who could not be treated with ibuprofen, and their parents agreed and they could be treated with paracetamol.
88933031|NCT01755728|No Intervention|DA closed spontaneously|Infants with PDA, who did not get any treatment for it, and the duct was closed spontaneously.
88933032|NCT01755741|Experimental|Placebo Vaginal Ring|Placebo vaginal ring with condom use
88933033|NCT01755741|Other|Condom|Male condoms during vaginal intercourse in presence and absence of the vaginal ring.
88933034|NCT01755754|Experimental|Silicone Elastomer Vaginal Ring|Silicone Elastomer Vaginal Ring
88933035|NCT01755754|Experimental|Female Condom|This trial will test the performance of female condoms when used concurrently with a placebo vaginal ring
88933036|NCT01755780||Left interscalene block|Left interscalene block on hypotension and bradycardia during beach chair positioning
88933037|NCT01755780||Right interscalene block|Right interscalene block on hypotension and bradycardia during beach chair positioning
88933038|NCT01755806||aortic root dimension change|those without aortic valve calcification
88933039|NCT01755806||aortic root dimension change, aortic valve calcium score|those with aortic valve calcification
88933040|NCT01755819|Other|Biocomposite interference screw|Thirty patients treated with ACL reconstruction and graft fixation is performed using Biocomposite interference screw on tibial and femoral side. Patients are randomized to one of the two study arms.
88933041|NCT01755819|Other|Extracortical ACL Tightrope fixation|Thirty patients treated with ACL reconstruction and graft fixation is performed using extracortical ACL Tightrope fixation on tibial and femoral side. Patients are randomized to one of the two study arms.
88933042|NCT01755832||Pool exercise group|Patients with inflammatory rheumatic disease
89014289|NCT05517421|Placebo Comparator|Placebo|Participants will be administered matching placebo SC weekly for 24 weeks.
89014290|NCT05515640||Karolinska Cohort|Observational cohort corresponding to patients treated at the Neurointensive Care Unit, Karolinska University Hospital, Stockholm, Sweden.
88933043|NCT01755845|Experimental|Arm 1|Patients in this arm will postoperatively receive paclitaxel 135 mg/m2 d1 and cisplatin 25mg/m2 d1-3 intravenously every 4 weeks with radiation. Radiotherapy consisted of 46-50 gray (5 x 2.0 gray/week) on pelvic area. After completion of chemoradiotherapy, patients receive paclitaxel 135 mg/m2 d1 and cisplatin 25mg/m2 d1-3. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.
88933044|NCT01755845|Active Comparator|Arm 2|Patients receive chemoradiotherapy as in arm 1.
88933045|NCT01755871|Experimental|Fingolimod|Gilenya 0,5mg per day, oral
88933046|NCT01755884|Experimental|Wheat oral immunotherapy|Well-cooked wheat spaghetti is given daily to the patients starting from a minimal dosage (0,0003 g of wheat protein) and increasing the dosing in every 1-2 weeks until a dosage corresponding the size of one meal.
88933047|NCT01755910||Left thoaracic paravertebral block|Surgery in the left breast under left thoracic paravertebral block and HRV
88933048|NCT01755910||Right thoracic paravertebral block and HRV|Surgery in the right breast under right thoracic paravertebral block and HRV
88933049|NCT01755923|Experimental|Gefitinib|Gefitinib (Iressa) 250mg once per day until progression disease or intolerant side effects
88933050|NCT01755923|Active Comparator|Docetaxel|Docetaxel 75mg/m2,d1,every 3 weeks, at least 2-6 cycles depending on the progression disease or the patient's physical condition
88933051|NCT01755936||Controls|Patients will undergo cardiac magnetic resonance imaging, echocardiography and 72 hour holter monitoring
88933052|NCT01755936||Aortic Stenosis patients|All patients who agreed to study will undergo cardiac magnetic resonance imaging, echocardiography and 72 hour holter monitoring
88933053|NCT01755962|Experimental|Low Glycemic Load + Resistance Training|12-week intervention diet + resistance training (1 hour, 3 times per week)
88933054|NCT01755962|Experimental|High Glycemic Load + Resistance Training|12-week control diet + resistance training (1 hour, 3 times per week)
88933055|NCT01755962|Experimental|Low Glycemic Load|12-week intervention diet
88933056|NCT01755962|Other|High Glycemic Load|12-week control diet
88933057|NCT01755988|No Intervention|Usual care|
88933058|NCT01755988|Experimental|Educational website.|Educational website (in addition to usual care).
88933059|NCT01755988|Experimental|Website and interactive platform with telemonitoring.|Adjusted care pathway, including both the educational website and an interactive web-based platform with telemonitoring facilities. In this arm all routine consultations with heart failure nurses and general practitioner will be substituted by this combination of telemonitoring facilities connected to an interactive web-based platform plus the Dutch version of the European Society of Cardiology (ESC) website on heart failure.
88933060|NCT01756001||Control Arm|Arm 1 will be the Control arm, in which subjects will be instructed to use the GlowCap for their chronic disease medication but will not be provided with any specific incentive for taking the medication or with any aid in remembering to do so.
88933061|NCT01756001||Reminder Arm|Arm 2 will be the Reminder arm with daily email, text message, or phone call reminders for intervention. Subjects will be told that to aid in daily adherence to the medication, they will be provided with reminders for the first three months of the study and possibly again later in the study. At the start of the study, subjects will be given the option to receive daily email reminders, text message reminders, or daily (automated) phone call reminders to take their pill, each at a time of day that they choose. The default setting will be for subjects to receive both text and email reminders at 8AM each day. Subjects will be instructed on how to change their settings if they would like to receive a different set of reminders at different points in time.
88933062|NCT01756001||Incentives Arm|Arm 3 will be the financial incentives arm, in which subjects will be paid for adherence. Their total earnings will be administered at the end of the experiment through the WTH platform.
88933063|NCT01756001||Incentives and Reminders Arm|Arm 4 will be the financial incentives and reminders arm, in which subjects will be paid for adherence. Their total earnings will be administered at the end of the experiment through the WTH platform. They will also receive daily email, text message, or phone call reminders for intervention. Subjects will be told that to aid in daily adherence to the medication, they will be provided with reminders for the first three months of the study and possibly again later in the study. At the start of the study, subjects will be given the option to receive daily email reminders, text message reminders, or daily (automated) phone call reminders to take their pill, each at a time of day that they choose. The default setting will be for subjects to receive both text and email reminders at 8AM each day. Subjects will be instructed on how to change their settings if they would like to receive a different set of reminders at different points in time.
88933064|NCT01756014||Controls|Age matched healthy subjects
88933065|NCT01756014||Mild DCM|Heart failure patients with dilated cardiomyopathy (DCM) with NYHA-functional class II
88933066|NCT01756014||Severe DCM|Heart failure patients with dilated cardiomyopathy (DCM) with NYHA-functional class III/IV
88933067|NCT01756027|Active Comparator|Group A|Ulthera System providing one treatment per cheek
88933068|NCT01756027|Active Comparator|Group B|Ulthera System providing two treatments per cheek
88933069|NCT01756066|Active Comparator|A|Participant has 50% subsidy, i.e. gets a 50% discount off regular price of the program
88933070|NCT01756066|Experimental|B|Participant has 100% subsidy, i.e. program attendance is free
88933071|NCT01756066|Experimental|C|Participant has 80% subsidy; i.e. gets 80% discount off regular price of the program
88933072|NCT01756066|Experimental|D|Participant has 50% subsidy up front (i.e. pays 50%), with possibility for 100% subsidy based on attaining monthly participation goals
88933073|NCT01756092|Experimental|Autologous Fat Graft|Participants will receive an autologous fat graft to correct either a benign breast deformity or a post segmental mastectomy deformity.
88933074|NCT01756105|Experimental|treatment by Metformin plus insulin if needed|Metformin: from 500 mg 2 time per day to 2500 mg per day; with increment of 500 mg every 5 days until abstention of
89014291|NCT05514405|Experimental|Remimazolam group|Remimazolam is started during induction of anesthesia at the rate of 6 mg/kg/hr and continued at the rate of 1 mg/kg/hr (within 0.3-2 mg/kg/hr). Remimazolam is stopped 20 minutes before end of operation.
89537098|NCT02467829|No Intervention|10° of elbow flexion|This handle height is the nearest position the walker can be set to to achieve 10° of elbow flexion. Elbow flexion is measured with the child standing in their walker using an electronic goniometer.
89537099|NCT02467829|Experimental|30° of elbow flexion|Increase in handle height. This handle height is the nearest position the walker can be set to to achieve 30° of elbow flexion.
89537100|NCT02467829|Experimental|50° of elbow flexion|Increase in handle height. This handle height is the nearest position the walker can be set to to achieve 50° of elbow flexion.
89537101|NCT02953145|Experimental|Tisseel applied|In this group, the fibrin sealant Tisseel will be applied as a hemostasis agent in patients undergoing primary palatoplasty
89537102|NCT02953145|No Intervention|No fibrin sealant|In this group, no fibrin sealant will be applied intra-operatively. Standard measures, such as electrocautery, will be used for hemostasis.
89537103|NCT02467049|Active Comparator|ECG-guided insertion of PICC|Placement of the PICC (Peripherally Inserted Central Catheter ) ECG-guided insertion.
89537104|NCT02467049|Experimental|ULTRASOUND-guided insertion of PICC|Placement of the PICC (Peripherally Inserted Central Catheter ) ULTRASOUND-guided.
88933075|NCT01756105|Active Comparator|treatment by insulin|Insulin therapy:If post meal (2 hours after meal) glycaemia is > to 120 mg/dl introduce Insulin rapid acting analog (Humalog*, Novorapid*) before the meal concerned and according to the weight. If weight is < 80 kg: breakfast 5U, lunch time 3U, and dinner 4U. If weight is > 80 kg :breakast 6U, lunch time 4U, dinner 5U.If post meal glycaemia stay over 120 mg/dl but lower than130 mg/dl: do 1 U more.If post meal glycaemia stay over 140 mg/dl : do 2 UI moreIf fasting glycaemia is over 95 mg/dl : introduce NPH Insulin (Umuline NPH*, insulatard*) before sleeping : 5U if weight is < 80 kg - 6U if weight is > 80 kgIf fasting glycaemia stay over 95 mg/dl increase NPH Insulin for 1 U and for 2 U if fasting glycaemia is over 110 mg/dl.
88933076|NCT01756131|Experimental|Cohort 1|100 mg GSK1265744 injectable suspension or placebo, intramuscular dosing
88933077|NCT01756131|Experimental|Cohort 2|200 mg GSK1265744 injectable suspension or placebo, intramuscular dosing
88933078|NCT01756131|Experimental|Cohort 3|400 mg GSK1265744 injectable suspension or placebo, intramuscular dosing
88933079|NCT01756131|Experimental|Cohort 4|800 mg GSK1265744 injectable suspension or placebo, intramuscular dosing
88933080|NCT01756131|Experimental|Cohort 5|100 mg GSK1265744 injectable suspension or placebo, subcutaneous dosing
88933081|NCT01756131|Experimental|Cohort 6|200 mg GSK1265744 injectable suspension or placebo, subcutaneous dosing
88933082|NCT01756131|Experimental|Cohort 7|400 mg GSK1265744 injectable suspension or placebo, subcutaneous dosing
88933083|NCT01756131|Experimental|Cohort 8|400 mg GSK1265744 injectable suspension or placebo, intramuscular dosing
88933084|NCT01756131|Experimental|Cohort 9|400 mg GSK1265744 injectable suspension or placebo, intramuscular dosing
88933085|NCT01756144|Active Comparator|Autologous bone grafting|autologous bone of the iliac crest
88933086|NCT01756144|Experimental|rhBMP-2|Inductos, recombinant human bone morphogenetic protein
88933087|NCT01756170|Active Comparator|Arm 2|Patients receive radiotherapy alone as in arm 1.
88933088|NCT01756170|Experimental|Arm 1|Patients in this arm will postoperatively receive paclitaxel 135 mg/m2 d1 and cisplatin 25mg/m2 d1-3 intravenously every 4 weeks with radiation. Radiotherapy consisted of 46-50 gray (5 x 2.0 gray/week) on pelvic area.
88933089|NCT01756183|Experimental|S-1 + Paclitaxel Chemotherapy|"S-1: 60mg twice daily (after the breakfast and supper) for two weeks, and then suspend for one week.~Paclitaxel: 150 mg/m2, iv, 3h, at D1"
88933090|NCT01756196||Steroid Injection|Reactions associated with spinal steroid injection
88933091|NCT01756261||Group 1|
88933092|NCT01756287|Experimental|Standardized Chinese ocular exercise|The participants are trained with standardized Chinese ocular exercise which contains accurate positions of acupuncture points and appropriate pressure on the points.
88933093|NCT01756287|Sham Comparator|Nonstandardized ocular exercise|The participants are trained with nonstandardized ocular exercise performed on wrong positions where no acupuncture points at all.
88933094|NCT01756287|No Intervention|Eye closure|The participants are told to close eyes and don't do ocular exercise at all.
88933095|NCT01756313|Experimental|Laser+Methylaminolevulinat|It's a single arm. Intervention as described in the detailed description.
88933096|NCT01756326|Experimental|PREOB® Implantation|Each patient will undergo a single administration of PREOB® into the non-union site, under local or loco-regional anesthesia.
88933097|NCT01756326|Active Comparator|Bone Autograft|Each patient will be treated by Bone Autograft according to standard-of-care procedure of the investigating site.
89014292|NCT05514405|Active Comparator|Propofol group|Propofol is continuously infused within 1-5 μg/mL.
88933098|NCT01756378|Experimental|Muligan mobilization with movement|"Interventions are:~medial glide mobilization with movement lateral glide mobilization with movement rotation mobilization with movement dorsal glide with active knee flexion"
88933099|NCT01756378|Active Comparator|traditional physical therapy program|Infra-red, stretching exercises, strengthening exercises,
88933100|NCT01756404|Experimental|Cohort 1|Each volunteer will receive a total daily dose of 30 mg of canagliflozin (JNJ-28431754) or placebo (inactive medication) on Days 1 through 14.
88933101|NCT01756404|Experimental|Cohort 2|Each volunteer will receive a total daily dose of 100 mg of canagliflozin (JNJ-28431754) or placebo (inactive medication) on Days 1 through 14.
88933102|NCT01756404|Experimental|Cohort 3|Each volunteer will receive a total daily dose of 300 mg of canagliflozin (JNJ-28431754) or placebo (inactive medication) on Days 1 through 14.
89014293|NCT05511844|Experimental|Part 1 Dose Escalation|All participants receive ORM-5029 in escalating dose cohorts in Part 1 Dose Escalation and at the Expansion Dose Level (EDL) in Part 2 Dose Expansion.
89014294|NCT05511844|Experimental|Part 2 Dose Expansion|All participants receive ORM-5029 at dose levels with pharmacodynamic activity or efficacy signals (Expansion Cohort A) or at the Expansion Dose Level (EDL) (Expansion Cohorts B and C).
89014295|NCT05508074|Experimental|IFB-088 50 mg/day + riluzole 100 mg/day|"The test product, IFB-088, will be administered orally in 50 mg/day dosage consisting of two uptakes of 25 mg each (morning and evening uptakes), as an add-on therapy to riluzole 100 mg.~Intervals for dosing should ideally be about 12 hours (± one hour). Tablets will be swallowed with a glass of water 30 minutes before the meal, in fasting condition.~Administration of riluzole 100 mg, tablet or suspension, will be at the patient's and/or investigator's choice, as per summary of product characteristics. The daily dose of 100 mg will be taken in two 50 mg doses every 12 hours, at the same time than the IMPs.~Patients will be treated for a period of 6 months (26 weeks)."
89014296|NCT05508074|Placebo Comparator|placebo + riluzole 100 mg/day|"The placebo will be administered orally in two uptakes (morning and evening uptakes), as an add-on therapy to riluzole 100 mg.~Intervals for dosing should ideally be about 12 hours (± one hour). Tablets will be swallowed with a glass of water 30 minutes before the meal, in fasting condition.~Administration of riluzole 100 mg, tablet or suspension, will be at the patient's and/or investigator's choice, as per summary of product characteristics. The daily dose of 100 mg will be taken in two 50 mg doses every 12 hours, at the same time than the IMPs.~Patients will be treated for a period of 6 months (26 weeks)."
89014297|NCT05497206|Experimental|Robotic-Assisted THA|Consecutive participants will receive THA via the ROSA Hip System.
89014298|NCT05495074|Experimental|Dietary Intervention|Participants will be assigned a diet for two months following the indications of the National Cholesterol Education Program Adult Treatment Panel III program.
89014299|NCT05490680|Placebo Comparator|Placebo|Placebo oral film, on-demand use once per day, at maximum 60 films during a 12-week period
89014300|NCT05490680|Experimental|Sildenafil|Sildenafil 25 mg, 50 mg, 75 mg or 100 mg oral film (flexible-dose), on-demand use once per day, at maximum 60 films during a 12-week period
89014301|NCT05482789|Experimental|Exenatide|Participant receives injection of 10 micrograms of Exenatide sub-cutaneously the given mixed meal test and blood samples will be drawn for laboratory testing.
89014302|NCT05479552||MCI-AD|Will be diagnosed using 'preclinical AD' criteria of mild cognitive impairment supported by a positive biomarker for AD. MCI defined as: 1. History of cognitive decline, noticed by either the patient, family member(s) or a medical practitioner but still independent in most complex daily activities. 2. Documentation of cognition not normal e.g., by MoCA or neuropsychological testing; 3. Does not meet the definition of dementia with MOCA <18 or global CDR 1 or greater (although exceptions may exist with appropriate justification). 4. Supportive AD biomarker (has positive biomarkers for both Aβ and neuronal injury using CSF or neuroimaging).
89014303|NCT05479552||MCI-DLB|Will be diagnosed as prodromal probable MCI-DLB based on consensus criteria using 2 or more core clinical features of DLB (with or without the presence of biomarkers) or 1 or more core clinical features with 1 or more indicative biomarkers (reduced dopamine transporter uptake in basal ganglia demonstrated by SPECT or PET reduced Iodine-MIBG uptake on myocardial scintigraphy, PSG confirmation of REM without atonia).
89014304|NCT05473234|Experimental|Azithromycin|Children in this arm will receive one dose of amoxicillin.
89014305|NCT05473234|Active Comparator|Amoxicillin|Children in this arm will receive a 5-day course of amoxicillin (standard care).
89014306|NCT05463679|Active Comparator|Enzastaurin 500 mg QD|Receive 500 mg enzastaurin QD plus background standard of care.
89014307|NCT05463679|Placebo Comparator|Placebo QD|Matching placebo QD plus background standard of care.
89014308|NCT05462756|Experimental|Insulin Efsitora Alfa + Insulin Lispro|Participants will be given insulin efsitora alfa by subcutaneous (SC) injection along with insulin lispro
89014309|NCT05462756|Active Comparator|Insulin Glargine + Insulin Lispro|Participants will be given insulin glargine by SC injection along with insulin lispro
89014310|NCT05462041|Other|DBD Donor Heart Transplantation|If the heart offer is from a DBD donor, the heart will be retrieved per standard of care.
89537105|NCT03300245||patients with nasal septal deviation|Maxillofacial CT scan
89014311|NCT05462041|Other|DCD Donor Heart Transplantation|If the heart offer is from a DCD donor, the heart will be retrieved using one of two strategies: Normothermic Regional Perfusion (NRP) or Direct Procurement and Perfusion (DPP). NRP procedures will be used to procure all DCD hearts unless contraindicated or prohibited by the donor hospital. In the event the donor hospital does not allow NRP for cardiac organ procurement, or the target number of eight DCD transplants with NRP has been achieved, DPP with the Organ Care System (OCS) should be utilized.
89447406|NCT06025344|Experimental|Probenecid 1000 mg (2x500 mg tablets)|Probenecid 500 mg tablets
89014313|NCT05455476|Experimental|CBT for Loneliness|CBT delivered over the course of 8, ~45 minute sessions delivered via telehealth more centrally focused addressing factors contributing to loneliness and social isolation.
89014314|NCT05455476|Active Comparator|CBT for Chronic Pain|CBT delivered over the course of 8, ~45 minute sessions delivered via telehealth broadly focused on increasing quality of life despite being in pain.
89447407|NCT06025318|Experimental|PanCytoVir™ 1000 mg fasted|Single oral dose of PanCytoVir™ 1000 mg (100 mg/mL suspension) following an overnight fast
89447408|NCT06025318|Experimental|PanCytoVir™ 1000 mg fed|Single oral dose of PanCytoVir™ 1000 mg (100 mg/mL suspension) following a standard, high-fat, high-calorie breakfast
89447409|NCT06020339|Experimental|Randomization group|"Pregnant women in the study group will be given a total of 4 modules, 3 modules during pregnancy and 1 module in the postpartum period;~1. module 20-28. During pregnancy weeks, trainings are in the form of face-to-face group training,~2. module 29-36. During pregnancy weeks, trainings are in the form of face-to-face group training,~3. module trainings 37-40. in the form of video-conference (zoom meeting) during pregnancy weeks,~4. module will be applied in 1 month postpartum with face-to-face interview technique).~Pregnancy 20-28. Pregnant women between weeks 29-36 should attend the 1st module education. 2nd module training in gestational weeks, 37-40. They will be trained in the 3rd module during the pregnancy weeks.~module training will be individualized during the mother's visit in the 1st month postpartum.~Version B (WDEQ) will be administered after the program is completed, and the Birth-Related Trauma Perception Scale will be administered after birth."
89447410|NCT06020339|No Intervention|Control group|"Pregnant women who will be included in the control group will receive routine midwifery care. In the postpartum period (WDEQ), version B and the Birth Trauma Perception Scale will be used.~The pregnant women will inform the researcher by telephone after the birth (within the first 24 hours) and the mother will be visited by the researcher within the first month after the birth, and the trauma perceptions of the mothers will be evaluated with the Birth Trauma Perception Scale."
89447411|NCT06017414|Experimental|Growth Path Intervention|Participants for this arm are members of the 7 Cups platform (signed up as 'members', but not signed up as 'listeners') who will receive the Systemic Psychotherapy-informed growth path intervention.
88933103|NCT01756404|Experimental|Cohort 4|Each volunteer will receive a total daily dose of 600 mg of canagliflozin (JNJ-28431754) or placebo (inactive medication) on Days 1 through 14.
88933104|NCT01756404|Experimental|Cohort 5|Each volunteer will receive 300 mg of canagliflozin (JNJ-28431754) twice daily (600 mg total daily dose) or placebo (inactive medication) twice daily on Days 1 through 14.
88933105|NCT01756417|Experimental|Metformin + canagliflozin (JNJ-28431754)|Each volunteer will receive a single dose of metformin on Day 1 followed by canagliflozin (JNJ-28431754) once daily on Days 4 to 7. On Day 8, volunteers will receive a single dose of canagliflozin in combination with a single dose of metformin.
88933106|NCT01756430|Experimental|Carvedilol SR 32mg, 64mg|•Carvedilol SR 32mg QD for first 4 weeks and Carvedilol SR 64mg QD for following 4 weeks.
88933107|NCT01756430|Active Comparator|Carvedilol IR 25mg|•Carvedilol IR 25mg QD for first 4 weeks and Carvedilol IR 25mg BID for following 4 weeks.
88933108|NCT01756443|Active Comparator|Premixed group|Patients will receive sciatic nerve block with premixed 7.5 mls of 2% lidocaine/adrenaline and 7.5 mls of 0.5% bupivacaine followed by an interval of 90 seconds with an injection of same amount of both drugs.
88933109|NCT01756443|Experimental|Sequential Group|Patients will receive a sciatic nerve block with 15 mls of 2% lidocaine/adrenaline followed by an interval of 90 seconds with 15 mls of 0.5% bupivacaine.
88933110|NCT01756469|No Intervention|Control|non-alcohol related information about nutrition
88933111|NCT01756469|Active Comparator|Intervention|Behavioral Intervention for Alcohol Use
88933112|NCT01756495|Experimental|Losmapimod 7.5 mg|Each subject will receive losmapimod 7.5 mg BID orally for 5 days, in one of the 4 study periods (per randomization sequence) separated by a minimum washout period of 5 days
88933113|NCT01756495|Experimental|Losmapimod 20 mg|Each subject will receive losmapimod 20 mg QD orally for 5 days, in one of the 4 study periods (per randomization sequence) separated by a minimum washout period of 5 days
89447412|NCT06017414|No Intervention|Waitlist followed by Growth Path Intervention|Participants for this arm are members of the 7 Cups platform (signed up as 'members', but not signed up as 'listeners'). The waitlist comparator condition has 7 Cups access and use as usual during the waitlist period. Participants will receive access to the Systemic Psychotherapy-informed growth path intervention after the waitlist condition of 7 weeks is completed.
88933114|NCT01756495|Active Comparator|Moxifloxacin 400 mg|Each subject will receive moxifloxacin 400 mg orally on Day 5, in one of the 4 study periods (per randomization sequence) separated by a minimum washout period of 5 days
88933115|NCT01756495|Placebo Comparator|Placebo|Each subject will receive losmapimod matched placebo and moxifloxacin placebo orally for 5 days, in one of the 4 study periods (per randomization sequence) separated by a minimum washout period of 5 days
88933116|NCT01756508|Experimental|eculizumab|Eculizumab 1200 mg/m2 will be administered once, 1 hour before graft reperfusion
89447413|NCT06017414|Experimental|Listener Training Intervention|Participants for this arm are listeners on the 7 Cups platform (signed up as 'listeners', but not signed up as 'members') who will receive the Systemic Psychotherapy-informed listener training intervention.
89447414|NCT06017414|No Intervention|Waitlist followed by Listener Training Intervention|Participants for this arm are listeners on the 7 Cups platform (signed up as 'listeners', but not signed up as 'members'). The waitlist comparator condition has 7 Cups access and use as usual during the waitlist period. Participants will receive access to the Systemic Psychotherapy-informed listener training intervention after the waitlist condition of 7 weeks is completed.
89447415|NCT06016556||Patients receiving Nirmatrelvir; Ritonavir (PAXLOVID)|Adult COVID-19 patients' HCRU within the 30-day period following nirmatrelvir, ritonavir prescription.
88933117|NCT01756508|No Intervention|control|No intervention will be applied instead eculizumab infusion
88933118|NCT01756521|Experimental|Moxifloxacin 400mg|moxifloxacin 400mg
88933119|NCT01756521|Experimental|Moxifloxacin 800mg|moxifloxacin 800mg
88933120|NCT01756521|Placebo Comparator|Placebo(No treatment)|Only drink water
89447416|NCT06006208|No Intervention|Arm 1: AMBU bag manual ventilation during transport to the ICU|
89447417|NCT06006208|Experimental|Arm 2: Hamilton C1 ventilator during transport to the ICU|
88933121|NCT01756534|No Intervention|CONVENTIONAL HEMOSTASIS|patients for whom conventional surgical procedures (i. e., ligatures and bipolar electrocautery alone) were used to achieve hemostasis
88933122|NCT01756534|Active Comparator|SURGICEL|patients will receive an oxidized cellulose patch (Surgicel®) in addition to conventional surgical procedures (i. e., ligatures and bipolar electrocautery alone)
88933123|NCT01756547|Experimental|Potassium citrate|Potassium citrate, oral solution contains Tripotassium citrate monohydrate 20 grams, Citric acid monohydrate 4 grams, distilled water 40 ml, and simple syrup 100ml. The solution contained in a bottle of glass that contains 20 ml of 2 meq/ml of potassium and 2.5 meq/ml of citrate. The dose is 0,3ml/kg/day of the solution until the 38-40 weeks of corrected gestational age.
89014315|NCT05452616|Active Comparator|"ART first arm"|ART initiation on the day of enrolment independent of TB investigations
89447418|NCT06005805|Experimental|Mastic gum with dietary modification|Mastic gum with dietary modification (for 21 days)
89447419|NCT06005805|Placebo Comparator|Dietary modification|Dietary modification (for 21 days)
89447420|NCT06000111|Experimental|Face-Down Positioning for 3-Days and Nights|Patients allocated to this study arm will maintain face-down positioning for 3-days and nights post-operatively. Patients will be advised to posture immediately following surgery and will be advised to posture for 50 minutes of each hour. Patients will be advised that during their 10-minute break each hour, they should avoid face-up positioning. FDP will be advised during both waking and sleeping hours.
88933124|NCT01756547|Placebo Comparator|Placebo|Oral solution 30ml, that contains distilled water and simple syrup, in the same dose like the active treatment 0,3ml/kg/day.
88933125|NCT01756599|Experimental|leukaemia during childhood or adolescence|
88933126|NCT01756612||Chronic Kidney Disease Participants|Participants for whom the treating physician has decided to initiate treatment with MIRCERA for medical reasons prior to study start, will be observed for 9 months.
88933127|NCT01756625||First line WT KRAS mCRC|
88933128|NCT01756638|Experimental|Abiraterone plus Prednisolone|Abiraterone 1000 milligram (mg) oral tablets will be administered once daily along with 5 mg oral prednisolone tablet administered twice daily for 28-daily dosing cycles and will be continued until disease progression or unacceptable toxicity.
88933129|NCT01756651|Experimental|Intranasal Fentanyl 100mcg|fentanyl pectin nasal spray 100mcg
88933130|NCT01756651|Experimental|Intranasal Fentanyl 200mcg|fentanyl pectin nasal spray 200mcg
88933131|NCT01756664|Placebo Comparator|Control|Vaseline has been used on the first day after laser treatment
88933132|NCT01756664|Active Comparator|Sunscreen|Sunscreen has been used on the first day after laser treatment
88933133|NCT01756703|Experimental|MT-3995 Low group|
88933134|NCT01756703|Experimental|MT-3995 High group|
88933135|NCT01756703|Placebo Comparator|Placebo group|
88933136|NCT01756716|Experimental|MT-3995 Low group|
88933137|NCT01756716|Experimental|MT-3995 High group|
88933138|NCT01756716|Placebo Comparator|Placebo group|
88933139|NCT01756729|Active Comparator|Best Standard of Care|Patients recruited to the BSC group will be treated according to the BSC practiced at each center.
88933140|NCT01756729|Experimental|NovoTTF-100A (monotherapy)|Patients will be treated continuously with the NovoTTF-100A device. NovoTTF-100A treatment will consist of wearing four electrically insulated electrode arrays on the head. The treatment enables the patient to maintain regular daily routine.
88933141|NCT01756742|Experimental|Respiratory physiotherapy|54 people according to the inclusion criteria were recruited to have a respiratory physiotherapy treatment added to their medical intervention.
88933142|NCT01756742|Placebo Comparator|Conservative treatment|49 people were recruited in this group. These participants received conservative medical treatment intervention
88933143|NCT01756755|No Intervention|Control|Treat with severe sepsis / septic shock practice guideline
88933144|NCT01756755|Experimental|PMX HP|Treat with severe sepsis / septic shock practice guideline Treat with PMX-20R Hemoperfusion [Polymyxin B adsorbs and remove endotoxin from the patient's circulating blood].
88933145|NCT01756768|Experimental|Radio-labeled Dose Arm|
88933146|NCT01756781|Experimental|Sequence 1|Subjects randomized to Sequence 1 will receive Treatment A followed by Treatment B. Treatment A is a single 2 mg oral dose of midazolam alone. Treatment B is made up of 8 daily 125 mg oral doses of PD-0332991 and a single 2 mg oral midazolam dose on day 7 immediately after the day 7 PD-0332991 dose.
89447421|NCT06000111|Active Comparator|Face-Down Positioning for 7-Days and Nights|Patients allocated to this study arm will maintain face-down positioning for 7-days and nights post-operatively. Patients will be advised to posture immediately following surgery and will be advised to posture for 50 minutes of each hour. Patients will be advised that during their 10-minute break each hour, they should avoid face-up positioning. FDP will be advised during both waking and sleeping hours.
88933147|NCT01756781|Experimental|Sequence 2|Subjects randomized to Sequence 2 will receive Treatment B followed by Treatment A with a washout of no less than 14 days in between.Treatment B is made up of 8 daily 125 mg oral doses of PD-0332991 and a single 2 mg oral midazolam dose on day 7 immediately after the day 7 PD-0332991 dose. There will be a minimum washout of 14 days prior to beginning Treatment A. Treatment A is a single 2 mg oral dose of midazolam alone.
89447422|NCT05999747|Experimental|White Light/near-infrared fluorescence - Adults with normal renal function or mild renal impairment|Adult participants with normal renal function or mild renal impairment will receive a single dose of ASP5354
88933148|NCT01756794|Other|Transplantation of alcoholic hepatitis|Patients of this arm will be selected for early liver transplantation for severe alcoholic hepatitis not responding to medical therapy. Selection process will be based on a specific algorithm and follow-up time will be 2 years
88933149|NCT01756794|Other|Transplantation for alcoholic cirrhosis|Patients of this arm will be selected for liver transplantation for alcoholic cirrhosis using an abstinence period of 6 months. Outcome of these patients will be compared to that of patients transplanted for severe alcoholic hepatitis.
89014316|NCT05452616|Active Comparator|"TB results first arm"|ART initiation only after active TB has been refuted or confirmed
89200558|NCT04009486|Experimental|Obstructive Sleep Apnea|Subjects will undergo 6 weeks of whole body vibration.
89537106|NCT03300167|Experimental|CE-marked coronary artery catheter|use of a novel CE-marked coronary artery catheter to obtain spatially-separated intravascular samples for laboratory measurement.
89447423|NCT05999747|Experimental|White Light - Adults with normal renal function or mild renal impairment|Adult participants with normal renal function or mild renal impairment will receive a single dose of ASP5354
89447424|NCT05999747|Experimental|White Light/near-infrared fluorescence - Adults with moderate or severe renal impairment|Adult participants with moderate or severe renal impairment will receive a single dose of ASP5354
89447425|NCT05998941|Experimental|TQB2868 injection + Paclitaxel injection + Cisplatin/Carboplatin injection ± Bevacizumab injection|TQB2868 injection + paclitaxel injection + cisplatin/carboplatin injection ± bevacizumab injection, 3 weeks (21 days) as a treatment cycle.
89447426|NCT05993351||Concussion|Individuals who have recently sustained a concussion within the past 2-weeks.
89447427|NCT05993351||Healthy Control|Individuals who have limited to no concussion history, and have not recently sustained a concussion.
89447428|NCT05992155|Experimental|Cohort 1, Severe RI: TAK-279 50 mg|Participants with severe RI will receive a single oral dose of TAK-279 50 mg, on Day 1 in Part A of the study.
89447429|NCT05992155|Experimental|Cohort 2, Normal Renal Function: TAK-279 50 mg|Participants with normal renal function will receive a single oral dose of TAK-279 50 mg, on Day 1 in Part A of the study.
89447430|NCT05992155|Experimental|Cohort 3, Moderate RI: TAK-279 50 mg|Participants with moderate RI will receive a single oral dose of TAK-279 50 mg, on Day 1 in Part B of the study.
89447431|NCT05988463|Experimental|Artesunate|
89447432|NCT05985018|Active Comparator|Traditional Dietary Advice|Its main elements are to adopt sensible eating habits and avoid excess fatty foods, spicy foods, processed foods, caffeine, fizzy drinks and alcohol.
89447433|NCT05985018|Active Comparator|Mediterranean Diet|The principle components is a diet rich in vegetables, pulses, whole grains, and olive oil
89447434|NCT05979974|Experimental|physiotherapy and high-PEMF|The patient undergoes physiotherapy and high-PEMF therapy twice a week, for a duration of three weeks.
89447435|NCT05979974|Sham Comparator|physiotherapy and sham high-PEMF|The patient undergoes physiotherapy and sham high-PEMF therapy twice a week, for a duration of three weeks.
89447436|NCT05979857|Experimental|Dose Escalation|For part 1 dose escalation, one patient per dose cohort will be initially recruited (accelerated titration dose-escalation, single-patient cohorts/dose level) for the first two dose levels or until the first instance of a ≥ Grade 2 toxicity (excluding Grade 2 neutropenia and lymphopenia and adverse events unequivocally due to the underlying disease or to an extraneous cause), or dose-limiting toxicity (DLT), whichever occurs earlier. Further cohorts will be recruited in blocks of three patients, i.e., 3+3 dose escalation design.
89447437|NCT05979857|Experimental|Dose Optimization|For part 2 dose selection optimization, two dose levels will be selected by the Safety Review Committee (SRC) based on review of all available data on safety, tolerability, PK, PD, and preliminary efficacy from part 1. The dose selection optimization will include only patients with R/R DLBCL and will randomize 1:1 approximately 30 new patients at the two selected dose levels (15 patients to each of the two selected dose levels) before declaring the RP2D. Assessment of PK/PD of SP-3164 will be included in part 2 dose selection optimization.
89447438|NCT05979727|Placebo Comparator|Placebo|
89447439|NCT05979727|Active Comparator|Low dose of RE02|
89447440|NCT05979727|Active Comparator|Moderate dose of RE02|
89447441|NCT05979727|Active Comparator|High dose of RE02|
89447442|NCT05976646|Placebo Comparator|Placebo|Subjects who are randomized to placebo will receive identical capsules to the test product at the same time periods noted above, administered orally.
88933150|NCT01756807|Experimental|The Combo Stent|The COMBO Stent is developed basing on the GENOUS stent platform, and in addition, it also delivers a drug called sirolimus to the treated coronary blood vessel. The stent's original CD34 antibody coating is designed to promote healing of the coronary artery by catching circulating endothelial progenitor cells as they pass through the stent. These cells are naturally flowing in the circulation and are responsible for endothelial healing. This is intended to help the blood vessel wall heal over the stent more quickly and restore normal tissue function in the stented area. The combination of these two technologies in this new COMBO stent is expected to produce even better clinical results, which have been investigated in the previous REMEDEE Study.
89447443|NCT05976646|Experimental|Auvelity|Orally-administered combination of dextromethorphan with Bupropion (trade name Auvelity)
89447444|NCT05976321|Experimental|Cohort 1, Moderate HI: TAK-279 50 mg|Participants with moderate HI will receive a single oral dose of TAK-279 50 mg, on Day 1 in Part A of the study.
89447445|NCT05976321|Experimental|Cohort 2, Normal Hepatic Function: TAK-279 50 mg|Participants with normal hepatic function will receive a single oral dose of TAK-279 50 mg, on Day 1 in Part A of the study. Based on an evaluation of the results from Part A, additional participants with normal hepatic function may be enrolled in Part B of the study.
89447446|NCT05976321|Experimental|Cohort 3, Mild/Severe HI: TAK-279 50 mg|Participants with mild/severe HI will receive a single oral dose of TAK-279 50 mg, on Day 1 in Part B of the study based on an evaluation of the results from Part A.
89200559|NCT05279404|Experimental|Group A - electroacupuncture|"electroacupuncture group Insert stainless steel acupuncture needles into Neiguan (cathode) and Jianshi (anode) on both sides and twist the needles.~After that, the electroacupuncture machine was connected and 2 Hz electrical stimulation was administered for 30 minutes.~The stimulation intensity was mainly based on slight muscle contractions and no pain in the subjects. At this time, cardiac function and electrogastrogram were recorded at the same time."
89447447|NCT05975255|Experimental|Study group|Remimazolam administration and evaluation of sedative effect
89447448|NCT05973903|Experimental|Single Arm|Single-arm: participants will be treated with TTFields (200 kHz) + intravenous pembrolizumab 200 mg every three weeks and oral lenvatinib 20 mg once daily until evident progressive disease by Response Assessment in Neuro-Oncology (RANO) criteria, unacceptable toxicity, withdrawal of consent, or until completion of 35 treatment cycles (approximately 2 years) with pembrolizumab. Participants who complete treatment with pembrolizumab after 35 cycles (approximately 2 years) or CR will continue to receive lenvatinib and TTF until disease progression, development of unacceptable toxicity, or withdrawal of consent.
89447449|NCT05973110|Experimental|Cognitive Remediation|
89447450|NCT05973110|Active Comparator|Active Control|
89447451|NCT05971225|Active Comparator|Follow up group|participants with experience of >6 months in-office device interrogation, then started remote monitoring
88933151|NCT01756820|Active Comparator|Single-portal Endoscopic Carpal Tunnel Release (Microaire®)|Single-portal Endoscopic Carpal Tunnel Release (Microaire®) will be used, according to the endoscopic technique described by Agee at al.
88933152|NCT01756820|Active Comparator|Knifelight®|A mini-open technique will be performed, using the Knifelight® (Stryker).
88933153|NCT01756859||Patients with HVPG measurements|Patients having HVPG measurements for clinical reasons will be recruited to undergo research MRI scan.
88933154|NCT01756872||Ovarian reserve study participants|Measurements of ovarian reserve for women attending the Oxford Fertility Unit having their first IVF/IVF-ICSI cycle.
88933155|NCT01756911|Experimental|Thotaco-abdominal aneurysm|MFM
88933156|NCT01756937|Active Comparator|Imotun|300.03mg/cap,orally, 1 capsule once daily for 24 weeks
88933157|NCT01756937|Placebo Comparator|Placebo|1 capsule once daily for 24 weeks
88933158|NCT01756950|Experimental|Cohort 1 - CR8020|2 mg/kg CR8020
88933159|NCT01756950|Placebo Comparator|Cohort 1 - Placebo|5% dextrose in water
88933160|NCT01756950|Experimental|Cohort 2 - CR8020|5 mg/kg CR8020
88933161|NCT01756950|Placebo Comparator|Cohort 2 - Placebo|5% dextrose in water
88933162|NCT01756950|Experimental|Cohort 3 - CR8020|15 mg/kg CR8020
88933163|NCT01756950|Placebo Comparator|Cohort 3 - Placebo|5% dextrose in water
88933164|NCT01756950|Experimental|Cohort 4 - CR8020|30 mg/kg CR8020
88933165|NCT01756950|Placebo Comparator|Cohort 4 - Placebo|5% dextrose in water
88933166|NCT01756950|Experimental|Cohort 5 - CR8020|50 mg/kg CR8020
88933167|NCT01756950|Placebo Comparator|Cohort 5 - Placebo|5% dextrose in water
88933168|NCT01756950|Experimental|Cohort 6 - CR8020|30 mg/kg CR8020
88933169|NCT01756950|Placebo Comparator|Cohort 6 - Placebo|5% dextrose in water
88933170|NCT01756963||IBD-SL cohort|
88933171|NCT01756989|Experimental|Thalidomide, etoposide, celecoxib|Single arm study,phase II
88933172|NCT01757002|Experimental|Tailored asthma management program|Teens randomized to the experimental arm will receive 4 sessions plus a booster of web-based, tailored asthma management.
88933173|NCT01757002|Active Comparator|Control|Teens in the control group will receive generic, web-based asthma education.
88933174|NCT01757015|Placebo Comparator|Placebo|Placebo to NVA237 (50 μg) o.d. in the morning Patients will also receive open label salmeterol/fluticasone propionate (50/500 µg) b.i.d., in the morning and evening
88933175|NCT01757015|Experimental|NVA237|NVA237 (50 μg) o.d. in the morning Patients will also receive open label salmeterol/fluticasone propionate (50/500 µg) b.i.d., in the morning and evening.
88933176|NCT01757054|Experimental|Probiotic group|
88933177|NCT01757054|No Intervention|Control group|This is a non-supplemented control group that will follow the same dietary and medication restrictions. The purpose of this group is to ensure results are due to supplementation and not due to random dietary exposure.
88933178|NCT01757080|Experimental|Diabetic-hypertensive elderly|Biochemical analysis and Cardiorespiratory performance assessment with ergospirometry test
88933179|NCT01757080|Active Comparator|Hypertensive elderly|Biochemical analysis and Cardiorespiratory performance assessment with ergospirometry test
88933180|NCT01757093|Experimental|Automatic tube compensation plus CPAP|The patients is going to undergo trials of spontaneous breathing with automatic tube compensation plus continuous positive airway pressure and later a trial with continuous positive airway pressure. During 30 minutes.
88933181|NCT01757093|Active Comparator|Continuous Positive Airway Pressure|The patients is going to undergo a trial of spontaneous breathing with continuous positive airway pressure and later with automatic tube compensation plus continuous positive airway pressure, during 30 minutes each.
88933182|NCT01757106|Experimental|Drug: Xenon|gaseous anesthetic, dosage: 50-60% (v/v) in oxygen, continuous application during surgery
89447452|NCT05971225|Experimental|Remote group|participants with newly implanted device with study agreement, and then started remote monitoring
88933183|NCT01757106|Active Comparator|Drug: Sevoflurane|inhalative anesthetic, dosage: 1.4% (v/v) in 50% oxygen/medical air , continuous application during surgery
88933184|NCT01757132|Other|Implantable Miniature Telescope|Post approval study
88933185|NCT01757145|Experimental|Eltrombopag|"Eltrombopag will be given orally as a single daily dose. From day +1 after cord blood transplantation, start eltrombopag 100 mg/d. If primary end point not reached on day +14,then from day +15 - 150 mg/d. If primary end point not reached on day +28 then from day +29 - 200 mg/d. If primary end point not reached on day +42 then from day +43 and on - 300 mg/d (maximal dose). If dose not tolerated, return to last tolerated dose.~Eltrombopag will be discontinued after platelet count has exceeded 50,000/microliter for 14 consecutive days without administration of platelets.~In case of decline of platelet count < 30,000/microliter within 15 days from eltrombopag discontinuation, it will be resumed for additional 4 weeks.~After 4 weeks we will re-attempt to hold the drug."
88933186|NCT01757158|Experimental|Cs-131 brachytherapy seeds|sub-lobar resection plus cesium-131 brachytherapy
88933187|NCT01757223|Experimental|Part A, Group 1 - 10^8 pu|Part A is a dose-escalation, open-label study, administering 3 doses of AdVEGF-All6A+ to n=9 individuals, with n=3 each at 10^8, 10^9, and 10^10 particle units. The purpose of Part A is to determine the highest tolerable dose. Group 1 will receive 10^8 particle units.
88933188|NCT01757223|Experimental|Part A, Group 2 - 10^9 pu|Part A is a dose-escalation, open-label study, administering 3 doses of AdVEGF-All6A+ to n=9 individuals, with n=3 each at 10^8, 10^9, and 10^10 particle units. The purpose of Part A is to determine the highest tolerable dose. Group 1 will receive 10^9 particle units.
88933189|NCT01757223|Experimental|Part A, Group 3 - 10^10 pu|Part A is a dose-escalation, open-label study, administering 3 doses of AdVEGF-All6A+ to n=9 individuals, with n=3 each at 10^8, 10^9, and 10^10 particle units. The purpose of Part A is to determine the highest tolerable dose. Group 1 will receive 10^10 particle units.
89447453|NCT05961124|Experimental|Single arm- Niraparib|Oral niraparib will be administered in a dose escalation design where patients will start at a dose of 100 mg PO daily for the first two cycles, then 200 mg PO daily for the third and fourth cycle. Patients will remain on the individualized dose until either they experience an adverse event and require a dose reduction or they have disease progression.
89447454|NCT05960864||Ankylosing spondylitis|Ankylosing spondylitis according to the modified New York criteria or with the clinical diagnosis of AS/r-axSpA fulfilling the ASAS Classification Criteria AND the mNY criteria plus having the indiaction for starting a bDMARD therapy according to the treating rheumatologist
89447455|NCT05960864||Non-radiographic axial spondyloarthritis|Patients with clinical characteristics of axial SpA but not fulfilling the modified New York criteria for which radiographic sacroiliitis is essential or with the clinical diagnosis of nr-axSpA fulfilling the ASAS Classification Criteria not fulfilling the mNY criteria and the indiaction for starting a bDMARD therapy according to the treating rheumatologist
89447456|NCT05960864||Juvenile spondyloarthritis|Patients with juvenile spondyloarthritis (juvenile ankylosing spondylitis, juvenile non-AS-spondyloarthritis).
89447457|NCT05960864||Crohn's disease|Patients with Crohn's disease
89447458|NCT05960864||Acute anterior uveitis|Patients with acute anterior uveitis
89447459|NCT05960864||Axial psoriatic arthritis|Patients with the clinical diagnosis of psoriatic arthritis with axial involvement (sacroiliac joints and/or spine) (axPsA)
89447460|NCT05960864||Reactive arthritis|Patients with reactive arthritis
89447461|NCT05957003|Active Comparator|occlusions test|Combined end expiratory (EEO) and inspiratory occlusion (EIO) test. A 15-s EEO separated by a time window of 1 minute to allow the hemodynamic parameters to return to baseline followed by a 15-s EIO
89447462|NCT05957003|Active Comparator|challenge test|Tidal volume (TV) challenge test (transient increase of TV from 6 to 8 mL/kg for 1 minute)
89447463|NCT05946642|Experimental|Sulphadoxine-Pyrimethamine/Amodiaquine (SPAQ)|"SPAQ treatment will be given according to child's age. Dispersible tablets of sulphadoxine-pyrimethamine (SP) will be given on day 1 only.~Dispersible tablets of amodiaquine (AQ) which will be given once a day for 3 days.~The full 3-day course will be administered each month under directly observed therapy (DOT)."
89447464|NCT05946642|Experimental|Dihydroartemisinin/Piperaquine (DP) plus Ivermectin (IVM)|"DP will be available as tablets of 320/40mg and 160/20mg piperaquine/dihydroartemisinin per tablet. DP will be given once daily for 3 days and according to body weight.~IVM will be given at 300-400μg/kg/day over 3 days (to the nearest whole tablet). IVM will also be taken on an empty stomach with water.~Ivermectin will be available as 3 mg or 6 mg tablets to be administered at the doses of 300- 400μg/kg/day for 3 days (to the nearest whole tablet). IVM should also be taken with water on an empty stomach."
89447465|NCT05946642|No Intervention|Control|The control/standard of care arm will consist of the standard malaria control measures provided by the malaria programme, including case management and long-lasting insecticidal nets (LLINs).
89447466|NCT05944731|Experimental|Arm 1|Arm 1 is those participants randomized to use of CGM in a continuous fashion; CGM use for the duration of 9 months.
89447467|NCT05944731|Experimental|Arm 2|Arm 2 is those participants randomized to intermittent use of CGM; CGM use for 4 time points consisting of 2 weeks of CGM use each, for the duration of 9 months.
89447468|NCT05944731|No Intervention|Arm 3|Arm 3 is those participants randomized to standard of care; regular use of self-monitoring of blood glucose (SMBG) for the duration of 9 months.
89447469|NCT05942560|Experimental|Cognitive behavioural therapy-based(CBT-based) intervention group|A specifically designed CBT-based intervention consisting of 8 weekly sessions will be conducted in a group format.
89447470|NCT05942560|Active Comparator|Control group|Participants will receive eight health education sessions simultaneously with the CBT-based intervention group.
89531308|NCT03336827|Other|Experimental Group|Patients include in the experimental group (EG) will receive one individual pre-group session and 8 sessions of group intervention combining cognitive-behavioral therapy and hypnosis after the first assessment (T1) (i.e., before the second assessment taking place 4 months later (T2)). They will resort to usual care only after the second assessment (T2) (i.e., before the third assessment taking place 4 months later (T3)).
88933190|NCT01757223|Experimental|Part B, Group 1 - AdVEGF-All6A+|Part B (n=32 subjects) is a randomized, double blind, placebo-controlled study that will compare the AdVEGF-All6A+ vector (n=24) to a placebo, AdNull (n=8). Group 1 will receive AdVEGF-All6A+ at the highest tolerable dose determined in Part A.
88933191|NCT01757223|Experimental|Part B, Group 2 - AdNull placebo|Part B (n=32 subjects) is a randomized, double blind, placebo-controlled study that will compare the AdVEGF-All6A+ vector (n=24) to a placebo, AdNull (n=8). Group 2 will receive AdNull, the placebo vector.
88933192|NCT01757236|Active Comparator|Treatment A|"IV vancomycin (15mg/kg every 12 hours or in a continuous infusion) and IV ceftriaxone (2g daily) until Day 2 to 7 (until the susceptibility test results are obtained).~Patients with only a confirmed Gram-positive infection will continue the study and will receive standard of care antibiotic therapy including oral rifampin (10-15mg/kg every 12 hours) combined with either oral clindamycin (600 mg every 8 hours) or oral sulfamethoxazole and trimethoprim (800/160 mg every 8 hours) or oral fluoroquinolone (Ofloxacin 200 mg every 12 hours). The total duration of antibiotic therapy from the day of the surgical procedure until the end of treatment (EOT) will be 6 weeks."
89447471|NCT05941286|Experimental|CGM system with glucose alerts on|Patients will wear a real-time CGM (The Guardian Connect CGM System with Guardian sensor 3, Medtronic), which provide glucose readings every 5 minutes for up to 7 days. High/low predictive/threshold alerts will be enabled in this group, with low glucose alert set at 3.9 mmol/L and high glucose alert set at 16.7 mmol/L. In addition, patients will undergo POC testing at least 4 times per day (usually before meals and bedtime). Intensive insulin therapy will be titrated based on daily CGM and POC printouts.
89447472|NCT05941286|Active Comparator|CGM system with glucose alerts off|Patients will wear a real-time CGM (The Guardian Connect CGM System with Guardian sensor 3, Medtronic), which provide glucose readings every 5 minutes for up to 7 days. High/low predictive/threshold alerts will be off in this group. In addition, patients will undergo POC testing at least 4 times per day (usually before meals and bedtime). Intensive insulin therapy will be titrated based on daily CGM and POC printouts.
89447473|NCT05939596|Experimental|SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021)|100 μg /1.0 mL/dose, One booster dose 1.0mL IM injection of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021).
89447474|NCT05939596|Placebo Comparator|Saline|One booster dose 1.0mL IM injection of saline.
89447475|NCT05936710|Other|Control group|Using acetate-based dialysate
89447476|NCT05936710|Experimental|Experimental group|Using citrate-based dialysate
89447477|NCT05931341|Experimental|Dosage 1|
88933193|NCT01757236|Experimental|Treatment B|"IV vancomycin (15mg/kg every 12 hours or in a continuous infusion) and IV ceftriaxone (2g daily) until Day 2 to 7 (until the susceptibility test results are obtained).~Patients with only a confirmed Gram-positive infection will continue the study and will receive oral linezolid (600mg every 12 hours) combined with oral rifampin (10-15mg/kg every 12 hours).~The total duration of antibiotic therapy from the day of the surgical procedure until the end of treatment (EOT) will be 6 weeks."
88933194|NCT01757236|Experimental|Treatment C|IV linezolid (600 mg every 12 hours)and IV ceftriaxone (2g daily) until Day 2. Oral or IV rifampin (10-15 mg/kg every 12 hours) will be added 48 hours after initiating the study treatment. Treatment with the study drug will continue until Day 2 to 7 (until the susceptibility test results are obtained). Patients with only a confirmed Gram-positive infection will continue the study. Treatment with ceftriaxone will be discontinued and the patient will switch to oral linezolid and oral rifampin. The total duration of antibiotic therapy from the day of the surgical procedure until the end of treatment (EOT) will be 4 weeks.
88933195|NCT01757249|Experimental|Group 1 OCP|Combined oral contraceptive pill (OCP) (Microgynon 30) containing Levonorgestrel/Ethinylestradiol 150/30mcg. Taken orally on a continuous regime for 8 weeks, once a day.
88933196|NCT01757249|No Intervention|Group 2 Control|Control Group - no intervention
88933197|NCT01757262|Experimental|Ticagrelor|90 mg Ticagrelor
88933198|NCT01757262|Active Comparator|Clopidogrel|75mg Clopidogrel
88933199|NCT01757314||CA 1 and 2 anethesia residents|palpation technique
88933200|NCT01757314||Ca1 and 2 residents|ultrasound guided technique
88933201|NCT01757327|Experimental|Arm I (erismodegib [LDE225])|400 mg daily and treatment repeats every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity.
88933202|NCT01757327|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO daily and treatment repeats every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity.
89447478|NCT05931341|Experimental|Dosage 2|
89447479|NCT05931341|Experimental|Dosage 3|
89447480|NCT05929859|Experimental|Intensive Treatment|Speech Motor Chaining will be delivered in an intensive fashion. Week 1: 8 sessions (2 sessions per day on 4 different days) Week 2: 3 sessions (1 per day on 3 different days) Week 3: 3 sessions (1 per day on 3 different days) Week 4: 2 sessions (1 per day on 2 different days)
89447481|NCT05929859|Experimental|Distributed Treatment|Speech Motor Chaining will be delivered twice weekly for 8 weeks
89447482|NCT05923944|Experimental|Eco-Rescue - Attentional Control - intervention|The Eco-Rescue training intervention will be delivered through a dedicated video game installed on each participant's personal computer through the Steam platform, following a recommended training regimen of 30 minutes per day, 4 days per week for 6 weeks, for an expected total training duration of 12 hours.
89447483|NCT05923944|Experimental|Bejeweled 3 - Casual gaming - intervention|The Bejeweled 3 training intervention will be delivered through a dedicated video game installed on each participant's personal computer through the Steam platform, following a recommended training regimen of 30 minutes per day, 4 days per week for 6 weeks, for an expected total training duration of 12 hours.
88933203|NCT01757340|No Intervention|Weight maintenance|Weight maintenance with normal protein and leucine intake
88933204|NCT01757340|Active Comparator|Weight loss with normal protein intake|
88933205|NCT01757340|Experimental|Weight loss with leucine supplementation|
89447484|NCT05923944|No Intervention|No-training intervention|The No-training intervention group does not involve any specific training program. Instead, participants assigned to this group will receive weekly phone calls, similar to the other groups, to answer the same questions as the other groups concerning their mental and emotional states and maintain regular contact throughout the 6-week study duration.
89447485|NCT05923905|Experimental|FB1006 test group|Take FB1006 at night,30mg/day
89447486|NCT05923905|Placebo Comparator|placebo group|Take placebo at night,30mg/day
89447487|NCT05923138|Experimental|NUTRITIONAL INTERVENTION|
89447488|NCT05923138|Placebo Comparator|CONTROL|
89447489|NCT05921604|Experimental|Group 1 (baclofen)|which will include 50 patients scheduled for sleeve gastrectomy and will receive 10 mg oral baclofen 1 h before anesthesia.
89447490|NCT05921604|Experimental|Group 2 (gabapentin)|which include 50 patients scheduled for sleeve gastrectomy and will receive 600 mg oral gabapentin 1 h before anesthesia.
89447491|NCT05917262|Experimental|Mindfulness-based breathing|20-minute mindfulness-based breathing training
89447492|NCT05917262|Experimental|HRV biofeedback|20-minute HRV biofeedback
89447493|NCT05917262|Active Comparator|cognitive-behavioral pain psychoeducation|20-minute psychoeducation session
89447494|NCT05917028|Experimental|Transcatheter Arterial Micro-Embolization|If abnormal blood vessels related to pain are identified by angiography, selective embolization is performed using Nexsphere-F.
89447495|NCT05915910||GSD1b G339C Homozygous (n=3)|
88933206|NCT01757353|Active Comparator|Self-directed: Information only|Participants in this arm will complete a baseline assessment, followed by a 50-minute brief motivational interview (the Brief Alcohol Screening and Intervention for College Students; BASICS) 10-14 days after the initial assessment. Participants in this arm will complete follow-up assessments at approximately 3 and 9 months.
88933207|NCT01757353|Active Comparator|BASICS motivational interview|Participants in this arm will complete a baseline assessment, immediately after which they will be administered alcohol-related informational sheets. These participants will participate in follow-up assessment sessions at approximately 3 and 9 months.
89447496|NCT05915910||GSD1b L348FS Homozygous (n=3)|
89447497|NCT05915910||GSD1b G339C/ L348FS Heterozygous (n=3)|
89447498|NCT05915910||GSD1b Parents (n=6)|
89447499|NCT05915897||CGD with p47phox phenotype|
89447500|NCT05915897||X-Linked CGD|
89447501|NCT05910853||Fanconi Anemia (Non-Specific Genotypes)|"Cohort 1-Fanconi Anemia (Non-Specific Genotypes) (N=4):~Inclusion:~The participant is willing and able to provide written informed consent~The participant is willing and able to provide appropriate photo identification~Participants aged 18 to 85~Participants have been diagnosed with Fanconi Anemia complementation group A*Inclusion preference (not required for enrollment into the study): 1)~Participants preferentially have one of the following genotypes:~c3788_3790delTCT, c295 G to T, c3558-3559 insertion of G, or c1115_1118delTTGG~Exclusion:~Participants who are pregnant or are nursing~Participants with a known history of HIV, hepatitis, or other infectious diseases~Participants who have taken an investigational product in the last 30 days Participants who have experienced excess blood loss, including blood donation, defined as 250 mL in the last month or 500 mL in the previous two months"
88933208|NCT01757353|Experimental|BASICS plus normative enhancement motivational interview|Participants in this arm will complete a baseline assessment, followed by a 60-minute brief motivational interview (the Brief Alcohol Screening and Intervention for College Students, with a normative enhancement module) 10-14 days after the initial assessment. Participants in this arm will complete follow-up assessments at approximately 3 and 9 months.
88933209|NCT01757366|Experimental|experimental|Ginsenoside Rg3 plus First-line Chemotherapy
88933210|NCT01757366|Active Comparator|Active Comparator|First-line Chemotherapy
88933211|NCT01757379|Experimental|13C-labeled acetate|
88933212|NCT01757379|Experimental|13C-labeled propionate|
88933213|NCT01757379|Experimental|13C-labeled butyrate|
88933214|NCT01757379|Experimental|Inulin|
88933215|NCT01757431|Other|ECULIZUMAB|
88933216|NCT01757444|Experimental|BiPAP - A40|BiPAP with AVAPS AE mode
88933217|NCT01757444|Active Comparator|BiPAP- ST|Patients receiving BiPAP- ST at home
89447502|NCT05910853||Fanconi Anemia (c3788_3790delTCT)|"Cohort 2 - Fanconi Anemia (c3788_3790delTCT) (N=1):~Inclusion:~The participant is willing and able to provide written informed consent~The participant is willing and able to provide appropriate photo identification~Participants aged 18 to 85~Participants have been diagnosed with Fanconi Anemia complementation group A~1 participant must be diagnosed with the following genotype: c3788_3790delTCT~Exclusion:~Participants who are pregnant or are nursing~Participants with a known history of HIV, hepatitis, or other infectious diseases~Participants who have taken an investigational product in the last 30 days Participants who have experienced excess blood loss, including blood donation, defined as 250 mL in the last month or 500 mL in the previous two months"
89531309|NCT03336827|Other|Waiting-List Control Group|Patients include in the waiting-list control group (CG) will resort to usual care only after the first assessment (T1) (i.e., before the second assessment taking place 4 months later (T2)). They will receive one individual pre-group session and 8 sessions of group intervention combining cognitive-behavioral therapy and hypnosis after the second assessment (T2) (i.e., before the third assessment taking place 4 months later (T3)).
88933218|NCT01757457|Experimental|Intracoronary abciximab|Intracoronary administration of an abciximab bolus during primary PCI
88933219|NCT01757457|Active Comparator|Intravenous abciximab|Intravenous standard administration of an abciximab bolus during primary PCI
88933220|NCT01757470||Caprelsa Patient|All patients treated with Caprelsa in Canada and participating in the restricted distribution programme.
88933221|NCT01757470||Caprelsa Prescriber|All physicians having prescribed at least one dose of Caprelsa and registered as a certified prescriber of Caprelsa in Canada.
88933222|NCT01757483||Prescribers|
88933223|NCT01757496|Experimental|Cough Assist|These children will receive 2 Cough Assist sessions daily.
88933224|NCT01757496|No Intervention|Control group|These children receive standard care but no physiotherapy.
88933225|NCT01757509|Other|Intervention group|Participants in this group will receive a set dancing intervention along with their usual care.
88933226|NCT01757509|No Intervention|Control Group|The control group will continue with their usual medical regime, activities of daily living and exercise habits and at the end of the study participants in this group will be offered the set dancing intervention.
88933227|NCT01757548|Experimental|open operation|high ligation of spermatic vein by open operation
88933228|NCT01757548|Experimental|microsurgery|high ligation of spermatic vein by microsurgery
88933229|NCT01757574|Experimental|Alemtuzumab|Open label study of alemtuzumab
88933230|NCT01757587|Active Comparator|Vildagliptin|
89014317|NCT05449769|Experimental|Intervention group|Those in the intervention group will receive eNutriCardio PN advice after completing the eNutriCardio FFQ at baseline only. At weeks 2, 4 and 8 of the study, participants will also receive coaching emails which includes reminders of their PN advice and questions asking them to reflect on their goal progress, if any. This will be in addition to their participation in an NHS CR programme (if they choose to join).
89014318|NCT05449769|No Intervention|Control group|Those in the control group will not receive any PN advice from eNutriCardio and hence, will not receive any coaching emails. They will record their diet using eNutriCardio's FFQ . They will still be eligible to take part in an NHS CR programme.
89447503|NCT05910853||Fanconi Anemia (c295 G to T)|"Cohort 3 - Fanconi Anemia (c295 G to T) (N=1):~Inclusion:~The participant is willing and able to provide written informed consent~The participant is willing and able to provide appropriate photo identification~Participants aged 18 to 85~Participants have been diagnosed with Fanconi Anemia complementation group A~1 participant must be diagnosed with the following genotype: c295 G to T~Exclusion:~Participants who are pregnant or are nursing~Participants with a known history of HIV, hepatitis, or other infectious diseases~Participants who have taken an investigational product in the last 30 days Participants who have experienced excess blood loss, including blood donation, defined as 250 mL in the last month or 500 mL in the previous two months"
89014319|NCT05444465|Experimental|Isolated Bioinductive Repair|Surgical treatment of partial-thickness rotator cuff tears with the REGENETEN Bioinductive Implant system.
89014320|NCT05444465|Active Comparator|Completion and Repair|Surgical treatment of partial-thickness rotator cuff tears using the standard surgical technique 'Completion and Repair'.
89014321|NCT05440669|Experimental|White Noise|white noise will reduce pain and stress
89014322|NCT05440669|No Intervention|control|white noise will not reduce pain and stress
89014323|NCT05439083|Experimental|Immunosuppressed Group|"N=90 Immunosuppressed patients, consisting of HIV-infected children and adolescents, hematopoietic stem cell transplant (HSCT) recipients, solid organ transplant (SOT) recipients and post-chemotherapy patients (PCT) under follow up at Hospital La Paz in Madrid Spain.~9-valent HPV vaccine: three-dose schedule: Months 0-2-6."
89014324|NCT05439083|Other|Control Group|N=30 Healthy controls aged 9-14 9-valent HPV vaccine: two-dose schedule: Months 0-6.
89014325|NCT05437055|Experimental|Single Arm|Use of Penumbra System including Thunderbolt in patients with acute ischemic stroke secondary to intracranial large vessel occlusion who are eligible for mechanical thrombectomy
89014326|NCT05433584|Experimental|Tirzepatide|Participants will receive tirzepatide at the maximum tolerated dose subcutaneously (SC)
89014327|NCT05433584|Active Comparator|Intensified Conventional Care Dose|Participants will receive an antihyperglycemic medication
89014328|NCT05417269|Experimental|Cohort 1 - Phase I (IMCY-0141 Dose 1)|The first dose (Cohort 1) will consist of the administration of 150 μg of peptide (IMCY-0141) in two separate injections of 75 μg each (500μl each).
89014329|NCT05417269|Experimental|Cohort 2 - Phase I (IMCY-0141 Dose 2)|The second dose (Cohort 2) will consist of the administration of 450 μg of peptide (IMCY-0141) in two separate injections of 225 μg each (500μl each).
89014330|NCT05417269|Experimental|Cohort 3 - Phase I (IMCY-0141 Dose 3)|The third dose (Cohort 3) will consist of the administration of 1350 μg of peptide (IMCY-0141) in two separate injections of 675 μg each (500μL each).
89014331|NCT05417269|Experimental|Group 1 - Phase II (IMCY-0141 Dose 1)|Administration of IMCY-0141, 150 μg combined with alum adjuvant.
89014332|NCT05417269|Experimental|Group 2 - Phase II (IMCY-0141 Dose 2)|Administration of IMCY-0141, 450 μg combined with alum adjuvant.
89014333|NCT05417269|Experimental|Group 3 - Phase II (IMCY-0141 Dose 3)|Administration of IMCY-0141, 1350 μg combined with alum adjuvant.
89014334|NCT05417269|Placebo Comparator|Group 4 (Placebo Group) - Phase II|Administration of placebo combined with alum adjuvant.
89014335|NCT05417269|Active Comparator|Group 5 (Active Control Group) - Phase II|Parallel, Open-Label, Active Control Group Oral administration of Dimethyl Fumarate (DMF) given according to its SmPC for the whole duration of the study.
89014336|NCT05414708|Experimental|Art Therapy Arm|8 weeks of individual art therapy
89014337|NCT05411744|Other|1 month Rifapentine, Isoniazid and Vitamin B6|"Participants will receive 28 days of self-administered daily doses of RPT, INH, and pyridoxine (vitamin B6).~There are no multiple arms or multiple interventions. All participants will receive all 3 drugs. There are no comparators."
89014338|NCT05411094|Experimental|Treatment (olaparib, durvalumab, radiation therapy)|Patients receive olaparib PO BID on days 1-28 and durvalumab IV over 55-65 minutes on day 1 of each cycle. Beginning cycle 2, patients also undergo radiation therapy daily on weekdays for 3 weeks. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo tumor biopsy, diagnostic imaging and blood sample collection throughout the study.
89447504|NCT05910853||Fanconi Anemia (c3558-3559 insertion of G)|"Cohort 4 - Fanconi Anemia (c3558-3559 insertion of G) (N=1):~Inclusion:~The participant is willing and able to provide written informed consent~The participant is willing and able to provide appropriate photo identification~Participants aged 18 to 85~Participants have been diagnosed with Fanconi Anemia complementation group A~1 participant must be diagnosed with the following genotype: c3558-3559 insertion of G~Exclusion:~Participants who are pregnant or are nursing~Participants with a known history of HIV, hepatitis, or other infectious diseases~Participants who have taken an investigational product in the last 30 days Participants who have experienced excess blood loss, including blood donation, defined as 250 mL in the last month or 500 mL in the previous two months"
89447505|NCT05910853||Fanconi Anemia (c1115_1118delTTGG)|"Cohort 5 - Fanconi Anemia (c1115_1118delTTGG) (N=1):~Inclusion:~The participant is willing and able to provide written informed consent~The participant is willing and able to provide appropriate photo identification~Participants aged 18 to 85~Participants have been diagnosed with Fanconi Anemia complementation group A~1 participant must be diagnosed with the following genotype: c1115_1118delTTGG~Exclusion:~Participants who are pregnant or are nursing~Participants with a known history of HIV, hepatitis, or other infectious diseases~Participants who have taken an investigational product in the last 30 days Participants who have experienced excess blood loss, including blood donation, defined as 250 mL in the last month or 500 mL in the previous two months"
89447506|NCT05903001||Patients with Asthma|
89447507|NCT05903001||Patients with COPD|
89447508|NCT05903001||Patients with Fibrosis|
89447509|NCT05903001||Patients with Pulmonary Hypertension|
89447510|NCT05899114|Experimental|Transitional Multidisciplinary Pharmacotherapeutic Care (TMPC)|The participants in hospitals allocated to the intervention arm will receive TMPC, which will be executed by a Pharmacotherapy-team and will take place during the index hospital stay. This Pharmacotherapy-team will be composed of a physician and a hospital pharmacist, preferably registered as clinical pharmacologists.
89447511|NCT05899114|No Intervention|Usual care|The comparator in this study is usual care, which refers to the entire spectrum of medication-related interventions by different healthcare providers (physician, pharmacist, nurse etc.) which the patient undergoes during hospital admission.
89447512|NCT05896371|Experimental|Cohort A|Lower risk of toxicity (no risk factor)
89447513|NCT05896371|Experimental|Cohort B|Extensive bone metastasis
89447514|NCT05896371|Experimental|Cohort C|Decreased bone marrow reserve
89447515|NCT05896371|Experimental|Cohort D|Renal function impairment
89447516|NCT05896371|Experimental|Cohort E|Higher risk of toxicity (more than one risk factor and others)
89447517|NCT05893979|Active Comparator|Test Lens Group|
89447518|NCT05893979|Active Comparator|Control Lens Group|
89447519|NCT05893069|Experimental|Treatment group|Oxandrolone
89447520|NCT05893069|Placebo Comparator|Placebo Group|Placebo
89447521|NCT05890807|Experimental|Patients whose oral cavity will be photographed in the diabetology department|The patient is seated in the chair. The trained staff member positions the mouth guard and takes a frontal photograph of the patient's oral cavity using the photo sensor (smart-phone). Only the oral cavity will be visible in the photograph and there will be no possibility for an external assessor to recognize the patient's face.
88933231|NCT01757587|Placebo Comparator|Placebo|
89447522|NCT05890222|Experimental|Community Model|In addition to the facility model, village clusters in this arm will receive community intervention strategies delivered by community volunteers.
89447523|NCT05890222|Active Comparator|Facility Model|The HAP, a manualized and evidence-based psychological treatment based on behavioural activation, will be delivered by existing healthcare workers (called counsellors from here onwards) within the health centres who will be trained to deliver the HAP.
88933232|NCT01757600||Macular Hole|
88933233|NCT01757613|Active Comparator|AK 3012 a for topical use|
88933234|NCT01757613|Active Comparator|AK 3012 b for topical use|
88933235|NCT01757613|Active Comparator|AK 3012 c for topical use|
88933236|NCT01757639|Experimental|Treatment (ipilimumab)|"INDUCTION: Patients receive ipilimumab IV on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Beginning 12 weeks after last dose of induction ipilimumab, patients receive ipilimumab IV on day 1. Treatment repeats every 12 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity."
88933237|NCT01757743||Interventional closure|Interventional catheterization closure
88933238|NCT01757743||Open Heart Surgery|Surgery for Atrial septal defect
89447524|NCT05889416|No Intervention|Usual care|Implementation of national guidelines on secondary prevention according to local plan and preferences
88933239|NCT01757756|Experimental|Arm Label Pf-05175157, placebo, midazolam|
88933240|NCT01757769|Experimental|Silodosin|Silodosin capsule 8 mg daily for 24 weeks
88933241|NCT01757795|Experimental|SP-8203|Active arm
89447525|NCT05889416|Active Comparator|Audit and feedback|Audit and feedback on implementation of national guidelines on secondary prevention through the national quality registry SWEDEHEART
89447526|NCT05889416|Active Comparator|Implementation support|Audit and feedback through the national quality registry SWEDEHEART and structured implementation support for implementation of national guidelines on secondary prevention
89447527|NCT05887479|Active Comparator|Study Group|This is the group that will be injected with botulinum toxin for spasticity and stretching exercises will be given.
89447528|NCT05887479|Placebo Comparator|Control Group|This is the group that will be injected with %0,9 NaCl for spasticity and stretching exercises will be given.
89447529|NCT05883267|Experimental|Virtual reality|"The VR glasses will be PICO model neo 2. The visual and vocal data content include both calming, affective imagery and interactive gaming, supplied by XR-Health Israel Ltd. The vocal-guided affective imagery during the procedure will be identical to the vocal guide in the VR glasses."
89447530|NCT05883267|Active Comparator|Audio|The vocal-guided affective imagery during the procedure will be identical to the vocal guide in the VR glasses.
89447531|NCT05882643|Experimental|block group|"Maintaining moderate to deep neuromuscular blockade during an intraoperative period (Train-of-four 0-3, post-tetanic count > 1)~Rocuronium (intravenous, 1.0 mg/kg)"
89014339|NCT05406713|Experimental|Experimental Group|"Cycles 1-2 (Pembrolizumab): 400 mg of Pembrolizumab intravenously (Administered Day 1 of 42 day Cycle)~If complete response of treatment is observed then maintenance therapy will be given. All other patients will receive with standard of care local therapy (cystectomy or chemo-radiation) as per their treating physicians followed by adjuvant pembrolizumab.~Cycle 3-9 (Maintenance or Adjuvant Single agent Pembrolizumab): 400 mg of Pembrolizumab intravenously (Administered Day 1 of 42 day Cycle)"
89014340|NCT05399589|Experimental|on1 abutment|The on1 abutment was directly used in the operation to protect the soft tissue mucosa. After three months, the mold was taken directly for formal teeth.
89014341|NCT05399589|Active Comparator|healing cap|After the operation, the embedded healing is selected. After waiting for three months, the second stage operation is needed to expose the healing cap
89014342|NCT05392582||Young|Young healthy adult participants
89014343|NCT05392582||Older|Older healthy adult participants
89014344|NCT05387603|Experimental|177Lu-DOTATOC + Capecitabine|"Patients with 68Ga-DOTA- and 18F-FDG-PET-positive NET will receive a combination of intravenous 7.5 GBG (gigabequerel) 177Lu-DOTATOC for about 7 cycles in combination with capecitabine (4 cycles, cycle length 3 weeks, with one week without capecitabine, dosing 825 mg twice daily) and PRRT to a cumulative renal AD (absorbed dose) limit of 30 Gy and dosimetry-based PRRT.~."
89014345|NCT05387603|Experimental|177Lu-DOTATOC|Intravenous infusion for about 7 treatment cycles with 7.5 GBq 177Lu-DOTATOC with an interval of 10 ± 2 weeks and PRRT to a cumulative renal AD limit of 30 Gy and dosimetry-based PRRT.
89014346|NCT05387603|Active Comparator|Standard 177Lu-DOTATOC|Standard treatment of 177Lu-DOTATOC with treatment for 4 cycles.
89014347|NCT05386147|Experimental|Study group|"Women with recurrent BV use the Flourish HEC Vaginal Care System, consisting of three components: 1) Balance external wash; 2) BioNourish vaginal moisturizing gel (an FDA 510k cleared class II medical device); and 3) BiopHresh homeopathic vaginal suppository with probiotics. All system components are currently available to the public at national retailers. Women will use the system for six months. They will have vaginal microbiome composition (next-generation sequencing and Nugent score) and vaginal pH tested at baseline, 3 months, and 6 months. At each timepoint they will also complete the vulvovaginal symptoms questionnaire (VSQ)."
89447532|NCT05882643|Active Comparator|control group|"Maintaining shallow to minimal neuromuscular blockade during an intraoperative period (Train-of-four 4, post-tetanic count < 0.9)~Rocuronium (intravenous, 0.3 mg/kg)"
89014350|NCT05368831|Experimental|Oral dose of NST-1024, Caffeine, Flurbiprofen, Omeprazole, Metoprolol, and Midazolam|"Day 1: single oral dose of 100 mg caffeine, 50 mg flurbiprofen, 20 mg omeprazole, 100 mg metoprolol, and 2.5 mg midazolam~Days 8 to 22: oral doses of 200 mg NST-1024 qd multiple-dose regimen~Day 8: single oral dose of 100 mg caffeine, 50 mg flurbiprofen, 20 mg omeprazole, 100 mg metoprolol, and 2.5 mg midazolam coadministered with an oral dose of 200 mg NST-1024~Day 21: single oral dose of 100 mg caffeine and 2.5 mg midazolam coadministered with an oral dose of 200 mg NST-1024."
89014351|NCT05364931|Experimental|Cotadutide 300μg|
89014352|NCT05364931|Placebo Comparator|Placebo 300μg|
89014353|NCT05364931|Experimental|Cotadutide 600μg|
89014354|NCT05364931|Placebo Comparator|Placebo 600μg|
89014355|NCT05362344||NICE-CF Cohort|Adults with CF ages 18 - 75 years who are due for a routine screening or surveillance colonoscopy for colon cancer.
89014356|NCT05361993|Experimental|Biofeedback therapy|three times a week, every other day interval, 30 minutes each time, each subject received 20 biofeedback training (using the Infiniti3000A biofeedback system Patients in the theta group decreased the theta amplitude at Cz. Patients in the theta group received positive feedback when their theta activity was below the feedback threshold.
89014357|NCT05361993|Active Comparator|Drug therapy|Considering the patients with chronic tic disorder (chronic motor or vocal tic disorder or Tourette's disorder), aripiprazole was selected as a single drug with constant dose during the treatment. In case of extrapyramidal side effects, benhexol was given to reduce the extrapyramidal side effects, and the dosage and duration of medication were recorded
88933242|NCT01757795|Placebo Comparator|Placebo|Matching Placebo
89014358|NCT05355805|Experimental|Part A (Open-label) izokibep every week|Participants will receive izokibep every week from Day 1 through Week 31
89014359|NCT05355805|Experimental|Part B (Double-blind) izokibep every week|Participants will receive izokibep weekly for 31 weeks.
89014360|NCT05355805|Experimental|Part B (Double-blind) izokibep every other week|Participants will receive izokibep every other week for 30 weeks.
89014361|NCT05355805|Placebo Comparator|Part B (Double-blind) placebo every week|Participants will receive placebo weekly up to Week 15, then izokibep from Week 16 to Week 31.
89014362|NCT05355805|Placebo Comparator|Part B (Double-blind) placebo every other week|Participants will receive placebo every other week up to Week 14, then izokibep from Week 16 to Week 30.
89447533|NCT05879120|Experimental|Neoadjuvant pembrolizumab|
88933243|NCT01757808|Experimental|Ranolazine|
89447534|NCT05879120|Experimental|Exablate MRgFUS + neoadjuvant pembolizumab|
88933244|NCT01757808|Placebo Comparator|Placebo|
89447535|NCT05874804|Active Comparator|Control CAPD treatment|The subjects will receive their standard CAPD treatment.
89447536|NCT05874804|Experimental|Carry Life UF|Three days per week, the subject will replace a 2.27% glucose dwell with the Carry Life® UF treatment. The remaining four days of the week, one 2.27% glucose dwell will be replaced by a 1.36% glucose dwell.
89447537|NCT05864261|Experimental|JT1801|
89447538|NCT05864261|Active Comparator|NESP|
89447539|NCT05861089||vascular surgery candidates|End-tidal CO2 will be measured day before surgery. Post-operative cardiovascular and pulmonary complications will be monitored fron the hospital stay, or first 30 days.
89447540|NCT05857631|Experimental|Hypofractionated Image guided External Beam Radiation|Adjuvant hypofractionated external beam radiotherapy for post operative patients with cervical or endometrial cancer.
89447541|NCT05846425|Experimental|Nose-breathing|Controlled nose-breathing
89447542|NCT05846425|Active Comparator|Mouth-breathing|Controlled mouth-breathing
89447543|NCT05846425|No Intervention|Control group|no intervention
89447544|NCT05844449|Experimental|VNZ/TEZ/D-IVA|Participants (Cohort 1: 6 through 11 years of age (inclusive); Cohort 2: 2 through 5 years of age (inclusive) and Cohort 3: 1 to less than (<) 2 years of age) will receive VNZ/TEZ/D-IVA once daily at doses determined based on their age and weight. The age range is based on date of informed consent in parent study.
89447545|NCT05844241|Experimental|Music and Theta Auditory Beat Stimulation (ABS)|Participants listen to 30 minutes of personalized music with theta auditory beat stimulation (ABS).
89447546|NCT05844241|Active Comparator|Audiobooks|Participants listen to a 30-minute audiobook.
88933245|NCT01757834|Experimental|SWUS Elastography|This is a noninvasive technique using focused ultrasonic beams (pushing beams.) Several pushing beams at increasing depths are transmitted to generate a quasi-plane shear wave frame that propagates throughout the imaging area. After generating the shear wave, an ultrafast imaging sequence is performed to acquire successive raw radiofrequency dots at a very high frame rate (up to 20,000 per second). A tissue elasticity assessment can be derived from shear wave propagation speed. A color-coded image is displayed; softer tissue in blue and stiffer tissue in red. Quantitative information is delivered by drawing regions of interest on the thyroid and surrounding tissues which is the Elasticity Index expressed in kilo-Pascal (kPa). Due to the lack of manual compression and known value of the strength of pushing beam, SWUS gives an objective number to stiffness within the nodule.
88933246|NCT01757860|Experimental|CARD-024|CARD-024 oral administered: 3, 9, 27 or 81 mcg.
88933247|NCT01757860|Placebo Comparator|Drug Carrier|Placebo: 20% ethanol:80% propylene glycol solution oral administered.
88933248|NCT01757873|Experimental|Z160|375 mg BID
88933249|NCT01757873|Placebo Comparator|Placebo|matching placebo control
88933250|NCT01757886||ST-elevation acute coronary syndrome|ARTERY is a prospective, multicenter, which will include patients admitted with the diagnosis of ST-elevation acute coronary syndrome and thrombus aspiration is performed during primary angioplasty
88933251|NCT01757899|Active Comparator|Methylprednisolone Arm|"The patients in this arm will receive methylprednisolone, which is available in vials containing 125 mg/2mL after dilution, as it follows:~Day 0 Loading dose 1 mg/kg IV bolus mixed in 5 mL NS (30 min) followed by continuous infusion Days 0 to 07 - 1 mg/kg/day mixed in 24cc NS and infused at 1 cc/hr Days 08 to 10 - 0.5 mg/kg/day mixed in 24cc NS and infused at 1 cc/hr Days 11 to 12 - 0.25 mg/kg/day Days 13 to 14 - 0.125 mg/kg/day"
88933252|NCT01757899|Placebo Comparator|Sterile Saline Arm|Patients randomized to the control arm will receive sterile normal saline in an amount that would equal the total diluted dose of study drug (ie. if initial loading dose equals a total of 24 cc [methylprednisolone + diluting fluid], then the patient will receive 24 cc of sterile normal saline). Tapering doses will be equivalent to that of the study arm, so that investigators will remain blinded to therapy. The unblinded party will be composed of the research ARDS pharmacist. Five days after the patient is able to ingest medications, placebo is administered per os (PO) in one single daily equivalent dose. The placebo will be manipulated by the pharmacist as to resemble identical to the active drug.
88933253|NCT01757912|Experimental|Cuff pressure after positioning|The patient will be positioned in 16 distinct body positions. Immediately after correct positioning, the cuff pressure is measured.
88933254|NCT01757925|Experimental|Active Gaming|Participants will receivce a weight management program plus active gaming device
88933255|NCT01757925|Active Comparator|Control Group|Participants will receive a weight management program without active gaming
89014363|NCT05355402|Experimental|Olezarsen|Olezarsen will be administered once every 4 weeks by subcutaneous (SC) injection for up to 49 weeks.
89014364|NCT05355402|Placebo Comparator|Placebo|Olezarsen-matching placebo will be administered once every 4 weeks by SC injection for up to 49 weeks.
89447547|NCT05842824||Disease Cohort|Observational
89447548|NCT05842824||Engaged Cohort|Observational
89447549|NCT05840055|Experimental|Acceptance and Commitment Therapy|
89447550|NCT05839366|Active Comparator|Remifentanil + propofol + esketamine|esketamine (2ml; 50mg), Remifentanil Hydrochloride for Injection (1mg;), propofol injection (50ml; 0.5g; )； The frequency of use is determined by responsible clinicians.All analgesic and sedative drugs used are adjusted according to the actual situation of the patient.
89447551|NCT05839366|Placebo Comparator|remifentanil + propofol + saline|Remifentanil Hydrochloride for Injection (1mg;), propofol injection (50ml; 0.5g; )； The amount of saline used is equivalent to the amount of esketamine.All analgesic and sedative drugs used are adjusted according to the actual situation of the
89447552|NCT05838716|Experimental|Arm I (HDVD)|Patients receive HDVD PO throughout the study. Patients also undergo collection of blood and DXA scan on study.
89447553|NCT05838716|Placebo Comparator|Arm II (placebo, DXA scan, blood collection, questionnaire)|Patients receive placebo PO throughout the study. Patients also undergo collection of blood and DXA scan on study.
89447554|NCT05836662|Active Comparator|2D Concussion Education|During their in person study visit, participants will complete a brief ( ~5 minute) pre-survey before viewing the CrashCourse and Brain Fly-Through concussion educations. Participants in this group will receive both of these educations in 2D (via a video on a laptop). Participants will then be asked to complete a brief ( ~2 minute) survey to assess their knowledge, self-efficacy, and empathy surrounding concussions.
89447555|NCT05836662|Experimental|3D Concussion Education|During their in person study visit, participants will complete a brief ( ~5 minute) pre-survey before viewing the CrashCourse and Brain Fly-Through concussion educations. Participants in this group will receive both of these educations in 3D (via a Virtual Reality headset). Participants will then be asked to complete a brief ( ~2 minute) survey to assess their knowledge, self-efficacy, and empathy surrounding concussions.
89447556|NCT05832138|Experimental|Intervention|"Usual care plus ONLOOP program materials:~Study invitation letter and invitation reminder 5 weeks later~For those who sign up: receipt of a personalized health toolkit and then a screening reminder 6 months later~Optional: Engagement of primary care provider through an introductory letter and then a reminder letter sent 6 months later"
89447557|NCT05832138|Other|Delayed Intervention|"Usual care plus delayed ONLOOP:~Survivors will receive usual care for 13 months after study invitation packages are mailed out to the intervention arm. At that point, survivors in this group will also receive the study invitation package."
89447558|NCT05822960|Experimental|far-infrared radiation on foot acupoints|experimental group far-infrared radiation on foot acupoints during dialysis,during dialysis,, and the irradiation distance was 20 cm for 40 minutes each time for six months.
89447559|NCT05822960|No Intervention|The control group received general clinical routine care|no far-infrared radiation on foot acupoints
89447560|NCT05822258|Experimental|Freezing of Gait|"Each patient will have 2 visits :~First visit in the ON state phase, i.e. when their oral treatment allows the maximum improvement of dopamine-responsive parkinsonian symptoms.~A second visit in the OFF phase after having stopped taking their antiparkinsonian medications for at least 12 hours before the start of the visit, in order to promote episodes of FOG~For each visit, the patient will be asked to walk at a comfortable speed under the following 3 conditions:~Normal condition without additional physical and verbal tasks~Condition with added physical tasks: The physical task of holding a ball in the center of a tray.~Condition with added verbal tasks: The verbal task of saying as many words as possible starting with a specific letter.~Conditions of passage are randomized per patient. Each subject will complete the course a maximum of 18 times in blocks of 3 conditions (normal, double physical task and double verbal task). A rest period will be observed."
89447561|NCT05819814|Experimental|Intervention|Participants will receive their high polygenic risk result for coronary artery disease.
89447562|NCT05819814|No Intervention|Control|Participants will receive standard of care, and disclosure of high polygenic risk result will be deferred until study completion.
89447563|NCT05810792|Experimental|Patients receiving immunomodulating treatment|
89447564|NCT05810168|Active Comparator|Traditional Dietary Advice|Recommended to eat smaller, regular meals and reduce the intake of caffeine/alcohol/fizzy drinks, fatty/processed/spicy foods, and fibre
89447565|NCT05810168|Active Comparator|Low FODMAP diet|FODMAPs are fermentable carbohydrates that increase intestinal water and gas production that, in those with visceral hypersensitivity, induces gastrointestinal symptoms. The low FODMAP diet therefore excludes fermentable carbohydrates, which are present in wheat-based products, many fruits/vegetables, pulses, beans, dairy, and sweeteners.
89447566|NCT05809258|Active Comparator|Supraclavicular block|In the supraclavicular group, the ultrasound probe will be positioned in the supraclavicular fossa, pointing caudad and locating the subclavian artery. The first rib is identified deep to the artery, and the hyperechoic pleura will be identified by sliding lung sign. The brachial plexus is consistently found with a characteristic ''honeycomb'' appearance lateral and superficial to the subclavian artery and superior to the first rib. The needle will be introduced through the skin from lateral to medial, in-plane with the transducer, with constant visualization, and directed toward the deep border of the nerve group. Three separate injections will be made at various sites in the bundle, tending to start deep, in the ''corner pocket'' close to the artery, and moving more superficially. The local anesthetics will be Lidocaine 2% 10 ml + Levobupivacaine 0.5% 10 ml.
88933256|NCT01757938|Experimental|Shang Ring Guided Circumcision|The Shang Ring (SR) (Wuhu Santa Medical Devices Technology Co Ltd, China) male circumcision performed by study surgeon (study PI). In both study groups, participants were cleaned with povidone iodine solution and draped in a sterile fashion. Local anesthesia was administered to the dorsal penile nerve and penile ring blocks using 3mg/kg of 1% lidocaine. The surgeon measured participants in the SR group to determine ring size. Patients for whom a suitable ring size was not available crossed over to the FG group, but remained in the SR group for intention to treat (ITT) analyses.
88933257|NCT01757938|Active Comparator|Forceps Guided Circumcision|Standard forceps guided adult male circumcision was performed. In both study groups, participants were cleaned with povidone iodine solution and draped in a sterile fashion. Local anesthesia was administered to the dorsal penile nerve and penile ring blocks using 3mg/kg of 1% lidocaine.
89014365|NCT05349123|Experimental|Intervention|Home-based pulmonary rehabilitation that includes health coaching with mindful breathing module
89537107|NCT05726435|Active Comparator|Experimental group|Seven randomly selected active basketball players will be supplemented with defined prebiotic fibre (20 grams per day divided in two 10 gram doses - 85% total fiber content) for the total duration of 4 weeks, while being stationed in the training camp under constant coach and nutrition expert surveillance.
88933258|NCT01757951|Experimental|Unimalleolar Fixation|Medial malleolus is fixed first and after that ankle mortise stability is assessed using external-rotation stress test. If talocrural joint is stable after fixation of medial malleolus, the patient is randomized to unimalleolar fixation group and no fixation of the lateral side is performed.
88933259|NCT01757951|Active Comparator|Bimalleolar Fixation|Medial malleolus is fixed first and after that ankle mortise stability is assessed using external-rotation stress test. If talocrural joint is stable after fixation of medial malleolus, the patient is randomized to bimalleolar fixation group i.e. additional fixation of the lateral malleolus fracture is performed.
88933260|NCT01757119|Experimental|Drug|
88933261|NCT01757977|Experimental|Vivasight DL|placement and intraoperative use of Vivasight DL double lumen endobronchial tube
88933262|NCT01757977|Active Comparator|standard DLT|placement and intraoperative use of a standard double lumen endotracheal tube.
88933263|NCT01757990|Experimental|Stevioside extract|After measuring baseline plaque pH, the subjects rinsed for 1 minute with the solution containing Stevioside extract. Plaque pH was then measured at 5, 10, 15, 30, 45 and 60 min after the mouth rinse.
88933264|NCT01757990|Experimental|Rebauside extract|After measuring baseline plaque pH, the subjects rinsed for 1 minute with the solution containing Rebaudioside extract. Plaque pH was then measured at 5, 10, 15, 30, 45 and 60 min after the mouth rinse.
88933265|NCT01757990|Sham Comparator|Saccarosio|After measuring baseline plaque pH, the subjects rinsed for 1 minute with the sucrose solution. Plaque pH was then measured at 5, 10, 15, 30, 45 and 60 min after the mouth rinse.
88933266|NCT01758029||Testosterone Undecanoate|treatment with testosterone undecanoate 1000mg intramuscular, at week 0, week 6, week 18.
88933267|NCT01758055|Experimental|Autologous MSCs transplantation|intra bronchial injection, Autologous MSCs transplantation derived bone marrow, 60millions cells, once
88933268|NCT01758068|Experimental|Coconut Oil Application|The oil (coconut oil) was applied by the trained nurse to the entire body surface of infant except the face two times a day started as early as possible Four ml of coconut oil was applied using both hands of the caregiver in four strokes starting from the level of clavicles over the chest and abdomen till the groin, from the front of thighs, knee, leg and upto the sole, from above the shoulders over the arm and forearm till the palm continuing medially over the forearm and arm till the axilla and the final stroke was used for the back reaching over the back of the thighs till the heel. Just prior to the first application, and thereafter prior to the subsequent applications the TEWL was recorded using the portable closed chamber evaporimeter. The oil application was continued twice daily (every 12 hrs at the same time as the hour of birth e.g. 11 am and 11pm) till the completion of the seventh day (168 hrs of life)..
89014366|NCT05349123|Active Comparator|Control|Home-based pulmonary rehabilitation that includes health coaching
89014367|NCT05345106||Premenopausal women with obesity|
89014368|NCT05345106||Postmenopausal women with obesity|
89014369|NCT05345106||Men with obesity|
89014370|NCT05345106||Premenopausal women without obesity|
89014371|NCT05345106||Postmenopausal women without obesity|
89014372|NCT05345106||Men without obesity|
89014373|NCT05337137|Experimental|Arm A: Relatlimab + Nivolumab + Bevacizumab|
89014374|NCT05337137|Experimental|Arm B: Placebo + Nivolumab + Bevacizumab|
89014375|NCT05336786|Experimental|Diagnostic (perflutren lipid microspheres, ultrasound)|Patients receive perflutren lipid microspheres IV over 5-6 minutes and undergo ultrasound over 30 minutes. Patients may receive up to 2 additional doses of perflutren lipid microspheres
89014376|NCT05331846|Experimental|SMELL OF BREAST MILK|the smell of breast milk will reduce pain and stress
89447567|NCT05809258|Active Comparator|Axillary block|Patients in the axillary group are placed in the supine position with the arm to be blocked, abducted and externally rotated. After sterilization of the axilla, the Ultrasound probe will be placed parallel to the anterior axillary fold at the axilla to identify the axillary artery and surrounding radial, ulnar, and median nerve, appearing as hypo-echoic round structures around the axillary artery. The musculocutaneous nerve will also be identified between the coracobrachialis and biceps muscle or in either of them. Lidocaine 1% was infiltrated subcutaneously 1 cm lateral to the probe, and then 0.5% bupivacaine will be injected around branches of the brachial plexus. The local anesthetics will be Lidocaine 2% 10 ml + Levobupivacaine 0.5% 15 ml. In this block, 5-7 ml of local anesthetic will block each nerve.
89447568|NCT05806450|Experimental|Intervention condition|Structured online intervention consists of three weekly sessions of cognitive therapy and psychoeducation about child sleep
89014377|NCT05331846|No Intervention|control|pain and stress will not decrease
89014383|NCT05322135|Experimental|PET scan|PET scans: an 11C-Glutamine PET scan and an 18F-FSPG PET scan. A small tube (called an IV) will be placed in a vein in your arm through which you will receive the radioactive material for the PET scan(s).
89014384|NCT05311488||Symptomatic TTRv|Patients with known TTR mutations and neuropathy
89014385|NCT05311488||Asymptomatic TTRv|Patients with TTR mutation and no symptoms within less than 10 years of typical onset of disease
89014386|NCT05311488||Healthy controls|Age and sex matched healthy controls without neuropathy or other neurological disorder.
89014387|NCT05311228|Experimental|Intervention group|Intervention group will give azithromycin for 14 days, 7 days 10 mg/body weight/24 hours, 7 days 5 mg/bw/hours
89014388|NCT05311228|No Intervention|Control group|No intervention
89014389|NCT05302752|Experimental|Bilateral rapid magnetic stimulation of the phrenic nerves|Each participant will be tested on three different days with optimal settings for bilateral rapid magnetic stimulation of the phrenic nerves established on visit 1 and then repeated on visits 2 and 3.
89014390|NCT05295433|Experimental|mRNA-3705|Participants will receive mRNA-3705 at the same dose levels at the same dosing interval (every 2 weeks [Q2W], or every 3 weeks [Q3W]) last received in the clinical study of mRNA-3705 in which they initially participated, unless the Sponsor recommends modification.
89014391|NCT05290844|Other|Pediatric cricoid force|one arm ( 3 groups)120 pediatric patients
89014392|NCT05286060|Experimental|GX-188E 2mg, IM: 1st day of week 1, 2, and 4; GX-I7 1200㎍/kg|"IV:1st day of week 1 and 4, IV:1st day of week 1 and 4~Triple combination of GX-188E HPV DNA Vaccine, GX-I7, and Pembrolizumab"
89014393|NCT05286060|Experimental|GX-188E 2mg, IM: 1st day of week 1, 2, and 4; Pembrolizumab 200mg, IV:1st day of week 1 and 4|Combination of GX-188E HPV DNA Vaccine and Pembrolizumab as an Expanded Cohort
89447569|NCT05806450|Active Comparator|Active control condition|Psychoeducation about basic sleep structure and sleep hygiene
89447570|NCT05801042|Experimental|Encapsulated probiotic|
89447571|NCT05801042|Active Comparator|Non-encapsulated probiotic|
89447572|NCT05801042|Placebo Comparator|Placebo|
89447573|NCT05796037||Disease Cohort|Observational
89447574|NCT05796037||Engaged Cohort|Observational
89447575|NCT05796037||Age Cohort|Observational
89447576|NCT05792163|Experimental|A (SNP318)|"Drug: SNP318, Dose level: Start from 1mg for single ascending dose and from 30mg for multiple ascending dose. Dose levels can be adjusted based on emerging safety, tolerability, pharmacokinetics data of previous cohorts.~Dosage form: Capsule Route of administration: Oral"
89447577|NCT05792163|Placebo Comparator|B (Placebo)|Placebo comparator taken by participants randomized to the placebo arm in each cohort in Part 1 and Part 2.
89447578|NCT05789264|Active Comparator|Standard of Care|Participants assigned to the standard of care arm will be guided through clearing out clots in the nose (if using oxymetazoline), correct head positioning and how to appropriately hold nasal pressure and +/- oxymetazoline applied by a trained medical provider. No packing material will be inserted into the nares and only external pressure will be applied.
89447579|NCT05789264|Experimental|Nasal Compression Device|Participants assigned to the nasal compression device arm will be provided with the device package which will include the compression device, nasal sponges, and +/- oxymetazoline nasal spray to apply to the sponges as well as written/graphical assembly and application instructions. Participants will then assemble and apply the device themselves under the supervision of a trained medical provider.
89447580|NCT05788172||Participants|Female 18-30 year olds, who have already been labelled with stable iron isotopes at least 12 months prior to study start.
89447581|NCT05784766|Active Comparator|Screen group|Patients randomized to screening will undergo a 30-second ECG using the Kardia Mobile device (AliveCor Inc, Cupertino, CA) paired with an iPad (Apple, Cupertino, CA). If the mobile ECG shows possible AF or unclassified, then patients will undergo a 12-lead standard ECG during the same visit, read by a cardiologist, to verify the correct diagnosis.
89447582|NCT05784766|Active Comparator|Usual Care|For patients in the usual care arm, medical record review will be done at end of study to assess for the newly diagnosed AF during the study period.
88933269|NCT01758068|No Intervention|No Oil Application|Babies in this group were not subjected to oil application. TEWL measurement was recorded every 12 hrs for the first week of life, at the same time as the hour of birth.
88933270|NCT01758094||Hypogonadotropic hypogonadism patients|Treatment naive 25 patients with idiopathic hypogonadotrophic hypogonadism
88933271|NCT01758107|Experimental|Sirolimus with Prednisolone|Sirolimus with Prednisolone, and withdraw cyclosporine
88933272|NCT01758107|No Intervention|Sirolimus with Cyclosporine with Prednisolone|
88933273|NCT01758120|Experimental|prednisone plus cyclophosphamide|prednisone plus cyclophosphamide: prednisone(0.5mg/kg/day*6 months) plus cyclophosphamide(1g intravenous use,per 1 month*6months)
88933274|NCT01758120|Experimental|prednisone alone|prednisone alone: prednisone(0.5mg/kg/day*6 months)
88933275|NCT01758133||Mothers exposed to medical clowns|Mothers of premature infants who have been exposed to medical clown activities
88933276|NCT01758133||Mothers not exposed to medical clown activity|
88933277|NCT01758146|Experimental|Arm A- Letrozole|Aromatase inhibitor- letrozole 2.5mg once daily for 5 years
88933278|NCT01758146|Active Comparator|Arm B- Tamoxifen|Tamoxifen 20 mg once daily for 5 years
88933279|NCT01758159|Experimental|CFR group|The children in this group will receive complementary feeding with locally available foods according to optimized complementary feeding recommendation (CFR)
88933280|NCT01758159|Experimental|Fe group|The children in this group will receive iron supplementation 2mg/kg/day of ferric Na EDTA (in the form of syrup) daily for 24 weeks duration.
88933281|NCT01758159|Experimental|CFR + Fe group|The children in this group will receive both local food-based complementary feeding according to CFR and Iron supplementation for 24 weeks duration
88933282|NCT01758159|Placebo Comparator|Control group|The children in this group will receive basic health services and placebo syrup.
88933283|NCT01758172|Active Comparator|Albumin|albumin was administered to reach CVP up to 7mmHg
88933284|NCT01758172|Experimental|6% hydroxyethyl starch 130/0.4|6% hydroxyethyl starch 130/0.4 was administered to reach CVP up to 7mmHg
88933285|NCT01758185|Placebo Comparator|recombinant hepatitis b vaccine|0.5ml intramuscular
88933286|NCT01758185|Experimental|Aleph influenza vaccine|0.5ml intramuscular
88933287|NCT01758198|Experimental|Group 1: Abatacept + Methotrexate (MTX)|"Abatacept 10 mg/kg solution intravenous (IV) infusion, once monthly for 12 months~Methotrexate ≥6 mg/week for 12 months"
88933288|NCT01758198|Placebo Comparator|Group 2: Placebo matching with Abatacept + Methotrexate|"Placebo matching with Abatacept 0 mg/kg solution, intravenous (IV) infusion once monthly for 12 months~Methotrexate ≥6 mg/week for 12 months"
89447583|NCT05783232|Placebo Comparator|Placebo Control 1 Capsules|Health Product Form 1 Capsules - control
88933289|NCT01758211|Experimental|fMRI guided resection of AVM|fMRI Navigation AVM resection in AVM patients
88933290|NCT01758211|Active Comparator|conventional AVM resection|conventional resection of AVM
88933291|NCT01758224|Experimental|Functional Magnetic Stimulation|This group will receive magnetic stimulation of the respiratory (breathing) muscles that may improve the breathing function in subjects with MS. The magnetic stimulation protocol (plan of study) consists of a daily expiratory (breathing out) muscle conditioning program (20 minutes).
88933292|NCT01758224|Active Comparator|Resistive Expiratory Muscle Training|Participants in this group will perform breathing exercises using a resistive breathing device. The training will take place in the FMS lab. After training, participants will perform the exercise for 20 minutes daily (5days each week for 6 weeks) in their home.
88933293|NCT01758237|Experimental|Superior Laser Peripheral Iridotomy|Neodymium-doped: Yttrium Aluminum Garnet (Nd:YAG) laser peripheral iridotomy was performed on the superior aspect of the iris in the eye being treated. This will be in the 11 to 1 o'clock position.
89014394|NCT05286060|Experimental|GX-188E 2mg, IM: 1st day of week 1, 2, and 4; GX-I7 360㎍/kg,GX-188E 2mg,|"IM: 1st day of week 1, 2, and 4; GX-I7 360㎍/kg, IM: 1st day of week 2; Pembrolizumab 200mg, IV:1st day of week 1 and 4~Triple combination of GX-188E HPV DNA Vaccine, GX-I7, and Pembrolizumab as an Expanded Cohort"
89447584|NCT05783232|Experimental|Active Product 1.1 Capsules|Health Product Form 1 Capsules - active product 1
89447585|NCT05783232|Experimental|Active Product 1.2 Capsules|Health Product Form 1 Capsules - active product 2
89447586|NCT05783232|Experimental|Active Product 1.3 Capsules|Health Product Form 1 Capsules - active product 3
89447587|NCT05778968|Active Comparator|low ETCO2|
89447588|NCT05778968|Active Comparator|normal ETCO2|
89447589|NCT05778968|Active Comparator|high ETCO2|
89447590|NCT05777018|Active Comparator|conventional|
89447591|NCT05777018|Active Comparator|ultrasound-guided|
88933294|NCT01758237|Experimental|Temporal Laser Peripheral Iridotomy|Neodymium-doped: Yttrium Aluminum Garnet (Nd:YAG) laser peripheral iridotomy was performed on the temporal aspect of the iris in the eye being treated. The position will be in the 2 to 4 o'clock in the left eye and 8 to 10 o'clock in the right eye.
88933295|NCT01758250||Systemic Sclerosis|Patients with SSc will have imaging studies performed at baseline and at 3, 6, 9, 12, 15, 18, 21 and 24 months.
88933296|NCT01758250||GVHD|Patients with GVHD will have imaging studies performed at baseline and at 3, 6, 9, 12, 18 and 24 months.
88933297|NCT01758250||Undergoing HSCT|Patients who are about to undergo HSCT will have imaging studies performed at 1 week pre-transplantation, day 40 and 80 post transplantation and at 3 months, 6 months, 12 months 18 months and 24 months post-transplant.
88933298|NCT01758250||Controls|Healthy Controls and Controls with hematologic and solid organ malignancies and dermatitis will have imaging studies performed at a single point in time.
88933299|NCT01758250||Sickle cell disease|Patients with SCD will have imaging studies performed at baseline and at 3, 6, 9, 12, 15, 18, 21 and 24 months.
88933300|NCT01758250||Cutaneous fibrosing disorder|Patients with active cutaneous fibrosing disorder will have imaging studies performed at a single point in time.
88933301|NCT01758263||Metoprolol to Nebivolol|Patients with high blood pressure (hypertension) who were continuously treated with metoprolol for a minimum of 6 months prior to switching to nebivolol. Patients were then continuously treated with nebivolol for a minimum of 6 months.
88933302|NCT01758276||Non smokers|Women who did not report smoking in pregnancy
88933303|NCT01758276||Smokers in pregnancy|Women who report smoking in pregnancy
88933304|NCT01758302|Active Comparator|No physical task + Taste cookies|Participants in this arm do not engage in a physical activity task. They are asked to taste test chocolate chip cookies.
88933305|NCT01758302|Active Comparator|No physical task + Taste vegetable|Participant does not complete a physical activity. Asked to taste test raw celery or radishes.
88933306|NCT01758302|Active Comparator|Simple physical task + Taste vegetables|Participants are asked to complete a simple physical task and are asked to taste test raw celery or radishes.
89447592|NCT05775653|Experimental|ADAPT program|The ADAPT program is a structured and individualized group-based program.
89447593|NCT05775653|Active Comparator|Usual Occupational Therapy (UOT)|UOT is delivered by one occupational therapist. .
89447594|NCT05774067|Active Comparator|control|
89447595|NCT05774067|Active Comparator|noradrenaline|
88933307|NCT01758302|Active Comparator|Complex physical task + Taste vegetables|Participants complete a more complex physical task that is novel and challenging. They are asked to taste test raw celery or radishes.
88933308|NCT01758315|Experimental|Improvement Sessions|We will implement a context-sensitive collaborative improvement model that will emphasize training and in-office coaching by quality improvement, efficiency and safety experts, as well as shared learning methods to develop, test and implement changes in the following four key risk areas: medication management; test and lab results management; follow-up and referral management; and communication - within and between practices as well as with patients.
88933309|NCT01758315|No Intervention|Control|Control practices will not receive training or in-office coaching.
88933310|NCT01758341|Experimental|Malignant biliary obstruction|All patients who underwent endoscopic radiofrequency ablation with the HabibTM EndoHBP as a treatment for malignant biliary obstruction in Austria between November 2010 and December 2012.
88933311|NCT01758354|Experimental|Pompe disease newborn screening|newborns will be tested if they were affected by Pompe disease
88933312|NCT01758367|Experimental|Decitabine+DLI|Patients with relapsed AML after Allo-HSCT will be treated with decitabine and DLI.
88933313|NCT01758380|Experimental|Vildagliptin + placebo to Gliclazide|Vildagliptin tablets will be given at 50mg twice daily (bid). Placebo to Gliclazide capsules will be given at an equivalent dose to previous sulfonylurea in multiples of 80mg only (80-320 mg/day). Patients will continue their open-label metformin therapy at dosage between 1500-2500 mg daily.
88933314|NCT01758380|Active Comparator|Gliclazide + placebo to Vildagliptin|Gliclazide capsules will be given in multiples of 80 mg (80-320 mg/day) at a dose equivalent to previous sulfonylurea dose, unless at the investigator's discretion it could be up-titrated to the next available dose (if HbA1c is higher than 7.5%). Placebo to Vildagliptin tablets will be given at 50mg twice daily (bid). Patients will continue their open-label metformin therapy at dosage between 1500-2500 mg daily.
88933315|NCT01758393|Experimental|Medium Dose|Patients are treated with prednisone or equivlent at doseage of 0.5-0.6 mg/kg/d (max 40mg daily) for 3 weeks, then tapering gradually to 15mg/d in 3 months.
88933316|NCT01758393|Experimental|High Dose|Patients are treated with prednisone or equivlent at doseage of 0.8-1.0 mg/kg/d (max 60mg daily) for 3 weeks, then tapering gradually to 15mg/d in 3 months.
88933317|NCT01758406|Experimental|cardiac stem cell transplantation|The patients with heart failure that underwent cardiac stem cell transplantation.
88933318|NCT01758406|Placebo Comparator|Placebo|The patients with heart failure that underwent placebo injection.
88933319|NCT01758419||Tomotherapy|Breast cancer female s/p scheduled RT will be arranged to undergo Thallium-201 Myocardial Perfusion Study. The scheduled RT will be arranged by clinical judgments of radiation-oncologists. All of the patients will receive myocardial SPECT before and after the scheduled RT. Comparing the clinical follow-up data between different groups (left-sided s/p tomography, left-sided s/p conventional RT, and right-sided RT), respectively.
88933320|NCT01758471|Experimental|Acarbose|The minimum dosage of acarbose in this study is 100mg tid p.o.(oral) for 3 month. With this dosage, patients should have similar glycemic control with those using glipizide, that is FBG(fasting blood glucose)<7.0,PBG(postprandial blood glucose)<10.0
89447596|NCT05774067|Active Comparator|glypressin|
89447597|NCT05774015|Active Comparator|Interventional group (Mg oxide supplementation):|Interventional group (Mg oxide supplementation): Patients in this group will receive Mg oxide tablet 500 mg (302 mg elemental), with a dosage regimen of 1 table once daily as per the recommended range of the daily dose (from 250 to 500 mg elemental) (29, 31, 41, 45). Tablets should be taken with food and 2 hrs. apart from other medications for 12 consecutive months.
89447598|NCT05774015|Placebo Comparator|Control group (placebo tablets)|Control group (placebo tablets): Patients in this group will receive placebo tablets labeled as 500 mg (302 mg elemental), with a dosage regimen of 1 tablet once daily. Tablets should be taken with food and 2 hrs. apart from other medications for 12 consecutive months.
89447599|NCT05773495|Experimental|Usual Care Followed by I-SITE Intervention|
89447600|NCT05769036|Active Comparator|Cardiac Resynchronization Therapy with Biventricular Pacing|Patients in this group will be implanted with a cardioverter-defibrillator with a resynchronization function using the biventricular pacing
89447601|NCT05769036|Experimental|Cardiac Resynchronization Therapy with Left Bundle Branch Pacing|Patients in this group will be implanted with a cardioverter-defibrillator with a resynchronization function using the left bundle branch pacing
89447602|NCT05763043|Experimental|Ferric derisomaltose|
89447603|NCT05761015|Experimental|Intervention|there is only one intervention arm and no control arm; the Bayesian analysis will be conducted under hypothetical estimates of superiority vs. control.
89447604|NCT05753033|Experimental|SR750 tablet|Ascending single and multiple doses of SR750 orally
88933321|NCT01758471|Active Comparator|glipizide|There is no fixed dosage of glipizide to control hyperglycemia for patients in this group. As long as the targeted blood glucose concentration is reached, FBG< 7.0, PBG< 10.0, patients will have the least dosage of glipizide according to their glucose level.
88933322|NCT01758484|Experimental|Supportive care (palliative care support)|Patients undergo palliative care support before transplantation and at least once monthly while they remain at the transplant center.
88933323|NCT01758497|Active Comparator|Ropivacaine|US guided injections of 30 ml 0.5% ropivacaine (Fascia Iliaca Compartment Block)
88933324|NCT01758497|Sham Comparator|Saline|US guided injections of 30 ml 0.9% NaCl (Fascia Iliaca Compartment Block)
88933325|NCT01758510|Experimental|HYNR-CS-Allo|HYNR-CS-Allo inj. 2 times by intrathecal administration with 28 days interval.
88933326|NCT01758536|Placebo Comparator|Placebo Pills|"12 g each time, twice daily.~3 months"
88933327|NCT01758536|Experimental|Huatuo Zaizao Pills|"12 g each time, twice daily.~3 months."
89014395|NCT05286060|Experimental|GX-188E 2mg, IM: 1st day of week 1, 2, and 4; GX-I7 360㎍/kg, IM: 1st day of week 2|Combination of GX-188E HPV DNA Vaccine and GX-I7 as an Expanded Cohort
89447605|NCT05753033|Placebo Comparator|Placebo|Ascending single and multiple doses of placebo orally
89447606|NCT05752266|Experimental|Probiotic Arm|Participants allocated to PRO arm will be administered personalized probiotic pills.
88933328|NCT01758549|Experimental|Aggressive Intravenous Hydration Group|Patients randomized to the aggressive intravenous hydration group receive lactated ringers (LR) IV at 3 mL kg-1 hr-1 during the procedure, a 20cc/kg LR IV bolus immediately afterward, and LR IV at 3 mL kg-1 hr-1 for 8 hours following the procedure.
88933329|NCT01758549|Active Comparator|Standard Fluids Arm|Those in the control arm receive standard fluids defined as LR at 1.5 mL kg-1 hr-1 during the procedure and for 8 hours afterwards.
88933330|NCT01758562|No Intervention|State-of-the-art mouth care|
88933331|NCT01758562|Active Comparator|Mouth rinse Caphosol|Mouth rinse,aqueous solution. Caphosol is a preparation comprising two separately packaged aqueous solutions, a phosphate solution and a calcium solution, which, when both solutions are combined in equal volumes, forms a solution supersaturated with respect to both calcium and phosphate ions.
88933332|NCT01758575||antiangiogenic tyrosine kinase inhibitors|Sunitinib: 50 mg orally once daily Sorafenib: 400 mg orally twice daily Pazopanib: 800 mg orally once daily
88933333|NCT01758575||EGFR inhibitors|Cetuximab 250 mg/m2 intravenously, weekly Panitumumab 6 mg/Kg intravenously, every 2 weeks
88933334|NCT01758575||mTOR inhibitors|Everolimus 10 mg orally once daily
88933335|NCT01758575||BRAF inhibitor|Vemurafenib 960 mg orally twice daily
88933336|NCT01758575||anti-CTL4 antibody|Ipilimumab 3 mg/kg intravenously, every 3 weeks
88933337|NCT01758601|Experimental|Fish - no fish|The individuals randomized to this arm continued with their previous alimentary habits, avoiding any significant nutritional imbalance, and with an ingestion of 7 serves of hake (each serve consisted of 100g of frozen Namibia hake, Pescanova S.A., Pontevedra, Spain) per week for a period of 8 weeks. Then switched to previous alimentary habits, avoiding any significant nutritional imbalance, as well as any fish or seafood.
88933338|NCT01758601|Active Comparator|No fish - fish|Patients were on previous diet except for the avoidance of fish and any other seafood for 8 weeks. Afterwards they were changed to the same diet but with 7 serves of hake per week.
88933339|NCT01758627|No Intervention|Peritoneal dialysis group|
88933340|NCT01758627|Experimental|Conventional treatment group|medical treatment such as diuretics
88933341|NCT01758640|Active Comparator|Pregnant|Group of Pregnant patients who will receive either warfarin or phenindione according to the study design
88933342|NCT01758640|Active Comparator|Non Pregnant|Group Of Non Pregnant patients who will receive either warfarin or phenindione according to the study design
88933343|NCT01758666|Experimental|Methotrexate and Calcium folinate|
88933344|NCT01758679|Experimental|Licartin，Licartin and CIK|Intravenous Licartin 27.75 M Bq(0.75 mCi)/kg Licartin and CIK
88933345|NCT01758705||Cohort 1|Cohort 1
88933346|NCT01758718|Active Comparator|Entropion with Down's syndrome|Eyelash resection surgery was performed for entropion with Down's syndrome
88933347|NCT01758744|Experimental|Treprostinil|Inhaled prostanoid therapy with Treprostinil
88933348|NCT01758757|Active Comparator|Proliferative diabetic retinopathy|
88933349|NCT01758783|Placebo Comparator|placebo group|
88933350|NCT01758783|Experimental|Glutamine group|
88933351|NCT01758809|Active Comparator|Bupivacaine|
88933352|NCT01758809|Other|Intravenous Patient Controlled Analgesia|postoperative pain control with intravenous patient controlled analgesia
88933353|NCT01758822|Experimental|No Endotracheal suction|In the experimental group, endotracheal suction will not be performed during the initial steps of resuscitation of non-vigorous meconium stained neonate
88933354|NCT01758822|No Intervention|Endotracheal suction|In the No intervention group endotracheal suction will be performed during the initial steps of resuscitation of non - vigorous meconium stained neonate
88933355|NCT01758835|Active Comparator|Splint 3 weeks|Removable ankle brace/splint
88933356|NCT01758835|Active Comparator|Cast 3 weeks|Below-the-knee cast (glass fiber)
88933357|NCT01758835|Active Comparator|Cast 6 weeks|Below-the-knee cast (glass fiber)
88933358|NCT01758861|Experimental|EPO group|EPO group received 300 IU/kg of rHuEPO-alpha via intravenous bolus administration after induction of anesthesia.
88933359|NCT01758861|Placebo Comparator|Placebo group|Placebo group received normal saline via intravenous bolus administration after induction of anesthesia.
88933360|NCT01758874|No Intervention|Non phlebotomy group (control group)|"• This control group is the patients who had Rutherford classification Grade 3, Category 5 or 6 (Fontaine stage IV) treatment-resistant chronic critical limb ischemia having tissue loss. They were treated with conventional standard treatment including revascularization operative procedure if feasible, maximum medical treatment with anticoagulation (heparin, low molecular weight heparin, etc), acetylsalicylic acid, cilostazol, and prostaglandin E1, dextran, and pain analgesia with opioid, and finally major amputation.~We records all control arms' amputation, day to amputation, mortality, etc. We will compare amputation and mortality between control and treatment groups.~Non phlebotomy arm has no phlebotomy treatment."
88933361|NCT01758874|Experimental|PH (study group)|"The patients will be pre-amputation and have Rutherford classification Grade 3, Category 5 or 6 (Fontaine stage IV) treatment-resistant chronic critical limb ischemia having tissue loss.~Procedures for therapeutic phlebotomy~Inject heparin 5000 units to prevent blood clot during phlebotomy~Inject volume expander equivalent to 5% of blood volume~Remove 5% of whole blood~Monitor the vital sign of the patient during the phlebotomy~They were treated both phlebotomy and conventional standard management including surgery, medication, amputation, etc.~We will compare amputation and mortality between control and study groups."
88933362|NCT01758887||Controls|Healthy control
88933363|NCT01758887||patients|clinical high risk subjects for psychosis
88933364|NCT01758913|Experimental|Ibuprofen|Infant who was assigned to ibuprofen, an initial dose of 10 mg/kg, followed by 5 mg/kg at 24 and 48 hours respectively as a course was given.
88933365|NCT01758926||Inflammatory bowel disease|Patients previously diagnosed as having IBD
88933366|NCT01758926||Health control|Asymptomatic individuals admitted for health surveillance or patients for follow up after polypectomy.
88933367|NCT01758939||Hepatitis C virus infected patients|
88933368|NCT01758952||Beijing Chaoyang Hospital|2000 cases
88933369|NCT01758952||Peking University Hospital|2000 cases
88933370|NCT01758952||Zhongshan Hospital of Fudan University|2000 cases
88933371|NCT01758952||Tongji Hospital, Wuhan|2000 cases
88933372|NCT01758952||Tangdu Hospital, Xi'an|2000 cases
89447607|NCT05752266|Placebo Comparator|Placebo Arm|Participants allocated to PRO arm will be administered maltodextrin placebo pills similar in appearance to probiotic pills.
88933373|NCT01758952||The Prince Welsh Hospital|1000 cases
88933374|NCT01758965|Experimental|combination therapy of H2RA and surgicel|H2RA and surgicel
88933375|NCT01758965|Experimental|Monotherapy of PPI|PPI
89014396|NCT05281094|Placebo Comparator|Placebo|One dose of placebo on Day 1 and one dose of placebo between Day 29 and Day 57.
89447608|NCT05747989|Active Comparator|skin stitched with two-component skin adhesive|After subcutaneous stitches a two-component skin adhesive, Glubran Tiss 2®, will be applied. G Each subject will receive 0.35 mL of Glubran Tiss® in the open wound, and before bandaging, subjects rested for 20 minutes for a polymerization process.
88933376|NCT01758978|Experimental|Treatment Group AB|"Subjects in this group will receive study drug in the following sequence:~Treatment A: two 30-mg hydrocodone bitartrate extended-release tablets (reference)~Treatment B: one 60-mg hydrocodone bitartrate extended-release tablet (test)."
88933377|NCT01758978|Experimental|Treatment Group BA|"Subjects in this group will receive study drug in the following sequence:~Treatment B: one 60-mg hydrocodone bitartrate extended-release tablet (test).~Treatment A: two 30-mg hydrocodone bitartrate extended-release tablets (reference)."
88933378|NCT01759004|Active Comparator|patient with lipoedema|"Lipedema group:~diagnosed with lipedema following the criteria of Wold~women~age ≥ 18 years~clinimetrics: volume, muscle strength, physical condition, BMI"
88933379|NCT01759004|Active Comparator|patients with obesity|"Obesity group:~BMI ≥ 30~women~age ≥ 18 years~clinimetrics: volume, muscle strength, physical condition, BMI"
88933380|NCT01759017||Infliximab responders|Gastroenterologist's overall assessment (response) Decrease in Harvey-Bradshaw index score of 2 or more points (clinical response) Harvey-Bradshaw index score less than 5 (clinical remission) Maintenance of steroid-free remission No Crohn's-related hospitalizations or surgeries
88933381|NCT01759017||Infliximab non-responders|Gastroenterologist's overall assessment (no response) Decrease in Harvey-Bradshaw index score of 1 or 0 points, or increase in HBI (no response) Harvey-Bradshaw index score greater than or equal to 5 (no remission) Resumption of steroid treatment Crohn's-related hospitalization or surgery
88933382|NCT01759030|Active Comparator|MabThera (F. Hoffmann-La Roche Ltd.)|"Stage 1 (week 1 - week 24) MabThera will be administered at a dose of 1000 mg, IV (on day 1 and day 15).~Stage 2 (week 24 - 48) If the disease activity remains on Week 24 the patient will undergo the second randomization (1:1 ratio): if he/she randomised into group A then he/she recieves BCD-020 at a dose f 1000 mg, IV, once in 2 weeks, 2 infusions per course (on day 1 and day 15); if he/she if he/she randomised into group B then he/she continues to recieve MabThera at a dose f 1000 mg, IV, once in 2 weeks, 2 infusions per course (on day 1 and day 15).~MabThera/BCD-020 will be used in combination with methotrexate (irrespectively to study stage)."
88933383|NCT01759030|Experimental|BCD-020 (CJSC BIOCAD)|"Stage 1 (week 1-week 24) BCD-020 will be administered at a dose of 1000 mg, IV (on day 1 and day 15).~Stage 2 (week 24-48) If the disease activity remains on Week 24 the patient will undergo the second randomization (1:1 ratio): if he/she randomised into group A then he/she recieves MabThera at a dose f 1000 mg, IV, on day 1 and day 15; if he/she if he/she randomised into group B then he/she continues to recieve BCD-020 at a dose f 1000 mg, IV, on day 1 and day 15.~MabThera/BCD-020 will be used in combination with methotrexate (irrespectively to study stage)."
88933384|NCT01759043|Experimental|guiding catheter|a single transradial guiding catheter for coronary angiography and intervention in patients with STEMI
88933385|NCT01759043|Active Comparator|Diagnostic catheter|Diagnostic catheter followed by guiding catheter selection for transradial primary PCI
88933386|NCT01759056|Active Comparator|AVX 470|AVX 470 0.2 g(Cohort 1), 1.6 g (Cohort 2) and 3.5 g (Cohort 3) will be administered daily for 28 days
88933387|NCT01759056|Placebo Comparator|Placebo|Placebo will be administered daily for 28 days as a comparator with AVX-470 (all dose groups)
88933388|NCT01759069|Experimental|treatment with microscope|treatment with microscope
88933389|NCT01759069|Experimental|treatment without microscope|treatment without microscope
88933390|NCT01759095|No Intervention|Control|At hospital discharge, patients of the control group will receive usual care at their community pharmacy.
88933391|NCT01759095|Experimental|Electronic Multidrug Blister Pack|
88933392|NCT01759108|Experimental|Rebamipide|Patients will be randomized 1:1 to receive 300mg/d (100mg x3/day) of rebamipide for 12 weeks together with their usual therapy
88933393|NCT01759108|Placebo Comparator|Placebo|Patients will be randomized 1:1 to receive 300mg/d (100mg x3/day) of placebo for 12 weeks together with their usual therapy.
88933394|NCT01759121|Active Comparator|T-PRP|532nm-short pulse panretinal photocoagulation with PASCAL function
88933395|NCT01759121|Experimental|S-PRP|532nm-partially subthreshold short pulse panretinal photocoagulation with PASCAL endpoint management function
88933396|NCT01759134|Experimental|Post Discharge Formula|Babies will be given formula for first three months post discharge
88933397|NCT01759147|Experimental|Surgery|Surgical repair of acromioclavicular dislocation.
88933398|NCT01759173||college athletes|
88933399|NCT01759199|Experimental|The six minute Stepper Test|Experimental : The six minute Stepper Test with a Conventional respiratory rehabilitation
89447609|NCT05747989|Placebo Comparator|skin stitched with transcutaneous nylon sutures|The skin is stitched with transcutaneous nylon sutures (polypropylene-polyethylene monofilament, non-absorbable surgical suture) 4-0. (Optilene® DSMP 19, 3/8 needle, thread size 4/0
89447610|NCT05741112|Other|Control: study provided wearables|Following consent and the completion of the baseline assessments the control group will receive basic education on symptom management. At the 3 month timepoint they will be prompted to order their device and receive enhanced education that will provide information on how wearable devices can be used to monitor and manage symptoms.
89447611|NCT05741112|Other|Treatment: study provided wearables|Following consent and the completion of the baseline assessments the treatment group will be prompted to order their device and receive basic education on symptom management along with the enhanced education on wearable devices.
89447612|NCT05741112|Other|Control: self provided wearables|Following consent and the completion of the baseline assessments the control group will receive basic education on symptom management. At the 3 month timepoint they will be receive enhanced education that will provide information on how wearable devices can be used to monitor and manage symptoms.
89447613|NCT05741112|Other|Treatment: self provided wearables|Following consent and the completion of the baseline assessments the treatment group will receive basic education on symptom management along with the enhanced education on wearable devices.
89447614|NCT05730764|Experimental|Support systems assist doctors in decision-making|Doctors judge the risk of fertilization disorders and make clinical decisions with the support of a decision-making system.
89447615|NCT05730764|Other|Clinicians follow a routine protocol|Doctors judge the risk of fertilization disorders and make clinical decisions based on clinical experience
89447616|NCT05719116|Experimental|Physical exercise for participants with psychotic disorder|Participants with a psychotic disorder will exercise in a group supervised by a physiotherapist for 16 weeks, three times a week.
89447617|NCT05719116|Active Comparator|Physical exercise for participants with psychiatric disorder, but not psychotic disorder|Participants with a psychiatric disorder will exercise in a group supervised by a physiotherapist for 16 weeks, three times a week.
89447618|NCT05713643|Active Comparator|ESPB group|
89447619|NCT05713643|Active Comparator|TPVB group|
89447620|NCT05713643|Active Comparator|QLB group|
89447621|NCT05709171|Experimental|Experimental|Each patient will undergo one standard of care 18FDG PET/CT and one 64Cu-DOTATATE PET/CT within 4 weeks.
89447622|NCT05700916|Experimental|MPL-rich dairy powder|Daily consumption of 50 g of dairy powder containing 6.5 g MPL for 8 weeks.
89447623|NCT05700916|Placebo Comparator|Control dairy powder|Daily consumption of 50 g of dairy powder containing <0.1 g MPL for 8 weeks
89447624|NCT05698693|Experimental|Sleep intervention|The sleep extension intervention is a 4-week intervention consisting of weekly one-on-one contact with the goal of increasing total sleep time by 60 minutes by the end of four weeks conducted by Dr. Wu or a trained counselor. The first session will last 60 minutes and the content will include psychoeducation about the importance of sleep, sleep guidelines and target setting, and basic sleep hygiene. Participants in this condition will receive hardcopy weekly daily diary worksheets, and receive an online version of the sleep daily diary every morning to complete via text messaging. Sessions 2-4 will be between 15-30 minutes where Dr. Wu or a trained counselor will review the sleep diary, problem solve barriers to weekly goals, and sleep promoting behaviors will be reinforced. Material that would be covered during a missed session will be included in the next session the participant attends.
89447625|NCT05698693|Active Comparator|Contact control|The content of the contacts for this intervention condition will be based on the National Center for Healthy Housing's Healthy Homes program, a program designed by the UT School of Public Health. Participants in this condition will meet with Dr. Wu or a trained research staff member. They will meet through Zoom once a week for four sessions to go through each educational module. Sessions will conclude with the development of an action plan for participants. Staff will check in with participants regarding whether they were able to complete the tasks on their action plan, and if not, the reasons for this and potential strategies that may facilitate completion.
88933400|NCT01759225||Cardiovascular Disease Patients|
89014397|NCT05281094|Experimental|Experimental|One dose of HIL-214 on Day 1 and one dose of HIL-214 between Day 29 and Day 57.
89014398|NCT05278091||Patients with CANVAS with genetic confirmation|Patients with CANVAS with genetic confirmation (RFC1 gene mutation)
89014399|NCT05278091||others patients|Patients with axonal neuropathy, autoimmune neuronopathy and anti-MAG neuropathy
89447626|NCT05685589|Experimental|Mindfulness-based Intervention|The intervention will include weekly 90-minute group meetings held online through Zoom. Adolescents and parents will meet in separate groups and will learn about mindfulness-based strategies that can be used to manage and reduce stress, anxiety, and depression. They will also learn evidence-based strategies to complete daily guided mindfulness meditations using Ten Percent Happier, a commercially-available mobile app. Participants will be encouraged to meditate using the mobile app for at least 10 minutes each day during and after the 8-week intervention.
89447627|NCT05685589|No Intervention|Delayed Treatment Control|Participants will be instructed to engage in treatment as usual during their 8-week wait period. After their wait period, participants will be enrolled in the mindfulness-based intervention.
89447628|NCT05681572|Experimental|Premedication Group (Midazolam)|Midazolam (0,5 mg/kg; max 10 mg), oral administration, 45 minutes prior entering in the operating room
89447629|NCT05681572|Experimental|Premedication Group (Dexmedetomidine)|Dexmedetomidine (2 µg/kg), oral administration, 45 minutes prior entering in the operating room
89447630|NCT05681572|Placebo Comparator|Placebo Group|grenadine syrup (3 mL), oral administration, 45 minutes prior entering in the operating room
89447631|NCT05676034|Experimental|AMX0035|AMX0035 administered by mouth for 48 weeks: Once daily for first 3 weeks and then twice daily for the remainder of the study if tolerated by participant
89447632|NCT05674071|Experimental|Articulation/HVT|This intervention will use articulation and high-velocity thrust techniques
89447633|NCT05674071|Experimental|Soft-tissue massage|This intervention will use soft-tissue massage
88933401|NCT01759303|Experimental|pazopanib|"For subjects > 18 years of age and subjects 16-17 years of age with a BSA ≥ 1.6 Pazopanib 800mg once daily will be started on Cycle 1 Day 1 and will be administered continuously for each 28-day cycle. Subjects may continue study treatment until they develop disease progression or unacceptable toxicity.~For subjects 16-17 years of age with a BSA < 1.6 m2, Pazopanib 600mg once daily will be started on Cycle 1 Day 1 and will be administered continuously for each 28-day cycle. Subjects may continue study treatment until they develop disease progression or unacceptable toxicity."
88933402|NCT01759316|Active Comparator|heliox|Heliox is use in this group
88933403|NCT01759316|Placebo Comparator|Placebo|Oxygen is used in this group
88933404|NCT01759329|Experimental|test coffee|test coffee
88933405|NCT01759329|Active Comparator|control coffee|control coffee
88933406|NCT01759342|Experimental|Comprehensive exercise program|Moderate to high intensity aerobic, resistance, flexibility, posture and balance exercise program
88933407|NCT01759342|Active Comparator|Usual care exercise|30 minutes/day of self selected mode and intensity of aerobic exercise
88933408|NCT01759355||Surgery|Participants undergoing surgical intervention will receive a PET/MR scan prior and following surgery for a total of two (2) scans.
88933409|NCT01759355||Chemoradiation|Participants undergoing chemoradiation intervention will receive a PET/MR scan prior, during, and following chemoradiation for a total of three (3) scans.
88933410|NCT01759394|Experimental|Avatrombopag maleate 40 mg|
88933411|NCT01759472||montelukast，vitamin C pill|leukotriene receptor antagonist:(montelukast)，montelukast (10 mg, once per night)，56 days vitamin C pill:100mg，once per night，56 days
89447634|NCT05674071|Experimental|Craniosacral techniques|This intervention will use craniosacral techniques
89447635|NCT05674071|Experimental|Combination|This intervention will use a combination of the three interventions: HVT, soft-tissue and craniosacral
89447636|NCT05671874|Experimental|Web-based Decision Aid + Communication (DA+C) tool|Surrogate(s) will read/click through the DA+C tool prior to the clinician-family meeting and complete the integrated worksheet. Surrogate(s) will have unlimited access to the DA+C tool and may return to the tool and edit the worksheet at any time.
88933412|NCT01759472||montelukast, vitamin C pill|montelukast:10 mg, once per night，56 days vitamin C pill:100mg，once per night，56 days
88933413|NCT01759485|Active Comparator|Vitamin D|Supplementation of Vitamin D as add-on to the regular anti-psychotic treatment
88933414|NCT01759485|Placebo Comparator|Placebo|Placebo as oral drops once weekly as add-on to the regular anti-psychotic treatment
88933415|NCT01759498|Experimental|HYDRO 2|Subjects in the second experimental group will follow the procedures of first experimental group with additional administration of hydrogen-rick packs 6 times per day for 20 minutes throughout the study.
88933416|NCT01759498|Active Comparator|ACTIVE|During the period of 2 weeks subjects will receive traditional treatment protocol after the soft-tissue injury, consisting of RICE protocol during the first 48 h (e.g. rest, ice packs for 20 minutes every 2 hours, compression with elastic bandage, elevation of the injured area above the level of the heart at all possible times) and sub-acute protocol thereafter (e.g. passive stretching 3 times per day for 90 sec, isometric strength exercise with 3 sets with 15 repetitions, 30 min of pain-free weight-bearing exercise).
88933417|NCT01759498|Experimental|HYDRO|Subjects in the first experimental group will follow the PLA procedures with additional administration of oral hydrogen-rich capsules (4 capsules three times per day) throughout the study.
89447637|NCT05671874|No Intervention|Usual Care|No decision aid
89447638|NCT05669560|No Intervention|Control group|Will receive SRP alone.
89014400|NCT05278091||Healthy controls|Patients without CANVAS or other neuropathy
89447639|NCT05669560|Experimental|Test group|Will receive SRP + PerioProtect ™.
89447640|NCT05651919||No-T2D +MS / No-HF (control group)|15 patients without T2D +MS and without Heart Failure will be included in group 1.
89447641|NCT05651919||No-T2D +MS / HFpEF or HFmrEF|15 patients without T2D+MS and presenting HFpEF or HFmrEF will be included in group 2
89447642|NCT05651919||T2D+MS / no-HF|15 patients presenting T2D +MS and without any type of HF will be included in group 3.
89447643|NCT05651919||T2D +MS / HFpEF or HFmrEF|15 patients presenting T2D +MS and HFpEF or HFmrEF will be included in group 4.
89447644|NCT05649553|Experimental|Intervention Group|"Experimental: Intervention Group Application of the Introductory Information Form and the Quality of Life Scale in Children with Diabetes Mellitus (PedsQL 3.0 Diabetes Scale) test Giving digital game and video animation-based diabetes education to the children in the experimental group, in addition to the education given by the diabetes nurse, Applying the first post-training follow-up test to children in the experimental and control groups 3 months after the training.~Applying the post-training-2nd follow-up test to the children in the experimental and control groups 6 months after the training."
89447645|NCT05649553|No Intervention|Control Group|The control group received routine nursing care in the endocrine policlinic.
89447646|NCT05647564|Other|Intrinsic Resistance Cohort (Cohort A)|Participants assigned to Cohort A have advanced prostate cancer and are scheduled to start a second-generation AR-targeted (such as enzalutamide, abiraterone, or apalutamide) or PSMA directed (e.g. Lu177-PSMA) therapies .
89447647|NCT05647564|Other|Acquired Resistance Cohort (Cohort B)|Participants are assigned to Cohort B if they have advanced prostate cancer, are already on a second-generation AR-targeted therapy, and have shown an increase in their PSA (prostate-specific antigen) levels.
89447648|NCT05645588|Experimental|Pranayama assisted trauma-focused standard psychotherapy (TF-SPT).|Behavioral: Pranayama assisted trauma-focused standard psychotherapy (TF-SPT) The pranayama intervention is placed directly at the begin of the respective TF-SPT unit and will be repeated for 10 subsequent TF-SPT units.
89447649|NCT05645588|Active Comparator|Trauma-focused standard psychotherapy (TF-SPT)|Behavioral: Patients wait for 10 TF-SPT units and then are offered to learn pranayama.
89447650|NCT05638815||Parkinson's Disease (PD)|
89447651|NCT05638815||Multiple System Atrophy (MSA)|
89447652|NCT05638815||Health volunteers|
89447653|NCT05630976|Experimental|Isavuconazole|This is a single arm study, all enrolled participants will receive the study medication.
89447654|NCT05625087|Experimental|ALPELISIB ARM|Oral alpelisib (300 mg daily, in 28-day cycle) and fulvestrant as per standard practice. Moreover, men and premenopausal women will receive an LH-RH analogue (goserelin, leuprorelin, or triptorelin) every 28 days ±3 days, as per standard practice
89447655|NCT05625087|Active Comparator|RIBOCICLIB ARM|Oral ribociclib (600 mg daily, 3 weeks on, then 1 week off treatment in 28-day cycles) and fulvestrant as per standard practice. Moreover, men and premenopausal women will receive an LH-RH analogue (goserelin, leuprorelin, or triptorelin) every 28 days ±3 days, as per standard practice.
89447656|NCT05624359|Experimental|ropivacaine plus FA|5 mL FA (50 mg; by Beijing Taide Pharmaceutical Co., Ltd) and 15 mL of 1% ropivacaine (Nai Le Pin 10mg/mL; by AstraZeneca AB, Sweden) diluted to a total volume of 30 mL in normal saline
89447657|NCT05624359|Active Comparator|ropivacaine alone|15 mL of 1% ropivacaine diluted to a total volume of 30 mL in normal saline
89447658|NCT05623501|Experimental|Cohort 1|DHM 300mg x1 dose
89447659|NCT05623501|Experimental|Cohort 2|DHM 900mg x1 dose
89447660|NCT05623501|Experimental|Cohort 3|DHM 300mg x1 dose + Lysine 140mg x1 dose
89447661|NCT05623501|Experimental|Cohort 4|DHM 900mg x1 dose + Lysine 420mg x1 dose
89447662|NCT05620641|Experimental|Group 1|include 50 patients scheduled for sleeve gastrectomy
89447663|NCT05620641|Experimental|Group 2|include 50 patients scheduled for sleeve gastrectomy
89447664|NCT05619939|Experimental|Pea protein to egg white protein|This arm will receive 10 days of pea protein isolate followed by 10 days of consuming egg white protein isolate, with the two treatment periods separated by a 14-day washout period.
89447665|NCT05619939|Experimental|Egg white protein to pea protein|This arm will receive 10 days of egg white protein isolate followed by 10 days of consuming pea protein isolate, with the two treatment periods separated by a 14-day washout period.
89447666|NCT05619185|Experimental|Intervention|Those randomized to the CRAFT intervention will receive a web-based intervention
89447667|NCT05619185|Active Comparator|Control|Those randomized to CONTROL will complete a self-guided intervention
89447668|NCT05619185|Experimental|Phone Based CRAFT|If a member of the recruited dyad does not respond, then participants will be randomized to receive phone-based CRAFT
89447669|NCT05619185|Active Comparator|CRAFT Workbook|If a member of the recruited dyad does not respond, then participants will be randomized to receive a CRAFT workbook
89447670|NCT05617157|No Intervention|Control|
89447671|NCT05617157|Experimental|Stair stepping|
89447672|NCT05610462|Active Comparator|Usual Care Control|Participants who are randomized to usual care will attend routine clinic visits but will not receive any teaching or supervision and will not participate in any in-person or virtual exercise sessions. Instead, they will receive standardized counseling about exercise, including an exercise pamphlet that is given to all thoracic aortic dissection (TAD) patients.
89447673|NCT05610462|Experimental|Guided Exercise Training Program|Participants who are randomized to the guided exercise group will undergo initial training that consists of: one video demonstration, one exercise training session or group session, one follow up home visit, and virtual check-ins.
89447674|NCT05609084|Other|Control|Patients will have speech therapy assessment in addition to standard care.
89447675|NCT05609084|Experimental|Experimental|Patients will have speech therapy assessment and intensive speech rehabilitation
89447676|NCT05605080|Experimental|Gelfoam as hemostatic agent after surgery|Use Gelfoam as hemostatic agent after surgery.
89447677|NCT05605080|Active Comparator|Gauze with Bosmin as hemostatic agent after anal surgery|Use gauze with Bosmin as hemostatic agent after anal surgery
89447678|NCT05602987|Experimental|Study Group: enema|receiving enema at the night before anal surgery
89447679|NCT05602987|Active Comparator|Control Group: no enema|no enema before anal surgery
89447680|NCT05599347|Experimental|Azithromycin|5-day consecutive treatment with oral azithromycin 500 mg once daily
89447681|NCT05599347|Placebo Comparator|Control|5-day consecutive oral placebo once daily
89447682|NCT05595161|Experimental|Intervention|Bright Bodies
89447683|NCT05589948|Placebo Comparator|Placebo Control 1|Calm Product Form 1 - control
89447684|NCT05589948|Placebo Comparator|Placebo Control 2|Calm Product Form 2 - control
89447685|NCT05589948|Experimental|Active Product 1.1|Calm Product Form 1 - active product 1
89447686|NCT05589948|Experimental|Active Product 2.1|Calm Product Form 2 - active product 1
89447687|NCT05589948|Experimental|Active Product 2.2|Calm Product Form 2 - active product 2
89447688|NCT05589935|Placebo Comparator|Control 1|Relief Product Form 1 - control
89447689|NCT05589935|Experimental|Active Product 1.1|Relief Product Form 1 - active product 1
89447690|NCT05588609|Experimental|Part 1: NSCLC harboring NRG1+ fusion|Participants will receive intravenous infusion of 750 mg of zenocutuzumab once every 2 weeks in combination with afatinib 40 mg orally once daily.
89447691|NCT05588609|Experimental|Part 1: mCRPC|"Participants will receive intravenous infusion of 750 mg of zenocutuzumab once every 2 weeks in combination with the AR targeting agent they experienced disease progression on prior to study entry:~enzalutamide 160 mg orally once daily or abiraterone 1000 mg orally once daily with prednisone 5 mg orally twice daily."
89447692|NCT05588609|Experimental|Part 2: NSCLC harboring NRG1+ fusion|Participants will receive intravenous infusion of 750 mg of zenocutuzumab once every 2 weeks in combination with afatinib 40 mg orally once daily.
89447693|NCT05588609|Experimental|Part 2: mCRPC|"Participants will receive intravenous infusion of 750 mg of zenocutuzumab once every 2 weeks in combination with the AR targeting agent they experienced disease progression on prior to study entry:~enzalutamide 160 mg orally once daily or abiraterone 1000 mg orally once daily with prednisone 5 mg orally twice daily"
89447694|NCT05580783|Experimental|Experimental 54Fe|Participants will receive 54Fe at two time points throughout their menstrual cycle.
89447695|NCT05580783|Experimental|Experimental 57Fe|Participants will receive 57Fe at two time points throughout their menstrual cycle.
89447696|NCT05580783|Experimental|Experimental 58Fe|Participants will receive 58Fe at two time points throughout their menstrual cycle.
89447697|NCT05580445|Experimental|Dose-escalation and dose-expansion|Dose-escalation study is designed to determine the dose-limiting toxicity (DLTs) and recommended phase II dose (RP2D). Dose-expansion study is designed to evaluate the antitumor activity of CT-707 in combination with toripalimab and gemcitabine in patients with advanced pancreatic cancer.
89447698|NCT05578274|Experimental|SBRT+LDRT|In the experimental group, stereotactic body radiotherapy (SBRT) and low-dose radiotherapy (LDRT) are administered concurrently. SBRT is administered three times, at intervals of 1-2 days, with LDRT. LDRT is planned to irradiate EQD2 6 Gy considering the scattered dose caused by SBRT.
89447699|NCT05578274|Active Comparator|SBRT alone|In the control group, stereotactic body radiotherapy (SBRT) alone is performed. SBRT is administered three times, at intervals of 1-2 days. The scattered dose should not exceed EQD2 2Gy to the non-irradiated lesion.
89447700|NCT05575024||Septic AKI|Patients with septic acute kidney injury requiring continuous renal replacement therapy
89447701|NCT05569954|Experimental|V116 Treatment|Participants receive a single intramuscular (IM) injection of V116 on Day 1.
88933418|NCT01759524|Experimental|Group L|40 mls of 2% lidocaine + 1.5 mcg/kg will be drawn up by an attending anaesthetist to blind the operator. Patients in this group will receive an ultra sound guided sciatic nerve block , 3 cm proximal to the nerve bifurcation, with 25 mls of the above mentioned solution and an ultra sound guided saphenous nerve block in the midthigh just lateral to the profunda femoris artery with 15 mls of the above mentioned solution.
88933419|NCT01759524|Active Comparator|Group B|40 mls of 0.5% bupivacaine will be drawn up by an attending anaesthetist to blind the operator. Patients in this group will receive an ultra sound guided sciatic nerve block , 3 cm proximal to the nerve bifurcation, with 25 mls of the above mentioned solution and an ultra sound guided saphenous nerve block in the midthigh just lateral to the profunda femoris artery with 15 mls of the above mentioned solution.
89447702|NCT05569954|Active Comparator|PPSV23 Treatment|Participants receive a single IM injection of PPSV23 on Day 1.
89447703|NCT05567744||CADASIL Registry Participants|Have a loved one or family member with CADASIL, or anyone with or at risk for CADASIL
89447704|NCT05566600|Experimental|Dose level 1|100 million iPSC-CMs administration
89447705|NCT05566600|Experimental|Dose level 2|200 million iPSC-CMs administration
88933420|NCT01759563|Other|single arm study|
88933421|NCT01759576|Experimental|Group 1 (normal kidney function)|Each volunteer will receive a single dose of canagliflozin (JNJ-28431754) on Day 1
88933422|NCT01759576|Experimental|Group 2 (mild kidney impairment)|Each volunteer will receive a single dose of canagliflozin (JNJ-28431754) on Day 1
88933423|NCT01759576|Experimental|Group 3 (moderate kidney impairment)|Each volunteer will receive a single dose of canagliflozin (JNJ-28431754) on Day 1
89447706|NCT05566600|Experimental|Dose level 3|400 million iPSC-CMs administration
89447707|NCT05566600|No Intervention|Control|Participants will received CABG surgery only
89447708|NCT05562622|Experimental|SightGlass Vision Test Arm 1|Single vision, impact-resistant spectacle lenses
89447709|NCT05562622|Other|Test Arm 2|Single vision, impact-resistant spectacle lenses
89447710|NCT05562271|Sham Comparator|sham radiation therapy|sham radiation therapy
89447711|NCT05562271|Experimental|low-dose radiation therapy, 30 cGy/6 fx (experimental 1)|low-dose radiation therapy, 30 cGy/6 fx
89447712|NCT05562271|Experimental|low-dose radiation therapy, 300 cGy/6 fx (experimental 2)|low-dose radiation therapy, 300 cGy/6 fx
89447713|NCT05552898|Placebo Comparator|Placebo Control 1|Sleep Product Form 1 - control
89447714|NCT05552898|Experimental|Active Product 1.1|Sleep Product Form 1 - active product 1
89447715|NCT05552898|Experimental|Active Product 1.2|Sleep Product Form 1 - active product 2
89447716|NCT05552898|Experimental|Active Product 1.3|Sleep Product Form 1 - active product 3
89447717|NCT05552898|Experimental|Active Product 1.4|Sleep Product Form 1 - active product 4
89447718|NCT05552898|Experimental|Active Product 1.5|Sleep Product Form 1 - active product 5
89447719|NCT05551403|Experimental|rest-EEG, TMS-EEG/TMS-electromyography(EMG) and photic stimulation|
89447720|NCT05541380||Cohort A|patients who were pathologically (histologically) diagnosed as papillary carcinoma (PTC). They are in advanced stage and need systemic therapies. These patients may be unresectable, recurrent, persistent, or metastatic disease with RAI refractory or ineligible and need systemic therapies.
88933424|NCT01759576|Experimental|Group 4 (severe kidney impairment)|Each volunteer will receive a single dose of canagliflozin (JNJ-28431754) on Day 1
88933425|NCT01759576|Experimental|Group 5 (hemodialysis)|Each volunteer will receive a single dose of canagliflozin (JNJ-28431754) on Day 1 following completion of hemodialysis. Approximately 10 days later, each volunteer will receive another single dose of canagliflozin before hemodialysis begins.
88933426|NCT01759589|Placebo Comparator|propofol (Group P)|The patients in Group P received 1 mg/kg propofol IV (over 15 sec) during anesthesia induction
88933427|NCT01759589|Active Comparator|remifentanil and propofol (Group R)|Patients in Group R received remifentanil 1 µg/kg IV (over 60 sec) and 0.5 mg/kg propofol IV (over 15 sec)during anesthesia induction
88933428|NCT01759589|Active Comparator|sevoflurane (Group S)|In Group S, sevoflurane was started at 6% for induction and continued at 1% until the electrical stimulus was delivered, at which time it was stopped.
88933429|NCT01759615|Experimental|Early enteral feeding|Early enteral feeding group received minimal enteral feed (MEF) of 8 ml/kg of expressed human milk of the biologic mother for 48 hours followed by regular feeding with feed increments of 20ml/kg/day to reach 150 ml/kg.
88933430|NCT01759615|Active Comparator|Late enteral feeding|Late enteral feeding group was kept NPO for a period of 48 hours followed by minimal enteral feed (MEF) of 8 ml/kg of expressed human milk of the biologic mother for 48 hours and thereafter received regular feeding with feed increments of 20ml/kg/day till full enteral feeds of 150 ml/kg/day were achieved
88933431|NCT01759628|No Intervention|Lifestyle modification|Obtaining ideal body weight by calorie restriction diet and programmed physical activity
88933432|NCT01759628|Experimental|H.pylori eradication|H.pylori eradication by quadruple antibiotic therapy for two weeks plus obtaining ideal body weight by calorie restriction diet and programmed physical activity
88933433|NCT01759641||Hypotension-prone patients|The study group included all patients treated with standard HD prone to acute intradialytic hypotension.
88933434|NCT01759654|Experimental|AdimFlu-V|
88933435|NCT01759667|Experimental|A standard mixed Meal|The standard mixed meal was composed of a chicken salad sandwich and 200ml of coconut water, totalling 260 kcal, distributed among carbohydrates (62%), proteins (12%) and lipids (26%).
88933436|NCT01759680|Experimental|Whole Body Vibration Group|The whole body vibration group received 3 training sessions every week composed of 5 series of 15 seconds of vibrations at 30 Hz intensity.
88933437|NCT01759680|No Intervention|Control Group|The control group had a normal daily life for the whole study period
88933438|NCT01759693||Skin disease|Patients with urticaria or atopic dermatitis
88933439|NCT01759693||Control|Healthy volunteers
88933440|NCT01759706|Experimental|Enhanced Recovery After Surgery (ERAS)|Patients treated with enhanced recovery after surgery protocol: preadmission counselling, preoperative immunonutrition, no preoperative bowel preparation, epidural analgesia with naropin + sufentanil, no pre-anesthetic medication, intraoperative iv fluid restriction, PONV prophylaxis with ondansetron + dexamethasone, hypothermia prophylaxis, removal of nasogastric tube (NGT) at the end of surgery, postoperative mobilization program, solid food diet from POD 2, early stop of iv infusions and removal of urinary catheter.
88933441|NCT01759706|Active Comparator|Standard perioperative care (Control)|Patients treated with standard care perioperative protocol: epidural analgesia with naropin + sufentanil, pre-anesthetic medication with diazepam, Preoperative bowel preparation with sodium phosphate, removal of nasogastric tube on POD 1, solid food diet from POD 4
88933442|NCT01759719||PtCr stent PCI treated patients|patients treated with PCI in whichat least 1 PtCr stent was used
88933443|NCT01759732|Experimental|HAPLO|
88933444|NCT01759745||Blepharospasm|Blepharospasm, patient's group
88933445|NCT01759745||Control|Healthy control subjects
88933446|NCT01759758|Active Comparator|Plaster Ulnar Gutter Splint|Patients will have their hand placed in a conventional Plaster ulnar gutter splint. This immobilizes all joints of the ring and small fingers and the wrist
88933447|NCT01759758|Experimental|Thermoplastic Splint|Patients will be fitted with a custom molded thermoplastic splint that stabilizes the metacarpals of the injured hand but does not immobilize any joints
89537108|NCT05726435|Placebo Comparator|Control group|Seven randomly selected active basketball players will be supplemented with placebo resembling prebiotic fibre in all visible and taste aspects (20 grams per day divided in two 10 gram doses) for the total duration of 4 weeks, while being stationed in the training camp under constant coach and nutrition expert surveillance.
88933448|NCT01759784|Experimental|stem cell recipient|The patients who underwent mesenchymal stem cell transplantation.
88933449|NCT01759797|Experimental|stem cell reciepient|the patients with ALS who underwent intravenous injection of mesenchymal stem cell.
88933450|NCT01759810|Experimental|allogeneic stem cells|3 ml suspension of allogeneic hematopoietic cells in 0.9%NaCl solution is administered in L3-L4 vertebrae interspace with 16-18G needle. The preparation is administered every 2 weeks for the first 2 months (at day 1, 14, 28, 42, 56). 2 ml of individual dendritic vaccine are administered subcutaneously in 4 points (shoulders and abdomen) 3 times every 14 days from the therapy beginning (at day 14, 28 and 42). Meloxicam, 7.5mcg once a day is started from day 7 till day 42. Preparation of cytotoxic lymphocytes is administered intrathecally once in 2 weeks during the first 3 months, and then once in a month for three months.
89014401|NCT05277116|Experimental|Participants receiving a Genome Informed Risk Assessment (GIRA)|All participants and their health care providers will receive a Genome Informed Risk Assessment (GIRA) report.
89014402|NCT05276570|Experimental|ARO-RAGE|ARO-RAGE Inhalation
89014403|NCT05276570|Placebo Comparator|Placebo|(0.9% NaCl)
89447721|NCT05541380||Cohort B|patients who were pathologically diagnosed as DTC other than PTC, which includes follicular carcinoma, Hurthle cell carcinoma, and poorly differentiated carcinoma. The patients are in advanced stage and need systemic therapies. These patients may be unresectable, recurrent, persistent, or metastatic disease with RAI refractory or ineligible and need systemic therapies.
89447722|NCT05541380||Cohort C|patients who were pathologically diagnosed as medullary thyroid cancer (MTC) with persistent disease.
89447723|NCT05541380||Cohort D|patients who were pathologically diagnosed as anaplastic thyroid cancer (ATC).
89447724|NCT05541380||Cohort E|"the patients who had performed large scale NGS oncopanel test previously and fulfil with the criteria in cohort A, B, C, or D.~The patients must meet all the inclusion criteria and none of the exclusion criteria in each cohort."
88933451|NCT01759810|Active Comparator|autologous stem cells|3 ml suspension of proteome-modified autologous hematopoietic cells in 0.9%NaCl solution is administered in L3-L4 vertebrae interspace with 16-18G needle. The preparation is administered every 2 weeks for the first 2 months (at day 1, 14, 28, 42, 56). 2 ml of individual dendritic vaccine are administered subcutaneously in 4 points (shoulders and abdomen) 3 times every 14 days from the therapy beginning (at day 14, 28 and 42). Meloxicam, 7.5mcg once a day is started from day 7 till day 42. Preparation of cytotoxic lymphocytes is administered intrathecally once in 2 weeks during the first 3 months, and then once in a month for three months.
88933452|NCT01759823|Experimental|mesenchymal stem cell transplantation|Patients with Type 2 Diabetes mellitus on full doses of Vildagliptin+Pioglitazone+Metformin and requiring Insulin at dose of >0.4unit/Kg for blood glucose control.
88933453|NCT01759823|Sham Comparator|Control|vildagliptin+metformin+pioglitazone and on Insulin >0.4unit/Kg who will act as active control.They will receive injectable placebo at Day 1 in addition to above and will be followed up for 6 months.Follow up investigation and Insulin dose titration will be similar to Group 1
88933454|NCT01759823|Experimental|MNC's TRANSPLANTATION|Patients with Type 2 Diabetes mellitus on full doses of Vildagliptin+Pioglitazone+Metformin and requiring Insulin at dose of >0.4unit/Kg for blood glucose control.
88933455|NCT01759849||Allergen challenge|Determination of the effects of a β-chain monoclonal antibody (MAb) on the function of cells naturally activated by in vivo allergen exposure, from donors with allergen-induced asthma
88933456|NCT01759875|Active Comparator|Ritonavir-boosted Atazanavir|
88933457|NCT01759875|Experimental|Ritonavir-boosted Atazanavir plus Rabeprazole|
88933458|NCT01759875|Experimental|Ritonavir-boosted Atazanavir plus Rabeprazole AND Betaine HCl|
88933459|NCT01759888|Experimental|18F-DTBZ for Parkinson's Disease|This study will compare the brain uptake of 18F- DTBZ in 60 PD patients, including 20 LRRK2 G2385R, 20 PARK6, and 20 idiopathic PD. Subjects will be evaluated sequentially with 18F-DTBZ during a 36 month period. 18F-DTBZ PET scans will be performed twice, at baseline, and 24 (21~27) months following the start of their participation in the study.
88933460|NCT01759914||Potent topical steroid-treated|Patients treated with potent topical steroids
88933461|NCT01759914||Superpotent topical steroid-treated|Patients treated with superpotent topical steroids
88933462|NCT01759927|No Intervention|Control condition|Physically inactive employees are measured on anthropometrics, fitness and psycho-social variables.
89447725|NCT05537636|Experimental|Regional Interdepence Intervention for the upper quarter|Physical therapist will perform interventions to the entire uppper extremity and spine to treat elbow pain. Physical therapy intervention will include manual therapy and soft-tissue massage to the shoulder, cervical, and thoracic spine. Participants will be prescribed specific exercises using a phased approach.
89447726|NCT05533814|Experimental|Perampanel|Participants will be administered oral perampanel at a starting dose of 2 milligram (mg) per day. Doses of perampanel will then be up titrated in increments of 2 mg every 2 weeks up to maximum of 8 mg per day at the discretion of the investigator, and the dose may be administered up to maximum tolerated dose (MTD) according to the clinical response and tolerance of individual participants.
89447727|NCT05519059|Experimental|Patients With Advanced or Metastatic Breast Cancer|Patients will receive Pelareorep with Paclitaxel for 8 cycles (28 days/cycle).
89447728|NCT05516953|No Intervention|Group 1(Control group)|include 50 patients scheduled for sleeve gastrectomy
89447729|NCT05516953|Experimental|Group 2|which include 50 patients scheduled for sleeve gastrectomy
89447730|NCT05516524|Experimental|HSAT prior to clinical sleep study|Participants will be randomized to undergo HSAT before receiving their clinical, in-lab polysomnography
88933463|NCT01759927|Experimental|Physical Activity Coaching|Physically inactive employees receiving a 12-week behavioural support intervention grounded in self-determination theory.
88933464|NCT01759940|Experimental|ropivacaine 0,375%|In the study group the intermediate cervical block will be performed by ultrasound guidance using 20ml ropivacaine 0,375%. Additionally 10ml prilocaine 1% will be used to infiltrate the perivascular tissue around the carotid artery. In the area of the expected incision the skin will also be infiltrated with 10ml prilocaine 1%.
89447731|NCT05516524|Active Comparator|PSG first Participants will be random|Participants will be randomized to undergo HSAT after receiving their clinical, in-lab polysomnography.
89447732|NCT05515419|Experimental|Allogeneic cord blood therapy|Allogeneic cord blood therapy
89447733|NCT05512689|No Intervention|Control group|In the control group, the healthcare professional ventilates the infants without any feedback about the ventilation. This represents the normal clinical setting. The RFM will be recording data on the ventilation quality.
89447734|NCT05512689|Active Comparator|Interventional group|In the interventional group, healthcare professionals will ventilate the infants using the RFM and are able to adapt their ventilations according to the RFM feedback.
88933465|NCT01759940|Active Comparator|ropivacaine 0,75%|In the control group the intermediate cervical block will be performed by ultrasound guidance using 20ml ropivacaine 0,75%. Additionally 10ml prilocaine 1% will be used to infiltrate the perivascular tissue around the carotid artery. In the area of the expected incision the skin will also be infiltrated with 10ml prilocaine 1%.
89447735|NCT05511818|Placebo Comparator|Placebo Control 1|Rest Product Form 1 - control
89447736|NCT05511818|Placebo Comparator|Placebo Control 2|Rest Product Form 2 - control
89447737|NCT05511818|Placebo Comparator|Placebo Control 3|Rest Product Form 3 - control
88933466|NCT01759953|Active Comparator|InsuOnline game|Playing the InsuOnline game, on the web, in the player´s own time and rhythm, until its end, as already described previously.
89447738|NCT05511818|Experimental|Active Product 1.1|Rest Product Form 1 - active product 1
89447739|NCT05511818|Experimental|Active Product 1.2|Rest Product Form 1 - active product 2
88933467|NCT01759953|Active Comparator|Traditional CME|Traditional learning session as used for Continuing Medical Education, on insulin therapy, including a short lecture and a group discussion of the same clinical cases presented in the InsuOnline game
89447740|NCT05511818|Experimental|Active Product 1.3|Rest Product Form 1 - active product 3
89447741|NCT05511818|Experimental|Active Product 1.4|Rest Product Form 1 - active product 4
89447742|NCT05511818|Experimental|Active Product 2.1|Rest Product Form 2 - active product 1
89447743|NCT05511818|Experimental|Active Product 2.2|Rest Product Form 2 - active product 2
89447744|NCT05511818|Experimental|Active Product 3.1|Rest Product Form 3 - active product 1
89447745|NCT05511818|Experimental|Active Product 3.2|Rest Product Form 3 - active product 2
89447746|NCT05511818|Placebo Comparator|Placebo Control 4|Rest Product Form 4 - control
89447747|NCT05511818|Experimental|Active Product 4|Rest Product Form 4 - active product 1
89447748|NCT05506241|Experimental|Repetitive Visual Scanning Training|Participants will receive 30 minutes of their usual occupational therapy treatment and a 30 minute session of the Dynavision for 10 sessions for short stay inpatients (~ 3 weeks) and 20 sessions for clients with longer 5-6 week stay.
89447749|NCT05506241|No Intervention|Usual Treatment|Participants will receive the standard 60 minutes of occupational therapy treatment.
89447750|NCT05503108|Experimental|Fasting Mimicking Diet group|Fasting Mimicking Diet 3 days before and the day of neoadjuvant chemotherapy (ddAC, T)
89447751|NCT05503108|No Intervention|Normal Diet group|Standard neoadjuvant chemotherapy (ddAC, T)
89447752|NCT05502900|Experimental|Melatonin|Melatonin tablet 5 mg. 4 tablets taken at night (20 mg) for 5 years.
89447753|NCT05502900|No Intervention|Control|No intervention. Follows the current standard of observation after primary tumor treatment.
89447754|NCT05502328|Placebo Comparator|Control 1|Energy Product Form 1 - control
89447755|NCT05502328|Placebo Comparator|Control 2|Energy Product Form 2 - control
88933468|NCT01759966||Heart transplant recipients|Patients receiving orthotopic heart transplant in the enrollment period
88933469|NCT01759966||Healthy controls|Healthy control subjects, having the same age and sex distribution as the heart transplant recipients
88933470|NCT01759979|Experimental|Laser and mechanical lithotripsy|Bile duct stones with be treated with cholangioscopy guided laser therapy in addition to mechanical basket and balloon techniques.
88933471|NCT01759979|Active Comparator|Mechanical lithotripsy|Patients in the mechanical lithotripsy arm will undergo treatment only with basket and balloon for removal of large stones.
88933472|NCT01759992|No Intervention|Control group|Usual care
88933473|NCT01759992|Experimental|Treatment group|Participants will breathe against a load ≥ 50% of their baseline MIP, after which loads will increase according to the participant's tolerance across the remaining training period, using a Borg scale rating of 4 to 6 on perceived exertion as an indicator of adequate training intensity.
88933474|NCT01760018|Experimental|Desflurane group|
88933475|NCT01760018|Active Comparator|TIVA(total intravenous anesthesia) group|
88933476|NCT01760031||Subjects with impaired renal function|Subjects with baseline impaired renal function undergoing cardiac catheterization with contrast-medium exposure
88933477|NCT01760044|Experimental|Tissue oxygenation monitoring|Tissue oxygenation monitoring
89447756|NCT05502328|Experimental|Energy Product 1.1|Energy Product Form 1 - active product 1
89447757|NCT05502328|Experimental|Energy Product 1.2|Energy Product Form 1 - active product 2
89447758|NCT05502328|Experimental|Energy Product 2.1|Energy Product Form 2 - active 1
89447759|NCT05502328|Experimental|Energy Product 2.2|Energy Product Form 2 - active 2
89447760|NCT05500196||Myotomy length|Extended myotomy >2.5cm
89447761|NCT05500196||MYOTOMY LENGTH|Extended myotomy>4
89447762|NCT05489172|Other|A Single arm study to evaluate the effectiveness of Hola Bebe application|"Participants will receive the handout It's never too early to prevent diabetes and will meet with the health educator at their CHC and download the Hola Bebe app. The health educator will advise participants to watch one module and complete an action plan for each of the first 12 weeks of study and encourage participants to weigh themselves weekly. The app includes the following features:1) educational/ behavioral audio visual modules, with automatic prompting to complete an action plan at the end of each module; 2) a motivational message library so that participants can chose which motivational texts they wish to receive, how often and time of day; 3) a community forum where participants can interact with each other and ask questions to the health educator; 4) tracking of weights to allow participants to see a graphic of their weight over time by inputting weekly weights; and 5) awards program where participants can earn badges for completing modules."
89447763|NCT05484414|Experimental|Experimental|SRP-3D (Diethylamide) Oral Suspension, 100 mg/mL
89447764|NCT05484414|Placebo Comparator|Placebo|Matching Placebo for SRP-3D (Diethylamide) Oral Suspension, 100 mg/mL
88933478|NCT01760057|Placebo Comparator|Health promotion message|Standard online message with an invitation for free HIV testing similar in content to other Peruvian websites
88933479|NCT01760057|Experimental|Combined Web-based HIV intervention|Online HIV testing motivational videos and messages sent via mobile-phone text messaging, e-mail or instant messaging
88933480|NCT01760070|Experimental|Hybrid knife|O-type Hybrid knife is used the whole ESD process except for minimum use of dual knife in border marking and initial mucosal cutting.
88933481|NCT01760070|Active Comparator|IT knife|IT knife is used the whole ESD process except for minimum use of dual knife in border marking and initial mucosal cutting.
88933482|NCT01760083|Active Comparator|Biolimus-eluting stent implantation|PCI of CTO using a Biomatrix drug-eluting stent system + optimal medical therapy.
88933483|NCT01760083|No Intervention|Medical therapy|Optimal medical therapy. Subsequent PCI only if symptoms of angina persist despite optimal medical therapy. At least 2 anti-anginal agents or the maximum tolerated anti-anginal therapy should be used before crossover. Medical therapy should include adequate ventricular rate-limiting medication (i.e. Beta-blocker or rate-limiting calcium antagonist) where appropriate.
88933484|NCT01760096|Experimental|Levamisole+cyclosporin A+Glucocorticoids|Levamisole+cyclosporin A+Glucocorticoids
88933485|NCT01760096|Active Comparator|cyclosporin A+Glucocorticoids|cyclosporin A+Glucocorticoids
88933486|NCT01760096|Active Comparator|Glucocorticoids|Glucocorticoids
88933487|NCT01760109|Experimental|Piperacillin Sodium and Sulbactam Sodium|"Drug:xintemie 1.5-3.0g,iv,bid 7-14 days~serious infections 6.0-12.0g,iv,tid for 7-14 days"
88933488|NCT01760122|Experimental|Ypeginterferon Alfa-2b|
88933489|NCT01760122|Active Comparator|Pegasys|
88933490|NCT01760135|Experimental|low calory|15kcal/kg caloric supplement
88933491|NCT01760135|Active Comparator|high calory|25kcal/kg
88933492|NCT01760148||Interferon and ribavirin|All the patients followed the standard treatment protocol.
88933493|NCT01760161|Active Comparator|Ropivacain|Ropicacain 3,75 mg/ml 15 ml x 4 when placing the Bilateral Dual Transverus Abdominis Plane block
89447765|NCT05475002|Experimental|Intervention group|care empowerment program
89447766|NCT05475002|Active Comparator|Control group|dementia education
89537109|NCT03300089|Active Comparator|General Anaesthesia|General Anaesthesia during surgery
89537110|NCT03300089|Experimental|Regional Anaesthesia|Regional Anaesthesia during surgery
89447767|NCT05461976|Experimental|Home-based self-management exercise program|A home-based self-management exercise program will be implemented based on behaviour change techniques on the approach of Social-Cognitive Theory and Control Theory. In the present study, we will use the following behaviour changes techniques: health consequences, action planning, graded tasks, problem-solving/coping planning, modelling of the behaviour, vicarious reinforcement and non-specific encouragement, feedback on behaviour, self-monitoring on behaviour, review behaviour goals and goal setting (behaviour). The program will include six sessions of self-management with an average duration of 60 minutes. The intervention will be delivered individually and face-to-face in the participant's home by a physical therapist over 10 weeks.
89447768|NCT05461976|No Intervention|Control Group|This group will receive one session about education on risk factors after stroke and usual care.
88933494|NCT01760161|Placebo Comparator|Isotonic potassium chloride|Isotonic potassium chloride 15 ml x 4 when placing the bilateral dual transverus abdominis plane block.
88933495|NCT01760174|Active Comparator|Bupivacain-infusion in epidural catheter|Bupivacain-infusion in epidural catheter and intermittent isotonic potassium chloride bolus in transversus abdominis plane catheter.
88933496|NCT01760174|Active Comparator|Ropivacaine bolus in transversus abdominis plane catheter|Intermittent ropivacaine bolus in bilateral transversus abdominis plane catheter and isotonic potassium chloride infusion in epidural catheter.
88933497|NCT01760200||Drug eluting balloon angioplasty|Drug eluting balloon angioplasty
88933498|NCT01760200||Drug eluting stent group|Drug eluting stent intervention
88933499|NCT01760213|Experimental|Treatment|intervention delivered via internet
89447769|NCT05459337|Experimental|Intervention|"This arm will receive the MuST AKT intervention, which is a multidisciplinary, tailored person-centered behavioural intervention designed to help and enable the potential kidney transplant recipients to achieve what is required to receive a living donor kidney transplantation."
89447770|NCT05459337|No Intervention|Usual Care (control)|In the usual care (control) condition, participants will go through the current standard of care, which is a social worker assessment.
89447771|NCT05455632||Group1:PORT|Oral squamous cell carcinoma (OSCC) patients received neoadjuvant therapy, surgery, and postoperative radiotherapy.
89447772|NCT05455632||Group2:non-PORT|Oral squamous cell carcinoma (OSCC) patients received neoadjuvant therapy and surgery, without postoperative radiotherapy
88933500|NCT01760213|No Intervention|Control|
88933501|NCT01760252|Experimental|CAPOXIRI Chemotherapy Regimen|"Capecitabine, Oxaliplatin and Irinotecan (CAPOXIRI)~The proposed chemotherapy regimen CAPOXIRI is:~Capecitabine 1000mg/m2 p.o. bid on days 1-7~Oxaliplatin 85mg/m2 intravenously (IV) on day 1~Irinotecan 150mg/m2 IV on day 1"
88933502|NCT01760278|Experimental|Study Arm|Subjects would receive recombinant Follicle Stimulating Hormone (rFSH) by S.C. injection 150 - 225 IU/day for 9 days. The embryos of subjects would be cultured by time-lapse imagery technique (embryoscope) and analysis would be done using patients receive rFSH (Gonembryo viewer equipped with latest software.
88933503|NCT01760278|Active Comparator|Control Arm|Subjects would receive recombinant Follicle Stimulating Hormone (rFSH) by S.C. injection 150 - 225 IU/day for 9 days. The embryos of subjects would be cultured in conventional culture environment and analysis would be done using established subjective morphological criteria.
89447773|NCT05453994||Non-bismuth group|Tegoprazan 50 mg bid, amoxicillin 1000 mg bid, clarithromycin 500 mg bid for 14 days
89447774|NCT05453994||Bismuth group|Tegoprazan 50 mg bid, amoxicillin 1000 mg bid, clarithromycin 500 mg bid, tripotassium dicitrate bismuthate (DENOL) 300 mg bid for 14 days
88933504|NCT01760317|Active Comparator|Midline|Midline Lumbar Epidural Steroid Injection
88933505|NCT01760317|Active Comparator|Parasagittal|Parasagittal Lumbar Epidural Steroid Injection
88933506|NCT01760330|Active Comparator|IV acetaminophen|IV acetaminophen administered q 4 hrs. for a total of 24 hrs.
88933507|NCT01760330|Placebo Comparator|Placebo|Normal saline administered IV every 4 hrs. for a total of 24 hrs.
89447775|NCT05444608|No Intervention|Control Group|Data will be collected during heel blood sampling for blood sugar control from newborns randomly assigned to the control group. Babies in the control group will not be allowed to smell breast milk or listen to white noise.The newborn in the control group will continue to receive routine care.Camera recording will start 5 minutes before the procedure and lasting 5 minutes after the procedure.
89447776|NCT05444608|Experimental|Breast Milk Odor Group|Data will be collected during heel blood sampling for blood sugar control from newborns randomly assigned to the breast milk odor group.Before the intervention, 2 ml of breast milk will be dripped into sterile sponge and the sponge will be placed within 3 cm of the newborn's nose.Babies in this group will start to smell their mother's milk 5 minutes before the procedure and will continue to smell for 5 minutes after the procedure.Camera recording will start 5 minutes before the procedure and lasting 5 minutes after the procedure.
89447777|NCT05444608|Experimental|White Noise Group|Data will be collected during heel blood sampling for blood sugar control from newborns randomly assigned to the white noise listening group.Before the intervention , a bluetooth speaker will be placed at the baby's feet. The speaker will be connected to the phone and the sound level will be adjusted to 50 decibels by means of a decibel meter. The baby will be started to listen to white noise 5 minutes before the procedure.Camera recording will start 5 minutes before the procedure and lasting 5 minutes after the procedure.
88933508|NCT01760343|Experimental|Berinert, then CSL830|A single intravenous dose of Berinert at 1500 units (1500 IU), followed by a single intravenous dose of CSL830 at 1500 IU.
88933509|NCT01760343|Experimental|CSL830, then Berinert|A single intravenous dose of CSL830 at 1500 IU, followed by a single intravenous dose of Berinert at 1500 IU.
88933510|NCT01760356||Healthy Volunteers No treatment|This is set as reference a cohort of untreated healthy volunteers, over which will be measured the biomarkers to determine the baseline. Implies PBMC ex-vivo exposure to Tacrolimus prior all cell incubations to study ex-vivo PD in stimulated conditions with mitogens to identify potential genetic sources of interindividual variability in physiological conditions Number proposed 30.
88933511|NCT01760356||Liver Transplant Patients on Tacrolimus|"To explore PD/PG/PK relationships of TAC residual PD activities ex-vivo in stimulated and non-stimulated conditions in liver recipients.~The number proposed is 50."
88933512|NCT01760356||Waiting List for Liver Transplantation|"To study the ex-vivo PD response to TAC in stimulated and non-stimulated conditions and the potential genetic sources of PD variability in pathological conditions.~The number proposed is 12."
89447778|NCT05436652|Experimental|SPI-62|Active drug / placebo by mouth each morning for up to 4 weeks + standard of care 10mg prednisolone. Each participant will receive both placebo and active drug but will be blinded to the sequence of active drug and placebo.
89447779|NCT05436652|Experimental|SPI-62 + additional prednisolone|Active drug / placebo by mouth each morning for up to 4 weeks + standard of care 10mg prednisolone + additional prednisolone or placebo. Each participant will receive both placebo and active drug but will be blinded to the sequence of active drug and placebo.
89447780|NCT05427318|Active Comparator|PATH Active Intervention Arm|Participants assigned to this group will receive care as usual if they are assigned to this group. In addition, participants in this arm will receive HIV care support from a trained peer navigator and have access to a mHealth web application designed to support their health and HIV care.
89447781|NCT05427318|No Intervention|Usual Care|Participants assigned to this group are in the control arm and will receive standard of care following the Ryan White model of care.
89447782|NCT05423951|Experimental|Remimazolam|
89447783|NCT05423951|Active Comparator|Propofol|
88933513|NCT01760356||Liver Transplant Patients on Cyclosporine|"To explore PD/PG/PK relationships of CsA residual PD activities ex-vivo in stimulated and non-stimulated conditions in liver recipients.~The number proposed is 10."
89447784|NCT05422781|Experimental|Participants With Polyomavirus-Positive Merkel Cell Carcinoma (MCC)|Eight participants with MCC (> 1.0 years since definitive treatment or participants who had recurrence >2 years since evidence of disease) and NEAD
89447785|NCT05417789|Experimental|Group 1 in Part 1/Part 2: Emactuzumab|Group 1: Subjects receiving emactuzumab administered on Day(D)1 and repeated once every two weeks (Q2W) for a total of 5 times, followed by an observation period of 3 months leading to a total period of 24 weeks in Part 1 and continued with a follow-up phase in Part 2.
89447786|NCT05417789|Placebo Comparator|Group 2 in Part 1 and Part 2: Placebo|Group 2: Subjects receiving placebo administered as iv infusion on D1 and repeated once every two weeks (Q2W) for 5 times followed by an observation period of 3 months to a total period of 24 weeks in Part 1 will have the option to crossover under certain circumstances to open-label emactuzumab once every 2 weeks (Q2W) for a total of 5 times in Part 2.
89447787|NCT05407311|Experimental|64Cu-SAR-BBN|Patients will receive a single administration of 200 megabecquerels (MBq) of 64Cu-SAR-BBN.
89447788|NCT05397886|Experimental|Remimazolam with flumazenil|Patients allocated to remimazolam with flumazenil group receives remimazolam as the main anesthetics during general anesthesia and then flumazenil administration at the end of anesthesia. Remifentanil continuous infusion can be used for hemodynamic stability and analgesia.
89447789|NCT05397886|Active Comparator|Propofol total intravenous anesthesia|Patients allocated to propofol total intravenous anesthesia group receives propofol as the main anesthetics during general anesthesia until the end of anesthesia. Remifentanil continuous infusion can be used for hemodynamic stability and analgesia.
88933514|NCT01760356||Longitudinal Cohort|"Patients form the waiting list for liver transplantation will be enrolled and monitored at different times after transplantation to study the relationships between TAC PD and the clinical responses.~The number proposed is 20."
88933515|NCT01760382||STEMI network Primary PCI patients|Patients with STEMI brought to the Hub Hospital by the STEMI network ambulance and treated by primary PCI.
88933516|NCT01760382||STEMI Hospital ED Primary PCI patients|Patients with STEMI who reached by themselves the Hub Hospital, where they were admitted for STEMI and tretated by Primary PCI
88933517|NCT01760408||Home PN - pediatric|Pediatric patients (under 18) on Home PN
88933518|NCT01760408||Adult patients on Home PN|Adult patients on Home PN
88933519|NCT01760421|Experimental|Hydroxychloroquine|Receive treatment with hydroxychloroquine
88933520|NCT01760434|Other|Long-Term Outcomes|Patients will be recruited who were diagnosed with adolescent idiopathic scoliosis prior to age 18 and before 1994 (minimum 20 year outcomes) with available xrays. Patients will be included who were treated with surgery, observation, or bracing. Patients will return for a one-time visit for new xrays, physical exam, health-related quality of life surveys, and pulmonary function testing.
88933521|NCT01760460|Experimental|Anacetrapib|Participants will receive 100-mg anacetrapib, orally, once-daily for 24 weeks. Participants will continue on once-daily 100-mg anacetrapib during 28 week open-label extension.
88933522|NCT01760460|Placebo Comparator|Placebo|Participants will receive placebo tablet, orally, once daily for 24 weeks. Participants will be switched to once-daily 100-mg anacetrapib during 28 week open-label extension.
88933523|NCT01760486|Active Comparator|Shape Up Rhode Island|Individuals who join Shape Up Rhode Island 2013, enter our research study, and lose 5% of their initial body weight during the first two months of Shape Up will be randomized to one of the three maintenance interventions. If randomized to this treatment arm, participants will receive periodic newsletters throughout the 12 month trial.
88933524|NCT01760486|Experimental|Shape Up Rhode Island + Professional Coach + Incentives|Individuals who join Shape Up Rhode Island 2013, enter our research study, and lose 5% of their initial body weight during the first two months of Shape Up will be randomized to one of the three maintenance interventions. If randomized to this treatment arm, participants will receive a professional weight loss coach and will be incentivized for submitting information to their coach and meeting weight goals.
89447790|NCT05396118|Experimental|Experimental|Injection of 18F-FDG and injections of hyperpolarized [1-13C]Pyruvate and subsequent PET/MRI/MRS scan
89447791|NCT05384873|Experimental|Immunonutrition|In addition to nutritional counseling, patients will receive two servings of an oral high-calorie-high-protein nutritional liquid supplement enriched in immunonutrients (Oral Impact®). The intervention will start approximately two weeks before anticancer treatment initiation and will continue up to first disease re-assessment (12-14 weeks) and prolonged according to patient's needs
89447792|NCT05384873|Active Comparator|Control dietary intervention|Patients will receive nutritional counseling as standard of care. Nutritional counseling may comprise the use of oral nutritional supplements (ONS), which are usually prescribed when patients are unable to maintain satisfactory spontaneous food intake (less than 50% of the requirement for more than one week or only 50-75% of the requirement for more than two weeks). Therefore, in this arm the use of isonitrogenous standard blend ONS will be considered according to the regular assessment of food intake.
89447793|NCT05379608|Experimental|intervention group|The patients with cardiovascular pathology who underwent confirmed by laboratory tests COVID-19 infection 1-3 months ago with the degree of lung lesion CT3, CT4, who were admitted to the University Clinical Hospital No. 4 of I.M. Sechenov First Moscow State Medical University will be included in the study.
89014404|NCT05275140|Experimental|Experimental group 1 (adapted taekwondo)|The general structure of the adapted taekwondo will include a 10-min warm-up consisting of joint mobility exercises and low intensity aerobic work, then, for 40-min of the adapted taekwondo (will consist of non-contact activities, distributed in 10-min of basic postures and specific movements with the upper limbs and 20-min of lower limb movements performed individually and in pairs with and without the implementation of taekwondo. In addition, choreographies or forms (sequence of arm and leg movements that simulate an imaginary combat) specific to this modality were adapted to the characteristics of older women for 10-min; and will be developed to finish with the cool down for 10-min through dynamic and static flexibility exercises.
89447794|NCT05379608|Placebo Comparator|control group|The patients with cardiovascular pathology who underwent confirmed by laboratory tests COVID-19 infection 1-3 months ago with the degree of lung lesion CT3, CT4, who were admitted to the University Clinical Hospital No. 4 of I.M. Sechenov First Moscow State Medical University will be included in the study.
89447795|NCT05377853|Experimental|Blindness history|Since this is a regression analysis, all participants are assigned to the same Arm with blindness history and the demographics as covariates.
89447796|NCT05372068|Experimental|Concrete household floor|
89447797|NCT05372068|No Intervention|Non-intervention|
89447798|NCT05370495|Experimental|SY-201 Ophthalmic Solution 2.0%|SY-201 Ophthalmic Solution 2.0%
89447799|NCT05370495|Experimental|SY-201 Ophthalmic Solution 1.0%|SY-201 Ophthalmic Solution 1.0%
89447800|NCT05370495|Experimental|SY-201 Ophthalmic Solution 0.5%|SY-201 Ophthalmic Solution 0.5%
89447801|NCT05370495|Placebo Comparator|SY-201 Ophthalmic Solution Vehicle|SY-201 Ophthalmic Solution Vehicle
89447802|NCT05369793|Active Comparator|Alpha-lipoic acid arm|Administration of alpha-lipoic acid 600 mg orally once daily for 3 months.
89447803|NCT05369793|Experimental|Roflumilast arm|Administration of roflumilast 500 mcg orally once daily for 3 months.
89447804|NCT05366361||Patients Undergoing Clinically-Indicated Maze Surgery|This group includes patients with persistent AF who will be undergoing clinically-indicated Maze surgery.
89447805|NCT05366361||Patients Undergoing Clinically-Indicated Ablation|This groups includes patients with persistent AF who will be undergoing clinically-indicated ablation.
89447806|NCT05365698||Cohort I|randomly assigned 12 health facilities (treatment/intervention group) that will have access to CHN program components
89447807|NCT05365698||Cohort II|randomly assigned 12 health facilities that will serve as a control for the first year of the program implementation and then transition into the intervention/treatment group
89447808|NCT05357859|Experimental|Intervention: solubilized vitamin D3 in MCT|The intervention dose and duration aims to correct their vitamin D deficiency to sufficient status (total serum 25(OH)D >/=30 ng/mL or 75 nmol/L). According to an oral cholecalciferol (D3) loading dose guideline for vitamin D-deficient adults (van Groningen et al. 2010), cumulative dose of more than 200,000 IU solubilized vitamin D3 would be applied in current RCT, with make sure the sufficient supplement. Intervention group will receive 144,000 IU in week0 (W0) and then every 2 weeks of 72,000 IU for total 8 weeks (totally 5 times: 144,000 IU wk0/ 72,000 IU wk2/ 72,000 IU wk4/ 72,000 IU wk6/ 72,000 IU wk8), theoretically to achieve sufficient levels of vitamin D.
89447809|NCT05357859|Placebo Comparator|Placebo: MCT with same amount|control group will receive same volume amount of medium chain triglyceride (MCT).
89447810|NCT05348356|Experimental|Nirogacestat Open-Label|All participants will receive open-label nirogacestat
89447811|NCT05348252|Experimental|Interventional group (Patient Journey App)|The interventional group will receive all information and instructions on discontinuing PPI use through the Patient Journey App.
88933525|NCT01760486|Experimental|Shape Up Rhode Island + Peer Coach + Incentives|Individuals who join Shape Up Rhode Island 2013, enter our research study, and lose 5% of their initial body weight during the first two months of Shape Up will be randomized to one of the three maintenance interventions. If randomized to this treatment arm, participants will receive a peer coach and will be incentivized for reporting to their coach and meeting weight goals.
88933526|NCT01760499|Experimental|Immunotherapy Followed by Surgery|PV-10 administration, adverse events assessment, surgery to remove melanoma tumors, follow-up visit.
88933527|NCT01760512|Experimental|Robot-assisted surgery|Robot-assisted (da Vinci surgical system) gastric bypass
88933528|NCT01760512|Active Comparator|Conventional laparoscopy|Laparoscopic gastric bypass
88933529|NCT01760525|Experimental|CGM097 - Dose escalation|
88933530|NCT01760525|Experimental|CGM097 - Dose Expansion at MTD or RP2D|
88933531|NCT01760538|Experimental|exercise group|exercise training
88933532|NCT01760538|Active Comparator|Control|usual care
88933533|NCT01760551||Patients assessed with AMA guide fifth edition|
88933534|NCT01760551||Patients assessed with AMA guide sixth edition|
88933535|NCT01760564|Experimental|Miglustat|miglustat 200mg tid
89447812|NCT05348252|Active Comparator|Control group (Conventional Care)|The control group will receive all information and instructions on discontinuing PPI use through email as a digital information folder.
89447813|NCT05338866||Cohort 1. Cohort 2|"A total of 6 courses of oxaliplatin plus capecitabine chemotherapy and 2 courses of capecitabine single drug chemotherapy were performed. Concurrent chemoradiotherapy starts at the second cycle.~Cohort 1: For patients with low rectal cancer who refused surgery before the initial diagnosis and treatment, the first stage of radiotherapy used conventional linear accelerated radiotherapy, with doses of GTV 50Gy/25f and CTV 45Gy/25f for 5-6 weeks. Subsequently, the second stage of radiotherapy boost was continued with MR linear accelerator, and the dose was GTV 16~20Gy/8~10f for 2 weeks.~Cohort 2: For locally advanced low rectal cancer patients who did not achieve clinical complete remission 6-8 weeks after neoadjuvant radiochemotherapy and refused surgery, radiotherapy was given in the first stage at the doses of GTV 50Gy/25f and CTV 45Gy/25f for 5-6 weeks. In the second stage, MR linear accelerator was used for radiotherapy boosting, and the dose was GTV 30Gy/15f for 3 weeks."
89447814|NCT05334407|Experimental|GroupA（DE+/DI+）|The treatment includes the combination of implant-supported full-arch fixed prostheses (dental intervention, DE) and dietary intervention tailored to the dental status (dietary intervention, DI) without waiting period
89447815|NCT05334407|Active Comparator|GroupB（DE+/DI-）|The treatment includes implant-supported full-arch fixed prostheses (dental intervention, DE) without waiting period and dietary intervention tailored to the dental status (dietary intervention, DI) 4-month later
89447816|NCT05334407|Active Comparator|GroupC（DE-/DI+）|The treatment includes dietary intervention tailored to the dental status (dietary intervention, DI) without waiting period and implant-supported full-arch fixed prostheses (dental intervention, DE) 4-month later
89447817|NCT05334407|Placebo Comparator|GroupD（DE-/DI-）|The treatment included implant-supported full-arch fixed prostheses (dental intervention, DE) and dietary intervention tailored to the dental status (dietary intervention, DI) with 4-month waiting period. Only general dietary information is provided at baseline.
89447818|NCT05327452|Experimental|Supervised aerobic and resistance exercise (SUP)|"Participants will be randomly assigned to receive 3x weekly at home, virtually supervised aerobic and resistance exercise sessions with a certified exercise trainer for 16 weeks.~Participants will also have a baseline test, mid intervention cardiovascular and strength tests and one postintervention and one follow up visit."
89447819|NCT05327452|Experimental|Unsupervised aerobic and resistance exercise (UNSUP)|"Participants will be randomly assigned to receive 3x weekly at home, unsupervised aerobic and resistance exercise sessions with a 1x weekly telehealth call with a certified exercise trainer for 16 weeks.~Participants will also have a baseline test, mid intervention cardiovascular and strength tests and one postintervention and one follow up visit."
89447820|NCT05327452|Active Comparator|Attention Control (AC)|"Participants will be randomly assigned to receive 3x weekly at home stretching exercise for 16 weeks.~Participants will also have a baseline test, mid intervention cardiovascular and strength tests and one postintervention and one follow up visit."
89447821|NCT05308641|Active Comparator|PreviousSurgery(PrevSurg)_YES/rESWT_4000|Previous Surgery on degenerative pathology in lumbar spine: YES rESWT: 4000 pulse, 20 Hz
89447822|NCT05308641|Active Comparator|PrevSurg_YES/rESWT_500|Previous Surgery on degenerative pathology in lumbar spine: YES rESWT: 500 pulse, 2 Hz
89447823|NCT05308641|Active Comparator|PrevSurg_YES/rESWT_no|Previous Surgery on degenerative pathology in lumbar spine: YES rESWT: no
89447824|NCT05308641|Active Comparator|PrevSurg_YES/rESWT_deny|Previous Surgery on degenerative pathology in lumbar spine: YES rESWT: denied
89447825|NCT05308641|Active Comparator|PrevSurg_NO/rESWT_4000|Previous Surgery on degenerative pathology in lumbar spine: NO rESWT: 4000 pulse, 20 Hz
89447826|NCT05308641|Active Comparator|PrevSurg_NO/rESWT_500|Previous Surgery on degenerative pathology in lumbar spine: NO rESWT: 500 pulse, 2 Hz
88933536|NCT01760577|Experimental|The Botulinum Toxin A group|The Botulinum Toxin A group received intraarticular injections of 100 units of Botulinum Toxin A (Allergan, Inc, Irvine CA) reconstituted in 2 cc normal saline.
88933537|NCT01760577|Active Comparator|The hyaluronate group (Hyalgan, Italy)|The hyaluronate group received intraarticular injections of 2 ml sodium hyaluronate (Hyalgan, molecular weight 500-730kDa, Fidia Pharmaceutical Corporation, Abano Terme, Italy) and subsequent 6 sessions of rehabilitation exercise for 50 miniutes/day, 3 days per week for 2 weeks and home exercise for 2 weeks .
88933538|NCT01760590|Experimental|Manual Manipulation|Patients will be randomized to receive a thrust manipulation
88933539|NCT01760590|Experimental|Manual Mobilization|Patients will be randomized to receive mobilization
88933540|NCT01760603|Experimental|ISFF|The patients performed ischia spinous fascia fixation surgery.
88933541|NCT01760616|Experimental|Test group|Test group: Adjuvant therapy + Huaier Granule group.Administration: the Huaier Granule Electuary should be orally taken from the 15th day after surgery. Usage: Huaier Granule Electuary is continuously taken three times per day, 20g per time, until 144 weeks after surgery or until study termination Adjuvant therapy: the adjuvant therapies are not limited, and for example, all the following treatments can be applied according to the individual's condition and guidelines of the research center: ablation therapy, immunotherapy, chemotherapy, radiotherapy, and Chinese herbs, as well as programs and medications that are used for post-operative liver protection and antiviral treatment
88933542|NCT01760616|No Intervention|Control group: adjuvant therapy|Control group: adjuvant therapy Adjuvant therapy: the adjuvant therapies are not limited, and for example, all the following treatments can be applied according to the individual's condition and guidelines of the research center: ablation therapy, immunotherapy, chemotherapy, radiotherapy, and Chinese herbs, as well as programs and medications that are used for post-operative liver protection and antiviral treatment.
88933543|NCT01760629|Experimental|Cooling arm|Whole body cooling to 33 to 34 C rectal temperature
88933544|NCT01760642|Experimental|Midazolam|"period 1: midazolam 1 mg IV single dose administration. period 2: midazolam 1 mg IV single dose after ketoconazole 400 mg oral dosing for 3 days.~period 3: midazolam 2.5 mg IV single dose after rifampicin 600 mg oral dosing for 10 days."
88933545|NCT01760668||Turner syndrome (TS)|TS verified by genotyping Age > 18 years awaiting operation due to aortic dilation
88933546|NCT01760668||Marfan syndrome (MS)|Females with MS verified clinically or by genotyping Age > 18 years awaiting operation due to aortic dilation
88933547|NCT01760668||Bicuspid aortic valve|females with bicuspid aortic valve Age > 18 years awaiting operation due to aortic dilation
88933548|NCT01760668||Controls|Men/females who died from conditions other than aortic dilation or dissection. Age 20-60 years.
88933549|NCT01760681|Experimental|H coil DTMS|20 daily deep TMS treatments
88933550|NCT01760681|Sham Comparator|inactive stimulation|20 daily sham deep TMS treatments
89447827|NCT05308641|Active Comparator|PrevSurg_NO/rESWT_no|Previous Surgery on degenerative pathology in lumbar spine: NO rESWT: no
89447828|NCT05308641|Active Comparator|PrevSurg_NO/rESWT_deny|Previous Surgery on degenerative pathology in lumbar spine: NO rESWT: denied
89447829|NCT05303064|Experimental|Group 1 OLZ/SAM|Fixed dose combination of olanzapine and samidorphan
89447830|NCT05303064|Active Comparator|Group 2 Olanzapine|Fixed dose of olanzapine
89447831|NCT05300074|Experimental|Training two times per week|Training two times per week. IMT with 5 rounds and 12 repetitions in each round at 60-80% MIP. The primary protocol will end at 6 weeks and the self-administered long-term protocol will end at 12 months after intervention start.
88933551|NCT01760694|Experimental|Resectable Patients|Surgery with Intraoperative Radiation Therapy (IORT). Radiation Therapy within 6-8 weeks after surgery followed by FOLFIRINOX every 2 weeks starting within 12 weeks of surgery
89447832|NCT05300074|Experimental|Training five times per week|Training five times per week. IMT with 5 rounds and 12 repetitions in each round at 60-80% MIP. The primary protocol will end at 6 weeks and the self-administered long-term protocol will end at 12 months after intervention start.
89447833|NCT05288751|No Intervention|Treatment as usual (TAU)|These patients will not be assigned to the CM programs, but will be invited to complete study measures at the same time points: baseline, 3-months, 6-months, and 12-months.
89447834|NCT05288751|Experimental|Attendance-only CM|Patients in this arm complete an appointments with his or her primary care provider (PCP) or member of the PCP's microteam . These appointments must be initiated by the PCP/microteam in accordance with the patient's treatment plan for regular follow-up appointments.
89447835|NCT05288751|Experimental|Attendance + abstinence CM|Patients who test stimulant-positive during the initial urine drug screen (UDS) at their intake visit will be invited to additionally enroll in the abstinence CM schedule. All of the attendance-only CM rules described previously will apply to patients in the attendance + abstinence program.
89447836|NCT05277194|Experimental|KeepCalm App|The KeepCalm app is designed to help manage stress and prevent challenging behaviors in children with autism. The app uses physiological stress tracking, assessed using heart rate monitoring, to indicate when challenging behaviors are likely to occur. The app then recommends strategies to help prevent the onset of challenging behaviors. The app can also be used to track trends in triggers, behaviors, and strategies, and to communicate this information to parents and other members of a child's educational team.
89447837|NCT05277194|No Intervention|Waitlist Control|Individuals assigned to the waitlist control condition will gain access to the KeepCalm app following the study's completion. During the trial, they will not receive any intervention, but will complete baseline and post-intervention measures during the trial.
89447838|NCT05270044|Experimental|Arm A|Encorafenib and Binimetinib
89447839|NCT05270044|Placebo Comparator|Arm B|Placebo to match Encorafenib Placebo to match Binimetinib
89447840|NCT05267041|Experimental|Cohort of Adults with lung cancer|Patients newly diagnosed with lung cancer.
89447841|NCT05258539|Experimental|Women aged 18 to 85 years who come to the CRMP for a breast cancer risk assessment.|
89447842|NCT05254756|Active Comparator|Traditional plastic 2-blade disposable speculum|Patients assigned to this arm will be evaluated using the traditional plastic 2-blade disposable speculum
88933552|NCT01760694|Experimental|Marginally Resectable Patients|2-3 cycles of neoadjuvant FOLFIRINOX then restaged, then undergo surgery with Intraoperative Radiation Therapy (IORT) within 2-4 weeks following chemotherapy. Then Radiation Therapy within 6-8 weeks followed by FOLFIRINOX every 2 weeks starting within 12 weeks of surgery for a total of 2-4 cycles
88933553|NCT01760707|Experimental|Exercise Training|aerobic exercise training
88933554|NCT01760707|Active Comparator|Control|
88933555|NCT01760720|No Intervention|control|Standard care
88933556|NCT01760720|Experimental|intervention|The MMT CARE intervention has 3 session/modules: 1) MMT protocol and procedures, understanding stigma and its impact; 2) effective communication with clients, introducing motivational interviewing; 3) application of motivational interviewing, motivating clients for behavior change. The intervention contents reflect challenges faced by service providers working at MMT clinics and the impact of these challenges on their clients. Sessions will occur once a week for three weeks, with each session featuring a different set of themes and relevant activities. Each session will be 90-100 minutes long and will be conducted with a group of 5 to 7 providers.
88933557|NCT01760746||PDR, Avastin/Lucentis, randomization, humour, inflamation|Patients will be randomized to receive pre-treatment with either bevacizumab or ranibizumab . Sample of aqueous humour will be taken before injection and before surgery.Both the patient and the treating physician will be masked to the identity of the study drug.
88933558|NCT01760759|No Intervention|Usual care|Patients receive usual care from their medical providers.
89447843|NCT05254756|Experimental|5-petal Bouquet speculum|Patients assigned to this arm will be evaluated using the 5-petal Bouquet speculum
89447844|NCT05253118|Experimental|Treatment|Tislelizumab (BGB-A317) 200mg will be administered on Day 1 of each 21-day cycle (once every 3 weeks) in combination with pemetrexed. And pemetrexed 500 mg/m2 will be administered on Day 1 of each 21-day cycle (once every 3 weeks).
89447845|NCT05251974||Compliant with beta blocker therapy|Patients observed to be compliant with beta blocker therapy by blood assay
89447846|NCT05251974||Non-compliant with beta blocker therapy|Patients observed to be non-compliant with beta blocker therapy by blood assay
89447847|NCT05251714|Experimental|Part A: Monotherapy Escalation and Expansion|Dose selection and expansion of CFI-402257
89447848|NCT05251714|Experimental|Part B: Combination Escalation and Expansion|Dose selection and expansion of CFI-402257 with Fulvestrant
89447849|NCT05251493|Active Comparator|Iron Isomaltoside/ferric derisomaltose|route: intravenous Dosage: 1000-1500 mg (100mg/mL), max dose 20mg/kg Frequency: max dose 1000 mg, if further doses required, must receive dosage divided Duration: one infusion or two infusions (dose dependent)
89447850|NCT05251493|Active Comparator|Iron Sucrose|Route: Intravenous Dosage: 100 mg/mL (maximum 300 mg per dose) Frequency: up to 3 doses per week or 1000 mg per week maximum Duration: until iron needs reached by simplified table
88933559|NCT01760759|Experimental|Usual care plus cell phone reminders|Patients receive reminders, scheduled to occur daily at time(s) of scheduled antiretroviral therapy dosing.
88933560|NCT01760759|Experimental|Usual care, reminders & contingency management for adherence|Patients receive reminders and reinforcement in the form of vouchers for each video that they send in indicating adherence at the appropriate time.
88933561|NCT01760772|Placebo Comparator|Saline|0.9% saline
88933562|NCT01760772|Experimental|Exendin-9 (Ex-9)|Bolus of Ex-9 (7,500 pmol/kg) followed by a continuous infusion at 750 pmol/kg/min
88933563|NCT01760772|Experimental|GLP-1|GLP-1 infusion at 0.3 pmol/kg/min
89447851|NCT05240807|Experimental|Clinical Coronary CTA Cohort|Subjects scheduled for a clinically indicated coronary CTA will receive a research contrast-enhanced coronary CT angiogram using photon-counting CT
89447852|NCT05240807|Experimental|Clinical Nuclear Medicine or MRI Cardiac Stress Test Cohort|Subjects scheduled for a clinically indicated nuclear medicine or MRI cardiac stress test will receive a research contrast-enhanced coronary CT angiogram using photon-counting CT at rest and after administration of a cardiac stress agent
89447853|NCT05240235|Active Comparator|Education, compression and exercise therapy|Patients will be given exercise therapy every day for the first two weeks. Afterwards, patients will be taken to the same therapy in the hospital for 1 day a week, and on other days they will do home exercise at home for 10 minutes.
89447854|NCT05240235|Active Comparator|Education, compression,exercise therapy and manual lymph drainage|Patients will be given manual lymph drainage for one and a half hours every day for the first two weeks. Afterwards, patients will be taken to the same therapy in the hospital for 1 day a week, and on other days they will do self manual lymph drainage at home for 10 minutes.
89447855|NCT05230732|Experimental|Experimental|Active LLTS will be performed by use of a neuromodulation device with electrodes attached to the tragus of the ear. Stimulator will be applied continuously for 1 hour daily for 12 weeks.
89447856|NCT05230732|Sham Comparator|Control arm|Sham LLTS will be performed by use of a neuromodulation device with electrodes attached to the ear lobule. Stimulator will be applied continuously for 1 hour daily for 12 weeks.
89447857|NCT05227755|Active Comparator|Whey protein isolate|Participants will receive 120 mls of whey protein isolate (total of 20 g protein) to consume 3x/week after dialysis treatment for 4 weeks.
89447858|NCT05227755|Experimental|Soy protein isolate|Participants will receive 120 mls of soy protein isolate (total of 20 g protein) to consume 3x/week after dialysis treatment for 4 weeks.
89447859|NCT05227456|Experimental|Etonogestrel implant|The participants will receive an etonogestrel 68mg implant
89447860|NCT05223894|Experimental|hiPSC-CM therapy|Injection of allogenic human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) during coronary artery bypass grafting surgery. 100 million hPSC-CMs in 2.5-5 mL medium suspension will be injected into the myocardium.
89447861|NCT05223894|Sham Comparator|Control|Coronary artery bypass grafting surgery only.
89447862|NCT05220904|Placebo Comparator|Placebo Comparator:placebo practice+spectacles|Patients will take placebo practices with spectacles every two days.
89447863|NCT05220904|Experimental|Experimental： perceptual learning practice+spectacles|Patients will take perceptual learning practices with spectacles every two days.
89447864|NCT05220735|Experimental|Experimental|Participants will receive three fish oil capsules daily for 14 weeks, and fractional iron absorption from test meals provided without and with ascorbic acid will be determined at baseline and endpoint.
89447865|NCT05220397|No Intervention|Initial Responders|Individuals who have received the Pfizer or Moderna vaccines and have high levels of spike antibodies in their blood, will receive standard of care immunosuppressive (IS) medications.
89014405|NCT05275140|Active Comparator|Experimental group 2 (multi-component training)|The general structure of the multi-component training will include a 10-min warm-up consisting of joint mobility exercises and low intensity aerobic work, then, for 40-min of the multi-component training (distributed work in a circuit, which includes resistance training focused on the large muscles of the upper limbs and lower limbs combined with exercises aimed at cardiorespiratory fitness, agility and postural control, using elastic bands, poles, 2-kg medicine balls and chairs). The training volume will start (the first 4-weeks) with 3 sets of 10 repetitions per muscular exercise with a 2-min rest period between sets, performing slow movements of two seconds in concentric contraction and four seconds in eccentric contraction. Between weeks 5 to 8, the volume will increase to 4 sets of 10 repetitions per muscular exercise with 2-min of rest between sets.
89014406|NCT05275140|Active Comparator|Experimental group 3 (walking program)|The walking program will be distributed in three weekly sessions of 45- to 60-min every other day, for 16-weeks (48 sessions). The general structure of the protocol will include a 5-min warm-up consisting of joint mobility and flexibility exercises. Next, the main part will be developed for 30- to 45-min (increased by 5-min every 4-weeks) consisting of walking on flat ground, touring the jogging circuit that the University has on campus, and ending with 5-min cool down through dynamic and static flexibility exercises.
89447866|NCT05220397|Experimental|Segment I|Segment I: individuals who have a spike protein test result less than 250 U/mL at the screening visit. Subjects will be randomized to receive a change or maintain their current immunosuppression medication regimen and then receive the Janssen Ad26.CoV2.S vaccine.
88933564|NCT01760798|Active Comparator|Daily Teriparatide group|This group will recieve 20µg of teriparatide by subcutaneous route daily at 8 pm for 1 year
89447867|NCT05220397|Experimental|Segment II|Segment II: individuals from Segment I who have a spike protein test result less than 250 U/mL 28 days after receiving the Janssen Ad26.CoV2.S vaccine in Segment I. Subjects will be randomized to receive a change or maintain their current immunosuppression medication regimen and then receive an additional Janssen Ad26.CoV2.S vaccine.
89447868|NCT05219617|Experimental|Carisbamate 200 mg BID arm|"Age: 4 to <12y* Titration: 2 mg/kg BID Maintenance: 4 mg/kg BID~Age: ≥12 y Titration: 100 mg BID Maintenance: 200 mg BID"
88933565|NCT01760798|Experimental|Weekly Teriparatide group|This group will recieve 60µg of teriparatide by subcutaneous route weekly at 8pm on Sunday for 1 year
88933566|NCT01760811|Other|Cetuximab ,neoadjuvant administration|Drug administration ,Cetuximab(merck Serono )given neoadjuvant ,3 courses prior surgery followed by post operatve radiation and Cetuximab
88933567|NCT01760824|Experimental|Sequential therapy|Esomeprazole 20mg bid for 10 days, amoxicillin 1g bid for first 5 days, clarithromycin 500mg bid for last 5 days and metronidazole 400mg qid for last 5 days
88933568|NCT01760824|Active Comparator|Quadruple therapy|Esomeprazole 20mg bid, metronidazole 400mg aid, bismuth sub citrate 120mg aid and tetracycline 500mg qid, all for 10 days
88933569|NCT01760837|Other|baked milk products, cow's milk allergy|to offer baked milk products to cow's milk allergic patients and to follow them for tolerance and if this intervention may have any impact on the natural history of milk allergy
88933570|NCT01760863|Experimental|Oral Antibiotics|Oral antibiotics for 3 months; recommendation for antibiotics will be made by an infectious disease specialist.
88933571|NCT01760863|No Intervention|No oral antibiotics|No oral antibiotics.
88933572|NCT01760902|Experimental|Diet and Physical Activity|Participants convene weekly for 12 consecutive weeks and then once per month for 9 months. Each sessions is 90 minutes
88933573|NCT01760928||Asthma patients|all
88933574|NCT01760967|Active Comparator|Dexmedetomidine|administer dexmedetomidine (0.1-0.7ug/kg/h) from the beginning of ICU treatment
88933575|NCT01760967|Active Comparator|non-Dexmedetomidine|administer sedatives except Dexmedetomidine
88933576|NCT01760980|Experimental|Test product (B)|B: Subjects receive Exemestane 25 mg tablets under fasting conditions
88933577|NCT01760980|Active Comparator|Reference product (A)|A: Subjects receive Aromasin 25 mg tablets on two occasions under fasting conditions
88933578|NCT01761032||Infrequent tanners|Individuals who tan less than twice a week and do not meet modified DSM-IV criteria for tanning addiction.
89447869|NCT05219617|Experimental|Carisbamate 300 mg BID arm|"Age: 4 to <12y* Titration: 2.75 mg/kg BID Maintenance: 5.5 mg/kg BID~Age: ≥12 y Titration: 150 mg BID Maintenance: 300 mg BID"
89447870|NCT05219617|Placebo Comparator|Placebo matched to 200 mg BID arm|"Age: 4 to <12y* Titration: Volume equivalent to 2 mg/kg BID Maintenance: Volume equivalent to 4 mg/kg BID~Age: ≥12 y Titration: Volume equivalent to 100 mg BID Maintenance: Volume equivalent to 200 mg BID"
89447871|NCT05219617|Placebo Comparator|Placebo matched to 300 mg BID arm|"Age: 4 to <12y* Titration: Volume equivalent to 2.75 mg/kg BID Maintenance: Volume equivalent to 5.5 mg/kg BID~Age: ≥12 y Titration: Volume equivalent to 150 mg BID Maintenance: Volume equivalent to 300 mg BID"
89447872|NCT05218642|Experimental|Arm A|KX-826: 2.5mg twice daily
89447873|NCT05218642|Experimental|Arm B|KX-826: 5mg once daily
89447874|NCT05218642|Experimental|Arm C|KX-826: 5mg twice daily
89447875|NCT05218642|Experimental|Arm D|Matching placebo to KX-826
89447876|NCT05216666|Active Comparator|Lateral approach|290 participants receive their hip prosthesis through a lateral approach. The anterior third of m. gluteus medius along with the corresponding part of m. vastus lateralis are detached from the greater trochanter and the anterior capsule is excised for the exposure of the hip joint. After implant insertion, the gluteus medius is reinserted into the greater trochanter with non-absorbable sutures. Participants are followed at three and 12 months by a physiotherapist.
89447877|NCT05216666|Active Comparator|Posterior approach|290 participants receive their hip prosthesis through a posterior approach. The m. piriformis gemelli and obturator internus are detached from the greater trochanter and the posterior capsule is incised for the exposure of the hip joint. After implant insertion, the posterior capsule as well as m piriformis and the external rotators are reinserted into the greater trochanter with non-absorbable sutures. Participants are followed at three and 12 months by a physiotherapist.
89447878|NCT05209074|Experimental|Ivosidenib+mFOLFIRINOX|
89447879|NCT05208619|Active Comparator|thoracic epidural analgesia|A thoracic epidural catheter is placed before induction of general anaesthesia. Sufentanil 10 µg and Ropivacaine are applied via the catheter.
89447880|NCT05208619|Active Comparator|paravertebral block|A single-shot paravertebral block (Ropivacaine 0,5%) is placed before induction of general anaesthesia.
89447881|NCT05206838|Experimental|Surgical reconstruction|22 patients undergo surgical reconstruction of gluteus medius with allograft consisting of Achilles tendon with calcaneus block. The calcaneus block is fixed into the greater trochanter and the Achilles tendon i passed through the gluteus medius muscle, tensioned and sutured into the muscle. Postoperatively, partial weight bearing for 2 months followed by physiotherapy for 10 months.
89447882|NCT05206838|No Intervention|Physiotherapy|22 patients receive non-operative treatment for their limp with physiotherapy alone during a 12-month period.
89447883|NCT05201339|Active Comparator|Standard method|Insert I-gel™ according to the manufacturer's instruction. Take the sniffing position and gently move the i-gel™ along the hard palate to the soft palate and the posterior oropharynx.
89447884|NCT05201339|Experimental|Head-neck rotation|After rotating the patient's head and neck to the left maximally, insert the i-gel™ from the right side of the tongue to the midline. When the tip reaches the soft palate and oropharynx positions, turn the head and neck back to the neutral position.
89447885|NCT05200897|Experimental|Amyloid positive mild cognitive impairment+ BDNF met carrier|Transdermal trigeminal electrical modulation for 3 months
89447886|NCT05200897|Experimental|Amyloid positive mild cognitive impairment+ BDNF Val/Val|Transdermal trigeminal electrical modulation for 3 months
89447887|NCT05200897|Experimental|Amyloid negative mild cognitive impairment+ BDNF met carrier|Transdermal trigeminal electrical modulation for 3 months
88933579|NCT01761032||Compulsive Tanners|Individuals who tan more than 3 times per week in a tanning bed. Tanning must cause disruption in daily functioning. Must meet modified DSM-IV criteria for tanning addiction
88933580|NCT01761045|Active Comparator|Soup 1|Consommé soup with Monosodium L-Glutamate (MSG)
88933581|NCT01761045|Active Comparator|Soup 2|Consommé soup with Monosodium L-Glutamate (MSG) and Nucleic Acid (IMP)
88933582|NCT01761045|Placebo Comparator|Soup 3|Placebo soup with no Monosodium L-Glutamate (MSG) or Nucleic Acid (IMP)
88933583|NCT01761071|Experimental|group KO|(ketorolac 0.5% in one eye, ofloxacin 0.3% in the other eye)
88933584|NCT01761071|Active Comparator|group DO|(diclofenac 0.1% in one eye, ofloxacin 0.3% in the other eye)
88933585|NCT01761097|Active Comparator|Endocuff assisted colonoscopy|Endocuff attachment
88933586|NCT01761097|Placebo Comparator|Control standard colonoscopy|Standard colonoscopy
88933587|NCT01761110|No Intervention|Pre-intervention|Participants will be enrolled prior to the implementation of the community-based buprenorphine treatment (CBBT) intervention.
88933588|NCT01761110|Experimental|Post-intervention|Participants will be enrolled after implementing the community-based buprenorphine treatment (CBBT) intervention
88933589|NCT01761123|Experimental|VXA-A1.1|Intestinal Delivery
88933590|NCT01761136|Active Comparator|Inoculation in upper arm deltoid|Inoculation of Hib vaccine of two brands in upper arm deltoid
88933591|NCT01761136|Experimental|Inoculation in vastus lateralis muscle|Inoculation of Hib vaccine of two brands in vastus lateralis muscle
88933592|NCT01761149|Active Comparator|Remifentanil (Low dose)|remifentanil(Low):dose of 0.2ug/kg/min. The dose of remifentanil is widely used intraoperatively clinically;
88933593|NCT01761149|Experimental|Remifentanil (High dose)|The high dose of remifentanil is 1.2ug/kg/min. The does is sometimes used in clinical practice.
88933594|NCT01761188|Experimental|STABLE-SR|CPVI plus electrophysiologic substrate ablation in the left atrium during sinus rhythm ( STABLE-SR)
88933595|NCT01761188|Experimental|Control Group|conventional stepwise ablation approach for persistent AF(CPVI + Lines +CFE) .
88933596|NCT01761201|Experimental|levofloxacin|Levofloxacin 500 mg daily for 9 months starting on the waiting list for liver transplant
88933597|NCT01761201|Active Comparator|Isoniazid|"Isoniazid 300 mg/day for 9 months beginning after transplantation, when the liver function is stable and not before 3 months nor after 6 months"
88933598|NCT01761214|Active Comparator|Fluroquinolones|The fluroquinolones employed in the present study are referred to as oral levofloxacin (500mg q.d.), moxifloxacin (400mg, q.d.) and ciprofloxacin (500mg, b.i.d.). All medications are administered based on the bronchiectasis guideline issued by British Thoracic Society.
89447888|NCT05200897|Experimental|Amyloid negative mild cognitive impairment+ BDNF Val/Val|Transdermal trigeminal electrical modulation for 3 months
89447889|NCT05200598||Mild psoriasis|
89447890|NCT05200598||Moderate psoriasis|
89447891|NCT05200598||Severe psoriasis not receiving systemic therapy|
89447892|NCT05200598||Severe psoriasis receiving systemic therapy with genetic-engineering biological drugs|
89447893|NCT05200598||Patients without psoriasis|
89447894|NCT05196737|No Intervention|Non-Intervention Week Reflex Measurements|Baseline reflex measurements will be collected during the first week of the study (Visits 1-4). No dry needling will occur during this week. The aim of this arm is to track any natural variability in nervous system excitability at the same time points as reflex measurements during the intervention week.
89447895|NCT05196737|Experimental|Dry Needling Reflex Measurements|All participants who participated in baseline reflex measurements during week 1 will continue to the second week of the study (Visits 5-7). Participants will receive dry needling to relieve spasticity in the target calf muscle (middle gastrocnemius) during Visit 5. The study team will examine the effects of this treatment on the nervous system by performing assessments just prior to DDN, immediately after DDN, 90 minutes after DDN, 24 hours after DDN, and 72 hours after DDN. These assessments will examine how you move your leg and how your nervous system responds to non-invasive nerve stimulation.
89447896|NCT05195060||COVID-19|Patients diagnosed with COVID-19
89447897|NCT05188040|Experimental|Virtual Reality Intervention Group|Hand Therapy Exercises utilizing Oculus Quest 2 VR system with augmented feedback for patient to perform active hand therapy. Specific interventions / games will be selected by the participants individual therapist.
89447898|NCT05183932||Surgery|"Participants will have standard of care lobectomy/segmentectomy/wedge resection. Decision for treatment will be made at the discretion of the treating physician.~PROMIS instruments include 8 domains and will be completed prior to treatment, 1 month post-treatment, 6 months post-treatment, 12 months post-treatment, 24 months post-treatment, and 36 months post-treatment~Bank 2.0 - Physical Function~Bank v1.1 - Pain Interference~Bank v1.0 - Fatigue~Bank v1.0 - Depression~Bank v1.0 - Anxiety~Bank v1.0 - Dyspnea Severity~Bank v2.0 - Ability to Participate in Social Roles and Activities~Bank v2.0 - Cognitive Function"
89447899|NCT05183932||Stereotactic body radiotherapy (SBRT)|"Participants will have standard of care 1-10 fractions of radiation therapy. Decision for treatment will be made at the discretion of the treating physician.~PROMIS instruments include 8 domains and will be completed prior to treatment, 1 month post-treatment, 6 months post-treatment, 12 months post-treatment, 24 months post-treatment, and 36 months post-treatment~Bank v2.0 - Physical Function~Bank v1.1 - Pain Interference~Bank v1.0 - Fatigue~Bank v1.0 - Depression~Bank v1.0 - Anxiety~Bank v1.0 - Dyspnea Severity~Bank v2.0 - Ability to Participate in Social Roles and Activities~Bank v2.0 - Cognitive Function"
89447900|NCT05182775|Experimental|experimental group|This trial is a prospective study without a control group. It is planned to recruit 15 patients with IgA nephropathy. The experimental group received fecal bacteria transplantation through FMT capsule. The researchers will judge the effectiveness and safety of fecal bacteria transplantation in the treatment of IgA nephropathy by observing the changes of monitoring indicators before and after fecal bacteria transplantation and during follow-up. Donor screening and FMT capsule preparation were completed by Dongyuan Yikang company (www.dongyuanyikang. com).The patients participating in the trial took 16 Enterobacteriaceae capsules on day 1, day 8 and day 15 respectively as a course of treatment. The researchers will collect stool samples from patients one day before taking the medicine, one week after the last taking the medicine and one month after the last taking the medicine, and analyze the intestinal flora by sequencing
89447901|NCT05178849|Experimental|Hypnosis + local anesthasia|"As part of this project, local anesthesia will be supported by hypnosis in patients randomized to the hypnosis + AL arm, and started as soon as the patient is in prone position.~Hypnosis is a particular psychological state marked by the functioning of the individual at a level of attention other than the ordinary state of consciousness. It can, under certain conditions, give the appearance of sleep or sleepwalking without sharing all of its characteristics.~As part of care, hypnosis is widely used for pain control. The side effects reported are nil. One of its main benefits is improved patient comfort. One of its main benefits is improved patient comfort.~For the local anesthesic, the doctor uses in both arms of the study a 20 ml vial of lidocaine hydrochloride without adrenaline for injection dosed at 2%."
89447902|NCT05178849|Active Comparator|Local anesthesia|For the local anesthesic, the doctor uses in both arms of the study a 20 ml vial of lidocaine hydrochloride without adrenaline for injection dosed at 2%.
89447903|NCT05177094|Experimental|LY3526318|Participants received 250 milligram (mg) of LY3526318 orally, once daily for the first 4 weeks and were switched to placebo once daily for the next 4 weeks of the treatment period.
89447904|NCT05177094|Placebo Comparator|Placebo|Participants received placebo orally, once daily, for 8-weeks treatment period.
89447905|NCT05176574||Physicians|Physicians from 12 different specialties (i.e. General Medicine, Endocrinologists, Neurologists, Cardiologists, Orthopedists, Pathologists, Rheumatologists, Phytochemists-Pneumonologists, Vascular Surgeons, Oncologists-Pathologists, Psychiatrists, Neurologists-Psychiatrists) who manage patients with non-communicable diseases.
89447906|NCT05167786|Experimental|Aim 1: Gait Training + Stimulation|Up to 60 min of locomotion training with transcutaneous spinal cord stimulation. However, the amount of time spent in side-lying locomotion training, treadmill training and over ground training will depend on individual tolerance and progression.
89447907|NCT05167786|Active Comparator|Aim 1: Stimulation Only|Up to 60 minutes of transcutaneous spinal cord stimulation while resting in a comfortable position.
89537111|NCT03300011|Experimental|recanalisation CTO lesion successful|Patients with CTO lesion performed PCI strategy and successfully recanalisation the CTO lesion with implanted stents .
89200560|NCT05279404|Sham Comparator|Group B - Sham electroacupuncture|Sham electroacupuncture group The method was the same as that of the electroacupuncture group, but the needles were only acupuncture under the skin of Neiguan and Jianshi without twisting the needles. The electroacupuncture machine was connected but no electrical stimulation was administered.
89447908|NCT05167786|Active Comparator|Aim 1: Gait Training + Sham Stimulation|Up to 30 seconds of transcutaneous spinal cord stimulation in order to blind them to the intervention while performing locomotion training. However, the amount of time spent in side-lying locomotion training, treadmill training and over ground training will depend on individual tolerance and progression.
88933599|NCT01761214|Active Comparator|Beta-lactamase inhibitor|In the present study, amoxicillin and amoxicillin clavulanate potassium compound are employed, based on the British Thoracic Society guideline for bronchietasis, as mainly determined by sputum microbiology during steady-state bronchiectasis.
89447909|NCT05167786|Sham Comparator|Aim 1: Sham Only|Up to 60 minutes of transcutaneous spinal cord stimulation while resting in a comfortable position during which they will receive up to 30 seconds of transcutaneous spinal cord stimulation in order to blind them to the intervention.
89447910|NCT05167786|Experimental|Aim 2: Gait Training + Stimulation|Up to 60 min of locomotion training with transcutaneous spinal cord stimulation. However, the amount of time spent in side-lying locomotion training, treadmill training and over ground training will depend on individual tolerance and progression.
89447911|NCT05167786|Active Comparator|Aim 2: Gait Training + Sham Stimulation|Up to 30 seconds of transcutaneous spinal cord stimulation in order to blind them to the intervention while performing locomotion training. However, the amount of time spent in side-lying locomotion training, treadmill training and over ground training will depend on individual tolerance and progression.
89447912|NCT05165173|Experimental|Intervention|Based on estimated glomerular filtration rate (eGFR) and vitamin D levels, participants will be placed into the nanoparticle group.
89447913|NCT05165173|Active Comparator|Comparator|Based on the estimated glomerular filtration rate (eGFR) and vitamin D levels, participants will be placed into the microparticle group.
89447914|NCT05164367|Experimental|0.1 mg of atropine|1 gram of gel by topical application in the oral cavity once.
89447915|NCT05161793||CGM-Tele-monitoring Type 1|Tele-CGM-monitoring: Subjects are remotely monitored daily through a continuous glucose monitoring (CGM) system (Libre 2) that communicates via smart phone to a Libreview designed dashboard. Alerts set for: ≥4 hours without CGM signal, ≥2 hours 54-70 mg/dl, and 15 minutes <54 mg/dl. Libreview dashboard automatically emails daily alerts to the Certified Diabetes Care and Education Specialist (CDCES). If alerts occurred, the CDCES performed telemedicine outreach based on type of alert.
89447916|NCT05161793||CGM-Tele-monitoring Type 2|Tele-CGM-monitoring: Subjects are remotely monitored daily through a continuous glucose monitoring (CGM) system (Libre 2) that communicates via smart phone to a Libreview designed dashboard. Alerts set for: ≥4 hours without CGM signal, ≥2 hours 54-70 mg/dl, and 15 minutes <54 mg/dl. Libreview dashboard automatically emails daily alerts to the Certified Diabetes Care and Education Specialist (CDCES). If alerts occurred, the CDCES performed telemedicine outreach based on type of alert.
89447917|NCT05156203|Experimental|T-1301 Capsules|T-1301 Capsules will be administered orally QD or BID in a 28-day cycle (21 days on treatment followed by 7 days off treatment) in sequential cohorts.
89447918|NCT05155800||TBI patients with intracranial bleeding|
89447919|NCT05155800||TBI patients without intracranial bleeding|
89447920|NCT05155800||Control Subjects with normal brain health|
89447921|NCT05149651|Experimental|Totalfill|Totalfill® Bioceramic Root Repair Material -Fast Set Putty used as pulpotomy agent to treat extensive decayed tooth indicated for pulpotomy
89447922|NCT05149651|Active Comparator|MTA|ProRoot White MTA® used as pulpotomy agent to treat extensive decayed tooth indicated for pulpotomy
89447923|NCT05145335|Experimental|Autoregulated cuff|two sessions in which an autoregulated cuff will be used to adapt the pressure in order to keep the total pressure given constant. First session will be within a 30-15-15-15 reps protocol, the second session will be performed until max fatigue.
88933600|NCT01761227|Experimental|Fufangdanshen Tablets|1 tablets contains contains tanshinoneⅡA 0.67mg , salvianolic acid B 8.2mg, Panax Notoginsenosides R1 0.53mg, ginsenoside Rb1 3.03mg, ginsenoside Rg1 2.73mg, 3 tablets per time, 3 times per day for 24 weeks
88933601|NCT01761227|Placebo Comparator|Placebo|3 tablets per time, 3 times per day for 24 weeks. The placebo has similar smile and appearance as the Fufangdanshen Tablets
88933603|NCT01761253||Assessing costs & cost-variability|Data for the approximately 15,000 patients who were continuously enrolled during the calendar years 2006 and 2007 in the Generations Plus/ Northern Manhattan Health Network and 226,000 members of a large self insured union trust fund from 2007-2010 will be combined. The data will include age, gender, length of plan enrollment, whether or not the patient is disabled, their diagnoses, and their use of medical and social services.
88933604|NCT01761318|Active Comparator|Liraglutide|"Liraglutide: Solution for subcutaneous injection 6 mg/ml; Flexpen 3 ml.~Dose: s.c. 0,6 mg (0,1 mL) once daily. After 1 week, the dose will be increased to 1,2 mg (0,2 mL) once daily. If tolerated, after 1 week, dose will be increased to 1.8 mg (0,3 mL) once daily. In case of a hypoglycaemic episode, the dosage of oral blood glucose lowering medicaments will be adjusted first. If hypoglycaemia persists, Liraglutide / Liraglutide placebo will be adjusted on the basis of clinical parameters.~Duration: 26 weeks"
89447924|NCT05145335|Active Comparator|non-autoregulated cuff|two sessions in which an non-autoregulated cuff will be used. In these two sessions, the pressure will not be adapted. Consequently, during each muscle contraction the pressure will rise because the cuff is not autoregulated. First session will be within a 30-15-15-15 reps protocol, the second session will be performed until max fatigue.
89447925|NCT05125458||Subjects with dermatological diseases|500 Subjects attending the Dermatology outpatient clinic of the Vanvitelli University hospital with a diagnosis of psoriasis or hidradenitis suppurativa or atopic dermatitis of any grade of severity.
89447926|NCT05125458||Subjects with HIV or HBV|500 Subjects attending the Infectious diseases outpatient clinic of the Vanvitelli University hospital and with HIV or HBV infection.
89447927|NCT05125055|Experimental|Neoadjuvant TTP|The participants will receive two cycles of intravenous Albumin paclitaxel (260mg/ m^2), Cisplatin (75mg/ m^2) and Toripalimab (anti-PD-1 inhibitor, 240 mg) on d1 and d22.
89447928|NCT05125055|Active Comparator|Neoadjuvant TPF|The participants will receive two cycles of intravenous Docetaxel (75 mg/m^2) on d1 and d22, Cisplatin (75 mg/m^2) on d1 and d22, and 5-Fluorouracil (750 mg/m^2/day) for 5 days (d1-5 and d22-26), the interval is 16±1 days.
89447929|NCT05117775||Patients with all stages of HNSCC (Full analysis set)|To describe median OS by primary tumor location (oral cavity, oropharynx, larynx, and hypopharynx) in HNSCC patients after stratification for prognostic factors, including tumor stage and treatment.
89447930|NCT05117775||Patients with early and locally advanced stages|To describe clinical characteristics and treatments and to compare OS in locally advanced HNSCC patients
89447931|NCT05117775||Patients with recurrent or metastatic disease|To describe the epidemiologic and clinical characteristics, and treatment and the impact of introducing immunotherapy in recurrent or metastatic HNSCC
89447932|NCT05115955|Experimental|DS group|Combination of routine analgesic regimen and preoperative administration of 2 ml NALDEBAIN® ER Injection (150 mg Dinalbuphine Sebacate, 75 mg/ml, 2 ml/vial).
89447933|NCT05115955|Placebo Comparator|Control group|Combination of routine analgesic regimen and preoperative administration of 2 ml sesame oil (2 ml/vial).
89447934|NCT05108844|Experimental|Early small bowel investigation|Patients in the early small bowel investigation group will undergo VCE immediately after their initial negative gastroscopy
89447935|NCT05108844|Active Comparator|Colonoscopy|Participants with negative gastroscopy will undergo bowel preparation and colonoscopy the next day
89447936|NCT05107921|Experimental|Bromfenac sodium hydrate eye drops|The patients will receive bromfenac sodium hydrate eye drops twice daily for 14 days.
89014407|NCT05275140|No Intervention|Control group|The control group, the individuals will participate in the assessments (initial and final) and will be asked to maintain their usual activities. An undergraduate student (support personnel) will contact the participants by telephone (once a week) to consult them about their health status and monitor their activities. At the end of the intervention period, the control group will be invited to participate in a physical activity program that will be developed at the University based on the results of this project.
89014408|NCT05260827|Experimental|Heated tobacco product|30 puffs of heated tobacco product IQOS
89014409|NCT05260827|Experimental|Sham|sham heated tobacco product
89014410|NCT05259501|Experimental|Guided video recording with tamper-evident packaging|This method uses automated visual recognition web-based platform and QR tamper-evident labels to enhance the security of the take-home regimen currently used in methadone clinics. Single-use liquid methadone bottles are made tamper-evident through the application of a QR security label.
89014411|NCT05256381|Experimental|Nanrilkefusp Alfa and Pembrolizumab|Participants will be treated with 12 μg/kg of nanrilkefusp alfa on Day 1, Day 2, Day 8, and Day 9 of each 3-week cycle in combination with 200 mg pembrolizumab on Day 1 of each 3-week cycle.
89014412|NCT05249036|Experimental|Ultrasound guided arterial cannulation|Anaesthetist will use real-time ultrasound guidance to guide arterial cannulation
89014413|NCT05249036|Active Comparator|Palpation guided arterial cannulation|Anaesthetist will use palpation (standard-of-care) technique to guide arterial cannulation
89014414|NCT05248997|Active Comparator|rimegepant 75 mg ODT|One dose of rimegepant 75 mg ODT
89014415|NCT05248997|Active Comparator|Matching Placebo|One dose of matching placebo
89014416|NCT05244655||Patients without painscores available during hospital stay|
89014417|NCT05244655||Patients with painscores available during hospital stay|
89014418|NCT05240924|Experimental|Exposure and Response Prevention (ERP)|ERP will be based upon the Treatments That Work series, which contains both a provider manual and client workbook. Sessions will last 90 minutes and occur weekly for 16 sessions. All ERP treatment will be delivered via VTH. Participants will receive instructions on accessing the VTH platform and take part in a brief practice run connecting to the VTH appointment with guidance from an RA. ERP treatment content includes psychoeducation about OCD, assessment of OCD symptoms, the rationale for treatment, construction of a hierarchy or a list of feared or avoided situations, and in-session in-vivo and imaginal exposures. Weekly homework assignments will include self-monitoring, reading chapters about the treatment, and practicing exposures daily. All therapy sessions will be audio-recorded. Although sessions are expected to occur weekly, accounting for delays due to scheduling, holidays, and missed appointments, the investigators will allow up to 6 months to complete the treatment.
89014419|NCT05240924|Other|Control Condition|Participants randomized to the control condition will receive 16 weekly sessions of stress management training via video telehealth. This control condition was chosen because it is expected to provide the therapeutic alliance and common factors associated with therapy generally and some specific effects in anxiety reduction.
89014420|NCT05240339||PD participants with minor phenomena|
89014421|NCT05239299||Adolescents with chronic pain|
89014422|NCT05239299||Parents of adolescents with chronic pain|
89014423|NCT05239299||Health care professionals who work with adolescents with chronic pain|
89447937|NCT05104749|Experimental|Homeopathic Treatment Group|Individualized homeopathic medicines on impregnated lactose pellets will be prescribed to each participant based on the totality of their physical, emotional, and mental symptoms. All medicines prescribed are listed in the Homeopathic Pharmacopoeia of the United States (HPUS) as outlined in the Food, Drug, and Cosmetics Act of 1939
89447938|NCT05104749|Placebo Comparator|Placebo Group|Identical lactose pellets in size, odor, and taste without the impregnated homeopathic medicines.
89447939|NCT05102981||emergency stoma|an emergency procedure including stoma construction, as first procedure at or shortly after diagnosis of colon or rectal cancer
89447940|NCT05102981||Planned stoma|a planned procedure including stoma construction, as first procedure after diagnosis of colon or rectal cancer
89447941|NCT05098041|Experimental|Soticlestat 300 mg + Rifampin 600 mg|Soticlestat 3*100 mg tablets, orally, administered once on Day 1 in fasted state in Period 1, followed by a washout period of 4 days, further followed by Rifampin 600 mg, administered as 2*300mg capsules, orally, once daily for 13 consecutive days, from Day 1 to Day 13 in fasted state in Period 2. Soticlestat 3*100 mg tablets, will be administered orally along with rifampin 600 mg (2*300mg) capsules, orally in the morning of Day 11 in Period 2.
89447942|NCT05081310|Experimental|SVC arm|Patients who will receive SVC isolation by the means of cryoballoon after the PVI procedure
89447943|NCT05081310|Active Comparator|PVI arm|Patients who will receive convectional cryoballoon PVI procedure
89014424|NCT05235867||dumpers|"male and female patients~age 13-24 years~diagnosis of restrictive-type anorexia nervosa~hospitalization for nutritional support~>4 cc/kg/day of urine output (a.k.a. fluid dumpers; n=5)"
89014425|NCT05235867||non-dumpers|"male and female patients~age 13-24 years~diagnosis of restrictive-type anorexia nervosa~hospitalization for nutritional support~<2 cc/kg/d of urine output (a.k.a. non-dumpers; n=5)"
89014426|NCT05226130|Active Comparator|Active cervical transcutaneous vagus nerve stimulation|Participants will be assigned to active transcutaneous vagus nerve stimulation, received once during each of the study visits and self-administered twice a day for a week.
89014427|NCT05226130|Placebo Comparator|Sham cervical transcutaneous vagus nerve stimulation|Participants will be assigned to sham transcutaneous vagus nerve stimulation, received once during each of the study visits and self-administered twice a day for a week.
89014428|NCT05224258|Experimental|MiniMed 780G System Utilizing Insulin Fiasp|Subjects with insulin-requiring type 1 diabetes age 7-80 using the MiniMed 780G system with Insulin Fiasp® for a period of three months.
89014429|NCT05215600||Anaverse Shoulder System subjects|Subjects implanted with the Anaverse Shoulder System in the reversed configuration and subjects who underwent total shoulder arthroplasty conversion from anatomical to reversed.
89014430|NCT05213481|Experimental|Tepotinib then Carbamazepine|Participants received a single oral dose of Tepotinib 500 milligrams (mg) on Day 1 and Day 26 in the morning under fed state followed by Carbamazepine 100, 200 or 300mg oral dose under fed state twice daily at the same time each day in the morning and evening from Days 8 to Day 32
89014431|NCT05192889|Experimental|Block 1|"All eligible patients receive intervention according to the Detailed Description section with the following:~Venetoclax, Navitoclax, Dexamethasone, Vincristine, Calaspargase Pegol, Pegaspargase, Erwinia asparaginase, Dasatinib, Leucovorin, Intrathecal (IT) MHA (methotrexate/hydrocortisone/cytarabine)"
89014432|NCT05192889|Experimental|Block 2|"Block 2a Therapy:~Patients receive intervention according to the Detailed Description section with the following:~Venetoclax, Navitoclax, Dexamethasone, Cytarabine, Calaspargase Pegol, Pegaspargase, Erwinia asparaginase, Dasatinib, IT MHA, Radiation~Block 2b Therapy:~Patients receive intervention according to the Detailed Description section with the following:~Venetoclax, Blinatumomab, Dexamethasone, Dasatinib, IT MHA~Following Block 2 of therapy, late (≥36 months from diagnosis) first relapse B-ALL who are MRD negative after Block 1 will continue chemotherapy using adapted R3 intensification, interim, and continuation therapies.~Patients receive intervention according to the Detailed Description section with the following:~Methotrexate, Mercaptopurine, IT MHA, Leucovorin, Dexamethasone, Vincristine, Cyclophosphamide, Etoposide, Cytarabine, Dasatinib, Calaspargase Pegol, Pegaspargase, Erwinia asparaginase, Radiation"
89014433|NCT05191264||percutaneous osteosynthesis and cementoplasty procedure|"Patient with percutaneous osteosynthesis and cementoplasty procedure will be included.~Patients have assessed for pain and quality of life during consultations as part of an interventional radiology procedure (pre-procedure consultation, and follow-up consultations at 1, 3, 6 and 12 months after the procedure."
89014434|NCT05179551|Experimental|Proximal Medial Gastrocnemius Recession Surgery|Patients will be operated with Proximal Medial Gastrocnemius Recession Surgery (PMGR) ad modum Barouk.
89014435|NCT05176639|Experimental|Phase 1/2 MAD (HV and TED)|Healthy participants and participants with TED will be randomized to receive two intravenous infusions of VRDN-001 or placebo with an interval of 3 weeks.
89447944|NCT05079984|Experimental|Graded Exposure Intervention|For Aim 2, adolescents with chronic pain will be enrolled in a single-arm feasibility trial examining acceptability, feasibility, and preliminary effectiveness of a novel, digitally delivered, graded exposure treatment.
89014436|NCT05176639|Experimental|Phase 3 Cohort (THRIVE)|Participants with TED will be randomized to either VRDN-001 10mg/kg or placebo.
89014437|NCT05172596|Experimental|PHE885|Patients will receive PHE885
89447945|NCT05076838|Experimental|Valtoco In Pediatric Subjects with Epilepsy|5 mg, 10 mg, or 15 mg dose of intranasal VALTOCO will be administered based on the subject's body weight.
89447946|NCT05076279|Experimental|Single port or reduced ports|Single port or reduced ports laparoscopic distal gastrectomy and D2 lymph node dissection
89447947|NCT05069857|Experimental|Neoadjuvant arm|The patients received three cycles of neoadjuvant therapy, with 14 days each. Dosage and administration: 200mg Carrelizumab intravenously on the first day of each cycle; Apatinib orally 250mg once a day from the first day of each cycle until the 9th day of the third cycle. Then the patients received the standard treatment of surgery and postoperative adjuvant therapy of radiotherapy or chemoradiotherapy.
89447948|NCT05069857|No Intervention|Control arm|The patients received the standard treatment of surgery and postoperative adjuvant therapy of radiotherapy or chemoradiotherapy.
89447949|NCT05068674|Active Comparator|Cohort 1|Low dose (50M cells)
89447950|NCT05068674|Active Comparator|Cohort 2|Medium dose (150M cells)
89447951|NCT05068674|Active Comparator|Cohort 3|High dose (300M cells)
89447952|NCT05059275|Experimental|Modified operation group|Undergo the modified ostium obstruction surgery due to symptomatic TCs.
89447953|NCT05049863|Experimental|Phase I Dose Level 1a: MMF + Irinotecan + Allopurinol|-Mycophenolate mofetil (MMF) will be administered at a dose of 1 g TID (3 g/day) on a daily basis (Days 1 through 21). Allopurinol will be administered at dose of 300 mg/day on a daily basis (Days 1 through 21). Irinotecan will be given at 90 mg/m^2 on Days 1 and 8. Cycles are 21 days.
89447954|NCT05049863|Experimental|Phase I Dose Level 1: MMF + Irinotecan + Allopurinol|-Mycophenolate mofetil (MMF) will be administered at a dose of 1 g TID (3 g/day) on a daily basis (Days 1 through 21). Allopurinol will be administered at dose of 300 mg/day on a daily basis (Days 1 through 21). Irinotecan will be given at 100 mg/m^2 on Days 1 and 8. Cycles are 21 days.
89447955|NCT05049863|Experimental|Phase II: MMF + Irinotecan + Allopurinol|-Mycophenolate mofetil (MMF) will be administered at a dose of 1 g TID (3 g/day) on a daily basis (Days 1 through 21). Allopurinol will be administered at dose of 300 mg/day on a daily basis (Days 1 through 21). Irinotecan will be given at the assigned dose level on Days 1 and 8. Cycles are 21 days.
89447956|NCT05035251||experimental|patients with a condition
88933605|NCT01761318|Placebo Comparator|Liraglutide-placebo|"Liraglutide placebo: Solution for injection; Flexpen 3 ml.~Dosage: same as Liraglutide~Duration: 26 weeks"
88933606|NCT01761331|Active Comparator|Group A: Standardized acupuncture|Infants come to the clinic twice a week for three weeks. Parents meet a nurse and hand the infant to her. The nurse brings the infant to a room where another nurse, trained in acupuncture, is alone with the infant for five minutes. Intervention: Infants in the standardized acupuncture group get minimal acupuncture: one needle is inserted about 3 mm in the point LI4 on the infants hands, unilaterally, for 2-10 seconds and then withdrawn.
88933607|NCT01761331|Active Comparator|Group B: Individualized acupuncture|Infants come to the clinic twice a week for three weeks. Parents meet a nurse and hand the infant to her. The nurse brings the infant to a room where another nurse, trained in acupuncture, is alone with the infant for five minutes. Infants in the individualized acupuncture group get acupuncture in points chosen by the acupuncturists according to symptoms: maximum 5 needles are inserted about 3 mm in points recommended in a guideline produced for the trial. Needles are retained for maximum one minute.
88933608|NCT01761331|No Intervention|Group C: No acupuncture|Infants come to the clinic twice a week for three weeks. Parents meet a nurse and hand the infant to her. The nurse brings the infant to a room where another nurse, trained in acupuncture, is alone with the infant for five minutes. The nurse hold the infant´s hand and talks to it but no acupuncture is given.
88933609|NCT01761344|Experimental|Intraoperative measurement of cortisol|Intervention: During a routine procedure intraoperative cortisol is measured. Upon unsuccessful sampling, the sampling will be repeated.
88933610|NCT01761370|Active Comparator|Treatment|AHA diet plus exercise with BIB placement
89447957|NCT05035251||control|patients without condition
89447958|NCT05027282|Experimental|CLEAR + BRILLIANT TOUCH(R) 1440-nm and 1927-nm handpieces|
89447959|NCT05026008|Experimental|SR1375 Capsule|Ascending single and multiple doses of SR1375 capsules orally
89447960|NCT05026008|Experimental|Matching placebo|Ascending single and multiple doses of placebo capsules orally
89447961|NCT04996693|Other|Scanner 1|Imaging performed on scanner 1: Photon-Counting Detector CT
89447962|NCT04996693|Other|Scanner 2|Imaging performed on scanner 2: Energy-Integrating Detector CT (128-slice)
89447963|NCT04996693|Other|Scanner 3|Imaging performed on scanner 3: Energy-Integrating Detector CT (20-slice)
89447964|NCT04995627|Active Comparator|Salt (NaCl)|"12 grams (12 capsules) of NaCl per day~Note: participants will be treated with active and placebo comparator (N-of-1 trial design)"
89447965|NCT04995627|Placebo Comparator|Placebo|"12 capsules of placebo per day~Note: participants will be treated with active and placebo comparator (N-of-1 trial design)"
89447966|NCT04993313|Experimental|Arm I (counseling, photo guide)|Patients undergo verbal counseling and view a photo guide. Patients also complete questionnaires at 2 weeks, 6 and 12 months.
89447967|NCT04993313|Active Comparator|Arm II (counseling)|Patients undergo verbal counseling. Patients also complete questionnaires at 2 weeks, 6 and 12 months.
89447968|NCT04987658|Experimental|Group 1 Olanzapine/ 5 mg Samidorphan|Olanzapine will be gradually increased to a target dose of 10mg/samidorphan 5mg (Range: 5-20mg Olanzapine/samidorphan 5mg)
89447969|NCT04987658|Experimental|Group 2 Olanzapine/ 10mg Samidorphan|Olanzapine will be gradually increased to a target dose of 10mg/samidorphan 10mg (Range: 5-20mg Olanzapine/samidorphan 10mg)
89447970|NCT04987229|Experimental|All subjects|All subjects will receive OLZ/SAM at a dose determined by the Investigator and based on the olanzapine dosing received in the antecedent study (ALKS 3831-A311 or ALKS 3831-A312 ENLIGHTEN-Youth)
89447971|NCT04981067|Other|Sciatic nerve block using same or decreased concentration of local anesthetic|If the sciatic nerve block in the previous participant was successful, the concentration of local anesthetic would be maintained or decreased 0.05% in the next patient based on a random assignment.
89447972|NCT04981067|Other|Sciatic nerve block using increased concentration of local anesthetic|If the sciatic nerve block in the previous participant was not successful, the concentration of local anesthetic would be increased 0.05% in the next patient.
89447973|NCT04980703|Experimental|Grain moxibustion|Grain moxibustion +standard care
89447974|NCT04980703|Sham Comparator|Sham grain moxibustion|Sham grain moxibustion +standard care
89447975|NCT04980703|Other|Wait-list control|Standard care
89447976|NCT04977882|Experimental|Abdominal drainage|19 Fr abdominal drainage placed intraoperatevely in right paracolic gutter
89447977|NCT04977882|Experimental|Postoperative antibiotico-prophylaxis|postoperative antibiotico-prophylaxis with Ceftriaxone 2gr and Metronidazole 1.5gr
89447978|NCT04977882|Sham Comparator|Control group|No drainage nor postoperative antibiotico-prophylaxis
89447979|NCT04965597|Experimental|Treatment (conditioning regimen; transplant; GVHD prophylaxis)|"CONDITIONING REGIMEN: Patients receive treosulfan IV over 120 minutes on days -6 to -4, fludarabine phosphate IV over 60 minutes on days -6 to -2, and rATG IV over 4-6 hours on days -4 to -2.~TRANSPLANTATION: Patients undergo bone marrow or peripheral blood stem cell transplant on day 0.~GVHD PROPHYLAXIS: Patients receive tacrolimus IV continuously beginning on day -2 and a taper beginning on day 180. Patients may also receive tacrolimus PO. Patients also receive methotrexate IV on days 1, 3, 6, and 11.~Patients undergo ECHO or MUGA during screening and undergo bone marrow biopsy and aspiration at baseline and follow up. Patients may optionally undergo blood sample collection throughout the trial."
89447980|NCT04963803|Experimental|Active transcranial direct current stimulation (tDCS) paired with speech-language therapy|Active transcranial direct current stimulation (tDCS) will be delivered using a Soterix mini-CT device. Participants receiving this treatment will be administered 2 milliamperes (mA) of current for 20 minutes/session with the anode electrode placed over F3 and the cathode electrode placed over Fp2 (according to the 1020 system). The tDCS will be paired with 60 minutes of speech-language therapy focusing simultaneously improving auditory comprehension and behavioral attention. All study participants will receive 10 sessions of this combination treatment with no more than one session per day 2-3 times per week.
89447981|NCT04963803|Sham Comparator|Sham transcranial direct current stimulation (tDCS) paired with speech-language therapy|Sham transcranial direct current stimulation (tDCS) will be delivered using a Soterix mini-CT device. Participants receiving this treatment will be administered 2 milliamperes (mA) of current for 1 minute to simulate the experience of tDCS, after which the current will be ramped down to zero for the remaining 19 minutes of the session with the anode electrode placed over F3 and the cathode electrode placed over Fp2 (according to the 1020 system). The tDCS will be paired with 60 minutes of speech-language therapy focusing simultaneously improving auditory comprehension and behavioral attention. All study participants will receive 10 sessions of this combination treatment with no more than one session per day 2-3 times per week.
88933611|NCT01761370|Sham Comparator|Sham control|AHA diet plus exercise with sham BIB placement
88933612|NCT01761383|Experimental|Nintendo Wii and Chronic Schizophrenia|Participants enrolled in the study will be provided with the Nintendo Wii console and Nintendo Wii Fit Plus video games to use for the duration of the study (6 months) with no restrictions or limitations on the games participants are allowed to play or duration of play. There will be 5 home visits over a 6-month period to evaluate Nintendo Wii use and assess patients'health, functioning and quality of life with the use of self report questionnaires and psychiatric assessment.
89447982|NCT04963374||respiratory inpatient|respiratory inpatient with VTE
88933613|NCT01761396|Experimental|CBT|Cognitive behavioral therapy
88933614|NCT01761396|Active Comparator|UC|Usual care
89447983|NCT04963127||Prospective Cohort|400 patients who are scheduled to undergo a clinically requested CT scan of parts of the skeleton using a Dual-Energy/Multi-Energy/Spectral acquisition mode to exclude or further define bone fractures.
89447984|NCT04963127||Retrospective Cohort|400 patients who had undergone a clinically requested CT scan of the skeleton in standard acquisition mode in the past to exclude or further define bone fractures.
89447985|NCT04956536||Group 1|Anterior cruciate ligament-injured patients
89447986|NCT04951999|Other|Blood sampling|
89447987|NCT04949542|Experimental|Bolster|Participants in the experimental arm will be provided access to the Bolster smartphone application designed to support caregivers of young adults with early psychosis. They will also have access to the research team by phone for technical troubleshooting and support as necessary.
89447988|NCT04949542|Other|Control|Participants in the control condition will be provided support resources from mental health advocacy organizations representing currently available resources for caregivers (including a selection from the National Alliance on Mental Illness and Mental Health America). They will also have access to the research team by phone for technical troubleshooting and support as necessary.
89447989|NCT04946084|Other|Healthy Children|Samples taken from nasal swabs, nasal wash, blood draws and in the case of acute otitis media, tympanocentesis
89447990|NCT04944693||Cohort 1|Anterior cruciate ligament-injured patients with excessive ATS
89447991|NCT04944693||Cohort 2|Anterior cruciate ligament-injured patients with minimal ATS
88933615|NCT01761435|Experimental|Influenza vaccine, second administration after 5 weeks|Drug: Influenza vaccine (split virion, inactivated) suspension for injection 0.5ml at the baseline and 5 weeks after the first one.
88933616|NCT01761435|Active Comparator|Influenza vaccine|Drug: Influenza vaccine (split virion, inactivated) suspension for injection 0.5ml at the baseline.
88933617|NCT01761448|Experimental|Device Guided Exercise|Both intervention and control group undergo a baseline evaluation and an end evaluation including tests of the clinical routine like cardiopulmonary test (CPX), echocardiography and lactate measurement. They will also answer questionnaires referring to quality of life and the use of the system. During the training phase at home the interventional group will test the supervised training system during endurance training such as running, biking or walking and during resistance training such as performing exercise with rubber bands (at least 3x a week for about 5-6 months according to the generated prescription plan during training at the hospital). They will report their daily activity by diary. The control group will only report their physical activities by diary without using the Gex- System. At the end data are investigated to determine whether the supervised training with the GEx- System will improve the physical capacities of patients.
89447992|NCT04931745|Experimental|Virtual Reality|The Oculus 2 headset will be used during port access. The device features a stereoscopic display mounted on a lightweight wireless head mounted display weighing 503 g with built-in 3D audio and an adjustable head strap and adjustable lens distance. The software used will be the Might Pebbles VR Game developed by ManageXR. It is a child-friendly VR game that does not require the use of hand controllers. It also provides an option to increase the cognitive load, making it appropriate for children of all ages. The experimental group will be given up to 10 minutes to familiarize themselves with the device, assisted by the research assistant and will begin using it 5-10 minutes prior to port access. Most participants will receive topical anesthestic in the form of 4% amethocaine (Ametop), eutectic mixture of lidocaine and amethocaine (EMLA), or 4% lidocaine (Maxilene) as per standard practice at our institution. However, some participants may refuse this co-intervention.
88933618|NCT01761461|Experimental|Arm A|S-1 40-60mg BID (4weeks - 2weeks off) x 8 cycles
88933619|NCT01761461|Active Comparator|Arm B|{S-1 40-60mg BID (2weeks - 1week off) + Oxaliplatin 130mg/m2 q 3 week} x 8 cycles
89447993|NCT04931745|Active Comparator|Tablet|The child will watch a video on a tablet or iPad that is appropriate for their age during port access. They will begin using it 5-10 minutes prior to port access. The content of the video will be at the discretion of the child life specialist, nurse, or caregiver. Most participants will receive topical anesthestic in the form of 4% amethocaine (Ametop), eutectic mixture of lidocaine and amethocaine (EMLA), or 4% lidocaine (Maxilene) as per standard practice at our institution. However, some participants may refuse this co-intervention.
89447994|NCT04931745|Active Comparator|No or non-technologic distraction|This is no distraction or non-technologic distraction measures such as bubbles, etc., facilitated by the child life specialist, nurse, or caregiver during port access. The measure will be documented for the purposes of analysis. They will begin using it 5-10 minutes prior to port access. Most participants will receive topical anesthestic in the form of 4% amethocaine (Ametop), eutectic mixture of lidocaine and amethocaine (EMLA), or 4% lidocaine (Maxilene) as per standard practice at our institution. However, some participants may refuse this co-intervention.
88933620|NCT01761461|Active Comparator|Arm C|{S-1 40-60mg BID (2weeks - 1week off) + Oxaliplatin 130mg/m2 q 3 weeks} x 2 cycles → S-1 40mg BID (2weeks - 1week off - 2weeks)+ RT 45 Gy (5weeks) → Rest for 4 weeks → {S-1 40-60mg BID (2weeks - 1week off) + Oxaliplatin 130mg/m2 q 3 weeks} x 4 cycles
89447995|NCT04930978||TB patients with SARS-CoV-2 PCR+|50 TB patients with SARS-CoV-2 PCR+ will be recruited in group 1
89447996|NCT04930978||TB patients with SARS-CoV-2 Ab+|100 TB patients with SARS-CoV-2 Ab+ will be recruited in group 2
89447997|NCT04930978||TB patients negative for SARS-CoV-2 PCR and Ab|100 TB patients with SARS-CoV-2 PCR and Ab negative will be recruited in group 3
89447998|NCT04927637||Orthopedic Infection|Subjects who have undergone previous orthopaedic trauma surgery and have developed and infection will be assessed for protocol inclusion criteria. Patients who meet all inclusion criteria and no exclusion criteria will be administered a single dose 2.5-5 mg/kg ICG dose intravenously ideally 24h prior to surgical debridement. Fluorescent images will be obtained pre and post irrigation and debridement
89447999|NCT04912817|Experimental|Off the Shelf VR (PR-VR program + usual care)|"One session per week x 4 weeks; total 4 sessions over 1 month~PR-VR program (30 min) + Usual care (30 min SVPT)~Total intervention time = 4 hours~10 selected for post-study telephone interview"
89014438|NCT05166980|Experimental|FePP-Q5S|Salt fortified with iron in the form of ferric pyrophosphate (at 1.3 mg of iron per gram of salt) plus ethylenediaminetetraacetic acid (EDTA) as an enhancer of absorption, zinc in the form of zinc oxide (at 1.4 mg of zinc per gram of salt), vitamin B12 (at 0.6 ug of vitamin B12 per gram of salt), folic acid (at 52 ug per gram of salt) and iodine (at 30 mg of iodine per gram of salt). Mean intake of discretionary salt among women of reproductive age in the study area is 4.6 grams per day. Therefore, the FePP-Q5S will deliver an average of 6.0 mg of iron, 6.4 mg of zinc, 2.8 ug of vitamin B12, 241 ug of folic acid, and 138 mg of iodine to each participating woman per day.
89014439|NCT05166980|Experimental|eFF-Q5S|Salt fortified with iron in the form of encapsulated ferrous fumarate (at 1.3 mg of iron per gram of salt), zinc in the form of zinc oxide (at 1.4 mg of zinc per gram of salt), vitamin B12 (at 0.6 ug of vitamin B12 per gram of salt), folic acid (at 52 ug per gram of salt) and iodine (at 30 mg of iodine per gram of salt). Mean intake of discretionary salt among women of reproductive age in the study area is 4.6 grams per day. Therefore, the eFF-Q5S will deliver an average of 6.0 mg of iron, 6.4 mg of zinc, 2.8 ug of vitamin B12, 241 ug of folic acid, and 138 mg of iodine to each participating woman per day.
89014440|NCT05166980|Active Comparator|Iodized Salt|Iodized salt containing 30 mg of iodine per gram of salt. Mean intake of discretionary salt among women of reproductive age in the study area is 4.6 grams per day. Therefore, the iodized salt will deliver an average of 138 mg of iodine to each participating woman per day.
89014441|NCT05166889|Experimental|Tozorakimab Dose 1|Dosing subcutaneously tozorakimab Dose 1 and placebo
89014442|NCT05166889|Experimental|Tozorakimab Dose 2|Dosing subcutaneously tozorakimab Dose 2
89014443|NCT05166889|Placebo Comparator|Placebo|Dosing subcutaneously with equivalent volume to tozorakimab
89014444|NCT05162144|Experimental|Proximal Medial Gastrocnemius Recession Surgery|All patients included in the Cohort Study will recieve this PMGR-surgery
89014445|NCT05158387|Experimental|Tozorakimab Dose 1|Dosing subcutaneously tozorakimab Dose 1 and placebo
89014446|NCT05158387|Experimental|Tozorakimab Dose 2|Dosing subcutaneously tozorakimab Dose 2
89014447|NCT05158387|Placebo Comparator|Placebo|Dosing subcutaneously with equivalent volume to tozorakimab
89448000|NCT04912817|Experimental|Custom VR (Modified PR-VR program + usual care)|"One session per week x 4 weeks; total 4 sessions over 1 month~Mod PR-VR program (30 min) + Usual care (30 min SVPT)~Total intervention time = 4 hours~10 selected for post-study telephone interview"
89448001|NCT04912817|No Intervention|Standard Virtual Physiotherapy Treatment (control; usual care),|"One session per week x 4 weeks; total 4 sessions over 1 month~Usual care (60 min SVPT)~Total intervention time = 4 hours"
89448002|NCT04907669|Experimental|Group 1a|After recruitment and baseline survey, participants will be randomized into Group 1 and Group 2. In Group 1, participants will receive brief contact intervention (BCI) monthly. If participants' suicide risk increased at 3 months after discharge, they will be re-randomized into Group 1a and Group 1b to receive BCIs weekly (Group 1a) and bi-weekly (Group 1b).
89014448|NCT05155709|Experimental|Arm 1: Unfit adult participants with AML who responded sub-optimally to standard of care|Unfit adult participants with AML who responded sub-optimally to at least 2 and not more than 4 cycles ( 1 cycle=28 days) of first-line venetoclax plus azacitidine therapy
89014449|NCT05155709|Experimental|Arm 2: Newly diagnosed unfit adult participants with high-risk AML|Unfit adult participants with newly diagnosed AML and with adverse genetic risk stratification (according to ELN 2022)(Except TP53 mutation positive participants).
89014450|NCT05147792|Experimental|CLAAS|Transcatheter left atrial occluder
89014451|NCT05147792|Active Comparator|WATCHMAN / Amulet|Transcatheter left atrial occluder
89014452|NCT05147636|Experimental|PEEP Extubation With Positive End-Expiratory Pressure|endo-tracheal aspiration followed by the application of PEEP = 10 cm of H2O, maintained for 3 minutes (reventilation and rest time) and continued until the end of the procedure removal of the extubation
89448003|NCT04907669|Experimental|Group 1b|After recruitment and baseline survey, participants will be randomized into Group 1 and Group 2. In Group 1, participants will receive brief contact intervention (BCI) monthly. If participants' suicide risk increased at 3 months after discharge, they will be re-randomized to receive BCIs weekly (Group 1a) and bi-weekly (Group 1b).
89448004|NCT04907669|Experimental|Group 1c|After recruitment and baseline survey, participants will be randomized into Group 1 and Group 2. In Group 1, participants will receive brief contact intervention (BCI) monthly. If participants' suicide risk decreased or did not change, they will remain receiving BCIs monthly as Group 1c.
89448005|NCT04907669|Experimental|Group 2a|After recruitment and baseline survey, participants will be randomized into Group 1 and Group 2. In Group 2, participants will receive brief contact intervention (BCI) weekly. If the suicide risk increased or did not change, they will remain receiving BCIs weekly as Group 2a.
89448006|NCT04907669|Experimental|Group 2b|After recruitment and baseline survey, participants will be randomized into Group 1 and Group 2. In Group 2, participants will receive brief contact intervention (BCI) weekly. If the suicide risk decreased, they will be re-randomized to receive BCIs monthly (Group 2b) and bi-weekly (Group 2c).
89448007|NCT04907669|Experimental|Group 2c|After recruitment and baseline survey, participants will be randomized into Group 1 and Group 2. In Group 2, participants will receive brief contact intervention (BCI) weekly. If the suicide risk decreased, they will be re-randomized to receive BCIs monthly (Group 2b) and bi-weekly (Group 2c).
89448008|NCT04905810|Experimental|Treatment (azacitidine, decitabine, venetoclax)|Patients receive azacitidine IV over 10-40 minutes or SC on days 1-7 (for patients with prior decitabine use), or decitabine IV on days 1-5 (for patients with prior azacitidine), and venetoclax PO daily on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89448009|NCT04893421|No Intervention|Standard of Care WGS or RSL|Patients will undergo the institutional standard of care approach (WGS or RSL) for BCS. For WGL, a hooked wire will be implanted to mark the center or outer edges of the lesion under imaging guidance. For RSL, patients will be implanted with a radioactive seed using an impregnated needle under imaging guidance. A special handheld probe will be used to find the radioactive seed during the lumpectomy surgery.
89448010|NCT04893421|Experimental|MOLLI Localization|Patients will be implanted with a MOLLI seed using a specialized introducer needle under imaging guidance. A special handhold probe and detection system will be used intraoperatively to assist in excision.
89448011|NCT04892342|Experimental|ESG401 dose level 1|
89448012|NCT04892342|Experimental|ESG401 dose level 2|
89448013|NCT04892342|Experimental|ESG401 dose level 3|
89448014|NCT04892342|Experimental|ESG401 dose level 4|
89014453|NCT05147636|Active Comparator|Aspiration Extubation With SUctioning|endo-tracheal aspiration concomitant with removal of extubation. Suction is maintained throughout the intubation tube ablation procedure
89448015|NCT04892342|Experimental|ESG401 dose level 5|
89448016|NCT04892342|Experimental|ESG401 dose level 6|
89448017|NCT04891809|Experimental|IRd followed by IR|Induction: 8 cycles isatuximab+lenalidomide+dexamethasone; Maintenance: up to 24 cylces isatuximab+lenalidomide
89448018|NCT04891809|Other|Rd followed by R|Induction: 8 cycles lenalidomide+dexamethasone; Maintenance: up to 24 cylces lenalidomide
89448019|NCT04883242|Experimental|Treatment (isatuximab, carfilzomib, pomalidomide, steroid)|"INDUCTION: Patients receive isatuximab IV on days 1, 8, 15, and 22 of cycle 1 and days 1 and 15 of subsequent cycles carfilzomib IV over 30 minutes on days 1, 8, and 15, pomalidomide PO QD on days 1-21, and dexamethasone PO or IV on days 1,8, 15, and 22. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive isatuximab IV days 1 and 15, carfilzomib IV over 30 minutes on days 1 and 15, pomalidomide PO QD on days 1-21, and dexamethasone PO or IV on days 1, 8, 15, and 22. Cycles repeat every 28 days for up to 24 months in the absence of disease progression or unacceptable toxicity."
89448020|NCT04881019||Type 2 Diabetes|Individuals who have been diagnosed with Type 2 diabetes.
89448021|NCT04881019||Non type 2 diabetes|Individuals who have not been diagnosed with Type 2 diabetes.
89448022|NCT04864067|Experimental|Short Course Radiotherapy and Consolidation Chemotherapy|This arm will receive short course radiotherapy (5x5 Gy) during 1 week. Between 7 to 14 days after radiotherapy, patient will receive 9 cycles of FOLFOX. CapeOX may be given as alternative for FOLFOX.
88933621|NCT01761474||1. Carbon dioxide insufflation with BPS|Both midazolam (0.05 mg/kg body weight; 1 mg if age[70 or ASA class III-IV) and fentanyl (50 lg; 25 lg if age[70 or ASA class III-IV) were given intravenously at the initiation of sedation. Thereafter, repeated doses of 10-20 mg propofol were administered to achieve a moderate level of sedation. Maintenance of sedation was also performed with repeated doses of 10-20 mg propofol.
88933622|NCT01761474||2. Carbon dioxide insufflation with Propofol|Sedation was induced by intravenous bolus injection of propofol (0.5 mg/kg body weight; 10 mg if age[70 or ASA class III-IV), followed by repeated doses of 10-20 mg propofol to induce sedation. Repeated doses of 10-20 mg propofol were then administered to maintain adequate sedation, according to the desired sedation depth and patient risk profile.
88933623|NCT01761474||3. Air insufflation with BPS|Both midazolam (0.05 mg/kg body weight; 1 mg if age[70 or ASA class III-IV) and fentanyl (50 lg; 25 lg if age[70 or ASA class III-IV) were given intravenously at the initiation of sedation. Thereafter, repeated doses of 10-20 mg propofol were administered to achieve a moderate level of sedation. Maintenance of sedation was also performed with repeated doses of 10-20 mg propofol.
88933624|NCT01761474||4. Air insufflation with Propofol|Sedation was induced by intravenous bolus injection of propofol (0.5 mg/kg body weight; 10 mg if age[70 or ASA class III-IV), followed by repeated doses of 10-20 mg propofol to induce sedation. Repeated doses of 10-20 mg propofol were then administered to maintain adequate sedation, according to the desired sedation depth and patient risk profile.
88933625|NCT01761487|Other|One arm only - Gentamicin and polymyxin E|All subjects will receive:Gentamicin and polymyxin E paste applied on buccal surface four times daily + gentamicin + polymyxin E PO + Strict contact precautions
88933626|NCT01761500|Other|Modified BFM-90 protocol|Using the Modified BFM-90 protocol to treat Chinese children and adolescents with NHL
88933627|NCT01761513|Experimental|Sequence 1|
88933628|NCT01761513|Experimental|Sequence 2|
88933629|NCT01761513|Active Comparator|Sequence 3|
88933630|NCT01761513|Active Comparator|Sequence 4|
88933631|NCT01761526|Experimental|Rotigotine in Healthy Japanese|"Rotigotine transdermal patch~Single dose application of 2 mg / 24 hours Rotigotine in Healthy Japanese subjects~Transdermal patch over 24 hours"
88933632|NCT01761526|Experimental|Rotigotine in Caucasian|"Rotigotine transdermal patch~Single-Dose application of 2 mg / 24 hours Rotigotine in healthy Caucasian subjects~Transdermal patch over 24 hours"
88933633|NCT01761539|Experimental|Aggressive Hydration|Receives Lactated Ringers solution at 3cc/kg/hr following an initial 20cc/kg bolus.
88933634|NCT01761539|Active Comparator|Moderate Hydration|Receives Lactated Ringers solution at 1.5cc/kg/hr following an initial 10cc/kg bolus.
88933635|NCT01761552|Experimental|Sugammadex (tradename Bridion)|
88933636|NCT01761552|Active Comparator|Traditional reversal or spontaneous recovery:|Atropine/Neostigmine: Atropine, 0.02 mg/ kg, and Neostigmine,0.05 mg/kg diluted in 100 ml Normal Saline and given over a 10 min drip. Reversal will be given only recommended if spontaneous recovery has occurred up to the reappearance of T2 (shallow blockade) following rocuronium induced blockade.
88933637|NCT01761578|Experimental|ART18Z Bioresorbable stent|
88933638|NCT01761591|Experimental|Acrobat|Device: PCI with Svelte Acrobat
88933639|NCT01761591|Active Comparator|Control BMS|Device: PCI with other BMS
88933640|NCT01761604|Other|Nasal ganglion block for TN|Sphenopalatine ganglion block using the Tx360™ device
88933641|NCT01761617|Active Comparator|Yoga Class Twice Per Week|Participants attend two hatha yoga classes each week for 12 weeks.
88933642|NCT01761617|Active Comparator|Yoga Class Once per Week|Participants attend one hatha yoga class each week for 12 weeks.
88933643|NCT01761630||Severe Asthma|"We will classify subjects as having severe asthma using the following stages:~Stage 1: Subjects must have asthma which requires treatment with high-dose inhaled corticosteroids plus a 2nd controller, or systemic corticosteroids with or without a 2nd controller to prevent it from becoming uncontrolled or which remains uncontrolled despite this therapy~Stage 2: Assess for uncontrolled asthma by any one of the following criteria:~Poor symptom control evidenced by an Asthma Control Questionnaire score consistently > 1.5 or an Asthma Control Test Score < 20 or not well controlled by NAEPP or GINA asthma treatment guidelines~Frequent severe exacerbations as reflected by ≥ 2 bursts of systemic corticosteroids (> 3 days each) in the previous 12 months~Serious exacerbations reflected by at least one hospitalization, ICU stay or mechanical ventilation in the previous 12 months~Presence of airflow limitation evidenced by FEV1 < 80% predicted (in the face of reduced FEV1/FVC)"
88933644|NCT01761630||Non-severe Asthma|Those with mild-to-moderate persistent asthma as defined by the NAEPP EPR-3 guidelines.
88933645|NCT01761630||Healthy Control|"The purpose of the SARP Control Sub-study is to generate reference data for outcomes measured in biospecimens collected from asthmatic subjects enrolled in the SARP Longitudinal Protocol.~Seven healthy subjects between the ages of 18-65 will be enrolled."
88933646|NCT01761656|Experimental|loading dose atorvastatin|For the arm of loading dose atorvastatin, patients will be treated with 80 mg atorvastatin 12 hours before PCI and 40 mg atorvastatin 2 hours before PCI and then 20mg/d after PCI.
88933647|NCT01761656|Active Comparator|conventional dose atorvastatin|For the arm of conventional dose atorvastatin, patients will be treated with 20 mg atorvastatin 12 hours before PCI and then 20mg/d after PCI.
88933648|NCT01761669||healthy voulnters|
88933649|NCT01761682||Ph-ALL|Diagnosed as ALL with Philadelphia-negative
88933650|NCT01761682||Ph+ALL|Diagnosed as ALL with Philadelphia-positive (including biphenotypic acute leukemia with Philadelphia-positive)
88933651|NCT01761682||Other ALL|Diagnosed as ALL of other type, including Burkitt leukemia
88933652|NCT01761695||CML CP|Diagnosed as CML with chronic phase
89448023|NCT04859504|Active Comparator|Active tACS|Active tACS will be applied twice daily for 5 days. In each session, dual-channel high-density theta(7Hz) tACS stimulations will be delivered over the right DLPFC (one anodal electrode at F4, between -1.2mA and 1.2 mA; two cathodal electrodes at AF4 and FC6, between -0.6mA and 0.6mA) and cerebellum (one anodal electrode at Oz, between -1 mA and 1mA; two cathodal electrodes at PO3 and PO4, between -0.5mA and 0.5mA) lasting 20 minutes.
89448024|NCT04859504|Sham Comparator|Sham tACS|Sham tACS will be also applied twice daily for 5 days.The parameters of tACS electrodes numbers, locations, and current duration are all the same with active tACS. But sham tACS begin with a fade in over 3s to the peak, followed immediately by no current stimulation for 20 minutes and a fade out of 3s.
88933653|NCT01761695||CML AP|Diagnosed as CML with accelerated phase
88933654|NCT01761695||CML BC|Diagnosed as CML with blast crisis
88933655|NCT01761695||CML other|Diagnosed as CML, which is not included in any of other category
88933656|NCT01761708||umbilical, epigastric and trocar-site hernia|
88933657|NCT01761721||RAHL|Women suspected of endometrial cancer planned to be treated by robotic assisted laparoscopy hysterectomy
88933658|NCT01761734|Experimental|text message|receipt of text message
88933659|NCT01761734|No Intervention|usual care|usual care
88933660|NCT01761760|Experimental|Contingent|"Patients will earn game-based incentives contingent on meeting carbon monoxide goals.~Behavioral: Videogame-based smoking cessation intervention"
88933661|NCT01761760|Active Comparator|Non-contingent|"Patients will earn game-based incentives independent of meeting carbon monoxide goals.~Behavioral: Videogame-based smoking cessation intervention"
88933662|NCT01761773|Experimental|Group 1|Subjects with normal renal function: healthy normal adult subjects with an eGFR ≥ 90 mL/min/1.73m2.
88933663|NCT01761773|Experimental|Group 2|Subjects with mild renal impairment: adult subjects with a eCFR ≥ 90 mL/min/1.73m2.
88933664|NCT01761773|Experimental|Group 3|Moderate renal impairment: adult subjects with an eGFR between ≥30 - ≤ 59 mL/min/1.73m2.
88933665|NCT01761773|Experimental|Group 4|Severe renal impairment: adult subjects with an eGFR ≤ 29 mL/min/1.73m2, not on dialysis.
88933666|NCT01761786|No Intervention|Control group|CYP2C19 genotyping will be performed after end of study. Patients will be treated with prasugrel or ticagrelor, according to local protocol.
88933667|NCT01761786|Active Comparator|Intervention group|CYP2C19 genotyping will be performed <48h after PCI and antiplatelet treatment will be chosen based on genotyping results.
88933668|NCT01761799|Experimental|P3 Vaccine Promotion Package|The 5 obstetric practices randomized to the intervention arm will receive and implement all components of the evidence-based P3 vaccine promotion package at the beginning of the study.
88933669|NCT01761799|No Intervention|No P3 vaccine promotion package intervention|The 5 obstetric practices randomized to the control arm will not receive the comprehensive vaccine promotion package at the beginning of the study and will instead be instructed to continue their standard of care regarding influenza and Tdap vaccination of pregnant patients.
88933670|NCT01761812|Experimental|Single arm study|
88933671|NCT01761825|Active Comparator|Ivabradine|Ivabradine 10 mg once
88933672|NCT01761825|Placebo Comparator|placebo|
88933673|NCT01761838|Experimental|SMT for low back pain patients|To investigate the effects of high velocity, low amplitude lumbopelvic spinal manipulative therapy on spinal stiffness and back muscle activity.
88933674|NCT01761838|Other|Asymptomatic arm|To investigate the sequential changes in spinal stiffness and back muscle activity of asymptomatic participants over time without any intervention. Participants of this arm can volunteer for an additional experimental pain protocol after their third visit (at 1 week) to investigate the effects of experimental pain on the changes of spinal stiffness and back muscle activity using a randomized crossover design (injecting 5% hypertonic saline or 0.9% isotonic saline to the interspinous ligaments at L3 to L5 levels in random order in two additional visits).
88933675|NCT01761838|Other|Low back pain participants without SMT|To investigate the temporal changes in lumbar disc diffusion within a 1-hour period without SMT
88933676|NCT01761851||Cases|Liver cirrhosis
89448025|NCT04856176|Experimental|GM-CSF Plus Maintenance Pembrolizumab +/- Pemetrexed|All patients will receive GM-CSF plus maintenance pembrolizumab with or without pemetrexed, following completion of 4 cycles of chemo-immunotherapy
89448026|NCT04853277|Experimental|Education Group|Participants will receive an educational intervention focusing on psychosocial stressors and timeline of symptoms associated with the transplant/CAR-T experience.
88933677|NCT01761864|Experimental|intervention group|academic detailing receiver
88933678|NCT01761864|No Intervention|control group|not receiving an academic detailing intervention
88933679|NCT01761903||Primary Focal Dystonia|Volunteers with primary focal dystonia
88933680|NCT01761903||Healthy Controls|'Healthy' volunteers, consisting of people of the same age as the PFD volunteers, w/o a diagnosis of PFD.
88933681|NCT01761916|Experimental|CLONIDINE|Postpartum patients with very high blood pressure will be treated with oral clonidine (0,1mg)
88933682|NCT01761916|Active Comparator|CAPTOPRIL|Postpartum patients with very high blood pressure will be treated with oral CAPTOPRIL (25mg)
88933683|NCT01761942|Placebo Comparator|placebo ,anorexia nervosa|2x3 placebo capsules with olive oil
88933684|NCT01761942|Experimental|fatty acids preparation- eye-q|2 x 3 tablets of eye -q preparation daily ( 558 mg of EPA, 175 mg of DHA, 60 mg fo GLA).
88933685|NCT01761955|Experimental|High Dairy|Consuming four or more servings of dairy per day.
88933686|NCT01761955|Placebo Comparator|Control, Low Dairy|Participants consumed less than 2 servings of low fat dairy per day.
88933688|NCT01761994|Active Comparator|M100|heparin free CRRT group
88933689|NCT01761994|Experimental|HF1000|CRRT with nafamostat mesilate anticoagulation group
88933690|NCT01762007||6Mo-2Yr old penile hypospadias patients before operation|
88933691|NCT01762007||6Mo-2Yr old male patients without hypospadias|
89537112|NCT03300011|No Intervention|recanalisation CTO lesion failure|Patients with CTO lesion performed PCI strategy and failure recanalisation the CTO lesion with PCI wire and balloon..
89537113|NCT03300011|No Intervention|OMT|Patients with CTO lesion optimal medicine treatment without PCI
89200561|NCT05191576||epileptic children|All patients were diagnosed based on the International League Against Epilepsy (ILAE) operational clinical definition criteria for epilepsy and pediatric neurologists made the diagnosis. The patients had been receiving treatment for at least one year. Epileptic patients were grouped into idiopathic generalized or self-limiting focal epilepsy syndromes according to the International League Against Epilepsy (ILAE) criteria for epileptic seizures and syndromes and guidelines for epidemiological studies for diagnosis and classification.
89200562|NCT05191576||healthy controls|healthy controls without any complaint (e.g., behavior problems, depression, or anxiety) that could interfere with sleep.
89200563|NCT00970762|Experimental|Rocuronium 0.6 INT, 0.1 MNT|Participants in this group received a 0.6 mg/kg intubating dose of rocuronium followed by 0.1 mg/kg maintenance dose of rocuronium.
89200564|NCT00970762|Experimental|Rocuronium 0.6 INT, 0.15 MNT|Participants in this group received a 0.6 mg/kg intubating dose of rocuronium followed by 0.15 mg/kg maintenance dose of rocuronium.
89200565|NCT00970762|Experimental|Rocuronium 0.6 INT, 0.2 MNT|Participants in this group received a 0.6 mg/kg intubating dose of rocuronium followed by 0.2 mg/kg maintenance dose of rocuronium.
89200566|NCT00970762|Experimental|Rocuronium 0.9 INT, 0.1 MNT|Participants in this group received a 0.9 mg/kg intubating dose of rocuronium followed by 0.1 mg/kg maintenance dose of rocuronium.
89200567|NCT00970762|Experimental|Rocuronium 0.9 INT, 0.15 MNT|Participants in this group received a 0.9 mg/kg intubating dose of rocuronium followed by 0.15 mg/kg maintenance dose of rocuronium.
89200568|NCT00970762|Experimental|Rocuronium 0.9 INT, 0.2 MNT|Participants in this group received a 0.9 mg/kg intubating dose of rocuronium followed by 0.2 mg/kg maintenance dose of rocuronium.
89200569|NCT00970762|Active Comparator|Vecuronium 0.1 INT, 0.025 MNT|Participants in this group received a 0.1 mg/kg intubating dose of vecuronium followed by 0.025 mg/kg maintenance dose of vecuronium.
89200570|NCT00980824|Experimental|therapy|Cognitive behavioural therapy. Six sessions of structured focused therapy.
89200571|NCT00980824|Active Comparator|Standard treatment|referral to specialised or generic mental health service
89200572|NCT00977626|Experimental|Part 1 AZD2423 or Placebo|AZD2423 or Placebo Oral Solution, multiple dosing during 10-14 days
89448027|NCT04849806||COPD patients (n=60)|"The following parameters will be determined in 60 consecutive patients with COPD without established cardiovascular disease (i.e. without an indication for beta blocker therapy or other pharmacological treatments attacking on the neurohormonal pathways like angiotensin-converting enzyme inhibitors or mineralocorticoid receptor antagonists).~OSA severity.~Determination of PH and right HF severity (defined as tricuspid annular plane systolic excursion ≤14 mm) and pulmonary arterial pressure (PAsys) using transthoracic echocardiography;~Comprehensive lung function and inspiratory muscle function testing ;Assessment of daytime hypoxia (PaO2 <55 mmHg) and hypercapnia (PaCO2 >45 mmHg) using capillary blood gas analysis;~Assessment of systemic inflammation"
89448028|NCT04849806||Controls (n=20)|(and in a group of healthy controls [3:1] matched for age, sex and BMI).
89448029|NCT04828967|Experimental|Hypnosis group|Hypnosis is added to the conventional group.
89448030|NCT04828967|No Intervention|conventional group|only conventional group
89537114|NCT00702143|Experimental|AD subjects|
89200573|NCT00977626|Experimental|Part 2 - AZD2423|AZD2423 Oral solution, multiple dosing
89200574|NCT00977626|Experimental|Part 3 - AZD2423|AZD2423 Oral solution single dosing or AZD2423 Oral solution, single dosing - With Food or AZD2423 Oral solution, single dosing - Fasting Condition.
89200575|NCT00970840|Experimental|LNS-20gM or LNS-P&L|
89200576|NCT00970918|Experimental|1|
89200577|NCT03923530|Experimental|Eplerenone|Eplerenone 50 mg daily, administered orally for 8 weeks.
89448031|NCT04819425|Experimental|Elastic Adhesive Strips|"Endotracheal tube fixed by elastic adhesive tape (Tensoplast type adhesive tape):~The adhesive tape will be attached to the patient's face (opposite side to the endotracheal tube) and then two turns around the endotracheal tube will be made. The rest of the adhesive tape will be attached to the other side of the face (side of the endotracheal tube).~The laminated tape will be kept on the adhesive tape until it passes over the neck in order to avoid adhering to the hair.~Finally, the end of the adhesive tape will be replaced on the part already attached to the patient.~It will be changed daily and after stain or examinations if necessary."
89448032|NCT04819425|Active Comparator|Lace in A Protective Sheath|"A loop is made with the lace then the endotracheal tube is passed through the loop. The loop is tightened by pulling each side on the remaining cords and a knot is made on one side of the fastener.~It will be changed daily and after stain or examinations if necessary."
89448033|NCT04814355|Experimental|Celecoxib 400 mg|Patients will receive 400 mg/day of celecoxib for 8 weeks.
89448034|NCT04814277||MRI Data Collection|A group of 34 subjects will be scanned on a 3Tesla (3T) and on a 7T MRI scanner. The images will be compared.
89448035|NCT04812691|Experimental|JWCAR029|The safety and efficacy of JWCAR029 will be evaluated in 1 x 10^8 CAR+T cells dose level
88933692|NCT01762007||penile hypospadias patients under the age of 5 Yr|penile hypospadias patients under the age of 5 Yr who got tubularized incised plate operation at out institution at the age between 6Mo and 2Yr old and more than 1 Yr have passed
88933693|NCT01762007||2Yr-5Yr old male patients without hypospadias|
89448036|NCT04809558|Active Comparator|Max intensity with no visual biofeedback|Tongue resistance exercises completed at maximum intensity with no visual biofeedback.
88933694|NCT01762020|Active Comparator|3M Cavilon No Sting Barrier Film|Two of four regions of the breast will be randomly chosen to receive 3M Cavilon No Sting Barrier Film treatment twice per week.
88933695|NCT01762020|Placebo Comparator|Standard preparations|Standard treatment
88933696|NCT01762033|Experimental|ASONEP|ASONEP will be administered by intravenous infusion over 90 minutes at 15 mg/kg once a week every 4 consecutive weeks per cycle
88933697|NCT01762046|Other|Glipizide and Metformin|On day 1, subjects will receive a single oral dose of glipizide 5 mg, and will have blood drawn at various time points for up to 240 minutes. During study days 2-7, the participants will fill out a dietary intake food record, including 3 weekdays and one weekend day. During days 6-8, the subject will receive a short-course metformin treatment of four 500-mg doses. On the morning of study day 8, 60 minutes after taking the fourth metformin dose, the subject will do a 75g Oral Glucose Tolerance Test. Blood draws will again be taken at time points for 120 minutes.
88933698|NCT01762072|Placebo Comparator|vitaminB12|VitB12 group (VitB12, n=10) receives 8 weeks of treatment with daily oral doses of 1000 μg of vitamin B12 (one capsule)
89448037|NCT04809558|Active Comparator|Progressive intensity with no visual biofeedback.|Tongue resistance exercises completed at a progressive intensity with no visual biofeedback.
89448038|NCT04809558|Active Comparator|Max intensity with visual biofeedback|Tongue resistance exercises completed at maximum intensity with visual biofeedback of performance.
89448039|NCT04809558|Active Comparator|Progressive intensity with visual biofeedback.|Tongue resistance exercises completed at a progressive intensity with visual biofeedback of performance.
89448040|NCT04802434|Experimental|Strengthening Skills Program|Adults with ASD and their study partners (i.e., spouse, parent, other family member, or friend) will attend weekly 3 hour meetings for 16 weeks, during which, behavioral intervention strategies will be used to teach cognitive compensation and mindfulness-based emotion regulation skills. Strategies from the PEERS Social Skills Program will also be taught. Participants will be assigned homework assignments each week to practice skills they are learning in a real-world setting.
88933699|NCT01762072|Experimental|Fish oil|Fish oil group (FO, n=10)receives 8 weeks of treatment with daily oral doses of 2g of fish oil in the form of two capsules of fish oil) .
88933700|NCT01762072|Experimental|Fish oil+vitaminB12|VitB12+Fish oil group (VitB12+FO, n=10) receives 8 weeks of treatment with daily oral doses of a combination of 1000 μg of vitamin B12 and 2g of fish oil
88933701|NCT01762085|Placebo Comparator|healed DFU control arm|"clinic-specific usual best care"
89448041|NCT04802434|Active Comparator|PEERS Social Skills Program|Adults with ASD and their study partners (i.e., spouse, parent, other family member or friend) will attend weekly 1.5 hour meetings for 16 weeks, during which, behavioral intervention strategies will be used to teach skills for improving social relationships and handling social rejection. Participants will be assigned homework assignments each week to practice skills they are learning in a real-world setting.
89448042|NCT04802434|No Intervention|Delayed Treatment Control Group|Participants in the delayed treatment control group will participate in a 10-month wait period, during which they will complete data collection procedures at three time points (Baseline, Post, and 6-month follow-up).
89448043|NCT04798833|Experimental|Integrated Newborn Care Kit|"The integrated newborn care kit will contain a clean birth kit to be used at the time of delivery either at home or in a facility, three misoprostol tablets (200ug each), 4% chlorhexidine solution, sunflower oil emollient, temperature monitoring strip or sticker, a fleece blanket, a reusable, non-electric, heating device, and a pictorial instruction guide. Lady Health Workers will be equipped with a hand-held electronic scale to identify low birth weight newborns.~Participants in this arm will receive the same local standard of care as the no intervention arm."
89537115|NCT00702143|Experimental|MCI Subjects|MCI (mild cognitive impairment)
89448044|NCT04798833|No Intervention|Control (Local Standard of Care)|"In the control arm, LHWs will deliver the local standard of care, which entails both anti-natal and post-natal LHW home visits. As part of standard practice, LHWs visit pregnant women in their homes during the 3rd trimester, at which time these health workers:~Provide instructions regarding proper nutrition during pregnancy~Encourage that delivery take place in a facility~Discuss the fundamentals of safe water, sanitation, and hygiene behavior~Encourage exclusive breastfeeding~These community health workers will identify early danger signs in newborns such as infections and teach caregivers to identify the same symptoms, so that early interventions can be made. If danger signs are identified, the LHW will refer newborns to the appropriate level of health care."
89448045|NCT04793334||Obese + OSA|"Inclusion Criteria:~Men and women~Ages >= 18-65 years old~BMI 35 kg/m2-above~Scheduled for sleeve gastrectomy (bariatric surgery)~OSA identified by PSG~Exclusion Criteria:~Any cardiovascular, pulmonary or renal disease other than well-controlled hypertension or asthma.~Pregnancy~Currently smoking~Any respiratory disorder other than OSA or well controlled asthma~contraindication to MRI"
89448046|NCT04793334||Obese without OSA|"Inclusion Criteria:~Men and women~Ages >= 18-65 years old~BMI 35kg/m2 and above~Scheduled for sleeve gastrectomy (bariatric surgery)~No OSA identified by PSG~Exclusion Criteria:~Any cardiovascular, pulmonary or renal disease other than well-controlled hypertension or asthma.~Pregnancy~Currently smoking~Any respiratory disorder other than OSA or well controlled asthma~contraindication to MRI"
89448047|NCT04759716|Experimental|Health Literacy-based Weight Control Intervention arm|intervention arm will receive weight control program
89448048|NCT04759716|No Intervention|control arm|routine care
89448049|NCT04759274|Experimental|Diuretic Tuner users|The Diuretic Tuner is a mobile device application that integrates a patient's estimated dry weight and starting diuretic dose (both defined by a healthcare provider) with daily weights and blood pressures to provide individualized guidance to the patient in day-to-day adjustments to his or her diuretic regimen. In addition, the application generates a diary of daily weights, blood pressures, fluid intake, and medication compliance.
89448050|NCT04748939|Active Comparator|vaccine|Shingrix vaccine
89448051|NCT04748939|Placebo Comparator|placebo|normal saline injection (0.5mL)
89448052|NCT04735705|Experimental|Cerviron vaginal ovules|Since Cerviron® has an innovative composition, we preferred an exploratory approach for the design of the present clinical investigation.
89448053|NCT04735419||Cases|Cases are defined as infants who develop invasive GBS disease (iGBS disease= isolation of GBS from a normally sterile site, i.e. blood or CSF) in the first 90 days of life.
89448054|NCT04735419||Controls|Controls are defined as infants who are exposed to the same serotype of GBS at birth as the case - but who do not develop iGBS disease in the first 90 days of life.
89448055|NCT04732000|Active Comparator|N-acetyl cysteine|N-acetyl cysteine will be administered as follows: A loading dose of 50 mg/kg will be started as a 1-hour infusion before surgical incision, and will be followed by a maintenance dose of 50 mg/kg administered over 4 hours.
88933702|NCT01762085|Experimental|healed DFU surgical intervention|"clinic-specific best care plus nerve decompression at 4 known sites of lower leg fibro-osseous entrapment"
88933703|NCT01762098||Recurrent miscarriages|
88933704|NCT01762098||Repeated embryo implantation failures|
88933705|NCT01762124|Experimental|Native Outflow Tract TPV|Implantation of the Native Outflow Tract TPV
88933706|NCT01762137|Active Comparator|Coiling|Coiling
88933707|NCT01762137|Active Comparator|Flow Diversion|Flow Diversion
88933708|NCT01762150|Experimental|sorafenib combined with chemotherapy|this trial is designed single arm. all the subjects enrolled will receive the experimental intervention,ie. sorafenib+gemcitabine+cisplatin.
88933709|NCT01762163|Experimental|Qizhitongluo Capsule|"Basic treatment：Aspirin Enteric-coated Tablets was administered orally at a dosage of 100mg/d once per night;the routine recovery training.~intervention treatment:the Capsules were administered orally, four capsules each time, three times a day after each meal（placebo was taken only after lunch, and Qizhitongluo Capsule was taken after breakfast and supper)for 12 weeks."
88933710|NCT01762163|Active Comparator|Naoxintong Capsule|"Basic treatment：Aspirin Enteric-coated Tablets was administered orally at a dosage of 100mg/d once per night; the routine recovery training.~intervention treatment:Naoxintong Capsule was administered orally, four capsules each time, three times a day after each meal for 12 weeks."
88933711|NCT01762163|Placebo Comparator|Placebo|"Basic treatment：Aspirin Enteric-coated Tablets was administered orally at a dosage of 100mg/d once per night and the routine recovery training.~intervention treatment:placebo capsule was administered orally four capsules each time, three times a day after each meal for 12 weeks."
88933712|NCT01762202|Experimental|Study therapy|
89200578|NCT00608907|Experimental|VELCADE|Control arm, bortezomib 1.3 mg/m^2 on days 1, 4, 8, 11 over a 21-day treatment cycle.
89200579|NCT00608907|Experimental|VELCADE + rifampicin|Treatment Arm, bortezomib 1.3 mg/m^2 on days 1, 4, 8, 11 over a 21-day treatment cycle, rifampicin 600 mg once daily days 4 to 10 in cycle 3.
89448056|NCT04732000|Placebo Comparator|Normal Saline|Normal will be administered as follows: A normal saline infusion will administered at a rate and duration to mimic the N-acetyl cysteine administration.
89448057|NCT04713345|Experimental|Experimental group|If the patient is included in the Virtual Reality group, they will be asked to observe 1 time per day for 9 days for 5 minutes Virtual Motor Actions (avatar moving in a virtual environment) using a headset. Virtual Reality, followed by 5 minutes of relaxation performed using soothing music played through headphones.
89448058|NCT04713345|Sham Comparator|Control group|If the patient is included in the Relaxation group, they will be offered 10 minutes of relaxation performed using soothing music played through headphones once a day for 9 days.
89448059|NCT04684628|Experimental|Biochemical Reoccurrence|"Patients with biochemical reoccurrence (post-prostatectomy or post radical radiotherapy) or patients with biochemical relapse with rising PSA in spite of taking hormone treatment (this situation is characterized as non-metastatic castration resistant prostate cancer M0CRPC) and compare it to bone scan and CT in 2 groups:~PSA >= 0.2 ng/mL and <= 0.5 ng/mL or PSA > 0.5 ng/ml"
89448060|NCT04684628|Experimental|High Risk Prostate Cancer|Patients with high risk prostate cancer who have not received any definitive treatment. These high-risk patients are defined using the D'Amico Classification System: Those with a PSA of more than 20, or a Gleason score equal to or greater than 8, or have a clinical stage greater than T2c.
89448061|NCT04682158|Active Comparator|Chemoradiation Therapy - Group I|Patients receiving beta-blockers undergo radiation therapy in the form of IMRT or 3D CRT over 23-28 fractions for 5 days per week (Monday-Friday) for 5 weeks, and receive paclitaxel IV QW and carboplatin IV QW for 5 weeks in the absence of disease progression or unacceptable toxicity.
89448062|NCT04682158|Active Comparator|Chemoradiation Therapy - Group II|Patients undergo CRT as in Group I in the absence of disease progression or unacceptable toxicity.
89448063|NCT04682158|Experimental|Chemoradiation Therapy plus Propanolol|Patients undergo radiation therapy as in Group I. Patients receive propranolol PO BID for 4-6 weeks while receiving CRT in the absence of disease progression or unacceptable toxicity.
89448064|NCT04681807|Experimental|Emotion Recognition Training|
89448065|NCT04681807|Active Comparator|Active Control Training|
89448066|NCT04670315||Single Group|Scale validation in stroke patients
89448067|NCT04666831|Experimental|AMI and CBT Intervention|Participants will receive four weekly sessions of individual therapy (60 minutes) with a graduate student therapist over videoconferencing technology or telephone. The intervention combines Adapted Motivational Interviewing (AMI) and Cognitive Behavioural Therapy (CBT) techniques for food addiction. Participants will complete questionnaires at baseline, postintervention or 1-month postbaseline, and 2- and 4-months postbaseline.
89448068|NCT04666831|No Intervention|Waitlist Control|Participants will complete questionnaires at baseline, 1-month postbaseline, and 2- and 4-months postbaseline (at timepoints comparable to the intervention arm). They will not receive any intervention during this time. Following the 3-month waitlist, they will cross over into the same procedure as the intervention arm.
89448069|NCT04663607|No Intervention|Control|Participants will receive paper-based health education as part of standard of care
89448070|NCT04663607|Experimental|PretermConnect App|Participants will receive health education via a mobile app, PretermConnect
89448071|NCT04662580|Experimental|ARX517 Alone and Combination Cohorts (Phase 1)|"Monotherapy:~ARX517 will be administered via intravenous (IV) infusion every 3, or 4 weeks.~Combination Cohorts:~ARX517 + enzalutamide"
89448072|NCT04658160|No Intervention|Control|None- normal care
89448073|NCT04658160|Experimental|Intervention/Tracking|This group will have access to the longitudinal tracking and intervention platform for Medicare Advantage patients. Members of this group's care team will have access to the longitudinal data on the platform and will be able to intervene if any red flags emerge (i.e. if a patient displays signs of depression on a patient reported outcome measure/survey)
89448074|NCT04651504|Experimental|Primary Care Clinics|"Southern Illinois Healthcare System will contact the site management and ask for participation in the study~Eligible providers and staff will be identified by clinic management. The research coordinator will work with the clinic to schedule a virtual site visit(s). The study team will interview providers and staff at the beginning and/or end of each active intervention period to assess knowledge and attitudes about CRC screening and follow-up processes, the Consolidated Framework for Implementation Research (CFIR) constructs such as role clarity within the clinical team, and satisfaction with the intervention and implementation. Post-implementation surveys will also ask about work-arounds and adaptations of the intervention tools and perceived efficacy."
89448075|NCT04648241|Experimental|≥16 Years Old|TBE vaccine 0.5 mL (intramuscular injection).
89448076|NCT04648241|Experimental|1 to <16 Years Old|TBE vaccine 0.25ｍL (intramuscular injection).
89448077|NCT04646460|Experimental|Observed Success - Experienced Success|"This participant group (N=30) will witness a successful placebo during the observation phase (i.e. the demonstrator will display reduced pain expressions after receiving the cream) and experience a successful placebo during the experience phase (i.e. the experimenter will reduce the intensity of the pain stimuli after applying the cream)."
89448078|NCT04646460|Experimental|Observed Failure - Experienced Failure|"This participant group (N=30) will witness a failed placebo during the observation phase (i.e. the demonstrator will not display reduced pain expressions after receiving the cream) and experience a failed placebo during the experience phase (i.e. the experimenter will not reduce the intensity of the pain stimuli after applying the cream)."
89448079|NCT04646460|Experimental|Observed Success - Experienced Failure|"This participant group (N=30) will witness a successful placebo during the observation phase (i.e. the demonstrator will not display reduced pain expressions after receiving the cream) and experience a failed placebo during the experience phase (i.e. the experimenter will not reduce the intensity of the pain stimuli after applying the cream)."
89448080|NCT04646460|Experimental|Observed Failure - Experienced Success|"This participant group (N=30) will witness a successful placebo during the observation phase (i.e. the demonstrator will display reduced pain expressions after receiving the cream) and experience a successful placebo during the experience phase (i.e. the experimenter will reduce the intensity of the pain stimuli after applying the cream)."
89448081|NCT04642755||Group 1|LTBI+ and severe to moderate malnutrition
89448082|NCT04642755||Group 2|LTBI+ and uncontrolled DM
89448083|NCT04642755||Group 3|LTBI+ and helminth infection
89448084|NCT04642755||Group 4|LTBI+ with more than one of the above conditions (severe to moderate malnutrition, DM, helminth infection)
89448085|NCT04642755||Group 5|"Healthy LTBI+ controls who are negative for all of the above conditions (severe to moderate malnutrition, DM, helminth infection)"
89448086|NCT04642755||Group 6|Healthy LTBI negative controls with none of the above conditions (severe to moderate malnutrition, DM, helminth infection).
89448087|NCT04630249|Experimental|Listening to Women|This group will receive text-message based SBIRT with phone based assessment and referral to treatment. The SBIRT is a survey with 9 questions related to depression, anxiety, substance abuse (alcohol, cigarettes, other drugs including prescription medication), and domestic violence.
89448088|NCT04630249|No Intervention|Treatment as Usual|This group will receive in-person screening and referral to treatment assessment. The same screening tools are used to assess substance abuse and mental health problems in LTW and TAU groups.
89448089|NCT04627701|Experimental|Omega Device|
89448090|NCT04624126|Experimental|3D-Erect arm|Participants will be asked to use the 3D-printed penile device during their intercourse with partners.
88933713|NCT01762215|Experimental|PLM|Upon consenting to the study, participants will be asked to register an account on PatientsLikeMe; no personal identifiers will be required. As part of registration patients create a user name and password for the website and share their email with PatientsLikeMe. Participants will be asked to provide a set of demographic variables and to complete a survey assessing elements of self-management, disease knowledge, social support, and quality of life. Paticipants will then use the PatientsLikeMe website for 6 weeks as much as they wish. After 6 weeks the participants are asked to complete a second survey.
89448091|NCT04614779|Experimental|CN128 Group|"All subjects will be given the lower (10 mg/kg bw, bid) or higher dose (15 mg/kg bw, bid) for 24 or 48 weeks, according to the administration plan.~All subjects will be given the lower (15 mg/kg bw, bid) or higher dose (20 mg/kg bw, bid) for 49 or 96 weeks, according to the administration plan.~The dosage form is tablets."
89200580|NCT00608907|Experimental|VELCADE + dexamethasone|Treatment arm, bortezomib 1.3 mg/m^2 on days 1, 4, 8, 11 over a 21-day treatment cycle, dexamethasone 40 mg once daily days 1 to 4, and 9 to 12 in cycle 3.
89200581|NCT00970996|Experimental|Biochemotherapy|Abraxane with Cisplatin, Temozolomide, interleukin-2 and interferon a2b
89448092|NCT04614584|Experimental|Mirtazapine|Mirtazapine 30 mg PO daily x 4 days
89448093|NCT04614584|Placebo Comparator|Placebo|Placebo 30 mg PO Daily x 4 days
89448094|NCT04609644|No Intervention|Passive|"Passive arm participants will be sent two devices, at no cost-an Apple Watch and a Beddit Sleep Monitor. These are commercially available and have not been modified for this study. Participants will be asked to use these devices regularly throughout study Year 1. Participants can optionally continue to use devices during Year 2, if they have met requirements during Year 1 to keep study devices. To be eligible to keep devices, participants must meet pre-specified levels of adherence to study procedures.~Access to the Study App will be provided to all participants. It will be used to administer informed consent and electronic patient reported outcome (ePRO) measures, and for other study purposes. However, passive participants will not have access to the Study App features designed to support asthma self-management."
89448095|NCT04609644|Experimental|Active|"Active arm participants will be sent the same devices, also at no cost, and asked to use them in the same manner.~Only the active arm will have access to Study App features for asthma self-management, including:~Smart nudges that may promote proactive asthma self-management~Asthma symptom and trigger tracking~Evidence-based asthma education~The ability to photograph and easily reference an asthma action plan from a healthcare provider.~A 90-day summary of self-reported asthma symptoms/triggers and device-recorded heart rate and respiratory rate. This summary can be shared with providers.~In-app viewing of active asthma medications, refills available, and phone numbers to call for refills (subject to prescription benefits).~Active participants can, but are not required to, use the Study App in Year 2. Those who choose to may keep using study devices in Year 2, provided they meet requirements to keep devices. These requirements are the same for both arms."
89448096|NCT04606264|Active Comparator|Major Abdominal: Neuraxial Analgesia|Intrathecal morphine
89448097|NCT04606264|Active Comparator|Major Abdominal: Regional Analgesia Block 1|Paravertebral block
88933714|NCT01762228|Active Comparator|Transcutaneus electrical stimulation|Sensorial transcutaneous electrical stimulation to the pharynx and larynx will be used 1 hour/day during 5 days/week for 2 weeks.
89200582|NCT00869193|Active Comparator|Grape seed|Grape seed extract
89200583|NCT00869193|Placebo Comparator|Placebo|Microcrystalline cellulose
89448098|NCT04606264|Active Comparator|Major Abdominal: PONV Optimal Prophylaxis|"Pre-op~-perphenazine~Induction -dexamethasone~Emergence~-ondansetron"
89448099|NCT04606264|Active Comparator|Major Abdominal: PONV Supraoptimal Prophylaxis|"Pre-op~aprepitant~dimenhydrinate~perphenazine~ondansetron~Induction -dexamethasone~Emergence~-ondansetron"
89448100|NCT04606264|Active Comparator|Major Abdominal: Regional Analgesia Block 2|QL1
88933715|NCT01762228|Active Comparator|TRPV1 agonist|Sensorial stimulation of TRPV1 receptors into the oropharynx of patients will be used 3 times/day (before meals) during 5 days/week for 2 weeks.
88933716|NCT01762241|Experimental|Intervention group|12 weeks systematically home based training 3 times per week one hour at the time using the Xbox Kinect system.
88933717|NCT01762241|No Intervention|Control group|No systematically training/standard of care
89200584|NCT04009018|Other|Psycometric analyses|It will be a validation study of the Perioperative Satisfaction Scale in Regional Anesthesia. This study is not experimental research. This is a psychometric assessment study of a questionnaire and data will collect pencil-paper survey and face to face from the patients who will get regional anesthesia in the postoperative second day.
89200585|NCT00869271|Experimental|1|folfox4 chemotherapy was done within 28 days after primary surgery. Per 3 weeks, patients will receive one cycle. After 3 cycles, patients will received transhepatic arterial chemotherapy(TAC) using oxaliplatin, fudr and mmc. Then begin folfox4 again.
89200586|NCT00869271|Active Comparator|2|folfox4 chemotherapy was done within 28 days after primary surgery. Per 3 weeks, patients will receive one cycle.
89537116|NCT00702143|Experimental|Healthy controls|
89200587|NCT00971074|Experimental|Hylan G-F 20|Single injection of Hylan G-F 20 into the affected knee.
89200588|NCT00971074|Sham Comparator|Sham Injection|A needle will be inserted through the knee capsule but no medication will be injected.
89200589|NCT00971152|Active Comparator|450 IU daily dose of gonadotrophin|
89200590|NCT00971152|Experimental|600 IU daily dose of gonadotrophin|
89448101|NCT04606264|Active Comparator|Major Abdominal: Neuraxial and Regional Analgesia Block 2|IT morphine and QL1
89448102|NCT04606264|Active Comparator|Major Abdominal: Neuraxial and Regional Analgesia Block 1|IT morphine and paravertebral
89448103|NCT04605263|Active Comparator|STN DBS|Subjects will receive traditional bilateral STN devices and stimulation.
89448104|NCT04605263|Experimental|STN-PPN DBS|Patients will be implanted with both bilateral STN and bilateral PPN devices. These patients will undergo a crossover between 3 and 15 months post-op in which they will double-blindly receive PPN stimulation for six months and have stimulation turned off for six months. All patients will receive stimulation from 0-3 months post-op (mapping visits occur in this window) and from 15-27 months.
89448105|NCT04604782|Experimental|adolescents aged 12 to <18 years|
89448106|NCT04604782|Experimental|children aged 2 to <12 years|
89448107|NCT04604782|Experimental|infants aged 1 to <24 months and who weigh at least 3 kg|
89448108|NCT04603781|Active Comparator|CBD-Isolate 300 mg.|Nightly oral administration of 300 mg. of CBD-Isolate for 28 consecutive days
89448109|NCT04603781|Active Comparator|Full-Spectrum CBD Oil 300 mg.|Nightly oral administration of 300 mg. of Full Spectrum CBD Oil for 28 consecutive days
89448110|NCT04603781|Active Comparator|Broad-Spectrum CBD oil 300 mg.|Nightly oral administration of 300 mg. of Broad-Spectrum CBD Oil for 28 consecutive days
89448111|NCT04603781|Placebo Comparator|Placebo Oil|Nightly oral administration of 300 mg. of Placebo Oil for 28 consecutive days
89448112|NCT04602598|Experimental|Zanubrutinib|Zanubrutinib orally at a dose of 80mg BID for 24 weeks
89448113|NCT04601376|Experimental|Mobile monitoring group|
89448114|NCT04593862|Experimental|Exercise Group|The exercise intervention will consist of 36 high-volume high-intensity interval sessions over a 12-week period. The exercise frequency will be three times per week during the 6 weeks of intravesical therapy and the 6 weeks of recovery (total 12 weeks) prior to a surveillance cystoscopy.
89448115|NCT04593862|No Intervention|Usual Care:|Patients randomized to the control group will be asked not to initiate any exercise program or to increase their exercise level from baseline during the 12-week study. After the post-intervention assessments and 3-month cystoscopy, patients in the control group will be offered a 4-week supervised exercise program at the Behavioural Medicine Fitness Centre, University of Alberta.
89448116|NCT04589832|Experimental|Study Treatment Arm|Phase 1b will determine the MTD of PAC-1 in combination with entrectinib. Study treatment will include: PAC-1 will be taken orally on Days 1-21 and Entrectinib will be taken orally on Days 1-28 of each 28-day cycle. Treatment will continue until disease progression (based on RECIST 1.1 criteria), unacceptable toxicity, subject withdrawal of informed consent, or subject death either from progression of disease, the therapy itself, or from other causes.
89448117|NCT04589312|Active Comparator|Pregnant women not living with HIV, Td vaccine|
89448118|NCT04589312|Experimental|Pregnant women not living with HIV, Tdap vaccine|
89448119|NCT04589312|Active Comparator|Pregnant women living with HIV, Td vaccine|
88933718|NCT01762254|Active Comparator|incisionless laparoscopic colectomy|incisionless laparoscopic colectomy: Laparoscopic colectomy is being performed in the same manner as conventional laparoscopic colectomy, except that at the end of procedure, the TEO device with the outer diameter of 4cm is inserted into the anus for the delivery of specimen and insertion of anvil instead of creating a small wound as in the conventional laparoscopic colectomy. Finally, intra-corporeal anastomosis is performed in the same manner with the TEO device removed.
88933719|NCT01762254|Active Comparator|conventional laparoscopic colectomy|conventional laparoscopic colectomy: The operation is completed by laparoscopic instruments using video laparoscopy. At the end of the procedure, pneumoperitoneum is abolished and a small wound was created for the delivery of bowel and insertion of anvil of the circular stapler. Finally, pneumoperitoneum is re-created for intra-corporeal anastomosis
88933720|NCT01762267|Active Comparator|diet intervention, DASH diet|intervention: nutrition intervention: DASH diet
89448120|NCT04589312|Experimental|Pregnant women living with HIV, Tdap vaccine|
89448121|NCT04585308|Experimental|Single arm|Patients with severe native aortic valve stenosis who meet the commercially approved indications for TAVR.
89448122|NCT04573192|Experimental|Phase 1 part: Dose Finding|"Phase I part:~Dose Finding Patients will be treated in cohorts according to a traditional 3+3 design with lomustine on Day 1 and L19TNF on Days 1, 3 and 5, and on Days 22, 24 and 26, of a 42-days cycle at different dose levels.~The RD will be confirmed following a traditional 3+3 design.~Cohort 1: 10 µg /kg L19TNF i.v. plus 90 mg/m2 lomustine Cohort 2: 10 µg /kg L19TNF i.v. plus 110 mg/m2 lomustine Cohort 3: 13 µg /kg L19TNF i.v. plus 110 mg/m2 lomustine~The dose of 13 ug/kg L19TNF will be declared the RD in case none of three or not more than one out of 6 patients experienced a DLT. Dose limiting toxicity will be assessed during the dose-escalation from Day 1 through Day 42 after the first administration of lomustine and study drug (Cycle 1). Not more than 2 patients might be treated simultaneously in Cycle 1."
89448123|NCT04573192|Experimental|Phase II part: Signal Seeking|"118 Patients will be randomized 1:1 and treated with either lomustine on day 1 and L19TNF on Days 1, 3 and 5, and on Days 22, 24, and 26 of a 42-days cycle at the RD established in the phase I part of the study or with lomustine on day 1 of a 42-days cycle.~Treatment Arm 1: L19TNF plus Lomustine~Treatment Arm 2: Lomustine"
89448124|NCT04570891|Experimental|FICB|Ultrasound-guided fascia iliaca compartment block (0.25% ropivacaine 1mL/kg, Max 30mL) will be provided at the end of surgery.
89448125|NCT04570891|Placebo Comparator|Control|No regional block is provided at the end of surgery.
89448126|NCT04564521|Experimental|Nitroglycerin|Intravenous nitroglycerin (0.5mcg/kg/min) is infused after the induction of general anesthesia and during intra-arterial chemotherapy.
89448127|NCT04564521|Active Comparator|Normal saline|Normal saline is infused after the induction of general anesthesia and during intra-arterial chemotherapy.
89448128|NCT04559919||Adults with epilepsy|"Adults over 18 years of age, with an unprovoked seizure in the last year or epilepsy, resident in VGR at the time of inclusion. Languages available: Swedish, English, Arabic.~Based on the clinical information, patients can be categorized into relevant groups; single seizure, seizure-free with epilepsy, and drug-resistant epilepsy. Subgroups may also be selected based on age, sex, epilepsy sub-diagnosis, cause of epilepsy, use of a particular antiepileptic drug, or experience of a particular side effect."
89448129|NCT04557995|Experimental|Erythropheresis treatment|Erythropheresis treatment was was added to routine treatment
89448130|NCT04557995|No Intervention|Routine treatment|Oxygen delivery and basic care
89448131|NCT04524013||School aged children|
89448132|NCT04524013||Pregnant women|
89448133|NCT04518124|Experimental|Propranolol|
89448134|NCT04515095|Experimental|Water-only Fasting Group|Participants who voluntarily elect and are approved to water-only fast.
89448135|NCT04507685|Experimental|Low Glycaemic Diet (LG)|Low carbohydrate, low saturated fat diet
89448136|NCT04507685|Active Comparator|Control Diet|High unrefined carbohydrate, low fat diet
89448137|NCT04504136|Experimental|Healthy Controls|Participants in this group will be healthy (not diagnosed with inflammatory bowel disease).
89448138|NCT04504136|Experimental|Inflammatory Bowel Disease|Participants in this group will have been diagnosed with ulcerative colitis (UC) or Crohn's disease (CD) and have either failed treatment with biologics or be naive to biologic therapy.
89448139|NCT04504136|Experimental|Rheumatoid/Psoriatic Arthritis|Participants in this group will have been diagnosed with rheumatoid (RA) or psoriatic arthritis (PsA) and will be receiving anti-TNF antibody therapy at the time of enrollment.
89448140|NCT04487834|Active Comparator|Simethicone Solution|Treatment with simethicone (Espumisan®, 100 mg/ml, Berlin-Chemie / Menarini Polska Sp z o.o., Warsaw, Poland) for four weeks. Simethicone was administered 3-6 times per day with each treatment comprising 6 drops of the 100 mg/ml emulsion.
89448141|NCT04487834|Experimental|Vivatlac Baby|Treatment with one stick pack of the multi-strain synbiotic (Vivatlac® Baby, Vivatrex GmbH, Rees, Germany) per day for four weeks. Each stick pack of Vivatlac® Baby contains a total of 10^9 colony forming units (CFU) with equal CFU amounts of the following probiotic bacteria: L. acidophilus LA-14, L. casei R0215; L. paracasei Lpc-3; L. plantarum Lp-115; L. rhamnosus GG, L. salivarius Ls-33, B. lactis Bl-04, B. bifidum R0071, B. longum R0175 and 1.43 g of the prebiotic fructooligosaccharides.
89448142|NCT04482634|Active Comparator|Tele-rehabilitation group|This group will perform the exercises at their home under remote supervision of a physiotherapist via internet connection.
89448143|NCT04482634|Active Comparator|Home exercise group|This group will perform the exercises at their home on their own, the first exercise program will be given at hospital and the patients will be followed up regular weekly by phone call.
89448144|NCT04473716|Experimental|Neoadjuvant therapy with Toripalimab, Paclitaxcel and Cisplatin|Pre-operative neoadjuvant therapy will be used with the combination of immune checkpoint inhibitor of Toripalimab, and chemotherapy agents of paclitaxcel and cisplatin in patients with locally advanced OSCC. After inductive therapy, the patients will receive radical surgery and post-operative radiotherapy/chemoradiotherapy.
89448145|NCT04469855||Ozempic®|Japanese people with type 2 diabetes being treated in normal clinical practice conditions
89448146|NCT04458259|Experimental|Monotherapy Dose Escalation: Part 1|Monotherapy dose escalation of PF-07265807 in participants with select tumor types.
89448147|NCT04458259|Experimental|Doublet Dose Escalation: Part 2|Doublet combination dose escalation of PF-07265807 with sasanlimab in participants with select tumor types. PF-07265807 will dose escalate. Sasanlimab dose will stay constant.
89448148|NCT04458259|Experimental|Triplet Dose Escalation: Part 3|Triplet combination dose escalation of PF-07265807 with sasanlimab plus axitinib in participants with select tumor types. PF-07265807 will dose escalate. Sasanlimab dose will stay constant. Axitinib dose will follow label.
89448149|NCT04458259|Experimental|Expansion Phase: Part 4, Cohort 1|PF-07265807 monotherapy in participants with METex14 mutant NSCLC.
89448150|NCT04458259|Experimental|Expansion Phase: Part 4, Cohort 2|PF-07265807 with sasanlimab in participants with MSS CRC
88933721|NCT01762267|No Intervention|not intervention, control diet|control weight loss diet
89448151|NCT04458259|Experimental|Expansion Phase: Part 4, Cohort 3|PF-07265807 with sasanlimab in participants with PD-L1+ gastric cancer/GEJ
89448152|NCT04458259|Experimental|Expansion Phase: Part 4, Cohort 4|PF-07265807 with sasanlimab plus axitinib in participants with RCC
88933722|NCT01762280|Experimental|Famitinib Malate|Famitinib either at 4,8,13,20,27,36 mg, p.o. once daily
88933723|NCT01762293|Experimental|Famitinib|Famitinib 25 mg qd p.o. and the medication continued until disease progression or intolerable toxicity or patients withdrawal of consent
88933724|NCT01762293|Placebo Comparator|Placebo|Placebo qd p.o., and the medication continued until disease progression or intolerable toxicity or patients withdrawal of consent
89448153|NCT04456621|Experimental|PBT arm|
89448154|NCT04444973||Invasive RV assessment|RV conductance catheter assessment of RV performance
89448155|NCT04432623|Experimental|Low dose|A low dose, by mouth, once per day, on Monday, Wednesday, and Friday for 12 weeks
89448156|NCT04432623|Experimental|Middle dose|A middle dose, by mouth, once per day, on Monday, Wednesday, and Friday, for 12 weeks
89448157|NCT04432623|Experimental|High dose 3 days per week|Highest dose, by mouth, once per day, on Monday, Wednesday, and Friday, for 12 to 24 weeks
89448158|NCT04432623|Experimental|High dose 5 days per week|The highest dose, by mouth once per day on 5 days per week for 24 weeks
89448159|NCT04432623|Experimental|Sickle Cell Disease Arm|The most active dose given once per day on the most active regimen for up 24 weeks
88933725|NCT01762306|Experimental|Diclofenac Potassium|Diclofenac Potassium 50 mg PO 1 hour prior to fractional curettage
88933726|NCT01762306|Placebo Comparator|Folic Acid|Folic acid 5 mg PO 1 hour prior to fractional curettage
88933727|NCT01762319|Experimental|Misoprostol|200 mcg Misoprostol SL 1 hour prior to fractional curettage
88933728|NCT01762319|Placebo Comparator|Vitamin B6|100 mg Vitamin B6 SL 1 hr prior to fractional curettage
88933729|NCT01762332|Active Comparator|Low opioid level|Base level of remifentanil effect side concentration: 2ng/ml Stopped recruitment (May 2014)
88933730|NCT01762332|Active Comparator|High opioid level|Base level of remifentanil effect side concentration: 4ng/ml Stopped recruitment (May 2014)
89537117|NCT02902601|Experimental|Group A: JNJ-54175446|Participants will receive a loading dose of JNJ-54175446, 600 milligram (mg) on Day 1 followed by JNJ-54175446, 150 mg once daily until Day 10.
89448160|NCT04426591|Experimental|Biotin labeled Red Blood Cells|Participants receiving a transfusion with biotin labeled RBCs. Samples will be taken for 12 weeks after the biotinylated transfusion. During this time participants will continue to receive regular monthly transfusions (non-biotinylated) as part of CTT.
89448161|NCT04425616|Experimental|Universal Interventions|"The delivery of nutrition, exercise and psychological interventions delivered in the following structure:~Month 1: Up to three times per week~Months 2-3: Once per week~Months 4 - 6: One session per month for the last 3 months"
89448162|NCT04396587|Experimental|Sufentanil|Sufentanil(0.1μg/kg)
89448163|NCT04396587|Experimental|Hydromorphone|Hydromorphone(20μg/kg）
89448164|NCT04396587|Experimental|Oxycodone|Oxycodone(60μg/kg)
89448165|NCT04396587|Placebo Comparator|normal saline|10ml
89448166|NCT04393506|Other|Inductive therapy|Inductive therapy with Camrelizumab and Apatinib, followed by radical surgery and post-operative radiotherapy/chemoradiotherapy.
89448167|NCT04392544||Pediatric|Pediatric CF population age 10-18 years.
89448168|NCT04392544||Adult|Adult CF population age ≥ 18 years.
89448169|NCT04381559|Experimental|Cognitive Behavioural Therapy|In sessions 1-2, the participant's sexual history and goals regarding social anxiety reduction and HIV risk reduction will be discussed, including reducing CAS, and considering use of PrEP to reduce HIV risk. In sessions 3-4, the role of social anxiety and substances in social avoidance and HIV risk will be discussed, and a fear hierarchy of the participant's social fears will be created. In sessions 5-7, cognitive restructuring and coping skills for anxiety reduction will be discussed. In sessions 8-9, participants will face their fears via exposures to feared situations using their new cognitive coping skills. In sessions 10-11, exposures are continued with a focus on (a) situations higher in the fear hierarchy and (b) the role of substance use as a barrier to personal goals. In session 12, relapse prevention and goals for progress regarding social anxiety, substance use, and HIV risk reduction beyond the end of therapy will be discussed.
89448170|NCT04381559|Active Comparator|Applied Relaxation|In AR, patients are trained in progressive muscle relaxation, and then taught to practice using relaxation when facing feared situations, as a new coping response. AR involves noticing early signs of anxiety, learning relaxation skills, and applying relaxation at the first sign of anxiety. This therapy is chosen because it does not involve the cognitive and exposure focused techniques that are used in the experimental condition. Reviews of psychological treatments show that AR does not statistically differ from cognitive restructuring with exposure in its effects on social anxiety. However, AR is an appropriate control arm for the present study because it is credible and can be time-matched to CBT, but has no theoretical or empirical support for substance use management or HIV risk behaviour reduction, the latter of which is the primary outcome of the present study.
89448171|NCT04379752|Experimental|Cold-atmospeheric pressure plasma activated solution|Treatment arm subjects receive the trial intervention
89448172|NCT04366726|Experimental|abaloparatide-sMTS|Abaloparatide-sMTS 300 micrograms (μg) was applied to the thigh for 5 minutes once daily for 29 days.
89023544|NCT05181735|Experimental|Arm B (Luspatercept + EPREX)|"Patients will receive Luspatercept (at the selected dose according to part A) subcutaneously on day 1 of each 21 day cycle (every three weeks) AND Epoetin alfa: At the selected dose (in part A) per week, subcutaneously, every week~Doses schedules Part A :~Level 1 : Luspatercept 0.8 mg/kg + EPREX 30000 UI~Level 2 : Luspatercept 1.33 mg/kg + EPREX 30000 UI~Level 3 : Luspatercept 1.75mg/kg + EPREX 30000 UI~Level 4 : Luspatercept 1.75mg/kg + EPREX 60000 UI"
89023545|NCT05175131|Experimental|Mebeverine+Simethicone combination|three times a day per os
89023546|NCT05175131|Active Comparator|mebeverine|three times a day per os
89023547|NCT05175131|Active Comparator|simethicone|80 mg (2 capsules 40 mg) three times a day per os
88933731|NCT01762332|Other|chronic beta-blocker treatment|"Patients with chronic beta-blocker treatment prior to surgery and study. Will all be allocated to the high opioid level arm without randomization.~Continue recruitment."
89014454|NCT05146726||Prospective BARMER insured patients|"Group I: BARMER insured patients with preoperative anemia and an elective (N5) surgical intervention with a probability of transfusion > 10%.~Central measures in this group are the IV contract for the creation of an organizational and financing structure for the guideline-compliant detection, diagnosis and treatment of preoperative anemia and the evaluation of the machine autotransfusion as part of the preoperative premedication visit in anesthesiology (implementation is the responsibility of the patient blood management (PBM) service)."
89200591|NCT00981136|Active Comparator|SILS|Single Incision Laparoscopic Surgery (SILS) where a single incision in the umbilicus is all that is used to remove the appendix. The specific methods (staple/tie/port use/etc) will vary depending on surgeon.
89200592|NCT00981136|Active Comparator|3 port|Standard laparoscopic appendectomy with 3 ports and intracorporeal stapling.
89200593|NCT00377611|Experimental|FLUARIX 50-64 YEARS GROUP|Adult subjects aged between and including 50-64 years who received a single dose of Fluarix™ vaccine intramuscularly into the deltoid region of the non-dominant arm, were enrolled for investigation of influenza and influenza-related complications.
89200594|NCT00377611|Experimental|FLUARIX 65+ YEARS GROUP|Elderly subjects aged 65 and over who received a single dose of Fluarix™ vaccine intramuscularly into the deltoid region of the non-dominant arm, were enrolled for investigation of influenza and influenza-related complications.
89448173|NCT04333771|Placebo Comparator|Placebo|
88933732|NCT01762358|Active Comparator|Standard Therapy|Standardized physiotherapy for 12 times (15 patients)
89200595|NCT00978328||001|oxycodone immediate release (OXYRX) Characteristics of pts. receiving prescription medications containing OXYRX
89200596|NCT00869427|Active Comparator|1 vitamin C|Vitamin C 1g bid
89448174|NCT04333771|Experimental|SHR0302 dose1|
89448175|NCT04333771|Experimental|SHR0302 dose2|
89448176|NCT04319510|Experimental|Craniosacral therapy|24 CST units à 45 minutes over 12 weeks. Follow-up assessment 6 months after randomization.
89448177|NCT04319510|Experimental|Craniosacral self-help group training|24 CST units à 45 minutes over 12 weeks. Follow-up assessment 6 months after randomization.
89200597|NCT00869427|No Intervention|2|Usual Care
89200598|NCT00971230|Experimental|FTC/TDF- Daily|FTC/TDF dosed daily
89200599|NCT00971230|Experimental|FTC/TDF-Intermittent|FTC/TDF dosed intermittently
89200600|NCT00971230|Placebo Comparator|Placebo-Daily|Placebo dosed daily
89448178|NCT04319510|Other|Treatment as usual / wait list control|Waiting period of six months.
89448179|NCT04318717|Experimental|Pembrolizumab + Hypofractionated radiation therapy|"Pembrolizumab will be given intravenously over 30 minutes (-5/+10 minutes) at a dose of 200 mg on an outpatient basis on Day 1 of each 21-day cycle for a total of up to 12 months (17 cycles).~Hypofractionated radiation therapy may be given at any point during the first 2 cycles of pembrolizuimab. It should begin within 90 days of surgical resection. Intensity modulated radiation therapy (IMRT) or intensity modulated proton therapy (IMPT) are to be used exclusively. IMRT or IMPT will be delivered twice per week in five fractions of 6 Gy given over 2.5 weeks totaling 30 Gy."
89448180|NCT04318041|Experimental|diacerein (Artrodar)|
89448181|NCT04318041|Placebo Comparator|placebo|
89448182|NCT04298242|Experimental|MRgFUS Treatment|The pancreatic tumor will be ablated with magnetic resonance guided focused ultrasound (MRgFUS).
89448183|NCT04291885|Experimental|Avelumab|6 months of Avelumab at a dose of 800mg as a 60-minute intravenous (IV) infusion once every 2 weeks (13 doses)
89448184|NCT04291885|Placebo Comparator|Placebo|6 months of Placebo as a 60-minute intravenous (IV) infusion once every 2 weeks (13 doses)
89448185|NCT04273542|Other|Control cohort|"In this cohort, women recruited participated to organised breast cancer screening. They must not have an invasive breast cancer.~They will have 3 liquid biopsy : the first at inclusion and then at each mammogram every two years (organised breast cancer screening)."
89200601|NCT00971230|Placebo Comparator|Placebo-Intermittent|Placebo dosed intermittently
89200602|NCT00892359|Experimental|Anidulafungin|
89200603|NCT00978406||Healthy volunteers|Healthy volunteers
89200604|NCT00892515|Experimental|exercise|
89448186|NCT04273542|Other|Patient cohort|"In this cohort, women for who an invasive breast cancer has been diagnose will be included.~Only one liquid biopsy will be collected before any treatment."
89448187|NCT04273542|Other|Exploratory cohort|"In this cohort, women with high risk of BRCA1/2 mutation but without invasive breast cancer.~6 liquid biopsies will be collected : each year after inclusion during 5 years."
89448188|NCT04270682|Experimental|Adult Cohort|Patients in the adult cohort will participate in a randomized, double-blind, placebo-controlled, 2 period × 2-treatment crossover study with rescue medication and open-label run-in to assess the efficacy and safety of CDCA.
89448189|NCT04270682|Experimental|Pediatric Cohort|Pediatric cohort patients (≥1 month and <16 years) will participate in a 24-week, open-label cohort with an 8-week titration period and a 16-week treatment period at the tolerated dose.
89448190|NCT04269850|Experimental|FMT+ruxolitinib+steroids|ruxolitinib 10 mg bid, fecal microbiota transplantation 2 caps/kg single dose, methylprednisone 0.5 mg/kg bid
89448191|NCT04269590|Experimental|Dual Task (DT) training - PD|Combination of practicing the Swipe Slide Pattern task and a secondary task for a group of patients with Parkinson's disease (PD)
89448192|NCT04269590|Active Comparator|Single Task (ST) training - PD|Practice of the Swipe Slide Pattern task alone for a group of patients with Parkinson's disease (PD)
89448193|NCT04269590|Experimental|Dual Task (DT) training - HC|Combination of practicing the Swipe Slide Pattern task and a secondary task for a group of healthy age-matched controls.
89448194|NCT04269590|Active Comparator|Single Task (ST) training - HC|Practice of the Swipe Slide Pattern task alone for a group of healthy age-matched controls
88933733|NCT01762358|Experimental|Standard + Khalifa|Initial one hour Khalifa therapy followed by twelve times standardized Physiotherapy (15 patients)
88933734|NCT01762371|Experimental|K-Pat|Getting one time one hour of Khalifa's therapy for ACL injury treatment.
88933735|NCT01762384|Active Comparator|LSC|procedure: laparoscopic sacral colpopexy.
88933736|NCT01762384|Active Comparator|Modified PFRS|procedure: modified pelvic floor reconstructive surgery with mesh.
88933737|NCT01762397|Experimental|PMK-S005|
88933738|NCT01762410|Experimental|P7170|Patients will receive study drug on a daily basis until disease progression or unacceptable toxicity in sequential cohorts following accelerated titration design.
88933739|NCT01762423|Experimental|Active Device|"Device Placement:~Upon completion of the subjects' standard of care body contouring surgery, the device will be placed directly on the operative dressings within an unobtrusive binder with Velcro strips and will be activated before the subject leaves the OR. Subjects will then be educated on the functionality and interpretation of the user interface of the device. They will be educated on the application, removal, and return of the device.~Active Devices The device will be activated at the time of placement. The active devices are programmed to automatically deliver treatment. Each treatment duration is 15 minutes. The active device delivers treatment every 2 hours. A light will flash on the device when the PEMF begins and will continue to flash every second until the end of the treatment. Between treatments the device will be in sleep mode and the light will flash every 5 seconds."
89023548|NCT05172843|Active Comparator|Knee Arthroplasty|Surgical knee replacement using either total knee replacement (TKA) or unicompartmental knee replacement (UKA)
89448195|NCT04261855|Experimental|Arm A|Avelumab plus External Beam Radiation Therapy (EBRT)
89448196|NCT04261855|Experimental|Arm B|Avelumab plus Lutetium-177 (177Lu)-DOTATATE
89448197|NCT04261413|Experimental|RS-0139|There will be only RS-0139 arm in the study.
89448198|NCT04259398|Experimental|TIVA|propofol infusion targeting bispectral index 40-60
89448199|NCT04259398|Active Comparator|inhalation (Sevoflurane)|sevoflurane targeting bispectral index 40-60
89448200|NCT04256486|Experimental|Family DSMES|
89448201|NCT04256486|Experimental|Wait List|
89448202|NCT04256018|Experimental|LD TSEBT|"Mogamulizumab with low dose total skin electron beam therapy. •~LD (12 Gy) TSEBT will be initiated on Cycle 1 Day 2 (± 2 days) of mogamulizumab over 2 to 3 week period per standard of care (SOC), as tolerated. Mogamulizumab (1 mg/kg) will be administered over 60 minutes as follows (per SOC and FDA approved use in MF and SS):~Cycle 1 only: Days1; 8; 15; and 22 (± 2 days)~Cycle 2 and beyond: Day 1 and Day 15 (± 3 days)"
89448203|NCT04251975|Experimental|CPAP treatment|Group of patients who will receive CPAP treatment
89448204|NCT04251975|No Intervention|Conservative measures|Group of patients who will receive conservative treatment based on hygienic-dietetic measures
89448205|NCT04250064|Experimental|Concurrent low-dose Bevacizumab|Low-dose concurrent Bevacizumab with standard radiotherapy
89448206|NCT04250064|Experimental|Ultra-low-dose RT|Ultra-low-dose RT
89448207|NCT04248803|No Intervention|Total etch control group|No gluma desensitizer application
89448208|NCT04248803|Experimental|TE - GLUMA application prior to acid etching|TE- Total Etch GLUMA - Desensitizing agent
89448209|NCT04248803|Experimental|TE - GLUMA application after acid etching|TE- Total Etch GLUMA - Desensitizing agent
89448210|NCT04248803|No Intervention|Self etch control group|No gluma desensitizer application
89448211|NCT04248803|Experimental|SE - GLUMA application prior to acid etching|SE - Self Etch GLUMA - Desensitizing agent
89448212|NCT04248803|Experimental|SE - GLUMA application after acid etching|SE - Self Etch GLUMA - Desensitizing agent
89448213|NCT04245514|Experimental|Durvalumab with 3 RT cohorts|Patients will be allocated in a 1:1:1 ratio to the three radiotherapy regimens (Arm A: 20 x 2 Gy weekdaily, Arm B: 5 x 5 Gy weekdaily, and Arm C: 3 x 8 Gy q2d) using the minimization method with a random component (80% allocation probability) to reduce predictability of allocation according to the following stratification factor: T classification (T1-2 vs T3-4).
89448214|NCT04239508||Minimal Neonatal Dataset MNDS|All Swiss live-born infants below 32 weeks gestational age or 1501g birth weight
89448215|NCT04239508||Below 34, B34|All Swiss live-born infants between 32 0/1 and 33 6/7 weeks gestational age that are above 1500g birth weight
89448216|NCT04239508||Swiss Asphyxia and Cooling Registry, ASP|Infants between 35 0/7 and 42 6/7 weeks' gestational age with moderate or severe encephalopathy due to perinatal asphyxia
89448217|NCT04233398|Experimental|Test group HIFU treatment|Patients in the test group (120) will be treated with high intensity focused ultrasound (HIFU). The primary objective of this clinical trial is to evaluate the efficacy of the test device in the treatment of benign thyroid nodules, and the secondary objective is to evaluate the safety of the test device in the treatment of benign thyroid nodules and the improvement of symptoms (VAS score).
89448218|NCT04233398|No Intervention|Control group|Patients in the control group (120) will be actively observed and followed up. The primary objective of this clinical trial is to evaluate the efficacy of the test device in the treatment of benign thyroid nodules, and the secondary objective is to evaluate the safety of the test device in the treatment of benign thyroid nodules and the improvement of symptoms (VAS score).
89014455|NCT05146726||Retrospective patients insured with another statutory health insurer than BARMER|Group II: Patients not insured with BARMER and with preoperative anemia and an elective (N5) surgical intervention with a probability of transfusion > 10% and receive early anemia detection.
89014456|NCT05139732||control|Healthy participants
89014457|NCT05139732||Functional Neurological Disorder (FND)|People with the subtype functional paralysis
89014458|NCT05139732||Spinal Cord Injury (SCI)|Incomplete and complete paralysis with the ability to hold a pen
89014459|NCT05125809|Experimental|Low Dose Setrusumab -> Open-Label (OL) Setrusumab Selected Dose|"Single-blind setrusumab low dose during phase 2 followed by open-label setrusumab selected dose~During treatment and treatment extension periods, participants may receive supplementation with calcium and vitamin D to maintain normal values as directed by the treating physician"
89448219|NCT04220463|Experimental|Hypnosis group|For the hypnosis group, hypnotic support is set up by a doctor/IDE previously trained and dedicated during the implementation of the NIV. The dedicated doctor/IDE will be presented before the start of the NIV setup procedure and will start the hypnosis session a few minutes before the mask is put on. The procedure for setting up the NAV may begin after agreement from the dedicated doctor/IDE.
89448220|NCT04220463|Placebo Comparator|Control group|In the control group, in order to preserve the knowledge of the evaluator, the doctor/IDE dedicated to hypnosis is present in the service but does not intervene in the care so as not to be tempted to involuntarily put hypnosis in place. The assessor will be chosen from the two other teams present in the other two modules (each module is a seven-bed unit and has no physical communication with the other two) after the start of the procedure for setting up the NIV, with or without hypnosis, in order to be certain that he had no visual contact with the patient and the caregivers present before the evaluation. The implementation of the NAV will take place as usually carried out in the service.
89448221|NCT04211129|Experimental|acupuncture group|Receiving acupuncture and moxibustion
89448222|NCT04211129|Sham Comparator|sham acupuncture group|Receiving sham acupuncture and sham moxibustion
89448223|NCT04206553|Experimental|dupilumab|
89448224|NCT04206553|Experimental|Matching placebo|
89448225|NCT04202926|Experimental|10hz group|a high frequency stimulation
89448226|NCT04202926|Sham Comparator|sham group|a sham coil which frequency is 10hz but do not induce stimulation
89448227|NCT04197102|Active Comparator|CBD Isolate|300 mg/day of CBD isolate
89448228|NCT04197102|Active Comparator|CBD Broad Spectrum|300 mg/day of CBD Broad Spectrum Oil
89448229|NCT04197102|Placebo Comparator|Placebo oil|Matched Placebo Oil
89448230|NCT04188964|Experimental|Treatment|Pediatric subjects > = 6 months to < 12 months will receive a starting dose of 0.4mg/kg administered subcutaneously (SC) every 2 weeks (Q2W) for 48 weeks with the option of the dose to be increased to 0.8mg/kg upon recommendation of the Data Safety Management Board (DSMB). The dose can be either increased up to a maximum of 2 mg/kg or decreased to 0.2 mg/kg depending on serum phosphate response. Upon recommendation of the DSMB subjects < 6 months can then start at 0.4mg/kg starting dose administered subcutaneously (SC) every 2 weeks (Q2W) for 48 weeks with the option to be increased to 0.8mg/kg upon recommendation of the DSMB and can be either increased up to a maximum of 2 mg/kg or decreased to 0.2 mg/kg depending on serum phosphate response.
89448231|NCT04187820|Experimental|Acupuncture group|Participants receiving acupuncture and mild moxibustion.
89448232|NCT04184999|Experimental|Intracameral dexamethasone 9% + postoperative topical prednisolone acetate|dexamethasone intraocular suspension, 9% injected intracamerally at the time of cataract surgery + topical ophthalmic prednisolone acetate for 3 weeks post-operatively
89448233|NCT04184999|Active Comparator|postoperative topical prednisolone acetate|topical ophthalmic prednisolone acetate for 3 weeks post-operatively
89448234|NCT04173416|Experimental|Youth Opioid Recovery Support (YORS)|"The Youth Opioid Recovery Support (YORS) model is an innovative wrap-around approach that attempts to address barriers to treatment engagement in this vulnerable young adult population, especially difficulties with medication adherence. Its components include: (1) Home delivery of extended release naltrexone (XR-NTX) for OUD; (2) Engagement of families in collaborative treatment planning and monitoring focusing on medication adherence; (3) Assertive outreach from the treatment team including actively tracking and communicating with youth and families by text messaging and social media to promote engagement and adherence; and (4) Contingency management to provide incentives for medication adherence.~The specific components of YORS will be refined and adapted based on feedback from interviews and focus groups with various stakeholders. However, the basic framework outlined above is expected to persists."
89448235|NCT04173416|No Intervention|Treatment As Usual|TAU will contain patients who will be receiving treatment for opioid use disorder through their usual venues without the family engagement, assertive outreach, contingency management, and home delivery of medication. This often includes a referral and warm hand off to intensive outpatient SUD services and/or mental health care.
89448236|NCT04168372|Experimental|High fructose meal, with fructose label|2-13C fructose incorporated into a meal with high fructose content
89014460|NCT05125809|Experimental|High Dose Setrusumab -> OL Setrusumab Selected Dose|"Single-blind setrusumab high dose during phase 2 followed by open-label setrusumab~During treatment and treatment extension periods, participants may receive supplementation with calcium and vitamin D to maintain normal values as directed by the treating physician"
89014461|NCT05125809|Experimental|Setrusumab Selected Dose -> OL Setrusumab Selected Dose|"Double-blind setrusumab selected dose during phase 3 followed by open-label setrusumab~During treatment and treatment extension periods, participants may receive supplementation with calcium and vitamin D to maintain normal values as directed by the treating physician"
89014462|NCT05125809|Placebo Comparator|Placebo -> OL Setrusumab Selected Dose|"Double-blind placebo during phase 3 followed by open-label setrusumab~During treatment and treatment extension periods, participants may receive supplementation with calcium and vitamin D to maintain normal values as directed by the treating physician"
89014463|NCT05121948|Experimental|Phase 1a Cohort 1 - 10 mg|10 mg capsules of HC-7366 administered orally once a day in the fasting state with water at least 1 hour before food or at least 2 hours after food of each 3-week treatment cycle
89014464|NCT05121948|Experimental|Phase 1a Cohort 2 - 20 mg|20 mg capsules of HC-7366 administered orally once a day in the fasting state with water at least 1 hour before food or at least 2 hours after food of each 3-week treatment cycle
89448237|NCT04168372|Experimental|High fructose meal, with pyruvate label|2-13C pyruvate incorporated into a meal with high fructose content
89448238|NCT04168372|Experimental|Low fructose meal, with fructose label|2-13C fructose incorporated into a meal with low fructose content
89448239|NCT04168372|Experimental|Low fructose meal, with pyruvate label|2-13C pyruvate incorporated into a meal with low fructose content
89448240|NCT04167163|Active Comparator|Treatment group|"Those with clinical osteoporosis who elect ABL treatment.~ABL therapy will begin 3 months pre-TKA and continue for a total of 18 months. ABL will be administered by injection pen with dose of 80 mcg SC qDay."
89448241|NCT04167163|No Intervention|Comparator group|Those with clinical osteopenia who receive no treatment.
89448242|NCT04137692|Experimental|Red Blood Cell Transfusion|Patients will undergo isovolemic hemodilution-red cell exchange (IHD- RBCx) with up to 10 units of red cell antigens (Rh group, Kell, Duffy, Kidd blood group antigens) matched normal donor red cells to replace a target of 70% of the patient's red cells with donor red cells.
89448243|NCT04132505|Experimental|Treatment (binimetinib, hydroxychloroquine)|Patients receive binimetinib PO BID and hydroxychloroquine PO BID on days 1-14. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.
88933740|NCT01762423|Sham Comparator|Sham Device|"Device Placement:~Upon completion of the subjects' standard of care body contouring surgery, the device will be placed directly on the operative dressings within an unobtrusive binder with velcro strips and will be activated before the subject leaves the OR. Subjects will then be educated on the functionality and interpretation of the user interface of the device. They will be educated on the application, removal, and return of the device.~Sham Devices The sham devices mirror the active device with the exception of the delivery of the PEMF. The sham device will be activated at the time of placement. A light will flash on the device when the SHAM PEMF begins and will continue to flash every second until the end each treatment interval. While in sleep mode the device will not deliver treatment and the light will flash every 5 seconds."
88933741|NCT01762436|Experimental|bisoprolol|initially received 5 mg of bisoprolol (Concor®, Merck Serono, Darmstadt, Germany) once daily. The heart rate was assessed every two weeks. If the RHR was ≤65 bpm, a 2-week maintenance treatment was added during the final visit. If the target RHR was not achieved, the dose was changed as recommended in the study protocol. The maximal dose was 10 mg Qd for bisoprolol. The longest treatment period was 8 weeks. If the patient's RHR did not reach below 65 bpm at week 6, the treatment was ended at week 8.
88933742|NCT01762436|Active Comparator|atenolol|initially received 50 mg atenolol (Beijing Double-Crane Pharmaceutical Co., Ltd, Beijing, China) once daily. The heart rate was assessed every two weeks. If the RHR was ≤65 bpm, a 2-week maintenance treatment was added during the final visit. If the target RHR was not achieved, the dose was changed as recommended in the study protocol. The maximal dose was 100 mg Qd for atenolol. The longest treatment period was 8 weeks. If the patient's RHR did not reach below 65 bpm at week 6, the treatment was ended at week 8.
88933743|NCT01762449||Patients who received cyclophosphamide|Patients who received cyclophosphamide on the Scleroderma Lung Study
88933744|NCT01762449||Patients who received placebo|Patients who received placebo on the Scleroderma Lung Study
88933745|NCT01762462|Experimental|SAR302503|single treatment with oral dose up to 300 mg of SAR302503
88933746|NCT01762475|Experimental|Experimental: Group 1--Symptomatic TBI|"Experimental Group, Group 1, will consist of twenty-four male and female adult participants who have persistent TBI symptoms lasting more than six months.~Participants in the experimental group will be randomized in a 1:1 ratio, assigned to group a or b.~Participants randomized into Group 1a will take placebo twice daily for 8 weeks, followed by 8 weeks of sildenafil 25 mg twice daily with a 2-week washout period between the two 8-week periods.~Participants randomized into Group 1b will take sildenafil 25 mg twice daily for 8 weeks, followed by 8 weeks of placebo twice daily with a 2-week washout period between the two treatment periods."
88933747|NCT01762475|Active Comparator|Active Comparator: Group 2--Healthy Controls|Group 2 will be comprised of twenty male and female adult participants who have never experienced a TBI or concussion to serve as age and gender-matched healthy controls. Participants in Group 2 will have a single visit to measure cerebrovascular reactivity before and after a single dose of sildenafil (50 mg by mouth).
88933748|NCT01762475|Active Comparator|Group 3--Recovered TBI|Group 3 will be comprised of twenty male and female adult participants who have experienced a TBI, have recovered, and are asymptomatic at the time of screening, to serve as age and gender-matched asymptomatic TBI controls. Participants in Group 3 will have a single visit to measure cerebrovascular reactivity before and after a single dose of sildenafil (50 mg by mouth).
88933749|NCT01762488|Active Comparator|Renal denervation by ablation of the renal arteries|By femoral access, renal angiography is performed. The patient will be sedated. In case of acceptable renal artery anatomy allowing renal ablation, the patient will be randomized in the cath. lab. If randomized to active treatment, renal artery ablation will be carried out straight away.
88933750|NCT01762488|Sham Comparator|Control|By femoral access, renal angiography is performed. The patient will be sedated. In case of acceptable renal artery anatomy allowing renal ablation, the patient will be randomized in the cath. lab. If randomized to sham treatment, the procedure stops.
88933751|NCT01762514|No Intervention|Program I|Patients with American Joint Cancer Committee/Union Internationale Contre le Cancer (UICC/AJCC) 2010 Stage I and II; Radiotherapy applied
88933752|NCT01762514|Experimental|Program II|Patients with UICC/AJCC 2010 Stage I and II; Radiotherapy applied; Amifostine every-other-day regimen
88933753|NCT01762514|Active Comparator|Program III|Patients with UICC/AJCC 2010 Stage I and II; Radiotherapy applied; Amifostine everyday regimen
88933754|NCT01762514|No Intervention|Program IV|Patients with UICC/AJCC 2010 Stage III, IVa and IVb; Concurrent chemoradiotherapy applied
89200605|NCT00978484|Active Comparator|Static Virtual Reality|Exposure Therapy using a still computer image
89448244|NCT04131829|No Intervention|Healthy Controls|The healthy control group will be an age matched sample of unmedicated healthy adults who will be recruited and imaged once at baseline and the data compared with that of OCD subjects at baseline.
89448245|NCT04131829|Experimental|OCD Group|The OCD group will comprise of unmedicated individuals with clinically significant OCD symptoms. OCD Subjects will be randomized, double-blind, to receive immediate or delayed (by 6 weeks as a placebo lead-in) pharmacotherapy.
88933755|NCT01762514|Experimental|Program V|Patients with UICC/AJCC 2010 Stage III, IVa and IVb; Concurrent chemoradiotherapy applied; Amifostine every-other-day regimen
88933756|NCT01762514|Active Comparator|Program VI|Patients with UICC/AJCC 2010 Stage III, IVa and IVb; Concurrent chemoradiotherapy applied; Amifostine everyday regimen
88933757|NCT01762527|Experimental|ART|Online adaptive radiotherapy
88933758|NCT01762540|Placebo Comparator|Calcium supplement|Capsule with tablet of calclium supplement
88933759|NCT01762540|Active Comparator|Glucocorticoids|Capsule with tablet of Prednisolone 37,5mg
88933760|NCT01762553|Experimental|intervention|The TEA intervention program will be implemented for the intervention group. The TEA intervention has three modules (healthy body & healthy mind, family interaction, and quality of life) logically connected to each other and implemented at three levels from individual, family to the community: 1) TEA Gathering is a small group training session for PLH and their family members to deal with HIV-related challenges at individual level; 2) TEA Time is home based family activities for PLHs and their family members to interact with their children after each TEA Gathering to promote family positive interaction; 3) TEA Garden is the community events that built social integration for HIV affected families to live a healthy social life and to build sustained, supportive relationships in their communities. There will be reunions once a month for 12 months after the completion of the TEA intervention.
88933761|NCT01762553|No Intervention|Control|In order to tease out the impact of the proposed intervention from the impact of attention in general, we will add limited activities to the control group condition. The differences between the intervention and control conditions consist in both contents and formats. For the control group, there will only be group sessions once a week for three weeks starting after baseline assessment. The content of the sessions for the control group will focus on basic care, health education and promotion, nutrition, personal and family hygiene. The Essential Care Package (ECP), a set of education materials originally developed by the World Health Organization (WHO) and supported by the Global Fund Project, will be used and explained in these group sessions. Health workers from villages in the control group will also visit participating families once a week for the initial three weeks and once a month for 12 months.
88933762|NCT01762566|Active Comparator|wheat|wheat is administered blindly versus placebo in capsules once
88933763|NCT01762566|Placebo Comparator|xylose|placebo (xylose) will be administered blindly versus wheat in capsules once
88933764|NCT01762592|Experimental|Iodine (124I) Girentuximab|Single infusion of radio labeled antibody: 30 mL will be infused using an infusion pump at a rate of 2mL/min over 15 minutes on study day 0.
88933765|NCT01762618|Experimental|Cognitive Behavioral Therapy Group|14 therapy sessions, once a week for one and a half hours.
88933766|NCT01762618|No Intervention|Control Group|Social support for caregiver (through the social worker) as usual. The social worker gives information when they considered that there is a social economic risk or upon request by the caregiver.
88933767|NCT01762644|Experimental|Arm 1|Immune Tolerance and Proton Pump Inhibitor
88933768|NCT01762644|Active Comparator|Arm 2|Proton Pump Inhibitor
88933769|NCT01762657|Experimental|Oral CyclosporineA and Oral Lansoprazole|Oral Cyclosporine A dosed at 7.5 mg/kg/day in two divided dosages given with Lansoprazole dosed at 30 mg per day in two divided dosages for subjects aged 8-15 year and 60 mg per day for those aged 16-60.
88933770|NCT01762657|Placebo Comparator|Placebos|
88933771|NCT01762670|Active Comparator|Metronidazole|Oral administration of metronidazole, 500 mg twice daily for 7 consecutive days
88933772|NCT01762670|Experimental|GoldenCare|GoldenCare administered intravaginally for at least 6 hours at night for 7 consecutive nights.
88933773|NCT01762683|Experimental|pre-conceptional obesity with a scheduled cesarean section|
88933774|NCT01762683|Active Comparator|non-obese women with a scheduled cesarean section|
88933775|NCT01762683|Active Comparator|women entering labour|women entering labour for vaginal delivery and for vaginal delivery
89448246|NCT04124952||Panoptix|Patients bilaterally implanted with the Panoptix intraocular lens.
89448247|NCT04117555||Control|Diagnostic Test: Pupillometry
88933776|NCT01762696|Active Comparator|MET only|Motivational Enhancement Therapy only
88933777|NCT01762696|Experimental|MOMENT|The full MOMENT intervention: Motivational Enhancement Therapy + momentary and daily mobile self-monitoring + motivational feedback messages prompting participants to consider their individualized coping strategies to avoid using marijuana
88933778|NCT01762709|Active Comparator|The VT 4 ml/kg group|Use of tidal volume of 4 ml/kg during one lung ventilation
88933779|NCT01762709|Active Comparator|The VT 6 ml/kg group|Use of tidal volume of 6 ml/kg during one lung ventilation
89448248|NCT04117555||Parkinson patients|Diagnostic Test: Pupillometry
89448249|NCT04114227|Active Comparator|Acceptance and Commitment Therapy|Participants will learn new ways to manage uncomfortable experiences and feelings and to engage in positive behaviors.
89448250|NCT04114227|Active Comparator|Supportive Psychotherapy|Participants will talk about their experiences to date.
89448251|NCT04111549|Experimental|Home-based telehealth GOALS|Participants in this arm will receive the GOALS intervention via in-home video telehealth.
89448252|NCT04111549|Active Comparator|In-person GOALS|Participants in this arm will receive the GOALS intervention in the traditional in-person format.
89448253|NCT04107285||Neurocognitive evaluation prior to and following CART|
89448254|NCT04105153||TKI-treated advanced EGFR+ NSCLC|Patients with advanced EGFR-mutated non-small cell lung cancer treated with tyrosine kinase inhibitors
88933780|NCT01762709|Experimental|The VT 8 ml/kg group|Use of tidal volume of 8 ml/kg during one lung ventilation
88933781|NCT01762735|Active Comparator|Air insufflation colonoscopy|Air insufflation colonoscopy is the conventional colonoscopy,which is inflating air to help searching the bowel cavity while advancing the colonoscope until reaching the cecum.All the patients were examined without sedation during the whole procedure.
88933782|NCT01762735|Experimental|Water injection colonoscopy|Water injection colonoscopy : Cut off air inflating before examination. Water was injected through the working channel to follow the intestinal cavity until reaching the caecum .All the patients were examined without sedation during the whole procedure.
88933783|NCT01762748|Experimental|S. boulardii 200mg (Floratil®)|"The patients received S. boulardii every 8h during 30 days as an oral capsule formulation which contained 200 mg lyophilized S. boulardii-17 (Floratil®).~The patients enrolled in the study were evaluated immediately before the beginning of treatment, after a thirty-day period of treatment with probiotic and at the end of the second study month (after a thirty-day period without treatment with probiotic)."
88933784|NCT01762761|Experimental|Eltrombopag (ETB115)|Thrombopoietin- receptor (TPO-R) agonist
88933785|NCT01762761|Placebo Comparator|Placebo|Placebo
89448255|NCT04101968||GBA-PD|People with Parkinson's disease who are known heterozygous carriers of pathogenic GBA gene mutations.
89448256|NCT04101968||Asymptomatic GBA|Known heterozygous carriers/obligated carriers of pathogenic GBA gene mutations.
89448257|NCT04091243|Experimental|Romosozumab|Romosozumab (210mg) subcutaneously every month for 12 doses
89448258|NCT04091243|Active Comparator|Denosumab|Denosumab subcutaneously (60mg) every 6 months for 2 doses
89448259|NCT04084301|No Intervention|Normal CPB flow|In this group, the target flow during cardiopulmonary bypass (CPB) will be 2.4 L/min/m2 throughout the CPB period.
89448260|NCT04084301|Experimental|High CPB flow|In this group, the target flow during cardiopulmonary bypass (CPB) will be 2.9 L/min/m2 throughout the CPB period.
89448261|NCT04081896||In Clinic Rehabilitation|Participants who are undergoing supervised exercise based rehabilitation in the SpineZone clinic
89448262|NCT04081896||Online Rehabilitation|Participants who will be undergoing online-based coaching and exercise as prescribed via telephone, online chat, or web-based interactions with SpineZone rehabilitation staff (physical therapists and physicians)
88933786|NCT01762774|Experimental|Cohort 1|Healthy male subjects in this cohort will take part in 4 treatment periods with one of the following treatments in each period. Subjects will receive single dose of all four treatments (one per period) in a random order. Treatment A = 2 mg GSK2256294 capsules, Treatment B = 6 mg GSK2256294 capsules, Treatment C = 18 mg GSK2256294 capsules, Treatment P = Matched Placebo capsules.
88933787|NCT01762774|Experimental|Cohort 2|Obese adult male smoker subjects in this cohort will take part in 4 treatment periods with one of the following treatments in each period. Subjects will receive single dose of all four treatments (one per period) in a random order. Treatment A = 15 mg GSK2256294 capsules, Treatment B = 40 mg GSK2256294 capsules, Treatment C = 100 mg GSK2256294 capsules, Treatment P = Matched Placebo capsules.
88933788|NCT01762774|Experimental|Cohort 3|Obese adult male smoker subjects in Cohort 3 will receive single or twice daily dose of GSK2256294 or placebo for 14 days. Dose selection for Cohort 3 will be based on the safety, PK profile and enzyme inhibition obtained in cohorts 1 and 2.
88933789|NCT01762774|Experimental|Cohort 4|Obese adult male smoker subjects in Cohort 4 will receive single or twice daily dose of GSK2256294 or placebo for 14 days. Dose selection for Cohort 4 will be based on the safety, PK profile and enzyme inhibition obtained in cohorts 1 and 2 as well as safety and PK profile obtained in cohort 3.
88933790|NCT01762787|Active Comparator|Effect of Aspirin|Positive control as previously used in the cantharidin blister experimental model of inflammation
88933791|NCT01762787|Experimental|Effect of steroid - Prednisolone|Prednisolone selected as steroids should provide the most robust positive control anti-inflammatory therapy
88933792|NCT01762787|Experimental|Cantharidin exposure to optimise blister formation|Cantharidin exposure to optimise blister formation
88933793|NCT01762813||open and laparoscopic surgery|Patients with primary and or metastatic colorectal cancer (CRC) eligible for curative surgery will be included. Subcohorts may be based on either colon cancer, rectal cancer, metastatic cancer, surgery (laparoscopy or open), node negative and node positive disease, and molecular profiling.
88933794|NCT01762826||Placebo control|Diet pills of 400 mcg of acid folic daily
89448263|NCT04080180|Active Comparator|Contingency Management (CM)|CM is a behavioral method that employs external rewards for target behavior. Participants will receive gift cards for adhering to treatment (attending physician visits and being adherent to buprenorphine-naloxone) for their first 4 clinic visits.
89448264|NCT04080180|Active Comparator|Brief Motivational Interviewing + Substance Free Activities + Mindfulness (BSM)|Participants will receive the BSM intervention at 4 timepoints.
89448265|NCT04080180|Active Comparator|BSM+CM|BSM+CM is a combination of the two other arms. Participants may be randomized to this arm only in stage 2 of the SMART design.
89448266|NCT04077281|Experimental|Intervention Arm|Clinical Pharmacology specialist team approach starting in hospital and following up with the patient at home using telemedicine and detailed communication with them, their caregiver, family physician, community pharmacist and other specialists.
89448267|NCT04077281|No Intervention|Control Arm (Usual care)|Patients will receive a best possible medication history (BPMH) as do the intervention patients, then usual care by their primary team.
89448268|NCT04058990|Experimental|Agent Paclitaxel-Coated PTCA Balloon Catheter|Treatment of a Small Vessel De Novo Native Coronary Artery Lesion with a paclitaxel-coated balloon. (Agent Paclitaxel-Coated PTCA Balloon Catheter with paclitaxel 2.0 μg/mm²)
89014465|NCT05121948|Experimental|Phase 1a Cohort 3 - 40 mg|40 mg capsules of HC-7366 administered orally once a day in the fasting state with water at least 1 hour before food or at least 2 hours after food of each 3-week treatment cycle
89448269|NCT04058990|Active Comparator|SeQuent Please Drug Eluting Balloon Catheter|Treatment of a Small Vessel De Novo Native Coronary Artery Lesion with a paclitaxel-coated balloon. (SeQuent Please Drug Eluting Balloon Catheter with paclitaxel 3.0 μg/mm²)
89448270|NCT04028466|Experimental|Vonoprazan|Patients will be randomized to receiving vonoprazan, which will be taken 30 minutes before the first meal of the day for 14 days
89014466|NCT05121948|Experimental|Phase 1a Cohort 4 - 75 mg|75 mg capsules of HC-7366 administered orally once a day in the fasting state with water at least 1 hour before food or at least 2 hours after food of each 3-week treatment cycle
89014467|NCT05121948|Experimental|Phase 1a Cohort 5 - 125 mg|125 mg capsules of HC-7366 administered orally once a day in the fasting state with water at least 1 hour before food or at least 2 hours after food of each 3-week treatment cycle
89014468|NCT05121948|Experimental|Phase 1a Cohort 6 - 150 mg|150 mg capsules of HC-7366 administered orally once a day in the fasting state with water at least 1 hour before food or at least 2 hours after food of each 3-week treatment cycle
89448271|NCT04028466|Active Comparator|Omeprazole|Patients will be randomized to receiving omeprazole, which will be taken 30 minutes before the first meal of the day for 14 days
89448272|NCT04007796|Experimental|Apnea and Insomnia Relief (AIR)|This treatment will be offered over six sessions. All appointments will be conducted via telehealth and will last 60 minutes. The main components of the AIR protocol are (a) psychoeducation, (b) motivational interviewing, (c) PAP adherence strategies, and (d) cognitive behavioral therapy for insomnia.
89448273|NCT04007796|Active Comparator|Sleep Education (SE)|This treatment will be offered over six sessions. All appointments will be conducted via telehealth and will last 60 minutes. Topics covered include the sleep cycle, sleep across the lifespan, sleep and the mind, evening activities and the sleep environment, and daytime activities and sleep.
89448274|NCT04007666|Experimental|Cognitive Processing Therapy (CPT)|CPT is a gold-standard evidence-based psychotherapy for PTSD that combines education about trauma with strategies to challenge the trauma-related cognitions that are theorized to maintain PTSD symptoms. It can be delivered in group and individual formats, but will be delivered in a group format in this project due to feasibility in the setting. Structure will be based on feedback obtained during completion of Aim 2 while remaining within the range evaluated in prior research (i.e., 8-12 sessions, 1-2x per week, each lasting 1.5-2 hours).
89448275|NCT04007666|Active Comparator|Coping Skills Group|The Coping Skills Group will match for attention and dose, without adding any cost to the system. Exact content will be determined during completion of Aim 2; however, project sites already provide coping-focused programming and coping-skill approaches to trauma treatment are a common alternative to evidence-based therapies for PTSD, such as CPT, that deal more directly with the index trauma. To provide an enhanced standard of care, the investigator will review treatment materials (workbooks, handouts) already used in prison settings and arrange a curriculum of skills similar to those in coping-focused trauma-informed interventions (e.g., psychoeducation, assertiveness).
89448276|NCT04007393|Other|LSMT x 12 weeks|Participants in this arm will start LSMT at baseline and have a weight loss response assessment at T=12 weeks: if body mass index (BMI) is down 5% at T=12 weeks, the participant will continue with LSMT for the remainder of the study (i.e. for another 36 weeks); if BMI is not down 5% at T=12 weeks, the participant will add phentermine to LSMT (phentermine+LSMT) and undergo a second weight loss response assessment after 12 weeks of phentermine+LSMT; i.e. at T=24 weeks. At T=24 weeks, if BMI is down 5% with phentermine+LSMT, the participant will continue with phentermine+LSMT for the the remainder of study (i.e. for another 24 weeks); if BMI is not down by 5% at T=24 weeks, the participant will be randomized to topiramate+phentermine+LSMT or topiramate+placebo+LSMT for the remainder of the study (i.e. for another 24 weeks).
89448277|NCT04007393|Other|LSMT x 24 weeks|Participants in this arm will start LSMT at baseline and have a weight loss response assessment at T=24 weeks: if body mass index (BMI) is down 5% at T=24 weeks, the participant will continue with LSMT for the remainder of the study (i.e. for another 24 weeks); if BMI is not down 5% at T=24 weeks, the participant will add phentermine to LSMT (phentermine+LSMT) and undergo a second weight loss response assessment after 12 weeks of phentermine+LSMT; i.e. at T=36 weeks. At T=36 weeks, if BMI is down 5% with phentermine+LSMT, the participant will continue with phentermine+LSMT for the the remainder of study (i.e. for another 12 weeks); if BMI is not down by 5% at T=36 weeks, the participant will be randomized to topiramate+phentermine+LSMT or topiramate+placebo+LSMT for the remainder of the study (i.e. for another 12 weeks).
89537118|NCT02902601|Experimental|Group B: Placebo + JNJ-54175446|Participants will receive placebo on Days 1 to 3 followed by a loading dose of JNJ-54175446, 600 mg on Day 4 followed by JNJ-54175446, 150 mg once daily until Day 10.
89014469|NCT05121948|Experimental|Phase 1b Cohort 7 - Dose 1 Chosen for Expansion|XX mg capsules of HC-7366 administered orally once a day in the fasting state with water at least 1 hour before food or at least 2 hours after food of each 3-week treatment cycle
89014470|NCT05121948|Experimental|Phase 1b Cohort 8 - Dose 2 Chosen for Expansion|XX mg capsules of HC-7366 administered orally once a day in the fasting state with water at least 1 hour before food or at least 2 hours after food of each 3-week treatment cycle
89014471|NCT05118789|Experimental|Phase 1 dose escalation|NVL-520 oral daily dosing
89014472|NCT05118789|Experimental|Cohort 2a|ROS1+ NSCLC naïve to TKI therapy and up to 1 prior chemotherapy and/or immunotherapy
89014473|NCT05118789|Experimental|Cohort 2b|ROS1+ NSCLC treated with 1 prior ROS1 TKI and no prior chemotherapy or immunotherapy
89014474|NCT05118789|Experimental|Cohort 2c|ROS1+ NSCLC treated with 1 prior ROS1 TKI and 1 prior platinum-based chemotherapy with or without immunotherapy
89014475|NCT05118789|Experimental|Cohort 2d|ROS1+ NSCLC treated with ≥2 prior ROS1 TKIs and up to 1 prior chemotherapy and/or immunotherapy
89014476|NCT05118789|Experimental|Cohort 2e|ROS1+ solid tumor and progressed on any prior therapy
89014477|NCT05118191|Active Comparator|OOLER|Participants will use the OOLER device.
89014478|NCT05118191|Active Comparator|EmbrWave|Participants will use the Embr Wave 2 device.
89448278|NCT03999203|Active Comparator|A - T2 High Severe Asthmatics|"Severe asthmatic patients with eosinophil count ≥ 0.15x10^9/mL andhigh FeNO levels ≥20 ppb.~Interventions include 24 hour ambulatory cough monitoring (Leicester Cough Monitor), citric acid cough challenge, fractional exhaled nitric oxide (FeNO) testing, patient reported outcome measures and blood, urine and sputum sampling"
89448279|NCT03999203|Active Comparator|B - T2 Low Severe Asthmatics|"Severe asthmatic patients with eosinophil count ≤ 0.15x10^9/mL and low FeNO levels <20 ppb.~Interventions include 24 hour ambulatory cough monitoring (Leicester Cough Monitor), citric acid cough challenge, fractional exhaled nitric oxide (FeNO) testing, patient reported outcome measures and blood, urine and sputum sampling"
89448280|NCT03999203|Active Comparator|C - Mild/Moderate Asthmatics|mild/moderate severe asthmatics (defined as step 2/3 using the GINA classification of severity) recruited from general respiratory clinics in the Belfast HSC Trust Interventions include 24 hour ambulatory cough monitoring (Leicester Cough Monitor), citric acid cough challenge, fractional exhaled nitric oxide (FeNO) testing, patient reported outcome measures and blood, urine and sputum sampling
89448281|NCT03999203|Active Comparator|D - T2 Intermediate|"Severe asthmatic patients with eosinophil count ≥ 0.15x10^9/mL OR high FeNO levels ≥20 ppb.~Interventions include 24 hour ambulatory cough monitoring (Leicester Cough Monitor), citric acid cough challenge, fractional exhaled nitric oxide (FeNO) testing, patient reported outcome measures and blood, urine and sputum sampling"
89448282|NCT03996265|Experimental|Arm I (bupropion hydrochloride controlled-release)|Patients receive bupropion hydrochloride controlled-release PO QD for up to 13 weeks in the absence of disease progression or unacceptable toxicity.
89448283|NCT03996265|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD for up to 13 weeks in the absence of disease progression or unacceptable toxicity.
89448284|NCT03994887|Experimental|Experimental group|Patients under general anesthesia will be included.
89448285|NCT03994471|Experimental|XyloCore peritoneal dialysis solution|Patients will receive 2 to 3 daily (short-dwell) exchanges with XyloCore of an osmotic strength comparable to their pre-randomization prescription of glucose peritoneal dialysis solution (XyloCore Low, Medium and High Strenght have an osmotic strength comparable to Physioneal, Fixioneal or Dianeal 1.36%, 2.27%, 3.86% glucose, respectively, and Balance, Bicavera, Bicanova or Equibalance with 1.5%, 2.5%, 4.25% glucose, respectively). All patients will receive Extraneal (7.5% Icodextrin) for nocturnal (long-dwell) exchange.
89448286|NCT03994471|Active Comparator|Glucose peritoneal dialysis solution|Patients randomized to glucose solution will continue the 2 to 3 daily (short-dwell) exchanges of Physioneal 40 or 35, Fixioneal 40 or 35 or Dianeal (1.36%, 2.27%, 3.86% glucose), Balance, Bicavera, Bicanova or Equibalance (1.5%, 2.5%, 4.25% glucose) with the same osmotic strength of their pre-randomization prescription. All patients will receive Extraneal (7.5% Icodextrin) for nocturnal (long-dwell) exchange.
89448287|NCT03989466|Experimental|Treatment (itacitinib, alemtuzumab)|"CYCLE 1: Patients receive itacitinib PO QD on days 1-28 and alemtuzumab IV over 2 hours on days 15, 17, 19, 21, 23, 25, and 27 in the absence of disease progression of unacceptable toxicity.~CYCLE 2 AND BEYOND: Patients receive itacitinib PO QD on day 1-28 and alemtuzumab IV over 2 hours on days 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, and 27. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients who achieve a response (CR/CRi or PR) may receive itacitinib for up to 8 additional cycles in the absence of disease progression or unacceptable toxicity."
89448288|NCT03988400|Experimental|Sensory augmentation|Participants will complete 8 training sessions over 4 weeks, in which they walk on a treadmill at their self-selected speed. During training sessions, the magnitude of the vibration delivered over the hip abductor musculature will scale with the mechanical state of the pelvis at the start of each step. For example, if the step begins with the pelvis far mediolaterally from the stance foot, the swing leg hip abductors will receive strong vibration. If instead the step begins with the pelvis close mediolaterally to the stance foot, the stance hip abductors will receive strong vibration.
89448289|NCT03988400|Active Comparator|Random vibration|Participants will complete 8 training sessions over 4 weeks, in which they walk on a treadmill at their self-selected speed. During training sessions, the magnitude of the vibration applied to the hip abductors will vary randomly (following a normal distribution) on a step-by-step basis.
89448290|NCT03987425|Experimental|CPAP treatment|Group of patients who will receive CPAP treatment
89448291|NCT03987425|No Intervention|Conservative measures|Group of patients who will receive conservative treatment based on hygienic-dietetic measures
89448292|NCT03984214|Active Comparator|Dronabinol|BX-1 contains 25 mg dronabinol/ml (2.5% delta-9-trans-tetrahydrocannabinol = THC), oral solution; three applications per day from 2.5 mg (3 x 1 droplet) up to 30 mg (3 x 12 droplets)
89448293|NCT03984214|Placebo Comparator|Placebo|Placebo: oral solution with cannabis flavor without active substance and otherwise identical to active comparator, three applications per day from 3 x 1 droplet up to 3 x 12 droplets
89448294|NCT03982381|Active Comparator|Metformin|Metformin 1000-3000 mg per day according to clinical guidelines. Split into 2-3 doses per day.
88933795|NCT01762826||D-chiro-inositol / Myo-inositol|Diet sachets 2000 mg myo-inositol and 250 mg d-chiro-inositol and 400 mcg folic acid daily
88933796|NCT01762826||D-chiro-inositol|Diet pills with 500 mg d-chiro-inositol and 400 mcg folic acid daily
88933797|NCT01762826||Myo-inositol|Diet sachets with 2000 mg myo-inositol and 200 mcg folic acid twice daily
88933798|NCT01762852|Experimental|Belimumab Arm|Subjects will receive belimumab 10 mg/kg intravenous infusion [will last for 1 hour (hr)] on Day 0, Week 2, Week 4, then every 4 weeks for up to 100 weeks with frequency adjusted for subjects with >1000 mg/mmol uPCR (>10 g/24 hrs). All subjects will receive background supportive therapy throughout the study.
88933799|NCT01762852|Placebo Comparator|Placebo Arm|Intravenous infusion (will last for 1 hr) on Day 0, Week 2, Week 4, then every 4 weeks for up to 100 weeks with frequency adjusted for subjects with >1000 mg/mmol uPCR (>10 g/24 hrs). All subjects will receive background supportive therapy throughout the study.
88933800|NCT01762878|Experimental|GSK2269557 100 mcg arm|Each subject will receive 4 treatments in 4 treatment periods in Part A of the study. Subjects in this arm will be randomized to receive GSK2269557 100 mcg in one of the 4 treatment periods.
88933801|NCT01762878|Experimental|GSK2269557 500 mcg arm|Each subject will undergo 4 treatments in 4 treatment periods in Part A of the study. Subjects in this arm will be randomized to receive GSK2269557 500 mcg in one of the 4 treatment periods
89448295|NCT03982381|Experimental|Dapagliflozin|Dapagliflozin 10 mg once daily
89448296|NCT03979365|Active Comparator|Tacrolimus twice-daily|Subjects assigned to this arm will take tacrolimus two times daily by mouth, at the clinically prescribed dose.
89448297|NCT03979365|Active Comparator|Envarsus XR|Subjects assigned to this arm will take Envarsus XR one time daily by mouth, at the clinically prescribed dose.
89448298|NCT03971630|No Intervention|Standard care group|These patients will be followed by standard protocol in the Unit of HMV of the University Hospital of Santa María- University Hospital Arnau de Vilanova.
89448299|NCT03971630|Experimental|MyVENT group|These patients will be followed up using the telemedicine (MyVENT System and APP)
89448300|NCT03971448|Active Comparator|Fiberglass above-knee walking cast (AKWC)|The standard treatment arm will be a posterior splint placed in the ED by the ED clinical team (nurse/physician) and then a fiberglass AKWC to be placed ideally within 72 hours in the fracture clinic. This AKWC will be in place for 3 weeks, which is currently the most common strategy to manage TF.
89448301|NCT03971448|Experimental|Landmark Pediatric Walker Boot (LPWB)|The Landmark Pediatric Walker Boot (LPWB) will be placed in the ED and will be kept on for a minimum of one week, and then for a duration dictated by the patient's comfort.
89448302|NCT03969823|Experimental|Osimertinib|Osimertinib at 80mg dose will be administered orally once daily.
89448303|NCT03958838|Experimental|Intervention Group|"Subjects will receive usual care from community health center staff. In addition, they will also receive a variety of community-level and individual-level interventions, categorized broadly into three levels.~At the community level, subjects will receive the 5 Key Diabetes Messages that Everyone Should Know and the 6 Modules of Basic Diabetes Education. At the individual level, subjects and their families will be invited to participate in group activities, co-organized by community health staff, CHC staff, and CSMG peer leaders. Subjects will receive in-person peer support through these group activities, with follow up through telephone calls and text messaging. For subjects that have poorly controlled diabetes or are experiencing emotional distress related to their diabetes, CSMG peer leaders will work closely with them to help them solve problems around their diabetes."
89448304|NCT03958838|No Intervention|Control Group|Subjects in the control group will receive usual care from community health center staff.
89448305|NCT03948373|Experimental|CPAP treatment|Group of patients who will receive CPAP treatment
89448306|NCT03948373|No Intervention|Conservative measures|Patients who will receive conservative treatment based on hygienic-dietetic measures
89448307|NCT03943238|Experimental|Combined kidney/stem cell transplants and recipient's Tregs|Preparatory regimen including TLI, TBI, ATG after kidney transplantation followed by infusion of donor CD34+, T cell and recipient Tregs
89448308|NCT03939689|Active Comparator|Enzalutamide|
89448309|NCT03939689|Experimental|I-131-1095 in combination with enzalutamide|
89448310|NCT03917940|Experimental|Omega 3 + glimepiride|group 1: 35 patients treated with (Omega - 3 1000mg / day oral plus glimepiride 2mg or 3mg /day.
89448311|NCT03917940|Placebo Comparator|Control|group 2: 35 patients treated with glimepiride 2mg or 3mg /day.
89448312|NCT03911531||Fetuses|DNA obtained from amniotic fluid samples
89448313|NCT03911531||Neonates|DNA obtained from neonatal blood samples
89448314|NCT03906669|Active Comparator|Letrozole|Letrozole 2.5mg PO daily for 14 days between diagnosis of breast cancer and definite surgery
89448315|NCT03906669|Experimental|Letrozole and Prometrium|Letrozole 2.5mg PO daily and Prometrium 300mg PO daily for 14 days between diagnosis of breast cancer and definite surgery
88933802|NCT01762878|Experimental|GSK2269557 3000 mcg arm|Each subject will undergo 4 treatments in 4 treatment periods in Part A of the study. Subjects in this arm will be randomized to receive GSK2269557 3000 mcg in one of the 4 treatment periods
88933803|NCT01762878|Placebo Comparator|Placebo arm|The subjects will receive single dose of placebo in each treatment period of part A and repeat doses of placebo in Part B of the study.
89448316|NCT03906669|Experimental|Tamoxifen and Prometrium|Tamoxifen 20mg PO daily and Prometrium 300mg PO daily for 14 days between diagnosis of breast cancer and definite surgery
89448317|NCT03906149|Experimental|Whole-body hyperthermia + standard medical care|Whole-body hyperthermia will be applied 2 times during 4 weeks in addition to guideline-based standard medical care for depression (anti-depressive drug treatment in combination with psychotherapy). At week 6, the primary outcome will be assessed. The participants will be reassessed 12 weeks after the start of the treatment with whole-body hyperthermia.
89448318|NCT03906149|Active Comparator|Standard medical care|Participants will maintain standard medical care for depression (anti-depressive drug treatment in combination with psychotherapy). At week 6, the primary outcome will be assessed. The participants will be reassessed 12 weeks after randomization.
89448319|NCT03885167||Affected Individuals with Known SCA3|In order to be eligible for this cohort, participants must have confirmed genetic testing results for Spinocerebellar Ataxia Type 3.
89448320|NCT03885167||Healthy Individual Control Subjects|In order to be eligible for this cohort, subjects must not have a diagnosis of Spinocerebellar Ataxia Type 3 and no major medical issues including but not limited to conditions that would cause an unsafe specimen collection.
89448321|NCT03882060|Experimental|rHuEPO|recombinant human erythropoietin 500 U/kg IVS x 3 times Preoperative day (12-24 hour before surgery) During surgery Postoperative day (12-24 hour after surgery)
89448322|NCT03882060|Placebo Comparator|Control|Normal saline 50mL x 3 times Preoperative day (12-24 hour before surgery) During surgery Postoperative day (12-24 hour after surgery)
88933804|NCT01762878|Experimental|Part B GSK2269557 arm|The selection of total daily doses of GSK2269557 for Part B will anticipated to be the maximum well tolerated dose selected from Part A. The subjects will receive GSK2269557 in ratio of 3:1.with placebo. If the dose selected for Part B is not well tolerated on repeat dosing the dose may be reduced during Part B or given as divided doses.
89448323|NCT03873636|Experimental|Active Stimulation|Active stimulation of targeted brain regions involved in task-switching and dual-tasking.
89448324|NCT03873636|Sham Comparator|Sham Stimulation|Sham stimulation of targeted brain regions involved in task-switching and dual-tasking.
89448325|NCT03839784||Neurocognitive Assessment Arm|
89537119|NCT02902601|Placebo Comparator|Group C: Placebo|Participants will receive placebo from Day 1 until Day 10.
89014479|NCT05108805|Experimental|YESCARTA in the Outpatient Setting|Participants will receive YESCARTA therapy in the outpatient setting
88933805|NCT01762891|Experimental|Celecoxib|Celecoxib 200mg/day oral rout Intervention: celecoxib 200mg oral rout administered durng 15 days and followed by administration of rofecoxib 25mg/day during 15 days, placebo 15 days and acetaminophen 3g/day during 15 days.
89448326|NCT03831295|Experimental|Treatment (SD-101, BMS-986178)|"SAFETY COHORT: Patients receive TLR9 agonist SD-101 IT on days 1, 8 and 15. Patients also receive anti-OX40 antibody BMS 986178 IT on days 8 and 15, and IV over 30 minutes on days 8, 29 and 58.~EXPANSION COHORT: Patients receive TLR9 agonist SD-101 IT on days 1, 8 and 15. Patients also receive anti-OX40 antibody BMS 986178 IT on days 1, 8 and 15, and IV over 30 minutes on days 1, 29 and 58."
89448327|NCT03830190|Experimental|Intervention group|Parkinson's disease nurse specialist care
89448328|NCT03830190|No Intervention|Control group|No intervention
89448329|NCT03818191|Active Comparator|Acamprosate|"All participants will be randomized to receive acamprosate or placebo in a double-blinded placebo-controlled trial.~The most common side effect associated with acamprosate use is diarrhea, which occurs in approximately 16% of patients. Other frequently occurring side effects include asthenia, nausea, pruritus, and flatulence, headache, abdominal pain, flu syndrome, edema, weight gain, and myalgia."
89448330|NCT03818191|Placebo Comparator|Placebo|All participants will be randomized to receive acamprosate or placebo in a double-blinded placebo-controlled trial.
89448331|NCT03814967|Experimental|DLPFC Stimulation|Intervention. 20 minutes of 2 mA direct current stimulation over the dorsolateral prefrontal cortex.
89448332|NCT03814967|Active Comparator|Occipital Stimulation|Intervention. 20 minutes of 2 mA direct current stimulation over the occipital cortex.
89448333|NCT03814967|Sham Comparator|Sham Stimulation|Placebo Comparator. 0.5-1 minutes of 2 mA direct current stimulation over the dorsolateral prefrontal cortex followed by 19-19.5 minutes of sham stimulation
89448334|NCT03810768||Intensive Care Patients|Postoperative high-risk patients who have been admitted to intensive care after surgery
89448335|NCT03810768||Operative Control patients|Elective operative patients where control blood samples and muscle ultrasound will be measured.
89448336|NCT03810131|No Intervention|Waitlist control|This is a group who are waiting for treatment (the control group)
89448337|NCT03810131|Experimental|BOA online intervention|The is the group who are receiving the BOA online intervention.
89448338|NCT03792763|Experimental|Arm A, denosumab|"Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]~Every 4 weeks (Q4W) for 6 months then every 3 months (Q3M) for a total of 3 years or until progression to active, symptomatic MM~Calcilac 500 mg/400 I.E. (Calcium/Vitamin D3) Concomitant medication, oral, 1 chewable tablet / day"
89448339|NCT03792763|Placebo Comparator|Arm B, placebo|"Placebo 1.7 ml Subcutaneous Solution~SC every 4 weeks (Q4W) for 6 months then every 3 months (Q3M) for a total of 3 years or until progression to active, symptomatic MM~Calcilac 500 mg/400 I.E. (Calcium/Vitamin D3) Concomitant medication, oral, 1 chewable tablet / day"
89448340|NCT03792347|Experimental|Arm 1|Arm 1:preoperative pembrolizumab with chemoradiotherapy group Participants will receive carboplatin (AUC=2) IV and paclitaxel (50mg/m²) IV on day 1,8,15,22,29. And radiotherapy will start on day 1 of chemotherapy. A total of 41.4 Gy, 23 fractions of 1.8 Gy, 5 fractions a week. Participants will also receive pembrolizumab (2mg/kg) IV on days 1 and 22. Surgery will be performed within 6 weeks after completion of preoperative therapy described above.
89448341|NCT03791788||QFR Group|Patients with suspected ischemic heart disease including stable angina, or acute coronary syndrome including unstable angina, NSTEMI (non ST-segment elevation myocardial infarction), or STEMI (ST-segment elevation myocardial infarction) with non-culprit stenosis who underwent FFR measurement and were able to analyze QFR.
89448342|NCT03775330||SRS|Stereotactic radiosurgery
88933806|NCT01762917||Obstruction|Patients suffering from pulmonary obstruction
88933807|NCT01762917||Restriction|Patients suffering from pulmonary restriction
88933808|NCT01762917||Controls|Pulmonary healthy controls
89448343|NCT03775330||SRS plus WBRT|Stereotactic radiosurgery plus whole brain radiation
89448344|NCT03771651|Experimental|Aspirin|Subjects will take 81mg tablets of aspirin daily for 14 days prior to surgery for removal of fallopian tubes.
89448345|NCT03770182|Experimental|Group A|"NEUROLITH~Cycle 1: Active treatment~Cycle 2: Sham treatment"
89448346|NCT03770182|Experimental|Group B|"NEUROLITH~Cycle 1: Sham treatment~Cycle 2: Active treatment"
89448347|NCT03768986|Active Comparator|Treatment Group A|Standard referral for HIV testing and online HIV risk reduction training
89448348|NCT03768986|Experimental|Treatment Group B|Standard referral for HIV testing and online HIV risk reduction training plus reinforcement
89448349|NCT03738696|Experimental|Liposomal bupivacaine Interscalene Block|"Interscalene block:~10cc (133mg) liposomal bupivacaine;PLUS~10cc 0.25% bupivacaine"
89448350|NCT03738696|Active Comparator|Ropivacaine Interscalene Catheter|"20cc 0.25% bupivacaine interscalene block; PLUS~Ropivacaine 0.25% interscalene catheter (6ml/hr for 48hrs)"
89448351|NCT03735992|Experimental|Mind-body medicine group program|Patients recieve an 11-week mind-body medicine group program including elements of mindfullness based stress reduction (MBSR), yoga, and education + treatment as usual.
89448352|NCT03735992|No Intervention|Wait list|Treatment as usual.
89448353|NCT03735589|Experimental|Treatment (nCTLs, alpha-DC1 vaccine)|Patients receive the alpha-type-1 polarized dendritic cell vaccine ID 2 weeks before day 0, on day 0, and on day 28. Patients also receive aDC1 IP over 3-10 seconds on day 0. In the absence of unacceptable side effects, patients may receive the alpha-type-1 polarized dendritic cell vaccine every 1-3 months at the discretion of the physician.
89448354|NCT03706625||Non-Hodgkin-Lymphoma (after transplantation)|Immune-suppressed patients suffering from Non-Hodgkin-Lymphoma (after transplantation) and followed in the four centers of reference for rare cancers (KVirogref, CANCERVIH, LOC and POLA)
89448355|NCT03706625||Non-small cell lung cancer|Immune-suppressed patients suffering from HIV-related non-small cell lung cancer, followed in the four centers of reference for rare cancers (KVirogref, CANCERVIH, LOC and POLA)
89448356|NCT03706625||Primary Central Nervous System Lymphoma|Patients suffering from primitive cerebral lymphomas and followed in the four centers of reference for rare cancers (KVirogref, CANCERVIH, LOC and POLA)
89448357|NCT03706625||Gliomas|Patients suffering from Gliomas and followed in the four centers of reference for rare cancers (KVirogref, CANCERVIH, LOC and POLA)
89448358|NCT03706625||Non-Hodgkin-Lymphoma with HIV infection|Immune-suppressed patients (during HIV infection) and followed in the four centers of reference for rare cancers (KVirogref, CANCERVIH, LOC and POLA)
89448359|NCT03706625||Immunocompetent Non-Hodgkin-Lymphoma|Immunocompetent patients and followed in the four centers of reference for rare cancers (KVirogref, CANCERVIH, LOC and POLA).
89448360|NCT03706625||Immunocompetent Non-small cell lung cancer|Immunocompetent patients suffering from non-small cell lung cancer and followed in the four centers of reference for rare cancers (KVirogref, CANCERVIH, LOC and POLA).
89448361|NCT03703609|Experimental|Tele-yoga|Intervention of doing medical yoga at home (tele-yoga) using (1) an online videoconference system (zoom) for particpating in group-yogaled by a live yoga instructor for 60 minutes twice a week and (2) daily individual yoga for a minimum of 10 minutes using a yoga-app. Participants are provided with a tablet with conference system zoom and yoga app for 12 weeks
89448362|NCT03703609|No Intervention|Individual physical activty advice|The active control group will receive advice to be physically active that corresponds to the intervention group in time and effort, equivalent to 60 minutes for 2 days a week and a minimum of 10 minutes for 5 days a week. To compensate for the extra attention received by the intervention group by the instructor via tele-yoga group, the participants in the activecontrol group's patients will be dialed or have SMS contact (the participant chooses a type of contact) with a physiotherapist or nurse after 2, 4, 8 and 12 weeks.
89448363|NCT03686306|Experimental|Experimental group|Sildenafil citrate 140 mg/day (single morning oral dose of 140 mg) for a total duration of 24 weeks.
89448364|NCT03686306|Placebo Comparator|Control group|Placebo (single morning oral dose) for a total duration of 24 weeks.
89448365|NCT03681652||Azathioprine or 6MP|Patients treated with thiopurines for post-operative prophylaxis.
89448366|NCT03681652||Anti-TNF drug|Patients treated with anti-TNF alpha monotherapy for post-operative prophylaxis.
89448367|NCT03677596|Experimental|Dose Level 2|Inotuzumab ozogamicin at starting dose 1.2 mg/m2/cycle (administered in 3 divided doses). Most patients expected to receive 2 or 3 cycles (cycle length 21 to 28 days)
89448368|NCT03677596|Active Comparator|Dose Level 1|Inotuzumab ozogamicin at starting dose 1.8 mg/m2/cycle (administered in 3 divided doses). Most patients expected to receive 2 or 3 cycles (cycle length 21 to 28 days)
89448369|NCT03666286||Intensive Care Patients|Patients >24h on intensive care
89448370|NCT03660722|Other|Blood and urinary sample|Blood and urinary sample in HIV 1 positive adults initiating treatment
89448371|NCT03632343|Experimental|Experimental Group A|Participants in this arm will receive the Pain Squad+ smartphone app with algorithm-driven pain management advice registered nurse (RN)-initiated pain support. Email alerts related to clinically important incoming pain reports (3 consecutive reports of pain >3/10) will be sent to the study RN who will contact the healthcare team at the participants' home center to initiate clinician-driven intervention, which may be outside of the scope of the self-management algorithm. The RN will contact the participant within 12 hours of receiving the alert, including on weekends.
89448372|NCT03632343|Experimental|Experimental Group B|Participants in this arm will receive the Pain Squad+ smartphone app with algorithm-driven pain management advice but without nurse (RN)-initiated pain support.
89448373|NCT03632343|No Intervention|Waitlist Control|Participants in this arm will be waitlisted to receive their choice of experimental group condition within 1 month of completing all post-study outcome measures.
89448374|NCT03614741|Active Comparator|Control group|Bolus of 4500 IU tinzaparin
89448375|NCT03614741|Active Comparator|Study group|Bolus of 4500 IU tinzaparin and continuous infusion of 4500 IU tinzaparin
89448376|NCT03548454|Experimental|Duloxetine|Duloxetine starting at 20 mg per day and increasing to 60 mg per day as tolerated.
89448377|NCT03548454|Experimental|Desipramine|Desipramine starting at 25 mg per day and increasing to 75 mg per day as tolerated.
89448378|NCT03537729|No Intervention|Control|There will be no modifications to décor or signage in the existing care community, and no education on wayfinding. However, subjects will receive the same testing that is provided for the other arms at the designated time periods.
89448379|NCT03537729|Experimental|Salient Cues|Special signs and salient cues will be added to the community along the routes being measured for wayfinding. The cues will be comprised of pictures, objects, and signage.
89448380|NCT03537729|Experimental|Spaced retrieval education|This condition will have signage and cues as in Arm 2 added to the care communities. In addition, a spaced retrieval (SR) memory intervention strategy will be implemented individually for each resident participating in the study to help them remember the presence and function of the environmental wayfinding cues.
89448381|NCT03534934|Experimental|Baseline|"Smokers, defined has having at least a 10 pack-year lifetime history, with and without COPD will participate in the following interventions:~Vital Signs Urine Pregnancy Test on woman of child bearing potential Pre- and Post-Bronchodilator Spirometry Questionnaires Blood Test for Vitamin D level, Hemoglobin A1c, and creatinine level Duel-energy X-ray absorptiometry scan (DXA) of the whole body, spine, and hip Duel-energy X-ray absorptiometry scan (DXA) for vertebral fracture assessment Multi-detector computed tomography (MDCT) of the hip and ankle"
89014480|NCT05105087|Experimental|Diagnostic (perflubutane microbubble, ultrasound)|Patients receive perflubutane microbubble injections subdermally and then undergo ultrasound over 30 minutes before standard of care cancer treatment.
89014481|NCT05095701|Experimental|Experimental Group|349 subjects who enrolled in the experimental group of clinical trial and included in the immunogenicity subgroup PPS set from August to September 2016 will be collected venous blood 3.0~3.5ml at 5 and 8 years after primary immunization.
89014482|NCT05095701|Placebo Comparator|Control Group|354 subjects who enrolled in the control group of clinical trial and included in the immunogenicity subgroup PPS set from August to September 2016 will be collected venous blood 3.0~3.5ml at 5 and 8 years after primary immunization.
89448382|NCT03534934|Experimental|3 year follow-up|"All subjects who completed a baseline visit will return for a follow-up visit and participate in the following interventions:~Vital Signs Urine Pregnancy Test on woman of child bearing potential Pre- and Post-Bronchodilator Spirometry Questionnaires Blood Test for Vitamin D level, Hemoglobin A1c, and creatinine level Duel-energy X-ray absorptiometry scan (DXA) of the whole body, spine, and hip Duel-energy X-ray absorptiometry scan (DXA) for vertebral fracture assessment Multi-detector computed tomography (MDCT) of the hip and ankle"
89448383|NCT03517891|Experimental|WIC +|"The intervention consist in the implementation of an enhanced nutritional education and services model through the use of a combination of modalities to disseminate messages and educational materials framed in the health empowerment model. Each component of the intervention has been developed to provide the information consistent with the theoretical framework of the modality being used.~The intervention targets the following behaviors: Infant activation, Healthy sleep patterns, Screen time, Healthy feeding practices."
89448384|NCT03517891|No Intervention|WIC Standard of care (Control)|Participants recruited in randomly assigned control clinics will receive the WIC program standard of care. This includes the projected implementation of a web page for the nutritional education contacts. We will update our definition of the PR WIC program standard of care upon recruitment initiation and throughout the study implementation phase. We will also document the utilization rate of the web base platform provided by WIC among the control participants to determine baseline use of distance learning platforms.
89448385|NCT03516838|Experimental|ACTIVA™ BioACTIVE|Restoring cavity using ACTIVA filling material
89448386|NCT03516838|Active Comparator|Compomer|Restoring cavity using compomer filling material
89448387|NCT03513211|Experimental|Dose escalation arm|Suba-itraconazole in combination dose escalating hydroxychloroquine H
89448388|NCT03513211|Experimental|Phase II: Dose expansion arm|Suba-itraconazole with recommended phase II dose of hydroxychloroquine as determined by phase I arm.
89448389|NCT03504826|Experimental|Locomotor training using adaptive robot|The intervention will consist of 60 sessions of locomotor training using the HAL adaptive robot. The training sessions will be scheduled 5 days per week for 12 weeks. A physical therapist with expertise in SCI walking rehabilitation and use of the HAL will oversee all intervention sessions. The intervention sessions will include up to a total of 40 minutes of stepping time, which may take up to 2 hours to complete due to set up time and rest breaks.
89448390|NCT03468868|Active Comparator|Facility-based rehabilitation|Participants will conduct the exercise program for people with MS in a facility, for example a gym, or rehabilitation center. They will receive coaching on site at the facility.
89448391|NCT03468868|Active Comparator|Telerehabilitation|Participants will conduct the exercise program for people with MS at home and receive coaching via phone or Skype sessions.
89014483|NCT05082896||Conscious Sedation|
89014484|NCT05082896||General Anesthesia|
89014485|NCT05082077||LIVERguard patient|Patients whose donor liver was transported with the LiverGuard device.
89014486|NCT05082077||Standard Transport Patients|Patients whose donor liver was transported with a method other than the LiverGuard
89014487|NCT05079035|Experimental|Experimental: TTAX03|TTAX03 is a sterile, lyophilized and micronized particulate human AM and UC product manufactured using aseptic processing followed by terminal sterilization by gamma irradiation in compliance with current Good Tissue Practices (cGTP) and current Good Manufacturing Practices (cGMP) to preserve extracellular matrices and growth factors/cytokines therein without any living cells. TTAX03 is suspended in a volume of 2.0mL of sterile, preservative free 0.9% NaCl.
89448392|NCT03458520||Image Registry|patients with proven solid tumors or newly diagnosed mass strongly suspected to represent a solid tumor will receive MR imaging, PET/MR imaging (and if available, PET/CT imaging)
89448393|NCT03458429|Experimental|Frail, older subjects|Treated subjects are the frail, older subjects who will be treated with Granulocyte-Colony Stimulating Factor (G-CSF) Mobilized Fresh Frozen Plasma (GMFFP) in this protocol.
89448394|NCT03448757|Experimental|Autonomic response|"Group for determination of biofeedback response - 40 individuals. For the formation of this study group of subjects, 20 healthy volunteers and 20 patients with advanced hepatocellular carcinoma will be selected and studied.~Group for determination of ideal frequency - 20 patients. For the formation of this study group of subjects, 20 patients with advanced hepatocellular carcinoma participants in the group will be selected and studied to determine biofeedback response.~Group for determination of new specific frequencies - 20 individuals. For the formation of this study group of subjects, 20 patients with advanced hepatocellular carcinoma not exposed to any specific frequency will be selected."
89014488|NCT05079035|Placebo Comparator|Control: Saline|2.0mL of sterile, preservative free 0.9% NaCl alone
89014489|NCT05070247|Experimental|Dose Escalation: TAK-500 Single Agent (SA)|TAK-500 dose escalation starting at 8 microgram per kilogram (mcg/kg), infusion, intravenously, once on Day 1 of each 21-day treatment cycle (once every 3 weeks, Q3W) or once on Day 1, 15 and 29 of each 42-day treatment cycle (once every 2 weeks, Q2W), for up to 1 year.
89014490|NCT05070247|Experimental|Dose Escalation: TAK-500 + Pembrolizumab|TAK-500, infusion, intravenously, once on Day 1 of each 21-day treatment cycle (once every 3 weeks, Q3W) or once on Day 1, 15 and 29 of each 42-day treatment cycle (once every 2 weeks, Q2W), for up to 1 year, along with pembrolizumab 200 milligram (mg) infusion, intravenously, once on Day 1 of each 21-day treatment cycle or on Days 1 and 22 in a 42-day cycle (Q3W) for up to 1 year. The exact starting dose of TAK-500 will be determined from the results of the TAK-500 SA arm dose escalation.
89023549|NCT05172843|Experimental|Supervised weight loss program|The supervised intensive dietary weight loss program with meal replacements
89023550|NCT05172557|Experimental|Healthy Living Program|In addition to usual clinical Inflammatory Bowel Disease medical care, subjects will participate in a Wellness Program.
89448395|NCT03448718|Experimental|Olaparib Monotherapy|The starting dose of olaparib tablets will be dependent on the subject's calculated creatinine clearance (CrCl). Subjects with a CrCl of ≥ 40 mL/min will start at a dose of olaparib tablets of 300 mg twice a day. Subjects with a CrCl of > 30 to < 40 mL/min will start at a dose of olaparib tablets 200 mg twice a day.
89448396|NCT03436979||Subjects|Subjects who are undergoing surgical treatment for uterine prolapse will be included in the study and will be treated using the NeuGuide™ System.
89448397|NCT03422627|Experimental|Phase 1: Efavaleukin Alfa Multiple Ascending Doses|Efavaleukin will be administered as multiple ascending doses (MAD) across cohorts 1-5. Each dosing cohort will consist of between 3 and 6 subjects who will receive efavaleukin alfa subcutaneously (SC) either every week or every 2 weeks plus protocol permitted background therapy for 52 weeks. At the discretion of the Sponsor, following discussion and agreement between the principal investigator and medical monitor, subjects responding to efavaleukin alfa (as assessed by the end of week 50), who wish to continue treatment, may continue to receive efavaleukin alfa treatment at their current dosing regimen.
88933809|NCT01762930|Active Comparator|Shanchol stored at 2-8oC|Vaccines will be stored at 2-8oC before administration.
88933810|NCT01762930|Experimental|Shanchol stored at 25oC|Vaccines will be stored at 25oC for 14 days before administration.
88933811|NCT01762930|Experimental|Shanchol stored at 37oC|Vaccines will be stored at 37oC for 14 days before administration.
88933812|NCT01762930|Experimental|Shanchol stored at 42oC|Vaccines will be stored at 42oC for 14 days before administration.
88933813|NCT01762956|Experimental|Training group (TG)|The group of patients undergoing radiotherapy and submitted to pelvic floor muscles training.
88933814|NCT01762956|No Intervention|Control group(CG)|The group of patients undergoing radiotherapy only.
88933815|NCT01762969|Experimental|Modified by molecular response|Patients will be treated with imatinib upon diagnosis of CML. Molecular response will be assessed at 3 months of therapy. Based on molecular response imatinib will be continued or changed to another TKI
88933816|NCT01762995|Experimental|Cohort 1|Subjects in this cohort will take part in 4 treatment periods with one of the following treatments in each period. Subjects will receive all four treatments (one per period) in a random order. Treatment A = single dose DTG 50 mg fasted. Treatment B = single dose DTG 50 mg + Calcium Carbonate 1200 mg fasted. Treatment C = single dose of DTG 50 mg + Calcium Carbonate 1200 mg fed. Treatment D = single dose DTG 50 mg 2 hours prior to single dose Calcium Carbonate 1200 mg fasted
88933817|NCT01762995|Experimental|Cohort 2|Subjects in this cohort will take part in 4 treatment periods with one of the following treatments in each period. Subjects will receive all four treatments (one per period) in a random order. Treatment A = single dose DTG 50 mg fasted. Treatment E = single dose DTG 50 mg + Ferrous Fumarate 324 mg fasted. Treatment F = single dose of DTG 50 mg + Ferrous Fumarate 324 mg fed. Treatment G = single dose DTG 50 mg 2 hours prior to single dose Ferrous Fumarate 324 mg fasted
88933818|NCT01763008||Doripenem|Patients will be administered doripenem as per the dosing regimen given on product insert approved in Philippines.
88933819|NCT01763021|Experimental|PCI-32765 + Rifampin|Participants will recieve a single oral dose of PCI-32765 560 mg on Day 1 and Day 11 along with rifampin; and rifampin 600 mg from Day 4 to Day 13.
88933820|NCT01763034|Sham Comparator|limb ischemia|
88933821|NCT01763060||ECMO survivors|CT scan of the chest of all ECMO survivors after 2009/2010 pandemics Tests for cognitive function MRI of the brain Lung function
88933822|NCT01763086|Experimental|Mesenchymal stem cells|Mesenchymal stem cells 1×10^6 cells/kg, intravenously
88933823|NCT01763099|Experimental|Mesenchymal stem cells|Mesenchymal stem cells group refers to treatment with mesenchymal stem cells (1×10^6 cells/kg, intravenously)
88933824|NCT01763099|Experimental|Mesenchymal stem cells and cord blood|Mesenchymal stem cells and cord blood group refers to treatment with mesenchymal stem cells (at a dose of 1×10^6 cells/kg) and cord blood
89537120|NCT05307315|Experimental|music|"The state/trait anxiety inventory and surgery-specific anxiety inventory will be administered to the experimental group before the surgery. Then they will listen to Turkish Classical Music for 30 minutes.~The scales will be applied again 15 minutes after the music ends."
88933825|NCT01763112|Placebo Comparator|Placebo group|This group will not do any specific training baseline and week 4 investigation will be done only
88933826|NCT01763112|Active Comparator|Exercise Group Galileo PAH|The intervention/exercise group will do whole body vibration training on 4 days a week for 60 minutes over 4 weeks
88933827|NCT01763138|Other|pamphlet and reminder|pictorial oral health pamphlet comprising of instructions on child's oral hygiene and feeding practices and a oral health education reminder phone call after a period of one month.
88933828|NCT01763138|Other|pamphlet only|oral health education pictorial pamphlet would be provided to mothers however there will be no reminder phone calls.
88933829|NCT01763138|No Intervention|control|no oral health education or reminder phone calls will be provided to mothers.
88933830|NCT01763151|Active Comparator|toric IOL|aspherical, toric acrylic IOL (Lentis L-312T, Oculentis, Germany)
88933831|NCT01763151|Active Comparator|IOL combined with opposite clear corneal incision (OCCI)|aspherical, acrylic IOL with OCCI
88933832|NCT01763177|No Intervention|No oxygen|No given oxygen at post-anesthetic care unit
88933833|NCT01763177|Active Comparator|Oxygen|Oxygen nebulizer via face mask, Fraction of inspired oxygen (FiO2) 0.4, flow 8 liter per minute (LPM) for 30 minutes
88933834|NCT01763190|Experimental|SAR302503|single treatment of 300 mg oral dose of SAR302503
88933835|NCT01763216|Experimental|Road Tour|Road Tour was designed to improve the efficiency and accuracy of visual information processing and the ability to perform complex visual attention tasks. It focuses on improving the speed and accuracy with which users identify and locate visual information using a divided attention format. Over time, the difficulty and complexity of each task is systematically increased as users attain specified performance criteria. Difficulty is increased by reducing visual stimuli duration, adding visual distracters, increasing similarity between target and distracter stimuli, and presenting visual targets over a broader spatial expanse.
89014491|NCT05070247|Experimental|Dose Expansion: 2L NSCLC: TAK-500 + Pembrolizumab (RDE 1)|Participants with second-line (2L) non-small cell lung cancer (NSCLC) will receive TAK-500, infusion, intravenously, in a 42-day treatment cycle (Q2W or Q3W) with pembrolizumab 200 mg infusion, intravenously, in a 42-day treatment cycle (Q3W) for up to 1 year. The recommended dose (RDE 1) and schedule of TAK-500 for expansion will be based on the results of the TAK-500 in combination with pembrolizumab Dose Escalation arm.
89200606|NCT00978484|Experimental|Dynamic Virtual Reality|Virtual Reality Exposure Therapy using full, immersive Virtual Reality
89200607|NCT01051531|Experimental|Paliperidone palmitate|
89448398|NCT03422627|Experimental|Phase 2: RP2D Efavaleukin Alfa|"The phase 2 portion of this study will be conducted as a single arm, multi-center, open label trial in subjects with steroid refractory chronic graft versus Host Disease (cGVHD). All subjects will receive the recommended phase 2 dose (RP2D) of efavaleukin alfa for up to 52 weeks plus protocol permitted background therapy for cGVHD.~Due to early study termination the Phase 2 portion of the study was never opened."
89448399|NCT03422003|Experimental|Arm 1: Hypofractionation|16 fractions of radiation therapy (daily, Monday through Friday) to the chest wall with or without internal mammary nodes, and 15 fractions to the supraclavicular (with or without axillary) lymph nodes.
89448400|NCT03422003|Active Comparator|Arm 2: Conventional Radiation Therapy|25 fractions of radiation therapy (daily, Monday through Friday) to the chest wall with or without internal mammary nodes, and 23-25 fractions to the supraclavicular (with or without axillary) lymph nodes.
89448401|NCT03403621|Experimental|Topical Pentamidine Isethionate|Subjects were randomly assigned to apply topical pentamidine isethionate to either the proximal or distal end of their incision every 48 hours for 4 weeks following surgical scar excision (14-16 treatments).
89448402|NCT03403621|Placebo Comparator|Placebo Control|Subjects were randomly assigned to apply topical placebo to either the proximal or distal end of their incision every 48 hours for 4 weeks following surgical scar excision (14-16 treatments). The subject served as their own control.
89448403|NCT03387917|Experimental|TLD-1|"Duration of treatment~1 cycle: 21 days~1 cycle: 28 days (only comparative PK part, in cycle 1 or 2)~until progression or occurrence of unacceptable toxicity or withdrawal, but~maximum 9 cycles for patients previously not treated with anthracyclines~maximum 6 cycles for patients previously treated with anthracyclines.~Dose: i.v., according to DL on day 1 of each cycle or tentative MTD"
88933836|NCT01763216|Sham Comparator|Boatload of Crosswords|Boatload of Crosswords offers the user a choice between three puzzle sizes, three levels of complexity, and varying font sizes. It also provides optional help features that the user may select, like filling in a letter or word to minimize frustration levels often associated with puzzle completion. Boatload of Crosswords was chosen for this study because it is computerized, it is very popular and easy to use, and many older adults enjoy doing crossword puzzles. Boatload of Crosswords, however, does not improve speed of processing because it does not focus on central discrimination and peripheral target location. Indeed, Boatload of Crosswords is not designed to train on any aspect of cognitive ability associated with visual speed of processing.
88933837|NCT01763229|Experimental|transthoracic echocardiography|
88933838|NCT01763242|Active Comparator|EMAN|Electronic auditing via synchronised blood tests and monthly dosing ESA and Home delivery of ESA from Pharmacy if required
88933839|NCT01763242|No Intervention|Control|Standard Outpatient Care with usual blood tests and follow up, and varied ESA dosing and frequency times. Patients are responsible for collecting their own ESA from Pharmacy
88933840|NCT01763255|Experimental|CD133 transplantation|The patients with cerebral palsy that underwent CD133 transplantation.
88933841|NCT01763255|No Intervention|Control|The patients with cerebral palsy that underwent regular observation.
89448404|NCT03387917|Experimental|Caelyx (only for comparative PK part)|"Duration of treatment~1 cycle: 28 days~Caelyx is given only in one cycle (cycle 1 or 2)~Dose: i.v., 40mg/m2"
89448405|NCT03370900|No Intervention|Learning and Assessment at 12 months|Study participants will complete an 80 case learning set followed by a 20-case post test. The study intervention in this group is a 20-case test at 12 months.
89448406|NCT03370900|Experimental|Testing Every Two Months|Study participants will complete an 80 case learning set followed by a 20-case post test. Study participants in this group will receive the following study interventions: 20-case post tests without any feedback at 2, 4, 6, 8, 10, 12 months.
89448407|NCT03370900|Experimental|Low Bolus Feedback|Study participants will complete an 80 case learning set followed by a 20-case post test. Study participants in this group will receive the following study interventions: 20-case post tests at 2, 4, 6, 8, 10, 12 months. At 6 months, the 20-case post-test will be delivered with feedback.
88933842|NCT01763268|Experimental|Trivivac|Children who receive Trivivac vaccine
88933843|NCT01763281|Active Comparator|CRH|"100 microgram bolus of Cortisol Releasing Hormone intravenous injection given at a 20 minutes prior to Fructose drink during one of the two visits.~The placebo comparator will be 0.9% saline (1ml) bolus injection given intravenously at the same time point during one of the two visits"
88933844|NCT01763281|Placebo Comparator|Normal Saline (0.9%)|"100 microgram bolus of Cortisol Releasing Hormone intravenous injection given at a 20 minutes prior to Fructose drink during one of the two visits.~The placebo comparator will be 0.9% saline (1ml) bolus injection given intravenously at the same time point during one of the two visits"
89200608|NCT00869505||Case Group|Intensive Residential Treatment with memantine augmentation
89014492|NCT05070247|Experimental|Dose Expansion: 2L NSCLC: TAK-500 + Pembrolizumab (RDE 2)|Participants with 2L NSCLC will receive TAK-500, infusion, intravenously, in a 42-day treatment cycle (Q2W or Q3W) with pembrolizumab 200 mg infusion, intravenously, in a 42-day treatment cycle (Q3W) for up to 1 year. The recommended dose (RDE 2) and schedule of TAK-500 for expansion will be based on the results of the TAK-500 in combination with pembrolizumab Dose Escalation arm.
89014493|NCT05070247|Experimental|Dose Expansion: 3L NSCLC: TAK-500 (RDE 1) SA|Participants with third-line (3L) NSCLC will receive TAK-500, infusion, intravenously, in a 42-day treatment cycle (Q2W or Q3W) for up to 1 year. The recommended dose (RDE 1) and schedule of TAK-500 for expansion will be based on the results of the TAK-500 as single agent in Dose Escalation arm.
89014494|NCT05070247|Experimental|Dose Expansion: 3L NSCLC: TAK-500 (RDE 2) SA|Participants with 3L NSCLC will receive TAK-500, infusion, intravenously, in a 42-day treatment cycle (Q2W or Q3W) for up to 1 year. The recommended dose (RDE 2) and schedule of TAK-500 for expansion will be based on the results of the TAK-500 as single agent in Dose Escalation arm.
89014495|NCT05070247|Experimental|Dose Expansion: 2L Pancreatic Adenocarcinoma: TAK-500 + Pembrolizumab (RDE 1)|Participants with 2L Pancreatic Adenocarcinoma will receive TAK-500, infusion, intravenously, in a 42-day treatment cycle (Q2W or Q3W) with pembrolizumab 200 mg infusion, intravenously, in a 42-day treatment cycle (Q3W) for up to 1 year. The recommended dose (RDE 1) and schedule of TAK-500 for expansion will be based on the results of the TAK-500 in combination with pembrolizumab Dose Escalation arm.
89014496|NCT05070247|Experimental|Dose Expansion: 2L Pancreatic Adeno: TAK-500 (RDE 1) SA|Participants with 2L Pancreatic Adenocarcinoma will receive TAK-500, infusion, intravenously, in a 42-day treatment cycle (Q2W or Q3W) for up to 1 year. The recommended dose (RDE 1) and schedule of TAK-500 for expansion will be based on the results of the TAK-500 as single agent in Dose Escalation arm.
89014497|NCT05070247|Experimental|Dose Expansion: 3L RCC: TAK-500 + Pembrolizumab (RDE 1)|Participants with 3L renal clear cell carcinoma (RCC) will receive TAK-500, infusion, intravenously, in a 42-day treatment cycle (Q2W or Q3W) with pembrolizumab 200 mg infusion, intravenously, in a 42-day treatment cycle (Q3W) for up to 1 year. The recommended dose (RDE 1) and schedule of TAK-500 for expansion will be based on the results of the TAK-500 in combination with pembrolizumab Dose Escalation arm.
89014498|NCT05064878|Experimental|ZX008 0.8 mg/kg/day|Part 1: ZX008 0.8 mg/kg/day will be administered twice a day (BID) in equally divided doses; maximum of 30 mg/day, (subjects taking concomitant stiripentol will receive 0.5 mg/kg/day, [maximum of 20 mg/day]) with or without food.
89014499|NCT05064878|Placebo Comparator|Placebo|Part 1: Matching ZX008 placebo will be administered twice a day (BID) in equally divided doses with or without food.
89014500|NCT05064878|Experimental|ZX008|Part 2: Open-label ZX008 will be administered using a flexible dosing regimen, up to ZX008 0.8 mg/kg/day; maximum dose: 30 mg/day (subjects taking concomitant stiripentol will receive 0.5 mg/kg/day, [maximum of 20 mg/day]). ZX008 will be administered twice a day (BID) in equally divided doses with or without food.
89014501|NCT05044819|Experimental|Cannabidiol|Cannabidiol solution 100 milligrams per milliliter (mg/mL) will be administered orally at a dose level of 5 mg/kg/day for 1 week, then increase to 10 mg/kg/day by the participant or their caregiver twice each day (morning and evening).
89014502|NCT05023317|Experimental|Strengths-based linkage to alcohol care (SLAC)|SLAC is a behavioral intervention designed to link persons with substance use/misuse to a care or help option
89014503|NCT05023317|Active Comparator|Usual care|Usual care consists of brief intervention in primary care and/or standard referral to more intensive alcohol care (e.g., outpatient/inpatient, pharmacotherapy)
89014504|NCT05015686|Experimental|Experimental Group with the immunization course of 0,28 days, 0,42 days or 0,56 days|960 subjects (including 480 children aged 13-17 years and 480 adults aged 18 years and older) will receive two doses of experimental vaccine with the immunization course of 0,28 days, 0,42 days or 0,56 days.
89014505|NCT05015686|Active Comparator|Control Group|960 subjects (including 480 children aged 13-17 years and 480 adults aged 18 years and older) will receive two doses of control vaccine with the immunization course of 0,28 days, 0,42 days or 0,56 days.
89014506|NCT05015686|Experimental|Experimental Group with the immunization course of 0, 70 days|320 subjects (including 160 children aged 13-17 years and 160 adults aged 18 years and older) will receive two doses of the experimental vaccine with the immunization course of 0, 70 days.
89014507|NCT05015686|Placebo Comparator|Placebo group|160 subjects (including 80children aged 13-17 years and 80 adults aged 18 years and older) will receive two doses of the placebo with the immunization course of 0, 70 days.
89014508|NCT05011058|Experimental|Nanatinostat with Valganciclovir|"Patients will receive nanatinostat 20 mg orally once daily, days 1-4 per week with valganciclovir 900 mg orally once daily.~Up to 10 PTCL patients will receive nanatinostat 20 mg orally once daily, days 1-4 per week."
89014509|NCT05002998|Other|Teprotumumab 4 Infusions|"• 4 infusions of teprotumumab (10 mg/kg for the first infusion and 20 mg/kg for the remaining 3 infusions) (Cohort 1) followed by 4 infusions of:~Placebo if a participant is a treatment responder at Week 12 or~Teprotumumab 20 mg/kg if a participant is a treatment non-responder at Week 12"
89014510|NCT05002998|Other|Teprotumumab 8 Infusions|8 infusions of teprotumumab (10 mg/kg for the first infusion and 20 mg/kg for the remaining 7 infusions) (Cohort 2)
89014511|NCT05002998|Other|Teprotumumab 16 Infusions|16 infusions of teprotumumab (10 mg/kg for the first infusion and 20 mg/kg for the remaining 15 infusions) (Cohort 3)
89014512|NCT04999384|Active Comparator|AN4005 dose level 0|One sentinel patient will be orally dosed at 50 mg AN4005 BID. If this dose for one cycle is deemed to be tolerable upon review of safety data and PK data, the dose of AN4005 will be escalated to next level: dose level 1.
89014513|NCT04999384|Active Comparator|AN4005 dose level 1|Three patients will be orally dosed at 100 mg AN4005 BID. Based on the number of DLT events during the first cycle, dosing decisions will be made, including add 3 patients at the same dose level (1 DLT), escalation to dose level 3 (<1/6 DLT), de-escalate to lower dose or stop (>1/6 DLT).
89200609|NCT00869505||Control Group|Intensive Residential Treatment without memantine augmentation
89200610|NCT00971308|Experimental|BMS-824393 (Panel 1)|
89200611|NCT00971308|Experimental|BMS-824393 (Panel 2)|
89200612|NCT00971308|Experimental|BMS-824393 (Panel 3)|
89537121|NCT05307315|No Intervention|control|The state/trait anxiety inventory and surgery-specific anxiety scale will be administered to the control group before surgery. The same scales will be applied again 45 minutes after the scales are applied.
89014514|NCT04999384|Active Comparator|AN4005 dose level 2|Three patients will be orally dosed at 200 mg AN4005 BID. Based on the number of DLT events during the first cycle, dosing decisions will be made, including add 3 patients at the same dose level (1 DLT), escalation to dose level 3 (<1/6 DLT), de-escalate to lower dose or stop (>1/6 DLT).
89014515|NCT04999384|Active Comparator|AN4005 dose level 3|Three patients will be orally dosed at 400 mg AN4005 BID. Based on the number of DLT events during the first cycle, dosing decisions will be made, including add 3 patients at the same dose level (1 DLT), escalation to dose level 4 (<1/6 DLT), de-escalate to lower dose or stop (>1/6 DLT).
89014516|NCT04999384|Active Comparator|AN4005 dose level 4|Three patients will be orally dosed at 600 mg AN4005 BID. Based on the number of DLT events during the first cycle, dosing decisions will be made, including add 3 patients at the same dose level (1 DLT), de-escalate to lower dose or stop (>1/6 DLT).
89014517|NCT04999384|Active Comparator|AN4005 food effect|The effect of a high-fat meal on the PK of AN4005 will be evaluated in a separate cohort of approximately 6 patients after a safe and clinically relevant dose is identified during the dose finding part of the study.
89448408|NCT03370900|Experimental|High Bolus Feedback|Study participants will complete an 80 case learning set followed by a 20-case post test. Study participants in this group will receive the following study interventions: 20-case post tests at 2, 4, 6, 8, 10, 12 months. At 4, 8, and 12 months, the 20-case post-test will be delivered with feedback.
89448409|NCT03361735|Experimental|Treatment (hormone therapy, SBRT, radium Ra 223 dichloride)|Beginning 4 weeks (28 days) prior to radiation therapy, patients receive leuprolide acetate or goserelin acetate, for up to 32 weeks. Patients also undergo 3-5 fractions of SBRT every 40 hours over 7-21 days beginning on day 1 of course 1, and receive radium Ra 223 dichloride IV over 1 minute on day 1 of courses 2-7. Treatment repeats every 28 days for up to 7 courses in the absence of disease progression or unacceptable toxicity.
89014518|NCT04997980||Amiodarone group|Patients who did receive amiodarone during the attempt of resuscitation
89448410|NCT03353974|Experimental|Video game therapy|Subjects belonging to the experimental group will receive a Video Game Therapy (VGT) protocol using the Xbox console. They will receive 12 sessions of treatment within 4 weeks (3 sessions per week); each session will last 1 hour. To manage possible absence lasting one or more treatment sessions, a potential window of 5 weeks will be set to ensure the achievement of all 12 sessions. Will be required to concentrate in games whose major purposes are increasing balance, selective attention and attention shifting. During sessions the patient will be carefully controlled by a researcher who will prevent the risk of falling
89448411|NCT03353974|Active Comparator|Balance platform therapy|"Subjects belonging to the control group will receive the same amount of therapy (12 sessions) using a balance platform (Biodex Medical Systems, Inc., Shirley, NY). Balance/rebalancing, postural stability and weight-shifting exercises ill be administered with and without visual feedback. During the first session, the tasks will be performed at an entry level, and the exercise progression will be adjusted over time according to the patients' functional level (intermediate and difficult level). Balance platform therapy offered visual feedback and knowledge of performance (augmented feedback). The physiotherapist, as during VGT, provided additional external feedback."
89448412|NCT03320837||Breastfeeding group|Infant are exclusively fed with breast milk
89448413|NCT03320837||Mixed feeding group|Infants are fed with mixed nutrition with breast milk and Rontamil Complete 1®
89448414|NCT03320837||Infant formula group|Infant are fed exclusively with Rontamil Complete 1®
89448415|NCT03298243|Experimental|Stroke Cohort - Progressive Training|Aim 1 intervention: Vibrotactile stimulation. Progressive training from simple to more complex reaching task using vibrotactile feedback to guide performance
89448416|NCT03298243|Experimental|Stroke Cohort - Whole Task Training|Aim2 intervention: Vibrotactile stimulation. Training on only the more complex reaching task using vibrotactile feedback to guide performance
89448417|NCT03264534|Active Comparator|limbal relaxing incisions|Manually performed limbal relaxing incisions
89448418|NCT03264534|Active Comparator|astigmatic keratotomy|femtosecond laser-guided astigmatic keratotomy
89448419|NCT03225105|Experimental|M3541 50 mg + RT|Participants received 50 milligrams (mg) M3541 orally once per fraction day (FD) in combination with palliative radiotherapy (RT) administered in fraction of 30 Gray (Gy) given in 10 fractions of 3 Gy/FD on FD 1 to FD 10, for 2 consecutive calendar weeks (ie, Monday through Friday, with the intervening Saturday and Sunday as M3541 / RT holidays).
89448420|NCT03225105|Experimental|M3541 100 mg + RT|Participants received 100 mg M3541 orally once per FD in combination with palliative RT administered in fraction of 30 Gray (Gy) given in 10 fractions of 3 Gy/FD on FD 1 to FD 10 for 2 consecutive calendar weeks (ie, Monday through Friday, with the intervening Saturday and Sunday as M3541 / RT holidays).
89448421|NCT03225105|Experimental|M3541 200 mg + RT|Participants received 200 mg M3541 orally once per FD in combination with palliative RT administered in fraction of 30 Gray (Gy) given in 10 fractions of 3 Gy/FD on FD 1 to FD 10 for 2 consecutive calendar weeks (ie, Monday through Friday, with the intervening Saturday and Sunday as M3541 / RT holidays).
89014519|NCT04997980||NO Amiodarone|Patients who did receive amiodarone during the attempt of resuscitation
89014520|NCT04995406||Active TB ATB|Participants with active tuberculosis with diagnosis confirmed by GeneXpert and/or culture positivity
89537122|NCT00702923|Experimental|1|Bicalutamide 150mg orally days 1-28 followed by CP-675,206 IV on day 29. Cycle is repeated once at month 3
89537123|NCT05294055|Experimental|lymphoma, chemotherapy plus Mecapegfilgrastim SC on day 2|
89014521|NCT04995406||Latent Tuberculosis Infections LTBI|Participants with presumed latent TB infection
89014522|NCT04995406||Healthy controls HC|Participants who do not have Active or Latent tuberculosis or other pathologies investigated in this study
89014523|NCT04995406||Non-tuberculous symptomatic participants|This cohort refers to participants who are known with chronic respiratory conditions and present with one or more signs and symptoms suggestive of TB, but in whom microbiological testing is negative.
89014524|NCT04980404|Experimental|Dose Escalation Inqovi|"Study will follow a standard '3+3' dose escalation design:~Initial group of 3 participants will receive Inqovi (decitabine/cedazuridine) on days 1-3 of a 42 day cycle/dose-limiting toxicity (DLT) period.~Additional enrollment, dosage and study cyles will be determined by number of dose-limiting toxicity (DLT) that occur in initial group"
89200613|NCT00971308|Experimental|BMS-824393 (Panel 4)|
89200614|NCT00971308|Experimental|BMS-824393 (Panel 5)|
89014525|NCT04980404|Experimental|Recommended Phase 2 Dose Expansion (RP2S) Inqovi|Once the Recommended Phase 2 Dose Expansion (RP2S) is established, 10 additional participants will be enrolled and receive Inqovi (decitabine/cedazuridine) on days 1-3 of a 28 day study cycle.
89014526|NCT04978272|Active Comparator|IPTc DP 1 year|DP given from 8 weeks to 52 weeks of age; DP placebo given from 52 weeks to 104 weeks of age; No IPTc in third and fourth years of follow-up.
89014527|NCT04978272|Active Comparator|IPTc DP 2 years|DP given from 8 weeks to 104 weeks of age; No IPTc in third and fourth years of follow-up.
89014528|NCT04978272|Placebo Comparator|No IPTc|DP placebo given from 8 weeks to 104 weeks of age; No IPTc in third and fourth years of follow-up.
89448422|NCT03225105|Experimental|M3541 300 mg + RT|Participants received 300 mg M3541 orally once per FD in combination with palliative RT administered in fraction of 30 Gray (Gy) given in 10 fractions of 3 Gy/FD on FD 1 to FD 10 for 2 consecutive calendar weeks (ie, Monday through Friday, with the intervening Saturday and Sunday as M3541 / RT holidays).
89448423|NCT03217071|Experimental|Pembrolizumab + Surgery|Patients will receive 200mg pembrolizumab on Day 1 of each 3 week cycle, for 2 cycles, prior to surgery. Pembrolizumab will be administered via IV infusion for 30 minutes. Surgery will occur no later than 6 weeks following the last dose of pembrolizumab.
89014529|NCT04975516|Experimental|Group I (SBRT, chemotherapy)|Patients undergo SBRT QD or every other day for 5 fractions, and receive chemotherapy per standard of care.
89014530|NCT04975516|Active Comparator|Group II (chemotherapy)|Patients receive chemotherapy per standard of care.
89537124|NCT05294055|Experimental|lymphoma, chemotherapy plus Mecapegfilgrastim SC on day 5|
89014531|NCT04969887|Experimental|Ipilimumab and Nivolumab|All Subjects will be treated with: Nivolumab at 3 mg/kg and ipilimumab at 1 mg/kg concurrently every 3 weeks for 4 doses followed by nivolumab only at 480mg every 4 weeks until progression (up to 2 years)
89014532|NCT04968860||Study group|Composed of children/adolescent individuals who have a definitive diagnosis of lymphoid leukemia or acute myeloid leukemia, who will be invited to participate in the research, regardless of race or gender.
89014533|NCT04968860||Control group|The control group is going to consist of healthy children/adolescent individuals, non-syndromic, without history of cancer, matched by age and gender in relation to the study group, who have not used antibiotics 48 hours before or in the day of evaluation.
89014534|NCT04966299|Active Comparator|Sucrose|15 participants receive 25g sucrose per day during 5 weeks
89014535|NCT04966299|Experimental|Erythritol|15 participants receive 36g eryhtritol per day during 5 weeks
89014536|NCT04966299|Experimental|EryClot-Pilot Erythritol|3 participants receive 50g erythritol dissolved in 300mL water once during the visit
89014537|NCT04966299|Active Comparator|EryClot-Pilot Glucose|3 participants receive 75g glucose dissolved in 300mL water once during the visit
89014538|NCT04966299|Active Comparator|EryClot-Pilot Fructose|3 participants receive 25g fructose dissolved in 300mL water once during the visit
89014539|NCT04949113|Experimental|A: Neoadjuvant|"2 cycles of neoadjuvant ipilimumab (80mg) + nivolumab (240mg) every 3 weeks followed by a total lymph node dissection (TLND) and if applicable, resection of in-transit metastases.~Patients with a pathologic partial or non-response in arm A will also receive adjuvant nivolumab 480 mg every 4 weeks 11 cycles. In case of BRAF V600E/K mutation-positivity, patients will be treated with adjuvant dabrafenib plus trametinib for 46 weeks instead."
89014540|NCT04949113|Active Comparator|B: Adjuvant|Standard upfront total lymph node dissection (TLND) and if applicable, resection of in-transit metastases followed by 12 cycles adjuvant nivolumab 480 mg every 4 weeks
89014541|NCT04930289||LungGuard patients|Patients whose donor lung(s) was transported with the LungGuard device.
89014542|NCT04930289||Standard Transport Patients|Patients whose donor lung(s) was transported with a method other than the LungGuard
89014543|NCT04907851|Experimental|Module 1 - RNF43 Mutated Advanced (unresectable)/Metastatic Pancreatic Cancer (Stage III/IV)|Patients (Karnofsky performance status ≥70) will be recruited and dosed with RXC004 (2 mg once daily [QD], orally) within 6 weeks of progression following 1st line SoC treatment.
89014544|NCT04907851|Experimental|Module 2 -Advanced (unresectable)/Metastatic Biliary Tract Cancer (Stage III/IV)|Patients (Eastern Cooperative Oncology Group [ECOG] performance status 0-1) will be recruited and dosed with RXC004 within 6 weeks of progression, following 1st line SoC treatment.
89014545|NCT04907851|Experimental|Module 3-Advanced (unresectable)/Metastatic Biliary Tract Cancer (Stage Ill/IV) Combination Therapy|Patients (ECOG performance status 0-1) will be recruited and dosed with RXC004 (1.5 mg QD, orally) in combination with pembrolizumab 400 mg IV infusion every 6 weeks (q6w) within 6 weeks of progression, following 1st line Soc treatment.
89014546|NCT04906395|Experimental|Active Comparator: TOL2506|TOL2506 in combinatination with standard endocrine therapy (Tamoxifen & Aromatase Inhibitors)
89014547|NCT04905563|Other|Control|Standard of care- weight based dose of liquid acetaminophen-hydrocodone- 0.15 mg/kg/dose every six hours with a max dose of 10 mg/dose
89014548|NCT04905563|Experimental|Treatment|Weight based dose of liquid acetaminophen and ibuprofen- acetaminophen 15 mg/kg/dose and ibuprofen 10 mg/kg/dose every six hours with a max dose of 650 mg/dose of acetaminophen and 600 mg/dose of ibuprofen.
89014549|NCT04891692|Experimental|Phasic Treatment Group|Muscle therapy for the lumbar spine at the StimaWell 120MTRS system's phasic setting. Treatment at 3 kHz, modulation 50 Hz. Supervised 10 week intervention, 2 times a week. Treatment time of 20 minutes for the first 3 weeks, 25 minutes for the second 3 weeks, and 30 minutes for the final 4 weeks. 120MTRS system recalibration every fifth treatment.
89014550|NCT04891692|Experimental|Combined Treatment Group|Muscle therapy for the lumbar spine at the StimaWell 120MTRS system's combined (tonic and phasic) setting. Treatment at 3 kHz, modulation 4 Hz and 50 Hz. Supervised 10 week intervention, 2 times a week. Treatment time of 20 minutes for the first 3 weeks, 25 minutes for the second 3 weeks, and 30 minutes for the final 4 weeks. 120MTRS system recalibration every fifth treatment.
89014551|NCT04886531|Experimental|A|"Weeks 1-3* patients receive either (a) Neratinib, (b) Letrozole or Anastrozole or (c) Neratinib + Letrozole or Anastrozole~Weeks 4-24 patients receive Neratinib + Letrozole or Anastrozole and Trastuzumab~*Starting drug intervention varies for the first 3 weeks depending on arms: a, b, and c by randomization."
89014552|NCT04881032|Experimental|AGuIX + chemoradiotherapy (radiotherapy + temozolomide)|addition of AGuIX nanoparticles to standard radiotherapy and concomitant treatment by temozolomide (TMZ) for patients of phase I and patients randomized in experimental arm of phase II
89014553|NCT04881032|Sham Comparator|chemoradiotherapy (radiotherapy + temozolomide)|standard of care : chemoradiotherapy (radiotherapy + temozolomide) for patients randomized in control arm of phase II
89014554|NCT04870112|Experimental|Patients with NSCLC|Patients with Non-Small Cell Lung Cancer
89014555|NCT04870112|Experimental|Patients with SCLC|Patients with Small Cell Lung Cancer
89014556|NCT04867473|Experimental|Teleyoga|Lyme disease participants will attend home-based yoga sessions using HIPAA-compliant telehealth software and devices and complete pain inventory questionnaires pre and post-treatment
89448424|NCT03217071|Experimental|Pembrolizumab + Radiation + Surgery|Patients will receive 200mg pembrolizumab on Day 1 of each 3 week cycle, for 2 cycles. Pembrolizumab will be administered via IV infusion for 30 minutes.Within the week (7 days +/- 3 days) following administration of the second cycle, a single 12 Gy dose of stereotactic radiation therapy (SRT) will be delivered to 50% of the primary tumor only. Definitive surgical resection will occur no later than 6 weeks following the last dose of pembrolizumab.
89448425|NCT03199053|Experimental|Low dose Dapagliflozin|Oral route. Start with a low dose of dapagliflozin administered once daily and remain on the low dose regardless of your HbA1c at week 12.
89448426|NCT03199053|Experimental|Low dose/high dose Dapagliflozin|Oral route. Start with a low dose of Dapagliflozin administered once daily and up titrate to the high dose Dapagliflozin administered once daily if HbA1c >= 7% at week 12
89448427|NCT03199053|Experimental|Low dose Saxagliptin|Oral route. Start with a low dose of saxagliptin administered once daily and remain on the low dose regardless of your HbA1c at week 12
89448428|NCT03199053|Experimental|Low dose/high dose Saxagliptin|Oral route. Start with a low dose of saxagliptin administered once daily and up titrate to the high dose if HbA1c >= 7% at week 12
89448429|NCT03199053|Placebo Comparator|Placebo arm|Oral route. Placebo tablets administered for 52 weeks
89448430|NCT03195699|Experimental|Dose escalation study|Participants will receive up to 4 dose levels of TTI-101 to determine RP2D
89200615|NCT00869583|Experimental|1|Participants will immediately take part in the physical activity program.
89200616|NCT00869583|No Intervention|2|
89448431|NCT03195699|Experimental|Dose expansion study|Enrollment in the dose expansion may commence with approval from the safety review committee. Participants will be enrolled and treated at the RP2D of TTI-101
89448432|NCT03195699|Experimental|Food effect study|Participants will be treated with TTI-101 at the RP2D under fed and fasted conditions to assess the bioavailability of TTI-101 and to determine the best conditions for taking the study drug
89448433|NCT03195699|Experimental|Dose expansion, cross-over study|Participants will be administered different formulations of TTI-101 to compare bioavailability.
89448434|NCT03186079|Active Comparator|Xiaojidaozhi Decoction|Xiaojidaozhi Decoction and Fiberform and Toilet training are used for treatment of childhood Constipation
89014557|NCT04852185|Experimental|Vi-TT Arm|A single dose of Vi-TT to children 9 months to 15 years of age.
89014558|NCT04852185|Active Comparator|MCV-A arm|A single dose of MCV-A vaccine to the comparator group.
89014559|NCT04841668||Patients with recently diagnosed T2DM|This group will consist of 36 recently diagnosed T2DM, according to the World Health Organization (WHO) patients (last 6 months), who have not received treatment with metformin.
89014560|NCT04841668||Patients with long-term T2DM|The group will consist of 100 patients with long-term T2DM, according to the WHO classification, regardless of whether they take metformin or another treatment.
89014561|NCT04840914|Experimental|LY3461767|LY3461767 administered subcutaneously (SC).
89014562|NCT04840914|Placebo Comparator|Placebo|Placebo administered subcutaneously (SC).
89014563|NCT04837417||Pathologic group|At least 10 male participants who underwent anterior cruciate ligament arthroscopic reconstruction using semitendinosus and gracilis tendons graft, between 6 and 18 months before the tests
89014564|NCT04835428|Experimental|Treatment with AGN1 LOEP SV Kit|The AGN1 LOEP SV Kit is intended for fixation of pathological fractures of the vertebral body using vertebral augmentation. Following saline lavage to create space, the AGN1 implant material is injected and hardens in situ to augment the fractured vertebral body. The AGN1 implant material is then resorbed and replaced with new bone.
89014565|NCT04835428|Active Comparator|Treatment with PMMA bone cement|High viscosity PMMA bone cement will be used for vertebral augmentation.
89448435|NCT03186079|Placebo Comparator|non-Xiaojidaozhi Decoction|Placebo and Fiberform and Toilet training are used for treatment of childhood Constipation
89448436|NCT03170453|Experimental|Cognitive Enhancement Therapy|"This research treatment aims to help with problems in thinking, planning, and socialization. Participants begin with cognitive training using computer software programs. They also participate in a small social-cognitive group to learn about their condition and how to act wisely in social situations by developing the abilities needed to understand another person's perspective, evaluate social contexts, and be foresightful.~Time commitment: about 3½ hours per week; Location: Pittsburgh, PA only"
89448437|NCT03170453|Active Comparator|Enriched Supportive Therapy|"This research treatment uses individual supportive therapy to help adults learn about autism spectrum disorder, manage their emotions and stress, improve their social skills, and cope with everyday problems. Participants will learn about the impact of stress on their lives, and how to identify their own early cues of distress and apply effective coping strategies.~Time commitment: about 1 hour per week; Location: Pittsburgh, PA only"
89448438|NCT03168880|Active Comparator|A|weekly Paclitaxel chemotherapy at the dose of 100 mg/m2/week for 8 weeks as a 1-hour infusion and AC/EC (60/600 or 90/600) / 3 weekly.
89200617|NCT02533843|Active Comparator|Arm I|ablation at sources guided by FIRMap (using RhythmView™ Workstation from TOPERA) Intervention: AF ablation
89200618|NCT02533843|Active Comparator|Arm II|ablation at sources guided by FIRMap (using RhythmView™ Workstation from TOPERA) + conventional pulmonary vein antrum isolation (PVAI) Intervention: AF ablation
89200619|NCT02533843|Active Comparator|Arm III|Extended PVAI plus ablation of non-PV triggers and complex fractionated atrial electrograms (CFAE) Intervention: AF ablation
89200620|NCT00971386|Other|Normal Healthy Subjects|Normal healthy subjects without history, signs-symptoms or diagnosis of heart failure
89200621|NCT00971386|Other|Chronic Ambulatory Heart Failure|Diagnosis of Chronic Heart Failure and currently on optimal medical therapy
89200622|NCT00971386|Other|Acute Heart Failure|Patients admitted to the hospital with acute congestive heart failure.
89448439|NCT03168880|Experimental|B|weekly Paclitaxel at 100mg /m2/week + weekly Carboplatin AUC-2 as an infusion over 60 minutes and AC/EC (60/600 or 90/600)/ 3 weekly.
89448440|NCT03149575|Experimental|VAL-083, Dianhydrogalactitol|Up to 120 eligible patients will be randomized to receive VAL-083.
89448441|NCT03149575|Active Comparator|Physician's Choice of Salvage Therapy|"Up to 60 patients will be randomized to receive Investigator's choice of salvage therapy temozolomide, lomustine, or carboplatin"
89448442|NCT03149185|Active Comparator|T-CBSM|Technology based cognitive behavioral stress management.
89448443|NCT03149185|Active Comparator|T-HP|Technology based health promotion (control condition)
89448444|NCT03137472|Experimental|Active Treatment|Participants will receive active TMS in the target area once daily for two days
89448445|NCT03137472|Sham Comparator|Sham Treatment|Participants will receive active TMS in a non-target area once daily for two days
89448446|NCT03102138||observation|subjects treated in B4711001 with PF-05206388 will be assessed
89448447|NCT03063749||Primary Cohort|Subjects receiving stents 2.0 mm - 4.0 mm in diameter will be included in the Primary Cohort.
89448448|NCT03063749||Extra Large Vessel (XLV) Cohort.|Subjects receiving stents 4.5 mm or 5.0 mm in diameter will be included in the Extra Large Vessel (XLV) Cohort.
89448449|NCT03042936|Experimental|Arm 1|Insulin Superheroes Club Curriculum
89448450|NCT03029884|Experimental|Sham DBS|"Chronic brain recording and stimulation with unilateral or bilateral implantation in pain-related brain regions. Both thalamic pain syndrome and phantom pain participants will participate in sham, open-loop and closed-loop DBS, blinded to the participant.~Open Loop involves tonic stimulation of ACC of OFC brain region. During closed-loop DBS sessions, stimulation will be delivered in response to identified personalized, brain biomarkers of chronic pain.Sham involves no active stimulation - brain recordings will remain active with no active stimulation. Because more than 6 sequences were used, only 1 Arm/Group is defined."
89448451|NCT03029884|Experimental|Open-Loop DBS and Closed-Loop DBS|"Chronic brain recording and stimulation with unilateral or bilateral implantation in pain-related brain regions. Both thalamic pain syndrome and phantom pain participants will participate in sham, open-loop and closed-loop DBS, blinded to the participant.~Open Loop involves tonic stimulation of ACC of OFC brain region. During closed-loop DBS sessions, stimulation will be delivered in response to identified personalized, brain biomarkers of chronic pain.Sham involves no active stimulation - brain recordings will remain active with no active stimulation. Because more than 6 sequences were used, only 1 Arm/Group is defined."
89448452|NCT03027388|Experimental|1/LB100 Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma|Treatment with LB100
89448453|NCT03010150||Observational (blood tests, questionnaires)|Participants provide blood samples prior to and at the 6-month visit after receiving radiation therapy. Participants also complete questionnaires either at home, in clinic, or via internet over 30 minutes prior to receiving radiation therapy and within 14 days of blood sample collection.
89448454|NCT03007589|Other|Location|Location and Intensity of Exposure to Sunlight otc sunscreens sun protection fabrics optical filters
89014566|NCT04834778|Experimental|Cohort 1 - 25 mg|25 mg capsules of HC-5404-FU administered orally twice a day with food or within 30 minutes of completing a meal of each 3-week treatment cycle
89014567|NCT04834778|Experimental|Cohort 2 - 50 mg|50 mg capsules of HC-5404-FU administered orally twice a day with food or within 30 minutes of completing a meal of each 3-week treatment cycle
89448455|NCT03007589|Other|Single Duration or SPF Test|Single exposure of interventions or multiple exposures of interventions (SPF or PPD-PF tests) otc sunscreens sun protection fabrics optical filters
89448456|NCT03002558||control (non-OSA)|Patients without sleep apnoea
89448457|NCT03002558||OSA-treated|Patients with sleep apnoea who are treated (CPAP, surgery or MAD)
89448458|NCT03002558||OSA-non treated|Patients with sleep apnoea who are not treated
89448459|NCT02993029|Experimental|99Tc-MDP|99Tc-MDP group:15mg in 100ml normal saline intravenously dripped every twice a week for 5 weeks, every 1weeks for 10 weeks, every 2weeks for 10 weeks, every 1 month for 6 months.
89448460|NCT02993029|Active Comparator|celecoxib|celecoxib capsule 200mg qd by mouth.
89448461|NCT02992964|Experimental|Nivolumab|"Regimen: Nivolumab will be administered every 14 days until disease progression or treatment discontinuation due to unacceptable toxicities. Treatment may extend up to 2 years in patients who show clinical and radiological benefit.~Dose: 3 mg/kg intravenously as a continuous infusion over 60 min (+/-10 min window)"
89448462|NCT02951338|Active Comparator|Group aerobic exercise only|"Supervised group exercise up to 3-times/week for 6 weeks. A typical exercise session will involve a 3-5 minute 'warm-up', 20-30 minutes of aerobic exercise at a target heart rate determined from a sub-maximal test, and a 3-5 minute 'cool-down' of low-intensity exercise. The choice of exercise modality for the submaximal test and for training (e.g., recumbent stepper, cycle ergometer, or treadmill) will be individually prescribed based on patients' sensori-motor recovery, postural control, functional abilities, and safety. Heart rate, blood pressure, rate of perceived exertion, workload, and duration of training will be documented for each session. These data will be reviewed by the physiotherapist with appropriate progression of the intensity and/or duration of exercise as necessary.~Participants may receive general advice to keep physically active after discharge, and may receive an individualized home exercise program, as is currently routine care at all sites."
89531310|NCT05052177||Patient with systemic right ventricles with severe tricuspid regurgitation and high surgical risk|"inclusion criteria:~> 18-years-old~Right systemic ventricle~Severe tricuspid regurgitation~Symptomatic patient (NYHA 2 - 4) despite optimal medical therapy~High-risk surgical patient deemed not eligible for surgery by a multi-disciplinary and thus having underwent a percutaneous treatment of tricuspid regurgitation~exclusion criteria - pregnant ou breastfeeding women"
89531311|NCT03094845|Placebo Comparator|Placebo|
89531312|NCT03094845|Experimental|hdmASIT+TM|
89531313|NCT03337841|Experimental|Pembrolizumab|Pembrolizumab 200 mg IV once only in the neoadjuvant phase. Pembrolizumab 200 mg IV every 3 weeks in the adjuvant phase.
89014568|NCT04834778|Experimental|Cohort 3 - 100 mg|100 mg capsules of HC-5404-FU administered orally twice a day with food or within 30 minutes of completing a meal of each 3-week treatment cycle
89014569|NCT04834778|Experimental|Cohort 4 - 200 mg|200 mg capsules of HC-5404-FU administered orally twice a day with food or within 30 minutes of completing a meal of each 3-week treatment cycle
89448463|NCT02951338|Experimental|PROPEL program|The PROPEL program involves both group aerobic exercise (as described above) and group discussion aimed at enabling participation in exercise after discharge. Components of the PROPEL program were developed according to the Transtheoretical Model of health behaviour change and Social Cognitive Theory. In addition to group exercise participants will attend 1-hour small group discussion sessions once weekly to learn self-management skills for exercise in preparation for discharge from rehabilitation. These discussions include: identifying and solving problems around barriers to exercise; understanding personal and general benefits of exercise; exploring appropriate community resources for exercise; and finding individualized and realistic strategies for incorporating exercise in a regular routine. Participants will become comfortable with progressing their exercise and will set short- and long-term exercise goals.
89448464|NCT02937155||Vaccinated|Patients who have received the HPV vaccine.
89448465|NCT02937155||Vaccine Naive|Patients who have not received the HPV vaccine.
89448466|NCT02900976|Experimental|Arm I (RTX)|Patients with newly diagnosed PTLD who achieve a complete response (CR) after induction receive additional rituximab or biosimilar as in induction.
89448467|NCT02900976|Experimental|Arm II (LMP-TC)|Patients with newly diagnosed PTLD who do not achieve a CR to induction, all relapsed patients after induction, and all patients with refractory disease who received rituximab or biosimilar within 90 days according to institutional guidelines, receive allogeneic LMP1/LMP2-specific cytotoxic T-lymphocytes IV over 1- 2 minutes on days 0 and 7. Cycle continues for up to 42 days in the absence of disease progression or unacceptable toxicity. Patients with PR or SD after first cycle of cycle allogeneic LMP1/LMP2-specific cytotoxic T-lymphocytes receive an additional cycle.
89448468|NCT02877433|Active Comparator|Roxolid short implant, 4 mm length (4)|Straumann Tissue Level Ø4.1 mm RN SLActive Roxolid Standard Plus Implants available in lengths 4mm, 10mm, 12mm and 14mm
89448469|NCT02877433|Experimental|Roxolid short implant, 4 mm length (2)|Straumann Tissue Level Ø4.1 mm RN SLActive Roxolid Standard Plus Implants available in lengths 4mm, 10mm, 12mm and 14mm
89448470|NCT02862210|Experimental|Lithium carbonate|Lithium will be prescribed starting at 150 mg/day, with subsequent dose titration to 300, 450, and 600 mg/day as tolerated according to side effects and blood lithium level.
89448471|NCT02862210|Placebo Comparator|Placebo|Placebo will be prescribed starting at 1 pill per day, with subsequent dose titration to 2,3, and 4 pills per day as tolerated by sham blood lithium levels provided by an unblinded study team member.
89448472|NCT02825901|Active Comparator|Djulis-Buckwheat & Placebo|Ingest Djulis-Buckwheat or placebo drink 100ml/day for 8 weeks
89448473|NCT02825901|Active Comparator|Buckwheat & Placebo|Ingest Buckwheat or placebo drink 100ml/day for 8 weeks
89448474|NCT02825901|Experimental|Djulis-Buckwheat & Buckwheat|Ingest Djulis-Buckwheat or Buckwheat drink 100ml/day for 8 weeks
89448475|NCT02761200||volunteer who completion of a recent ATI|
89448476|NCT02717962|Experimental|VAL-083, Dianhydrogalactitol (Group 1)|Patients with recurrent/progressive GBM
89448477|NCT02717962|Experimental|VAL-083, Dianhydrogalactitol (Group 2)|Newly diagnosed GBM patients who have completed chemoradiation treatment with temozolomide and received no subsequent maintenance temozolomide
89448478|NCT02693535|Other|Group 4 (CDKN2A, CDK4, CDK6)|Participants receive palbociclib - dosage, frequency and duration per label; acceptable genomic matches include CDKN2A loss or mutation, CDK4, CDK6 amplifications, CDKN2B loss or mutation
89200623|NCT00971464|Experimental|Eccentric viewing|"Eccentric viewing is the use of a retinal locus other than the anatomical fovea for fixation in cases when there is central vision loss. This other area (or areas) is called the preferred retinal locus (PRL). In eccentric viewing the patient is aware that they are looking to the side or using their side vision. Most patients with a dense central scotoma will develop eccentric viewing naturally over time. It is thought, however, that, in many cases the naturally developed PRL is not in the ideal position. The four components of eccentric viewing that will be taught are: 1) The optimal direction for eccentric viewing 2) Using large objects to teach eccentric viewing 3) Repetitive practicing of the technique and 4) Maintaining the eye in the eccentric viewing position."
88933845|NCT01763294|Active Comparator|Nicolet Endeavor CR: 30min|Apply 1 session of 2 milliampere intensity for 30 minutes. The stimulation mode will be continuous with frequency of 3 Hz. The site of application depends on the basal EEG findings based on the international 10/20 system.
89448479|NCT02693535|Other|Group 5 (CSF1R,PDGFR,VEGFR)|Participants receive sunitinib - dosage, frequency and duration per label; acceptable genomic matches include CSF1R, PDGFR, VEGFR1/2/3, KIT, FLT-3, RET, FGFR1/2/3, VHL amplifications or mutations
89448480|NCT02693535|Other|Group 6 (mTOR, TSC)|Participants receive temsirolimus - dosage, frequency and duration per label; acceptable genomic matches include mTOR, TSC1/2, AKT1 mutations
89531314|NCT05041413|Experimental|Moms Quit Intervention|12 weeks of the Moms Quit text message intervention
89531315|NCT05041413|Active Comparator|Text4Baby|12 weeks of Text4Baby messages
89014570|NCT04834778|Experimental|Cohort 5 - 400 mg|400 mg capsules of HC-5404-FU administered orally twice a day with food or within 30 minutes of completing a meal of each 3-week treatment cycle
89014571|NCT04834778|Experimental|Cohort 6 - 600 mg|600 mg capsules of HC-5404-FU administered orally twice a day with food or within 30 minutes of completing a meal of each 3-week treatment cycle
89014572|NCT04834778|Experimental|Cohort 7 - 900 mg|900 mg capsules of HC-5404-FU administered orally twice a day with food or within 30 minutes of completing a meal of each 3-week treatment cycle
89014573|NCT04834778|Experimental|Cohort 8 - 300 mg|300 mg capsules of HC-5404-FU administered orally twice a day with food or within 30 minutes of completing a meal of each 3-week treatment cycle
89448481|NCT02693535|Other|Group 8 (ERBB2)|Participants receive trastuzumab and pertuzumab - dosage, frequency and duration per label; acceptable genomic matches include ERBB2 amplification or overexpression, and specific ERBB2 mutations
89448482|NCT02693535|Other|Group 9 (BRAF V600E/D/K/R)|Participants receive vemurafenib and cobimetinib - dosage, frequency and duration per label; acceptable genomic matches include BRAF V600E/D/K/R mutations
89448483|NCT02693535|Other|Group 13 (RET,VEGFR1/2/3,KIT,PDGFRβ,RAF-1,BRAF)|Participants receive regorafenib - dosage, frequency and duration per label; acceptable genomic matches include RET, VEGFR1/2/3, KIT, PDGFRβ, RAF-1, BRAF mutations or amplifications
89448484|NCT02693535|Other|Group 14 (BRCA1/2; ATM)|Participants receive olaparib - dosage, frequency and duration per label; acceptable genomic matches include germline or somatic BRCA1/2 inactivating mutations; ATM mutations or deletions
89448485|NCT02693535|Other|Group 15 (POLE, POLD1)|Participants receive pembrolizumab - dosage, frequency and duration per label; acceptable genomic matches include specific POLE and POLD1 mutations
89448486|NCT02693535|Other|Group 16 (MSI-H, high mutational load and others)|Participants receive nivolumab and ipilimumab - dosage, frequency and duration per label; acceptable genomic matches include MSI high status, high tumor mutational burden, MLH1, MSH2/6, PMS2, EPCAM mutations, specific POLE or POLD1 mutations, BRCA1/2, ATM, MSH3, PMS1, MLH3, EXO1, RFC1/2/3/4/5, PCNA, RPA1/2/3/4, and SSBP1 loss of function mutations
89448487|NCT02693535|Other|Group 17 (CDKN2A, CDK4, CDK6)|Participants receive abemaciclib - dosage, frequency and duration per label; acceptable genomic matches include CDKN2A loss or mutation, CDK4, CDK6 amplifications, CDKN2B loss or mutation
89448488|NCT02693535|Other|Group 19 (BRCA1/2, PALB2)|Participants receive talazoparib - dosage, frequency and duration per label; acceptable genomic matches include germline or somatic BRCA1/2 and PALB2 mutations
89448489|NCT02693535|Other|Group 20 (ERBB2)|Participants receive atezolizumab plus PHESGO - dosage, frequency and duration per label; acceptable genomic matches include ERBB2 amplification or overexpression
89448490|NCT02693535|Other|Group 21 (BRCA1/2, PALB2, ATM, and others)|Participants receive atezolizumab plus talazoparib - dosage, frequency and duration per label; acceptable genomic matches include germline or somatic mutations in BRCA1/2, PALB2, ATM, ATR, CHEK2, FANCA, RAD51C, NBN, MLH1, MRE11A, CDK12; positive genomic instability score reported on the Myriad MyChoice CDx test; or Genomic Loss of Heterozygosity (LOH) Score above threshold as reported on a FoundationOne CDx test or another qualifying test for TAPUR with MTB approval
89448491|NCT02693535|Other|Group 22 (ROS1 fusion)|Participants receive entrectinib - dosage, frequency and duration per label; acceptable genomic matches include any ROS1 fusion
89448492|NCT02693535|Other|Group 23 (NTRK amplification)|Participants receive larotrectinib - dosage, frequency and duration per label; acceptable genomic matches include NTRK1/2/3 amplification
89448493|NCT02693535|Other|Group 24 (ERBB2)|Participants receive tucatinib plus trastuzumab SC - dosage, frequency and duration per label; acceptable genomic matches include ERBB2 amplification or overexpression, and specific ERBB2 mutations
89448494|NCT02693535|Other|Group 25|Participants receive futibatinib- dosage, frequency and duration per label; acceptable genomic matches include FGFR 1,2,3,4 fusion (or other rearrangement) or mutation
89448495|NCT02693080|Experimental|Diagnostic (CT perfusion imaging)|Patients undergo CT perfusion imaging of the lungs at baseline, within 48 hours of first SABR, and at 2-4 months after completion of SABR. Isovue-200 is used as contrast agent
89448496|NCT02672917|Experimental|Group A|MVT-5873 monotherapy dose escalation, initial to maximum tolerated dose
89448497|NCT02672917|Experimental|Group B|MVT-5873 is administered in Group B every 1 week in combination with gemcitabine and nab-paclitaxel
89014574|NCT04834427|Experimental|S (+)-Ketamine group|Patients who undergo general anesthesia using S(+)-ketamine hydrochloride for anesthesia induction, maintenance or postoperative analgesia.
89014575|NCT04834427|Active Comparator|Control group|Patients who undergo conventional therapy without S (+)-Ketamine hydrochloride injection during perioperative period.
89014576|NCT04829539|Experimental|Group I (BBT-CI)|Patients complete face to face/video sessions with a trained staff member. Patients also complete phone sessions.
89014577|NCT04829539|Active Comparator|Group II (HEAL)|Patients complete face to face/video sessions with a trained staff member. Patients also complete phone sessions.
89014578|NCT04816383|Experimental|Experimental Arm|The participant will receive usual breastfeeding care such as counseling by her physician, access to lactation consults, nursing assistance in the hospital, access to our online resources. The participant will also receive the Apple breastfeeding application in the office once enrolled in the study between 32 to 36 weeks gestation. The participant will be taught how to use the application, and will have access to the study to continue use throughout the duration of follow-up.
89448498|NCT02672917|Experimental|Group C|MVT-5873 is administered in Group C every 4 weeks by intravenous infusion following a lead in dose. Each cycle is 28 days. During dose escalation, doses of MVT-5873 will be increased to define the MTD. Up to 30 patients will be treated at the RP2D.
89448499|NCT02672917|Experimental|Group D|MVT-5873 is administered in Group D every 2 weeks by intravenous infusion following a lead in dose. During dose escalation, doses of MVT-5873 will be increased to defined he MTD. Up to 30 patients will be treated at the RP2D.
89448500|NCT02672917|Experimental|Group E - metastatic|MVT-5873 is administered in combination with mFOLFIRINOX every 2 weeks. Both MVT-5873 and mFOLFIRINOX will be administered by intravenous infusion. During dose escalation, doses of MVT-5873, will be increased to define the MTD in combination with mFOLFIRINOX. mFOLFIRINOX will be administered according to institutional standards in compliance with the package insert for each drug. Up to 30 patients will be treated at the RP2D.
89014579|NCT04816383|No Intervention|Control Arm|The participant will receive usual breastfeeding care such as counseling by her physician, access to lactation consults, nursing assistance in the hospital, access to our online resources.
89014580|NCT04813484|Experimental|Kicking it with the Gurlz|This multicomponent intervention includes a violence and gender affirmation screening tool, a peer delivered adaptation of the group-level Seeking Safety Program, and individual-level peer navigation sessions.
89014581|NCT04807179|Experimental|Alexandrite Laser|Single arm, self-controlled
89014582|NCT04796337|Experimental|Sotatercept Treatment|Participants rolling over from a blinded parent study will begin sotatercept at a dose of 0.3 mg/kg SC for Visit 1. Dose will escalate to 0.7 mg/kg SC at Visit 2 through remainder of the study. Participants rolling over from an unblinded parent study will continue sotatercept at their current dose and if at dose < 0.7 mg/kg SC can titrate up to 0.7 mg/kg SC for the remainder of the study.
89014583|NCT04738942|Experimental|Vedolizumab 300 mg in UC cohort|Vedolizumab 300 mg, IV infusion, for up to 12 weeks Q4W for Treatment phase, and until the date of marketing approval of vedolizumab IV Q4W or study termination for Extension phase.
89448501|NCT02672917|Experimental|Group F - adjuvant|MVT-5873 is administered in combination with mFOLFIRINOX every 2 weeks. Both MVT-5873 and mFOLFIRINOX will be administered by intravenous infusion. During dose escalation, doses of MVT-5873, will be increased to define the MTD in combination with mFOLFIRINOX. mFOLFIRINOX will be administered according to institutional standards in compliance with the package insert for each drug. Up to 30 patients will be treated at the RP2D.
89448502|NCT02672475|Experimental|Treatment (Paclitaxel, Galunisertib)|Patients receive Paclitaxel IV on days 1, 8, and 15. Patients also receive GalunisertibPO BID on days 1-14. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89014584|NCT04738942|Experimental|Vedolizumab 300 mg in CD cohort|Vedolizumab 300 mg, IV infusion, for up to 12 weeks Q4W for Treatment phase, and until the date of marketing approval of vedolizumab IV Q4W or study termination for Extension phase.
89014585|NCT04729114|Experimental|Cohort 1|180 mg PRL-02 + dexamethasone or prednisone
89448503|NCT02654015|Experimental|Medical Management plus Apollo MIES|Subjects will receive best medical management for ICH plus they will receive the MIES surgery and use of the Apollo System for clot evacuation.
89448504|NCT02620319|Experimental|biodegradable stent|endoscopic implantation of biodegradable airway stent, the SX-ELLA Stent DV Tracheal (DV Stent)
89448505|NCT02601755|Experimental|iCanCope app and website|Intervention: Behavioral: iCanCope app and website
89448506|NCT02601755|Active Comparator|Attention control group|Intervention: Behavioral: Attention control group
89448507|NCT02591563||Healthy children|6-36 months of age who will have the following study procedures: Venipuncture, Nasopharyngeal swab, nasopharyngeal wash, tympanocentesis
89014586|NCT04729114|Experimental|Cohort 2|360 mg PRL-02 + dexamethasone or prednisone
89014587|NCT04729114|Experimental|Cohort 3|720 mg PRL-02 + dexamethasone or prednisone
89448508|NCT02578810||Eclampsia|In 24 patients with Eclampsia or pre-eclampsia investigators will use an artefact-free 20-min mean BIS value, as well as biomarkers sFIT (soluble FMS-like Tyrosine Kinase): PIGF (Placental Growth Factor) ratio and adrenomedullin mortality risk stratifier to classify the degree of pre-eclampsia correlated the PIERS Pre-eclampsia risk assessment PIERS percentage (http://piers.cfri.ca/PIERSCalculatorH.aspx) will be calculated from patients' clinical and laboratory findings documented in their charts.
89014588|NCT04729114|Experimental|Cohort 4|1260 mg PRL-02 + dexamethasone or prednisone
89448509|NCT02578810||Control|In 24 control patients without Eclampsia or pre-eclampsia investigators will use an artefact-free 20-min mean BIS value, as well as biomarkers sFIT (soluble FMS-like Tyrosine Kinase): PIGF (Placental Growth Factor) ratio and adrenomedullin mortality risk stratifier to classify the degree of pre-eclampsia correlated the PIERS Pre-eclampsia risk assessment PIERS percentage (http://piers.cfri.ca/PIERSCalculatorH.aspx) will be calculated from patients' clinical and laboratory findings documented in their charts
89014589|NCT04729114|Experimental|Cohort 5|1800 mg PRL-02 + dexamethasone or prednisone
89014590|NCT04729114|Experimental|Phase 1 Expansion Group D|Prior abiraterone
89531316|NCT05031039||Female Egyptian subjects with Cleft Lip and Palate Deformity|Egyptians females that have unilateral or bilateral cleft lip and palate deformity
89537125|NCT05294055|Experimental|myltiple myeloma, chemotherapy plus Mecapegfilgrastim SC on day 2|
89014591|NCT04729114|Experimental|Phase 1 Expansion Group E|Prior enzalutamide, apalutamide and/or darolutamide
89014592|NCT04729114|Experimental|Phase 2a Dose Expansion Group F1|Dosing at recommended Phase 2 dose (RP2D); high volume mCSPC
89014593|NCT04729114|Experimental|Phase 2a Dose Expansion Group F2|Dosing at RP2D; low volume mCSPC
89014594|NCT04729114|Experimental|Phase 2a Dose Expansion Group G|Dosing at RP2D; mCRPC
89448510|NCT02572843|Experimental|MEDI4736|Patients whose tumor is deemed resectable at diagnosis will receive 3 cycles (21 days each) of standard chemotherapy with cisplatin/docetaxel followed by 2 cycles (14 days each) of neoadjuvant immunotherapy with MEDI4736 750 mg. Following surgery, patients with complete resection (R0) of their tumor will be administered adjuvant treatment with MEDI4736 750 mg for up to one year or until recurrence, death, unacceptable toxicity or consent withdrawal (whichever occurs first). Patients with incomplete R1/R2 resection, including patients with extracapsular spread of mediastinal lymph node metastases, may undergo standard radiotherapy prior to adjuvant treatment with MEDI4736.
89448511|NCT02571946|Experimental|Proton beam therapy|
89448512|NCT02546583|Experimental|Increased Intravenous Loop Diuretic (Bumetanide or Furosemide)|2.5x Visit 1 dose
89014595|NCT04716894|Experimental|Sequence: BI 474121 alone (Reference) - Itraconazole + BI 474121 (Test)|"Period 1:~Reference (R) treatment: Healthy subjects received a single dose of 0.5 milligram (Powder for oral solution, 0.5 milligram (mg)/milliliter (mL) formulation) BI 474121 on day 1 of period 1.~Period 2:~Test (T) treatment: Healthy subjects received a daily dose of 200 milligram (oral solution, 10 mg/mL) Itraconazole for 14 days (days -3 - 11 of period 2) and a single dose of 0.5 milligram (Powder for oral solution, 0.5 milligram mg/mL formulation) BI 474121 on day 1 of period 2.~BI 474121 administrations in treatment R and treatment T were separated by a wash-out period of at least 10 days.~Administration of trial medication with 240 mL of water was performed after subjects had fasted overnight; fasting was to start no later than 10 hours before the scheduled dosing of BI 474121 or 9 hours before itraconazole administration."
89014596|NCT04713618||Supportive Care (pelvic exam, survey)|Patients undergo standard of care pelvic exam at baseline and 1, 3, 6, 12, and 24 month follow ups. Patients also complete patient reported outcome measures at baseline and 1, 3, 6, 12, 18, and 12 month follow ups.
89014597|NCT04696133|Experimental|conventional training|children received fine motor exercises
89014598|NCT04696133|Experimental|sensory integration training|Children received designed sensory integration program
89014599|NCT04683848|Experimental|MT-3921|Intravenous (IV)
89014600|NCT04683848|Placebo Comparator|Placebo|Intravenous (IV)
89448513|NCT02546583|Experimental|Loop Diuretic (Bumetanide or Furosemide) + IV Chlorothiazide|Loop diuretic (Bumetanide or Furosemide) dose remains the same as visit 1 dose but now with the addition of 500-1000 mg IV chlorothiazide
89448514|NCT02546583|No Intervention|Observational Arm|Subjects taking an IV loop diuretic (Bumetanide or Furosemide) that have sodium output greater than 100 mmol. These subjects will continue to be followed and have data collected on them.
89014601|NCT04678869|Experimental|Cirprofloxacin prophylaxis|prophylactic ciprofloxacin (10mg/kg BD, enteral/IV)
89014602|NCT04678869|Active Comparator|Standard of care|standard of care
89014603|NCT04676373|Experimental|Alglucosidase Alfa|A dose of 20 mg/kg body weight once every 2 weeks for a minimum of 52 weeks
89014604|NCT04653896|Experimental|Knee OA group|Individuals who are over 18 years and have medical diagnosis of Grade 3 or 4 knee OA
89014605|NCT04652544|Experimental|"Low dose"|One vial with 600 µg cholecalciferol (corresponding to a total of 24'000 IU vitamin D) and one vial with placebo every month.
89014606|NCT04652544|Experimental|"High dose"|Two vials with 600 µg cholecalciferol each (corresponding to a total of 48'000 IU vitamin D) every month.
89014607|NCT04652544|Placebo Comparator|Placebo|Two vials with a placebo every month.
89014608|NCT04645355|Experimental|New-onset guttate psoriasis|Subjects will initially be treated with guselkumab 100 mg SQ at weeks 0, 4, and then every 8 weeks thereafter until week 44. At week 44, patients who have not achieved PASI 50 (nonresponders) will be removed from the trial. Patients who achieve between PASI 50 and PASI 75 (partial responders) will continue on drug throughout the remainder of the study. Patients who achieve PASI 75 or greater at week 44 (responders) will have their guselkumab therapy withdrawn and re-treated upon relapse.
89537126|NCT05294055|Experimental|myltiple myeloma, chemotherapy plus Mecapegfilgrastim SC on day 5|
88933846|NCT01763294|Active Comparator|Nicolet Endeavor CR: 60min|Apply 1 session of 2 milliampere intensity for 60 minutes. The stimulation mode will be continuous with frequency of 3 Hz. The site of application depends on the basal EEG findings based on the international 10/20 system.
89448515|NCT02542696|Experimental|APL-130277|APL-130277 sublingual thin film (10 mg, 15 mg, 20 mg, 25 mg, 30 mg and 35 mg)
89448516|NCT02526329|Experimental|Treatment (donor regulatory T lymphocytes)|Patients receive donor regulatory T lymphocytes intravenously (IV) over 5 minutes or less on day 0. Some patients receive a second infusion of frozen donor regulatory T lymphocytes 5-7 days after the initial infusion or 2 additional infusions separated by 5-7 days.
89448517|NCT02503722|Experimental|Treatment (sapanisertib, osimertinib)|Patients receive sapanisertib PO QD on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26 (day 1 is omitted in cycle 1). Patients also receive osimertinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89448518|NCT02464007|Experimental|sSIFN-co|Dose escalation of rSIFN-co
89448519|NCT02378636|Experimental|600S|Modified 600C (axis marks) monofocal aspheric intraocular lens
89448520|NCT02375165||Cohort with lymphedema|Participants with a history of acquired lymphedema of at least 6 months' duration, will have phlebotomy for serum and plasma.
89448521|NCT02375165||Cohort without lymphedema|Healthy volunteers; will have phlebotomy for serum and plasma.
89448522|NCT02346253|Experimental|Treatment (HDR brachytherapy, ADT and LHRH agonist therapy)|Patients undergo high-dose-rate brachytherapy over 2 fractions. Patients also receive ADT comprising bicalutamide PO QD. Patients may also receive LHRH agonist therapy comprising leuprolide acetate IM or SC, goserelin acetate SC, triptorelin pamoate IM, or degarelix SC for 4-6 months (intermediate-risk patients receiving ADT) or 6-36 months (high-risk patients) at the discretion of the treating physician.
89448523|NCT02339740|Experimental|Treatment (tretinoin, arsenic trioxide, chemotherapy)|See Detailed Description
89448524|NCT02311179|Active Comparator|Prosthesis, BoneMaster-Exceed cup|Prosthesis, BoneMaster-Exceed cup: A hemispheric joint cup of the type Exceed cup (Biomet) characterized by a porous surface of titanium plasma spray. The surface is coated with hydroxyapatite deposited electrochemically (BoneMaster)
89448525|NCT02311179|Active Comparator|Prosthesis Exceed cup without HA|Prosthesis Exceed cup without HA: A hemispheric joint cup of the type Exceed cup (Biomet) characterized by a porous surface of titanium plasma spray
89448526|NCT02306993||Healthy volunteers without SCT|Includes Healthy African American female volunteer between the ages of 18 and 45 years without sickle cell trait. Their blood and bone density x-ray will help researchers gain a better understanding of what might be different about the way having sickle cell trait affects bone.
89448527|NCT02306993||Healthy volunteers with SCT|Includes Healthy African American female volunteer between the ages of 18 and 45 years with sickle cell trait. Their blood and bone density x-ray will help researchers gain a better understanding of what might be different about the way having sickle cell trait affects bone.
89448528|NCT02306993||Volunteers with SCD|Healthy African American female volunteer between the ages of 18 and 45 years with sickle cell disease. Their blood and bone density x-ray will help researchers gain a better understanding of what might be different about the way having sickle cell disease affects bone.
88933847|NCT01763294|Active Comparator|Nicolet Endeavor CR: 30min for 3 days|Apply 3 sessions of 2 milliampere intensity for 30 minutes. The stimulation mode will be continuous with frequency of 3 Hz. The site of application depends on the basal EEG findings based on the international 10/20 system.
88933848|NCT01763294|Active Comparator|Nicolet Endeavor CR: 30min for 5 days|Apply 5 sessions of 2 milliampere intensity for 30 minutes. The stimulation mode will be continuous with frequency of 3 Hz. The site of application depends on the basal EEG findings based on the international 10/20 system.
88933849|NCT01763294|Placebo Comparator|Nicolet Endeavor CR: Placebo|The same procedures just that in this case the machine produces only a 60 second stimulus at the beginning so the patient can feel the initial electric stimulus.
88933850|NCT01763385|Experimental|Erlotinib & secondary brain radiotherapy|Erlotinib until brain tumor progression, then given brain radiotherapy, and continued to take Erlotinib till extracranial lesions progression.
88933851|NCT01763385|Other|Erlotinib & concurrent brain radiotherapy|Erlotinib with concurrent brain radiotherapy, and continued to take Erlotinib after radiotherapy until recurrence or termination for other reasons
88933852|NCT01763398||non-Hodgkin's lymphoma|Patients with non-Hodgkin's lymphoma, high risk group for neutropenic fever, treated by CHOP-like regimen and primary G-CSF prophylactic therapy
89448529|NCT02290145|Experimental|TPF group|TPF induction chemotherapy followed with surgery and post-operative radiotherapy docetaxel 75mg/m2 cisplatin 75 mg/m2 5-Fu 750 mg/m2/day
89448530|NCT02290145|Other|surgery group|surgery with post-operative radiotherapy
89448531|NCT02285543|Experimental|TPF group|"The patients in the experimental group received the TPF induction chemotherapy for 2 cycles followed with surgery and radiotherapy/chemoradiotherapy.~docetaxel:75mg/m2 cisplatin：75 mg/m2 5-Fu：750 mg/m2/day"
89448532|NCT02285543|Other|Control group|The patients in the control group received the radical surgery and radiotherapy/chemoradiotherapy.
89448533|NCT02234219|Active Comparator|Circular Anastomosis|
89448534|NCT02234219|Active Comparator|Heart-shaped Anastomosis|
89531317|NCT05031039||Male Egyptian subjects with Cleft Lip and Palate Deformity|Egyptians males that have unilateral or bilateral cleft lip and palate deformity
88933853|NCT01763411||Multifocal Spheric Intraocular Lens (Restor SN60D3 IOL)|No Intervention: Multifocal Spheric IOL implantation
88933854|NCT01763411||Monofocal Spheric Intraocular Lens (AcrySof SN60AT IOL)|No Intervention: Monofocal Spheric IOL implantation
88933855|NCT01763411||Multifocal Aspheric Intraocular Lens (Tecnis ZMA00 IOL)|No intervention Multifocal IOL implantation
88933856|NCT01763411||Monofocal Aspheric Intraocular Lens (AcrySof SN60WF IOL)|No Intervention: Monofocal IOL implantation
88933857|NCT01763411||Multifocal Aspheric Intraocular Lens (Tecnis ZMB00 IOL)|No intervention Multifocal IOL implantation
88933858|NCT01763411||Multifocal Spheric Intraocular Lens (Restor SN6AD1 IOL)|No intervention Multifocal IOL implantation
88933859|NCT01763437|No Intervention|Observation|30 patients will be randomized to observation alone. These patients will return 4 weeks (+/- 2 weeks) after their initial visit for lesion measurement and photographs.
89448535|NCT02215928||Ancillary-correlative (tumor genomic profiling)|Tissue samples are collected at baseline and blood for liquid biopsy is collected at baseline and every 6-8 weeks during active treatment. Tissue samples are analyzed via sequencing for tumor genomic profiling.
89448536|NCT02163395|Other|FullCeram implant|Straumann FullCeram Implant is a monotype ZrO2 implant with a diameter of 4.1 mm, available in lengths of 8, 10, 12 and 14 mm and abutment heights of 4.0 or 5.5 mm
89448537|NCT02161900|Active Comparator|Routine exercise|All newly diagnosed cases with stage I-III of breast cancer who present to Tata Memorial Hospital will be randomly assigned to perform either a set of 'Yogic and Routine Exercises (referred to as exercise I) or Routine Exercises'(referred to as exercise II) . Patients will begin the exercises within a week of starting treatment.
89448538|NCT02161900|Experimental|Yogic and Routine exrcises (exercise I)|All newly diagnosed cases with stage I-III of breast cancer who present to Tata Memorial Hospital will be randomly assigned to perform either a set of 'Yogic and Routine Exercises (referred to as exercise I) or Routine Exercises'(referred to as exercise II) . Patients will begin the exercises within a week of starting treatment.
89448539|NCT02139605|Active Comparator|D2 Lymphadenectomy|Intervention D3 Lymphadenectomy
89448540|NCT02139605|Experimental|D3 Lymphadenectomy|Comparator D2 Lymphadenectomy
89448541|NCT01934725||Patients w/ cryptogenic ischemic stroke|Patients aged 15 to 49 years with unexplained first-ever ischemic stroke
89448542|NCT01934725||Stroke-free control subjects|Stroke-free subjects age- and gender-matched to patients
89448543|NCT01916317|No Intervention|Arm B:Control|: No peritumoral Local Anesthesia prior to excision
89448544|NCT01916317|Active Comparator|Arm A: Intervention|Arm A: 60mM of 0.5% Inj. Lignocaine will be injected peri tumoral prior to excision.
89448545|NCT01913132|No Intervention|Standard wound dressing OPEN|Standard wound dressing
89448546|NCT01913132|Experimental|PICO dressing OPEN|Negative pressure wound therapy with PICO (Smith & Nephew)
89448547|NCT01913132|No Intervention|Standard dressing EVAR|Standard wound dressing
89448548|NCT01913132|Experimental|PICO dressing EVAR|Negative pressure wound therapy with PICO (Smith & Nephew)
89448549|NCT01911897|Experimental|MobiusHD|MobiusHD
89448550|NCT01910909|Experimental|Stereotactic body radiotherapy|Stereotactic body radiotherapy 60 Gy/3 fraction standard dose The highest allowable dose with maintain normal tissue constraints
89448551|NCT01860027||Children with reading disabilities|Children diagnosed with reading disabilities (age 7 to 13).
89448552|NCT01860027||Children with eye movement disorders|Children diagnosed with eye movement disorders (age 7 to 13).
89448553|NCT01860027||Control Group|Children with normal reading ability and normal eye movements (age 7 to 13.
89448554|NCT01852422||Pelvic prolapse|
89448555|NCT01785420|Experimental|Drug Trastuzumab|A single dose of Trastuzumab (Herceptin, Hoffman La Roche) at 8 mg/Kg as a 90 minute infusion in 250 ml of normal saline, in the window period of 14 days (both days inclusive) prior to the planned date of surgery.
89448556|NCT01785420|Placebo Comparator|Control|A 90 minute intravenous infusion of saline as placebo
89448557|NCT01719887|Active Comparator|Conservative treatment|Conservative treatment with functional brace and physiotherapy.
89448558|NCT01719887|Experimental|Operative treatment|Operative treatment with open reduction and internal fixation with 4,5mm locking compression plate. Physiotherapy at 3 and 9 wks.
89448559|NCT01690715||Hepatocellular carcinoma underwent surgery|
89448560|NCT01682941|Active Comparator|Soy Bread Intervention|Arm I Soy Bread
89448561|NCT01682941|Experimental|Soy -Almond Bread Intervention|Arm II Soy-Almond Bread
89448562|NCT01661998||Harms Study Group|
89448563|NCT01631292|Placebo Comparator|600 IU D3|
89448564|NCT01631292|Active Comparator|2000 IU D3|
89448565|NCT01631292|Active Comparator|4000 IU D3|
89448566|NCT01592552||Neurological Condition|Collect blood and other biospecimens like saliva, urine and CSF for research purposes.
88933860|NCT01763437|Experimental|Tetracycline|30 patients will be randomized to treatment with an intralesional injection of 0.05 mL of 2% tetracycline solution. These subjects will return 4 weeks (+/- 2 weeks) after treatment for lesion measurement and photographs.
89448567|NCT01592552||Control|Collect blood and other biospecimens like saliva, urine and CSF for research purposes.
89448568|NCT01580241||Surgery group|Patients with pancreatic cancer who undergo surgical treatment only
89448569|NCT01580241||Chemotherapy group|Patients with pancreatic cancer who undergo chemotherapy treatment only
89448570|NCT01580241||Neoadjuvant group|Patients with pancreatic cancer who undergo neoadjuvant chemotherapy and surgery
89448571|NCT01580241||Adjuvant group|Patients with pancreatic cancer who undergo surgery followed by chemotherapy
89448572|NCT01523223|Experimental|Treatment (DLI)|Patients undergo CD8+ memory T-cell infusion over 10-20 minutes.
88933861|NCT01763450|Experimental|Bevacizumab plus chemotherapy|"Bevacizumab:~7.5mg/kg, iv, on day 1 of each 21 day cycle or 5mg/kg, iv, on day 1 of each 14 day cycle;~Oxaliplatin+capecitabine(XELOX):( The total dose not less than 70% of the recommended dose of this standard) Oxaliplatin: 130mg/m2,d1; capecitabine: 850-1,000mg/m2，d1-d14, bid，each 21 day cycle;~Oxaliplatin+5-Fluorouracil+ Levomisole（FOLFOX）:~Oxaliplatin: 85mg/m2,iv for 2 hours ,d1; Levomisole（LV）: 400mg/m2,iv for 2 hours,d1; 5-Fluorouracil（5-FU） :400mg/m2 iv,d1,then 1200mg/m2/d ×2d continuous intravenous infusion(volume dose:2400mg/m2,iv for 46-48 hours ) each 14 day cycle;"
88933862|NCT01763463||Patients with COPD who develop severe pneumonia|Patients with COPD who develop severe pneumonia
88933863|NCT01763463||Patients with COPD who do not develop severe pneumonia|Patients with COPD who do not develop severe pneumonia
89448573|NCT01447667|Experimental|Magnetic resonance elastography|Magnetic resonance elastography before radiofrequency ablation therapy will be performed.
88933864|NCT01763476|Active Comparator|Paclitaxel-coated balloon angioplasty|Target lesion to be treated with paclitaxel-coated balloon
88933865|NCT01763476|Active Comparator|Atherectomy + paclitaxel-balloon|Target lesion to be treated with atherectomy (TurboHawk, ev3) and paclitaxel-coated balloon
88933866|NCT01763489|Experimental|ASSIST tool group|Surgeons will assess the applicability of a trial using the ASSIST
88933867|NCT01763489|Active Comparator|Synopsis Group|Surgeons will assess the applicability of a trial using the synopsis presented in a case vignette
88933868|NCT01763502|Experimental|FOOD|Food transfer linked to preschool enrollment
89448574|NCT01397552|Active Comparator|Dexamethasone|Subjects randomized to receive dexamethasone, will undergo epidural using this medication, however the physician and subject will be blinded
89448575|NCT01397552|Active Comparator|methylprednisolone acetate|Subjects randomized to receive methylprednisolone acetate, will undergo epidural using this medication, however the physician and subject will be blinded
89448576|NCT01256710||Trifecta™ Valve Group|Subjects implanted with the Trifecta™ aortic bioprosthesis.
89448577|NCT01096368|Experimental|Arm I (chemotherapy, observation)|Patients with classic histology(WHO Grade II) supratentorial ependymoma who have undergone microscopic gross total resection (GTR1) or achieved CR either after first or second resection or after post-operative induction chemotherapy are assigned to observation. For patients without GTR1, induction chemotherapy is comprised of vincristine intravenously (IV) over 1 minute on days 1 and 8 of cycles 1 and 2, carboplatin IV over 15-60 minutes on day 1 of cycles 1 and 2, and cyclophosphamide IV over 30-60 minutes on days 1-2 of cycle 1 only. Patients also receive etoposide IV over 60-120 minutes on days 1-3 of cycle 2 only. Cycle 1 continues for 3 weeks and cycle 2 continues for 4 weeks in the absence of disease progression or unacceptable toxicity.
89448578|NCT01096368|Experimental|Arm II (radiotherapy, chemotherapy)|Patients with supratentorial ependymoma (Grade II without GTR1 or Grade III) or any infratentorial ependymoma who have undergone gross or near total resection (GTR or NTR) or achieved CR either after first or second resection or after post-operative induction chemotherapy are randomized to undergo conformal radiotherapy over 6-7 weeks followed by maintenance chemotherapy. Maintenance chemotherapy comprised of vincristine IV on days 1, 8, and 15 of cycles 1-3 only, etoposide IV over 60-120 minutes on days 1-3, cisplatin IV over 1-8 hours on day 1, and cyclophosphamide IV over 30-60 minutes on days 2-3. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients without GTR or NTR at enrollment require induction chemotherapy (see Arm I) and possibly second surgery before randomization.
89448579|NCT01096368|Active Comparator|Arm III (radiotherapy, observation)|Patients with supratentorial ependymoma (Grade II without GTR1 or ST Grade III) or any infratentorial ependymoma (Grade II or III) who have undergone gross or near total resection or achieved CR either after first or second resection or after post-operative induction chemotherapy are randomized to undergo conformal radiotherapy over 6-7 weeks and then undergo observation. Patients without GTR or NTR at enrollment require induction chemotherapy (see Arm I) and possibly second surgery before randomization.
89448580|NCT01096368|Active Comparator|ARM IV (radiotherapy, chemotherapy)|Patients with subtotal resection after induction chemotherapy (see Arm I) and second surgery are nonrandomly assigned to Arm II treatment.
89448581|NCT01090908||Ages 6-11 years|
89448582|NCT01090908||Ages 12-17 years|
89448583|NCT01057173|Experimental|Transcatheter Aortic Valve Implantation|
89448584|NCT01057173|Active Comparator|Surgical Aortic Valve Replacement|
88933869|NCT01763502|Experimental|CASH|Cash transfer linked to preschool enrollment
88933870|NCT01763502|No Intervention|CTRL|No transfer linked to preschool enrollment
88933871|NCT01763515|Experimental|Laterally wedged insoles|Patients will use laterally wedged insoles with 5o tilt toward medial side and made of ethylene vinyl acetate coated with leather. The medial thickness is 4 mm with lateral thickness of 10 mm.
88933872|NCT01763528|Active Comparator|nutrition intervention|high protein diet
88933873|NCT01763528|No Intervention|control group|control diet
88933874|NCT01763541|Other|Testosterone|"To determine the effect of testosterone on the NP responses to acute and chronic salt loading.~One testosterone patch (Androderm 5 mg) applied to each male subject each day for 14 days.~Intervention: Leuprolide acetate and anastrozole"
88933875|NCT01763541|Other|Estradiol|"To determine the effect of estradiol on the NP responses to acute and chronic salt loading.~Two estradiol patches (Vivelle Dot 0.1mg) will be applied to each female subject twice-a-week for 2 weeks.~Intervention: leuprolide acetate"
88933876|NCT01763593||Aurosleek blades|Patients having cataract will undergo surgery by using Aurosleek blades
88933877|NCT01763619|Experimental|Freedom Cervical Disc|
88933878|NCT01763658|Experimental|Antioxidant, drug therapy for ITP|interventional arm 1 and will receive antioxidant therapy (Antox tablets ( 1 tablet contains : Vit. A 2000 IU, Vit C 90 mg, Vit E 15 mg and selenium yeast 55 ug ) with the therapy selected for ITP tailored according to patient's presentation.For Antox tablets it will be given daily for 6 months.
88933879|NCT01763658|Active Comparator|drug therapy for ITP|drug therapy for ITP according to ASH, 2011 guidelines.
88933880|NCT01763697|Active Comparator|Morhpine/Taste acuity|Taste acuity assessment after 1mg subcutaneous morphine injection
88933881|NCT01763697|Placebo Comparator|Placebo/Taste acuity|Taste acuity assessment after subcutaneous placebo injection
88933882|NCT01763697|Active Comparator|Morphine4/Taste acuity|Taste acuity assessment after 4mg subcutaneous morphine injection
88933883|NCT01763710|Active Comparator|Arm A|Paclitaxel 80 mg/m2 days 1, 8 and 15
88933884|NCT01763710|Experimental|Arm B|Nab-paclitaxel 100 mg/m2 days 1, 8 and 15
88933885|NCT01763710|Experimental|Arm C|Nab-paclitaxel 150 mg/m2 days 1, 8 and 15
88933886|NCT01763710|Experimental|Arm D|Nab-paclitaxel 150 mg/m2 days 1 and 15
89014609|NCT04645355|Experimental|Chronic plaque psoriasis|Subjects will initially be treated with guselkumab 100 mg SQ at weeks 0, 4, and then every 8 weeks thereafter until week 44. At week 44, patients who have not achieved PASI 50 (nonresponders) will be removed from the trial. Patients who achieve between PASI 50 and PASI 75 (partial responders) will continue on drug throughout the remainder of the study. Patients who achieve PASI 75 or greater at week 44 (responders) will have their guselkumab therapy withdrawn and re-treated upon relapse.
89448585|NCT01020903|Active Comparator|Aprepitant|
89448586|NCT01020903|Placebo Comparator|Placebo|
89448587|NCT00984321|Experimental|Psychoeducational Intervention Group|
89448588|NCT00984321|Experimental|Expressive Writing Intervention|
89448589|NCT00984321|Active Comparator|Control Group|
89448590|NCT00938587|Experimental|PF-04171327 10 mg|
89448591|NCT00938587|Experimental|PF-04171327 25 mg|
89448592|NCT00938587|Active Comparator|Prednisone|
89448593|NCT00938587|Placebo Comparator|Placebo|
89448594|NCT00937937|Experimental|Arm I|Patients receive dinaciclib IV over 2 hours on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
89448595|NCT00900497|Experimental|White Blood Cells/Granulocytes|Fresh, non-irradiated granulocytes from ABO-Rh compatible, HLA-mismatched donors
89448596|NCT00898313||Sample Collection|
89448597|NCT00810693|Experimental|Riociguat (Adempas, BAY63-2521) up to 2.5 mg_IDT|Participants received Riociguat orally as a film-coated tablet up to 2.5mg three times daily (tid) (titration between 1.0 mg and 2.5 mg tid based on an individual dose titration (IDT) scheme) for 12 weeks
88933887|NCT01763723|Experimental|IPL after UV-exposure|8 UV-exposures followed by 3 weekly IPL exposures
88933888|NCT01763736|Experimental|Music|Everyone enrolled with receive music sessions.
88933889|NCT01763749|Experimental|Closone|75mg/100mg per day, 4weeks, PO
88933890|NCT01763749|Active Comparator|Plavix with Astrix|Plavix 75mg with Astrix 100mg, 4weeks, PO
88933891|NCT01763762|Experimental|Electrical pudendal nerve stimulation|At a frequency of 2.5 Hz and an intensity (45~55 mA) as high as the patient can tolerate without discomfort; 60 minutes three times a week for a total of four weeks
88933892|NCT01763762|Active Comparator|PFM training with Transvaginal ES|"PFM training: EMG-biofeedback assisted PFMT was performed by specially trained therapists, 20 min three times a week for a total of four weeks. Patients conduct 30 maximal high intensity PFM contractions for 2-6 sec (with 2-6 sec rest), three sessions a day at home for a total of four weeks.~Transvaginal ES: At a current intensity of < 60 mA (as high as possible to get a contraction) and frequencies of 15 Hz and 85 Hz (alternate 3-min periods of stimulation); 20 min three times a week for a total of four weeks."
88933893|NCT01763775|Experimental|Transtek 125X|Which measured by DUT (Transtek 125X): GBF-1251-B, BF-1255-B, BF-1256-B, GBF-1257-B.
88933894|NCT01763775|Experimental|Transtek 950D|Measured by Reference (Transtek 950D): GBF-950-D.
89014610|NCT04644224|Experimental|Group I (coaching session, navigation session, support group)|Parents/caregivers whose churches are randomized to Group I, attend monthly health coaching sessions over 1 hour each for 12 months, 9 resource navigation sessions over 12 months, and monthly support groups for 12 months.
89448598|NCT00810693|Experimental|Riociguat (Adempas, BAY63-2521) up to 1.5 mg_IDT|Participants received Riociguat orally as a film-coated tablet up to 1.5mg three times daily (tid) (titration between 1.0 mg and 1.5 mg tid based on an individual dose titration (IDT) scheme) for 12 weeks
89448599|NCT00810693|Placebo Comparator|Placebo|Participants received Placebo orally as a film-coated tablet three times daily (tid) for 12 weeks
89448600|NCT00709150|Experimental|1|Patients will receive collaborative depression care management.
89448601|NCT00709150|Active Comparator|2|Patients will receive enhanced usual care.
89448602|NCT00679120|Active Comparator|1|Cemented single pegged femur with standard tibial bearing tray
89448603|NCT00679120|Active Comparator|2|Cemented twin pegged femur with standard tibial bearing tray
89448604|NCT00679120|Active Comparator|3|Cementless tibial bearing tray and femur (porous coated and HA coated)
89448605|NCT00655200||A|
89448606|NCT00381641|Experimental|Treatment (sunitinib malate)|Patients receive sunitinib malate PO QD on days 1-28. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity
89448607|NCT00186147||Graft recipients and donors|
89448608|NCT05269563|Experimental|Double flap technique to secure macular hole closure.|Single ILM flap technique is already performing worldwide; however, sometimes it is associated with flap displacement. To overcome this issue, the double flap technique was tried.
89448609|NCT05267834||Positive high-risk HPV|Women with adenocarcinoma of the uterine cervix and positive for high-risk HPV (genotype16/18/31/33/35/39/45/51/52/56/58/59/68).
89448610|NCT05267834||Negative high-risk HPV|Women with adenocarcinoma of the uterine cervix and negative for high-risk HPV (genotype16/18/31/33/35/39/45/51/52/56/58/59/68).
88933895|NCT01763788|Experimental|Necitumumab + Gem and Cis|"Phase 1b Dose Escalation: Necitumumab 800 milligram (mg) on Days 1 and 8 of every 21 day cycle, administered as an intravenous (IV) infusion. Gemcitabine (Gem) dose escalation of 1000 or 1250 milligram per square meter (mg/m^2) on Days 1 and 8 of every 21 day cycle, administered as an IV infusion for a maximum of 4 cycles. Cisplatin (Cis) 75 mg/m^2 on Day 1 of every 21 day cycle, administered as an IV infusion for a maximum of 4 cycles.~Phase 2 Randomized: Necitumumab 800 mg on Days 1 and 8 of every 21 day cycle, administered as an IV infusion. Gemcitabine at fixed dose determined in Phase 1b (1000 or 1250 mg/m^2) on Days 1 and 8 of every 21 day cycle, administered as an IV infusion for a maximum of 4 cycles. Cisplatin 75 mg/m^2 on Day 1 of every 21 day cycle, administered as an IV infusion for a maximum of 4 cycles."
88933896|NCT01763788|Active Comparator|Gemcitabine + Cisplatin|Phase 2 Randomized: Gemcitabine at fixed dose determined in Phase 1b (1000 to 1250 mg/m^2) on Day 1 and Day 8 of every 21 day cycle,administered as an IV infusion over approximately 30 minutes for a maximum of 4 cycles. Cisplatin 75 mg/m^2 on Day 1 of every 21 day cycle, administered as an IV infusion over approximately 120 minutes for a maximum of 4 cycles .
88933897|NCT01763801|Active Comparator|P-Max group|Includes cases in which the catheter tip was considered correctly positioned when the Maximal P wave was obtained
88933898|NCT01763801|Active Comparator|P-Submax group|Includes cases in which the catheter tip was considered correctly positioned when the Submaximal P wave was obtained
88933899|NCT01763814|Active Comparator|Single shot femoral nerve block|A ultrasound probe will be used to identify the nerve, and correct needle placement.
88933900|NCT01763814|Active Comparator|Femoral nerve block non stimulating catheter|A ultrasound probe will be used to identify the nerve, and correct needle placement. The catheter will be placed with the nerve stimulator powered off.
88933901|NCT01763814|Active Comparator|Femoral nerve block stimulating catheter|A ultrasound probe will be used to identify the nerve, and correct needle placement. The catheter will be placed with the nerve stimulator powered on.
88933902|NCT01763840|Experimental|Contrast enhanced Ultrasound|Presence and grade of solid organ injury on contrast enhanced ultrasound
88933903|NCT01763853|Other|albumin|The main objective of our prospective double blind, randomized, controlled trial is to compare the rate of alveolar fluid clearance, a marker of alveolar edema fluid resorption, in 2 groups of patients with ARDS and suffering from hypovolemia: those treated with albumin and those treated with crystalloid (fluid challenge of 7 mL/kg over 15 minutes, that can be repeated 3 times if hypovolemia persists).
88933904|NCT01763853|Other|crystalloid|The main objective of our prospective double blind, randomized, controlled trial is to compare the rate of alveolar fluid clearance, a marker of alveolar edema fluid resorption, in 2 groups of patients with ARDS and suffering from hypovolemia: those treated with albumin and those treated with crystalloid (fluid challenge of 7 mL/kg over 15 minutes, that can be repeated 3 times if hypovolemia persists).
89448611|NCT05266287|Experimental|Investigational supplement|Participants in this arm will take a supplement containing 2'-fucosyllactose (2'-FL)
89448612|NCT05266287|Placebo Comparator|Placebo supplement|Participants in this arm will take a placebo supplement
89448613|NCT05253547|Experimental|Healthy climate-friendly dietary guidelines|Personalised healthy dietary recommendations aimed at reducing diet-related greenhouse gas emissions
89448614|NCT05253547|Active Comparator|Healthy eating guidelines|Personalised healthy dietary recommendations based on Ireland's Healthy Eating Guidelines
89448615|NCT05243043||Control|Mothers who experienced premature infant resuscitation in Labor and Delivery without the information provided by a computerized informational app.
89448616|NCT05243043||Intervention (future)|Mothers who experienced premature infant resuscitation in Labor and Delivery with the information provided ahead of time by the computerized informational application.
89448617|NCT05233982|Experimental|OLAPARIB|
89448618|NCT05226702|Experimental|COVAC-2 10 µg group|20 healthy adults ≥18 years of age receive the vaccine on Day 0.
89448619|NCT05226702|Experimental|COVAC-2 25 µg group|20 healthy adults ≥18 years of age receive the vaccine on Day 0
89448620|NCT05226702|Placebo Comparator|Placebo Control|20 healthy adults ≥18 years of age receive a dose of normal saline (placebo) on Day 0.
89448621|NCT05209009|Experimental|Group A|COVAC-2 25 µg: 200 generally healthy adults > 18 years of age receive the vaccine on Day 0, followed by a second dose on Day 28.
89448622|NCT05209009|Placebo Comparator|Group B|100 generally healthy adults > 18 years of age receive a dose of normal saline (placebo) on Day 0, followed by a dose of normal saline (placebo) on Day 28.
89448623|NCT05199493|Experimental|Angiotensin II|Intravenous infusion of max. 80 ng/kg/min Angiotensin II (titrated for each individual patient by effect) over 12 h after start of infusion
89448624|NCT05199493|Placebo Comparator|Control|Intravenous infusion placebo (matched infusion volume) over 12 h after start of infusion
89448625|NCT05193279|Experimental|SCB-2019/SCB-2019/placebo, 12 to < 18 yrs|Day 1 and 22: SCB-2019, Day 43: placebo
89448626|NCT05193279|Experimental|Placebo/SCB-2019/SCB-2019, 12 to < 18 years|Day 1: placebo, Day 22 and 43: SCB-2019
89448627|NCT05193279|Experimental|SCB-2019/placebo/SCB-2019, 12 to < 18 years|Day 1 and 43: SCB-2019, Day 22: placebo
89448628|NCT05193279|Experimental|Low dose SCB-2019, 5 to < 12 years|Day 1 and 22: SCB-2019
89448629|NCT05193279|Experimental|Mid dose SCB-2019, 5 to < 12 years|Day 1 and 22: SCB-2019
89448630|NCT05193279|Experimental|High dose SCB-2019, 5 to < 12 years|Day 1 and 22: SCB-2019
89448631|NCT05193279|Experimental|SCB-2019/SCB-2019/placebo, 5 to < 12 yrs|Day 1 and 22: SCB-2019, Day 43: placebo
89448632|NCT05193279|Experimental|Placebo/SCB-2019/SCB-2019, 5 to < 12 years|Day 1: placebo, Day 22 and 43: SCB-2019
89448633|NCT05193279|Experimental|SCB-2019/placebo/SCB-2019, 5 to < 12 years|Day 1 and 43: SCB-2019, Day 22: placebo
89448634|NCT05193279|Experimental|Low dose SCB-2019, 2 to < 5 years|Day 1 and 22: SCB-2019
89448635|NCT05193279|Experimental|Mid dose SCB-2019, 2 to < 5 years|Day 1 and 22: SCB-2019
89448636|NCT05193279|Experimental|High dose SCB-2019, 2 to < 5 years|Day 1 and 22: SCB-2019
89448637|NCT05193279|Experimental|SCB-2019/SCB-2019/placebo, 2 to < 5 yrs|Day 1 and 22: SCB-2019, Day 43: placebo
89448638|NCT05193279|Experimental|Placebo/SCB-2019/SCB-2019, 2 to < 5 years|Day 1: placebo, Day 22 and 43: SCB-2019
89448639|NCT05193279|Experimental|SCB-2019/placebo/SCB-2019, 2 to < 5 years|Day 1 and 43: SCB-2019, Day 22: placebo
89448640|NCT05193279|Experimental|Low dose SCB-2019, birth to < 2 years|Day 1 and 22: SCB-2019
89448641|NCT05193279|Experimental|Mid dose SCB-2019, birth to < 2 years|Day 1 and 22: SCB-2019
89448642|NCT05193279|Experimental|High dose SCB-2019, birth to < 2 years|Day 1 and 22: SCB-2019
89448643|NCT05193279|Experimental|SCB-2019/SCB-2019/placebo, birth to < 2 yrs|Day 1 and 22: SCB-2019, Day 43: placebo
89448644|NCT05193279|Experimental|Placebo/SCB-2019/SCB-2019, birth to < 2 years|Day 1: placebo, Day 22 and 43: SCB-2019
88933905|NCT01763879|Active Comparator|The PCV-VCV group|The dependent lung will be ventilated with pressure controlled (PCV) followed by the volume-controlled ventilation (VCV)
89448645|NCT05193279|Experimental|SCB-2019/placebo/SCB-2019, birth to < 2 years|Day 1 and 43: SCB-2019, Day 22: placebo
89448646|NCT05189236|Other|Control Group (Only Algorithm of Febrile Neutropenia Management)|The algorithm of febril neutropenia management is used to treat children who are followed up at the paediatric oncology service, where the study will be conducted, due to febrile neutropenia. The control group will consist of children who have been treated using this algorithm (only the Algorithm of Febrile Neutropenia Management).
89448647|NCT05189236|Experimental|Experimental Group (Algorithm of Febrile Neutropenia Management+Cold Steam)|The experimental group will consist of the children who will be applied to cold steam in addition to this algorithm (Algorithm of Febrile Neutropenia Management + cold steam application).
89448648|NCT05178017|Experimental|Participants|Individuals with Irritable Bowel Syndrome (IBS)
89448649|NCT05157906|Experimental|Experimental Group|Subjects will have access to the Grow Happy program materials, including the Grow Happy Book, 99+ Ways to Grow Happy Tips and Engagement Videos, which are provided digitally during the trial duration of 12 weeks.
89448650|NCT05157906|Active Comparator|Control Group|No additional education materials will be proactively provided during trial duration. Subjects will only be provided with the Indonesian standard of care only.
89448651|NCT05109455|Experimental|Food supplement|MANOSAR® is an authorized food supplement that contains D-mannose, Proanthocyanidins, Ursolic Acis, vitamin complexes and ions, and protects against urinary tract infections.
89448652|NCT05109455|Active Comparator|Comparator|The comparator are Proanthocyanidins of continuous-release, which are isolated from cranberry, and prevents the adhesion of uropathogenic bacteria such a E.coli to the wall of the urothelium.
88933906|NCT01763879|Active Comparator|The VCV-PCV group|The dependent lung will be ventilated with volume-controlled ventilation (VCV) followed by the pressure controlled (PCV)
89448653|NCT05097014|Active Comparator|CHF5993|pMDI fixed combination product of beclometasone dipropionate (BDP) 100 µg plus 6 µg of formoterol fumarate (FF) and 10 µg of glycopyrronium (G)
89448654|NCT05097014|Active Comparator|CHF1535|pMDI fixed combination product beclometasone dipropionate (BDP) 100 µg plus 6 µg of formoterol fumarate (FF)
89448655|NCT05097014|Placebo Comparator|Matched placebo|Matched placebo pMDI
89448656|NCT05085483|Experimental|Active intervention (one month)|Nutritional Ketogenic Supplement (NKS) 2 x 12 g of EKS/day
89448657|NCT05085483|Placebo Comparator|Placebo (one month)|Isocaloric placebo supplement
89448658|NCT05079360|Experimental|Sabizabulin Treatment Group|Subjects in the Sabizabulin Treatment Group will receive sabizabulin 32mg each day by mouth until disease progression is observed and confirmed by BICR.
89448659|NCT05079360|Active Comparator|Control Treatment Group|Subjects in the Control Treatment Group will receive an ER targeted therapy limited to exemestane monotherapy, exemestane plus everolimus, or selective estrogen receptor modulator (SERM) approved for the treatment of breast cancer and is part of the standard of care at the clinical study site until disease progression is observed and confirmed by BICR. The investigator decision of which comparator treatment will be used will be made prior to randomization.
89448660|NCT05078060||VaxigripTetra®|Participant vaccinated with VaxigripTetra® as per routine clinical practice
88933907|NCT01763892||Children admitted to hospital with a TBI|non-intervention study
88933908|NCT01763944|Active Comparator|Low carbohydrate, lifestyle counseling|The Low carbohydrate arm will receive counseling to follow a carbohydrate restriction diet (<20 grams per day) for 6 months.
88933909|NCT01763944|No Intervention|Control|The control arm will receive no dietary intervention.
88933910|NCT01763957|Active Comparator|Pelvic Floor Muscle Training (PFMT)|
88933911|NCT01763957|Active Comparator|Paula Method|
88933912|NCT01763983|Experimental|Aerobic Exercise|12-week structured and monitored aerobic exercise program
88933913|NCT01763983|Experimental|CBT and Aerobic Exercise|Combined 12-week individual Cognitive Behavioural Therapy and Exercise Program
89014611|NCT04644224|Experimental|Group II (coaching session, navigation session, support group)|Families whose churches are randomized to Group II, attend monthly health coaching sessions over 1 hour each for 12 months, 9 resource navigation sessions over 12 months, and monthly support groups for 12 months.
89014612|NCT04644224|Active Comparator|Group III (educational handbook)|Families whose churches are randomized to Group III, receive an educational handbook on cancer prevention.
89014613|NCT04644068|Experimental|Module 1: AZD5305 Monotherapy|AZD5305 Monotherapy
89014614|NCT04644068|Experimental|Module 2: AZD5305 + Paclitaxel|AZD5305 + Paclitaxel
89448661|NCT05078060||Efluelda®|Participant vaccinated with Efluelda® as per routine clinical practice
89448662|NCT05066373|Experimental|EDP1815 capsule A (fasted)|In part 1, 12 healthy volunteers will receive a single dose of EDP1815 capsule A, dosed in the fasted state
89448663|NCT05066373|Experimental|EDP1815 capsule B (fasted/fed)|In part 1, 2 & 3, 12 healthy volunteers will receive a single dose of EDP1815 capsule B, dosed in the fasted and/or fed state
89448664|NCT05066373|Experimental|EDP1815 tablet (fasted/fed)|In part 1, 3 & 4, 12 healthy volunteers will receive a single dose of EDP1815 tablet, dosed in the fasted and/or fed state
89448665|NCT05063786|Experimental|Experimental Arm (Arm A) Cohort 1 (HER2+/HR-)|"Trastuzumab either intravenous (IV) or subcutaneous (SC): 6 mg/kg IV every 3 weeks (3-weekly schedule), or 2 mg/kg IV weekly (weekly schedule)*, or 600 mg SC every 3 weeks.~Alpelisib 300 mg oral once daily.~*If using trastuzumab IV, a loading dose of 8 mg/kg (for the 3-weekly schedule), or 4 mg/kg (for the weekly schedule) is necessary if more than 6 weeks have passed since the previous trastuzumab dose."
89448666|NCT05063786|Experimental|Experimental Arm (Arm A) Cohort 2 (HER2+/HR+)|"Trastuzumab either intravenous (IV) or subcutaneous (SC): 6 mg/kg IV every 3 weeks (3-weekly schedule), or 2 mg/kg IV weekly (weekly schedule)*, or 600 mg SC every 3 weeks.~Alpelisib 300 mg oral once daily.~Fulvestrant 500 mg intramuscular every 4 weeks plus loading dose on day 15 cycle 1.~Males and females who are not post-menopausal must have been on a gonadotropin-releasing hormone (GnRH) agonist (e.g. goserelin or leuprorelin) for at least 28 days prior to starting study treatment, and should continue with this therapy.~*If using trastuzumab IV, a loading dose of 8 mg/kg (for the 3-weekly schedule), or 4 mg/kg (for the weekly schedule) is necessary if more than 6 weeks have passed since the previous trastuzumab dose."
89448667|NCT05063786|Active Comparator|Control Arm (Arm B ) Cohorts 1 and 2|"Trastuzumab either intravenous (IV) or subcutaneous (SC): 6 mg/kg IV every 3 weeks (3-weekly schedule), or 2 mg/kg IV weekly (weekly schedule)*, or 600 mg SC every 3 weeks.~Chemotherapy (CT): vinorelbine, capecitabine or eribulin (according to investigator preference):~Vinorelbine either oral (60 mg/m2) or IV (25 or 30 mg/m2 per investigator preference) on days 1 and 8, every 3 weeks.~Capecitabine: 1250 or 1000 mg/m2 (per investigator preference) twice a day (BID) oral, 2 weeks on, 1 week off, every 3 weeks.~Eribulin: 1.23 mg/m2 IV on days 1 and 8, every 3 weeks.~If using trastuzumab IV, a loading dose of 8 mg/kg (for the 3-weekly schedule), or 4 mg/kg (for the weekly schedule) is necessary if more than 6 weeks have passed since the previous trastuzumab dose."
89448668|NCT05054335|Experimental|Supportive care (walking function test, X-ray)|Patients undergo walking function assessment using optical motion capture and bi-plane dynamic X-ray imaging pre- and post-hemipelvectomy.
89448669|NCT05054335|No Intervention|Retrospective Group|"Acquisition of pre- and post-operative MRI data of the pelvic region (when available) collected previously as part of standard clinical care~Acquisition of pre-operative CT data of the pelvic region (when available) collected previously as part of standard clinical care~Acquisition of Physical Therapy Assessment data collected previously by a physical therapist and/or physical therapist assistant under protocol PA12-1046"
89448670|NCT05045040|Experimental|Mobile-based empathetic communication support program group|Patients are provided a mobile-based empathetic communication support program to promote ACP discussion for patients with advanced cancer and physicians. The experimental group also receives the usual care as is standard practice.
89448671|NCT05045040|No Intervention|Usual care group|Patients receive the usual care. The usual care includes routine medical treatment and care by physicians, nurses, pharmacists, and others as well as support from the palliative care team and others as per the patient's situation.
89448672|NCT05032612|Experimental|PBM Therapy|
89448673|NCT05032612|Sham Comparator|PBM Sham|
89448674|NCT05012787|Experimental|SCB-2019 Group|CpG 1018/Alum-adjuvanted SCB-2019 vaccine
89448675|NCT05012787|Placebo Comparator|Control Group|Havrix and Placebo
89448676|NCT04991740|Experimental|Part 1: Dose Escalation|Participants with renal cell carcinoma (RCC), ovarian cancer, colorectal cancer (CRC), and other tumor types with sponsor approval will receive JNJ-78306358. The dose will be escalated sequentially based on the decisions of the study evaluation team until the recommended phase 2 dose (RP2D) regimen(s) have been identified.
89448677|NCT04991740|Experimental|Part 2: Dose Expansion|Participants with RCC, ovarian cancer, CRC and other types of tumors will receive JNJ-78306358 at the RP2D regimen(s) determined in Part 1.
89448678|NCT04988087|Experimental|SjS participants: MHV370|SjS participants randomized in the MHV370 arm will be treated with MHV370 for 24 weeks. Double-blind supply will be used.
89014615|NCT04644068|Experimental|Module 3: AZD5305 + Carboplatin with or without Paclitaxel|AZD5305 + Carboplatin with or without Paclitaxel
89014616|NCT04644068|Experimental|Module 4: AZD5305 + Trastuzumab Deruxtecan|AZD5305 + T- DXd
89014617|NCT04644068|Experimental|Module 5 AZD5305 + Datopotamab Deruxtecan|AZD5305 + Dato-DXd
89448679|NCT04988087|Placebo Comparator|SjS participants: Placebo|SjS participants randomized in the placebo arm will be treated with placebo for 24 weeks. Double-blind supply will be used.
89448680|NCT04988087|Experimental|MCTD participants: MHV370|MCTD participants randomized in the MHV370 arm will be treated with MHV370 for 24 weeks. Double-blind supply will be used.
89014618|NCT04644068|Experimental|Module 6 AZD5305 + Camizestrant|AZD5305 + Camizestrant
89014619|NCT04640051||LAAO group|Patients scheduled for LAAO with Amplatzer Amulet (Abbott) and for whom a 3D in silico simulation by FEops HEARTguide is available and reviewed before implantation
89023551|NCT05166798|Experimental|Intervention group|Cognitive control training: The adaptive Paced Auditory Serial Addition Task (aPASAT) is a Cognitive Control Training where participants need to click on the sum of the last two heard digits. Task difficulty is modified based on the participants' current task performance, allowing training of cognitive control. Five intervention groups will each receive a different amount of sessions.
89448681|NCT04988087|Placebo Comparator|MCTD participants: Placebo|MCTD participants randomized in the placebo arm will be treated with placebo for 24 weeks. Double-blind supply will be used.
89448682|NCT04981717|Experimental|REGN1908-1909|Randomized 1:1
89448683|NCT04981717|Placebo Comparator|Placebo|Randomized 1:1
89448684|NCT04978207|Experimental|Multilevel, religiously-culturally tailored COVID-19 testing and linkage to care|Church-based COVID19 promoted with a religiously-culturally tailored Faithful Response COVID19 Toolkit delivered by church health workers (trained in an enhanced communication style) through multilevel church outlets (e.g., sermon guide, responsive reading, church bulletin inserts, automated text messages) and linkage to care delivered by community health workers who also conduct contact tracing; inclusive of 2 church-based COVID-19 testing events at each participating site.
89448685|NCT04978207|Active Comparator|Standard COVID19 information (non-tailored) attention control arm|Standard COVID-19 information that has not been tailored delivered by trained church health workers via a toolkit; inclusive of 2 church-based COVID19 testing evens at each participating site.
89448686|NCT04969575||day 3 refreshment|"All MII oocytes will be inseminated by ICSI 39-41 hours post final oocyte maturation trigger.~Following ICSI, oocytes will be cultured in 2-4 culture dishes placed in 2 separate chambers.~Media refreshment: Zygote scoring on day 1 (18-20hpi). Culture medium refreshment will be done 67-69 hours post insemination (Day3). Embryo grading will not be done day2-5. Culture media preparation and refreshment: 30µL of culture medium (Global total LP is added to each well of the 8 wells of LifeGlobal GPS Dish (EGPS-010) and 50µL to the center 3 drops.~Dishes will be equilibrated overnight in a CO2 incubator. Embryo grading should be done prior to media refreshment. Time out of the incubator during media refreshment will be assessed on day 3 and day 5.~One operator should perform the ICSI. In case of multiple operators, each operator's injected oocytes will be split between the 2 groups."
89448687|NCT04969575||day 5 refreshment|"All MII oocytes will be inseminated by ICSI 39-41 hours post final oocyte maturation trigger.~Following ICSI, oocytes will be cultured in 2-4 culture dishes placed in 2 separate chambers.~Media refreshment and embryo grading timings: Zygote scoring on day 1 (18-20hpi). Embryo grading and culture media refreshment will be done 114-118 hours post insemination (Day5).~Culture media preparation and refreshment: 30µL of culture medium (Global total LP is added to each well of the 8 wells of LifeGlobal GPS Dish (EGPS-010) and 50µL to the center 3 drops. Dishes will be equilibrated overnight in a CO2 incubator.~Embryo grading and media refreshment is done prior to blastocyst biopsy. Time out of the incubator during media refreshment will be assessed on day 3 and day 5.~One operator should perform the ICSI. In case of multiple operators, each operator's injected oocytes will be split between the 2 groups."
89448688|NCT04962035||Alprem RTF Brain Follow-up|Neurocognitive Follow-up of children previously having participated in the Alprem RTF study
89448689|NCT04946292|Experimental|Theory-derived intervention|Questionnaire will be used including the scales for three dominant theoretical models, Health Belief Model (HBM), Theory of planned behaviour (TPB) and Social Cognitive Theory (SCT). The theoretical model that best explains the health behaviours of the selected participants will be selected for designing oral health intervention.The theory-derived intervention will address the constructs/domains of the selected model(s) in the context of the three target behaviours (diet, toothbrushing and dental flossing).
89448690|NCT04946292|Active Comparator|Conventional health education|Participants will be randomly assigned to the control group, stratified by gender and education level. Allocation concealment will be ensured by using sealed opaque envelopes.
89448691|NCT04918927|Experimental|Arm 1: Favipiravir + Nitazoxanide|Oral Favipiravir 1800 mg twice daily on Day 1, followed by 400 mg four (4) times daily from Day 2 to Day 7 PLUS Nitazoxanide at 1000 mg twice daily on Day 1 followed by 500 mg four (4) times daily from Day 2 to Day 7
89448692|NCT04918927|Experimental|Arm 2: Favipiravir + Nitazoxanide placebo|Oral favipiravir, 1800 mg twice daily on Day 1, followed by 400 mg four (4) times daily from Day 2 to Day 7 PLUS Nitazoxanide matched placebo at 1000 mg twice daily on Day 1 followed by 500 mg four (4) times daily from Day 2 to Day 7.
89448693|NCT04901247||day 3|embryo grading and culture refreshment will be done 67-69 hours post insemination
89448694|NCT04901247||day 5|embryo grading and culture medium refreshment will be done 114-118 hours post insemination
89448695|NCT04857983|Placebo Comparator|TCT + PBO|"Suppressing active psychosis with antipsychotics benefits cognitive interventions for schizophrenia, but it is possible that drugs with pro-cognitive effects will specifically, and perhaps synergistically, augment the clinical benefits of cognitive therapies. A proof of concept for this approach is found in the use of the pro-extinction drugs to selectively enhance the impact of cognitive therapy for anxiety disorders. In this proof of concept, a learning-based therapy is paired with a medication that enhances a brain mechanism (extinction) that is both 1) critical to that form of learning, and 2) known to be deficient in some anxiety disorders."
89531318|NCT03336749|Experimental|Sensory group|Sensory re-learning in combination with task-specific training
89531319|NCT03336749|Active Comparator|Control group|Traditional task-specific training
88933914|NCT01763983|No Intervention|Waitlist Condition|12-week waitlist control condition, after which participants will have the chance to receive CBT group treatment.
88933915|NCT01764009|Experimental|Plasmid AMEP electrotransfer in muscle|
88933916|NCT01764035|Active Comparator|Brief Supportive Psychotherapy (SP)|30 people will be randomized to receive Brief Supportive Psychotherapy.
88933917|NCT01764035|Experimental|Body Scan (BS) Meditation Intervention|30 people will be randomized receive the Body Scan Meditation Intervention.
88933918|NCT01764048|Experimental|Fix protocol|"During 48 hours following surgery pain medications will be given as followed (listed in brackets are the generic names of each medication):~At patient arrival to the department: Intravenous Tramadol hydrochloride 100 milligrams + TAB. Paracetamol 500 milligrams + TAB. Diclofenac 100 milligrams~After 6 hours from patient arrival and every 6 hours: TAB. Zaldiar (Paracetamol 650 milligrams + Tramadol 75 milligrams).~After 12, 24 and 48 hours from patient arrival: TAB. Diclofenac 100 milligrams.~Rescue medication: TAB. Percocet (Oxycodone 5MG/Paracetamol 325 MG)as necessary up to 4 times per day.~The total amount of paracetamol is limited to 4 gr per day."
88933919|NCT01764048|Experimental|medications following demand protocol|The same combinations will be given as in the fixed protocol however only after patient request
88933920|NCT01764074|Experimental|Brief Sleep Intervention|Every participant in the study will complete a 3-session sleep intervention with a clinician to improve sleep problems such as insomnia or hypersomnia.
88933921|NCT01764087|Experimental|KX2-391 and Paclitaxel|"The phase I portion is a standard, three-patient per cohort, dose escalation schedule will be used. 3 or 6 subjects with solid tumor per dose group will likely be necessary to determine the MTD of KX2-391 in combination with weekly paclitaxel. With paclitaxel dose fixed at 80 mg/m2/weekly, KX2-391 treatment will be started at 20 mg dose once daily (QD)~The phase II portion of this trial has a design to determine the efficacy of KX2-391 when administered in combination with paclitaxel in 20 subjects with stomach cancer and 20 subjects with breast cancer"
88933922|NCT01764100|Experimental|Mesenchymal Stromal Cells (MSC)|Intravenous injections for a dose of 1 ± 0.5 x 106 MSC/kg recipient body weight
88933923|NCT01764113|Experimental|Mindful Eating|Subjects and at least one of their parents will receive mindful eating based behavioral modification program
89531320|NCT05052021||Perioperative or Recent Covid19 Infection|"Patients will be classified as having Perioperative Covid19 Infection if they test positive for SARS-CoV-2 within 7 days before and 30 days after surgery.~Patients will be classified as having Recent Covid19 infection if they tested positive for Covid19 within 1-6 weeks before surgery.~These patients will be analysed together as a group, as it is likely that their risk for complications will be similar."
88933924|NCT01764113|Active Comparator|Standard Dietary Couseling|Subjects and their parents will receive standard nutritional counseling provided by a registered dietician
88933925|NCT01764126|Active Comparator|Pneumococcal protein vaccine|Pneumococcal protein vaccine
88933926|NCT01764126|Placebo Comparator|Placebo|Placebo
88933927|NCT01764139||Knee pain patients with minimal knee changes|Male & no pregnant female age between 18-40 yrs.
88933928|NCT01764152|Experimental|Nasopharyngeal sample|one will be taken nasopharyngeal all patients hospitalized for 24 hours with ILI in the last seven days.
88933929|NCT01764165|Active Comparator|oxygen|nocturnal oxygen of 2 L/min
88933930|NCT01764165|Experimental|High Flow of room air|Warm and humidified air at a rate of 20 L/min through a small nasal cannula (similar to oxygen cannula)
88933931|NCT01764178|Experimental|Livalo fixed combination drug|Livalo fixed combination drug(Pitavastatin + Valsartan)
88933932|NCT01764178|Active Comparator|Pitavastatin + Valsartan|Pitavastatin, Valsartan
88933933|NCT01764204||Qingkailing Injection|
88933934|NCT01764230|Experimental|case group|Throughout the course of chemotherapy, patients were administered triptorelin (Diphereline SR 3 mg, Ibsen) in the form of i.m. injections, always once a month and simultaneously with the chemotherapy.
88933935|NCT01764230|No Intervention|control group|no intervention
88933936|NCT01764243|Experimental|MT-4666 Low Dose|low dose
88933937|NCT01764243|Experimental|MT-4666 High Dose|high dose
89448696|NCT04857983|Active Comparator|TCT + MEM|"Suppressing active psychosis with antipsychotics benefits cognitive interventions for schizophrenia, but it is possible that drugs with pro-cognitive effects will specifically, and perhaps synergistically, augment the clinical benefits of cognitive therapies. A proof of concept for this approach is found in the use of the pro-extinction drugs to selectively enhance the impact of cognitive therapy for anxiety disorders. In this proof of concept, a learning-based therapy is paired with a medication that enhances a brain mechanism (extinction) that is both 1) critical to that form of learning, and 2) known to be deficient in some anxiety disorders."
89448697|NCT04846790|No Intervention|Control|The control group will complete the first three assessments similar to the two treatment groups but will not participate in the nature-based or virtual mindfulness interventions. At the end of their study participation (~week 3), they will be offered the opportunity to partake in the nature-based and virtual mindfulness interventions.
89448698|NCT04846790|Active Comparator|Nature Only|The nature-based intervention is three days long, is offered at various locations throughout the United States, and includes activities such as hiking, mountain-biking, and kayaking. The healthcare workers can participate in the programs that are offered locally pending availability. Each program will enroll between 15 and 30 healthcare workers. All First Descents nature-based interventions have been intentionally designed with input from more than 450 hospital partners nationwide to improve psychosocial health, nurture supportive peer relationships, and better position healthcare workers to carry out their critical mission. There is no cost to attend, and meals and lodging are included. Special precautions against SARS-CoV-2 transmission are implemented.
89448699|NCT04846790|Experimental|Nature+Mindfulness|In the combined nature-based and virtual mindfulness intervention, participants will complete the nature intervention followed by the mindfulness intervention. The virtual mindfulness intervention is 10 days long and offered online. Each day the participant will receive a notification that a new mindfulness audio is ready for viewing, which is from 10 to 25 minutes long. Mindfulness exercises include mindful breathing, body scan, and loving-kindness meditation. Participants can view the daily audio as many times as they wish but cannot view the next day's content to maintain treatment fidelity. At the end of each day, participants will be asked to indicate if they viewed the mindfulness audio to track adherence.
89448700|NCT04800588|Experimental|Older participant group|We will evaluate the performance of healthy older participants (N = 300, age range 60 to 89 years) for three days at enrollment and then at 6-month intervals for three years thereafter. The goal is to characterize changes in performance to aging and task experience in a group of older subjects.
89448701|NCT04800588|Experimental|CCAB vs. manual test group|We will compare the performance of normal participants (N = 100, age range 18 to 89) on computerized and manually administered cognitive tasks.
89448702|NCT04800588|Experimental|Test-Retest Reliability group|We will gather normative data from participants across the age range (N = 100, ages 18 to 89) for three days at enrollment, to better characterize test-retest reliability scores on Day 1 tasks.
89448703|NCT04800588|Experimental|Health Disparities group|We will evaluate the performance of healthy older participants (N = 1200, age range 50 to 89 years) for three days at enrollment and then at 6-month intervals for three years thereafter. In the aim of better understanding health disparities in cognitive testing, this group will be divided into four cohorts: 300 African American participants; 300 Asian American participants; 300 Latino English-speaking participants; and 300 Latino Spanish-speaking participants, who will complete a Spanish translation of our computerized cognitive tests.
89448704|NCT04788836||Obesity treatment Group|60 (minimum) to 150 (maximum) overweight/obese adults referred for or who started obesity (surgical or non-surgical) treatment within 6 months
89448705|NCT04788836||Control Group|Comparison of food purchase behaviour with control subjects will be performed using an already existing cohort from a previous study. This does not required recruiting control subjects.
89448706|NCT04784117||Subgroup 2016-2018|Subgroup before change of dispatcher protocol
89448707|NCT04784117||Subgroup 2019-2021|Subgroup after change of dispatcher protocol
89448708|NCT04777708|Experimental|Treatment (pembrolizumab, BO-112)|Patients receive pembrolizumab IV over 30 minutes on day 1 of odd number cycles. Patients also receive BO-112 by intratumoral injection on day 1, 8, and 15 of cycle 1, and day 15 of subsequent cycles. Treatment repeats every 3 weeks for up to 17 cycles in the absence of disease progression or unacceptable toxicity.
89448709|NCT04774016|Experimental|Test formula C|
89448710|NCT04774016|Experimental|Test formula B|
89448711|NCT04774016|Placebo Comparator|Test formula A|
89448712|NCT04769648|Placebo Comparator|Vehicle|
89448713|NCT04769648|Experimental|Pro-ocular™ Topical Gel 1%|
89448714|NCT04765852|Experimental|Experimental Group 1|High dose probiotic supplement and maltodextrin as the excipient
89448715|NCT04765852|Experimental|Experimental Group 2|Low dose probiotic supplement and maltodextrin as the excipient
89448716|NCT04765852|Placebo Comparator|Control Group|Placebo supplement containing only maltodextrin but having the same appearance as the probiotic supplements
89448717|NCT04763512|Experimental|Intact Cow's Milk Protein Formula Group (CMFG)|All enrolled subjects will be fed Stage 1 CMF libitum for 4 months. Thereafter, they will discontinue study formula and complete the study.
89448718|NCT04763512|Experimental|Partially Hydrolysed Whey Formula Group (pHFG)|All enrolled subjects will be fed Stage 1 pHF libitum for 4 months. Thereafter, they will switch to Stage 2 pHF at age 6 months (Study Month 4) and to Stage 3 pHF at age 12 months (Study Month 9) and continue until age 18 months (Study Month 15). Thereafter, they will discontinue study formula and complete the study.
89448719|NCT04760093|Other|Low-to-High group|As this is a crossover study, each participant will be assigned to each treatment intervention. Participants (randomly) assigned to Arm 1 will first receive low polyphenol concentration EVOO for consumption, followed by high polyphenol concentration EVOO for consumption following a 14- day washout phase.
89448720|NCT04760093|Other|High-to-Low group|As this is a crossover study, each participant will be assigned to each treatment intervention. Participants (randomly) assigned to Arm 2 will first receive high polyphenol concentration EVOO for consumption, followed by low polyphenol concentration EVOO for consumption following a 14- day washout phase.
89448721|NCT04746248|No Intervention|Baseline|The baseline arm includes participants from before the implementation of the outpatient regime. All participants are induced according to the standard inpatient protocol.
88933938|NCT01764243|Placebo Comparator|Placebo|placebo
89448722|NCT04746248|Active Comparator|Women choosing to stay at the hospital|Include women who choose to stay at the hospital after implementing an outpatient alternative.
89448723|NCT04746248|Experimental|Women choosing to go home|Include women who choose the outpatient regime.
89448724|NCT04743206|Experimental|PIAPD-Portable Internal Airway Percussion device|There will be an Inpatient Arm and Outpatient Arm using the Smart One® portable home spirometer
89448725|NCT04743206|Active Comparator|SACD-Standard Airway Clearance device|"There will be an Inpatient Arm and Outpatient Arm using the SACD.~A large majority of patients will be using VEST therapy as their standard of care airway clearance. A few might be using an Intrapulmonary Percussion Device that uses a mechanism different from the device the study will be testing."
89448726|NCT04730349|Experimental|A1W Dosing schema|
89448727|NCT04730349|Experimental|A1F Dosing schema|
89448728|NCT04730349|Experimental|A2W Dosing schema|
89448729|NCT04730349|Experimental|A2F Dosing schema|
89448730|NCT04730349|Experimental|Part B: Cohort B1 Neuroblastoma|
89448731|NCT04730349|Experimental|Part B: Cohort B2 Ewing sarcoma|
89448732|NCT04730349|Experimental|Part B: Cohort B3 Rhabdomyosarcoma|
89448733|NCT04730349|Experimental|Part B: Cohort B4 Miscellaneous solid tumors|
89448734|NCT04730349|Experimental|Part B: Cohort B5 NHL/leukemia|
89448735|NCT04730349|Experimental|Part B: Cohort B6 High-grade glioma|
89448736|NCT04730349|Experimental|Part B: Cohort B7 Medulloblastoma and Embryonal Tumors|
89448737|NCT04730349|Experimental|Part B: Cohort B8 Ependymoma|
89448738|NCT04730349|Experimental|Part B: Cohort B9 Miscellaneous brain tumors|
89448739|NCT04720443|Experimental|SAD Part 1 Cohort 1|Eight subjects will be randomized at a ratio of 3:1 in each cohort to receive either NIP292 (oral tablet at 10 mg) or placebo. In each cohort, to mitigate any unforeseen safety issues, the first 2 subjects (1 active + 1 placebo) will be admitted and dosed, and at least 48 hours apart from the other 6 subjects. The remaining 6 subjects of each cohort will be dosed after review of the safety data of the first 2 subjects.
89448740|NCT04720443|Experimental|SAD Part 1 Cohort 2|Eight subjects will be randomized at a ratio of 3:1 in each cohort to receive either NIP292 (oral tablet at 30 mg) or placebo. In each cohort, to mitigate any unforeseen safety issues, the first 2 subjects (1 active + 1 placebo) will be admitted and dosed, and at least 48 hours apart from the other 6 subjects. The remaining 6 subjects of each cohort will be dosed after review of the safety data of the first 2 subjects.
89448741|NCT04720443|Experimental|SAD Part 1 Cohort 3|Eight subjects will be randomized at a ratio of 3:1 in each cohort to receive either NIP292 (oral tablet at 100mg) or placebo. In each cohort, to mitigate any unforeseen safety issues, the first 2 subjects (1 active + 1 placebo) will be admitted and dosed, and at least 48 hours apart from the other 6 subjects. The remaining 6 subjects of each cohort will be dosed after review of the safety data of the first 2 subjects.
89448742|NCT04720443|Experimental|SAD Part 1 Cohort 4|Eight subjects will be randomized at a ratio of 3:1 in each cohort to receive either NIP292 (oral tablet at 300 mg) or placebo. In each cohort, to mitigate any unforeseen safety issues, the first 2 subjects (1 active + 1 placebo) will be admitted and dosed, and at least 48 hours apart from the other 6 subjects. The remaining 6 subjects of each cohort will be dosed after review of the safety data of the first 2 subjects.
89448743|NCT04720443|Experimental|SAD Part 1 Cohort 5|Eight subjects will be randomized at a ratio of 3:1 in each cohort to receive either NIP292 (oral tablet at 500 mg)or placebo. In each cohort, to mitigate any unforeseen safety issues, the first 2 subjects (1 active + 1 placebo) will be admitted and dosed, and at least 48 hours apart from the other 6 subjects. The remaining 6 subjects of each cohort will be dosed after review of the safety data of the first 2 subjects.
89448744|NCT04720443|Experimental|MAD Part 2 Cohort 1|Eight subjects will be randomized at a ratio of 3:1 in each cohort to receive either NIP292 (oral tablet dosage 1) or placebo. All subjects will receive either NIP292 or placebo on an empty stomach for 7 days (from Day 1 to Day 7), and dosing frequency will be identical and either QD, Q12H, or Q8H (depending on the observed PK data in Part 1). Two dose levels (dose 1 and dose 2) proposed for MAD part will be determined based on the doses evaluated in SAD part.
89448745|NCT04720443|Experimental|MAD Part 2 Cohort 2|Eight subjects will be randomized at a ratio of 3:1 in each cohort to receive either NIP292 (oral tablet dosage 2) or placebo. All subjects will receive either NIP292 or placebo on an empty stomach for 7 days (from Day 1 to Day 7), and dosing frequency will be identical and either QD, Q12H, or Q8H (depending on the observed PK data in Part 1). Two dose levels (dose 1 and dose 2) proposed for MAD part will be determined based on the doses evaluated in SAD part.
89448746|NCT04719637|Experimental|PRDS-001|Renal denervation
88933939|NCT01764269|Other|inactivated influenza vaccine (IIV)|Patients whose provider chooses to administer to them inactivated influenza vaccine (IIV)
89448747|NCT04704856|Active Comparator|Interventiongroup|Interventiongroup, undergo supervised exercise for the first 6 weeks.
89448748|NCT04704856|No Intervention|Controlgroup|Controlgroup, do not undergo supervised exercise for the first 6 weeks (possibility to undergo supervised exercise after 6 weeks).
89448749|NCT04685252|Experimental|Pre-Partum and Post-Partum (BL) NCC3001|One stickpack containing probiotic strain (BL) NCC3001, dissolved and consumed oral daily over a period of 6 months; 3 months pre- and post-partum.
89448750|NCT04685252|Placebo Comparator|Placebo Control|One Placebo stickpack containing maltodextrin, dissolved and consumed oral daily over a period of 6 months; 3 months pre- and post-partum.
89448751|NCT04685252|Experimental|Post-Partum (BL) NCC3001 (Crossover Arm)|One Placebo stickpack containing maltodextrin, dissolved and consumed oral daily for 3 months during pre-partum, followed with switch to one stickpack containing probiotic strain (BL) NCC3001, dissolved and consumed oral daily for 3 months post-partum.
89448752|NCT04676451|Experimental|Femto-AK Patients|Femtosecond laser assisted cataract surgery with creation of astigmatic keratotomies for the correction of corneal astigmatism.
88933940|NCT01764269|Other|Live attenuated influenza vaccine (LAIV)|Patients whose provider chooses to administer to them Live attenuated influenza vaccine (LAIV)
88933941|NCT01764282|Experimental|Intervention|comprehensive intervention components
89206110|NCT04914052||Study group|"Patients will be requested to sign an informed consent in which they will agree to have their face filmed in the post-anesthesia care unit.~The facial expressions will be filmed in 30 second segments. A pain assessment will be measured immediately following filming of each segment using two modalities:~Pain score assessed by an attending anesthesiologist assigned to the study team.~VAS assessment by the patient. Following data collection, the data will be forwarded in a coded manner, according to Clalit's data security regulations, to Third Eye systems a facial recognition software company.~Third Eye systems will analyze and process the data using AI and machine learning models and develop an algorithm that can predict pain level by watching facial expressions."
89448753|NCT04673513|Active Comparator|Cognitive Behavioral Therapy (CBT)|Cognitive behavioral therapy will be provided as described in Beck et al. (1979) and Beck (2011), with adaptations for the treatment of comorbid personality disorders as described in Beck et al. (2015).
89448754|NCT04673513|Active Comparator|Cognitive Behavioral Therapy - Skill enhanced (CBT-SE)|This condition includes a variation of CBT (as provided in the other condition) with special emphasis on helping clients to develop the skills of CBT.
89448755|NCT04655092|Experimental|P1101 (Ropeginterferon alfa-2b)|Conventional treatment based on phlebotomies, lowdose aspirin (acetylsalicylic acid, 75-150 mg/day) plus the subcutaneous administration of pegylated prolineinterferon alpha-2b (P1101, Ropeginterferon alfa-2b) once every 2 weeks.
89448756|NCT04639518|Experimental|Sub-study 1|Pre-term formulas with HMO
89448757|NCT04639518|Experimental|Sub-study 2|Pre-term formulas without HMO
89448758|NCT04627545|Experimental|IVF: 2h exposure|Half of a patients' oocytes will be subjected to 2h exposure to sperm
89448759|NCT04627545|Active Comparator|IVF: overnight exposure|Half of a patients' oocytes will be subjected to overnight incubation with sperm (=usual practice).
89448760|NCT04612452||Lighthouse Trust in Lilongwe|
89448761|NCT04612452||CIDRZ in Lusaka|
89448762|NCT04605497|Experimental|Intervention Arm|Use of Dexcom G6 real-time CGM to monitor blood glucose levels continually.
89448763|NCT04605497|Other|Referent Arm|Self-capillary blood glucose monitoring (SCBG) testing 4x/day with blinded CGM every 2 weeks.
89448764|NCT04597450|Experimental|Lu AG06466|
89448765|NCT04597450|Placebo Comparator|Placebo|
89448766|NCT04569435|Experimental|ANX005|Participants will receive induction dosing of ANX005 on Days 1 and 5 or 6, followed by maintenance doses of ANX005 every 2 weeks up to Week 22.
89448767|NCT04539639|Experimental|Jaktinib 50mg Bid|Jaktinib 50mg Bid+ Placebo 50mg Bid+Placebo 75mg Bid
89448768|NCT04539639|Experimental|Jaktinib 75mg Bid|Jaktinib 75mg Bid+ Placebo 100mg Bid
89448769|NCT04539639|Experimental|Jaktinib 100mg Bid|Jaktinib 100mg Bid+ Placebo 75mg Bid
89448770|NCT04539639|Placebo Comparator|placebo|Placebo 100mg Bid+ Placebo 75mg Bid
89448771|NCT04535245||LCI testing|LCI testing will be performed on all study subjects
89448772|NCT04517396|Experimental|Fenofibrate + Usual Care|The randomized intervention will be Fenofibrate, in combination with usual care. Dosing: 145 mg of Tricor or a dose-equivalent preparation
89448773|NCT04517396|Placebo Comparator|Placebo + Usual Care|The randomized intervention will a matching placebo, in combination with usual care.
89448774|NCT04506619||SHP607 250 mcg/kg/24 hours|Participants who received 250 micrograms per kilogram per 24 hours (mcg/kg/24 hours) in the previous study SHP607-202 (NCT03253263) will be followed into this long-term study SHP607-203.
89448775|NCT04506619||SHP607 400 mcg/kg/24 hours|Participants who received 400 mcg/kg/24 hours in the previous study SHP607-202 (NCT03253263) will be followed into this long-term study SHP607-203.
88933942|NCT01764282|No Intervention|Usual|According the National HIV Antiretroviral treatment Guideline, provide treatment referrals for those treatment-eligible HIV-positive patients.
88933943|NCT01764295|Experimental|DWJ1276|Once daily, administered orally, 8 week
89448776|NCT04506619||Standard Neonatal Care|Participants who received standard neonatal care in the previous study SHP607-202 (NCT03253263) will be followed into this long-term study SHP607-203.
89448777|NCT04483167|Experimental|99mTccAbVCAM1-5|"Healthy volunteers and asymptomatic patients~Pré-screening of the volunteers by the CIC or the Vascular Surgeon and sending or handing over the newsletter~Visit 0 Selection: Validation of IC / NIC + Consent collection + additional exams~Visit 1 Inclusion: J0 Scintigraphic imaging following injection 99mTc-cAbVCAM1-5 (370 MBq - 550 MBq - 750 MBq depend of the SAE or AE )~Visit 2: Follow-up visit (Day 14 +/- 7 days post injection)~Visit 3: End of the study, follow-up visit (70 days +/- 10 days post injection)"
89448778|NCT04471623|Experimental|DeTAP Study App and Home Devices|Monitoring of OAC administration, OAC adherence, and clinical status through combined decentralized technologies
89448779|NCT04423146||Patients scheduled for elective scoliosis surgery|Patients scheduled for elective scoliosis surgery will be anesthetized in TIVA mode,combining propofol and remifentanil with titration to the target BIS value. Motor evoked potentials will be measured and evaluated by members of operating team perioperatively. The quality of evoked potentials (poor vs good quality) and the actual value of amplitude and latency at different BIS levels (40 - 60) will be monitored.
89448780|NCT04407546||Families with Children|Families containing an immunocompromised individual that have children in the family setting.
88933944|NCT01764295|Active Comparator|Olmesartan|Once daily, administered orally, 8 week
88933945|NCT01764295|Active Comparator|Rosuvastatin|Once daily, administered orally, 8 week
88933946|NCT01764295|Placebo Comparator|Placebo|Once daily, administered orally, 8 week
89448781|NCT04407546||Famlies without children|Families containing an immunocompromised individual that do not have children in the family setting.
89448782|NCT04402593|Experimental|Modified Heidelberg Model of Neuro-Music Therapy (mHNMT)|The mHNMT for Tinnitus program was modified based on participant feedback of the original HNMT. This study will include 6 sessions, 2 sessions a week including the following interventions: resonance training, music relaxation, Intonation Training and session review/homework.
89537127|NCT03378219||Cohort 1|Sarilumab-Exposed Cohort: Pregnant women exposed to Kevzara (sarilumab) for the treatment of an approved Kevzara (sarilumab) indication, for any number of days, at any dose, and at any time from the first day of the last menstrual period (LMP) up to and including the end of pregnancy
89014620|NCT04640038|Experimental|Contrast-enhanced Ultrasonography|Intravenous administration of contrast agent Sulfur hexafluoride lipid-type A microspheres before performing contrast-enhanced ultrasound (CEUS). In pediatric patients, after reconstitution 0.03 mL per kg is administered intravenously. The weight-based dose of 0.03 mL per kg will be repeated one time during a single examination. Following each injection, an intravenous flush of 0.9% Sodium Chloride is injected. The study duration per subject will be approximately 15 minutes including the time to prepare the contrast agent and perform the CEUS, as well as the 60 minute monitoring period after the first and second injection (if there are two injections of contrast) of the contrast agent.
89014621|NCT04629170|Experimental|MAD HV: SYNB8802 (1 x 10^11 live cells)|HV subjects receive SYNB8802 (1 x 10^11 live cells) TID for 5 days in the MAD study (Part 1).
89014622|NCT04629170|Experimental|MAD HV: SYNB8802 (3 x 10^11 live cells)|HV subjects receive SYNB8802 (3 x 10^11 live cells) TID for 5 days in the MAD study (Part 1).
89014623|NCT04629170|Experimental|MAD HV: SYNB8802 (1 x 10^12 live cells)|HV subjects receive SYNB8802 (1 x 10^12 live cells) TID for 5 days in the MAD study (Part 1).
89014624|NCT04629170|Experimental|MAD HV: SYNB8802 (optional cohort 1)|HV subjects receive SYNB8802 (at a dose to be determined based on the data from the first 3 cohorts) TID for 5 days in the MAD study (Part 1).
89014625|NCT04629170|Experimental|MAD HV: SYNB8802 (optional cohort 2)|HV subjects receive SYNB8802 (at a dose to be determined based on the data from the first 3 cohorts) TID for 5 days in the MAD study (Part 1).
89014626|NCT04629170|Placebo Comparator|MAD HV: Placebo|HV subjects receive placebo TID for 5 days in the MAD study (Part 1).
89014627|NCT04629170|Other|Crossover Arm 1: SYNB8802 crossover to Placebo|In Part 2 subjects will be randomized (1:1) to receive SYNB8802 TID for 6 days and then, following a washout period, receive Placebo TID for 6 days.
89014628|NCT04629170|Other|Crossover Arm 2: Placebo crossover to SYNB8802|In Part 2 subjects will be randomized (1:1) to receive Placebo TID for 6 days and then, following a washout period, receive SYNB8802 TID for 6 days.
89448783|NCT04390828|Experimental|Guided Imagery Meditation|the guided image meditation invention program of the intervention measures of this study include four important elements: 1) Meditation exercises: the exercises to adjust the body and mind through specific attention, so that people gradually feel the state of relaxation through practice; (2) Guided image: the simple visualization and use of mental images produced by imagination as a form of psychotherapy, images come from natural scenes (e.g., forests and mountains, streams and oceans), positive feelings and emotions are generated through psychological imagination to induce psychological and physiological relaxation state; (3) Music aids: reaching a relaxed state with comfortable and slow background music; (4) Breathing relaxation training: the patient is taught to take abdominal breathing to divert attention and stimulate the parasympathetic nervous system to achieve muscle relaxation. The entire intervention process takes about 15 to 20 minutes, 2 times a day.
89448784|NCT04390828|No Intervention|Usual care|usual care
89014629|NCT04616612|Experimental|SystemCHANGE (TM)|"SystemCHANGE™ focuses on using patients' already established and reliable systems to support medication-taking, rather than focusing on personal effort and remembering.When applied to medication adherence, the goal is to reduce medication-taking variability and move towards consistently taking medication with a 6-hour window of time (for daily medications like RAAS) and avoid missing medications. SystemCHANGE™ improvement cycles rely on efficient use of performance feedback in order to make decisions about whether system solutions work or if there is a need to select other solutions."
89014630|NCT04616612|Active Comparator|Attention Control|Participants in the attention control will receive educational materials about chronic kidney disease (CKD). The content will be focused on diet, exercise, and living with CKD.
89014631|NCT04613375||All participants|
89448785|NCT04384913||MA (mechanical alignment)|Patients in group MA (mechanical alignment) will be operated according to mechanical implantation technique. In the mechanical group, femoral and tibial cutting blocks will be designed for a 0-degree angle according to the mechanical axis. Femoral rotation will be aligned with the femoral trans-epicondylar axis. Tibial rotation will follow femoral rotation.
89448786|NCT04384913||KA (kinematic alignment)|Patients in group KA (kinematic alignment) will be operated according to kinematic implantation technique. The kinematic cutting blocks will be designed to resurface the femoral and tibial bones to restore each patient´s pre-arthritic anatomy and Joint line. Based on a available CT dat the prearthritic anatomy is reconstructed by compensating bone defects and restoring the physiological cartilage height of 1,7mm. Femoral Flexion is evaluated by the anterior Cortex of the distal femur, tibia slope is defined to 3° due to ACL (Anterior Cruciate Ligament) loss, but cab be adapted during surgery.
89014632|NCT04605276||Pre-biopsy cohort|"Male patients of age ≥18 suspected for prostate cancer who are scheduled for systematic and/or targeted biopsy after mpMRI examination.~No intervention study"
89014633|NCT04605276||Pre-radical prostatectomy cohort|Male patients of age ≥18 diagnosed with prostate cancer who are scheduled for radical prostatectomy
89014634|NCT04604912||Peanut-allergic patients' group|The aim is to include 30 patients with peanut allergy. Those patients will undergo diagnostic food challenges (incremental doses) while blood will be samples before, during and after the testing. The patients will receive standard of care during and after the challenge. Allergic symptoms will be treated according to established guidelines.
89014635|NCT04604912||Control group|The aim is to include 20 control participants, 10 peanut-tolerant and 10 fish-tolerant individuals. Those participants will undergo diagnostic food challenges (incremental or single doses) while blood will be samples before, during and after the testing. Same safety measures will be applied for food challenges of control individuals, as for the allergic patients.
89014636|NCT04595474||Study Cohort|533 adult subjects with type 1 diabetes with no secondary causes of fatty liver
89014637|NCT04594590||Patients with SLC25A46 deficiency|Male and female patients from age 2 to age 65 with clinically confirmed SLC25A46 mutations. Both living and deceased patients will be included, if eligible. For deceased patients, the patient's medical history records will be reviewed, and an interview of the parent(s) or caregiver(s) will be performed.
89014638|NCT04587427||Radium-223|Subjects who received the treatment of radium-223 during the before or after label change study periods.
89014639|NCT04584294|Experimental|Intervention (MyPath)|Patients scheduled to see providers randomized to this arm will receive a weblink to the decision tool via text message after study enrollment and prior to their scheduled visit.
89448787|NCT04383080|Experimental|Low-level laser therapy|Low-level laser irradiation on specific acupuncture points
89206111|NCT00628758|Experimental|Symbicort|Symbicort Single Inhaler Therapy ( Turbuhaler 160/4.5 microgram, 1 inhalation bid + as needed)
89014640|NCT04584294|No Intervention|Usual Care|Patients scheduled to see providers randomized to the usual care arm will receive no intervention and will receive usual primary care.
89014641|NCT04580979||Patients with ferredoxin reductase deficiency|Male and female patients from age 2 to age 65 with clinically confirmed FDXR mutations. Both living and deceased patients will be included, if eligible. For deceased patients, the patient's medical history records will be reviewed, and an interview of the parent(s) or caregiver(s) will be performed.
89014642|NCT04580485|Experimental|Treatment Group A (TGA) - INCB106385|"In part 1 dose escalation, the dose levels will be escalated following a BOIN design.~In part 2 dose expansion, participants will be assigned to different groups based on their tumor types and treated at the RDE."
89014643|NCT04580485|Experimental|Treatment Group B (TGB) - INCB106385+INCMGA00012|"In part 1 dose escalation, the dose levels will be escalated following a BOIN design.~In part 2 dose expansion, participants will be assigned to different groups based on their tumor types and treated at the RDE."
89448788|NCT04383080|Active Comparator|Acupuncture therapy|Dry needle inserting specific acupuncture points
89206112|NCT00628758|Experimental|Conventional BP|Conventional Best Practice for Treatment of Asthma
89206113|NCT04491604|Experimental|B-VEC|Topical gel of non-integrating, replication-incompetent HSV-1 expressing the human collagen VII protein
89448789|NCT04382352|Experimental|Humanized Anti-HER2 Monoclonal Antibody Compound for Injection|Registration number: CTR20181455 Indications: HER2-positive recurrent or metastatic breast cancer Experimental popular topic: Phase Ia clinical study of recombinant anti-HER2 humanized monoclonal antibody composition
89448790|NCT04372693|Experimental|group of students who are learning by Online Distance|"The following principals implemented while online learning will be processing;~Address and consider the students' differences in online learning application as a new experience.~Allow for Individual Locus of Control.~Motivate the student:~Avoid information overload,~Create A real-life context,~Encourage social interaction,~Provide hands-on activities,~Encourage student reflection."
89448791|NCT04372693|No Intervention|students who were learned by Traditional Classroom-Based|
89448792|NCT04328207|Other|No financial incentive|This group will receive standard of care eye health education alone and no financial incentive for completing a referral visit.
89448793|NCT04328207|Experimental|Financial incentive|This group will receive a financial incentive once the referral visit is completed (if one was required) as well as eye health education.
89448794|NCT04317794||All Participants|Participants who were prescribed with nusinersen sodium injection in Korea according to local marketing authorization.
89448795|NCT04317092|Experimental|tocilizumab treatment|All the patients enrolled are treated with tocilizumab.
89448796|NCT04311866|Active Comparator|Spica cast|Standard practice for the management of the femoral shaft fractures.
89448797|NCT04311866|Experimental|Synthetic fabric|Offer resistance, durability and low weight to treatment of femoral shaft fractures
89448798|NCT04311424|Experimental|14C Tirzepatide|A single dose of [14C]-tirzepatide administered subcutaneously (SC).
89448799|NCT04307394|Experimental|LifePlans|LifePlans is a video series using real patients telling their stories of overcoming suicidal thoughts and behaviors to help others who are struggling with these issues.
88933947|NCT01764308|Experimental|O3FA|Omega 3 Fatty Acid 1200mg twice a day for 24 weeks
88933948|NCT01764308|Placebo Comparator|Placebo|4 tablets twice a day for 24 weeks
89448800|NCT04301414|Other|Safety lead-in|The first 4 subjects enrolled will be given degarelix plus BMS-986218.
89448801|NCT04301414|Active Comparator|Arm A|Degarelix 240mg subcutaneous (SQ) x1 dose 2 weeks prior to radical prostatectomy
88933949|NCT01764321||Certolizumab Pegol treatment|Certolizumab Pegol in combination with at least one Disease Modifying Antirheumatic Drug (DMARD)
88933950|NCT01764321||Other Tumor Necrosis Factor TNF inhibitor treatment|Other subcutaneous (sc) Tumor Necrosis Factor (TNF) inhibitor (Adalimumab, Golimumab, Etanercept) in combination with at least one Disease Modifying Antirheumatic Drug (DMARD)
89206114|NCT04491604|Placebo Comparator|Placebo|Matching masked inactive topical gel
88933951|NCT01764334|Active Comparator|Fractional flow reserve|"Fractional flow reserve - guided group:~The initial treatment decision and the coronary arteries for fractional flow reserve (FFR) measurement will be established and recorded before randomization. FFR will then be measured by the cardiologist immediately after randomization and the FFR result will used to guide treatment decisions based on a threshold of 0.80. An FFR ≤ 0.80 should result in a treatment decision for revascularization by PCI or CABG combined with optimal medical therapy and an FFR>0.80 should result in treatment with optimal medical therapy alone. Changes in treatment compared to the treatment plan prior to FFR disclosure will be recorded at the time."
88933952|NCT01764334|Placebo Comparator|Angiography-guided|FFR is measured by but not disclosed to the clinical team. Treatment decisions are therefore guided by angiography but not by FFR. The patient and the clinical team, including the cardiologists and nurses, will be blinded to FFR. The RadiAnalyzer Xpress (St Jude Medical) will be turned away from the clinical team who will not see the pressure wire data. FFR will not be displayed on any other monitor. Quality control checks, such as assessments of equalized pressure, will be done in the usual way, by the unblinded clinical research team. These steps will be followed for all FFR measurements. Adherence to the blinding protocol, including any non-protocol FFR disclosure at any time, will be prospectively recorded and blinding procedures will be monitored with site visits.
88933953|NCT01764347|Experimental|Diagnostic (MRI-TRUS fusion image-guided biopsy)|Patients undergo robotic radical prostatectomy, followed by 3 MRI-TRUS fusion image-guided prostate biopsies.
88933954|NCT01764373|Experimental|16-Week Exercise Program|Subjects to participate in 16-week3 supervised aerobic exercise 3 times per week. Exercise sessions to last between 30 and 60 minutes.
88933955|NCT01764412||Healthy women|Non interventional
88933956|NCT01764425|Active Comparator|P7435|Tablets for once daily oral administration, For SAD part of the study dose would be 10 mg for Cohort 1; Cohorts 2, 3, 4 and 5 will be dosed subsequently at 30 mg, 100 mg, 300 mg, 1000 mg respectively Dose for MAD and food effects part of the study would be based on SAD study results
88933957|NCT01764425|Placebo Comparator|Placebo|Placebo tablets for oral administration
88933958|NCT01764438||very early or early staged patients|Performance of Primovist-enhanced MRI in HCC patients with very early or early stage disease, but with no suspicious HCC by liver dynamic CT
88933959|NCT01764477|Experimental|PRI-724 and Gemcitabine|This study will have one arm: all enrolled subjects will be treated with both PRI-724 and Gemcitabine.
88933960|NCT01764516||Zinc level (micro gram per deciliter)|In all cases
88933961|NCT01764516||Selenium level (micro gram per deciliter)|In all cases
88933962|NCT01764516||Zinc level in male (micro gram per deciliter)|
88933963|NCT01764516||Selenium level in male (micro gram per deciliter)|
88933964|NCT01764516||Zinc level in Female (micro gram per decilitre)|
88933965|NCT01764516||Selenium level in Female (micro gram per decilitre)|
88933966|NCT01764542|Other|Endoscopy and biopsy|Endoscopy with biopsy taken Endoscopy and biopsy Blood samples Questionnaire
88933967|NCT01763424|Active Comparator|Calcipotriol|Patients applied calcipotriol 0.005% (By LEO Pharmaceuticals, Ballerup, Denmark) for lesions of the other side of the body. The patients uses the medications twice daily (in the morning and before sleeping) for 12 weeks; the total doses of medication used not more than 100 gram per week.
88933968|NCT01763424|Experimental|Calcipotriol plus Nicotinamide|Patients applied calcipotriol 0.005% and nicotinamide 4% in combination (By LEO Pharmaceuticals, Ballerup, Denmark) for lesions of one side of the body. The patients uses the medications twice daily (in the morning and before sleeping) for 12 weeks; the total doses of medication used not more than 100 gram per week.
88933969|NCT01764555|Experimental|normal weight patients|normal weight patients receiving acetaminophen 2 g instead of 1 g
88933970|NCT01764555|Experimental|mobidly obese patients|morbidly obese patients receiving acetaminophen 2 g instead of 1 g
88933971|NCT01764568|Experimental|Metacognitive Training for Psychosis|Individuals with psychosis (Schizophrenia, Schizoaffective, Schizophreniform, etc.) who will receive Metacognitive Training twice weekly for 8 weeks (16 sessions).
88933972|NCT01764568|Experimental|Cognitive Remediation for Psychosis|Individuals with psychosis (Schizophrenia, Schizoaffective, Schizophreniform, etc.) who will receive Cognitive Remediation treatment twice weekly for 8 weeks (16 sessions).
88933973|NCT01764568|No Intervention|Treatment as Usual for Psychosis|Individuals with psychosis (Schizophrenia, Schizoaffective, Schizophreniform, etc.) who will continue to receive treatment as usual (TAU) as defined by their health care team (i.e., medication, other therapies) while still taking part in baseline, midpoint, and end-point assessments.
88933974|NCT01764581|Experimental|Tacrolimus dose regulation|Tacrolimus dose was reduced by 25% when ImmuKnow values were below 130 ng/mL ATP and increased by 25% when ImmuKnow values exceeded 450 ng/mL.
88933975|NCT01764581|No Intervention|Control|immunosuppressive therapy is managed either by standard practice at our center (Control)
88933976|NCT01764594|Experimental|CDP7657|"CDP7657 100 mg/ ml solution~30 mg/ kg initial dose~15 mg/ kg every other week~10 weeks"
88933977|NCT01764594|Placebo Comparator|Placebo|Placebo
88933978|NCT01764620|Other|Control|In this session, the athletes will be evaluated before and after the fatigue protocol, without any taping application.
88933979|NCT01764620|Experimental|Kinesio taping|A kinesio taping technique for facilitating lower trapezius muscle function will be applied just before fatigue protocol and removed after in the end of the evaluation session.
88933980|NCT01764620|Sham Comparator|Sham|A similar technique, using the same tape, will be applied but without any tension (tension is considered to be the therapeutic effect). The tape will be applied just before the fatigue protocol and removed in the end of the session.
88933981|NCT01764646|Experimental|9 days|Patients undergo extreme hypofractionated radiation therapy (Intensity modulated radiation therapy, Volumetric modulated arc therapy, Image guided radiation therapy) once a week over 28 days
88933982|NCT01764646|Experimental|28 days|Patients undergo extreme hypofractionated radiation therapy (Intensity modulated radiation therapy, Volumetric modulated arc therapy, Image guided radiation therapy) other 9 days.
88933983|NCT01764672|Experimental|Attention Deficit Hyperactivity Disorder|Adult males with Attention Deficit Hyperactivity disorder will participate in a crossover design and receive both methylphenidate and placebo on two separate days.
89448802|NCT04301414|Experimental|Arm B|BMS-986218 20mg IV every 2 weeks x 2 doses starting 3 weeks prior to radical prostatectomy plus degarelix 240mg SQ x1 dose 2 weeks prior to radical prostatectomy.
89448803|NCT04291456|Experimental|Minocycline|Minocycline 100 mg oral twice daily for up to 24 month
89448804|NCT04290845|Experimental|Relief-Hybrid|Relief-Hybrid relies on a neurobiological model to simplify its behavioral targets and uses mobile technology to augment its interventions. Relief was co-developed with our primary care partners with the goal to be usable by non-physician clinicians of primary care offices eligible to provide billable services.
89448805|NCT04290845|No Intervention|Referral to Mental Health/Usual Care|Continuation of medical attention and treatment provided by physicians and other medical professionals at the primary care practice. Referral for mental health based on clinical indication. Participants receive an educational booklet on pain.
89448806|NCT04284449||Enrolled Participants|This is a whole-practice precision medicine model in which a participant-specific Naturopathic treatment program is developed and implemented for older adults with cognitive complaints.
89448807|NCT04266977|Experimental|Treatment Dexamethasone|"The restrictive DEX regimen is applied from referral to the neurosurgical center until discharge. All administered steroids will be stopped immediately after study inclusion.~If one or more of the previously defined failure criteria occurs, patients will be treated with DEX."
89448808|NCT04263480|Experimental|Arm A: Carfilzomib + Ibrutinib|Patients will be treated with Ibrutinib until evidence of progressive disease or no longer tolerated. Patients will receive in addition Carfilzomib for two years.
88933984|NCT01764672|Experimental|Healthy adults|Healthy male adults will participate in a crossover design and receive both methylphenidate and placebo on two separate days.
88933985|NCT01764698|Experimental|CALM-SUD|Participants receive the adaptation of the Coordinated Anxiety Learning and Management (CALM) protocol that demonstrated effectiveness in a large primary care sample. CALM will be adapted for those with anxiety and substance use disorder comorbidity, and will consist of an orientation session and 6 group treatment sessions. These participants will also receive substance abuse treatment as usual at a community Intensive Outpatient Program.
88933986|NCT01764698|Active Comparator|Treatment as usual|Participants in this arm receive the standard Intensive Outpatient treatment for their substance use disorder at a community addictions treatment facility.
88933987|NCT01764724||Canadian Consumer Monitor Panel|Canadian Consumer Monitor Panel is a online consumer monitor panel which answers surveys every 8-10 weeks about diet and health.
88933988|NCT01764737|Experimental|VX15/2503|
88933989|NCT01764737|Experimental|Placebo|
88933990|NCT01764750|Experimental|Low Dose Intrasite Vancomycin|10 patients will be enrolled to receive low dose (see protocol) intrasite Vancomycin at the time of surgery. This will be the first group enrolled in the dose-escalation trial.
88933991|NCT01764750|Experimental|Mid-dose Intrasite Vancomycin|10 patients will be enrolled to receive mid-dose intrasite Vancomycin at the time of surgery.
88933992|NCT01764750|Experimental|High-dose Intrasite Vancomycin|10 patients will be enrolled to receive high-dose intrasite Vancomycin at the time of surgery.
89448809|NCT04263480|Active Comparator|Arm B: Ibrutinib|Patients will be treated with Ibrutinib until evidence of progressive disease or no longer tolerated.
89448810|NCT04250441|Experimental|Treatment|All patients enrolled will receive transcranial focused ultrasound. Target location is dependent on patient condition.
89448811|NCT04250376|Experimental|Treatment|All patients enrolled will receive transcranial focused ultrasound. Target location is dependent on patient condition.
89448812|NCT04245540|Experimental|Active|1,050 mg per day of encapsulated Pau d' Arco taken orally for 2 months.
89448813|NCT04196023|Active Comparator|GG genotype and magnesium treatment|Participants who have the GG genotype will be assigned to magnesium glycinate
89448814|NCT04196023|Placebo Comparator|GG genotype and placebo|Participants who have the GG genotype will be assigned to placebo group
89448815|NCT04196023|Active Comparator|GA/AA genotype and magnesium treatment|Participants who have the GA/AA genotype will be assigned to magnesium glycinate
89448816|NCT04196023|Placebo Comparator|GA/AA genotype and Placebo|Participants who have the GA/AA genotype will be assigned to placebo group
89448817|NCT04172922|Experimental|Open label, topical sirolimus arm|Single arm, open label study of1% sirolimus ointment applied to affected area twice daily for the first four weeks followed by once daily for 5 months.
89448818|NCT04168567|Experimental|Obese patients|Patients who have BMI higher than 30
89448819|NCT04168567|Experimental|Normal weight patients|Patients who have BMI between 20 and 25.
89448820|NCT04139772|Active Comparator|Docetaxel|Docetaxel 75 mg/m2 intravenous (iv) infusion every 3 weeks plus oral prednisone 5 mg twice daily for a maximum of 10 cycles.
89448821|NCT04139772|Experimental|Abiraterone or Enzalutamide|"Patient will receive Abiraterone or Enzalutamide based on previous treatment.~Abiraterone given orally at the dose of 1000 mg daily plus oral prednisone 5 mg twice daily until progression or unacceptable toxicity. One course of therapy corresponds to four weeks of treatment.~Enzalutamide given orally at the dose of 160 mg daily until progression or unacceptable toxicity. One course of therapy corresponds to four weeks of treatment."
89448822|NCT04129281|Other|Surgery|Surgery
88933993|NCT01764750|Active Comparator|Optimally-dosed IV Vancomycin|10 patients will be enrolled to receive optimally-dosed IV Vancomycin at the time of surgery and two doses post-operatively (standard peri-operative IV antibiotics)
88933994|NCT01764763||non epiaortic group|non epiaortic group ( n=1019)
88933995|NCT01764763||epiaortic group|epiaortic group ( n=1273)
88933996|NCT01764776|Experimental|LDE225|LDE225
88933997|NCT01764789|Experimental|Supportive care (psychosocial intervention)|Patients participate in a multi-component intervention based on cognitive and behavioral principles comprising MBSR, an intervention to promote hopefulness, and a problem solving approach which navigates around obstacles or generates alternatives when goals become blocked. Additional topics may be covered as indicated by clinical need and patients goals. Biobehavioral components include addressing social and disease-specific quality of life, and pain education. Intensive treatment sessions continue weekly for 16 weeks followed by 2 biweekly and 2 monthly maintenance sessions.
88933998|NCT01764802|Active Comparator|Arm I (enhanced standard care)|Patients participate in enhanced standard care intervention comprising stress reduction, information delivery regarding cancer treatments and sexuality delivered over two sessions.
88933999|NCT01764802|Experimental|Arm II (psychological intervention)|Patients participate in individual or group therapy over 1.5 hours weekly for 6 weeks, bi-weekly for 8 weeks, and monthly for 2 months and complete assessment interviews.
88934000|NCT01764815|Experimental|Directional lead|
89448823|NCT04129281|No Intervention|Active surveillance|Follow up
88934001|NCT01764828|Experimental|Refametinib (BAY86-9766)+ Gemcitabine|Single dose of BAY86-9766 on Cycle 1 Day -17; twice daily dosing every day starting on day -14, start dose 50mg bid ( 30mg or 20mg are possible based on adverse events need) in addition with Gemcitabine intravenous on day 1,8 and 15 1000mg/m2
89448824|NCT04121832|Experimental|Case|"32 women with fibromyalgia diagnosis corresponding to the diagnostic criteria of the American College of Rheumatology (ACR) will be taken in charge at the pain therapy centre of San Giovanni di Dio Hospital. All patients over the age of 18 will be included.~Other patients with rheumatologic diagnoses in comorbidity with fibromyalgia will be considered exclusion criteria/will be excluded. Patients with cognitive difficulties and / or diagnoses of intellectual disability and male patients will not be included in the study. In addiction to standard therapies, the sample will be treated with 10 sessions of biofeedback training."
89448825|NCT04121832|Active Comparator|Controls|32 women with fibromyalgia diagnosis corresponding to the diagnostic criteria of the American College of Rheumatology (ACR) will be taken in charge at the pain therapy centre of San Giovanni di Dio. All patients over the age of 18 will be included. Other patients with rheumatologic diagnoses in comorbidity with fibromyalgia will be considered exclusion criteria/will be excluded. Moreover, patients with cognitive difficulties and / or diagnoses of mental retardation and male patients will not be included in the study. The sample will be treated only with standard therapies without the use of biofeedback training
89448826|NCT04091204|Experimental|Olaparib|Olaparib is given orally at the dose of 300 mg bid continually as maintenance therapy after a platinum based chemotherapy
89448827|NCT04075721|Experimental|M3258 10 mg QD|
88934002|NCT01764867|Active Comparator|Algorithm Guided Treatment (AGT)|Algorithm Guided Treatment (AGT) strategies include two steps. In the first step, participants will be randomly assigned to escitalopram (10-20mg/d) or mirtazapine (30-45mg/d) group. In the second step those non-remitted will be allocated into a set of different intervention groups including mirtazapine monotherapy (only for those taken escitalopram in the first step), escitalopram monotherapy (only for those taken mirtazapine in the first step), or combination therapies (i.e. escitalopram plus mirtazapine, escitalopram or mirtazapine plus either modified electroconvulsive therapy with 6-10 sessions or repetitive transcranial magnetic stimulation with 20 sessions respectively) according to intent-to-treat principle. Medication dosage in combination therapy has the same range as the first.
88934003|NCT01764867|Active Comparator|Treatment As Usual (TAU)|This control arm refers to routine antidepressant treatment strategies for participants. Any of the new-generation antidepressants including fluoxetine, citalopram, escitalopram, paroxetine, sertraline, fluvoxamine, venlafaxine, duloxetine, mirtazapine, bupropion, or trazodone, which are all available in Chinese psychiatric clinics, may be used for participants who are randomly assigned to this treatment arm based on clinician's expertise and clinical judgement. The dosage range of any of the above antidepressants depends on clinician's judgement. The follow-up period will last up to 6-12 weeks. During follow-ups, clinician can decide to continue current treatment or start a switch or combination strategy based on his/her own clinical judgement.
88934004|NCT01764880|Experimental|SST0001 (Roneparstat)|"SST0001 once daily for 5 or 10 days in a cycle of 28 days. Starting dose 25 mg, to be escalated in subsequent cohorts.~Duration of treatment depending on toxicities observed or until documentation of disease progression or other discontinuation criteria are met."
88934005|NCT01764893|Active Comparator|PTNS and solifenacin|PTNS bladder neuromodulation weekly for 12 treatments; solifenacin 5 mg capsule daily for 15 weeks
88934006|NCT01764893|Placebo Comparator|PTNS and placebo|PTNS bladder neuromodulation weekly for 12 treatments; placebo 1 capsule daily for 15 weeks
88934007|NCT01764906|Experimental|Novosis|Bongros/rhBMP-2
88934008|NCT01764906|Active Comparator|Iliac crest bone graft|Iliac crest bone graft
88934009|NCT01764932|Other|Thoracic epidural catheter insertion|Fluoroscopic imaging. For patients undergoing thoracic epidural analgesia (TEA) with catheter placement for pain associated with thoracic or upper abdominal surgery
88934010|NCT01764958||preterm infants and their mothers|"Inclusion criteria are: preterm infants born between 26-34 weeks of gestation, whose mothers speak and write Hebrew fluently. Exclusion criteria are: preterm infants who suffer from perinatal asphyxia, genetic or metabolic diseases, necrotizing colitis that requires operation, intra uterine growth retardation, deafness, retinopathy of prematurity (ROP) or major congenital defects.~Infants and their mothers will be recruited from child developmental centers and Pediatric Clinics of Maccabi. No intervention is included in the research."
88934011|NCT01764971||chronic itp and cerebral dysfunction|patients with chronic itp and had behavioral and or cognitive dysfunction
88934012|NCT01764971||chronic itp only|chronic ITP patients without cerebral dysfunction
88934013|NCT01764984|Experimental|Trabecular metal|Primary Total Knee Arthroplasty is performed with a non cemented trabecular metal tibial baseplate.
88934014|NCT01764984|Active Comparator|Titanium|Primary total knee arthroplasty is performed with cemented titanium traditional tibial base plate
88934015|NCT01765010|Placebo Comparator|Placebo control|Placebo control
88934016|NCT01765010|Active Comparator|Cholecalciferol 1000IU|Cholecalciferol 1000IU qd for 8 weeks
88934017|NCT01765010|Experimental|alfacalcidol|alfacalcidol 0.5ug qd for 8 weeks
88934018|NCT01765010|Experimental|Calcitriol|Calcitriol 0.25ug qd for 8 weeks
89448828|NCT04075721|Experimental|M3258 10 mg Twice per Week|
89448829|NCT04075721|Experimental|M3258 20 mg Twice per Week|
89448830|NCT04074304|Other|I-HoME prototype|Participants will be shown prototype of I-HoME and provide feedback as part of the user-center design process.
89448831|NCT04063514|Experimental|Focused Ultrasound|The ultrasound treatment will last either 1 hour or 20 minutes total time for the DWL device or Brainsonix Focused Ultrasound Device, respectively.
89448832|NCT04058418||Familial breast cancer risk assessment services in England|All familial breast cancer risk assessment services in England
89448833|NCT04028245|Experimental|Spartalizumab and Canakinumab|Subjects with renal cell carcinoma will receive study treatment Q4 weeks x 2 doses prior to radical nephrectomy.
89448834|NCT03994406|Experimental|CLM2 Topical Gel|CLM2 topical gel to be applied dermally to forehead twice daily, in the morning and at bedtime.
89448835|NCT03994406|Placebo Comparator|Placebo Topical Gel|Placebo topical gel to be applied dermally to forehead twice daily, in the morning and at bedtime.
89448836|NCT03990051|Experimental|Pro-ocular™|Pro-ocular™ 1% topical gel applied dermally to forehead twice daily, morning and before bedtime.
88934019|NCT01765023|Experimental|Part A|single administration : atorvastatin 40mg, qd, 7days(oral) combination administration : atorvastatin 40mg and metformin XR 1000mg, qd, 7days(oral)
88934020|NCT01765023|Experimental|Part B|single administration : metformin XR 1000mg, qd, 7days(oral) combination administration : atorvastatin 40mg and metformin XR 1000mg, qd, 7days(oral)
88934021|NCT01765036|Experimental|SonoVue®|"Non randomised study~Sonovue 4,8 ml intravenous administration, in 1 bolus, during the EUS examination"
88934022|NCT01765062||Before Rapid Maxillary Expansion|T0
88934023|NCT01765062||3 months After Rapid Maxillary Expansion|T1
88934024|NCT01765062||One year After Rapid Maxillary Expansion|T2
88934025|NCT01765075||Patients undergoing cardiac ablation for permanent AF|
89448837|NCT03990051|Placebo Comparator|Placebo|Vehicle topical gel without active ingredient applied dermally to forehead twice daily, morning and before bedtime.
89448838|NCT03975114|Active Comparator|Chemo first|Standard chemotherapy followed at progression by durvalumab
89448839|NCT03975114|Experimental|Immuno Monotherapy first|Experimental single agent immunotherapy with durvalumab followed at progression by chemotherapy
89448840|NCT03975114|Experimental|Immuno Combination Therapy first|experimental single agent immunotherapy with durvalumab followed at progression by chemotherapy
89448841|NCT03969355||Paediatric patients 2008-2012|Paediatric patients admitted to intensive care in 2008-2012 who died during PICU stay
89448842|NCT03969355||Paediatric patients 2013-2017|Paediatric patients admitted to intensive care in 2013-2017 who died during PICU stay
89448843|NCT03957343|Experimental|Pacing and Planning App|The Pacing and Planning Program is a points system to aid individuals with an acquired brain injury/concussion in planning daily activities and managing symptoms. Activities are allotted various points, depending on the energy the task requires and the symptoms they create. Activities can include anything from grocery shopping to driving or watching TV, etc. Patients are allotted a number of points for a day, and therefore learn to sparingly perform activities. This results in a reduction of symptoms and improved recovery time.
89448844|NCT03955783|Experimental|Treatment (venetoclax, selinexor)|Patients receive venetoclax PO QD on days 1-28. Patients with DLBCL receive selinexor PO on days 1, 8, 15, and 22 of each cycle. Venetoclax naïve AML patients receive selinexor on days 8, 15, and 22 of cycle 1, followed by days 1, 8, 15, and 22 of subsequent cycles. Venetoclax refractory AML patients receive selinexor PO on days 1, 8, 15, and 22 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89448845|NCT03942120||Participants with Crohn's Disease|Participants that are diagnosed with Crohn's disease will be observed in this study who are being treated with ustekinumab under real world clinical practice. Only data available per clinical practice will be collected within this study.
88934026|NCT01765088|Active Comparator|temozolomide|Four weeks after radiotherapy, patients will be received 6 cycle of temozolomide (150 mg/m^2 daily on Days 1-5 of each 28 day study cycle and 200 mg/m^2 daily of subsequent cycles)
88934027|NCT01765088|Experimental|temozolomide +α-IFN|Four weeks after radiotherapy, patients will be received 6 cycle of temozolomide plus α-IFN α-IFN：3mIU (3million) Day1,3,5 of each 28 day TMZ：150 mg/m^2 daily on Days 2-6 of each 28 day study cycle and 200 mg/m^2 daily of subsequent cycles
88934028|NCT01765101|Experimental|customized insoles|"customized full-length lateral wedged shoe insoles~1 month and 3 months study the immediate, short-term and intermediate-term therapeutic effects"
88934029|NCT01765101|Placebo Comparator|ready made insoles|"ready-made full-length lateral wedged shoe insoles at 1 and 3 months~study the immediate, short-term and intermediate-term therapeutic effects"
88934030|NCT01765114|Experimental|PEG-Formulation|PEG-Formulation, applied twice daily during the treatment period (duration: 6 months)
88934031|NCT01765127||Asenapine|Patients prescribed asenapine for any indication by a National Health Service (NHS) general practitioner (GP) in England.
88934032|NCT01765166|Experimental|Control(ChO)|Children receive traditional SSGRIN child treatment with no parent involvement
88934033|NCT01765166|Experimental|Parent attention control(PAC)|Children will participate in traditional SSGRIN treatment, and parents will participate in a weekly support group to meet with other parents regarding their child's peer relations and behavior. The support group will meet for a parallel amount of time (1 hour/week for 10 weeks) and be facilitated by two parents with no SSGRIN or Parent Guide experience. The PAC condition will reflect the social support functions of a parenting group, but no therapeutic skills training or other instructional materials will be provided.
88934034|NCT01765166|Experimental|Parent Guide-Home Study(PG-HS)|Children will receive traditional SSGRIN treatment, and parents will receive the Parent Guide to SSGRIN training by participating in the online Parent Guide Home Study (PG-HS) course. The PG-HS course will include all instructional content and materials for the in-person Parent Guide course, but parent will receive the training online.
88934035|NCT01765166|Experimental|Parent Guide(PG)|Children will receive traditional SSGRIN treatment and parents will receive parallel traditional in-person SSGRIN-Parent Guide treatment.
88934036|NCT01765205||Newborns with Pulse oximetry|Up to 50 healthy newborn participants will receive 15 minutes of pulse oximetry to determine the effectiveness of measuring somatic oxygen saturation.
88934037|NCT01765205||CHD infant with pulse oximetry|Up to 10 infants diagnosed with congenital heart disease will receive 15 minutes of pulse oximetry using the INVOS Cerebral/Somatic Oximeter to determine the effectiveness of measuring somatic oxygen saturation.
88934038|NCT01765231|Experimental|Entecavir prophylaxis|Participants will initiate entecavir 0.5 mg/day orally on day 1 of the first course of antitumor therapy, and will be continued until at least 6 months after completion of antitumor therapy.
88934039|NCT01765231|Active Comparator|Observation arm|Entecavir 0.5mg daily will be prescribed for patients with hepatitis B virus reactivation.
88934040|NCT01765244|Experimental|Anterior lamellar nanostructured artificial human cornea|Anterior lamellar nanostructured artificial human cornea with allogenic from dead donor and cultured in its inside and allogeneic corneal epithelium cultured in its surface
89448846|NCT03941613|Experimental|Anterior temporal lobectomy|surgical treatment for mTLE
89448847|NCT03941613|Active Comparator|SEEG guided RF-TC|SEEG recording and minimal invasive treatment for mTLE
89448848|NCT03940742|Active Comparator|Normal Hepatic Function|Participants with normal hepatic function received single subcutaneous dose of 5 milligrams (mg) tirzepatide.
89448849|NCT03940742|Experimental|Mild Hepatic Impairment|Participants with mild hepatic impairment received single subcutaneous dose of 5 mg tirzepatide.
89448850|NCT03940742|Experimental|Moderate Hepatic Impairment|Participants with moderate hepatic impairment received single subcutaneous dose of 5 mg tirzepatide.
89448851|NCT03940742|Experimental|Severe Hepatic Impairment|Participants with severe hepatic impairment received single subcutaneous dose of 5 mg tirzepatide.
89448852|NCT03917654|Experimental|Arm 1a/3c|Arm 1a (pilot) + Arm 3c (main) to receive 40ug of Pfs230D1M-EPA/AS01 on days 0, 28, 168; receipt of artemether/lumefantrine (AL) on day -7
89448853|NCT03917654|Active Comparator|Arm 1b/3d|Arm 1b (pilot) + Arm 3d (main) to receive HAVRIX (day 0), TYPHIM Vi (day 28), HAVRIX (day 168); receipt of AL on day -7
89448854|NCT03917654|Experimental|Arm 2a/3a|Arm 2a (pilot) + Arm 3a (main) to receive 40ug of Pfs230D1M-EPA/AS01 on days 0, 28, 168; receipt of AL on day -7 and 154
89448855|NCT03917654|Active Comparator|Arm 2b/3b|Arm 2b (pilot) + Arm 3b (main) to receive HAVRIX (day 0), TYPHIM Vi (day 28), HAVRIX (day 168); receipt of AL on day -7 and 154
89448856|NCT03917654|Experimental|Arm 3e|Arm 3e (main) to receive 40microg of Pfs230D1M-EPA/AS01 on days 0, 28, 168; receipt of AL on day -7
89448857|NCT03917654|Active Comparator|Arm 3f|Arm 3f (main) to receive HAVRIX (day 0), TYPHIM Vi (day 28), HAVRIX (day 168); receipt of AL on day -7
89448858|NCT03917654|No Intervention|Arm 4a|Receipt of AL on day 154
89448859|NCT03917654|No Intervention|Arm 4b|Receipt of AL on day 154
89448860|NCT03903120|Experimental|ASSIST|Study 1 and 2
89448861|NCT03903120|No Intervention|Delayed Control|Study 1 and 2
89448862|NCT03903120|Experimental|Massed ASSIST|Study 3
89448863|NCT03903120|Experimental|Distributed ASSIST|Study 3
89448864|NCT03893240|Other|Participants with Late Onset Pompe disease|This is a multi-center, low-interventional study with a retrospective component in participants with LOPD. During a single study visit, assessments including but not limited to, liver health, neutralizing antibodies to SPK-3006 capsid and GAA, anti-GAA binding antibodies, GAA activity and GAA antigen levels will be performed. Additional information will be collected to provide retrospective evaluations relating to muscle and liver inflammation and/or injury. Historic data relating to Pompe disease will be collected from medical records. The retrospective and laboratory data collected may assist in providing baseline information for a future investigational gene therapy study.
88934041|NCT01765244|Active Comparator|Amniotic membrane transplantation|Amniotic membrane transplantation as conventional treatment of corneal trophic ulcers.
88934042|NCT01765257|Experimental|rasagiline|Randomized, double-blind, rasagiline (1 mg) vs placebo study. Parallel group (randomization 1/1). Duration 3 months 16 recruiting centers in France
88934043|NCT01765257|Placebo Comparator|placebo|Randomized, double-blind, rasagiline (1 mg) vs placebo study. Parallel group (randomization 1/1). Duration 3 months 16 recruiting centers in France
88934044|NCT01765283|Experimental|Hepastem Low dose|12.5x106cells/kg
88934045|NCT01765283|Experimental|Hepastem Intermediate dose|50x106cells/kg
88934046|NCT01765283|Experimental|Hepastem High dose|200x106cells/kg
88934047|NCT01765309|Experimental|Bilateral mastectomy with reconstruction|The trial was a comparison between each breast in a single patient undergoing bilateral mastectomy with reconstruction
89448865|NCT03875274|Placebo Comparator|Ropivacaine group|Ropivacaine 0.375% 20 ml + Normal saline 2 ml via FICB
89448866|NCT03875274|Experimental|Ropivacaine and morphine group|Ropivacaine 0.375% 20 ml + Morphine 2 ml via FICB
89448867|NCT03794050|Experimental|resistance training exercise|All participants complete one session of resistance training exercise
89448868|NCT03794050|Experimental|aerobic training exercise|All participants complete one session of aerobic training exercise
89448869|NCT03775850|Experimental|Cohort A|Cohort A includes patients with microsatellite stable (MSS) colorectal cancer (CRC). Patients will receive a 14 day run-in of EDP1503 alone, following which they will be treated with a combination of EDP1503 and pembrolizumab.
89448870|NCT03775850|Experimental|Cohort B|Cohort B includes patients with Triple Negative Breast Cancer (TNBC). Patients will receive a 14 day run-in of EDP1503 alone, following which they will be treated with a combination of EDP1503 and pembrolizumab.
88934048|NCT01765322|Experimental|Assisted hatching group (AH group)|The subjects are going to participate the treatment of assisted hatching in vitro fertilization by Zona Infrared Laser Optical System (ZILOS-TK IVOS Analyzer,Hamilton Thorne Biosciences,USA).
88934049|NCT01765322|No Intervention|Control group|The subjects are going to undergo the same procedure except for the treatment of assisted hatching.
88934050|NCT01765335|Experimental|NICaS system efficacy in HF patients|NICaS system efficacy in HF patients
88934051|NCT01765348|Experimental|Sentence combining|
88934052|NCT01765348|Active Comparator|Narrative based method|
88934053|NCT01765374|Experimental|rituximab|Only one arm; all patients are treated by rituximab (monotherapy or in combination with conventional DMARD)
88934054|NCT01765387|Experimental|Spa therapy|A cycle of 3 Vichy shower and whirlpool baths are applied during 30-minutes period. Vichy sedative shower is applied for 90-120 sec to the sides of the trunk and the abdomen, avoiding as much as possible the gall bladder area, at a temperature of 36-38ºC. A short, partial jet spray followed the shower. A whirlpool bath is administered where subjects immersed the body until their clavicle level for a 10min period with a water temperature ranging 33.5-35.5 ºC. Aromatherapy application using lavender and chamomile oils is used in all Spa therapy sessions.
89448871|NCT03775850|Experimental|Cohort C|Cohort C includes patients with non-small-cell lung cancer (NSCLC), bladder cancer; gastroesophageal (GE) cancer, any microsatellite unstable, or renal cell carcinoma (RCC) who are relapsed to prior PD-1/L1 therapy. Patients will receive a 14 day run-in of EDP1503 alone, following which they will be treated with a combination of EDP1503 and pembrolizumab.
89448872|NCT03762109|Experimental|Dantrolene Group|Patients will receive 25 mg of Dantrolene orally at four different time points: immediately before surgery, as well as at 12, 24 and 36 hours after surgery.
89448873|NCT03762109|Placebo Comparator|Placebo Oral Tablet Group|Patients will receive a 25 mg of a placebo pill orally at four different time points: immediately before surgery, as well as at 12, 24 and 36 hours after surgery.
89448874|NCT03732664|Other|Single arm|
89448875|NCT03703583||Exclusively/predominantly Breastfeeding group|
89448876|NCT03703583||Exclusively/predominantly Formula feeding group|
88934055|NCT01765387|No Intervention|Control group|"The control group perform a rest session in supine position in a room with neutral temperature condition with a same duration to Spa session. Participants of both groups are encouraged to drink water ad libitum to prevent dehydration."
88934056|NCT01765413|Experimental|Varilrix|Participants receive one dose of 'Varilrix' varicella-zoster vaccine.
88934057|NCT01765413|Experimental|Stamaril|Participants receive one dose of 'Stamaril' yellow fever vaccine.
88934058|NCT01765413|Placebo Comparator|Placebo|Participants receive one injection of placebo.
88934059|NCT01765452|Experimental|Closone|75mg/100mg per day, 8weeks, PO
88934060|NCT01765452|Active Comparator|Plavix with Astrix|75mg per day, 8weeks, PO 100mg per day, 8weeks, PO
88934061|NCT01765478|Experimental|Treatment A Period 2|40mg HM71224 single dose
88934062|NCT01765478|Experimental|Treatment B Period1|20mg HM71224 single dose
88934063|NCT01765478|Experimental|Treatment A Period1|10mg HM71224 single dose
88934064|NCT01765478|Experimental|Treatment B Period2|80mg HM71224 single dose
89448877|NCT03679260|Experimental|Arm A|Carbohydrate restricted diet and phone counseling with dietitian. After 6 months, patients will crossover to a non-restricted diet.
89448878|NCT03679260|Experimental|Arm B|Non-restricted diet and after 6 months, patients will crossover to a carbohydrate restricted diet and phone counseling with dietitian
88934065|NCT01765478|Experimental|TreatmentA Period3|160mg HM71224 single dose
88934066|NCT01765478|Experimental|TreatmentB Period3|200mg HM71224 single dose
88934067|NCT01765478|Experimental|Food effect period1|active 4subjects + placebo 4subjects
88934068|NCT01765478|Experimental|Food effect period2|active 4subjects + placebo 4subjects
88934069|NCT01765478|Experimental|TreatmentC|HM71224 Xmg multiple dose for 14days
88934070|NCT01765478|Experimental|TreatmentD|HM71224 Ymg 14days multiple dose
88934071|NCT01765478|Experimental|TreatmentE|HM71224 Zmg 14days multiple dose
88934072|NCT01765517|Experimental|Probiotics|Probitoics
88934073|NCT01765517|Placebo Comparator|Placebo|Placebo
88934074|NCT01765556|Experimental|Ketoconazole treatment|
88934075|NCT01765556|Experimental|Vemurafenib treatment|
88934076|NCT01765595|Experimental|DDI+|DDI+ Incorporated in routine ambulatory practice
88934077|NCT01765595|No Intervention|Control|Standard care
89023552|NCT05166798|No Intervention|Control group|Waitlist control group: Participants randomized to the control group will not perform the cognitive control training during the study, but will be given the opportunity to follow the training afterwards.
89200624|NCT00971464|Active Comparator|CCTV arm|A CCTV is an electro-optical device mainly used for reading, but which can also be used for writing or viewing pictures. It is comprised of a video camera which faces downwards towards the reading material and which inputs the image to a digital monitor. Magnification is variable over a large range. By means of a zoom lens and the brightness, contrast, and image polarity (black letters on white or white on black) can be controlled to provide the best combination of viewing conditions for an individual user. The significant advantages of CCTV over optical magnifiers are that it provides high levels of magnification with a greater field of view (compared to the equivalent optical device), allows reading at a more normal viewing distance of about 40 - 50 cms and allows binocular viewing.
89200625|NCT03992911|Experimental|FOLFSIM Plus Teripalimab|Simmtecan and 5-FU/LV Regimen (FOLFSIM) Plus Teripalimab
89448879|NCT03651154|Experimental|Hypovolemic Phlebotomy|"Hypovolemic Phlebotomy will consist of the withdrawal of 7-10 mL/kg of whole blood from the patient, as tolerated (e.g. for a 70kg patient, 490 to 700 mL of whole blood will be removed) The volume of removed blood will not be replaced by the administration of intravenous fluids.~Removed blood will be transfused back to participant at the end of surgery. The phlebotomized whole blood will be transfused back after liver transection regardless of blood loss."
88934078|NCT01765608|Experimental|Zonisamide|Zonisamide (Zonegran®) 300 mg. Hard white capsule. The total length of zonisamide treatment will be 20 and 24 weeks ± 2 weeks including one or two 4 week titration phases in the placebo and zonisamide groups respectively. Dosing will be down titrated after finished study during 2-3 weeks.The maximum dose after titration will be administrated once daily. Evening medication should be taken 2 hours before bedtime. The tablets will be swallowed with 200 ml of water (room temperature) in an upright body position.
88934079|NCT01765608|Active Comparator|Placebo|Matched for Zonisamide. Hard white capsule. Manufactured by Eisai Inc. Placebo tablets will be administered according to a forced stepwise weekly titration scheme with weekly 1 tablet escalations from 1 to 3 tablets daily matching the Zonisamide (Zonegran ®) dosing regimen for a total duration of 4 weeks. Evening medication should be taken 2 hours before bedtime. The tablets will be swallowed with 200 ml of water (room temperature) in an upright body position.
88934080|NCT01765608|Active Comparator|nCPAP|Continuous positive nasal airway pressure (nCPAP) delivers slightly pressurized air throughout the breathing cycle and will be given through a mask that is placed and secured over the person's nose. nCPAP titration will follow clinical routines whereby the patient is equipped with an autotitrating device (Sullivan S8 or S9). The standard setting is a pressure delivery in the pressure range 5-15 mbar and the full treatment is maintained in the patient´s home. The adequate performance of the device is controlled by user time readers and built-in memory cards and control readings are routinely performed within the first 4 weeks of treatment initiation. Patients will be encouraged via telephone calls for maximum use. Total duration of CPAP treatment is 24 weeks.
89448880|NCT03651154|No Intervention|Control (Standard of Care)|Standard of care (low CVP surgery). In this arm, standard anesthesia will be maintained.
89448881|NCT03613025|Other|Case : confirmed PCP diagnosis|Sampling of non-invasive and/or non-targeted respiratory tract specimens
89448882|NCT03613025|Other|Control : non confirmed PCP diagnosis|Sampling of non-invasive and/or non-targeted respiratory tract specimens
89448883|NCT03561207||Tumor tissue tested with EV3D Assay|Cancer tissue from multiple sites in the body, to include ovarian, brain, and other rare tumors.
89448884|NCT03509441||South Asians with Insulin Resistance|125 patients (anticipated)
89448885|NCT03509441||South Asians without Insulin Resistance|125 patients (anticipated)
89448886|NCT03473379||Phase 1: concept elicitation and coding|The aim of this phase is to elicit concepts from patients, caregivers, and oncology clinicians through focus groups of patients and caregivers, qualitative interviews and surveys. Approximately 55 patients or caregivers will participate in this phase.
89448887|NCT03473379||Phase 2: Item generation and analysis|The aim of this phase is produce a draft version of the questionnaire. Approximately 90 patients or caregivers will be recruited in this phase for item ranking and analysis through questionnaire evaluation and cognitive interviews.
89448888|NCT03473379||Phase 3: Instrument refinement and internal validation|The aim of this phase is generate the final version of the instrument. Approximately 101 patients or caregivers will participate in this phase by completing the questionnaire
89200626|NCT03992911|Active Comparator|EP/EC|Etoposide plus Cisplatin or Carboplatin
89200627|NCT00895479|Experimental|Trinam|Graft placement plus Trinam therapy
89448889|NCT03473379||Phase 4: External validation|In this phase the questionnaire will undergo further psychometric testing for validation and approximately 220 patients or caregivers will be asked to complete the PROFTC-I questionnaire along with quality of life instruments
89448890|NCT03410784|Other|First-line chemotherapy with pembrolizumab|"Pembrolizumab 200 mg i.v. on Day 1 every 3 weeks for up to 22 cycles~Paclitaxel 175 mg/m2 on Day 1 every 3 weeks for up to 6 cycles~Carboplatin (AUC 5) on Day 1 every 3 weeks for up to 6 cycles"
89448891|NCT03396367|Experimental|PARTNER Intervention|This intervention is a four-session intervention designed to increase PrEP uptake, increase PrEP adherence, and reduce drug use and HIV transmission risk behaviors of individuals in relationships.
89448892|NCT03396367|Active Comparator|Education Intervention|This intervention is a four-session intervention that discussed drug use and its effect on physiological social functioning.
89448893|NCT03363841|Experimental|SCY-078|SCY-078
89448894|NCT03323580|Experimental|GDFT group|The patients will receive fluid therapy under goal directed.
89448895|NCT03323580|Sham Comparator|Routine group|The patients will receive routine fluid therapy.
89448896|NCT03310619|Experimental|Arm A: JCAR017 in combination with Durvalumab|JCAR017 will be administered at a single flat dose of 50 x 10^6 CAR+T cells or 100 x 10^6 CAR+T cells. The combination agent will be administered at different doses and/ or schedules
89448897|NCT03310619|Experimental|Arm B: JCAR017 in combination with CC-122|This arm will test JCAR017 in combination with the CC-122. In adult subjects with R/R aggressive B-cell NHL. JCAR017 will be administered at a dose of 100 x 10^6 CAR+T cells. The combination agent will be administered at different doses
89448898|NCT03310619|Experimental|Arm C: JCAR017 in combination with CC-220|This arm will test JCAR017 in combination with CC-220. In adult subjects with R/R aggressive B-cell NHL. JCAR017 will be administered at a dose of 100 x 10^6 CAR+T cells. The combination agent will be administered at different doses
89448899|NCT03310619|Experimental|Arm D: JCAR017 in combination with Ibrutinib|This arm will test JCAR017 in combination with ibrutinib. In adult subjects with R/R aggressive B-cell NHL. JCAR017 will be administered at a dose of 100 x 10^6 CAR+T cells. The combination agent will be administered at a fixed dose of 420 mg daily
89448900|NCT03310619|Experimental|Arm E: JCAR017 in combination with relatlimab and/or nivolumab|This arm will test JCAR017 in combination with relatlimab and/or nivolumab in adult subjects with R/R aggressive B-cell NHL. JCAR017 will be administered at a dose of 100 x 10^6 CAR+T cells. The combination agent will be administered at different doses and/or schedules
89448901|NCT03310619|Experimental|Arm F: JCAR017 in combination with CC-99282|This arm will test JCAR017 in combination with CC-99282 in adult subjects with R/R aggressive B-cell NHL. JCAR017 will be administered at a dose of 100 x 10^6 CAR+T cells. The combination agent will be administered at different doses and/or schedules.
88934081|NCT01765621|Experimental|DDI+ and Pharmacogenetic data|DDI+ System and Pharmacogenetic data
88934082|NCT01765621|No Intervention|Standard Care|Control
88934083|NCT01765634|Experimental|Mesenchymal stem cells|Mesenchymal stem cell group refers to treatment with mesenchymal stem cells (1×10^6 cells/kg, intravenously)each week, four times for a cycle
88934084|NCT01765634|Experimental|Non-mesenchymal stem cells|Non-mesenchymal stem cell group refers to treatment with other second line drugs
88934085|NCT01765660|Experimental|Non-mesenchymal stem cells|Non-mesenchymal stem cell group refers to treatment with other second line drugs
88934086|NCT01765660|Experimental|Mesenchymal stem cells|Mesenchymal stem cell group refers to treatment with mesenchymal stem cells (1×10^6 cells/kg, intravenously)every two weeks, four times for a cycle
89200628|NCT00895479|No Intervention|Control|Graft placement surgery alone
89448902|NCT03280589|Active Comparator|Sitting Quietly|Participants will be instructed to sit comfortably in a chair with both feet flat on the floor, hands on their lap or thighs, rest their eyes (closed or slightly open gazed cast down), release tension in the body, remain still, and allow the chair to support them. Instructions will be displayed to them with on-screen video segments while the study personnel helps explains the steps, answers questions, and monitors adherence. There will be 4 five-minute sessions with a one-minute break in between to allow the participant to rest, adjust posture, and answer any questions. The total duration of this session will be approximately 40 minutes.
89448903|NCT03280589|Experimental|Deep Breathing Self Paced|Participants will be instructed to sit comfortably in a chair with both feet flat on the floor, hands on their lap or thighs, rest their eyes (closed or slightly open gazed cast down), release tension in the body, remain still, and allow the chair to support them. There will be 4 five-minute sessions with a one-minute break in between to allow the participant to rest, adjust posture, and answer any questions. Instruction will be displayed to them with on-screen video segments while the study personnel helps explains the steps, answers questions, and monitors adherence. The total duration of this session will be approximately 40 minutes.
89014644|NCT04567706||Ancillary-correlative (biospecimen collection)|Patients undergo collection of blood samples at the time of the initial diagnostic work-up, and possibly prior to the initiation of surgery, chemotherapy, immunotherapy, or radiation therapy, at tumor progression or recurrence, and annually during routine follow-up (no more than 4 blood draws per year). Patients may also undergo collection of tissue sample during standard of care surgical or radiologic procedures. Healthy individuals undergo collection of blood samples up to 4 times over 1 year.
88934087|NCT01765686|Active Comparator|Harmonic|Harmonic scalpel uses ultrasound technology to coagulate and to cut tissues.
89448904|NCT03280589|Experimental|Deep Breathing Externally paced|Participants will have an instructional video with auditory queues prompting them to inhale and exhale at 6 bpm (approximately 4 seconds between inhale and exhale). Participants will be instructed to sit comfortably in a chair with both feet flat on the floor, hands on their lap or thighs, rest their eyes (closed or slightly open gazed cast down), release tension in the body, remain still and allow the chair to support them. There will be 4 five-minute sessions with a one-minute break in between to allow the participant to rest, adjust posture, and answer any questions. Instruction will be displayed to them with on-screen video segments while the study personnel helps explains the steps, answers questions, and monitors adherence. The total duration of this session will be approximately 40 minutes.
89448905|NCT03280589|Experimental|Sheetali/Sheetkali, self-paced:|Participant will follow on-screen instructions for Sheetali/Sheetkari with shaped lips/mouth as indicated (i.e., inhaling through the mouth held specific to each practice and exhaling through nostrils), fully filling and emptying the lungs with each breath. In Sheetali, the tongue is allowed to protrude from the mouth at a comfortable distance and rolled into a tube. Following 10 minutes of Sheetali practice, participants will have a one minute rest followed by Sheetkari. In Sheetkari, the tongue is not rolled into a tube; instead, it is rolled up to touch the upper palate. The teeth are then exposed and the lips are kept apart for inhalation and the mouth is closed, tongue is relaxed, and exhalation occurs through the nose. Study personnel will monitor their posture and breathing rate and pause the recording if additional coaching is necessary. The total duration of this session will be approximately 40 minutes.
89448906|NCT03280589|Experimental|Sheetali/Sheetkari, externally-paced|The participant will follow on screen instruction for Sheetali/Sheetkari with shaped lips/mouth as indicated, fully filling and emptying the lungs with each breath. The tongue is allowed to protrude from the mouth at a comfortable distance and rolled into a tube. Following 10 minutes of Sheetali practice, participants will have a one-minute rest before continuing. In Sheetkari the teeth are exposed and the lips are kept apart for inhalation and the mouth is closed, tongue is relaxed, and exhalation occurs through the nose. Instruction will be displayed to them with on-screen video segments while the study personnel helps explains the steps, answers questions, and monitors adherence. There will be an auditory queue to prompt the participant to breathe in and out. Study personnel will monitor their posture and breathing rate and pause the recording if additional coaching is necessary.The total duration of this session will be approximately 40 minutes.
89448907|NCT03279510|Experimental|Hearing aids|All study participants will be fit with hearing aids.
89448908|NCT03244696|Experimental|Step Tracking|Participants will track their physical activity in steps using an accelerometer for a period of 6 months. Participants will monitor their overall step-count using the accelerometer, and daily and weekly summaries of their progress provided by the experimenters.
89448909|NCT03244696|Active Comparator|Water Tracking|Participants will track their water-intake using a smart water bottle for a period of 6 months. Participants will monitor their overall water consumption using a smart water bottle, and daily and weekly summaries of their progress provided by the experimenters.
89448910|NCT03201198|Experimental|Active Life|The Active Life intervention includes structured walking, functional circuit training, stretching and behavior/educational components.
89448911|NCT03201198|Sham Comparator|Chair exercises|The Chair exercise intervention includes chair exercises, behavioral relaxation and health education.
88934088|NCT01765686|Active Comparator|Small Jaw|Small Jaw device uses bipolar electrical energy and pressure to form a seal and a micro blade to divide the sealed tissues.
88934089|NCT01765699||Primary knee arthroplasty|Patients with osteoarthritis of the knee undergoing primary knee arthroplasty
88934090|NCT01765725|No Intervention|Control group|The control group will be offered to take part in the patient education group as soon as they have completed the last outcome evaluations
88934091|NCT01765725|Experimental|Patient education program|Patient education program
88934092|NCT01765738|Active Comparator|Antibiotic coated PICC|Cook Medical Spectrum Turbo-Ject Minocycline/Rifampin Power-Injectable PICC (5fr double lumen or 6fr triple lumen)
88934093|NCT01765738|Active Comparator|Non-antibiotic coated PICC|Bard Access PowerPICC Power Injection PICCs (6fr double lumen or 6fr. triple lumen)
88934094|NCT01765790|Experimental|Malignant Solid Tumor (Arm 1)|"Dose Escalation Phase- Standard dose escalation of anti-MIF antibody in 5 dose groups of 3-6 participants each according to 3+3 design: 1. Dose escalation will be performed after safety data review, following completion of dosing of each cohort. -> 2. Safety data review. If dose escalation permissible -> 3. Next dose group -> 4. Safety data review, etc.~Dose Expansion Phase- Enrollment of up to 6 participants to receive anti-MIF antibody (at the maximum tolerated dose or lower) in order to gain further experience with the investigational product at a specific dose level(s)."
88934095|NCT01765790|Experimental|Metastatic Adenocarcinoma of the Colon or Rectum (Arm 2)|"Dose Escalation Phase- Standard dose escalation of anti-MIF antibody in 3 dose groups of 3-6 participants each according to 3+3 design: 1. Dose escalation will be performed after safety data review, following completion of dosing of each cohort. -> 2. Safety data review. If dose escalation permissible -> 3. Next dose group -> 4. Safety data review, etc.~Dose Expansion Phase- Enrollment of up to 6 participants to receive anti-MIF antibody (at the maximum tolerated dose or lower) in order to gain further experience with the investigational product at a specific dose level(s)."
88934096|NCT01765816|Experimental|high intensity interval training|one interval training session with 1 x 4 and 4 x 4 minutes interval training at 90-95% of peak heart rate
88934097|NCT01765816|Active Comparator|moderate intensity training|45 minutes of moderate continuous training at 75% of maximal heart rate
88934098|NCT01765829|Active Comparator|Antipsychotic treatment|"Antipsychotic treatment according to common clinical practice~Drugs: Aripiprazole, Olanzapine, Zuclopenthixol, Clotiapine, Flupentixol, Risperidone, Sulpiride, Trifluoperazine, Haloperidol, Quetiapine, Paliperidone, Chlorpromazine, Pipotiazine, Flufenazine, Periciazine, Clozapine, Pimozide, Perfenazine, Sertindole, Levomepromazine, Amisulpride, Asenapine, Tiapride, Droperidol, Ziprasidone."
88934099|NCT01765829|Experimental|Discontinuation antipsychotic treatment|Dose reduction of antipsychotic treatment (25% every 4 weeks).
89014645|NCT04564885|Experimental|BAGUERA®C|surgical placement of the BAGUERA®C Cervical Disc Prosthesis at 2 contiguous levels
89448912|NCT03190785|Experimental|Benzoic acid washout and exposure|All subjects will be in this arm which employs a pre-post exposure design. Subjects will undergo a 2 week washout period where they avoid consumption of benzoate containing beverages. Then there is a 1 week exposure period comprising daily consumption of benzoate containing beverages to result in up to 5 mg/kg per day benzoic acid intake.
89448913|NCT03188627|Experimental|Bronchial basal cells|Transplantation of autologous bronchial basal cells
89448914|NCT03188627|No Intervention|Control|Conventional treatment
89448915|NCT03123042|Experimental|Sentinel basin dissection|Intervention: Sentinel basin dissection
89448916|NCT03060577|Experimental|Inclisiran-only|Participants received subcutaneous injections of inclisiran 300 milligrams (mg) on Day 1 and every 180 days thereafter for up to 4 years.
89448917|NCT03060577|Active Comparator|Switching|Participants received self-administered subcutaneous injections of evolocumab 140 mg on Day 1 and every 14 days thereafter until Day 336. Then, participants received subcutaneous injections of inclisiran 300 mg on Day 360 and every 180 days thereafter for up to 4 years.
88934100|NCT01765842|Active Comparator|Rituximab (1 cycle)|"1 cycle of Rituximab (4 i.v. infusions):~Day 0: 375 mg/m2 Day 7: 375 mg/m2 Day 14: 375 mg/m2 Day 21: 375 mg/m2"
88934101|NCT01765842|Experimental|Rituximab (2 cycles)|"A second cycle of Rituximab~First cycle of Rituximab (4 i.v. infusions):~Day 0: 375 mg/m2 Day 7: 375 mg/m2 Day 14: 375 mg/m2 Day 21: 375 mg/m2~Second cycle of Rituximab (4 i.v. infusions, 6 months later)"
88934102|NCT01765881|Experimental|Misoprostol|one 25 micrograms capsule all 4 hours by intravaginal route
88934103|NCT01765881|Active Comparator|Dinoprostone|one unique intravaginal sustained released of 10 milligrams
88934104|NCT01765894||Normal glucose tolerance subjects|Healthy controls. If any medication then paused 3 days prior to test days. BMI: 20-35. VO2max: 20-50. Age: 30-60 years All subjects perform same tests. - See protocol for description.
88934105|NCT01765894||DM2|"Type 2 diabetics in diet treatment or type 2 diabetics who have paused their oral medication for 3 whole days.~Insulin treatment is an exclusion criteria. If any other medication then paused 3 days prior to test days.~BMI: 20-35. VO2max: 20-50. Age: 30-60 years All subjects perform same tests. - See protocol for description."
88934106|NCT01765894||DM2 + Metformin|"Type 2 diabetics in metformin treatment. Insulin treatment is an exclusion criteria. If any other medication (besides from metformin) then paused 3 days prior to test days.~BMI: 20-35. VO2max: 20-50. Age: 30-60 years All subjects perform same tests. - See protocol for description"
88934107|NCT01765907|Experimental|HIFU|
88934108|NCT01765933|Experimental|DMAA|Single oral dose 25 mg DMAA
88934109|NCT01765946|Experimental|Metformin|Metformin tablets 500 mg tid for 2 months
88934110|NCT01765946|Placebo Comparator|Placebo|Placebo tables tid for 2 months
88934111|NCT01765959|Active Comparator|Auricular acupuncture (AA)|Auricular acupuncture (AA) group will receive treatment twice a week for four weeks. Each session will take approximately 60 minutes in which there will be active treatment time for 40 minutes. During treatment the respondents will have 5 thin sterile, disposable steel needles superficially placed in each outer ear. Before needle insertion the outer ears will be cleaned with disinfection solution. During treatment the respondents will sit down in silence; with eyes shut and focus on a normal calm breathing. The acupuncturist will not be in the room during treatment. After 40 minutes the respondents remove the needles and put them in a box suited for disposed needles. If needed, assistance to remove needles will be given from the acupuncturist.
88934112|NCT01765959|Active Comparator|Cognitive behavioral therapy (CBT)|"Cognitive behavioral therapy (CBT) group will receive manual based sessions for sleeping disorders. The group meets once a week during six weeks according to following program:~Session 1 - introduction, self-help concept Session 2 - biology of sleep, sleep restriction, Session 3 - stimulus control Session 4 - visualization as relaxation, Session 5 - how to deal with negative and automatic thoughts, Session 6 How to solve problems, planning for the future"
88934113|NCT01765985|Experimental|Intercurrent PSORIAMED|5 minutes twice a day for 12 weeks
89014646|NCT04564885|Active Comparator|Mobi-C®|surgical placement of the Mobi-C® Cervical Disc at 2 contiguous levels
89014647|NCT04557150|Experimental|Part I: Dose Escalation|Participants will receive forimtamig as intravenous (IV) infusion and/or subcutaneous (SC) injection in a step-up dosing fashion.
89200629|NCT01324765|Experimental|TARGET|12-session affect regulation therapy for PTSD
89200630|NCT01324765|Active Comparator|SGT|12 session supportive group therapy
89448918|NCT02940236||Multimodal analgesia|Patients scheduled for general surgery and requiring multimodal analgesia in preoperative period.
89448919|NCT02916810|Active Comparator|Active rTMS stimulation|Real active rTMS stimulation.
89448920|NCT02916810|Sham Comparator|Sham rTMS stimulation|Sham repetitive TMS stimulation.
89448921|NCT02872714|Experimental|Cohort A-ID (Intermittent Dose) Pemigatinib|Pemigatinib in subjects with FGFR3 mutations or fusions.
89448922|NCT02872714|Experimental|Cohort A-CD (Continuous Dose) Pemigatinib|Pemigatinib in subjects with FGFR3 mutations or fusions.
89448923|NCT02872714|Experimental|Cohort B Pemigatinib|Pemigatinib in subjects with other FGF/FGFR alterations.
89448924|NCT02863380|Experimental|Individualized rTMS (transcranial magnetic stimulation)|"The target region will be defined by comparing the rCBF scan of the patient to a control population (n = 38). rCBF will be measured using the QUIPS2 arterial spin labeling sequence on a Siemens 3T Verio.~The therapeutic protocol will be design to correct the rCBF anomaly first by defining each point where to deliver the stimulation than the stimulation protocol for each point (180% of active motor threshold, 4-second 10 Hz train duration, with 26-second intertrain interval for a total of 3000 pulses). The whole target will be homogeneously stimulated.~The active motor threshold will be assessed. The procedure will be repeated twice a day for 10 days over 2 weeks."
89448925|NCT02863380|Active Comparator|Classical rTMS (transcranial magnetic stimulation)|rTMS will be performed as usual using a figure-eight coil: Defining the active motor threshold. For each session positioning the coil on F3, stimulating at 180% of active motor threshold (10 Hz, 4-second train duration, and 26-second intertrain interval) for 37.5 minutes (3000 pulses per session), twice a day for 10 days over 2 weeks.
89448926|NCT02863380|Active Comparator|Classical tDCS (transcranial direct current stimulation)|tDCS will be performed as usual: After controlling for skin healthiness, the anode and the cathode will be respectively placed over F3 and right shoulder. A commercial devices (MagStim), will deliver a constant current of 2 mA through 25 cm2 saline-soaked rubber sponges for 20 min per session. The procedure will be repeated twice a day for 10 days over 2 weeks.
89448927|NCT02797275|Experimental|Albuterol & Placebo|Participants will be placed on the albuterol treatment (2 puffs twice a day, equivalent to 360 mcg per day) after the completion of the baseline screening visit. They will use albuterol for 4 weeks prior to their scheduled second visit during which they will undergo testing. Subsequently, and after a minimum washout period of 2 weeks, they will be placed on the placebo treatment for 4 weeks prior to their scheduled third visit, after which they will come back to undergo testing.
88934114|NCT01765985|Active Comparator|PLACEBO|"V0 : Selection: Information of the patient, control of inclusion and non inclusion criteria.~V1 : Control of inclusion and non inclusion criteria (treatment against psoriasis have to be discontinued for at least 3 weeks and 3 months for anti-IL12/23). Clinical scores and photographs. Explanation of the functioning of the device, then the treatment is followed at home, twice a day 5 minutes. 10% salicylic acid ointment will be applied after each session.~V2 : End of the treatment (12 weeks after V1). Clinical scores and photographs. V3 : End of the follow-up (24 weeks after V1). Clinical scores and photographs."
88934115|NCT01765998|Experimental|Probiotic|To study the effect of probiotic on the ability to build endothelial progenitor stem cells and to study clinical recovery of patients with Crohn's Disease.
88934116|NCT01765998|Placebo Comparator|placebo|This will be the comparison group to the experimantal group that recives Probiotic.
88934117|NCT01766011|Experimental|study pre-term formula|Pre-term formula with a modified stabilizer system in 2 oz. ready to feed plastic bottles
88934118|NCT01766063||Group 1|
88934119|NCT01766089|Active Comparator|Dexmedetomidine|dexmedetomidine intravenous infusion rate of 0.4 µg/kg/h
88934120|NCT01766089|Placebo Comparator|Remifentanil|remifentanil intravenous infusion rate of 0.1 µg/kg/min
88934121|NCT01766115|Experimental|Telaprevir|750 mg oral tablet of telaprevir will be given three times per day for 4 weeks within a five (5) day period from health care worker exposure.
88934122|NCT01766141|No Intervention|Acute versus chronic low back pain|No manipulative intervention. Phlebotomy for inflammatory biomarker determinations to compare acute versus chronic at baseline.
88934123|NCT01766141|Experimental|Spinal manipulation (SMT)|Inflammatory biomarker determinations after a course of 6 SMT interventions over the period of 2 weeks; a single SMT per treatment.
88934124|NCT01766141|No Intervention|No treatment controls|Asymptomatic subjects. Biomarker determinations at time zero and again two weeks later.
88934125|NCT01766154|Experimental|Subjects with normal renal function given tirofiban|Subjects with normal renal function (CrCl >90 mL/min)
88934126|NCT01766154|Experimental|Subjects with moderate renal insufficiency given tirofiban|Subjects with moderate renal insufficiency (CrCl 30-59 mL/min)
88934127|NCT01766154|Experimental|Subjects with severe renal insufficiency given tirofiban|Subjects with severe renal insufficiency (CrCl <30 mL/min).
88934128|NCT01766167|Experimental|MP-424|
89448928|NCT02797275|Experimental|Placebo & Albuterol|Participants will be placed on the placebo treatment after the completion of the baseline screening visit. They will use placebo for 4 weeks prior to their scheduled second visit during which they will undergo testing. Subsequently, and after a minimum washout period of 2 weeks, they will be placed on the albuterol treatment (2 puffs twice a day, equivalent to 360 mcg per day) for 4 weeks prior to their scheduled third visit, after which they will come back to undergo testing.
89448929|NCT02787005|Experimental|Cohort 1: PD-L1 positive with measurable disease|Participants with programmed cell death ligand 1 (PD-L1)-positive, measurable disease receive pembrolizumab 200 mg via intravenous infusion on Day 1 of every 3-week cycle for up to 2 years.
89448930|NCT02787005|Experimental|Cohort 2: PD-L1 negative with measurable disease|Participants with PD-L1 negative, measurable disease receive pembrolizumab 200 mg via intravenous infusion on Day 1 of every 3-week cycle for up to 2 years.
89206115|NCT03999112|Experimental|Metacognitive Reflection and Insight Therapy (MERIT) 4 week|Standard MERIT + 4 week baseline period
89448931|NCT02787005|Experimental|Cohort 3: Bone metastases with non-measurable disease|Participants with bone metastases and non-measurable disease receive pembrolizumab 200 mg via intravenous infusion on Day 1 of every 3-week cycle for up to 2 years.
89448932|NCT02787005|Experimental|Cohort 4: RECIST 1.1-measureable disease|Participants with Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1)-measureable disease receive pembrolizumab 200 mg via intravenous infusion on Day 1 of every 3-week cycle for up to 2 years.
88934129|NCT01766180|No Intervention|Placebo / Placebo|In this control group, subjects receives placebo supplement pills without Fruitflow or ResVida ingredients.
88934130|NCT01766180|Active Comparator|Fruitflow-II / Placebo|In this group subjects receive Fruitflow-II daily supplied in capsules which contain 150 mg active ingredient. They also receive placebo capsules for resVida.
88934131|NCT01766180|Active Comparator|Placebo / resVida|In this group subjects receive resVida daily supplied in capsules which contain 150 mg active ingredient. They also receive placebo capsules for Fruitflow-II.
88934132|NCT01766180|Active Comparator|Fruitflow-II / resVida|In this group subjects receive resVida and Fruitflow-II daily supplied in capsules which contain 150 mg active ingredient.
88934133|NCT01766193||vaginal birth|women whose first child was born by spontaneous vaginal delivery
88934134|NCT01766193||cesarean section|women whose first child was born by cesarean section
88934135|NCT01766193||forceps|women whose first child was born by forceps extraction
88934136|NCT01766193||vacuum|women whose first child was born by vacuum extraction
88934137|NCT01766232||Obstructed nasolacrimal drainage group|This group of patients is clinically identified as having epiphora due to an obstruction of the lacrimal drainage system.
88934138|NCT01766232||Ectropion group|This group of patients is clinically determined to have functional epiphora due to ectropion and a patent lacrimal drainage system.
88934139|NCT01766245|Experimental|Formulation A followed by Formulation B|
88934140|NCT01766245|Active Comparator|Formulation B followed by Formulation A|
88934141|NCT01766258|Active Comparator|Stalevo|levodopa/carbidopa/entacapone
88934142|NCT01766258|Experimental|ODM-101 65mg Carbidopa|levodopa/carbidopa/entacapone
88934143|NCT01766258|Experimental|ODM-101 105mg Carbidopa|levodopa/carbidopa/entacapone
88934144|NCT01766271|Experimental|Standard Risk Assessment (SRA) Only|
88934145|NCT01766271|Experimental|SRA plus Health Coaching|
88934146|NCT01766271|Experimental|SRA plus Genetic Testing|
88934147|NCT01766271|Experimental|SRA plus Health Coaching plus Genetic Testing|
88934148|NCT01766284|Experimental|Niris 1300e OCT imaging|OCT imaging of the cervix using Niris 1300e will include computer aided calculations for epithelial brightness.
88934149|NCT01766323|Placebo Comparator|Arm Placebo|Oral placebo b.i.d, along with the dose of oral morphine required for pain palliation
88934150|NCT01766323|Active Comparator|Arm-Modafinil|Oral modafinil at a dose of 100mg b.i.d along with the dose of oral morphine required for pain palliation
88934151|NCT01766349||esophagus cancer patients|Respiratory muscle performance will be followed in patients with esophagus cancer during CCRT or RT treatments.
88934152|NCT01766362|Experimental|A session|
88934153|NCT01766362|Other|Four sessions|Every session are spaced out of month
88934154|NCT01766375|Experimental|IDBUCY|"Idarubicin: 20mg/m2 a day, d-12 ~d-10, intravenous infusion for 1 hour. Busulfan: 4mg/Kg a day, oral administration, d-7 ~d-4, or 3.2mg/Kg a day, intravenous infusion, d-7~d-4.~cyclophosphamide: 60mg/Kg a day, intravenous infusion, d-3~d-2."
88934155|NCT01766375|Active Comparator|BUCY|"Busulfan: 4mg/Kg a day, oral administration, d-7 ~d-4, or 3.2mg/Kg a day, intravenous infusion, d-7~d-4.~Cyclophosphamide: 60mg/Kg a day, intravenous infusion, d-3~d-2."
88934156|NCT01766388||Pregnant women|Pregnant women of 13-22 weeks gestation
88934157|NCT01766414|Active Comparator|C1-esterase inhibitor|C1-esterase inhibitor 100 U/kg infusion followed by administration of Endotoxin 2ng/kg
88934158|NCT01766414|Placebo Comparator|Placebo|Placebo (saline 0.9%) infusion followed by administration of Endotoxin 2ng/kg
88934159|NCT01766427||morning electroacupuncture with pills|
88934160|NCT01766427||afternoon EA with pills|
88934161|NCT01766427||no EA group with pills|
88934162|NCT01766453|No Intervention|Non exercise control|Non exercise control will undergo baseline testing and follow up testing but will not participate in an exercise intervention.
89200631|NCT02541201|Experimental|Plant sterols-enriched low-fat milk|Daily consumption of 1.5g of plant sterols as provided by two servings of 273 ml of plant sterols-enriched low-fat milk for consecutive 3 weeks, each serving taken right before breakfast and lunch.
89448933|NCT02787005|Experimental|Cohort 5: Bone metastases only or bone-predominant disease|Participants with bone metastases only or bone-predominant disease receive pembrolizumab 200 mg via intravenous infusion on Day 1 of every 3-week cycle for up to 2 years.
89448934|NCT02755467|Experimental|Laser treatment|Each subject will receive a 532 nm KTP laser treatment for their spider angioma(s).
89448935|NCT02656394|Active Comparator|GL101|GL101 topical gel
89448936|NCT02656394|Placebo Comparator|Placebo|Placebo topical gel
89448937|NCT02633189|Experimental|erlotinib and bevacizumab|
89448938|NCT02633189|Active Comparator|erlotinib|
89448939|NCT02633085||Fixed Bearing or Mobile Bearing UKA|
88934163|NCT01766453|Experimental|Standard Exercise|The standard exercise group will attend exercise sessions under the supervision of a Certified Personal Trainer. Intensity will increase every four weeks by 10% from 50-80% of maximal heart rate to ensure that exercise is progressive in nature. Participants will be provided with a heart rate monitor during their exercise sessions and have the option to perform the aerobic training on a treadmill, upright bike, elliptical machine or recumbent bike as long as heart rate is kept within the prescribed training intensity. Intensity, duration, resting and exercise heart rates will be recorded for each exercise session for the duration of the intervention to ensure compliance to the exercise program.
88934164|NCT01766453|Experimental|Bhangra Dance Exercise|Bhangra dance classes taught be a certified instructor progressing in difficulty over the 12 week period. Bhangra dance is an Indian folk dance that consists of jumping and kicking of a high intensity. This group will attend exercise sessions under the supervision of a Bhangra Dance Instructor. The intensity of bhangra dance will be tracked through heart rate monitors worn by participants.
88934165|NCT01766479|Experimental|Family Degree-relatives of pts. with CRC|Consecutive patients admitted with CRC diagnosis (index case, IC) were prospectively evaluated. Following the systematic identification of ICs with inherited predispositions to CRC, ICs who agreed to contact their FDRs ≥40 years old were included. Available FDRs were invited to undergo non-cathartic CTC, with OC the following day.
88934166|NCT01766518|Experimental|MY-REPT capsule|MY-REPT capsule: Mycophenolate mofetil, 250mg/cap, orally
88934167|NCT01766531|Experimental|Body bioelectrical impedance|comparison with four methods for assessing nutritional status. ; compare length of mechanical ventilation, length in ICU and energy expenditure rest between malnourished and non-malnourished patient
88934168|NCT01766544|Active Comparator|Standard practice group (SPG)|Send a copy of the latest Canadian asthma and COPD guidelines to all PCPs.
88934169|NCT01766544|Active Comparator|Targeted Intervention Strategy (TISG)|interactive educational intervention, expert mentorship, practice-based tools. Consisting of 3 interactive sessions, 2 of which would be live meetings of 3h each and the third a one-hour teleconference.
88934170|NCT01766557|Experimental|Semi-controlled intervention with fish protein diet|Women with polycystic ovarian syndrome who are assigned to a 12 weeks experimental diet containing cod as the protein source.
88934171|NCT01766557|Active Comparator|Semi-controlled intervention with other animal proteins|Women with polycystic ovarian syndrome who are assigned to a 12 week experimental diet containing beef, pork, veal, eggs and milk products (BPVEM) as protein sources.
88934172|NCT01766570|Experimental|Phenol|Men and women who are assigned to a 6 weeks experimental period where they consume the rich polyphenol berries extract mix.
88934173|NCT01766570|Placebo Comparator|Control|Men and women who are assigned to a 6 weeks experimental period where they consume a placebo.
88934174|NCT01766583|Experimental|CC-292 + lenalidomide|Combination of CC-292 + lenalidomide
88934175|NCT01766596|Other|3C cohort|
89014648|NCT04557150|Experimental|Part II: Dose Expansion|Dose Expansion cohorts with IV and/or SC administration, respectively, will be initiated at the Recommended Phase 2 Doses (RP2Ds) determined in Part I: Dose Escalation phase.
89014649|NCT04551950|Experimental|Cohort 1A:M7824+Cisplatin/Carboplatin+Paclitaxel+Bevacizumab|
89014650|NCT04551950|Experimental|Cohort1B:M7824+Cisplatin or Carboplatin+Paclitaxel|
89014651|NCT04551950|Experimental|Cohort 2: M7824+Cisplatin+ Radiotherapy|
89014652|NCT04542135|Active Comparator|Sulindac|sulindac 150 mg
89014653|NCT04542135|Placebo Comparator|Placebo|placebo pill
89448940|NCT02621242|Other|Cohort|All subjects will undergo all procedures
89448941|NCT02619435|Experimental|regorafenib|
89200632|NCT02541201|Placebo Comparator|Low-fat milk|Daily consumption of two servings of 273 ml of low-fat milk (without plant sterols) for consecutive 3 weeks, each serving taken right before breakfast and lunch.
89200633|NCT00545272|Experimental|indacaterol 62.5 μg|Indacaterol 62.5 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.
89448942|NCT02618850|Other|Advanced CRC patients undergoing first-line chemotherapy|single cohort
89448943|NCT02526368|Experimental|Pre-surgical Prostate Cancer patients|Infusion of co-hyperpolarized 13C pyruvate and undergo and hyperpolarized 13C, 15N urea injection prior to metabolic/perfusion High spatial resolution MRI/1H MRSI staging exam (PROSE) using both a phased-array abdominal coil and an endorectal coil will be performed within 12 weeks of subsequent radical prostatectomy. At least 20 patients will be required to have high risk disease as defined by primary Gleason score of 4 or 5 on prior prostate biopsy
89448944|NCT02514083|Experimental|Ibrutinib and short-course fludarabine|"Ibrutinib 420 mg PO daily for the duration of the study~Fludarabine 25 mg/m2/day IV on days 1-5 of cycles 3 and 4"
89448945|NCT02500576|Experimental|Arm I (pembrolizumab, high-dose aldesleukin)|Patients receive standard lymphodepleting chemotherapy comprising cyclophosphamide IV over 2 hours on days -7 and -6 followed by fludarabine phosphate IVPB over 15-30 minutes on days -5 to -1. Patients also receive therapeutic tumor infiltrating lymphocytes IV over 15-60 minutes on day 0 followed by high-dose aldesleukin IV over 15 minutes every 8-16 hours for up to 15 doses on days 1-5. Beginning between 21-28 days after TIL infusion, patients receive maintenance therapy comprising pembrolizumab IV over 30 minutes every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
89448946|NCT02500576|Experimental|Arm II (pembrolizumab, low-dose aldesleukin)|Patients receive standard lymphodepleting chemotherapy comprising cyclophosphamide and fludarabine phosphate and therapeutic tumor infiltrating lymphocytes as in Arm I, followed approximately 6 hours later by low-dose aldesleukin SC for 14 days. Patients also receive pembrolizumab as in Arm I.
89448947|NCT02441777|Experimental|Control: Healthy|Polarization Sensitive Optical Coherence Tomography (PS-OCT) Imaging will be used to look at the nerve fiber layer (NFL) in the healthy retina.
88934176|NCT01766609|Active Comparator|A: Triamcinolone acetonide|Injections will be given within one half of a single vitiligo patch. The concentration of triamcinolone acetonide (TA) that will be used initially is 2.5 mg/ml. Dilution will be done using a bacteriostatic normal saline. Each half will receive injections with either TA 2.5 mg/ml or normal saline as a control. Only one investigator will know the intervention each half has received. If the patient did not show any evidence of repigmentation during the 3rd visit (i.e. after two injection sessions with TA 2.5 mg/ml) , the concentration of TA will be increased to 5 mg/ml. A total of 4 injections will be given over 4 visits. The treatment will be repeated every 3 to 5 weeks for a total of 4 treatment sessions.
88934177|NCT01766609|Placebo Comparator|B: Normal saline|Bacteriostatic normal saline will injected into one half of the vitiligo patch.
88934178|NCT01766661|Active Comparator|Coloanal anastomosis with ileostomy|Hand-sewn coloanal anastomosis protected by a loop ileostomy
88934179|NCT01766661|Experimental|Two stage Turnbull-Cutait anastomosis|Two staged coloanal anastomosis without protective ileostomy (Turnbull-Cutait procedure).
88934180|NCT01766674|Experimental|Kyphosis spinal exercises|Investigator developed the intervention protocol (Kyphosis spinal exercises) of targeted spine exercises during our pilot study based upon the literature and clinical experience.We standardized the protocol with a written script and a video. Each exercise session will be preceded by light aerobic activity, ended with cool-down and stretching the neck, chest and all extremities. All participants will be carefully monitored to ensure that all exercises will be performed slowly, with correct body alignment and technique to minimize risk of injury.
88934181|NCT01766674|No Intervention|Control|Control group will be enrolled in the usual care waitlist group
88934182|NCT01766687|Experimental|Hydration|Participants randomized to the hydration-intervention group will be asked to drink 1.0 to 1.5 L of water per day (depending on sex and weight), in addition to usual consumed beverages, for 12 months.
88934183|NCT01766687|No Intervention|Control|
88934184|NCT01766700|Experimental|No calorie beverages|2 no calorie beverages per day.
88934185|NCT01766700|Active Comparator|Water|2 water beverages per day.
88934186|NCT01766726||Healthy control subjects|Historical healthy control subjects matched to HIV+ patients on traditional cardiovascular risk factors will be studied at baseline with respect to arterial inflammation and coronary atherosclerotic plaque. Prospectively recruited healthy control subjects matched to HIV+ patients on traditional cardiovascular risk factors will be studied at baseline with respect to lipid and immune function.
88934187|NCT01766726||ART-naïve HIV+ patients starting QUAD/Stribild|ART-naïve HIV+ patients who are about to be started QUAD/Stribild by their treating clinicians will be studied at baseline and 6 months after initiating QUAD/Stribild therapy.
88934188|NCT01766752|Experimental|GlucoTab System|Investigational system: GlucoTab system supports the glycaemic management of non-critically ill patients with type two diabetes at the general ward.
88934189|NCT01766752|No Intervention|no intervention|standard care
88934190|NCT01766765|Experimental|Early jejunostomy nutrition|
88934191|NCT01766765|Active Comparator|Early oral nutrition|
88934192|NCT01766791|Experimental|HIT-exercise, low repetition range|High Intensity Resistance Exercise Training, low repetition range, > 75% 1 Repetition Maximum (1RM)
88934193|NCT01766791|Experimental|HIT-exercise, high repetition range|High Intensity Resistance Exercise Training, high repetition range, 60 - <75% 1RM
89448948|NCT02395848|Experimental|Fidaxomicin|30-day Fidaxomicin ( 200mg twice daily x 10 days and 200mg once daily x 20 days.
89448949|NCT02364791|Active Comparator|standard treatment|standard techniques to achieve air leak control after complex thoracic surgical procedures
88934194|NCT01766791|Experimental|HIT-exercise with protein|High Intensity Resistance Exercise Training with protein supplementation
88934195|NCT01766791|Placebo Comparator|Control|No physical exercise intervention
88934196|NCT01766804|Experimental|Bovine colostrum|A daily supplement of bovine colostrum powder.
88934197|NCT01766804|Placebo Comparator|Placebo|A daily placebo supplement consisting of whole milk powder and whey protein.
88934198|NCT01766830|Experimental|Phase 3 Diagnostic|A total of 10 RDTs will be assessed in the patients cohort for the respective target condition
88934199|NCT01766843|Active Comparator|Seretide Diskus and charcoal|Single-dose of Seretide Diskus (50/500 mcg/inhalation) and charcoal
88934200|NCT01766843|Active Comparator|Seretide Diskus|Single-dose of Seretide Diskus (50/500 mcg/inhalation)
88934201|NCT01766843|Experimental|SF Easyhaler and charcoal|Salmeterol/fluticasone Easyhaler (50/500 mcg/inhalation) with charcoal
88934202|NCT01766843|Experimental|SF Easyhaler|Salmeterol/fluticasone Easyhaler (50/500 mcg/inhalation)
88934203|NCT01766856||children undergoing myringoplasty/tympanoplasty|child having repair of eardrum because of hole in eardrum after tube extruded or after tube removal
88934204|NCT01766882|Experimental|Treatment|"Lower sodium intervention:~Dietary sodium restriction of ≤2.0 g/day or ≤85 mmol/day~Lower dialysate sodium at 137 mmol/L.~Progressive Challenge to Post Dialysis Weight:~The existing target post-HD weight will be progressively challenged by removing additional fluid in small increments."
88934205|NCT01766882|No Intervention|Control|Usual care in addition to Blood pressure monitoring and and Hydration status monitoring
88934206|NCT01766895||uremic patients|blood sampling of viral hepatitis in uremic patients
89200634|NCT00545272|Experimental|indacaterol 125 μg|Indacaterol 125 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.
89206116|NCT03999112|Experimental|Metacognitive Reflection and Insight Therapy (MERIT) 6 week|Standard MERIT + 6 week baseline period
89448950|NCT02364791|Experimental|standard treatment plus hemopatch|the addition of hemopatch to standard techniques to achieve air leak control after complex thoracic surgical procedures
89448951|NCT02340585|Experimental|Next Generation Neuroform Stent System|The Next Generation Stent System is a self-expanding, open cell, nitinol stent designed to provide support of the coil mass within the aneurysm and minimize stent deflection.
89448952|NCT02214381|Active Comparator|Mycet/Cyclophosphamid|4 x Myocet 60 mg/m² q3w in combination with 4 x cyclophosphamide 600 mg/m² q3w depending on early response assessment by ultrasound or on toxicity profile.
89448953|NCT02214381|Active Comparator|Myocet/Cyclophosphamide/Paclitaxel|2 x Myocet 60 mg/m² q3w in combination with 2 x cyclophosphamide 600 mg/m² q3w followed by 6 x paclitaxel 80 mg/m² q1w depending on early response assessment by ultrasound or on toxicity profile.
89014654|NCT04537897|Experimental|BI 474121 2.5mg (Part A)|"Young participants administered 1 tablet of 2.5 milligrams (mg) BI 474121 orally once daily over a treatment period of 14 days.~On Day -1, 1, and 14, 75 micrograms (μg) of midazolam for injection used as oral solution were administered orally once daily."
89448954|NCT02081326|Experimental|Bacillus Calmette-Guérin|2 BCG vaccinations spaced 4 weeks apart during the first year and then 1 vaccination every year for the next 4 years
89448955|NCT02081326|Placebo Comparator|Saline injection|2 injections spaced 4 weeks apart during the first year, then 1 injection per year for the next 4 years
89448956|NCT02061761|Experimental|Part A - relatlimab (Dose escalation)|
89448957|NCT02061761|Experimental|Part C - relatlimab + nivolumab (Dose escalation)|
89448958|NCT02061761|Experimental|Part B - relatlimab (Cohort expansion)|
89448959|NCT02061761|Experimental|Part D - relatlimab + nivolumab (Cohort expansion)|
89448960|NCT01990053|Experimental|Beating the Blues|Beating the Blues plus helper support.
89448961|NCT01990053|No Intervention|Waitlist Condition|Eight week waitlist condition group parallel to the immediate treatment condition with optional entrance into the Beating the Blues after the first eight weeks
89448962|NCT01927068|Experimental|Global Cohort 1|All subjects to be treated with the Stellarex 035 Drug Coated Balloon (DCB) for Percutaneous Transluminal Angioplasty (PTA).The drug coating is paclitaxel (PTX).
89448963|NCT01927068|Experimental|ISR Cohort 2|All subjects to be treated with the Stellarex 035 Drug Coated Balloon (DCB) for Percutaneous Transluminal Angioplasty (PTA).The drug coating is paclitaxel (PTX).
89014655|NCT04537897|Experimental|BI 474121 5mg (Part A)|Young participants administered 2 tablets of 2.5 mg BI 474121 orally once daily (daily dose: 5 mg) with 240 milliliter (mL) of water after an overnight fast of at least 10 hours (h) over a treatment period of 14 days.
89206117|NCT03999112|Experimental|Metacognitive Reflection and Insight Therapy (MERIT) 8 week|Standard MERIT + 8 week baseline period
89448964|NCT01898104|Active Comparator|SCRT|short course radiotherapy (SCRT) alone 25 Gy in 5 fractions over one week.
89448965|NCT01898104|Active Comparator|V-SCRT|Valproic acid (V) + short course radiotherapy
89448966|NCT01898104|Active Comparator|C-SCRT|capecitabine (C) + short course radiotherapy
89448967|NCT01898104|Active Comparator|VC-SCRT|valproic acid + capecitabine + short course radiotherapy
89448968|NCT01817452|Experimental|Arm A|Trastuzumab + Pertuzumab
89448969|NCT01817452|Active Comparator|Arm B|Trastuzumab + Pertuzumab + Paclitaxel
89448970|NCT01815242|Experimental|Arm A|nab-Paclitaxel + gemcitabine
89448971|NCT01815242|Experimental|Arm B|nab-Paclitaxel + carboplatin
89448972|NCT01802749|Active Comparator|chemotherapy|"Combination chemotherapy with ONE of the following regimens:~PLD-C: Pegylated liposomal doxorubicin 30 mg/m2 + Carboplatin AUC (area under curve) 5 on day 1 every 4 weeks;~GEM-C: Gemcitabine 1000 mg/m2 on day 1, 8 every 21 + Carboplatin AUC of 4 on day 1 every 21 days;~PAC-C: Paclitaxel 175 mg/m2 on day 1, every 21 + Carboplatin AUC of 5 on day 1 every 21 days."
89448973|NCT01802749|Experimental|Chemotherapy and bevacizumab|"Combination chemotherapy AND bevacizumab with ONE of the following regimens:~PLD-C: Pegylated liposomal doxorubicin 30 mg/m2 + Carboplatin AUC 5 on day 1 every 4 weeks and Bevacizumab 10 mg/kg i.v. on Day 1 every 2 weeks;~GEM-C: Gemcitabine 1000 mg/m2 on day 1, 8 every 21 + Carboplatin AUC of 4 on day 1 every 21 days AND Bevacizumab 15 mg/kg i.v. on Day 1 every 3 weeks;L~PAC-C: Paclitaxel 175 mg/m2 on day 1, every 21 + Carboplatin AUC of 5 on day 1 every 21 days AND Bevacizumab 15 mg/kg i.v. on Day 1 every 3 weeks.~Patients whose disease has not progressed after the initial six cycles of combination treatment will continue bevacizumab, at 15 mg/kg every 3 weeks until disease progression,unacceptable toxicity or patient withdrawn."
89448974|NCT01801904|Experimental|Panitumumab|
89448975|NCT01781338|Experimental|Induction Therapy|The kind of induction therapy is dependent on the respective sub-protocol.
89448976|NCT01779206|Active Comparator|Anthracycline - Taxane|Study sites can choose between either Epirubicin (90mg/m²) Cyclophosphamide (600mg/m²) q3w OR Epirubicin (90mg/m²) Cyclophosphamide (600mg/m²) q2w for anthracycline treatment and between either 4 x Docetaxel (100mg/m²) q3w OR 12 x Paclitaxel (80mg/m²) q1w for taxane treatment.
89448977|NCT01779206|Experimental|Taxane - Anthracycline|Study sites can choose between either Epirubicin (90mg/m²) Cyclophosphamide (600mg/m²) q3w OR Epirubicin (90mg/m²) Cyclophosphamide (600mg/m²) q2w for anthracycline treatment and between either 4 x Docetaxel (100mg/m²) q3w OR 12 x Paclitaxel (80mg/m²) q1w for taxane treatment.
89448978|NCT01745965|Experimental|T-DM1|single agent T-DM1 for 12 weeks (3,6 mg/kg q3w)
89448979|NCT01745965|Experimental|T-DM1 + endocrine therapy|Single agent T-DM1 for 12 weeks (3,6 mg/kg q3w) with standard endocrine therapy (tamoxifen in premenopausal women and an aromatase inhibitor in postmenopausal women, if no contraindications are present, in a standard daily dosage).
89448980|NCT01745965|Active Comparator|Trastuzumab + endocrine therapy|The control group will receive trastuzumab in 3-weekly schedule (8 mg/kg as loading dose and then 6 mg/kg q3w)with endocrine therapy tamoxifen in premenopausal women and an aromatase inhibitor in postmenopausal women, if not contraindications are present, in a standard daily dosage).
89448981|NCT01706120|Other|First-line chemotherapy with bevacizumab|"Bevacizumab 15 mg/kg i.v. on Day 1 every 3 weeks for up to 22 cycles~Paclitaxel 175 mg/m2 on Day 1 every 3 weeks for up to 6 cycles~Carboplatin (AUC 5) on Day 1 every 3 weeks for up to 6 cycles"
89448982|NCT01656551|Active Comparator|A: Gemcitabine|Single agent gemcitabine dose 1200 mg/m2 days 1 and 8, every 3 weeks
89448983|NCT01656551|Experimental|B: Gemcitabine + Cisplatin|Gemcitabine dose 1000 mg/m2 days 1 and 8, every 3 weeks
89448984|NCT01656551|Active Comparator|C: Pemetrexed|
89448985|NCT01656551|Experimental|D: Pemetrexed + Cisplatin|
89448986|NCT01651026||rectal cancer|
89448987|NCT01651013||metastatic colorectal cancer|
89448988|NCT01649674|Active Comparator|PEG|polyethylene glycol solution 2 liters
89448989|NCT01649674|Active Comparator|NapP|Sodium picosulphate and magnesium citrate solution 300 ml
89448990|NCT01628211|Experimental|Second look laparoscopy|Second look laparoscopy to evaluate for and treat peritoneal carcinosis
89448991|NCT01628211|No Intervention|standard follow up|
89448992|NCT01593488|Experimental|Intrathecal liposomal cytarabine|
89448993|NCT01406691|Experimental|Light|one hour of a sequence of light flashes (4000 lux, 3 msec, every 30 seconds); occurs during hour immediately prior to desired waketime
89448994|NCT01406691|Placebo Comparator|Fake light|during hour immediately prior to desired waketime, subjects will receive one light flash (insufficient to cause phase shift)
89448995|NCT01405586|Active Comparator|gemcitabine|
89448996|NCT01405586|Experimental|gemcitabine + cisplatin|
89448997|NCT01309230|Experimental|Group A (Vigil™)|Vigil immunotherapy was administered at a concentration of at 1 x 10e7 cells/injection via intradermal injection for a minimum of 4 doses and a maximum of 12 doses starting ≥3 weeks following completion of chemotherapy (no longer than 2.5 months post chemotherapy). Participants were treated monthly for up to 12 months as long as sufficient Vigil was available and the participant was clinically stable.
89448998|NCT01309230|No Intervention|Group B (Observational - Standard of Care)|Participants received standard of care without maintenance therapy.
89448999|NCT01238692|Experimental|LBH589|
89449000|NCT01238692|Experimental|LBH589 plus Rituximab|
89449001|NCT01173341||Subgroup 2|Subgroup2 represents will undergo trastuzumab therapy only
89449002|NCT01173341||Subgroup 1|Subgroup 1 are anthracycline only treated patients.
89449003|NCT01173341||Subgroup 3|Subgroup 3 are patients that will undergo trastuzumab therapy with anthracyclines.
89449004|NCT01127854||Cases|
89449005|NCT01127854||Controls|
89449006|NCT01035112|Experimental|Magnetic Resonance Imaging (MRI) of Breast Cancer|Contrast-enhanced magnetic resonance imaging (MRI) using the standard department of Radiology MRI screening procedures. The duration of scanning may be variable, but will not exceed 90 minutes.
89449007|NCT00996983|Experimental|A|
89449008|NCT00819832|Experimental|Phase 1 Group 1 Vertebroplasty|Vertebroplasty
89449009|NCT00819832|Experimental|Phase 1 Group 2 Kyphoplasty|Kyphoplasty
89449010|NCT00819832|Active Comparator|Phase 2 Group 1 Vertebroplasty|Vertebroplasty
89449011|NCT00819832|Active Comparator|Phase 2 Group 2 Vertebroplasty + Cavity SpineWand|Vertebroplasty with Cavity SpineWand
89449012|NCT00819832|Active Comparator|Phase 2 Group 3 Kyphoplasty|Kyphoplasty
89449013|NCT00819832|Active Comparator|Phase 2 Group 4 Kyphoplasty + Cavity SpineWand|Kyphoplasty with Cavity SpineWand
89449014|NCT00660842|Experimental|A|weekly chemotherapy
89449015|NCT00660842|Active Comparator|B|every 3 weeks chemotherapy
89449016|NCT00526396|Active Comparator|A|standard fixed doses
89449017|NCT00526396|Experimental|B|toxicity adjusted dosing
89449018|NCT00499421||CT Scan|CT Scan with Fiducial markers + external beam radiation therapy
89449019|NCT00431704|Experimental|vinorelbine, carboplatin, trastuzumab|
89449020|NCT00412022|Active Comparator|A|Triptorelin 3.75 mg IM every 4 weeks and Tamoxifen 20 mg daily, for 5 years
89449021|NCT00412022|Active Comparator|B|Triptorelin 3.75 mg IM every 4 weeks and Letrozole 2.5 mg daily, for 5 years
88934207|NCT01766908|Active Comparator|Cord Clamp 20 Seconds After Delivery|Intervention is cord clamp at 20 seconds following vaginal or cesarean delivery
88934208|NCT01766908|Active Comparator|Cord Clamp 40 seconds After Delivery|Timing of cord clamp at 40 seconds following vaginal or cesarean delivery.
88934209|NCT01766908|Active Comparator|Cord Clamp 60 seconds After Delivery|Intervention is timing of cord clamp at 60 seconds following vaginal or cesarean delivery
88934210|NCT01766947|Experimental|Triggerfish|Device : Sensimed Triggerfish
88934211|NCT01766960|Experimental|Healthy volunteers|Subjects will be asked to fast overnight. Upon presentation, FibroScan procedure with CAP will be conducted and baseline and postprandial bile acid profile will be assessed. Then, intravenous morphine will be administered and the pharmacokinetic profile will be assessed over 8 hours.
88934212|NCT01766960|Experimental|Advanced nonalcoholic fatty liver disease patients|Subjects will be asked to fast overnight. Upon presentation, FibroScan procedure with CAP will be conducted and baseline and postprandial bile acid profile will be assessed. Then, intravenous morphine will be administered and the pharmacokinetic profile will be assessed over 8 hours.
88934213|NCT01766973||Chronic back pain|Adults, >6months duration
88934214|NCT01766973||Control|Age and sex matched controls
88934215|NCT01766999||SpMetHb > 8%|hemoximetric MetHb measurements triggered
89449022|NCT00412022|Experimental|C|Triptorelin 3.75 mg IM every 4 weeks and Letrozole 2.5 mg daily for 5 years + zoledronic acid 4 mg every 6 months.
89449023|NCT03474510|Experimental|EXPAREL|Those patients randomized to receive LIA of EXPAREL will have 266mg EXPAREL diluted to 100mL, and drawn into (5) 20mL syringes affixed with (5) 22-gauge needles. Investigators will administer the syringes to the tissue in small increments with the plunger held steady while withdrawn from the tissue to avoid saturating the area around the needle sticks since EXPAREL doesn't readily travel through the tissue.
89449024|NCT03474510|Active Comparator|interscalene nerve block|Patients will then receive 0.2% preservative-free ropivacaine at 8mL/hr beginning at the conclusion of surgery and delivered for approximately 50 hours (or finish of 400mL) via elastomeric infusion system (OnQ Pain Relief System: Select A Flow, Kimberly-Clark Corporation, Roswell, Georgia). Patients are instructed prior to discharge how to pull the catheters at home. Patients may also return to surgeon's office for catheter removal once the pain ball is empty if they prefer.
89449025|NCT02227953|Experimental|YBand (YDT-201N)|transcranial Direct Current Stimulation (tDCS) application 7 days a week for 12 weeks (total of 84 applications)
89449026|NCT02227953|Sham Comparator|sham-Yband (YDT-201N)|sham-tDCS application 7 days a week for 12 weeks (total of 84 applications)
89449027|NCT02470832|Experimental|Combination therapy RG1662 + itraconazole|Days 20-29: Oral administration RG1662 twice daily within 30 minutes of a meal + 2 x 100 mg itraconazole once daily with food
89449028|NCT02470832|Experimental|RG1662 Monotherapy|Days 1-10: RG1662 120 mg twice daily (b.i.d.) within 30 minutes of a meal for 10 days (Days 1 to 9, Day 10 only a.m. dose). (Cohort A subjects will receive 1 x 120 mg RG1662 tablets twice daily. In Cohorts B and C the dose of RG1662 will be decided upon following review of the interim safety and pharmacokinetic data of the 4 subjects in Cohort A.)
88934216|NCT01767012|Active Comparator|Polylens EC-Y10-PAL (uncoated)|hydrophobic acrylic IOL (no coating) implantation during cataract surgery
88934217|NCT01767012|Active Comparator|Polylens EC-Y10H-PAL (coated)|hydrophobic acrylic heparin-coated IOL implantation during cataract surgery
88934218|NCT01767025|Experimental|Oxytocin|Oxytocin 24 IU (3 puffs) per nostril
88934219|NCT01767025|Placebo Comparator|Sea water|Sea water 3 puffs per nostril
88934220|NCT01767051||Children born from mothers who are diagnosed with PCOS|Children at the age of 2.5-4 years or at the age of 6-8 years born from mothers who are diagnosed with PCOS at the University Medical Centre in Utrecht (UMCU) in the period 2004-2012 (n=891) will be asked to participate. Children who were born before the diagnosed PCOS of their mothers at the UMCU will be asked to participate too. All mothers have been diagnosed with PCOS according to standardised extensive diagnostic work-up and have given informed consent to be approached for future research purposes.
88934221|NCT01767051||Children who participated in the WHISTLER study|Children who participated in the WHISTLER 3 (11-163) and WHISTLER/Cardio study (10-194) in 2002-2012. The children were born from mothers with a regular cycle prior to conception who conceived naturally. The children were examined at the age of 2.5-4 years or at the age of 7-8 years. The data of the WHISTLER 3 and WHISTLER/Cardio study have already been collected.
88934222|NCT01767077|Placebo Comparator|Butter oil|Daily intake of 40 g butter oil
88934223|NCT01767077|Active Comparator|Cream|Daily intake of 100 g cream (40%)
88934224|NCT01767090|Placebo Comparator|Placebo|Applicable to first 12 week period (Part One); subjects in this arm will be randomized to one of the ASP1707 dose levels for the second 12 week period (Part Two)
89206118|NCT00821028|Experimental|Paclitaxel|Participants will receive Paclitaxel.
89449029|NCT02470832|Experimental|itraconazole Monotherapy|Days 15-19: 200 mg of itraconazole twice daily for 5 days (Days 15 to 18, Day 19 only a.m. dose)
89449030|NCT05258682|Experimental|BromAc|BromAc (Bromelain and Acetylcysteine combination) will be administered three times (3x) per day for five (5) days in a dose escalation format via inhalation using an approved vibrating mesh nebuliser (Aerogen Pro). Dose escalation concentration levels are BromAc 125ug/20mg/ml, 250ug/20mg/ml, 375ug/20mg/ml. All levels will receive 5ml of BromAc.
89449031|NCT03310112|Experimental|4-week MBAT|Participants will engage in Mindfulness-Based Attention Training (MBAT) in 4, 2-hour training classes over 4 weeks.
89449032|NCT03310112|Active Comparator|2-week MBAT|Participants will engage in Mindfulness-Based Attention Training (MBAT) in 4, 2-hour training classes over 2 weeks.
89449033|NCT03310112|No Intervention|No training control (NTC)|Participants will receive no intervention but will be tested before and after a no-training interval.
89200635|NCT00545272|Experimental|indacaterol 250 μg|Indacaterol 250 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.
89200636|NCT00545272|Experimental|indacaterol 500 μg|Indacaterol 500 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.
89449034|NCT02258841|Experimental|Personalized online Safety Decision Aid|Setting priorities for safety; Danger Assessment; Personalized Action Plan
89449035|NCT02258841|Active Comparator|General Online Risk/Safety Information|General Risk and Safety Information; Basic Emergency Safety Plan
89449036|NCT05258604|Experimental|argon plasma coagulation (APC).|APC Standard APC equipment will be used, consisting of a high-frequency electrosurgical generator (ICC 350; ERBE, Tübingen, Germany), an argon source which is regulated automatically (APC 300) and APC probe.
89449037|NCT05258604|Experimental|endoscopic band ligation.|endoscopic band ligation will be carried out using a Saeed Multi-Band Ligator (Cook Medical, WinstonSalem, NC), and ligation bands were placed on the GAVE.
89449038|NCT03310034|Active Comparator|Intervention|
89449039|NCT03310034|Placebo Comparator|Control|
89449040|NCT02228031|Experimental|Oxytocin|The experimental oxytocin group will receive 24 international units (IU) of oxytocin using an intranasal administration (self-administered nasal spray) one time before the experimental session.
89449041|NCT02228031|Placebo Comparator|Placebo|The placebo comparator group will receive sterile saline through intranasal administration, consisting of the same salt solution in which the hormone will be dissolved , but lacking the hormone itself.
88934225|NCT01767090|Experimental|ASP1707 lowest dose|Subjects in this arm will be dosed with ASP1707 once daily for a total of 12 weeks (Part One) and continue taking the assigned dose for a further 12 weeks during the extension phase of the study (Part Two) for a total of 24 weeks
88934226|NCT01767090|Experimental|ASP1707 low dose|Subjects in this arm will be dosed with ASP1707 once daily for a total of 12 weeks (Part One) and continue taking the assigned dose for a further 12 weeks during the extension phase of the study (Part Two) for a total of 24 weeks
88934227|NCT01767090|Experimental|ASP1707 medium dose|Subjects in this arm will be dosed with ASP1707 once daily for a total of 12 weeks (Part One) and continue taking the assigned dose for a further 12 weeks during the extension phase of the study (Part Two) for a total of 24 weeks
88934228|NCT01767090|Experimental|ASP1707 high dose|Subjects in this arm will be dosed with ASP1707 once daily for a total of 12 weeks (Part One) and continue taking the assigned dose for a further 12 weeks during the extension phase of the study (Part Two) for a total of 24 weeks
88934229|NCT01767090|Active Comparator|Leuprorelin acetate|Subjects in this arm will be treated with leuprorelin acetate for a total of 24 weeks
88934230|NCT01767181|No Intervention|A|Control group without intervention
88934231|NCT01767181|Experimental|B|Intensive light therapy during the first half of the night shift
88934232|NCT01767181|Experimental|C|Exercise before the beginning of the night shift
88934233|NCT01767181|Experimental|D|Exercise after the end of the night shift
88934234|NCT01767207||screening for mental disorders|screening for mental disorders
88934235|NCT01767220|Active Comparator|Strategy 1- endocardial ablation|VT substrate mapping and VT ablation are done only from endocardial.
88934236|NCT01767220|Active Comparator|Strategy 2 - endocardial and epicardial ablation|VT substrate mapping and ablation are done from endocardial and epicardial.
89449042|NCT01799265|Active Comparator|Transcend followed by REMstar|The patient will receive treatment with Transcend during the first night sleep study, followed by treatment with the REMstar on the second night.
89449043|NCT01799265|Active Comparator|REMstar followed by Transcend|The patient will receive treatment with REMstar during the first night sleep study followed by treatment with Transcend on the second night.
89449044|NCT02232321|Other|PsA MDA|
89449045|NCT03478410|Other|Atrial fibrillation|An epicardial fat biopsy will be taken from patients with chronic atrial fibrillation or paroxysmal atrial fibrillation who undergo any cardiac surgery
89449046|NCT03478410|Other|Control|An epicardial fat biopsy will be taken from patients without any history of atrial fibrillation who undergo any cardiac surgery
88934237|NCT01767233|Experimental|Pancreatic stenting|Pancreatic stenting versus observation
89014656|NCT04537897|Experimental|BI 474121 10mg (Part A)|"Young participants administered 1 tablet of 10 milligrams (mg) BI 474121 orally once daily with 240 milliliter (mL) of water after an overnight fast of at least 10 hours (h) over a treatment period of 14 days.~On Day -1, 1, and 14, 75 micrograms (μg) of midazolam for injection used as oral solution were administered orally once daily with 240 milliliter (mL) of water after an overnight fast of at least 10 hours (h)."
89449047|NCT00704522||Patients with hepatitis C|Patients receiving a patient assistance program during therapy for hepatitis C at sites in Austria.
89449048|NCT03474432|Other|Optical Coherence Tomography|Patients who have undergone clinically-indicated PCI of LM where OCT was performed as part of the routine index procedure will be approached for the study and enrolled if eligible.
89449049|NCT02228109|Experimental|Acuvue Oasys for Presbyopia|Acuvue Oasys for Presbyopia contact lenses worn
88934238|NCT01767246|Experimental|PFS algorithm treatment|The Patellofemoral Syndrome algorithm is designed to determine what deficits a patient may have and addressing these sequentially. This subgrouping first assesses a patient fear avoidance beliefs, flexibility, body mechanics, and then strength and functional ability. The reason for sequential treatment is that there is evidence that without adequate flexibility a patient will be unable to perform exercises with proper body mechanics, and without proper mechanics strengthening and functional activity can cause increased stress on the patellofemoral joint. Progression through each specific subgroup is based on objective goals. Once the patient has met these goals they are progressed to the next treatment subgroup until discharge.
88934239|NCT01767246|Active Comparator|Multimodal Treatment|Patients randomized to the this treatment group will be treated in a manner consistent with a Multimodal treatment approach previously described in literature that has been found effective in treating Patellofemoral Syndrome (Lowry, 2008). Treatment consists of strengthening, flexibility and manual treatments aim to improve patients knee pain.
88934240|NCT01767259|Other|Valsartan 160 mg alone|Valsartan alone
88934241|NCT01767259|Other|Hydrochlorothiazide 12.5 mg alone|Hydrochlorothiazide alone
88934242|NCT01767259|Other|Valsartan160 mg + Hydrochlorothiazide12.5 mg|Concomitant administration of valsartan 160 mg + Hydrochlorothiazide 12.5 mg
88934243|NCT01767259|Other|Valsartan / Hydrochlorothiazide 160 mg/12.5mg|Fixed dose combination of valsartan 160 mg + Hydrochlorothiazide 12.5 mg
88934244|NCT01767272|Other|fexofenadine 60 mg|First dose strength
88934245|NCT01767272|Other|fexofenadine 120 mg|Second dose strength
88934246|NCT01767272|Other|fexofenadine 180 mg|Third dose strength
88934247|NCT01767272|Other|fexofenadine 240 mg|Fourth dose strength
88934248|NCT01767272|Other|fexofenadine 360 mg|Fifth dose strength
88934249|NCT01767298|Other|Valsartan 320 mg alone|Valsartan alone
88934250|NCT01767298|Other|Hydrochlorothiazide 25 mg alone|Hydrochlorothiazide alone
88934251|NCT01767298|Other|Valsartan 320 mg + Hydrochlorothiazide 25 mg|Concomitant administration of valsartan 320 mg + Hydrochlorothiazide 25 mg
88934252|NCT01767298|Other|Valsartan / Hydrochlorothiazide 320 mg/25mg|Fixed dose combination of valsartan 320 mg + Hydrochlorothiazide 25 mg
89200637|NCT00545272|Active Comparator|formoterol|Formoterol 12 μg delivered by the AEROLIZER® device twice a day and placebo to indacaterol (placebo TWISTHALER® device) once a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.
89200638|NCT00545272|Placebo Comparator|placebo|Placebo to indacaterol (placebo TWISTHALER® device) once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.
89449050|NCT02228109|Experimental|PureVision2 for Presbyopia|PureVision2 for Presbyopia contact lenses worn
89449051|NCT02228109|Experimental|Biofinity Multifocal|Biofinity Multifocal contact lenses worn
88934253|NCT01767324|Experimental|Injection to deltoid|Deliver saline from FLUGEN 101.2 microneedle-based delivery device.
88934254|NCT01767324|Experimental|Injection to forearm|Deliver saline from FLUGEN 101.2 microneedle-based delivery device.
88934255|NCT01767324|Experimental|Injection to thigh|Deliver saline from FLUGEN 101.2 microneedle-based delivery device.
88934256|NCT01767337|Experimental|injection of 0.1 mL saline|deliver from FluGen 101.2 device
88934257|NCT01767337|Experimental|injection of 0.25 mL saline|deliver from FluGen 101.2 device
88934258|NCT01767337|Experimental|Injection of 0.5 mL saline|deliver from FluGen 101.2 device
88934259|NCT01767350||children with organ transplant|Subjects who received an solid organ transplant at our institution at the age of 0-19 yrs and who were subject to pharmacokinetic evaluation during their follow up. Additional blood withdrawal for DNA will be performed
88934260|NCT01767363||5-alpha reductase inhibitors with or without alpha-blockers|Men using 5-alpha reductase inhibitors with or without alpha-blockers over the course of the study period.
88934261|NCT01767363||Alpha-blockers|Men using alpha-blockers over the course of the study period.
89200639|NCT00377455|Experimental|Bosentan|
89200640|NCT00377455|Placebo Comparator|Placebo|
89449052|NCT03309956|Other|Holter Monitor and Zio Patch|All subjects will wear the Holter monitor and Zio patch for a total of 48 hours.
89449053|NCT04458558|Experimental|Medical abortion patients|Oral mifepristone 200 mg followed by misoprostol 800 mcg administered buccally (at 24-48 hours following mifepristone).
89449054|NCT04872777|No Intervention|Standard of care|"Standard of care (SOC) control condition: Following study group assignment, the following procedures will be completed for SOC control:~Digital scale provision (subjects may keep the scale)~Reinforcement of need to comply with SOC treatment as directed by their NASH clinician~Capture of available clinical information over preceding 28-days."
89449055|NCT04872777|Experimental|Noom Healthy Weight|"Following study group assignment, the following procedures will be completed for the Noom HW mHealth lifestyle intervention:~Noom application set-up and troubleshooting on smartphone (license provided)~Digital scale provision (subjects may keep the scale)~Capture of available clinical information over preceding 28-days."
89449056|NCT02228187|Active Comparator|BCI Intervention|Subjects will undergo the Brain-Computer Interface Intervention for 24 sessions over the span of 8 weeks. Each session will take 30-minute to complete. The intervention group will undergo the intervention in the first 8 weeks of the trial.
88934262|NCT01767389||Type 2 diabetes patients taking antidiabetic agents|Subjects should also have at least 1 claim of T2D diagnosis identified using ICD-9 codes 250.x0 or 250.x2 (excluding 250.x1 and/or 250.x3 - Type 1 diabetes and 648.0x - gestational diabetes).
89449057|NCT02228187|No Intervention|Waitlist Control Group|The waitlist control will start their 8 week treatment after the completion of the intervention group from week 9 onwards. They will undergo the BCI intervention for 24 sessions over the span of 8 weeks.
89449058|NCT03309800|Experimental|Experimental|HL301: 2Tab/day: 1 Tablet at once, 2 times a day, 7 days of treatment
89449059|NCT03309800|Placebo Comparator|Placebo comparator|HL301(Placebo): 2Tab/day: 1 Tablet at once, 2 times a day, 7 days of treatment
89449060|NCT04035174|Experimental|LTS-2 DEC patch|This is a transdermal device with diethylcarbamazine (DEC) applied directly on the skin. The reading will be done 24 hours after.
89449061|NCT04035174|Active Comparator|Skin snip|A skin snip will be performed using a 2 mm Holth corneoscleral's punch. Once done, the microfilariae of Onchocerca volvulus will be counted with a microscope.
89449062|NCT02232477|Experimental|Open-label treatment|laronidase 1.74 mg IT q 3 months for five years
89449063|NCT03478332|Active Comparator|Treatment group|The aim of the arm is to test if the addition of Yangxinshi pills to the conventional coronary heart disease medicine will improve the exercise tolerance of the coronary heart disease
89449064|NCT03478332|Placebo Comparator|Control group|The patients of the control group are treated with conventional coronary heart disease medicine plus the placebos-Yangxinshi simulant
89449065|NCT04105062|Experimental|Phase I: LS301 Dose Level 1 (0.05 mg/kg)|"The patient will undergo intravenous injection of LS301 4-24 hours prior to surgery.~The operating surgeon will conduct surgery as usual without using a device to visualize LS301 fluorescence. To prevent bias in data acquisition, a second surgeon will wear the CVG at the completion of the surgery to examine the excised tissue at the surgical margins and the surgical resection bed.~The operating surgeon will remain blinded to the fluorescence images throughout the operation. The examining surgeon will wear the CVG and image all six anatomical aspects (superior, inferior, anterior, posterior, medial and lateral) of the surgical specimen as well as the surgical cavity for LS301 fluorescence."
89449066|NCT04105062|Experimental|Phase I: LS301 Dose Level 2 (0.075 mg/kg)|"The patient will undergo intravenous injection of LS301 4-24 hours prior to surgery.~The operating surgeon will conduct surgery as usual without using a device to visualize LS301 fluorescence. To prevent bias in data acquisition, a second surgeon will wear the CVG at the completion of the surgery to examine the excised tissue at the surgical margins and the surgical resection bed.~The operating surgeon will remain blinded to the fluorescence images throughout the operation. The examining surgeon will wear the CVG and image all six anatomical aspects (superior, inferior, anterior, posterior, medial and lateral) of the surgical specimen as well as the surgical cavity for LS301 fluorescence."
89449067|NCT04105062|Experimental|Phase I: LS301 Dose Level 3 (0.1 mg/kg)|"The patient will undergo intravenous injection of LS301 4-24 hours prior to surgery.~The operating surgeon will conduct surgery as usual without using a device to visualize LS301 fluorescence. To prevent bias in data acquisition, a second surgeon will wear the CVG at the completion of the surgery to examine the excised tissue at the surgical margins and the surgical resection bed.~The operating surgeon will remain blinded to the fluorescence images throughout the operation. The examining surgeon will wear the CVG and image all six anatomical aspects (superior, inferior, anterior, posterior, medial and lateral) of the surgical specimen as well as the surgical cavity for LS301 fluorescence."
89449068|NCT04105062|Experimental|Phase II: LS301 Dose determined in Phase I|"The patient will undergo intravenous injection of LS301 4-24 hours prior to surgery.~The operating surgeon will conduct surgery as usual without using a device to visualize LS301 fluorescence. To prevent bias in data acquisition, a second surgeon will wear the CVG at the completion of the surgery to examine the excised tissue at the surgical margins and the surgical resection bed.~The operating surgeon will remain blinded to the fluorescence images throughout the operation. The examining surgeon will wear the CVG and image all six anatomical aspects (superior, inferior, anterior, posterior, medial and lateral) of the surgical specimen as well as the surgical cavity for LS301 fluorescence."
88934263|NCT01767402|Experimental|PhtD Group 1|Subjects will receive PhtD vaccine formulation 1 without any adjuvant.
88934264|NCT01767402|Experimental|PhtD Group 2|Subjects will receive adjuvanted PhtD vaccine formulation 2.
88934265|NCT01767402|Experimental|PhtD Group 3|Subjects will receive adjuvanted PhtD vaccine formulation 3.
88934266|NCT01767402|Experimental|PhtD Group 4|Subjects will receive adjuvanted PhtD vaccine formulation 4.
88934267|NCT01767402|Experimental|PhtD Group 5|Subjects will receive adjuvanted PhtD vaccine formulation 5.
88934268|NCT01767402|Active Comparator|23 PPV Group|Subjects will receive the Pneumovax 23TM vaccine and NaCl.
88934269|NCT01767428|Experimental|Experimental Paracetamol Tablet|Experimental paracetamol tablet (500 milligrams [mg]) administered with 240 milliliters (mL) of water.
88934270|NCT01767428|Active Comparator|Standard Paracetamol Tablet (500 mg)|Standard paracetamol tablet (500 mg) administered with 240 mL of water.
88934271|NCT01767441||Roux-en-Y-gastric bypass|morbidly obese subjects undergoing gastric bypass surgery
88934272|NCT01767441||gastric banding|morbidly obese subjects undergoing laparoscopic adjustable gastric banding
89200641|NCT00895557|Active Comparator|chantix|
89200642|NCT01051609||Intervention Group|There is only one arm in this trial. Please see interventions for more detailed descriptions.
89200643|NCT00869895|Experimental|1|
89449069|NCT02223741||Korean medicine conjugate rehabilitation|those with more than 30 days of herbal drugs or more than 12 times of acupuncture (Korean medical treatment) within six months in addition to conventional rehabilitation
89449070|NCT02223741||Conventional rehabilitation|those with one of the treatments; physical, occupational, speech-language or cognitive-behavioral therapies
88934273|NCT01767441||sleeve gastrectomy|morbidly obese subjects undergoing laparoscopic sleeve gastrectomy
88934274|NCT01767441||control group|morbidly obese subjects not undergoing bariatric surgery, on diet treatment
88934275|NCT01767454|Experimental|Doublet arm|Subjects will be started with dabrafenib 150 mg twice daily (BID) orally for 2 weeks (run-in). The doublet arm will comprise 2 cohorts. Cohort A1 (Dabrafenib 150 mg BID + ipilimumab). Cohort A-1 (Dabrafenib 100 mg BID +ipilimumab). Ipilimumab will be administered as 3 mg/kg every 3 weeks (Q3W) for a total of 4 infusions over approximately 12-16 weeks. Dabrafenib will be continued through combination with ipilimumab and post-ipilimumab until no longer of clinical benefit, in the opinion of the treating physician, or until unacceptable AE or death
89014657|NCT04537897|Experimental|BI 474121 20mg (Part A)|"Young participants administered 2 tablets of 10 milligrams (mg) BI 474121 orally once daily (daily dose: 20 mg) with 240 milliliter (mL) of water after an overnight fast of at least 10 hours (h) over a treatment period of 14 days.~On Day -1, 1, and 14, 75 micrograms (μg) of midazolam for injection used as oral solution were administered orally once daily with 240 milliliter (mL) of water after an overnight fast of at least 10 hours (h)."
89023553|NCT05162976|Experimental|Treatment (CC-486, nivolumab)|Patients receive azacitidine PO QD on days 1-7 and nivolumab IV over 30 minutes on day 8. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
89200644|NCT00978640|Experimental|fasting and exercise|36 h fast and 1 h ergometer cycling 50% VO2max
89449071|NCT03930498|Experimental|PD-1 antibody plus chemoradiotherapy|
89449072|NCT02228265||Ancillary-Correlative (genetic analysis)|Patients undergo collection of blood and tissue samples at baseline, during administration of enzalutamide and after the time of disease progression for analysis via immunohistochemistry, comparative genome hybridization, and sequencing.
89449073|NCT03130920|No Intervention|Control|
89449074|NCT03130920|Active Comparator|Remote ischemic preconditioning|
89449075|NCT03130920|Active Comparator|Local ischemic preconditioning|
89449076|NCT03817554|Experimental|Treatment group|Peritoneal dialysis patients diagnosed with restless legs syndrome will receive pramipexole.
89449077|NCT03817554|Placebo Comparator|Control group|Peritoneal dialysis patients diagnosed with restless legs syndrome will receive placebo.
89449078|NCT02223897|Experimental|Conventional treatment, huc-MSCs|Received conventional treatment and huc-MSCs once per week for the first month and once per month for 6 months(9 times in total), at a dose of 1×106 huc-MSCs/kg body weight.
89449079|NCT02223897|Placebo Comparator|Conventional plus placebo|Received conventional treatment and 50 ml saline once per week for the first month and once per month for 6 months(9 times in total).
89449080|NCT02723630|Experimental|Sequence A:|Participants will receive one dose of Treatment 1 followed by one dose of Treatment 2, then one dose of Treatment 3
89449081|NCT02723630|Experimental|Sequence B|Participants will receive one dose of Treatment 2, followed by one dose of Treatment 3, then one dose of Treatment 1
89449082|NCT02723630|Experimental|Sequence C|Participants will receive one dose of Treatment 3, followed by one dose of Treatment 1, then one dose of Treatment 2
89449083|NCT02723630|Experimental|Sequence D|Participants will receive one dose of Treatment 3, followed by one dose of Treatment 2, then one dose of Treatment 1
89449084|NCT02723630|Experimental|Sequence E|Participants will receive one dose of Treatment 1, followed by one dose of Treatment 3, then one dose of Treatment 2
89449085|NCT02723630|Experimental|Sequence F|Participants will receive one dose of Treatment 2, followed by one dose of Treatment 1, then one dose of Treatment 3
89449086|NCT02223975||Vulval Disease|Patients who have undergone vulval skin biopsy or surgery for a vulval condition within Gloucestershire Hospitals NHS Foundation Trust.
89449087|NCT04459962|Experimental|Study Arm|Breath Test and Cheek Swab collection
89449088|NCT02228655|Other|FMX-8|FMX-8 for injection, 15mg/kg, twice weekly, 29 days
89449089|NCT03478176||Patients|
89449090|NCT02866227|Experimental|BV and/or VVC infection - Gel Treatment|Randomized 1:1 to gel nightly for 7 days. N = 40
89449091|NCT02866227|Experimental|BV and/or VVC infection - Vaginal Insert Treatment|Randomized 1:1 to insert nightly for 7 days. N = 40
89449092|NCT05258136|Experimental|EBV-DNA positive patients|EBV-DNA positive patients
88934276|NCT01767454|Experimental|Triplet arm|This arm will be initiated using dabrafenib and ipilimumab doses established in the doublet dose-finding. Subjects will be started with dabrafenib and trametinib orally for 2 weeks (run-in), followed by ipilimumab 3 mg/kg Q3W for a total of 4 infusions over approximately 12-16 weeks. The triplet arm will comprise 3 planned cohorts. Cohort B-1: Dabrafenib 100 mg BID + trametinib 1 mg once daily + ipilimumab, Cohort B1: Dabrafenib 150 mg BID + trametinib 1 mg once daily+ ipilimumab, Cohort B2: Dabrafenib 150 mg BID + trametinib 2 mg once daily + ipilimumab. Dabrafenib and trametinib wil be continued through combination with ipilimumab and post-ipilimumab until no longer of clinical benefit, in the opinion of the treating physician, or until unacceptable AE or death
89014658|NCT04537897|Experimental|BI 474121 30mg (Part A)|"Young participants administered 3 tablets of 10 milligrams (mg) BI 474121 orally once daily (daily dose: 30 mg) with 240 milliliter (mL) of water after an overnight fast of at least 10 hours (h) over a treatment period of 14 days.~On Day -1, 1, and 14, 75 micrograms (μg) of midazolam for injection used as oral solution were administered orally once daily with 240 milliliter (mL) of water after an overnight fast of at least 10 hours (h)."
89449093|NCT02228733|Experimental|KBP-5074: Cohort 1|Healthy Volunteers will receive one dose of KBP-5074
89449094|NCT02228733|Experimental|KBP-5074: Cohort 2|Healthy Volunteers will receive one dose of KBP-5074
89449095|NCT02228733|Experimental|KBP-5074: Cohort 3|Healthy Volunteers will receive one dose of KBP-5074
89449096|NCT02228733|Experimental|KBP-5074: Cohort 4|Healthy Volunteers will receive one dose of KBP-5074
89200645|NCT00978640|Experimental|exercise|1 h ergometer cycling 50% VO2max
89449097|NCT02228733|Experimental|KBP-5074: Cohort 5|Healthy Volunteers will receive one dose of KBP-5074
89449098|NCT02228733|Experimental|KBP-5074: Fed Group|Healthy Volunteers will receive one dose of KBP-5074
89449099|NCT02224131|Experimental|Monitoring Arm|dose adjustment of both aspirin and clopidogrel in suboptimal responders identified based on a point of care assay(TEG)
89449100|NCT02224131|Active Comparator|Conventional Arm|fixed dose regiment of both aspirin and clopidogrel in all patients following stent deployment according to international guidelines
89449101|NCT02469584|Experimental|1|symptomatic cystocele described as Points Aa or Ba >= 0 according to the International Continence Society pelvic organ prolapse quantification system (POP-Q). The changes in POPQ score preoperatively and three months after the anterior colporrhaphy with the new small stitch technic will be analyzed.
89449102|NCT03474120||IVF treatment group|Patients treated with IVF. IVF promotion process, ovulation, fertilization, embryo quality, transplantation and final outcome were collected after the treatment cycle was completed.
89449103|NCT03474120||No IVF treatment group|the patients who did not have received IVF treatment .Patients were followed up to collect hormone levels, ultrasound results.
89449104|NCT03474042|Experimental|GLPG2737|GLPG2737 will be provided as capsules for oral use.
89449105|NCT03474042|Placebo Comparator|Placebo|Placebo will be provided as capsules for oral use.
89449106|NCT03309722||early stage|
89449107|NCT03309722||advanced|
89449108|NCT02810184||CBCT arm|all participating patients receive an additional CBCT scan at 24 and 36 months, for analysis of evolution of bone volume
89449109|NCT03473964||Treatment|The study intervention is the observation of study subjects who have received H.P. Acthar® Gel (adrenocorticotrophic hormone), 40 units twice weekly injections in patients who have sarcoid uveitis and to assess it's effectiveness by measuring changes the degree of aqueous and vitreous inflammatory cells present, the degree of aqueous flare, and changes in visual acuity, macular thickness, intraocular pressure and quality of life measures assessed by using the National Eye Institute Visual Function Questionnaires (VFQ-25)
89449110|NCT03309644||Peripheral nerve block|Peripheral nerve block
89449111|NCT03309644||No peripheral nerve block|No peripheral nerve block
89449112|NCT04319445|Experimental|Migraine Patients/Providers/Faculty/Staff/Other|
89449113|NCT04459572|Other|Sepsis and sepstic shock|The study consists patients and healty-control group. Patients divided into 3 groups based on severity: sepsis, severe sepsis and septic shock
89449114|NCT03478020|Experimental|Pre-Treatment, Treatment Cycles A & B|"Pre-Treatment: Two cycles of a combined oral contraceptive (COC) taken orally once daily for 21 days followed by 7 COC-free days.~Treatment Period A: COC containing taken orally once daily for 21 days followed by 7 COC-free days.~Treatment Period B: COC taken orally once daily for 21 days, with once daily oral 200 mg AQX-1125 (2 x 100 mg tablets) co-administered from Day 13 to 21, followed by 7 COC-free days"
88934277|NCT01767480|Experimental|Higher-intensity RT group|All participants received a duration-matched intervention for 90-120 minutes/day, 5 days/week for 4 consecutive weeks. For the RT groups, they will receive RT training together with functional rehabilitation trainings. Within 1 training session, each patient in the higher-intensity RT group will use Bi-Manual-Tract to practice 400-600 repetitions of the mode 1 and 800-1000 repetitions of mode 2, totaling 1200-1600 repetitions, respectively for the forearm and the wrist movements. In addition, the patients will practice 100-200 repetitions in mode 3, if application.
88934278|NCT01767480|Experimental|Lower-intensity RT group|Patients in the lower-intensity RT received half the number of the repetitions per unit of time than patients in the higher-intensity RT group. Within 1 training session, patients in the lower-intensity RT group will practice 200-300 repetitions of the mode 1 and 400-500 repetitions of mode 2, totaling 600-800 repetitions, respectively for the forearm and the wrist movements. In addition, the patients will practice 50-100 repetitions in mode 3, if application.
89449115|NCT02224209|Experimental|Staged angioplasty|"Using Abbott EPD systems (Accunet/Emboshield), a balloon, stent~Method of stage-1 angioplasty~The stent can be placed into the distal stenosis under Abbott EPD systems (Accunet/Emboshield) if distal filter cannot be used, balloon angioplasty can be performed under proximal protection device; Use a balloon with diameter of 2mm × 2cm for stage-1 dilation until angiography shows residual stenosis <70%.~Method of stage-2:~The stent systems (Acculink/Xact) can be placed into the distal stenosis under Abbott EPD systems (Accunet/Emboshield); Use an Abbott balloon (diameter of 4 ~ 6mm) for pre-dilation or post-dilation; After the placement of stent, the angioplasty is a success when residual stenosis is <30%."
89449116|NCT02224209|Active Comparator|Routine single-stage CAS|"Using a balloon, stent~Routine stenting procedure:~The stent systems (Acculink/Xact) can be placed into the distal stenosis under Abbott EPD systems (Accunet/Emboshield); Use an Abbott balloon (diameter of 4 ~ 6mm) for pre-dilation or post-dilation; After the placement of stent, the angioplasty is a success when residual stenosis is <30%."
89449117|NCT03481764||FS: Febrile Seizures|Involved patient with diagnosed Febrile Seizures which were hospitalized or recieved ambulatory treatment in University Children´s Hospital in Belgrade. Ages 5-14 years
89449118|NCT03481764||CN: Control group|The control group was made of healthy children older than 5 years of age, which have never had any neurological disorders in their anamnesis and who were patients in preschool or school dispensaries in the city of Belgrade
89449119|NCT03481764||SFS : group of individuals with simple FS|Simplex febrile seizures (SFS) last shorter than 15 minutes and their type is tonic-clonic. Also, they did not show signs of recidivism during the first 24 hours and were diagnosed at the patients aged from 6th months to 5th year
89449120|NCT03481764||CFS : group of individuals with complex FS|Complex febrile seizures (CFS) were diagnosed at those patients that had focal seizure or epileptic status or seizure having the body temperature lower than 38 degree, which occurred outside of the typical age group and finally which repeated in the first 24 hours again
89449121|NCT03481764||WFS: group of individuals with FS and without epilepsia|group of children with Febrile Seizure and not developed epilepsia
89449122|NCT03481764||EFS: group of individuals with epilepsia and Febrile Seizures|Group of children with Febrile Seizures, who have developed Epilepsy
89449123|NCT05235360|Experimental|Condition 1|1) Episodic future thinking; 2) Positive affect imagery; 3) Action planning; 4) High intervention dose
89449124|NCT05235360|Experimental|Condition 2|1) Episodic future thinking; 2) Positive affect imagery; 3) Action planning; 4) Low intervention dose
89449125|NCT05235360|Experimental|Condition 3|1) Episodic future thinking; 2) Positive affect imagery; 3) High intervention dose
89449126|NCT05235360|Experimental|Condition 4|1) Episodic future thinking; 2) Positive affect imagery; 3) Low intervention dose
89449127|NCT05235360|Experimental|Condition 5|1) Recent thinking; 2) Positive affect imagery; 3) Action planning; 4) High intervention dose
88934279|NCT01767480|Active Comparator|Conventional rehabilitation (CR) group|The CR group will be designed to control for the duration of therapeutic activities. CR will focus on neurodevelopmental techniques with emphasis on functional tasks when possible. The functional training will be designed based on patients' motor capacity and include gross motor and fine motor dexterity training, and transitive and intransitive training. Stretching of the more affected limb, passive and active range of movements, and normalizing muscle tone by applying reflex inhibition patterns, inhibiting abnormal patterns, weight bearing with the affected limb will be applied to assist in functional task practice.
88934280|NCT01767532|Experimental|A(reference)/B(test)|initial administration of reference and cross-over to test
88934281|NCT01767532|Experimental|B(test)/A(reference)|initial administration of test and cross-over to reference
89449128|NCT05235360|Experimental|Condition 6|1) Recent thinking; 2) Positive affect imagery; 3) Action planning; 4) Low intervention dose
88934282|NCT01767545|Active Comparator|Dexamethasone-implant (Group 1)|Group 1 included 38 patients (22 with CRVO and 16 with BRVO) and was treated with a dexamethasone-implant injection from the beginning.
88934283|NCT01767545|Active Comparator|Bevacizumab/Dexamethasone-implant (Group 2)|Group 2 included 26 patients (14 CRVO, 12 BRVO) and was treated with three consecutive injections of bevacizumab at a monthly interval, followed by a dexamethasone-implant injection four weeks after the last bevacizumab injection.
89200646|NCT02533687|Active Comparator|Bipolar TURP-1|Transurethral resection of prostate (TURP) with bipolar resectoscope (Gyrus brand)
89449129|NCT05235360|Experimental|Condition 7|1) Recent thinking; 2) Positive affect imagery; 3) High intervention dose
88934284|NCT01767558|Other|Ablation / MRI|"All subjects will undergo a standard of care ablation procedure for paroxysmal AF with the CE-Marked PVAC GOLD catheter.~MRIs will be performed on all subjects at Enrollment and Pre-Discharge (Post Ablation). Subjects with a positive MRI (cerebral lesion) at Pre-Discharge will undergo another MRI at the 1 month follow-up visit."
88934285|NCT01767571|Experimental|A(reference)/B(test)|initial administration of reference and cross-over to test
88934286|NCT01767571|Experimental|B(test)/A(reference)|initial administration of test and cross-over to reference
89449130|NCT05235360|Experimental|Condition 8|1) Recent thinking; 2) Positive affect imagery; 3) Low intervention dose
89449131|NCT05235360|Experimental|Condition 9|1) Episodic future thinking; 2) Neutral imagery; 3) Action planning; 4) High intervention dose
89449132|NCT05235360|Experimental|Condition 10|1) Episodic future thinking; 2) Neutral imagery; 3) Action planning; 4) Low intervention dose
89449133|NCT05235360|Experimental|Condition 11|1) Episodic future thinking; 2) Neutral imagery; 3) High intervention dose
89449134|NCT05235360|Experimental|Condition 12|1) Episodic future thinking; 2) Neutral imagery; 3) Low intervention dose
88934287|NCT01767584|Experimental|A (reference)/ B (test)|initial administration of reference and cross-over to test
89449135|NCT05235360|Experimental|Condition 13|1) Recent thinking; 2) Neutral imagery; 3) Action planning; 4) High intervention dose
89449136|NCT05235360|Experimental|Condition 14|1) Recent thinking; 2) Neutral imagery; 3) Action planning; 4) Low intervention dose
89449137|NCT05235360|Experimental|Condition 15|1) Recent thinking; 2) Neutral imagery; 3) High intervention dose
89449138|NCT05235360|Experimental|Condition 16|1) Recent thinking; 2) Neutral imagery; 3) Low intervention dose
89449139|NCT01733433|Experimental|taped ankle|Subjects will be taped in at the ankle for a series of exercises.
88934288|NCT01767584|Experimental|B (test)/ A (reference)|initial administration of test and cross-over to reference
88934289|NCT01767623|Active Comparator|Cohort 1: Participants with Normal Liver Function|Participants with normal liver function (according to National Cancer Institute [NCI] liver dysfunction criteria) will receive vemurafenib 960 mg BID from Day 1 until the morning dose on Day 20 and then from Day 27 onward until disease progression, safety-related treatment termination, withdrawal of consent, death, or a decision by the Sponsor to terminate the study, whichever occurs first.
89449140|NCT02008292|Experimental|physostigmine and amphetamine|There is only one arm to the study. All subjects will receive physostigmine and amphetamine.
89449141|NCT02228811|Experimental|DCC-2701 tablet|DCC-2701 tablets in escalating dose cohorts given orally BID (twice daily) every 12 hours for a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met.
89449142|NCT02224287|Other|Fluoroscopy|Technologist control of fluoroscopy Surgeon control of fluoroscopy
89449143|NCT04809519|Experimental|UHTINuM|UHTINuM is an acronym that defines multimodal interventions consisting of three components. These interventions are as follows: (1) Structured yoga program including meditation and breathing techniques (2) Hypertensive Treatment Compliance Training (3) Teaching blood pressure measurement and monitoring at home.
89449144|NCT04809519|Active Comparator|Control group|Control group will be receive information notes and standard brochures related to physical activity, healthy lifestyle behaviors advice, stop smoking etc. and will be referred to a specialist physician.
89200647|NCT02533687|Active Comparator|Bipolar TURP-2|TURP with bipolar resectoscope (Olympus brand)
89449145|NCT03477864|Experimental|Arm A (REGN2810, SBRT, surgery)|Participants receive anti-PD-1 monoclonal antibody REGN2810 IV over 30 minutes on day 1 of week 1 and in week 4, and undergo SBRT for 4 fractions on days 2-5 of week 3. Within 14-21 days, participants undergo radical prostatectomy.
89449146|NCT03477864|Experimental|Arm B (ipilimumab, SBRT, surgery)|Participants receive ipilimumab via intraprostatic injection on day 1 of week 1, and undergo SBRT for 4 fractions on days 2-5 of week 3. Within 14-21 days, participants undergo radical prostatectomy.
89449147|NCT03477864|Experimental|Arm C (REGN2810, ipilimumab, SBRT, surgery)|Participants receive anti-PD-1 monoclonal antibody REGN2810 as in Arm A and ipilimumab as in Arm B. Participants also undergo SBRT for 4 fractions on days 2-5 of week 3. Within 14-21 days, participants undergo radical prostatectomy.
89449148|NCT02229045|Experimental|Albumin Bound Paclitaxel With 5-FU/CF|Albumin Bound Paclitaxel 150 mg/m2 (on day 1),5FU 400 mg/m2 iv d1, 2.4g/ m2 civ,d1-d3 every 2 weeks until disease progress or intolerable toxicity.
89449149|NCT02717364||Population With Yervoy Exposure|Population With Yervoy Exposure
89449150|NCT02682810|Active Comparator|DNA PCR HIV diagnostic test|SOC or control arm through existing PMTCT program, with DBS samples sent to an off-site laboratory for DNA PCR testing.
89449151|NCT02682810|Experimental|Alere Q POC nucleic acid-based platform|POC test to provide same-day diagnosis
89449152|NCT02229201|Experimental|Propofol|intravenous anaesthetic
89449153|NCT02229201|Active Comparator|Sevoflurane|volatile anaesthetic
89449154|NCT03164226|Other|Patient consulting for chest Pain in ED|Any patient ≥ 25 years consulting for chest pain in the emergency department from 8:00 am to 8:00 pm (for the unavailability of the endopat device during the guard).
88934290|NCT01767623|Experimental|Cohort 2: Participants with Severe Liver Dysfunction|Participants with severe liver dysfunction (according to NCI liver dysfunction criteria) will receive vemurafenib 720 mg BID from Day 1 until the morning dose on Day 20 and then from Day 27 onward until disease progression, safety-related treatment termination, withdrawal of consent, death, or a decision by the Sponsor to terminate the study, whichever occurs first.
89449155|NCT02224365|Experimental|Apple|12 weeks of 75 g dried apple powder taken in 480 ml per day.
89449156|NCT02224365|Placebo Comparator|Placebo|12 weeks of 75 g apple-flavored placebo powder taken in 480 ml per day.
89449157|NCT03477786|Active Comparator|tight BP|"Interventions: anti-hypertension drug prescription by physician and case management by health educator.~Blood pressure is targeted at 120/80 mmHg in the tight BP control group."
88934291|NCT01767649||Caesarean|Normal pregnant women at term without complication during pregnancy and without inflammatory disorders
89449158|NCT03477786|Placebo Comparator|usual BP|"Interventions: The physicians follow their usual care patterns to prescribe anti-HT drugs.~Blood pressure is targeted at < 140/90 mmHg in the usual BP control group."
89449159|NCT02224443|Experimental|Group A, dexmedetomidine , 0.3µg.kg-1.h-1|Continuous pump infusion dexmedetomidine with loading dose at 0.8µg.kg-1 over 10 minutes,followed Continuous pump infusion dexmedetomidine at 0.3µg.kg-1.h-1 until 30 minutes before end of operation
89449160|NCT02224443|Experimental|Group B,dexmedetomidine , 0.5µg.kg-1.h-1|Continuous pump infusion dexmedetomidine with loading dose at 0.8µg.kg-1 over 10 minutes,followed continuous pump infusion dexmedetomidine at 0.5µg.kg-1.h-1 until 30 minutes before end of operation
89449161|NCT02224443|Placebo Comparator|Group C ,normal saline|Normal saline infusion will be given with the same infusion volume as group A and B
89449162|NCT04184037|Experimental|Auditory neurofeedback (NFB)|Participants in this arm will meditate with the help of a custom version of the Muse app, which guides users in meditation while providing auditory neurofeedback on their state of mindfulness. Participants will wear the EEG headband and headphones when completing the meditation sessions using the app. The neurofeedback consists of changing weather sounds that are heard against a background soundscape (e.g., a beach or rainforest sound). When a user is in a focused state, the weather in the soundscape is good (e.g., it is quiet or a light breeze can be heard). When a user starts mind-wandering, the weather sounds change for the worse: it begins to rain, the wind gets louder, and there may be thunder. When the user returns to a calm state, the weather sounds quiet down again and only the background soundscape is heard. Participants are asked to pay attention to the weather sounds and to use this feedback to train their mind to remain focused on the present moment.
89449163|NCT04184037|Active Comparator|No neurofeedback (no-NFB)|Participants in this arm will meditate using a custom version of the Muse app that is identical in all respects to the mobile app used by the NFB group, expect that the auditory neurofeedback is not active. Participants will wear the EEG headband and headphones when completing the meditation sessions using the app, but the soundscape during the sessions will only contain the background sounds (e.g., the breach or rainforest scene), without any changes to the weather.
89449164|NCT02229279|Active Comparator|Teleconsulting|Teleconsulting
89449165|NCT02229279|No Intervention|No Teleconsulting|
88934292|NCT01767649||Vaginal Delivery|Normal pregnant women at term without complication during pregnancy and without inflammatory disorders
88934293|NCT01767662|Experimental|manipulation|home program for parents manipulation
88934294|NCT01767662|Placebo Comparator|observe|observation
88934295|NCT01767714|Experimental|G-CSF + plerixafor|Patients will receive G-CSF for 4 mornings for mobilization, followed by another dose each morning before apheresis on days that the patient is to continue apheresis (up to 8 doses total). Patients will also receive plerixafor in the evening up to a maximum of 4 doses.
88934296|NCT01767714|Placebo Comparator|G-CSF + Placebo|Patients will receive G-CSF for 4 mornings for mobilization, followed by another dose each morning before apheresis on days that the patient is to continue apheresis (up to 8 doses total). Patients will also receive placebo in the evening up to a maximum of 4 doses.
89449166|NCT02229357|Experimental|OrniFlu® inactivated vaccine|
89449167|NCT02229435||eGFR <60ml/min|Patients with CKD with eGFR <60 ml/min (CKD-EPI or MDRD) 12/2004-08/2014 of Medical Laboratory, Prof. Schenk / Dr. Ansorge and Colleagues, GbR, Am Neustädter Feld 47, 39124 Magdeburg, Germany.
89449168|NCT02224521|Experimental|Cohort 1|Subjects will be assigned to any of the 4 dosage regimen (A, B, C, D) in four periods. A= GSK2190915 Solution, 50mg single dose, fasted; B = GSK2190915 Capsule Formulation A, 50mg single dose (1 x 50mg capsule), fasted; C= GSK2190915 Capsule Formulation B, 50mg single dose (1 x 50mg capsule), fasted; D= GSK2190915 Capsule Formulation C, 50mg single dose (1 x 50mg capsule), fasted.
89449169|NCT02224521|Experimental|Cohort 2|The selected formulation will be dosed with GSK2190915 capsule formulation at 20mg (fasted), 100mg (fasted), 100mg (fed) and 200mg (fasted).
89449170|NCT02224521|Experimental|Cohort 3|Cohort 3 will be a 4-way complete crossover study with single doses of 20mg and 200mg of up to two capsule formulations taken forward from cohort 2 in 10 healthy adult subjects in the fasted state.
88934297|NCT01767727|Other|Surgical flap|Surgical flap is based on the dorsal branch of the digital artery, and is used for soft tissue coverageof multiple finger defects.
88934298|NCT01767740|Experimental|ULTRABRAID PLUS SUTURE|ULTRABRAID Plus Suture manufactured by Smith & Nephew used in subjects undergoing rotator cuff repair.
88934299|NCT01767740|Active Comparator|ULTRABRAID SUTURE|ULTRABRAID Suture is a marketed suture manufactured by Smith & Nephew used in subjects undergoing rotator cuff repair.
89200648|NCT02533687|Active Comparator|Monopolar TURP|TURP with monopolar resectoscope (Karl Storz brand)
89200649|NCT00869973|Experimental|1|Aprepitant
89200650|NCT00869973|Active Comparator|2|dexamethasone
89200651|NCT01048645|Placebo Comparator|P/PC arm|Patients were assigned to receive placebo (P/PC) 1 week prior to treatment until completing two cycles
89200652|NCT01048645|Experimental|RA/PC arm|Patients were assigned to receive ATRA 20 mg/m2/day (RA/PC) 1 week prior to treatment until completing two cycles
89200653|NCT04008784||Crisaborole 2% Topical Application Ointment [EUCRISA]|Crisaborole 2% Topical Application Ointment [EUCRISA] applied twice a day for 8 weeks
89200654|NCT04008784||Crisaborole 2% plus Triamcinolone Acetonide 0.1%Ointment|Crisaborole 2% plus Triamcinolone Acetonide 0.1% Ointment applied twice a day for the first 2 weeks, followed by Crisaborole 2% alone applied twice a day for the following 6 weeks
89200655|NCT03544905|Experimental|Dose escalation study of CYH33|To determine the maximum tolerated dose (MTD) of CYH33
89200656|NCT04008394|Experimental|Anti-CD30 CAR T cells|Patients receive CD30 CAR-T cells transduced with a lentiviral vector on day 0 in the absence of disease progression or unacceptable toxicity. Autologous 3th generation anti-CD30 CAR T cells.
89200657|NCT00895635|Experimental|Treadmill Exercise Training|Participants will take part in a 12-week supervised treadmill exercise training program.
89200658|NCT00895635|Experimental|Arm Ergometry Exercise Training|Participants will take part in a 12-week supervised aerobic arm ergometry exercise training program.
89200659|NCT00895635|Active Comparator|Usual Care Control Group|Participants will receive usual care for PAD from their doctor.
89200660|NCT01051687|No Intervention|control skin patches|no intervention will be given to the patches
89200661|NCT01051687|Active Comparator|botulinum toxin A|Dilution of 1 ml of unpreserved saline per 100 U vial of BOTOX (Allergen pharmaceuticals, Irvine, CA). 2 units were injected intradermally every 1 cm2 with a 1ml syringe and 30 gauge needle.
89200662|NCT00978718|Placebo Comparator|Arm I|Patients receive oral placebo daily. Treatment continues for up to 57 months in the absence of unacceptable toxicity or diagnosis of prostate cancer.
89200663|NCT00978718|Experimental|Arm II: 200 μg selenium (Se) as high-Se Baker's yeast daily|Patients receive 200 μg of oral selenium (Se) as high-Se Baker's yeast daily. Treatment continues for up to 57 months in the absence of unacceptable toxicity or diagnosis of prostate cancer.
89200664|NCT00978718|Experimental|Arm III: 400 μg Se as high-Se baker's yeast daily|Patients receive 400 μg of oral Se as high-Se baker's yeast daily. Treatment continues for up to 57 months in the absence of unacceptable toxicity or diagnosis of prostate cancer.
89200665|NCT00894153|Experimental|chemo plus p53|chemotherapy plus p53
89200666|NCT00894153|Active Comparator|chemo only|chemotherapy group
89200667|NCT00894153|Active Comparator|radio|radiotherapy
89200668|NCT01048801|Active Comparator|Rapid diagnostic test and treatment|
89200669|NCT01048801|Other|Treatment without rapid daignostic test|
89200670|NCT00971542|Experimental|low dose of antigen + low dose of adjuvant|
89449171|NCT02224521|Experimental|Cohort 4|The regimen for Cohort 4 will be either the highest dose (200mg) of the capsule formulation (A, B or C) taken forward from the previous cohorts or the solution formulation (200mg).
89449172|NCT02224521|Experimental|Cohort 5|Subjects will take milled and micronised tablet formulations of GSK2190915 in the fasted state in periods 1 and 2, and will take milled and micronised tablet formulations of GS2190915 in the fed state in periods 3 and 4.
89449173|NCT02224521|Experimental|Cohort 6|Tablet formulations (milled and micronised, different to the Cohort 5 formulations) of GSK2190915 will be dosed in the fasted and fed (after a light breakfast) states.
89449174|NCT02224677||Children with Craniofacial Microsomia|125 children with craniofacial microsomia will be asked to come in for two study visits - when they are about 12 months old and again when they are about 36 months old. Procedures for children at the first visit include: assessment of development, video, photographs, and a hearing evaluation. Procedures for the final study visit include: assessment of development, photographs (2D & 3D), video, saliva sample, hearing evaluation, speech assessment.
89449175|NCT02224677||Children without Craniofacial Microsomia|Please note: we are not recruiting this group through ClinicalTrials.gov 100 children without craniofacial microsomia will be asked to come in for two study visits - when they are about 12 months old and again when they are about 36 months old. Procedures for the first visit include: assessment of development, video, and photographs. Procedures for the final study visit include: assessment of development, photographs (2D & 3D), video, and speech assessment.
89449176|NCT02224677||Parents of Children with Craniofacial Microsomia|125-250 parents of children with craniofacial microsomia will be asked to complete three visits - when their child is about 12 months old, 24 months old, and 36 months old. Parents will be asked to complete an interview at the first visit. The second visit consists of a telephone interview where parents will be asked about their child's hearing and health history. At the final study visit, parents will be asked to complete more questionnaires, have their picture taken, and donate saliva.
88934300|NCT01767753|Experimental|Triggerfish|Device: Sensimed Triggerfish
89449177|NCT02224677||Parents of Children without Craniofacial Microsomia|Please note: we are not recruiting this group through ClinicalTrials.gov 100 parents of children without craniofacial microsomia will be asked to complete three visits - when their child is about 12 months old, 24 months old, and 36 months old. Parents will be asked to complete an interview at the first visit. The second visit consists of a telephone interview where parents will be asked about their child's hearing and health history. At the final study visit, parents will be asked to complete questionnaires and an interview.
89449178|NCT02224677||Teacher/Day Care Provider|When the children participants are around 36 months old, we will ask parents for permission to contact their child's teacher/day care provider. We would like the teacher/day care provider to fill out a questionnaire.
89449179|NCT01944800|Experimental|Ticagrelor|
89449180|NCT01944800|Active Comparator|Prasugrel|
89449181|NCT03617367|Experimental|daxibotulinumtoxinA (DAXI) for injection|DAXI for injection
89449182|NCT02229591||EFL patients|Patients with Expiratory Flow Limitation undergoing surgery
89449183|NCT02229591||Control group|Patients withouth Expiratory Flow Limitation undergoing surgery
89449184|NCT02470676|Active Comparator|Progesterone|200 mg daily of vaginal progesterone suppositories (Utrogestan)
89449185|NCT02470676|Experimental|Progesterone plus Experimental device|Experimental device + 200 mg daily progesterone vaginal suppositories (Utrogestan)
89449186|NCT02229669|Experimental|Horizontal incisions|Coronally advanced flap was performed by using horizontal interdental incisions. An initial horizontal incision was made slightly coronal to the CEJ from the distal to the mesial papilla of the teeth with the recessions. A second incision, 1 to 2 mm apart and parallel to the first incision, was made apically. A sulcular incision was made to link the second incisions and the blade was inserted extending beyond the mucogingival junction, to create a uniform split-thickness flap. The tissue between the two incisions was partially removed to obtain a uniform receptor site that permitted primary closure. Approximation sutures to place the edge of the flap at the base of the remaining papilla were performed.
89449187|NCT02229669|Experimental|Oblique incisions|Coronally advanced flap was performed by using oblique incisions in interdental areas, according to the technique proposed by Zucchelli & De Sanctis (2000). Oblique submarginal interdental incisions were performed and continued with the intrasulcular incisions at the recession defects, resulting in a envelop flap that was raised with a split-full-split approach in the coronal-apical direction. During coronal advancement, each surgical papilla was dislocated with respect to the de-epithelized anatomic papilla by the oblique incisions. Interrupted sutures were performed to stabilize single surgical papilla over the interdental connective tissue bed.
89449188|NCT01933724|Experimental|5 mg prednisone|Subjects will be randomized to 5 mg per day of prednisone for a 6 month period.
89449189|NCT01933724|Experimental|0 mg prednisone|Subjects will be randomized to 0 mg per day of prednisone dose for a 6 month period.
89449190|NCT02229747|Experimental|Meloxicam suspension|
89449191|NCT02229747|Active Comparator|Diclofenac suspension|
89449192|NCT02229747|Active Comparator|Nimesulide suspension|
89449193|NCT02232789|Experimental|Mephedrone|Mephedrone 200 mg, single dose, oral administration
89449194|NCT02232789|Active Comparator|3,4-methylenedioxymethamphetamine|3,4-methylenedioxymethamphetamine (MDMA) 100 mg, single dose, oral administration
89449195|NCT02232789|Placebo Comparator|Lactose|Placebo, single dose, oral administration
89449196|NCT03030222|Active Comparator|Empagliflozin|Empagliflozin 10 mg tab, once daily, for 12 weeks
89449197|NCT03030222|Placebo Comparator|Placebo|Empagliflozin matching placebo oral tablet, once daily for 12 weeks
89449198|NCT02258997||HbSS|Subjects are homozygous for the sickle hemoglobin mutation (HbS).
89449199|NCT02258997||HbS-beta thalassemia|Subjects are heterozygous for the HbS mutation and beta thalassemia
89449200|NCT04089735|Experimental|APP13007 0.05% twice daily (BID) [Part A]|1 drop 0.05% APP13007 twice daily for 21 days to the operated eye
89449201|NCT04089735|Experimental|APP13007 0.05% Placebo twice daily (BID) [Part A]|1 drop matching vehicle placebo for 0.05% APP13007 twice daily for 21 days to the operated eye
88934301|NCT01767766|Experimental|TGR-1202|TGR-1202 Daily Oral Dose
88934302|NCT01767779||seizure free infants with dx of TSC|infants that are seizure free at the time of the study enrollment and meets genetic or clinical diagnostic criteria for TSC
89449202|NCT04089735|Experimental|APP13007 0.05% twice daily (BID) and once daily (QD) [Part B]|1 drop 0.05% APP13007 twice daily for 3 days followed by 1 drop once daily for 11 days to the operated eye
89449203|NCT04089735|Experimental|APP13007 0.05% Placebo twice daily (BID) and once daily (QD) [Part B]|1 drop matching vehicle placebo for 0.05% APP13007 twice daily for 3 days followed by 1 drop once daily for 11 days to the operated eye
89449204|NCT04089735|Experimental|APP13007 0.1% twice daily (BID) and once daily (QD) [Part B]|1 drop 0.1% APP13007 twice daily for 3 days followed by 1 drop once daily for 11 days to the operated eye
89449205|NCT04089735|Experimental|APP13007 0.1% Placebo twice daily (BID) and once daily (QD) [Part B]|1 drop matching vehicle placebo for 0.1% APP13007 twice daily for 3 days followed by 1 drop once daily for 11 days to the operated eye
89449206|NCT02892708|Active Comparator|Surgery|Surgical resection followed by radiation therapy
89449207|NCT02892708|Experimental|radiotherapy alone|radiotherapy after a brain biopsy
89449208|NCT02523222|No Intervention|CONTROL|Infants at risk for transient neonatal hypoglycemia following standard-of-care.
89449209|NCT02523222|Active Comparator|Dextrose Gel|Infants given 40% Dextrose gel (0.5ml/kg) in the buccal mucosa after their first feed, within the first hour of life.
89449210|NCT02232867|Experimental|Arm and Leg Cycling Exercise Program|Multiple baseline test sessions will be used for the same participant to establish a meaningful baseline thus confirming consistency of all outcome measures prior to the intervention.
89449211|NCT05224596||Cancer arm|Baseline blood samples will be collected from new diagnosis cancer participants.
89449212|NCT05224596||Benign disease arm|Baseline blood samples will be collected from new diagnosis benign gastric disease participants.
89449213|NCT02232945|Placebo Comparator|placebo|placebo of oseltamivir phosphate and placebo of Banlangen(Radix Isatidis) granules.
89449214|NCT02232945|Experimental|Banlangen granules & placebo|Banlangen(Radix Isatidis) granules and placebo of oseltamivir phosphate
89200671|NCT00971542|Experimental|high dose of antigen + high dose of adjuvant|
89449215|NCT02232945|Active Comparator|oseltamivir phosphate & placebo|oseltamivir phosphate and placebo of Banlangen(Radix Isatidis) granules
89449216|NCT01876784|Experimental|Vandetanib|Vandetanib 300 mg tablet, orally once daily until disease progression or death.
89449217|NCT01876784|Placebo Comparator|Placebo|Placebo matched to vandetanib tablet, orally once daily until disease progression or death.
89449218|NCT02546622||Arm A Prospective|"Patients who are switching to a new Factor VIII and Factor IX Replacement Product for Hemophilia A and B which was FDA approved after January 1, 2013.~These patients will be followed prospectively for up to 1 year."
89449219|NCT02546622||Arm B Retrospective|"Patients who have recently switched to a new Factor VIII and Factor IX Replacement Product for Hemophilia A and B which was FDA approved after January 1, 2013.~Patients must have switched products within the past 50 weeks at the time of enrollment.~These patients will be assessed retrospectively and/or followed prospectively for up to 1 year."
89014659|NCT04537897|Placebo Comparator|Placebo (Part A)|"Young participants administered matching placebo to part A once daily with 240 milliliter (mL) of water after an overnight fast of at least 10 hours (h) over a treatment period of 14 days.~On Day -1, 1, and 14, 75 micrograms (μg) of midazolam for injection used as oral solution were administered orally once daily with 240 milliliter (mL) of water after an overnight fast of at least 10 hours (h) for placebo participants matched to 2.5mg BI, 10mg BI, 20mg BI, and 30mg BI groups."
89200672|NCT00971542|Experimental|high dose of antigen|
89200673|NCT00895713|Experimental|im HBIG Grifols|
89449220|NCT02229903|Active Comparator|Active DTMS Treatment|Active DTMS Treatment constitutes the Deep Transcranial Magnetci Stimulation (DTMS) which is a new form of TMS which allows direct stimulation of deeper neruonal pathways than the standard TMS. The DTMS coil is designed to allow deeper brain stimulation without significant increase of electric fields included in superficial cortical regions.
89449221|NCT02229903|Sham Comparator|Sham Treatment|The Sham Treatment consists of an electrical field which cannot invoke any action potentials and if no action potentials are induced, then the electric field is insignificant and there is no treatment effect on the brain.
89449222|NCT05218746|Experimental|Serratus anterior block|Regional analgesic block of anterolateral chest wall
89449223|NCT05218746|Experimental|Erector spinae block|Regional analgesic block for the whole chest wall
89449224|NCT05195658||Acute ischemic stroke with culprit lesion at the carotid bifurcation|Consecutive patients with acute ischemic stroke culprit lesion at the carotid bifurcation, accepted for emergent interventional management by the NeuroVascular Team Committee according to stroke management guidelines
89449225|NCT04205162|Experimental|Verofilcon A / Etafilcon A|The participant will wear Verofilcon A in their right eye and Etafilcon A in their left eye.
89449226|NCT04205162|Experimental|Etafilcon A / Verofilcon A|The participant will wear Etafilcon A in their right eye and Verafilcon A in their left eye.
89449227|NCT02229981|Experimental|ABC294640|Patients will receive ABC294640 orally in gelatin capsules BID.
89449228|NCT02523378|Experimental|ESAS Self-Administration - Group A|Participants complete the symptom questionnaire alone. It is then counterchecked by health care professional (HCP).
89449229|NCT02523378|Experimental|ESAS Assisted-Completion - Group B|Participants complete the symptom questionnaire with the help of the research nurse or assistant.
89200674|NCT01051765|Experimental|irinotecan/cisplatin|irinotecan 130mg/m2 d1 cisplatin: 30mg/m2, d1,d2 every three weeks
89200675|NCT00978796|Active Comparator|Sitagliptin|Patients will receive sitagliptin for 4 weeks and then cross over to sugar pill
89449230|NCT03309566|Experimental|Test - Reference|A new formulation containing a combination of efavirenz 600 mg, emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg (T) followed by a branded formulation (R).
89449231|NCT03309566|Experimental|Reference - Test|A branded formulation (R) followed by a new formulation containing a combination of efavirenz 600 mg, emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg (T).
89449232|NCT00735657|Active Comparator|Group 1|Control
89449233|NCT00735657|Active Comparator|Group 2|Block with short needle
89449234|NCT03309488||Food allergic|Patients with a positive oral challenge to the food being studied.
89449235|NCT03309488||Non food allergic|Patients with a negative oral challenge to the food being studied.
88934303|NCT01767779||Parents or family guardian of cohort 1|Parent or family guardian of infants that are seizure free at the time of the study enrollment and meets genetic or clinical diagnostic criteria for TSC.
88934304|NCT01767805|Other|Type of incubator|Embryos are cultured in a standard incubator or a mini-incubator
89449236|NCT02230059||Metastatic Castration-resistant Prostate Cancer|Medical charts of participants with metastatic castration-resistant prostate cancer will be observed.
89449237|NCT03309410||Pre-study|In the pre-study, venous samples were collected in paired 2 mL ABG syringes and 4.5 mL tubes from each of the 10 patients, to determine which blood collection method was preferred. VBG samples were collected via a butterfly needle with a three-way stopcock in conjunction with routine venous blood sampling upon admission. VBG samples were collected by the biomedical laboratory technician in the same manner as PVB samples in the normal clinical setting. Results from the pre-study were used to determine the preferred blood collection method in the main study. In this study, paired ABG and VBG samples were collected simultaneously from each of the 20 patients. The ABG samples were collected by the responsible physician. Allocation to either the pre-study or the main study was performed by simple quasi-random allocation in order of admission.
89449238|NCT03309410||Main study|In this study, paired ABG and VBG samples were collected simultaneously from each of the 20 patients. The ABG samples were collected by the responsible physician. Allocation to either the pre-study or the main study was performed by simple quasi-random allocation in order of admission. The clinical indication for ABG analysis was decided by the responsible physician in the ED upon patient admission and based on national guidelines and criteria.
89449239|NCT02230137|Experimental|Text message arm|
89449240|NCT02230137|No Intervention|No text message arm|
88934305|NCT01767805|Other|Oxygen concentration|Embryos are cultured in an incubator with a gas mixture with 20% oxygen or with 5% oxygen
88934306|NCT01767818||Previously treated PD patients|220 subjects with PD treated and responsive to dopaminergic medication
88934307|NCT01767818||Previously untreated PD|20 subjects with de-novo, previously untreated PD confirmed by I-123 Ioflupane SPECT
88934308|NCT01767818||Healthy age-matched controls|46 age-matched healthy controls will be studied.
88934309|NCT01767831||Group A: CGM monitoring (1) vs Intervention|Participants will undergo a 1 week CGM monitoring period (session 1), followed by a 4 week intervention period using the iBOLUSED intervention. The 4 week intervention period will be followed by an additional CGM monitoring period (session 2). For those in Group A, we compare the data collection in CGM monitoring session 1 to the data collection in the intervention period.
88934310|NCT01767831||Group B: CGM monitoring (2) vs Intervention|Participants will undergo a 1 week CGM monitoring period (session 1), followed by a 4 week intervention period using the iBOLUSED intervention. The 4 week intervention period will be followed by an additional CGM monitoring period (session 2). For those in Group B, we compare the data collection in CGM monitoring session 2 to the data collection in the intervention period.
88934311|NCT01767844|Experimental|Creatine|Creatine, often found in meat and fish, make up an essential part of the systems that provide energy to the muscles for movement and exercise.
88934312|NCT01767844|Placebo Comparator|Fruit powder drink|A regular fruit flavoured powder that has no benefits
88934313|NCT01767870|Experimental|FIT-Sigmoidoscopy|This arm (FIT-Sigmoidoscopy) will take fecal immunochemical test (FIT) followed by sigmoidoscopy for evaluation of advanced colorectal adenoma detection rate. Immediately after sigmoidoscopy, a total colonoscopy will be performed as a standard method for advanced colorectal adenoma detection.
88934314|NCT01767870|Experimental|Colonoscopy|This arm (Colonoscopy) will take a total colonoscopy as a control group that will represent the efficacy of colonoscopy for advanced colorectal adenoma detection rate.
88934315|NCT01767883|Experimental|Facilitated Clinical Decision Support|"The primary care practices in this arm will receive:~CKD decision support algorithms added to their Clinical Decision Support~System Academic detailing concerning the rationale for the algorithms~On-going mentoring and practice facilitation"
88934316|NCT01767883|Active Comparator|Clinical Decision Support Only|"The primary care practices in this arm will receive:~CKD decision support algorithms added to their Clinical Decision Support System~Academic detailing concerning the rationale for the algorithms"
88934317|NCT01767896|Experimental|ASP7374 group|cell-culture-derived vaccine group
88934318|NCT01767896|Active Comparator|TIV group|approved egg-derived TIV group
88934319|NCT01767922|Experimental|Extramel 10 mg - 140 UI SOD|This arm receives daily one capsule Extramel 10 mg containing 140 UI of SOD.
88934320|NCT01767922|Placebo Comparator|Placebo - exipients only|This arm receives daily one capsule Placebo containing excipients only.
88934321|NCT01767948|Experimental|Patients with mild hepatic function|Patients will receive PCI-32765 140 mg, orally, as a single dose, on Day 1.
88934322|NCT01767948|Experimental|Patients with moderate hepatic function|Patients will receive PCI-32765 140 mg, orally, as a single dose, on Day 1.
88934323|NCT01767948|Experimental|Patients with severe hepatic function|Patients will receive PCI-32765 140 mg, orally, as a single dose, on Day 1.
89200676|NCT00978796|Placebo Comparator|Sugar pill|Subjects will receive sugar pill for 4 weeks and then cross over to active sitagliptin
88934324|NCT01767948|Experimental|Patients with normal hepatic function|Patients will receive PCI-32765 140 mg, orally, as a single dose, on Day 1.
88934325|NCT01767961|Experimental|Diagnostic (modified barium swallow)|Patients undergo the modified barium swallow, comprising swallowing boluses of thin liquid barium, barium honey, barium pudding, and barium crackers while undergoing fluoroscopic imaging.
88934326|NCT01767974||Non-Small Cell Lung Cancer|Locally advanced stage IIIB or IV (metastatic) or Relapsed Non-Small Cell Lung Cancer
88934327|NCT01768026||No treatment|Subjects diagnosed with Dystrophic Epidermolysis Bullosa
88934328|NCT01768039|Active Comparator|Vitamin D|treatment with weekly 50000IU vitamin D
88934329|NCT01768039|Placebo Comparator|Placebo|Treatment with placebo
89449241|NCT05232422|Experimental|Yoga-Intervention Group|This arm will participate in a hatha yoga course for a time period of 8 weeks with a frequency of at least 3 up to 5 times per week. Further they will participate in the pre- as well as the post-tests before and after the intervention.
89449242|NCT05232422|No Intervention|Waiting Control Group|For the first 8 weeks of the study this group will not receive any intervention. After the second measurement is completed they will get the possibility to participate in a hatha yoga course as well. Further they will participate in the pre- as well as the post-tests around the same time as the Yoga-Intervention group.
89449243|NCT02470442|Experimental|Sevoflurane/Desflurane|After induction of general anesthesia with sevoflurane, anesthesia was maintained with desflurane.
89449244|NCT02470442|Experimental|Sevoflurane|the anesthetic induction and maintenance with sevoflurane.
89449245|NCT04021797|Sham Comparator|Sham|For the sham condition, the electrodes will be attached to an ear location that has not been shown to engage the vagus nerve. The stimulation frequency, intensity and duration will be aligned with the same parameters presented for the active tVNS condition (8Hz frequency, 5.0 mA electrical current and 200 ms pulse width).
89449246|NCT04021797|Experimental|Active|For the active condition, the electrodes will be attached to the ear at a place previously demonstrated to stimulate the vagus nerve. The stimulation frequency, intensity and duration will be aligned with the same parameters presented for the sham condition (8Hz frequency, 5.0 mA electrical current and 200 ms pulse width).
89449247|NCT02470520||AKI without CRRT|Patients with AKI who are not treated with continuous renal replacement therapy
89449248|NCT02470520||AKI with CRRT|Patients with AKI who are treated with continuous renal replacement therapy
89449249|NCT03519711|Experimental|Cohort 1: PTC923 2.5 and 10 mg/kg/day|Participants will receive PTC923 suspension 2.5 milligrams (mg)/kilogram (kg)/day (dose divided in 2 for twice daily administration) orally for 7 days in Period 1, undergo a 3 (±1) day washout period, then escalate to a dose of 10 mg/kg/day (dose divided in 2 for twice daily administration) administered orally for 7 days in Period 2 (14 days total treatment).
89449250|NCT03519711|Experimental|Cohort 2: PTC923 5 and 20 mg/kg/day|Participants will receive PTC923 suspension 5 mg/kg/day (dose divided in 2 for twice daily administration) orally for 7 days in Period 1, undergo a 3 (±1) day washout period, then escalate to a dose of 20 mg/kg/day (dose divided in 2 for twice daily administration) administered orally for 7 days in Period 2 (14 days total treatment).
88934330|NCT01768052||functional Near Infrared Spectroscopy|Noninvasive functional Near Infrared Spectroscopy (fNIRS) monitoring will take place during patients' clinical rTMS treatment sessions.
89449251|NCT03108950|Experimental|Home-Based Movement to Music|The Movement to Music classes are composed of a set of exercises tailored to the specific needs and capabilities of each target group. The class will consist of and aerobic component and a strength component performed to varying music tempos. All movements will be choreographed by qualified dance instructors. Intervention is delivered using video-conferencing to connect the participant to their instructor.
88934331|NCT01767610|Experimental|micronized fenofibrate|
88934332|NCT01767610|Experimental|pitavastatin Ca|
88934333|NCT01767610|Experimental|micronized fenofibrate plus pitavastatin Ca|
88934334|NCT01768065|Experimental|Nasal Expiratory Positive Airway Pressure Devices|Nasal Expiratory Positive Airway Pressure Device
88934335|NCT01768065|Sham Comparator|placebo sham|A sham device
88934336|NCT01768078|Experimental|with corticoids|
88934337|NCT01768078|Other|without corticoids|
89200677|NCT00894231|Placebo Comparator|placebo|Sugar tablet
89200678|NCT00894231|Active Comparator|Xyzal|
89200679|NCT00971698||Sickle Cell Patients|Patients with homozygous Sickle Cell Anemia
89449252|NCT04491734|Other|Tolerability Arm|Single arm study of active study product
89449253|NCT01329939|Experimental|Obese atopic asthmatics, montelukast|Obese/overweight (BMI 85%ile or above for children and > 25 for adults) mild to moderate persistent asthmatics age 7 and above, with environmental allergies who were on daily inhaled corticosteroid treatment and not on montelukast, were randomized to receive montelukast in a double blinded fashion.
89449254|NCT01329939|Placebo Comparator|Lean atopic asthmatics, placebo|Normal weight (BMI less than 85%ile or above for children and < 25 for adults) mild to moderate persistent asthmatics age 7 and above, with environmental allergies who were on daily inhaled corticosteroid treatment and not on montelukast, were randomized to receive placebo in a double blinded fashion.
88934338|NCT01768091|Experimental|POEM|POEM for patients with esophageal achalasia
88934339|NCT01768091|Active Comparator|Pneumatic dilation|Pneumatic dilation for patients with esophageal achalasia
88934340|NCT01768104|Experimental|ESTD|Endoscopic submucosal tunnel dissection (ESTD) for patients with upper gastrointestinal submucosal tumors (SMTs)
88934341|NCT01768104|Active Comparator|VATS|Video-assisted thoracoscopic surgery (VATS) for patients with upper gastrointestinal submucosal tumors (SMTs)
88934342|NCT01768143||Nurse Trainees|unexperienced endoscopy nurses
88934343|NCT01768143||Nurse Experts|Educated endoscopy Nurses
88934344|NCT01768156|Experimental|Study arm|
88934345|NCT01768169||fish oil capsule|10 capsules per day will provide 2130 mg of EPA (1280 mg) and DHA (850 mg)
89200680|NCT00971698||Sickle Cell Thalassemia|Patients with Sickle Cell Thalassemia
88934346|NCT01768182|Experimental|Folinic Acid|Participants were randomly assigned to a 4-week treatment with either folinic acid (n=15) or placebo (n=15). The study supplementation regimens consisted of the capsules containing 5 mg of folinic acid or placebo. Participants were provided with 1 bottle, which contained 30 capsules. Subjects were instructed to take 1 capsule daily, in the morning.
88934347|NCT01768182|Placebo Comparator|Placebo|Participants were randomly assigned to a 4-week treatment with either folinic acid (n=15) or placebo (n=15). The study supplementation regimens consisted of the capsules containing 5 mg of folinic acid or placebo. Participants were provided with 1 bottle, which contained 30 capsules. Subjects were instructed to take 1 capsule daily, in the morning.
88934348|NCT01768195|Experimental|Entecavir prophylaxis|Participants will initiate entecavir 0.5 mg/day orally on day 1 of the first course of immunochemotherapy and/or chemotherapy, and will be continued until 12 months after completion of the immunochemotherapy and/or chemotherapy.
88934349|NCT01768208|Experimental|Saxagliptin|
88934350|NCT01768221|Other|Caregiver intervention|
88934351|NCT01768234|Experimental|Supplemental water|This arm receives up to 2 L of supplemental water during the course of the testing day.
88934352|NCT01768234|No Intervention|Control|No supplemental water provided
88934353|NCT01768247|Experimental|HCG priming|Patients in this arm after 7-9 days of estrogen replacement they will receive a 150 international units (IU) HCG every day for 7 days concomitantly with the estradiol
88934354|NCT01768260|Active Comparator|Enhanced External conterpulsation|Enhanced external counterpulsation (EECP) is a noninvasive modality for the treatment of ischemic cardiovascular disease. EECP therapy is done by sequential inflation of 3 sets of cuffs wrapped around the lower extremities during diastole and deflation of the cuffs during systole.
88934355|NCT01768260|Active Comparator|aspirin|The subjects with Anterior ischemic Optic Neuropathy received aspirin therapy.
88934356|NCT01768273|Experimental|Midazolam and 824|2 mg midazolam (oral syrup) Day 1 and Day 17. 400 mg PA-824 once daily Day 4 - 17.
88934357|NCT01766505|Experimental|Candemore tablet|Candemore tablet: candesartan cilexetil 8mg, 16mg, 32mg/tab, orally, 1 tablet once a day during 16 weeks
88934358|NCT01766505|Active Comparator|Cozzar tablet|Cozzar tablet: Losartan potassium 50mg, 100mg/cap, orally, 1 capsule once a day during 16 weeks
88934359|NCT01768299|Experimental|Mifepristone at home 24 hours before miso dosing starts|"All women will receive study packet one containing mifepristone to swallow at home on study day 1. They will be told to return to the hospital for induction and will be scheduled to return to the hospital 24 hours later. Upon their return, they will be hospitalized and receive another study packet containing a placebo. Simultaneously, they will receive one dose of 400 mcg buccal misoprostol. Women will remain hospitalized and receive repeated doses of 400 mcg buccal misoprostol every three hours.~Participants will receive up to eight doses of misoprostol (e.g. 3200 mcg misoprostol) over 24 hours. Misoprostol dosing will stop when both the fetus and placenta are expelled."
88934360|NCT01768299|Experimental|Mifepristone and first dose of misoprostol simultaneously.|"Will receive study packet one containing placebo to swallow at home on study day 1. They will be told to return to the hospital for induction and will be scheduled to return to the hospital 24 hours later. Upon their return, they will be hospitalized and receive another study packet containing mifepristone. Simultaneously they will receive one dose of 400 mcg buccal misoprostol. Women will remain hospitalized and receive repeated doses of 400 mcg buccal misoprostol every three hours.~Participants will receive up to eight doses of misoprostol (e.g. 3200 mcg misoprostol) over 24 hours. Misoprostol dosing will stop when both the fetus and placenta are expelled. The procedure will be considered complete once both the fetus and placenta are expelled."
89200681|NCT00870207|Other|Immediate Intervention Group|The immediate intervention group will receive the TSSC pilot worksite intervention in the initial 12 week period from the pre-test/enrollment visit.
89449255|NCT01329939|Active Comparator|Lean atopic asthmatics, montelukast|Normal weight (BMI less than 85%ile or above for children and < 25 for adults) mild to moderate persistent asthmatics age 7 and above, with environmental allergies who were on daily inhaled corticosteroid treatment and not on montelukast, were randomized to receive montelukast in a double blinded fashion.
89449256|NCT01329939|Placebo Comparator|Obese atopic asthmatics, Placebo|Obese/overweight (BMI 85%ile or above for children and > 25 for adults) mild to moderate persistent asthmatics age 7 and above, with environmental allergies who were on daily inhaled corticosteroid treatment and not on montelukast, were randomized to receive placebo in a double blinded fashion.
89449257|NCT01320956|Experimental|Hypnosis|"Pre operative nurse consultation and Hypnosis:~will have hypnosis"
89449258|NCT01320956|Active Comparator|Control|"Pre operative nurse consultation:~usual nurse consultation without hypnosis"
89449259|NCT02230215|Experimental|Patient-Specific Instrumentation|Patients to have a total knee replacement surgery completed using Patient-Specific Instrumentation
89449260|NCT02230215|No Intervention|Traditional Instrumentation|Patients to have a total knee replacement surgery done using traditional instrumentation.
89449261|NCT02230293|Active Comparator|Conventional Group|Conventional treatment and follow up
89449262|NCT02230293|Experimental|Multidisciplinary Group|Multidisciplinary assistance
89449263|NCT04491656|Active Comparator|7 minutes group|surgeries performed with this group would wait 7 minutes after lidocaine+epinephrine injection prior to skin incision
89449264|NCT04491656|Active Comparator|30 minutes group|surgeries performed with this group would wait 30 minutes after lidocaine+epinephrine injection prior to skin incision
89449265|NCT02499900|Experimental|Copaxone® 40 mg/mL|Subcutaneous Injections 40 mg/mL Three Times a Week for the core period which last 6 months. In the extension period patient are administered Copaxone® 40 mg/mL for months 7 - 12.
89449266|NCT02499900|Active Comparator|Copaxone® 20 mg/mL|Subcutaneous Injections 20 mg/mL Daily for the core period which last 6 months. In the extension period patient are administered Copaxone® 40 mg/mL for months 7 - 12.
89449267|NCT03505749|Experimental|TI-MBRP|Trauma Informed-Mindfulness-Based Relapse Prevention (TI-MBRP) will be a 4-week intervention integrating trauma intervention approaches based on Cognitive Processing Therapy (CPT) into standard Mindfulness-Based Relapse Prevention (MBRP). TI-MBRP honors the spirit and cognitive-behavioral foundation of MBRP while introducing components of CPT. Each TI-MBRP session will include mindfulness practices that bring awareness to cognitive and behavioral processes of substance abuse, and how substance use may function as a mechanism to cope with trauma symptoms. Clients are trained to observe internal, triggering stimuli without reactively attempting to avoid these experiences through substance use as well as complete exercises that promote cognitive and emotional processing of traumatic events.
89449268|NCT03505749|Active Comparator|Standard MBRP|The Treatment as Usual (TAU) group implemented for this trial will be the standard protocol for Mindfulness-Based Relapse Prevention (MBRP). MBRP is a 4-week exposure-based intervention that integrates integrating mindfulness and acceptance-based techniques with cognitive-behavioral approaches and psycho-education to increase awareness of patterns associated with addictive behaviors and individual factors precipitating and maintaining substance use. These skills are also used to train individuals in responding skillfully in high-risk situations associated with use.
89449269|NCT03901430|Experimental|Class|Group navigation model
89449270|NCT03314090|Experimental|Silicone Gel Group|Intervention: Silicone gel (Dermatix Ultra, Menarini, Singapore) was applied twice per day (BID). The amount being similar in size to a grain of rice.
89449271|NCT03314012|Experimental|Catheter-Based Carotid Body Ablation|All subjects undergo catheter-based ablation of the carotid body using the Cibiem Transvenous Ultrasound System (CTUS).
89449272|NCT03207282||Participants with Diagnosis of Depression|Study population consists of participants with a clinical diagnosis of depression, being treated in a psychiatry reference site (example, clinic, ambulatory, hospital, day-hospital) in 4 Latin American countries. Participants with Major Depressive Disorder (MDD) enrolled in Phase 1, will be assessed to estimate the prevalence of Treatment Resistant Depression (TRD) and participants with this diagnosis will be included in Phase 2. Participants with TRD will be followed-up for 1 year.
89449273|NCT02230371|Experimental|Granisetron|Granisetron (Kytril®; 1 mg/mL, Roche, Stockholm, Sweden) is injected into a maximum of six muscle sites in each patient. The most painful sites to palpation of the masticatory muscles is chosen, either in the same muscle (maximum 3 sites per muscle) or in a different. The injected volume into each site is0.5 mL, hence the maximum dose of granisetron a patient can receive is 3 mg per treatment. This is repeated after one and two weeks.
88934361|NCT01768312|Active Comparator|Restasis eye drop|Cyclosporine 0.05% : 1 drop twice a day for 12 weeks to both eyes
88934362|NCT01768312|Experimental|T-sporin eye drop|Cyclosporine 0.05% : 1 drop twice a day for 12 weeks to both eyes
88934363|NCT01768351|Active Comparator|Control|Patients receiving treatment for secondary hyperparathyroidism with calcitriol. The calcitriol dosage schedule provided for an initial dose of 0.5 mch every other day and titration was performed on the basis of the serum levels of intact PTH (iPTH) (target 150-300 pg/mL), Ca, P and Ca x P product as suggested by the US National Kidney Foundation Dialysis outcomes Quality Initiative (NKF-DOQI) and Kidney Disease: Improving Global Outcomes (KDIGO) guidelines.
89449274|NCT02230371|Placebo Comparator|Control (placebo)|Placebo (isotonic saline (NaCl); 0.9 mg/mL, Fresenius Kabi, Uppsala, Sweden) is injected into a maximum of six muscle sites in each patient. The most painful sites to palpation of the masticatory muscles is chosen, either in the same muscle (maximum 3 sites per muscle) or in a different. The injected volume into each site is 0.5 mL. This is repeated after one and two weeks.
89449275|NCT03859700|Experimental|DBV712 250mcg|
89449276|NCT03996447|Other|gadopiclenol-enhanced MRI then gadobutrol-enhanced MRI|cross-over design. each patient will receive gadopiclenol for the first MRI and gadobutrol for the second MRI
89449277|NCT03996447|Other|gadobutrol-enhanced MRI then gadopiclenol-enhanced MRI|cross-over design. each patient will receive gadobutrol for the first MRI and gadopiclenol for the second MRI
89449278|NCT01111110|Experimental|Anti-static then Static for Albuterol|albuterol anti-static first then static chamber second.
89449279|NCT01111110|Experimental|Static then Anti-static for Albuterol|static then antistatic albuterol
89449280|NCT05338736||Control group|Control patients with a complete first-cycle vaccination against SARS-CoV-2, received between 4 to 7 months before the inclusion, and with a nasopharyngeal swab negative for SARS-CoV-2 isolation.
89449281|NCT05338736||Asymptomatic group|Patients with a complete first-cycle vaccination against SARS-CoV-2, received between 4 to 7 months before the inclusion, with a nasopharyngeal swab positive for SARS-CoV-2 isolation, in absence of any symptoms of COVID-19
89449282|NCT05338736||Symptomatic group|Patients with a complete first-cycle vaccination against SARS-CoV-2, received between 4 to 7 months before the inclusion, with a nasopharyngeal swab positive for SARS-CoV-2 isolation, with moderate to severe symptoms of COVID-19
89449283|NCT03473652|Other|Adapted walking platform|
89449284|NCT03313934|Placebo Comparator|Hyaluronic Acid Filler with Saline|For each subject, one tear trough will be injected with hyaluronic acid filler mixed with saline. This arm will act as a control to evaluate the efficacy of PRF with hyaluronic acid.
89449285|NCT03313934|Experimental|Hyaluronic Acid Filler with Platelet Rich Fibrin (PRF)|For each subject, one tear trough will be injected with hyaluronic acid filler mixed with Platelet Rich Fibrin (PRF). This study seeks to determine the efficacy of PRF in volumization of the tear trough and improvement of skin quality. This is the experimental condition.
89449286|NCT03941301|Experimental|Bright treatment light|
89449287|NCT03941301|Placebo Comparator|Red light|
89449288|NCT03313856|Placebo Comparator|Placebo|The patients were randomly assigned to received placebo (calcinaned magnesia), 1 capsule before each meal for a period of 90 days.
89449289|NCT03313856|Experimental|Guazuma ulmifolia plus Tecoma stans|The patients were randomly assigned to received the herbarium mixture (GU/TS) , 1 capsule of 400mg, before each meal for a period of 90 days.
89449290|NCT02230605|Experimental|Cognitive Exercise|The cognitive exercises will consist of a series of computer games focusing on five categories: memory, speed, attention, flexibility and problem-solving. Participants will be expected to complete 1 hour of Lumosity exercise daily for a minimum of 8 days prior to surgery. Participants will be instructed to complete no less than 15 minutes of exercise at a time throughout each day. Each hour of exercise, participants will work through at least 1 game under each category. Research assessments will include Mini-Mental State Examination, Self-Administered Gerocognitive Examination, Geriatric Depression Scale, Charlson Comorbidity Index, Short Form 36 Health Survey, Confusion Assessment Method, Memorial Delirium Assessment Scale and Postoperative Quality of Recovery Scale.
88934364|NCT01768351|Experimental|Paricalcitol|Patients treated by Paricalcitol for hyperparathyroidism. The paricalcitol initial dose was 1 mcg/die, and titration was performed on the basis of the serum levels of iPTH, Ca, P and Ca x P product as suggested by the NKF-DOQI and KDIGO guidelines.
88934365|NCT01768364|Active Comparator|Antibiotics|will receive antibiotics
88934366|NCT01768364|Active Comparator|No antibiotics|will not receive antibiotics
88934367|NCT01768377|Active Comparator|Intubation with sedation|Sedation with midazolam and analgesia with fentanyl
88934368|NCT01768377|Experimental|Intubation with Nerve block|Laryngeal plus supraglottic plus intratracheal nerve block plus sedation with midazolam
88934369|NCT01768390|Experimental|5000 Test|Twice daily use of a toothpaste containing 5,000 ppm fluoride
88934370|NCT01768390|Active Comparator|1450 GCP|Twice daily use of a toothpaste containing 1,450 ppm fluoride
88934371|NCT01768429|Experimental|Fatty fish|Four fatty fish meals per week
88934372|NCT01768429|Experimental|Lean Fish|Four lean fish meals per week
88934373|NCT01768429|Experimental|Alpha-linolenic acid|10 g of alpha-linolenic acid daily from camelina sativa oil
88934374|NCT01768429|Experimental|Control diet|Limited fish and alpha-linolenic acid intake
88934375|NCT01768455|Experimental|Gemigliptin and Glimepiride|Multiple administrations of gemigliptin and single concomitant administration of gemigliptin and glimepiride
88934376|NCT01768455|Experimental|Glimepiride|Single administration of glimepiride
88934377|NCT01768468|Experimental|LAYLA|Drug : LAYLA tablet/ bid
88934378|NCT01768468|Active Comparator|JOINS|Drug : JOINS tablet/ tid
88934379|NCT01768481|Experimental|Statin|Atorvastatin 10 mg every day for one year
88934380|NCT01768481|Placebo Comparator|Sugar pill|Same size, taste and size placebo tablet (manufactured by sponsor) given every day for one year.
88934381|NCT01768507|Placebo Comparator|Placebo|no medication
88934382|NCT01768507|Experimental|Resveratrol|Trans-resveratrol (Resveratrol - Terraternal®): 5 g (10 capsules) as single oral dose on day 1 of the investigation period.
88934383|NCT01768533||Survey|A lifestyle survey was administered to primary-care givers or legal guardians who take their children 4-10 y/o to the pediatric well-child visits.
88934384|NCT01768546|Experimental|Video on Demand (VOD)|Virtual Diabetes Prevention Program: All participants will view the 16 Comcast on Demand episodes, weigh themselves, and track their progress weekly. Participants in the VOD arm of the study received access to a paper tracker to track food and activity during the program.
89200682|NCT00870207|Other|Delayed Intervention Group|The delayed intervention group will receive the TSSC pilot worksite intervention beginning in month 6 of the study (6 months from the enrollment/pre-test visit).
89449291|NCT02230605|Placebo Comparator|Normal Activity|Participants randomized into the Normal Activity group will be encouraged to maintain their normal activity level prior to surgery. These participants are asked not to alter their normal daily routine of mental exertion (i.e. watching television, reading, puzzles, etc.) and not permitted to subscribe to Lumosity while in the research study. Research assessments will include Mini-Mental State Examination, Self-Administered Gerocognitive Examination, Geriatric Depression Scale, Charlson Comorbidity Index, Short Form 36 Health Survey, Confusion Assessment Method, Memorial Delirium Assessment Scale and Postoperative Quality of Recovery Scale.
89449292|NCT03313700|Experimental|Robotic Distal Gastrectomy|Robotic Distal Gastrectomy will be performed for the treatment of patients assigned to this group.
89449293|NCT03313700|Active Comparator|Laparoscopic Distal Gastrectomy|Laparoscopic Distal Gastrectomy will be performed for the treatment of patients assigned to this group.
89449294|NCT05137626|Experimental|AT-527 + digoxin (simultaneous)|n=14
89449295|NCT05137626|Experimental|AT-527 + digoxin (staggered)|n=14
89449296|NCT05114226|Experimental|experimental group (BH4 solvent 50 ug/ml)|A sterile gauze was soaked with BH4 solvent (50 ug/ml), wringed out, and applied to the treated skin area for 15 minutes. It was applied three times a day (morning, noon, and evening), until three months after the end of treatment.
89449297|NCT05114226|Experimental|experimental group (BH4 solvent 100 ug/ml)|A sterile gauze was soaked with BH4 solvent (100 ug/ml), wringed out, and applied to the treated skin area for 15 minutes. It was applied three times a day (morning, noon, and evening), until three months after the end of treatment.
89449298|NCT05114226|Experimental|experimental group（BH4 solvent 200 ug/ml)|A sterile gauze was soaked with BH4 solvent (200 ug/ml), wringed out, and applied to the treated skin area for 15 minutes. It was applied three times a day (morning, noon, and evening), until three months after the end of treatment.
89449299|NCT05114226|Experimental|experimental group（BH4 solvent 400 ug/ml)|A sterile gauze was soaked with BH4 solvent (400 ug/ml), wringed out, and applied to the treated skin area for 15 minutes. It was applied three times a day (morning, noon, and evening), until three months after the end of treatment.
89449300|NCT05114226|Experimental|experimental group（BH4 solvent 600 ug/ml)|A sterile gauze was soaked with BH4 solvent (600 ug/ml), wringed out, and applied to the treated skin area for 15 minutes. It was applied three times a day (morning, noon, and evening), until three months after the end of treatment.
89449301|NCT05114226|Experimental|experimental group（BH4 solvent 800 ug/ml)|A sterile gauze was soaked with BH4 solvent (800 ug/ml), wringed out, and applied to the treated skin area for 15 minutes. It was applied three times a day (morning, noon, and evening), until three months after the end of treatment.
89449302|NCT05114226|Experimental|experimental group（BH4 solvent 1000 ug/ml)|A sterile gauze was soaked with BH4 solvent (1000 ug/ml), wringed out, and applied to the treated skin area for 15 minutes. It was applied three times a day (morning, noon, and evening), until three months after the end of treatment.
89449303|NCT03473262||EMPA|Empagliflozin 25 mg/day
89449304|NCT03473262||INS|Insulin Glargine dose-titrated
89449305|NCT02233023|Experimental|Pramixpexole|
89449306|NCT02233023|Active Comparator|Bromocriptine and other dopamine agonists|
89449307|NCT03473106|Experimental|Surgical Side|Surgical side requiring the use of a pneumatic tourniquet.
89449308|NCT03473106|No Intervention|Non Surgical Side|Contralateral side (Control Thigh).
89449309|NCT03322137|Active Comparator|SNA-120 (0.05% )|Pegcantratinib Ointment
89449310|NCT03322137|Active Comparator|SNA-120 (0.5%)|Pegcantratinib Ointment
89449311|NCT03322137|Placebo Comparator|Vehicle|
89449312|NCT03710642|Active Comparator|Treatment (Prazosin)|"Eligible participants will be randomized using a 2:1 schedule to prazosin or placebo and stratified by site and gender, and will follow a fixed titration scheme for the first 15 days, followed by a flexible does titration from days 15-29, then a maintenance phase stable dose from days 29 to the end of the 12 weeks study period.~Prazosin Fixed titration dose schedule for Days 1 to 14 1 mg QHS for Days 1 to 3~1 mg QAM and 1 mg QHS for days 4 to 7~mg QAM and 2 mg QHS for days 8 to 10~mg QAM and 2 mg QHS for days 11 to 14~Prazosin Flexible titration dose schedule for Days 15 to 29. 3 mg QAM and 3 mg QHS on day 15, 4 mg QAM and 4 mg QHS on day 22, 4 mg QAH and 6 mg QHS on day 29,~Dose increases will be allowed only during the fixed and flexible dosing periods."
89449313|NCT03710642|Placebo Comparator|Placebo oral capsule|Placebo medication will be administered in a titration schedule mimicking the active comparator treatment.
89449314|NCT04458870|Experimental|Acceptance and Commitment Therapy|
89449315|NCT02259309|Experimental|Misoprostol administration - buccal then vaginal|Vaginal or buccal administration
89449316|NCT02259309|Experimental|Misoprostol administration - vaginal then buccal|Vaginal or buccal administration
89449317|NCT04459026|Experimental|group A - combination|Group A patients will receive intra-abdominal instillation 0.75% Ropivacaine 2 mg / kg in 200 ml of NaCl through the trocars and 2) Infiltration of the surgical wounds at the trocar sites with 0.75% Ropivacaine 1 mg / kg in 20 ml of NaCl
89449318|NCT04459026|Experimental|Group B - infiltration|Group B patients will receive infiltration of the surgical wounds at the trocar sites with 0.75% Ropivacaine 3 mg / kg in 20 ml of NaCl.
89449319|NCT04459026|Active Comparator|Group C - instillation|Group C patients will receive intra-abdominal instillation 0.75% Ropivacaine 3 mg / kg in 200 ml of NaCl through the trocars.
89449320|NCT02470052|Experimental|OL-BF-001|Subjects assigned to this study will undergo a bronchoscopic procedure to have valves placed in the most diseased lobe of the lung to occlude all segments of the lobe. The subjects will also receive medical management.
89449321|NCT04286958|Experimental|Camrelizumab|All patients who had received radical concurrent chemoradiotherapy were treated with camrelizumab.
89449322|NCT03473418|Experimental|Ketoconazole gel|use of Ketoconazole in situ gel for treatment of vaginal candidiasis
89449323|NCT03473418|Active Comparator|terconazole cream|use of terconazole 0.8 cream for treatment of vaginal candidiasis
89449324|NCT03917511|Experimental|Robotic training with mirror therapy|20 minutes mirror therapy followed by 40 minutes robotic-assisted training
89449325|NCT03917511|Sham Comparator|Robotic-assisted training|20 minutes sham mirror therapy followed by 40 minutes robotic-assisted training
89449326|NCT04282278|Experimental|Group A|
89449327|NCT04282278|Experimental|Group B|
89449328|NCT04282278|Experimental|Group C|
89449329|NCT03916731|Experimental|STARgraft AV|Participants will be implanted with 6mm diameter STARgraft AV grafts as an upper arm Brachial Artery to Axillary Vein shunt for hemodialysis access.
89014660|NCT04537897|Placebo Comparator|Placebo (Part B)|Elderly participants administered matching placebo to part B once daily with 240 milliliter (mL) of water after an overnight fast of at least 10 hours (h) over a treatment period of 14 days
89449330|NCT03916731|Active Comparator|Control (ePTFE)|Participants will be implanted in the same upper arm location with standard 6mm diameter ePTFE dialysis access grafts. All other aspects of this study arm are identical to the Experimental one.
89449331|NCT00705224||Patients with chronic hepatitis C|Naïve patients with chronic hepatitis C (CHC) of any genotype will be treated with a standard treatment regimen (pegylated interferon and ribavirin) according to routine clinical practice in Russia.
89449332|NCT03267147||antiCCP positive|"Patients with a positive result in the anti-CCP quick test and positive in antiCCP ELISA will be examined by Rheumatologist for detection of RA symptoms and followed-up for 3 years or until RA diagnosis~no intervention is given"
89449333|NCT03267147||antiCCP negative|Patient with negative result in antiCCP quick test or negative antiCCP ELISA will be followed-up after one year (and 3 years for ELISA negative patients) with a short questionnaire if musculoskeletal symptoms are still present or if RA was diagnosed
89449334|NCT02457156|Experimental|Blumgart Anastomosis|"Re-construction of the pancreatic remnant following pancreatico-duodenectomy using a Blumgart method of pancreatico-jejunostomy.~Octreotide will be administered."
89449335|NCT02457156|Active Comparator|Cattell-Warren Anastomosis|"Re-construction of the pancreatic remnant following pancreato-duodenectomy using a Cattell-Warren method of pancreatico-jejunostomy.~Octreotide will be administered."
89449336|NCT03313466|Experimental|iCBTI|Intervention: An internet-based cognitive behavioral therapy program for insomnia (iCBTI) that is tailored to the individual's needs based on responses to questions.
89449337|NCT03313466|Active Comparator|Usual care|Intervention: A group class on insomnia provided at each Kaiser Permanente Southern California medical center.
89449338|NCT02470130|Active Comparator|relax actor|actor during simulation and relaxation before debriefing
89449339|NCT02470130|No Intervention|no relax actor|actor during simulation and no relaxation before debriefing
89449340|NCT02470130|Active Comparator|relax observer|observer during simulation and relaxation before debriefing
89449341|NCT02470130|No Intervention|no relax observer|observer during simulation and no relaxation before debriefing
89449342|NCT02523300|Experimental|TEVAR+GC|The patients underwent TEVAR. Then glucocorticoids will be intravenously given after TEVAR
89449343|NCT02523300|Placebo Comparator|TEVAR+Vehicle|The patients underwent TEVAR. Then saline will be given after TEVAR
89449344|NCT03313388|Experimental|Tart Cherry Juice|290 mL per day of Tart Cherry juice for 7 days
89449345|NCT03313388|Active Comparator|Gatorade|290 mL per day of Gatorade for 7 days
89449346|NCT03471546|Experimental|Palliative care|Newly diagnosed patients will be referred to a palliative care provider in the clinic for initial consultation and follow-up during their initial treatment for WHO Grade IV malignant glioma. Patients will be asked to complete a number of questionnaires and assessment forms at different time intervals during the course of their initial treatment. In addition, we will ask patients' neuro-oncology providers for feedback regarding their satisfaction with the Palliative Care services provided to the patient.
89449347|NCT04491500||study group|This is a self-control study. Subjects who plan togo to 4000m altitude to work for two weeks will be enrolled. And before and after they arrive high altitude, they will have visual acuity, OCTA, and intraocular pressure; blood pressure, blood oxygen measurement.
89449348|NCT05057871|Experimental|PEMF+exercise|A total of 20 sessions of pulse electromagnetic field therapy using an electromagnetic field device (ASA Pmt Quatro Pro, ASA Srl Via A.Volta 9-36057, Italia), five times a week and once a day for four weeks, were applied to the patients. The patients were then given a daily exercise program once a day by a physiotherapist.
89449349|NCT05057871|Sham Comparator|Sham PEMF+exercise|Sham therapy was applied in five sessions a week for four weeks, with a total of 20 sessions, with no current flowing through the device. This was followed by the exercise programs described above, performed once a day with the physiotherapist.
89014661|NCT04537897|Experimental|BI 474121 5mg (Part B)|Elderly participants administered 2 tablets of 2.5 mg BI 474121 orally once daily (daily dose: 5 mg) with 240 milliliter (mL) of water after an overnight fast of at least 10 hours (h) over a treatment period of 14 days.
89014662|NCT04537897|Experimental|BI 474121 10mg (Part B)|Elderly participants administered 1 tablet of 10 milligrams (mg) BI 474121 orally once daily with 240 milliliter (mL) of water after an overnight fast of at least 10 hours (h) over a treatment period of 14 days.
89014663|NCT04537312|Experimental|Supportive care (RNSM, surveys)|RNMS Surveys
89449350|NCT03471468|Experimental|kinetics of microparticles under chemotherapy|kinetics of microparticles under chemotherapy in patients with pancreatic or gastric cancer by serial measurements of microparticles procoagulant activity.
89014664|NCT04532541||Patients with childhood onset SLE|Participants in this group were derived from patients diagnosed with SLE at an age of less than 18 years old, and these patients were hospitalized in our center. Peripheral blood was collected from the patient and their biological parents for gene analysis to obtain the overall incidence of monogenic lupus in the cohort.
89014665|NCT04512716|Experimental|B-Cell Acute Lymphoblastic Leukemia/Diffuse Large B-Cell Lym|Participants will have relapsed or refractory B-Cell Acute Lymphoblastic Leukemia or Diffused Large B-Cell Lymphoma
89449351|NCT05278286|Experimental|Crawli Group|Participants from the Crawli Group will benefit from the crawling stimulation intervention with the crawliskate
89449352|NCT05278286|Active Comparator|Mattress Group|Participants from the Mattress Group will benefit from the tummy time intervention
89449353|NCT05278286|No Intervention|Control Group|Control group infants benefit from usual care.
89449354|NCT02325960|Active Comparator|exenatide|5 μg BID for the first 4 weeks of treatment and 10 μg thereafter
89449355|NCT02325960|Active Comparator|Insulin glargine|≥8 IU QD, and titrate based on a dosing algorithm targeting FPG <6.1 mmol/L. Titration is only allowed in first 4 weeks.
89449356|NCT03304964|Experimental|100 mg FP-025 (b.i.d)|
89449357|NCT03304964|Experimental|200 mg FP-025 (b.i.d.)|
89449358|NCT03304964|Experimental|400 mg FP-025 (b.i.d)|
89449359|NCT03304964|Experimental|200 mg FP-025 (single dose; fasted)|
89449360|NCT03304964|Experimental|200 mg FP-025 (single dose; fed condition)|
89449361|NCT03471390|Experimental|ProQuaS 2- Intervention|
89449362|NCT05265650|Experimental|Single Treatment Arm|"Treatment will consist of IT administrations of BO-112 in combination with ablative radiotherapy (SABR) and concurrent with systemic administration of nivolumab in patients with metastatic PD-1/PD-L1-refractory NSCLC.~In the initial cohort A, BO-112 will be IT injected on a weekly basis during the first cycle on the accessible lesions, and every 2 weeks thereafter. The minimum dose to be injected per visit is 1 mg (unless injected lesion in case of response, if solitary, becomes smaller than 1.5 cm) and the maximum dose is 2 mg (3.4 mL), distributed in the different lesions.~Stereotactic ablative radiotherapy (SABR) will be initiated on week 3.~In the cohort B, BO-112 and SABR will be administered as described previously.~Nivolumab will be administered at the dose of 240 mg every 2 weeks in both cohorts, starting at cycle 4 (week 7) in cohort A and at cycle 3 (week 5) in cohort B."
89449363|NCT04136730|No Intervention|Control|Usual Care
89449364|NCT04136730|Active Comparator|Home-based|Home-based resistance exercise training
89449365|NCT03313232|Experimental|Fragrance allergic patients|Patients with a previous positive patch test to oxidized R-Limonene. Patients will have an initial patch test dilution series with oxidized R-limonene performed on the back followed by twice daily exposure to oxidized R-limonene at three different concentrations and a vehicle control on the forearms for up to three weeks.
89449366|NCT03313232|Experimental|Possible fragrance allergic patients|Patients with a previous doubtful patch test to oxidized R-limonene. Patients will have an initial patch test dilution series with oxidized R-limonene performed on the back followed by twice daily exposure to oxidized R-limonene at three different concentrations and a vehicle control on the forearms for up to three weeks.
89449367|NCT03313232|Experimental|Healty controls|Healthy controls with no contact allergy to oxidized R-limonene. Healthy controls will have en initial diagnostic patch test with oxidized R-limonene performed followed by twice daily exposure to oxidized R-limonene at one concentration and a vehicle control on the forearms for up to three weeks.
89449368|NCT02234349|Experimental|pancreas kidney transplant|Patients with pancreas kidney transplantation
89449369|NCT02234349|Experimental|kidney transplant subjects|Patients with kidney transplantation
89014666|NCT04506190||Robotic-assisted revisional bariatric surgery|Subjects who undergo robotic-assisted revisional bariatric surgery
89449370|NCT02234349|No Intervention|Control|
89023554|NCT05157919|No Intervention|Control|Usual care continues. The caregiver will not get to use the app. The caregiver will be asked daily measures and the patient will be asked about thirst and anxiety daily when the patient is awake enough to answer these questions. The caregiver will be asked questions at 3 different times: Day 1, 24-48 hours after enrollment, and 2-4 weeks after the patient is discharged from the ICU.
89449371|NCT03304886||Migraineurs|with a migraine
89449372|NCT03304886||Control|Participants without migraine
89449373|NCT02234505|Experimental|Trans-tibial prosthesis users|prosthetic alignment perturbation
89449374|NCT03304808|Experimental|device|
89449375|NCT03304808|Active Comparator|behavioral|
89449376|NCT03304808|No Intervention|waiting list|
89449377|NCT04458636|Active Comparator|Standard care|Blinded prednisolone 30mg orally once per day for 14 days
89449378|NCT04458636|Placebo Comparator|Biomarker care|Blinded prednisolone 30mg orally once per day for 14 days if peripheral eosinophil count is equal or greater than 2%. Placebo equivalent if peripheral blood eosinophil count is <2%.
89449379|NCT02469350|Experimental|Rehabilitation with serious game|18 rehabilitation sessions with serious game during a 6-8 weeks period
89449380|NCT05000619|Experimental|Outreach Postcard|This group receives a postcard with a stock image on the front and a message encouraging regular visits to manage health on the back.
89449381|NCT05000619|Experimental|Humorous Postcard|This group receives a postcard with with a cartoon image and a visit-related joke on the front and a humorous message on the back, with additional information about why visits are important, and what to expect at the appointment.
89449382|NCT05000619|Experimental|Physician Letter|This group receives a personalized letter signed by a physician with information about why visits are important, and what to expect at the appointment.
89449383|NCT05000619|No Intervention|No-contact Control|This group will not receive a study mailer during the trial.
89449384|NCT03898323|Experimental|AABM Training|Alcohol Approach Bias Modification (AABM) training is a computer training program that participants interact with by pushing and pulling a joystick. Participants are asked to respond to the format of a presented picture, irrespective of the pictures' content. Training effect is achieved by presenting alcohol pictures in push format only and non-alcoholic drinks in pull format only. AABM training consists of 3 sessions per week over 2 weeks, for a total of 6 sessions.
89449385|NCT02722148|Experimental|Enrolled Patients|All enrolled subjects will receive a novel allergen-specific immune signature directed approach to dietary elimination therapy
89449386|NCT03471312||treated with magnesium therapy|will receive magnesium sulphate 10 mg \kg \day as a single oral dose for one month duration
89449387|NCT03471312||treated with placebo drug|will receive placebo drug
89449388|NCT03162783|Experimental|ADX-102 Ophthalmic Solution (0.5%)|
89449389|NCT03162783|Experimental|ADX-102 Ophthalmic Solution (0.1%)|
89449390|NCT03162783|Experimental|ADX-102 Ophthalmic Lipid Solution (0.5%)|
89449391|NCT02523144|Active Comparator|Chloral Hydrate + placebo|Oral chloral hydrate sedation in flavored syrup plus nasal saline placebo
89449392|NCT02523144|Active Comparator|Dexmedetomidine 2mcg/kg + placebo|Nasal dexmedetomidine sedation 2 mcg/kg plus oral flavored syrup placebo
89449393|NCT02523144|Active Comparator|Dexmedetomidine 3mcg/kg + placebo|Nasal dexmedetomidine sedation 3 mcg/kg plus oral flavored syrup placebo
89449394|NCT03304574|No Intervention|Control|Participants will complete the electronic health assessment only and will not receive integrated personalized feedback
89449395|NCT03304574|Experimental|Intervention|Participants will complete the electronic health assessment and will receive integrated personalized feedback
89449396|NCT02469272|Experimental|Fecal Microbiota Transplantation|Intervention: standardized preparation of frozen fecal material from lean healthy donors Route: infused into the duodenum through the working channel of the instrument at upper endoscopy Dosing: 1 dose
89449397|NCT05154942|Experimental|DOXO+electroacupuncture|EA is given every day for the first three days before DOXO pumping, and EA is given when DOXO is pumped for 30 minutes each time
89449398|NCT05154942|No Intervention|Non-electroacupuncture|Compared to the experimental group without EA treatment
89449399|NCT03894306||medication lock box + brief counseling|
89449400|NCT03894306||medication lock bag + brief counseling|
89449401|NCT03894306||brief counseling alone|
89449402|NCT00704132|Experimental|sitagliptin|Participants randomized to this arm will be administered sitagliptin 100mg daily, for six weeks.
89449403|NCT00704132|Placebo Comparator|Placebo|Participants randomized to this arm will be administered matching placebo, daily for six weeks.
89449404|NCT04900545||beta blocker navie patients with acute coronary syndrome|
89449405|NCT03304496|Experimental|Nitroglycerin|"The intervention group will receive a subcutaneous cocktail with 0,5 ml of 500 mcg of nitroglycerin + 1 ml of 2% simple lidocaine."
89449406|NCT03304496|Placebo Comparator|Control|The placebo group will receive a subcutaneous injection with 0,5 ml of 0,9% saline solution + 1 ml of 2% simple lidocaine.
89449407|NCT03313154||Neuropsychiatric screening (treatment+)|Subjects affected by chronic hepatitis HCV-related, undergoing new antiviral drugs treatment, will be screened by psychiatric and neuropsychological questionnaires/tests
89449408|NCT03313154||Neuropsychiatric screening (treatment-)|Subjects affected by chronic hepatitis HCV-related, in wait list for new antiviral drugs treatment, will be screened by psychiatric and neuropsychological questionnaires/tests
89449409|NCT03128853|Experimental|Test subjects|Each subject receives the Rad-67 and DCI Mini sensor that will measure hemoglobin repeatedly in order to compare those measurements against a blood sample reference.
89449410|NCT02469428|Sham Comparator|Clean air|Exposure to clean air will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus.
89449411|NCT02469428|Experimental|Ozone|Exposure to ozone will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus.
89449412|NCT03643146|Experimental|Wedge 1- Step 1|
89449413|NCT03643146|Experimental|Wedge 1-Step 2|
89449414|NCT03643146|Experimental|Wedge 1-Step 3|
89449415|NCT03643146|Experimental|Wedge 1-Step 4|
89449416|NCT03643146|Experimental|Wedge 1-Step 5|
89449417|NCT03643146|Experimental|Wedge 2- Step 1|
89449418|NCT03643146|Experimental|Wedge 2-Step 2|
89449419|NCT03643146|Experimental|Wedge 2-Step 3|
89449420|NCT03643146|Experimental|Wedge 2-Step 4|
89449421|NCT03643146|Experimental|Wedge 2-Step 5|
89449422|NCT03643146|Experimental|Wedge 3-Step 1|
89449423|NCT03643146|Experimental|Wedge 3- Step 2|
89449424|NCT03643146|Experimental|Wedge 3- Step 3|
89449425|NCT03643146|Experimental|Wedge 3- Step 4|
89449426|NCT03643146|Experimental|Wedge 3- Step 5|
89449427|NCT03643146|Experimental|Wedge 4-Step 1|
89449428|NCT03643146|Experimental|Wedge 4- Step 2|
89449429|NCT03643146|Experimental|Wedge 4-Step 3|
89449430|NCT03643146|Experimental|Wedge 4-Step 4|
89449431|NCT03643146|Experimental|Wedge 4-Step 5|
89449432|NCT03312998|Experimental|Xrays|
89449433|NCT04897035|Experimental|Subjects with Lower Extremity Lymphedema and phlebolymphedema|Lower Extremity Lymphedema and phlebolymphedema
89449434|NCT03304340|Experimental|TENS+SR|For each participant in the transcutaneous nerve stimulation (TENS) group, standard rehabilitation (SR) in addition a TENS stimulator (BioTENS, Skylark Device & Systems Co., Ltd) was applied with 0.2-ms pulses at 100 Hz in the constant mode within the subject's sensory level without muscle contraction via (5 × 3.5 cm) electrodes attached to the motor points of the tibia anterior (TA) and quadriceps muscles on the affected lower extremity. For the TENS group, the given electric stimulation treatment lasted for 30 min per session, once per day, 5 days a week, for 2 weeks.
89449435|NCT03304340|Experimental|FES + SR|For each participant in the functional electrical stimulation (FES) group, standard rehabilitation (SR) in addition two dual-channel FES stimulators (MEDTRONIC Respond Select; EmpiInc) were used. The FES was delivered with 0.3-ms pulses at 30 pps and the stimulation intensity was set to the movement threshold to induce visible muscle contractions. For the FES group, the given electric stimulation treatment lasted for 30 min per session, once per day, 5 days a week, for 2 weeks.
89449436|NCT03304340|Active Comparator|SR-only|All the participants received functional training and motor relearning physiotherapy treatment as early standard rehabilitation (SR) for 30 minutes per day, 5 days a week throughout the study. Subjects in the SR group received only SR .
89449437|NCT03527238|Active Comparator|Standard of Care|Standard of Care Tacrolimus Drug Dosing
89449438|NCT03527238|Experimental|Phenotypic Precision Medicine (PPM)|PPM-based Computation Assisted Drug Dosing
89449439|NCT02469506|Experimental|NMES group|Patients will receive twice daily sessions of neuromuscular electrical stimulation (NMES).
89449440|NCT02469506|No Intervention|Control group|Patients will receive daily visits by the investigator to check progress.
89449441|NCT03832179|Active Comparator|Anti-vascular endothelial growth factor|Intravitreal Bevacizumab, Ranibizumab, or Aflibercept
88934385|NCT01768546|Experimental|Video on Demand Plus (VOD+)|Virtual Diabetes Prevention Program: All participants will view the 16 Comcast on Demand episodes, weigh themselves, and track their progress weekly. Participants in the VOD+ arm of the trial received access an interactive tracking and problem solving web portal offered by SparkPeople™ (Cincinnati, Ohio).
88934386|NCT01768585|Active Comparator|Ivabradine|Drug: Ivabradine bid administration of 7.5mg ivabradine Other Name: Procoralan, I(f)-inhibitor
88934387|NCT01768585|Placebo Comparator|Placebo|Drug: Placebo bid placebo Other Name: Placebo control
89449442|NCT03832179|Experimental|Ozurdex|Intravitreal Ozurdex
89449443|NCT03312764|Experimental|Online Diabetes Prevention Program|Participants will receive access to a 12-month online diabetes prevention program modeled after the CDC DPP curriculum. Participants in the online program receive paced curriculum, access to a live health coach, interactive group message forums, and connected weight scale and activity monitoring devices.
89449444|NCT03312764|Active Comparator|Enhanced Standard Care|All participants randomized to the standard-care/control group (SC) will be offered the opportunity to attend a single 90-minute diabetes prevention class with a trained health professional (MPH, RD, or related advanced degree). The class will focus on healthful eating based on the current MyPlate recommendations, guidance on gradual increases in moderate intensity physical activity, and action planning to be shared with friends and/or family. Control participants will also be given the opportunity to participate in the online digital intervention upon completion of the 12-month follow-up assessment.
89449445|NCT05154630|Experimental|TQB2858 injection|Participants will receive 3 mg/60 mg/600 mg/1200 mg/1800 mg single dose of TQB2858 injection on Day 1, iv (injection of vein), once every three weeks.
89449446|NCT03312608||mild myelopathy (JOA>12)|40 patients (JOA>12) suffering from symptomatic or asymptomatic degenerative cervical myelopathy scheduled for surgery or conservative treatment. The radiological inclusion criteria are cervical spinal stenosis associated with or without intramedullary high signal intensity lesion on T2-weighted MRI. Exclusion criteria are other pathologies in the vicinity of the corticospinal tract above the lesion site (i.e. tumor, infarction), neuroinflammatory disease, high grade paresis of the upper extremity (BMRC<3), the existence of a cardiac pacemaker, deep brain stimulation electrodes or pregnancy. By means of navigated transcranial magnetic stimulation the resting motor threshold, recruitment curve, cortical silent period and motor area will be determined.
89449447|NCT03312608||moderate myelopathy|40 patients (JOA≤12) suffering from symptomatic degenerative cervical myelopathy scheduled for surgery (anterior and/ or posterior decompression) or conservative treatment. The radiological inclusion criteria are cervical spinal stenosis associated with or without intramedullary high signal intensity lesion on T2-weighted MRI. Exclusion criteria are other pathologies in the vicinity of the corticospinal tract above the lesion site (i.e. tumor, infarction), neuroinflammatory disease, high grade paresis of the upper extremity (BMRC<3), the existence of a cardiac pacemaker, deep brain stimulation electrodes or pregnancy. By means of navigated transcranial magnetic stimulation the resting motor threshold, recruitment curve, cortical silent period and motor area will be determined.
88934388|NCT01768598||Fracture - Boys|Boys who have sustained a distal radius fracture
88934389|NCT01768598||Fracture - Girls|Girls who have sustained a distal radius fracture
88934390|NCT01768598||Non Fracture - Boys|Boys who have not sustained a distal radius fracture
88934391|NCT01768598||Non Fracture - Girls|Girls who have not sustained a distal radius fracture
88934392|NCT01768611||Withou Diabetic Nephropathy|Patients who have persistent normoalbuminuria (<30 mg/g creatinine or <20 μg/min).
88934393|NCT01768611||Incipient Nephropathy|Patients who have persistent microalbuminuria (30-300 mg/g creatinine or 20-200 μg/min).
88934394|NCT01768611||Overt Diabetic Nephropathy|Patients who have persistent macroalbuminuria (>300 mg/g creatinine or >200 µg/min), proteinuria (>500 mg/24 h) or renal replacement therapy.
88934395|NCT01768624||Stage 5 chronic kidney disease|Patients receiving home hemodialysis Patients receiving home peritoneal dialysis Patients receiving center-based hemodialysis Patients who had a pre-emptive kidney transplant Patients who planned for renal conservative care
88934396|NCT01768650|Experimental|Self-Management #2|Self-Management #2 will consist of eight 60-minute sessions conducted by phone over eight weeks (1 session/week on average). The sessions will cover a variety of topics, including: (1) the definition of chronic pain, (2) the physiological processes underlying chronic pain, (3) common pain-related conditions such as sleep and mood disturbance (including posttraumatic stress disorder, due to its prevalence among Veterans), (4) the potential effects of chronic pain on activity level, (5) communication (including communication with healthcare providers), and (6) the role of social support in managing pain.
88934397|NCT01768650|Experimental|Self-Management #1|Self-Management #1 will consist of eight 60-minute sessions conducted by phone over eight weeks. Sessions will include: (1) education about the role of cognitions and pain beliefs (including control) in chronic pain and adjustment; (2) instruction in how to identify negative thinking and cognitive distortions about pain; (3) instruction in thought-stopping and cognitive-restructuring techniques, including challenging negative thoughts and core beliefs about pain; (4) instruction in utilization of positive coping self-statements; (5) relaxation techniques; (6) activity pacing and scheduling; (7) coping with pain flare-ups; and (8) relapse prevention/maintenance of gains. Most sessions will include a brief relaxation exercise introduced over the phone.
88934398|NCT01768663|Experimental|Treatment Group (Cohort 1)|Subjects will take lumacaftor in combination with ivacaftor for 14 days. Beginning on Day 15, subjects will take lumacaftor in combination with ivacaftor and ciprofloxacin through Day 21.
89449448|NCT03312608||healthy control|As a control group, 40 subjects will be included into the study. Exclusion criteria and examination protocol are identical with the patient group. By means of navigated transcranial magnetic stimulation the resting motor threshold, recruitment curve, cortical silent period and motor area will be determined.
89449449|NCT05154396|Experimental|Neratinib escalation 2 weeks（group A）|Neratinib: 120mg/ day for days 1-7, 160mg/ day for days 8-14, and then 240mg/ day to complete 1-year treatment, or to tumor recurrence and metastasis, new breast cancer, or unacceptable adverse reactions within 1 year.
89449450|NCT05154396|Experimental|Neratinib escalation 4 weeks（group B）|Neratinib: 160mg/ day for days 1-14, 200mg/ day for days 15-28, and then 240mg/ day for 1 year, or to tumor recurrence and metastasis, new breast cancer, or unacceptable adverse reactions within 1 year.
89449451|NCT05154396|Placebo Comparator|Neratinib standard dose control （group C）|"Neratinib: 240mg/ day for 1 year, or to tumor recurrence and metastasis, new breast cancer or unacceptable adverse reactions within 1 year.~Loperamide prophylaxis: 4mg three times daily on days 1-14 and 4mg twice daily on days 15-56, followed by as needed, not exceeding 16mg/ day."
89449452|NCT03185234|Active Comparator|Real tDCS|Anodal tDCS at an intensity of 2 mA is applied for 10 minutes at a time on 5 consecutive days. The anodal electrode is placed over the left parietal cortex (P3 in 10/20 EEG) of the lesioned hemisphere, the cathodal electrode is located supraorbital on the right side. Motor tasks are performed before and after the stimulation.
89449453|NCT03185234|Sham Comparator|Sham tDCS|Sham stimulation is applied for 10 minutes at a time on 5 consecutive days. One electrode is placed over the left parietal cortex (P3 in 10/20 EEG) of the lesioned hemisphere and a second electrode supraorbital on the right side. Motor tasks are performed before and after the stimulation.
89449454|NCT02259387||Cases|Children with migraines will be placed into this group.
89449455|NCT02259387||Controls|Children without migraines or headaches will be placed into this group.
89449456|NCT02600130|Experimental|Cohort 1|Cohort 1 (10 subjects) Target dose 20 million Longeveron Mesenchymal Stem Cells (LMSCs) via peripheral intravenous infusion.
89449457|NCT02600130|Experimental|Cohort 2|Cohort 2 (10 subjects) Target dose 100 million Longeveron Mesenchymal Stem Cells (LMSCs)via peripheral intravenous infusion.
89449458|NCT02600130|Placebo Comparator|Cohort 3|Cohort 3 (5 subjects) Placebo (Plasmalyte A and 1% human serum albumin (HSA)) via peripheral intravenous infusion.
89449459|NCT03303872||AF-pacemaker registry|
89449460|NCT04740645||NOCDURNA cohort|
89449461|NCT04740645||Lower urinary tract symptoms (LUTS) Cohort|
89449462|NCT02553876||Observational|All patients referred with pain in the hand and/or upper limb will be evaluated. Patients will first be assessed for suitability for neurostimulation implantation and then included in the study. Patients wiil fill in questionnaires (pain scores, Quality of Life and satisfaction) at baseline and post-operatively at regular intervals (as per standard of care in the Netherlands.)
89449463|NCT03312452|Experimental|Infusion pump group|Study subjects assigned to this group will receive intravenous fluid via an infusion pump (Hospira plum pump) during their surgery.
89449464|NCT03312452|Active Comparator|Gravity drip group|Study subjects assigned to this group will receive intravenous fluid via a gravity drip device during their surgery.
89449465|NCT02497248||- Patients with paroxysmal AF.|Patients with AF episodes that terminates spontaneously or with intervention in less than seven days with clinical indication of pulmonary vein ablation.
89449466|NCT02497248||- Patients with persistent AF.|Patients with AF episodes that fails to self-terminate within seven days or require pharmacologic or electrical cardioversion to restore sinus rhythm with clinical indication of pulmonary vein ablation..
89449467|NCT02497248||- Patients with mitral stenosis.|- Patients with mitral stenosis and clinical indication for AF ablation undergoing percutaneous balloon mitral valvuloplasty (PBMV) with clinical indication of pulmonary vein ablation..
89449468|NCT04441970|Active Comparator|Neutral position|General anesthesia will be induced and nasotracheal tube will be placed through the patient's nose. After 30 seconds, the cuff pressure will be measured using a cuff manometer. Inspiratory tidal volume, expiratory tidal volume, peak inspiratory pressure, and end-tidal carbon dioxide waveform will be recorded three times according to breathing. Whether ventilation is not adequate and air is leaking will be recorded.
89449469|NCT04441970|Experimental|Head extension position|After changing the posture of the head and neck into head extension, cuff pressure will be recorded.
89449470|NCT04441970|Experimental|Head flexion position|After changing the posture of the head and neck into head flexion, cuff pressure will be recorded.
89449471|NCT04441970|Experimental|Head rotation position|After changing the posture of the head and neck into head rotation, cuff pressure will be recorded.
88934399|NCT01768663|Experimental|Treatment Group (Cohort 2)|Subjects will take lumacaftor in combination with ivacaftor for 14 days. Beginning on Day 15, subjects will take lumacaftor in combination with ivacaftor and itraconazole through Day 21.
89449472|NCT04458480||Exposed Group|Both exposed group and control group are undertaken TKA surgery and routine postoperative management for 2 days in orthopedics department. Exposed group patients are transferred from orthopedics department to rehabilitation department on 2nd day after TKA, and accept fast inpatient rehabilitation for 1 week before hospital discharge, while control group patients continue to accept routine peri-operative management and conventional oral instructions of exercises in orthopedics department until hospital discharge.
89449473|NCT04458480||Control Group|Both exposed group and control group are undertaken TKA surgery and routine postoperative management for 2 days in orthopedics department. Exposed group patients are transferred from orthopedics department to rehabilitation department on 2nd day after TKA, and accept fast inpatient rehabilitation for 1 week before hospital discharge, while control group patients continue to accept routine peri-operative management and conventional oral instructions of exercises in orthopedics department until hospital discharge.
89449474|NCT02802813|Active Comparator|Intervention arm|Dihydroartemisinin-piperaquine (DP) therapy plus 14 days of supervised primaquine (7mg/kg total dose) administered once per day (0.5 mg/kg).
89449475|NCT02802813|Placebo Comparator|Control arm|Dihydroartemisinin-piperaquine therapy plus 14 days identical placebo not containing primaquine.
89449476|NCT03312374||stage II CRC|Patients with stage II colorectal cancer
89449477|NCT03312374||stage III CRC|Patients with stage III colorectal cancer
88934400|NCT01768663|Experimental|Treatment Group (Cohort 3)|Subjects will take lumacaftor in combination with ivacaftor for 14 days. Beginning on Day 15, subjects will take lumacaftor in combination with ivacaftor and rifampin through Day 24.
88934401|NCT01768663|Experimental|Treatment Group (Cohort 4)|Subjects will take a single dose of lumacaftor in combination with ivacaftor on 3 occasions separated by 7 days.
88934402|NCT01768689|No Intervention|Run-in period|First 3 months of study during which adherence will be measured for each consecutively included study subject, but no intervention will be performed. Patient will receive routine treatment for CML according to the physician discretion.
89449478|NCT05134584|Experimental|linaclotide|Patients in linaclotide group were given with oral, once daily 290 μg linaclotide for consecutively 4 weeks, along with once daily 20 mg omeprazole, three times daily 50 mg Itopride, for the first ten days of the treatment.
89449479|NCT05134584|Active Comparator|lactulose|Patients in Lactulose group were given with oral, once daily 20 mL Lactulose for 4 weeks, along with once daily 20 mg omeprazole, three times daily 50 mg Itopride, for the first ten days of the treatment.
89449480|NCT02468960|Other|OPN strategy (study group)|"Interventions planned in this arm are as follows:~Predilatation with OPN NC balloon catheter.~Absorb BVS implantation.~Treated segment visualization by OCT.~Clinical FU at 12 months."
89449481|NCT02468960|Other|Standard strategy (control group)|"Interventions planned in this arm are as follows:~Predilatation with standard compliant balloon.~Absorb BVS implantation.~Treated segment visualization by OCT.~Clinical FU at 12 months."
89449482|NCT03792555|Experimental|Paltusotine|
89449483|NCT03792555|Placebo Comparator|Placebo|
89449484|NCT01811862|Experimental|Acupuncture|Acupuncture treatment once daily inpatient for 5 consecutive days starting at on the day after chemotherapy plus usual pre- and post-transplantation care.
89014667|NCT04499937|Experimental|Streak incentive|Subjects start with no money in an account, but they earn a fixed amount with each response. In this arm, each adult report is worth $3.17 so an adult subject can earn up to $200 if he/she responds to all surveys. If an adult completes at least 75% of the reports, he/she will receive an $100 bonus for a total maximum of $300. In this arm, each child report is worth 0.52 cents so a child subject can earn up to $33 if he/she responds to all surveys. If a child completes at least 75% of the reports, he/she will receive a $17 bonus for a total maximum of $50.
89014668|NCT04499937|Experimental|Loss-based incentive|Subjects start with the maximum possible compensation, but money is deducted for each missed response. Adult subjects will lose $4.76 for each missed survey. Child subjects will lose $0.79 for each missed survey.
89449485|NCT01811862|Sham Comparator|Sham acupuncture|Sham acupuncture once daily inpatient for 5 consecutive days starting at on the day after chemotherapy plus usual pre- and post-transplantation care.
89449486|NCT05095610||Adult Type 1 Diabetes|"All adult patients with type 1 diabetes previously followed in the DIACAM study (see bellow reference).~Sastre J, Pinés PJ, Moreno J, Aguirre M, Blanco B, Calderón D, Herranz S, Roa C, Lopez J; Grupo de estudio DIACAM 1. Metabolic control and treatment patterns in patients with type 1 diabetes in Castilla-La Mancha: the DIAbetes tipo 1 in Castilla La Mancha study. Endocrinol Nutr. 2012 Nov;59(9):539-46. doi: 10.1016/j.endonu.2012.07.003."
89449487|NCT05633277|Active Comparator|Arm 1: Combination Sclerotherapy & Ablation|"Standard Practice:~Arm 1 will be patients receiving sclerotherapy and ablation at the start of treatment along with compression therapy. The patients in arm 1 will not receive any further treatment during the duration of the study."
89449488|NCT05633277|Experimental|Arm 2: Sclerotherapy Only|"Experimental Timeline:~Arm 2 will be patients who receive sclerotherapy at the start of treatment along with compression therapy, and ablation 3 months later. All patients in arm 2 will receive ablation at their 3 month appointment. After ablation, the patients in arm 2 will not receive any further treatment for the remainder of the study."
89449489|NCT03469830|Experimental|SSCP & SPMS|"The smart scar care pad (SCCP):~The SCCP is a newly invented insert material that can maximise treatment outcomes via enhanced compression and occlusion. The wearing regime for SCCP is 4 hours a day for the first day, with 2-hour increments added every other day until the total wearing time reached 23 hours. SSCP was cleaned twice a day for hygienic reasons.~The smart pressure monitored suit(SPMS):~The SPMS is a type of custom-made pressure garment. SPMS was used 23 hours a day and only removed when showering."
89449490|NCT03469830|Active Comparator|SPMS|"The smart pressure monitored suit(SPMS):~The SPMS is a type of custom-made pressure garment. SPMS was used 23 hours a day and only removed when showering."
89014669|NCT04499937|Active Comparator|Flat-fee control status quo condition|Subjects will receive the maximum possible compensation at the end of the study regardless of response rate.
89014670|NCT04499937|Active Comparator|Flat-Fitbit control status quo condition|Subjects will be compensated by keeping the Fitbit at the end of the study regardless of response rate.
89449491|NCT04490954|Other|Patients examined with MRI/CT|
89449492|NCT04490954|Other|Patients examined with biological electrical impedance|
89449493|NCT04458402|Experimental|Hypofractionated Whole-Pelvis Radiotherapy|Hypofractionated WPRT Cohort 1: 41.25 Gy in 15 fx Cohort 2: 38 Gy in 10 fx
89449494|NCT03312140|Other|Choline Chloride|Patients receive choline chloride (1g Choline) three times a day for 12.6 weeks as a food supply
89449495|NCT03469752|Experimental|Intervention group|8 weekly education sessions 2.5 hours
89449496|NCT03469752|No Intervention|Wait-list control group|No education sessions
89449497|NCT03303638|Other|Multi-sensory Environment during bathing|The MSE intervention will be provided by an interactive waterproof fiber optic kit that includes: a light-emitting diode (LED) wall-washer light, a waterproof fiber optic cable that can be controlled by a waterproof switch held by the participant while bathing, showering, and or tub bathing, and a mobile MSE cart. The wall-washer LED light creates the illusion that the room is painted a variety of bright colors that can be changed by the veteran being bathed. The mobile MSE cart includes an LED solar projector providing visual sensory stimulation by projecting scenes on the wall, an aroma therapy diffuser and a portable bubble tube to create positive distraction during the bathing process.
89449498|NCT02233179|Experimental|Removable Cast Walker|An offloading device that can be removed by the patients
89449499|NCT02233179|Active Comparator|Irremovable Cast Walker|A removable cast rendered irremovable using instant total contact cast, so patients cannot remove offloading device.
89449500|NCT03312062|Experimental|Foam Rolling Group|The participants in this group will receive foam rolling exercise.
89014671|NCT04489147|Active Comparator|metformin|Group A ( involve 200 patients ) will receive metformin 850 mg twice daily along the cycle of ICSI
89014672|NCT04489147|No Intervention|No Metformin|Group B ( involve 200 patients) will not receive metformin
89014673|NCT04478695|Experimental|Cohort 1|
89014674|NCT04478695|Experimental|Cohort 2|
89014675|NCT04458194|Active Comparator|Standard Care|Cancer survivors receive their standard care
89014676|NCT04458194|Experimental|YOCAS|Cancer survivors receive 8 virtual yoga sessions (75 minutes/session, 2 times a week for 4 weeks) delivered via an electronic platform (e.g., Zoom)
89014677|NCT04450927||1|Data collection and treatment according to guidelines of standard of medical evaluation and care. No investigational treatments or procedures will be administered on this protocol.
89014678|NCT04432493|Experimental|Active TMS - OUD|Participants in the opioid used disorder group (OUD) in the active condition will receive repetitive TMS (rTMS), delivered at 110% of participants' resting motor threshold at 10 Hz continuously over the predefined DLFPC target for a total of 2000 pulses
89014679|NCT04432493|Placebo Comparator|Sham TMS - OUD|Identical parameters will be applied to the opioid used disorder (OUD) SHAM group with the exception that the TMS coil will be flipped 180º to mimic auditory stimulation
89014680|NCT04432493|Active Comparator|Active TMS - HC|Healthy Control (HC) participants in the active condition will receive repetitive TMS (rTMS), delivered at 110% of participants' resting motor threshold at 10 Hz continuously over the predefined DLFPC target for a total of 2000 pulses
89014681|NCT04432493|Sham Comparator|Sham TMS - HC|Identical parameters will be applied to the healthy control (HC) SHAM group with the exception that the TMS coil will be flipped 180º to mimic auditory stimulation
89014682|NCT04431232|Experimental|Band Ligation|Band ligation of gastric body for weight loss
89449501|NCT03312062|No Intervention|Control Group|The participants in this group will receive no foam rolling. They will only be evaluated.
89014683|NCT04420884|Experimental|Part 1 (Monotherapy Dose Escalation Phase): Dazostinag Safety Lead-in + Dazostinag SA [Part 1A]|"Safety Lead-in: Dazostinag 0.1 mg, infusion, intravenously (IV), once weekly, on Days 1, 8 and 15 in 21-day treatment cycles.~Dazostinag single agent (SA) Dose Escalation (Part 1A): Dazostinag SA, infusion, IV, once weekly on Days 1, 8 and 15 in each 21-day treatment cycles with escalating doses (0.2 mg and above). The dosing will be initiated in the Dazostinag SA Dose Escalation Phase based on the available safety and tolerability data from the Safety Lead-in."
89449502|NCT03303482|Experimental|Intervention Group|
89449503|NCT03303482|No Intervention|Waitlist Control Group|
89449504|NCT03759795|Experimental|Intervention Group|Acceptance and Commitment Training (ACTr)
89449505|NCT03759795|No Intervention|Wait-list control|No intervention during trial. Participants in this group will be offered the training once the study is complete.
89449506|NCT05159154||Septic Shock Patients|Patients admitted with diagnosis of septic shock
89449507|NCT03311984||LMWH qd|receiving Low-molecular-weight Heparin（LMWH）qd
89449508|NCT03311984||LMWH q12h|receiving Low-molecular-weight Heparin（LMWH）q12h
89449509|NCT03311906|Experimental|Test side|Scaling and Root Planing 0.8% Hyaluronic acid gel
89449510|NCT03311906|Active Comparator|Control Side|Scaling and Root Planing
89449511|NCT04458246|Experimental|Intervention|10 patients from each chronic diseases conditions (1- Inflammatory bowel disease; 2- autoimmune hepatitis; 3- liver transplant; 4- renal transplant; 5- systemic lupus erythematosus; 6- juvenile dermatomyositis; 7- juvenile idiopathic arthritis) will receive an online home-based aerobic training, three times a week, during 3 months.
89449512|NCT04458246|No Intervention|Control|10 patients from each chronic diseases conditions (1- Inflammatory bowel disease; 2- autoimmune hepatitis; 3- liver transplant; 4- renal transplant; 5- systemic lupus erythematosus; 6- juvenile dermatomyositis; 7- juvenile idiopathic arthritis) will be advised to maintain their daily routine.
89449513|NCT02259465|Active Comparator|Oligofructose|Participants will be asked to follow the low FODMAP diet for a week, supplementing the diet with oligofructose, 7grams twice daily
89449514|NCT02259465|Placebo Comparator|Maltodextrin|Participants will be asked to follow the low FODMAP diet for a week, supplementing the diet with maltodextrin, 7grams twice daily
89449515|NCT03303326|Experimental|Immediate Interview|A 60-minute interview about women's health conducted immediately after baseline questionnaires.
89014684|NCT04420884|Experimental|Part 1B (Combination Dose Escalation Phase): Dazostinag + Pembrolizumab|Dazostinag escalating doses (0.2 mg and above) in combination with pembrolizumab 200 mg, infusion, IV, once weekly on Days 1, 8 and 15 in each 21-day treatment cycle. Pembrolizumab 200 mg will be administered 1 hour prior to Dazostinag once every 3 weeks (Q3W). The dosing will be initiated when at least two dose levels (DLs) of Part 1A have been evaluated.
89206119|NCT00821106|Experimental|Right transradial approach|Coronary diagnostic or interventional procedures performed through right radial approach
89449516|NCT03303326|No Intervention|Delayed Interview|The interview is conducted after the follow-up questionnaires are completed, rather than after baseline.
89449517|NCT03311750|Experimental|Panitumumab|On day 1 of each cycle patients will receive panitumumab followed by 5-fluorouracil and leucovorin in combination with either irinotecan (FOLFIRI regimen) or oxaliplatin (FOLFOX regimen) or followed by irinotecan monotherapy. This treatment will be repeated every 2 weeks for FOLFIRI and FOLFOX regimens and every 3 weeks for irinotecan monotherapy.
89449518|NCT04911972||Functional muscle transfer group|Patients who have undergone functional muscle transfer to restore function after tumour surgery or injury, in which the tumour surgery or injury has resulted in functional loss.
89449519|NCT04911972||Non-functional muscle transfer group|Patients who have not undergone functional muscle transfer to restore function after tumour surgery or injury, in which the tumour surgery or injury has resulted in functional loss.
89449520|NCT03311672|Experimental|Cohort 1 - Immunotherapy Alone|Approximately 10 patients will be enrolled in the immunotherapy alone cohort under a larger two-year industry-funded, investigator-initiated single-institution, phase II, open-label clinical trial (NCT03217071; Pembrolizumab With and Without Radiotherapy for Non-Small Cell Lung Cancer) in which patients with stage I-IIIA non-small cell lung cancer (NSCLC) are randomized to receive two cycles of systemic immunotherapy (pembrolizumab, a PD-1 inhibitor) with or without immune-priming stereotactic radiation therapy (SRT, 12 Gy) to the lateral half of the primary lung tumor prior to resection.
89449521|NCT03311672|Experimental|Cohort 2 - Immunotherapy with Stereotactic Radiation|Approximately 10 patients will be enrolled in the immunotherapy with stereotactic radiation therapy cohort under a larger two-year industry-funded, investigator-initiated single-institution, phase II, open-label clinical trial (NCT03217071; Pembrolizumab With and Without Radiotherapy for Non-Small Cell Lung Cancer) in which patients with stage I-IIIA non-small cell lung cancer (NSCLC) are randomized to receive two cycles of systemic immunotherapy (pembrolizumab, a PD-1 inhibitor) with or without immune-priming stereotactic radiation therapy (SRT, 12 Gy) to the lateral half of the primary lung tumor prior to resection.
89449522|NCT03303014|Experimental|5-0 Prolene|Half of the wound will be treated with 5-0 prolene
89014685|NCT04420884|Experimental|Japan Safety Lead-in Dazostinag ± Pembrolizumab|"Dazostinag 5.0 mg, infusion, IV, once on Day 1 in Cycle 0 (cycle length=7 days) in Japanese participants with advanced or metastatic solid tumors. Following the 7-day Cycle 0, participants who do not develop any DLT in Cycle 0 will be administered Dazostinag on Days 1, 8, and 15 of a 21-day cycle in combination with pembrolizumab administered Q3W, IV, in Cycle 1. If no DLTs are observed, study treatment will start with Dazostinag in combination with pembrolizumab administered on Day 1 of each 21-day treatment cycle.~Additional dose levels of Dazostinag (such as 3.5 mg or 7.0 mg and higher) in combination with pembrolizumab (200 mg, Q3W) may be explored in the Safety Lead in."
89014686|NCT04420884|Experimental|Part 2A (SCCHN CPS ≥ 1 Dose Expansion and Optimization Phase): Dazostinag + Pembrolizumab|Dazostinag 5.0 mg, infusion, IV, will be administered in participants with squamous cell carcinoma of head and neck (SCCHN) at the identified dose level from Part 1 on Days 1, 8, and 15 in a 21-day cycle along with pembrolizumab 200 mg infusion, IV, Q3W. Dose optimization may be performed in this phase.
89014687|NCT04420884|Experimental|Part 2B (SCCHN Dose Expansion Phase): Dazostinag + Pembrolizumab + Chemotherapy|Dazostinag 5.0 mg, infusion, IV, will be administered in participants with SCCHN at the identified dose level from Part 1 on Days 1, 8, and 15 in a 21-day cycle. Pembrolizumab infusion, IV will be administered at 200 mg Q3W. Platinum-based chemotherapy comprising the combination of carboplatin (target area under the curve of 5 mg/mL/minute[AUC 5]) or cisplatin (100 milligrams per square meter [mg/m^2] Day 1 of each treatment cycle), and 5-fluorouracil ([5-FU]; 1000 mg/m^2 per day for 4 consecutive days) every 3 weeks for up to 6 cycles.
89014688|NCT04420884|Experimental|Experimental: Part 3A (Expansion Phase in CRC): Dazostinag + Pembrolizumab in MSI-H/dMMR CRC|Dazostinag 5.0 mg, infusion, IV, will be administered in participants with microsatellite instability-high /mismatch repair deficient (MSI-H/dMMR) colorectal cancer (CRC) at the identified dose level from Part 1 on Days 1, 8, and 15 in a 21-day cycle along with pembrolizumab 200 mg infusion, IV, Q3W.
89014689|NCT04420884|Experimental|Part 3B (Expansion and Dose Optimization Phase in CRC): Dazostinag + Pembrolizumab in MSS/pMMR CRC|"Dazostinag 5.0 mg, infusion, IV, will be administered in participants with microsatellite stable/mismatch repair proficient (MSS/pMMR) CRC at the identified dose level from Part 1 on Days 1, 8, and 15 in a 21-day cycle. along with pembrolizumab 200 mg infusion, IV, Q3W.~Dose optimization may be performed in this phase."
89449523|NCT03303014|Experimental|5-0 Fast Absorbing Gut|Half of the wound will be treated with 5-0 fast absorbing gut
89449524|NCT03311516|Experimental|Group A|Group A = intervention group (new functional insulin therapy) who adjusts the insulin bolus according to a dose titration algorithm taking into account the lipid and protein content in addition to that of carbohydrates. The functional insulin therapy is based on a Carbohydrate / Lipid / Protein count
89449525|NCT03311516|Other|Group B|Group B=control group (functional insulin tehrapy) who adjusts the insulin bolus taking into account only the carbohydrate content. The functional insulin therapy is based on a Carbohydrate count only.
89449526|NCT03311438|Other|Oral health intervention program|Oral Health intervention program: All parents were encouraged to brush their children's teeth twice a day, with adjusted amount of fluoride toothpaste according to age. Additional fluoride tablets with dose according to age were recommended from two years of age. The children's parents were given written information about the importance and benefits of optimal oral hygiene and explaining the link to infective endocarditis. A pamphlet, lift the lip program, with instruction of looking for early signs of tooth decay, how to intervene and contact local Public Dental Service (PDS) clinic. Dietary advice was also given. The child's responsible dentist or dental hygienist at the local PDS was contacted with information about the project and the findings from examination.
89449527|NCT04678206|Experimental|BLU-5937 Dose A|BLU-5937 oral dose A twice a day.
89449528|NCT04678206|Experimental|BLU-5937 Dose B|BLU-5937 oral dose B twice a day.
89449529|NCT04678206|Experimental|BLU-5937 Dose C|BLU-5937 oral dose C twice a day.
89449530|NCT04678206|Placebo Comparator|Placebo|Matching Placebo for BLU-5937 oral dose twice a day.
89449531|NCT04678206|Experimental|BLU-5937 Dose A (Population with baseline cough < 25 coughs/hour)|BLU-5937 oral dose A twice a day.
89449532|NCT04678206|Placebo Comparator|Placebo (Population with baseline cough < 25 coughs/hour)|Matching Placebo for BLU-5937 oral dose twice a day.
89014690|NCT04416919|Other|Assembled Mask|Participant will be fitted with a full-face mask that covers the mouth and nose or a Whole face mask that covers the eyes, nose, and mouth depending on participant's preferences. The Fitted Mask will be attached to a bacterial/viral filter for fit testing. After completing the Fit test, the mask will be placed on the face for 15 minutes while the participant performs various activities to document the ability to tolerate the respirator. Participants oxygen and carbon dioxide level will be measured in the beginning and at the end of the 15 minutes. The individuals will be able to remove the Mask anytime if they experience significant discomfort or claustrophobia. At the end, the mask will be removed.
89014691|NCT04409795|Other|HLA+ Group|Participants who are high-risk HLA-DR3 and/or DR4 (+); monogenic variant (+) with rare exome variant ensemble learner (REVEL) score>0.75; and both glutamic acid decarboxylase (GAD65) and islet antigen (IA2) autoantibody (-)
89449533|NCT03311360||drug-coated balloon|patients with vertebral artery origin stenosis treated with drug-coated balloons
89449534|NCT03311360||bare metal stent|patients with vertebral artery origin stenosis treated with bare metal stent
89449535|NCT03311282|Experimental|Feeding Bottle 0m+|10 infants aged 0-4 weeks (+/- 7 days): 0-4 m bottle. 0-4 months, 250 ml, 2 angled teats: newborn (also referred to as low flow) and infant (also referred to as medium flow), for infants aged 0-4 weeks (+/- 7 days) / over 9 weeks of participation.
89449536|NCT03311282|Experimental|Feeding Bottle 4m+|10 infants aged 4 months (+/- 10 days): 4-6 m bottle. 4-6 months, 250 ml, non-angled teat), for infants aged 4 months (+/- 10 days) / over 9 weeks of participation.
89449537|NCT03311282|Experimental|Feeding Bottle 6m+|10 infants aged 6-10 months (+/- 10 days): 6m+ bottle. 6 months and over, 250 ml, longer teat) for infants aged form 6 to 10 months (+/- 10 days) / over 9 weeks of participation.
89449538|NCT03311282|No Intervention|exclusively or prevalently breast-fed infants 0m+|10 infants aged 0-4 weeks (+/- 7 days)
89449539|NCT03311282|No Intervention|exclusively or prevalently breast-fed infants 4m+|10 infants aged 4 months (+/- 10 days)
89449540|NCT03311282|No Intervention|exclusively or prevalently breast-fed infants 6m+|10 infants aged 6-10 months (+/- 10 days) (at least 2 breastfeeding sessions per day)
89449541|NCT03302702|Other|Exercise program|Treatment group
88934403|NCT01768689|Experimental|Adherence-encouraging period|"Months 4 to 9 of study during which adherence will be measured for each consecutively included study subject, while implementing adherence-encouraging interventions:~adherence-encouraging interventions - Group meetings~adherence-encouraging interventions - Individual meetings~adherence-encouraging interventions - Monthly phone calls~Patient will receive routine treatment for CML according to the physician discretion."
88934404|NCT01768702|Sham Comparator|Control|Sham, no injection
88934405|NCT01768702|Experimental|C3BS-CQR-1 Treated|Injection of C3BS-CQR-1
88934406|NCT01768715||Good response|Patients with severe alcoholic hepatitis and good response to therapy.
88934407|NCT01768715||Non transplant candidates|Patients with severe alcoholic hepatitis and poor response to therapy, that are not candidates to transplantation, according to the specified criteria.
88934408|NCT01768715||Transplant candidates|Patients with severe alcoholic hepatitis and poor response to therapy, that are candidates to transplantation, according to the specified criteria.
88934409|NCT01768728|Active Comparator|Laparoscopic left hemihepatectomy group|Group of patients that are operated with laparoscopic left hemihepatectomy
88934410|NCT01768728|Active Comparator|Open left hemihepatectomy|Group of patients operated with open left hemihepatectomy
88934411|NCT01768741|Active Comparator|Laparoscopic liver resection group|
88934412|NCT01768741|Active Comparator|Open liver resection|
88934413|NCT01768754||COPD patients|Usual and Fast Walking Speeds
88934414|NCT01768780|Experimental|sensory nerve block level of spinal anesthesia|This test group and the control group. Because within the group in two ways to check the level after spinal anesthesia will be.
88934415|NCT01768793|Experimental|Parents As Teachers + Lifestyle Int.|Participants assigned to this group will receive Parents As Teachers Plus (PAT+). This will be a diet and physical activity lifestyle intervention integrated within the standard Parents As Teachers home visiting curriculum. There will be a total of 28 home visits, delivered over 24 months (6 month prenatal phase and 18 month post-partum phase).
88934416|NCT01768793|Active Comparator|Standard Parents as Teachers (PAT)|Participants assigned to this group will receive the standard Parents As Teachers (PAT) home visiting curriculum, focusing on parenting and child development. There will be a total of 28 home visits, delivered over 24 months (6 month prenatal phase and 18 month post-partum phase).
88934417|NCT01768806|Experimental|P.L.A.Y. Project Intervention for Autism|Children diagnosed with autism were recruited to the PLAY Project Intervention grant and assigned to a community standard arm (CS) or a CS plus PLAY Project arm of the study. Those in the PLAY Project arm of the study received a one time per month home visit to train caregivers in the PLAY Project methods including video feedback and caregivers also receive mid month feedback based on the video review of interaction.
88934418|NCT01768806|Active Comparator|Special Education Pre-school|Special education pre-school services include 10-12 hours per week of special education preschool, occupational therapy, and speech and language therapy. No intensive intervention is provided.
88934419|NCT01768819|Experimental|Intervention Group|Physical Activity
88934420|NCT01768819|No Intervention|Control Group|
88934421|NCT01768884|Experimental|Nitric oxide inhalation + standard treatment|Inhalation of 160 ppm gNO for 30 minutes, 5 times daily, for 5 consecutive days or until discharged, which occurs first.
88934422|NCT01768884|Placebo Comparator|Standard treatment|Standard treatment
88934423|NCT01768897|Experimental|Treatment (CPI-613, cytarabine, mitoxantrone hydrochloride)|"Patients receive CPI-613 IV over 2 hours on days 1-5, cytarabine IV over 3 hours every 12 hours for 5 doses beginning on day 3, and mitoxantrone hydrochloride IV over 15 minutes after the 1st, 3rd, and 5th doses of cytarabine. Treatment repeats every 14 days for up to 2 courses* in the absence of disease progression or unacceptable toxicity.~NOTE: *Patients undergoing a second course of therapy receive CPI-613 IV over 2 hours on days 1-3, cytarabine IV over 3 hours every 12 hours for 5 doses beginning on day 2, and mitoxantrone hydrochloride IV over 15 minutes after the 1st and 3rd doses of cytarabine."
89014692|NCT04409795|Other|HLA- Group|Participants who are high-risk HLA-DR3 and DR4 (-); with known or yet unknown monogenic variants with REVEL score>0.75; and either GAD65 and IA2 autoantibody (-), or autoantibody (+) with titers close to the cutoff
88934424|NCT01768910|Experimental|Healthy controls|Procedure: 1-2 fMRI measurements within 4 weeks from first exam. Measurements include repetitive retrograde bladder filling via transurethral catheter at different bladder volumes and temperatures (e.g. bladder cooling, body warm or room temperature)of the filling liquid.
88934425|NCT01768910|Experimental|MS with OAB|Procedure: 1-2 fMRI measurements within 4 weeks from first exam. Measurements include repetitive retrograde bladder filling via transurethral catheter at different bladder volumes and temperatures of the filling liquid.
88934426|NCT01768910|Experimental|MS without OAB|Procedure: 1-2 measurements within 4 weeks from first exam. Measurements include repetitive bladder filling via transurethral catheter at different bladder volumes and temperatures of the filling liquid.
89014693|NCT04405297||Hip Osteoarthritis|Subjects will receive autologous adipose-derived regenerative stem cells into their affected hip joint.
89449542|NCT02234661|Experimental|CareerAdvance®|CareerAdvance® provides education, career coaching, and soft-skills training for parents while their children attend Head Start programs.
89449543|NCT02234661|No Intervention|Control Standard of CAP|Control participants access to CAP array of service
89449544|NCT04596072|No Intervention|control|basic treatment+ Cognitive rehabilitation training
89449545|NCT04596072|Experimental|treatment|basic treatment+ Cognitive rehabilitation training+Chinese traditional rehabilitation
89449546|NCT03311204|Experimental|Microblepharon Exfoliation|This treatment is provided using BlephEx tool from Optimed Pty Ltd.
89449547|NCT03311204|Experimental|Eyelid cleansing using Lid Hygenix|Foam-based hypoallergenic cleanser used as a control treatment in this study.
89449548|NCT04490876||Retinal Detachment with PVR|Proliferative vitreoretinopathy (PVR), a major complication of rhegmatogenous retinal detachment (RRD), is an abnormal process whereby proliferative, contractile cellular membranes form in the vitreous and on both sides of the retina, resulting in tractional retinal detachment with fixed retinal folds. Patients with RD complicated by PVR will be included, and the proposed intervention will be performed.
89449549|NCT02811939|Experimental|Active THC and Placebo Pregnenolone|
89449550|NCT02811939|Experimental|Active THC and Active Pregnenolone|
88934427|NCT01768910|Experimental|NNOAB|Procedure: 1-2 measurements within 4 weeks from first exam. Measurements include repetitive bladder filling via transurethral catheter at different bladder volumes and temperatures of the filling liquid plus additional post-treatment fMRI scan 5 to 7 weeks after OAB treatment (such as antimuscarinics, intradetrusor injections of botulinum toxin type A)
88934428|NCT01768910|Experimental|SCI with neurogenic detrusor overactivity|Procedure: 1-2 measurements within 4 weeks from first exam. Measurements include repetitive bladder filling via transurethral catheter at different bladder volumes and temperatures of the filling liquid plus 1 additional post-treatment fMRI scan 5 to 7 weeks after intradetrusor injections of botulinum toxin type A
88934429|NCT01768923|Active Comparator|SDAI remission group|SDAI remission
88934430|NCT01768923|Active Comparator|Minimal disease activity group|Minimal disease activity remission
88934431|NCT01768936||eliminated infectious abdominal focus|
88934432|NCT01768936||persisting/progressing infectious abdominal focus|
88934433|NCT01768949|Other|Echocardiography|An echocardiography will be systematically realised in all the patients included in the study in order to evaluate whether any echocardiographic criterion exploring the right ventricle can predict the efficacy and/or safeness of recruitment maneuvers in patients suffering from acute respiratory distress syndrome.
88934434|NCT01768962|Active Comparator|Sequence A|2 weeks, 6 week washout, 2 weeks
88934435|NCT01768962|Active Comparator|Sequence B|2 weeks, 6 week washout, 2 weeks
89449551|NCT02811939|Experimental|Placebo THC and Active Pregnenolone|
89449552|NCT02811939|Placebo Comparator|Placebo THC and Placebo Pregnenolone|
89449553|NCT02468882|Experimental|Intervention group|"Watercress will be tested in its natural form as a food item that will supplement the usual diet, via the prescription of watercress as whole food added daily to the usual diet. The intervention group will be asked to consume 100 grams of watercress per day, in addition to their usual diet for the total time of RT treatment. These 100 grams of watercress per day will allow the achievement of the daily therapeutic dose."
89449554|NCT02468882|No Intervention|Control group|The control group will receive the standard of care, thus will maintain their ad libitum diet.
89449555|NCT01329549|Experimental|BIBF 1120 (low) + Carboplatin + PLD|BIBF 1120 (low dose) + carboplatin (AUC5 mg/mL*min) + PLD (30 mg/m2)
89449556|NCT01329549|Experimental|BIBF 1120 (medium) + Carboplatin + PLD|BIBF 1120 (medium dose) + carboplatin (AUC5 mg/mL*min) + PLD (30 mg/m2)
89449557|NCT01329549|Experimental|BIBF 1120 (high) + Carboplatin + PLD|BIBF 1120 (high dose) + carboplatin (AUC5 mg/mL*min) + PLD (30 mg/m2)
89449558|NCT03302624||Patients who were included in ELVIS study|
88934436|NCT01768988|Experimental|Group I|Conventional analgesic treatment + pregabalin.
88934437|NCT01768988|Placebo Comparator|Group II|Conventional analgesic treatment + placebo.
88934438|NCT01769040|Experimental|Rifaximin|Rifaximin tablets for oral ingestion, 550 mg twice daily for 28 days.
88934439|NCT01769040|Placebo Comparator|Placebo tablets|Placebo tablets similar in shape and size to intervention treatment, 1 tablet twice daily for 28 days.
88934440|NCT01769053|Active Comparator|Variable Ventilation|Patients are ventilated with variable pressure support mode.
88934441|NCT01769053|No Intervention|Conventional (non-variable) Ventilation|Patients are ventilated with non-variable(conventional) pressure support ventilation mode.
88934442|NCT01769066|Experimental|Sequential Gefitinib With Pemetrexed/Platinum|Pemetrexed IV 500 mg/m2 ，DAY2 DDP IV 75mg/m2 ，DAY1 OR CAP IV AUC 5,DAY1 Gefitinib PO. 250mg DAY3-16
88934443|NCT01769066|Active Comparator|Pemetrexed/Platinum|Pemetrexed IV 500 mg/m2 ，DAY2 DDP IV 75mg/m2 ，DAY1 OR CAP IV AUC 5,DAY1
89206120|NCT00821106|Experimental|Left transradial approach|Diagnostic or interventional procedures performed through left radial approach
89449559|NCT03302546|Active Comparator|Incremental Hemodialysis|Subjects on this arm will be treated with 2 hemodialysis sessions of at least 4 hour per week.
89449560|NCT03302546|Active Comparator|Conventional hemodialysis|Subjects on this arms will be treated with 3 hemodialysis sessions of at least 3.5 hour per week.
89449561|NCT02234739|Experimental|active treatment|Chinese patients with invasive pulmonary aspergillosis treated by voriconazole, who has COPD as underlying condition
88934444|NCT01769079|Active Comparator|oral nitrate|In nitrate group will be provided the same prescribed dose for this drug. One group remains on nitrate use and other on placebo (same number of pills) use.
89449562|NCT04442516||Adults receiving Cisplatin as part of their cancer therapy|
88934445|NCT01769079|Placebo Comparator|Placebo|In the placebo group will be given the same dose and frequency prescribed nitrate.
88934446|NCT01769118||Caffeine|caffeine will be given according to clinical judgment
88934447|NCT01769131||Allis|
88934448|NCT01769131||Tenaculum|
88934449|NCT01769144|Active Comparator|Acticoat Absorbent|Acticoat Absorbent wound dressing
88934450|NCT01769144|Experimental|BCT wound dressing|wound dressing
88934451|NCT01769157|Active Comparator|L-carnitine|L-carnitine 330mg, 3 tablet twice daily
88934452|NCT01769157|Placebo Comparator|Placebo|placebo drug, 3 tablet twice daily
88934453|NCT01769183|Experimental|Squalamine|Study eyes will be assigned to receive Squalamine. The dose will be one drop twice daily. If neovascularization fails to regress at week one or if neovascularization returns within the study, the dose will be increased to four times daily. In that case, a one day and one week visit will be added after increasing the dose. Patients will continue administering study drug until week 20.
88934454|NCT01769235|Experimental|Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%|Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% (Taro Pharmaceuticals Inc.)
88934455|NCT01769235|Active Comparator|Acanya® Gel, 1.2%/2.5%|Acanya® (Clindamycin Phosphate and Benzoyl Peroxide) Gel, 1.2%/2.5% (Dow Pharmaceutical Sciences, Inc., marketed by Valeant Pharmaceuticals North America LLC)
88934456|NCT01769235|Placebo Comparator|Vehicle of test product|Vehicle of test product (Taro Pharmaceuticals Inc.)
88934457|NCT01769261|Experimental|Internet, eligible patients|Patients randomized in the internet arm. They will directly complete their health evolution after hospital discharge via the internet.
88934458|NCT01769261|Active Comparator|Telephone, eligible patients|Patients randomized in the telephone arm. Their health evolution after hospital discharge will be documented via a telephone interview at J45 after hospital discharge..
88934459|NCT01769261|Other|" Non eligible patients"|Patients who do not have an internet access at home. Their health evolution after hospital discharge will be documented via a telephone interview at J45. after hospital discharge.
88934460|NCT01769287||Surgical operation|The study aims to recruit a total of 20 patients, 10 of whom have AF and 10 who do not.
88934461|NCT01769300|No Intervention|Control practices|Practices that do not use the ADHD clinical decision support
88934462|NCT01769300|Experimental|Clinical decision support|Electronic health record-based clinical decision support for ADHD medication titration.
89449563|NCT04442516||Children receiving Cisplatin as part of their cancer therapy|
88934463|NCT01769313|Experimental|Group A|In Group A the anterior capsulotomy and lens fragmentation will be performed by means of femtosecond laser surgery
88934464|NCT01769313|Active Comparator|Group B|Group B acts as a control group where the capsulotomy as well as the lens fragmentation is performed manually.
88934465|NCT01769417|Placebo Comparator|Placebo|
88934466|NCT01769417|Active Comparator|MEDI4893|
88934467|NCT01769430||Community acquired respiratory infection|Measurement of exhaled breath aerosol
88934468|NCT01769482|Experimental|Udenafil|70 subjects will undergo baseline testing and then be randomized into a clinical parallel trial of udenafil 100mg or placebo po q d for 3 months.
88934469|NCT01769482|Placebo Comparator|Placebo|70 subjects will undergo baseline testing and then be randomized into a clinical parallel trial of udenafil 100mg or placebo po q d for 3 months.
88934470|NCT01769495|No Intervention|Control|Standard post ED care
88934471|NCT01769495|Experimental|2-3 day return appointment|Patients will receive further treatment in Geriatric Clinic 2-3 days post ED discharge.
88934472|NCT01769521|Experimental|Triggerfish|Device: Sensimed Triggerfish
88934473|NCT01769547|Experimental|Dovitinib|Dovitinib 500 mg PO OD (5 days on, 2 days off); Each cycle = 28 days
88934474|NCT01769560|No Intervention|Centers for Disease Control and Prevention (CDC) Fact Sheet|Participants will receive the CDC Fact sheet about HPV vaccination while they are taking the survey.
89206121|NCT00826878|Experimental|Tivozanib (AV-951)|
89206122|NCT00827034|Other|A|A: Warfarin alone
89449564|NCT02736474|Experimental|Naltrexone and Bupropion|Naltrexone 3 tablets（15mg） once per day and Bupropion 1 capsule（150mg） once per day in the first two weeks. Then Naltrexone 5 tablets（25mg） once per day and Bupropion 2 capsules（300mg） once per day during the rest of the study.
88934475|NCT01769560|Experimental|MeFirst Intervention|Participants will receive a tailored website regarding their own individualized risk for HPV and information about HPV Vaccination while they are taking the survey as opposed to receiving the CDC fact sheet. This tailored website is generated based on answers provided by each subject in the baseline survey.
89449565|NCT02736474|Placebo Comparator|Placebo Naltrexone and Bupropion|Placebo Naltrexone 3 tablets+Placebo Bupropion 1 capsule once per day in the first two weeks. Then Placebo Naltrexone 5 tablets+Placebo Bupropion 2 capsule once per day during the rest of the study.
89449566|NCT04490798||Lumbar back pain|Patients with lumbar back pain treated following the Acupuncture Treatment Clinic Pathway.
89449567|NCT04490798||Musculoskeletal pain|Patients with musculoskeletal pain treated following the Acupuncture Treatment Clinic Pathway.
89449568|NCT04490798||Cervicalgia|Patients with cervicalgia treated following the Acupuncture Treatment Clinic Pathway.
89449569|NCT04490798||Knee osteoarthritis|Patients with knee osteoarthritis treated following the Acupuncture Treatment Clinic Pathway.
89449570|NCT04490798||Headache|Patients with headache treated following the Acupuncture Treatment Clinic Pathway.
89449571|NCT04490798||Shoulder pain|Patients with shoulder pain treated following the Acupuncture Treatment Clinic Pathway.
89449572|NCT02234895|Experimental|Lateral wedge plus medial arch support|The lateral wedge plus medial support orthotic will be custom-made and designed using a 3D volumetric cast of the foot with the participant's foot in a subtalar joint neutral position. The cast will be balanced so that it rests in a neutral position then smoothed to address any irregularities and to allow for soft tissue splay. Polypropylene sheets of 3mm or 4mm thickness will be vacuum formed or milled directly to produce a ¾ length shell. An ethyl-vinyl-acetone (EVA) lateral post in the heel and forefoot of 5 degrees will be incorporated into the orthotic. The orthotic will be finished with a neoprene cover for improved comfort and patient compliance.
89449573|NCT02234895|Experimental|Lateral wedge|The lateral wedge only orthotic will be constructed of EVA, made to full length of the subject's footwear and incorporate a 5 degree posting. The wedge will be finished with a neoprene cover for improved comfort and patient compliance.
89449574|NCT04442672|Experimental|compartment syndrome model group(CSM group)|
88934476|NCT01769599||Grid Treatment|30 patients that were treated with laser grid treatment
88934477|NCT01769599||Avastin Treatment|patients that were treated with Avastin injections
88934478|NCT01769625|Placebo Comparator|placebo & cholecalciferol 400 IU|In this arm, the placebo is in place of celecoxib and the current RDA for cholecalciferol is used the control of the cholecalciferol higher dose.
88934479|NCT01769625|Active Comparator|placebo & cholecalciferol 2,000 IU|Placebo & cholecalciferol 2,000 IU
88934480|NCT01769625|Experimental|celecoxib 400mg & cholecalciferol 2,000 IU|celecoxib 400 mg & cholecalciferol2,000 IU
88934481|NCT01769638|Experimental|SPO1101|
88934482|NCT01769638|Experimental|SPO1101D|
88934483|NCT01769651||Drug service users|Those patients who receive Methadone replacement therapy as part of their treatment plan. In addition, those drug user patients who have a first consultation session with their Addiction Nurses.
89449575|NCT04442672|Sham Comparator|sham group|
89449576|NCT02233491|Placebo Comparator|Control|This group will be counselled in clinic by clinicians about the risks of glucose intolerance and will receive leaflets outlining lifestyle modification advice. The leaflets include advice on healthy eating, exercise and the importance of weight loss. However there will be no dietician referral, psychosocial intervention or focused exercise and weight loss monitoring programme. Follow up will be at routine clinic visits only where lifestyle modification advice will be reinforced as per usual clinical practise.
89449577|NCT02233491|Active Comparator|Active intervention|This group will receive active lifestyle modification intervention and will consist of dietician referral, graded exercise programme and weight loss advice. The dietician will be supported by Clinical Psychology services and our collaboration with a recognised expert in behavioural change therapy. The dietician will be trained with motivational interviewing skills and psychological tools will be utilised to support the active lifestyle intervention.
89449578|NCT05157750||IBD patients with endoscopic remission|No intervention will be administered. All patients with endoscopic remission will be monitored for the future development of major clinical events. Diagnostic performances of endoscopic remission for predicting major clinical events will be calculated.
88934484|NCT01769664|Experimental|Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel|Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel (Taro Pharmaceuticals Inc.)
88934485|NCT01769664|Active Comparator|Duac® Topical Gel|Duac® (Clindamycin 1%/Benzoyl Peroxide 5%) Topical Gel (Stiefel)
88934486|NCT01769664|Placebo Comparator|Placebo Topical Gel|Placebo (Vehicle) Topical Gel (Taro Pharmaceuticals Inc.)
88934487|NCT01769677|Experimental|Treatment Group AB|"Subjects in this group will receive study drug in the following sequence:~Treatment A: two 45-mg hydrocodone bitartrate extended-release tablets (reference).~Treatment B: one 90-mg hydrocodone bitartrate extended-release tablet (test)."
88934488|NCT01769677|Experimental|Treatment Group BA|"Subjects in this group will receive study drug in the following sequence:~Treatment B: one 90-mg hydrocodone bitartrate extended-release tablet (test).~Treatment A: two 45-mg hydrocodone bitartrate extended-release tablets (reference)."
88934489|NCT01769690|Experimental|DBS stimulator setting alteration|
88934490|NCT01769703|Experimental|Dabigatran|
88934491|NCT01769716|Experimental|Umbilical cord blood transplantation|Allogeneic umbilical cord blood will be administered intravenously or intraarterially under non-myeloablative immunosuppression. In case of autologous umbilical cord blood, immunosuppression is not required.
88934492|NCT01769729|Experimental|PEPP + care management|"This 4-month collaborative psychotherapy, entitled Program for Emotional and Physical Pain (PEPP), will include 1 joint meetings with the behavioral health specialist (BHS), primary care provider (PCP), and patient, 10 psychotherapy sessions, and continued collaboration between the BHS and the PCP to assure a shared treatment plan.~Care management will include monthly calls with a depression care manager."
88934493|NCT01769729|Active Comparator|Care management alone|Care management will include monthly calls with a depression care manager.
88934494|NCT01769742|Experimental|Early mobility bundle|Delivery of early targeted physiotherapy to patients on the interventional wards; to comprise assessment and communication of mobility to ward staff and patient, provision of mobility aids, guidance and encouragement to patient and staff to allow patient to dress and mobilise independently if clinically safe to do so
88934495|NCT01769742|No Intervention|Usual care|Usual physiotherapy service only
88934496|NCT01769755|Experimental|Human Placenta-Derived Cells PDA001 Intravenous Infusion|Intravenous infusion of Human Placenta-Derived Cells PDA001 over the course of 2 hours.
88934497|NCT01769755|Placebo Comparator|Vehicle controlled placebo|Intravenous infusion of Vehicle Controlled Placebo over the course of 2 hours
88934498|NCT01769768|Experimental|LDE225+Warfarin|At least 15 evaluable patients with advanced solid tumors will be enrolled into the study into the warfarin group.
88934499|NCT01769768|Experimental|LDE225+Bupropion|At least 15 evaluable patients with advanced solid tumors will be enrolled into the study into the Bupropion group
88934500|NCT01769781|Experimental|anastrazole|women with endometriosis recurrence will be treated with Leuprolide acetate 11,25mg plus anastrazole 1mg/day for three months
88934501|NCT01769781|Active Comparator|GnRH analog alone|women with endometriosis recurrence will be treated with leuprolide acetate 11.25mg
89449579|NCT05157750||IBD patients with histologic remission|No intervention will be administered. All patients with histologic remission will be monitored for the future development of major clinical events. Diagnostic performances of histologic remission for predicting major clinical events will be calculated.
89449580|NCT05157750||IBD patients with barrier healing|No intervention will be administered. All patients with barrier healing will be monitored for the future development of major clinical events. Diagnostic performances of barrier healing for predicting major clinical events will be calculated.
89449581|NCT02234973||11 First Nations Community and Clinical Teams|11 Community & Clinical Teams in each First Nation community participated in the intervention.
89449582|NCT04320732||Individuals with COVID-19 infection|"Confirmed by routine laboratory diagnosis. All types of COVID-19 disease from asymptomatic carriers to hospitalized patients can be included.~Only subjects >18 years old will be included in the study."
89449583|NCT04320732||Individuals tested for COVID-19 infection with negative test|Confirmed by routine laboratory diagnosis
89449584|NCT04320732||Healthy individuals|Recruitet from the general population
89449585|NCT04320732||Risk groups for COVID-19 exposure|Including, but not limited to healthcare workers.
89449586|NCT04320732||Patients admitted to hospital|Without COVID-19 infection.
89449587|NCT03302390||Biopsy of Skin with Psoriasis|Shave biopsy of psoriasis lesion
89449588|NCT03726957|Experimental|Intervention group|The intervention arm included households which received improved cookstoves
89449589|NCT03726957|No Intervention|Control group|The control group included households, which did not receive improved cookstoves, and cooked in their usual traditional cookstoves.
88934502|NCT01769794|Active Comparator|Western therapy & Placebo|Western therapy(oral care, skin care and reducing temperature) Placebo for JET(Jinlianqingre Effervescent Tablets )
88934503|NCT01769794|Experimental|Western therapy & JET|Jinlianqingre Effervescent Tablets plus western therapy
88934504|NCT01769807|Experimental|CPAP treatment|67 consecutive male patients with OSA were recruited: 36 with mild-moderate OSA and 31 with severe OSA. Data were collected in all subjects at baseline and after 1 month of CPAP.
88934505|NCT01769820|Active Comparator|Dexamethasone|Study 1, and study2(2 arms); Dexamethasone 1.5mg daily Study 3 (adaptive -7 arms): Dexamethasone of 0.4, 0.8, 1.0, 1.2, 1.5, and 1.8 mg total dose per day
88934506|NCT01769820|Placebo Comparator|Placebo|Placebo
88934507|NCT01769833|Active Comparator|PEG-interferon-alfa 2A|PEG-interferon-alfa 2A
88934508|NCT01769833|Placebo Comparator|Nucleosides|Nucleosides
88934509|NCT01769846|Experimental|Early Mobilization protocol|Early Mobilization protocol: Patients in the treatment group additionally received a progressive cycling exercise session 7 days a week, until the last day of ICU stay, using a bedside cycle ergometer (MOTOmed Letto 2, RECK-Technik GmbH & Co. KG, Betzenweiler, Germany). Cycling exercise will be realized during 30 consecutive minutes, initially in continuos and passive (classified patients with RASS - 4) exercise, at a fixed pedaling rate of 20 cycles/min and after in actively (classified patients with RASS 0), with an exercise intensity of 3-5 on the Borg rate of perceived exertion scale.
88934510|NCT01769846|No Intervention|Control group|Group will undergo usual mobilization per standard ICU care. Conventional physical and respiratory therapy were provided by the ICU physical therapists twice daily, for approximately 30 min, 7 days per week. The protocol included vibrocompression maneuvers; lung hyperinflation by the mechanical ventilator; and tracheal aspiration, when necessary; as well as passive and active-assisted motor exercises for arms and legs, depending on the clinical course of patients.
88934511|NCT01769872|Experimental|Autologous Adipose Tissue derived MSCs|
88934512|NCT01769898|Placebo Comparator|Placebo+formoterol-budesonide|"Placebo(for Theophylline sustained-release tablet) tablet by mouth 100mg every 12hours for 24weeks.~Inhaled Formoterol-budesonide combined treatment 4.5µg/160µg every 12hours for 24weeks."
88934513|NCT01769898|Experimental|Theophylline+formoterol-budesonide|"Theophylline sustained-release tablet by mouth 100mg every 12hours for 24weeks.~Inhaled formoterol-budesonide combined treatment 4.5µg/160µg every 12hours for 24weeks."
88934514|NCT01769911|Experimental|Treatment (gene modified peripheral blood cell transplant)|"CONDITIONING: Patients receive carmustine IV over 3 hours on day -7, cytarabine IV over 2 hours BID and etoposide IV over 2 hours BID on days -6 to -3, and melphalan IV over 30 minutes on day -2.~TRANSPLANTATION: Patients receive an autologous PBSC infusion and/or infusion of autologous transduced hematopoietic cells on day 0.~Beginning 28-120 days later, patients eligible for in vivo selection after detection of gene-marked cells receive O6-benzylguanine IV over 1 hour and carmustine IV over 3 hours on days 14, 28, and then monthly until completion of therapy. Patients achieving > 10% gene marking and CD4 count of >= 500 cells/uL receive up to 2 courses of structured treatment interruption without undergoing in vivo selection."
88934515|NCT01769937|Experimental|H.P. Acthar Gel SQ injection|Patients will administer single dose (80 units) of Acthar subcutaneously every day for 10 days (with a possible 5 day dosing rescue).
89014694|NCT04405297||Knee Osteoarthritis|Subjects will receive autologous adipose-derived regenerative stem cells into their affected knee joint.
89206123|NCT00827034|Other|B|B: Dimebon and Warfarin co-administration
89449590|NCT05124834|Experimental|Subject glucometer measurement|Blood glucose measurement BGM for personal use
89449591|NCT03712371|Experimental|Chitosan dose escalation|
89449592|NCT03302312||Participants|Service members who received at least one SGB study procedure as part of the clinical effectiveness trial during the three months prior to qualitative data collection or service members who received at least one SGB for PTSD symptoms at a study site in the three months prior to qualitative data collection.
89449593|NCT03302312||Providers|Behavioral Health or other (e.g., Family Medicine) clinicians who have referred or could potentially have referred service members for SGB for PTSD symptoms, as well as physicians who provide SGBs.
89449594|NCT02467088|Experimental|Individualised Homoeopathic Remedy|Each participant will receive an individualised homoeopathic remedy, in a vehicle of sucrose pillules, according to the symptoms of their PMS. Although different individualised remedies may be dispensed, each remedy will be homoeopathic. Each individualised homoeopathic remedy will have an individualised dosage, frequency and duration based on the laws of individualised homoeopathic prescribing as outlined by De Schepper.
89449595|NCT02235129|Experimental|6 minutes walking test|
89449596|NCT03469518|Sham Comparator|β-Cx plus PS|Fruit and milk based beverage enriched with beta-cryptoxanthin and plant sterols
88934516|NCT01769950|Experimental|Choline-PET arm|Every eligible patient will be scanned with Choline-PET at the time of diagnosis of prostate cancer. MRI will also be obtained as it is the current standard of care. CT scan will be obtained as part of the same procedure while procuring the Choline-PET scan with PET-CT dual imaging hardware.
89449597|NCT03469518|Active Comparator|β-Cx plus PS plus GOS|Fruit and milk bases beverage enriched with beta-criptoxanthin, plant sterols and galactooligosaccharides
89449598|NCT04434846||1|Adults ages 18-55 with ZIKV, DENV, and/or CHIKV seroprevalence.
89449599|NCT03302078|Experimental|Treatment T|Fed state
89449600|NCT03302078|Experimental|Treatment R|Fasted state
89449601|NCT04378920|Experimental|4L6715|exploring various doses of LEAF-4L6715
89449602|NCT03473028|Active Comparator|transabdominal ultrasound|400 obese female undergo transabdominal ultrasound guided embryo transfer
89449603|NCT03473028|Active Comparator|transvaginal group|400 obese female undergo transvaginal ultrasound guided embryo transfer
88934517|NCT01769963|Experimental|Dietary intervention|All participants will be fed a high AGE diet followed by a low AGE diet (single arm study)
89449604|NCT03712137|Experimental|VOLUX XC|Participants will be treated with VOLUX XC hyaluronic acid (HA) injectable gel on day 1 with optional touch-up at day 30 and optional maintenance treatment at Month 12.
89449605|NCT03712137|Experimental|No-treatment control|No-treatment during the control period. Optional delayed-treatment with VOLUX XC (initial with optional touch-up) at the beginning of the Post-Control period.
89449606|NCT03472950|Experimental|Ranolazine 500mg|Participants will take Ranolazine 500mg twice daily for up to 4 weeks.
89449607|NCT03472950|Experimental|Ranolazine 1000mg|Participants will take Ranolazine 1000mg twice daily for up to 4 weeks.
88934518|NCT01769976|Experimental|Daily energy restriction|25% reduction in daily energy intake
88934519|NCT01769976|Active Comparator|Energy balance diet|Diet provides 100% of energy requirements and is designed to achieve weight stability
88934520|NCT01769976|Experimental|Periodic fasting with weight loss|Fast 3 days per week, and consume 1.5 times usual amount of food on other days
88934521|NCT01769976|Experimental|Periodic fasting without weight loss|Fast 3 days per week, and consume double usual amount of food on other days
88934522|NCT01769989|Active Comparator|Eletrodermabrasion|The side treated with electrodermabrasion will be burned with an electric cautery machine to remove the outermost layer of skin as well as the lumps and bumps and a small area of surrounding skin.
88934523|NCT01769989|Active Comparator|Dermabrasion|The side treated with dermabrasion will be scraped with a sterile piece of sandpaper until the outermost layer of skin and lumps and bumps have been removed and a small layer of surround skin.
88934524|NCT01770002|Active Comparator|Everted suture technique|Technique that everts the skin; the edges will sit up against each other in a little peak, raised above the surrounding skin.
88934525|NCT01770002|Active Comparator|Non-everted suture technique|Surgical wound will be approximated such that the suture line is flat relative to the surrounding skin.
88934526|NCT01770028||Intervention partners|Partners of pregnant women randomized to lifestyle intervention. Note: There is no intervention in partners of pregnant women.
88934527|NCT01770028||Standard care partners|Partners of pregnant women randomized to Standard Care. Note: There is no intervention in partners of pregnant women.
88934528|NCT01770041||Liver resection group|Patients undergoing liver resection and receiving paracetamol (observation of routine administration)
88934529|NCT01770054||obtention of a blood sample|all Atahualpa residents aged 40 years or more
88934530|NCT01770080|Active Comparator|Euminz®|Acute treatment (3 to 5 time topical use of Euminz® = 10%ethanolic solution of peppermint oil) will start immediately after assessment of a baseline pain intensity of at least moderate pain (3 on VPRS).
88934531|NCT01770080|Placebo Comparator|Placebo|Acute treatment (3 to 5 time topical use of Placebo= 0,5% ethanolic solution of peppermint oil) will start immediately after assessment of a baseline pain intensity of at least moderate pain (3 on VPRS).
88934532|NCT01770093||Parents of Pediatric Inpatients|
88934533|NCT01770106|Experimental|Denosumab|Patients in this arm will receive subcutaneous injection of denosumab 60mg every 6 months (1 dose for the study period).
88934534|NCT01770106|Active Comparator|Standard treatment|Patients (n=20) in this arm will receive oral alendronate (Fosamax®)70mg once.
88934535|NCT01770119|Experimental|MMR vaccination|MMR vaccine to seronegative pediatric SOT recipients
89014695|NCT04405297||Ankle Osteoarthritis|Subjects will receive autologous adipose-derived regenerative stem cells into their affected ankle joint.
89014696|NCT04405297||Shoulder Osteoarthritis|Subjects will receive autologous adipose-derived regenerative stem cells into their affected shoulder joint.
89014697|NCT04405297||Wrist Osteoarthritis|Subjects will receive autologous adipose-derived regenerative stem cells into their affected wrist joint.
89014698|NCT04399603||COVID critically unwell patients|
89449608|NCT02467244||Euthyroid group|Fifty (50) age and sex matched euthyroid subjects will serve as the control group. Control euthyroid subjects will be evaluated once at baseline and after 12 weeks.
88934536|NCT01770132|Experimental|porfimer sodium, EUS-PDT, gemcitabine|Patients receive porfimer sodium IV over 3-5 minutes on day 1 and undergo endoscopic ultrasonography-photodynamic therapy (EUS-PDT) on days 1, 3, 8, and 21. After completion of EUS-PDT, patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15 of courses 1 and 2 and on day 22 of courses 3 and 5. During courses 1-5, treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. After course 5, treatment with gemcitabine hydrochloride repeats every 2 months in the absence of disease progression or unacceptable toxicity.
88934537|NCT01770171|Experimental|Carboplatin-paclitaxel-bevacizumab|Carboplatin AUC 5+ Paclitaxel 175 mg/mq+Bevacizumab 15 mg/kg q 21 for 6 -8 cycles + Bevacizumab 15 mg/kg every 3 weeks until disease progression
88934538|NCT01770171|Active Comparator|carboplatin-paclitaxel|Carboplatin AUC 5+Paclitaxel 175 mg/mq q 21 for 6-8 cycles
88934539|NCT01770184|Experimental|Intervention Group|The intervention group will receive the rehabilitation services and support that is recommended and provided in the current health care structure. The intervention group will also receive the Chronic Disease Self-Management Program (CDSMP). The CDSMP is an education program based on the concept of self-management. Self-management refers to the ability of an individual to manage the day-to-day responsibilities of living with a chronic condition. The CDSMP will be delivered in two and a half hour sessions, once a week, for six weeks, in group format.
88934540|NCT01770184|No Intervention|Usual Care Group|The usual care group for this study will receive the rehabilitation services and support that is recommended and provided in the current health care structure. No additional intervention will be provided to the usual care group within this study.
88934541|NCT01770197||recombinant tissue plasminogen activator|Stroke patients with rt-PA treatment in the 3-4.5 hour time window were compared with those within 3h.
88934542|NCT01770197||rt-PA|One group of was treated with standard recombinant tissue plasminogen activator therapy in 3h and the other group of stroke patients was treated within 3-4.5h.
88934543|NCT01770210||Cardiovascular events|Patients on atorvastatin treatment hospitalised due to cardiovascular events
88934544|NCT01770223|Experimental|Boceprevir + PegIFN-2b + RBV|All participants will start treatment with 4 weeks of PegIFN-2b subcutaneously, 1.5μg/kg per week + RBV capsules orally, at a weight-based dose between 800-1400 mg/day divided into two daily doses (double therapy). Participants without cirrhosis will then continue on the PegIFN-2b and RBV with the addition of boceprevir capsules orally, 800 mg three times per day for 32 weeks (triple therapy), and will transition back to double therapy for the final 12 weeks of treatment (48 total weeks of therapy). Participants with cirrhosis or documented as null responders will receive triple therapy for 44 weeks (48 total weeks of therapy).
88934545|NCT01770236|Experimental|IV acetaminophen|Patients in this group will receive intraoperative intercostal block + IV acetaminophen (1000 mg every 6 hours for adults and weight-based for any patient under 50 kg)
88934546|NCT01770236|No Intervention|On-Q Pain Pump catheter|Patients in this group will receive the current standard care which includes an intraoperative intercostal block + On-Q Pain Pump catheter (continuous dosing).
88934547|NCT01770262||Osteoporosis|Hospitalized subjects diagnosed with osteoporosis
89449609|NCT02467244||Hypothyroid group|Fifty (50) hypothyroid patients attending the outpatient department of General Medicine, AIIMS, Bhubaneswar, will be recruited for the present study following inclusion and exclusion criteria.
89449610|NCT03706521|Experimental|0.07 mg SM04690|Single intra-articular injection of 0.07 mg SM04690 in 2 mL vehicle
89449611|NCT03301688|Experimental|A group (JS001 20161002)|The subjects of A group will use 3 mg/kg doses every 2 weeks.Drug batch number is 20161002.
89449612|NCT03301688|Experimental|B group (JS001 20161108)|The subjects of B group will use 3 mg/kg doses every 2 weeks.Drug batch number is 20161108.
89449613|NCT02259543|No Intervention|G0|Root decontamination performed by scaling and root planing followed by rinsing with saline solution during the treatment of recession defects by subepithelial connective tissue graft (SCTG). Control group.
89449614|NCT02259543|Active Comparator|G90|Root conditioning with citric acid+tetracycline solution (1:1) for 90 seconds after scaling and root planing, followed by rinsing with saline solution for root decontamination during the treatment of recession defects by subepithelial connective tissue graft (SCTG).
89449615|NCT02259543|Active Comparator|G180|Root conditioning with citric acid+tetracycline solution (1:1) for 180 seconds after scaling and root planing, followed by rinsing with saline solution for root decontamination during the treatment of recession defects by subepithelial connective tissue graft (SCTG).
89449616|NCT05727722|Experimental|Micro-encapsulated Hepatocyte Intraperitoneal Transplantation Cohort 1|Participants will each be administered the dosage of 0.15×10^9 for one time, with 60 days follow-up after the cell infusion.
88934548|NCT01770262||Healthy|
88934549|NCT01770275||patients with esophageal cancer|Patients with esophageal cancer who underwent esophagectomy
88934550|NCT01770288|Experimental|Anaerobic Performance|
88934551|NCT01770301|Active Comparator|A - Paclitaxel|patients will receive paclitaxel alone at the dose 80 mg/m² administered by intravenous injection at D1, D8 and D15 every 4 weeks for 6 cycles. Thereafter, patients will be followed-up with imaging exams every 12 weeks. At the time of confirmed progression, patients could receive bevacizumab 15 mg/kg every 3 weeks for 12 months following investigator's decision. In some cases, longer therapy may be allowed after discussion with the Principal Investigator/Sponsor
88934552|NCT01770301|Experimental|B - Paclitaxel + Bevacizumab followed by Bevacizumab|patients will receive paclitaxel at the dose 80 mg/m² administered by intravenous injection at D1, D8 and D15 every 4 weeks + Bevacizumab at the dose 10 mg/kg administered by intravenous injection every 2 weeks (D1 and D15) for 6 cycles. Thereafter, patients will receive IV injection of bevacizumab 15 mg/kg every 3 weeks for up to 1 year
88934553|NCT01770327|Placebo Comparator|Group 1 (placebo) - Water|This group will drink water in 1st trial
88934554|NCT01770327|Experimental|Group 2 (Intervention) - Milk|This group will drink Non-Fat Milk in 1st trial
88934555|NCT01770327|Experimental|Group 3 (Intervention) - Orange Juice|This group will drink Orange Juice in 1st trial
89200683|NCT05030974|Active Comparator|stratum A1 - one extra dose of mRNA-1273|Patients treated with triple immunosuppressive therapy consisting of a calcineurin inhibitor, MMF/MPA, and steroids, receiving a 3rd or 4th dose of mRNA-1273 (100 μg, i.m)
89200684|NCT05030974|Active Comparator|stratum A2 - one extra dose of mRNA-1273 with discontinuation of MMF/MPA|patients treated with triple immunosuppressive therapy consisting of a calcineurin inhibitor, MMF/MPA, and steroids, receiving a 3rd or 4th dose of mRNA-1273 (100 μg, i.m), with temporary discontinuation of MMF/MPA during one week before and one week after the extra dose
88934556|NCT01770327|Experimental|Group 4 (Intervention) - Iced Tea|This group will drink Iced Tea in 1st study
89200685|NCT05030974|Active Comparator|stratum B1 - 3rd dose of mRNA-1273|patients treated with any combination of immunosuppressive drugs, receiving a 3rd dose of mRNA-1273 (100 μg, i.m)
89200686|NCT05030974|Active Comparator|statum B2 - 3rd double dose of mRNA-1273|patients treated with any combination of immunosuppressive drugs, receiving a 3rd dose of mRNA-1273 (100 μg, i.m) in both upper arms
89200687|NCT05030974|Active Comparator|stratum B3 - Ad26.COV2.S vaccine|patients treated with any combination of immunosuppressive drugs, receiving a 3rd COVID vaccination with Ad26.COV2.S vaccine (Janssen, 5x1010 viral particles i.m.)
89200688|NCT00377299|Experimental|Citicoline|Citicoline is an over the counter supplement that may have neuroprotective properties and may have antidepressant effects.
89200689|NCT00377299|Placebo Comparator|Placebo|Placebo matching active medication.
89200690|NCT00981604|Active Comparator|SILS Cholecystectomy|Single Incision Laparoscopic Cholecystectomy
89200691|NCT00981604|Active Comparator|Standard Laparoscopic Cholecystectomy|4 port laparoscopic cholecystectomy
89206124|NCT00754559|Experimental|Tocilizumab|
89449617|NCT05727722|Experimental|Micro-encapsulated Hepatocyte Intraperitoneal Transplantation Cohort 2|Participants will each be administered the dosage of 0.5×10^9 for one time, with 60 days follow-up after the cell infusion.
89449618|NCT05727722|Experimental|Micro-encapsulated Hepatocyte Intraperitoneal Transplantation Cohort 3|Participants will each be administered the dosage of 1.5×10^9 for one time, with 60 days follow-up after the cell infusion.
89449619|NCT05727722|Experimental|Micro-encapsulated Hepatocyte Intraperitoneal Transplantation Cohort 4|Participants will each be administered the dosage of 4.5×10^9 for one time, with 60 days follow-up after the cell infusion.
89449620|NCT03301610|Experimental|Mobile Education Delivery|The participants in the study arm will receive comprehensive pain management education delivered using mobile iPads at the point of care. The mobile based education modules will be inclusive of the use of the pain rating scale and assessment of pain; communication with healthcare providers; daily expectations for pain and pain management; pharmacologic and non-pharmacologic treatment options; medication side effects and safety; and discharge instructions including safe handling of opioids, disposal, tapering, and when to call the provider. It will also include an interactive pain and discomfort menu, knowledge based questions, and medication tracking log.
89449621|NCT03301610|Placebo Comparator|Standard verbal and written education|The control group will receive the current standard of care which consists of verbal instruction and pain management educational pamphlets. At a minimum, the patients will receive two educational pamphlets titled Your Pain and Discomfort Management Menu and Communicating About Your Pain. Verbal instruction is nurse dependent. At a minimum the nurse will provide the two pamphlets to the patient and follow-up with the patient to address any questions.
89449622|NCT02235207|Experimental|Neuromuscular exercise|The exercise group will participate in Fustra20 Neck & Back neuromuscular exercise program.
89449623|NCT02235207|No Intervention|Control group|Participants are encouraged to continue there usual physical activity and exercise
89449624|NCT05727566||Patients with primer myofascial pain sydrome|pain for at least three months (myofascial pain) reproductive-aged married womens (18-50 years)
88934557|NCT01770340|Sham Comparator|Control group|Radical prostatectomy without implantation of allograft
88934558|NCT01770340|Experimental|Treatment group|Radical prostatectomy with implantation of allograft
88934559|NCT01770405||pancreatic cysts|Patient indicated for a first endoscopic ultrasound fine needle aspiration (EUS-FNA) for a pancreatic cyst,
88934560|NCT01770444|Experimental|Low-dose cardiac CT|Patients randomized to this group will be assessed by low-dose cardiac CT protocol.
88934561|NCT01770444|Other|Conventional cardiac CT|Patients randomized to this group will be assessed by conventional cardiac CT protocol.
88934562|NCT01770470||Patients receiving chronic hemodialysis|Dialysis patients chewing chitosan-containing gum
88934563|NCT01770496|No Intervention|No reminder / recall notice|No childhood vaccination reminder / recall notification sent. Stratified by age cohort of subjects: 7 month recall; 12 month reminder; 19 month recall
88934564|NCT01770496|Experimental|mailed reminder / recall notice|Childhood vaccination reminder / recall notification sent by postal mail. Stratified by age cohort of subjects: 7 month recall; 12 month reminder; 19 month recall
88934565|NCT01770548|Experimental|Autism|Analysis of the glutamate synapse in autism
88934566|NCT01770548|Other|Relative|Analysis of the glutamate synapse in autism
88934567|NCT01770548|Other|Major control|DNA collection
88934568|NCT01770548|Other|Minor control|auditory evoked potentials
88934569|NCT01770561|Experimental|Integrated sensor and infusion set.|All subjects must have been previously diagnosed Type 1 Diabetics and being used to sensor augumented pumps
88934570|NCT01770574|Experimental|ReproBone|calcaneal lengthening
88934571|NCT01770574|Active Comparator|Autologous bone graft|calcaneal lengthening
88934572|NCT01770587|Experimental|Behavioral Insomnia Treatment|Brief Behavioral Insomnia Treatment
88934573|NCT01770600|Active Comparator|Risperidone|Administer pill of risperidone 1 mg once a day by mouth for 5 days.
88934574|NCT01770600|Placebo Comparator|Placebo|Administer pill of placebo once a day by mouth for 5 days.
88934575|NCT01770613|Experimental|Stem Cells|ALLOGENEIC MESENCHYMAL BONE MARROW CELLS
88934576|NCT01770613|Placebo Comparator|Control|Lactated Ringer's Solution
89014699|NCT04399603||Non-Covid critically unwell Patietns|
89449625|NCT05727566||Healthy controls|Healthy control of reproductive-aged married women with compatible sociodemographic characteristics
89449626|NCT03301454|Experimental|Arm A|Pursuit of chemotherapy.
89449627|NCT03301454|No Intervention|Arm B|Interruption of chemotherapy, best supportive care
89449628|NCT03916458||Subjects with reported metastatic renal cell carcinoma|The subjects have been treatment with sunitinib and they reached complete remission
89449629|NCT02467790|Experimental|Mild renal insufficiency|PEX 168: 200µg,Subcutaneous,one time.
89449630|NCT02467790|Experimental|Moderate renal insufficiency|PEX 168: 200µg,Subcutaneous,one time.
89449631|NCT02467790|Experimental|Normal renal function|PEX 168: 200µg,Subcutaneous,one time.
88934577|NCT01770626|No Intervention|Single arm|evaluate the composition of a participant's body, diagnosed with a brain tumor (glioblastoma multiforme) as determined by bioelectrical impedance analysis
88934578|NCT01770639||MFB|Surgical arthrodesis of the midfoot with the Midfoot Fusion Bolt (MFB)
88934579|NCT01770665||Mesothelioma|
88934580|NCT01770665||all cancer types|
88934581|NCT01770678|Experimental|Constraint induced movement therapy (prolonged restraint)|Constraint induced movement therapy(prolonged restraint)consists of a combination of prolonged restraint of the unaffected upper limb and massed practice of the affected upper limb over a forty-two day period.
88934582|NCT01770678|Active Comparator|Constraint induced movement therapy(manual restraint)|Constraint induced movement therapy(manual restraint)consists of a combination of manual restraint of the unaffected upper limb and massed practice of the affected upper limb over a forty-two day period.
88934583|NCT01770704||Patients diagnosed with bipolar disorder I or II|
88934584|NCT01770730|Experimental|LAM plus standard care|Patients allocated to this study arm will receive urine LAM strip testing in addition to the standard TB diagnostic tools WHO approved and available at each site
88934585|NCT01770730|No Intervention|Standard care|Patients allocated to this study arm will receive standard TB diagnostics currently WHO approved and available at the study site
88934586|NCT01770769|Active Comparator|Internal fixation - standard treatment|Internal fixation with two parallel cancellous screws (Hip Pins(R)) Current standard treatment
88934587|NCT01770769|Experimental|Hemi - arthroplasty|cemented Hemi - arthroplasty (Exeter(R)) modular system V40 by Stryker. Refobacin cement.
88934588|NCT01770782|Other|Laser Scanner|Laser Scanner (Vivid 9i® - Konica Minolta)was used to digitize the study casts. After scanning the dental casts a 3D virtual dental casts was used to realize all measurements (pre-treatment, 4 months and 10 months).
89200692|NCT03472365|Experimental|Cohort 1|Participants receive SHR-1210 200 mg, intravenously (IV) every 3 weeks(Q3W) plus capecitabine 1000 mg/m^2 twice daily (BID) by continuous oral administration for 14 days, followed by a recovery period of 7 days, plus oxaliplatin 130 mg/m^2, IV q3w; for 4-6 cycles followed by SHR-1210 plus apatinib 375 mg PO qd if there is no PD.
89200693|NCT03472365|Experimental|Cohort 2|Participants receive SHR-1210 200 mg, intravenously (IV) every 3 weeks(Q3W) plus apatinib 375 mg daily (QD) continuous oral administration of each 3-week cycle.
89449632|NCT02235363|Experimental|facelift|In facial rejuvenating surgery, the current trend calls for fewer and less noticeable scars with desired results. Especially to improve the jowls and nasolabial folds, the thread lift is a simple and inexpensive technique for patients who do not wish to undergo the typical facelift surgery, but the weak points of it are less effective and shorter duration than the conventional facelift.The investigators propose the new method of the thread lifting the subdermal and subcutaneous layer by use of the retaining ligaments with two fixation points on both temporal fascia and retaining ligaments.
89200694|NCT03200977||Exposed to nivolumab prior to allogeneic HCT|patients who were treated with nivolumab-based regimen prior to an allogeneic HCT
89200695|NCT03200977||Unexposed to nivolumab prior to allogeneic HCT|patients who were not treated with nivolumab-based regimen prior to an allogeneic HCT
89449633|NCT03469440|Active Comparator|Goal-directed therapy|Patients randomized to this group will be monitoring by continuous central venous oxygen saturation. Central venous oxygen saturation will be targeted higher than 65% in non-cyanogenic patients and 55% in cyanogenic.
89449634|NCT03469440|Other|Standard protocol|The control group will keep the standard therapy.
89449635|NCT02801331|Experimental|Stochastic Vibrotactile Stimulation (SVS)|Infants randomized to this arm will receive daily intervals of continuous SVS (ON) and no SVS (OFF) throughout hospitalization, starting within 48-hrs post birth. SVS will be complementary to standard of clinical care (e.g., clinically-determined pharmacological management; routine parental/volunteer holding; breast and/or bottle feed). Infants will be scored for severity of withdrawal using standardized, modified Finnegan scoring system by clinical care nurses per routine clinical care throughout hospitalization.
89449636|NCT02801331|No Intervention|Treatment as Usual (TAU)|Infants randomized to this arm will be enrolled within 48-hours post birth and receive treatment as usual (TAU)- standard of clinical care (e.g., clinically-determined pharmacological management, routine/volunteer holding; breast and/or bottle feed). Infants will not receive any SVS. Infants will be scored for severity of withdrawal using standardized, modified Finnegan scoring system by clinical care nurses per routine clinical care throughout hospitalization.
89449637|NCT03234738|Active Comparator|Cohort A|Multiple IV doses of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 0.5 mg/kg once daily for 7 days, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
89449638|NCT03234738|Active Comparator|Cohort B|Multiple IV doses of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 1.0 mg/kg once daily for 7 days, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
89200696|NCT00978952|Experimental|Investigational Group|Use of Large Diameter Advanta™ V12 Covered Stent.
89200697|NCT00896259||THA control|those with THA not participating in exercise and education program
89200698|NCT00896259||THA exercise|those with THA and participating in exercise and education program
89200699|NCT00896259||healthy control|Healthy control, people with no lower limb gait abnormalities
89200700|NCT00971854|Experimental|60 Hz stimulation|Experimental reduced frequency pallidal stimulation
89200701|NCT00971854|No Intervention|130 Hz stimulation|Current standard pallidal stimulation setting
89200702|NCT00894621|Experimental|Norepinephrine|
89200703|NCT00894621|Placebo Comparator|Placebo|
89200704|NCT00901095|No Intervention|Control|Usual Care
89449639|NCT03234738|Active Comparator|Cohort C|Multiple IV doses of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 2.0 mg/kg once daily for 7 days, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
89449640|NCT03234738|Active Comparator|Cohort D|Multiple IV doses of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 2.5 mg/kg once daily for 7 days, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
89449641|NCT03234738|Active Comparator|Cohort E|Multiple IV doses of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 3.0 mg/kg once daily for 7 days, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
89449642|NCT03301142|Experimental|Device laser|treatment with application of Erbium Laser: YAG 2940nm, SMOOTH mode, one session per month for three months (n=20
89449643|NCT03301142|Active Comparator|kinesiotherapy|with supervision twice a week for three months (n=20)
89449644|NCT04457388|Experimental|Tele-Yoga Therapy|Individualised Yoga therapy based on participant's clinical condition and personal needs. Twice a week sessions were carried out by trained and experienced Yoga therapist via video conference with each therapy for individualized based on each participant.
89449645|NCT03302000|Experimental|Visual stimulation|"Early visual stimulation (EVS) will be implemented by caregivers.~Three phases:~the caregiver will establish eye-to-eye contact with the infant. The caregiver will communicate with the infant talking, singing, changing facial expressions, touching his/her face. Total duration of this part of stimulation is between 2 and 3 minutes~the caregivers will present visual contrast cards at a distance of 15-20 centimetres~the caregiver will present two toys to the infant~Stimulation will last for 28 days (4 weeks) in total, one time a day for 10-15 minutes, all days week."
89449646|NCT03302000|Other|standard care|Caregivers will receive an Illustrated Handbook, according to the age range of birth to three months. Assessors will explain all information contained in the handbook after the first assessment and randomisation.
89449647|NCT05727410|Experimental|nivolumab, docetaxel, cisplatin Group|nivolumab, docetaxel, cisplatin (IV infusion every 3 weeks)
89449648|NCT03653715|Experimental|Test Device|Within this arm the Clerio Vision LIRIC-modified Bifocal Contact Lens is administered.
89449649|NCT03653715|Active Comparator|Control Devices|Within this arm the Johnson & Johnson 1-Day Acuvue Moist Multifocal Contact Lens, Johnson & Johnson 1-Day Acuvue Moist Contact Lens, and Clerio Vision Single Vision Contact Lens are administered.
89449650|NCT02467010|Experimental|Bortezomib, cyclophosphamide, dexamethason|"To assess the efficacy of bortezomib, cyclophosphamide and dexamethasone during re-induction and in maintenance therapy.~To assess the safety of bortezomib, cyclophosphamide and dexamethasone during re-induction and in maintenance therapy in patients with refractory or relapsed multiple myeloma."
89449651|NCT02232555|Experimental|Duloxetine|
89449652|NCT02232555|Placebo Comparator|Placebo|
89449653|NCT02235441|Experimental|Cardiopulmonary Fitness|All eligible subjects will participate in treadmill exercise to measure cardiopulmonary fitness during chemoradiation therapy.
89449654|NCT03300986||Functional Electrical Stimulation (FES) users|
89449655|NCT02235519|Active Comparator|Azilsartan low dosage|Patients will take azilsartan 40 mg during 12 weeks
89449656|NCT02235519|Active Comparator|Azilsartan high dosage|Patients will take azilsartan 80 mg during 12 weeks
89449657|NCT03300908|Experimental|Project ADHERE|Participants will receive a 3-session antiretroviral medication adherence and risk reduction intervention called Project ADHERE.
89449658|NCT03300908|Active Comparator|Control MACE|Participants will receive a one-session antiretroviral medication adherence intervention called MACE.
89449659|NCT05376501|Experimental|Astaxanthin|"Active Ingredient:~Astaxanthin~Inactive ingredients:~Modified food starch, sucrose, water, sodium ascorbate, DL- alpha tocopherols"
89449660|NCT05376501|Placebo Comparator|Placebo|Modified food starch, sucrose, hylocereus polyrhizus (pitaya) concentration
89449661|NCT02466932||Birth Weight|
89449662|NCT02235597||Patients and Staff of Community Clinics|Patients and Staff of Community Clinics who shared strategies and solutions to overcome barriers to accessing health care
89449663|NCT05727254|Experimental|Agility Training|16 weeks, two times per week, 1 hour of multi-component exercise training, exercise guidelines and exercise diary.
89449664|NCT05727254|Active Comparator|Control|Exercise guidelines and exercise diary.
89449665|NCT02235675|Experimental|Tack-It|Implant of the Intact Vascular Tack-It Endovascular System to repair post angioplasty dissections.
89449666|NCT02235753|Experimental|High-intensity interval training, HIT-S|High-intensity aerobic interval training, short interval (HIT-S)
88934589|NCT01770782|Other|SARME|Surgically Assisted rapid Maxillary Expansion -SARME was used for the treatment of transverse maxillary deficiency.This procedure is a combination of a surgical procedure and orthopedic expansion of the maxilla.
88934590|NCT01770795|Experimental|Genexol-PM/Gemcitabine|
88934591|NCT01770808|Experimental|AquaCal|AquaCal is produced by Marigot Ltd. The daily dose of 4 capsules of AquaCal provide 800mg calcium, (the EU RDA for calcium) and 74 mgs Magnesium (EU RDA 375mg).
88934592|NCT01770808|Experimental|AquaPT|AquaPT are produced by Marigot Ltd. The daily dose of 4 capsules of AquaPT provides 720mg calcium, 200mgs green tea (polyphenols) and 50 mgs pine bark extract.
88934593|NCT01770808|Placebo Comparator|Placebo|Produced by Marigot Ltd
88934594|NCT01770834||Cohort|
88934595|NCT01770847||Healthy controls|Healthy age matched controls
88934596|NCT01770847||Chronic kidney diease|Chronic kidney disease patients stage 2-4
89449667|NCT02235753|Experimental|High-intensity interval training, HIT-L|High-intensity aerobic interval training, long interval (HIT-L)
89449668|NCT02235753|No Intervention|Usual care|control group
89449669|NCT00702650|Experimental|Testosterone MD-Lotion|"Participants received Testosterone Metered Dose (MD)-Lotion for 120 days. Participants started by receiving 3.0 mL (60 mg) of 2% Testosterone MD-Lotion, and based upon restoration to eugonadal levels, may have had their dose of testosterone adjusted upwards or downwards on Days 45 and 90.~Doses could be titrated to one of the following:~1.5 mL (30 mg) of 2% Testosterone MD-Lotion applied daily by 1 dose to the axilla (1.5 mL to one axilla).~3.0 mL (60 mg) of 2% Testosterone MD-Lotion applied daily by 2 doses to the axilla (1.5 mL to each axilla).~4.5 mL (90 mg) of 2% Testosterone MD-Lotion applied daily by 3 doses to the axilla (2 x 1.5 mL to one axilla and 1 x 1.5 mL to the other axilla).~6.0 mL (120 mg) of 2% Testosterone MD-Lotion applied daily by 4 doses to the axilla (2 x 1.5 mL to each axilla)."
89449670|NCT03300596|Experimental|brief intervention to prevent suicide attempt|Individuals presenting to hospital following a suicide attempt who are age 18-plus and screen positive for alcohol or drug use problem
89449671|NCT03300596|Other|standard of care|Individuals presenting to hospital following a suicide attempt who are age 18-plus and screen positive for alcohol or drug use problem
89449672|NCT01337115|Active Comparator|Continuous femoral nerve block (CFNB)|A continuous femoral nerve block is performed for peri-operative analgesia and a bolus of 30 ml of ropivacaine 0.375% is injected before induction of general anesthesia and surgery starts. An infusion of 8ml/h of ropivacaine 0.2% is started in post anesthesia care unit (PACU) and maintained for 48h
88934597|NCT01770873|Experimental|Take Charge 2|Receipt of BBBS mentoring plus youth and parent violence prevention curriculum
88934598|NCT01770873|No Intervention|Control|Standard emergency room protocol followed
88934599|NCT01770886|Active Comparator|UE2343|Oral capsule
88934600|NCT01770886|Placebo Comparator|Placebo|Oral capsule
88934601|NCT01770899|Experimental|Montelukast|Montelukast 5mg capsules for 2-5 year old every 24h and 8mg capsules for 6-14 year olds every 24h.
88934602|NCT01770899|Placebo Comparator|Placebo|One placebo capsule given every 24h
88934603|NCT01770925|Active Comparator|n-CPAP|"The n-CPAP group will receive at extubation a single level continuous positive airway pressure of 7 cm water for at least 48 hours before weaning is commenced. If the infant is stable for the preceding 48 hours defined by having fewer than three minor apneas and no increase in oxygen requirement, weaning will be permitted.~CPAP will be decreased from 6 cm water by 1 cm water every 24 hours if tolerated based on the above criteria. This will be done until a pressure of 4 cm water is reached.~If a pressure of 4 cm water is successfully tolerated for 48 hours then time off n-CPAP will be allowed. Thereafter, no fixed weaning regime based on number of hours in a day the infant will be allowed to come off CPAP will be prescribed."
89014700|NCT04397939||Patients with Acute Cardiac Injury|Patients with acute cardiac injury
89449673|NCT01337115|Experimental|Single shot SNB plus CFNB|A single shot sciatic nerve block (SNB) is performed before surgery with 25ml of 0.2% ropivacaine in addition to the continuous femoral nerve block (CFNB) performed in the control group before induction of general anesthesia and surgery starts. An infusion of 8ml/h of ropivacaine 0.2% is started in Post anesthesia care unit (PACU) and maintained for 48h
89449674|NCT03761784|Experimental|S6G5T-3|Participants will topically apply S6G5T-3 cream, once daily to face for 12 weeks.
89200705|NCT00901095|Experimental|Lifestyle intervention|The Lifestyle intervention group consists of in-person meetings co-led by an exercise specialist and dietician as well as follow-ups with an interventionist by phone.
89200706|NCT00979108|Active Comparator|Standard exercise|Subjects will be instructed in neck and postural exercises.
89449675|NCT03761784|Placebo Comparator|S6G5T-8 Vehicle Cream|Participants will topically apply S6G5T-8 vehicle cream, once daily to face for 12 weeks.
89449676|NCT04100187|Experimental|experimental:3|Leukemia treated with chimeric antigen receptor modified T cells(Anti-CD19-CAR) targeting CD19.
89449677|NCT03300440|Experimental|Intervention group|Probiotics and vitamin B7
89449678|NCT03300440|Placebo Comparator|Control group|Placebo and vitamin B7
89449679|NCT02236065|Experimental|UCB + G-CSF|UCB + G-CSF
89449680|NCT02467556|Other|intervention|Open label study with psychological intervention and physiotherapy intervention with medication of morphine, memantine for ten weeks (morphine 30mg tbl per day and memantine up to 40mg tbl per day if tolerated).
89449681|NCT02262585|Experimental|BIBR 277 tablet|(Mannitol based)
89449682|NCT02262585|Active Comparator|BIBR 277 capsule|
88934604|NCT01770925|Active Comparator|n-BiPAP|"The n-BiPAP group will receive at extubation a mean airway pressure of 7 cm water (positive end expiratory pressure of 5 cm water and peak inspiratory pressure of 9 cm of water). Inspiratory time of one second and respiratory rate of 30/min will always be maintained.~The infant will then receive a mean airway pressure of 5 cm water (positive end expiratory pressure of 4 cm water and peak inspiratory pressure of 6 cm of water)."
88934605|NCT01770925|Active Comparator|NIPPV|o The NIPPV group will receive at extubation a positive end expiratory pressure of 5 cm water, peak inspiratory pressure of 15cm of water, RRof35 and Ti of 0.32
88934606|NCT01770938|Active Comparator|Effective light-emitting diode therapy and training|Effects of effective light-emitting diode therapy therapy on muscle performance of young males submitted to physical strength training
88934607|NCT01770938|Placebo Comparator|Placebo light-emitting diode therapy and training|Effects of placebo light-emitting diode therapy on muscle performance of young males submitted to physical strength training
88934608|NCT01770964|Other|Training Type A, pregabalin|Subjects randomized to receive pregabalin at a site that received training Type A
88934609|NCT01770964|Other|Training Type B, pregabalin|Subjects randomized to receive pregabalin at a site that received training Type B
88934610|NCT01770964|Other|Training Type A, placebo|Subjects randomized to receive placebo at a site that received training Type A
88934611|NCT01770964|Other|Training Type B, placebo|Subjects randomized to receive placebo at a site that received training Type B
88934612|NCT01770977|Active Comparator|Effective Light-emitting diode therapy|Effects of light-emitting diode therapy on clinical, biochemical and biomechanical of muscle performance in athletes
89014701|NCT04397939||Patients without cardiac injury|Patients without cardiac injury
89200707|NCT00979108|Experimental|Over-door traction and exercise.|Subjects will receive traction utilizing an over-the-door traction unit in addition to neck and postural exercises.
89200708|NCT00979108|Experimental|Mechanical traction and exercise|Mechanical cervical traction will be utilized in addition to neck and postural exercises.
89200709|NCT00376675|Experimental|Arm I|Patients receive oral methylphenidate hydrochloride daily on days 1-28.
89200710|NCT00376675|Placebo Comparator|Arm II|Patients receive oral placebo daily on days 1-28.
89200711|NCT02539875|Experimental|AWARD, Brief leaflet, Referral leaflet, active referral|AWARD will be delivered to smokers onsite and this includes: Ask about smoking history, Warn about the high risk, Advise to quit as soon as possible and not later than a quit date (which will qualify them for the QTW prizes), Refer smokers to smoking cessation services, and Do it again: to repeat the intervention. Brief innovative leaflet on health warning and smoking cessation. A 2-side color printed A4 leaflet will be designed to systematically cover the most important messages to motivate smoking cessation. A 2-side color printed A4 referral leaflet will be used for motivate and assist the smokers to use the smoking cessation services. the smokers will be active refer to various smoking cessation services in Hong Kong (using the referral leaflet) and motivate the smokers to use the smoking cessation services.
89449683|NCT03309254|Experimental|High Glycemic Index|White Bread with Turkey breast meat (2 slices) Turkey Breast (7 slices) Chamomile Tea with 25 grams glucose Almonds 15 grams
89449684|NCT03309254|Experimental|Low Glycemic Index|Multi-grain Bread with Turkey breast meat (2 slices) Turkey Breast (6 slices) Chamomile Tea with 25 grams fructose Cashews 10 grams
89449685|NCT03195894|Experimental|Conventional treatment and TripleA|Conventional treatment and TripleA medical device consisting of alcoholometer, a Bluetooth mobile app on cell phone and information stored on computer for caregiver
89449686|NCT03195894|No Intervention|Conventional treatment|Conventional treatment
89014702|NCT04397939||Patients with Chronic Cardiac Injury|Patients with chronic cardiac injury
89014703|NCT04396574|Experimental|Lasmiditan Dose 1|Lasmiditan administered orally.
89014704|NCT04396574|Experimental|Lasmiditan Dose 2|Lasmiditan administered orally.
89014705|NCT04394819||experimental and control groups|"Task-oriented EMG-triggered ES treatment will be applied to the experimental group 2 days a week for 5 weeks and will continue with conventional physiotherapy.~The control group will only continue conventional physiotherapy treatment."
89449687|NCT02262663|Experimental|Vilaprisan [0.5mg]|0.5 mg BAY1002670, oral administration, one tablet to be taken daily, 84 consecutive days
89014707|NCT04380987||Predicovid|
89014708|NCT04362072|Experimental|Lorlatinib|Participants will take 100 mg (four, 25 mg tablets) once daily.
89014709|NCT04356183|Other|Counseling Health As Treatment (CHAT)|CHAT is a control arm designed to reflect traditional clinical counselling.
89014710|NCT04356183|Experimental|Supervised Weight loss and Exercise Training (SWET)|SWET includes supervised aerobic (3x/w) and resistance (2x/w) training plus a weekly weight loss session.
89014711|NCT04353687||Cohort 1 Open Surgeons|Primarily open inguinal hernia surgeon with no or limited previous robotic-assisted experience.
89014712|NCT04353687||Cohort 2 Laparoscopic Surgeons|Primarily laparoscopic inguinal hernia surgeon with no or limited previous robotic-assisted experience.
89014713|NCT04325958|Other|Age group 19 to 25|Participants will complete two sessions: one where they drive the simulator before and after smoking a placebo cannabis cigarette (<1% THC), the other where they drive the simulator before and after smoking an active cannabis cigarette (15% ± 5% THC).
89014714|NCT04325958|Other|Age group 35 to 45|Participants will complete two sessions: one where they drive the simulator before and after smoking a placebo cannabis cigarette (<1% THC), the other where they drive the simulator before and after smoking an active cannabis cigarette (15% ± 5% THC).
89449688|NCT02262663|Experimental|Vilaprisan [1mg]|1 mg BAY1002670, oral administration, one tablet to be taken daily, 84 consecutive days
89014716|NCT04278352|Experimental|Mindfulness Based Relapse Prevention|MBRP is a group aftercare program that integrates mindfulness skills training with cognitive-behavioral relapse prevention strategies. The intervention consists of eight weekly two-hour group therapy sessions, delivered by two facilitators with 6-12 people. The experimental group will complete the intervention in weeks 1-8. They will continue treatment as usual for weeks 9-16.
89014717|NCT04278352|No Intervention|Control|The waitlist control group will not receive the MBRP program during weeks 1-8 and will continue treatment as usual. During weeks 9-16, the control group will receive MBRP.
89449689|NCT02262663|Experimental|Vilaprisan [2mg]|2 mg BAY1002670, oral administration, one tablet to be taken daily, 84 consecutive days
89449690|NCT02262663|Experimental|Vilaprisan [4mg]|4 mg BAY1002670, oral administration, one tablet to be taken daily, 84 consecutive days
89014718|NCT04277026|Experimental|Mindful Walking|Eight weekly 60 minute mindful walking sessions involving observations of bodily sensations, experiences, and breath. Discussion of mindful walking experiences and encouragement to meet physical activity goals. The intervention will take place two times per week for four weeks (Weeks 1-4). During weeks 5-8 the experimental group will continue treatment as usual and will not be receiving the mindful walking intervention.
89014719|NCT04277026|No Intervention|Control|Participants will engage in treatment as usual during the first four weeks and will not be receiving the experimental intervention (mindful walking) during weeks 1-4. After the experimental group completes the mindful walking intervention, the control group will complete the mindful walking intervention (weeks 5-8).
89014720|NCT04270409|Experimental|Isatuximab, lenalidomide, and dexamethasone (ILd)|Participants will receive isatuximab [intravenous (IV) administration] in combination with lenalidomide [per os (PO) administration] and dexamethasone [IV on Day 1 of Cycle 1 for participants receiving isatuximab IV only and PO otherwise for subsequent cycles] for 24 cycles followed by isatuximab monotherapy for 12 cycles for a total duration of 36 cycles. 1 cycle = 28 days. Participants may receive other treatments as pre-medication.
89014721|NCT04270409|Active Comparator|Lenalidomide and dexamethasone (Ld)|Lenalidomide [PO administration] in combination with dexamethasone [PO administration] for 24 cycles. 1 cycle = 28 days
89449691|NCT03309176|Active Comparator|Standard group|Intervention:Medroxyprogesterone acetate (Provera) 10 mg daily for 10 days will be used prior to starting ovulation induction with clomiphene citrate (CC) and between anovulatory cycles. On cycle day (CD) 3 CC 50 mg is administered daily for 5 days. Follicle growth will be monitored by ultrasound, starting from CD11. Anovulatory patients (defined as no follicle ≥ 14 mm) on CD20, will receive Provera 10mg daily for 10 days. The CC dosage will be increased in the next cycle. On CD3 patients will receive CC 100 mg daily for 5 days with ultrasounds performed from CD11 onwards. Anovulatory patients will receive Provera 10mg daily for 10 days. In the next cycle the CC dose will be increased to 150 mg, starting from CD3, daily for 5 days with ultrasounds starting from CD11-20.
89449692|NCT03309176|Experimental|Stair Step group|Intervention: Stair step protocol without medroxyprogesterone acetate 10 mg prior to ovulation induction with clomiphene citrate (CC), nor in between anovulatory cycles. After performing an ultrasound to check for the presence of cysts or any other abnormalities and a negative pregnancy test, patients will receive CC 50 mg daily for 5 days. Ultrasounds will be performed on CD11-14. If there is no response on CD14 (no follicle ≥ 14 mm), the dose of CC is immediately increased to 100 mg CC daily for 5 days and an ultrasound is performed 1 week following the last ultrasound. If there is no response, 150 mg CC daily is initiated immediately for 5 days and the ultrasound is repeated 1 week after the previous ultrasound.
89449693|NCT05727020||VAPOR 1 - PDAC (pancreatic ductal adenocarcinoma)|"257 treatment-naive patients with histologically-confirmed* PDAC will be recruited to provide breath samples.~*Patients that are due to undergo surgery for suspected PDAC (without pre-operative histological confirmation) may still be recruited despite the lack of pre-operative histological confirmation, assuming PDAC is subsequently confirmed within the resected specimen."
89014722|NCT04270266|Experimental|Group I (meditation)|Patients attend meditation group sessions over 75 minutes once weekly for up to 5 weeks.
89014723|NCT04270266|Active Comparator|Group II (educational)|Patients attend educational group sessions over 75 minutes once weekly for up to 5 weeks.
89449694|NCT05727020||VAPOR 1 - Control patients with benign pancreatic disorders|"257 patients with new-onset diabetes mellitus or chronic pancreatitis will be recruited to provide breath samples.~New-onset diabetes is defined as: HbA1c≥48mmol/mol (6.5%), diagnosed within the preceding 6 months."
89449695|NCT05727020||VAPOR 1 - Control patients with non-specific GI symptoms and a normal pancreas|"257 patients with non-specific gastrointestinal symptoms but a radiologically-normal pancreas will be recruited to provide breath samples.~Imaging to confirm a normal pancreas (CT / MRI / ultrasound) must have occurred within the preceding 12 months."
88934613|NCT01770977|Placebo Comparator|Placebo light-emitting diode therapy|Effect of placebo light-emitting diode therapy on clinical, biochemical and biomechanical of muscle performance in athletes
88934614|NCT01770990|Active Comparator|Tel-PT without mail|Telephone-based psychotherapy (1 personal session, 8-10 telephone sessions, educational materials and monitoring questionnaires) without additional motivating letters.
88934615|NCT01770990|Experimental|Tel-PT including mail|Telephone-based psychotherapy (1 personal session, 8-10 telephone sessions, educational materials and monitoring questionnaires) with an additional motivating letter after every telephone session.
88934616|NCT01771003|Placebo Comparator|Without CellAegis' autoRIC™ Device|patients will have a blood pressure cuff attached to their arm that will not inflate/deflate as in the active group
88934617|NCT01771003|Active Comparator|With CellAegis' autoRIC™ Device|Patients will have the CellAegis' autoRIC™ Device attached and it will inflate to 200 mmHg in four 5 minute cycles with intervening 5 minutes of reperfusion with the cuff deflated between cycles (while under general anesthetic)
88934618|NCT01771042|Experimental|Normal glucose tolerant|"Weight loss attained by 25% caloric restriction.~This arm will be both a glycemic and time control. Initially they will undergo a 4-month weight maintenance phase (acting as time control), followed by 4 month weight loss."
88934619|NCT01771042|Experimental|Impaired glucose tolerant|"Weight loss using 25% caloric restriction.~Impaired glucose tolerant subjects will undergo 4 months weight loss (25% caloric deficit) followed by 3 months weight loss maintenance"
88934620|NCT01771042|Experimental|Type 2 diabetic hyperinsulinemic|"Weight loss using 25% caloric restriction.~This group will undergo 4 months weight loss (25% caloric deficit) followed by 3 months weight loss maintenance"
88934621|NCT01771042|Experimental|Type 2 diabetic hypoinsulinemic|"Weight loss via 25% caloric restriction.~This group will undergo 4 months weight loss (25% caloric deficit) followed by 3 months weight loss maintenance"
88934622|NCT01771068|No Intervention|Waiting list|
89449696|NCT05727020||VAPOR Bioresource - PDAC (pancreatic ductal adenocarcinoma)|"96 treatment-naive patients with histologically-confirmed* PDAC will be recruited to provide samples of breath, saliva, blood, urine, pancreatic tissue and duodenal aspirate.~*Patients that are due to undergo surgery for suspected PDAC (without pre-operative histological confirmation) may still be recruited despite the lack of pre-operative histological confirmation, assuming PDAC is subsequently confirmed within the resected specimen."
89449697|NCT05727020||VAPOR Bioresource - Control patients with benign pancreatic disorders|96 patients with benign pancreatic disorders (such as intraductal papillary mucinous neoplasms, pancreatic mucinous cystic neoplasms, chronic pancreatitis) will be recruited to provide samples of breath, saliva, blood, urine, pancreatic tissue and duodenal aspirate.
89449698|NCT02602353|Experimental|Loxoprofen Pain Patch|One Active Pain Patch containing loxoprofen applied once daily for 3 days
89449699|NCT02602353|Placebo Comparator|Placebo Patch|One Placebo Patch applied once daily for 3 days
89449700|NCT02602353|Other|No Treatment|No Treatment for 3 days
89449701|NCT02467634|Experimental|HuCNS-SC|HuCNS-SC sub-retinal transplantation
89449702|NCT04983498|Experimental|Prospective Experimental Group|For the experimental group, we will recruit 200 participants who will receive the Enhanced Recovery Pathway, which will be ordered as a standing order set by the attending provider and managed by their peri-procedural nurses. The modified ERP for this study includes the following interventions: nursing managed order sets with ERP instructions to receive goal-directed fluid management within anesthesia approved parameters utilizing the NMH Colorectal ERAS protocol for IV fluid administration, PONV prophylaxis for participants with an apfel score of 2 or greater (ondansetron 4 mg IV), an additional dose of ondansetron 4mg IV will be available in recovery if the patient has nausea/vomiting despite prophylaxis, early mobilization up to chair (within 5-30 minutes of admission to the recovery room) based on nursing parameters, and early PO intake within 15-30 minutes of admission to the recovery room post-procedure based on nursing parameters.
89449703|NCT04983498|No Intervention|Retrospective Control Group|The retrospective group will consist of 200 randomly selected medical records of patients who had colonoscopy procedures for a 6 month period prior to study implementation (between 10/1/2019 to 4/1/2020). The retrospective control group will have received the current standard of care including: IV fluids for management of intra-procedural hypotension as indicated/ordered by the physician, PO intake at 30-45 minutes, up to a chair at 60 minutes, and all procedure related complications will have been treated (e.g. PONV) per physician order as is the current standard of practice in the GI Lab recovery area.
89449704|NCT04831424|Experimental|Healthy controls|No diagnosis of mitochondrial disease
88934623|NCT01771068|Experimental|Parenting Discussion Group|Two-hour discussion group on child noncompliance. Groups were composed by a maximum of 10 parents and were facilitated by the principal researcher, who is an accredited practitioner. The groups were interactive and discussion based, and a power point presentation with embedded-video clips was used to aid the facilitator. The key points covered in the discussion group included reasons for disobedience, parenting traps, encouraging good behaviour, and managing disobedience. Parents also received a workbook that included the content covered in the discussion group and 2 follow up telephone calls to check how they were doing after the discussion groups.
88934624|NCT01771081||Group1|
88934625|NCT01771094|Placebo Comparator|Group 1 (placebo) - Water|This group will drink water in 1st trial
88934626|NCT01771094|Experimental|"Group 3 (Intervention) - Low Sucralose"|This group will drink Decarbonized Pineapple with a 50% decrease of sucralose face to standard beverage in 1st trial
88934627|NCT01771094|Experimental|"Group 2(Intervention)-High Sucralose"|This group will drink Decarbonized Pineapple Diet Soda with a 50% increase of sucralose face to standard beverage in 1st trial
88934628|NCT01771120||Asthma Group|Subjects will undergo diagnostic tests, medical interview and questionnaires
88934629|NCT01771120||Rhinitis Group|Subjects will undergo diagnostic tests, medical interview and questionnaires
89449705|NCT04831424|Experimental|Mutation|Participants carrying the m.3243A>G point mutation, without a diagnosis of MELAS (mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes)
88934630|NCT01771120||Asthma and Rhinitis Group|Subjects will undergo diagnostic tests, medical interview and questionnaires
89449706|NCT04831424|Experimental|Mutation with MELAS|Participants carrying the m.3243A>G point mutation, with a diagnosis of MELAS (mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes)
89449707|NCT04831424|Experimental|Deletion|Participants carrying a single, large-scale mtDNA deletion
89449708|NCT01337973|Experimental|Arm 1: MI-CBT|MI-CBT (six sessions during acute treatment phase integrating motivational interviewing and cognitive behavioral approaches)
89449709|NCT01337973|Experimental|Arm 2: MI-CBT+CC|MI-CBT+CC (acute phase MI-CBT intervention plus a subsequent 12-week phone based continuing care counseling intervention)
88934631|NCT01771120||Healthy Group|Subjects will undergo diagnostic tests, medical interview and questionnaires
89449710|NCT01337973|Active Comparator|Arm 3: E-TAU|E-TAU (enhanced treatment as usual - includes brief session and provision of resources)
89449711|NCT03300362|Experimental|Seasonal influenza & MVA-NP+M1|Two vaccinations will be administered: Seasonal influenza vaccine & MVA-NP+M1
89449712|NCT03300362|Placebo Comparator|Seasonal influenza & saline placebo|Two vaccinations will be administered: Seasonal influenza vaccine & sodium chloride
89449713|NCT04787874|No Intervention|Control|The control arm will receive no additional prehabilitation material prior to material. Rather, they will receive standard preoperative care in which they will be given standard advice on nutrition and fitness. REDcap surveys will be administered.
89449714|NCT04787874|Experimental|Prehab Intervention Arm|The intervention arm will receive access to the prehab program (abdominal workout videos) and surveys via RedCAP.The program will start no less than 14 days before the date of surgery.
89449715|NCT03469206|Sham Comparator|Direct MT|Direct mechanical thrombectomy (MT) with no intravenous thrombolysis
89449716|NCT03469206|Active Comparator|IVT combine with MT|Intravenous thrombolysis before mechanical thrombectomy
88934632|NCT01771133|No Intervention|Lifestyle and nutrition control group|The control arm will receive routine prenatal care in the prenatal clinic. They will receive regular phone calls and mailings, token gifts and some useful information from data collected in the study, such as physical activity, feedback on behavior throughout the study. To additionally promote adherence (since they will have less contact with study staff), we will include 2 pre-partum and 1 post-partum group sessions meant to increase bonding between participants and retention of control participants. These sessions will include general pregnancy information not related to our interventions.
89449717|NCT02467400|Placebo Comparator|placebo|Sugar pill 2/day for 20 weeks; The once daily groups will receive a placebo as the second dose
88934633|NCT01771133|Active Comparator|Lifestyle intervention group|The lifestyle intervention will be delivered within an empowerment framework which promotes behavioral changes by facilitating health self-efficacy, utilizing self-praise and using active coping skills to address and manage emotions. A nutrition component primarily focuses on total calories, for which energy requirements will be individually calculated for each pregnant women and on general diet quality with an emphasis on carbohydrate quality. It will also promote an overall healthy diet, emphasizing improvement of fat quality and reducing salt intake. A physical activity component focuses on promoting regular movement and minimizes the duration of bouts of sitting or lying during waking hours as well as non-exercise activity.
88934634|NCT01771146|Other|Neoadjuvant FOLFIRINOX Regimen|Single arm, treated with neoadjuvant FOLFIRINOX prior to surgical resection
88934635|NCT01771159|Experimental|Population|All subjects will undergo the implantation of the TBC.
88934636|NCT01771185|Active Comparator|Best medical treatment|Metformin 2 g/day; gliclazide 30 mg
88934637|NCT01771185|Active Comparator|Duodenal jejunal bypass plus sleeve gastrectomy|Duodenal jejunal bypass plus sleeve gastrectomy is a metabolic surgical procedure
88934638|NCT01771198|Experimental|SIMVASTATIN 40mg|SIMVASTATIN tablet of 40mg once a day during 30 days. Single arm with pre and post treament assessment
88934639|NCT01771211|Experimental|anodal tDCS|anodal tDCS will be administered for 20 minutes with 1 milliampere (1 mA) to the left inferior frontal gyrus
89449718|NCT02467400|Active Comparator|Atenolol|Atenolol 50 mg 1/day for 20 weeks
89449719|NCT02467400|Active Comparator|Nebivolol|Nebivolol 5 mg/day for 20 weeks
89449720|NCT02467400|Active Comparator|Propranolol 40 mg|Propranolol 20 mg bid for 20 weeks
89449721|NCT02467400|Active Comparator|Propranolol 80 mg|Propranolol 40 mg bid for 20 weeks
89449722|NCT02467322|Experimental|Albumin|MVP (Moderate Volume Paracentesis) of less than 5 liters with iv albumin at a dose 8 gms/l of ascitic fluid.
89449723|NCT02467322|Active Comparator|No Albumin|MVP(Moderate Volume Paracentesis) of less than 5 liters without albumin.
89449724|NCT03472638|Experimental|Active -> Sham|15 days of active, followed by 15 days of sham rTMS, targeting dorsomedial prefrontal cortex bilaterally, two sessions per day (1 hour apart), 20 Hz stimulation, at 120% resting motor threshold
89449725|NCT03472638|Experimental|Sham -> Active|15 days of sham, followed by 15 days of active rTMS, targeting dorsomedial prefrontal cortex bilaterally, two sessions per day (1 hour apart), 20 Hz stimulation, at 120% resting motor threshold
89200712|NCT02539875|Experimental|AWARD, Brief leaflet|AWARD will be delivered to smokers onsite and this includes: Ask about smoking history, Warn about the high risk, Advise to quit as soon as possible and not later than a quit date (which will qualify them for the QTW prizes), Refer smokers to smoking cessation services, and Do it again: to repeat the intervention. Brief innovative leaflet on health warning and smoking cessation. A 2-side color printed A4 leaflet will be designed to systematically cover the most important messages to motivate smoking cessation.
89206125|NCT02600585||Flublok|Recombinant influenza vaccine (RIV); Intramuscular injection of vaccine of recombinant uncleaved hemagglutinin (rHA0) derived from influenza A/H1N1, A/H3N2, and B viruses, as identified for the season by the FDA Vaccines and Related Biological Products Advisory Committee (VRBPAC) in a total volume of 0.5 mL.
89449726|NCT03914469|No Intervention|Waitlist Control Group|The waitlist control group will continue with management of chronic back pain and depression per usual care. All participants, regardless of what group they have been assigned to will undergo several outcome assessments (pre-screening, baseline, mid-point, final assessments) conducted by a blinded research assistant. Subjects randomized to the waitlist control group will be offered the same intervention once the active intervention group has completed the active sessions and assessments.
89449727|NCT03914469|Experimental|Behavioral Intervention Group|For participants assigned to the intervention arm, trained health coaches will deliver the intervention via telephone. All participants, regardless of what group they have been assigned to will undergo several outcome assessments (pre-screening, baseline, mid-point, final assessments) conducted by a blinded research assistant.
89449728|NCT03308864|Experimental|Interpersonal Psychotherapy for Adolescents (IPT-A)|All adolescents who present at Child and Adolescent Outpatient Service (CAOS) for a diagnostic intake evaluation and who report any symptoms of depression.
89449729|NCT03308864|Active Comparator|Treatment as Usual|All adolescents who present at Child and Adolescent Outpatient Service (CAOS) for a diagnostic intake evaluation and who report any symptoms of depression.
89449730|NCT03446352|Experimental|Psychomotor exercise program|The experimental group 1 (EG1) intervention comprises a psychomotor program. The program integrates 3 sessions / week of 75 minutes on alternated days. The psychomotor intervention includes exercises promoting simultaneous motor and cognitive stimulation (interval training).
89449731|NCT03446352|Experimental|Combined exercise program|The experimental group 2 (EG2) intervention combines the psychomotor program with a WBV program. The program integrates 3 sessions / week of 75 minutes (including the 6 minutes of WBV) on alternated days.
89449732|NCT03446352|No Intervention|Control Group|Usual care. After the study, control group (CG) participants will be offered the opportunity to integrate a similar fall prevention program.
88934640|NCT01771211|Sham Comparator|sham tDCS|sham tDCS will be administered to the left inferior frontal gyrus
89449733|NCT03308708|No Intervention|Control group|
89449734|NCT03308708|Experimental|NE group|
89449735|NCT03443700|Active Comparator|sLT|Standard neurorehabilitation locomotor training during the whole study period (8 weeks).
89449736|NCT03443700|Experimental|sLT + EX-T|Standard neurorehabilitation locomotor training (sLT) during the whole study period (8 weeks), plus a training with a new-generation robotic anthropomorphic exoskeleton (EKSO-GT locomotor training) during the first 4 study weeks.
89449737|NCT03897465|Experimental|Lomatuell Pro|Lomatuell Pro® is a wound contact layer consisting of wide-meshed tulle, impregnated with a polymer matrix, which form a gel on contact with wound exudate to facilitate moist wound healing.
89449738|NCT03897465|Active Comparator|UrgoTul|UrgoTul® is a flexible contact layer with TLC healing matrix comprised of a conformable polyester mesh impregnated with hydrocolloid and petroleum jelly particles.
89449739|NCT03472482||Ab+ cognitively intact volunteers|"amyloid-positive cognitively intact controls (55-80 years)~interventions: non-invasive retinal imaging with Optical Coherence Tomography (OCT), OCT-angiography (OCT-A), Autofluorescence, Fundus Photography, Hyperspectral Imaging"
89449740|NCT03472482||Ab- cognitively intact volunteers|"amyloid-negative cognitively intact controls (55-80 years)~interventions: non-invasive retinal imaging with Optical Coherence Tomography (OCT), OCT-angiography (OCT-A), Autofluorescence, Fundus Photography, Hyperspectral Imaging"
88934641|NCT01771224|Experimental|palmitoleic acid|Palmitoleic acid: 720 mg/day for 56 days
89449741|NCT03472482||amyloid-positive MCI patients|"amyloid-positive patients with Mild Cognitive Impairment~interventions: non-invasive retinal imaging with Optical Coherence Tomography (OCT), OCT-angiography (OCT-A), Autofluorescence, Fundus Photography, Hyperspectral Imaging"
88934642|NCT01771224|Placebo Comparator|Sugar pill|Sugar pill: 720 mg/day for 56 days
88934643|NCT01771237|Experimental|MyPeeps Manualized Group Intervention|Highly interactive, HIV prevention skills-based group intervention in 6 sessions. Tailored to YMSM.
88934644|NCT01771237|Active Comparator|Standard Sexual Health Education|Educational group intervention focused on HIV and STI knowledge using a lecture-based format in 6 sessions. Non-tailored to YMSM.
89449742|NCT03472482||amyloid-negative MCI patients|"amyloid-negative patients with Mild Cognitive Impairment~interventions: non-invasive retinal imaging with Optical Coherence Tomography (OCT), OCT-angiography (OCT-A), Autofluorescence, Fundus Photography, Hyperspectral Imaging"
89449743|NCT03472482||AD patients|"patients in the dementia stage of Alzheimer's Disease~interventions: non-invasive retinal imaging with Optical Coherence Tomography (OCT), OCT-angiography (OCT-A), Autofluorescence, Fundus Photography, Hyperspectral Imaging"
89449744|NCT03472482||LBD patients|"patients with Lewy Body Dementia~interventions: non-invasive retinal imaging with Optical Coherence Tomography (OCT), OCT-angiography (OCT-A), Autofluorescence, Fundus Photography, Hyperspectral Imaging"
88934645|NCT01771263|Other|iControl-RP|iControl-RP is a system which performs controlled delivery of both remifentanil and propofol infusions.
88934646|NCT01771276|Experimental|Ultimate Anchor|Use of the g-Cath Suture Anchor Delivery Catheter and accessories in placing the ultimate number of anchors for weight loss.
88934647|NCT01771289|Experimental|chemoradiation|
88934648|NCT01771302|Active Comparator|Bio-Oss|the xenograft is of bovine origin where the organic phase has been eliminated.
89449745|NCT03143556|Experimental|Magnetic Stent|Patients who are undergoing renal transplant surgery for the treatment of end stage renal failure and randomized for magnetic stent group will receive magnetic stent and the removal of stent would be done by help of magnetic device.
89449746|NCT03143556|No Intervention|Routine stent|Patients who are undergoing renal transplant surgery for the treatment of end stage renal failure and randomized for routine stent would receive routine stent and the removal of stent would be done by cystoscopy
89449747|NCT03799107||Retrospective|Children born with assistance
89449748|NCT03799107||Prospective|People who have sought evaluation/treatment for infertility
89449749|NCT04476615|Experimental|FMD|Fasting-Mimicking diet (ProLon®)
89449750|NCT04476615|Placebo Comparator|Placebo|Low-energy bars (L-Nutra®) supplementation
89449751|NCT02929056|Placebo Comparator|SOC alginate dressing|SOC absorptive alginate primary dressing in conjunction with a class II multi-layer compression wrap and standard debridement
89449752|NCT02929056|Experimental|AmnioExCel dressing|AmnioExCel dressing in conjunction with a class II multilayer compression wrap and standard debridement
89449753|NCT02262741|Experimental|MEDI4736 + tremelimumab|
89449754|NCT04659408|Experimental|Bactosan - oat bran|This group will receive Bactosan first, followed by oat bran.
89449755|NCT04659408|Experimental|Oat bran - Bactosan|This group will receive oat bran first, followed by Bactosan.
89449756|NCT02233569|Active Comparator|PH|Intraperitoneal onlay mesh (IPOM) repair with the use of Phisiomesh implant and Securestrap fixation device.
89449757|NCT02233569|Active Comparator|VS|Intraperitoneal onlay mesh (IPOM) repair with the use of Ventralight ST implant with SorbaFix fixation device.
89449758|NCT02582073|Placebo Comparator|Placebo (0.5ml)|Six 0.5ml injections of placebo consisting of L-Tyrosine, Ph. Eur 2%
88934649|NCT01771302|Experimental|calcium phosphate ceramic|is a calcium phosphate biomaterial
89449759|NCT02582073|Placebo Comparator|Placebo (1.0ml)|Six 1.0ml injections of placebo consisting of L-Tyrosine, Ph. Eur 2%
89449760|NCT02582073|Experimental|Grass MATA MPL (0.5ml) 5100SU|Six 0.5 mL injections sequentially of placebo, placebo, 300, 800, 2000 and 2000 SU of Grass MATA with 50 µg/0.5 mL of MPL® adjuvant adsorbed to L tyrosine (2%) and 0.5% phenol (cumulative dose 5100SU).
89449761|NCT02582073|Experimental|Grass MATA MPL (1.0ml) 10200SU|Six 1.0 mL injections sequentially of placebo, placebo, 600, 1600, 4000 and 4000 SU of Grass MATA per 1.0 mL and 50 µg/1.0 mL of MPL® adjuvant adsorbed to L tyrosine (2%) and 0.5% phenol (cumulative dose 10200 SU).
89449762|NCT02582073|Experimental|Grass MATA MPL (1.0ml) 18200SU|Six 1.0 mL injections sequentially of placebo, 600, 1600, 4000, 4000, 4000 and 4000 SU of Grass MATA per 1.0 mL and 50 µg/1.0 mL of MPL® adjuvant adsorbed to L tyrosine (2%) and 0.5% phenol (cumulative dose 18200 SU).
89449763|NCT02582073|Active Comparator|Grass MATA (0.5ml) 5100SU|Six 0.5ml injections sequentially of placebo, placebo, 300, 800, 2000 and 2000 SU of Grass MATA adsorbed to L tyrosine (2%) and 0.5% phenol (cumulative dose 5100SU).
89449764|NCT02769000|Experimental|Subjects 1-30|15 subjects in each RT dose schedule 10 GY in 5 daily fractions 20 GY in 10 daily fractions
89449765|NCT02633670|Experimental|Hemopatch|The hemopatch is a promising new sealing synthetic hemostatic agent with a noval dual mechanism of action. The hemopatch is a polyethylene glycol coated (PEG coated) collagen patch. The PEG coating helps in rapid adhesion to the tissue surface while the collagen layer causes platelet activation and adhesion.
88934650|NCT01771315|Experimental|telephone follow-up|Nurse led follow-up in form of consultation by telephone 4 days and 2weeks after discharge, respectively as a supplement to conventional admission course.
89449766|NCT02633670|Active Comparator|Standard technique|Standard hemostatic agents (floseal, tisseal).
89449767|NCT00250341|Active Comparator|Advair|
89449768|NCT00250341|Experimental|QVAR|
89449769|NCT03472248|Experimental|Acceptance and Commitment Therapy|Eight weeks of smartphone delivered Acceptance and Commitment Therapy for the adolescent and eight weeks of internet delivered parental support to one or two parents of the adolescent.
89449770|NCT03711903|Experimental|Treatment arm|The study drug, CN-105, will be administered at 1.0 mg/kg every 6 +/- 1 hour. The calculated volumes of study agent will be removed from the vials and transferred to 250 mL of normal saline (0.9% sodium chloride injection, USP). The recorded weight at baseline will be used to determine the appropriate amount of CN-105 drug product to administer. Estimated weight may be used if recorded weight is not available. Each dose of CN-105 or placebo will be administered as a slow IV bolus over 30 minutes.
89449771|NCT03711903|Placebo Comparator|Placebo arm|The Placebo arm will be given 0.9% NaCL
89449772|NCT01995396|Active Comparator|APE with intersphincteric dissection|Abdominoperineal excision with intersphincteric dissection and a stoma is performed in patients with rectal cancer and fecal incontinence and/or severe co-morbidity
89449773|NCT01995396|Active Comparator|Hartmann´s procedure|Hartmann´s operation and stoma is performed in patients with rectal cancer and fecal incontinence and/or severe co-morbidity
89449774|NCT05196633|Experimental|Conventional physiotherapy, visual feedback training, rESWT|conventional physiotherapy (5 times/week), visual feedback training (5 times/week), radial extracorporeal shock wave therapy (once/week for 2 weeks)
89449775|NCT05196633|Sham Comparator|Conventional physiotherapy, visual feedback training, sham rESWT|conventional physiotherapy (5 times/week), visual feedback training (5 times/week), sham radial extracorporeal shock wave therapy (once/week for 2 weeks)
89449776|NCT03471000|Experimental|Short implants Treatment|Group 2 (G2; n=15 patients) had short implants (OsseoSpeed ™ L6mm Ø4 mm) [DENTSPLY Implants, Waltham, MA, USA] placed without sinus lift and augmentation procedure.
89449777|NCT03471000|Active Comparator|Regular Implants Treatment|Group 1 (G1; n=15 patients) had conventional dental implants (OsseoSpeed ™ L11 Ø4 mm and L13 Ø4 mm) [DENTSPLY Implants, Waltham, MA, USA] placed, preceded by the sinus lift procedure from a lateral window approach with the application of the xenogeneic bone graft Geistlich Bio-Oss® [Geistlich AG, Wolhusen, Switzerland]. The lateral window approach sinus lift surgery was performed 6 weeks prior to the implant placement by the same surgeon.
89449778|NCT03702465|Active Comparator|Control Arm|Pre-diabetic participants will receive general health guidelines according to the NICE guidelines, as per standard care. These will be delivered via an initial consultation with a dietitian. Participants in the control group will receive 2 follow up phone calls from the dietitian to answer any questions they may have during the study.
89449779|NCT03702465|Active Comparator|Intervention Arm|DNA-based dietary intervention: participants will receive DNA-based health guidelines via a genetic report. These will be delivered via an initial consultation with a dietitian. Participants in the control group will receive 2 follow up phone calls from the dietitian to answer any questions they may have during the study.
89449780|NCT03702465|Experimental|Exploratory Arm|DNA-based dietary intervention using an app: participants will receive DNA-based health guidelines via the DnaNudge App.
89531321|NCT05052021||No or Previous Covid19 Infection|"Patients will be classified as having No Covid19 Infection if they have never tested positive for Covid19.~Patients will be classified as having Previous Covid19 Infection when they tested positive for Covid19 infection 7 weeks or more before surgery.~These patients will be analysed together as a group, as it is likely that their risk for complications will be similar."
88934651|NCT01771315|No Intervention|Usual treatment|All patients follow conventional admission course which implies preoperative seminar and a discharge planning consultation on the day of discharge. The patients are discharged to home, referred to physiotherapy in the community and a scheduled follow-up by the surgeon after 3 month in the orthopedic outpatient clinic.
88934652|NCT01771328|Active Comparator|hydrocortisone|Treatment B ( Solu-Cortef) the initial standard dose of 10mg/m2/24hrs. Hydrocortisone infusate will be given as Solu-Cortef Act-o-Vial 50mg/ml, produced by Pfizer. Treatment will take 4 months.
88934653|NCT01771328|Active Comparator|cortisone acetate|Treatment A (Cortisone tbl.) is current treatment, i.e. glucocorticoid and mineralocorticoid replacement according to best clinical judgement. This treatment period will take 6 months.
88934654|NCT01771341|Placebo Comparator|Pressure support|
88934655|NCT01771341|Experimental|NAVA|
88934656|NCT01771354|Placebo Comparator|Placebo|Placebo
88934657|NCT01771354|Active Comparator|Vaccine|Engerix B vaccine
88934658|NCT01771367|Active Comparator|Fluad|Participants receive one dose of Fluad vaccine.
88934659|NCT01771367|Active Comparator|Agrippal|Participants receive one dose of Agrippal vaccine.
88934660|NCT01771367|Placebo Comparator|Placebo|Participants receive one dose of saline placebo.
88934661|NCT01771380||Subjects with impaired glucose tolerance|
88934662|NCT01771393|Experimental|CBCT prior to MDCT|To avoid systematic bias in performance or image quality due to dilution of the contrast enhancement within the joint, the order of the CBCT and the MDCT will be randomized. This arm is composed of patients who will have the CBCT performed prior to the MDCT.
88934663|NCT01771393|Experimental|MDCT prior to CBCT|To avoid systematic bias in performance or image quality due to dilution of the contrast enhancement within the joint, the order of the CBCT and the MDCT will be randomized. This arm is composed of patients who will have the MDCT performed prior to the CBCT.
88934664|NCT01771406|Experimental|Nebivolol then CPAP|8 weeks of Nebivolol treatment (5m/day), 6 weeks of washout, 8 weeks of CPAP and if the patient is still hypertensive 8 weeks of Nebivolol plus CPAP treatment
88934665|NCT01771406|Experimental|CPAP then Nebivolol|8 weeks of CPAP treatment, 6 weeks of washout, 8 weeks of Nebivolol and if the patient is still hypertensive 8 weeks of Nebivolol plus CPAP treatment
88934666|NCT01771432|Active Comparator|Antibiotic treatment|Kidney transplant recipients with asymptomatic bacteriuria will be treated with antibiotics.
88934667|NCT01771432|Other|No treatment|Kidney transplant recipients with asymptomatic bacteriuria will be followed without antibiotic therapy
88934668|NCT01771445|Active Comparator|IL-1Ra|
89449781|NCT02233725|Active Comparator|Definity Perflutren Suspension|Injection of Definity Perflutren Injectable Suspension- which travels in the bloodstream throughout the body. These microbubbles are identifiable on ultrasound imaging, and studies of the liver and kidney have identified it as a useful adjunct to identifying vascular lesions. Areas of regular blood flow will not have as large a concentration of the microbubble agent as will areas that have increased blood flow and neovascularisation. It has been well documented that cancerous solid lesions undergo neovascularisation and have increased blood flow to the area.
89449782|NCT05157204||adult 20 patients with moderate to severe covid-19|adult 20 covid-19 patients with moderate to severe covid-19. for measurment of interleukin-6 from exhaled condensate during first 10 days of postive PCR
89449783|NCT05157204||20 healthy controls adult non pregnant humans f|20 healthy adults above 18 years non pregnant for measurment of interleukin-6 from exhaled condensate
89449784|NCT05157204||adult 20 patients with moderate to severe postcovid-19|adult 20 post covid-19 patients with moderate to severe covid-19 for measurment of interleukin-6 from exhaled condensate
89449785|NCT02236299|Placebo Comparator|saline placebo infusion|30 minute infusion of a saline placebo Right coronary artery percutaneous coronary intervention
88934669|NCT01771445|Placebo Comparator|Placebo|
89200713|NCT02539875|Active Comparator|Smoking cessation booklet, general advices|"Participants will receive minimal intervention, including: (1) the 12-page smoking cessation booklet (provided by COSH); (2) very brief, minimal and general smoking cessation advice include: Please quit smoking for improving health and save money, Please refer to the booklet for the details about smoking cessation and Please call us if you have any enquiry."
89200714|NCT04017663||Public group|patients who performed cardiovascular rehabilitation in a public center
89449786|NCT02236299|Experimental|GLP-1 infusion|30 minute infusion of GLP-1 Right coronary artery percutaneous coronary intervention
89449787|NCT00976014||Intensive Lipid-lowering therapy|Subjects on intensive long-term lipid lowering therapy (lowering LDL-C plus raising of HDL-C).
89449788|NCT00976014||Usual Care|"Subjects with Atherosclerosis who have been on conventional standard of care treatment."
89449789|NCT02236455|Experimental|Audio Relaxation technique|Relaxation is a process that decreases the effects of stress on your mind and body. Relaxation techniques can help you cope with everyday stress and with stress related to various health problems, such as cancer and pain.
88934670|NCT01771458|Active Comparator|Standard chemotherapy|Treatment choice is based on Investigator decision.
88934671|NCT01771458|Experimental|Personalized treatment|"Targeted therapy based on the patient molecular profil (if there is at least one abnormality that could be targeted)~Elligible therapies in this trial are :~Imatinib Everolimus Vemurafenib Sorafenib Erlotinib Lapatinib Trastuzumab Dasatinib Tamoxifen (or letrozole if contra-indication) Abiraterone"
88934672|NCT01771471|Experimental|NuQu treatment|single administration
88934673|NCT01771471|Other|Saline|single administration
88934674|NCT01771484|Experimental|Low Sodium Diet|participants will consume a diet (10 milliequivalent Na+/day)for 4-5 days prior to study day.
88934675|NCT01771484|Experimental|High sodium diet|Participants will consume a diet high in sodium (300 milliequivalent Na+/day) for 4-5 days prior to study intervention.
88934676|NCT01771419|Experimental|loop-tip arm|The cannulation of CBD will be obtained using the loop-tip wire (Cook Medical inc.)
88934677|NCT01771419|Active Comparator|Control arm|The cannulation of CBD will be obtained with a Cook Medical sphincterotome CT-25 mm (tradictional technique)
88934678|NCT01771497||Women undergoing neoadjuvant therapy|
88934679|NCT01771523|Active Comparator|Group 1|thyroidectomy
88934680|NCT01771523|Active Comparator|Group 2|thyroidectomy use of drain
88934681|NCT01771549||Group 1|Patients with breast cancer beginning chemotherapy with a dose-dense regimen including adriamycin without concurrent trastuzumab.
88934682|NCT01771549||Group 2|Patients receiving trastuzumab in the adjuvant, neo-adjuvant, or metastatic setting in a regimen not containing simultaneous adriamycin therapy.
88934683|NCT01771575|Experimental|Treatment Arm|PoNS™ device
88934684|NCT01771575|Placebo Comparator|Placebo Arm|placebo device
88934685|NCT01771588|Experimental|New human milk fortifier|New human milk fortifier
88934686|NCT01771588|Active Comparator|Currently marketed fortifier|Currently marketed fortifier
88934687|NCT01771588|Experimental|New human milk fortifier with new Ca source|a subgroup of patients will receive the new milk fortifier containing a new source of calcium.
88934688|NCT01771601||Near-infrared spectroscopy sensors|Term infants born by elective Caesarean section
88934689|NCT01771614|Experimental|Normoglycemia + exercise|At T = 0 h participants will undergo an intravenous glucose tolerance test (IVGTT, 0.33 g/kg glucose) immediately followed by a 4-hour rest period. At T = 5 h, participants will undertake 45 minutes of moderate-intensity (70% VO2max) bicycle ergometry. Immediately following (T = 6 h) and 1- (T = 7 h), 3- (T = 9 h), and 18- hours (T = 24 h) after exercise, participants will undergo additional IVGTTs.
88934690|NCT01771614|Experimental|Steady-State Hyperglycemia + exercise|At T = 0 h participants will undergo an intravenous glucose tolerance test (IVGTT, 0.33 g/kg glucose) immediately followed by a 4-hour rest period. During this time, steady-state hyperglycemia (~10 mM) will be induced experimentally via a variable-rate intravenous infusion of 20% dextrose. At T = 5 h, participants will undertake 45 minutes of moderate-intensity (70% VO2max) bicycle ergometry. Immediately following (T = 6 h) and 1- (T = 7 h), 3- (T = 9 h), and 18- hours (T = 24 h) after exercise, participants will undergo additional IVGTTs.
88934691|NCT01771614|Experimental|Fluctuating Hyperglycemia + exercise|At T = 0 h participants will undergo an intravenous glucose tolerance test (IVGTT, 0.33 g/kg glucose) immediately followed by a 4-hour rest period. During this time, fluctuating hyperglycemia (~8-15 mM) will be induced by intravenously injecting 0.15 g/kg boluses of 20% dextrose every 30 minutes. At T = 5 h, participants will undertake 45 minutes of moderate-intensity (70% VO2max) bicycle ergometry. Immediately following (T = 6 h) and 1- (T = 7 h), 3- (T = 9 h), and 18- hours (T = 24 h) after exercise, participants will undergo additional IVGTTs.
88934692|NCT01771640|Experimental|stem cell reciepient|The patients with ALS that underwent mesenchymal stem cell transplantation
88934693|NCT01771653||Previously treated|Data from patients who were previously treated with Peg, interferon (IFN), alfa, and ribavirin
88934694|NCT01771653||Previously untreated|Records of patients who have never received anti-HCV treatment.
88934695|NCT01771692|Active Comparator|Conventional ligation|Modules ligated in a conventional manner (figure of 0)
88934696|NCT01771692|Active Comparator|Figure of 8 ligation|Modules ligated in a figure of 8 configuration
88934697|NCT01771705|Experimental|Dose adjust group (NFAT)|Within 4 weeks of a 6 month management biopsy, if eligibility is confirmed, NFAT dependent cytokines including IL-2, IFNg, and GMCSF at times C0 and C1.5 will be performed with the residual expression calculated based on the ratio of C1.5/C0 x 100%. If the average residual expression of the 3 cytokines is <20%, the CNI daily dose will be reduced by 15%. If the average residual gene expression of the 3 cytokines is > 60% the CNI daily dose will be increased by 15%.
88934698|NCT01771705|No Intervention|Standard of care group|A CNI trough level will be obtained. Adjustments of CNI will be based on target trough drug levels as per standard of care.
88934699|NCT05318365|Active Comparator|Treatment of constipation and/or faecal incontinence|Medical treatment of bowel symptoms in accordance with the guidelines of The European Society for Paediatric Gastroenterology, Hepatology and Nutrition
89200715|NCT04017663||Private group|patients who performed cardiovascular rehabilitation in a private center
89200716|NCT00979264|No Intervention|Control|Standard quality improvement approaches available through participation in Get With the Guidelines - Heart Failure.
89200717|NCT00979264|Active Comparator|Intervention|Enhanced and/or intensive quality improvement approaches, coupled with standard approaches available through participation in Get With the Guidelines - Heart Failure.
89200718|NCT02539719|Experimental|SC-003|Phase 1a (Escalation) - IV infusion Phase 1b (Expansion) - IV infusion
89449790|NCT02236455|Experimental|Medical Music Intervention|Music intervention is use to assist with relaxation and reduce stress levels in patients.
89449791|NCT02236455|Experimental|Nature Therapy without Music|Ecotherapy is the use of nature to reduce stress and to increase levels of well-being in patients.
89449792|NCT02236455|Experimental|Nature Therapy with Music|Nature therapy videos were produced with and without music for surgical patients.
89449793|NCT02578095|Placebo Comparator|Placebo|Placebo QD
89449794|NCT02578095|Experimental|VK5211- 0.5mg|0.5mgQD
89449795|NCT02578095|Experimental|VK5211- 1.0mg|1.0mg QD
89449796|NCT02578095|Experimental|VK5211- 2.0mg|2.0mg QD
89449797|NCT00545766|Experimental|Interventional|
89449798|NCT02236533|Placebo Comparator|Control pasta|Volunteers were fed with control pasta, without B-glucans and spores of B. coagulans once a day for 12 weeks.
89449799|NCT02236533|Experimental|Probiotic Whole Grain Pasta|Volunteers were fed with probiotic fortified pasta, including B-glucans and spores of B. coagulans once a day for 12 weeks.
89449800|NCT05156970|Experimental|Camrelizumab + Chemotherapy|Participants receive Camrelizumab 200 mg intravenously (IV) on Day 1 of each 3-week cycle for up to 24 months;plus cisplatin 75 mg/m^2 IV or carboplatin at a target area under the curve of 5 (AUC 5) IV, per Investigator's choice, on Day 1 of each 3-week cycle (6 cycle maximum); plus docetaxel 75 mg/m^2 IV on Day 1 of each 3-week cycle (6 cycle maximum).
89449801|NCT05156970|Experimental|Camrelizumab +Apatinib mesylate|Participants receive Camrelizumab 200 mg intravenously (IV) on Day 1 of each 3-week cycle for up to 24 months;plus Apatinib 250mg qd for up to 24 months.
89449802|NCT02233881||Chronic obstructive pulmonary disease patients|
89449803|NCT02233959||Healthy Adults|
89449804|NCT02261571|Experimental|Moxibustion|A series of moxibustion sessions within six weeks from baseline with adjuvant chemotherapy.
89449805|NCT02261571|No Intervention|Waiting|Participants who will be allocated to waitlist will receive no moxibustion treatments throughout the 6 weeks while receiving adjuvant chemotherapy
89449806|NCT02234037|Experimental|Decitabine and Exercise|8-week program of physical conditioning and decitabine treatment in newly diagnosed AML patients ≥ 60 years of age who are not candidates for standard induction chemotherapy.
89449807|NCT04476771|No Intervention|TAU + waiting list|Feliz-Mente (third generation psychotherapy):The intervention is delivered in a group format with a total of 12 sessions and a maximum of 10 patients per group. The protocol consists of specific exercises: 1: welcome and identification of emotions, 2: identification and amplification of positive emotions, 3: regulation of negative emotions, 4: gratitude, 5: forgiveness, 6: self-compassion, 7: personal strengths, 8: loving-kindness and positive interpersonal relationships, 9: values, 10: purpose of life, 11: resilience, 12: keeping the change and farewell party.
89449808|NCT04476771|Experimental|TAU + Feliz-Mente Intervention|Feliz-Mente (third generation psychotherapy):The intervention is delivered in a group format with a total of 12 sessions and a maximum of 10 patients per group. The protocol consists of specific exercises: 1: welcome and identification of emotions, 2: identification and amplification of positive emotions, 3: regulation of negative emotions, 4: gratitude, 5: forgiveness, 6: self-compassion, 7: personal strengths, 8: loving-kindness and positive interpersonal relationships, 9: values, 10: purpose of life, 11: resilience, 12: keeping the change and farewell party.
89449809|NCT02234193|Active Comparator|Micro biopsies 2mm x control|2 mm diameter micro biopsies will be performed on all subjects.
89449810|NCT02234193|Active Comparator|Micro biopsies 1mm x control|1 mm diameter micro biopsies will be performed on all subjects.
89449811|NCT02234193|Active Comparator|Micro biopsies 0.8 mm x control|0.8 mm diameter micro biopsies will be performed on all subjects.
89449812|NCT02234193|Active Comparator|Micro biopsies 0.6 mm x control|0.6 mm diameter micro biopsies will be performed on all subjects.
89449813|NCT02234193|Active Comparator|Micro biopsies 0.5 mm x control|0.5 mm diameter micro biopsies will be performed on all subjects.
89449814|NCT02234193|Active Comparator|Micro biopsies 0.40 mm x control|0.4 mm diameter micro biopsies will be performed on all subjects.
89449815|NCT02234193|Active Comparator|Micro biopsies 0.20 mm x control|0.2 mm diameter micro biopsies will be performed on all subjects.
89449816|NCT04476459|Experimental|camrelizumab in combination with apatinib|Apatinib should be given at a fixed time. On the day of camrelizumab infusion, Apatinib should be taken 30 minutes after the end of camrelizumab infusion
89449817|NCT02262897|Experimental|Nab-paclitaxel single agent|Nab-paclitaxel single agent, either in 130mg/m2 weekly regimen, d1,8,15 every 4 weeks or in 230mg/m2 d1 every 3 weeks
89449818|NCT02262975||donepezil (Aricept)|
89449819|NCT02653599|Experimental|TTP273 300 mg daily (150 mg BID)|Two 75 mg tablets of TTP273 administered orally twice daily for 12 weeks
89449820|NCT02653599|Experimental|TTP273 150 mg daily|Two 75mg tablets of TTP273 administered orally once daily and two placebo tablets administered orally once daily for 12 weeks
89449821|NCT02653599|Placebo Comparator|Placebo|Two matching placebo tablets administered orally twice daily for 12 weeks
88934700|NCT05318365|Active Comparator|Treatment of constipation and/or faecal incontinence combined with urotherapy|Medical treatment of bowel symptoms in accordance with the guidelines of The European Society for Paediatric Gastroenterology, Hepatology and Nutrition combined with standard urotherapy in accordance with International Children's Continence Society (ICCS)
88934701|NCT01771744||Morbidly obese patients|48 morbidly obese patients with revisional gastric bypass
88934702|NCT01771744||48 morbidly obese patients|with primary gastric bypass
88934703|NCT01771783|Experimental|ACEI-ARB-RI|angiotensin converting enzyme inhibitor (ACEI) angiotensin receptor antagonist (ARB) renin inhibitor (RI)
88934704|NCT01771783|Experimental|ARB-RI-ACEI|ARB-RI-ACEI
88934705|NCT01771783|Experimental|RI-ACEI-ARB|RI-ACEI-ARB
88934706|NCT01771796|Experimental|Aerobic and muscle resistance training|
88934707|NCT01771796|No Intervention|Usual care group|All patients (intervention and usual care group) are patients with lung cancer who underwent a resection surgery.
88934708|NCT01771822|Experimental|Ibuprofen 5% topical gel|
88934709|NCT01771822|Experimental|Topical gel vehicle|
88934710|NCT01771822|Active Comparator|Sodium lauryl sulfate 0.2%|
88934711|NCT01771822|Sham Comparator|Sodium chloride solution 0.9% (saline)|
88934712|NCT01771835||Diabetes patients|Patients with diabetes mellitus type I + II, without diabetic retinopathy
88934713|NCT01771848|Experimental|Grp 1-10ul x 2; 2,500 PfSPZ Challenge-Part A|"PART A:~Group 1 (n=6): 2,500 PfSPZ administered IM in a volume of 10 µL in 2 sites (one injection of 10µL containing 1,250 PfSPZ in each deltoid)."
88934714|NCT01771848|Experimental|Grp 2-50ul x 2; 2,500 PfSPZ Challenge-Part A|"PART A:~Group 2 (n=6): 2,500 PfSPZ administered IM in a volume of 50 µL in 2 sites (one injection of 50µL containing 1,250 PfSPZ in each deltoid)."
89449822|NCT02653443|Experimental|Day 6|Each subject will provide two apheresis platelet donations (one per period) and receive two infusions (one per period) of autologous radiolabeled fresh platelets combined with INTERCEPT treated platelet components stored for either 6 or 7 days (approximately 10 to 30 mL).
89449823|NCT02653443|Experimental|Day 7|Each subject will provide two apheresis platelet donations (one per period) and receive two infusions (one per period) of autologous radiolabeled fresh platelets combined with conventional untreated platelet components stored for either 6 or 7 days (approximately 10 to 30 mL).
89449824|NCT03308630|Experimental|Energy Alignment and Mantra|
89449825|NCT03308552|Active Comparator|SIB-IMRT combined chemotherapy followed by chemotherapy|"SIB-IMRT: Patients receive radiotherapy once daily, 5 days a week for an average of 5.5 weeks. Radiotherapy is delivered to achieve a prophylactic dosage of 50.4Gy to PTV and 59.92Gy to PGTV in 28 fractions, respectively.~Concurrent chemotherapy: Paclitaxel and platinum based drug are administered once a week for at least 5 weeks during radiotherapy treatment days."
89531322|NCT02493335|Experimental|Budesonide 0.5mg orodispersible tablet twice daily|Budesonide 0.5mg orodispersible tablet twice daily
88934715|NCT01771848|Experimental|Grp 3-250ul x 2; 2,500 PfSPZ Challenge-Part A|"PART A:~Group 3 (n=6): 2,500 PfSPZ administered IM in a volume of 250 µL in 2 sites (one injection of 250 µL containing 1,250 PfSPZ in each deltoid)."
88934716|NCT01771848|Experimental|Grp 4-50ul x 2; 25,000 PfSPZ Challenge, Part B|"PART B: BEGINS AFTER COMPLETION OF PART A~Group 4 (n=6) (control group) 25,000 PfSPZ administered IM in a volume of 50 µL in 2 sites (one injection of 50 µL containing 12,500 PfSPZ in each deltoid)."
88934717|NCT01771848|Experimental|Grp 5-Optimal vol Part A x 2; 25,000 PfSPZ Challenge, Part B|"PART B: BEGINS AFTER COMPLETION OF PART A~Group 5 (n=6) 25,000 PfSPZ administered IM in the optimum volume determined in Part A in 2 sites (one injection of the optimum volume containing 12,500 PfSPZ in each deltoid).~If the optimal volume in Part A is 50µL, then Group 5 will be modified to avoid duplication of regimens between groups 4 and 5. In this case, volunteers in group 5 will be administered a dose of 25,000 PfSPZ administered intradermally in four 10 µL injections. (Every volunteer will receive 4 ID injections of 6,250 PfSPZ in a volume of 10 µL each, with 2 injections in each arm respectively)."
88934718|NCT01771848|Experimental|Grp 6-Optimal vol Part A x 2; 125,000* PfSPZ Challenge, Part B|"PART B: BEGINS AFTER COMPLETION OF PART A~Group 6 (n=6) 125,000 PfSPZ administered IM in the optimum volume determined in Part A in 2 sites (one injection of the optimum volume containing 62,500 PfSPZ in each deltoid) if the volume is 50 µL or 250 µL.~*If the optimal volume in Part A is 10 µL, then Group 6 will receive 100,000 PfSPZ (2 inoculations of 50,000 PfSPZ) instead of 125,000 PfSPZ."
88934719|NCT01771861||Seriously injured or potentially seriously injured patients|
88934720|NCT01771874|Experimental|MDMA, bupropion, placebo|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but two (actually 4) treatment conditions in the same subject. The four treatment conditions are placebo-placebo, bupropion-placebo, placebo-MDMA, and bupropion-MDMA.
88934721|NCT01771887|Experimental|education program|education program in 6 hours for groups of 10 people. The content will be divided into 2 sessions with an interval of 2 weeks, the duration of each session is 3 hours. Means active learning, teaching materials in Arabic accompany the content masterful discussions on flipcharts, situation analysis, computer-assisted presentation, demonstration, 150 photos of Lebanese dishes. After, patients receive a 10-page illustrated book, a logbook of diabetes control. 2 weeks after the second education session, each participant will receive 5 calls every 15 days in 2 months. During each call, the research assistant will ask the patient about diet, exercise and self-monitoring, medication and foot care and this according to a checklist.
88934722|NCT01771926|Experimental|High Resistant Starch Potatoes|Subjects will receive 1 serving daily for 8 weeks during the weight loss group sessions.
89449826|NCT03308552|Placebo Comparator|SIB-IMRT Alone followed by chemotherapy|SIB-IMRT: Patients receive radiotherapy once daily, 5 days a week for an average of 5.5 weeks. Radiotherapy is delivered to achieve a prophylactic dosage of 50.4Gy to PTV and 59.92Gy to PGTV in 28 fractions, respectively.
88934723|NCT01771926|Experimental|Low Resistant Starch Potatoes|Subjects will receive 1 serving daily for 8 weeks during the weight loss group sessions.
88934724|NCT01771926|Placebo Comparator|Other Carbohydrate Source|Subjects will receive 1 serving daily for 8 weeks during the weight loss group sessions.
88934725|NCT01771939|Experimental|idiopathic epiretinal membranes|Patients in first arm, with worse visual condition, treated with 25-G Vitrectomy and phacoemulsification (cataract intervention)
88934726|NCT01771939|Active Comparator|idiopathic epiretinal membrane|Patient in second arm, with better pre-operative condition, treated with phacoemulsification (cataract intervention) only
88934727|NCT01771978|Placebo Comparator|Arm1: control group|Received 250 ml of a 5% dextrose solution as placebo drug
88934728|NCT01771978|Experimental|Arm 2: diltiazem group|Received a 100 µg/kg bolus followed by a 0.3 µg/kg infusion diluted in 250 ml of 5% dextrose solution
88934729|NCT01771978|Experimental|Arm 3: acetylcystein group|Received 150 mg/kg acetylcystein diluted in 250 ml of 5% dextrose solution
88934730|NCT01771978|Experimental|Arm 4: diltiazem and acetylcystein group|"Received a combination of drug :~bolus diltiazem 100 µg/kg followed by a 0.3 µg/kg infusion diluted in 125 ml of a 5% dextrose solution and 150 mg/kg acetylcystein diluted in 125 ml of 5% dextrose solution"
88934731|NCT01772017|Experimental|Device Treatment|Tongue Advancement Retainer Device
88934732|NCT01772030|Other|Recurrent Atrial Fibrillation|
88934733|NCT01772043||Duchenne muscular dystrophy|
88934734|NCT01772056|Experimental|Fluticasone, cream|fluticasone propionate (FP) cream of 0.05%. The vehicle is:Base PFCO/W, Propyleneglycol and Water conservant.
88934735|NCT01772056|Placebo Comparator|Placebo, cream|Vehicle cream is composed by Base PFCO/W, Propyleneglycol and Water conservant.
88934736|NCT01772082|Active Comparator|Pedometer alone|pedometer
88934737|NCT01772082|Experimental|Pedometer plus website|pedometer and website
88934738|NCT01772095||Patients with Dementia|Patients diagnosed with dementia and evaluated by specific Alzheimer disease scales
88934739|NCT01772108|Experimental|MitraClip Device|Subjects randomized to the Device group will undergo the MitraClip procedure in addition to optimal standard medical therapy.
88934740|NCT01772108|No Intervention|Control|Subjects randomized to the Control group will receive optimal standard of care therapy alone.
88934741|NCT01772121||HCV Cohort|A total of 1000 subjects were enrolled in the study and of that 500 subjects had a diagnosis of chronic HCV infection
88934742|NCT01772121||HBV Cohort|A total of 1000 subjects were enrolled in the study and of that 500 subjects had a diagnosis of chronic HBV infection
88934743|NCT01772173||subjects with diabetes developing hypertension|subjects with diabetes not developing hypertension
88934744|NCT01772186|No Intervention|Without real-time somatosensory cue|Parkinson patients wear the somatosensory stimulation system but not receive the real-time somatosensory cue during freezing-of-gait episodes.
88934745|NCT01772186|Experimental|With real-time somatosensory cue|Parkinson patients wear the somatosensory stimulation system and receive the real-time somatosensory cue during freezing-of-gait episodes.
88934746|NCT01772199|Experimental|GSK239512 Arm|GSK239512 once daily orally, started at 10 mcg and titrated to the maximum tolerated dose, Up to the highest dose of 80 mcg (10 mcg first week, 20 mcg second week, 40 mcg third week, 80 mcg fourth week) followed by 44 week maintenance treatment period
88934747|NCT01772199|Placebo Comparator|Placebo Arm|Placebo once daily orally
88934748|NCT01772212|Experimental|A(test)/B(reference)|Initial administration of test and crossover to reference
88934749|NCT01772212|Experimental|B(reference)/A(test)|Initial administration of reference and crossover to test
88934750|NCT01772225||Deceased Group|Subjects in this group will include the deceased patients from each of the three countries.
88934751|NCT01772225||Living Group|Subjects in this group will include living patients aged 18 years or older from each of the three countries.
88934752|NCT01772238|Experimental|A(reference)/B(test)|initial administration of reference and cross-over to test
88934753|NCT01772238|Experimental|B(test)/A(reference)|initial administration of test and cross-over to reference
89449827|NCT03308318||the supratemporalis approach|patients operated upon with zygomaticofacial or craniofacial fractures using the supratemporalis approach
89449828|NCT03308240|Experimental|Magic Therapy Group|"Medical student magicians who have completed MagicAid training will provide the therapy.~Three or four tricks will be performed per patient at the discretion of the magician to cater to patient age and cognition capabilities. Patients in the experimental group may be given the opportunity to learn a magic trick that has been presented to them as well."
89449829|NCT03308240|No Intervention|Standard Child Life Therapy Group|Stony Brook Child Life Specialists will provide standard therapies available to all patients, such as pet therapy, art therapy, music therapy.
89449830|NCT03308162|Experimental|Group Intervention|Cognitive behavioral experiential group therapy for health behavior change
89449831|NCT03308084|Active Comparator|Local Depomedrol plus IV dexamethasone|Local intraoperative application of methylprednisolone (Depomedrol) plus standard systemic (IV) dexamethasone
89449832|NCT03308084|Placebo Comparator|IV dexamethasone|Standard systemic (IV) dexamethasone only
89449833|NCT02468492|Experimental|Platelet Rich Plasma|Approximately 5mL of intraarticular PRP once at baseline
89449834|NCT02468492|Other|Normal Saline|Approximately 5mL of intraarticular normal saline once at baseline
89449835|NCT00702962|Experimental|Phase I: Vorinostat 200 mg|"Vorinostat 200 mg PO QD D1-14; Administer with Carbo 6 (AUC) D3; Etoposide 100 mg/m2 D1,2,3 Vorinostat, Carboplatin, Etoposide"
89449836|NCT01379508|Experimental|telbivudine|telbivudine 600 mg tablet orally (p.o.) once daily for up to 156 weeks. Patients with HBV DNA ≥ 300 copies/mL at Week 24 were to initiate add-on therapy with tenofovir 300 mg tablets p.o. once daily for the remaining weeks of treatment. The investigator was to initiate tenofovir add-on therapy within 2 weeks of central laboratory confirmation. Patients with HBV DNA < 300 copies/mL at Week 24 were to continue to receive telbivudine monotherapy
89449837|NCT01379508|Active Comparator|tenofovir|tenofovir 300 mg tablets p.o. once daily for up to 156 weeks. Patients with HBV DNA ≥ 300 copies/mL at Week 24 were to initiate add-on therapy with telbivudine 600 mg tablet p.o. once daily for the remaining weeks of treatment. The investigator was to initiate telbivudine add-on therapy within 2 weeks of central laboratory confirmation. Patients with HBV DNA < 300 copies/mL at Week 24 were to continue to receive tenofovir monotherapy
89449838|NCT03300206||Brevera Breast Biopsy System|The Brevera Breast Biopsy System with CorLumina imaging technology is a vacuum-assisted biopsy device, which is used to remove breast tissue in a minimally invasive manner using stereotactic or tomosynthesis imaging.
89449839|NCT03300206||Standard of Care|Each of the participating sites will currently be using a vacuum assisted breast biopsy system along with a specimen radiography system (or other specimen imaging system).
89449840|NCT03300128|Experimental|Incredible Years - ASD|The intervention, The Incredible Years Parent Program for Autism Spectrum and Language Delays (IY-ASD; more information is here: http://www.incredibleyears.com/programs/parent/autism-spectrum-language-delays/) is a 14-week course that meets for 2 hours every week. Ideally, an IY-ASD group will be composed of approximately 10 parents and other primary caregivers of children who have autism.
89449841|NCT03300128|Active Comparator|Circle of Parents|"Circle of Parents, the comparison condition, is an open parent support group led by a parent leader. (For more information, see http://circleofparents.org/). Participants are encouraged to share resources and other support both during groups, and between meetings."
89449842|NCT03299972|Placebo Comparator|Control|
89449843|NCT03299972|Experimental|Whey Protein|
89449844|NCT03299972|Experimental|Resistance Exercise + Control|
89449845|NCT03299972|Experimental|Resistance Exercise + Whey Protein|
89449846|NCT02261649||Cerebellar Tumor Surgically Removed|"Quantitative Sensory Testing and Neuroimaging~Medoc Advanced Medical Systems PATHWAY Model ATS (Contact thermal stimulator)~Cold water bath~MRI scanner~Questionnaires"
89449847|NCT02261649||Healthy Volunteer|"Quantitative Sensory Testing and Neuroimaging~Medoc Advanced Medical Systems PATHWAY Model ATS (Contact thermal stimulator)~Cold water bath~MRI scanner~Questionnaires"
89449848|NCT03299894|Experimental|systematic calculation of qSOFA|Usual procedure for patient triage AND systematic calculation of qSOFA at Emergency Department triage in patients admitted with a suspected or proven bacterial infection.
89449849|NCT03299894|No Intervention|no systematic calculation of qSOFA|Usual procedures for patient triage at Emergency Department admission and management of suspected or proven bacterial infection. No systematic calculation of qSOFA.
89531323|NCT02493335|Experimental|Budesonide 1mg orodispersible tablet twice daily|Budesonide 1mg orodispersible tablet twice daily
89449850|NCT02263053|Active Comparator|Posterior Mobilization|Patient supine on the gurney, previously trained physiotherapist with disposable gloves, one hand place your thumb on the lower lateral incisors and canines. Applies a force previous distraction grade III and performs oscillating for 1 minute.
89449851|NCT02263053|Active Comparator|Caudal Mobilization|Patient supine on the gurney, previously trained physiotherapist with disposable gloves, one hand place your thumb on the lower molars of patients. Apply simultaneous flow and force the previous direction, and performs the degree of oscillation III for 1 minute.
89449852|NCT03299738|Experimental|C-CAR011|Lymphocytes will be transduced with lentiviral vector containing CAR-CD19 gene
89449853|NCT04457934||IBD patients|"Patients with IBD will undergo preparation for Standard endoscopy with PLENVU, since it is considered to be less affecting for patients. IBD patients have to undergo endoscopy often and mostly suffer from non-efficient preparation.~Patients will drink 1 Liter of Plenvu and 1 Liter of water or tea in preparation for endoscopy and will follow the Guidelines for preparation of endoscopy.~The only Change from Standard care is that patients will receive Plenvu instead of Movicol."
89449854|NCT04457934||Screening patients|"Screening patients will undergo Standard endoscopy to prevent colon Cancer. Patients will drink 1 Liter of Plenvu and 1 Liter of water or tea in preparation for endoscopy and nd will follow the Guidelines for preparation of endoscopy.~The only Change from Standard care is that patients will receive Plenvu instead of Movicol."
89449855|NCT05726630|Experimental|Divozilimab|
89449856|NCT05726630|Placebo Comparator|Placebo|
89449857|NCT04306146|Experimental|CAD-9303|Capsules of CAD-9303 will be administered as a single or multiple dose(s). The initial dose will be 3 mg up to 1000 mg total daily dose.
89449858|NCT04306146|Placebo Comparator|Placebo|Matching placebo will be provided in capsules and administered as a single or multiple dose(s).
89449859|NCT02558439|Placebo Comparator|Placebo|Subjects will receive a single injection of placebo into the index knee following local anesthesia and adjunct joint cooling.
89449860|NCT02558439|Experimental|0.5 mg CNTX-4975|Subjects will receive a single injection of 0.5 mg CNTX-4975 into the index knee following local anesthesia and adjunct joint cooling.
89449861|NCT02558439|Experimental|1.0 mg CNTX-4975|Subjects will receive a single injection of 1.0 mg CNTX-4975 into the index knee following local anesthesia and adjunct joint cooling.
89449862|NCT05162430|Experimental|P1 group|Administration of 0.1 mg/kg of propofol and 5mg dexamethasone phosphate sodium
89449863|NCT05162430|Experimental|P2 group|Administration of 0.2mg/kg of propofol and 5mg dexamethasone phosphate sodium
89449864|NCT05162430|Experimental|P3 group|Administration of 0.3mg/kg of propofol and 5mg dexamethasone phosphate sodium
89449865|NCT05162430|Experimental|P4 group|Administration of 0.4 mg/kg of propofol and 5mg dexamethasone phosphate sodium
89449866|NCT05162430|Experimental|P5 group|Administration of 0.5mg/kg of propofol and 5mg dexamethasone phosphate sodium
89449867|NCT05162430|No Intervention|D1 group|Administration of 5mg dexamethasone phosphate sodium
89449868|NCT05156502|Experimental|Fractionated Laser|
89449869|NCT05156502|Active Comparator|Fractionated.Laser|
89449870|NCT02615067|Experimental|99mTc-MIP-1404 Injection|20 ± 3 millicurie (mCi) intravenous (IV) injection of 99mTc-MIP-1404
89449871|NCT05006612|Active Comparator|Group 1 ((Serratus Anterior Plane Block SAPB)|N=3o Patients will receive Ultrasound guided Serratus Anterior Plane Block with injection of 30 ml levobupivacaine 0.25%.
89449872|NCT05006612|Active Comparator|Group 2 ((Serratus Anterior Plane Block SAPB combined with Modified Pectoral Nerve Block)|N=3o Patients will receive Ultrasound guided Serratus Anterior Plane Block with injection of 20 ml levobupivacaine 0.25%and Modified Pectoral Nerve Block with injection of 10 ml levobupivacaine 0.25%between the two pectoralis muscles, after that, the probe was turned toward the axilla, and as the serratus anterior muscle was recognized above the third and fourth ribs, 10 mL of levobupivacaine 0.25% was injected above this muscle
89449873|NCT05005520|Active Comparator|Active Comparator: Single ascending dose DTRI-031|Drug: DTRI-031 Single doses of DTRI-031 delivered via intravenous injection. Ascending dose levels will be evaluated.
89449874|NCT05005520|Placebo Comparator|Placebo Comparator: Single Dose Placebo|Drug: Placebo Single doses of placebo delivered via intravenous injection, matched to DTRI-031 cohorts
89449875|NCT05162352|Experimental|Donafenib+sintilimab|Donafenib combined with sitilimab.
89449876|NCT04490408|Active Comparator|long surgical bypass|long surgical bypass for multilevel lower limb ischemia
88934754|NCT01772251|Experimental|Oshadi Icp & placebo|
88934755|NCT01772264|Experimental|Arm A - active treatment|
88934756|NCT01772264|Placebo Comparator|Arm B - placebo|
88934757|NCT01772277||MMC group|patients were scheduled to undergo Endoscopic dacryocystorhinostomy with intraoperative MMC
89449877|NCT04490408|Experimental|Hybrid approach|surgical bypass and endovascular treatment for multilevel lower limb ischemia
89449878|NCT05087121|Experimental|Cognitive Behavioral Therapy for Insomnia for Firefighters (CBT-I-F) [Treatment Group]|The Cognitive Behavioral Therapy for Insomnia for Firefighters (CBT-I-F) is a 6-week training course that focuses on mitigating poor sleep quality and promoting the adoption of behaviors conducive to quality sleep. This course includes modules on developing habits conducive to better sleep, adapting variable bedroom environments, and establishing techniques to reduce worry and frustration around falling asleep while recognizing and working through barriers unique to the career of firefighting.
89449879|NCT05087121|No Intervention|No Intervention Control Group|Non-Intervention Control Group (NIC) will not receive training during the course of the study, but will be offered the opportunity to receive training after the study ends.
89449880|NCT05156424|Experimental|Aerobic Emphasised Exercise Intervention|The intervention will comprise of 24 weeks of twice weekly supervised exercise sessions, emphasising aerobic exercise. To reflect a real-world setting, each group will experience both aerobic and resistance exercise, but there will be a 75%:25% predominant: subsidiary mode emphasis based on exercise duration within each session.
89531324|NCT02493335|Placebo Comparator|Placebo orodispersible tablet twice daily|Placebo orodispersible tablet twice daily
89449881|NCT05156424|Experimental|Resistance Emphasised Exercise Intervention|The intervention will comprise of 24 weeks of twice weekly supervised exercise sessions, emphasising resistance exercise. To reflect a real-world setting, each group will experience both aerobic and resistance exercise, but there will be a 75%:25% predominant: subsidiary mode emphasis based on exercise duration of exercise within each session.
89449882|NCT03307928|Experimental|Cardiopulmonary Exercise Test Protocol|All subjects performed an incremental cardiopulmonary exercise test (CPET) to maximum exercise tolerance. All the procedures were performed in agreement with the American Thoracic Society/American College of Chest Physicians guidelines for cycle ergometer tests.
89449883|NCT03307928|Experimental|Polysomnography Assessment|All hypertensive subjects were submitted to a polysomnography exam to diagnose OSA. The OSA diagnose was confirmed by the apnea/hypopnea index (AHI) and classified as follows: AHI < 5 events/h, absence of OSA; 5 ≤ AHI ≤ 15 events/h, low OSA; 15 ≤ AHI ≤ 30 events/h, moderate OSA; AHI > 30 events/h, severe OSA.
89449884|NCT02234271|Active Comparator|Health Educator Arm|Health Educator for contraception information
89449885|NCT02234271|Experimental|Mobile Health Application Arm|Plan A Birth Control - iPad based application for contraception information
89449886|NCT03307850|Experimental|Observation of Exercise|Observation During Exercise and Stress
89449887|NCT02264769|Active Comparator|Carbetocin 20mcg|Patient is given carbetocin 20 mcg intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby.
89449888|NCT02264769|Active Comparator|Carbetocin 100mcg|Patient is given carbetocin 100 mcg intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby.
88934758|NCT01772277||Control group|patients were scheduled to undergo Endoscopic dacryocystorhinostomy without intraoperative MMC
88934759|NCT01772290|Active Comparator|A: Vismodegib|
88934760|NCT01772290|Experimental|B: Rabeprazole + Vismodegib|
88934761|NCT01772290|Experimental|C: Itraconazole + Vismodegib|
88934762|NCT01772290|Experimental|D: Fluconazole + Vismodegib|
88934763|NCT01772303|Experimental|HO/03/03 10-40 micro gram|Topically treatment with HO/03/03 10-40µg once daily for up to 24 weeks. Subjects will receive treatment with HO/03/03 10µg at a dose of 1-4 vials (i.e. 10-40 µg/administration) daily depending on their wound size.
89531325|NCT05040945|Active Comparator|Traditional corticotomy|Adult patients will be treated by en-masse retraction associated with traditional corticotomy
88934764|NCT01772342|Experimental|Nocturnal Air Purification|"Hepa Filtration with PureNight~SHAM with PureNight"
88934765|NCT01772355|Other|tissue core|semi automated core needle biopsy of the orbital tumors
88934766|NCT01772381|Experimental|Dexamethasone|Dexamethasone, im , 12 mg twice, 12 hrs apart, 48 hrs before elective cesarean section
88934767|NCT01772394|Active Comparator|Cognitive Remediation Therapy (CRT)|Active : CRT
88934768|NCT01772394|Sham Comparator|Sham Therapy (ST)|Sham : ST
88934769|NCT01772407||1|laparoscopic surgery in right colon cancer operations
88934770|NCT01772407||2|open surgery in right colon cancer operations
88934771|NCT01772433|Placebo Comparator|Phonophoresis Gel|The Phonophoresis gel will be used as placebo
88934772|NCT01772433|Experimental|Olive Oil|Olive oil will be used as a replacement to phonophoresis gel in this arm
88934773|NCT01772446|No Intervention|CONTROL GROUP|ROUTINE CLINICAL PRACTICE
88934774|NCT01772446|Experimental|SMS MESSAGING|SMS MESSAGES TO MOBILE PHONE TO REMEMBER THE NEXT CONTROL OF GLYCATED HEMOGLOBIN
88934775|NCT01772459||Paper/Paper|This group will complete paper questionnaires at baseline and two week follow up.
88934776|NCT01772459||Paper/Internet|This group will complete paper questionnaires at baseline and internet questionnaires at two week follow up.
88934777|NCT01772459||Internet/Paper|This group will complete internet questionnaires at baseline and paper questionnaires at two week follow up.
88934778|NCT01772459||Internet/Internet|This group will complete internet questionnaires at baseline and two week follow up.
88934779|NCT01772485|Experimental|Cognitive Training|Training group participants will engage in 30 hours of at-home online training on the novel neuroplasticity-based cognitive training program ('Rewired') in 30 minute sessions completed approximately 3-5 days per week, for a total training period lasting 12-20 weeks. Both visual and auditory exercise forms will be practiced daily. Level progression criteria will be flexibly set to assure that almost all individuals can reach them in a reasonable time. Training compliance and performance data (accuracies and reaction times) will be continuously monitored remotely, and analyzed over secure online servers to assure that subjects are completing their training as scheduled and to deal with any unexpected road-blocks in training.
88934780|NCT01772485|Active Comparator|Active Control|The active control group shall engage in an at-home computer game suite, as used in a prior cognitive training trial in a psychiatric population (Fisher et al., 2009), for the same number of hours as the training group to control for the effects of computer exposure and interaction, contact with clinical research personnel and monetary rewards. Compliance will be monitored via an online data portal.
89200719|NCT02539719|Experimental|SC-003 in combination with ABBV-181|Phase 1a (Escalation) - IV infusion of SC-003 followed by IV infusion of ABBV-181 Phase 1b (Expansion) - IV Infusion of SC-003 followed by IV infusion of ABBV-181
89531326|NCT05040945|Experimental|Flapless corticotomy|Adult patients will be treated by en-masse retraction associated with flapless corticotomy
89449889|NCT05162040||Experimental Group|Twenty participants joined the experimental group (15 males and 5 females, mean aged=61.10; SD=12.62) and provided written informed consent to be enrolled onto the study. Participants with neurological pathologies were diagnosed with (6) ischemic strokes, (1) hemorrhagic stroke, (1) thalamic stroke, (1) internal capsule stroke (3) traumatic brain injury (TBI), (1) Parkinson syndrome, (1) mixed axonal neuropathy with sensory demyelination, (1) progressive multifocal leukoencephalopathy, (1) secondary obstructive hydrocephalus, (1) angioma avernosus hemorrhage, (1) hemiprotuberancial hemorrhage - cavernoma, (1) ataxia and (1) cerebral artery aneurysm.
89449890|NCT03307772|Placebo Comparator|placebo drink|The placebo drink consists of fermented low-fat milk with no added Lactobacillus GG.(placebo)
89449891|NCT03307772|Active Comparator|LGG Drink (|The probiotic drink consists of fermented low-fat milk with added Lactobacillus GG. (probiotics)
89449892|NCT03307772|Active Comparator|FOS Drink|The prebiotics drink consists of fermented low-fat milk with fructooligosaccharides. (prebiotics)
89449893|NCT03307772|Active Comparator|LGG e FOS Drink|The probiotics and prebiotics drink consists of acidified low-fat milk with added Lactobacillus GG and fructooligosaccharides (prebiotics and probiotics)
89531327|NCT04494269|Active Comparator|Subjects with normal hepatic function|Single dose of Tegoprazan 50mg
89531328|NCT04494269|Experimental|Subjects with mild hepatic impairment|Single dose of Tegoprazan 50mg
88934781|NCT01772498|Experimental|Heart rate variability biofeedback|Heart rate variability biofeedback training administered in eight, individual, weekly, one hour sessions. There will also be 20 minutes a day of resonant frequency breathing to be conducted at home. This intervention involves teaching subjects how to breath at their resonant frequency in a relaxed, diaphramatic manner.
88934782|NCT01772511||Questionnaire|Patients will be asked by a member of the research team if they would like to participate in this study evaluating patients' comprehension of the informed consent for the oncology treatment study that they are participating in. Patients will be consented and will be told that, at their next clinical visit, they will be given the questionnaire to complete. They will be given the option to complete the questionnaire on site after being given the document or have the ability to mail the completed questionnaire into the research office once completed. If the questionnaire is not returned within 2-weeks, the participant will be approached again during their normal clinical visit and asked if they still wish to participate in this study.
88934783|NCT01772524|Experimental|ALD403|Single IV Dose on Day 0
88934784|NCT01772524|Placebo Comparator|Saline|Single IV infusion on Day 0
88934785|NCT01772589|Active Comparator|New saw blade|New saw blade
88934786|NCT01772589|Active Comparator|Reprocessed saw blade|Reprocessed saw blade
88934787|NCT01772615|Experimental|ciprofloxacin-EcN|
88934788|NCT01772615|Experimental|ciprofloxacin-placebo|
88934789|NCT01772615|Experimental|placebo-EcN|
88934790|NCT01772615|Placebo Comparator|placebo-placebo|
88934791|NCT01772628|Experimental|Promoting parent-child communication|This is the arm in which all interventions of Promoting parent-child communication on selected sexual and reproductive health issues among young secondary school adolescents in Kampala and Wakiso Districts were implemented. The interventions included; classroom-based component, STI/HIV prevention education, parenting component and homework assignment component.
88934792|NCT01772628|No Intervention|Comparison|The 11 comparison schools did not receive any form of intervention. Instead the students continued with the official standard school curriculum and regular parent/guardian involvement in school activities. No homework assignments were given to the senior one students.
88934793|NCT01772641|Experimental|Scheduled Gradual Reduction + Varenicline|Participants will be given the behavioral intervention of Scheduled Gradual Reduction along with the smoking cessation drug, Varenicline.
88934794|NCT01772641|Experimental|Scheduled Gradual Reduction + Placebo Drug|Participants will be given the behavioral intervention, SGR, along with a placebo drug matching the schedule of the VN group.
88934795|NCT01772641|Experimental|Basic Advice + Varenicline|Participants will be given basic advice about quitting smoking along with the smoking cessation drug Varenicline
89449894|NCT02264847|Active Comparator|Clomiphene citrate plus hCG|Women will receive clomiphene citrate from day 2 to day 6 of the cycle with a starting dose of 100 mg daily. If no response could be observed, the daily dose of clomiphene citrate in subsequent cycles will be increased by 50 mg until a response will be obtained or a maximum daily dose 200 mg of clomiphene citrate will be used. Once a follicle will reach more than 18 mm in size . Women will receive 5,000 IU human chorionic gonadotrophin trigger in the morning between 9 and 10 a.m. and the couple will be advised to have intercourse the following night, about 36 hours later.
89449895|NCT02264847|Active Comparator|Clomiphene Citrate alone|Women will receive clomiphene citrate from day 2 to day 6 of the cycle with a starting dose of 100 mg daily. If no response will be observed, the daily dose of clomiphene citrate in subsequent cycles will be increased by 50 mg until a response will be obtained or a maximum daily dose 200 mg of clomiphene citrate will be used. Once a follicle will reach more than 18 mm in size , the women will be advised to have intercourse frequently over the next few days.
89449896|NCT05156190|Experimental|bright classrooms with skylight or renovated artificial light|Students will study in bright classrooms with either skylight or renovated artificial light with light level of over 1000 lux on school time for three years and vision will be screened annually.
89449897|NCT05156190|No Intervention|conventional classrooms|Students will study in conventional classrooms with normal light level for three years and vision will be screened annual.
89449898|NCT02262195||Carboxyhemoglobin|Induced carboxyhemoglobin levels up tp 15 percent.
89449899|NCT02262195||Methemoglobin|Induced methemoglobin levels up to 15 percent.
88934796|NCT01772641|Placebo Comparator|Basic Advice + Placebo Drug|Participants will be given basic advice along with a placebo drug matching the schedule of the VN group.
88934797|NCT01772667|No Intervention|Usual care|Usual care during the whole study period without pulmonary rehabilitation. The patients will perform their normal daily life.
88934798|NCT01772667|Active Comparator|Inpatient Rehabilitation|3-week inpatient multimodal pulmonary rehabilitation program, including daily exercise training, breathing therapy, medical treatment and psychological support. In the following 3 month, the patients will perform their normal daily life.
88934799|NCT01772680|Experimental|Zinc Supplementation|25 mg elemental Zinc as Zn sulfate in capsule form taken daily for 3 months
88934800|NCT01772706|Experimental|laser low-level energy functional|The material used will be a diode laser of 100 mW, with a wavelength of 658 nm. Application will be made after each radiotherapy session in an adapted room (low light intensity, possibility of ENT examination) on all grade superior or equal to 2 stomatitis injuries. The energetic dose delivered will be 4 J/cm2. The duration of the treatment for one will be determined by an abacus.
88934801|NCT01772706|Placebo Comparator|laser low-level energy nonfunctional|The procedure is identical to the one used in arm A but the laser will not be functional. The period of application will be around one minute.
88934802|NCT01772732|Experimental|Simotinib Treatment|"3+3 design, ascending multiple doses. Simotinib Hydrochloride: 100mg, 200mg, 300mg, 400mg, 500mg, bid, for 28 days"
88934803|NCT01772745|Active Comparator|Group 1|SILS cholecystectomy
88934804|NCT01772745|Active Comparator|Group 2|TPCL cholecystectomy
88934805|NCT01772784|Experimental|phenolic acids|Maltodextrine + Phenolic acids
88934806|NCT01772784|Placebo Comparator|placebo|Maltodextrine
88934807|NCT01772784|Experimental|phenolic acid|Maltodextrine + Phenolic acids
88934808|NCT01772784|Active Comparator|polyphenol|
88934809|NCT01772797|Experimental|LDK378 and AUY922|
88934810|NCT01772810|Experimental|Surgical implantation of human spinal cord stem cells|Surgical implantation of human spinal cord derived neural stem cells.
88934811|NCT01772836|Placebo Comparator|Normal saline|Single and multiple dose of normal saline
88934812|NCT01772836|Experimental|Single dose IV of biapenem or RPX7009|Single dose IV infusion of biapenem or RPX7009
88934813|NCT01772836|Experimental|Single dose of biapenem or RPX7009|Single IV dose of biapenem or RPX7009 (for those on active drug, this will be the drug not given in the first IV treatment)
88934814|NCT01772836|Experimental|Biapenem and RPX7009 in combination|Single dose followed by a multiple dose of biapenem and RPX7009 in combination
88934815|NCT01772849|Experimental|Intervention group|"The intervention components includes (real time sequence):~An educational session where the child is educated on his/her cancer disease An education session in the child's school where the child´s teachers, classmates and their parents are educated on the child´s cancer disease.~Appointment of two classmates as ambassadors Continued individualized education at the hospital school or at home that parallels/copies the educational curriculum in the child regular school At two weks intervals joined education, physical (separate study) and social activity days at the hospital with together with one of the ambassadors"
88934816|NCT01772849|No Intervention|Standard educational programme|The children receive the standard of care with respect to education this include education in the hospitals school or at home without a class mate and no specific activity to secure continuous linkage with community school and class mates
88934817|NCT01772862|No Intervention|Only conventional supportive care|The children receive conventional supportive care with respect to physical training
88934818|NCT01772862|Experimental|Intervention group|"The intervention components includes (real time sequence):~An educational session where the child is educated on his/her cancer disease. An education session in the child's school where the child´s teachers, classmates and their parents are educated on the child´s cancer disease.~Appointment of two classmates as ambassadors. An individualized physical training program combining supervised and non-supervised training 3-5 times per week.~Continued specialized physical training when relevant. At two weeks intervals joined education, physical and social activity days at the hospital with together with one of the ambassadors"
89449900|NCT05161962|Experimental|One group received standard oral care.|
89449901|NCT05161962|Placebo Comparator|It was applied to the other group by aspiration.|
89531329|NCT04494269|Experimental|Subjects with moderate hepatic impairment|Single dose of Tegoprazan 50mg
88934819|NCT01772875|Active Comparator|lavage Isobetadine Dermicum solution|Patient will receive 1 bladder lavage daily with a solution of 5ml Isobetadine Dermicum in 100cc saline
89449902|NCT05726552|Experimental|Laughter Therapy group|Hemodialysis patients(40) enrolled in the laughter therapy group will receive a total of 12 sessions of laughter therapy, 50 minutes, 3 days a week.
89449903|NCT05726552|No Intervention|Control|No attempt will be made to hemodialysis patients in this group.
89449904|NCT03469128|Active Comparator|Cognitive processing therapy|Cognitive Processing Therapy (CPT) in which participants completed 12 sessions of CPT
89449905|NCT03469128|Active Comparator|Sertraline|Patients with co-occurrence PTSD & SUD disorders were treated by Sertraline.
89449906|NCT03469128|Placebo Comparator|Control group|Placebo Control group
89449907|NCT02542215|Experimental|Cobiprostone 30 mcg four times daily|Cobiprostone oral spray, four times daily, in addition to standard care radiation and chemotherapy
89449908|NCT02542215|Placebo Comparator|Placebo 0 mcg four times daily|Matching placebo oral spray, four times daily, in addition to standard care radiation and chemotherapy
89449909|NCT05270174||lncRNA-ELNAT1 high expression group|
89449910|NCT05270174||lncRNA-ELNAT1 low expression group|
89449911|NCT03299582|Experimental|Healthy subjects (Hypothermia)|To investigate the safety and tolerability of limb hypothermia in subjects without cancer
89449912|NCT03299582|Experimental|Healthy subjects (Cryocompresion)|To investigate the safety and tolerability of cryocompression in subjects without cancer
89449913|NCT03299582|Experimental|Cancer subjects (Hypothermia)|To investigate the safety and tolerability of limb hypothermia in subjects with breast cancer being treated with paclitaxel chemotherapy.
89449914|NCT03299582|Experimental|Cancer subjects (Cryocompresion)|To investigate the safety and tolerability of cryocompression in subjects with cancer being treated with taxane-based chemotherapy.
89449915|NCT02264925|Experimental|Deep Brain Stimulation|All of included patients will receive a standard deep brain stimulation of the thalamus in order to reduce their essential tremor
89449916|NCT05161572|Experimental|Perioperative chemotherapy plus PD-1 antibody plus preoperative chemoradiotherapy|In this arm, patients will receive preoperative chemoradiotherapy (45Gy/25Fractions), two cycles of SOX and three cycles of PD-1 antibody, followed by D2 surgery and three more cycles of SOX and PD-1 antibody. Then PD-1 antibody will be given until one year after surgery.
89449917|NCT05161572|Experimental|Perioperative chemotherapy plus PD-1 antibody|In this arm, patients will receive three cycles of SOX and PD-1 antibody, followed by D2 surgery and three more cycles of SOX and PD-1 antibody. Then PD-1 antibody will be given until one year after surgery.
89449918|NCT02524197|Active Comparator|CR845 0.25 mg|"Study medication will be taken b.i.d., in the morning (at least 2 hours before breakfast) and later in the afternoon (at least 2 hours before dinner), beginning on the morning of Day1 at the Baseline Visit.~Analgesic rescue medication (Acetaminophen) for the treatment of pain will be provided at the Screening Visit.~Patients will record their daily intake of study medication on the diary provided."
89449919|NCT02524197|Active Comparator|CR845 0.50 mg|"Study medication will be taken b.i.d., in the morning (at least 2 hours before breakfast) and later in the afternoon (at least 2 hours before dinner), beginning on the morning of Day1 at the Baseline Visit.~Analgesic rescue medication (Acetaminophen) for the treatment of pain will be provided at the Screening Visit.~Patients will record their daily intake of study medication on the diary provided."
89449920|NCT02524197|Active Comparator|CR845 1 mg|"Study medication will be taken b.i.d., in the morning (at least 2 hours before breakfast) and later in the afternoon (at least 2 hours before dinner), beginning on the morning of Day1 at the Baseline Visit.~Analgesic rescue medication (Acetaminophen) for the treatment of pain will be provided at the Screening Visit.~Patients will record their daily intake of study medication on the diary provided."
89449921|NCT02524197|Active Comparator|CR845 5 mg|"Study medication will be taken b.i.d., in the morning (at least 2 hours before breakfast) and later in the afternoon (at least 2 hours before dinner), beginning on the morning of Day1 at the Baseline Visit.~Analgesic rescue medication (Acetaminophen) for the treatment of pain will be provided at the Screening Visit.~Patients will record their daily intake of study medication on the diary provided."
89449922|NCT05161416|Experimental|Bubble Group|The children started to blow bubbles 3 minutes before the procedure. The procedure and the bubble blowing intervention were terminated simultaneously.
89449923|NCT05161416|Experimental|Cartoon Group|The children started to watch the cartoon 3 minutes before the procedure. The children were supported by their parents in holding the tablet. The procedure and the cartoon watching intervention were terminated simultaneously.
89449924|NCT02262273||Serous ovarian cancer:|Women with platinum-sensitive recurrent serous ovarian cancer
89449925|NCT02722928|No Intervention|Conventional 1:1 oxygen/air gas mixture|80 patients will receive ventilation during the surgery with a 1:1 oxygen / air gas mixture
89449926|NCT02722928|Experimental|Pure oxygen ventilation|Patients will receive controlled ventilation with a conventional 1:1 oxygen / air gas mixture (60% oxygen concentration) during the approach and tumor removal phases. Once tumor resection is completed and hemostasis started, this group of patients will be switched to ventilation with 100% (pure) oxygen concentration
89449927|NCT03470844||5-10 years post severe burn injury|"Interventions:~Face-to-face neurocognitive tests examining attention, processing speed, working memory and executive function.~Psychological screening for the symptoms of depression, anxiety and post-traumatic stress disorder using the patient health questionnaire (PHQ9), generalised anxiety (GAD7) scoring systems and the trauma screening questionnaire.~fMRI studies including resting state fMRI, T1w-mpr, T2w-FLAIR, Diffusion Tensor Imaging (DTI) with 30 directions, Spectroscopy CSI chemical shift imaging, Spectroscopy SVS single voxel, susceptibility weighted imaging (SWI), double inversion recovery (DIR) and Perfusion ASL.~Quality of Life Self-Assessment data."
89531330|NCT04494269|Experimental|Subjects with severe hepatic impairment|Single dose of Tegoprazan 50mg
89449928|NCT03470844||2-5 years post severe burn injury|"Interventions:~Face-to-face neurocognitive tests examining attention, processing speed, working memory and executive function.~Psychological screening for the symptoms of depression, anxiety and post-traumatic stress disorder using the patient health questionnaire (PHQ9), generalised anxiety (GAD7) scoring systems and the trauma screening questionnaire.~fMRI studies including resting state fMRI, T1w-mpr, T2w-FLAIR, Diffusion Tensor Imaging (DTI) with 30 directions, Spectroscopy CSI chemical shift imaging, Spectroscopy SVS single voxel, susceptibility weighted imaging (SWI), double inversion recovery (DIR) and Perfusion ASL.~Quality of Life Self-Assessment data."
89449929|NCT03470844||1-2 years post severe burn injury|"Interventions:~Face-to-face neurocognitive tests examining attention, processing speed, working memory and executive function.~Psychological screening for the symptoms of depression, anxiety and post-traumatic stress disorder using the patient health questionnaire (PHQ9), generalised anxiety (GAD7) scoring systems and the trauma screening questionnaire.~fMRI studies including resting state fMRI, T1w-mpr, T2w-FLAIR, Diffusion Tensor Imaging (DTI) with 30 directions, Spectroscopy CSI chemical shift imaging, Spectroscopy SVS single voxel, susceptibility weighted imaging (SWI), double inversion recovery (DIR) and Perfusion ASL.~Quality of Life Self-Assessment data."
89449930|NCT03470844||Control|"Healthy age, gender, socioeconomic and educational level matched control.~Interventions:~Face-to-face neurocognitive tests examining attention, processing speed, working memory and executive function.~Psychological screening for the symptoms of depression, anxiety and post-traumatic stress disorder using the patient health questionnaire (PHQ9), generalised anxiety (GAD7) scoring systems and the trauma screening questionnaire.~fMRI studies including resting state fMRI, T1w-mpr, T2w-FLAIR, Diffusion Tensor Imaging (DTI) with 30 directions, Spectroscopy CSI chemical shift imaging, Spectroscopy SVS single voxel, susceptibility weighted imaging (SWI), double inversion recovery (DIR) and Perfusion ASL.~Quality of Life Self-Assessment data."
89531331|NCT03336593|Experimental|QIV batch 1|1 dose of 0.5 ml of quadrivalent influenza vaccine batch 1
89531332|NCT03336593|Experimental|QIV batch 2|1 dose of 0.5 ml of quadrivalent influenza vaccine batch 2
89531333|NCT03336593|Experimental|QIV batch 3|1 dose of 0.5 ml of quadrivalent influenza vaccine batch 3
89531334|NCT03336593|Active Comparator|Trivalent Influenza Vaccine|1 dose of 0.5 ml of trivalent influenza vaccine
89531335|NCT03336593|Experimental|QIV (subjects 6-35 months)|2 dose of 0.25 ml of quadrivalent influenza vaccine
88934820|NCT01772875|Active Comparator|lavage Acetic Acid solution|Patients will receive a daily bladder lavage during 5 consecutive days with a solution of 0.5% acetic acid in 100cc of saline
88934821|NCT01772875|Sham Comparator|lavage with saline|patients will receive during 5 consecutive days a bladder lavage with 100cc saline
88934822|NCT01772875|Active Comparator|lavage Urotainer Suby G|patients will receive during 5 consecutive days a bladder lavage with 100cc of Urotainer Suby G
88934823|NCT01772888||Patients with ALS|All subjects aged > 18 years, diagnosed with an ALS and included in the multidisciplinary follow-up of the HUG at time of diagnosis will be considered and included, if possible, at their first visit.
89200720|NCT04007614||Patients|Patients who have taken a macro progestin treatment for more than 6 months between 16 and 25 years of age.
89449931|NCT03472170|Experimental|Experimental Arm|"The nutritional supplement used will be bovine lactoferrin, a product marketed according to the regulations of the European Union, and approved by the European Food Safety Agency (EFSA) in 2012, and by the American Agency for Food and Drug Administration ( FDA) in 2013. It will be acquired after purchase from Dicofarm® (Rome, Italy).~The Hospital Pharmacy Service will provide the established dose of lactoferrin, according to the administration schedule of 150 mg / kg / day (maximum 300 mg / day).~The treatments will be administered in liquid form, in the least amount possible. The administration of lactoferrin will be carried out enterally, orally or by nasogastric tube.~The intervention will be done in the first 72 hours of life, once a day, and for 4 weeks, extending to 6 weeks in the NB with EG ≤ 28 weeks and / or birth weight ≤ 1000 gr, or until discharge if this happens before."
88934824|NCT01772888||Healthy age and gender-matched subjects|Controls matched for age and gender and dental status and without a medical history for neurological or otolaryngologic disease (1 control for 1 patient). They will be recruited among hospital staff and patients of the dental school.
89449932|NCT03472170|Placebo Comparator|Control Arm|"Placebo with similar visual and taste characteristics to the nutritional supplement of bovine lactoferrin.~It will be administered in liquid form, in the least amount possible. The administration of placebo will be carried out enterally, orally or by nasogastric tube. The intervention will be done in the first 72 hours of life, once a day, and for 4 weeks, extending to 6 weeks in the NB with EG ≤ 28 weeks and / or birth weight ≤ 1000 gr, or until discharge if this happens before."
89449933|NCT04156698|Experimental|Camrelizumab (PD-1 inhibitor) group|"Induction chemotherapy combined with immunotherapy (TPF + Camrelizumab), q3w, 3 cycles in total:~Docetaxel (domestic) 75 mg/m2 i.v. d1, Cisplatin 25 mg/m2 i.v. d1-3, Capecitabine 800 mg/m2 po bid d1-d14, Camrelizumab 200mg i.v. d1;~Radical radiotherapy plus concurrent immunotherapy (CR or PR):~Radiotherapy: Using intensity-modulated radiation therapy (IMRT). Primary site: GTV dose 66 (2.2Gy / fraction)-70 Gy (2Gy / fraction)；CTV 1.6-1.9 Gy / fraction. Cervical lymph nodes: Radiotherapy plan is the same as the radiotherapy plan of original site; Concurrent immunotherapy : Camrelizumab 200mg i.v. d1, d22;~Maintenance period:~After completing concurrent chemoradiotherapy combined with immunotherapy, Camrelizumab 200 mg q3w will be given up to 12 months (calculated from the time of the first dose of PD-1 immunotherapy)."
89449934|NCT03108326||Group 1a|CD-patients (age at enrollment: 18-80 years) receiving a newly introduced Ustekinumab therapy (n=150). A prior therapy with biologics is not allowed.
89449935|NCT03108326||Group 1b|CD-patients (age at enrollment: 18-80 years) receiving a newly introduced Ustekinumab therapy (n=150). A prior therapy with 1 biologics is allowed
89449936|NCT03108326||Group 2|CD-patients (age at enrollment: 18-80 years) receiving a newly introduced Ustekinumab therapy (n=150). A prior therapy with ≥2 biologic is allowed.
89449937|NCT03108326||Group 3a|CD-patients (age at enrollment: 18-80 years) receiving a newly introduced biologics therapy other than Ustekinumab (n=150). A prior therapy with biologic is not allowed.
88934825|NCT01772901|No Intervention|Control|Usual outpatient antenatal care consists of routine checking of the maternal and foetal health by either clinic midwives or obstetricians along with health education to promote a healthy pregnancy.
88934826|NCT01772901|Experimental|Influenza Vaccine Intervention|The intervention group will receive a brief 5 to 10-minute educational talk by research nurse explaining the facts of influenza and influenza vaccine and answering participant questions.
88934827|NCT01772927||Very low birth weight infants,|Parenteral nutrition
89531336|NCT03336593|Experimental|QIV (subjects 3-8 years)|2 dose of 0.5 ml of quadrivalent influenza vaccine
88934828|NCT01772940|Active Comparator|nevirapine and tenofovir/emtricitabine|nevirapine 200 mg twice daily combined with tenofovir 300 mg/emtricitabine 200 mg (fixed-dose combination) once daily, per os for 96 weeks
88934829|NCT01772940|Experimental|lopinavir/r and tenofovir/emtricitabine|ritonavir-boosted lopinavir 800/200 mg once daily or 400/100 mg twice daily combined with tenofovir 300 mg/emtricitabine 200 mg (fixed-dose combination) once daily, per os for 96 weeks
88934830|NCT01772940|Active Comparator|Nevirapine and zidovudine/lamivudine|nevirapine 200 mg/zidovudine 300 mg/lamivudine 150 mg (fixed-dose combination) twice daily, per os for 96 weeks
88934831|NCT01772940|Experimental|Lopinavir/r and zidovudine/lamivudine|ritonavir-boosted lopinavir 800/200 mg once daily or 400/100 mg once daily combined with zidovudine 300 mg/lamivudine 150 mg once daily, per os for 96 weeks
89014724|NCT04266080|Experimental|childhood cancer survivors & and one parent/legal guardian|The study plans to recruit 30 childhood cancer survivors and a parent/legal guardian for each survivor. Participants will be provided with a Fitbit Inspire HR wearable device to record their step counts for two weeks pre-intervention, and over the six-month follow-up period (3-month intervention and 3month follow-up).
89449938|NCT03108326||Group 3b|CD-patients (age at enrollment: 18-80 years) receiving a newly introduced biologics therapy other than Ustekinumab (n=150). A prior therapy with 1 biologic is allowed.
89449939|NCT03108326||Group 4|CD-patients (age at enrollment: 18-80 years) receiving a newly introduced biologics therapy other than Ustekinumab (n=150). A prior therapy with ≥2 biologics is allowed.
89449940|NCT03307694||MAC-SWEI, standard SWEI, ultrasound|Participants in this group will receive all three imaging techniques
89449941|NCT03307694||Standard SWEI, ultrasound|Participants in this group will receive two imaging techniques
89449942|NCT01439919|Experimental|SSR411298 200 mg|SSR411298 200 mg, one tablet once daily for 4 weeks
89449943|NCT01439919|Placebo Comparator|Placebo|Placebo (for SSR411298), one tablet once daily for 4 weeks
89449944|NCT03470766|Active Comparator|Active Lead (AL)|One octad lead placed where contacts 4 and 5 span the T9-T10 disc space.
89449945|NCT03470766|Sham Comparator|Sham Lead (SL)|One octad lead implanted subcutaneously behind the IPG and will serve to dissipate the current from the battery
89449946|NCT02262351|Experimental|Screening|"Subjects will undergo three screening methods for atrial fibrillation:~30 Second Pulse Check Watch BP Home A HeartCheck Hand-held ECG device"
89449947|NCT04034082|Experimental|IHT group|Intermittent hypoxia therapy on top of the conventional phase 2 in-hospital rehabilitation program
89449948|NCT04034082|Active Comparator|Conventional group|Conventional phase 2 in-hospital rehabilitation program
89449949|NCT03307538|Experimental|Stereotactic body radiation therapy|
89449950|NCT05131464|Experimental|CM310|
89449951|NCT04964024||Residents in Nursing homes|
89449952|NCT04964024||Health professionals in Nursing homes|
89449953|NCT03810144||Vectra Guided|For patients in the guided care arm, treating physicians will receive the Vectra MBDA Test score prior to the patient visit and will have a set of guidance for decision-making based on these scores. Treating physicians will be strongly encouraged to follow the guidance but will not be required to do so. For test results to be available at the time of each visit in the MBDA guided treatment arm, blood testing will be performed 7-10 days before the visit.
89449954|NCT03810144||Usual Care|For patients in the UC arm, treating physicians will not have access to MBDA scores until the end of the study.
89449955|NCT03299270||Group 1|Elderly patiences with solid malignancy
89014725|NCT04253626|Experimental|Intravenous iron|Participants will receive 510mg intravenous iron ferumoxytol, with a maximum of 2 doses based on the baseline hemoglobin level. The ferumoxytol is administered as an infusion for approximately 15 - 30 minutes.
89014726|NCT04253626|Active Comparator|Oral iron|Participants will be prescribed 1-2 ferrous sulfate 325mg tablets by mouth (based on severity of anemia) until delivery. For standardization, the dosage is as follows based on severity: one ferrous sulfate tablet for women with baseline hemoglobin 9-11, and two ferrous sulfate tablets for hemoglobin < 9.
89014727|NCT04252989||Children with active myopia treated with ATROPINE eye drops|
89014728|NCT04252573|Experimental|ChEVAS System|The ChEVAS procedure involves the use of the Nellix System in conjunction with parallel branch chimney stents for the treatment of juxtarenal, pararenal, or paravisceral abdominal aortic aneurysms.
89014729|NCT04251715|Experimental|mFOLFIRINOX, Floxuridine-DEX, mFOLFIRI|"Treatment Period 1 - mFOLFIRINOX for 4 cycles (cycle = 14 days) Cycle 1~Oxaliplatin 85 mg/m2 intravenously (iv) over 2 hours~Folinic acid 400 mg/m2 iv over 2 hours~Irinotecan 165 mg/m2 iv over 90 minutes~Fluorouracil 400 mg/m2 iv bolus after folinic acid~Fluorouracil 2,400 mg/m2 continuous infusion over 46 hours~Dosages on Cycle 2, 3, and 4 will be reduced by 25% Treatment Period 2 - HAI delivery of floxuridine + mFOLFIRI for 2 cycles (cycle = 28 days)~Floxuridine-DEX (with heparin and saline) - 0.12 mg/kg/day; via HAI pump, adjusted for weight and flow rate~mFOLFIRI on Day 15~Irinotecan 180 mg/m2 iv over 30 minutes to 1 hour~Folinic acid 400mg/m2 iv over 30 minutes to 1 hour~5-FU 1000 mg/m2 continuous infusion over 46 hours"
89014730|NCT04232553|Experimental|Mirikizumab SC|Mirikizumab given subcutaneously (SC).
89014731|NCT04232553|Experimental|Mirikizumab IV and SC|Mirikizumab given intravenously (IV) and SC.
89449956|NCT03470688||Originator|Originator anti-TNF agents. Dosage as per physician's decision based on approved indication.
89449957|NCT03470688||Biosimilar|Biosimilar anti-TNF agents. Dosage as per physician's decision based on approved indication.
89449958|NCT02262429||ONS QIP|Two (2) hospitals will administer the new rapid, comprehensive oral nutritional supplementation (ONS) QIP.
89200721|NCT05178628|Experimental|Patients treated with Innohep® and chemotherapy|The patients in this arm will receive Innohep and chemotherapy with Gemcitabine + Nab-Paclitaxel (NabG) as per clinical practice.
89449959|NCT02262429||ONS Standard Feeding|"Two (2) hospitals will use their current standard ONS feeding protocol."
89449960|NCT03307460|Experimental|uPAR PET/MRI|68Ga-NOTA-AE105 is injected once for performing a PET/MRI scan
89449961|NCT02265003||Healthy young age|Healthy subjects in age of 18-35 years, without cardiac dysrhythmia, hypertension, diabetes mellitus, acute inflammations and terminal kidney disease
89449962|NCT02265003||Healthy middle age|Healthy subjects in age of 35-45 years, without cardiac dysrhythmia, hypertension, diabetes mellitus, acute inflammations and terminal kidney disease
89449963|NCT02265003||Healthy old|Healthy subjects in age of >70 years, without cardiac dysrhythmia, hypertension, diabetes mellitus, acute inflammations and terminal kidney disease
89449964|NCT02265003||Patients|Patients with atherosclerosis
89449965|NCT05072886|Experimental|AT193|Topical applied daily
89449966|NCT05072886|Placebo Comparator|Placebo|Topical applied daily
89449967|NCT02466542|Placebo Comparator|Placebo group|Patients in placebo group will receive general balanced inhaled anesthesia with sevoflurane and remifentanil and a saline 0,9% infusion pump.
89449968|NCT02466542|Active Comparator|Esmolol group|Patients in esmolol group will receive general balanced inhaled anesthesia with sevoflurane and remifentanil and a bolus infection of esmolol 500 mgc/kg followed by a continuous infusion of esmolol 100 mcg/kg/min
89531337|NCT05030727|Other|Evaluation of intraoperative NGAL levels in terms of acute kidney injury in geriatric patients|only one group
89531338|NCT03120377|Active Comparator|Platform group|Group submitted to the whole body vibration training program
89531339|NCT03120377|Sham Comparator|Platform sham group|Group that will receive the whole body vibration simulation treatment without the therapeutic effect of the platform, but with vibrating platform connected with the display on and a sound device coupled with vibration-generated noise recording, but without therapeutic purposes.
89531340|NCT05040789|Experimental|Group 1|CoVLP Lot 1
89531341|NCT05040789|Experimental|Group 2|CoVLP Lot 2
89531342|NCT05040789|Experimental|Group 3|CoVLP Lot 3
88934832|NCT01772953|Experimental|treosulfan, fludarabine and low-dose TBI prep regimen|"Treosulfan: 10-14 g/m2/day IV over 120 minutes on days -6, -5 and -4. Treosulfan will be administered prior to fludarabine on days -6 to -4 to facilitate PK testing.~Fludarabine: 30 mg/m2 IV for patients > 10 kg (or 1 mg/kg IV for patients < 10 kg) once daily per institutional infusion standards on days -6 through -2 for a total dose of 150 mg/m2 (or 5 mg/kg).~A single fraction of 200 cGy TBI will be administered on day -1. Stem cell infusion on day 0"
88934833|NCT01772966|Experimental|Spinal manipulation|Participants will receive spinal manipulation delivered as segmental thrust to a specific site in the neck. They will receive three intervention sessions over 7-10 days.
88934834|NCT01772966|Sham Comparator|Control manipulation|Participants will receive spinal manipulation delivered as non-segmental thrust to the neck. They will receive three intervention sessions over 7-10 days.
88934835|NCT01772979|Experimental|Trabectedin|"Trabectedin 1.3 mg/m2 q 21 days~Patients will receive trabectedin until disease progression or unacceptable toxicity"
89531343|NCT03337607|Active Comparator|rESWT plus C-E drugs|Patients will receive rESWT, Celecoxib and Eperisone
89531344|NCT03337607|Active Comparator|rESWT alone|Patients will receive rESWT
89449969|NCT05067270|Experimental|Sequence 1:Arm Region,Abdomen 6mm,Buttock,Abdomen 9mm,Thigh|Participants had cannulas inserted into each of the designated infusion sites (6 millimeter (mm) for all the sites. Additionally for the abdominal area only, a 9 mm cannula was also inserted into the opposite side of the lower abdomen), and the first infusion site was initiated subcutaneously (SC) with 15 millimolar (mM) sodium citrate and 1 microgram per milliliter (μg/mL) treprostinil in Humalog diluent with 5 mM magnesium chloride (without insulin) solution at a basal infusion rate of 1 unit per hour (U/h). The same procedure occurred at subsequent infusion sites with an approximately 30-minute (min) interval between each initiation. Approximately 3, 6, and 9 hours after the start of the basal infusion, a bolus dose of 15 U was delivered at quick bolus speed (15 U/min) to each infusion site according to the treatment sequence with an approximately 30-minute interval between infusion sites.
89449970|NCT05067270|Experimental|Sequence 2:Abdomen 6mm,Abdomen 9mm,Arm Region,Thigh,Buttock|Participants had cannulas inserted into each of the designated infusion sites (6 mm for all the sites. Additionally for the abdominal area only, a 9 mm cannula was also inserted into the opposite side of the lower abdomen), and the first infusion site was initiated with 15 mM sodium citrate and 1 μg/mL treprostinil in Humalog diluent with 5 mM magnesium chloride (without insulin) solution at a basal infusion rate of 1 U/h. The same procedure occurred at subsequent infusion sites with an approximately 30-minute interval between each initiation. Approximately 3, 6, and 9 hours after the start of the basal infusion, a bolus dose of 15 U was delivered at quick bolus speed (15 U/min) to each infusion site according to the treatment sequence with an approximately 30-minute interval between infusion sites.
89531345|NCT03337607|Active Comparator|C-E drugs alone|Patients will receive Celecoxib and Eperisone
89531346|NCT03336515|Other|Group A-General Recommendation|General recommendation not sleeping in supine position without the postural device
89531347|NCT03336515|Placebo Comparator|Group B-Postural device no activated|General recommendation not sleeping in supine position and the postural device without any activation (placebo)
89531348|NCT03336515|Experimental|Group C-Postural device activated|General recommendation not sleeping in supine position and the postural device activated (intervention group).
89014734|NCT04228991|Active Comparator|Control|Conventional fractionation for locoregional radiotherapy
89449971|NCT05067270|Experimental|Sequence 3:Abdomen 9mm,Thigh,Abdomen 6mm,Buttock,Arm Region|Participants had cannulas inserted into each of the designated infusion sites (6 mm for all the sites. Additionally for the abdominal area only, a 9 mm cannula was also inserted into the opposite side of the lower abdomen), and the first infusion site was initiated with 15 mM sodium citrate and 1 μg/mL treprostinil in Humalog diluent with 5 mM magnesium chloride (without insulin) solution at a basal infusion rate of 1 U/h. The same procedure occurred at subsequent infusion sites with an approximately 30-minute interval between each initiation. Approximately 3, 6, and 9 hours after the start of the basal infusion, a bolus dose of 15 U was delivered at quick bolus speed (15 U/min) to each infusion site according to the treatment sequence with an approximately 30-minute interval between infusion sites.
89449972|NCT05067270|Experimental|Sequence 4:Thigh,Buttock,Abdomen 9mm,Arm Region,Abdomen 6mm|Participants had cannulas inserted into each of the designated infusion sites (6 mm for all the sites. Additionally for the abdominal area only, a 9 mm cannula was also inserted into the opposite side of the lower abdomen), and the first infusion site was initiated with 15 mM sodium citrate and 1 μg/mL treprostinil in Humalog diluent with 5 mM magnesium chloride (without insulin) solution at a basal infusion rate of 1 units per U/h. The same procedure occurred at subsequent infusion sites with an approximately 30-minute interval between each initiation. Approximately 3, 6, and 9 hours after the start of the basal infusion, a bolus dose of 15 U was delivered at quick bolus speed (15 U/min) to each infusion site according to the treatment sequence with an approximately 30-minute interval between infusion sites.
89014735|NCT04228991|Experimental|Experimental|Hypofractionation for locoregional radiotherapy
89014736|NCT04219137||Localized Esophagogastric Adenocarcinoma|Patients diagnosed with gastroesophageal adenocarcinoma who will undergo surgical resection for curative intent, with or without neo-adjuvant chemotherapy or chemoradiotherapy.
89014737|NCT04219137||Metastatic Esophagogastric Adenocarcinoma|Patients diagnosed with de novo metastatic gastroesophageal adenocarcinoma who will undergo platinum based first line chemotherapy.
89014738|NCT04209686|Experimental|Cohort 1 - Measurable Disease|All Participants will receive Paclitaxel, Olaparib and Pembrolizumab.
89014739|NCT04209686|Experimental|Arm 2: Cohort 2-Unmeasurable Disease|All Participants will receive Paclitaxel, Olaparib and Pembrolizumab.
89014740|NCT04207905||Exempt for Evaluation Purposes|Individuals who would have been subject to the Healthy Michigan Plan (HMP) work requirements but have been randomly assigned to a control group that is exempt from reporting for evaluation purposes
89014741|NCT04207905||Work Requirement|Individuals who are subject to the Healthy Michigan Plan (HMP) work requirements
89014742|NCT04207476|Experimental|Treatment arm|Active magnetic field exposure will be performed by use of a EMF resonator. Stimulator will be applied continuously for 1 hour.
89014743|NCT04207476|Placebo Comparator|Placebo|Placebo magnetic field exposure will be performed by use of a EMF resonator. Stimulator will be applied continuously for 1 hour.
89014744|NCT04198428|Experimental|Receives OUD-CDS|Clinics will have access to the OUD-CDS (Opioid Wizard)
89014745|NCT04198428|No Intervention|Does not Receive the OUD-CDS|"Clinics will not have access to the OUD-CDS (Opioid Wizard). These will be usual care clinics."
89014746|NCT04184622|Experimental|5 mg Tirzepatide|5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.
89014747|NCT04184622|Experimental|10 mg Tirzepatide|10 mg tirzepatide administered SC once a week.
89014748|NCT04184622|Experimental|15 mg Tirzepatide|15 mg tirzepatide administered SC once a week.
89014749|NCT04184622|Placebo Comparator|Placebo|Placebo administered SC once a week.
89014750|NCT04168970||PSGB group|MD will perform PSGB using Lidocaine. The PGSB will be performed after the administration of the 4th shock if the 3rd shock was unsuccessful in restoring a stable perfusing rhythm, considering all the shocks administered both by an AED or by manual defibrillator. PSGB will be performed after all the actions provided in the ACLS algorithm and which are considered useful in the clinical situation (intubation and ventilation, administration of iv/io adrenaline, amiodarone or lidocaine, use of mechanical chest compression, etc.).
89014751|NCT04168970||Control group|Historical cohort of patients with the same OHCA characteristics (first shockable rhythm and who received more than 4 shocks) enrolled in the Cardiac Arrest Registry of the Province of Pavia
89014752|NCT04161781||Cohort 1|10 participants will receive one injection of 18F-BMS-986229 (370 MBq) and will then undergo whole-body PET/CT (80 mA) encompassing the vertex of the skull to the proximal thigh performed at 60 minutes (within the range of 55-70 minutes) postinjection. The scan itself is expected to last about 30 minutes and participants will be asked to remain in the waiting area or dedicated room for an additional 30 minutes post scan. The total time from injection will be 120 minutes. In both cohorts, participants whose treatment includes nivolumab and who have positive tumor localization observed at baseline will be asked to undergo an additional round of imaging.
89449973|NCT05067270|Experimental|Sequence 5:Buttock,Arm Region,Thigh,Abdomen 6mm,Abdomen 9mm|Participants had cannulas inserted into each of the designated infusion sites (6 mm for all the sites. Additionally for the abdominal area only, a 9 mm cannula was also inserted into the opposite side of the lower abdomen), and the first infusion site was initiated with 15 mM sodium citrate and 1 μg/mL treprostinil in Humalog diluent with 5 mM magnesium chloride (without insulin) solution at a basal infusion rate of 1 U/h. The same procedure occurred at subsequent infusion sites with an approximately 30-minute interval between each initiation. Approximately 3, 6, and 9 hours after the start of the basal infusion, a bolus dose of 15 U was delivered at quick bolus speed (15 U/min) to each infusion site according to the treatment sequence with an approximately 30-minute interval between infusion sites.
89449974|NCT01437735|Experimental|QAW039 po dose 1|
89449975|NCT01437735|Experimental|QAW039 po dose 2|
89449976|NCT01437735|Experimental|QAW039 po dose 3|
89449977|NCT01437735|Experimental|QAW039 po dose 4|
89014753|NCT04161781||Cohort 2|25 participants may receive 370 MBq of 18F-BMS-986229 given intravenously and will undergo a single PET/CT scan 60 minutes (within the range of 55-70 minutes) postinjection. The scan itself is expected to last about 30 minutes and participants will be asked to remain in the waiting area or dedicated room for an additional 30 minutes post scan. The total time from injection will be 120 minutes. In both cohorts, participants whose treatment includes nivolumab and who have positive tumor localization observed at baseline will be asked to undergo an additional round of imaging. If the participant agrees, they will receive a second injection while undergoing nivolumab treatment (after at least 2 cycles or 6 weeksof therapy).
89014754|NCT04151940|Experimental|Research (PET/CT scan)|Patients undergo PET/CT scan within 4 weeks before starting standard of care chemoimmunotherapy and a second PET/CT scan within 5 days of the second chemoimmunotherapy cycle. Patients receiving standard of care radiation treatment undergo additional PET/CT scans within 4 weeks prior to radiation treatment and 1 month post-radiation treatment.
89200722|NCT05178628|Active Comparator|Patients treated with chemotherapy|The patients in this arm will receive chemotherapy with Gemcitabine + Nab-Paclitaxel (NabG) as per clinical practice.
89449978|NCT01437735|Experimental|QAW039 po dose 5|
89449979|NCT01437735|Experimental|QAW039 po dose 6|
89449980|NCT01437735|Experimental|QAW039 po dose 7|
89449981|NCT01437735|Experimental|QAW039 po dose 8|
89200723|NCT00896571|Experimental|Arm 1|
89200724|NCT00981838|Experimental|1|Rituximab (375 mg/m2).
89449982|NCT01437735|Experimental|QAW039 po dose 9|
89449983|NCT01437735|Experimental|QAW039 po dose 10|
89449984|NCT01437735|Experimental|QAW039 po dose 11|
89449985|NCT01437735|Experimental|QAW039 po dose 12|
89449986|NCT01437735|Experimental|QAW039 po dose 13|
89449987|NCT01437735|Active Comparator|Montelukast po 10 mg|Comparator leukotriene receptor antagonist (LRTA)
89449988|NCT01437735|Placebo Comparator|Placebo|
89449989|NCT02722304|Experimental|ARALAST NP 60 mg/kg|60 mg/kg body weight/week
89449990|NCT02722304|Experimental|ARALAST NP 120 mg/kg|120 mg/kg body weight/week
89449991|NCT02722304|Experimental|GLASSIA 60 mg/kg|60 mg/kg body weight/week
89449992|NCT02722304|Experimental|GLASSIA 120 mg/kg|120 mg/kg body weight/week
89449993|NCT02722304|Placebo Comparator|Placebo|Human Albumin 2%
89449994|NCT04984902|Experimental|Treatment|Treatment with Microbind® Affinity Blood Filter
89449995|NCT04984902|No Intervention|Control|Antibiotics
89449996|NCT01437657|Placebo Comparator|Placebo|Matching RO4917523 placebo orally daily, 6 weeks
89449997|NCT01437657|Experimental|RO4917523 0.5 mg|0.5 mg orally daily, 6 weeks
89449998|NCT01437657|Experimental|RO4917523 1.5 mg|1.5 mg orally daily, 6 weeks
89449999|NCT03299192|Experimental|Tai Chi|twice weekly classes for 12 weeks and then weekly for 6 weeks, every other week for 6 weeks and monthly for 3 months
89450000|NCT03299192|Active Comparator|Health Education|twice weekly classes for 12 weeks
89450001|NCT03299192|Active Comparator|Usual Medical Care|the usual care to which participants are entitled by their health insurance
89531349|NCT05030181|Active Comparator|kinesiotaping and exercise|'I'' strip kinesiotape will be applied with the space correction technique for the upper trapezius muscle, for a total of 4 sessions, 2 days a week, and the patients will be included in the 1-month home exercise program.
89531350|NCT05030181|Active Comparator|exercise|1-month home exercise program.
89450002|NCT05728112|Experimental|Hydrogen Inhalation|The manufacturer installs the hydrogen inhalation machine at the subject's home and explains the relevant operation methods. The research executor will take care of it in the LINE group on the first day of installation, and after obtaining the pre-test baseline data (baseline data) through the google form, carry out each test. Continuous inhalation of hydrogen was carried out every day, and four post-test assessments were performed before inhalation and on the 1st, 3rd, 7th, and 14th days after inhalation.
89450003|NCT05728112|Placebo Comparator|Ordinary Air Inhalation|This group used the same model to inhale, but the gas released was only ordinary air, as a placebo control.
89450004|NCT01436487|Experimental|Cohort 1|Low dose MultiStem or Placebo
89450005|NCT01436487|Experimental|Cohort 2|High dose MultiStem or Placebo
89450006|NCT01436487|Experimental|Cohort 3|Highest, safe MultiStem dose (from Cohorts 1 and 2) or Placebo
89450007|NCT04653714|Experimental|Full mouth debridement|Supragingival plaque/calculus removal and scaling and root planing
89450008|NCT04653714|Sham Comparator|Supragingival plaque/calculus removal|Supragingival plaque and calculus removal
89450009|NCT04653714|Experimental|Probiotic lozenges|Daily usage of probiotic lozenges
89450010|NCT04653714|Active Comparator|Placebo lozenges|Daily usage of placebo lozenges
89450011|NCT02509845|Experimental|Adolescent Safety Only Cohort|Prior to commencing enrollment of subjects 12-17 years of age in Study Arms 1 & 2, a safety only cohort of 4 to 8 adolescent subjects will receive 4 administrations of C16G2 on Day 0.
89450012|NCT02509845|Experimental|Study Arm 1|Subjects will receive 2 mL of study drug or placebo over two 7 day C16G2 administration periods, which will be separated by approximately 4 months. Subjects enrolled in Study Arm 1 will receive 4 study drug or placebo administrations on the first day of dosing followed by morning (AM) and evening (PM) dosing for 6 consecutive days. Study drug will be administered via manual toothbrush and custom dental trays.
89450013|NCT02509845|Experimental|Study Arm 2|Subjects will receive 4 mL of study drug or placebo over two 7 day C16G2 administration periods, which will be separated by approximately 4 months. Subjects enrolled in Study Arm 2 will receive 4 study drug or placebo administrations on the first day of dosing followed by morning (AM) and evening (PM) dosing for 6 consecutive days. Study drug will be administered via manual toothbrush and custom dental trays.
89450014|NCT04628754|Experimental|Intervention|Resistance exercise and dietary protein guidance
89450015|NCT04628754|No Intervention|Control|Usual care
89450016|NCT03307148|Experimental|ATRA in combination with Gemcitabine and Nab-Paclitaxel|Patients will receive ATRA, Gemcitabine and nab-Paclitaxel in 28 day cycles. ATRA will be administered for 6 cycles whereas Gemcitabine/nab-Paclitaxel will be administered until disease progression.
89450017|NCT04604808||Non hypocalcemic group|Patients that don't develop post-thyroidectomy hypocalcemia
89450018|NCT04604808||Hypocalcemic group|Patients that develop post-thyroidectomy hypocalcemia
89450019|NCT03984591|Active Comparator|Spironolactone|Spironolactone used according to heart failure guidelines
89450020|NCT03984591|Active Comparator|Eplerenone|Eplerenone used according to heart failure guidelines
89450021|NCT04568538|Experimental|İntervention group|"Randomization with a sealed envelope will be applied to mothers who have 2-4 months old babies who apply to Akdeniz University Hospital Pediatric Outpatient Clinic for health control and who accept the study. A pre-test application will be made in the intervention group. The Researcher will fill in the Personal Information Form and the Shaken baby syndrome assessment survey at this stage.~The training prepared to prevent shaken baby syndrome, which was prepared immediately after the end of the pre-test application, will be given to the mothers in the intervention group. The training will be given with mothers using one-to-one face-to-face interview method. Necessary equipment will be provided for training. At the end of the training, the questions of the mothers will be answered and a booklet prepared to prevent shaken baby syndrome will be given and tele-consultancy will be provided for 2 months."
89450022|NCT04568538|No Intervention|Control group|No application will be made to the mothers in the control group after the pre-test application. After 2 months, the final test application will be made. After the last test, the mothers in the control group will be given a training and a booklet prepared to prevent shaken baby syndrome.
89450023|NCT04816058||Ankle Instability Group|Patients with a history of ankle instability or injury.
89450024|NCT04816058||Healthy Group|Participants without a history of ankle injury
89450025|NCT02503137|Experimental|Experimental Arm 1|Topical SM04554 0.15% solution, once daily for approximately 90 days
89450026|NCT02503137|Experimental|Experimental Arm 2|Topical SM04554 0.25% solution, once daily for approximately 90 days
89450027|NCT02503137|Placebo Comparator|Vehicle|Topical vehicle solution, once daily for approximately 90 days
89450028|NCT03470532|Experimental|Group A|buccal infiltration of 4% Articaine with epinephrine
89450029|NCT03470532|Active Comparator|Group B|buccal infiltration of 2% Mepivacaine with epinephrine
89450030|NCT02468336|Experimental|AngioDefender|The AngioDefender device uses a novel, proprietary software algorithm to analyze pulse wave amplitude data collected before and after BA occlusion by a standard upper arm sphygmomanometric blood pressure (BP) cuff. The procedure is non-invasive and employs neither ultrasound nor Doppler flow analysis.
89450031|NCT02468336|Active Comparator|Brachial Artery Ultrasound Imaging|A non-invasive procedure for detecting endothelial dysfunction by measuring the flow-mediated dilation of the brachial artery (BA) using high resolution continuous ECG-gated B-mode (2D) ultrasound imaging during reactive hyperemia, a state of transient increase in tissue blood flow that occurs following a brief period of ischemia, e.g., BA occlusion. BA diameter is measured at end-diastole, coincident with the R wave of a simultaneously recorded ECG.
89450032|NCT02502669|Active Comparator|Finasteride 23.5 mg tablets group|Finasteride 23.5mg tablets and large placebo tablets once per week
89450033|NCT02502669|Active Comparator|Finasteride 33.5 mg tablets group|Finasteride 33.5 mg tablets and small placebo tablets once per week
89450034|NCT02502669|Placebo Comparator|Placebo group|Large and small placebo tablets once per week
89450035|NCT04839510|Experimental|MRG002|MRG002 will be administrated by an IV infusion of 2.6 mg/kg on Day 1 of every 3 weeks (21-day cycle).
89450036|NCT03306914|Active Comparator|Albumin group|Albumin resuscitation Albumin 5%
89450037|NCT03306914|Experimental|Hydroxyethylstarch group|Hydroxyethylstarch resuscitation Hydroxyethylstarch 6%
89450038|NCT03135093||Stroke subjects|
89450039|NCT03135093||Healthy subjects|
88934836|NCT01772992|No Intervention|Control group (iVCT)|Male couples randomized to the control group (iVCT) will each receive individual HIV counseling and testing, separately.These couples in the control group (iVCT) will return every 6 months, up to 18 months, for individual visits, in which they will have STI testing and repeat HIV testing. All follow-up visits will be conducted separately.
88934837|NCT01772992|Experimental|Experimental group (CVCTPLUS)|Male couples randomized to the experimental group (CVCTPLUS) will each receive HIV counseling and testing as a couple. These couple will return for two additional visits that members of the control arm do not get, for two one-hour sessions of the Partner-STEPS. Couples in the experimental group (CVCTPLUS) at 8 and 10 weeks after the initial enrollment. They will also return every 6 months, up to 18 months, for visits in which they will be seen as a couple, in which they will have STI testing and repeat HIV testing. All follow-up visits will be conducted for the couples together.
88934838|NCT01773005|Sham Comparator|Caldolor|Subject receives the interventional drug, intravenous ibuprofen (800 mg Caldolor) at the induction of anesthesia, followed by 800 mg Caldolor every 6 hours until discharge or for a total of up to 120 hours (5 days)
88934839|NCT01773005|Active Comparator|Ofirmev|Subject receives the interventional drug, intravenous ibuprofen (800 mg Caldolor) at the induction of anesthesia and intravenous Acetaminophen (1000 mg Ofirmev) at the time of surgical wound closure, followed by 800 mg Caldolor plus 1000 mg Ofirmev every 6 hours until discharge for a total of up to 120 hours (5 days)
88934840|NCT01773018|Experimental|Volitinib(HMPL-504)|"There are six dose cohorts,including 100, 200, 400, 600,800 and 1000 mg/day, HMPL-504 will be administered orally to patients once daily for each dose cohort.~An alternative dosing schedule of twice every day (BID) may be investigated if pharmacokinetic studies indicate faster than anticipated clearance of Volitinib(HMPL-504)."
88934841|NCT01773044|Active Comparator|alkalinized lidocaine & lidocaine|
88934842|NCT01773044|Active Comparator|alkalinized lidocaine &Placebo|
88934843|NCT01773057|Experimental|Active decision support|Regular NHGDoc domains plus NHGDoc domain heart failure
88934844|NCT01773057|No Intervention|Passive decision support|Regular NHGDoc domains
88934845|NCT01773096|Experimental|Study group|Weight-based dose (0.15 mg/kg for patients less than 38 kg, 8 mg for patients weighing 38-62 kg, or 12 mg for patients weighing greater than 62 kg) of methylnaltrexone will be administered on post-operative day 3 and again, if indicated, on post-operative day 4. This group will also receive the standard bowel protocol beginning on postoperative day one as per protocol.
88934846|NCT01773096|Active Comparator|Institutional bowel protocol|Patient will receive institutional standard bowel protocol. Beginning on post-operative day one either miralx,docusate sodium or senna, on a weight-based dose. If no bowel movement in 72 hours, either oral bisacodyl or magnesium hydroxide, on a weight-based dosing, will be added.
88934847|NCT01773148|Experimental|Arstasis Access System (AXERA) placement|Placement of AXERA device in subjects undergoing common femoral artery access for PCI and/or PVI through a 5F or 6F introducer sheath.
88934848|NCT01773161||Cerebral palsy, post hip surgery|Children between the ages of 4-18 undergoing surgical treatment for hip subluxation or dislocation secondary to cerebral palsy.
88934849|NCT01773174|Experimental|dabigatran etexilate|single dose treatment with dabigatran oral solution
88934850|NCT01773200||Aneurysmal Subarachnoid Hemorrhage|Each consecutive patient suffering from aneurysmal subarachnoid hemorrhage
88934851|NCT01773213|Other|Bladder dysfunction, ice-water-test|
88934852|NCT01773213|Other|Bladder dysfunction, warm water-test|
88934853|NCT01773239|Experimental|TARA computer-based exercises|"TARA is a computerized social cognitive (SC) remediation program consisting of a set of specific SC exercises. The program creates a game-like experience where the participant is encouraged to earn points and in-game rewards to further advance in each 'game'. Participants perform tens to hundred of trials over the course of their session, with each trial providing auditory and visual feedback and rewards to indicate if the trial was performed correctly or incorrectly. After each trial, the difficulty of the next trial is updated to ensure that within each session, the participant gets ~85% of trials correct. Summary screens including game metrics (points, levels) and exercise metrics (usage, progress) are shown to the participant at the end of each session.~Participants in the TARA computer-based exercises arm will complete baseline- assessments, 24 hours of TARA computer based-exercises, and repeat post-assessments."
88934854|NCT01773252|Experimental|TEE|Within patient comparison of TEE, FDS and a TCD from select study sites
88934855|NCT01773304|Experimental|Meal rich in dairy protein|
88934856|NCT01773304|Experimental|Meal rich in meat protein|
88934857|NCT01773317|Experimental|Perturbation|Subjects complete the training protocol and peturbation training exercises
88934858|NCT01773317|Experimental|Control|Subjects will complete the training protocol (including nordic hamstrings, standing squats, drop jumps, triple single leg hopping, and tuck jumps)
88934859|NCT01773330|Experimental|esophageal manometry|Esophageal manometry will be performed by swallowing different amounts of Gatorade depending on the protocol being followed. There will be alternate assignment of positions: supine position, semi-recumbent position,sitting position and standing up position.
88934860|NCT01773343|Active Comparator|CO2 laser at 1 month interval|CO2 laser treatment of mild to severe acne scars at 1 month interval
89450040|NCT03306836|Experimental|Standard dose group of Heparin Sodium|First infused with 5000 IU of Heparin Sodium, then continuous infusion at a rate of 18 IU / kg.h during the hybrid operation.
89450041|NCT03306836|Active Comparator|Low dose group of Heparin Sodium|infusion Heparin Sodium at a rate of 18 IU / kg.h during the hybrid operation.
89450042|NCT04487145|Experimental|HIV-infected children on EFV-based ART (E3)|30 HIV-infected children age 3 - 10 years on EFV-based ART for at least 10 days will take standard 3 consecutive once-daily oral doses of DP (20/120mg tablets) based on weight per 2015 WHO guidelines for DP. The brand name Duocotexin will be used.
89531351|NCT02493179|Active Comparator|Serodase 5 mg|Serodase ( Serratiopeptidase) 5 mg
89531352|NCT02493179|Placebo Comparator|Placebo|Placebo
89531353|NCT05030259||patients with fasciotomy|
89200725|NCT03931330|Experimental|Percutaneous neurostimulation|Subjects will have 4 weeks of active therapy.
89200726|NCT00901251||1|
89200727|NCT00901329|Experimental|1: Gender prosthesis|
89200728|NCT00901329|Active Comparator|2: LPS flex prosthesis|
89200729|NCT01051999|Experimental|Glutamine|Patients randomized to the glutamine arm will receive 0.7g/kg of oral glutamine powder per day
89200730|NCT01051999|Placebo Comparator|Placebo|Patients randomized to the placebo arm will receive 0.7g/kg of oral isonitrogenous L-alanine powder per day
89200731|NCT00894777||1|Patients with moderate and severe psoriasis under treatment with topical and/or systemic drugs
89200732|NCT00981994|Experimental|Electronic Decision Support|Use of electronic decision support to provide the treatment algorithm for providers managing patients with acute respiratory infections.
89200733|NCT00981994|Experimental|Paper Decision Support|Use of paper based tools to provide the treatment algorithm for providers managing patients with acute respiratory infections.
89200734|NCT00981994|No Intervention|Usual Care|Usual Care
89200735|NCT01049113|Experimental|ON 013105|ON 013105 administered intravenously as 2-hour infusion once a week for 3 weeks of 3-week cycles. This is dose escalation study; starting dose is 17 mg.
89200736|NCT04017585|Active Comparator|patients with IBS treated with gluten|patients receiving gluten
89200737|NCT04017585|Placebo Comparator|patients with IBS treated with placebo|patients receiving placebo
89200738|NCT02533765|Experimental|Olaparib|Olaparib 300mg twice daily continuously
89200739|NCT00979342|Experimental|Cervical Block, 6 injection sites|Subject will receive a cervical block of 1% lidocaine and 0.25% bupivacaine, with injections in the following locations: 2cc at 12:00, 10cc at 3:00, 10 cc at 9:00, 5 cc at 4:00, 5 cc at 8:00, and 5 cc at 6:00.
89200740|NCT00979342|Experimental|Cervical Block, 2 injection sites|Subject will receive a cervical block of 1% lidocaine and 0.25% bupivacaine, with injections in the following locations: 10 cc at 4:00, and 10 cc at 8:00.
89200741|NCT00979342|Experimental|Ibuprofen q. 8 hours|Subjects will receive a post procedure pain management regimen of ibuprofen 800 mg every 8 hours, for the first 24 hours and then PRN.
89200742|NCT00979342|Experimental|Ibuprofen PRN|Subjects will receive a post procedure pain management regimen of ibuprofen 800 mg PRN.
89200743|NCT04035993|Experimental|Intervention group|
89200744|NCT00367237|Experimental|Infliximab + methotrexate (IFX + MTX)|Remicade (infliximab [IFX]) 5 mg/kg infusions at Weeks 0, 2, 6, 14 and oral methotrexate (MTX) 15 mg/week
89200745|NCT00367237|Active Comparator|Methotrexate (MTX)|Oral methotrexate (MTX) 15 mg/week
89200746|NCT04006912|Experimental|Minimal residual theoretical astigmatism group|
89200747|NCT04006912|Active Comparator|Steep meridian incision design group|
89200748|NCT02540889|Experimental|trial arm|100 hours of therapy.
89200749|NCT02540889|No Intervention|Normal therapy arm|12 weeks of normal therapy.
89200750|NCT00894855|Active Comparator|education only|This comprehensive education program included a health educator visit, on the education van, who gave education about sun safety.
89200751|NCT00894855|Experimental|education plus dermatologist skin exam|"In addition to the education program, participants received free skin exams by board certified dermatologists from Brigham and Women's Hospital. The van was equipped with a private clinical setting conducive to carry out such examinations. Based on the recommendations of the American Academy of Dermatology (AAD), a visual full body exam was provided to participants. At the end of each skin exam the dermatologist provided a presumptive diagnosis to the participant, and made appropriate recommendations and referrals for follow up with the participants' physician/dermatologist (if and when necessary). All participants undergoing the skin exam were required to complete an AAD Skin Cancer Screening Registration and Report form."
89200752|NCT00894855|Experimental|educ, biometric fb, and derm skin exam|Participants received the active components of the other three conditions.
89200753|NCT00894855|Experimental|education plus biometric feedback|In addition to the educational program, participants received biometric feedback using a Dermascan Analyzer and Ultra Violet (UV) Reflectance Photography. The Dermascan Analyzer is an educational tool that enhances visibility of skin texture, markings or lesions and is commonly used in health fairs and at schools all over the country. The analyzer highlights the sun damage on the participants skin as dark purple blotches, which the participants are able to see in the mirror placed inside the analyzer. Ultra Violet (UV) Reflectance Photography provides participants with a visual image of their skin damage that can be taken with them.
89200754|NCT00984646|Experimental|Intradermal Prevascar|
89200755|NCT00984646|Placebo Comparator|Placebo (vehicle)|
89014755|NCT04140513|Experimental|Diagnostic (dPET)|Patients receive fludeoxyglucose F-18 via injection and undergo dPET over 20 minutes after standard of care computed tomography (CT) imaging (week -2), after receiving 20-26 Gy and 40-46 Gy of radiation (weeks 3 and 5), and 3 months after completion of treatment. Patients with concern for residual disease may receive an additional dPET 6 months after treatment.
89450043|NCT04487145|Experimental|HIV-infected children on DTG-based ART (D3)|30 HIV-infected children age 11 - 17 years on DTG-based ART for at least 10 days will take standard 3 consecutive once-daily oral doses of DP (20/120mg tablets) based on weight per 2015 WHO guidelines for DP. The brand name Duocotexin will be used.
89450044|NCT04487145|Experimental|HIV-infected children on LPV/r-based ART (L1)|20 HIV-infected children age 3 - 10 years on LPV/r-based ART for at least 10 days will take one oral dose DP (20/120mg tablets) based on weight per 2015 WHO guidelines for DP. The brand name Duocotexin will be used.
89450045|NCT04487145|Experimental|HIV-infected children on LPV/r-based ART (L3)|30 HIV-infected children age 3 - 10 years on LPV/r-based ART for at least 10 days will take standard 3 consecutive once-daily oral doses of DP (20/120mg tablets) based on weight per 2015 WHO guidelines for DP. The brand name Duocotexin will be used.
89450046|NCT04487145|Active Comparator|HIV-uninfected children (C1)|20 HIV-uninfected children age 3-10 years not on ART will take standard 3 consecutive once-daily oral doses of DP (20/120mg tablets) based on weight per 2015 WHO guidelines for DP. The brand name Duocotexin will be used. PK samples are collected after the 1st dose. Control group for L1.
89450047|NCT04487145|Active Comparator|HIV-uninfected children (C3a)|30 HIV-uninfected children age 3-10 years not on ART will take standard 3 consecutive once-daily oral doses of DP (20/120mg tablets) based on weight per 2015 WHO guidelines for DP. The brand name Duocotexin will be used. PK samples are collected after the 3rd dose. Control group for E3 and L3.
89450048|NCT04487145|Active Comparator|HIV-uninfected children (C3b)|30 HIV-uninfected children age 11-17 years not on ART will take standard 3 consecutive once-daily oral doses of DP (20/120mg tablets) based on weight per 2015 WHO guidelines for DP. The brand name Duocotexin will be used. Control group for D3.
89450049|NCT02265081|Active Comparator|nulliparous women|internal ultrasound in the 3rd trimester uroflow meter in 3rd trimester
89450050|NCT02265081|Experimental|parous women|those who had vaginal delivery in the past; internal ultrasound in the 3rd trimester uroflow meter in 3rd trimester
89014756|NCT04114942|Experimental|Constant Coach|Randomized to have coach during didactic training and internship.
89014757|NCT04114942|Experimental|Internship Only Coach|Randomized to have coach during internship only.
89450051|NCT02265081|Experimental|parous women - VBAC|those with previous LSCS and no vaginal births; internal ultrasound in the 3rd trimester uroflow meter in 3rd trimester
89014758|NCT04114942|Experimental|Never Coach|Randomized to never have coach.
89014759|NCT04109027|Experimental|BrainStrong-GSR|Goal-directed State Regulation Training (GSR)
89014760|NCT04109027|Active Comparator|BrainStrong-OPT|Optimization of Brain Functioning (OPT)
89014761|NCT04107545|Experimental|athletes|48 elite athletes, 24 men and 24 women, experiencing regular weight cycling.
89450052|NCT01252641|Experimental|SB-728-T|Subjects will receive one intravenous infusion of SB-728-T
89450053|NCT00709956|Experimental|Active / placebo|Single dose of iloprost (5 µg) on study day 2 followed by single dose of placebo on study day 3
89450054|NCT00709956|Placebo Comparator|Placebo / active|Single dose of placebo on study day 2 followed by single dose of iloprost (5 µg) on study day 3
89450055|NCT03306758|Experimental|Experimental: sodium bicarbonate|
89450056|NCT03306758|No Intervention|No Intervention|
89450057|NCT02268201|Experimental|ADV group|Once daily
89014764|NCT04087018|Experimental|TMB-H|Participants with a tumor biomarker status of TMB-H will receive zimberelimab every 3 weeks.
89014765|NCT04087018|Experimental|Strata Immune Signature positive|Participants with a tumor biomarker status Strata Immune Signature positive will receive zimberelimab every 3 weeks.
89014766|NCT04080895|Experimental|group A|
89014767|NCT04080895|Experimental|group B|
89014768|NCT04076462|Experimental|CAM2029 (octreotide subcutaneous depot)|CAM2029 (octreotide subcutaneous depot) 20mg/1.0 mL for 20 mg dose, subcutaneous injection once monthly, six months treatment. If down-titration is required, 10mg/0.5 mL for 10 mg dose is available.
89014769|NCT04076462|Placebo Comparator|Matching placebo|Placebo (subcutaneous depot) 1.0 mL, subcutaneous injection once monthly, six months treatment. If down-titration is required, 0.5 mL dose is available.
89450058|NCT02268201|Experimental|PRG group|Twice daily
89450059|NCT03306602|Experimental|Bulk Fill Composite|In the experimental cavity, Filtek Bulk Fill Posterior Restorative (3M ESPE) will be placed in 5 mm increments, eliminating the need for additional layers or multiple steps.
89450060|NCT03306602|Active Comparator|Layered Composite|The control restoration will be filled with Filtek Z350 XT (3M ESPE) using the 2 mm incremental layering technique.
89450061|NCT02265159|Other|Focal Therapy Using High Intensity Focused Ultrasound|
89450062|NCT05722574|Active Comparator|Information Only Control Condition|The information only control condition is designed to mimic relationship education that could be easily found online by adolescents. This condition does not teach romantic competence skills such as insight, communication/mutuality, or emotion regulation skills; rather, it focuses on educating subjects about the healthy and unhealthy signs of a romantic relationship. In addition, this condition is designed to control for nonspecific aspects of the intervention, such as engaging in an online program and taking time to reflect on one's relationships.
89450063|NCT05722574|Experimental|Romantic Competence Intervention|The Romantic Competence Single-Session Intervention provides adolescents with the opportunity to learn one of three relational skills online: (1) Insight, the ability to understand what one needs in relationships and act in alignment with one's needs, (2) Communication, the capacity to listen to others and express one's needs effectively, and (3) Stay vs. Go, the ability to reflect and make difficult decisions in relationships. Adolescents are presented with the opportunity to choose which module they would like to complete. Each module has the following components: psychoeducation, a personalized action plan, and practice overcoming barriers.
89450064|NCT02265315|Sham Comparator|LSVT +sham TMS|Lee Silverman Voice Treatment (LSVT) and Transcranial Magnetic Stimulation (TMS)
89450065|NCT02265315|Active Comparator|LSVT +left rTMS|Lee Silverman Voice Treatment (LSVT) and Transcranial Magnetic Stimulation (TMS) applied to left side of head
89450066|NCT02265315|Active Comparator|LSVT + right rTMS|Lee Silverman Voice Treatment (LSVT) and Transcranial Magnetic Stimulation (TMS) applied to right side of brain
88934861|NCT01773343|Active Comparator|CO2 laser at 3 monrths interval|CO2 laser treatment of mild to severe acne scars at 3 month intervals
88934862|NCT01773356|Placebo Comparator|Placebo 0 mg/d|0 mg/d of Dihydrocapsiate will be consumed in ready to ear cereal, cereal bars or crackers
88934863|NCT01773356|Active Comparator|Dihydrocapsiate 9 mg/d|9 mg/d of Dihydrocapsiate will be consumed in ready to ear cereal, cereal bars or crackers
89450067|NCT02268279|Experimental|solithromycin|oral dosing (capsules and powder for suspension) by weight once per day intravenous dosing by weight once per day
89450068|NCT03306524|Experimental|SIPPV_VG_0_08|SIPPV VG ventilation for 15 minutes slope time = 0.08 seconds inspiratory time = 0.40 seconds
89450069|NCT03306524|Experimental|PSV_VG_0_08|PSV VG ventilation for 15 minutes slope time = 0.08 seconds maximum inspiratory time = 0.60 seconds
88934864|NCT01773369|Experimental|Early treatment group|These children will undergo the intervention (i.e., early leg training) shortly after recruitment. Measures will be taken before, during and after the intervention.
88934865|NCT01773369|Experimental|Delayed treatment group|These children will undergo the intervention (delayed leg training) after a delay of ~3 months, during which outcome measures will be taken so that they can serve as a control for the early treatment group. Their intervention is identical to the Immediate treatment group.
88934866|NCT01773369|No Intervention|Control group|These children will be recruited close to the age of 4 years old, and will only undergo gait analysis and GMFM-66 scoring.
88934867|NCT01773369|Experimental|Parent training group|These children will undergo the intervention (i.e., parent leg training) shortly after recruitment. Parents will be trained to provide the intervention instead of a physical therapist. Measures will be taken before, during and after the intervention.
88934868|NCT01773382|No Intervention|control|standard treatment of IgA nephropathy including ACEI/ARB for blood pressure control (target BP <130/80 mmHg)
88934869|NCT01773382|Experimental|weight reduction|target weight reduction is 3-5% from baseline
88934870|NCT01773408|Experimental|Part 1: RO5503781|Participants will receive RO5503781 alone in escalating doses on Days 1 to 5 of each 28-day cycle until disease progression or unacceptable toxicity.
88934871|NCT01773408|Experimental|Part 2: RO5503781 + Cytarabine|Participants will receive RO5503781 in escalating doses on Days 1 to 5 and cytarabine on Days 1 to 6 of each 28-day cycle until disease progression or unacceptable toxicity.
89450070|NCT03306524|Experimental|SIPPV_VG_0_16|SIPPV VG ventilation for 15 minutes slope time = 0.16 seconds inspiratory time = 0.40 seconds
89450071|NCT03306524|Experimental|PSV_VG_0_16|PSV VG ventilation for 15 minutes slope time = 0.16 seconds maximum inspiratory time = 0.60 seconds
89450072|NCT03306524|Experimental|SIPPV_VG_0_24|SIPPV VG ventilation for 15 minutes slope time = 0.24 seconds inspiratory time = 0.40 seconds
89450073|NCT03306524|Experimental|PSV_VG_0_24|PSV VG ventilation for 15 minutes slope time = 0.24 seconds maximum inspiratory time = 0.60 seconds
89531354|NCT05030259||patients without fasciotomy|
88934872|NCT01773408|Experimental|Part3:RO5503781+Cytarabine+Anthracycline|Participants will receive RO5503781 on Days 1 to 5, cytarabine on Days 1 to 7, and anthracycline (daunorubicin or idarubicin) on Days 1 to 3 of each 28-day cycle until disease progression or unacceptable toxicity.
88934873|NCT01773408|Experimental|Part 4: Optimized RO5503781 + Cytarabine|Participants will receive optimized RO5503781 formulation on Days 1 to 5 and cytarabine on Days 1 to 6 of each 28-day cycle until disease progression or unacceptable toxicity.
88934874|NCT01773434|Experimental|MORAb-004|
88934875|NCT01773447|Active Comparator|Set-back suture|Wound to be close by set-back suture technique.
88934876|NCT01773447|Active Comparator|Vertical mattress suture technique|Wound to be closed by vertical mattress technique.
88934877|NCT01773460|Experimental|Everolimus|Everolimus is given beyond progress
88934878|NCT01773460|Placebo Comparator|Everolimus-placebo|Everolimus-placebo is given beyond progress
88934879|NCT01773499||Patient with Cellulitis|Patients with uncomplicated cellulitis treated as outpatients
88934880|NCT01773512|Experimental|Rosuvastatin|All patients will be using rosuvastatin 40 mg
88934881|NCT01773031||Autoimmune pancreatitis|Patients with autoimmune pancreatitis based on clinical and CT findings
88934882|NCT01773538|Active Comparator|Anti cHE treatment arm|Of 150 included patients aprox. 44 regardless of CRT and PSE test outcome will be offered to enter randomisation and 3 months follow up. Half of 44 patients will receive both lactulose, rifaximin and branched chain aminoacids (Bramino) the other half placebo.
88934883|NCT01773538|Placebo Comparator|Placebo arm|The goal of this intervention is to investigate whether the CRT method can detect an expected treatment response after initiation of the 3 named drugs know to ameliorate HE symptoms including psychometric test results.
88934884|NCT01773551||Optical Index of Breast Density|Breast Density
88934885|NCT01773564|Active Comparator|Available current hospital dressing|Control group: depending on the type of dressing available at the hospital, either 3M™ HP Dressing or Smith & Nephew IV3000 ™
88934886|NCT01773564|Experimental|3M™ IV Advanced Securement dressing|New generation transparent dressing
88934887|NCT01773577||Physician Pract. Employee and Off. Staff|The office staff and providers and physician practices enrolled in the RHIO
88934888|NCT01773590|Other|Asthmatics|Rhinovirus Infection
88934889|NCT01773590|Other|Healthy Volunteers|Rhinovirus Infection
88934890|NCT01773603|No Intervention|Conventional incubation|Five-day embryo culture in conventional incubators
88934891|NCT01773603|Active Comparator|Embryoscope|Five-day embryo culture in embryoscope which is an incubator with a built-in camera
88934892|NCT01773616|Experimental|Rituximab|Rituximab, methyl prednisolone and mycophenolate mofetil
88934893|NCT01773616|Active Comparator|Oral prednisolone|Oral prednisolone, methyl prednisolone and mycophenolate mofetil
88934894|NCT01773629|Experimental|Intervention|Participants in the intervention arm will receive standard care plus the addition of a care manager. Care managers will function to provide culturally competent and linguistically appropriate support for the care of women identified as being at high risk for depression in pregnancy. Working with both the care providers and these study participants care managers will serve as connectors, coaches, collaborators, and negotiators working to overcome barriers to depression care delivery.
88934895|NCT01773629|Other|Control|"Standard of care: within the current care processes, a woman initiating prenatal care completes a depression risk assessment using a two-step approach. Women with high risk of depression are then scheduled for a separate visit with a member of the care team (a physician, psychologist, or other mental health provider) referred to as a perinatal depression champion for a timely formal diagnostic interview."
88934896|NCT01773642|Experimental|Cognitive-behavioral intervention|A cognitive-behavioural intervention aimed at supporting caregivers through paediatric HIV diagnosis disclosure to the child in their care.
88934897|NCT01773642|No Intervention|Standard of Care|
88934898|NCT01773655||tissue|This is a protocol to obtain and/or analyze tumor and germline DNA specimens of patients with MPM, choroidal nevus, and UM.
88934899|NCT01773668|Experimental|Integrated sensor and infusion set|
88934900|NCT01773694|Active Comparator|Early Water Exposure|The Intervention group will receive written and verbal instructions to remove the dressing after 6 hours and wet the wound for at least 10 minutes. Wetting of the wound will include shower, tub bath, or pool exposure.
88934901|NCT01773694|No Intervention|Standard Care|The Standard Care group will receive standard wound care instructions and verbal education by the staff to keep the dressing dry and intact for 48 hours.
89014770|NCT04075435|Other|All subjects|This arm will include all subjects, individuals will administer a high CBD, low THC full spectrum sublingual solution twice daily on a variable dosing schedule.
89014771|NCT04030871|Active Comparator|Capsule Dome G-Tube|Capsule Dome G-Tube
89014772|NCT04030871|Active Comparator|Balloon Bolus feeding tube|Balloon Bolus feeding tube
89014773|NCT04022616||Immediate Surgery|Adult patients with breast malignancy.
89014774|NCT04022616||Neo-adjuvant Chemotherapy|Adult patients with biopsy proven operable breast cancer who in the opinion of treating physician are suited to receive neo-adjuvant chemotherapy.
89014775|NCT04022616||Lymph Node Tissue|Adult patients with breast malignancy who will be having a primary lymph node removed during breast surgery.
89014776|NCT04022616||Metastatic Breast Cancer|Adult patients with biopsy proven stage IV breast cancer who are starting a new line palliative systemic therapy. A palliative systemic therapy will be defined in this trial as any chemotherapy regimen or combination of endocrine therapy with targeted agents such as cyclin dependent kinase 4/6 (CDK 4/6) inhibitors, HER2 targeting agents or inhibitors of mammalian target of rapamycin (mTOR).
89014777|NCT04015700|Experimental|Vaccine (GNOS-PV01 + INO-9012)|"Standard radiation therapy will be administered per standard of care and is outside the scope of this study.~GNOS-PV01 + INO-9012 will be given on Days 1, 22, and 43 of Cycle 1 and then on Day 1 of each subsequent cycle beginning with Cycle 2."
89014778|NCT04011644|Active Comparator|Self monitored|"Patients of this group will continue receiving regular care from their physician with no interference from the two experimental groups. Patient subjects will download the app on their Android or Apple smart phone that will direct them to external information hosted on the internet that may help reduce their drinking (e.g., NIAAA resources). For the first 12 weeks, once a week patients can set a weekly goal related to their alcohol use or other health related behaviors (e.g., I will only drink on Friday this week.). At the end of the week subjects will be prompted to take a weekly survey, which will include questions such as a variation of the brief alcohol monitor (BAM) and timeline followback. Patients will then receive feedback on the amount of drinks they had compared to their goal. Then the patient will set a new goal for the following week. Patients will complete quarterly surveys on the A-CHESS app to assess study outcomes."
89014779|NCT04011644|Experimental|Peer supported|Patients will be asked to take the same surveys and have the access to the same information as the self-monitoring group. Patient subjects in this group will have access to discussion boards where they can talk to one another and have the ability to share and see stories of other patients. The only involvement of someone other than patients themselves in the peer-supported group will be by a sponsor (i.e., a dedicated user from the area with a sustained history of successful alcohol reduction). The sponsor will participate in discussion groups and encourage use of the system. Patient-reported feedback will be presented directly to the patient.
89200756|NCT03991585|Experimental|Three times a week MCRF|Participants in this arm will participate in the MCRF intervention sessions three times a week for 12 consecutive weeks.
89450074|NCT03306524|Experimental|SIPPV_VG_0_32|SIPPV VG ventilation for 15 minutes slope time = 0.32 seconds inspiratory time = 0.40 seconds
89200757|NCT03991585|Experimental|One time a week MCRF|Participants in this arm will participate in the MCRF intervention sessions one time a week for 12 consecutive weeks.
89200758|NCT00901407|Experimental|1|lamotrigine
89200759|NCT00901407|Placebo Comparator|2|placebo
89200760|NCT00896883|Experimental|Middle Turbinate Implant|Subjects to receive Middle Turbinate Implant
89200761|NCT00984724|Experimental|Standard Treatment|Standard Treatment (ST): Mailed Packet with standard self-help materials; ST delivered a total of 4 times (at Baseline, 6, 12, and 18 months). Referral to Quitline.
89200762|NCT00984724|Experimental|MAPS-6|Standard Treatment (ST) plus 6 proactive telephone counseling sessions; ST delivered 4 times (at Baseline, 6, 12, and 18 months). 6 MAPS proactive telephone counseling sessions over 2-year period.
89200763|NCT00984724|Experimental|MAPS-12|Standard Treatment (ST) plus 12 proactive telephone counseling sessions; ST delivered 4 times (at Baseline, 6, 12, and 18 months). 12 MAPS proactive telephone counseling sessions over 2-year period. Referral to Quitline.
89200764|NCT00984724|Experimental|Standard Treatment + NRT|Standard Treatment (ST): Mailed Packet with standard self-help materials; ST delivered a total of 4 times (at Baseline, 6, 12, and 18 months). Nicotine replacement therapy (NRT) consisting of 300 pieces of nicotine gum issued at baseline visit.
89450075|NCT03306524|Experimental|PSV_VG_0_32|PSV VG ventilation for 15 minutes slope time = 0.32 seconds maximum inspiratory time = 0.60 seconds
89200765|NCT00984724|Experimental|MAPS-6 + NRT|Standard Treatment (ST) plus 6 proactive telephone counseling sessions; delivered 4 times (at Baseline, 6, 12, and 18 months). 6 MAPS proactive telephone counseling sessions over 2-year period. Referral to Quitline. Nicotine replacement therapy (NRT) consisting of 300 pieces of nicotine gum issued at baseline visit.
89200766|NCT00984724|Experimental|MAPS-12 + NRT|Standard Treatment (ST) plus 12 proactive telephone counseling sessions; ST delivered 4 times (at Baseline, 6, 12, and 18 months). 12 MAPS proactive telephone counseling sessions over 2-year period. Referral to Quitline. Nicotine replacement therapy (NRT) consisting of 300 pieces of nicotine gum issued at baseline visit.
89450076|NCT03306524|Experimental|SIPPV_VG_0_40|SIPPV VG ventilation for 15 minutes slope time = 0.32 seconds inspiratory time = 0.40 seconds
89200767|NCT04035915|Experimental|Limited driving pressure ventilation|
89200768|NCT04035915|Experimental|Conventional mechanical ventilation strategies|
89200769|NCT00896961|Experimental|Observational (EF5)|Approximately 24-48 hours prior to surgical resection or biopsy, patients receive EF5 IV over no more than 2½ hours. Tissue samples are analyzed by immunohistochemistry for EF5 binding. Blood samples are analyzed for genetic markers and cytokines associated with hypoxia and EF5 concentration.
89200770|NCT00984802|Experimental|Low dose|
89200771|NCT00984802|Experimental|Mid Dose|
89200772|NCT00984802|Experimental|High Dose|
89200773|NCT00984802|Placebo Comparator|Placebo|
89450077|NCT03306524|Experimental|PSV_VG_0_40|PSV VG ventilation for 15 minutes slope time = 0.40 seconds maximum inspiratory time = 0.60 seconds
89450078|NCT04425096|Experimental|Skin to skin contact|The mothers and their babies in the experimental group received a 30-minute skin to skin contact immediately after birth (n:34)
89450079|NCT04425096|No Intervention|Routine care|The babies in the control group received routine care (n:34)
89014780|NCT04011644|Experimental|Clinically integrated|Patients in the clinically integrated group will receive the same intervention as the peer-supported group aside from three differences: 1) patients have the option to share selected elements of their app data with the University of Wisconsin (UW) Health health coach, 2) the health coach will replace the role of the sponsor in the peer-support group, and 3) patients will have the option to attend an initial 60- to 90-minute and two 30-minute follow-up consultations with the health coach in-person, via phone, or via video chat.
89014781|NCT04009850|Experimental|Menthol e-cigarette|Adult smokers will be switched from using menthol cigarettes to non-menthol cigarettes and a menthol flavored e-cigarette
89014782|NCT04009850|Experimental|Tobacco e-cigarette|Adult smokers will be switched from using menthol cigarettes to non-menthol cigarettes and a tobacco flavored e-cigarette
89014783|NCT04009681|Experimental|Cohort A-THOR-707 Q2W Monotherapy (Dose Escalation)|Subjects with advanced or metastatic solid tumors will receive THOR-707 in sequential ascending doses as a monotherapy via intravenous (IV) administration every 2 weeks (Q2W) until unacceptable toxicity, disease progression, or withdrawal of consent.
89014784|NCT04009681|Experimental|Cohort B-THOR-707 Q3W Monotherapy (Dose Escalation)|Subjects with advanced or metastatic solid tumors will receive THOR-707 in sequential ascending doses as a monotherapy via IV administration every 3 weeks (Q3W) until unacceptable toxicity, disease progression, or withdrawal of consent.
89014785|NCT04009681|Experimental|Cohort C-THOR-707 Q3W with checkpoint inhibitor (Dose Escalation)|Subjects with advanced or metastatic solid tumors will receive THOR-707 Q3W in sequential ascending doses in combination with a checkpoint inhibitor Q3W or every 6 weeks (Q6W) via IV administration until unacceptable toxicity, disease progression, or withdrawal of consent.
89014786|NCT04009681|Experimental|Cohort D-THOR-707 Q3W with anti-EGFR antibody (Dose Escalation)|Subjects with advanced or metastatic solid tumors will receive THOR-707 Q3W in sequential ascending doses in combination with an anti-EGFR antibody weekly dosing (QW) via IV administration until unacceptable toxicity, disease progression, or withdrawal of consent.
89014787|NCT04009681|Experimental|Cohort E-THOR-707 Q2W with checkpoint inhibitor (Dose Expansion)|Subjects with advanced or metastatic solid tumors will receiveTHOR-707 Q2W at recommended Phase 2 dose (RP2D) with a checkpoint inhibitor via IV administration Q6W; it will consist of one 8-week cycle of THOR-707 monotherapy on Cycle 1 Day 1 followed by THOR-707 Q2W + checkpoint inhibitor Q6W starting at Cycle 1 Day 15. Subsequently treatment will consist of repeated 6-week cycles with combination therapy.
89014788|NCT04009681|Experimental|Cohort F-THOR-707 Q3W with checkpoint inhibitor (Dose Expansion)|Subjects with advanced or metastatic solid tumors will receive THOR-707 Q3W at recommended Phase 2 dose (RP2D) with a checkpoint inhibitor via IV administration Q6W will consist of one 9-week cycle of THOR monotherapy on Cycle 1 Day 1 followed by THOR-707 Q3W + checkpoint inhibitor at Cycle 1 Day 22. Subsequently treatment will consist of repeated 6-weeks cycles with combination therapy.
89014789|NCT04009681|Experimental|Cohort G Monotherapy QW/Q2W (Dose Escalation)|Subjects with advanced or metastatic solid tumors will receive THOR707 monotherapy QW for 6 weeks (induction period), and then every Q2W (maintenance period), which is referred as QW/Q2W thereafter, until unacceptable toxicity, disease progression, or withdrawal of consent.
89014790|NCT04009681|Experimental|Cohort H Monotherapy QW/Q2W (Dose Expansion)|Subjects with late-line metastatic melanoma will receive THOR707 monotherapy at RP2D for Cohort G. Cycle 1 will consist of THOR-707 QW for 6 weeks; Cycle 2 and beyond will consist of THOR-707 Q2W.
89014791|NCT03992378|Experimental|Active Treatment|Patients will receive a single 4-hour session of active transcutaneous vagus nerve stimulation.
89014792|NCT03992378|Sham Comparator|Sham Control|Patients will receive a single 4-hour session of sham transcutaneous vagus nerve stimulation.
89014793|NCT03984565|Experimental|Cannabidiol Treatment Arm|High-CBD sublingual product administered three times daily for 6 weeks
89014794|NCT03984565|Placebo Comparator|Placebo Treatment Arm|Placebo sublingual product administered three times daily for 6 weeks
89014795|NCT03972657|Experimental|mCRPC - dose escalation cohort|"Participants will receive REGN5678 monotherapy for presumptive recommended phase 2 dose(s) (presumptive RP2D) identification~Note: Dose escalation on monotherapy lead-in of REGN5678 followed by combination therapy of REGN5678 with full dose cemiplimab is no longer actively enrolling new participants. The prophylactic use of sarilumab is no longer in use."
89450080|NCT02268357|Experimental|Propranolol|capsules PROPRANOLOL (study medication); 80 mg 1 hour preoperative; 40 mg directly postoperative
89450081|NCT02268357|Placebo Comparator|Placebo|capsules MICROCRYSTALLINE CELLULOSE (study medication); 80 mg 1 hour preoperative; 40 mg directly postoperative
89450082|NCT05430386|Experimental|Dose escalation and dose expansion|HS-10241 in combination with Almonertinib
89200774|NCT00901563|Active Comparator|Rotigaptide|Prior to 20 mins of ischaemia induced by a blood pressure cuff inflated to 200 mmHg around the upper non-dominant arm, rotigaptide will be infused for 30mins. During the ischaemic period no drug will be infused but the infusion will be restarted once the blood pressure cuff has been deflated and blood flow returns to the limb.
89450083|NCT04416906|Experimental|Biktarvy|This is a fixed dose combination regimen containing 50 mg of Bictegravir + 200 mg of Emtricitabine + 25 mg of Tenofovir alafenamide.
89450084|NCT02268435|Experimental|Dovitinib plus Imatinib|Dovitinib once daily on a 5 days on/2 days off dosing schedule, and imatinib once daily on a continuous dosing schedule
89450085|NCT02466464|Active Comparator|Microporous Polysaccharide Hemospheres (MPH)|Subjects with acute epistaxis will receive microporous polysaccharide hemospheres (Arista) powder. In the event that Arista fails to assist in resolving nosebleed in 15 minutes, subjects will be promptly escalated to the control group and will receive Merocel.
88934902|NCT01773746|Active Comparator|Room Air|Neonatal Resuscitation using continuous positive airway pressure(CPAP) or positive pressure ventilation (PPV) will be provided with 21% oxygen. Infants will remain on 21% oxygen until they have a functioning oximeter when SpO2 will be managed as below. FiO2 will be increased by 10% increments when the infant's SpO2 is below the lower sat limit for 30 seconds and repeated if the SpO2 remains outside the limit for a subsequent interval of 30 seconds as often as is necessary to bring the SpO2 within the pre-specified range. The FiO2 will be decreased by 10% increments when the SpO2 is above the upper limit for 30 seconds and repeated if the SpO2 remains outside the limit for a subsequent interval of 30 second as often as is necessary to bring the SpO2 within the pre-specified range.
88934903|NCT01773746|Active Comparator|60% Group|Neonatal Resuscitation using CPAP or PPV will be provided with 60% oxygen. Infants will remain on 60% oxygen until they have a functioning oximeter at which time their SpO2 will be managed as described below FiO2 will be increased by 10% increments when the infant's SpO2 is below the lower sat limit for 30 seconds and repeated if the SpO2 remains outside the limit for a subsequent interval of 30 seconds as often as is necessary to bring the SpO2 within the pre-specified range. The FiO2 will be decreased by 10% increments when the SpO2 is above the upper limit for 30 seconds and repeated if the SpO2 remains outside the limit for a subsequent interval of 30 second as often as is necessary to bring the SpO2 within the pre-specified range.
88934904|NCT01773759|Experimental|Intervention child care programs|Intervention child care programs will receive immunization outreach and education.
88934905|NCT01773759|No Intervention|Control child care programs|Control programs will receive no more than usual training regarding childhood immunization requirements.
88934906|NCT01773772|Experimental|Progesterone|Subjects will take 25-50 mg oral micronized P or placebo at 1600 h and again at 2000 h. P dosing will be based on weight, with 25 mg administered to girls < 42kg and 50 mg given to those > or = 42 kg.
88934907|NCT01773772|Placebo Comparator|Placebo|Subjects will take placebo at 1600 h and again at 2000 h.
88934908|NCT01773798|Experimental|IDegAsp 15|
88934909|NCT01773798|Experimental|IDegAsp|
88934910|NCT01773798|Experimental|IDeg|
88934911|NCT01773798|Active Comparator|IAsp|
88934912|NCT01773798|Experimental|IDeg + IAsp|
88934913|NCT01773811|No Intervention|Control|Individuals will write objectively about the events of their day.
89450086|NCT02466464|Active Comparator|Merocel (Control)|Subjects with acute epistaxis will receive standard-of-care treatment, nasal tampon (Merocel). In the event that Merocel fails to assist in resolving nosebleed in 15 minutes, subjects will be promptly escalated to the MPH group and will receive Arista powder.
89450087|NCT04402944|Experimental|Study Drug|Study drug
89450088|NCT04402944|Placebo Comparator|Placebo|Placebo
89450089|NCT01423149|Experimental|36 mg/m2 Combretastin A-4 Phosphate|
89450090|NCT01423149|Experimental|45 mg/m2 Combretastatin A-4 Phosphate|
89450091|NCT01423149|Experimental|27 mg/m2 Combretastatin A-4 Phosphate|
89450092|NCT01235559|Placebo Comparator|Placebo|
89450093|NCT01235559|Experimental|bitopertin [RO4917838] 1|
89450094|NCT01235559|Experimental|bitopertin [RO4917838] 2|
89200775|NCT00901563|Placebo Comparator|Saline|Saline will be infused through-out the study.
89450095|NCT03470454||diabetics on linagelptin|Diabetic patients were given linagelptin for blood glucose control
89200776|NCT00901641|Experimental|cognitive training|CogniFit Personal Coach® computer cognitive training program. The program provides individually tailored cognitive training based on the results of a baseline evaluation (the Neuropsychological Examination - CogniFit Personal Coach®). The program assigns scores to 17 cognitive abilities that are subsequently trained by means of 21 different tasks.
89200777|NCT00972556|Experimental|GMTA|
89450096|NCT03470454||diabetics on other DPP4 inhibitors|Diabetic pateints were given other DPP4 inhibitors eg: vlidagliptin for blood glucose control
89450097|NCT04490252|No Intervention|Free diet|Free diet
89450098|NCT04490252|Experimental|FMD|Fasting mimetic diet for 5 days, next cycle after 25 days of free diet
89450099|NCT02268513||MASALA study|"Mediators of Atherosclerosis in South Asians Living in America (MASALA) study participants will be invited to participate in this ancillary study.~Objective of MASALA study:~The Mediators of Atherosclerosis in South Asians Living in America (MASALA) study is investigating the prevalence, correlates, and outcomes associated with subclinical CVD in a population-based sample of South Asian men and women age 40-79 years at 2 US clinical field centers."
89450100|NCT03130842|Active Comparator|Sublingual alprazolam|
89450101|NCT03130842|Active Comparator|Oral midazolam|
89450102|NCT03130764|Experimental|Durvalumab/Tremelimumab|Patients with resected stage IB-IIIA NSCLC who have completed standard adjuvant therapy (as recommended by the treating physician) to receive durvalumab-tremelimumab will be enrolled. Patients will receive durvalumab (20 mg/kg) intravenously every 4 weeks for 1 year and tremelimumab (1 mg/kg) intravenously every 4 weeks for 4 doses.
89450103|NCT01234779|Experimental|A|
89450104|NCT01234779|Experimental|B|
89450105|NCT01234779|Active Comparator|C|
89450106|NCT01234779|Placebo Comparator|D|
89450107|NCT01234311|Placebo Comparator|placebo|Matching placebo
89450108|NCT01234311|Experimental|tasquinimod|Tasquinimod up to a maximum maintenance dose of 1 mg once daily, administrated orally (capsule)
89450109|NCT03223350|Experimental|Capsaicin|0.1% capsaicin cream, one application
89450110|NCT03223350|Placebo Comparator|Placebo|Topical cream with no active drug
89450111|NCT03306368|No Intervention|Treatment as Usual (TAU)|Participants receiving treatment as usual post-residential detox. TAU clinic-based treatment receiving standard clinic-based XR-NTX.
89450112|NCT03306368|Experimental|Youth Opioid Recovery Support (YORS)|"Youth Opioid Recovery Support consists of the following component:~Home delivery of XR-NTX, family framework, assertive continuing care incorporates outreach, home delivery of evidence based psychosocial treatment and case management in a model that specifically targets engagement and motivation in youth, contingency management."
89450113|NCT02840136|Experimental|Standard of care|Sputum is collected from patients receiving standard of care therapy with IV piperacillin-tazobactam, ceftazidime or meropenem
89450114|NCT04491188|Experimental|Probiotic|1 x10-9 CFU Bacillus subtilis DE111 was consumed daily for 28-days
89450115|NCT04491188|Placebo Comparator|Placebo|Maltodextrin placebo was consumed for 28-days
89450116|NCT02468258|Active Comparator|endometrial flushing (A)|Oocytes were retrieved 34-36 h after hCG administration and aspirated FF was collected in a sterile container and was centrifuged at 600 rpm for 10 min at room temperature and a 5-ml sample of the supernatant was obtained for laboratory workup, while the remaining amount of supernatant was used to flush the endometrium through an applied uterine catheter in FF group and was discarded in the other group.
88934914|NCT01773811|Experimental|Narrative Writing: Trauma-Assigned|Trauma-assigned: Individuals will write about their most traumatic life experience and be instructed to continue to think about their writing topic in the weeks following writing.
89014796|NCT03972657|Experimental|mCRPC - dose expansion cohort|Participants will receive the REGN5678 presumptive RP2D(s)
89200778|NCT00972556|Active Comparator|20% FC|
89200779|NCT00984880|Experimental|1|Intravenous solution given as a single ascending bolus dose
89200780|NCT00984880|Experimental|2|Intravenous solution given as a single ascending bolus dose followed by a single infusion
89450117|NCT02468258|No Intervention|B|no intervention Control group included 40 women would not have FF endometrial flushing.
89450118|NCT04015050|Experimental|Test product|Cow's milk based infant formula containing prebiotics and postbiotics
89450119|NCT04015050|Active Comparator|Control product|Cow's milk based infant formula without prebiotics and postbiotics
89450120|NCT02263287|Other|Alzheimer disease (AD)|Patients with AD according to NINCDS-ADRDA (National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association) criteria Intervention: LeSCoD scale
89450121|NCT02263287|Other|Dementia with Lewy Bodies (DLB)|Patients with probable DLB according to McKeith criteria. Intervention: LeSCoD scale
89450122|NCT02263287|Other|Probable AD and possible DLB|Patients with clinical criteria for possible or probable AD and possible DLB Intervention: LeSCoD scale
89450123|NCT03306290|Other|Bariatric surgery candidate|"Patients included in this study belong to this arm and put up with intervention Serum dosage of antibiotic prophylaxis CEFOXITIN"
89450124|NCT01616199|Experimental|Phase 1 Dose Escalation of PX-866 + vemurafenib|PX-866 given with vemurafenib
89450125|NCT01616199|Experimental|Phase 2 Combination PX-866 + vemurafenib|PX-866 given with vemurafenib
89450126|NCT01616199|Active Comparator|Phase 2 Single-agent vemurafenib|vemurafenib given as a single agent
89450127|NCT03306212|Experimental|Casting Group|Patients treated by botulinum toxin A and occupational therapy and intermittent serial casting
89450128|NCT03306212|Active Comparator|Control Group|Patients treated by botulinum toxin A and occupational therapy
89450129|NCT04506138|Experimental|Camrelizumab plus Chemotherapy|
89450130|NCT02265471||university hospital|university hospital
89450131|NCT02265471||large or small public hospitals|large or small public hospitals
89450132|NCT02265471||private HCFs|private HCFs
89450133|NCT02265471||referral centers for cancer|referral centers for cancer
89450134|NCT02265471||chirurgical facilities, clinic|chirurgical facilities, clinic
89450135|NCT02265471||mixed group|local hospitals, long term care and post-op and rehabilitation facilities, and nursing homes
89450136|NCT03306134||BETA-BLOCKERS|Patients taking beta-blockers with or without dysphagia
89450137|NCT03306134||NO BETA-BLOCKERS|Patients not taking beta-blockers with or without dysphagia
89200781|NCT02540499|Experimental|DIBH VMAT|"Volumetric modulated arc radiotherapy in visually guided voluntary -deep inspiration breath-hold for patients with locally advanced NSCLC referred for concomitant radiotherapy 2 Gy x 33, 5 F/W and 3 courses of platinum based combination chemotherapy.~Will be compared to a historic cohort of patients treated with VMAT in free breathing"
89450138|NCT04456452|Experimental|Ampion|Ampion
89450139|NCT04456452|Other|Standard of Care|Standard of Care
89450140|NCT01598103|Placebo Comparator|Placebo to SAF312|
89450141|NCT01598103|Experimental|SAF312|
89014797|NCT03972657|Experimental|ccRCC - dose escalation cohort|"Participants will receive REGN5678 monotherapy for presumptive RP2D identification~Note: Dose escalation on monotherapy lead-in of REGN5678 followed by combination therapy of REGN5678 with full dose cemiplimab is no longer actively enrolling new participants. The prophylactic use of sarilumab is no longer in use."
89014798|NCT03972657|Experimental|ccRCC - dose expansion cohort|Participants will receive the REGN5678 presumptive RP2D(s)
89014799|NCT03953703|Experimental|Experimental: Levocarnitine, Placebo|1000 mg of levocarnitine twice per day for six weeks, a two week washout period, 1000 mg of placebo twice per day for 6 weeks
89014800|NCT03953703|Experimental|Experimental: Placebo, Levocarnitine|1000 mg of placebo twice per day for six weeks, a two week washout period, 1000 mg of levocarnitine twice per day for 6 weeks
89014801|NCT03945175|Experimental|Treatment|After a two-week, single-blinded, placebo lead-in, all patients will receive four weeks of order-fixed treatment with Mydayis.
89014802|NCT03945058|Experimental|Experimental|Active TVS will be performed by use of a Tragus stimulator device with electrodes attached to the tragus of the ear. Stimulator will be applied continuously for 1 hour daily for 4 weeks.
89450142|NCT04456530|Experimental|Testosterone Group|Participants receiving two IM Testosterone injections.
89450143|NCT04456530|Placebo Comparator|Control Group|Participants receiving two IM Normal Saline Injections.
89450144|NCT05395754|Experimental|PCheck|"Participants allocated to the intervention arm will receive the intervention (use of the PCheck app) for 12 months of follow-up. Participants will be encouraged to use the app as much as they wish throughout the study and will be informed that there will be no set expectation for how frequently they must use the app, although they will be encouraged to use it regularly to thoroughly test it. The app will send notification reminders to check in (in other words, use the daily check-in feature to track their mood, stress, and behaviors related to STI-prevention over time). The notification settings can be adjusted in phone settings by the participant. To encourage peer support and a sense of community, users can interact with community members anonymously through a message board, monitored by research staff. Participants in the intervention will continue routine PrEP care and STI testing through the clinic."
89450145|NCT05395754|No Intervention|Routine Care|Participants in the routine care arm will continue routine PrEP care and STI testing through the clinic.
89450146|NCT02268591|Active Comparator|Transcranial Stimulator|We will apply oscillating current at a slow frequency of 0.5-1.5 Hz during early sleep, which is rich in slow waves [ie non-REM sleep]. The peak intensity of stimulation which allows for optimal phase entrainment will be determined in pilot studies. However, peak stimulation intensities will not exceed 2 mA (as discussed above). The current will be applied over the left and right prefrontal cortex (F3, F4), corresponding to the predominant region of slow oscillations, during the onset of deep sleep to the first REM episode (early non-REM-rich sleep).
89450147|NCT02268591|No Intervention|Sham Stimulation|The EEG and stimulation electrodes will be placed as in the stimulation sessions, but stimulation will not be administered.
89450148|NCT04456374||Under-12 (U12) players|
89450149|NCT04456374||Under-14 (U14) players|
89450150|NCT04456374||Under-16 (U16) players|
89450151|NCT04456374||Under-18 (U18) players|
89450152|NCT03471936|Other|Acquisition of pressure-volume loops|
89450153|NCT02268669|Active Comparator|Primary angioplasty|Patients assigned to this treatment will undergo cardiac catheterization within the time recommended by current guidelines. Double antiagregation will be used, vascular access wil be obtained and bivalirudin will be used as anticoagulation; all following current guidelines recommendations
89450154|NCT02268669|Active Comparator|Post-thrombolysis angioplasty|Patients will receive tenecteplase, enoxaparin, and double antiagreagation with clopidogrel or aspirin as recommended guidelines. Criteria of no reperfusion after fibrinolysis is defined as absence of ST-segment lowering >50%, 90 minutes after fibrinolysis. If not reperfusion is achieved recue angiplasty will be performed inmmediately if reperfusion is achieved cardiac catheterization will be performed the mornig following the day of randomization
89014803|NCT03945058|Sham Comparator|CONTROL|Sham TVS will be performed by use of a Tragus stimulator device with electrodes attached to the ear lobule. Stimulator will be applied continuously for 1 hour daily for 4weeks.
89450155|NCT01407003|Experimental|LIK066 in healthy subjects|
89450156|NCT01407003|Placebo Comparator|Matching placebo in healthy subjects|
89450157|NCT01407003|Experimental|LIK066 in patients with type 2 diabetes mellitus|
89450158|NCT01407003|Placebo Comparator|Matching placebo in patients with type 2 diabetes mellitus|
89450159|NCT02724774|Experimental|Promoting First Relationships® (PFR)|10 week home visiting program
89450160|NCT02724774|No Intervention|Parent Information Packet|A packet is mailed to the families, including handouts related to child development, health, and local resources.
89450161|NCT05359952|Experimental|Starting the Conversation|"Participants are asked to watch an educational video along with an accompanying workbook (called Starting the Conversation). Participants are also asked to review a list of resources about sexual and menopausal health relevant to gynecologic cancer."
89450162|NCT05359952|Active Comparator|Sexual and Menopausal Health Resources Only|Participants are given the list of resources about sexual and menopausal health only.
89450163|NCT01233375|Experimental|CO-1.01|
89450164|NCT05346302|Active Comparator|Pneumococcal (PPSV23) vaccine|PNEUMOVAX 23 is a clear, colorless solution. Each 0.5-mL dose of vaccine contains 25 micrograms of each polysaccharide type in isotonic saline solution containing 0.25% phenol as a preservative under the supervision of a licensed pharmacist.
89450165|NCT05346302|Active Comparator|Typhoid (inactivated) vaccine|Typhoid vaccine is a clear, colorless solution. Each dose of 0.5 mL is formulated to contain 25 mcg of purified Vi polysaccharide in a colorless isotonic phosphate buffered saline (pH 7 ± 0.3), 4.150 mg of Sodium Chloride, 0.065 mg of Disodium Phosphate, 0.023 mg of Monosodium Phosphate, and 0.5 mL of Sterile Water for Injection under the supervision of a licensed pharmacist.
89450166|NCT05346302|Placebo Comparator|Saline|Saline will be purchased commercially and compounded under the supervision of a licensed pharmacist in sterile syringes for administration of the placebo group.
89450167|NCT01232595|Experimental|LFF571 (POC)|
89450168|NCT01232595|Active Comparator|Vancomycin (POC)|
89450169|NCT01232595|Experimental|LFF571 Dose level 1 (cohort 2)|
89450170|NCT01232595|Experimental|LFF571 Dose level 2 (cohort 2)|
89450171|NCT01232595|Experimental|LFF571 Dose level 3 (cohort 2)|
89450172|NCT01232595|Experimental|LFF571 Dose level 4 (cohort 2)|
89450173|NCT02721498|Active Comparator|Visit A|Rest period for 30-60 minutes
89450174|NCT02721498|Active Comparator|Visit B|Airway clearance session utilising the Active Cycle of Breathing techniques (ACBT) supervised by a specialist physiotherapist for 30-60 minutes.
89450175|NCT04472676|Experimental|LY3473329 (Part A)|LY3473329 administered orally.
89450176|NCT04472676|Placebo Comparator|Placebo (Part A)|Placebo administered orally.
89450177|NCT04472676|Experimental|LY3473329 (Part B)|LY3473329 administered orally.
89450178|NCT04472676|Experimental|Placebo (Part B)|Placebo administered orally.
89450179|NCT01231347|Active Comparator|AMG 479 12 mg/kg dose + gemcitabine|Arm 2: AMG 479 12 mg/kg IV days 1 and 15 plus gemcitabine 1000 mg/m2 IV days 1, 8, and 15 of a 28 day cycle
89450180|NCT01231347|Placebo Comparator|Placebo + gemcitabine|Arm 1: AMG 479-placebo IV days 1 and 15 plus gemcitabine 1000 mg/m2 IV days 1, 8, and 15 of a 28 day cycle
89450181|NCT01231347|Active Comparator|AMG 479 20 mg/kg + gemcitabine|Arm 3: AMG 479 20 mg/kg IV days 1 and 15 plus gemcitabine 1000 mg/m2 IV days 1, 8, and 15 of a 28 day cycle
89450182|NCT02457000||Normal, healthy volunteers|Normal, healthy volunteers without any skin pathology will be asked to undergo various procedures to evaluate their sleep and skin health.
89450183|NCT02457000||Volunteers with skin pathology|Volunteers with skin pathology including but not limited to eczema, psoriasis, acne, and other inflammatory dermatoses will be asked to undergo various procedures to evaluate their sleep and skin health.
89450184|NCT02466152|Experimental|GSK2894512 2.0% Cohort|Subjects will apply a thin layer of GSK2894512 2.0% topical cream twice daily (morning and evening) for 20 days and only in morning on day 21, to all affected skin areas (15-35% BSA) identified at baseline, excluding the scalp and around the eyes
89450185|NCT02466152|Experimental|GSK2894512 1.0% Cohort|Subjects will apply a thin layer of GSK2894512 1.0% topical cream twice daily (morning and evening) for 20 days and only in morning on day 21, to all affected skin areas (15-35% BSA) identified at baseline, excluding the scalp and around the eyes
89450186|NCT03470376|Experimental|Nutraceutical combination (NC)|Patients on standardized diet regimen taking a NC (red yeast rice-derived monacolin K 3 mg, berberine 500 mg, policosanol 10 mg, astaxanthin 0.5 mg, folic acid 0.2 mg and coenzyme Q10 2 mg) one pill/day for 3 months
89450187|NCT03470376|Active Comparator|No nutraceutical combination (noNC)|Patients on standardized diet regimen without taking any NC
89450188|NCT01852968||Patients with type 1 diabetes|"Hippocampal neurochemistry and metabolism will examined in Patients with type 1 diabetes using magnetic resonance spectroscopy.~Patients with type 1 diabetes will also undergo neurocognitive testing to assess hippocampal function"
89450189|NCT01852968||healthy controls|"Hippocampal neurochemistry and metabolism will be examined in healthy controls using magnetic resonance spectroscopy.~Healthy controls will also undergo neurocognitive testing to assess hippocampal function"
89450190|NCT02719028|Placebo Comparator|Placebo|Subjects with screening central laboratory with a diagnosis of primary hypercholesterolemia (nonfamilial) or mixed hyperlipidemia (TG between 150 mg/dL and 500 mg/dL, and cholesterol between 160 mg/dL and 250 mg/dL or LDL-C > 130 mg/dL ) who meet inclusion/exclusion criteria will be randomized to 4 groups patient will take (antroquinnonol 50mg or Placebo) 3 capsules once a day.
89450191|NCT02719028|Experimental|Antroquinonol 50 mg PO|Subjects with screening central laboratory with a diagnosis of primary hypercholesterolemia (nonfamilial) or mixed hyperlipidemia (TG between 150 mg/dL and 500 mg/dL, and cholesterol between 160 mg/dL and 250 mg/dL or LDL-C > 130 mg/dL ) who meet inclusion/exclusion criteria will be randomized to 4 groups patient will take (antroquinnonol 50mg or Placebo) 3 capsules once a day.
89014806|NCT03917381|Experimental|Dose escalation|Acasunlimab will be administered as monotherapy
89014807|NCT03917381|Experimental|Expansion|Acasunlimab will be administered as monotherapy (or in combination with docetaxel or in combination with pembrolizumab or in combination with pembrolizumab and standard chemotherapy in separate expansion cohorts)
89450192|NCT02719028|Experimental|Antroquinonol 100 mg PO|Subjects with screening central laboratory with a diagnosis of primary hypercholesterolemia (nonfamilial) or mixed hyperlipidemia (TG between 150 mg/dL and 500 mg/dL, and cholesterol between 160 mg/dL and 250 mg/dL or LDL-C > 130 mg/dL ) who meet inclusion/exclusion criteria will be randomized to 4 groups patient will take (antroquinnonol 50mg or Placebo) 3 capsules once a day.
89450193|NCT02719028|Experimental|Antroquinonol 150 mg PO|Subjects with screening central laboratory with a diagnosis of primary hypercholesterolemia (nonfamilial) or mixed hyperlipidemia (TG between 150 mg/dL and 500 mg/dL, and cholesterol between 160 mg/dL and 250 mg/dL or LDL-C > 130 mg/dL ) who meet inclusion/exclusion criteria will be randomized to 4 groups patient will take (antroquinnonol 50mg or Placebo) 3 capsules once a day.
89206126|NCT02600585||Inactivated Influenza Vaccine|Injectable, inactivated, egg-based influenza vaccines (IIV); Intramuscular injection of vaccine (whether trivalent or quadrivalent) derived from influenza A/H1N1, A/H3N2, and B viruses, as identified for the season by the FDA Vaccines and Related Biological Products Advisory Committee (VRBPAC) in a total volume of 0.5 mL.
89450194|NCT01230957|Experimental|Group 1|Participants will receive a dose Low-dose ACAM-CDIFF™ vaccine with adjuvant on Day 0, 7, and 30, respectively.
89450195|NCT01230957|Experimental|Group 2|Participants will receive a dose Low-dose ACAM-CDIFF™ vaccine without adjuvant on Day 0, 7, and 30, respectively.
89450196|NCT01230957|Experimental|Group 3|Participants will receive a dose High-dose ACAM-CDIFF™ vaccine with adjuvant on Day 0, 7, and 30, respectively.
89450197|NCT01230957|Experimental|Group 4|Participants will receive a dose High-dose ACAM-CDIFF™ vaccine without adjuvant on Day 0, 7, and 30, respectively.
88934915|NCT01773811|Active Comparator|Narrative Writing: Trauma-Spontaneous|Individuals will write about their most traumatic life experience but will not be given further instructions for processing. Any additional processing about their writing topic in the weeks following writing will be considered spontaneous.
88934916|NCT01773824|Other|No feedback|Physicians in the control group will only be monitored for their antibiotic prescription rates (Physicians are unaware of the trial).
89200782|NCT00901719|Experimental|Sodium depletion|Subjects will be randomised to normal diet or sodium depleted diet. The sodium depletion protocol comprises of a single oral dose of 40 mg of furosemide followed by an out-patient diet containing >2000 kcal of energy, >60 g of protein, <12 mmol of sodium and <70 mmol of potassium per day for 3 days prior to study. This diet is know to increase the activity of the renin-angiotensin system.
88934917|NCT01773824|Experimental|Antibiotic prescription feedback|Physicians receive quarterly electronic feedback on their antibiotic prescriptions
88934918|NCT01773837|Experimental|methylphenidate|methylphenidate (pill) p.o. 15 to 25 mg daily for six days
89450198|NCT01230957|Placebo Comparator|Group 5|Participants will receive a dose Placebo (0.9% normal saline) on Day 0, 7, and 30, respectively.
89450199|NCT01230957|Experimental|Group 6|Participants will receive a dose of High-dose ACAM-CDIFF™ vaccine with adjuvant on Day 0, 7, and 180, respectively.
89450200|NCT01230957|Experimental|Group 7|Participants will receive a dose of High-dose ACAM-CDIFF™ vaccine with adjuvant on Day 0, 30, and 180, respectively.
89450201|NCT03306056|Experimental|Control|Nutritional therapy / no exercise
89450202|NCT03306056|Experimental|Standard Strength Training|Nutritional therapy combined with a Standard Strength Training program
89450203|NCT03306056|Experimental|Low-volume Strength Training|Nutritional therapy combined with a low-volume Strength Training program
89450204|NCT03306056|Experimental|Whole-body Electromyostimulation|Nutritional therapy combined with Whole-Body Electromyostimulation
89450205|NCT01228383|Experimental|CL184+PVRV|CL184 with rabies vaccine (PVRV)
89450206|NCT01228383|Active Comparator|HRIG+PVRV|HRIG with rabies vaccine
89450207|NCT01228383|Placebo Comparator|Placebo+PVRV|Placebo with rabies vaccine (PVRV)
89450208|NCT01228383|Experimental|CL184+HDCV|CL184 with rabies vaccine (HDCV)
89450209|NCT01228383|Placebo Comparator|Placebo+HDCV|Placebo with rabies vaccine (HDCV)
89450210|NCT03305978|Experimental|Ultra low dose chest CT|
89450211|NCT03305978|Active Comparator|Low dose chest CT|
89450212|NCT01594983|Experimental|LCQ908 1|LCQ908 (Diacylglycerol acyltransferase inhibitor)once daily for 12 weeks
88934919|NCT01773837|Placebo Comparator|placebo|the same number of pills (p.o.) than methylphenidate for six days
88934920|NCT01773850||Patients|Patients with a breast lesion undergoing surgical biopsy. All patients will undergo stationary Carbon Nanotube x-ray digital breast tomosynthesis imaging in addition to routine conventional digital mammography.
88934921|NCT01773876|Active Comparator|Micafungin|MYCAMINE 100 mg intravenous an injection of 24 hours
88934922|NCT01773876|Placebo Comparator|PLACEBO|0.9% sodium chlorides 100ml infusion
88934923|NCT01773902|Experimental|High Dose Protein (Individualized)|Protein supplementation according to breast milk content aiming for 4.5g/kg/d of enteral protein if <1500g b.w. or 4.0g/kg/d of enteral protein if >1500g b.w. until 1 week before discharge
88934924|NCT01773902|Experimental|High Dose Protein (Standardized)|Protein supplementation independent of individual breast milk content using a new high-dose-protein breast milk fortifier until 1 week before discharge
88934925|NCT01773902|Active Comparator|Standard protein supplementation|Protein supplementation independent of individual breast milk content using a standard dose of a standard breast milk fortifier until 1 week before discharge
88934926|NCT01773915||AD patients|Subject fulfilling the McKhann criteria for clinical probable AD
88934927|NCT01773915||Healthy elder persons|Healthy controls with abscence of any cognitive disorder
88934928|NCT01773980||Patient and Clinic Intervention|"The patient intervention consists of a single 90-minute interactive in-person session.~The Clinic intervention consists of an educational video, an interactive meeting with clinicians and clinic staff, and a facilitated follow-up meeting with clinic staff."
88934929|NCT01773980||Patient Intervention Only|The patient intervention consists of a single 90-minute interactive in-person session.
88934930|NCT01773980||Clinic Intervention Only|The Clinic intervention consists of an educational video, an interactive meeting with clinicians and clinic staff, and a facilitated follow-up meeting with clinic staff.
88934931|NCT01773980||Neither Clinic nor Patient Intervention|Consists of no intervention
88934932|NCT01774006||Group culture|Embryos cultured in groups of 2-10
88934933|NCT01774006||Individual culture|Embryos cultured individually
88934934|NCT01774032|Experimental|Influenza Vaccine|One dose of the vaccine will be administered at a volume of 0.5 mL by intramuscular injection into the musculus deltoideus in the upper arm on Day 1 and 22.
88934935|NCT01774058|Experimental|Ilomedin, bloodflow volume, measurement,|Surgery was performed under general anesthesia via a longitudinal skin incision. After systemic administration of 5000 IU of unfractionated Heparin, the peripheral vessels were clamped. Following a longitudinal arteriotomy, thrombendarterectomy of the common femoral artery was performed in all cases, extending into the deep femoral artery and superficial femoral artery when necessary. At the end of the reconstruction, 3000 ng of iloprost (Ilomedin), diluted in 15ml saline solution, were administered into the common femoral artery. Distal to the injection site doppler flow measurement was performed at the common femoral artery prior to arteriotomy, prior to the intraarterial application of iloprost and 5 and 10 minutes afterwards, using the Sono TT FlowLab instrument. During the procedure, systemic arterial blood pressure was continuously documented using a pressure transducer connected to an intraarterial cannula placed in the radial artery of the forearm.
88934936|NCT01774123||Healthy|Healthy controls
88934937|NCT01774123||MS-ON|Multiple sclerosis with optic neuritis
88934938|NCT01774123||MS-NON|Multiple sclerosis without optic neuritis
88934939|NCT01774136|Experimental|Enhanced HIV and MCH training for CHW|The intervention includes two components: (1) a 2-week HIV/C-IMCI training for CCGs and their associated facilitators and supervisors, and (2) continuous support and supervision following the continuous quality improvement (CQI) framework, a low-technology approach to management and supervision of health programs.
88934940|NCT01774136|No Intervention|Standard of Care|
88934941|NCT01774162|Active Comparator|FNA for cytology|Fine needle aspiration using conventional FNA for cytology
88934942|NCT01774162|Experimental|FNB core biopsy for histology|Fine needle biopsy using ProCore needle for histology.
88934943|NCT01774175||Coolprep|A total of 2L A : NaCl 5.382g KCl 2.03g Sodium sulfate 15g Polyethylene glycol 3350 200.0g B : Ascorbic acid 9.4g Sodium ascorbate 11.8g
88934944|NCT01774175||Picolyte|Sodium picosulfate 30.0mg Magnesium citrate 10.5g + 36.0g
88934945|NCT01774188||Intraocular pressure, EECP, no glaucoma|To examine no glaucoma patients' intraocular pressure before and after the treatment of Enhanced Extracorporeal Counterpulsation. EECP one hour per day, 5 hours a week for a total of 35 hours lasting 7 weeks
89450213|NCT01594983|Experimental|LCQ908 2|LCQ908 once daily for 12 weeks
89450214|NCT01594983|Experimental|LCQ908 3|LCQ908 once daily for 12 weeks
89450215|NCT01594983|Active Comparator|Fenofibrate|Intervention Type: Drug Intervention Name: Fenofibrate
89450216|NCT01594983|Active Comparator|Fish Oil|Fish oil once daily for 12 weeks
89450217|NCT01594983|Placebo Comparator|Arm Label: Placebo|Intervention Type: other Intervention Name: other
89450218|NCT03305744||Endurance Athlete with Atrial Fibrillation|These are middle-aged athletes who are diagnosed with paroxysmal Atrial Fibrillation in the last 4 years, but are otherwise free of disease.
89450219|NCT03305744||Endurance Athlete without Atrial Fibrillation|These are middle-aged athletes who will serve as our control group- they have not been diagnosed with AF or any other disease.
89450220|NCT01404585|Placebo Comparator|Arm 1: Placebo|
89450221|NCT01404585|Experimental|Arm 2: BMS-817399 (200 mg)|
89450222|NCT01404585|Experimental|Arm 3: BMS-817399 (400 mg)|
89450223|NCT03305510||Vitamin D deficiency|The level of vitamin D is below 20ng/ml.
89450224|NCT03305510||Vitamin D insufficient|The level of vitamin D is between 20ng/ml and 30ng/ml.
88934946|NCT01774188||intraocular pressure, EECP, glaucoma|To examine glaucoma patients' intraocular pressure before and after the treatment of Enhanced Extracorporeal Counterpulsation. EECP one hour per day, 5 hours a week for a total of 35 hours lasting 7 weeks.
89450225|NCT03305510||Vitamin D sufficient|The level of vitamin D is above 30ng/ml.
89450226|NCT01224795|Experimental|Peramivir|Adults (≥ 18 years): Peramivir 600 mg, administered intravenously. Adolescents (12 to < 18 years): Peramivir 10 mg/kg (not to exceed a maximum dose of 600 mg), administered intravenously.
89450227|NCT01224795|Placebo Comparator|Placebo|Placebo Peramivir, administered intravenously.
89450228|NCT02263443|Experimental|Soap sus enema (S.S.E.)|Patients in S.S.E. group will receive bowel preparation by soap suds enema until clear at night before surgery.
88934947|NCT01774201|Experimental|Breathing exercises|Daily deep breathing exercises during two month
88934948|NCT01774201|No Intervention|Control|Control group
88934949|NCT01774214|Experimental|A|"As this is a crossover trial, the study arms denote the order in which the two interventions are performed by the subject. In Arm A, subjects will perform the Push-Pull Technique of manual fluid resuscitation first, followed by the Disconnect-Reconnect Technique second. A washout period of at least 30 minutes between each of the two interventions will be observed."
88934950|NCT01774214|Experimental|B|"As this is a crossover trial, the study arms denote the order in which the two interventions are performed by the subject. In Arm B, subjects will perform the Disconnect-Reconnect Technique of manual fluid resuscitation first, followed by the Push-Pull Technique second. A washout period of at least 30 minutes between each of the two interventions will be observed."
88934951|NCT01774227|Experimental|The pops-titration group|"The titration method uses power that is titrated according to the audible pop."
88934952|NCT01774227|Experimental|The slow-coagulation group|The slow-coagulation group utilize the low-energy using the Gaasterland's slow-coagulation technique
88934953|NCT01774266||Molina - Chile|Molina is one of the counties with the highest mortality rate of gastric cancer in Chile. Molina has a population of 40.000 hab mostly rural. Half of the population lives in Molina city and the other half in the suburbs. Molina is located near the Mountain Andes.
88934954|NCT01774279||anaplastic thyroid cancer|
88934955|NCT01774292|Active Comparator|Alkalized lidocaine|160 mg of 4% lidocaine (4 ml) in the endotracheal cuff and add bicarbonate 8,4% until appropriate seal.
88934956|NCT01774292|Placebo Comparator|Sterile saline|4 mL of sterile saline in the endotracheal cuff and add bicarbonate 8,4% until appropriate seal.
89450229|NCT02263443|Experimental|sodium chloride enema|Patients in unison enema group will receive Unison enema 100 ml per rectal at night before surgery.
89450230|NCT02263443|Placebo Comparator|no enema|Patients will receive none of bowel preparation. NPO after midnight
88934957|NCT01774318|Other|preterm cohort|preterm infants born at medical university of vienna and born at gestational age 23+0 - 28+6 weeks of gestation intervention: aEEG and conventional EEG measurements will be performed every two weeks untill 36 weeks of gestation
88934958|NCT01774331||Immunoglobulin Therapy|Immunoglobulin Therapy
88934959|NCT01774370||Pradaxa group|
88934960|NCT01774396|Other|group 2|The intervention will be the injection of Emervel® Volume Lidocaine alone in the dorsa of one hand and Emervel® Deep Lidocaine alone in the dorsa of the contralateral hand.
88934961|NCT01774396|Experimental|group 1|EThe intervention will be the injection of mervel® Volume Lidocaine plus Emervel® Touch in the dorsa of one hand and Emervel® Deep Lidocaine plus Emervel® Touch in the dorsa of the contralateral hand
88934962|NCT01774422|Experimental|noninvasive ventilation alone|"After validation of the inclusion and exclusion criteria, the patients include in this clinical trial will be randomized between the two arms of the study:~Noninvasive ventilation alone~Noninvasive ventilation associated with the DECAP CO2 device"
88934963|NCT01774422|Other|noninvasive ventilation associated with the DECAP CO2 device|"After validation of the inclusion and exclusion criteria, the patients include in this clinical trial will be randomized between the two arms of the study:~Noninvasive ventilation alone~Noninvasive ventilation associated with the DECAP CO2 device"
88934964|NCT01774435|Experimental|EN3342|EN3342 (risperidone) subcutaneous implant
89450231|NCT02265627|Experimental|BIIL 284 BS, normal hepatic function|
89450232|NCT02265627|Experimental|BIIL 284 BS, mild hepatic impairment|
88934965|NCT01774448|No Intervention|Waitlist Control|Participants in the control group will undergo a non-intervention 8-week period while on the 'waitlist control' then will be crossed-over to the Mindfulness-Based Cognitive Therapy intervention.
88934966|NCT01774448|Experimental|Mindfulness-Based Cognitive Therapy|Mindfulness-Based Cognitive Therapy is an 8-week intervention, one session per week for 2 hours, where participants will learn and practice formal and informal mindfulness meditation, and participate in group discussion and inquiry.
88934967|NCT01774461|No Intervention|Sham RIC|Control treatment (sham RIC) will consist of four 5-minute simulated inflations of a blood pressure cuff placed on the upper arm. The inflations will be separated by 5-minute periods when the blood pressure cuff will be deflated.
88934968|NCT01774461|Active Comparator|Remote ischemic conditioning|Blood pressure cuff placed on upper arm and inflated to 200mmHg for 5 minutes then deflated for 5 minutes - this cycle is repeated a total of 4 times.
88934969|NCT01774474|Active Comparator|Non diabetics: bromfenac|bromfenac 0.09% eye drops twice daily starting two days before surgery and continuing 2 weeks postoperatively
89450233|NCT02265627|Experimental|BIIL 284 BS, moderate hepatic impairment|
89450234|NCT01402401|Experimental|AUY922 + Trastuzumab|
89450235|NCT02720510|Active Comparator|Arm 1 - RVD + Pan|Revlimid, Velcade, dexamethasone and Farydak
89450236|NCT02720510|Active Comparator|Arm 2 - RVD|Revlimid, Velcade and Dexamethasone
89450237|NCT02263521||physicians|Nationally-representative sample of physicians in all specialties who have direct or indirect patient care responsibilities
89450238|NCT02263521||resident physicians|Nationally-representative of resident physicians in all specialties
89450239|NCT02263521||medical students|Nationally-representative sample of 4th year medical students in all US allopathic medical schools.
89450240|NCT01220271|Experimental|Phase 1: 160 mg LY2157299|"During Radiation therapy:~Radiation:Approximate 1.8 - 2.0 Gy x 30 fractions. Approximate total dose = 60.0 Gy taken 5 days per week for 6 weeks.~LY2157299: 80 mg taken twice daily for 14 days on followed 14 days of pause. This on/off schedule constitutes a cycle of 28 days.~Temozolomide: 75 mg/m2 taken daily for 6 weeks.~After Radiation Therapy:~LY2157299: 80 mg taken twice daily for 14 days on followed 14 days of pause. This on/off schedule constitutes a cycle of 28 days. Taken for a 6 cycles.~Temozolomide: 150 mg/m2 and then 200 mg/m2 daily during the off time of LY2157299. Starting 28 days after the completion of radiation therapy. Taken for 5 days followed by 23 days of rest for 6 cycles."
89450241|NCT01220271|Experimental|Phase 1: 300 mg LY2157299|"During Radiation therapy:~Radiation:Approximate 1.8 - 2.0 Gy x 30 fractions. Approximate total dose = 60.0 Gy taken 5 days per week for 6 weeks.~LY2157299: 150 mg taken twice daily for 14 days on followed 14 days of pause. This on/off schedule constitutes a cycle of 28 days.~Temozolomide: 75 mg/m2 taken daily for 6 weeks.~After Radiation Therapy:~LY2157299: 150 mg taken twice daily for 14 days on followed 14 days of pause. This on/off schedule constitutes a cycle of 28 days. Taken for a 6 cycles.~Temozolomide: 150 mg/m2 and then 200 mg/m2 daily during the off time of LY2157299. Starting 28 days after the completion of radiation therapy. Taken for 5 days followed by 23 days of rest for 6 cycles."
89450242|NCT01220271|Experimental|Phase 2: Established dose LY2157299|"During Radiation therapy:~Radiation:Approximate 1.8 - 2.0 Gy x 30 fractions. Approximate total dose = 60.0 Gy taken 5 days per week for 6 weeks.~LY2157299: Phase 1 established dose taken twice daily for 14 days on followed 14 days of pause. This on/off schedule constitutes a cycle of 28 days.~Temozolomide: 75 mg/m2 taken daily for 6 weeks.~After Radiation Therapy:~LY2157299: Phase 1 established dose taken twice daily for 14 days on followed 14 days of pause. This on/off schedule constitutes a cycle of 28 days. Taken for a 6 cycles.~Temozolomide: 150 mg/m2 and then 200 mg/m2 daily during the off time of LY2157299. Starting 28 days after the completion of radiation therapy. Taken for 5 days followed by 23 days of rest for 6 cycles."
89450243|NCT01220271|Experimental|Phase 2: no LY2157299 (control)|"During Radiation therapy:~Radiation:Approximate 1.8 - 2.0 Gy x 30 fractions. Approximate total dose = 60.0 Gy taken 5 days per week for 6 weeks.~Temozolomide: 75 mg/m2 taken daily for 6 weeks.~After Radiation Therapy:~Temozolomide: 150 mg/m2 and then 200 mg/m2 daily during the off time of LY2157299. Starting 28 days after the completion of radiation therapy. Taken for 5 days followed by 23 days of rest for 6 cycles."
89450244|NCT03305432|Experimental|PPI group|take preoperative PPI for 10 days
89450245|NCT03305432|Active Comparator|Control group|take placebo for for 10 days preoperative
89450246|NCT01396785|Experimental|Active|Product 33525
89450247|NCT01396785|Placebo Comparator|Placebo|Product 33525 Placebo
89450248|NCT02468102||Rivaroxaban / Cohort 1|Patients who have filled a prescription for rivaroxaban in any pharmacy in Sweden during the study period.
88934970|NCT01774474|Active Comparator|Non diabetics: dexamethasone|dexamethasone 0.1% eye drops four times daily starting two days before surgery and continuing four times daily during the first postoperative week and one drop less per day every following week
88934971|NCT01774474|Active Comparator|Non diabetics: bromfenac & dexamethasone|bromfenac 0.09% eye drops twice daily starting two days before surgery and continuing 2 weeks postoperative & dexamethasone 0.1% eye drops four times daily starting two days before surgery and continuing four times daily during the first postoperative week and one drop less per day every following week
88934972|NCT01774474|Active Comparator|Diabetics: eye drops|bromfenac 0.09% eye drops twice daily starting two days before surgery and continuing 2 weeks postoperative & dexamethasone 0.1% eye drops four times daily starting two days before surgery and continuing four times daily during the first postoperative week and one drop less per day every following week
88934973|NCT01774474|Active Comparator|Diabetics: eye drops & TA|"bromfenac 0.09% eye drops twice daily starting two days before surgery and continuing 2 weeks postoperative & dexamethasone 0.1% eye drops four times daily starting two days before surgery and continuing four times daily during the first postoperative week and one drop less per day every following week~& a peroperative subconjunctival injection of 40 mg triamcinolone acetonide (TA, Triesence/Vistrec)"
88934974|NCT01774474|Active Comparator|Diabetics: eye drops & bevacizumab|"bromfenac 0.09% eye drops twice daily starting two days before surgery and continuing 2 weeks postoperative & dexamethasone 0.1% eye drops four times daily starting two days before surgery and continuing four times daily during the first postoperative week and one drop less per day every following week~& a peroperative intravitreal injection of 1.25 mg bevacizumab (Avastin)"
89450249|NCT02468102||Standard of care drugs / Cohort 2|Patients who have filled a prescription for standard of care drugs (warfarin, aspirin, clopidogrel, ticlopidine, prasugrel or ticagrelor) in any pharmacy in Sweden during the study period.
89200783|NCT00901719|Placebo Comparator|Normal diet|Subjects will be randomised to a normal diet, with no restriction on sodium intake during the three days prior to the study.
89200784|NCT00972712|Experimental|A|Bortezomib and Tipifarnib
89450250|NCT04491266|Experimental|FBA|N-(1-carbamoyl-2-phenyl-ethyl) butyramide (FBA) has been developed.
89450251|NCT04491266|Placebo Comparator|placebo|maltodextrins
89450252|NCT01204749|Experimental|AMG 386|Arm A: Paclitaxel 80mg/m2 IV QW and Blinded AMG 386 15mg/kg IV QW
89450253|NCT01204749|Placebo Comparator|AMG 386 Placebo|Arm B: Paclitaxel 80mg/m2 IV QW and Blinded AMG 386 Placebo IV QW
89450254|NCT02466698|Experimental|Intestinal Lavage|A nasojejunal tube and fecal management system will be inserted. Intestinal lavage with PEG is initiated and increased to a goal rate of 400cc/hour to a total of 8L of PEG. In the absence of an ileus, lavage should be initiated at 200cc/hr. Tolerance is confirmed if the rectal effluent volume is ≥50% of the lavage volume over the first 6 hours and no emesis has developed. If the consulting surgical service suspects a significant ileus, the lavage is initiated at 100cc/hr. If tolerance is confirmed the lavage rate is increased in a stepwise fashion. Antibiotic regimen will consist of Vancomycin 500mg via nasojejunal every 6 hours and Metronidazole 500 mg IV three times daily for 14 days. PEG will be held for 2 hours after administration of Vancomycin.
89450255|NCT02466698|Active Comparator|Usual Care|Patients will receive usual care for severe CDI. This includes an antibiotic regimen of Vancomycin 500mg orally every 6 hours and Metronidazole 500mg IV three times daily for 14 days. The usual care group will receive the same antibiotic doses as the experimental arm of the study. For both arms, indications to escalate treatment to surgical intervention will ultimately be based on the clinical assessment by the surgical service. An absolute indication for surgery is perforation. Other indications such as toxic megacolon, worsening peritonitis or biochemical profile lavage are relative indications that vary according to clinician and individual patient characteristics.
88934975|NCT01774474|Active Comparator|Diabetics: eye drops, TA & bevacizumab|"bromfenac 0.09% eye drops twice daily starting two days before surgery and continuing 2 weeks postoperative, dexamethasone 0.1% eye drops four times daily starting two days before surgery and continuing four times daily during the first postoperative week and one drop less per day every following week~& a peroperative subconjunctival injection of 40 mg triamcinolone acetonide (TA)~& a peroperative intravitreal injection of 1.25 mg bevacizumab"
88934976|NCT01774513|Experimental|Procore Needle|
88934977|NCT01774539||Physeal Injury - Distal Radius|Patients who suffer a physeal fracture of the distal radius will be scanned and compared to their healthy contralateral limb.
88934978|NCT01774565|Experimental|Fully Automated Closed-Loop Insulin Delivery (phase 1-4)|The control algorithm will automatically direct between meals and meal-related subcutaneous insulin delivery utilizing real-time continuous glucose monitoring (RT-CGM) data. The subcutaneous insulin pump will deliver insulin Aspart or similar. In phase 1, a once daily basal insulin analogue will also be given subcutaneously at 20% the patient's usual total daily dose. In phase 3 and 4 faster-acting insulin aspart (Fiasp) is applied.
88934979|NCT01774565|Active Comparator|Usual care/ fully-automated closed-loop using Iasp|"Phase 1-3: During usual care (conventional therapy), subject's s.c. insulin dose and regimen on admission will be adjusted as necessary by the clinical team according to local centres' usual clinical practice. Subjects will have masked CGM sensors inserted during the study (CGM readings will be masked throughout the study).~Phase 4: subjects will receive fully-automated insulin delivery using standard insulin aspart (Iasp)"
88934980|NCT01774617||Patients with advanced liver disease|Inclusion criteria are diagnosis of cirrhosis with portal hypertension detected by abdominal ultrasound with color Doppler flowmetry or upper digestive endoscopy. Exclusion criteria were age 18 or older, previous contrast allergy, hepatocellular carcinoma or any malignancy except basocellular carcinoma, renal failure (creatinine level >1.5 mg/dL), severe bleeding disorder (prothrombin activity test < 30% or platelets count <35,000/mcL) or decompensated cirrhosis characterized by severe ascites or grade II or higher encephalopathy. Patients with alcoholic cirrhosis should be abstinent for at least six months.
88934981|NCT01774656|Experimental|HeartMate II plus Pharmacological Treat|"The HM II pump contains a single moving component, the rotor. The pump is implanted just below the left hemidiaphragm with the inflow attached to the apex of the left ventricle and the outflow graft anastomosed to the ascending aorta. Blood is pumped continuously throughout the cardiac cycle from the left ventricle to the aorta.~The pharmacological treatment intended to enhance reverse remodeling includes 4 drugs initiated immediately after weaning of inotropic support once achieving adequate end-organ recovery and titrated (against symptoms, potassium, and renal function) to the following maximum doses: lisinopril 40 mg daily; carvedilol 25 mg 3 times daily; spironolactone 25 mg daily; digoxin 125g daily, and losartan 150 mg daily."
88934982|NCT01774669|Experimental|YouGrabber training device from YouRehab Ltd.|Patients in the experimental group (EG) will receive 16 training sessions lasting for 45 minutes each.
88934983|NCT01774669|Active Comparator|Conventional therapy|Patients in the control group (CG) will receive 16 therapy sessions (physiotherapy or occupational therapy) lasting for 45 minutes each.
88934984|NCT01774682|Other|6-minute walk test|the 6-minute walk test is performed for each patient prior to the surgery and 6 months after by a specialist.
88934985|NCT01774695|Other|Control and intervention|In the first study half of the subjects first served as controls for 12 weeks and then they went through the intervention. The other half only went through the intervention.
89200785|NCT02540421||Case|Recurrent lesions
89200786|NCT02540421||Control|Absence of lesions
89200787|NCT00984958|Other|Bulkamid|Injection with Bulkamid
89200788|NCT00984958|Other|expectance|The expectance arm will after 2 month have the same treatment as the treatment arm
89531355|NCT03336437|Active Comparator|Estrogen Vaginal Ring|At the time of initial study visit, a estrogen vaginal ring (Estring) will be placed. Participants will retain this ring for 12 weeks.
89531356|NCT03336437|Placebo Comparator|Inactive Vaginal Placebo Ring|At the time of initial study visit, a placebo vaginal ring will be placed. Participants will retain this ring for 12 weeks.
89531357|NCT05040867|No Intervention|Control group (CG)|Participants will continue with their daily life and usual care.
89450256|NCT05244590|Experimental|Intervention|"GPs' eligibility criteria~Working in the centre health care region in Portugal.~Authorisation of the coordinator of each GP health care unit to integrate the study.~Patients' eligibility criteria~Inclusion criteria~Belonging to the list of patients of the recruited GPs.~18 years or older.~Diagnosis of advanced stage neoplasm (ASN), Chronic Obstructive Pulmonary Disease (COPD) Gold III/IV, Congestive Heart Failure (CHF) NYHA III/IV, Chronic Kidney Disease (CKD) stage IV/V.~Exclusion Criteria~Refusal, at any time, to participate in the study.~Level of understanding or execution that compromises taking part in the study and answering the IPOS patient version (evaluated using Mini Mental State Examination score).~Level of disease severity requiring urgent intervention (GP clinical judgement)."
89450257|NCT02720198|Active Comparator|Levomilnacipran|Levomilnacipran ER is switched from SSRI.
89450258|NCT02720198|Active Comparator|Quetiapine|Quetiapine XR is added in addition to current SSRI.
89450259|NCT05212467|Active Comparator|AIR-program|• The Amygdala and insula retraining program consists of novel brain retraining approaches focused on hypothetically interrupting and retraining the conditioned defensive hyper-stimulation of the sympathetic nervous system and aspects of the immune system by the amygdala and insula, to bring the brain and body back to homeostasis. It includes supportive techniques such as breathing, meditation, and neurolinguistic programming. The patients are invited to an online program of video session and eight weekly 2 h webinar sessions followed by three monthly sessions. The patients are assigned to do daily homework that takes approximately 15 to 20 min to complete
89450260|NCT05212467|Active Comparator|HUS Internet therapy|The HUS internet therapy for bodily stress syndromes (iHUSbss) includes psychoeducation about autonomic nervous system and of the effects of patient's own thinking and action on the nervous system. The exercises aim at relaxing the body, at novel ways to observe the symptoms, and at developing acceptance and self-compassion. The program includes exercises that are done regularly in everyday life.
89450261|NCT05212467|Placebo Comparator|Treatment as usual|The patients may have appointments with their physician, physiotherapist, or another health professional, and they may attend group interventions. If possible, medication is kept the same during the intervention and three months afterwards. If there is need to change the medication during the trial, the changes will be recorded. Appointments with health professionals and attendance in group interventions are monitored.
89450262|NCT01194375|Experimental|Low Strength IDP-107|
89450263|NCT01194375|Experimental|High Strength IDP-107|
89450264|NCT01194375|Placebo Comparator|Placebo|
89450265|NCT01193361|Experimental|Arm 1 - BMS-791325 plus peg-interferon alfa-2a and ribavirin|
89450266|NCT01193361|Experimental|Arm 2 - BMS-791325 plus peg-interferon alfa-2a and ribavirin|
89450267|NCT01193361|Placebo Comparator|Arm 3 - Placebo plus peg-interferon alfa-2a and ribavirin|
89450268|NCT03305354|Experimental|CBTI app intervention|Cognitive Behavioral Therapy for Insomnia delivered for 6 weeks via the CBT-I Coach app with use guided by a self-management guide
89450269|NCT03305354|Active Comparator|CBTI app+Physical Activity Intervention|Cognitive Behavioral Therapy for Insomnia delivered for 6 weeks via the CBT-I Coach app with use guided by a self-management guide plus self-management guidance on increased step counts
89014808|NCT03912519|Active Comparator|Parallel placement of 16 gauge electrodes|Parallel Group will undergo radiofrequency ablation via the approach described in Spine Intervention Practice Guidelines via 16 gauge electrodes. Specifically, the target nerve will be targeted with a parallel approach so as the electrode lay parallel to the nerves location within the sulcus formed by the neck of superior articular process and transverse process (or sacral ala for L5) cephalad to the point it is covered by the mamillo-accessory ligament.
89014809|NCT03912519|Active Comparator|Perpendicular placement with 22 gauge electrodes|Perpendicular Group will undergo radiofrequency ablation via the approach described in Spine Intervention Society Practice Guidelines for medial branch blocks, using a 22 gauge electrode. Specifically, the target nerve will be targeted with a perpendicular approach so as the tip of electrode contact the nerve at some point of it course along the sulcus formed by the neck of superior articular process and transverse process (or sacral ala for L5) cephalad to the point it is covered by the mamillo-accessory ligament.
89014810|NCT03907878|Experimental|Ligelizumab 120 mg per 1 mL qw4|Subjects received one subcutaneous injection every 4 weeks at 13 visits during the treatment period
89014811|NCT03904862|Experimental|Phase I - Skeletally-immature|Skeletally-immature children with refractory or recurrent medulloblastoma of the SHH group
89014812|NCT03904862|Experimental|Phase II - Skeletally-mature|Skeletally-mature subjects with refractory or recurrent medulloblastoma of the SHH group
89450270|NCT02263599||Conservatively treated ventral hernias|
89450271|NCT02263599||Surgically treated ventral hernias|
89450272|NCT02263677|Experimental|Sitagliptin|60 day supply of 100mg Sitagliptin
89200789|NCT04007302|Experimental|walking with distraction|the patient walks in front of a screen with virtual reality simulation
89450273|NCT01390545|Active Comparator|Veltuzumab 80 mg|
89450274|NCT01390545|Active Comparator|Veltuzumab 160 mg|
89450275|NCT01390545|Active Comparator|Veltuzumab 320 mg|
89450276|NCT01390545|Placebo Comparator|Placebo|
89450277|NCT01591473|Experimental|FluMist + Ampligen, Group 1|Nasal administration; dose group 1; FluMist + Poly I:Poly C12U 50 ug; 3 doses separated by 28 days
89450278|NCT01591473|Experimental|FluMist + Ampligen, Group 2|Nasal administration; dose group 2; FluMist + Poly I:Poly C12U 200 ug; 3 doses separated by 28 days
89450279|NCT01591473|Experimental|FluMist + Ampligen, Group 3|Nasal administration; dose group 3; FluMist + Poly I:Poly C12U 500 ug; 3 doses separated by 28 days
89450280|NCT01591473|Experimental|FluMist + Ampligen, Group 4|Nasal administration; dose group 4; FluMist + Poly I:Poly C12U 50 ug; 3 doses separated by 28 days
89450281|NCT01591473|Experimental|FluMist + Ampligen, Group 5|Nasal administration; dose group 5; FluMist + Poly I:Poly C12U 1250 ug; 3 doses separated by 28 days
89450282|NCT01591473|Experimental|FluMist + Placebo, Group 6|Nasal administration; dose group 6; FluMist + placebo; 3 doses separated by 28 days
88934986|NCT01774708||Bed Exit|"Participants will be up to 60 ambulatory Budd Terrace residents.~Inclusion/Exclusion:~Inclusion:~Ambulatory patient able to leave the bed.~Willingness to consent and participate in a 30-night study~Exclusion:~Lack of capacity to consent, without an identifiable surrogate.~Terminal Prognosis~Unstable health, as determined by the principal investigator, medical doctor, or registered nurse."
88934987|NCT01774734|Experimental|neck strength exerciser (NSE) group|Traditional physiotherapy 30 minutes per session for three times weekly + home-based NSE training 20 minutes daily
88934988|NCT01774734|Placebo Comparator|Physical therapy group|Traditional physiotherapy 30 minutes per session for three times weekly + home-based general neck exercise 20 minutes daily
89450283|NCT02265861|Experimental|Group 1|typical PCOS
89450284|NCT02265861|Experimental|Group 2|PCOS without PCO
89450285|NCT02265861|Experimental|Group 3|PCOS without HA
89450286|NCT02265861|Experimental|Group 4|Control
89450287|NCT02263755||chronic hepatitis B subjects|Subjects who have been diagnosed with chronic hepatitis B.
89450288|NCT01192035|Active Comparator|NNRTI|
88934989|NCT01774747|Experimental|DSP-1053|DSP-1053 10, 15, 20, 30, 45, 60, 90 mg once daily for 14 days
89450289|NCT01192035|Active Comparator|Protease inhibitor|
89450290|NCT02268747|Experimental|Dacomitinib|"Patients will assume Dacomitinib 30 mg daily for the first 2 weeks. If the highest skin toxicity will be of grade <2, then the patients will start dacomitinib at 45 mg once daily and they will be clinically assessed every cycle (i.e. every 28 days).~If the highest skin toxicity will be grade >2, then the patient will interrupt the treatment following the criteria for dose reduction."
89450291|NCT01590459|Placebo Comparator|Placebo Arm|
89450292|NCT01590459|Experimental|VX-509 100 mg qd Arm|
89450293|NCT01590459|Experimental|VX-509 150 mg qd Arm|
89450294|NCT01590459|Experimental|VX-509 100 mg bid Arm|
89450295|NCT01590459|Experimental|VX-509 200 mg qd Arm|
89450296|NCT01384383|Experimental|Arm 1|Response-Guided Therapy with GS-5885 30 mg plus GS-9451 200 mg, plus PEG and RBV for 6 or 12 weeks.
89450297|NCT01384383|Experimental|Arm 2|Response-Guided Therapy with PEG and RBV for 24 weeks.
89450298|NCT01557777|Experimental|Navitoclax, ABT-263|
89450299|NCT02268825|Experimental|MK-3475 treatment arm, all patients|
89450300|NCT01381731|Experimental|Diquafosol tetrasodium ophthalmic solution 2%|topical ophthalmic solution
89450301|NCT01381731|Placebo Comparator|Placebo|saline ophthalmic solution
89450302|NCT02268903|Active Comparator|Diuretics|
89450303|NCT02268903|Placebo Comparator|Placebo|
89450304|NCT01381107|Experimental|ALKS 5461 (ALKS 33 and buprenorphine)|
89450305|NCT01381107|Placebo Comparator|Placebo|
89450306|NCT02268981|Experimental|Oxymizer® compared to CNC|"From 7am to 7pm oxygen saturation is measured by a pulse oximeter. One day with conventional nasal cannula, one day with Oxymizer®, one day with Oxymizer® and reduced Oxygen flow (-1l/min). The order of these days is randomized in 6 groups.~The intervention will be performed on consecutive days and twice during study period."
89450307|NCT01370421||Knee OA patients undergoing Total Knee Arthroplasty (TKA)|Participants will be 45 years or older, diagnosed with Osteoarthritis of the knee and be scheduled for a unilateral total knee replacement surgery.
89450308|NCT02269059|Experimental|GT1 Participants|Participants take MK-7680 capsules by mouth once daily (QD) for 7 days. The starting dose will be 200 mg and the dose will be adjusted in successive panels of participants based on analysis of results of the previous panel.
89450309|NCT02269059|Experimental|GT3 Participants|Participants take MK-7680 capsules by mouth QD for 7 days. The starting dose will be 200 mg and the dose will be adjusted in successive panels of participants based on analysis of results of the previous panel.
89450310|NCT03135405|No Intervention|Usual care|
89450311|NCT03135405|Experimental|Intervention|
89450312|NCT01369095|Active Comparator|Arm 1: Duloxetine / Escitalopram + BMS-820836 placebo|
89450313|NCT01369095|Experimental|Arm 2: BMS-820836 (0.25 mg) + BMS-820836 placebo|
89450314|NCT01369095|Experimental|Arm 3: BMS-820836 (0.50 mg) + BMS-820836 placebo|
89450315|NCT01369095|Experimental|Arm 4: BMS-820836 (1.0 mg) + BMS-820836 placebo|
89450316|NCT01369095|Experimental|Arm 5: BMS-820836 (2.0 mg) + BMS-820836 placebo|
89450317|NCT03135561|Experimental|pedometer-plus-email|
89014813|NCT03904862|Experimental|Surgical|Subjects who are eligible for the Phase I or Phase II arm of the trial and are candidates for surgery, may be enrolled in the surgical arm prior to initiation of the Phase I or Phase II treatment.
89014814|NCT03889132||Premenopausal women with obesity|
89014815|NCT03889132||Postmenopausal women with obesity|
89450318|NCT03135561|Active Comparator|pedometer-only|
89014816|NCT03889132||Men with obesity|
89014817|NCT03889132||Premenopausal women without obesity|
89014818|NCT03889132||Postmenopausal women without obesity|
89014819|NCT03889132||Men without obesity|
89014820|NCT03873922|Experimental|Ketogenic diet intervention|Ketogenic meals will be offered for the participants during the trial.
89014821|NCT03873922|No Intervention|Control group|Conventional hospital meals as usual will be offered during the trial.
89014822|NCT03872154|Experimental|Intervention|"In this group (intervention), physicians will conduct checklist-guided shared decision making to determine the patient's code status. Additionally, physicians will be given a decision aid, which they are told to use to illustrate impact and outcome of in-hospital cardiac arrests.~Ancillary project (patients considered as futile): In this group (intervention), physicians will conduct checklist-guided communication."
89014823|NCT03872154|No Intervention|Usual Care|In this group (control), physicians will conduct code status discussions as usually.
89014824|NCT03828201|Experimental|Investigational: DRAMATIC-16 weeks|delamanid 300 mg orally, by mouth (PO) once a day (QD), 16 weeks levofloxacin 1000 mg PO QD, 16 weeks clofazimine 100 mg PO QD, 16 weeks bedaquiline 200 mg PO QD x 8 wk then 100 mg PO QD remainder linezolid 600 mg PO QD, Initial 16 weeks only
89450319|NCT02269215|Experimental|BIII 890 CL single rising dose|
89450320|NCT02269215|Placebo Comparator|Placebo|
89450321|NCT02266095|Active Comparator|Oval-8 Splint|"Patients will be asked to wear their assigned splint 24 hours per day with removal for hygiene care. Follow-up appointments will occur at week 4 and 12. Each visit will include a clinical examination, splint assessment for continued appropriate fit and evaluation of skin for irritation or breakdown.~Standard non-operative therapy includes activity modification, therapy, NSAIDS, splinting (thumb spica or Tee-Pee). Oval-8 splints are not commonly used for treatment of thumb CMC arthritis.~Procedures will be undertaken to minimize patient discomfort. Participants will be instructed to continue with range of motion exercises to 2-5th digits and elbow to try to avoid stiffness."
89531358|NCT05040867|Experimental|Traditional periodization exercise group (TEG)|Participants will participate in a physical exercise program with a preplanned intensity progression.
89014825|NCT03828201|Experimental|Investigational: DRAMATIC-24 weeks|delamanid 300 mg orally, by mouth (PO) once a day (QD), 24 weeks levofloxacin 1000 mg PO QD, 24 weeks clofazimine 100 mg PO QD, 24 weeks bedaquiline 200 mg PO QD x 8 wk then 100 mg PO QD remainder linezolid 600 mg PO QD, Initial 16 weeks only
89014826|NCT03828201|Experimental|Investigational: DRAMATIC-32 weeks|delamanid 300 mg orally, by mouth (PO) once a day (QD), 32 weeks levofloxacin 1000 mg PO QD, 32 weeks clofazimine 100 mg PO QD, 32 weeks bedaquiline 200 mg PO QD x 8 wk then 100 mg PO QD remainder linezolid 600 mg PO QD, Initial 16 weeks only
89014827|NCT03828201|Experimental|Investigational: DRAMATIC-40 weeks|delamanid 300 mg orally, by mouth (PO) once a day (QD), 40 weeks levofloxacin 1000 mg PO QD, 40 weeks clofazimine 100 mg PO QD, 40 weeks bedaquiline 200 mg PO QD x 8 wk then 100 mg PO QD remainder linezolid 600 mg PO QD, Initial 16 weeks only
89014828|NCT03795194|Other|8-day|8-day course of ampicillin clavulanate antibiotic
89014829|NCT03795194|Other|4-day|4--day course of ampicillin clavulanate antibiotic
88934990|NCT01774747|Placebo Comparator|Placebo|Placebo 10, 15, 20, 30, 45, 60, 90 mg once daily for 14 days
88934991|NCT01774773|Experimental|Group A|E5501 5mg, then 20mg, then 40 mg, then 5mg
88934992|NCT01774773|Experimental|Group B|E5501 20mg, then 40mg, then 5 mg, then 5mg
88934993|NCT01774773|Experimental|Group C|E5501 40mg, then 5mg, then 20 mg, then 5mg
88934994|NCT01774812|Active Comparator|Vitamin D Sequence 1|6 weeks - alfacalcidol 0.25mcg + placebo 3x per week, 12 week washout, 6 weeks - alfacalcidol 0.25mcg 3x per week + 50,000IU ergocalciferol 1x per week (placebo the 2 remaining days)
88934995|NCT01774812|Active Comparator|Vitamin D Treatment Sequence 2|6 weeks - alfacalcidol 0.25mcg 3x per week + 50,000IU ergocalciferol 1x per week (placebo the 2 remaining days), 12 week washout, 6 weeks - alfacalcidol 0.25mcg + placebo 3x per week
88934996|NCT01774825|Active Comparator|IQP-CL-101|2 softgels twice a day
88934997|NCT01774825|Placebo Comparator|Placebo|2 softgels twice a day
88934998|NCT01774838|Experimental|Prasugrel|3 months treatment with 10 mg prasugrel
88934999|NCT01774838|Active Comparator|Clopidogrel|3 months treatment with clopidogrel 75 mg
88935000|NCT01774864|Experimental|DA-8159 dose 1|Udenafil
88935001|NCT01774864|Experimental|DA-8159 dose 2|Udenafil
88935002|NCT01774864|Placebo Comparator|Placebo|
88935003|NCT01774877|Experimental|Xinfeng capsule & placebo|"Xinfeng capsule:Three each time, 3 times a day, Oral,for 3 months~placebo(for leflunomide): 10 mg each time, 1 time a day, Oral,for3 months"
88935004|NCT01774877|Active Comparator|leflunomide & placebo|"leflunomide :10mg each time, one time a day, by mouth,for 3 months~placebo(for xinfeng capsule):Three each time, 3 times a day, Oral,for3 months"
88935005|NCT01774916|Other|patients|
88935006|NCT01774916|Other|volunter|
88935007|NCT01774942|Experimental|Procedure/Surgery (Impants/Overdentures)|One-arm clinical intervention study: All teeth out, full dentures, dental implants, blood draw. The interventions are not experimental in nature, they are standard procedures, namely extraction of all natural teeth followed by suturing to hold soft tissue in place during initial healing; surgical insertion of commercially available dental implants; and fabrication and re-lining (filling in with acrylic the base of the denture as needed during healing and shrinking of underlying tissue) of full dentures, that is full plates in upper and lower jaw to replace all teeth.
88935008|NCT01774994|Experimental|stable isotopes|stable isotope infusion for measurement of metabolism
88935009|NCT01775020|Experimental|L-arginine|L-arginine
88935010|NCT01775033|Experimental|Multicomponent intervention|Hospitals in the experimental arm will receive a four-component intervention that integrates local education, community outreach, telemedicine and protocolized triage and transport
89014830|NCT03763396|Experimental|Ketoconazole (KCZ) Single Dose Group|Single dose 400mg oral tablets 4-24 hours prior to surgery
88935011|NCT01775033|No Intervention|Control|Hospitals in the control arm will receive usual care.
88935012|NCT01775059|Experimental|Integrated sensor and infusion set.|
88935013|NCT01775098|Experimental|Allopurinol|treatment with allopurinol
88935014|NCT01775098|Placebo Comparator|placebo|placebo comparator
88935015|NCT01775111|Sham Comparator|Cognitive Training|Cognitive Training (riddles, skill games, ...) is performed twice a week in small groups
88935016|NCT01775111|Experimental|Strength Training|Progressive strength training is applied, meaning that the intensity is adjusted continuously in order to obtain a sufficient training stimulus. Exercises are chosen to involve the major muscle groups and are performed by using the own body weight or elastic bands.
88935017|NCT01775111|Experimental|Strength Training and Supplement|In addition to strength training as described above, participants receive a water-soluble dietary supplement 9x/week (FortiFit, Nutricia) consisting of 20.7 g of protein (56 En%, 19.7 g whey protein, 3 g leucine,> 10 g essential amino acids), 9.3 g carbohydrates (25 En%, 0.8 BE), 3.0 g fat (18 En%), 1.2 g fiber (2 En%), 800 IU (20μg) of vitamin D, 250mg calcium, vitamins B6 and B12, folic acid and magnesium.
88935018|NCT01775150|Experimental|health education|health education via text messaging
88935019|NCT01775150|No Intervention|no health education|no health education via text messaging
88935020|NCT01775163||Self Directed Exercise|Participants randomized to the self-directed group will receive information on physical activity recommendations and guidelines on nutrition aimed at promoting weight loss. Participants will not be given a specific exercise recommendation in terms of weekly energy expenditure.
89014831|NCT03763396|Experimental|Ketoconazole (KCZ) Repeated Dose Group|400mg oral tablets twice a day (BID) for 2-5 days prior to surgery
89014832|NCT03763396|Experimental|Posaconazole (PCZ) Single Dose group|Single dose 300 mg delayed release oral tablets 4-24 hours prior to surgery
89014833|NCT03763396|Experimental|Posaconazole (PCZ) Repeated Dose group|300 mg delayed release oral tablets twice a day (BID) for day 1; every day thereafter is a single dose of 300 mg delayed release oral tablets. Total treatment time is 7-10 days prior to surgery.
89450322|NCT02266095|Active Comparator|Tee Pee Splint|"Patients will be asked to wear their assigned splint 24 hours per day with removal for hygiene care. Follow-up appointments will occur at week 4 and 12. Each visit will include a clinical examination, splint assessment for continued appropriate fit and evaluation of skin for irritation or breakdown.~Standard non-operative therapy includes activity modification, therapy, NSAIDS, splinting (thumb spica or Tee-Pee).~Procedures will be undertaken to minimize patient discomfort. Participants will be instructed to continue with range of motion exercises to 2-5th digits and elbow to try to avoid stiffness."
89450323|NCT02266095|Active Comparator|Forearm Based Splint|"Patients will be asked to wear their assigned splint 24 hours per day with removal for hygiene care. Follow-up appointments will occur at week 4 and 12. Each visit will include a clinical examination, splint assessment for continued appropriate fit and evaluation of skin for irritation or breakdown.~Standard non-operative therapy includes activity modification, therapy, NSAIDS, splinting (thumb spica or Tee-Pee).~Procedures will be undertaken to minimize patient discomfort. Participants will be instructed to continue with range of motion exercises to 2-5th digits and elbow to try to avoid stiffness."
89450324|NCT02266173||Pertuzumab|Participants for whom the treating physician has decided to administer pertuzumab according to standard of care and in line with the current summary of product characteristics (SmPC)/local labeling, will be observed.
89450325|NCT01168713|Active Comparator|Levofloxacin|
89450326|NCT01168713|Experimental|CEM-101|
89450327|NCT02269293|Experimental|Regimen 1|Paclitaxel 175 mg/m^2 IV, Day 1 (administered over approximately 3 hours) Carboplatin AUC 5 IV, Day 1 (administered over approximately 30 minutes) Selinexor (to be taken orally once daily on days 1, 4, 8, 11, 15, and 18 of each chemotherapy cycle) The selinexor tablet should not be crushed and/or chewed.
89450328|NCT02269293|Experimental|Regimen 2|Paclitaxel 80 mg/m^2 IV, Days 1, 8, 15 (administered over approximately 1 hour) Carboplatin AUC 5 IV, Day 1 (administered over approximately 30 minutes) Selinexor orally (to be taken orally once daily on days 1, 4, 8, 11, 15, and 18 of each chemotherapy cycle) The selinexor tablet should not be crushed and/or chewed.
89450329|NCT02269293|Experimental|Regimen 3|Paclitaxel 80 mg/m^2 IV, Days 1, 8, 15 (administered over approximately 1 hour) Carboplatin AUC 5 IV, Day 1 (administered over approximately 30 minutes) Selinexor orally (to be taken orally once weekly on days 1, 8, and 15 of each chemotherapy cycle) The selinexor tablet should not be crushed and/or chewed.
88935021|NCT01775163||Low Intensity Exercise|Individuals assigned to the low dose exercise group will be required to expend 8 calories per kg of body weight per week in structured aerobic exercise on a treadmill or stationary bicycle. The exercise intensity will be maintained at 65% of VO2peak. The caloric goal of each session will be calculated by dividing the weekly caloric expenditure goal by participant selected exercise frequency (i.e., 3, 4 or 5 times per week). The training program consists of a 3-min warm-up at a progressively increasing intensity until the prescribed training intensity is reached. All exercise sessions are conducted at the PBRC Fitness Center and will be supervised by staff trained on the aspects of the study protocol.
88935022|NCT01775163||High Intensity Exercise|Individuals assigned to the low dose exercise group will be required to expend 20 calories per kg of body weight per week in structured aerobic exercise on a treadmill or stationary bicycle. The exercise intensity will be maintained at 65% of VO2peak. The caloric goal of each session will be calculated by dividing the weekly caloric expenditure goal by participant selected exercise frequency (i.e., 3, 4 or 5 times per week). The training program consists of a 3-min warm-up at a progressively increasing intensity until the prescribed training intensity is reached. All exercise sessions are conducted at the PBRC Fitness Center and will be supervised by staff trained on the aspects of the study protocol.
89014834|NCT03756896|Experimental|Carfilzomib, pomalidomide, dexamethasone|Patients receive carfilzomib IV over 30 minutes on days 1, 8, and 15, pomalidomide PO daily on days 1-21, and dexamethasone PO daily on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89450330|NCT02269293|Experimental|Regimen 4|Paclitaxel and carboplatin will be delivered intravenously (IV) on day 1 of each cycle. Selinexor will be taken orally once a week on days 1, 8 and 15 of each chemotherapy cycle.
89200790|NCT04007302|Active Comparator|Walking without distraction|the patient walks on a treadmill without virtual reality simulation
88935023|NCT01775176||Polycystic Ovary Syndrome|Overweight women with polycystic ovary syndrome. 20 - 40 years, inclusiveBody mass index ≥ 25kg/m2History of irregular menstrual cycles (fewer than 8 regular cycles in the past year)Clinical and/or biochemical androgen excess (Free androgen index>3.85 and/or hirsuitism rating ≥8)Anovulatory menstrual cycles (determined during screening)
88935024|NCT01775215||A - Symptomatic severe AS|Patients with symptomatic severe aortic stenosis (AS) as per ESC guidelines, requiring aortic valve replacement.
88935025|NCT01775215||B - Asymptomatic moderate to severe AS|Asymptomatic patients with moderate to severe aortic stenosis (AS) as per ESC guidelines ,with Left Ventricular ejection fraction >50%, not yet requiring aortic valve replacement.
88935026|NCT01775228|No Intervention|Regular follow up care|No intervention group - received routine follow up care following discharge from hospital after cardiac surgery (no peer support intervention).
88935027|NCT01775228|Active Comparator|Peer Support intervention|Support (informational, emotional and appraisal) in the form of like persons (i.e. age, gender) who have undergone CABG surgery with successful outcomes (post-recovery at least one year); peer support was provided by telephone for 6 weeks post cardiac surgery recovery.
88935028|NCT01775254||Chemotherapy Group|Colon cancer survivors who undergo open or laparoscopic resection of their colon cancers followed by adjuvant chemotherapy.
88935029|NCT01775254||No Chemotherapy Group|Colon cancer survivors who undergo open or laparoscopic resection of their colon cancer and who do not receive chemotherapy.
89200791|NCT00901797|Active Comparator|Arthroscopic Bankart repair|
89200792|NCT00901797|Active Comparator|ABR+ARIC|
89200793|NCT02539641|Other|Good responder RYGB|Good responders after Roux-en-Y gastric bypass (RYGB). EWL > 50%. Interventions: Gastric emptying scintigraphy and Determination of gut hormones.
89450331|NCT01545453|Experimental|lebrikizumab - highest dose|
89450332|NCT01545453|Experimental|lebrikizumab - lowest dose|
89450333|NCT01545453|Experimental|lebrikizumab - middle dose|
89450334|NCT01545453|Placebo Comparator|placebo|
89450335|NCT04476303|Experimental|SAD (#6 Cohort)|Drug: BEY2153 or placebo subjects will receive single ascending dose of BEY2153 or placebo once.
89450336|NCT04476303|Experimental|SAD (#1 Cohort) - Food effect evaluation|Drug: BEY2153 or placebo subjects will receive single ascending dose of BEY2153 or placebo for two periods at 7 days interval, with both fasting and after high fat meal.
89450337|NCT04476303|Experimental|MAD (#4 Cohort)|Drug: BEY2153 or placebo subjects will receive multiple ascending dose of BEY2153 or placebo for 7 days.
88935030|NCT01775267|Experimental|ALPPS|Patients undergo Liver partition and portal vein ligation to induce hypertrophy of the future liver remnant
89450338|NCT04476381|Experimental|Dry needling of a trigger point in the infraspinatus muscle|Insertion a a acupuncture type needle into a trigger point in the infraspinatus muscle on the painful side to decrease the stiffness and tone and increase the elasticity
88935031|NCT01775267|Active Comparator|PVO|Patient undergo portal vein embolization or ligation
88935032|NCT01775280|Experimental|Radioembolization|Radioembolization using Yttrium-90 microspheres using a transarterial approach
88935033|NCT01775293|Experimental|Non-absorbable polypropylene mesh|"2 step procedures~first step is insertion of Non-absorbable polypropylene mesh under the facial skin~second step is pulling of Non-absorbable polypropylene mesh after 3 weeks of 1 step"
88935034|NCT01775319|Active Comparator|Biofortified wheat|Biofortified wheat
88935035|NCT01775319|Placebo Comparator|Control wheat|Control wheat with low level of Zn
88935036|NCT01775319|Active Comparator|Fortified wheat|Wheat fortified before consumption
88935037|NCT01775332|Experimental|Educational Intervention|Educational Intervention - Access to educational materials provided (i.e. website, videos, brochure)
88935038|NCT01775332|No Intervention|No Intervention/Use of Own Resources|No educational materials are provided to participants, but they can use their own resources
88935039|NCT01775345|Experimental|Isotonic exercises + ST|"This group will realize 20 sessions of muscular force work by means of isotonic exercises, that to the beginning will consist of 2 series of 10 repetitions to 60, 65 and 70 % of a maximum repetition (MR)(MR is the maximum resistance that a muscle can conquer).~Later, a gradual progression will be realized and the load will be increasing up to being able to realize, before the session 30: 2 series of 15 repetitions to 60, 65 and 70 %, of 1MR, 2 series of 10 repetitions to 75 and 80 % of 1MR and one series of 6 repetitions to 85 and 90 % of 1MR."
88935040|NCT01775345|Experimental|Isokinetic exercises + ST|This group will realize 20 sessions of muscular force work by means of isokinetic exercises, that to the beginning will consist of 2 series of 10 repetitions to 150, 180 and 210 º / seg in the first session and it will be increasing in a progressive and gradual way up to being able to realize, before the last session: 3 series of 15 repetitions to 180 º, 210 º and 240 º / seg, 2 series of 10 repetitions to 120 º and 150 º / seg and 2 series of 6 repetitions of 60 º and 90 º / seg.
88935041|NCT01775345|Experimental|Isotonic and isokinetic exercises + ST|This group will realize 20 sessions of muscular force work by means of isotonic and isokinetic exercises. To the beginning it will consist of 1 series of 10 repetitions to 150, 180 and 210 º / seg and 1 series of 10 repetitions to 60, 65 and 70 % of 1MR. A gradual progression will be realized up to reaching, before the last session, a load of: 2 series of 15 repetitions to 180, 210 and 240 º / seg, 1 series from 10 to 120 and 150 º / seg and 1 series of 6 repetitions to 60 and 90 º / seg, and 1 series of 15 repetitions to 60, 65 and 70 %, of 1MR, 1 series of 10 repetitions to 75 and 80 % of 1MR and 1 series of 3 repetitions to 85 and 90 % of 1MR.
88935042|NCT01775358|Experimental|ALRN-5281 0.015 mg/kg|Dosage-0.015 mg/kg
88935043|NCT01775358|Experimental|ALRN-5281 0.05 mg/kg|Dosage- 0.05 mg/kg
88935044|NCT01775358|Experimental|ALRN-5281 0.15 mg/kg|Dosage- 0.15 mg/kg
89450339|NCT01161615|Placebo Comparator|Placebo|Therapy with placebo
89450340|NCT01161615|Experimental|MRX-7EAT|Therapy with experimental drug
89450341|NCT01366131|Experimental|A|
89450342|NCT01366131|Experimental|B|
89450343|NCT01365195|Placebo Comparator|Control|"Loading and Infusion:~Saline at infusion rate calculated and adjusted for weight to match ketamine bolus-infusion rate"
89450344|NCT01365195|Active Comparator|Ketamine low-dose|Loading: 0.5 mg/Kg Infusion: 5 mcg/kg/min
88935045|NCT01775358|Placebo Comparator|Placebo 0.015 mg/kg|Dosage- 0.015 mg/kg
88935046|NCT01775358|Placebo Comparator|Placebo 0.05 mg/kg|Dosage- 0.05 mg/kg
88935047|NCT01775358|Placebo Comparator|Placebo 0.15 mg/kg|Dosage - 0.15 mg/kg
88935048|NCT01775384|Experimental|Nutrasorb|Soy protein powder sorbed with polyphenols from blueberries and green tea extract
88935049|NCT01775384|Placebo Comparator|Placebo|Soy protein isolate powder without polyphenols (with food coloring)
88935050|NCT01775397|Experimental|Fidaxomicin|Fidaxomicin with alternating matching placebo
88935051|NCT01775397|Active Comparator|Vancomycin|Participants received 4 doses (1 dose every 6 hours) of oral vancomycin hydrochloride each day for the duration of the 10-day treatment period
88935052|NCT01775436|Active Comparator|Healthy Living Control|"Two-60 to 90 minute sessions scheduled one week apart.~Session 1: Developmental History: Goal: To take a non-medical developmental history. The Research Assistant (RA)-Control will conduct the session in a structured interview format. Administered with all medical questions removed to prevent any risk of contamination with the experimental condition.~Session 2: Nutrition and Exercise: Assess nutritional status and provide advice for maintaining optimal nutrition to boost immune functioning. Administered by the RA Control and will be videotaped to control for what occurs in the FACE intervention."
88935053|NCT01775436|Experimental|FAmily-CEntered Advance Care Planning|"Two-60 to 90 minute sessions scheduled one week apart.~Session 1: Respecting Choices Interview (R)to facilitate conversations and shared decision-making between the patient and surrogate about palliative care & prepare the surrogate to be able to fully represent the patient's wishes.~Session 2: Five Wishes (C). Patient selects which person the patient wants to make health care decisions for him/her; the kind of medical treatment the patient wants; how comfortable the patient wants to be; how the patient wants people to treat him/her; what patient wants loved ones to know; and any spiritual or religious concerns the patient may have."
89450345|NCT01365195|Active Comparator|Ketamine high-dose|Loading: 1 mg/Kg Infusion: 10 mcg/kg/min
89450346|NCT02269371|Experimental|Group 1|Group 1: Standard of care weight loss intervention plus auricular acupuncture at Shen Men, Point Zero, and Appetite Control Point/Hunger Point in each ear.
89450347|NCT02269371|Sham Comparator|Group 2|Group 2: Standard of care weight loss intervention plus sham acupuncture at three nonacupoints in each ear.
89450348|NCT02269449|Experimental|6Fr Glidesheath Slender sheath|TRI will be performed using a new 6Fr sheath (Glidesheath slender: GSS).
89450349|NCT02269449|Active Comparator|5Fr contemporary sheath|TRI will be performed using a contemporary safety of 5Fr sheath.
89450350|NCT02269449|Experimental|Hemostasis with TR band|Hemostasis is achieved by randomization of using TR band (TERUMO) Patent hemostasis.
89450351|NCT02269449|Active Comparator|Any hemostasis procedure|Hemostasis is achieved by randomization of any hemostasis of each hospital's routine procedure.
89450352|NCT02266251||Surgical AVR|No interventions will be administered. Retrospective data analysis will be completed to compare health outcomes among patients with a similar baseline health satus who are eligible for both procedures (operative transcatheter AVR patients enrolled in the Transcatheter Valve Therapies (TVT) Registry (Nov 2011-Dec 2013) and surgical AVR patients with STS perioperative risk of mortality whose index procedure is included in the STS Adult Cardiac Surgical DAtabase (ACSD) (Jan 2011-Dec 2013).
88935054|NCT01775449|Experimental|polyamines depleted diet|• in the group with a polyamines depleted diet : 2-4 cans per day of Polydol® (oral alimentation without polyamines), associated to predefined menus low in polyamines, according to the chemotherapy cycle and for 107 days
88935055|NCT01775449|Other|normal polyamines containing diet|• in the control group with a normal polyamines containing diet: 1 can per day of Polydol® associated with predefined menus with normal average in polyamines and for 107 days.
88935056|NCT01775462|Experimental|EDI200, 3mg/kg|Five doses of EDI200 given at 3 mg/kg twice weekly
88935057|NCT01775462|Experimental|EDI200, 10 mg/kg|Five doses of EDI200 given at 10 mg/kg twice weekly
88935058|NCT01775488|Experimental|Vortx Rx - Histotripsy BPH Device|The Vortx Rx, is a portable ultrasound therapy device system that is intended for the treatment of BPH by using very intense, low duty-cycle ultrasound pulses to debulk prostatic tissue.
88935059|NCT01775514||Participants With Cancer|Participants from Turkey with non-small cell lung, colon cancer, breast cancer, gastric cancer and malignant melanoma will be included.
88935060|NCT01775527|Other|blood test|
88935061|NCT01775540|Experimental|Systane Ultra|Artificial tear Eyedrop, 1 drop used four times a day (QID) for 4 weeks
88935062|NCT01775540|Placebo Comparator|Saline solution|Saline solution Eyedrop, 1 drop used QID for 4 weeks
88935063|NCT01775540|Active Comparator|Maxidex|Steroid eyedrop, 1 drop QID for 4 weeks
88935064|NCT01775566||Eperisone SR tablet 75mg, Myonal 50mg|Eperisone SR tablet 75mg Myonal 50mg
88935065|NCT01775579|Experimental|Crestor tablet 20 mg|Crestor tablet 20 mg single--->wash out---->Glucophage SR tablet 750 mg single---->washout--->Glucophage SR tablet 750 mg, Crestor tablet 20 mg both
88935066|NCT01775579|Experimental|Glucophage SR tablet 750 mg and Crestor tablet 20 mg both|Glucophage SR tablet 750 mg, Crestor tablet 20 mg both--->wash out---->Glucophage SR tablet 750 mg single------>washout--->Crestor tablet 20 mg single
88935067|NCT01775579|Experimental|Glucophage SR tablet 750 mg|Glucophage SR tablet 750 mg single --->wash out---->Crestor tablet 20 mg single---->washout--->Glucophage SR tablet 750 mg, Crestor tablet 20 mg both
88935068|NCT01775592|Other|Arterakin|"Number of DHA- PPQ (Arterakin™) tablets per day at 0hour, 8hours, 24hours, 48hours (according to age): 2 - 3 years:0.5, 0.5, 0.5, 0.5 3 - < 8 years: 1.0, 1.0, 1.0, 1.0 8 - < 15 years:1.5, 1.5, 1.5, 1.5~≥ 15 years:2.0, 2.0, 2.0, 2.0"
88935069|NCT01775605|Active Comparator|Synera|Synera Pain Patch
88935070|NCT01775605|No Intervention|No patch control|No intervention group
88935071|NCT01775605|Sham Comparator|Control|Sham
88935072|NCT01775618|Experimental|Main study|Participants were treated and prophylaxis administered with BAY94-9027 at a dose of 25-60 international units/kilogram (IU/kg) twice per week or 45-60 IU/kg every 5 days or 60 IU/kg every 7 days as an intravenous (IV) infusion as per clinical needs of each subject up to at least 50 exposure days (EDs) and a minimum of at least 6 months.
88935073|NCT01775618|Experimental|Part 2 (Expansion group)|Participants were administered with BAY94-9027 at a dose of 25-60 IU/kg twice per week for prophylaxis for 12 weeks.
88935074|NCT01775618|Experimental|Extension study|Participants were treated and prophylaxis administered with BAY94-9027 at a dose of 25- 60 IU/kg twice per week or 45-60 IU/kg every 5 days or 60 IU/kg every 7 days as an IV infusion as per clinical needs of each subject for at least 50 EDs or until marketing authorization of the drug.
88935075|NCT01775631|Experimental|Arm -1 - Urelumab + Rituximab|"Urelumab (BMS-663513) flat dose intravenous infusion on specified days~Rituximab intravenous flat dose infusion on specified days"
88935076|NCT01775631|Experimental|Arm 1 - Urelumab + Rituximab|"Urelumab (BMS-663513) flat dose intravenous infusion on specified days~Rituximab intravenous flat dose infusion on specified days"
88935077|NCT01775683||Group A - chronically homeless|Men and women, greater than or equal to age 18 years, English-speaking, who are currently homeless and/or housed in an emergency shelter or housing facility for chronically homeless individuals ≥ 6 months.
88935078|NCT01775683||Group B - control/formerly homeless|Men and women, greater than or equal to 18 years, English-speaking who are not homeless ≥4 times in the last 3 years and currently living in stable housing ≥ 6 months and in the last 3 years, has been homeless ≤ 1 month
88935079|NCT01775696||sporadic AD|80 sporadic AD patients (40 at the stage of MCI, 40 at the stage of mild or moderate dementia)
88935080|NCT01775696||familial forms of AD|15 familial forms of AD caused by APP, PSEN1 or PSEN2 mutations
88935081|NCT01775696||asymptomatic relatives|30 asymptomatic relatives to familial AD patients
88935082|NCT01775696||controls|40 controls
88935083|NCT01775696||genetic FTD|5 genetic forms of FTD
88935084|NCT01775748|Other|Active First|Active Concord Grape Juice 12 oz per day Placebo Grape Juice 12 oz per day
88935085|NCT01775748|Other|Placebo First|Placebo Grape Juice 12 oz per day Active Concord Grape Juice 12 oz per day
88935086|NCT01775761|Experimental|Period 1: 960 mg tafamidis (Vyndaqel)|
88935087|NCT01775761|Experimental|Period 2: 400 mg moxifloxacin|400 mg moxifloxacin
89450353|NCT02266251||Transcatheter AVR|No interventions will be administered. Retrospective data analysis will be completed to compare health outcomes among patients with a similar baseline health satus who are eligible for both procedures (operative transcatheter AVR patients enrolled in the TVT Registry (Nov 2011-Dec 2013) and surgical AVR patients with STS perioperative risk of mortality whose index procedure is included in the STS ACSD (Jan 2011-Dec 2013).
89450354|NCT01359969|Experimental|Recombinant Human C1 Inhibitor|Patients presented to the clinic within 5 hours of onset received rhC1INH 50 U/kg body weight up to a maximum of 4200 U.
89450355|NCT01160601|Experimental|paclitaxel/carboplatin plus bavituximab|Patients will receive paclitaxel (200 mg/m2) and carboplatin (target area under the concentration-time curve [AUC] 6) on Day 1 of each 21 day cycle for up to 6 cycles, in combination with 3 mg/kg bavituximab administered weekly.
89450356|NCT01160601|Active Comparator|paclitaxel/carboplatin|Patients will receive paclitaxel (200 mg/m2) and carboplatin (target area under the concentration-time curve [AUC] 6) on Day 1 of each 21 day cycle for up to 6 cycles.
88935088|NCT01775761|Experimental|Period 3: Placebo|
88935089|NCT01775826|Other|All Purposes|All participants.
88935090|NCT01775839|Experimental|Aspirin+Clopidogrel/Digoxin(oral)|Aspirin: Day 1 ~ Day 59(~65; till the EGC) Clopidogrel: Day -3, 26, 54 Digoxin: Day -2, 27, 55
88935091|NCT01775839|Experimental|Aspirin+Clopidogrel/Digoxin(IV)|Aspirin: Day 1 ~ Day 59(~65; till the EGC) Clopidogrel: Day -3, 26, 54 Digoxin: Day -2, 27, 55
88935092|NCT01775878|No Intervention|Usual Care|This arm received usual care from the diabetes care managers
88935093|NCT01775878|Experimental|Telemonitoring Device|Patients in this arm received a telemonitoring device installed in their homes
88935094|NCT01775891|Active Comparator|pilsicainide|The dose of pilsicainide will be 50mg tid PO. Pilsicainide will be started on the night of the ablation for a duration of at least 3 months. Physicians were encouraged to stop the drugs following the 3 months treatment if possible.
88935095|NCT01775891|Placebo Comparator|other class IC antiarrhythmic drug|Other class IC antiarrhythmic drug that they had been taking before catheter ablation will be administrated.(flecainide 100mg bid PO or propafenone 225mg tid) Antiarrhythmic drug will be started on the night of the ablation for a duration of at least 3 months. Physicians were encouraged to stop the drugs following the 3 months treatment if possible.
88935096|NCT01775969|No Intervention|Standard of Care|Written discharge instructions only
88935097|NCT01775969|Experimental|Text Message|Written discharge instructions plus a text message with antibiotic prescription instructions
88935098|NCT01775969|Experimental|Voicemail|Written discharge instructions plus a voicemail with antibiotic prescription instructions
88935099|NCT01775982||Study population|"See inclusion and exclusion criteria.~Intervention: Psychiatric evaluation Intervention: Geriatric evaluation~A potential intervention order effect will be taken into account by balancing in each center the number of evaluations beginning with the geriatric assessment and those starting with the psychiatric assessment."
88935100|NCT01776021|Active Comparator|cranberry juice|cranberry juice beverage at a dose of one 8 oz. beverage per day for six months
88935101|NCT01776021|Placebo Comparator|Placebo|placebo beverage at a dose of one 8 oz. beverage per day for six months
88935102|NCT01776047|Active Comparator|Exforge® 10/160 (Amlodipine besylate 10mg / Valsartan 160mg)|Exforge® 10/160
88935103|NCT01776047|Experimental|G-0081 (Amlodipine orotate 10mg / Valsratan 160mg)|G-0081
88935104|NCT01776073|Experimental|Patient navigation|In addition to receiving the standard of care, these patients will be connected with a patient navigator who will provide personalized assistance with regard to completion of the pre-waitlisting process
88935105|NCT01776073|No Intervention|Standard of Care|These patients will receive the standard of care, which includes assistance from the current Emory Transplant Center team of social workers, physicians, and other support staff with regard to completion of the pre-waitlisting process
88935106|NCT01776086|Other|Normal patients|for patients with normal score on neurological testing with Folstein Mini-Mental Status Exam will then take the Scenes Task
88935107|NCT01776099|Active Comparator|pure galactose|5 grams of galactose, three times a day with the main meals, duration: 4 weeks
88935108|NCT01776099|Placebo Comparator|pure palatinose|5 grams of palatinose, three times a day with the main meals, duration: 4 weeks
88935109|NCT01776099|Placebo Comparator|soluble non-fermentable fibers|5 grams of soluble non-fermentable fibers, three times a day with the main meals, duration: 4 weeks
88935110|NCT01776099|Active Comparator|non-soluble non-fermentable fibers|5 grams of non-soluble non-fermentable fibers, three times a day with each main meal, duration: 4 weeks
89450357|NCT01529853|Experimental|SAR156597 dose 1|SAR156597 dose 1, subcutaneous injection once every week
89450358|NCT01529853|Experimental|SAR156597 dose 2|SAR156597 dose 2, subcutaneous injection once every week
88935111|NCT01776112|Experimental|SZ-Exercise|Standard treatment and participation in the sports program (cycling) including cognitive training, 3 sessions cycling (30 min. each) per week for 3 months and 2 sessions Cogpack per week for the last 6 weeks.
89014835|NCT03741023|Other|Trauma Patients|"During Hospitalization:~Patients routinely have blood drawn at time of admission and every 12 hours following admission up until 2 weeks post-admission or until discharge. Remnants of the blood draw will be stored in the Vanderbilt Lab core and retrieved for further analysis by key research personnel. Patients will have an additional 5.2ml of blood drawn (2 blue-top tubes) per time point during their normal course of care for this study, for a total of 72.8 mL of blood drawn per week. In addition to the routine blood draws, a finger stick may also be obtained the same day. Approximately 3 drops of blood (100μL maximum) will be removed by the finger stick.. Finger sticks will not be collected in the pediatric population.~Follow-Up Visits Any complications resulting from traumatic injury will be documented at these routine care visits. These complications will be documented if they occur within 2 years of injury."
89014836|NCT03741023|Other|Invasive Elective Surgery Patients|"During Hospitalization:~Patients routinely have blood drawn pre-, intra- and post-operatively. Remnants of the blood draw will be stored in the Vanderbilt Lab core and retrieved for further analysis by key research personnel. Patients will have an additional 5.2ml of blood drawn (for patients 7 years of age or older) or 2mL of blood drawn (for patients under the age of 7 years old) immediately prior to surgery, every 30 minutes intraoperatively, every 6 hours for 3 days post-operatively, and every 12 hours from 3 days post-operative until discharge. Total blood volume drawn within one week will not exceed 150mL for patients ≥7 years of age and 55mL for patients <7 years of age (~3% total blood volume).~Follow-Up Visits Any complications resulting from surgery will be documented at these routine care visits. These complications will be documented if they occur within 2 years of surgery."
89014837|NCT03741023|Other|Healthy Volunteers|Blood will be taken from healthy, non-pregnant adults who weigh at least 110 pounds by research staff trained in venipuncture at a one-time study visit.
89014838|NCT03730636|Experimental|PCT-guided strategy|Measurement of PCT concentration will be performed every two days and the ATB therapy will be stopped when PCT level reaches a value equal or below 0.5ng/mL.
89450359|NCT01529853|Experimental|SAR156597 dose 3|SAR156597 dose 3, subcutaneous injection once every week
89450360|NCT01529853|Placebo Comparator|Placebo|Placebo (for SAR156597), subcutaneous injection once every week
89450361|NCT01357395|Experimental|Amuvatinib|Amuvatinib 300 mg PO TID + standard-of-care platinum-etoposide
89450362|NCT02269605|Placebo Comparator|Group 1|Patients receiving placebo (sodium chloride) at single dose
89450363|NCT02269605|Active Comparator|Group 2|Patients receiving Bryostatin 1 (10ug/m2) at single dose
89450364|NCT02269605|Active Comparator|Group 3|Patients receiving Bryostatin 1 (20ug/m2) at single dose
89450365|NCT02269683|Experimental|Robot-assisted|Distal pancreatectomy via robot-assisted minimally-invasive approach
89450366|NCT02269683|Active Comparator|Laparoscopic|Distal pancreatectomy via a conventional laparoscopic approach
89450367|NCT01356849|Placebo Comparator|Group A - Placebo QD|
89450368|NCT01356849|Active Comparator|Group B - Low dose Atrasentan QD|
89450369|NCT01356849|Active Comparator|Group C - High dose Atrasentan QD|
89450370|NCT02266407|Active Comparator|ASEPTIC Revision TKA & Aquamantys System|Single-stage revision TKA cases performed for aseptic failure requiring an extended osteotomy for component removal and intra-operative blood management (bipolar sealing) with the Aquamantys® System. These will be compared to in-house matched historic control using patients presenting with ASEPTIC failed primary TKA and revised without use of the Aquamantys® System.
89450371|NCT02266407|Active Comparator|SEPTIC Revision TKA & Aquamantys System|Single-stage revision TKA cases performed for septic failure requiring an extended osteotomy for component removal and intra-operative blood management (bipolar sealing) with the Aquamantys® System. These will be compared to in-house matched historic control using patients presenting with SEPTIC failed primary TKA revised without use of the Aquamantys® System.
89450372|NCT01521663|Experimental|IPX159|IPX159 90 mg daily at week 1 with titration to 180 mg daily at week 2 with possible titration to 270 mg daily at week 3.
89450373|NCT01521663|Placebo Comparator|Sugar Pill|IPX159 90 mg matching placebo daily at week 1 with titration to 180 mg matching placebo daily at week 2.
89450374|NCT02266485|Experimental|BIBB 515 BS|
89450375|NCT02266485|Active Comparator|Pravastatin|
89450376|NCT02266485|Placebo Comparator|Placebo|
89450377|NCT01344993|Experimental|MA09-hRPE|"Experimental: Subretinal injection of MA09-hRPE~Cohort 1 50,000 cells~Cohort 2 100,000 cells~Cohort 2a Better Vision 100,000 cells~Cohort 3 150,000 cells~Cohort 4 200,000 cells"
89450378|NCT02269839|Active Comparator|theta-burst rTMS|Active treatment will consist of sessions of continuous theta-burst rTMS on consecutive days for 5 days. This will be delivered with a circular coil to the temporal scalp region overlying the auditory cortex, contralateral to the symptomatic side in unilateral tinnitus and to the left side in bilateral tinnitus. The treatment protocol will consist of treatment at 80% of individual motor threshold (established at the first treatment session) for 600 pulses of 40 seconds duration, which will be repeated after 15 minutes. Each patient will receive 1200 pulses per day.
89450379|NCT02269839|Sham Comparator|Control arm|The control (sham) stimulation will consist of stimulating with the rTMS coil held at right angles to the participants' head. This will result in no active stimulation of brain tissue but would feel similar to the patient. Each treatment session will therefore last approximately 20 minutes.
89450380|NCT02263989|Experimental|Telmisartan film coated tablet|
89450381|NCT02263989|Active Comparator|Telmisartan conventional tablet|
89531359|NCT05040867|Experimental|Heart Rate Variability exercise group (HRVG)|Participants will participate in a physical exercise program guide by participants' daily heart rate variability to plan the intensity progression.
89531360|NCT03337529|Experimental|Vitamin C|RLS positive patients will be assessed for the severity. They will be given 200 mg Vitamin C for 8 weeks duration. Patients will be re-assessed for the severity of restless leg syndrome.
89014839|NCT03730636|No Intervention|Usual practice (control group)|Management of LOS and treatment is based on the attending clinician's practice and according to the usual practice.
89450382|NCT02266563||Traumatic Brain Injury (TBI) Group|TBI subjects will have a history of one or more concussions and have a memory complaint and objective decline that is considered to be worse than others of the same age (in the absence of an acute medical event). Severity classifications of the subjects selected for past history of TBI will be based upon established criteria used in TBI research (i.e., traumatically induced physiologic disruption of brain function as indicated by at least one of the following: any period of loss of consciousness, any loss of memory for events immediately before or after the accident, any alteration in mental state at the time of the accident, focal neurologic deficits that may or may not be transient). TBI cases will be those with mTBI (single or multiple concussion). Most recent injury must have occurred at least 1 year prior to study enrollment.
89450383|NCT02266563||Mild Cognitive Impairment (MCI) Group|MCI Subjects will have MMSE scores between 24-30 (inclusive), a CDR of 0.5, have no depression, no history of TBI, and no dementia.
89014840|NCT03727139||Rasagiline 1 mg|Rasagiline 1 milligram (mg), orally, once daily for up to 24 months. Participants received interventions as part of routine medical care.
89450384|NCT02266563||Healthy Control Group|Healthy control subjects will have no self or informant-reported problems with cognition, no depression, no history of TBI, and no dementia.
89450385|NCT02264067|Experimental|Talsaclidine|single rising doses
89014841|NCT03719430|Experimental|Doxorubicin/APX005M|"Patients will be treated with doxorubicin and APX005M in 21 day cycles. All patients receive the same treatment (there is no placebo arm). After completing 8 cycles of study treatment, patients without evidence of disease progression or unacceptable toxicity may continue treatment with APX005M alone. Doxorubicin will not be continued beyond cycle 8 due to the risk for cardiac toxicity from cumulative dosing."
89014842|NCT03704363|Experimental|Infliximab|Intravenous infusion(biosimilar infliximab). Each participant will be given 4 infusions, at day 0, day 14, day 42 and day 98, unless unacceptable toxicity is encountered.
89014843|NCT03704363|Placebo Comparator|Placebo|Intravenous infusion (NaCl intravenous infusion). Each participant will be given 4 infusions, at day 0, day 14, day 42 and day 98.
89014844|NCT03697109|Experimental|Relacorilant (open-label phase)|The dose of relacorilant will be increased sequentially from 100 mg orally once daily to a target dose of 400 mg once daily.
89450386|NCT02264067|Placebo Comparator|Placebo|
89450387|NCT02269995||E7040|
89450388|NCT02270073|Experimental|TAU + mindfulness intervention|"In the first five minutes of each of 25 therapy sessions (duration: about 25 weeks), both patient and therapist perform together the brief intervention with mindfulness elements. Participants sit upright in their chairs in a comfortable position at a distance about one meter from the audio recorder. The text is standardized and spoken by Dr. Thomas Heidenreich. During the exercise, participants are instructed to observe their breathing and body sensations. After completion of the mindfulness intervention, the regular therapy session begins.~Intervention: Cognitive behavior therapy of trainee therapists"
89450389|NCT02270073|Active Comparator|TAU + progressive muscle relaxation|"In the first five minutes of each of 25 therapy sessions (duration: about 25 weeks), both patient and therapist perform together a short version of progressive muscle relaxation (PMR). Both patient and therapist sit upright in their chairs in a comfortable position at a distance about one meter from the audio recorder. The PMR text is standardized and spoken by Dr. Thomas Heidenreich. Wording is as similar as possible to the mindfulness interventions.During the exercise, participants are instructed to tense and relax arms, face, body and legs. After completion of PMR, the regular therapy session begins.~Intervention: Cognitive behavior therapy of trainee therapists"
89450390|NCT02270073|Other|Treatment as usual|"No specific intervention is conducted at the beginning of therapy sessions. Standard cognitive behavior therapy treatment, based on the individualized case conception of the trainee therapist, is conducted during the whole treatment sessions.~Intervention: Cognitive behavior therapy of trainee therapists"
89450391|NCT02270151|Active Comparator|MyDiagnostick|Everyone aged 65 years or over, who visits the GP practice will be screened for AF with the MyDiagnostick. When the device indicates a positive result, the single lead ECG will be assessed to confirm/reject the diagnosis. Every new case of diagnosed AF will be evaluated for further treatment by the general practitioner.
89450392|NCT02270151|No Intervention|Control|Control arm will perform care as usual with selective screening by feeling the pulse.
89450393|NCT02266641|Active Comparator|healthy pregnant women|Supply nutrition counseling and multivitamin supplement to people with poor nutritional status
89450394|NCT02266641|Experimental|healthy pregnant women's lineal relative with cancer|Supply nutrition counseling and multivitamin supplement to people with poor nutritional status
89450395|NCT02266641|Experimental|pregnant women or lineal relative with overweight/obesity|Supply nutrition counseling and multivitamin supplement to people with poor nutritional status
89450396|NCT02266641|No Intervention|healthy pregnant women's lineal relative with diabetes|Supply nutrition counseling and multivitamin supplement to people with poor nutritional status
89450397|NCT02270853|Other|sleep apnea screening with ApneaLinkTM|This is the only group in the present study. Patients with bronchial carcinoma (or reasonable suspicion) perform sleep screening with ApneaLinkTM at home or during the hospitalization.
89450398|NCT02271633|Active Comparator|Sodium nitrate|Dietary supplement: 800 mg of nitrate in sodium nitrate added with water to get a 140 mL solution (BASF, Ludwigshafen, Germany)
89014845|NCT03697109|Experimental|Relacorilant (randomized-withdrawal phase)|Patients who meet any of the response criteria will advance to the randomized-withdrawal phase of the study and receive the same highest dose as in the open-label phase.
89014846|NCT03697109|Placebo Comparator|Placebo (randomized-withdrawal phase)|Placebo matched to study drug
89014847|NCT03674619|Active Comparator|Surgical treatment|Anterior discectomy
89014848|NCT03674619|Active Comparator|Conservative treatment|Patients will attend an experienced specialist in physical medicine and rehabilitation and a physiotherapist.
89014849|NCT03665675|Experimental|Treatment (CMV-specific CTLs)|Participants receive allogeneic cytomegalovirus-specific cytotoxic T lymphocytes IV. Participants with persistent infection are eligible for second infusion after 28 days.
89014850|NCT03665675|Experimental|Treatment (AdV-specific CTLs)|Patients receive allogeneic adenovirus-specific cytotoxic T Lymphocytes IV. Participants with persistent infection are eligible for second infusion after 28 days.
89014851|NCT03657771|Active Comparator|DED|Diet eliminating dairy
89450399|NCT02271633|Active Comparator|Beetroot juice|Dietary supplement: 800 mg of nitrate in concentrated beetroot juice (Beet-IT)
89450400|NCT02271633|Active Comparator|Spinach|Dietary supplement: 800 mg of nitrate in a spinach based beverage
89450401|NCT02271633|Active Comparator|Rocket salad|Dietary supplement: 800 mg of nitrate in a rocket salad based beverage
89450402|NCT04475601|Experimental|Enzalutamide+Standard of Care|Up to 5 days with 4x40 mg enzalutamide tablets orally once daily
89014852|NCT03657771|Active Comparator|FREE|Diet eliminating dairy and food additives
89014853|NCT03651505||Prior Burosumab Clinical Trial Participants|Patients who participated in burosumab clinical trials and continue to receive burosumab via prescription from their physician.
89014854|NCT03651505||Not from Prior Burosumab Clinical Trial|Patients may take other treatments for XLH and may start burosumab treatment at any time as prescribed by a physician.
89014855|NCT03635840|No Intervention|Control|Group of patients not receiving IABP
89450403|NCT04475601|No Intervention|Standard of Care|Standard of care
89450404|NCT01516203|Experimental|Arm 1|AZD5847 500 mg orally once daily given to 15 male and female subjects aged 18 to 65 years with newly diagnosed sputum smear positive pulmonary tuberculosis
89450405|NCT01516203|Experimental|Arm 2|AZD5847 500 mg orally twice daily given to 15 male and female subjects aged 18 to 65 years with newly diagnosed sputum smear positive pulmonary tuberculosis
89450406|NCT01516203|Experimental|Arm 3|AZD5847 1200 mg orally once daily given to 15 male and female subjects aged 18 to 65 years with newly diagnosed sputum smear positive pulmonary tuberculosis
89450407|NCT01516203|Experimental|Arm 4|AZD5847 800 mg orally twice daily given to 15 male and female subjects aged 18 to 65 years with newly diagnosed sputum smear positive pulmonary tuberculosis
89450408|NCT01516203|Active Comparator|Arm 5|Rifafour e-275 mg tablets given to 15 male and female subjects aged 18 to 65 years with newly diagnosed sputum smear positive pulmonary tuberculosis
89450409|NCT01321359|Placebo Comparator|Vehicle|Vehicle
89450410|NCT01321359|Active Comparator|Active|Active NB-001(0.3%)
89450411|NCT00703118|Experimental|Group A: T12/PR48|Participants will receive 12 weeks of 750 mg telaprevir eight hourly followed by 4 weeks of Placebo in combination with 48 weeks of Peg-IFN-alfa-2a and ribavirin at standard doses.
89450412|NCT00703118|Experimental|Group B: T12(DS)/PR48|Participants will receive 4 weeks of Placebo followed by 12 weeks of 750 mg telaprevir eight hourly in combination with 48 weeks of Peg-IFN-alfa-2a and ribavirin at standard doses.
89014856|NCT03635840|Experimental|Intra Aortic Balloon Pump|Group of patients receiving Intra Aortic Balloon Pump prior to revascularization
89014857|NCT03624608|Experimental|Auryzon-Processed Ear/Nose|Patients in this category underwent reconstruction and implantation of a completed ear/nose cartilaginous graft that was processed using the AuryzoN device.
89450413|NCT00703118|Experimental|Group C: Pbo/PR48|Participants will receive placebo in combination with Peg- IFN-alfa-2a and ribavirin for 16 weeks. Participants will receive Peg- IFN-alfa-2a and ribavirin for next 32 weeks.
89450414|NCT01510119|Experimental|Intervention - Dose Level 1|RAD001 given 10mg/daily by mouth and 400mg hydroxychloroquine twice daily by mouth. Cycle 1 will include 1 week run-in of RAD001. Following this, both RAD001 and hydroxychloroquine given without interruption. Cycle 1 duration is 35 days; all subsequent cycles are 28 days. RAD001 and hydroxychloroquine continuously administered until progression of disease or unacceptable toxicity.
89450415|NCT01510119|Experimental|Intervention - Dose Level 2 Phase 2|RAD001 given 10mg/daily by mouth and 600mg hydroxychloroquine twice daily by mouth. Cycle 1 will include 1 week run-in of RAD001. Following this, both RAD001 and hydroxychloroquine given without interruption. Cycle 1 duration is 35 days; all subsequent cycles are 28 days. RAD001 and hydroxychloroquine continuously administered until progression of disease or unacceptable toxicity.
89450416|NCT01501383|Active Comparator|VX-765 Dose 1 Part A|
89450417|NCT01501383|Active Comparator|VX-765 Dose 2 Part A|
89450418|NCT01501383|Active Comparator|VX-765 Dose 3 Part A|
89450419|NCT01501383|Active Comparator|VX-765 Dose 4 Part A|
89450420|NCT01501383|Placebo Comparator|Placebo Dose Part A|Placebo
89450421|NCT01501383|Active Comparator|VX-765 Dose Part B|
89450422|NCT04475367|Experimental|hypertensive patients using HyperCrossApp|"Interdisciplinary health care~+ HyperCross App"
89450423|NCT04475367|Active Comparator|hypertensive patients without using HyperCrossApp|Interdisciplinary health care
89014858|NCT03612713|Active Comparator|Oxycodone Medication First|one hour before fMRI scan participants will be given a single dose 15mg immediate release oxycodone
89014859|NCT03612713|Placebo Comparator|Placebo First|one hour before fMRI scan participants will be given a single dose placebo.
89014860|NCT03579290|Experimental|CBT4CBT program|"The 'CBT for CBT' program is modeled closely on our NIDA-published CBT manual. Seven core skill modules will cover the following topics, which correspond to the major session topics in the manual:~Understanding and changing patterns of drug use, Coping with craving, Substance refusal skills, Seemingly irrelevant decisions, Planning for emergencies, and Problem-solving skills. Staying Safe"
89014861|NCT03564821|Experimental|Ivosidenib (500mg/day)|-Ivosidenib will be administered orally every day
89014862|NCT03564821|Experimental|Ivosidenib (250mg/day)|-Ivosidenib will be administered orally every day
89450424|NCT03305276||general population|the study is open to all population, (14-90 years, male/female) to verify the impact of lifestyles (mediterranean style) on intermediate and hard endpoint.
89450425|NCT01150695|Experimental|Group A (DVC-LVS)|Single dose of the Dynport Vaccine Company Live Vaccine Strain (DVC-LVS) product in one arm and normal saline (NS) control in the other arm on Day 0.
89014863|NCT03551496|Experimental|DES BTK|Treatment with DES BTK
89014864|NCT03551496|Active Comparator|Conventional PTA|Treatment with standard PTA
89450426|NCT01150695|Experimental|Group B (USAMRIID-LVS)|Single dose of the United States Army Medical Research Institute of Infectious Diseases Live Vaccine Strain (USAMRIID-LVS) product in one arm and normal saline (NS) control in the other arm on Day 0.
89450427|NCT02272023|Experimental|9 sessions of Intensive Motivational Interviewing|Experimental condition will consist of 9 1-hour intensive motivational interviewing sessions.
89450428|NCT02272023|Active Comparator|1 Standard Motivational Interview plus 8 nutrition classes|The standard MI intervention will consist of a commonly used, single session of MI (50 minutes) plus 8 hours of nutrition education to achieve time and attention equivalence of study conditions.
89450429|NCT02272179|Experimental|ASAP Treatment and Brite|Participants in the experimental arm received the ASAP treatment, during their transition from inpatient to outpatient care, as well as the Brite app for distress tolerance/emotion regulation and safety planning.
89014865|NCT03538639||1|Adult index cases (affected) and relatives (affected and unaffected)
89450430|NCT02272179|Active Comparator|Treatment as Usual|Participants in this grouping were studied as they proceed from inpatient to outpatient care, per usual treatment protocols at each site. Participants completed paper safety plans as part of their regular treatment, which is a standard of care for suicidal youth.
89450431|NCT05205044||Recurrent pregnancy loss|
89450432|NCT05205044||Healthy|
89450433|NCT01302249|Experimental|AR-12286|AR-12286 Ophthalmic Solution 0.5%
89014866|NCT03538639||2|Child index cases (affected) and child relatives (affected and unaffected)
89014867|NCT03538639||3|Healthy adult volunteers
89014868|NCT03519945|Experimental|Mirikizumab|Mirikizumab administered subcutaneously (SC).
89014869|NCT03517917||Arm 1|Tumour tissue, blood and leukapheresis collection to enable a manufacturing process for immunotherapies to be developed.
89014870|NCT03515512|Experimental|Enasidenib|Enasidenib will be administered orally once daily in 28-day cycles
89014871|NCT03508765|Experimental|rsfMRI + Neurocognitive Tests|Participants diagnosed with multiple myeloma in complete, partial or very good partial remission per standard International Myeloma Working Group Criteria will complete neurocognitive tests and structural and functional rsfMRI (brain MRIs).
89014872|NCT03468257|Active Comparator|Progressive Muscle Relaxation only|Condition 1: 7-dose control - Progressive Muscle Relaxation only
89014873|NCT03468257|Experimental|Pairs Progressive Muscle Relaxation with fruit|Condition 2: 5-dose - Pairs Progressive Muscle Relaxation with fruit 5 consecutive days; Condition 3: 7-dose - Pairs Progressive Muscle Relaxation with fruit 7 consecutive days; Condition 4: 9-dose - Pairs Progressive Muscle Relaxation with fruit 9 consecutive days
89014874|NCT03458676|Experimental|Advanced MR Imaging (AMRI) Scan|"AMRI scan performed within 2 weeks before standard of care brain surgery.~During the surgery, neurosurgeon(s) use the information collected from the AMRI to decide what area of the brain tumor will be biopsied."
89200794|NCT02539641|Other|Bad responder RYGB|Bad responders after Roux-en-Y gastric bypass (RYGB). EWL < 50% Interventions: Gastric emptying scintigraphy and Determination of gut hormones.
89200795|NCT02539641|Other|Good responder SG|Good responders after sleeve gastrectomy (SG). EWL > 50% Interventions: Gastric emptying scintigraphy and Determination of gut hormones.
89450434|NCT01302249|Active Comparator|Timolol|Timolol maleate ophthalmic solution 0.5%
89450435|NCT02261636||Pentasa|Treatment according to standard clinical practice.
89531361|NCT03337529|Placebo Comparator|Placebo|RLS positive patients will be assessed for the severity. They will be given 200 mg placebo for 8 weeks duration. Patients will be re-assessed for the severity of restless leg syndrome.
89531362|NCT03336359|Active Comparator|LCI|Tandem colonoscopy with Linked Color Imaging system
89531363|NCT03336359|Active Comparator|NBI|Tandem colonoscopy with Narrow band imaging system
89014875|NCT03458234|Experimental|Focal SBRT with intra-urethral radiotransponder|This study will enroll patients that have a confirmed histology of prostate cancer. They will undergo a 3T MRI scan as well as a CT simulation with 16 French Foley Catheter containing dummy beacons for treatment planning purposes. The patient will then receive focal stereotactic body radiotherapy (SBRT) at a dose of 40 gy in 5 total fractions. Patients will be followed for 24 total months with specific follow-ups at 3, 6, 9, 12, 18, and 24 months.
89014876|NCT03456076|Experimental|Alectinib|
89014877|NCT03456076|Active Comparator|Platinum-Based Chemotherapy|
89014878|NCT03440697||Aortopathy- Closed to external enrollment|Subjects with aortic disease including TAA or dissection, aortic tortuosity, or aortic hypoplasia/stenosis (based on any cardiac imaging modality including echocardiography, CT, MRI, or angiography)
89014879|NCT03440697||Syndromic- Open to external enrollment|"Subjects with a genetic diagnosis of Marfan Syndrome (MFS), Loeys-Dietz Syndrome (LDS), Vascular Ehlers-Danlos Syndrome (EDS)~•positive genetic testing and/or a previous cardiac study required to be eligible"
89450436|NCT02272257|Experimental|Early Direct Access Physical Therapy|All care will be administered by one or more physical therapists employed by Temple University. This arm will be early, direct access, physical therapy (immediately evaluation following contacting the front desk administrator or reporting a work injury). Intervention will include interventions matched to their stratified risk category incorporating biopsychosocially oriented education, therapeutic exercise, and manual therapy tailored to the patient's needs.
89450437|NCT02272257|Active Comparator|Physician management|All usual care by physician will be administered by one or more employee health physicians employed by Temple University. Recommendations may or may not include referral to physical therapy.
89450438|NCT03305198|Experimental|Patients undergoing exercise oximetry|Patients with PAD referred for treadmill testing and exercise oximetry will have a capillary blood sampling from the earlobe
89450439|NCT05628519|Experimental|Captain Sonar|Participants will receive a training by a game session at Captain SonarTM of 60 min (including 15 min of presentation and prize in hand of the game) against a standardized investigator team
89450440|NCT05628519|Placebo Comparator|Placebo Monopoly|"The control group participants will benefit from a 60 min session to play a Placebo game: monopoly"
89014880|NCT03440697||Aortopathy with Positive Genetic Results- Open to Enrollment|Subjects with aortic disease including TAA or dissection, aortic tortuosity, or aortic hypoplasia/stenosis (based on any cardiac imaging modality including echocardiography, CT, MRI, or angiography) who also have positive genetic testing results related to aortopathy.
89450441|NCT05628441||CADe system|All patients included in the study will undergo the endoscopic procedure according to standard clinical care and the study protocol. The CADe system will run in the back, not interfering with care.
89450442|NCT03305042||21-54 y|Ages 21-54 y
89450443|NCT03305042||55-74 y|Ages 55-74 y
89450444|NCT03305042||>75 y|Age >75 y
89450445|NCT01493505|Placebo Comparator|Placebo|Placebo Paclitaxel Carboplatin
89450446|NCT01493505|Active Comparator|AMG 386|AMG 386 Paclitaxel Carboplatin
89450447|NCT02464748|Experimental|Intervention|Patients and their primary carer will use a weekly telehealth system. This involves a series of questions on a tablet computer that is transmitted to their regional MND care centre for review and action.
89014881|NCT03440697||Aortic Valve Disease- Closed to enrollment|Subjects with aortic valve disease (bicuspid, unicuspid, or tricuspid disease)
89014882|NCT03440697||Family Members- Open to external enrollment|"Family members of eligible subjects~•Only family members of subjects with syndromic diagnoses are eligible for external enrollment at this time"
89014883|NCT03440697||Controls- Closed to external enrollment|Control subjects having tissue removed during a surgical procedure (e.g. coronary artery bypass graft surgery (CABG), cardiac transplant, etc.)
89014884|NCT03423953||Anatomic|Patients receiving the Anatomic or Hemi verison of the Comprehensive Nano.
89014885|NCT03423953||Reverse|Patients who have received the Reverse version of the Comprehensive Nano.
89014886|NCT03412396|Experimental|Treatment (apalutamide, radical prostatectomy)|Patients receive apalutamide PO daily for 24 weeks in the absence of disease progression or unacceptable toxicity. Within 2 weeks of completing apalutamide, patients undergo radical prostatectomy.
89014887|NCT03398304|Experimental|Graded Exercise|Volunteers will participate in 3 study visits. The study visits will consist either of 20 minutes of walking, 20 minutes of running or 20 minutes of sitting. At the beginning of each study visit, prior to any exercise, a 4.5mL blood sample will be collected. The participant will then complete either 20 minutes of walking, running or sitting and will then have a 4.5mL blood draw taken from a new site.
89200796|NCT02539641|Other|Bad responder SG|Bad responders after sleeve gastrectomy (SG). EWL < 50% Interventions: Gastric emptying scintigraphy and Determination of gut hormones.
89200797|NCT02539641|Other|Duodenal-jejunal bypass liner|Patients who will have a duodenal-jejunal bypass liner (DJBL) Intervention: Gastric emptying scintigraphy before and after implantation of DJBL
89450448|NCT02464748|No Intervention|Control|Usual care
89450449|NCT02464592|Active Comparator|Biopsy with Cryoprobes|Transbronchial lung biopsy with a cryoprobe.
89450450|NCT02464592|Active Comparator|Biopsy with Conventional Forceps|Transbronchial lung biopsy with conventional forceps.
89450451|NCT01493271|Placebo Comparator|Placebo|
89450452|NCT01493271|Experimental|RO5093151|
89450453|NCT01301781|Experimental|BLI801 laxative|BLI801 laxative - oral solution
89450454|NCT01301781|Placebo Comparator|Placebo|BLI801 placebo - oral solution
89450455|NCT02466308|Experimental|SAM Ultrasound Diathermy Device|SAM (sam Professional System) 3 MHz ultrasound diathermy device: 4 hours/day, at least 5 days per week, for 6 weeks
89450456|NCT01301157|Experimental|25ug M518101|
89450457|NCT01301157|Placebo Comparator|Vehicle|
88935112|NCT01776112|Placebo Comparator|SZ-TableSoccer|Standard treatment and participation in an activity without physical improvement as placebo condition (table soccer in groups of 4), but including cognitive training, 3 sessions (30 min. each) per week for 3 months and 2 sessions Cogpack per week for the last 6 weeks.
88935113|NCT01776112|Experimental|HC-Exercise|Standard treatment and participation in an activity without physical improvement as placebo condition (table football in groups of 4), but including cognitive training, 3 sessions (30 min. each) per week for 3 months and 2 sessions Cogpack per week for the last 6 weeks.
88935114|NCT01776125||Dystrophic Scolisis and NF1|Patients with NF1 diagnosed with dystrophic scoliosis that have been clinically treated will be asked for a cheek swab for genetic testing
88935115|NCT01776125||Non-dystrophic scoliosis and NF1|NF1 patients with non-dystrophic scoliosis that have been treated clinically. will be asked for a cheek swab for genetic testing
88935116|NCT01776138||Bladder Cancer Patients|Patients diagnoses with bladder cancer who are eligible to undergo treatment.
88935117|NCT01776177||Continue Therapy Group|Patients who continued to recieve Omalizumab therapy beyond 6 month period
88935118|NCT01776177||Discontinued Therapy group|Patients who discontinued Omalizumab therapy prior to 6 month period from the start of therapy
88935119|NCT01776203|Active Comparator|medroxyprogesterone acetate|
88935120|NCT01776203|No Intervention|control|
88935121|NCT01776216|Experimental|Dairy diet|During the DAIRY diet, subjects will be asked to incorporate 3 servings of dairy into their everyday diet.
88935122|NCT01776216|Placebo Comparator|Control diet|During the CONTROL diet of the study, participants will be asked to consume energy equivalent replacement products into their everyday diet.
88935123|NCT01776255|Experimental|Healthy Children, Strong Families (first)|Healthy Children, Strong Families intervention (first). This is a series of monthly educational tool kits mailed to primary caregivers for use with the participating child. This arm crosses over to receive the Child Safety in Year 2.
88935124|NCT01776255|Active Comparator|Child Safety (first)|A series of 12 monthly newsletters and providing education on child safety mailed to primary caregivers. This Arm crosses over to receive the Healthy Children, Strong Families intervention in Year 2.
88935125|NCT01776281|Experimental|Kangaroo Mother Care|Other than routine clinical care per hospital policy. Infants will receive skin-to-skin contact for minimum one hour daily during hospital stay and at home till one month.
88935126|NCT01776281|Active Comparator|Standard Care|Routine incubator or cot care with breastfeeding support from nurses as per policy.
88935127|NCT01776294||prehypertensives|students will be classified as prehypertensives as per the JNC-7 (Joint National Commission) guidelines based on their Blood Pressure measurement
88935128|NCT01776294||normotensives|students will be classed as normotensives based on their BP measurement as per JNC-7 guidelines (systolic <120 AND diastolic <80)
88935129|NCT01776320|Experimental|VITAROS|VITAROS (Alprostadil) 330 ug PRN (as needed) transdermal topical 4-8 weeks
88935130|NCT01776333|No Intervention|usual care|
88935131|NCT01776333|Experimental|video arm|video decision aid intervention
88935132|NCT01776346||Barrett's Esophagus/Esophageal Adenocarcinoma|Patients who have Barrett's esophagus or esophageal adenocarcinoma.
88935133|NCT01776346||Healthy control|
88935134|NCT01776359|Active Comparator|High Protein|High Protein
88935135|NCT01776359|Placebo Comparator|Low Protein|Low Protein
88935136|NCT01776372|Active Comparator|Digital thoracic drainage system|Medela Thopaz Thoracic Drainage System
88935137|NCT01776372|Active Comparator|Non-digital thoracic drainage system|Atrium Express Dry Seal Chest Drain
88935138|NCT01776385|Experimental|Group patients|Patients with Malignant Pleural Mesothelioma (all stages)
88935139|NCT01776385|Placebo Comparator|Control group|Patients with pneumothorax or of benign tumor of the thyroid
88935140|NCT01776411|Experimental|Single Arm|Drug: forodesine hydrochloride 600 mg / body/day (3 x 100 mg capsules twice daily)
88935141|NCT01776437|Experimental|Treatment A|Period 1: fasted control → Period 2: fed control
88935142|NCT01776437|Experimental|Treatment B|Period 1: fed control → Period 2: fasted control
88935143|NCT01776463|Experimental|Z-360|1)Single dose study (60, 120, 240, 480, 720mg), 2)Food effect study(120mg), 3)Multiple doses study(120, 240mg (BID))
88935144|NCT01776463|Placebo Comparator|Placebo|1)Single dose study, 2)Multiple doses study
88935145|NCT01776489||food allergic|positive reaction during DBPCFC
88935146|NCT01776489||Non-food allergic|no reaction during DBPCFC
89450458|NCT01301157|Active Comparator|Dovonex|
89450459|NCT01301157|Experimental|50ug M518101|
89531364|NCT03097965|Active Comparator|DIET|"High Phyto-PRO food plan~Physical activity~Cognitive behavioral program"
89450460|NCT02465996|Other|postprandial distress syndrome (PDS)|"FD patients fulfilled Rome III criteria were subclassified into postprandial distress syndrome (PDS) or epigastric pain syndrome (EPS).~pCLE examination was performed in PDS patients, and then those who were willing to receive Puyuanhewei to treat FD were given 4 pills three times a day for 4 weeks after pCLE examination."
89450461|NCT02465996|Other|epigastric pain syndrome (EPS)|pCLE examination was performed in EPS patients, and then those who were willing to receive Puyuanhewei to treat FD were given 4 pills three times a day for 4 weeks after pCLE examination.
89450462|NCT01296087|Experimental|TC-6987|
89450463|NCT01296087|Placebo Comparator|Placebo|
89450464|NCT02264145|Experimental|Ethanolic Solution From HFA134a-MDI - low|
89450465|NCT02264145|Experimental|Ethanolic Solution From HFA134a-MDI - medium|
89450466|NCT02264145|Experimental|Ethanolic Solution From HFA134a-MDI - high|
89450467|NCT02264145|Experimental|Ethanolic Solution From Respimat®|
89450468|NCT02266953|Experimental|Use of communication tool about diet|The children and parents in the intervention group are visiting consultations at the child health centre where the public health nurses use a communication tool about diet in order to promote dialogue about themes concerning food and feeding practices. This intervention is carried out at consultations when the child is 10-, 12- and 15-18 months old.
88935147|NCT01776502||Patients with Hyperparathyroidism|The cohort of patients is made of patients with primary mild hyperparathyroidism and who have received a surgery at Nantes, Angers, Limoges or Marseille University Hospitals
88935148|NCT01776515|Active Comparator|Tramadol hydrochloride/Acetaminophen Tab.|
88935149|NCT01776515|Experimental|Tramadol hydrochloride/Acetaminophen SR Tab.|
88935150|NCT01776528|Experimental|Cohort 1 SAD|NGM282 Dose 1 vs Placebo
88935151|NCT01776528|Experimental|Cohort 2 SAD|NGM282 Dose 2 vs Placebo
88935152|NCT01776528|Experimental|Cohort 3 SAD|NGM282 Dose 3 vs Placebo
88935153|NCT01776528|Experimental|Cohort 4 SAD|NGM282 Dose 4 vs Placebo
88935154|NCT01776528|Experimental|Cohort 5 SAD|NGM282 Dose 5 vs Placebo
89450469|NCT02266953|Active Comparator|Treatment as usual|The children and parents in the control group are visiting consultations at the child health centre where the public health nurses will conduct the consultations as usual and without use of the actual communication tool about diet. The consultations are carried out when the child is 10-, 12- and 15-18 months old.
89450470|NCT02267031|Active Comparator|normoxia and normocapnia|Normoxia PaO2 of 70-140 mm Hg Normocapnia PaCO2 of 35-48 mmHg
88935155|NCT01776528|Experimental|Cohort 6 SAD|NGM282 Dose 6 vs Placebo
88935156|NCT01776528|Experimental|Cohort 7 MAD|NGM282 Dose 1 vs Placebo
88935157|NCT01776528|Experimental|Cohort 8 MAD|NGM282 Dose 2 vs Placebo
88935158|NCT01776528|Experimental|Cohort 9 MAD|NGM282 Dose 3 vs Placebo
88935159|NCT01776528|Experimental|Cohort 10 MAD|NGM282 Dose 4 vs Placebo
88935160|NCT01776528|Experimental|Cohort 11 MAD|NGM282 Dose 5 vs Placebo
88935161|NCT01776528|Experimental|Cohort 12 MAD|NGM282 Dose 6 vs Placebo
88935162|NCT01776567|Active Comparator|Cobalt Chromium Everolimus-eluting stent (Xience Prime)|Cobalt Chromium Everolimus-eluting stent (Xience Prime)
89450471|NCT02267031|Active Comparator|hyperoxia and normocapnia|Hyperoxia 150-300 mm Hg Normocapnia PaCO2 of 35-48 mmHg
89450472|NCT02267031|Active Comparator|normoxia and hypocapnia|Normoxia PaO2 of 70-140 mm Hg Hypocapnia PaCO2 of 25-35 mmHg
89450473|NCT02267031|Active Comparator|hyperoxia-hypocapnia|Hyperoxia 150-300 mm Hg Hypocapnia PaCO2 of 25-35 mmHg
89450474|NCT02264301|Active Comparator|Puerarin injection 400 mg|Patients under the treatment of Puerarin injection 400 mg,daily,for 24 weeks
89450475|NCT02264301|Experimental|Qingkailing injection 40 ml|Patients under the treatment of Qingkailing injection 40 ml,daily,for 24 weeks
88935163|NCT01776567|Active Comparator|Platinum Chromium Everolimus-eluting stent (Promus Element)|Platinum Chromium Everolimus-eluting stent (Promus Element)
88935164|NCT01776580||Lower urinary tract symptoms|Women with lower urinary tract symptoms
88935165|NCT01776593||Lower urinary tract symptoms|
88935166|NCT01776619|Experimental|Multiple Dose: Cohort 1|
88935167|NCT01776619|Experimental|Multiple Dose: Cohort 2|
88935168|NCT01776619|Experimental|Multiple Dose: Cohort 3|
88935169|NCT01776619|Experimental|Multiple Dose: Cohort 4|
88935170|NCT01776619|Experimental|Relative Bioavilability: Cohort 1|
88935171|NCT01776658|Experimental|SYL1001 eye drops dose A|Ocular topical administration of SYL1001 eye drops dose A
88935172|NCT01776658|Placebo Comparator|Placebo|Ocular topical administration of placebo eye drops
88935173|NCT01776671|Other|Gralise|Efficacy of Gralise
88935174|NCT01776684|Experimental|EGFR positive arm|Patients with NSCLC harboring activating EGFR mutation (deletion in exon 19, L858R mutation in exon 21)
88935175|NCT01776697|Active Comparator|pelubiprofen (30mg) tablet IR TID, fasting|
88935176|NCT01776697|Active Comparator|pelubiprofen (30mg) tablet IR TID, fed|
89450476|NCT02267109|Experimental|2.5 x 10(10) vp|Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO Z) 2.5 x 10(10):
89450477|NCT02267109|Experimental|5 x 10(10) vp|Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO Z) 5 x 10(10):
89450478|NCT02267109|Experimental|1.0 x 10(10) vp|Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO Z) 1.0 x 10(10):
89450479|NCT02267109|Experimental|1.0 x 10(11) vp|Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO Z) 1.0 x 10(11):
89450480|NCT02267109|Experimental|Booster-MVA-BN® Filo or saline placebo|MVA-BN® Filo or saline placebo
89450481|NCT05596838||Patient operated at Somain institute with the placement of intracorneal rings|patient operated in the last 10 years on one or both eyes
89450482|NCT01487109|Placebo Comparator|Placebo|matching placebo tablets
89450483|NCT01487109|Active Comparator|CTP-499|600 mg tablet
88935177|NCT01776697|Experimental|pelubiprofen SR (as a pelubiprofen 90 mg) tablet QD|
88935178|NCT01776710|Experimental|Structured education|The structured education intervention will comprise a 3-hour education workshop delivered by two trained facilitators and a follow-up telephone call 2 weeks later. The aims of the education programme are to enhance patients' understanding of peripheral arterial disease and intermittent claudication, and to support patients in increasing their daily walking activity. Key behaviour change techniques that will be incorporated will include goal setting, action planning, barrier identification/problem solving, prompt review of behavioural goals, prompt self-monitoring of behaviour, and instructions on how to perform the behaviour.
88935179|NCT01776710|No Intervention|Standard care control|Standard care will consist of general advice to increase walking and an information sheet on peripheral arterial disease, plus a consultation with a Consultant Vascular Surgeon.
88935180|NCT01776749|No Intervention|no SubQ|No subcutaneous leads due to adequate low back stimulation by only SCS. Patient not randomised
88935181|NCT01776749|Active Comparator|SubQ ON|Subcutaneous stimulation on
88935182|NCT01776749|Sham Comparator|SubQ OFF|subcutaneous leads implanted, but no stimulation
88935183|NCT01776775|Active Comparator|abdominal binder|use of postoperative abdominal binder 30 days after the hernia repair
88935184|NCT01776775|No Intervention|No abdominal binder|No intervention
88935185|NCT01776788|Experimental|insulin lispro injection, exenatide injection|
88935186|NCT01776788|Active Comparator|insulin lispro injection|
88935187|NCT01776801|Experimental|Hydrocephalus|Patients suffering of hydrocephalus (cognitive impairment, gait disturbance, urinary incontinence and enlargement of the ventricles) require for clinical purpose infusion studies i.e. injection of mock cerebrospinal fluid (CSF) in the sub arachnoid space to artificially increase ICP. We aim at using infusion studies as a indirect tool to assess whether a moderate increase in ICP has any influence on haemodynamics.
88935188|NCT01776853|Placebo Comparator|Glucose|40g glucose in 500ml water flavoured with lime juice
88935189|NCT01776853|Experimental|Fructose|40g fructose in 500ml water flavoured with lime juice
88935190|NCT01776853|Experimental|Fructans|40g fructans in 500ml water flavoured with lime juice
88935191|NCT01776866|Other|Coronary Angiography|"Patient first undergo standard coronary angiography(SA) of either left or right coronary system followed by dual-axis rotational coronary angiography(DARCA). The SA protocol consist of six different projections (right anterior oblique (RAO)-caudal, RAO-cranial (CRA), left anterior oblique (LAO)-CRA, LAO-caudal (CAU), antero-posterior (AP)-CRA and AP-CAU) for left coronary artery (LCA) and two projections (LAO and AP-cranial) for right coronary artery (RCA).~The DARCA protocol consist of two coronary acquisitions specified by the protocol: one for LCA (Swing LCA CRA 35 5.8s), another for RCA (Swing RCA AP 4.0s)."
88935192|NCT01776879||early & advanced PD 1st degree relatives|no intervention is performed in the study
88935193|NCT01776879||recording speech and voice|no intervention(s) will be administered
88935194|NCT01776879||speech intelligibility|no intervention(s) will be administered
88935195|NCT01776892|Experimental|Collagenase and needle aponeurotomy|"Participants in this arm of the study will be treated once with needle aponeurotomy and up to 3 times at 4 week intervals with collagenase injection.~Affected Dupuytren's cords will be treated with 1-3 collagenase clostridium histolyticum injections at 4 week intervals, based on clinical response of the contracture. Cords will be treated until motion of the joint is within 0-5 degrees of normal, for up to 3 total injections.~Percutaneous needle aponeurotomy will be performed using an 18 gauge needle. The needle is inserted through the skin into the Dupuytren's cord. The needle is moved very slowly through the cord until complete rupture of the cord is obtained."
88935196|NCT01776892|Active Comparator|Needle aponeurotomy|Percutaneous needle aponeurotomy will be performed using an 18 gauge needle. The needle is inserted through the skin into the Dupuytren's cord. The needle is moved very slowly through the cord until complete rupture of the cord is obtained. Participant feedback is obtained throughout the procedure to prevent digital nerve or flexor tendon injury. Participants are asked to report Tinel's sign which indicates that the needle is in close proximity to the digital nerve and to report pain with needle advancement which indicates proximity to the flexor tendon.
88935197|NCT01776892|Active Comparator|Collagenase injection|Collagenase clostridium histolyticum will be used to treat participants in this arm of the study. Affected cords will be treated with 1-3 collagenase injections at 4 week intervals, based on clinical response of the contracture. Cords will be treated until motion of the joint is within 0-5 degrees of normal, for up to 3 total injections. Metacarpophalangeal cords will be injected with 0.58mg (10 000 units) of collagenase in 0.25ml of sterile diluent. Proximal interphalangeal cords will be injected with 0.58mg (10 000 units) of collagenase in 0.20ml of sterile diluent.
88935198|NCT01776918||Metabolic Disease- Phenylketonuria|
88935199|NCT01776918||Mitochondrial disorder|
88935200|NCT01776931|Experimental|Lysine intake|Dietary supplement:lysine intake
89450484|NCT02465918|Active Comparator|Original Setting- MCS 30 min off/0 min off|Patients at baseline with their original MCS settings: on 30 minutes, off 0 minutes in any single half-hour.
89450485|NCT02465918|Experimental|MCS 25 min on/5 min off|Patient MCS settings programmed to: on 25 minutes, off 5 minutes in any single half-hour.
89450486|NCT02465918|Experimental|MCS 20 min on/10 min off|Patient MCS settings programmed to: on 20 minutes, off 10 minutes in any single half-hour.
89450487|NCT02465918|Experimental|MCS 15 min on/15 min off|Patient MCS settings programmed to: on 15 minutes, off 15 minutes in any single hour.
88935201|NCT01776944||Obese children|
88935202|NCT01776957||IUD|Repeat abortion rate in women receiving IUDs immediately post-abortion
88935203|NCT01776970|Experimental|Sativex|Cannabis Sativa extract Oromucosal spray, containing THC (27 mg/ml):CBD (25 mg/ml)
89450488|NCT04476069|Experimental|Ibuprofen|30 minutes before extraction, once/day orally
89450489|NCT04476069|Placebo Comparator|Placebo|30 minutes before extraction, once/day orally
89450490|NCT04475913|Active Comparator|(CIG Axial)|received 4 axial implants and conventional impression
89450491|NCT04475913|Experimental|(DIG Axial)|received 4 axial implants and digital impression
89450492|NCT04475913|Active Comparator|CIG Tilted|received two anterior axial implants and two distal tilted implants, and conventional impression
89450493|NCT04475913|Experimental|(DIG Tilted)|received two anterior axial implants and two distal tilted implants, and digital impression
89450494|NCT05627973||Aortic valve replacement with mechanical valves|
89450495|NCT05627973||Aortic valve replacement with bioprostheses|
89450496|NCT02464826|Experimental|Edit arms|Nailprotex apply to the abnormal nail twice daily
89450497|NCT02464670|Experimental|Group 1|INO-4201 IM + EP, 2 mg, 3 doses
89450498|NCT02464670|Experimental|Group 2|INO-4202 IM + EP, 2 mg, 3 doses
89450499|NCT02464670|Experimental|Group 3|INO-4201 ID + EP 0.2A, 2 mg, 3 doses
89450500|NCT02464670|Experimental|Group 4|INO-4212 IM + EP, 4 mg, 3 doses
89450501|NCT02464670|Experimental|Group 5|INO-4212 + INO-9012 IM + EP, 4+1 mg, 3 doses
89450502|NCT02464670|Experimental|Group 6|INO-4201 ID + EP 0.2A, 1 mg, 3 doses
89450503|NCT02464670|Experimental|Group 7|INO-4201 ID + EP 0.2A, 2 mg, 2 doses
89450504|NCT02464670|Experimental|Group 8|INO-4201 ID + EP 0.2A, 1 mg, 2 doses
88935204|NCT01776970|Placebo Comparator|Placebo|Placebo oromucosal spray
88935205|NCT01777009|Experimental|Patellar Eversion|Patients randomized to the Patellar Eversion arm of the study were surgically exposed by everting the patella during their Primary Total Knee Replacement Surgery.
89450505|NCT02464670|Experimental|Group 9|INO-4201 + INO-9012 ID + EP 0.2A, 1.6 + 0.4 mg, 3 doses
88935206|NCT01777009|Active Comparator|Patellar Lateral Retraction|Patients randomized to the Patellar Lateral Retraction arm of the study were surgically exposed by laterally retracting the patella during their Primary Total Knee Replacement Surgery.
88935207|NCT01777022|No Intervention|Current treatment|Current education and management protocols will be followed
88935208|NCT01777022|Other|A package of interventions|"A package of interventions consisting of strategies for increasing pregnant women's awareness of the need to report early when they perceive a reduction in fetal movements, followed with a management plan for identification and delivery of the at risk fetus in such women, will reduce rates of stillbirth"
89450506|NCT02464670|Experimental|Group 10|INO-4201 + INO-9012 ID + EP 0.2A, 1.6 + 0.4 mg, 2 doses
89450507|NCT02464670|Experimental|Group 11|INO-4201 + INO-9012 ID + EP 0.2A, 0.8 + 0.2 mg, 3 doses
89450508|NCT02464670|Experimental|Part II: Group 3A|INO-4201 ID + EP 0.2A, 2 mg, 3 doses
89450509|NCT02464670|Experimental|Part II: Group 3B|INO-4201 ID + EP 0.1A, 2 mg, 3 doses
89450510|NCT02267265|Experimental|Treatment intervention|The treatment group will complete a demographics questionnaire and the knowledge survey before the intervention. Participants will then view the 10 minute TMW-Newborn Intervention video around the time of the newborn hearing screening. Participants whose newborn does not pass the hearing screen will view an additional 3 minute video detailing the importance of following up for an outpatient re-screening. The participant will complete the knowledge survey again before discharge, and after approximately four to six weeks.
89450511|NCT02267265|Active Comparator|Control intervention|The control group will complete a demographics questionnaire and knowledge survey. Participants will subsequently view the 10-minute Safe Sleep for your Baby (SIDS) educational video. It is an educational video developed by the National Institute of Child Health and Development (NICHD) promoting the prevention of Sudden Infant Death Syndrome. This will be around the time of the newborn hearing screening. Participants will complete the knowledge survey again before discharge, and after approximately four to six weeks.
89450512|NCT01481571|Experimental|Vitrification media and device|Vitrification medium oocyte, warming medium oocyte and Rapid-i
89450513|NCT01124565|Experimental|RT001|RT001 (Botulinum Toxin Type A) Topical Gel
89450514|NCT02465840|Placebo Comparator|Immobilization programs|custom-made protective hand splint physical therapy and occupational therapy
89450515|NCT02465840|Experimental|Kleinert programs|custom-made dynamic hand splint physical therapy and occupational therapy
89450516|NCT01123785|Placebo Comparator|Control|Matched vehicle-control
89450517|NCT01123785|Experimental|INO-8875|Adenosine agonist eye drop
89450518|NCT01293669|Experimental|TC-6987|
89450519|NCT01293669|Placebo Comparator|Placebo|
89450520|NCT02465762|Experimental|ultrashape fat reduction treatment|all patient undergo non-invasive fat and circumference reduction at the flanks area
89450521|NCT02465684|Experimental|tourniquet|UKA surgery with tourniquet
89450522|NCT02465684|Experimental|no tourniquet|UKA without tourniquet
89450523|NCT01480479|Experimental|Rindopepimut/GM-CSF plus Temozolomide|
89450524|NCT01480479|Active Comparator|KLH plus Temozolomide|
89450525|NCT01116141|Active Comparator|Methotrexate (MTX) + Folic Acid|20 mg MTX weekly + 1 mg folic acid daily
89450526|NCT01116141|Experimental|0.3 mg CH-4051|0.3 mg CH-4051 daily
89450527|NCT01116141|Experimental|1.0 mg CH-4051|1.0 mg CH-4051 daily
89450528|NCT01116141|Experimental|3.0 mg CH-4051|3.0 mg CH-4051 daily
89450529|NCT01116141|Experimental|3.0 mg CH-4051 + folic acid|3.0 mg CH-4051 + 1.0 mg folic acid daily
89450530|NCT01287585|Experimental|ADI-PEG 20|Arginine deiminase formulated with polyethylene glycol.
89450531|NCT01287585|Placebo Comparator|Placebo|an inert treatment with no therapeutic value.
89450532|NCT01284387|Experimental|3 μg ACC-001 / QS-21 50 μg IM dose 1|3 μg ACC-001 / QS-21 50 μg IM
89450533|NCT01284387|Experimental|10 μg ACC-001 / QS-21 50 μg IM dose 2|10 μg ACC-001 / QS-21 50 μg IM
89450534|NCT01284387|No Intervention|Placebo - Phosphate buffered saline (PBS) IM dose|Placebo - Phosphate buffered saline (PBS) IM
89450535|NCT02264457|Other|First eye closed loop haptic|subjects implanted with the Closed loop haptic during first eye surgery and the plate haptics toric intraocular lens during second eye surgery
88935209|NCT01777048|Experimental|Omega-3 Fatty Acids|1g of Omega-3 per day [400mg DHA & 600mg EPA] for 12 weeks: 2 capsules after breakfast and 2 capsules after dinner
89450536|NCT02264457|Other|First eye plate haptic|subjects implanted with the plate haptic toric during first eye surgery and the closed loop haptic toric intraocular lens during second eye surgery
89450537|NCT01280565|Experimental|Masitinib|Participants receive masitinib (7.5 mg/kg/day), given orally twice daily.
89450538|NCT01280565|Active Comparator|Dacarbazine|Participants receive dacarbazine, given via IV bolus at 1,000 mg/m2 once every 3 weeks. Following a protocol amendment, the dacarbarzine treatment group has been closed
89450539|NCT04476147||Participates|This is an observational study
89450540|NCT01113957|Experimental|Arm A|ABT-888 in combination with temozolomide
89450541|NCT01113957|Active Comparator|Arm B|pegylated liposomal doxorubicin alone
89450542|NCT01111773|Experimental|Heated Lidocaine and Tetracaine Patch|
89450543|NCT01103037|Experimental|QAV680|
89450544|NCT01103037|Placebo Comparator|QAV680 Placebo|
89450545|NCT01280331|Experimental|Q8003 12 mg/8 mg|Combination
89450546|NCT01280331|Active Comparator|Morphine sulfate 24 mg|Single component
89450547|NCT01280331|Active Comparator|Oxycodone HCl 16 mg|Single component
89450548|NCT01474083|Experimental|GK1-399, low dose|
89450549|NCT01474083|Experimental|GK1-399, high dose, once per day|
89450550|NCT01474083|Experimental|GK1-399, high dose, twice per day|
89450551|NCT01474083|Placebo Comparator|Placebo|
89450552|NCT01266525|Experimental|SAR110894 - 0.5 mg|SAR110894, 0.5 mg once daily along with Donepezil.
89450553|NCT01266525|Experimental|SAR110894 - 2 mg|SAR110894, 2 mg once daily along with Donepezil.
89450554|NCT01266525|Experimental|SAR110894 - 5 mg|SAR110894, 5 mg once daily along with Donepezil.
89450555|NCT01266525|Placebo Comparator|Placebo|Placebo (for SAR110894) once daily along with Donepezil.
89450556|NCT01472991|Experimental|TC-5619-238 (25mg)|TC-5619-238 25 mg will be provided as hard gelatin capsules
89450557|NCT01472991|Placebo Comparator|Placebo|Placebo will be provided as hard gelatin capsules similar to TC-5619-238
89450558|NCT01472991|Experimental|TC-5619-238 (5 mg)|TC-5619-238 5 mg will be provided as hard gelatin capsules.
89450559|NCT01266135|Experimental|Arm 1: QAX576 10 mg/kg|
89450560|NCT01266135|Placebo Comparator|Arm 2: Placebo|
89450561|NCT01265901|Active Comparator|Sunitinib|Sunitib as Standard therapy per Label.
89450562|NCT01265901|Experimental|IMA901 plus GM-CSF added to sunitinib after single dose of cy|After 1 cycle of sunitinib, intradermal vaccinations with IMA901 plus GM-CSF as adjuvant after a single dose of cyclophosphamide will be applied for a period of 4 months while continuing treatment with sunitinib
89450563|NCT02267499|Experimental|LLM training|Participants use the FitForAll exergaming computer platform as the physical training component (PTC); Participants use the language adapted Version of the BrainFitness Program as the cognitive training component (CTC)
89450564|NCT02267499|No Intervention|Passive Control|Participants do not receive an intervention serving as passive controls
89450565|NCT05627505||Pneumonia group|Patients in the MICU after lung transplantation were enrolled, and alveolar lavage fluid was obtained within 48 hours of the patient's surgery, divided into aliquots, and subjected to macrogenomic sequencing, routine microbiological testing and cytokine testing. Patients will be divided into pneumonia group if they had a co-infection at the time of sampling.
89450566|NCT05627505||control group|Patients in the MICU after lung transplantation were enrolled, and alveolar lavage fluid was obtained within 48 hours of the patient's surgery, divided into aliquots, and subjected to macrogenomic sequencing, routine microbiological testing and cytokine testing. Patients will be divided into non-pulmonary infection （control）group if they had no co-infection at the time of sampling.
89450567|NCT05627427|Experimental|Surufatinib in combination of Sintilimab|Surufatinib Sintinlimab
89450568|NCT02267733|Experimental|Early Disease|Patients not requiring anti-tumor therapy
89450569|NCT02267733|Experimental|Disease Requiring Anti-tumor therapy|Patients that have disease requiring anti-tumor therapy at any time
89450570|NCT02264535|Experimental|0.1mg/ml Ginkgolides Meglumine Injection|Injection, 0.1mg/ml.
89450571|NCT02264535|Experimental|1mg/ml Ginkgolides Meglumine Injection|Injection, 1mg/ml.
89450572|NCT02264535|Experimental|5mg/ml Ginkgolides Meglumine Injection|Injection, 5mg/ml.
89450573|NCT02264613|Experimental|Dose Regimen A (DR-A)|Drug: ALRN-6924 Weight-based-dosing administered IV on days 1, 8 and 15 of a 28-day cycle.
89450574|NCT02264613|Experimental|Dose Regimen B (DR-B)|Drug: ALRN-6924 Weight-based-dosing administered IV on days 1, 4, 8 and 11 of a 21-day cycle
89450575|NCT02264613|Experimental|Dose Regimen C (DR-C)|Drug: ALRN-6924 Weight-based-dosing administered IV on days 1, 3 and 5 of a 21-day cycle
89450576|NCT02264613|Experimental|Combination with palbociclib|Drug: ALRN-6924 Weight-based-dosing administered IV on days 1, 8 and 15 of a 28-day cycle Drug: Palbociclib Fixed-dose capsule administered orally on days 1 through 21 of a 28-day cycle
89450577|NCT02267889|Experimental|Image guided GP ablation|Use of cardiac nuclear imaging data to guide GP ablation procedures.
89450578|NCT01850082|Other|Endoscopic Vein Harvest (EVH)|An endoscopic vein harvest allows a portion of vein from the inside of the leg to be removed through small incisions. This reduces the length of the incision by several inches. An endoscope, or video camera, is used to view the vein and remove the needed length.
89450579|NCT01850082|Other|Open Vein Harvest (OVH)|"Open vein harvesting is the traditional method for vein harvesting. It is performed under direct vision using a single long incision or, more commonly, multiple-smaller incisions (referred to as bridging technique) along the course of the vein."
89450580|NCT01463397|Experimental|SAR292833 dose level 1|Dose level 1 twice daily immediately after breakfast/dinner
89450581|NCT01463397|Experimental|SAR292833 dose level 2|Dose level 2 twice daily immediately after breakfast/dinner
89450582|NCT01463397|Placebo Comparator|Placebo|Placebo (for SAR292833) twice daily immediately after breakfast/dinner
89450583|NCT05231382|Experimental|Experimental group SALOX regimen|The therapeutic scheme was SLAOX regimens including oxaliplatin (130 mg/m2 infusion for 3 hours on day 1), Raltitrexed (2mg/m2 infusion for 30-60 minutes on day 1)
89450584|NCT05231382|Active Comparator|Control group FOLFOX regimen|The therapeutic scheme was modified FOLFOX6 regimens including oxaliplatin (130 mg/m2 infusion for 3 hours on day 1), leucovorin (200 mg/m2 from hour 3 to 5 on day 1) and Fluorouracil (400 mg/m2 in bolus, and then 2,400 mg/m2 continuous infusion 46 hours).
89450585|NCT02264691||Normal (healthy volunteers)|No Research Intervention. Clinically indicated interventions only.
89450586|NCT02264691||Mild Asthmatics|No Research Intervention. Clinically indicated interventions only.
89450587|NCT02264691||Mild to Moderate Asthmatics|No Research Intervention. Clinically indicated interventions only.
88935210|NCT01777048|Placebo Comparator|Omega-3 Placebo|1g of Omega-3 Placebo per day for 12 weeks: 2 capsules after breakfast and 2 capsules after dinner
89450588|NCT02264691||Severe Asthmatics|No Research Intervention. Clinically indicated interventions only.
89450589|NCT05627037|Experimental|Loading in 30 days|Implant allocated to the study arm will be restored with a temporary restoration after 30 days of implant placement, that will be replaced with definitive restoration after 90 days of implant placement.
89450590|NCT05627037|Active Comparator|Loading in 90 days|Implant allocated to the study arm will be restored directly with the definitive restoration after 90 days of implant placement.
89450591|NCT03949140|Experimental|Laser hair removal treatment|Patients who choose to enroll will plan to undergo a total of up to 8 laser hair removal sessions every 4-6 weeks. If patients develop abscess or infection during this time, they will undergo I&D and/or antibiotics, consistent with standard therapy for infection or abscess. If patients have 2 or more infections in 1 year, pain or drainage for more than 1 month, or miss more than 1 week of school or work due to ineffective treatment of pilonidal disease, these patients will undergo surgical excision and subsequent follow-up at surgeon's discretion. Patients will follow up at 2-4-week intervals for 3 months, then at 6, 9, and 18 months after conclusion of the laser therapy sessions. At all follow-up sessions, patients will be given the DQLI, CDQLI, and Promis 3A Pain survey. Unscheduled visits such as unplanned clinic visits, emergency department encounters, and hospitalizations, will be included in data collected for analysis of primary and secondary outcomes.
89450592|NCT02267967|Experimental|Sulfatinib|Sulfatinib 300 mg once a day (QD) will be orally administrated on a 28-day cycle.
89450593|NCT01262235|Experimental|TKM-080301|
88935211|NCT01777074||Generalist physicians Cohort|
88935212|NCT01777074||Paediatricians Cohort|
88935213|NCT01777087|Experimental|Healthy normal volunteers|Healthy normal volunteers
88935214|NCT01777100|Experimental|sufentanil|Anesthetic induction with IV sufentanil at 0.5 mcg.kg-1 and analgesic maintenance with IV remifentanil at 0.1 to 0.3 mcg.kg-1.min-1 on demand target-controlled infusion
88935215|NCT01777100|No Intervention|remifentanil|Anesthetic induction with target-controlled infusion IV remifentanil at 0.5 mcg.kg-1.min-1 in 5 minutes followed by analgesic maintenance on demand of IV target-controlled infusion remifentanil at 0.1 to 0.3 mcg.kg-1.min-1.
89450594|NCT05161104||left ventricular systolic dysfunction(LVSD)|
89450595|NCT05161104||left ventricular diastolic dysfunction(LVDD)|
89450596|NCT05161104||right ventricular dysfunction(RVD)|
89450597|NCT05161104||diffuse ventricular dysfunction|
89450598|NCT05161104||hyperdynamic state left ventricular function|
89450599|NCT05161104||Normal|
89450600|NCT01262001|Experimental|Cohort 1/1-EX|Subjects with moderate to severe idiopathic pulmonary fibrosis (IPF) who have evidence of disease progression
89014888|NCT03398304|Experimental|Marathon Participation|On the day of the marathon prior to start, the participant will be seated for 10 minutes prior to measuring their baseline heart rate. A 4.5 mL blood sample will be collected prior to initiation of exercise. Immediately after completion of the marathon, a 4.5 mL blood draw will be completed. Additional 4.5 mL blood draws will be taken at 1 and 2 days post-marathon to measure to length of time required to return to baseline coagulation, fibrinolysis, and inflammation following the prolonged, intense exercise.
89450601|NCT01262001|Experimental|Cohort 2/2-EX|Subjects with mild to moderate idiopathic pulmonary fibrosis (IPF) who have evidence of disease progression
89450602|NCT05161026|Other|Patients with AML|Patients with AML
89450603|NCT01100151|Experimental|RDC-1036 (ALKS 37)|Capsules for oral administration
89450604|NCT01100151|Placebo Comparator|Placebo|Capsules for oral administration
89450605|NCT01460511|Placebo Comparator|P - Placebo-HFA|Placebo-HFA, 0 mcg/inhalation, 2 inhalations QID
89450606|NCT01460511|Experimental|T - E004 (Epinephrine Inhalation Aerosol) HFA-MDI|E004 (Epinephrine Inhalation Aerosol) HFA-MDI, 125 mcg/inhalation, 2 inhalations QID
89450607|NCT01458405|Placebo Comparator|Placebo|
89450608|NCT01458405|Active Comparator|CAP-1002 Allogeneic Cardiosphere-Derived Cells|
89450609|NCT03135171|Experimental|Trastuzumab, Pertuzumab and Tocilizumab|
89450610|NCT01449591|Experimental|BFH772|
89450611|NCT01449591|Placebo Comparator|Vehicle|
89450612|NCT01449591|Active Comparator|Metronidazole|
89014890|NCT03382561|Experimental|Arm A (nivolumab, CE)|Patients receive nivolumab IV over 30 minutes on day 1, carboplatin IV over 30-60 minutes on day 1 or cisplatin IV over 60-120 minutes on day 1, and etoposide IV over 60-120 minutes on days 1-3. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients continue to receive nivolumab IV over 30 minutes every 2 weeks for up to 2 years.
89450613|NCT04475445|Experimental|Ultrasound guided transforaminal epidural steroid injection|
89450614|NCT04475445|Experimental|Interlaminar epidural steroid injection|
89450615|NCT00909753|Experimental|Ursodiol (test) First|Ursodiol Tablets, 500 mg
89450616|NCT00909753|Active Comparator|Urso Forte™ (reference) First|Urso Forte™ Tablets, 500 mg
89450617|NCT01444365|Experimental|ABT-652 NSAID|ABT-652 capsules -2 ABT-652 capsules twice daily (add-on) NSAID - as prescribed
89450618|NCT01444365|Placebo Comparator|Placebo NSAID|Placebo - 2 placebo capsules twice daily NSAID - as prescribed
89450619|NCT03991377|Experimental|EMDR therapy|Patients in the psychotherapy intervention will receive up to 20 individual sessions of EMDR, weekly sessions, of 60 minutes each, using the standard EMDR therapy protocol developed by Shapiro to treat both current and past trauma-related symptom.
89450620|NCT03991377|Active Comparator|Treatment as usual|Multidisciplinary approach that includes pharmacological treatment and psychological support.
89450621|NCT01442337|Experimental|ASP8597 low dose|
89450622|NCT01442337|Experimental|ASP8597 high dose|
89450623|NCT01442337|Experimental|ASP8597 highest dose|
89450624|NCT01442337|Placebo Comparator|Placebo|Placebo comparator used in Part 2 only
89450625|NCT01098435|Experimental|RDC-0313 (ALKS 33)|2-capsules taken orally
89450626|NCT01098435|Placebo Comparator|Placebo|2-capsules taken orally
89450627|NCT05626959|Experimental|NTI164|"Full-Spectrum Medicinal Cannabis Plant Extract with less than 0.08% THC (NTI164)~Randomised Controlled Phase:~Part A: 5mg/kg, 10mg/kg, 15mg/kg, 20mg/kg (1 week each, total duration = 4 weeks) Part B: 20mg/kg or maximum tolerated dose (total duration = 4 weeks).~Open-Label Phase 20mg/kg or maximum tolerated dose (total duration = 8 weeks).~Extension Phase 20mg/kg or maximum tolerated dose (total duration = 36 weeks)."
89450628|NCT05626959|Placebo Comparator|Placebo|"Randomised Controlled Phase:~Part A: 5mg/kg, 10mg/kg, 15mg/kg, 20mg/kg (1 week each, total duration = 4 weeks) Part B: 20mg/kg or maximum tolerated dose (total duration = 4 weeks)."
89450629|NCT00909597|Active Comparator|pioglitazone|
89450630|NCT00909597|Experimental|taspoglutide 10mg|taspoglutide 10mg sc weekly
89450631|NCT00909597|Experimental|taspoglutide 10mg/20mg|taspoglutide 20mg sc weekly after 4 weeks of taspoglutide 10mg sc weekly
88935216|NCT01777113|Experimental|High Intensity Aerobic training|The subjects will perform a high intensity treadmill training
88935217|NCT01777113|Experimental|High Intensity Strength Training|The subjects will perform and high intensity training on the same leg horizontal press.
89450632|NCT05626881|Active Comparator|PRP group|It will include patients with melasma treated with PRP sessions every two weeks for three monthsPRP is injected intralesionally at the site of melasma using a 30 G hypodermic needle through an insulin syringe. A maximum of 2.0 ml of PRP will be injected into the dermis (about 1.5-2.0 mm deep) about 1 cm apart to raise dermal papules
89450633|NCT05626881|Active Comparator|Silymarin group|It will include patients with melasma applying with topical Silymarin cream. Silymarin cream will be prepared in the Faculty of Pharmcy according to the following formulation: stearic acid 15 g, glycerin 5 g, KOH 0.72 g, H2O 79 g, sodium benzoate (0.1%), and Tween-80 (1%). Silymarin was manufactured with concentration of 1.4%. Silymarin will be applied twice daily. The duration of treatment will be 3 months.
89450634|NCT05626881|Active Comparator|PRP + silymarin group|It will be treated by using both PRP sessions and applying topical Silymarin cream. Silymarin will be applied twice daily, while PRP sessions every 2 weeks.
89450635|NCT01094067|Experimental|1|Placebo at visit 1, tezosentan at visit 2
89450636|NCT01094067|Experimental|2|Tezosentan at visit 1, placebo at visit 2
89450637|NCT01077297|Experimental|Tezosentan|
89450638|NCT05653245|Placebo Comparator|Group 1|Fifteen periodontitis patients will receive Phase I therapy, reevaluation after four weeks with modified minimally invasive surgical technique (M-MIST) alone
89450639|NCT05653245|Placebo Comparator|Group 2|Fifteen periodontitis patients will receive Phase I therapy, reevaluation after four weeks with (M-MIST) and hydrogel injection
89450640|NCT05653245|Active Comparator|Group 3|Fifteen periodontitis patients will receive Phase I therapy, reevaluation after four weeks with (M-MIST) and RGD peptide hydrogel.
88935218|NCT01777113|Active Comparator|Mixed Training|Conventional training consisted of group mobility, balance and stretching exercises.
88935219|NCT01777178|Experimental|Low bicarbonate dialysis|
88935220|NCT01777204||Tacrolimus|Influence of tacrolimus on gastrointestinal transit and motility in renal transplant recipients.
88935221|NCT01777204||Cyclosporine|Influence of cyclosporine on gastrointestinal transit and motility in renal transplant recipients.
89450641|NCT04766931|Experimental|A1 FB2001 or Placebo|single dose
89450642|NCT04766931|Experimental|A2 FB2001 or Placebo|single dose
89450643|NCT04766931|Experimental|A3 FB2001 or Placebo|single dose
89450644|NCT04766931|Experimental|A4 FB2001 or Placebo|single dose
89450645|NCT04766931|Experimental|A5 FB2001 or Placebo|single dose
89450646|NCT04766931|Experimental|A6 FB2001 or Placebo|single dose
89450647|NCT04766931|Experimental|A7 FB2001 or Placebo|single dose
89450648|NCT04766931|Experimental|B1 FB2001 or Placebo|Once daily for 5 days
89450649|NCT04766931|Experimental|B2 FB2001 or Placebo|Once daily for 5 days
89450650|NCT04766931|Experimental|A8 FB2001 or Placebo|single dose
89450651|NCT04766931|Experimental|B3 FB2001 or Placebo|Twice daily for 5 days
89450652|NCT00905385|Experimental|Low Dose: 3,200 CFU|5 subjects inoculated with 3,200 colony forming units (CFU).
89450653|NCT00905385|Experimental|High Dose: 32,000 CFU|5 subjects inoculated with 32,000 colony forming units (CFU).
89450654|NCT05379855|Experimental|low concentration atropine group|Subjects of the low concentration atropine group received 0.01% atropine eye drops both eyes once every night. Eye drops are prepackaged with identical eye drops bottle, pasted with number and shelf life, and stored in 4℃.
89450655|NCT05379855|Placebo Comparator|placebo group|Subjects of the control group received placebo eye drops (0.9% preservative free sodium chloride) both eyes once every night. Eye drops are prepackaged with identical eye drops bottle, pasted with number and shelf life, and stored in 4℃.
89450656|NCT03731910|Experimental|HCC group|Participants who are scheduled for TARE for HCC treatment. They undergo MRI three times- before, 1- and 2-week after TARE.
89450657|NCT01070433|Experimental|MEBO Wound Ointment (MEBO)|Topical application twice a day
89450658|NCT01070433|Active Comparator|Standard of Care|Topical application twice a day
88935222|NCT01777204||Mycophenolate mofetil|Influence of mycophenolate mofetil on gastrointestinal transit and motility in renal transplant recipients.
89450659|NCT03715764|Other|Physical therapy assessment|Patients allocated to the intervention group will be assigned to an assessment and evaluation by a physical therapist. If they are diagnosed with knee osteoarthritis they will get an offer to participate in a patient education program and physical training with an individualized exercise program made by a physical therapist. Patients will be offered individual treatment if they decline to participate in the education program, or if they have another diagnosis than osteoarthritis. Anytime after the first assessment by the physical therapist, the patient will be able to contact a physician if they want to.
89450660|NCT03715764|Other|Physician assessment|Allocation to the control group will involve an assessment and evaluation made by a physician. Further measures will then be determined by attending physician and the procedures that might get included are drug prescriptions, referral to x-ray examination, referral to a physical therapist or another health care provider. Anytime after the first assessment by the physician, the patient will be able to contact a physical therapist if they want to, even though if they have not been referred by the physician.
89450661|NCT00904683|Experimental|LY2062430|
89450662|NCT00904683|Placebo Comparator|Placebo|
89450663|NCT02718326|Experimental|Dosing regimen 1|Participants will receive IVT aflibercept dosing regimen 1
89450664|NCT02718326|Experimental|Dosing regimen 2|Participants will receive IVT aflibercept dosing regimen 2
89450665|NCT02718326|Sham Comparator|Dosing regimen 3|Participants will receive matching sham injections
89450666|NCT03691584|Experimental|BAL PK study|Bronchoalveolar lavage procedure performed at either 2, 4, 8, or 24 hours after final dose of TP-6076 on Day 4
89450667|NCT03683628|Active Comparator|PB-MNC therapy|The patientsin PB-MNC therapy group will be injected with G-CSF mobilized PB-MNC into calf or thigh muscle of ischemic limb, Aspirin 81 mg/day, cilostazol 200 mg/day and walking exercise 3 times per week.
89450668|NCT03683628|Active Comparator|No PB-MNC therapy|In patients in No PB-MNC therapy, they will receive aspirin 81 mg/day, cilostazol 200 mg/day and walking exercise 3 times per week.
89450669|NCT05160792|Experimental|Volunteers|Index leg - compression with GraduCheck Control leg - compression without Graducheck
89450670|NCT03470298|Active Comparator|Mid luteal Endometrial Scratching (MLES)|Making injury to endometrium by using Manual Vacuum Aspiration cannula size 5 . At this arm scratching done at mid luteal phase (day21) of the cycle before induction for ICSI
89450671|NCT03470298|Active Comparator|Retrieval Endometrial Scratching (RES)|Making injury to endometrium by using Manual Vacuum Aspiration cannula size 5 .Here scratching done at same day of ovum pick up of ICSI cycle the difference only between arm of MLES and RES only in the timing of scratching .
89450672|NCT04009512|Experimental|Primary Study Arm|The Valiant Thoracoabdominal Stent Graft System is comprised of two investigational devices including the Thoracic Bifurcate and the Visceral Manifold. These devices work to facilitate endovascular stenting of the visceral vessels (renals, celiac, SMA) while maintaining flow to the visceral and infrarenal segments.
89450673|NCT04009512|Experimental|Expanded Use Arm|The Valiant Thoracoabdominal Stent Graft System is comprised of two investigational devices including the Thoracic Bifurcate and the Visceral Manifold. These devices work to facilitate endovascular stenting of the visceral vessels (renals, celiac, SMA) while maintaining flow to the visceral and infrarenal segments. The expanded use arm provides broaden inclusion criteria to include select patients excluded from the primary study arm.
89450674|NCT05527262|Experimental|Queen Square Upper limb training programme|Patients will undergo 45-60 hours of conventional physiotherapy and occupational therapy over 3 weeks as part of the Queen Square Upper Limb Neurorehabilitation Programme (QSUL) (Ward et al., 2019).
89450675|NCT05527262|Experimental|Mindpod Dolphin|Patients will undergo 45-60 hours of arm, hand and finger training using immersive gaming technology (e.g. MindPod Dolphin) over 3 weeks.
89450676|NCT05527262|No Intervention|Wait-list Control|Patients will receive no planned treatment but will be on a waiting list for QSUL Programme after their follow up period if over.
89450677|NCT03891888|No Intervention|Control|Patients in this group will undergo standard treatment for their open tibia shaft fracture (irrigation and debridement of their open fracture and reamed intramedullary nailing)
89450678|NCT03891888|Experimental|Intervention|Patients in this group will receive a bone graft in addition to the undergoing standard treatment for their open tibia shaft fracture (irrigation and debridement of their open fracture and reamed intramedullary nailing)
89450679|NCT05160402|Experimental|Cohort 1 (SAD)|In Cohort 1, subjects will be randomized to receive a single intranasal and intraoral administration of 1 mg of IGM 6268 or placebo
89450680|NCT05160402|Experimental|Cohort 2 (SAD)|In Cohort 2, subjects will be randomized to receive a single intranasal and intraoral administration of 3.75 mg of IGM 6268 or placebo
88935223|NCT01777204||Mycophenolate sodium|Influence of mycophenolate sodium on gastrointestinal transit and motility in renal transplant recipients.
88935224|NCT01777204||Everolimus|Influence of everolimus on gastrointestinal transit and motility in renal transplant recipients.
89450681|NCT05160402|Experimental|Cohort 3 (SAD)|In Cohort 3, subjects will be randomized to receive a single intranasal and intraoral administration of 7.5 mg of IGM 6268 or placebo
89450682|NCT05160402|Experimental|Cohort 4 (MAD)|In Cohort 4, subjects will be randomized to receive a single intranasal and intraoral administration of 3.75 mg of IGM 6268 or placebo once a day for 5 days.
89450683|NCT05160402|Experimental|Cohort 5 (MAD)|In Cohort 5, subjects will be randomized to receive a single intranasal and intraoral administration of 7.5 mg of IGM 6268 or placebo once a day for 5 days.
89450684|NCT05160402|Experimental|Cohort 6 (MAD)|In Cohort 6, subjects will be randomized to receive a single intranasal and intraoral administration of 7.5 mg of IGM 6268 or placebo twice a day for 5 days.
89450685|NCT05052086|Experimental|Magnetomotoric ultrasound|Magnetomotoric ultrasound in addition to MRI.
88935225|NCT01777204||Sirolimus|influence of sirolimus on gastrointestinal transit and motility in renal transplant recipients.
88935226|NCT01777204||Without immunosuppression|Gastrointestinal transit and motility in healthy volunteers.
88935227|NCT01777230||All patients|Alle subjects included retain in one cohort.
88935228|NCT01777243|Experimental|Part A Arm|Two subjects in Part A will receive starting dose level of GSK2398852 as 5 milligram (mg) [approximately equivalent to 0.1 mg/kilogram (kg)]. The next escalation dose levels in two subjects each are proposed as 1 mg/kg, 3 mg/kg, 10 mg/kg and 30 mg/kg. GSK2315698 will be administered at variable dosed until the concentration of the SAP mAb has fallen below 100 ng/mL.
88935229|NCT01777243|Experimental|Part B Arm|The precise selection of numbers of subjects and dose levels in Part B will be informed by the results from Part A.
88935230|NCT01777256|Experimental|GSK2586184 50 mg Arm|Subjects in the GSK2586184 50 mg Arm will receive twice daily dose of GSK2586184 50 mg 1 x 50 mg tablet + 1x placebo tablet) orally up to 12 weeks. Study medication should be taken with food, immediately following a meal
88935231|NCT01777256|Experimental|GSK2586184 100 mg Arm|Subjects in the GSK2586184 100 mg Arm will receive twice daily dose of GSK2586184 100 mg (2 x 50 mg tablets) orally up to 12 weeks. Study medication should be taken with food, immediately following a meal.
88935232|NCT01777256|Experimental|GSK2586184 200 mg Arm|Subjects in the GSK2586184 200 mg Arm will receive twice daily dose of GSK2586184 200 mg (1 x 200 mg tablet + 1x placebo tablet) orally up to 12 weeks. Study medication should be taken with food, immediately following a meal.
88935233|NCT01777256|Experimental|GSK2586184 400 mg Arm|Subjects in the GSK2586184 400 mg Arm will receive twice daily dose of GSK2586184 400 mg (2 x 200 mg tablets) orally up to 12 weeks. Study medication should be taken with food, immediately following a meal.
88935234|NCT01777256|Placebo Comparator|Placebo|Subjects in the placebo arm will receive twice daily dose of 2 matching placebo tablets orally up to 12 weeks; taken with food, immediately following a meal.
88935235|NCT01777295|Experimental|HBsAg/AS Group|Subjects in this group received 1 dose of Placebo at Day -30 followed by 2 doses of HBsAg/AS, at Day 0 and Day 30.
88935236|NCT01777295|Active Comparator|Engerix-B Group|Subjects in this group received 1 dose of Placebo at Day -30 followed by 3 doses of Engerix-B at Day 0, Day 30 and Day 180.
88935237|NCT01777347|Experimental|3% Saline|Nebulized 3% Saline
88935238|NCT01777347|Placebo Comparator|0.9% Normal Saline|Nebulized 0.9% normal saline
88935239|NCT01777360|Experimental|THERMOPLASTY|ALAIR, radiofrequency catheter for bronchial THERMOPLASTY
88935240|NCT01777373||Idiopathic pulmonary fibrosis (IPF)|Idiopathic pulmonary fibrosis (IPF)
89450686|NCT03468972|Experimental|Immunosuppression|corticosteroids or cyclophosphamide added on corticosteroids
89450687|NCT03468972|Active Comparator|Intensive supportive care|intensive supportive care with RAS blockers, blood pressure control, and protein restriction diet
89450688|NCT03468894|No Intervention|Control|The control group will continue to work as usual at their regular workstations.
89450689|NCT03468894|Experimental|Intervention|A shared treadmill workstation will be installed in participating offices, or in a nearby location in case there is no space to fit the workstation in the office, enrolled to this group. Within the intervention group there will be a maximum allocation of two participants per treadmill desk. The participants in the intervention group will be asked to interrupt their sitting with 20 minutes of self-selected light-intensity walking at a speed of 1-4 km/h each hour for a minimum of 6 hours per shift to accumulate a total of 2 hours of light-intensity activity per work day.
89450690|NCT03470220||Ultrasound|All included patients will be examined with ultrasound
89450691|NCT03471858|Active Comparator|Cervical Balloon|Transcervical 2-way 18 French (18F) single balloon Foley catheter, applied using a sponge-holding forceps into the cervical canal with the balloon inflated to a minimum of 30ml and maximum of 60ml with sterile water or saline [1]. This will be administered once during the study and will be retained for a maximum of 12 hours within the 24 hour study period.
89450692|NCT03471858|Active Comparator|Prostaglandin|Prostaglandin E2 (Prostin®) 3mg tablet, placed high in the vaginal fornix. This will be administered per vaginum once in the first 6 hours; a second dose is administered at the discretion of the clinician / clinical team 6 hours after the first pessary, for a cumulative total of 6mg within the 24 hour study period.
89450693|NCT03600714|Experimental|Treatment|Treatment with Lonafarnib, Ritonavir, and Peginterferon lambda
88935241|NCT01777373||Control|Control
88935242|NCT01777373||Non-IPF interstitial lung disease (ILD)|Non-IPF interstitial lung disease (ILD)
88935243|NCT01777373||Uncharacterized ILD|Uncharacterized ILD
88935244|NCT01777386|Active Comparator|preexpanded flap|Fourteen patients were treated with fifteen '' preexpanded perforator flap surgery '' interventions. The last six cases were evaluated in terms of perforator artery diameter before and after expansion process. The preexpanded flap donor sites' perforator artery diameters were also compared with their anatomic equivalents located in the symmetric side of the body.
88935245|NCT01777386|No Intervention|control side|In six of the 14 patients, perforator artery diameter of the nonexpanded symmetric anatomical side of the body (equivalent to the expanded site)were measured.
89450694|NCT05493488|Active Comparator|DBI-001 Gel|Topical application of DBI-001 Gel on foot/feet affected with tinea pedis
89450695|NCT05493488|Active Comparator|DBI-002 Gel|Topical application of DBI-002 Gel on foot/feet affected with tinea pedis
89450696|NCT05493488|Placebo Comparator|Aqueous Gel|Topical application of Aqueous Gel on foot/feet affected with tinea pedis
89450697|NCT03112902|Active Comparator|Effects of tACS during SWS- Standard/Nested 1|This is a triple cross-over with a sham control condition; the standard tACS administered first, then Nested, then sham.
89450698|NCT03112902|Active Comparator|Effects of tACS during SWS- Older Adults Active 1|This is a double cross-over with a sham control condition; the tACS administered first, then the sham
89450699|NCT03112902|Active Comparator|Effects of tACS during SWS- MCI Active 1|This is a cross-over with a sham control condition; the standard tACS administered first, then sham.
89450700|NCT03112902|Active Comparator|Effects of tACS during SWS- Standard/Nested 2|This is a triple cross-over with a sham control condition; the standard tACS administered first, then sham, then nested tACS.
89450701|NCT03112902|Active Comparator|Effects of tACS during SWS- Standard/Nested 3|This is a triple cross-over with a sham control condition; the sham tACS administered first, then nested tACS, then standard tACS.
89450702|NCT03112902|Active Comparator|Effects of tACS during SWS- Older Adults Active 2|This is a double cross-over with a sham control condition; the sham administered first, then the tACS.
89450703|NCT03112902|Active Comparator|Effects of tACS during SWS- MCI Active 2|This is a cross-over with a sham control condition; the sham administered first, then standard tACS.
89450704|NCT03112902|Active Comparator|Effects of tACS during SWS- Standard/Nested 4|This is a triple cross-over with a sham control condition; the sham tACS administered first, then standard tACS, then nested tACS.
89450705|NCT03112902|Active Comparator|Effects of tACS during SWS- Standard/Nested 5|This is a triple cross-over with a sham control condition; the nested tACS administered first, then sham, then standard tACS.
89450706|NCT03112902|Active Comparator|Effects of tACS during SWS- Standard/Nested 6|This is a triple cross-over with a sham control condition; the nested tACS administered first, then standard tACS, then sham.
89450707|NCT02720042|Experimental|Phasix™ Mesh|Patients treated with Phasix™ Mesh for hernia repair
89450708|NCT01352793|Experimental|rLP2086 vaccine|rLP2086 vaccine
89450709|NCT01352793|Other|control|The control treatment will be HAVRIX vaccine at month 0 and 6 and a normal saline injection at month 2.
89450710|NCT03470142|Active Comparator|traditional laparoscopy-assisted surgery|The traditional laparoscopic operation undergo and then a small incision(5cm) is made in the middle of the lower abdominal wall to trim the mesangial membrane and remove the specimen. At last the anastomosis operation undergo by the laparoscopic operation.
89450711|NCT03470142|Experimental|total laparoscopic surgery with no incision (NOSES)|The whole procedures undergo by total laparoscopic surgery with no incision in the abdominal wall. The specimen then will be removed through natural orifice such as anal.
89450712|NCT03471702|Experimental|Single Arm Study|All subjects enrolled on study will utilize Aqueduct's Smart External Drain (SED) from the time of external drain implementation until end of study upon discharge of SED or switch to standard of care external drain.
89450713|NCT04489862|Experimental|CAR T cells therapy|The safety and efficacy of αPD1-MSLN-CAR T cells will be assessed in a standard 3+3 dose escalation approach. Four doses of CAR T cells will be evaluated in this study: 1×10^5 CAR+ T cells/kg, 3×10^5 CAR+ T cells/kg, 1×10^6 CAR+ T cells/kg, and 3×10^6 CAR+ T cells/kg.
89450714|NCT05163366|Experimental|GROUP A|Group A will receive rectal ketamine(Ket)
89450715|NCT05163366|Active Comparator|GROUP B|Group B will receive only traditional standard of care protocols.
89450716|NCT04489784|Experimental|Treatment|Laser treatment on ballerina's feet.
89450717|NCT05159544||Multi-omics model developing and training arm|Blood samples and individual health information from 50,000 participants in community, who got 3-year follow-up are selected.
89450718|NCT05159544||Multi-omics model validating arm|10,000 participants in routine annual physicals from hospitals will be selected, and they will be followed up for 2 years.
89014891|NCT03382561|Active Comparator|Arm B (CE)|Patients receive carboplatin IV over 30-60 minutes on day 1 or cisplatin IV over 60-120 minutes on day 1, and etoposide IV over 60-120 minutes on days 1-3. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
89450719|NCT05159544||Multi-omics model evaluating arm|Participants in Taizhou cohort will be selected.
89450720|NCT05004428||Type 2 Diabetes Mellitus patients with Chronic Kidney Disease|Canadian patients with type 2 diabetes mellitus data will be collected retrospectively.
89450721|NCT01038843|Experimental|VA106483 1mg|
89450722|NCT01038843|Experimental|VA106483 2mg|
89450723|NCT01038843|Experimental|VA106483 4mg|
89200798|NCT00544882|Experimental|DR-1021|After randomization, participants received DR-1021 consisting of 150 μg desogestrel (DSG)/20 μg ethinyl estradiol (EE) administered orally as a combination tablet once daily for 21 days followed by EE 10 μg tablet once daily for 7 days (Cycle 2). Participants who completed Cycle 2 then received Kariva, consisting of 150 μg DSG/20 μg EE administered orally as a combination tablet taken once daily for 21 days followed by placebo tablet once daily for 2 days followed by 10 μg EE taken once daily for 5 days (Cycle 3).
89200799|NCT00544882|Active Comparator|Mircette|After randomization, participants received Mircette consisting of 150 μg desogestrel (DSG)/20 μg ethinyl estradiol (EE) administered orally as a combination tablet once daily for 21 days followed by placebo tablet once daily for 2 days followed by 10 μg EE tablet once daily for 5 days (Cycle 2). Participants who completed Cycle 2 then received Kariva, consisting of 150 μg DSG/20 μg EE administered orally as a combination tablet taken once daily for 21 days followed by placebo tablet once daily for 2 days followed by 10 μg EE taken once daily for 5 days (Cycle 3).
89200800|NCT04035603|Experimental|D-Cycloserine Augmentation|D-cycloserine (DCS) augmentation of CET sessions
89200801|NCT04035603|Placebo Comparator|Placebo Augmentation|Placebo (PBO) augmentation of CET sessions
89200802|NCT00606801|Active Comparator|Galantamine 8 mg/day|Galantamine 8 mg/day
89200803|NCT00606801|Placebo Comparator|Placebo|placebo
89200804|NCT00972790|Sham Comparator|Control Group|The patients in the control arm will receive sham nerve blocks with 20 ml of saline + epinephrine 1:200,000, in a manner identical to that described for the treatment group.
89450724|NCT01038843|Placebo Comparator|Sugar pill|
89450725|NCT02462954|Experimental|ContraGel|ContraGel, a personal lubricant has a Conformite Europeenne (CE) mark and has been used with barrier devices in Europe and other countries outside the US, but it is not currently approved by the US FDA.
89450726|NCT02462954|Placebo Comparator|HEC Placebo|The placebo gel is supplied by CONRAD in pre-filled individual applicators, each applicator containing 4.0 mL of HEC gel. Placebo gel contains HEC as the gel thickener, purified water, sodium chloride, sorbic acid and sodium hydroxide.
89450727|NCT05159232|Active Comparator|laparoscopic trans abdominal preperitoneal repair|length of hospital stay
89450728|NCT05159232|Active Comparator|open mesh repair of inguinal hernia|length of hospital stay
89450729|NCT02462408|Experimental|Posterior approach|The main difference between this block approach and the conventional infraclavicular approach is the site and angle of needle insertion. Otherwise, the end point of local anaesthetic injection remained the same for both approaches.
89450730|NCT02462408|Active Comparator|Conventional approach|The main difference between this block approach and the conventional infraclavicular approach is the site and angle of needle insertion. Otherwise, the end point of local anaesthetic injection remained the same for both approaches.
89450731|NCT00900783|Experimental|2|FV-100, 400 mg once daily AND valacyclovir placebo, three times a day, for seven days
88935246|NCT01777451||Neurofibromatosis 1|"All patients diagnosed with neurofibromatosis type 1. GROUP 1:ADDITIONAL IMAGING OR SURGERY There will be patients with high-risk neurofibromas (potential malignant). These patients will underwent additional examinations or surgery (outside this study). Follow-up MRI within 2 years (study MRI )~GROUP 2:~No suspicious lesions at MRI. Follow-up within 2 years(Study MRI)."
88935247|NCT01777464|Experimental|patients|patients allergic to house dust mite receive sham solution for 5 minutes on first visit and histamine (16mg/ml) for 5 minutes on second visit
88935248|NCT01777464|Sham Comparator|healthy controls|healthy controls receive sham solution for 5 minutes on first visit and histamine (16mg/ml) for 5 minutes on second visit
88935249|NCT01777477|Experimental|Chloroquin in addition to Gemcitabine|Gemcitabine 1000 mg/m2 i.v. at days 1, 8, 15 of every 28-day cycle. Chloroquine 100 mg, 200 mg or 300 mg (according to dose level) p.o. at days 2, 9, 16 of every 28-day cycle.
88935250|NCT01777503|Experimental|prasugrel|prasugrel 60 mg loading dose, followed by 5 mg once daily until the end of follow-up
88935251|NCT01777503|Active Comparator|clopidogrel|Clopidogrel 300 mg loading dose followed by 75 mg once day until the end of follow-up
88935252|NCT01777516||healthy volunteers|1 group with no treatment : They provide the blank plasma to be used at in vitro study.
88935253|NCT01777529|Experimental|Multidose|Multidose from MMR Vaccine produced by Bio-Manguinhos/Fiocruz
88935254|NCT01777529|Active Comparator|Singledose|Singledose from MMR (GSK-TV), produced by GlaxoSmithKline
88935255|NCT01777607|Experimental|Intervention|
88935256|NCT01777633|Experimental|re-irradiation|re-irradiation for progressive DIPG in children
88935257|NCT01777646|Experimental|MSC-NTF|
88935258|NCT01777659|Experimental|TENS CABG|Eligible patients will be randomized to a transcutaneous electrical nerve stimulation program (TENS; n = 20) or to placebo-TENS (P-TENS; n = 18). All patients were followed by their own physicians, received routine nursing assistance, and were visited daily by one of the investigators, but P-TENS group will be not exposed to any specific electrical stimulation or motor physical intervention.
89014892|NCT03335072|Active Comparator|WHO-recommended|Annual mass azithromycin distribution of all residents
89014893|NCT03335072|Experimental|Age-based core group|Annual mass azithromycin treatment of everyone plus quarterly treatment of children
89450732|NCT00900783|Active Comparator|3|Valacyclovir, 1 gram, three times a day AND FV-100 placebo, once daily, for seven days
89450733|NCT00900783|Experimental|1|FV-100, 200 mg once daily AND valacyclovir placebo, three times a day, for seven days
89450734|NCT05139576||Pediatric Subjects and adults|Subjects were categorized into two age groups: <18 years (pediatric) and ≥18 years (adult).
89450735|NCT05139576||Pediatrics and adults|Subjects were categorized into two age groups: <18 years (pediatric) and ≥18 years (adult).
89450736|NCT04993196|Experimental|T1rho MRI|
89450737|NCT01035879|Experimental|MBX-2982 25 mg|
89450738|NCT01035879|Experimental|MBX-2982 100 mg|
89450739|NCT01035879|Experimental|MBX-2982 300 mg|
89450740|NCT01035879|Active Comparator|Sitagliptin 100 mg|
89450741|NCT01035879|Placebo Comparator|Placebo|
89450742|NCT05164536|Experimental|[18F]Florbetapir|Participants will undergo amyloid PET imaging with an approved amyloid radiotracer (ie, [18F]Florbetapir (Amyvid™)) to assess β-amyloid neuritic plaque density.
89450743|NCT01029873|Experimental|ALT-801|
89450744|NCT05164380||PWA|Persons with Aphasia
89450745|NCT05164380||CG|Control Group healthy adults without aphasia
88935259|NCT01777659|Placebo Comparator|P-TENS CABG|Patients will be treated with placebo-TENS (P-TENS) condition for 5 days (4 times/day; 30 min/session) applied on cervical region (C7-T4). P-TENS device underwent modifications in its internal programming: the control capacitor of the time constant was changed and the active time between pulses was modified from 330 milliseconds to 33 seconds, in order to prevent an analgesic effect (33).
88935260|NCT01777672|Active Comparator|Dietary and oral hygiene recommendations|Patients in this group will receive recommendations from their healthcare providers about bolus volume and viscosity adaptation for fluids, dietary and nutritional adjustments (liquids and solids) of bolus volume and viscosity/texture. Before leaving each hospital they will also learn basic rehabilitation strategies for OD including swallow postures, compensatory manoeuvres and oropharyngeal rehabilitation exercises and oral hygiene to follow at home.
88935261|NCT01777672|Experimental|oral TRPV1 agonist|Patients will receive the same recommendations as the control group and also recommendation for the administration of a TRPV1 agonist (natural capsaicin) supplement (5 mL bolus before each meal), 3 meals/day, 5 days/week for 2 consecutive weeks.
88935262|NCT01777672|Experimental|pharyngeal electrical stimulation|Treatment in this group will also include the same measures as in the control group, plus neuron stimulation treatment of 1 session / day of pharyngeal electrical stimulation of 10 min duration, 3 days/week during one week, done at the same center.
88935263|NCT01777672|Experimental|transcutaneous electrical stimulation|Treatment in this group will be the same as the control group plus trans-cutaneous electrical stimuli will be applied 5 seconds every minute during 1 hour daily session, 5 days/week during 2 consecutive weeks at the same centre.
88935264|NCT01777685|Other|sulpiride 50 mg|
88935265|NCT01777711|Active Comparator|Couple condition|Couples randomized to the couple condition will undergo the experimental manipulations and both partners will complete all study measures. Both members of the couple will be given body mass index (BMI) based on measurements taken during the intervention. Both will complete three surveys on paper and do some prompted planning and goal-setting together regarding weight loss through healthier eating and physical activity.
88935266|NCT01777711|Active Comparator|Individual Condition|Couples randomized to the individual condition will be stratified on gender and one partner, chosen at random, will undergo the experimental manipulations and complete all study surveys while the other will not (heretofore called the active partner vs. the passive partner). The active partner will receive BMI feedback based on measurements taken during the intervention appointment, complete three surveys, and verbally state some goals and plans for weight loss to the passive partner. The passive partner will not complete any study materials or participate in the intervention during the session.
88935267|NCT01777724|Experimental|Intervention|The intervention is a combination of Triple P Discussion Groups and Stress Control
88935268|NCT01777724|No Intervention|Control|Waitlist control. Participants allocated to the waitlist control will be able to access the intervention after post-intervention equivalent measures have been completed.
88935269|NCT01777737|Experimental|Cotrimoxazole|Sulfamethoxazole 400 mg. + trimethoprim 80 mg. weight-adjusted
88935270|NCT01777737|Placebo Comparator|Placebo|Identical capsules to cotrimoxazole
88935271|NCT01777750|Active Comparator|Pre- and perinterventional hypothermia|Cooling will be initiated by the application of cooling pads in the out-of-hospital setting followed by an infusion of 1000-2000ml of cold saline. In the cath lab a endovascular cooling catheter will be placed into the inferior vena cava via a femoral vein to achieve a core temperature of <35°C prior to revascularization.
88935272|NCT01777750|No Intervention|Standard treatment|Standard treatment
88935273|NCT01777815|Experimental|Implanting ePTFE sutures|Implanting ePTFE sutures as artificial neochordae using the NeoChord DS1000 Artificial Chordae Delivery System
88935274|NCT01777841|Other|Electronic Care plan delivery|
88935275|NCT01777867||Healthy Volunteers|Subjects in this arm were healthy volunteers. Subjects underwent both Cough Reflex Sensitivity and the Methacholine Challenge procedures.
88935276|NCT01777867||Non-erosive reflux disease with reflux|Subjects enrolled in this arm had non-erosive reflux disease with reflux (heartburn) for at least 6 of the preceding 12 months. Subjects underwent both Cough Reflex Sensitivity and the Methacholine Challenge procedures.
88935277|NCT01777867||Non-erosive reflux disease without reflux|Subjects enrolled in this arm had non-erosive reflux disease with normal levels of reflux (heartburn). Subjects underwent both Cough Reflex Sensitivity and the Methacholine Challenge procedures.
88935278|NCT01777893|Experimental|HP-HI|High protein/ high intensity physical activity
88935279|NCT01777893|Experimental|HP-MI|High protein/ moderate intensity physical activity
88935280|NCT01777893|Experimental|MP-HI|Moderate protein/ high intensity physical activity
88935281|NCT01777893|Experimental|MP-MI|Moderate protein/ moderate intensity physical activity
88935282|NCT01777906||Fluticasone|Fluticasone nasal spray will be given 2 sprays twice a day for 6 weeks.
88935283|NCT01777906||Dexamethasone sodium phosphate 0.032%|Dexamethasone 0.032% nasal spray will be given at a dose of 2 sprays twice a day for 6 weeks.
89450746|NCT02462642|Experimental|Brahmi - 36 subjects|36 subjects both male and female will consume 2 capsules of Brahmi for 84 days.
89450747|NCT02462642|Placebo Comparator|Placebo- 36 subjects|36 subjects male and female who will take 2 capsules of placebo every day
89450748|NCT02462642|Experimental|Brahmi - 8 Subjects|For PK part of the study 8 male subjects will be taken for treatment arm. Each volunteer will consume 2 capsules of Brahmi each day for 84 days.
89450749|NCT02462642|Placebo Comparator|Placebo- 4 subjects|4 male subjects in PK part will be in the placebo arm. Each volunteer will consume 2 capsules of Brahmi each day for 84 days.
89450750|NCT01024101|Experimental|Paclitaxel|
89450751|NCT05164224||No secondary suture|The participants who will develop post-cesarean surgical site infection and follow-up only antibiotic treatment for their wound care.
89450752|NCT05164224||secondary suture|The participants who will develop post-cesarean surgical site infection and need a secondary suture for their wound care
89450753|NCT04489706|Experimental|P53 mutation arm|patients of recurrent and metastatic ovarian cancer and endometrial cancer associated with P53 mutation
89450754|NCT00818571|Experimental|Vildagliptin 25 mg qd in Renal Impaired (RI) patients|
89450755|NCT00818571|Experimental|Vildagliptin 50 mg qd in RI Patients|
89450756|NCT00818571|Experimental|Vildagliptin 25 mg qd in matched Healthy Volunteer (HV)|
89450757|NCT00818571|Experimental|Vildagliptin 50 mg qd in matched HV|
89450758|NCT05118516|Experimental|Experimental|ASC43F for all subjects under the fasted state.
89450759|NCT00818493|Experimental|1|Q8003, flexible ascending dose
89450760|NCT00818493|Experimental|2|Low dose Q8003
89450761|NCT00818493|Active Comparator|3|Percocet (oxycodone and acetaminophen)
89450762|NCT05164068|Experimental|Information video|The experimental group likewise consisted of 60 individuals that received information about the biopsy procedure in video format
89450763|NCT05164068|No Intervention|Information face-to -face|The control group consisted of 60 patients that received face-to-face verbal information in a homogeneous and reproducible manner
89450764|NCT02717546||Group One|Distal Tibia Fracture repaired with Zimmer MotionLoc Screw
89450765|NCT04455126|Experimental|Preservative-free tafluprost|This was an open-label, non-randomized clinical study that aimed to assess the ocular signs and symptoms in 60 eyes of 30 newly diagnosed Egyptian glaucoma patients receiving preservative-free tafluprost eye drops
89450766|NCT03134469|Experimental|Probiotics|Intake of a probiotic capsule once daily
89450767|NCT03134469|Placebo Comparator|Placebo|Intake of a placebo capsule once daily
89450768|NCT05119062|Placebo Comparator|Control group|Participants in the control group will receive usual care.
89450769|NCT05119062|Experimental|an online intergenerational co-parenting programme|Those who are randomized to the intervention group will receive the intergenerational co-parenting program in addition to the usual care, including 3 weekly antenatal sessions (start from 33-35 weeks gestation) and 2 weekly postnatal sessions (start from the first week after discharge from hospital). The essential components and focus of the intergenerational co-parenting program were developed based on the themes identified from the two qualitative studies, the systematic review of co-parenting interventions, and the proposed intergenerational co-parenting model. The intervention will be delivered online through an education platform of the study hospital.
89450770|NCT05622903|Experimental|Treatment Group|Participants in the treatment group received up to $400 per month.
89450771|NCT05622903|Active Comparator|Control Group|Participants in the control group did not receive monthly cash benefits.
89450772|NCT00893139|Experimental|AL-38583 0.05%|AL-38583 ophthalmic solution 0.05%, 1 drop per eye, 3 times a day, for 35 days
89450773|NCT00893139|Experimental|AL-38583 0.10%|AL-38583 ophthalmic solution 0.10%, 1 drop per eye, 3 times a day, for 35 days
89450774|NCT00893139|Placebo Comparator|AL-38583 vehicle|Inactive ingredients used as a placebo comparator, 1 drop per eye, 3 times a day, for 35 days
89450775|NCT01378962|Experimental|Single Arm|
89450776|NCT00892203|Experimental|Active|
89450777|NCT00892203|Active Comparator|Comparator|
89450778|NCT00892203|Placebo Comparator|Placebo|
89450779|NCT05377983|Experimental|the intervention group|Lavender oil inhalation will be performed by placing two drops of 2% lavender oil on a 5x5 cm sterile gauze cloth and asking the patient to smell it for three to five minutes. Pain intensity and vital signs will be evaluated and recorded before each application and in the first five minutes after the application.
89450780|NCT05377983|No Intervention|the control group|The control group will only receive routine care.
89450781|NCT05113524|Experimental|Dance|Dance intervention for 3 months, 2 times/week (1 instructor lecture session and 1 home session following a prepared video), 2 hours per week. Dance is a safe and effective form of activity, which has been used in PD population (Delabary et al., 2017; Sharp and Hewitt, 2014). Participants take part in a dance class specifically for people with PD lead by a qualified dance instructor. The dance class typically include a warm-up, dance related activities (specific to the genre of the class) and a cool-down.
89450782|NCT05113524|Active Comparator|Control Group|Controls, not alter their personal lifestyle, but undergo the same testing as the exercise intervention group.
89450783|NCT05342922|Active Comparator|Ultrasound group|Ultrasound assited technique will be used for spinal anesthesia performance.
89450784|NCT05342922|Experimental|Landmark group|Land-mark assisted technique will be used for spinal anesthesia performance.
89450785|NCT00890409|No Intervention|Normothermia|Rectal temperature was maintained at 36.0-37.5 degree C.
89450786|NCT00890409|Experimental|Hypothermia|The group was fitted with a cooling cap around the head for 72 hours. The temperature of the cap could be adjusted between 5 to 20 degree C and was automatically regulated by a servo-controlled temperature probe placed in the nasopharynx to maintain the nasopharyngeal temperature at (34±0.2)degree C. All infants were nursed under a servo-controlled radiant warmer and the rectal temperature was maintained at 34.5 to 35 degree C. Head cooling was started within 6 hours after birth for 72 hours followed by spontaneous re-warming and the average time to reach the target temperature was 2 hours.
89450787|NCT05163756|Experimental|DW1903(Test)|once a day, q.d. PO / DW1903 + Placebo of DW1903-R1
89450788|NCT05163756|Active Comparator|DW1903-R1(Reference)|once a day, q.d. PO / Placebo of DW1903 + DW1903-R1
89450789|NCT00889473|Experimental|Larazotide acetate 1 mg|larazotide acetate 1 mg capsules TID + 900 mg gluten capsules TID for 6 weeks
89450790|NCT00889473|Placebo Comparator|Placebo|placebo capsules TID + 900 mg gluten capsules TID for 6 weeks
89450791|NCT05391204|Active Comparator|Healthy Volunteers|To answer the question of reproducibility of the measurement (1st objective), half of the group control will carry out two handover of the battery of functional tests to a week apart.
89450792|NCT05391204|Experimental|Patients Volunteers|To answer the question of reproducibility of the measurement (1st objective), half the group patient will perform two examinations at two months apart.
89450793|NCT00810147|Active Comparator|A1|
89450794|NCT00810147|Active Comparator|A2|
89450795|NCT00810147|Active Comparator|A3|
89450796|NCT00810147|Active Comparator|A4|
89450797|NCT00810147|Placebo Comparator|A5|
89450798|NCT04375956|Experimental|Pembrolizumab|Pembrolizumab 200 mg d1 q 21 iv infusion, until disease progression of disease, unacceptable toxicity or patient's refusal. Pembrolizumab will be administered for a maximum of 2 years.
89450799|NCT04495478|Experimental|Placebo - Intravenous (IV)|Participants received single dose of placebo administered IV.
89450800|NCT04495478|Placebo Comparator|350 mg Ramucirumab IV|Participants received single 350 milligram (mg) ramucirumab administered as a 60-minute intravenous infusion at a concentration of 10 milligram per millilitre (mg/mL) as one 35 mL infusion.
89450801|NCT04495478|Experimental|Placebo - Subcutaneous (SC)|Participants received single dose of placebo administered SC.
89450802|NCT04495478|Placebo Comparator|350 mg Ramucirumab SC (1x2 mL)|Participants received single 350 mg ramucirumab SC administered at a concentration of 175 mg/mL as one 2 mL injection.
89450803|NCT04495478|Experimental|350 mg Ramucirumab SC (2x2 mL)|Participants received single 350 mg ramucirumab SC administered at a concentration of 87.5 mg/mL as two 2 mL injections.
89450804|NCT04495478|Experimental|350 mg Ramucirumab SC (2x1 mL)|Participants received single 350 mg ramucirumab SC administered at a concentration of 175 mg/mL as two 1 mL injections.
89450805|NCT04495478|Experimental|700 mg Ramucirumab SC (2x2 mL)|Participants received single 700 mg ramucirumab SC administered at a concentration of 175 mg/mL as two 2 mL injections.
89450806|NCT04487444|Experimental|Ta1 treatment arm|Ta1 at a dose of 1.6 mg will be administered SC in 1 mL of diluent daily for a total of 1 week, in addition to standard of care.
89014894|NCT03335072|Experimental|PCR infection-based core group|Annual mass azithromycin treatment plus quarterly treatment of a PCR-based cohort that would be a subset of the age-based core group.
89450807|NCT04487444|No Intervention|Control arm|No treatment will be provided in addition to standard of care.
89450808|NCT04708028||Control|No exposure to the therapy dog.
89450809|NCT04708028||Dog Therapy|Introduced to a therapy dog and allowed to pet the dog for up to 2 minutes (timed) prior to the dental procedure.
89450810|NCT02462564||postoperative cognitive dysfunction|Z score>1.96
89450811|NCT02462564||non-postoperative cognitive dysfunction|Z score<1.96
89450812|NCT00152763|Experimental|Cognitive Behavior Therapy - males|Eight telephone sessions of cognitive behavior therapy tailored to psychological adaptation to an ICD, plus a psycho-educational booklet for participants and a therapist manual. This arm included the males.
89450813|NCT00152763|Experimental|Cognitive Behavior Therapy - females|Eight telephone sessions of cognitive behavior therapy tailored to psychological adaptation to an ICD, plus a psycho-educational booklet for participants and a therapist manual. This arm included the females.
89450814|NCT00152763|Active Comparator|Usual Cardiac Care - Males|The UCC was defined as whatever the respective ICD treatment sites routinely offer their patients. All patients received standard educational materials explaining their heart disease and the ICD device. Follow-up appointments include device interrogation (i.e., to extract arrhythmia events and ICD therapies) and trouble-shooting at 6-months intervals, cardiac care as necessary, and nonsystematic supportive reassurance delivered informally in the clinic. Each centre also had access to a cardiac rehabilitation program and psychiatric consultation as needed. This arm was just for males randomized.
89450815|NCT00152763|Active Comparator|Usual Cardiac Care - females|The UCC was defined as whatever the respective ICD treatment sites routinely offer their patients. All patients received standard educational materials explaining their heart disease and the ICD device. Follow-up appointments include device interrogation (i.e., to extract arrhythmia events and ICD therapies) and trouble-shooting at 6-months intervals, cardiac care as necessary, and nonsystematic supportive reassurance delivered informally in the clinic. Each centre also had access to a cardiac rehabilitation program and psychiatric consultation as needed. This arm was for females randomized.
89014895|NCT03335072|Experimental|TI-based core group|Annual mass azithromycin treatment plus quarterly treatment of a conjunctival photography-based cohort that would be a subset of the age-based core group
89450816|NCT03181542|Experimental|Infrared vein illumination|Infrared illumination of veins, using the FDA approved AccuVein device, will be used to assist in vein location when inserting an intravenous access line
89450817|NCT03181542|No Intervention|Standard Technique|Standard vein location techniques will be used when inserting an intravenous access line
89450818|NCT00809679|Experimental|T-62 100 mg bid|
89450819|NCT00809679|Experimental|T-62 200 mg bid|
89450820|NCT00809679|Placebo Comparator|Placebo|
89450821|NCT00884715|Experimental|1 implant|117 mg Octreotide implant
89014896|NCT03323294||Healthy Lean|Healthy lean individuals (n=20) defined with a Body Mass Index (BMI) ≥ 5th percentile and <85th percentile for age/sex will be recruited. Participants in this cohort will be asked to complete a one-time study visit.
89014897|NCT03323294||Healthy Obese|Healthy obese individuals (n=20) defined with a Body Mass Index (BMI) ≥ 95th percentile for age/sex will be recruited. Participants in this cohort will be asked to complete a one-time study visit.
89450822|NCT00884715|Experimental|2 implants|234 mg Octreotide implant
89450823|NCT03603080|Experimental|Medication arm|
89450824|NCT03603080|No Intervention|No medication arm|
89450825|NCT03126552|Experimental|Intervention|Four healthy hookworm-naive volunteers will be infected with 50 Necator americanus L3 larvae.
89450826|NCT01019187|Placebo Comparator|Arm I|Patients receive oral placebo twice daily for 47 days.
89450827|NCT01019187|Experimental|Arm II|Patients receive oral armodafinil twice daily for 47 days.
89450828|NCT01019187|Experimental|Arm III|Patients receive oral placebo twice daily for 47 days. Patients undergo cognitive behavioral therapy for insomnia comprising sleep restriction therapy, stimulus control instruction, sleep hygiene guidelines, and a session of cognitive therapy for 7 weeks.
89450829|NCT01019187|Experimental|Arm IV|Patients receive oral armodafinil twice daily for 47 days. Patients undergo cognitive behavioral therapy for insomnia as in Arm III for 7 weeks.
89450830|NCT02464514|Other|Healthy obese children|High carbohydrate meal High fat meal
89450831|NCT02464514|Other|Children with Prader Willi Syndrome|High carbohydrate meal High fat meal
89450832|NCT01018875|Experimental|Arm 1, Dose 1, ABT-288|Low Dose
89450833|NCT01018875|Experimental|Arm 2, Dose 2, ABT-288|High dose
89450834|NCT01018875|Active Comparator|donepezil|
88935284|NCT01777919|Experimental|Temozolomide+Disulfiram/copper|"Disulfiram/copper combination will be started on the 5th postoperative day and before the initiation of the standard radiochemotherapy (fractionated irradiation with a total dose of 60 Gy with concomitant 75 mg/m2 body surface temozolomide each day, including weekends, during irradiation). After completion of the radiation therapy patients will receive maintenance temozolomide 150-200 mg/m2 body surface on Days 1-5 every 28 days for 6 months. Daily administration of disulfiram and copper will take place for the whole study period.~NOTE: Patients may receive additional maintenance temozolomide at the discretion of the treating medical oncologist."
88935285|NCT01777958||Cohort|
88935286|NCT01777971||Patients with cirrhosis|Male and female subjects who have cirrhosis of the liver and diuretic-resistant ascites (based on International Ascites Clib criteria) and have been evaluated and approved to have a large-volume paracentesis as part of standard of care treatment.
88935287|NCT01778036||Neck pain patients following physiotherapy treatment|Neck pain patients will follow physiotherapy treatment in primary health care.
88935288|NCT01778075|Experimental|Treatment sequence AB|Treatment A: Newly developed Ultracet ER; Treatment B: Marketed Ultracet ER
88935289|NCT01778075|Experimental|Treatment sequence BA|Treatment A: Newly developed Ultracet ER; Treatment B: Marketed Ultracet ER
89450835|NCT01018875|Placebo Comparator|sugar pill|
89450836|NCT01018173|Placebo Comparator|placebo|
89450837|NCT01018173|Experimental|taspoglutide|
88935290|NCT01778088|Other|Single Group|I-131-CLR1404 Injection
88935291|NCT01778101|Experimental|lansoprazole|lansoprazole 1mg/kg twice a day for 14days
88935292|NCT01778114|Placebo Comparator|Placebo + orange juice without vitamin D|Placebo + orange juice without vitamin D
88935293|NCT01778114|Experimental|Placebo + 1000 IU vitamin D3 in OJ|Vitamin D3 in orange juice
88935294|NCT01778114|Experimental|Placebo + 1000 IU vitamin D2 in OJ|Vitamin D2 in orange juice
88935295|NCT01778114|Active Comparator|1000 IU vitamin D3 + placebo OJ|1000 IU vitamin D3 + placebo OJ
88935296|NCT01778114|Active Comparator|1000 IU vitamin D2 + placebo OJ|1000 IU vitamin D2 + placebo OJ
88935297|NCT01778140|Experimental|Patient-specific reminder|Intervention: Patient-specific computerized reminder. The physicians assigned to this arm will use the patient-specific CDSS on CPOE. The patient-specific reminder is designed as a real-time CDSS implemented on CPOE to monitor physician's contrast-enhanced image study orders. Computerized pop-up reminders provide the patient-specific CIN risk profile and optimal decision options which are generated when patients with high risk or with unknown risk of CIN are encountered.
89200805|NCT00972790|Active Comparator|Intervention Group|The patients in the intervention group will receive bilateral scalp nerve blocks with a total of 20 ml of 0.5% bupivacaine + epinephrine 1:200,000.
89200806|NCT04007458|Active Comparator|Letter|Patients will receive a letter reminding them that they are overdue for repeat annual screening.
89200807|NCT04007458|Experimental|Community Health Worker phone call|Patients will receive a phone call from community health worker, offering to help them overcome barriers to repeat annual screening and offering to help them schedule their screening.
89200808|NCT04008862|Experimental|Partnership-based care|Each patient will serve as his/her own control
89200809|NCT00901875|Experimental|Suboxone, maximum 8mg|
89200810|NCT00901875|Experimental|Buprenorphine + naloxone|
89200811|NCT00901875|Experimental|Buprenorphine + naloxone (Suboxone)|
89200812|NCT00972868|Experimental|COPD|Thirty adult (> 18 years of age) patients in acute hypercapnic respiratory failure resulting from COPD and requiring Noninvasive Positive Pressure Ventilation (NPPV)
89450838|NCT04453956|Sham Comparator|Control group|Patients will receive colonoscopy without assistance of EndoAngel's any function.
89450839|NCT04453956|Experimental|Polyp detection function group|Patients will receive colonoscopy with the assistance of EndoAngel's polyp detection function.
89450840|NCT04453956|Experimental|Quality monitoring function group|Patients will receive colonoscopy with the assistance of EndoAngel's quality monitoring function.
89450841|NCT04453956|Experimental|Polyp detection plus quality monitoring functions group|Patients will receive colonoscopy with the assistance of EndoAngel's polyp detection plus quality monitoring function.
89450842|NCT03271190|Experimental|ENGAGE SPANISH/MUSIC|Cognitive strategies to improve attention and memory skills and application in selected leisure activities (music or Spanish lessons, and videogames) over 4 months.
89450843|NCT03271190|Active Comparator|ENGAGE DISCOVERY|Educational program about brain and healthy aging complemented by learning of new information with videogames, documentaries and group discussions over 4 months.
89531365|NCT03097965|Experimental|PROGRAM|"High Phyto-PRO food plan~Physical activity~Cognitive Behavioral Program~Protein Shakes~Phytosterols supplement~Berberine supplement~Anti-oxidant supplement~Probiotic supplement~Fish Oil supplement~Multiple Vitamin/Multiple Mineral supplement"
89531366|NCT05041179|Active Comparator|7.2 g of actives (3.6 g NAC and 3.6 g glycine) per day split in two doses (arm A)|"First dose (1.8 g NAC and 1.8 g glycine) consumed in the morning~Second dose (1.8 g NAC and 1.8 g glycine) taken in the evening"
89450844|NCT04155450|Experimental|McKenzie Extension with External Limb Loading Protocol|"Moist Heat Pack for 10 mins~McKenzie Extension Exercise Protocol~Static:~Lying Prone~Lying prone in extension~Sustained extension~Posture correction~Dynamic:~Extension in lying~Extension in lying with clinician overpressure~Extension mobilization~Extension in standing~Limb loading for basic stabilization progression of the lumbar extensors. Begin in the quadruped position and progress the intensity by~Flexing one upper extremity~Extending one lower extremity with a leg slide~Extending one lower extremity by lifting it off the mat~Flexing one upper extremity while extending contralateral lower extremity and then alternate to opposite extremities.~Progress to prone position:~Extending one lower extremity~Extending both lower extremity"
89450845|NCT04155450|Active Comparator|McKenzie Extension Group|"Moist Heat Pack for 10 mins~McKenzie Extension Protocol Sequence~Static:~Lying Prone~Lying prone in extension~Sustained extension~Posture correction~Dynamic:~Extension in lying~Extension in lying with clinician overpressure~Extension mobilization~Extension in standing"
89450846|NCT04455204||non-pregnant women (group 1)|20 non-pregnant women who serve as a control group (group 1)
89450847|NCT04455204||pregnant women (group 2)|20 pregnant women with normal pregnancy at their third trimesters (group 2)
89450848|NCT04455204||pregnant women with Preeclampsia (group 3)|20 pregnant women with Preeclampsia in their third trimester (group 3) will be screened to fit the inclusion and exclusion criteria.
89450849|NCT00806403|Active Comparator|thrombolysis|
89450850|NCT00806403|Active Comparator|invasive|
89450851|NCT04852874|Experimental|Ultrasound-guided Quadratus Lumborum Block|
89450852|NCT04076280|Experimental|SWAP Intervention|The participants are randomized using a table of random numbers pre-generated by a computer assigning them to the Sodium Watcher Program.
89450853|NCT04076280|Active Comparator|Usual Care|The participants are randomized using a table of random numbers pre-generated by a computer assigning them to the usual care group.
89450854|NCT01958528||Cohort 1 Progressors|
89450855|NCT01958528||Cohort 2 - Non-Progressors|
89450856|NCT05399940||Group 1|:PSA<4 ng/mL
88935298|NCT01778140|Active Comparator|Non-patient-specific reminder|Intervention: Non-patient-specific Computerized reminder. The physicians assigned to this arm will use the Non-patient-specific reminders through CPOE. Non-patient-specific reminders always pops up to remind physicians to check their patient's CIN risk no matter what CIN risk is.
88935299|NCT01778140|No Intervention|Control Arm|The physicians assigned to this arm will not use and any computerized reminder.
88935300|NCT01778153|Experimental|Equinox Personal Coaching|Participants assigned the Coached group will receive up to 36 sessions about three times a week, consisting of both strength and aerobic exercises, through a program designed by Equinox Fitness Centers.
88935301|NCT01778153|No Intervention|Self-directed exercise training|Participants in the Self-directed group will receive general exercise training advice as any member of the fitness club would, and will record the details of their exercise in log sheets. They will be asked to continue their usual exercise routine.
88935302|NCT01778166|Active Comparator|Standard early enteral nutrition|There would be 100 patients in this group
88935303|NCT01778166|Experimental|Immuno-enhanced early enteral nutrition|There would 100 patients in this group
88935304|NCT01778192|Active Comparator|Same day PEG|group 1 (same day PEG, N=50) received 4 L of PEG at 6 hours before procedure on the day of the colonoscopy
88935305|NCT01778192|Active Comparator|split PEG|group 2 (split PEG, N=50) received 2 L of PEG at 6:00 p.m the evening before colonoscopy and 2 L of PEG at 4-6 hours before procedure
88935306|NCT01778192|Active Comparator|SPMC 2|group 3 (SPMC 2, N=50) received one sachet of SPMC at 6 p.m the evening before colonoscopy and another sachet of SPMC at 4-6 hours before procedure
88935307|NCT01778192|Active Comparator|SPMC 3|group 4 (SPMC 3, N=50) received one sachet of SPMC at 6 p.m and the other sachet at 9 p.m the evening before colonoscopy and another sachet at 4-6 hours before procedure.
88935308|NCT01778205||Pregnant women|Pregnant women with confirmed viable fetus at first prenatal check-up at <12 gestational weeks
88935309|NCT01778218|Experimental|99mTc-EC-DG|99mTc-EC-DG injection followed by SPECT imaging during a cardiac rest study (Visit 1) and an exercise/regadenoson study (Visit 2)
88935310|NCT01778231|Experimental|Vitamin Supplement|1 capsule of Nutrof Total made by Laboratories Thea for 16 weeks
88935311|NCT01778231|Placebo Comparator|Inert oil capsule|1 capsule daily for 16 weeks
89450857|NCT05399940||Group 2|PSA>4 ng/mL
89450858|NCT02465294|Placebo Comparator|Potato starch and magnesium stearate|This arm will be used as a control to asses the efficacy of the other probiotic arms. The placebo will contain encapsulated potato starch and magnesium stearate which is used the matrix in the probiotic supplements. The placebo refers only to the intervention supplement, not the behavioral lifestyle intervention. All subjects will participate in the same behavioral lifestyle intervention. In addition, blood tests will be performed.
89450859|NCT02465294|Experimental|Lactobacillus|Lactobacillus will be taken as a capsule once daily for 12 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded). All subjects will participate in the same behavioral lifestyle intervention. In addition, blood tests will be performed.
89450860|NCT02465294|Experimental|Mix of Bifidobacterium and Lactobacillus|A blend of Bifidobacterium and Lactobacillus will be taken as a capsule once daily for 12 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded). All subjects will participate in the same behavioral lifestyle intervention. In addition, blood tests will be performed.
89450861|NCT00803517||Photodynamic therapy (PDT)|
88935312|NCT01778244|Experimental|metformin|metformin
88935313|NCT01778244|Placebo Comparator|placebo|placebo
88935314|NCT01778257|Experimental|Mate extracts group|Mate extract(3150 mg/day)for 12 weeks
89450862|NCT00803517||Focal laser photocoagulation (focal)|
89450863|NCT05390658||Survival|
89450864|NCT05390658||Death|
89450865|NCT02464982||Women with 1 year non-invasive technology areola tattoo|Women with 1 year non-invasive technology areola tattoo realized in standard care as part of 1 breast mammary reconstruction following an operated breast cancer
89450866|NCT05390424|Experimental|Drug user|Drug users will be screened for Hepatitis C, Hepatitis B and AIDS using Dried Blood Spot for blood collection
89450867|NCT00802425|Experimental|2|AM-111 low dose
88935315|NCT01778257|Placebo Comparator|Placebo group|Placebo (3150 mg/day) for 12 weeks
89200813|NCT00897429||Ancillary-Correlative (laboratory biomarker analysis)|Previously collected tissue samples are analyzed for K-ras mutations; COX-2, phospho-AKT, and VEGF overexpression; microvessel density; association of genomic instability with microsatellite instability and p53 mutations; and methylation status of MLH1, MGMT, and WRN and to identify prognostic biomarkers by LINE-1 hypomethylation, PIK3CA mutation, BRAF mutation, FASN expression, and VDR expression via immunohistochemistry, PCR, RT-PCR, and microarray.
89200814|NCT00985036||Glioma|patients who are diagnosed with and are being treated for glioma
88935316|NCT01778270|Other|non invasive sensor pleural drainage|feasibility data will be collected with thorax impedance measurements via body bioimpedance sensor in Ohm before and after pleura drainage, via impedance cardiography stroke volume and cardiac output will be calculated and also respiratory parameters determined via capnograph as carbon dioxide (CO2) in %/ml exhaled volume before and after pleura drainage. Additionally heart sound analysis via electronic stethoscope will be compared to standard methods.
88935317|NCT01778270|Other|non invasive sensor healthy control|"the same measurements as in arm 1: feasibility data will be collected with thorax impedance measurements via body bioimpedance sensor before and after pleura drainage in Ohm, via impedance cardiography stroke volume and cardiac output will be calculated and also respiratory parameters determined via capnograph as carbon dioxide (CO2) in %/ml exhaled volume once in 25 healthy controls.~Additionally heart sound analysis via electronic stethoscope will be compared to standard methods."
89450868|NCT00802425|Placebo Comparator|1|
88935318|NCT01778283|Experimental|Acetate-free solution first|Acetate-free solution first : hemodialysis 4 hours with Acetate-free solution (Acetate 0 mEq/L Citrate 2 mEq/L) at the first session after enrollment, and then switch to Acetate-based solution (Acetate 3 mEq/L Citrate 0 mEq/L) at the next 4-hr hemodialysis session
88935319|NCT01778283|Active Comparator|Acetate-based solution first|Acetate-based solution first : hemodialysis 4 hours with Acetate-based solution (Acetate 3 mEq/L Citrate 0 mEq/L) at the first session after enrollment, and then switch to Acetate-free solution (Acetate 2 mEq/L Citrate 2 mEq/L) at the next 4-hr hemodialysis session
88935320|NCT01778309|Experimental|n-acetylcysteine/placebo supplementation|n-acetylcysteine supplementation, orally in three daily dosages, at 20 mg/kg/day, daily for eight days after exercise placebo, orally in three daily dosages, content: 500 mL drink that contained water (375 mL), sugar-free cordial (125 ml), and 2 g of low-calorie glucose/dextrose powder.
88935321|NCT01778335|No Intervention|Control|Control arm subjects will receive best medical care.
88935322|NCT01778335|Experimental|Endovascular thrombectomy/thrombolysis|Endovascular mechanical thrombectomy or endovascular delivery of thrombolytic agent
88935323|NCT01778348|Experimental|Overnight closed-loop combined with CGM|Glucose level is controlled by the automated closed loop glucose control system. After initial training with the closed-loop system devices, subjects will use the closed-loop system overnight at home for a total duration of 12 weeks.
88935324|NCT01778348|Active Comparator|Real-time CGM alone|The subjects will use the study CGM alone at home for the period of 12 weeks. Glucose level will be controlled by usual insulin pump therapy in conjunction with real time continuous glucose monitoring (CGM)
88935325|NCT01778361||HIV positive|
88935326|NCT01778361||HIV negative|
88935327|NCT01778374|Experimental|No participant choice of counselor|Participants in this arm of the study are randomized to an interactive video counselor with no choice of counselor. This is delivered via a touchscreen tablet device.
89014898|NCT03323294||Obese Insulin Resistant|Obese insulin resistant individuals (n=70) as defined with a Body Mass Index (BMI) ≥ 95th percentile for age/sex and will be recruited. Participants will be asked to complete a total of 2 study visits. The second study visit will occur at 12 months (± 2 weeks) after the initial study visit.
89200815|NCT00985036||meningioma|patients who are diagnosed with and are being treated for meningioma
89200816|NCT00972946|Experimental|Administration of labelled cells|MRI scanning before and after administration of iron-labelled cells
89200817|NCT00972946|Experimental|Administration of Endorem|MRI scanning before and after intravenous administration of Endorem
89450869|NCT00802425|Experimental|3|AM-111 high dose
89450870|NCT02464358|Experimental|IMB Intervention Group|"The IMB group received an HPV Vaccination Information Statement (VIS) often given to individuals prior to vaccination. In addition, they received the following:~Additional educational content related to HPV, Cervical Cancer, and HPV vaccination,~Motivational content to help identify and problem-solve benefits and barriers to vaccination,~Skills-building content, including brief communication skills training and ways to access the vaccine."
89450871|NCT02464358|Active Comparator|Attention Control Group|The attention control group also received an HPV Vaccination Information Statement (VIS) often given to individuals prior to vaccination. In addition, to maintain consistency with the treatment's presentation format, participants watched a set of short video clips encompassing aspects of women's general and sexual health.
89450872|NCT05399862|Active Comparator|Group A|Patients will be given Lactobacillus reuteri probiotic in addition to standard triple therapy. The probiotic is prepared in a capsule form (200mg each capsule), given as 1 capsule per day after meal for 4 weeks.
89450873|NCT05399862|Placebo Comparator|Group B|Placebo used in the study contains corn starch with 0.12% of iron oxide yellow, prepared in indistinguishable capsule form as probiotic,; given as 1 capsule per day after meal for 4 weeks.
88935328|NCT01778374|Experimental|Participant choice of counselor|Participants in this arm of the study are randomized to an interactive video counselor with a choice of four different counselors. These gender and ethnically diverse counselors are delivered via a touchscreen tablet device.
88935329|NCT01778387|Active Comparator|Laparoscopic ventral hernia repair|Laparoscopic repair: Pneumoperitoneum was performed to 12 mmHg. Herniary contents and sac are reduced releasing adhesions with diathermy or harmonic scalpel. Defects are repaired with a polytetrafluoroethylene (PTFE) patch (Dual Mesh; W.L Gore and Associates, FlagstaV, AZ USA) with double crown fixation as technique of Carbajo et al, ensuring exceed 3 cm edge of defect, using 5mm tackers (Protack, Autosuture; Tyco Healthcare, USA), reducing intrabdominal pressure to 8 mmHg. All operations were performed by experienced surgeons, over than 40 laparoscopic ventral hernia repairs.
89200818|NCT00973180|Experimental|Enhanced Label|Subjects in this arm will receive their prescriptions labeled with our enhanced, patient-friendly label.
89450874|NCT00802347|Experimental|I5NP|
89450875|NCT00802347|Placebo Comparator|Saline|
89450876|NCT02464280||Patients scheduled for lung imaging|"Patients with lung changes and scheduled for lung imaging will undergo:~the scheduled conventional X-ray examination~the scheduled CT scan~the tomosynthesis scan"
89450877|NCT02464280||Patients scheduled for wrist imaging|"Patients with wrist fracture or with osteoprotetic material in the wrist and scheduled for wrist imaging will undergo:~the scheduled conventional X-ray examination~the scheduled CT scan~the tomosynthesis scan"
89450878|NCT04253444|Active Comparator|slow deep breathing|Patients are instructed to do deep breathing at full inspiratory capacity for 4 seconds followed by forced expiration in 6 seconds (forced vital capacity) for 10 minutes.
89450879|NCT04253444|Sham Comparator|sham breathing|Patients are instructed to count 10 breaths and tick a box every time they count ten breaths. The counting distracts the patient reducing the effect of focussing of breathing on their autonomic nervous system.
89450880|NCT01912950|Experimental|Prowave LX IPL|One area on forearm will receive treatment with Prowave LX IPL
89450881|NCT01912950|No Intervention|No Treatment|No treatment administered on one area of forearm
88935330|NCT01778387|Placebo Comparator|Open ventral hernia repair|Open repair: Incision was made over hernia defect, reducing herniary contents by opening sac if it is necessary. We made 4 cm soft tissue flaps around edge of defect depending on available healthy fascial tissue. Chevrel technique with fascial closure using anterior rectus sheath with continuous and absorbable suture and placement of polypropylene mesh (Parietene standart polypropylene mesh, Covidien, Norwalk, CT) in an onlay position fixed with polypropylene suture.
88935331|NCT01778400|Experimental|Radiofrequency ablation|Treatment with radiofrequency ablation for the thyroid lesions and compare the results with ethanol ablation in terms of volume reduction at 6-month follow-up (primary end point).
88935332|NCT01778400|Active Comparator|Ethanol|Treatment of predominantly cystic nodule with ethanol ablation and compare these results to radiofrequency ablation in terms of volume reduction at 6-month follow-up.
88935333|NCT01778413|Experimental|ATRIPLA three times a week.|Atripla (600 mg/200 mg/245 mg) three times a week.
88935334|NCT01778413|Active Comparator|ATRIPLA one time a day.|Atripla (600 mg/200 mg/245 mg) one time a day.
88935335|NCT01778439|Experimental|OMP-52M51|
88935336|NCT01778452|Active Comparator|Natural cycle|Natural cycle endometrial biopsy, lh+7
89450882|NCT03134391|Active Comparator|vapocoolant spray|Subjects received Vapocoolant spray before spinal anesthesia
89450883|NCT03134391|Active Comparator|EMLA|Subjects received EMLA before spinal anesthesia
89450884|NCT02463968||CHRONIC CHIKUNGUNYA|Twenty participants with chronic chikungunya defined as continued knee joint effusion at least three months after diagnosis of chikungunya will be enrolled in the study.
89450885|NCT02463968||ACUTE CHIKUNGUNYA|Ten participants with acute chikungunya defined as clinical symptoms of chikungunya with acute fever and joint pain within 10 days the onset of symptoms.
89450886|NCT02463968||HEALTHY CONTROLS|Five healthy controls will have only blood drawn once.
89450887|NCT05399394|Experimental|LAPC patients|Patients treated with induction FOLFIRINOX; for patients without disease progression as detected through restaging exams, chemotherapy was followed by chemoradiation which consisted of conformal radiation therapy and concurrent gemcitabine at the dose of 600 mg/mq weekly.
88935337|NCT01778452|Experimental|Antagonist cycle + endometrial priming.|Antagonist cycle + endometrial priming for egg donation program. endometrial biopsy, p4+5
88935338|NCT01778452|Experimental|Agonist cycle + endometrial priming.|Agonist cycle + endometrial priming for egg donation program endometrial biopsy, p4+5
88935339|NCT01778621|Experimental|Acupuncture (Hwato®)|30-40 minutes acupuncture at certain acupoints that chosen according to traditional Chinese medicine and included LIV3,SP6,SP8,ST36,SP10,ST29,LI14,Ren 04;starting at follicular phase of the cycle till 2 days before oocyte picked up.
88935340|NCT01778621|No Intervention|No acupuncture|No intervention was done for this group of patients.
88935341|NCT01778660|Active Comparator|Standard Counselling|Patients in this arm are randomised to standard counselling.
88935342|NCT01778660|Experimental|Mnemonic Counselling|Patients in this arm are randomised to counselling with the aid of a mnemonic.
88935343|NCT01778673||Distal radius fractures Sundsvall Hospital|
88935344|NCT01778673||Distal radius fractures Östersund Hospital.|
89450888|NCT05399316|Active Comparator|Inulin|15g of powdered inulin is given in a sachet. The powder is dissolved in water and consumed
89450889|NCT05399316|Placebo Comparator|Maltodextrin|15g of powdered maltodextrin is given in a sachet. The powder is dissolved in water and consumed
89450890|NCT05399238||Healthy subjects|The objective is to measure the temperature of the lingual dorsum
89450891|NCT05399238||Burning mouth syndrome|The objective is to measure the temperature of the lingual dorsum
89450892|NCT01007721|Experimental|BI 671800 ED 100 mg|2 capsules of BI 671800 ED 25 mg plus 2 capsules of BI 671800 ED placebo (bid in the morning and evening) plus 1 over-encapsulated montelukast placebo tablet (qd in the morning) plus fluticasone propionate placebo nasal spray (2 puffs each nostril qd in the morning)
89450893|NCT01007721|Experimental|BI 671800 ED 400 mg|2 capsules of BI 671800 ED 100 mg plus 2 capsules of placebo (bid in the morning and evening) plus 1 over-encapsulated montelukast placebo tablet (qd in the morning) plus fluticasone propionate nasal spray placebo (2 puffs each nostril qd in the morning)
89450894|NCT01007721|Active Comparator|Montelukast 10 mg|1 over-encapsulated montelukast 10 mg tablet (qd in the morning) plus 4 capsules of BI 671800 ED placebo (bid in the morning and evening) plus fluticasone propionate placebo nasal spray (2 puffs each nostril qd in the morning)
89450895|NCT01007721|Active Comparator|Fluticasonepropionate nasal spray 200¿g|Fluticasonepropionate nasal spray 200 mcg (qd, 2 puffs of 50 ¿g per nostril) plus 4 capsules of BI 671800 ED placebo (bid in the morning and evening) plus 1 overencapsulated montelukast placebo tablet (qd in the morning)
89450896|NCT01007721|Placebo Comparator|BI 671800 ED placebo|4 capsules of BI 671800 ED placebo (bid in the morning and evening), plus 1 over-encapsulated montelukast placebo tablet (qd in the morning) plus fluticasone propionate placebo nasal spray (2 puffs each nostril qd in the morning)
89450897|NCT01007721|Experimental|BI 671800 ED 800 mg|4 capsules of BI 671800 ED 100 mg (bid in the morning and evening) plus 1 over-encapsulated montelukast placebo tablet (qd in the morning) plus fluticasone propionate nasal spray placebo (2 puffs each nostril qd in the morning)
89450898|NCT00701558|Experimental|Erlotinib + Gemcitabine|Participants received erlotinib 150 mg/day, orally (po) on a continuous schedule in combination with gemcitabine at 1000 mg/m^2 administered intravenously (iv) on days 1, 8, 15 of each 4 week cycle for 6 cycles as per standard medical care, or until disease progression or participant's withdrawal due to any reason or death.
89450899|NCT03233828|Experimental|Intralesional IL-2 Injection|Two subcutaneous intralesional injections of Aldesleukin, prepared by the pharmacy such that the contents will be masked, will be administered by the care provider in a clinic seven days apart.
89450900|NCT03233828|Placebo Comparator|Saline Injection|Two subcutaneous intralesional injections of Saline, prepared by the pharmacy such that the contents will be masked, will be administered by the care provider in a clinic seven days apart.
89450901|NCT04454814|Active Comparator|Rotary Engine-driven Instruments|The instrumentation protocol with Protaper Universal rotary files was began with an S1 file with a brushing movement to the two thirds of the working length and then an SX file was introduced to the two thirds of the working length with a brushing movement Afterwards, S1, S2, F1, F2 files in mesial roots and F4 files in distal roots were used to the working length, respectively. Protaper F2 instrument was then used to complete the canal preparation in mesial roots and Protaper F4 instrument was used to complete the canal preparation in distal roots.
89450902|NCT04454814|Active Comparator|Reciprocal Engine-driven Instruments|The instrumentation of the root canal in the Reciproc Blue group began with a R25 instrument with a slow in-and-out pecking movement.According to the manufacturer instructions, a #10 K-file was inserted to the canal to check the canal is free to 1 mm beyond the prepared canal section. After each 3 pecks or when a resistance was encountered the instrument was pulled out of the canal. Afterward, the R25 instrument was inserted in to root canal until approximately two thirds of the working length.RB R25 instrument was then used to complete the canal preparation in mesial roots and RB R40 instrument was used to complete the canal preparation in distal roots.
89450903|NCT03882177|Experimental|Arm 1: Pravastatin (40 mg) and Rifafour|"Participants will receive pravastatin (40 mg) and Rifafour daily for 14 days. Pravastatin will be given alone on Day 1, and pravastatin + Rifafour will be given on Days 2-15.~Vitamin B6 will be added to each of the regimens."
89450904|NCT03882177|Experimental|Arm 2: Pravastatin (80 mg) and Rifafour|"Participants will receive pravastatin (80 mg) and Rifafour daily for 14 days. Pravastatin will be given alone on Day 1, and pravastatin + Rifafour will be given on Days 2-15.~Vitamin B6 will be added to each of the regimens."
89450905|NCT03882177|Experimental|Arm 3: Pravastatin (120 mg) and Rifafour|"Participants will receive pravastatin (120 mg) and Rifafour daily for 14 days. Pravastatin will be given alone on Day 1, and pravastatin + Rifafour will be given on Days 2-15.~Vitamin B6 will be added to each of the regimens.~(Arm 3 will only be recruited if pravastatin 80 mg is well tolerated and safe, yet drug exposures are significantly reduced due to the known interaction with rifampin.)"
88935345|NCT01778686|Experimental|Citalopram and Pindolol|"Citalopram intravenous infusion starting 30 min before scanning, 40 mg/h for 1 hour.~Pindolol peroral administration starting 3 days before scanning:~Day 1: 2.5 mg 3 times daily, day 2: 5 mg 3 times daily, day 3: 7.5 mg 3 times daily, Day 4 (scan day) 7.5 mg morning and noon."
88935346|NCT01778686|Placebo Comparator|Placebo|"Placebo for pindolol: sugar tablets that resembles pindolol~Placebo for ATD: amino acid drink balanced formula (containing tryptophan)~Placebo for Seropram: NaCl infusion"
88935347|NCT01778686|Experimental|Acute tryptophan depletion|Amino acid drink without tryptophan. Ingested 4-5 hours prior to PET scanning.
88935348|NCT01778699|Experimental|Lozenges with Lactobacillus brevis CD2|During the treatment phases subjects will use 2 lozenges a day.
88935349|NCT01778699|Placebo Comparator|Lozenges|During the treatment phases subjects will use 2 lozenges a day.
88935350|NCT01778712|Experimental|Intervention|Multi-level intervention
88935351|NCT01778790|Sham Comparator|Sham Stimulation for 8 weeks|Implantation of internal pulse generator (IPG), Sham Stimulation
88935352|NCT01778790|Active Comparator|Stimulation for 8 weeks|Implantation of IPG and active stimulation
88935353|NCT01778803|Experimental|defactinib (VS-6063) plus paclitaxel|Oral defactinib (VS-6063) administered twice daily, in combination with intravenous paclitaxel administered on Days 1, 8, and 15 of a 28 day cycle.
88935354|NCT01778829|Active Comparator|CPAP ventilation mode|Once the patient is extubated, CPAP ventilation mode is inmediately administered in order to prevent reintubation
88935355|NCT01778829|Experimental|NIPPV ventilation mode|NIPPV: Non Invasive Ventilation mode is administered inmediately after extubation to prevent reintubation
88935356|NCT01778842|Experimental|Prasugrel low dose|Patient will be randomized to this intervention will receive prasugrel 5 mg and after 15 days and 30 days we will control the responsivness of the study drug.
88935357|NCT01778842|Experimental|Clopidogrel standard dose|Patient will be randomized to this intervention will receive clopidogrel 75 mg and after 15 days and 30 days we will control the responsivness of the study drug.
89014899|NCT03323294||Type 2 Diabetes or Insulin Resistant|Obese individuals with Type 2 Diabetes or insulin resistance (n=20)
88935358|NCT01778868||Overweight and obese individuals|
88935359|NCT01778868||Normal weight individuals|
88935360|NCT01778881|Experimental|Massage + Exercise|Massage and stretching exercises
88935361|NCT01778881|Experimental|Relaxation +Imagination|Relaxation and Imagination therapies
88935362|NCT01778881|Experimental|Dental treatment|Reconstruction with composite resin
88935363|NCT01778881|Experimental|Massage + Exercise + Relaxation + Imagination|Massage, stretching exercises, relaxation and imagination
89014900|NCT03322215|Experimental|Palbociclib and fulvestrant|"Combination of palbociclib and fulvestrant~Palbociclib:~125 mg capsule administered orally once daily for 21 consecutive days followed by 7 days off treatment. Dose modification is recommended based on individual safety and tolerability.~Fulvestrant:~500 mg administered intramuscularly on days 1 and 15 of cycle 1, and then on day 1 of each subsequent 28-day cycle."
89450906|NCT03882177|Experimental|Arm 4: Pravastatin (160 mg) and Rifafour|"Participants will receive pravastatin (160 mg) and Rifafour daily for 14 days. Pravastatin will be given alone on Day 1, and pravastatin + Rifafour will be given on Days 2-15.~Vitamin B6 will be added to each of the regimens.~(Arm 4 will only be recruited if pravastatin 120 mg is well tolerated and safe, yet drug exposures are significantly reduced due to the known interaction with rifampin.)"
89450907|NCT03231644||FD/MAS Patients|Patients with fibrous dysplasia and/or McCune-Albright syndrome and related disorders.
89450908|NCT01007097|Experimental|TAK-875 6.25 mg QD|
89450909|NCT01007097|Experimental|TAK-875 25 mg QD|
89450910|NCT01007097|Experimental|TAK-875 50 mg QD|
89450911|NCT01007097|Experimental|TAK-875 100 mg QD|
89450912|NCT01007097|Experimental|TAK-875 200 mg QD|
89450913|NCT01007097|Active Comparator|Glimepiride 2 mg or 4mg QD|
89450914|NCT01007097|Placebo Comparator|Placebo QD|
89450915|NCT02461082|Other|EMST and sham-TMS|Active expiratory muscle strength training in combination with sham transcranial magnetic stimulation
89450916|NCT02461082|Other|sham-EMST and TMS|Sham expiratory muscle strength training in combination with active transcranial magnetic stimulation
89450917|NCT02461082|Other|EMST and TMS|Active expiratory muscle strength training in combination with active transcranial magnetic stimulation
89450918|NCT02461082|Other|sham-EMST and sham-TMS|Sham expiratory muscle strength training in combination with sham transcranial magnetic stimulation
89450919|NCT01663402|Placebo Comparator|Placebo|Placebo (for alirocumab) subcutaneous (SC) injection every 2 weeks (Q2W) added to stable Lipid-Modifying Therapy (LMT) for up to 64 months.
89200819|NCT00973180|No Intervention|Standard Label|Subjects in this arm will receive their prescriptions labeled with a standard label.
89200820|NCT00606177|Experimental|1|
89450920|NCT01663402|Experimental|Alirocumab 75 mg Q2W/Up to 150 mg Q2W|Alirocumab 75 mg SC injection Q2W added to stable LMT for up to 64 months. Alirocumab dose up-titrated to 150 mg Q2W from Month 2 when Low-Density Lipoprotein Cholesterol (LDL-C) levels >=50 mg/dL (1.29 mmol/L) at Month 1; or if up-titration was missed due to unavailability of LDL-C value, it was up-titrated at month 4 based on LDL-C value at Month 2. For participants receiving 150 mg Q2W, alirocumab dose was down-titrated in a blinded manner to 75 mg Q2W if two consecutive values of LDL-C were <25 mg/dL (0.65 mmol/L). For participants receiving 75 mg Q2W, alirocumab dose was switched to placebo in a blinded manner if two consecutive values of LDL-C were <15 mg/dL (0.39 mmol/L).
89450921|NCT04454892||Amyotrophic lateral sclerosis patients|Although previous studies have provided reference for the diagnosis and treatment of ALS, the etiology of ALS is still unknown, and the relevant clinical features and natural history of ALS still lack the verification of large samples. Therefore, the research on the natural history of ALS is of great significance to further increase the understanding of ALS and provide new evidence for the diagnosis and treatment of ALS
89450922|NCT03297164||optimized group|the patients in this group have been given the suggestive treatment from guideline.
89450923|NCT03297164||un-optimized group|the patients in this group have not been given the suggestive treatment from guideline.
89531367|NCT05041179|Active Comparator|4.8 g of actives (2.4 g NAC and 2.4 g glycine) per day split in two doses (arm B)|"First dose (1.2 g NAC and 1.2 g glycine, +1.2 g placebo) consumed in the morning~Second dose (1.2 g NAC and 1.2 g glycine, +1.2 g placebo) taken in the evening"
89014901|NCT03322215|Active Comparator|Capecitabine|1,000 mg/m2 tablet administered orally twice daily for 2 weeks followed by one week of rest. Depending on adverse reactions, both dose escalation and dose reductions will be performed.
89014902|NCT03308448|Active Comparator|Group 1|Intervention is Intra-Venous injection of Eprex or EPO [recombinant human erythropoietin, Pooyesh Darou Biopharmaceuticals CO., Tehran, Iran, 4000 unit/ml solution in prefilled syringe], 300 units/kg/day for three consecutive days (total:900/kg in 3 days)
89014903|NCT03308448|Active Comparator|Group 2|Intervention is Intra-Venous injection of Eprex or EPO [recombinant human erythropoietin, Pooyesh Darou Biopharmaceuticals CO., Tehran, Iran, 4000 unit/ml solution in prefilled syringe], 600 units/kg/day for three consecutive days (total:1800/kg in 3 days)
89014904|NCT03308448|Active Comparator|Group 3|Intervention is Intra-Venous injection of Eprex or EPO [recombinant human erythropoietin, Pooyesh Darou Biopharmaceuticals CO., Tehran, Iran, 4000 unit/ml solution in prefilled syringe], 600 units/kg/day for three consecutive days then repetition of the same treatment in month 1 (Total: 3600/kg in 2 set of 3-day treatment, 1 month apart)
89014905|NCT03298477|Other|Single Arm|Single Arm Safety and Effectiveness Confirmatory Study of EVAS using the Nellix® System
89014906|NCT03293030|Experimental|Dupilumab treatment|15 subjects will receive dupilumab for a treatment period of 52 weeks (i.e. last injection on week 50). All subjects will undergo skin biopsies for molecular profiling.
89014907|NCT03275974|Experimental|Treatment|Patients receive carbon C 11 Glutamine (11C-glutamine) IV and undergo PET imaging over 120 minutes. Beginning 2 hours to 7 days after 11C-glutamine PET, patients receive fluorine F 18 L-glutamate derivative BAY94-9392 (18F-FSPG) IV and also undergo PET imaging over 120 minutes. During each of the 11C-Glutamine and 18F-FSPG PET/CT scans, venous blood draws will be performed.
89450924|NCT03223298|Experimental|Botulinum Toxin Type A|The intramuscular injections will be performed with the patient awake in the oral and maxillofacial surgery clinic. Three injection sites into bilateral masseter muscles and two injection sites into bilateral temporalis muscles will be identified by having the patient clench. The sites will be marked with a surgical pen prior to injections. The skin at the injection sites will be cleaned with an alcohol swab. Via a 1cc TB syringe and a 30-gauge needle, the subject will then receive 100 units of reconstituted botulinum toxin A. 37.5 units will be injected into each masseter muscle and 12.5 units into each temporalis muscle. A written post-operative instruction sheet will be provided to all patients.
89450925|NCT03223298|Placebo Comparator|0.9% Sodium Chloride Injection|The intramuscular injections will be performed with the patient awake in the oral and maxillofacial surgery clinic. Three injection sites into bilateral masseter muscles and two injection sites into bilateral temporalis muscles will be identified by having the patient clench. The sites will be marked with a surgical pen prior to injections. The skin at the injection sites will be cleaned with an alcohol swab. Via a 1cc TB syringe and a 30-gauge needle, the subject will then receive unpreserved 0.9% sodium chloride. A written post-operative instruction sheet will be provided to all patients.
89450926|NCT05399160|Experimental|Nurse-led Supportive Care Group|
89450927|NCT05399160|No Intervention|Control Group|The control group did not receive any intervention during the study period.
89450928|NCT05390346|Experimental|college athletes|Screening Program of RED-S in College Athletes and Establish Diagnosis and Intervention Model
89014908|NCT03246087|Active Comparator|Acupuncture|Patients will receive acupuncture for plantar fasciosis. The standard of care home exercise program will be reviewed along with the stretching and strengthening exercises.
89014909|NCT03246087|Experimental|Standard of Care|The standard of care home exercise program will be reviewed along with the stretching and strengthening exercises.
89014910|NCT03246087|Experimental|Crossover|At the end of the study, patients in the Standard of Care group whom are still experiencing pain and symptoms will be rolled into the acupuncture treatment arm of the study.
89014911|NCT03189446|Experimental|Vaginal Cuff Brachytherapy + Chemotherapy|Vaginal cuff brachytherapy followed by Carboplatin (AUC 6) on day 1and Paclitaxel 80 mg/m2 IV over 1 hour days 1, 8, and 15 X 3 total cycles
89450929|NCT03297086|Active Comparator|Bi-Flex|Medicontur Bi-Flex 677MY IOL was implanted into 24 eyes of 12 patients during cataract surgery. Angle kappa, biometric data and IOL decantation were measured.
89450930|NCT03297086|Active Comparator|ReStor|and Alcon Acrysof Restor SN6AD1 IOL was implanted into 36 eyes of 18 patients during cataract surgery. Angle kappa, biometric data and IOL decantation were measured.
89450931|NCT00869661|Experimental|Group 1|RO5024048 500 mg bid + Pegasys + Copegus for 12 weeks, followed by SOC for 12 weeks. After 24 weeks, patients who have achieved rapid viral response will stop treatment, and those who have not will receive SOC for a further 24 weeks.
89450932|NCT00869661|Experimental|Group 2|RO5024048 1000mg bid + Pegasys + Copegus for 8 weeks, followed by SOC for 16 weeks. After 24 weeks, patients who have achieved rapid viral response will stop treatment, and those who have not will receive SOC for a further 24 weeks.
89450933|NCT00869661|Experimental|Group 3|RO5024048 1000mg bid + Pegasys + Copegus for 12 weeks, followed by SOC for 12 weeks. After 24 weeks, patients who have achieved rapid viral response will stop treatment, and those who have not will receive SOC for a further 24 weeks.
89450934|NCT00869661|Experimental|Group 4|Group 4 will receive RO5024048 1000mg bid + Pegasys + Copegus for 12 weeks, followed by SOC for 36 weeks
89450935|NCT00869661|Active Comparator|Group 5|Group 5 will receive SOC for 48 weeks
89450936|NCT00869661|Experimental|Group 6|Group 6 provides retreatment on an open-label basis for patients of Group 5 who failed treatment. Patients will receive RO5024048 1000mg bid + Pegasys + Copegus for 24 weeks, followed by SOC for 24 weeks.
89450937|NCT03192566|Experimental|Tylenol Dosing|"Dosing of Tylenol for postoperative pain relief will include:~children < 16 years; 650 mg every 6 hours, max 2.6 gram per 24 hours and children > or equal to 16 years every 6 hours 1 g of acetaminophen, max 4 gram per 24 hours)."
89014913|NCT03162536|Experimental|Phase 1: Dose Escalation and Determination of RP2D|Phase I: Dose Escalation and determination of RP2D, multiple dose levels of nemtabrutinib to be evaluated (Up to approximately 22 months).
89200821|NCT00606177|Placebo Comparator|2|
89200822|NCT00985270|Active Comparator|Rifampicin|
89450938|NCT04455984||Neoadjuvant chemoradiotherapy|Patients with advanced NSCLC treated with neoadjuvant platinum-based chemoradiotherapy followed by curative-intent surgery
89450939|NCT04455984||Neoadjuvant chemotherapy|Patients with advanced NSCLC treated with neoadjuvant platinum-based chemotherapy followed by curative-intent surgery
89450940|NCT03296930|Active Comparator|first drug group|Sofosbuvir 400 MG Oral Tablet
89450941|NCT03296930|Active Comparator|second drug group|Ombitasvir/paritaprevir/ritonavir
89450942|NCT04605510|Experimental|Intervention Group|24 female participants with non-specific neck pain included in the mobilization group will undergo detailed manual cervical examination. In the evaluation, the most painful segment with dysfunction will be selected and mobilization application and algometric measurements will be performed on this segment. Grade 3 Central Posterior-Anterior (CPA) passive joint mobilization with Maitland method will be applied in 3 sets, 30 seconds, to the segment with the detected dysfunction.
89450943|NCT04605510|No Intervention|Healthy Control Group|Healthy volunteer participants included in the control group will only be applied an evaluation protocol and blood samples will be taken without any application.
89450944|NCT05563545|Experimental|CAR-NK-CD19 Cells|After preconditioning with chemotherapy, CAR-NK-CD19 Cells will be evaluated.
88935364|NCT01778907|No Intervention|Normal genotype- control (NG-C)|In the external control group, an advice for dose adaptation based on patients serum drug levels will be given to the physician according to current daily practice. Allocation to this arm is not based on randomization.
88935365|NCT01778907|No Intervention|Deviating genotype -control (DG-C)|In the internal control group, an advice for dose adaptation based on patients serum drug levels will be given to the physician according to current daily practice
88935366|NCT01778907|Experimental|Deviating genotype (DG-I)|In the intervention group, genotype information accompanied by a drug dosing advice will be given to the treating physician. Blood level of the drug will be communicated by a dedicated research team to the treating physician according to daily practice.
88935367|NCT01778920|Experimental|IV Injection of EC17|The group will receive a single dose of EC17, infused over 10 minutes, prior to surgery. Then, during surgery, the EC-17 will be imaged with a camera that the investigators have developed.
88935368|NCT01778933|Experimental|EC17 Injection Group|The group will receive a single dose of EC17, infused over 10 minutes, prior to surgery. Then, during surgery, the EC-17 will be imaged with a camera that the investigators have developed.
88935369|NCT01778959|Active Comparator|standard OVD|
88935370|NCT01778959|Active Comparator|Iris hooks|
88935371|NCT01778959|Active Comparator|Malyugin Ring|
88935372|NCT01778959|Active Comparator|OVD|
88935373|NCT01778972|Experimental|Otago home training programme|"Otago home exercise programme was designed specifically to prevent fall. It consists of a set of leg muscle strengthening and balance retraining exercises progressing in difficulty, and a walking plan.~The exercise are individually prescribed and increase in difficulty during a series of five home visits by a physiotherapist."
88935374|NCT01778972|Experimental|Motivational interviewing plus Otago|This group is not only exercising at home but also getting motivational interviewing from the physiotherapist at he five home visits. The physiotherapists doing motivational interviewing are specially trained in motivational interviewing.
88935375|NCT01778972|No Intervention|Control grop|Participants are instructed to live their ordinary lives.
88935376|NCT01778998|Active Comparator|MICS-group|
88935377|NCT01778998|Active Comparator|SICS-group|
88935378|NCT01778998|Active Comparator|SICS pre-cut|
88935379|NCT01778998|Active Comparator|SICS stab-incision|
88935380|NCT01779011||A cohort post amputation|Those patients undergoing either traumatic amputation or surgical amputation of limb
88935381|NCT01779011||A cohort post limb conserving surgery|Patients whose surgical management involved conservation of their injured limb
88935382|NCT01779037||Inpatient Rehabilitation Patients|
88935383|NCT01779063|Experimental|web based multimedia intervention|interactive,web based multimedia intervention
88935384|NCT01779063|Active Comparator|education booklet|printed educational booklet
89450945|NCT04607772|Experimental|Arm A: Selinexor with Bendamustine and Rituximab (S-BR))|Participants will receive a dose of 40 or 60 or 80 milligrams (mg) of selinexor oral tablets on Days 1, 3, and 8 for Cycle 1 to 6 (each cycle consists of 21 days) during primary treatment and 60 mg on Days 1, 8, 15, and 22 during continuous treatment (each cycle consists of 28 days). Participants will also receive an intravenous (IV) dose of bendamustine 90 milligram per square meter (mg/m^2) on Days 1 and 2 and IV dose of rituximab 375 mg/m^2 on Day 1 during primary treatment for Cycle 1 to 6.
89450946|NCT04607772|Experimental|Arm B: Selinexor with Polatuzumab Vedotin and Rituximab (S-PR)|Participants will receive a dose of 40 or 60 or 80 mg of selinexor oral tablets on Days 1, 3, and 8 for Cycle 1 to 6 (each cycle consists of 21 days) during primary treatment and 60 mg on Days 1, 8, 15, and 22 during continuous treatment (each cycle consists of 28 days). Participants will also receive an IV dose of polatuzumab vedotin 1.8 milligram per kilogram (mg/kg) and IV dose of rituximab 375 mg/m^2 on Day 1 during primary treatment for Cycle 1 to 6.
89450947|NCT04607772|Experimental|Arm C: Selinexor, Polatuzumab Vedotin, Bendamustine, Rituximab (S-PBR)|Participants will receive a dose of 40 or 60 or 80 mg of selinexor oral tablets on Days 1, 3, and 8 for Cycle 1 to 6 (each cycle consists of 21 days) during primary treatment and 60 mg on Days 1, 8, 15, and 22 during continuous treatment (each cycle consists of 28 days). Participants will also receive an IV dose of polatuzumab vedotin 1.8 mg/kg and IV dose of rituximab 375 mg/m^2 on Day 1, and IV dose of bendamustine 90 mg/m^2 on Days 1 and 2 during primary treatment for Cycle 1 to 6.
89450948|NCT04607772|Experimental|Arm D: Selinexor, Rituximab, Gemcitabine, Oxaliplatin (S-R-GemOx)|Participants will receive a dose of 40 or 60 or 80 mg of selinexor oral tablets on Days 1 and 3 for Cycle 1 to 6 (each cycle consists of 14 days) during primary treatment and 60 mg on Days 1, 8, 15, and 22 during continuous treatment (each cycle consists of 28 days). Participants will also receive an IV dose of rituximab 375 mg/m^2, IV dose of gemcitabine 1000 mg/m^2, and Oxaliplatin IV dose of 100 mg/m^2 on Day 1 during primary treatment for Cycle 1 to 6.
89014914|NCT03162536|Experimental|Phase 2: Expansion Cohort A|Relapsed/Refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (R/R CLL/SLL) participants with at least 2 prior systemic therapies and previously treated with a covalent Bruton's tyrosine kinase inhibitor (BTKi) who must have a documented BTK mutation on C481 residue receive up to 65 mg of nemtabrutinib per day orally in each cycle (Cycle length = 28 days) until progressive disease (PD), unacceptable adverse events (AEs), or discontinuation at investigator's discretion (up to approximately 64 months).
89014915|NCT03162536|Experimental|Phase 2: Expansion Cohort B|R/R CLL/SLL participants who have failed or were intolerant to a BTKi with documentation of the absence of BTK mutation on C481 residue receive up to 65 mg of nemtabrutinib per day orally in each cycle (Cycle length = 28 days) until PD, unacceptable AEs, or discontinuation at investigator's discretion (up to approximately 64 months).
89014916|NCT03162536|Experimental|Phase 2: Expansion Cohort C|Richter's transformation (RT) participants who have failed at least one prior therapy receive up to 65 mg of nemtabrutinib per day orally in each cycle (Cycle length = 28 days) until PD, unacceptable AEs, or discontinuation at investigator's discretion (up to approximately 64 months).
89014917|NCT03162536|Experimental|Phase 2: Expansion Cohort D|Follicular Lymphoma (FL) participants who have failed at least 2 prior systemic therapies and are histology grade 1, 2, or 3A receive up to 65 mg of nemtabrutinib per day orally in each cycle (Cycle length = 28 days) until PD, unacceptable AEs, or discontinuation at investigator's discretion (up to approximately 64 months).
89450949|NCT04607772|Experimental|Arm E: Selinexor with Ibrutinib and Rituximab (S-IR)|Participants will receive a dose of 40 or 60 or 80 mg of selinexor oral tablets on Days 1, 8, and 15 for Cycle 1 to 6 during primary treatment and 40 mg (dose level 1) then 60 mg (dose level 2-4) during continuous treatment (each cycle consists of 28 days). Participants will also receive an IV dose of rituximab 375 mg/m^2 on Day 1, and ibrutinib oral dose of 420 or 560 mg once daily on Day 1 to 28 during primary treatment for Cycle 1 to 6. Participants will also receive ibrutinib oral dose of 420 mg once daily at all dose levels during continuous treatment.
89450950|NCT04607772|Experimental|Arm F: Selinexor with Lenalidomide and Rituximab (S-LR)|Participants will receive a dose of 40 or 60 mg of selinexor oral tablets on Days 1, 8, and 15 for Cycle 1 to 6 during primary treatment and 40 mg (dose level 1) then 60 mg (dose level 2) during continuous treatment (each cycle consists of 28 days). Participants will also receive an IV dose of rituximab 375 mg/m^2 on Day 1, and lenalidomide oral dose of 20 mg once daily on Days 1 to 21 during primary treatment for Cycle 1 to 6. Participants will also receive lenalidomide oral dose of 20 mg on Days 1 to 21 at all dose levels during the continuous treatment.
89450951|NCT04607772|Experimental|Arm G: Selinexor with Lenalidomide and Tafasitamab (S-LT)|Participants will receive a dose of 40 or 60 mg of selinexor oral tablets on Days 1, 8, and 15 for Cycle 1 to 12 during primary treatment and 40 (dose level 1) then 60 mg (dose level 2) during continuous treatment (each cycle consists of 28 days). During the primary treatment, participants will also receive lenalidomide oral dose of 25 mg once daily on Days 1 to 21, and tafasitamab IV dose of 12 mg/kg on Days 1, 8, 15, and 22 for Cycle 1 to 3 and Days 1 and 15 for Cycle 4 to 12. Participants will also receive an IV dose of tafasitamab 12 mg/kg on Days 1 and 15 for all dose levels during the continuous treatment.
89450952|NCT04607772|Experimental|Arm H: Selinexor with Venetoclax (S-V)|Participants will receive 40 or 60 or 80 mg of selinexor oral tablets on Days 1, 8 and 15 for Cycle 1 to 6 of primary treatment and 40 mg (dose level 1) then 60 mg (dose level 2-5) during continuous treatment (28 days per cycle). Participants who received 40 and 60 mg of selinexor during primary treatment will also receive oral dose of venetoclax 200 mg on Days 1 to 7 then 400 mg on Days 8 to 28 for Cycle 1; 400 mg daily for Cycle 2 to 6. Participants who received 60 and 80 mg of selinexor during primary treatment will also receive venetoclax 400 mg orally on Days 1 to 7 then 600 mg on Days 8 to 28 for Cycle 1; 600 mg daily for Cycle 2 to 6. Participants who received 80 mg selinexor during primary treatment will also receive venetoclax 400 mg orally on Days 1 to 7, then 600 mg from Days 8 to 14, then 800 mg from Day 15 to 28 for Cycle 1; 800 mg daily for Cycle 2 to 6. Participants during continuous treatment will also receive venetoclax 400 mg orally daily.
89450953|NCT03296852|Experimental|Healthy Volunteers|
89450954|NCT02464124|Experimental|lactulose plus nitazoxanide|"Nitazoxanide dosing: 500 mg tablets twice daily~Lactulose dosing: 30-60 mL PO TID with goal 2-3 semisoft stools per day"
89450955|NCT02464124|Active Comparator|Lactulose alone|Lactulose dosing: 30-60 mL PO TID with goal 2-3 semisoft stools per day
89450956|NCT00859521|Experimental|Levetiracetam|Levetiracetam 1000 mg Tablet (test) dosed in first period followed by Keppra® 1000 mg Tablet (reference) dosed in second period
89450957|NCT00859521|Active Comparator|Keppra®|Keppra® 1000 mg Tablet (reference) dosed in first period followed by Levetiracetam 1000 mg Tablet (test) dosed in second period
89450958|NCT04455672|Experimental|interventional group|patient using two types of splints (3d Anterior Rrepositioning Splint then printed stabilizing splint)
89450959|NCT04455672|Active Comparator|control group|patient using two types of splints (3d printed stabilizing splint then Anterior Rrepositioning Splint)
89450960|NCT02463890|Experimental|Training|"In this group, patients will perform 3 sessions of one hour per week of the NeuroGyV training program. It is a physical activity program with one session of Nordic walking, one session of aquagym and one session of gymnastic. Program lasts 9 months."
89450961|NCT02463890|Other|Control|In this group, patients will receive only diets and physical activity counselling
89450962|NCT05398770|Experimental|Vitamin D3 (30 µg/d)|Subjects will take 30 µg vitamin D3 per day
89450963|NCT05398770|Placebo Comparator|Placebo|Subjects will take placebo
89450964|NCT04649775|Active Comparator|Device intervention|Intervention participants will receive the AirFLO2 device and training via video with reinforcement from the coordinator how to use and to self-apply it. Clinical data will be recorded before and after intervention. Questionnaires will be completed at baseline and at serial time points after intervention starts.
89450965|NCT04649775|No Intervention|Standard of Care- Control|Participants will receive standard of care, clinical data will be recorded. Baseline and end of study questionnaires will be performed.
89450966|NCT05398692|Active Comparator|+ PEM|Patients who experience Post Exertional Malaise (PEM) will receive 10 weeks of virtual rehabilitation.
89200823|NCT00985270|Placebo Comparator|Placebo|
89200824|NCT00982384|Experimental|Disease management|Comprehensive disease management in addition to best care according to clinical guidelines for COPD patients
89450967|NCT05398692|Experimental|No PEM|Patients who do not experience Post Exertional Malaise (PEM) will receive 10 weeks of traditional pulmonary rehabilitation.
89450968|NCT03130374|Experimental|Mesenchymal stem cell treated group|Patients treated according to current clinical protocols plus autologous olfactory mucosa-derived mesenchymal stem cells
89450969|NCT03130374|No Intervention|Control group|Patients treated according to current clinical protocols
89450970|NCT04159454|Experimental|PITA Participants|"All patients in the study are part of the PITA arm, where PITA will be on for Weeks 0-8, and off from Weeks 8-12."
88935385|NCT01779076|Experimental|100% oxygen during extubation|In this arm the intervention will consist of 100 % oxygen.
88935386|NCT01779076|Experimental|30% oxygen during extubation|In this arm the intervention will consist of 30 % oxygen.
88935387|NCT01779089|Experimental|Minocycline|Minocycline 100 mg po bid for 6 months
88935388|NCT01779089|Placebo Comparator|Placebo|Placebo one tablet po bid
88935389|NCT01779102|Experimental|0.1 µg C-Tb|The C-Tb agent is given alone to volunteers in the RIGHT or LEFT forearm according to a double blind randomisation scheme
88935390|NCT01779102|Active Comparator|2 T.U Tuberculin PPD RT 23 SSI|The 2 T.U Tuberculin PPD RT 23 SSI agent is given alone to volunteers in the RIGHT or LEFT forearm according to a double blind randomisation scheme
88935391|NCT01779102|Experimental|0.1 µg C-Tb / 2 T.U Tuberculin PPD|The C-Tb and 2 T.U Tuberculin PPD RT 23 SSI agents are given concomitantly to volunteers in the RIGHT and LEFT forearms according to a double blind randomisation scheme
88935392|NCT01779128|Experimental|Experimental Arm|PET/CT Scan MR-PET Scan
88935393|NCT01779154||eosinophilic gastrointestinal disorders|Individuals with a diagnosis of EGID including: eosinophilic esophagitis, eosinophilic gastritis, eosinophilic enteritis, eosinophilic colitis
88935394|NCT01779193|Experimental|latic acid bacteria and cranberry|oral latic acid bacteria and cranberry capsule (dose of 2 * 10^9 cfu per capsule), one pill daily
88935395|NCT01779193|Active Comparator|cranberry|oral cranberry capsule without lactic acid bacteria, one pill daily
88935396|NCT01779193|Placebo Comparator|placebo|placebo without lactic acid bacteria and cranberry, one pill daily
89450971|NCT03176004|Experimental|Attention Bias Modification|Participants play a game in which they can move up in levels by reducing their reaction time to targets presented in the location of a threatening word.
89450972|NCT03176004|Active Comparator|Active Control Condition|Participants play a game in which they can move up in levels by reducing their reaction time to targets presented in the location of a word with a specific color.
88935397|NCT01779232|Placebo Comparator|control|patients treated with placebo for at least 4 months before IVF attempt
88935398|NCT01779232|Active Comparator|danazol|patients treated with danazol (100mg/day)for at least 4 months before IVF attempt
88935399|NCT01779245|Placebo Comparator|Control|A chocolate milkshake with a normal calcium content will be consumed daily (235 kcal; 13 g protein; 42 g carbohydrate; 1 g fat, 400 mg calcium per serving).
88935400|NCT01779245|Experimental|High-Calcium|A chocolate milkshake with a high calcium content will be consumed daily (235 kcal; 13 g protein; 42 g carbohydrate; 1 g fat, 1400 mg calcium per serving).
88935401|NCT01779258|Other|Group 2|Active control arm, Locatop@, Locapred@
88935402|NCT01779258|Other|Group 3|Absence of emollient treatment, Locatop@, Locapred@
88935403|NCT01779258|Experimental|Group 1|"glycerol, paraffin (liquid and white soft), Locatop@~, Locapred@"
88935404|NCT01779271|Experimental|Pelubiprofen|
88935405|NCT01779271|Active Comparator|Loxoprofen|
88935406|NCT01779284|Active Comparator|Travoprost/Timolol therapy|Enrolled patients will be treated for 3 months with travoprost/timolol drops administered once in the evening. Evaluation of 24-hour pressure efficacy for this drug after 3 months of chronic therapy
88935407|NCT01779284|Active Comparator|Latanoprost/Timolol therapy|Enrolled patients will be treated for 3 months with travoprost/timolol drops administered once in the evening. 24-hour pressure monitoring will be carried out for this drug after 3 months of chronic dosing. All patients will be crossed over to therapy for 3 months with latanoprost/timolol fixed combination drops administered once in the evening. Evaluation of 24-hour pressure efficacy for this drug after 3 months of chronic therapy
88935408|NCT01779310||Alzheimer's disease|Outpatients with clinically significant cognitive impairment per judgment of the participating physicians are enrolled.
88935409|NCT01779336|Experimental|PL225B|Patients will receive study drug on a daily basis until disease progression or unacceptable toxicity in sequential cohorts following accelerated titration design.
88935410|NCT01779349|Experimental|"Dynamic Urine Vibration Holter"|"each subject will undergo intervention for the diagnosis of bladder outlet obstruction first using the Dynamic Urine Vibration Holter and then urodynamically by pressure flow study"
88935411|NCT01779362|Active Comparator|Metformin alone|Metformin will be titrated to the maximum dose tolerated (up to 2000 mg/day). Participants randomized to the metformin-alone arm will be blinded to treatment.
88935412|NCT01779362|Active Comparator|Glargine followed by Metformin|Basal insulin glargine for 3 months titrated to achieve a morning fasting blood glucose of 80-90 mg/dl, followed by open-label metformin (titrated up to 2000 mg/day) for 9 months.
88935413|NCT01779362|Placebo Comparator|Placebo|Placebo - masked to metformin-alone. Placebo will be titrated to the maximum number of tablets equivalent to maximum dose of metformin.
89450973|NCT03176004|No Intervention|Wait List|Participants simply return after 8 weeks.
89450974|NCT04642131|Experimental|Personalized insoles|Personalized insoles without supplementation
89450975|NCT04642131|Experimental|Caffeine supplementation|Standard insoles with caffeine supplementation (3mg/kg)
89450976|NCT04642131|Placebo Comparator|Control condition|Standard insoles without supplementation
89450977|NCT05390190|Experimental|Non ablative radiofrequency|Device
89450978|NCT02866526||group1|adolescents (14-17 years old)
89450979|NCT02866526||group 2|young adults (20-29 years old)
89450980|NCT05398614|Experimental|CD7 CAR-T|SENL101
89450981|NCT01001715|Experimental|REGN475/SAR164877|REGN475/SAR164877, single injection, dose depending on the participant's body weight
89450982|NCT01001715|Placebo Comparator|Placebo|Placebo (for REGN475/SAR164877), single injection
89450983|NCT04473729|Experimental|Children with an autism spectrum disorder|The intervention as described above with children with an ASD.
89450984|NCT04473729|Experimental|Children with Hearing Loss|
88935414|NCT01779362|Active Comparator|Liraglutide + Metformin|Liraglutide + open-label Metformin. Liraglutide will be titrated to the maximum dose tolerated (up to 1.8 mg/day) after which metformin will be titrated to the maximum dose tolerated (up to 2000 mg/day).
88935415|NCT01779401|Active Comparator|Clopidogrel + Aspirit|A Standard antiplatelet therapy control group： Clopidogrel 75mg Qd + Aspirin 100mg Qd
88935416|NCT01779401|Active Comparator|Clopidogrel + Aspirin|B Double-dosage Clopidogrel group： Clopidogrel 150mg Qd + Aspirin 100mg Qd
88935417|NCT01779401|Active Comparator|Clopidogrel + Aspirin + Cilostazol|C triple antiplatelet therapy group： Cilostazol 100mg Bid + Aspirin 100mg Qd + Clopidogrel 75mg Qd
88935418|NCT01779414|No Intervention|Enhanced Usual Care|Participants in this arm of the study will receive a standard, usual care psychological risk assessment by a social worker and then recommended to a mental health referral.
88935419|NCT01779414|Experimental|STAT-ED Intervention|Participants in this group will receive a motivational interview conducted by a study trained social worker, where the social worker and the family will discuss the participants issues, thoughts and feelings about receiving treatment, barriers to treatment and methods of overcoming those barriers. The study trained social worker will also make a referral for a mental health follow-up for the patient.
88935420|NCT01779427|Experimental|AIM Intervention|
88935421|NCT01779427|Experimental|Wait List Control|Participants are in the Wait List Control group for 10 weeks and then they will participate in the AIM Intervention
88935422|NCT01779466|Experimental|Experimental A|
88935423|NCT01779466|Experimental|Experimental B|
88935424|NCT01779466|Placebo Comparator|Placebo|
88935425|NCT01779479|Experimental|Cabacitaxel|
88935426|NCT01779479|Active Comparator|Paclitaxel|
88935427|NCT01779492|Experimental|GL2907|Oxycodone HCl 20mg
88935428|NCT01779492|Active Comparator|Oxycontine CR 10mg|Oxycodone HCl 10mg
88935429|NCT01779505|Experimental|GS-4774 at 10 yeast units (YU)|10 YU of GS-4774 given either weekly or monthly
88935430|NCT01779505|Experimental|GS-4774 at 40 YU|40 YU of GS-4774 given either weekly or monthly
88935431|NCT01779505|Experimental|GS-4774 at 80YU|80 YU of GS-4774 given either weekly or monthly
88935432|NCT01779531||pCR，XT|
88935433|NCT01779544|Active Comparator|Brief intervention only|Brief intervention, an educational model, consists of information
89450985|NCT04473729|Experimental|Typically developing children with normal hearing acuity|
89450986|NCT02463812|Experimental|Intralipid|Patients will receive Intralipid infusion in the recovery room.
89450987|NCT02463812|Placebo Comparator|Control|Patients will receive infusion of normal saline in the recovery room.
89450988|NCT00789633|Experimental|Masitinib & gemcitabine|Participants receive masitinib (9 mg/kg/day), given orally twice daily, plus gemcitabine at 1000mg/m2 by intravenous infusion during 30 minutes, once every 7 days, for up to 7 weeks, followed by a week of rest. Subsequent cycles should consist of an IV infusion, once every 7 days, for 3 consecutive weeks out of every 4 weeks, until disease progression, death, limiting toxicity or patient consent withdrawal.
89450989|NCT00789633|Placebo Comparator|Placebo & gemcitabine|Participants receive matching placebo, given orally twice daily, plus gemcitabine at 1000mg/m2 by intravenous infusion during 30 minutes, once every 7 days, for up to 7 weeks, followed by a week of rest. Subsequent cycles should consist of an IV infusion, once every 7 days, for 3 consecutive weeks out of every 4 weeks, until disease progression, death, limiting toxicity or patient consent withdrawal.
89450990|NCT02463188|Experimental|Sleep Fitness Intervention|The intervention consists of 5-7 sessions on sleep science, the connection between sleep and substance use, behavior change strategies, and motivation to change behavior.
89450991|NCT02463188|No Intervention|Psychoeducation (PE)|The control classes will receive an 1-session psycho-educational (PE) intervention that provides information on sleep but does not provide guidance for implementing behavior change and does not explicitly teach about sleep's relationship to substance use.
88935434|NCT01779544|Active Comparator|Exercise group|Brief educational intervention combined with exercise therapy
88935435|NCT01779570|Experimental|Macrolide treatment|Azithromycin 500 mg daily for 5 days
88935436|NCT01779570|No Intervention|No macrolide treatment|No azithromycin
88935437|NCT01779583||Advanced gastric cancer patients|Treatment näive advanced gastric cancer patients candidates to first-line chemotherapy
88935438|NCT01779583||Control group|Healthy adult volunteers without a cancer diagnosis
88935439|NCT01779596|Experimental|Bosentan|Single dose of Bosentan (125 mg)
88935440|NCT01779596|Placebo Comparator|Placebo|Single dose of placebo (125 mg)
88935441|NCT01779609|Experimental|Bosentan + Exercise|2x/day 62.5 mg Bosentan for 4 weeks alongside 3x/week supervised exercise 2x/day 125 mg Bosentan for 4 weeks alongside 3x/week supervised exercise
88935442|NCT01779609|Placebo Comparator|Placebo + Exercise|2x/day 62.5 mg Placebo for 4 weeks alongside 3x/week supervised exercise 2x/day 125 mg Placebo for 4 weeks alongside 3x/week supervised exercise
88935443|NCT01779609|Other|Exercise|3x/week supervised exercise for 8 weeks
88935444|NCT01779622|Experimental|1|Healthy volunteers are ingesting a mixed meal either rapidly or slowly
88935445|NCT01779635|Active Comparator|oXiris as first filter|Start off the first CRRT circuit with oXiris, then cross-over to M150, then oXiris, then back to M150
88935446|NCT01779635|Other|M150 as first filter|Patients in M150 arm will start off with M150 as first filter for CRRT, then cross-over to oXiris after the former clots, then back to M150, then to oXiris.
88935447|NCT01779661|Active Comparator|Infant Aquatics|
88935448|NCT01779661|Active Comparator|Infant Massage|Infant Massage
88935449|NCT01779687|Active Comparator|raltegravir alone|Raltegravir 400 mg BID for 7 days
88935450|NCT01779687|Active Comparator|Atorvastatin alone|Atorvastatin 20 mg QD for 7 days
88935451|NCT01779687|Experimental|Raltegravir + atorvastatin|Raltegravir 400 mg BID + Atorvastatin 20 mg QD for 7 days
89200825|NCT00982384|Active Comparator|Best care|Best care according to clinical guidelines for COPD patients
89200826|NCT00901953||1|migrainous vertigo
89450992|NCT00788541|Experimental|3 mg Anecortave Acetate, low volume high dose|Anecortave Acetate Sterile Suspension, 6 mg/mL, one injection of 0.5 mL in the study eye monthly for 6 months.
88935452|NCT01779713||Vasospastic patients|Any patient send to the neuro-anesthesia intensive care unit in the 48 hours following an aneurismal sub-arachnoid hemorrhage and treated in the 96 first hours (embolization or surgery) and developing a vasospasm during the first 12 days after the bleeding; aged more than 18; of Caucasian origin; affiliated to a social care service; having (or one of is related if he is comatose) given its informed consent
88935453|NCT01779713||Control patients|Any patient send to the neuro-anesthesia intensive care unit in the 48 hours following an aneurismal sub-arachnoid hemorrhage and treated in the 96 first hours (embolization or surgery) not developing a vasospasm during the first 12 days after the bleeding; aged more than 18; of Caucasian origin; affiliated to a social care service; having (or one of is related if he is comatose) given its informed consent
89450993|NCT00788541|Experimental|3 mg Anecortave Acetate, high volume low dose|Anecortave Acetate Sterile Suspension, 3.75 mg/mL, one injection of 0.8 mL in the study eye monthly for 6 months.
89450994|NCT00788541|Experimental|48 mg Anecortave Acetate, low volume high dose|Anecortave Acetate Sterile Suspension, 96 mg/mL, one injection of 0.5 mL in the study eye monthly for 6 months.
88935454|NCT01779726|Experimental|CT scan before chest physician|CT scan before chest physician
88935455|NCT01779726|Active Comparator|Usual diagnostic workup|Usual diagnostic workup
88935456|NCT01779739|No Intervention|No perineorrhaphy|Subjects will not have a perineorrhaphy procedure added to the vaginal prolapse repair
88935457|NCT01779739|Active Comparator|Perineorrhaphy|Subjects will have a perineorrhaphy added to the vaginal repair of prolapse
88935458|NCT01779765|Experimental|PHGG|2.5gr per day for the first week and then 5gr per day for 11 weeks.
88935459|NCT01779765|Placebo Comparator|Maltodextrin|2.5gr per day for the first week and then 5gr per day for 11 weeks.
88935460|NCT01779791|Experimental|PCI-32765 (Ibrutinib)|
88935461|NCT01779804||Patients with foot and ankle injury|After baseline data is obtained a cohort of patients with acute foot and ankle injuries will have OFAR applied
88935462|NCT01779817|Other|child born to hyperthyroid mother during pregnancy|Assessment of intellectual development, capacities of attention, learning process and degree of hyperactivity of the children between 6 and 9 years.
88935463|NCT01779817|Other|child born to euthyroid mother during pregnancy|Assessment of intellectual development, capacities of attention, learning process and degree of hyperactivity of the children between 6 and 9 years.
88935464|NCT01779830|Experimental|0.3 mg LY2624803|Single dose of 0.3 mg LY2624803 administered orally in up to 2 of 4 treatment periods.
88935465|NCT01779830|Experimental|3.0 mg LY2624803|Single dose of 3.0 mg LY2624803 administered orally in up to 2 of 4 treatment periods.
88935466|NCT01779830|Experimental|6.0 mg LY2624803|Single dose of 6.0 mg LY2624803 administered orally in up to 2 of 4 treatment periods.
88935467|NCT01779830|Active Comparator|10 mg Zolpidem|Single dose of 10 mg zolpidem administered orally in up to 1 of 4 treatment periods.
88935468|NCT01779830|Placebo Comparator|Placebo|Single dose of placebo administered orally in up to 1 of 4 treatment periods.
88935469|NCT01779843|Experimental|Treatment|"Induction: 100 mg/m2/day Cytarabine intravenous, days 1-7 of induction cycle. 12 mg/m2/day Idarubicin intravenous, days 1-3. Alisertib orally, twice a day for one week starting on day 8, dose escalation-starting dose 10 mg PO BID.~Consolidation: Cytarabine 3 g/m2 by IV infusion over 3 hours given every 12 hours on Days 1, 3 and 5 (subjects younger than age 60) or Cytarabine 2 g/m2 per day by IV infusion over 3 hours on days 1-5 (subjects at or older than age 60)"
88935470|NCT01779882|Active Comparator|BU-CY|Group A (standard group): conditioning regimen with Busulfan (BU) followed by Cyclophosphamide (CY)
88935471|NCT01779882|Experimental|CY-BU|Group B (experimental group): conditioning regimen with Cyclophosphamide (CY) followed by Busulfan (BU)
88935472|NCT01779895|Active Comparator|NCC2461|probiotic blended in maltodextrin powder to be taken daily
88935473|NCT01779895|Placebo Comparator|Placebo|maltodextrin
88935474|NCT01779908|Experimental|Vitamin D supplementation|5000 IU of vitamin D3 for 6 months
88935475|NCT01779908|Placebo Comparator|Placebo|Placebo pill for 6 months
89450995|NCT00788541|Experimental|48 mg Anecortave Acetate, high volume low dose|Anecortave Acetate Sterile Suspension, 60 mg/mL, one injection of 0.8 mL in the study eye monthly for 6 months.
89450996|NCT00788541|Placebo Comparator|Anecortave Acetate Vehicle, low volume|Anecortave Acetate Vehicle, one injection of 0.5 mL in the study eye monthly for 6 months.
89450997|NCT00788541|Placebo Comparator|Anecortave Acetate Vehicle, high volume|Anecortave Acetate Vehicle, one injection of 0.8 mL in the study eye monthly for 6 months.
88935476|NCT01779921||FVII|
88935477|NCT01779960||Londrina|20 patients with moderate-severe COPD from State University of Londrina, Brazi
88935478|NCT01779960||Leuven|20 patients with moderate-severe COPD from Catholic University of Leuven, Belgium
88935479|NCT01779973|Experimental|Remote Observed Dosing|Compliance with dosage observations of suboxone doses using remote observed dosing 4 days per week and 1 weekly in-office visit.
88935480|NCT01779999||PICC-carrying patients|All patients carrying a peripherally inserted central catheter in our service
88935481|NCT01780012|Experimental|Intervention|Osteoporosis prevention program: Women will receive oral and written information and advices on osteoporosis, a letter and a leaflet on osteoporosis management to give to their family physician, and phone call reminders.
88935482|NCT01780012|No Intervention|Control|Control women will receive usual post-fracture care without information
88935483|NCT01780038|Experimental|Receipt of Genetic Results|Receipt of Genetic Results indicates that participants have received the results of genotyping for RS1051730
88935484|NCT01780038|Active Comparator|No results given|Participants will not be offered to receive the results of genotyping for RS1051730 until all data collection has been completed.
89450998|NCT03296618|Experimental|NSI-566 neural stem cell implantation|
89450999|NCT03296540|Active Comparator|Uncrushed|6 Integral tablets Prasugrel as loading dose
89451000|NCT03296540|Experimental|Crushed|6 Crushed tablets Prasugrel as loading dose
89451001|NCT00787059|Experimental|Ad5.hAC6|Will receive intracoronary adenovirus encoding human adenylyl cyclase type 6
89451002|NCT00787059|Placebo Comparator|sucrose solution|Will receive intracoronary sucrose solution
89451003|NCT04489160|Experimental|C1-inhibitor|One dose 6000 IU C1-inhibitor intravenously
89451004|NCT04489160|Placebo Comparator|Placebo|0.9% saline
88935485|NCT01780051|Experimental|Sequence A|
88935486|NCT01780051|Experimental|Sequence B|
88935487|NCT01780064|Placebo Comparator|Standard group|routine monitoring with questionnaires
88935488|NCT01780064|Active Comparator|Interviews with psychologist|Patients have interviews with a psychologist (at cure one of chemotherapy treatment,at cure six of chemotherapy treatment, at last radiotherapy session, and three months after the end of radiotherapy) and questionnaires
88935489|NCT01780077|Experimental|RXI-109|
88935490|NCT01780077|Placebo Comparator|Placebo|
88935491|NCT01780090|Experimental|iPad software|Student participants will use specialized, iPad software under the direction of the SLP, 1 time a week over the course of 2 months.
89451005|NCT00786201|Placebo Comparator|Placebo|
88935492|NCT01780116|Experimental|Medicaiton adherence therapy|"Adherence therapy, consisting of six, 2-hour sessions over 3 months, in three phases:~Engaging patients: assessing needs and concerns in medication adherence;~Reviewing strengths and barriers and developing coping strategies; and~Rationalizing beliefs and concerns and preventing relapse."
88935493|NCT01780116|No Intervention|Routine community care|Routine Community psychiatric nursing services provided by the Community Psychiatric Nurses in the practice field
88935494|NCT01780129|Experimental|Polydatin Injectable (HW6)|10ml(2 ampoules) diluted in 500ml of 0.9% NaCl solution for i.v. infusion over 2 hours; once daily for 5 consecutive days
88935495|NCT01780129|Placebo Comparator|HW6 blank dummy (0.9%NaCl)|10ml (2 ampoules) diluted in 500ml of 0.9% NaCl solution for i.v. infusion over 2 hours; once daily for 5 consecutive days
88935496|NCT01780155||1|Parents and premature newborns with a birth weight less than or equal to1250 g from member institutions of the hospital network will be invited to participate in this study.
88935497|NCT01780181||TCM plus chemotherapy|TCM:oral granules,YangYinFang or YiQiFang or YiQiYangYinFang, four packages,twice a day, three months; Chemotherapy : Intravenous drug use, treated with single-agent chemotherapy :DOC、NVB、GEM.Each cycle was 21-days. Cycles were repeated until disease progression, unacceptable toxicity, or chemotherapy taboo;
88935498|NCT01780181||Placebo plus chemotherapy|TCM Placebo: oral granules,YangYinFang orYiQiFang or YiQiYangYinFang, 10% of the original dose,four packages,twice a day ,three months; Chemotherapy : Intravenous drug use, treated with single-agent chemotherapy :DOC、NVB、GEM.Each cycle was 21-days. Cycles were repeated until disease progression, unacceptable toxicity, or chemotherapy taboo;
88935499|NCT01780194||Lumbar fusion group|
88935500|NCT01780194||Conservative treatment group|
88935501|NCT01780207|No Intervention|OSA without PFO|
88935502|NCT01780207|Other|OSA with PFO|PFO closure
88935503|NCT01780233|Experimental|Fentanyl 400 µg sublingual spray + naltrexone 50 mg|Patients received a single administration of 400 µg of fentanyl spray sublingually + naltrexone hydrochloride 50 mg orally.
88935504|NCT01780233|Active Comparator|Actiq® 400 µg transmucosally + naltrexone 50 mg|Patients received a single administration of 400 µg of Actiq® transmucosally + naltrexone hydrochloride 50 mg orally.
88935505|NCT01780233|Active Comparator|Fentanyl citrate injection 100 µg iv + naltrexone 50 mg|Patients received a single administration of 100 µg of fentanyl citrate intravenously + naltrexone hydrochloride 50 mg orally.
88935506|NCT01780246|Experimental|nusinersen|
88935507|NCT01780259|Experimental|Cohort 1: Treatment A|Participants will receive 1 spray of esketamine solution in each nostril once (total dose: 28 mg).
88935508|NCT01780259|Experimental|Cohort 1: Treatment B|Participants will receive 1 spray of esketamine solution in each nostril twice, with 5 minutes interval (total dose: 56 mg).
89451006|NCT00786201|Experimental|CNTO 888 1 mg/kg|
89451007|NCT00786201|Experimental|CNTO 888 5 mg/kg|
89451008|NCT00786201|Experimental|CNTO 888 15 mg/kg|
89451009|NCT05536557|Active Comparator|Group (EOI) Plane Block|After tracheal intubation, a high-frequency linear probe will be in a cephalad to caudad paramedian direction at the anterior axillary line, and the external oblique muscle identified at the level ribs 6 and 7 in line. A block needle will inserted with in-plane technique and 25 ml 0.25 bupivacaine will be applied to EOI plane. The same procedure will be repeated on the contralateral side. Patients will receive standard multimodal analgesia comprising paracetamol, deksketoprofen, and tramadol.
89451010|NCT05536557|Sham Comparator|Group N|The patients in Group N will not receive any intervention. In the intervention and control groups, block sites will be covered with dressings, and patients and other health care workers will be blinded to treatment allocation. Patients will receive standard multimodal analgesia comprising paracetamol, deksketoprofen, and tramadol.
89451011|NCT03296384|Other|Patients with schizophrenia|
89451012|NCT03296384|Other|Relatives|
89451013|NCT00841815|Experimental|Amlodipine Besylate|Amlodipine Besylate 10 mg tablet (test) dosed in first period followed by Norvasc® 10 mg tablet (reference) dosed in second period
89451014|NCT00841815|Active Comparator|Norvasc®|Norvasc® 10 mg tablet (reference) dosed in first period followed by Amlodipine Besylate 10 mg tablet (test) dosed in second period
89451015|NCT03296306|Active Comparator|6 cycles arm|Patients without evidence of disease progression or unacceptable toxicities after completion of two or four treatment cycles of cisplatin based chemotherapy (GP, GP-S, MVAC, HD-MVAC with GCSF) were randomly assigned to receive additional two to four cycles of chemotherapy (totally six cycles)
89451016|NCT03296306|Experimental|4 cycles arm|Patients without evidence of disease progression or unacceptable toxicities after completion of two or four treatment cycles of cisplatin based chemotherapy (GP, GP-S, MVAC, HD-MVAC with GCSF) were randomly assigned to receive additional zero to two cycles of chemotherapy (totally four cycles)
88935509|NCT01780259|Experimental|Cohort 1: Treatment C|Participants will receive 1 spray of esketamine solution in each nostril thrice, with 5 minutes interval between each repeated sprays (total dose 84 mg).
88935510|NCT01780259|Experimental|Cohort 1: Treatment D|Participants will receive 1 spray of esketamine solution in each nostril thrice, with 10 minutes interval between each repeated sprays (total dose 84 mg).
88935511|NCT01780259|Experimental|Cohort 2: Treatment D|Participants will receive 1 spray of esketamine solution in each nostril thrice, with 10 minutes interval between each repeated sprays (total dose 84 mg).
88935512|NCT01780259|Experimental|Cohort 3: Treatment E|Participants will receive 1 spray of esketamine solution in each nostril, 4 times with 10 minutes interval between each repeated sprays (total dose: 112 mg). Single dose of oral placebo will be administered 5 minutes before the first intranasal spray of esketamine solution.
88935513|NCT01780259|Experimental|Cohort 3: Treatment F|Participants will receive 1 spray of placebo solution in each nostril, 4 times with 10 minutes interval between each repeated sprays (total dose: 112 mg). Single 0.25-mg oral dose of triazolam will be administered 5 minutes before the first intranasal spray of placebo solution.
88935514|NCT01780272|Other|Normoglycaemia followed by hypoglycaemia|
88935515|NCT01780272|Other|Hypoglycaemia followed by normoglycaemia|
88935516|NCT01780285|Active Comparator|Nitinol-framed PTFE mesh hiatal repair|Nitinol-framed lightweight PTFE mesh for hiatal repair
88935517|NCT01780285|Active Comparator|Lightweight mesh hiatal repair|Partially absorbable lightweight mesh for hiatal repair
88935518|NCT01780298||Group 1: COPD GOLD Stage 1-2|Sixty subjects with a clinical diagnosis of COPD, according to the GOLD guidelines (Stages 1-2), who are current smokers with at least a 10 pack-year smoking history.
88935519|NCT01780298||Group 2: Current Cigarette Smokers|Sixty subjects who are current smokers with at least a 10 pack-year smoking history and matched to the COPD cases by ethnicity, gender and age (within 5 years).
88935520|NCT01780298||Group 3: Ex-Smokers|Sixty subjects who are ex-smokers with at least a 10 pack-year smoking history who have not smoked for at least one year and matched to the COPD cases by ethnicity, gender and age (within 5 years).
88935521|NCT01780298||Group 4: Never Smokers|Sixty subjects who have never smoked (non-smokers) and matched to the COPD cases by ethnicity, gender and age (within 5 years).
88935522|NCT01780311|Active Comparator|Antiarrhythmic drugs|Flecainide or Propafenone or Sotalol (oral, standard dosage)
88935523|NCT01780311|Experimental|ABLATION|Catheter Ablation
88935524|NCT01780363||controls|frequency of mevalonate kinase gene frequency
88935525|NCT01780363||Behçet patients|frequency of mevalonate kinase gene mutations
88935526|NCT01780376|Experimental|WBV group|whole-body vibration (WBV) group
88935527|NCT01780402|Experimental|Hand feeding intervention delivery|Trained Research Feeding Assistants (TRFA), blind to the study outcomes, will assist enrolled PWDs with all three meals for two days using a pre-specified hand feeding technique. Videotaping will occur for two enrolled PWD during the six day time frame to promote efficiency. Coding of the video will be done by a trained Data Technician after meals have been recorded to determine frequency of aversive feeding behaviors, calculate meal intake, and time spent assisting with the meal.
88935528|NCT01780415||Bastovit|all the patients that have supernumerary embryos to vitrify at blastocyst stage
88935529|NCT01780441||Tuberous Sclerosis Complex (TSC)|Tuberous Sclerosis Complex
88935530|NCT01780467|Experimental|patients with and without treatment by L dopa)|to study the role of dopamine in the loss aversion phenomenon by comparing brain activity in parkinsonian patient with and without treatment with L Dopa, when they are exposed to mixed (gain/loss) gambles using money.
88935531|NCT01780467|Other|healthy paired control|to highlight the role of a dopamine depletion by comparing patient without treatment vs healthy paired control.
89014918|NCT03162536|Experimental|Phase 2: Expansion Cohort E|Mantle Cell Lymphoma (MCL) participants who have failed at least 2 prior systemic therapies receive up to 65 mg of nemtabrutinib per day orally in each cycle (Cycle length = 28 days) until PD, unacceptable AEs, or discontinuation at investigator's discretion (up to approximately 64 months).
89200827|NCT00901953||2|migraine without vertigo
89451017|NCT03296228||Hong Kong|"Radiation: Flexibility Radiographs (supine, supine side-bend, FB)~supine side-bending and fulcrum bending films"
89014919|NCT03162536|Experimental|Phase 2: Expansion Cohort F|Marginal Zone Lymphoma (MZL) participants who have failed at least 2 prior systemic therapies receive up to 65 mg of nemtabrutinib per day orally in each cycle (Cycle length = 28 days) until PD, unacceptable AEs, or discontinuation at investigator's discretion (up to approximately 64 months).
89451018|NCT03296228||Turkey|"Radiation: Flexibility Radiographs (supine, supine side-bend, FB)~Radiation: Flexibility Radiographs (awake traction)~Radiation: Flexibility Radiographs (STUGA)~supine side-bending, fulcrum bending films, awake traction and supine traction under GA"
89014920|NCT03162536|Experimental|Phase 2: Expansion Cohort G|High-grade B-cell lymphoma (BCL) participants who have failed at least 2 prior systemic therapies and have known MYC and BCL2 and/or BCL6 translocations confirmed by flourescence in situ hybridization (FISH) or overexpression by immunohistochemistry (IHC) receive up to 65 mg of nemtabrutinib per day orally in each cycle (Cycle length = 28 days) until PD, unacceptable AEs, or discontinuation at investigator's discretion (up to approximately 64 months).
89014921|NCT03162536|Experimental|Phase 2: Expansion Cohort H|Waldenström macroglobulinemia (WM) participants who have failed at least 2 prior systemic therapies receive up to 65 mg of nemtabrutinib per day orally in each cycle (Cycle length = 28 days) until PD, unacceptable AEs, or discontinuation at investigator's discretion (up to approximately 64 months).
89014922|NCT03162536|Experimental|Phase 2: Expansion Food Effect Cohort I|B-cell Non-Hodgkin's lymphoma (NHL), CLL/SLL and WM participants receive up to 65 mg of nemtabrutinib fasted (1 hour prior to or 2 hours after meal) and non-fasted per day orally in each cycle (Cycle length = 28 days) until PD, unacceptable AEs, or discontinuation at investigator's discretion (up to approximately 64 months).
89014923|NCT03153683||Cerebrovascular procedure patients|This is a registry. No above standard of care interventions will take place. Participants must be undergoing a clinically routine cerebrovascular procedure.
89014924|NCT03093064|Experimental|Patient Group: Natalizumab|Natalizumab 300mg, intravenous, once monthly, total of 3 doses
89014925|NCT03093064|Placebo Comparator|Patient Group: Placebo|Saline, intravenous, once monthly, total of 3 doses
89014926|NCT03070392|Experimental|IMCgp100 (tebentafusp, Kimmtrak)|Biologic:IMCgp100 (Soluble gp 100-specific T cell receptor with anti - CD3 scFV: IMCgp100)
89014927|NCT03070392|Active Comparator|Investigator's Choice|"1 of 3 Investigator's Choice options: Systemic Dacarbazine~1 of 3 Investigator's Choice options: Systemic Ipilimumab~1 of 3 Investigator's Choice options: Systemic Pembrolizumab"
89014928|NCT03053141||All Subjects|All subjects are included in this cohort and are treated with the Rhythmia Mapping System
89014929|NCT03042689|Experimental|Regorafenib|
89014930|NCT03036930|Experimental|Prevention (Gardasil 9 HPV vaccine)|Participants receive the first dose of the recombinant human papillomavirus nonavalent vaccine IM at baseline, at least 30 days prior to the kidney transplant surgery. The second dose is given at least one month after the first dose. The third dose is given at least five months after the first dose and at least three months after the second dose. The timing of the second and third doses is dependent on the scheduling of the kidney transplant surgery. Patients are followed up at 6- and 12-months after the kidney transplant surgery to measure vaccine-induced immune responses. Patients may receive either one, two, or all three vaccine doses prior to the kidney transplant surgery, and are offered additional visits at least one year after the surgery to complete any remaining doses of the three-dose vaccine series. Patients also undergo collection of blood samples and self-collection of cervical/vaginal samples (female participants only) on study.
89014931|NCT03009240|Experimental|Treatment (pevonedistat, decitabine)|Patients receive pevonedistat IV over 1 hour on days 1, 3, and 5 and decitabine IV over 1 hour on days 1-5 and 8-12. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unexpected toxicity.
89014932|NCT03007030|Experimental|Treatment (brentuximab vedotin)|Patients receive brentuximab vedotin IV over 30 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89014933|NCT03000751|Active Comparator|Track A|Simple Audit Report; In-Person Meeting (timed to coincide with the multi-component intervention); Multi-Component Intervention
89014934|NCT03000751|Active Comparator|Track B|In-Person Meeting (timed to coincide with the simple audit report); Simple Audit Report; Multi-Component Intervention
89014935|NCT03000751|Other|Track C|Simple Audit Report; Multi-Component Intervention
89014936|NCT02993354||Pregnant women|Pregnant women with singleton pregnancy with gestational age greater than or equal to 24 weeks.
89014937|NCT02972840|Experimental|Acalabrutinib in combination with bendamustine and rituximab|Acalabrutinib administered twice per day (BID) orally (PO) plus bendamustine on Days 1 and 2 and rituximab on Day 1; cycles are repeated every 28 days.
89200828|NCT00982462|Placebo Comparator|Corn oil placebo|Micro-encapsulated powder containing corn oil placebo.
89451019|NCT04572412|Experimental|Low Dose Radiotherapy|Low Dose Radiotherapy
89451020|NCT03295916|Experimental|Systemic therapy plus SBRT to OM|Stereotactic Body Radiotherapy (SBRT) up to 5 OM sites
89451021|NCT00782535|Experimental|Treatment A|Single therapeutic dose of CHF 4226 pMDI
89451022|NCT00782535|Experimental|Treatment B|Single therapeutic dose of CHF 4226 pMDI
89451023|NCT00782535|Experimental|Treatment C|Single supratherapeutic dose of CHF 4226 pMDI
88935532|NCT01780480|Experimental|Dynamic Chinese herbal granule formula|Based on standard medical care, after evaluated the style of the syndrome (Zhenghou) by an experienced integrative medicine doctor, the patients should be given a combination therapy of a Chinese herbal granule formula twice a day for 4 weeks, which should be selected from 10 kinds of Chinese herbal granules, including 3 gram of Huangqi(Astragalus root), 2 gram of Renshen(ginseng), 2.5 gram of Danggui(Angelica sinensis), 2 gram of Danshen(Salvia miltiorrhiza), 2 gram of Dilong(Geosaurus), 3 gram of Chishao(Radix Paeoniae Rubra), 2 gram of Honghua(Safflower), 2 gram of Chuanxiong(Rhizoma Chuanxiong), 2 gram of Sanqi(Radix Notoginseng), 3 gram of Shudihuang(Radix Rehmanniae Preparata). The Chinese herbal granule formula could be weekly changed according to differentiation of Zhenghou.
88935533|NCT01780480|Placebo Comparator|Placebo|The process is the same as the experimental arm, except that the matched placebo granules should be in turn of Chinese herbal granules.
88935534|NCT01780493|Other|Direct Nipple Ureteroneocystostomy|
88935535|NCT01780519|Other|L/VL APOE e3/e4 carrier|long and very long poly - T variants of TOMM40 and APOE e3/e4 carrier
88935536|NCT01780519|Other|L/S APOE e3/e4 carrier|long and short poly - T variants of TOMM40 and APOE e3/e4 carrier
88935537|NCT01780519|Other|S/VL APOE e3/e3 carrier|short and Very long poly - T variants of TOMM40 and APOE e3/e3 carrier
88935538|NCT01780519|Other|VL/VL APOE e3/e3 carrier|Very long poly - T variants of TOMM40 and APOE e3/e3 carrier
88935539|NCT01780519|Other|S/S APOE e3/e3 carrier|short poly - T variants of TOMM40 and APOE e3/e3 carrier
88935540|NCT01780532|Experimental|Photo Acoustic Imaging|An exploratory, single armed, pilot study designed to evaluate the feasibility of Photo Acoustic Imaging (PAI) in a clinical setting.
88935541|NCT01780558|Other|group NC-A|Patients with regular cycles undergoing FET in reproductive medicine renter of Sun Yat-sen Memorial Hospital will be recruited, who should not be elder than 40 and had more than 3 frozen embryos.They will be randomized to receive the natural cycles.
88935542|NCT01780558|Other|group HRT-B|Patients with regular cycles undergoing FET in reproductive medicine renter of Sun Yat-sen Memorial Hospitalwill be recruited , who should not be elder than 40 and had more than 3 frozen embryos will be randomized to receive the estradiol and progesterone replacement therapy cycles.
88935543|NCT01780571|No Intervention|Control group|Neutral pressure breathing after 2 min preoxygenation
88935544|NCT01780571|Active Comparator|Active group|CPAP 5cm H2O + PSV 5cm H2O breathing after 2 min preoxygenation
88935545|NCT01780597||Organ Donors (declared Brainstem-Dead)|This group of subjects is defined as those who have previously expressed their future wish to organ donation and who have suffered events leading to declaration of brainstem-death. Furthermore these subjects will have had their hearts declined for heart transplantation on the basis of poor function.
88935546|NCT01780610|Other|group OI-A|Patients with irregular cycles undergoing FET in reproductive medicine renter of Sun Yat-sen Memorial Hospital will be recruited , who should not be elder than 40 and had more than 3 frozen embryos.They will be randomized to receive the Letrozole and human chorionic gonadotrophin ovulation induced cycles.
88935547|NCT01780610|Other|group HRT-B|Patients with irregular cycles undergoing FET in reproductive medicine renter of Sun Yat-sen Memorial Hospital will be recruited, who should not be elder than 40 and had more than 3 frozen embryos will be randomized to receive the estradiol and progesterone replacement therapy cycles.
88935548|NCT01780623|Experimental|Bright White Light|Bright white light exposure every morning for 30 minutes for 28 consecutive days
88935549|NCT01780623|Active Comparator|Dim Red Light|Dim red light exposure every morning for 30 minutes for 28 consecutive days
88935550|NCT01780649|Experimental|IMSI|Intracytoplasmic Morphologically Selected Sperm Injection (IMSI)
88935551|NCT01780649|Active Comparator|ICSI|Intracytoplasmic sperm injection (ICSI)
88935552|NCT01780688|Active Comparator|smoking conventional cigarettes (CC)|After a 1-day nicotine deprivation, subjects are smoking one single cigarette (usual own brand) on one day and then smoking ad libitum on the subsequent day
88935553|NCT01780688|Experimental|using the Tobacco Heating System 2.1 (THS 2.1)|After a 1-day nicotine deprivation, subjects are puffing one single tobacco stick using the THS 2.1 on one day and then puffing ad libitum on the subsequent day
88935554|NCT01780701||High risk prostate cancer patients|Men who have been recently diagnosed with high risk prostate cancer (Gleason score 7 and above) and who choose prostate removal for their cancer treatment will undergo Magnetic Resonance Spectroscopy Imaging (MRSI) with rectal probe at the Oregon Health & Science University's Advanced Imaging Research Center.
88935555|NCT01780701||Low risk prostate cancer patients|Men who have been recently diagnosed with low risk prostate cancer (Gleason score 7 [3+4] and below) and who choose prostate removal for their cancer treatment will undergo Magnetic Resonance Spectroscopy Imaging (MRSI) with rectal probe at the Oregon Health & Science University's Advanced Imaging Research Center.
88935556|NCT01780714|Active Comparator|Conventional cigarettes (CC)|Smokers are continuing to smoke exclusively their usual own brand of CC, for 5 days, ad libitum, under highly controlled conditions
88935557|NCT01780714|Experimental|Tobacco Heating System 2.1 (THS 2.1)|Smokers are switching to the exclusive and ad-libitum use of THS 2.1 for 5 days, under highly controlled conditions
88935558|NCT01780740|Experimental|Atorvastatin|Atorvastatin (80 mg od) started not earlier than 6 days before surgery and continued until the 5th post-operative day included;
88935559|NCT01780740|Placebo Comparator|Sugar pill|Placebo started not earlier than 6 days before surgery and continued until the 5th post-operative day included.
88935560|NCT01780753|Experimental|Primaquine|Primaquine GPO® (Government Pharmaceutical Organization, Thailand) 0.5 mg/kg will be given once daily for 14 days.
88935561|NCT01780766||Indolent myeloma patient|
88935562|NCT01780766||Symptomatic Myeloma patient|
88935563|NCT01780779||Osteosarcoma|"All patients with Osteosarcoma), proven by surgical biopsy and histopathology.~All included patients will be treated by chemotherapy (EURAMOS protocol)~An MRI will be performed before, during and post-treatment"
88935564|NCT01780779||Ewing Sarcoma|"All patients with proven diagnosis of Ewing sarcoma, proven by surgical biopsy and histopathology.~All included patients will be treated by chemotherapy (EURO-EWING protocol)~An MRI will be performed in all included patients before, during and after the chemotherapy"
88935565|NCT01780792|Experimental|Dance Dance Revolution game play|Dance Dance Revolution video game play
88935566|NCT01780792|No Intervention|control|individuals continue usual care for 8 weeks
88935567|NCT01780805||Young adult alcohol drinkers|Young adults between the ages of 21-25 who regularly drink alcohol
88935568|NCT01780818|Active Comparator|Air insufflation method.|Colonoscopy will be performed in the standard fashion, with the minimal air insufflation required to aid insertion and allowing for washing as needed. Considered to be standard procedure.
88935569|NCT01780818|Experimental|Water Immersion method.|Air will not be insufflated until the cecum is reached. It will be allowed only 3 times and no more than 10 seconds each time (ITT failure if >3) if the lumen cannot be seen. Infusion of water during the insertion phase of colonoscopy mainly to open the colonic lumen and progress to the cecum immersed in the water environment thus created, without attempting to clear the colon contents. Residual air in the colon will not be removed. Infused water and residual feces will be suctioned back predominantly during withdrawal.
88935570|NCT01780818|Experimental|Water Exchange method.|Air will not be insufflated until the cecum is reached. Infusion of a sufficient amount of water to render the lumen of the colon a slit to progress with the colonoscope. Part of the infused water will be constantly suctioned back exchanging clean for dirty or hazy water. Suction of water will also be applied when colonoscope insertion proceeds smoothly. Air pockets will be always aspirated to collapse the lumen. After cecal intubation as much residual water as possible will be aspirated before beginning the withdrawal phase. During withdrawal residual water and feces will be suctioned.
88935571|NCT01780857||PPP patients|Patients with palmoplantar pustulosis who have had blood and tissue samples taken.
88935572|NCT01780857||Healthy controls|Patients without palmoplantar pustulosis or any inflammatory skin condition who have had blood and tissue samples taken.
88935573|NCT01780896||Study Group|
88935574|NCT01780909|Experimental|Paromomycin Sulfate Fasted State|Intake of Gabbroral® oral tablet formulation, which will be dissolved in a glas of 240mL water, in fasted state. Fasted state means that you have eaten nothing for 12 hours for the investigation and only have been drinking water. • After intake of the medicine at regular intervals, gastrointestinal fluids will be aspirated over 4 hours. You sit in a comfortable position in bed; eating and sleeping is not permitted (after 2 hours you have the possibility to drink some water). After 4 hours, the gastrointestinal catheters will be removed and you may eat and roam freely.
88935575|NCT01780909|Experimental|Paromomycin Sulfate Fed State|Intake of Gabbroral® oral tablet formulation, which will be dissolved in a glas of 240mL water, in fed state. Fed state means that you have eaten nothing for 12 hours for the investigation and only have been drinking water. When you arrive at the hospital for the clinical trial, you will receive an Ensure Plus Shake, after the gastrointestinal catheters are placed. 20 minutes after the intake of the shake, you will receive the a glass of water, where Gabbroral is in dissolved. After intake of the medicine at regular intervals, gastrointestinal fluids will be aspirated over 4 hours. You sit in a comfortable position in bed; eating and sleeping is not permitted (after 2 hours you have the possibility to drink some water). After 4 hours, the gastrointestinal catheters will be removed and you may eat and roam freely.
88935576|NCT01780909|Experimental|Paromomycin Sulfate w/ Domperidone|Intake of Gabbroral® oral tablet formulation, which will be dissolved in a glas of 240mL water, in fasted state, in addition of the intake of Motilium® (API: domperidone 10 mg). Fasted state means that you have eaten nothing for 12 hours for the investigation and only have been drinking water. 20 minutes for the intake of the medicine, you will take 2 tablets of Motilium®, which stimulates the gastric emptying. After intake of the medicine at regular intervals, gastrointestinal fluids will be aspirated over 4 hours. You sit in a comfortable position in bed; eating and sleeping is not permitted (after 2 hours you have the possibility to drink some water). After 4 hours, the gastrointestinal catheters will be removed and you may eat and roam freely.
89014938|NCT02972840|Placebo Comparator|Placebo in combination with bendamustine and rituximab|Matching placebo administered BID PO plus bendamustine on Days 1 and 2 and rituximab on Day 1; cycles are repeated every 28 days.
89014939|NCT02932748|Experimental|Group Phone Conference Call|Delivery: Group Phone Diet: PCMs
89014940|NCT02932748|Experimental|Individual Phone Call|Delivery: Individual Phone Call Diet: PCMs
89014941|NCT02932748|Active Comparator|Enhanced Usual Care|Delivery: Face-to-Face Diet: Conventional Diet
89451024|NCT00782535|Experimental|Treatment D|Single supratherapeutic dose of CHF 4226 pMDI
88935577|NCT01780909|Experimental|Paromomycin Sulfate w/ Loperamide HCl|Intake of Gabbroral® oral tablet formulation, which will be dissolved in a glas of 240mL water, in fasted state, in addition of the intake of Imodium® (API: loperamide HCl 2 mg). Fasted state means that you have eaten nothing for 12 hours for the investigation and only have been drinking water. 20 minutes for the intake of the medicine, you will take 2 tablets of Imodium®, which has an inhibited effect on the intestine. After intake of the medicine at regular intervals, gastrointestinal fluids will be aspirated over 4 hours. You sit in a comfortable position in bed; eating and sleeping is not permitted (after 2 hours you have the possibility to drink some water). After 4 hours, the gastrointestinal catheters will be removed and you may eat and roam freely.
88935578|NCT01780948|Placebo Comparator|everolimus|Everolimus administration with adjusted dose to target C trough (C0) level between 3-12 ng/mL
88935579|NCT01780948|Experimental|everolimus with atorvastatin 20 mg|"Co-administration of everolimus and atorvastatin. Everolimus administration with adjusted dose to target C trough (C0)level between 3-12 ng/mL.~Atorvastatin 20 mg/day (fixed dose)"
88935580|NCT01781000|Experimental|Auditiory verbal discrimination training|Brain Fitness & Brain Training- Posit Science
88935581|NCT01781000|Experimental|Facial affect discrimination training|Behavioral: Facial Affect Training- FAT
88935582|NCT01781000|Active Comparator|Treatment as usual|standard treatment/rehabilitation protocol of schizophrenia ward
88935583|NCT01781013|Experimental|Technology-supported care|This arm consists of Clinic Resource Management (CRM) clinics and serves as our intervention arm where the tested technology is implemented. Our overarching aim in these comparisons is to assess the potential effects of technology-facilitated depression symptom monitoring, relapse prevention, and medication adjustments and to examine depression care receipt and symptom improvement, patient/provider acceptance, and cost.
88935584|NCT01781013|No Intervention|Supported-Care|This arm consists of CRM (Clinic Resource Management) clinics and serves as one of the two control arms in the study.
88935585|NCT01781013|No Intervention|Usual Care|This arm consists of non-CRM (Clinic Resource Management) clinics and serves as one of the two control arms in the study.
88935586|NCT01781052||Group 1|
88935587|NCT01781065|Experimental|transcranial direct current stimulation|Anodal stimulation on motor cortex
88935588|NCT01781065|Sham Comparator|Sham transcranial direct current stimulation|Turn off after 10 s of stimulation
88935589|NCT01781091|Experimental|FULLY CLOSED-LOOP VENTILATION|IntelliVent-ASV automatic mode
88935590|NCT01781091|Active Comparator|Conventional modes ventilation|Conventional modes
88935591|NCT01779323||Pre and Post Sling Pelvic MRI|Cohort: Measure change in hypermobility of urethra after transobturator sling surgery via pelvic MRI.
88935592|NCT01781117|Experimental|HoLEP group|Holmium Laser Enucleation of the Prostate (HoLEP)
88935593|NCT01781130|Placebo Comparator|Percutaneous release alone|The patients who perform percutaneous release of trigger finger only
88935594|NCT01781130|Experimental|Percutaneous release + Steroid injection|Steroid local injection after percutaneous release of trigger finger
88935595|NCT01781195||Advagraf-based immunosuppression|50 patients after liver transplantation (25 with a MELD-score ≤20 and 25 patients with a MELD-score >20) under CNI-based immunosuppression with Advagraf
88935596|NCT01781221|Active Comparator|Alpha-Bio's GRAFT Natural Bovine Bone|two different bone substitutes commonly used in dental procedures.
88935597|NCT01781221|Active Comparator|Bio-Oss xenograft|two different bone substitutes commonly used in dental procedures.
88935598|NCT01781247|Experimental|Intervention group|Patients in the intervention group will participate in one single counseling session of 45 minutes (the minimal behavioral intervention) that targets specific MI-triggered traumatic reactions.
89014942|NCT02921282||Genotype dopamine|Genotyping will be conducted at the conclusion of the study
89014943|NCT02921282||Genotype cannabinoids|Genotyping will be conducted at the conclusion of the study
89200829|NCT00982462|Experimental|Long-chain polyunsaturated fatty acids|Micro-encapsulated powder containing 1:1 ratio of the omega-3 long-chain polyunsaturated fatty acids, docosahexaenoic acid (DHA) and the omega-6 fatty acid, arachidonic acid (ARA) from algal and fungal sources, respectively.
89200830|NCT03992287|Experimental|Hydrolysed Red Ginseng Extract|10 ml/day, 2.4g/day for 12 weeks
89451025|NCT00782535|Placebo Comparator|Treatment E|Single dose of placebo
89451026|NCT00841659|Experimental|Paroxetine|Paroxetine HCl 40 mg Tablet (test) dosed in first period followed by Paxil® 40 mg Tablet (reference) dosed in second period
89451027|NCT00841659|Active Comparator|Paxil®|Paxil® 40 mg Tablet (reference) dosed in first period followed by Paroxetine HCl 40 mg Tablet (test) dosed in second period
89451028|NCT04061252|Experimental|KHK4827 210mg Q2W SC|
89451029|NCT04061252|Placebo Comparator|Placebo Q2W SC|
89014944|NCT02847871|Other|Multimodal Intervention|The multimodal intervention on mobility will consist of the implementation of a care pathway dedicated in primary care. It will include awareness and training of general practitioners for easy identification, a care associating a dedicated geriatric consultation to rule out underlying pathology, teaching exercises by MAPA (+/- taken care in the presence of MAPA) and nutritional counseling by a dietician. Close collaboration between general practitioners, geriatrician, MAPA and dietician will be established.
89014945|NCT02847871|No Intervention|Non interventional|Patients received treatment as part of their standard care: at the discretion of the general practitioner patients
89014946|NCT02839447||Normal Semen|"Semen that meet the criteria for normal on sperm number, motility, and morphology as described by the current WHO manual."
89014947|NCT02839447||Abnormal Semen|"Semen that fail to achieve one or more of the criteria for normal on sperm number, motility, and morphology as described by the current WHO manual."
89014948|NCT02812680||Esophageal Cancer Patients - Blood Draw|Look at blood samples to assess the use of circulating microRNA (miRNA) and circulating tumour cells (CTC) as biomarkers of cancer and predictive markers for neoadjuvant therapy in patients with Esophageal Adenocarcinoma.
89014949|NCT02812680||Healthy volunteers - Blood Draw|Comparators for the esophageal cancer group
89014950|NCT02795806||1|Everybody for whom a clinical narrative report is created.
89014951|NCT02763566|Experimental|Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI)|Abemaciclib given orally every 12 hours (Q12H) plus anastrozole or letrozole given orally every 24 hours (Q24H) on days 1 to 28 of a 28 day cycle. Participants receiving benefit may continue until disease progression.
89014952|NCT02763566|Experimental|Placebo + NSAI|Placebo given orally Q12H plus anastrozole or letrozole given orally Q24H on days 1 to 28 of a 28 day cycle. Participants receiving benefit may continue until disease progression.
89014953|NCT02763566|Experimental|Abemaciclib + Fulvestrant|Abemaciclib given orally Q12H on days 1 to 28 of a 28 day cycle plus fulvestrant intramuscularly (IM) on days 1 and 15 of cycle 1, then on day 1 of cycle 2 and beyond. Participants receiving benefit may continue until disease progression.
89014954|NCT02763566|Experimental|Placebo + Fulvestrant|Placebo given orally Q12H on days 1 to 28 of a 28 day cycle plus fulvestrant IM on days 1 and 15 of cycle 1, then on day 1 of cycle 2 and beyond. Participants receiving benefit may continue until disease progression.
89014955|NCT02740530|Experimental|rTMS Active|High frequency pulsed repetitive magnetic stimulation at 100 % resting motor threshold will be delivered using a figure of 8 air film cooled coil attached to the Magstim® Rapid 2 machine. Resting motor threshold will be determined minimum energy needed to elicit the a reliable visible contraction in the contra-lateral first interosseous muscle using single pulse rTMS applied to the area between C1-C3 using the 10-20 international EEG electrode system. For stimulation, the coil will be positioned on the scalp corresponding to F4 then F3 electrode position using the 10-20 international EEG system. Real stimulation will consist of delivering 1200 pulses at 20 hz frequency to F4 location followed by the same stimulation to F3. The total time needed to deliver pulses is 20 minutes.
89014956|NCT02740530|Placebo Comparator|rTMS Sham|Sham stimulation will also involve delivering the same stimulus but with angulation of the coil at 45 degrees, which will give similar scalp sensation but unlikely to deliver magnetic stimulation to the cortex
89014957|NCT02709226|Experimental|1/Radiation|Dose escalation is as follows: dose level 1 (DL1) 3.5 Gy x 10; dose level 2 (DL2) 3.5 Gy x 12; dose level 3 (DL3) 3.5 Gy x 14. If 2 DLTs are observed in the second dose level a step down dose of 3.0 Gy x 14 fractions will be tested. If 2 DLTs are observed in the third dose level a step down dose of 3.0 Gy x 17 fractions will be tested. The study will have 3 planned re-irradiation dose levels, with 1 to 6 patients per dose level using the 3+3 design to define the MTD. The number of patients may be increased to 9 total patients at the MTD ( provided no DLT) with a maximum of 21 evaluable patients enrolled.
89014958|NCT02639312||1|hemifacial microsomia
89014959|NCT02639312||2|mandibular prognathism
89014960|NCT02639273|Experimental|Drug|single dose nalmefene
89014961|NCT02639273|Placebo Comparator|Placebo|single dose placebo
89014962|NCT02617056||Observational group|Subjects with dementia
89014963|NCT02548559|Experimental|Full-Spectrum Cannabidiol|1 ml of full-spectrum sublingual cannabidiol solution (10 mg/ml CBD) administered three times per day (TID) for four weeks.
89014964|NCT02548559|Experimental|Single-Compound Cannabidiol|1 ml of single-compound sublingual cannabidiol solution (10 mg/ml CBD) administered three times per day (TID) for four weeks.
89200831|NCT03992287|Placebo Comparator|Placebo|Placebo for 12 weeks
89014965|NCT02548559|Placebo Comparator|Placebo|1 ml of placebo solution administered three times per day (TID) for four weeks.
89014966|NCT02544074||eSAGE score of 10|Participants who score a 10 on the eSAGE. Interventions include neuropsychological testing.
89200832|NCT02540343||acute neck pain patients|Participant recently received the diagnosis of neck pain (< 30 days) >18 years old able to speak, read and write German, questionnaires
88935599|NCT01781247|Active Comparator|Control group|Patients in the control group will participate in one single counseling session of 45 minutes (the control intervention) that targets more general information about the role of psychological stress in coronary heart disease.
88935600|NCT01781260||Young. Fit. Minor neurosurgical operation. Prone position.|18-65 year old patients, without serious medical co-morbidities (assessed as ASA I/II status) who are having minor to moderate severity neurosurgical operations in the prone position.
88935601|NCT01781273|Placebo Comparator|Cranberry juice alone|500 mL of cranberry juice
88935602|NCT01781273|Experimental|BAC 0.5 g/L|Cranberry juice with ethanol to rise BAC to 0.5 g/L
88935603|NCT01781273|Experimental|BAC 0.65 g/L|Cranberry juice with ethanol to rise BAC to 0.65 g/L
88935604|NCT01781273|Experimental|BAC 0.8 g/L|Cranberry juice with ethanol to rise BAC to 0.8 g/L
88935605|NCT01781312|Experimental|ProTectis|
88935606|NCT01781312|Experimental|Gastrus|
88935607|NCT01781325|Active Comparator|IBEHR|IBEHR
88935608|NCT01781325|No Intervention|Standard therapy|written instructions
88935609|NCT01781351|Experimental|taping the ankle|
88935610|NCT01781364|Experimental|Cognitive Training|Brain Fitness Training, Posit Science SF
88935611|NCT01781377|Experimental|PROPOFOL|PROPOFOL SINGLE BOLUS 10 mg + 1mg/kg/hr INFUSION AT UMBILICAL CORD RESECTION
88935612|NCT01781377|Experimental|METOCLOPRAMIDE|METOCLOPRAMIDE 10 mg I.V. AT UMBILICAL CORD RESECTION
88935613|NCT01781377|Experimental|PROPOFOL & METOCLOPRAMIDE|PROPOFOL SINGLE BOLUS of 10 mg + 1mg/kg/hr INFUSION AND METOCLOPRAMIDE 10 mg I.V. AT UMBILICAL CORD RESECTION
88935614|NCT01781377|Placebo Comparator|PLACEBO|SALINE INFUSION
88935615|NCT01781416||1|
88935616|NCT01781442||Patient Arm- temsirolimus|
88935617|NCT01781494|Active Comparator|Immobilization|Immobilization followed by protected range of motion
88935618|NCT01781494|Experimental|Immediate range of motion|Immediate motion after anterior submuscular ulnar nerve transposition
88935619|NCT01781507|Experimental|Cetirizine|Cetirizine 10 mg orally once a day
88935620|NCT01781507|Placebo Comparator|Sugar pill|This will be the placebo arm
88935621|NCT01781520|Experimental|S-1 plus DC-CIK|"Chemotherapy: S-1 is administered orally twice daily at a dose of 80,100, or 120mg/day for body surface areas of less than 1.25m2, between 1.25m2 and less than 1.5, or 1.5m2 or greater, respectively, for 14 consecutive days, followed by a 7-day rest, repeated every 3 weeks.~DC-CIK Immunotherapy:Mononuclear cells were collected aseptically with blood cell separator composition aphaeresis, and then cultured DC-CIK cells were infused back to the patients on days 15, 17, and 19 of 21-day cycles."
88935622|NCT01781520|Active Comparator|DC-CIK alone|DC-CIK Immunotherapy:Mononuclear cells were collected aseptically with blood cell separator composition aphaeresis, and then cultured DC-CIK cells were infused back to the patients on days 15, 17, and 19 of 21-day cycles.
88935623|NCT01781520|Active Comparator|S-1 alone|Chemotherapy: S-1 is administered orally twice daily at a dose of 80,100, or 120mg/day for body surface areas of less than 1.25m2, between 1.25m2 and less than 1.5, or 1.5m2 or greater, respectively, for 14 consecutive days, followed by a 7-day rest, repeated every 3 weeks.
88935624|NCT01781520|Active Comparator|Best supportive care|
88935625|NCT01781533|Experimental|algorithm|
88935626|NCT01781546|Experimental|drug-eluting balloon (DEB)|Patients treated with drug-eluting balloon (DEB). Provisional stenting with BMS is permitted in case of a flow-limiting dissection or significant recoil (>30% in main branch and >50% side-branch), Includes both stable CAD and ACS patients.
88935627|NCT01781546|Active Comparator|bare-metal stent (BMS)|Patients treated with bare-metal stent (BMS). Includes both stable CAD and ACS patients.
88935628|NCT01781559|Experimental|phenolic acid + maltodextrin|phenolic acid + maltodextrin;
88935629|NCT01781559|Placebo Comparator|Maltodextrin|Maltodextrin
88935630|NCT01781559|Active Comparator|flavanol + maltodextrin|flavanol + maltodextrin
88935631|NCT01781585||sustained low-efficiency dialysis|Patients were randomized to receive CVVH or SLED and the next day on the other.
88935632|NCT01781585||continuous veno-venous hemofiltration|Patients were randomized to receive CVVH or SLED and the next day on the other.
88935633|NCT01781598||Patients treated with Patient specific instruments in TKA|
88935634|NCT01781624|Experimental|Study Oral Nutritional Supplement|2 containers a day of a high calorie, complete, balanced, ready-to-drink oral nutritional supplement with a new protein blend.
88935635|NCT01781650|Active Comparator|Air insufflation method.|Colonoscopy will be performed in the standard fashion, with the minimal air insufflation required to aid insertion and allowing for washing as needed. Considered to be standard procedure.
88935636|NCT01781650|Experimental|Water Immersion method.|Air will not be insufflated until the cecum is reached. It will be allowed only 3 times and no more than 10 seconds each time (ITT failure if >3) if the lumen cannot be seen. Infusion of water during the insertion phase of colonoscopy mainly to open the colonic lumen and progress to the cecum immersed in the water environment thus created, without attempting to clear the colon contents. Residual air in the colon will not be removed. Infused water and residual feces will be suctioned back predominantly during withdrawal.
89451030|NCT05503654|Experimental|intervention group|Intervention Arm is an arm in which nutrition education will be given to caregivers of infants and young children less than two years aged using the Health Belief Model and Theory of Planned Behavior.
89451031|NCT05503654|No Intervention|Control group|Control Arm is an arm to which the intervention will not be implemented.
89451032|NCT04057586|Experimental|Nonintubated|Nonintubated thoracoscopic surgery
89451033|NCT04057586|Active Comparator|Intubated|Intubated thoracoscopic surgery
89451034|NCT05079243|Experimental|Scaffold and adipose-derived stromal cell enriched fat grafts|Randomized and paired injections. Each participant will receive all 11 solutions.
89451035|NCT05079243|No Intervention|Controls samples|Control samples of untreated skin
89451036|NCT04473417|Experimental|Part A, Sequence I|Period I: Forxiga® → DA-2811, Period II: DA-2811 → Forxiga®
89451037|NCT04473417|Experimental|Part A, Sequence II|Period I: DA-2811 → Forxiga®, Period II: Forxiga® → DA-2811
89014967|NCT02544074||eSAGE score of 11|Participants who score an 11 on the eSAGE. Interventions include neuropsychological testing.
89014968|NCT02544074||eSAGE score of 12|Participants who score a 12 on the eSAGE. Interventions include neuropsychological testing.
89014969|NCT02544074||eSAGE score of 13|Participants who score a 13 on the eSAGE. Interventions include neuropsychological testing.
89014970|NCT02544074||eSAGE score of 14|Participants who score a 14 on the eSAGE. Interventions include neuropsychological testing.
89200833|NCT02540343||chronic neck apin patients|Participant has neck pain for a longer period of time (> 90 days) > 18 years old able to speak, read and write German, questionnaires
89200834|NCT02540343||test persons|no neck pain > 18 years old able to speak, read and write German, questionnaires
89451038|NCT04473417|Experimental|Part B, Sequence I|Period I: DA-2811 under fasting state → DA-2811 under fed state, Period II:DA-2811 under fed state → DA-2811 under fasting state
89451039|NCT04473417|Experimental|Part B, Sequence II|Period I: DA-2811 under fed state → DA-2811 under fasting state, Period II: DA-2811 under fasting state → DA-2811 under fed state
89451040|NCT05503576|Experimental|reminder mobile application group|"The mobile application will be introduced with a video demonstration. Then, with the help of the researcher, the mobile application will be downloaded to his phone. A user name and password will be created for the patient to enter the application. It will be explained that medication and appointment reminders are available in the application. It will be emphasized that the application will direct you to the hospital appointment system to create a control appointment. In addition, it will be announced that the training content prepared with the contribution of experts to increase drug compliance can be accessed through the application. It is thought that the patient will be interviewed for approximately 20 minutes for the information and procedure process. In the next process, the Drug Protocol Information Form, Modified Morisky Scale and Complications Follow-up Form sent to the patient through the application will be filled in at the 1st, 4th, 8th and 12th weeks."
89200835|NCT00973258|Experimental|Nutritional Intervention|Nutritional intervention
89200836|NCT00973258|Experimental|Physical Exercise|Physical exercise training intervention
89200837|NCT00973258|Experimental|Cognitive Training|Cognitive training intervention
89200838|NCT00973258|Experimental|Combined|Nutritional Intervention + Physical Exercise + Cognitive Training
89200839|NCT00973258|Placebo Comparator|Control Group|Participants will receive their usual diet and placeboes.
89200840|NCT00902031|Experimental|Docusate + Sennoside|
89200841|NCT00902031|Placebo Comparator|Sennoside + Placebo|
89200842|NCT03991039|Active Comparator|Gamma knife group|Patients selected to be treated with gamma knife radiosurgery
89200843|NCT03991039|Active Comparator|MVD Group|Patients treated with microvascular decompression
89451041|NCT05503576|No Intervention|standard protocol group|"If the patient is in the control group in group assignment; After the first encounter and obtaining consent, the Personal Information Form will be filled in. Next 1., 4.,8. And in the 12th weeks, the Drug Protocol Information Form, Modified Morisky Scale and Complications Follow-up Form will be filled in by telephone interviewing the patient. It is estimated that each phone call with the patient for data collection will take approximately 10 minutes."
89014971|NCT02544074||eSAGE score of 15|Participants who score a 15 on the eSAGE. Interventions include neuropsychological testing.
89014972|NCT02544074||eSAGE score of 16|Participants who score a 16 on the eSAGE. Interventions include neuropsychological testing.
89014973|NCT02544074||eSAGE score of 17|Participants who score a 17 on the eSAGE. Interventions include neuropsychological testing.
89014974|NCT02544074||eSAGE score of 18|Participants who score a 18 on the eSAGE. Interventions include neuropsychological testing.
89014975|NCT02544074||eSAGE score of 19|Participants who score a 19 on the eSAGE. Interventions include neuropsychological testing.
88935637|NCT01781650|Experimental|Water Exchange method.|Air will not be insufflated until the cecum is reached. Infusion of a sufficient amount of water to render the lumen of the colon a slit to progress with the colonoscope. Part of the infused water will be constantly suctioned back exchanging clean for dirty or hazy water. Suction of water will also be applied when colonoscope insertion proceeds smoothly. Air pockets will be always aspirated to collapse the lumen. After cecal intubation as much residual water as possible will be aspirated before beginning the withdrawal phase. During withdrawal residual water and feces will be suctioned.
88935638|NCT01781663|Experimental|KAM2904 Face Cream and KAM3008 Body Lotion|A group treated with KAM2904 Face Cream and KAM3008 Body Lotion
88935639|NCT01781663|Sham Comparator|petrolatum-based moisturizer|control group
88935640|NCT01781702|Experimental|Pelubiprofen 30 mg|Pelubiprofen 30 mg, tid
88935641|NCT01781702|Active Comparator|Celebrex 200 mg|Celebrex 200 mg, tid
88935642|NCT01781715|Experimental|Multivessel stenting|This group comprises the patients who undergo a one-time primary percutaneous coronary intervention (PCI) of the culprit and nonculprit lesions
88935643|NCT01781715|Active Comparator|Staged revascularization|This group comprises the patients who undergo PCI of only the culprit lesion and staged nonculprit PCI at a later date (3-15 days)
88935644|NCT01781754||Diabetic patients|Un balanced diabetic patients
88935645|NCT01781780|Active Comparator|General Nutrition Recommendations|Participants will be provided with a free USDA nutrition pamphlet describing general good nutrition habits. They will also receive an instruction handout to emphasize some of the points in the dietary guidelines in the handout. The clinician will go through both documents with participants in detail by reading them aloud and answering any questions, and it will be recommended that they incorporate the suggestions as best they can into their daily life.
89014976|NCT02544074||eSAGE score of 20|Participants who score a 20 on the eSAGE. Interventions include neuropsychological testing.
89451042|NCT01001091|Experimental|AL-38583 0.01%|AL-38583 ophthalmic solution, 1 drop instilled in each eye 3 times per day for 2 weeks
89451043|NCT01001091|Experimental|AL-38583 0.05%|AL-38583 ophthalmic solution, 1 drop instilled in each eye 3 times per day for 2 weeks
89014977|NCT02544074||eSAGE score of 21|Participants who score a 21 on the eSAGE. Interventions include neuropsychological testing.
89014978|NCT02544074||eSAGE score of 22|Participants who score a 22 on the eSAGE. Interventions include neuropsychological testing.
89014979|NCT02544074||eSAGE score of 9|Participants who score a 9 on the eSAGE. Interventions include neuropsychological testing.
89451044|NCT01001091|Experimental|AL-38583 0.2%|AL-38583 ophthalmic solution, 1 drop instilled in each eye 3 times per day for 2 weeks
89451045|NCT01001091|Placebo Comparator|AL-38583 Vehicle|AL-38583 ophthalmic solution vehicle, 1 drop instilled in each eye 3 times per day for 2 weeks
89451046|NCT01001091|Active Comparator|MAXIDEX|Dexamethasone ophthalmic suspension, 0.1%, 1 drop instilled in each eye 3 times per day for 2 weeks
89451047|NCT05076045|Experimental|Personal sound amplification products|Speech perception will be evaluated using personal sound amplification products.
89451048|NCT05076045|No Intervention|Control|Speech perception will be evaluated without using hearing devices.
89451049|NCT02716298|Active Comparator|fanfilcon A|Study participants are randomized to wear fanfilcon A lens during the crossover study
89451050|NCT02716298|Active Comparator|lotrafilcon B|Study participants are randomized to wear lotrafilcon B lens during the crossover study.
89451051|NCT05076682|Experimental|Choline|Choline with anti-PD-1 immunotherapy
89451052|NCT05076682|Experimental|Sodium cromoglicate|Sodium cromoglicate with anti-PD-1 immunotherapy
89451053|NCT05076682|Experimental|Efavirenz|Efavirenz with anti-PD-1 immunotherapy
89451054|NCT05066139|No Intervention|Arm A Standard of care|"Patients will receive standard care before treatment initiation (i.e. geriatric assessment only).~Geriatric assessment includes: Mini Mental State Examination ; mini-Geriatric Depression Scale (mini-GDS) ; Body Mass Index (BMI) calculation ; Mini Nutritional Assessment (MNA) ; Time up and Go ; Cumulative Illness Rating Scale - Geriatric (CIRS-G) ; Activities of Daily Living (ADL) and Instrumental Activities of Daily Living (IADL) questionnaires."
89451055|NCT05066139|Experimental|Arm B Multidisciplinary EPODIG program|Patients will undergo the same geriatric assessment as in Arm A plus EPODIG-G program before treatment initiation.
89014980|NCT02544074||eSAGE score of 8|Participants who score an 8 on the eSAGE. Interventions include neuropsychological testing.
89014981|NCT02544074||eSAGE score of 6|Participants who score a 6 on the eSAGE. Interventions include neuropsychological testing.
89451056|NCT00840879|Experimental|Meloxicam|Meloxicam 15 mg Tablet (test) dosed in first period followed by Mobic® 15 mg Tablet (reference) dosed in second period
89451057|NCT00840879|Active Comparator|Mobic®|Mobic® 15 mg Tablet (reference) dosed in first period followed by Meloxicam 15 mg Tablet (test) dosed in second period
89451058|NCT05503498||AFIBRINOGENEMIA, CIRRHOSIS, TRAUMATICS|PATIENTS WITH CONGENIAL AFIBRINOGENEMIA:RECORD OF PLASMA FIBRINOGEN LEVEL PATIENTS WITH ADQUIRED CRONIC HIPOFIBRINOGENEMIA AND END STAGE OF THE LIVER DISEASE: RECORD OF PLASMA FIBRINOGEN LEVEL PATIENTS WITH ADQUIRED ACUTE HIPOFIBRINOGENEMIA AND ACUTE TRAUMA: RECORD OF PLASMA FIBRINOGEN LEVEL
89451059|NCT02163434|Experimental|gabapentin|1800-2400mg/day divided tid or qid, orally.
89451060|NCT02163434|Experimental|metoclopramide|45-60mg/day divided tid or qid, orally
89451061|NCT04638946|Experimental|Titration to high intensity exercise|
89451062|NCT04638946|Active Comparator|Low intensity exercise|
89451063|NCT04571463||HUCS A|Mothers visiting the prenatal care units within the Helsinki area.
89451064|NCT04571463||HUCS HAL|Mothers visiting the prenatal care units dedicated for the alcohol and drug abusing mothers within the Helsinki area.
89014982|NCT02544074||eSAGE score of 7|Participants who score a 7 on the eSAGE. Interventions include neuropsychological testing.
89014983|NCT02544074||eSAGE score of 5|Participants who score a 5 on the eSAGE. Interventions include neuropsychological testing.
89014984|NCT02544074||eSAGE score of 4|Participants who score a 4 on the eSAGE. Interventions include neuropsychological testing.
89014985|NCT02544074||eSAGE score of 3|Participants who score a 3 on the eSAGE. Interventions include neuropsychological testing.
89014986|NCT02544074||eSAGE score of 2|Participants who score a 2 on the eSAGE. Interventions include neuropsychological testing.
89014987|NCT02544074||Smartphone eSAGE score of 13|Participants who score a 13 on the smartphone eSAGE. Interventions include neuropsychological testing.
89014988|NCT02544074||Smartphone eSAGE score of 14|Participants who score a 14 on the smartphone eSAGE. Interventions include neuropsychological testing.
89014989|NCT02544074||Smartphone eSAGE score of 15|Participants who score a 15 on the smartphone eSAGE. Interventions include neuropsychological testing.
89014990|NCT02544074||Smartphone eSAGE score of 16|Participants who score a 16 on the smartphone eSAGE. Interventions include neuropsychological testing.
89014991|NCT02544074||Smartphone eSAGE score of 17|Participants who score a 17 on the smartphone eSAGE. Interventions include neuropsychological testing.
89014992|NCT02544074||Smartphone eSAGE score of 18|Participants who score a 18 on the smartphone eSAGE. Interventions include neuropsychological testing.
89014993|NCT02544074||Smartphone eSAGE score of 19|Participants who score a 19 on the smartphone eSAGE. Interventions include neuropsychological testing.
89451065|NCT04571463||PHHYKY A|Mothers visiting the prenatal care units within the Lahti area.
89451066|NCT04571463||PHHYKY HALSO|Mothers visiting the prenatal care units dedicated for the alcohol and drug abusing mothers within the Lahti area.
89451067|NCT05563324||clinical sample|adolescents with nonsuicidal self-injury
89451068|NCT05563324||original control group|adolescents with no history of nonsuicidal self-injury
89451069|NCT05563324||general control group|adolescents from the general population
89451070|NCT00840411|Experimental|Clarithromycin (test) First|
89451071|NCT00840411|Active Comparator|Biaxin® XL (reference) First|
89451072|NCT00840099|Experimental|1|
89451073|NCT00840099|Active Comparator|2|
89451074|NCT03108248||ISP-TACE group|During the study period, a total of 44 patients with HCC with PVTT underwent the irradiation stent placement and TACE were included in the ISP-TACE group.
89451075|NCT03108248||TACE group|During the study period, a total of 82 patients with HCC with PVTT underwent TACE monotherapy were included in the ISP-TACE group.
89451076|NCT04634890|Other|Type 2 Diabetes|Subjects with type 2 diabetes, diagnosed within the last 3-5 years, treated with metformin only as an anti-diabetic drug
89451077|NCT04634890|Other|Prediabetes|Subjects with prediabetes, defined as impaired fasting glucose or/and impaired glucose tolerance
89451078|NCT04634890|Other|Normoglycemia|Subjects with normal fasting glucose and normal glucose tolerance
89451079|NCT00836901|Experimental|Amoxicillin Calvulanic Acid|Amoxicillin Clavulanic Acid 400-57 mg Chewable Tablet (test) dosed in first period followed by Augmentin® 40-57 mg Chewable Tablet (reference) dosed in second period
89451080|NCT00836901|Active Comparator|Augmentin®|Augmentin® 400-57 mg Chewable Tablet (test) dosed in first period followed by Amoxicillin Clavulanic Acid 400-57 mg Chewable Tablet (reference) dosed in second period
88935646|NCT01781780|Experimental|Breakfast Recommendation|Participants randomized to the breakfast group will be instructed to consume breakfast before 10:00 a.m. every day, and will be asked to not eat again until after 11:00 a.m. Participants will be counseled on what a healthy breakfast is using an instruction handout. No specific restrictions will be given on types of foods that can be consumed for the breakfast meal. They will be instructed to keep track of their breakfast consumption (yes/no) using a calendar diary that will be provided to them. Participants will also be provided with a free USDA nutrition pamphlet describing general good nutrition habits. The clinician will go through both documents with participants in detail by reading them aloud and answering any questions, and it will be recommended that they incorporate the recommendations into their daily life as much as they can.
89451081|NCT04466384|Other|Propofol|Subjects will be sequentially assigned to start with propofol or propofol with remifentanil. Propofol will be started at a concentration of 0.5 µg/ml followed by incremental increases in the target effect-site concentrations of 1.5, 2, 2.5, 3, 4, 6, and 8 µg/ml until a MOAA/S score less than 2 is reached.
89451082|NCT04466384|Other|Propofol with Remifentanil|Subjects will be sequentially assigned to start with propofol or propofol with remifentanil. Approximately 2 minutes before starting propofol, to attain an effect-site targeted concentration of remifentanil of 4 ng/ml, remifentanil will be given by a continuous infusion. Within approximately 7 minutes, the infusion rate of Remifentanil may be adjusted to maintain the effect-site concentration of remifentanil of 4 ng/ml throughout the study.
88935647|NCT01781780|Experimental|No Breakfast Recommendation|Participants randomized to the no breakfast group will receive a detailed handout with instructions to not consume any calories before 11:00 a.m. every day. Only water or 0 calorie beverages may be consumed from the time of waking until 11:00 a.m. They will be instructed to keep track of their breakfast consumption (yes/no) using a calendar diary that will be provided to them. Participants will also provided with a free USDA nutrition pamphlet describing general good nutrition habits. The clinician will go through both documents with participants in detail by reading them aloud and answering any questions, and it will be recommended that they incorporate the recommendations into their daily life as much as they can.
88935648|NCT01781793|Placebo Comparator|Fibrotic ILD Patients, Room Air|Fibrotic ILD patients will breathe room air (21% oxygen) during a constant work rate exercise test
88935649|NCT01781793|Active Comparator|Fibrotic ILD Patients, Hyperoxia|Fibrotic ILD patients will breathe hyperoxia (60% oxygen) during a constant work rate exercise test
88935650|NCT01781819|Experimental|ARFI SVI ultrasound imaging|Acoustic Radiation Force Impulse (ARFI) Shear Wave Velocity Imaging (SVI) ultrasound imaging
88935651|NCT01781845|Experimental|ARFI-SVI Ultrasound|Ultrasound scan using acoustic radiation force impulse-shear wave velocity imaging in the characterization of pediatric hydronephrosis. This is a non-invasive scan that uses sound waves to create the images.
88935652|NCT01781858||pulmonary embolism|Consecutive outpatients and inpatients with first episode of acute pulmonary embolism
88935653|NCT01781871|Experimental|Prevenar13|68 kidney transplant patients vaccinated with Prevenar13 as they enter the transplant waiting list. Pre- and postvaccination serotype specific ELISA and OPA measured. Revaccination at 6 months after the transplantation with Prevenar13, again pre- and postvaccination serotype specific ELISA and OPA measured
88935654|NCT01781871|Active Comparator|Pneumovax|68 kidney transplant patients vaccinated with Pneumovax as they enter the transplant waiting list, serotype specific ELISA and OPA measured before and after the vaccination. At six and seven months after transplantation ELISA and OPA measured parallel to the experimental group
88935655|NCT01781871|Experimental|liver Prevenar13|30 liver transplant patients vaccinated with Prevenar13 once they enter the transplant waiting list. Serotype specific ELISA and OPA measured before and after the vaccination. Revaccinated with Prevenar13 at 6 months after the transplantation. ELISa and OPA measured pre- and postvaccination.
89014994|NCT02544074||Smartphone eSAGE score of 20|Participants who score a 20 on the smartphone eSAGE. Interventions include neuropsychological testing.
89451083|NCT05503420|Experimental|exerciser|Participants will be asked to use a masticatory muscle training exerciser twice daily, 10 minutes each time, and also perform active range of motion for 4 minutes each time.
89451084|NCT05503420|No Intervention|Control|Participants in this group will receive the normal stroke rehabilitation training in the centre without additional provision of masticatory muscles training exercises.
89451085|NCT04444466|Experimental|UCB8600|Study participants randomized to this arm will receive various single doses and multiple doses of UCB8600 administered to various cohorts.
89451086|NCT04444466|Placebo Comparator|Placebo|Study participants randomized to this arm will receive various single doses and multiple doses of Placebo administered to various cohorts.
89451087|NCT03295838|Experimental|Mentalization-based Treatment|MBT was conducted according to the treatment manual developed by Bateman & Fonagy. Patients were offered individual sessions with a psychotherapist and group sessions with 6-8 participants and 1-2 group therapists for 18 months. An introductory psycho-educational component (9-12 sessions) was also offered focusing on explicit mentalising skills (i.e. understanding one's own or others' intentions). Group and individual MBT focused on implicit mentalising towards self and others.
89451088|NCT04288804||Control (healthy, non-PD participants)|An audio file made up of a voice recording of the sustained short a vowel sound, along with accelerometer data while maintaining various positions, will be collected.
89451089|NCT04288804||PD|An audio file made up of a voice recording of the sustained short a vowel sound, along with accelerometer data while maintaining various positions, will be collected.
89451090|NCT04537689|Experimental|Ixekizumab|"Participants will be offered ixekizumab as first-line systemic treatment for moderate to severe PsO. The indication for ixekizumab will be equivalent to current registered indications. Standard dose of subcutaneous ixekizumab for moderate to severe PsO will be given at 160 mg at week 0, followed by ixekizumab 80mg at weeks 2, 4, 6, 8, 10 and 12, then 4 weekly thereafter, for a total duration of 6 months.~Ixekizumab will be withdrawn after 6 months. For some participants, there may be relapse of PsO.~Relapses will be managed as per standard care."
89451091|NCT04537689|Active Comparator|Standard Care|"The management of PsO in the control arm will be the same as that in the standard care.~The standard care for moderate to severe PsO in Singapore is to start either phototherapy, methotrexate, acitretin or cyclosporin A."
89451092|NCT02462096|Experimental|Treatment|Subject to undergo the ReLeaf study procedure.
89451093|NCT03295760||Children with cyclic vomiting syndrome|Children followed at Children's Hospital of Nancy treated with Q10 coenzyme for cyclic vomiting syndrome
89451094|NCT05563012|Experimental|Patients with untreated, operable locally advanced gastric adenocarcinoma|"Drug: Sintilimal Injection Sintilimal (200mg) will be given i.v. on day 1 of each 3-week cycle.~Drug: Capecitabine Capecitabine (1000mg/m2) will be administered orally twice daily on days 1-14 of each 3-week cycle.~Drug: Oxaliplatin Oxaliplatin (130mg/m2) will be given i.v. on day 1 of each 3-week cycle."
89451095|NCT03295604|Experimental|test group|Miller class I-II gingival recession defects operated with sub epithelial connective tissue graft (SCTG) in addition with enamel matrix derivatives (EMD) (Emdogain ®, Switzerland ) in SCTG+EMD group.
89451096|NCT03295604|Experimental|control group|Miller class I-II gingival recession defects operated with only sub epithelial connective tissue graft (SCTG). No drug or something else were used
89451097|NCT04501653|Experimental|Psilocybin first|Participants will receive 25 mg of psilocybin at the first of two neuroimaging sessions, taken orally in capsule form. Participants in this arm will receive the control drug (methylphenidate) at their second drug exposure neuroimaging session.
89451098|NCT04501653|Active Comparator|Methylphenidate first|Participants in this group will be randomized to receive 40 mg of methylphenidate at the first of two neuroimaging sessions, taken orally in capsule form. Participants in this arm will receive the active comparator (psilocybin) at their second drug exposure neuroimaging session.
89451099|NCT04730206|Experimental|Camostat|4 x 200 milligram per day for 7 days
89451100|NCT04730206|Placebo Comparator|Placebo|4 x per day for 7 days
89451101|NCT04730206|Experimental|Molnupiravir|2 x 800 milligram per day for 5 days
89451102|NCT02463344||MA09-hRPE|"Experimental: Subretinal injection of MA09-hRPE~Cohort 1 50,000 cells~Cohort 2 100,000 cells~Cohort 2a Better Vision 100,000 cells~Cohort 3 150,000 cells~Cohort 4 200,000 cells"
89451103|NCT00781443|Experimental|A|
89451104|NCT00781443|Placebo Comparator|B|
88935656|NCT01781871|Active Comparator|liver Pneumovax|30 liver transplant patients vaccinated with Pneumovax once they enter the transplant waiting list. Serotype specific ELISA and OPA measured pre- and postvaccination. At 6 and 7 months posttransplant ELISA and OPA measured parallel to the experimental group.
89451105|NCT03134937|Other|Study Arm|Participants will undergo one session of high-flow heated and humidified oxygen therapy (HFHHNO) (up to 60-70 litre/min). They will undergo a gastric ultrasound scan after session of HFHHNO therapy.
88935657|NCT01781884|Active Comparator|Gamma Aminobutyric Acid (GABA)|GABA will be given 50mg/kg/Day, thrice daily for 52 weeks
88935658|NCT01781884|Active Comparator|Gamma Aminobutyric Acid GABA)|GABA will be given 100mg/kg/Day, thrice daily for 52 weeks.
88935659|NCT01781884|Placebo Comparator|placebo|placebo will be given thrice daily for 52 weeks
88935660|NCT01781897|Active Comparator|mosapride|mosapride
88935661|NCT01781897|Experimental|Electro-acupuncture|Electro-acupuncture
88935662|NCT01781897|Sham Comparator|mosapride + sham acupuncture|mosapride + sham acupuncture
88935663|NCT01781910|Experimental|Branch Chain Amino Acid supplement|A drink supplement containing 1.22 grams of branched chain amino acids, plus glucose.
89451106|NCT05503342|Active Comparator|Control|"They will be followed up in a 12-week pharmacotherapeutic follow-up program, where they will have to record three measurements of peak expiratory flow weekly and fill out a questionnaire to assess control on paper.~Depending on the evolution of each patient, the pharmacist will provide the relevant guidelines to improve control, as well as referral to a medical care service, if applicable."
89451107|NCT05503342|Experimental|Application|They will be followed up in a 12-week pharmacotherapeutic follow-up program, where they will have to record three measurements of peak expiratory flow weekly and fill in an exacerbation risk score included in the cell phone application, which the pharmacist will have access to through a web platform. Depending on the evolution of each patient, the pharmacist will provide the relevant guidelines to improve control, as well as referral to a medical care service, if applicable.
89451108|NCT04473027||Patients with advanced melanoma|Patients receiving anti-PD-1 monotherapy (Nivolumab or Pembrolizumab) in the first-line setting
88935664|NCT01781910|Placebo Comparator|Placebo supplement|The placebo was formulated to match both the taste and color of the test supplement. Crystal Light Lemonade powder (Kraft Foods, Northfield, IL, USA) was mixed with 5.6g of powdered dextrose (Now Foods, Bloomingdale, IL, USA) to match the amount of dextrose present in the BCAA supplement.
88935665|NCT01781923|Experimental|Cognitive Remediation|"12 week computer-based cognitive remediation program aimed to improve working memory, processing speed, and verbal learning/memory.~40 week small group social skills training sessions aimed to improve social skills and cognition."
88935666|NCT01781923|No Intervention|Control|No intervention
88935667|NCT01781936|Experimental|Low dose FA-i (Fluocinolone Acetonide insert)|Each FA-i contains 180 µg FA (Fluocinolone Acetonide) designed to be released over 15 - 30 months.
88935668|NCT01781988|Experimental|A.individual therapy|Carboplatin was administrated at an area under the plasma concentration time curve (AUC) of 5 on day 1 every 21 days, while gemcitabine was administrated at a dose of 1250 mg/m2 on day 1 and 8 and pemetrexed was administrated at a dose of 500 mg/m2 on day 1.
88935669|NCT01781988|Experimental|B. non-individualized therapy|Carboplatin was administrated at an area under the plasma concentration time curve (AUC) of 5 on day 1 every 21 days, while gemcitabine was administrated at a dose of 1250 mg/m2 on day 1 and 8 and pemetrexed was administrated at a dose of 500 mg/m2 on day 1.
88935670|NCT01782001|Experimental|Vitamin A and zinc|combination of vitamin A and zinc supplements
88935671|NCT01782001|Active Comparator|Vitamin A and placebo|vitamin A with placebo
88935672|NCT01782014|Experimental|Water Insufflation|Colonoscopy using water insufflation
88935673|NCT01782014|Active Comparator|Carbon dioxide insufflation|Colonoscopy using carbon dioxide insufflation
88935674|NCT01782014|Active Comparator|Air insufflation|Colonoscopy using air insufflation
88935675|NCT01782040|No Intervention|Control Group|Control Group didn't receive any treatment and it was evaluated at the same time and the same way of interventions group
88935676|NCT01782040|Experimental|Auriculotherapy group|The chinese auriculotherapy is a intervention used by Chinese Traditional Medicine in order to treat several kind of diseases using semi-permanent needles in specific points of the auricular pavilion.It was used 6 points: Kidney, Liver, Stomach, Brain Stem, Ovary and Uterus point with semi-permanent needles one time per week for 8 sessions
88935677|NCT01782053|Experimental|Control condition|Current packaging with warning on side replaced with one of 9 mandated warning statements
88935678|NCT01782053|Experimental|Text plus picture|Revised packaging with half of front and back of pack showing FDA proposed warning including image.
88935679|NCT01782053|Experimental|Picture plus additional warning text|Same as text plus picture but containing additional text elaborating on the basis for the warning.
88935680|NCT01782066|Experimental|Menveo, dose escalating|
88935681|NCT01782066|Experimental|Nimenrix, dose escalating|
88935682|NCT01782079|Experimental|L. brevis|
88935683|NCT01782092||Chiropractic & Diabetes|All subjects will also receive chiropractic care and receive spinal adjustments as indicated by Basic and Intermediate Activator Methods Protocols, which uses a combination of provocative tests designed to elicit a relative change in leg length in the presence of subluxation. Special shoes designed for improved accuracy of leg length analysis will be used for all visits. The patients will be analyzed two times per week for the first month followed by once per week for the remainder of the study. The Activator Methods protocol will be followed for all visits by all doctors in accordance with the guidelines set forth by Activator Methods International, Ltd. The first four visits will be limited to Basic Protocol to allow the patients to become accustomed to the process.
88935684|NCT01782105|Active Comparator|Control group|In addition to the usual monitoring of pregnancy, this group will receive information about the recommended weight gain during pregnancy and an evaluation about of their nutritional and physical activity habits.
89014995|NCT02544074||Smartphone eSAGE score of 21|Participants who score a 21 on the smartphone eSAGE. Interventions include neuropsychological testing.
89014996|NCT02544074||Smartphone eSAGE score of 22|Participants who score a 22 on the smartphone eSAGE. Interventions include neuropsychological testing.
89451109|NCT04432480||Children|0-15 years old children undergoing surgery under general anesthesia
89451110|NCT00990327|Experimental|Apadenoson|In period 1, subjects will receive a clinically-indicated rest/stress gated SPECT-MPI with adenosine. In period 2, subjects will receive a rest/stress gated SPECT-MPI with apadenoson or the active comparator: adenosine.
89451111|NCT00990327|Active Comparator|Adenosine|In period 1, subjects will receive a clinically-indicated rest/stress gated SPECT-MPI with adenosine. In period 2, subjects will receive a rest/stress gated SPECT-MPI with apadenoson or the active comparator: adenosine.
89451112|NCT03050814|Active Comparator|Standard of Care (SOC) - Arm A|Participants will receive leucovorin calcium (folinic acid), fluorouracil, and oxaliplatin (FOLFOX)- + bevacizumab + for up to 12 2-week cycles followed by maintenance therapy with bevacizumab + capecitabine until disease progression.
88935685|NCT01782105|Experimental|Intervention group|"This group will receive a regular monitoring by health professionals (nutritionist and kinesiologist) who will ensure nutritional changes and physical activity necessary to secure the adoption of a healthy lifestyle and could participate to a physical activity group session once a week until week 36 of gestation.~The intervention include:~A nutritional counseling every 2 weeks by a nutritionist until week 36 of gestation; a physical activity group session once a week lead by a kinesiologist until week 36 of gestation; 2 sessions of physical activity counseling (weeks 12 and 24)."
88935686|NCT01782118|Experimental|Lactobacillus GG|Lactobacillus GG given for six weeks two times per day.
88935687|NCT01782118|Placebo Comparator|Placebo|Placebo two times per day for six weeks
88935688|NCT01782144|Active Comparator|NutriSystem|weekly behavior group weight loss education
88935689|NCT01782144|Placebo Comparator|Education|monthly behavior group weight loss education
89451113|NCT03050814|Experimental|Standard of Care (SOC) - Arm B + Lead in|Participants will receive leucovorin calcium (folinic acid), fluorouracil, and oxaliplatin (FOLFOX)- + bevacizumab + avelumab + Ad-CEA vaccine (given weeks 0,2,4,8,12,16 and then every 12 weeks) for up to 12 2-week cycles followed by maintenance therapy with bevacizumab + capecitabine + avelumab + Ad-CEA vaccine (following the every 12-week dosing schedule) until disease progression.
89451114|NCT04430218|Experimental|iSens|3 months trial with the iSens system
88935690|NCT01782170|Active Comparator|Iocide Oral Rinse|Iocide Oral Rinse once daily 30 second rinse for 24 weeks
88935691|NCT01782170|Placebo Comparator|Placebo Control|Once daily 30 second rinse for 24 weeks
88935692|NCT01782183|Experimental|Thermal camera by Flir HM series|all patients in both study and control groups will undergo thermal camera photo of the tonsils by Flir HM series
88935693|NCT01782196|Experimental|Type A Pouch followed by Type B pouch|Enhanced one piece drainable pouch with Type A mouldable adhesive for Stage 1 and 2 followed by pouch with Type B mouldable adhesive for Stage 3
88935694|NCT01782196|Experimental|Type B Pouch followed by Type A pouch|Enhanced one piece drainable pouch with Type B mouldable adhesive for Stage 1 and 2 followed by pouch with Type A mouldable adhesive for Stage 3
88935695|NCT01782235|Experimental|Tocilizumab arm|Tocilizumab arm will receive tocilizumab.
88935696|NCT01782235|Placebo Comparator|Placebo arm|Placebo arm will receive placebo.
88935697|NCT01782248|Other|Alzheimer disease|Patients with Alzheimer disease
88935698|NCT01782248|Other|Fronto-temporal lobar dementia|Patients with Fronto-temporal lobar dementia
89451115|NCT04430218|No Intervention|State of the Art Prosthesis|3 months trial with their own prosthesis.
89451116|NCT04429750|Active Comparator|Immediate umbilical cord clamping|"This group includes newborn infants with isolated CDH who will benefit from the standardized CDH management procedure as described in the French national CDH management guidelines (Programme National de Soins).The resuscitation maneuvers are started after the umbilical cord is clamped."
88935699|NCT01782248|Other|Control|Control group
88935700|NCT01782261|Experimental|Liraglutide|Liraglutide subcutaneous injection every day. first week 0.6mg, week 2-4 1.2mg.
88935701|NCT01782261|Active Comparator|Saxagliptin|Saxagliptin 5mg tablet by mouth every day for 4 weeks
88935702|NCT01782274|Experimental|allogeneic stem cells|3 ml suspension of allogeneic hematopoietic cells in 0.9%NaCl solution is administered in L3-L4 vertebrae interspace with 16-18G needle. The preparation is administered every 2 weeks for the first 2 months (at day 1, 14, 28, 42, 56). 2 ml of individual dendritic vaccine are administered subcutaneously in 4 points (shoulders and abdomen) 3 times every 14 days from the therapy beginning (at day 14, 28 and 42). Meloxicam, 7.5mcg once a day is started from day 7 till day 42. Preparation of cytotoxic lymphocytes is administered intrathecally once in 2 weeks during the first 3 months, and then once in a month for three months.
89014997|NCT02508454||Greater Miami Area Community|Members of the Miami area who qualify for the study, are not an employee of BHSF, and enroll.
88935703|NCT01782274|Active Comparator|autologous stem cells|3 ml suspension of proteome-modified autologous hematopoietic cells in 0.9%NaCl solution is administered in L3-L4 vertebrae interspace with 16-18G needle. The preparation is administered every 2 weeks for the first 2 months (at day 1, 14, 28, 42, 56). 2 ml of individual dendritic vaccine are administered subcutaneously in 4 points (shoulders and abdomen) 3 times every 14 days from the therapy beginning (at day 14, 28 and 42). Meloxicam, 7.5mcg once a day is started from day 7 till day 42. Preparation of cytotoxic lymphocytes is administered intrathecally once in 2 weeks during the first 3 months, and then once in a month for three months.
89014998|NCT02508454||Baptist Health South Florida Employees|Employees of BHSF who qualify for the study and enroll.
89014999|NCT02504879||Melorheostosis patients|Patients aged > 18 years with possible and confirmed melorheostosis.
89451117|NCT04429750|Experimental|Intact cord resuscitation|"This group includes newborn infants with isolated CDH who will benefit from the standardized CDH resuscitation maneuvers as described in the French national CDH management guidelines (Programme National de Soins) before the umbilical cord is clamped. The resuscitation maneuvers are started at birth while the umbilical cord still bridges mother and child."
89451118|NCT02463422||San Diego, CA|Toddlers detected with ASD and other disorders based on the Get SET Early Model in San Diego.
89451119|NCT02463422||Phoenix, AZ|Toddlers detected with ASD and other disorders based on the Get SET Early Model in Phoenix.
89451120|NCT02462174|Active Comparator|Topical ketamine and topical bupivacaine|0.5 mg/ kg ketamine in 0.3 ml/kg bupivacaine 0.25% (maximum volume = 20 ml) administered directly around the spermatic cord in the wound after end of surgery and before closure of the wound.
89451121|NCT02462174|Active Comparator|Caudal ketamine and caudal bupivacaine|0.5 mg/ kg ketamine in 1 ml/kg bupivacaine 0.25% (maximum volume = 20 ml) administered by caudal epidural route after anesthesia and before the start of surgery.
89451122|NCT02564146|Active Comparator|nab-paclitaxel and gemcitabine (A)|"Induction treatment: 3 cycles nab-paclitaxel and gemcitabine~Continuous treatment after randomization: Continuing application of nab-paclitaxel and gemcitabine treatment cycles"
89451123|NCT02564146|Experimental|gemcitabine monotherapy and nab-paclitaxel and gemcitabine (B)|"Induction treatment: 3 cycles nab-paclitaxel and gemcitabine~Continuous treatment after randomization: alternating application of gemcitabine monotherapy and nab-paclitaxel and gemcitabine treatment cycles"
88935704|NCT01782287|Experimental|allogeneic stem cells|3 ml suspension of allogeneic hematopoietic stem cells in 0.9%NaCl solution is administered in L3-L4 vertebrae interspace with 16-18G needle. The preparation is administered every 2 weeks for the first 2 months (at day 1, 14, 28, 42, 56). 2 ml of individual dendritic vaccine are administered subcutaneously in 4 points (shoulders and abdomen) 3 times every 14 days from the therapy beginning (at day 14, 28 and 42). Meloxicam, 7.5mcg once a day is started from day 7 till day 42. Preparation of cytotoxic lymphocytes is administered intrathecally once in 2 weeks during the first 3 months, and then once in a month for three months.
88935705|NCT01782287|Active Comparator|autologous stem cells|3 ml suspension of proteome-modified autologous hematopoietic stem cells in 0.9%NaCl solution is administered in L3-L4 vertebrae interspace with 16-18G needle. The preparation is administered every 2 weeks for the first 2 months (at day 1, 14, 28, 42, 56). 2 ml of individual dendritic vaccine are administered subcutaneously in 4 points (shoulders and abdomen) 3 times every 14 days from the therapy beginning (at day 14, 28 and 42). Meloxicam, 7.5mcg once a day is started from day 7 till day 42. Preparation of cytotoxic lymphocytes is administered intrathecally once in 2 weeks during the first 3 months, and then once in a month for three months.
88935706|NCT01782300|Experimental|TV003 Vaccine|Participants will receive an injection of the TV003 vaccine at study entry and Day 360.
88935707|NCT01782300|Placebo Comparator|Placebo Vaccine|Participants will receive an injection of the placebo vaccine at study entry and Day 360.
88935708|NCT01782339|Experimental|Combination Chemotherapy|"4 cycles of: Day 1 Actinomycin D 1mg/m2, Paclitaxel 80mg/m2, Methotrexate Day 4 Oxaliplatin 100mg/m2 Pegfilgrastim 6mg Day 8* Paclitaxel 80mg/m2 Day 15 Paclitaxel 80mg/m2~*Day 8 will be omitted for the first three patients treated in this study and will be given at the end of treatment in a fifth cycle where Paclitaxel 80mg/m2 will be administered on Days 1, 8, 15 and 22. Before adding the extra Paclitaxel 80mg/m2 dose on day 8 the safety data for these patients will be reviewed by a DMC.~NB This 5th cycle for patients 1-3 has been included to ensure that the four 'missed doses of paclitaxel are not omitted from the patients treatment regimen. Cycles 1-4 are 21 days cycles; Cycle 5 (for the first three patients only) is a 28 day cycle."
88935709|NCT01782365|Experimental|0,75 Hz stimulation|transcranial slow oscilliating stimulation (tSOS)during periods of SWS
88935710|NCT01782365|Sham Comparator|SHAM stimulation|SHAM stimulation during periods of SWS
88935711|NCT01782391|Experimental|0,75 Hz stimulation|slow transcranial oscillating stimulation (~0,75Hz) during periods of Slow Wave Sleep
89451124|NCT03747276|Other|Clinical Trial Kiosk|
89451125|NCT00981357|Experimental|PF-04457845 followed by placebo|
89451126|NCT00981357|Experimental|Placebo followed by PF-04457845|
89451127|NCT00981357|Active Comparator|Naproxen followed by placebo|
89451128|NCT00981357|Active Comparator|Placebo followed by Naproxen|
89451129|NCT02462252|Experimental|BL-8040 plus hATG, methylprednisolone, cyclosporine|"BL-8040 0.75mg/kg will be administered Subcutaneously (SC ) on Days 1-10, then on first 5 days of months 2-6.~Standard therapy: hATG: Days 11-14: 40mg/kg/day IV over 6-8 hours, in all AA subjects, or in MDS subjects less than 55 years old. 35mg/kg/day IV over 6-8 hours in MDS subjects 55 years and older.~Standard therapy: methylprednisolone: Days 11-14: 40mg/kg/day IV over 6-8 hours, in all AA subjects, or in MDS subjects less than 55 years old. 35mg/kg/day IV over 6-8 hours in MDS subjects 55 years and older.~Standard therapy: cyclosporine: 5mg/kg/day orally, given in 2 divided doses, starting on day 11 and continuing through Month 6 Day 30 (end of treatment)"
89451130|NCT04613362|Experimental|TENACITY Telehealth Cognitive Behavioral Therapy for Migraine|Six sessions of standardized Cognitive Behavioral Therapy for patients with diagnosed chronic migraine headaches will be delivered by a clinical health psychologist via telehealth platform. All patients have access to a set of standardized educational, headache self-management materials.
88935712|NCT01782391|Sham Comparator|SHAM stimulation|SHAM stimulation during periods of Slow Wave Sleep
88935713|NCT01782404|Experimental|Chlorhexidine|
88935714|NCT01782417|Other|Patient and provider intervention|participants will receive a patient and provider intervention
88935715|NCT01782430|Experimental|Standard oxygenation|Prospective randomized clinical multicentric study in ICU, comparing standard oxygenation, high flow nasal oxygen therapy and non invasive ventilation (NIV) , with pulse oxymetry values (SpO2), during preoxygenation for hypoxemic patients
89451131|NCT04613362|Active Comparator|Behavioral Usual Care|Behavioral usual care may include outpatient clinic-based health psychology in the VA or Community Care, or mindfulness sessions with LCSW. Behavioral usual care will be delivered by clinicians for patients with diagnosed chronic migraine.
89451132|NCT03130452|Active Comparator|concomitant group|lansoprazole 30 mg tablet, amoxicillin 1.0 g tablet, metronidazole 500 mg tablet and clarithromycin 500 mg tablet by mouth every 12 hours for 2 weeks, regardless of 23S ribosomal RNA point mutation.
89015000|NCT02504879||Relatives of patients with melorheostosis|Relatives of patients with melorheostosis may be included for genetic testing only.
89451133|NCT03130452|Experimental|tailored treatment group I|23S ribosomal RNA point mutation negative, lansoprazole 30 mg, amoxicillin 1.0 g, and clarithromycin 500 mg were administered twice a day for 2 weeks.
89451134|NCT03130452|Experimental|tailored treatment group II|23S ribosomal RNA point mutation positive, lansoprazole 30 mg, amoxicillin 1.0 g and metronidazole 500 mg For 2 weeks.
89451135|NCT04473495||video|patients who enjoyed an educational video
89451136|NCT04473495||control|patients who didn't enjoy any educational video
89451137|NCT00979251|Experimental|ADS-8902|Amantadine and Ribavirin administered with Oseltamivir phosphate
89451138|NCT00979251|Active Comparator|Comparator|Oseltamivir Phosphate
89451139|NCT03108170|Active Comparator|3 programs group|The participants will receive 3 programs.The educational pelvic floor dysfunction prevention program, pelvic floor muscle exercise program and perineal massage program will be educated by an investigator during the participant visit 4 weeks before her duo date
89451140|NCT03108170|Active Comparator|one program group|The participants will receive one program. That is the educational pelvic floor dysfunction prevention program.The instructions of the program will be given by an investigator once during the participant visit 4 weeks before her duo date.
89451141|NCT04551352|Experimental|Part I: Single Participant Cohorts (IV)|Part I is a dose escalation in single participant cohorts. RO7293583 will be administered intravenously (IV) every three weeks (Q3W). The starting dose will be 0.045mg and the maximum dose explored will be 1.5mg.
89451142|NCT04551352|Experimental|Part II: Multiple Participant Cohorts (IV/SC)|Multiple ascending dose-escalation of RO7293583 in multiple participant cohorts: The starting-dose for the initiation of the IV dose-escalation will be determined by Part I and RO7293583 will be administered IV or SC every 3 weeks. Dose-escalation will be undertaken based on safety until determination of the MTD or the highest safe dose if MTD is not reached. Fractionated, step up or subcutaneous dosing may be implemented. The maximum dose explored will be 600mg IV and 160mg SC.
89451143|NCT02462798|Placebo Comparator|Whole grain rye bread|Whole grain rye bread, 200 g/d. Control intervention.
89451144|NCT02462798|Experimental|Whole grain sourdough rye bread|Whole grain rye bread, 200 g/d. Experimental intervention.
89451145|NCT05398224|Experimental|Experimental arm: Zanubrutinib, high-dose methotrexate (HD-MTX), rituximab|Zanubrutinib in combination with rituximab and methotrexate, followed by zanubrutinib maintenance in patients with secondary central nervous system lymphoma (SCNSL)
89451146|NCT04496271|Experimental|Successor of Phonak Audéo M-90|Phonak Hearing aid with modified precalculation.
89015001|NCT02495337||TIssue Collection|Only one arm will be used to collect tissue from Esophageal Adenocarcinoma
89015002|NCT02464696|Experimental|Arm A (NIPPV therapy)|Patients undergo intermittent NIPPV, with the recommended schedule comprising 2 hours on NIPPV followed by =< 2 hours off NIPPV and continuous NIPPV at night or while sleeping for 8 hours per day, for 28 days or until discharged from the hospital.
89015003|NCT02464696|Active Comparator|Arm B (high flow oxygen therapy)|Patients continue to receive high flow nasal cannula oxygen therapy using current protocol for titration of high flow oxygen therapy for 28 days or until discharged from the hospital. Patients may receive NIPPV if they develop evidence of accessory muscle use with breathing or at the discretion of the treating physician.
89015004|NCT02413970|Other|Inspire® UAS System|This is a single-arm study; all participants will be implanted with the Inspire® UAS System.
89451147|NCT04496271|Active Comparator|Phonak Audéo M-90|Phonak Audéo M-90 is the most recent Receiver In Canal hearing aid by Phonak which will be fitted to the participants individual hearing loss.
89451148|NCT04542304|Active Comparator|Metolazone then placebo|Metolazone will be taken orally during the first week, followed by washout of 1-2 weeks, then placebo will be taken the following week.
89451149|NCT04542304|Placebo Comparator|Placebo then Metolazone|Placebo will be taken orally during the first week, followed by washout of 1-2 weeks, then metolazone will be taken the following week.
89451150|NCT02463110|Experimental|1: Sertraline|ACS, depression
89451151|NCT02463110|Placebo Comparator|2: Placebo|ACS, depression
89451152|NCT02463110|Other|3: Control|ACS, no depression, no treatment
89451153|NCT05398146|Experimental|Pre-Dressing|Information about the children and their parents who agreed to participate in the study was recorded on the 'Information Form' 5 minutes before the dressing procedure by the researcher.
89451154|NCT05398146|Experimental|During Dressing|The first dressing of all children included in the study after appendectomy was performed by the doctor in the clinic. No distraction method was applied to the children in the control group during dressing. The children in the LM group were dressed while listening to music. The children in the BS group continued to squeeze the ball during the dressing. The children in the MO group were asked to perform mathematical operations given by the nurse. While the dressing was in progress, the pulse and oxygen saturation levels were recorded in the information form by the nurse. At the last stage of dressing, the children were asked to mark the level of pain they experienced during dressing on the VAS, immediately after the sticking plaster was placed on the surgical area. Parents and nurses assessed the pain level of the child during dressing through the VAS.
89451155|NCT05398146|Experimental|Post-Dressing|When the dressing was over, the application of distraction methods was terminated. After the dressing, the child's pulse and oxygen saturation levels were recorded in the information form by the nurse.
89451156|NCT05241314|Experimental|Phase 1 Youth Focus Group|Intervention adaptation and Community Health Worker Interventionist (CHWI) training through the delivery of the intervention to an adolescent focus group. CHWI from WellShare International will lead the recruitment of adolescent youth from the existing cohort of families and up to two Zoom focus groups will be held.
89451157|NCT05241314|Experimental|Phase 2 Youth|One randomly selected index youth per participating Karen family. Community health worker interventionists (CHWI) will deliver 7 weeks of home-based intervention with optional post-intervention focus groups to examine the feasibility of the community-based participatory research approach and intervention delivery by CHWIs.
89451158|NCT05241314|Experimental|Phase 2 Caregivers/Adults|Maternal and paternal caregivers (if present) of participating Karen family. Community health worker interventionists (CHWI) will deliver 7 weeks of home-based intervention with optional post-intervention focus groups to examine the feasibility of the community-based participatory research approach and intervention delivery by CHWIs.
89451159|NCT05241314|Experimental|Phase 1 Community Leadership Board (CLB)|Intervention adaptation and community health worker interventionist (CHWI) training through the delivery of the intervention to Community Leadership Board (CLB) members. The CLB will be made up of 4-7 Karen professionals representing prominent local organizations supporting Karen refugees in resettlement. Representatives will have lived cultural and historical expertise as well as professional expertise supporting the resettled community from mental health and social services perspectives. The expertise of the board ensures culturally centered preparations for intervention dissemination. The CLB will take an active role in the adaptation of the intervention.
89451160|NCT04473573|Other|Lot to Lot Reproducibility|The purpose of this arm is to provide evidence to support that each lot of manufactured reagents for the Spartan Cube CYP2C19 Test produce the same result. Each participant, over the course of the study at the various sites, will be tested using 3 different lots of manufactured Spartan CYP2C19 Test Kits.
89451161|NCT04473573|Other|Site to Site Reproducibility|The purpose of this arm was to provide supporting evidence that showed the same samples (subjects), when tested at different locations, produce the same result.
89451162|NCT04473573|Other|Operator Reproducibility|The purpose of this arm was to provide supporting evidence that showed the same samples (subjects), when collected and tested by different operators, produce the same result.
89451163|NCT04535908|Experimental|Hypofractionated radiotherapy|
89451164|NCT04438629||Mild disease|COVID-19 hospitalized patients
88935716|NCT01782430|Experimental|High flow nasal oxygen therapy|Prospective randomized clinical multicentric study in ICU, comparing standard oxygenation, high flow nasal oxygen therapy and non invasive ventilation (NIV) , with pulse oxymetry values (SpO2), during preoxygenation for hypoxemic patients
88935717|NCT01782430|Other|invasive ventilation (VNI)|Prospective randomized clinical multicentric study in ICU, comparing standard oxygenation, high flow nasal oxygen therapy and non invasive ventilation (NIV) , with pulse oxymetry values (SpO2), during preoxygenation for hypoxemic patients
88935718|NCT01782456|Experimental|Study Oral Nutritional Supplement|2 servings per day of a complete and balanced, ready-to-drink oral nutritional supplement with a new protein blend.
88935719|NCT01782508|Experimental|imatinib|Participants will take 400mg tablets once daily for one year
88935720|NCT01782508|Active Comparator|inteferon|Participants will receive Interferon 1500wiu/m2 d1-5for 4 weeks followed by 900wiu IH TIW for 11 months
88935721|NCT01782521|No Intervention|Primer|Metal brackets bonded with primer
88935722|NCT01782521|Experimental|No primer|Metal brackets bonded without primer
88935723|NCT01782534||aortic dissection|aortic dissection
88935724|NCT01782547|Experimental|Telehealth Intervention|Telehealth intervention - 6 months
88935725|NCT01782547|Active Comparator|Usual care|Usual care control with comparable frequency of contact
88935726|NCT01782560|Placebo Comparator|Placebo|Two different placebo formulations will be created which will designed to be identical in appearance, taste, and consistency to the two study medications.
89451165|NCT04438629||Severe disease|COVID-19 hospitalized patients in intensive care unit
89451166|NCT04438629||paucisymptomatic syndrome|Mild symptomatic patients in home quarantine
89451167|NCT05502952|Experimental|Alopecia areata|
89451168|NCT05389059|Other|Control arm|Patients with Gingival recessions are type 1 recession RT1 (cairo et al,2011) which correspond to Miller I&II gingival recession.
89451169|NCT05389059|Other|Experimental arm|Patients with Gingival recessions are type 1 recession RT1 (cairo et al,2011) which correspond to Miller I&II gingival recession.
89451170|NCT04414449|Experimental|Intervention group|During the tutoring time, the intervention program is carried out in the experimental group, through emoTIC. EmoTIC is an emotional education program focused on the development of social-emotional competences through an application that can be used in mobile devices and tablets.
89451171|NCT04414449|No Intervention|Control group|During the period in which the intervention program is conducted in the experimental group, the control group will remain in the waitlist (will not participate in the intervention), and will carry out the program once the study is finished.
89451172|NCT04441658|Experimental|experimental group|The volunteers of the experimental group will be given peripheral intravenously a dose of 0.75*10^6/ kg human umbilical cord mesenchymal stem cells at 0,1,5,6 week.
89451173|NCT04441658|Placebo Comparator|control group|The control group will be given the same dose of saline containing human albumin.
89451174|NCT04412811||Patients with hematological disease|Adult and children allogenic Hematopoietic stem cell transplantation recipients
89451175|NCT03295526|No Intervention|Control group|IB-IIA Cervical Cancer Patients with positive lymph node metastasis confirmed by intraoperative frozen pathological examination who will undergo radical hysterectomy and systematic pelvic lymphadenectomy
89451176|NCT03295526|Experimental|Experimental group|IB-IIA Cervical Cancer Patients with positive lymph node metastasis confirmed by intraoperative frozen pathological examination who will undergo radical hysterectomy and selective enlarged lymph node dissection.
89451177|NCT03295448|Active Comparator|Fat - Sugar - Fiber|Intervention: consuming diets rich in fat, rich in sugar, and rich in fibers during treatment periods 1, 2, and 3, respectively. Treatment periods are separated by one week of habitual diet.
89451178|NCT03295448|Active Comparator|Fat - Fiber - Sugar|Intervention: consuming diets rich in fat, rich in fiber, and rich sugar during treatment periods 1, 2, and 3, respectively. Treatment periods are separated by one week of habitual diet.
89451179|NCT03295448|Active Comparator|Sugar - Fiber - Fat|Intervention: Consuming diets rich in sugar, rich in fiber, and rich in fat during treatment periods 1, 2, and 3, respectively. Treatment periods are separated by one week of habitual diet.
89451180|NCT03295448|Active Comparator|Sugar - Fat - Fiber|Intervention: Consuming diets rich in sugar, rich in fat, and rich in fiber during treatment periods 1, 2, and 3, respectively. Treatment periods are separated by one week of habitual diet.
89451181|NCT03295448|Active Comparator|Fiber - Sugar - Fat|Intervention: Consuming diets rich in fiber, rich in sugar, and rich in fat during treatment periods 1, 2, and 3, respectively. Treatment periods are separated by one week of habitual diet.
89451182|NCT03295448|Active Comparator|Fiber - Fat - Sugar|Intervention: consuming diets rich in fiber, rich in fat, and rich in fiber during treatment periods 1, 2, and 3, respectively. Treatment periods are separated by one week of habitual diet.
89451183|NCT00835575|Experimental|1|
89451184|NCT00835575|Active Comparator|2|
89451185|NCT03295370|Experimental|Active Group|Needle electrical stimulation of accessory spinal nerve
89451186|NCT03295370|Sham Comparator|Sham Group|Needle of accessory spinal nerve without electrical stimulation
88935727|NCT01782560|Active Comparator|Omeprazole|Omeprazole (a proton-pump inhibitor) is the most common treatment given to infants with laryngomalacia, in the hope that this will reduce their symptoms. Although this is an effective anti-reflux medication in this population, its use is off-label, and like any medication has potential risks, particularly in very young children. 2 mg/kg/day omeprazole.
88935728|NCT01782573|Active Comparator|Chlorhexidine gluconate ( CHG )|(i)a sterile washcloth was saturated with 60ml of chlorhexidine gluconate (4%) cleansing solution and generously applied to the predefined surgical site followed by vigorous scrubbing for 3 min. (ii) after being patted with a sterile towel, the standardized 3-step disinfection was performed (iii) the applied iodine-alcohol disinfectant contained 70 ml of ethyl alcohol and 10 g of povidone-iodine per 100 ml
88935729|NCT01782573|Active Comparator|0.9% Sodium Chloride ( N/S )|(i)a sterile washcloth was saturated with 60ml of sodium chloride (0.9%) and generously applied to the predefined surgical site followed by vigorous scrubbing for 3 min. (ii) after being patted with a sterile towel, the standardized 3-step disinfection was performed (iii) the applied iodine-alcohol disinfectant contained 70 ml of ethyl alcohol and 10 g of povidone-iodine per 100 ml
88935730|NCT01782612|Active Comparator|General Ansethesia|Subjects undergoing Total uni-Hip Replacement will receive standard General Anesthesia with Laryngeal Mask Airway and Multimodal analgesic techniques
88935731|NCT01782612|Experimental|Peripheral Nerve Blocks|Subjects undergoing Total uni-Hip Replacement will receive Lumbar plexus block and Sciatic nerve block with 0.4% Ropivacaine and Multimodal analgesic techniques
89451187|NCT03295292|Sham Comparator|Standard Surgery with Vehicle|After the standard surgical procedure (PRK/PTK or CXL), patients will receive 50uL Fibrin Sealant (sham) without cells.
89451188|NCT03295292|Experimental|Standard Surgery with Stem Cells|After the standard surgical procedure (PRK/PTK or CXL), patients will receive 50uL of a mixture of limbus derived corneal epithelial cells and limbus derived corneal stromal cells in a ratio of 2:1, at a concentration of 50000 cells/uL diluted in the thrombin component of Fibrin Sealant (TISEEL, Baxter).
89451189|NCT00777309|Experimental|1|Erlotinib (150 mg) once daily plus ARQ 197 (360 mg) twice daily.
89451190|NCT00777309|Active Comparator|2|Erlotinib (150 mg) once daily plus ARQ 197 placebo twice daily
89451191|NCT03295214|Active Comparator|Acetaminophen 975mg Per Os|975mg of Acetaminophen given by mouth
89451192|NCT03295214|Active Comparator|Acetaminophen 1000mg Intravenous|1000mg of Acetaminophen given intravenously
89451193|NCT04604704|Experimental|Treatment with LDN and NAD+|LDN will be used at a dosage of 4.5 mg/day, which will be taken orally in the form of tablets. NAD+ will be administered using the IontoPatch iontophoresis patch containing 400 mg of NAD+ solution which is worn on the skin for 4-6 hours once per week.
89451194|NCT03295058|Experimental|Non ATG regimen|the first 50% of patients will receive Fludarabine + cyclophosphamide prior to hematopoietic cell transplantation. GVHD Prophylaxis: Cyclosporine A All the patient will do allogenic stem cell transplantation from peripheral blood
89451195|NCT03295058|Experimental|ATG regimen|the other 50% will receive Cyclophosphamide + ATG prior to hematopoietic cell transplantation. GVHD Prophylaxis: Cyclosporine A All the patient will do allogenic stem cell transplantation from peripheral blood
89451196|NCT00777231|Experimental|Sickle Cell Disease|Recipients treated with an enriched hematopoetic stem cell infusion
89451197|NCT00777231|Experimental|Non-Malignant Disorders|Recipients treated with an enriched hematopoetic stem cell infusion
89451198|NCT00777231|Experimental|Aplastic Anemia|Recipients treated with an enriched hematopoetic stem cell infusion
89451199|NCT00777231|Experimental|Sickle Cell Disease : Extended Protocol|Recipients treated with an enriched hematopoetic stem cell infusion and Campath 1H conditioning
89451200|NCT02462018|Experimental|WalkAide|
89451201|NCT00776373|Experimental|Arm 1|Rapamycin in combination with High Dose Etoposide and Cytarabine (HiVAC)
89451202|NCT04601194|Experimental|Coaching and Virtual Provider Group|Mental Health Coaching and assigned practice with a Virtual Provider Program
88935732|NCT01782625|Experimental|dive to 122 feet, no exercise|Subjects will undergo a simulated dive to a maximum depth of 122 feet of seawater with no exercise at depth
88935733|NCT01782625|Experimental|dive to 158 feet, no exercise|Subjects will undergo a simulated dive to a maximum depth of 154 feet of seawater with no exercise at depth
88935734|NCT01782625|Experimental|dive to 122 feet, exercise|Subjects will undergo a simulated dive to a maximum depth of 122 feet of seawater with exercise at depth
88935735|NCT01782625|Experimental|dive to 158 feet, exercise|Subjects will undergo a simulated dive to a maximum depth of 154 feet of seawater with exercise at depth.
88935736|NCT01782651||HER2+ metastatic breast cancer patients treated with lapatinib|HER2+ metastatic breast cancer patients treated with lapatinib plus capecitabine
88935737|NCT01782677|Experimental|Bilateral Surgical Resection of Carotid Bodies|Patients undergoing Bilateral Surgical Resection of Carotid Bodies.
89451203|NCT04373577|Experimental|ESP group|Under ultrasound guidance, patients of this group will receive (0.5ml/kg) plain bupivacaine 0.25%with adrenaline 2.5 µg/ml injected beneath the erector spinae muscle sheath at the level of the transverse process of the second lumbar vertebrae
89451204|NCT04373577|Experimental|PENG group|Under ultrasound guidance, patients of this group will receive (0.5ml/kg) plain bupivacaine 0.25%with adrenaline 2.5 µg/ml injected as the tip of the needle in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly
88935738|NCT01782716||ASA|
89451205|NCT04065802|Experimental|Radioablation Treatment|Patients will receive radioablation to scar regions of the heart responsible for ventricular tachycardia
89451206|NCT00772785|Experimental|Probuphine|buprenorphine implant
88935739|NCT01782716||ASA+Euroscore|
88935740|NCT01782755|Active Comparator|Lactobacillus rhamnosus GG|Patients allocated to the intervention group will receive 1x1010 colony forming units (CFU) of Lactobacillus rhamnosus GG (Culturelle, Locin Industries Ltd) in 1 capsule suspended in sterile water, administered through a nasogastric, nasoduodenal, percutaneous gastrostomy or percutaneous jejunal tube twice daily while patients are mechanically ventilated until 24 hours of spontaneous breathing. The first dose will be within 48 hours of intubation.
88935741|NCT01782755|Placebo Comparator|Placebo|Patients allocated to the placebo group will receive a capsule identical in appearance to the L. rhamnosus GG capsule, but containing microcrystalline cellulose. The placebo will also be suspended in sterile water and similarly administered twice a day. When suspended in water, the placebo has identical appearance and consistency as the probiotic. The placebo will be prepared by the manufacturer of L. rhamnosus GG, Culturelle, and has been used successfully in a recent RCT in the ICU population
89451207|NCT05497648|Experimental|Choose to Move|Individuals responsible for delivering Choose to Move and older adults enrolled in Choose to Move
89451208|NCT04474665|Other|Implant placement accuracy|Blueprint planning software will be used to plan reverse shoulder replacement surgery. Accuracy of the placement compared to the plan will be assessed post-surgery.
89451209|NCT02460848|Experimental|Outpatient therapeutic program, counseling and cash transfer|Ten outpatient therapeutic program sites (OTP) will be randomly allocated to unconditional cash transfer for children admitted for treatment of SAM according to the integrated management of acute malnutrition national protocol which will be associated with counseling on infant and young child feeding (IYCF).
89451210|NCT02460848|Active Comparator|Outpatient therapeutic program and counseling|Ten outpatient therapeutic program sites (OTP) will be randomly allocated for children admitted for treatment of SAM according to the integrated management of acute malnutrition national protocol which will be associated with counseling on infant and young child feeding (IYCF).
89451211|NCT04474431|Other|Patients admitted in the ICU of hospital of Rouen|Patients admitted in the intensive care unit (ICU) of the teaching hospital of Rouen.
89451212|NCT03294902||Critical Limb Ischaemia (CLI) Group with tibial arterial dis|Up to 20, but at least 8 subjects with a Rutherford grade 4 or 5 critically ischemic foot, where the primary intention is to treat at least one occluded tibial vessel or 2 severely stenosed tibial vessels. The treatment of SFA stenoses of less than 70%, as confirmed by duplex or CT, is acceptable in parallel in this group.
89015006|NCT02367131||JARDIANCE®|
89015007|NCT02359812||Healthy|Healthy volunteers with no history of neurological disorders
89015008|NCT02359812||Stroke|Patients had a recent stroke, two weeks or earlier prior to enrollment
89451213|NCT03294902||Peripheral Artery Disease (PAD) Group with SFA disease|Up to 20, but at least 8 subjects with a clinical diagnosis of claudication and duplex or CT-confirmed SFA stenoses greater than 70%, with no intention of primarily treating any tibial disease at this encounter.
89451214|NCT03294902||PAD-free group (Healthy Volunteer Group)|Up to 20 subjects with no clinical diagnosis of peripheral vascular disease.
89451215|NCT05497570|Active Comparator|Tenoxicam|The Tenoxicam group (n:16) received both arthrocentesis and a 2-ml injection of tenoxicam (Oksamen-L, Mustafa Nevzat İlaç Sanayi, Istanbul, Turkey) to the temporomandibular joint.
89451216|NCT05497570|Active Comparator|Control|Only arthrocentesis was given to patients in the control group
89200844|NCT00897663||Single group|Tissue samples from patients enrolled on clinical trials NCCTG-N0177 or NCCTG-N0074 are analyzed by microarray analysis and immunohistochemistry for biological markers predicting progression-free survival and overall survival. Biological markers include epidermal growth factor expression, vIII mutant p53 gene, P-AKT, p7056k, S6, 4EBP1, STAT-3, PLC-g, Erk, ErbB2, ErbB3, ErbB4, platelet-derived growth factor receptor, IGF1R, interleukin-6, FADD, and MGMT.
89451217|NCT00963885|Placebo Comparator|Part 1: Placebo|Placebo in combination with standard doses of Pegasys and Copegus.
89451218|NCT00963885|Experimental|Part 1: RO5190591 300mg po|RO5190591 300mg po every 8 hours in combination with standard doses of Pegasys and Copegus.
89451219|NCT00963885|Experimental|Part 1: RO5190591 600mg po|RO5190591 600mg po every 12 hours in combination with standard doses of Pegasys and Copegus.
89451220|NCT00963885|Experimental|Part 1: RO5190591 900mg po|RO5190591 900mg po every 12 hours in combination with standard doses of Pegasys and Copegus.
89451221|NCT00963885|Placebo Comparator|Part 2: Placebo|If the safety and virological response data from Part 1 of the study are supportive, in Part 2 patients will be randomized to receive placebo in combination with standard doses of Pegasys and Copegus.
89015009|NCT02359253|Experimental|IntelliArm with passive stretching|Groups are split into 2 conditions based on stretching and 2 conditions based on target of intervention (arm or hand). Subjects will complete up to 30 minutes of strong passive stretching, then followed by 45-60 minutes of active movement training with the IntelliArm.
89015010|NCT02359253|Experimental|IntelliArm with passive movement|Groups are split into 2 conditions based on stretching and 2 conditions based on target of intervention (arm or hand). Subjects will wear the IntelliArm for up to 30 minutes with gentle passive movement or little stretching, then followed by 45-60 minutes of active movement training with the IntelliArm.
89015011|NCT02359253|Experimental|The hand robot with passive stretching|Groups are split into 2 conditions based on stretching and 2 conditions based on target of intervention (arm or hand). Subjects will complete up to 30 minutes of strong passive stretching, then followed by 45-60 minutes of active movement training with the hand robot.
89015012|NCT02359253|Experimental|The hand robot with passive movement|Groups are split into 2 conditions based on stretching and 2 conditions based on target of intervention (arm or hand). Subjects will wear the hand robot for up to 30 minutes with gentle passive movement or little stretching, then followed by 45-60 minutes of active movement training with the hand robot.
89200845|NCT00985348|Experimental|Treatment 1/Treatment 2|
89451222|NCT00963885|Experimental|Part 2: RO5190591 300mg po|If the safety and virological response data from Part 1 of the study are supportive, in Part 2 patients will be randomized to receive RO5190591 300mg po every 8 hours or 600mg po every 12 hours or 900mg po every 12 hours in combination with standard doses of Pegasys and Copegus.
89451223|NCT02461862||Intra Uternine Device|Women who came to the medical service, to insert an intra uterine Device (IUD) of Cu or a Levonorgestrel Intra Uterine System( Lng- IUS) after have been attended in the Family Planning Service of Federal University of São Paulo . All patient have had the pain evaluated by Application of the Visual Analog Scale of Pain (VAS), and also their vital signs ( Evaluation of blood pressure,Evaluation of radial pulse) evaluated pre and five minutes after the IUD/ IUS insertion.
89451224|NCT02461940|No Intervention|Standard care|The control group will receive the standard care provided by the STI clinic.
89451225|NCT02461940|Active Comparator|Adolescent Behavioral intervention|Participants allocated to the intervention arm receive 4 on-site personalised counselling and 2 phone/online sessions over a 12-month period, targeting individual, relational, sociocultural and environmental factors pertaining to the acquisition of STI/HIV.
89451226|NCT00958971|Experimental|TKI258 - Positive|These are the participants who had a positive T(4;14) status
89451227|NCT00958971|Experimental|TKI258 - Negative|These are the participants who had a negative T(4;14) status
89451228|NCT00958971|Experimental|TKI258 Non-interpretable|These are the participants who had a non-interpretable T(4;14) status
89451229|NCT03294824||patients who reactivate CMV or AdV after allogeneic HSCT|allotransplanted patients who reactivated respectively CMV (n=30) and AdV (n=10)
89451230|NCT03294824||Control group: allogeneic HSC transplanted patients|allotransplanted patients who didn't reactivate CMV
89451231|NCT03294824||Healthy donors group|healthy donors serologically + for CMV
89451232|NCT05497414|Experimental|Sleep deprived|Overnight sleep deprivation
89451233|NCT05497414|No Intervention|Rested|Well-rested sleep pattern
89451234|NCT00835497|Experimental|Glipizide Metformin|Glipizide Metformin Hydrochloride 5/500 mg Tablet (test) dosed in first period followed by Metaglip® 5/500 mg Tablet (reference) dosed in second period
89451235|NCT00835497|Active Comparator|Metaglip®|Metaglip® 5/500 mg Tablet (reference) dosed in first period followed by Glipizide Metformin Hydrochloride 5/500 mg Tablet (test) dosed in second period
89451236|NCT00763503|Experimental|CD 2027|
89451237|NCT00761709|Experimental|AL-39256|AL-39256 Ophthalmic Suspension, 1%, 1 drop in the study eye(s) at 8 AM from the morning bottle and 1 drop in the study eye(s) at 8 PM from the evening bottle for 4 weeks.
89451238|NCT00761709|Active Comparator|XALATAN|Latanoprost Ophthalmic Solution, 0.005%, 1 drop in the study eye(s) at 8 PM from the evening bottle (morning bottle contained vehicle and was dosed 1 drop in the study eye(s) at 8 AM) for 4 weeks.
89451239|NCT00761709|Placebo Comparator|Vehicle|Inactive ingredients, 1 drop in the study eye(s) at 8 AM from the morning bottle and 1 drop in the study eye(s) at 8 PM from the evening bottle for 4 weeks.
89451240|NCT00760539|Experimental|Travoprost/Timolol BAC-free|Travoprost 0.004%/Timolol 0.5% BAC-free ophthalmic solution, 1 drop in each eye, once daily (QD) at 9 AM (±30 minutes), for 6 weeks
89451241|NCT00760539|Active Comparator|Travoprost/Timolol|Travoprost 0.004%/Timolol 0.5% ophthalmic solution, 1 drop in each eye, once daily (QD) at 9 AM (±30 minutes), for 6 weeks
89451242|NCT04976049||Orthopedic infection|Subjects who have undergone previous trauma surgeries and have developed an infection will be assessed for protocol inclusion criteria. Patients will be administered a single, oral, 20mg/kg dose of 5-Aminolevulinic Acid (ALA) by a qualified member of their care team. This dose will be administered ideally 3 hours prior to surgery. Fluorescent imaging will be obtained pre and post irrigation and debridement.
89451243|NCT00759135|Experimental|1|Single therapeutic dose of 2.5 mg NX-1207
88935742|NCT01782768|Experimental|Effect of different NPPV mode on NRD|13 hypercapnic recovering AECOPD patients were placed on different mode of noninvasive positive pressure ventilation(NPPV,such as the PAV or PSV mode) randomly.For each mode, three levels (PA-, PA, PA+or PS-, PS, PS+), ) of support were applied.PS and PA are set for the patient's comfort . On the basis of these two levels, 25% increase and reduction assisted level of pressure were set both for PS and PA (PA-, PA+or PS-, PS+). At each level, the patients were ventilated at least 20 minutes until the breathing was stable.
88935743|NCT01782781|Placebo Comparator|Group P|"Group P (Placebo) receives a local infiltration of saline in the operating field and ketorolac iv.~In Group P the injectant consists of saline, total volume 156 mL. This is infiltrated by the surgeon into the soft tissue of the vagina, tubosacral and rotundum ligaments, in the abdominal fascia and subcutaneous at the end of surgery. Ketorolac 30 mg (1 mL) is also injected iv."
88935744|NCT01782781|Active Comparator|Group A|"Group A (Active) receives a local infiltration of ropivacaine, ketorolac and epinephrine in the operating field and saline iv.~Drug: ropivacaine, ketorelac and epinephrine~In Group A the injectant mixture consists of ropivacaine 300 mg mixed with 30 mg ketorolac and 0.5 mg epinephrine, total volume 156 mL. This mixture is infiltrated by the surgeon into the soft tissue of the vagina, tubosacral and rotundum ligaments, in the abdominal fascia and subcutaneous at the end of surgery. One mL saline is also injected iv."
88935745|NCT01782794||Cohort A|Children aged 12-15 months at the time of the study. Measurements of Hepatitis B vaccination cover prior to InfanrixHexa reimbursement was obtained from this cohort.
88935746|NCT01782794||Cohort B|Children aged 24-27 months at the time of the study. Measurements of Hepatitis B vaccination cover prior to InfanrixHexa reimbursement was obtained from this cohort.
88935747|NCT01782807|No Intervention|Hysterectomy|Hysterectomy without oophorectomy or salpingectomy
88935748|NCT01782807|Experimental|Hysterctomy with salpingectomy or fimbriectomy|Salpingectomy or Fimbriectomy
88935749|NCT01782846|Active Comparator|Ixprim®|2 capsules of Ixprim® given orally (1000 mg Paracetamol + 75 mg Tramadol)
88935750|NCT01782846|Active Comparator|Dafalgan Codeine®|Two capsules of Dafalgan Codeine® given orally (1000 mg Paracetamol + 46.8 mg Codeine)
88935751|NCT01782911|Experimental|Resveratrol|Patients will be given 2 g of resveratrol a day from the onset of menses until ovarian pick-up.
89451244|NCT00759135|Experimental|2|Single low dose of 0.125 mg NX-1207 for dose-response evaluation
88935752|NCT01782911|Placebo Comparator|Control|Patients will be given pills lacking medication from the onset of menses until the ovum pick-up.
88935753|NCT01782924|Experimental|KHK4827 140mg SC|
88935754|NCT01782924|Experimental|KHK4827 210mg SC|
88935755|NCT01782937|Experimental|KHK4827|
88935756|NCT01782950|Other|anti-tuberculosis drugs|Rifampicin, Isoniazid, Ethambutol, Pyrazinamide tablets 3 to 5 tablets once daily for 2 months followed by Rifampicin, Isoniazid 3 to 5 tablets once daily for 4 months
88935757|NCT01782976|Experimental|Cilengitide + Bevacizumab|Cilengitide administered intravenously at 2000 mg twice weekly, while Bevacizumab administered intravenously at 10 mg/kg every other week. Each cycle of therapy will be 4 weeks long.
88935758|NCT01783002|Experimental|Primary hyperparathyroidism|Subjects with biochemical evidence, including elevated serum calcium and PTH levels, of primary hyperparathyroidism. All patients will undergo 11C-methionine PET/CT, SPECT-CT and 18F-FDG PET/CT scanning.
88935759|NCT01783028|Experimental|Community Health Worker support|home visits from community health workers providing education and support for self-management of asthma, assessment of the home for environmental triggers, resources for asthma control, and assistance in effective communication with medical providers
88935760|NCT01783028|No Intervention|the usual care control group|Usual care is defined as services received by participants in the absence of the intervention plus information about community resources that support asthma self-management (such as classes and support groups) and educational pamphlets
88935761|NCT01783067|Experimental|Iron and zinc biofortified pearl millet|Participants in the experimental arm consume pearl millet which has been biofortified with iron and zinc.
89451245|NCT00759135|Active Comparator|3|5.0 mg finasteride q.d.
89451246|NCT05439447||Patients scheduled for VFSS examination due to dysphagia.|
89451247|NCT04474041|Experimental|Visual Acuity with a Hand-held Device Supported by Mobile App.|The Insight will be compared to a standard ETDRS eyechart
89451248|NCT00835263|Experimental|Lamotrigine|Lamotrigine 200 mg Tablet (test) dosed in first period followed by Lamictal® 200 mg Tablet (reference) dosed in second period
89451249|NCT00835263|Active Comparator|Lamictal®|Lamictal® 200 mg Tablet (reference) dosed in first period followed by Lamotrigine 200 mg Tablet (test) dosed in second period
89451250|NCT04946019|Experimental|MR-Linac Guided Adaptive FSRT|Patients will receive FSRT (30Gy in 5 fractions) on the MR-Linac treatment machine.
89451251|NCT02639910|Experimental|Cohort A|tafasitamab (MOR208) in combination with idelalisib
89451252|NCT02639910|Experimental|Cohort B|tafasitamab (MOR208) in combination with venetoclax
89451253|NCT04892667|Other|Patients with lymphoma (Hodgkin's or non Hodgkin's)|
89451254|NCT00954057|Experimental|LIPO-102|Intraorbital Injection
88935762|NCT01783067|Active Comparator|Pearl millet|Participants in the control arm consume non-biofortified pearl millet.
88935763|NCT01783093||Sickle cell and pulmonary hypertension|
89200846|NCT00985348|Experimental|Treatment 2/Treatment 1|
88935764|NCT01783106|Active Comparator|budesonide|Oral Budesonide 9mg per day for 8 weeks followed by 6mg per day for 2 weeks and subsequent 3mg per day over a further 2 weeks
88935765|NCT01783106|Experimental|Ciprofloxacine, doxycycline and hydroxychloroquine|Oral Ciprofloxacin 500mg bd plus Doxycycline 100mg bd and Hydroxychloroquine 200mg tds followed by a further 20 weeks continued therapy with Doxycycline 100mg bd and Hydroxychloroquine 200mg tds
88935766|NCT01783119|Experimental|Aloe Vera|Consume 200 ml of aloe vera gel per day over a period of three months
88935767|NCT01783119|Placebo Comparator|water|Consume 200 ml of placebo per day over a period of three months
88935768|NCT01783132|Other|Budesonide|Asthma treated patient with Budesonide for 1 year, 4 different dosage according to measurement of exhaled NO done with NIOX MINO.
89200847|NCT00973336|Experimental|Calcium and vitamin D|Intervention
89200848|NCT00973336|No Intervention|No treatment (control)|
89200849|NCT00902109||perimetry, HRT, OCT|perimetry, HRT, OCT
89200850|NCT03991273|Experimental|Y-M2M©|a group-based M2M© program conducted onsite at a local YMCA
89200851|NCT03991273|Experimental|B-M2M©|a blended program that provides Y-M2M© and a home-based M2M© via videoconferencing
89200852|NCT00973414|Active Comparator|Prior crystalloid|Crystalloid (Ringer's Lactate) was given before CSEA
89200853|NCT00973414|Active Comparator|Posterior crystalloid|Crystalloid (Ringer's Lactate) was given after CSEA
89200854|NCT00973414|Active Comparator|Prior colloid|Colloid (6% hydroxyethyl starch) was given before CSEA
89200855|NCT00973414|Active Comparator|Posterior colloid|Colloid (6% hydroxyethyl starch) was given after CSEA
88935769|NCT01783132|No Intervention|Standard of care|Asthma treated patient with standard of care during 1 year. Exhaled NO measurement will be done 4 times/year, and compared afterwards with the Budesonide group.
88935770|NCT01783158||Diagnostic group|A total of 132 patients with HNSCC were enrolled in this study. The patients underwent esophagoscopy and chromoendoscopy. The most frequent primary tumors were oropharyngeal (49/132), tumors of the oral cavity (36/132) and larynx (35/132). The majority of subjects (107/132 patients, 81.1%) had advanced HNSCC carcinomas (stages III and IV). Multiple LVLs were discovered in 24 subjects (18.2%), and no LVLs in 108 (81.8%) subjects. Fifty-five LVL biopsy specimens were obtained and assessed. Squamous cell carcinomas were detected in two patients, peptic esophagitis in 11 patients, gastric heterotopic mucosa in two patients, hyperplasia in two patients, and low- and high-grade dysplasia in three patients.
88935771|NCT01783171|Experimental|Arm A (dinaciclib, Akt inhibitor MK2206)|"Patients receive dinaciclib IV over 2 hours on day 1 of course 1.~After day 1, all patients receive Akt inhibitor MK2206 PO on days 1, 8, and 15 and dinaciclib IV over 2 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
88935772|NCT01783171|Experimental|Arm B (Akt inhibitor MK2206, dinaciclib)|"Patients receive Akt inhibitor MK2206 PO on day 1 of course 1.~After day 1, all patients receive Akt inhibitor MK2206 PO on days 1, 8, and 15 and dinaciclib IV over 2 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
88935773|NCT01783210|Experimental|TLC(Therapeutic Lifestyle Changes) group|"Intervention: Specific Therapeutic Lifestyle Changes program in pregnancy. TLC Program includes a diet (with a specific amount of calories and macronutrients) and a mild physical activity."
89200856|NCT00902187|Other|Reference|fesoterodine (Toviaz™ 4 mg) tablet manufactured at Zwickau (Reference)
89200857|NCT00902187|Other|Test|fesoterodine (Toviaz™ 4 mg) tablet manufactured at Vega Baja (Test)
89200858|NCT01052233|Active Comparator|Arthroscopic partial meniscectomy|Arthroscopic partial resection of degenerative tear of medial meniscus
89200859|NCT01052233|Sham Comparator|Arthroscopy (diagnostic)|Diagnostic arthroscopy of the knee
89200860|NCT00902343|Experimental|1|nomogram-based selection for acute normovolemic hemodilution
89200861|NCT00902343|Active Comparator|2|standard selection for ANH based on a planned resection of 3 or more segments.
89200862|NCT01052311|Placebo Comparator|Placebo|Placebo pills once daily
89200863|NCT01052311|Active Comparator|Active treatment|Laropiprant (LRP; Merck & Co., Inc, Whitehouse Station, NJ, USA) is a potent, once-daily, highly selective PGD2-receptor (DP1) antagonist. A combination tablet containing 1 g of extended-release niacin and 20 mg of laropiprant (ERN/LRPT) = tredaptive once daily from day 1 to 30. From day 31 to day 90 2 g of extended-release niacin and 20 mg of laropiprant once daily.
89200864|NCT00988078|Experimental|Metformin|Metformin 500mg three times a day for six months
89200865|NCT00988078|Placebo Comparator|Placebo|1 capsule three times a day for six months
89200866|NCT00895089|Experimental|A: Moxifloxacin|Moxifloxacin 400mg IV once daily for 14 days, then 400mg PO once daily for 7 days.
89200867|NCT00895089|Active Comparator|B: Ceftriaxone|Ceftriaxone 2gm IV every 12 hours for 14 days, then cephalexin 1gm PO every 6 hours for 7 days.
89200868|NCT01049191||Fracture|Subjects experiencing a prior osteoporotic fracture.
89200869|NCT01049191||Control|These will be age and bone density matched controls to the fracture group.
89200870|NCT00982540|No Intervention|preemptive|Patients with persistent fever and neutropenia despite appropriate antibacterial therapy
89200871|NCT01049269||1:one group|
89200872|NCT04674358|Experimental|Reproxalap Ophthalmic Solution (0.25%) administered QID over two consecutive days.|
89200873|NCT04674358|Placebo Comparator|Vehicle Ophthalmic Solution administered over two consecutive days.|
89451255|NCT00954057|Placebo Comparator|Placebo|Intraorbital Injection
89451256|NCT00951405|Experimental|A|
89451257|NCT00951405|Experimental|B|
89451258|NCT00951405|Experimental|C|
89451259|NCT05397990|Experimental|Exercise|12 weeks exercise intervention. 3 times a week, 45 minutes per session, 30 minutes of exercise.
88935774|NCT01783210|Other|Control group|"Intervention: Dietary and behavioral counselling in pregnancy. The Control group receives only a simple nutritional booklet about a lifestyle and healthy diet during pregnancy without explicit caloric restriction, in accordance with Italian Guidelines for a healthy diet during pregnancy, compatible with a recommended nutritional intake."
88935775|NCT01783249|No Intervention|Control|Usual care monitoring
88935776|NCT01783249|Other|Exercise using stationary cycling|Stationary cycling exercise program
88935777|NCT01783262|Active Comparator|Extracorporeal shock wave therapy|an energy level of 0.09 mJ/mm2, 2400 pulses once a week for 4 weeks.
88935778|NCT01783262|Placebo Comparator|sham extracorporeal shock wave therapy|The second grouop of patients received 0.04 mJ/mm2, 2400 pulses once a week for 4 weeks.
88935779|NCT01783275|Experimental|Aerobic Exercise|12 weeks of aerobic exercise
88935780|NCT01783275|No Intervention|Control|12 weeks with no change in diet or exercise habits (weight maintenance).
88935781|NCT01783301|Active Comparator|Antral follicle count|"Start dose of recombinant Follicle-Stimulating Hormone (rFSH) based on AFC guide~AFC < 6 on both ovary: 375 IU FSH~6<AFC <=15 on both ovary: 225 IU FSH~AFC> 15 on both ovary: 150 IU FSH"
88935782|NCT01783301|Active Comparator|Anti-Mullerian Hormone|"Start dose of FSH based on AMH guide~AMH < 5 pmol/L or < 0.7ng/ml: 375 IU FSH~AMH 5 to < 15 pmol/L or 0.7 to 2.1ng/ml: 225 IU FSH~AMH ≥ 15 pmol/L or > 2.1ng/ml: 150 IU FSH"
88935783|NCT01783314|Active Comparator|Normal liver function|Control group. Subjects will obtain MRI of liver.
88935784|NCT01783314|Experimental|Hepatitis C|Subjects with hepatitis C. Subjects will obtain both MRI of liver and limited CT of liver.
88935785|NCT01783327|Experimental|Teens-Connect|The Teens-Connect Program is an internet-based program that combines Managing Diabetes and TEENCOPE.
88935786|NCT01783327|Active Comparator|Planet D|Planet D is an internet program developed by the American Diabetes Association for children and adolescents with diabetes.
88935787|NCT01783340|Active Comparator|CQ and falciparum immunization|"This arm will receive chloroquine prophylaxis, a placebo during immunizations and three times 5 infected mosquito-bites (immunizations). Standard Chloroquine prophylactic regime: a loading dose of 300 mg on day 1 and day 3 and then 300 mg once a week, starting on day 7, for a total duration of 13 weeks.~Placebo capsules daily on three consecutive days starting on each of three immunization days.~Challenge: Exposure to the bites of 5 Plasmodium falciparum infected mosquitoes.~When thick smear positive, of at day 21 after challenge, a standard 3 day treatment of Malarone will be given."
88935788|NCT01783340|Experimental|CQ/AZM and falciparum immunization|"This arm will receive chloroquine and azithromycin prophylaxis and three times 5 infected mosquito-bites (immunizations).~Standard Chloroquine prophylactic regime: a loading dose of 300 mg on day 1 and day 3 and then 300 mg once a week, starting on day 7, for a total duration of 13 weeks.~Azithromycin capsules 1000mg daily on three consecutive days starting on each of three immunization days.~Challenge: Exposure to the bites of 5 Plasmodium falciparum infected mosquitoes.~When thick smear positive, of at day 21 after challenge, a standard 3 day treatment of Malarone will be given."
89200874|NCT00366535|Active Comparator|Placebo first, then Neurotropin (G-1)|Double blind cross-over study: receive Placebo for 12 weeks and then Neurotropin for 12 weeks (after at least 1 week washout period). Assignment to each group was in random order, selected by the pharmacy with all others blind.
89451260|NCT05397990|No Intervention|Control|Continue with habitual routine. Take part in weekly online socials with others in the control group.
89451261|NCT04454502|Experimental|Experimental|"In the first stage of data collection, the information in the Mother-Preterm Introductory Information Form study and control groups before colostrum administration, and the information in Preterm Follow-up Form including questions related to physiological parameters, body measurements and nutrition will be obtained. In the second stage, oral colostrum, will be administered once every 3 hours and for at least 5 days until the newborn begins oral feeding. In accordance with the oral colostrum protocol, a total of 0.2ml colostrum will be administered in approximately 1 minute for infants weighing between 1001-1500 g. The third stage, the effectiveness of the first breastfeeding will be evaluated by the observers in experimental group using the Bristol Breastfeeding Assessment Tool. In the last stage, one week after the first breastfeeding sucking / breastfeeding experience will be evaluated again."
89451262|NCT04454502|No Intervention|Control Groups|The infants in the control group will be followed up by oral care with sterile physiological saline in routine care of the service
89451263|NCT00950937||HIV Group|HIV infected persons
89451264|NCT00950937||Control Group|Non HIV-infected persons
89451265|NCT04454580||treated patients|hypomethylating agent (azacitidine or decitabine) in combination with venetoclax
89451266|NCT05389878||Stroke group|Patients with stroke addressing intensive inpatient rehabilitation, including and treatment, delivered according to an Individual Rehabilitation Project (IRP), defined according AHA ASA Stroke rehabilitation Guidelines (2016. The IRP was defined by an interdisciplinary team, coordinated by a physiatrist and designed according to patients' and caregivers' needs. The team included internists, physiotherapists, occupational therapists, nurses, speech therapists, and psychologists. The assessment protocol aimed to provide a reliable and synthetic assessment of patients' clinical conditions and function at admission and discharge. Each patient received at least three hours of specific rehabilitation per day. All patients received clinical observation and management, nurse management, physiotherapy. Speech, neuropsychological, and occupational therapy treatment were prescribed by physiatrist.
89451267|NCT00948909|Placebo Comparator|A. Sugar Pill|
89451268|NCT00948909|Experimental|B. ABT-126|
89451269|NCT00948909|Experimental|C. ABT-126|
89451270|NCT00948909|Active Comparator|D. donepezil|
89451271|NCT03735576|Experimental|LLD-adapted cognitive behavioural therapy (CBT)|manualized 15-session individually-delivered cognitive behavioural therapy (CBT) specific for late life depression (LLD)
89015013|NCT02282358|Experimental|Mocetinostat|Patients who harbor mutations for CREBBP and/or EP300 will be started on mocetinostat 70 mg orally three times per week on a 28 day schedule in cycle 1. The dose will be escalated in cycle 2 to 90 mg orally three times per week on a 28 day schedule if there are no grade 3 or higher drug related toxicities. Therapy will continue until disease progression, intolerable toxicities or death.
89015014|NCT02281747||affected with arthritis|arthritis may be either rheumatoid, osteoarthritis, or ankylosing spondylitis
89015015|NCT02281747||unaffected with arthritis|in some analyses, the comparison is by arthritis status. in other analyses, it is within arthritis status by clinically relevant subgroups.
89015016|NCT02279550||hip fracture|aged >65 with hip fracture
89015017|NCT02262325|Experimental|Treatment (hypofractionated radiation boost, chemoradiation)|Patients undergo hypofractionated radiation boost over 2 fractions (at least 40 hours apart) during week 1. Beginning week 2, patients receive cisplatin IV on days 8, 15, 36, and 43; and etoposide IV over 60 minutes on days 8-12 and 36-40. Patients also undergo standard 3-D conformal radiation therapy QD 5 days a week for a total of 30 fractions. Treatment continues for 6 weeks in the absence of disease progression or unacceptable toxicity.
89015018|NCT02248259|Experimental|Extensive Metabolisers: Ref / Test|"Participants who were extensive metabolisers received two treatments in a randomised order, the treatments were:~Reference (ref) treatment (1 single tablet of 25 mg BI 409306 taken orally on day 1).~Test treatment (2 capsules of 100 mg itraconazole taken orally twice daily on day -3 (loading dose) and once daily on day -2 to day 2, plus 1 tablet of 25 mg BI 409306 taken orally as a single dose 1 hour after the itraconazole administration on day 1."
89015019|NCT02248259|Experimental|Poor Metabolisers: Ref / Test|"Participants who were poor metabolisers received two treatments in a randomised order, the treatments were:~Reference (ref) treatment (1 single tablet of 25 mg BI 409306 taken orally on day 1).~Test treatment (2 capsules of 100 mg itraconazole taken orally twice daily on day -3 (loading dose) and once daily on day -2 to day 2, plus 1 tablet of 25 mg BI 409306 taken orally as a single dose 1 hour after the itraconazole administration on day 1."
89451272|NCT03735576|Active Comparator|supportive unspecific intervention (SUI)|manualized 15-session individually-delivered supportive unspecific intervention (SUI)
89451273|NCT04419090|Experimental|Monogenic positive FH, direct contact|
89015020|NCT02248259|Experimental|Extensive Metabolisers: Test / Ref|"Participants who were extensive metabolisers received two treatments in a randomised order, the treatments were:~Test treatment (2 capsules of 100 mg itraconazole taken orally twice daily on day -3 (loading dose) and once daily on day -2 to day 2, plus 1 tablet of 25 mg BI 409306 taken orally as a single dose 1 hour after the itraconazole administration on day 1.~Reference (ref) treatment (1 single tablet of 25 mg BI 409306 taken orally on day 1)."
89015021|NCT02248259|Experimental|Poor Metabolisers: Test / Ref|"Participants who were poor metabolisers received two treatments in a randomised order, the treatments were:~Test treatment (2 capsules of 100 mg itraconazole taken orally twice daily on day -3 (loading dose) and once daily on day -2 to day 2, plus 1 tablet of 25 mg BI 409306 taken orally as a single dose 1 hour after the itraconazole administration on day 1.~Reference (ref) treatment (1 single tablet of 25 mg BI 409306 taken orally on day 1)."
89451274|NCT04419090|No Intervention|Monogenic positive FH, usual care|
89451275|NCT04419090|Experimental|Monogenic negative FH, direct contact|
89451276|NCT04419090|No Intervention|Monogenic negative FH, usual care|
89451277|NCT02522910|Experimental|Roniciclib with Docetaxel|
89451278|NCT00948753|Experimental|Phase 1: 150mg Maraviroc|150mg twice daily
89451279|NCT00948753|Experimental|Phase 1: 300mg Maraviroc|300mg twice daily
89451280|NCT00948753|Experimental|Phase 2: 300mg Maraviroc|300mg twice daily
89451281|NCT05397834|Experimental|Test|Fluticasone Propionate 250 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals
89451282|NCT05397834|Active Comparator|Reference|FLOVENT DISKUS® 250 mcg/Blister Oral Inhalation Powder /GSK
89451283|NCT03991650||Control|"n=30 healthy participants will be recruited using social networks and leaflets of information distributed by the research team at the Hospital Cliníc de Barcelona.~The participants will be monitored over the course of one month using the humanITcare app U-Shine, which will track participant's sociability, device usage, and location frequency using mobile sensors. Participants' data will also be monitored with a FitBit device to track sleep schedules, heart rate, and step count. During the weekly follow-up, they will have to complete the three clinical questionnaires taken at the initial visit."
89451284|NCT03991650||Experimental|"The recruitment process will be carried out in patients of external consultations and the day hospital of the Addictions Unit at the Hospital Clinic of Barcelona.~n=30 patients with Anxiety and Alcohol Use Disorder.~The participants will be monitored over the course of one month using the humanITcare app U-Shine, which will track participant's sociability, device usage, and location frequency using mobile sensors. Participants will also be monitored using a FitBit device to track sleep schedules, heart rate, and step count. During the weekly follow-up, they will have to complete the three clinical questionnaires taken at the initial visit."
89451285|NCT03134547|Active Comparator|low volume volatile anesthetics|1.0 % sevoflurane sedation via face mask , low dose sevoflurane group
89451286|NCT03134547|Active Comparator|high volume volatile anesthetics|2.5 % sevoflurane sedation via face mask, high dose sevoflurane group
89451287|NCT02522676|Active Comparator|Conventional PCNL|Endoscopic kidney stone surgery: Patients will undergo conventional percutaneous nephrolithotripsy.
89451288|NCT02522676|Active Comparator|Mini PCNL|Endoscopic kidney stone surgery: Patients will undergo mini percutaneous nephrolithotripsy.
89451289|NCT02522676|Active Comparator|Ultra-mini PCNL|Endoscopic kidney stone surgery: Patients will undergo ultra-mini percutaneous nephrolithotripsy.
89451290|NCT02522676|Active Comparator|Micro PCNL|Endoscopic kidney stone surgery: Patients will undergo micro percutaneous nephrolithotripsy.
89451291|NCT02522676|Active Comparator|Retrograde intrarenal surgery|Endoscopic kidney stone surgery: Patients will undergo retrograde intrarenal surgery.
89451292|NCT02522676|Active Comparator|Extracorporeal shock wave lithotripsy|Non-invasive kidney stone treatment: Patients will undergo extracorporeal shock wave lithotripsy.
88935789|NCT01783340|Placebo Comparator|CQ and AZM control|"This arm will receive chloroquine and azithromycin prophylaxis and three times 5 uninfected mosquito-bites during immunization. Standard Chloroquine prophylactic regime: a loading dose of 300 mg on day 1 and day 3 and then 300 mg once a week, starting on day 7, for a total duration of 13 weeks.~Azithromycin capsules 1000mg daily on three consecutive days starting on each of three immunization days.~Challenge: Exposure to the bites of 5 Plasmodium falciparum infected mosquitoes.~When thick smear positive, of at day 21 after challenge, a standard 3 day treatment of Malarone will be given."
89200875|NCT00366535|Active Comparator|Neurotropin first, then Placebo (G-2)|Double blind cross-over study: receive Neurotropin for 12 weeks and then Placebo for 12 weeks (after at least 1 week washout period). Assignment to each group was in random order, selected by the pharmacy with all others
88935790|NCT01783353|Placebo Comparator|Corn starch pill|Two (2) corn starch pills will be taken three (3) times a day for 60 days.
89200876|NCT02540733||Diabetic stroke|
89200877|NCT02540733||Non-diabetic storke|
89200878|NCT00982618|Experimental|LIDOCAINE group|LIDOCAINE group : Beside general anesthesia, patients will receive intravenous lidocaine bolus 1.5 mg/kg just prior induction and an infusion of lidocaine 2mg/kg/h will be started and maintained during the whole surgical procedure. Entering the recovery room, this infusion will be decreased at the rate of 1mg/kg/hour for the 48 first hours
89200879|NCT00982618|Experimental|Epidural Group|Epidural Group: Beside general anesthesia, patient will receive epidural freezing medication for 48 hours.
89200880|NCT00982618|Active Comparator|PCA group|Beside general anesthesia, the patients will receive neither lidocaine nor epidural catheter. The patients will receive the same analgesia protocol consisting of PCA morphine for a total duration of 48 hours.
89200881|NCT00895167|Experimental|curcumin|every subject receives 12 g of oral curcumin
89200882|NCT00988234|Experimental|SGPP|ultrasound guided posterior lumbar plexus block and subgluteal sciatic nerve block under prone position
89200883|NCT00988234|Experimental|SGTPP|ultrasound guided posterior lumbar plexus block and sub-greater trochanter approach under prone position
89200884|NCT00988234|Experimental|SGLP|ultrasound guided posterior lumbar plexus block and subgluteal sciatic nerve block under lateral decubitus position
89200885|NCT00988234|Experimental|SGTLP|ultrasound guided posterior lumbar plexus block and sub-greater trochanter approach under lateral decubitus position
89200886|NCT00902421|Active Comparator|Antimuscarinics|
89200887|NCT00902421|Experimental|Selective serotonin reuptake inhibitors|Selective serotonin reuptake inhibitor
89200888|NCT00985660|Experimental|Test:|Nisoldipine ER Tablets, 30 mg
89200889|NCT00985660|Active Comparator|Reference|Sular Extended-release Tablets, 30 mg
89200890|NCT00902499||NC|Normal older controls, not cognitively impaired; MMSE 27-30 and performance above education adjusted cutoff scores on the Logical Memory II subscale (LM-II Delayed Paragraph Recall) of the Wechsler Memory Scale
89200891|NCT00902499||vMCI|Very mild cognitive impairment; less severe objective memory deficit, scoring .5 to 1.5 S.D. (standard deviation) below education adjusted norms on the LM-II
89200892|NCT00902499||sMCI|significant mild cognitive impairment; objective cut off of 1.5 S.D. level below education adjusted norms on the LM-II
89451293|NCT05397756|Experimental|group (OT+)|In this group (OT +), during the whole training day, the observers will use an observer tool (based on non-technical skills) when they will be not role role-playing
89451294|NCT05397756|No Intervention|group (OT-)|In this group (OT-), the resident will not be given the observer tool and will observe other residents without any physical support.
89451295|NCT01963208|Experimental|Double Blind - Cohort 1 - Ganaxolone|1200 mg/day and 1800 mg/day + AED
89200893|NCT00902499||AD|Mild Alzheimer's disease; meet NINCDS/ADRDA criteria for probable AD with mild dementia severity (CDR Total = 1), MMSE 20-26
89451296|NCT01963208|Placebo Comparator|Double Blind - Cohort 1 - Placebo|Placebo + AED
89451297|NCT01963208|Experimental|Open Label - Ganaxolone in Double-blind phase|1800 mg/day + AED
89451298|NCT01963208|Experimental|Double Blind - Cohort 2 - Ganaxolone|1800 mg/day + AED
88935791|NCT01783353|Experimental|Zinc gluconate|Two (2) zinc gluconate 50 mg capsules will be taken three (3) times a day for 60 days.
88935792|NCT01783366|No Intervention|CONTROL|In the control group (Group A) inserting the lubricated NG tube through the nostril, at that time head maintained in the neutral position.
88935793|NCT01783366|Active Comparator|tube-exchanger|The tube-exchanger group (Group B) made use of tube-exchanger G36402 (CAEC, [cook medical, Bloomington, IN]) as a stylet that was lubricated and inserted within 20-F NGT until the tip of the tube-exchanger was at the tip of the NGT
89451299|NCT01963208|Placebo Comparator|Double Blind - Cohort 2 - Placebo|Placebo +AED
89451300|NCT01963208|Experimental|Open Label - Placebo in Double-blind phase|1800 mg/day + AED
89451301|NCT00834873|Experimental|Carvedilol|Carvedilol 25 mg Tablet (test) dosed in first period followed by Coreg® 25 mg Tablet (reference) dosed in second period
89451302|NCT00834873|Active Comparator|Coreg®|Coreg® 25 mg Tablet (reference) dosed in first period followed by Carvedilol 25 mg Tablet (test) dosed in second period
89451303|NCT03294746|Other|Clinical evaluations and Thoracic CT scan scoring of DIILD|
89537128|NCT03378219||Cohort 2|Disease-matched Comparison Cohort: Pregnant women diagnosed with Kevzara (sarilumab) approved indication. Approximate frequency matched to the exposed group by disease indication, validated by medical records, who have not been exposed to Kevzara (sarilumab) any time in the current pregnancy, and have taken another biologic DMARD medication for their disease within 2 years before the current pregnancy and have an indication for such treatment at enrollment
88935794|NCT01783379||ICU patient on micafungin|ICU patients with an invasive fungal infection on micafungin treatment
88935795|NCT01783392|Active Comparator|Unilateral Posterior Tibial Nerve Stimulation|Transcutaneous posterior tibial nerve stimulation applied 40 minutes every day for a duration of 4 weeks. The patient places the cathode electrode above, and the anode electrode behind, the medial malleolus, over the posterior tibial nerve and sets the stimulation intensity to a comfortable level.
88935796|NCT01783392|Active Comparator|Bilateral Posterior Tibial Nerve Stimulation|Transcutaneous posterior tibial nerve stimulation applied 40 minutes every day for a duration of 4 weeks. The patient places the cathode electrode above, and the anode electrode behind, the medial malleolus, over the posterior tibial nerve on both legs and sets the stimulation intensity to a comfortable level.
88935797|NCT01783392|Active Comparator|Shoulder stimulation|Stimulation applied 40 minutes every day for a duration of 4 weeks. The patient places the cathode and the anode electrodes on the lateral side of the left shoulder.
88935798|NCT01783405||Cases|FH heterozygous
88935799|NCT01783405||Controls|Parents of FH heterozygotes with FH
88935800|NCT01783431|Experimental|Leukapheresis and Poly-ICLC|Screening tests will be conducted to determine whether or not subjects can participate in this study. If subjects are eligible and choose to participate, they will have a procedure called leukapheresis. The leukapheresis product that is collected from you will be taken to a special lab at MUSC where it will undergo a process that will grow additional dendritic cells under controlled conditions in the lab. These cells will be given together with Poly-ICLC therapy when you begin study treatment. Some days you will receive both Poly-ICLC and dendritic cells, but on other days you will receive the Poly-ICLC by itself. After study treatment, subjects may be asked to return to MUSC approximately every 3 months for the first 2 years, then every 6 months thereafter for follow up procedures.
88935801|NCT01783457|Experimental|Individual psychoeducation|Usual treatment + individual psychoeducational intervention (14 sessions). The psychoeducational programme consists of 14 sessions of 60 minutes every other week for six months, focused on improving patient awareness of their condition, adherence to treatment, identification of prodromes, early intervention in potential relapses, anxiety management techniques, social skills, healthy lifestyle habits and problem solving.
88935802|NCT01783457|Active Comparator|Control|Usual treatment
88935803|NCT01783600|Other|NanoCross .014 balloon catheter|NanoCross .014 balloon catheter
88935804|NCT01783613|Experimental|Docosahexaenoic acid administration|50 patients will receive docosahexaenoic acid
88935805|NCT01783613|Placebo Comparator|placebo|50 patients will receive placebo
88935806|NCT01783626|Sham Comparator|Evodial|Period I: HDF post dilution Total Volume 8 liters : 1 HD session (2nd HD of the week) Period II: HDF post dilution Total Volume 20 liters : 1 HD session (2nd HD of the week)
88935807|NCT01783626|Experimental|Evodial+ Condition B1|Period I: HDF post dilution Total Volume 8 liters : 1 HD session (2nd HD of the week) Period II: HDF post dilution Total Volume 20 liters : 1 HD session (2nd HD of the week)
88935808|NCT01783626|Experimental|Evodial+ Condition B2|Period I: HDF post dilution Total Volume 8 liters : 1 HD session (2nd HD of the week) Period II: HDF post dilution Total Volume 20 liters : 1 HD session (2nd HD of the week)
88935809|NCT01783626|Experimental|Evodial+ Condition C|Period I: HDF post dilution Total Volume 8 liters : 1 HD session (2nd HD of the week) Period II: HDF post dilution Total Volume 20 liters : 1 HD session (2nd HD of the week)
88935810|NCT01783665|Experimental|Aerobic Exercise|3x/week supervised moderate intensity aerobic exercise on recumbent stepper
88935811|NCT01783665|Active Comparator|Home exercise program|Walking and stretching exercises performed 3x/week for 30 minutes at intensity considered non-aerobic
88935812|NCT01783691|Experimental|NKTT120|
88935813|NCT01783717|Experimental|Exenatide|5mcg twice a day for 4 weeks increased to 10 mcg twice a day for 8 weeks
88935814|NCT01783756|Experimental|Treatment (lapatinib ditosylate, everolimus, capecitabine)|Patients receive lapatinib ditosylate PO QD and everolimus PO QD on days 1-21, and capecitabine PO BID on days 1-14. Treatment repeats every 21 days for 17 courses in the absence of disease progression or unacceptable toxicity.
88935815|NCT01783769|No Intervention|Normal O.R. Traffic|"This Normal O.R. Traffic protocol follows the national standards of care."
88935816|NCT01783769|Active Comparator|"Low O.R. Traffic"|"This protocol will restrict personnel movement thru the operating room to a bare minimum of personnel traffic."
88935817|NCT01783782|Experimental|DIET|Group A followed the standard regime consisting of a clear liquid diet for 12 hours on the day before CE, followed by an overnight fast.
88935818|NCT01783782|Experimental|HIGH PEG|Group B received a high volume regime consisting of a 50 mL/Kg (up to 2 Lt/die) of polyethylene glycol 4000 solution with simethicon solution the evening before the examination, followed always by an overnight fast.
88935819|NCT01783782|Experimental|LOW PEG|Group C, defined as a low volume regime, received 25 mL/Kg (up to 1Lt/die) of polyethylene glycol 4000 solution with simethicon solution the evening before the examination, followed by an overnight fast.
88935820|NCT01783782|Experimental|SIMETHICONE|Group D received 20 mL oral simethicone (Panamir, DMG, Italy, containing 40 mg simethicone in 1mL emulsion) and 200mL water 30 minutes before capsule ingestion.
88935821|NCT01783782|Experimental|SIMETH+PEG|Group E received 25 mL/Kg (up to 1 Lt/die) of polyethylene glycol 4000 solution with simethicon solution followed by an overnight fast plus 20mL oral simethicone and 200mL water 30 minutes before capsule ingestion.
88935822|NCT01783795|Other|Genetic Analysis|Genetic Analysis
88935823|NCT01783834|Active Comparator|pemetrexed|pemetrexed
88935824|NCT01783834|Active Comparator|gefitinib|gefitinib
89451304|NCT01377480|Experimental|Posaconazole|Posaconazole (POS) 400 mg (10 mL) oral suspension twice daily for 60 days
89451305|NCT01377480|Placebo Comparator|Placebo|Posaconazole placebo (10 mL) oral suspension twice daily for 60 days
89451306|NCT01377480|Experimental|Posaconazole + Benznidazole|Posaconazole 400 mg (10 mL) oral suspension twice daily for 60 days and benznidazole (BNZ) 100 mg oral tablet twice daily (200-mg daily dose) for 60 days
89451307|NCT01377480|Active Comparator|Benznidazole + Placebo|Posaconazole placebo (10 mL) oral suspension twice daily for 60 days and benznidazole 100 mg oral tablet twice daily (200-mg daily dose) for 60 days
89451308|NCT04263909|Experimental|sufentanil SL arm|Each patient will receive 30mcg of sufentanil SL prior to extubation in the operating room, and then as needed in the recovery room, guided by pain scores.
89451309|NCT04488848|Placebo Comparator|continous glucose|continous glucose infusion (60 grams over 3 hours)
88935825|NCT01783873|Placebo Comparator|Placebo|
88935826|NCT01783873|Active Comparator|flour allergen extract or quaternary ammonium compound|
88935827|NCT01783899|Experimental|Hemospray Group|"Hemospray device consists of a syringe containing the Hemospray powder (21 g per syringe), a delivery catheter that will be inserted into the working channel of the endoscope, and an introducer handle with a built-in carbon dioxide canister to propel the Hemospray powder out of the catheter.~In addition to Hemospray device any other required endoscopic accessories can be used during the procedure."
88935828|NCT01783951|Experimental|DC-CIK plus S-1 based chemotherapy|Patients will be receive S-1 based chemotherapy, including S-1 plus cisplatin or S-1 alone. Meanwhile those patients will receive DC-CIK cell therapy at days 15, 17 and 19 per cycle and received cycles of treatment once every 21 days.Treatment was continued until disease progression, unacceptable toxic effects, or the withdrawal of consent.
88935829|NCT01783951|Active Comparator|S-1 based chemotherapy|Patients will be receive S-1 based chemotherapy, including S-1 plus cisplatin or S-1 alone.Cycles were repeated every 21 days. Treatment was continued until disease progression, unacceptable toxic effects, or the withdrawal of consent.
88935830|NCT01783964|Experimental|[14C]-Elacytarabine Microdose|intravenous (IV) administration of one dose of elacytarabine
88935831|NCT01783977|Experimental|Part A: Group 1: Treatment|Participants will receive the DNA-HIV-PT123 vaccine administered as 1 mL intramuscularly (IM) in the same deltoid at Days 0, 14, and 28.
88935832|NCT01783977|Experimental|Part B: Group 2: Treatment|Participants will receive the DNA-HIV-PT123 vaccine administered as 1 mL IM in the same deltoid at Days 0, 14, and 28. They will then receive the NYVAC-HIV-PT1 vaccine and the NYVAC-HIV-PT4 vaccine; each will be administered as 1 mL IM in the same deltoid (opposite deltoid to where the DNA-HIV-PT123 injection was given) at Day 84.
88935833|NCT01783977|Placebo Comparator|Part B: Group 2: Placebo|Participants will receive the placebo vaccine for DNA-HIV-PT123 administered as 1 mL IM in the same deltoid at Days 0, 14, and 28. They will then receive the placebo vaccine for NYVAC-HIV-PT1 and the placebo vaccine for NYVAC-HIV-PT4; each will be administered as 1 mL IM in the same deltoid (opposite deltoid to where the placebo for DNA-HIV-PT123 injection was given) at Day 84.
88935834|NCT01783977|Experimental|Part B: Group 3: Treatment|Participants will receive the DNA-HIV-PT123 vaccine administered as 1 mL IM in the same deltoid at Days 0 and 28. They will then receive the NYVAC-HIV-PT1 vaccine and the NYVAC-HIV-PT4 vaccine; each will be administered as 1 mL IM in the same deltoid (opposite deltoid to where the DNA-HIV-PT123 injection was given) at Day 84.
88935835|NCT01783977|Placebo Comparator|Part B: Group 3: Placebo|Participants will receive the placebo vaccine for DNA-HIV-PT123 administered as 1 mL IM in the same deltoid at Days 0 and 28. They will then receive the placebo vaccine for NYVAC-HIV-PT1 and the placebo vaccine for NYVAC-HIV-PT4; each will be administered as 1 mL IM in the same deltoid (opposite deltoid to where the placebo for DNA-HIV-PT123 injection was given) at Day 84.
88935836|NCT01783977|Experimental|Part B: Group 4: Treatment|Participants will receive the DNA-HIV-PT123 vaccine administered as 1 mL IM in the same deltoid at Days 0, 28, and 56. They will then receive the NYVAC-HIV-PT1 vaccine and the NYVAC-HIV-PT4 vaccine; each will be administered as 1 mL IM in the same deltoid (opposite deltoid to where the DNA-HIV-PT123 injection was given) at Day 140.
88935837|NCT01783977|Placebo Comparator|Part B: Group 4: Placebo|Participants will receive the placebo vaccine for DNA-HIV-PT123 administered as 1 mL IM in the same deltoid at Days 0, 28, and 56. They will then receive the placebo vaccine for NYVAC-HIV-PT1 and the placebo vaccine for NYVAC-HIV-PT4; each will be administered as 1 mL IM in the same deltoid (opposite deltoid to where the placebo for DNA-HIV-PT123 injection was given) at Day 140.
88935838|NCT01784003||Non-amputee|People without an amputation will be recruited to participate in the study.
88935839|NCT01784003||Below the knee amputee|People with a unilateral transtibial amputation will be recruited to participate in the study.
88935840|NCT01784016|Experimental|Healthy Smokers|Healthy smokers aged 18-50 years reporting average cigarette consumption of 15 or more cigarettes/day for the past year, providing an expired breath carbon monoxide reading exceeding 10 ppm at screening.
88935841|NCT01784016|Experimental|Healthy Nonsmokers|Healthy nonsmoking controls aged 18-50 reporting consumption of <100 cigarettes in their lifetime, none in the last 6 months, providing an exhaled breath carbon monoxide reading of < 9 ppm at screening.
88935842|NCT01784042|Placebo Comparator|No dietary energy restriction plus Placebo|No dietary energy restriction plus Placebo
88935843|NCT01784042|Placebo Comparator|Dietary energy restriction plus placebo|Dietary energy restriction plus placebo
88935844|NCT01784042|Experimental|Lovaza|Lovaza only
88935845|NCT01784042|Experimental|Dietary energy restriction plus Lovaza|Dietary energy restriction plus Lovaza
88935846|NCT01784081||palliative care with iPC3|Palliative care with decision aids will be administered at each palliative care visit.
89451310|NCT04488848|Experimental|bolus (excursion)|3 x 20 grams of glucose as a bolus over 6 minutes at t0, 60 minutes and 120 minutes
89451311|NCT00754455|Experimental|Low dose|
89451312|NCT00754455|Experimental|Mid dose|
89451313|NCT00754455|Experimental|High dose|
89451314|NCT00754455|Placebo Comparator|Placebo|
89451315|NCT01421264|Experimental|Gabapentin|
89531368|NCT05041179|Active Comparator|2.4 g of actives (1.2 g NAC and 1.2 g glycine) per day split in two doses (arm C)|"First dose (0.6 g NAC and 0.6 g glycine, +2.4 g placebo) consumed in the morning~Second dose (0.6 g NAC and 0.6 g glycine, +2.4 g placebo) taken in the evening"
89451316|NCT05397522|Experimental|Experimental group 1: Supervised Exercise by a physiotherapist via face to face|Participants in this group will be included in an exercise program for 6 weeks, 2 days a week and 45 minutes each session with supervised by a physiotherapist via face to face. The exercises will focus on breathing exercises, passive range of motion exercises within the pain limit for the joints associated with the surgery area, and strengthening exercises for the non-surgical areas.
89015024|NCT02193425|Experimental|PET FDG &amp; MRI Scans|The test-retest reproducibility of the gender and aging effects on FC measures (lFCD, C, L and S) acquired in RS and TS conditions.
89015025|NCT02156895||Patients who are using Axitinib|
89015026|NCT02128906|Active Comparator|Cisplatin-IMRT|Cisplatin 40 mg/m2 weekly x 7; IMRT: once daily, M-F, 7 weeks (70 Gy)
89015027|NCT02128906|Active Comparator|Docetaxel-Cetuximab-IMRT|Docetaxel 15 mg/m2 weekly x 7; Cetuximab 400 mg/m2 load, one week prior to IMRT; Cetuximab 250 mg/m2 weekly x 7; IMRT: once daily, M-F, 7 weeks (70 Gy)
89015028|NCT02101775|Experimental|Arm I (WEE1 inhibitor MK-1775, gemcitabine hydrochloride)|Patients receive WEE1 inhibitor MK-1775 PO on days 1, 2, 8, 9, 15, and 16 and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89015029|NCT02101775|Active Comparator|Arm II (placebo, gemcitabine hydrochloride)|Patients receive placebo PO on days 1, 2, 8, 9, 15, and 16 and gemcitabine hydrochloride as patients in Arm I. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89015030|NCT02007356|Experimental|allogeneic HSCT|"The present study will evaluate and validate in a single-center, open-label, single arm fashion the safety and feasibility of direct infusions of donor-derived pathogen-specific IFN-γ positive T-cells in recipients of HSCT with post-transplant viral infection according to the previously clinically certified CCS® [3-6]. The Investigator will first generate and apply IFN-γ positive selected T-cells to recipients of HSCT with CMV, EBV or adenovirus as previously published. The Investigator aim is to include 6 patients from the University Hospital of Basel.~With confirmed safety the investigator will in the future perform an efficacy study and extend this treat-ment for other clinically relevant pathogens including human herpesvirus (HHV)-6, HHV-8, polyomaviruses JC and BK and fungi including Aspergillus fumigatus and Candida albicans, to other immunosuppressed patients such as solid organ transplant (SOT) recipients."
89451317|NCT05397522|Experimental|Experimental group-2: Supervised Exercise by a physiotherapist via video conference|Participants in this group will be included in an exercise program for 6 weeks, 2 days a week and 45 minutes each session with supervised by a physiotherapist via video conference. The exercises will focus on breathing exercises, passive range of motion exercises within the pain limit for the joints associated with the surgery area, and strengthening exercises for the non-surgical areas.
89451318|NCT05397522|No Intervention|Control group: Unsupervised exercise|Home based exercises will be explained to the patients and they will be asked to perform these exercises 2 days a week for 6 weeks.
89451319|NCT00946569|Experimental|Treatment A (JNJ39758979)|Participants will receive JNJ39758979 300mg once daily for 12 weeks.
89451320|NCT00946569|Placebo Comparator|Treatment B (Placebo)|Participants will receive matching placebo once daily for 12 weeks.
89015031|NCT01978288||Cohort 1 Newborns with asthmatic mothers|Infants born to mothers who have diagnosis of Asthma that were enrolled in study from 5/7/14 to 6/1/16.
89015032|NCT01978288||Cohort 2 Newborns with asthmatic mothers|Infants born to mothers who have a diagnosis of Asthma with enrollment from June 2, 2016 going forward.
89015033|NCT01978288||Cohort 3 Newborns with healthy parents|Infants born to healthy parents without atopy (asthma, eczema, seasonal allergies) from June 2, 2016 going forward.
89015034|NCT01961232||Pulmonary Hypertension & WHO group I|Participants with Pulmonary Hypertension with a WHO classification group I and are scheduled to have a right heart catheterization.
89015035|NCT01961232||Pulmonary Hypertension & WHO group II|Participants with Pulmonary Hypertension with a WHO classification group II and are scheduled to have a right heart catheterization.
89015036|NCT01961232||Without Pulmonary Hypertension|Participants without Pulmonary Hypertension
89451321|NCT04488614||Early Stage Breast Cancer (Stage I and II)|Consecutive early stage breast cancer patients who are treated according to the national guidelines. Observation over 11 years.
89451322|NCT05397444||Full robust|no low HGS without HGS asymmetry
89451323|NCT05397444||low HGS alone|low HGS without HGS asymmetry
89451324|NCT05397444||HGS asymmetry alone|no low HGS with HGS asymmetry
89451325|NCT05397444||low HGS with HGS asymmetry|non
89451326|NCT03134859|Experimental|0 to 30 min/day tummy time|Group tasked to engage in an accumulation of 0 to 30 minutes of deliberate tummy time activities daily from study entry until the time at which the infant can independently transition in and out of sitting
89451327|NCT03134859|Experimental|31-60 min/day tummy time|Group tasked to engage in an accumulation of 31 to 60 minutes of deliberate tummy time activities daily from study entry until the time at which the infant can independently transition in and out of sitting
89451328|NCT03134859|Experimental|>61 min/day tummy time|Group tasked to engage in an accumulation of 61 or more minutes of deliberate tummy time activities daily from study entry until the time at which the infant can independently transition in and out of sitting
89451329|NCT04293159|Experimental|Lactobacillus casei DG (Enterolactis duo®)|Lactobacillus casei DG (Enterolactis duo®)
89451330|NCT00834795|Experimental|Carvedilol|Carvedilol 25 mg Tablet (test) dosed in first period followed by Coreg® 25 mg Tablet (reference) dosed in second period
89200894|NCT00350545|Experimental|rituximab + prednisone arm|Rituximab will be given as an IV fusion as initial treatment, followed by predisone (given during registration) which will be continued through-out trial and tapered off by physician. Cyclosporine A and tacrolimus will be used if chances of new diagnosis of chronic GVHD occur. Both drugs have no interaction with Rituxan, but will be tapered off after predisone is completely tapered.
89451331|NCT00834795|Active Comparator|Coreg®|Coreg® 25 mg Tablet (reference) dosed in first period followed by Carvedilol 25 mg Tablet (test) dosed in second period
89451332|NCT00834717|Experimental|Granisetron|Granisetron 1 mg Tablet (test) dosed in first period followed by Kytril® 1 mg Tablet (reference) dosed in second period
89451333|NCT00834717|Active Comparator|Kytril®|Kytril 1 mg Tablet (reference) dosed in first period followed by Granisetron 1 mg Tablet (test) dosed in second period
89451334|NCT00834639|Experimental|1|
89451335|NCT00834639|Active Comparator|2|
89451336|NCT00940095|Experimental|Clazosentan 5 mg/h|Continuous intravenous infusion of clazosentan (5 mg/h) started within 56 hours post-aSAH and scheduled to continue until Day 14 post-aSAH, or at least until Day 10 post-aSAH, for patients discharged before Day 14
89451337|NCT00940095|Experimental|Clazosentan 15 mg/h|Continuous intravenous infusion of clazosentan (15 mg/h) started within 56 hours post-aSAH and scheduled to continue until Day 14 post-aSAH, or at least until Day 10 post-aSAH, for patients discharged before Day 14
89451338|NCT00940095|Placebo Comparator|Placebo|Continuous intravenous infusion of placebo matching clazosentan started within 56 hours post-aSAH and scheduled to continue until Day 14 post-aSAH, or at least until Day 10 post-aSAH, for patients discharged before Day 14
89451339|NCT00834561|Experimental|Lamotrigine|Lamotrigine 200 mg Tablet (test) dosed in first period followed by Lamictal® 200 mg Tablet (reference) dosed in second period
89451340|NCT00834561|Active Comparator|Lamictal®|Lamictal® 200 mg Tablet (reference) dosed in first period followed by Lamotrigine 200 mg Tablet (test) dosed in second period
89451341|NCT00939237|Experimental|Active Ateronon|7 mg lycopene dietary supplement supplied as one Ateronon capsule taken daily
89451342|NCT00939237|Placebo Comparator|Placebo|placebo dietary supplement supplied as one capsule taken daily
89451343|NCT00754221|Experimental|1|
89451344|NCT00753285|Experimental|Renal Denervation|
89451345|NCT00752505|Experimental|A|
89451346|NCT00752505|Experimental|B|
89451347|NCT00834405|Experimental|Leflunomide|Leflunomide 20 mg Tablet
88935847|NCT01784094||Low back pain subjects|Subjects with chronic or recurrent low back pain
88935848|NCT01784094||No low back pain subjects|Subjects who are generally healthy with no low back pain
88935849|NCT01784107|Experimental|Belotecan and Ifosfamide|
88935850|NCT01784120|Experimental|doxotubicin/Genexol-PM|
88935851|NCT01784146|Placebo Comparator|Oxygen|
88935852|NCT01784146|Experimental|PEEP + Heliox|
88935853|NCT01784146|Experimental|Oxygen + PEEP|
88935854|NCT01784146|Active Comparator|Heliox|
88935855|NCT01784172|Experimental|electroacupuncture group|"Bilateral BL33 are given acupuncture of 50～60mm with 30～45°angle to inward and downward. Bilateral B L35 are given acupuncture of 50～60mm to outward and upward. The electric stimulator is applied to bilateral BL33 and BL35.~Every session lasts for 30 min per day. The participants are treated continuously for 6 weeks for 3 sessions a week, 18 sessions for each patient in all."
88935856|NCT01784172|Experimental|sham electroacupuncture group|"Bilateral sham BL33 and sham BL35 are given sham electroacupuncture with no current output.~Every session lasts for 30 min per day. The participants are treated continuously for 6 weeks for 3 sessions a week, 18 sessions for each patient in all."
88935857|NCT01784185|Experimental|virtual bronchoscopy guided transbronchial needle aspiration|virtual bronchoscopy guided transbronchial needle aspiration (VB-TBNA)(experimental method) and EBUS-TBNA (reference method) are performed in the same diagnostic session
88935858|NCT01784198|Experimental|Protein Intake|Dietary supplement:Protein intake
89451348|NCT00834405|Active Comparator|Arava®|Arava® 20 mg Tablet
89451349|NCT00834249|Experimental|Venlafaxine|Venlafaxine 25 mg Tablet (test) dosed in first period followed by Effexor® 25 mg Tablet (reference) dosed in second period
89451350|NCT00834249|Active Comparator|Effexor®|Effexor® 25 mg Tablet (reference) dosed in first period followed by Venlafaxine 25 mg Tablet (test) dosed in second period
89451351|NCT00751803|Experimental|BI 44370 TA Low Dose|
89451352|NCT00751803|Experimental|BI 44370 TA Medium Dose|
89451353|NCT00751803|Experimental|BI 44370 TA High Dose|
89451354|NCT00751803|Placebo Comparator|Placebo|
89451355|NCT00751803|Active Comparator|Eletriptan|
89451356|NCT05420961|Experimental|Cohort 1: V116|Participants will receive a single 0.5 mL intramuscular (IM) injection of V116 on Day 1. Participants in this arm received PPSV23 prior to the enrollment.
88935859|NCT01784224|Experimental|Speaking Valves|"All participants will either have a Blom tracheotomy tube in place or have their current tracheotomy tube changed to a Blom tracheotomy tube to allow for use of both the Blom low profile voice inner cannula and the Passy-Muir one-way speaking valves.~The Blom low profile voice inner cannula and Passy-Muir speaking valves will be provided to participants in a random order. All valves will be placed by the PI. Duration of data collection trials will range from 10 to 30 minutes."
88935860|NCT01784237|Experimental|Anterior meatuscopy|All patients in the study group receive anterior meatoscopy whereas patients in the control group perform a sniff test to select the most patent nostril for nasal anesthesia and transnasal endoscopic insertion.
89015037|NCT01961232||Connective Tissue Disease|Participants without PH, but with connective tissue disease
89451357|NCT05420961|Active Comparator|Cohort 1: PCV15|Participants will receive a single 0.5 mL IM injection of PCV15 on Day 1. Participants in this arm received PPSV23 prior to the enrollment.
89451358|NCT05420961|Experimental|Cohort 2: V116|Participants will receive a single 0.5 mL IM injection of V116 on Day 1. Participants in this arm received PCV13 prior to the enrollment.
89451359|NCT05420961|Active Comparator|Cohort 2: PPSV23|Participants will receive a single 0.5 mL IM injection of PPSV23 on Day 1. Participants in this arm received PCV13 prior to the enrollment.
89451360|NCT05420961|Experimental|Cohort 3: V116|Participants will receive a single 0.5 mL IM injection of V116 on Day 1. Participants in this arm received PCV15, PCV20, PCV13+PPSV23, PCV15+PPSV23, or PPSV23+PCV13 prior to the enrollment.
89451361|NCT05402397|Active Comparator|Enalapril|"Children with proteinuric nephropathies will receive enalapril prior or after a losartan period, according to randomization sequence.~Enalapril will be given at a dose between 0.1 to 0.4 mg/kg/day (according to the dose that they usually receive), once a day."
89451362|NCT05402397|Experimental|Losartan|"Children with proteinuric nephropathies will receive losartan prior or after a enalapril period, according to randomization sequence.~Losartan will be given at a dose 5 times the dose of enalapril that they usually receive, (with a maximum dose of 1.4 mg/kg/day), once a day."
89451363|NCT00833937|Experimental|Zolpidem|Zolpidem Tartrate 10 mg Tablet (test) dosed in first period followed by Ambien® 10 mg Tablet (reference) dosed in second period
89451364|NCT00833937|Active Comparator|Ambien®|Ambien® 10 mg Tablet (reference) dosed in first period followed by Zolpidem Tartrate 10 mg Tablet (test) dosed in second period
88935861|NCT01784237|Active Comparator|Nasal sniff test|A sniff test for nasal patency is a common method before ultrathin transnasal esophago-gastro-duodenoscopy (UT-EGD) to select the right or left nostril for insertion.
88935862|NCT01784250|Experimental|Propanolol|Propranolol 40mg tablets, one tablet administered 1 hour before surgery
88935863|NCT01784250|Placebo Comparator|Placebo|Placebo tablets, one tablet administered 1 hour before surgery
88935864|NCT01784250|Experimental|Clonidine|clonidine 150mcg tablets, one tablet administered 1 hour before surgery
88935865|NCT01784263|Experimental|Individual Cognitive Behavioral Therapy|
88935866|NCT01784263|Active Comparator|Standard Community Treatment|
88935867|NCT01784276|No Intervention|Control|Children assigned to Group A (control group) received usual care and therefore had no intervention before or during the return visit.
88935868|NCT01784276|Experimental|Video peer modeling|Video peer modeling (at home, the child watched a DVD recording of a typically developing child undergoing a dental visit);
88935869|NCT01784276|Experimental|Video goggles or portable DVD only|Video goggles/DVD (during the dental visit, the child watched their favorite movie using sunglass style video eyewear, or portable DVD player);
88935870|NCT01784276|Experimental|Video peer modeling plus video goggles|Video peer modeling plus video goggles/DVD. At home, the child watched a DVD recording of a typically developing child undergoing a dental visit; During the dental visit, the child watched their favorite movie using sunglass style video eyewear, or portable DVD player.
88935871|NCT01784289||normal|Patients with no overweight and no type 2 diabetes
88935872|NCT01784289||lipodystrophy|patients with a lipodystrophy, most are diabetics
88935873|NCT01784289||obese non diabetics|Patients with obesity (BMI <30kg/m2), without diabetes
88935874|NCT01784289||obese diabetics|Patients with obesity (BMI <30 kg/m2), with diabetes
88935875|NCT01784302|Active Comparator|Maalox Plus extra|Subjects will receive doses of raltegravir 400 mg and maalox plus extra
88935876|NCT01784302|Active Comparator|Multivitamin|Subjects will receive doses of raltegravir 400 mg along with a multivitamin tablet
88935877|NCT01784302|Active Comparator|Sodium bicarbonate|Subjects will receive doses of raltegravir 400 mg along with sodium bicarbonate
88935878|NCT01784315||Chloroquine, primaquine and ACT|"Standard dose of Chloroquine( 10mg/kg on day 0 and 5mg/kg on day1 and day2) and Primaquine(0.25mg/kg for 14 days).~Artemisinin combination therapies (ACT) of 4 tablets on 0,8,24,36,48 and 60 hours will be used for Chloroquine resistant P.vivax infection"
88935879|NCT01784328|Other|Use of a bowel irrigation system|Open label. No placebo use in this study. All volunteers will trial the bowel irrigation system. Eligible volunteers will be those patients who have failed conventional supportive bowel care.
88935880|NCT01784354|Placebo Comparator|Education|target education toward Raynaud's
88935881|NCT01784354|Active Comparator|Acupressure|acupressure- dilatation
88935882|NCT01784354|Active Comparator|Acupressure relaxation|acupressure relaxation protocol
88935883|NCT01784367|Experimental|ECLA-group|Treatment with a pump driven, venovenous extracorporeal lung assist
88935884|NCT01784380||the case group|
88935885|NCT01784380||the control group|
89015038|NCT01949883|Experimental|CPI-0610|
89200895|NCT04006054|Experimental|Dexmedetomidine treatment group|Dexmedetomidine will be administrated at a dose of 0.25-0.75 µg/(kg*h) for 5 days
89200896|NCT04006054|Active Comparator|Midazolam treatment group|Midazolam will be administrated at a dose of 0.25-0.75 µg/(kg*h) for 5 days
89200897|NCT00897975|Experimental|red yeast rice (RYR) plus phytosterol|arm will take red yeast rice and phytosterol supplement
89200898|NCT00897975|Placebo Comparator|red yeast rice plus placebo|
89200899|NCT00897975|Active Comparator|TLC plus red yeast rice plus placebo|subjects attend 12 week therapeutic lifestyle program and take above supplement
89200900|NCT00897975|Experimental|TLC plus RYR plus phytosterol|Therapeutic lifestyle program for 12 weeks plus red yeast rice plus phytosterol
89451365|NCT04245111||Open Fracture Cohort|Patients 18 years of age or older. Open extremity fracture. Planned definitive fracture management with external fixation, internal fixation, or joint fusion. Open fracture wound management that includes formal surgical debridement within 72 hours of their injury. Will have all planned fracture care surgeries performed by a participating surgeon or delegate. Provision of informed consent.
89451366|NCT04245111||Complication Cohort|Patients 18 years of age or older. Extremity fracture. Prior definitive fracture management with external fixation, internal fixation, or joint fusion. Superficial, deep, or organ space SSI (as per CDC criteria) at the fracture site that requires operative management. Will have all fracture care surgeries performed by a participating surgeon or delegate. Provision of informed consent
89451367|NCT04245111||Closed Fracture Cohort|"Patients 18 years of age or older Closed extremity fracture Planned definitive fracture management with external fixation, internal fixation, or joint fusion.~Provision of informed consent"
89451368|NCT00831051|Experimental|Q8003 12mg/8mg|Combination
88935886|NCT01784380||the treatment group|Patients of the treatment group recieved drugs,then we observed drugs' treatment effect.
88935887|NCT01784406|Experimental|Autonomy-supportive counselling|"2-4 autonomy-supportive conversations with an experienced nurse, educated both theoretically and practically in the method Guided Self-Determination that includes specific reflection sheets and use of advanced communication; in addition to standard care."
88935888|NCT01784406|No Intervention|Control|Standard of care.
88935889|NCT01784432|Active Comparator|Low-level laser therapy and training|Effects of low-level laser therapy on muscle performance during physical strength training and gene expression of muscle tissue.
88935890|NCT01784432|Active Comparator|Training without low-level laser therapy|Effects of physical strength training without low-level laser therapy on muscle performance and gene expression of muscle tissue
88935891|NCT01784445|Experimental|Ceftazidime plus placebo|Procedure/Surgery: ERCP Each patient will receive: Ceftazidime 2 g i.v. once daily 30 minutes prior to procedure and glycerin suppository as placebo
88935892|NCT01784445|Active Comparator|Diclophenac sodium plus placebo|Procedure/Surgery:ERCP Each patient will receive 100 mg Diclophenac suppositories, once daily immediately prior to procedure plus 100 ml of saline as placebo
88935893|NCT01784458||intra-abdominal hypertension(IAH)|IAH group : patients developing IAH non-IAH group : patients without IAH
88935894|NCT01784471|Experimental|Magic foot shoe|Magic Foot™ will be dispensed to all subjects. Shoes will be activated at the clinic for 30 minutes. Subjects will self-use and activate the shoes at home daily for 30 days.
88935895|NCT01784484||patients with abnormal liver enzymnes|
88935896|NCT01784497||Recipients of Living Donor Liver Transplantation|Patients who will undergo Living Donor Liver Transplantation (LDLT) In Ain Shams Center For Organ Transplantation (ASCOT) .
88935897|NCT01784510|Active Comparator|2 cm|
88935898|NCT01784510|Experimental|6 cm|
88935899|NCT01784549|Active Comparator|Cisplatin Docetaxel|- Cisplatin + Docetaxel day 1 q 21 days for 3 cycles
88935900|NCT01784549|Experimental|Gefitinib Pemetrexed Vinorelbine Gemcitabine|"Gefitinib day for 8 wks;~Pemetrexed day 1 q 21 days for 3 cycles;~Docetaxel day 1 + Vinorelbine days 1,8 q 21 days for 3 cycles;~Docetaxel days 1,8 + Gemcitabine days 1,8 q 21 days for 3 cycles;~Cisplatin + Docetaxel day 1 q 21 days for 3 cycles;~Cisplatin day 1+ Gemcitabine days 1,8 q 21 days for 3 cycles;"
88935901|NCT01784575|Experimental|Patient Navigator Intervention|The Patient Navigator Intervention arm will have two 20 minute interactive sessions with a patient navigator in which they will learn about quality measures and view scores on the Massachusetts Health Quality Partner's website.
88935902|NCT01784575|Active Comparator|Control|The control arm will receive an information pamphlet about health care quality.
88935903|NCT01784627|No Intervention|Treatment at Usual|Participants in this group will receive treatment as usual (TAU) from their provider, which may or may not include screening and brief advice regarding alcohol use.
88935904|NCT01784627|Experimental|c-ASBI|Participants in this group will receive the computerized alcohol screening and brief intervention (c-ASBI).
88935905|NCT01784640|Experimental|Treatment (Hsp90 inhibitor AUY922, pemetrexed disodium)|Patients receive Hsp90 inhibitor AUY922 IV over 60 minutes weekly and pemetrexed disodium IV over 15 minutes every 3 weeks. Courses repeat every 21 days for 6 months in the absence of disease progression or unacceptable toxicity.
89451369|NCT00831051|Active Comparator|Morphine sulfate 12 mg|Single component
88935906|NCT01784653|No Intervention|Treatment as Usual|Patients will receive the usual care from the treatment program
88935907|NCT01784653|Experimental|iMET|Participants will complete a self-guided computerized Motivational Enhancement Therapy
88935908|NCT01784653|Experimental|MET|Clinician-delivered Motivational Enhancement Therapy
88935909|NCT01784679||Natural History Prospective Observational Group|
88935910|NCT01784679||Online Registry Patient Reported Group|
88935911|NCT01784692|Placebo Comparator|Placebo|10 participants will be randomized to take 1 capsule of placebo daily.
88935912|NCT01784692|Experimental|Immulina 200 mg/day|10 participants will be randomized to take 200 mg/day of Immulina.
88935913|NCT01784692|Experimental|Immulina 400 mg/day|10 participants will be randomized to take 400 mg/day of Immulina.
88935914|NCT01784692|Experimental|Immulina 800 mg/day|10 participants will be randomized to take 800 mg/day of Immulina.
89451370|NCT00831051|Active Comparator|Oxycodone HCl 8mg|Single component
89451371|NCT00831051|Experimental|Q8003 6mg/4mg|Combination
89451372|NCT00831051|Active Comparator|Morphine sulfate 6mg|Single component
89451373|NCT00831051|Active Comparator|Oxycodone HCl 4mg|Single component
89451374|NCT00750633|Experimental|Moxidex|Moxidex otic solution
89451375|NCT00750633|Active Comparator|Moxifloxacin|Moxifloxacin otic solution
89451376|NCT00750633|Active Comparator|Dexamethasone|Dexamethasone phosphate otic solution
89451377|NCT00750243|Experimental|A|
89451378|NCT00750243|Active Comparator|B|
89451379|NCT05380011|Experimental|Group A (CIMT and Bimanual Task Training)|Constraint Induced Movement Therapy and Bimanual Task Training
89451380|NCT05380011|Experimental|Group B (Bimanual Task Training)|Bimanual Task Training
89451381|NCT04438707|Experimental|Experimental group|
89451382|NCT04438707|Active Comparator|Control group|
89451383|NCT00748605|Placebo Comparator|Placebo|S-2367 placebo + LCD (Low Calorie Diet) +RCD (Reduced Calorie Diet)
89451384|NCT00748605|Experimental|S-2367 1600 mg q.d. 54 weeks|S-2367 placebo + LCD for 6 weeks and 1600 mg S-2367 + RCD for 54 weeks
89451385|NCT00748605|Experimental|S-2367 1600 mg q.d. 60 weeks|S-23671600 mg q.d. + LCD for 6 weeks and S-2367 1600 mg q.d + RCD for 54 weeks
89451386|NCT00924170|Experimental|Fludarabine and Cyclophosphamide/LMB-2|Administer cycle 1 with Fludarabine and Cyclophosphamide (FC) alone. Two weeks after starting cycle 1, begin up to 6 cycles of FC plus LMB-2 at minimum 20-day intervals.
89451387|NCT00747123|Placebo Comparator|Placebo|Subcutaneous injection on days 1, 29, 57 and 85.
89451388|NCT00747123|Experimental|ACE-011 0.1 mg/kg|Subcutaneous injection of ACE-011 0.1 mg/kg every 28 days totaling four doses (days 1, 29, 57 and 85).
88935915|NCT01784705|Experimental|Transcranial bright light therapy|
88935916|NCT01784705|Placebo Comparator|Transcranial placebo treatment|
88935917|NCT01784731||Patients|
89451389|NCT00747123|Experimental|ACE-011 0.3 mg/kg|Subcutaneous injection of ACE-011 0.3 mg/kg every 28 days totaling four doses (days 1, 29, 57 and 85).
88935918|NCT01784744||ASD Control|Patients aged 5 to 17 diagnosed with ASD.
88935919|NCT01784744||ASD Case|Patients diagnosed with ASD aged 5 to 17 with a history of amelioration of symptoms during febrile episodes.
88935920|NCT01784757|Experimental|ODM-201 Tablet A|ODM-201 tablet A in fed and fasted states plus ODM-201 capsule in fed state in randomised order.
88935921|NCT01784757|Experimental|ODM-201 Tablet B|ODM-201 Tablet B in fed and fasted states plus ODM-201 capsule in fed state in randomised order.
89015039|NCT01898494|Experimental|Arm S (Surgery) then Arm A (Low risk, observation)|Patients undergo transoral surgical resection of the oropharyngeal tumor. After transoral surgical resection of the oropharyngeal tumor, low risk patients are under observation.
89015040|NCT01898494|Experimental|Arm S (Surgery) then Arm B (Intermediate risk, low-dose IMRT)|Patients undergo transoral surgical resection of the oropharyngeal tumor. After transoral surgical resection of the oropharyngeal tumor, intermediate risk patients receive low-dose IMRT (50 Gy) QD five days a week for 5 weeks.
89451390|NCT00747123|Experimental|ACE-011 0.5 mg/kg|Subcutaneous injection of ACE-011 0.5 mg/kg every 28 days totaling four doses (days 1, 29, 57 and 85).
89451391|NCT03294512|Experimental|Heart Failure Patients|Patients who are seen at Intermountain Medical Center with heart failure, based on the Intermountain-specific Heart Failure Identification and Risk Stratification, will be screened for this study. The Principal Investigator and/or his delegate will confirm the presence of heart failure, based on established standard of care criteria for diagnosis.
89451392|NCT00920985|Experimental|Arm 1|
89451393|NCT00920985|Active Comparator|Arm 2|
89451394|NCT00828321|Experimental|1|
89451395|NCT00828321|Active Comparator|2|
89451396|NCT01352715|Experimental|Arm A: LPV/r plus RAL|Participants were administered LPV/r plus RAL orally twice daily throughout follow-up.
89451397|NCT01352715|Experimental|Arm B: LPV/r plus best available NRTIs|"Participants were administered LPV/r orally twice daily, plus NRTI options provided by the study, to include the best available NRTIs (listed below) throughout follow-up-~FTC/TDF orally twice daily~ABC/3TC/ZDV orally twice daily~ABC/3TC orally once daily~3TC/ZDV orally twice daily~ABC 300mg orally twice daily or 600 mg once daily~3TC orally twice daily~ZDV orally twice daily"
89451398|NCT00743925|Active Comparator|1|A-002 (500 mg QD) plus Atorvastatin (80 mg QD)
89451399|NCT00743925|Placebo Comparator|2|Matching Placebo tablets plus Atorvastatin (80 mg QD)
89451400|NCT00740727|Experimental|EASI|Subjects will undergo placement of EASI catheters. All subjects in whom EASI catheters are placed, will receive Human Recombinant Hyaluronidase (HRH) as part of the EASI placement. (No subject will receive HRH, other than as part of EASI catheter placement.)
89451401|NCT00826059|Active Comparator|Active Stimulation|"Implantation/ISS Stimulation during 5 consecutive days & Standard of Care (SoC).~Day 1: First stimulation initiated within 24 hours from stroke onset, following implantation completion. All subjects will be treated according to SoC for treatment of Acute Ischemic Stroke.~Day 2-4: ISS Stimulation treatment sessions repeated daily. Each treatment will be initiated within 18-26 hours from the preceding treatment.~Day 5: Following completion of the last ISS Stimulation treatment session, imaging performed for assessing Injectable Neuro Stimulator (INS) positioning and/or lesion. Implant removal procedure will then be performed. Subsequently, patients will be evaluated for safety and effectiveness.~Subjects will continue with SoC as needed and discharged from the hospital based on the judgment of the study investigator."
89451402|NCT00826059|Sham Comparator|Sham Stimulation|"Sham Implantation and Sham Stimulation during 5 consecutive days & Standard of Care (SoC).~Day 1: First Sham stimulation initiated within 24 hours from stroke onset, following Sham implantation procedure. All subjects will be treated according to SoC for treatment of Acute Ischemic Stroke.~Day 2-4: Sham Stimulation sessions repeated daily. Each Sham Stimulation will be initiated within 18-26 hours from the preceding treatment.~Day 5: Following completion of the last Sham Stimulation session, imaging performed for lesion assessment. Sham Implant removal will then be performed. Subsequently, patients will be evaluated for safety and effectiveness.~Subjects will continue with SoC as needed and discharged from the hospital based on the judgment of the study investigator."
89451403|NCT00825513|Experimental|Akreos Toric|Akreos Toric Intraocular Lens
89451404|NCT00825513|Active Comparator|Akreos Advanced|Akreos Advanced Optics Aspheric Intraocular Lens (Akreos AO)
89451405|NCT00919893|Active Comparator|Cernilton|Men with inflammatory chronic prostatitis-chronic pelvic pain syndrome (CP-CPPS)
89451406|NCT00919893|Placebo Comparator|Placebo|Men with inflammatory chronic prostatitis-chronic pelvic pain syndrome (CP-CPPS)
89451407|NCT04789863|Other|Intervention group|Intervention group (IG) patients will receive usual care plus the SMILe-ICM (see below) when they come to their planned follow-up appointments at the University Hospital Basel. Thus, while IG participants will receive the same number of follow-up appointments as CG participants (depending on their state of health), they will also receive the SMILe-ICM, i.e., tailored self-management and behavioural support delivered by the combination of totally 12 face-to-face meetings with a Care Coordinator (CC) and the SMILeApp. The personal meetings with the CC will last around 40-90 minutes. The first three of them will occur during the initial alloSCT hospitalization, and the other nine will occur in the outpatient setting, beginning with biweekly and expanding to bi-monthly intervals until one year post-alloSCT.
89451408|NCT04789863|Other|Control group|"see Intervention section"
89451409|NCT04472871||patients with atrial fibrillation and heart failure|Patients with cardiac function ejection fraction less than 35% and underwent Left atrial appendage closure in the period covered by the study
89451410|NCT04472871||patients with atrial fibrillation without heart failure|Patients with cardiac function ejection fraction more than 35% and underwent Left atrial appendage closure in the period covered by the study
89451411|NCT00738387|Experimental|ASA404 + docetaxel|"1800 mg/m2 of ASA404 intravenous (IV) on day 1 of each 21 day cycle~75 mg/m2 of docetaxel intravenous (IV) an hour for 1st 6 cycles; cycle: every 21 days"
89451412|NCT00738387|Placebo Comparator|Placebo + docetaxel|"Placebo i.v. on day 1 of each 21 day cycle~75 mg/m2 of docetaxel intravenous (IV) an hour for 1st 6 cycles; cycle: every 21 days"
88935922|NCT01784783|Experimental|HOPE Intervention|"Pregnant women and their male partners will receive home-based couple HIV testing and counseling and partner education 1-2 weeks after enrollment. The intervention will include educational messages concerning socio-behavioral, condom-based, and treatment-oriented approaches to prevention of horizontal and vertical HIV transmission, based on the status of each of the partners. The couple will also be educated about the importance of facility delivery, exclusive breastfeeding, family planning, and post-partum contraception.~During the HOPE Intervention, the purpose and design of the study will be explained to male partners. Men will be asked to provide written informed consent for study participation. Provided they consent, men will complete a questionnaire asking for sociodemographic characteristics, medical and sexual history, behavioral data and information on prior HIV testing and counseling."
88935923|NCT01784783|Experimental|INVITE Intervention|Pregnant women will be tested and encouraged to bring their male partners to the antenatal clinic for testing. Women will receive a clinic invitation to give to their male partners to attend the next visit for couple HIV counseling and testing. The couples will also be offered the relevant components of the intervention at the final study visit, 6 months postpartum.
88935924|NCT01784809|Experimental|Multimedia HIV/STI prevention|Multimedia WORTH is a 4-session group based gender specific HIV and drug abuse prevention intervention.
88935925|NCT01784809|Active Comparator|Traditional HIV/STI prevention|Traditional WORTH is a 4-session group-based HIV/STI and drug abuse prevention intervention that covers the same content as Multimedia WORTH without the use of interactive videos, computerized assessments, and other audiovisual tools.
88935926|NCT01784809|Placebo Comparator|Wellness Promotion|Wellness Promotion is a 4-session group based intervention that aims to improve diet, physical fitness and well-being which is designed as an attentional control condition.
88935927|NCT01784822||Zenapro™ Hybrid Hernia Repair Device|Device to be used to reinforce or bridge the abdominal wall for the repair of ventral hernias.
88935928|NCT01784835|Other|control|patients under standard medical care
88935929|NCT01784835|Experimental|OMT|patients under usual medical care plus osteopathic treatment
88935930|NCT01784887|Active Comparator|Bioelectric Dressing|SOC + Bioelectric Dressing
88935931|NCT01784887|No Intervention|SOC|Standard of Care
88935932|NCT01784900|Experimental|Schema B (140µg)|"D0 : 20 μg of catumaxomab~D2 : 40 μg~D4 : 80 μg"
88935933|NCT01784900|Experimental|Schema A (100µg)|"D0 : 10 μg of catumaxomab~D2 : 30 μg~D4 : 60 μg"
88935934|NCT01784913|Experimental|UV1 synthetic peptide vaccine and GM-CSF|GM-CSF (Leukine) followed by UV1 peptide vaccine with escalating concentrations (100, 300 and 700 microgram) will be injected intradermally at the same injection in the lower abdomen.
88935935|NCT01784952|Experimental|Whole grains and lequmes|
88935936|NCT01784952|Placebo Comparator|refined rice|
88935937|NCT01784978|Experimental|Rotational arm|Alternating cycles of treatment with sunitinib and everolimus; repeating cycles of 24 weeks of treatment consisting of 12 weeks of sunitinib 4weeks on 2 weeks off, 50 mg pd followed by 12 weeks of everolimus 10 mg per day 11 weeks on 1 week off in patients with metastatic clear cell renal cancer.
88935938|NCT01784978|Active Comparator|Sequential arm|The comparative arm will be the standard regimen of sunitinib (50 mg pd 4/2) until progression, followed thereafter by everolimus (10 mg per day continuously, 11/1) until progression.
89451413|NCT04472715|Experimental|follicular unit extraction|extraction of hair follicle unit from donar area and tranplant it into recepient bald area
89451414|NCT04472715|Experimental|foolicular unit extraction and platelet rich plasma|the same procedure mentioned above coupled with session of platelet rich plasma before and after transplantation
89531369|NCT05041179|Placebo Comparator|Placebo control (7.2 g isomaltulose)(arm D)|"First dose (3.6 g isomaltulose) consumed in the morning~Second dose (3.6 g isomaltulose) taken in the evening"
89537129|NCT03378219||Cohort 3|Non-diseased Comparison Cohort: Healthy pregnant women not diagnosed with a Kevzara (sarilumab) indication and unexposed to Kevzara (sarilumab) during the course of the pregnancy
89451415|NCT00645177|Active Comparator|A|"In study, this arm is a randomized (blinded) to ABT-869 arm plus paclitaxel.~Note: Prior to randomization, approximately 6-12 subjects will be enrolled in open-label lead-in to assess the tolerability of the combination. The initial open-label, lead-in cohort of six subjects will be monitored for 2 cycles (8 weeks) to assess the PK interactions and the safety of the combination of 0.20 mg/kg QD ABT-869 and paclitaxel (90 mg/m2). Enrollment into the randomized portion will begin after a cohort has completed two cycles (8 weeks) of therapy and no toxicities prohibit the cohort from continuing on to Cycle 3.~Alternative doses may be explored based on the tolerability of the combination"
89451416|NCT00645177|Placebo Comparator|B|"In study, this arm is a randomized (blinded) to placebo for ABT-869 plus paclitaxel arm.~Note: Prior to randomization, approximately 6-12 subjects will be enrolled in open-label lead-in to assess the tolerability of the combination. The initial open-label, lead-in cohort of six subjects will be monitored for 2 cycles (8 weeks) to assess the PK interactions and the safety of the combination of 0.20 mg/kg QD ABT-869 and paclitaxel (90 mg/m2). Enrollment into the randomized portion will begin after a cohort has completed two cycles (8 weeks) of therapy and no toxicities prohibit the cohort from continuing on to Cycle 3.~Alternative doses may be explored based on the tolerability of the combination"
89451417|NCT00645021|Experimental|Mild hepatic function|
89451418|NCT00645021|Experimental|Moderate hepatic function|
89451419|NCT00645021|Experimental|Normal hepatic function|
89451420|NCT00643383|Active Comparator|1|
89451421|NCT00643383|Placebo Comparator|2|
89451422|NCT02559622|Experimental|300 mg secukinumab|300 mg secukinumab every week for 4 weeks followed by 300 mg secukinumab every 4 weeks until week 48 (last injection)
88935939|NCT01783652|Experimental|Intervention group|Study participants in the intervention group will be given access to an anti-depression website and have four telephone follow-up within the 1-year study period.
88935940|NCT01783652|No Intervention|Control group|Study participants in the control group will not received any depression-related service other than an interactive anti-smoking website provided by the University of Hong Kong.
88935941|NCT01785004|Active Comparator|Vitamin D + fish oil|Vitamin D3 (cholecalciferol), 2000 IU per day and 840 mg of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])
88935942|NCT01785004|Active Comparator|Vitamin D + fish oil placebo|Vitamin D3 (cholecalciferol), 2000 IU per day and fish oil placebo
88935943|NCT01785004|Active Comparator|Vitamin D placebo + fish oil|Vitamin D placebo and 840 mg of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])
88935944|NCT01785004|Placebo Comparator|Vitamin D placebo + fish oil placebo|Vitamin D placebo and fish oil placebo
88935945|NCT01785017||Chidren with critical asthma|Pre- and post-SCAMP
88935946|NCT01785030|Experimental|50% Nitrous oxide|
88935947|NCT01785043|Experimental|Liraglutide|Liraglutide will be administered once a day by subcutaneous injection (under the skin) in the abdomen, thigh, or upper arm. It will be given independently of meals and preferably at the same each day. The starting dose will be 0.6 mg. After one week, the dose will be increased to 1.2 mg, and then it will be increased to 1.8 mg one week later to achieve better control of blood glucose. When Liraglutide is added to existing treatment containing metformin, as it is our scenario, the dose of metformin does not have to be changed.
88935948|NCT01785043|Active Comparator|Sitagliptin|"Sitagliptin will be administered once daily at a 100 mg dose. When Sitagliptin is used in combination with metformin, as it is our scenario, the dose of metformin should be maintained. If a dose of Sitagliptin is missed, it should be taken as soon as the patient remembers. A double dose should not be taken on the same day.~Sitagliptin will be used daily during the study period of 12 weeks."
88935949|NCT01785056|Experimental|Privigen|Privigen is a ready-to-use, sterile, 10% protein liquid preparation of polyvalent human immunoglobulin G (IgG) for intravenous administration. Subjects will be given 2 g/kg/month of IVIGfor 6 months. Each dose will be split into 2 to 4 infusions on consecutive days to achieve the total monthly dose.
89451423|NCT02559622|Experimental|150 mg secukinumab|150 mg secukinumab every week for 4 weeks followed by 150 mg secukinumab every 4 weeks until week 48 (last injection)
88935950|NCT01785056|Placebo Comparator|Placebo (Albuminar-5)|Albuminar-5 is a sterile solution of albumin obtained from large pools of adult human venous plasma and used as the placebo in this study. Albuminar-5 will be administered by the intravenous route and each dose will be split into 2 to 4 infusions on consecutive days to achieve the total monthly dose.
88935951|NCT01785082|Experimental|LiMAx-group|Intravenous pre- and post-surgical injection of 0.4% 13-C-Methacetin solution. Dosage is adapted due to body weight (2 mg/kg). A LiMAx-test of >150 µg/kg/h would correspond to a general ward indication.
88935952|NCT01785082|No Intervention|control group|Control group without intervention. Post-surgical management as defined prior to surgery following well-established clinical standards.
89451424|NCT02559622|Other|Placebo followed by 300 mg secukinumab|Placebo until week 12 followed by 300 mg secukinumab every week for 4 weeks followed by 300 mg secukinumab every 4 weeks until week 48 (last injection)
89451425|NCT02559622|Other|Placebo followed by 150 mg secukinumab|Placebo until week 12 followed by 150 mg secukinumab every week for 4 weeks followed by 150 mg secukinumab every 4 weeks until week 48 (last injection)
89537130|NCT03299777||Control group|A control group will consist 100 normotensive women with normal pregnancy outcomes who were admitted to our fetal-maternal unit during the same period
89501726|NCT02230267|Experimental|High intensity boot camp|Each of the two HIBCs will have 10 participants (20 total) with a 1:5 physical therapist-to-patient ratio. Each HIBC session will last 1.5 hours and will be held on 4 days of the week. Participants will be required to attend 3 of those 4 days but may attend all. Because this is a pragmatic trial, therapists will have some leeway to control the intensity and the modality of the exercise. However, the basic format of the HIBC will consist of the following exercise components: A. 30 minutes of moderate-high intensity aerobic exercise at 70%+ of estimated maximum heart rate; B. 15 minutes of strengthening the major muscle groups of the trunk and upper/lower extremities; C. 15 minutes of balance training; and, D. 15 minutes of rest and stretching. Participants will rotate through these four different exercise components in a circuit fashion.
88935953|NCT01785108|Active Comparator|GAD-Alum (Diamyd) 20µg, Vitamin D and Ibuprofen|"GAD-Alum (Diamyd) 20 µg given twice with one month interval~Vitamin D oral drops, 2000 IU/day, from Day 1 to Day 450~Ibuprofen, 400 mg/day, from Day 1 to Day 90"
88935954|NCT01785108|Active Comparator|GAD-Alum (Diamyd) 20µg and Vitamin D|"GAD-Alum (Diamyd) 20 µg given twice with one month interval~Vitamin D oral drops, 2000 IU/day, from Day 1 to Day 450"
88935955|NCT01785108|Active Comparator|GAD-Alum (Diamyd) 20 µg x 2 and Vitamin D|"GAD-Alum (Diamyd) 20 µg X 2 given twice with one month interval~Vitamin D oral drops, 2000 IU/day, from Day 1 to Day 450"
88935956|NCT01785108|Placebo Comparator|Placebo|
88935957|NCT01785121|Active Comparator|Control Group|Patients who are randomized to the MSO group will get a protocoled exercise advice from a member of the HF team (nurse, cardiologist or physiotherapist). During the first three months after inclusion, patients will be phoned after 2, 4, 8, 12 weeks to discuss their current activity.
88935958|NCT01785121|Experimental|Wii Group|Patients who are randomized to the Wii group will be introduced to the Nintendo Wii game computer in an introduction lesson of approximately two hours and the Wii will be installed at home. During the first three months after inclusion, patients will be phoned after 2, 4, 8, 12 weeks to discuss their experiences with the Wii or to solve possible problems
88935959|NCT01785147|Experimental|BP1.4979 3mg|BP1.4979 3mg during 3 months
88935960|NCT01785147|Experimental|BP1.4979 10mg|BP1.4979 10mg during 3 months
88935961|NCT01785147|Experimental|BP1.4979 15mg|BP1.4979 15mg during 3 months
88935962|NCT01785147|Placebo Comparator|Placebo|Placebo during 3 months
88935963|NCT01785173|Experimental|Endoscopic-guided gauze pledgetting|All patients in the study group receive endoscopic-guided gauze pledgetting (EGGP) nasal anesthesia. Each patient will receive an anterior rhinoscopy to select the most patent meatus for gauze pledegetting by a validated meatus scoring scale. The endoscope is preloaded with a 1.8 mm biopsy forceps to pick up the acute angle between the shorter leg and hypotenuse of a right-angled gauze strip (already soaked with anesthesia/decongestant) and retract back just into the biopsy channel. When the transnasal endoscope tip is set in the nasal vestibule, the preloaded biopsy forceps is protruded slowly into the desired meatus under endoscope monitoring. A gauze strip is at least brought onto the posterior end of the inferior or middle turbinate.
88935964|NCT01785173|Active Comparator|Cotton-tipped applicator pledgetting|"Another randomized group of patients will receive cotton-tipped applicator gauze pledgetting (CTGP) method of nasal anesthesia. Two cotton-tippled applicators help determine the following: (a) right or left side, (b) inferior or middle nasal meatus (INM or MNM) and (c) the need of local epinephrine. The investigators apply gently in parallel two sterile 3 x 1/10, double-ended, plastic shaft cotton-tipped applicators, pretreated with minimal amount of 2% viscous lidocaine plus 4% liquid lidocaine, to lubricate and anesthetize the more patent meatus One cotton-tipped applicator is re-used to deliver a triangular gauze strip to the selected meatus during the gauze pledgetting procedure."
88935965|NCT01785199|Placebo Comparator|normal (AHI < 5)|Patients who are eligible for this study will sleep on an automatic adjustable bed with a second PSG performed within the next one month.
88935966|NCT01785199|Active Comparator|mild OSA (AHI between 5 and 15)|Patients who are eligible for this study will sleep on an automatic adjustable bed with a second PSG performed within the next one month.
88935967|NCT01785199|Active Comparator|moderate OSA (AHI between 15 and 30)|Patients who are eligible for this study will sleep on an automatic adjustable bed with a second PSG performed within the next one month.
88935968|NCT01785199|Active Comparator|severe OSA (AHI > 30)|Patients who are eligible for this study will sleep on an automatic adjustable bed with a second PSG performed within the next one month.
88935969|NCT01785212|Other|Stapler-hepatectomy|The liver parenchyma is crushed with a Pean clamp and subsequently divided using Covidien Endo-Gia™ Ultra Handle Short Staplers and Endo Gia™ TRI staple 60 mm or 45 mm AVM/AMT loading units (Covidien). Hepatic veins and portal pedicles clamped and suture ligated.
88935970|NCT01785212|Other|CUSA-hepatectomy|The liver parenchyma is divided along the transection line by CUSA (Cavitron ultrasonic aspirator; Valleylab, Boulder, CO) and bipolar forceps in a two surgeon technique. Vessels of less than 2 mm in diameter are coagulated with bipolar forceps. The remaining vessels are clipped or ligated. Hepatic veins and portal pedicles clamped and suture ligated.
88935971|NCT01785225|Experimental|modified commercial drape Tegaderm (R)|
88935972|NCT01785238|Experimental|cases with neonatal acute renal failure in preterm|
88935973|NCT01785238|Other|controls without neonatal acute renal failure in preterm|
88935974|NCT01785251|Experimental|NMES|Application of neuromuscular electrical stimulation to the calf muscles of the patient in order to elicit contraction of the calf muscle pump and thus, eject venous blood proximally.
89015041|NCT01898494|Experimental|Arm S (Surgery) then Arm C (Intermediate risk, standard-dose IMRT)|Patients undergo transoral surgical resection of the oropharyngeal tumor. After transoral surgical resection of the oropharyngeal tumor, intermediate risk patients receive standard-dose IMRT (60 Gy) QD five days a week for 6 weeks.
89451426|NCT05491486|Experimental|Mindfulness-based Group Therapy (MBGT+TAU)|Participants randomized into the experimental condition attend MBGT for four weeks in addition to regular university hospital outpatient treatment as usual (TAU). Overall, the core modules of the program are based on mindfulness-based cognitive therapy, taking into account both Chadwick's recommendations for implementing mindfulness in psychosis as well as patient feedback. Each week, a new topic is introduced to enhance the understanding of four core aspects of mindfulness (breath, senses, detachment, and body awareness). The therapy sessions will be held by a psychotherapist in training in cognitive behavioral therapy with over three years of experience in mindfulness practice and supervised by a psychotherapist with more than a decade of experience in mindfulness-based therapeutic approaches. Within the sessions, short periods of meditation are used to avoid prolonged periods of silence, and basic anchoring techniques and easy-to-understand language are used.
89451427|NCT05491486|No Intervention|Treatment as Usual|All participants will be recruited from the outpatient facility at the Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin and therefore, the heterogeneity of the obtained treatment options can be limited. As the standard procedure in our outpatient facility, patients will be seen monthly by a psychiatrist as well as individual sessions by a psychotherapist or psychiatric nurse (1:2 ratio). Hence, regardless of the study condition, all participants will obtain high standard health care at a renowned university hospital outpatient facility according to official national and international treatment guidelines providing pharmacological therapy, psychological consultation, and, on-demand, psychosocial support by social workers. The amount of psychotherapy received and on-demand psychosocial support will be recorded during the study period.
88935975|NCT01785264|Active Comparator|Open surgery|Treatment is divided into three arms, and patients between 18 and 60 years of age sustaining first time achilles tendon ruptures will be invited to participate. All three groups will have identical rehabilitation protocol. Open surgical repair is done through a 10 cm longitudinal incision, through the fascia curries and the paratenon. After necessary revision of the injure site, the tendons ends is sutured with a double layer, three knot, Krakow whip suture technique. 5 to 10 degrees of overcorrection compared to the uninjured side is endeavored. The paratenon is sewn as much as possible back over the injure site and suture material. The fascia is sutured and then continuous lying mattress skin suture.
88935976|NCT01785264|Active Comparator|Non-operative treatment|Non-operative treatment starts with casting the ankle in equinus position. The rest of the treatment from there on will be identical to the two other arms: Minimal invasive and open surgery. Casting lasts for 2 weeks for all three arms.
88935977|NCT01785264|Active Comparator|Mini-invasive surgery|Patients allocated to mini-invasive treatment will (as patients treated with open surgery) be operated within 7 days from injury with the technique developed by Dr Amlang and Prof Zwipp in Dresden. Patients in all three arms will have an active, early weight bearing rehabilitation protocol.
88935978|NCT01785277||SCIM scores for patients with SCI|All patients with SCI included in the study
88935979|NCT01785290|Experimental|Haloperidol 1mg/q8h|Prophylactic haloperidol of 1 mg/q8h i.v.
88935980|NCT01785290|Experimental|Haloperidol 2mg/q8h|Prophylactic haloperidol 2mg/q8h i.v.
88935981|NCT01785290|Placebo Comparator|Sodium chloride 0.9%|Placebo (Sodium chloride 0.9%) three times a day
88935982|NCT01785303|Active Comparator|Model A|Model A consists of a 4 session CBT-I in phase I and CPAP for OSA in Phase II.
88935983|NCT01785303|Active Comparator|Model B|Model B consists of 4 weeks of monitoring using sleep diaries in Phase I. Phase II consists of concurrent initiation of CBT-I and CPAP for OSA.
88935984|NCT01785303|Other|Model C|Model C consists of 4 weeks of monitoring with sleep diaries in Phase I. Phase II consists of CPAP for OSA.
88935985|NCT01785329|Experimental|alirocumab SAR236553 (REGN727) - Dose A|"alirocumab SAR236553 (REGN727) - Dose A - Injection in healthy subjects through subcutaneous administration in the abdomen.~alirocumab SAR236553 (REGN727) is a fully human monoclonal antibody that binds PCSK9 (proprotein convertase subtilisin/kexin type 9)"
88935986|NCT01785329|Experimental|alirocumab SAR236553 (REGN727) - Dose B|alirocumab SAR236553 (REGN727) - Dose B - Injection in healthy subjects through subcutaneous administration in the upper arm.
88935987|NCT01785329|Experimental|alirocumab SAR236553 (REGN727) - Dose C|alirocumab SAR236553 (REGN727) - Dose C - Injection in healthy subjects through subcutaneous administration in the thigh.
88935988|NCT01785355||Dental treatment|Assessment of the clinical state of the patient. Professional prophylaxis and removal of calculus. Extraction of hopeless teeth.Education of patient for oral hygiene. Periodic reevaluation.
88935989|NCT01785368|Other|Before guideline implementation|"This study population consists of all patients for whom a participating ER doctor requests an imaging exam during the observation period BEFORE the implementation of the referral guidelines.~[This study is composed of (1) a period of observation for 1 month BEFORE the implementation of the referral guidelines, followed by (2) the implementation of the referral guidelines, then (3) a 5-6 month washout period, and finally (4) a 1 month observational period AFTER the implementation of the referral guidelines.]~Intervention: Baseline observation"
88935990|NCT01785368|Other|After guideline implementation|"This study population consists of all patients for whom a participating ER doctor requests an imaging exam during the observation period AFTER the implementation of the referral guideline.~[This study is composed of (1) a period of observation for 1 month BEFORE the implementation of the referral guidelines, followed by (2) the implementation of the referral guidelines, then (3) a 5-6 month washout period, and finally (4) a 1 month observational period AFTER the implementation of the referral guidelines.]~Intervention: Implementation of guidelines"
88935991|NCT01785381|No Intervention|usual care|usual care
88935992|NCT01785381|Other|Added value of coordinator|Added value of coordinator
88935993|NCT01785394|Active Comparator|5 grass allergen extract|30 patients will receive the active component 5 grass allergen extract daily during the active pollen season (February-July)
88935994|NCT01785394|Placebo Comparator|Placebo|30 patients will receive placebo
88935995|NCT01785407|Active Comparator|80 mg FeSO4|
88935996|NCT01785407|Active Comparator|40 mg FeSO4|40 mg FeSO4
88935997|NCT01785407|Active Comparator|160 mg FeSO4|
88935998|NCT01785407|Active Comparator|240 mg FeSO4|
89451428|NCT05491408||patients exposed to cough assist device|the first group will include patients with COPD who received conventional management in addition to cough assist device
89451429|NCT05491408||patients not exposed to cough assist device|the second group will include COPD patients who received conventional management only.
89451430|NCT04285450|Experimental|Vitamin K 1mg|
89451431|NCT04285450|Placebo Comparator|Control|
89451432|NCT05497102|Experimental|Single arm of Lenalidomide maintenance|"[KRd #1~6, Every 4 weeks] D1, 2, 8, 9, 15,16 Carfilzomib 20mg/m2 + 5% dextrose in water 50 mL over 10 mins (From Cycle1Day8 27mg/m2) D1 - 21 Lenalidomide 25mg P.O. D1, 8, 15, 22 Dexamethasone 40mg IV or PO~[Autologous stem cell transplantation phase]~[Lenalidomide maintenance phase, Every 4 weeks] D1-28 Lenalidomide 10 mg"
89451433|NCT05496946|Experimental|Model with low proximity to reality group|The students included in the experimental group 1 practiced the head bathing skill on a model with low proximity to reality. The model used here is a human model belonging to the Gaumard Scientific company with low proximity to reality.
89451434|NCT05496946|Experimental|Standardized patient Group|The students in the experimental group 2 practiced the head bath skill on the standardized patient. A standardized patient is a healthy individual pretending to be a patient.
89451435|NCT03998254|Experimental|V503|Single 0.5-mL intramuscular injection at Day 1, Month 2, and Month 6
88935999|NCT01785446|Active Comparator|P 1|"In this group patients were aged from 20 to 45. Propofol infusion was used to maintain Bispectral Index (BIS) between 45 and 55.~Intermittent doses of sufentanil 10-20 microgram were given intra-operatively on a required basis."
88936000|NCT01785446|Active Comparator|P 2|"In this group patients were aged from 46 to 65. Propofol infusion was used to maintain Bispectral Index (BIS) between 45 and 55.~Intermittent doses of sufentanil 10-20 microgram were given intra-operatively on a required basis."
88936001|NCT01785446|Active Comparator|P 3|"In this group patients were aged from 66 to 85. Propofol infusion was used to maintain Bispectral Index (BIS) between 45 and 55.~Intermittent doses of sufentanil 10-20 microgram were given intra-operatively on a required basis."
88936002|NCT01785446|Active Comparator|D|"In this group patients were aged from 46to 65. Propofol infusion was used to maintain Bispectral Index (BIS) between 45 and 55.~Dexmedetomidine infusion is started at induction,a bolus dose of 0.5 µg/kg is given over the first hour which is followed by infusion of 0.4 µg/kg/hr.~Intermittent doses of sufentanil 10-20 microgram were given intra-operatively on a required basis."
88936003|NCT01785485||Primary care patients|Primary care patients who are members of UAIHC.
88936004|NCT01785498|No Intervention|Control Group|Receive standard clinical care and supports.
88936005|NCT01785498|Experimental|Supplementary resources|Receive standard care and supports plus supplementary resources developed for the intervention.
88936006|NCT01785511|Sham Comparator|Sham UVA|sham exposure will be provided by covering the UVA lamps with space blanket.
88936007|NCT01785511|Experimental|UVA Radiation|Patients will be exposed to UVA radiation for 20 minutes
88936008|NCT01785537||E-cigarettes only|Smokers of e-cigarettes containing nicotine only (non smoking traditional cigarettes and inhaling at least 50 puffs per week since six or more months). This group will be further split in the secondary analyses: never or former smokers of traditional cigarettes
88936009|NCT01785537||Traditional cigarettes only|Smokers of traditional cigarettes only (smokers of at least one traditional cigarette per day since six or more months). This group will be further split in the secondary analyses: recent and older smokers.
88936010|NCT01785537||Mixed group|Smokers of both electronic and traditional cigarettes (at least one per day since six or more months). This group will be further split in the secondary analyses: mixed smokers who quit and who did not quit traditional cigarette smoking during follow-up
88936011|NCT01785550||Control Group|No intervention to be performed.
88936012|NCT01785550||Ultrasound Group|All will receive nerve and muscle ultrasound.
88936013|NCT01785576|Experimental|Couple-Based CBT Intervention|Patients and partners will receive 4 sessions of a couple-based cognitive behavioral intervention focusing on communication and spousal support.
88936014|NCT01785576|No Intervention|Treatment as Usual|The treatment as usual group will complete all assessements and will not receive the psychosocial couple based intervention.
88936015|NCT01785589|Other|coronary angiography-FFR-CZT|Patients who were referred to our cardiology department for stress-rest CZT SPECT for known or suspected CAD and submitted for a clinical reason to invasive coronary angiography within 2 month of the SPECT studies. for these patients, A 6 French arterial sheath was introduced into the radial artery. After administration of 5000 U heparin, the guiding catheter was advanced into the coronary ostium. Intracoronary nitroglycerin 0.2 mg was administered, and reference images were made. Significant CAD was defined as presentation of a stenosis ≥70 % in the three-epicardial vessels and ≥ 50 % in left main coronary disease. If necessary (at the discretion of the practitioner) the pressure wire was advanced across the stenosis, and Fractional flow reserve (FFR) was measured.
88936016|NCT01785654||reventilation collapse|
88936017|NCT01785667||Young Danish adults with type 1 diabetes|This is an observational study with no interventions.
88936018|NCT01785693|Other|NaC1|The aim of this study is to assess, in patients scheduled for femoropopliteal bypass, the benefit of a double peripheral nerve block (femoral + sciatic) with levobupivacaine and clonidine in a single dose, performed before induction of general anaesthesia, on analgesia postoperatively assessed by morphine consumption.
88936019|NCT01785693|Other|Levobupivacaine + clonidine|The aim of this study is to assess, in patients scheduled for femoropopliteal bypass, the benefit of a double peripheral nerve block (femoral + sciatic) with levobupivacaine and clonidine in a single dose, performed before induction of general anaesthesia, on analgesia postoperatively assessed by morphine consumption.
88936020|NCT01785732|Active Comparator|Renal denervation|Patients are randomized to renal denervation
89451436|NCT03998254|Active Comparator|Gardasil|Single 0.5-mL intramuscular injection at Day 1, Month 2, and Month 6
89451437|NCT03994978||Surgical group|Patients with uncomplicated recurrent diverticulitis undergoing elective sigmoid resection
89451438|NCT03994978||Conservative group|Patients with uncomplicated recurrent diverticulitis with conservative treatment
89451439|NCT05496400||Group I|(anemic group)
89451440|NCT05496400||Group II|(non-anemic group)
89451441|NCT05490628|Active Comparator|Control Group|"Traditional exercises:~stretching exercises, strengthening exercises, balance exercises, walking exercises and fine motor skill exercises."
89451442|NCT05490628|Experimental|Cognitive Rehabilitation Group|Cognitive rehabilitation; memory, executive function, attention, concentration and calculation exercises.
89451443|NCT05496088|Active Comparator|Group 1: Re-PVI only|Repeat ablation of pulmonary veins (Re-PVI), followed by electrical cardioversion if AF persists, n=100 pts
89451444|NCT05496088|Active Comparator|Group 2: Re-PVI + substrate ablation|Repeat ablation of pulmonary veins (Re-PVI) + mapping & ablation of areas of continuous, complex activity, n=100 pts
89451445|NCT04175938|Active Comparator|Subjects with Fuch's Endothelial Dystrophy|Persons with a diagnosis of Fuch's Endothelial Dystrophy will wear a contact lens in an affected eye for three hours.
89451446|NCT04175938|Other|Subjects with healthy eyes|Persons with healthy eyes will wear a contact lens in one eye for three hours.
89451447|NCT05490160||Tranexamic acid group|During the total knee arthroplasty, the patients received a 2-g retrograde injection of tranexamic acid through the drain after closure, with subsequent clamping of the drain for 6 hours.
89451448|NCT05490160||Non-tranexamic acid group|During the total knee arthroplasty, the patients did not receive tranexamic acid administration.
88936021|NCT01785732|No Intervention|Optimization of medical therapy|Antihypertensive treatment is optimized
89451449|NCT05495620||Relapsed and/or refractory multiple myeloma|Multiple myeloma in relapsed but not refractory, relapsed and refractory, and primary refractory status
89451450|NCT05490082|Active Comparator|Mirabegron arm|50 mg PO once daily
89451451|NCT05490082|Active Comparator|Propevirine arm|15 mg PO twice daily
88936022|NCT01785745|Active Comparator|Traditional therapeutic exercise|The traditional exercise protocol contains mainly strengthening exercises, stretching exercises, Codman's pendulum exercises and exercises against elastic band resistance.
89451452|NCT05490082|Active Comparator|Solifenacin arm|10 mg PO once daily
89451453|NCT05490082|Placebo Comparator|Placebo arm|starch tablet once daily
89451454|NCT02559310|Experimental|Lefamulin|Intravenous lefamulin with potential step-down to oral lefamulin
89451455|NCT02559310|Active Comparator|Moxifloxacin +/- Linezolid|Intravenous moxifloxacin with potential step-down to oral moxifloxacin +/- linezolid
89451456|NCT05495542|Experimental|Shotblocker group|In the ShotBlocker group, ShotBlocker was placed on the previously determined injection site before vaccination, and the vaccination was performed by holding it on the surface of the skin and pressing lightly with the fingertips. All vaccinations were carried out by an experienced nurse. ShotBlocker was removed after removing the needle.
89451457|NCT05495542|No Intervention|Control group|In the control group, the steps of administering a normal intramuscular injection were used. Except for this, no additional method was used. All vaccinations were carried out by an experienced nurse.
89451458|NCT05490004|Active Comparator|Facilitator-Led VEGA|"Facilitator-led VEGA uses a group-based approach where participants complete the Violence, Evidence, Guidance, Action Project (VEGA) content as a virtual or face-to-face workshop (i.e., facilitator-led VEGA). In this study, all workshops will be virtual to prevent social gathering during COVID-19.~If a participant is randomized to this arm, the active control arm, they will be informed that they need to attend a facilitator-led VEGA session via virtual workshop format. The AC intervention will be facilitated via Zoom technology, by two trained facilitators with between 10 to 20 participants in each workshop (keeping the recommended 10:1 participant-to-facilitator ratio) and will last approximately 3 hours. The workshop approach is delivered by trained facilitators and is standardized via the use of a flexibly structured facilitator's guide. Facilitator-led VEGA will deliver material didactically with synchronous lecturing, use case-based role play, and include group-based polling."
89537131|NCT03299777||Preeclampsia group|All patients diagnosed with preeclampsia will undergo the fibroscan test.
88936023|NCT01785745|Experimental|Neurocognitive therapeutic exercise|The neurocognitive exercise protocol contains ten exercises involving specific instruments (e.g., table inclined with a board with five concentric circles, sponges of various texture).
88936024|NCT01785758|Experimental|Renal Group|Sugammadex (4mg/Kg) single dose to reverse profound neuromuscular blockade
88936025|NCT01785758|Active Comparator|Control group|Sugammadex (4mg/Kg) single dose to reverse profound neuromuscular blockade
88936026|NCT01785784|Experimental|burn patients|
88936027|NCT01785797|No Intervention|Control: burr hole drainage only|Burr hole drainage of chronic subdural hematoma under general or local anesthesia without the subsequent placement of a subdural drain.
88936028|NCT01785797|Experimental|Intervention: silicon subdural drain|Placement of a silicon subdural drain after burr hole drainage of a chronic subdural hematoma.
88936029|NCT01785823|Experimental|FX2-2-2|Their background infusions of fentanyl diluent (2 ml/hr of diluent was equivalent with 0.5 μg/kg/hr of fentanyl) were maintained at the fixed-rate of 2 ml/hr until the postoperative 24 hr
88936030|NCT01785823|Active Comparator|D6-4-2|Their background infusions of fentanyl diluent (2 ml/hr of diluent was equivalent with 0.5 μg/kg/hr of fentanyl) were maintained at the decremental rates of 6.0 ml/hr (D6-4-2) during 1 hr, 4.0 ml/hr during 1~3 hr and 2.0 ml/hr during 3~24 hr,
88936031|NCT01785823|Active Comparator|D8-4-2|Their background infusions of fentanyl diluent (2 ml/hr of diluent was equivalent with 0.5 μg/kg/hr of fentanyl) were maintained at at the decremental rates of 8.0 ml/hr (D8-4-2) during 1 hr, 4.0 ml/hr during 1~3 hr and 2.0 ml/hr during 3~24 hr,
88936032|NCT01785836|Experimental|Dapsone Formulation A|Dapsone Formulation A applied once daily to the face and upper chest, upper back, and shoulders (as per protocol) for 12 weeks.
88936033|NCT01785836|Experimental|Dapsone Formulation B|Dapsone Formulation B applied once daily to the face and upper chest, upper back, and shoulders (as per protocol) for 12 weeks.
88936034|NCT01785836|Experimental|Dapsone Formulation C|Dapsone Formulation C applied once daily to the face and upper chest, upper back, and shoulders (as per protocol) for 12 weeks.
88936035|NCT01785836|Active Comparator|Dapsone 5% Gel|Dapsone 5% gel (ACZONE®) applied twice daily to the face and upper chest, upper back, and shoulders (as per protocol) for 12 weeks.
88936036|NCT01785862|Experimental|Drug|V0498, Ibuprofen 25 mg
88936037|NCT01785862|Placebo Comparator|Placebo|Placebo
88936038|NCT01785888||Locally advanced/metastatic NSCLC pts.|Patients(pts.) with locally advanced (stage IIIA/B) or metastatic NSCLC who have not received any local or systemic chemotherapy, and are not eligible for curative treatment (including surgery and chemoradiotherapy)
88936039|NCT01785901||Target subject population 1500|Asthma patients who have already received the treatment of budesonide/formoterol by physicians' determination and whose medications are aligned with the package insert of budesonide/formoterol approved in China
88936040|NCT01785914||1|
88936041|NCT01785927|Other|ABCD|ABCD A = rifampicin, B = isoniazid, C= pyrazinamide, D = levofloxacin
88936042|NCT01785927|Other|BCDA|BCDA A = rifampicin, B = isoniazid, C= pyrazinamide, D = levofloxacin
88936043|NCT01785927|Other|CDAB|CDAB A = rifampicin, B = isoniazid, C= pyrazinamide, D = levofloxacin
88936044|NCT01785927|Other|DABC|DABC A = rifampicin, B = isoniazid, C= pyrazinamide, D = levofloxacin
88936045|NCT01785940|Experimental|Interscalene block|Interscalene catheters will be placed under aseptic precautions in each patient by one of the investigators using combined peripheral nerve stimulation and ultrasound guidance to get twitch in the C5-C6 dermatomes and documented spread of injectate near C5-6 nerve roots. Twenty mL of 0.2% ropivacaine will be injected while documenting adequate drug spread under ultrasound. After 20 min of injection, the interscalene nerve block will be evaluated and considered successful with inability to abduct the shoulder and a decrease in perceived sensation to cold of the skin over the deltoid muscle.
88936046|NCT01785953||1|
88936047|NCT01785966|Experimental|Daily checklist and clinician prompting|Checklist during multidisciplinary daily visits + clinician prompting + audit & feedback
88936048|NCT01785966|No Intervention|Usual care|Usual care
88936049|NCT01785979|Experimental|Prednisone induction - chloroquine|0.5 mg/Kg daily of prednisone for 4 weeks after randomization, 0.25 mg daily for weeks 5-6, 0.15 mg daily for week 7 and 2.5 mg daily for week 8 and chloroquine at a fixed dose (300 mg base per week) for months 1-12
88936050|NCT01785979|Active Comparator|chloroquine|chloroquine at a fixed dose (300 mg base per week) for months 1-12
88936051|NCT01785992|Other|Irosustat (Single arm study)|Patients will receive 40mg of Irosustat once daily in addition to the aromatase inhibitor on which they progressed until disease progression or the development of unacceptable toxicities.
88936052|NCT01786005|Sham Comparator|Sham|Imitation of stimulation.
88936053|NCT01786005|Experimental|High-frequency stimulation|High-frequency stimulation
88936054|NCT01786005|Experimental|TBS Theta burst stimulation|TBS Theta burst stimulation
88936055|NCT01786005|Experimental|Low-frequency stimulation|Low-frequency stimulation
88936056|NCT01786018|Experimental|1|"Thiotepa 5 mg/kg/day on days -7, -6 (Total Dose 10 mg/kg)~Busulfan (i.v.) 3.2 mg/kg on days -5,-4,-3 (Total Dose 9.6 mg/kg)~Fludarabin: 50 mg/m2/day on days -5,-4,-3 (Total Dose 150 mg/m2)"
89451459|NCT05490004|Experimental|Self-Directed VEGA|"Self-directed VEGA uses an approach where participants complete the Violence, Evidence, Guidance, Action Project (VEGA) content online as a self-directed educational activity, at their own pace in a series of modules. Individuals will register to access the VEGA Education Resources site. Participants have the option of completing the self-directed VEGA arm in either English or French as the VEGA Educational Resources site offers the content in French and English.~If a participant is randomized to the experimental arm, they will be asked to complete the self-directed VEGA at their convenience, within one week of when they are informed they have been asked to complete the self-directed VEGA program. It will take approximately 3 hours for participants to complete all modules.~Participants will read didactic material, complete case-based animated simulations, and complete individual multiple-choice questions with response feedback."
88936057|NCT01786031|Experimental|experimental|metastasis biopsy
88936058|NCT01786044|Experimental|MasterMed|MasterMed, an online interactive educational program
88936059|NCT01786044|Placebo Comparator|Usual care|Access to an online patient portal
88936060|NCT01786057|Active Comparator|Extracorporeal shock wave therapy 1|Extracorporeal shock wave therapy , (3000 shock waves/session of 0.2 mJ/mm2) for heel region and (400 shock waves/session of 0.2 mJ/mm2 per each trigger point) for gastrosoleus trigger points , 3 sessions at weekly intervals
88936061|NCT01786057|Placebo Comparator|Extracorporeal shock wave therapy 2|Extracorporeal shock wave therapy , (3000 shock waves/session of 0.2 mJ/mm2) for heel region , 3 sessions at weekly intervals
88936062|NCT01786070|Active Comparator|Budesonide|Budesonide : 1 mg/4ml every 12 hrs for 48 hrs
88936063|NCT01786070|Placebo Comparator|Placebo|Normal saline at an equivalent volume (4 ml every 12 hrs for 48 hrs)
88936064|NCT01786083|Experimental|Lifestyle counseling|Application of Problem Solving Technique
88936065|NCT01786083|No Intervention|No counseling|Usual care by caregiver
88936066|NCT01786096|Experimental|SGN-CD19A|SGN-CD19A (IV) once (Day 1) or twice (Days 1 and 8) every 21 days; dose range: 0.3-6 mg/kg
88936067|NCT01786122|Experimental|Exercise group|supervised exercise program education program on healthy habits Pharmacological treatment and selfcare encouragement
88936068|NCT01786122|No Intervention|control group|Pharmacological treatment and selfcare encouragement.
88936069|NCT01786135|Experimental|SGN-CD19A|SGN-CD19A (IV) once every 21 days (3 weeks) or 42 days (6 weeks)
89451460|NCT04150276|Active Comparator|ZEEP during awakening|ZEEP will be used during emergence preoxygenation and awakening.
88936070|NCT01786200|Active Comparator|Aspirin|20 patients randomised to aspirin 75mg PO once daily
88936071|NCT01786200|Active Comparator|Ibuprofen|20 patients randomised to ibuprofen 400mg PO three times daily
88936072|NCT01786200|No Intervention|Control|20 patients randomised to receive no treatment
88936073|NCT01786213||Colonoscopist A|
88936074|NCT01786213||Colonoscopist B|
88936075|NCT01786213||Colonoscopist C|
88936076|NCT01786213||Colonoscopist D|
88936077|NCT01786213||Colonoscopist E|
88936078|NCT01786213||Colonoscopist F|
88936079|NCT01786213||Colonoscopist G|
88936080|NCT01786213||Colonoscopist H|
88936081|NCT01786213||Colonoscopist I|
88936082|NCT01786213||Colonoscopist J|
88936083|NCT01786226|Experimental|Mifepristone 2.5 mg daily for three months|Experimental: 1
88936084|NCT01786226|Experimental|Mifepristone 5 mg daily for three months|Experimental: 2
88936085|NCT01786278|Experimental|Brachytherapy|Single dose of 12 Gy generated using a flexible applicator containing Iridium 192 with the range of irradiation of 1cm from the applicator axis. The extent of irradiation will cover the whole length of cancer stricture and 2cm beyond proximal and distal end of the tumor.
88936086|NCT01786278|Other|Endoscopic Stenting|Endoscopic stenting with partially covered selfexpandable metalic stents positioned across the cancer stricture and extending 2cm proximally and 2cm distally to the proximal and distal end of the tumor, respectively
88936087|NCT01786291||CPAP compliant|CPAP (continuous positive airway pressure) compliant patients
88936088|NCT01786291||CPAP non-compliant|patients who did not use CPAP therapy
88936089|NCT01786304||Fecal incontinence|Patient with fecal incontinence and referred for a treatment with sacral nerve stimulation
88936090|NCT01786317||Fecal incontience|Patient with fecal incotinence who will be explored using high resoltuion manometry
88936091|NCT01786317||Healthy controls|Healthy volunteers who will be explored using high resoltuion manometry
88936092|NCT01786356|Other|HOYA iMics Y-60H|eyes with implanted intraocular lens HOYA iMics Y-60H
88936093|NCT01786356|Other|B&L MI60|eyes with implanted intraocular lens B&L MI60
89451461|NCT04150276|Active Comparator|PEEP during awakening|PEEP is maintained throughout emergence preoxygenation and awakening.
89451462|NCT05495308||NON-DISTANT METASTASES|Those patiens who do not develop distant metastasis during the follow-up time.
89451463|NCT05495308||DISTANT METASTASES|Those patiens who develop distant metastasis during the follow-up time.
89451464|NCT04149808|Active Comparator|Xeroform Control|A single wound is treated with both the control (xeroform dressing) and intervention (Mepilex Ag). Approximately 50% of the wound is treated with xeroform dressing, which is the standard of care.
89451465|NCT04149808|Experimental|Mepilex Ag Intervention|A single wound is treated with both the control (xeroform dressing) and intervention (Mepilex Ag). Approximately 50% of the wound is treated with Mepilex Ag; the product being tested.
89451466|NCT05495152|Experimental|Adjuvant Arm|Patients in arm A receive 17 cycles of Sintilimab within 4 to 12 weeks after esophagectomy for ESCC. Sintilimab was administered intravenously at a dose of 200 mg over 30 minutes every 3 weeks.
89451467|NCT05495152|No Intervention|Observation Arm|Patients in observation arm receive routine follow-up after surgery.
88936094|NCT01786369||Admitted Patients with Acute Psychosis|Patients 18 years of age or older with a documented diagnosis of schizophrenia, schizoaffective disorder, or bipolar 1 disorder who are admitted to an inpatient psychiatric unit at Zucker Hillside Hospital for a psychotic compensations. Patients must have been in the outpatient setting for at least one month prior to admission on a regimen including risperidone, olanzapine, quetiapine, paliperidone or aripiprazole.
88936095|NCT01786382|Experimental|midazolam|potential effects of PPI-668 on midazolam pharmacokinetics
88936096|NCT01786382|Experimental|omeprazole|potential effects of PPI-668 on omeprazole pharmacokinetics
88936097|NCT01786382|Experimental|telaprevir|potential effects of PPI-668 on telaprevir pharmacokinetics
88936098|NCT01786395|Experimental|- UF-021|UF-021 is experimental code for isopropyl unoprostone
88936099|NCT01786395|Placebo Comparator|- Placebo|
88936100|NCT01786408|Experimental|TAP20-C|Single Use Integrated Capillary Blood Collection System
88936101|NCT01786408|Active Comparator|SAFE-T-FILL CAPILLARY SYSTEM|Single Use Capillary Blood Collection System
88936102|NCT01786421||General population|Healthy volunteers,patients with hyperlipidemia,a known medical history of cardiovascular diseases or type 2 diabetes mellitus.
88936103|NCT01786447||Traumatic Brain Injury|Patients who present to the health care facility with mild or moderate traumatic brain injury (Glasgow Coma Scale 9-15) within 4 hours of injury
88936104|NCT01786447||Orthopedic Control|Patients who present to the health care facility with isolated extracranial orthopedic injury within 4 hours of injury
88936105|NCT01786460||Healthy Volunteers|
88936106|NCT01786473|Experimental|Testogel 1% 5g QD|
88936107|NCT01786473|Placebo Comparator|Placebo gel 5g QD|
88936108|NCT01786499|Other|Relaxation Response Training|
88936109|NCT01786525|Experimental|House Calls only|60-minute educational intervention in patient's home which will be delivered by a health educator.
88936110|NCT01786525|Active Comparator|House Calls + Web-Based Decision Support|Home based intervention plus web-based patient-centered decision support program that will be offered to participants following the home based intervention.
88936111|NCT01786525|No Intervention|Control|100 patients on the Organ Transplant Tracking Record who are not receiving the study intervention
88936112|NCT01786538|Experimental|Regorafenib/FOLFOX|
88936113|NCT01786538|Active Comparator|Placebo/FOLFOX|
88936114|NCT01786577||Surgery|80 patients will undergo total knee replacement surgery; two Magnetic Resonance Imaging scans; cognitive assessment testing.
88936115|NCT01786577||Non-Surgery|80 non-surgery participants will be included as part of the control group; two Magnetic Resonance Imaging scans; cognitive assessment testing.
88936116|NCT01784939||HEPFER cohort|"male, aged 18 and over, hereditary hemochromatosis C282Y homozygous diagnosed and followed in the service of Liver Diseases, University Hospital of Rennes~- Maintenance therapy with phlebotomy for at least 1 year with stable iron stock on the basis of at least four previous plasma ferritin < 50μg / L"
88936117|NCT01786616||Formoterol|12 mcg BID for four weeks
88936118|NCT01786642||conscious|bronchoscopy without sedative drugs
88936119|NCT01786642||conscious sedation|bronchoscopy under midazolam
88936120|NCT01786655|Experimental|Neosaxitoxin in saline|Subjects receive only one injection of NeoSTX in saline on the back of one calf (test side). Subjects receive NeoSTX in saline in subsequent dose escalation levels: 5mcg, 10mcg, 15mcg, 20mcg, 30mcg, and 40mcg NeoSTX.
88936121|NCT01786655|Experimental|Neosaxitoxin + bupivacaine 0.2%|Subjects receive only one injection of NeoSTX in combination with 0.2% bupivacaine on the back of one calf (test side). Subjects receive NeoSTX in bupivacaine in subsequent dose escalation levels: 5 mcg, 10 mcg, 15 mcg, 20 mcg, 30 mcg, and 40 mcg NeoSTX.
88936122|NCT01786655|Experimental|Neosaxitoxin + bupivacaine 0.2% + epinephrine 5mcg/ml|Subjects receive one injection of NeoSTX in bupivacaine 0.2% with epinephrine 5 mcg/ml on the back of one calf (test side). Subjects receive NeoSTX in bupivacaine 0.2% with epinephrine 5 mcg/ml in doses of 10 mcg or 30 mcg of NeoSTX.
88936123|NCT01786655|Placebo Comparator|Saline placebo|Subjects receive one injection of saline on the back of one calf (test side).
88936124|NCT01786681|Experimental|Positive pressure before surgery|Subjects treated with positive pressure in the BiPAP mode (Bi-Level Positive Airway Pressure) for one hour before bariatric surgery.
88936125|NCT01786681|Experimental|Positive pressure during the surgery|Individuals treated with 10 cm H2O of PEEP (Positive End Expiratory Pressure) during the surgical procedure.
89451468|NCT04147624|Experimental|Treatment Group|Participants in the treatment group will receive 125 mL of Souvenaid taken by mouth, once daily, for 6 consecutive months.
89451469|NCT04147624|Placebo Comparator|Placebo Group|Participants in the treatment group will receive 125 mL of iso-caloric placebo taken by mouth, once daily, for 6 consecutive months.
89451470|NCT05489848|Experimental|Arm1: Chemotherapy group|Paclitaxel plus carboplatin (TC) regimen, intravenous chemotherapy. Once every three weeks with total of 6 cycles.
88936126|NCT01786681|Experimental|Positive pressure after surgery|Subjects treated with positive pressure in the BiPAP mode (Bi-Level Positive Airway Pressure) for one hour after bariatric surgery.
88936127|NCT01786681|No Intervention|Control|Individuals treated with conventional physiotherapy according to the routine service of physiotherapy of the hospital.
88936128|NCT01786694|Experimental|cma microdialysis catheter placement|At the end of the surgery the cma microdialysis catheter is placed near the anastomosis
88936129|NCT01786720||Prior Triple Therapy|Patients prescribed triple therapy prior to initial date of COPD diagnosis
88936130|NCT01786720||Triple therapy at COPD diagnosis|Patients prescribed triple therapy on date of initial COPD diagnosis
88936131|NCT01786720||Triple therapy after COPD diagnosis|Patients prescribed triple therapy after initial date of COPD diagnosis
88936132|NCT01786733|Experimental|Behavioral Activation|Behavioral Activation + Treatment as Usual. 12 sessions twice weekly (i.e. 6 weeks). Individual therapy. Therapy is initiated during inpatient admission and continue after discharge. Protocol aimed at increased activation towards goals and personal values and decreased avoidance behaviors.
89200901|NCT00985816|Active Comparator|L reuteri DSM 17938|L. reuteri DSM 17938 will be given at a dose of 1x108 colony forming units (CFU)/day in an oil formulation delivered from a drop bottle. In the active study product, freeze-dried L. reuteri is suspended in a mixture of pharmaceutical grade medium chain triglycerides and sunflower oil together with pharmaceutical grade silicon dioxide to give the product the correct rheological properties (Connolly, 2005). The placebo consists of an identical formulation except that the L. reuteri is not present. This dose of the oil formulation with L. reuteri has been shown to induce significant colonisation in infants and is well-tolerated (Abrahamsson et al., 2007; Savino et al., 2007; Indrio et al., 2008).
88936133|NCT01786733|Active Comparator|Supportive Therapy|Supportive Therapy + Treatment as Usual. 12 sessions twice weekly (i.e. 6 weeks). Individual therapy. Therapy is initiated during inpatient admission and continue after discharge. Protocol aimed at providing psychological non-directive support.
88936134|NCT01786746|Experimental|Psychotherapy|Psychotherapy arm that consists of a randomization into 12 session manualized cognitive behavioral therapy or culturally adapted cognitive behavioral therapy for Chinese Americans.
88936135|NCT01786759|Active Comparator|LCT lipid emulsion|the LCT lipid emulsion is Intralipid
88936136|NCT01786759|Experimental|Olive oil lipid emulsion|the olive oil lipid emulsion is ClinOleic
88936137|NCT01786772|Experimental|Cryotherapy and compression|Cryotherapy and intermittent pneumatic compression will be applied to the knee joint using a recirculating compression unit and knee sleeve. This unit will recirculate water which is between 1-3° C. Circumferential intermittent pneumatic compression to the knee joint (5 to 50 mm Hg) will be applied in conjunction with cryotherapy. The duration of intervention will be 20 minutes.
88936138|NCT01786772|Active Comparator|Cryotherapy|Cryotherapy will be applied to the knee joint using a recirculating compression unit and knee sleeve. This unit will recirculate water which is between 1-3° C. The duration of intervention will be 20 minutes.
88936139|NCT01786798|Other|Transvaginal sonography|
88936140|NCT01786811|Experimental|Trained Clinicians|Clinicians randomized into this group will receive training in using the Serious Illness Conversation Guide with their patients. Patients of these clinicians will also be in the intervention arm.
88936141|NCT01786811|No Intervention|Non-trained Clinicians|Clinicians randomized into this group will not receive training in using the Serious Illness Conversation Guide with their patients. They will provide usual care. Patients of these clinicians will also be in the control arm.
88936142|NCT01786811|No Intervention|Non-volunteer Clinicians|These clinicians do not agree to participate in the study. They will continue to provide usual care. Their patients will be invited to participate and be followed.
88936143|NCT01786824|Experimental|Bicarbonate|"The patients included in this arm will be administered a hydration regime for the prevention of contrast-induced nephropathy containing sodium bicarbonate.~Intervention: Hydration strategy using sodium bicarbonate Intervention: Coronarography"
88936144|NCT01786824|Active Comparator|Saline|"The patients included in this arm will be administered a hydration regime for the prevention of contrast-induced nephropathy using sodium chloride solution.~Intervention: Hydration strategy using saline Intervention: Coronarography"
88936145|NCT01786824|Experimental|Bicar + L-Carnitine|"The patients included in this arm will be administered a hydration regime for the prevention of contrast-induced nephropathy containing sodium bicarbonate. They will also receive an oral L-carnitine solution on days -1, 0, 1 to 7.~Intervention: Hydration strategy using sodium bicarbonate Intervention: L-carnitine Intervention: Coronarography"
88936146|NCT01786824|Experimental|Saline + L-carnitine|"The patients included in this arm will be administered a hydration regime for the prevention of contrast-induced nephropathy using sodium chloride solution. They will also receive an oral L-carnitine solution on days -1, 0, 1 to 7.~Intervention: Hydration strategy using saline Intervention: L-carnitine Intervention: Coronarography"
88936147|NCT01786837|Experimental|Treatment|FMS will be administered for 5 weeks
88936148|NCT01786837|Sham Comparator|Sham|FMS at 5% intensity for 5 weeks
88936149|NCT01786863||Neuromuscular blockade|
88936150|NCT01786889|Experimental|Patient with angiosarcoma of the liver|Blood and urine collections, questionnaire and telephone interview
89200902|NCT00985816|Placebo Comparator|Placebo|
88936151|NCT01786915|Experimental|Bendavia 10mg|Bendavia capsule, 10mg, once daily for 7 days
88936152|NCT01786915|Placebo Comparator|Placebo|Placebo (matching), once daily for 7 days
88936153|NCT01786915|Experimental|Bendavia 50mg|Bendavia capsule, 50mg, once daily for 7 days
88936154|NCT01786928|Experimental|resistance training|resistance training of the upper and lower limbs, two series of 80% of repetition maximum test
88936155|NCT01786928|No Intervention|Control|Traditional Respiratory Therapy for bronchial hygiene
88936156|NCT01786941|No Intervention|Lean Group|Healthy Controls - no intervention
89451471|NCT05489848|Active Comparator|Arm2: Radiotherapy plus chemotherapy group|"Stage IA: TC(Paclitaxel plus carboplatin) regimen for 4 course+/-VBT.~Stage IB-II ( with no residual disease): TC regimen for 2 course +EBRT (external irradiation radiotherapy) plus cisplatin concurrent chemotherapy +TC regimen for 2 course ±VBT.~Stage III-IVA ( with no residual disease) and any stage except IVB (residual disease <2cm): TC regimen for 2 course +EBRT (external irradiation radiotherapy) plus cisplatin concurrent chemotherapy +TC regimen for 2 course ±VBT.~Radiotherapy can be started 3 weeks after the completion of the chemotherapy, and Chemotherapy can be started 2 - 3 weeks after the completion of radiotherapy."
89451472|NCT05489770|Active Comparator|Sambucol® Black Elderberry Original (Sambucus nigra) Liquid|"Constituents: 29.4 % (w/w) Black Elderberry (Sambucus nigra) fruit juice, 70% (w/w) of glucose syrup.~The main ingredient is black elderberry juice and it meets the requirements of the European Parliaments Directive (2012/12/EU) relating to fruit juices. The product also contains two food additives: citric acid (E330) as acidity regulator and potassium sorbate (E202) as preservative. Primary packaging: Plastic Polyethylene terephthalate (PET) amber bottles 120ml. Caps are white tamper-proof caps with security seal. Secondary Packaging: None. Outer Carton: Cardboard 376mm x 191mm x 116mm. 32 bottles per case."
89451473|NCT05489770|Placebo Comparator|Placebo for Sambucol® Black Elderberry Original (Sambucus nigra) Liquid|"Constituents: 70% (w/w) of glucose syrup, Flavouring agent: Elderberry Blossom. Colourants:~Carmoisine (311804) (E-122) and Brilliant Black (419358) E-151. The product also contains two food additives: citric acid (E330) as acidity regulator and potassium sorbate (E202) as preservative. Primary packaging: Plastic PET amber bottles 120ml. Caps are white tamper-proof caps with security seal. Secondary Packaging: None. Outer Carton: Cardboard 376mm x 191mm x 116mm. 32 bottles per case."
88936157|NCT01786941|Other|Pre-Diabetes Group|Pre-Diabetes Group will undergo a 6-mo Aerobic and Resistance combined exercise training intervention
88936158|NCT01786941|Other|Gastric Bypass Group|Non-diabetic patients intending to undergo Gastric Bypass surgery
88936159|NCT01786980||liver cancer, Radical hepatic resection|
88936160|NCT01787019|Experimental|30 weeks|initiation of oral feedings at 30 weeks
88936161|NCT01787019|Active Comparator|33 weeks|initiation of oral feedings at 33 weeks
88936162|NCT01787045|Experimental|Intervention Group|"Early and Active Physical Therapy will be performed by physiotherapist twice a day. During first week patients will be positioned in chair or bed and performed cycle-ergometer exercise during 30 min.~Our physiotherapy protocol will be continued until Intensive Care Unit (ICU) discharge."
88936163|NCT01787045|Other|Control Group|Routinary Passive Range of Motion will be performed by physiotherapist 20 min and twice a day until ICU discharge.
88936164|NCT01787058||Dubai Cares beneficiary|Pupils who attend a school that has benefitted from a water, sanitation and hygiene intervention as part of the Dubai Cares program.
88936165|NCT01787058||Control|Pupils who attend a school of the same size and location as a school that benefitted from a water, sanitation and hygiene (WASH) intervention through the Dubai Cares program, but which has not benefitted from that program or any other WASH program since 2009.
88936166|NCT01787071||one group|Patients receiving fluid challebnge
88936167|NCT01787084||Inoperable Patients Alternative Access|Non-femoral delivery (or alternative access) in patients iwht severe symptomatic native aortic valve stenosis who have been determined by a cardiac surgeon to be inoperable for open aortic valve replacement and in whom existing co-morbidities would not preclude the expected benefit from correction of the aortic stenosis
88936168|NCT01787110|No Intervention|No oxygen|"For patients randomised to withholding oxygen treatment~no oxygen is administered at any time as long as the oxygen saturation is ≥90% on pulse oximeter (repetitive checks are performed)~all patients receive standard acute coronary syndrome treatment including reperfusion strategies~observation duration 12 hours"
88936169|NCT01787110|Active Comparator|Oxygen|"For patients randomised to oxygen therapy:~6 L/min of oxygen delivered by oxymask® started immediately after inclusion of the ambulance service or in the emergency department given continuously for 6-12 hours (at least 6 hours)~all patients receive standard acute coronary syndrome treatment including reperfusion strategies"
88936170|NCT01787123|Placebo Comparator|Control: standard management|Standard management for patient suffering from aneurysmal subarachnoid haemorrhage
88936171|NCT01787123|Active Comparator|Intervention: standard management AND Cerebrolysin|Standard management for aneurysmal subarachnoid hemorrhage and a 14-day administration of intravenous Cerebrolysin
88936172|NCT01787149|Placebo Comparator|Placebo|DMARDs alone
88936173|NCT01787149|Experimental|ENIA11|ENIA11 25 mg
88936174|NCT01787162||myeloproliferative disorders|Echocardiography, spiroergometry, cardiac catheterization
88936175|NCT01787214|Active Comparator|Full dose|full dose of walnuts (20% energy needs)
88936176|NCT01787214|Active Comparator|Half-dose|Half dose of walnuts (10% of energy needs)
88936177|NCT01787214|Other|Control|Walnut free meals
89451474|NCT05489692||FOLFOX-HAIC plus targeted therapy and/or PD-1 inhibitors|"FOLFOX-HAIC as the following dosage: 130 mg/m2 oxaliplatin infusion for 2 hours; 400 mg/m2 of leucovorin infusion for 2 hours; and 400 mg/ m2 of 5-FU bolus and 1200 of mg/m2 continuous infusion of 5-FU for 23 hours.~Patients received targeted therapy, three different targeted therapy were applied including: 1. lenvatinib 2. sorafenib; 3. apatinib. A portion of patients received PD-1 inhibitor administered intravenously every three weeks."
89451475|NCT05494684|Experimental|Intervention Group|Children and parents receive a multisensoral nature-based intervention during venous blood sampling.
89015042|NCT01898494|Experimental|Arm S (Surgery) then Arm D (High risk, IMRT, chemotherapy)|Patients undergo transoral surgical resection of the oropharyngeal tumor. After transoral surgical resection of the oropharyngeal tumor, high risk patients then receive IMRT (66Gy) QD five days a week for 6-7 weeks. Patients also receive cisplatin IV over 60 minutes on days 1, 8, 15, 22, 29, 36, and 43 during radiation therapy.
89015043|NCT01893307|Experimental|Arm I (IMRT)|Patients undergo IMRT QD five days a week for approximately 6.5 weeks.
89015044|NCT01893307|Experimental|Arm II (IMPT)|Patients undergo IMPT QD five days a week for approximately 6.5 weeks.
89015045|NCT01892384|Experimental|BI 409306 dose 1|low dose, once daily
89015046|NCT01892384|Experimental|BI 409306 dose 2|medium dose, once daily
89015047|NCT01892384|Experimental|BI 409306 dose 3|high dose, once daily
89451476|NCT05494684|No Intervention|Control Group|The control group receives the usual standard care during venous blood sampling
89451477|NCT05489536|Experimental|A Web/smartphone-based Lifestyle Program Intervention Group|As this study is designed specifically to isolate the effect of introducing the web/app into the existing care pathway, the intervention group will receive standard prenatal care provided by health clinics and the web/smartphone app.
89451478|NCT05489536|No Intervention|Control Group|A standard usual prenatal care includes ten clinic visits for routine pregnancy checks (weight gain, iron status, blood pressure, fasting blood glucose etc.)
89451479|NCT05489458||Exploratory Surgery with Resection|Type A BR-PDAC patients that underwent surgical exploration after neoadjuvant therapy and had their tumors resected.
89451480|NCT05489458||Exploratory Surgery without Resection|Type A BR-PDAC patients that underwent surgical exploration after neoadjuvant therapy and did not have their tumors resected.
89451481|NCT00640419|Experimental|1|
89451482|NCT00640419|Experimental|2|
89451483|NCT00640419|Placebo Comparator|3|
89451484|NCT00640185|Placebo Comparator|1|
89451485|NCT00640185|Experimental|2|
89015048|NCT01892384|Placebo Comparator|Placebo|placebo, once daily
89015049|NCT01793662|Active Comparator|Open aortobifemoral bypass|Patients with aortoiliac occlusive disease (only, TASC Type D lesions) shall be randomized to either laparoscopic aortobifemoral bypass or open aortobifemoral bypass operation.
89015050|NCT01793662|Experimental|Laparoscopic aortobifemoral bypass|Patients with aortoiliac occlusive disease (only, TASC Type D lesions) shall be randomized to either laparoscopic aortobifemoral bypass or open aortobifemoral bypass operation.
89015051|NCT01778569||Group 1|Patient with a diagnosis of chronic plaque psoriasis, psoriatic arthritis, or pustular psoriasis
89015052|NCT01778504||Probands|Children, adolescents, and adults
89015053|NCT01778504||Relatives of Probands|1st, 2nd, and 3rd degree relatives
89015054|NCT01616758|Experimental|GTx-024 9mg|GTx-024 dosage of three soft gels once daily to equal 9mg
89015055|NCT01611311|Placebo Comparator|Placebo (Young subjects)|Young healthy subjects received placebo matching film-coated tablets of BI 409306 orally after an overnight fast once daily for 14 days
89015056|NCT01611311|Experimental|BI 409306 - 25 milligram (mg) (Young subjects)|Young healthy subjects received 25 mg of BI 409306 film-coated tablets orally after an overnight fast once daily for 14 days
89451486|NCT00640185|Experimental|3|
89451487|NCT00721695|Experimental|1|OMS302 Irrigation Solution
89451488|NCT00721695|Active Comparator|2|OMS302-PE HCl Irrigation Solution
89451489|NCT00721695|Placebo Comparator|3|Standard topical mydriatics and BSS Irrigation Solution
89451490|NCT00625833|Placebo Comparator|Placebo|
89015057|NCT01611311|Experimental|BI 409306 - 50 milligram (mg) (Young subjects)|Young healthy subjects received 50 mg of BI 409306 film-coated tablets orally after an overnight fast once daily for 14 days
89015058|NCT01611311|Placebo Comparator|Placebo (Elderly subjects)|Elderly healthy subjects received placebo matching film-coated tablets of BI 409306 orally after an overnight fast once daily for 14 days
89015059|NCT01611311|Experimental|BI 409306 - 25 milligram (mg) (Elderly subjects)|Elderly healthy subjects received 25 mg of BI 409306 film-coated tablets orally after an overnight fast once daily for 14 days
89015060|NCT01611311|Experimental|BI 409306 - 50 milligram (mg) (Elderly subjects)|Elderly healthy subjects received 50 mg of BI 409306 film-coated tablets orally after an overnight fast once daily for 14 days
89015061|NCT01569568||Subjects with OTCD|"males and females ages 7-60 years with OTCD who are able to undergo MRI and cognitive testing MRI scanning~1H MRS, DTI, FMRI Cognitive testing Neuropsychological testing"
89015062|NCT01569568||Healthy controls|"males and females ages 7-60 years who are healthy controls who are able to undergo MRI and cognitive testing MRI scanning~1H MRS, DTI, FMRI Cognitive testing Neuropsychological testing"
89451491|NCT00625833|Experimental|2|
89451492|NCT03299114|Active Comparator|Intervention Group|Treated with warm whirlpool
89451493|NCT03299114|Placebo Comparator|Placebo group|Treated with sham whirlpool
89451494|NCT03294356|Experimental|FT210771 Group|7 day at-home use of electronic cigarette FT210771 followed by a 2 day in-clinic period.
89451495|NCT03294356|Experimental|FT210751 Group|7 day at-home use of electronic cigarette FT210751 followed by a 2 day in-clinic period.
89451496|NCT03294356|Experimental|6T30134157764 Group|7 day at-home use of electronic cigarette 6T30134157764 followed by a 2 day in-clinic period.
89451497|NCT03294356|Experimental|G41A7C071 Group|7 day at-home use of electronic cigarette G41A7C071 followed by a 2 day in-clinic period.
89451498|NCT03294356|Experimental|M011161212 Group|7 day at-home use of electronic cigarette M011161212 followed by a 2 day in-clinic period.
89451499|NCT03294356|Experimental|FT21002 Group|7 day at-home use of combustible cigarette FT21002 followed by a 2 day in-clinic period.
89451500|NCT00718965|Experimental|25 mg/day AVE5530|
89451501|NCT00718965|Experimental|50 mg/day AVE5530|
88936178|NCT01787227||Blinded, Pre-selected Arm|For targets that exhibit lower prevalence rates in the intended use population, banked, pre-selected, positive clinical specimens will be tested.
88936179|NCT01787227||Blinded, Prospective Arm|Diagnostic accuracy for the more prevalent targets will be evaluated in prospectively collected, de-identified, left-over, clinical specimens accrued during the 2012/2013 flu season.
89451502|NCT00718965|Placebo Comparator|Placebo|
89451503|NCT03294200|Experimental|Tricinch Coil System treatment|
88936180|NCT01787253||Irritable bowel syndrome (IBS)|
88936181|NCT01787253||Healthy controls|
88936182|NCT01787253||Microscopic Colitis (MC)|
88936183|NCT01787253||Irritable bowel disease (IBD)|
88936184|NCT01787266||1|pregnant women
88936185|NCT01787318|Experimental|ePID closed loop system using Insupatch|Insupatch activated at mealtimes
88936186|NCT01787318|Active Comparator|ePID closed loop system without InsuPatch|InsuPatch will not be activated at mealtimes
88936187|NCT01787344|Experimental|Botulinum toxin type A (Botulax®)|Botulinum toxin type A (Botulax®)
88936188|NCT01787344|Active Comparator|Botulinum toxin type A(Botox®)|Botulinum toxin type A(Botox®)
88936189|NCT01787357|Experimental|Sequence 1 (ADBC)|Each volunteer will receive Treatment A on Day 1 of Treatment Period 1, followed by Treatment D on Day 1 of Treatment Period 2, followed by Teatment B on Day 1 of Treatment Period 3, and followed by Treatment C on Day 1 of Treatment Period 4. Each treatment period will be 2 days in duration and there will be a washout period (with no medication) of 10 to 14 days between each treatment period.
88936190|NCT01787357|Experimental|Sequence 2 (BACD)|Each volunteer will receive Treatment B on Day 1 of Treatment Period 1, followed by Treatment A on Day 1 of Treatment Period 2, followed by Treatment C on Day 1 of Treatment Period 3, and followed by Treatment D on Day 1 of Treatment Period 4. Each treatment period will be 2 days in duration and there will be a washout period (with no medication) of 10 to 14 days between each treatment period.
89015063|NCT01505894|Placebo Comparator|Placebo - Young Subjects|Placebo - Young Subjects
89015064|NCT01505894|Placebo Comparator|Placebo - Elderly Subjects|Placebo - Elderly Subjects
89451504|NCT03290924|Experimental|Intervention|Low-dose high-frequency health worker training approach to update skilled birth attendants in key evidence-based intrapartum and immediate newborn care practices
89451505|NCT03290924|Active Comparator|Comparison|Training on data collection and reporting
89451506|NCT03299036|Experimental|Taiwan ACE Beads with doxorubicin|The use of Taiwan ACE Beads (T-ACE) microspheres embolization with doxorubicin as a treatment for patients with hepatoma.
89451507|NCT03290846|Experimental|Secretin study|PET and MRI scannings will be performed twice. Subjects will be given secretin hydrochloride and placebo on separate days. In addition, subjects will undergo cold exposure PET scanning once.
89451508|NCT03298958|Placebo Comparator|Placebo Oral Tablet|Subject will be randomized to take the Placebo once daily for 2 years or until disease recurrence
89451509|NCT03298958|Active Comparator|Sirolimus (Rapamycin) 0.5 mg/day for 2 years|Subject will be randomized to take Sirolimus (Rapamycin) 0.5mg once daily for 2 years or until disease recurrence
89451510|NCT03294122||PCa patients - Discovery cohort|External beam radiotherapy for prostate cancer
89451511|NCT03294122||HNCa patients - Discovery cohort|External beam radiotherapy for head and neck cancer
89451512|NCT03294122||PCa patients - Validation cohort|External beam radiotherapy for prostate cancer
88936191|NCT01787357|Experimental|Sequence 3 (CBDA)|Each volunteer will receive Treatment C on Day 1 of Treatment Period 1, followed by Treatment B on Day 1 of Treatment Period 2, followed by Treatment D on Day 1 of Treatment Period 3, and followed by Treatment A on Day 1 of Treatment Period 4. Each treatment period will be 2 days in duration and there will be a washout period (with no medication) of 10 to 14 days between each treatment period.
89015065|NCT01505894|Experimental|BI 409306 25 mg - Young Subjects QD|25 milligram (mg) of BI 409306 were administered in young subjects once daily (QD).
89015066|NCT01505894|Experimental|BI 409306 25 mg - Elderly Subjects QD|25 mg of BI 409306 were administered in elderly subjects once daily (QD).
89015067|NCT01505894|Experimental|BI 409306 50 mg - Young Subjects QD|50 mg of BI 409306 were administered in young subjects once daily (QD).
89015068|NCT01505894|Experimental|BI 409306 50 mg - Young Subjects BID|50 mg of BI 409306 were administered in young subjects twice daily (BID).
89451513|NCT03294122||HNCa patients - Validation cohort|External beam radiotherapy for head and neck cancer
89451514|NCT03294044|Experimental|ICT programs|ICT programs that include health information learning by disease, and self-management based on Smart Management Strategy for Health (SMASH) are provided. After that, subjects will conduct self-management health care for 12 weeks. After 3 months, they finish self-management ICT programs, and then they fill out the questionnaire.
89200903|NCT01052389|Experimental|Aripiprazole|Aripiprazole (N05AX12)
89200904|NCT01052389|Experimental|Olanzapine|Olanzapine (N05AH03)
88936192|NCT01787357|Experimental|Sequence 4 (DCAB)|Each volunteer will receive Treatment D on Day 1 of Treatment Period 1, followed by Treatment C on Day 1 of Treatment Period 2, followed by Treatment A on Day 1 of Treatment Period 3, and followed by Treatment B on Day 1 of Treatment Period 4. Each treatment period will be 2 days in duration and there will be a washout period (with no medication) of 10 to 14 days between each treatment period.
88936193|NCT01787370||Patients undergoing coronary angiography|Consecutive patients referred for coronary angiography for the suspect of coronary artery disease
88936194|NCT01787396|Experimental|Arm1|Gemigliptin 50mg + Metformin Once daily with dinner
88936195|NCT01787396|Experimental|Arm 2|Gemigliptin 50mg + Placebo(Metformin)Once daily with dinner
88936196|NCT01787396|Experimental|Arm3|Metformin+ Placebo(Gemigliptin 50mg)Once daily with dinner
88936197|NCT01787422|Experimental|Telemedicine Visit|Patients who are seen by use of an off-site telemedicine physician.
88936198|NCT01787422|Active Comparator|Traditional Visit|Patients who are seen in followup with a traditional in-office visit.
88936199|NCT01787435||All women exposed to PPI at any time during pregnancy|Exposure to PPI defined as presence of at least one prescription of a PPI any time between last menstrual period and delievry date
88936200|NCT01787435||All women exposed to H2RA at any time during pregnancy|Exposure to H2RA defined as presence of at least one prescription of H2RA any time between last menstrual period and delivery date
88936201|NCT01787435||Pregnant women with no recorded use of acid suppressing drugs|Pregnant women with no recorded use of acid suppressing drugs at any time during pregnancy
88936202|NCT01787448|Experimental|Ibuprofen 5% topical gel|
88936203|NCT01787448|Experimental|Topical gel vehicle|
88936204|NCT01787448|Active Comparator|Sodium lauryl sulfate 0.1%|
88936205|NCT01787448|Sham Comparator|Sodium chloride solution 0.9% (saline)|
88936206|NCT01787474|Experimental|Treatment (NK cells)|Patients receive filgrastim-sndz SC QD beginning on day -7 and continuing until ANC are equal or over 1000. Patients also receive fludarabine phosphate IV over 30 minutes and approximately 4 hours later followed by cytarabine IV over 1 hour on days -6 to -2 (days -6 to -3 for patients over age 60). Beginning 2-7 days after the last dose of fludarabine phosphate and cytarabine, patients receive membrane-bound interleukin-21-expanded haploidentical natural killer cells IV over 30 minutes thrice weekly for 3 doses over 4 days (Monday-Thursday only).
88936207|NCT01787513|Experimental|CBM Version A + iCBT|CBM Version A is an Internet-based intervention taking place over 1 week followed by iCBT, an Internet-based treatment for depression taking place over 10 weeks.
88936208|NCT01787513|Placebo Comparator|CBM Version B (Control) + iCBT|CBM Version B (Control) is an Internet-based intervention taking place over 1 week (identical to CBM Version A without the putative active components) followed by iCBT, an Internet-based treatment for depression taking place over 10 weeks.
88936209|NCT01787526|Active Comparator|Oral Iron|oral iron in a corresponding dose of 10g (assuming an absorption of 10%, 100 capsules a 100mg iron each) taken over 8-12 weeks
88936210|NCT01787526|Experimental|Intravenous high dose iron|high dose intravenous iron (ferric carboxymaltose, 1000mg)
88936211|NCT01787539|Experimental|Complete Perioperative Chemotherapy|"Preoperative chemotherapy with EOX regimen: Epirubicin with intravenous bolus at a dose of 50 mg/m2 an on day 1; Oxaliplatin with intravenous infusion during a 2-hour period at a dose of 130 mg/m2; Capecitabine administrated orally at a twice daily dose of 625 mg /m2 during 21 days. Treatment cycles will be repeated every 3 weeks.~Surgery: total or subtotal gastrectomy with D2 lymph node dissection. The surgical resection will be conducted 4-6 weeks after preoperative chemotherapy.~Postoperative chemotherapy will be administrated in patients with tumor regression grade 0, 1, 2 randomized to perioperative chemotherapy and will be initiated 6 to 12 weeks after surgery with the same regimen as in the preoperative part."
88936212|NCT01787539|No Intervention|Preoperative Chemotherapy|"Preoperative chemotherapy with EOX regimen: Epirubicin with intravenous bolus at a dose of 50 mg/m2 an on day 1; Oxaliplatin with intravenous infusion during a 2-hour period at a dose of 130 mg/m2; Capecitabine administrated orally at a twice daily dose of 625 mg /m2 during 21 days. Treatment cycles will be repeated every 3 weeks.~Surgery: total or subtotal gastrectomy with D2 lymph node dissection. The surgical resection will be conducted 4-6 weeks after preoperative chemotherapy.~Patients with tumor regression grade 0, 1, 2 randomized to preoperative chemotherapy will not undergo postoperative chemotherapy and will be followed-up."
89200905|NCT01052389|Experimental|Haloperidol|Haloperidol (N05AD01)
89200906|NCT02539485|Other|heating precondition|The mean maximum sealing pressure, gas leakage, gastric distension, postoperative sore throat and other complication were compared between heating precondition group and control group.
89200907|NCT05277987|Experimental|HEC-016|Anti-claudin18.2 the Specificity of Chimeric Antigen Receptor T Cells
89451515|NCT03294044|Active Comparator|A book about chronic disease|Subjects in the group get a book about chronic disease for patients. After 3 months, they finish reading the materials, they fill out the questionnaire.
88936213|NCT01787552|Experimental|LDE225 + INC424|LDE225 and INC424 in combination
88936214|NCT01787565||painPREMIER cohort|
88936215|NCT01787565||Control cohort|
88936216|NCT01787578|Experimental|Sobetirome|Subjects will receive oral doses of sobetirome. All subjects will start with a 50 mcg dose, once-daily for 14 days. If this dose proves safe and well tolerated, subjects will receive a 100 mcg dose once-daily for an additional 14 days.
88936217|NCT01787617|Placebo Comparator|Control Group|We will randomly assign 52 individuals to a no exercise healthy living group.
88936218|NCT01787617|Experimental|Aerobic Plus Resistance Training Group|We will randomly assign 52 individuals to an aerobic plus resistance training group.
88936219|NCT01787630|Experimental|Hyaluronic acid|Hyaluronic acid will be injected in the space between the prostate and rectum prior to radiotherapy to perform a dorsal movement of rectum.
88936220|NCT01787669|Active Comparator|Avastin (bevacizumab)|Intravitreal Avastin loading doses followed by as prn for remainder of 6 months according to defined retreatment criteria
89200908|NCT01055587||major abdominal surgery|The investigators compare the levels of biomarkers in patients with and without complications in the early postoperative course following major abdominal surgery
89200909|NCT01055587||severe burn injury|The investigators compare levels of biomarkers within the first 20 days in patients with and without complications following severe burn injury
88936221|NCT01787669|Active Comparator|Ozurdex (dexamethasone)|single dose at baseline and repeat dose when required according to defined re-treatment criteria
88936222|NCT01787695|No Intervention|No treatment (covered)|
89451516|NCT02460770|Experimental|autologous mesenchymal stem cells|After bone-marrow aspiration by an authorized person, Mesenchymal Stem Cells were isolated and cultured during 17 days by the French Blood Establishment. Then, patients receive intramyocardial injections of Mesenchymal Stem Cells during Left Ventricular Assist Device surgery
89537132|NCT04983147|Experimental|health belief model based training manuel|"A training manual entitled Do Not Stay Silent Towards Obesity was prepared by the researcher to guide women in obesity management by affecting their beliefs on obesity in a positive way."
88936223|NCT01787695|Active Comparator|UVA1|
88936224|NCT01787708|Active Comparator|Low intensity red laser|"Patients with a vitiligo patch larger than 25cm2 will be recruited. The target patch will be divided into four quadrants. Two opposite quadrants will be shielded by foil and served as control, the third quadrant will be exposed to low intensity red laser (at 3 J/cm¬2), and the fourth quadrant will be exposed to high intensity red light (at 37 J/cm¬2).~Treatments will be given twice weekly for 10 weeks. This will be followed by assessments at 4, 8, and 12 weeks post treatment."
88936225|NCT01787708|Active Comparator|High intensity red light|"Patients with a vitiligo patch larger than 25cm2 will be recruited. The target patch will be divided into four quadrants. Two opposite quadrants will be shielded by foil and served as control, the third quadrant will be exposed to low intensity red laser (at 3 J/cm¬2), and the fourth quadrant will be exposed to high intensity red light (at 37 J/cm¬2).~Treatments will be given twice weekly for 10 weeks. This will be followed by assessments at 4, 8, and 12 weeks post treatment."
88936226|NCT01787708|No Intervention|No treatment1 (covered)|"Patients with a vitiligo patch larger than 25cm2 will be recruited. The target patch will be divided into four quadrants. Two opposite quadrants will be shielded by foil and served as control, the third quadrant will be exposed to low intensity red laser (at 3 J/cm¬2), and the fourth quadrant will be exposed to high intensity red light (at 37 J/cm¬2).~Treatments will be given twice weekly for 10 weeks. This will be followed by assessments at 4, 8, and 12 weeks post treatment."
88936227|NCT01787708|No Intervention|No treatment2 (covered)|"Patients with a vitiligo patch larger than 25cm2 will be recruited. The target patch will be divided into four quadrants. Two opposite quadrants will be shielded by foil and served as control, the third quadrant will be exposed to low intensity red laser (at 3 J/cm¬2), and the fourth quadrant will be exposed to high intensity red light (at 37 J/cm¬2).~Treatments will be given twice weekly for 10 weeks. This will be followed by assessments at 4, 8, and 12 weeks post treatment."
88936228|NCT01787721|Experimental|Ankle manipulation|Treatment will consist of manipulation of the tibiotalar joint intended to produce anterior to posterior glide of the tibia on the talus
88936229|NCT01787721|Sham Comparator|Sham manipulation|Sham manipulative procedure of the tibiotalar joint.
89451517|NCT03290690||All Subjects|"All subjects in this study will have their wounds imaged and assessed in the following manner:~Capture and save ST-image Capture and save FL-image Identify discrete locations of cyan (blue/green) fluorescent bacteria (FL_C) Acquire sample of tissue where cyan fluorescent bacteria are present (using curette method) Consent patient for inclusion in this study Note location of sample acquisition by annotating FL-image obtained in step 2 Send sample for microbiology analysis Note naming of microbiology sample on Case Report Form"
89451518|NCT03298724|Experimental|TAPP Intervention|The Teachers and Partners intervention will be provided
89451519|NCT03290456|Experimental|Prednisone 5mg/day extended of 12 additional months|Prednisone 5mg/day will be administered from Day 1 to Month 12
88936230|NCT01787747|Experimental|Cohorts A and C|Single dose (D1) followed by twice daily dosing for 7 days
88936231|NCT01787747|Experimental|Cohorts B and D|Single dose (D1) followed by twice daily dosing for 7 days
88936232|NCT01787747|Experimental|Cohorts E and F|Single dose (D1) followed by twice daily dosing for 7 days
88936233|NCT01787747|Experimental|Cohorts G and I|Single dose (D1) followed by twice daily dosing for 7 days
88936234|NCT01787747|Experimental|Cohorts H and J|Single dose (D1) followed by twice daily dosing for 7 days
88936235|NCT01787773|Experimental|Veniti Inferior Vena Cava Filter|
88936236|NCT01787786||Irritable Bowel Disease|Infliximab administered according to current FDA and EMS approved doses and intervals.
88936237|NCT01787851|Active Comparator|Triheptanoin oil|The standard dose of triheptanoin oil for adults is 1-2gm/kg/24 hours. For purposes of this study, we will administer 0.25mg/kg four-times per day. The liquid study drug will be mixed into sugar-free, low fat yogurt, pudding or nutritional supplement shake, depending on patient preference.
89451520|NCT03290456|Placebo Comparator|Placebo 5mg/day extended of 12 additional months|Placebo 5mg/day will be administered from Day 1 to Month 12
88936238|NCT01787851|Placebo Comparator|Simple sugar|0.25mg/kg of sugar syrup will be mixed into sugar-free, low fat yogurt, pudding or nutritional supplement shake four-times per day before meals.
88936239|NCT01787864||Cross-Sectional Post-Ablation|"The cross-sectional arm will consist of patients who have undergone ablative therapy for Barrett's Esophagus (BE) and have had at least one clear pathology report with no evidence of Barrett's Esophagus (BE) since their first ablation.~Cross-sectional participants will receive one-time study biopsies during a routine care follow-up endoscopy."
88936240|NCT01787864||Prospective Longitudinal Pre-Ablation|"Concurrently enrolled will be a prospective longitudinal arm which will consist of patients prior to their first ablation procedure. The prospective cohort will be followed for 12 months or longer if Barrett's Esophagus (BE) is not yet clear 6 months after the initial treatment.~Prospective longitudinal participants will receive biopsies prior to ablation therapy and 6 and 12 months after the initial treatment. If Barrett's Esophagus (BE) is not yet clear at 6 months, biopsies will be taken at the first endoscopy after Barrett's Esophagus (BE) clearance and again at the next clinically scheduled follow-up visit."
88936241|NCT01787877||Stroke patients reporting to the ER|
88936242|NCT01787903|Active Comparator|Real-time continuous glucose monitor|16 weeks use of a real-time continuous glucose monitor
88936243|NCT01787903|Placebo Comparator|Continuous glucose monitor|16 weeks use of a (blinded, retrospective) continuous glucose monitor
89451521|NCT02555878|Experimental|Rivaroxaban|Participants will be administered rivaroxaban 10 milligram (mg) tablet orally once daily for 180 days.
88936244|NCT01787942|Active Comparator|Blepharoplasty|"Participants under this group will undergo blepharoplasty from the oculoplastic clinic. These patients will form the case group of the cross-sectional study, and will be on follow-up for the prospective study."
88936245|NCT01787942|Placebo Comparator|Control|"Participants under this group will be recruited from the general ophthalmology clinic. These patients are cleared to have no lid disturbances in terms of function or anatomy, and will serve as the control group of the cross-sectional study."
88936246|NCT01787955|Experimental|Braun anastomosis group|
88936247|NCT01787955|Active Comparator|conventional group|conventional Pylorus preserving pancreaticoduodenectomy
88936248|NCT01787968||TcI, TcII|TcI: T. cruzi seropositive mothers from countries where TcI predominates, or/and with TcI genotyping TcII: T. cruzi seropositive mothers from countries where TcII (non-TcI) predominates, or/and with TcII (non-TcI) genotyping
88936249|NCT01787994|Experimental|Cohort 1|"Cohort 1: HIV-1-positive women and men ≥18 years with a CD4 count > 350 cells/mm3, HIV-1-RNA levels undetectable by ultrasensitive HIV PCR Abbott assay. Subjects with HIV-1 RNA < 400 copies/mL are also eligible; however, the HIV-1 RNA must be < 50 copies/mL within 60 days prior to study entry based on the Abbott assay. Subjects with intermittent isolated episodes of detectable low level viremia (> 50 but <1,000 copies RNA/mL; blips) will be eligible.~There should be at least 2 documented HIV-1 RNA assays, one drawn >3 months before study entry, one drawn <3 months before study entry. Subjects should be on HAART (no changes to treatment within 4 weeks of study entry) for at least 3 months.~Cohort 1 subjects will receive a single dose of MazF-T cells."
88936250|NCT01787994|Experimental|Cohort 2|"Cohort 2: HIV-1-positive men and women ≥18 years with a CD4 count > 450 cells/mm3, having well controlled HIV replication on HAART. The subjects should have a CD4 nadir ≥200 cells/mm3. Subjects in Cohort 2 will participate in a 16 week analytical treatment interruption beginning 2 weeks after T cell infusion.~Cohort 2 subjects will receive a single dose of MazF-T cells."
88936251|NCT01788007|Experimental|Imiquimod Topical Cream 3.75%|Imiquimod Topical Cream 3.75% (Taro Pharmaceutical Industries Ltd.)
88936252|NCT01788007|Placebo Comparator|Vehicle Topical Cream|Vehicle Topical Cream (Taro Pharmaceutical Industries Ltd.)
88936253|NCT01788007|Active Comparator|Zyclara® (imiquimod) Topical Cream 3.75%|Zyclara® (imiquimod) Topical Cream 3.75% (Medicis Pharmaceutical Co.)
88936254|NCT01788033|Active Comparator|XOMA 052|0.3 mg/kg XOMA 052. Beginning on Day 0, each subject will receive one subcutaneous (SC) injection of study drug every 4 weeks for 12 weeks, a total of four injections
88936255|NCT01788033|Placebo Comparator|Placebo|0.3 mg/kg placebo. Beginning on Day 0, each subject will receive one subcutaneous (SC) injection of study drug every 4 weeks for 12 weeks, a total of four injections
88936256|NCT01788059|Experimental|mesenchymal stem cell|stem cells drived from iliac bone marrow with centrifuge and ficoll method then inject to non union site 2-3 ml with approximately 40 X 10E6 Mesenchymal Stem Cells (MSC) will be injected in the nonunion site of the bone fracture under fluoroscopic gide and general or spinal anesthesia as deemed appropriate by the anesthetist.
88936257|NCT01788072|Active Comparator|Intranasal Oxytocin|
88936258|NCT01788072|Placebo Comparator|Placebo|
88936259|NCT01788085|Experimental|pH monitoring procedure|Bravo pH monitoring procedure
88936260|NCT01788098||Rheumatoid Arthritis|Patients with rheumatoid arthritis
89451522|NCT02555878|Experimental|Placebo|Participants will be administered matching placebo tablet orally once daily for 180 days.
89451523|NCT02460536|Experimental|Attention Bias Modification treatment (ABMT)|Attention training via repeated trials of a dot-probe task intended to direct attention away from threat stimuli using threat and neutral face stimuli.
89451524|NCT02460536|Active Comparator|Exposure only +ABMT|Identical discrimination task including exposure to a single threat or neutral face stimulus in each trial.
88936261|NCT01788098||Healthy controls|Healthy control subjects
88936262|NCT01788111|Experimental|Low back exercises 1|Specific low back extensor exercises in special training bench
88936263|NCT01788111|Active Comparator|Low back exercise 2|Traditional low back exercises.
88936264|NCT01788124||Metal Speculum|exam with metal speculum
88936265|NCT01788124||Plastic Speculum|exam with plastic speculum
88936266|NCT01788137|Active Comparator|CHOP|CHOP regimen Treatment Arm A (CHOP): cyclophosphamide(C), 750mg/m2 for injection on day1; doxorubicin(H), 50 mg/m 2 for injection on day1; and Vincristine(O), 1.4 mg/ m2 for injection on day1, prednisone(P) 60 mg/m2 orally on days 1 to 5. The therapy was repeated every 21 days for a total of 6 cycles.
88936267|NCT01788137|Active Comparator|c-ATT regimen|c-ATT regimen Treatment Arm B (c-ATT):Alternative 3 regimen to be used sequentially(CHOPB→IMVP-16→DHAP).The therapy was repeated every 21 days for a total of 6 cycles.
88936268|NCT01788176|Placebo Comparator|Saline|One single intravenous infusion of 100ml of saline (placebo control group).
89015069|NCT01505894|Experimental|BI 409306 50 mg - Elderly Subjects QD|50 mg of BI 409306 were administered in elderly subjects once daily
89200910|NCT00898053||Correlative studies|Previously archived tumor samples are analyzed for p53 mutations and p16 deletion by immunohistochemistry, FISH, PCR, and DNA sequencing.
89200911|NCT00349921|Active Comparator|clonidine first, then adenosine|clonidine given in first injection adenosine given in second injection
89200912|NCT00349921|Active Comparator|adenosine first, then clonidine|adenosine given in first injection clonidine given in second injection
89200913|NCT00349921|Placebo Comparator|clonidine given first, then placebo|placebo
89200914|NCT00349921|Placebo Comparator|adenosine given first, then placebo|placebo
89200915|NCT00902655|Experimental|Desmopressin|
89200916|NCT01052623|Experimental|Growth hormone-testing (GH/IGF-1-testing)|"Patients (girls over 8 years and boys over 10 years) are primed with estradiol 1 mg orally for 2 days, to help avoid false results of growth hormone (GH) levels in blood samples. Then provocation testing is done, with two tests back to back. It determines blood levels of GH and the body's response to testing with drugs called arginine and clonidine. Patients are admitted to the pediatric inpatient unit and will have an intravenous (IV) line placed in the arm. Arginine is given by IV over 30 minutes, and blood samples are taken as indicated.~The next day, the clonidine test is performed according to current guidelines. Then the IGF-1 generation test is done to see if the patient has the ability to generate IGF-1 in response to injections of GH for 5 consecutive days."
89200917|NCT01058785|Experimental|Lucanix|Patients will receive injections of Lucanix for each dose cohort.
89200918|NCT00898209||Health Volunteers|Blood and exhaled breath condensate will be collected.
89200919|NCT00898209||Patients at risk or already identified as having lung cancer|Blood and exhaled breath condensate will be collected.
89200920|NCT01325077|Experimental|Conventional model, Study model|Conventional model(C): Nurses give fixed-dose analgesic according to surgeons' prescription Study model(S): Nurses give initial-dose analgesic according to surgeons' prescription. In case of inadequate pain relief, another half of initial dose will be given twice at 15-min interval and acute pain service will be consulted if there is still pain.
89200921|NCT00902811|Active Comparator|AM(LT)|Artesunate (Arsumax®, Sanofi)
89200922|NCT00902811|Experimental|AM(FDC)|Artesunate-mefloquine fixed dose combination
89200923|NCT00902811|Experimental|AL|artemether 20 mg - lumefantrine 120 mg co-formulated tabs
89200924|NCT00902811|Experimental|DP|40 mg dihydroartemisinin/320 mg piperaquine tablets and Dihydropiperaquine 20mg/Piperaquine 160 mg tablets
89200925|NCT00902811|Experimental|AA (FDC)|Artesunate-amodiaquine fixed dose combination
89451525|NCT02460536|Active Comparator|Attention training only +ABMT|Attention training via repeated trials of a dot-probe task using non-emotional stimuli.
89451526|NCT02460536|Placebo Comparator|Placebo group|Identical discrimination task including a single non-emotional stimulus in each trial.
89537133|NCT04983147|Experimental|powerpoint presentation with computer|The presentation prepared based on the Health belief model was used in group training.
89015070|NCT01505894|Experimental|BI 409306 100 mg - Young Subjects QD|100 mg of BI 409306 were administered in young subjects once daily (QD).
89015071|NCT01505894|Experimental|BI 409306 100 mg - Elderly Subjects QD|100 mg of BI 409306 were administered in elderly subjects once daily (QD).
89200926|NCT04035681|Experimental|Problem-Solving Therapy|Participants who are assigned to receive problem-solving therapy will work with a research team member for six, one-hour sessions. During each session, participants will identify a problem (big or small) and create a plan to work on that problem.
89200927|NCT04035681|Active Comparator|Stroke-Related Health Education|Participants who are assigned to receive stroke-related health education will work with a research team member who will teach them about various topics related to stroke over six, one-hour sessions. Each session will cover information about a different topic related to stroke.
89200928|NCT05278143||type1diabetes patients who use CGM|Males and females diagnosed with T1D, aged less than 18 years old who are currently under the care of the Unit of Endocrinology and Diabetes of Bambino Gesù Children's Hospital, Rome, Italy and who already use continuous glucose monitoring (CGM) systems are eligible to be involved in the study. Participants will wear an additional non-invasive wearable device, Medtronic Zephyr BioPatch, for recording physiological data for three days.
89200929|NCT02539173|Experimental|Experimental|Ultrasound scan of diaphragm is made preoperatively during the pre-anesthetic visit, patients are informed of the purpose of the study. Written consent is collected after oral and written information.
89200930|NCT00898287|Experimental|P276-00 plus Gemcitabine|"Subjects will be enrolled at different levels of P276-00 dosage as follows:- Level 1 - 100mg/m2/day x 5 q 3 weeks Level 2 - 140 mg/m2/day x 5 q 3 weeks Level 3 - 185 mg/m2/day x 5 q 3 weeks P276-00 will be administered as intravenous infusion in 200 ml of 5% dextrose over 30min from days 1 to 5 per 21 day cycle. Six such cycles will be administered unless there is progression of disease or unacceptable toxicity.~Gemcitabine will be administered as an intravenous infusion at dose of 1000mg/m2 over 30 mins every week for 7 weeks followed by a gap of one week and then 3 weekly doses every 4 weeks. This treatment will be continued for six P276-00 cycles of 3 weeks each unless there is progression of disease or unacceptable toxicity."
89200931|NCT02539251||Validation of Arabic ASQ-3|This group of patients will serve as a reference for validation of the Arabic ASQ-3
88936269|NCT01788176|Active Comparator|Zoledronic acid|one single dose of 5mg intravenous infusion of zoledronic acid (interventional group)
89451527|NCT03298646|Experimental|Lidacaine hydrochloride|"Adding 10 ml of 2% Lidocaine hydrochloride on hysteroscopic saline media during office hysteroscopy to test its efficacy in reducing pain.~22 women."
89451528|NCT03298646|Active Comparator|Diclofenac|"100 mg Diclofenac oral tablet is administered 1 hour before the procedure to test its efficacy in reducing pain.~22 women."
89451529|NCT03298568|Experimental|DAOsin treatment|Patients suffering from histamine intolerance and a diamin oxidase activity below 10 Units/ml get a DAOsin treatment for one month 3 times a day.
89451530|NCT05489224|Experimental|CT-P47|CT-P47(Tocilizumab)
89451531|NCT05489224|Active Comparator|EU-approved RoActemra|EU-approved RoActemra(Tocilizumab)
89451532|NCT02460614|Experimental|Rhinopharyngeal clearance + 0.9% saline|The retrograde rhinopharyngeal clearance (RRC) is based on the inspiratory reflex that follows a slow and prolonged expiration (passive exhalation technique performed using a slow thoracic-abdominal compression that begins at the end of a spontaneous exhalation and continues until the expiratory reserve volume). At the end of the expiratory time, the child's mouth was closed by the hand of the researcher (raising the lower jaw), leading the child to perform a nasal aspiration maneuver. The instillation of saline (0.9%) preceded this step, resulting in the inhalation of the substance during the forced inspiration, contributing to the nasopharyngeal clearance.
89451533|NCT02460614|Active Comparator|Aspiration + 0.9% saline|Nasopharyngeal aspiration consisted in the introduction of a catheter that, by using negative pressure (vacuum), promotes the suction of secretion from the airways. In order to do that, a sterile aspiration catheter was connected to an extension and carefully introduced into the nasal cavity of the patient. The saline instillation of 0.9% was used for humidification before the procedure.
89451534|NCT03293732|Active Comparator|HA antigen only|All subjects in this group received 2 doses of 22.2 μg HA antigens
89451535|NCT03293732|Experimental|7.5 μg of DCB07010|All subjects in this group received 7.5 μg of DCB07010 in 22.2 μg HA antigens twice.
89451536|NCT03293732|Experimental|15 μg of DCB07010|All subjects in this group received 15 μg of DCB07010 in 22.2 μg HA antigens twice.
89451537|NCT03293732|Experimental|30 μg of DCB07010|All subjects in this group received 30 μg of DCB07010 in 22.2 μg HA antigens twice.
89451538|NCT03293732|Experimental|45 μg of DCB07010|All subjects in this group received 45 μg of DCB07010 in 22.2 μg HA antigens twice.
89451539|NCT04139980|Experimental|Virtual Reality supported therapy|"The Virtual Reality (VR) interface will be used during patients stay at the rehabilitation center. A research employee will install the VR system in the patient's room. Participants will be comfortable sitting while in VR session. Each interface consists of a head mounted display (HMD) allowing participants to see their arms and legs represented in the virtual environment. Participants will be able to control their virtual legs using hand controllers, which will allow them to walk through several virtual environments and gather points (no additional gaming elements are included)."
88936270|NCT01788189|Experimental|Lenalidomide|"The LeMLAR protocol:~Lenalidomide 25 mg p.o., days 1 - 21; Methotrexate 30 - 60 - 90 - 120 - 150 mg/m² i.v. bolus, days 1, 8, 15; Leucovorin 4 x 45 mg p.o. (every 6 hrs), days 2, 9, 16; Cytarabine (Ara-C) 75 - 150 - 225 - 300 - 375 mg/m² i.v. bolus, days 1, 8, 15; Rituximab 375 mg/m² i.v. infusion, day 1.~28-day cycles, maximum 6 cycles, definition of dose-limiting toxicity in cycles 1 and 2, intra-patient dose escalation after cycles 2 and 4 in case of absence of dose-limiting toxicity in previous cycles"
88936271|NCT01788241||CAG and CT group|CAG group = patients included based on coronary angiography screening; CT group = patients included based on computed tomography screening
88936272|NCT01788254|Experimental|Drug cocktail|A single oral low dose of codeine 5 mg and midazolam 1 mg administered as drop, pravastatin 5 mg, talinolol 2.5 mg, and torsemide 0.25 mg provided in capsules will be given together at the same time point (cocktail).
88936273|NCT01788267|Experimental|Healthy volunteers|Volunteers realize a HR-pQCT scanner
88936274|NCT01788267|Experimental|Cystic Fibrosis patient|Patients realize a HR-pQCT scanner
88936275|NCT01788280|Experimental|All participants|All enrolled participants
88936276|NCT01788293|Active Comparator|Intervention group|Intervention group will receive hydroxyethylstarch 6% bolus in order to minimize and maintain PVI below 14 %.
88936277|NCT01788293|No Intervention|Control group|Control group will receive fluid at the discretion of the anesthetist
88936278|NCT01788319|Experimental|lasertrabeculoplasty|
88936279|NCT01788332|Active Comparator|Olaparib|3 100mg tablets to be administered twice a day with approximately 240ml of water.
89451540|NCT03290222||TRACK|Children will be followed for four weeks (3 to 5 weeks) after the inclusion in the study. Parents will complete the TRACK questionnaire in both visit and will answer additional questions about respiratory symptoms and use of medication.
89531370|NCT00706901|Experimental|Arm 1 GMI|Patients randomized to GMI received four structured 75-minute sessions consistent with the central principles and style of motivational interviewing (Miller & Rollnick, 2012). The goal of MI is to develop a sense of discrepancy between personal goals and current behavior and enhance change talk among participants, particularly for taking responsibility of one's substance use and being proactive for remaining in treatment.
88936280|NCT01788332|Placebo Comparator|Placebo|3 100mg tablets to be administered twice a day with approximately 240ml of water.
88936281|NCT01788345|Experimental|non-invasive ventilation|
88936282|NCT01788371|No Intervention|No antiviral arm|provide standard of care to mothers and standard immunoprophylaxis to their infants
88936283|NCT01788371|Experimental|Lamivudine|lamivudine treatment from 28 weeks of pregancy to week 4 of postpartum for mothers and standrd immunoprophylaxis to their infants
88936284|NCT01788371|Experimental|Telbivudine|Telbivudine treatment from 28 weeks of pregancy to week 4 of postpartum for mothers and standrd immunoprophylaxis to their infants
88936285|NCT01788384|Active Comparator|Acanya|Acanya® (Clindamycin Phosphate and Benzoyl Peroxide) Gel, 1.2%/2.5% gel (Valeant Pharmaceuticals, North America)
88936286|NCT01788384|Experimental|Clindamycin Phosphate / Benzoyl Peroxide|Clindamycin Phosphate / Benzoyl Peroxide Gel, 1.2%/2.5%
88936287|NCT01788384|Placebo Comparator|Vehicle Gel|Placebo (Vehicle Gel)of the test product (Watson Laboratories, Inc.)
88936288|NCT01788397|Experimental|Physical activity|Physical activity 2-4 times pr. day
88936289|NCT01788397|No Intervention|Control group|No intervention in the control group
88936290|NCT01788436|Experimental|Group 1: Patients with schizophrenia|
88936291|NCT01788436|Active Comparator|Group 2: Young healthy volunteers|
88936292|NCT01788436|Experimental|Group 3: Elderly healthy volunteers|
88936293|NCT01788462||HIV and Lipodystrophy|The study population will consist of HIV patients with lipodystrophy who receive Tesamorelin (Egrifta).
88936294|NCT01788488|No Intervention|Standard Therapy|
88936295|NCT01788488|Experimental|Procalcitonin-guided therapy|Procalcitonin levels will be measured to determine when it is appropriate to discontinue antibiotic therapy.
88936296|NCT01788501|Experimental|Tacrolimus/Methotrexate|"Tacrolimus D-1~D20: iv infusion, q24hr (first daily dose: 0.03mg/kg) D20~D100: po q12hr (first daily dose: the quadruple of last iv dose) Dose modification according to therapeutic drug monitoring(TDM) (10-20ng/ml)~Methotrexate D1: 15mg/m2 iv push D3,6,(11): 10mg/m2 iv push"
88936297|NCT01788501|Active Comparator|Cyclosporine/Methotrexate|"Cyclosporine D-1~D20: iv infusion, q24hr (first daily dose: 3mg/kg) D20~D100: po q12hr (first daily dose: the 3 times of last iv dose) Dose modification according to TDM (200-300ng/ml)~Methotrexate D1: 15mg/m2 iv push D3,6,(11): 10mg/m2 iv push"
88936298|NCT01788514|Other|Videogame|Subject will play educational videogame
88936299|NCT01788527|Experimental|CGM|Continuous Glucose Monitoring
88936300|NCT01788527|No Intervention|HGM|Standard of care, Home Glucose Monitoring
88936301|NCT01788540|Experimental|Intralipid|"IV infusion of intralipid 20% is administrated on the day of vaginal egg collection in a dose of 9 mg/ml total blood volume corresponding to intralipid 2 ml 20% diluted in 250 ml saline over 30-60 minutes.~the intralipid infusion is then repeated within the one week of positive pregnancy test and every 2 weeks till end of first trimester"
88936302|NCT01788540|No Intervention|Control|No intervention
88936303|NCT01788579|Experimental|Multimedia WINGS|A one-hour session of a self-paced multimedia IPV screening, brief intervention and referral service delivered on a computer.
88936304|NCT01788579|Active Comparator|Caseworker Delivered WINGS|A one-hour session of IPV screening, brief intervention and referral service delivered by a case manager.
89200932|NCT04034823|Experimental|KN035 in combination with trastuzumab and docetaxel|
89200933|NCT00902889|Experimental|1|6 weeks stimulation with GPI (lower caudal two contacts), 4 weeks wash-out, 6 weeks stimulation with GPE (upper cranial two contacts).
89200934|NCT00902889|Experimental|2|6 weeks stimulation with GPE (upper cranial two contacts), 4 weeks wash-out, 6 weeks stimulation with GPI (lower caudal two contacts)
89200935|NCT00895401|Active Comparator|Standard of Care|Standard of Care for malnourished maintenance hemodialysis patients
89200936|NCT00895401|Experimental|Nepro with Carb Steady|Nepro with Carb Steady is a commercially available nutritional supplement designed to meet the nutritional needs of malnourished hemodialysis patients. The serving size is 8 oz which provides 425 kcal and 19 g protein
89200937|NCT00606021|Experimental|A: Pemetrexed + Best Supportive Care|"Pemetrexed: 500 milligrams per square meter (mg/m²) , intravenous (IV), Day 1 of each 21-day cycle for 6 cycles~Best Supportive Care: Patients will receive best supportive care (dose, frequency, duration) as judged by their treating physician."
89200938|NCT00606021|Active Comparator|B: Best Supportive Care|Best Supportive Care: Patients will receive best supportive care (dose, frequency, duration) as judged by their treating physician.
89200939|NCT00337675|Active Comparator|Arm 1: drug + episodic supplemental placebo|Montelukast once a day (qd) + episode driven supplemental placebo qd for 12 days for a 52-wk treatment period
89537134|NCT04983147|Experimental|video for obesity based on health beliefs|In the literature; It is explained that the educator's use of representations such as video is more effective than verbal expression and reading, and facilitates learning both by hearing and seeing.For this reason, videos that will create awareness about the subject in the trainings were prepared by the researcher and used in the trainings.
88936305|NCT01788605|Experimental|ramosetron|
88936306|NCT01788618|Other|Experimental group|Cognitive exams at T0 and T3. Patients will achieve 9 standardized cognitive rehabilitation sessions with the RehaCom ® software (over 3 months), and a self-assessment of their monthly experienced cognitive functioning using the self-administered questionnaire FACT-Cog
88936307|NCT01788618|Other|The control group 1 (Homework)|Cognitive exams at T0 and T3. These patients will take part in 9 sessions standardized home exercise (over 3 months), and a self-assessment every month felt their cognitive functioning using the self-administered questionnaire FACT Cog
88936308|NCT01788618|Other|Control group 2 ( telephone follow)|Cognitive exams at T0 and T3. These patients receive follow-up by phone (9 telephone calls over a period of 3 months) standardized optics to know the evolution of the disorder and felt the same way as for the other groups, a monthly self-assessment the feeling of cognitive functioning using the self-administered questionnaire FACT-Cog
88936309|NCT01788644||No treatment (observational study)|
88936310|NCT01788670|Placebo Comparator|Water|Lemon-flavoured water (150 ml)
88936311|NCT01788670|Active Comparator|Ethanol high dose|The high dose corresponds to 30 g of ethanol in pilot cohort 1, to 12 g of ethanol in pilot cohort 2 and to 42 g of ethanol in pilot cohort 3. For the definitive study the high dose corresponds to 30 g of ethanol. Ethanol was administered as a single dose of pure ethanol diluted in lemon-flavoured water (150 ml each beverage).
88936312|NCT01788670|Active Comparator|Ethanol low dose|The low dose corresponds to 18 g of ethanol in pilot cohort 1, to 6 g of ethanol in pilot cohort 2 and to 24 g of ethanol in pilot cohort 3. For the definitive study the low dose corresponds to 18 g of ethanol. Ethanol was administered as a single dose of pure ethanol diluted in lemon-flavoured water (150 ml each beverage).
88936313|NCT01788696|Active Comparator|Group A - Early Imaging|Group A will receive SPECT imaging 3 times during the study. The first scan will take place prior to the initiation of any treatment, followed by scans at week 26 and week 52.
88936314|NCT01788696|Active Comparator|Group B - Delayed Imaging|Group B will receive SPECT imaging 2 times during the study. Group B will not have the first scan (prior to the initiation of any treatment). Scan will take place at week 26 and week 52.
88936315|NCT01788709|Active Comparator|A|Fortrans (split dose) + Mentholyptus drops
88936316|NCT01788709|Active Comparator|B|MoviPrep (split dose)
88936317|NCT01788722||Group 1|
88936318|NCT01788748|Active Comparator|bipolar radiofrequency and infrared|The abdomen of each patient will be divided in four quadrants around the navel. One quadrant, selected randomly at the subject enrollment, will receive only bipolar radiofrequency potentiated by infrared, 3 treatments one month apart.
88936319|NCT01788748|Active Comparator|fractional bipolar radiofrequency|The abdomen of each patient will be divided in four quadrants around the navel. One quadrant, selected randomly at the subject enrollment, will receive only fractional bipolar radiofrequency , 3 treatments one month apart.
88936320|NCT01788748|Active Comparator|combined treatment|The abdomen of each patient will be divided in four quadrants around the navel. One quadrant, selected randomly at the subject enrollment, will receive first bipolar radiofrequency potentiated by infrared, followed in the same session by fractional bipolar radiofrequency, 3 treatments one month apart.
88936321|NCT01788761|Experimental|Probiotic Supplemented Group|500,000,0000 cells of Lactobacillus GG (utilizing either Culturelle for Kids or Kids Culturelle preparation) and 500,000,000 cells of Bifidobacterium Infantis (utilizing Align capsule) diluted in 3 ml breastmilk/formula and administered enterally from first day of enteral feeds until term gestation/discharge/transfer/death (whichever occurs first) every day infant is receives enteral feedings
88936322|NCT01788761|Sham Comparator|Control Group|3 ml enteral feeding of breastmilk/formula administered once daily in addition to regularly prescribed enteral feedings from day of first feeding until term gestation/discharge/transfer/death (which ever occurs first) and administered every day that infant receives enteral feedings
88936323|NCT01788787||Texas Quitline|Patients interested in smoking cessation treatment by calling the Texas Quitline.
88936324|NCT01788787||Training Providers|Medical staff (i.e., medical assistants, licensed vocational nurses, registered nurse and physicians).
88936325|NCT01788800|Experimental|Exercise training|"Cognitive Behavioural Therapy (CBT)~+ Exercise training 3 times/week, 30 minutes on a treadmill, 70% maximal oxygen uptake (VO2max), 8 weeks"
88936326|NCT01788800|Active Comparator|Movements|"Cognitive Behavioural Therapy (CBT)~+ Low intensity physical activity without cardiovascular activation, 3 times/week, 30 minutes, 8 weeks"
88936327|NCT01788813|Experimental|GSK2245035 Arm|Subjects participating prior to 2014 will receive i.n GSK2245035 80 ng once weekly for 8 weeks (each dose will be split between the two nostrils). Subjects participating in 2014 will receive i.n GSK2245035 20 ng once weekly for 8 weeks (each dose will be split between the two nostrils).
88936328|NCT01788813|Placebo Comparator|Placebo Arm|Subjects will receive i.n placebo once weekly for 8 weeks (each dose will be split between the two nostrils)
88936329|NCT01788826|Experimental|Prophylactic Mesh|Use of a prefascial polypropylene mesh when closing midline laparotomy
88936330|NCT01788826|Experimental|No prophylactic mesh closure|In this arm the laparotomy of the patients are closed with a running absorbable suture without a mesh
88936331|NCT01788852||Perinatally HIV-infected adolescents|Perinatally HIV-infected adolescents
88936332|NCT01788852||behaviorally HIV-infected adolescents|behaviorally HIV-infected adolescents
88936333|NCT01788852||HIV negative adolescents|HIV negative adolescents
88936334|NCT01788865|Experimental|cSEMS|Patients with malignant ureteral obstruction have cSEMS(Covered self-expandable dual-layered metal stent) implant
88936335|NCT01788878|Experimental|Questionnaires|completion of questionnaires
88936336|NCT01788891||second-line pediatric cohort|Asian HIV-positive children <18 years old who are receiving HIV care at one of the participating TREAT Asia Pediatric HIV Observational Database (TApHOD) sites that have been identified for TASER-P participation will be monitored for treatment failure of second-line ART
88936337|NCT01788904||Patients with acute mesenteric ischemia|Patients with acute mesenteric ischemia meeting the in-/exclusion criteria
88936338|NCT01788930|Active Comparator|CPAP|"This device consists in a nasal continuous positive airway pressure (CPAP). It will be applied 3 months after the beginning of drug treatment and for 3 months.~Other Name: positive airway pressure"
88936339|NCT01788930|Placebo Comparator|Sham-CPAP|This device consists in a sham CPAP. It will be applied 3 months after the beginning of drug treatment and for 3 months.
88936340|NCT01788956||ICU Patients|80 subjects (male and female)
88936341|NCT01788969|Experimental|Gait Training with Lexapro|Gait training 2 weeks, gait training 4 weeks (3 X week) with Lexapro (10mg SSRI), wash out period of 1 week, gait training, for 4 weeks with placebo (10 mg). Patients will also be provided prescribed TIZ by their physician to help control of spastic motor behaviors.
88936342|NCT01788969|Active Comparator|Gait Training with Placebo|Gait training 2 weeks, gait training for 4 weeks (3X week) with Placebo (10 mg), wash out period of 1 week, gait training for 4 weeks with Lexapro(10 mg). Patients will also be provided prescribed TIZ by their physician to help control of spastic motor behaviors.
88936343|NCT01788982|Experimental|Nintedanib|Nintedanib should be administered orally at a dose of 200 mg twice daily.
88936344|NCT01788982|Placebo Comparator|Placebo|Placebo should be administered orally at a dose of 200 mg twice daily. Cross-over to nintedanib is allowed after progression.
88936345|NCT01788995||Cohort|
88936346|NCT01789060||p-AKT|p-AKT immunohistochemical staining,high p-AKT expression (upper quartile), low p-AKT expression (lower 3 quartiles)
88936347|NCT01789073|Experimental|Oral Impact, Nestlé Health Science|Oral Impact-arm receives the intervention the last 7 days prior to surgery
88936348|NCT01789073|No Intervention|Control|The control-arm receives no intervention but is treated according to the standard procedures
88936349|NCT01789086|Experimental|Liraglutide|
88936350|NCT01789086|Placebo Comparator|Placebo|
89537135|NCT04983147|Experimental|successful patients in obesity management|Real-life stories of people who could manage obesity before and thought themselves healthier compared to their previous condition were shared with the group. People were invited to the trainings who had obesity before and managed to lose weight and trainings were given in the affective field.
88936351|NCT01789099|Experimental|UV1 synthetic peptide vaccine and GM-CSF|GM-CSF (Leukine) followed by UV1 peptide vaccine with escalating concentrations (100, 300 and 700 microgram) will be injected intradermally in the lower abdomen.
88936352|NCT01789112|Experimental|CCM aggregate|Taking of 10 blood samples
88936353|NCT01789125|Active Comparator|Smoking Termination and Anxiety Reduction Treatment|Cognitive-behavioral treatment program that blends smoking cessation and anxiety reduction treatment strategies
88936354|NCT01789125|Active Comparator|Educational-Support Psychotherapy|Educational-based psychotherapy and standard smoking cessation treatment program
88936355|NCT01789164||Healthy group|Healthy group with no history of TBI or concussion. Gender matched non-TBI volunteers
88936356|NCT01789164||TBI group|Males and females between 18 and 60 years who have a diagnosis of TBI and are symptomatic with DSM-IV Research Criteria for Post-Concussional Disorder (see below), gender matched non-TBI volunteers
88936357|NCT01789177|Experimental|Modified incentive spirometry|Patients will be given a disposable incentive spirometer postoperatively and instructed to use the spirometer every hour while awake.
88936358|NCT01789177|Active Comparator|Postoperative chest physiotherapy|Patients will be given standard postoperative chest physiotherapy, according to hospital protocol, but will not receive incentive spirometers.
88936359|NCT01789190||Group S (sedentary)|Group S included patients that did not perform any physical activity at the moment of onset, continuing with the same habits during the subsequent observational period.
88936360|NCT01789190||Group A (active)|The inclusion criteria for group distribution took in account the principles of the American College of Sports Medicine, considering as active physical activity to practice a moderate-vigorous exercise during 1h, 5 days or more/week. In this context, a sedentary or less active person should be a person that practices any or less than 5h weekly
88936361|NCT01789216|Placebo Comparator|Placebo|"Standard pain management + perioperative intravenous placebo & oral placebo.~Control group will receive an oral dose of placebo up to two hours prior to surgery and twice daily for up to 48 hours following any surgery, in addition to an intravenous dose of placebo up to two hours prior to surgery and every 6 hours for up to 48 hours following surgery. All study medications will be in addition to standard of care pain medication.~*Previous preoperative protocol was removed due to difficulty of medication adherence and limited importance of preoperative regimen to the intervention overall."
88936362|NCT01789216|Active Comparator|NSAID|"Standard pain management + perioperative intravenous ketorolac & oral placebo.~The NSAID group will receive 30 mg of intravenous (IV) ketorolac (Ketorolac 30 mg/ml dose vial, NDC 00409-3795-01; manufacturer: Hospira) administered up to two hours prior to the procedure and every 6 hours for up to 48 hours following the procedure. In addition, as part of the perioperative protocol, patients will receive an oral dose of placebo up to two hours prior to the procedure and every 12 hours for up to 48 hours following the procedure.~*Previous preoperative protocol was removed due to difficulty of medication adherence and limited importance of preoperative regimen to the intervention overall."
89537136|NCT04983147|Experimental|Post-training follow-up|"After the trainings given to women were completed, women were included in the follow-up program.For 6 mounts. This application will only be made in the experimental group.~This follow-up will increase motivation and answer questions regarding obesity management.~It was made by calling every 15 days.It will be made by phone call."
89015073|NCT01416285||control group|control group receiving regular education from a nurse
89537137|NCT05723939|Experimental|Carnosine|Intake of carnosine supplement in form of capsules or functionally enriched chicken meet for three weeks
88936363|NCT01789216|Active Comparator|Gabapentinoid|"Standard pain management + perioperative intravenous placebo & oral pregabalin.~The Pregabalin group will receive an oral bolus dose of 300 mg of pregabalin up to two hours prior to the procedure and a 75 mg dose every 12 hours for up to 48 hours following the procedure. In addition, as part of the perioperative protocol, patients will receive an IV dose of placebo up to two hours prior to the procedure and every 6 hours for up to 48 hours following the procedure.~*Previous preoperative protocol was removed due to difficulty of medication adherence and limited importance of preoperative regimen to the intervention overall."
88936364|NCT01789242|Experimental|Carfilzomib|All eligible subjects will receive the study intervention of Carfilzomib. Patients with suboptimal hematologic responses (<VGPR after 4 cycles) will have Dexamethasone added to their treatment.
88936365|NCT01789294|Experimental|Mesalamine|A standard 50 mg/kg/die daily dose of oral mesalamine was prescribed by Pediatric Gastroenterologists, which informed parents of potential side effects
89451541|NCT05494294|Active Comparator|Intraoral|In this group, the grafts were de-epithelialized at the donor site before harvesting. The calibrated surgeon removed the epithelium with a sharp Kirkland knife under magnification. To be sure of the elimination whole epithelial layer, bleeding was observed. Recipient site was prepared as follows; A after sulculer incision had done (blade 15c) two vertical incions were made from the gingival margin to 3 mm beyond the mucogingival junction A partial-thickness flap was elevated under the recession area and full thickness flap elevated adjacent flap portions. then relasing incisions were made apically from the mucogingival junction. After the preparation of the recipient site, obtained graft was sutured 1 mm apically to the cemento-enamel junction. Finally flap was positioned without tension and stabilized at least 2mm coronally from the cemento-enamel margin with the single interrupted sutures.
88936366|NCT01789294|No Intervention|Observation|A close clinical observation without therapy was taken in control patients, whom parents were alerted to refer immediately if symptoms persisted or get worse.
89451542|NCT05494294|Active Comparator|Extraoral|In this group, the grafts were de-epithelialized after graft harvesting. The calibrated surgeon removed the epithelium with 15 c knife under magnification. all remnants were removed under magnification. Same recipient site procedure was conducted in this group.
89451543|NCT05494138||The obese group|Obese patients (BMI ≥25 kg/m2) with chronic diseases such as cardiovascular disease, hypertension, diabetes, and metabolic syndrome. More than 10% of the patients in the obese group will be patients with a BMI ≥30.
89451544|NCT05494138||The control group|Adults with BMI 18.5~24.9 kg/m2.
89451545|NCT03290144||with diabetes|
89451546|NCT03290144||without diabetes|
89451547|NCT05489068|Experimental|Motivational Interviewing at Intake (MII)|Clients allocated to the MII condition will receive a 90-minute pure Motivational Interviewing (MI) session.
89451548|NCT05489068|Active Comparator|Intake as Usual (IAU)|Clients allocated to the IAU condition will receive the 90-minute standard assessment that is delivered to all clients entering intensive outpatient program (IOP)/outpatient program (OP).
89451549|NCT03290066|Active Comparator|Kinesiotape|"Kinesiotape will be applied as a self-treatment. All participants will be instructed in an indvidual session and will receive a tutorial video to remember the kinesiotaping procedure. 3 band of a special and hypoallergenic tape (Kinematix Tex) will be attached to the abdominal (2 strips) and lower back (1 strip).~Patients will be taped for four days , ıt will start at the beginning of the menstruation."
89451550|NCT03290066|Active Comparator|Usual care|"Participants will use the usual self-care for primary dysmenorrhea. It will start at the beginning of the menstruation.~They will note the treatment indicating the dosage in a calendar."
89451551|NCT03289988||Normal group|Normal group(control group): patients with negative colonoscopy findings (n= 238).
89451552|NCT03289988||Low risk adenoma group|Low risk adenoma group: patients having at least one low risk adenoma (n=250).
89451553|NCT03289988||High-risk adenoma group|High-risk adenoma group: patients having at least one of following criteria (more than 1 cm in size, villous or tubulovillous histologic type, high-grade dysplasia findings) (n=316).
89451554|NCT03289988||Colon cancer|Colon cancer: histologically confirmed colon cancer patients (n=160).
89451555|NCT05488990|Experimental|Single arm with several test fields|Altogether six test fields (two active formulations, their corresponding vehicles and two comparators) located on the torso, or the extremities were randomly assigned for treatments per subject.
89451556|NCT03293576|Experimental|Intervention|Volitional help sheet
89451557|NCT03293576|No Intervention|Control|Short Zimbardo's time perspective inventory (Orosz et al. 2017)
89451558|NCT03289832|Active Comparator|Crucera-SGS®|"Drug: Subjects will follow a cruciferous vegetable-free diet and will first undergo a 10 day nonintervention phase. For the second phase they will be instructed to maintain a non-cruciferous diet and to ingest daily for 10 days, Crucera-SGS® as a source of glucoraphanin which is converted to sulforaphane; 9 capsules (450 mg or 1.03 mmol GR) per day.~On the 7th day of each phase, they will be asked to fast overnight, come in to the clinic, provide urine and blood, and receive a dose 2-times their M.E.D. at up to 5 sites on the upper buttocks. Following the first and third days of chromometer readings, 2 biopsies will be taken from the upper buttocks for a total of 8 skin-punch biopsies per individual."
89451559|NCT03289832|Active Comparator|Meriva 500-SF®|"Drug: Subjects will follow a cruciferous vegetable-free diet and will first undergo a 10 day nonintervention phase. For the second phase they will be instructed to maintain a non-cruciferous diet and to ingest daily for 10 days, Meriva 500-SF® as a source of curcumin; 2 capsules (1000 mg or 2.72 mmol total curcuminoids) per day.~On the 7th day of each phase, they will be asked to fast overnight, come in to the clinic, provide urine and blood, and receive a dose 2-times their M.E.D. at up to 5 sites on the upper buttocks. Following the first and third day of chromometer readings, 2 biopsies will be taken from the upper buttocks, for a total of 8 skin-punch biopsies per individual."
89501727|NCT02230267|Active Comparator|Usual care arm|The low intensity exercise group will participate in the Fitness Counts Exercise Program (FCEP) which is a basic low intensity, sitting and standing exercise program (10 minutes of stretching, 10 minutes of aerobic exercise (60% of heart rate maximum), and 10 minutes of strengthening). This exercise program was developed by the National Parkinson Foundation and is commonly used in PD exercise classes. The physical therapist-to-patient ratio will be 1:5. As there are two clinical sites, there will be 10 participants in each of the two boot camps (20 total). The FCEP will be 1 hour daily on four days of the week. Participants will be required to attend 3 days per week but may attend more if they are able.
89451560|NCT03289832|Active Comparator|Crucera-SGS® and Meriva 500-SF®|"Drug: Subjects will follow a cruciferous vegetable-free diet and will first undergo a 10 day nonintervention phase. For the second phase they will be instructed to maintain a cruciferous vegetable-free diet and to ingest daily for 10 days, Crucera-SGS® as a source of glucoraphanin which is converted to sulforaphane; 9 capsules (450 mg or 1.03 mmol GR) and Meriva 500-SF® as a source of curcumin; 2 capsules (1000 mg or 2.72 mmol total curcuminoids) per day.~On the 7th day of each phase, they will be asked to fast overnight, come in to the clinic, provide urine and blood, and receive a dose 2-times their M.E.D. at up to 5 sites on the upper buttocks. Following the first and third day of chromometer readings, 2 biopsies will be taken from the upper buttocks for a total of 8 skin-punch biopsies per individual."
89451561|NCT02461472||Dr.Tang's research group|Dr.Tang's research group for clinical risk analysis of human complex disease
88936367|NCT01789294|Experimental|DIET|Dietetic avoidance of cow's milk and egg, plus foods eventually detected by skin tests, was prescribed by Pediatric Allergologists
88936368|NCT01789307|Active Comparator|corn syrup solids|corn syrup solids oral ingestion
88936369|NCT01789307|Experimental|sucrose|sucrose oral ingestion
88936370|NCT01789359|Other|anthocyanin-free diet|Maintain anthocyanin-free diet throughout study. Day 1 to day 30, consume daily 250 ml single strength blueberry juice containing 229 mg anthocyanins, taken either as 1 morning dose or 1/3 dose morning, 1/3 mid-day and 1/3 evening. At d 31-38 continue anthocyanin-free diet. On d 39 consume daily dose.
88936371|NCT01789385|Other|dexmedetomidine|Precedex 200 mcg 2ml
88936372|NCT01789398|Experimental|BF2.649 (pitolisant)|BF2.649 (5mg, 10mg, 20mg or 40mg) in capsules
88936373|NCT01789398|Placebo Comparator|placebo|Placebo of BF2.649 (5mg, 10mg, 20mg or 40mg) in capsules
88936374|NCT01789411||ATHEROREMO-IVUS cohort|Drawing blood samples. Coronary intravascular ultrasound imaging. Coronary near-infrared spectroscopy.
88936375|NCT01789437|Active Comparator|Dexamethasone Intravitreal Implant|
88936376|NCT01789450|Experimental|Section of Periareolar Dermis|Section of Periareolar Dermis
88936377|NCT01789463|Active Comparator|Self rehabilitation|Self rehabilitation
88936378|NCT01789463|Experimental|Self rehabilitation plus physiotherapy|Self rehabilitation plus physiotherapy
88936379|NCT01789489|Active Comparator|3 dimensional sonohysterography|3 dimensional sonohysterography
88936380|NCT01789489|Active Comparator|Standard hysteroscopy|Standard hysteroscopy
88936381|NCT01789502|Active Comparator|Plastic stents|Plastic stents are inserted by ERCP
88936382|NCT01789502|Experimental|Fully covered metal stents|Fully covered metal stents are inserted by ERCP
88936383|NCT01789515||rectal cancer|Low Anterior Resection for Rectal Cancer
88936384|NCT01789528|Experimental|CAZ-AVI or CXL|"Cohort 1: CAZ-AVI (2000 mg ceftazidime and 500 mg avibactam) by intravenous infusion given over 2 hours, every 8 hours~Cohort 2: CXL (600 mg ceftaroline fosamil and 600 mg avibactam)"
88936385|NCT01789541||Atrial fibrillation|Patients with atrial fibrillation undergoing ablation
88936386|NCT01789541||AV-nodal reentry tachycardia|Patients with AV-Nodal Reentry Tachycardia undergoing ablation
88936387|NCT01789554|Experimental|MLS dispatch for bystander CPR|When an alarm call of a suspected OHCA suspected is received by the EMS dispatch operator a Mobile positioning system (MPS) is activated. The MPS uses the mobile phone network to geographically locate all lay volunteers connected to a tailored mobile phone service called mobile life saver (MLS). The MPS then locates all lay volunteers within a pre defined radius from the suspected OHACA an alerts them with a computer generated voice call and an sms containing data about were about were the suspected OHCA is located. A map is also sent in order to make route finding easy.
88936388|NCT01789554|No Intervention|NO MLS dispatch for bystander CPR|No activation of mobile positioning system to locate and recruit lay responders to nearby OHCAs
88936389|NCT01789580|No Intervention|Control group|The participants play on their preferred online gambling site (experimental gambling session) without gambling moderator.
88936390|NCT01789580|Experimental|Bonus group|The participants play on their preferred online gambling site (experimental gambling session) with the first gambling moderator sudied : bonus (with different modalities of the moderator).
89501728|NCT02151695|Active Comparator|Panretinal photocoagulation|
88936391|NCT01789580|Experimental|Auto-exclusion group|The participants play on their preferred online gambling site (experimental gambling session) with the first gambling moderator sudied : auto-exclusion.
88936392|NCT01789580|Experimental|Auto- limitation group|The participants play on their preferred online gambling site (experimental gambling session) with the first gambling moderator sudied : auto- limitation(with different modalities of the moderator).
88936393|NCT01789580|Experimental|Information group|The participants play on their preferred online gambling site (experimental gambling session) with the first gambling moderator sudied : information (with different modalities of the moderator).
88936394|NCT01789593|Other|Hypoglycaemia / euglycaemia clamp|
88936395|NCT01789593|Other|Euglycaemia clamp / hypoglycaemia|
88936396|NCT01789619||Extended release tacrolimus (Advagraf®)|
88936397|NCT01789645|Experimental|Conservative group|The conservative group will received 3 treatment sessions of physical therapy based on neuromodulation of nociceptive processing of 30 minutes of duration, once per week.
88936398|NCT01789645|Active Comparator|Surgical group|The surgical group will receive the surgical procedure consisting of the decompression and release of the median nerve at the carpal tunnel performed by an experienced surgeon according to standardized protocols.
88936399|NCT01789658|Experimental|Cryotherapy|Cryotherapy during conditioning treatment with chemotherapy prior to HSCT
88936400|NCT01789658|No Intervention|Control|Standard oral Care. No Cryotherapy during conditioning treatment prior to HSCT
89451562|NCT02555722|Experimental|fanfilcon A (test)|Subjects will be randomized to wear fanfilcon A lens (test) for one month of daily wear during the study.
89451563|NCT02555722|Active Comparator|enfilcon A (control)|Subjects will be randomized to wear enfilcon A lens (control) for one month of daily wear during the study.
89451564|NCT05493748|Other|Frequency|Main symptom: Increased daytime urinary frequency: complaint that micturition occurs more frequently during waking hours than previously deemed normal by the woman.
88936401|NCT01789671|Experimental|Peer Interventionist|Families randomized to this family-based behavioral intervention arm will receive 20 weeks of family-based behavioral pediatric overweight intervention delivered by parents who previously received this treatment (PEER). This behavioral treatment includes behavioral skills training and accountability, including food and activity self-monitoring, goal setting, and home environment change.
88936402|NCT01789671|Active Comparator|Professional Interventionist|Families randomized to this family-based behavioral intervention arm will receive 20 weeks of family-based behavioral pediatric overweight intervention delivered by behavioral specialists(PROFESSIONAL). This behavioral treatment includes behavioral skills training and accountability, including food and activity self-monitoring, goal setting, and home environment change.
88936403|NCT01789684|Experimental|Active Provider Intervention|Participating Sites assigned to the active intervention cluster will receive a multi-faceted provider education and decision support intervention to improve 1) appropriate referral of breast cancer patients at risk for HBOC to genetic counseling in the community cancer center setting and 2) pre-surgical referral among newly diagnosed patients. They will also receive the National Comprehensive Cancer Network (NCCN) guidelines and Commission on Cancer definition of qualified genetics professional.
88936404|NCT01789684|No Intervention|Passive Provider Intervention|Participating Sites assigned to the passive intervention cluster will only receive the National Comprehensive Cancer Network (NCCN) guidelines and Commission on Cancer definition of qualified genetics professional.
88936405|NCT01789697|Experimental|Receives text messages/emails|Will receive text messages and emails periodically from the surgeon from Day 1 (day after discharge) through day 21.
88936406|NCT01789697|No Intervention|Does not receive text messages/emails|Will not receive text messages and emails periodically from the surgeon from Day 1 (day after discharge) through day 21.
88936407|NCT01789710|Experimental|Active Contingency Management|All participants are assigned to a single arm, active contingency management. In this arm, participants are provided monetary rewards for remaining abstinent from smoking.
88936408|NCT01789723|Experimental|Cohort 1: Fusilev - 10 doses|"Fusilev: 5 mg/m2 QID, starting on Day 2 (24 ± 3 hours after Folotyn dose) for a total of 10 doses Day 2: 4 doses Day 3: 4 doses Day 4: 2 doses.~Folotyn: 30 mg/m2 once weekly for 6 weeks"
89015074|NCT01416285||Case management group|This is the study group. Extensive education and case management program will be performed in this group.
89015075|NCT01412333|Active Comparator|Interferon beta-1a 44 mcg SC|Interferon beta-1a 44 mcg SC injections three times per week (with placebo infusions matching ocrelizumab infusions every 24 weeks).
89015076|NCT01412333|Experimental|Ocrelizumab|Ocrelizumab 600 mg or matching placebo intravenous (IV) as 300 mg infusions on Days 1 and 15 for the first dose and as a single infusion of 600 mg for all subsequent infusions every 24 weeks, with placebo injections matching interferon beta-1a SC three times per week.
89015077|NCT01036581|Experimental|MR Methodology Development and Evaluation|Methodology development and evaluation consists of pulse sequence development, testing, and parameter optimization. For each method we develop or evaluate, we may recruit up to 40 participants to come in for up to 4 visits each. Each participant will be scanned for up to 2 sessions per visit, not to exceed 4 total scan hours per visit.
89015078|NCT01036581|Experimental|TMS-fMRI Experiment 1|To evaluate the relationship between BOLD activation and MEP and establish a BOLD activation marker of cortical excitability. Participants will start with a set of two short task-based EPI scans and anatomical scan. RMT will then be determined. Participants will undergo a single-pulse TMS-fMRI scan with stimulation intensities relative to the RMT over the motor cortex and/or the DLPFC. In total, six (6) intensities will be tested, 80% 100%, 105%, 110%, 115%, and 120% relative to the RMT. The fMRI design will be event-related. Each intensity (event type) will be presented 50 times. The order of the intensities will be randomized, and the inter-stimulus-interval (ISI) will range from 12s to 20s (centered at 16s plus random jittering in between, about 0.06Hz). The highest intensity of stimulation will be 120% RMT. EMG recordings in the corresponding hand muscle will be simultaneously acquired during the scan. Total approximate time required for this experiment is about 6-8 hours.
89015079|NCT01036581|Experimental|TRPMS Experiment 1|To evaluate the prolonged effect of TPRMS on motor cortex excitability and help interpret and design subsequent experiments investigating the effect of TRPMS on BOLD signal. The experiment design consists of four groups, each group will include 10 participants (8 completers/group). For TRPMS stimulation sessions, our test conditions will be a 10 stimuli-session (approximately 2min), 50 stimuli-session (approximately 7min), 100 stimuli-session (approximately 14min), and 150 stimuli-session (20min) for each of the four groups, respectively. Therefore, the outcome will be measured with the spontaneous motor unit potentials (sMUPs) in the contralateral abductor pollicis brevis muscle (APB). After the stimulation session, we will measure sMUPs continuously for another 20min to observe the prolonged effect of the TRPMS stimulation and to compare these four conditions. The total approximate time required for this experiment is about 2-2.5 hours.
89015080|NCT01036581|Experimental|TRPMS Experiment 2|To evaluate cortical excitability changes caused by TRPMS measured with simultaneous TMS-fMRI. Participants will undergo a baseline TMS/fMRI session to get a measurement of baseline cortical excitability in the form of single-pulse TMS induced BOLD activation and determine motor hot-spot and RMT. We will then conduct an event-related single-pulse TMS/fMRI session with TMS stimulus at 120% RMT, 50 events with jittered inter-stimulus-interval (ISI) averaging 16s. Simultaneous EMG recording will be gathered from the corresponding hand muscle. Next we will use TRPMS to stimulate the left motor cortex over the hot-spot : 20-min application of TRPMS, 100ms duration, 0.2Hz (one stimulus every 5s), total 240 stimuli. Then we will evaluate the modulatory effect of the TRPMS stimulation via a second TMS/fMRI session with a similar procedure as the baseline session using the RMT determined at baseline. Total time for this experiment is about 5-6 hours.
89015081|NCT00861705|Active Comparator|Arm I (paclitaxel, doxorubicin, cyclophosphamide)|Patients receive paclitaxel IV over 60 minutes once weekly in weeks 1-12. Patients then receive dose-dense doxorubicin hydrochloride IV over 5-10 minutes and cyclophosphamide IV over 5-30 minutes (ddAC) once in weeks 13, 15, 17, and 19.
89015082|NCT00861705|Experimental|Arm II (paclitaxel, ddAC, bevacizumab)|Patients receive paclitaxel and ddAC as in Arm I. Patients also receive bevacizumab IV over 30-90 minutes in weeks 1, 3, 5, 7, 9, 11, 13, 15, and 17.
89015083|NCT00861705|Experimental|Arm III (paclitaxel, ddAC, carboplatin)|Patients receive paclitaxel and ddAC as in Arm I. Patients also receive carboplatin IV over 30 minutes once in weeks 1, 4, 7, and 10.
89451565|NCT05493748|Other|Nocturia|Main symptom: Complaint of interruption of sleep one or more times because of the need to micturate.
89015084|NCT00861705|Experimental|Arm IV (paclitaxel, ddAC, bevacizumab, carboplatin)|Patients receive paclitaxel and ddAC as in Arm I, bevacizumab as in Arm II, and carboplatin as in Arm III.
89015085|NCT00602641|Active Comparator|Arm I (thalidomide)|"INDUCTION THERAPY: Patients receive melphalan PO and prednisone PO QD on days 1-4, and thalidomide PO QD on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive thalidomide PO QD and continue in the absence of disease progression."
89015086|NCT00602641|Experimental|Arm II (lenalidomide)|"INDUCTION THERAPY: Patients receive melphalan PO and prednisone PO QD on days 1-4, and lenalidomide PO on days 1-21. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive lenalidomide PO QD on days 1-21. Courses repeat every 28 days in the absence of disease progression."
89015087|NCT00588770|Active Comparator|Arm IA (docetaxel, cisplatin)|Patients receive docetaxel IV over 1 hour and cisplatin IV over 1-2 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89015088|NCT00588770|Experimental|Arm IB (docetaxel, cisplatin, bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes on day 1 and docetaxel and cisplatin as in Arm IA.
89015089|NCT00588770|Active Comparator|Arm IIA (docetaxel, carboplatin)|Patients receive docetaxel IV over 1 hour and carboplatin IV over 30 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89015090|NCT00588770|Experimental|Arm IIB (docetaxel, carboplatin, bevacizumab)|Patients receive bevacizumab as in Arm IB and docetaxel and carboplatin as in Arm IIA.
89451566|NCT04119388|Experimental|Adapted sports practice|patients with osteogenesis imperfect will practice adapted sport twice a week during 12 months in order to improve their aerobic capacity, cardiovascular and bone benefits, and gain of quality of life.
89451567|NCT03289598|Experimental|Interventionsgroup|
89451568|NCT03289598|No Intervention|Controlgroup|
89451569|NCT03293342|Experimental|D CBT|Dentist administered cognitive behaviioral treatment
89451570|NCT03293342|Active Comparator|Control|Treatment as usual
89451571|NCT03293186|Experimental|Use MEDICLORE|use mediclore at the end of surgery
89451572|NCT03293186|No Intervention|No antiadhesive product|use no antiadhesive product at the end of surgery
89451573|NCT02461316||Combination Treatment in Chronic Lymphocytic Leukemia (CLL)|All participants receiving combination treatment in Chronic Lymphocytic Leukemia (CLL)
89451574|NCT03289520|Experimental|Clopidogrel|
89451575|NCT03289520|Placebo Comparator|Placebo|
89451576|NCT03298100||Postmenopausal women|
89451577|NCT03289442|Experimental|supine position group|
89451578|NCT03289442|No Intervention|left lateral position|
89451579|NCT03289364|Experimental|Penguin Cold Caps|Penguin Cold-cap therapy will commence at least 50 minutes prior to chemotherapy infusion, and will continue for 4 hours following completion of chemotherapy.
89451580|NCT03289286|Other|Patients with breast cancer operated in ambulatory|
88936409|NCT01789723|Experimental|Cohort 2: Fusilev - 6 doses|"Fusilev: 5 mg/m2 BID, on Days 2 (24 ± 3 hours after Folotyn dose), 3, and 4.~Folotyn: 30 mg/m2 once weekly for 6 weeks"
88936410|NCT01789723|Experimental|Cohort 3: Fusilev - 4 doses|"5 mg/m2 BID, on Days 2 (24 ± 3 hours after Folotyn dose) and 3.~Folotyn: 30 mg/m2 once weekly for 6 weeks"
88936411|NCT01789723|Experimental|Cohort 4: Fusilev - 2 doses|"5 mg/m2 BID, on Day 2 (24 ± 3 hours after Folotyn dose.~Folotyn: 30 mg/m2 once weekly for 6 weeks"
88936412|NCT01789723|Experimental|Cohort 5: Fusilev - 1 dose|"Fusilev: 5 mg/m2 once on Day 2.~Folotyn: 30 mg/m2 once weekly for 6 weeks"
88936413|NCT01789749|Active Comparator|No Coagulation Arm|Patients do not receive Snare Tip Soft Coagulation to the edge of the endoscopic resection defect
88936414|NCT01789749|Experimental|Coagulation Arm|Patients to receive Snare Tip Soft Coagulation to the edge of the endoscopic resection defect
88936415|NCT01789762|Active Comparator|Historical control arm|Patients transfused with platelet concentrates re-suspended in autologous plasma
88936416|NCT01789762|Active Comparator|Control arm|Patients transfused with platelets prepared in additive solution
88936417|NCT01789762|Experimental|Experimental arm|Patients transfused with platelets treated by pathogen reduction process
88936418|NCT01789788|Placebo Comparator|Placebo|
88936419|NCT01789788|Experimental|RO6811135|
88936420|NCT01789801|Active Comparator|Palpation only|"Patients randomized to this arm will have radial artery puncture via palpation of arteries.~Intervention: RAP palpation only"
88936421|NCT01789801|Experimental|Ultrasound guidance|"Patients randomized to this arm will have radial artery puncture with ultrasound guidance for artery localisation.~Intervention: RAP with ultrasound guidance"
89451581|NCT03293108|Experimental|AryoGen Pharmed Denosumab|"Arylia (Denosumab Prefilled Syringe produced by AryoGen Pharmed) 60 mg/1 ml in a prefilled syringe.~Denosumab 60 mg is subcutaneously administered to osteoporotic patients at baseline, month 6 and month 12. Along with, all women will receive daily supplements containing at least 1000 mg of elemental calcium (divided into two doses) and at least 400 IU vitamin D daily during 18 months of the study."
89451582|NCT03293108|Active Comparator|Amgen Denosumab|"Prolia® (Denosumab Prefilled Syringe produced by Amgen) 60 mg/1 ml in a prefilled syringe.~Denosumab 60 mg is subcutaneously administered to osteoporotic patients at baseline, month 6 and month 12. Along with, all women will receive daily supplements containing at least 1000 mg of elemental calcium (divided into two doses) and at least 400 IU vitamin D daily during 18 months of the study."
89451583|NCT03292796|Other|Stop prostaglandin eye drops post op|Stop prostaglandin eye drops post operatively. Prostaglandins either stopped or continued after cataract surgery. Latanoprost Travaprost Bimatoprost Tafluprost
88936422|NCT01789827|Experimental|Cohort I (scintigraphy prior to immunotherapy and 12 weeks)|Patients undergo technetium Tc 99 hydrazinonicotinamide-tricine-linked interleukin-2 scintigraphy prior to receiving ipilimumab or pembrolizumab and at 12 weeks.
88936423|NCT01789827|Experimental|Cohort II (scintograpy prior to immunotherapy, 3-4, 12 weeks)|Patients undergo technetium Tc 99 hydrazinonicotinamide-tricine-linked interleukin-2 scintigraphy prior to receiving ipilimumab or pembrolizumab, at 3-4 weeks, and at 12 weeks.
88936424|NCT01789853|Experimental|Intensive Walking|High intensity walking training in variable context for 8 weeks
88936425|NCT01789853|Active Comparator|Conventional Physical Therapy|Regular physical therapy for 8 weeks
88936426|NCT01789892|Experimental|Diagnostic (methylprednisolone and FDG PET/CT scan)|Within 1-14 days of undergoing standard FDG PET/CT scan, patients receive methylprednisolone IV and then undergo a second FDG PET/CT scan.
88936427|NCT01789918|Experimental|Percutaneous renal denervation|PARADISE percutaneous renal denervation
89451584|NCT03292796|Other|Continue prostaglandin eye drops post op|Continue prostaglandin eye drops post operatively Prostaglandins either stopped or continued after cataract surgery. Latanoprost Travaprost Bimatoprost Tafluprost
89451585|NCT03297866||Incentive schemes 1|No incentive will be given after completing the follow-up survey
89451586|NCT03297866||Incentive schemes 2|Receiving $100 supermarket coupon after completing the follow-up survey
89451587|NCT03297866||Incentive schemes 3|Receiving $200 supermarket coupon after completing the follow-up survey
89451588|NCT03297866||Incentive schemes 4|Receiving $100 supermarket coupon before completing the follow-up survey and another $100 supermarket coupon after completing the follow-up survey
89451589|NCT03292718|Experimental|use of MyCyFAPP|use of MyCyFAPP during 6 months
89501729|NCT02151695|Experimental|Aflibercept intravitreal injections|
89501730|NCT03889405|Experimental|Study group|Healthy 32 weeks or more pregnant women, at an early stage of labor.
89501731|NCT02156219||Under separation|Exposure to the separation of women and men in the metro of Mexico City.
89501732|NCT02156219||No treatment|Non exposure to the separation of women and men in the metro of Mexico City.
89537138|NCT05723939|Placebo Comparator|Control|Intake of placebo capsules or regular chicken meet for three weeks
89451590|NCT03288896|Experimental|Alerta Alcohol|Intervention Group: The Experimental Group receives the Alerta Alcohol intervention, which consists of four sessions at school (baseline questionnaire, two sessions in three scenarios: at home, celebrations, and public places, and a final evaluation). The adolescents are provided with answers related to their views of each scenario; this information is used to provide highly specific feedback regarding their knowledge, risk perception, self-esteem, attitude, social influence (modelling, norms and social pressure), self-efficacy and action plans. In addition, two booster sessions are given at home to reinforce the contents of the three scenarios. Evaluation takes place after four months.
88936428|NCT01789931|Experimental|Research arm|"The participants will undergo an examination day in which they will complete VO2max test to evaluate their aerobic fitness. Afterwards they'll undergo 3 heat tolerance test (HTT) days: without CB protective clothing, with CB protective clothing, and with work clothes. During the tests, a Lifebeam sensor will be attached to their skin."
89451591|NCT03288896|No Intervention|Control Group|Control Group: The Control Group just completes the baseline and the evaluation questionnaires and then they are allowed to receive the intervention as well (as a waiting list control condition). Evaluation takes place after four months from baseline
89451592|NCT03288818|Experimental|low dose TSEBT, mechlorethamine hydrochloride gel|Patients undergo low dose TSEBT for 2 weeks. After 30 days of observation, patients receive mechlorethamine hydrochloride gel topically daily at week 7 and then once weekly up to week 54.
89451593|NCT03288740|Experimental|Semaglutide 0.5 mg|Participants will enter a 13 weeks treatment with 4 weeks dosing at dose level 0.25 mg and 9 weeks at 0.5 mg semaglutide.
89451594|NCT03288740|Placebo Comparator|Semaglutide 0.5 mg placebo|Participants will enter a 13 weeks treatment with 4 weeks dosing at dose level 0.25 mg and 9 weeks at 0.5 mg semaglutide placebo.
89451595|NCT03288740|Experimental|Semaglutide 1.0 mg|Participants will have 13 weeks treatment with 4 weeks dosing at dose level of 0.25 mg, 4 weeks at 0.5 mg, and 5 weeks at 1.0 mg semaglutide.
89451596|NCT03288740|Placebo Comparator|Semaglutide 1.0 mg placebo|Participants will have 13 weeks treatment with 4 weeks dosing at dose level of 0.25 mg, 4 weeks at 0.5 mg, and 5 weeks at 1.0 mg semaglutide placebo.
89451597|NCT03297632|Experimental|Intervention Group|Receives instructor-based functional resistance exercise. 45 minutes per session. 3 times per week, during 10 weeks in total.
89451598|NCT03297632|No Intervention|Control group|Asked to normally active according to their current lifestyle
88936429|NCT01789944|Experimental|Provide Treatment|Peers provide treatment to 2nd generation following receipt of the intervention.
88936430|NCT01789944|Experimental|Treatment Only|Peers receive treatment and return for a 6-month follow-up
88936431|NCT01789957|Experimental|Open-label AC2993|
88936432|NCT01789996|Active Comparator|Alternative six minute walk test|"Subjects will be given the following instructions~walk as fast as they can in 6 minutes~walk as normally as they can in 6 minutes~walk leisurely as they can in 6 minutes. Pts will serve as their own controls."
88936433|NCT01789996|Placebo Comparator|Standard six minute walk test|"Subjects will be given the following instruction~1. walk as far as they can in 6 minutes"
88936434|NCT01790620|Experimental|CVVHD-ST150|Patients with sepsis whom present AKI meeting CRRT initiation criteria will be started on CVVHD with PrismafleX eXeed™ II (Hospal) using an ST150SET copolymer of acrylonitrile and sodium methylsulfonate (AN 69) with polyethylenimine treated surface. Anticoagulation of the ST150 set with unfractioned heparin will only be initiated if there´s no clinical contraindication. ST150 set will be changed when clotted and every 24 hours during the first 72 hours of CVVHD. No citrate anticoagulation will be used.
88936435|NCT01790620|Active Comparator|CVVH-ST150|Patients with sepsis whom present AKI meeting CRRT initiation criteria will be started on CVVH with PrismafleX eXeed™ II (Hospal) using an ST150SET copolymer of acrylonitrile and sodium methylsulfonate (AN 69) with polyethylenimine treated surface. Anticoagulation of the ST150 set with unfractioned heparin will only be initiated if there´s no clinical contraindication. ST150 set will be changed when clotted and every 24 hours during the first 72 hours of CVVH. No citrate anticoagulation will be used.
88936436|NCT01790711|Experimental|FMT by endoscopy|Once, fresh or frozen bacteria
88936437|NCT01790854|Experimental|Prasugrel dose 5 mg/day|225 patients will be treated with 325 mg of aspirin (followed by a maintenance dosage of 100 mg of aspirin for at least 1 year and with 60 mg loading dose of prasugrel followed by a maintenance dosage of 5 mg/day of prasugrel for 12 months
88936438|NCT01790854|Active Comparator|Prasugrel dose 10 mg/day|225 patients will be treated with 325 mg of aspirin (followed by a maintenance dosage of 100 mg of aspirin for at least 1 year and with 60 mg loading dose of prasugrel followed by a maintenance dosage of 10 mg/day of prasugrel for 12 months
88936439|NCT01791257||SAH with DCI|After 21 days from ictus the patients with subarachnoid hemorrhage are stratified to group 1 or 2 depending on their development of delayed cerebral ischemia.
88936440|NCT01791257||SAH without DCI|After 21 days from ictus the patients with subarachnoid hemorrhage are stratified to group 1 or 2 depending on their development of delayed cerebral ischemia.
88936441|NCT01791257||Neurological healthy controls|12 patients (ASA 1) undergoing spinal anesthesia for orthopedic surgery have 2 ml of cerebrospinal fluid drawn preceding injection of local analgetic.
88936442|NCT01791270||OSA versus Control subjects.|sleep apnea-hypopnea syndrome and control
88936443|NCT01791270||OSA patients before and after treatment, CPAP|Continuous positive pressure CPAP
88936444|NCT01791387|Experimental|Dovitinib|Dovitinib 500 mg taken orally once daily 5 days on / 2 days off, until disease progression
89451599|NCT03297632|Active Comparator|Home-based group|Receives home-based exercises with written instructions and digital video support. 45 minutes per session. 3 times per week, during 10 weeks in total.
89501733|NCT02151929|Experimental|Bioresorbable Vascular Scaffold|Implantation of of an everolimus eluting bioresorbable scaffold in patients with STEMI treated with primary PCI
89451600|NCT03288662|Experimental|CT and histopathological classification|With each histopathological type of thymic epithelial tumors, we measure the maximun diameter in chest CT scan. Comparison of some characteristics of the tumor on preoperative chest CT scans and histopathological type of thymic epithelial tumors .
89451601|NCT03108092|Experimental|STRIP intervention|The intervention will take place during the initial hospital admission (Index Hospitalisation) or an equivalent situation for outpatients. STRIP is a structured method to perform pharmacotherapy optimisation. The STRIP-intervention consists of 9 steps.
88936445|NCT01791790|Experimental|0,75 Hz stimulation|slow transcranial oscillating stimulation (~0,75Hz) during periods of Slow Wave Sleep
88936446|NCT01791790|Sham Comparator|SHAM stimulation|SHAM stimulation during periods of Slow Wave Sleep
88936447|NCT01792063|Active Comparator|Sevoflurane A|Generic sevoflurane
88936448|NCT01792063|Active Comparator|Sevoflurane B|Orginal sevoflurane
88936449|NCT01792232|Active Comparator|Filtered air|Exposure for 2 hours to filtered air followed by subject specific allergen placed in lung
88936450|NCT01792232|Experimental|Diesel exhaust|Exposure for 2 hours to diesel exhaust followed by subject specific allergen placed in lung
88936451|NCT01792232|Active Comparator|Filtered air control|Exposure for 2 hours to filtered air followed by subject saline placed in lung
88936452|NCT01792232|Active Comparator|Diesel exhaust control|Exposure for 2 hours to diesel exhaust followed by saline placed in lung
88936453|NCT01792258||critical ill patients|The investigator will enroll all the critical ill patients undergoing percutaneous tracheostomy performed in ICU
88936454|NCT01792297|Experimental|Bovine Colostrum|60 g/d bovine colostrum in powder form to be mixed with drinks. The dose will be spread out 3 times per day (20 g per dose)
88936455|NCT01792297|Active Comparator|Whey protein|60 g/d whey protein powder mixed into drinks. It is to be divided into 3 daily doses (20 g per dose)
88936456|NCT01792349|Experimental|STARFISH intervention|STARFISH is a smartphone-based programme designed as a behavioural intervention to encourage the user to become more physically active
88936457|NCT01792349|No Intervention|Control group|A smartphone application will record levels of physical activity, but subjects will not have access to daily step count or to the STARFISH application.
88936458|NCT01792414|Active Comparator|Active TES|Active TES
88936459|NCT01792414|Sham Comparator|Sham TES|Sham TES
88936460|NCT01792570|Experimental|RPV + DRV/r|switch to RPV + DRV/r
89451602|NCT03108092|Sham Comparator|Control|Participants in the control group will receive medication review by the prescribing physicians in accordance with usual care. If an extended drug review is in place in a ward/specialty corresponding characteristics are collected on cluster level.
89451603|NCT03292328|Experimental|Yoga Arm|After randomization, participants in the Yoga group will meet twice weekly for 8 weeks of classes taught by MSK yoga instructors. Each class will last for sixty minutes. In addition to these group classes, participants will utilize a home-based program on the days group classes are not held. The daily home practice will continue for four weeks after the group classes are finished.
88936461|NCT01792570|Active Comparator|continue the PI/r-containing HAART.|continue the PI/r-containing HAART
88936462|NCT01792622||Phase I Patient Interviews|Indepth interviews will be completed with approximately 15 patients.
88936463|NCT01792622||Phase II Patient Questionnaire|Patients will be asked to provide subjective ratings of their experience on a questionnaire developed from the responses from Phase I
88936464|NCT01792661|Active Comparator|MyChart|The control group receives standard Cleveland Clinic care and has access to MyChart which is the standard Cleveland Clinic electronic PHR.
88936465|NCT01792661|Active Comparator|Enhanced MyChart|The enhanced PHR functionality adds the ability to securely receive and review CKD-education related messages to the existing features available to all PHR users. The CKD-educational related messages can be automatically delivered at pre-defined intervals and customized for each individual patient at their discretion and convenience.
88936466|NCT01792661|Active Comparator|Patient Navigator|A tracking log is kept by the Patient Navigator of each interaction regarding type of encounter, length of encounter, barriers addressed, and actions that occurred, adapting what is in use for the NIH-funded Patient Navigator program.
88936467|NCT01792661|Active Comparator|Patient Navigator and Enhanced MyChart|Combines patient self empowerment, regarding their CKD, with the Enhanced MyChart along with the aid and direction of a Patient Navigator.
88936468|NCT01792674|Experimental|In situ simulation|'In situ simulation' which is training in the actual patient care unit, in this situation the labour suite and operation theatre
88936469|NCT01792674|Active Comparator|Off site simulation|The control group will receive the same training 'off site simulation', i.e., in training rooms away from the actual patient care unit.
89200940|NCT00337675|Active Comparator|Arm 2: placebo comparator + episodic supplemental drug|Placebo qd + episode driven supplemental Montelukast qd for 12 days for a 52-wk treatment period
88936470|NCT01792804|Experimental|Orally administered antibiotic|First choice (MRSA and MSSA): trimethoprim-sulfamethoxazole, or Second choice (MSSA): clindamycin, or Second choice (MRSA): linezolid administered for 7-9 days
88936471|NCT01792804|Experimental|Intravenously administered antibiotic|First choice (MSSA): flucloxacillin [Spain: cloxacillin], or cefazolin or Second choice (MSSA): vancomycin, or First choice (MRSA): vancomycin, or Second choice (MRSA): daptomycin administered for 7-9 days
88936472|NCT01792856|Experimental|intervention group|Subjects are scheduled to receive a 6-month group-based recovery-oriented coaching program. This is a structured, manualised treatment program based on life coaching principles with cognitive-behavioural and solution-focused elements incorporated. It guides subjects to undergo an active, yet stepwise change process by stimulating motivation, setting achievable goals, generation of action plans via collaborative exploration, fostering self-regulatory capacity, and provision of autonomy-supportive treatment environment and peer support. Subjects' perceived competence, sense of control, self-management skills and hence functioning will be improved via successful experiences and positive feelings generated after attainment of self-initiated goals. Cognitive-behavioural techniques such as self-monitoring, activity scheduling and behavioural modification will be employed.
88936473|NCT01792856|Experimental|control group|Subjects will receive group-based supportive therapy provided by case managers of JCEP project. The therapy provides patients with psychoeducation about psychosis, stress management, emotional and social support. Coaching and cognitive-behavioural techniques will not be incorporated. Therapy sessions and duration will be comparable to that of recovery-oriented coaching program.
88936474|NCT01793038|Active Comparator|CC-plus uFSH|clomiphene citrate 50 mg tablets twice/day for cycle days 3-7 plus daily IM injection of 37.5 IU HP uFSH for days 3-12
88936475|NCT01793038|Experimental|Aromataze inhibitor plus uFSH|Aromataze inhibitor (litrezole )2.5 mg twice daily for cycle days 3-7 plus daily IM injection of uFSH 37.5 IU for cycle days 3-12
88936476|NCT01793090|Active Comparator|EPI-743|"EPI- 743 in capsule or formulation comprised of USP/NF (United States Pharmacopeia and The National Formulary)Sesame Oil at a potency of 100 mg EPI-743/ 1 mL total volume. Mode of Administration: Oral with meal or G-Tube infusion with food.~Dose: 100mg or 200 mg tid for 12 months, to be continued if clinically effective"
88936477|NCT01793090|Placebo Comparator|Placebo supplementation|placebo in the same formulation as the active comparator will be administered to patients, assigned to this arm in a randomized design
88936478|NCT01793337|Other|Cold first|temperature is measured in cold (-20°C) environment first, and warm (23°C) environment afterwards
88936479|NCT01793337|Other|Warm first|temperature is measured in warm (23°C) environment first, and cold (-20°C) environment afterwards
88936480|NCT01793779|Placebo Comparator|Control|Placebo supplement given prior to exercise and two times per day following exercise
88936481|NCT01793779|Experimental|cold water immersion|Placebo supplement to be give prior to exercise and two times per day following exercise in combination with cold water immersion therapy following exercise
88936482|NCT01793779|Experimental|HMB-FA|beta-hydroxy-beta-methylbutyrate free acid supplement to be give prior to exercise and two times per day following exercise
88936483|NCT01793779|Experimental|cold water immersion group + HMB-FA|beta-hydroxy-beta-methylbutyrate free acid supplement give prior to exercise and two times per day following exercise in combination with cold water immersion therapy following exercise
88936484|NCT01793818|Placebo Comparator|Group 1 Phase I/II|Three injections with no active principle
88936485|NCT01793818|Active Comparator|Group 2 Phase I/II|Three injections of Tat Oyi vaccine containing 11 µg of active principle
88936486|NCT01793818|Active Comparator|Group 3 Phase I/II|Three injections Tat Oyi vaccine containing 33 µg of active principle
88936487|NCT01793818|Active Comparator|Group 4 Phase I/II|Three injections Tat Oyi vaccine containing 99 µg of active principle
88936488|NCT01794104|Experimental|1|Open-label Phase I trial evaluating weekly administration of LMP400, on days 1, 8, and 15, in 28-day cycles.
88936489|NCT01794182|Placebo Comparator|Matching Placebo|Participants received a bolus dose of matching placebo over 2 minutes, followed by a continuous matching placebo infusion for 72 hours.
88936490|NCT01794182|Experimental|Glyburide for Injection|Participants received a 0.13 mg bolus dose of glyburide over 2 minutes, followed by a 0.16 mg/hr continuous infusion for 6 hours and than a 0.11 mg/hr for 66 hours for a total dosing period of 72 hours.
88936491|NCT01794208|Experimental|treatment 1|Follitropin Epsilon 52.5 IU quaque die (QD) s.c.
88936492|NCT01794208|Experimental|treatment 2|Follitropin Epsilon 75 IU QD s.c.
88936493|NCT01794208|Experimental|treatment 3|Follitropin Epsilon 112.5 IU QD s.c.
88936494|NCT01794208|Experimental|treatment 4|Follitropin Epsilon 150 IU QD s.c.
88936495|NCT01794208|Experimental|treatment 5|Follitropin Epsilon 150 IU quaque altera die (QAD) s.c.
88936496|NCT01794208|Active Comparator|treatment 6|Follitropin alfa 150 IU QD s.c.
88936497|NCT01794247|Experimental|Intrathecal magnesium|Intrathecal magnesium sulfate 15% 0,5 mL (75 mg) is added to lidocaine 5% 1 mL (50 mg)as anesthetic adjuvant
88936498|NCT01794247|Active Comparator|Intrathecal fentanyl|Intrathecal fentanyl 0.5 mL (25 micrograms)is added to lidocaine 5% 1 ML (50 mg) as anesthetic adjuvant
88936499|NCT01794364|Experimental|Experimental: Cohort A|Each subjects in Cohort A will receive 2 single doses of PF-06291874 and 1 placebo dose in random order in Periods 1-3; in addition, 1 dose of PF-06291874 will be administered in Period 4 in the fed state.
88936500|NCT01794390||Turbuhaler and MDI patients (Arm 1)|Patients (Diskus naive) will be randomised to receive training on the PulmoJet© device followed by Diskus, or vice versa
88936501|NCT01794390||Diskus patients (Arm 2)|Patients (Turbuhaler naive) will be randomised to receive training on the PulmoJet© device followed by Turbohaler, or vice versa
88936502|NCT01794429|Placebo Comparator|Placebo|Subcutaneum injection of placebo once-weekly for 3 months
88936503|NCT01794429|Active Comparator|exenatide|Subcutaneum injection of exenatide once-weekly for 3 months
88936504|NCT01794494||Open surgical group|Bypass surgery for critical limb ischemia
88936505|NCT01794494||Endovascular treatment|Endovascular recanalization for critical limb ischemia
88936506|NCT01794637||the end-stage liver disease patients|the end-stage liver disease scheduled for liver transplantation
88936507|NCT01794754|Other|Control|Care as usual
88936508|NCT01794754|Experimental|Occupational therapy|Occupational therapy
88936509|NCT01794819|Experimental|C-reactive protein test|"The C-reactive protein test was performed in the intervention group at both the first and second consultations.~The Afinion test system (Axis Shield) was used, which provides results within 5 minutes and before treatment was determined. This test is based on solid-phase sandwich immunometric analysis. The measurement range in whole blood samples is 8-200 mg/L."
88936510|NCT01795248|Experimental|Liraglutide|1.8 mg liraglutide, subcutaneous, once-daily for five years
88936511|NCT01795248|Placebo Comparator|Placebo|Placebo, subcutaneous, once-daily for one year
88936512|NCT01795248|No Intervention|Control|Control without previous GDM.
88936513|NCT01795261||Lifestyle counseling|Prevention of mother to child transmission of HIV
88936514|NCT01795261||Lifestyle counseling Male|male partners and PMTCT completion rate among HIV-infected pregnant women.
88936515|NCT01795274|Experimental|Carbon Ion Radiotherapy|Step 1 14 x 3 Gy E 42 Gy E Step 2: 15 x 3 Gy E 45 Gy E Step 3: 16 x 3 Gy E 49 Gy E Step 4: 17 x 3 Gy E 51 Gy E Step 5: 18 x 3 Gy E 54 Gy E
88936516|NCT01795482|Experimental|Group 2, Prewarming only before general anaesthesia|Active forced-air warming for 15 min after completion of epidural anaesthesia / before start of general anaesthesia. Continued active forced-air warming after induction of general anaesthesia until operation is finished (intraoperatively). Application of warmed infusions (41 °C).
88936517|NCT01795482|Experimental|Group 3, Prewarming before epidural and general anaesthesia|Active forced-air warming for 15 min before start of epidural anaesthesia and for 15 min after completion of epidural anaesthesia / before start of general anaesthesia. Continued active forced-air warming after induction of general anaesthesia until operation is finished (intraoperatively). Application of warmed infusions (41 °C).
88936518|NCT01795482|No Intervention|Group 1, control group|No active warming before start of epidural or general anaesthesia, active forced-air warming after induction of general anaesthesia until operation is finished (intraoperatively). Application of warmed infusions (41 °C).
88936519|NCT01795872|Other|Several diagnostic procedures|
88936520|NCT01796132|No Intervention|Control|Pregnant and/or nursing mothers not taking a SSRI or SNRI antidepressant are recruited in a non-exposed group (Control or no SSRI/SNRI). Control group participates only in the sub-studies related to neonatal adaptation, neurodevelopment, growth and early mother-infant relationship.
88936521|NCT01796132|Experimental|SSRI/SNRI exposure|Pregnant and/or nursing mothers under SSRI or SNRI treatment are recruited in an exposed group (SSRI/SNRI exposure). Drug regimen including dosage, frequency and duration is not modified by the study.
88936522|NCT01796223|Experimental|Feedback|Feedback system included in psychotherapy
88936523|NCT01796223|Active Comparator|control|Psychotherapy as usual
88936524|NCT01796314|Experimental|Group A : intervention|"85 dyads patient/caregiver in witch the patient suffers from mild to moderately severe Alzheimer's disease patients (MMSE 11 to 26), and lives at home with a caregiver"
88936525|NCT01796314|No Intervention|Group B : Control|There si no associated intervention
88936526|NCT01796327|Experimental|Treatment|Dacomitinib will be administered as a single oral dose and as an intravenous infusion
88936527|NCT01796353|Experimental|sexual rehabilitation|exercise plus psycho-education
88936528|NCT01796353|Active Comparator|usual care|usual care
88936529|NCT01796379|Experimental|High Intensity Interval Training|
88936530|NCT01796379|Other|Moderate Training|Regular exercise training offered as usual care to all heart transplant recipients.
88936531|NCT01796418|Experimental|Beraprost sodium|Beraprost sodium 0.02 mg capsule by mouth every 12 hours for 12 weeks
88936532|NCT01796418|Placebo Comparator|Placebo|Placebo capsule by mouth every 12 hours for 12 weeks
88936533|NCT01796496|Experimental|Manipulative Therapy Techniques|Manipulative Therapy Techniques involve three techniques on lumbar and sacral areas. This protocol will be administered one a week for 3 weeks.
88936534|NCT01796496|Active Comparator|Functional Technique|Manipulative Therapy Technique involves one technique on lumbar area. This protocol will be administered one a week for 3 weeks.
88936535|NCT01796522|Active Comparator|Nifedipine (60 mg / day orally)|The name of this arm is Nifedipine. These Prolonged release tablets(Oros) presents a release system for 24h, acting as an osmotic pump releasing the nifedipine through an orifice in the tablet produced by laser technology.The Nifedipine tablet 60mg administered once daily to week 34 of gestation.
89200941|NCT00337675|Placebo Comparator|Arm 3: placebo comparator + episodic supplemental placebo|Placebo qd + episode driven supplemental placebo qd for 12 days for a 52-wk treatment period
89451604|NCT03292328|Active Comparator|Wait List Control Arm (WLC)|Participants in the WLC group will continue usual care for twelve weeks before participating in Yoga classes for eight weeks. At the end of the twelve week follow-up, these participants will receive eight weeks of group Yoga classes and the home Yoga practice recording. At week 20, they will complete a final follow-up visit.
89451605|NCT03292172|Experimental|Group 1 - Escalation Dose: RO6870810 + Atezolizumab|Participants will be administered escalating doses of RO6870810 (0.3 milligram per kilogram [mg/kg], 0.45 mg/kg, and 0.65 mg/kg) subcutaneously (SC) once daily (QD) along with fixed dose of atezolizumab 1200 mg intravenously (IV) on Day 1 of each cycle (21 day cycles), every 3 weeks. RO6870810 will be given during the first 14 days.
89451606|NCT03292172|Experimental|Group 2 - Sequential Dose: RO6870810 + Atezolizumab|Participants will be administered RO6870810 monotherapy (starting dose 0.30 mg/kg) during the first 14 days of 21-day Run-in period. Following the Run-in period, participants will continue to receive RO6870810 at the same dose in combination with fixed dose of atezolizumab 1200 mg IV every 3 weeks in 21-day cycles.
89451607|NCT03292172|Experimental|Group 3 - Expansion in TNBC Group: RO6870810 + Atezolizumab|Participants will be administered dose of RO6870810 established in Group 1 (either 0.3 mg/kg, 0.45 mg/kg, or 0.65 mg/kg) SC QD along with fixed dose of atezolizumab 1200 mg IV on Day 1 of each cycle (21 day cycles), every 3 weeks. RO6870810 will be given during the first 14 days.
89451608|NCT03292172|Experimental|Group 4 - Expansion in OC Group: RO6870810 + Atezolizumab|Participants will be administered dose of RO6870810 established in Group 1 (either 0.3 mg/kg, 0.45 mg/kg, or 0.65 mg/kg) SC QD along with fixed dose of atezolizumab 1200 mg IV on Day 1 of each cycle (21 day cycles), every 3 weeks. RO6870810 will be given during the first 14 days.
89451609|NCT03292094||Black men|294 young healthy men were included (clinic normotensive, non-HIV)
89451610|NCT03292094||White men|284 young healthy men were included (clinic normotensive, non-HIV)
88936536|NCT01796522|Active Comparator|Progesterone 200 mg / day vaginally|The name of this arm is Progesterone. Soft gelatin capsule vaginal use, used in clinical practice as maintenance tocolytic therapy after episode of threatened preterm labor. The 200mg capsule administered once daily to week 34 of gestation. The patients assigned to this arm will begin treatment while the patient assigned to the arm of nifedipine.
88936537|NCT01796652||Home and hospital treatment groups|Patients were randomized into either home or hospital groups after a brief hospitalization(≤24 hours. Hospital patients were followed 5 days in hospital.Home patients were visited on 2nd,3rd and 5th days by a staff nurse and the vital signs, symptoms, and general condition were recorded and transmitted back to the attending physician. On the 7th, 14th and 30th days, the home and hospital group patients were requested to return for a follow-up clinic visit at Bezmialem, at which time an assessment of their symptoms, physical examination, and laboratory evaluation was conducted.
88936538|NCT01796691||Standard therapy|Antiplatelet therapy following coronary stenting without platelet function testing
88936539|NCT01796691||Optimized antiplatelet therapy|"Platelet function testing and according to a test and treat strategy improve the antiplatelet therapy in low-responder.~Treatment adjustments were done as published before - see BOCLA-Plan manuscript. (Reference: Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance--the BOchum CLopidogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapy. BMC Med. 2011 Jan 12;9:3.)"
88936540|NCT01796717|Active Comparator|C Group|Controlled group will receive piperacillin/tazobactam of 4.5g Q6h, intermittent infusion for 30 minutes
88936541|NCT01796717|Experimental|E Group|Therapy group will receive piperacillin/tazobactam of 4.5g Q6h, prolonged infusion for 4 hours
88936542|NCT01796730|Experimental|sequence I|10mg (21 days) -washout (7 days) - bambuterol 5mg (21 days) -washout (7 days) -placebo (21 days)
89451611|NCT03292094||Black women|312 young healthy women were included (clinic normotensive, non-HIV)
89451612|NCT03292094||White women|312 young healthy women were included (clinic normotensive, non-HIV)
89451613|NCT02460926|Experimental|Scaling & Root Planing - Quadrant|Periodontal treatment (PT), consisting in both supra- and sub-gingival mechanical instrumentation of the root surface (scaling and root planing), was performed by a single periodontist . Treatment was provided using both hand and ultrasonic instrumentation with fine tips. Local anaesthesia was used when needed and no time constraints were enforced. Q-SRP patients received four quadrants sessions of PT with an interval of 1 week between sessions
89451614|NCT02460926|Experimental|Scaling & Root Planing - Full Mouth|Periodontal treatment (PT), consisting in both supra- and sub-gingival mechanical instrumentation of the root surface (scaling and root planing), was performed by a single periodontist . Treatment was provided using both hand and ultrasonic instrumentation with fine tips. Local anaesthesia was used when needed and no time constraints were enforced. FM-SRP patients received treatment within 24 hrs in two separate sessions, one side of the mouth for each session: two quadrants were instrumented in an afternoon session, whereas the other two were instrumented the following morning
89451615|NCT03291938|Experimental|Treatment (oxidative phosphorylation inhibitor IACS-010759)|"INDUCTION PHASE: Patients receive oxidative phosphorylation inhibitor IACS-010759 PO QD on days 1-7 of cycle 1 in the absence of disease progression or unacceptable toxicity.~MAINTENANCE PHASE: Patients receive oxidative phosphorylation inhibitor IACS-010759 PO QD on days 8 and 15 of cycle 1 and then on days 1, 8, and 15 of subsequent cycles. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity."
89451616|NCT03288584||Tocilizumab|Inhibition of Interleukin-6 activity by tocilizumab (Actemra®) 150mg od, sc injection
89451617|NCT03288584||Other biological agent|Other biological agent (TNFa inhibitor, abatacept, rituximab, IL-1Ra)
89451618|NCT03288584||Corticosteroid and non-biological agents.|Enhanced treatment with corticosteroid and non-biological agents.
89451619|NCT02461004|Experimental|TR group|CKD-391 and combination dose of Atrovastatin and Ezetimibe in order
89200942|NCT00898521|Experimental|DGD|
88936543|NCT01796730|Experimental|sequence II|bambuterol 5mg (21 days) -washout (7 days) - placebo (21 days) -washout (7 days) - bambuterol 10mg (21 days)
89200943|NCT03985579|Experimental|Standard care and Kinesiology taping Group|Application of elastic cotton strip with an acrylic adhesive that is used with the intent of treating pain and disability from athletic injuries and a variety of other physical disorders.
89200944|NCT03985579|No Intervention|Standard care Group|Assistance in baby feeding, manual of device-assisted (lactator) milk expression, cold compress, ibuprofen, gentle breast massage, breathing and shoulder girdle exercise.
89200945|NCT00902967|Active Comparator|1|Tablet Atorvastatin 10 mg once daily for 5 weeks (1 week before operation till 2 weeks after the operation)
89200946|NCT00902967|Placebo Comparator|2|Placebo tablets of similar shape and color given at night time dosing
89200947|NCT01324921|Placebo Comparator|No breakfast/beverage only|12 fluid ounces made up of one of some combination of the following: decaffeinated coffee, decaffeinated tea or water, with non-nutritive sweetener
89200948|NCT01324921|Active Comparator|Breakfast|1 serving of unflavored instant oatmeal and 12 fluid ounces made up of one of some combination of the following: decaffeinated coffee, decaffeinated tea or water, with non-nutritive sweetener
89200949|NCT01324921|Experimental|10004RF|1 serving (8 fluid ounces) of the experimental beverage and 4 fluid ounces made up of one of some combination of the following: decaffeinated coffee, decaffeinated tea or water, with non-nutritive sweetener
89200950|NCT00898599|Placebo Comparator|Maltodextrin|
89200951|NCT00898599|Experimental|Prebiotic|Inulin type fructooligosaccharides
89200952|NCT00903045|Experimental|1|
89200953|NCT00903045|Placebo Comparator|2|
89200954|NCT02539095|Experimental|Cartizol, collagen injection|Their eligibility to participate in the study is checked, and they are randomized either into the intra-articular collagen injection group based on a randomization table.
89200955|NCT02539095|Placebo Comparator|Normal Saline injection|Their eligibility to participate in the study is checked, and they are randomized either into the (placebo) injection group based on a randomization table.
89200956|NCT00337285|Experimental|1|
89200957|NCT03991117|Experimental|80 %1RM, Regular Tempo|Participants performed three sets of unilateral knee extension with a load that was 80 % of their one-repetition maximum (1RM) at a tempo of three seconds per repetition.
89200958|NCT03991117|Experimental|80 %1RM, Slow Tempo|Participants performed three sets of unilateral knee extension with a load that was 80 % of their one-repetition maximum (1RM) at a tempo of seven seconds per repetition.
89200959|NCT03991117|Experimental|30 %1RM, Regular Tempo|Participants performed three sets of unilateral knee extension with a load that was 30 % of their one-repetition maximum (1RM) at a tempo of three seconds per repetition.
89200960|NCT03991117|Experimental|30 %1RM, Slow Tempo|Participants performed three sets of unilateral knee extension with a load that was 30 % of their one-repetition maximum (1RM) at a tempo of seven seconds per repetition.
89200961|NCT04035525|Experimental|MaxSimil® fish oil + CoQ10|The participant will arrive fasted at he research center. After installing a cathether and drawing 5 mL of blood, the participants will be given one of the active comparator or the treatment. The choice of the treatment/comparator will be random. In this arm, the participant will receive 1 dose of 1 g MaxSimil® fish oil + 200 mg CoQ10. The participant will consume this unique dose with a standardized breakfast. There will thereafter be blood sample collection over 24 h to evaluate the level of omega-3 fatty acids in the plasma and a side effect questionnaire will be administered to monitor side effects.
88936544|NCT01796730|Experimental|sequence III|placebo (21 days) -washout (7 days) - bambuterol 10mg (21 days) - washout (7 days) - bambuterol 5mg (21 days)
88936545|NCT01796808|Other|Pathway A|"Screening visit followed by pedal fat grafting procedure with local anesthetic and visits at:~1 week~Post op study visit 2 (1 month)~Post op study visit 3 (2 month)~Post op study visit 4 (6 month)~Post op study visit 5 (12 month)~Crossover to standard podiatry visits~Study visit 6 (18 months)~Study visit 7 (24 months)"
89200962|NCT04035525|Active Comparator|Rice bran oil + CoQ10|The participant will arrive fasted at he research center. After installing a cathether and drawing 5 mL of blood, the participants will be given one of the active comparator or the treatment. The choice of the treatment/comparator will be random. In this arm, the participant will receive 1 dose of 1 g rice bran oil + 200 mg CoQ10. The participant will consume this unique dose with a standardized breakfast. There will thereafter be blood sample collection over 24 h to evaluate the level of omega-3 fatty acids in the plasma and a side effect questionnaire will be administered to monitor side effects.
89200963|NCT04035525|Active Comparator|CoQ10 as powder form|The participant will arrive fasted at he research center. After installing a cathether and drawing 5 mL of blood, the participants will be given one of the active comparator or the treatment. The choice of the treatment/comparator will be random. In this arm, the participant will receive 1 dose of 1 g rice bran oil + 200 mg CoQ10. The participant will consume this unique dose with a standardized breakfast. There will thereafter be blood sample collection over 24 h to evaluate the level of omega-3 fatty acids in the plasma and a side effect questionnaire will be administered to monitor side effects.
89200964|NCT04035057|Experimental|Behaviorally Enhanced Training Strategies|Both training conditions will receive a 1.5 day training followed by ongoing supervision while they implement exposure therapy with patients recruited to the study. The first full day will consist of the same foundational information in both conditions. The two conditions will differ in their training focus during the subsequent half-day training. The Behaviorally Enhanced condition will involve therapist engagement in repeated self-exposure and partner-exposure exercises with the goal of targeting and reducing therapists' reservations about using exposure with their patients. The focus of ongoing supervision following the initial 1.5 day training workshop will also differ by condition. The Behaviorally Enhanced condition will include regular sampling and feedback on therapists' remaining reservations about exposure in additional to counseling the implementation of exposure with therapists' patients.
89015091|NCT00588770|Active Comparator|Arm IIIA (cisplatin, fluorouracil)|Patients receive cisplatin IV over 1-2 hours on day 1 and fluorouracil IV continuously on days 1-4. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89015092|NCT00588770|Experimental|Arm IIIB (cisplatin, fluorouracil, bevacizumab)|Patients receive bevacizumab as in Arm IB and cisplatin and fluorouracil as in Arm IIIA.
89015093|NCT00588770|Active Comparator|Arm IVA (carboplatin, fluorouracil)|Patients receive carboplatin IV over 30 minutes on day 1 and fluorouracil IV continuously on days 1-4. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89015094|NCT00588770|Experimental|Arm IVB (carboplatin, fluorouracil, bevacizumab)|Patients receive bevacizumab as in Arm IB and carboplatin and fluorouracil as in Arm IVA.
89015095|NCT00557726||1|Patients with a variety of infections and inflammatory diseases.
89015096|NCT00539162|Experimental|CA 125 Analysis|"Participants will have blood (about 2-3 tablespoons) drawn for CA-125 testing and other tumor markers.~Depending on CA-125 level:~Blood (about 2-3 tablespoons) drawn for CA-125 testing and other tumor markers in 1 year.~Blood (about 2-3 tablespoons) drawn for CA-125 testing and other tumor markers in 3 months, OR Blood (about 2-3 tablespoons) drawn for CA-125 testing and other tumor markers, and a transvaginal ultrasound in 6 weeks +/- 2 weeks.~Questionnaires completed at baseline and during each follow up visit."
89451620|NCT02461004|Experimental|RT group|combination dose of Atrovastatin and Ezetimibe and CKD-391 in order
89451621|NCT03288428|Experimental|nalbuphine|using nalbuphine for patient controlled analgesia
89451622|NCT03288428|Active Comparator|morphine|using morphine for patient controlled analgesia
89451623|NCT03288350|Experimental|mDCF + Avelumab|"Patients will receive neoadjuvant therapy consisting of 4 cycles of avelumab added to the modified chemotherapy regimen of docetaxel, cisplatin, 5-fluorouracil, followed by surgery and assessment of pathologic response. Then they will receive 4 cycles of adjuvant therapy of docetaxel, cisplatin, 5-fluorouracil and avelumab.~Docetaxel as a one-hour 40 mg/m2 IV infusion on day 1. Cisplatin 40 mg/m2 IV infusion on day 1. 5-FU 1000 mg/m2/day over 2 days. Avelumab 10 mg/kg following the completion of the mDCF regimen."
89451624|NCT04488380|Experimental|high-viscosity glass ionomer restoration|One of the carious mandibular 2nd molar teeth (according to randomisation) will be restored with high-viscosity glass ionomer restoration (Equia, GC)
89451625|NCT04488380|Experimental|nano-hybrid composite resin|One of the carious mandibular 2nd molar teeth will be restored with nano-hybrid composite resin (GrandioSO, Voco)
89451626|NCT02461238|Active Comparator|Vouchers|Families included in the Voucher arm will receive vouchers for fruits and vegetables by mail every month for a period of 1 year coupled to nutritional education from a dietician
89451627|NCT02461238|Other|Control|Families included in the control arm will only receive nutritional education
89451628|NCT03291782|Experimental|D-0120 Dose 1|D-0120 Dose 1 Patients will get D-0120 single agent or placebo of matching size during dose escalation
89451629|NCT03291782|Experimental|D-0120 Dose 2|D-0120 Dose 2 Patients will get D-0120 single agent or placebo of matching size during dose escalation
89451630|NCT03291782|Experimental|D-0120 Dose 3|D-0120 Dose 3 Patients will get D-0120 single agent or placebo of matching size during dose escalation
89451631|NCT03291782|Experimental|D-0120 Dose 4|D-0120 Dose 4 Patients will get D-0120 single agent or placebo of matching size during dose escalation
89451632|NCT03291782|Experimental|D-0120 Dose 5|D-0120 Dose 5 Patients will get D-0120 single agent once in the fasted state and once in the fed state.
89451633|NCT03291704|Experimental|Thermal Therapy|Heat application using at home thermal therapy device
89451634|NCT03288272|Active Comparator|Arm 1 - WBRT 10 x 2 Gy|Arm 1 - WBRT 10 x 2 Gy Whole brain radiotherapy with a total dose of 20 Gy in single fractions of 2 Gy
89015097|NCT00523627||Healthy Volunteers with normal glucose regulation|Healthy volunteers with normal glucose regulation
89015098|NCT00433511|Active Comparator|Arm I (chemotherapy, placebo)|Patients receive doxorubicin hydrochloride IV, cyclophosphamide IV over 20-30 minutes, and placebo IV over 30-90 minutes on day 1. Treatment repeats every 2 or 3 weeks for 4 courses. Beginning 3 weeks later, patients then receive paclitaxel IV over 1 hour on days 1, 8, and 15 and placebo IV over 30-90 minutes on day 1. Treatment with paclitaxel and placebo repeats every 3 weeks for 4 courses.
89015099|NCT00433511|Experimental|Arm II (chemotherapy, bevacizumab)|Patients receive doxorubicin hydrochloride and cyclophosphamide as in arm I and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 2 or 3 weeks for 4 courses. Beginning 3 weeks later, patients then receive paclitaxel as in arm I and bevacizumab IV over 30-90 minutes on day 1. Treatment with paclitaxel and bevacizumab repeats every 3 weeks for 4 courses.
89451635|NCT03288272|Active Comparator|Arm 2 - WBRT 15 x 2 Gy|Arm 2 - WBRT 15 x 2 Gy Whole brain radiotherapy with a total dose of 30 Gy in single fractions of 2 Gy
89451636|NCT03288272|Active Comparator|Arm 3 - Best Supportive Care|Symptomatic treatment includes steroids, pain medication, nutritional support etc.
89451637|NCT03297320|Active Comparator|Team Referrals|In-depth conversations about Goals of Care and ACP (the intervention) will be held for the patients referred to the research team by the three healthcare teams in Internal Medicine at London Health Sciences Centre (University Campus)
89451638|NCT03297320|Active Comparator|Random selection|A random selection of patients (not referred to the research team by the healthcare team) in Internal Medicine at London Health Sciences Centre (University Campus) will be selected to have in-depth conversations about Goals of Care and ACP (the intervention)
89451639|NCT03288116||patient|Scheimplug imaging and contrast and sensitivity test
89451640|NCT03288116||early disease|Scheimplug imaging and contrast and sensitivity test
89451641|NCT03288116||normal|Scheimplug imaging and contrast and sensitivity test
89451642|NCT00003224|Experimental|Group 1: peptide 946 plus QS-21|100 mcg peptide gp100 [280-288] plus 0.2 ml (100 mcg) QS-21 vaccine adjuvant
89451643|NCT00003224|Experimental|Group 2. p946 plus IFA|100 mcg peptide gp100 [280-288] plus 0.5 ml IFA (Montanide ISA-51) vaccine adjuvant
89451644|NCT00003224|Experimental|Group 3: p946 plus Tet-p plus QS-21|100 mcg peptide gp100 [280-288],190 mcg tetanus peptide, plus 0.2 ml (100 mcg) QS-21 vaccine adjuvant
89451645|NCT00003224|Experimental|Group 4. p946, Tet-p plus IFA|100 mcg peptide gp100 [280-288], 190 mcg tetanus peptide, plus 0.5 ml IFA (Montanide ISA-51) vaccine adjuvant
89451646|NCT00003224|Experimental|Group 5: p946/Tet-p plus QS-21|282 mcg gp100 [280-288]/tetanus peptide conjugate, plus 0.2 ml (100 mcg) QS-21 vaccine adjuvant
89451647|NCT00003224|Experimental|Group 6. p946/Tet-p plus IFA|282 mcg gp100 [280-288]/tetanus peptide conjugate, plus 0.5 ml IFA (Montanide ISA-51) vaccine adjuvant
89451648|NCT03291548|Experimental|Quinoa Biscuit|The quinoa-enriched biscuits containing 7.11g quinoa flour.
89451649|NCT03291548|Placebo Comparator|Control biscuit|The placebo control biscuit: an iso-energetic, matched product in terms of appearance, taste, texture and smell.
89451650|NCT04489316|No Intervention|Control|Subjects in the Control group will proceed through the standard pediatric oncology curriculum. They will not receive any sessions in narrative medicine. They will take the pretest and the post-test.
89451651|NCT04489316|Experimental|Intervention|Subjects in the Intervention group will receive 2-3 sessions in narrative medicine. They will also take the pretest and the postest.
89451652|NCT03288038|Experimental|RSV5mg + EZE 10mg|Rosuvastatin 5mg/Ezetimibe 10mg
88936546|NCT01796808|Other|Pathway B|"Screening visit followed by:~Study visit 1 (6months)~Study Visit 2 (12 months)~Crossover to Pathway A~pedal fat grafting procedure and local anesthetic and visits at:~1 week~Post op study visit 2 (1 month post procedure)~Post op study visit 3 (2 month post procedure)~Post op study visit 4 (6 month post procedure)~Post op study visit 5 (12 month post procedure)"
88936547|NCT01796925|Experimental|aura6000 THN Therapy|The aura6000 THN system will be implanted and activated for nightly therapy during sleep.
89206127|NCT00525148|Experimental|BIBW 2992|Patients start continuous once daily oral treatment of BIBW 2992 at high dose, until progression or undue Adverse Events (AEs) develop. Patients can be dose-reduced up to two times if needed after temporary discontinuation of treatment due to drug-related AEs. After protocol amendment 2 (17 Dec 2008), the starting dose of BIBW 2992 was reduced to a medium dose, with 2 possible dose reductions if needed after discontinuation due to drug-related AEs.
89451653|NCT03288038|Active Comparator|RSV5mg|Rosuvastatin 5mg
89451654|NCT03288038|Experimental|RSV10mg + EZE10mg|Rosuvastatin 10mg/ Ezetimibe 10mg
89451655|NCT03288038|Active Comparator|RSV10mg|Rosuvastatin 10mg
89451656|NCT03288038|Experimental|RSV20mg + EZE10mg|Rosuvastatin 20mg/Ezetimibe 10mg
89451657|NCT03288038|Active Comparator|RSV20mg|Rosuvastatin 20mg
89451658|NCT03283358|Experimental|Person-centered follow up|The intervention program is a person-centered health promotion program led by a nurse and consists of two telephone calls (15 minutes each) at two weeks and nine months after surgical treatment for Intermittent Claudication and three visits (45 - 60 min) at six weeks, six months and one year after treatment. The program includes a baseline assessment, an individual plan for self-care and educational information about Intermittent Claudication, received treatment and secondary prevention (medication and modifiable risk factors). The purpose is to enhance self-care in terms of adherence to medication and to recommended changes of lifestyle.
89451659|NCT03283358|No Intervention|Standard follow up|Standard follow-up consist of two follow up appointments á 20 minutes at four-six weeks and one year after surgical treatment of Intermittent Claudication. The patients meet a vascular surgeon at the first follow up and a vascular nurse or a surgeon at the second follow up visit.
89451660|NCT03287960|Experimental|Setmelanotide|Participants received titrated doses of setmelanotide once daily, by SC injection during titration period for 2 - 12 weeks. Thereafter, participants continued setmelanotide at their specific therapeutic dose for an additional 10 weeks during the open label treatment period. Participants who achieved at least a 5 kg weight loss (or at least 5% weight loss if baseline body weight was <100 kg) at the end of the open label treatment period, continued into the 8-week double-blind withdrawal period and received 4 weeks setmelanotide and 4 weeks placebo. Following the withdrawal period, participants entered open label treatment period and received setmelanotide to complete approximately 52 weeks (~1 year) of treatment at a therapeutic dose.
89537139|NCT04490447||Bronchiectasis|"Patient meets diagnose of bronchiectasis refering to BTS guideline 2010 will be included."
89015100|NCT00433511|Experimental|Arm III (chemotherapy, bevacizumab monotherapy)|Patients receive doxorubicin hydrochloride and cyclophosphamide as in arm I and bevacizumab as in arm II. Treatment repeats every 2 or 3 weeks for 4 courses. Beginning 3 weeks later, patients then receive paclitaxel as in arm I and bevacizumab as in arm II. Treatment with paclitaxel and bevacizumab repeats every 3 weeks for 4 courses. Beginning 2 months later, patients then receive bevacizumab IV over 30-90 minutes on day 1. Treatment with bevacizumab alone repeats every 3 weeks for 10 courses.
89015101|NCT00428987||lean|Normal weight men and women over the age of 18 years with BMI greater than 18.5 and less than 25, who are reasonably healthy
89015102|NCT00428987||obese|Obese men and women over the age of 18 years with BMI greater than 30, who are reasonably healthy
89015103|NCT00428987||overweight|Overweight men and women over the age of 18 years with BMI greater than 25 and less than 30, who are reasonably healthy
89451661|NCT03287882|No Intervention|Standard of care|"Preconception period: none~Pregnancy period: daily iron (60 mg) and folic acid (400 µg) supplementation from confirmation of pregnancy; daily balanced energy protein supplements will additionally be provided to those participants who are underweight at the confirmation of pregnancy for the duration of the pregnancy~Postpartum period: daily iron and folic acid supplementation to 6 months postpartum"
89451662|NCT03287882|Experimental|MMN supplementation and life skills education|"Preconception period: twice-weekly MMN supplementation and bi-monthly group session including life skill based education materials~Pregnancy period: daily MMN supplementation from confirmation of pregnancy; daily balanced energy protein supplements will additionally be provided to those participants who are underweight at the confirmation of pregnancy for the duration of the pregnancy~Postpartum period: daily MMN supplementation to 6 months postpartum"
89015106|NCT00341276||1|First, several hundred cases of esophageal cancer and gastric cancer (both cardia and body) ascertained in Taiyuan at the Shanxi Cancer Hospital.
89015107|NCT00334815|Experimental|Group 1 (cisplatin, etoposide, radiotherapy)|Patients receive cisplatin IV over 1 hour on days 1, 8, 29, and 36 and etoposide IV over 1 hour on days 1-5 and 29-33. Patients undergo concurrent thoracic radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, 36-40, and 43-47.
89451663|NCT03287726|Experimental|probiotics|
89451664|NCT03287726|Placebo Comparator|placebo|
89451665|NCT03291314|Experimental|Axitinib + Avelumab|On day 1 of the treatment phase, patients recruited to this arm will initiate concomitant continuous daily treatment with axitinib (InlytaTM, 5 mg comp BID) in combination with avelumab (10 mg/kg IV Q2 weeks)
89451666|NCT03291314|Experimental|Axitinib (+Avelumab)|"On day 1 of the treatment phase, patients recruited to this arm will initiate treatment with continuous daily axitinib (InlytaTM, 5 mg comp BID).~Patients who tolerate treatment with axitinib and are able to taper the dose of corticosteroids to a maximal daily dose of 8 mg methylprednisolone (or an equivalent dose of another oral corticosteroid) will initiate combination therapy with avelumab (10 mg/kg IV Q2 weeks) on day 43, following the the first MRI-based tumor response evaluation in week 6.~Patients who do not tolerate monotherapy with axitinib, or cannot decrease their daily dose of corticosteroids to a maximal daily dose of 8 mg methylprednisolone will not be allowed to initiate avelumab treatment."
89451667|NCT03283280|Experimental|Short fiber RC|Short fiber reinforced resin composite restoration (Ever X Posterior, Gc Europe) that is used in high stress bearing areas as direct onlay restoration.
89451668|NCT03283280|Active Comparator|Nanohybrid RC|Nanohybrid resin composite (GrandioSO, VOCO GmbH Germany ) that can be used to make indirect restorations in posterior teeth.
89015108|NCT00334815|Experimental|Group 2 (cisplatin, etoposide, radiotherapy, bevacizumab)|Patients receive cisplatin, etoposide, and thoracic radiotherapy as in group 1. Patients also receive bevacizumab IV over 30-90 minutes on days 15, 36, and 57.
89451669|NCT03287570|Experimental|Cettum (Electric moxibustion)|The patients in this group receive Cettum (Electric moxibustion) treatment prescribed by a certified Korean Medicine Doctor with more than 6 years of Oriental Medicine College education.
89451670|NCT03287570|Active Comparator|Traditional indirect moxibustion|The patients in this group receive traditional indirect moxibustion treatment using the same points, applied by a certified Korean Medicine Doctor with more than 6 years of Oriental Medicine College education.
89015109|NCT00334815|Experimental|Group 3 (cisplatin, etoposide, radiotherapy, bevacizumab)|Patients receive cisplatin, etoposide, and thoracic radiotherapy as in group 1. Patients also receive bevacizumab IV over 30-90 minutes on days 1, 22, and 43.
89015110|NCT00310180|Experimental|Group 1 (Oncotype DX recurrence score =< 10)|Patients in this group receive hormone therapy with tamoxifen, anastrozole, letrozole, or exemestane PO for up to 5 years. Some patients then continue to receive hormone therapy for an additional 5 years.
89015111|NCT00310180|Experimental|Group 2, Arm I (experimental)|Patients receive hormonal therapy as in Group 1 at the discretion of the treating physician.
89015112|NCT00310180|Active Comparator|Group 2, Arm II (standard)|Patients receive standard combination chemotherapy at the discretion of the treating physician. Within 4 weeks after the last dose of chemotherapy, patients receive hormonal therapy as in Group 1 at the discretion of the treating physician.
89206128|NCT00754325|Active Comparator|Arm 1 (Dasatinib +Fulvestrant)|
89015113|NCT00310180|Experimental|Group 3 (Oncotype DX recurrence score >= 26)|Patients in this group receive combination chemotherapy followed by hormone therapy similar to the patients in group two who are assigned to receive both types of treatment.
89015114|NCT00250159||1/CAH Patients Managed at the NIH|Patients with Congenital Adrenal Hyperplasia (CAH).
89206129|NCT00754325|Active Comparator|Arm 2 (Fulvestrant)|
89206130|NCT00524680|Experimental|Arm I|Patients receive 4,000 IU of oral cholecalciferol (vitamin D3) once daily.
89451671|NCT03287570|Other|Usual care|The patients in this group maintain the usual treatment and self-care.
89451672|NCT03283202|Experimental|Avadomide (CC-122) plus R-CHOP-21|Avadomide (CC-122) by mouth (PO) at varying dose levels (Ph 1) on Days 1 through 5 and Days 8 through 12 plus Rituxan 375 mg/m2 by intravenous (IV) infusion, cyclophosphamide 750mg/m2 by IV infusion, doxorubicin 50 mg/m2 IV, vincristine 1.4 mg/m2 (max is 2.0 mg) IV and 100 mg PO prednisone/prednisolone on Days 1 through 5 of each 21-day treatment cycles for up to 6 total treatment cycles (approximately 18 weeks or 4 months)
89451673|NCT04570358|Experimental|Static stretching|An 8-week home-based static stretching training for the calf muscles will be performed by group A. Altogether, 10 stretches are performed per leg 4 times a week.
89451674|NCT04570358|No Intervention|Control|While group A performs the 8-week static stretching training, group B acts as control group performing its daily life activities as usual.
89451675|NCT04570358|Experimental|Proprioceptive neuromuscular facilitation stretching|After group A has finished the 8-week static stretching training, group B starts with the 8-week home-based proprioceptive neuromuscular facilitation stretching training. Altogether, 10 stretches are performed per leg 4 times a week.
89451676|NCT04570358|No Intervention|Follow-up|While group B performs the 8-week proprioceptive neuromuscular facilitation stretching, group A is in its follow-up period performing its daily life activities as usual.
89451677|NCT03283124|Active Comparator|self-cut mesh procedure|This procedure is transvaginal mesh implantation surgery for POP patients. Self-cut mesh procedure is an economic pelvic reconstructive surgical operation with use of specially designed puncture needles and self-cut mesh, which mainly provide anterior and apical compartments support, with posterior compartment reinforced by bridge technique repair. The mesh pieces used in this surgery was cut from a single piece of mesh material(TiLOOP 10*15cm) which is much cheaper and readily available. Patients could have transvaginal hysterectomy concomitantly.
89451678|NCT03283124|Active Comparator|mesh-kit procedure|This procedure is transvaginal mesh implantation surgery for POP patients.Mesh-kit procedure is refered to pelvic floor reconstructive surgery with titanium-coated meshes kit(TiLOOP TOTAL6).Patients could have transvaginal hysterectomy concomitantly.
89451679|NCT03283046|Experimental|Nivolumab + Ipilimumab + Dexamethasone + Lenalidomide|"The first 4 study cycles are 21 days long, and all remaining cycles are 28 days long.~On Day 1 of Cycles 1-4, Nivolumab by vein over 60 minutes. Thirty (30)minutes after Nivolumab, Ipilimumab given by vein over 90 minutes. On Days 1 and 15 of Cycles 5 and beyond, Nivolumab given by vein over 60 minutes.~Lenalidomide tablets take by mouth on Days 1-14 of Cycles 1-4 and on Days 1-21 of Cycles 5 and beyond. Dexamethasone tablets taken by mouth on Days 1, 8, and 15 of Cycles 1-4, and on Days 1, 8, 15, and 22 of Cycles 5 and beyond.~For participants who are eligible for autologous stem cell transplant, those who achieve at least a partial response after at least 4 cycles of initial therapy will be eligible for:~EITHER Stem cell collection and storage OR Stem cell collection and autologous stem cell transplantation."
89451680|NCT03287258|Active Comparator|three program|200 patients are subjected to educational Pelvic floor dysfunction prevention program with perineal massage and Pelvic floor muscle exercise.
89451681|NCT03287258|Active Comparator|one program|200 patients are subjected to educational Pelvic floor dysfunction prevention program
89451682|NCT03287180|Experimental|Experimental group|Participants in the experimental group will attend one individual assessment with the study physician for combination of buprenorphine/naloxone 4/1 prescription and urinalysis, along with one weekly Adolescent Community Reinforcement Approach (A-CRA) session (approximately 50 minutes).
89451683|NCT03287180|Active Comparator|Control group|Participants in the control condition will attend weekly individual medical management sessions with the MD who will also provide a prescription for a combination of buprenorphine/naloxone 4/1 (approximately 25 minutes in duration).
88936548|NCT01796990|Active Comparator|REF group|The participants will get written feedback about their physical activity level after the baseline, and after 3, 6, 9 and 15 months of baseline compared to the current physical activity recommendations. Feedback will be created to illustrate participants´ activity level during the measurement week combining also the information from the diary. Feedback will be posted home and don´t include face to face interaction. As an incentive for participation, participants will also have opportunity to attend a body composition analyze and get short interpretation (15 min) of their own results in the research center.
88936549|NCT01796990|Other|ACT group|"The ACT group gets the same procedure as the REF group. In addition, they will participate the ACT based program. The intervention program consists of six group sessions, about 90 minutes per session during the 9 weeks period of time. All the participants get also pedometers for monitoring their physical activity during the intervention.~The program aims to enhance physically active lifestyle and well-being through important life values and build committed action based on the chosen important things. The importance is also placed to a mindful awareness and flexibility to everyday actions related to physical activity. The program don´t include psycho-educational elements or counseling of the health or the health benefits of physical activity."
88936550|NCT01797211|Experimental|diet group A|Mediterranean diet+olive oil
88936551|NCT01797211|Experimental|Diet Group B|Mediterranean diet+not-fried fish
88936552|NCT01797211|Experimental|Diet Group C|Mediterranean diet+nuts
88936553|NCT01797289|Experimental|First episode of loss of consciousness|
88936554|NCT01797653|Placebo Comparator|Placebo CPAP|patients established on CPAP therapy, who are randomized to the placebo comparator, will use a CPAP device with subtherapeutic pressure during two weeks.
89206131|NCT00524680|Experimental|Arm II|Patients receive 6,000 IU of vitamin D3 once daily.
88936555|NCT01797653|Active Comparator|therapeutic CPAP|patients who are randomized to the active comparator, will continue with CPAP treatment with therapeutic pressure during two weeks
88936556|NCT01797718|Active Comparator|Testosterone|~1mg/kg every 4 weeks for 6 months
88936557|NCT01797718|Active Comparator|Letrozole|2.5mg daily for 6 months
88936558|NCT01797796|Experimental|PF-06305591|
89451684|NCT03282812||cases|
89451685|NCT03282812||controls|
89451686|NCT03287102|Other|Temporal inverted ILM peeling group|The internal limiting membrane is peeled from the temporal side of the fovea only
89451687|NCT03287102|Other|Complete ILM peeling group|The internal limiting membrane is completely removed around the fovea
89451688|NCT03287024|Experimental|BeGrow Stent System|All enrolled subjects will receive the BeGrow Stent System
89451689|NCT03286946|Experimental|Blunt-type block needle|block with Blunt-type block needle.
89451690|NCT03286946|Active Comparator|Sharp-type block needle|block with Sharp-type block needle.
89451691|NCT03286868|Placebo Comparator|Standard of Care TKA|Standard of Care Total Knee Arthroplasty (TKA): No data from the Verasense sensor will be used to influence the surgery
89451692|NCT03286868|Experimental|TKA with Verasense sensor|Total Knee Arthroplasty (TKA) with Verasense sensor for Intraoperative Balancing: Surgeon will attempt to optimize the intraoperative pressures using the data from the Verasense sensor
89451693|NCT03974204|Experimental|Cerebrospinal fluid and Blood sample collection|"Collection of cerebrospinal fluid and blood samples:~At initial diagnostic assessment;~1 month and 3 months after initial diagnostic assessment, for patients classified possible, probable or confirmed according to EANO-ESMO classification, leading to specific leptomeningeal metastase treatment;~In case of symptoms leading to leptomeningeal metastase suspicion and at least 3 months after diagnostic assessment, for patients classified lack of evidence according to EANO-ESMO classification."
89015115|NCT00250159||2/CAH Patients Managed by Outside Physicians|Patients with Congenital Adrenal Hyperplasia (CAH) followed by home physician post visit at NIH.
89451694|NCT03921320|Active Comparator|Bilateral sympathectomy|Bilateral sequential (one surgical procedure) videothoracoscopic R4 sympathectomy
89451695|NCT03921320|Experimental|Unilateral sympathectomy|Unilateral videothoracoscopic R4 sympathectomy on the right (dominant) side
89451696|NCT03921320|Experimental|Contralateral sympathectomy|Unilateral videothoracoscopic R4 sympathectomy on the left (contralateral) side
89451697|NCT03282734|Experimental|The smart rehab group|Home-based exercise program with smart rehabilitation system ((Uincare®, D-gate Co.) for 4 weeks
89015116|NCT00250159||3/Relatives of Patients|Relatives (mostly parents) of patients will be genotyped. This is often necessary to establish the genotype of the patient.
89206132|NCT00524680|Experimental|Arm III|Patients receive 8,000 IU of vitamin D3 once daily.
89451698|NCT03282734|Active Comparator|The control group|Conventional home rehabilitation exercise education for 4 weeks
88936559|NCT01797796|Placebo Comparator|Placebo|
89451699|NCT03918980|Experimental|Part 1 Dose A|(Single Ascending Dose) Healthy volunteers will receive a single dose of LOU064.
89451700|NCT03918980|Experimental|Part 1 Dose B|(Single Ascending Dose) Healthy volunteers will receive a single dose of LOU064.
89451701|NCT03918980|Experimental|Part 1 Dose C|(Single Ascending Dose) Healthy volunteers will receive a single dose of LOU064.
89451702|NCT03918980|Experimental|Part 1 Dose D|(Single Ascending Dose) Healthy volunteers will receive a single dose of LOU064.
89451703|NCT03918980|Experimental|Part 1 Dose E|(Single Ascending Dose) Healthy volunteers will receive a single dose of LOU064.
89451704|NCT03918980|Experimental|Part 1 Dose F|(Single Ascending Dose) Healthy volunteers will receive a single dose of LOU064.
89451705|NCT03918980|Experimental|Part 1 Dose G|(Single Ascending Dose) Healthy volunteers will receive a single dose of LOU064.
89015117|NCT00250159||4/FMPP Patients|Patients with Familial Male-Limited Precocious Puberty (FMPP).
89015118|NCT00250159||5/Patients with Androgen Excess of Unknown Etiology|Patients with Androgen Excess of Unknown Etiology followed by home physician post visit at NIH.
89015119|NCT00097474|Experimental|Combination|Both HC 30 and ML 5 will be administered
89015120|NCT00097474|Experimental|Hydrocortisone|30mg Hydrocortisone will be administered
89015121|NCT00097474|Experimental|Melatonin|5 mg Melatonin will be administered
89015122|NCT00097474|Placebo Comparator|Placebo|Placebo
89015123|NCT00095784|Experimental|Treatment (decitabine)|Patients receive decitabine SC on days 1-5 and 8-12. Treatment repeats every 42 days in the absence of disease progression or unacceptable toxicity.
89015124|NCT00091871||Affected family members|Family members with peripheral blood eosinophilia
89451706|NCT03918980|Experimental|Part 1 Dose H|(Single Ascending Dose) Healthy volunteers will receive a single dose of LOU064.
89015125|NCT00091871||Unaffected family members|Family members without peripheral blood eosinophilia
89015126|NCT00070499|Experimental|Arm I (QD imatinib mesylate)|Patients receive imatinib mesylate PO QD. Treatment repeats every 4 weeks for up to 5 years in the absence of disease progression or unacceptable toxicity.
89015127|NCT00070499|Experimental|Arm II (BID imatinib mesylate)|Patients receive imatinib mesylate PO BID. Treatment repeats every 4 weeks for up to 12 months in the absence of disease progression or unacceptable toxicity.
89015128|NCT00070499|Experimental|Arm III (dasatinib)|Patients receive dasatinib PO BID. Treatment repeats every 4 weeks for up to 5 years in the absence of disease progression or unacceptable toxicity.
89015129|NCT00055055||Healthy Volunteers|A healthy individual who has not used any NSAIDS, with no infectious disease, or severe trauma within 8 weeks of enrollment, doesn't have a first degree relatives with RA, SLE, SSc or IIM
89015130|NCT00055055||Parent of Proband|Biological mother or father of the proband who is willing to enroll in the study
89015131|NCT00055055||Primary Unaffected Dizygous Twin|Dizygotic twin pair of the proband who does not meet criteria for one of the rheumatic diseases
89206133|NCT00524680|Experimental|Arm IV|Patients receive 10,000 IU of vitamin D3 once daily.
89451707|NCT03918980|Experimental|Part 1 Dose I|(Single Ascending Dose) Healthy volunteers will receive a single dose of LOU064.
89451708|NCT03918980|Experimental|Part 1 Dose J|(Single Ascending Dose) Healthy volunteers will receive a single dose of LOU064.
89015132|NCT00055055||Primary Unaffected Monozygous Twin|Monozygotic twin pair of the proband who does not meet criteria for one of the rheumatic diseases
89015133|NCT00055055||Primary Unaffected Non-twin Sibling|Sibling of the same biological parents, same gender, within 5 years of age of the proband who does not meet criteria for one of the rheumatic diseases
89015134|NCT00055055||Proband|Proband should have documented evidence that he/she meets criteria for adult and juvenile forms of systemic rheumatic disorders
89015135|NCT00050310||Acute Infection (confirmed or suspected)|adults and children with acute anthrax infection
89015136|NCT00050310||AVA Recipient/Healthy Volunteer|healthy adults who have received AVA vaccine
89015137|NCT00050310||Recovered|adults and children in recovering phase of anthrax infection
89015138|NCT00050310||Suspected Exposure|adults and children with suspected exposure to anthrax
89015139|NCT00271362|Active Comparator|1|comparing 2 surgical procedures
89451709|NCT03918980|Placebo Comparator|Part 1 Placebo|(Single Ascending Dose) Healthy volunteers will receive a single dose of placebo.
89451710|NCT03918980|Experimental|Part 2 Dose K|(Multiple Ascending Dose) Healthy Volunteers with asymptomatic atopic diathesis will take LOU064 once daily for 12 days
89451711|NCT03918980|Experimental|Part 2 Dose L|(Multiple Ascending Dose) Healthy Volunteers with asymptomatic atopic diathesis will take LOU064 once daily for 12 days
89451712|NCT03918980|Experimental|Part 2 Dose M|(Multiple Ascending Dose) Healthy Volunteers with asymptomatic atopic diathesis will take LOU064 once daily for 12 days
89451713|NCT03918980|Experimental|Part 2 Dose N|(Multiple Ascending Dose) Healthy Volunteers with asymptomatic atopic diathesis will take LOU064 once daily for 12 days
89451714|NCT03918980|Experimental|Part 2 Dose O|(Multiple Ascending Dose) Healthy Volunteers with asymptomatic atopic diathesis will take LOU064 once daily for 12 days
89451715|NCT03918980|Experimental|Part 2 Dose P|(Multiple Ascending Dose) Healthy Volunteers with asymptomatic atopic diathesis will take LOU064 once daily for 12 days
89451716|NCT03918980|Placebo Comparator|Part 2 Placebo|(Multiple Ascending Dose) Healthy Volunteers with asymptomatic atopic diathesis will take placebo once daily for 12 days
89451717|NCT03918980|Experimental|Part 3 Dose Fasted|Healthy volunteers will receive a single dose of LOU064 given under fasting conditions followed by a single dose of LOU064 given after a high fat meal (cross-over design).
89451718|NCT03918980|Experimental|Part 3 Dose Fed|Healthy volunteers will receive a single dose of LOU064 given after a high fat meal followed by a single dose of LOU064 given under fasting conditions (cross-over design).
89451719|NCT03918980|Experimental|Part 4 Dose R|(Multiple Ascending Dose) Healthy Volunteers with asymptomatic atopic diathesis will take LOU064 twice daily for 12 days
89451720|NCT03918980|Experimental|Part 4 Dose S|(Multiple Ascending Dose) Healthy Volunteers with asymptomatic atopic diathesis will take LOU064 twice daily for 12 days
89451721|NCT03918980|Placebo Comparator|Part 4 Placebo|(Multiple Ascending Dose) Healthy Volunteers with asymptomatic atopic diathesis will take placebo twice daily for 12 days
89451722|NCT03918980|Experimental|Part 5 Formulation A|Healthy Volunteers will receive a single dose of LOU064 formulation A followed by a single dose of LOU064 formulation B (cross-over design).
89451723|NCT03918980|Experimental|Part 5 Formulation B|Healthy Volunteers will receive a single dose of LOU064 formulation B followed by a single dose of LOU064 formulation A (cross-over design).
89451724|NCT03918980|Experimental|Part 6 Dose T|Subjects with atopic dermatitis will receive a twice daily dose of LOU064 for 4 weeks
89451725|NCT03918980|Placebo Comparator|Part 6 Placebo|Subjects with atopic dermatitis will receive a twice daily dose of placebo for 4 weeks
89451726|NCT03282578|Active Comparator|Sternalock 360 sternal plating system|use of the SternaLock 360 system to close the sternum: 3 plates with 3 bands and measured screw length to engage but not penetrate the posterior sternal cortex, used to close the sternum
89451727|NCT03282578|Active Comparator|Sternal wires|"Stainless steel sternal wires applied in a figure of 8 configuration to close the sternum"
89451728|NCT02460146|Active Comparator|CXA-10|CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitrated oleic acid
89451729|NCT02460146|Placebo Comparator|CXA-10 placebo|The placebo contains olive oil with BHT (0.08% to 0.10%).
89451730|NCT03282500|Experimental|Mindfulness Based Cognitive Therapy|In the experimental condition, participants will receive 12 sessions including the instruction of mindfulness skills and cognitive behavioral therapy.
88936560|NCT01798108|Experimental|Radium-223 dichloride|The study had 2 parts. Part 1a was designed with single injections of Radium-223 given to cohorts of 5 patients for each of 5 pre-defined dose levels. Part 1b was designed to retreat and fractionate the dose of Radium-223 in multiple injections.Based on the revised correction factor by calibration, recalculations verified that the single injection doses administered in the part 1a were : 46, 93, 163, 213 and 250 kBq/kg b.w. Two re-treated patients (dose group 6) received a second dose that resulted in a total dose of 250 kBq/kg b.w. The fractionated doses were 1/5 and ½ of the highest dose in part1b (i.e. 250kBq so 5 x 50 and 2 x 125 kBq/kg b.w. respectively).
88936561|NCT01798329|Active Comparator|Probiotic|Probiotic VSL#3 for 15 weeks, dosage variations according to the weight
88936562|NCT01798329|Placebo Comparator|Placebo|subjects treated with placebo for 15 weeks
88936563|NCT01798355|Experimental|Cognitive Behavioral Therapy|
88936564|NCT01798355|Active Comparator|Treatment as usual|
88936565|NCT01798446|Experimental|Axitinib|This is a single arm study. Axitinib arm is the only arm who receive axitinib.
88936566|NCT01798680|Experimental|Vitamin D3 (cholecalciferol)|
88936567|NCT01798680|Placebo Comparator|Placebo|
88936568|NCT01798823||EIB+A+|"children with EIB and asthma~History, physical, LF, SPT, blood sample, FeNO, EBC"
88936569|NCT01798823||EIB+A-|"children with EIB without asthma~History, physical, LF, SPT, blood sample, FeNO, EBC"
88936570|NCT01798823||EIB-A+|"children without EIB and asthma~History, physical, LF, SPT, blood sample, FeNO, EBC"
88936571|NCT01798823||EIB-A-|"children without EIB without asthma~History, physical, LF, SPT, blood sample, FeNO, EBC"
89451731|NCT03282500|No Intervention|Psychoeducation on brain injury and treatment|In the control condition, participants will receive 12 sessions on the psychoeducation of brain injuries, outcomes, treatment, and support.
89451732|NCT04264910|Experimental|Calm Meditation|Participants (n=49) will be provided free access to and asked to register for the consumer-based mobile meditation app on their phone. Participants (n=49) will then receive an email containing 28 weeks of free access to Calm. Participants (n=49) will be asked to use Calm at least 10 minutes per day and encouraged to use it as much as they would like during the intervention. This prescription mimics how a new, paying member would use the app (full exposure with autonomy).
89451733|NCT04264910|No Intervention|Control|The control group will be asked to maintain normal activity and refrain from using Calm meditation app.
89451734|NCT03680846|Other|CMM|Conventional Medical Management
89451735|NCT03680846|Active Comparator|HF10 + CMM|Addition of HF10 therapy to CMM
89451736|NCT03650816||Alzheimer Disease|"Patients with Alzheimer's disease, as defined by the established clinical consensus criteria (DSM IV-TR and NINCDS-ADRDA)~Doppler ultrasonography will be used in these patients to assess CVR CO2 , as a change in blood flow in the internal and common carotid arteries during the 10th minute of inhalation of a gas mixture containing 5% CO2, 16% O2 and 79% N2, compared to the baseline blood flow value measured after 10 minutes rest in lying position.~Biospecimen collection will be performed in these patients : a blood sample of 10 ml will be drawn in addition to the blood sample taken as part of patient usual care, to determine plasma concentration of ET-1, bigET-1, ADMA and plasma renin activity"
89451737|NCT03650816||Subjective Cognitive impairment|"Patients with subjective cognitive impairment, who consulted for cognitive complaint without cognitive impairment on neuropsychological tests and normal performances according to daily life activities scores.~Doppler ultrasonography will be used in these patients to assess CVR CO2 , as a change in blood flow in the internal and common carotid arteries during the 10th minute of inhalation of a gas mixture containing 5% CO2, 16% O2 and 79% N2, compared to the baseline blood flow value measured after 10 minutes rest in lying position.~Biospecimen collection will be performed in these patients : a blood sample of 10 ml will be drawn in addition to the blood sample taken as part of patient usual care, to determine plasma concentration of ET-1, bigET-1, ADMA and plasma renin activity"
89451738|NCT03107936|Experimental|smokeSCREEN game play|Participants are instructed to access the web-based videogame intervention, smokeSCREEN, through a secured website and play the game using their unique User ID and password.
89451739|NCT03282422|Experimental|Intervention group|Upper-limb splint and home-based protocol in specific tasks
89451740|NCT03282422|Active Comparator|Control group|Home-based protocol in specific tasks
89451741|NCT03286712|Experimental|Incident Peritoneal Dialysis|After signing informed consent form, the patients will be started on Renogen® at 150 units/kg/week. Oral iron supplements will be started at 105 mg elemental iron per day. If the patients will not have an increase in Hb by 1-2 g/dl or an increase in the reticulocyte count after the first month of treatment, the dose of Renogen® will be increased to 200 units/kg/week. If there will still be no increase in the Hb or reticulocyte count in the second month, other causes of anemia will be ruled out. If the Hb/Hct will increase beyond the target, the Renogen® dose will be reduced by 50 units/kg/week. If the Hb/Hct will be below target, the Renogen® dose will be increased by 50 units/kg/week.
89451742|NCT03286478|Experimental|Mindfulness|Mindfulness-based body image intervention
89451743|NCT03286478|Experimental|Dissonance|Cognitive dissonance-based body image intervention
89451744|NCT03286478|Experimental|Confident Me|Dove Confident Me body image intervention
89451745|NCT03286478|No Intervention|Control|Classes as usual, assessment-only control group.
89451746|NCT02458586|Placebo Comparator|MUFA|daily intake of 50 g of olive oil over a period of 8 weeks
89451747|NCT02458586|Active Comparator|PUFA|daily intake of 50 g of canola oil (rapeseed oil) over a period of 8 weeks
89451748|NCT03417674|Experimental|Intervention group|Lifestyle intervention with meal replacement by formula diet, exercise stimulation, and telemedicine coaching.
89451749|NCT03417674|No Intervention|Control group|Routine care.
89451750|NCT03282188|Experimental|GROUP A (Reovirus only)|Group A patients will receive an initial low 'immunisation' dose of intravenous reovirus (1x108 TCID50), to ensure that neutralising antibody (NAB) levels have risen by the time a full cycle of reovirus is given. Group A patients will then receive only 1 cycle of treatment which will comprise of reovirus only at 1x1010 TCID50 as a 1-hour IV infusion on 2 consecutive days.
89451751|NCT03282188|Experimental|GROUP B (Reovirus plus GM-CSF)|Group B patients will receive an initial low 'immunisation' dose of intravenous reovirus (1x108 TCID50), to ensure that neutralising antibody (NAB) levels have risen by the time a full cycle of reovirus plus GM-CSF is given. Group B patients will be given a subcutaneous injection of GM-CSF (50mcg/day) for 3 days, followed by only 1 cycle of treatment which will comprise of reovirus at 1x1010 TCID50 as a 1-hour IV infusion on 2 consecutive days
89451752|NCT03384212|Experimental|CBA group|"CBA as HSCT conditioning:~cladribine 5mg/m2 day -6 to day -2 busulfan(iv) 3.2mg/kg day-6 to day -3 cytarabine 2g/m2 day-6 to day -2"
89451753|NCT03384212|Active Comparator|FBA group|"FBA as HSCT conditioning:~fludarabine 30mg/m2 day -6 to day -2 busulfan(iv) 3.2mg/kg day-6 to day -3 cytarabine 2g/m2 day-6 to day -2"
89451754|NCT02458508||GBM patients|patients with diagnosis of glioblastoma treated with concomitant radio-chemotherapy with temozolomide as Stupp protocol will be evaluated for pharmacogenetic evaluation
89451755|NCT03272516|Active Comparator|Control group|This group receives treatment as usual (TAU) from his/hers physician. This treatment is different for each physician, but mainly consists of cognitive therapy, personal interviews or antidepressants or anxiolytics.
89451756|NCT03272516|Experimental|Intervention group|Mindfulness Based Cognitive Therapy (MBCT). This group receives 8 weeks of MBCT in addition to usual treatment (TAU). The MBCT consists of weekly group sessions of 2,5 hours, where participants receive cognitive therapy as well as mindfulness meditation. This group is also assigned homework, according to the MBCT protocol..
89451757|NCT03271658|Experimental|Intervention|Patient/family are randomized to either the active intervention (web based life support patient decision aid - eLSDA and decision coaching) or usual care comparison.
89451758|NCT03271658|No Intervention|Usual Care Comparison|Patients may also randomized to review current web based resources provided by the health region for seriously ill patients.
89451759|NCT02460068|Active Comparator|fotemustine|fotemustine alone
89451760|NCT02460068|Experimental|fotemustine and ipilimumab|fotemustine in combination with ipilimumab
89537140|NCT04490447||Healthy control|Healthy volunteers will be included.
89451761|NCT02460068|Experimental|ipilimumab and nivolumab|ipilimumab in combination with nivolumab
89451762|NCT03286244|Experimental|CM082 plus paclitaxel|"In dose-escalation part, patients will be treated in dose levels at the following daily doses of CM082 and paclitaxel to establish the MTD and RP2D:~CM082 100mg qd + paclitaxel 80mg/m2/day; CM082 150mg qd + paclitaxel 80mg/m2/day; CM082 200mg qd + paclitaxel 80mg/m2/day; In dose-expansion part, patients will be treated at the RP2D established in dose escalation part."
89451763|NCT03282110|Experimental|ta-VNS & Electro-acupuncture|"Device:ta-VNS(transcutaneous vagus nerve stimulation):2 times per day,5 consecutive days per week for two months~Other:Electro-acupuncture:3 times per week, once every other day for two months"
89451764|NCT03282110|Active Comparator|Citalopram|citalopram for oral administration; 10mg for the first 1-3 days, 20mg for the following 4-7 days；40mg for the left days within two months
89451765|NCT03282032|Experimental|One-lung ventilation|Before surgical incision, 2-min of OLV followed by 2-min of TLV (1 cycle) is performed for 5 cycles.
89451766|NCT03282032|No Intervention|Two-lung ventilation|Maintain two-lung ventilation until surgical incision
89451767|NCT03270878|Experimental|Glasdegib Oral tablet then IV|Subjects will receive a single 100 mg oral tablet of glasdegib under fasted conditions in the first study period followed by washout. Then in the second period, a 50 mg IV solution will be infused over approximately 1.25 hours under fasted conditions.
89451768|NCT03270878|Experimental|Glasdegib IV solution followed by Oral tablet|Subjects will receive a 50 mg IV solution will be infused over approximately 1.25 hours in the fasted condition followed by washout in the first study period . Then in the second period, a single 100 mg oral tablet of glasdegib will be administered under fasted conditions
89451769|NCT02459522||Dr.Tang's research group|This group included participants with completed both the short-term HRV test and Ewing's test.
89451770|NCT03269942|Active Comparator|Endovascular Flow-Diversion|Implantation of flow-diversion device
88936572|NCT01798836|Experimental|Oestradiol and ultrashort GnRH agonist/antagonist protocol|Women will begin pretreatment with 4 mg/day of 17 β-estradiol before the combination of GnRH ultashort agonist and antagonist protocol
88936573|NCT01798836|Active Comparator|GnRH agonist or antagonist protocol.|Women will undergo either a conventional short or long GnRH agonist or an antagonist protocol during COH for IVF
88936574|NCT01798862|Experimental|Endometrial injury by hysteroscopy or pipelle sapling|Endometrial Sampling by pipelle or hysteroscopy performed once between 6th to 10th day in the cycle prior to the fresh IVF/ ICSI cycle.
88936575|NCT01798862|Active Comparator|COH for IVF without hysteroscopy or pipelle sampling|Procedure: COH for IVF Both GnRH agonists (long, starting at day 2 or 21) with triptorelin acetate 0.1 mg (Gonapeptyl daily) and antagonists with ganirelix 0.25mg (Orgalutran) or cetrorelix 0.25mg (Cetrotide) protocols will be used; for ovarian stimulation both recombinant FSH ( Puregon) and human menopausal gonadotrophin ( Menopur) will be used. Ovarian response will be monitored by ultrasonography, oocyte retrieval will be performed 36-38 hours after the Hcg triggering and for luteal phase support 600 mg progesterone tablets ( Utrogestan) will be applied.
88936576|NCT01798901|Experimental|Treatment (HDAC inhibitor AR-42, decitabine)|"INDUCTION THERAPY: Patients receive HDAC inhibitor AR-42 PO daily on days 1, 3, and 5 or 1, 3, 4, 5 and decitabine IV over 1 hour on days 6-15. Treatment repeats every 28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients achieving CR or CRi receive HDAC inhibitor AR-42 as in Induction Therapy and decitabine IV over 1 hour on days 6-10. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
88936577|NCT01799148||Particulate air pollutants|Cohort of consecutive patients admitted with diagnosis of acute coronary syndrome in the cardiology unit of a tertiary hospital, which will quantify the exposure of particulate air pollutants 24 hours a day 7 days earlier prior to admission.
88936578|NCT01799304|Experimental|no distractor control group|postural control and locomotion of CP children without attentional distractor and without additional cognitive task (control condition)
88936579|NCT01799304|Experimental|visual and sound attentional distractors|postural control and locomotion of CP children with visual and sound attentional distractors (video film).
88936580|NCT01799304|Experimental|sound attentional distractor alone|postural control and locomotion of CP children with sound attentional distractor alone (sound track of the video film).
88936581|NCT01799304|Experimental|additional cognitive task|postural control and locomotion of CP children with an additional cognitive task (adapted Stroop task with animals)
89015140|NCT01603693|Experimental|Bio-Oss|In this arm,GBR will be performed with DBBM (Bio-Oss, Geistlich) in 25 patients.
89451771|NCT03269942|Active Comparator|Cerebral Revascularization|Cerebral revascularization procedure with trapping of aneurysm
89451772|NCT03269786||cirrhotic patients with esophagel varisces|Endoscopic band ligation or injection scelerotheraby will be done for all patients
89451773|NCT03269864|Active Comparator|pedicled perforator flaps|"Once the perforator is identified, the flap will be designed around the perforator or perforators according to the location and size of the defect.~A tourniquet is inflated without prior exsanguination. This maneuver facilitates identification of perforators as they remain filled with the blood.~An exploratory incision along the margin of flap is made keeping the position of marked perforator in mind. The incision is made through the skin, subcutaneous tissue, deep fascia (sub-fascial approach) and the perforator vessel is directly visualized. The incision is initially always made from one side of the flap only to properly identify the perforator.~Careful and meticulous dissection is done in a blunt way isolating the perforator.~After deflation of the tourniquet, hemostasis is performed."
89451774|NCT03269864|Active Comparator|free perforator flaps|"A two-team approach is used for microvascular free tissue transfer. The first team starts exploring the limb for the recipient vessel. The second team simultaneously begins elevating the perforator flap and its vascular pedicle.~Microvascular anastomosis will be carried out under operating microscope for one artery and one or two accompanying veins."
89451775|NCT03285932|Experimental|Post-operative SRS of resection cavity|"High-resolution contrast-enhanced post-operative MRI imaging in preparation for Cyberknife SRS. Cyberknife SRS of the resection cavity and all potential additional metastases diagnosed in the treatment planning MRI (up to 10 lesions)~Resection cavity:~7 x 5 Gy @ 95%-isodose~Potential additional brain metastases:~20 Gy @ 70%-isodose (lesions < 2 cm max. diameter) 18 Gy @ 70%-isodose (lesions 2 - 3 cm max. diameter) 6 x 5 Gy @ 70%-isodose (lesions > 3 cm max. diameter)"
89451776|NCT03285932|Other|Post-operative WBRT|Post-operative WBRT will be performed according to the following dose regimen: 10 x 3 Gy
89451777|NCT03285776||Study group|Children with coordination disorder between the ages of 5 to 7 years.
89451778|NCT03285776||control group|children with typical development between the ages of 5 to 7 years.
89451779|NCT03285698|Other|Integra®|Integra® is a bilayer wound matrix made out of bovine tissue.
89451780|NCT03285698|Experimental|DermACELL®|DermACELL® is a bilayer wound matrix made out of human tissue.
89451781|NCT03285620|Experimental|Part 1: Single Ascending Dose (SAD)|Participants will receive single oral dose of AL-034 (oral solution) (the starting dose in Cohort 1 of Part 1 will be 0.2 milligram [mg]) or matching placebo under fasted condition (Cohorts 1 to 5 or optional Cohort 7) on Day 1. Participants may receive AL-034 in a fed state (Cohort 6) to evaluate the effect of food on the pharmacokinetics (PK) of AL-034.
89451782|NCT03285620|Experimental|Part 2: Multiple-Dose Administration (MAD)|Participants will receive multiple oral doses of AL-034 or matching placebo for 4 consecutive weeks either once weekly (Qwk - for 4 doses) or every two weeks (Q2wk - for 3 doses) under fed or fasted conditions. The starting dose for Part 2 will be determined based on the initial PK and safety/tolerability data from Part 1.
89451783|NCT02459600|Experimental|All participants|"The measurement will be done at all the participants. the results will the divides in the following way:~Refraction measurements under general anesthesia without cycloplegic eye drops.~Refraction measurements under general anesthesia with cycloplegic eye drops."
89451784|NCT03285464|Active Comparator|Hip|This group will perform a known hip strengthening program
89451785|NCT03285464|Experimental|Trunk|This group will use the trunk as a lever to strengthen the hip
89451786|NCT03269708|No Intervention|Control|Participants receive standard care in cardiac rehabilitation program
89451787|NCT03269708|Experimental|Knowledge transfer group|Participants receive standard care in cardiac rehabilitation program plus education regarding telomere length
89451788|NCT02459912|Other|Unilateral Nerve-Sparing Cryoablation|Unilateral Nerve-Sparing Cryoablation of the Prostate using Galil Medical Precise Cryoablation System with IceRod Needles.
89015141|NCT01603693|Experimental|Bio-Oss and BondBone|In this arm, GBR will be performed using a combination of DBBM (Bio-Oss, Geistlich) and bi-phasic calcium sulphate (BondBone, Augma) in 25 patients.
89015142|NCT01603732||Moms w HLHS or variant|Mom's fetal diagnosis Hypoplastic Left Heart Syndrome/variant
89015143|NCT01603732||Moms w/ Other congential heart defect)|Moms fetal diagnosis -other congenital heart defects
89206134|NCT04794322||Pelvic Mass Cohort (cohort #1)|200 participants scheduled for surgery for suspected ovarian cancer due to a pelvic mass but without a confirmed tissue or cytology diagnosis.
89206135|NCT04794322||BRCA1/2 Carriers Cohort (cohort #2)|50 participants with an inherited BRCA1 or BRCA2 deleterious mutation without suspected ovarian cancers who are scheduled for risk-reducing salpingo-oophorectomy (RRSO) to remove ovaries and fallopian tubes.
89206136|NCT00628212|Experimental|Teneligliptin 10 mg|Teneligliptin 10 mg, orally, once daily
89451789|NCT03269630||Clinic patients (Comprehensive Pulmonary Hypertension Center)|"Pulmonary hypertension patients (WHO group 1-5)~Systemic sclerosis patients without pulmonary hypertension~Mixed connective tissue disease patients without pulmonary hypertension"
89451790|NCT03269630||Outpatient right heart catheterization patients|-Outpatients undergoing right heart catheterization for any indication
89451791|NCT03269630||Healthy controls|"Age>18~Not actively smoking~No chronic medical conditions"
89451792|NCT03285386|Experimental|Priming Exercise|Participants will perform constant power output tests at four separate, fixed intensities to exhaustion on a cycle ergometer on separate days. These exhaustive, constant power tests will be preceded by 3 minutes of light cycling, 6 minutes of high intensity cycling, 7 minutes of rest and 3 minutes of light cycling.
89451793|NCT03285386|Active Comparator|Control|Participants will perform constant power output tests at four separate, fixed intensities to exhaustion on a cycle ergometer on separate days. These exhaustive, constant power tests will be preceded by 3 minutes of light cycling only.
89451794|NCT03269240|Experimental|LDHF plus m-Mentoring|"Participants will undergo pre-training assessment comprising multiple-choice questions and objective structured clinical examination (OSCE) using manikins. Training is divided into two 4-day low-dose sessions at the health facility or onsite training. Pre-training and immediate post-training assessments results will be compared. A score of ≥80% is acceptable competence (pass). During the one-month intervals between training sessions, participants practice using manikins to reinforce their competencies through simulation-based practices, facilitated by facility-based trained Peer Practice Coordinators (PPCs). The PPCs will also receive structured, monthly half-hour mentoring calls that will provide remote support, answering questions, providing guidance and reinforcing key messages. Acquisition of knowledge and clinical skills is measured."
89451795|NCT03269240|Active Comparator|Traditional training|The health providers will receive the same content of training in eight days, Off-site training, the way it's currently done in Nigeria. Both theoretical and practical through use of manikins - simulation. No reinforcement and further practice will take place once the participants are back in their work stations. Acquisition of knowledge and clinical skills is measured.
89451796|NCT03281486|Experimental|HA formulation Oral Spray|Subjects will be instructed to mouth spray with 0.3 ml ( 2 sprays to the mouth) of their assigned mouth spray, 2 times daily (morning and evening), using only the assigned mouth spray provided for the 4 week duration of the study.
89451797|NCT03281486|Placebo Comparator|Placebo Oral Spray|Subjects will be instructed to mouth spray with 0.3 ml ( 2 sprays to the mouth) of their assigned mouth spray, 2 times daily (morning and evening), using only the assigned mouth spray provided for the 4 week duration of the study.
89451798|NCT03269318|Experimental|Personalised Medicine|Personalised Medicine who will be prescribed controller medication based on genetic test, Arg/Arg or Arg/Gly - montelukast (LTRA) or Gly/Gly -salmeterol (LABA).
89451799|NCT03269318|No Intervention|Standard Care|Standard of care (Standard Care will be prescribed controller medication based on guidelines)
89501734|NCT02151929|Active Comparator|Everolimus Eluting stent|Implantation of of an everolimus eluting stent in patients with STEMI treated with primary PCI
89501735|NCT03542357|Active Comparator|Sumatriptan|headache is induced with CGRP. This headache is treated double-blinded with 1 tablet of sumatriptan 50 mg as a pre-treatment
89200965|NCT04035057|Active Comparator|Standard Didactic Training|Both training conditions will receive a 1.5 day training followed by ongoing supervision while they implement exposure therapy with patients recruited to the study. The first full day will consist of the same foundational information in both conditions.The two conditions will differ in their training focus during the subsequent half-day training. The Standard Didactic condition will involve additional didactic instruction related to common barriers and more advanced delivery concepts than will be presented in the half-day training for the Behaviorally Enhanced condition. The focus of ongoing supervision following the initial 1.5 day training workshop will also differ by condition. The Standard Didactic condition will involve counseling on the implementation of exposure with therapists' patients without explicit focus on therapists' remaining reservations about exposure.
89200966|NCT04034979|No Intervention|Phase I-Baseline evaluation|The first two months of the investigator's project will be a baseline evaluation of the current decision making process about goals-of-care in a local ICU setting (Levis, Quebec). A PhD student will collect sociodemographic data (age, gender, education level, religion), observe and video record (or audio record) dyads of physicians and newly admitted elderly patients discussing goals-of-care.
89206137|NCT00628212|Experimental|Teneligliptin 20 mg|Teneligliptin 20 mg, orally, once daily
89206138|NCT00628212|Experimental|Teneligliptin 40 mg|Teneligliptin 40 mg, orally, once daily
88936582|NCT01799343|Experimental|Immersion into water|Normal healthy singleton pregnant women. The case serves as its own control. Measurements of mean arterial pressure, deepest vertical pocket of amnion fluid and Doppler flow in the umbilical and uterine arteries will be assessed before immersion (Baseline), during immersion (Immersion) and after immersion (Post-immersion).
89015144|NCT01603732||Moms-fetal - echo normal|Moms echo fetal diagnosis is normal.
89206139|NCT00628212|Placebo Comparator|Placebo|Teneligliptin placebo-matching tablets, orally, once daily
89015145|NCT01603732||Random Healthy Moms|Mom with healthy pregnancy.
89451800|NCT03268928|Experimental|Story Starters Intervention|"Children will receive the the Story Starters intervention for six months. Each child will be visited by a trained Story Starter volunteer twice a week while the child is in preschool. The sessions will last 20 minutes and in each session the Story Starter volunteer and child will read books and play with toys. The Story Starter volunteers will keep a record of the number of sessions each child attends.~Each child will receive one new book per month delivered to their home address by Dolly Parton's Imagination Library."
89451801|NCT03268928|Other|Wait-list Control|"Children in the wait-list control arm will continue to attend preschool as normal during the randomised controlled trial (RCT) and will receive the Story Starters intervention after the RCT has finished.~Each child will receive one new book per month delivered to their home address by Dolly Parton's Imagination Library."
89451802|NCT03284918|Experimental|Plant stanol ester|Cereal based snack bar with added plant stanol ester (0.8 g plant stanols/bar). Two bars consumed daily as a snack, between meals, for 4 weeks (1.6 g plant stanols/d).
89451803|NCT03284918|Placebo Comparator|Placebo|Cereal based snack bar without plant stanol ester. Two bars consumed daily as a snack, between meals, for 4 weeks (0 g plant stanols/d).
89451804|NCT03284840||Adults (18-65 years)|
89451805|NCT03284840||Elderly (65-74 years)|
89451806|NCT03284762||Treatment-naïve NVAF patients in Korea and Taiwan|Patients will be followed according to routine medical practice and the frequency of visits and procedures will be performed under routine conditions. NVAF: Non-valvular atrial fibrillation
89451807|NCT03284684||circulating DNA plasma level test|
89451808|NCT03268694|Experimental|Cognitive and Emotion Processing Tasks|As a part of the clinical monitoring, intracranial EEG is continuously collected when the participant is at the Epilepsy Monitoring Unit at the UNC Neuroscience Hospital. We will use an FDA approved EEG amplifier/data acquisition system to collect the research data. Computer-based tasks will be presented through a laptop and task related timing information will be transmitted from the laptop to the data acquisition system. Computer-based tasks will include Working Memory task, Reward Learning Task and Facial Emotion Recognition Task
89451809|NCT03281408||Suspected OSA Patients Undergoing Knee or Hip Arthroplasty|These 100 subjects will be cared for and monitored in hospital following current hospital protocol. No change or intervention is to be administered. Troponin testing will be done post-op with other routine blood work.
88936583|NCT01799512|Experimental|real-time continuous glucose monitoring|"real-time continuous glucose monitoring: Use will be made of the online real-time (RT) monitoring facility of the GlucoDay® (a continuous glucose monitoring (CGM)system). This will allow immediate adaptation of the insulin dose in order to maintain values within an optimal range.~The same IV insulin infusion protocol will be used in the experimental and the active comparator group (adapted Yale protocol).~When glycaemic changes of >25 mg/dl per 30 minutes are observed from the RT-CGM - GlucoDay data, this will be checked by measuring arterial blood glucose and the insulin infusion rate will be adapted according to the adapted Yale protocol."
88936584|NCT01799512|Active Comparator|blinded continuous glucose monitoring|"In the active comparator group the same continuous glucose monitoring device (GlucoDay) will be used in a blinded fashion. Glucose data will be analysed retrospectively.~IV insulin infusion will be adapted according to arterial blood glucose values, using the adapted Yale protocol."
88936585|NCT01799694|Experimental|Autologous Expanded Stem Cells|Inject of Autologous Adipose-derived expanded stem cells
88936586|NCT01799863|Experimental|Ketorolac trometamol 0.45%|Ketorolac trometamol 0.45% associated with carboxymethylcellulose eye drops (Acular CMC®, Allergan, Irvine, USA) qid for 7 days.
88936587|NCT01799863|Placebo Comparator|Artificial tears|Preservative free artificial tears (Optive UD®, Allergan, Irvine, USA) qid for 7 days.
88936588|NCT01800006||Group 1|
88936589|NCT01800019|Active Comparator|NRT arm|"Drug: Nicotine Replacement Therapy (Nico-Derm® and Nicorette®)~Dose: 7mg - 42mg depending on # of cigarettes smoked per day at study baseline, and withdrawal symptoms.~Mode of Administration: Transdermal Patch~Duration of Treatment: up to 24 Weeks~Additionally, participants will be provided with a supply of short-acting nicotine gum in order to supplement their long acting NRT patch regimen.~Individuals who smoke their first cigarette more than 30 minutes after waking are advised to use the 2 mg NRT gum. Participants who smoke their first cigarette within 30 minutes of waking will be advised to use the 4 mg NRT gum. Both NRT gum dosages will be recommended for use on an ad lib basis to address cravings and/or withdrawal symptoms, up to a maximum of 12 pieces of NRT gum per day."
88936590|NCT01800019|Active Comparator|NRT and HIV Tailored Quit Smoking Counseling|"Drug: Nicotine Replacement Therapy (Nico-Derm®)~Dose: 7mg - 42mg depending on # of cigarettes smoked per day at study randomization and withdrawal symptoms.~Mode of Administration: Transdermal Patch~Duration of Treatment: up to 24 Weeks~HIV tailored Smoking Cessation Counseling: The counseling consists of face-to-face sessions with a trained smoking cessation counselor at the start of the study, on your chosen quit date, and then at weeks 4, 8, 12 and 24; supportive telephone calls if needed."
88936591|NCT01800019|Active Comparator|Varenicline (VR) Arm|"Drug: Varenicline (Champix®)~Doses: 0.5 mg once daily for 3 days(i.e.day 1-3 of the week prior to quit date) 0.5 mg twice daily for 4 days i.e. day 4-7) and 1 mg twice daily for the remainder of the treatment period~Mode of Administration: Oral~Duration of Treatment: 24 Weeks (+ 1 Week of Dose Escalation, total of 25 weeks)"
89200967|NCT04034979|Experimental|Phase II-Impact of the decision aid|The two following months will be an evaluation of the decision making process about goals-of-care in the same local ICU setting using only the decision aid without any training. A PhD student will collect sociodemographic data (age, gender, education level, religion), observe and video record (or audio record) new dyads of physicians and newly admitted elderly patients discussing goals-of-care, whether the physician chooses to use the context-adapted decision-aid or not.
89206140|NCT05160610|Experimental|Intervention group|receiving multilevel intervention, electronic monitoring and stroke registry participation
89451810|NCT02458664||Colo-rectal cancer|All patients undergoing curative colorectal cancer in general and digestive surgery department at Saint-Antoine hospital
89451811|NCT03269006|Experimental|Inesfly Paint|Inesfly 5AIGRNG TM containing Alphacypermethrin 0.7%; D-Allethin 1.0% and Pyriproxyphen (0.063%). The formulation is vinyl paint with an aqueous base, with the active ingredients residing within Ca CO3 and resin microcapsules, allowing a gradual release of active ingredients. Microcapsules range from one to several hundred micrometers in size.
89451812|NCT03269006|Experimental|IDWL (1m)|Install durable wall lining up to one meter from the floor of the intervention room containing deltamethrin to kill immature stage and as well as adult sand flies.
89451813|NCT03269006|Experimental|ITN (KO-Tab 123)|impregnation of existing bed net by the insecticide tablet, K-O Tab 1-2-3 containing deltamethrin.
89451814|NCT03269006|Experimental|IRS (Delthamethrin)|indoor residual spraying with Delthamethrin in the living rooms
88936592|NCT01800019|Active Comparator|Varenicline (VR) and HIV Tailored Quit Smoking Counseling|"Drug: Varenicline (Champix®)~0.5 mg once daily for 3 days(i.e.day 1-3 of the week prior to quit date) 0.5 mg twice daily for 4 days i.e. day 4-7) and 1 mg twice daily for the remainder of the treatment period~Mode of Administration: Oral~Duration of Treatment: 24 Weeks (+ 1 Week of Dose Escalation, total of 25 weeks)~Intervention: HIV tailored Smoking Cessation Counseling: The counseling consists of face-to-face sessions with a trained smoking cessation counselor at the start of the study, on your chosen quit date, and then at weeks 4, 8, 12 and 24; supportive telephone calls if needed."
88936593|NCT01800032||Plexiform Neurofibroma|NF1 associated plexiform neurofibroma
88936594|NCT01800032||Optic Glioma|NF1 associated optic glioma
88936595|NCT01800045|Experimental|Pitolisant|Pitolisant at 5, 10, 20 or 40mg
88936596|NCT01800045|Placebo Comparator|Placebo|Capsules of placebo containing lactose
88936597|NCT01800084|Experimental|Patients undergoing SPECT-CT|"The patients in this study are scheduled for a SPECT-CT at the Nîmes University Hospital as part of their normal care regimen.~Intervention: Device: Asir Image Acquisition"
88936598|NCT01800097|Placebo Comparator|placebo|placebo
88936599|NCT01800097|Active Comparator|Modafinil|Modafinil
88936600|NCT01800110|Experimental|2|label I- 200 cc pomegranate juice once daily for 6 weeks post partum. label II- control group, no placebo is givening.
88936601|NCT01800123||Acute poisoning|Consecutive acute drug self poisoned patients admitted in the ED.
88936602|NCT01800136|Experimental|rTMS; tDCS|
88936603|NCT01800149|Active Comparator|BBM+collagen|Ridge Augmentation After tooth extraction, edentulous sockets will be filled with BioOss Collagen and covered with Bio-Gide
88936604|NCT01800149|Active Comparator|BBM granules|Ridge Augmentation After tooth extraction, edentulous sockets will be filled with Bio-Oss Granules, 0-25-1 mm, and covered with Bio-Gide
88936605|NCT01800175|Experimental|Formulation C|Two formulations of the OTX Punctum Plug will be evaluated in this trial. The difference in formulations is the time required for degradation of the PEG hydrogel. The persistence of OTX Punctum Plug (Formulation C) is anticipated to be slightly shorter than the persistence of OTX Punctum Plug (Formulation D).
88936606|NCT01800175|Experimental|Formulation D|Two formulations of the OTX Punctum Plug will be evaluated in this trial. The difference in formulations is the time required for degradation of the PEG hydrogel. The persistence of OTX Punctum Plug (Formulation C) is anticipated to be slightly shorter than the persistence of OTX Punctum Plug (Formulation D).
88936607|NCT01800188||Dialysis|Patients with dialysis dependent ESRD and normal fasting glucose will undergo a meal test during a hemodialysis and hemodiafiltration session. A meal test without dialysis is optional.
88936608|NCT01800253|Experimental|Total sleep deprivation|Participants will be required to stay up for the entire night before 'Blood Samples' and 'Tissue samples' will be taken and the 'Portion Size Task' and 'Inhibitory task' will be performed. This will then be followed by the 'Oral glucose tolerance test' with additional 'Blood Samples' to be taken as described for that test.
88936609|NCT01800253|Experimental|Sleep|Participants will have an 8-h sleep opportunity before 'Blood Samples' and 'Tissue samples' will be taken and 'Portion Size Task' and 'Inhibitory task' will be performed. This will be followed by the 'Oral glucose tolerance test' with additional 'Blood Samples' to be taken as described for that test.
89206141|NCT05160610|No Intervention|Control group|receiving routine care , electronic monitoring and stroke registry participation
89451815|NCT03269006|No Intervention|Control|without any study interventions
89451816|NCT04172558|Active Comparator|BTX100 group|ICI of Botox 100 U
89451817|NCT04172558|Active Comparator|Trimix group|ICI of Trimix
89451818|NCT03107858|Active Comparator|Norepinephrine|
89451819|NCT03107858|Active Comparator|Dopamine|
89451820|NCT03281330||persons with Multiple Sclerosis|
89451821|NCT03281330||Healthy controls|
89451822|NCT03269162|Experimental|Jinfukang + Chemotherapy Group|
89451823|NCT03269162|Placebo Comparator|Chemotherapy Group|
89451824|NCT03268772|Experimental|PLD-IFO|pegylated liposomal doxorubicin (PLD) combined with ifosfamide (IFO)
89451825|NCT03268616|Experimental|Healthy Subjects|increase the inspiratory threshold load step by step(30%-80%MIP),in order to increase neural respiratory drive.
89451826|NCT03268616|Experimental|Sever COPD Patients|increase the pressure support ventilation step by step, in order to decrease neural respiratory drive.
89451827|NCT03284450|Experimental|Dance performance fitness test (DPFT)|
89451828|NCT03284450|Active Comparator|Sport specific repeated sprints (SSRS)|
89451829|NCT03284372|Experimental|Intervention 1|Text Message Only
89451830|NCT03284372|Experimental|Intervention 2, Incentive|Text message + Incentive
89451831|NCT03284372|No Intervention|Cohort|For the cohort multiple randomized controlled trial (cmRCT), investigators will recruit 130 participants (the base cohort) ages 15-19. The base cohort allows investigators to measure normative food allergy self-management practices, while also serving as a control for experiments in Interventions 1 and 2.
89451832|NCT03284372|No Intervention|Control|The baseline cohort serves as the control group in this cmRCT. Participants will not receive text message reminders (during Intervention 1) or incentives (during Intervention 2). However, they will participate in all data collection points, including text message check-ins to assess epinephrine-carrying. Participants in the base cohort will receive usual care.
89451833|NCT03284372|No Intervention|Adolescent Allergy Advisors|We will pilot the text messages to be used in Interventions 1 and 2 through interviews and cognitive testing among 20 Adolescent Allergy Advisors, who will critique message content, framing, and language. These advisors will not be part of the cohort multiple randomized controlled trial.
89451834|NCT03284294|Placebo Comparator|Placebo|Oral placebo daily for 8 weeks
89451835|NCT03284294|Active Comparator|Vitamin D|Vitamin D Cholecalciferol 2000 IU oral daily for 8 weeks
89451836|NCT03284216|Other|Normal glycemia + exercise|Participants will be studied in the fasting state under normal blood glucose conditions whereby no glucose will be administered, but an exercise bout will be completed.
89451837|NCT03284216|Experimental|Steady-state hyperglycemia + exercise|Participants will be studied during experimental steady-state hyperglycemia-induced via a variable-rate intravenous glucose infusion, and an exercise bout will be completed.
89451838|NCT03284216|Experimental|Fluctuating hyperglycemia + exercise|Participants will be studied during experimental fluctuating hyperglycemia-induced via repeated intravenous glucose injections, and an exercise bout will be completed.
89451839|NCT03284216|No Intervention|Normal glycemia, no exercise|Participants will be studied in the fasting state under normal blood glucose conditions whereby no glucose will be administered and no exercise will be completed.
89451840|NCT03281174||EV71 vaccine group|The group which received two doses EV71 vaccine (400U/0.5ml) on day 0,28 in phase III clinical trial.
89451841|NCT03281174||Placebo group|The group which received two doses placebo (0U/0.5ml) on day 0,28 in phase III clinical trial.
89451842|NCT03281018|Experimental|Interventional arm|Caregiver Accompaniment Time (CAT) + preoperative hypnosis session (experimental arm): The hypnosis session is performed by a nurse trained in medical hypnosis; this interview lasts approximately one hour and is carried out 5 to 15 days before the hospitalisation. During the hypnosis session, the patient is free to choose what issues she wants to address. The patient will then go from a state of ordinary consciousness to a modified state of consciousness. This state will allow her to activate her own resources to handle difficulties, especially anxiety. Using a post-hypnotic suggestion, the patient will be able to revisit her work at any time she needs
88936610|NCT01800266|Experimental|Symptom and Fidelity Monitoring (SFM)|Half of the study clinicians will be randomized to this supervision condition of TF-CBT.
88936611|NCT01800266|Experimental|SFM + Behavioral Rehearsal|Half of the study clinicians will be randomized to this supervision condition of TF-CBT.
88936612|NCT01800279|Active Comparator|Deontology Therapy|The patients in the control group will port a deprogramming occlusal splint to sleep every night, an average of 8 hours per day, for 12 weeks of the treatment.
88936613|NCT01800279|Experimental|Physiotherapy Protocol|The physiotherapy protocol involves the application of kinesitherapy techniques and a myofascial therapy protocol. This protocol will be administered twice a week for 12 weeks.
88936614|NCT01800292|Experimental|sildenafil therapy|Subjects will have 2D-Echocardiogram measuring left ventricular strain and strain rate using speckle tracking techniques, have 6 minute walk test, World Health Organization functional class (I-IV)assignment, and BNP lab result at baseline and at 3 months. Subjects will be started on sildenafil at 20 mg by mouth three times per day at the baseline visit. Each individual will serve as his/her own control.
88936615|NCT01800305|Experimental|Pegylated rhEPO|Subcutaneous single-dose administration of 0.5mcg/kg, 1.0mcg/kg, 1.6 mcg/kg, 2.4 mcg/kg, 3.2 mcg/kg，3.2mcg/kg, 4.2mcg/kg, 5.5 mcg/kg, 7.2 mcg/kg, 9.3 mcg/kg (in dose-escalation, if the previous dose is confirmed to be safe.started with the second 3.2mcg/kg dose,Every subject takes Niferex 150mg every day, from day 1 to day 20. ) of the test drug (Pegylated rhEPO)
88936616|NCT01800305|Active Comparator|EPIAO®|Subcutaneous six-dose administration of 50IU/kg or 150IU/kg, as randomization, of the comparator drug(EPIAO®) at day 1, 3, 5, 8, 10, 12.
88936617|NCT01800331|Experimental|Text2bHealthy|The intervention arm receives the Text2bHealthy program on a PDA
88936618|NCT01800331|No Intervention|Control group|The control group will complete a paper dairy to keep track of their lifestyle behaviours
88936619|NCT01800344|Active Comparator|The laryngeal mask airway-ClassicTM (LMA)|The LMA is a large foreign body that exerts pressure on the pharyngeal mucosa. High LMA intracuff pressures may reduce pharyngeal mucosal perfusion and lead to throat discomfort.
88936620|NCT01800344|Active Comparator|The AES Ultra CPVTM LMA (Ultra)|Ultra is a new supraglottic airway with anatomical features and insertion technique virtually identical to the LMA-ClassicTM. The cuff and the shaft are made of silicone with a built-in CPV pilot balloon valve which provides continuous monitoring of the intracuff pressure. The CPV cuff pressure indicator has 3 zones indicated by color: yellow corresponds to pressure < 50 cm H2O; green 60 cm H2O; and red >70 cm H2O
88936621|NCT01800357|Experimental|mildronate|infusion of mildronate
88936622|NCT01800357|Placebo Comparator|placebo|infusion of placebo mildronate
89206142|NCT00298363|Experimental|Tenofovir DF|TDF 300 mg + FTC/TDF placebo + ETV placebo once daily (QD)
89501736|NCT03542357|Placebo Comparator|Placebo|headache is induced with CGRP. This headache is treated double-blinded with 1 tablet of placebo as a pre-treatment
89501737|NCT02150915|Experimental|new acupoint|Subjets in this arm receive acupuncture therapy in a new acupoint (leopard spot needling technique)
89015146|NCT01603771||Combined|Participants assigned to this group have been randomized to the Combined group of the parent study, Combining Exercise and Cognitive Training to Improve Everyday Function(EXACT)(Unique Protocol ID 201102416). Participants perform a 6-month standardized aerobic training program at a local recreational center, 3 times per week for 1 hour. Participants in this group also perform an 8-week cognitive training program 3 days per week for 1 hour, during months 5 and 6. The cognitive training program is computer-based, and focuses on 3 types of cognitive processes: task coordination, prospective memory, and retrospective memory retrieval. The cognitive training is conducted on concurrent days with aerobic exercise training sessions, also on site at the recreational center.
89015147|NCT01603771||Control|Participants assigned to this group have been randomized to the Control group of the parent study, Combining Exercise and Cognitive Training to Improve Everyday Function(EXACT)(Unique Protocol ID 201102416). Participants perform a 6-month home exercise program consisting of stretching, range of motion, and simple yoga exercises designed to improve flexibility. They are instructed to perform these exercises at home at least 3 times per week for 30 - 45 minutes and record their activity on a calendar. Participants also attend weekly 1-hour Health Education sessions for 8 weeks, during months 5 and 6. These sessions cover topics unrelated to exercise or cognition, such as nutrition, hearing loss, stroke, and home energy conservation.
89451843|NCT03281018|No Intervention|Control (CAT)|CAT is performed in routine care for all patients after the announcement of the illness by a trained nurse, if possible on the same day as the consultation or before the consultation of anesthesia. This is an interview of approximately 45 minutes to listen to the patient, to answer her questions and to re-explain the information delivered to her. The patient will tackle the history of the disease and then the treatment, this time dedicated evolves according to the desire of the patient and her ability to accept the disease. The patient can express her feelings, then the family circle is evoked talking about the resource persons and the future. The purpose of this interview is to obtain the autonomy of the patient by the setting up of supportive care
89451844|NCT03284060|Experimental|Cognitive remediation program|
89451845|NCT03283904|Experimental|Multicomponent PA intervention|Intervention schools will adopt a multicomponent intervention by integrating physical activities into different parts of the school day
89451846|NCT02558296|Active Comparator|Bexagliflozin tablets, 20 mg|Each subject will receive bexagliflozin 20 mg once daily for the duration of the study.
89451847|NCT02558296|Placebo Comparator|Placebo tablets|Each subject will receive placebo (inactive tablet) once daily for the duration of the study.
89451848|NCT03268226|Experimental|CHF5993|Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium Bromide administered via pMDI
89451849|NCT03283748|Experimental|Measurement of Motor Movements|Wearable Accelerometer Sensors manufactured by leading manufacturers will be given to the participants to be worn around hands and legs. These sensors will be used to measure accelerations which will be impacted by the motor movements.
89451850|NCT03280940||Dolutegravir treatment group|Naïve patients having documented HIV-1 infection and starting their first antiretroviral treatment with a dolutegravir containing regimen
89451851|NCT03280940||Raltegravir treatment group|Naïve patients having documented HIV-1 infection and starting their first antiretroviral treatment with a raltegravir containing regimen
89451852|NCT03280940||Elvitegravir treatment group|Naïve patients having documented HIV-1 infection and starting their first antiretroviral treatment with a elvitegravir containing regimen
89451853|NCT03280940||Protease inhibitors treatment group|Naïve patients having documented HIV-1 infection and starting their first antiretroviral treatment with a protease inhibitors containing regimen
89501738|NCT02150915|Active Comparator|classical acupoint|Subjects in this arm receive acupuncture therapy in a classical acupoint in the pericardial conduit (leopard spot needling technique)
89015148|NCT01603810||BCC|Adult of any age or gender with capacity to give informed consent who has a basal cell carinoma requiring surgical excision and involving the periocular skin
89451854|NCT05234996|Active Comparator|virtual reality|In The VRE arm, patients will use Virtual Reality headset (VR Headset), containing a selection of audiovisual productions made with 360 degrees technology and selected on the basis of content, plot and production dynamics. During the entire experience, an operator dedicated to patient care will be present to allow the most possible comfortable experience.
89451855|NCT05234996|Active Comparator|control arm|In control arm, patients will entertain themselves with conventional means such as listening to music, watching a mobile program, reading newspapers, books, magazines or also doing nothing, according to the patient's preferences
89451856|NCT03268148|Experimental|low level laser group|LaserPen is applied to the local point for 20 seconds where heel-lancing will be performed in the low level laser group.
89451857|NCT03268148|No Intervention|breast milk group|Subjects in breast milk group are given 5ml expressed breast milk by mouth using a syringe tube inserted to the participant's oral cavity over a 2-minute period before heel-lancing.
89451858|NCT03283592|Experimental|Rank-Heat Plot|The intervention group will receive an online survey to evaluate their interpretation of the results from the NMA with a rank-heat plot including results from 2 outcomes that were selected by our knowledge users (#injurious falls, #fractures).
89451859|NCT03283592|Active Comparator|SUCRA (surface under the cumulative ranking) Plot|The control group will receive an online survey to evaluate their interpretation of the results from the NMA with the SUCRA plots including results from the same 2 outcomes that will be presented to the intervention group (i.e., #injurious falls, #fractures).
89451860|NCT02737475|Experimental|Part 1: Dose Escalation|"BMS-986178 at specified doses at specified intervals~Enrollment is closed for this arm"
89451861|NCT02737475|Experimental|Part 2: Dose Escalation and Expansion|"BMS-986178 in combination with Nivolumab at specified doses at specified intervals~Enrollment is closed for this arm"
89451862|NCT02737475|Experimental|Part 3: Dose Escalation and Expansion|"BMS-986178 in combination with Ipilimumab at specified doses at specified intervals~Enrollment is closed for this arm"
88936623|NCT01800370|Experimental|Hyperglycemia|Hyperglycemia (rest controlled) will be induced by i.v. injection of 25 mL of dextrose 50% over 3 minutes with the subject supine. Includes blood draws and fasting requirements.
88936624|NCT01800370|Placebo Comparator|Saline|Saline (rest controlled) will be induced by i.v. injection of 25 mL of saline over 3 minutes with the subject supine. Includes blood draws and fasting requirements.
88936625|NCT01800370|Experimental|Exercise|"Monitored exercise of 7-minute biking, 2-minute arm weights and a blood draw at the 10-minute time point will be repeated 3 times,which takes 30 minutes.~Bilateral arm curls begin at 20 pounds and decrease by 5 pounds as needed to sustain 2 minutes of exercise at a rate of 1 complete curl every 2 seconds.~Includes blood draws and fasting requirements."
88936626|NCT01800396|Placebo Comparator|Milk protein|Milk powder, twice daily at breakfast and dinner.
88936627|NCT01800396|Experimental|Milk protein rich in phospholipids|Milk powder, twice daily at breakfast and dinner.
88936628|NCT01800409|Experimental|AFES training|Participants will take part in AFES training sessions five times per week (Mon-Fri) for a total of 8 weeks During these sessions participants will receive AFES for 40 minutes. Training sessions are designed to strengthen the participants abdominal muscles in order to improve respiratory function
88936629|NCT01800409|No Intervention|Control period|Four week control period. The order of the control and training periods will be randomised for each participant.
88936630|NCT01800422|Experimental|Arm I (telapristone acetate)|Patients receive telapristone acetate orally once daily for 2-10 weeks and then undergo surgical resection.
88936631|NCT01800422|Placebo Comparator|Arm II (placebo)|Patients receive placebo orally once daily for 2-10 weeks and then undergo surgical resection.
88936632|NCT01800435|Active Comparator|aPCC, aPCC + TXA|aPCC 75IU/kg i.v aPCC 75IU/kg i.v +TXA 20mg/kg
88936633|NCT01800435|Active Comparator|rFVIIa, rFVIIa + TXA|rFVIIa 90 µg/kg i.v rFVIIa 90 µg/kg i.v + TXA 20 mg/kg
88936634|NCT01800461|Experimental|OPC-Stroke, Usual care|OPC-Stroke - 10 weekly sessions of goal setting followed by problem solving process
88936635|NCT01800461|Other|Usual care|Usual care - Follow-up by physician and possible receipt of home care services
88936636|NCT01800487|Active Comparator|silymarin|Silymarin 140 mg three times a day for 4 weeks
89451863|NCT02737475|Experimental|Part 4: Dose Schedule and Exploration|"BMS-986178/Nivolumab at specified doses at specified intervals~Enrollment is closed for this arm"
89451864|NCT02737475|Experimental|Part 5: Dose Schedule and Exploration|"BMS-986178/Ipilimumab at specified doses at specified intervals~Enrollment is closed for this arm"
88936637|NCT01800487|Placebo Comparator|placebo|"Placeo~1 tab three times a day for 4 weeks"
88936638|NCT01800513|Experimental|Endometrial Biopsy|Subjects will have a vaginal speculum placed and visualization of the cervix will be obtained. The cervix will be cleaned with betadine (or hibiclens for those with an iodine allergy). Those randomized to the treatment arm (endometrial biopsy) will have an endometrial pipelle (Endocell, Wallach, Orange, Connecticut) inserted gently through the cervix into the uterus. Two passes will be performed with the pipelle catheter. For each pass the catheter will be rotated and scraped 4 times, once in each quadrant.
88936639|NCT01800513|Sham Comparator|Control|Those randomized to the control group will have a small cotton swab placed gently into the cervix. No tissue will be obtained with this method. The randomization to a placebo control is necessary to prove that any positive effects seen are due to the biopsy and not just random chance.
88936640|NCT01800526|Experimental|Oral N-acetylcysteine (NAC)|Eligible subjects who did not participate in Intravenous NAC or subjects who are at least 4 weeks after participation in Intravenous NAC, will be given Oral NAC at a dose of 2400mg daily, in two equally divided doses, for 4 weeks. Subjects will have blood drawn prior to beginning the phase and weekly for 4 weeks. At each visit interim medical events and adverse events will be collected.
88936641|NCT01800526|Experimental|Intravenous N-acetylcysteine (NAC)|"For part 1, Eligible subjects who did not participate in Oral NAC or subjects at least 4 weeks after oral NAC will receive IV NAC 150 mg/kg over 8 hours. At least four weeks after the first infusion, the subject will receive IV NAC 300 mg/kg over 8 hours.~For part 2, Eligible subjects with sickle cell disease and hospitalization for VOC within the past 2 years, who now present in VOC will be enrolled. Subjects will receive IV NAC 75 mg/kg over 1 hour every 6 hours for 5 days or discharge, whichever occurs earlier."
88936642|NCT01800565|Other|pubertal progression|A collection of first voided urine sample for the measurement of LH.
88936643|NCT01800578||Bispectral Index Group|
88936644|NCT01800591|No Intervention|Control Arm|No other financial incentive other than for enrollment, 6-month weigh in, and completion.
88936645|NCT01800591|Experimental|Delayed gratification|In addition to the standard enrollment, 6-month, and completion incentives, if the subject loses 5% of their initial weight by the end of the study, they will receive an annual discount (distributed across bi-weekly pay periods) for 12 months beginning after the 12-month study ends. Their premium will return to normal price after this 12-month discount ends.
88936646|NCT01800591|Experimental|Immediate gratification|In addition to the standard enrollment, 6-month, and completion incentives, the subject will be told that they can weigh in again any time before the study ends when they think they have lost 5% of their initial body weight. If they did meet their 5% goal, they will begin receiving a bi-weekly premium discount during the next pay period for a total duration of 12 months. Subjects that do not meet the 5% cut off during a weigh in are allowed to re-weigh themselves as many times as they like although they are encouraged to do so when they think they have met their target weight. Their premium goes back to normal price after this 12-month discount ends.
88936647|NCT01800591|Experimental|Financial incentive with frequent feedback|In addition to the standard enrollment, 6-month, and completion incentives, the subject will be asked to weigh in on the IncentaHEALTH scales everyday they are at work. These subjects will participate in a daily lottery with the possibility of winning the same amount as the discount in Arms 2 and 3 over the course of the study. The subject can choose to select or be designated a two digit number that ranges from 00 to 99. Each day a lottery will be held and the subject will be given a 1% chance of matching both digits or an 18% chance of matching one digit. In order to get the lottery winnings, the subject must meet a weight goal that consistently decreases to accumulate to a 5% weight loss by the 6 month mark. After 6 months, the subject will receive the lottery winnings if they maintain that target weight (initial weight minus 5%) until the end of the 12-month study.
88936648|NCT01800604|Experimental|Pain Self-Management Arm #1|Pain Self-Management Intervention #1
89451865|NCT02737475|Experimental|Part 6: Dose Safety and Expansion|"BMS-986178/Ipilimumab/Nivolumab at specified doses at specified intervals~Enrollment is closed for this arm"
89451866|NCT02737475|Experimental|Part 7: Dose Safety and Expansion|"BMS-986178/Ipilimumab/Nivolumab at specified doses at specified intervals~Enrollment is closed for this arm"
88936649|NCT01800604|Experimental|Pain Self-Management Arm #2|Pain Self-Management Intervention #2
88936650|NCT01800604|Experimental|Pain Self-Management Arm #3|Pain Self-Management Intervention #3
88936651|NCT01800604|Experimental|Pain Self-Management Arm #4|Pain Self-Management Intervention #4
88936652|NCT01800617|Experimental|Liothyronine, Sodium|
88936653|NCT01800630|Experimental|Gemcitabine HCl Oral Formulation (D07001-F4)|Subjects will receive a single 5-mg (nontherapeutic) dose of gemcitabine (Gemzar®) via an IV push and then treated with Gemcitabine HCl Oral Formulation (D07001-F4)according to assigned cohort (2 mg to 80 mg) on Day 1, 3, 5, 8, 10, and 12 of 4 21-day cycles study treatment period.
88936654|NCT01800643|Other|Orally Busulfan PK|Evaluate the Pharmacokinetics of orally busulfan
89451867|NCT02737475|Experimental|Part 8: Dose Exploration|"BMS-986178/Nivolumab with tetanus vaccine at specified doses and interval~Enrollment is closed for this arm"
89451868|NCT02737475|Experimental|Part 9: Dose Exploration|"BMS-986178/Nivolumab/DPV-001 vaccine/cyclophosphamide (cohort 1) at specified doses at specified intervals OR Nivolumab/DPV-001 vaccine/cyclophosphamide (cohort 2) at specified doses at specified intervals~Enrollment is open for this arm [Tumor type triple negative breast cancer (TNBC)]"
89451869|NCT03265262|Experimental|Children receiving OFC during a diagnost|paediatric patients attending food allergy
89451870|NCT02459834|Experimental|Allulose + 75g OGTT|Allulose added to a 75 g OGTT of 500 mL at 2 doses (5g and 10g). The drinks will be matched as much as possible in appearance, taste (sweetness), texture, and packaging.
89451871|NCT02459834|Experimental|Fructose + 75g OGTT|Fructose added to a 75 g OGTT of 500 mL at 2 doses (5g and 10g). The drinks will be matched as much as possible in appearance, taste (sweetness), texture, and packaging.
88936655|NCT01800643|Other|Intravenously Busulfan PK|Evaluate the Pharmacokinetics of intravenously busulfan
88936656|NCT01800656|Experimental|Ligate and let go|"Subjects are submitted to endoloop-assisted ligate and let go colorectal polypectomy."
88936657|NCT01800656|Active Comparator|Snare polypectomy|Subjects are submitted to endoloop-assisted snare colorectal polypectomy
88936658|NCT01800682|Experimental|Tramodol Extended-release (ER), 25 milligram (mg)|Tramodol ER, 25 mg tablets will be administered orally once daily on Day 1 of each treatment period (separated with washout period of 4-14 days).
88936659|NCT01800682|Experimental|Tramodol ER, 50 mg|Tramodol ER, 50 mg tablets will be administered orally once daily on Day 1 of each treatment period (separated with washout period of 4-14 days).
88936660|NCT01800682|Experimental|Tramodol ER, 100 mg|Tramodol ER, 100 mg tablets will be administered orally once daily on Day 1 of each treatment period (separated with washout period of 4-14 days).
88936661|NCT01800695|Experimental|Arm A|ABT-414 in combination with radiation and temozolomide
88936662|NCT01800695|Experimental|Arm B|ABT-414 in combination with temozolomide
88936663|NCT01800695|Experimental|Arm C|ABT-414 monotherapy
89451872|NCT02459834|Active Comparator|75g OGTT (Control)|A 75 g OGTT (alone) of 500 mL will be given to each participant. The drinks will be matched as much as possible in appearance, taste (sweetness), texture, and packaging.
89451873|NCT05488834|Other|Intensive care units|The unit will be subject to the intervention. Data will be collected from all 8 units in the control phase of this study. Units will then be randomised in blocks to the intervention.
89451874|NCT03280706|Experimental|Maltodextrin|Fasted pregnant woman with an empty stomach (assessed by ultrasound) will drink 500ml of maltodextrin 200kcal, no protein or fat, 49,5g of carbohydrate.
89451875|NCT03280706|Active Comparator|Orange Juice|Fasted pregnant woman with an empty stomach (assessed by ultrasound) will drink 500ml of orange juice, 200kcal, 2,82g of protein, 0,67g of fat, 47,08g of carbohydrate.
88936664|NCT01800708|Active Comparator|Triamcinolone acetonide|The study group will receive an intraoperative intracameral injection of triamcinolone acetonide
89451876|NCT03280706|Active Comparator|Coffee with milk|Fasted pregnant woman with an empty stomach (assessed by ultrasound) will drink 500ml of coffee with milk, 200kcal, 10,6g of protein, 10,73g of fat, 14,9g of carbohydrate.
89451877|NCT05493592|No Intervention|Standardized physical activity protocol (EXA control group)|Physical activity protocol for 24 weeks. Protocol of dietetics and food hygiene for 24 weeks.
89451878|NCT05493592|Experimental|Standardized physical activity protocol associated with the consumption of Cajanus cajan (EXACAJAN)|The EXACAJAN protocol will be continued for 24 weeks. It will combine 3 times a week with 100 grams of pigeon peas in the diet. Protocol of dietetics and food hygiene for 24 weeks.
89451879|NCT02457806|Experimental|Kovacaine Mist|3 sprays of Kovacaine Mist (Tetracaine HCl 3% and Oxymetazoline HCl 0.05%) in each nostril (bilateral dosing) administered 4 minutes apart
89451880|NCT02457806|Active Comparator|Kovacaine Mist and Placebo|3 sprays of Kovacaine Mist (Tetracaine HCl 3% and Oxymetazoline HCl 0.05%) in the right nostril and three sprays of placebo in the left nostril (right-sided unilateral dosing) administered 4 minutes apart
89451881|NCT02457806|Active Comparator|Placebo and Kovacaine Mist|3 sprays of Kovacaine Mist (Tetracaine HCl 3% and Oxymetazoline HCl 0.05%) in the left nostril and 3 sprays of placebo in the right nostril (left-sided dosing) administered 4 minutes apart
89451882|NCT02457806|Placebo Comparator|Placebo spray|3 sprays of placebo in each nostril administered 4 minutes apart
89451883|NCT05493514||People with neurological disease according to inclusion criteria|People with neurological disease (Multiple Sclerosis, Parkinson Disease, Stroke and acquired brain injuries) will be recruited according to inclusion and exclusion criteria.
88936665|NCT01800708|Active Comparator|Prednisolone syrup|The control group will receive prednisolone syrup postoperatively
88936666|NCT01800721|Experimental|Experimental Condition SNAP|"Behavioral Intervention SNAP HIV training and peer outreach~Participants learn skills for sexual health and peer outreach which includes talking with network members about HIV testing and prevention."
88936667|NCT01800721|Active Comparator|SNAP Control Condition|"SNAP Control~Participants receive information on HIV/STDs as well as healthy eating and nutrition instruction."
88936668|NCT01800734|Other|Clamp-Mixed Meal Arm|Twenty adults patients with type 1 diabetes, regularly attending the Division of Endocrinology and Metabolic Diseases of University of Verona School of Medicine, using continuous subcutaneous fast insulin analogue infusion (CSII) through a permanent pump and on subcutaneous glucose sensing will be enrolled.
88936669|NCT01800747|Active Comparator|Direct antibiotic treatment|The doctor gives to parents an antibiotic prescription for their son's respiratory infection which he should start immediately.
88936670|NCT01800747|No Intervention|No antibiotic treatment|The doctor does not give to parents an antibiotic prescription for their son's respiratory infection.
88936671|NCT01800747|Experimental|Delayed antibiotic prescription|The doctor gives to parents an antibiotic prescription for their son's respiratory infection with the advice to use it if needed, in case of worsening of symptoms or not improve.
89451884|NCT02457572||Valsalva maneuver|This is an observational study and as a diagnostic intervention, subjects in the study would receive valsalva maneuver. Valsalva maneuver was performed after sternotomy with the constant airway pressure of 30cmH2O for 2 breaths duration. The investigators perform this procedure to every patients and do not assign this intervention to the subjects of the study.
89451885|NCT02459756|Active Comparator|Intervention|Spray dried blackcurrant powder dissolved in water
89451886|NCT02459756|Placebo Comparator|Placebo|(sucrose, glucose, fructose, maltodextrin, malic acid, citric acid, vitamin C, artificial blackcurrant flavouring and low-nitrate water)
89501739|NCT04579393|Active Comparator|Intervention|fostamatinib in combination with standard of care (SOC) for the treatment of COVID-19
89501740|NCT04579393|Placebo Comparator|Intervention - Placebo|Placebo in combination with standard of care (SOC) for the treatment of COVID-19
89501741|NCT04811001|Experimental|Arm A (Osimertinib->Dacomitinib)|"Osimertinib 80 mg/day until progression, unacceptable toxicity or patient refusal.~At treatment discontinuation patients maintaining the original EGFR mutation will switch to Dacomitinib 45 mg/day until progression, unacceptable toxicity or patient refusal."
89537141|NCT05263869|Experimental|MRG002|MRG002 will be administrated via intravenous infusion of 2.6 mg/kg once on Day 1 of every 3 weeks (21-day cycle).
89451887|NCT02557672|Active Comparator|Fresh frozen plasma|After cardiopulmonary bypass, patients will receive protamine at dose 0.01 mg/unit of heparin given with target activated clotting time (ACT) within 10% of baseline value. After protamine administration the ACT, complete blood count (CBC), prothrombin time (PT)/ international normalized ratio (INR), activated partial thromboplastin time (APTT), and fibrinogen, will be collected via preexisting arterial access. If ACT >10% baseline additional protamine will be given at the anesthesiologists discretion. Evaluation and determination of excessive microvascular bleeding in the surgical field will occur 10 minutes after return of ACT to within 10% of baseline. Patients with clinical evidence of excessive microvascular bleeding in the surgical field as determined by the surgical team, along with a PT >16.6 sec/ INR >1.6 sec will receive fresh frozen plasma as this is standard therapy per our institutional algorithm at a dose of 10-15 mL/kg rounded up to the nearest unit.
89451888|NCT02557672|Experimental|Prothrombin complex concentrate|After cardiopulmonary bypass, patients will receive protamine at dose 0.01 mg/unit of heparin given with target ACT within 10% of baseline value. After protamine administration the ACT, CBC, PT/ INR, APTT, and fibrinogen, will be collected via preexisting arterial access. If ACT >10% baseline additional protamine will be given at the anesthesiologists discretion. Evaluation and determination of excessive microvascular bleeding in the surgical field will occur 10 minutes after return of ACT to within 10% of baseline. Patients with clinical evidence of excessive microvascular bleeding in the surgical field as determined by the surgical team, along with a PT >16.6 sec/ INR >1.6 sec will receive Prothrombin complex concentrate (Human) 15 units/kg.
89451889|NCT02459678|Other|Standard of Care|The MOH-recommended approach is opt out HIV testing in pregnancy followed by immediate initiation of ART for HIV-infected pregnant women. ART initiation is accompanied with counseling geared to educate and prepare women to take up and be retained on ART lifelong. Women who do not return for clinical or drug refill visits are traced by phone or in person.
89451890|NCT02459678|Experimental|Enhanced adherence package|The enhanced adherence package will be designed on the basis of the results of formative research. The intervention will support women who are eligible for ART under Option B+.
89451891|NCT03280472|Experimental|Cognitive Bias Modification|Participants will complete three session of cognitive bias modification.
89451892|NCT03280472|Other|Symptom Tracking|Participants will track their symptoms.
89451893|NCT03267602|Experimental|Continuous Positive Airway Pressure (CPAP) Therapy|
89451894|NCT03267446|Experimental|Interventional group|Patients confirmed having one or more of the signs of morbidly adherent placenta will be examined by 3D Ultrasound and 3D power Doppler. Patients will then be prepared for the operation.Cesarean hysterectomy will be done with removal of the uterus and the placenta as one mass.Cases with focal invasion of the uterus will be given a trial for conservative management. The whole specimen will be sent for histopathological examination, and the determination of length and depth of invasion.
89451895|NCT02458196|Experimental|Prednisone|Prednisone: started with prednisone 0. 6-0. 8mg/kg.d for 1 month, decreased 5mg per 2 weeks, maintained at 7.5mg to 10mg/d to 12 months.
89451896|NCT02458196|Experimental|Prednisone and Mycophenolate mofetil|"Prednisone: started with prednisone 0. 6-0. 8mg/kg.d for 1 month, decreased 5mg per 2 weeks, maintained at 7.5mg to 10mg/d to 12 months.~Immunosuppressive drugs: Mycophenolate mofetil 1g/d-1.5g/d for 6 months and 0.5/d-1.0g/d for 6 months."
89451897|NCT02502071|Experimental|Sodium Bicarbonate|All participants will receive 2 doses of 1950mg Sodium Bicarbonate
89451898|NCT03265184|Experimental|intervention group|400 mg green coffee extract capsules twice per day for 8 weeks The Green coffee extract is standardised with 45% total chlorogenic acid by HPLC
89451899|NCT03265184|Placebo Comparator|placebo group|placebo capsules twice per day for 8 weeks have identical appearance to Green coffee extract capsules and contain starch
88936672|NCT01800773|Experimental|Written Exposure Therapy|Written exposure treatment is a 5 session treatment in which participants write about their trauma event in a specified manner.
88936673|NCT01800773|Active Comparator|Cognitive Processing Therapy|cognitive processing therapy will be included as the evidence-based treatment for PTSD in this study.
88936674|NCT01800799|Experimental|UTI (WBC>10 per high power field)|"Antimicrobial agent (Baktar 800mg h.s.)~Anti-inflammatory agent (Celecoxib 200mg QD)"
88936675|NCT01800799|Experimental|Recurrent UTI|"Antimicrobial agent (Baktar 800mg h.s.)~Anti-inflammatory agent (Celecoxib 200mg QD)"
88936676|NCT01800799|No Intervention|Normal control|Normal control
88936677|NCT01800825|Active Comparator|Clindamycin|Clindamycin 300mg orally twice daily for five days
88936678|NCT01800825|Placebo Comparator|placebo|This will be an identical placebot
89206143|NCT00298363|Experimental|FTC/TDF|FTC 200 mg/TDF 300 mg + TDF placebo + ETV placebo QD
89451900|NCT05207735|Experimental|GROUP 1|"Sintilizumab, 200 mg, intravenous infusion, a treatment cycle every 3 weeks, administration on the first day of each cycle, 6 cycles.~Capecitabine: 1250 mg/m2, orally, twice a day, 1-14 days, one treatment cycle every three weeks, 8 cycles."
88936679|NCT01800851|Experimental|no weight gain|The characteristics of the renal transplant patients are compared with those of 10 healthy volunteers matched for age and lean body mass
88936680|NCT01800851|Experimental|weight gain|The characteristics of the renal transplant patients are compared with those of 10 healthy volunteers matched for age and lean body mass
88936681|NCT01800851|Other|lean body mass|The characteristics of the renal transplant patients are compared with those of 10 healthy volunteers matched for age and lean body mass
88936682|NCT01800864|Other|Normal|Normal weight subjects
88936683|NCT01800864|Other|Over weight /obese subjects|Overweight and obese subjects
88936684|NCT01800929|Experimental|N6|The N6 system comprises an investigational sound processor, remote assistant and fitting software
88936685|NCT01800929|Active Comparator|N5|The current commercially-available cochlear implant system Performance of N5 will be compared to performance with N6 using a within-subject design.
88936686|NCT01800942|Placebo Comparator|Placebo|"830 women will be recruited into the study and randomised in a ratio of 1:1 per study arm to receive either Azithromycin or placebo.~A single dose of Azithromycin 2g or Placebo will be given orally to pregnant women in labour."
88936687|NCT01800942|Experimental|Azithromycin|"830 women will be recruited into the study and randomised in a ratio of 1:1 per study arm to receive either Azithromycin or placebo.~A single dose of Azithromycin 2g or Placebo will be given orally to pregnant women in labour."
88936688|NCT01800955|Experimental|resistive capacitive diathermy|in the resistive capacitive diathermy protocol patients are administered the resistive capacitive diathermy treatment for a thirty minutes session, three times per week for a total of ten sessions
88936689|NCT01800955|Sham Comparator|sham placebo group|"The sham treatment is administered with the resistive capacitive diathermy device set on on but not active (not supplying energy) with the same type of application, the same frequency and duration of experimental diathermy group"
88936690|NCT01800981||Debrase|Patients previously treated with Debrase for burn debridement
88936691|NCT01800981||Standard of Care|Patients previously treated with local Standard of Care for burn debridement
88936692|NCT01800994||asthma, COPD|patients with asthma and COPD treated with inhalation devices
88936693|NCT01801020|Experimental|temperature measuremts|A temporal artery measurement will be taken from two points a strait line across the forehead and an additional measurement behind the earlobe. In addition tympanic temperature will be measured.
88936694|NCT01801046|Experimental|Treatment (chemotherapy, G-PBSC)|INDUCTION CHEMOTHERAPY: Patients receive mitoxantrone hydrochloride IV on days 1-3 and cytarabine IV on days 1-7. HMMACT: Patients receive G-PBSC on day 9.
88936695|NCT01801059|Active Comparator|Arm I education CRC and CRC screening|Educational intervention: Patients receive CRC and CRC screening information from an educational video and received a brochure focused on healthy hints to prevent CRC. Questionnaire administration prior to and after the intervention.
89200968|NCT04034979|Experimental|Phase III- Impact of the decision aid and the|This phase will be an evaluation of the decision making process about goals-of-care in the same local ICU setting after intensivists complete the training program and using the DA. A PhD student will collect sociodemographic data (age, gender, education level, religion), observe and video record (or audio record) new dyads of physicians and newly admitted elderly patients discussing goals-of-care using the context-adapted decision aid and the new skills learned in the training program.
89200969|NCT00905853|Active Comparator|Ventricular Tachycardia Ablation|Catheter ablation for Ventricular tachycardia will be performed within 14 days of randomization.
89451901|NCT03264950|Other|SIngle Arm|All patients undergo Elastography. This is a single arm study
89451902|NCT03264638|Experimental|Dingkundan|Dingkundan 7g capsule by mouth, twice daily, beginning on Day 5 of menstrual cycle for 21 consecutive days followed by a 7-day interval without medication; for three cycles
89451903|NCT03264638|Experimental|Dingkundan & Diane-35|Dingkundan 7g capsule by mouth, twice daily, and Diane-35 one pill by mouth, once daily, beginning on Day 5 of menstrual cycle for 21 consecutive days followed by a 7-day interval without medication; for three cycles
89451904|NCT03264638|Active Comparator|Diane-35|Diane-35 one pill by mouth,once daily, beginning on Day 5 of menstrual cycle for 21 consecutive days followed by a 7-day interval without medication; for three cycles
89451905|NCT05741801||health care professionals|Hospital healthcare professionals who use, or help implement, deteriorating patient/sepsis alerts in NHS trusts.
89451906|NCT05741801||ex-patients/survivors and family members/carers|Ex-patients recruited from NHS trusts and other charities, who have previously had sepsis or family members of patients who have had sepsis.
88936696|NCT01801059|Experimental|Arm II education and patient activation intervention|Educational intervention administered: Patients receive patient activation intervention comprising CRC and CRC screening information and communication skills training intervention by educational video and brochure, and they also receive a brochure focused on healthy hints to prevent CRC. Questionnaire administration prior to and after the intervention.
88936697|NCT01801085||FOLFOX4|Leucovorin 200 mg/m2 iv over 2 hrs before 5-FU, d1 and 2 5-FU 400 mg/m2 iv bolus and then 600 mg/m2 iv over 22 hrs, d 1 and d2 Oxaliplatin (Eloxatin) 85 mg/m2 iv d1 Q2w x 12 cycles
88936698|NCT01801085||XELOX|Capecitabine (Xeloda) 1000 mg/m2 po bid x 14 days Oxaliplatin (Eloxatin) 130 mg/m2 iv over 2 hrs d1 Q3w x 8 cycles
88936699|NCT01801137|Experimental|Afinitor|Treatment by Afinitor 10 mg per day
88936700|NCT01801150|No Intervention|lifestyle and diabetes treatment|Counseil about lifestyle and current diabetes treatment
88936701|NCT01801150|Experimental|CPAP nasal treatment|Continuous positive airway pressure (CPAP) nasal during the night and current diabetes treatment. Device
88936702|NCT01801163|Experimental|Sorafenib plus Stereotactic Radiotherapy|Single agent Sorafenib x 2 weeks followed by Stereotactic Radiotherapy, then Sorafenib until disease progression.
88936703|NCT01801176|Experimental|Initial monitoring group|
88936704|NCT01801202|Experimental|Hair removal|hair removal treatment using 805nm LightSheer Duet HS handpiece
88936705|NCT01801228|Experimental|Eplerenone|oral daily treatment with doses 100 to 400 mg
88936706|NCT01801228|Active Comparator|Spironolactone|oral daily treatment with doses 100 to 400 mg
88936707|NCT01801254|Experimental|STRIDES|Brain-computer interface training protocol designed to up-regulate specific types of neural activity in regions including the left dorsolateral prefrontal cortex, the anterior cingulate cortex, and Brodmann area 6 bilaterally. Targeted neural activity types are positively associated with self-controlled behavior.
88936708|NCT01801254|Sham Comparator|Sham Control|Brain-computer interface training protocol that is designed to have no effect on self-controlled behavior. Stimuli used and durations of training sessions for this protocol are identical to those used in the treatment condition.
88936709|NCT01801267|Experimental|Endoscopic third ventriculostomy (ETV)|Pediatric patients in need of CSF-diversion surgery will undergo an endoscopic third ventriculostomy (ETV).
88936710|NCT01801267|Active Comparator|Ventricular shunt|Pediatric patients in need of CSF-diversion surgery will undergo ventricular shunt placement or revision.
88936711|NCT01801293|Experimental|Intervention Arm|One-time single dose of 50 mg radiolabeled GS-5806 administered orally in 3 capsules in the morning.
88936712|NCT01801306|Other|NeMoProbe|The NeMo System is used for intracranial pressure (ICP) and brain temperature monitoring, as well as the determination of the brain tissue oxygenation saturation (SbtO2) and cerebral blood flow. The sensors for NIRS are implemented into a conventional brain tissue probe for ICP monitoring (NeMo Probe).
88936713|NCT01801319|Active Comparator|Stimulation|Libra Deep Brain Stimulation System is implanted and activated post implantation
88936714|NCT01801319|Sham Comparator|No Stimulation|The Libra DBS System is implanted and not activated
88936715|NCT01801332|Experimental|intensive arm|Corticosteroïds (Methylprednisolone 32 mg/d) for 28 days + intensive enteral nutrition by feeding tube for 14 days
88936716|NCT01801332|Active Comparator|control arm|"Corticosteroïds (Methylprednisolone 32 mg/d) for 28 days +  classical  oral alimentation for 14 days"
88936717|NCT01801345|Other|Rested|Subjects will perform the scenario, once during a normal workday (rested)
88936718|NCT01801345|Active Comparator|Fatigued|Subjects will perform the scenario after working a 12-24 hour overnight shift (fatigued).
88936719|NCT01801371|Experimental|68Ga-BNOTA-PRGD2|In patients in suspicion of glioma, single bolus of nearly 111 MBq 68Ga-BNOTA-PRGD2 will be intravenously injected 30 minutes before brain PET/CT to determine 68Ga-BNOTA-PRGD2 uptake in tumor and brain.
89200970|NCT00905853|Active Comparator|Escalated Antiarrhythmic Drug Therapy|Patients are prescribed a loading dose of amiodarone or the addition of mexiletine to their current anti-arrhythmic medication which is stratified by the dose and type of antiarrhymic medication at the time of the index arrhythmic event.
89200971|NCT00905931|Experimental|Active|
89200972|NCT00905931|Placebo Comparator|Placebo|
89200973|NCT02540187||haemophilia A|"Blood specimen for measuring :~Free TFPI and TFPI activity levels~Thrombin generation in platelet rich plasma (PRP) and platelet poor plasma (PPP)~Thrombin generation assay (TGA) in fresh PRP and frozen PPP~Hemorrhage score for each patient"
89537142|NCT03299621|Experimental|PLE (Phase Lag Entropy) monitoring|Investigators monitor the change of PLE value using the sensor of PLEM™ during propofol anesthesia.
89451907|NCT02714426|Active Comparator|Brain Health|In weeks 1 and 14, participants receive: Montreal Cognitive Assessment (MoCA), Wechsler Test of Adult Reading (WTAR), Functional Activities Questionnaire (FAQ), Older Americans Resources and Services (OARS) Complete Activities of Daily Living Scale, The Short Form (36) Health Survey (SF-36), Attention measures (Attention Network Test (ANT); Continuous Performance Test (CPT); Auditory Dual Task (ADT); Mind wandering; Cued Stroop), Positive and Negative Affect Scale (PANAS), Geriatric Depression Scale (GDS), Mindfulness Attention Awareness Scale (MAAS), Five Facet Mindfulness Questionnaire (FFMQ), Emotion Regulation Questionnaire (ERQ), State-Trait Anxiety Inventory (STAI), and Starkstein Apathy Scale (AS). In weeks 4-11, participants receive the Brain Health control instruction.
89451908|NCT02714426|Experimental|Mindfulness-inspired Treatment/Testing|"Participants receive all of the same measures as the active comparator Brain Health condition in Weeks 1-14. In weeks 4-11, participants receive Mindfulness Inspired Treatment"
89451909|NCT04500821|Experimental|Activator LFD-2100|LipiFlow treatment with the Activators LFD-2100 will be performed on both eyes with MGD
89451910|NCT03264794|Experimental|trial group|Gefitinib tablets (CTTQ），First medication.From the 8th day of the experiment, treated with Gefitinib Tab（CTTQ）
89451911|NCT03264794|Active Comparator|control group|Gefitinib tablets (Yi Ruisha），First medication.From the 8th day of the experiment, treated with Gefitinib Tab（CTTQ）
89451912|NCT02925923|Active Comparator|Ticagrelor|crushed ticagrelor (180 mg); (n=50 patients)
89451913|NCT02925923|Active Comparator|Eptifibatide bolus+clopidogrel|Eptifibatide bolus (180 mcg/kg x 2 boluses) + clopidogrel 600 mg and heparin low-dose (n=50 patients)
89451914|NCT02459366||control|establish the reliability of measurement of lumbopelvic asymmetry, mechanical and physical properties of thoracolumbar fascia, and the norm of different age
89451915|NCT02459366||low back pain|compare the differences among asymptomatic subjects and patients with and without lumbopelvic asymmetry, and investigate whether lumbopelvic symmetry, core muscle contractility, proprioception and standing balance change after manipulating thoracolumbar fascia tissue by physical therapy
88936720|NCT01801397|Other|Teriparatide|one arm study. All patients receive teriparatide
89206144|NCT00298363|Experimental|Entecavir|ETV 0.5 mg or 1 mg + TDF placebo + FTC/TDF placebo QD
89451916|NCT03267368|Experimental|Comprehensive Care Program|Pulmonary rehab and smoking cessation program/intervention/assessment
89451917|NCT03267290|Experimental|Sonazoid- CEUS+CEMRI or CECT+CEMRI|Comparing Diagnostic Accuracy for Liver Tumours Between the Combination of CEUS and CEMRI Versus CECT and CEMRI
89451918|NCT03280316|Experimental|patients with SVMs undergoing SNM|patients with SVMs are of consistent OAB (Overactive Bladder) after surgery and undergo sacral neuromodulation (SNM)
89451919|NCT03280316|Experimental|patients with SVMs receiving BTXA|patients with SVMs are of consistent OAB after surgery and accept botulinum toxin A (BTXA) injection
89451920|NCT03280316|Experimental|patients with SVMs receiving drug|patients with SVMs are of consistent OAB (Overactive Bladder) after surgery and accept M receptor antagonist
89451921|NCT02410343|Placebo Comparator|Placebo|Placebo was injected subcutaneously once weekly on the same day and time for 24 weeks. To maintain the blind, placebo could be titrated by an unblinded central reader on weeks 4, 8, 12 and 16 to match the effect of dose titration.
89451922|NCT02410343|Experimental|TV-1106|TV-1106 was injected subcutaneously once weekly on the same day and time for 24 weeks. A common starting dose was 5.0 mg. Doses could be titrated by an unblinded central reader on weeks 4, 8, 12 and 16 until the participant's insulin-like growth factor 1 (IGF-1) standard deviation score (SDS) was within the range of -0.5 to +1.5.
89451923|NCT03267056||DCB arm|drug eluting balloon catheter
89451924|NCT03264872|Experimental|Peer-Enhanced Motivational Interviewing|Both dyad members, the target client and their peer support person, in this Peer-Enhanced Motivational Interviewing arm will receive separate one-hour Motivational Interviewing (MI) sessions with a trained counselor.
89451925|NCT03264872|Other|Waitlist Control|Delayed Treatment.
88936721|NCT01801410|Active Comparator|Misoprostol|Group 2 will be induced using oral misoprostol tablets (25 mcg) every 2 hours for a maximum of 12 doses or until active labour commences. In primigravid women, if contractions have not commenced after 2 doses, the dosage may be increased to 50mcg every 2 hours. Once in labour (regular painful contractions with a cervical dilatation of at least 4cm) no more misoprostol will be used and artificial membrane rupture and/or oxytocin infusion will be used as clinically indicated. If labour has still not commenced after 24 hours, they will be deemed to have a 'failed induction' and the decision on further management will be made by the clinical team (their choice could include the use of repeat misoprostol, Foley catheter, dinoprostone, caesarean section or delay as deemed appropriate).
88936722|NCT01801410|Active Comparator|Foley Catheter|Group 1 will undergo induction using a transcervical Foley catheter (silicone, size 18F with 30ml balloon) which will remain until active labour starts, the Foley catheter falls out, or 12 hours have elapsed. If the Foley catheter falls out within 12h, membranes will be ruptured and/or oxytocin infusion started. If the Foley catheter does not fall out within 12h, it will be removed at 12h and oxytocin commenced with an artificial rupture of membrane when possible. If labour has still not commenced after 24 hours, they will be deemed to have a 'failed induction' and the decision on further management will be made by the clinical team (their choice could include the use of misoprostol, repeat Foley catheter, dinoprostone, caesarean section or delay as deemed appropriate).
88936723|NCT01801423|Experimental|Hydroxyurea|Study investigators propose to enroll 60 children with SCA and an elevated TCD measurement between 5 and 12 years of age in this one arm feasibility study of hydroxyurea therapy, with follow-up of at least 12 months per subject. The study intervention will include HU to begin at ~ 20 mg/kg/day(range 17.5 - 26 mg/kg/day). No dose escalation will occur. Given the success of the first year of enrollment and the favorable response of TCD measurement after 3 months on HU therapy, the study investigators have participants as an internal pilot. The definitive phase III trial will now compare low dose HU therapy to the result of no treatment arm from the STOP Trial.
89200974|NCT02540187||Haemophilia B|"Blood specimen for measuring :~Free TFPI and TFPI activity levels~Thrombin generation in platelet rich plasma (PRP) and platelet poor plasma (PPP)~Thrombin generation assay (TGA) in fresh PRP and frozen PPP~Hemorrhage score for each patient"
89206145|NCT00821262|Experimental|sevoflurane|The study group will receive Sevoflurane for a 4-6 hours period (from anesthesia induction to transfer to ICU).
89451926|NCT03264716|Experimental|HepaSphere TACE (transarterial chemoembolization)|Using HepaSphere TACE (transarterial chemoembolization) for colorectal liver metastasis. TACE using HepaSphere load with doxorubicin.
89451927|NCT03064841||Outpatient with confirmed T2DM|subjects with confirmed T2DM
89451928|NCT02457416|Active Comparator|Peanut oral immunotherapy|Oral immunotherapy with peanut
89451929|NCT02457416|No Intervention|Controls|Avoid peanut exposure
89451930|NCT03280238|Experimental|Experiment|"Individualized painful electrical stimuli, Surpass LT stimulator (EMS Biomedical, Korneuburg, Austria) with a bipolar felt pad electrode~Measurement of pupil diameter, Algiscan® (iDMed, Marseille, France)~Measurement of Analgesia Nociception Index, PhysioDoloris® (MetroDoloris, Lille, France)"
89451931|NCT03280082|Other|MUAC Program|"At the CRENAS, MUAC as unique anthropometric criteria for admission, monitoring, and care for the SAM output will be used.~The criteria for admission include:~MUAC <120 mm~Bilateral edema of grade + or ++~The criteria for release of care include:~MUAC ≥ 125 mm at 2 consecutive visits~Minimum stay 3 weeks in the program~Absence of acute medical complications~Absence of edema"
89451932|NCT03280082|Other|Standard Program|"Regular screenings in the communities on children between 6 and 59 months of age. Children with MUAC<125 mm will be referred to Nutrition Centers for admission.~The criteria for admission include:~MUAC<115 mm and/or~Z score <-3 and /or~Bilateral edema of grade + or ++~The criteria for release of care include:~MUAC ≥ 125 mm at 2 consecutive visits~Minimum stay 3 weeks in the program~Absence of acute medical complications~Absence of edema"
89451933|NCT02045303|Experimental|Ambulatory Wound Clinic|Intervention with contact ultrasound therapy and noncontact ultrasound therapy following the study protocol on subjects receiving care at the wound clinic.
89451934|NCT05234840|Active Comparator|Triamcinolone group|Patients were placed in the prone position. Transforaminal triamcinolone injections were performed under a C-arm fluoroscopy.
89451935|NCT05234840|Experimental|Platelet-rich plasma|Patients were placed in the prone position. Transforaminal PRPinjections were performed under a C-arm fluoroscopy.
89451936|NCT03264482|Active Comparator|THUVAP|thulium vaporization
89451937|NCT03264482|Active Comparator|M-TURP|monopolar transurethral resection
89451938|NCT03266744|Other|Main study group|"Patients will have repeat CT (Computerised Tomography) scans and WB-MRI (Whole Body Magnetic Resonance Imaging) every 12 weeks until disease progression. A baseline bone scan (99mTc-MDP) will be performed.~At the point of disease progression, a repeat bone scan will be obtained in addition to the CT and WB-MRI."
89451939|NCT03266744|Other|WB-MRI sub-study group|Patients will be given the opportunity to participate in a sub-study of WB-MRI reproducibility. This involves a repeat scan of the Whole Body Magnetic Resonance Imaging (WB-MRI) diffusion-weighted sequences. This will be shorter in duration than the full WB-MRI scan and will take place within one hour of completing the full WB-MRI scan.
89451940|NCT05740163|Experimental|Egg allergy with asthma with intervention|Immunotherapy Egg product including egg white and yolk allergens
88936724|NCT01801462|Experimental|Simulation-based ultrasound training|The initial training is provided on a high-fidelity Virtual-Reality (VR) simulator (Scantrainer, Medaphor). The VR simulator provides images obtained from real patients and haptic feedback from the ultrasound probe. The basic gynecologic and advanced gynecologic modules are selected for training purposes. When all modules are passed on the VR simulator, the participants receive 30 minutes of training on the low-fidelity simulator (BluePhantom) to allow participants to review the functions, they just trained, using real ultrasound equipment.
88936725|NCT01801462|No Intervention|Control|Participants randomized to the control group receive traditional clinical introduction locally in the departments. This may include observation and supervised practice and the different types of clinical training provided by each department are gathered through the department's head of education and registered.
88936726|NCT01801488||AVM Patients|Patients receiving surgical intervention for an intracranial arterial-venous malformation.
88936727|NCT01801488||Ruptured Aneurysm|Patients receiving surgical intervention for a ruptured intracranial aneurysm.
88936728|NCT01801488||Unruptured Aneurysm|Patients receiving surgical intervention for an unruptured intracranial aneurysm.
88936729|NCT01801501||Critical Care Patients|Patients admitted in Critical Care Unit with diagnosis of severe sepsis/septic shock
88936730|NCT01801527|Experimental|Telerehabilitation group|
88936731|NCT01801527|No Intervention|Control group|Information about usual care
88936732|NCT01801540|Experimental|0% arabinose meal sucrose/starch|A meal containing a bon with butter and marmalade, a cup cake, The and water
88936733|NCT01801540|Other|5 % arabinose meal sucrose/starch|A meal containing a bon with butter and marmalade, a cup cake, The and water
88936734|NCT01801540|Other|10 % arabinose meal sucrose/starch|A meal containing a bon with butter and marmalade, a cup cake, The and water
88936735|NCT01801540|Other|0 % arabinose meal Starch|A meal containing two bons with butter and cheese, The and water
88936736|NCT01801540|Other|5 % arabinose meal starch|A meal containing two bons with butter and cheese, The and water
88936737|NCT01801540|Other|10 % arabinose meal starch|A meal containing two bons with butter and cheese, The and water
88936738|NCT01801553|Active Comparator|spinal manipulation intervention group|Spinal manipulation: 3 sessions within one week of true lumbopelvic manipulation
88936739|NCT01801553|Sham Comparator|Spinal manipulation control group|Sham spinal manipulation: 3 sessions within one week of sham lumbopelvic manipulation
88936740|NCT01801566|Active Comparator|Conventional implant loading protocol|Single implant-retained mandibular overdenture
88936741|NCT01801566|Experimental|Immediate loading implant protocol|Single implant-retained mandibular overdenture
89451941|NCT05740163|Experimental|Egg allergy without asthma with intervention|Immunotherapy Egg product including egg white and yolk allergens
89451942|NCT05740163|No Intervention|Egg allergy with asthma without intervention|No intervention, control
89451943|NCT05740163|No Intervention|Egg allergy without asthma without intervention|No intervention, control
89451944|NCT03266822||Healthy control|
89451945|NCT03266822||RA patients on anti-TNF therapy|
89451946|NCT03266822||RA patients on anti-IL-6R therapy|
89451947|NCT03280004||Moxifloxacin group|
89451948|NCT03280004||β-lactams group|
89451949|NCT03279068||Without Pattern Interpretation|All women who are admitted for labor at Ayder Referral Hospital in Mekelle, Ethiopia will be asked to participate and a physician will obtain consent. If an indication arises and they are designated to receive EFM per previously established standard practice at Ayder Hospital, then their patient information will be collected. Patients who require EFM will be asked to provide basic health and demographic information, along with collection of information on labor and delivery course, post-partum outcome, and neonatal outcomes. The investigators estimate enrollment of up to 1800 patients which will result in at least 300 patients who will require EFM.
89501742|NCT04811001|Experimental|Arm B (Dacomitinib->Osimertinib)|"Dacomitinib 45 mg/day until progression, unacceptable toxicity or patient refusal.~At treatment discontinuation, patients harboring the EGFR-T790M will receive Osimertinib 80 mg/day until progression, unacceptable toxicity or patient refusal."
89015149|NCT00258050|Experimental|Subjects with cancer|"In Part 1 of the study, subjects will be randomized to one of four sequences. All subjects will receive oral or intravenous (IV) midazolam on Days 1, 3, 9 and 11 as per assigned randomization scheme. Starting on Day 4 through Day 11, subjects will receive a daily dose of 1500 milligrams (mg) of oral lapatinib.~In Part 2, which will begin on Day 12, the subjects will be required to take 1500 mg of lapatinib daily until removed from the study for disease progression, adverse events, withdrawal of consent, or transfer to another lapatinib study."
89015150|NCT01603888||healthy newborns, BNP, NT-proBNP|healthy newborns
89015151|NCT01603888||infants, BNP, NT-proBNP|infants
89015152|NCT01603888||children with heart disease, BNP, NT-proBNP|children with heart disease
89015153|NCT00271401|Experimental|Angioplasty With Abciximab Plus Low-Dose Heparin|Participants will receive conventional angioplasty/atherectomy along with bolus abciximab 0.25 milligram per kilogram (mg/kg) of body weight followed by a 0.125 microgram per kilogram per minute (mcg/kg/minute) infusion for 12 hours plus 7 unit per kilogram per hour (U/kg/hr) continuous infusion of heparin.
89015154|NCT00271401|Experimental|Intracoronary Stent With Reo Pro Plus Low Dose Heparin|Participants will receive intracoronary stent along with receive bolus abciximab 0.25 mg/kg of body weight followed by a 0.125 mcg/kg/minute infusion for 12 hours plus 7 U/kg/hr continuous infusion of heparin (low dose).
89015155|NCT00271401|Placebo Comparator|Intracoronary Stent With Placebo Plus Standard Dose Heparin|Participants will receive intracoronary stent along with bolus placebo followed by placebo infusion for 12 hours plus 10 U/kg/hr continuous infusion of heparin (standard dose).
89015156|NCT01604005|Experimental|PIT Arm|
89015157|NCT01604005|No Intervention|No PIT Arm|
89451950|NCT03279068||With Pattern Interpretation|"All women who are admitted for labor at Ayder Referral Hospital in Mekelle, Ethiopia will be asked to participate and a physician will obtain consent. If an indication arises and they are designated to receive EFM per previously established standard practice at Ayder Hospital, then their patient information will be collected.~Their labor will be managed as in Phase 1 except that EFM will be interpreted and managed as per ACOG/FIGO guidelines using paper on which fetal heart tracings will be recorded. All other aspects of their care will proceed as per standard at Ayder Referral Hospital.~Patients who require EFM will be asked to provide basic health and demographic information, along with collection of information on labor and delivery course, post-partum outcome, and neonatal outcomes. The investigators estimate enrollment of up to 1800 patients which will result in at least 300 patients who will require EFM."
89451951|NCT03628937|Experimental|Intervention group|"Interventions: Decaffeinated green tea polyphenol capsule (400 mg, EGCG accounted for 50%) will be given to participants in intervention group, and they need take it once a day after breakfast for 12 weeks.~Decaffeinated green tea polyphenol: 400mg/capsule, 1 capsule/d, qd, 12 weeks"
89015158|NCT01604044|Active Comparator|HP-hMG|
89451952|NCT03628937|Placebo Comparator|Control group|The placebo control group will be given placebo capsules, and participants need take it once a day after breakfast for 12 weeks.
89451953|NCT03266666|Other|Intervention Arm - WellnessRX|This is a longitudinal outcome study. All participants will receive the class and grocery credit intervention.
89451954|NCT01950377||Healthy Adults|Healthy adults healthy adults - male and female
89451955|NCT03266510|Experimental|Inspiratory muscle strength training|Using a handheld device, subjects were perform 30 breaths a day, six days a week. The device produces resistance that increases the effort of breathing in. The resistance to breathing will be strong.
89451956|NCT03266510|Sham Comparator|Sham training|Using a handheld device, subjects were perform 30 breaths a day, six days a week. The device produces resistance that increases the effort of breathing in. The resistance to breathing will be weak.
89451957|NCT05214521|Experimental|"digital interactive technology Smart glove SensoRehab"|"The operation of the digital interactive complex Smart glove SensoRehab is based on the visual and kinesthetic (proprioceptive) biofeedback principle by using a set of cognitive interactive computer games controlled by finger and hand movements. The technique involves neurosensory training and retraining to improve the fine use of the hand and arm, and the patient's cognitive and emotional state."
89015159|NCT01604044|Active Comparator|rFSH plus rLH|
89015160|NCT01604161||Somatropin|
89015161|NCT01604200||Dentists|Dentists in practice
89015162|NCT01604239|Experimental|Shinbaro|
89015163|NCT01604356|Experimental|Electro-acupuncture|
89015164|NCT04708314|Other|30 mg/kg|Golodirsen 30 mg/kg will be administered as an intravenous (IV) infusion over approximately 35 to 60 minutes once a week during the treatment period (up to 96 weeks). After the treatment period, patients can go into a safety extension period (not to exceed 48 weeks) until the patient is able to transition to commercially available drug or a separate golodirsen study.
89015165|NCT00258245|Experimental|Bortezomib, AT, Thalidomide, Dexamethasone, Vit C, ASA|Bortezomib (Velcade)- 0.7→1.0 mg/m2 IVP d 1, 4, 8, 11; Arsenic Trioxide [AT] (Trisenox)- 0.10→0.15→0.25 mg/kg/dose IVPB days 1, 4, 8, 11; Thalidomide (Thalomid)- 50 mg/day by mouth (PO); Dexamethasone (Decadron)- 40 mg/d IVPB or by mouth (PO) d 1, 4, 8, 11; Ascorbic Acid (Vit C)- 1000 mg IVPB p Arsenic Trioxide (ATO) days 1, 4, 8, 11; Aspirin (ASA)- 325 mg by mouth (PO) every day
89015166|NCT01604395||growth hormone|
89015167|NCT01604434|Sham Comparator|Incubator-no plastic bag|Placement into an incubator without a plastic bag
89015168|NCT01604434|Active Comparator|Incubator-torso bag|Placement into a plastic bag inside incubator
89015169|NCT01604590||glioblastoma patients on bevacizumab|
89015170|NCT00271440|Experimental|CHX 1.0%|1.0% CHX wiping
89015171|NCT00271440|Experimental|CHX 0.5%|0.5% Chlorhexidine
89015172|NCT00271440|Experimental|CHX 0.25%|chlorhexidine cleansing with pre-soaked pre-sealed wipe
89015173|NCT01604629|Experimental|Reduced doses of anti-TNF|Standardized schedule of reduced doses of anti-TNF, reached either through the interval spacing of administration (adalimumab, etanercept or golimumab) or reducing doses of infliximab
89206146|NCT00821262|Active Comparator|propofol|The control group will receive propofol for the same 4-6 hours period.
89015174|NCT01604629|Active Comparator|Stable doses of anti-TNF|Stable doses of anti-TNF according clinical practice based on approved summary product characteristics (SPC) and SER consensus about biological therapies in Ankylosing Spondylitis and other Spondylarthropathies, except Psoriatic Arthritis
89451958|NCT03264326|Experimental|BFR Group|Blood Flow Restriction Training with Eccentric Exercise Protocol
89451959|NCT03264326|Sham Comparator|Sham BFR Group|Sham Blood Flow Restriction Training with Eccentric Exercise Protocol
89451960|NCT05189951|Experimental|circular motion|The phlebotomy site was wiped in a circular motion from the center outwards, approximately 5x5 cm wide.
89451961|NCT05189951|Experimental|vertical motion|The phlebotomy site was wiped vertically from top to bottom with a single maneuver.
89451962|NCT05189951|Experimental|first vertical then circular motion|The phlebotomy site was first vertically wiped from top to bottom with a single maneuver, and then it was wiped in a circular motion from the center to the outside. Different swabs were used in both wipes.
89451963|NCT02459444|Experimental|IMT group and physiotherapy|Inspiratory muscle training with POWERBREATHE an approximate load of 50 % of MIP , for 1 set of 30 breaths twice a day, 7 days a week for 4 weeks ( total 56 sessions). Associated with physiotherapy program.
88936742|NCT01801605|Active Comparator|on|active session
88936743|NCT01801605|Placebo Comparator|off|fictive session
88936744|NCT01801631|Experimental|Home visits|In addition to usual care the patients will receive three home visits from a trained diabetes nurse. The first visit (65 minutes) is within three weeks after discharge from the hospital; the second visit (45 minutes) is two weeks later and the third visit (45 minutes) is two months after the second home visit.
88936745|NCT01801631|Other|Consultation by telephone|In addition to usual care patients will receive a consultation by telephone within three weeks after discharge to offer them personal attention. In this consultation they will get the opportunity to discuss in ten to fifteen minutes how they feel in the period after discharge.
88936746|NCT01801644|Experimental|gemcitabine plus cisplatin|gemcitabine plus cisplatin: 3 cycles of gemcitabine 1000 mg/m2 on days 1,8,15 as a 30 minute infusion and cisplatin 70 mg/m2 on day 1 as an 2 hour infusion will be applied
88936747|NCT01801657||Bronchiectasis,stable|A patient was defined as stable if there was no exacerbation for the previous 4 wk
88936748|NCT01801657||Bronchiectasis,exacerbations|Bronchiectasis exacerbations were defined by subjective and persistent(>24 h) deterioration in at least three respiratory symptoms, including cough, dyspnea, hemoptysis, increased sputum purulence or volume, chest pain (with or without fever), radiographic deterioration, systemic disturbances, or changes in chest auscultation
88936749|NCT01801670||MF patients for blood & biopsy|Participants who are cared for at Boston Medical Center will first be assessed by physicians of the CTCL multi-specialty clinic if vorinostat, administered per standard of care, is an appropriate therapy for their CTCL. The decision to invite patients to participate in this study is (1) separate from the above described clinical decision to utilize vorinostat, and (2) will be offered subsequent to the clinical decision to utilize vorinostat. Vorinostat (Zolinza) will be administered as follows: each subject will receive each month for the first 3 months (cycle 1 to 3) 3 capsules of vorinostat 100 mg po daily. For months 4-6 (cycles 4 to 6), subjects will receive each month for 4 capsules of vorinostat 100 mg po daily.
88936750|NCT01801683|Other|Intervention: PEARLS (evidence based reports)|Intervention was modified academic detailing method, performed by sixth-year medical students/academic detailers.Each mentor chose two patients from real life who represented diagnostic, therapeutic or prognostic challenge. The students formed an answerable question, using PICO, and wrote report according to PEARLS.
88936751|NCT01801683|No Intervention|Control group of GPs|GPs not mentors who do not receive academic detailing intervention using PICO/PEARLS.
88936752|NCT01801696|Experimental|Parent massage tx group|Children in this group receive the parent-delivered massage intervention right after randomization.
88936753|NCT01801696|Experimental|Parent massage wait-list control group|Children in this group receive the parent-delivered massage intervention 5 months after randomization.
88936754|NCT01801722||NT-proBNP,ejection fraction ,COPD stage.|The group comprised 25 women (47%) and 28 men (53%). The mean age was 75.4 years (SD 7.9), 76.3 (SD 7.6) for men and 74.4 (SD 8.2) for women.
88936755|NCT01801748|Experimental|oral wheat challenge|
88936756|NCT01801761||develop group|previous COPD study
88936757|NCT01801761||validation group|consecutive COPD patients from outpatient clinics
88936758|NCT01801774|Placebo Comparator|Dexamethasone|Dexamethasone 0.1%/Tobramycin 0.3% eye drop 4 times per day for 28 days
88936759|NCT01801774|Active Comparator|Triamcinolone|Subtenon 20-mg Triamcinolone injection
88936760|NCT01801787|Experimental|verum tDCS|left-hemispheric tDCS: anode placed midway between F3 and FP1, cathode placed midway between T3 and P3
88936761|NCT01801787|Sham Comparator|sham tDCS|left-hemispheric sham tDCS: anode placed midway between F3 and FP1, cathode placed midway between T3 and P3
88936762|NCT01801800||Aneurysmal subarachnoid haemorrhage|Speckle-tracking images in Echocardiography
88936763|NCT01801813||Neurosurgery for brain tumor patients|Collecting pre-operative and per-operative data, neuro-radiological data and post-operative complications
88936764|NCT01801826||Treatment|Treatment with CryoTouch IV device
88936765|NCT01801839||SIRS,sepsis,normal|"SIRS~(1) temperature > 38 centigrade or < 36 centigrade; (2) pulse rate > 90 beats/min; (3) ventilation rate > 20 breaths/min or hyperventilation with a partial pressure of arterial carbon dioxide (PaCO2) < 32 mmHg; (4) white blood cell (WBC) count >1 2,000/μL or < 4000/μL , or > 10% immature cells.~sepsis~SIRS + infection.~normal~not SIRS and have no infection."
88936766|NCT01801852|Experimental|NKT cells|NKT cells treatment plus regular treatment
88936767|NCT01801878|Experimental|Adipose SVF cell|adipose SVF cell transfer to the half of irradiated breast
88936768|NCT01801878|Active Comparator|Normal saline|Normal saline inject to the half of irradiated breast
88936769|NCT01801891|Active Comparator|Control group|Patients randomised to the control group will, in addition to their routine compression bandaging, be given muscle stimulators for home use and instructed to apply 3x 30 minute sessions of comfortable electrical stimulation daily for 12 weeks. The stimulators given to the control group will be set to provide minimal stimulation resulting in no visible muscular contraction.
89015175|NCT00258284|Experimental|Docetaxel & Capecitabine|Patients receive docetaxel IV over 30 minutes on days 1, 8, and 15 and oral capecitabine twice daily on days 5-18. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 2 additional courses of therapy beyond CR
89015176|NCT01604668||RevF vs RevG vs Pronto-7|Comparison of hemoglobin levels derived by continuous hemoglobin sensor RevF versus continuous hemoglobin sensor RevG versus an intermittent hemoglobin level derived from the Pronto-7 hand-held device versus a hemoglobin derived from a blood sample.
89015177|NCT01604707|No Intervention|Control group|Standard care
89015178|NCT01604707|Experimental|Medical Yoga|Group training with medical yoga in primary health care.
89015179|NCT01604746|No Intervention|Safety assessment|Vaccine safety will be assessed in the period between 6 and 12 months after the 3rd vaccination in precursor Study 880801 based on diaries distributed to all subjects for documentation of SAEs or AESI. Females who became pregnant after the 3rd vaccination in Study 880801 will be followed until end of pregnancy.
89015180|NCT01604863|Experimental|Arm A|HGS1036 + Paclitaxel + Carboplatin
89015181|NCT01604863|Experimental|Arm B|HGS1036 + Cisplatin + Etoposide
89015182|NCT01604863|Experimental|Arm C|HGS1036 + Docetaxel
89015183|NCT00258401|Active Comparator|low-residue diet|At the onset of diarrhea symptoms, patients are instructed to eat a low-residue diet. Patients continue on this diet for 2-4 weeks.Patients are interviewed weekly for up to six weeks.
89015184|NCT00258401|Active Comparator|no dietary intervention|At the onset of diarrhea symptoms, patients undergo no dietary intervention but are interviewed weekly for up to six weeks.
89015185|NCT01604902||Psoriasis vulgaris|Patients with psoriasis vulgaris who are going to be treated with biological drugs independent of this project(according to national guidelines).
89015186|NCT01604980|Experimental|Protein Intakes|subjects will recieve differnt levels of protein intakes varying from 0.2 to2.0g/kg/day.
89015187|NCT01605331|Experimental|sustained-release recombinant human GH (SR-rhGH)|12-week subcutaneous administration, 2mg/week
89015188|NCT01605409|Active Comparator|Standard ACLS|Patients in the standard ACLS group will be resuscitated until ROSC or termination of efforts. If ROSC is achieved they will be transported to the emergency department and treated according to ERC guidelines and GCP.
89451964|NCT02459444|Placebo Comparator|Sham IMT group|Inspiratory muscle training with the same device in the experimental group , however without charge , for 1 set of 30 breaths twice a day, 7 days a week for 4 weeks ( total 56 sessions). Associated with physiotherapy program.
89451965|NCT03264170|Active Comparator|Prediction of pregnancy outcome|Women will receive an individualised prediction score of the pregnancy being viable at the follow-up ultrasound generated from the prediction tool.
89451966|NCT03264170|No Intervention|Control|Women will not receive the prediction score
89451967|NCT03266120|Active Comparator|Art Intervention|Participants randomly assigned to this arm will receive a hands-on art intervention that will consist of twice weekly group sessions of approximately 60 minutes each in duration that will take place indoors over a period of four weeks for a total of eight art sessions. Participants will complete sets of self-report psychometric assessments and blood pressure and heart rate will be monitored before, during, and following the conclusion of the intervention.
89451968|NCT03266120|Experimental|Gardening Intervention|Participants randomly assigned to this arm will receive a hands-on gardening intervention that will consist of twice weekly group sessions of approximately 60 minutes each in duration that will take place in a greenhouse over a period of four weeks for a total of eight gardening sessions. Participants will complete sets of self-report psychometric assessments and blood pressure and heart rate will be monitored before, during, and following the conclusion of the intervention.
89015189|NCT01605409|Experimental|ECPB|"ACLS provided for 15 minutes by EMS personnel according to current guidelines of the ERC.~CPR during transportation will be performed by EMS personnel according to ERC guidelines.~At the ED cannulation will be performed percutaneously if feasible. The femoral artery will be cannulated with a 17-19 - Fr and the femoral vein will be cannulated simultaneously with heparin coated 19-25 - Fr catheter or a smart cannula. An antegrade 8 - Fr cannula will be placed to supply perfusion for the cannulated leg if feasible. The procedures will be performed ultrasound-guided and the size of the cannulae will be adapted according to vessel size. Correct placement of the venous cannulae will be verified via ultrasound. Cardiopulmonary bypass will be performed by using the Lifebridge(Sorin®) or the Cardiohelp(Maquet®) ECMO device, according to protocol."
89451969|NCT01841333|Experimental|PF-04449913|Beginning 80 days after allogeneic stem cell transplant, patients receive PF-04449913 (100mg) orally once daily on days 1-28. Treatment repeats every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
89015190|NCT00258479|Experimental|Modafinil|
89015191|NCT00258479|Placebo Comparator|Placebo|
89015192|NCT00258479|No Intervention|Nicotine Replacement Therapy|The effects of nicotine replacement therapy will be investigated - alone and in combination with modafinil - on nicotine withdrawal in nicotine-dependent adolescents.
89015193|NCT00271518|Experimental|LB03002, sustained release human hGH|LB03002
89015194|NCT01340014|Other|AZARGA/COSOPT|1 drop AZARGA instilled in each eye twice a day for 7 days, followed by 1 drop COSOPT instilled in each eye twice a day for 7 days. A 48-hour washout period separated the two treatment periods.
89015195|NCT01340014|Other|COSOPT/AZARGA|1 drop COSOPT instilled in each eye twice a day for 7 days, followed by 1 drop AZARGA instilled in each eye twice a day for 7 days. A 48-hour washout period separated the two treatment periods.
89451970|NCT03277742|Active Comparator|Control|This arm will receive the standard of care for patients with TB and DM2
89451971|NCT03277742|Experimental|Intervention|This arm will receive the community intervention
89015196|NCT00258518||1|ALI/ARDS patients
89451972|NCT03619967|Experimental|Multispectral imaging device|Bio-inspired multispectral imaging device will be used to record fluorescence signals emited by dyes (Indocyanine green and methylene blue) routinely used for visual identification of sentinel lymph nodes per current standard of care worldwide.
89451973|NCT03266432|Other|60 pregnant women|60 pregnant women diagnosed with placenta previa will take from them 3 blood samples : one pre intervention and two samples postintervention
89451974|NCT05234918|Experimental|(Kedo S plus file study group)|Group1: Kedo S plus file study group (The teeth will be instrumented by Kedo S plus file)
89015197|NCT00291057|Experimental|1|MALG
89015198|NCT00258557|Experimental|002|TMC-114/RTV two 400 mg tablets of TMC114 + one 100 mg capsule of RTV daily for max. 192 weeks
89015199|NCT00258557|Active Comparator|001|LPV/RTV 400/100 mg twice daily or 800/200 mg daily depending on the country for max. 192 weeks
89015200|NCT01339897|Active Comparator|5 mg/N6022|Injectable formulation, given at doses per cohort of 5 mg given QD each day over 7 days.
89451975|NCT05234918|Experimental|(Kidzo-file study group)|Group2: Kidzo file study group (The teeth will be instrumented by Kidzo file)
89451976|NCT05234918|Experimental|(Manual K-file control group)|Group3: Manual K-file control group (The teeth will be instrumented by Manual K-file)
89451977|NCT02459288|Experimental|Clopidogrel first|Clopidogrel (Plavix) 75 mg qd, 2 weeks; followed with Ticagrelor (Brilinta) 90 mg bd, 2 weeks
89451978|NCT02459288|Experimental|Ticagrelor first|Ticagrelor (Brilinta) 90 mg bd, 2 weeks; followed with Clopidogrel (Plavix) 75 mg qd, 2 weeks
89451979|NCT03064451|Experimental|Intervention|cartofinder guided ablation followed by PVI
89451980|NCT00734253|Experimental|1|Pyridorin 150 mg bid
89451981|NCT00734253|Experimental|2|Pyridorin 300 mg bid
89451982|NCT00734253|Placebo Comparator|3|Placebo bid
89451983|NCT00730665|Experimental|100ug|
89451984|NCT00730665|Experimental|300ug|
89451985|NCT00730665|Experimental|1mg|
89451986|NCT00730665|Experimental|3mg|
89451987|NCT00730665|Placebo Comparator|Placebo|
89451988|NCT03263858|Experimental|Cohort 1 and 2|
89451989|NCT03277508|Experimental|BCI robot assisted hand therapy|Brain-computer integration robot assisted hand therapy
89015201|NCT01339897|Placebo Comparator|Placebo|Injectable formulation normal saline
89015202|NCT01339897|Active Comparator|10mg/N6022|Injectable formulation, given at doses of 10 mg given QD each day over 7 days.
89015203|NCT01339897|Active Comparator|20mg/N6022|Injectable formulation, given at doses per cohort of 20 mg given QD each day over 7 days.
89015204|NCT00271635|Experimental|1|Ascorbic acid
89015205|NCT00271635|Placebo Comparator|2|Placebo
89451990|NCT03277508|Active Comparator|CPM robot assisted hand therapy|Continue Passive Movement robot assisted hand therapy
89451991|NCT02280681||Couples with ovarian failure|Heterosexual couples confronted with infertility due to ovarian failure between the age of 18 and 44 years old treated in the K.U.Leuven and
89451992|NCT02280681||Clinicians|Clinicians who indicated an interest in reproductive medicine in their membership of the Belgian Society for Reproductive Medicine (BSRM).
89451993|NCT03058679|Experimental|Specific Carbohydrate Diet|For the first six 6 weeks of the trial, participants received a weekly delivery of prepared meals compliant with the SCD (breakfast, lunch, dinner, and two 2 snacks per day). Meals were prepared by Healthy Chef Creations (Orlando, FL) based on menus developed by the food vendor in consultation with study dietitians. Participants assigned to the SCD received a three3-day starter diet as recommended in Breaking the Vicious Cycle. Meals were designed to be heated in an oven or microwave. No other preparation was required.
89451994|NCT03058679|Active Comparator|Mediterranean Style Diet|For the first six 6 weeks of the trial, participants received a weekly delivery of prepared meals compliant with the MD (breakfast, lunch, dinner, and two 2 snacks per day). Meals were prepared by Healthy Chef Creations (Orlando, FL) based on menus developed by the food vendor in consultation with study dietitians. Meals were designed to be heated in an oven or microwave. No other preparation was required.
89451995|NCT02280759|Active Comparator|Gelatin Tannate|"Gelatin Tannate:~4 times 250 mg/daily for 5 days for children under 3. years old or 4 times 500mg/daily for 5 days for children older then 3. years and under 5 years."
89451996|NCT02280759|Placebo Comparator|Placebo|Placebo consists of an identical formulation, except active substance.
89015206|NCT01339429|Experimental|simplified Negative Pressure Wound Therapy|The simplified Negative Pressure device will be placed on subjects selected from the hospital ward and meeting the eligibility criteria.
89015207|NCT01339390|Experimental|Arm 1: MOVE OUT|The MOVE OUT intervention builds on the high quality information provided by the nationally-developed MOVE! program by adding 1) peer support; 2) convenient local access to educational sessions, which allows the material to be delivered in smaller, more easily retained aliquots; 3) convenient local exercise opportunities; and 4) open-ended availability of both education and exercise support.
89015208|NCT01339390|Active Comparator|Arm 2: MOVE!|"As part of routine care at the ZVAMC, all patients who are eligible for the present study are identified by a clinical reminder. This reminder prompts the primary care provider (PCP) to determine if the person would benefit from a weight loss program, and to refer them to MOVE! if they and the patient agree that it would be beneficial. The MOVE! program in Milwaukee can be tailored by the patient and PCP, but includes dietitian assessment, education, weekly weigh-ins, follow-up classes, and exercise programs."
89015209|NCT01339273|Experimental|TAP block|Patients in this arm will receive ultrasound guided TAP bock with Bupivacaine 0.25% 20ml per side or to a maximum 1mg/kg per side and the skin puncture will be covered with a small plaster
89206147|NCT00824304||Fe, Zn, Fe+Zn, Placebo|placebo comparator
89451997|NCT03275948|Experimental|whole grain|
89451998|NCT03275948|Other|refrence|white wheat based product
89451999|NCT00714597|Experimental|Semuloparin|Semuloparin sodium 20 mg (10 mg if Severe Renal Impairment [SRI]) once daily for 10-14 days
89452000|NCT00714597|Active Comparator|Enoxaparin|Enoxaparin sodium 40 mg (20 mg if Severe Renal Impairment [SRI]) once daily for 10-14 days
89452001|NCT02457104||normal weight individuals not taking PPI|
89452002|NCT02457104||normal weight individuals taking PPI|
89452003|NCT02457104||obese individuals not taking PPI|
89452004|NCT02457104||obese individuals taking PPI|
89452005|NCT02280837||Patients with suspected or diagnosed coronary artery disease|
89452006|NCT00729027|Experimental|25 mg/day AVE5530|
89452007|NCT00729027|Experimental|50 mg/day AVE5530|
89452008|NCT00729027|Placebo Comparator|Placebo|
89452009|NCT03265886|Experimental|Warm bupivacaine at (37°c)|Warmed bupivacaine at body temperature will be administered
89452010|NCT03265886|Active Comparator|Bupivacaine at operating room temperature (23°c)|Bupivacaine at temperature of 23°C will be administered
89452011|NCT00728091|Experimental|Satavaptan Dose 1|Fixed Low dose up to day 4, followed by optional titration up to day 30
89452012|NCT00728091|Experimental|Satavaptan Dose 2|Fixed High dose up to day 4, followed by optional titration up to day 30
89452013|NCT00728091|Placebo Comparator|Placebo|
89015210|NCT01339273|Active Comparator|Local anaesthetic infiltration|Laparoscopic port sites and specimen extraction site will be infiltrated with a total of 40 mls 0.25% bupivacaine subcutaneously at the end of the procedure in the control group and plasters will be stuck on either side approximately where a skin puncture for tap block would be made.
89452014|NCT03275792|Experimental|Admission/Intravascular Volume Expansion|"Infusion of 40 mL/kg of 0.9% normal saline (NS) IV over 60 minutes~0.9% NS with 5% dextrose at 150% of standard maintenance volume~If urine output is <0.5 ml/kg/hr over a 12-hour period (AKI Stage 2), repeat 20 mL/kg bolus or boluses of 0.9% NS will be infused as long as there are no signs of central volume overload~Oral fluids ad lib along with strict input/output documentation~Fluids will be restricted if: A) Anuria for 12 hours OR B) Evidence of fluid overload~Daily laboratory tests and in-person assessment until inpatient discharge criteria reached:~A) 2 - 4 days since symptom onset AND rising platelet count (>5% increase) documented over 48 hours in a clinically well child B) ≥5 days since symptom onset AND stable platelet count (<5% decrease) documented over 48 hours in a clinically well child~Repeat hematocrit, platelet, renal function 24 and 72-hours post-discharge."
89452015|NCT03275792|Active Comparator|Outpatient Observation|"Following standard emergency department (ED) care [volume status assessed; dehydration corrected employing oral rehydration in children with mild to moderate dehydration (most common); IV if severe (rarely)], children are discharged with saline lock IV (routine procedure across Canadian pediatric EDs).~Oral fluids (preferably electrolyte maintenance solutions) ad lib following ED discharge~Additional health assessments as required~Daily blood tests at a local laboratory with results conveyed daily to the site-investigator until outpatient discharge criteria achieved; no in-person assessment given logistics (i.e. distance), impact on family, and mirroring of standard practice A) 2 - 4 days since symptom onset AND rising platelet count (>5% increase) documented over 48 hours in a clinically well child B) ≥5 days since symptom onset AND stable platelet count (<5% decrease) documented over 48 hours in a clinically well child"
89452016|NCT03275090|Active Comparator|Intralipid injectable product (MOFS)|20 preterm infants receive parenteral nutrition containing 20% MOFS lipid emulsion (Smoflipid ®)
89452017|NCT03275090|No Intervention|Pure Soybean oil lipid emulsion|20 preterm infants with sepsis receive the usual parenteral nutrition containing soybean oil based lipid emulsion (20% Intralipid ®) at daily increasing doses guided by serum triglycerides.
89452018|NCT03382821|Active Comparator|Transforaminal ESI with dexamethasone|Group 1: Transforaminal cervical ESI with dexamethasone sodium phosphate
89452019|NCT03382821|Active Comparator|Transforaminal catheter-targeted ESI with triamcinolone|Group 2: Catheter-targeted cervical ESI with triamcinolone acetonide
89452020|NCT02557516|Experimental|Phase 1 Level 1 - 1 mg/kg|In phase 1, Monalizumab given at the first dose level of 1 mg/kg.
89015211|NCT04709315|Active Comparator|saline pretreatment/succinyl group (SS group).|patients receive pretreatment with 10 ml 0.9% saline over 10 minutes, and succinyl choline 1mg/ kg is the intubating muscle relaxant.
89015212|NCT04709315|Experimental|Dex pretreatment/ rocuronium group (DR group),|patients receive pretreatment with Dex 1 µg / kg in 10 ml 0.9% saline over 10 minutes and rocuronium 0.6 mg/kg is the intubating muscle relaxant.
89015213|NCT01334710|Experimental|Sorafenib and OSI-906|This is a single arm phase II trial designed to evaluate the effect of adding OSI-906 to sorafenib in patients with hepatocellular cancer. The study is designed to evaluate the safety of the regimen in the first six patients.
89015214|NCT00271713|Active Comparator|ibandronate|150 mg ibandronate monthly plus 500mg calcium and 800 UI vitamin D daily
89015215|NCT00271713|Placebo Comparator|2|placebo monthly plus 500mg calcium and 800 UI vitamin D daily
89015216|NCT00258713|Active Comparator|1|
89015217|NCT00258713|Active Comparator|2|
89452021|NCT02557516|Experimental|Phase 1 Level 2 - 2 mg/kg|In phase 1, Monalizumab given at the second dose level of 2 mg/kg.
89452022|NCT02557516|Experimental|Phase 1 Level 3 - 4 mg/kg|In phase 1, Monalizumab given at the third dose level of 4 mg/kg.
89452023|NCT02557516|Experimental|Phase 2 RP2D - 2 mg/kg|In phase 2, Monalizumab given at the Recommended Phase 2 Dose (RP2D) of 2 mg/kg, selected by a safety committee.
89452024|NCT03263624|Experimental|Group (A)|fractional carbon dioxide laser plus tazarotene 0.1% cream
89452025|NCT03263624|Active Comparator|Group (B)|Tazarotene Cream 0.1%
89452026|NCT03274544|Experimental|PROLUNG|Herbal formula treatment PROLUNG in additional to current therapy
89452027|NCT02280915|Experimental|Fortified savoury food product 1|Savoury food product fortified with iron
89452028|NCT02280915|Experimental|Fortified savoury food product 2|Savoury food product fortified with iron
89452029|NCT02280915|Experimental|Fortified savoury food product 3|Savoury food product fortified with iron
89015218|NCT00258713|Active Comparator|3|
89015219|NCT01334554|Experimental|Sildenafil|Sildenafil 20 mg three times a day
89015220|NCT01334554|Placebo Comparator|Placebo|placebo
89452030|NCT02280915|Experimental|Fortified savoury food product 4|Savoury food product fortified with iron
89452031|NCT05493436||normoweight|GERD patient with normoweight was evaluating by MII pH-meter
89452032|NCT05493436||obesity|GERD patient with obesity was evaluating by MII pH-meter
89452033|NCT00711555|Experimental|Single arm study with Emend|"On day 1, the subject will receive a total daily dose of oral dexamethasone 12mg, oral ondansetron 24mg, and oral aprepitant 125mg. On days 2 to THE LAST DAY OF THE MODERATELY-HIGH TO HIGHLY EMETOGENIC CHEMOTHERAPY, subjects will receive a total daily dose of oral dexamethasone 12mg, oral ondansetron 24mg, and oral aprepitant 80mg. All anti-emetics should be give one hour before starting chemotherapy administration.~FOR TWO DAYS AFTER RECEIVING CHEMOTHERAPY, the subject will be prescribed oral dexamethasone 4mg every 12 hours and oral aprepitant 80 mg every day."
89015221|NCT00291213|Experimental|Levetiracetram Administration|
89452034|NCT05488756|Active Comparator|Group 1|Conventional training plus isometric neck exercises
89452035|NCT05488756|Experimental|Group 2|Conventional training plus deep cervical flexor exercises
89452036|NCT05488756|Experimental|Group 3|Conventional training plus stabilization exercises of the neck and core region
89452037|NCT00701181|Active Comparator|Laser|This is a procedure - not a drug intervention.
89452038|NCT00701181|Experimental|PF-04523655 (High)|
89452039|NCT00701181|Experimental|PF-04523655 middle|
89015222|NCT00291213|Placebo Comparator|Placebo|
89015223|NCT01332799|Active Comparator|Allopurinol|
89452040|NCT00701181|Experimental|PF-04523655 low|
89452041|NCT03263390||Bariatric Surgery|Subjects that have demonstrated extreme response to bariatric surgery.
89452042|NCT03263390||Anti Obesity Medications|Subjects that have demonstrated extreme response to anti obesity pharmacotherapy.
89452043|NCT04277182|Placebo Comparator|Control group|It will be accepted as the control group and 4 experimental burn wounds will be created on the back of the rats in the group and no treatment will be given.
89452044|NCT04277182|Active Comparator|1% Silver Sulfadiazine|4 experimental burn wounds will be created on the back of the rats in the group and dressing with 1% Silver Sulfadiazine will be done on the back of the rats every day for 21 days.
89452045|NCT04277182|Active Comparator|%0.2 Nitrafurozon|4 experimental burn wounds will be created on the back of the rats in the group and dressing with %0.2 Nitrafurozon will be done on the back of the rats every day for 21 days.
89452046|NCT04277182|Experimental|10% Propolis|4 experimental burn wounds will be created on the back of the rats in the group and dressing with 10% Propolis will be done on the back of the rats every day for 21 days.
89452047|NCT04277182|Experimental|15% Propolis|4 experimental burn wounds will be created on the back of the rats in the group and dressing with 15% Propolis will be done on the back of the rats every day for 21 days.
89015224|NCT01332799|Placebo Comparator|Placebo (sugar pill)|
89015225|NCT00258752|Experimental|1|Interpersonal Psychotherapy-Adolescent Skills Training (IPT-AST)
89015226|NCT00258752|Experimental|2|Enhanced IPT-AST
89015227|NCT00258752|Active Comparator|3|Typical school counseling
89015228|NCT00271752|Experimental|PCT guided|Procalcitonin guided treatment of infections in the ICU. Intervention: Intensification of antibiotics, surgery, microbiologic testing and diagnostic imaging, when Procalcitonin levels are increasing
89015229|NCT00271752|Sham Comparator|Control|"These patients receive Standard of Care which is the recommended treatment in the given ICU"
89015230|NCT00258869||1|Emergency department patients with sepsis
89015231|NCT00271791|Experimental|1|Prednisone
89015232|NCT00271791|Placebo Comparator|2|Placebo
89015233|NCT01332331|Experimental|Low Dose Ambrisentan|body weight 20 to 35 kg - 2.5 mg; body weight 35 kg and over - 5.0 mg
89015234|NCT01332331|Experimental|High Dose Ambrisentan|body weight 20 to 35 kg - 5.0 mg; body weight 35 to 50 kg - 7.5 mg; body weight 50 kg and over - 10.0 mg
89015235|NCT00259064|Experimental|Gefitinib|ZD1839 + BSC (best supportive care)
89452048|NCT04277182|Active Comparator|Propolis vehicle|4 experimental burn wounds will be created on the back of the rats in the group and dressing with Propolis vehicle will be done on the back of the rats every day for 21 days.
89452049|NCT03273920|Experimental|Robotic gastrectomy|Robotic distal gastrectomy with D2 nodal dissection
89452050|NCT03273920|Active Comparator|Laparoscopic gastrectomy|Laparoscopic distal gastrectomy with D2 nodal dissection
89452051|NCT02280993|Experimental|DHAP-BV|Brentuximab Vedotin with DHAP chemotherapy follow by Autologous Peripheral Blood Stem Cell Transplantation
89452052|NCT02459210|Experimental|CLUES|active treatment
89452053|NCT02459210|Active Comparator|therapy and computer games|supportive therapy + computer games
89452054|NCT05493202||Study group|30 patients undergoing gonadotropin stimulation for IVF or egg freezing.
89501743|NCT02150993|Experimental|Arm A : TDF + FTC (or 3TC) + ZDV|Tenofovir + Emtricitabine or Lamivudine + Zidovudine
89501744|NCT02150993|Experimental|TDF+FTC (or 3TC) +LPV/r|Tenofovir + Emtricitabine or Lamivudine + Lopinavir/ritonavir
89501745|NCT02150993|Experimental|Arm C : TDF +FTC (or 3TC) + RAL|Tenofovir + Emtricitabine or Lamivudine + Raltegravir
88936770|NCT01801891|Experimental|VASGARD stimulator|Patients randomised to this group, in addition to their routine treatment with compression bandaging, will be given muscle stimulators for home use and instructed to apply 3x 30 minute sessions of comfortable electrical stimulation daily for 12 weeks. The intervention group stimulators will be capable of causing muscular contraction with a maximum force ranging from 30-40% of voluntary contractions.
88936771|NCT01801956|Active Comparator|Motivational interviewing|A one hour motivational interview
88936772|NCT01801956|Experimental|Physical activity|Four motivational interviews, free membership of a sport club, virtual arena to upload training data from a GPS-watch
88936773|NCT01801969||Rehabilitation service|"Centralized or Decentralized rehabilitation~Size of municipality"
88936774|NCT01802008|Active Comparator|3-minute withdrawal time|"For subjects randomized to the 3-minute withdrawal time, advancement to the cecum will be followed by segmental withdrawal in each of 3 segments of the examined colon. Each segment will be examined over 1 minute, followed by a second look over each segment over 2 minutes by the same endoscopist."
88936775|NCT01802008|Active Comparator|6-minute withdrawal time|"For subjects randomized to the 6-minute withdrawal, advancement to the cecum will be followed by segmental withdrawal in each of 3 segments of the examined colon. Each segment will be examined over 2 minutes, followed by a second look over each segment over 2 minutes by the same endoscopist."
88936776|NCT01802021|Experimental|Qingshu-Yiqi-Tang+standard therapy|"Plus astragalus-based formula: Qingshu-Yiqi-Tang 7.2gm BID during 1st line chemotherapy and 2nd line target therapy, maximal for 6 months.~1st line doublet chemotherapy: Cisplatin 70 mg/m2+Taxotere 60 mg/m2 D1/Q3W x 6 cycles, and then 2nd line target therapy: Erlotinib 150mg QD."
88936777|NCT01802021|No Intervention|1st line doublet chemotherapy|1st line doublet chemotherapy: Cisplatin 70 mg/m2+Taxotere 60 mg/m2 D1/Q3W x 6 cycles, and then 2nd line target therapy: Erlotinib 150mg QD.
88936778|NCT01802047|Experimental|Electric Pump Modality|Each mother follows all 3 electric pump modalities in a randomized order.
88936779|NCT01802099|Other|Parenteral nutrition|Patients will receive parenteral nutrition during the first week of mechanical ventilation. After Day 3, the parenteral route may be switched to the enteral route if shock resolve (vasoactive drug stopped since 24 hours and serum lactate level < 2 mmol/l). After Day 7, all patients will be fed via the enteral route.
88936780|NCT01802099|Other|Enteral nutrition|Patients will receive nutrition only via the enteral route during the firs week of invasive mechanical ventilation.
88936781|NCT01802112|Placebo Comparator|Maltodextrins|15 grams of maltodextrins per day dissolved in water during 21 days
88936782|NCT01802112|Experimental|Resistant maltodextrins|15 grams of resistant maltodextrins per day, dissolved in water during 21 days
88936783|NCT01802125||Basic science (SNP array analysis)|Tissue samples are analyzed using laboratory biomarker analysis for LOH and SNP array profiling using microarray and immunohistochemistry.
88936784|NCT01802138|Experimental|Activated T-lymphocyte|"This was designed as a single-center, single group clinical trial, and subjects include patients with refractory refractory/relapsed neuroblastoma.~If subjects agree to participate in the clinical trial by signing a written consent, only appropriate subjects, who meet the criteria on the examinations and tests, will undergo this clinical trial. To participate in the clinical trial, subject's blood of more than 60 ml should be withdrawn to make a study drug at least 3 weeks before administration. Subjects should visit to hospital according to the protocol and receive a study drug. Therapeutic response rate, overall survival rate, time to progression should be investigated."
88936785|NCT01802164|Experimental|1|Conventional abdominal wall closure with mesh implantation
88936786|NCT01802164|No Intervention|2|Conventional abdominal wall closure without mesh implantation
88936787|NCT01802177|Experimental|UVB excimer light|Patches of alopecia will be treated twice weekly with UVB excimer light. Only one half of a single alopecia areata patch will be treated. In order to treat the same half during each visit, a transparent sheet will be marked, using a marking pen, to delineate the borders of the treatment area with a central dividing line. The other half will be covered and used as a control. Treatments will be given randomly (by sealed envelope randomization method) into one of the two halves in different patients but will be given into the same half in each patient in all treatment sessions. Only one investigator will know the intervention each half has received. A total of 23 treatments will be given over 12 weeks.
88936788|NCT01802177|No Intervention|No treatment (covered)|
88936789|NCT01802190||Deafness patients|Deafness patients
88936790|NCT01802229|Active Comparator|Suture|Umbilical port-site closure with simple suture of the fascia.
88936791|NCT01802229|Experimental|Prophylactic mesh|Umbilical port-site closure with mesh placement
88936792|NCT01802255|Experimental|Inhalatory sedation|Sevoflurane given via AnaConDa for sedation minimum 48 hours
88936793|NCT01802255|Active Comparator|Intravenous sedation|Midazolam given intravenously for sedation minimum 48 hours
88936794|NCT01802268|Active Comparator|Sirolimus|Conversion from Tacrolimus to Sirolimus
88936795|NCT01802268|Active Comparator|Tacrolimus|Maintenance on tacrolimus
88936796|NCT01802294|Experimental|Parenting Program|12-week group-based parenting program (Sinovuyo Caring Family Programme) delivered in weekly sessions. Program is manualized.
88936797|NCT01802294|No Intervention|Wait-list control|Wait-list control group. Program delivered 3 months after posttest.
88936798|NCT01802307|Experimental|Focal Therapy|
88936799|NCT01802359||Mirodenafil|
88936800|NCT01802372|Active Comparator|WHO CVD Risk Assessment package|Arm#1 (Intervention Group): Provided Ghana's National Health Insurance and the WHO CVD Risk Assessment package for 12 months.
88936801|NCT01802372|Sham Comparator|Health Insurance only|Arm#2 (Control group): Provided Ghana's National Health Insurance for 12 months, brief behavioral counseling at baseline,and usual care.
88936802|NCT01802398||No treatment|Observational cohort study of older (age≥60 years) adults who present to an emergency department with syncope (otherwise known as fainting)
89452055|NCT02459132|Experimental|Exercise Group|Subjects in the exercise group will attend supervised exercise sessions three times a week, for 12 weeks. The exercise intervention will consist of uphill walking or jogging on a treadmill between 50% and 95% of VO2peak for 35 minutes (including a 5-minute warm up and cool down). The participants will complete four, 4-minute, high-intensity intervals at 85-95% of VO2peak. The work period intervals will be interspersed with three, 3-minute periods of active recovery at an intensity below that of their ventilatory threshold.
89452056|NCT02459132|No Intervention|Usual Care|The usual care group will not receive an intervention, and they will be asked to maintain baseline physical activity levels throughout the observation period.
89452057|NCT05493124|Experimental|Manpixiao treatment group|A traditional Chinese medicine composition (has applied for Chinese patent)，Take 17.15g daily, twice in the morning and evening, for a total of 24 weeks
89452058|NCT05493124|No Intervention|Blank treatment group|
89452059|NCT05493124|Active Comparator|Active comparator|Including treated with Chinese patent drugs such as Weifuchun and morodan, or treated with antacids, motivational drugs, gastric mucosal protectants, vitamins, folic acid, selenium containing preparations and other drugs. Take it according to the instructions.
89452060|NCT03263312|Experimental|Fontan Patients|All Fontan patients included in this study will be part of an exercise intervention 2-6 times/week for 3-6 months.
89452061|NCT05493046|Experimental|Interactive Hand Exercise Game|Participants will receive an Interactive Hand Exercise Game for 30 minutes every day for consecutive two months.
89452062|NCT05493046|Active Comparator|Soft ball exercise ( routine care)|Participants will receive a soft ball exercise for 30 minutes every day for consecutive two months.
89452063|NCT03263468|Experimental|Same sitting complete revascularization|After treatment of the IRA, subjects will undergo PCI of all suitable significant non-IRA lesions (≥70% by visual assessment or FFR<0.80 in 50-70% lesions with vessel diameter >2mm).
89452064|NCT03263468|Active Comparator|Staged non-IRA PCI|Only the IRA will be intervened upon during the index primary PCI procedure. Staging of the non-IRA lesions will be performed 48 hours to 45 days after the primary PCI procedure. All suitable non-IRA lesions (≥70% by visual assessment or FFR<0.80 in 50-70% lesions with vessel diameter >2mm) will be treated with PCI irrespective of whether there are clinical symptoms or evidence of ischemia.
89452065|NCT05492968|Experimental|Epinephrine Group|Patients in the epinephrine group will receive a continuous infusion containing epinephrine with a concentration of 0.02mg/ml for intraoperative blood pressure management. The infusion will be started with 0.15mL/kg/h and will be titrated to receive a mean arterial pressure of at least 75mmHg.
89452066|NCT05492968|Active Comparator|Norepinephrine Group|Patients in the norepinephrine group will receive a continuous infusion containing norepinephrine with a concentration of 0.02mg/ml for intraoperative blood pressure management. The infusion will be started with 0.15mL/kg/h and will be titrated to receive a mean arterial pressure of at least 75mmHg.
89452067|NCT05492968|Active Comparator|Phenylephrine Group|Patients in the phenylephrine group will receive a continuous infusion containing phenylephrine with a concentration of 0.2mg/ml for intraoperative blood pressure management. The infusion will be started with 0.15mL/kg/h and will be titrated to receive a mean arterial pressure of at least 75mmHg.
88936803|NCT01802424|Experimental|The Friends program|Youth with increased levels of anxiety are thought to regulate their fear by recognizing bodily cues, learning relaxation, regulating thoughts and feelings and expose themselves to situations and objects that activate their anxiety.
88936804|NCT01802450|Experimental|Dasatinib (Sprycel)|Dasatinib (Sprycel): 100 mg QD administered orally as continuous daily dosing (CDD)until disease progression or adverse events that, by protocol definition or Investigator judgment, would preclude further treatment with dasatinib
88936805|NCT01802463||Controls|Healthy volunteers with no family history of glaucoma, an increased or asymmetrical cup/disc ratio or any other optic disc structural change (notching, disc hemorrhage) or an intraocular pressure (IOP) above 21 mmHg that could suggest possible glaucoma suspects.
88936806|NCT01802463||Primary open-angle glaucoma|Patients with a characteristic optic disc damage (based on cup/disc ratio, thinning of neuroretinal rim, notching, disk hemorrhages, etc.) and visual field defects, with at least one measurement of IOP of >21 mmHg required
88936807|NCT01802463||Normal Tension Glaucoma|Patients with a characteristic optic disc damage (based on cup/disc ratio, thinning of neuroretinal rim, notching, disk hemorrhages, etc.) and visual field defects, with at maximum recorded IOP of < 21 mmHg
88936808|NCT01802476|Other|Fixed Sequence Crossover Arm|This study arm consists of a fixed sequence crossover where study subjects will receive Treatment A and following a washout of no less than 10 days will then receive Treatment B. The drug class is a CDK4/6 inhibitor.
89452068|NCT02457026|Experimental|Adjunctive PDT + Aflibercept|Participants will receive adjunctive verteporfin PDT at Study Visit 1 as well as intravitreal aflibercept at Study Visits 1, 2, 3. At Study Visit 4, participants will have repeat assessment of disease activity. If disease activity is resolved or trivial, the individual will be maintained on aflibercept injections. If PDA remains unresolved, the individual will undergo repeat verteporfin PDT at Study Visit 4, as well as intravitreal aflibercept at Study Visits 4, 5, and 6. Disease activity will be reassessed at Study Visit 7. If disease activity is resolved or trivial, the individual will be switched to aflibercept injections once every three months. If PDA remains unresolved, then the individual will default to a standard-of-care treatment strategy with aflibercept (monthly injections).
88936809|NCT01802489|Active Comparator|Amiloride|Amiloride capsules 10mg once per day for 5 months
88936810|NCT01802489|Placebo Comparator|Placebo|Placebo capsules one per day for 5 months
88936811|NCT01802502|Active Comparator|Rifampicin 600 mg|Subjects in this arm receive 600 mg rifampicin intravenously
88936812|NCT01802502|Experimental|rifampicin 750 mg|Subjects in this arm receive 750 mg rifampicin orally
89501746|NCT02151071|Other|Breast conserving surgery|Females ≥ 30 years of age with a diagnosis of invasive breast cancer or ductal carcinoma in situ (DCIS), scheduled for BCS +/- SLNB or ALND
89537143|NCT03299621|Experimental|Muscle relaxant injection|Investigators monitor the change for PLE value using the sensor of PLEM™ before and after the injection of muscle relaxant.
89015236|NCT00259064|Placebo Comparator|Placebo|Placebo + BSC (best supportive care)
89015237|NCT01332292|Active Comparator|COHORT 1 RANDOMISATION A|(8-11 years old) Repeat dose session: Fluticasone furoate 100µg; Day 1 and Day 14 = in house dosing; Day 2-13 = home dosing
89015238|NCT01332292|Placebo Comparator|COHORT 1 RANDOMISATION B|(8-11 years old) Repeat dose session: matching placebo; Day 1 and Day 14 = in house dosing; Days 2-13 = home dosing
89015239|NCT01332292|Active Comparator|COHORT 2 RANDOMISATION A|(5-7 years old) Repeat dose session: Fluticasone furoate 100µg; Day 1 and Day 14 = in house dosing; Days 2-13 = home dosing
89015240|NCT01332292|Placebo Comparator|COHORT 2 RANDOMISATION B|(5-7 years old) Repeat dose session: Matching placebo; Day 1 and Day 14 = in house dosing; Days 2-13 = home dosing
89015241|NCT00271908||Cohort #1|Venue-tracking survey subjects recruited annually for 4 years: N= 320-640 (10-20 members of the population of focus per site, per year). The purpose of this cohort is to identify and track venues at which the population of focus congregates.
89015242|NCT00271908||Cohort #2|HIV-related risk survey subjects recruited annually for 4 years: N = 1280-2880 (20-30 members of the population of focus per 2-3 congregation venues, per site, per year). These subjects will complete a survey designed to assess HIV-related risk. In the fourth and final year only, HIV Antibody [Ab] assays will also be conducted with survey participants to assess HIV serostatus. The survey and HIVAb assay data will be used to evaluate the intervention within and across sites.
89015243|NCT00259103|Experimental|7.5 µg/kg/d|Participants who received intravenous (IV) infusion of 7.5 µg/kg/d serelaxin, all during part A.
89015244|NCT00259103|Experimental|25 µg/kg/d|Participants who received intravenous (IV) infusion of 25 µg/kg/d serelaxin, all during part A.
89452069|NCT02457026|Active Comparator|Aflibercept Alone|"Participants in this group will receive intravitreal aflibercept at Study Visits 1, 2, and 3. At Study Visit 4, participants will have repeat assessment of disease activity. From Study Visit 4 onwards, aflibercept will be administered according to a treat-and-extend strategy. If disease activity is considered to be resolved or trivial, then the interval between treatments can be initially extended from every 28 days to every 42 days. If disease activity remains stable, treatments can be extended in 14-day increments, up to 10 weeks between treatments. For individuals who have PDA that remains unresolved, aflibercept will continue to be administered every days, but if disease quiescence is achieve at a later time point, the treatment period can be extended at that time."
89015245|NCT00259103|Experimental|75 µg/kg/d|Participants who received IV infusion of 75 µg/kg/d serelaxin, some during part A and others during part B.
89015246|NCT00259103|Experimental|Placebo|Participants who received IV infusion of placebo, some during part A and others during part B.
89015247|NCT00291720|Active Comparator|Spironolactone|25mg spironolactone daily
89015248|NCT00291720|Placebo Comparator|Placebo|matching placebo medication for the control group
89452070|NCT05488210||Malnourished DM2 patients|Diabetic patients who present malnutrition through the GLIM criteria
89452071|NCT02458898|Experimental|Text Message Intervention|A series of 45 unique educational text messages sent over a period of 3 months in the evenings. Text messages include humorous reminders, links to online celiac disease resources, and bidirectional questions.
89452072|NCT02458898|No Intervention|Control (No Text Messages)|Routine care by primary gastroenterologist with no text messages.
89452073|NCT05488132|Experimental|anti-siglec-6 CAR-T cell therapy|anti-siglec-6 CAR-T cell therapy
89452074|NCT02456870|Other|MA|Middle-aged overweight and obese men (age 25-40yr)
89452075|NCT02456870|Other|OA|Older overweight and obese men (age 55-75yr)
89452076|NCT05492890||Dexcom CGM|Continuous glucose monitoring
89452077|NCT05492890||Point of care testing|Finger poke glucose measure
89452078|NCT03273842|Experimental|PF-06881894|PF-06881894 6 mg SC
89452079|NCT03273842|Active Comparator|US-approved Neulasta|US-approved Neulasta 6 mg SC
89015249|NCT00259220|Experimental|drug|erythromycine
89015250|NCT00259220|Other|2|gastric lavage alone
89015251|NCT00259220|Active Comparator|3|erythromycine and gastric lavage
89015252|NCT00272025|Active Comparator|1|There is a 50% chance of being randomized to Escitalopram in addition to current atypical antipsychotic (minimum dose risperidone 3mg, olanzapine 10mg or seroquel 400mg) or mood stabilizer (lithium, epival or lamotrigine)
89015253|NCT00272025|Placebo Comparator|2|to be filled in
89015254|NCT04709081|Experimental|Part 1: ACH-0145228, Midazolam, and Digoxin|"Period 1: Participants received single doses of midazolam and digoxin.~Period 2: Participants received ACH-0145228 twice daily, in addition to coadministration with single doses of midazolam and digoxin.~Scheduled pharmacokinetics (PK) blood and urine samples were collected, with a washout period of at least 7 days between collection of the last PK blood sample in Period 1 and the first dose of ACH-0145228 in Period 2."
89015255|NCT04709081|Experimental|Part 2: ACH-0145228 and Itraconazole|"Period 1: Participants received a single dose of ACH-0145228.~Period 2: Participants received itraconazole once daily, in addition to coadministration with a single dose of ACH-0145228.~Scheduled PK blood samples were collected, with a washout period of at least 2 days between collection of the last PK blood sample in Period 1 and the first dose of itraconazole in Period 2."
89452080|NCT05492812|Experimental|Chloral Hydrate|Chloral hydrate was administered orally to children at a dose of 25-50 mg/kg/dose. After the sedative drug administration, the child was taken to a quiet and dark sleep room in the polyclinic environment with his parents in order to enable the child to fall asleep. In this process, the child was evaluated by the nurse every 5 minutes with the Ramsay Sedation Score. Children with a Ramsay Sedation Score of 4-6 were taken to the EEG room for recording. During the sedation, the child's blood pressure, oxygen saturation and pulse were checked every 5 minutes. EEG electrodes were placed in accordance with the international 10-20 electrode positioning system. An average of 30 minutes of EEG recording was made for each patient. The awakening process of children whose EEG recordings were completed was evaluated with the Steward Recovery Score. Individuals with a score of 6 were accepted as awake, and the child's procedure was completed.
89501747|NCT04563637||Computer Based Vision|A 15 second long video will be obtained at the research site using a smart phone or tablet. Then subjects will undergo a whole body dual energy x-ray absorptiometry scan . Then the subject will go home and take a second 15 second long video. The videos will then be analyzed by computer based vision application and the body fat percentage measured by dual energy x-ray absorptiometry scan will be compared.
89501748|NCT02776553|Experimental|Active (physical training program)|physical activity + behavioral therapy + nutritional intervention
89501749|NCT02776553|Active Comparator|Control|nutritional intervention
89501750|NCT02230345|Experimental|Probiotic yogurt|Daily administration, during two weeks, of two probiotic yogurts (200 mL each)
89501751|NCT02230345|Active Comparator|Acidified milk|Daily administration, over two consecutive weeks, of an isocaloric dose (compared to probiotics) of unfermented acidified milk
89501752|NCT02690727|Experimental|RP6530 in fast condition|A single dose of RP6530 following fast condition
88936813|NCT01802502|Experimental|rifampicin 900 mg|Subjects in this arm receive rifampicin 900 mg orally
88936814|NCT01802528||Obturator externus muscle injection|patients were treated with obturator externus injection
88936815|NCT01802541|Experimental|DAG oil|
88936816|NCT01802541|Placebo Comparator|TAG oil|
88936817|NCT01802593|Experimental|Immunomodulator therapy 26 weeks|IFX 5mg/kg for 76 weeks, continuing immunomodulator for 6 months from first infusion
88936818|NCT01802593|Experimental|Immunomodulator therapy 2 weeks|IFX 5mg/kg induction for 76 weeks, discontinuing immunomodulator on day of second infusion( after 14 days).
88936819|NCT01802619|Placebo Comparator|inhaled nitrogen|Using an Inovent (Ikaria Inc, N.J., USA) or volumetrically-calibrated flowmeters, pure nitrogen (placebo) is mixed with pure O2 or air. During CPB the gas mixture is delivered through the extracorporeal oxygenator, after CPB the NO is delivered through the inspiratory limb of the anesthetic or ventilator circuit.
88936820|NCT01802619|Experimental|inhaled nitric oxide|Using an Inovent (Ikaria Inc, N.J., USA) or volumetrically-calibrated flowmeters, 800 ppm NO gas is mixed with pure O2 or air to obtain a final concentration of 80 ppm NO. During CPB the gas mixture is delivered through the extracorporeal oxygenator, after CPB the gas is delivered through the inspiratory limb of the anesthetic or ventilator circuit. NO, NO2 and O2 and methemoglobin levels are monitored by an unblinded observer.
88936821|NCT01802645|Active Comparator|Cetuximab/FOLFIRI|"Cetuximab 250 mg/m² (1 h) weekly Irinotecan 180 mg/m² (1 h)*, d-l Folinic acid 400 mg/m² (2 h), 5-FU 400 mg/m² (Bolus), 5-FU 2400 mg/m² (46 h) every 2 weeks~*reduced in UGT1A1 7/7 patients"
88936822|NCT01802645|Experimental|Cetuximab/FOLFOXIRI|"Cetuximab 250 mg/m² (1 h) weekly Irinotecan 125 mg/m² (1 h),* Oxaliplatin 85 mg/m² (2 h), d-l Folinic acid 400 mg/m² (2 h), 5-FU 3200 mg/m² (46 h) every 2 weeks~*reduced in UGT1A1 7/7 patients"
88936823|NCT01802645|Active Comparator|FOLFOXIRI|"Irinotecan 165 mg/m² (1 h)*, Oxaliplatin 85 mg/m² (2 h), d-l Folinic acid 400 mg/m² (2 h), 5-FU 3200 mg/m² (46 h) every 2 weeks~*reduced in UGT1A1 7/7 patients"
88936824|NCT01802645|Experimental|Bevacizumab/FOLFOXIRI|"Bevacizumab 5 mg/kg (30-90 min i.v.), Irinotecan 165 mg/m² (1 h),* Oxaliplatin 85 mg/m² (2 h), d-l Folinic acid 400 mg/m² (2 h), 5-FU 3200 mg/m² (46 h) every 2 weeks~*reduced in UGT1A1 7/7 patients"
88936825|NCT01802658|Active Comparator|Zoledronic acid|Zoledronic acid 5 mg. IV. 3 infusions. Administration 3 times over two years.
88936826|NCT01802658|Placebo Comparator|NACL|NACl 100 ml IV. 3 infusions. Administration 3 times over two years.
88936827|NCT01802671|Experimental|cognitive behaviour therapy supported by ICT|The patients of this group will receive the same interventions that the CBT group but will receive a reinforcements of the sessions' content through two different ways: a web tool named TEO (Emotional Therapy Online) and SMS that will send to the patients' mobile phone with reminders and reinforcements.
88936828|NCT01802671|Active Comparator|Rehabilitation treatment and information|Patients will receive the traditional rehabilitation treatment and information
88936829|NCT01802671|Experimental|cognitive behavioural therapy (CBT)|Patients will receive the same treatment in physical therapy than the control group and additionally they will receive CBT.
88936830|NCT01802684|Experimental|OPTIMOX-aflibercept|"Induction therapy (sequence #1)~Regimen : aflibercept + modified FOLFOX7~Duration : 6 cycles (3 months) Maintenance after induction (sequence #2) First phase (sequence #2A)~Regimen : aflibercept + fluoropyrimidine (simplifed LV5FU2 or capecitabine)~Duration : 6 cycles (3 months) Second phase (sequence #2B)~Regimen : aflibercept +/- fluoropyrimidine (simplifed LV5FU2 or capecitabine) according to eligibility criteria for chemotherapy-free interval)~Duration : until PD or limiting toxicity Reintroduction (sequence #3)~Regimen : aflibercept + modified FOLFOX7~Duration : 6 cycles (3 months) Maintenance after reintroduction (sequence #4)~Regimen : aflibercept + fluoropyrimidine~Duration : until PD or limiting toxicity"
88936831|NCT01802697|Experimental|IdeS|Intravenous infusion
89501753|NCT02690727|Experimental|RP6530 in fed condition|A single dose of RP6530 following fed condition
89501754|NCT02224105|Experimental|BI 653048 BS|escalating doses
89015256|NCT00272064|Other|1|Telecare system
89015257|NCT00272064|Other|2|Self Monitoring Blood Glucose (SMBG)system.
89015258|NCT00259337|Experimental|1|
89452081|NCT05492812|Experimental|Hydroxyzine|Hydroxyzine was administered orally to children at a dose of 1-2 mg/kg/dose. After the sedative drug administration, the child was taken to a quiet and dark sleep room in the polyclinic environment with his parents in order to enable the child to fall asleep. In this process, the child was evaluated by the nurse every 5 minutes with the Ramsay Sedation Score. Children with a Ramsay Sedation Score of 4-6 were taken to the EEG room for recording. During the sedation, the child's blood pressure, oxygen saturation and pulse were checked every 5 minutes. EEG electrodes were placed in accordance with the international 10-20 electrode positioning system. An average of 30 minutes of EEG recording was made for each patient. The awakening process of children whose EEG recordings were completed was evaluated with the Steward Recovery Score. Individuals with a score of 6 were accepted as awake, and the child's procedure was completed.
89452082|NCT05492812|Experimental|Melatonin|Melatonin was administered orally 3 mg up to 15 kilograms, and 6 mg after 15 kilograms.After the sedative drug administration, the child was taken to a quiet and dark sleep room in the polyclinic environment with his parents in order to enable the child to fall asleep. In this process, the child was evaluated by the nurse every 5 minutes with the Ramsay Sedation Score. Children with a Ramsay Sedation Score of 4-6 were taken to the EEG room for recording. During the sedation, the child's blood pressure, oxygen saturation and pulse were checked every 5 minutes. EEG electrodes were placed in accordance with the international 10-20 electrode positioning system. An average of 30 minutes of EEG recording was made for each patient. The awakening process of children whose EEG recordings were completed was evaluated with the Steward Recovery Score. Individuals with a score of 6 were accepted as awake, and the child's procedure was completed.
89452083|NCT05492734|Experimental|Treatment|Drug: EDG-5506
89452084|NCT03265418|Experimental|BioXmark liquid fiducial markers|Placement of 4 BioXmark liquid fiducial markers, standard treatment (chemo-radiotherapy followed by surgery or wait-and-see) with extra imaging to evaluate the behaviour of the markers before, during and after the radiotherapy
89452085|NCT05487976|Experimental|Recombinant human activated coagulation factor VII for injection|Each subject in this study received on-demand treatment with recombinant human activated coagulation factor VII for injection for 24 weeks. The single dose for each bleeding event was 90 μg/kg, and the number of doses was increased according to the remission after treatment.
89015259|NCT00259376|Experimental|Dronedarone 400mg bid|dronedarone 400mg tablets
89452086|NCT05487898|Experimental|Cycyling wheelchair|Volunteers join the cycling wheelchair training
89452087|NCT03265652|Experimental|Intense Pulsed Light (IPL) therapy|Subjects with receive 10-15 intense pulsed light (IPL) pulses on the skin of the malar region (both cheeks, from tragus to tragus including the nose) and up to 3 mm from the lid margin of the lower eyelid. Following the administration of IPL pulses, subjects will undergo meibomian gland expression.
89452088|NCT03265652|Placebo Comparator|Sham therapy|Participants will undergo a sham treatment that will mimic the intense pulsed light (IPL) therapy. The tip of the IPL lightguide will be placed in 10-15 locations on the skin of the malar region (both cheeks, from tragus to tragus including the nose) and up to 3 mm from the lid margin of the lower eyelid, but IPL pulses will not be actually delivered. Following this sham procedure, subjects will undergo meibomian gland expression.
89452089|NCT03265028||Intervention|Invited to take the TRACE e-learning.
89452090|NCT03265028||Control|Not (yet) invited to take the TRACE e-learning.
89452091|NCT02458118|Experimental|Secretin|Secretin 1 IU/kg over 3 min
89452092|NCT05487742|Placebo Comparator|Group I (control group):|Patients of this group receive placebo infusion for 72 hours.
89452093|NCT05487742|Active Comparator|Group II (DEX group):|Patients of this group receive 0.5 ug/kg/hr dexmedetomidine continuous infusion for 72 hour
89452094|NCT02457650|Experimental|Anti-NY ESO-1 TCR-transduced T cells|Patients will receive a lymphodepleting conditioning regimen followed by an infusion of anti-NY-ESO-1 TCR-transduced T cells.
89452095|NCT02456948|Experimental|Minocycline|Minocycline and standard antidepressant treatment
89015260|NCT00259376|Experimental|Placebo|matching placebo tablets
89015261|NCT01332019|Experimental|peginterferon beta-1a Q4W|125 µg peginterferon beta-1a administered by subcutaneous (SC) injection every 4 weeks (Q4W) for at least 2 years and up to 4 years.
89015262|NCT01332019|Experimental|peginterferon beta-1a Q2W|125 μg peginterferon beta-1a administered by SC injection every 2 weeks (Q2W) for at least 2 years and up to 4 years.
89015263|NCT02961140|Experimental|Cardiac Output Maximization|maximize stroke volume, and maintain cardiac index and stroke volume variation during the whole operation
89015264|NCT02961140|Active Comparator|Cardiac Output Normalization|keep cardiac index (CI) ≥ 2.2, and maintain CI and stroke volume variation during the whole operation
89015265|NCT04718688|Experimental|CO-OP intervention|CO-OP intervention
89015266|NCT00415454|Experimental|Gene therapy|Adenovirus injection followed by 3 weeks of 5-FC + vGCV prodrug therapy and a 6 week course of capecitabine-based chemoradiation
89452096|NCT02456948|Placebo Comparator|Placebo|Placebo and standard antidepressant treatment
89452097|NCT05487508|Active Comparator|Dexamethasone CCABG|Dexamethasone administered 1 mg per kg body weight (maximum dose 100 mg), given single dose after induction of anesthesia. Surgeon then carried out the conventional coronary artery bypass graft procedure with the use of cardiopulmonary bypass machine.
89452098|NCT05487508|Placebo Comparator|Placebo CCABG|Normal saline (NaCl 0.9%) administered 1 mg per kg body weight (maximum dose 100 mg), given single dose after induction of anesthesia. Surgeon then carried out the conventional coronary artery bypass graft procedure with the use of cardiopulmonary bypass machine.
89452099|NCT05487508|Active Comparator|Dexamethasone OPCAB|Dexamethasone administered 1 mg per kg body weight (maximum dose 100 mg), given single dose after induction of anesthesia. Surgeon then carried out the off-pump coronary artery bypass procedure without the use of cardiopulmonary bypass machine.
89452100|NCT05487508|Placebo Comparator|Placebo OPCAB|Normal saline (NaCl 0.9%) administered 1 mg per kg body weight (maximum dose 100 mg), given single dose after induction of anesthesia. Surgeon then carried out the off-pump coronary artery bypass procedure without the use of cardiopulmonary bypass machine.
89452101|NCT04185142||combined procedure group|patients underwent cryoballoon ablation and left atrial appendage closure
89452102|NCT04175704|Other|Cohort 1|0.2 mg/kg UB-221 or placebo
89452103|NCT04175704|Other|Cohort2|0.6 mg/kg UB-221 or placebo
89452104|NCT04175704|Other|Cohort 3|2 mg/kg UB-221 or placebo
89452105|NCT04175704|Other|Cohort 4|6 mg/kg UB-221 or placebo
89015267|NCT00272181|Experimental|Dose Determination|The recommended dose (RD) for Proxinium is to be determined based on the rate of Dose Limiting Toxicities (DLT) within each dose cohort. The RD is to be established as the highest dose at which one or fewer patients out of six within a dose cohort experienced a DLT. The initial dose level is 500 μg of Proxinium in PBS (the amount of PBS used will be based on the estimated volume of the target tumour). Doses are to be escalated to a maximum of 700 μg or de-escalated to a minimum of 260 μg according to the prescribed algorithm outlined in the study protocol.
89015268|NCT00291954|Experimental|1|Henogen hepatitis B vaccine
88936832|NCT01802697|Placebo Comparator|PBS Buffer|Intravenous infusion
89015269|NCT00291954|Active Comparator|2|HBVAXPRO hepatitis B vaccine
89015270|NCT00259688|No Intervention|1|Women with gestational hypertension
89015271|NCT00259688|No Intervention|2|Women with uncomplicated pregnancies
89015272|NCT00259688|No Intervention|3|Re-test of women one to two years post-partum.
89015273|NCT00272220|Experimental|1|receive 6-week intervention of peer-delivered mDOT
89015274|NCT00272220|No Intervention|2|
89015275|NCT00259727||1|
89015276|NCT00292032||Cardiac Arrest Survivors or Post Mortem Unexplained Cardiac|Probands - Unexplained Cardiac Arrest Survivors and Post Mortem Unexplained Cardiac Arrest Cases
89015277|NCT00292032||First Degree Family Members|First Degree Family Members of those affected by Sudden Unexplained Cardiac Arrest
89015278|NCT00292071|Other|1|IV caspofungin acetate (50 mg/m²/day)
89015279|NCT00292071|Other|2|IV caspofungin acetate (70 mg/m²/day)
89452106|NCT02713490|Active Comparator|EXPAREL|Single dose of EXPAREL 266 mg in 20 mL admixed with bupivacaine HCl 0.5% in 20 mL and expanded in volume with 80 mL normal saline (total volume of 120 mL).
89452107|NCT02713490|Active Comparator|Bupivacaine|Bupivacaine HCl 0.5% in 20 mL expanded in volume with 100 mL normal saline (total volume of 120 mL).
89452108|NCT05491954||Euglycemic|Women who pass a 50g GCT with 1-hour glucose <135 mg/dL
89452109|NCT05491954||Possible glucose intolerance|Women who fail a 50g GCT (1-hour glucose >135 mg/dL) and have 0/4 abnormal values on a 100g oral glucose tolerance test (OGTT) by Carpenter-Coustan values
89452110|NCT05491954||Confirmed glucose intolerance|Women who fail a 50g GCT (1-hour glucose >135 mg/dL) and have 1/4 abnormal values on 100g GTT test by Carpenter-Coustan values
89452111|NCT05491954||Gestational Diabetes Mellitus|Women who fail a 50g GCT (1-hour glucose >135 mg/dL) and have ≥2/4 abnormal values on 100g GTT test by Carpenter-Coustan values (Table 1), meeting criteria for GDM
89452112|NCT03263234|Active Comparator|Group 1|Group 1 consists of elderly people with frailty and/or dementia living in elderly housing in Sundhedshuset, Albertslund, Denmark, and who are having CALED installed. Group 1 starts the 8 week control period and ends with the intervention consisting of 8 weeks of circadian adjusted LED-based lighting (CALED).
89452113|NCT03263234|Active Comparator|Group 2|Group 2 consists of elderly people with frailty and/or dementia living in elderly housing in Sundhedshuset, Albertslund, Denmark, and who are having CALED installed. Group 2 starts with the intervention consisting of 8 weeks of circadian adjusted LED-based lighting (CALED) and ends with the 8 week control period
89452114|NCT03263234|No Intervention|Group 3. Control group|"Group 3 consists of elderly people with frailty living in elderly housing in Sundhedshuset, Albertslund, Denmark, and who are not having CALED installed.~This group serves as a control for:~Physiological or mental decline in participants during the study period~Seasonal variation"
89501755|NCT02224105|Active Comparator|Prednisolone low|
89501756|NCT02224105|Active Comparator|Prednisolone high|
89501757|NCT02224105|Placebo Comparator|Placebo|
89501758|NCT02777333|Experimental|Simulation training|Addition of simulation training during usual clinical training as part of a GMC (General Medical Council) recognised Deanery training programme
89537144|NCT03299543||Healthy adults|Healthy adults who are able to provide duplicate breath samples and pin-drop blood samples
89015280|NCT04709159|Active Comparator|Intervention|"Participants on this arm will use Interactive Voice Response (IVR) daily pill reminders, thrice-weekly health messages, clinic appointment reminders, remote symptom reporting service and a 24 hour toll-free number to access services. These participants will also have the option to co-register a caregiver who will also receive daily pill reminders, clinic appointment reminder, weekly health tips and remote symptom reporting service.~In addition, these participants will receive the standard of care according to Uganda National Tuberculosis Treatment guidelines."
89015281|NCT04709159|No Intervention|Standard|These participants will receive the standard of care according to Uganda National Tuberculosis Treatment guidelines.
89015282|NCT00292110|Active Comparator|Arm Four|
89015283|NCT00292110|Experimental|Arm One|
89015284|NCT00292110|Active Comparator|Arm Three|
89015285|NCT00292110|Active Comparator|ArmTwo|
89015286|NCT00259805|Experimental|IV Infusion|
89015287|NCT00259883|Experimental|paroxetine|paroxetine 20 to 40mg/day
89015288|NCT02961335|Experimental|Patient who need to undergo bronchoscopy|Patient who need to undergo bronchoscopy. During bronchoscopy, biopsy sampling and Confocal microendoscopy will be done
89015289|NCT00272415|Experimental|1|
89015290|NCT00259922|Placebo Comparator|Placebo|
89015291|NCT00259922|Experimental|Alvimopan 0.5 mg once daily|0.5 mg once daily (QD)
89015292|NCT00259922|Experimental|Alvimopan 0.5 mg twice daily|0.5 mg twice daily (BID)
89015293|NCT00272493|Active Comparator|A|Arm A participants will receive 40 mcg of HBV vaccine at study entry, Week 4, and Week 12.
89015294|NCT00272493|Experimental|B|Arm B participants will receive 40 mcg of HBV vaccine and 250 mcg of GM-CSF at study entry, Week 4, and Week 12.
89015295|NCT00292266|Experimental|Rebif®|
89015296|NCT00292266|Active Comparator|Avonex®|
89015297|NCT00292305|Experimental|T-crush stenting|Percutaneous coronary intervention with implantation of a stent
89015298|NCT00292305|Active Comparator|Culotte stenting|Percutaneous coronary intervention with stent
89015299|NCT00260039|Active Comparator|1|Gardasil
89015300|NCT00260039|Experimental|2|HPV VLP vaccine -Dose regimen 1
89015301|NCT00260039|Experimental|3|HPV VLP vaccine -Dose regimen 2
89015302|NCT00260039|Experimental|4|HPV VLP vaccine -Dose regimen 3
89015303|NCT00417768|Active Comparator|Tissue Plasminogen Activator|tPA administered by drainage tube into abscess, allowed to dwell for one hour and then drained into drainage bag. Dose of tPA administered to be determined by the volume of drainage immediately post drain insertion. This intervention is done on day 0, 1 and 2.
89015304|NCT00417768|Sham Comparator|Instillation of Normal Saline|Insertion of abdominal drainage tube to drain intra-abdominal abscess. Normal Saline administered immediately post drain insertion. Normal Saline (10 cc) allowed to dwell for one hour, then allowed to drain into drainage bag.
89015305|NCT00260234|Experimental|PEG Islet Cells|
89015306|NCT00260273|Active Comparator|1|cognitive Behavioural Therapy
89501759|NCT02777333|No Intervention|Non-simulation/Routine training|Usual clinical training as part of a GMC (General Medical Council) recognised Deanery training programme
89501760|NCT03857659|Experimental|Point of care ultrasound (POC-US)|Point of care ultrasound (POC-US) to measure abdominal circumference and amniotic fluid every 4 weeks from 28-36 weeks
89015307|NCT00260273|No Intervention|2|supportive therapy
89015308|NCT00260351|Experimental|Group 1|Participants on Thai Red Cross, TRC-ID regimen
89015309|NCT00260351|Experimental|Group 2|Participants on Zagreb-IM regimen
89015310|NCT00260351|Experimental|Group 3|Participants on Essen-IM regimen.
89015311|NCT00292500|No Intervention|C-Port|Automated distal anastomotic device
89015312|NCT00292695|Experimental|chemoradiation|Chemoradiation: IF-RT 50.4 Gy/28 Fractions, DEP: (Q4W, CCRT) X 2 Dexamethosone 20 mg/m2/d iv D1-3 VP-16 (etoposide) 75 mg/m2 iv 1 hr D1-3 Cisplatin 75 mg/m2 ivd 4 hr D1
89015313|NCT00260663|Other|Arm 1|
89015314|NCT00260819|Experimental|1|Experimental and Placebo Comparator administered in random order during to successive experimental phase
89015315|NCT00260819|Placebo Comparator|2|Experimental and Placebo Comparator administered in random order during to successive experimental phase
89015316|NCT00298311|Experimental|mci guidance & peer social support|home visits to promote maternal-child interaction & social support
89015317|NCT00298311|Sham Comparator|peer social support|social support
89015318|NCT00298428|Other|SPACE group|
89015319|NCT02960451|Experimental|PRIME care|Specialized care in the PRIME clinic
89015320|NCT02960451|Active Comparator|Usual care|Usual care in the community
89015321|NCT00424853|Experimental|A|
89015322|NCT00424853|Experimental|B|
89015323|NCT00298506|Active Comparator|FK506+MMF|
89015324|NCT01331239|Experimental|Part l: Core cohort|Participants took an ascending dose of LCI699 (osilodrostat) from 2mg bid or 5 mg bid, up to 30 mg bid and participated in Part I of this study. 4 patients in this cohort moved to Part II of the study
89015325|NCT01331239|Experimental|Part II Core: Expansion cohort|Participants took an ascending dose from 2mg bid or 5 mg bid, up to 30 mg bid and participated in the Part II Core Expansion of this study. These patients were all newly enrolled into the phase II part of the study
89015326|NCT01331239|Experimental|Part II Core: Follow-up cohort|Participants took an ascending dose from 2mg bid or 5 mg bid, up to 30 mg bid and participated in the Part II Core Follow-up of this study. These patients were patients who transferred from Part I Core phase of the study
89015327|NCT00424931|Experimental|001|JNJ-17216498 10mg one time
89015328|NCT00424931|Experimental|002|JNJ-17216498 50mg one time
89015329|NCT00424931|Active Comparator|003|Modafinil 200 mg X 2
89015330|NCT00298545|Placebo Comparator|placebo and Calcitriol|placebo tablets together with an oral tablet of 1, 25 dihydroxy vitamin D3 (Calcitriol)
89015331|NCT00298545|Active Comparator|2|calcium together with an oral tablet of 1, 25 dihydroxy vitamin D3 (Calcitriol)
89015332|NCT01331161|Experimental|Older group|Participants between the ages of 60-79
89015333|NCT01331161|Experimental|Younger group|Participants between the ages of 25-40
89015334|NCT00424970|Placebo Comparator|acetazolamide|acetazolamide 250mg /day oral administration, for 6 months
89015335|NCT00260936||HIV-negative|HIV-infected and -uninfected males, ages 12 to 24 years, of Tanner Stage 4 or 5
89015336|NCT00260936||HIV-positive, has never been on ART|HIV-positive, has never been on ART
89452115|NCT05487430|Experimental|Intervention Group|"Self-affirmation audio recording included 40 positive sentences in order to increase the sensation of well-being of the patients. Some examples are:~Now I have decided to think more positively.~I am in control of my thoughts.~I am completely relaxed.~I am strong, and I am aware of my strength.~I can be comfortable and positive in any situation.~I love myself as I am and accept myself for who I am.~I know very well how to relax.~All my muscles relax with every deep breath I take.~I leave myself in peace.~I am a relaxed, joyful, and happy person.~I am calm at all times and in all situations.~I know that everything that happens in my life happens for my own good.~I am very good at relaxing.~My life energy is rising.~I am surrounded by positive energy.~In the background of the recording there were sounds of birds crowing and river-like flowing water together for increasing the effect of relaxation."
89452116|NCT05487430|No Intervention|Control Group|The participants of the control group only received the conventional care given in the inpatient clinic.
89452117|NCT02459054|Experimental|Primary Pediatric Arm|Cardiac transplant-eligible pediatric patients at imminent risk of death from biventricular failure who are 10 - 18 years old at time of TAH-t implant. The intervention is implantation with the 50cc temporary Total Artificial Heart as a bridge to transplantation.
89015337|NCT00260936||HIV-positive, non PI containing NNRTI-based regimen|HIV-positive, currently on a non-PI-containing NNRTI-based regimen for at least 12 weeks. Must never have received a total of more than 6 months of PI-containing regimen, and at least one year must have passed since receipt of last PI-containing regimen
89015338|NCT00260936||HIV-positive, non-NNRTI-containing PI-based regimen|HIV-positive, currently on a non-NNRTI-containing PI-based regimen for at least 12 weeks. Must never have received a total of more than 6 months of NNRTI-containing regimen, and at least one year must have passed since receipt of last NNRTI-containing regimen.
89015339|NCT01331005|Placebo Comparator|Placebo|Placebo will be given three times per day for one year
89015340|NCT01331005|Active Comparator|nepafenac 0.1% drops|Nepafenac drops will be given three times per day for one year
89015341|NCT01330459|Active Comparator|Hydrocodone/acetaminophen|"Subject will receive hydrocodone/acetaminophen 45-90 minutes prior to abortion procedure.~Subject will also recieve ibuprofen, lorazepam, and lidocaine 45-90 minutes prior to abortion procedure."
89452118|NCT02459054|Experimental|Primary Adult Arm|Cardiac transplant-eligible adult patients at imminent risk of death from biventricular failure who are 19 - 75 years old at time of TAH-t implant. The intervention is implantation with the 50cc temporary Total Artificial Heart as a bridge to transplantation.
89452119|NCT02459054|Experimental|Secondary Arm|Cardiac transplant-eligible pediatric and adult patients at imminent risk of death from biventricular failure who do not meet enrollment criteria for a Primary Arm, but meet less restrictive enrollment criteria for the Secondary Arm. The intervention is implantation with the 50cc temporary Total Artificial Heart as a bridge to transplantation.
89452120|NCT05487352||hyperglycemia in the first trimester|The 75g oral glucose tolerance test was performed before 14 weeks of gestation, and any of the fasting, 1-hour and 2-hours blood glucose was ≥ 5.1, 10.0 and 8.5 mmol/L, respectively.
89452121|NCT05487352||euglycemia in the first trimester|The 75g oral glucose tolerance test was performed before 14 weeks of gestation, and the fasting, 1-hour and 2-hours blood glucose were all < 5.1, 10.0 and 8.5 mmol/L, respectively.
89452122|NCT03263156|Experimental|Intervention group|The intervention will involve two face-to-face consultation sessions and one follow-up phone call with parents to help them learn sleep hygiene practices and specific behavioural strategies to improve their child's sleep and follow up on the progress.
89452123|NCT03263156|No Intervention|Waiting-list control|Children in the waiting-list control group will receive usual clinical care.
89452124|NCT04057144|Experimental|ACT with mindfulness|4-hour weekly session of acceptance and commitment therapy (ACT) with mindfulness exercises during 8 weeks in groups of 8
89452125|NCT04057144|Experimental|ACT without mindfulness|4-hour weekly acceptance and commitment therapy (ACT) without mindfulness exercises during 8 weeks in groups of 8
89452126|NCT04057144|Active Comparator|Education program|Self-management education program during 8 weeks in groups of 8.
89452127|NCT03263000||Healthy|24 healthy volunteers (HVs)
89452128|NCT03263000||Patients|24 patients with blepharospasm
88936833|NCT01802736|Active Comparator|Standard Positive Prevention Counselling|"Standard positive prevention counseling which includes alcohol reduction and sexual risk behavior counseling provided in the clinic by the clinic medical counselors on the day of enrollment and at month 3 visit.~Although there is awareness of the need to engage and include PLWHA in HIV prevention, there are little practical efforts devoted towards this engagement even in developed countries. One of the major reasons is the lack of a well-defined standard positive prevention package that needs to be delivered to PLWHA. The approach proposed by Kennedy et al modified to suit the local setting and involves a simpler understandable classification of the goals, interventions and expected outcomes of the treatment."
88936834|NCT01802736|Experimental|Alcohol Motivational intervention counselling plus SPP|
88936835|NCT01802762|Other|NeMo Patch and NeMo Probe|TBI and SAH patients, one arm
88936836|NCT01802801||1|
88936837|NCT01802827||VAT patients|Patients developing Ventilator Associated Tracheobronchitis
88936838|NCT01802827||VAP|Patients presenting ventilator associated pneumonia
89452129|NCT03263000||Patients 2|24 patients with increased blinking alone.
89452130|NCT05487118|Placebo Comparator|Placebo PBMT + MCE|Placebo photobiomodulation therapy (PBMT), with a dose of 0 J, will be applied before a protocol of motor control exercises (MCE).
89452131|NCT05487118|Active Comparator|Active PBMT + MCE|Active photobiomodulation therapy (PBMT), with a dose of 30 J, will be applied before a protocol of motor control exercises (MCE).
89452132|NCT03262844|Placebo Comparator|Conservative treatment|Conservative physiotherapy, intermittent catheterization, or drug treatment for bladder or bowel dysfunction
88936839|NCT01802827||No ventilator associated infection|patients who do not present ventilator associated infection during their stay in ICU
88936840|NCT01802853|Experimental|A: RO6811135 s.c.|
88936841|NCT01802853|Active Comparator|B: RO6811135 i.v.|
88936842|NCT01802892|Experimental|Ronacaleret 100 mg|Subjects will receive ronacaleret (100 mg once daily) for 5 consecutive days, given in conjunction with a single dose of plerixafor (0.24 mg/kg) SC on the evening of Day 5.
89452133|NCT03262844|Experimental|Capsule surgery|Nerve root axial decompression surgery (Capsule surgery)
89452134|NCT03265106|Experimental|BinD19|BinD19 (autologous T cells transduced with CD19 TCR-ζ/4-1BB vector) administered as an IV infusion on days 0, 1 and 2 in the absence of disease progression or unacceptable toxicity. Minimum/ maximum dose: 1x10^6/kg / 1x10^7/kg administered to childhood patients with R/R B cell Acute Lymphoblastic Leukemia (ALL) or Lymphoma.
89452135|NCT03265340|Active Comparator|A|dTMS standard protocol 10 min session
89452136|NCT03265340|Active Comparator|B|dTMS standard protocol 20 min session
89452137|NCT03265340|Active Comparator|C|dTMS standard protocol 40 min session
89452138|NCT02457884|Active Comparator|Temporal Group|Receive 6 weekly 1-hour training sessions by Trigrams (A tailor made reading-task training programme).
89452139|NCT02457884|Active Comparator|Spatial Group|Receive 6 weekly 1-hour training sessions by Trigrams (A tailor made reading-task training programme).
88936843|NCT01802892|Experimental|Ronacaleret 400 mg|Subjects will receive ronacaleret (400 mg once daily) for 5 consecutive days, given in conjunction with a single dose of plerixafor (0.24 mg/kg) SC on the evening of Day 5.
89452140|NCT02457884|Active Comparator|Combined Group|Receive 6 weekly 1-hour training sessions by Trigrams (A tailor made reading-task training programme).
89452141|NCT02457884|Placebo Comparator|Control Group|Receive 6 weekly 1-hour training sessions of leisure reading activities
89452142|NCT05387954|Active Comparator|Antiplatelet therapy|Aspirin OR clopidogrel
89452143|NCT05387954|Experimental|Oral anticoagulants, Direct-Acting|Apixaban (5mg twice a day) OR Dabigatran (150 mg twice a day) OR Rivaroxaban (20 mg once a day)
89452144|NCT05387954|Experimental|PFO closure|PFO closure followed by dual antiplatelet therapy (aspirin 75 mg/d + clopidogrel 75 mg/d) for 3 months, then by single antiplatelet therapy by aspirin or clopidogrel
89452145|NCT05074784|Active Comparator|Control Group|Tongue depressor exercise protocol for tongue strengthening for control group. Using the tongue depressor, participants will be prompted to stick their tongue out as much as they can and to push hard against the tongue depressor for 10 seconds. They will be required to repeat this action 10 times, constituting one set. They will be asked to perform 3 sets, with 30 secs of rest between each set. Arrange for 5 sessions for a week; sessions can take place on consecutive days.
89452146|NCT05074784|Experimental|Intervention Group|IOPI exercise protocol for tongue strengthening for intervention group. Using the IOPI, participants will perform 24 sets of 5 repetition at anterior position, allowing for 30 secs rest in between sets. Arrange for 5 sessions for a week; sessions can take place on consecutive days.
89452147|NCT03944018|Experimental|Intervention with rehabilitation coordinator|Intervention with rehabilitation coordinator (RECO)
89452148|NCT03944018|No Intervention|Control|TAU
89452149|NCT03262688|Experimental|INL-001|Bupivacaine HCl collagen-matrix implant
89452150|NCT03262688|Active Comparator|Infiltration|Bupivacaine HCl infiltration
89452151|NCT05486884|Experimental|high MAP threshold|"Norepinephrine will be titrated to maintain MAP ≥ 90 mmHg. This threshold will be maintained for the 24 hours following inclusion by the perfusion of norepinephrine at an appropriate dose.~From 24 hours after inclusion until ICU discharge, a MAP ≥ 65 mmHg will be targeted"
89452152|NCT05486884|Active Comparator|standard MAP threshold|"Norepinephrine will be titrated to maintain MAP ≥ 65 mmHg. This target MAP will be maintained for 24 hours after randomization through the perfusion of norepinephrine at an appropriate flow rate.~From 24 hours after inclusion until ICU discharge, a MAP ≥ 65 mmHg will be targeted"
89452153|NCT02458820|No Intervention|Usual Care|Patients will be recorded and interpreted as per standard of care. If a seizure is noted by the neurology service, the standard seizure treatment protocol will be used by the clinical team.
89452154|NCT02458820|Experimental|DSA EEG + Usual Care|Patients will undergo at least hourly interpretation of DSA by the ICU bedside care provider. If the bedside care provider is concerned that there is a seizure on DSA they will contact the EEG tech on call for confirmation. If a seizure is confirmed by neurology, the standard seizure treatment protocol will be used by the clinical team.
89452155|NCT05485870||Panvascular disease group|patients with panvascular diseases
89452156|NCT05485870||Healthy controls|Healthy controls
89452157|NCT03262532||Experimental|Learning TEE manipulation with a Web-based TEE simulation module
89452158|NCT03262532||Control|Learning a TEE manipulation without the Web-based TEE simulation
89452159|NCT05485792|Experimental|18F-FAPI PET/CT|Each subject undergone both 18F-FDG and 68Ga-FAPI PET/CT scans within 2 week
89452160|NCT03870464||Prospective arm|Quality of Life questionnaires EORTC-QoL30 and Euro EQ-5D-5L questionnaires are distributed. Blood samples are collected consecutively during ICI and at a follow-up period of one year. CT-scans extended of thorax, abdomen and the lower extremities are performed at baseline and at 6 months. MRI scan of the brain screening for brain metastases. If brain metastases are diagnosed - the possibility of giving radiotherapy along the course of ICI is discussed with the patient. In case of brain metastases consecutive MRI scans of the brain will be performed in order to follow the course (natural or post-radiotherapy) of the disease.Prospective registration of irAEs are registered during ICI and for one year of follow-up.Enrolment period 1th of April 2018- 31th of April 2021.
89452161|NCT05485402|Placebo Comparator|Control group (Group A)|Refined olive oil (38.6 mg hydroxytyrosol and tyrosol/kg oil), maltodextrin, and nutritional and physical activity recommendations
89452162|NCT05485402|Experimental|Intervention group (Group B)|Virgin olive oil rich in phenolic compounds (156 mg hydroxytyrosol and tyrosol/kg oil), maltodextrin, and nutritional and physical activity recommendations
89452163|NCT05485402|Experimental|Intervention group (Group C)|Virgin olive oil rich in phenolic compounds (156 mg hydroxytyrosol and tyrosol/kg oil), prebiotic supplementation (FOS and inulin), and nutritional and physical activity recommendations
89452164|NCT05485324||retrospective analysis|A retrospective analysis of disease histories for the period from 2014 to 2021 was carried out. Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury.
89452165|NCT05485324||prospective study|Recruitment of patients for the prospective study was carried out in the period from 02.24.2022 to 05.24.2022
88936844|NCT01802905|Experimental|Sequenced patients|Patients enrolled on the study who have successful sequencing of their cancers will be closely monitored for: what chemotherapy agents are next used, what response and toxicity do they have, is there any early sign of response detected on PET-CT, overall did the genomic information change treatment decision-making.
88936845|NCT01802918|Experimental|Cohort 1|Subject in this cohort will be randomized to one of the four following treatment sequences (1 treatment per visit): ABCD, BACD, BCAD, or BCDA. Where A=Placebo, B= GSK2838232 5mg, C=GSK2838232 10mg, and D=GSK2838232 20mg
88936846|NCT01802918|Experimental|Cohort 2|Subject in this cohort will be randomized to one of the four following treatment sequences (1 treatment per visit): EGHJ, FEHJ, FGIJ, or FGHK. Where E=Placebo, F= GSK2838232 50mg, G= GSK2838232 100mg, H= GSK2838232 50mg + food, I= Placebo + food, J= GSK2838232 10mg + RTV, K= placebo + RTV.
88936847|NCT01802931|Active Comparator|Session 1 or Session 2|Single dose sessions without ketoconazole co-administration
88936848|NCT01802931|Active Comparator|Co-dose Session|Single dose session with ketoconazole co-administration
88936849|NCT01802944|Experimental|10 IU BID|10 IU BID Intranasal Insulin
88936850|NCT01802944|Experimental|20 IU BID|20 IU BID Intranasal Insulin
88936851|NCT01802944|Experimental|PLACEBOS|Saline nasal solution used as placebo
88936852|NCT01802957|Other|St. Paul and Networked Health Centers|An uncontrolled before and after design with baseline and follow-up cross sectional measurements will be used at the overall site level (St. Paul Hospital and the 8 associated HCs). There will be no control unit.
88936853|NCT01802970|Experimental|Anakinra plus Standard of Care|Patients will undergo a 2-week run-in treatment of daily anakinra alone. This will be followed by daily anakinra (100 mg SC) plus the physician's chemotherapy ( TPC) choice of standard of care (SOC) for a maximum of 6 months.TPC choice includes nab paclitaxel (100 mg/m^2 Intravenous on day 1,8 &15 of a 28 day cycle), or capecitabine (1000mg/m^2 per oral; BID choice: 14 days on, 7 days off OR 7 days on, 7 days off of a 21 day cycle), or eribulin (1.4 mg/m^2 intravenous on day 1 & 8 of a 21 day cycle), or vinorelbine (25mg/m^2 on day 1,8,15 of a 28 day cycle). After 6 months, patients may continue their SOC treatment alone until disease progression or intolerable toxicity.
88936854|NCT01802996|Experimental|Arm I|Magnesium Isoglycyrrhizinate Injection 200mg IV on days 1-5
88936855|NCT01802996|No Intervention|Arm II|Only chemotherapy
88936856|NCT01803009|Experimental|One arm|View CRC RAT and view presentation regarding risk of advanced adenoma
88936857|NCT01803022||Low Molecular Weight Heparin|
88936858|NCT01803035|Experimental|1 % LTX-109|LTX-109 topical gel in 1 % strength
88936859|NCT01803035|Experimental|2 % LTX-109|LTX-109 topical gel in 2 % strength
88936860|NCT01803035|Placebo Comparator|Placebo|Placebo gel, containing all ingredients except LTX-109
88936861|NCT01803048||TBI|30 individuals who will be tested at two weeks post-TBI; 30 individuals who will be tested at one month post-TBI; 30 individuals who will be tested at three months post-TBI; 30 individuals who will be tested at six months post-TBI; 30 individuals who will be tested at 12 months post-TBI.
88936862|NCT01803048||Healthy Control|30 healthy individuals with no history of TBI
88936863|NCT01803061|Experimental|WebCan|Provides computerized PRO to the treating physician at the point of care
88936864|NCT01803061|No Intervention|Usual care|
88936865|NCT01803087|Active Comparator|CHF 1535 100/6 pMDI (Foster®) TEST 1|Adolescents CHF 1535 100/6, 4 puffs (total dose: BDP 400 µg/FF 24 µg) pMDI
88936866|NCT01803087|Active Comparator|CHF 1535 100/6 pMDI (Foster®) AeroChamber Plus™ (TEST 2).|CHF 1535 100/6 pMDI (Foster®) using AeroChamber Plus™ spacer device in adolescents (TEST 2)
88936867|NCT01803087|Active Comparator|(Qvar®: BDP 400 µg)+(Atimos®: formoterol 24 µg)|BDP 100 µg pMDI, 4 puffs (Qvar®, total dose: BDP 400 µg) + formoterol fumarate 6 µg pMDI, 4 puffs (Atimos®, total dose: formoterol 24 µg)
88936868|NCT01803087|Active Comparator|CHF 1535 100/6, 4 puffs (total dose: BDP 400 µg/FF 24 µg) pMDI|Adults CHF 1535 100/6, 4 puffs (total dose: BDP 400 µg/FF 24 µg) pMDI
88936869|NCT01803100||Hospitalized inpatients|Inpatients newly admitted into freshly-cleaned rooms.
88936870|NCT01803126||atherosclerosis|No treatment.
88936871|NCT01803139|Active Comparator|Standard breast radiotherapy|The treatment is planned using 2D wedges optimisation on the central CT-planning slice.
88936872|NCT01803139|Experimental|Breast IMRT|The treatment is planned 3D IMRT optimisation using all CT-planning slices.
88936873|NCT01803178|Active Comparator|Plant Sterols|Plant Sterols
88936874|NCT01803178|Placebo Comparator|Placebo Product|Placebo Product
88936875|NCT01803191|Experimental|Fosfomycin 3 g|Unique oral dosis of 3 g of fosfomycin 1hour before of biopsy
88936876|NCT01803191|Active Comparator|Ciprofloxacin 500 mg|Unique oral dosis of ciprofloxacin 500 mg before biopsy
88936877|NCT01803217|Experimental|mode switch to atrial pacing|
88936878|NCT01803217|Active Comparator|atrioventricular hysteresis function|
88936879|NCT01803230|Placebo Comparator|placebo|placebo (dextrose)
88936880|NCT01803230|Experimental|creatine|creatine supplementation
88936881|NCT01803243|Experimental|Leg length correction|The shorter leg in a sample of 15 patients with structural leg length inequality will be corrected by either a shoe insole or a modified shoe with sole lift.
89452166|NCT03797924|Active Comparator|ICBN with ropivacaine|Participants will receive ICBN with ropivacaine. In order to blind anesthesia providers in the room and nurses in PACU, the site of injection for ICBN will be prepped with tinted chlorhexidine in all patients.
89452167|NCT03797924|Placebo Comparator|No ICBN block|Participants will have the site prepped, but no ICBN block given. In order to blind anesthesia providers in the room and nurses in PACU, the site of injection for ICBN will be prepped with tinted chlorhexidine in all patients.
89452168|NCT02456792|Active Comparator|IVF group|Women will undergo one full IVF cycle
88936882|NCT01803243|Experimental|Control of foot position 1|The foot position in in a sample of 15 patients with hemiplegic cerebral palsy will be controlled by an ankle foot orthosis.
88936883|NCT01803243|Experimental|Control of foot position 2|The foot position in in a sample of 15 patients with diplegic cerebral palsy will be controlled by an ankle foot orthosis.
88936884|NCT01803243|No Intervention|Control|A sample of 15 healthy controls from a simultaneously conducted study (UKBB-Spine-1315-1) will be used for comparative purposes.
88936885|NCT01803256||Scoliosis patients:|15 patients with adolescent idiopathic scoliosis.
88936886|NCT01803256||Control subjects:|15 adolescent healthy control subjects
88936887|NCT01803295|Experimental|40 mg MMC gel|"Device: TC-3 gel mixed with Mitomycin C (MMC) Six weekly intravesical instillations of 60 cc of TC-3 gel mixed with 40 mg MMC will be instilled using catheter.~Other Name: MMC Gel"
88936888|NCT01803295|Active Comparator|Standard of care MMC mixed with water|40 mg MMC mixed with 40cc water. Six weekly intravesical instillations of 40 mg of MMC mixed with 40 cc of water will be instilled using catheter
88936889|NCT01803295|Experimental|80 mg MMC gel|"Device: TC-3 gel mixed with Mitomycin C (MMC) Six weekly intravesical instillations of 60 cc of TC-3 gel mixed with 80 mg MMC will be instilled using catheter.~Other Name: MMC Gel"
88936890|NCT01803308|Experimental|Experimental Part A|"Experimental: Part A: Part A will use a single ascending dose protocol in small, open-label cohorts to determine the starting dose for Part B in the potentially therapeutic range.~Intervention: SB9200"
88936891|NCT01803308|Experimental|Experimental Part B|"Experimental: Part B: Part B will use a multiple ascending dose protocol to further explore the safety, tolerability, pharmacokinetics and pharmacodynamics of SB9200 over 7-14 days of dosing.~Intervention: SB9200 and Placebo"
88936892|NCT01803321|Experimental|Cohort 1|Dose 1
88936893|NCT01803321|Experimental|Cohort 2|Dose 2
88936894|NCT01803334|Experimental|Marking abdomen|If the patient is randomized to the marking the abdomen group (study group) she will then have the anticipated incision needed to place the trocars during her surgery marked on her abdomen by the surgeon attending physician involved in the patient care during the preoperative counseling visit.
88936895|NCT01803334|No Intervention|Control|If she is randomized to the control group, then she will undergo traditional preoperative counseling by the same team without marking the abdomen.
88936896|NCT01803347|Experimental|ASC + fibrin glue|Intervention: drug: ASC + fibrin glue Experimental: ASCs+fibrin glue: Subjects will be treated with a dose of 100 million ASCs plus fibrin glue plus a deep curettage and closure of the internal orifice and evaluated after 16 weeks. If needed a second dose of 100 million ASCs plus fibrin glue will be applied then.
88936897|NCT01803347|Active Comparator|Fibrin glue|Intervention: fibrin glue Fibrin glue: Subjects will be treated with a dose fibrin glue plus a deep curettage and closure of the internal orifice, and evaluated after 16 weeks. If needed a second dose of fibrin glue will be applied then.
89452169|NCT02456792|Active Comparator|LOD group|Women will be subjected to LOD followed by ovarian stimulation if spontaneous ovulation does not occur within 2 months
89452170|NCT02458976|Experimental|PDL|Pre-treatment of surgical area with PDL
89452171|NCT05074628|Experimental|Nitrofurantion|is the drug of choice for the treatment of infections caused by multidrug resistant pathogens.
89452172|NCT05074628|Active Comparator|Calcium Hydroxide|Most commonly used intracanal medicaments . Antimicrobial activity of calcium hydroxide is related to the release of hydroxyl ions in an aqueous environment.
89452173|NCT02458742|Experimental|Morphine|0.5%Bupivacaine 2 ml with morphine 50 mcg for spinal anesthesia
89452174|NCT02458742|Placebo Comparator|Placebo|0.5%Bupivacaine 2 ml for spinal anesthesia
88936898|NCT01803360|Experimental|Neridronate|Neridronate 100 mg solution for infusion: 4 intravenous administrations in a course of 10 days treatment
88936899|NCT01803360|Placebo Comparator|Placebo|Saline solution for infusion: 4 intravenous administrations in a course of 10 days treatment
88936900|NCT01803373|Experimental|Treatment Sequence ABC|Participants in Panel 1 will take the sequence of 3 treatments with a standardized breakfast, participants in Panel 2 will take the sequence of 3 treatments with yogurt, and participants in Panel 3 will take the sequence of 3 treatments after a 10-hour overnight fast (without food). Each treatment in each treatment sequence to be separated by 4 weeks.
88936901|NCT01803373|Experimental|Treatment Sequence ACB|Participants in Panel 1 will take the sequence of 3 treatments with a standardized breakfast, participants in Panel 2 will take the sequence of 3 treatments with yogurt, and participants in Panel 3 will take the sequence of 3 treatments after a 10-hour overnight fast (without food). Each treatment in each treatment sequence to be separated by 4 weeks.
88936902|NCT01803373|Experimental|Treatment Sequence BAC|Participants in Panel 1 will take the sequence of 3 treatments with a standardized breakfast, participants in Panel 2 will take the sequence of 3 treatments with yogurt, and participants in Panel 3 will take the sequence of 3 treatments after a 10-hour overnight fast (without food). Each treatment in each treatment sequence to be separated by 4 weeks.
89015342|NCT01330459|Placebo Comparator|Placebo|"Subject will receive placebo 45-90 minutes prior to abortion procedure.~Subject will also recieve ibuprofen, lorazepam, and lidocaine 45-90 minutes prior to abortion procedure."
89452175|NCT03237910|Experimental|AMSA-CPR|The professional rescuer decides to deliver the defibrillation attempt based on the AMSA value displayed in the defibrillator
89452176|NCT03237910|Active Comparator|Standard-CPR|The defibrillation is delivered based on the 2015 European Resuscitation Council CPR guidelines
89501761|NCT03857659|Active Comparator|Routine antenatal care|Routine care with fundal height measurement at each antenatal appointment every 2 weeks from 28-36 weeks. As well as clinically indicated obstetric ultrasound by a Registered Diagnostic Medical Sonographer (RDMS)
88936903|NCT01803373|Experimental|Treatment Sequence BCA|Participants in Panel 1 will take the sequence of 3 treatments with a standardized breakfast, participants in Panel 2 will take the sequence of 3 treatments with yogurt, and participants in Panel 3 will take the sequence of 3 treatments after a 10-hour overnight fast (without food). Each treatment in each treatment sequence to be separated by 4 weeks.
88936904|NCT01803373|Experimental|Treatment Sequence CBA|Participants in Panel 1 will take the sequence of 3 treatments with a standardized breakfast, participants in Panel 2 will take the sequence of 3 treatments with yogurt, and participants in Panel 3 will take the sequence of 3 treatments after a 10-hour overnight fast (without food). Each treatment in each treatment sequence to be separated by 4 weeks.
88936905|NCT01803373|Experimental|Treatment Sequence CAB|Participants in Panel 1 will take the sequence of 3 treatments with a standardized breakfast, participants in Panel 2 will take the sequence of 3 treatments with yogurt, and participants in Panel 3 will take the sequence of 3 treatments after a 10-hour overnight fast (without food). Each treatment in each treatment sequence to be separated by 4 weeks.
88936906|NCT01803386||ALS Subjects|EIM measurements will be taken on two upper and two lower extremity muscles with several different electrode arrays. The ALSFRS-R will also be administered. Subcutaneous fat measurement will also be performed on all four muscles using skinfold calipers.
88936907|NCT01803386||Healthy Subjects|EIM measurements will be taken on two upper and two lower extremity muscles with several different electrode arrays. Subcutaneous fat measurement will also be performed on all four muscles using skinfold calipers.
88936908|NCT01803399|Experimental|GSK1322322 1200 mg Arm|Each subject will receive a single dose of GSK1322322 1200 mg IV over 60 minutes on Day 1 of one of the 4 treatment periods
88936909|NCT01803399|Experimental|GSK1322322 3000 mg Arm|Each subject will receive a single dose of GSK1322322 3000 mg IV over 60 minutes on Day 1 of one of the 4 treatment periods
88936910|NCT01803399|Placebo Comparator|Placebo Arm|Each subject will receive a single dose of GSK1322322 Placebo IV over 60 minutes on Day 1 of one of the 4 treatment periods
88936911|NCT01803399|Active Comparator|Moxifloxacin 400 mg Arm|Each subject will receive a single dose of moxifloxacin 400 mg administered orally on Day 1 of one of the 4 treatment periods
88936912|NCT01803425||Synflorix™ cohort|Only those subjects to whom Synflorix™ will be administered as per normal clinical practice, according to the locally approved PI, will be included in the study.
88936913|NCT01803438|Active Comparator|AADs|AAD therapy based on hospital clinical practice according to ESC Guidelines 2012
88936914|NCT01803438|Experimental|Cryoablation procedure|electrical pulmonary veins isolation performed with cryoballoon ablation system
88936915|NCT01803477|Active Comparator|Picato® 0.05% gel|once daily for two consecutive days
88936916|NCT01803477|Experimental|ingenol mebutate vehicle formulation 1|once daily for two consecutive days
88936917|NCT01803477|Experimental|ingenol mebutate vehicle formulation 2|once daily for two consecutive days
88936918|NCT01803477|Experimental|ingenol mebutate vehicle formulation 3|once daily for two consecutive days
88936919|NCT01803503|Active Comparator|Docetaxel|Docetaxel 75mg/m2 day 1, every 3 weeks. Patients will be treated for a maximum of 6 cycles of chemotherapy in the absence of tumor progression or unacceptable toxicities.
88936920|NCT01803503|Experimental|Docetaxel + Sunitinib|"Docetaxel 75mg/m2 day 1, every 3 weeks, preceded by 7 days of sunitinib 12.5mg orally daily during each cycle.~Patients will be treated for a maximum of 6 cycles of chemotherapy in the absence of tumor progression or unacceptable toxicities."
88936921|NCT01803516||Breast cancer survivors with radiation-induced Telangiectasias|A quality of life assessment will also be completed by the patient using the Skindex-16 and a subscale of the BREAST-Q Breast Conserving Module questionnaire.
88936922|NCT01803529|Experimental|heat-pack with massage|deep friction massage and standard heat-pack given a maximum of 8 treatments
88936923|NCT01803529|Active Comparator|heatpack only|standard heat-pack given a maximum of 8 treatments
88936924|NCT01803568|Experimental|Exercise in normoglycaemic individuals|
88936925|NCT01803568|Experimental|Exercise in hyperglycaemic individuals|
88936926|NCT01803581|Experimental|X92001327|the X92001327 product is a lotion to be applied on dry hair for 15 minutes and then washed out using shampoo. The product is to be applied on Day 0 and repeated again on Day 7.
88936927|NCT01803581|Active Comparator|RID shampoo|The RID shampoo is to be applied on dry the hair for 10 minutes and then rinsed out with water. the product is to be applied on Day 0 and repeated again on Day 7.
88936928|NCT01803659|Experimental|b-carotene|600 ug RAE/d as b-carotene, 6 d/wk for 3 weeks
88936929|NCT01803659|Active Comparator|retinyl palmitate|600 ug retinol equivalent/d, 6 d/wk for 3 weeks
88936930|NCT01803659|Placebo Comparator|placebo (corn oil)|0 ug RAE/d as corn oil
88936931|NCT01803672|Experimental|health talk and adventure-based training|Participate will join a four-day integrated health education and adventure-based training programme, which contains education talks, workshop and adventure-based training activities. The programme will be implemented on four different days within six months in a day camp training centre. The integrated programme will be implemented in small group with maximum 15 participants in one group. Health education talks and workshop will be implemented in between adventure-based training activities in day camp centre, which will be conducted by healthcare professionals working in a local university.
88936932|NCT01803672|Placebo Comparator|Placebo Control|Participants will receive an amount of time and attention that mimicked that received by the experimental group, but which is thought not to have any specific effect on the outcome measures. They will be invited to attend leisure activities organized by a community centre in four different days during the study period. Activities will include cartoon film shows, handicraft workshops, chess games, health talks on the prevention of influenza and healthy diet, day visit to museum and theme park.
88936933|NCT01803685||Surgical treatment|Surgical resection of intracranial arteriovenous malformations.
88936934|NCT01803685||Stereotaxic radiosurgery|Deliver a relatively high dose of focused radiation precisely to the arteriovenous malformations.
88936935|NCT01803685||Endovascular treatment|Deliver embolic materials to the feeding arteries or the nidus by microcatheters
88936936|NCT01803685||Comprehensive treatment|Use two or three methods ( Surgical treatment stereotaxic radiosurgery endovascular treatment ) to cure the intracranial arteriovenous malformations
88936937|NCT01803685||Conservative treatment|Patients refused to any of the treatment above
89452177|NCT03262766|Active Comparator|Acute intermittent hypoxia (AIH)|"Subjects will be exposed to acute intermittent hypoxia, daily for 5 days. Each session will consist of up to 90 seconds of 9-10% Oxygen (FiO2 0.09), alternating with up to 90 seconds of 21% Oxygen (normoxic air FiO2 0.21). The delivery of hypoxia and normoxic air mixtures will be repeated up to 18 times per session each, for up to 45 minutes, to maintain SpO2 at 80-90%. If the SpO2 drops below 75%, hypoxia exposure will be terminated immediately.~There is continuous monitoring of respiratory rate, heart rate and peripheral arterial oxyhemoglobin saturation (SpO2)."
89452178|NCT03262766|Experimental|AIH+ Upper extremity training|"Subjects will be exposed to acute intermittent hypoxia, daily for 5 days. Each session will consist of up to 90 seconds of 9-10% Oxygen (FiO2 0.09), alternating with up to 90 seconds of 21% Oxygen (normoxic air FiO2 0.21). The delivery of hypoxia and normoxic air mixtures will be repeated up to 18 times per session each, for up to 45 minutes, to maintain SpO2 at 80-90%. If the SpO2 drops below 75%, hypoxia exposure will be terminated immediately.~There is continuous monitoring of respiratory rate, heart rate and peripheral arterial oxyhemoglobin saturation (SpO2).~Following the AIH protocol, subjects will receive 45 minutes of task-specific, high repetition upper extremity training, given using an upper-limb robotic rehabilitation device, the Armeo Spring®."
89452179|NCT03262766|Active Comparator|Sham AIH + Upper extremity training|"Subjects will be exposed to sham hypoxia daily for 5 days. Each session will consist of up to 90 seconds of 21% Oxygen (FiO2 0.21), alternating with up to 90 seconds of 21% Oxygen (normoxic air FiO2 0.21). The delivery will be repeated up to 18 times per session each, for a total of up to 45 minutes.~There is continuous monitoring of respiratory rate, heart rate and peripheral arterial oxyhemoglobin saturation (SpO2).~Following the sham AIH protocol, subjects will receive 45 minutes of task-specific, high repetition upper extremity training. Upper extremity training will be given using an upper-limb robotic rehabilitation device, the Armeo Spring®."
89452180|NCT03262766|Sham Comparator|Sham Acute intermittent hypoxia|"Subjects will be exposed to sham hypoxia daily for 5 days. Each session will consist of up to 90 seconds of 21% Oxygen (FiO2 0.21), alternating with up to 90 seconds of 21% Oxygen (normoxic air FiO2 0.21). The delivery will be repeated up to 18 times per session each, for a total of up to 45 minutes.~There is continuous monitoring of respiratory rate, heart rate and peripheral arterial oxyhemoglobin saturation (SpO2)."
89452181|NCT02403310|Experimental|Dose Escalation - Selinexor|"Dose escalation of selinexor with fixed doses of daunorubicin and cytarabine.~Induction Therapy may be followed by Consolidation Phase and Maintenance Phase as outlined in the Detailed Description and Intervention Descriptions."
89452182|NCT03258944|Experimental|Breath-Stacking|Participants will be seated, with their elbows resting on the table, holding the face mask attached to a T-tube and a one-way valve. They will be instructed to inspire and force the expiration inside the mask. The training will be conducted three times a week for a period of four weeks, totaling twelve sessions. The breath-stacking application protocol will consist of three three-minute series, with a three-minute recovery interval between each series, obtaining a total time of fifteen minutes in each session
89452183|NCT01665274|Active Comparator|XELOX adjuvant group|"D2 resection~XELOX (Drug: Capecitabine 1,000 mg/m² twice daily. Film coated tablets of 500 mg. d1-14 q3w Drug: Oxaliplatin IV infusion, 130mg/m² d1 q3w) 6 cycles"
88936938|NCT01803698|Experimental|Training in the use of IOM charts|"Training family physicians to regularly refer to the Institute of Medicine guideline trajectories and provide feedback about GWG (training in the use of IOM charts) during routine prenatal visits."
88936939|NCT01803698|No Intervention|Usual care|Family physicians providing usual prenatal care.
88936940|NCT01803750||Primary Care Providers|Conduct and analyze in-depth, semi-structured interviews with community-based primary care providers serving large Latino populations and Form a community-based participatory committee.
88936941|NCT01803763|Active Comparator|Omalizumab (Xolair)|Fixed dose of 300 mg omalizumab is subcutaneously administered in total 4 monthly doses
88936942|NCT01803763|Placebo Comparator|Placebo|Fixed dose of Placebo is subcutaneously administered in total 4 monthly doses
88936943|NCT01803776|Experimental|lifestyle counseling|Physical activity and dietary counseling
88936944|NCT01803776|No Intervention|Control|No active intervention
88936945|NCT01803789|Active Comparator|Single Kirschner Wire|Antegrade intramedullary fixation of with a single Kirschner wire.
88936946|NCT01803789|Active Comparator|Double Kirschner Wire|Antegrade intramedullary fixation with double Kirschner wire.
88936947|NCT01803802|Placebo Comparator|Time management|Writing prompts oriented towards objective recounting of previous day
88936948|NCT01803802|Experimental|Sexual schema writing|Expressive writing prompts oriented towards beliefs about sexuality
88936949|NCT01803802|Active Comparator|Trauma writing|Expressive writing prompts oriented towards processing traumatic experiences
88936950|NCT01803828|Active Comparator|Drug Group (Tadalafil)|Tadalafil 20 mg
88936951|NCT01803828|Placebo Comparator|Placebo Group (PLC)|Placebo 20 mg
88936952|NCT01803841|Active Comparator|Transradial access|Coronary angiography and intervention via radial artery approach
88936953|NCT01803841|Active Comparator|Transfemoral access|Coronary angiography and intervention via femoral artery approach
88936954|NCT01803867|Placebo Comparator|rHIgM22|"Cohorts 1-5: In each dosing cohort, the first 2 eligible patients will be enrolled and randomized 1:1 to receive rHIgM22 or placebo, and monitored for safety for a minimum of 7 days before the remaining 8 patients in the cohort are randomized (7 active: 1 placebo) and dosed.~Expanded Cohort: Upon establishment of a Maximally Tolerated Dose (MTD), a new group of 21 patients will be enrolled in an Expansion Cohort. Randomly assigned in a 1:1:1 ratio to 1 of 3 treatment groups: placebo, Investigational Product (IP) at MTD, or IP at one full dose level lower than MTD."
88936955|NCT01803893||Embryo culture media|measurement using immunoassay
88936956|NCT01803893||maternal serum|measurement by immunoassay
88936957|NCT01803919|Experimental|Silver Alloy-Coated Urinary Catheters|Bactiguard® Infection Protection coating consists of noble metals such as gold, palladium and silver. Trained health staff performs urethral catheterization and select the most adequate catheter size. To ensure aseptic conditions they are asked to strictly follow the current protocol in their respective centers. Indwelling urethral catheters are periodically replaced about 30 days of use; to not interfere with current clinical practice, the policy of each center (or the investigator criteria) for catheter replacement and removal is considered valid for this study.
88936958|NCT01803919|Other|Conventional Urinary Catheter|Conventional or standard urinary catheters are those commonly used in each study center, most of them made of silicone or silicone-latex. Trained health staff performs urethral catheterization and select the most adequate catheter size. To ensure aseptic conditions they are asked to strictly follow the current protocol in their respective centers. Indwelling urethral catheters are periodically replaced about 30 days of use; to not interfere with current clinical practice, the policy of each center (or the investigator criteria) for catheter replacement and removal is considered valid for this study.
88936959|NCT01803932|Experimental|Behavioral intervention|Male-focused group violence prevention intervention
89452184|NCT01665274|Experimental|XELOX neoadjuvant|"XELOX (Drug: Capecitabine 1,000 mg/m² twice daily. Film coated tablets of 500 mg. d1-14 q3w Drug: Oxaliplatin IV infusion, 130mg/m² d1 q3w) 3 cycles chemotherapy before operation.~D2 resection~After operation:~CR/PR: XELOX (Drug: Capecitabine 1,000 mg/m² twice daily. Film coated tablets of 500 mg. d1-14 q3w Drug: Oxaliplatin IV infusion, 130mg/m² d1 q3w) 3 cycles chemotherapy after operation. SD/PD:,ST(Drug: S-1，40-75mg twice daily. d1-14 q3w Drug: Paclitaxel IV infusion 135mg/m2 d1; q3w) 3 cycles chemotherapy after operation."
89452185|NCT03259256|Experimental|Allogeneic transplantation of human islet|Each subject may receive 1-3 transplantations of allogeneic human islets we will inject the least dose of 3,000 IEQ/kg body weight of the recipient. Tacrolimus 1 mg p.o. bid adjusted to reach target trough levels of 3-6 ng/ml.
89452186|NCT01216540||Patients receiving vancomycin|
89452187|NCT03262298|Experimental|anti-CD22 CAR-T|Patients will receive a full dose CART infusion at day 0.
89452188|NCT05484856|Experimental|Experimental|Patients with Osteoarthritis A total of 140 patients ( May 2016 to june 2020) were treated with intra articular adipose derived stromal cells (ADSC)) also known as Stromal vascualr fraction administration
89452189|NCT05387876|Placebo Comparator|Placebo intervention|A gummie candy the same consistency and nutrient value as the vitamin D gummie without any vitamin D will be taken as four gummies at the largest meal for 12 weeks once per day
89452190|NCT05387876|Experimental|Vitamin D intervention|A vitamin D gummie the same consistency and nutrient value as the placebo gummie will be taken as four gummies at the largest meal for 12 weeks once per day providing 4000 IUs per day or 1000 IUs per gummie
89452191|NCT02456402|Experimental|Drug Coated Balloon|PCB (SeQuent Please®, paclitaxel-coated balloon catheter, B. Braun, Melsungen, Germany)
89452192|NCT02456402|Active Comparator|Bare Metal Stent|BMS (Vision®)
89452193|NCT03890536||Biliary atresia|Biliary atresia is an obstructive cholangiopathy of infancy. It is the most common cause of neonatal cholestasis and the most frequent indication for liver transplantation in children. Patients with biliary atresia have conjugated hyperbilirubinemia (serum direct bilirubin > 1mg/dL) AND are scheduled for/undergo exploratory laparotomy for diagnosis and Kasai portoenterostomy for surgical treatment of BA.
89452194|NCT03890536||Non-BA=disease controls|All infants with other cholestatic syndromes (except biliary atresia) will be eligible for study enrollment in disease controls/non-biliary atresia. This involves the diagnosis of liver diseases caused by syndromes of intrahepatic cholestasis with or without hyperbilirubinemia.
89452195|NCT03890536||Normal|All healthy infants with no acute or chronic liver related illness.
89452196|NCT05074004|No Intervention|control group|"No intervention was applied to the control group in this process.~be receiving treatment in Clinic Day Hospital~Volunteering to participate in research"
89452197|NCT05074004|Experimental|Psychoeducation|"be receiving treatment in Clinic Day Hospital~Volunteering to participate in research"
89452198|NCT03262376|Experimental|Mineral + vits + botanical A|Mineral and vitamin complex combined with Botanical A
89452199|NCT03262376|Experimental|Mineral + vits + botanical B|Mineral and vitamin complex combined with Botanical B
89452200|NCT03262376|Experimental|Mineral+vits +botanical A+Botanical B|Mineral and vitamin complex combined with Botanical A and Botanical B
89452201|NCT03262376|Placebo Comparator|Placebo|Cellulose crystalline placebo
89452202|NCT03261986|Other|Trident II acetabular cup|Subjects receive the Trident II acetabular cup and RSA beads and undergo a series of post-operative RSA exams.
89452203|NCT02456714|Experimental|Progressive cholangiocarcinoma, second line treatment|FOLFIRINOX
89452204|NCT05480020|Active Comparator|Streptococcus salivarius M18 toothpaste dose 1|Streptococcus salivarius M18 toothpaste containing 1 million cfu/g
89452205|NCT05480020|Active Comparator|Streptococcus salivarius M18 toothpaste dose 2|Streptococcus salivarius M18 toothpaste containing 10 million cfu/g
89452206|NCT05480020|Active Comparator|Streptococcus salivarius M18 toothpaste dose 3|Streptococcus salivarius M18 toothpaste containing 100 million cfu/g
89452207|NCT03259646|Experimental|Universal Education|Train providers to integrate screening, universal education, trauma informed counseling, and mobile health (mHealth) technology through the myPlan app safety decision aid in collaboration with local IPV programs as well as the integration of documentation and quality improvement templates and measures into clinical settings.
89452208|NCT03259646|No Intervention|Standard Practice|Standard clinical practice
89452209|NCT03258866|Experimental|group A|In group A, Rituximab was given with a fixed dose of 100 mg administered as an intravenous infusion weekly (on day 1, 8, 15 and 22).
89452210|NCT03258866|Experimental|group B|In group B, Rituximab was given with a single dose of 375mg/m2
89452211|NCT02456168||SLE|
89452212|NCT02456168||Healthy control|
89015343|NCT00260975||Chemotherapy patients|Breast cancer patients treated with adjuvant chemotherapy of various types.
89452213|NCT04784546||Mild COVID-19 Infection Group|Mild cases present with acute symptoms of respiratory tract infection and gastrointestinal complaints.
89452214|NCT04784546||Moderate COVID-19 Infection Group|Moderate patients experience pneumonia, they don't have clinically aberrant hypoxemia(O2 saturation is more than 90%) but they have positive findings on chest computerized tomography (CT) scans.
89452215|NCT04784546||Severe COVID-19 Infection Group|Severe patients present with pneumonia, they have hypoxemia (O2 saturation is less than 90%) and have positive findings on chest computerized tomography (CT) scans.
89452216|NCT02456324|Experimental|Treatment Group|Patients Treated with PICS-AF device
89452217|NCT02456324|Other|Historical Controls|Patients Treated with Commercially Available Fistula Plug Devices at Same Sites
89452218|NCT03258476|Experimental|GXR and Mindfulness Skills|Guanfacine Extended Release (GXR) will be started at 1 mg/day at Week 1 and tapered up by 1 mg per week to a maximum dose of 7 mg/day by week 7 (maximum of 6 weeks on drug). GXR dosing will be flexible for the first 5 weeks of the study based upon patient response and tolerability to drug. Optimal dose will be defined as that necessary to achieve ≥ 30% reduction in symptoms and a CGI-Improvement Score ≤ 2. Upon re-evaluation at (T1) and entry into the psychotherapy protocol dosing will become fixed for the remainder of the study. Mindfulness Skills Therapy will occur for the next 10 weeks.
89452219|NCT03258476|Active Comparator|Placebo and Mindfulness Skills|"Placebo will be started at 1 mg/day at Week 1 and tapered up by 1 mg per week to a maximum dose of 7 mg/day by week 7 (maximum of 6 weeks on drug). Placebo dosing will be flexible for the first 5 weeks of the study based upon patient response. Optimal dose will be defined as that necessary to achieve ≥ 30% reduction in symptoms and a CGI-Improvement Score ≤ 2. Upon re-evaluation at (T1) and entry into the psychotherapy protocol dosing will become fixed for the remainder of the study. Mindfulness Skills Therapy will occur for the next 10 weeks."
89452220|NCT03258398|Experimental|Part 1: eFT508 plus avelumab dose finding Arm|subjects will receive eFT508 in combination with a fixed dose of avelumab
89452221|NCT03258398|Experimental|Part 2: eFT508 plus avelumab|subjects will receive eFT508 in combination with a fixed dose of avelumab
89452222|NCT03258398|Experimental|Part 2: eFT508 alone|subjects will receive eFT508 alone
89452223|NCT05479942|Experimental|Group A|Study group
89452224|NCT05479942|Experimental|Group B|Control group
89452225|NCT03261752||patient with cancer|blood sample will be collected from patient before and after treatment (surgery or chemotherapy)
89452226|NCT03261752||healthy people|blood sample will be collected for comparison
89452227|NCT03261596|Experimental|100 mg solid tablets 2x/day for 3 days|Assess the efficacy (Cure Rate/CR) and safety of 100 mg dose regimen of mebendazole in children aged 6 to 18 years, inclusive, infected with hookworm.
89452228|NCT03261596|Experimental|Single dose 500 mg solid tablets|Assess the efficacy (Cure Rate/CR) and safety of 500 mg dose regimen of mebendazole in children aged 6 to 18 years, inclusive, infected with hookworm.
89452229|NCT04072588||Sacrospinous Ligament Fixation patients|Patients who underwent Sacrospinous Ligament Fixation for the treatment of vaginal cuff prolapse in patients who had previously undergone hysterectomy for benign causes
89452230|NCT04072588||lateral suspension surgery patients|Patients who underwent lateral suspension surgery for vaginal cuff prolapse in patients who had previously undergone hysterectomy for benign causes
89452231|NCT04488458|Experimental|MBEC and MIC susceptibility testing|"For all administered antimicrobials staphylococcal strains must be susceptible in disc diffusion tests/MIC, regardless of MBEC-level. Antibiotic combinations will be selected from 5 already recommended non-cell wall active anti-staphylococcal antibiotics with high per-oral bio-availabilities and acceptable bone penetration used in the treatment of PJIs: rifampicin, fusidic acid, ciprofloxacin/levofloxacin and clindamycin.~MBEC cut-off for replacement with 2nd or 3rd line antibiotic: RIF MBEC/MIC > 8; LEV MBEC/MIC > 5; FUS MBEC/MIC > 3; CLI MBEC/MIC > 4; LIN MBEC/MIC > 2; T/S MBEC > MIC~Second line of treatment:~RIF and Fusidic acid 500 mg TID (ter in die) RIF and Clindamycin 450 - 600 mg TID LEV and Fusidic acid 500 mg TID LEV and Clindamycin 450 mg TID~Third line of treatment:~Linezolid 600 mg BID (bis in die) Sulfamethoxazole/Trimethoprim 800/160 mg TID Clindamycin 450 mg TID and Fusidic acid 500 mg TID"
89452232|NCT04488458|Active Comparator|MIC susceptibility testing|If the causative bacterium is susceptible according to MIC diagnostics, the patient will follow the first line of treatment: Rifampicin 750-900 mg/day + Levofloxacin 750 mg BID
89452233|NCT05479864|Other|Anterior cervical corpectomy and fusion|removal of damaged vertebrae and intervertebral disc that are compressing the spinal cord and spinal nerves. Various graft materials or spacers are used to maintain height and stability followed by anterior plating
89452234|NCT03261908||wild genotype|Through next generation sequencing, distinguish wild genotype of simvastatin
89452235|NCT03261908||mutant genotype|Through next generation sequencing, distinguish mutant genotype of simvastatin
89452236|NCT03825874||amikacin IV|Febrile urinary tract infection treated with amikacin IV
89452237|NCT03825874||Other antibiotics|Febrile urinary tract infection treated with other antibiotic, according to the recommendations: ceftriaxone or cefixime
89452238|NCT03772574|Experimental|THRIVE|THRIVE preoxygenation (tidal volume breathing with the OptiFlow system applied at 100% oxygen).
89452239|NCT03772574|Active Comparator|Facemask|Facemask preoxygenation (tidal volume breathing via a face mask set at 100% oxygen).
88936960|NCT01803932|No Intervention|Control communities|Communities in which male-focused group prevention activities will not be conducted
88936961|NCT01803945|Placebo Comparator|Placebo Group|Sequential cohorts of eight patients with PD will be administered ascending oral doses of AVE8112 (n=6) or placebo (n=2) once a day for 14 days. Patients will be assessed in clinic for 30 hours following the initial oral dose of AVE8112 or placebo
89452240|NCT05483842|Experimental|Reiki Group|Personal Information Form (PIF) and Beck Anxiety Scale (BAS) were administered to the Reiki group through face-to-face interviews. Then, blood was taken for biochemical blood and cortisol findings and ECG was taken. After the pre-tests of the patients were completed, the application was made under the guidance of a researcher with a Usui Reiki Master & Teacher degree and by a researcher with Reiki II training. In accordance with the Reiki Practice Protocol, an empty and silent room was selected in the hospital. Reiki was applied one-on-one to energy centers (crown chakra, forehead chakra, throat chakra, heart chakra, solar plexus, sacral region, root chakra, knees, ankle and feet) for 30 minutes. On the second day, 30 minutes of distant Reiki was applied. BAS was administered 1 week later; ECG was taken and biochemistry blood was taken.
89501762|NCT02224183|Active Comparator|Education|Individuals randomized to the education group will receive The Back Pain Helpbook, an educational book with strategies for self-care including an exercise program, lifestyle modification, and tips for managing flare-ups. In addition, they will receive an assignment sheet outlining specific chapters to read over the course of the 12-weeks. In addition, participants receive at 3, 6, 9, and 12 weeks newsletters highlighting main points from the assigned chapters.
88936962|NCT01803945|Active Comparator|AVE8112|Sequential cohorts of eight patients with PD will be administered ascending oral doses of AVE8112 (n=6) or placebo (n=2) once a day for 14 days. Dosing for subsequent cohorts will only proceed, and the dose level selected, after the safety and tolerability of the previous cohort has been reviewed. Doses are planned to be 1.0, 2.0, 3.0, and 4.0 mg once a day for 14 days. These are planned treatments, but doses may be modified based on safety review of previous cohort(s). In addition, cohorts may be added to reconfirm a previously administered dose, and/or a titration strategy may be employed to reach a desired dose. Patients will be assessed in clinic for 30 hours following the initial oral dose of AVE8112 or placebo
89015344|NCT00260975||Hormonal patients|Breast cancer patients treated with adjuvant hormonal therapy but not chemotherapy.
89452241|NCT05483842|Placebo Comparator|Sham Reiki Group|Personal Information Form (PIF) and Beck Anxiety Scale (Scale) were administered to this group by face-to-face interviews. Then, blood was taken for biochemical blood and cortisol findings and ECG was taken. After the pre-tests of the patients were completed. The Sham Reiki group was practiced by a student nurse who did not receive Reiki training by imitating the hand positions used in Reiki practice. Before the applications, the researcher, the student was told about aura equalization and chakras, the student only imitated gestures and facial expressions, but did not give Reiki energy to the patients. BAS was administered 1 week later; ECG was taken and biochemistry blood was taken.
89452242|NCT05483842|No Intervention|Control Group|Personal Information Form (PIF) and Beck Anxiety Scale (BAS) were administered to this group by face-to-face interviews. Then, blood was taken for biochemical blood and cortisol findings and ECG was taken. After 1 week, BAS, blood tests and ECG have applied again.
89452243|NCT05479786||Ectopic pregnancy|Women with diagnosed tubal ectopic pregnancy
89452244|NCT05499208|Experimental|Giving side position with patient turning and movement system|On the day she was admitted to the clinic, the pregnant woman was taken to the room with the turning and movement system, the system was introduced and the personal information form was filled. When she came to the clinic from the operating room, the puerperant was placed on the bed with the turning and motion system (side position) and a follow-up form for LATCH, GKO and Lactogenesis Free symptoms was filled in the first three breastfeedings. Before discharge, LATCH, GCS, and Lactogenesis symptoms follow-up forms were filled in the last three breastfeedings. WHO was filled 1-2 hours before discharge. On the 3rd and 4th days after discharge, the lactogenesis symptoms follow-up form was filled by phone.
89452245|NCT05499208|No Intervention|Control: Assigned Interventions standard care group|routine maintenance of the hospital
88936963|NCT01803958|Experimental|partial breast irradiation|38.5 Gy total in 10 fractions (3.85 Gy per fraction), twice a day with an interval of at least 6 hours between the two fractions, for five consecutive working days
88936964|NCT01803958|Active Comparator|whole breast irradiation|50.0 Gy in 25 fractions (2 Gy per fraction), once a day for 5 days in the week, or other biologically equivalent schedule
88936965|NCT01803971|Experimental|vascular access in out-of-hospital cardiac arrest patients|Obtention of vascular access according to the current strategy, ie after one unsuccessful attempt to obtain a peripheral venous access, use of an intra osseous device
88936966|NCT01803984||Patient with migraine with aura|Patients with a clearly defined migraine (as per IHS criteria) with aura, who are aged 30 and older and are able to fluently speak French.
88936967|NCT01803984||Patient with migraine without aura|patients with a clearly defined migraine (as per IHS criteria) without aura who are aged 30 and older, are able to fluently speak French, and who are willing to participate
88936968|NCT01803997|Other|STRIDE|12 cooking classes offered over 6 weeks (approximately 2 classes/week)
88936969|NCT01803997|Other|SPARK|12 physical activity classes offered over 6 weeks (approximately 2 classes/week)
88936970|NCT01804010|Active Comparator|Ivabradine|Single and repeated oral administrations of 3 doses of ivabradine
88936971|NCT01804010|Placebo Comparator|Placebo|Placebo administration
88936972|NCT01804023||Healthy women|
88936973|NCT01804127|Experimental|R-CHOP|rituximab 375mg/m2 day 0, cyclophosphamide 750mg/m2 IV day 1, doxorubicin 50mg/m2 IV day 1, vincristine 1.4mg/m2 IV day1 (maximum: 2mg), prednisone 50mg PO days 1-5 twice per day
88936974|NCT01804153|Experimental|Autologous expanded stem cells|Adipose-derived expanded stem cells
88936975|NCT01804192|Experimental|Acu-TENS to LI4 and LI11|"Acu-TENS Group (Experimental Group), subjects received TENS over right L14 and LI11.~Systolic and diastolic blood pressures will be taken on the left arm by a digital blood pressure monitor. The mean arterial pressure (MAP) will be recorded from the machine. Three ECG electrodes will be applied over left and right clavicles and left upper quadrant of abdomen respectively and then connect to a digital patient monitor device. The heart rate (HR) will be measured. The ECG signals will be transferred to the PowerLab 16/30 for data acquisition and analysis of the HRV."
88936976|NCT01804192|Active Comparator|Control group|"Control Acu-TENS Group (Control Group), subjects received TENS over tips of bilateral knee caps.~Systolic and diastolic blood pressures will be taken on the left arm by a digital blood pressure monitor. The mean arterial pressure (MAP) will be recorded from the machine. Three ECG electrodes will be applied over left and right clavicles and left upper quadrant of abdomen respectively and then connect to a digital patient monitor device. The heart rate (HR) will be measured. The ECG signals will be transferred to the PowerLab 16/30 for data acquisition and analysis of the HRV."
88936977|NCT01804192|Placebo Comparator|Placebo group|Placebo Acu-TENS Group (Placebo Group), subjects received the same protocol as the Acu-TENS group and TENS was applied over right LI4 and LI11 that covered with non-conducting plastics (with the same dimension as the TENS electrodes) Systolic and diastolic blood pressures will be taken on the left arm by a digital blood pressure monitor. The mean arterial pressure (MAP) will be recorded from the machine. Three ECG electrodes will be applied over left and right clavicles and left upper quadrant of abdomen respectively and then connect to a digital patient monitor device. The heart rate (HR) will be measured. The ECG signals will be transferred to the PowerLab 16/30 for data acquisition and analysis of the HRV.
88936978|NCT01804205|Experimental|Magnesium sulfate group|In the magnesium group, patients received MgSO4 30 mg/kg in 0.9% physiological saline (total volume 100 ml) intravenously, for 10 min, and then continuous intravenous infusion of MgSO4 at a rate of 1 g/h during the surgical procedure until the maximum of 3 h.
88936979|NCT01804205|Placebo Comparator|Control group|Controls received 100 ml of 0.9% physiological saline, for 10 min, and then continuous intravenous infusion of saline at a rate of 33 ml/h during the surgical procedure until the maximum of 3 h.
88936980|NCT01804218|Placebo Comparator|Placebo|Placebo
88936981|NCT01804218|Experimental|Active, nadolol|Active
88936982|NCT01804231|Other|18F-FCH PET/MRI imaging|Patients eligible for the study will have an 18F-FCH PET/MRI in addition to standard of care clinical assessment and imaging (CT and bone scan)
88936983|NCT01804244|Experimental|TMC278|All participants will receive a single-dose of TMC278 (1 25-mg tablet [27.5 mg as the hydrochloride salt]) after an overnight fast (going without food) of at least 10 hours before eating a standard breakfast. Study drug will be taken within 10 minutes after completion of a standardized breakfast.
88936984|NCT01804283|Sham Comparator|CON|Patients undergoing double valve replacement (aortic and mitral).
89452246|NCT04319380|Active Comparator|SMC with SP+AQ|Administration of tetanus/diphtheria toxoids vaccine followed by 4 cycles of SMC with sulphadoxine/pyrimethamine plus amodiaquine in Year 1 and 2.
89452247|NCT04319380|Active Comparator|RTS,S/AS01|Administration of the malaria vaccine RTS,S/AS01 followed by 4 cycles of SMC with placebo in Year 1 and 2.
89452248|NCT04319380|Active Comparator|RTS,S/AS01 plus SMC with SP+AQ|Administration of the malaria vaccine RTS,S/AS01 followed by 4 cycles of SMC with sulphadoxine/pyrimethamine plus amodiaquine in Year 1 and 2.
89452249|NCT02456558|Experimental|Intravenous deferiprone, 1.5 g|Subjects in this arm will receive an infusion of intravenous deferiprone at a dose of 1.5 g, twice-daily
89452250|NCT02456558|Experimental|Intravenous deferiprone, 2 g|Subjects in this arm will receive an infusion of intravenous deferiprone at a dose of 2 g, twice-daily
89452251|NCT02456558|Placebo Comparator|Placebo|Subjects in this arm will receive an infusion of placebo twice-daily for 10 days, at a volume equivalent to that of the active product in the respective cohort
89452252|NCT03798080|Experimental|Soliqua (insulin glargine/lixisenatide)|iGlarLixi (insulin glargine/lixisenatide) will be self-administered subcutaneously once daily in the morning with or without metformin for 30 weeks
89452253|NCT03798080|Active Comparator|Lantus (insulin glargine)|Insulin glargine will be self-administered subcutaneously once daily at any time of the day with or without metformin for 30 weeks
89452254|NCT05498974||Individuals diagnosed with type 1 diabetes|All patients diagnosed with type 1 diabetes of all ages.
89452255|NCT05498974||Individuals with diabetes who had an age of onset <= 20 years.|All patients with diabetes who had an age of onset <= 20 years.
89452256|NCT03258242|Experimental|Experimental: Keluo Xin Capsule|
89452257|NCT03258242|Placebo Comparator|Placebo Comparator: Placebo|
89452258|NCT03258086|Experimental|Blood sample|2ml blood sample of of blood will be taken for assessment of vitamin D
89452259|NCT03257930|Experimental|injection of ethanol|use of ethanol injection in the treatment of cystic thyroid nodule
89452260|NCT03257852|Experimental|ASP5094 Group|To be intravenously administered ASP5094 in patients with rheumatoid arthritis (RA) treated with methotrexate.
89452261|NCT03257852|Placebo Comparator|Placebo Group|To be intravenously administered ASP5094 in patients with rheumatoid arthritis (RA) treated with methotrexate.
89452262|NCT05498896|Other|Atezolizumab + Chemotherapy|Atezolizumab (1200mg IV Q3W x 1 cycle) followed by Paclitaxel (80 mg/m2 Q1W x 12) plus Atezolizumab 840 mg (Q2W x 6) followed by Doxorubicin (60 mg/m2) plus Cyclophosphamide (600 mg/m2 Q2W x 4) plus Atezolizumab (840 mg Q2W x 4)
89452263|NCT05498896|Experimental|Atezolizumab + Chemotherapy + Ipatasertib|Atezolizumab (1200 mg, Q3W x 1 cycle), plus Ipatasertib (400 mg OD, days 1-14) followed by Paclitaxel (80 mg/m2 Q1W x 12) plus Atezolizumab (840 mg Q2W x 6), plus Ipatasertib, (400 mg OD, days 1-21 Q4W) followed by Doxorubicin (60 mg/m2) plus Cyclophosphamide (600 mg/m2 Q2W x 4) plus Atezolizumab (840 mg Q2W x 4).
89452264|NCT04765358|Other|All Participants|All participants will be provided with a commercially available CGM system. Training and data collection for the study will be completed remotely. After initial CGM training (initiation of unblinded CGM use or initial training with virtual clinic) has been completed, participants will continue to be followed by the virtual clinic team for approximately six months. Psychosocial screening questionnaires are administered at enrollment and during follow up. The virtual clinical team member will follow up with the study participant if there is an elevated score on the psychosocial screening questionnaires. After the initial six months of follow up, participants who decide to continue to use CGM will be asked to extend follow up and complete questionnaires, submit HbA1c samples, and share data. During the extended follow up phase, participants will be able to contact the virtual clinic with questions or to request assistance as needed.
89452265|NCT03257774|Experimental|Test of three new adhesive strips|"The subjects test three new adhesive strips~adhesive strip A~adhesive strip B~adhesive strip C"
89452266|NCT04779476||Control Group|No dressing material will be used post dental extraction
89452267|NCT04779476||Alveogyl Group|Alveogyl will be placed in the dental socket after extraction
89452268|NCT04779476||Cutanplast Group|Absorbable gelatin sponges contain will be placed in the dental socket after extraction
89452269|NCT04667156|Experimental|Sequence 1|Intervention: Drug: SHR6390 new formulation 1(T1) in the first period; SHR6390 new formulation 2 (T2) in the second period; SHR6390 traditional formulation (R) in the last period
89452270|NCT04667156|Experimental|Sequence 2|Intervention: Drug: SHR6390 traditional formulation (R) in the first period; SHR6390 new formulation 1 (T1) in the second period; SHR6390 new formulation 2 (T2) in the last period
89452271|NCT04667156|Experimental|Sequence 3|Intervention: Drug: SHR6390 new formulation 2(T2) in the first period; SHR6390 traditional formulation (R) in the second period; SHR6390 new formulation 1 (T1) in the last period
89452272|NCT04667156|Experimental|Sequence 4|Intervention: Drug: SHR6390 new formulation 1(T1) in the first period; SHR6390 traditional formulation (R) in the second period; SHR6390 new formulation 2 (T2) in the last period
89452273|NCT04667156|Experimental|Sequence 5|Intervention: Drug: SHR6390 new formulation 2(T2) in the first period; SHR6390 new formulation 1 (T1) in the second period; SHR6390 traditional formulation (R) in the last period
89452274|NCT04667156|Experimental|Sequence 6|Intervention: Drug: SHR6390 traditional formulation (R) in the first period; SHR6390 new formulation 2 (T2) in the second period; SHR6390 new formulation 1 (T1) in the last period
89452275|NCT03257540||Small Bone Intramedullary Nail|All study participants
88936985|NCT01804283|Experimental|IPO|Patients undergoing double valve replacement (aortic and mitral) with ischemic postconditioning.
88936986|NCT01804309||Early breast cancer patients|Clinical stage T1-2 N0M0 primary unilateral invasive breast cancer patients
88936987|NCT01804322|Active Comparator|Usual care|usual care according to the practice of participating Epilepsy Centers
88936988|NCT01804322|Experimental|Standardized educational plan|"The comprehensive and standardized educational plan consists in the discussion with the patient each of the following points:~The cause and nature of the adverse event and/or drug interaction~The tolerability profile of each drug present in the schedule~The clinical manifestations associated with the current drug interactions~Any contraindication to the use of over-the-counter drugs potentially interfering with the current treatment schedule~The reasons for and the potential benefits of the suggested treatment change~An encouragement to withdraw any potentially interfering or contraindicated drug"
89452276|NCT02455700|Active Comparator|Hand driven enamel reduction|This group will have enamel reduction in the lower incisor region carried out using hand held devices
89015345|NCT00298623|Placebo Comparator|Placebo|
89015346|NCT00298623|Experimental|XP13512 (GSK1838262)|
89015347|NCT00293085|Active Comparator|Docetaxel|"Docetaxel (Taxotere ) 75 mg/m² as a 1 hour i.v. infusion, followed immediately by cisplatin 75 mg/m² as a 1 hour i.v. infusion, on day 1 every 21 days for 6 cycles.~Dose reductions and/or treatment delays or discontinuation of treatment are planned for arm A in case of severe haematological and/or non haematological toxicities.~Premedication:~Dexamethasone 8 mg p.o. (or any other steroid commonly used) will be given -12 h, -3 h, -1 h before start of docetaxel infusion, then + 12 h, +24 h and + 36 h post infusion.~All patients should receive a prophylactic antiemetic premedication to prevent nausea and vomitus, which includes a 5-HT3 antagonist prior to start of each docetaxel infusion.~Hyperhydration Patients will require intravenous hydration according to institutional guidelines."
89015348|NCT00293085|No Intervention|Comparative arm|No chemotherapy will be administered. No specific salvage therapy after progression is defined.
89452277|NCT02455700|Active Comparator|Rotary ( motor driven) device|This group will ahve enamel reduction in the lower incisor region carried out using a rotary (motor driven) device
89452278|NCT03257306|Active Comparator|Magnetic double-J ureteric stent|Double-J ureteric stent removed using magnet
89452279|NCT03257306|Active Comparator|Standard double-J ureteric stent|Double-J stent removed using cystoscopy
89452280|NCT03252704|Experimental|High fiber - low fiber|Treatment order described in arm title, resistant starch (high fiber muffin top) - conventional flour (low fiber muffin top)
89452281|NCT03252704|Experimental|low fiber - high fiber|Treatment order described in arm title, conventional flour (low fiber muffin top)- resistant starch (high fiber muffin top)
89452282|NCT03257462|Experimental|Cohort A|The first cohort of 9 patients will be administered SPR001 at dose strength of Dose A daily for 2 weeks, and escalating through Dose B per day for 2 weeks and Dose C per day for 2 weeks.
89452283|NCT03257462|Experimental|Cohort B|Cohort B will begin enrollment after Cohort A has been fully enrolled. Starting dose selection and the stepwise dosing paradigm for Cohort B will be determined by an interim review of safety and PK/PD data from from Cohort A.
89452284|NCT03257462|Experimental|Cohort C|Cohort C will begin enrollment after Cohort B has been fully enrolled. Starting dose selection and the stepwise dosing paradigm for Cohort C will be determined by an interim review of safety and PK/PD data from from Cohort A and B.
89452285|NCT03257228||oral lichen planus and diabetes mellitus|Histopathologically confirmed samples of oral lichen planus underwent immunohistochemical analysis of IGF1 and IGF2 expression. Blood glucose level was determined one day before taking biopsy.
89452286|NCT03257228||oral lichen planus|Histopathologically confirmed samples of oral lichen planus underwent immunohistochemical analysis of IGF1 and IGF2 expression. Blood glucose level was determined one day before taking biopsy.
89015349|NCT00261053|Other|1|Open-label i.v. administration of 100 U/kg rhC1INH
89015350|NCT01330381|Experimental|prucalopride|drug
89015351|NCT01330381|Placebo Comparator|Placebo|
89452287|NCT03257228||healthy mucosa|Samples of healthy mucosa underwent immunohistochemical analysis of IGF1 and IGF2 expression. Blood glucose level was determined one day before taking mucosa samples.
89452288|NCT03257072|Experimental|A: 50 Necator americanus L3 larvae|Mock infections with water at week 0 and 2, infection with 50 Necator americanus L3 larvae at week 4
89452289|NCT03257072|Experimental|B: 100 Necator americanus L3 larvae|Mock infections with water at week 0, infection with 50 Necator americanus L3 larvae at week 2 and 4
89452290|NCT03257072|Experimental|C: 150 Necator americanus L3 larvae|Infection with 50 Necator americanus L3 larvae at week 0, 2 and 4
89452291|NCT03252470||2D laparoscopic surgeries|Two-Dimensional Laparascopic Surgical Video System
89452292|NCT03252470||3D laparoscopic surgeries|Three-Dimensional Laparascopic Surgical Video System
89452293|NCT03256604||Fresh left-over sputum|All fresh sputum samples that were sent to the Department of Microbiology between November 1 2015 and January 30 2016 under the standard requirements for sputum cultures at the accredited (ISO 17025 and 15189 beginning in 1993) laboratory were kept cold (4-8 ͦC) after analysis by microscope and cultures until it was collected and coded by the study nurse in the evening (left-over samples).
89452294|NCT03256838|Experimental|Ferric citrate|Ferric Citrate (Nephoxil® Capsules) will be dosed three times a day (with meals).
89452295|NCT02455544||Pregnant Women|Any pregnant women that is referred to or presents to our tertiary care facility with concern for preeclampsia, will have a Congo Red Dot test preformed by research nurses. The research nurses are not involved in patient management and the results are blinded to the clinical providers and have no impact on clinical diagnosis or patient management.
89452296|NCT02743221|Experimental|Trifluridine/tipiracil + bevacizumab|"Trifluridine/tipiracil (S95005): film-coated tablets containing 15mg of trifluridine and 7.065mg of tipiracil hydrochloride, or 20mg of trifluridine and 9.42mg of tipiracil hydrochloride.~Bevacizumab: concentrate for solution for IV infusion containing 25mg/ml of bevacizumab.~Trifluridine/tipiracil was administered at 35 mg/m2/dose orally within 1 hour after completion of morning and evening meals, for 5 days on/2 days off, over 2 weeks, followed by a 14-day rest period, with bevacizumab administered intravenously at the dose of 5 mg/kg every 2 weeks at Day 1 and Day 15.This treatment cycle was repeated every 4 weeks."
89452297|NCT02743221|Active Comparator|Capecitabine + bevacizumab|Capecitabine was administered at 1250 mg/m² orally BID (bis in die)on Days 1-14 of each cycle, with bevacizumab (7.5 mg/kg, IV) administered on Day 1 of each cycle. This treatment cycle was repeated every 3 weeks
89452298|NCT03256682|Experimental|Mobile Video Counseling|Utilize mobile imaging equipment, receive a total of 4 stress management consultations every 50 minutes at a time, once a week.
89452299|NCT03256682|Active Comparator|Offline Counseling|Receive a total of 4 stress management counseling, once a week for 50 minutes each session.
89452300|NCT03256682|No Intervention|Selfcare|Use stress management materials to manage yourself.
89452301|NCT03261128||Group D-FOG|Filling of a self-questionnaire before each chemotherapy cure
89452302|NCT03252158|Experimental|Decrease less healthy item availability|"Intervention: Availability of healthier vs. less healthy foods~Remove less healthy items in 20% of slots, then fill the empty slots with healthier items."
89452303|NCT03252158|Experimental|Decrease healthier item availability|"Intervention: Availability of healthier vs. less healthy foods~Remove healthier items in 20% of slots, then fill the empty slots with less healthy items."
88936989|NCT01804335|Experimental|CD5789 0.01% Cream|CD5789 0.01% cream applied on the lesions once daily for twelve weeks.
89452304|NCT03260972|Active Comparator|Chloroprocaine arm|20 mls of Chloroprocaine Hcl 2% Inj (1 vial containing 400mg/20 mls of chloroprocaine) will be instilled into the abdomen prior to fascia closure.
88936990|NCT01804348|Experimental|AL-SENSE 1-Step|a single AL-SENSE 1-Step to use up to 12 hours or until they notice any wetness.
88936991|NCT01804361|Experimental|Haporine-S|Moderate to severe dry patients administered with with Haporine-S
88936992|NCT01804361|Active Comparator|Restasis, Cyclosporine 0.05%|Moderate to severe dry eye patients with Restasis(cyclosporine 0.05%)
88936993|NCT01804374|Experimental|sorafenib and everolimus|This is an open label study: all patients will be treated with sorafenib 400 mg twice a day in combination with everolimus 5mg per day
89452305|NCT03260972|Placebo Comparator|Normal saline arm|20 mls of normal saline will be instilled into the abdomen prior to fascia closure.
89015352|NCT01330381|Active Comparator|PEG 4000|4-20g administered as an oral solution once daily
89452306|NCT03370263||Benlysta intravenous (IV)|This arm will include subjects who will receive Benlysta IV. Observation period per subject will be for 52 weeks from start of Benlysta administration.
89452307|NCT03370263||Benlysta subcutaneous (SC)|This arm will include subjects who will receive BENLYSTA SC. Observation period per subject will be for 52 weeks from start of Benlysta administration.
89452308|NCT03260816|Experimental|Internet-Delivered Parent Training|Families will receive weekly sessions of Internet-delivered Parent-Child Interaction Therapy (I-PCIT), a short-term parent-training intervention emphasizing positive attention, consistency, problem-solving, and communication. Using videoconferencing, webcams, and wireless Bluetooth earpieces, I-PCIT therapists provide in-the-moment feedback to parents during live parent-child interactions.
89452309|NCT03260816|Active Comparator|Referrals as Usual (RAU)|Families in the referrals as usual (RAU) group will be referred to services as usual in their Early Intervention exit interview, which includes a variety of clinic-based mental health services at local community agencies. At each assessment, the access and extent of participation in other services will be monitored.
89452310|NCT00692445|Active Comparator|citalopram + TC-5214|
89452311|NCT00692445|Placebo Comparator|citalopram + placebo|
89452312|NCT03256370||Infants with allergic diseases|allergic disease : atopic dermatitis or food allergy
89452313|NCT03256370||Healthy infants with atopic mothers|atopic mothers : mothers with asthma or allergic rhinitis or allergic dermatitis (diagnosed by doctors)
88936994|NCT01804387|Active Comparator|Telbivudine plus adefovir|study drugs
88936995|NCT01804387|Active Comparator|Lamivudine plus adefovir|standard drugs
88936996|NCT01804400|Experimental|QAW039 + Montelukast|
88936997|NCT01804400|Experimental|QAW039 Once a day (q.d.)|
88936998|NCT01804400|Experimental|QAW039 Twice a day (b.i.d.)|
88936999|NCT01804400|Active Comparator|Montelukast|
88937000|NCT01804400|Placebo Comparator|Placebo|
88937001|NCT01804413|Active Comparator|Pegvisomant-glucagon test|To compare the combined pegvisomant with the glucagon test to the insulin tolerance test and the glucagon test in diagnosing adult growth hormone and cortisol insufficiency.
89452314|NCT03256370||Healthy infants with non-atopic mothers.|non-atopic mothers : mothers without history of asthma or allergic rhinitis or allergic dermatitis
89452315|NCT03256058|Active Comparator|Reinflation after early deflation|The tourniquet would be inflated immediately before incision and deflated after the use of the cement, and 10 minutes later (after the hardening of the cement) , reinflate the tourniquet and deflate at the end of the operation.The total time of tourniquet inflation is controlled within 90 minutes.
89452316|NCT03256058|Placebo Comparator|Control|The tourniquet would be inflated immediately before incision and deflated at the end of the operation. The inflation of tourniquet should not last more than 90 minutes.
88937002|NCT01804413|Active Comparator|Insulin tolerance test|To compare the combined pegvisomant with the glucagon test to the insulin tolerance test and the glucagon test in diagnosing adult growth hormone and cortisol insufficiency.
89452317|NCT03252392||children with autism spectrum disorder|Children aged 3-12 years diagnosed to have mild to moderate autism spectrum disorder diagnosed by childhood autism spectrum disorder(CARS 35% or less)
89452318|NCT03252392||healthy non autistic age matched volunteers|children aged 3-12 years old never diagnosed to have autism spectrum disorder
89452319|NCT03836625|No Intervention|Control|The control arm will receive standard CareConekta, which will track their mobility with no additional features.
88937003|NCT01804426||Trauma Exposed participants|18-50 years old men and women who have been brought to the ER after being involved or witnessing a life threatening event (or an event which was perceived as such).
88937004|NCT01804439||CALIBER Healthy Cohort|We will report findings from the CALIBER (CArdiovascular disease research using Linked BEspoke studies and Electronic Records) collaboration where we linked primary care data (from the General Practice Research Database [GPRD]) to three further sources of electronic health records: the Myocardial Ischemia National Audit Project registry (MINAP),cause specific discharge data from Hospital Episodes Statistics (HES) and cause specific mortality from the Office for National Statistics (ONS).
88937005|NCT01804478|Experimental|Pneumatic Compression|Both diabetic and control subjects will undergo mild pneumatic compression while tissue oxygenation and blood flow are recorded with a non-invasive NIRS and PPG device
88937006|NCT01804491||Control group|Healthy age matched control subjects
88937007|NCT01804491||Cheilectomy prospective group|"Patients with hallux rigidus treated by the surgery type cheilectomy"
88937008|NCT01804491||Arthrodesis prospective group|"Patients with hallux rigidus treated by the type of surgery arthrodesis"
88937009|NCT01804491||Mixed prospective group|"Patients with hallux rigidus treated by other type of surgery: Arthoplasty, joint resection (Keller-Brandes technique)"
88937010|NCT01804491||Cheilectomy retrospective group|Patients after cheilectomy due to hallux rigidus
88937011|NCT01804491||Arthrodesis retrospective group|Patients after arthrodesis of the metatarsophalageal joint due to hallux rigidus
88937012|NCT01804491||Mixed retrospective group|Patients after other types of surgery due to hallux rigidus: arthroplasty or resection of the first metatarso-phalangeal joint
88937013|NCT01804504|No Intervention|Control|"Food Frequency Questionnaire(FFQ) and KAP Questionnaire will be carried out before and after the trial to evaluate changes in calorie and nutrients intake, dietary structure, and KAP scores.~Physical examination and biochemical examination before and after the trial."
88937014|NCT01804504|Experimental|Nutrition education|"FFQ and KAP Questionnaire will be carried out before and after the trial to evaluate changes in calorie and nutrients intake, dietary structure, and KAP scores.~Physical examination and biochemical examination before and after the trial.~Do nutrition education"
88937015|NCT01804517||Physician based approach|Patients will be managed as usual at the clinic without the intervention of the nurse.
88937016|NCT01804517||Physician and nurse|Patients will be managed with the help of the nurse for education and follow-up.
88937017|NCT01804530|Experimental|PLX7486-TsOH, Dose escalation and RP2D|Part 1: Open-label, sequential PLX7486-TsOH single-agent dose escalation in approximately 60 patients with solid tumors.
88937018|NCT01804543||Angina, Heart Disease|ranolazine 500 mg twice daily for 1 week, then 1000 mg twice daily for 3 weeks
88937019|NCT01804556|Other|Myofascial trigger point injection|Myofascial trigger point injection on gastrocnemius muscle
88937020|NCT01804569|Experimental|moxa|moxibustion treatment 3 times a week for 3 weeks
88937021|NCT01804595|Experimental|Sunscreen|To reduce barriers to obtaining sunscreen and serve as cues to action, this group will be mailed during the months of May through September, a supply of SPF30 sunscreen lotion (known to prevent sun burning and skin cancer). The mailing will consist of large bottles of sunscreen and a small bottle that can be refilled and attached to their huge key rings that hang off of their belts.
88937022|NCT01804595|Experimental|Text Message Reminders|"As cues to action, this group will receive 60 cellular telephone text-messages on three random mornings per week during the month of May, June, July, August, and September when UV rays are the highest. Using an internet text-messaging service, the messages will be computer generated and sent to Operating Engineers and contain information about weather conditions and various reminders (e.g., Put on sunscreen today or Wow, it's a hot one, you know what to do!)."
88937023|NCT01804595|Experimental|Sunscreen and Text Message Reminders|Just as multimodal interventions such as surgery and radiation can be used to treat skin cancer, multimodal behavioral interventions may reduce sun burning and prevent skin cancer. To determine if the combination of these interventional components results in improvements above and beyond the individual parts, both sunscreen and text messaging interventions will be provided in addition to education.
89015353|NCT01330303|Active Comparator|tamsulosin - Reference|Reference drug administration followed by Test drug administration
89015354|NCT01330303|Active Comparator|tamsulosin - Test|Test drug administration followed by Reference drug administration
89015355|NCT01330108|Experimental|Ambrisentan|patients currently on bosentan to ambrisentan for the treatment of pulmonary arterial hypertension.
89015356|NCT00261170|Active Comparator|1|bupropion and behavioral counseling
88937024|NCT01804595|Active Comparator|Education|A 30-minute, picture enhanced power point presentation will be offered to all Operating Engineers during their annual safety trainings. The content of the power point presentation will include information on incidence and prevalence of skin cancer especially among outdoor workers, types of skin cancers and skin cancer risk, sunburn, Sun Protection Factor (SPF), sun protection behaviors including sunscreen use, correct application of sunscreen, types of products, and the new Food and Drug Administration (FDA) labeling of sunscreen products. In addition, other sun protection behaviors such as wearing hats, sunglasses, using shade, etc., will be discussed.
88937025|NCT01804608|Experimental|Sensorimotor|Sensorimotor, this arm will receive sensorimotor and hip muscle strengthening.
89452320|NCT03836625|Experimental|Intervention|The intervention arm will receive standard CareConekta, plus text notifications of nearby ART facilities when they have traveled >50 km from the study site for >7 days. At enrollment, participants in the intervention arm also will be able to opt-in to phone call(s) and/or WhatsApp message(s) from study staff to when they have met this travel threshold. The study staff calls and messages will ask about medication supply and will provide assistance with nearby facilities, if requested.
89452321|NCT03252236|Experimental|Tai Chi|Subjects in this group were trained with Tai Chi exercise. The training lasted for 12 weeks, one hour per session and twice a week. Subjects were asked to practice outside of the class 30 minutes at least once a week.
89452322|NCT03252236|Active Comparator|Conventional exercise|Subjects in this group were trained with conventional exercises. Subjects were also asked to practice the exercises outside of the class 30 minutes at least once a week
89452323|NCT03252236|No Intervention|Control|No training was given to the subjects in this group
88937026|NCT01804608|Active Comparator|Strength|Strength, this arm will receive only hip muscle strengthening.
88937027|NCT01804621|Experimental|Exercise|Participant received health newsletter with targeted articles about exercise behavior.
88937028|NCT01804621|Experimental|Fruit & Vegetable|Participant received health newsletter with targeted articles about fruit & vegetable consumption.
88937029|NCT01804621|Experimental|Colorectal Cancer Screening|Participant received health newsletter with targeted articles about colorectal cancer screening.
88937030|NCT01804621|Experimental|Mammography|Participant received health newsletter with targeted articles about mammography screening.
88937031|NCT01804647||33 RRMS patients|No study treatments administered
88937032|NCT01804647||9 PPMS patients|No study treatments administered
88937033|NCT01804647||12 SPMS patients|No study treatments administered
88937034|NCT01804647||4 CIS patients|No study treatments administered
88937035|NCT01804660||25 healthy volunteers|No study treatments administered
88937036|NCT01804699||Proband|Probands - Participants diagnosed with ARVC according to the 2010 Task Force Criteria
88937037|NCT01804699||Family|First Degree Family member (blood related mother, father, sister, brother, child) of the proband
88937038|NCT01804712|Experimental|rituximab|Rituximab will be administered intravenously at a dose of 375 mg/m2 of body surface area once per week for 4 weeks (Days 1, 8, 15, and 22 of a 28-day cycle).
88937039|NCT01804738|No Intervention|Glucose|Glucose anhydrous 50g dissolved in 250ml water
88937040|NCT01804738|Active Comparator|Jasmine rice|50g available carbohydrate portion
88937041|NCT01804738|Active Comparator|Parboiled basmati rice|50g available carbohydrate portion
88937042|NCT01804777|Experimental|Amiloride 10 mg, 20 mg, and diet|Amiloride 10 mg for 14 days and diet. Then dose titrated up at day 14 to 20 mg, and diet.
88937043|NCT01804777|Active Comparator|HCTZ 12.5 mg, 25 mg and diet|HCTZ 12.5 mg for 14 days and diet. Then dose titrated up at day 14 to 25 mg, and diet
88937044|NCT01804803|Experimental|T-SMBG|This group will perform SMBG using a smartphone-connected glucometer implemented with a software for real-time collection and transmission of measured glucose values to the remote server. SMBG results will be immediately transmitted to the remote server, which will perform data collection and analysis, and provide feed-back to the patient and the medical staff according to pre-defined specific algorithms (Decision Supported Software, DSS). A specific algorithm incorporated into the DSS will allow the patients to self-calculate the dose of basal insulin to be administered according to the measured fasting blood glucose levels for consecutive periods of three days. Glucose data and analyses will be made accessible to the patients and medical staff anytime and anywhere via the web. Patients will be also assisted by the diabetes medical team located at or connected with a call center 24-hours/day, 7 days/week.
88937045|NCT01804803|Active Comparator|SMBG|This group will perform SMBG using a regular glucometer and will report glucose data on paper charts (or download data from the glucometer onto the PC) at the planned study visits. Patients will not receive feed-back on their glucose levels nor instructions on how to potentially modify their drug therapy except when undergoing medical visits at the planned intervals. Patients, finally, will not be assisted by the diabetes team/call center.
88937046|NCT01804855|Active Comparator|W82GO|Usual face-to-face care as per the W82GO multidisciplinary treatment intervention (phase 1 for 6 weeks and phase 2 for 46 weeks).
88937047|NCT01804855|Experimental|Smartphone|Usual care for Phase 1 of treatment. Treatment during Phase 2 of intervention using the Reactivate smartphone application only.
88937048|NCT01804868|Experimental|case vignette tutorial|The web tutorial composed of 4 case vignettes.
89452324|NCT03256292||testosterone, diet, and increased physical activity|Group receiving standard of care consisting of diet and regular exercise counseling + testosterone replacement therapy
89452325|NCT04473261|Experimental|Iodine Complex (Capsule form)|Iodine Complex) capsule (200mg) will be given three times a day
89452326|NCT04473261|Experimental|Iodine Complex (Syrup form)|Iodine Complex syrup form (40ml) will be given three times a day
89452327|NCT04473261|Placebo Comparator|Standard Care Alone|Placebo as empty capsule. Treatment will be given for all 4 arms will be receiving standard care as per version 3.0 of clinical management guidelines for COVID-19 established by the Ministry of National Health Services of Pakistan COVID-19 guidelines of the study setting.
89452328|NCT04473261|Experimental|Iodine Complex (Nasal Spray)|Iodine complex throat spray of 2 puffs three times a day.
88937049|NCT01804868|Active Comparator|passive web presentation on research regulation|The presentation will be a web-based voice commented video presentation on research regulation.
88937050|NCT01804894||athletes with lower extremity injury|athletes who were injured during one season of play
88937051|NCT01804907|Experimental|CBT|Cognitive Behavioral Therapy
88937052|NCT01804907|Sham Comparator|Behavioral Modification|Standard sleep hygiene education/desensitization therapy
88937053|NCT01804920|Experimental|D-serine adjuvant treatment|"Random assignment, parallel group, double blind, placebo controlled 8 weeks trial.~First arm: D-serine adjuvant treatment, up to 4 g/day Second arm: Placebo adjuvant treatment"
88937054|NCT01804920|Placebo Comparator|Placebo adjuvant treatment|"Random assignment, parallel group, double blind, placebo controlled 8 weeks trial.~First arm: D-serine adjuvant treatment, up to 4 g/day Second arm: Placebo adjuvant treatment"
88937055|NCT01804933|No Intervention|conventional neuromuscular blockade|No rocuronium will be administered intraoperatively unless there is surgeons' complain or patients movement
88937056|NCT01804933|Active Comparator|optimal neuromuscular blockade|Rocuronium dose will be infused to maintain depth of NMB at TOF count 1 intraoperatively
88937057|NCT01804933|Experimental|profound neuromuscular blockade|Rocuronium dose will be infused to maintain a depth of NMB to PTC 1~2 intraoperatively
88937058|NCT01804959|Placebo Comparator|Active vs Placebo|In phase I, subjects will be randomized into either the Vivomixx probiotics or placebo arm of the study at a 1:1 ratio. All randomized subjects will receive probiotics (4 sachets/ day or 1800 billion bacteria/day) or placebo (4 placebo sachets/day) for the first 60 days.
88937059|NCT01804959|Active Comparator|60 days of Active vs 120 days of Active|In phase II, subjects from both arms in phase I will receive Vivomixx probiotics 4 sachets/ day for another 60 days. Comparison will be made between the arm receiving 60 days of Vivomixx probiotics vs 120 days of Vivomixx probiotics
88937060|NCT01804972|Active Comparator|Verbal and written infomation|Verbal and written information:Patients will receive both verbal information and written patient information leaflets
89452329|NCT01358968|Experimental|LY2603618|"Single 50 milligrams (mg) oral dose of desipramine on day 1 of study period 1. Single 275 mg intravenous infusion over one hour of LY2603618 followed by single 50 mg oral dose of desipramine on day 1 of study period 2. Participants may then receive additional doses of LY2603618 in combination as follows: 1000 milligrams per square meter (mg/m²) intravenous administration over 30 minutes of gemcitabine on days 1, 8 and 15 and 230 mg intravenous dose of LY2603618 on days 2, 9 and 16 of 28-day cycles OR 500 mg/m² intravenous administration over 10 minutes of pemetrexed on day 1 and 275 mg intravenous dose of LY2603618 on day 2 of 21-day cycles.~Participants will be allowed to continue to receive the combination therapy until fulfilling one of the criteria for discontinuation, such as unacceptable toxicity or disease progression."
89452330|NCT03256214|Experimental|Closed suction system|Patients in mechanical ventilation were aspirated with closed suction system.
89452331|NCT03256214|Active Comparator|Open suction system|Patients in mechanical ventilation were aspirated with open suction system.
89452332|NCT04473339|Experimental|HRR mt 1|Patients are HRR mutated type, will undergo CRS plus HIPEC and then go on to receive standard platinum-based combination doublet intravenous chemotherapy.
88937061|NCT01804972|Experimental|Verbal and electronic information|Patient will receive both verbal information and a web address to access patient information electronically
88937062|NCT01804985|Experimental|De-escalated Treatment|Imatinib, nilotinib or dasatinib; de-escalated to half the standard dose for 12 months
88937063|NCT01805011||50 healthy mothers|
88937064|NCT01805050||New Technique|All patients who underwent surgical repair of the anterior instability due an HAGL lesion.
88937065|NCT01805063||Fire suppression|Firefighters will attend for vascular assessments following a night shift where they have performed fire suppression
88937066|NCT01805063||Non-fire emergency duty|Firefighters will attend for vascular assessments following a night shift where they have had an emergency response without fire suppression eg. road traffic collision.
88937067|NCT01805063||Sedentary shift|Firefighters will attend for vascular assessments following a night shift where they have remained sedentary throughout the shift.
88937068|NCT01805102||maternal serum|measurement by immunoassay
88937069|NCT01805115|Experimental|Oral misoprostol|The oral group (misoprostol 400 ug) self-administered the medications orally 8-10 h before surgery.
88937070|NCT01805115|Experimental|Sublingual misoprostol|The sublingual group (misoprostol 400 ug) self-administered the medications sublingually 8-10 h before surgery.
88937071|NCT01805115|Experimental|Vaginal misoprostol|The vaginal group (misoprostol 400 ug) self-administered the medications vaginally 8-10 h before surgery.
88937072|NCT01805115|Experimental|Control|The no-misoprostol group did not administer the medication of misoprostol before the procedure
88937073|NCT01805128|Experimental|schizophrenia|child with a DSM-IV diagnosis of schizophrenia
88937074|NCT01805128|Experimental|autism spectrum disorder|child with a DSM-IV diagnosis of autism spectrum disorder
88937075|NCT01805128|Experimental|Healthy|child having no DSM-IV diagnosis of schizophrenia spectrum disorder or autism
88937076|NCT01805167|Other|subjects with a cochlear implant|
88937077|NCT01805193||Suspected coronary heart disease|
88937078|NCT01805206|Experimental|iFABP Monitored|Subjects monitored for urinary iFABP content during the first 4-12 days of life. Enteral feedings administered when iFABP levels are normal during the first four days of life or, if elevated during the first four days of life, have normalized for five days.
88937079|NCT01805219||healthy subjects|
88937080|NCT01805232|Experimental|artesunate|intravenous artesunate 80 mg/kg initially then after 8 hours then daily
88937081|NCT01805232|Active Comparator|quinine|quinine infusion 80 mg/kg every 8 hours
88937082|NCT01805245|Experimental|Mindfulness Based Stress Reduction|
88937083|NCT01805245|Active Comparator|Health Education Control|
88937084|NCT01805258|Experimental|Intervention 2: Nevirapine|HIV and Tuberculosis co-infected patients on standard dose nevirapine (Intervention) based ART and Rifampicin based ATT.
88937085|NCT01805258|Active Comparator|Intervention 2: Efavirenz|HIV and Tuberculosis co-infected patients on standard dose Efavirenz(Intervention)based ART and Rifampicin based ATT.
89452333|NCT04473339|Experimental|HRR mt 2|Patients are HRR mutated type, will undergo CRS and then go on to receive standard platinum-based combination doublet intravenous chemotherapy.
89452334|NCT04473339|Experimental|HRR wt 3|Patients are HRR wild type, will undergo CRS plus HIPEC and then go on to receive standard platinum-based combination doublet intravenous chemotherapy.
89452335|NCT04473339|Experimental|HRR wt 4|Patients are HRR wild type, will undergo CRS and then go on to receive standard platinum-based combination doublet intravenous chemotherapy.
89452336|NCT03260738|Experimental|"Robot Poppy group"|30 minutes of daily rehabilitation program (physical exercises dedicated to the mobility of the spine) supervised by Poppy robot during 3 weeks included in a 3hours daily (5 days a week) rehabilitation program.
89452337|NCT03260738|Active Comparator|Control group|Usual 3hours daily (5 days a week) rehabilitation program without robot during 3 weeks
89452338|NCT02281071|Experimental|laterally moved coronally advanced flap microsurgical|For the test group (LMCAF-M), the surgical procedures were performed with the aid of a galilean loupe, under 2.5x magnification vision, microsurgical instruments and microsurgical suture material .
89452339|NCT02281071|Active Comparator|laterally moved coronally advanced flap macrosurgical|For the control group (LMCAF), LMCAF was performed with conventional instruments (detaylı) and materials (stur). Loupe magnification, microsurgical instruments and suture material were not used in the control group.
89452340|NCT05498740|Experimental|drug eluting balloon catheter|use drug eluting balloon catheter to treat the stenosis or occlusion in superficial femoral artery(SFA) and/or popliteal artery
89452341|NCT02281227|Active Comparator|compression group|skin compression with an indicator for determination of needle entry point
89452342|NCT02281227|Active Comparator|non-compression group|non skin compression with an indicator for determination of needle entry point
89452343|NCT03252080|Active Comparator|Education (Group A)|short-intensive education for one month
89452344|NCT03252080|Experimental|Education & holistic management(Group B)|short-intensive education for one month followed with holistic management for 6 months
89452345|NCT02281305|Experimental|Colchicine Active treatment group|Drug: Colchicine 2 mg loading dose; 0.5 mg bid for 5 days
89452346|NCT02281305|Placebo Comparator|Control group|Drug: Placebo
89452347|NCT00624351|Placebo Comparator|Placebo|Phosphate-buffered Saline (PBS) infusions at study weeks 0, 1, 2, and 3.
89452348|NCT00624351|Experimental|EMAB 600mg|600 mg Epratuzumab infusions at study weeks 0, 1, 2, and 3.
89452349|NCT00624351|Experimental|EMAB 100mg|100 mg Epratuzumab infusions at study weeks 0, and 2, and placebo at study weeks 1 and 3.
89452350|NCT00624351|Experimental|EMAB 400mg|400 mg Epratuzumab infusions at study weeks 0, and 2, and placebo at study weeks 1 and 3.
89452351|NCT00624351|Experimental|EMAB 1200mg|1200 mg Epratuzumab infusions at study weeks 0, and 2, and placebo at study weeks 1 and 3.
89452352|NCT00624351|Experimental|EMAB 1800mg|1800 mg Epratuzumab infusions at study weeks 0, and 2, and placebo at study weeks 1 and 3.
89452353|NCT03251690|Experimental|Switching TDF/FTC/EFV to TDF/FTC/RPV|Switching from Tenofovir 300 mg/day + Emtricitabine 200 mg/day + Efavirenz 600 mg/day (once daily) to Tenofovir 300 mg/day + Emtricitabine 200 mg/day + Rilpivirine 25 mg/day (once daily) Intervention: Tenofovir/Emtricitabine/Rilpivirine
89452354|NCT03251690|Active Comparator|Continuing TDF/FTC/EFV|Continuing Tenofovir 300 mg/day + Emtricitabine 200 mg/day + Efavirenz 600 mg/day Intervention: Tenofovir/Emtricitabine/Efavirenz
89452355|NCT00620685|Placebo Comparator|1|
89452356|NCT00620685|Experimental|2|
89452357|NCT00620685|Experimental|3|
89452358|NCT03260582|No Intervention|Control arm (n=50)|Patients randomized to the control arm will receive usual cardiac rehabilitation care post-myocardial infarction.
89452359|NCT03260582|Experimental|Intervention arm: LifePod arm (n=100)|In addition to usual cardiac rehabilitation care, patients randomized to the LifePod arm will receive access to the LifePod® support software for six months.
89452360|NCT05498584||Post-acute systolic heart failure patients|Patients who received at least one exercise training section within 3 months of acute heart failure discharge are placed in the CR group. Patients will receive a multi-disciplinary disease management program by a qualified HF nursing specialist. A board-certified physiatrist prescribes moderate continuous training according to a cardiopulmonary exercise test.
89452361|NCT03252002|Experimental|Single/multiple doses of 10 mg BAY1101042 or placebo|Single oral dose of 10 mg BAY1101042 (given as 5 mg MR tablets) or corresponding placebo followed by once daily dosing for 7 days
89452362|NCT03252002|Experimental|Single/ multiple doses of 20 mg BAY1101042 or placebo|Single oral dose of 20 mg BAY1101042 (given as 5 mg MR tablets) or corresponding placebo followed by once daily dosing for 7 days
89015357|NCT00261170|Placebo Comparator|2|placebo medication
89015358|NCT00261209|Experimental|Collagenase Injection|Injection of collagenase into adhesion restricting tendon gliding
89452363|NCT03252002|Experimental|Single/ multiple doses of 30 mg BAY1101042 or placebo|Single oral dose of 30 mg BAY1101042 (given as 5 mg MR tablets) or corresponding placebo followed by once daily dosing for 7 days
89452364|NCT03252002|Experimental|Single/ multiple doses of 40 mg BAY1101042 or placebo|Single oral dose of 40 mg BAY1101042 (given as 5 mg MR tablets) or corresponding placebo followed by once daily dosing for 7 days
89452365|NCT03252002|Experimental|Single/ multiple doses of 50 mg BAY1101042 or placebo|Single oral dose of 50 mg BAY1101042 (given as 5 mg MR tablets) or corresponding placebo followed by once daily dosing for 7 days
89452366|NCT03252002|Experimental|Optional: Single/multiple doses of 5 mg BAY 1101042 or placebo|Single oral dose of 5 mg BAY1101042 MR tablets or corresponding placebo followed by once daily dosing for 7 days
89452367|NCT05478928|Experimental|Dynamic dry needling|Dynamic dry needling will be done in the upper trapezius trigger point.
89452368|NCT05478928|Experimental|Fixed dose dynamic MEP|Dynamic low intensity percutaneous electrolysis will be applied in the upper trapezius trigger point with a fixed dose.
89452369|NCT05478928|Experimental|Static dry needling:|Static dry needling will be done in the upper trapezius trigger point.
88937086|NCT01805310|Other|Bowel Preparation|Women randomized to the bowel preparation arm will be instructed to consume 300cc of magnesium citrate no later than 3PM on preoperative day number one. They will also be placed on a clear liquid diet on preoperative day number one.
88937087|NCT01805310|Other|No bowel preparation|Subjects randomized to no bowel preparation will be instructed to continue a regular diet on preoperative day number one.
88937088|NCT01805336|Other|Arm A|"Inclusion : cognitive complaint,fatigue, anxiety an depression questionnaires.~Assessment 1 : attentional function by traditional tests + executive function by virtual reality tests.~One week later, Assessment 2 : attentional function by virtual reality tests + executive function by traditional tests."
88937089|NCT01805336|Other|Arm B|"Inclusion : cognitive complaint,fatigue, anxiety an depression questionnaires.~Assessment 1 : attentional function by virtual reality tests + executive function by traditional tests.~One week later, Assessment 2 : attentional function by traditional tests + executive function by virtual reality tests."
88937090|NCT01805362|Active Comparator|MORNING|patients continue to take their treatments (RAS blockers and diuretics) on awaking
88937091|NCT01805362|Experimental|EVENING|Patients take their treatments(RAS blockers and diurectics)at bedtime
88937092|NCT01805388|Experimental|Regeneration Treatment Group|RTC with Triple Antibiotic Study Drug
88937093|NCT01805388|No Intervention|Control Non-study Drug Group|RTC on contralateral tooth with no study drug
88937094|NCT01805401|Experimental|Left OFC Group|Anode applied to the left OFC and cathode applied to the right OFC
88937095|NCT01805401|Experimental|Right OFC Group|Anode applied to the right OFC and cathode applied to the left OFC
88937096|NCT01805401|Sham Comparator|Sham tDCS|
88937097|NCT01807507||Healthy Volunteers|
88937098|NCT01807533|Experimental|Family-centered intervention program|FCIP: family members were encouraged to present in all intervention sessions included 5 in-hospital intervention, 7 after-discharge interventions (0, 1, 2, 4, 6, 9, and 12 months of corrected age), and neonatal follow-up at 0, 1, 6, 12, 18, and 24 months of corrected age.
88937099|NCT01807533|Other|Usual care intervention program|UCP: family members were invited to present at least one session of the 5 in-hospital intervention session. Parents and infants in the UCP group received 7 after-discharge phone calls (0, 1, 2, 4, 6, 9, and 12 months of corrected age) and neonatal follow-up at 0, 1, 6, 12, 18, and 24 months of corrected age.
88937100|NCT01807572||obesity risk status|Lean adolescents at high-risk for obesity, by virtue of parental obesity, and lean adolescents at low-risk for obesity, by virtue of lean parents.
88937101|NCT01807663|Experimental|healthy volunteers|Free breath monitoring. Correlation between two device for recording parameters of ventilation.
88937102|NCT01807663|Experimental|Chronic patient|Free breath monitoring. Number of pathological respiratory events (apneas, hypopneas, paradoxical breath) compared with the recording of the PtCO2 and the SpO2)
88937103|NCT01807663|Experimental|ACUTE PATIENT|Free breath monitoring. Number of pathological respiratory events (apneas, hypopneas, paradoxical breath) compared with the recording of the PtCO2 and the SpO2)
88937104|NCT01807676|Active Comparator|ET View Double Lumen Tube|Patients assigned to the thisgroup will be intubated using the VivaSight-DL.
88937105|NCT01807676|Active Comparator|conventional Double Lumen Tube|Patients assigned to the first group will be intubated using conventional DLT (Bronchocath, left sided; Rüsch, Kernen, Germany).
88937106|NCT01807702|Experimental|13C-pyruvate,13C-Lactate and dichloroacetate|During the first day of the subjects participation pyruvate will be given and blood, breath and buccal cell samples will be collected over a two hour period. On the last day DCA will be given.
88937107|NCT01807741|Experimental|Asenapine Group|Asenapine will be given beginning on day 0 at 5 mg bid. Dose will be increased to 10 mg bid if there is less than 50% decrease in MADRS score by week 2. Dose increases may be held if clinically indicated. Doses may be decreased at any time, if clinically indicated, by increments of 5 mg/day to a minimum of 5 mg qHS. Daily treatment with asenapine will be for 8 weeks.
88937108|NCT01807741|Active Comparator|Placebo Group|Sublingual tablets similar to the asenapine tablets.
88937109|NCT01807754||Imaging scans for breast cancer screening|"To simulate the performance of the combination of three new breast imaging systems to digital mammography and hand-held ultrasound that are currently used to find and evaluate breast masses.~These three different systems make images of the breast in several ways to find breast masses and to distinguish normal and abnormal masses. This may result in less unnecessary call-backs from mammography."
88937110|NCT01807767|Experimental|Everolimus, Myfortic and Tacrolimus|"Tacrolimus discontinued (within 8 weeks of initiation of everolimus conversion).~Everolimus 1mg BID started (targeted trough 6-12ng/mL). Patients must have an everolimus concentration between 6-12ng/mL before tacrolimus is discontinued.~Myfortic 360-720 mg BID"
88937111|NCT01807767|Other|Myfortic and Tacrolimus|Normal Care: Myfortic BID 360-720 mg Tacrolimus (5-12ng/mL)
88937112|NCT01807780|Other|single arm :vaccinated|military personnel vaccinated with multiple vaccines and monitored about safety, immunogenicity and efficacy
88937113|NCT01807793|Active Comparator|Psychoeducation|Psychoeducation will include attending individual and group sessions.
88937114|NCT01807793|No Intervention|Care as usual|Receive care as usual
88937115|NCT01807806|Experimental|Role-playing game|All eligible participants were invited to play the role playing game
88937116|NCT01807832|Other|chronic cough|Capsaicine challenge in chronic cough patients
88937117|NCT01807845|Active Comparator|Skimmilk VD will be emulsified using Tween 80|Skimmilk enriched with VD wherein the VD will be emulsified using Tween 80;
88937118|NCT01807845|Placebo Comparator|Placebo: un-enriched skimmilk.|Placebo: un-enriched skimmilk.
88937119|NCT01807845|Active Comparator|enriched skimmilk with VD|enriched skimmilk with VD
88937120|NCT01807858|Active Comparator|Bifidobacterium lactis|5 billion Bifidobacterium lactis
88937121|NCT01807858|Active Comparator|İnulin|900 mg İnulin per day will be given
88937122|NCT01807858|Placebo Comparator|Maltodextrin|Maltodextrin
88937123|NCT01807858|Active Comparator|Bifidobacterium lactis plus İnülin|5 billion active Bifidobacterium lactis plus 900 mg İnülin per day
89015359|NCT04718298|Experimental|Inguinal hernia repair laparoscopic|recurrent inguinal hernia after open repair or bilateral hernia patients
89015360|NCT00261326|Active Comparator|B|simvastatin tablets 80 mg daily
89015361|NCT00261326|Placebo Comparator|A|calcium tablets 80 mg
89015362|NCT00261365|Active Comparator|A1|
89015363|NCT00261365|Active Comparator|A2|
89015364|NCT00298974|Experimental|hydrocodone/acetaminophen extended release|
89015365|NCT00298974|Placebo Comparator|Placebo|
89015366|NCT00261794|Experimental|1|computer-assisted cognitive remediation (CACR)
89452370|NCT05478928|Experimental|Fixed dose static MEP|Static low intensity percutaneous electrolysis will be applied in the upper trapezius trigger point with a fixed dose.
89452371|NCT05478928|Experimental|Algorithm-based dose static MEP|Low intensity percutaneous electrolysis will be applied in the upper trapezius trigger point with an algorithm-based dose.
89452372|NCT05478928|Placebo Comparator|Placebo|An acupuncture needle will be slightly introduced into the upper trapezius trigger point.
89452373|NCT00620451|Experimental|Larazotide acetate 4 mg|larazotide acetate capsules 4 mg TID
89452374|NCT00620451|Experimental|Larazotide acetate 8 mg|Larazotide acetate capsules 8 mg TID
89452375|NCT00620451|Placebo Comparator|Placebo|Placebo capsules
89452376|NCT03255278|Experimental|Safety and portable study group|"12 persons who have got a single decreased dose (0.25 of the planned dose for regular administration) of the GamTBvac recombinant subunit vaccine.~The intervention for the Arm: single GamTBvac vaccination (0.25 dose)."
89452377|NCT03255278|Placebo Comparator|Placebo safety study group|12 persons who have got a single dose of placebo (0.5 ml). The intervention for the Arm: Placebo administration (0.5 ml)
89452378|NCT03255278|Experimental|Immunogenicity study group #1|"12 persons who will get a double sequential administration of the decreased dose (0.25 of the planned dose for regular applying) of the GamTBvac recombinant subunit vaccine.~The intervention for the Arm: double GamTBvac vaccination (0.25 dose)."
89015367|NCT00261794|Active Comparator|2|computer-based cognitive activity
89015368|NCT00293475|Experimental|Treatment (rituximab, mannitol, methotrexate, carboplatin)|Patients receive rituximab IV over 5 hours on day 1, mannitol IA, methotrexate IA over 10 minutes, and carboplatin IA over 10 minutes on days 2 and 3. Patients then receive sodium thiosulfate IV over 15 minutes at 4 and 8 hours after carboplatin. Treatment repeats monthly for up to 12 courses in the absence of disease progression or unacceptable toxicity.
89015369|NCT00299013|Active Comparator|1|Prednisolone 40mg oral tablets, once daily, dose tapering weekly (40,40,30,20,15,10,5,0mg) over 8 weeks.
89015370|NCT00299013|Experimental|2|COLAL-PRED 40mg oral capsule, once daily for 8 weeks.
89015371|NCT00299013|Experimental|3|COLAL-PRED 60mg oral capsule, once daily for 8 weeks.
89015372|NCT00299013|Experimental|4|COLAL-PRED 80mg oral capsule, once daily for 8 weeks.
89015373|NCT00299052|Active Comparator|A|Bone reamings with 5cc of DMB putty
89015374|NCT00299052|Active Comparator|B|Bone reamings
89015375|NCT00299091|No Intervention|Control|Efavirenz capsules 600 mg
89015376|NCT00299091|Experimental|Experimental|Modification of doses of efavirenz guided by its plasma concentration (therapeutic drug monitoring)
89015377|NCT00299169|Experimental|1|N of 1 trials of statin therapy
89015378|NCT00299169|Other|2|usual care
89015379|NCT00293592|Active Comparator|Dexamethasone|
89015380|NCT00293592|Placebo Comparator|Placebo|
89015381|NCT00262340|Experimental|1|This arm will have treatment changed based on measures of inflammation
89015382|NCT00262340|Active Comparator|2|Treatment will be changed on the basis of reported asthma symptoms
89015383|NCT00262379|No Intervention|Group A|HCV treatment with peginterferon plus ribavirin during 48 weeks
89015384|NCT00262379|Active Comparator|Groupb|HCV treatment with peginterferon plus ribavirin during 48 weeks plus epoetin beta under anemia conditions
89015385|NCT00299286|Experimental|Lapatinib|lapatinib oral 1500mg daily taken as 6 tablets as one dose 10-14 days presurgery
89015386|NCT00299286|Placebo Comparator|Lapatinib-Placebo|placebo comparator 6 tablets taken as one dose daily
89015387|NCT00262457|Other|Arm 1|
89015388|NCT00293787|Experimental|Travoprost 0.004%/Timolol 0.5%|Travoprost 0.004%/Timolol 0.5% in both eyes each morning at 8 a.m. and Timolol vehicle in both eyes each evening at 8 p.m. for 3 months
89015389|NCT00293787|Active Comparator|Xalatan + Timolol 0.5%|Timolol 0.5% in both eyes each morning at 8 a.m. and Xalatan in both eyes each evening at 8 p.m. for 3 months
89015390|NCT00415649|Experimental|A|DNA vaccine at baseline, Month 1, and Month 2, and the adenoviral vector vaccine at Month 6.
89015391|NCT00415649|Placebo Comparator|B|Placebo vaccine
89015392|NCT00293826|Experimental|1|196 subjects
89015393|NCT00293826|Experimental|3|196 subjects
89015394|NCT00293826|Experimental|2|196 subjects
89015395|NCT00293826|Placebo Comparator|4|196 subjects
89015396|NCT00299403|Active Comparator|1|Right frontal low frequency rTMS
89452379|NCT03255278|Experimental|Immunogenicity study group #2|"12 persons who will get a double sequential administration of the mean dose (0.5 of the planned dose for regular applying) of the GamTBvac recombinant subunit vaccine.~The intervention for the Arm: double GamTBvac vaccination (0.5 dose)."
89452380|NCT03255278|Experimental|Immunogenicity study group #3|"12 persons who will get a double sequential administration of the maximum (regular) dose of the GamTBvac recombinant subunit vaccine.~The intervention for the Arm: double GamTBvac vaccination (1.0 dose)."
89452381|NCT03251768|Experimental|Test group|"intervention: rHSA-GCSF 2.4 mg Drug: TE or TEC TE: Taxotere+Epirubicin Taxotere (75mg/m2)and Epirubicin(75mg/m2), IV on day 1 of each 21 chemotherapy cycle.~TEC:Taxotere+Epirubicin+Cyclophosphamide Taxotere (75mg/m2),Epirubicin (75mg/m2) and Cyclophosphamide (500mg/m2), IV on day 1 of each 21 chemotherapy cycle.~Recombinant Human Serum Albumin/Granulocyte Colony-Stimulating Factor Fusion Protein（2.4mg）will be injected subcutaneously at at 10 am (±90 min) on the 3th and 7th day of each chemotherapy cycle.After injection, stop administrating if Absolute Neutrophil Count (ANC) in peripheral blood exceeded 5.0×109/L at two contiguous times at least. If not up to standard, investigator should decide whether or not the third administration."
89452382|NCT03251768|Active Comparator|Positive control group|"intervention: GCSF Drug: TE or TEC TE: Taxotere+Epirubicin Taxotere (75mg/m2)and Epirubicin(75mg/m2), IV on day 1 of each 21 chemotherapy cycle.~TEC:Taxotere+Epirubicin+Cyclophosphamide Taxotere (75mg/m2),Epirubicin (75mg/m2) and Cyclophosphamide (500mg/m2), IV on day 1 of each 21 chemotherapy cycle.~Recombinant Human Granulocyte Colony-Stimulating Factor Injection (5μg/kg/day) will be injected subcutaneously at 10 am (±90 min) from the 3rd of per chemotherapy cycle. After the injection, stop administrating if Absolute Neutrophil Count (ANC) in peripheral blood exceeded 5.0×109/L at two contiguous times at least. (The minimum of usage was continuous 7 days ,The maximum of usage was continuous 14 days)"
89452383|NCT00617331|Experimental|Dose 7.5 mcg|7.5 micrograms of vaccine administered on Day 0 and Day 28.
89452384|NCT00617331|Experimental|Dose 30 mcg|30 micrograms of vaccine administered on Day 0 and Day 28.
89015397|NCT00299403|Active Comparator|2|electroconvulsive therapy (ECT). Right unilateral ECT 3 time a week in 3 weeks
89015398|NCT00299442|Experimental|1|Self-help Triple P Behavioural Family Intervention
89015399|NCT00299442|No Intervention|2|Wait-list control
89015400|NCT00262769|Experimental|A - Gemcitabine|Gemcitabine alone
89015401|NCT00262769|Experimental|B - Gemcitabine and Cisplatin|Gemcitabine and Cisplatin
89015402|NCT00261755|Experimental|Acupuncture Group|Acupuncture treatment during labor
89015403|NCT00261755|Active Comparator|TENS Group|Transcutaneous Electric Nerve Stimulation (TENS treatment)during labor
89015404|NCT00261755|Active Comparator|Traditional Group|Traditional pain treatment during labor
89015409|NCT06259994||women treated with dexamethasone during pregnancy at risk of Congenital Adrenal Hyperplasia|All women treated with DEX during pregnancy at risk of Congenital Adrenal Hyperplasia over the defined period (retrospective and prospective).
89015410|NCT06259981|Experimental|GLY-200|Participants will receive 2.0 g GLY-200 orally twice daily for 16 weeks.
89015411|NCT06259981|Placebo Comparator|Placebo|Participants will receive placebo (identical in appearance to GLY-200) orally twice daily for 16 weeks.
89015412|NCT06259968|Experimental|NMES+|Neuromuscular electrical stimulation with superimposed voluntary contraction
89015413|NCT06259968|Active Comparator|NMES|Neuromuscular electrical stimulation without voluntary contraction
89015414|NCT06259955|Experimental|intervention group|The trainings were conducted in Gazi University Faculty of Health Sciences Seminar Hall and Nursing Practice Laboratory with one group on Monday and Tuesday and the other group on Wednesday and Thursday. Students could miss the eight-session program at most two times. It was planned to make up for the absent course in consultation with the instructor. 37 Students attended the training regularly.
89015415|NCT06259955|No Intervention|control group|Throughout the study, the control group continued its routine lecture and clinical practice program. They were called only at the end of the course for the pre-test, interim measurement and post-test on the course days.
89015416|NCT06259942|Experimental|Intervention 1 group|only the group heated throughout surgery with carbon fiber underbody heaters
89015417|NCT06259942|Active Comparator|Intervention 2 group|the group that was both warmed throughout the operation with carbon fiber underbody heaters and given warmed intravenous fluids
89452385|NCT05483374||epithelial tumours of nasal cavity and paranasal sinus|adult patients diagnosed with nasal cavity and paranasal sinus cancers (any stage of disease)
89452386|NCT05483374||epithelial tumours of nasopharynx|adult patients diagnosed with nasopharyngeal cancers (any stage of disease)
89452387|NCT05483374||minor and major salivary gland tumours|adult patients diagnosed with minor or major salivary gland cancers (any stage of disease)
89452388|NCT05483374||middel ear tumours|adult patients diagnosed with cancers of the middle ear (any stage of disease)
89452389|NCT02455778|Experimental|Cinnamon|3 grams of oral cinnamon per day in form of capsules (6) along with standard diet and exercise protocol
89452390|NCT02455778|Placebo Comparator|Placebo|2.5 grams of wheat flour per day in form of capsules ( 6) along with standard diet and exercise protocol
89452391|NCT00687687|Experimental|Pacitaxel/Carboplatin/Iniparib|Participants will be administered pacitaxel, carboplatin and BSI-201 (Iniparib) in 21 day treatment cycles. Treatment will continue until disease progression or adverse effects prohibit further therapy.
89452392|NCT03952312|Experimental|"OncoTool Intervention"|
89452393|NCT03952312|Active Comparator|"Oncotool Control"|
88937124|NCT01807884|Experimental|Optimized oral care|An optimization of the oropharyngeal suction procedure will include use of a subglottic drainage in a specified order: 1. subglottic suction, 1.oral suction followed by mouth care 3. subglottic suction 4. tracheal suction
88937125|NCT01807884|Placebo Comparator|Routine oral care|Oral suction followed by mouth care and tracheal suction
88937126|NCT01807910|Experimental|Fructose|Participants will receive fructose (3g/kg/day) for 2 weeks.
88937127|NCT01807910|Active Comparator|Glucose|Participants will receive glucose (3g/kg/day) for 2 weeks.
88937128|NCT01807962|Active Comparator|rapidocain and bethametsaone|"Rapidocain and Bethametsaone :~Lidocaine (Rapidocain(R)): 4ml of 1% Lidocaine Bethametasone (Diprophos): 1ml ampoule (containing 5mg/ml dipropionate de bétaméthasone and 2mg/ml phosphate disodique de bétaméthasone)"
88937129|NCT01807962|Placebo Comparator|sterile saline|Placebo arm with 5ml of sterile saline (NaCl) solution
88937130|NCT01807975|Experimental|post allogreffe patients|Functional evaluation of distal airway by forced oscillation technique : relevance earlier diagnostic of pulmonary syndrom of oblitérant bronchiolit in post allogreffe patients
88937131|NCT01807988|Experimental|iCBT|Internetbased cognitive behavior therapy (iCBT) aimed att preventing relapse into major depression.
88937132|NCT01807988|No Intervention|Control group|The control group in the study will fill out questionnaires every month and will be interviewed every month to detect any relapses. They will also receive feedback on there self-reported symptoms.
88937133|NCT01808014|Experimental|The addition of Nefopam|The addition of Nefopam for intravenous patient-controlled analgesia in patients with lumbar spinal surgery would reduce the side effects seen in monotherapy with opioid analgesia and result in effective pain management.
88937134|NCT01808027||Acute myocardial infarction|patient with suspected acute coronary syndrome (ACS).
88937135|NCT01808040|Experimental|1|"Tak700 (orteronel) dose escalation schedule:~1a 200 mg PO BID TAK700~1b 200mg PO BID TAK + glucocorticoid~1a 300mg PO BID TAK700 starting dose~1b 300 mg po BID + glucocorticoid 2a 400mg PO BID TAK700 2b 400 mg po BID + glucocorticoid"
88937136|NCT01808053||Healthy older and independently living adults|The BodyGuardian remote health monitoring system will used by healthy older and independently living adults
88937137|NCT01808079||Ancillary-correlative (genetic markers of Wilms tumor)|Samples are analyzed for SNP profiling using real-time PCR and MLPA.
88937138|NCT01808105|Other|Human Milk|Reference group, breast feeding ad libitum
88937139|NCT01808105|Active Comparator|Control Formula|Ready to feed infant formula, feed ad libitum
88937140|NCT01808105|Experimental|Experimental Formula 1|Ready to feed infant formula with human milk oligosaccharides, feed ad libitum
88937141|NCT01808105|Experimental|Experimental Formula 2|Ready to feed infant formula with human milk oligosaccharides, feed ad libitum
88937142|NCT01808131|Experimental|lesinurad 200 mg + allopurinol|
88937143|NCT01808131|Experimental|lesinurad 400 mg + allopurinol|Patients on lesinurad 400 mg had their dose changed to lesinurad 200 mg after implementation of protocol amendment 4, dated 07 October 2015.
88937144|NCT01808157|Experimental|0.05% w/w CT327 ointment|Active
88937145|NCT01808157|Experimental|0.5% w/w CT327 ointment|Active
88937146|NCT01808157|Placebo Comparator|vehicle|Placebo
88937147|NCT01808170|Active Comparator|laparoscopic ovarian cystectomy|laparoscopic ovarian cystectomy will be performed on proliferative phase of menstrual cycle.Anti-mullerian hormone level measurement and estimation of antral follicle count will be done before surgery and will be repeated one month after surgery.
88937148|NCT01808170|Active Comparator|laparoscopic cyst deroofing|laparoscopic cyst deroofing will be performed on proliferative phase of menstrual cycle.Anti-mullerian hormone level measurement and estimation of antral follicle count will be done before surgery and will be repeated one month after surgery.
89015418|NCT06259942|No Intervention|Control group|routine practice of the hospital where the surgery was performed (no heater applied group)
89015419|NCT06259929|Experimental|Patients with ER-positive, HER2-negative Early breast cancer|Abemaciclib 150 mg oral twice daily (BID) and giredestrant 30 mg oral once daily (OD) on Days 1-28.
89015420|NCT06259916|Experimental|Cannabis Group|Participants in this group will self-administer their own flower cannabis product (that they purchased for use in the study from a legal-market dispensary) ad libitum inside their homes. Researchers will not handle the product or instruct participants on how much to use during the session.
89452394|NCT00685113|Experimental|1|
89452395|NCT00685113|Experimental|2|
89452396|NCT00685113|Placebo Comparator|3|
89452397|NCT03260114|No Intervention|Physical activity recommendations|Participants in this group will be advised to engage in physical activity recommendations from health authorities, i.e., 150 minutes per week of moderate intensity activity or 75 minutes per week of vigourous intensity activity or combination of both that results in same caloric expenditure.
89452398|NCT03260114|Active Comparator|PAI equal to or more than 100|Participants in this group will be advised to obtain a PAI score of 100 or more over a week.
89452399|NCT03260114|Active Comparator|PAI between 50 and 99|Participants in this group will be advised to obtain a PAI score between 50-99 over a week.
89452400|NCT05498350|Experimental|Early Trigger|
89452401|NCT05498350|Experimental|Delayed trigger|
89452402|NCT04267900|Experimental|99mTc-HPArk2 SPECT/CT|The patients were injected with 11.1 (MBq) per kilogram body weight of 99mTc-HPArk2 in one dose intravenously and underwent SPECT/CT scan 30-60 min later.
89452403|NCT02978859|Experimental|MGCD516|Patients with locally advanced and unresectable or metastatic sarcoma will receive MGCD516 at the discretion of the principal investigator until disease progression, unacceptable toxicity or adverse event(s) or withdrawal of consent.
89452404|NCT04267588||Navio App|The investigators propose to collect self-report and passively collected biological data and evaluate participants' relation to clinical and laboratory pain as well as patients' willingness to use and level of comfort with the mobile pain management digital platform and wearable biosensors. Eligible participants will be consented, given two biosensors (i.e., Apple Watch Series 1 with KardiaBand; Spire), a sleep monitoring device (actigraph watch), and a mobile app enabled smartphone, then trained on how to use the app (and device if appropriate) and biosensors. Participants will keep medications constant and not have any new pain treatment procedures over the course of the study period and 2 weeks prior to starting the study.
89452405|NCT00615693|Experimental|1|
89452406|NCT00701090|Experimental|1|sitagliptin
89452407|NCT00701090|Active Comparator|2|glimepiride
89452408|NCT00614601|Experimental|1|Vaccine + chemo + chemoradiation therapy
89452409|NCT00614601|Experimental|2|Vaccine Only
89452410|NCT03255356||Cohort|An anonymised questionnaire will be answered for each includable consecutive patient after verifying the absence of exclusion criteria.
89452411|NCT02283489|Experimental|Combination therapy A|Recombinant human endostatin adenovirus (EDS01), 5.0 × 1011 VP intratumorally on days 0 and 7; paclitaxel, 160 mg/m2 intravenously on day 1; cisplatin, 25 mg/m2 intravenously on days 1 to 3.
89452412|NCT02283489|Experimental|Combination therapy B|Recombinant human endostatin adenovirus (EDS01), 1.0 × 1012 VP intratumorally on days 0 and 7; paclitaxel, 160 mg/m2 intravenously on day 1; cisplatin, 25 mg/m2 intravenously on days 1 to 3.
89452413|NCT02283489|Experimental|Chemotherapy|Paclitaxel, 160 mg/m2 intravenously on day 1; cisplatin, 25 mg/m2 intravenously on days 1 to 3.
89452414|NCT02455232|Experimental|hemiplegic patient|muscle participation in upper limb spasticity
89452415|NCT03259958|Experimental|Donepezil TDS|Corplex Donepezil TDS 5 mg/day followed by Donepezil TDS 10mg/day applied weekly for 5 consecutive weeks
89452416|NCT03259958|Active Comparator|Aricept|Aricept 5 mg/day followed by Aricept 10 mg/day once daily for 5 consecutive weeks
89452417|NCT03251456|Experimental|Tertiary care|
89452418|NCT03251456|Active Comparator|Usual care|
89452419|NCT00679731|Experimental|A|ABT-874
89452420|NCT00679731|Active Comparator|B|Methotrexate
89452421|NCT00605553|Experimental|1|Active medication Tozadenant 20 mg oral capsules with a daily dosage of either 20 mg BID or 60 mg BID
89452422|NCT00605553|Placebo Comparator|2|Crossover from arm 1 to arm 2 with one week washout. One of the arms is placebo control
89452423|NCT03254888||Low Grade group|"• 50 tumor tissue samples from patients with Low Grade Bladder Cancer undergoing either trans urethral resection of bladder tumor or Radical Cystectomy ,~The followings markers must be estimated :~Autophagy markers:~( Atg7) level using (quantitative real time polymerase chain reaction).~(LC3A)level using immunohistochemistry .~ER-stress marker: (ATF6) level using ELISA(Enzyme Linked Immuno sorbent Assay)~Oxidative stress Marker:(MDA)using chemical method~Apoptotic marker:(caspase 3) using(quantitative real time polymerase chain reaction) ."
89452424|NCT03254888||High Grade group|"• 50 tumor tissue samples from patients with High Grade Bladder Cancer undergoing either trans urethral resection of bladder tumor or Radical Cystectomy,~The followings markers must be estimated :~Autophagy markers:~( Atg7) level using (quantitative real time polymerase chain reaction).~(LC3A)level using immunohistochemistry .~ER-stress marker: (ATF6) level using ELISA(Enzyme Linked Immuno sorbent Assay)~Oxidative stress Marker:(MDA)using chemical method~Apoptotic marker:(caspase 3) using (quantitative real time polymerase chain reaction) ."
89452425|NCT03254888||Safety margin group|"• 50 normal bladder urothelial tissue samples from the safety margin around the tumor(0.5cm to the tumor),~The followings markers must be estimated :~Autophagy markers:~( Atg7) level using (quantitative real time polymerase chain reaction).~(LC3A)level using immunohistochemistry .~ER-stress marker: (ATF6) level using ELISA(Enzyme Linked Immuno sorbent Assay)~Oxidative stress Marker:(MDA)using chemical method~Apoptotic marker:(caspase 3) using (quantitative real time polymerase chain reaction)."
89452426|NCT03254888||Control group|"• 50 (age and sex matched )control~The followings markers must be estimated :~Autophagy markers:~( Atg7) level using (quantitative real time polymerase chain reaction).~(LC3A)level using immunohistochemistry .~ER-stress marker: (ATF6) level using ELISA(Enzyme Linked Immuno sorbent Assay)~Oxidative stress Marker:(MDA)using chemical method~Apoptotic marker:(caspase 3) using (quantitative real time polymerase chain reaction).."
89452427|NCT00678171|Experimental|OP-1 Putty|Patients randomized to the OP-1 Putty Spinal System arm will receive OP-1 Putty with AVS™TL PEEK Spacer System and XIA® Spinal System.
89452428|NCT00678171|Active Comparator|Autograft|Patients randomized to the Autograft Spinal System arm will receive iliac crest autograft with AVS™TL PEEK Spacer System and XIA® Spinal System.
89452429|NCT02455934|Placebo Comparator|Sucrose|Sucrose 50 g
89452430|NCT02455934|Active Comparator|SAlloulose2.5|Sucrose 50 g + D-allulose (psicose) 2.5 g
89452431|NCT02455934|Active Comparator|SAllulose5|Sucrose 50 g + D-allulose (psicose) 5 g
89452432|NCT02455934|Active Comparator|SAllulose7.5|Sucrose 50 g + D-allulose (psicose) 7.5 g
89452433|NCT02455934|Active Comparator|SAllulose10|Sucrose 50 g + D-allulose (psicose) 10 g
89537145|NCT05718167|Experimental|TQB2450 Injection and Anlotinib Hydrochloride Capsules|"In the induction stage:~TQB2450 injection: 1200 mg, Intravenous drip on d1; Carboplatin injection: Area Under Curve 5mg/mL/min, Intravenous drip on d1; Paclitaxel injection: 175mg/m2, Intravenous drip on d1. The above schemes are repeated every three weeks.~In the maintenance stage:~TQB2450 injection: 1200 mg, Intravenous drip on d1; Anlotinib Hydrochloride Capsules: 10mg, orally administered every day from d1-d14.~The above schemes are repeated every three weeks."
89452434|NCT00507741|Experimental|Ertafolide + Vintafolide|Screening: After completion of all screening procedures and confirmation of eligibility, all participants receive a 1- to 2-mL injection of 0.1 mg ertafolide labeled with 20 to 25 mCi of technetium-99m Part A: Induction phase of treatment: Two 4-week cycles; if stable disease or better at week 8 computed tomography (CT), participant may proceed into maintenance phase, comprised of 4-week cycles with CT every 8 weeks. Participants continue on study until they experience disease progression, unacceptable toxicity, or attain protocol-defined clinical benefit. Part B: 4-week cycles with CT every 8 weeks. Participants continue until they experience disease progression, unacceptable toxicity, or attain protocol-defined clinical benefit.
89452435|NCT03251066|Other|Test group|Proponent Nasal Spray Medical device
89452436|NCT00677313|Experimental|1|
89452437|NCT02455856|Experimental|JNJ-42847922 plus Itraconazole|Participants will receive single dose of 5 milligram (mg) JNJ-42847922 as 5 mg/milliliter [mL] oral solution on Day 1 and Day 6 and itraconazole as 200 mg (2*100 mg capsule) from Day 2 to Day 6.
89452438|NCT02283645|Experimental|Minoxidil|3% Minoxidil lotion is applied twice daily to the chest.
89452439|NCT02283645|Placebo Comparator|Placebo|Placebo lotion is applied twice daily to the chest.
89452440|NCT02283723|Experimental|Patient Group 1|This patient group will begin receiving the Health TAPESTRY intervention from time zero.
89452441|NCT02283723|Active Comparator|Patient Group 2|Using a step-wedge approach, this patient group will receive the intervention after a six month waiting period where they will be used as a comparable group. In the first six months, they will receive usual care.
89452442|NCT03259412|Experimental|Fish Oil|Fish oil 5.1g/ day - Premium Omega-3, Norwegian Pure-3, Oslo, Norway
89200975|NCT04035291|Active Comparator|Interventional|The first group (n = 25) will be asked to apply the physiotherapy program by the family at home that includes the principles of therapeutic handling-holding-positioning of NDT principles, starting at the third month for 8 weeks. And It will last for at least 45 minutes, 3 days a week. Family education will be evaluated after 4 weeks and improvements will be made in accordance with the motor development of the infant. The program will be implemented by families for 8 weeks.
89452443|NCT03259412|Placebo Comparator|Placebo|Olive Oil 6g/ day - Premium Omega-3, Norwegian Pure-3, Oslo, Norway
89452444|NCT00602745|Active Comparator|5-Fluorouracil|
89452445|NCT00602745|Experimental|S-1|
88937149|NCT01808235|Experimental|Oral health intervention|The dental hygienist will assess the IMD's tooth brushing technique and will provide specific feedback on the tooth brushing technique, including areas of the dentition missed in brushing. The IMDs will be given a powered toothbrush that records time, date and duration of toothbrushing activity, along with the direction and extent of motion of the toothbrushing activity. In addition, use of interdental cleaning aids will be recommended. The dental hygienist will review the findings from the oral health evaluation with the IMDs and caregivers, and provide detailed feedback on treatment and prevention of the oral health conditions and symptoms. The dental hygienist or study coordinator will call subjects by telephone biweekly to monitor oral hygiene practices and to provide coaching, if needed. Oral hygiene technique assessments will be conducted again three months after the first visit, and once more three months later, at the end of the intervention.
88937150|NCT01808261|Placebo Comparator|Placebo|Placebo is a clear, colorless solution (50mM acetate buffer, pH 5.5 containing 0.02% (w/v) polysorbate-80 and made isotonic with 111.2 mM sodium chloride). Placebo is for intravenous (IV) use only.
89452446|NCT03251222|Experimental|Dexmedetomidine group|Patients who will receive Dexmedetomidine intranasal prior the sedation with remifentanil
89452447|NCT03251222|Placebo Comparator|Placebo Concentrate|Patients will recive 0.9% NaCl
89452448|NCT04487912|Active Comparator|Injection of 99m-Tc Tilmanocept|
88937151|NCT01808261|Active Comparator|GSK249320 100/mg|Clear to opalescent, colorless to pale yellow or pale brown, and is supplied as a sterile, concentrated solution (1000mg/vial). GSK249320 is for IV use only.
88937152|NCT01808274|Experimental|TAVR|with CENTERA self-expanding valve
89452449|NCT04487912|Active Comparator|Injection of 99m-Tc Nanocolloid|
89452450|NCT04471857|Experimental|Hypnosis|A brief session of hypnosis just before child starts with anorectal manometry
89452451|NCT04471857|No Intervention|Control|No hypnosis session, standard care
89452452|NCT04471389||Hanzhong adolescent hypertension cohort|A total of 4623 adolescents aged 6-15 years old in Hanzhong rural areas was recruited in 1987. During the follow-up period, the information about the incidence and risk factors of hypertension will be collected.
89452453|NCT04471389||Mei county adult salt-sensitive hypertension cohort|A total of 675 individuals from 126 families were recruited in this family-based dietary intervention study. A community-based BP screening was conducted among adults aged 18-60 years in the study villages. The probands who had a mean systolic BP (SBP) between 130-160 mmHg and/or a diastolic BP (DBP) between 85-100 mmHg and no use of antihypertensive medications and their parents, siblings, spouses, and offspring were recruited in this study. During the follow-up period, the information about the incidence and risk factors of hypertension will be collected.
89452454|NCT02281461|Experimental|Early ifants|Intervention Male circumcision using a non-surgical device
89452455|NCT02281461|Experimental|Cildren|Intervention Male circumcision using a non-surgical device
89452456|NCT04487600|Experimental|Active Voiding Trial|At the completion of surgery, a Foley catheter was left in place. When the patient was determined to be ambulatory by the recovery room nurse, the bladder was backfilled with 300cc of sterile normal saline. Voiding 200cc or (2/3) of the backfill amount was considered passing.
89452457|NCT04487600|No Intervention|Passive Voiding Trial|At the completion of surgery, a Foley catheter was removed in the operating room. Study participants were allowed six hours to void spontaneously, with 200cc being considered adequate consistent with institution standard practice. At the completion of six hours, if spontaneous voiding has not occurred, a bladder scan was performed and additional time was allowed based on bladder volume with criteria previously established as institution standards based on published practices.
89452458|NCT02281539|Experimental|Treatment using myoelectric signals|Virtual- and augmented reality, are controlled by the patient's phantom limb using muscle (myoelectric) signals from the stump. The patient learns to reactivate areas in the brain related to motor control of the missing limb. The medical device is non-invasive and based on surface electromyography
89452459|NCT03250910|Experimental|HIV/HCV compensated liver disease|Patients without cirrhosis or with compensated cirrhosis (Child-Pugh A) received a generic version of Sofosbuvir and Velpatasvir fixed-dose combination (Sofosvel®, VEL/SOF 100/400 mg film coated tablet, Beacon Pharmaceuticals Ltd. Mymensingh, Bangladesh) 1 tablet per day for 12 weeks.
89452460|NCT03250910|Experimental|HIV/HCV decompensated liver disease|Patients with decompensated cirrhosis (Child-Pugh B or C) received Sofosvel® 1 tablet per day in combination with weight-based ribavirin (RBV)(Robatrol®, 200 mg capsule, Genovate Biotechnology Co. Ltd., Hsinchu, Taiwan; 1,200 mg per day if the body weight ≥ 75 kg; 1,000 mg per day if the body weight < 75 mg) for 12 weeks.
89452461|NCT03250910|Active Comparator|HCV compensated liver disease|Patients without cirrhosis or with compensated cirrhosis (Child-Pugh A) received a generic version of Sofosbuvir and Velpatasvir fixed-dose combination (Sofosvel®, VEL/SOF 100/400 mg film coated tablet, Beacon Pharmaceuticals Ltd. Mymensingh, Bangladesh) 1 tablet per day for 12 weeks.
89452462|NCT03250910|Active Comparator|HCV decompensated liver disease|Patients with decompensated cirrhosis (Child-Pugh B or C) received Sofosvel® 1 tablet per day in combination with weight-based ribavirin (RBV)(Robatrol®, 200 mg capsule, Genovate Biotechnology Co. Ltd., Hsinchu, Taiwan; 1,200 mg per day if the body weight ≥ 75 kg; 1,000 mg per day if the body weight < 75 mg) for 12 weeks.
89452463|NCT02283801|Experimental|Group A|"Group A~Pre-treatment: 600 mg once daily dose of eslicarbazepine acetate (ESL) administered for two consecutive days;~Treatment 1: 1200 mg once daily dose of eslicarbazepine acetate (ESL) administered for six consecutive days~Treatment 2: Concomitant doses of eslicarbazepine acetate (ESL) 1200 mg and lamotrigine 50 mg for two consecutive days~Treatment 3: Concomitant doses of eslicarbazepine acetate (ESL) 1200 mg and lamotrigine 150 mg for seventeen consecutive days"
89452464|NCT02283801|Experimental|Group B|"Group B~Pre-treatment: 50 mg once daily dose of lamotrige (LMT) administered for two consecutive days;~Treatment: 150 mg once daily dose of lamotrige (LMT) administered for six consecutive days;~Treatment 2: Concomitant doses of eslicarbazepine acetate (ESL) 1600 mg and lamotrigine 150 mg for two consecutive days~Treatment 3: Concomitant doses of eslicarbazepine acetate (ESL) 1200 mg and lamotrigine 150 mg for seventeen consecutive days"
89452465|NCT02455154|Placebo Comparator|Letrozole|"Early Breast Cancer patients receiving adjuvant endocrine therapy~Adjuvant Endocrine Therapy: letrozole 2.5 mg qd po."
89452466|NCT02455154|Active Comparator|Letrozole + Xinglinggubao|"Early Breast Cancer patients receiving adjuvant endocrine therapy plus Xianlinggubao~Adjuvant Endocrine Therapy: letrozole 2.5 mg qd po.~Xinglinggubao: 0.5g bid po"
89452467|NCT02455154|Active Comparator|Letrozole + Zhongyaofufang|"Early Breast Cancer patients receiving adjuvant endocrine therapyplus Zhongyaofufang (Traditional Chinses Medicine)~Adjuvant Endocrine Therapy: letrozole 2.5 mg qd po.~Zhongyaofufang: qow po"
89452468|NCT00502515|Experimental|25 mg SSR180575|orally once daily for 24 weeks
89452469|NCT00502515|Experimental|100 mg SSR180575|orally once daily for 24 weeks
89452470|NCT00502515|Placebo Comparator|Placebo|orally once daily for 24 weeks
89452471|NCT03254810|Experimental|SYN060|a single 0.57 mg/kg dose of SYN060
89452472|NCT03254810|Active Comparator|Adalimumab North American source|a single 0.57 mg/kg dose of adalimumab from North American source
89452473|NCT03254810|Active Comparator|Adalimumab European source|a single 0.57 mg/kg dose of adalimumab from European source
89452474|NCT03255122|Experimental|Immediate treatment|Individuals in this condition will immediately receive I-CALM treatment, which draws on videoconferencing to remotely deliver real time cognitive-behavioral therapy for early child anxiety to families in their home.
89452475|NCT03255122|Other|Waitlist|Individuals in Waitlist will participate in an initial waitlist condition, and then after post-waitlist assessment will be offered the I-CALM intervention. Accordingly families in this condition receive Delayed I-CALM.
89452476|NCT02419365||PCD|Individuals with Primary Ciliary Dyskinesia will be assessed in a pure observational design without intervention
89452477|NCT03255044|Active Comparator|Lipophilic statin|Atorvastatin 40 mg administered daily in addition to guideline directed therapy for heart failure.
89452478|NCT03255044|Active Comparator|Hydrophilic statin|Rosuvastatin 20 mg administered daily in addition to guideline directed therapy for heart failure.
89452479|NCT00499239|Experimental|GS-9219|Escalating doses of GS-9219 (5, 8, 11.5, 16, 22.5, 31.5, 44, and 61.5 mg/m^2) until determination of the maximum tolerated dose (MTD)
89452480|NCT03246464|Placebo Comparator|Single-vision spectacles|
89452481|NCT03246464|Active Comparator|Orthokeratology lenses|
89452482|NCT02454998|Experimental|Orthodontic treatment arm|Previous to the surgical alveolar bone grafting, orthodontic treatment is performed several months before surgery
89452483|NCT02454998|No Intervention|No orthodontic treatment arm|No orthodontic treatment previous to surgical alveolar bone grafting
89452484|NCT00677079|Experimental|Iniparib|Iniparib, twice weekly on Days 1 and 4 of each week during 8-week cycles
89452485|NCT03245996|Experimental|Subjects|Subjects with a cardiac pacemaker
89452486|NCT05209503|Experimental|AccuFFRangio Group|STEMI patients with multiple lesions who met the requirements of the study were enrolled and received coronary angiography. First, the revascularization of the criminal vessel (PCI) was completed. The patients were randomly grouped and divided into AccuFFRangio Group and Angiography Group if the treatment results were good. The AccuFFRangio Group was defined as non-IRA of these patients who were treated with PCI after angio-FFR measurement with FFR≤0.8.
89452487|NCT05209503|Active Comparator|Angiography Group|The Angiography Group was defined as PCI treatment for non-IRA when diameter stenosis > 70% based on angiographic results.
89452488|NCT03254966|Experimental|SHR0302 dose level 1|
89452489|NCT03254966|Experimental|SHR0302 dose level 2|
89452490|NCT03254966|Experimental|SHR0302 dose level 3|
89452491|NCT03254966|Experimental|SHR0302 dose level 4|
89452492|NCT03254966|Placebo Comparator|Placebo|
89452493|NCT03786484|Experimental|PBF-999 20 mg|
89452494|NCT03786484|Experimental|PBF-999 40 mg|
89452495|NCT03786484|Experimental|PBF-999 80 mg|
89452496|NCT03786484|Experimental|PBF-999 120 mg|
89452497|NCT03786484|Experimental|recommended phase 2 dose (RP2D)|
89452498|NCT02281929|Active Comparator|amoxicillin+ prednisolone|Oral antibiotherapy during 30 days using amoxicillin+clavulanic acid at a daily dose of 3 gram (amoxicillin) and 375 mg (clavulanic acid) in three daily doses of 1g/125mg. Oral corticotherapy during 30 days with prednisolone at 40 mg/j in a single daily dose in the morning.
88937153|NCT01808287|Experimental|High risk population|SAPIEN 3 transcatheter heart valve was implanted in high risk patients
88937154|NCT01808287|Experimental|Intermediate risk population|SAPIEN 3 transcatheter heart valve was implanted in intermediate risk patients
88937155|NCT01808300|Experimental|A-B-C|Drug will be administered to according to A-B-C sequence for 3 period.
88937156|NCT01808300|Experimental|A-C-B|Drug will be administered to according to A-C-B sequence for 3 period.
88937157|NCT01808300|Experimental|B-C-A|Drug will be administered to according to B-C-A sequence for 3 period.
88937158|NCT01808300|Experimental|B-A-C|Drug will be administered to according to B-A-C sequence for 3 period.
88937159|NCT01808300|Experimental|C-A-B|Drug will be administered to according to C-A-B sequence for 3 period.
88937160|NCT01808300|Experimental|C-B-A|Drug will be administered to according to C-B-A sequence for 3 period.
88937161|NCT01808352|Other|Daily PrEP + coordination of client centered svs|All participants will be offered once daily oral emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg (FTC/TDF) combined with C4.
88937162|NCT01808365||Study cohort|
88937163|NCT01808378|Experimental|Autologous Stem Cells|Autologous expanded adipose-derived stem cells
88937164|NCT01808391||Clinical Follow-up Cohort|The clinical FU cohort comprises among patients who underwent clinical FU at 9, 12, and 24 months after index PCI those who arbitrarily underwent angiographic FU at 22 months (±60 days) after index PCI and those who did not undergo angiographic follow-up at all during the entire study period.
88937165|NCT01808391||Routine Angiographic Follow-up Cohort|The routine angiographic FU cohort comprises patients who underwent clinical FU at 9, 12, and 24 months after index PCI those who undergo angiographic FU at 10 months (±60 days) after index PCI.
88937166|NCT01808404|Experimental|Web-Based Guided Self-Help|The study is an open trial and all participants will be assigned to the same intervention arm.
88937167|NCT01808417|Experimental|Near Infrared Imaging|The intervention to be administered is the indocyanine green for NIR Lymphatic Mapping. All study subjects will receive this same intervention; there is only one arm.
88937168|NCT01808430||VATS for NSCLC patients|VATS for confirmed non-small cell lung cancer (NSCLC)
89452499|NCT02281929|Placebo Comparator|Placebo + prednisolone|Oral placebo of amoxicillin- clavulanic acid in three daily doses during 30 days Oral corticotherapy during 30 days with prednisolone at 40 mg/j in a single daily dose in the morning.
89452500|NCT03254498|Active Comparator|Endocuff assisted colonoscopy|Participants are randomised to undergo first either with Endocuff or cap assisted colonoscopy during colonoscopy.
89452501|NCT03254498|Placebo Comparator|Cap assisted colonoscopy|Participants are randomised to undergo first either with Endocuff or cap assisted colonoscopy during colonoscopy.
89452502|NCT02283879|Experimental|hUC-MSC treatment|Patients will receive human umbilical cord mesenchymal stem cells transplantation with a 12 months follow-up.
89452503|NCT04424056|Experimental|Anakinra +/- Ruxolitinib|"Anakinra +/- Ruxolitinib~According to clinical stage (gradual strategy):~Stage 2b or 3 : Anakinra +/- ruxolitinib depending of evolution; Advanced stage 3 : Anakinra and Ruxolitinib"
89452504|NCT04424056|Experimental|Tocilizumab +/- Ruxolitinib|"Tocilizumab +/- Ruxolitinib~According to clinical stage (gradual strategy):~Stage 2b or 3 : Tocilizumab +/- ruxolitinib depending of evolution; Advanced stage 3: Tocilizumab +ruxolitinib"
89452505|NCT04424056|Active Comparator|Standard of care|Treatment with drugs or procedures in routine clinical practice
89452506|NCT02454374|Experimental|Knee Loading|Progressive joint loading intervention will be taught by a program of exercises by the treating physiotherapist. The intervention consists of knee flexion (bending) and knee extension (straightening). Participants will be assessed for their immediate response to treatment during each assessment or treatment session and advised on the appropriate level of self-directed exercises to be performed twice daily. The clinician will review the patient at follow up appointments during the treatment period, progressing to the next level of exercises or by increasing intensity, duration or repetitions as appropriate. The physiotherapist will encourage compliance during the treatment period and beyond
89537146|NCT05718167|Active Comparator|Tislelizumab Injection|"In the induction stage:~Tislelizumab injection: 200 mg, Intravenous drip; Carboplatin injection: Area Under Curve 5mg/mL/min, Intravenous drip; Paclitaxel injection: 175mg/m2, Intravenous drip. The above schemes are repeated every three weeks.~In the maintenance stage:~Tislelizumab injection: 200 mg, Intravenous drip on d1 Placebo capsule: 0mg, orally administered every day from d1-d14. The above schemes are repeated every three weeks."
89015421|NCT06259916|Experimental|Alcohol Group|Participants in this group will be administered a dose of alcohol by researchers in our mobile lab. The dose is designed (based on participant sex and body weight) to bring blood alcohol concentration to .06 g/dL.
89452507|NCT02454374|Active Comparator|Routine physiotherapy care|Normal care delivered to the control group will be based on current NICE guidelines (2014) for non-pharmacological management of OA which includes verbal and written advice/education; education regarding weight loss; exercise to include local muscle strengthening and general aerobic fitness; with or without manual therapy. Clinicians will be asked to refrain from using the progression of techniques specifically documented in the progressive loading protocol (not currently considered to constitute 'normal care'). Treating clinicians will be asked to record specific exercises and manual therapy techniques employed in the patient's records. Participants will be asked to complete a home treatment record sheet.
89452508|NCT03250442|Other|Group A: Standard Dry Dressing|The standard dry dressing is comprised of nonadherent dressing, dry gauze, cotton undercast padding, compression, and immobilization.
89452509|NCT03250442|Active Comparator|Group B: Foam, Drape, and PrevenaTM|This arm is comprised of foam, drape, the PrevenaTM Device, compression, and immobilization.
89452510|NCT00497757|Experimental|Cardiac Failure Patients|Recipients treated with an enriched hematopoetic stem cell infusion from the heart donor's bone marrow
89452511|NCT05478772|Experimental|CTP-543 and Fluconazole Treatment|On Day 1, each subject will receive a single oral dose of 12 mg CTP-543. Following a washout on Day 2, each subject will receive an oral dose of 200 mg fluconazole once daily on Days 3 through to Day 8. On Day 7, approximately 1 hour after the 200 mg dose of fluconazole, each subject will receive a single oral dose of 12 mg CTP-543.
89452512|NCT02945852|Experimental|refractory SCLC|Patients receive apatinib 500mg/d until progressive Disease(PD).
89452513|NCT03245684|Experimental|Pressure Support Ventilation|"after 48h of controlled ventilation the patient randomised in this arm will desedated and switched on Pressure Support Ventilation (PSV): patient's spontaneous activity will maintained and sedation will be maintained at a level of Richmond Assessment Sedation Scale (RASS) between -2 and -3. The level of pressure support (including PEEP) will be limited to ≤ 30 cmH2O; the pressure support level will ensure a tidal volume of 6 ml / Kg ideal body weight. PEEP, FiO2 and respiratory rate will be regulated according the ARDSnet protocol.~assessment of inflammatory response during PSV"
89452514|NCT03245684|Active Comparator|Controlled Mechanical Ventilation|patient's spontaneous activity will be shut done by sedation and/or respiratory muscles paralysis. Volume (during volume control) or pressure (during pressure control), PEEP, FiO2 and respiratory rate will be regulated according the ARDSnet protocol
89452515|NCT00672009|Experimental|One|
89452516|NCT05478616||Natural cycles|Endometrium will be sampled at the day of LH surge + 7 days.
89452517|NCT05478616||Artificial cycles|Endometrium will be sampled at the day of P4 + 5 days.
89452518|NCT00495885|Experimental|Volinanserin|Volinanserin 2 mg for a maximum of 87 days
89452519|NCT00495885|Placebo Comparator|Placebo|Placebo for volinanserin for a maximum of 106 days
89452520|NCT03245606||Patients with Non Alcoholic Fatty Liver Disease|"Patients (240) will undergo a medical examination in order to analyse their medical history and check inclusion and non-inclusion criterions.~Then will be performed:~a liver biopsy~an abdominal MRI~a transient elastography"
89452521|NCT00592995|Placebo Comparator|1|
89452522|NCT00592995|Active Comparator|2|
89452523|NCT03254030|Placebo Comparator|Inspection on withdrawal|Participants colonic mucosa will be examined only during withdrawal phase of the examination.
89452524|NCT03254030|Active Comparator|Inspection on insertion and withdrawal|Participants colonic mucosa will be examined during insertion and withdrawal phase of the examination
89452525|NCT03254186|Experimental|Propranolol Hydrochloride|Two week up-titration to reach a total dose of 20mg per oral four times per day over the first two weeks then will remain on a stable dose for six weeks. The patients will be treated for eight weeks, complete a one week washout and then crossed over to another arm for eight weeks.
89452526|NCT03254186|Placebo Comparator|Placebo Oral Tablet|Identical placebo. The patients will be treated for eight weeks, complete a one week washout and then crossed over to another arm for eight weeks.
89452527|NCT04272424|Active Comparator|group A|laparoscopic hernioplasty with no fixation
89452528|NCT04272424|Active Comparator|group B|laparoscopic hernioplasty with tacker fixation
89452529|NCT04272424|Active Comparator|group C|laparoscopic hernioplasty with histoacryl fixation
89452530|NCT03250598|Experimental|Cohort A|
89452531|NCT03250598|Experimental|Cohort B|
89452532|NCT03250598|Experimental|Cohort C|
89452533|NCT02282085|Experimental|Aripiprazole Once-Monthly|Switch to 400 mg aripiprazole once-monthly injection
89452534|NCT02282085|Active Comparator|Standard of Care|Continue current SOC oral antipsychotic medication
89452535|NCT03254342||Major depressive disorder|There is no intervention/treatment in this study.
89452536|NCT03254342||Non-depressed individuals|There is no intervention/treatment in this study.
89452537|NCT05482984|Experimental|Lectures with video-recorded role-play and guided reflection|The learning method used with the intervention group was role-playing with videos and guided reflection.
89452538|NCT05482984|No Intervention|Lectures without video-recorded role-play and guided reflection|The control group was exposed to classroom lectures without video-recorded role-play and guided reflection.
89452539|NCT05475496||Elderly cardiac patients with multimorbidity and their caregivers|"elderly patients (60 years and over) [2] with multimorbid conditions and a cardiovascular disease is one of them .~caregivers of elderly patients included in the study"
89452540|NCT00671073|Active Comparator|1|Oglemilast low dose, oral administration once daily for 12 weeks
89452541|NCT00671073|Active Comparator|2|Oglemilast middle dose, oral administration, once daily for 12 weeks
89452542|NCT00671073|Active Comparator|3|Oglemilast high dose, oral administration, once daily for 12 weeks.
89452543|NCT00671073|Placebo Comparator|4|Placebo
89452544|NCT03245216|Experimental|aerobic exercise + motor skill practice|acute bout of aerobic exercise before motor learning
89452545|NCT03245216|Active Comparator|rest + motor skill practice|seated rest before motor learning
89452546|NCT03245294|Active Comparator|Lumbar ESI with paramedian approach|Lumbar ESI with paramedian approach
89452547|NCT03245294|Active Comparator|Lumbar ESI with midline approach|Lumbar ESI with midline approach
89452548|NCT04471467||group F|Using tracheal tube fixation method （According to the needs of the surgery, the surgeon who did not participate in the trial）
89452549|NCT04471467||group N|No tracheal tube fixation （According to the needs of the surgery, the surgeon who did not participate in the trial）
89452550|NCT03250754||Pharmacological treatment group|Treatment decision making is based on physician's choice and patient preferences. Patients were referred to the Pain Service Unit. Patients continued with a prophylactic treatment alone
89452551|NCT03250754||Electroacupuncture group|Treatment decision making is based on physician's choice and patient preferences. Patients were referred to the Pain Service Unit. Patients continued with a new prophylactic treatment and additionally, received 12 sessions of acupuncture. The treatments, which included electro-stimulation.
88937169|NCT01808443|Active Comparator|Cryotherapy|Cryotherapy, at most 4 times
88937170|NCT01808443|Experimental|laser|laser, at most 4 times
88937171|NCT01808469|Experimental|NI-0101|NI-0101 is an anti-Toll-like receptor monoclonal antibody.
88937172|NCT01808469|Placebo Comparator|Placebo|The placebo to be used for the proposed clinical trial is a sterile solution for intravenous infusion. The placebo is identical to the NI-0101 drug product but does not include the active substance.
88937173|NCT01808482|Experimental|Part A: GSK2618960|Subjects will receive ascending single dose in 3:1 ratio of active:placebo respectively in each dosing session.
88937174|NCT01808482|Placebo Comparator|Part A: Placebo|Subjects will receive ascending single dose in 3:1 ratio of active:placebo respectively in each dosing session
88937175|NCT01808482|Experimental|Part B: GSK2618960|Subjects will receive ascending repeat dose (dose decided from Part A) in 3:1 ratio of active:placebo respectively in each cohort.
88937176|NCT01808482|Placebo Comparator|Part B: Placebo|Subjects will receive ascending repeat dose (dose decided from Part A) in 3:1 ratio of active:placebo respectively in each cohort.
88937177|NCT01808482|Experimental|Part C: GSK2618960|Subjects will receive active treatments for 2 to 4 repeated doses (dose decided from Part A& B)
88937178|NCT01808521|Experimental|N-acetylcysteine|IV administration of N-acetylcysteine (Acetadote) at 150mg/Kg loading bolus over 60 minutes followed by 150mg/Kg over 17 hours if loading dose was well tolerated.
88937179|NCT01808586|Experimental|Dexamethasone|Intra-articular corticosteroid number 2.
88937180|NCT01808586|Experimental|Betamethasone|Subjects will receive either betamethasone or dexamethasone injected into the cervical facet joints (levels determined by experienced physician).
88937181|NCT01808586|Active Comparator|Intramuscular injection|Subjects in this group will receive lidocaine injection directly into tender myofascial trigger points.
88937182|NCT01808586|Active Comparator|Home exercise|Subjects in this group will receive education and a pamphlet on a set of standardized home exercises for neck pain
88937183|NCT01808625|Other|HYPERBARIC OXYGEN STIMULATION|30 daily sessions, 6 days a week of 90 min exposure to 100% oxygen at 2 atmospheres absolute(ATA).
89452552|NCT03245060|Experimental|Intervention: immediate SFBT|The Intervention arm will receive up to six Adapted Solution Focused Brief Therapy (SFBT) sessions immediately post randomisation. The sessions will be spaced over 3 months. Participants will also receive all usual care.
89452553|NCT03245060|Other|Intervention: delayed SFBT|The wait-list control arm will receive the same intervention (Adapted Solution Focused Brief Therapy, SFBT) as the intervention arm, but after a delay of six months. Participants will also receive all usual care.
88937184|NCT01808638|Other|Lead in safety period|Cohort of three subjects with non-pancreatic cancer for whom conventional treatment options have failed, will be treated. If one of the subjects in the safety cohort experiences an unacceptable toxicity, the safety cohort is expanded to six subjects.
88937185|NCT01808638|Experimental|Treatment arm 1|Subjects with advanced pancreatic cancer will be treated.
88937186|NCT01808638|Experimental|Treatment arm 2|Subjects with advanced pancreatic cancer will be treated.
88937187|NCT01808664|Experimental|Standardized Patient Instructor Intervention|"Primary care physicians (PCPs) randomized to intervention will receive over a three month run-in period two visits by standardized patient instructors portraying: 1) a 48 year-old patient with low back pain for less than six-weeks and no red flags for immediate spinal imaging; and 2) a 50 year-old recently menopausal woman establishing care with concerns about osteoporosis risk."
88937188|NCT01808664|Active Comparator|Control|"In the latter half of visits with control PCPs, standardized patient instructors (SPIs) will share information regarding low back pain or bone health that are unrelated to diagnostic testing, but will not discuss patient-centered techniques or conduct training. The total duration of the control information sharing will be about one-third the SPI intervention to enhance patient-centeredness."
88937189|NCT01808677||Thoracic Reirradiation Registry|Data collection on patients being treated with thoracic reirradiation with PBT or IMRT for NSCLC, with or without chemotherapy.
89452554|NCT03250364|Experimental|Multilayer bandage group|"Manual lymphatic drainage (MLD) + upper limb (UL) exercises + educational strategy + multilayer bandage consisting of three layers. The first was a 100% cotton tubular bandage which will be directly placed on the skin to prevent any injury (Tubinylex TM). The second layer is a paddle with the purpose of unify and increase pressure (Emulsified Latex FoamTM 8mm, Thuasne, France); and the third layer of inelastic bandages (6, 8 and/or 10 cm Rosidal K Short Stretch Bandage, Germany). All the bandage layers will be placed from caudal to cranial in a circular disposition, overlapping in one third the previous layer for a correctly cover of the limb and not to leave open spaces. The cotton tubular bandage and the short-stretch bandage could be cleaned without losing their material properties."
89537147|NCT03299465|Experimental|Yoga arm|A six-week restorative yoga intervention consisting of a weekly, 60-minute yoga group class led by a certified yoga instructor along with twice-weekly home practice using yoga DVD.
89537148|NCT03299387|Active Comparator|Oral Nitrofurantoin|Participants will randomized to oral nitrofurantoin
88937190|NCT01808703|Experimental|Scaling and root planing plus PerioPatch|"All subjects in this group will receive scaling and root planing (full mouth during no more than 2 sessions within two weeks following the Baseline exam). Thereafter, PeriZone PerioPatch will be dispensed to subjects per randomization for administration over the trial period. Subjects will apply study patches (i.e., BID on Days 1, 28 and 42; QD on Days 2-6; Days 14-20, 29-30 and 43-44) to designated treatment sites (i.e., measuring 6 mm or more in pocket depth at Baseline)."
88937191|NCT01808703|Active Comparator|Scaling and root planing alone|Subjects in this group will receive only scaling and root planing (full mouth during no more than 2 sessions within two weeks following the Baseline exam).
88937192|NCT01808716|Active Comparator|Low-level laser therapy (LLLT) on muscle damage|Effects of low-level laser therapy (LLLT)on muscle damage
88937193|NCT01808716|Active Comparator|Low-level laser therapy (LLLT) placebo on muscle damage|Effects of low-level laser therapy (LLLT) placebo on muscle damage
88937194|NCT01808729||FMD or CAD (as appropriate)|The study group will either have FMD, early onset CAD, or other rare/unusual vascular disorder. These differing disorders will be sub-groups within the overall study
88937195|NCT01808729||Healthy control subjects without vascular disease|Healthy controls will not exhibit signs, symptoms or other evidence of vascular disease.
88937196|NCT01808742||Treatment|Treatment with CryoTouch III device
88937197|NCT01808768|Experimental|Alcaftadine|subject on any ocular allergy ophthalmic treatment or no treatment will be started on Alcaftadine 0.25%(study drug)- 1 drop each eye daily for 1-2 weeks
88937198|NCT01808781|Experimental|Intervention group|Home exercise program plus walking program during 8-week period
88937199|NCT01808781|Active Comparator|Comparison group|Walking only program throughout the 8-week period.
88937200|NCT01808807||cesarean section rate after audit|cesarean section rate after audit
88937201|NCT01808833||Frail patients|
88937202|NCT01808833||Non-frail patients|
88937203|NCT01808846||Lean Adolescents|Kids aged 12-17 with body mass index less than 25% and normal glucose tolerance test results
88937204|NCT01808846||Obese Insulin Sensitive|Obese Insulin Sensitive Adolescents aged 12-17 with BMI>95th% and whole body insulin sensitivity index > 3.
88937205|NCT01808846||Obese Insulin Resistant Adolscent|Obese Insulin Resistant Adolescents 12-17 with BMI> 95th% and WBISI<1.2.
88937206|NCT01808859|Experimental|Tourniquet|The Torniquet will be inflated to 100 mmHg over systolic pressure just before skin incision. The tourniquet will be deflated when the last stich/agraf is fixed
88937207|NCT01808859|No Intervention|No tourniquet|"The patients operated on in the non-tourniquet group will have the same surgery and surgical technique but without tourniquet~hyperbaric bupivacaine 12.5-15 mg Celecoxib 400 mg and paracetamol 1 g will be given preoperatively. Postoperatively celecoxib 200 mg x 2 and paracetamol 1 g/6 h is given is given for 2 weeks."
88937208|NCT01808872||Heart Failure|
88937209|NCT01808885|Experimental|olesoxime (TRO19622)|"olesoxime (3 caps: 495 mg, od) will be administered orally as 165 mg soft capsules for 6 months.~Investigational products will be allocated in a 1:1 ratio from Baseline/Visit 0 to Week 24 (Visit 3/Final Visit)."
88937210|NCT01808885|Placebo Comparator|placebo|placebo (3 soft capsules, od) will be administered orally for 6 months
88937211|NCT01808898|Experimental|Local anaesthetic|2mls consisting of 1ml of 3% mepivacaine (short / medium acting) and 1ml of 0.5% bupivacaine (long acting)
88937212|NCT01808898|Placebo Comparator|Saline|2mls of Normal Saline solution in a 5ml syringe
88937213|NCT01808911|Active Comparator|Bras A|Steroid 1mg/kg/d and Cyclophosphamide 2mg/kg/d
88937214|NCT01808911|Experimental|Bras B|Steroid 1mg/kg/d and Rituximab 375 mg/m2 every week during four weeks
88937215|NCT01808976|Active Comparator|Evolution|This app is designed to be a cognitive training game that conditions the CCN. This is done by having participants play a multitasking game that targets their perceptual discrimination abilities, selective attention, and visuomotor tracking skills. At the first session, participants will be directed to an initial assessment of each of these cognitive control skills in a single task and dual-task setting (a total of 3 different diagnostics, described below). Each week, this diagnostic phase will reflect the training paradigm they will encounter for that week, as each week the perceptual and tracking challenges will increase.
88937216|NCT01808976|Experimental|Problem Solving Therapy|This app is based on the social problem solving protocol developed by Nezu and D'Zurilla . The app begins with explaining the PST steps. Participants are informed that they can learn each step one session at a time, or they can chose to learn all the steps at once. After each step completed, participants are asked if they want to continue onto the next step or save it for the next session, thus the app tailors itself to the users ability to absorb new information.
88937217|NCT01808976|Active Comparator|Basic health push app|This app provides daily suggestions for overcoming depressed mood and allows users to track their mood, using the 0-9 scale available for all three apps. In the first app session, participants are given a general education about depression and its known causes and consequences. Participants are told that to overcome mood problems, they must engage in one mood improvement strategy a day and that the app will suggest one to try each day.
88937218|NCT01809015||Cohort A: Regular medical care|Patients treated with vitamin K antagonists in regular medical care system
88937219|NCT01809015||Cohort B: Coagulation service|Patients with oral anticoagulation therapy in a telemedicine-based coagulation service
88937220|NCT01809028|Active Comparator|EUS FNA with 2 passes|biopsy with 2 passes of the needle
88937221|NCT01809028|Active Comparator|EUS FNA with 4 passes|biopsy with 4 passes of the needle
88937222|NCT01809067|Active Comparator|Lavender Aromatherapy Inhalers|Lavender Aromatherapy Inhalers
88937223|NCT01809067|No Intervention|No aromatherapy|No aromatherapy
88937224|NCT01809093||Blood draw|Blood (approximately equal to 3 to 4 tablespoons) will be drawn at the Wills Eye Institute, 1 time.
88937225|NCT01809119|Experimental|Laparoscopic Partial Nephrectomy|Patients with kidney neoplasms submitted to laparoscopic partial nephrectomy
88937226|NCT01809119|Active Comparator|Open Partial Nephrectomy|Patients with kidney neoplasms submitted to open partial nephrectomy
88937227|NCT01809145|Other|metal hypersensitivity|peripheral blood test for metal hypersensitivity (MELISA test)
89200976|NCT04035291|Experimental|Experimental|In the second study group (n = 25), family collaborative physiotherapy program will be applied by the family. This program will start from the postterm third month, and will include family trainings based on the goal-oriented active motor learning model of the baby in an 8-week in enriched environment and to include holding-carrying-positioning trainings in daily routines. Also it will last for at least 45 minutes, 7 days a week. All members of the family will be included in the family trainings and home visits will be made at 2-week intervals. Families will be encouraged to apply the physiotherapy processes of their babies in their natural environment at every moment of their daily routines (feeding, carrying on lap, gas extraction, changing the bed, sleeping, waking time, shopping moment, playing games etc.).
89452555|NCT03250364|Experimental|Simplified multilayer bandage group|"Manual lymphatic drainage (MLD) + upper limb (UL) exercises + educational strategy + double compression bandage consisting of two layers, made up of a first rigid cotton bandage (11 cm Bande coton Short Stretch; Thuasne, France) and a second elastic bandage (BiflexTM 16 light; Thuasne, France). The two layers will be placed caudal to cranial in a circular manner, overlapping in one third the previous layer. The elastic bandage have squares drawn to help to the physiotherapist to control the stretch they given to the bandage. The two bandages could be cleaning without losing their properties. If there was any oedema concentration or a fibrous place, a paddle pad will be put in these places (Mobiderm TM, Thuasne, France)."
89452556|NCT03250364|Experimental|Cohesive bandage group|Manual lymphatic drainage (MLD) + upper limb (UL) exercises + educational strategy + cohesive bandage consisting of a single short-stretched layer that will be put directly on the subject skin and stick on itself (10cm 3M CobanTM Minnesota Mining and Manufacturing Co, United States). It will be placed in a circular manner distal to cranial with a paddle pad in the elbow fold not to damage this moving part. This bandage will be reused twice in the same subject.
89452557|NCT03250364|Experimental|Adhesive compression bandage group|"Manual lymphatic drainage (MLD) + upper limb (UL) exercises + educational strategy + adhesive compression bandage consisting of an elastic bandage (BiplastTM Thuasne, France. Measures: 10cm x 2,5 m) which will put over a pre-tape bandage not to damage the skin. It will be placed in a circular disposition from distal to cranial. In each physiotherapy session, the bandage has to be replaced with a new one."
89452558|NCT03250364|Experimental|Kinesiotaping bandage group|"Manual lymphatic drainage (MLD) + upper limb (UL) exercises + educational strategy + kinesiotaping bandage consisting of K-Active Tape. The k-tape will be pasted directly on the skin and put longitudinally in thin bands in a cranio-caudal disposition. The width of the bandage will be of 5cm, and will be cut in four bands that will cover all the upper limb cranial to caudal in a spiral way surrounded it. The bandage will be placed moving the limb into internal and external rotation for putting the skin in a little stretch without lengthen the tape."
88937228|NCT01809158|Active Comparator|minocycline|Subjects randomized to the minocycline group will take 2 tablets per day, each 100mg of minocycline, for a total daily dose of 200mg of minocycline.
88937229|NCT01809158|Placebo Comparator|placebo|Subjects randomized to the placebo group will take 2 tablets of placebo (matched for minocycline) per day.
88937230|NCT01809171|Experimental|vitamin D3|1000 mg Ca2+/800IU vitamin D3 daily + 25 000IU vitamin D3 weekly during 6 months
88937231|NCT01809171|Placebo Comparator|Placebo|1000 mg Ca2+/ 800IU vitamin D3 daily + 25000IU placebo every week during 6 months
88937232|NCT01809184|Experimental|Dose level 1|Each subject will be randomly assigned to receive either insulin 287, placebo or insulin glargine within the dose group.
88937233|NCT01809184|Experimental|Dose level 2|Each subject will be randomly assigned to receive either insulin 287, placebo or insulin glargine within the dose group.
88937234|NCT01809184|Experimental|Dose level 3|Each subject will be randomly assigned to receive either insulin 287, placebo or insulin glargine within the dose group.
88937235|NCT01809184|Experimental|Dose level 4|Each subject will be randomly assigned to receive either insulin 287, placebo or insulin glargine within the dose group.
88937236|NCT01809184|Experimental|Dose level 5|Each subject will be randomly assigned to receive either insulin 287, placebo or insulin glargine within the dose group.
88937237|NCT01809184|Experimental|Dose level 6|Each subject will be randomly assigned to receive either insulin 287, placebo or insulin glargine within the dose group.
88937238|NCT01809184|Experimental|Dose level 7|Each subject will be randomly assigned to receive either insulin 287, placebo or insulin glargine within the dose group.
88937239|NCT01809223|Experimental|conbercept treatment group|Subjects will receive conbercept injections at a dose of 0.5 mg/eye, once a month for first 3 months. In the next 6 months, the investigator will decide whether repeat injections are needed base on the monthly assessment results.
88937240|NCT01809223|Sham Comparator|sham injection group|Subjects will receive sham injections monthly for 3 months and will receive 0.5 mg/eye conbercept at month 4. The investigator will decide whether repeat injections are needed base on the monthly assessment results from month 5 to month 9.
88937241|NCT01809236|Experimental|0.5 mg Conbercept|patients will receive monthly intravitreal injections of Conbercept to month 3 (total 3 times) and then on an as needed (PRN) dosing schedule based on the pre-specified retreatment criteria till to month 9.
88937242|NCT01809275|Experimental|QBECO|Individualized maintenance dose ranging from 0.01 - 0.2 mL, administered subcutaneously, every other day for a maximum of 16 weeks
88937243|NCT01809275|Placebo Comparator|Placebo|Individualized maintenance dose ranging from 0.01 - 0.2 mL, administered subcutaneously, every other day for a maximum of 16 weeks
88937244|NCT01809301|Active Comparator|Niaspan|Single dose of one NIASPAN® 1000 mg Extended-Release Tablet following dinner
88937245|NCT01809301|Experimental|TRIA-662|Single dose of two TRIA-662, 500 mg Immediate-Release Tablets following dinner
88937246|NCT01809340|Experimental|Minocycline|Following a 12-day open-label treatment phase (involving ketamine and minocycline), responders may receive oral minocycline twice daily for up to 6 weeks in a blinded manner. In addition, non-responders may receive oral minocycline twice daily for up to 6 weeks in an open-label manner.
88937247|NCT01809340|Placebo Comparator|Placebo|Following a 12-day open-label treatment phase (involving ketamine and minocycline), responders may receive placebo twice daily for up to 6 weeks in a blinded manner
88937248|NCT01809340|Experimental|Ketamine and Minocycline|All patients will receive 6 IV infusions of ketamine and oral minocycline twice daily during a 12-day open-label treatment phase
89452559|NCT03245138|Experimental|endoscopic third ventriculostomy|endoscopic third ventriculostomy for the treatment of iNPH
89452560|NCT03245138|Active Comparator|ventricular peritoneal shunt|Insertion of a ventriculo-peritoneal Shunt for the treatment of iNPH
89452561|NCT03244982|Active Comparator|Full-Dose|Participants in this arm will receive Fluorescein Na 10% Inj 500mg pushed over several seconds one time, prior to their fluorescein angiogram. If they return for a second (clinically indicated) angiogram, they will receive Fluorescein Na 10% Inj 250mg pushed over several seconds one time.
89452562|NCT03244982|Experimental|Half-Dose|Participants in this arm will receive Fluorescein Na 10% Inj 250mg pushed over several seconds one time, prior to their fluorescein angiogram. If they return for a second (clinically indicated) angiogram, they will receive Fluorescein Na 10% Inj 500mg pushed over several seconds one time.
89452563|NCT03250286|Experimental|EUS-ERCP group|EUS is performed first, and when the examiner finds bile duct stone in the EUS examination, ERCP is performed to remove the stone.
89452564|NCT03250286|Active Comparator|ERCP group|ERCP without EUS is performed in all patients.
89452565|NCT03244748||Group 1|Patients underwent ablation and continued having amiodarone after the procedure
89452566|NCT03244748||Group 2|Patients underwent ablation and not having amiodarone after the procedure
89452567|NCT03253718||Healthy Volunteers|Healthy Volunteers between 18 and 68 years of age
89452568|NCT04487366|Active Comparator|Double Operator Ultrasound-Guided Regional Anesthesia|resident control block needle and ultrasound probe and asistant operator inject the solution. resident reach the target area created in the phantom model using a block needle with ultrasound guidance
89452569|NCT04487366|Active Comparator|Jedi Grip|resident control block needle, ultrasound probe and syringe independently with jedi grip; reach the target area created in the phantom model using a block needle with ultrasound guidance; inject and aspirate the solution.
89452570|NCT04487366|Active Comparator|On-lock grip|resident control block needle, ultrasound probe and syringe independently with on-lock grip; reach the target area created in the phantom model using a block needle with ultrasound guidance; inject the solution.
89452571|NCT04487366|Active Comparator|Bedforth alternative grip|resident control block needle, ultrasound probe and syringe independently with bedforth's alternative grip; reach the target area created in the phantom model using a block needle with ultrasound guidance; inject the solution.
88937249|NCT01809353|Experimental|Group A: JNJ-54452840 20 mg|Each participant will receive 20 mg of JNJ-54452840 as a single intravenous dose.
88937250|NCT01809353|Experimental|Group A: JNJ-54452840 80 mg|Each participant will receive 80 mg of JNJ-54452840 as a single intravenous dose.
88937251|NCT01809353|Experimental|Group A: JNJ-54452840 240 mg|Each participant will receive 240 mg of JNJ-54452840 as a single intravenous dose.
88937252|NCT01809353|Placebo Comparator|Group A: Placebo|Each participant will receive matching placebo as a single intravenous dose.
88937253|NCT01809353|Experimental|Group B: JNJ-54452840 20 mg|Each participant will receive 20 mg of JNJ-54452840 as a single intravenous dose.
88937254|NCT01809353|Experimental|Group B: JNJ-54452840 80 mg|Each participant will receive 80 mg of JNJ-54452840 as a single intravenous dose.
88937255|NCT01809353|Experimental|Group B: JNJ-54452840 240 mg|Each participant will receive 240 mg of JNJ-54452840 as a single intravenous dose.
88937256|NCT01809353|Placebo Comparator|Group B: Placebo|Each participant will receive matching placebo as a single intravenous dose.
89452572|NCT03253640||Patients with HAI during hospital stay|Patients who meet the European Centre for Disease Control (ECDC) Healthcare Associated Infection (HAI) case definitions. Case note review will be undertaken during hospital stay. Questionnaire will be administered at recruitment, pre-discharge, one, three, six and twelve months post discharge.
89452573|NCT03253640||Patients without HAI during hospital stay|Patients who do not meet the European Centre for Disease Control (ECDC) Healthcare Associated Infection (HAI) case definitions. Case note review will be undertaken during hospital stay. Questionnaire will be administered at recruitment, pre-discharge, one, three, six and twelve months post discharge.
89452574|NCT03250208|Placebo Comparator|Control Group|Participants randomized to this group will take two placebo capsules daily during days 21-60.
89452575|NCT03250208|Experimental|Intervention group|The intervention in this study is a probiotic. Participants randomized to this group will take two capsules of a probiotic daily during days 21-60
89452576|NCT03253484|Experimental|NAFL-treated wounds|NAFL treated wounds
89452577|NCT03253484|No Intervention|Control|untreated control wound
89452578|NCT03250130|Experimental|Hypnosis|The patient achieve self-hypnosis sessions in these chemotherapy treatments
89452579|NCT03249974||Target group|Children (5 to 18 years) with type 1 diabetes mellitus treated with an insulin pump and wearing a FreeStyle Flash Libre glucosesensor will switch to the Enlite sensor communicating with Minimed 640G pump
89452580|NCT03244592|Active Comparator|Minocycline|200 mg/day
89452581|NCT03244592|Placebo Comparator|Sugar Pill|Matched placebo
89452582|NCT03244514|Experimental|Intervention group|"Implementation of the cardiovascular surgery AKI bundle~discontinuation of all nephrotoxic agents when possible~optimization of volume status and hemodynamic parameters~close monitoring of serum creatinine, fluid balance and urinary output~avoidance of hyperglycemia~considerations of alternatives to radiocontrast agents~discontinuation of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in the perioperative period~avoidance of HES, gelatin, and chlorid-rich solutions"
89452583|NCT03244514|No Intervention|Control group|The patients will receive standard of care (according to each center)
89537149|NCT03299387|Active Comparator|Intravesical Gentamicin|Participants will be randomized to intravesical gentamicin
88937257|NCT01809366|Experimental|seminal plasma insemination|seminal plasma insemination
88937258|NCT01809366|Placebo Comparator|culture medium insemination|culture medium insemination
88937259|NCT01809392|Experimental|decitabine|36 mg/m2 on day 42 after transplantation and administered daily for 5 consecutive days every 28 days for up to a total of 10 cycles
88937260|NCT01809392|No Intervention|no decitabine|
88937261|NCT01809418|Experimental|keePAP|
88937262|NCT01809431|Experimental|intervention|Breastfeeding, progression to type 2 diabetes, nutrition, and exercise education, coping skills training, exercise training, a home-based exercise program and educational and motivational text messaging.
89452584|NCT03253328|Active Comparator|Active Arm N-acetyl cysteine (NAC)|Upon study enrollment, patients will be randomized 1:1 by Investigational Pharmacy to a standard adult intravenous dose of NAC (1200mg twice a day) for 6 days post-amputation.
89452585|NCT03253328|Placebo Comparator|Placebo Arm|Upon study enrollment, patients will be randomized 1:1 by Investigational Pharmacy to placebo ½ normal saline infusion (twice a day) for 6 days post-amputation.
89452586|NCT03253874|Experimental|Intervention Site-LAC+USC Medical Center|In this arm or study site,new guidelines are disseminated to all residents attending and faculty physicians within the department of Ophthalmology and Anesthesiology. New guidelines call for the across the board elimination of pre-operative testing and visits for patients undergoing cataract surgery.
89452587|NCT03253874|No Intervention|Control Site--Harbor-UCLA Medical Center|In this arm or study site, patients will undergo standard of care for cataract surgery without any new guidelines.
89452588|NCT03253406|Experimental|Polar M400 + Facebook Group (PM400+FG)|Will be provided a Polar M400 to track physical activity and energy expenditure while also being included in a Facebook group wherein Social Cognitive Theory-based physical activity and nutritious eating tips will be provided twice weekly for 12 weeks.
89452589|NCT03253406|Active Comparator|Facebook Only Group (FG)|Included exclusively in a separate, but content-identical, Facebook group for 12 weeks.
89452590|NCT03253250|Active Comparator|Group A|The subjects will be treated by NAs (ETV, 0.5mg，qd；TDF，300mg，qd；ADV，10mg，qd）for 96 weeks
89452591|NCT03253250|Experimental|Group B|The subjects will be treated by peginterferon alfa-2a （135μg/week）combination with NAs(ETV\TDF\ADV) for 96 weeks.
89452592|NCT03253562|No Intervention|Healthy control|healthy volunteers not suffering from diabetes or hypertension
89452593|NCT03253562|No Intervention|diabetic hypertensive recently diagnosed patients|recently diagnosed patients suffers from diabetes type 2 and hypertension but didnot receive their proper treatment yet
89452594|NCT03253562|Other|Metformin treated group|diabetic hypertensive patients which were treated with captopril for their hypertension and metformin for their diabetes
89452595|NCT03253562|Other|Vildagliptin treated group|diabetic hypertensive patients which were treated with captopril for their hypertension and vildagliptin for their diabetes
89452596|NCT03244280|Other|MOB015B|
89452597|NCT03249818|Other|HITT Device|HITT device to scan eyes of participants 3 times (30 seconds each) at time of admittance to hospital for diagnosed traumatic brain injury. If patient is still in hospital 2 weeks post-enrollment, a second set of 3 tests will be performed
89452598|NCT03249896|Experimental|Intervention|Patients in the intervention arm will receive standard medical care and in addition to that, be given the Aina or Aina Mini device for self-monitoring of blood glucose (SMBG), the Habits-GDM mobile app, and a weighing scale.
89452599|NCT03249896|No Intervention|Control|"Patients in the control arm will receive standard medical care and only be given the Aina or Aina Mini device for SMBG.~Standard medical care involves one session of face-to-face education by a diabetes nurse educator and a dietician. Patients are initiated on capillary glucose monitoring. Subsequently, standard clinical care is provided by their obstetrician. Participation in this study will not increase the frequency of clinic visits. The frequency of SMBG will be as clinically indicated and not increased as a result of participation in this study. Should the obstetrician feels that insulin is required, it will be initiated and if necessary the patient will be referred to the endocrinology service for management of insulin therapy. In some patients, the clinician may decide to prescribe metformin."
89452600|NCT03253016|Experimental|cervicall cerclage|to test vaginal microbiome distribution in women with cervical cerclage due to cervical incompetence in weeks: 12 14 18 26 32
89452601|NCT03253016|Experimental|vaginal progesterone|to test vaginal microbiome distribution in women treated with vaginal progesterone due to cervical shortening in weeks: 12 14 18 26 32
89200977|NCT04035291|No Intervention|control|In the third study group, families who are out of town or who cannot participate in the treatment program for other reasons will be included in the evaluations.
89452602|NCT03253016|No Intervention|contol|to test vaginal microbiome during pregnancies without cerclage or progesterone
88937263|NCT01809431|No Intervention|Wait-listed control group|Wait-listed control group receive usual care delivered by their health care provider and after completion of their time in the study they are offered the intervention
89200978|NCT00898833||Group 1|Previously collected plasma and urine samples are analyzed for VEGF via ELISA, plasma samples are analyzed for CgA and IL-6 via ELISA, hK2 via immunometric assay, plasma samples are analyzed for PSA via Tandem-R PSA kit, plasma samples are analyzed for TNF-alpha, sTNF-R1, and IL-8 via quantikine IL-8 immunoassay.
89452603|NCT03250052|Experimental|Part A|Period 1(fimasartan) x 7days - Period 2(fimasartan + linagliptin) x 7days
89452604|NCT03250052|Experimental|Part B|Period 1(linagliptin) x 7days - Period 2(fimasartan + linagliptin) x 7days
89452605|NCT02455310||Outpatients with dementia|Medication use will be evaluated among outpatients with dementia in intervention and control counties, as well as statewide to evaluate the long-term effectiveness of the statewide intervention.
89452606|NCT02455310||Nursing home residents|Medication use and behavioral outcomes will be evaluated among nursing home residents in intervention and control counties, as well as statewide to evaluate the long-term effectiveness of the statewide intervention.
89452607|NCT05478382|Placebo Comparator|Placebo|3 capsules of placebo drug are administered once prior to surgery and every 12 hours after surgery for 72 hours
89452608|NCT05478382|Experimental|Pregabalin 25mg|1 capsule of Kabalin 25mg Cap and 2 pills of placebo drug are administered once prior to surgery and every 12 hours after surgery for 72 hours
89452609|NCT05478382|Experimental|Pregabalin 50mg|2 capsules of Kabalin 25mg Cap and 1 pill of placebo drug are administered once prior to surgery and every 12 hours after surgery for 72 hours
89200979|NCT04035135|Experimental|Open Label Treatment Arm|One (1) dose of ANX005, 75 mg/kg, will be administered IV. IVIg, 0.4 g/kg, will be administered for 5 consecutive Days.
89200980|NCT04034745||Standard of Care telotristat ethyl (Xermelo) Treatment|Treatment of telotristat ethyl (Xermelo) with DXA scans and bionutritional assessments (24-hour food recall and taste/smell alteration) conducted 3x during telotristat ethyl treatment.
89200981|NCT00903279|Placebo Comparator|Placebo|
89452610|NCT05478382|Experimental|Pregabalin 75mg|3 capsules of Kabalin 25mg Cap are administered once prior to surgery and every 12 hours after surgery for 72 hours
89452611|NCT03244358|Experimental|Epalrestat|Epalrestat added to standard treatment
89452612|NCT05482750|Experimental|Resistance training in the fasted state|Subjects will maintain the standard diet and will perform resistance exercise sessions after overnight fasting (10 to 12 hours). Over the 12 weeks of intervention, participants will perform two sessions a week of resistance exercises.
89452613|NCT05482750|Active Comparator|Resistance training in the fed state|Subjects will maintain the standard diet and will perform resistance exercise sessions in the fed state, between 1 and 2 hours after consuming a carbohydrate-containing meal. Over the 12 weeks of intervention, participants will perform two sessions a week of resistance exercises.
89452614|NCT03249740|Experimental|Experimental: Phase 1 - GB-102|Subjects will be assigned to 1 of 4 cohorts to receive a single intravitreal injection of up to 2.0 mg (50 μL) GB-102.
88937264|NCT01809444|Active Comparator|Prednisone+placebo of Doxycycline|Prednisone: 50 mg/d for 14 day, tailed by 40 mg/d for 14 day, 30 mg/d for 28 day, 20 mg/d for 28 day, 15 mg/d for 14 day, 10 mg/d for 14 day, in total 16 weeks; Placebo of doxycycline: administered for 16 weeks.
88937265|NCT01809444|Experimental|Doxycycline+placebo of Prednisone|Doxycycline: 50 mg/d for 12 weeks, and placebo for another 4 weeks; Placebo of prednisone: administered for 16 weeks.
88937266|NCT01809457|Experimental|educational poster|poster display for 2 weeks in classrooms,
88937267|NCT01809457|No Intervention|control|no intervention, waiting for two weeks
88937268|NCT01809470|Experimental|Watching TV|Watching TV (comedy, 'Friends') for 1 hour
88937269|NCT01809470|Experimental|FIFA2013|Playing the video game 'FIFA2013' for 1 hour
88937270|NCT01809470|Experimental|Call of Duty|Playing the video game 'Call of duty' for 1 hour
88937271|NCT01809483|Experimental|Bandage contact lens group|subject received antibiotic eye drops (combination of Polymyxin B, neomycin and gramicidin, q.i.d), and cycloplegic eye drops (tropicamide 0,5 %, q.d) and bandage contact lens. Bandage contact lenses maintained for 24 hours. Antibiotic eye drops were instilled without removing the contact lenses
88937272|NCT01809483|Active Comparator|Pressure patching group|Subject received antibiotic eye drops (combination of Polymyxin B, neomycin and gramicidin, q.i.d), and cycloplegic eye drops (tropicamide 0,5 %, q.d) and pressure patching. Pressure patching maintained for 24 hours and only opened for drug application. Subject and their families were educated on how to perform a good pressure patching
88937273|NCT01809496|Active Comparator|Informational counseling, patient only|The purpose of this experimental group is to evaluate the effectiveness of informational counseling alone. This type of counseling is considered the standard of care in audiologic practice. Patients in this will review this material in detail with a member of the study team for approximately 30 minutes at the second visit. Spouses in this experimental group will be will review material regarding VA services with a member of the study team for about 30 minutes.
88937274|NCT01809496|Experimental|Informational Counseling, couples|The purpose of this experimental group is to evaluate the influence of spousal involvement when receiving informational counseling. In this manner, both patients and spouses are presented with the same information regarding hearing loss and hearing aids. Couples in this experimental group will be given the same information that the patients in the first group were given. At the second visit, couples in this group will review this information together with a member of the research team for approximately 30 minutes.
88937275|NCT01809496|Experimental|Patient Centered Counseling,patient only|In order to assess the effects of enhanced patient-centered counseling (PCC), the patients assigned to this group will meet together with either Dr. Lewis or the Research Audiologist for approximately 30 minutes of counseling. In addition to the PCC techniques used in audiology, this counseling also will involve the core components of motivational interviewing. These principles and methods will be used to allow the patient to clearly express his/her expectations of, concerns about, and motivations for hearing-aid use. The spouses in this experimental group will be given information regarding VA services. This material will be reviewed with a member of the research team for about 30 minutes at the second visit.
88937276|NCT01809496|Experimental|Patient Centered Counseling, couples|In order to assess the influence of the spouse on the enhanced PCC process, the couples assigned to this group will meet together with either Dr. Lewis or the Research Audiologist for approximately 30 minutes of counseling. This counseling will be conducted with both the patient and the spouse together, giving both partners time to express their thoughts.
88937277|NCT01809522|Experimental|Posterior reconstruction of the musculofascial plate|These patients will receive reconstruction of the muscolofascial plate after radical prostatectomy. The reconstruction will be performed using two 3-0 Poliglecaprone sutures (on RB-1 needles) tied together, with each individual length being 12-15 cm. seven - Ten knots will be placed when tying the sutures to provide a bolster. The free edge of the remaining Denonvillier's fascia will be identified after the prostatectomy and approximated to the posterior aspect of the rhabdosphincter and the posterior median raphe using one arm of the continuous suture. As a rule, four passes will be taken from the right to the left and the suture is locked. The second layer of the reconstruction will be then performed with the other arm of the suture approximating the posterior lip of the bladder neck (full thickness) and the vesicoprostatic muscle to the posterior urethral edge and to the already reconstructed median raphe .This suture will be then tied to the end of the first suture arm.
88937278|NCT01809522|No Intervention|Standard radical prostectomy|
88937279|NCT01809535|Experimental|The Monthly EVL|Patients in the Monthly group were received EVL at 28-day treatment intervals.
88937280|NCT01809535|Active Comparator|The Biweekly EVL|Patients in the Biweekly group received repeating EVL every 2 weeks.
88937281|NCT01809561||endometriosis|The study group will consist of women with suspected endometriosis facing surgical treatment
88937282|NCT01809561||no endometriosis|The control group will consist of healthy women facing gynecologic surgery for different indication
88937283|NCT01809587|Experimental|IQP-PO-101|Day 1 to Day 7 - 1 sachet to be mixed in 250ml of water and consumed twice a day Day 8 to Day 28 - 1 sachet to be mixed in 250ml of water and consumed once a day Day 28 to Day 42 - no investigational product intake (post treatment observation only)
88937284|NCT01809600||Patients with Burkitt's Lymphoma|should be diagnosed pathologically by WHO 2008 criteria
89452615|NCT03249740|Experimental|Experimental: Phase 2 - GB-102|Low dose or high dose injected every 6 months
89015422|NCT06259916|Experimental|Alcohol + Cannabis Group|Participants in this group will first self-administer their own flower cannabis product (that they purchased for use in the study from a legal-market dispensary) ad libitum inside their homes. Researchers will not handle the product or instruct participants on how much to use during the session. They will then return to the mobile lab which will be parked outside their residence and will be administered a dose of alcohol by researchers. The dose is designed (based on participant sex and body weight) to bring blood alcohol concentration to .06 g/dL.
89015423|NCT06259903|Experimental|40 milligram (mg) MD-18 OR 40 milligram(mg) Placebo|A single dose of subcutaneous injection of 40mg MD-18 OR 40mg Placebo will be given on day zero.
89015424|NCT06259903|Experimental|80 milligram (mg) MD-18 OR 80 milligram (mg) Placebo|A single dose of subcutaneous injection of 80mg MD-18 OR 80mg Placebo will be given on day zero.
89015425|NCT06259903|Experimental|160 milligram (mg) MD-18 OR 160 milligram (mg) Placebo|A single dose of subcutaneous injection of 160mg MD-18 OR 160mg Placebo will be given on day zero.
89015426|NCT06259903|Experimental|240 milligram (mg) MD-18 OR 240 milligram (mg) Placebo|A single dose of subcutaneous injection of 240mg MD-18 OR 240mg Placebo will be given on day zero.
89015427|NCT06259903|Experimental|320 milligram (mg)MD-18 OR 320 milligram (mg) Placebo|A single dose of subcutaneous injection of 320mg MD-18 OR 320mg Placebo will be given on day zero.
89015428|NCT06259890|Other|Patients with radiographic/non-radiographic Axial Spondylitis or psoriatic arthritis|Patients with radiographic/non-radiographic Axial Spondylitis or psoriatic arthritis managed in the rheumatology departments of the study centres.
89015429|NCT06259877||Individuals with stroke over the age of 18|
89015430|NCT06259877||Healthy individuals over the age of 18|
89015431|NCT06259864|Active Comparator|Neurodevelopmental treatment program group|NDT aims to bring the child to the maximum level of independence possible within the limits of age and ability. Treatment sessions are planned for a certain functional result, and the patient's active participation as much as possible is requested. As the child fulfills postural and motor requirements, the physical therapist provides less assistance and less guidance. Positionings supported by auxiliary materials, appropriate hand contacts, correct ways to hold the child, tonus regulation, family education, environmental regulations and goal-oriented quality movement approaches; These are some of the methods used by the NDT approach, which is based on facilitation, stimulation and communication. Neurodevelopmental treatment physiotherapy session for 2 days in a week, over 8 week.
89015432|NCT06259864|Experimental|Mollii Suit method group|The Exopulse Mollii Suit is designed to restore normality and healthy balance of muscle groups in the body. The suite uses one of several different forms of neuromodulation, based on gently stimulating the affected muscle groups with electrical signals. This approach has been shown to help resynchronize muscle signals that have been disrupted due to spasticity and muscle groups that may have stopped working together. 58 electrodes embedded in the suit send mild and imperceptible impulses to both tense and spastic muscles and the weakened muscles that balance them. These stimulations not only relax tense muscles and reactivate weak ones, but also restore the natural balance of the group and help the body move as it should. Children will wear the outfit twice a week for 8 weeks and each session will last 60 minutes. During this practice, children will also receive NDT twice a week.
89200982|NCT00903279|Experimental|Altabax|
89200983|NCT00898989||Inclusion Body Myositis|
89200984|NCT00898989||Control|
89452616|NCT03249740|Active Comparator|Active Comparator: Phase 2 - Aflibercept|Aflibercept 2 mg injected every 2 months
89452617|NCT05478226||control group|healthy people as control group
89452618|NCT05478226||IPAH group|patients with IPAH as IPAH group
89452619|NCT05478226||CTEPH group|patients with CTEPH as CTEPH group
89200985|NCT02539017|Experimental|Combined|Combined Chemo Therapy and immunotherapy with double dendritic cell (DC) and cytokine-induced killer (CIK) cell
89200986|NCT02539017|Active Comparator|Chemo|Control group: Chemo Therapy group
89200987|NCT00605865||Sertraline hydrochloride.|Patients taking Sertraline hydrochloride.
89452620|NCT05478226||group D|Including CTEPH group and IPAH group
89452621|NCT03057977|Experimental|Empagliflozin|
89452622|NCT03057977|Placebo Comparator|Placebo|
89452623|NCT03244046|Active Comparator|Physiotherapy (Phys)|12 sessions of guided physiotherapy for low back pain. Cognitive Behavioral Therapeutic elements included targeting Fear Avoidance Beliefs.
89452624|NCT03244046|Experimental|Somatic Experiencing + phys|12 sessions of psychotherapy (somatic experiencing) and 12 sessions of guided physiotherapy for low back pain. Cognitive Behavioral Therapeutic elements included targeting Fear Avoidance Beliefs.
89452625|NCT05482594||Systemic sclerosis|Patients followed regularly at CHU Brugmann in rheumatology/Dermatology for limited or diffuse systemic sclerosis in accordance with the ACR/EULAR 2013 criteria.
89452626|NCT05482594||Control|Control patients recruited among patients followed for mechanical pathology in rheumatology.
89452627|NCT03252782|Active Comparator|Functional Treatment|Acrylic Splint Herbst Appliance
89452628|NCT03252782|Active Comparator|Distalization Treatment|Mini-implant-borne Distal Jet Appliance
89537150|NCT05691179||COVID-19 infection group|the patients with IMN and COVID-19 infection
89537151|NCT03299153|Experimental|Intervention group|patients in this group were received 200 ml/d barberry juice for tow month
89452629|NCT03249506||Cohort 1: Non-SGLT2i new Users|This is a retrospective cohort study identifying participants with type 2 diabetes mellitus (T2DM) and established cardiovascular (CV) disease using the Military Health System (MHS) over a 3-year period. Cohort 1 included participants with incident exposure of one or more non-sodium glucose co-transporter 2 inhibitor (SGLT2i) anti-hyperglycemic agent (AHA) therapy during the study period with no prior or subsequent SGLT2i exposure throughout the study period. New users are defined as participants whose first exposure to any non-metformin AHA medication occurs greater than or equal to (>=) 365 days after their start of observation in the database with no prior exposure to any medication within the same AHA medication class in the prior 365 days.
89452630|NCT03249506||Cohort 2: SGLT2i new Users|Cohort 2 included participants with incident SGLT2i exposure during the study period regardless of prior or concurrent exposure to one or more additional AHA therapy. New users are defined as participants whose first exposure to SGLT2i medication occurs >= 365 days after their start of observation in the database with no prior exposure to the same AHA medication class in the prior 365 days.
89452631|NCT03243968||Ischemic patient - IP|25 participants with myocardial ischemia detected by scintigraphy and normal coronarography
89452632|NCT03243968||Control group - CG|25 healthy non-ischemic individuals
89452633|NCT03244202|Experimental|Decision Aid Plus Counselling|Participants will use a decision aid to learn about genomic sequencing and select which incidental findings they would like to receive from genomic sequencing. After using the decision aid the participants will speak with a genetic counsellor over the phone about their choice.
89452634|NCT03244202|Active Comparator|Genetic Counselling Only|Participants will a genetic counsellor over the phone to learn about genomic sequencing and select which incidental findings they would like to receive from genomic sequencing.
88937285|NCT01809613||Deep Brain Stimulation|Functional Magnetic Resonance Imaging (fMRI) will be performed to determine the areas of BOLD signal modulation with DBS.
88937286|NCT01809626|Experimental|Zolpidem (10 mg)|Oral administration of the drug zolpidem (Ambien)
88937287|NCT01809626|Placebo Comparator|Gelatin capsule|Oral administration of a placebo pill that is packaged identically to the active condition.
88937288|NCT01809652|Experimental|Remote Implant Support|Implant supported through remote implant support capability
88937289|NCT01809665||ICD/CRT-P therapy|Standard indication for ICD or triple-chamber pacemaker therapy
88937290|NCT01809678|Experimental|Smoking Cessation plus Yoga|Twice weekly, 1-hour yoga classes delivered for 8 weeks combined with once-weekly, 1-hour cognitive-behavioral smoking cessation classes.
88937291|NCT01809678|Active Comparator|Smoking Cessation plus Wellness|Twice-weekly, 1-hour Wellness classes given on a variety of health topics twice weekly to match schedule of the yoga classes, plus 1-hour per week of cognitive-behavioral smoking cessation
88937292|NCT01809717|Experimental|Weight Lifting Exercises|
88937293|NCT01809730||Cardiovascular risk|patients with CV disease
88937294|NCT01809743|Active Comparator|Regadenoson central - peripheral|First bolus regadenoson administered central, second bolus administered peripheral
89452635|NCT03249662|Experimental|bupivacaine 100 mg|bupivacaine 100 mg ketorolac 30 mg epinephrine 400 mcg add Normal saline solution(NSS) to 80 ml divided to two syringes for bilateral periarticular infiltration
89452636|NCT03249662|Active Comparator|bupivacaine 200 mg|bupivacaine 200 mg ketorolac 30 mg epinephrine 400 mcg add NSS to 80 ml divided to two syringes for bilateral periarticular infiltration
89452637|NCT02454062|Experimental|Dose Escalation TAS-114 (PART 1)|Each cycle will be 21 days: 14 days of treatment and 7 days recovery. TAS-114 and S-1 will be escalated according to a defined dosing table and specific DLT criteria.
89537152|NCT03299153|No Intervention|control group|patients in this group received no intervention
88937295|NCT01809743|Active Comparator|Regadenoson peripheral - central|First bolus regadenoson administered peripheral, second bolus administered central
88937296|NCT01809743|Active Comparator|Regadenoson central - central|First bolus regadenoson administered central, second bolus administered central
88937297|NCT01809743|Active Comparator|Regadenoson peripheral - peripheral|First bolus regadenoson administered peripheral, second bolus administered peripheral
88937298|NCT01809756|Active Comparator|Caphosol|
88937299|NCT01809756|No Intervention|No intervention|
88937300|NCT01809769|Experimental|Mesenchymal stem cells low-dose group|Biological: Mesenchymal progenitor cells. Administrated for intra-articular use. Dosage: 1 x 10 E7 cells (3 ml), Frequency: 0,3 weeks.
88937301|NCT01809769|Experimental|Mesenchymal stem cells mid-dose group|Biological: Mesenchymal progenitor cells. Administrated for intra-articular use. Dosage: 2 x 10 E7 cells (3 ml). Frequency: 0,3 weeks.
88937302|NCT01809769|Experimental|Mesenchymal stem cells high-dose group|Biological: Mesenchymal progenitor cells. Administrated for intra-articular use. Dosage:5 x 10 E7 cells (3 ml). Frequency: 0,3 weeks.
88937303|NCT01809782||Study group:20 patients undergoing two stage liver-operation|Patients undergo two liver operations.First surgery: insitu-split for induction of proliferation in the remaining liver tissue; Second surgery: resection of the liver Tumor (4 cognitive measurements: Baseline, 7 days, 3 months and 1 year)
88937304|NCT01809782||Control group: 20 patients (ASA class II/III)|Relatives from study personel or patients from outpatient clinics from Charité in Berlin and surrounding area (4 cognitive measurements: Baseline, 7 days, 3 months and 1 year)
88937305|NCT01809795|Experimental|Blueberry Smoothie|Participants in this group will receive a smoothie containing 1 1/2 cups of freeze-dried whole blueberries crushed into a powder.
88937306|NCT01809795|Sham Comparator|Sham Smoothie|Participants in this group will receive a smoothie that contains no blueberries.
88937307|NCT01809821|Experimental|Online Sleep Education|The sleep intervention is a multi-component online intervention consisting of sleep information and sleep hygiene education, along with behavioural and cognitive components.
88937308|NCT01809821|No Intervention|Usual CV care|Specialist nurses will administer the CV risk factor education intervention to participants in small groups over one hour.
88937309|NCT01809847|Experimental|Ofatumumab|First dose of 300 mg Ofatumumab followed by seven weekly infusions of 2000 mg. Dexamethasone will be given orally at doses of 40 mg on days 1-4 in weeks 1, 3, 5, and 7. Maintenance therapy consists of 6 monthly infusions of 1000 mg ofatumumab.
89452638|NCT02454062|Experimental|Expansion phase TAS-114 (PART 2)|"The TAS-114 and S-1 MTD established in the Dose Escalation Phase will be administered BID for 14 days followed by a 7 day recovery period.~This regimen is repeated every 21 days thereafter. Approximately 40 to 60 evaluable patients will be enrolled in the Expansion Phase. PGx, PD and PK analysis will be performed based on specific criteria."
89452639|NCT03239444|Other|Assigned Intervention|Device: Foresight ICE System The Foresight ICE System is composed of a sterile, single-use catheter intended to operate with a Foresight ICE PIM and Hummingbird console. The Foresight ICE system will be used in guiding the physician during the trans-septal puncture and provide physiological information during the course of the procedure.
89452640|NCT03239366|Active Comparator|Active arm|Active product 'BioK+ 100% probiotic: Bio-K+50B® probiotic will be administered orally for a period of 12 weeks. Dose: two (2) capsules of 50 billion (B) colony forming units (CFU) providing a dosage of 100 billion CFU per day
89452641|NCT03239366|Placebo Comparator|Placebo arm|Placebo product (without the 3 strains of bacterias) will be administered orally for a period of 12 weeks. Dose: Two (2) capsules of Placebo per day
89452642|NCT03239288|Placebo Comparator|Control digestible carbohydrate|Control baked breakfast bar
89452643|NCT03239288|Experimental|Test resistant starch type 4|Test baked breakfast bar
89452644|NCT03249428|Active Comparator|Nicotine Replacement Therapy & One-on-One Counseling|Standard NRT such as the nicotine patch, gum, inhaler, and/or lozenge as per participant liking and clinical indication deemed necessary by the expert smoking cessation nurse. Counseling will include a number of approaches such as reviewing smoking history, development and revision of a reduced or quit plan, encouragement of self-monitoring, review of triggers and challenges, and coping skills.
89452645|NCT03249428|Active Comparator|Electronic Nicotine Delivery Systems & One-on-One Counseling|Electronic Nicotine Delivery Systems with nicotine. Counseling will include a number of approaches such as reviewing smoking history, development and revision of a reduced or quit plan, encouragement of self-monitoring, review of triggers and challenges, and coping skills.
89452646|NCT05213975|Experimental|intervention group|kinesio taping group
89452647|NCT05213975|No Intervention|control group|Standard of care
88937310|NCT01809860|Experimental|isavuconazole and sirolimus|Single dose of sirolimus on Days 1 and 26, isavuconazole 3 times a day (TID) for 2 days (Days 22 to 23) followed by once a day (QD) for 11 days
88937311|NCT01809873|Experimental|Performance based incentives|Performance based incentives: The Incentive arm will receive monthly visits and external quality assurance of malaria diagnostic accuracy, identical to the comparison. Incentive arm will also receive quarterly incentives linked to performance of the facility around six indicators of appropriate malaria case management
88937312|NCT01809873|No Intervention|Comparison|The comparison arm will receive monthly visits and monthly external quality assurance of malaria diagnostic accuracy.
88937313|NCT01809886|Experimental|Sugammadex|50 patients, aged between 2 and 11 years scheduled for surgery and requiring muscle relaxation. The reversal will be made with sugammadex 4 mg/kg when surgery is over, maintaining a profound block level until that point in time (no response to TOF and PTC<2).
88937314|NCT01809886|Active Comparator|Neostigmina|50 patients aged between 2 and 11 years scheduled for surgery and requiring muscle relaxation. The reversal will be made with neostigmine 0. 05 mg/kg and atropine 0.025 mg/kg (conventional reverser treatment) when surgery is over, maintaining a profound block level unit that point in time (no response to TOF and PTC<2).
88937315|NCT01809912|Experimental|Greenstatin|"Cohort 1 : 6 mg/m2 Cohort 2 : 12 mg/m2 Cohort 3 : 24 mg/m2 Cohort 4 : 48 mg/m2 Cohort 5 : 96 mg/m2 Cohort 6 : 192 mg/m2 28 Day Course Subjects will receive MG1102 (Recombinant human apolipoprotein(a) Kringle V ) by IV administration on Day 0. If no DLTs are observed during the 6 days following the initial infusion, the same dose will be administered once daily for 5 consecutive days followed by a 2-day rest period three times (over 21 days), completing the course on Day 27.~Additional 21 Day Courses In the absence of a DLT, and in the case of stable disease or better, a subject may continue to receive MG1102 (Recombinant human apolipoprotein(a) Kringle V~) on a compassionate use basis at the same dose and regimen ."
88937316|NCT01809925|Experimental|psyllium fiber 6.8g|Two (2) packets Metamucil Orange Sugar Free Fiber Singles (psyllium 6.8 g) thoroughly mixed in Ten (10) ounces of water. Subjects will drink their assigned test product as quickly as possible immediately before eating breakfast at each visit.
88937317|NCT01809925|Placebo Comparator|placebo|One (1) level teaspoon of placebo product thoroughly mixed in Ten (10) ounces of water. Subjects will drink their assigned test product as quickly as possible immediately before eating breakfast at each visit.
88937318|NCT01809951||Isomil Advance with LCP|4 spoonful of Isomil Advance with LCP in 240 mL of water, 4 times a day
88937319|NCT01809977|Other|total removal|patients underwent Corneal collagen cross-linking procedure with totally corneal epithelium removing. Total removal was performed by mechanical debridement of the corneal epithelium over the central 9 mm.
88937320|NCT01809977|Other|partial removal|patients underwent Corneal collagen cross-linking procedure with partially corneal epithelium removing. Partial removal was performed by removing a 3-mm width ring and leaving the central 3 mm of the cornea intact.
88937321|NCT01809990|Experimental|internet-delivered cognitive behavior therapy|Participants will be assigned to a 12 weeks internet-delivered cognitive behavior therapy program including therapist contact via an internet platform and telephone.
88937322|NCT01810003|Experimental|High DHA|High DHA supplementation (3g/day)
88937323|NCT01810003|Experimental|High EPA|EPA supplementation (3g/day)
88937324|NCT01810003|Placebo Comparator|Placebo|Placebo (3g corn oil/day)
88937325|NCT01810029|Experimental|Cardiac Rehabilitation plus Transcendental Meditation|a standard validated cardiac rehabilitation program plus a standard validated stress reduction component, the Transcendental Meditation program
88937326|NCT01810029|Active Comparator|Cardiac Rehabilitation|This control is a standard Cardiac Rehabilitation without a stress reduction technique
88937327|NCT01810068|Sham Comparator|Placebo|patients who are undergoing diagnostic cystoscopy
88937328|NCT01810068|Active Comparator|HOLEP|Holmium laser enucleation of the prostate
88937329|NCT01810068|Active Comparator|monopolar TURP|Monopolar transurethral resection of the prostate
88937330|NCT01810068|Active Comparator|Bipolar TURP|Bipolar transurethral resection of the prostate
88937331|NCT01810081||cholecystectomy|cholecystectomy group: H.Pylori infection in gall bladder
88937332|NCT01810094||Minimally invasive Approach|Patients with a thoracolumbar Fracture A3.1 to A 3.3 treated by fracture fixation by a minimally invasive approach
88937333|NCT01810107||Children Examined with the OCT Probe|Children undergoing surgery will also have the Optical Coherence Tomography probe.
88937334|NCT01810107||Adults|Adults undergoing surgery will also have the Optical Coherence Tomography probe.
88937335|NCT01810120|Experimental|TCR alfa beta depleted graft, infusion|The leukapheresis product will undergo TCR alfa beta negative selection following the standardized protocol.
88937336|NCT01810133||Anesthesia patients|All patients undergoing general anesthesia between January 2006 and December 2011 in Charité - University Berlin
88937337|NCT01810146|No Intervention|Digestive functions investigations|Results from digestive functions investigations will be compared between patients eligible for bariatric surgery (BMI>40kg/m2) and volunteers (BMI between 20 and 25kg/m2).
88937338|NCT01810159|Experimental|ICC|Integrated collaborative care
88937339|NCT01810159|Active Comparator|E&R|Education and Resources--enhanced usual care
88937340|NCT01810172|Active Comparator|Dry suction pleural drainage system|The control group will have their chest tube connected to a dry suction pleural drainage system The intervention will be the dry suction pleural drainage system
88937341|NCT01810172|Experimental|Digital pleural drainage system|The experimental group will have their chest tube connected to a digital pleural drainage. The intervention will be the digital pleural drainage system.
88937342|NCT01810185|Experimental|Low dose naltrexone|Subjects in this arm will recieve low dose naltrexone (4.5 mg) daily for 12 weeks.
88937343|NCT01810185|Placebo Comparator|Placebo|Subjects in this arm will recieve a placebo daily for 12 weeks.
88937344|NCT01810198|Active Comparator|Cardiac CT|Patients who undergo Cardiac CT (instead of Invasive Coronary Angiography)
88937345|NCT01810198|Active Comparator|Invasive Coronary Angiography|Patients did not undergo Cardiac CT, went straight to Invasive Coronary Angiography
88937346|NCT01810211|Experimental|Horizontal Adduction Stretch and Pendulums|"Horizontal Adduction Stretch- Individual standing with their operative scapula against a wall and rotating toward the side to be stretched to stabilize scapula and the operative arm is relaxed. The opposite hand is placed under the elbow of the involved extremity and assists the operative shoulder into horizontal adduction attempting to bring the hand to the opposite shoulder.~Pendulum -Individual leans over with support from uninvolved extremity placed on an immovable object while involved extremity is relaxed. The individual than rotates their hips in order to allow the involved extremity to create small circles passively in a clockwise direction."
88937347|NCT01810211|Experimental|Modified Sleeper Stretch and Pendulum|"Modified Sleeper Stretch: Individual in supine with operative shoulder abducted to approximately 45 degrees and elbow at 90 degrees of flexion with neutral rotation of the glenohumeral joint. The individual then places other hand on the wrist of the involved extremity and passively moves the glenohumeral joint into internal rotation.~Pendulum Exercise: Individual leans over with support from uninvolved extremity placed on an immovable object while involved extremity is relaxed. The individual than rotates their hips in order to allow the involved extremity to create small circles passively in a clockwise direction."
88937348|NCT01810211|No Intervention|Pendulum Exercise|Pendulum Exercise: Individual leans over with support from uninvolved extremity placed on an immovable object while involved extremity is relaxed. The individual than rotates their hips in order to allow the involved extremity to create small circles passively in a clockwise direction.
88937349|NCT01810224|Active Comparator|Angio-guided arm|In this arm will be included the patient randomized to a Angiography-guided surgical revascularization strategy.
88937350|NCT01810224|Experimental|FFR-guided arm|In this arm will be included the patient randomized to a FFR-guided surgical revascularization strategy.
88937351|NCT01810237|Experimental|Dabigtran instead of LMWH for perioperative bridging.|
88937352|NCT01810276|Placebo Comparator|Saline|400 mL of Saline will be given intravenously over 2 hours once.
88937353|NCT01810276|Active Comparator|Platelets|2 apheresis units of platelets (approximately 200 ml) will be given intravenously over 2 hours.
88937354|NCT01810315|No Intervention|Baseline|Premenopausal women will undergo baseline sampling in each the follicular and luteal phase. Postmenopausal women will undergo baseline sampling one time.
88937355|NCT01810315|Experimental|TFV 1% Gel|"Participants will vaginally insert 1 applicator of TFV gel followed by a 2nd applicator 2 hours later. Each applicator contains 4.4 gm of TFV 1% gel.~Premenopausal women will undergo sampling after TFV gel use in each the follicular and luteal phase. Postmenopausal women will undergo sampling after TFV gel use one time."
88937356|NCT01810315|Experimental|Estradiol Vaginal Cream|Post menopausal women only: Participants will insert 2 grams of estradiol cream into the vagina every night for 14 days and then one gram of estradiol cream into the vagina every other night
88937357|NCT01810315|Experimental|TFV 1% gel and estradiol cream|Postmenopausal women only: Participants will vaginally insert 1 applicator of TFV gel followed by a 2nd applicator 2 hours later. Each applicator contains 4.4 gm of TFV 1% gel. In addition, participants will one gram of estradiol cream into the vagina every other night.
89452648|NCT03243812|Active Comparator|SS genotype group|"Sickle cell patients with SS genotype. Each subject will undergo the following :~Blood sample~Maximum Voluntary Contraction (MVC) test force before and after a localized muscle endurance test~Localized muscle endurance test: 4 series of 20 submaximal dynamic contractions at 50% of the MVC interspaced with 1 min recovery.~Self-paced six-minute walk test will be conducted according to the guidelines of the American Thoracic Society"
89452649|NCT03243812|Active Comparator|SC genotype group|"Sickle cell patients with SC genotype. Each subject will undergo the following :~Blood sample~Maximum Voluntary Contraction (MVC) test force before and after a localized muscle endurance test~Localized muscle endurance test: 4 series of 20 submaximal dynamic contractions at 50% of the MVC interspaced with 1 min recovery.~Self-paced six-minute walk test will be conducted according to the guidelines of the American Thoracic Society"
88937358|NCT01810328|Active Comparator|Traumatized population|In the traumatized population (severe blunt traumatic injury), blood samples will be collected at admission, days 1, 4, 7, 14, 21 and 28, or until discharge from the ICU or death. A total of 5 mLs of blood will be collected at admission and day 1, 4 mLs of blood will be collected at each remaining time point.
88937359|NCT01810328|Active Comparator|Healthy Volunteers|The healthy volunteer participants will donate a one-time 5 mL blood sample which will undergo rapid leukocyte genomic screening. These controls will allow the investigators to determine if the values obtained are accurate, reliable, and repeatable.
88937360|NCT01810341||Development Group|In the Development Phase, analyses will be performed until the classification algorithm is finalized.
88937361|NCT01810341||Validation Group|The Validation Phase will assess the performance of the finalized classification algorithm in 300 subjects.
88937362|NCT01810354|Experimental|Two grams cefazolin|Two grams of cefazolin will be given by intravenous bolus zero to 60 minutes prior to the start of the cesarean section.
88937363|NCT01810354|Active Comparator|Three grams cefazolin|Three grams of cefazolin will be given by intravenous bolus zero to 60 minutes prior to the start of the cesarean section.
88937364|NCT01810367|Experimental|ABX Combined With Cisplatin|ABX，100mg/m2，d1、8、15，ivgtt,in 30 min，28day one cycle； cisplin 75mg/m2 d1 ivgtt
88937365|NCT01810367|Active Comparator|Gemcitabine Combined With Cisplatin|gemcitabine 1000mg/m2，d1、8；cisplatin 75mg/m2 d1 ivgtt,3 weeks one cycle.
88937366|NCT01810393|Experimental|Trastuzumab IV Then Trastuzumab SC|Participants will receive treatment with Trastuzumab IV for the first 3 cycles (cycle length = 21 days) followed by Trastuzumab SC for the next 3 cycles. Participants will continue receiving treatment with trastuzumab SC for another 12 cycles (if SC treatment is well tolerated, otherwise participants will continue IV treatment) for a total of 18 cycles of treatment during the study.
88937367|NCT01810393|Experimental|Trastuzumab SC Then Trastuzumab IV|Participants will receive treatment with Trastuzumab SC for the first 3 cycles (cycle length = 21 days) followed by Trastuzumab IV for the next 3 cycles. Participants will continue receiving treatment with trastuzumab SC for another 12 cycles (if SC treatment is well tolerated, otherwise participants will continue IV treatment) for a total of 18 cycles of treatment during the study.
88937368|NCT01810406|Experimental|Epidural Volume Extension|CSE with 10 ml EVE
88937369|NCT01810406|Active Comparator|No Epidural Volume Extension|CSE without EVE
88937370|NCT01810419|Experimental|normal and various degrees splenomegaly|"Vscan Ultrasound (GE Healthcare, USA) Conventional Ultrasound (Ultrasonix) used to determine spleen size Crossover design, all subjects will be measured with both devices. half will have the handheld done first, then conventional half the Conventional done first, then handheld~Will complete questionaire for both:~Adequacy of image quality~What is best view obtained~Greatest Longitudinal Measure~Diagnosis~Diagnostic Certainty~Time to Complete exam"
88937371|NCT01810445||1|Patients undergoing a surgical bladder procedure in the main O.R.
88937372|NCT01810458||AATD ZZ and Rare Alleles Group|Participants will get a history and physical (H&P) and have an intravenous catheter (IV) placed, for blood draws, at the screening and years 1-3 visits. An IV will also be placed at the liver biopsy visit(s) for the administration of medication. An abdominal ultrasound will be done at the screening and year 3 visits along with the completion of a liver questionnaire. Finally, participants will have a liver biopsy done, with the use of lidocaine, lorazepam, or midazolam and fentanyl, after the screening visit and potentially at the year 3 study visit, depending on the results of the first liver biopsy. Participants who experience pain after the liver biopsy may receive acetaminophen or oxycodone/acetaminophen. Any subject experiencing nausea may receive ondansetron.
88937373|NCT01810471|Experimental|ankle supports|
88937374|NCT01810497|Active Comparator|Seven-day bandage use|Patients randomized and instructed to use of ear bandage 24h/day for seven days after otoplasty
88937375|NCT01810497|Active Comparator|Thirty-day bandage use|Patients randomized and instructed to use of ear bandage 24h/day for thirty days after otoplasty
88937376|NCT01810510|Experimental|PAV Ventilation|PAV is a mode of ventilation in which the only set parameter is the proportion of work/effort that is provided regardless of the ventilatory pattern the patient chooses- the patient has full control over pressure, volume, flow and time of inspiration as well as respiratory rate. In this mode, the ventilator measures patient respiratory mechanics every 10-15 breaths and delivers a level of pressure proportional to patient effort, thereby maintaining a set proportion of patient effort regardless of the patient's ventilatory pattern. The patients will be on this mode of ventilation for 60 minutes.
88937377|NCT01810510|Experimental|NAVA Ventilation|With NAVA, delivery from the ventilator is triggered, controlled and cycled by the diaphragmatic EMG signal (Edi), which is measured by a specially designed nasogastric or orogastric catheter (NGT or OGT) containing EMG electrodes that cross the diaphragm. In this mode, the ventilator measures the Edi with each breath and instantaneously delivers a level of pressure proportional to Edi magnitude, thereby providing a set proportion of effort on a breath-to-breath basis. The patients will be on this mode of ventilation for 60 minutes.
88937378|NCT01810523|Experimental|Narrative|This arm will receive information regarding leg injuries and X-ray usage in narrative form in addition to standard of care discharge information.
89200988|NCT00899145||Ancillary-Correlative (biomarker sampling and analysis)|Previously collected DNA samples and associated clinical information obtained from BRCA mutation-positive participants enrolled on GOG-0199 are studied. DNA samples are analyzed by mutation testing for variants (i.e., SNPs) in candidate genes of interest. Once genetic testing for a given set of variants has been completed, the coded laboratory data file is merged with selected demographic, clinical, and epidemiological data obtained from the GOG-0199 baseline questionnaire and submitted to the CIMBA Central Database to analyze and publish the data. The epidemiological and SNP data contributed to the central database are then distributed to the investigators responsible for analysis of a particular SNP or set of SNPs from a candidate gene or genetic pathway.
89452650|NCT03243812|Active Comparator|control group|"Healthy subjects. Each subject will undergo the following :~Blood sample~Maximum Voluntary Contraction (MVC) test force before and after a localized muscle endurance test~Localized muscle endurance test: 4 series of 20 submaximal dynamic contractions at 50% of the MVC interspaced with 1 min recovery.~Self-paced six-minute walk test will be conducted according to the guidelines of the American Thoracic Society"
89452651|NCT05751161|Experimental|effect of gait training with AS on dynamic balance, gait and functional independence in stroke|Patients with chronic stroke receive gait training with auditory stimuli to improve dynamic balance, gait and functional independence.
89452652|NCT05751161|Other|effect of conventional gait training on dynamic balance, gait and functional independence in stroke|Patients in this group receive conventional gait training only to improve dynamic balance, gait and functional independence .Patients did not receive auditory stimuli for gait training.
89452653|NCT03243500|Sham Comparator|Group C|"2.5 ml of lidocaine 2% 2.5 ml of bupivacaine 0.5% hyaluronidase powder 15 IU/ml~1 ml normal saline to make a total volume of 6 ml from which the patient received 5-6 ml through percaruncular peribulbar injection."
89452654|NCT03243500|Active Comparator|Group A|"5 mg atracurium 2.5 ml of lidocaine 2% 2.5 ml of bupivacaine 0.5% hyaluronidase 15 IU/ml~1 ml normal saline to make a total volume of 6 ml from which the patient received 5-6 ml through percaruncular peribulbar injection."
89452655|NCT00941915|Experimental|Stereotactic Radiotherapy|Five fractions of 7.4 Gy each
89452656|NCT02454218|Active Comparator|Transcranial Direct Current Stimulation|The intensity of the asset is little perceived and painless.
89452657|NCT02454218|Placebo Comparator|Simulation Transcranial Current|Will receive only simulation.
89452658|NCT05213819|Other|Carpal tunnel syndrome|Patients with carpal tunnel syndrome were treated with phonophoresis, low level laser therapy and exercise.
89452659|NCT03238898|Active Comparator|botulinum toxin type A|Botulinum toxin type A (100 or 30 units) was injected for each side into the gastrocnemious or the small flexor foot muscles, respectively, according to the predominance of leg or foot cramps.
89452660|NCT03238898|Placebo Comparator|Normal saline|The same dosage as the active group, but with normal saline alone were injected into the gastrocnemious or the small flexor foot muscles, respectively, according to the predominance of leg or foot cramps.
89452661|NCT03249194|Experimental|HCV+ Donor Kidney Recipient|"All HCV- participants who receive an HCV+ donor kidney transplant will receive a first 'on-call' dose of Epclusa (sofosbuvir/velpatasvir; Gilead) and then three more doses on post-operative Day 1, 2 and 3. Donor HCV Genotype data will be available by Day 7 of transplant.~Patients will then be followed by serial HCV PCRs. Patients who are HCV PCR positive by Day 14 will be treated with Epclusa once daily x 12 weeks."
89452662|NCT03062891|Experimental|Online CBT for insomnia|"CBT participants will receive six weekly sessions delivered by an animated 'virtual therapist' (The Prof) via the online platform 'Sleepio'. The programme comprises a fully automated media-rich web application, driven dynamically by baseline, adherence, performance and progress data, and provides additional access to elements such as an online library with background information, a community of fellow users, and support, prompts and reminders sent by e-mail.~CBT content was consistent with the literature (4) and covered behavioral (e.g., sleep restriction, stimulus control) and cognitive (e.g., putting the day to rest, thought restructuring, imagery, articulatory suppression, paradoxical intention, mindfulness) strategies, as well as additional relaxation strategies (progressive muscle relaxation and autogenic training) and advice on lifestyle and bedroom factors (sleep hygiene). The intervention was based upon a previously validated manual (4)."
89452663|NCT03062891|No Intervention|Puzzles|Each week participants will be sent a puzzle to complete online (e.g. logic puzzles, crosswords etc). The puzzles have been designed to be cognitively engaging and take a similar amount of time to one session of Sleepio (20-25 minutes).
89452664|NCT04486508|Experimental|Intermediate dose anticoagulation|Intermediate dose anticoagulation will be the the tested regimen. The anticoagulation regimen will be modified according to weight/ body mass index, and creatinine clearance level (Cl Cr). Enoxaparin will be the primary agent for anticoagulation, with unfractionated heparin reserved only for patients with creatinine clearance of ≤15 mL/min according to Cockcroft-Gault Formula.
89452665|NCT04486508|Active Comparator|Standard Prophylaxis|Standard prophylaxis dose anticoagulation will be the anticoagulation of choice in the control arm. Enoxaparin will be the primary agent for anticoagulation, with unfractionated heparin reserved only for patients with creatinine clearance of ≤15 mL/min according Cockcroft-Gault Formula.
89452666|NCT04486508|Experimental|Atorvastatin 20|Atorvastatin 20 mg daily will be the statin therapy of choice in the intervention arm
88937379|NCT01810523|Placebo Comparator|Control|This arm will receive a blank piece of paper in addition to the standard of care discharge information.
88937380|NCT01810536|Experimental|Hi-flow nasal cannula|This group will receive supplemental oxygen by nasal cannula using the Optiflow system, with high flows of 100% humidified oxygen
88937381|NCT01810536|Active Comparator|Venturi mask|This group will receive supplemental oxygen by the current standard in our Institution: Venturi masks
88937382|NCT01810549|Active Comparator|Anakinra|Anakinra 100mg. Every subject will receive one subcutaneous injection of study drug once during the study, a total of one injection.
88937383|NCT01810549|Placebo Comparator|Placebo|Every study participant will receive a single subcutaneous injection of Placebo once during the study, a total of one injection.
88937384|NCT01810562|Experimental|Specific treatment + std stroke care|Specific treatment in addition to standard stroke care
88937385|NCT01810562|No Intervention|Std stroke care|Patients receive only standard stroke treatment and no specific treatment.
89452667|NCT04486508|Placebo Comparator|Atorvastatin 20 mg Matched placebo|Matching placebo will be used for the control arm
89452668|NCT03243266||CBC/Diff Reference Interval|Hematology routine diagnostic test
89452669|NCT02552212|Experimental|Certolizumab Pegol 200 mg Q2W|Certolizumab Pegol (CZP) 400 mg subcutaneous (sc) on Weeks 0, 2 and 4, followed by 200 mg CZP sc every 2 weeks (Q2W) from Week 6 onwards.
89452670|NCT02552212|Placebo Comparator|Placebo|Matching placebo to Certolizumab Pegol (CZP) injections are administered every 2 weeks from Week 0 onwards.
89452671|NCT02454764|Experimental|Tenofovir + Interferon alpha 2 b|
89452672|NCT02454764|Active Comparator|Tenofovir|
89452673|NCT03243188||Participants|Cancer patients with palliative care needs (+/- their carers)
89452674|NCT00685919|Experimental|Carbidopa then Placebo|Carbidopa 200 mg every 6 hours orally for 5 doses followed by Placebo every 6 hours for 5 doses
89452675|NCT00685919|Experimental|Placebo then Carbidopa|Placebo matching carbidopa given every 6 hours orally for 5 doses followed by Carbidopa
89452676|NCT03243344|Experimental|Surgiflo|Using Surgiflo® (Absorbable Gelatin Hemostatic) for the post-operative haemostasis in endonasal surgery.
89452677|NCT03243344|Experimental|Floseal|Using Floseal® (Absorbable Gelatin Hemostatic) containing human thrombin for the post-operative haemostasis in endonasal surgery
89452678|NCT03243344|Experimental|Algosteril|Using Algosteril® (Hemostatic Sterile Wick) for the post-operative haemostasis in endonasal surgery
89452679|NCT03243344|No Intervention|Abstention|Not using device for the post-operative haemostasis in endonasal surgery
89452680|NCT03243110||Asthmatics requiring breathing test|"Participants must have had a diagnosis of asthma by a physician. The participant must have had a self-reported health care interaction related to asthma (physician visit, ED visit, hospitalization) in the past 5 years.~Participants must be 1 to 85 years old."
88937386|NCT01810601|Experimental|Ultrasound guided embryo transfer|GnRh, HMG, HCG, Progesterone 45 patients had ultrasound guided embryo transfer during ICSI
88937387|NCT01810601|Placebo Comparator|clinical touch technique|GnRh, HMG, HCG, Progesterone 45 patients had embryo transfer using clinical touch technique during ICSI
88937388|NCT01810614|Experimental|ADPKD Diet|All study participants will follow their regular diet for 8 days. After that, they will be asked to follow the ADPKD diet for a total of 4 weeks.
88937389|NCT01810627||MVCT|Patients will receive an additional MVCT scan at their one month follow up visit.
89452681|NCT03238820|Experimental|The robot group|Patients undergo robotic gastric gastrointestinal stromal tumors resection.
89452682|NCT03239054|Experimental|Study Group|Participants in the study group will complete the Parmed-X Pregnancy form and be provided with a prescription for exercise.
89452683|NCT03239054|Other|Control Group|"The control group will be provided with the ACOG Pamphlet entitled Exercise during pregnancy and will be encouraged to become physically active during their pregnancy. They will receive routine care as scheduled."
88937390|NCT01810640|No Intervention|Control|In this group a liver biopsy will not be performed. All management would be as per standard of practice
88937391|NCT01810640|Active Comparator|Percutaneous liver biopsy|In this group a percutaneous biopsy of the liver will be performed prior to organ recovery
88937392|NCT01810653|Experimental|Macrogol (Transipeg)|
88937393|NCT01810653|Active Comparator|Macrogol (Forlax)|
88937394|NCT01810679|Experimental|Perceval S Aortic Heart Valve|Treatment with the Perceval S Aortic Heart Valve
88937395|NCT01810731|Experimental|Quadrivalent Influenza Vaccine (QIV)|"15µg of each of 2 influenza A strains (H1N1 and H3N2) and 2 influenza B strains in a buffer solution totaling 0.5mL which is administered intramuscularly.~Administered as a single dose on the day of enrollment."
88937396|NCT01810731|Active Comparator|Inactivated Polio Vaccine|A sterile suspension of three types of poliovirus: Type 1 (Mahoney), Type 2 (MEF1) and Type 3 (Saukett). This vaccine is prepared from types 1, 2 and 3 of poliomyelitis virus cultured on Vero cells, purified and then inactivated by formaldehyde and administered as a 0.5ml intramuscular or subcutaneous injection. A single dose of vaccine will be administered upon enrollment.
88937397|NCT01810731|Experimental|Double Dose QIV|"30µg of each of 2 influenza A strains (H1N1 and H3N2) and 2 influenza B strains in a buffer solution totaling 1.0mL which is administered intramuscularly.~Administered as a single dose on the day of enrollment."
88937398|NCT01810744|Other|metastatic colorectal cancer|Patients treated by bevacizumab will be follow up by capillaroscopy and blood pressure measurements.
88937399|NCT01810744|Other|glioblastoma|Patients treated by bevacizumab will be follow up by capillaroscopy and blood pressure measurements.
88937400|NCT01810757|Active Comparator|Standard planning|Standard planning radiotherapy
88937401|NCT01810757|Experimental|Adaptive planning|Adaptive planning radiotherapy
88937402|NCT01810770|Experimental|Radium-223 dichloride|
88937403|NCT01810796|Experimental|Ranolazine treatment|Ranolazine 500-1000mg bid
88937404|NCT01810796|Placebo Comparator|Placebo|Placebo
88937405|NCT01810809|Active Comparator|Articular Lavage|Patients from Group Zero will receive articular lavage with saline injection
88937406|NCT01810809|Experimental|Group 1|Patients from Group 1 will receive articular lavage with saline injection and viscosupplementation with 2ml (1 ampoule) of Hylan GF-20
88937407|NCT01810809|Experimental|Group 2|Patients from Group 2 will receive articular lavage with saline injection and viscosupplementation with 4ml (2 ampoules) of Hylan GF-20
89452684|NCT03238742|Experimental|Intervention Group|100ml Xuebijing Injection will be dissolved in 100 mL of normal saline every 12 hours for 5 days in blind fashion.
89452685|NCT03238742|Placebo Comparator|Placebo group|normal saline 200 mL every 12 hours for 5 days
89452686|NCT05478148|Experimental|Gingival phenotype|A Periodontal probe was used to differentiate between thick and thin phenotypes and Color coded Biotype Probe was used to classified the phenotype as thin, moderate, thick and very thick phenotypes. Endodontic File and Florida probe were used to measure the gingival thickness.
89015433|NCT06259734|Experimental|Transfusion Camp Rwanda course participants|This group will participate in a 3 day course on best practices in Transfusion Medicine in Rwanda. They will participate in testing before and after the course to ascertain knowledge gained. They will then begin to work in hospitals ordering blood for their patients. Data collectors will access their blood product orders and determine the level of appropriateness of their orders based on the Rwanda Biomedical Centre National Transfusion Guidelines.
89015434|NCT06259734|No Intervention|Intern Physicians not participating in Transfusion Camp|Blood product ordering practices with be assessed for appropriateness in physicians who did not participate in Transfusion Camp.
89015435|NCT06259708|Experimental|Vim first|Participants assigned to this arm get LIFU stimulation in the Vim before the ZI.
89015436|NCT06259708|Experimental|ZI first|Participants assigned to this arm get LIFU stimulation in the Vim before the ZI.
89015437|NCT06259695|Experimental|Adjustable Aquatic Therapy Prosthesis|The prosthesis will be designed to be adjustable in circumference, residual limb length, and overall height. This will allow adjustability to accommodate most limb shapes. The design will also provide secure suspension, on both land and in the water. This will maximize safety for the patient and translate motion from the residual limb to the prosthesis. Additionally, the prosthesis design will include a comfortable fit and interface, protecting the participant's skin. Skin will be assessed prior to use, during initial fitting, and after each therapy session. Finally, the prosthesis will be test fit and used with maximum assistance from clinical staff, minimizing risk.
89015438|NCT06259656|Other|Thai term pregnant woman who have at least One dose of Covid vaccination|Maternal and cord blood was collected to test COVID-19 Spike Protein IgG Quantitative Antibody (CMIA)
89015439|NCT06259643|Experimental|Power wheelchair soccer|soccer game performed with a wheelchair
89015440|NCT06259630|Experimental|Placebo followed by Nicotine Arm|Participant receives placebo on day 1 and nicotine on day 2.
89015441|NCT06259630|Experimental|Nicotine followed by Placebo Arm|Participant receives nicotine on day 1 and placebo on day 2.
89015442|NCT06259630|Placebo Comparator|Placebo followed by Placebo Arm|Participant receives placebo on day 1 and day 2.
89200989|NCT00903669||Peripheral Facial Paralysis (PFP)|Patients who are diagnosed with peripheral facial paralysis.
89452687|NCT03243032|Experimental|Local Anesthetic Group 1|Group 1 (Pre-emptive analgesia with long acting local anesthesia - experimental group): Ibuprofen 600mg given 30 minutes prior to beginning of surgery. Surgery will be performed only using 0.5% bupivacaine with 1:200,000 epinephrine as the local anesthetic. Following the procedure, all patients will be prescribed Chlorhexidine rinse ( 0.12%) (Rinse with 15 ml two times a day and spit) for 10 days and Antibiotics: Amoxicillin 500 mg three times a day for 7 days or if allergic to penicillin, clindamycin 300 mg four times a day for 7 days. Ibuprofen (600 mg) q 6 hours: prn for pain will be provided to all patients at no charge. Tramadol 50 mg (one every 4-6 hours as needed for pain; maximum 400 mg/day) for uncontrolled pain.
89452688|NCT03243032|Placebo Comparator|Local Anesthetic Control|Group 2 (Control / standard of care group): Placebo oral capsule (Microcrystalline Cellulose NF (Avicel PH 105) - compounded at the University of Iowa College of Dentistry Pharmacy) given 30 minutes prior to beginning of surgery. Surgery will be performed using 2% lidocaine with 1:100,000 epinephrine as the local anesthesia. Following the procedure, all patients will be prescribed Chlorhexidine rinse ( 0.12%) (Rinse with 15 ml two times a day and spit) for 10 days and Antibiotics: Amoxicillin 500 mg three times a day for 7 days or if allergic to penicillin, clindamycin 300 mg 4 times a day for 7 days. Ibuprofen (600 mg) q 6 hours: prn for pain will be provided to all patients at no charge. Tramadol 50 mg (one every 4-6 hours as needed for pain; maximum 400 mg/day) for uncontrolled pain.
89452689|NCT05478070|Other|Dexcom CGM|Proof of concept randomized study to evaluate the utility of Dexcom-G6 continuous glucose monitors for assessment of glycemic control in pregnant and postpartum women with insulin-requiring diabetes mellitus during hospitalizations
89452690|NCT05473546||CRITICALLY ILL PATIENTS|"ADULTS PATIENTS ADMITTED TO ICU DUE TO ACUTE ILLNESS THAT REQUIRE AT LEAST 72H OF STAY.~FOR THE FIRST 7 DAYS OF STAY IN ICU, DATA ABOUT NUTRITIONAL INTERVENTION WILL BE RECORDED SUCH AS: ROUTE OF NUTRITION ADMINISTRATION, AMOUNT OF NUTRITION DELIVERED PER DAY, CALORIC TARGETS, PROTEIN REQUIREMENTS, diarrhea, CONSTIPATION, BIA ANALYSIS."
89452691|NCT03061331|Experimental|Treatment Sequence 1|LUM/IVA in Treatment Period 1; washout; placebo in Treatment Period 2
89452692|NCT03061331|Experimental|Treatment Sequence 2|Placebo in Treatment Period 1; washout; LUM/IVA in Treatment Period 2
89452693|NCT03242876|Placebo Comparator|Control meal|Control will be 109 g white bread and 200 mL water. The glycaemic response to the test meal will be compared to the response of the control meal.
89200990|NCT00922467|Placebo Comparator|Placebo|patients will receive a closed-loop administration of propofol and remifentanil according to bispectral level and a placebo
89452694|NCT03242876|Experimental|Test meal|Test will be 109 g white bread and 200 mL water containing 3.819 g citric acid and 119 mg malic acid adjusted to pH 3.2. The glycaemic response to this meal will be compared to that of the control meal.
89452695|NCT00700778|Experimental|Recombinant human chorionic gonadotropin|Patients receive recombinant human chorionic gonadotropin subcutaneously three times weekly. Treatment continues weekly for 90 days in the absence of unacceptable toxicity.
89015443|NCT06259604|Experimental|PIOMI|Babies in this group will be administered PIOMI once a day, 30-45 minutes before feeding, for 14 days. When the intervention ends, the baby's feeding will be carried out by the researcher neonatal nurse in a semi-elevated side position, taking into account cue-based feeding symptoms, and the transition to full oral feeding will be evaluated by two researchers. These babies will be evaluated with the Early Feeding Skills Assessment Tool for early feeding skills before any intervention is applied (day 0) and on the 14th day of the PIOMI intervention. In addition, the weight of the babies will be monitored every morning for 14 days, on an empty stomach and naked, and will be recorded in the Nutrition Tracking Chart. The time it takes for babies to transition to full oral feeding will be evaluated according to cue-based feeding and recorded in the Feeding Follow-Up Chart.
89015444|NCT06259604|Experimental|PIOMI+kangaroo care|Babies in this group will start using PIOMI once a day, 30-45 minutes before feeding, and kangaroo care for at least 30 minutes during the last 2 minutes of non-nutritive sucking phase of PIOMI, for 14 days. When the intervention ends, the baby's feeding will be carried out by the researcher neonatal nurse in a semi-elevated side position, taking into account cue-based feeding symptoms, and the transition to full oral feeding will be evaluated by two researchers. These babies will be evaluated with the Early Feeding Skills Assessment Tool before any intervention is applied (day 0) and on the 14th day of PIOMI+kangaroo care in terms of early feeding skills. In addition, the weight of the babies will be monitored every morning for 14 days, on an empty stomach and naked, and will be recorded in the Nutrition Tracking Chart. The time it takes for babies to transition to full oral feeding will be evaluated according to cue-based feeding and recorded in the Feeding Follow-Up Chart.
89452696|NCT05213585|Experimental|Treated eyes|All participants will have one eye randomly selected for treatment.
89452697|NCT05213585|No Intervention|Untreated eyes|No treatment will be given to the control eye.
89452698|NCT03238664|Experimental|Arm A (laparoscopic HIFU, RARC)|Patients undergo pre-HIFU CEUS, standard of care biopsy of the bladder tumor, laparoscopic HIFU, and post-HIFU CEUS. Patients then undergo standard of care RARC.
89452699|NCT03238664|Active Comparator|Arm B (RARC)|Patients undergo standard of care RARC.
89452700|NCT03238508||Immediate stenting group|Conventional stenting immediate after the re-opening of infarct-related artery during primary PCI
89452701|NCT03238508||Deferred stenting group|Elective stenting following cooling down of infarct- related artery for several days after restoration of epicardial coronary blood flow during primary PCI
89452702|NCT03238586|Experimental|WELL Program|Five-week treatment program that aims to improve knowledge, motivation, and skills. It is designed to motivate participants to take their medications routinely, improve the quality of life for those living with HIV, and decrease risky behaviors that may lead to HIV transmission.
89452703|NCT03238586|No Intervention|Standard of Care|Five-week standard of care program.
89452704|NCT05209607|Experimental|Interventional group|Participants will be given mobile medical and bundle care
89452705|NCT05209607|Other|Control group|Participants will be given mobile medical and standard of care.
89452706|NCT03683680|Experimental|MRiS|"The specimens to be collected will include at least five pleural biopsy samples~MPT test and the CLDN15/VIM test will be performed"
89452707|NCT02453828|Experimental|Checklist|after non-cardiac surgery, patients will have current standard-of-care anesthesia handover during anesthesia transitions in care with an additional, electronically pre-populated checklist displayed on the anesthesia record keeping system
89452708|NCT02453828|Active Comparator|Standard of Care|after non-cardiac surgery, patients will have current standard-of-care anesthesia handover during anesthesia transitions in care
88937408|NCT01810809|Experimental|Group 3|Patients from Group 3 will receive articular lavage with saline injection and viscosupplementation with 6ml (3 ampoules) of Hylan GF-20
89452709|NCT05482282|Experimental|Recombinant Hep B new Bulk + Penta with Recombinant HepB new Bulk|1 dose Recombinant Hepatitis B new Bulk vaccine at birth + 3 doses Pentavalent with Recombinant HepB new Bulk vaccine
89452710|NCT05482282|Active Comparator|Hep B (Registered) + Pentabio (Registered)|1 dose Recombinant Hepatitis B vaccine (Registered) + 3 doses Pentabio with Recombinant HepB new Bulk vaccine
89452711|NCT03238274||Arm 1|Arm 1 is a multi-site, single visit, prospective clinical study where subjects will be enrolled based on a physician's assessment of current Lyme specific symptoms from recent contact with a tick.
89452712|NCT03238274||Arm 2|Arm 2 will consist of subjects selected from a pool of patients that were previously determined to have Lyme disease either by the presence of the diagnostic rash (erythema migrans) or through laboratory findings and physician diagnosis based on patient symptoms. In this Arm the site may recruit by contacting subjects previously diagnosed with Lyme disease no longer than 16 months post diagnosis and no earlier than 1 week post diagnosis.
89452713|NCT03238274||Arm 3|Arm 3 will consist of subjects selected from a pool of patients that were previously determined to have Lyme disease either by the presence of the diagnostic rash (erythema migrans) or through laboratory findings and physician diagnosis based on patient symptoms. In this Arm the site may recruit by contacting subjects previously diagnosed with Lyme disease between 17 months and 50 months post diagnosis. For the subject to be enrolled, a physician must have diagnosed the subject to have Lyme disease based on clinical symptoms.
89452714|NCT05209529|Experimental|Olaparib|Olaparib treatment for a total of 16 weeks
89452715|NCT05209529|Experimental|Olaparib and durvalumab|Olaparib and durvalumab treatment for a total of 16 weeks
89452716|NCT04424134|Experimental|Bromhexine And Spironolactone|
88937409|NCT01810822||Genesis French-Belgium Study|Cross-sectional, multi-center, binational (Belgian and France) study designed to evaluate the genetic components of diabetic nephropathy. It is a cohort with 501 patients, including 279 individuals (55.7%) with diagnosis of diabetic nephropathy.
88937410|NCT01810822||GENEDIAB|Cross-sectional, multi-center, binational (Belgian and France) study designed to evaluate the genetic components of diabetic nephropathy. It is a cohort with 444 patients, including 310 individuals (69.8%) with diagnosis of diabetic nephropathy.
88937411|NCT01810822||Brazilian cohort|The cohort comprised 451 patients with type 1 diabetes for more than 10 years (56% women; aged 36 ± 11 years, mean ± SD) recruited in diabetes/endocrinology departments of three university hospitals in the cities of São Paulo (SP), Campinas (SP) and Porto Alegre (RS), Brazil.
88937412|NCT01810848|Active Comparator|Hylan G-F 20|Patients will receive a single injection of hylan G-F 20 6ml into affected knee. Injections will be performed under fluoroscopic guidance.
88937413|NCT01810848|Sham Comparator|Control|Patients will receive a single sham puncture into the affected knee. Sham punctures will be identical to the treatment injections in all other respects, including duration, use of sterile drapes, sterile preparation, and dimming of the lights. This procedure will include a 22g needle stick through the skin without violating the joint capsule or performing arthrocentesis.
88937414|NCT01810874|Active Comparator|Transperitoneal|Patients who where randomized to transperitoneal laparoscopic aortic lymphadenectomy.
89452717|NCT04424134|Active Comparator|Base therapy|
88937415|NCT01810874|Experimental|Extraperitoneal|Patients who where randomized to extraperitoneal laparoscopic aortic lymphadenectomy.
88937416|NCT01810887|Experimental|Ritonavir and darunavir|Ritonavir will be administered orally twice daily at a dose of 100 milligram (mg) from Day 1-5. Darunavir ethanolate will be administered as single oral dosing of two tablets of 300 mg on Day 3.
89452718|NCT04486430|Experimental|Neu2000KWL 2750mg dose group|Low dose group
89452719|NCT04486430|Experimental|Neu2000KWL 5250mg dose group|Middle dose group
89452720|NCT04486430|Experimental|Neu2000KWL 6000mg dose group|High dose group
89452721|NCT04486430|Placebo Comparator|Placebo|Placebo
89452722|NCT05213117|Experimental|Co-localized Residents|Investigators plan to randomize 15 PGY-1 residents in internal medicine from the possible 74 PGY-1 incoming residents who agree to partake in the study, to one general medicine clinical floor for the academic year. These co-localized residents will complete 16-20 weeks of scheduled rotation time on White 9
88937417|NCT01810900|Experimental|Protescal|Protescal is applied to this arm.
89452723|NCT05213117|No Intervention|Normally Schedule Residents|The control arm will consist of 18 PGY-1 residents who are scheduled by the residency program's algorithm in the usual fashion to complete general medicine rotations on 5 difference clinical floors. The 18 active comparator participants will be selected based on completing one of four general medicine rotation on the control floor White 8. These participants will then be followed while completing the remaining general medicine rotations on all clinical floors.
89452724|NCT05482204|No Intervention|Control (QR) label|QR label on all menu items
88937418|NCT01810900|No Intervention|non-treatment|
89452725|NCT05482204|Experimental|Low Climate Impact Label|'Low Climate Impact' label on all chicken, fish and vegetarian menu items
89452726|NCT05482204|Experimental|High climate Impact Label|'High Climate Impact' label on all beef menu items
89452727|NCT05209373|Experimental|Group-Delivered Self-Compassion Intervention|"A 4-week intervention pairing behaviour change and self-compassion education, aimed to increase physical activity and help women cope with their risk of cardiovascular disease. Participants in the group condition will complete Sessions 2-4 with 6-9 other participants plus a facilitator. Both conditions will be exposed to identical intervention content. All intervention sessions will be hosted on an institution-sponsored Zoom videoconferencing account.~Week 1, Session 1 (60 minutes): Participants will meet in their group to discuss CVD risk factors and set physical activity goals.~Weeks 2-4, Sessions 2-4 (60 minutes each): Participants will meet in their group to receive self-compassion education to aimed at encouraging adaptive coping with cardiovascular risk and physical activity behaviour change. Brief self-compassionate writing exercises will be assigned as home practice after Sessions 2-4."
89452728|NCT05209373|Other|Positive control condition: Individually-Delivered Self-Compassion Intervention|"A 4-week intervention pairing behaviour change and self-compassion education, aimed to increase physical activity and help women cope with their risk of cardiovascular disease. Participants in the individual condition will complete Sessions 2-4 individually with a facilitator. Both conditions will be exposed to identical intervention content. All intervention sessions will be hosted on an institution-sponsored Zoom videoconferencing account.~Week 1, Session 1 (60 minutes): Participants will meet individually with a facilitator to discuss CVD risk factors and set physical activity goals.~Weeks 2-4, Sessions 2-4 (60 minutes each): Participants will meet individually with a facilitator to receive self-compassion education to aimed at encouraging adaptive coping with cardiovascular risk and physical activity behaviour change. Brief self-compassionate writing exercises will be assigned as home practice after Sessions 2-4."
89452729|NCT03248726|Experimental|Polyethylene glycol and bisacodyl|In order to decrease the dose and frequency of polyethylene glycol, we added bisacodyl at the night before examination to facilitate the action of polyethylene glycol given solely in the morning of examination.
89452730|NCT03248726|Active Comparator|Split-dose polyethylene glycol|The standard regimen of polyethylene glycol was used in this group. The participant of this arm receives polyethylene glycol in the evening before examination and the morning of examination .
89452731|NCT04486274|Experimental|non MOSE arm|Three needle passes will be performed for each mass
89452732|NCT04486274|Experimental|MOSE arm|The endoscopist will perform biopsy until a macroscopic visible core (MVC) will be obtained and specimen will be placed in a container (Container A-MOSE). If the needle passes performed are less than 3 (1 or 2 passes) the specimens acquired in the remnant passes to join standard care of 3 passes, according to ESGE guidelines, will be placed in a second container (Container B).
89452733|NCT04486196|Experimental|Control (No Laser) Group|The final irrigation was performed using 5ml 2.5% NaOCI, followed by 5 ml 17% EDTA for 3 min and 5 ml distilled water.
89452734|NCT04486196|Experimental|Laser Disinfection (LD) Group|After final irrigation was performed using 5ml 2.5% NaOCI, followed by 5 ml 17% EDTA for 3 min and 5 ml distilled water, root canals were irradiated with 980 nm diode laser coupled with optical fiber 200 µm with setting at the average power 1.2-W in pulsed mode. 10 seconds irradiation followed by 10 seconds pause, which comprised one lasting cycle. This cycle was applied 4 times for each root canal. The optical fiber (Medency) was inserted 1 mm short of the apex and the root canals were slowly (at a speed of 2mm/s) irradiated from apical to coronal in continuous circling movements to treat all dentinal tubules in one cycle for each power.
89452735|NCT03248804|Experimental|Soy Group|Subjects in the soy group were asked to participate in the Colorado Diet program and to consume 3 soy food items per day.
89452736|NCT03248804|Other|Non-soy Group|Subjects in the non-soy group were asked to participate in the Colorado Diet program and to avoid soy food products.
89452737|NCT04557280|Experimental|Treatment A: liquid formulation via auto-injector|Selatogrel will be administered as a liquid formulation in a sealed prefilled syringe in an auto-injector forming an integral ready-to-use single-dose drug delivery system.
89452738|NCT04557280|Experimental|Treatment B: liquid formulation via syringe|Selatogrel will be administered as a liquid formulation in a sealed prefilled syringe.
89452739|NCT04557280|Experimental|Treatment C: lyophilizate-based formulation via syringe|Selatogrel will be administered as a reconstituted lyophilizate-based formulation for injection.
89452740|NCT03242330|Experimental|Two-piece subperiosteal implant|The two-piece subperiosteal implant will be designed with an internal connection that will receive its prosthetic counterpart later in the second stage surgery, which will retain the final prosthesis in place. Two-piece constructions allow for undisturbed submerged healing, without being exposed to the oral environment, achieved by attaining primary closure over the inserted implant body.
89452741|NCT03242330|Active Comparator|Single-piece subperiosteal implant|The single-piece subperiosteal implant will be designed in the from of a framework with protruding posts that will appear penetrating through the mucosa, and will later carry the overlying superstructure (prosthesis). Single-piece subperiosteal implants do not require a second stage surgery.
88937419|NCT01810926|Experimental|MRD-Regimen&Polyclonal antibody|Patients MRD will be randomized to receive Treosulfan iv at a dose of 14 g/m² within 120 minutes on day -7, - 6, -5 + Fludarabine iv at a dose of 30 mg/ m² within 30 minutes on day -7, -6, -5,-4,-3 after treosulfan + Thiotepa iv at a dose of 8 mg/kg on day - 3 divided into 2 infusions at 12 hrs intervals + Cyclosporine A iv at a dose of 3 mg/kg/day starting from day -1 and a dose adjustment will be done to obtain plasma levels of 150-250 ng/mL + Methotrexate iv at a dose of 15 mg/m2 on day +1, at a dose of 10 mg/m2 on day + 3 and + 6 & ATG-Fresenius S® iv at a dose of 5 mg/kg within 8 hours on day -4,-3,-2
88937420|NCT01810926|Sham Comparator|MRD-Regimen|Patients receiving stem cell transplantation from a matched related donors (MRD) will be randomized to receive only Treosulfan iv at a dose of 14 g/m² within 120 minutes on day -7, - 6, -5 (total dose of 42 g/m²) + Fludarabine iv at a dose of 30 mg/ m² within 30 minutes on day -7, -6, -5,-4,-3 (total dose of 150 mg/m²) after treosulfan + Thiotepa iv at a dose of 8 mg/kg on day - 3 divided into 2 infusions at 12 hrs intervals (total dose of 8 mg/kg)+ Cyclosporine A iv at a starting dose of 3 mg/kg/day starting from day -1 and a dose adjustment will be done to obtain plasma levels of 150-250 ng/mL (In the absence of GvHD CSA will be tapered after day + 180 and stopped at 9-12 months) + Methotrexate iv at a dose of 15 mg/m2 on day +1, at a dose of 10 mg/m2 on day + 3 and + 6
88937421|NCT01810926|Experimental|MUD-Regimen & Rituximab|Patients MUD will be randomized to receive Treosulfan iv at a dose of 14 g/m² within 120 minutes on day -7, - 6, -5 + Fludarabine iv at a dose of 30 mg/ m² within 30 minutes on day -7, -6, -5,-4,-3 after treosulfan + Thiotepa iv at a dose of 8 mg/kg on day - 3 divided into 2 infusions at 12 hrs intervals + Cyclosporine A iv at a dose of 3 mg/kg/day starting from day -1 and a dose adjustment will be done to obtain plasma levels of 150-250 ng/mL + Methotrexate iv at a dose of 15 mg/m2 on day +1, at a dose of 10 mg/m2 on day + 3 and + 6 and at a dose of 10 mg/m2 on day +11 + ATG-Fresenius S ® iv at a dose of 5 mg/kg within 8 hours on day -4,-3,-2 & Rituximab in a single infusion of 200 mg/m2 on day -1
88937422|NCT01810926|Sham Comparator|MUD-Regimen|Patients MUD will be randomized to receive only Treosulfan iv at a dose of 14 g/m² within 120 minutes on day -7, - 6, -5 + Fludarabine iv at a dose of 30 mg/ m² within 30 minutes on day -7, -6, -5,-4,-3 after treosulfan + Thiotepa iv at a dose of 8 mg/kg on day - 3 divided into 2 infusions at 12 hrs intervals + Cyclosporine A iv at a dose of 3 mg/kg/day starting from day -1 and a dose adjustment will be done to obtain plasma levels of 150-250 ng/mL + Methotrexate iv at a dose of 15 mg/m2 on day +1, at a dose of 10 mg/m2 on day + 3 and + 6 and at a dose of 10 mg/m2 on day +11 + ATG-Fresenius S ® iv at a dose of 5 mg/kg within 8 hours on day -4,-3,-2
88937423|NCT01810965|Experimental|Cohort|
88937424|NCT01810978|Active Comparator|Bifidobacterium lactis plus inulin|Bifidobacterium lactis plus inulin
88937425|NCT01810978|Placebo Comparator|maltodextrin|maltodextrin
88937426|NCT01811017|Experimental|755nm Alexandrite Laser|755nm Alexandrite Laser
88937427|NCT01811017|Experimental|Nanosecond 755nm Alexandrite Laser|Nanosecond 755nm Alexandrite Laser
88937428|NCT01811056|No Intervention|In-Center Use of Mifepristone|Participants who choose to take mifepristone in the center
88937429|NCT01811056|Experimental|Out-of-Center Use of Mifepristone|Participants who choose to take the mifepristone outside of the center
88937430|NCT01811082|Experimental|Coenzyme A 400mg|Coenzyme A 400mg per day
88937431|NCT01811082|Active Comparator|Pantethine 600mg|Pantethine 600mg per day.
88937432|NCT01811095|Experimental|Training arm|"The training arm participates in the robotic suturing simulation curriculum, a proficiency curriculum that it is focused on the goal of achieving proficiency targets for five simulator tasks. Those six tasks are : Camera targeting 1, Camera targeting 2, Suture sponge 1, Suture sponge 2, and Suture sponge 3. The curriculum also includes a sixth task, Suturing Skills (Symbionix): Horizontal suturing defect. Participants are encouraged to complete this task ten times rather than to attain a certain score. Participants set their own hours about when and how much to train during the 5 week intervention period. They are instructed that approximately one hour per week over 5 weeks will be required to achieve the targets, on average."
88937433|NCT01811095|Placebo Comparator|Control|Participants in this group carry on with regular training (residents) or regular clinical work (attending surgeons) without robotic simulator training during the five week period when they are in the control group.
88937434|NCT01811108||Avastin regimens|Patients who have either received or who are going to receive chemotherapy plus Avastin (bevacizumab)
88937435|NCT01811121|Experimental|5-aminolévulinique acid (5-ALA)|5-aminolévulinique acid :microsurgical resection guided by fluorescence (CGF) in addition to the usual techniques of neuronavigation, after oral administration of 20mg/kg of 5-ALA 3-5 hours prior to surgical incision
88937436|NCT01811121|Placebo Comparator|Placebo|Laroscorbine :microsurgical excision guided solely by neuronavigation, after oral administration of a placebo 3 to 5 hours before the surgical incision
88937437|NCT01811134|Experimental|PIPELINE flow diverter stent|flow diverter stent
88937438|NCT01811134|Active Comparator|Coils, with or without expendable stent|Coils
88937439|NCT01811160|Experimental|Melatonin 5mg (extended release capsules)|Subjects received melatonin (extended release) 5mg nightly during the follow up period
88937440|NCT01811160|Placebo Comparator|Placebo|Subjects received a placebo capsule nightly during the eight week follow up period.
88937441|NCT01811173|Experimental|Nurse-physician comprehensive care|Comprehensive self management support and care coordination by a nurse-primary care physician team
88937442|NCT01811173|No Intervention|Usual care survey control group|Patients will receive usual primary care and asked to complete questionnaires on four time points throughout the study
88937443|NCT01811173|No Intervention|Usual care blinded control group|Patients will receive usual primary care.
88937444|NCT01811251|Experimental|Pregabaline (150mg), Dexamethasone (20mg/5ml; 0.2mg/kg)|The aim of the study is to show a decrease in postoperative pain during the first postoperative mobilization surgery lumbar disc herniation through a co-analgesia with a single dose of dexamethasone, pregabalin, or a combination of these two products
88937445|NCT01811251|Placebo Comparator|Lactose (150mg), NaC1 0.9% (50ml)|The aim of the study is to show a decrease in postoperative pain during the first postoperative mobilization surgery lumbar disc herniation through a co-analgesia with a single dose of dexamethasone, pregabalin, or a combination of these two products
89200991|NCT00922467|Experimental|Esmolol|patients will receive a closed-loop administration of propofol and remifentanil according to bispectral level and esmolol
89200992|NCT00903747|Experimental|1|Prucalopride
89200993|NCT00903747|Placebo Comparator|2|Placebo/moxifloxacin
89200994|NCT02538627|Experimental|MM-151+MM-121 Dose Escalation|MM-151 and MM-121 dose escalation in lung, head and neck, and colorectal cancers
89200995|NCT02538627|Experimental|MM-151+ trametinib Dose Escalation|MM-151 and trametinib dose escalation in lung, head and neck, and colorectal cancers.
89200996|NCT02538627|Experimental|MM-151+MM-141 Dose Escalation|MM-151 and MM-141 dose escalation in lung, head and neck, and colorectal cancers
89015445|NCT06259604|No Intervention|Control|Babies in this group will receive standard care in the clinic. They will be evaluated with the Early Nutrition Skills Assessment Tool in terms of early feeding skills on the day they are included in the study (day 0) and on the 14th day. In addition, the weight of the babies will be monitored every morning for 14 days, on an empty stomach and naked, and will be recorded in the Nutrition Tracking Chart. The time it takes for babies to transition to full oral feeding will be evaluated according to cue-based feeding and recorded in the Feeding Follow-Up Chart. All measurements will be carried out and evaluated separately by two independent researchers. During discharge, discharge time, discharge weight and postmenstrual week at discharge will be recorded in the Baby Information Form.
89015446|NCT06259591|Experimental|Pedometer follow-up and coaching|Pedometer follow-up plus text message coaching Monday/ Wednesday/ Friday
89015447|NCT06259591|Active Comparator|Pedometer follow up|Pedometer follow-up from day 8- 30 after surgery
89015448|NCT06259578|Experimental|INAVAC (Vaksin Merah Putih - UA-SARS CoV-2 (Vero Cell Inactivated) 5 μg|The study product is provided in the form of liquid in vial single dose (0.5 ml). The vaccine will be given 1 dose (0.5 ml) once.
89015449|NCT06259565|Experimental|Dexmedetomidine Intervention|"Dexmedetomidine (Dex) is an α2-adrenergic agonist sedative commonly used in IMV that promotes patient wakefulness, has no effect on respiratory drive, has important analgesic properties, and reduces delirium.~Patients randomized to the experimental arm will receive dexmedetomidine. At initiation, a bolus will NOT be administered. In keeping with Health Canada Guidelines, we will start the infusion at a mid-range dose of 0.5mcg/kg/h with titration either up or down by 0.1mcg/kg/h every 20-30 minutes to a maximum rate of 1.2mcg/kg/h to maintain light sedation (RASS = -2 to +1 or SAS 3-4). Each bag will be composed of a 200mcg/mL dexmedetomidine vial mixed in a 100mL 0.9% sodium chloride mini-bag and labeled as per Health Canada guidance for labelling pharmaceutical drugs for use in humans."
89015450|NCT06259565|Placebo Comparator|Placebo Control|Those in the control group will receive a placebo that is identical in colour and packaging and at equal volume to the intervention group. Each bag of placebo contains 100mL of 0.9% sodium chloride and labeled as per Health Canada guidance for labelling pharmaceutical drugs for use in humans
89015451|NCT06259539|Experimental|Intervention|This group completed an 8-week virtual, YouTube-delivered nutrition education intervention. They were expected to watch the assigned videos per week at least once and practice the skills and strategies with their child with autism. This group completed all the baseline, mid-point, and end-point data using the questionnaires/surveys on Qualtrics.
89015452|NCT06259539|No Intervention|Control|This group completed all surveys but received no intervention. They received access to all study materials at the end of the study.
89015453|NCT06259526|Placebo Comparator|Placebo group|
89015454|NCT06259526|Experimental|JS1-1-01 low-dose group|
89015455|NCT06259526|Experimental|JS1-1-01 medium dose group|
89015456|NCT06259526|Experimental|JS1-1-01 high-dose group|
89015457|NCT06259526|Active Comparator|Active drug group|
89015458|NCT06259513|Experimental|patients with omission of SLNB|early breast cancer patients with cT1-2N0 Luminal A subtype with omission of SLNB
89015459|NCT06259513|Experimental|patients with </=2 macrometastasis and omission of ALND|breast cancer patients with 1-2 macrometastasis on SLNB and had omission of ALND
89015460|NCT06259513|No Intervention|patients with cT1-2N0 and SLNB|early breast cancer patients with cT1-2N0 Luminal A subtype and SLNB
89015461|NCT06259513|No Intervention|patients with </=2 macrometastasis and ALND|breast cancer patients with 1-2 macrometastasis on SLNB and had ALND
89015462|NCT06259487|Experimental|Coordinated Vaccination against RSV and Influenza|Patients receiving vaccinations against Respiratory Syncytial Virus (RSV) and influenza provided by the research team (i.e. during cardiology visits).
89015463|NCT06259487|Active Comparator|Standard of care|Patients following standard recommendations for protective vaccinations (i.e., receiving vaccinations at vaccination points).
89015464|NCT06259448|Experimental|urine self-sampling|urine self-sampling
89015465|NCT06259409|Experimental|Treatment Arm|This group will receive the study device, Regenn® Negative Pressure Therapy System, a form of Negative Pressure Wound Therapy (NPWT). Regenn® Therapy manages the surgical wound by the application of reduced pressure therapy (i.e., mild vacuum). Reduced pressure therapy is controlled by a hand-sized, battery-operated pump and is delivered by an attached small, dressing that the surgeon places in the surgical wound at the end of the surgery. Reduced pressure therapy is applied while the patient recovers from surgery.
89015466|NCT06259409|Active Comparator|Control Arm|This group will receive the control device, also a form of Negative Pressure Wound Therapy (NPWT), which manages the surgical wound by the application of reduced pressure therapy (i.e., mild vacuum). Reduced pressure therapy is controlled by a hand-sized, battery-operated pump and is delivered by a small tube connected to a wound dressing placed over the closed surgical wound at the end of the surgery. Reduced pressure therapy is applied while the patient recovers from surgery.
89015467|NCT06259396|Active Comparator|The 8x5 Diet|The 8x5 Diet is a healthy dietary pattern administered virtually by a specialist dietitian
89015468|NCT06259396|No Intervention|Control|Continuation of habitual diet, no dietary changes.
89015469|NCT06259383|Experimental|Patients received oral ivermectin, adjunctive to conventional treatment|
89015470|NCT06259383|No Intervention|Patients received conventional treatment|
89015471|NCT06259370|Experimental|intervention group|The intervention measures encompass the implementation of simulated vigorous intermittent lifestyle physical activity for all participants. The specific exercise regimen involves performing rope jumping activities three times a day, with each session aimed at surpassing the exercise threshold (not conducted in a continuous manner), where the heart rate should exceed 160 beats per minute. This routine will be undertaken five times a week, continuously for a span of 8 weeks.
89200997|NCT02538627|Experimental|MM-151+trametinib Dose Escalation|MM-151 and trametinib dose escalation in lung, head and neck, and colorectal cancers.
89200998|NCT02538627|Experimental|Colorectal cancer Expansion|Doses established in part 1 of the study
89200999|NCT02538627|Experimental|Head and neck Expansion|Doses established in part 1 of the study
89201000|NCT00899457||Healthy, non-smokers|
89201001|NCT00903825|Active Comparator|Manual palpation|Local anesthetic before femoral artery puncture will be injected with the classic manual palpation technique
88937446|NCT01811264|Experimental|Intervention|Participants will begin with a pre-visit structured interview to determine emotional and physical well-being, anxiety, depression, and self-efficacy. Then they will be helped through the Patient-Participation Aid (PPA) by the research assistant (RA). Then they will meet with their doctor while the visit is video-recorded. After they will complete a post-visit interview to see if there were any health decisions made, patients level of involvement, and doctor communication. Follow up phone interviews will be conducted at 1 week and 3 months to assess patients self-reported changes in well-being, anxiety, depression, and decision regret.
88937447|NCT01811264|No Intervention|Usual Care|Participants will begin with a pre-visit structured interview to determine emotional and physical well-being, anxiety, depression, and self-efficacy. They will have their doctor's visit video recorded. After they will complete a post-visit interview to see if there were any health decisions made, patients level of involvement, and doctor communication.Follow up phone interviews will be conducted at 1 week and 3 months to assess patients self-reported changes in well-being, anxiety, depression, and decision regret.
88937448|NCT01811277|Experimental|SOX sequential S-1|4-6 cycles of SOX followed by S-1 monotherapy until disease progression
88937449|NCT01811290||Gilenya Subjects|Gilenya therapy group subjects must have been treated with Gilenya a minimum of 3 months uninterrupted prior to screening visit, and approved by the principal investigator to continue on this agent.
88937450|NCT01811290||Controlled Therapy Group|Control therapy group subjects must have been consistently on an FDA approved disease modifying therapy other than Gilenya or off such therapy a minimum of 6 months prior to screening visit.
88937451|NCT01811342||Hemoglobin Measurement|Patients requiring intra-operative hemoglobin measurement.
88937452|NCT01811381|Experimental|Curcumin and aerobic exercise|For the first 6 months of the study, subjects will take 800 mg of curcumin (4 capsules x BID, p.o.) before meals. From six to 12 months after the beginning of the study, subjects will take curcumin (4 capsules BID before meals, total 800 mg/day) and also participate in an aerobic yoga exercise program (Attendance at 2 classes of 1 hour duration [or 1 hr SecureVideo Live videoconference remote classes for subject who become proficient] and 2 home practices of 30 minute duration per week).
88937453|NCT01811381|Placebo Comparator|Placebo vs non-aerobic yoga|For the first 6 months of the study, subjects will take Placebo (4 capsules x BID, p.o.) before meals. From six months to 12 months from the beginning of the study, subjects will take Placebo (4 capsules x BID) and participate in a weekly non-aerobic yoga program (Attendance at 2 classes of 1 hour duration or 1 hr SecureVideo Live videoconference remote classes for subject who become proficient] and 2 home practices of 30 minute duration per week).
88937454|NCT01811381|Active Comparator|Placebo vs Aerobic Yoga|For the first 6 months of the study, subjects will take Placebo (4 capsules x BID, p.o.) before meals. From six months to 12 months from the beginning of the study, subjects will take Placebo (4 capsules x BID) and participate in a weekly aerobic yoga program (Attendance at 2 classes of 1 hour duration [or 1 hr SecureVideo Live videoconference remote classes for subject who become proficient] and 2 home practices of 30 minute duration per week).
88937455|NCT01811381|Active Comparator|Curcumin vs non aerobic yoga|For the first 6 months of the study, subjects will take 800 mg of curcumin (4 capsules x BID, p.o.) before meals. From six months to 12 months from the beginning of the study, subjects will take Curcumin (4 capsules x BID, total 800 mg/day) and participate in a weekly non-aerobic yoga program (Attendance at 2 classes of 1 hour duration [or 1 hr SecureVideo Live videoconference remote classes for subject who become proficient] and 2 home practices of 30 minute duration per week).
88937456|NCT01811407|Other|Private/private|Participants will wear a pedometer for 14-15 weeks and receive a weekly step count target each week. Participants will be required to set a forward-looking commitment each week as to how many days during the following week they will meet their step count target. Commitment and results will be private.
88937457|NCT01811407|Experimental|Public/private|Participants will wear a pedometer for 14-15 weeks and receive a weekly step count target each week. Commitments are made as in the Private/Private condition. In addition, one Facebook announcement will be posted at the beginning of the week that says how many days the participant thinks they will meet their walking target the following week. An email will also be sent directly to 3 friends the participant chose with the same announcements.
88937458|NCT01811407|Experimental|Public/public|Participants will wear a pedometer for 14-15 weeks and receive a weekly step count target each week. Commitments will be made as in the Private/Private condition. In addition, one message will be posted to Facebook at the beginning of the week that says how many days the participant thinks they will meet their walking target the following week, and how they did on their previous weekly commitment. An email will also be sent directly to 3 friends the participant chose with the same announcements.
88937459|NCT01811420|Experimental|CHEMOMECHANICAL CARIES REMOVAL|Dental caries removal using papain based gel
88937460|NCT01811420|Active Comparator|conventional method|Dental caries removal using rotatory instrument
88937461|NCT01811446|Experimental|Obese|Subjects with BMI > 30
88937462|NCT01811446|Experimental|COPD|Non-hospitalized COPD patients
88937463|NCT01811459|Experimental|Quetiapine|Drug: Quetiapine 50-250 mg PO BID (5 levels of treatment) + IV Placebo Rescue IV haloperidol available.
88937464|NCT01811459|Experimental|Haloperidol|Drug: Haloperidol 1-5 mg BID (5 levels of treatment) + PO placebo Rescue IV haloperidol available.
88937465|NCT01811459|Placebo Comparator|Placebo|IV placebo + PO placebo Rescue IV haloperidol available.
88937466|NCT01811511|Experimental|Chungkookjang|Chungkookjang(35g/day)
88937467|NCT01811511|Placebo Comparator|Placebo|Placebo(35g/day)
88937468|NCT01811524||Glioma and meningioma patientsl|Glioma and meningioma patients of Tampere University Hospital during the study period
88937469|NCT01811537|Experimental|Experimental: premeasured Neochordae|Transthoracic echocardiography(TTE) is done for all patients. The new device will be setup using the TTE measurements.The artificial Chordae loops will be made at the operation room before starting the surgery. These loops will be attached to the respective papillary muscle's head and the free edge of respective prolapsed scallop.
88937470|NCT01811550||SHINE study subjects|Subjects enrolled in the SHINE trial who are not receiving intra-arterial therapy nor systemic anticoagulation; have no known moderate/severe hepatic insufficiency; have no known history of hypercoaguable or thrombotic condition; have INR =<1.5 (if known) at baseline and provide informed consent (self or LAR) will be enrolled in the I-SPOT study.
88937471|NCT01811589|Experimental|Thomale-Guide|Positioning of ventricular catheter with the Thomale-Guide instrument
88937472|NCT01811589|Other|Free-hand|Ventricular catheter placement without a guidance (free-hand)
88937473|NCT01811602|Other|Training|Pelvic floor muscle training delivered by a physiotherapist with clinical expertise and training in treating pelvic floor dysfunction
88937474|NCT01811602|Other|Usual Care Control|Participants randomized to this arm will receive a 1-page educational pamphlet on pelvic floor muscle training, specifically Kegel exercises, which is equivalent to current standard care. Individuals randomized to this group will be placed on the clinic waiting list and be eligible for treatment following completion of the 12 week (end of study) measures.
88937475|NCT01811615|Active Comparator|toothbrushing plus rinsing|0.06% CHX + 0.025% NaF plus toothbrushing and alcohol-containing mouth rinsing
88937476|NCT01811615|Experimental|alcohol-free experimental mouth rinse|0.06% CHX + 0.025% NaF plus toothbrushing
88937477|NCT01811615|Experimental|toothbrushing and rinsing|0.06% CHX + 0.03% CPC + 0.025% NaF, alcohol-free, mouth rinsing
88937478|NCT01811615|No Intervention|toothbrushing alone|negative control
88937479|NCT01811628||Questionnaire + Interview|Latinos and Hispanics who are smokers and recent quitters.
88937480|NCT01811641||maternal methyl-donors, infant epigenetics|women of reproductive age in rural Gambia, infants born to these women
88937481|NCT01811667|Experimental|Sirolimus|Seric level between 10 to 15 ng/ml Pills for the adults and liquid for the children. Twice a day.
88937482|NCT01811719|Experimental|Enhanced NFP (NFP+)|"Enhanced NFP(NFP+)provides for the usual NFP services plus a three-prong experimental preventive intervention:~Structured and regularly occuring assessments for intimate partner violence (IPV);~McFarlane and Parker Brochure Driven Intervention for women experiencing IPV, including safety planning, referrals, and advocacy; and~Markman and Stanley Within My Reach Training which is a skills-based curriculum delivered to all participants focusing on improving relationship deicsions and outcomes."
88937483|NCT01811719|Active Comparator|NFP as usual|The Nurse Family Partnership is a well-known and widely used nurse home visit program developed by David Olds. It has been rigorously tested and replicated and is now considered a best practice.
88937484|NCT01811745|Experimental|Jaques-Dalcroze eurhythmics training|Once-weekly 60-min Jaques-Dalcroze eurhythmics class, for 12 months.
88937485|NCT01811745|Active Comparator|Multicomponent exercise training|Once-weekly 60-min multicomponent exercise class supplemented by one 30-min home-based exercise session, for 12 months.
88937486|NCT01811758|Experimental|Culturally Specific CBT|Culturally specific cognitive behavioral therapy. Group format, 8 sessions, approximately 90 minutes. Up to 8-weeks of transdermal nicotine patches. Focused on African Americans: smoking patterns, health outcomes, discrimination, stress, weight concerns, cultural beliefs and practices.
88937487|NCT01811758|Active Comparator|Standard CBT (control)|Standard cognitive behavioral therapy. Group format, 8 sessions, approximately 90 minutes each. Up to 8-weeks of transdermal nicotine patches. Traditional CBT, with no focus on race: smoking and health, benefits of quitting, weight control, relapse prevention, coping skills.
88937488|NCT01811771|Active Comparator|Shanchol vaccine|Around 30,000 individuals will be vaccinated with two doses of oral cholera vaccine at least 14 days apart.All male and non-pregnant female residents above one year age will be targeted for vaccination.
88937489|NCT01811771|No Intervention|Non-intervention|No intervention will be given. Health education will be provided to the study participants.
88937490|NCT01811784|Experimental|Use skirt on raw sap consumption|"Phase one: Test the effectiveness of a single message of do not drink raw sap."
88937491|NCT01811784|Experimental|Ask people not to drink sap|Test the effectiveness of a risk reduction approach, encouraging people to avoid drinking sap, if they do, they should only drink sap from skirt protected trees.
88937492|NCT01811784|No Intervention|Phase 1: Routine raw sap consumption among household members.|"Test the effectiveness of a single message of do not drink raw sap"
88937493|NCT01811784|No Intervention|Phase 2:|Raw sap consumption from skirt protected trees
88937494|NCT01811797|Experimental|Low Intensity Shockwave treatment|4 weekly sessions of Low Intensity Shockwave treatment.
88937495|NCT01811797|Sham Comparator|Control group|
88937496|NCT01811810|Other|xrt and long term ADT|Radiation therapy (XRT) and long term androgen deprivation therapy
88937497|NCT01811810|Other|xrt, chemotherapy and short term ADT|radiation therapy (XRT), chemotherapy and short term ADT
88937498|NCT01811823|Other|TIV|"Trivalent Inactivated Influenza Vaccine The study vaccine will be the seasonal 2013 un-adjuvanted TIV which is provided as a 0•5 milliliter suspension of split virus mixture of 15 micrograms each of circulating H1N1- like strain, H3N2- like strain and B - like strain.~The WHO recommended vaccine formulation for Southern Hemisphere 2013 Influenza Season contains the following influenza strains:~A/California/7/2009 (H1N1)pdm-like virus~A/Victoria/361/2011 (H3N2)-like virus~B/Wisconsin/1/2010-like virus. (Yamagata lineage)"
88937499|NCT01811836|Experimental|Resistant Starch|"Oral and intravenous zinc stable isotopes. Zinc: 67Zn (>97% enrichment),68Zn (>99% enrichment) and 70Zn (>95% enrichment) Days 1 and 38: children will be administered 40-75 μg of 67Zn through consumed food. At the end of these days, children will be given an intravenous injection of an accurately measured quantity of ~800 μg of 68Zn.~Days 3-35: resistant starch feeding -- which will be given to mothers and integrated into the food."
88937500|NCT01811849|Experimental|BIOD-238|Subcutaneous injection
88937501|NCT01811849|Experimental|BIOD-250|Subcutaneous injection
88937502|NCT01811849|Active Comparator|Humalog|Subcutaneous injection
88937503|NCT01811888||Patients with knee osteoarthritis|
88937504|NCT01811901|Active Comparator|Intervention group (SITS-WATCH centers)|15-item list of suggested interventions aiming to reduce DNT sent to SITS-WATCH centers.
88937505|NCT01811901|No Intervention|Control group (non SITS-WATCH centers in SITS registry)|Centres that do not use 15-item list of suggested interventions aiming to reduce DNT.
88937506|NCT01811914|Experimental|intraoperative TTE|TTE if a hemodynamic instability occurs
88937507|NCT01811927|Experimental|PRO-Kinetic Energy Stent|PRO-Kinetic Energy Stent
88937508|NCT01811966|Sham Comparator|Control|preoperative none substitution of i.v. fluids.
89452742|NCT05477992|Experimental|Endovascular embolisation|Embolisation is an effective measure to reduce intraoperative bleeding for vascular tumours of the head and neck. It is often carried out from 24 to 72 hours prior to the surgical resection to allow time for maximal thrombosis of the occluded vessels and prevent recanalisation of the occluded arteries or formation of collateral arterial channels. Data will be collected for primary and secondary outcome measures
89452743|NCT03248414|Experimental|Lactobacillus sakei|2 packs per day
89452744|NCT03248414|Placebo Comparator|Control|2 packs per day
89452745|NCT04961021|Active Comparator|Medial rectus advancement with resection|Surgery will be done to strengthen the medial rectus muscle with resection and anterior displacement again to the original insertion site 5 mm from limbus
89452746|NCT04961021|Active Comparator|Medial rectus advancement with lateral rectus recession|Surgery will be done to strengthen the medial rectus muscle with anterior displacement again to the original insertion site 4- 5 mm from limbus with weakening procedure to the lateral rectus muscle at the same time
89452747|NCT05208827|Experimental|Experimental group|Take two tablets once a day.Each tablet contains 800 units of vitamin D3, for a total of 1600 units taken orally daily
89452748|NCT05208827|Placebo Comparator|Control Group|The control group received the same packaged, similar-looking, similar-tasting placebo from the same manufacturer, containing starch, peanut oil (no pharmaceutical value)
89452749|NCT03242564|Experimental|Active Device|"Active Device: Vevazz LED red light therapy system~Vevazz LED red light therapy system is a treatment regimen using the Vevazz LED device for fat removal using LED red light therapy."
89452750|NCT03242486|Experimental|toric intraocular lens|toric intraocular lens is implanted to all subjects
89452751|NCT04947059|Active Comparator|Gemcitabine|Bladder cancer patients, who are treated with a transurethral resection of a bladder tumor, receive postoperatively, within 6 hours after the resection, an immediate single intravesical instillation with gemcitabine hydrochloride 2gr in 100ml of saline for 45-60 minutes and continuous saline irrigation for 24 hours
89452752|NCT04947059|Active Comparator|Epirubicin|Bladder cancer patients, who are treated with a transurethral resection of a bladder tumor, receive postoperatively, within 6 hours after the resection, an immediate single intravesical instillation with epirubicine hydrochloride 50mg in 50ml of saline for 45-60 minutes and continuous saline irrigation for 24 hours
89452753|NCT03237962|Experimental|High Flow Nasal Cannula|Patients are randomly assigned into High flow nasal cannula group for the exercise training
89452754|NCT03237962|Experimental|Nasal Cannula|Patients are randomly assigned into nasal cannula group for the exercise training.
89452755|NCT04945967|Experimental|New Method|This intervention will be given once a day, 30 minutes before feeding schedule based on the neonatologist. Each session of intervention will take time about 18 minutes.
89452756|NCT04945967|Active Comparator|Conventional Method|This intervention will be given once a day, 30 minutes before feeding schedule based on the neonatologist. Each session of intervention will take time about 15 minutes.
89452757|NCT03238118|Experimental|Attention bias modification training|For attention-toward-positive, stimuli are colour-pictures of 16 angry and 16 happy faces (half female). Each happy face is presented 10 times, and each angry face presented 80 times across trials, balanced across the different positions in the 3 × 3 matrix. This yielded 160 training trials (two blocks of 80 trials). Children had to mouse-click on the happy face within the 3 × 3 matrix of angry faces as quickly and as accurately as possible. The matrix disappeared after the child mouse-clicked on the correct face and the next trial began.
89452758|NCT03238118|Placebo Comparator|Attention Control Training|For attention-training-control, stimuli are 20 colour-pictures of individual birds and flowers used in prior visual-search tasks with children. Children mouse-clicked on the bird presented amongst flowers as quickly and accurately as possible. Other task parameters were similar to the attention-toward-positive task (160 training trials). No performance feedback is given in either condition.
88937509|NCT01811966|Active Comparator|Volume|preoperative substitution of a defined amount of i.v. fluids (8 ml/kg RingerAcetate solution for 15 min prior to introduction of anesthesia).
88937510|NCT01811979|Active Comparator|oral sucrose solution|local anesthetic eye drops (Alcaine 0.5% drop) and a pacifier, plus 0.5 cc/kg of 24% sucrose, to relieve pain associated with eye examinations for retinopathy of prematurity will be given
88937511|NCT01811979|Placebo Comparator|steril water|steril water 0,5 cc/kg plus topical anesthetics (Alcaine %0.5 damla) before eye examination will be given
88937512|NCT01811992|Experimental|Dose escalation of Ad-hCMV-TK and Ad-hCMV-Flt3L|"This protocol is a dose escalation study of Ad-hCMV-TK and Ad-hCMV-Flt3L infused at the time of surgical resection followed by systemic oral administration of valacyclovir in addition to current standard of care with temozolomide and radiotherapy. Eligible subjects will be enrolled in six sequential dosing cohorts:~A= Ad-hCMV-TK: 1x10^10 vp and Ad-hCMV-Flt3L: 1x10^9 vp~B= Ad-hCMV-TK: 1x10^11 vp and Ad-hCMV-Flt3L: 1x10^9 vp~C= Ad-hCMV-TK: 1x10^10 vp and Ad-hCMV-Flt3L: 1x10^10 vp~D= Ad-hCMV-TK: 1x10^11 vp and Ad-hCMV-Flt3L: 1x10^10 vp~E= Ad-hCMV-TK: 1x10^10 vp and Ad-hCMV-Flt3L: 1x10^11 vp~F= Ad-hCMV-TK: 1x10^11 vp and Ad-hCMV-Flt3L: 1x10^11 vp~Subjects will be treated sequentially with a minimum of 21 days before treatment of new subjects within a cohort or before dose escalation."
88937513|NCT01812018|Experimental|Endostar|Endostar, Gemcitabine, Docetaxel
88937514|NCT01812031|Experimental|Lung nodules|"Medical imaging intervention applied on patients included in the trial"
88937515|NCT01812070|Experimental|ACT|Acceptance & Commitment Therapy
88937516|NCT01812070|Active Comparator|CBT|Cognitive Behavioral Therapy
88937517|NCT01812096|Experimental|the pharmacokinetic of bortezomib|the pharmacokinetic and pharmacodynamic, and assessed safety and efficacy of subcutaneous administration of bortezomib
88937518|NCT01812096|Active Comparator|Intravenous|the pharmacokinetic and pharmacodynamic, and assessed safety and efficacy of intravenous administration of bortezomib
88937519|NCT01812122|Experimental|Glimepiride|Starting with Glimepiride. After 3 month, switching to vildagliptin.
88937520|NCT01812122|Experimental|Vildagliptin|Starting with vildagliptin. After 3 month, switching to Glimepiride.
88937521|NCT01812135|Experimental|Group 1: 400U EV71 vaccine without adjuvant|60 infants received 2 doses of 400U EV71 vaccine without aluminium hydroxide adjuvant 28 days apart
88937522|NCT01812135|Experimental|Group 2: 400U EV71 vaccine without adjuvant|60 infants received 1 doses of 400U EV71 vaccine without aluminium hydroxide adjuvant
88937523|NCT01812135|Experimental|Group 3: 400U EV71 vaccine with adjuvant|60 infants received 1 doses of 400U EV71 vaccine with aluminium hydroxide adjuvant
88937524|NCT01812148||Peritoneal Mesotheliomas|Cytoreductive surgery and HIPEC
88937525|NCT01812161|Active Comparator|Acupuncture protocol 1|Acupuncture protocol 1：participants will receive treatment (acupuncture protocol 1, real acupuncture) twice a week; each treatment session can be separated by an interval of 2-4 days, with a maximum of 32 treatment sessions during 16 weeks. Each treatment session lasts for 30 minutes.
88937526|NCT01812161|Sham Comparator|Acupuncture protocol 2|Acupuncture protocol 2：participants will receive treatment (acupuncture protocol 2, sham acupuncture) twice a week; each treatment session can be separated by an interval of 2-4 days, with a maximum of 32 treatment sessions during 16 weeks. Each treatment session lasts for 30 minutes. All participants will receive treatment twice a week; each treatment session can be separated by an interval of 2-4 days, with a maximum of 32 treatment sessions during 16 weeks. Each treatment session lasts for 30 minutes.
88937527|NCT01812187|Experimental|SHIFT Cognitive Behavioral Therapy|Service to Home for Individually-Focused Therapy (SHIFT), a Cognitive Behavioral Treatment for Substance Use Disorders
88937528|NCT01812200|Active Comparator|Dabigatran, Ticagrelor, ASA|Dabigatran 150mg td Ticagrelor 90 mg td ASA 100 mg od for 5 days
88937529|NCT01812200|Active Comparator|Rivaroxaban, Ticagrelor, ASA|Rivaroxaban 20 mg od Ticagrelor 90 mg td ASA 100 mg od for 5 days
88937530|NCT01812200|Active Comparator|Phenprocoumon, Ticagrelor, ASA|Phenprocoumon X mg to reach an INR of 2-3 on day 5 of triple therapy Ticagrelor 90 mg td ASA 100 mg od for 5 days
88937531|NCT01812213|Experimental|[18F]NAV4694|Intravenous [18F]NAV4694 (8.1 mCi) administered once every 18 months
88937532|NCT01812239|Active Comparator|Vaginal Progesterone|Daily administration of Vaginal Progesterone (200mg) Gel between 20 weeks of pregnancy and 34 weeks of pregnancy.
88937533|NCT01812239|Placebo Comparator|Placebo|Daily vaginal administration of Placebo gel (Vanicream)between 20 weeks of pregnancy and 34 weeks of pregnancy.
88937534|NCT01812265|Experimental|PF-06305591 Dose 1|
88937535|NCT01812265|Experimental|PF-06305591 Dose 2|
88937536|NCT01812265|Placebo Comparator|Placebo|
88937537|NCT01812278|Experimental|ACT|Acceptance & Commitment Therapy
89452759|NCT03238118|Placebo Comparator|Psychoeducation|Psychoeducation is an intervention that is characterized by informing the participant of their irritability symptoms. The goal is to teach participants how to understand their symptoms, explain their treatment modalities, recognize signs that may lead to a possible crisis, and provide tips and strategies on how to deal with irritability.
89452760|NCT04934657||normal steps|patients in this group have normal preoperative step counts
89452761|NCT04934657||low steps|patients in this group have low preoperative step counts
89452762|NCT05212805|Experimental|Aerobic Exercise Promotion|This group will be submitted to an aerobic exercise program combined with upper-limb motor training.
89452763|NCT05212805|Active Comparator|Control|This group will be submitted to a standard motor rehabilitation. No aerobic nor sport activity will be delivered to the Control group.
88937538|NCT01812278|Active Comparator|CBT|Cognitive Behavioral Therapy
88937539|NCT01812317|Active Comparator|Real-fire training exercise|Subjects will undergo a 20 minute standardised training exercise in a fire simulation facility.
88937540|NCT01812317|Sham Comparator|Sedentary training session|Subjects will undergo a training exercise where they will remain sedentary for 20 mins in an ambient temperature.
88937541|NCT01812330|Experimental|group 1|Group 1 will be administered with Clopidogrel 75mg daily until the end of the trial
88937542|NCT01812330|Experimental|group 2|Group 2 will be administered with Clopidogrel 150mg daily until the end of trial
89452764|NCT03248960|Experimental|iTreat Flu A+B Test and ellume.lab Flu A+B Test|"Upper respiratory tract samples from participants will be tested with:~iTreat Flu A+B Test; ellume.lab Flu A+B Test; Reverse Transcriptase Polymerase Chain Reaction (RT-PCR); and viral culture."
89452765|NCT03248648|Active Comparator|Neostigmine group|At the end of the surgery patients receive 0.5mg/dose neostigmine +18ml 0.25%bupivacaine in a total volume of 20 ml.
89452766|NCT03248648|Active Comparator|ketamine group|At the end of the surgery patients receive 0.5 mg/kg ketamine+18ml 0.25%bupivacaine in a total volume of 20 ml.
89452767|NCT01563575|Experimental|Intervention Group|fast-track implementation process
89452768|NCT01563575|No Intervention|Control Group|Continue usual routine
88937543|NCT01812330|Experimental|group 3|Group 3 will be administered with Ticagrelor 90mg twice daily until the end of the trial
89452769|NCT03237806|No Intervention|Baseline|In this phase, patients were sedated to the level of Ramsay 6 before Deep sedated or Light sedated
88937544|NCT01812356|Experimental|Argon gas probe|Cryomaze procedure using Argon gas probe
88937545|NCT01812356|Active Comparator|Nitrous oxide probe|Cryomaze procedure using Nitrous oxide probe
88937546|NCT01812369|Experimental|GC|gemcitabine 1250 mg/m2 D1 and D8 cisplatine 70 mg/m2 D1 each cycle every 3 weeks, 4 cycles
88937547|NCT01812369|Active Comparator|MVAC-HD|Methotrexate 30 mg/m2 D1 Vinblastine 3 mg/m2 D2 Doxorubicine 30 mg/m2 D2 Cisplatine 70 mg/m2 D2 G-CSF D3 and D9 Each cycle every 2 weeks, 6 cycles
88937548|NCT01812382|Experimental|Microdialysis arm|Three microdialysis probes will be placed in the thigh of each subject prior to the start of the microdialysis procedure/infusion using a microdialysis device. All subjects will receive Sodium Chloride solution perfused for 30 minutes followed by Retapamulin perfusion for 90 minutes and then Saline perfusion will occur during the washout period.
88937549|NCT01812395|Active Comparator|Ultrasonic Dissector Thyroidectomy|Thyroidectomy using harmonic focus (r) device
88937550|NCT01812395|Active Comparator|Classic thyroidectomy|Patients having conventional thyroidectomy
88937551|NCT01812421|Experimental|Ischemic Stroke or TIA (ISTIA) patients|
88937552|NCT01812434|Experimental|Sildenafil|Patients will be randomized to sildenafil arm taken three times a day for 28 days and then crossed over to the alternate arm.
88937553|NCT01812434|Experimental|Placebo|Subject randomized to either Sildenafil or placebo arm
88937554|NCT01812460|Experimental|Intervention-training-group|"The patients begin training on day 1 of admittance. The training consists of knee extension performed in the sitting position on the bed with a 90 degrees of flexion of the knees. The weight cuffs are tired to the angles with a weight corresponding to 10 RM (the weight lifted 10 times) The weights and exercises are subjected to supervision on daily basis by the physiotherapist. The weight is increased after every session of training if more than 10 rep. can be performed with a given weight. Limitations to exercise is also recorded along with the degree of dyspnoe as assessed by the Borg CR10, possible oxygen supplementation and saturation is recorded before and following exercise.~The weight cuffs are handed over to the patients for self guided exercise during weekends"
89452770|NCT03237806|Experimental|Deep sedation|In this Arm, patients were sedated to the level of Ramsay 5(Deep sedated) by Midazolam IV continuously
89452771|NCT03237806|Experimental|Light sedation|In this Arm, patients were sedated to the level of Ramsay 3(Light sedated)by Midazolam IV continuously
88937555|NCT01812460|No Intervention|Control group|The patients randomized to the control group receive lung physiotherapy from day two of admittance. Lung physiotherapy consists of help to bring up sputum from the bronchi and lungs. The patients are instructed in breath exercises, use of Positiv Ekspiratory Pressure, breathing exercises, cough and pursed lip breathing. The patients are encouraged to spend as little time in bed as possible.
88937556|NCT01812486|Active Comparator|control arm|NID2Gy = 50 Gy Swallowing apparatus: standard dose
88937557|NCT01812486|Experimental|Experimental de escalated arm|NID2Gy = 40 Gy Swallowing apparatus: Dmax ≤ 60 Gy at 1 cm Dmax ≤ 50 Gy at 1.5 cm from the GTV or PSTB edge
89452772|NCT03237728|Experimental|0.06mg/kg,KB and Placebo|Group A:0.06mg/kg,Q8h,Day1-Day7
89452773|NCT03237728|Experimental|0.12mg/kg,KB|Group B:0.12mg/kg,Q8h,Day1-Day7
89452774|NCT03237728|Experimental|0.24mg/kg,KB|Group C:0.24mg/kg,Q8h,Day1-Day7
89452775|NCT03237728|Experimental|Placebos|Group D:Placebos,Q8h,Day1-Day7
89452776|NCT05212415||Children with CP|Children and adolescents with spastic CP are the group of the observational study.
89452777|NCT03241784|Experimental|Treatment arm|All subjects are enrolled in the one arm consisting of infusions of autologous T-regulatory lymphocytes at a dose of 1x10 to the sixth/kg and subcutaneous injections of Interleukin-2 at a dose of 2x10 to the fifth IU/m2 three times a week.
89452778|NCT03242096|Experimental|Sirolimus coated balloon|Treatment of in-stent restenosis with a sirolimus coated balloon
89452779|NCT03242096|Active Comparator|Paclitaxel coated balloon|Treatment of in-stent restenosis with a paclitaxel coated balloon
89452780|NCT05211557|Experimental|fhB7H3.CAR-T cells|In phase I study, 9 enrolled patients diagnosed with advanced ovarian cancer will receive one-time infusion of fhB7H3.CAR-Ts at the doses of 1×10^6/kg, 3×10^6/kg and 5×10^6/kg, 3 patients for each dose. To further confirm the therapeutic efficacy, in phase II study, 6 enrolled patients will receive an optimal dose (balancing effectiveness and toxicity) of fhB7H3.CAR-Ts. Prior to receiving the infusions, patients will undergo lymphodepletion with fludarabine and cyclophosphamide.
89452781|NCT03248336|Experimental|Vision therapy group|Twelve, 60-minute, weekly visits of office-based vergence/accommodation therapy will be administered by a trained therapist combined with procedures to practice at home (15 minutes, 5 times per week). This treatment sequence is a well-accepted approach for treatment of CI and has been successfully implemented in previous studies. Fifteen minutes of home-based therapy was prescribed to be performed 5 days per week, and compliance with home-based therapy was monitored at each visit by the therapist
89452782|NCT04716803|Experimental|Bone marrow aspiration concentrate using the Angel System|"Bone marrow aspirate concentrate (BMAC) will be administered via injection to the knee of interest on day 14 of the study.~Bone marrow aspiration will be concentrated using the Angel System."
89452783|NCT03241472|Experimental|Lertozole|oral tablets 5 mg start from third day cycle for 5 days
89452784|NCT03241472|Active Comparator|clomiphene plus N- acetyl cystiene|clomiphene 100 mg plus N-acetyl cystiene 600 mg start from third day cycle for 5 days
88937558|NCT01812512|Other|TIPS for HF Intervention HT Training-Charleston-Pre/Post|Group 1 (Charleston): In the proposed intervention, called Teaching for Interactive Patient Self-Management (TIPS) for Heart Failure (HF) , the observations from the previous RRP are used along with best practices from other studies of patient-centered communication in the VA , telephone coaching for chronic disease , problem-solving and counseling skills for telehealth nurse care managers , difficulties identified by patients working with the Health Buddy for telemonitoring , participation in provider-patient communication , essentials of patient education in heart failure process and content, and teach to goal theory to improve HF self-management for patients with low health literacy . Rather than an experimental trial, this implementation quasi-experimental pilot study examines pre- and post-training nurse practices and Veteran outcomes before and after communication skills training. The same intervention will then be delivered to Group 2 HT nurse care coordinators.
88937559|NCT01812512|Other|TIPS for HF Intervention HT Training-Columbia-Pre/Post|Group 2 (Columbia VAMC): To test the TIPS for HF educational intervention sufficiently in a sample not previously exposed to the information, the HT program at Dorn VA Medical Center in Columbia, South Carolina has volunteered to participate as a second study site. There are six nurse care coordinators who will be recruited; the larger number supports recruitment of a comparable number with 25 Veterans with HF to be recruited in the second site for a total of 50 Veterans. Both groups will use a purposeful sampling plan, beginning with an IRB-approved flyer for recruitment. The demographic make-up of the Charleston VAMC group is comparable Columbia HT group in age, race, and NYHA HF class. Also, consistent with an implementation quasi-experimental pilot study, the second site will examine pre-training and post-training nurse care coordinator communication practices and Veteran outcomes before and after communication skills training.
88937560|NCT01812525|Active Comparator|NaCl 3% inhalations + standard therapy|"In this group, patients receive NaCl 3% inhalations ( 4ml QID) together with standard therapy.~Standard therapy includes suctioning nasal secretions, water-electrolyte balance maintenance and oxygen supplementation when needed."
88937561|NCT01812525|Placebo Comparator|Standard therapy|Standard therapy includes suctioning nasal secretions, water-electrolyte balance maintenance and oxygen supplementation when needed
88937562|NCT01812538|Placebo Comparator|Placebo|Placebo
89452785|NCT03241628||Dressing Glove|"Fitting bespoke dressing gloves (viscose Class 1 medical device) and evaluating dressing glove performance in the management of blisters using patient recorded outcome measures. The aim is to obtain proof of concept data for the dressing glove as an acceptable alternative to patch work dressings held in place with bandages.~The study protocol recommends a daily change of the dressing glove but the patients also contribute their preference for frequency of dressing changes."
89452786|NCT03248180||Guided dose reduction (GDR)|Patients in the GDR group will be advised to reduce < 25% of their current dose of antipsychotic agents estimated on a weekly base and follow-up every 4 weeks for at least 12 weeks.
89452787|NCT03248180||Maintenance treatment group (MTG)|Patients in the MTG will be advised to stay on their current dose of antipsychotics throughout the observational period, follow-up every 12 weeks.
89452788|NCT02551666|Active Comparator|Tai Chi exercise intervention|Participants will perform 30-minute Tai Chi sessions (Yang Short form) 3 times a week for 4 weeks.
89452789|NCT02551666|Experimental|Balance recovery training|Participants will practice balance recovery on a modified treadmill for approximately 30-minutes per session, 3 sessions a week for 4 weeks.
89452790|NCT04306523||Observational Cohort|One group of 100 sets of twin infants, observed from 4 months of age until 2years of age.
88937563|NCT01812538|Experimental|Experimental 1|DIC075V 37.5 mg
89452791|NCT05481580||Restored|Molars with a 2nd class restoration or a crown
89452792|NCT05481580||Non-restored|Molars with no restorations
88937564|NCT01812538|Experimental|Experimental 2|DIC075V 75 mg
88937565|NCT01812538|Active Comparator|Active control|Moxifloxacin hydrochloride 400 mg
88937566|NCT01812551|Active Comparator|Alendronate|"128 subjects participated in the study's Phase 2 (1-year double-blind, randomized, placebo-controlled, parallel group study).~65 subjects were randomized to this arm. Oral alendronate dose: 5 mg/day, if body weight ≤25 kg; 10 mg/day, if body weight >25 kg."
89201002|NCT00903825|Experimental|Ultrasound guidance|Local anesthetic before femoral artery puncture will be performed with the use of duplex ultrasound guidance
89452793|NCT05211167|Active Comparator|Group A|Intravenous administration, maintaining the same dose and frequency administrated in the sceening period, for 32 weeks
89452794|NCT05211167|Experimental|Group B|Intravenous administration,50μg, once every two weeks, for 32 weeks
89452795|NCT05477446|Experimental|CD207 CAR-T cells|Cohort 1 will receive 1 x 10^6 CAR+ T cells/kg. Cohort 2 will receive 3 x 10^6 CAR+ T cells/kg. Cohort 3 will receive 5 x 10^6 CAR+ T cells/kg. Cohort 4 will receive 1 x 10^7 CAR+ T cells/kg.
89452796|NCT03241394||Lean|Individuals with Body Mass Index (BMI) = 18.5 - 25.0 Kg/m2
89452797|NCT03241394||Obese with MS|Individuals with BMI ≥ 30.0 Kg/m2 and metabolic syndrome (MS) MS was defined as the presence of three or more of the following criteria: 1) waist circumference ≥ 102 cm in men and ≥ 88 cm in women, 2) serum triglycerides ≥ 150 mg/dL, 3) high density lipoprotein-cholesterol (HDL-C) < 40 mg/dl in men and < 50 mg/dl in women, 4) systolic blood pressure (SBP) ≥ 130 mmHg or diastolic blood pressure (DBP) ≥ 85 mmHg or antihypertensive drug treatment, 5) fasting glucose ≥ 100 mg/dL
89452798|NCT03241394||Obese without MS|Individuals with BMI ≥ 30.0 Kg/m2 but not MS
89452799|NCT03248102|Experimental|Patients with suspected appendicitis|Patients with suspected appendicitis Aged 5 and up to their 16th birthday on arrival to A&E
89452800|NCT03903562|Experimental|V503|V503 administered as a 0.5 mL intramuscular injection at Day 1, Month 2 and Month 6.
89452801|NCT03237416|Experimental|BAY1841788/Healthy subjects|Period 1: intake of Midazolam and Dabigatran etexilate at day 1 followed by Period 2: intake of Darolutamide at days 1-11 (twice daily), intake of dabigatran etexilate at days 3 and 9, intake of Midazolam at day 9
89452802|NCT05211011|Experimental|Fosfomycin Arm|Include intravenous fosfomycin in the treatment of PJI according to predetermined algorithm
89452803|NCT05481346|Experimental|Multidomain training group|Participants will use free weights and functional materials to work the main muscle groups. In addition, they will perform cardiorespiratory training and cognitive training with proposed tasks. Participants will follow the planned training progression. The researchers will record the number of sets completed and the load lifted for each exercise for each participant and the perception of effort in each class.
89452804|NCT05481346|No Intervention|Control group|The control group did not receive a training program and were asked not to modify their physical activity habits.
89452805|NCT03247946|Active Comparator|Intervention group|intervention: upright head position
89452806|NCT03247946|No Intervention|Control group|no feeding position instructions
88937567|NCT01812551|Placebo Comparator|Placebo|"128 subjects participated in the study's Phase 2 (1-year double-blind, randomized, placebo-controlled, parallel group study).~63 subjects were randomized to this arm. Oral placebo (inactive pills)."
88937568|NCT01812564|Placebo Comparator|PPP|"Placebo: Platelet Poor Plasma~Under sterile conditions, patients will receive under ultrasound guidance 3 times, 1 cc injection of PPP each, administered by a sports medicine physician (total 3 cc PPP).~Following the completion of the injections (treatment or control) physiotherapy will commence. Physiotherapy protocols will be based on current ASPETAR best practice models (usual care)"
88937569|NCT01812564|Active Comparator|PRP|"Biological: Platelet Rich Plasma~Under sterile ultrasound conditions, patients will receive under ultrasound guidance 3 times, 1 cc injection of PRP each, administered by a sports medicine physician (total 3 cc PRP).~Following the completion of the injections (treatment or control) physiotherapy will commence. Physiotherapy protocols will be based on current ASPETAR best practice models (usual care)"
88937570|NCT01812564|No Intervention|Physiotherapy|"These patients will not receive an injection.~Following the inclusion physiotherapy will commence. Physiotherapy protocols will be based on current ASPETAR best practice models (usual care)"
88937571|NCT01812577||Thoracic paravertebral block (TPVB)|Twenty patients receiving thoracic paravertebral block at level of T7, before the interventistic procedure.
88937572|NCT01812577||Deep Sedation (DS)|Twenty patients receiving local and intravenous anesthesia during the procedure.
88937573|NCT01812590|No Intervention|Resting Trial|Pancreatic endocrine function will be determined the morning following a day where no exercise is performed
88937574|NCT01812590|Experimental|Exercise Trial|Pancreatic endocrine function will be determined the morning following a day where a 1-hour aerobic exercise is performed at 65% of pre-determined HRmax (maximal heart rate measured during an incremental work-load exercise test to volitional exhaustion)
88937575|NCT01812629|Experimental|Experimental Infant Formula|Complete peptide amino acid-based infant formula
88937576|NCT01812642|Experimental|JNJ-37822681 10 milligram|JNJ-37822681 oral capsule will be administered at a starting dose of 10 milligram (mg) twice daily for the first 3 days and thereafter dose will be titrated from Day 3 to Day 10 up to 80 mg per day and will be continued at same dose up to Day 14.
88937577|NCT01812642|Experimental|JNJ-37822681 20 milligram and placebo|JNJ-37822681 oral capsule will be administered at a starting dose of 20 mg once daily for the first 3 days and thereafter dose will be titrated from Day 3 to Day 10 up to 80 mg per day and will be continued at same dose up to Day 14. Matching Placebo will be administered orally in the evening for 14 days (12 hour post JNJ-37822681 administration).
88937578|NCT01812720|Experimental|Treatment (carfilzomib, dexamethasone)|Patients receive carfilzomib IV over 30 minutes and dexamethasone PO on days 1, 2, 15, and 16. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
88937579|NCT01812746|Experimental|BIND-014|
88937580|NCT01812772|Experimental|Double J-stent with a long tether|Following ureteroscopy patients will have placed a double J-stent with a long tether.
88937581|NCT01812772|Active Comparator|Double J-stent without a long tether|Following ureteroscopy patients will have a double J-stent placed without a long tether
88937582|NCT01812798|Active Comparator|Peanut|"Double Blind Placebo Controlled Food Challenge 5 gram peanut challenge~17 doses of peanut will be administered. Dose will be increased every 20-30 minutes. All doses listed are in g of peanut flour.~0.1 0.25 0.5 0.75~1 2.5 5 10 25 50 100 250 500 750 1000 2500 5000"
88937583|NCT01812798|Placebo Comparator|Placebo|Double Blind Placebo Controlled Food Challenge (No peanut - placebo only)
89452807|NCT05470894||COVID-19 Vaccination Group|Subjects who have received at lease one dose of approved COVID-19 vaccine
89452808|NCT04534049|Experimental|Intensive strength training (IST)|
89452809|NCT04534049|Experimental|Strength Endurance training (SET)|
89452810|NCT04534049|Other|Flexibility training (FT)|
89452811|NCT03237338|Experimental|Insomnia-ture acupuncture|"True acupuncture at the Magical-door, Si-shen-cong, Shen-ting, Local-cave acupoints will be administered on CID patients Intervention: Procedure: true acupuncture"
89452812|NCT03237338|Sham Comparator|Insomnia-sham acupuncture|"Sham acupuncture at the Magical-door, Si-shen-cong, Shen-ting, Local-cave acupoints will be administered on CID patients Intervention: Procedure: true acupuncture"
89452813|NCT04243343|Experimental|Intervention + Standard of care|Acupuncture with electrostimulation plus standard of care prescribed home exercise program.
89452814|NCT04243343|Active Comparator|Standard of care|Standard of care prescribed home exercise program.
89452815|NCT03237104||acute spondylolysis|Athletes who meet the inclusion criteria and consent to participate in the pilot study will be referred directly to PT care for 2 times per week until cleared to return to sport.
89452816|NCT04486820||Chordoma|Patients diagnosed with chordoma
89452817|NCT05210855|Experimental|Patients with head trauma|
88937584|NCT01812824|Experimental|Intervention (Virtual Patient Advocate)|Participants assigned to the Intervention (Virtual Patient Advocate) arm will have access to the Virtual Patient Advocate system on-line for 6 months; they will be encouraged, but not required, to log on once a week.
88937585|NCT01812824|No Intervention|Control (Letter)|Participants in the Control (Letter) arm will take the online Preconception Risk Assessment at baseline, but not have access to the Virtual Patient Advocate system during the 6 month study period. They will be sent a list of the Preconception Risks identified through their answers to the Risk Assessment, which they can choose to share with their healthcare provider(s).
88937586|NCT01812850||Invisalign®|All subjects in the study (estimation of 40 subjects) will be treated using the Invisalign® appliance.
88937587|NCT01812863|Experimental|Supraclavicular Nerve Block|Maximum dose of 5 mL of 0.25% bupivacaine, and we base the dose on a ml/ kg (0.2 ml/kg) with a maximum dose not to exceed 2.5 mg/kg. Bupivacaine is given with 1:200,000 epinephrine
88937588|NCT01812863|Placebo Comparator|No Nerve Block|A band-aid will be placed on all patients where a supraclavicular nerve block would have been inserted, and parents will be asked to leave the band-aid on for 3 days to maintain the blindness to the treatment type by the patient.
88937589|NCT01812889|Active Comparator|Part 2|10 women diagnosed with BV, 10 diagnosed with VVC will be randomized to receive either TOL-463 gel or TOL-463 ovules administered intravaginally once daily for 7 consecutive days
88937590|NCT01812889|Active Comparator|Part 1|20 Healthy women randomized, two-way crossover design will receive a single dose of TOL-463 gel and ovule intravaginally, separated by a minimum of 7 day washout period between administrations
88937591|NCT01812902|Experimental|Extended LND|Radical Prostatectomy with extended lymphadenectomy
88937592|NCT01812902|Active Comparator|Limited LND|Radical Prostatectomy with Limited lymphadenectomy
88937593|NCT01812915|Experimental|Cylindrical-shape cuff ETT (Group C)|Control group: Mallinckrodt HiLo(TM) endotracheal tube. Intracuff pressures of the tubes every 10 minutes, Adult patients under general anesthesia with Mallinckrodt Hi-Lo(TM) tube.
88937594|NCT01812915|Experimental|Tapered-shape cuff ETT (Group T)|Experimental group: Mallinckrodt TaperGuard(TM) endotracheal tube. Intracuff pressures of the tubes every 10 minutes, Adult patients under general anesthesia with Mallinckrodt TaperGuard(TM) tube.
88937595|NCT01812928|No Intervention|Gel only|This group will be given only intraurethral gel during flexible cystoscopy.
88937596|NCT01812928|Experimental|Diclofenac and Gel|This group will also receive intraurethral gel during cystoscopy but additionally diclofenac suppository will be given per rectally one hour before procedure as preemptive analgesia.
88937597|NCT01812941|Other|Burn: blood collection|Procedure: Blood draws as the intervention.
88937598|NCT01812941|Other|trauma: blood collection|blood to be collected at different time intervals. Blood draw as the intervention
88937599|NCT01812941|Other|healthy volunteers: blood collection|Blood draws as the intervention
88937600|NCT01812980|Experimental|Trivalent Inactivated Influenza Vaccine|"Single dose, intramuscular injection from a pre-filled syringe~WHO recommendation for influenza vaccines for 2013 for the Southern-hemisphere included the following vaccine strains:~an A/California/7/2009 (H1N1)pdm09-like virus;~an A/Victoria/361/2011 (H3N2)-like virus; - a B/Wisconsin/1/2010-like virus."
88937601|NCT01812993|No Intervention|Control|No ventilatory treatment; standard stroke care
88937602|NCT01812993|Experimental|Active|Non-invasive ventilatory treatment with auto-BPAP plus standard stroke care
88937603|NCT01813006|Active Comparator|Omega-3|Omega-3 fatty acids
88937604|NCT01813006|Placebo Comparator|Placebo|Placebo/olive oil
88937605|NCT01813032||Firefighters|20 firefighters will attend for vascular assessments following a minimum of 48 hours off-duty.
88937606|NCT01813032||Police Officers|20 police officers will attend for vascular assessments following a minimum of 48 hours off-duty.
88937607|NCT01813045||Chronic Coronary Occlusion group|"We will also recruit 10 patients with an angiographically documented chronic (>6 months) proximal coronary artery occlusion that has not been revascularised but has extensive collateral coronary blood flow.~We will perform CT-coronary angiogram, cardiac MRI scan and CT-PET scan."
88937608|NCT01813045||MI (non-revascularised)|"These patients (n=15) will undergo Cardiac MRI, CT-PET scan and CT-coronary angiogram scan 2 weeks following their myocardial infarction.~They will undergo a second CT-PET scan 9 weeks following their myocardial infarction.~They will undergo a second cardiac MRI scan 6 - 12 months following their myocardial infarction."
88937609|NCT01813045||MI (revascularised)|"These patients (n=15) will undergo Cardiac MRI, CT-PET scan and CT-coronary angiogram scan 2 weeks following their myocardial infarction.~They will undergo a second CT-PET scan 9 weeks following their myocardial infarction.~They will undergo a second cardiac MRI scan 6 - 12 months following their myocardial infarction."
88937610|NCT01813084|Experimental|Part A: single dose escalation|
89452818|NCT05481268|Experimental|Kinesiotaping Group|In the Kinesiotaping Group patients had muscle technique-inhibition method. An 'I' shaped tape was used for both SCM and upper trapezius.
89452819|NCT05481268|Experimental|Stretching Group|The patient was stretched in a relaxed and supported position and physiotherapist positioned the patient passively for stretching.
89452820|NCT05481268|Other|Control Group|Control Group patients, after the assessment by the dentist, the treatment method approved by the dentist was performed.
89452821|NCT04103333|Experimental|Angelman Syndrome: Group 1|Participants aged 0-6 years old with Angelman Syndrome will undergo lumbar puncture (LP) for CSF and blood collection while under general anesthesia or conscious sedation during or after a prescheduled procedure unrelated to the study.
89452822|NCT04103333|Experimental|Angelman Syndrome: Group 2|Participants aged 7-12 years old with Angelman Syndrome will undergo lumbar puncture (LP) for CSF and blood collection while under general anesthesia or conscious sedation during or after a prescheduled procedure unrelated to the study.
89452823|NCT04103333|Experimental|Angelman Syndrome: Group 3|Participants aged 13-18 years old with Angelman Syndrome will undergo lumbar puncture (LP) for CSF and blood collection while under general anesthesia or conscious sedation during or after a prescheduled procedure unrelated to the study.
89452824|NCT04103333|Experimental|Angelman Syndrome: Group 4|Participants aged 19-50 years old with Angelman Syndrome will undergo lumbar puncture (LP) for CSF and blood collection while under general anesthesia or conscious sedation during or after a prescheduled procedure unrelated to the study.
89452825|NCT04103333|Experimental|Dup15q Syndrome: Group 1|Participants aged 0-6 years old with Dup15q Syndrome will undergo lumbar puncture (LP) for CSF and blood collection while under general anesthesia or conscious sedation during or after a prescheduled procedure unrelated to the study.
88937611|NCT01813084|Experimental|Part B: 14 day repeat dose escalation (healthy volunteers)|
88937612|NCT01813084|Experimental|Part C: 14 day repeat dose (asthma patients)|
88937613|NCT01813097||combination iodine 125 seed implants|30 cases should be treated with iodine 125 seed implants 0.5 mc transperineal prostate implant +Zoladex 3.6mg im 1/28d (LHRH agonist, 3.6mg subcutaneous injection 1/4weeks).
88937614|NCT01813097||LHRH agonists|30 cases should be treated with Zoladex 3.6mg im 1/28d (LHRH agonist, 3.6mg subcutaneous injection 1/4weeks).
88937615|NCT01813123|No Intervention|Control|
88937616|NCT01813123|Experimental|Intervention|RealTeen
88937617|NCT01813136|Active Comparator|Continuous pazopanib (Arm A)|Daily oral administration of pazopanib 800mg (28 days cycles) from randomization until progression (according to RECIST 1.1) under treatment, after an initial period of 6 cycles (28 days) of daily administration of pazopanib 800mg from inclusion until randomization
88937618|NCT01813136|Experimental|Intermittent pazopanib (Arm B)|"Temporary discontinuation of pazopanib at randomization, after an initial period of 6 cycles (28 days) of daily administration of pazopanib 800mg from inclusion until randomization. Pazopanib will be reintroduced for 6 cycles of 28 days, with daily administration of pazopanib 800mg, as soon as the patient relapses (progressive disease according to RECIST 1.1). At the end of this additional 6 cycles, study drug will be stopped a second time.~This sequential scheme will be maintained until the patient experiences on-treatment progression"
88937619|NCT01813162|Active Comparator|Tenofovir 1% gel|Participants will vaginally insert 1 applicator of TFV gel twice a day for 7 days, with each dose inserted approximately 12 hours after the previous dose (for a total of 13 doses). Each applicator contains 4.4 gm of TFV 1% gel.
88937620|NCT01813162|Active Comparator|Vaginal product alone|"Participants will use their assigned vaginal product for 5 to 21 days depending on the dosing instructions for the particular product:~Terconazole 0.4% vaginal cream: once a day for seven days. 1 applicator (5 gm) of terconazole cream contains 20 mg terconazole.~Metronidazole gel: once a day for 5 days. 1 applicator (5 gm)of metronidazole gel contains 37.5 mg metronidazole.~Contraceptive IVR: insert ring and leave in place for 21 days; return to clinic for removal on day 21. The IVR contains two active components, etonogestrel (progestin) and ethinyl estradiol (estrogen)."
89201003|NCT00899535||Group 1|This research study is looking at the cancer genome using tumor samples from patients with stage I or stage II non-small cell lung cancer treated on clinical trial ACOSOG-Z0030. Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
89452826|NCT04103333|Experimental|Dup15q Syndrome: Group 2|Participants aged 7-12 years old with Dup15q Syndrome will undergo lumbar puncture (LP) for CSF and blood collection while under general anesthesia or conscious sedation during or after a prescheduled procedure unrelated to the study.
89452827|NCT04103333|Experimental|Dup15q Syndrome: Group 3|Participants aged 13-18 years old with Dup15q Syndrome will undergo lumbar puncture (LP) for CSF and blood collection while under general anesthesia or conscious sedation during or after a prescheduled procedure unrelated to the study.
89452828|NCT04103333|Experimental|Dup15q Syndrome: Group 4|Participants aged 19-50 years old with Dup15q Syndrome will undergo lumbar puncture (LP) for CSF and blood collection while under general anesthesia or conscious sedation during or after a prescheduled procedure unrelated to the study.
89452829|NCT04486664|Experimental|Mediterranean diet|Mediterranean diet twice per day for four weeks
89452830|NCT04486664|Placebo Comparator|Conventional diet|Conventional diet for four weeks
89015472|NCT06259344|Active Comparator|Fragmented Pain Neuroscience Education + Manual Therapy + Orofacial and Neck Exercises|All participants in this arm will initially receive eight sessions in which a workshop on PNE will be administered and discussed. A power-point presentation with metaphors and animated videos will be employed. The PNE program will be held in 8 sessions of 15 minutes each. Two protocols of Orofacial Exercises and Manual Therapy and of Neck Motor Control will be adopted in the present study. The exercises will be administered during six weeks, twice a week. One session will run in the outpatient clinic and the other will be home based. Half of the sessions will consist of orofacial therapy and exercises and the other half neck motor control exercises. Each exercise and technique will be administered 10 times for 10 seconds.
89015473|NCT06259344|Experimental|Condensed Pain Neuroscience Education + Manual Therapy + Orofacial and Neck Exercises|All participants in this arm will initially receive two sessions in which a workshop on PNE will be administered and discussed. A power-point presentation with metaphors and animated videos will be employed. The PNE program will be held in 2 sessions of 60 minutes each. Two protocols of Orofacial Exercises and Manual Therapy and of Neck Motor Control will be adopted in the present study. The exercises will be administered during six weeks, twice a week. One session will run in the outpatient clinic and the other will be home based. Half of the sessions will consist of orofacial therapy and exercises and the other half neck motor control exercises. Each exercise and technique will be administered 10 times for 10 seconds.
89015474|NCT06259331|Experimental|Cohort 1|Up to 15 healthy, lactating women will be enrolled in the study.
89015475|NCT06259318|Experimental|Intervention|
89015476|NCT06259318|No Intervention|Control|
89015477|NCT06259305|Experimental|Creation of a memory track combined with the baby's heartbeat|"A memory track will be created by the music therapist with the family and this will be overlaid with a recording of the baby's heartbeat, provided by the family.~This recording will be placed inside a memory bear and given to the family to keep.~This will be offered to form part of the memory making process alongside existing processes."
89015478|NCT06259279|Experimental|Intervention Group|Patients in the intervention group will receive a 32-week exercise-based intervention that includes supervised and group-based exercise training in the hospital, twice a week. Each session lasts approximately 30 minutes.
89015479|NCT06259279|No Intervention|Control Group|standard care. Patients in the control group are referred to the municipal standard rehabilitation programs if the patient so wishes.
89015480|NCT06259266|Experimental|valce arm|"Two strategies are compared in a parallel plan : a valve arm  (implementation of TEGO ® valve associated with interdialytic saline locks) and a control arm ( standard care )."
89015481|NCT06259266|Other|control arm|"Two strategies are compared in a parallel plan : a valve arm  (implementation of TEGO ® valve associated with interdialytic saline locks) and a control arm ( standard care )."
89015482|NCT06259253||Observational Cohort 1 - Patient/Provider|Participant will complete a computer-based questionnaire about your age, gender, income, highest level of education, patient experience, medical mistrust, social support and health care access.
89015483|NCT06259253||Observational Cohort 2 - Patient/Provider|Participant will complete a computer-based questionnaire about your age, gender, income, highest level of education, patient experience, medical mistrust, social support and health care access.
89015484|NCT06259240|Active Comparator|Prone Plank Exercises|Forty two post partum woman will recieve progressive prone plank exercises, three times a week, for eight weeks, and with a moderate hard intensity.
89015485|NCT06259240|Sham Comparator|Electrical Stimulation|Forty two post partum woman will recieve electrical stimulation for the rectus abdominis muscle day after day for 8 weeks. The patient position was relaxed in the crook lying position. The session parameters were 30 minutes/session with a low frequency current (50-100Hz).
89015486|NCT06259227|Experimental|Intervention group|During the primary rehabilitation program, the intervention group will receive 2-3 individualized cardiorespiratory fitness training sessions per week.
89015487|NCT06259227|No Intervention|Control group|The control group will receive usual care.
89015488|NCT06259214|No Intervention|regular brushing|regular brushing
89452831|NCT03247868|Experimental|Botulinum toxin+SPRInt protocol|patients affected by cervical dystonia receive botulinum toxin treatment (EMG-US guided injections in dystonic muscles) for two times at T0 and T2; after T2 patients are treated also with SPRInt rehabilitation protocol based on motor learning techniques.
89452832|NCT04207229||CODMAN CERTAS Programmable Valves|CODMAN CERTAS Plus Programmable Valve, CODMAN CERTAS Plus Small Inline Programmable Valve, and CODMAN CERTAS Plus Right Angle Programmable Valve.
89452833|NCT04487288|Experimental|CEUS with fusion|Control group: The historic cohort is used to compare the results of the biopsy using fusion only technique from 2013 to 2019.
89015489|NCT06259214|Active Comparator|15% HCl gel|15% HCl gel (Icon Etch, DMG, Hamburg, Germany) was applied to the WSLs for 2 min, followed by water rinsing and drying with compressed air (each for 30 s)
89015490|NCT06259214|Active Comparator|37% H3PO4 gel|37% H3PO4 gel (Scotchbond Etchant, 3M ESPE, St. Paul, MN, USA) was applied to the WSLs for 30 s, which were then water rinsed and dried with compressed air (each for 30 s)
89015491|NCT06259214|Active Comparator|Er:YAG laser|Er:YAG laser (Fotona AT Fidelis III, Ljubljana, Slovenia) was applied for 10 s with the following operating parameters: energy 300 mJ, frequency 10 Hz, wavelength 2.94 μm, short pulses of 10 pulses per second, pulse time 180 ms, distance 1 mm away from lesion, water spray cooling 80%.
89015492|NCT06259201|Experimental|Vagus Nerve Stimulation (VNS)|"Single-subject design: ABA, ABBA, or ABBBA~This study allows for a flexibility in the duration of research participation depending on one's response. The participant will be able to select one of the three design options (1, 2, or 3 months of VNS twice per day) in consultation with the study staff. That is, after the initial 1-month trial of VNS, the participant may choose to extend the VNS two more times (i.e., 1 or 2 months), for a total of 90 days."
89201004|NCT00903903||1|RA patients with at least one active synovitis
89201005|NCT00903903||2|Non-RA patients with at least one active synovitis
89201006|NCT00903981|Experimental|Avanafil 100mg|
89201007|NCT00903981|Experimental|Avanafil 200mg|
89201008|NCT00903981|Placebo Comparator|Placebo|
89201009|NCT00904059|Experimental|Treatment Group A|
89201010|NCT00904059|Experimental|Treatment Group B|
88937621|NCT01813162|Experimental|Vaginal product and Tenofovir 1% gel|"Tenofovir gel: Participants will vaginally insert 1 applicator of TFV gel twice a day for 7 days, with each dose inserted approximately 12 hours after the previous dose (for a total of 13 doses). Each applicator contains 4.4 gm of TFV 1% gel.~In addition, Participants will use their assigned vaginal product for 5 to 21 days depending on the dosing instructions for the particular product:~Terconazole 0.4% vaginal cream: once a day for seven days. 1 applicator (5 gm) of terconazole cream contains 20 mg terconazole.~Metronidazole gel: once a day for 5 days. 1 applicator (5 gm)of metronidazole gel contains 37.5 mg metronidazole.~Contraceptive IVR: insert ring and leave in place for 21 days; return to clinic for removal on day 21. The IVR contains two active components, etonogestrel (progestin) and ethinyl estradiol (estrogen). Use of TFV gel will begin on day 15 of IVR use."
88937622|NCT01813175|Active Comparator|Intervention Group I|Regular non-hydrolysed cow's milk based infant formula with synbiotics mixture I
88937623|NCT01813175|Active Comparator|Interventional Group II|Regular non-hydrolysed cow's milk based infant formula with synbiotics mixture II
88937624|NCT01813175|Placebo Comparator|Control Group|Regular non-hydrolysed cow's milk based infant formula
88937625|NCT01813175|No Intervention|Reference Group|Exclusively breast-fed infants
89452834|NCT04094519|Experimental|digoxin plus rosuvastatin and enzalutamide|Participants will receive a single oral dose cocktail containing 0.25 mg digoxin and 10 mg rosuvastatin on Day 1 and 64. A single oral dose of placebo to match enzalutamide will be given on Day 1 and 160 mg enzalutamide once daily on Days 8 through 71.
89452835|NCT03241238|Other|Regular Brownie|Regular Brownie For the regular brownie condition (RB), participants will consume the brownie preload and then consume a meal 20 minutes later.
89452836|NCT03241238|Other|Psyllium Brownie|For the psyllium brownie (PG), participants will consume a psyllium brownie and then consume a meal 20 minutes later.
89452837|NCT03241238|Other|β-glucan Brownie|For the β-glucan Brownie (BG), participants will consume a β-glucan Brownie preload and then consume a meal 20 minutes later
89452838|NCT03307564|Experimental|TraceIT tissue marker injection|The TraceIT injection will be performed during the endoscopic fiducial placement which is the standard of care. CTs to serially confirm TraceIT positioning will be performed on the same day during patient visits for their middle (2nd or 3rd fraction) and last (5th fraction) radiation therapy treatments
89452839|NCT02454452|Active Comparator|Saphenous vein stripping|Saphenous venous stripping surgical technique
89452840|NCT02454452|Active Comparator|CHIVA|conservative hemodynamic treatment venous insufficiency (CHIVA)
89452841|NCT02454452|Experimental|Radiofrequency|Radiofrequency treatment applied to the vein with VNUS Closure Fast catheter
89452842|NCT03061175|Experimental|Arm I (Web-Based Contralateral Prophylactic Mastectomy CPM-DA)|Patients receive a website address, a secure username and password, and instructions for using the web-based Contralateral Prophylactic Mastectomy (CPM)- Decision Aid (DA).
88937626|NCT01813188|Experimental|ABM seeded onto a porous TCP and DBM|ABM seeded onto a porous TCP and DBM
88937627|NCT01813188|Active Comparator|autologous bone graft|autologous bone graft
88937628|NCT01813201|Active Comparator|Testosterone undecanoate|Testosterone undecanoate intramuscular long-acting, 1000 mg/dose, administered at inclusion and every 12 weeks for 9 months (4 dose)
88937629|NCT01813201|Placebo Comparator|Saline isotonic solution (Placebo)|Placebo (saline isotonic solution)administered at inclusion and every 12 weeks for 9 months (4 dose) (control group).
88937630|NCT01813240|Experimental|Minocycline, Spinal Tumor patients, quality of life|
88937631|NCT01813240|Experimental|Minocycline, Trauma patuents, quality of life|
88937632|NCT01813240|Placebo Comparator|Placebo, Trauma patients, quality of life|
88937633|NCT01813240|Placebo Comparator|Placebo, Spinal cord tumors, quality of life|
88937634|NCT01813253|Experimental|Irinotecan and nimotuzumab|Adminitration of irinotecan 150 mg/m2 IV once every 2 weeks and nimotuzumab 400 mg IV once weekly
88937635|NCT01813253|Active Comparator|Irinotecan|Administration of irinotecan 150 mg/m2 IV once every 2 weeks
88937636|NCT01813266||Usual practice in screening for Hepatitis C virus.|Three clinics in this group will use this approach.
88937637|NCT01813266||USPTF risk factors to screen for chronic HCV infection.|3 internal medicine clinics will use this screening strategy.
88937638|NCT01813266||USPTF/CDC recommendations to screen for chronic HCV infection.|3 internal medicine clinics.
88937639|NCT01813279|Experimental|patients|
88937640|NCT01813318|Placebo Comparator|Placebo/sugar pill|Placebo will be dosed similar to acamprosate, in terms of dosage form, frequency and duration.
89452843|NCT03061175|Experimental|Arm II (Usual Care)|Patients undergo usual care available to patients considering CPM and receive information from a medical oncologist about CPM.
88937641|NCT01813318|Active Comparator|Acamprosate|"Acamprosate: The maximum dose of acamprosate to be used in this study is 1998 mg per day for those subjects weighing greater than 50kg and 1332 mg per day for those less weighing less than 50kg.~Other Name: Campral"
88937642|NCT01813331||Chronic Heart Failure Patients|Chronic Heart Failure patients older than 65 years, which accept to participate to the study and give their informed written consent and consecutively refer to the A.R.C.A Campania Cardiologists in the pertaining healthcare districts.
88937643|NCT01813383||HLA-DR3-DQ2 patients|Patients with HLA-DR3-DQ2 haplotype
88937644|NCT01813383||HLA-DR7-DQ2 patients|Patients with HLA-DR7-DQ2 haplotype
89452844|NCT02359838|Other|Usual Care|Frail/pre-frail hematologic oncology patients receive usual care
89452845|NCT02359838|Active Comparator|Geriatrician Co-Management|Frail/pre-frail hematologic oncology patients receive co-management by a geriatrician
89452846|NCT02189798|Experimental|Newly Implanted Group|HiRes 90K™ Advantage implant with HiFocus™ Mid-Scala electrode will be implanted in adults with partial deafness. Patients retaining considerable low frequency acoustic hearing after the surgery, will be fitted with the EAS sound processor.
89452847|NCT02189798|Experimental|Existing Implanted Group|Adults unilaterally implanted with HiRes 90K™ Advantage implant with HiFocus™ Mid-Scala electrode with partial deafness will be fitted with the EAS sound processor.
89452848|NCT02189798|Experimental|EAS Extended Use Arm|Adults who are unilaterally implanted with HiRes 90K™ Advantage implant with HiFocus™ Mid-Scala electrode with partial deafness and completed the 12 Month visit using the EAS sound processor in either the Newly Implanted Group or Existing Implanted Group.
89452849|NCT03061097|Experimental|Treatment (autologous fecal microbiota preparation)|"Participants randomized into the treatment arm will receive a single dose of autologous fecal microbiota preparation (auto-FMP) via enema following an infectious episode requiring antibiotics, with follow-up at day 3, 7, 28, and 6 months.~Route of Administration: Enema Dosing Regimen: 125mL x 1 dose"
88937645|NCT01813396|Experimental|joint mobilization/massage|"joint mobilization: End-range joint mobilization~massage: massage twice a week on the identified muscle(s) of the involved shoulder about 6 minutes for each muscle for 3 months. The techniques of massage include petrissage for 3 minutes and rolling for 3 minutes of soft tissues"
88937646|NCT01813396|Experimental|joint mobilization/shoulder physical activity guide|joint mobilization: End-range joint mobilization shoulder physical activity guide: shoulder physical activity guide is based on the appropriate cut off activity level identified in the predication rule
88937647|NCT01813448|Experimental|Cohort 1: Fidaxomicin low dose in Japanese males|
88937648|NCT01813448|Experimental|Cohort 2: Fidaxomicin high dose in Japanese males|
88937649|NCT01813448|Experimental|Cohort 3: Fidaxomicin high dose in Caucasian males|
88937650|NCT01813448|Placebo Comparator|Matching Placebo in Caucasian males|
88937651|NCT01813448|Placebo Comparator|Matching Placebo in Japanese males|
88937652|NCT01813461|Experimental|14C-labeled prodrug isavuconazonium sulfate|single dose
88937653|NCT01813487|Other|HBsAg vaccine with Entecavir|
88937654|NCT01813500||IBD Patients|Subjects with Crohn's Disease or Ulcerative colitis. IBD patients will be asked to provide a blood and stool sample.
88937655|NCT01813500||Control Subjects|Subjects without Crohn's Disease or Ulcerative Colitis. Controls will also be asked to provide a blood and stool sample.
88937656|NCT01813513|Experimental|Group A: IDX719 then IDX719/Simeprevir|Healthy participants take IDX719 150 mg once daily (QD) on Days 1-7 and IDX719 150 mg QD + simeprevir 150 mg QD on Days 8-14.
88937657|NCT01813513|Experimental|Group B: Simeprevir then IDX719/Simeprevir|Healthy participants take simeprevir 150 mg QD on Days 1-7 and IDX719 150 mg QD + simeprevir 150 mg QD on Days 8-14.
88937658|NCT01813513|Experimental|Group C: IDX719|Healthy participants take IDX719 150 mg QD on Days 1-14.
88937659|NCT01813513|Experimental|Group D: IDX719/Simeprevir|Participants from Groups A and B will be asked to return for Group D. Participants take IDX719 and simeprevir QD on Days 1-7 to determine the impact of food on single-dose (on Day 1) and steady state (Day 7) PK.
88937660|NCT01813513|Experimental|Group E: High-Fat then Low-Fat PK|Participants from Group C will return to determine the PK of IDX719 after high-fat (Day 1) and low-fat (Day 7) meals (Days 2-6 are drug-free washout).
88937661|NCT01813513|Experimental|Group F: Low-Fat then High-Fat PK|Participants from Group C will return to determine the PK of IDX719 after low-fat (Day 1) and high-fat (Day 7) meals (Days 2-6 are drug-free washout).
88937662|NCT01813526|Experimental|Experimental Infant Formula|Experimental formula to be fed ad libitum.
89452850|NCT03061097|Placebo Comparator|Placebo|Participants randomized to the placebo arm will receive a single dose of placebo FMT via enema following an infectious episode requiring antibiotics, with follow-up at day 3, 7, 28, and 6 months. The placebo enema preparation will be identical in appearance but will not contain human feces to prevent unmasking of the trial arms.
88937663|NCT01813552|Experimental|Samatasvir + Ritonavir|Days 1, 9 and 13: Healthy Volunteers will take samatasvir in the mornings under fed or fasted conditions with water. Days 5-16: Healthy Volunteers will take ritonavir in the mornings under fasted or fed conditions with water.
88937664|NCT01813552|Experimental|Samatasvir + Omeprazole|Days 1, 9 and 13: Healthy Volunteers will take samatasvir in the mornings under fasted conditions with water or Coke. Days 5-16: Healthy Volunteers will take omeprazole in the mornings under fasted conditions with water or Coke.
88937665|NCT01813565|Experimental|Additional instillation of hyaluronic acid/chondroitin sulfate|Transurethral resection of bladder ulcer + instillation of hyaluronic acid/chondroitin sulfate
88937666|NCT01813565|Active Comparator|Transurethral resection of bladder ulcer|Transurethral resection of bladder ulcer
88937667|NCT01813578|Experimental|Intervention|An SSED study is an open-label design where the individual is his or her own control. All patients included received the same exercise intervention.
88937668|NCT01813591|Experimental|H.P. Acthar Gel 80IU|H.P. Acthar Gel of 80IU (1.0 ml)
88937669|NCT01813591|Experimental|H.P. Acthar Gel 40IU|H.P. Acthar Gel of 40IU (0.5 mL)
88937670|NCT01813604|Active Comparator|Group A: Trivalent Oral Polio Vaccine|Group A will receive 3 doses of trivalent oral polio vaccine (tOPV) at 6, 10 and 14 weeks of age. A challenge dose of tOPV will be administered at 18 weeks of age.
88937671|NCT01813604|Active Comparator|Group B: Bivalent Oral Polio Vaccine|Group B will receive 3 doses of bivalent oral polio vaccine (bOPV) at 6, 10 and 14 weeks of age. A challenge dose of tOPV will be administered at 18 weeks of age.
88937672|NCT01813604|Active Comparator|Group C: Inactivated Polio Vaccine|Group C will receive 2 doses of inactivated polio vaccine (IPV) at 6 and 14 weeks of age. IPV will be administered intramuscularly using standard needle and syringe. A challenge dose of tOPV will be administered at 18 weeks of age.
88937673|NCT01813604|Active Comparator|Group D: fractional IPV (f-IPV)|Group D will receive 2 doses of fractional inactivated polio vaccine (f-IPV) at 6 and 14 weeks of age. f-IPV (one-fifth dose of IPV) will be administered intradermally using MicroJet 600 microneedle hub by NanoPass Technologies. A challenge dose of tOPV will be administered at 18 weeks of age.
88937674|NCT01813604|Active Comparator|Arm E: f-IPV and bOPV|Group E will receive 2 doses of f-IPV at 6 and 14 weeks of age with bOPV at 10 weeks of age. f-IPV will be administered intradermally using MicroJet 600 microneedle hub by NanoPass Technologies. A challenge dose of tOPV will be administered at 18 weeks of age.
88937675|NCT01813617||Recent onset polymyositis and dermatomyositis|Patients in this cohort was diagnosed with polymyositis or dermatomyositis during 2003-2010 and was treated with corticosteroids and other immunosuppressive agents according to standard care. They were all diagnosed and treated at the Rheumatology Clinic, Karolinska University Hospital.
88937676|NCT01813630|Experimental|DA-3002|0.14 IU (0.045-0.050mg)/kg/day of DA-3002 is injected for 52 weeks by changing injecting areas
88937677|NCT01813630|Active Comparator|Genotropin®|0.14 IU (0.045-0.050mg)/kg/day of Genotropin is injected for 52 weeks by changing injecting areas
88937678|NCT01813643|Experimental|Aripiprazole|Aripiprazole arm,5mg/pill,20-30mg/day,non-forced titration method.last2-4weeks.
88937679|NCT01813643|Active Comparator|Risperidone|Risperidone arm and placebo tables,1mg/pill,2mg-6mg/day,non-forced titration method.last2-4weeks.
88937680|NCT01813656|Experimental|Aripiprazole|Aripiprazole arm,5mg/pill,10mg/day.last12weeks.
88937681|NCT01813656|Placebo Comparator|Sugar pill|placebo arm,5mg/pill,10mg/day,last12weeks
88937682|NCT01813682|No Intervention|control group|preterm infants of this group with iron-free TPN for more than ten days, compare serum iron, iron protein, total iron binding force, MDA, 8-iso-PGF2α on baseline and after intervention.
88937683|NCT01813682|Experimental|treatment group1|preterm infants of this group with iron supplementation of 200μg/kg/d for more than ten days, compare serum iron, iron protein, total iron binding force, MDA, 8-iso-PGF2α on baseline and after intervention.
88937684|NCT01813682|Experimental|treatment group2|preterm infants of this group with iron supplementation of 400μg/kg/d for more than ten days, compare serum iron, iron protein, total iron binding force, MDA, 8-iso-PGF2α on baseline and after intervention.
88937685|NCT01813708|Experimental|Intensive Life-Style Counseling|16 weekly sessions conducted by certified nutritionists certified in behavioural modification, and self-care techniques, including self-monitoring, healthy nutrition, physical activity, problem solving, relapse prevention, self-reinforcement, long-term motivation, and stress management
88937686|NCT01813708|Active Comparator|Collaborative Educational|16 weekly sessions conducted by certified diabetes educators including: diabetes knowledge, nutrition, exercise, goal establishment in diabetes, problem solving, relapse prevention, self-monitoring, family and sexuality in diabetes, emotional management in diabetes, and stress management. Patients established their own goals
88937687|NCT01813747|Experimental|1440 nm wavelength laser with hand piece|To assess the effectiveness of the 1440 nm wavelength laser with handpiece for skin tightening and laser lipolysis for the mandibular and sub-mandibular areas
88937688|NCT01813760|Experimental|Diode laser|Diode laser to treat peri-orbital and peri-oral wrinkles
88937689|NCT01813773|Experimental|Group A - IAI every 4 weeks|Receives 5 injections of Intravitreal Aflibercept Injection (IAI) beginning Day 1, and then at weeks 4, 8, 12, and 16. Following the 5 initial injections, this group will continue to receive IAI every 4 weeks, beginning week 20, through week 48.
88937690|NCT01813773|Experimental|Group B - IAI every 8 weeks|Receives 5 injections of Intravitreal Aflibercept Injection (IAI) beginning Day 1, and then at weeks 4, 8, 12, and 16. Following the 5 initial injections, this group will receive IAI every 8 weeks, beginning week 24, through week 48.
88937691|NCT01813786|Experimental|755nm Alexandrite Laser with Handpiece 2|Focusing energy on skin
88937692|NCT01813786|Experimental|755nm Alexandrite Laser with handpiece 3|Focusing energy on skin
88937693|NCT01813786|Experimental|755nm Alexandrite laser with handpiece 1|Focusing energy on skin
88937694|NCT01813799|Experimental|DA-9801 300mg|
88937695|NCT01813799|Experimental|DA-9801 600mg|
88937696|NCT01813799|Experimental|DA-9801 900mg|
88937697|NCT01813799|Placebo Comparator|Placebo|
88937698|NCT01813812|Experimental|DA-6034 45mg|two tablets (of DA-6034 45mg) are administered for 2 continuous weeks, three times a day.
89452851|NCT03107702||Melatonin and bariatric surgery|the relationship between melatonin level and analgesia requirement.
88937699|NCT01813812|Experimental|DA-6034 90mg|two tablets (of DA-6034 90mg) are administered for 2 continuous weeks, three times a day.
88937700|NCT01813812|Active Comparator|Rebamipide 300mg|two tablets (of Rebamipide 300mg) are administered for 2 continuous weeks, three times a day.
88937701|NCT01813825||Female >=45 years, negative margins, DCIS|
88937702|NCT01813838|Experimental|ACADESINE 140mg/kg/d|3 patients will be included at the initial dose of Acadesine 140mg/kg/d
88937703|NCT01813838|Experimental|ACADESINE 210mg/kg/d|In absence of toxicity at the dose of 140mg/kg/d. There is a dose escalation of acadesine at the dose of 210mg/kg/d for 3 additionnal patients
88937704|NCT01813838|Experimental|ACADESINE 315mg/kg/d|In absence of toxicity at the dose of 210mg/kg/d. There is a dose escalation of acadesine at the dose of 315mg/kg/d for 3 additionnal patients
89452852|NCT02554318|Experimental|Intervention|"TB standard therapy with fixed dose combination :~once per day by mouth for 2 months Fixed dose combination = RHZE (150mg/75mg/400mg/275mg) R=rifampicin, H=isoniazid, Z=pyrazinamide, E=ethambutol,~Patients with body weight: 30 - 37 kg = 2 tablets, 38 - 54 kg = 3 tablets, 55 - 70 kg = 4 tablets, and ≥71 kg = 5 tablets~and 166.5 grams cooked fermented soybean (tempeh) daily for two months"
89452853|NCT02554318|Active Comparator|Control|"TB standard therapy with fixed dose combination :~once per day by mouth for 2 months Fixed dose combination = RHZE (150mg/75mg/400mg/275mg) R=rifampicin, H=isoniazid, Z=pyrazinamide, E=ethambutol,~Patients with body weight: 30 - 37 kg = 2 tablets, 38 - 54 kg = 3 tablets, 55 - 70 kg = 4 tablets, and ≥71 kg = 5 tablets"
89452854|NCT04487054|No Intervention|Usual care|Subjects in the ICU with a poor prognosis will receive usual care in time period one.
89452855|NCT04487054|Experimental|Usual care plus palliative care|Subjects in the ICU with a poor prognosis will receive usual care plus targeted pro-active palliative care intervention within 48 hours of ICU admission in time period two.
89452856|NCT03628157|Experimental|intervention|using a bio-oss bovine bone alone
89452857|NCT03628157|Active Comparator|control|using a bio-oss bovine bone with autogenous bone ratio 1:1
89452858|NCT03241160||Children with cerebral palsy|Children with a diagnosis of spastic cerebral palsy aged between 2 to 12 years who will be referred by pediatric neurologists will be included. Children under the age of 24 months, and used any medicine and/or oral appliances that could affect the chewing performance, will be excluded. Chewing evaluation will be performed.
89452859|NCT04487132|Active Comparator|Active physical education lessons and physical education plan|Active physical education lessons and physical education plan provided to the controlled group
89452860|NCT04487132|Active Comparator|Recess or lunch time activities|Preparing the playground by offering adequate spaces and games provided to the experimental group
89452861|NCT03976973|Experimental|Intervention|Participants with inoperable pseudomyxoma peritonei or peritoneal mucinous tumour that meet the entry criteria and consent to the intervention will receive intratumoural treatment/s with the combination drug BromAc. The drug product will be injected directly into the tumour via a radiologically placed drain
89452862|NCT03241316||district-level representative rural survey|Approximately 4,800 adults in 60 villages across Thailand and Lao PDR to study health and antimicrobial resistance (AMR)-related behaviour in breadth.
89452863|NCT03241316||village-level social network census|Approximately 4,800 adults across 6 villages in rural Thailand and Lao PDR that are exposed to AMR awareness activities to study health behaviour within social networks.
89452864|NCT05476978||Pancreas-EUS|Patients since 2014 with EUS pictures of normal pancreas or pancreatic solid lesions have been included in this cohort.
89452865|NCT04066751|Active Comparator|Ivacaftor|Ivacaftor, 150 mg PO every 12 hrs for 84 days
89452866|NCT04066751|Placebo Comparator|Placebo|Placebo, 150 mg PO every 12 hrs for 84 days
88937705|NCT01813851|No Intervention|control group|"Patients in the control group will receive:~Dietary counseling by a dietician and if necessary modification of the prescription of oral nutritional supplements or intradialytic parenteral nutrition to reach recommended targets according to the European Best Practice Guidelines on Nutrition (energy intake 30-40 kcal/kg of ideal weight/day, protein intake 1.1 g/kg of ideal weight/day"
88937706|NCT01813851|Experimental|activity group|"Patients in the group exercise will:~Dietary counseling by a dietician and if necessary modification of the prescription of oral nutritional supplements or intradialytic parenteral nutrition to reach recommended targets according to the European Best Practice Guidelines on Nutrition (energy intake 30-40 kcal/kg of ideal weight/day, protein intake 1.1 g/kg of ideal weight/day A program of physical activity consisting of progressive endurance and resistance training on a cycle ergometer, performed during the dialysis session under supervision and counseling by a qualified trainer"
88937707|NCT01813877|No Intervention|Standard Diagnostics without PET|
88937708|NCT01813877|Experimental|Diagnostics with PET|All 18F-DOPA PET/CT studies will be interpreted qualitatively during a clinical readout session. Based on a previous study scans will be classified as positive if tumor regions defined on CT exhibited tracer uptake above the level of the contra-lateral caudate nucleus. Scans will be classified as negative if tumor 18F-FDOPA uptake is lower than that of the contra lateral caudate nucleus. Uptake at the level of the contra-lateral caudate will be considered equivocal for malignancy.
88937709|NCT01813903|Experimental|Nutrition|Intensified dietary counseling and use of web application.
88937710|NCT01813903|Experimental|Flexible mind|Use of mobile applications.
88937711|NCT01813903|No Intervention|Normal maternity clinic visits|In control maternity clinics, nurses continue their usual counseling.
88937712|NCT01813916|No Intervention|proteomic analysis|
89452867|NCT03241004|Experimental|Intensive Care Unit|"Patients will be induced in a standard fashion using intravenous (IV) anesthetics. A continuous administration of propofol will be used for maintenance of anesthesia.~Baseline EEG readings will be established for 30 minutes, then EEG data will be recorded and a sleep mask applied to the patient for one hour. After one hour, eye masks will be removed for an hour and reapplied after another hour. During the hour that the mask is off, 2 hours into sedation, EEG data will again be recorded."
88937713|NCT01813955|Experimental|Papaverine|Patients will receive either Papaverine or placebo added to their current medical treatment. Then after one week, they will receive the other treatment (if it was placebo first, then it will be papaverine; if it was papaverine first, then it will be placebo)
88937714|NCT01813981|Placebo Comparator|High roast coffee|110mg caffeine with 108 mg chlorogenic acid at start of study
88937715|NCT01813981|Active Comparator|Low roast coffee|110 mg caffeine with 235 mg chlorogenic acid at start of the study
88937716|NCT01813981|Placebo Comparator|Control|110 mg caffeine at start of study
88937717|NCT01813994|Placebo Comparator|Control group|Without simvastatin
88937718|NCT01813994|Experimental|Statin group|With simvastatin
88937719|NCT01814033|Experimental|LRU Pillow|Experimental: LRU Pillow
88937720|NCT01814033|Active Comparator|Control Group|Other: Control Group
89452868|NCT03241004|Experimental|Operating Room|"Patients will be induced in a standard fashion using intravenous (IV) anesthetics. A continuous administration of propofol and inhalational anesthetics will be used for maintenance of anesthesia.~Baseline EEG readings will be established for 30 minutes, then EEG data will be recorded and a sleep mask applied to the patient for one hour. After one hour, eye masks will be removed for an hour and reapplied after another hour. During the hour that the mask is off, 2 hours into sedation, EEG data will again be recorded."
89452869|NCT03240770|No Intervention|14 Day Tray + Sham|Trays worn at 14 day intervals + Sham
89452870|NCT03240770|Experimental|7 Day Tray + Sham|"Trays worn at 7 day intervals (Deviation from Standard Tray Wear Time (14 Days))~+ Sham"
89452871|NCT03240770|Experimental|5 Day Tray + Sham|"Trays worn at 5 day intervals (Deviation from Standard Tray Wear Time (14 Days))~+ Sham"
89452872|NCT03240770|Experimental|7 Day Tray + VPro5|"Trays worn at 7 day intervals (Deviation from Standard Tray Wear Time (14 Days))~+ HFV with the VPro5 device at 5 min/day"
89452873|NCT03240770|Experimental|5 Day Tray + VPro5|"Trays worn at 5 day intervals (Deviation from Standard Tray Wear Time (14 Days))~+ HFV with the VPro5 device at 5 min/day"
89452874|NCT02550106|Experimental|OMALIZUMAB|sub cutaneous injections of 300 mg every 4 weeks until Week 8.
89452875|NCT05209919||Pulmonary arterial hypertension|All patients with pulmonary arterial hypertension and significant functional tricuspid regurgitation
89452876|NCT05209919||HFrEF|All patients with HFrEF and significant functional tricuspid regurgitation
89452877|NCT05209919||HFpEF|All patients with HFpEF and significant functional tricuspid regurgitation
89452878|NCT05209919||Heart Failure mildly-reduced ejection fraction|All patients with Heart Failure mildly-reduced ejection fraction and significant functional tricuspid regurgitation
89452879|NCT03237260|Experimental|Vedolizumab 300mg|vedolizumab open label
89452880|NCT03247478||invasive breast cancer|Patients with invasive breast cancer who underwent computed tomography (CT) reconstruction of axillary lymph node for assessment of lymph node response after NAC are eligible for this study. Axillary lymph node metastasis is confirmed by fine needle aspiration (FNA) or core needle biopsy (CNB) at initial diagnosis.
89452881|NCT03237026||Cohort A|Ttaining chort will be recruited in the first 36 months of the study period to generate the first batch of urine metabolomic and proteomic profiles as predictive and prognostic markers.
89452882|NCT03237026||Cohort B|Validation cohort will be recruited in the next 24 months of the study period .
89452883|NCT03247400|Active Comparator|1% simvastatin-acid sodium salt ointment|1% simvastatin-acid sodium salt ointment applied onto a predefined limb compared with placebo ointment applied onto an opposite limb
89452884|NCT03247400|Active Comparator|1% atorvastatin calcium salt ointment|1% atorvastatin calcium salt ointment applied onto a predefined limb compared with placebo ointment applied onto an opposite limb
89452885|NCT03247400|Placebo Comparator|Vehicle ointment|Placebo ointment applied onto limbs opposite to treated with active substances
89452886|NCT03060551|Experimental|SVF injection|SVF was obtained from lipoaspirates, using an automated processing system, and subsequently injected into the subcutaneous tissue of each finger in contact with neurovascular pedicles
88937721|NCT01814085|Experimental|Escitalopram|Escitalopram tablets will be administered orally in the dose range of 10 to 20 milligram per day (mg/day) for 8 weeks. Dose can be adjusted as per Investigator's discretion depending on participant's response.
89452887|NCT03236948|Experimental|WfWI Intervention|Women receive the WfWI intervention. This comprises of three main components. First, a social empowerment and health intervention. Second a livelihood strengthening intervention, including numeracy training, and vocational training. Third, a cash transfer conditional on attendance at the intervention to cover costs of attendance and provide start-up capital. The intervention is delivered over 12 months.
89452888|NCT03236948|No Intervention|Control|
89452889|NCT02453516|Experimental|Serratus Block Group|Patients will receive a preoperative ultrasound-guided serratus block with 0.4ml/kg (max.30ml) of ropivacaine 0.5% with 1:4000,000 epinephrine injected between the serratus anterior (superficial) and external intercostal (deep) muscles followed by subsequent general anesthesia
89452890|NCT02453516|Placebo Comparator|Placebo Block - Control Group|Patients will receive a preoperative placebo injection with a subcutaneous injection of 1ml normal sterile saline solution in the midaxillary line and the ultrasound probe will be used to simulate the pressure and block duration associated with the serratus block. These patients will then receive general anesthesia.
89452891|NCT03716609|Experimental|Magnesium supplement group|Subjects receive citrate acid drinks with additional magnesium citrate (300mg magnesium)
88937722|NCT01814098|Experimental|Escitalopram|Escitalopram tablets will be administered orally at 10 milligram per day (mg/day). The dose may be increased to maximum of 20 mg/day depending on Investigators discretion for 24 weeks
88937723|NCT01814111|Experimental|renal sympathetic denervation|Perform renal angiogram immediately prior to renal sympathetic denervation procedure to confirm anatomic eligibility，The treatment catheter was introduced into each renal artery using a guiding catheter. Up to six ablations at 10 W for 1 min each were performed in both renal arteries. Treatments were delivered from the first distal main renal artery bifurcation to the ostium proximally and were spaced longitudinally and rotationally under fluoroscopic guidance. Catheter tip impedance and temperature were constantly monitored, and radio frequency energy delivery was regulated according to a predetermined algorithm. Visceral pain at the time of energy delivery was managed with intravenous analgetics and sedatives.
89452892|NCT03716609|Placebo Comparator|placebo group|Subjects receive citrate acid drinks without additional magnesium
88937724|NCT01814111|No Intervention|Drug Treatment Group|All the patients in this group will take their baseline antihypertensive medication at the original doses, without any changes except when medically required. AAD treatment is consistent in both arms.
88937725|NCT01814124|Active Comparator|Advice and home exercise|All participants will be given a handout consisting of education about avoidance of certain activities as well as 3 stretches and 3 strengthening exercises to be performed as a home exercise program 2-3x/week
89452893|NCT03709355|Active Comparator|Elpida® single dose|Single dose of Elpida® (capsule 20 mg)
89452894|NCT03709355|Experimental|Rifampin & Elpida®|Single dose of Rifampin (capsule 150 mg), Rifampin + Elpida® 20mg single dose
89452895|NCT03709355|Experimental|Rifabutin & Elpida®|Single dose of Rifabutin capsule 150 mg, Rifabutin + Elpida® 20mg single dose
89452896|NCT03709355|Experimental|Clarithromycin & Elpida®|Single dose of Clarithromycin capsule 250 mg, Clarithromycin + Elpida® 20mg single dose
89452897|NCT03709355|Experimental|Omeprazole & Elpida®|Single dose of Omeprazole capsule 20 mg, Omeprazole + Elpida® 20mg single dose
89452898|NCT03709355|Experimental|Atorvastatin & Elpida®|Single dose of Atorvastatin tablet 80 mg, Atorvastatin + Elpida® 20mg single dose
89452899|NCT03709355|Experimental|Levonorgestrel+Ethinylestradiol & Elpida®|Single dose of Levonorgestrel 150 µg + Ethinylestradiol 150 µg tablet, Levonorgestrel + Ethinylestradiol + Elpida® 20mg single dose
89452900|NCT03709355|Active Comparator|Elpida® multiple dose|Elpida® QD dosing for 14 days
89452901|NCT03240848|Experimental|artificial intelligent clinic|"Procedure: the initial diagnosis from artificial intelligent clinic Participants in group A assigned to artificial intelligent clinic to get the initial diagnosis after the eye examinations, including images of ocular anterior segment.~Procedure: the final definite diagnosis from experts After making the initial diagnosis in artificial intelligent clinic, participants in group A went to get the final definite diagnosis from experts with more than 10 years of clinical experience."
89452902|NCT03240848|Active Comparator|normal clinic|"Procedure: the initial diagnosis from normal clinic Participants in group B assigned to normal clinic to get the initial diagnosis after the eye examinations, including images of ocular anterior segment.~Procedure: the final definite diagnosis from experts After making the initial diagnosis in normal clinic, participants in group B went to get the final definite diagnosis from experts with more than 10 years of clinical experience."
89452903|NCT05209217||Participant Group|Participants will all have history of good to excellent clinical response to intranasal ketamine for at least two months and on a treatment schedule varying from use every other day to every fifth day. Participants will be tested one or two days beyond their customary administration date and again 2-3 hours after their administration of ketamine.
89452904|NCT03240926|Experimental|Loop Band|Measure accuracy of vital sign measurements
89452905|NCT03247244|Other|1|Three cannabis drug product formulations with different THC and CBD contents and placebo will be used in the following order: A (THC 10%, CBD <0.5%), B (THC 8.6%, CBD 8.6%), C (THC 0.6%, CBD 14%) and placebo D (THC <0.3%, CBD <0.3%).
89452906|NCT03247244|Other|2|Three cannabis drug product formulations with different THC and CBD contents and placebo will be used in the following order: B (THC 8.6%, CBD 8.6%), placebo D (THC <0.3%, CBD <0.3%), A (THC 10%, CBD <0.5%), C (THC 0.6%, CBD 14%).
89452907|NCT03247244|Other|3|Three cannabis drug product formulations with different THC and CBD contents and placebo will be used in the following order: C (THC 0.6%, CBD 14%), A (THC 10%, CBD <0.5%), placebo D (THC <0.3%, CBD <0.3%), B (THC 8.6%, CBD 8.6%).
89452908|NCT03247244|Other|4|Three cannabis drug product formulations with different THC and CBD contents and placebo will be used in the following order: placebo D (THC <0.3%, CBD <0.3%), C (THC 0.6%, CBD 14%), B (THC 8.6%, CBD 8.6%), A (THC 10%, CBD <0.5%).
89452909|NCT03988829|Active Comparator|Low-C|In an experimenter-designed simulation game, participants will be trained on predictable low attentional control shifts during working memory.
88937726|NCT01814124|Experimental|Manual Therapy Plus Exercise|"Participants in this group will be given the same handout consisting of education about avoidance of certain activities as well as 3 stretches and 3 strengthening exercises to be performed as a home exercise program 2-3x/week.~Participants in this group will also receive 12 individualized physical therapy treatment sessions (2x/week for 6 weeks) consisting of both manual therapy and exercise directed at the hip and surrounding areas based upon findings from the initial examination. Participants will also be given additional exercises to be performed at home as directed by the treating physical therapist"
88937727|NCT01814150||Oncology Institute, Meir Medical Center|Metastatic cancer patients treated with docetaxel at the Oncology Institute, Meir Medical Center
88937728|NCT01814163||Paclitaxel, carboplatin and bevacizumab|Paclitaxel 200 mg/m2, carboplatin area under curve (AUC) 6 mg/ml/min plus bevacizumab 15 mg/kg on day 1, every 21 days. Total number of cycles: 6. After 6 cycles bevacizumab on monotherapy until progression
88937729|NCT01814176|Active Comparator|Macintosh Direct Laryngoscope|2 main forces - a 'lifting' force to elevate the structures not in the line of sight and a force exerted by the user's wrist to counterbalance the torque effect of the tongue tissues on the blade
88937730|NCT01814176|Active Comparator|GlideScope Video Laryngoscope|The GlideScope has a 60º angulation anteriorly at the distal portion of the blade, allowing an anterior view of the larynx.
88937731|NCT01814189|Active Comparator|sumatriptan+promethazine (SPr)|The SPr group denote patients receiving oral sumatriptan (50 mg) plus oral promethazine (50 mg).
88937732|NCT01814189|Placebo Comparator|Sumatriptan+placebo (SP)|The SP group denote patients receiving oral sumatriptan (50 mg) plus tablet of placebo matched to promethazine.
88937733|NCT01814202|Experimental|PTM202|PTM202 is a medical nutrition product
88937734|NCT01814202|Placebo Comparator|Placebo|The placebo is a placebo for PTM202, a food product that can not be distinguished from PTM202 by appearance, taste or odor
89015493|NCT06259188|Experimental|Personalized Breathing Exercise Device Group|In the personalized respiratory exercise device group, the initial pressure load will be set to the resistance level corresponding to 40% of the MIP and MEP measurements. Participants will be asked to rest following 5 breathing cycles and repeat the training for 10 sets. In each set, there will be a one-minute rest break between repetitions. Participants will be able to practice both inspiratory and expiratory respiratory muscle training in a single breathing cycle. As the progression progresses, the perceived exertion level will be increased by 5-10% on a weekly basis, to be in the range of 4-6 according to the Modified Borg scale.
89452910|NCT03988829|Experimental|High-C|In an experimenter-designed simulation game, participants will be trained on unpredictable high attentional control shifts during working memory.
89452911|NCT03988829|Experimental|High-C+|In this commercially-available video game, in addition to unpredictable shifts of attentional control in working memory, task switching and resource planning will be trained.
89452912|NCT02453906|Experimental|healthy subjects|they receive XNKQ acupuncture, as well as control 1, control 2, and control 3 in a randomized order.
89452913|NCT01662310|Experimental|Paliperidone: Run-in or Stabilization phase|Paliperidone extended-release (ER) oral tablet will be administered at a starting dose of 3 milligram (mg) once daily for 8 weeks. Dose will be increased from milligram per day (3 mg/day) after 5 days based on Investigator's discretion, up to maximum of 12 mg/day.
89452914|NCT01662310|Experimental|Paliperidone: Double blind (DB) phase|Participants who transitioned from run-in or stabilization phase received 3 to 12 mg fixed dose of paliperidone ER oral tablet once daily during DB phase of the study. Participants who will experience a relapse event during the DB phase or who will remain relapse free for the entire duration of the DB phase and participants, who will be enrolled at the time the study termination will enter in open label extension phase, wherein paliperidone ER oral tablet will be administered once daily as 3 to 12 mg.
89452915|NCT01662310|Active Comparator|Placebo: DB phase|Participants who transitioned from run-in or stabilization phase received matching placebo to paliperidone ER once daily during DB phase of the study. Participants who will experience a relapse event during the DB phase or who will remain relapse free for the entire duration of the DB phase and participants, who will be enrolled at the time the study termination will enter in open label extension phase, wherein paliperidone ER oral tablet will be administered once daily as 3 to 12 mg.
89452916|NCT03973853|Experimental|Active group with virtual reality stimulation|The subjects in this arm will undertake 14 sessions of virtual reality stimulation. The program will be delivered by a nurse, trained to the use of such a tool, and familiar with cognitive remediation techniques. Before and after these 14 sessions, social autonomy, daily life skills, cognitive domains and self-esteem will be measured
89452917|NCT03973853|Placebo Comparator|Treatment as Usual group (TAU)|Patients in this group will carry on benefiting from their usual care with no additional program. They will be assessed before and after a 3 month period for social autonomy, daily life skills, cognitive domains and self-esteem.
89452918|NCT00700622|Experimental|TI + Insulin glargine|Technosphere Insulin Inhalation Powder in combination with Lantus (insulin glargine)
89452919|NCT00700622|Experimental|Insulin lispro + Insulin glargine|Humalog (insulin lispro) in combination with Lantus (insulin glargine)
89452920|NCT03425825||LD-SCLC receiving 1st line treatment|patients with LD-SCLC receiving first-line treatment, including potential maintenance treatment
88937735|NCT01814215|Experimental|Healthy Lifestyles Group|The Experimental Arm will receive the Keys to Healthy Family Child Care Homes intervention to be delivered over 9 months in 3 modules (3 months/module). The intervention group will be asked to participate in 3 workshops on 3 content areas. Participants will be asked to meet with a coach 3 times in-person, as well 3-9 times by phone/email, over the course of the 9-months. Three content areas are designed to help providers:(1) modify their own weight-related behaviors so they can role model healthy behaviors for children in their care (Healthy You module), (2) create environments that support children's physical activity and healthy dietary intakes (Healthy Home module), and (3) adopt sound business practices that will help them sustain the changes introduced (Healthy Business module).
88937736|NCT01814215|Placebo Comparator|Healthy Business Group|The Control Arm will receive the Healthy Business Education and Coaching program to be delivered over 9 months in 3 modules (3 months/module). The control group will be asked to participate in 3 workshops and a similar number of coaching contacts about their business practices. The focus on business topics is relevant, but not directly related to physical activity or nutrition.
88937737|NCT01814228|Experimental|right atrium ganglionated plexi transcatheter ablation|right atrium ganglionated plexi transcatheter ablation
88937738|NCT01814254||Receiving hemodialysis|
88937739|NCT01814267|Experimental|Telemedicine|care and follow-up through telemedicine.
88937740|NCT01814267|Active Comparator|Conventional care|care and follow-up through iterative diabetes physician consultations (conventional care and follow-up)
88937741|NCT01814280|Other|Medication review|Medication review performed by either a clinical pharmacist or a clinical pharmacologist
88937742|NCT01814293|Active Comparator|Handheld humidifier|Study design is a nonblinded randomized controlled comparison study of pediatric patients presenting to the UCSF Emergency Department (ED) with upper respiratory infection (URI) symptoms for which the ED physician has recommended supportive care only (ie. non-prescription symptom relief). Subjects will be randomized into 2 groups: handheld humidifier group (FDA cleared medical device that uses distilled water) & control group. Both groups may use any supportive modalities desired such as over-the-counter cold medications (OTCs), room air humidifier etc. Follow up surveys will be obtained on days 1 and 2 following the ED visit to assess whether then intervention (use of handheld humidifier) improved symptom scores or reduced the use of OTC medications or room humidifier.
88937743|NCT01814293|No Intervention|Control group|Subjects will manage cold symptoms with any desired supportive over the counter treatment, and complete surveys related to symptom scores and modalities used.
88937744|NCT01814306|Active Comparator|Supreme|Supreme LMA
88937745|NCT01814306|Active Comparator|Proseal|Proseal LMA
89452921|NCT03425825||ED-SCLC receiving 1st line treatment|patients with ED-SCLC receiving first-line treatment, including potential maintenance treatment
89452922|NCT03425825||relapsed/refractory receiving 2nd or later-line treatment|relapsed/refractory patients receiving second- or later-line treatment
89452923|NCT05480410|Experimental|Active intervention|Patients will receive 20 sessions of transcranial magnetic stimulation applied with the MagVenture Mag Pro R20 equipment, these sessions will be held daily from Monday to Friday, lasting 20 minutes at an intensity of 81% with a motor threshold of 90 A/ns.
89452924|NCT03236636|Experimental|Icaritin|Icaritin:600mg/time, 6 capsules/time(6×100mg/capsule), 2 times/day(30 minutes after breakfast, lunch and dinner), take orally, continuous administration until reach the standard of termination.
89452925|NCT03236636|Active Comparator|HUACHANSU PIAN|HUANCHANSU PIAN:Take orally 4 tablets/time(0.3g/tablet), 3 times/day(30 minutes after breakfast, lunch and dinner), continuous administration until reach the standard of termination.
89452926|NCT03628625|Experimental|Study group|3 tablets of Letrozole 2.5 mg will be given as single daily dose, 7.5 mg per day for two days at home and the third dose will be given on admission to hospital on day 3 and will be followed by vaginal misoprostol 800 mcg every three hours up to maximum two doses.
89452927|NCT03628625|Placebo Comparator|Control group|three tablets of placebo will be given as a single daily dose, for two days at home and will be admitted on day 3 and continue treatment with misoprostol 800 mcg every three hours up to maximum two doses
89452928|NCT03359993||Preterm infants intubated|All participants were preterm infants intubated in the delivery room for Infantile Respiratory Distress Syndrome (IRDS). The purpose of this research is to determine a premedication of intubation. This consists of describing a simple and effective method for premedication in the delivery room, using the umbilical vein, directly perforated through the Wharton jelly.
89452929|NCT04468594|Experimental|rigid tape|the rigid tapping technique using zinc oxide tape and protective tape (reference). With the participant assuming a relaxed standing position, the tape was applied bilaterally starting from the first to the last thoracic vertebra. A second tape was then applied to form a position of scapular depression and retraction. This tape was applied bilaterally and extended from the midpoint of the spine of the scapula to the last thoracic vertebra (figure ). This taping was applied for 12 weeks and changes every 3 days
89452930|NCT04468594|Experimental|scapular stabilizing exercises|scapular stabilizing exercises in the form of (1)wall slides with squat, (2) Wall push-ups with ipsilateral leg extension, (3) lawnmower with diagonal squat, (4) resisted retraction to scapula with opposite leg squat (5) robbery with squat. ten repetitions / exercises/ session were perform
89452931|NCT04468594|Active Comparator|control|a standard physical therapy protocol will be introduced. This protocol consisted of (1) progressive strengthening exercises for rotator cuff muscles. The resistance was applied first by a red-colored elastic Thera-band. Then progressed, using the green-colored band. Each exercise was performed 10 times /session, (2) Self-stretching exercises for levator scapula, posterior deltoid, pectoralis minor, and latissimus dorsi muscles. Five repetitions of stretching were performed for each muscle per session
89452932|NCT03238235|Active Comparator|givinostat|Givinostat oral suspension (10 mg/mL) twice daily in a fed state
89452933|NCT03238235|Placebo Comparator|placebo|Placebo oral suspension (10 mg/mL) twice daily in a fed state
89452934|NCT03247166|Experimental|Lower Back and Leg Pain Patients|Patients suffering from lower back and leg pain resulting in degenerative spondylolisthesis and/or spinal stenosis will undergo treatment using the TOPS™ System
89452935|NCT05187923||Retrospective cohort|The internal cohort was retrospectively enrolled in West China Hospital, Sichuan University from June 2010 and December 2020. It is a training and internal validation cohort.
89452936|NCT05187923||Prospective cohort|The same inclusion/exclusion criteria were applied for the same center prospectively. It is an external validation cohort.
88937746|NCT01814319|Experimental|Probenecid|Probenecid 1 gr oral twice daily or placebo will be given to the subject for 1 week (randomly assigned). A subsequent 1 week washout period will occur followed by the alternate therapy.
88937747|NCT01814319|Placebo Comparator|placebo|Probenecid 1 gr oral twice daily or placebo will be given to the subject for 1 week (randomly assigned). A subsequent 1 week washout period will occur followed by the alternate (placebo) therapy.
88937748|NCT01814384|Other|Control group|Control group will be constituted of patients with the prosthesis GMK ® without the ancillary MyKnee ® LBS.
88937749|NCT01814384|Other|Matched patient|Treated group will consist of patients which the GMK ® prosthesis with ancillary ® MyKnee LBS.
88937750|NCT01814410|Placebo Comparator|intravenous ethanol placebo and nicotine infusions|Each subject will participate in three separate interventions. Each intervention will include three nicotine infusions (placebo and 2 active conditions). The interventions will differ on the ethanol infusion: placebo or one of two ethanol concentrations.
88937751|NCT01814410|Active Comparator|intravenous ethanol 40% and nicotine infusions|Each subject will participate in three separate interventions. Each intervention will include three nicotine infusions (placebo and 2 active conditions). The interventions will differ on the ethanol infusion: placebo or one of two ethanol concentrations.
88937752|NCT01814410|Active Comparator|intravenous ethanol 100% and nicotine infusions|Each subject will participate in three separate interventions. Each intervention will include three nicotine infusions (placebo and 2 active conditions). The interventions will differ on the ethanol infusion: placebo or one of two ethanol concentrations.
88937753|NCT01814423|Experimental|Chloroquine-base 50 mg|Chloroquine-base 10 mg/kg twice a day for 2 days and 5 mg/kg twice a day for another day.
88937754|NCT01814423|Active Comparator|Chloroquine-base 70 mg|Chloroquine-base 10 mg/kg twice a day for 2 days and 5 mg/kg twice a day for another 3 days.
88937755|NCT01814436|Experimental|scaffold-free SHED-derived pellet|
88937756|NCT01814449||Hypoxic Group|Higher 18FMISO uptake (Target to background Ratio, TBR>1.2) in Primary breast cancer by 18FMISO PET/CT scan.Primary endocrine therapy Letrozole was given to the patients.
89452937|NCT02553928|Experimental|Memantine (once daily)|Memantine 20 mg once daily, tablets, orally AND Placebo tablets once daily, orally
89452938|NCT02553928|Experimental|Memantine (twice daily)|Memantine 10 mg twice daily, tablets, orally AND Placebo tablets twice daily, orally
89452939|NCT04486976|Experimental|Normal|
89452940|NCT04486976|Experimental|Glaucoma|
89452941|NCT04486976|Experimental|Cataract|
89452942|NCT03240380|Experimental|joint crisis plan|Subjects benefit from a joint crisis plan and the process of its negotiation in addition to the usual in-patient or out-patient care.
89452943|NCT03240380|Active Comparator|crisis card|Subjects benefit from a crisis card in addition to the usual in-patient or out-patient care.
89452944|NCT03908255|Placebo Comparator|Control Group|The control group will receive current standard of care (locoregional therapy of the liver, serial bloodwork and imaging, serial assessments in clinic), consume a maltodextrin placebo supplement beginning two weeks prior to liver directed therapy and continue supplementation for the following 12 months.
89452945|NCT03908255|Experimental|Intervention Group|In the intervention group, patients will receive current standard of care (locoregional therapy of the liver, serial bloodwork and imaging, serial assessments in clinic) and consume BCAA supplements beginning two weeks prior to liver directed therapy and continue supplementation for the following 12 months.
89452946|NCT03246854|Experimental|DBPR112|
89452947|NCT04527718|Experimental|Cohort 1|611 dose 1 (45mg) plus placebo
89452948|NCT04527718|Experimental|Cohort 2|611 dose 2 (150mg) plus placebo
89452949|NCT04527718|Experimental|Cohort 3|611 dose 3 (300mg) plus placebo
89452950|NCT04527718|Experimental|Cohort 4|611 dose 4 (450mg) plus placebo
89452951|NCT04527718|Experimental|Cohort 5|611 dose 5 (600mg) plus placebo
89452952|NCT03246776|Experimental|Halometasone Triclosan Cream|All subjects receive external Use of Halometasone Triclosan Cream
89201011|NCT00904059|Experimental|Treatment Group C|Treatment Groups A and B are followed by Treatment Group C: A combination of BMS-650032 (200 mg) and BMS-790052 (30 mg)
89452953|NCT03972826|Other|1|Subjects serve as self-controls. Subjects first perform hand-hygiene with alcohol-based hand rub then doff gloves contaminated with either S. marcescens or MS2 phage and the hands are cultured using a bag-broth method to determine whether the subjects self-contaminated while doffing. Subjects then clean their hands thoroughly, perform hand hygiene with Provodine, then repeat the doffing and culture process.
89452954|NCT05480332||EndoPAT Measured|Study participants who will undergo EndoPAT testing to obtain a non-invasive measurement of their endothelial function
89452955|NCT03240146|Active Comparator|Study Group|Subjects in this group will receive an active pulsed shortwave therapy device.
89452956|NCT03240146|Placebo Comparator|Control Group|Subjects in this group will receive a placebo pulsed shortwave device that it does not emit energy.
89452957|NCT03076775|Experimental|Intervention|Women will undergo regular maternal blood glucose screening and treatment of hyperglycemia following BMZ administration to achieve maternal glycemic control until delivery or hospital discharge, for a maximum of 5 days.
89452958|NCT03076775|No Intervention|Usual Care|Routine antenatal care will be performed without any maternal blood glucose screening nor treatment as is usual care at each of the study sites.
89452959|NCT05480254|Experimental|clamped catheter group|Q3 clamped catheter protocol is applied before urinary catheter removal
89452960|NCT05480254|No Intervention|free dranaige group|Free dranaige is applied before urinary catheter removal
89452961|NCT03240224|Active Comparator|Cancer ablation|In this group, the patients will receive ablation therapy (e.g. cryosurgery or irreversible electroporation) first for big tumors (> 2 cm). The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
89452962|NCT03240224|Active Comparator|Life information rehabilitation therapy|"In this group, the patients will drink Qilisheng Immunoregulatory Oral Solution for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
89452963|NCT03240224|Experimental|Combination therapy|"In this group, the patients will receive combination therapy, including ablation and life information rehabilitation therapy. They will receive ablation therapy (e.g. cryosurgery or irreversible electroporation) first for big tumors (> 2 cm), then drink Qilisheng Immunoregulatory Oral Solution for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
89452964|NCT03240224|No Intervention|Control|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
89452965|NCT03240302|Active Comparator|ICSI Procedure|The ICSI procedure is the standard procedure of selection and injection of sperm into the oocyte using a standard ICSI petri dish.
89452966|NCT03240302|Active Comparator|PICSI Procedure|The PICSI procedure is based on a selection of mature spermatozoa with CD44 receptors and their injection into the oocyte using the PICSI petri dish that has been coated with hyaluronic acid on its bottom.
89452967|NCT05480176||Non-COPD high-risk population|The local residents gain a COPD-SQ score < 16.
89452968|NCT05480176||COPD high-risk population|The participants have a COPD-SQ score ≥ 16 with a FEV1/FVC ≥ 0.70 either with or without bronchodilator administration.
89452969|NCT05480176||Confirmed COPD patients|The participants have a COPD-SQ score ≥ 16 with a FEV1/FVC ≥ 0.70 after administration of bronchodilators.
89452970|NCT03067493|Experimental|Neo-MASCT group|Patients in the treatment group will receive a total of 6 courses of Neo-MASCT treatment. The whole period of Neo-MASCT treatment for each patient will be up to 24 months.Three stratification factors are considered, i.e.tumor size (2.1-3.0cm, 3.1-5.0cm), tumor number (1, >1) and type of surgery (RFA，hepatectomy).
89452971|NCT03067493|No Intervention|Control group|Patients in the control group will be actively monitored during the trial period. Patients will receive assessment every 3 months in the first 3 years.
89452972|NCT03239912|Experimental|Twin-block group|Functional treatment will be applied using the Twin-block appliance.
89452973|NCT03239912|Experimental|Twin-block combined with low level laser|Functional treatment will be applied using the Twin-block appliance combined with low level laser.
89452974|NCT05476666|Experimental|Pressures measured|Venous pressure measured through a peripherial and a central venous catheter/cannula
89452975|NCT03236402||Early young adult (20 years - 30 years)|Adults who were in the age group of 20 - 30 years was the first group. There were made two separate same age group one for rural and one for urban areas adults. Each areas age group consist 50 adults of 20-30 years.
89452976|NCT03236402||Middle age adult (31 -50 years)|Adults who were in the age group of 31-50 years were in second group. There were made two separate same age group one for rural and one for urban areas adults. Each areas age group consist 50 adults of 31-50 years.
89452977|NCT03236402||Late adult (51 years - 65 years)|Adults who were in the age group of 51-65 years were in third group. There were made two separate same age group one for rural and one for urban areas adults. Each areas age group consist 50 adults of 51-65 years.
88937757|NCT01814449||Non-Hypoxic Group|Lower 18FMISO uptake (TBR<1.2)in primary breast cancer by 18FMISO PET/CT scan.Primary endocrine therapy letrozole was given to the patients.
88937758|NCT01814462|Experimental|6 months CPAP|Application of continuous positive airway pressure (CPAP) therapy as established per routine clinical treatment. Home use of therapy for a period of 6 months.
88937759|NCT01814475|Active Comparator|A: Fludarabine + Busulphan|Conventional conditioning regimen with Fludarabine and Busulphan (Busilvex)for allogeneic stem cell transplantation in myelofibrosis
88937760|NCT01814475|Experimental|B: Fludarabine + Thiotepa|Reduced-intensity conditioning with Fludarabine and Thiotepa for allogeneic stem cell transplantation in myelofibrosis
88937761|NCT01814501|Experimental|Treatment (panitumumab, combination chemotherapy)|5-Fluorouracil, irinotecan, and panitumumab
88937762|NCT01814514|Active Comparator|Timolol-trusopt|Dosage:One drop/12hours,duration:3 months
88937763|NCT01814514|Placebo Comparator|placebo,Artificial tear|dosage:one drop/12 hours,duration:3 months
89015494|NCT06259188|Active Comparator|Respiratory Muscle Training Group|Respiratory muscle training will be done with Threshold® IMT and Threshold™ PEP devices. Training intensity will be set to 40% of MIP and MEP measurements in the first week. For inspiratory muscle training, participants will be asked to rest after 5 breathing repetitions and repeat the training for 10 sets. Participants will be asked to rest after 5 exhalation repetitions for expiratory muscle training and repeat the training for 10 sets. In each set, there will be a one-minute rest break between repetitions. As the progression progresses, the perceived exertion level will be increased by 5-10% on a weekly basis, to be in the range of 4-6 according to the Modified Borg scale. At this point, if the training threshold exceeds the upper pressure limits of Threshold® IMT + Threshold™ PEP devices, the training intensity will continue at the upper limit.
89015495|NCT06259162|Experimental|LAG-3 expression/immune checkpoint protein expression evaluation|
89015496|NCT06259149||Early initiation of drug prophylaxis (within 24 hours after surgery)|Patients who underwent surgery received prophylactic administration of low molecular weight heparin (nardraparin calcium injection) at a time point of 24 hours after surgery，this group carries out early initiation of drug prophylaxis (within 24 hours after surgery)
89015497|NCT06259149||Late initiation of drug prophylaxis (24 hours after surgery)|Patients who underwent surgery received prophylactic administration of low molecular weight heparin (nardraparin calcium injection) at a time point of 24 hours after surgery，this group carries out late initiation of drug prophylaxis ( 24 hours after surgery)
89015498|NCT06259097|Active Comparator|Misoprostol and Pitocin|Patient receives misoprostol and foley catheter for initial induction of labor, followed by pitocin later on.
89015499|NCT06259097|Active Comparator|Pitocin only|Patient receives pitocin and foley catheter for initial induction of labor, followed by more pitocin later on.
89015500|NCT06259045||Advanced heart failure|Patients enrolled will all have advanced heart failure, defined by a set criteria
89015501|NCT06259032|Experimental|Mechanical alignment|
89015502|NCT06259032|Experimental|Functional alignment|
89015503|NCT06259019|Other|Liquid Biopsy System|Main trial arm, all recruited and enrolled patients will undergo intracoronary blood sampling using the Liquid Biospy System Device.
89015504|NCT06258980||heavily menstruating females with glanzmannns Thrombaesthenia|
89452978|NCT03236402||>65 years|Adults who were in the age group of >65 years were in fourth group. There were made two separate same age group one for rural and one for urban areas adults. Each areas age group consist 50 adults of >65 years.
89452979|NCT03875495|Experimental|Temferon|"Autologous CD34+-enriched hematopoietic progenitor cells exposed ex vivo to a specific lentiviral vector encoding for the human IFN-ɑ2 gene.~Its expression is tightly controlled by the human TIE2 enhancer/promoter sequence and by a post-transcriptional regulation layer represented by target miRNA sequences. This enables suppression of IFN-ɑ2 expression in HSPCs, thereby further increasing the specificity of the delivery strategy for their Tie2 expressing myeloid cell progeny."
89452980|NCT03236558|Experimental|Patients with diabetes|T1D patients with blood collection
89452981|NCT05160467||Deresuscitation cohort|"Patients with fluid overload (defined by a cumulative fluid balance > 5%), stable hemodynamic (defined by Norepinephrine equivalent < 0.5µg/kg/min and nor clinical nor biological sign of hypoperfusion) and continuous renal replacement therapy. All these patients benefit in our service from a protocol directed, perfusion based deresuscitation strategy with a 2mL/kg/h net ultra filtration to induce negative fluid balance and correct fluid overload. If hypoperfusion occurs, the net ultra filtration is stopped; if pulmonary oedema or right ventricular dysfunction occurs, the net ultra filtration is set to 3mL/kg/h.~We carried out at day 0, 1,3 and 5 bio electrical impedance analysis with an eight polar multifrequency bio impedance monitor (InBody S10), and monitor cumulative fluid balance with our prescription software and daily weight assessment."
89452982|NCT02453204|Experimental|Sitting|Participants will remain sitting throughout the test period whilst undertaking typical sedentary behaviours such as watching TV, using a computer, reading and writing. Walking and standing will be restricted.
89452983|NCT02453204|Experimental|Standing|Participants will be asked to break their sitting time by standing for five minutes every 30 minutes. Participants will be asked to stand in the same position with no further instructions provided. In total, individuals will accumulate 12 bouts (60 minutes) of standing throughout the test period.
89452984|NCT02453204|Experimental|Walking|The walking condition will be identical to standing, but the breaks in sitting time will be punctuated with five minute bouts of self-paced walking rather than standing.
89452985|NCT05160389|Experimental|Fasted|Study drug will be administered with water, after an overnight fast.
89452986|NCT05160389|Experimental|Low-fat Meal|Study drug will be administered with water, after an overnight fast, after which time a standard low-fat breakfast will be given.
89452987|NCT05160389|Experimental|High-fat Meal|Study drug will be administered with water, after an overnight fast, after which time a standard high-fat breakfast will be given.
89452988|NCT03246386|Experimental|Obese subjects|Subjects with a BMI>35 kg/m2
89452989|NCT03246386|Active Comparator|Non-obese subjects|Subjects with a BMI>18.5 and <25 kg/m2
89015505|NCT06258967|Active Comparator|Propofol|Propofol is administered at a rate of 15mg/kg*h for patient induction. After 60 seconds, a sedation assessment is initiated until the patient loses consciousness.Then adjust the propofol dose to 5mg/kg/h and make further dose adjustments based on the patient's response and BIS value, with increments or decrements ranging from 1mg/kg/h, within a total range of 3-8mg/kg/h.
89015506|NCT06258967|Experimental|Ciprofol|Cprofol is administered at a rate of 3mg/kg*h for patient induction. After 60 seconds, a sedation assessment is initiated until the patient loses consciousness.Then adjust the propofol dose to 1mg/kg/h and make further dose adjustments based on the patient's response, with increments or decrements ranging from 0.2mg/kg/h, within a total range of 0.6-1.6mg/kg/h.
89015507|NCT06258954|Experimental|3D group|Using automatic comparison software for 3D reconstruction to determine the size of DLT.
89015508|NCT06258954|Placebo Comparator|control group|The size of DLT is based on patient's sex and height.
89201012|NCT00348673|Experimental|Stage 1|
89201013|NCT00348673|Experimental|Stage 2|
89201014|NCT00904137|Active Comparator|Cast|Above elbow fiberglass cast with a collar-and-cuff
89201015|NCT00904137|Active Comparator|Splint|Long arm posterior plaster splint with a collar-and-cuff
89015509|NCT06258928||patients with a distal radius fracture|Functional examination included evaluating range of motion (ROM), grip strength, and isokinetic evaluation of force moments (Biodex) for wrist flexion, extension, forearm pronation, and forearm supination. Michigan's questionnaire and the Disability of the Arm, Shoulder, and Hand (DASH) questionnaire were used to subjectively evaluate the effects of therapy.
89452990|NCT03851081|Experimental|Treatment (inotuzumab ozogamicin, liposomal vincristine)|See Detailed Description.
89452991|NCT03239756|Experimental|60 mg single dose cohort|patients would receive a 60 mg single dose of TK006.
89452992|NCT03239756|Experimental|120 mg single dose cohort|patients would receive a 120 mg single dose of TK006.
89452993|NCT03239756|Experimental|180 mg single dose cohort|patients would receive a 180 mg single dose of TK006.
89452994|NCT03239756|Experimental|120 mg Q4W cohort|patients would receive 120 mg TK006 every 4 weeks, for a total of 3 doses.
89452995|NCT05156645|Experimental|SCTA01 and SCTA01C+SOC|
89452996|NCT05156645|Placebo Comparator|Placebo+SOC|
89452997|NCT03239834||OncAlert RAPID test in oral cavity biopsy patients.|Patients at an intermediate and high level of clinical risk for HNSCC and scheduled for initial and immediate incisional diagnostic biopsy of their Oral Cavity.
89452998|NCT03239834||OncAlert RAPID test in oropharyngeal biopsy patients.|Patients at an intermediate to high level of clinical risk for HNSCC and scheduled for initial and immediate incisional diagnostic biopsy of their Oropharnyx
89452999|NCT03239834||OncAlert RAPID test in clinical decision to biopsy.|Patients at a lower level of clinical risk for HNSCC and not scheduled for an immediate biopsy. Patients will be offered medical management and have an initial RAPID test. All patients will return within 1-3 months for follow-up test and a possible biopsy if clinically indicated.
89453000|NCT05130671|Active Comparator|Standard of care|This arm will receive the standard of care as per the hospital guidelines.
89453001|NCT05130671|Experimental|Investigational treatment|This arm will receive combination of nutritional supplements quercetin and curcumin as add-on to the standard of care.
89453002|NCT05112419|Experimental|Cohort 1: Participants with moderate hepatic impairment and moderate renal impairment|Participants will receive a single oral dose of zibotentan under fasted conditions.
89453003|NCT05112419|Experimental|Cohort 2: Healthy participants|Participants will receive a single oral dose of zibotentan under fasted conditions.
89453004|NCT03239600|Experimental|Part I & II: GSK2618960 2 milligram per kilogram (mg/kg)|GSK2618960 2mg/kg will be administered intravenously (IV) with Methotrexate (MTX)
89453005|NCT03239600|Placebo Comparator|Part II: Placebo|Placebo will be administered IV with MTX
89453006|NCT03234998|Experimental|motor-cognitive dual-task training|Participants in the motor-cognitive dual-task training group will participate in 12-session programs administered for 60 minutes each session, 3 times per week for 4 weeks.
89453007|NCT03234998|Active Comparator|cognitive dual-task training|Participants in the cognitive dual-task training group will also participate in a 12-session program conducted 60 minutes per session, 3 days a week, for a total of 4 weeks.
89453008|NCT03628547||soccer players|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 10 amateur soccer players and10 professional soccer players.
89453009|NCT03628547||basketball players|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 10 amateur basketball players and10 professional basketball players.
89453010|NCT03628547||volleyball players|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 10 amateur volleyball players and10 professional volleyball players.
89453011|NCT03628547||runners|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 10 amateur runners and 10 professional runners.
89453012|NCT03628547||table tennis athlete|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 10 amateur table tennis athlete and 10 professional table tennis athlete.
89453013|NCT03628547||field tennis athlete|10 amateur field tennis athlete 10 professional field tennis athlete
89453014|NCT03628547||kickboxers|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 10 amateur kickboxers and 10 professional kickboxers.
88937764|NCT01814527|Active Comparator|Docosahexaenoic acid|The experimental group will be given a standardized dose of omega-3 fatty acid containing 2200mg of DHA for 30 days after onset of concussion or longer for those with continued symptomatology. Brain Armor an over the counter DHA supplements that is independently tested and certified by the National Science Foundation Athletic Banned Substance Certified for Sport Program. The Docosahexaenoic acid supplement has 440mg of DHA per capsule and each subject will be given 5 capsules of Brain Armor once daily for a DHA dose of 2200mg/day.
88937765|NCT01814527|Placebo Comparator|Placebo|The placebo group will be given an equal amount of capsules.
88937766|NCT01814579|Experimental|V-Loc Vaginal Cuff Closure|Patients in this arm will receive vaginal cuff closure with unidirectional barbed suture at time of their robotic hysterectomy.
88937767|NCT01814579|Active Comparator|Vicryl Vaginal Cuff Closure|Patients enrolled in this arm will have their vaginal cuff closed with polyglactin 910 (Vicryl) at the time of their robotic hysterectomy.
88937768|NCT01814592|Experimental|coronally mucosal thickness flap|coronally mucosal thickness flap plus connective tissue graft for root coverage (subepithelial connective tissue graft)
88937769|NCT01814592|Active Comparator|coronally partial thickness flap|coronally partial thickness flap plus connective tissue for root coverage (subepithelial connective tissue graft)
89015510|NCT06258915|Experimental|Adalimumab|
89015511|NCT06258915|Active Comparator|Mycophenolate mofetil|
89453015|NCT03628547||archers|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 10 amateur archers and 10 professional archers.
89453016|NCT02966093|Experimental|Lenvatinib|In the randomization phase, participants will receive lenvatinib until disease progression. Participants who discontinue due to confirmed disease progression will enter Extension Phase. Participants who discontinue without confirmed disease progression will be followed for tumor assessment until confirmed disease progression or initiation of anticancer therapy, at which time the participants will enter Follow-up period of Extension Phase.
89015512|NCT06258889|Experimental|reward-focused intervention + exposure|Psychoeducation reward-focused interventions based on Positive Affect Treatment (Finding the silver lining, taking ownership, imagining the positive) Exposure & reward-focused interventions before and after exposure trials
89015513|NCT06258889|Active Comparator|Cognitive flexibility intervention + exposure|Psychoeducation Cognitive Flexibility based on Unified Protocol of emotional disorders Exposure & cognitive flexibility interventions before and after exposure trials
89015514|NCT06258876||Patients with an indication for PrEP|"- Any patient presenting to a general medicine consultation for initial PrEP prescription or having previously received a hospital-initiated PrEP prescription, in a CEGGID (Centres gratuits d'information, de dépistage et de diagnostic), in a sexual health center, and not having had a PrEP prescription renewal for at least 4 months.~OR~- Any patient seen in a general medicine consultation with an indication for PrEP."
89015515|NCT06258863||inframammary fold incision|A total mastectomy was performed using an inframammary fold incision
89015516|NCT06258863||lateral chest wall incision|A longitudinal incision was made in the lateral chest wall for a total mastectomy
89453017|NCT02966093|Experimental|Placebo|In the randomization phase, participants will receive lenvatinib matched placebo until disease progression. Participants who discontinue due to confirmed disease progression will enter Extension Phase. Participants who discontinue without confirmed disease progression will be followed for tumor assessment until confirmed disease progression or initiation of anticancer therapy, at which time the participants will enter Follow-up period of Extension Phase.
89453018|NCT03229616|Experimental|BUCY+VP-16|For DLBCL patients undergoing auto-HSCT，BUCY+VP-16 conditioning regimen was BU 3.2 mg/kg/day on days -7 and -4；CY 60 mg/kg/day on days -3 and -2; VP-16 15mg/kg/day on days -3 and -2.
89453019|NCT03229616|Active Comparator|BUCY|For DLBCL patients undergoing auto-HSCT，BUCY conditioning regimen was BU 3.2 mg/kg/day on days -7 and -4；CY 60 mg/kg/day on days -3 and -2.
89453020|NCT03236480||COPD|Patients who admitted to Peking Universtiy People's Hospital and Ningde City Hospital between January 2017 and January 2019 with AECOPD will be enrolled
89453021|NCT03236480||healthy control|People aged over 40, without any chronic respiratory disease or acute respiratory infections in the last 2 weeks, and be willing to participate in the study
89453022|NCT03058991|Experimental|Distress Tolerance Intervention|For the Distress Tolerance Intervention, the investigators will use a Mindfulness Based Stress Reduction (MBSR) program that has been adapted for use with adolescents. This version of MBSR follows closely the original conceptualization developed by Kabat-Zinn. The focus is on formal and informal mindfulness practices, which encourage participants to foster intention, attention and attitude. The investigators will make slight modifications to the delivery of the MBSR intervention to take into account the developmental period of their participants (e.g., attention span) to encourage retention and increase relevancy. These changes will also allow the investigators to match the duration with their Working Memory Intervention.
89453023|NCT03058991|Experimental|Working Memory Intervention|"For the working memory training, the investigators will use the Cogmed RM program. Participants will be asked to use the program, while supervised twice a week, each time for an hour, for 8 weeks. Participants will also be asked to use the program on the other days for 25-35 minutes. The program resembles a video game, and comprises several different games that require visuo-spatial working memory (remembering the position of objects) and a combination of verbal and visual working memory (remembering phonemes, letters, and digits). The program adapts to the user's performance, such that trainees are able to perform at the limit of their ability, stimulating WM capacity adaptation."
89453024|NCT03058991|Active Comparator|Control Informational Intervention|This Control Informational Intervention has been used in the investigators' and other's previous studies. In the current application, it will match the session time of the Distress Tolerance and Working Memory interventions and will omit a focus on smoking (which is specific to the SPII intervention provided across all interventions), and will consist of discussions of a variety of healthy lifestyle topics, such as healthy eating, stress/time management, and recommended health screenings.
89453025|NCT03234920|Placebo Comparator|Group 1- Control Group|Placebo The placebo will be 200 ml of fruit juice twice a day. Placebo will be provided for 12 weeks
89453026|NCT03234920|Experimental|Group 2 - Treatment group|HMB Supplementation with 1.5 g of HMB dissolved in 200 ml of fruit juice and taken twice daily. Supplementation will be provided for 12 weeks
89453027|NCT03236090|Active Comparator|Outpatients with refractory ascites|20 consecutive outpatients with cirrhosis and refractory ascites Vivomixx®sachets containing 450 x 109 bacteria, 2 every 12 hours (n=25), or placebo (n=25)
89453028|NCT03236090|Active Comparator|Patients hospitalized because bacterial infection|30 consecutive patients with cirrhosis and bacterial infections. All patients will receive endovenous antibiotics and, only in the case of patients with SBP, also intravenous albumin Vivomixx®sachets containing 450 x 109 bacteria, 2 every 12 hours (n=25), or placebo (n=25)
89453029|NCT03229460|Active Comparator|standard low flow therapy|In the standard low flow therapy is applied continuously through a nonrebreather face mask at a flow rate of 10 liters per minute or more. The rate was adjusted to maintain an oxygen saturation level of 92% or more.
89453030|NCT03229460|Experimental|high flow nasal oxygen therapy|In the high-flow-oxygen group is passed through a heated humidifier and applied continuously through large-bore binasal prongs, with a gas flow rate of 30-60 liters per minute . The fraction of oxygen in the gas flowing in the system was subsequently adjusted to maintain an Spo2 of 92% or more.
89453031|NCT03229460|Placebo Comparator|Noninvasive ventilation|In the noninvasive-ventilation group is delivered to the patient through a face mask that was connected to an ICU ventilator,with pressure support applied in a noninvasive ventilation mode. The Fio2 or PEEP level (or both) were then adjusted to maintain an Spo2 of 92% or more.
89453032|NCT02744651|Active Comparator|EUS-FNA|All patients with a confirmed suspicion of a submucosal tumor in the upper GI tract will be included in this study. A senior endoscopist will perform multiple passes of EUS-FNA until she/he has collected enough material for the pathologist to establish a possible diagnosis.
89015517|NCT06258863||circumareolar incision|A total mastectomy was performed with an arc-shaped incision around the areola without limiting the distance to the nipple
89015518|NCT06258863||radial incision|A total mastectomy was performed with a radial incision around the nipple
89015519|NCT06258850|Experimental|Calcifediol|Calcifediol (25-OH vitamin D3) in oral soft capsules (Hidroferol® 0,266 mg, equivalent to 15960 IU vitamin D).
89015520|NCT06258850|Placebo Comparator|Placebo|Placebo in oral soft capsules (externally indistinguishable from Hidroferol®).
89453033|NCT02744651|Active Comparator|EUS-Endodrill biopsy|All patients who are included in the study will also be examined by a senior endoscopist performing multiple EUS guided passes with the Endodrill biopsy. The harvested tissue from the tumor will be examined by a pathologist in order to establish a diagnosis.
89453034|NCT03234842|Experimental|Proton|Proton beam therapy of 59.4 Gy in 1.8 Gy fractions (50.4 Gy if unable to meet cardiac/lung- organs at risk (OAR) constraints) plus concurrent standard chemotherapy
89453035|NCT03234842|Active Comparator|Photon|Photon Radiation therapy of 59.4 Gy in 1.8Gy fractions ( 50.4 Gy if unable to meet cardiac/lung- organs at risk (OAR) constraints) plus concurrent standard chemotherapy
89453036|NCT03229070|No Intervention|Control Group|Control Group: Pre-surgical evaluations (Six-minute walk test, sit and lift test 30 in seconds, and Piper fatigue scale) and assessments at discharge
89453037|NCT03229070|Experimental|Interval effort group|Interval effort group: Pre-surgical evaluations (Six-minute walk test, sit and lift test 30 in seconds, and Piper fatigue scale) Active phase (high load) lasting 60 seconds, followed by an active recovery phase with light / moderate load (60% of the maximum load) lasting 4 minutes. The pedaling speed should be maintained between 30-60rpm. There will be 5 cycles that will total 20 minutes of physical effort, and assessments at discharge.
89453038|NCT03229070|Experimental|Continuous effort group|Pre-surgical evaluations (Six-minute walk test, sit and lift test 30 in seconds, and Piper fatigue scale) Intensity used will be mild / moderate, ie 60% of the maximum load reached in the incremental test. The pedaling speed should be maintained between 30-60rpm. The execution time, from this exercise regime will be 20 minutes, and assessments at discharge.
89453039|NCT03234530||WTC responders|WTC Health Program participants
89453040|NCT03234530||Urban workers|Control group of urban workers in NYC not exposed to the dust from the WTC
89453041|NCT03229226||2016 OPPE|All faculty participating in yearly ongoing professional Practice evaluation were eligible for enrollment
89453042|NCT03229148|Active Comparator|General anaesthesia|In the general anesthesia group, rapid sequence induction is used. Conduction of general anesthesia and drugs used are left to the expertise of each investigating center. Systolic blood pressure has to be maintained between 140 and 180 mmHg with an intravenous norepinephrine infusion if necessary, tele-expiratory carbon dioxyde concentration (EtCO2) has to be maintained between 30 and 35 mmHg and SpO2 has to be maintained between 94 and 98 %.
89453043|NCT03229148|Active Comparator|Conscious Sedation|In the conscious sedation group, drugs choice as well as pharmacological modulation will be left to the expertise of each investigating center. A sedation level between 0 and -3 with spontaneous breathing will be targeted, using the Richmond Agitation Sedation Scale (RASS) score validated in French. The lightest sedation level will be targeted, i.e. minimal to moderate sedation according to the US recommendations for sedation / analgesia. Systolic blood pressure will be maintained between 140 and 180 mmHg with an intravenous norepinephrine infusion if necessary and SpO2 will be maintained between 94 and 98%.
89453044|NCT04485962|Experimental|Fibroblasts and keratinocytes treated patients|Fibroblasts and keratinocytes treated patients
89453045|NCT03228992|Active Comparator|Ibuprofen|Subjects will receive a total of 4 doses of oral ibuprofen 400 mg over a 24 hour period.
89453046|NCT03228992|Placebo Comparator|Placebo|Subjects will receive a total of 4 doses of oral placebo over a 24 hour period.
89453047|NCT03234452|Experimental|Lactoflorene plus|10 ml mixture of Lactobacillus acidophilus LA-5®, Bifidobacterium animalis subsp. lactis, BB-12®, Lactobacillus paracasei subsp. paracasei, L. CASEI 431® , Bacillus coagulans BC513, zinc and B-vitamins (niacin, B1, B2, B5, B6, B12 and folic acid) twice a day
89453048|NCT03234452|Placebo Comparator|Placebo Lactoflorene plus|Identical placebo mixture without probiotics, B-vitamins and zinc. The active and placebo products had similar appearance, taste and smell and were provided in identical bottles of 10 ml with identical labelling.
89453049|NCT00700310|Active Comparator|1|
89023555|NCT05157919|Experimental|Intervention with App|The caregiver gets access to use the app. Each day, investigators will ask the patient to rate their thirst and anxiety and the caregiver to answer daily measures through the application. The caregiver will be asked questions at 3 different times: Day 1, 24-48 hours after enrollment, and 2-4 weeks after the patient is discharged from the ICU. The caregiver will be taught how to use the app. The caregiver will be given the supplies that the caregiver needs to perform the symptom management intervention. Investigators will ask the caregiver to use the app at least once a day, but the caregiver can use it as much as desired while the patient is in the ICU.
89453050|NCT00700310|Active Comparator|2|
89453051|NCT00700310|Active Comparator|3|
89453052|NCT00700310|Placebo Comparator|4|
89453053|NCT03235856||Keratoconus patients|This study involves a retrospective analysis of data recorded during routine clinical follow-up of keratoconus patients. As such, the impact for the patient is minimal as no additional tests need to be performed
89453054|NCT02452502|Active Comparator|moderate dose|Drug: Atorvastatin Atorvastatin 20 mg daily for 2 weeks administrated within 24 hours after receiving rt-PA thrombolysis, continued statin use for at least 12 months Other Name: Lipitor
89453055|NCT02452502|Experimental|high dose|Drug: Atorvastatin Atorvastatin 80 mg daily for 2 weeks administrated within 24 hours after receiving rt-PA thrombolysis, continued statin use for at least 12 months Other Name: Lipitor
89453056|NCT03228524|Experimental|D-aspartato+ET|Patients will be administered oral D-aspartate (2660 mg once daily) for 6 weks. Moreover, patients will receive therapeutic exercise.
89453057|NCT03228524|Placebo Comparator|Placebo+ET|Patients will be administered oral placebo for 6 weks. Moreover, patients will receive therapeutic exercise.
89453058|NCT03234296|Active Comparator|Antibiotic treatment|Ertapenem 1 g x 1 intravenously for 3 days, followed by per oral levofloxacin 500 mg x 1 and metronidazole 500 mg x 3 for 4 days, duration of treatment 7 days.
89453059|NCT03234296|Active Comparator|Placebo|Intravenous placebo once a day for 3 days, followed by per oral placebo for 4 days with similar p.o. tablets as in the antibiotic group.
89453060|NCT03234140||"Group Genome Wide Association Studies"|"Patients are adults, male or female, with a follicular lymphoma, homogeneously treated by immunochemotherapy included in one of the following cohorte :~PRIMA Cohort : phase III (Sponsor LYSARC, France; NCT00140582): N=396~RELEVANCE Cohort : phase III (Sponsor LYSARC, France; NCT01476787 ): N=441~FOLL05 Cohort: phase III (Sponsor Italian lymphoma Foundation, Italy; NCT00774826): N=229~MER1 Cohorts : prospective, observational (Sponsor Mayo Clinic, USA; IRB#09-001987): N=178~MER2 Cohorts : prospective, observational (Sponsor Mayo Clinic, USA; IRB#09-001987):N=321~Using the Genome wide association studies (GWAS) approach on these 1,565 patients, the project plan to identify new prognostic markers. These markers will then be analyzed to decipher the impact of host genetics on somatic alterations and tumor biology, using public or matched patient data."
89023556|NCT05156671|Experimental|Adrecizumab (HAM 8101)|Adrecizumab (HAM 8101) on top of standard of care. Adrecizumab (HAM8101) is a humanized IgG1 monoclonal antibody (mAb). 2 mg/kg body weight Adrecizumab diluted in up to 100 mL saline as single dose infusion.
89453061|NCT03234140||"Group EPIC"|"Patients are adults, male or female, included in the EPIC Cohort (European Prospective Investigation Into Cancer and Nutrition study between 1992 and 2000. (Sponsor IARC, Lyon, France).~The investigators plan to analyze the influence of single-nucleotide polymorphisms on circulating t(14;18) levels in these 318 healthy individuals including 100 who will develop follicular lymphoma later on, and assess if these biomarkers are helpful to refine the identification of high-risk follicular lymphoma individuals."
89453062|NCT03228368||Atezolizumab (MPDL3280)|Atezolizumab 1200 milligrams (mg) will be administered via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurs first.
89453063|NCT05095805|Experimental|Test group|additional weight-bearing exercise
89453064|NCT05095805|Active Comparator|Control group|standard weight-bearing exercise
89453065|NCT03228758|Active Comparator|Anterior Orientation|"The anterior endoscopic myotomy of the lower esophageal sphincter will be performed between the 11 o'clock to 3 o'clock position in the esophagus determined by the usual endoscopic convention of 12 o'clock representing the most anterior aspect of the esophagus on endoluminal view.~Intervention is the endoscopic myotomy of the lower esophageal sphincter."
89453066|NCT03228758|Active Comparator|Posterior Orientation|"The posterior endoscopic myotomy of the lower esophageal sphincter will be performed between the 5 o'clock to 6 o'clock position in the esophagus determined by the usual endoscopic convention of 12 o'clock representing the most anterior aspect of the esophagus on endoluminal view.~Intervention is the endoscopic myotomy of the lower esophageal sphincter."
89453067|NCT03228446|Experimental|Young subjects|Working memory training & attentional filter training for participants (18-30 years)
89453068|NCT03228446|Experimental|Old subjects|Working memory training, attentional filter training and no training (control) for participants (60-80 years)
89453069|NCT03235466|Active Comparator|Voice Therapy|(Group 1) will undergo active training in behavioral cough suppression and laryngeal relaxation exercises, but will not receive HRVB. Traditional cough suppression and laryngeal relaxation exercises include pursed lip breathing, swallowing (water, lozenge, gum, ice chips), sustained semi-occluded voicing, discussion and mitigation of triggers, maintaining a cough journal, addressing muscle tension dysphonia if indicated, and developing prophylaxis suppression and laryngeal relaxation based on stimulability. Participants in Group 1 will receive handwritten guidance indicating exercises to practice at home.
89453070|NCT03235466|Active Comparator|Voice Therapy and Heart Rate Variability Biofeedback|Voice therapy as described in Arm 1. HRVB involves measure respiratory rate, heart rate, body temperature and skin conductance. Participants are guided through reduced breathing rate until a resonant frequency is attained. HRVB breathing simulates resonance between the baroreflex rhythm and respiration based rhythm, increasing heart rate variability and baroreceptor sensitivity. Evidence suggests HRVB improves autonomic regularity. We propose this novel modality to address centrally regulated hypersensitivity that perpetuates coughing.
89453071|NCT03235466|Active Comparator|Heart Rate Variability Biofeedback|HRVB as indicated in Arm 2. No instruction will be provided for cough suppression, laryngeal desensitization, voice tasks or hygiene that traditionally reduces cough frequency and severity. This is the experimental arm.
89453072|NCT03665129|Experimental|Dose escalation|IPH5401 at different doses and schedule + Durvalumab
89453073|NCT03665129|Experimental|Cohort expansion NSCLC anti-PD-(L)1 pretreated|IPH5401 at recommended dose and schedule + Durvalumab in NSCLC anti-PD-(L)1 pretreated patients
89453074|NCT03665129|Experimental|Cohort expansion HCC anti-PD-(L)1 naive|IPH5401 at recommended dose and schedule + Durvalumab in HCC anti-PD-(L)1 naive patients
89453075|NCT03665129|Experimental|Cohort expansion HCC anti-PD-(L)1 pretreated|IPH5401 at recommended dose and schedule + Durvalumab in HCC anti-PD-(L)1 pretreated patients
88937770|NCT01814605|Experimental|Subgluteal space group|"The patients in Subgluteal space group will receive sciatic block according to the approach described by Karmakar et al. Ultrasound scanning will be used to identify and mark the greater trochanter laterally and the ischial tuberosity medially. The midpoint will be designated with a marker and will be the site of needle entry.~A 50 to 90 mm 22 G insulated needle will be inserted at the midpoint previously designated and advanced under real time guidance in an out-of-plane approach until the needle reaches the subgluteal space."
88937771|NCT01814605|Active Comparator|Infragluteal space group|The patients in this group will receive sciatic bock according to the approach described by Chan et al. Ultrasound scanning will be used to identify and mark the greater trochanter laterally and the ischial tuberosity medially. The midpoint between these two structures is a rough non-binding estimate of the approximate location of the sciatic nerve. After skin and transducer preparation, a curved 5 MHz(megahertz) transducer will be placed over the subgluteal region in a transverse plane to scan the sciatic nerve. A 50 to 90 mm 22 G needle is used and advanced under real time guidance in an out-of-plane approach until the needle tip is adjacent o the nerve.
88937772|NCT01814618|No Intervention|Observation|These subjects did not have improved sense of smell after surgery and were randomized to this observation group or treatment group. These patients will be observed post-operatively but will not receive the trial medication.
89453076|NCT03235700|Experimental|Adenosine followed by nicorandil|
89453077|NCT03235700|Experimental|Nicorandil followed by adenosine|
88937773|NCT01814618|Experimental|Treatment|"These subjects did not have improved sense of smell after surgery and were randomized to this treatment group or the observation. These patients will be observed post-operatively and will receive a 3-month course of topical nasal steroids(budesonide respules).~Drug: Budesonide Respules~Other Names:~Pulmicort respules~Subjects irrigate their noses with budesonide respules. They will use one respule per nostril twice daily for three months."
88937774|NCT01814631||Aloka|image quality and resolution
88937775|NCT01814644|Active Comparator|Standard Care|Individual assessment Lifestyle counseling
88937776|NCT01814644|Experimental|TRIMM Intervention|Individual assessment Lifestyle counseling Text messages
88937777|NCT01814683|Experimental|Primaquine 7 day|Standard blood schizontocidal therapy plus 7 days of supervised primaquine (7mg/kg total dose) administered once per day (1.0 mg/kg OD) followed by 7 days of placebo.
88937778|NCT01814683|Placebo Comparator|Placebo controlled arm|Standard blood schizontocidal therapy plus 14 days placebo.
88937779|NCT01814683|Active Comparator|Primaquine 14 day|Standard blood schizontocidal therapy plus 14 days of supervised primaquine (7mg/kg total dose) administered once per day (0.5 mg/kg).
88937780|NCT01814709|Experimental|Itraconazole Arm|
88937781|NCT01814709|Experimental|Rifampin Arm|
88937782|NCT01814826|Experimental|MLN4924 and Azacitidine|
88937783|NCT01814839|Active Comparator|ALN-TTRSC (revusiran)|
88937784|NCT01814839|Placebo Comparator|Sterile Normal Saline (0.9% NaCl)|
88937785|NCT01814852|Experimental|Shockwaves|4 weekly sessions of low-intensity shockwave therapy
88937786|NCT01814852|Sham Comparator|Control Group|
88937787|NCT01814865|Experimental|Abiraterone Acetate + Prednisone|Abiraterone 1000mg PO OD + Prednisone 5mg PO OD x 2 weeks
88937788|NCT01814865|Active Comparator|Aromatase Inhibitor|Anastrozole 1mg PO OD x 2 weeks
88937789|NCT01814891|Experimental|Orange maize|"Children were fed orange maize and the intervention name was orange"
88937790|NCT01814891|Active Comparator|Blue vitamin A group|Received vitamin A in the form of retinyl palmitate in oil at the estimated average requirment.
88937791|NCT01814891|Placebo Comparator|White|Received oil only at the same volume as the vitamin A group
88937792|NCT01814904|Experimental|MCI-196-L|MCI-196 BSA eq 3g
88937793|NCT01814904|Experimental|MCI-196-M|MCI-196 BSA eq 6g
88937794|NCT01814904|Experimental|MCI-196-H|MCI-196 BSA eq 9g
88937795|NCT01814904|Active Comparator|CBPB|Calcium-based P binder
88937796|NCT01814917|Experimental|MCI-196 (Flexible dose)|MCI-196 BSA eq 3g, 6g, 9g, 12g or 15g
88937797|NCT01814917|Active Comparator|CBPB|Calcium-based P binder
88937798|NCT01814930|No Intervention|Routine Care|Routine postpartum contraceptive counseling
88937799|NCT01814930|Experimental|Individual counseling|Brief standardized contraceptive counseling intervention
88937800|NCT01814943||Patients with prescription for low dose ASA (75-300 mg/day)|
88937801|NCT01814956|Experimental|1|i.v. lipid emulsion for parenteral nutrition
88937802|NCT01814956|Active Comparator|2|i.v. lipid emulsion for parenteral nutrition
88937803|NCT01814969|Experimental|Hyperfractionated Radiochemotherapy|"radiotherapy in rectal tumor area due to the placing of pelvic nodal groups to a total dose of 42 Gy, 1.5 Gy d fx 2 times a day; (gap between the factions min. 6-8h) - duration of treatment 2.5 weeks with simultaneous two cycles of chemotherapy according to the scheme: 5FU-325mg/m2 (bolus) on 1-3 and 16-18 (last 3 days of radiotherapy).~Surgical resection has to be done within 14 days or 5-6 weeks after the completion of hyperfractionated radiochemotherapy (HRTCT)."
88937804|NCT01814969|Active Comparator|Hyperfractionated Radiotherapy|"radiotherapy in rectal tumor area due to the placing of pelvic nodal groups to a total dose of 42 Gy, 1.5 Gy d fx 2 times a day; (gap between the factions min. 6-8h) - duration of treatment 2.5 weeks.~Surgical resection has to be done within 14 days or 5-6 weeks after the completion of hyperfractionated radiotherapy (HRT)."
88937805|NCT01814982|Experimental|Part 1: JNJ-17299425|JNJ-1729425 will be administered once as 1 milligram (10 milliliter of a 0.1 milligram/milliliter (mg/ml) solution) intravenous bolus injection over 2 minutes in central vein. In case of no toxicity or Intra cranial pressure response, dose will be increased to a maximum of 200 milligram (mg).
88937806|NCT01814982|Experimental|Part 2: JNJ-17299425|JNJ-1729425 will be repeated once at a dose (which is, determined by Investigator in Part 1) as intravenous bolus injection over 2 minutes in central vein.
88937807|NCT01814995|Experimental|Nutrition/Physical Activity Intervention|There will be four in-person group sessions (1/month), two including the participants' partners, and all with on-site child care. Sessions will include preparation of a healthy meal (hands-on) and discussions of mindful eating, balanced meals, portion sizes, and preparing food at home, under a dietitian's supervision. Sessions will also include a one-hour physical activity information/practice session with a kinesiologist. Participants will track daily step counts with a pedometer and aim to eventually reach more than 10,000 steps/day. They will also receive instruction and demonstration from a kinesiologist of some simple resistance exercises they may perform at home. Between sessions, participants will receive advice and support through a study-specific website and telephone calls.
88937808|NCT01815021|Experimental|amorphous calcium carbonate|50, 100 and 200 mg elemental calcium tablets, according to the doctor's decision
88937809|NCT01815021|Active Comparator|crystalline calcium supplements|Tablets, according to the doctor's decision
88937810|NCT01815047|Experimental|200 IU Vitamin D3|A singular daily dose of 200 IU vitamin D3
88937811|NCT01815047|Experimental|2000 IU Vitamin D3|A singular daily dose of 2000 IU vitamin D3
88937812|NCT01815073|Experimental|Live Attenuated Varicella Vaccine + Live Attenuated JE Vaccine|use the left arm flank deltoid muscle adheres to stick cohere place the skin after 75% ethyl alcohol disinfection the hypodermic injection
88937813|NCT01815073|Experimental|Live Attenuated Varicella Vaccine|use the right arm flank deltoid muscle adheres to stick cohere place the skin after 75% ethyl alcohol disinfection the hypodermic injection
88937814|NCT01815073|Experimental|Live Attenuated JE Vaccine|use the right arm flank deltoid muscle adheres to stick cohere place the skin after 75% ethyl alcohol disinfection the hypodermic injection
88937815|NCT01815086|Experimental|124I-labeled anti-amyloid mAb 11-1F4|124I-labeled anti-amyloid mAb 11-1F4 will be infused on day 0. Two and 5 days later, PET/CT scans will be performed.
89453078|NCT03234062|Experimental|25%Cho, 50%Cho, 100%Cho|Diets containing 137.5mg (25% Cho diet), 275mg (50% Cho diet), and 550mg (100% Cho diet) will be given in that order for two weeks each with 2 weeks of washout between.
89453079|NCT03234062|Experimental|25% Cho, 100% Cho, 50% Cho|Diets containing 137.5mg (25% Cho diet) , 550mg (100% Cho diet), and 275mg Cho (50% Cho diet) will be given in that order for two weeks each with 2 weeks of washout between.
89453080|NCT03234062|Experimental|50% Cho, 25% Cho, 100% Cho|Diets containing 275mg (50% Cho diet), 137.5mg (25% Cho diet), and 550mg Cho (100% Cho diet) will be given in that order for two weeks each with 2 weeks of washout between.
89453081|NCT03234062|Experimental|50% Cho, 100% Cho, 25% Cho|Diets containing 275mg (50% Cho diet), 550mg (100% Cho diet), and 137.5mg Cho (25% Cho diet) will be given in that order for two weeks each with 2 weeks of washout between.
89453082|NCT03234062|Experimental|100% Cho, 25% Cho, 50% Cho|Diets containing 550mg (100% Cho diet), 137.5mg (25% Cho diet), and 275mg Cho (50% Cho diet) will be given in that order for two weeks each with 2 weeks of washout between.
89453083|NCT03234062|Experimental|100% Cho, 50% Cho, 25% Cho|Diets containing 550mg (100% Cho diet), 275mg (50% Cho diet), and 137.5mg Cho (25% Cho diet) will be given in that order for two weeks each with 2 weeks of washout between.
89453084|NCT03233984|No Intervention|Leaflet only|Women will only receive a leaflet about endocrine disruptor at home.
89453085|NCT03233984|Active Comparator|non immersive program|In addition of the leaflet, women will sit in the sensibilisation program that will take place in a neutral environment
89453086|NCT03233984|Experimental|immersive program|In addition of the leaflet, women will si in the sensibilisation program that will take place in an immersive environment
89453087|NCT04882631|Experimental|Cumulative Irritation Test|Participants will receive topical applications of three concentrations of PBI-100 Topical Cream, one application of vehicle, one application of sodium lauryl sulfate as a positive control and one application of a plain patch as a negative control daily (excluding weekends) for 21 days or 15 applications.
89453088|NCT03235778|Experimental|group1|Generic name:Felbinac Trometamol Injection;Placebo: normal saline Dosage form:Injection Dosage:11.78mg Volume:0.50ml Frequency:Once Duration:30min A total of 10 subjects, 2 subjects served as pre-test groups, given to the test drug；the remaining 8 subjects,6 received the test drug and 2 received the placebo.
89453089|NCT03235778|Experimental|group2|Generic name:Felbinac Trometamol Injection;Placebo: normal saline Dosage form:Injection Dosage:23.56mg Volume:1.00ml Frequency:Once Duration:30min A total of 8 subjects,6 received the test drug and 2 received the placebo.
89453090|NCT03235778|Experimental|group3|Generic name:Felbinac Trometamol Injection;Placebo: normal saline Dosage form:Injection Dosage:47.13mg Volume:2.00ml Frequency:Once Duration:30min A total of 8 subjects,6 received the test drug and 2 received the placebo.
89453091|NCT03235778|Experimental|group4|Generic name:Felbinac Trometamol Injection;Placebo: normal saline Dosage form:Injection Dosage:94.25mg Volume:4.00ml Frequency:Once Duration:30min A total of 8 subjects,6 received the test drug and 2 received the placebo.
89453092|NCT03235778|Experimental|group5|Generic name:Felbinac Trometamol Injection;Placebo: normal saline Dosage form:Injection Dosage:164.92mg Volume:7.00ml Frequency:Once Duration:30min A total of 8 subjects,6 received the test drug and 2 received the placebo.
89453093|NCT03235778|Experimental|group6|Generic name:Felbinac Trometamol Injection;Placebo: normal saline Dosage form:Injection Dosage:259.16mg Volume:11.00ml Frequency:Once A total of 8 subjects,6 received the test drug and 2 received the placebo. Duration:30min
89453094|NCT03235778|Experimental|group7|Generic name:Felbinac Trometamol Injection;Placebo: normal saline Dosage form:Injection Dosage:377.00mg Volume:16.00ml Frequency:Once A total of 8 subjects,6 received the test drug and 2 received the placebo. Duration:30min
89453095|NCT04439513|Experimental|Dual Artery Compression|time to hemostasis and incidence of radial artery occlusion will be monitored while using a dual artery compression device (Terry-2-band) to achieve hemostasis.
89453096|NCT04439513|Active Comparator|Radial Artery-Only|time to hemostasis and incidence of radial artery occlusion will be monitored while using the device currently approved by the institution (Hemo-Stop) and following institutional protocols for hemostasis.
89453097|NCT03233906|Active Comparator|Chia Seeds|10% of a participants total kcal estimated needs given in chia seeds everyday for 8 weeks.
89453098|NCT03233906|No Intervention|Control|Habitual diet with avoidance of high fiber and high omega-3 fatty acid foods.
89453099|NCT02452970|Experimental|RRx-001 the cisplatin and gemcitabine|Patients with advanced and metastatic biliary tract adenocarcinoma (cholangiocarcinoma) who had been treated with and failed first-line chemotherapy will be treated with RRx-001 (20 mg) intravenously weekly for up to six weeks followed by retreatment with Gemcitabine 1000 mg/m2 and Cisplatin 25 mg/m2 on Days 1 and 8 of a 21 Day Cycle until tumor progression
89453100|NCT04302077|Active Comparator|Telemedicine Post Op|Patients with an even-ending medical record number (0,2,4,6,8) will be randomized to virtual visit/telemedicine. This will be done by using Epic and MyChart-integrated telemedicine functionality for video visits with the Principal Investigator's patients. This is considered standard of care.
89453101|NCT04302077|Active Comparator|In-Office Post Op|Patients with an odd-ending medical record number (1,3,5,7,9) will be randomized to the office visit.
89453102|NCT03233672|Other|Hypo-fractionated postoperative IMRT-SIB|All patients underwent combined, intensified and modulated radiotherapy for five days a week with the following doses: 62.5 Gy to the prostate bed and 45 Gy to pelvis nodes in 25 fractions.
88937816|NCT01815112|Experimental|Alzheimer|Alzheimer patients detected via conventional clinical and neuropsychological tests. They will undergo Magnetic resonance imaging and positron emission tomography examinations.
88937817|NCT01815112|Experimental|Vascular dementia|Vascular dementia patients detected via conventional clinical and neuropsychological tests. They will undergo magnetic resonance imaging and positron emission tomography examinations.
88937818|NCT01815112|Experimental|Mild cognitive impairment (MCI)|Mild cognitive impairment (MCI) patients detected via conventional clinical and neuropsychological tests. They will undergo magnetic resonance imaging and positron emission tomography examinations.
88937819|NCT01815112|Experimental|Healthy subjects (MRI)|Healthy subjects agreeing to undergo magnetic resonance imaging examination.
89023557|NCT05156671|Placebo Comparator|Placebo/ control substance (NaCl 0.9%)|100 mL saline as single dose infusion
89023558|NCT05155163|No Intervention|Treatment as Usual|Treatment as usual for opioid use disorder
89453103|NCT04854941|Experimental|Probiotics group (PRO)|99 patients with COVID-19 infection who have been supplemented with a Lactobacillus and Bifidobacterium containing probiotic in addition to standard regimen (oxygen support, antiviral, antibacterial, anticoagulant, anticytokine (tocilizumab and olokizumab) drugs and dexamethasone treatment according to indications and contraindications)
89453104|NCT04854941|No Intervention|Control group (CON)|101 patients with COVID-19 infection who have been treated with standard regimen only (oxygen support, antiviral, antibacterial, anticoagulant, anticytokine (tocilizumab and olokizumab) drugs and dexamethasone treatment according to indications and contraindications)
89453105|NCT03227900|Active Comparator|Lidocaine|LIdocaine dissolved in water for injections
89453106|NCT03227900|Placebo Comparator|Placebo|Water for injections
89453107|NCT03227978|Experimental|PCL mesh group|Intervention: The participants will be received thoracoscopic bullectomy and abrasion of pleura, then PCL mesh will be applied over the lung.
89453108|NCT03227744|Active Comparator|Enrolled in group therapy|Patients in the group therapy arm will be enrolled in group therapy and be issued surveys.
89453109|NCT03227744|Placebo Comparator|Not enrolled in group therapy|Patients in control arm will be issued surveys
89453110|NCT03233516||Cases with clinical CAP|Children 1-59 months at Sachs' Children and Youth Hospital with clinical CAP (both severe and non-severe) according to WHO-criteria.
89453111|NCT03233516||Control subjects|Children 1-59 months at Sachs' Children and Youth Hospital treated for a minor orthopedic (elective (e.g. hand surgery) or acute) or minor surgical disease, e.g. minor trauma (excluding e.g. appendicitis, major burns, major trauma).
89453112|NCT03227822|Experimental|Short spot stenting|Short spot stenting
89453113|NCT03227822|Experimental|Long lesion stenting|Long lesion stenting
89453114|NCT02452736|Experimental|Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System|This is a Single arm, Non-randomized Study. All patients meet the eligibility criteria and sign the informed consent form will participate in this study.
88937820|NCT01815112|Experimental|Healthy subjects (PET)|Cognitively healthy subjects. These subjects are people addressed in the nuclear medicine department for cancer-related positron emission tomography examination. If they agree, an extended neuropsychological test will assess that they do not suffer any cognitive disorder.
88937821|NCT01815125|Experimental|Ondansetron|The intervention of interest will be the administration of one dose of oral ondansetron in the emergency department. The dosage will be 8 mg.
88937822|NCT01815125|Placebo Comparator|Placebo|The control group will receive a similar looking/ tasting pill of placebo.
88937823|NCT01815164|Active Comparator|Hypnotherapy|Hypnotherapy
88937824|NCT01815164|Active Comparator|Educational intervention|Educational intervention
88937825|NCT01815190||IgA-positive vasculitis|Patients with immune complex vasculitis who show perivascular deposits of IgA
88937826|NCT01815190||IgA-negative vasculitis|Patients with immune complex vasculitis who show no perivascular deposits of IgA
88937827|NCT01815203|Experimental|Caffeine|Administration of one gelatin capsule containing 200-300 mg of caffeine with subsequent cognitive tasks and food test.
88937828|NCT01815203|Placebo Comparator|Placebo|Administration of placebo (one gelatin capsule containing starch) with subsequent cognitive tasks and food test.
88937829|NCT01815216|Experimental|Bariatric surgery|patients participating in the intervention group , i.e. assessing effects of bariatric surgery on: Brain activity in resting state Memory performance
88937830|NCT01815216|Active Comparator|Control|"Patients in the control group will not undergo surgery during study.~These patients will be examined twice:~9 weeks before the operation (i.e. clinical intervention to reduce body weight has not started).~after 4 weeks of low-calorie diet (which will be a week before their surgery, when patients are in a catabolic metabolism because they eat much less energy than is needed) to assess effect of acute weight loss on: Brain activity in resting state Memory performance"
88937831|NCT01815255||tenofovir (TDF)|HIV-infected children who are currently on TDF-based regimen or are changing to TDF based on their clinical indication
88937832|NCT01815268|Experimental|HD Vaccine (Residents) + Free Vaccine (Staff)|NH facilities randomized to receive high-dose trivalent influenza vaccine (Fluzone High-Dose) for the residents and provided free SD vaccine (Fluzone) for the staff.
88937833|NCT01815268|Experimental|HD Vaccine (Residents) + Usual Care (Staff)|NH facilities randomized to receive high-dose trivalent influenza vaccine (Fluzone High-Dose) for the residents and not provided free vaccine for the staff.
88937834|NCT01815268|Active Comparator|SD Vaccine (Residents) + Free Vaccine (Staff)|NH facilities randomized to receive standard dose influenza vaccine (Fluzone) for the residents and provided free standard dose vaccine (Fluzone) for the staff.
88937835|NCT01815268|Active Comparator|SD Vaccine (Residents) + Usual Care (Staff)|NH facilities randomized to receive standard dose influenza vaccine (Fluzone) for the residents and not provided free vaccine for the staff.
89453115|NCT03120104|Active Comparator|Pre-intervention group|Pre-intervention group interventions:pelvic floor muscle training for one month (2~3 times a week, for 4 weeks) just one month before the stoma closure
89453116|NCT03120104|Active Comparator|Post-intervention group|Post-intervention group: pelvic floor muscle training for one month (2~3 times a week, for 4 weeks) two weeks after the stoma closure
89453117|NCT03120182|Active Comparator|Aspirin Arm|The patients will receive acetylsalicylic acid (100mg once a day, orally) for 12 days whereas the normal ASA treatment will be resumed 12 days after randomization
89453118|NCT03120182|Placebo Comparator|Placebo Arm|The patients will receive placebo oral tablets for 12 days whereas the normal ASA treatment will be resumed 12 days after randomization
89453119|NCT02074436|Experimental|Prophylactic EACA|Prophylactic EACA 1000 mg PO twice daily if platelets < 20 x 10⁹/L
89453120|NCT02074436|Active Comparator|Platelet transfusion|Platelet transfusion if platelet count is < 20 x 10⁹/L in the outpatient or < 10 x 10⁹/L in the inpatient setting
89453121|NCT02452814||Cohort|
89453122|NCT01575548|Experimental|Arm A (Pazopanib)|Patients receive pazopanib hydrochloride PO QD on days 1-28. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
89453123|NCT01575548|Placebo Comparator|Arm B (Placebo)|Patients receive placebo PO QD on days 1-28. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
89453124|NCT03233282|Other|Cognitive Fatigability|
88937836|NCT01815294|Experimental|Treatment A: DOXIL/CAELYX (doxorubicin)|50 mg/m2 of doxorubicin manufactured at the current site of manufacturing administered by IV infusion over 90 minutes on Day 1
88937837|NCT01815294|Experimental|Treatment B: DOXIL/CAELYX (doxorubicin)|50 mg/m2 of doxorubicin manufactured at the new site of manufacturing (test product) administered by IV infusion over 90 minutes on Day 1
88937838|NCT01813669|Experimental|Integrative Coping Group|"The proposed 12-week intervention will integrate yoga-based skills with cognitive-behavioral principles. The development of this program was based on existing and empirically-validated cognitive-behavioral interventions for youth (i.e., Coping Cat and Cat Project; Kendall et al.) and therapeutic yoga interventions (e.g., Galantino et al., 2008 for review). The intervention will be broken down into four three-week modules, which address the following:~Module 1: Introduction to group and awareness of body Module 2: Awareness of emotion and developing an understanding of the mind-body connection Module 3: Focus on cognitive process Module 4: Experiential practice and therapeutic discussions"
88937839|NCT01813669|No Intervention|Waitlist Control|Participants in the waitlist condition will not receive any experimental intervention. They can continue any treatments as usual. The waitlist will be approximately 10-14 weeks in duration. At the end they will be offered the opportunity to participate in the intervention. If they elect to participate in the intervention, post-study data will also be collected from this group, approximately 13-weeks following the first group session.
88937840|NCT01815307|Experimental|Gemcitabine group|1000mg/m2, day 1 every 2 weeks
88937841|NCT01815307|Experimental|S-1 group|80mg/m2/day, day 1-28, every 6 weeks
88937842|NCT01815320|Experimental|Contrast-enhanced ultrasound (CE-US)|Ce-US is performed by contrast agent infusion SonoVue. The acquisition protocol will consist of two different administrations of SonoVue, performed 10 minutes apart. In the first session, SonoVue microbubbles will be administered as a fast 1.5 ml bolus immediately followed by 5 ml saline solution. In the second session, max 2 vials (9.6 ml) of SonoVue will be infused at an infusion rate between 0.5 and 1.0 ml/min.
88937843|NCT01815346|Experimental|Acupuncture Group - Twice a Week|Acupuncture 2 times a week for 6 weeks. Participants receive acupuncture to the arms, legs, and abdomen. The acupuncture needles will be left in place for about 20 minutes.
88937844|NCT01815346|Experimental|Acupuncture Group - Three Times a Week|Acupuncture 3 times a week for 4 weeks. Participants receive acupuncture to the arms, legs, and abdomen. The acupuncture needles will be left in place for about 20 minutes.
88937845|NCT01815372|Experimental|SPEDI|These are the patients that will be randomized to receive a SPEDI block of the sciatic and saphenous nerve with at single needle penetration of the skin
88937846|NCT01815372|Active Comparator|Popliteal sciatic and mid-femoral saphenous|These are the patients that will be randomized to the administration of a popliteal sciatic nerve block combined with a mid-femoral saphenous nerve block with two separate injections
88937847|NCT01815398|Active Comparator|Computer skills training|26 sessions conducted 2-3 times a week to train in computer skills related to the workforce.
88937848|NCT01815398|Experimental|Cognitive Remediation|26 sessions conducted 2-3 times a week of cognitive remediation
88937849|NCT01815411|Experimental|Mushroom extract|The patients are given the mushroom extract (Andosan) in doses 30 mlx2 per day for 1 days. The experimental group is selected by randomisation.
88937850|NCT01815411|No Intervention|Control group|The control group is selected by randomisation.
88937851|NCT01815437|Active Comparator|2000 IU Vitamin D3- Cholecalciferol|Take 2000 IU crystalline vitamin D3 once/day for 12 weeks.
88937852|NCT01815437|Active Comparator|2000 IU Vitamin D2- Ergocalciferol|Take 2000 IU crystalline vitamin D2 supplement once/day for 12 weeks.
88937853|NCT01815437|Experimental|2000 IU Mushroom Vitamin D2|Take 2000 IU vitamin D2 in a mushroom supplement once/day for 12 weeks
88937854|NCT01815437|Placebo Comparator|Mushroom Extract|Capsules with mushroom extract and no vitamin D. The intervention is mushroom extract.
88937855|NCT01815463||colorectal neoplasia|No interventions Record colorectal neoplasia
88937856|NCT01815476|Other|RT Positioning Intervention: Supine|Patient will be treated in a supine position as per standard of care/control.
88937857|NCT01815476|Experimental|RT Positioning Intervention: Prone|Patient will be treated in the prone position.
88937858|NCT01815528|Experimental|Catumaxomab|Catumaxomab treatment followed by an established chemotherapy regimen
88937859|NCT01815541|Experimental|teicoplanin|this group receive the teicoplanin
88937860|NCT01815554||DPS Cohort|All patients implanted with a DPS within the past 5 years at one of 6 collaborating sites will be included. Patients will be interviewed as they cross their 1st, 3rd, 5th or 7th anniversary with the DPS.
88937861|NCT01815567||controlled hypertension|hypertension with medication controlled
88937862|NCT01815567||uncontrolled hypertension|non-controlled hypertension
88937863|NCT01815567||hypertensive urgency|hypertensive urgency no previous history or antihypertensives
88937864|NCT01815567||asymptomatic normotensive|asymptomatic normotensive control group
88937865|NCT01815593|Experimental|Enhanced External Counterpulsation|Men with erectile dysfunction receive Enhanced External Counterpulsation treatment
88937866|NCT01815593|No Intervention|Control|Men with erectile dysfunction without Enhanced External Counterpulsation treatment
89453125|NCT03233282|Other|Physical Fatigability|
88937867|NCT01815606|Active Comparator|19 Gauge needle biopsy|biopsy with 19 gauge needle
88937868|NCT01815606|Active Comparator|25 gauge needle biopsy|biopsy with 25 gauge needle
88937869|NCT01815632|Experimental|Early infusion of autologous marrow|Intravenous infusion of autologous bone marrow (without myeloablation) on the day of bone marrow harvest. Infusion of autologous blood at one year post-harvest
88937870|NCT01815632|Experimental|Late infusion of autologous marrow|Intravenous infusion of autologous blood on the day of bone marrow harvest. Infusion of autologous bone marrow (without myeloablation) at one year post-harvest
88937871|NCT01815658||Broken humerus shaft|Patients presenting with broken humerus shaft
89453126|NCT03222986||Sepsis with organ failure|Patients have organ failure
88937872|NCT01815684|Experimental|ASP3652 Group 1|Dosed according to the following scheme: placebo, low dose, medium dose, high dose
88937873|NCT01815684|Experimental|ASP3652 Group 2|Dosed according to the following scheme: low dose, placebo, medium dose, high dose
89453127|NCT03222986||Sepsis without organ failure|Patients have no organ failure
88937874|NCT01815684|Experimental|ASP3652 Group 3|Dosed according to the following scheme: low dose, medium dose, placebo, high dose
88937875|NCT01815684|Experimental|ASP3652 Group 4|Dosed according to the following scheme: low dose, medium dose, high dose, placebo
88937876|NCT01815697|Experimental|Enhanced External Counterpulsation|Men with benign prostatic hyperplasia receive 35- 36 hours Enhanced External Counterpulsation treatment
88937877|NCT01815697|No Intervention|Control|Men with benign prostatic hyperplasia without Enhanced External Counterpulsation treatment as control
88937878|NCT01815710||Vomiting & Diarrhea|Alberta Health Services Acute Childhood Vomiting & Diarrhea Pathway
88937879|NCT01815710||Pediatric Asthma Clinical Pathway|Pediatric Asthma Clinical Pathway
88937880|NCT01815723|Experimental|FP187|500 mg FP187 daily (250 mg twice daily)
88937881|NCT01815723|Active Comparator|Dimethyl fumarate|720 mg Fumaderm® daily (240 mg three times daily)
88937882|NCT01815723|Placebo Comparator|Placebo|Matching FP187 and Fumaderm® placebo
88937883|NCT01815762|Active Comparator|active arm of the study|The number of ultrasound lung comets (ULC) will directly adjust the prescribed post-hemodialysis dry weight. The US B-line score (BLS) will be measured before dialysis. In patients presenting moderate to severe lung congestion (≥15 BLS pre-dialysis) LUS measurements will be repeated once a week until the treatment goal was achieved (<15 BLS pre-dialysis) and once a month thereafter. monthly monitoring frequency will be adopted also in patients without pulmonary congestion (BLS <15). Patients without evidence of lung congestion at baseline who developed pulmonary congestion (≥ 15 BLS) during the trial will received the same treatment contemplated for those with lung congestion at baseline during the trial.
88937884|NCT01815762|No Intervention|Standard care arm|In the control arm of the study, the dry weight will be assessed only clinically.Patients in the control arm of the study will be followed up and managed strictly with standard criteria according to current recommendations (implying optimization of fluids volume control on the basis of clinical criteria and the use of carvedilol, ACE inhibitors/sartans whenever deemed necessary); the use of lung US / bioimpedance assistance was not allowed in these patients.
88937885|NCT01815775|Experimental|Normal pressure hydrocephalus|Hydrocephalus patients planned for shunting surgery. They will undergo clinical and imaging examinations at day 1, 3 months and 1 year after their surgery.
88937886|NCT01815801|Experimental|Ventilated group|Lungs were mechanically ventilated during subclavian vein catheterization.
88937887|NCT01815801|Active Comparator|Control group|Lungs were not mechanically ventilated during subclavian vein catheterization.
88937888|NCT01815814|Experimental|Rolfing After 3-Month Wait|The children in this arm receive the therapy (rolfing / myofascial structural integration) 3 months after they start the study.
88937889|NCT01815814|Other|Rolfing After 6-Month Wait|The children in this arm receive the therapy (rolfing / myofascial structural integration) 6 months after they start the study.
88937890|NCT01815827|Active Comparator|Caucasian Healthy volunteers|
88937891|NCT01815827|Experimental|Japanese Healthy volunteers|
88937892|NCT01815853|Experimental|Neoadjuvant Chemoradiotherapy|Radiotherapy (45Gy/25f) + 3 cycles of XELOX Chemotherapy (Capecitabine 1000mg/m2, d1-14 + Oxaliplatin 130mg/m2 D1; 21-days/cycle) following with D2 Gastrectomy and 3 cycles of Adjuvant XELOX Chemotherapy
88937893|NCT01815853|Active Comparator|Neoadjuvant Chemotherapy|3 cycles of XELOX Chemotherapy (Capecitabine 1000mg/m2, d1-14 + Oxaliplatin 130mg/m2 D1; 21-days/cycle) following with D2 Gastrectomy and 3 cycles of Adjuvant XELOX Chemotherapy
88937894|NCT01815866||CF with culturable NTM|CF patients who produce culturable aerosols of NTM will receive the following test: pulmonary function test, collecting a sputum culture if possible, coughing for 5 minutes into a tube connected to a canister, hypertonic saline and albuterol will be given after the 5 minutes of coughing and then they would repeat with another 5 minutes of coughing. There can be a break inbetween the coughing if needed.
88937895|NCT01815879||Control Group|Retrospective review of clinical data on at least 1,000 evaluable US patients with 12+weeks follow up that were treated with 90Y resin microsphere radioembolization for metastatic colorectal liver metastases
88937896|NCT01815892|Active Comparator|Withdrawal of Furosemide|The patient's Furosemide will be withdrawn
88937897|NCT01815892|Experimental|Administration of furosemide|The patient will receive furosemide 120 mgms daily
88937898|NCT01815905|Active Comparator|Traditional therapy|Traditional rehabilitation therapy
88937899|NCT01815905|Experimental|Mobile program|Mobile program for occupational and speech therapy
88937900|NCT01815931||ED patients|
88937901|NCT01815944|Active Comparator|0.75% Ropivacaine and normal saline|Ultrasound-guided supraclavicular block using 0.75% ropivacaine diluted with normal saline
88937902|NCT01815944|Experimental|0.75% ropivacaine and dextrose 5%|Ultrasound guided supraclavicular block using 0.75% ropivacaine diluted with dextrose 5%
88937903|NCT01815970|Experimental|Pulmonary Rehabilitation|8 weeks of Pulmonary Rehabilitation
88937904|NCT01815996||Pregnant Women|"Females between the age of 18-80 who are pregnant~One time blood draw to look at patient's DNA"
88937905|NCT01815996||Pulmonary Embolism Patients|"Male and Female patients that have suffered a pulmonary embolism within the past 48 hours~One time blood draw to look at patient's DNA"
88937906|NCT01815996||Myocardial Patients|"Male and Female patients who have myocardial infarction in the past 48 hours.~One time blood draw to look at patient's DNA"
88937907|NCT01815996||Autoimmune Patients|"Male and Female patients that have been diagnosed with an Autoimmune disease~One time blood draw to look at patient's DNA"
88937908|NCT01815996||Healthy Controls|"Self-declared healthy adults (men and women).~One time blood draw to look at patient's DNA"
88937909|NCT01814735|Experimental|Brown rice|Brown Rice
88937910|NCT01814735|Active Comparator|White rice|White rice
88937911|NCT01816009|Experimental|6 weeks|the duration of antibiotic treatment will be six weeks.
88937912|NCT01816009|Active Comparator|12 weeks|the duration of antibiotic treatment will be 12 weeks.
88937913|NCT01816035|Experimental|Treatment (trastuzumab emtansine)|Patients receive trastuzumab emtansine IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity. Patients achieving response may continue treatment.
89201016|NCT00904137|Active Comparator|Tape|Elastoplast tape applied to keep the elbow in flexion, with a collar-and-cuff
89453128|NCT02451722|Active Comparator|Healthy subjects|"Kyboot shoes will be administered to the healthy subjects.~Pressure distribution and gait parameters will be recorded in comparison with their normal footwear."
89453129|NCT02451722|Active Comparator|Diabetic patients|"Kyboot shoes will be administered to the diabetic patients.~Pressure distribution and gait parameters will be recorded in comparison with their normal footwear."
89453130|NCT02451644|Experimental|high risk for PTD with pedometer|Patient with high risk for preterm delivery including short cervix or rapture of membranes
89453131|NCT03222908|No Intervention|Control: Prescriptive Advice|Amenable patients will be enrolled into the study, their intervention will be current standard of care smoking cessation counseling by their surgeon, they will undergo 3 urine tests and a chart review for outcomes.
89453132|NCT03222908|Experimental|Intervention1: Contract Agreement|Amenable patients will be enrolled into the study, their intervention will be a smoking cessation contract with their surgeon, they will undergo 3 urine tests and a chart review for outcomes.
89453133|NCT03222908|Experimental|Intervention2: Implementation Intentions|Amenable patients will be enrolled into the study, their intervention will be a worksheet to fill out with their smoking cessation implementation intentions that will be signed by patient and surgeon, they will undergo 3 urine tests and a chart review for outcomes.
89453134|NCT03228056|Experimental|uniportal VATS lobectomy|"uniportal VATS lobectomy~thoracic epidural block (0.125% bupivacaine with epinephrine 1:50000, continuous infusion 3-4 ml/hour)~ketoprofene 100 mg i.v every 12 hours~paracetamol 1000 mg i.v every 8 hours~rescue doses of morphine in PCA system (bolus dose 2 mg i.v)~pain intensity measured in VAS scale"
89453135|NCT03228056|Active Comparator|two-ports VATS lobectomy|"two-ports VATS lobectomy~thoracic epidural block (0.125% bupivacaine with epinephrine 1:50000, continuous infusion 3-4 ml/hour)~ketoprofene 100 mg i.v every 12 hours~paracetamol 1000 mg i.v every 8 hours~rescue doses of morphine in PCA system (bolus dose 2 mg i.v)~pain intensity measured in VAS scale"
89453136|NCT03228056|Active Comparator|three-ports VATS lobectomy|"three-ports VATS lobectomy~thoracic epidural block (0.125% bupivacaine with epinephrine 1:50000, continuous infusion 3-4 ml/hour)~ketoprofene 100 mg i.v every 12 hours~paracetamol 1000 mg i.v every 8 hours~rescue doses of morphine in PCA system (bolus dose 2 mg i.v)~pain intensity measured in VAS scale"
89453137|NCT02452658|Experimental|Changed menu|All participants will be exposed to the same changed menu after making their hypothetical choice. Changes will include reduced calorie labels, reduced prices, and changes to item descriptions.
89453138|NCT03227666|Experimental|Intervention Group|The intervention group will perform three supervised group training sessions a week, consisting of 30 minutes of balance training for 4 weeks.
89453139|NCT03227666|No Intervention|Control group|The control group recieves a health consultation that highlights the importance of physical activity and balance exercise according to standard practice within the HAI project. They are asked to return after 4 weeks for follow up.
89453140|NCT04486040|Active Comparator|Drainage group|Patients with drainage after hip revision arthroplasty
89453141|NCT04486040|Active Comparator|No-drainage group|Patients without drainage after hip revision arthroplasty
89453142|NCT04485884|Experimental|Group A|IN-C005 dose A
89453143|NCT04485884|Experimental|Group B|IN-C005 dose B
89453144|NCT04485884|Experimental|Group C|IN-C005 dose C
89453145|NCT04485884|Experimental|Group D|IN-C005 dose D
89453146|NCT04485884|Experimental|Group E|IN-C005 dose E
89453147|NCT04485884|Experimental|Group F|IN-C005 dose F
89453148|NCT03227510||HCC Cases (Group 1)|This group will include 63 subjects and the diagnoses will be based on clinical examination, laboratory tests such as (Liver Function tests, Alpha-fetoprotein , Ultrasound, and biopsy in some cases if possible (Depends on the patients and their financial issues).
89453149|NCT03227510||Chronic Liver Diseases (group 2)|This group will be including 31 patients, and the diagnoses will be based on laboratory such as (liver function tests, viral markers, AFP,) and by ultrasound findings (shrunken liver, coarse echo-pattern, attenuated hepatic vein and finding nodular surface)
89453150|NCT03227510||Healthy Volunteer (group 3)|"It will include 32 subjects that serve as control group.~These all patients and control groups will be subject the following parameters: Biochemical tests such as (Liver function tests, viral markers, serum AFP, CBC, Kidney functions and others) and circulating MicroRNAs levels of all these subjects."
89453151|NCT03227432|Experimental|Nivolumab + Elotuzumab|"22 patients will be entered, If > 4 patients achieve at least a partial response (PR) within 4 cycles an additional 18 patients will be treated.~Nivolumab will be administered intravenously twice per cycle for cycle 1-4~Nivolumab will be administered intravenously once per cycle for cycle 5~Elotuzumab will be administered intravenously 4 times per cycle for cycle 1-2~Elotuzumab will be administered intravenously twice per cycle for cycle 3-4~Elotuzumab will be administered intravenously once per cycle for cycle 5"
89453152|NCT03227432|Experimental|Nivolumab+Elotuzumab+Pomalidomide+Dexamethasone|"Nivolumab will be administered intravenously twice per cycle for cycle 1-4~Nivolumab will be administered intravenously once per cycle for cycle 5~Elotuzumab will be administered intravenously 4 times per cycle for cycle 1-2~Elotuzumab will be administered intravenously twice per cycle for cycle 3-4~Elotuzumab will be administered intravenously once per cycle for cycle 5~Pomalidomide will be administered for 21 days per cycle~Dexamethasone will be administered weekly"
89453153|NCT03222596|Experimental|Multiple Sclerosis Exercise|Ambulatory and non-ambulatory MS individuals that will exercise-group (MSE). Intervention is exercise training.
89453154|NCT03222596|No Intervention|Multiple Sclerosis Control (no-Exercise)|Ambulatory and non-ambulatory MS individuals that will not exercise-group (MSC).
89453155|NCT03222674|Experimental|Single arm|CAR T cells to treat AML
89453156|NCT04485572||Straight Leg Raise test and Bragard test|Patients referred to the radiology department, allocated to undergo MRI scan and neurodynamic tension tests
89453157|NCT04485572||Fajersztajn test (F) and Sicard test (S)|Patients referred to the radiology department, allocated to undergo MRI scan and neurodynamic tension tests
89453158|NCT04485572||Passive Neck Flexion test (PNF)and Kernig test (K)|Patients referred to the radiology department, allocated to undergo MRI scan and neurodynamic tension tests
89453159|NCT04485572||Slump test (ST) and Dejerine triad (DT)|Patients referred to the radiology department, allocated to undergo MRI scan and neurodynamic tension tests
88937914|NCT01816087|Experimental|brief assessment tool (BAT)|all participants will have a brief assessment tool (BAT) for the identification of geriatric syndromes performed by their general practitioner. Afterwards, all participants will have a full geriatric assessment performed by geriatricians
88937915|NCT01816113|Experimental|Group 1|4 volunteers; 1 dose of ChAd63 PvDBP 5 x 10^9 vp intramuscularly
88937916|NCT01816113|Experimental|Group 2A|4 volunteers; 1 dose of ChAd63 PvDBP 5 x 10^10 vp intramuscularly
88937917|NCT01816113|Experimental|Group 2B|8 volunteers; 1 dose of ChAd63 PvDBP 5 x 10^10 vp intramuscularly and 1 dose MVA PvDBP 1 x 10^8 pfu 8 weeks later intramuscularly
88937918|NCT01816113|Experimental|Group 2C|8 volunteers; 1 dose of ChAd63 PvDBP 5 x 10^10 vp intramuscularly and 1 dose MVA PvDBP 2 x 10^8 pfu 8 weeks later intramuscularly
88937919|NCT01816126||one-operator technique|
88937920|NCT01816126||two-operator technique|
88937921|NCT01815177|Experimental|Arthroscopic transosseous fixation|Patients with torn rotator cuff randomized to experimental treatment receive a complete arthroscopic transosseous cuff repair
88937922|NCT01815177|Other|Repair using suture anchors|Patients randomized to this arm receive an arthroscopic rotator cuff repair using suture anchors.
88937923|NCT01816178|Experimental|communication training|Participants were instructed in the use of a voices output communication aid.
88937924|NCT01816191|Experimental|Diltiazem Hydrochloride|Topical cream and oral pill
88937925|NCT01816204|Experimental|Therapist assisted online treatment (TAO)|Students assigned to treatment with weekly online modules and weekly 10-15 minute video conference with counselor.
88937926|NCT01816204|Active Comparator|face-to-face individual therapy|weekly individual 50 minute psychotherapy sessions.
88937927|NCT01816217|Experimental|Intubated patient|Adult intubated in Intensive Care Unit (ICU) with The McGrath Mac videolaryngoscope (intervention described)
88937928|NCT01816269||Patients with scaling and patients without scaling|No drug
88937929|NCT01816269||Helicobacter eradicated or non-eradicated|
88937930|NCT01816282|Experimental|Evicel|
88937931|NCT01816282|No Intervention|Control|
88937932|NCT01816321|Experimental|Corifollitropin alfa followed by hpHMG|
88937933|NCT01816321|Active Comparator|recombinant FSH|
88937934|NCT01816334|Active Comparator|methylprednisolone|administration of 60 mg of methylprednisolone at 8:00 am and 100 ml of 0.9 % sodium chloride (placebo) at 6:00 pm
88937935|NCT01816334|Active Comparator|Ketoprofen|administration of 100 mg of ketoprofen at 8:00 am and at 6:00 pm
88937936|NCT01816334|Placebo Comparator|sodium chloride|administration of 100 ml of 0.9% sodium chloride (placebo) at 8:00 am and at 6:00 pm
88937937|NCT01816347||Routine PCI patients|
88937938|NCT01816360|Experimental|Aromatherapy group|20 sessions of olfactory aromatherapy using protocol.
88937939|NCT01816360|Experimental|Yogatherapy group|20 sessions of yogatherapy with aroma-placebo using protocol.
88937940|NCT01816360|Experimental|Aromatherapy-Yogatherapy group|20 sessions of yogatherapy with olfactory aromatherapy, using protocol.
88937941|NCT01816360|No Intervention|Control group|Control group in the waiting-list model (all volunteers were offered the treatment after the completion of data collection).
88937942|NCT01816373|Other|Vacuum Bell|Patients with pectus excavatum will be treated with the Vacuum Bell device
88937943|NCT01816399||Routine coronary angiography patients|
88937944|NCT01816412|Experimental|LDCB|Paclitaxel Coated Balloon
88937945|NCT01816412|Active Comparator|PTA|Standard Uncoated Balloon Angioplasty Catheter PTA Catheter
88937946|NCT01816425|Experimental|thermoplastic partial denture|The patients that need oral rehabilitation with partial denture will receive a thermoplastic partial denture as treatment
88937947|NCT01816425|Active Comparator|CoCr partial denture|The patients that need oral rehabilitation with partial denture will receive a CoCr partial denture as treatment
88937948|NCT01816464|Experimental|Trivalent Influenza Vaccine|"The formulation based on the WHO recommendation for influenza vaccines for 2013 for the Southern-hemisphere included the following vaccine strains:~an A/California/7/2009 (H1N1)pdm09-like virus;~an A/Victoria/361/2011 (H3N2)-like virus;~a B/Wisconsin/1/2010-like virus.~Dose: Single Dose 0.5 mL of TIV from pre-filled syringe."
88937949|NCT01816503||Fentanyl matrix|
88937950|NCT01816516|Experimental|Healthy Babies|Participants receive the Healthy Babies curriculum via 6 in home lessons and 3 follow up telephone calls delivered by Extension paraprofessionals.
88937951|NCT01816516|Active Comparator|EFNEP|Participants receive the Expanded Food and Nutrition Education Program (EFNEP) curriculum via 6 in home lessons delivered by Extension paraprofessionals.
88937952|NCT01816529|Experimental|Topical Diltiazem Hydrochloride 2% Cream|0.2 g cream applied topically to the infrascapular area of the back under occlusive patch conditions, 3 times weekly for 3 weeks and one time at Challenge. A total of 10 patch applications over 6-8 weeks.
88937953|NCT01816529|Placebo Comparator|Vehicle Cream|0.2 g cream applied topically to the infrascapular area of the back under occlusive patch conditions, 3 times weekly for 3 weeks and one time at Challenge. A total of 10 patch applications over 6-8 weeks.
88937954|NCT01816529|Active Comparator|0.1% solution of sodium lauryl sulfate (SLS)|0.2 mL applied topically to the infrascapular area of the back under occlusive patch conditions, 3 times weekly for 3 weeks and one time at Challenge. A total of 10 patch applications over 6-8 weeks.
88937955|NCT01816529|Placebo Comparator|0.9% Saline|0.2 mL applied topically to the infrascapular area of the back under occlusive patch conditions, 3 times weekly for 3 weeks and one time at Challenge. A total of 10 patch applications over 6-8 weeks.
88937956|NCT01816542|Other|patch tests on healthy skin|
88937957|NCT01816555|Experimental|Vitamin D- Normal Level at Screening|Subjects will have surgery as their initial breast therapy. If subjects have a normal level of Vitamin D(25-hydroxyVit D 30-100ng/mL), they will be assigned to this group.
89453160|NCT03222518|Active Comparator|Parcetamol Group|The patient receives an envelope containing Paracetamol 1000 mg at the dose of 3 times / day + follow-up sheet + appointment card.
88937958|NCT01816555|Experimental|Vitamin D- Insufficient or Deficient Level at Screening|Subjects will have surgery as their initial breast therapy. If subjects are insufficient (25-hydroxy Vit D 21-29 ng/mL)or deficient (25-hydroxyVit D <20ng/mL) Vitamin D levels, they will be assigned to this group.
88937959|NCT01816568|Active Comparator|Group 1|SILS appendectomy
88937960|NCT01816568|Active Comparator|Group 2|Three port laparoscopic appendectomy
88937961|NCT01816581|Active Comparator|Targin/OxyNorm|Patients randomized to this study arm will receive Targin as basis pain medication and additional OxyNorm (Oxycodone), if requested by the patients.
88937962|NCT01816581|Active Comparator|PCA|Patients randomized to this group will receive a PCA pump with morphine. The basic rate is 0.3 mg/h. Patients will be allowed to administer 1 mg each five minutes after a vesting period of five minutes, if subjectively needed.
88937963|NCT01816607||Rectal cancer|
88937964|NCT01816620|Experimental|Lenalidomide, dexamethasone|Lenalidomide 10mg qd d1-21 & dexamethasone 40mg qw d1,8,15,22
88937965|NCT01816633|Experimental|AutoloGel|Subjects will be treated on average twice a week for the first 2 weeks, and then, once a week thereafter while under active treatment, but actual frequency of treatment will be determined by the treating physician. All subjects will receive AutoloGel treatment.
88937966|NCT01816646|Experimental|Cidofovir|Patients receive a single dose of 2.5 mg/kg of cidofovir administered in 100 ml of normal saline solution through a transurethral catheter inside the bladder. The urinary catheter will be clamped for 2 hours. Probenecid 2 grams by mouth given approximately 3 hours prior to the bladder instillation of cidofovir.
88937967|NCT01816659|Experimental|Metformin + Colon Surgery|Patients randomized to Metformin-ER 500 mg once daily for one week and then escalation to 1000 mg/day for the duration of the trial. The duration of the trial will be from the preoperative endoscopy till the surgery, and should be not less than 10 days and not more than 30 days.
88937968|NCT01816659|No Intervention|Colon Surgery Alone|Patients will not receive any study drug from the time of colonoscopy until surgery.
88937969|NCT01816672|Active Comparator|AutoloGel|AutoloGel treatment
88937970|NCT01816672|Other|Usual and Customary Care|Standard of care
88937971|NCT01816698|Active Comparator|Taurine|Interventions Drug: Taurine granule Arms: Group 1
88937972|NCT01816698|Placebo Comparator|Placebo|Interventions Drug: Placebo Arms: Group 2
88937973|NCT01816724||Men with nocturia|Men older than 60 years old suffering from nocturia (one or more voidings overnight) without exclusion criteria
88937974|NCT01816724||Women with nocturia|Women older than 60 years old suffering from nocturia (one or more voidings overnight) without exclusion criteria
88937975|NCT01816750|Experimental|Anatomical accuracy Cardiac GSI vs ICA|The identification and quantification of coronary artery stenoses using Cardiac in comparison to ICA.
88937976|NCT01816750|Experimental|Stress perfusion Cardiac GSI vs MPI-SPECT|Assessment of the functional impact of coronary stenoses using Cardiac GSI in comparison to MPI-SPECT
88937977|NCT01816750|Experimental|Delayed enhancement Cardiac GSI vs CMR|Assessment of abnormal myocardial tissue characteristics representing ischaemic or scarred tissue using Cardiac GSI in comparison to CMR.
88937978|NCT01816789|Active Comparator|"Group A: age"|Group A: long standard protocol (buserelin 0.1 ml s.c. twice per day from the 21st day of the cycle, until the end of gonadotropin administration) + 150 IU of rFSH (starting dose) if female age was ≤35 years or 225 IU of rFSH if female age was ≥ 36 years.
88937979|NCT01816789|Experimental|"Group B: nomogram"|Group B: long standard protocol (buserelin 0.1 ml s.c. twice per day from the 21st day of the cycle until the end of gonadotropin administration) + individualized starting dose of rFSH on the basis of the nomogram.
88937980|NCT01816802||In-vitro fertilization using Eeva|Patients undergoing in-vitro fertilization treatment who provide informed consent and use Eeva in their treatment cycle.
88937981|NCT01816815|Experimental|BAY1002670 [0.1mg]|0.1 mg BAY1002670, oral administration, four tablets to be taken daily, 84 consecutive days
88937982|NCT01816815|Experimental|BAY1002670 [0.5mg]|0.5 mg BAY1002670, oral administration, four tablets to be taken daily, 84 consecutive days
88937983|NCT01816815|Experimental|BAY1002670 [1.0mg]|1.0 mg BAY1002670, oral administration, four tablets to be taken daily, 84 consecutive days
88937984|NCT01816815|Experimental|BAY1002670 [2.0mg]|2.0 mg BAY1002670, oral administration, four tablets to be taken daily, 84 consecutive days
88937985|NCT01816815|Experimental|BAY1002670 [5.0mg]|5.0 mg BAY1002670, oral administration, four tablets to be taken daily, 84 consecutive days
88937986|NCT01816815|Placebo Comparator|Placebo|Placebo for BAY1002670, oral administration, four tablets to be taken daily, 84 consecutive days
88937987|NCT01816828|Experimental|Immediate|In the immediate arm, participants will begin the 8 session group motivational interviewing intervention, Gay Poz Sex, within 2 weeks of randomization.
88937988|NCT01816828|Active Comparator|Wait List/Standard of Care|Participants in the wait list/standard of care group will be given active referrals to existing community resources available to HIV+ MSM. For ethical reasons, participants randomized to the control group will have the option to attend the Gay Poz Sex program after a 6-month wait period.
88937989|NCT01816841|Experimental|Diagnostic (COE and DVFE)- Arm I|Arm I - Patients undergo COE followed by DVFE. Patients with tissue abnormalities found by COE or DVFE undergo biopsy within 2 weeks.
88937990|NCT01816841|Experimental|Arm II - Comparison of surgical margins using COE vs. DVFE|Comparison of surgical margins using COE vs. DVFE
88937991|NCT01816854||Patients with PAD|
88937992|NCT01816867||Patients with a ventral hernia|
89453161|NCT03222518|Active Comparator|NSAID Group|The patient receives an envelope containing NSAID 20 mg piroxicam twice daily / day + follow-up sheet + appointment card.
89453162|NCT03222518|Active Comparator|NSAID + Paracetamol Group|The patient receives an envelope containing NSAID 20 mg piroxicam at a dose of 2 times/day + Paracetamol 1000 mg at a dose of 3 times / day + follow-up sheet + appointment card.
89453163|NCT03222440|Experimental|SHR-1210+ Radiotherapy|Radiotherapy,intensity modulated radiation therapy (IMRT), 54-60 Gy, 1.8-2.0 Gy per fraction ,5 fractions per week, for 6 weeks. Radiation begun the day after the first dose of SHR-1210. SHR-1210 (200mg fixed dose every 2 weeks, one cycle is four weeks, total 8 cycles ) will be administered as an intravenous infusion over 30 minutes.
89453164|NCT03222206|Experimental|Salsalate|17 patients received continuous medication with salsalate 2g/day after run-in period
89453165|NCT03222206|Placebo Comparator|Placebo|17 patients received continuous medication with Placebo 2g/day after run-in period
89453166|NCT04484714|Experimental|Behavioural: Exercise|"Participants will take part in a twelve week resistance and aerobic exercise program twice per week delivered virtually.~Exercise sessions will include a combination of aerobic, resistance, balance, and flexibility exercises"
89453167|NCT03227276|Placebo Comparator|Placebo|
89453168|NCT03227276|Experimental|Litramine|
89453169|NCT04485650|Experimental|Music group|The music were chosen by a researcher under guidance of an expert and grouped as relaxing, classical, mystical, and Turkish folk music. One of them was chosen by the patients following the application of spinal anesthesia in the music group. The number of participants:30
89453170|NCT04485650|Active Comparator|Sedated group|Sedation was performed to the sedated group after spinal anesthesia based on the height and weight data and the doctor's decision. The number of participants:30
89453171|NCT04485650|Other|Non-sedated group|The patients in the non-sedated group were followed without any procedure (sedation and music). The number of participants:30
89453172|NCT03227120|Experimental|Prehabilitation Exercise|Receives Prehabilitation exercise program for three times a week for eight weeks of direct outpatient exercise instruction.
89453173|NCT03227120|No Intervention|Control|Receives the usual standard of care which is a one time Strength and Flexibility written home exercise program provided during total joint education pre-surgery class.
89453174|NCT03227198|Experimental|Intramyocardial injection of stem cell|Intramyocardial injection of autologous bone marrow mononuclear cells in patients with Heart Failure
89453175|NCT03227198|Placebo Comparator|Placebo|Placebo intramyocardial injection in patients with Heart Failure
89453176|NCT03222284|Experimental|Group 1|"N=10 Device intervention~1. Cornerstones4Care Powered by Glooko App Visits Day 1 Day 7 Day 28"
89453177|NCT03222284|Experimental|Group 2|"N=20 Device intervention~1. Cornerstones4Care Powered by Glooko App Visits Day 1 Day 28"
89453178|NCT03222362||patients 85 years and above|120 consecutive patients (male and female), aged 85 years and above, who underwent pars plana vitrecromy in the Tel Aviv Medical Center during the years 01/01/2006 - 31/12/2013, and were followed by physicians in the ophthalmology department in the center until December 2015.
89453179|NCT02451566||Fast-Track Group|Includes subject who complete the Fast-Track EVAR protocol.
89453180|NCT02451566||Standard P-EVAR Group|Includes subjects who do not complete the Fast-Track EVAR protocol, and their procedures are completed with bilateral percutaneous access.
89453181|NCT02451566||Standard EVAR Group|Includes subjects who do not complete the Fast-Track EVAR protocol, and their procedures are not completed with bilateral percutaneous access (i.e. converted to femoral cutdown or open surgical repair).
89453182|NCT03232970|Experimental|FPD group|This group will undergo three months of weekly lectures to incorporate more fiber in their diet.
89453183|NCT03232970|No Intervention|FPD Control group|This group will receive all the assessments before, during and after the three months program period but will not attend the weekly lectures.
89453184|NCT04484792|Experimental|Group A|
89453185|NCT04484792|Experimental|Group B|
89453186|NCT04484792|Placebo Comparator|Group C|
89453187|NCT03222050|Experimental|electronic toy group|Distraction technique was given by electronic toy during immunization and started 30 seconds before immunization and it lasted until 15 seconds
89453188|NCT03222050|Experimental|key toy group|Distraction technique was given by key toy during immunization and started 30 seconds before immunization and it lasted until 15 seconds
89453189|NCT03222050|Experimental|Simple toy group|Distraction technique was given by simple toy during immunization and started 30 seconds before immunization and it lasted until 15 seconds
89453190|NCT03222050|No Intervention|control group|Routine care was given during immunization and no intervention was given
89453191|NCT03221816|Placebo Comparator|Placebo Oral Tablet|"Sixty women were postmenopausal selected from the outpatient Gynecology Hospital Santa Marcelina that passed by routine consultations and fulfilling the inclusion criteria were invited to the study.~The women were randomly allocated to control or experimental group (30 in each group) in a double-blind controlled clinical trial.~The control group received the same tablet with the organoleptic characteristics of Tenavit® for a period of 4 months."
89453192|NCT03221816|Experimental|Experimental group (Tenavit®)|"Sixty women were postmenopausal selected from the outpatient Gynecology Hospital Santa Marcelina that passed by routine consultations and fulfilling the inclusion criteria were invited to the study.~The experimental group received one tablet of Tenavit® (pyridoxine hydrochloride 4.00mg + folic acid 0.80mg + cyanocobalamin 0.40 mg) daily and the placebo group received the same tablet with the organoleptic characteristics of Tenavit® for a period of 4 months."
89453193|NCT03221894||Conventional therapy with herbs|Patients were treated with conventional therapy with Chinese herbal medicine (GRAPE granules).
89453194|NCT03221894||Conventional therapy alone|In conventional therapy group, donepezil was the commonly used ChEI(cholinesterase inhibitor) to treat mild to severe AD patients. Memantine, a NMDA(N-methyl-D-aspartate ) antagonist, was given to moderate and severe AD patients. The dose of donepezil ranged from 5 to 10 mg once a day according to patients.
89453195|NCT03226964|Experimental|High flow nasal oxygen|(Optiflow; Fisher & Paykel, Auckland, New Zealand)
89453196|NCT03226964|Active Comparator|Nasal prongs|
89453197|NCT03119870|Experimental|1|Each subject will conduct 3 sessions, i.e. a training session, an anatomical MRI session and an EEG session. The first session will be to train the subject to carry out the different behavioral tasks that he will then have to perform during the session of EEG.
89453198|NCT03120026|Experimental|Experimental Product|Two servings (40 grams each) of powder (Fortifit; Nutricia) which has to be dissolved in 125 ml of water. Per serving, 20 g whey protein, 3 g total leucine, 9 g carbohydrates, 3 g fat, 800 IU vitamin D, and a mixture of vitamins, minerals, and fibers.
89453199|NCT03120026|Placebo Comparator|Isocaloric Placebo|Two servings (40 grams each) of an isocaloric (maltodextrins) powder which has to be dissolved in 125 ml of water.
89453200|NCT03226886||All patients|"In London renal cell carcinoma patients undergo nephrectomy at centres for urological oncology, including the Royal Marsden, Guy's and St Thomas', St Georges, Charing Cross and Kings Hospitals. It is not uncommon for the same patients to undergo palliative resection for metastatic sites of disease. The majority of tissue from these resections does not undergo routine histopathological examination. As such, it is ethically feasible to use these specimens for laboratory research in the presence of patient consent. Practically, these specimens are often large, thereby offering considerable scope for a range of molecular analyses.~CAPTURE Sub-study:~We plan to enrol patients/participants into three groups:~Group A: patients with confirmed or suspected COVID-19 and a history of cancer Group B: patients without a history of COVID-19 infection and a history of cancer Group C: Hospital staff with or without a history of COVID-19"
89453201|NCT03107468|Experimental|Mokhuri intensive treatment group|Patients in this arm will be treated with 35-week of Mokhuri intensive treatment program which compromise 10 sessions of acupuncture, Chuna and patient consultation during 5 weeks.
89453202|NCT03107468|Active Comparator|Non-surgical conventional treatment group|Patients in this arm will be treated with 10 sessions of non-surgical conventional standard treatment including conventional drug treatment and injection treatment during 5 weeks.
88937993|NCT01816880||Healthy Elderly|Age 90 and over Gender: Male and Female Enrolled in the Healthy Elderly (HEAL) study prior to enrollment in this sub-study Blood sample of approximately 20mL is drawn.
89453203|NCT03226574|Experimental|RTX epidural injection|Epidural injection of 1.5mL/min RTX under the guidance of epidurogram.
89453204|NCT03119636|Experimental|NPC transplantation|The patients will receive Levodopa combined with a regular neural precursor cell (NPC) transplantation
89453205|NCT03119636|Experimental|HLA-matched NPC transplantation|The patients will receive Levodopa combined with a HLA-matched neural precursor cell (NPC) transplantation
89453206|NCT03119636|Experimental|HLA-non-matched NPC transplantation|The patients will receive Levodopa combined with a HLA-non-matched neural precursor cell (NPC) transplantation
89453207|NCT03107234||Patient with breast cancer requiring surgery to|
89453208|NCT03232814|Experimental|Group-based walking|Participants will engage in one supervised outdoor group-based walking session per week for the 8 week program.
89453209|NCT03226496|Experimental|Intervention Group|This group receives a brief motivational interviewing session about PrEP
89453210|NCT03226496|No Intervention|Control Group|This group receives standard of care clinic based counseling about PrEP
89453211|NCT03232502|No Intervention|Control|
88937994|NCT01816919|Experimental|eNose breath samples|
88937995|NCT01816958||chronic depression and/or pain|co-administration of TMS and infused ketamine for patients with chronic pain of psyche and/or soma
89453212|NCT03232502|Experimental|Intervention|
89453213|NCT03226340|Experimental|S-amlodipine + Chlorthalidone|patients will receive S-amlodipine 2.5mg + Chlorthalidone 25mg p.o. once a day for 12 weeks.
89453214|NCT03226340|Active Comparator|S-amlodipine + Telmisartan|patients will receive S-amlodipine 2.5mg + Telmisartan 40mg p.o. once a day for 12 weeks.
89453215|NCT03221504|Active Comparator|Antibiotic therapy for 10 days|After 7 days of cefuroxime treatment (oral, intravenous or sequential), patients from day 8 to day 10 will continue to receive the antibiotic (in blinded bottle).
89453216|NCT03221504|Experimental|Antibiotic therapy for 7 days|After 7 days of cefuroxime therapy (oral, intravenous or sequential), children from day 8 to day 10 will receive placebo (in blinded bottle).
89453217|NCT03221582|Experimental|EBR/GZR (Zepatier) - HCV/HIV co-infected|Drug: Elbasvir (EBR) 50 mg and Grazoprevir (GZR) 100 mg single tablet by mouth, once daily.
89453218|NCT03221582|Experimental|EBR/GZR (Zepatier) - HCV monoinfected|Drug: Elbasvir (EBR) 50 mg and Grazoprevir (GZR) 100 mg single tablet by mouth, once daily.
89453219|NCT03232268|Experimental|HLA-mismatched microtransplantation|HLA-mismatched microtransplantation without immunosuppressive treatment
89453220|NCT03221348|Experimental|Open label treatment|Study drug (CHO-H01) administered on Day 1 of 28 day cycles up to 6 cycles total.
89453221|NCT03221114|Experimental|Positive Psychological Intervention|Our culturally-tailored Positive Psychology (PP) Intervention is a non-pharmacotherapy approach aimed at increasing positive emotional experiences by teaching individuals to engage in intentional activities known to increase psychological and emotional well-being through targeting of constructs such as optimism, gratitude, mindfulness/relaxation, and resilience.
89453222|NCT03221114|No Intervention|Wait list control|Receipt after the active treatment group has completed the positive psychological intervention.
89453223|NCT03232034|Placebo Comparator|Calcium Citrate|Calcium citrate (1000 mg calcium) will be consumed by participants in the morning between 8-10 am after 8-14 h fasting. Blood samples, appetite scales and expired breath samples will be taken in a regular intervals for 2 h after ingestion.
89453224|NCT03232034|Active Comparator|Milk Mineral Supplement|Milk mineral supplement (equating to 1000 mg calcium) will be consumed by participants in the morning between 8-10 am after 8-14 h fasting. Blood samples, appetite scales and expired breath samples will be taken in a regular intervals for 2 h after ingestion.
88937996|NCT01816997|Placebo Comparator|Control|IFG subjects with total cholesterol less than 200 mg/dL will be served as controls.
88937997|NCT01816997|Active Comparator|Pravastatin|The impaired fasting glucose (IFG) subjects with total cholesterol 200-280 mg/dL will be randomized into two groups: pravastatin 40 mg or rosuvastatin 10 mg.
88937998|NCT01816997|Experimental|Rosuvastatin|The impaired fasting glucose (IFG) subjects with total cholesterol 200-280 mg/dL will be randomized into two groups: pravastatin 40 mg or rosuvastatin 10 mg.
88937999|NCT01817010|Experimental|Multi-Component Rehabilitation (CMC)|The CMC group will receive a multi-component program focused on rehabilitation of the abdominal and core musculature, neuromuscular re-education through therapeutic exercise as well as hip and knee muscle strengthening beginning 2 weeks after THA.
88938000|NCT01817010|Active Comparator|Control (CON)|The CON group will participate in physical therapist recommended activities based on their home rehabilitation and then will complete the same CMC rehabilitation intervention beginning 10 weeks after THA.
88938001|NCT01817023|Experimental|RT alone|SIB-IMRT was given to the patients with a regimen of 69.96Gy-73.92Gy to the gross target volume, 60Gy to the high risk clinical target volume, 50Gy to the low risk clinical target volume
89015521|NCT06258824||Pancreatic Cancer (PDAC)|A clinical diagnosis of PDAC was defined by results of a multidisciplinary team meeting consisting of at least a consultant hepatopancreaticobiliary surgeon, consultant hepatopancreaticobiliary physician, consultant histopathologist and consultant radiologist. ERCP findings, endoscopic ultrasound findings, biliary brushing cytology, and fine needle aspiration cytology were anonymised and recorded. The combination of a pancreatic mass on radiographic imaging without acute cholangiopathy, and clinical or radiographic progression after ≥12 months of follow-up, or death clinically and radiographically determined to be due to pancreatic cancer. For surgical resection and biopsy specimens, diagnoses and staging were rendered based on standard histo-morphological criteria. For the purposes of analysis, pathological staging was used in preference to clinical staging where possible.
89015522|NCT06258824||Cholangiocarcinoma (CCA)|A clinical diagnosis of CCA was defined by radiological criteria according to results of a multidisciplinary team meeting consisting of at least a consultant hepatopancreaticobiliary surgeon, consultant hepatopancreaticobiliary physician, consultant histopathologist and consultant radiologist. ERCP findings, endoscopic ultrasound findings, biliary brushing cytology, and fine needle aspiration cytology were anonymised and recorded. This was also determined based on clinical or radiographic progression after ≥12 months of follow-up, or death clinically and radiographically determined to be due to cancer. For surgical resection and biopsy specimens, diagnoses and staging were rendered based on standard histo-morphological criteria. For the purposes of analysis, pathological staging was used in preference to clinical staging where possible.
89015523|NCT06258824||Benign|A clinical diagnosis of benign disease was defined by assessment at ERCP as well as results of a multidisciplinary team meeting consisting of at least a consultant hepatopancreaticobiliary surgeon, consultant hepatopancreaticobiliary physician, consultant histopathologist and consultant radiologist. Any patients with a benign aetiology were either clinically determined on the basis of no further progression after ≥12 months follow-up with either documented resolution or stability of prior ductal abnormalities or no further intervention as documented in electronic hospital records at 12 months.
89015524|NCT06258798||One group of patients (double gate)|"Study design:~Direction of data collection: retrospective~Number of gates (sets of eligibility criteria): double gate (AI, human)~Participant sampling method: Consecutive~Method of allocating participants to index tests: Each participant received all index tests~Number of reference standards: Single test standard~Limited verification: Full verification (not limited)"
89015525|NCT06258772||Severe, uncontrolled CRSwNP patients in therapy with Mepolizumab|
89015526|NCT06258759|Experimental|experimental: semen|a semen of normal semen analysis
89015527|NCT06258759|Experimental|placebo: semen|a semen of normal semen analysis
89015528|NCT06258720|Experimental|Lu AF82422 Dose Level 1|Participants will receive a single intravenous (IV) infusion of Lu AF82422
89015529|NCT06258720|Experimental|Lu AF82422 Dose Level 2|Participants will receive a single IV infusion of Lu AF82422
89015530|NCT06258707|Experimental|LuxBoost Group|the experimental group will receive the LuxBoost intraocular lens.
89015531|NCT06258707|Active Comparator|LuxGood group|the control group will receive the LuxGood parent intraocular lens.
89015532|NCT06258681|Active Comparator|Incentive spirometry group|The incentive spirometry group will continue the 8-week training with Volumetric Triflo. Individuals will be expected to exhale normally and hold their breath for at least 3 seconds after taking as deep a breath as possible. In the first week after surgery, the individual will be asked to work with an incentive spirometry in 10 repetitions every hour when awake. The group also followed standard program which includes phases of chest physiotherapy (modified postural drainage and assisted coughing techniques) and early progressive mobilization (gradually increasing walking distance in the corridor depending on patient tolerance). Participants in both groups will continue aerobic exercise training in the clinic until the end of the 8th week after discharge. Aerobic exercise training includes a bicycle ergometer, two days a week, 20-30 minutes, and perceived effort in the range of 60-70% of the maximal heart rate, in the range of 4-6 according to the Modified Borg Scale.
89015533|NCT06258681|Experimental|Individualized respiratory training group|In the first week after surgery, the personalized breathing exercise device will be adjusted to the resistance level corresponding to 40% of the initial pressure load, MIP, and MEP measurements. Participants will be asked to rest and repeat the training for ten sets following five breathing cycles. In each set, there will be a one-minute rest break between repetitions. Participants can practice both inspiratory and expiratory respiratory muscle training in a single breathing cycle. As the progression progresses, the perceived exertion level will be increased by 5-10% every week to a range of 4-6 according to the Modified Borg Scale. The training will continue for eight weeks.
89015534|NCT06258668||Participants diagnosed with moderate-to-severe plaque psoriasis|
89015535|NCT06258655|No Intervention|Pre-intervention|The sample collected before the intervention
89015536|NCT06258655|Experimental|Post-intervention|The sample collected after the intervention
89015537|NCT06258642|Experimental|Irinotecan Liposome and anlotinib|The treatment is continued until disease progression or intolerable toxicity
89015538|NCT06258629||control group|Age and sex matched healthy control individuals
89015539|NCT06258629||Case group|Available number of patients with newly diagnosed as hematological malignancy
89015540|NCT06258629||Case group after 6 months|Available number of patients with newly diagnosed as hematological malignancy after 6 months of starting treatment.
89015541|NCT06258577||candidates|In the first phase, patients with hepatosplenomegaly of unknown etiology will be initially screened using an electronic medical record database, and in the second phase, laboratory analysis of biomarkers, including Dry blood spot (DBS) for GBA1 enzyme activity, plasma Lyso-GB1 levels and GBA1 gene sequencing, will be performed.
89015542|NCT06258577||control|Compare the blood test with the candidates group.
89015543|NCT06258551||Intensive Care Unit|Patients admitted to an intensive care unit (No interventions administered)
89015544|NCT06258551||Bone Marrow Transplant Unit|Patients admitted to a cancer treatment center for allogeneic stem cell transplantation (No interventions administered)
89453225|NCT03232034|Experimental|Milk mineral supplement plus Whey Protein Hydrolysate|Milk mineral supplement (equating to 1000 mg calcium) plus whey protein hydrolysate (50 g) will be consumed by participants in the morning between 8-10 am after 8-14 h fasting. Blood samples, appetite scales and expired breath samples will be taken in a regular intervals for 2 h after ingestion.
89453226|NCT03225950||Chronic periodontitis donors|"Donors are medically healthy.~Slow to moderate attachment loss and bone destruction.~Good correlation between etiological factors and serverity of attachment loss."
88938002|NCT01817023|Active Comparator|CCRT group|SIB-IMRT was given to the patients with regimen of 69.96Gy-73.92Gy to the gross target volume, 60Gy to the high risk clinical target volume, 50Gy to the low risk clinical target volume and cisplatin 100mg/m2 was given at d1, d22,d43 during radiotherapy.
89453227|NCT03225950||Aggressive periodontitis donors|"Donors are medically healthy.~Rapid attachment loss and bone destruction.~Familial aggregation.~No correlation between etiological factors and serverity of attachment loss."
89453228|NCT03225950||Control donors|"Donors are medically healthy.~No sign of inflammatory conditions."
89453229|NCT03119948|Placebo Comparator|Group 1|Placebo in soleus and placebo in rectus femoris, and placebo in additional muscles as per investigator's choice among tibialis posterior, toe flexors (long or short), gastrocnemius muscles or peroneus longus.
89453230|NCT03119948|Active Comparator|Group 2|Botulinum toxin type A in soleus and placebo in rectus femoris, and Botulinum toxin type A in additional muscles as per investigator's choice among tibialis posterior, toe flexors (long or short), gastrocnemius muscles or peroneus longus.
89453231|NCT03119948|Active Comparator|Group 3|Botulinum toxin type A in soleus and in rectus femoris, and Botulinum toxin type A in additional muscles as per investigator's choice among tibialis posterior, toe flexors (long or short), gastrocnemius muscles or peroneus longus.
89453232|NCT03221270|Experimental|tACS Treatment & tACS Maintenance|10 Hz (alpha) tACS with a peak-to-peak amplitude of 2 mA for 20 minutes twice daily during 5 consecutive days of stimulation. 10 Hz (alpha) tACS with a peak-to-peak amplitude of 2 mA for 40 minutes once weekly for 8 weeks of maintenance stimulation.
89453233|NCT03221270|Sham Comparator|Sham tACS Treatment & Sham tACS Maintenance|10 seconds of ramp in to 1 minute of 10 Hz (alpha) tACS with a ramp out of 10 seconds for a total of 80 seconds of stimulation twice daily during 5 consecutive days of stimulation. 10 seconds of ramp in to 1 minute of 10 Hz (alpha) tACS with a ramp out of 10 seconds for a total of 80 seconds of stimulation once weekly for 8 weeks of maintenance stimulation.
89453234|NCT03221270|Other|Sham tACS Treatment & tACS Maintenance|10 Hz (alpha) tACS with a peak-to-peak amplitude of 2 mA for 40 minutes once weekly for 8 weeks of maintenance stimulation.10 Hz (alpha) tACS with a peak-to-peak amplitude of 2 mA for 40 minutes once weekly for 8 weeks of maintenance stimulation.
89453235|NCT03221270|Other|tACS Treatment & Sham tACS Maintenance|10 Hz (alpha) tACS with a peak-to-peak amplitude of 2 mA for 20 minutes twice daily during 5 consecutive days of stimulation. 10 seconds of ramp in to 1 minute of 10 Hz (alpha) tACS with a ramp out of 10 seconds for a total of 80 seconds of stimulation once weekly for 8 weeks of maintenance stimulation.
89453236|NCT03232112|Active Comparator|Exenatide 2 MG Injection|Bydureon® (exenatide) is supplied as powder and solvent for prolonged release injection (once-weekly). Bydureon® is delivered in a carton containing four pens. Each single-dose, dual-chamber pen contains 0.65 ml of diluent and 2 mg of exenatide, which are isolated until mixed by the person administering the drug. Needles are supplied with the pen.
89453237|NCT03232112|Placebo Comparator|BD PosiFlush (saline)|The placebo will be supplied for as pre-filled saline syringes (BD PosiFlush™, BD Worldwide) containing 3 ml each. Needles are bought separately.
89453238|NCT04485806|Other|GPS / LM versus SPL/LM|to determine the effect of micro droplet geometry in 3D dishes (GPS) or 2D dishes (SPL) in combination with light mineral oil (LM).
89453239|NCT04485806|Other|GPS/PO versus SPL/PO|to determine the effect of micro droplet geometry in 3D dishes (GPS) or 2D dishes (SPL) in combination with paraffin oil (PO).
89453240|NCT04485806|Other|GPS/PO versus GPS/LM|to determine the effect of oil overlay light mineral(LM) or paraffin oil (PO) in combination with paraffin oil 3D dishes (GPS).
89453241|NCT04485806|Other|SPL/PO versus SPL/LM|to determine the effect of oil overlay light mineral(LM) or paraffin oil (PO) in combination with paraffin oil 2D dishes (SPL).
89453242|NCT03119558|Experimental|18F-Florbetaben (Neuraceq®) PET/MRI|Participants with known or suspected cardiac amyloidosis will be injected with 8 mCi of 18F-Florbetaben (Neuraceq®) and undergo the PET/MRI image acquisition 45-60 minute post-injection. PET and MRI data will be acquired simultaneously to ensure optimal timing and spatial correspondence between MRI and PET data. Total scan time will take approximately 60 minutes.
89453243|NCT03119480||Hospital-acquired AKI|Adult patients with Hospital-acquired AKI
89453244|NCT03231956||Group 0|Control Sepsis Mimic Group (minor infections or asthma/COPD exacerbations) venous blood lactate levels are not required for this subgroup.
89453245|NCT03231956||Group 1|Suspected infection plus Initial Venous Blood Lactate ≥ 0 - 1.9 mmol/dL
89453246|NCT03231956||Group 2|Suspected infection plus Initial Venous Blood Lactate ≥ 2.0 - 3.9 mmol/dL
89453247|NCT03231956||Group 3|Suspected infection plus Initial Venous Blood Lactate ≥ 4.0 mmol/dL
89015545|NCT06258538|Experimental|distal robot-assisted and task-oriented therapy|Participants in the Circuit group received interventions for 20-min exoskeleton(EXO) and 20-min end-effector(EE) robot-assisted therapy, followed by 20-min uni- and 20-min bi- task-oriented therapy/session, 3 sessions/week for 6 consecutive weeks.
89015546|NCT06258538|Experimental|distal robot-assisted therapy alone|Participants in the Robot group received interventions for 40-min exoskeleton(EXO) and 40-min end-effector(EE) robot-assisted therapy/session, 3 sessions/week for 6 consecutive weeks.
89015547|NCT06258538|Active Comparator|task-oriented therapy alone|Participants in the task-oriented therapy(TOT) group received interventions for 40-min uni- and 40-min bi- task-oriented therapy/session, 3 sessions/week for 6 consecutive weeks.
89015548|NCT06258512|Experimental|Intervention with narrative approach + standard care|"Intervention with a narrative approach. The objectives will be:~Know significant moments in the personal history of the participant and her family according to her life cycle. as well as structural elements.~Know information regarding symptoms of non-organic origin, pain crises, personal and family resources for their management.~Implement a narrative technique as an alternative for the management of symptoms of non-organic origin, including the following strategies: the participant will be able to tell and retell their story, recognize situations or moments that exacerbate the pain, feel the pain and name it, externalization of the pain. problem, the problem is the problem, absolving oneself from traumatic life experiences, constructing meaning to one&#39;s dominant stories through the organization of the experience, to obtain a new meaning of what was experienced through the story, construction of alternative stories."
89015549|NCT06258512|No Intervention|control with standard care|Participants randomly assigned to the control group will receive usual care from their primary care professionals.
89015550|NCT06258499|Experimental|BHA|Subjects treated with BHA + standard of care
89015551|NCT06258499|No Intervention|Control|Subjects treated as per standard of care
89015552|NCT06258486|Experimental|ICG Injection|This patient will undergo ICG injection into the lymph nodes in order to see if there are any leaks.
89015553|NCT06258486|Placebo Comparator|ICG non-injection|This patient will not have ICG injection. the lymphadenectomy is considered complete at this point.
89015554|NCT06258473|Experimental|Multicomponent decentralized care|mHealth plus decentralized primary care The multi-component intervention aims to increase access to primary care, and to improve care quality and patient retention. The intervention package includes mHealth, decentralization with task sharing, community-based care, and supportive monitoring visits
89015555|NCT06258473|Active Comparator|mHealth|In subdistrict with mHealth intervention only, we will provide the same training on hypertension and diabetes care to physicians and nurses at NCD corner in UHC, and training to use Simple App for hypertension and diabetes management. Quarterly supervision by higher-level health administrators and medical professionals to NCD corner helps solve issues with patient management, medication supply, etc. Visits may be informed by a performance summary made available by the Simple App dashboard. Two supportive visits by the study team will be organized to help NCD Corner solve technical issues with Simple App. The healthcare providers at NCD Corner will decide how they react to the information made available by the digital tool, and similarly, the patient component will not be included. Patient pathways remain the same as usual care.
89015556|NCT06258473|No Intervention|Usual care|Existing usual care provided by government primary care system including screening, treatment initiating, drug refill, and routine follow-up, at subdistrict NCD corner. Community clinics and CHWs have less involvement in NCD care provision.
89015557|NCT06258434||high risk CRC screening group|Prospective enrollment of subjects with pre-defined high risk factors for developing colorectal cancer or CRC patients
89453248|NCT02554786|Experimental|QMF149 150/160 µg|QMF149 (Indacaterol acetate/Mometasone furoate) 150/160 μg was delivered once daily (o.d) via Concept1 inhaler in the evening.
89453249|NCT02554786|Experimental|QMF149 150/320 µg|QMF149 (Indacaterol acetate/Mometasone furoate) 150/320 μg was delivered o.d via Concept1 inhaler in the evening.
89453250|NCT02554786|Active Comparator|MF 400 µg|Mometasone furoate (MF) 400 μg was delivered o.d via Twisthaler® in the evening
89015558|NCT06258434||CRC group|Prospective enrollment of subjects with confirmed colorectal cancer
89015559|NCT06258421||Desmoid Tumor Patients|People who have been diagnosed with a desmoid tumor after the age of 18
89015560|NCT06258408|Experimental|BB102 monotherapy|The study is composed of fasted dose cohorts and fed dose cohort. BB102 will be administered orally daily alone as monotherapy in all cohorts. In the fasted dose cohorts, the subjects will receive once daily of BB102 monotherapy fasted across approximately 6 ascending dose levels. The starting dose is 50mg/day. In the fed dose cohort, the subjects will receive once daily of BB102 monotherapy in a fed condition. The dose selected for fed dose cohort must be deemed safe as assessed by safety monitoring committee (SMC).
89015561|NCT06258395||Nursing 2st year|second year nursing students
89453251|NCT02554786|Active Comparator|Salmeterol /fluticasone 50/500 μg|Salmeterol xinafoate/fluticasone propionate 50/500 μg was delivered twice daily (in the morning and in the evening) via Accuhaler®.
89015562|NCT06258395||Nursing 3st year|third year nursing students
89015563|NCT06258395||Nursing 4st year|fourth year nursing students
89015564|NCT06258382||Male with Fontan circulation|Different data will be collected along with several questionnaires concerning reproductive health. Approximate 100 individuals will be included-
89015565|NCT06258382||Female with Fontan circulation|Different data will be collected along with several questionnaires concerning reproductive health. Approximate 100 individuals will be included-
89015566|NCT06258382||Partner to male with Fontan circulation|Different data will be collected along with several questionnaires concerning reproductive health. Approximate 100 individuals will be included-
89453252|NCT02554786|Active Comparator|MF 800 μg|MF 800 μg of total daily dose (400 μg twice daily, in the morning and in the evening) was delivered via Twisthaler®.
89453253|NCT03232190|Experimental|INTNIC|NICU Intervention Group Web Application Infants < 32 weeks
89453254|NCT03232190|No Intervention|CNIC|NICU Control Group No Web Application Infants < 32 weeks
89015567|NCT06258382||Partner to female with Fontan circulation|Different data will be collected along with several questionnaires concerning reproductive health. Approximate 100 individuals will be included-
89015568|NCT06258382||Male control group|Different data will be collected along with several questionnaires concerning reproductive health . Approximate 100 individuals will be included
89015569|NCT06258382||Female control group|Different data will be collected along with several questionnaires concerning reproductive health. Approximate 100 individuals will be included
89015570|NCT06258369|Other|Patients with primary coxarthrosis (any stage).|
89015571|NCT06258369|Experimental|Patients with primary coxarthrosis (any stage) and operated with Total Hip prosthesis (THP).|
89015572|NCT06258369|Experimental|Patients with primary coxarthrosis (any stage) and operated with RTH (Hip resurfacing).|
89015573|NCT06258330|Experimental|Cohort 1 - low dose|AM003 34 mg
89015574|NCT06258330|Experimental|Cohort 2 - mid dose|AM003 68 mg
89015575|NCT06258330|Experimental|Cohort 3 - high dose|AM003 136 mg
89015576|NCT06258317|Experimental|Mesh fixation|Procedure/Surgery: fixation of conventional polypropylene mesh. This group includes patients with fixation of conventional polypropylene mesh.
89015577|NCT06258317|Experimental|Non-mesh fixation|Procedure/Surgery: non-fixation of the mesh. This group includes patients without fixation of the mesh.
89015578|NCT06258278|Experimental|Massive Irreparable Rotator Cuff Tears|Patients scheduled for arthroscopically assisted lower trapezius transfer due to irreparable massive rotator cuff tears
89453255|NCT03232190|No Intervention|CMAT|Maternity Unit Control Group No Web Application Infants > 37 weeks
89015579|NCT06258265|Experimental|Cohort 1, Therapeutic Dose Cohort: TAK-279 30 mg + TAK-279 Placebo + Moxifloxacin Placebo|Participants will receive TAK-279 30 milligrams (mg) and matching placebo, capsules, once daily (QD) on Days 1 to 7 with moxifloxacin matching placebo, capsule, once on Days 1 and 8.
89015580|NCT06258265|Experimental|Cohort 2, Supratherapeutic Dose Cohort: TAK-279 100 mg + Moxifloxacin Placebo|Participants will receive TAK-279 100 mg, capsules, QD on Days 1 to 7 with moxifloxacin matching placebo, capsule once on Days 1 and 8.
89015581|NCT06258265|Experimental|Cohort 3A, Control Cohort: Moxifloxacin 400 mg + TAK-279 Placebo + Moxifloxacin Placebo|Participants will receive moxifloxacin 400 mg, over-encapsulated tablet on Day 1 with TAK-279 matching placebo, QD on Days 1 to 7 and moxifloxacin placebo, capsule, once on Day 8.
89015582|NCT06258265|Experimental|Cohort 3B, Control Cohort: TAK-279 Placebo + Moxifloxacin Placebo + Moxifloxacin 400 mg|Participants will receive moxifloxacin matching placebo, capsule on Day 1 with TAK-279 matching placebo, QD on Days 1 to 7 and moxifloxacin 400 mg, over-encapsulated tablet, once on Day 8.
89015583|NCT06258252||Patients who are diagnosed as sepsis, with type 2 diabetes.|1. myocardial injury-related biomarkers: troponin T and B natriuretic peptide levels; 2. cardiac structure-related indicators: the size of the left and right ventricle, left ventricular ejection fraction, etc.3. septic cardiomyopathy incidence: Troponin T>0.01ng/ml is the standard for the diagnosis of septic cardiomyopathy.
89015584|NCT06258252||Patients who are diagnosed as sepsis, without type 2 diabetes.|1. myocardial injury-related biomarkers: troponin T and B natriuretic peptide levels; 2. cardiac structure-related indicators: the size of the left and right ventricle, left ventricular ejection fraction, etc.3. septic cardiomyopathy incidence: Troponin T>0.01ng/ml is the standard for the diagnosis of septic cardiomyopathy.
89015585|NCT06258239|Other|Enhanced communication|"In the enhanced communication study arm the nurse will say to the patient: I will now give you a combination of two drugs that will greatly ease your pain. One of the two drugs is morphine, which is a drug from the opioid family, which is the strongest drug family for pain relief that medicine has to offer. This drug is very effective against severe pain after surgery. In addition, the second drug is called XEFO. This drug is from the family of non-steroidal anti-inflammatory drugs. We know that the combination of these two drugs is particularly successful in reducing the kind of pain that you experience. According to my experience, you will feel significant pain relief very soon. I will come to you every 10 minutes to assess if you are still in pain. As long as you are suffering from pain, I will continue to give you additional doses of the treatment. We are allowed to give up to 4 doses of treatment. As the treatment is very strong, not everyone needs all 4 doses."
89015586|NCT06258239|Other|Normal communication|In the normal communication study arm the communication between the nurse and patients will be as usual in clinical practice - i.e. - no instruction are given to the nurses regarding on how to communicate with patients while administrating the treatment.
89023559|NCT05155163|Experimental|SC-POWR|Treatment as usual for opioid use disorder with the addition of CBT with possible stepped care to exercise and stress reduction
89453256|NCT05202314|Experimental|Immunotherapy group|After clinical success of colonic stenting, regardless of the MSI state all patients will receive Immunotherapy (Camrelizumab 200mg) for 2 cycles compined with neoadjuvant chemotherapy with mFOLFOX6 regimen for 3 cycles or CapeOx regimen for 2 cycles. Patients will undergo surgery 2-3 weeks after the last cycle of chemotherapy, type and extent of the surgery will be selected by the surgeon.
89453257|NCT03225638|Other|Group 1|Nominal strength thigh injection of 0.65ml of saline solution (0.9%) Low threshold (upper limit) strength thigh injection of 0.65ml of saline solution (0.9%)
89453258|NCT03225638|Other|Group 2|Nominal strength thigh injection of 0.65ml of saline solution (0.9%) Low threshold (lower limit) strength thigh injection of 0.65ml of saline solution (0.9%)
89453259|NCT03225326|Experimental|Computer controlled 4% articaine delivery by Anaeject|
89453260|NCT03225326|Active Comparator|Conventional 4% articaine delivery by carpule syringe|
89453261|NCT03119792|Experimental|Investigational|An education intervention will be implemented for 600 children from the original cohort (300) and comparable cohort (300) over a four month period at community centers. These sessions will occur twice a month on the weekends. The education intervention will help increase the children's knowledge of attitudes, and habits of healthy lifestyles.
89453262|NCT03119792|Active Comparator|Control|The control group will consist of 600 children from the original cohort (300) and comparable cohort (300). The control group will meet twice a month for four months at community centers. During these sessions, investigators will teach a curriculum that is not related to knowledge, attitudes, and habits towards healthy lifestyles.
89453263|NCT03225014|Active Comparator|Physical Therapy|
89453264|NCT03225014|Active Comparator|ARP Wave Therapy|
89015587|NCT06258226|Active Comparator|Conventional dosage reduction group|The drug reduction method of estazolam tablets (Shanghai Xinyi Pharmaceutical Co., Ltd., Shanghai, China, State Drugs Administration License No.: H31020644, 1 mg) will be given, with a starting dose of 1 mg, that is, the dosage of estazolam will be reduced by 25% (0.25mg) every week until the dosage will be stopped completely on the premise of no aggravation of insomnia symptoms.
89015588|NCT06258226|Experimental|Auricular acupressure group|"Auricular acupressure therapy will be added based on the estazolam reduction method in the control group. The specific auricular points to be treated are Shenmen (TF4), Sympathetic (AH6), Endocrine (CO18), Heart (CO15), Liver (CO12) and Kidney (CO10). During the treatment, the acupuncturist will use a metal probe to identify the auricular points and ask the patients if they experience deqi sensations such as heat, numbness, distension, or pain. Once the auricular points have been confirmed, the ear will be disinfected using a 75% ethanol solution and dried using a sterile dry cotton ball. The acupuncturist will then hold the ear in place with their left hand while using their right hand to manipulate a tweezer and apply tape (0.5 x 0.5 cm) with vaccaria (Suzhou Konakang Medical Instrument Co., LTD., Suzhou, China) to the selected auricular point."
89015589|NCT06258226|Sham Comparator|Sham auricular acupressure group|Based on the estazolam reduction method in the control group, the acupuncturist will place the same skin-colored adhesive tapes without vaccaria on the auricular points, but these tapes will not be pressed during treatment.
89015590|NCT06258213|Placebo Comparator|Placebo|
89015591|NCT06258213|Active Comparator|ABP-745|
89015592|NCT06258200|Experimental|Intervention group|Participants in this arm will receive behavioral interventions, including household visits, participation in couples discussion groups, and messaging from community leaders.
89015593|NCT06258200|Experimental|Comparison|Participants in this arm will not receive any interventions.
89015594|NCT06258174|Experimental|Pirtobrutinib (Test)|Test formulation of pirtobrutinib administered orally.
89015595|NCT06258174|Experimental|Pirtobrutinib (Reference)|Reference formulation of pirtobrutinib administered orally.
89015596|NCT06258161||Adult spinal deformity surgery patients|Adults diagnosed with spinal deformity and who are undergoing spinal realignment fusion surgery.
89015597|NCT06258161||Asymptomatic adult controls|Adults with no history of spinal deformity or previous spinal fusions.
89015598|NCT06258148|Experimental|TG103, 7.5 mg|TG103 (7.5 mg) will be administered via subcutaneous injection once a week in subjects with type 2 diabetes.
89015599|NCT06258148|Placebo Comparator|TG103, 7.5 mg placebo|Placebo will be administered via subcutaneous injection once a week in subjects with type 2 diabetes.
89015600|NCT06258148|Experimental|TG103, 15 mg|TG103 (15 mg) will be administered via subcutaneous injection once a week in subjects with type 2 diabetes.
89015601|NCT06258148|Placebo Comparator|TG103, 15 mg placebo|Placebo will be administered via subcutaneous injection once a week in subjects with type 2 diabetes.
89015602|NCT06258135|Active Comparator|Treatment|
89453265|NCT03225248|Experimental|UI05MSP015CT|UI05MSP015CT and Placebo of Gasmotin
89453266|NCT03225248|Active Comparator|Gasmotin|Placebo of UI05MSP015CT and Gasmotin
89453267|NCT03225092|Experimental|PRP Injection|Ultrasound-guided platelet rich plasma injection
89453268|NCT03224936||DISE group|All patients in this study group will receive a propofol PSI controlled DISE (drug induced sleep endoscopy).
89015603|NCT06258135|Placebo Comparator|Placebo|
89453269|NCT04791137|No Intervention|Monitoring|Participants complete weekly questionnaires (QIDS-SR, PMH, GAD-7) on a weekly basis but receive no intervention.
89453270|NCT04791137|Experimental|Standard imagery cognitive bias modification|Participants are scheduled to complete a first introductory session then 12 further training sessions of a 'standard' imagery cognitive bias modification (CBM) intervention derived from that implemented in previous studies.
89015604|NCT06258109||Women with pregnancy after index CeAD|Women who became pregnant at least once after first index CeAD
89015605|NCT06258109||Women without pregnancy after index CeAD|Women who did not became pregnant after first index CeAD
89015606|NCT06258096|Experimental|Photobiomodulation therapy (PBMT)|Patients will receive either PBMT or sham-PBMT during admission to the hospital. The oral cavity of the patients will be exposed to LED light using a new intra-oral device on the THOR Control Unit at the intensity of 50mW/m2 for 60 seconds per dose. Additionally, the perioral region will be exposed to LED light using an extra-oral device on the THOR Control Unit at the intensity of 50mW/m2 for 60 seconds per dose.
89015607|NCT06258096|Sham Comparator|Sham-PBMT|Patients will receive either PBMT or sham-PBMT during admission to the hospital. The sham-PBMT is the placebo treatment and consists of light of the same colour (white light with a red filter), applied in the same way as in the experimental group.
89015608|NCT06258083||Systemic right ventricle patients|
89453271|NCT04791137|Experimental|Standard imagery cognitive bias modification plus additional rationale and transfer instructions|Participants are scheduled to complete a first introductory session then 12 further training sessions of a 'standard' imagery cognitive bias modification (CBM) intervention, but in addition are first presented with a more extended rationale for completing the training, and during each training session are provided with instructions to practice retrieval and rehearsal of the training contents in between sessions.
89537153|NCT03068013|Experimental|Managing Cancer Living Meaningfully|Patients in the experimental group will receive the brief, individual, manualized CALM intervention, a semi-structured psychotherapy designed for patients with advanced cancer. CALM was developed based on empirical results, clinical observation and the theoretical foundations of supportive-expressive and existential approaches, as well psychodynamic and attachment theories. The sessions are delivered bimonthly over a period of 6 months. Sessions are reviewed to ensure treatment fidelity.
89015609|NCT06258070|Other|Duration of symptoms before BTX injections|"All the participants received BTX injections. Informed consent was obtained. Doses and sessions of injections varied between them according to the time of recurrence and the duration of the primary symptoms.~The investigator carried out injections using Dysport (Ipsen Pharma, Germany). The toxin was reconstituted with 0.9% sodium chloride solution so that 0.1 ml corresponded to 25 U. The patient received the same doses in each session, delivered to TrPs detected by carefully palpating the muscle. 0.05 ml was injected into each TrPs."
89201017|NCT00906477|Experimental|Early intervention|Modified CI therapy starting between 7 and 28 days post stroke.
89201018|NCT00906477|Active Comparator|Delayed intervention|Modified CI Therapy starting 6 months post stroke
89453272|NCT04791137|Experimental|Standard imagery cognitive bias modification with frequent brief sessions|"Participants are scheduled to complete a first introductory session then 40 brief (~5 min) sessions of a 'standard' imagery cognitive bias modification (CBM) intervention, with 2 per day five days per week for each of the four training weeks. In addition, as with the arm Standard imagery cognitive bias modification plus additional rationale and transfer instructions, participants are first presented with a more extended rationale for completing the training, and during many of the training sessions are provided with instructions to practice retrieval and rehearsal of the training contents in between sessions. This arm was added into the ongoing trial on 30.05.21."
89453273|NCT04791137|Experimental|Standard imagery cognitive bias modification with a less intensive schedule|"Participants are scheduled to complete a first introductory session then 11 further sessions of a 'standard' imagery cognitive bias modification (CBM) intervention, with 3 sessions scheduled for each of the four training weeks. Sessions have fewer training scenarios than the Standard imagery cognitive bias modification condition and more varied task instructions. In addition, as with the arm Standard imagery cognitive bias modification plus additional rationale and transfer instructions, participants are first presented with a more extended rationale for completing the training, and during many of the training sessions are provided with instructions to practice retrieval and rehearsal of the training contents in between sessions. This arm was added into the ongoing trial on 09.06.21."
89453274|NCT03220880||Intranasal dexmedetomidine|Intranasal dexmedetomidine (100 mcg/mL), 0.5 to 4 mcg/kg
89453275|NCT02949479|Other|Dissociation Investigation in Sex Offenders|The study will be proposed to the subjects after their usual clinical evaluation in the center for sexual offence, and to extend this evaluation by a specific focus on childhood abuse and neglect, trauma and dissociative history
89453276|NCT04787549|Experimental|Virtual reality exergames|Cognitively challenging exergames using fully immersive virtual reality with a head-mounted display (HTC Vive; HTC Co., New Taipei City, Taiwan)
89453277|NCT02910635|Experimental|Volanesorsen, Intravenous (IV)|300 mg of volanesorsen (ISIS 304801) administered Intravenous (IV) single dose
89453278|NCT02910635|Experimental|Volanesorsen, Subcutaneous (SQ)|300 mg of volanesorsen (ISIS 304801) administered Subcutaneous (SQ) single dose
89453279|NCT02910635|Active Comparator|Moxifloxacin Hydrochloride|Moxifloxacin Hydrochloride 400 mg tablet administered orally, Single Dose
89453280|NCT02910635|Placebo Comparator|Placebo Intravenous (IV) single dose|Administered as normal saline (0.9% Sodium Chloride)
89453281|NCT02910635|Placebo Comparator|Placebo Subcutaneous (SC) single dose|Administered as normal saline (0.9% Sodium Chloride)
89453282|NCT04769531|Experimental|Hip Joint Mobilizations|Hip joint mobilizations Hip strength training Knee exercises
89453283|NCT04769531|Experimental|Hip & Knee Muscles strength training|Hip strength training Knee exercises
89453284|NCT04769531|Active Comparator|Knee Muscles strength training|Knee exercises
89453285|NCT03628469|Experimental|Proactive Health Support|The purpose of the intervention is to enhance patients' self-management strategies and thereby enable patients to cope with illness at home and prevent the development of those conditions, that are sensitive to preventive efforts.The intervention includes active listening, coaching and counselling and elements from case management such as assessing the need for healthcare services. Emphasis is on supporting and empowering the patient to make the necessary contacts to healthcare professionals.
89453286|NCT03628469|No Intervention|Usual care|Usual care
89453287|NCT01347645|Active Comparator|1|Experimental Irinotecan plus E7820
89453288|NCT01347645|Active Comparator|2|FOLFIRI alone
89453289|NCT04472403||PFLL Group|"Patients were treated with PFLL regimen: 5-fluorouracil intravenous infusion at 200mg/m2/d for 30 continuous days and intravenous infusion of platinum (cisplatin 70 mg/m2 or nedaplatin 80/m2 or lobaplatin 30 mg/m2) on day 1 and day 28, every 60 days.~Local treatment, molecular-targeted or immune checkpoint therapy, and supportive treatment were allowed."
89453290|NCT04472403||Non-PFLL Group|"Patients were treated with other platinum-based chemotherapy every 21 days including:~PF regimen: 5-fluorouracil at a dose of 1,000 mg/m2 daily by continuous intravenous infusion on days 1-4 and intravenous infusion of cisplatin at a dose of 80 mg/m2 on day 1.~GP regimen: gemcitabine at a dose of 1,000 mg/m2 by intravenous infusion on days 1, 8, and intravenous infusion of cisplatin at a dose of 80 mg/m2 on day 1.~TP regimen: paclitaxel intravenous infusion at a dose of 175 mg/m2 or docetaxel at a dose of 75 mg/m2 on day 1 and intravenous infusion of cisplatin at a dose of 75 mg/m2 on day 1.~TPF regimen: paclitaxel intravenous infusion at a dose of 175 mg/m2 or docetaxel at a dose of 75 mg/m2 on day 1; cisplatin intravenous infusion at a dose of 75 mg/m2 on day 1 and continuous intravenous infusion of 5-FU at a dose of 750 mg/m2 daily on days 1-5.~Local treatment, molecular-targeted or immune checkpoint therapy, and supportive treatment were allowed."
89201019|NCT03987607||Patients scheduled for elective surgery|Patients scheduled for elective surgery requiring neuromuscular blockade
89201020|NCT00900003||pancreatic cancer patients|pancreatic cancer patients with excess tissue collected at the time of standard of care surgery
89201021|NCT00906555|No Intervention|1|hemodialysis patients with baseline Kt/V between 1.2 and 1.7 (1.2 ≤ Kt/V < 1.7)
89201022|NCT00906555|Experimental|2|Modification of hemodialysis parameters such as dialysis time, blood flow rate and dialysate flow rate to reach a Kt/V ≥ 1.7.
89201023|NCT00337207|Experimental|Avastin|
89201024|NCT01052857|Experimental|1|acupuncture daily fo 7 days
88938003|NCT01817036|Placebo Comparator|Placebo|5 placebo pills per day, 16 weeks
88938004|NCT01817036|Experimental|400 IU|(4 placebo pills + 1 vitamin D pill) per day, 16 weeks
88938005|NCT01817036|Experimental|800 IU|(3 placebo pills + 2 vitamin D pills) per day, 16 weeks
88938006|NCT01817036|Experimental|1200 IU|(2 placebo pills + 3 vitamin D pills) per day, 16 weeks
88938007|NCT01817036|Experimental|2000 IU|5 vitamin D pills per day, 16 weeks
88938008|NCT01817049|Experimental|HAPA intervention|Coaches will receive a 3.5 hour HAPA-based coach education workshop prior to the start of the first study season.
88938009|NCT01817049|Placebo Comparator|Attention control|Coaches will receive a 3.5 hour workshop prior to the start of the first study season, consisting of innocuous sport nutrition and sport psychology information as an attention control.
88938010|NCT01817062||Neonates|Neonates with very low birth weight and surgery therapy of acute abdomen
88938011|NCT01817088|Experimental|New targeting procedure without electrophysiology|Patients with the high precision procedure under general anesthesia alone without electrophysiological stimulation
88938012|NCT01817088|Active Comparator|Classical neurosurgical procedure|patients with a first step of electrode implantation under awake surgery with electrophysiological control followed by a second step under general anesthesia
88938013|NCT01817101|Active Comparator|Dietary Supplement capsule|One capsule at meals (3 each day) during 1 year with Omega-3 fatty acid supplementation
88938014|NCT01817101|Placebo Comparator|Empty gelatine capsule|One capsule at meals (3 each day during 1 year)
88938015|NCT01817114|Experimental|Chronic Remote Ischemic Conditioning|Remote ischemic conditioning will be induced using an AutoRIC device (occluding arm bloodflow exactly like manual bloodpressure cuff). With the participant in a supine or seated upright position, the AutoRIC device will be placed on the right arm and will inflate to a pressure of 200mmHg for 5 minutes (ischemia). The device will then auto-deflate (reperfusion), completing one cycle of ischemia-reperfusion. A total of 4 inflation and deflation cycles will occur. This will be initiated at first medical contact just prior to the performance of primary PCI in eligible subjects (RIPerC), and then repeated daily for 28 days following MI.
88938016|NCT01817114|Sham Comparator|SHAM Remote Ischemic Conditioning|Sham conditioning will involve the AutoRIC device being placed on the right arm and will inflate to a pressure of 10mmHg for 5 minutes (ie. no limb ischemia will occur). The device will then auto-deflate, completing one cycle. A total of 4 inflation and deflation cycles will occur. This will be initiated at first medical contact just prior to the performance of primary PCI in eligible subjects (RIPerC), and then repeated daily for 28 days following MI.
88938017|NCT01817140||Patient MRI|Adult patients with possible maxillofacial and/or mandibular bone invasion with oral cancer or osteoradionecrosis who are scheduled for surgery. All eligible and consented participants will have MRI scans obtained using 3T and 4T magnets prior to their surgery.
88938018|NCT01817140||Normal MRI|Healthy adult volunteers recruited to test the comfort of the coil apparatus and to determine configurations which lead to satisfactory image acquisition.
88938019|NCT01817153|Placebo Comparator|placebo|10 mL normal saline iv at H0 and H6 (2 first injections blinded), followed by hydrocortison (open label) 50 mg iv at H8, H14 and H20
88938020|NCT01817153|Active Comparator|hydrocortison|50 mg hydrocortison iv at H0 and H6 (2 first injections blinded), followed by hydrocortison (open label) 50 mg iv at H12, H18 and H24
88938021|NCT01817179|Experimental|FES neuroprosthesis to dorsiflexors on affected side|Participants will use FES neuroprosthesis to dorsiflexors on affected leg for 3 months at home.
88938022|NCT01817205|Other|TACE with Hyperthermia treatment|Interventions: TACE to all liver lesions and two sessions of systemic hyperthermia performed at 24 hours and 48 hours respectively after TACE.
88938023|NCT01817218|Experimental|PRP (Platelet Rich Plasma)|PRP treatment of vascular ulcers one a week PRP: a volume of 9-30 ml of blood will be collected from the patient (depending of the size of their ulcer) in sterile 4.5-ml tubes containing 3.8% sodium citrate, which will bind to the calcium ions, preventing clot formation we will add 50 μl of CaCl2 per ml liquid plasma. The extraction of the PRP fraction by sticking with a syringe and the adding of CaCl2 should be performed under sterile conditions.
88938024|NCT01817218|Active Comparator|Osakidetza protocol|"Patients in the control group will be treated following the recommendations of the Ezkerraldea-Enkarterri Health Region, that is, using a moist healing environment (as described in Uso racional de los productos de cura en ambiente húmedo. Plan de formación continuada de Osakidetza, 2011).~The type of material used to treat and dress the wound will be chosen after the assessment of the wound and surrounding skin, type and quantity of exudate and whether there are signs of infection. Wound care will be carried out every 48-72 hours, as is the current usual practice."
88938025|NCT01817231||breast cancer cases|breast cancer cases versus controls
88938026|NCT01817244|Experimental|care management type 1|2-month care management
88938027|NCT01817244|Active Comparator|care management type 2|6-month care management
88938028|NCT01817257|Experimental|A: Continue treatment|Continue low molecular weight heparin (LMWH) at treatment dose according to body weight for further six months.
88938029|NCT01817257|No Intervention|B: Discontinue treatment|Discontinue low molecular weight heparin (LMWH) once patient has received six months treatment following index VTE case.
88938030|NCT01817270|Experimental|Live Attenuated Varicella Vaccine|use the left arm flank deltoid muscle adheres to stick cohere place the skin after 75% ethyl alcohol disinfection the hypodermic injection
88938031|NCT01817283|Placebo Comparator|placebo + cART|combined with antiretroviral therapy, the control group will take placebo 2 tabs tid per day lasting for 6 months and then switch to take Triplitode 2 tabs tid po for anther 6 months
88938032|NCT01817283|Experimental|Triptolide + cART|combined antiretroviral therapy, the experimental group will take Triptolide 2 tabs tid po per day for 12 months.
88938033|NCT01817296|Experimental|Single arm|
88938034|NCT01817309|Experimental|Study group|endotoxin assay in peritoneal dialysis effluent
88938035|NCT01817322|Experimental|Myfortic® (Enteric-coated Mycophenolate Sodium)|reduced cyclosporine+steroids+standard dose of myfortic
88938036|NCT01817322|Active Comparator|Myfortic|Conventional Dose+cyclosporine+steroid+Reduced Dose of Myfortic
89015610|NCT06258057||Adacel-Exposed Cohort|Cohort will include all pregnant individuals with a record of Adacel vaccination during the third trimester of pregnancy (ie, first day of 27th week of gestation up to the end of pregnancy) and their offspring
89453291|NCT02614547|Placebo Comparator|Placebo|Participants received infusion rates of placebo matched to SAGE-547.
89453292|NCT02614547|Experimental|SAGE-547|Participants received a 4-hour dose titration of 30 micrograms per kilogram per hour (micrograms/kg/hr) (0 to 4 hours), then 60 micrograms/kg/hr (4 to 24 hours), then 90 micrograms/kg/hr (24 to 52 hours), followed by a taper to 60 micrograms/kg/hr (52 to 56 hours), and 30 micrograms/kg/hr (56 to 60 hours).
89453293|NCT04472481|Other|group II|50000 IU of Vitamin D2 (Ergocalciferol 1.25 mg tablet) weekly for 3 months
89453294|NCT04472247||Critical Care Patients|Critical care patients requiring mechanical ventilation via an endotracheal tube, with invasive hemodynamic monitoring via an arterial line, and receiving intravenous sedation by continuous infusion (propofol, midazolam).
89453295|NCT00581997|Experimental|1|QAX576
89453296|NCT00581997|Placebo Comparator|2|Placebo
89453297|NCT02478983|Experimental|LMA Supreme|1 arm will receive LMA supreme for airway management
89453298|NCT02478983|Active Comparator|LMA Proseal|1 arm will receive LMA Proseal for airway management
89453299|NCT04702763||Multiple Sclerosis (Eye-Tracker®T2 + e-VOG)|Multiple Sclerosis subjects who first perform standard video-oculography assessment, followed by e-VOG digital assessment.
89453300|NCT04702763||Multiple Sclerosis (e-VOG + Eye-Tracker®T2)|Multiple Sclerosis subjects who first perform e-VOG digital assessment, followed by the standard video-oculography assessment.
89453301|NCT04681079||Crossover Sequence 1|Subjects randomized to receive commercially available albuterol sulfate via MDI with spacer first, followed by albuterol sulfate via nebulizer with filtered mouthpiece.
89453302|NCT04681079||Crossover Sequence 2|Subjects randomized to receive commercially available albuterol sulfate via nebulizer with filtered mouthpiece first, followed by albuterol sulfate via MDI with spacer.
89453303|NCT00580125|Experimental|A2|
89453304|NCT00580125|Placebo Comparator|A5|
89453305|NCT00580125|Active Comparator|A4|
89453306|NCT00580125|Experimental|A3|
89453307|NCT00580125|Experimental|A1|
89453308|NCT04423900|Experimental|Plantar Fasciitis App Exercise Group|Video simulation of patient education (definition of the disease, risk factors, lifestyle modifications, prevention methods) will be performed to people via smart phone app application. Individuals will receive feedback after completing the training program and will then be included in the exercise program. The mobile application provides feedback so that the exercise program (stretching, strengthening, self-myofascial relaxation exercises) determined according to the diagnosis of the patients is performed by the patients at twice a day for eight weeks.
89453309|NCT04423900|Experimental|Achilles Tendinopathy App Exercise Group|Video simulation of patient education (definition of the disease, risk factors, lifestyle modifications, prevention methods) will be performed to people via smart phone app application. Individuals will receive feedback after completing the training program and will then be included in the exercise program. The mobile application provides feedback so that the exercise program (stretching, strengthening, self-myofascial relaxation exercises) determined according to the diagnosis of the patients is performed by the patients at twice a day for eight weeks.
89453310|NCT04423900|Experimental|Plantar Fasciitis Home Exercise Group|Patients will learn the exercises by the physiotherapist in the clinic. Patients will be included in the training program (stretching, strengthening, self-myofascial release exercises) -only once. Then, patients will do this program at their home twice a day for eight weeks.
89453311|NCT04423900|Experimental|Achilles Tendinopathy Home Exercise Group|Patients will learn the exercises by the physiotherapist in the clinic. Patients will be included in the training program (stretching, strengthening, self-myofascial release exercises) -only once. Then, patients will do this program at their home twice a day for eight weeks.
89453312|NCT04423900|Experimental|Plantar Fasciitis Conventional Physiotherapy Group|In this group, patients will first be included in the patient education and exercises program in the clinic-only once. Mulligan Concept - Manual Therapy and Compressive myofascial relaxation methods will be applied to the individuals who have completed the patient training program by the physiotherapist. Patients will participate in the rehabilitation program twice a week for eight weeks. These patients will perform their home exercises twice daily and for eight weeks.
89453313|NCT04423900|Experimental|Achilles Tendinopathy Conventional Physiotherapy Group|In this group, patients will first be included in the patient education and exercises program in the clinic-only once. Mulligan Concept - Manual Therapy and Compressive myofascial relaxation methods will be applied to the individuals who have completed the patient training program by the physiotherapist. Patients will participate in the rehabilitation program twice a week for eight weeks. These patients will perform their home exercises twice daily and for eight weeks.
88938037|NCT01817335|Experimental|Supportive care (psycho-educational program)|Patients participate in a psycho-educational program focused on medical/symptom management and communication with a medical team, coping skills, self image, and relationships and communication for 1.5 hours once weekly for 6 weeks.
88938038|NCT01817348|Experimental|Lidocaine group|"1% lidocaine 5ml intra-articular injection to shoulder joint + physiotherapy three times weekly~Injection is performed if pain during intervention equals to or greater than 7cm in a 10-cm VAS scale.~Injection frequency is not greater than twice per week and total injection time is limited to 10 times in the whole course~In each week, patient will receive 3 times of PT with or without intra-articular lidocaine injection."
88938039|NCT01817348|Placebo Comparator|PT group|- Apply to every patient, each by the same physical therapist, 3 times weekly for 3 months or till the patients gain satisfactory results.
88938040|NCT01817387|Experimental|PRIME + CT|4 months use of PRIME mobile application on mobile device and 30 hours of cognitive training
88938041|NCT01817387|Experimental|Daily Goals + CT|4 months use of Daily Goals mobile application on mobile device and 30 hours of cognitive training
89015611|NCT06258057||Tdap-Unvaccinated Comparator Cohort|Cohort will include all pregnant individuals meeting eligibility criteria and with no record of any Tdap vaccination from pregnancy onset date until the end of pregnancy and their offspring
89015612|NCT06258044||maligant|Thyroid nodules with surgical or puncture biopsy-confirmed pathological findings of malignancy in the TI-RADS4 category
89015613|NCT06258044||benign|Thyroid nodules with surgical or puncture biopsy-confirmed pathological findings of benign TI-RADS4 category
89015614|NCT06258031|Experimental|All participants|Up to 10mg of psilocybin on two separate dosing days (separated by 4 weeks)
89201025|NCT01052857|No Intervention|2|observation
89453314|NCT00579189|Experimental|Moxidex|Moxidex otic solution
89453315|NCT00579189|Active Comparator|Moxifloxacin|Moxifloxacin otic solution
89453316|NCT00667953|Experimental|Arm A:|Temozolomide plus imatinib
89453317|NCT00578955|Experimental|1|
89453318|NCT00578955|Active Comparator|2|
89453319|NCT00578955|Active Comparator|3|
89453320|NCT00576537|Experimental|Dendritic Cell Immunotherapy|Patients who consent to participate in the study and receive the Dendritic Cell vaccine manufactured from their own tumor cells.
89453321|NCT00575055|Experimental|Bapineuzumab 0.5 mg/kg|infusion every 13 weeks for a total of 6 infusions
89453322|NCT00575055|Placebo Comparator|Placebo Dose|infusion every 13 weeks for a total of 6 infusions.
89453323|NCT00575055|Experimental|Bapineuzumab 1.0 m/kg|infusion every 13 weeks for a total of 6 infusions.
89453324|NCT02282241|Placebo Comparator|Placebo|Patients given once daily placebo (cellulose) orally in the evening, for 14 days.
89453325|NCT02282241|Experimental|Melatonin|Patients given once daily melatonin 1.5mg orally in the evening, for 14 days.
89453326|NCT02424851|Active Comparator|Arm A (BBD)|Bortezomib, Bendamustine and Dexamethasone
89453327|NCT02424851|Active Comparator|Arm B (BTD)|Thalidomide, Bendamustine and Dexamethasone
89453328|NCT02284035|Experimental|Group 1 Raltegravir / 3TC (MK0518B|Raltegravir / 3TC (MK0518B ) (50 patients)
89453329|NCT02284035|Active Comparator|Group 2 standard combination therapy|"NNRTI-Based Regimen:~• EFV/TDF/FTC~PI-Based Regimens:~ATV/r + TDF/FTC or DRV/r + TDF/FTC~INSTI-Based Regimens:~DTG+ABC/3TC DTG+TDF/FTC EVG/cobi/TDF/FTC RAL+TDF/FTC~NNRTI-Based Regimens:~EFV plus ABC/3TC or RPV/TDF/FTC~PI-Based Regimen:~ATV/r plus ABC/3TC~PI-Based Regimens:~DRV/r + ABC/3TC or LPV/r + ABC/3TC or LPV/r + TDF/FTC~INSTI-Based Regimen:~RAL plus ABC/3TC~And other ART regimens"
89453330|NCT00484419|Experimental|colesevelam|colesevelam tablets 625 mg
89453331|NCT00484419|Active Comparator|rosiglitazone|rosiglitazone maleate 4mg
89453332|NCT00484419|Active Comparator|sitagliptin|sitagliptin phosphate tablets
89453333|NCT02422355||Femoral Neck Fractures AO/OTA 31-B1:3|Fixation using the implant FNS.
89453334|NCT02162615||Restorelle Direct Fix A|Anterior/Apical prolapse repair with Restorelle Direct Fix A
89453335|NCT02162615||Native Tissue Repair Anterior|Anterior/Apical prolapse repair with native tissue only
89453336|NCT02162615||Restorelle Direct Fix P|Posterior/Apical prolapse repair with Restorelle Direct Fix P
89453337|NCT02162615||Native Tissue Repair Posterior|Posterior/Apical prolapse repair with native tissue only
89453338|NCT03220724|Experimental|Part A: Group 1|Participants will receive 20 mcg of CH505TF (admixed with GLA-SE) at Months 0, 2, 4, 8, and 12.
88938042|NCT01817400|Experimental|Microdialysis|"Microdialysis probes will be inserted into the abdominal and femoral subcutaneous adipose tissue. Two control probes at each site will be perfused at 2.0 µL/min with Ringer's solution to measure basal interstitial testosterone and estradiol levels. One experimental probe at each site will be perfused with the 'compound' 20ug/dl at 2.0 µL/min to assess the interstitial conversion of androstenedione to estrone and estradiol. The 'compound' will be infused. Either one or the other hormone (androstenedione OR testosterone) will be used per experiment. The second control probe will be positioned at each site to ensure acquisition of data in the event that one of the other probes becomes dysfunctional. We will then collect microdialysis samples every 60 min over the next 120 min."
89201026|NCT01055743|Experimental|Radical resection + Fluorouracil Implants|
89453339|NCT03220724|Experimental|Part A: Group 2|Participants will receive 100 mcg of CH505TF (admixed with GLA-SE) at Months 0, 2, 4, 8, and 12.
89453340|NCT03220724|Experimental|Part A: Group 3|Participants will receive 400 mcg of CH505TF (admixed with GLA-SE) at Months 0, 2, 4, 8, and 12.
89453341|NCT03220724|Placebo Comparator|Part A: Group 4|Participants will receive placebo at Months 0, 2, 4, 8, and 12.
89453342|NCT03220724|Experimental|Part B: Group 5|Participants will receive CH505TF at Month 0; CH505w53 at Month 2; and CH505w78 at Months 4, and 8. GLA-SE adjuvant is admixed with all the CH505 gp120 proteins.
89453343|NCT03220724|Experimental|Part B: Group 6|Participants will receive CH505TF at Month 0; CH505TF and CH505w53 at Month 2; CH505TF, CH505w53, and CH505w78 at Month 4; CH505w53 and CH505w78 at Month 8. GLA-SE adjuvant is admixed with all the CH505 gp120 proteins.
89453344|NCT03220724|Experimental|Part B: Group 7|Participants will receive CH505 M5 (admixed with GLA-SE) at Months 0, 2, 4, and 8.
89453345|NCT03220724|Placebo Comparator|Part B: Group 8|Participants will receive placebo at Months 0, 2, 4, and 8.
89453346|NCT03220724|Experimental|Part C: Group 9|Participants will receive CH505TF at Month 0; CH505w53 at Month 2; and CH505w78 at Months 4.
89453347|NCT00484029|Experimental|1|Nasal Carbon Dioxide
89453348|NCT00484029|Placebo Comparator|2|Air
89453349|NCT00483171|Placebo Comparator|Placebo|
89453350|NCT00483171|Other|Non-pharmacological weight loss program (NPP)|
89453351|NCT00483171|Other|Low Calorie Diet|
89453352|NCT02273895|Active Comparator|Control|Scopolamine
89453353|NCT02273895|Active Comparator|MCI|Scopolamine
89453354|NCT02273895|Active Comparator|AD|Scopolamine
89453355|NCT00480831|Experimental|1|
89453356|NCT00480831|Placebo Comparator|2|
89453357|NCT00667173|Experimental|1|
89453358|NCT00667173|Placebo Comparator|2|
89453359|NCT00667173|Placebo Comparator|3|
89453360|NCT03220334|Experimental|Apply platelet rich plasma to the artificial gastric ulcer|
89453361|NCT03220334|Placebo Comparator|Apply normal saline to the artificial gastric ulcer|
89453362|NCT03220256|Experimental|Lamotrigine tolerance|The dose of lamotrigine (0.1mg) started to increase and gradually increased according to the drug tolerance induction protocol, and the efficacy was evaluated by dosing to the commercial capacity (100mg bid) within 2 weeks.
89453363|NCT00479505|Experimental|Active|
89453364|NCT00479505|Placebo Comparator|Placebo|
89453365|NCT02451410|Experimental|Nutrition and physical activity|This arm includes all preschool classes receiving the educational and behavioral intervention to improve nutrition and physical activity
89453366|NCT02451332|Experimental|vaccinated|These women will have received the seasonal influenza vaccine.
88938043|NCT01817400|Experimental|Anti-inflammatory treatment|We will perform a control cycle of daily, first-morning voided urine, as previously reported by our group to assess the hormonal features of the menstrual cycle of each of the five participants in this arm. Upon completion of the control cycle, the participant will initiate therapy with aspirin 81mg per day, plus Vascepa - Fish Oil 30mg daily. Participants will collect urine for a second menstrual cycle while on treatment, using methods that we have previously employed. At the completion of the second cycle of urine collection, the medications will be stopped and the study will be completed.
88938044|NCT01817400|Experimental|Insulin-lowering therapy|We will perform a control cycle of daily, first morning voided urine as previously reported by our group, to assess the hormonal features of the menstrual cycle of each of the five participants. Upon completion of the control cycle, the participant will initiate therapy with pioglitazone, 45 mg daily, a dose that has previously been shown to result in a 30% reduction in fasting insulin. She will take the pioglitazone without any monitoring for a second menstrual cycle and then collect urinary hormones for the third menstrual cycle, continuing the pioglitazone until the third menstrual cycle is completed.
88938045|NCT01817413|Active Comparator|Apexification with MTA|"The control group will receive:~Visit 1: root canal dressing with calcium hydroxide Visit 2: apexification with mineral trioxide aggregate (MTA), followed by obturation of the root canal with gutta percha.~Treatment will be carried out over two visits, two weeks apart."
88938046|NCT01817413|Experimental|Pulp revascularisation|"The experimental group will receive:~Visit 1: root canal dressing with triple antibiotic paste Visit 2: pulp revascularisation procedure Treatment will be carried out over two visits, two weeks apart."
88938047|NCT01817439|Experimental|oral amiodarone, group A|oral amiodarone 400 mg three times a day for 2 days
88938048|NCT01817439|Experimental|IV amiodarone, Group B|"Amiodarone:~IV loading of 300 mg for 30 min in 100cc glucose 5% IV infusion with 900 mg/24h in 1000cc glucose 5%"
88938049|NCT01817465|Experimental|Motilione®|30 mg is administered with a tablet of placebo (Pantoline®)
88938050|NCT01817465|Active Comparator|Pantoline®|40mg is administered with a tablet of Motilitone®
88938051|NCT01817465|Active Comparator|Motilitone® and Pantoline®|Both drugs are administered at once
88938052|NCT01817478|Experimental|medical staff|
88938053|NCT01816386|Active Comparator|Acupuncture Regimen|Standard anaesthetic procedure plus press needle acupuncture
88938054|NCT01816386|No Intervention|Standard Treatment Control|"Standard anaesthetic procedure plus No treatment.~All standardized medication according to the perioperative anaesthetic guideline, Department of Anaesthesiology, University of Munich, will be allowed. In special:~According to the guidelines, anxiolysis will be performed intravenously according to the standard guidelines with opioid immediately prior to the induction of anaesthesia.~Intraoperative anaesthesia will be performed according to our in-house guidelines: on general recommendations and guidelines of the German society for anaesthesiology (DGAI). Opioids and propofol will be administered via TCI pumps according to the standard protocol.~It is allowed to treat the subject for pain with metamizol (4*1.25 g/day) and additional piritramide (PCA; 2 mg each 10 minutes; maximum dosage 30 mg/4 hours) .~Variation of this guideline based regimen are allowed if medically indicated."
88938055|NCT01816386|Active Comparator|Acupressure Regimen|Standard anaesthetic procedure plus press plaster acupressure
88938056|NCT01817543|Experimental|AutoloGel|Subjects will be treated on average twice a week for the first 2 weeks, and then, once a week thereafter while under active treatment, but actual frequency of treatment will be determined by the treating physician. All subjects will receive Autologel treatment
88938057|NCT01817556|Experimental|Stillen Tab.|administered three times daily for four weeks
88938058|NCT01817556|Active Comparator|Mucosta Tab.|administered three times daily for four weeks
88938059|NCT01817569||Byetta|
88938060|NCT01817595|Active Comparator|BG Star (Conventional Meter)|25 patients will use the (conventional) BG star meter in which patients will upload their readings onto a computer and send in their readings via email.
88938061|NCT01817595|Active Comparator|IBG Star Group (iPhone)|25 patients will be randomized to the iBGstar system will upload their readings to their iPhone and send in their readings using the iPhone.
88938062|NCT01817621|Experimental|Experimental Intervention|
88938063|NCT01817621|Active Comparator|TAU Condition|
88938064|NCT01817634|Experimental|Food supplement Intervention - Capsule Intervention|Omega 3 food supplement + Omega 3 capsule.
88938065|NCT01817634|Experimental|Food Supplement Intervention - Capsule Control|Omega 3 food supplement + Control Capsule.
88938066|NCT01817634|Experimental|Food Supplement Control - Capusle Intervention|Food supplement control + Omega 3 Capsule.
88938067|NCT01817634|Active Comparator|Food Supplement Control - Capsule Control|Food supplement control + Control Capsule.
88938068|NCT01817647||PCT|Patients undergoing colorectal surgery with an anastomosis performed
88938069|NCT01817660|Active Comparator|Open Surgery|In this arm, patients randomized to open surgical repair of popliteal artery aneurysm (OPAR).
88938070|NCT01817660|Active Comparator|Endovascular Surgical repair (EPAR)|In this arm, patients randomized to endovascular repair of popliteal artery aneurysm (EPAR).
89201027|NCT01055743|Active Comparator|Radical resection|
88938071|NCT01817673|Experimental|creatine|20 g/d for 5 d followed by 5 g/d throughout the trial
88938072|NCT01817673|Placebo Comparator|placebo (dextrose)|20 g/d for 5 d followed by 5 g/d throughout the trial
88938073|NCT01817686|Experimental|Comfort Default|ADs with pre-selected defaults that focus on providing comfort at end-of-life.
88938074|NCT01817686|Experimental|Life Extension Default|ADs with pre-selected defaults that focus on extending life.
89201028|NCT00604695|Active Comparator|1|Two (4mg) doses of tenecteplase
89453367|NCT00566397|Experimental|1|
89453368|NCT00566397|Experimental|2|
89453369|NCT00566397|Placebo Comparator|3|
89453370|NCT03220490|Experimental|Short term: interval no-interval eye|"On the first day of the study, in the selected eye the investigators will examine the short term effect of IOP reduction of Brimonidine and Timolol with time interval.~One drop of two types of IOP reduction drugs (Brimonidine and Timolol) will be given with a 5 minutes interval between the first (Brimonidine) and the second (Timolol) drop. IOP measurements will be taken every hour up to 6 hours after treatment.~On the second day of the study (two weeks after the first day) the investigators will examine the short term effect of IOP reduction of Brimonidine and Timolol no time interval. Again one drop of the same two types of drugs will be given at the same order but with no time interval between them. IOP measurements will be taken in the same manner as on the first day."
89453371|NCT03220490|Experimental|Short term: No-interval interval eye|"On the first day of the study, in the selected eye the investigators will examine the short term effect of IOP reduction of Brimonidine and Timolol with time interval.~One drop of two types of IOP reduction drugs (Brimonidine and Timolol) will be given with no waiting period between the first (Brimonidine) and the second (Timolol) drop. IOP measurements will be taken every hour up to 6 hours after treatment.~On the second day of the study (two weeks after the first day) the investigators will examine the short term effect of IOP reduction of Brimonidine and Timolol with time interval. Again one drop of the same two drugs will be given at the same order but with a five minute time interval between the first and second drop. IOP measurements will be taken in the same manner."
89453372|NCT03220490|Experimental|Long term: interval no-interval eye|"In the first phase the effect of 5 minute interval between regular glaucoma drops - long term will be examined. The patients will be asked in this eye to wait 5 minutes after taking one of their IOP reduction drugs, before instilling the second type for a total duration of 1 month.~After the one month has passed IOP measurement will be taken and the patients will be asked to switch to the no interval between regular glaucoma drops - long term phase in which they will be asked to take the drops for this eye at the same order but with no waiting period for a duration of 1 month. After the second month has passed IOP measurements will be repeated."
89453373|NCT03220490|Experimental|Long term: No-interval interval eye|"In the first phase no interval between regular glaucoma drops - Long term will be examined. The patients will be asked in this eye to take both IOP reduction drugs, with no waiting period between them for a total duration of 1 month.~After the one month has passed IOP measurement will be taken and the patient will be asked to switch to the to 5 minute interval between regular glaucoma drops - Long term phase and take the drops for the same eye at the same order but with a five minute waiting period for a duration of 1 month. After the second month has passed IOP measurements will be repeated."
89201029|NCT00604695|Placebo Comparator|2|Two (4mL) doses of sterile saline
89201030|NCT01055821|Active Comparator|Arm A|Standard of care (SOC)
89453374|NCT03056573|Experimental|Subclavian/axillary|Subclavian/axillary access route
89453375|NCT03056573|Experimental|Transaortic|Transaortic access route
89453376|NCT03220100|Experimental|Stepped Palliative Care|All participants will receive palliative care Participants will complete the Functional Assessment of Cancer Therapy-Lung (FACT-L) every six weeks FACT-L scores will be used to determine which patients need to step up to every 6 week palliative care visits Patients on step 1 of the intervention will have a palliative care visit every 9 weeks Patients on step 2 of the intervention will have a palliative care visit every 6 weeks
89453377|NCT02553772|Experimental|OM3 Tear|Carboxymethylcellulose based eye drop [Omega-3 (OM3) Tear] administered as 1-2 drops in each eye, as needed, at least 2 times daily for 90 days.
89453378|NCT02553772|Active Comparator|REFRESH OPTIVE® ADVANCED|Carboxymethylcellulose sodium 0.5% (REFRESH OPTIVE® ADVANCED) administered as 1-2 drops in each eye, as needed, at least 2 times daily for 90 days.
89453379|NCT00665145|Experimental|1|Cohort 1
88938075|NCT01817686|Experimental|Standard Default|ADs without pre-selected defaults.
88938076|NCT01817699|No Intervention|Low Hb target without cholecalciferol|Target Hemoglobin level: ≥9.5 and <10.5 g/dL
88938077|NCT01817699|Active Comparator|Low Hb target with cholecalciferol|Target Hemoglobin level: ≥9.5 and <10.5 g/dL Cholecalciferol: 1,000 IU/day
88938078|NCT01817699|Active Comparator|High Hb target without cholecalciferol|Target Hemoglobin level: ≥12.5 and <13.5 g/dL
88938079|NCT01817699|Experimental|High Hb target with cholecalciferol|Target Hemoglobin level: ≥12.5 and <13.5 g/dL Cholecalciferol: 1,000 IU/day
89453380|NCT00665145|Experimental|2|Cohort 2
89453381|NCT00665145|Placebo Comparator|3|Cohort 3
89453382|NCT00665145|Experimental|4|Cohort 4
89453383|NCT03119714|Active Comparator|Pemirolast|Pemirolast 200mg bid 14-16 days
89453384|NCT03119714|Placebo Comparator|Placebo Oral Tablet|Matching placebo bid 14-16 days
88938080|NCT01817738|Active Comparator|CV9104|CV9104 intradermal injection
88938081|NCT01817738|Placebo Comparator|Placebo|Placebo intradermal injection
88938082|NCT01817803|Active Comparator|1) Add furosemide/no spironolactone|
88938083|NCT01817803|Active Comparator|2) Add metolazone/no spironolactone|
88938084|NCT01817803|Active Comparator|3) Add furosemide/spironolactone|
88938085|NCT01817803|Active Comparator|4) Add metolazone/spironolactone|
88938086|NCT01817816|Experimental|Botox_A|receiving Botulinum Toxin Type-A (Botox-A, Allergan) at both affected lower extremity (aLE) and upper extremity (aUE)
88938087|NCT01817816|Placebo Comparator|placebo_A|receiving placebo injection at both aLE & aUE ; receiving Botox-A at both aLE & aUE at 6-month.
88938088|NCT01817816|Experimental|Botox_B|receiving Botox-A injection at aLE and placebo injection (sterile normal saline) at aUE.
88938089|NCT01817816|Placebo Comparator|placebo_B|receiving placebo injection at both aLE & aUE ; receiving Botox-A only at aLE at 6-month.
88938090|NCT01817829|Active Comparator|paracetamol|paracetamol 2 tablets1000mg PO.
88938091|NCT01817829|Placebo Comparator|placebo|placebo 2 tablets containing Starch PO
88938092|NCT01817842|Experimental|mEX support|Participants in this arm receive both standard DC Quitline Support and Mobile EX cessation support. Mobile EX cessation support is designed to enhance the Washington D.C. Quitline (DCQL) by giving participants the ability track their cessation attempt on a phone-based app and thus create a profile documenting their progress and set-backs over the days or weeks in between QL contacts. Participants receive summary information and graphics that help them understand what is working best for them. Participants also receive 24-hr, momentary access to a set of interactive cessation tools on their phone.
88938093|NCT01817842|Active Comparator|Device Control|Participants randomized to this arm receive standard DC Quitline Support plus the device control. Device control includes an identical device (i.e., mobile phone) to that provided to the intervention group, but participants do not receive any of the phone-based mEX support features. Those in the device control group receive their device at the 1-month time point - a design feature that allows a direct comparison of the mEX intervention to standard quitline services over the first month.
88938094|NCT01817868||Group 1|
88938095|NCT01817894|Other|split-face eflornithin vs. no treatment|Eflornithine cream 11.5 W/W% applied twice daily to one side of the face for six months
88938096|NCT01817920|Experimental|integrated multidisciplinary fall prevention program|
88938097|NCT01817933|Experimental|Physical therapy|
88938098|NCT01817946||Genetic testing|All participants determined eligible for the study will be placed into genetic testing arm.
88938099|NCT01817972|Placebo Comparator|Certolizumab pegol-Placebo Azathioprine|Certolizumab pegol (Cimzia) 400mg Subcutaneous injection (per standard induction protocol) - which is at week 0, week 2, week4, week 6, then every 4 weeks until week 26. You will also be receiving Azathioprine placebo tablets at a dosage of 1.5mg per kilogram of body weight once a day for 26 weeks. They will be 50mg tablets. This is not active Azathioprine.
88938100|NCT01817972|Active Comparator|Certolizumab pegol plus Azathioprine|Certolizumab pegol (Cimzia) 400mg Subcutaneous injection (per standard induction protocol) - which is at week 0, week 2, week4, week 6, then every 4 weeks until week 26. You will also be receiving Azathioprine tablets at a dosage of 1.5mg per kilogram of body weight once a day for 26 weeks. They will be 50mg tablets.
89201031|NCT01055821|Experimental|Arm B|Vaccine and Standard of care
89201032|NCT01055821|Experimental|Arm C|vaccine and standard of care
89201033|NCT03990727||Retinitis pigmentosa|Any type of retina dystrophy with pigment / retinitis pigmentosa
89453385|NCT02274597||Environmental impact on epitympanic temperature measurment|volunteers exposed to different environmental factors to simulate field settings
89537154|NCT03068013|Active Comparator|Supportive psycho-oncology intervention|Supportive psycho-oncology intervention (SPI) includes counseling, psychoeducation and crisis intervention, which is the usual care intervention provided in our centres.
88938101|NCT01817985|Experimental|Cohort 1|(N = 20 Moderately Impaired / Normal Hepatic Function) 100 mg GS-5816.
88938102|NCT01817985|Experimental|Cohort 2|(N = 20 Severely Impaired / Normal Hepatic Function) up to 100 mg GS-5816.
88938103|NCT01817998|Experimental|High Intensity Endurance Physical Exercise|High Intensity endurance physical exercise, intensity measured on Borg Scale with progression from Borg 10-13 (50% of maximum) to 17-18 (80 % of maximum). One hour of exercise twice weekly for 12 weeks supervised by physiotherapists.
88938104|NCT01817998|Active Comparator|Low Intensity Endurance Physical Exercise|Low Intensity endurance physical exercise, intensity measured on Borg Scale, Borg 10-13 (50% of maximum) with no progression in intensity. One hour of exercise twice weekly for 12 weeks supervised by physiotherapists.
88938105|NCT01818011|Experimental|Part A GSK1322322 single dose Arm|Subjects will receive single dose of one of the following 4 GSK1322322 treatments in 4 treatment periods (one per period) with an aqueous suspension of a low dose of GSK1322322F (stable isotope labeled drug substance) PO in a fed condition: 1500 mg (fit for purpose formulation), 1500 mg (intended commercial formulation), 1500 mg (over granulated formulation), and 2000 mg (intended commercial formulation)
88938106|NCT01818011|Experimental|Part B Cohort 1- GSK1322322 Oral Arm|Subjects in this part will receive single dose of GSK1322322 on Day 1 of each of the three treatment periods. Subjects in Cohort 1 will receive following GSK1322322 (intended commercial formulation) doses po in fed state: 1000 mg, 1500 mg and 2000 mg
88938107|NCT01818011|Experimental|Part B Cohort 2 -GSK1322322 IV Arm|Subjects in this part will receive single dose of GSK1322322 on Day 1 of each of the three treatment periods. Subjects in Part B Cohort 2 will receive following GSK1322322 IV fasted doses (one per period): 600 mg, 900 mg and 1200 mg
88938108|NCT01818011|Experimental|Part C GSK1322322 Arm|Subjects in this arm will receive repeat doses of GSK1322322 as following: GSK1322322 1200 mg IV fasted for 4 days twice a day (BID), followed by GSK1322322 2000 mg orally fed for 6 days BID
89201034|NCT03990727||Usher Syndrome|Retina dystrophy or retinitis pigmentosa associated with audition problems
89453386|NCT04617977|Experimental|Parent-child I-BMS intervention group|Children with eczema and their parent caregivers will attend the six sessions simultaneously in a parallel group format. Parent caregivers will attend the parents group in the first 2.5 hours; while children will attend the children group in the first 2.5 hours. Both parents and children will later reunite in the joint group in the final 0.5 hours.
89453387|NCT04617977|Experimental|Parent only I-BMS intervention group|Only parent caregivers of children with eczema will attend the six sessions. The content of the 2.5-hour parents group will be the same as the one in Arm 1 (Parent-child I-BMS intervention group), with an additional 0.5 hour of reflective discussion among group members. The children group will simultaneously attend a group activity class in a separate room for 3 hours.
89453388|NCT04617977|Active Comparator|Parent only health education active control group|Only parent caregivers of children with eczema will attend the six sessions. Each session consists of teaching in the first 2.5 hours and Q&A in the final 0.5 hour. The children group will simultaneously attend a group activity class in a separate room for 3 hours.
89453389|NCT00562887|Placebo Comparator|1|
89453390|NCT00562887|Experimental|400 mg|
89453391|NCT00562887|Experimental|700mg|
89453392|NCT05468554|Experimental|Metformin|patients qualified to receive metformin and 131I treatment
89453393|NCT05468554|Active Comparator|Placebo|patients receiving placebo and 131 I treatment
89453394|NCT05468554|No Intervention|Observational|observation group, patients after thyroidectomy, characterized by low risk of cancer progression, in this case, not qualified for 131I treatment
89453395|NCT04617821|Experimental|albumin bound paclitaxel plus gemcitabine|Albumin-bound paclitaxel and gemcitabine were given intravenous infusion, repeated every 4 weeks for 1, 8, and 15 days, for a total of 4 to 6 cycles.
89453396|NCT04617821|Active Comparator|mFOFLIRINOX|Intravenous oxaliplatin for 2 hours, day 1;Intravenous infusion of calcium formyl tetrahydrofolate (LV) for 2 h, day 1;Irinotecan intravenous infusion is added 30 minutes later for 90 minutes, day 1;Intravenous infusion of 5-fluorouracil (5-FU) continued for 46 hours.Repeat every 2 weeks for a total of 4-6 cycles.
89453397|NCT03219008|Experimental|Depression/underload 1|This group would be treated with fluoxetine from the minimum dosage.
89453398|NCT03219008|Experimental|Depression/underload 2|This group would be treated with fluoxetine combined with cognitive behavior treatment
89453399|NCT03219008|Experimental|Depression/underload 3|This group would be treated with fluoxetine and amfebutamone from the minimum dosage.
89453400|NCT03219008|Experimental|Depression/underload 4|This group would be treated with fluoxetine + physical treatment to help to cure depressive disorder.
89453401|NCT03219008|Experimental|Atypical 1|This group would be treated with fluvoxamine from the minimum dosage.
89453402|NCT03219008|Experimental|Atypical 2|This group would be treated with fluoxetine + cognitive behavior treatment
89453403|NCT03219008|Experimental|Atypical 3|This group would be treated with fluvoxamine + lithium from the minimum dosage.
89453404|NCT03219008|Experimental|Atypical 4|This group would be treated with fluvoxamine + lithium + physical treatment
89453405|NCT03219008|Experimental|Anxiety/somatization 1|This group would be treated with mirtazapine/selective serotonin-norepinephrine reuptake inhibitors（SNRIs） from the minimum dosage.
89453406|NCT03219008|Experimental|Anxiety/somatization 2|This group would be treated with mirtazapine/SNRIs + cognitive behavior treatment.
89453407|NCT03219008|Experimental|Anxiety/somatization 3|This group would be treated with mirtazapine + SNRIs from the minimum dosage.
89453408|NCT03219008|Experimental|Anxiety/somatization 4|This group would be treated with mirtazapine + SNRIs + physical treatment.
89453409|NCT03219008|Experimental|treatment as usual(TAU)|The investigators recommend therapy strategies according to accessible methods.
89453410|NCT02553538|Experimental|Patient Navigation Intervention|Participants randomized to the intervention arm were transferred to a navigator roster within the TopCare application for the 8-month study period. Navigators utilized TopCare to track these participants, reach out to them in their own language, and provide intense outreach to help them complete cancer screening.
88938109|NCT01818011|Placebo Comparator|Part C Placebo Arm|Subjects in this arm will receive repeat doses of Placebo IV fasted for 4 days BID, followed by placebo po fed for 6 days BID
88938110|NCT01818024|Experimental|Part 1: Cohort 1a|Single IV dose of GSK2862277 as a continuous infusion over 2 hours.
88938111|NCT01818024|Experimental|Part 1: Cohort 1b|Single IV dose of GSK2862277 as a continuous infusion over 3 hours.
88938112|NCT01818024|Experimental|Part 1: Cohort 1c|Single IV dose of GSK2862277 as a continuous infusion over 3 hours.
88938113|NCT01818024|Experimental|Part 2: Cohort 2a GSK2862277|Single IV dose of GSK2862277 as a continuous infusion over 1 hour.
88938114|NCT01818024|Experimental|Part 2: Cohort 2a Placebo|Matching placebo will be administered as a continuous IV infusion over 1 hour.
88938115|NCT01818024|Experimental|Part 2: Cohort 2b GSK2862277|Single IH dose of GSK2862277.
88938116|NCT01818024|Experimental|Part 2: Cohort 2b Placebo|Matching placebo will be administered.
89453411|NCT02553538|No Intervention|Standard of Care - No Intervention|Participants randomized to the control arm received usual care within TopCare, which meant that clinicians and staff could elect to send the participant a reminder letter about their overdue cancer screening exams, reach out to schedule overdue exams, or document appropriate reasons for deferral or exclusion.
89453412|NCT03218930|Other|Social marketing intervention|Participants will receive a total combination of four interventions.
89453413|NCT00562497|Placebo Comparator|Placebo|Participants will receive 6 infusions of placebo-matching Prochymal® intravenously (IV) during the first 4 weeks of the study. The first infusion will be administered within 72 hours of the start of systemic corticosteroid therapy. Participants will receive 4 infusions during the first 2 weeks (twice weekly at least 3 days apart), followed by 2 infusions administered once weekly over the subsequent 2 weeks up to Day 28.
89453414|NCT00562497|Active Comparator|Prochymal® 2x10^6 hMSC/kg|Participants will receive 6 infusions of Prochymal® 2x10^6 human mesenchymal stem cells (hMSC)/kg IV during the first 4 weeks of the study. The first infusion will be administered within 72 hours of the start of systemic corticosteroid therapy. Participants will receive 4 infusions during the first 2 weeks (twice weekly at least 3 days apart), followed by 2 infusions administered once weekly over the subsequent 2 weeks up to Day 28.
89453415|NCT03218540|Experimental|SVV group|Fluid management protocol
89453416|NCT03218540|Active Comparator|CVP group|Fluid management protocol
89453417|NCT02548156|Other|Test dentifrice|1.5g (± 0.05g) of Test dentifrice followed by 10mL of de-ionised water rinse, then 10 mL orange juice rinse
89453418|NCT02548156|Other|Reference dentifrice|1.5g (± 0.05g) of Reference dentifrice followed by 10mL of de-ionised water rinse, then 10 mL water rinse
88938117|NCT01818024|Experimental|Part 3: Cohort 3a GSK2862277|IV dose of GSK2862277 (decided from Part 2) as a continuous infusion over 1 hour for daily 5 days.
88938118|NCT01818024|Experimental|Part 3: Cohort 3a Placebo|Matching placebo will be administered as IV infusion over 1 hour daily for 5 days.
88938119|NCT01818024|Experimental|Part 3: Cohort 3b GSK2862277|Repeat IH dose of GSK2862277 (decided from Part 2) daily for 5 days.
88938120|NCT01818024|Experimental|Part 3: Cohort 3b Placebo|Matching placebo will be administered as IH daily for 5 days.
88938121|NCT01818037||Microphthalmos with congenital cataract|72 eyes of 36 patients with microphthalmos who underwent bilateral congenital cataract surgery between January 2003 and June 2008.
88938122|NCT01818050|Other|Wing stent arm|There is only one arm in this study. Intervention: checking liver function tests to evaluate stent patency
88938123|NCT01818089||Lung Sound Analyzer|Patient with pneumonia admitted to hospital will receive additional auscultation with lung sound analyzing stethoscope
89453419|NCT02548156|Other|Comparator dentifrice|1.5g (± 0.05g) of Comparator dentifrice followed by 10mL of de-ionised water rinse, then 10 mL orange juice rinse
89453420|NCT03217994|Active Comparator|37.5% gel|37.5% gel to bleach teeth
89453421|NCT03217994|Experimental|6% gel|6% gel to bleach teeth
89453422|NCT01503515|Experimental|Arm I (caspofungin acetate)|Patients receive caspofungin acetate IV over 1 hour once daily (QD) beginning within 24 hours of allogeneic HSCT (day -1 or 0) and continuing until day 42 in the absence of invasive fungal infections or disease progression.
89453423|NCT01503515|Active Comparator|Arm II (fluconazole or voriconazole)|Patients receive fluconazole IV over 1-2 hours QD or PO QD; or voriconazole IV over 1-2 hours QD or PO BID beginning within 24 hours of allogeneic HSCT (day -1 or 0) and continuing until day 42 in the absence of invasive fungal infections or disease progression.
89453424|NCT03231566|Active Comparator|Usual education control group (CG)|The CG received the traditional hospital preoperative program, which was consistent with current preoperative TKA protocols. The CG received education covering anatomy of the knee joint, information about the joint replacement surgery, what to expect when they were admitted for surgery, what to expect immediately after surgery, pain medications, postoperative rehabilitation/physical therapy, etc. The CG received a hospital-based booklet with this information.
89453425|NCT03231566|Experimental|Experimental group (EG)|The EG underwent an additional 30-minute group PNE program, followed by the usual preoperative education program from the hospital. The PNE program used in this TKA study was an adaptation of the PNE program developed for LS. The educational program was designed to be delivered by a physical therapist in a group session to patients prior to their TKA.
89453426|NCT00468273|Experimental|Intravenous Immune Globulin|Subjects with primary humoral immunodeficiency
89453427|NCT03217916||normotensive groups|pregnant women with normal blood pressure
89453428|NCT03217916||hypertensive groups|pregnant women with severe preclampsia
88938124|NCT01818102|Experimental|Width 1000 HU/Level -450 HU|
88938125|NCT01818102|Active Comparator|Width 400 HU/Level 25 HU|
88938126|NCT01818115|Experimental|IOL placement with Hydrus Implant|Cataract extraction with intraocular lens (IOL) placement and Hydrus Implant
88938127|NCT01818115|Active Comparator|IOL placement only.|Cataract Extraction with IOL placement only.
88938128|NCT01818128|Active Comparator|Neutral shape of bronchial tip|
88938129|NCT01818128|Experimental|Bent shape of bronchial tip|
88938130|NCT01818180|Experimental|Urell|
88938131|NCT01818180|Placebo Comparator|Placebo|
88938132|NCT01818206|Experimental|Cystic fibrosis (CF) patients|Cystic fibrosis patients whom induced sputum is collected in order to evaluate the efficacy of a cocktail of 10 bacteriophages.
89015615|NCT06258018|Experimental|Niraparib + Temodal Level 0|Niraparib 100 mg/die + TMZ 75 mg/m2 both given for 7 consecutive days, followed by 7 days OFF, in a cycle of 28 days (starting dose).
88938133|NCT01818219|Experimental|Study|
88938134|NCT01818271|Active Comparator|conventional physical Therapy|will receive a conventional out-patient program which will include: lower extremity stretching and strengthening exercise; fitness using cycle ergometer; balance exercises in standing; over ground walking and stair exercises
88938135|NCT01818271|Experimental|community-based group rehabilitation|"Group training will include different workstations to target dynamic standing balance and walking. The key features includes facilitate repetition of task-related movements, tailored to the patient and patient's goals, in a meaningful context. Specifically:~Advanced dynamic tasks, including stepping and other transitional tasks to treadmill & over ground walking) with use of various inexpensive exercise assistive equipment such as mini-exercise stepper or elliptical machines.~Treadmill walking exercise program."
89453429|NCT00468117|Experimental|Islet transplantation|Up to three separate islet transplants will occur and a regimen of immunosuppressive medications consisting of antithymocyte globulin (ATG) and etanercept throughout study.
89453430|NCT03231488|Experimental|Mindfulness intervention|
89453431|NCT03231488|Active Comparator|Control intervention (unfocused attention)|
89453432|NCT03217604|Placebo Comparator|Placebo|Placebo
89453433|NCT03217604|Experimental|PF-06852231|Single ascending doses of PF-06852231
89453434|NCT03231254||Chinese patients with OSA|
89453435|NCT03231254||Canada patients with OSA|
89453436|NCT02276079|Experimental|mTBI Aerobic Exercise Group|Participants are two-three weeks post-mild traumatic brain injury are randomized to receive a daily aerobic exercise intervention lasting 1-week.
89453437|NCT02276079|Experimental|mTBI Non-Aerobic Exercise Group|Participants are two-three weeks post-mild traumatic brain injury are randomized to receive a daily non-aerobic exercise intervention lasting 1-week.
89453438|NCT02276079|No Intervention|Non-injured Reference Group|Non-injured, healthy participants will serve as a reference group for functional outcome measures.
89453439|NCT03216824|Active Comparator|Dressing|A dressing is maintained on the CVAD exit site.
89453440|NCT03216824|Experimental|No-Dressing|The CVAD exit site is not covered with a dressing.
89453441|NCT00468039|Experimental|vildagliptin + metformin|
89453442|NCT02451254|Experimental|Atrial Fibrillation|Atrial Fibrillation patients electively admitted for circumferential ablation of the pulmonary veins.
89453443|NCT02451254|Active Comparator|control|patients electively admitted for SVT ablation
89453444|NCT02451020|Experimental|Altitude exposure|Stay at 3200 m for 3 weeks
89453445|NCT03224702|Experimental|M6495|
89453446|NCT03224702|Placebo Comparator|Placebo|
89453447|NCT02742519|Experimental|Part 1-Sequence 1|ivacaftor in Treatment Period 1 →washout→placebo in Treatment Period 2
89453448|NCT02742519|Experimental|Part 1 - Sequence 2|placebo in Treatment Period 1→washout→ivacaftor in Treatment Period 2
89453449|NCT02742519|Experimental|Part 2: ivacaftor|open label period
89453450|NCT01375010|Placebo Comparator|Group A|Placebo vitamin D3 capsule daily plus vitamin supplements that contains 1000 IU vitamin D3 and 1000 mg calcium carbonate daily. Total daily vitamin D3 dose = 1000 IU.
89453451|NCT01375010|Experimental|Group B|2000 IU vitamin D3 daily plus vitamin supplements that contains 1000 IU vitamin D3 and 1000 mg calcium carbonate daily. Total daily vitamin D3 dose = 3000 IU.
89453452|NCT03231332|Experimental|H.pylori Eradication index|Microbiome diversity detection in Participants Positive for H.pylori and undergoing Eradication therapy with Clarythromycin-containing eradication therapy
89453453|NCT03231332|No Intervention|Control|Microbiome diversity detection in Participants Without H.pylori Eradication therapy
89453454|NCT03231332|Active Comparator|H.pylori Eradication comparative|Microbiome diversity detection in Participants Positive for H.pylori and undergoing Eradication therapy with high dose Amoxicillin and bismuth containing eradication therapy
89453455|NCT00548925|Experimental|1|
89453456|NCT00548925|Placebo Comparator|2|
89453457|NCT03231176|Experimental|Varlitinib and Capecitabine|
88938136|NCT01818310|Experimental|Group A: Intramuscular|"Intramuscular BMAC application The study subjects in the Group A will receive a treatment of 35ml BMAC administered intramuscularly into the affected limb, in individual punctures of 1 ml.~The punctures will be applied into the crural muscle around the defect, the procedure takes approx. 60 minutes."
88938137|NCT01818310|Experimental|Group B: Intraarterial|Intraarterial BMAC application The study subjects in the Group B will receive a treatment of 35ml BMAC administered intraarterially into the affected limb.
88938138|NCT01818310|Experimental|Group C: Intravenous|Group C: Intravenous The study subjects in the Group C will receive a treatment of 35ml BMAC administered intravenously into the affected limb.
88938139|NCT01818310|Other|Group D: Control-standard treatment|Group D: Control Group Study subjects in Group D will receive a standard treatment for NO-option CLI.
88938140|NCT01818349|Active Comparator|isokinetic lower-limb training|3 times/week for 6 weeks
88938141|NCT01818349|Placebo Comparator|isokinetic uppe-limb training|3 times/week for 6 weeks
88938142|NCT01818362|Experimental|Group 2|ChAdOx1 NP+M1 2.5 x 10¹⁰vp followed by MVA NP+M1 1.5 x 10⁸pfu 52 weeks later.
89453458|NCT02276235|Experimental|catgut embedding group|Catgut will be embedding in acupoints as below. Acupoints: Qihai (REN-6), Shuifen (REN-9), bilateral Shuidao (ST-28),bilateral Siman (K-14) ,zusanli(ST-26) Frequency: one time per week Duration: 6 weeks
89453459|NCT02276235|Sham Comparator|sham catgut embedding group|"The stainless-steel acupuncture needles (3.8cm long) was inserted into 23 gouge needle as plunger without chromic catgut in front of the syringe needle. All the procedure will be performed as in catgut embedding group.~Acupoints: Qihai (REN-6), Shuifen (REN-9), bilateral Shuidao (ST-28),bilateral Siman (K-14) ,zusanli(ST-26)~The other procedure were the same as catgut embedding group Frequency: one time per week Duration: 6 weeks"
89453460|NCT02450942|Experimental|18F-FDS injection and PET/CT scan|The patients were intravenously injected with 18F-FDS and underwent PET/CT scan 1 h after the injection.
89453461|NCT00467025|Experimental|Arm A|
89453462|NCT00467025|Experimental|Arm B|
89453463|NCT00467025|Active Comparator|Arm C|
89453464|NCT02276469|Experimental|peer support|peer support is delivered on individual basis for half a year, the frequency depends on the patients requirement, but at least 3 sessions has to occur
89453465|NCT02276469|No Intervention|usual care|usual care was delivered to the patients
89453466|NCT03231020||Adherent Group|Parent(s) that submitted a high rate of data transfer (top 25th percentile) with rate of data days of mHealth technology for data transfer
89453467|NCT03231020||Non-Adherent Group|Parent(s) that chose to return mHealth technology before the end of the interstage period and/or low rate of data transfer (bottom 25th percentile) with rate of data days
89537155|NCT05178381|Experimental|Target: frontal pole; Order: frontal pole first|In this arm the target stimulation site is the frontal pole, the control stimulation site is the vertex. Participants will receive the frontal pole stimulation in the first TMS session and vertex stimulation in the second TMS session.
89015616|NCT06258018|Experimental|Niraparib + Temodal Level 1|Niraparib 100 mg/die + TMZ 100 mg/m2 both given for 7 consecutive days, followed by 7 days OFF, in a cycle of 28 days.
89453468|NCT02277795|Experimental|AccuCirc|"The AccuCirc procedure is performed according to manufacturer instructions: http://www.clinicalinnovations.com/site_files/files/AccuCirc_IFUs.pdf~Before the surgery, the mother (and father, if available) will be counseled on benefits and risks of EIMC in their language of choice (English, Kiswahili, DhoLuo). At least one parent/guardian will provide documented informed consent using IRB-approved Consent Form. Providers will record demographic and locator information and EIMC eligibility criteria. If the infant is eligible for EIMC, the provider will perform the procedure and document the outcome of the surgery on a post-operative form. Information recorded will include: amount and type of anesthesia provided, intra-operative adverse event and outcome, and procedure start and end time."
89453469|NCT00546585|Experimental|90 mcg of Influenza A/H7N7|25 subjects to receive 90 mcg of Influenza A/H7N7.
89453470|NCT00546585|Experimental|15 mcg of Influenza A/H7N7|25 subjects to receive 15 mcg of Influenza A/H7N7.
89453471|NCT00546585|Experimental|7.5 mcg of Influenza A/H7N7|25 subjects to receive 7.5 mcg of Influenza A/H7N7.
89453472|NCT00546585|Experimental|45 mcg of Influenza A/H7N7|25 subjects to receive 45 mcg of Influenza A/H7N7.
89453473|NCT00546585|Placebo Comparator|Saline placebo|25 subjects to receive placebo.
89453474|NCT03230786|Placebo Comparator|Placebo|Placebo QD for 12 weeks as add-on to metformin
89453475|NCT03230786|Experimental|15µg KBP-042 QD|Up to 15µg KBP-042 QD for 12 weeks as add-on to metformin
89453476|NCT03230786|Experimental|30µg KBP-042 QD|Up to 30µg KBP-042 QD for 12 weeks as add-on to metformin
89453477|NCT03230786|Experimental|50µg KBP-042 QD|Up to 50µg KBP-042 QD for 12 weeks as add-on to metformin
89015617|NCT06258018|Experimental|Niraparib + Temodal Level 2|Niraparib 200 mg/die + TMZ 75 mg/m2 both given for 7 consecutive days, followed by 7 days OFF, in a cycle of 28 days
89453478|NCT02282397|No Intervention|Phase 1: SMBG|Type 1 or Type 2 diabetes mellitus subjects using SMBG testing and usual care for diabetes management. No intervention to be administered
89453479|NCT02282397|Other|Phase 1: CGM|Type 1 or Type 2 diabetes mellitus subjects using RT-CGM and SMBG testing for diabetes management. RT-CGM (Continuous Glucose Monitoring) is the intervention.
89453480|NCT02282397|No Intervention|Phase 2: CGM/MDI|Type 1 Diabetes Mellitus subjects using RT-CGM and injections for diabetes management.
89453481|NCT02282397|No Intervention|Phase 2: CGM/CSII|Type 1 Diabetes Mellitus subjects using RT-CGM and CSII for diabetes management.
89453482|NCT02451098|Experimental|Atorvastatin10mg, Ezetimibe10mg|Atorvastatin10mg, Ezetimibe10mg will be administered (Duration 8 weeks)
89453483|NCT02451098|Active Comparator|Atorvastatin10mg, Ezetimibe placebo|Atorvastatin10mg, placebo will be administered (Duration 8 weeks)
89453484|NCT02451098|Experimental|Atorvastatin20mg, Ezetimibe10mg|Atorvastatin20mg, Ezetimibe10mg will be administered (Duration 8 weeks)
89453485|NCT02451098|Active Comparator|Atorvastatin20mg, Ezetimibe placebo|Atorvastatin20mg, placebo will be administered (Duration 8 weeks)
89453486|NCT02451098|Experimental|Atorvastatin40mg, Ezetimibe10mg|Atorvastatin40mg, Ezetimibe10mg will be administered (Duration 8 weeks)
89453487|NCT02451098|Active Comparator|Atorvastatin40mg, Ezetimibe placebo|Atorvastatin40mg, placebo will be administered (Duration 8 weeks)
89453488|NCT00546273|Experimental|RUTI 5 micrograms of FCMtb|RUTI dose: 5 micrograms of FCMtb (for fragmented cells of M. tuberculosis) (n=4)
89453489|NCT00546273|Experimental|RUTI 25 micrograms of FCMtb|RUTI dose: 25 micrograms of FCMtb (for fragmented cells of M. tuberculosis) (n=4)
89453490|NCT00546273|Experimental|RUTI 100 micrograms of FCMtb|RUTI dose: 100 micrograms of FCMtb (for fragmented cells of M. tuberculosis) (n=4)
89453491|NCT00546273|Experimental|RUTI 200 micrograms of FCMtb|RUTI 200 micrograms of FCMtb (for fragmented cells of M. tuberculosis) (n=4)
89453492|NCT00546273|Placebo Comparator|placebo|placebo of the vaccine RUTI (total n=8, n=2 for each period)
89453493|NCT02452112|Active Comparator|Lidocaine|Active arm with administration of active 5% Lidocaine patch
89015618|NCT06258018|Experimental|Niraparib + Temodal Level 3|Level 3: Niraparib 200 mg/die + TMZ 100 mg/m2 both given for 7 consecutive days, followed by 7 days OFF, in a cycle of 28 days.
89015619|NCT06258018|Experimental|Niraparib + Temodal Level -1|Niraparib 100 mg given on alternate days for 7 days, followed by 7 days of OFF + TMZ given 75 mg/m2 for 7 consecutive days, followed by 7 days OFF, in a cycle of 28 days.
89453494|NCT02452112|Placebo Comparator|Placebo|Placebo arm with administration of placebo patch
89453495|NCT00659061|Active Comparator|Intervention|Multiple micronutrient fortificant (Sprinkles) and nutrition education given by LHWs.
89453496|NCT00659061|No Intervention|Control|Routine public health massages by Lady Health Workers (LHWs) during their community visits.
89453497|NCT02451956|Experimental|AZD5363 in combination with paclitaxel|AZD5363 400mg bid 4 days on/ 3 days off of a 7 day cycle for each week that paclitaxel is given + paclitaxel 80mg/m2 given days 1, 8 and 15 of a 28 day cycle. AZD5363 and paclitaxel will be received for 3 consecutive weeks, followed by one week off-therapy in 4-week cycles.If paclitaxel therapy is stopped then AZD5363 can be given on a 4on/3off continuous schedule.
89453498|NCT02725372|Experimental|Inhaled Nitric Oxide 75mcg/KgIBW/Hr|"Part 1:~15Mcg/kg IBW/hr during Run-in Period dose titrated to Inhaled Nitric Oxide / 75mcg/KgIBW/Hr upon randomization to treatment arm.~Part 2: iNO 75 mcg/kg IBW/hr Open Label Treatment (Open Label Treatment - All Subjects)"
89453499|NCT02725372|Placebo Comparator|Placebo|"Part 1:~Placebo dose setting 15mcg/kg IBW/hr Run In Period / Placebo dose setting 75 mcg/kg IBW/hr treatment period"
89015620|NCT06258018|Experimental|Niraparib + Temodal Expansion Phase|Niraparib RP2D dose given on alternate days for 7 days, followed by 7 days of OFF + TMZ given RP2D for 7 consecutive days, followed by 7 days OFF, in a cycle of 28 days.
89015621|NCT06257992|Experimental|Dry Needling Group|
89015622|NCT06257992|Active Comparator|Stretch Group|
89015623|NCT06257966|Experimental|Exendin-4 Fc fusion protein injection(1.2mg）+Metformin|1.2mg,Subcutaneous injection in the abdomen,Bi-weekly for 54 weeks.
89015624|NCT06257966|Experimental|Exendin-4 Fc fusion protein injection(2.4mg）+Metformin|The first dose of 1.2 mg of JY09 injection was administered, the dose was adjusted to 2.4 mg after two weeks, after which 2.4 mg was maintained to continue subcutaneous injection in the abdomen, bi-weekly treatment for 52 weeks.
89453500|NCT00542685|Experimental|PD 0332334 300 mg BID|
89453501|NCT00542685|Placebo Comparator|Placebo BID|
89453502|NCT00542685|Experimental|PD 0332334 225 mg BID|
89453503|NCT00542685|Experimental|PD 0332334 175 mg BID|
89453504|NCT02450786|Experimental|Donepezil group|Donepezil is started in 5mg for 8 weeks followed by dose escalation to 10mg and then maintained for 40 weeks. Participants who are not tolerable to dose of 10mg due to any issues of adverse effects would be maintained with donepezil 5mg exclusively in remained period.
89453505|NCT02450786|No Intervention|control group|No administration of any therapeutic medications for dementia including cholinesterase inhibitor or NMDA receptor blocking agents. Standard treatment protocol of Parkinson's disease with mild cognitive impairment would be fulfilled including dopaminergic or nondopaminergic medications as well as nootropic drugs.
89453506|NCT03214718|Experimental|CML patients treated with imatinib 400 mg/day|Measurement of the level of myeloid derived suppressor cells (MDSCs) by flowctytometry for each newly diagnosed chronic phase chronic myeloid leukemia (CML) patients treated with imatinib 400 mg/day before starting treatment and every 3 months till one year and correlate between it and level of BCR-ABL gene level and the sokal score of the patients and deep molecular response of the patients after one year .
89453507|NCT03214718|Active Comparator|CML patients treated with nilotinib 600 mg/day|Measurement of the level of myeloid derived suppressor cells (MDSCs) for each newly diagnosed chronic phase chronic myeloid leukemia ( CML) patients treated with nilotinib 600 mg/day before starting treatment and every 3 months till one year and correlate between it and level of BCR-ABL gene, the sokal score and deep molecular response of the patients after one year .
89453508|NCT00539721|Experimental|Rolapitant Dose 1|
89453509|NCT00539721|Experimental|Rolapitant Dose 2|
89453510|NCT00539721|Experimental|Rolapitant Dose 3|
89453511|NCT00539721|Experimental|Rolapitant Dose 4|
89453512|NCT00539721|Active Comparator|Ondansetron|
89453513|NCT00539721|Placebo Comparator|Placebo|
89453514|NCT02282475||Cohort study of pregnant women|"Participants will complete the following at 12-16 weeks gestation and again at 32-36 weeks gestation:~Fasting glucose, insulin and insulin sensitivity testing;~Blood tests for cholesterol and fatty acids, liver function, inflammation, and markers of metabolism;~Measurements of body fat using air displacement technology and MRI;~Ultrasound to measure placental blood flow, visceral fat thickness (12-16 weeks only) and to estimate fetal weight (32-36 weeks only);~24 hour diet recalls~Questionaires regarding activity level"
89453515|NCT02282475||Case-control study Gestational Diabetes|"Participants diagnosed with gestational diabetes (cases) and without gestational diabetes (controls) will complete the following at 32-36 weeks gestation:~Fasting glucose, insulin and insulin sensitivity testing;~Blood tests for cholesterol and fatty acids, liver function, inflammation, and markers of metabolism;~Measurements of body fat by using air displacement technology and MRI;~Ultrasound to measure placental blood flow and to estimate fetal weight;~24 hour diet recalls~Questionaires regarding activity level"
89453516|NCT00464061|Experimental|Volinanserin|
89453517|NCT00464061|Placebo Comparator|Placebo|
89453518|NCT00460941|Placebo Comparator|Placebo|sc weekly
89453519|NCT00460941|Experimental|Taspoglutide 20mg|sc weekly
89453520|NCT00460941|Experimental|Taspoglutide 20mg-30mg|sc weekly
89453521|NCT00460941|Experimental|Taspoglutide 20mg-40mg|sc weekly
89015625|NCT06257966|Active Comparator|Dulaglutide+Metformin|1.5 mg dulaglutide injection subcutaneously once a week for 26 weeks.
89201035|NCT03990727||Cone>rod syndromes|Retina dystrophy diagnosed or started in central vision.
89201036|NCT03990727||Retinitis pigmentosa sx|Retinitis pigmentosa with any type of other features
89453522|NCT03224078||adult Emergency Department Patients|adult patients that were treated with any condition in one of the participating emergency departments in 2016 (n≈680.000 cases)
89453523|NCT03213782|Experimental|Experimental group|Nature based sounds are administered via head phones continuously for 20 minutes.
89453524|NCT03213782|No Intervention|Control group|Usual routine care was continued
89453525|NCT00460317|Placebo Comparator|Arm B|All subjects on this treatment arm will receive a standard paclitaxel and carboplatin chemotherapy regimen (paclitaxel 200mg/m2 and carboplatin at AUC of 6mg/mL x min by Calvert formula) on day 1 of each 3 week cycle + - 3 days for a maximum of 6 cycles and placebo 125mg QD orally
89453526|NCT00460317|Active Comparator|Arm A|All subjects on this treatment arm will receive a standard paclitaxel and carboplatin chemotherapy regimen (paclitaxel 200mg/m2 and carboplatin at AUC of 6mg/mL x min by Calvert formula) on day 1 of each 3 week cycle + - 3 days for a maximum of 6 cycles and AMG 706 125mg QD orally.
89453527|NCT03230552|Experimental|Video group|Residents assigned to this group will watch an instructional surgical video prior to LSO surgery.
89453528|NCT03230552|No Intervention|No video group|Residents assigned to this group will not watch an instructional surgical video prior to LSO surgery.
89453529|NCT03213548|Experimental|Alar facial groove Incision|Alar Base surgical modification with surgical inions in the alar facial groove
89453530|NCT03213548|Active Comparator|Alar facial groove spared|Alar Base surgical modification with surgical incisions 1mm above the alar facial groove
89453531|NCT00534027|Experimental|Arm 2|Low Dose AMG 655 with paclitaxel/carboplatin
89453532|NCT00534027|Placebo Comparator|Arm 3|Placebo with paclitaxel/carboplatin
89453533|NCT00534027|Experimental|Arm 1|AMG 655 High doseplus paclitaxel/carboplatin
89453534|NCT02450864|Experimental|patient with ESWT|Preoperatively, the ROM of the shoulder is measure with the patient in a sitting position. A goniometer is used to measure the angle to which the patient could maximally passively forward flex or abduct the shoulder. External rotation and internal rotation of the shoulders are determined with the patient's arm in a resting position. The investigators assessed shoulder ROM using the SROMD. Normal shoulder ROM without scapular stabilization is considered to be 180° of forward flexion, 180° of abduction, 90° of external rotation, and 90° of internal rotation with the arm at the side. By summation of the measured deficit of ROM, the SROMD is obtained. Patients are defined as having shoulder stiffness if SROMD >270degrees.
89537156|NCT05178381|Experimental|Target: frontal pole; Order: vertex first|In this arm the target stimulation site is the frontal pole, the control stimulation site is the vertex. Participants will receive the vertex stimulation in the first TMS session and frontal pole stimulation in the second TMS session.
89453535|NCT02450864|Sham Comparator|patient without ESWT|Preoperatively, the ROM of the shoulder is measure with the patient in a sitting position. A goniometer is used to measure the angle to which the patient could maximally passively forward flex or abduct the shoulder. External rotation and internal rotation of the shoulders are determined with the patient's arm in a resting position. The investigators assessed shoulder ROM using the SROMD. Normal shoulder ROM without scapular stabilization is considered to be 180° of forward flexion, 180° of abduction, 90° of external rotation, and 90° of internal rotation with the arm at the side. By summation of the measured deficit of ROM, the SROMD is obtained. Patients are defined as having shoulder stiffness if SROMD >270degrees.
89453536|NCT02451878|Experimental|Intervention|The E-Couch self-help social anxiety module which is based on cognitive behavioural therapy principles. This module contains a literacy section and 5 toolkits comprising exposure practice, cognitive restructuring (modifying your thinking), attention practice, social skills training and relaxation. E-Couch is designed to be completed at the participant's own pace. It is free to use, browser-based and widely accessible on a range of connected devices.
89453537|NCT02451878|No Intervention|Control|Wait list control (WLC)
89453538|NCT03230942|Experimental|Patient education program|Pre-operative education and pos-operative rehabilitation in individuals will be undergo knee arthroplasty.
89453539|NCT03230942|Active Comparator|Control - only pos-op rehabilitation|Pos-operative rehabilitation in individuals will be undergo knee arthroplasty.
89453540|NCT02284191|Active Comparator|CT Coronary Angiogram|CT Coronary Angiogram plus standard care
89453541|NCT02284191|No Intervention|Standard Care|Standard care only
89453542|NCT03212846|Experimental|Treatment group|Children will receive hippotherapy by a licensed physical therapist. Before riding, stretching and warming exercises of the adductor muscles will be performed. Later, the patient will be seated astride with the therapist behind. In any case, the participant had no control of the horse. Therapist will be responsible for correctly positioning the subject on the horse, but no position changes or active intervention of the subject with the therapist will be made. This positioning consists on achieving the optimal body alignment with neutral pelvis.
89453543|NCT03212846|No Intervention|Control group|Children will receive the conventional treatment, based on physiotherapy related techniques, such as neurodevelopmental treatment (twice a week).
89453544|NCT02548078|Experimental|GSK3390107A+Nimenrix Group|Subjects in the GSK3390107A+Nimenrix Group received the investigational GSK3390107A vaccine at the Day 0 visit and Nimenrix at the Month 6 visit, intramuscularly into the deltoid region, or thigh region for smaller children.
89453545|NCT02548078|Experimental|Nimenrix+GSK3390107A Group|Subjects in the Nimenrix +GSK3390107A Group received Nimenrix at the Day 0 visit and the investigational GSK3390107A vaccine at the Month 6 visit, intramuscularly into the deltoid region, or thigh region for smaller children.
89453546|NCT00532311|Experimental|Lapaquistat Acetate 50 mg QD|(and stable statin therapy)
89453547|NCT00532311|Active Comparator|Stable statin therapy|
89453548|NCT03224156||Dilated Cardiomyopathy|
89453549|NCT03230708|Experimental|Erythrocytes derived MPs containing MTX|Suspension of erythrocytes derived MPs containing MTX, qd×6, 6 units MPs a time , Two courses.
89453550|NCT03230708|Active Comparator|convention drugs|Chemotherapeutic drugs, biologicals or traditional Chinese medicine.Dosage form, dosage, frequency and duration according to respective medicine instructions.
89453551|NCT03230474|Active Comparator|group 1|50 patients of this group will receive 5 mg of 0.5% hyperbaric bupivacaine with 0.2 mg morphine in 0.5 ml volume plus 0.5 ml as placebo (total volume 2 mL)
89453552|NCT03230474|Active Comparator|group 2|50 patients of this group will receive 5 mg of 0.5% hyperbaric bupivacaine with 0.2 mg morphine in 0.5 ml volume plus 5ng\ kg naloxone in 0.5 ml volume (total volume 2mL).
89453553|NCT00532233|Experimental|1|QAX576
89453554|NCT03212924|Experimental|Pupillometry|"Measure of pupil dilatation while listening to speech (monosyllabic words) in quiet and in noise.~Evaluation of speech comprehension in quiet~Evaluation of speech comprehension in noise~Measure of cognitive functions with the MOCA (Montreal Cognitive Assessment)~Auto evaluation of listening effort in quiet~Auto evaluation of listening effort in noise"
89453555|NCT02282553|Experimental|Magnetically steerable pill camera|Capsule endoscopy uses a swallowable pill camera which passes through the GI tract by the action of peristalsis. The procedure utilizes a battery powered wireless capsule to transmit images of the gastrointestinal tract as it passes through the small intestine. The images are later downloaded to a computer and reviewed by a trained physician. Magnetically steerable gastric capsule endoscopy uses a pill camera containing a small amount of magnetic material, that can be manoeuvred in the gut and intestine by the physician using a handheld magnet. This technique will be compared to conventional gastroscopy which uses a flexible endoscope. Both techniques will be used to diagnose upper gastrointestinal pathology in patients with recurrent/refractory iron deficient anemia.
89453556|NCT02279901|No Intervention|Traditional|Patients will attend a 1 hour OSA Class where OSA education is provided and home sleep testing is set up. These patients return the next day for individual appointments where study is scored and test results are discussed with patient. If study is consistent with OSA based on AHI4% at least 5/hour, patients undergo a 1 week autoCPAP trial. During this week, wireless remote monitoring is performed and troubleshooting is provided via telephone if problems with CPAP use are identified. The autoCPAP is returned during an individual visit, and CPAP is ordered for long-term use based on trial results and patient feedback. Patients are scheduled a 3 month follow-up appointment but are also instructed to call their sleep center case manager prior to that visit if there are problems with CPAP use.
89453557|NCT02279901|Experimental|Telemedicine Education Pathway|Patients follow our usual workflow as outlined in the Traditional Pathway. In addition, patients are emailed a link to view the Emmi OSA program within 2 weeks prior to their initial OSA class. If the patient tests positive for OSA and agrees to an autoCPAP trial, the patient is emailed a link to view the Emmi CPAP program. These patients are also scheduled for a 3 month follow-up visit to check CPAP usage.
89537157|NCT05178381|Experimental|Target: IFG; Order: IFG first|In this arm the target stimulation site is the IFG, the control stimulation site is the vertex. Participants will receive IFG stimulation in the first TMS session and vertex stimulation in the second TMS session.
89537158|NCT05178381|Experimental|Target: IFG; Order: vertex first|In this arm the target stimulation site is the IFG, the control stimulation site is the vertex. Participants will receive vertex stimulation in the first TMS session and IFG stimulation in the second TMS session.
89453558|NCT02279901|Experimental|Telemedicine IVR Pathway|Patients follow our usual workflow as outlined in the Traditional Pathway. Additionally, if CPAP is ordered for long-term therapy, the patient is enrolled into an IVR protocol that automatically analyzes the patient's CPAP use. If specific provider-defined thresholds are met, the platform will automatically deliver feedback messages to the patient (phone call, text messaging, or email) with the intention of encouraging better CPAP use. Patients are instructed to contact the sleep center for any issues with their therapy. This platform also includes a method for patients to track their own usage online. Automated messaging mechanism will be active for 3 months after CPAP is ordered, after which the messaging will stop. These patients are also scheduled for a 3 month follow-up visit.
89453559|NCT02279901|Experimental|Telemedicine Both Pathway|Patients follow our usual workflow as outlined in the Traditional Pathway. In addition, patients are provided both Emmi education programs and IVR follow-up as previously outlined. These patients are also scheduled for a 3 month follow-up.
89453560|NCT03230396|Placebo Comparator|Placebo|"Commercially-available chewing gum not supplemented with vitamins. Contains: Sugar; Dextrose; Gum Base; Corn Syrup; Natural and artificial flavors; artificial colors; carnauba wax; resinous glaze; neotame; butylated hydroxytoluene.~For saliva collection phase: No placebo is used. For blood collection phase: Subjects will chew two pieces at time = 0, 0.75, 4, and 8 h for 30 min at each time point."
89453561|NCT03230396|Experimental|Vitamingum Sport|"Same gum base as placebo but supplemented with vitamins (per piece): retinyl palmitate (1250 IU); ascorbic acid (15 mg); cholecalciferol (100 IU); dl-tocopherol acetate (7.5 IU); thiamine mononitrate (375 microg); riboflavin (425 microg); niacinamide (5 mg); calcium d-panothenate (2.5 mg); pyroxidine HCl (500 microg); cyanocobalamin (1.5 microg); folic acid (100 microg); biotin (11.25 microg).~For saliva collection phase: Subjects will chew 2 pieces for 30 min. For blood collection phase: Subjects will chew two pieces at time = 0, 0.75, 4, and 8 h for 30 min at each time point."
88938143|NCT01818362|Experimental|Group 3|MVA NP+M1 1.5 x 10⁸pfu followed by ChAdOx1 NP+M1 2.5 x 10¹⁰vp 8 weeks later.
88938144|NCT01818362|Experimental|Group 4|MVA NP+M1 1.5 x 10⁸pfu followed by ChAdOx1 NP+M1 2.5 x 10¹⁰vp 52 weeks later.
88938145|NCT01818362|Experimental|Group 1|ChAdOx1 NP+M1 2.5 x 10¹⁰vp followed by MVA NP+M1 1.5 x 10⁸pfu 8 weeks later.
88938146|NCT01818362|Experimental|Group 5|ChAdOx1 NP+M1 2.5 x 10¹⁰vp
88938147|NCT01818362|Experimental|Group 6|ChAdOx1 NP+M1 2.5 x 10¹⁰vp followed by MVA NP+M1 1.5 x 10⁸pfu 8 weeks later.
88938148|NCT01818375|Experimental|Goal Directed Fluid Therapy (GDFT)|"During surgery, patients in the Goal Directed Fluid Therapy (GDFT) will receive:~maintenance infusion of intravenous infusion of ringer lactate at a rate of 1.5 ml/Kg/hr to compensate insensible blood loss and fluid shift during surgery as recommended by perioperative fluid management guidelines for patients undergoing surgery with an enhanced recovery program and receiving a GDFT approach;~intraoperative intravenous boluses of colloids (6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride-Voluven) guided by an algorithm based on Esophageal Doppler (ED) estimation of the stroke volume (SV) provided by the manufacture, and also used in other clinical trials."
88938149|NCT01818375|Active Comparator|Standard Fluid Therapy|During surgery, patients will receive a maintenance infusion of intravenous infusion of ringer lactate as recommended by international guidelines and anesthesia text-books (Standard Fluid Therapy). In the Standard Fluid Therapy arm, the Esophageal Doppler (ED) monitor will be turned away from the anesthesia care provider, and the screen will be covered with an opaque card. The ED variables will be collected by an independent research personnel. Hemodynamic variables triggering extra fluid administration (Ringer Lactate or Voluven) will be decided based on the clinical judgment of the anesthetist in charge and will include: urinary output less than 0.5/ml/kg/hr, an increase in heart rate more than 20% above baseline or more than 110 beats/min, a decrease in mean systolic blood pressure less than 20% below baseline or less than 90 mmHg and intraoperative blood loss. Boluses of 200 ml of intravenous fluid will be administered until the above targets will be restored
88938150|NCT01818388||IVTM system, therapeutic hypothermia|Induced therapeutic hypothermia post cardiac arrest
88938151|NCT01818401|Other|Control group|The control group will be constituted of patients with the prosthesis GMK ® without the ancillary MyKnee ® LBS.
88938152|NCT01818401|Other|Matched patient|The treated group will consist of patients which the GMK ® prosthesis with ancillary ® MyKnee LBS.
88938153|NCT01818440|Active Comparator|A|Patients will have the procedure performed with regular fluoroscopy (X-ray). Regular fluoroscopy is the standard method
88938154|NCT01818440|Experimental|B|Patients will have the procedure performed using the 3-D Roadmap software.With the 3DRoadmap, images from a Cone-Beam CT are analyzed. Software shows the vessels supplying the tumor and the plan is displayed on top of fluoroscopy
88938155|NCT01818453|Active Comparator|Computerized self-help program for depression|Participants will have access to a computerized self-help program for depression, called deprexis, for 8 weeks.
88938156|NCT01818453|No Intervention|Wait List Control|"Participants randomly assigned to a wait list control condition will wait 8 weeks after assignment before they can access the deprexis program."
88938157|NCT01818479|Experimental|All participants|
88938158|NCT01818505||Gouty arthritis|Patient with gouty arthritis
88938159|NCT01818505||Asymptomatic hyperuricemia|Patient with asymptomatic hyperuricemia
88938160|NCT01818505||OA without hyperuricemia|Patient of osteoarthritis but without hyperuricemia and gout
88938161|NCT01818544|Experimental|BAY85-8501|
88938162|NCT01818544|Placebo Comparator|Placebo|
88938163|NCT01818557|No Intervention|Every day blood glucose testing|Patients will test their blood glucose values 4 times every day
88938164|NCT01818557|Experimental|Every other day blood glucose testing|Patients will test their blood glucose 4 times every other day
88938165|NCT01818570|Placebo Comparator|Placebo solution|A 100 ml placebo solution will be administered through an esophageal probe. 100 ml will be administered as an infusion with a rate of 7ml/min. Healthy volunteers will be treated with placebo in one out of three visit days.
88938166|NCT01818570|Active Comparator|PPC-5650|"PPC-5650 is a asic-sensing ion channel-1a antagonist that can block the acid-sensing ion channels, leading to a reduction in the pain signal under up-regulated conditions. A dose of 2.5 mg PPC-5650 in a 100 ml solution will be administered through an esophageal probe to assess local effects. 100 ml will be administered as an infusion with a rate of 7ml/min. Healthy volunteers will be treated with PPC-5650 in one out of three visit days."
88938167|NCT01818583|Experimental|Potassium|Potassium chloride infusion at a rate of 15 mmol/h (60 mmol KCl in 1000 ml of 5% glucose with a concentration of 0.05 mmol/mL, flow rate 265 mL/h). If the serum Mg ≤0.8 mmol/L, MgSO4 infusion (0.5 mmol/kg/24 hours in 1000 mL NaCl 0.9% corresponding to an infusion rate of approximately 42 mL/hour) will also be administered.
88938168|NCT01818583|Placebo Comparator|Placebo|5% glucose (flow rate 265 ml/h) as placebo infusion.
88938169|NCT01818609|Experimental|Step Reduction|"Step reduction:~Take less than 1500 steps/d~No disease"
88938170|NCT01818622|Experimental|Patient-group blue-blockers|N= 21 Blue-blocking goggles/screens from 6 p.m. to 08 a.m. in addition to treatment as usual (TAU). The goggles may be taken of when going to bed and turning of the light. For consenting patients who are unable to use goggles according to the protocol blue-blocking screens covering light-sources will be used.
88938171|NCT01818622|Placebo Comparator|Patient group clear-lensed goggles|N= 21 (Patient group) clear-lensed goggles from 06 p.m. to 08 a.m. in addition to TAU.
88938172|NCT01818622|Experimental|Non-bipolar control-group blue-blockers|N= 42 For baseline day 1-7: Actiwatch Spectrum worn at the wrist of dominant hand, day 8-14 continued wearing of Actiwatch spectrum + blue-blocking goggles from 6 p.m. to 08 a.m. In addition to selfreport forms described in the outcome section self report forms Horne-Ostberg Morningness-Eveningness Questionaire (HOMEQ)and Seasonal Pattern Assessment Questionaire (SPAQ).
88938173|NCT01818648|Experimental|Exenatide|Qualifying participants will be assigned to 2 different treatment arms consisting of placebo or exenatide 5 mcg administered subcutaneously twice: the first dose during fasting and the second four hours later. Subsequently, participants will switch over to the alternate treatment arm. In both arms participants will undergo a series of measurements including 24 hour GI transit, permeability measurements by using mannitol and lactulose, and 24 hour urine and stool collections.
88938174|NCT01818648|Placebo Comparator|Placebo|Qualifying participants will be assigned to 2 different treatment arms consisting of placebo or exenatide 5 mcg administered subcutaneously twice: the first dose during fasting and the second four hours later. Subsequently, participants will switch over to the alternate treatment arm. In both arms participants will undergo a series of measurements including 24 hour GI transit, permeability measurements by using mannitol and lactulose, and 24 hour urine and stool collections.
88938175|NCT01818687|Experimental|MCI-196 (Flexible dose)|MCI-196 BSA eq 3g, 6g, 9g, 12g or 15g
88938176|NCT01818713|Experimental|2B3-101|A single dose of 2B3-101 (a glutathione (GSH) pegylated liposomal doxorubicin hydrochloride formulation) will be administrated intravenously once per cycle. To minimize the risk of infusion reactions, 5% of the total dose of 2B3-101 (in mg) will be administrated over the first 30 minutes. If tolerated, the infusion may then be completed over the next hour for a total infusion time of 90 minutes
88938177|NCT01818778|Experimental|Stimulation Group|Cognitive Stimulation Group: One-on-one (one volunteer visiting one resident at a time), stimulation-group residents and stimulation-group volunteers met 3 times each week, for 8 weeks, to work through a variety of memory, reasoning, and selective attention exercises. Each visit was 20 minutes in length.
88938178|NCT01818778|Active Comparator|Control Group|"Standard Friendly Visit: Control-group residents and control-group volunteers, one-on-one, met for 8 weeks, 3 times each week, for friendly visits. Each visit was 20 minutes in length."
88938179|NCT01818791|Active Comparator|Making Proud Choices alone|These sites will be trained in Making Proud Choices.
88938180|NCT01818791|Experimental|Making Proud Choices+Getting To Outcomes|These sites will receive training in Making Proud Choices and receive the Getting To Outcomes intervention.
88938181|NCT01818817||TPVB group|In this group of patients thoracic paravertebral block is performed.
88938182|NCT01818817||GA group|In this group of patients general anesthesia is performed.
88938183|NCT01818830||SIRS group|(1) temperature > 38oC or < 36oC; (2) pulse rate > 90 beats/min; (3) ventilation rate > 20 breaths/min or hyperventilation with a partial pressure of arterial carbon dioxide (PaCO2) < 32 mmHg; (4) white blood cell (WBC) count >1 2,000μL-1 or < 4000 μL-1 , or > 10% immature cells.
88938184|NCT01818830||sepsis|SIRS+infection
88938185|NCT01818830||normal control|For the healthy control outpatients, possibilities of acute or past chronic diseases were excluded. Moreover, we made sure that the healthy control subjects had not been hospitalized or taken vitamin-based substitutive drugs in the last 12 months, and proved normal in physical checkups and lab examinations.
88938186|NCT01818843|Experimental|Safety and Adverse Reaction in CO|Inhaled Carbon Monoxide
88938187|NCT01818856|Experimental|Telaprevir interactions|"Telaprevir 750 mg/8h or 1125 mg/12h (+ pegIFN alfa and ribavirin) plus Atazanavir/ritonavir 300/100 mg/24. Pharmacokinetic profile on day 0.~Intervention: Ritonavir will be withdrawn and the atazanavir dose increased to 200 mg/12h for days 1 to 7. On day 8: a morning dose of Telaprevir (750 mg or 1125 mg) plus Atazanavir 200 mg. Pharmacokinetic profile for 12 hours"
88938188|NCT01818869|Experimental|AZD8848|Subjects will participate in 1 of 3 groups and receive multiple doses of AZD8848 or matching placebo In each group 6 subjects will receive AZD8848 and 2 subjects will receive matching placebo.
88938189|NCT01818869|Placebo Comparator|Placebo to match AZD8848|Subjects will participate in 1 of 3 groups and receive multiple doses of AZD8848 or matching placebo. In each group 6 subjects will receive AZD8848 and 2 subjects will receive matching placebo.
88938190|NCT01818882|Active Comparator|Standard care|"Patients randomized to this arm will receive standard care.~Intervention: Standard care."
88938191|NCT01818882|Experimental|Standard care + ultrasound|"Patients randomized to this arm will receive standard care + pleuropulmonary ultrasound.~Intervention: Standard care + ultrasound"
88938192|NCT01818895||Withdrawal of mechanical ventilation|
88938193|NCT01818908|Experimental|DA-EPOCH|"Infused agents:~Etoposide 50 mg/m2/day CI24h d1-d4; Doxorubicin 10 mg/m2/day CI24h d1-d4; Vincristine 0.4mg/m2/day CI24h d1-d4;~Bolus agents:~Rituximab(B-NHL) 375 mg/m2/day IV d0; Cyclophosphamide 750 mg/m2/day IV d5 ; Prednisone 60 mg/m2/bid oral or IV d1-d5;~The details of dose adjustment are described in ref 1.~If enrolled patient was histologically confirmed CD20+ B cell lymphoma, standard dose of rituximab will be recommend to combined with DA-EPOCH regimen."
88938194|NCT01818934|Active Comparator|expert clinical exam only|all babies assigned to this group had expert clinical examination only, no hip ultrasound
88938195|NCT01818934|Active Comparator|selective hip ultrasound screening|all children classified at increased risk, based on clinical findings and/or risk factors (breech presentation, family history, foot deformity)received a hip ultrasound at birth, in addition to expert clinical screening
89015626|NCT06257953|Active Comparator|Patients with a BMI of 18-24.9 kg/m2|Following the visualization of the anatomical structures, the nerve block needle was advanced via the in-plane technique beneath the erector spinae muscles until the interfascial space was reached. After hydrodissection with 2 ml normal saline, 15 ml of 0.25% bupivacaine was injected into the area. Then the block process will be applied to the other side in the same way. A total of 30 ml of 15 ml 0.25% bupivacaine will be injected.
89015627|NCT06257953|Active Comparator|Patients with a BMI of 25-29.9 kg/m2|Following the visualization of the anatomical structures, the nerve block needle was advanced via the in-plane technique beneath the erector spinae muscles until the interfascial space was reached. After hydrodissection with 2 ml normal saline, 15 ml of 0.25% bupivacaine was injected into the area. Then the block process will be applied to the other side in the same way. A total of 30 ml of 15 ml 0.25% bupivacaine will be injected.
89015628|NCT06257953|Active Comparator|Patients with a BMI of 30-40 kg/m2|Following the visualization of the anatomical structures, the nerve block needle was advanced via the in-plane technique beneath the erector spinae muscles until the interfascial space was reached. After hydrodissection with 2 ml normal saline, 15 ml of 0.25% bupivacaine was injected into the area. Then the block process will be applied to the other side in the same way. A total of 30 ml of 15 ml 0.25% bupivacaine will be injected.
89015629|NCT06257940||intra-operative glove changing group|in which, the surgeon will replace his/her outer surgical gloves with a new pair of sterile gloves just prior to abdominal closure
89453562|NCT03230396|Experimental|Vitamingum Immunity|"Same gum base as placebo but supplemented with vitamins (per piece): retinyl palmitate (2000 IU); ascorbic acid (62.5 mg); cholecalciferol (200 IU); dl-tocopherol acetate (20 IU); niacinamide (10 mg); calcium d-panothenate (10 mg); pyroxidine HCl (1 mg); cyanocobalamin (5 microg); folic acid (200 microg); biotin (75 microg); zinc sulfate (2.5 mg); sodium selenite (17.5 microg); chromium picolinate (60 microg); and potassium iodide (40 microg).~For saliva collection phase: Subjects will chew 1 pieces for 30 min. For blood collection phase: Subjects will chew 1 piece at time = 0, 0.75, 4, and 8 h for 30 min at each time point."
89453563|NCT03210194|Active Comparator|Standard Neonatal Resuscitation Training|Standard training will be conducted through a theoretical-practical course, which will be administered once during the study period, to all health professionals of the selected facilities, according to the randomization. It is an 8-hour course, with 3 hours of theory and 5 hours of practice, which will take place during a single day. The course will be performed by staff of the Neonatal Unit of the Instituto Nacional de Salud del Niño (National Institute of Child Health, Lima, Peru), and will be coordinated by an NRP instructor accredited by the American Academy of Pediatrics. Participants who have completed their attendance to theoretical sessions, participated in the simulated practices and approved the printed exams taken the same day will we granted a Standard Certification.
89453564|NCT03210194|Experimental|MP-ICT Neonatal Resuscitation Training|The Multi-platform ICT (MP-ICT) training includes continuous certification in neonatal resuscitation and is being developed for online and offline access, and will be complemented with simulated practices on every site. The platform is being improved and adjusted to the needs of the fieldwork in Ayacucho and Cusco. The adaptations include increasing hosting; ameliorate friendly usability, uploading packages and videos, improvement of examination and certifications, and tests for readiness. The MP-ICT resource will be accessed from remote Peruvian locations through computers, personal portable devices and cell phones. To be granted an MP-ICT Certification the trainee needs to have passed the online theoretical exam, assist to the practice and approve practical skills assessment.
89453565|NCT00529503|Experimental|1|SGN-40, rituximab, etoposide, carboplatin, ifosfamide
89453566|NCT00529503|Placebo Comparator|2|placebo, rituximab, etoposide, carboplatin, ifosfamide
89453567|NCT05459350||Safe Discharge Positive|Safe Discharge Positive
89453568|NCT05459350||Safe Discharge Negative|Safe Discharge Negative
89015630|NCT06257940||usual care group|in which, surgeon won't change his/her gloves before abdominal closure
89453569|NCT05459194|Active Comparator|Test|Fluticasone/Salmeterol Elpenhaler active vs Fluticasone/Salmeterol Diskus placebo
89453570|NCT05459194|Placebo Comparator|Refere|Fluticasone/Salmeterol Elpenhaler placebo vs Fluticasone/Salmeterol Diskus active
89453571|NCT03230240||HIPEC|Patients with carcinomatosis or other peritoneal surface malignancy
89453572|NCT05476198|Active Comparator|Group BPB|The investigators performed a brachial plexus block on that patient group for preoperative anxiety
89453573|NCT05476198|Active Comparator|Group GA|The investigators performed general anesthesia on that patient group for preoperative anxiety
89453574|NCT02280057|Active Comparator|Metformin|Metformin 850 mg x 2 in six months
89453575|NCT02280057|Placebo Comparator|Placebo|Placebo 2 tablets daily for six months
89453576|NCT05459116|Experimental|Overall group|Placement of a nasogastric balloon
89453577|NCT02280135|Experimental|Intravitreal injection of Autologous bone marrow Stem Cell|"Patients included in the trial will receive a pars plana intravitreal injection of autologous mononuclear cells (MNC) of bone marrow (BM) in one eye (experimental group A or group). The eye in which autologous BM MNCs were injected will be determined randomly.~The average dose will be 30 million of cells (5-60 million) diluted in 0.1 ml. of saline."
89453578|NCT02280135|Placebo Comparator|Subconjunctival injection of saline|Patients included in the trial will receive a subconjunctival injection of 0.1 ml of saline (SF) (placebo) in the fellow eye (group B or control group). In this way the patient will receive an injection in the control eye but avoid the risks of intraocular injection.
89453579|NCT02279589|Active Comparator|Group A|"Description :~15 subjects with : Prevenar13® 0,5 then Pneumo 23® 0,5 then Pneumo 23® 0,1~Route : Intramuscular vaccination schedule : M0, M2, M12"
89453580|NCT02279589|Active Comparator|Group B|"Description 15 subjects with : Prevenar13® 0,5 then Pneumo 23® 0,1 then Pneumo 23® 0,1~Route : Intramuscular vaccination schedule : M0, M2, M12"
89453581|NCT02279589|Active Comparator|Group C|"Description :~15 subjects with : Prevenar13® 0,5 then Pneumo 23® 0,1 then Pneumo 23® 0,5~Route : Intramuscular vaccination schedule : M0, M2, M12"
89015631|NCT06257927|Experimental|Intervention|
89015632|NCT06257914||Cataract|Patients with cataract in both eyes
89015633|NCT06257901||Adults with Fabry disease|Focus groups and participatory workshops
89015634|NCT06257901||Lay specialist stakeholders|Focus groups
89453582|NCT02279589|Active Comparator|Group D|"Description:~15 subjects with : Prevenar13® 0,5 then Pneumo 23® 0,5 then Pneumo 23® 0,5~Route : Intramuscular vaccination schedule : M0, M2, M12"
89453583|NCT03209804|Other|Traditional neurosurgical techniques|Unsimultaneous endovascular interventional embolisation/radiotherapy followed by microsurgical resection, as traditional clinical routines.
89453584|NCT03209804|Experimental|Hybrid operating techniques|A one-stage hybrid operation combining endovascular intervention and microsurgical techniques will be conducted simultaneously
88938196|NCT01818934|Active Comparator|universal hip ultrasound screening|All newborns assigned to this arm received hip ultrasound at birth in addition to expert clinical examination
88938197|NCT01818947||Gefitinib|
88938198|NCT01818960|Active Comparator|SS-PCI|Same sitting multivessel PCI as an adjunct to primary PCI
88938199|NCT01818960|Active Comparator|IRA-PCI|IRA only PCI with planned staging for non-IRA lesions
88938200|NCT01818973|Experimental|Single Arm|"Neoadjuvant chemotherapy with XELOX: Xeloda, po, 1000mg/m2/12h daily, day 1 in the afternoon until day 15 in the morning; Oxaliplatin, iv, 130mg/m2, day 1; and Bevacizumab, iv, 7.5 mg/kg, day 1, during the first cycle (each cycle has 3 weeks).~Followed by chemoradiotherapy, 50 Gy/25 fractions during 5 weeks plus 2 cycles XELOX and Bevacizumab: Xeloda, po, 1000mg/m2/12h daily, day 1 in the afternoon until day 15 in the morning; Oxaliplatin, iv, 100mg/m2, day 1; and Bevacizumab, iv, 7.5 mg/kg, day 1.~6-7 weeks from the last radiation therapy, Total Mesorectal Excision (TME) surgery will be performed.~3-4 weeks after operation, 3 cycles XELOX (the same as the neoadjuvant chemotherapy) and 2 cycles Xeloda (po, 1000mg/m2/12h daily, day 1 in the afternoon until day 15 in the morning) will be administered."
88938201|NCT01818999|Experimental|arm one|IXABEPILONE and STEREOTACTIC BODY RADIATION THERAPY (SBRT)
88938202|NCT01819012|Experimental|Isoflurane 1.0 MAC|10 min-inhalation of each concentration of isoflurane, 1.0 MAC
88938203|NCT01819012|Experimental|Isoflurane 1.5 MAC|10 min-inhalation of each concentration of isoflurane, 1.5 MAC
88938204|NCT01819012|Experimental|Isoflurane 2.0 MAC|10 min-inhalation of each concentration of isoflurane, 2.0 MAC
88938205|NCT01819025|Experimental|4 face-to-face and smartphone-app|Four face-to-face therapy sessions and smartphone app as a complement and support to the four sessions.
88938206|NCT01819025|Active Comparator|TAU|10 sessions of face-to-face therapy, full behavioral activation
88938207|NCT01819038|Experimental|High NGAL and early RRT|NGAL level > 400 ng/ml and start continuous renal replacement therapy early
88938208|NCT01819038|Experimental|High NGAL and late RRT|NGAL > 400 ng/ml and start continuous renal replacement therapy late
88938209|NCT01819038|Active Comparator|Low NGAL|NGAL < 400 ng/ml and starting continuous renal replacement therapy follow with absolute indication
88938210|NCT01819051|Experimental|Plasma|Apply plasma to great toenail for up to 20 minutes, 1X/week for 3 weeks
88938211|NCT01819077||TMMR|Patients with cervical cancer Stages IB - IIA treated with TMMR and tLNE
88938212|NCT01819090|Active Comparator|No ventilation switch control|Neuromuscular patients non invasively ventilated in a stable state at the time of the study testing an usual (with no ventilation switch control) Elysee 150 ventilator while speaking
88938213|NCT01819090|Active Comparator|Ventilation switch control|Neuromuscular patients non invasively ventilated in a stable state at the time of the study testing an Elysee 150 ventilator with a ventilation switch control allowing them to control ventilation while speaking
89453585|NCT02282709|Experimental|Daclatasvir and asunaprevir|daclatasvir 60 mg once daily asunaprevir 100 mg BID
88938214|NCT01819103||Acute myocardial infarction|Drug Adherence
88938215|NCT01819142|Experimental|AutoloGel|Subjects will be treated with AutoloGel on average twice a week for the first 2 weeks, and then, once a week thereafter while under active treatment, but actual frequency of treatment will be determined by the treating physician. All patients will receive Autologel treatment
88938216|NCT01819155|Experimental|adjTIV|Children randomized to receive adjTIV
88938217|NCT01819155|Experimental|TIV|Children randomized to receive TIV
88938218|NCT01819155|Placebo Comparator|Placebo|Children randomized to receive Placebo
88938219|NCT01819207|Experimental|TEG group|
88938220|NCT01819220|Active Comparator|amlodipine/valsartan|
88938221|NCT01819220|Experimental|hydrochlorothiazide/telmisartan|
89453586|NCT03119402|Experimental|RRT + active tDCS|Rhythmic Reading Training, administered for 5 hours over 10 days consecutive (30-minute training sessions per day) + simultaneous 20 minutes of active tDCS (1.5 mA, 5x5cm anodal electrode on left parieto-temporal regions and 5x5cm cathodal electrode on right parieto-temporal regions).
89453587|NCT03119402|Sham Comparator|RRT + sham tDCS|Rhythmic Reading Training, administered for 5 hours over 10 days consecutive (30-minute training sessions per day) + simultaneous 20 minutes of sham tDCS (with the same active tDCS setup, current applied for 30 seconds,
89453588|NCT02282787|Experimental|5 micron dex arm|
89453589|NCT02282787|Experimental|10 micron dex arm|
89453590|NCT03223844|Experimental|Healthy subjects|Measurement of Dextroamphetamine Sulfate-induced dopamine release and synthesis before and after amphetamine sensitization.
89453591|NCT00458601|Experimental|CDX-110 with GM-CSF|
89453592|NCT03223688|Experimental|Day-Care early intervention program|The daily treatment session had eight children along with their major caregivers. The treatment was conducted by two experienced occupational therapists (OT), and each session lasted for four hours in the week-day morning with a 10-minute break. The goal of the sessions was to enhance children's development through cognitive training, behavioral modification plan and parenting skill training. Said therapists assisted the caregivers in improving their nurturing and parenting skills with their children, as well as their techniques with regards to influencing them.
89453593|NCT03223688|Experimental|OPD+SI intervention program|The treatment program had eight children along with their major caregivers. The treatment was also performed by two experienced OT, and each session lasted for one hours, once a week. The sessions consisted of cognitive training, behavioral modification plan and parenting skill training. Adjunctive SI therapy was also performed by said OT for improving children's sensory motor development in an additional hour.
89453594|NCT03223688|Active Comparator|OPD intervention program|The treatment program had eight children along with their major caregivers. The treatment was also performed by two experienced OT, and each session lasted for one hours, once a week. The sessions consisted of cognitive training, behavioral modification plan and parenting skill training.
89453595|NCT00658047|Experimental|0.25 mg CH-1504|0.25 mg CH-1504
89453596|NCT00658047|Experimental|0.5 mg CH-1504|0.5 mg CH-1504
89453597|NCT00658047|Experimental|1.0 mg CH-1504|1.0 mg CH-1504
89453598|NCT00658047|Active Comparator|Methotrexate|Methotrexate (MTX) 10 mg/week for 2 weeks, 15 mg/week for 2 weeks, 20 mg/week for 8 weeks
89453599|NCT03230162|Experimental|sildenafil citrate|50 pregnant female will be treated with sildenafil citrate 25 mg every 8 hours (Silden EIPICO co.) orally, starting at the diagnosis of FGR till delivery.
89453600|NCT03230162|Experimental|low molecular weight heparin|50 pregnant female will be treated with a single daily dose of LMWH (tinzaparin) (Innohep LEO pharmaceutical products.) subcutaneously starting at diagnosis of FGR till delivery according to body weight as follow < 50 kg 3500 units daily 50-90 kg 4500 units daily 91-130 kg 7000 units daily 131-170 kg 9000 units daily > 170 kg 75 u/kg/day
89453601|NCT03223532|Active Comparator|PrePex Day 7 FRP|"Standard PrePex procedure, 1 week after device placement foreskin and device are removed.~*Subjects must be adequately vaccinated, or willing to be vaccinated, against Tetanus based on appropriate national guidance for male circumcision"
89453602|NCT03223532|Experimental|PrePex Day 0 FRP|On the day of device placement the foreskin is removed, the device is removed 1 week later.
89453603|NCT00455559|Experimental|Perifosine 100 mg/d + imatinib mesylate|Perifosine 100 mg/d x 28 days Oral daily dose of perifosine 100 mg and oral daily dose of imatinib mesylate (current dose at time of progression of disease [PD] without interruption). Both drugs will be taken on a continuous basis and should be taken with food. Each cycle will be defined as 28 days.
89453604|NCT00455559|Experimental|Perifosine 900 mg/d + imatinib mesylate|Perifosine 900 mg/d (300 mg tid), 1 x weekly Oral once-weekly dose of perifosine 900 mg (300 mg tid) + oral daily dose of imatinib mesylate (current dose at time of PD without interruption). Perifosine will be taken on days 1, 8, 15, and 22 of a 28-day cycle. Both medications should be taken with food.
89453605|NCT03230084|Experimental|Urine PDG test|Urine pregnanediol 3-glucuronide (PDG) test strip
89453606|NCT02916433|No Intervention|Usual care|This group will continue to receive treatments that have already been initiated to manage bronchial secretions.
89453607|NCT02916433|Experimental|Octreotide|This group will continue to receive treatments that have already been initiated to manage bronchial secretions. Additionally, this group will receive parenteral octreotide.
89453608|NCT02282865||Visual analogue scale (VAS) >5|The degree of surgery-related anxiety assessment using VAS
89453609|NCT02282865||Visual analogue scale (VAS) ≤5|The degree of surgery-related anxiety assessment using VAS
88938222|NCT01819246|Active Comparator|Pheresis Treatment Arm|
88938223|NCT01819246|Sham Comparator|Control Arm|
88938224|NCT01819259|Active Comparator|ADHD Nonsmokers|All participants will be non-smokers defined as never having smoked an entire cigarette and no tobacco use in the past 3 years. The group will then be split into those diagnosed with ADHD/ADD and controls for comparison.
88938225|NCT01819259|Active Comparator|Non-ADHD Nonsmokers|All participants will be non-smokers defined as never having smoked an entire cigarette and no tobacco use in the past 3 years. The group will then be split into those diagnosed with ADHD/ADD and controls for comparison.
88938226|NCT01819285|Active Comparator|Immediate Endocrine Therapy|Immediate Endocrine Therapy. Orchiectomy or LHRH Agonist Therapy plus (initially) Antiandrogen Therapy. Buserelin (BSRL); Cyproterone acetate (Androcur) (CPTR), Cyproterone acetate (Androcur)(NSC-81430). Treatment initiated within 1 month of randomization.
88938227|NCT01819285|Experimental|Delayed Endocrine Therapy|Orchiectomy or LHRH Therapy plus (initially) Antiandrogen Therapy. BSRL; CPTR. Treatment delayed until onset of symptoms.
88938228|NCT01819298||bacteria colonization in CAT less 20|the incidence of sputum potential pathogenic microoragnism in patients with CAT scores less than 20
88938229|NCT01819298||the PPM in change of CAT >2|the change of potential pathogenic microorganism in CAT difference more than 2 while follow-up
88938230|NCT01819298||the change of CAT<=2|the change of potential pathogenic microorganism in CAT difference less than or equal to 2 while follow-up
88938231|NCT01819298||PPM in CAT>=20|the incidence of sputum potential pathogenic microoragnism in patients with CAT scores more than or equal to 20
88938232|NCT01819324|Experimental|Targeting the Teachable Moment|Receiving Targeting the Teachable Moment Intervention materials (focusing on health behaviors and issues specific to breast cancer survivors) every other week for 4 months
89453610|NCT02451800|Experimental|in-class yoga|"The intervention is a in-class yoga course taught by yoga instructors for 3 times per week for 3 months. This class is based on Peggy Cappy's Program: More Yoga for Every Body. Class is taught at Sanford Wellness Centers in Sioux Falls, South Dakota and Fargo, North Dakota. Each class in 1 hour in length."
89453611|NCT02451800|Active Comparator|yoga by DVD|"For the intervention participants are asked to do yoga at home following the Peggy Cappy's Program: More Yoga for Every Body DVD. They are asked to complete these exercises 3 times per week for 3 months. The DVD is 1 hour in length."
89453612|NCT02451800|Active Comparator|stretching by DVD|"For the intervention participants are asked to do stretching exercises at home following Bob Anderson's DVD-Stretching: the DVD. They are asked to complete these exercises 3 times per week for 3 months. The DVD is 1 hour in length."
89453613|NCT04059523|Experimental|S6G5T-3|topical cream
89453614|NCT04059523|Active Comparator|Retin-A® 0.1% Cream|topical cream
89453615|NCT02282943|Active Comparator|Laser|vapourisation/excision of endometriosis using CO2 laser
88938233|NCT01819324|Active Comparator|Standardized Lifestyle Management|Receiving Standardized Lifestyle Management materials (focusing mostly on health behaviors) every other week for 4 months
88938234|NCT01819324|No Intervention|Usual Care|Receiving SLM materials at the end of the 7 months
88938235|NCT01819350|Experimental|G4 and G5|Application of antibiotic group of pediatric medicines and control group (sucrose 10 %)on dental biofilm.
88938236|NCT01819350|Experimental|G1, G2 and G3|Application of Nutritional, Respiratory and Endocrine groups medicines pediatric on dental biofilm
88938237|NCT01819363||Study group|Patients with Malignant pleural effusion according to inclusion and exclusion criteria.
88938238|NCT01819389|Experimental|Imatinib and nilotinib combination|All patients will receive treatment as follows: imatinib 100 mg tablets, 200 mg daily for 6 months; and nilotinib 150 mg capsule, 300 mg daily for 6 months.
88938239|NCT01819402|Active Comparator|Active Comparator: 1|up to 30 mg pioglitazone, tablet, orally, once daily
88938240|NCT01819402|Sham Comparator|Sham Comparator: 1|up to 4 mg/day glimepiride, tablet, orally, once daily
89453616|NCT02282943|Experimental|Harmonic scalpel|excision of endometriosis using Harmonic scalpel
89453617|NCT03223454|Experimental|biological amnion loaded with hAECs|Biological amnion loaded with 100 million hAECs is placed into uterine cavity immediately after TCRA.
89453618|NCT03223454|Placebo Comparator|biological amnion|Biological amnion is placed into uterine cavity immediately after TCRA.
89453619|NCT03223454|Experimental|intravenous infusion of hAECs|intravenous infusion of 100 million hAECs immediately after TCRA
89453620|NCT03223454|Experimental|intrauterine infusion of hAECs|100 million hAECs is infused into uterine cavity immediately after TCRA.
88938241|NCT01819428|Experimental|NOV120101 (Poziotinib)|Single arm study with NOV120101(poziotinib)12mg PO daily administration
88938242|NCT01819441|Sham Comparator|Normal Azelnidipine/Perindopril|Systole blood pressure controlled between 130 mmHg~140 mmHg(with or without hydrochlorothiazide).
88938243|NCT01819441|Experimental|Intensive Azelnidipine/Perindopril|Systole blood pressure controlled below 130 mmHg(with or without hydrochlorothiazide).
88938244|NCT01819454|Experimental|pH monitoring sinusitis no polyps|30 patients with chronic rhinosinusitis without nasal polyposis, without asthma bronchiale or ASA syndrome
88938245|NCT01819454|Experimental|pH monitoring sinusitis with polyp|30 patients with chronic rhinosinusitis with nasal polyposis, without asthma bronchiale or ASA syndrome
88938246|NCT01819454|Experimental|pH monitoring sinusitis, polyps, asthma|30 patients with chronic rhinosinusitis with nasal polyposis and with asthma bronchiale and/or ASA syndrome
88938247|NCT01819467|Active Comparator|Treatment Group|Patients in this group will receive Seprafilm onto the uterine incision and the anterior midline of the uterus.
88938248|NCT01819467|No Intervention|Control Group|This arm will be known as the control/no intervention group. This group will not receive Seprafilm or any other adhesion barrier method
88938249|NCT01819493|Active Comparator|Standard Family-Based intervention|"Families randomized to the Standard Family-based Intervention will receive three-month family YMCA memberships, one orientation training session, access to available equipment and programming at the YMCA, and receive diabetes educational materials from the Power to Prevent curriculum via email. Based on our previous experience with AA adults, the investigators anticipate that all families will have access to email either at home or at work. Educational materials will be mailed to families without access to email. The study will also maintain contact with participants by sending holiday and birthday cards, as well as postcard reminders of scheduled data collection visits."
88938250|NCT01819493|Experimental|Lifestyle Intervention|"The lifestyle intervention for adults will involve a dietary weight loss program and an increase in caloric expenditure through moderate PA. Parents will be encouraged to decrease caloric intake in a sound manner to produce a total weight loss of 5%. The PA component will be to promote an increase in family home-based activity.~Children. The study will promote healthy eating behaviors, rather than restrictive eating plans with caloric restrictions."
88938251|NCT01819519|No Intervention|Standard Prenatal Care|Participants will receive standard prenatal care from the time they are screened for CMV to delivery. This includes a CMV brochure.
89015635|NCT06257901||Specialist stakeholders|Interviews
89453621|NCT03223454|Experimental|hydrogel loaded with hAECs|Hydrogel loaded with 100 million hAECs is infused into uterine cavity immediately after TCRA.
89453622|NCT04059133|Experimental|LiESWT arm|"For SUI: The LiESWT was applied with 0.25 mJ/mm2 intensity, 3000 pulses of shocks, and frequency of 3 pulses/second, once weekly for 4-weeks (W4) and 8-weeks (W8). Probe be transcutaneous applied to the left and right labia minora of the genital area, and the applicator was gently placed on the middle, the left side and the right side of the labia with 0.25 mJ/mm2 intensity and 1000 pulses of shocks individually.~For OAB: The LiESWT was applied with 0.25 mJ/mm2 intensity, 3000 pulses of shocks, and frequency of 3 pulses/second, once weekly for 4-weeks (W4) and 8-weeks (W8). Probe be transcutaneous applied to the lower abdomen with two fingers apart from the pubic symphysis, tilting to 45°, and the applicator was gently placed on suprapubic skin area over the bladder dome and bilateral bladder walls with 0.25 mJ/mm2 intensity and 1000 pulses of shocks individually."
88938252|NCT01819519|Experimental|Educational Intervention|This group will be approached during a routine prenatal visit and will receive a 5-10 minute educational intervention (CMV prevention video, preventive information, weekly text messages/emails as reminders for hygiene behaviors, developmental calendar with hygiene reminders).
88938253|NCT01819532|Active Comparator|Immediate umbilical cord clamping|The umbilical cord will be clamped immediately after delivery.
88938254|NCT01819532|Experimental|Cord milking group|"The umbilical cord will be milked in direction towards neonate 4 times over the course of 10 minutes."
88938255|NCT01819545||Alzheimer's disease|no intervention
88938256|NCT01819545||Mild cognitive impairment|no intervention
88938257|NCT01819545||Normal aging|no intervention
88938258|NCT01819558|Experimental|immune therapy|6 administration every 2 weeks of intra-muscular 200 micrograms of protein recwt1-A10+AS01B at week 1, 3, 5, 7, 9 and 11.
88938259|NCT01819571|Experimental|Normal diastolic function group|
88938260|NCT01819571|Active Comparator|Diastolic dysfunction group|
88938261|NCT01819584||Patients below 15 years old|
88938262|NCT01819584||Patients above 15 years old|
88938263|NCT01819610|Experimental|SPRIX|Subjects will be administered open label SPRIX according to subject weight.
88938264|NCT01819623|Experimental|Non-pharmacological therapy|This group will be supervised nonpharmacologic therapy
88938265|NCT01819623|No Intervention|Control|This group will receive the standard treatment for mild cognitive impairment
88938266|NCT01819636|Experimental|Sparkling highly mineral bicarbonated sodium water|1.25 liter a day of sparkling highly mineral bicarbonated sodium water
88938267|NCT01819636|Placebo Comparator|Sparkling low mineralized water|1.25 liter a day of sparkling low mineralized water
88938268|NCT01819649|Experimental|Selenium enriched-yeast tablet; SelenoPRECISE 100 mcg/d|
88938269|NCT01819649|Experimental|Selenium enriched-yeast tablet; SelenoPRECISE 200 mcg/d|
88938270|NCT01819649|Experimental|Selenium enriched-yeast tablet; SelenoPRECISE 300 mcg/d|
88938271|NCT01819649|Placebo Comparator|Yeast tablet|
88938272|NCT01819662|Placebo Comparator|Standard management|No echocardiogram
88938273|NCT01819662|Active Comparator|Enhanced standard management|Echocardiogram performed, with results to GP
88938274|NCT01819662|Active Comparator|Optimised heart failure management|Echocardiogram, followed by referral to comprehensive heart failure program for those with left ventricular dysfunction
88938275|NCT01819675|Experimental|High frequency (10Hz) rTMS|<high frequency rTMS parameters> Intensity: 120% of resting motor threshold; Location: Motor hotspot in primary motor cortex for the dominant hand; Frequency: 10Hz; Number of total stimuli: 750; Coil orientation: tangential to scalp
88938276|NCT01819675|Experimental|Low frequency (1Hz) rTMS|<low frequency rTMS parameters> Intensity: 120% of resting motor threshold; Location: Motor hotspot in primary motor cortex for the dominant hand; Frequency: 1Hz; Number of total stimuli: 1200; Coil orientation: tangential to the scalp
88938277|NCT01819675|Sham Comparator|Sham rTMS|<Sham rTMS parameters> Intensity: 120% of resting motor threshold; Location: Motor hotspot in primary motor cortex for the dominant hand; Frequency: 1Hz; Number of total stimuli: 1200; Coil orientation: perpendicular to scalp
88938278|NCT01819701|Placebo Comparator|Placebo|starch
88938279|NCT01819701|Experimental|LC and Coenzyme Q10|L-carnitine: 1000 mg/d and 2000 mg/d Coenzyme Q10: 150 mg/d and 300 mg/d
88938280|NCT01819714|Experimental|Study population|Patients hospitalized at the Serre-Cavalier centre and who have Alzheimer's-type neurodegenerative disease (see inclusion criteria).
88938281|NCT01819740||patients with suspected prostate cancer|
88938282|NCT01819753|Active Comparator|Single access|It was performed only single access standard PCNL in this group.
88938283|NCT01819753|Active Comparator|Multiple access|It was performed multiple access standard PCNL in this group
88938284|NCT01819766||IBD or PSC|Subjects will be men and women, 18 to 84 years of age, inclusive, who are at increased risk of developing colorectal cancer.
88938285|NCT01818232|Experimental|[14C]-LX4211|400 mg LX4211 administered orally
88938286|NCT01819779|Active Comparator|Exforge tab. 10/160mg|"amlodipine besylate (10mg as amlodipine)~valsartan 160mg"
88938287|NCT01819779|Experimental|Lodivixx tab. 5/160mg|"S-amlodipine nicotinate (5mg as S-amlodipine)~valsartan 160mg"
88938288|NCT01819792|Other|patient with Acute Myeloïd Leukemia|
88938289|NCT01819805||Patients taking tramadol hydrochloride and acetaminophen|
88938290|NCT01819818||Paliperidone palmitate|
88938291|NCT01819857|Active Comparator|Droperidol 0.625 mg intravenously|
88938292|NCT01819857|Active Comparator|Droperidol 1.25 mg intravenously|
88938293|NCT01819857|Active Comparator|Ondansetron 8 mg intravenously|
88938294|NCT01819870|Experimental|Dilatrend SR capsule 32mg|
88938295|NCT01819870|Active Comparator|Dilatrend IR tablet 25mg|
88938296|NCT01819896||pacemakers and defibrillators|
88938297|NCT01819948|Experimental|single-arm|Two capsules in the morning, one at night, every day for a month, taken with a glass of water.
88938298|NCT01819961|Experimental|MCT/LCT|Structural Fat Emulsion Injection 250ml per day, for 7 days
88938299|NCT01819961|Experimental|MCT/LCT and fish oil|Structural Fat Emulsion Injection 250ml and fish oil 100ml for 7 days.
88938300|NCT01819974|No Intervention|Control|The normal procedure at the ward
88938301|NCT01819974|Active Comparator|Stratified medication review|Medication review performed by either a clinical pharmacist or a clinical pharmacologist in patients with highest medication error risk
88938302|NCT01819987|Active Comparator|Mailing information|Participants in the mailing information group will receive general health promotion topics relevant to preschool-age children (such as immunization, injury prevention and school readiness) via mailing materials that are bilingual weekly for eight weeks. These materials will be obtained from CDC and AAP.
88938303|NCT01819987|Experimental|Tablet computer|Participants in the intervention group will receive eight weekly online sessions and interactive activities delivered through tablet computers. Intervention participants will receive instructions for accessing the program via the tablet at an in-person session. Automated weekly emails will be sent to participating mothers for the intervention duration to encourage study engagement.
88938304|NCT01820000|Experimental|Diffusion Weighted Imaging with MRI scans|Subjects will undergo a MRI (magnetic resonance imaging) scan where DWI (diffusion weighted imaging) will be performed. Subjects will not receive contrast during this sequence, but will receive contrast as standard MRI protocol.
88938305|NCT01820013|Experimental|Customised Orthoses|Customised Dynamic Elastomeric Fabric Orthoses (DEFO)
88938306|NCT01820013|Active Comparator|Rigid 'off the shelf' pelvic support|Serola Sacroiliac Belt.
88938307|NCT01820026|Experimental|Imipenem & Vancomycin & Azithromycin|"Tienam combined with vancomycin (1g/12 h) for Spontaneous bacterial peritonitis, cholangitis, sepsis without evidence of a source of infections.~Tienam combined with vancomycin (1g/12 h)and azythromycin (500 mg/24 h)for pneumonia"
88938308|NCT01820026|Active Comparator|Cefotaxime & Amoxicillin & Azithromycin|Cefotaxime IV(2g/12 h): for Spontaneous bacterial peritonitis, cholangitis, sepsis without evidence of specific site of infection Amoxicillin/clavulanic acid (2,2 g/8 h)or Ciprofloxacin (500 mg/12 h: urinary tract infections Amoxicillin/clavulanic acid (2,2 g/8 h)and azithromycin (500 mg/24 h): pneumonia Amoxicillin/clavulanic acid (2,2 g/8 h)for skin or soft tissue infection
88938309|NCT01820039|Experimental|FertiScreen|all patients between 18 and 38 years, consulting their general practitioner for infertility will be asked to use FertiScreen.
88938310|NCT01820052|Active Comparator|Oral Iron|Patient will receive 230 mg of oral elemental iron daily for 3 months
88938311|NCT01820052|Placebo Comparator|Oral Placebo|Oral Placebo tablets will be administered daily for 3 months
88938312|NCT01820065||Patients undergoing phacoemulsification|Patients undergoing phacoemulsification for age-related cataract with implantation of a single-piece Acrysof IOL (SN60AT)
88938313|NCT01820078|Experimental|Paricalcitol, Daily treatment, CKD|Experimental Arm
88938314|NCT01820078|Other|Daily treatment for CKD|Comparator Arm
88938315|NCT01820091|Experimental|Cohort 1 - Fusilev - 20 doses|"5 mg/m2 QID (6 hours apart) starting on Days 2 and 16 (24 hours after Folotyn dose) for a total of 20 doses in a 28-day cycle~Days 2 and 16: 4 doses/day~Days 3 and 17: 4 doses/day~Days 4 and 18: 2 doses/day~Folotyn: 190 mg/m2 on Days 1 and 15 in a 28-day cycle"
88938316|NCT01820091|Experimental|Cohort 2 - Fusilev - 12 doses|"5 mg/m2 BID 8 hours apart on Days 2, 3, 4, 16, 17, and 18 for a total of 12 doses in a 28-day cycle.~Fusilev dose to start 24 hours after Folotyn dose.~Folotyn: 190 mg/m2 on Days 1 and 15 in a 28-day cycle"
88938317|NCT01820091|Experimental|Cohort 3 - Fusilev - 8 doses|"5 mg/m2 BID 8 hours apart on Days 2, 3, 16, and 17 for a total of 8 doses in a 28-day cycle.~Fusilev dose to start 24 hours after Folotyn dose.~Folotyn: 190 mg/m2 on Days 1 and 15 in a 28-day cycle"
88938318|NCT01820091|Experimental|Cohort 4 - Fusilev - 4 doses|"5 mg/m2 BID 8 hours apart on Days 2 and 16 for a total of 4 doses in a 28-day cycle.~Fusilev dose to start 24 hours after Folotyn dose.~Folotyn: 190 mg/m2 on Days 1 and 15 in a 28-day cycle"
88938319|NCT01820091|Experimental|Cohort 5 - Fusilev - 2 doses|"5 mg/m2 once on Days 2 and 16 for a total of 2 doses in a 28-day cycle~Folotyn: 190 mg/m2 on Days 1 and 15 in a 28-day cycle"
88938320|NCT01820104|Placebo Comparator|Placebo|oral sitagliptin 100 mg on day 6 after administration of placebo (30 mg per day) for 6 days
88938321|NCT01820104|Experimental|Combination of lansoprazole and sitagliptin|oral sitagliptin 100 mg on day 6 after administration of lansoprazole (30 mg per day) for 6 days
88938322|NCT01820117||Hodgkin lymphoma|"Participants previously treated at St. Jude Children's Research Hospital with thoracic radiation therapy for Hodgkin lymphoma.~Interventions: Neurocognitive Evaluation, Quantitative Brain Imaging, Neurologic Evaluation, Comprehensive Health Questionnaire, Vascular Testing, Cardiopulmonary Exercise Testing, Echocardiography, Pulmonary Function Testing, Serum Biomarkers, and Ophthalmology Examination."
88938323|NCT01820117||Normal control|"A group of healthy individuals matched for age, sex and race.~Interventions: Neurocognitive Evaluation, Quantitative Brain Imaging, Neurologic Evaluation, Comprehensive Health Questionnaire, Vascular Testing, Cardiopulmonary Exercise Testing, Echocardiography, Pulmonary Function Testing, Serum Biomarkers, and Ophthalmology Examination."
88938324|NCT01820130|Experimental|Spinal Cord Stimulation system therapy|St Jude Medical EON mini rechargeable system
88938325|NCT01820143|Experimental|Treatment sequence ADBC|Regimen A: 10 mg of ilaprazole administered QD for 5 days with 240 mL of water. Regimen B: 20 mg of ilaprazole administered QD for 5 days with 240 mL of water. Regimen C: 40 mg of ilaprazole administered QD for 5 days with 240 mL of water. Regimen D: 40 mg of esomeprazole administered QD for 5 days with 240 mL of water.
89453623|NCT04059133|Sham Comparator|Sham arm|"For SUI: The LiESWT was applied with 3000 pulses of shocks, frequency of 3 pulses/second but no energy, once weekly for 4-weeks (W4) and 8-weeks (W8). Probe be transcutaneous applied to the left and right labia minora of the genital area, and the applicator was gently placed on the middle, the left side and the right side of the labia with 0.25 mJ/mm2 intensity and 1000 pulses of shocks individually.~For OAB: The LiESWT was applied with 3000 pulses of shocks, frequency of 3 pulses/second but no energy, once weekly for 4-weeks (W4) and 8-weeks (W8). The applicator was gently placed on the suprapubic skin area over the bladder dome (1000 pulses) and bilateral bladder walls (each side 1000 pulses). The probe was placed on the lower abdomen with two fingers apart from the pubic symphysis, tilting to 45°."
89453624|NCT00657501|Experimental|testosterone gel|1% testosterone transdermal gel
89453625|NCT00657501|Placebo Comparator|Placebo gel|placebo transdermal gel
89453626|NCT02452580||Family Centered Care Unit|Cohort of premature infants and their families receiving Family Centered Care hospitalized at VVHF
89453627|NCT02452580||Open-bay Care Unit|Cohort of premature infants and their families receiving and traditional open-bay care hospitalized at HUH
88938326|NCT01820143|Experimental|Treatment sequence BACD|Regimen A: 10 mg of ilaprazole administered QD for 5 days with 240 mL of water. Regimen B: 20 mg of ilaprazole administered QD for 5 days with 240 mL of water. Regimen C: 40 mg of ilaprazole administered QD for 5 days with 240 mL of water. Regimen D: 40 mg of esomeprazole administered QD for 5 days with 240 mL of water.
88938327|NCT01820143|Experimental|Treatment sequence CBDA|Regimen A: 10 mg of ilaprazole administered QD for 5 days with 240 mL of water. Regimen B: 20 mg of ilaprazole administered QD for 5 days with 240 mL of water. Regimen C: 40 mg of ilaprazole administered QD for 5 days with 240 mL of water. Regimen D: 40 mg of esomeprazole administered QD for 5 days with 240 mL of water.
88938328|NCT01820143|Experimental|Treatment sequence DCAB|Regimen A: 10 mg of ilaprazole administered QD for 5 days with 240 mL of water. Regimen B: 20 mg of ilaprazole administered QD for 5 days with 240 mL of water. Regimen C: 40 mg of ilaprazole administered QD for 5 days with 240 mL of water. Regimen D: 40 mg of esomeprazole administered QD for 5 days with 240 mL of water.
88938329|NCT01820156|Experimental|HRP-PSG|First performance three nights of HRP and following one night of laboratory PSG
88938330|NCT01820156|Experimental|PSG-HRP|First perform laboratory PSG and following three nights of HRP
88938331|NCT01820169|Experimental|Single arm|
88938332|NCT01820195|Active Comparator|Intravenous N Acetyl Cystein|1200 mg IV N- Acetyl Cystein half an hour before contrast administration. This group will also take oral placebo
88938333|NCT01820195|Placebo Comparator|Placebo|Patients on both oral placebo and IV placebo just like patients on oral and IV N-acetyl cystein groups in regard of dose and timing.
88938334|NCT01820195|Active Comparator|Oral N Acetyl Cystein|Patients on 600 mg oral N-Acetyl Cystein bid started at the day before contrast exposure and continue until the next day of contrast exposure.These patients will also take IV placebo
88938335|NCT01820208|Placebo Comparator|Placebo|Placebo would be given s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses)
89453628|NCT03675841|Experimental|0.1% single-dose pre|Three subjects will be treated with Pazufloxacin Mesilate ear drops 0.1% single dose
89453629|NCT03675841|Experimental|0.1% single-dose|Ten subjects will be treated with Pazufloxacin Mesilate ear drops 0.1% single dose
88938336|NCT01820208|Experimental|G-CSF|G-CSF would be given at a dose of 5 microgram/kg daily for 5 days followed by once in 3 days for a total of 12 doses.
88938337|NCT01820221|Active Comparator|Arm 1: Skin closure with suture|Subjects in this group will be randomized to suture for skin closure with computer generated random card draw.
88938338|NCT01820221|Active Comparator|Arm 2: Skin closure with staples|Subjects randomized to skin closure with staples with computer generated random card draw.
88938339|NCT01820234|Other|In-person dermatology evaluation|Health care modality
88938340|NCT01820234|Other|Store-and-forward teledermatology evaluation|Health care modality
88938341|NCT01820247|Experimental|enteral nutrition|The patients receive treatment of enteral nutrition only.
89453630|NCT03675841|Experimental|0.3% single-dose|Ten subjects will be treated with Pazufloxacin Mesilate ear drops 0.3% single dose
89453631|NCT03675841|Experimental|0.5% single-dose|Ten subjects will be treated with Pazufloxacin Mesilate ear drops 0.5% single dose
88938342|NCT01820247|Experimental|tripterygium glycosides|The patients receive treatment of tripterygium glycosides only.
88938343|NCT01820247|Experimental|tripterygium glycosides and enteral nutrition|The patients receive treatment of tripterygium glycosides and enteral nutrition.
89453632|NCT03229694|Experimental|Tracleer (or Bosentan)|Tracleer (Tracleer 125Mg Tablet) was administered orally at two hours before surgery and six hours after surgery
89453633|NCT03229694|Placebo Comparator|Placebo|Placebo was administered orally at two hours before surgery and six hours after surgery
89453634|NCT03223142|Experimental|Multi-modal Precision Ablation|In Multi-modal Precision Ablation group, patients received cryoablation immediately followed by radiofrequency ablation
89453635|NCT03675607||Caregivers infants <2years old|Caregivers of infants under 2 years of age (parents or other), of any gender, who prepare complementary feeding regularly (more than once a week).
89453636|NCT00452127|Experimental|1|
89453637|NCT03223064|Experimental|PSMA PET-CT and USPIO MRI|
89453638|NCT03675529|Experimental|High Intensity Interval Training bout|Patients randomized to this group will perform a wattmax test immediately followed by 4 intervals of high and low intensity based on percentage of wattmax. Immediately after the exercise bout is finished patients will receive one dose of pimonidazole hydrochloride (500 mg per m2 body surface) in order to quantify tumor hypoxia by pathological analyses after removal of the prostate by radical prostatectomy the following day.
89453639|NCT03675529|No Intervention|Controls (usual care)|Patients randomized to the control group will not be doing any exercise, but will after approximately 35 min from baseline blood sampling receive one dose of pimonidazole hydrochloride (500 mg per m2 bodysurface) in order to quantify tumor hypoxia by pathological analyses after removal of the prostate by radical prostatectomy the following day.
89453640|NCT02280213|Experimental|Intubation without chest compression|Endotracheal intubation of infant mannikin using different laryngoscope blades (MAC, MIL, PHIL, WIS) during resuscitation without chest compressions.
89453641|NCT02280213|Experimental|Intubation with chest compression|Endotracheal intubation of infant mannikin using different laryngoscope blades (MAC, MIL, PHIL, WIS) with uninterrupted chest compressions. Chest compressions with the two thumb-encircling hands technique were performed by the same Basic Life Support (BLS) instructor at a rate of 100 compressions per minute and at a depth of about 1.5 inches according to the European Resuscitation Council guidelines of 2010 year.
89453642|NCT03209648|Experimental|Debio 1450|In Treatment Period 1, participants will receive single oral dose of Debio 1450 40 mg on Day 1. In Treatment Period 2, participants will receive itraconazole 200 mg, twice daily (BID) orally, on Day 1, followed by itraconazole 200 mg once daily (QD), on Days 2 to 4, and then single oral dose of Debio 1450 40 mg and itraconazole 200 mg on Day 5, followed by a single oral dose of itraconazole 200 mg on Days 6 and 7.
89453643|NCT04058899|Active Comparator|, Dexmedetomidine group(DEX group)|dexmedetomidine group (DEX)group who will receive 0.5 µg/kg dexmedetomidine diluted in 50 ml of normal saline 0.9% to be given by IV infusion over 10 minutes after induction of anesthesa then 5ml of 0.9% normal saline IV ,
89453644|NCT04058899|Active Comparator|Nalbuphine group(NAL group)|nalbuphine group (NAL)group will receive IV infusion of 50 ml of 0,9%normal saline by IV infusion over 10 minutes then 0.1mg/kg nalbuphine diluted in 5ml of 0.9%normal saline IV after induction of anesthesia.
88938344|NCT01820286|Experimental|Positive psychology intervention|4-week positive psychology intervention of 1 positive psychology exercise per week. Exercises will include 1) recalling 3 good events, 2) writing a letter of thankfulness, 3) using a personal strength, 4) envisioning a best possible future.
88938345|NCT01820286|Active Comparator|Recollection intervention|4-week recollection intervention of 1 recollection exercise per week. Exercises will include recalling events related to 1) daily activities, 2) health, 3) social life, 4) morning and evening.
88938346|NCT01820299|Experimental|Grape Seed Extract and Vitamin D|All patients will take Grape Seed Extract from Day 1 to Day 21. All patients will take Grape Seed Extract and Vitamin D together from Day 22 until Day 64. For all patients on the study, patients will take Vitamin D once a day at a dose of 4000IU.
88938347|NCT01820325|Experimental|Buparlisib + Carboplatin + Paclitaxel|Carboplatin and paclitaxel plus buparlisib for up to 6 cycles, followed by blinded buparlisib maintenance
88938348|NCT01820325|Placebo Comparator|Placebo + Carboplatin + Paclitaxel|Carboplatin and paclitaxel plus buparlisib-matching placebo for up to 6 cycles, followed by blinded placebo maintenance
88938349|NCT01820338|Experimental|Behavioral Family Intervention|Child and Parent attend intervention including nutrition and physical activity education, plus behavioral strategies to facilitate behavior and weight status change
88938350|NCT01820338|Experimental|Behavioral Parent-Only Intervention|Only parents attend intervention including nutrition and physical activity education, plus behavioral strategies to facilitate behavior and weight status change
88938351|NCT01820338|Active Comparator|Education Control|Child and parent attend intervention that includes only nutrition and physical activity education; no instruction or assistance in the use of behavioral strategies are included in this condition
88938352|NCT01820377|Experimental|Aboriginal Youth Mentorship Program|High school students volunteer as mentors, and develop an after-school program that they then deliver to children in grade 4. The mentors meet twice a week. The first day, they develop an activity plan and decide roles and responsibilities to ensure successful delivery of each activity. The second day, they deliver the program to the grade 4 students, which incorporates a healthy snack, 45-minutes of physical activity, and educational games/activities. Grade 4s act as the intervention group.
88938353|NCT01820377|No Intervention|Control Group|This group acts as a control, and are not apart of the Aboriginal Youth Mentorship Program
88938354|NCT01820403|Experimental|portion size small|400 kcal box lunch was delivered each weekday to each participant at the worksite for a six month period.
88938355|NCT01820403|Experimental|portion size medium|800 kcal box lunch was delivered each weekday to each participant at the worksite for a six month period.
88938356|NCT01820403|Experimental|portion size large|1600 kcal box lunch was delivered each weekday to each participant at the worksite for a six month period.
88938357|NCT01820403|No Intervention|control|no box lunch provided to participants.
88938358|NCT01820429||First 48 hours|Patients in the first 48 hours of non ST-elevation acute coronary syndromes.
89453645|NCT00657189|Experimental|1|MEDI-545
89453646|NCT00657189|Experimental|2|MEDI-545
89453647|NCT00657189|Experimental|3|MEDI-545
89453648|NCT00657189|Experimental|4|MEDI-545
88938359|NCT01820429||3 months after discharge|Patients with 3 months after hospital discharge for non ST-elevation acute coronary syndromes.
89453649|NCT00657189|Placebo Comparator|5|Placebo
89453650|NCT03670459|Experimental|Group 1|Patients in G1 will receive traditional physical therapy program (balance exercises) for twelve sessions; day after day
89453651|NCT03670459|Experimental|Group 2|Patients in G2 will receive Cawthorne Cooksey Exercises in addition to traditional physical therapy program for twelve sessions; day after day .
89453652|NCT03670459|Experimental|Group 3|Patients in G3 will receive vestibular habituation exercises in addition to traditional physical therapy program for twelve sessions; day after day.
89453653|NCT00656097|Experimental|A|CL184 combined with rabies vaccination
89453654|NCT00656097|Active Comparator|B|HRIG combined with rabies vaccination
89453655|NCT00656097|Placebo Comparator|C|Placebo combined with rabies vaccination
89453656|NCT03670381||ASD group|ASD patients with HDAC4 CNVs
89453657|NCT03670381||TD group|Typically developing controls without lifetime ASD or a family history of ASD
89453658|NCT03209180|Active Comparator|Carvedilol IR (Immediate Release)|Carvedilol IR 3.125mg, 6.25mg, 12.5mg, 25mg twice daily p.o. for 6 months
89453659|NCT03209180|Experimental|CarVeDilol-SR (Slow Release)|CarVeDilol-SR 8mg, 16mg, 32mg, 64mg once daily p.o. for 6 months
89453660|NCT02280369||automated abdominal binder|automated abdominal binder with waist and thigh accelerometers, and ActivPAL
89453661|NCT03215017|Experimental|Transanal irrigation|Manual transanal irrigation to control bowel function.
89453662|NCT03215017|Active Comparator|Medication|Medication to control bowel function.
89453663|NCT00447993|Experimental|1 NT-501|High Dose Implant
89453664|NCT00447993|Experimental|2 NT-501|Low Dose Implant
89453665|NCT03229928||Stakeholder Advisory Panel|The investigators will recruit 2 parents of children with IDD, 2 special education teachers, and 2 behavior health professionals to assist with the development and initial testing of the upgraded MOCHA application features to test usability.
88938360|NCT01820442|Active Comparator|Lofexidine Titration in Buprenorphine Maintained Subjects|Buprenorphine maintained subjects will be titrated on lofexidine up to the target therapeutic dose of 0.8 mg QID (4 tablets QID) or to the highest level tolerated. Following this initial titration attempt, all subjects will have their buprenorphine dose reduced by 50% and lofexidine titration efforts will resume.
88938361|NCT01820442|Placebo Comparator|Placebo Titration in Buprenorphine Maintained Subjects|Buprenorphine maintained subjects will be titrated on placebo tablets in ascending doses of 1 tablet starting with 2 tablets (e.g., Day 1 2 tablets QID, Day 2 3 tablets QID, etc.) to mimic titration for subjects randomized to lofexidine.
88938362|NCT01820455|Active Comparator|Chlorhexidine, Mupirocin|Chlorhexidine baths and intranasal Mupirocin ointment daily for 5 days
88938363|NCT01820455|Placebo Comparator|Soap baths, Lubricating jelly|Soap and water baths with lubricating jelly to each nare daily for 5 days
88938364|NCT01820468|Experimental|Adapted critical time intervention team|Community-based team will help facilitate early inpatient discharge and re-entry into the community.
88938365|NCT01820468|No Intervention|Regular inpatient care|
88938366|NCT01820481|Experimental|Treatment 1|
88938367|NCT01820481|Experimental|Treatment 2|
88938368|NCT01820481|Experimental|Treatment 3|
88938369|NCT01820481|Placebo Comparator|Placebo|
89453666|NCT03229928||Primary Participants|The study primarily involves recruitment of clinically referred minor patients with IDD and their parents and teachers. Parents and teachers of 10 patients with IDD and co-morbid behavior problems will be asked to collect data via the MOCHA application on the frequency, antecedents,consequences, and other correlates of specific behavioral concerns.
89453667|NCT03229928||Sensor Wearing Participants|These will be the same participants from aim 2. All participants will be offered the opportunity to wear the sensors and provide and chose which ones they would prefer to wear. Two participants will be asked to wear the sensor for 48 hours in order to pilot test the feasibility of syncing sensor and MOCHA application data collection.
89453668|NCT03675373|Experimental|Intervention group|Alcohol brief intervention+mobile chat-based instant messages
89453669|NCT03675373|Active Comparator|control group|Alcohol brief intervention
89453670|NCT02283021||NSCLC Patients|Sample biopsies from normal and cancerous lung tissue.
89453671|NCT02283021||Patients without NSCLC|Sample biopsies from normal lung tissue.Control group.
88938370|NCT01820494|Experimental|Experimental Infant Formula|Complete amino acid-based infant formula
89453672|NCT03229772|Other|Subjects indicated for dynamic nuclear medicine scanning|The trial will consist of a single arm composed of subjects with preexisting indications for dynamic nuclear medicine scanning at the site. All patients will undergo nuclear medicine scintigraphy using the GE Discovery 670 NM/CT device with and without CZT enabled during a single visit.
88938371|NCT01820507|Experimental|High Flow Conditioned Oxygen Therapy|Intervention: The Optiflow(R) device supplies oxygen in controlled concentrations and at high flow (from 10 to 70 liters/min) through special nasal cannulae. The device also humidifies the gases mixtures up to 100% relative humidity.
88938372|NCT01820507|Active Comparator|Standard Oxygen Therapy|The standard way of oxygen supply after extubation is either by nasal cannulae at flow between 1 and 5 liters/min or by mask with controlled oxygen concentration from 24% to 50%.
88938373|NCT01820520|Experimental|Double staining with brilliant blue G during vitrectomy|
88938374|NCT01820533||smokers|
88938375|NCT01820598|Other|m-NMES first|Multisite electrostimulator first (Visit 1) and conventional electrostimulator then (Visit 2)
89453673|NCT03670303|Experimental|Intervention group|This group will include randomly selected two boys and two girls schools. Vision screening and refraction will be carried out at base line.Compliance will be assessed at 6 months follow-up after baseline assessment than educational intervention will be given. Six months after intervention compliance will be assessed again.
88938376|NCT01820598|Other|c-NMES first|Conventional electrostimulator first (Visit 1) and multisite electrostimulator then (Visit 2)
88938377|NCT01820611||With Bonemaster HA|100 patients using Arcos Revision Stem System with BoneMaster Hydroxyapatite
88938378|NCT01820611||Without BoneMaster HA|100 patients using Arcos Revision Stem System without BoneMaster Hydroxyapatite
89453674|NCT03670303|No Intervention|Control group|This group will also include randomly selected two boys and two girls schools. Vision screening and refraction will be carried out at base line.Compliance towards spectacle use will be assessed at 6 months after baseline assessment. No intervention will be given in this group. Compliance will be assessed again at the same time when assessed in intervention group 6 months after the intervention.
88938379|NCT01820624|Experimental|Treatment (tretinoin, lithium carbonate)|Patients receive tretinoin PO every 12 hours on days 1-7 and 15-21 and lithium carbonate PO TID on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
88938380|NCT01820663|Experimental|Modified Atkins Diet|Patients will receive a 14 day menu consisting of the Modified Atkins diet, a low-carbohydrate, high protein, high fat diet.
88938381|NCT01820663|Placebo Comparator|Control Diet|Patients will receive a diet (e.g. regular, low cholesterol, diabetic) determined by the attending physician.
88938382|NCT01820689|Experimental|Tympanometry measurement|
88938383|NCT01820702|Active Comparator|defined training programme|
88938384|NCT01820702|No Intervention|Control|
88938385|NCT01820715|Experimental|600㎍ of DA-3030 Injection|600㎍ of DA-3030 is injected once a day, for 5 continuous days.
88938386|NCT01820715|Placebo Comparator|Placebo|Placebo(a salin drip) is injected once a day, for 5 continuous days.
88938387|NCT01820728|Experimental|DA-3801 injection|Recominant human follicle stimulating hormone 75 IU/day is injected for 14 days
88938388|NCT01820728|Active Comparator|Gonal-F®|75 IU/day is injected for 14 days
88938389|NCT01820767|Experimental|Paricalcitol|SUBGROUP 1 (G1): Paricalcitol oral dosis triphosphoinositide mgc/100, 3 days a week.
88938390|NCT01820767|Active Comparator|Paricalcitol, Atorvastatin|SUBGROUP 2 (G2): Paricalcitol (same dosis than G1) + Atorvastatin (1 daily dosis 20 mg)
88938391|NCT01820767|Active Comparator|Atorvastatin|SUBGROUP 3 (G3): Atorvastatin (same G2 dosis)
88938392|NCT01820780|Experimental|intensive disease management|Planned consultations with HF specialist including biological test at weeks 1, 2 and 4; in addition to usual care.
88938393|NCT01820780|Active Comparator|usual disease management|usual care according to guidelines; including first medical consultation and biological test within the 4-week time following discharge.
88938394|NCT01820793|Experimental|cefoxitin|this study is centered on women with pyelonephritis without severity symptoms due to ESBL-producing E. coli.
88938395|NCT01820806|Experimental|[14C] GLPG0634|Subjects will be dosed with a single oral 100 mg dose of [14C] GLPG0634 on one occasion
88938396|NCT01820819||Registered or not on the transplantation national waiting list|
88938397|NCT01820832|Experimental|Calcitriol|General treatments (such as blood pressure control, lipid lowering, and so on) plus Calcitriol 0.5 ug/BIW for 24 weeks.
88938398|NCT01820832|No Intervention|Control|General treatments.
88938399|NCT01820845||Cohort of children with scoliosis surgery|
88938400|NCT01820871|Experimental|application arm|"The patients of application arm have the smartphone application (android) for management of type 2 DM.~The application contains action plans and alarm system for each situation of serum fasting glucose, blood pressure, body weight, exercise amount, calori intake, medication, etc."
89015636|NCT06257836||MPFL reconstruction with quadriceps graft|Children with medial patellofemoral reconstruction operated with epiphyses sparing quadriceps technique from 2016-2022.
89015637|NCT06257836||Healthy Cohort|A healthy cohort matched on age (+/- 2 years) and gender
89015638|NCT06257797||Allergic patients to fenugreek|
89015639|NCT06257797||Non allergic patients to fenugreek|
89015640|NCT06257784||Acute Respiratory Failure|Every patient admitted in Emergency department with any acute respiratory failure will be screened according to inclusion and exclusion criteria to being recruited in the study
89015641|NCT06257758|Experimental|Dose Escalation|Dose escalation: Multiple dose levels of VIO-01 will be administered via intravenous infusion over a 60-minute period once weekly.
89015642|NCT06257758|Experimental|Dose Expansion HRRm or HRD+ Solid Tumors|Participants with advanced HRRm or HRD+ solid tumors will be administered recommended Phase 2 dose of VIO-01 via intravenous infusion over a 60-minute period once weekly.
89015643|NCT06257758|Experimental|Dose Expansion HRRm or HRD+ Ovarian Cancer|Participants with advanced HRRm or HRD+ ovarian cancer will be administered recommended Phase 2 dose of VIO-01via intravenous infusion over a 60-minute period once weekly.
89015644|NCT06257745||ERACS group|Any patient admitted to our post-anesthesia care unit following cardiac surgery and planned for overnight stay.
89015645|NCT06257732|No Intervention|Control Group|This group will consist of individuals with liver fat accumulation under standard care and no exercise intervention will be implemented.
89015646|NCT06257732|Experimental|Fatmax Exercise Group|Individuals with liver fat accumulation under standard care will have their Fatmax values calculated and an exercise prescription will be designed accordingly.
89015647|NCT06257732|Experimental|Fatmax Exercise and Motivational Interviewing Group|In addition to the prescription of Fatmax exercise for individuals with liver fat accumulation under standard care, motivational interviewing principles will be applied.
89015648|NCT06257732|Experimental|HIIT Group|Individuals with liver fat accumulation under standard care will be provided with a High-Intensity Interval Training (HIIT) exercise prescription.
89015649|NCT06257732|Experimental|HIIT and Motivational Interviewing Group|In addition to formulating a High-Intensity Interval Training (HIIT) exercise prescription for individuals with liver fat accumulation under standard care, motivational interviewing principles will be applied.
89015650|NCT06257732|Experimental|Resistance Exercise Group|Individuals with liver fat accumulation under standard care will be provided with a resistance exercise prescription.
89015651|NCT06257732|Experimental|Resistance Exercise and Motivational Interviewing Group|In addition to formulating a resistance exercise prescription for individuals under standard care with liver fat accumulation, motivational interviewing principles will be applied.
89453675|NCT03209336|Experimental|A group|Colorectal cancer patients first are given antineoplastic drugs and then transfer to operative room to be treated by surgical resection and the radiotherapy is given during the operation after the removal of the tumour.
89015652|NCT06257719||Paediatric group|The investigators defined participants under 14 years old as the paediatric group.
89015653|NCT06257719||Adult group|The investigators defined participants over 14 years old as the adult group.
89015654|NCT06257706|Other|Group 1: Corticosteroid-free IUS-based outcomes + clinical remission + biomarker remission|Group 1 will be treated over 48 weeks to achieve a target of corticosteroid-free IUS-based outcomes + clinical remission + biomarker remission. At Week 22 and 30, the IUS-based component of the target will be IUS response and at Week 38, the final treatment target will be TMH.
89015655|NCT06257706|Other|Group 2: Corticosteroid-free clinical remission + biomarker remission.|Group 2 will be treated over 48 weeks to achieve a target of corticosteroid-free clinical remission + biomarker remission.
89015656|NCT06257693|Experimental|Enolen (tm)|Enolen (tm) implants containing enzalutamide
89015657|NCT06257680|Experimental|ReT01 ACT|
89015658|NCT06257667|Active Comparator|"OptiflowTM"|"Patients treated with high flow nasal cannula, using the OptiflowTM Nasal Cannula"
89015659|NCT06257667|Experimental|"Optiflow+DuetTM"|"Patients treated with high flow nasal cannula using the Optiflow+DuetTM Nasal Cannula"
89015660|NCT06257628||Index Event|Patients with at least one Beckman High Sensitivity Troponin test at the Emergency Department visit
89015661|NCT06257615|Experimental|Education provided via TeleNursing|Nursing intervention consists of 3 online video calls with educational content to the intervention group (1st, 2nd and 3rd weeks after discharge), 3 audio phone calls (4th, 5th and 6th weeks after discharge) and an educational booklet.
89015662|NCT06257615|No Intervention|Control|No intervention was made
89015663|NCT06257602||Endoscopic tympanoplasty group|Endoscopc tympanoplasty group: rigid endoscope 3 mm diameter/14 cm long/0 angle of view will be used together with a high-definition camera head and monitor and using tragal graft to reconstruct perforations of tympanic membrane.
89015664|NCT06257602||Microscopic tympanoplasty group|Microscopic tympanoplasty group: operating microscope and microscopic instruments will be used, and using tragal graft to reconstruct tympanic membrane perforations.
89015665|NCT06257589||Intrathoracic Approach|"Patients who have undergone the intrathoracic approach of phrenic nerve reconstruction for the treatment of diaphragmatic paralysis.~NO INTERVENTION."
89015666|NCT06257589||Cervical Approach|"Patients who have undergone the cervical approach of phrenic nerve reconstruction for the treatment of diaphragmatic paralysis.~NO INTERVENTION."
89453676|NCT03209336|No Intervention|B group|Colorectal cancer patients first are given antineoplastic drugs and then transfer to operative room to be treated only by surgical resection and no radiotherapy afer the removal of the tumour.
89015667|NCT06257537|Experimental|SAM Ultrasound Device and Diclofenac Patch|Patients receive treatment from the wired SAM Ultrasonic Diathermy Device for 4 hours at least 5 days a week for 24 weeks combined with 2.5% diclofenac patch. The SAM Device emits continuous ultrasound at 3 megahertz(MHz) frequency and 0.132 watts/cm^2 intensity.
89015668|NCT06257537|Active Comparator|SAM Ultrasound Device and SAM Patch|Patients receive treatment from the wired SAM Ultrasonic Diathermy Device for 4 hours at least 5 days a week for 24 weeks combined with SAM patch (0% diclofenac).
89453677|NCT05208021|Experimental|Intervention group|"Health Promotion Model and the Motivational Interview-Based Health Protection and Promotion Program was applied to the intervention group"
89453678|NCT05208021|No Intervention|Control Group|Only data collection was carried out. No attempt was made by the researcher during the study
89453679|NCT03209102|Experimental|BPD adolescents|Adolescents suffering from Borderline Personality Disorder. Clinical assessment, Stress Elicitation Experiment, Structural and Functional MRI, salivary collections of amylase and cortisol
89015669|NCT06257537|Active Comparator|Diclofenac Patch|Patients wear 2.5% diclofenac patch for 4 hours at least 5 days a week for 24 weeks combined.
89453680|NCT03209102|Experimental|Healthy controls adolescents|Healthy controls adolescents. Clinical assessment, Stress Elicitation Experiment, Structural and Functional MRI, salivary collections of amylase and cortisol
89453681|NCT02283099|Experimental|rVSVΔ-ZEBOV-GP (BPSC1001)|Subjects will be allocated to three cohorts of 10 subjects each receiving one single vaccine injection administered as an i.m. injection.
89453682|NCT03670225|Other|Invia Motion Endure|
89453683|NCT03208400|Other|virtual reality exposure|one-session exposure conveyed via virtual reality technology
89453684|NCT02280447|Experimental|1/3 IPV-Al SSI|"Reduced dose Al(OH)3 adjuvated IPV SSI with 1/3 of dose in full dose non-adjuvated IPV SSI (i.e.: Type 1:40 DU; Type 2:8 DU; Type 3:32 DU)~1 X 0.5 mL suspension for injection for intramuscular use"
89453685|NCT02280447|Experimental|1/5 IPV-Al SSI|"Reduced dose Al(OH)3 adjuvated IPV SSI with 1/5 of dose in full dose non-adjuvated IPV SSI (i.e.: Type 1:40 DU; Type 2:8 DU; Type 3:32 DU)~1 X 0.5 mL suspension for injection for intramuscular use"
89453686|NCT02280447|Experimental|1/10 IPV-Al SSI|"Reduced dose Al(OH)3 adjuvated IPV SSI with 1/10 of dose in full dose non-adjuvated IPV SSI (i.e.: Type 1:40 DU; Type 2:8 DU; Type 3:32 DU)~1 X 0.5 mL suspension for injection for intramuscular use"
89453687|NCT02280447|Active Comparator|IPV SSI|"Non-adjuvated full dose IPV SSI (i.e.: Type 1:40 DU; Type 2:8 DU; Type 3:32 DU)~1 X 0.5 mL solution for injection for intramuscular use"
89453688|NCT03675295|Active Comparator|Comparator: Hyalase|injection of Hyalase + 10 cc saline injection nearby median nerve as hydro-dissection
89453689|NCT03675295|Active Comparator|Saline|Injection 10 cc saline injection as a median nerve hydro-dissection
89453690|NCT00528333|Experimental|1|Lintuzumab plus low dose cytarabine
89453691|NCT00528333|Active Comparator|2|Placebo plus low dose cytarabine
89453692|NCT03675217|Experimental|PE and PCFPC|Physical Exercise and primary care family caregivers program
89015670|NCT06257537|Placebo Comparator|SAM Patch|Patients wear 0% diclofenac patch for 4 hours at least 5 days a week for 24 weeks combined.
89015671|NCT06257524|Experimental|PDIM component 1, 2, and 3|"Intervention component 2 to be tested. Pediatric resources toolkits availability via Translating Emergency Knowledge for Kids network (TREKK). Investigators will provide resource toolkits to support clinical care in pediatric sepsis, seizure, diabetes ketoacidosis, dehydration, hypovolemic shock, and respiratory conditions.~Intervention component 3 to be tested: Ongoing interactions, and intensive training and education sessions. Investigators will hold training and education sessions at the sites. These will include (a) One on-site training (for 4-4.5 hours) with simulation sessions."
89015672|NCT06257524|Active Comparator|PDIM component 1|Customized report to the general EDs and discussion with the general EDs on the gaps identified. Investigators will discuss customized baseline WPRS with each general ED, including implications of the gaps identified relative to their local context and the general ED priorities (1.5hrs/session x 2).
89015673|NCT06257511|Experimental|Non Technical Skills for Cardiac Surgery (NOTSCS) intervention group|These are the members of the cardiac surgical teams who will be trained in the non-technical skills.
89453693|NCT03675217|Active Comparator|Usual Care|Usual Care: PCFPC (primary care family caregivers program)
89453694|NCT00526227|Experimental|Secura ICD implant|Secura ICD device implanted
89453695|NCT02284425|Experimental|Part A|Participants in Part A will consist of 4 sequential ascending dose cohorts. Each cohort will receive 1 of 4 ascending dose levels of study drug (REGN1193) or placebo.
89453696|NCT02284425|Experimental|Part B|Participants in Part B will consist of a single cohort and will receive three doses of study drug (REGN1193) or placebo.
89453697|NCT03134157|Experimental|Simvastatin and vaginal placebo|The patients with leiomyoma receive simvastatin 40 mg orally+ vaginal placebo will be given every day for 3 months.
89453698|NCT03134157|Experimental|Simvastatin and oral placebo|The patients with leiomyoma receive simvastatin 40 mg orally+ oral placebo will be given every day for 3 months.
89453699|NCT03134157|Experimental|Vaginal placebo+ oral placebo|The patients with leiomyoma receive Vaginal placebo+ oral placebo every day for 3 months.
89453700|NCT02280603|Experimental|DA-4001C|DA-4001C is administered
89453701|NCT02280603|Active Comparator|5% minoxidil|5% minoxidil is administered
89453702|NCT03134235|Experimental|Raw, plant-based diet|A raw, plant-based diet was prescribed for 4 weeks.
89453703|NCT00524277|Experimental|Arm I|HLA-A2-positive patients receive GP2 peptide + GM-CSF vaccine intradermally (ID) every 3-4 weeks for a total of up to 6 inoculations.
89453704|NCT00524277|Active Comparator|Arm II|HLA-A2-positive patients receive GM-CSF ID every 3-4 weeks for a total of up to 6 inoculations.
89453705|NCT00524277|Experimental|Arm III|HLA-A2-negative patients receive AE37 peptide/GM-CSF vaccine ID every 3-4 weeks for a total of up to 6 inoculations.
89453706|NCT00524277|Active Comparator|Arm IV|HLA-A2-negative patients receive GM-CSF ID ID every 3-4 weeks for a total of up to 6 inoculations
89453707|NCT02284503|Experimental|40mg Rosuvastatin group|The subjects in this group will receive Rosuvastatin 40mg within 12±2h before PCI, follow 20mg post PCI for 30days.
89453708|NCT02284503|Experimental|20mg Rosuvastatin group|The subjects in this group will receive Rosuvastatin 20mg within 12±2h before PCI, follow 20mg post PCI for 30days.
89453709|NCT02284503|Experimental|no statin group|The subjects in this group will not receive Rosuvastatin before PCI, follow 10mg post PCI for 30days.
89453710|NCT00650949|Experimental|CYT997|
89453711|NCT00520923|Experimental|1|160mg of LY2140023, taken orally as 80mg twice daily, for up to 4 weeks.
89453712|NCT00520923|Experimental|2|80mg of LY2140023, taken orally as 40mg twice daily, for up to 4 weeks.
89453713|NCT00520923|Experimental|3|40mg of LY2140023, taken orally as 20mg twice daily, for up to 4 weeks.
89453714|NCT00520923|Experimental|4|10mg of LY2140023, taken orally as 5mg twice daily, for up to 4 weeks.
89453715|NCT00520923|Placebo Comparator|5|Placebo of LY2140023, taken orally twice daily, for up to 4 weeks.
89453716|NCT00520923|Active Comparator|6|Placebo, taken orally every morning, followed by Olanzapine 15mg taken orally every evening for up to 4 weeks.
89453717|NCT02547922|Experimental|Anifrolumab - Lower Dose|Anifrolumab - Lower Dose
89453718|NCT02547922|Experimental|Anifrolumab - Higher Dose|Anifrolumab - Higher Dose
89453719|NCT02547922|Placebo Comparator|Placebo|Placebo IV Q4W plus SOC
88938401|NCT01820871|Active Comparator|conventional arm|The patients of conventional arm have the booklet for management of type 2 DM. The application contains general medical guideline and knowledge for management of type 2 DM such as,exercise amount, calori intake, medication, etc.
88938402|NCT01820897|Experimental|Fosfomycin-Trometamol, Sulfamethoxazole trimethoprim, placebo|Fosfomycin-Trometamol 3 grams every 10 days for 6 months Plus Sulfamethoxazole trimethoprim 800/160 mg monday, wednesday and friday for 6 months Plus Placebo of Sulfamethoxazole trimethoprim Tuesday,thursday, saturday and sunday for 6 months.
88938403|NCT01820897|Active Comparator|Sulfamethoxazole trimethoprim, placebo|Sulfamethoxazole trimethoprim 800/160 mg every day for 6 months plus Placebo of Fosfomicyn-trometamol every 10 days for 6 months
88938404|NCT01820923|Experimental|Brain stimulation|"Brain stimulation will consist of 4 types of intervention:~real transcranial direct current stimulation (two weeks, five days a week)~a week of wash-out~Sham transcranial direct current stimulation (two weeks, five days a week)~two weeks of wash-out~real repetitive transcranial magnetic stimulation (two weeks, four days a week)~a week of wash-out~Sham repetitive transcranial magnetic stimulation (two weeks, three days a week)~Stimulations will be counterbalanced between patients."
88938405|NCT01820936|Experimental|Treatment A: PCI-32765|420 mg capsules administered by mouth with 240 mL noncarbonated water 30 minutes after completing a high-fat breakfast
88938406|NCT01820936|Experimental|Treatment B: PCI-32765|420 mg capsules administered by mouth with 240 mL noncarbonated water after fasting for at least 10 hours and 30 minutes before starting a high-fat breakfast
88938407|NCT01820936|Experimental|Treatment C: PCI-32765|420 mg capsules administered by mouth with 240 mL noncarbonated water 2 hours after completing a high-fat breakfast
88938408|NCT01820936|Experimental|Treatment D: PCI-32765|420 mg capsules administered with 240 mL noncarbonated water after fasting at least 10 hours
88938409|NCT01820936|Experimental|Treatment E: PCI-32765|840 mg capsules administered with 240mL noncarbonated water 30 minutes after completing a high-fat breakfast
88938410|NCT01820949||Control cohort|Standard care before implementation (pre-implementation)
88938411|NCT01820949||PBM cohort|After implementation of PBM program (post-implementation)
88938412|NCT01820962|Active Comparator|A: heparin (Heparin LEO)|After each use, the central venous catheter lumen will be flushed with 10 ml 0.9% NaCl and then locked with heparin 5000 IU/ml(standard treatment)using a volume exactly equivalent to the internal volume noted on each catheter.
88938413|NCT01820962|Experimental|B: concentrated citrate (Citralock)|locking the central venous catheter with concentrated citrate after each use
88938414|NCT01820975|Experimental|High protein intake|High protein intake: large bolus of protein in teh diet the day before testing
88938415|NCT01820975|Placebo Comparator|No protein intake|No protein in the diet the day before testing
88938416|NCT01820988||Sarcopenic vs. non-sarcopenic|Participants are classified as sarcopenic/non-sarcopenic according to the criteria of the European Working Group of Sarcopenia in Older People (EWGSOP).
88938417|NCT01821001|Experimental|Vaginal Bromocriptine|Patients will receive 2.5 mg of vaginal bromocriptine tablet twice a day for the intervention. This will be administered for 6 months.
88938418|NCT01821014|Experimental|Telemedicine First|Patients whose first physician visit during the clinic was using videoconference, a form of telemedicine, and whose second physician visit during the clinic was with a physician in-person.
88938419|NCT01821014|Experimental|Telemedicine Second|"Patients whose first physician visit during the clinic was with a physician in-person, and whose second physician visit during the clinic was using videoconference, a form of telemedicine. This is the reverse order of visits of the Telemedicine fist arm."
88938420|NCT01821014|Active Comparator|Two physician visits|Patients who had two sequential visits with different in-person physicians.
89453720|NCT02286375|Experimental|Intervention group|Interventions include providing comprehensive assessment from Omaha system, giving information regarding the self-care management, assisting and coordinating self-regulating skills and abilities, and providing social support from health-social care team to community-dwelling older adults for three months
89453721|NCT02286375|Placebo Comparator|customary care group|Customary care includes receiving community services from the community center in the district, providing monthly social call by a reserch assistant for three months
89453722|NCT00514371|Experimental|tanespimycin and bortezomib|A patient will receive a standard dose of bortezomib followed by a high dose of tanespimycin.
89453723|NCT00514371|Experimental|bortezomib and tanespimycin|A patient will receive a standard dose of bortezomib followed by a mid dose of tanespimycin.
89015674|NCT06257511|No Intervention|Control group|These are members of the cardiac surgical teams who will not participate in the intervention.
89015675|NCT06257498|Other|MRI upright open scanner|"All participants will undergo MRI scanning in the dedicated open upright 0.5T MRI research MRI scanner , with parents or guardian in attendance if desired, and with their own choice of music or video during the scan.~Immediately following the MRI scan we will collect information relating to their experience of the upright scanner using an age-appropriate questionnaire, based on similar questionnaires that we have used for paediatric MRI studies previously. A photograph of the upright MRI room will be used to prompt this discussion. The parent or carer may also be involved in prompting the child's responses.~We will also collect the views of the parent / carer using a questionnaire."
89453724|NCT00514371|Experimental|bortezomib tanespimycin|A patient will receive a standard dose of bortezomib followed by a low dose of tanespimycin.
89453725|NCT04471077||Favorable outcome of bariatric surgery|Excess weight loss above 50%
89453726|NCT04471077||Unfavorable outcome of bariatric surgery|Excess weight loss below 50%
89453727|NCT04470765|Active Comparator|Active Treatment|Active Zida device to be delivered for use by patient
89453728|NCT04470765|Sham Comparator|Sham Treatment|Identical Sham device to be delivered for use by patient
89453729|NCT02547766|Experimental|Anakinra Arm|All patients in this arm receive Anakinra in a pre-post design. That is, outcome markers are measured, the intervention (Anakinra) is applied, and the outcome markers are measured again at various intervals to determine effect.
89453730|NCT04470531|No Intervention|Control|"Arm A :No Intervention/control: Standard treatment~Antibiotics for secondary bacterial infection as per institutional guidelines~Supplemental oxygen (to keep saturations between 90% to 96%)~Intravenous hydration (to maintain euvolumia)~Thrombo-prophylaxis as per local guidelines~Paracetamol (oral or I/V 1gram QDS as required or regular)~To consider steroids if indicated (i.e. acute exacerbation of COPD or acute severe asthma)"
89015676|NCT06257485||Patients referred for 99mTc-pyrophosphate Single Photon Emission Computed Tomography|Patients with suspected transthyretin cardiac amyloidosis referred for 99mTc-pyrophosphate Single Photon Emission Computed Tomography
89015677|NCT06257472|Experimental|IBS/VR Program (SynerGI)|
89015678|NCT06257472|Sham Comparator|Sham VR Program|
89015679|NCT06257459|Active Comparator|Lipoma Excision (group A)|excison of spermatic cord lipoma detected during subinguinal varicocelectomy in infertile males
89015680|NCT06257459|Active Comparator|Lipoma Preservation (group B)|preservation of spermatic cord lipoma detected during subinguinal varicocelectomy in infertile males
89453731|NCT04470531|Experimental|intervention /experimental|"Arm B: Experimental Arm received oral co-trimoxazole + standard therapy~The following treatments are recommended as standard therapy:~Antibiotics for secondary bacterial infection as per institutional guidelines~Supplemental oxygen (to keep saturations between 90% to 96%)~Intravenous hydration (to maintain euvolumia)~Thrombo-prophylaxis as per local guidelines~Paracetamol (oral or I/V 1gram QDS as required or regular)~To consider steroids if indicated (i.e. acute exacerbation of COPD or acute severe asthma)"
89453732|NCT02286453|Experimental|1|Benjakul
89453733|NCT02286453|Active Comparator|2|diclofenac
89453734|NCT02286531|Experimental|FET imaging|FET Imaging. Patient 0.1 mCi / kg (maximum 185 MBq) of FET with 'O-(2[18F]FLUOROETHYL)-L-TYROSINE' will be injected through the venous catheter. At the same time, will trigger a PET 3D dynamic acquisition of 60 minutes (5 pictures 1 minute and 11 images of 5 minutes)
89453735|NCT04470999|Experimental|Single arm|Venous blood and apheresis collection will be conducted
89453736|NCT00385515|Experimental|1|SNX-1012 (meclocyline sulfosalicylate) tablets dissolved in water for oral swish and expectorate; 30 mg 4 times daily for 10 days
89453737|NCT00385515|Placebo Comparator|2|placebo (matched to SNX-1012) tablets dissolved in water for oral swish and expectorate; 4 times daily for 10 days
89015681|NCT06257446|Experimental|Motivation|Trials in which participants are motivated by agency or not in a within-subjects design
89015682|NCT06257433|Experimental|Motivation|Trials in which participants are motivated by hypothesis testing or not.
89015683|NCT06257420||ME/CFS patients with serological evidence of autophagy disruption|ME/CFS patients with serological evidence of autophagy disruption at baseline will be prescribed once weekly rapamycin at a max dose of 6mg per week.
89453738|NCT04471155|Active Comparator|Holep|patient underwent laser prostatectomy
89453739|NCT04471155|Active Comparator|open prostatectomy|patient underwent open prostatectomy
89453740|NCT00443391|Experimental|1|
89453741|NCT02286609|Experimental|Hepatic Impairment|Eight (8) subjects with moderate hepatic insufficiency (a score of 7 to 9, on the Child-Pugh scale) will receive one 18 mg dose of deflazacort
89453742|NCT02286609|Experimental|Healthy Volunteer|Eight (8) healthy subjects. Subjects will be matched for age [± 15 years], BMI [± 15 %], and gender [1:1] to the subjects in the moderate hepatic impaired cohort; will receive 18 mg dose of deflazacort
89453743|NCT00511485|Experimental|Etarfolatide + Vintafolide|Screening: After completion of all screening procedures and confirmation of eligibility, all participants receive a 1- to 2-mL injection of 0.1 mg etarfolatide labeled with 20 to 25 mCi of technetium-99m. Induction phase of treatment: Two 4-week cycles; if stable disease or better at (week 8) computed tomography (CT), participant may proceed into maintenance phase. Maintenance phase of treatment: 4-week cycles with CT every 8 weeks. Participants continue on study until they experience disease progression, unacceptable toxicity, or attain protocol-defined clinical benefit.
89453744|NCT00508989|Experimental|1|
89453745|NCT00508989|Placebo Comparator|2|
89453746|NCT02742441|Experimental|122-0551 Foam|"122-0511 Foam, topically applied twice daily~Intervention: Drug: 122-0551 Foam"
89453747|NCT02742441|Placebo Comparator|Vehicle Foam|"Vehicle Foam, topically applied twice daily~Intervention: Drug: Vehicle Foam"
89453748|NCT05457166|Experimental|patients|patients in a before/after experimental design to assess the value of using the KASPARD technology compared to the conventional management of patients with falls in nursing homes
89453749|NCT04470141|Experimental|SHC014748M treatment|SHC014748M capsule, 200mg QD, 28 days for each cycle
89453750|NCT03981328|Active Comparator|self-monitored blood glucose|The control group participants will perform self-monitored blood glucose testing with a study-provided blood glucose meter, including testing supplies. They will perform capillary blood glucose monitoring as routinely used for patients with GDM i.e. at least four capillary blood glucose values daily including measurements at fasting as well as 1h after starting each meal by using a routinely available blood glucose measurement device.
88938421|NCT01821027|Experimental|Canagliflozin + simvastatin|Each volunteer will receive a single dose of simvastatin on Day 1, followed by canagliflozin (JNJ-28431754) once daily on Days 2 through 6. On Day 7 volunteers will receive a single dose of simvastatin in combination with a single dose of canagliflozin.
88938422|NCT01821040|Experimental|Lodotra®|Lodotra, starting dose of 15mg administered in the evening
88938423|NCT01821040|Active Comparator|Prednisone IR|Prednisone IR 15mg daily start dose (immediate release) administered in the morning
88938424|NCT01821053||pregestational type 1 diabetes|It is an observational study. No intervention is made.
88938425|NCT01821066|Experimental|Two-Period Fixed-Sequence Arm|This arm is comprised of two treatment periods in fixed sequence. Period 1 is 7 days long, while Period 2 is 28 days long. In Period 1 the subjects receive a single 125 mg oral dose of PD-0332991 on Day 1. In Period 2 the subjects receive 4 daily 60 mg oral doses of tamoxifen (Days 1-4), followed by 23 daily 20 mg oral doses of tamoxifen (Days 5-27). On Day 22 of Period 2 the subjects receive a second 125 mg oral dose of PD-0332991.
88938426|NCT01821079|Experimental|PF-05175157 PIC in fed state|200 mg single dose of PF-05175157 administered as PIC in the fed state (following a standard high fat meal).
88938427|NCT01821079|Experimental|PF-05175157 tablet in fed state|200 mg single dose of PF-05175157 administered as tablet formulation in the fed state (following a standard high fat meal).
89015684|NCT06257420||ME/CFS patients without serological evidence of autophagy disruption|ME/CFS patients without serological evidence of autophagy disruption at baseline will be prescribed once weekly rapamycin at a max dose of 6mg per week.
89015685|NCT06257407||Adults Patients with Liver transplant|No intervention during this observational study. Patient who meet the inclusion criteria will be included
89015686|NCT06257394|Experimental|[Arm A, Dasatinib(Sprycel) Arm]|"▪ Arm A : Philadelphia chromosome-positive : Induction (Except Consolidation #3 using Blinatumomab, all administration should be given with Dasatinib.)~Morphologic CR after the Induction : Consolidation #1 → Consolidation #2 → Consolidation #3~If MRD & qPCR not detected after the post-consolidation #1 : Consolidation #3 using HD MTX, HD Cytarabine → DI #1 → IM #2 → DI #2 → Maintenance~If MRD or qPCR positive after the post-consolidation #1 : Consolidation #3 using Blinatumomab →Allogeneic HSCT~M2 or M3 after the Induction : Re-induction → Consolidation #2 → Consolidation #3 → Allogeneic HSCT~If MRD & qPCR not detected after the post-consolidation #1 : Consolidation #3 using HD MTX, HD Cytarabine~If MRD or qPCR positive after the post-reinduction : Consolidation #3 using Blinatumomab~In Arm A, except Consolidation #3 using Blinatumomab, all administration should be given with Dasatinib."
89015687|NCT06257394|Experimental|[Arm B, Non-Dasatinib(Sprycel) Arm]|"▪ Arm B : Other VHR ALL except Philadelphia chromosome-positive : Induction~Morphologic CR after the Induction : Consolidation #1 → Consolidation #2 → Consolidation #3~If MRD not detected after the post-consolidation #1 : Consolidation #3 using HD MTX, HD Cytarabine → Allogeneic HSCT~If MRD positive after the post-consolidation #1 : Consolidation #3 using Blinatumomab →Allogeneic HSCT~M2 or M3 after the Induction : Re-induction → Consolidation #2 → Consolidation #3 → Allogeneic HSCT~If MRD not detected after the post-consolidation #1 : Consolidation #3 using HD MTX, HD Cytarabine~If MRD positive after the post-reinduction : Consolidation #3 using Blinatumomab"
89015688|NCT06257381||COPD-patients|We aim to include 16 patients with COPD across the FEV1% of predicted spectrum, ranging from mild to severe COPD. Participants will undergo lung function test and VO2max
89015689|NCT06257381||Matched healthy volunteers|We aim to include 16 healthy matched controls (sex +-3year age).
89015690|NCT06256705|Experimental|PET-MRI added in care pathway|
89537159|NCT05145855||Anosognosia-positive group|Patients will be included in the anosognosia-positive group if they achieved at least one positive anosognosia score before rehabilitation. The anosognosia score for HN will be calculated by subtracting the patient's self-evaluation score from the score assigned by the rehabilitation nurse using the parallel Catherine Bergego Scale.
89015693|NCT06256393||Patients|Patients of both sexes, over 18 years of age, with an established diagnosis of IBD (Crohn's desease, ulcerative colitis, unclassified IBD or chronic pouchitis) will be eligible for inclusion in a consultation to schedule surgery or colonoscopy for disease relapse (at diagnosis or prior to initiation of treatment), irrespective of treatment received
89015694|NCT06256354|Placebo Comparator|Routine thermal management|Patients assigned to routine thermal management will not be pre-warmed and ambient intraoperative temperature will be maintained near 20°C per routine. Only transfused blood will be warmed. An upper- or lower-body forced-air cover will be positioned over an appropriate non-operative site but will not initially be activated. Should core temperature decrease to 35.5°C, the warmer will be activated as necessary to prevent core temperature from decreasing further. The target nasopharyngeal temperature is 35.5°C.
89015695|NCT06256354|Experimental|Target temperature management|"Pre-warming is performed with a full-body forced-air cover and electrically heated blanket for about 30 minutes before induction of anesthesia. The warmer will initially be set to high which corresponds to about 43°C. It will be subsequently adjusted to make patients feel warm, but not uncomfortably so. Patients will be warmed during surgery using two forced-air covers or combining forced-air covers with electric heating blanket when clinically practical. All intravenous fluids will be warmed to body temperature. There is no need to control ambient temperature since ambient temperature has little effect on core temperature in patients warmed with forced air. The target nasopharyngeal temperature is 36.8°C."
89015696|NCT06256146|Experimental|Standard Protocol - High Dose Arm|Subjects will progress through desensitization to a high maintenance dose - 1200 mg of crushed peanut, 200 ml of milk or 1200 mg of egg powder.
89015697|NCT06256146|Experimental|Modified Protocol - Low Dose Arm|Subjects will progress through desensitization to a low maintenance dose - 120 mg of crushed peanut, 50 ml of milk or 300 mg of egg powder.
89015698|NCT06256146|Experimental|Modified Protocol - Cooked/Transformed Allergen Arm|Subjects will begin desensitization with cooked versions of the allergen (muffins in the case of egg and milk) or transformed versions (Bamba puffs for peanut). They will progress up to a full muffin or 4 Bamba puffs (for egg/milk and peanut respectively). Once subjects have reached these doses, they will transition to doses of pure allergen. They will then progress to the same top dose as subjects in the High Dose Arm.
89015699|NCT06256016|Experimental|Neck pain massage|Subjects in this group will be treated with a neck muscle massage protocol.
89015700|NCT06256016|Experimental|Neck and thoracic massage|Subjects in this group will be treated with a massage protocol of the neck muscles and the posterior thoracic region.
89015701|NCT06254924|Experimental|QI App Users|Participants will be asked to use the QI App once per day for 5-10 minutes per day for 6 weeks.
89015702|NCT06254924|Experimental|Parents/Guardians of QI App Users|Parents/guardians of QI App users will be aware that their child is using the QI App once per day for 5-10 minutes per day for 6 weeks.
89015703|NCT06254872|Experimental|Peer Mentors|Participants will be trained in how to be peer mentors to anonymous participants through a smartphone app. Participants will provide daily prompts to their mentees to encourage anonymous discussion in the group chat feature of the smartphone app. Participants will provide daily encouragement to their mentees to use features of the smartphone app to practice mindfulness skills.
89453751|NCT03981328|Experimental|Continuous glucose monitoring|Patients randomized to the intervention group will be equipped with a real-time CGM sensor (Dexcom G6 sensor, a small flexible device that records interstitial glucose levels every five minutes). The sensor will be inserted into the subcutaneous tissue of the anterior abdomen wall. Additionally, patients will be advised to record capillary blood glucose values if glucose alerts or readings do not match with symptoms or expectations. Participants will be educated how to exchange the sensor (has to be exchanged every ten days) and will be equipped with a real-time CGM monitor and instructed in its use. The monitor provides the user with information about current glucose levels and notifies the patient before she reaches her upper or lower glucose threshold and when glucose levels change rapidly. All patients in the intervention group will specifically trained how to use the system.
89015704|NCT06254365|Experimental|LEAP2 infusion then placebo infusion|"Participants are randomized to either first recieve LEAP2 infusion and then LEAP2 infusion or th other way around.~This arm describes - first LEAP2 infusion and then placebo infusion"
89015705|NCT06254365|Experimental|Placebo infusion then LEAP2 infusion|"Participants are randomized to either first recieve LEAP2 infusion and then LEAP2 infusion or th other way around.~This arm describes - first placebo infusion and then LEAP2 infusion"
89201037|NCT02540031|Experimental|Additional oral preparation|"The investigational or experimental arm will receive standard oral preparation plus additional oral preparation (1l of polyethylene glycol (PEG)+ascorbic acid (Asc)) for colonoscopy.~* Compositions/1L : Sodium Chloride 2.691g Potassium Chloride 1.015g Anhydrous sodium sulfate 7.5g PEG 3350 100g ascorbic acid 4.7g sodium ascorbate 5.9g"
89201038|NCT02540031|Active Comparator|Standard oral preparation|"The control arm will receive currently used oral preparation (2L of polyethylene glycol+ascorbic acid) for colonoscopy.~* Compositions/1L : Sodium Chloride 2.691g Potassium Chloride 1.015g Anhydrous sodium sulfate 7.5g PEG 3350 100g ascorbic acid 4.7g sodium ascorbate 5.9g"
89015706|NCT06253416|Active Comparator|Exercise group|The exercise group was received a home exercise program consist of stretching and strengthening exercises, which was demonstrated by a physiotherapist and supported by visual cards. The exercises were shown to the patients in practice for at least 5 repetitions three days a week for 12 weeks. The exercise tracking form was given to the patients. The patients were called by the physiotherapist every week by telephone, and were allowed to fill out the exercise tracking form and adapt to exercise. Once every four weeks, patients were called to the hospital a total of three times and exercises were shown again in practice. Exercises started with stretching exercises; for ten seconds for three times with ten seconds of rest between each exercise. After stretching exercises extremity strengthening exercises were practiced with half-kilogram weights for the upper and lower extremities, each exercise is performed ten times with ten seconds of rest.
89015707|NCT06253416|Active Comparator|Control group|The control group was told to exercise freely and without supervision. They were advised to exercise regularly, only verbally.
89015708|NCT06252636|Active Comparator|A2 Milk|A2 milk, 275 mL, twice daily after meal (550 mL/day)
89015709|NCT06252636|Placebo Comparator|A1/A2 Milk|A1/A2 milk, 275 mL, twice daily after meal (550 mL/day)
89015710|NCT06250413|Experimental|Intervention|The participants will be given 4 capsules containing fecal matter (Capsule 1) after treatment with antibiotics on day 7. Intervention group will be given placebo (Capsules 2) on day 28.
89453752|NCT04470297|Placebo Comparator|Placebo|A placebo with the same physical characteristics of the experimental drug pill will be administered at the same time and daily schedule as the experimental intervention for 10 days.
89453753|NCT04470297|Experimental|Ramelteon|A pill containing ramelteon 8mg will be administered daily at bedtime for 10 days.
89453754|NCT03104842|Experimental|Arm A Transplantation|Patients ≤ 70 years of age and eligible for stem cell transplantation will enter study arm A They will undergo 6 cycles of Induction Treatment : Carfilzomib, Lenalidomid, Isatuximab (I-KRd), after intensification another 4 cycles of I-KRd as consolidation will be followed by IKR maintenance until PD or Toxicity
89453755|NCT03104842|Experimental|Arm B No-Transplantation|Patients > 70 years or ineligible for stem cell transplantation will enter study arm B They will undergo 12 cycles of Treatment : Carfilzomib, Lenalidomid, Isatuximab (I-KRd) (6 Cycles Induction, 2 Cycles Intensification, 4 Cycles Consolidation),to be followed by I-KR maintenance util PD or Toxicity
89453756|NCT00436683|Experimental|1|Dose titration on active
89453757|NCT00436683|Active Comparator|2|Dose titration
89453758|NCT02286999|Experimental|B.infantis|Infants in the experimental arm will have two doses of the probiotic Bifidobacterium longum subsp. infantis (B. infantis) on Day 7 and Day 14 of life.
89453759|NCT02286999|Placebo Comparator|Placebo|Infants in the experimental arm will have two doses of placebo (powdered maltodextrin) on Day 7 and Day 14 of life.
89453760|NCT00434811|Experimental|Islet Transplantation|Participants will receive up to three separate islet transplants and a regimen of immunosuppressive medications consisting of antithymocyte globulin (ATG), sirolimus, and low-dose tacrolimus.
89453761|NCT02284659|Sham Comparator|FES-sham|Functional Electro Stimulation (FES-sham)
89453762|NCT02284659|Active Comparator|Intervention (FES)|functional electro stimulation
89453763|NCT03133845|Active Comparator|General anesthesia|In this group patients will receive general anesthesia. Anesthetic induction will occur with propofol (generally 1-2 mg/kg), maintenance with a volatile anesthetic, muscle paralysis with a muscle relaxant, and pain control with fentanyl (generally 2-5 mcg/kg titrated). Patients on baseline opioids may receive additional opioids (such as dilaudid) based on clinical criteria. The anesthetic provider will be blinded to BIS values. Discretionary use of intrathecal morphine may be used.
89015711|NCT06250413|Placebo Comparator|Control|"The participants will be given 4 placebo capsules (Capsule 2) after treatment with antibiotics on day 7.~Control group will be given FMT capsules (Capsules 1) as rescue therapy on day 28."
89453764|NCT03133845|Experimental|Spinal anesthesia with light sedation|In this group patients will receive light sedation with propofol and a spinal anesthetic. Spinal anesthesia will be obtained by injecting approximately 10-15 mg of bupivacaine into the subarachnoid space. Up to 2 mg of midazolam may be given during spinal needle insertion. Although spinal anesthesia is sufficient for surgery, sedation is routinely administered using a propofol infusion, titrated to a BIS>60-70. Discretionary use of intrathecal morphine may be used.
89453765|NCT04441671|Experimental|Open label|Disodiumpyrophosphate, capsuled powder, First day: 30 mg/kg fasting at 08.00 and with standard mixed meal at 12.00 Second day: 50 mg/kg fasting at 08.00 and with standard mixed meal at 12.00
89453766|NCT03209024|Other|Control|Participants complete a 3-week home blood pressure monitoring regimen using a handwritten logbook to record all blood pressure readings.
89453767|NCT03209024|Experimental|Intervention|Participants complete a 3-week home blood pressure monitoring regimen using a smartphone app and Bluetooth® technology to wirelessly record all blood pressure readings.
89453768|NCT00120393|Active Comparator|G1|
89453769|NCT00120393|Active Comparator|G2|
89453770|NCT05476120|Experimental|BATHE|In each interview, the intervention group was intervened by the physician to increase compliance with the treatment using the BATHE technique, and brief information was given emphasizing the importance of drug compliance and lifestyle changes routinely applied by the Family Medicine Department in hypertension patients. The patients in the intervention group were interviewed face-to-face at the 0th and 6th months, and online at the 3rd month.
89453771|NCT05476120|No Intervention|Control|In the control group, brief information was given at each interview, emphasizing the importance of drug compliance and lifestyle changes routinely applied by the Department of Family Medicine in hypertension patients. No intervention was made. The patients in the control group were interviewed face-to-face at 0 and 6 months, and online at 3 months.
89453772|NCT03201224||Group without image transmission|"Before Group"
89453773|NCT03201224||Group with image transmission|"After Group"
89201039|NCT00904293|Experimental|Genotype-guided warfarin dosing|A dosing algorithm including clinical factors and genotype information (VKORC1 and CYP2C9) will be used to determine initial warfarin doses.
89201040|NCT00904293|Active Comparator|Non-genotype guided warfarin dosing|Initial warfarin dosing will be determined using the same algorithm as in the experimental group, but only including the clinical factors and not including the genotype information
88938428|NCT01821079|Experimental|PF-05175157 tablet in fed state (repeat)|200 mg single dose of PF-05175157 administered as tablet formulation in the fed state (following a standard high fat meal).
88938429|NCT01821079|Experimental|PF-05175157 tablet in fasted state|200 mg single dose of PF-05175157 administered as tablet formulation in the fasted state (following at least a 10 hour fast).
88938430|NCT01821092|Active Comparator|standard implant, switching platform|osseointegrated implant insertion and abutment connection Implants inserted in healed ridge, prosthetic connection with switching platform
88938431|NCT01821092|Active Comparator|immediate implant, switching platform|osseointegrated implant insertion and abutment connection Implants inserted in immediate post-extraction sites, prosthetic connection with switching platform
89201041|NCT00900549|Experimental|CRT|
89453774|NCT00117819|Experimental|[123I]ß CIT and SPECT imaging|To assess [123I]ß-CIT and SPECT imaging
89453775|NCT03208946|Experimental|High-CML diet|An isocaloric, high-CML content diet with a distribution of 55 to 63% carbohydrates, 12 to 15% protein, 25 to 30% lipids and less than 10% saturated fat.
89453776|NCT03208946|Sham Comparator|Low-CML diet|An isocaloric, low-CML content diet with a distribution of 55 to 63% carbohydrates, 12 to 15% protein, 25 to 30% lipids and less than 10% saturated fat.
89453777|NCT05726019|Active Comparator|Colchicine|Oral tablet colchicine 0.5mg, twice a day, will be started within 24 hours after randomization and maintained until 30 days after coronary artery bypass grafting.
89453778|NCT05726019|No Intervention|Conventional treatment|The control group will follow conventional treatment guided by current guidelines.
89453779|NCT03208790|Experimental|Group A|patients with oral premalignant lesions will receive Nigella sativa buccal tablets 10mg for 3 months.
89453780|NCT03208790|Experimental|Group B|patients with oral premalignant lesions will receive Nigella sativa buccal tablets 5mg for 3 months.
89453781|NCT03208790|Placebo Comparator|Group 3|patients with oral premalignant lesions will receive placebo buccal tablets for 3 months.
89453782|NCT03207698|Active Comparator|Group 1|Scaling and Root Planing (SRP) with Open flap debridement (OFD) alone for treating furcation defect
89453783|NCT03207698|Active Comparator|Group 2|SRP with Open flap debridement (OFD) with Platelet rich fibrin (PRF) for treating furcation defect
89453784|NCT03207698|Active Comparator|Group 3|SRP with Open flap debridement (OFD) with Platelet rich fibrin (PRF)+1% Metformin for treating furcation defect
89453785|NCT02287077|No Intervention|Immediate cord clamping|At birth, neonate will be held at the level of placenta and umbilical cord will be clamped immediately (standard of care for depressed neonates).
89453786|NCT02287077|Experimental|Umbilical cord milking|At birth, neonate will be held below the level of placenta and umbilical cord will be milked 3 times before clamping the cord.
89453787|NCT03201302|Experimental|School physical education class|Children who participated only in their school physical activity classes only for the entire school year.
89453788|NCT03201302|Experimental|Taekwondo|Children who participated in organized Taekwondo training for the entire school year.
89453789|NCT03201302|Experimental|Martial arts|Children who participated in organized Martial arts training for the entire school year.
88938432|NCT01821157|Active Comparator|Flapless|Flapless: Gingivectomy and osteoplasty, as necessary, will be performed without flap elevation.
88938433|NCT01821157|Active Comparator|Open-flap|Gingivectomy and osteoplasty, as necessary, will be performed with flap elevation
88938434|NCT01821170|Experimental|Cognitive remediation|
88938435|NCT01821170|Active Comparator|Supportive psychotherapy|
88938436|NCT01821170|Active Comparator|Methylphenidate|
88938437|NCT01821183||hip rotators muscle strength|
88938438|NCT01821183||control group|no intervention
88938439|NCT01821196|Experimental|biopsy|Additional biopsies by means endoscopy, 5 from tumor tissue, 5 from adjacent normal mucosa per patient.
88938440|NCT01821209|No Intervention|Control|Standard robot assisted radical prostatectomy
88938441|NCT01821209|Experimental|Sling|Placement of sling at time of robot assisted radical prostatectomy
88938442|NCT01821222|Experimental|Wired mothers intervention|The wired mothers' intervention consisted of two components: an automated short messaging service (SMS) system providing wired mothers with unidirectional text messaging and a mobile phone voucher system providing the possibility of direct two-way communication between wired mothers and their primary health care providers. While only women with registered phone numbers received text messages, all women in the intervention group were given mobile phone vouchers to contact their local primary health care provider.
88938443|NCT01821222|No Intervention|Control|The control group received standard care
88938444|NCT01821235|Experimental|Neurontin® (gabapentin) batch A|
88938445|NCT01821235|Experimental|Neurontin® (gabapentin) batch B|
88938446|NCT01821235|Experimental|Gabasandoz® (gabapentin) batch A|
88938447|NCT01821235|Experimental|Gabasandoz® (gabapentin) batch B|
88938448|NCT01821248|Experimental|Gemcitabine, Cisplatin, S-1|1000mg/m2/day1, 25mg/m2/day1, 100mg/body/day1-7
89015712|NCT06249204|Active Comparator|Coaching Group|The intervention group will be exposed to six coaching sessions (one a month for 6 months) as well as a nine month touch point to complete the 3-month post survey. This group will have access to a care community coach, resources and use these supports to create action steps towards adopting and implementing person-centered best practices based on an initial self-assessment of their current practices.
89015713|NCT06249204|No Intervention|Training Group|This group will complete the same pre, immediate post and 3-month post surveys as the intervention group but will receive no intervention during the six month period.
89015714|NCT06248177|Active Comparator|Group 1|6 weeks daily consumption of one probiotic capsule + 4 weeks wash-out period+ 6 weeks daily consumption of one placebo capsule
89453790|NCT03201302|Experimental|Climbing|Children who participated in organized climbing training for the entire school year.
89453791|NCT03201302|Experimental|Volleyball|Children who participated in organized volleyball training for the entire school year.
89015715|NCT06248177|Active Comparator|Group 2|6 weeks daily consumption of one placebo capsule + 4 weeks wash-out period+ 6 weeks daily consumption of one probiotic capsule
89015716|NCT06244589|Active Comparator|Laparoscopic cholecystectomy|Cases that laparoscopic cholecystectomy performed without need for open-conversion
89015717|NCT06244589|Experimental|Open-conversion cholecystectomy|Cases converted to open surgery based on intraoperative findings.
89015718|NCT06243263|Experimental|Group BNAI+|"Randomization process will be used to preoperatively assign patient's left or right side to receive inferior alveolar nerve block. At the end of the surgery, each patient will receive an inferior alveolar nerve block with 2ml of bupivacaine 0.5% on one side ;the other side will not be injected. This arm include the group of fracture which will receive an inferior alveolar nerve block with bupivacaine.~All patient will receive during the postoperative period 1 gram of paracetamol each 8 hours."
89015719|NCT06243263|No Intervention|Group BNAI-|"Randomization process will be used to preoperatively assign patient's left or right side to receive inferior alveolar nerve block. At the end of the surgery, each patient will receive an inferior alveolar nerve block with 2ml of bupivacaine 0.5% on one side ;the other side will not be injected. This arm include the group of fracture which will not receive an inferior alveolar nerve block with bupivacaine ( control group).~All patient will receive during the postoperative period 1 gram of paracetamol each 8 hours."
89015720|NCT06241820|Other|Lumbar Sympathetic Ganglion Block (LSGB)|FS-guided LSGB at L3 level.
89453792|NCT03201302|Experimental|Artistic gymnastics|Children who participated in organized artistic gymnastics training for the entire school year.
89453793|NCT03201302|Experimental|Swimming|Children who participated in organized swimming training for the entire school year.
89453794|NCT03201302|Experimental|Dance|Children who participated in organized dance training for the entire school year.
89015721|NCT06234865|Active Comparator|Control Group|Patients in the control group will receive the routine care of the orthopaedic clinic and education with a brochure about preventing constipation.
89453795|NCT03201302|Experimental|Basketball|Children who participated in organized basketball training for the entire school year.
89453796|NCT03201302|Experimental|Wrestling|Children who participated in organized wrestling training for the entire school year.
89453797|NCT03201302|Experimental|Football (soccer)|Children who participated in organized football (soccer) training for the entire school year.
89453798|NCT03201302|Experimental|Rhythmic gymnastics|Children who participated in organized rhythmic gymnastics training for the entire school year.
89453799|NCT03201302|Experimental|Track and field|Children who participated in organized track and field training for the entire school year.
89453800|NCT03201302|Experimental|Tennis|Children who participated in organized tennis training for the entire school year.
89453801|NCT03201302|Experimental|Combination of activities 1|Children who participated in two different weight-bearing activities for the entire school year.
89453802|NCT03201302|Experimental|Combination of activities 2|Children who participated in one weight-bearing and in one non weight-bearing activity for the entire school year.
89015722|NCT06234865|Experimental|Video Education Group|Patient in the experimental group will receive the routine care of the orthopaedic clinic and a video education about preventing constipation.
89015723|NCT06233942|Experimental|Phase 1a: Part A (Monotherapy Dose Escalation)|BG-C9074 monotherapy dose escalation
89015724|NCT06233942|Experimental|Phase 1a: Part B (Monotherapy Safety Expansion)|BG-C9074 dose levels that have been determined to be safe and tolerable in Part A will be investigated.
89015725|NCT06233942|Experimental|Phase 1a: Part C (Combination Therapy Dose Escalation)|BG-C9074 plus tislelizumab combination at the recommended dose for expansion (RDFE).
89015726|NCT06233942|Experimental|Phase 1b: Monotherapy Dose Expansion|The monotherapy dose expansion phase will begin once the BG-C9074 monotherapy RDFE and dosing schedule have been determined from Parts A and B in Phase 1a.
89015727|NCT06232161|Experimental|red-light therapy group|The red-light therapy group would be treated with red-light therapy twice daily including the single focus spectacles during the follow-up.
89201042|NCT00900549|Sham Comparator|No CRT|
89453803|NCT02287155|Experimental|occupation based health promotion|"The description of the health promotion intervention is provided in the detailed description of the study. It's a single arm study."
89453804|NCT03208712|Experimental|Radium-223 and Atezolizumab|"Radium- 223 IV (55 kBq/kg) every 3 weeks for up to 6 doses~Atezolizumab 1200 mg IV once every 3 weeks until investigator determined lack of benefit, unacceptable toxicity, or 17 doses"
89453805|NCT05725941|Active Comparator|Control Group|"Individuals who will participate in the control group will receive a traditional functional exercise training protocol (conventional physiotherapy program) for one hour. It will focus on the enhancement of muscle strength, joint range of motion, arm &hand activities, and daily living functions of the affected upper limbs.~The treatment, for the control group, will be conducted over a period of 4 successive weeks, with 3 sessions per week."
89453806|NCT05725941|Experimental|Experimental Group|"Participants in the experimental group will receive the conventional treatment program similar to that will be provided to the control group. The treatment, for the experimental group, will be conducted over a period of 4 successive weeks, with 3 sessions per week.~Moreover, they will ¬wear an upper limb spiral strapping system with a hand splint 8 hours daily/ 6 days per week."
89015728|NCT06232161|Other|control group|The control group including both the stopping red-light therapy group from the first 12 months (who obtained red-light therapy but stopped during the second 12-month follow-up) and those never use red-light therapy.
89453807|NCT03208556|Experimental|iPD1 CD19 eCAR T cells|patients will receive a lymphodepletion chemotherapy prior to CAR T cell infusion
89453808|NCT00429429|Experimental|Peanut protein solution|Subjects receiving the peanut sublingual peanut protein drops. Sublingual Immunotherapy.
89453809|NCT03201146|Experimental|Apatinib 750mg + AP or AC|Phase 1 study of Apatinib in combination with platinum-based doublet chemotherapy.
89453810|NCT03201146|Experimental|Apatinib 500mg + AP or AC|Phase 1 study of Apatinib in combination with platinum-based doublet chemotherapy.
89453811|NCT03201146|Experimental|Apatinib 250mg + AP or AC|Phase 1 study of Apatinib in combination with platinum-based doublet chemotherapy(PBDC).
89453812|NCT03201146|Experimental|Apatinib|Phase 2 study of Apatinib in combination with platinum-based doublet chemotherapy(PBDC).
89453813|NCT03201146|Active Comparator|AP or AC|Pemetrexed/Cisplatin(AP) or Pemetrexed/Carboplatin(AC), The platinum-based doublet chemotherapy, as the control group in the phase 2 study.
88938449|NCT01821261|Experimental|Mouth Rinse 19668-012|Twice each day, brush with about one inch of toothpaste 035000513007 in the usual manner, rinse mouth with water, and then rinse with 20 ml of mouth rinse 19668-012 for 30 seconds and spit it out - do not swallow.
88938450|NCT01821261|Active Comparator|Mouth Rinse 500347078842|"Twice each day, brush with about one inch of toothpaste 035000513007 in the usual manner, rinse mouth with water, and then rinse with 10 ml of mouth rinse 500347078842 for 60 seconds and spit it out - do not swallow.~Attention: Toothpastes can stop mouth rinse from working. Rinse your mouth thoroughly with water and wait 5 minutes after brushing your teeth before using the mouth rinse. You can also use the mouthwash at a different time of day."
88938451|NCT01821261|Other|Toothpaste 035000513007|Twice each day, brush with about one inch of toothpaste 035000513007 in the usual manner. Subjects in this arm will not use any mouth rinse.
88938452|NCT01821274|Experimental|topical Diltiazem Hydrochloride 2% Cream|0.2 g applied topically under occlusive patch conditions to the infrascapular area of the back, once daily for 21 consecutive days over 3 weeks.
88938453|NCT01821274|Placebo Comparator|Vehicle Cream|0.2 g applied topically under occlusive patch conditions to the infrascapular area of the back, once daily for 21 consecutive days over 3 weeks.
88938454|NCT01821274|Active Comparator|0.2% sodium lauryl sulfate (SLS)|0.2 mL applied topically under occlusive patch conditions to the infrascapular area of the back once daily for 21 days over 3 weeks, will serve as a positive control.
88938455|NCT01821274|Placebo Comparator|0.9% saline|0.2 mL, applied topically under occlusive patch conditions to the infrascapular area of the back once daily for 21 days over 3 weeks, will serve as a negative control.
88938456|NCT01821287||CHD Infants|Infants with a single ventricle (Congenital Heart Disease) CHD admitted to Cincinnati Children's Hospital Medical Center (CCHMC) for neonatal medical management or surgical palliation
88938457|NCT01821287||Normal Controls|Healthy newborns (full-term infants with no known medical problems) recruited from Cincinnati Children's Hospital Medical Center (CCHMC) and private practices
88938458|NCT01821313|Experimental|Moderate exercise|The subject will participate in a 6-week exercise intervention, 3 days per week on a cycle ergometer. The moderate exercise group will begin with a five-minute warm-up, cycling at 50-55% of the subject's maximal heart rate as determined by the initial fitness assessment. Following the warm-up, the moderate group will cycle for 30 minutes at 65-70% of maximal heart rate. The subject will then complete a 5-minute cool-down at 50-55% of maximal heart rate. Heart rate will be measured via individual heart rate monitors.
88938459|NCT01821313|Active Comparator|High Intensity Interval Exercise (HIIE)|The subject will participate in a 6-week exercise intervention, 3 days per week on a cycle ergometer. The subjects in the HIIE group will begin with a five-minute warm-up at 50-55% of the subject's maximal heart rate as determined by the initial fitness assessment. Following the warm-up, the HIIE group will perform 10, two-minute exercise bouts at 90-95% of maximal heart rate, with one minute of active recovery at 55% of maximal heart rate between each interval for a total of 30 minutes. They will complete the test with a 5-minute cool-down at 50-55% of maximal heart rate. Heart rate will be measured via individual heart rate monitors.
88938460|NCT01821404|Placebo Comparator|Placebo|Similar capsules as in the atorvastatin arm, but including no active ingredient. Used daily for 3-5 weeks before prostatectomy
88938461|NCT01821404|Experimental|Atorvastatin|Atorvastatin capsules orally, 80 mg daily for 3-5 weeks before prostatectomy
88938462|NCT01821430|Experimental|Pregabalin|Pregabalin 400mg / Day
88938463|NCT01821430|Placebo Comparator|Placebo Control|Placebo Tablet
88938464|NCT01821443|Experimental|Stereotactic Radiosurgery (SRS)|Stereotactic radiosurgery technique via Gamma Knife® Perfexion™ radiosurgical system
88938465|NCT01821456||Antiinfectives|To analyze the efficacy of antiinfectives at high risk patients
88938466|NCT01821469|Experimental|psychoeducation|psychoeducation (12 weeks)
88938467|NCT01821482|Experimental|A|After complete resection or TACE, patients will receive 3 cycles of Dendritic and Cytokine-induced Killer Cells (DC-CIK) (every 4 weeks)
88938468|NCT01821482|No Intervention|B|After complete resection or TACE, Patient only regularly follow up
88938469|NCT01821495|No Intervention|B|After accepting concurrent radiotherapy and chemotherapy, patients will just regularly follow up.
88938470|NCT01821495|Experimental|A|After accepting concurrent radiotherapy and chemotherapy, patients will receive 3 cycles of Dendritic and Cytokine-induced Killer Cells (DC-CIK)treatment.
89453814|NCT00370383|Experimental|Satraplatin|Satraplatin administered orally once daily for 5 consecutive days followed by erlotinib for 14 consecutive days
89453815|NCT00370383|Experimental|Erlotinib|Erlotinib administered orally once daily. Erlotinib - [6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-y]- (3-ethynyl-phenyl)amine hydrochloride, molecular weight 393.4. This is a small molecule that competes with the binding of ATP to the intracellular tyrosine kinase domain of EGFR, thereby inhibiting receptor autophosphorylation and blocking downstream signal transduction.
89201043|NCT00904449|Experimental|Open Label|
89453816|NCT03107312||Known vaccination history|Single blood sample collection from subjects with verified records of vaccination or recent booster immunization against measles, mumps, rubella, varicella, tetanus, pertussis, poliomyelitis, diphtheria, meningococcal infection
89453817|NCT03107312||Migrants|Single blood sample collection from recent migrants to Germany without verified vaccination records
89453818|NCT02450630|Experimental|training on diagnosis, treatment and referral of children|Intervention Arm : training in diagnosis, treatment and referral of sick children
89015729|NCT06231290|Active Comparator|Postgraduate operator with magnification|
89201044|NCT00904527|Experimental|Relaxation|Relaxation (Schultz)+ medical treatment (beta-bloquant or Oxetorone)+ patient's education
88938471|NCT01821508|Active Comparator|Clinical treatment|Best and most modern clinical treatment of type 2 diabetes mellitus.
88938472|NCT01821508|Active Comparator|Roux-En-Y gastric bypass surgery|"A metabolic surgery consists of any surgical procedure in which there is any anatomical alteration in the gastrointestinal tract by means of a diversion of food passage, resulting in improved metabolic control in patients with type 2 diabetes mellitus [SCHULMAN, 2009]."
88938473|NCT01821521|Experimental|AGSPT_L20|tablet, q.d.
88938474|NCT01821521|Active Comparator|Pantoloc 40mg|tablet, q.d.
88938475|NCT01821573|Experimental|Botox Injection|Patients treated by botulinum toxin.
88938476|NCT01821573|Placebo Comparator|Saline Solution|Patients treated with saline solution.
88938477|NCT01821586|Experimental|Modified ORS-1|Modified ORS -1 will be assigned to the enrolled particfipants according to the randomization schedule.
88938478|NCT01821586|Experimental|Modified ORS-2 (ReSoMal)|Modified ORS -2 (ReSoMal) will be assigned to the enrolled particfipants according to the randomization schedule.
88938479|NCT01821586|Experimental|Modified ORS-3 (Benefibre)|Modified ORS -3 (Benefibre) will be assigned to the enrolled particfipants according to the randomization schedule.
88938480|NCT01821599|Active Comparator|Conventional group|Nonaccelerated Rehabilitation After Anterior Cruciate Ligament Reconstruction
88938481|NCT01821599|Experimental|Accelerated group|Accelerated Rehabilitation After Anterior Cruciate Ligament Reconstruction
88938482|NCT01821612|Other|mFOLFIRINOX, chemoradiation, surgery and gemcitabine|"Each patient will receive mFOLFIRINOX therapy administered every other week for a total of 4 cycles. Each treatment cycle is a total of 14 days. This treatment program consists of four drugs (oxaliplatin 85 mg/m^2 IV over 2 hours on day 1 followed by irinotecan 180 mg/m^2 IV over 90 minutes on day 1 followed by, leucovorin 400 mg/m^2 IV over 2 hours on day 1 followed by 5-FU 2400 mg/m^2 IV over 46-48 hours).~Two to six weeks following treatment with the mFOLFIRINOX, if the tumor has not spread to other parts of the body then the patient will receive capecitabine 825 mg/m^2, twice daily for 28 days along with radiation therapy. Patients will have surgery within 4-10 weeks of the last dose of chemoradiation if the tumor has gotten smaller or stayed the same.~Within 6-8 weeks following surgery, patients will receive gemcitabine for 2 cycles (1 cycle is 28 days). Gemcitabine will be given IV on days 1, 8 and 15 of every 28 day cycle."
88938483|NCT01821638||Older adults with heart failure|Older adults with heart failure
88938484|NCT01821651|Experimental|HeartNavigator|Group with HeartNavigator-Software
88938485|NCT01821651|Active Comparator|Control|Control-group without HeartNavigator-Software
88938486|NCT01821651|Experimental|EchoNav|Group with EchoNav-Software
88938487|NCT01821651|Active Comparator|Conrol|Control-group without EchoNav-Software
88938488|NCT01821664||Prosthetic vascular graft implantation, follow up|
88938489|NCT01821703|Experimental|LY3045697|Escalating dose (0.1 milligrams [mg] up to 100 mg) of LY3045697 administered once daily, orally, for 8 days in 2 of 3 dosing periods
88938490|NCT01821703|Active Comparator|Spironolactone|25 mg spironolactone administered once daily, orally, for 8 days in up to 1 of 3 dosing periods
88938491|NCT01821703|Placebo Comparator|Placebo|Placebo matching LY3045697 administered once daily, orally for 8 days in up to 1 of 3 dosing periods
88938492|NCT01821716|Experimental|1|"Three concentrations of Dermatophagoides pteronyssinus allergen extract (10, 1, 0.1 mg/ml)~Positive control (10 mg/ml histamine dihydrochloride)~Negative control (glycerinated phenol saline solution)"
88938493|NCT01821742||Children requiring fluid bolus on PICU|
88938494|NCT01821755|Experimental|Behavioral: Foster parent intervention|Foster parents receive a foster parent intervention consisting of 10 individual home visits and three group sessions. Duration of the intervention is four months
88938495|NCT01821755|No Intervention|Control|waiting-list control group who receive care-as-usual
88938496|NCT01821768|No Intervention|Arm 1: No sentinal lymph node biopsy|Patients will receive no additional axillary surgery which is experimental.
88938497|NCT01821768|Active Comparator|Arm 2: Sentinel lymph node biopsy|Patients will receive standard of care sentinel lymph node biopsy
88938498|NCT01821820|Experimental|Pistachios|Pistachio treatment (3 oz/d) for two weeks; 3 oz pistachio nuts and water (1.5 oz. before, and 1.5 oz during) cycling 75 km.
88938499|NCT01821820|No Intervention|No pistachios|No pistachios for two weeks, or before and during 75 km cycling.
88938500|NCT01821846||Liraglutide|
88938501|NCT01821872|Active Comparator|Sampling at approx 15 minutes|Plasma and CSF samples to be taken at 15 minutes post administration of intravenous paracetamol
88938502|NCT01821872|Active Comparator|Sampling at approx 30 minutes|Plasma and CSF samples to be taken at 30 minutes post administration of intravenous paracetamol
88938503|NCT01821872|Active Comparator|Sampling at approx 120minutes|Plasma and CSF samples to be taken at 120 minutes post administration of intravenous paracetamol
88938504|NCT01821885|Experimental|Spirometry and a brief advice to quit smoking|"Intervention group:~The intervention consists of completing a questionnaire and undergo spirometry with bronchodilator test by a trained nurse. Later, the patients receives a brief advice to quit smoking and a report of the spirometry results by their family doctor."
88938505|NCT01821885|Active Comparator|Brief advice to quit smoking|"Control group:~Patients in the control group complete a questionnaire by a nurse and then receive a brief advice to quit smoking by their family doctor."
88938506|NCT01821911|Experimental|Zagreb2-1-1|Injection on day 0、7、21
88938507|NCT01821911|Active Comparator|Essen|Injection on day 0、3、7、14、28
88938508|NCT01821950|No Intervention|Physical education as usual|Physical education curriculum established by the school, including competitive sports, aerobic and anaerobic activities, balance and coordination skills. Yoga is not a component of the curriculum.
89453819|NCT02450630|No Intervention|Presumptive treament of sick children|Control Arm - Training of private providers in completing study tools i.e. filling in register and referral forms. No training in diagnosis, treatment and referral and no community awareness on referral
89453820|NCT00367887|Active Comparator|1|
89453821|NCT00367887|Active Comparator|2|
89453822|NCT00367887|Active Comparator|3|
89453823|NCT03207932||ultrasound|CVC insertion using ultrasound
89453824|NCT03207932||landmark technique|CVC insertion using landmark technique
89453825|NCT02547220|Experimental|Cinryze®|Participants will receive 5000 Units of CINRYZE (50 millilitre [mL] of CINRYZE/ 50 mL of normal saline) on Day 1 and 2500 Units of CINRYZE (25 mL of CINRYZE/ 75 mL of normal saline) on Day 3, 5, 7, 9, 11, and 13 respectively.
89453826|NCT02547220|Placebo Comparator|Placebo|Participants will receive 7 doses of matched placebo over 13 days of treatment.
89453827|NCT03207308|Experimental|Vitamin A supplementation|55 children will receive a Mega-dose of preformed Vitamin A as recommended by the Senegalese Ministry of Health
89453828|NCT00366795|Experimental|Satavaptan|
89453829|NCT00366795|Placebo Comparator|Placebo|
89453830|NCT04484870|Experimental|Danshu capsule group|The patients in Danshu group were treated with Danshu capsule, 2 tablets per time, 3 times a day (0.45g/ tablets)，The course of treatment was 6 months
88938509|NCT01821950|Experimental|Yoga during physical education|12 to 16 weeks of group yoga classes (approximately 32 classes per student), 30-45 minutes per class, 2-3 times per week, during physical education class. Yoga program includes physical postures and movement, breathing exercises, partner/group games, deep relaxation and meditative techniques.
88938510|NCT01821989|Active Comparator|Low Dose|Lactoferrin,dose of 100 mg/day.
89453831|NCT04484870|Active Comparator|ursodeoxycholic acid group|UDCA group, 250mg/ was taken orally twice a day (0.25g/, Losan Pharma GmbH company). The course of treatment was 6 months
89453832|NCT00366327|Experimental|A|
89453833|NCT03207464|Experimental|Multiple Sclerosis|Subjects meeting the definition for Multiple Sclerosis by the International Panel Criteria, with an Expanded Disability Status Scale (EDSS) less than 6.5.
88938511|NCT01821989|Experimental|High Dose|Lactoferrin, dose of 150 mg/kg/ twice daily.
88938512|NCT01821989|Placebo Comparator|Control|Receive placebo in form of distilled water.
88938513|NCT01822002|Active Comparator|Canalith repositionig maneuver; Epley maneuver group|Patients with PC-BPPV will be randomly assigned to Epley maneuver or Semont maneuver.
88938514|NCT01822002|Active Comparator|Canalith repositioning maneuver : Semont maneuver group|Patients with PC-BPPV will be randomly assigned to Epley maneuver or Semont maneuver group.
88938515|NCT01822028|Placebo Comparator|Treatment A|"Treatment A: Florastor® 500 mg twice per day from Day 1 to Day 16 of the treatment period, and Zavesca® 100 mg three times per day from Day 3 to Day 16.~For Period 2, subjects will receive the alternate dosing regimen."
88938516|NCT01822028|Experimental|Treatment B|"Treatment B: Florastor® 500 mg twice per day from Day 1 to Day 16 of the treatment period, and Zavesca® 100 mg three times per day from Day 3 to Day 16.~For Period 2, subjects will receive the alternate dosing regimen."
88938517|NCT01822041|Active Comparator|Part A - 14C labeled ARN-509|Single oral dose of 240 mg ARN-509, followed after 2 hours (at the average tmax of ARN-509) by an intravenous (i.v.) microdose of 100 μg (9.25 kBq, 250 nCi) 14C-ARN-509
88938518|NCT01822041|Active Comparator|Part B: 14C labeled ARN-509|Single oral dose of 240 mg ARN-509, followed after 2 hours (at the average tmax of ARN-509) by an oral dose of 240 mg ARN-509 with 37 kBq (1000 nCi) of 14C-ARN-509
89453834|NCT03207464|Experimental|Healthy Control|This group will serve as non disease population.
89453835|NCT03207230|Experimental|Standard|All participants will perform the CPET at Baseline visit and will be provided with the Cardea SOLO, ActiGraph wGT3X-BT and Wavelet Wristband. The participants will be asked to response to KCCQ and Stanford 7 day recall surveys.
89453836|NCT02542072|Active Comparator|comfilcon A|Participants were randomized to wear the comfilcon A lens pair for one month during the cross over study.
89453837|NCT02542072|Active Comparator|samfilcon A|Participants were randomized to wear the samfilcon A lens pair for one month during the cross over study.
88938519|NCT01822080|Experimental|Dienogest|50% of the participants will be randomized to this arm and will receive 2 mg dienogest (DNG) once daily by mouth from 0-52 weeks
88938520|NCT01822080|Placebo Comparator|Placebo|50% of the participants will be randomized to this arm and will receive placebo once daily by mouth from 0-24 weeks then switch to 2 mg dienogest (DNG) once daily by mouth from 25-52 weeks
88938521|NCT01822093|Experimental|Cytovir-ADV|Adenovirus-specific T-cells
88938522|NCT01822106|Active Comparator|Omeprazole|Omeprazole at a rate of 20mg once per day
88938523|NCT01822106|Experimental|Wu-Chu-Yu Tang|Wu-Chu-Yu Tang at a rate of 3.0 g three times per day
88938524|NCT01822145||ICD recipients|ICD recipients with documented cardiac arrest or ventricular arrhythmias
89015730|NCT06231290|Experimental|Postgraduate operator without magnification|
89453838|NCT03207152|Experimental|Influenza A/California/04/2009|Participants will be inoculated with Influenza A/California/04/09 3.5x10(4) tissue culture infective dose 50% (TCID50) in 1 mL in Dulbecco's phosphate buffered saline (DPBS) delivered by intranasal drops. They will then be monitored as in-patients for 10 days with daily clinical assessment and blood and respiratory tract sampling. Following discharge, they will be followed up for up to 6 months post-inoculation.
89453839|NCT00422019|Experimental|AMG 102 at 20 mg/kg Dose Level|Up to 40 subjects will be treated at 20 mg/kg of AMG 102 Q2W (every 2 weeks) depending upon the stage of the study and number of responses observed.
89453840|NCT00422019|Experimental|AMG 102 at 10 mg/kg Dose Level|Up to 40 subjects will be dosed at 10mg/kg of AMG 102 Q2W (every two weeks) based upon the stage of the study and number of responses observed.
89453841|NCT03207542|Experimental|B-Cell Precursor Acute Lymphoblastic Leukemia (ALL)|"Participants receive Daratumumab by vein over about 4 hours on Days 1, 8, 15, and 22 of Cycles 1 and 2, Days 1 and 15 of Cycles 3-6, and then on Day 1 of Cycles 7 and beyond.~Each cycle is 28 days."
89453842|NCT03207542|Experimental|T-Cell Precursor Acute Lymphoblastic Leukemia (ALL)|"Participants receive Daratumumab by vein over about 4 hours on Days 1, 8, 15, and 22 of Cycles 1 and 2, Days 1 and 15 of Cycles 3-6, and then on Day 1 of Cycles 7 and beyond.~Each cycle is 28 days."
89453843|NCT00360867|Other|1|Single Arm
89453844|NCT03208634|Experimental|Robotic intervention|Robotic intervention.
89453845|NCT03481114|Active Comparator|Standard chemoradiotherapy|Patients receiving standard radiotherapy will receive a total dose of 60 Gy in 30 fractions over 6 weeks, delivered to all involved lesions (tumors and lymph nodes).
89453846|NCT03481114|Experimental|PET-based, dose-painted, accelerated chemoradiotherapy,|For patients receiving PET-based, dose-painted, accelerated chemoradiotherapy, lesions with MTV exceeding 20 cc will be treated with 55 Gy in 20 fractions over 4 weeks, while lesions with MTV below 20 cc will receive 44 Gy in 20 fractions over the same 4 weeks.
89453847|NCT02450474|Other|A: baseline - IPC|"A: baseline - IPC - washout - NMES - washout - follow up~The baseline phase, washout phase and follow up phase will consist of treatment as normal. IPC phase will consist of normal care plus IPC of the lower limbs for the duration of each dialysis session."
89453848|NCT02450474|Other|B: baseline - NMES|"B: baseline - NMES - washout - IPC - washout follow up~The baseline phase, washout phase and follow up phase will consist of treatment as normal. NMES phase will consist of normal care plus stimulation of the foot and calf muscles for a period of one hour during dialysis."
89453849|NCT00074997|Experimental|001|OZ1 Single intravenous infusion of 2-20 x 10 to the power of 7 OZ1 transduced autologous CD34+ cells per kilogram of body weight
89453850|NCT00074997|Placebo Comparator|002|Placebo Single intravenous infusion of placebo transduced autologous CD34+ cells per kilogram of body weight
89453851|NCT03200990|Experimental|iVAC2L pVAD|Clinically indicated ventricular support for high-risk PCI with Pulsecath iVAC2L.
89453852|NCT02287389|Experimental|balloon dilation|give the cases balloon dilation as the intervention
89453853|NCT02287389|Experimental|balloon dilation plus cryotherapy|give the cases balloon dilation plus cryotherapy as the intervention
89453854|NCT02287389|Experimental|BD plus spiculiform electrosurgery|give the cases balloon dilation plus spiculiform electrosurgery as the intervention
89453855|NCT02287389|Experimental|BD plus mitomycin C|give the cases Balloon dilation plus mitomycin C as the intervention
89453856|NCT03200756|Experimental|Sedentary Group|The experimental group undergoes a behavioral intervention to reduce sedentary behavior which includes a patient centered approach with monitoring and goal setting.
89453857|NCT03200756|Active Comparator|Exercise Group|The Active Comparative group undergoes a standard clinical approach to increase exercise which is patient centered with monitoring and goal setting.
89453858|NCT02448290|Experimental|docetaxel+selumetinib|Selumetinib 75 mg will be administered orally twice a day with continuous dosing schedule Docetaxel 60 mg/m2 will be administered via intravenous access every 3 weeks.
89453859|NCT00357279|Placebo Comparator|1|Placebo
89453860|NCT00357279|Experimental|2|
89453861|NCT02448134|Experimental|Youth Access|"Youth Engagement in Prosocial Alcohol-Free Activities Participate in the Reward and Reminder program in their community"
89453862|NCT02448134|No Intervention|Control|Student will receive regular information and programs.
89453863|NCT02284815|Active Comparator|Glutenfree diet|Self-chosen glutenfree diet
89453864|NCT02284815|Placebo Comparator|Normal diet|Those not following the glutenfree diet
89453865|NCT00055575|Experimental|Depressed Patients with Major Depression DIsorder|
89453866|NCT00055575|Experimental|Depressed Patients with Bipolar Disorder|
89453867|NCT00055575|Experimental|Healthy Control|
89453868|NCT03206996|Experimental|Child Interventional|A 12 week patient-centered modified E/RP protocol for up to 5 participants with ASD and auditory hyper-reactivity. E/RP protocols will include face-to-face treatment sessions as well as the provision of home programs. Treatment fidelity checklists will be utilized each session to ensure that each participant receive the same general protocol/treatment process
89453869|NCT03206996|Experimental|Parental Interventional|A 12 week patient-centered modified E/RP protocol for up to 5 participants with ASD and auditory hyper-reactivity. E/RP protocols will include face-to-face treatment sessions as well as the provision of home programs. Treatment fidelity checklists will be utilized each session to ensure that each participant receive the same general protocol/treatment process
89453870|NCT00051129|Experimental|Anecortave Acetate|Posterior juxtascleral injection in the study eye at 6 month intervals (Day 0, Month 6, Month 12, Month 18)
89453871|NCT00051129|Placebo Comparator|Anecortave Acetate Vehicle|Posterior juxtascleral injection in the study eye at 6 month intervals (Day 0, Month 6, Month 12, Month 18)
89453872|NCT03200600|Experimental|Dexamethasone and flurbiprofen axetil|"Dexamethasone 10 mg is administered before anesthesia induction.~Flurbiprofen axetil 50 mg is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg/ml sufentanil and 2 mg/ml flurbiprofen axetil, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h."
89453873|NCT03200600|Experimental|Dexamethasone and lipid microsphere|"Dexamethasone 10 mg is administered before anesthesia induction.~Lipid microsphere 5 ml is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg/ml sufentanil and 20 ml lipid microsphere, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h."
88938525|NCT01822158|Other|vaginal delivery debrief checklist|Utilization of a Vaginal Delivery Debrief Checklist after vaginal deliveries for a period of three months, by team members who have consented to be a part of this study and who are present at vaginal deliveries. The Vaginal Delivery Debrief checklist consists of 2 levels. The first level includes a list of 6 key elements, such as APGAR scores,estimated blood loss, perineal repair, etc. The second level,or extended debrief, occurs whenever unanticipated outcomes, such as low APGAR scores, postpartum hemorrhage or a difficult delivery occurs. Team members complete the checklist after each delivery they attend.
89015731|NCT06231290|Experimental|Undergraduate operator with magnification|
89015732|NCT06231290|Experimental|Undergraduate operator without magnification|
89537160|NCT05145855||Anosognosia-negative group|Patients will be included in the anosognosia-negative group if they achieved zero or negative anosognosia score before rehabilitation.
89015733|NCT06227000|Experimental|Living Longer and Stronger (LLS) intervention|
89015734|NCT06227000|Active Comparator|Control Group|
89015735|NCT06225349|Experimental|Microencapsulated Magnesium|This group will be provided with a the product Microencapsulated Magnesium.
89015736|NCT06225349|Experimental|Magnesium Oxide|This group will be provided with a the product Magnesium Oxide.
89015737|NCT06225349|Experimental|Magnesium Citrate|This group will be provided with a the product Magnesium Citrate.
89015738|NCT06225349|Experimental|Magnesium Bisglycinate|This group will be provided with a the product Magnesium Bisglycinate.
89015739|NCT06224101|No Intervention|Conventional training group|The conventional training group will visualize a video-recorded simulation procedure with duration of 20 minutes, in which the steps of the ICA are explained.
89015740|NCT06224101|Experimental|Simulation training group|The simulation training group will perform coronary angiography simulated training with 3D printed simulator SimulHeart in groups of two, with debriefing and feedback. Participants will be taught on how to perform each step of the procedure and guide on safety measures concerning catheter handling, radiation exposure, and contrast administration. The duration of simulated training will be 20 minutes per group.
89453874|NCT03200600|Experimental|Normal saline and flurbiprofen axetil|"Normal saline 2 ml is administered before anesthesia induction.~Flurbiprofen axetil 50 mg is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg/ml sufentanil and 2 mg/ml flurbiprofen axetil, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h."
89453875|NCT03200600|Experimental|Normal saline and lipid microsphere|"Normal saline 2 ml is administered before anesthesia induction.~Lipid microsphere 5 ml is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg sufentanil and 20 ml lipid microsphere, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h."
89453876|NCT02547454||CKD participants treated with Mircera|Participants with CKD received Mircera, as per routine clinical practice and was followed for approximately 36 months.
89453877|NCT05725785|Other|FOCUS participants|FOCUS is a smartphone application system designed to improve illness self-management and facilitate recovery in individuals with serious mental illness. It delivers both system initiated (i.e. pre-programmed) and patient initiated (i.e. on demand) real-time assessment to individuals in their own environment.
89453878|NCT00040677|Experimental|ICA-17043 Low Dose 6 mg/day|Active study medication: 100 mg loading dose; 6 mg maintenance dose per day
89453879|NCT00040677|Placebo Comparator|Placebo|
89453880|NCT00040677|Experimental|ICA-17043 High Dose 10 mg/day|Active study medication: 150 mg loading dose; 10 mg maintenance dose per day
89453881|NCT03206840|Experimental|Group 1|"three instructions will be given to each participant: control, meditation, hypnosis. The order of meditation and hypnosis will be randomized amongst two groups to avoid order effects."
89453882|NCT03206840|Experimental|Group 2|"three instructions will be given to each participant: control, meditation, hypnosis. The order of meditation and hypnosis will be randomized amongst two groups to avoid order effects."
89453883|NCT05725707|Active Comparator|Face to face Friendship Group|8-week face-to-face peer-led intervention to support their mental health
89453884|NCT05725707|Active Comparator|Online Friendship Group|8 week online peer-led intervention to support their mental health
89453885|NCT03206684|Experimental|PEG-rhG-CSF|PEG-rhG-CSF single-dose was administered subcutaneously 48h after chemotherapy，with patients' weight ≥ 45kg were given 6mg once per chemotherapy cycle, weight <45kg were given 3mg once per chemotherapy cycle.
89015741|NCT06222775|Active Comparator|Control group|Control group receive activities on diabetes and obesity by Primary Care professionals on a care routine
89453886|NCT03206684|Active Comparator|rhG-CSF|rhG-CSF was daily administered subcutaneously 48h after chemotherapy，weight≥45kg were given 300μg/d, weight<45kg were given 150μg/d,continuous injection for 3-5 days until the absolute neutrophils count≥2×10^9/L.
89453887|NCT05219123||No PD cannulation|Patients with native papilla undergoing ERCP for biliary indications with no inadvertent pancreatic duct cannulation
89015742|NCT06222775|Experimental|Experimental group|"Experimental group receive multicomponent intervention based on:~De Cos AI, Gutiérrez Medina S, Luca B, Galdón A, Simon Chacín J, De Mingo ML, et al. Recommendations for clinical practice in diabetes and obesity. The Madrid Agreements. Document agreed by the working groups of the scientific societies: SENDIMAD, SOMAMFYC, SEMG Madrid, SEMERGEN Madrid and RedGDPS. Nutr Hosp [Internet]. 2018;35(4):971-8. Disponible en: http://dx.doi.org/10.20960/nh.1646 Kojdamanian Favetto V. Guía NICE 2022: actualización en el manejo de la diabetes mellitus tipo 2 en personas adultas. Evid actual pract ambul [Internet]. 2022;25(2):e007015. Disponible en: http://dx.doi.org/10.51987/evidencia.v25i3.7015"
89015743|NCT06221046|Placebo Comparator|Control|Patients will be treated with a standard of care for MASD.
89015744|NCT06221046|Experimental|Cream D|Patients will be treated with Cream D.
89015745|NCT06218368|Experimental|Intervention|Participants in the intervention arm will receive our vaccine toolkit intervention, which includes two main components: 1) our educational toolkit on MMR and polio vaccination in the form of a video, which will be introduced and presented to the participants from Week 12 to Week 15 of the Transform program, 2) reminding messages regarding vaccination, which will be delivered following the video session and embedded in Saving Groups program run in the communities. Additionally, participants in the intervention arm will also receive a series of 15 soap opera videos, one for each week, to complement the 15-week Transform Program's education session, which is the core intervention of the Soap Opera Trial developed and run by the ICM.
89015746|NCT06218368|No Intervention|Control|In the control group, participants will attend the standard 15-week Transform program, with education sessions delivered through traditional lectures by health educators from ICM on the topics of income creation, education, food security, and resilience. Our educational toolkit of MMR and polio vaccination will not be provided and there will be no specific reminders or discussions regarding MMR and polio vaccinations.
89015747|NCT06216509|Other|cirrhosis|patients with cirrhosis undergoing TIPS placement
88938526|NCT01822171|Experimental|Discharge counseling and MTM follow-up|"At the time of hospital discharge the subject will receive:~Discharge medication counseling from a pharmacist~Home medication if needed~Approximately 7 days after hospital discharge the subject have a Follow-up visit at Medication Therapy Management clinic."
88938527|NCT01822184||No treatment|Observational non-treatment study
88938528|NCT01822210|Experimental|Botox|Injection of Botox in the tumor and surrounding stomach wall.
88938529|NCT01822236|Experimental|Craniosacral Therapy Program|A program of 10 craniosacral therapy techniques
88938530|NCT01822236|Active Comparator|One technique of craniosacral therapy|Decompression L5-S1.
88938531|NCT01822249|Active Comparator|EPI-743 15 mg/kg|Subjects in this arm will receive EPI-743 at a dose of 15 mg/kg three times daily
88938532|NCT01822249|Placebo Comparator|Placebo|Subjects in this arm will receive placebo at a volume equivalent to the volume of EPI-743 they would receive if in active group based on their weight
88938533|NCT01822262|Experimental|gallbladder reservation|Patients in trial group all took minimally invasive cholecystolithotomy with gallbladder reservation
88938534|NCT01822262|Experimental|laparoscopiccholecystectomy|Patients in control group all received LC.
88938535|NCT01822327|Experimental|Contingent Vouchers Unmatched|CRA therapy plus Voucher incentives contingent on cocaine abstinence with monetary values set at usual monetary values across all patients.
88938536|NCT01822327|Experimental|Contingent Vouchers, Matched|CRA therapy plus Vouchers contingent on cocaine abstinence, with more severe patients receiving twice the usual voucher monetary values.
88938537|NCT01822327|Active Comparator|Non-Contingent Vouchers control|CRA therapy plus Vouchers earned independent of drug use
88938538|NCT01822340|Experimental|Cohort 1|Once weekly HM10560A
88938539|NCT01822340|Experimental|Cohort 2|Once weekly HM10560A
88938540|NCT01822340|Experimental|Cohort 3|Once weekly HM10560A
88938541|NCT01822340|Experimental|Cohort 4|Biweekly HM10560A
88938542|NCT01822340|Active Comparator|Cohort 5|Once daily Genotropin
88938543|NCT01822379|Experimental|Cell transplantation|All patients will undergo transplantation of two distinct vitiligo lesions. One lesion will receive cells prepared with trypsin. The other lesion will receive cells prepared with dispase.
88938544|NCT01822392|Active Comparator|Online treatment, High therapist contact|Participants receive online Parent Management Training (interactive).
88938545|NCT01822392|Experimental|Online treatment, Low therapist contact|Participants receive online Parent Management Training (recorded).
88938546|NCT01822405|Active Comparator|Pentoxifylline + Tocopherol|Pentoxifylline 800 mg/day (400 mg/12hours) + Tocopherol 1000 mg/day oral during 6 months
88938547|NCT01822405|Experimental|pentoxifylline + tocopherol + Hyperbaric Oxygen Therapy|
88938548|NCT01822418|Experimental|Treatment|Open-label treatment with agomelatine 25 mg/day (or 50 mg/day after week 3).
88938549|NCT01822431||Patients with type 1 diabetes mellitus|Metaiodobenzylguanidine scintigraphy, Autonomic function tests, Pupillometry, Holter monitoring
88938550|NCT01822431||Healthy controls|Autonomic function tests, Pupillometry, Holter monitoring
88938551|NCT01822483|Experimental|Mycophenolate sodium|Arm1(Conversion):MPA AUC below 30mcg*h ml-1 - MPS+Calcineurin inhibitor+prednisone
88938552|NCT01822483|Active Comparator|Mycophenolate mofetil|Arm2(Maintained):MPA AUC between 30 to 60 mg*h ml-1 or above 60 mg - MMF+Calcineurin inhibitor+prednisone
88938553|NCT01822600|Experimental|Normal albumin group|"Based on the serum albumin level at enrollment, the patients were assigned into the normal albumin group if their serum albumin ≥ 30 g/L.~Patients in this group receive intravenous omeprazole treatment."
88938554|NCT01822600|Experimental|Intervention group|"Based on the serum albumin level at enrollment, the patients were assigned into an intervention group if their serum albumin < 30 g/L.~Patients in this group receive both Human albumin and intravenous omeprazole."
88938555|NCT01822600|Experimental|Cohort control group|"The study also included 29 patients with peptic ulcer bleeding and with hypoalbuminemia (serum albumin level < 30 g/L), but without receiving albumin supply from our previous study to serve as the cohort control group.~Patients in this group receive intravenous omeprazole treatment."
88938556|NCT01822613|Experimental|LJM716-BYL719 arm|approximately 42 previously treated esophageal squamous cell carcinoma (ESCC) patients will be enrolled to the LJM716-BYL719 combination arm to evaluate the anti-tumor activity and further assess the safety, tolerability and anti-tumor activity of the combination versus current therapies (physician's choice of paclitaxel, docetaxel or irinotecan).
88938557|NCT01822613|Active Comparator|Paclitaxel, Docetaxel or Irinotecan arm|approximately 42 previously treated esophageal squamous cell carcinoma (ESCC) patients will be enrolled to the Paclitaxel, Docetaxel or Irinotecan arm (physician's choice arm) to evaluate the anti-tumor activity and further assess the safety, tolerability and anti-tumor activity of the LJM716-BYL719 combination versus current therapies (physician's choice of paclitaxel, docetaxel or irinotecan).
88938558|NCT01822626|Experimental|motivational counseling|
88938559|NCT01822626|No Intervention|Usual Care|
88938560|NCT01822639|Experimental|Sequence 1|Subjects in this arm will receive Treatment A in period 1 and Treatment B in period 2. Treatment A is co-administration of 5mg amlodipine tablet and 20 mg enalapril maleate tablet. Treatment B (GSK2944404) is fixed dose combination tablet of 5 mg amlodipine and 20 mg enalapril.
88938561|NCT01822639|Experimental|Sequence 2|Subjects in this arm will receive Treatment B in period 1 and Treatment A in period 2. Treatment A is co-administration of 5mg amlodipine tablet and 20 mg enalapril maleate tablet. Treatment B (GSK2944404) is fixed dose combination tablet of 5 mg amlodipine and 20 mg enalapril.
88938562|NCT01822704|Active Comparator|Control|This group will undergo three 45-minute exercise sessions per week for 10 weeks. No whole body vibration will be given.
88938563|NCT01822704|Experimental|Low intensity vibration|This group will receive three 45-minute whole body vibration training sessions for 10 consecutive weeks. The vibration will be of low intensity (frequency: 20 Hertz, amplitude: 1mm).
88938564|NCT01822704|Experimental|High intensity vibration|This group will receive three 45-minute whole body vibration training sessions per week for 10 consecutive weeks.The vibration will be of higher intensity than the low intensity vibration group (frequency: 30 Hertz, amplitude: 1mm).
88938565|NCT01822717|Experimental|Nonvisual foot inspection|Instruction for nonvisual foot inspection included in comprehensive diabetes self-management education
88938566|NCT01822717|Active Comparator|Usual Care for foot inspection|Usual instruction for foot care included in comprehensive diabetes self-management education
88938567|NCT01822730|Experimental|paliperidone|paliperidone arm,6mg/pill,6-12mg/day,non-forced titration method.last2-4weeks.
88938568|NCT01822730|Active Comparator|.Risperidone|Risperidone arm and placebo tables,1mg/pill,2mg-6mg/day,non-forced titration method.last2-4weeks
88938569|NCT01822769|Experimental|Cardiopulmonary rehabilitation|The subjects will attend 2 sessions each week for 12 weeks. Each session will be approximately 2 hours in duration, consisting of both exercise (aerobic and strength,~60 minutes) and education. In addition, subjects will be directed to participate in 3 weekly ~40 minute home exercise training sessions, personalized to their level of aerobic conditioning.
88938570|NCT01822769|Other|Standard of care|Subjects randomized to standard of care will not be enrolled in a rehabilitation program, but may receive any other clinically indicated exercise training or other intervention (e.g., an exercise prescription).
88938571|NCT01822782||Cases|"The study population consists of all consecutive women meeting inclusion/exclusion criteria and delivering at the Nîmes University Hospital, France during an inclusion period of 6 months. Cases are classified as those with a vaginal lesion due to delivery."
88938572|NCT01822782||Controls|"The study population consists of all consecutive women meeting inclusion/exclusion criteria and delivering at the Nîmes University Hospital, France during an inclusion period of 6 months. Controls are classified as those without a vaginal lesion due to delivery."
88938573|NCT01822795|Experimental|Lung volume reduction coïl treatment|Lung volume reduction coïl treatment,added to usual medical treatment and follow up after the intervention
88938574|NCT01822795|Other|Regular Medical Treatment|No intervention, just a follow up under usual medical treatment
88938575|NCT01822808|Active Comparator|Hydralazine|24 week course of Hydralazine 25mg 3 times daily for 4 weeks, thereafter uptitrating to 50mg hydralazine 3 times daily up to week 24. Those assigned to the Hydralazine control arm will receive the same number of identical placebo tablets.
88938576|NCT01822808|Active Comparator|Isosorbide dinitrate|24 week course of Isosorbide dinitrate 10mg 3 times daily for 4 weeks, thereafter uptitrating to 20mg isosorbide dinitrate 3 times daily up to week 24. Those assigned to the Isosorbide dinitrate control arm will receive the same number of identical placebo tablets.
88938577|NCT01822847||catheterization|patients undergoing elective heart catheterization
88938578|NCT01822860|Placebo Comparator|Placebo|Subjects will receive chlorthalidone, hydrochlorothiazide, and placebo each for 4 weeks in a randomized sequence.
88938579|NCT01822860|Experimental|Chlorthalidone 12.5 mg|Subjects will receive chlorthalidone, hydrochlorothiazide, and placebo each for 4 weeks in a randomized sequence.
88938580|NCT01822860|Active Comparator|Hydrochlorothiazide 25 mg|Subjects will receive chlorthalidone, hydrochlorothiazide, and placebo each for 4 weeks in a randomized sequence.
88938581|NCT01822873||Normal|
88938582|NCT01822873||Age-related macular degeneration|
88938583|NCT01822912|Active Comparator|Heart Failure Disease Management Program|Patients will receive personalized care to include medication titration, daily weights, symptom and activity assessment, documentation of ejection fraction, patient and caregiver education,dietary surveillance, discharge instructions and follow up visit within 7 days of SNF discharge
88938584|NCT01822912|Placebo Comparator|Heart Failure Usual Care|SNF patients with HF will receive usual care
88938585|NCT01822938|Experimental|effects of a incentive program for physical activity|The aim of the study is the assessment of the effects of a incentive program for physical activity on people following/with stroke
88938586|NCT01822938|No Intervention|control group|No intervention
88938587|NCT01822951|Experimental|Cerebrolysin Verum|"Intravenous medication is given in three treatment courses (TC). Each treatment course lasts for two weeks and consists of 10 infusions (5 infusions weekly). For the infusion 2x10 ml Cerebrolysin (215.2 mg/ml) is diluted with 80 ml 0.9% NaCl (saline) to a total volume of 100 ml, i.v.~Placebo for donepezil: 1 tablet per day from TC 1 Day 1 on and 2 tablets per day from Visit 3 - Visit 5, p.o."
88938588|NCT01822951|Active Comparator|Donepezil Verum|"5-10 mg donepezil: 1x5 mg donepezil as 1 tablet per day from TC 1 Day 1 on and 2x5 mg donepezil as 2 tablets from Visit 3- Visit 5, p.o.~Placebo for Cerebrolysin: 100 ml 0.9% NaCl (saline), i.v. infusion. Intravenous medication is given in three treatment courses (TC). Each treatment course lasts for two weeks and consists of 10 infusions (5 infusions weekly)."
88938589|NCT01822964|Active Comparator|targeted brain cooling|In these 15 pts, targeted brain cooling (tympanic temperature of 33°C) will be applied during the TAVI intervention by the use of the RhinoChill device (Benechill Inc, San Diego cA)
88938590|NCT01822964|Placebo Comparator|no use of targeted brain cooling|In these 15 pts, no cooling techniques will be applied and current clinical practice as to maintenance of normothermia will be followed during these TAVI interventions
88938591|NCT01822977|No Intervention|Proton pump inhibitor|"We will recruit 10 healthy adult individuals and 5 adult patients with an initial episode of CDI cared for at Mayo Clinic in Arizona. A baseline stool sample will be collected from the healthy individuals. They will then be given a PPI, omeprazole 20 mg, to be taken once (n=5) or twice (n=5) daily for 1 month. Stool samples will be collected after 1 week and again after 1 month. A final stool sample will be collected 1 month after stopping the omeprazole.~A stool sample will be collected from the CDI subjects before treatment of the infection and again 2 months after treatment to avoid enrolling those at risk for relapse (which most commonly occurs during the first 2 months after treatment)."
88938592|NCT01822990||Atherosclerotic patients|Male patients with intermittent claudication.
88938593|NCT01822990||Control subjects|healthy male subjects with normal results on vascular examination and no cardiovascular risk factors, who are not in receipt of any pharmacological treatment, matched by age within two years with peripheral arterial disease patients
88938594|NCT01823003|Experimental|A. 34 Gy in a single fraction|34 Gy by single fraction Risk-adapted radiation dose.
88938595|NCT01823003|Experimental|B. 54Gy (18Gy/fr. x 3 fractions)|54Gy administered in 3 fraction of 18 Gy, risk adapted radiation dose
88938596|NCT01823003|Experimental|C. 50Gy (12 x 5 fr.s)|54Gy administered in 5 fraction of 12 Gy, risk adapted radiation dose
88938597|NCT01823003|Experimental|D. 60Gy (7.5Gy x 8fr.)|60 Gy administered in 8 fraction of 7.5 Gy, risk adapted radiation dose
89453888|NCT05219123||Single PD cannulation|Patients with native papilla undergoing ERCP for biliary indications with a single inadvertent pancreatic duct cannulation with a guide wire
89453889|NCT03200444|Experimental|Testing of 6 adhesive strips|"Each subject tests six adhesive strips on pre-striped skin.~Standard adhesive 1~standard adhesive 2~Standard adhesive 3~P-4~P-15~P-16~The six strips are applied on abdominal skin. The order to which the adhesive strips are located on the skin is randomized. The subjects will change the adhesive strips at home and the adhesion of the adhesive strips will be measured at 5 visits."
89453890|NCT03119324|Experimental|B-Cure® diode laser|"Thirty patients receiving LLLT by the B-Cure® diode laser (Good Energies, Haifa, Israel) 808nm low power device at 5 Joules/min, 250 milliWatts 15 KiloHertz for 8', (40 Joules each) in contact mode directly over the painful area, twice a day for 7 consecutive days.~The laser must be placed directly over the painful area, after having cleaned it with a soft cotton socket to remove skin impurities that could interfere with therapeutic light absorption.~The first application is performed at the Department of Oral Sciences of Sapienza University of Rome by a laser expert investigator and serves as instruction. The remnants must be performed by the patients themselves at home, once on the first day and twice a day in the following 6 days.~Patients were instructed to perform the applications always at the same time."
89453891|NCT03119324|Placebo Comparator|B-Cure® diode laser sham device|"Thirty patients that follows the same protocol of the SG but receive a B-Cure laser® sham device, seemingly identical to the effective one but devoid of main diode source.~The laser must be placed directly over the painful area, after having cleaned it with a soft cotton socket to remove skin impurities that could interfere with therapeutic light absorption.~The first application is performed at the Department of Oral Sciences of Sapienza University of Rome by a laser expert investigator and serves as instruction. The remnants must be performed by the patients themselves at home, once on the first day and twice a day in the following 6 days.~Patients were instructed to perform the applications always at the same time."
89537161|NCT04983303|Experimental|TICK-B group as intervention group|TICK-B group: The children will receive a picture as they want. They will be asked to trace and color the pictures that need coloring. After the procedure, the child will take his or her picture which he colored during the procedure.
88938598|NCT01823029|Experimental|erythropoietin,injection of iron and enteral nutrition|The patients receive treatment of erythropoietin,injection of iron and enteral nutrition.
88938599|NCT01823029|Experimental|erythropoietin and enteral nutrition.|The patients receive treatment of erythropoietin and enteral nutrition.
88938600|NCT01822509|Experimental|Treatment (ipilimumab, nivolumab)|See Detailed Description.
88938601|NCT01823042|Experimental|enteral nutrition+azathioprine|Patients is fasting and receive enteral nutrition and azathioprine treatment.
88938602|NCT01823042|Experimental|azathioprine|Patients have regular diet and receive only azathioprine treatment.
88938603|NCT01823055|Experimental|Surgery|Transvaginal suture capturing mesh device
88938604|NCT01823068|Experimental|Vandetanib treatment arm|Vandetanib 300 mg once daily orally
88938605|NCT01823081|Active Comparator|Intravitreal bevacizumab (Avastin)|Dosage: 1.25 mg/0.05 ml Frequency: 3 consecutive injections every 4 weeks
88938606|NCT01823081|Active Comparator|Combined intravitreal fasudil and bevacizumab (Avastin)|Dosage: bevacizumab 1.25 mg/0.05 ml + fasudil 0.025mg/0.05ml Frequency: 3 consecutive injections every 4 weeks
88938607|NCT01823094||Variability of measurements|variability of CTP measurements will be determined by repeating the CTP examination, and comparing the resultant blood flow estimates
88938608|NCT01823094||Treatment induced effects|The magnitude of treatment induced effects will be assessed by comparing tumor blood flow estimates before and after treatment
88938609|NCT01823120|No Intervention|No text messages|Patients in the non-intervention group will not receive any text messages. However, they will also receive the routine outpatient follow-up arrangements associated with attendance at an ED with self-harm including the provision of a contact phone number for the Samaritans.
88938610|NCT01823120|Experimental|Supportive and interactive text messages|We will deliver daily supportive and informative text messages for one month followed by one supportive and informative text message every other day the second month and then one weekly text message the third month to patients in the intervention group after they have been discharged from the ED following an episode of self-harm. Supportive text messages will mainly target relieving the patients of mood symptoms and providing them with strategies for dealing with suicidal thoughts while the informative ones will provide patients with a dedicated mobile phone number through which they can receive interactive support from the Samaritans. The text messages will encourage participants to text the Samaritans in times of crisis. Please see appendix I for examples of the relevant text messages.
88938611|NCT01823133|Experimental|gemigliptin only|Multiple administrations of gemigliptin
88938612|NCT01823133|Experimental|rosuvastatin only|Multiple administrations of rosuvastatin
88938613|NCT01823133|Experimental|gemigliptin and rosuvastatin|Multiple administrations of gemigliptin and rosuvastatin
88938614|NCT01823159|Active Comparator|Retigabine|Administration of a single dose of 400 mg retigabine, two hours before the measures
88938615|NCT01823159|Placebo Comparator|placebo|Randomized administration of a single dose of placebo, two hours before the measures.
88938616|NCT01823172|Experimental|Methylene Blue|1% Methylene Blue - 1 ml. Methylene blue dye injection of sentinel lymph node
88938617|NCT01823185|Active Comparator|Clopidogrel|CYP2C19 genotyping will be carried out at the end of the study period. Clopidogrel will be used for treatment for one year according to local protocol. Patients will receive clopidogrel 75 mg per day.
88938618|NCT01823185|Experimental|Ticagrelor or prasugrel|Ticagrelor (90 mg twice daily) or prasugrel ( 10mg once daily or 5mg once daily if the patient older than 75 years or a body weight < 60kg) according to local protocol.
88938619|NCT01823211||ischaemic cardiomyopathy|EP (Electrophysiology) study,magnetic resonance with LGE (Late gadolinium enhancement), ICD implantation
88938620|NCT01823211||non-ischaemic cardiomyopathy|EP study,magnetic resonance imaging with LGE, ICD implantation
89015748|NCT06216509|Other|porto sinusoidal vascular disorder and portal vein thrombosis|patients with porto sinusoidal vascular disorder and portal vein thrombosis either in the context of cirrhosis or non cirrhotic portal vein thrombosis
88938621|NCT01823250|Experimental|CIFFTA|Culturally Informed and Flexible Family-Based Treatment for Adolescents (CIFFTA)involves four months of intervention. Adolescents and families receive one family therapy session per week and an additional session which is either a psycho-educational session for the adolescent and/or parents, or an individual therapy session with the adolescent. There is a total of 2 sessions per week.
88938622|NCT01823250|Active Comparator|Traditional Family Therapy (TFT)|The Traditional Family Therapy condition consists of once per week family therapy based on Structural Family Theory and a didactic group intervention once per week in which HIV/STI risk is discussed.
89453892|NCT03119324|Active Comparator|Nimesulide Ratiopharm® and Flexiban®|"Thirty patients follows the conventional drug therapy protocol, of two non-consecutive cycles of 5 days of Non Steroidal Anti Inflammatory drug, Nimesulide Ratiopharm® (100 mg a day), interspersed with one 5 days cycle of Myorelaxant, Flexiban® (10 mg a day).~From day 1 to 5, patients assumed 50mg of Nimesulide Ratiopharm®, twice a day; from 6th to 10th day they assumed 10mg of Flexiban® in single dose, from day 11 to 15 they assumed 50mg of Nimesulide Ratiopharm® twice a day.~Patients were instructed to assume the therapy always at the same time"
89453893|NCT00415623|Active Comparator|Amlodipine 5mg|
89453894|NCT00415623|Experimental|Amlodipine 10mg|
89453895|NCT05219045|Experimental|RETAIN Programming|The experimental group receives the full set of RETAIN intervention activities.
89453896|NCT05219045|No Intervention|Control|Medical providers who treat both treatment and control group enrollees receive training on stay-at-work/return-to-work best practices
89453897|NCT03206606||Control Group|Primary care physicians and residents in family medicine of family medicine units affiliated with Laval University.
89453898|NCT03206606||Experimental Group|Primary care physicians and residents in family medicine of family medicine units affiliated with Laval University that will use the mobile application SPIRO(c) for a period of four months.
89453899|NCT02287545||Glaucoma, primary|Glaucoma patients undergoing trabeculectomy
89453900|NCT02448056||Pre-treatment|All enrolled HCC patients.
89453901|NCT02448056||Post-treatment one week|All enrolled HCC patients.
89453902|NCT02448056||Post-treatment one month|All enrolled HCC patients.
88938623|NCT01823263|Experimental|Partial sleep deprivation|Partial sleep deprivation: participants will have a 4-h sleep opportunity before a 'Blood Sample' will be taken, and the 'Memory tasks', 'Working memory function task' and 'Portion size task' will be performed. This will be followed by an 'Interference task', followed by repeated blood sampling and an 'Intake task'.
88938624|NCT01823263|Experimental|Normal sleep|Normal sleep: participants will have an 8-h sleep opportunity before a 'Blood Sample' will be taken, and the 'Memory tasks', 'Working memory function task' and 'Portion size task' will be performed. This will be followed by an 'Interference task', followed with repeated blood sampling and an 'Intake task'.
88938625|NCT01823276|Active Comparator|Tyrosine-Containing Bar|150 mg/kg dose of tyrosine per administration, administered twice
88938626|NCT01823276|Placebo Comparator|Placebo Bar|0 mg/kg dose of tyrosine per administration, administered twice
88938627|NCT01823302|Other|nutritional counseling|nutritional counseling
88938628|NCT01823302|Other|nutritional counseling and milk-based supplement|nutritional counseling plus oral milk-based nutrition supplement
88938629|NCT01823315|Experimental|Methotrexate Single-coure chemotherapy|Regimen: Methotrexate 0.4mg/(kg·d) intramuscularly (IM) on days 1-5. If 10-fold fall of hCG achieved 18 days after treatment completion, success of primary single-course chemotherapy was defined and further treatment was withheld; otherwise, failure was defined and the patient was referred to multi-course chemotherapy. During the period of observation for those with success, if the level of hCG became stationary for at least 3 weeks or rose again, the patient was also referred to multi-course chemotherapy. Additional consolidation chemotherapy with 1-3 courses was given for those who achieved CR by multi-course chemotherapy, but not by single-course regimen.
88938630|NCT01823315|Experimental|Methotrexate+dactinomycin Single-dose chemotherapy|"Regimen: dactinomycin d 0.6mg/m2, IV, on day1, 2; methotrexate 100mg/m2, IV, on day1 (after Act-d); methotrexate 200mg/m2, IVgtt, on day1 (after methotrexate, 500ml NS, >4h).~If 10-fold fall of hCG achieved 18 days after treatment completion, success of primary single-course chemotherapy was defined and further treatment was withheld; otherwise, failure was defined and the patient was referred to multi-course chemotherapy. During the period of observation for those with success, if the level of hCG became stationary for at least 3 weeks or rose again, the patient was also referred to multi-course chemotherapy. Additional consolidation chemotherapy with 1-3 courses was given for those who achieved CR by multi-course chemotherapy, but not by single-course regimen."
88938631|NCT01823315|Active Comparator|MTX multiple courses chemotherapy|"Regimen: methotrexate 0.4mg/(kg·d) intramuscularly (IM) on days 1-5, 2-week intervals. Patients continue on treatment until 1 beta HCG titer is below the institutional normal. Patients then receive at least 1 additional consolidation treatment.~After treatment, all the patients were asked for contraception with condom or oral contraception. Regular hCG surveillance, once a month for 3 consecutive months and once every 3 months for 2 years, was performed. During follow-up period, pelvic ultrasound and pulmonary X ray or CT scan were conducted if needed."
88938632|NCT01823354|Other|Patients|Polysomnography, Assessment of executive functions, Clinical scales, Medical consultation
88938633|NCT01823354|Other|Controls|Polysomnography, Assessment of executive functions, Clinical scales Medical consultation
88938634|NCT01823367|Experimental|Lifestyle counseling mom only|This intervention, delivered to groups of mothers only, builds upon the evidence-based curriculum used in the Diabetes Prevention Program (DPP) and incorporates into the curriculum detailed education regarding ways to help their children adopt healthier lifestyle behaviors.
89201045|NCT00904527|No Intervention|without relaxation|Patients have no relaxation (only medical treatment+ education)
89453903|NCT03134001|Experimental|Test Group|Patients receiving oral analgesics via the PCoA™ Acute device
89453904|NCT03134001|No Intervention|Control Group|Patients receiving oral analgesics by nurse, upon request
89453905|NCT03118544||Patients undergoing CTO PCI|Evaluates the effect of the DyeVert System on contrast volume administration in patients undergoing clinically-indicated CTO PCI. The system allows monitoring and display of contrast volumes that are manually injected during the procedure which will be compared to physician entered contrast usage thresholds during angiographic procedures.
89453906|NCT01969409|Placebo Comparator|Placebo|These subjects will receive i.v. placebo (5% dextrose in water) administered identically to the rituximab.
89453907|NCT01969409|Experimental|Rituximab|Rituximab i.v. given on two occasions, with 14 days between doses.
89453908|NCT00413205|Placebo Comparator|Placebo|po daily
89453909|NCT00413205|Experimental|RAR Gamma|5mg po daily
88938635|NCT01823367|Experimental|Lifestyle counseling mom and child|The second intervention is delivered to both mothers and children in separate groups using the same parent Diabetes Prevention Program (DPP) curriculum, but adds a group program for children that directly teach these children strategies for eating better and increasing physical activity.
88938636|NCT01823380|Other|Amyotrophic lateral sclerosis|Blood test
88938637|NCT01823393|Experimental|Heparin|injection of unfractionated heparin (50 IU / kg)
88938638|NCT01823393|Placebo Comparator|NaCl|without heparin
88938639|NCT01823406|Experimental|Type 1 Diabetes no complications.|Each cohort group will be admitted to the Michigan Clinical Research Unit for Blood glucose Clamp studies. Each subject will have a Euglycemic clamp (normal blood sugar clamp) for 4 hours and a hyperglycemic clamp (elevated blood sugar to 300) for 4 hours. Once the subject is clamped, bloods and urine will be collected to assay for specific metabolomics and proteomic biomarkers. We will perform the same clamps for each cohort.
88938640|NCT01823406|Experimental|Type 1 Diabetes with microalbuminuria|Each cohort group will be admitted to the Michigan Clinical Research Unit for Blood glucose Clamp studies. Each subject will have a Euglycemic clamp (normal blood sugar clamp) for 4 hours and a hyperglycemic clamp (elevated blood sugar to 300) for 4 hours. Once the subject is clamped, bloods and urine will be collected to assay for specific metabolomics and proteomic biomarkers. We will perform the same clamps for each cohort.
88938641|NCT01823406|Experimental|Type 1 Diabetes with advanced complications.|Each cohort group will be admitted to the Michigan Clinical Research Unit for Blood glucose Clamp studies. Each subject will have a Euglycemic clamp (normal blood sugar clamp) for 4 hours and a hyperglycemic clamp (elevated blood sugar to 300) for 4 hours. Once the subject is clamped, bloods and urine will be collected to assay for specific metabolomics and proteomic biomarkers. We will perform the same clamps for each cohort.
88938642|NCT01823406|Experimental|Aged and sex matched healthy control volunteers|Each cohort group will be admitted to the Michigan Clinical Research Unit for Blood glucose Clamp studies. Each subject will have a Euglycemic clamp (normal blood sugar clamp) for 4 hours and a hyperglycemic clamp (elevated blood sugar to 300) for 4 hours. Once the subject is clamped, bloods and urine will be collected to assay for specific metabolomics and proteomic biomarkers. We will perform the same clamps for each cohort.
88938643|NCT01823419||7-9 year olds|Typically developing 7- to 9-year-olds will be enrolled and tested.
88938644|NCT01823445|Experimental|Xylitol disk|Daily use of 8 disks containing 0.5 grams xylitol each for two weeks. The disks adhere to gum tissue with a food grade adhesive backing and slowly dissolve. The disks are applied one on each side of the mouth in the morning after breakfast, again at midday, and four are applied, two on each side, at bedtime.
88938645|NCT01823458|Experimental|Lottery Insurance|All participants receive a one time, $10 payment for attending the first exercise class of the 12 week session. Participants in the 'Lottery Insurance' arm receive a lottery ticket valued at $20 for attending either a Monday or Tuesday exercise class. They have the option to insure their lottery ticket by attending a second exercise class during the week on either Wednesday or Thursday. If they do not attend the second class, they have a 90% chance of winning the weekly lottery. This sequence is repeated each week over the 12 week exercise session.
88938646|NCT01823458|Experimental|Standard Lottery|All participants receive a one time, $10 payment for attending the first exercise class of the 12 week session. Subjects in the 'Standard Lottery' arm receive a lottery ticket valued at $20 for attending either a Monday or Tuesday exercise class. They also receive the expected value of the insurance ($2) for attending a second exercise class during the week on either Wednesday or Thursday. They have a 90% chance of winning the weekly lottery. This sequence is repeated each week over the 12 week exercise session.
88938647|NCT01823471|Experimental|I-scan first group|After the caecum is reached patients will be first examined with high definition i-scan endoscopy. Each colonic segment will be investigated in a back to back fashion, during the second pass white light will be used.
88938648|NCT01823471|Active Comparator|White light first group|After the caecum is reached patients will be first examined with high definition white light endoscopy. Each colonic segment will be investigated in a back to back fashion, during the second pass i-scan will be used.
88938649|NCT01823484|Experimental|AN 69 ST hemofilter|Use AN 69 ST hemofilter during CRRT
88938650|NCT01823484|Active Comparator|AN 69 hemofilter|Use AN 69 hemofilter during CRRT
88938651|NCT01823523|Active Comparator|Cefazolin, Cephalexin, Clindamycin|"Group will be receiving 1 day of IV cefazolin or clindamycin followed by 2 days of oral cephalexin or clindamycin~Clindamycin will be used in patients with allergy"
88938652|NCT01823523|Placebo Comparator|cefazolin, clindamycin, placebo|"Group will receive 1 day IV cefazolin, or clindamycin followed by 2 days of oral placebo~clindamycin will be used if patient has allergy"
88938653|NCT01823575|Experimental|Silicone-covered metallic ureteral stent|Deployment of a silicone-covered metallic ureteral stent for malignant ureteral obstruction and compare the results with placement of a double-J stent in terms of primary patency rate at 3 month follow-up (primary end point)
88938654|NCT01823575|Active Comparator|Double-J stent|Placement of a double-J stent for malignant ureteral obstruction and compare these results to deployment of a silicone-covered metallic stent in terms of primary patency rate at 3 month follow-up.
88938655|NCT01823588|No Intervention|Usual care|Educational program and usual cardiovascular prevention.
88938656|NCT01823588|Experimental|Nurse-led reminder through email|In addition to usual care and educational program, the intervention group will also receive email alerts and phone calls from the nurse-care manager (NCM)
88938657|NCT01823601|Active Comparator|Seminars in Health|This group of volunteers will attend to seminars in health. Each seminar will last about 120 minutes, a similar period of time used for training experimental group.
89453910|NCT03118856||HD-WLE|Intervention: Prediction of polyp histology with HD-WLE
89453911|NCT03118856||EC|Intervention: Prediction of polyp histology with EC
89453912|NCT02448212|Experimental|PART 1 (Test/Retest)|Dosing with [11C]TASP0410699 for PET imaging without dosing of TS-121
89453913|NCT02448212|Experimental|PART 2 (PET Receptor Occupancy Study)|Dosing with [11C]TASP0410699 for PET imaging with dosing of TS-121
89453914|NCT05218577|Experimental|HSFF group|the group was given high selenium funtion selenium for 3 months
88938658|NCT01823601|Experimental|Behavioral Management Program|"Behavioral Management Program consists in to teach to the volunteers procedures which involve autogenic muscle relaxation, progressive self-focus meditation and cognitive-behavioral training to change thoughts, beliefs and behavior in order to control emotions. This program will consist in 10 weekly sessions of about 120 minutes each."
88938659|NCT01823627|Other|Spirometry with reversibility test|Spirometry with reversibility test
88938660|NCT01823640|Experimental|Placebo-HRV|inoculation with placebo followed by inoculation with HRV
88938661|NCT01823640|Experimental|HRV-HRV|inoculation with HRV followed by a second inoculation with HRV
88938662|NCT01823666||Mild cognitive impairment|People with cognitive complaint will be recruited. Who can be diagnosed as mild cognitive impairment will be enrolled according to the MCI criteria.
88938663|NCT01823666||Control|Normal cognition.
88938664|NCT01823692|Other|Distal Radius Fracture|after manipulation and reduction were performed by single emergency medicine specialist under Bier block regional anesthesia or procedural sedation-analgesia, The ultrasonography was performed by the single emergency department physician in a long axis both in a anterioposterior and lateral views in determining whether the distal and proximal distal to a fracture was in a straight line (less than 3 mm difference) or not?
88938665|NCT01823705|Experimental|Gastric Electrical Stimulation (GES)|Gastric Electrical Stimulation (GES) therapy for the treatment of obesity.
88938666|NCT01823744|Experimental|micronutrient supplementation|"All the enrolled subjects will recieve orally, onca a day, during school days a chocolate bar including vitamins and minerals.~The micronitrient supplementation will be consumed over 6 weeks, 5 days/week."
88938667|NCT01823757||Non-pharmaceutical care|Veterans do not receiving pharmaceutical care
88938668|NCT01823757||Pharmaceutical care|Veterans receiving pharmaceutical care
88938669|NCT01823770|Active Comparator|Rotigotine|Patients randomized to rotigotine who will be treated with rotigotine patchs
88938670|NCT01823770|Placebo Comparator|Placebo|Patients randomized on the placebo group who will be treated with placebo patchs
88938671|NCT01823770|No Intervention|Control group|Volunteers matched on sex, age and BMI with RLS patients who will not receive treatment(no treatment)
88938672|NCT01823783|Other|DMD infant|Muscle biopsy
88938673|NCT01823783|Other|Control infant|Muscle biopsy (during lower limb operation surgery for pure orthopedic causes)
88938674|NCT01823796||Healthy women.|35 healthy women. Control group.
88938675|NCT01823796||Fibromyalgia women group|35 women with fibromyalgia were measured at baseline of the observational study.
88938676|NCT01823809|Other|Imaging arm|There is one study arm only. The imaging modalities will be performed in all patients.
88938677|NCT01823822|Experimental|Oral protein supplement (Tested product)|
88938678|NCT01823822|Active Comparator|Iso-caloric supplement (Control product)|
88938679|NCT01823874|Experimental|ID virtual reality distraction|virtual reality distraction
88938680|NCT01823874|Experimental|HMD virtual reality distraction|virtual reality distraction
88938681|NCT01823887|Experimental|Left Sided Stimulation|Left cervical Vagus Nerve Stimulation (VNS)
88938682|NCT01823887|Experimental|Right Sided Stimulation|Right Cervical Vagus Nerve Stimulation (VNS)
88938683|NCT01823900|Experimental|Test and reference formulations|Test formulation and reference formulation given orally 7 days apart in a fasted state
88938684|NCT01823913|Experimental|Test and reference formulations|Test formulation and reference formulation given orally 14 days apart in a fasted state
88938685|NCT01823926|Active Comparator|Control Group|Noninvasive ventilation + jet nebulizer
88938686|NCT01823926|Experimental|Experimental Group|Noninvasive ventilation + vibrating mesh nebulizer
88938687|NCT01823939|Other|Males / Females (Healthy)|Part A: This initial part of the study will be conducted in adult Bangladeshi healthy volunteers (4 males, 4 females) to assess the pharmacokinetics, safety, and tolerability of single doses of iOWH032. Participants will be admitted to the Clinical Trial Unit (CTU) of icddr,b (located at a 10 minute drive from the icddr,b main campus) the day prior to dosing and remain for 48 hours after dosing, unless treatment and/or follow-up of an adverse event (AE) require longer in-unit observation or treatment.
88938688|NCT01823939|Other|Males (Patient)|Part B: Patients will be eligible for the study if they have clinically severe dehydration and meet all other inclusion and exclusion criteria. Upon signing consent, they will be admitted to the Research Ward of the Dhaka Hospital of icddr,b.
88938689|NCT01823952||Males|Adult 18-65
88938690|NCT01823965|Experimental|ranibizumab|
89453915|NCT05218577|Experimental|Selenium suplemen group|the group was given selenium suplemen
89453916|NCT05218577|Placebo Comparator|Control group|the group was given placebo
88938691|NCT01823978|Experimental|BPX-201|BPX-201 vaccine plus AP1903
88938692|NCT01824004|Experimental|S-1,chemoradiotherapy, adjuvant treatment|Pts with radically D2 resected adenocarcinoma of the stomach or GEJ in AJCC stage Ib-IV (M0) were eligible for this study. Pts were treated with S-1 (40-60 mg depending on BSA) b.i.d. for 3 wks, and cisplatin (60 mg/m²) iv on day 1, followed by a 2-wk rest period, within a 5-wk cycle. Subsequently, radiotherapy (RT) started which consisted of 25 fractions of 1.8 Gy to a total dose of 45 Gy in 5 wks (5 fractions/wk). On RT days, S-1 (40-60 mg depending on BSA ) b.i.d., 5 days/wk was given. One month after the completion of RT, two 5-wk cycles of S-1/ciplatin chemotherapy were given.
88938693|NCT01824017|Other|Blood Draw|Data will be collected at patients' usual follow-up intervals for monitoring their metabolic conditions (i.e., T2D, hyperlipidemia, hypertriglyceridemia, etc.), which will be at 3 or 6 month intervals with a +/- 30 day window. Standard treatment surveillance measures such as hemoglobin A1c, LDL, and triglyceride levels will be performed as the standard of care for patients with MsY. Blood samples for these tests will be drawn while subjects are fasting
88938694|NCT01824030|Active Comparator|FFR guided PCI arm|Patients with angiographic intermediate coronary artery stenosis randomized to FFR assessment. PCI performed only if FFR ≤ 0.80
89201046|NCT00348595|Active Comparator|1|5mg/day Arm: one 5 mg active Revlimid capsule and one 25 mg matched placebo capsules PO QAM (every morning) (at approximately the same time) days 1-21 days (28-day cycles).
89537162|NCT04983303|Experimental|Coughing trick|Coughing trick: Children in this group will be taught how to cough during the procedure. coughs with start moderate force and then coughs again which coincides with a needle procedure, such as venipuncture for example.
89201047|NCT00348595|Active Comparator|2|25 mg/day Arm: one 25 mg active Revlimid capsule and one 5 mg matched placebo capsule PO QAM (every morning) (at approximately the same time) days 1-21 (28 day cycles).
89201048|NCT02538939|Experimental|Injection of sodium thiosulfate|Needling and lavage of calcific tendinitis of the rotator cuff followed by the injection of sodium thiosulfate
88938695|NCT01824030|Active Comparator|OCT guided PCI arm|"Patients with angiographic intermediate coronary artery stenosis randomized to OCT. PCI will be performed if:~percentage area stenosis ≥75 %~percentage area stenosis between 50 and 75% and minimal lumen area <2.5 mm2~percentage area stenosis between 50 and 75% and major plaque ulceration"
89201049|NCT00904605|Experimental|1- Lidoderm®|Lidocaine patch 5% (Lidoderm®, Endo Pharmaceuticals Inc.), 1⅓ patches applied topically to each affected knee every 24 hours (q24h)
89201050|NCT00904605|Active Comparator|2-Celecoxib 200mg|Celecoxib (Celebrex®, G.D. Searle & Co., Chicago, IL), one 200 mg oral capsule QD
89201051|NCT00904761|Experimental|exercise|arm: intervention
89201052|NCT00337129|Experimental|eribulin mesylate|eribulin mesylate
89201053|NCT00905073|Experimental|cyclosporin+Methotrexate|cyclosporin treatment at 7.5 mg/kg/day for 6 weeks and then 4 mg/kg/day for on year and methotrexate 5 mg/kg/day for one year.
89201054|NCT02538705|Experimental|Neovasculgen|
89201055|NCT00905229|Active Comparator|PO (by mouth)|2.5 mg P.O Vitamin K
89201056|NCT00905229|Active Comparator|IV (intravenous )|0.5 mg IV Vitamin K
89201057|NCT01052935|No Intervention|Arm 1|This is a phlebotomy study.
89201058|NCT00905463||Transplantation|Lung transplantation candidates
89201059|NCT00905541|No Intervention|No treatment|Phase A: No treatment
88938696|NCT01824056|Experimental|18F-DTBZ for Parkinson's Disease|This study will compare the brain uptake of 18F- DTBZ in 40 patients with PD, 40 patients with MSA, 20 patients with CBD, and 20 patients with PSP . Each evaluable subject involved in this study must fulfill all the inclusion and exclusion criteria according the subject grouping, each subject will have 3 visits in this study. Safety measurement will be evaluated by medical history, vital signs, physical examinations, laboratory examinations and collecting of adverse events.
89201060|NCT00905541|Experimental|simvastatin chronic|Phase B: 40 mg/day simvastatin
89201061|NCT00905541|Experimental|simvastatin acute-on-chronic|Phase C: 80 mg simvastatin acute-on-chronic
89201062|NCT00348283|Placebo Comparator|Double Blind|Blinded study through Week 52. Adalimumab compared to placebo during blinded portion.
89453917|NCT03134079|Active Comparator|full sugar recipe|"Each subject was randomly assigned to one of six possible sequences to taste three recipes of each test item. Oatmeal and tea were served together and tastings occurred over three weeks; tasting of apple crisp occurred over three different weeks. Tastings of the three recipes occurred one week apart. The three recipes were full sugar recipe (FS), reduced sugar recipe (RS) and reduced sugar plus spice recipe (RSS). Each subject was randomly assigned to one of the below sequence schedules for each taste test whereby A, B, and C refer to one of the three recipes (FS, RS, or RSS):~Sequence 1: A, B, C Sequence 2: A, C, B Sequence 3: B, A, C Sequence 4: B, C, A Sequence 5: C, A, B Sequence 6: C, B, A"
89537163|NCT04983303|Experimental|Balloon inflation group as intervention group|Balloon inflation group: In this group, the children will receive a balloon colored as their favorite, and they will be asked to inflate the balloon before starting the venipuncture procedure.
89201063|NCT00348283|Other|Open Label|Note: No comparator was used in Open-Label portion of study. From Week 8, subjects could have switched to open-label (OL) adalimumab 40mg administered subcutaneously (SC) every other week (eow)or OL adalimumab 40 mg SC every week (ew) dosing to treat disease flare or non-response. At Week 52, all remaining subjects were allowed to switch to the Open-Label portion of the study.
89201064|NCT00905619||Control|No kidney disease
89201065|NCT00905619||PreHD kidney disease|Kidney disease stage 4 or below
89201066|NCT00905619||Hemodialysis|Kidney disease receiving hemodialysis
89201067|NCT00905697||Living donor lung transplantation|Living lung transplantation donors
89201068|NCT00905775||1 Isoflurane|The first group (G1) will be submitted to inhalational general anesthesia with isoflurane (1 CAM, evaluated by expired concentration of isoflurane)
89201069|NCT00905775||2 Propofol|The second group (G2) to targeted venous general anesthesia controlled with propofol. The targeted concentration of propofol will be kept at the predicted plasma concentration from 1 to 2 µg.ml-1 by means of a Diprifusor® infusion pump. During the interval from 10 minutes preceding ECC initiation to 10 minutes after ECC, the propofol concentration will be increased to 2 or 3 µg.ml-
89201070|NCT00906633||Outcome of combination antifungal therapy|
89201071|NCT01055899|Experimental|Dose 1|First dose of SC REGN88
89201072|NCT01055899|Experimental|Dose 2|Second dose of SC REGN88
89201073|NCT01055899|Experimental|Dose 3|Third dose of SC REGN88
89201074|NCT00336895|Experimental|Liver Transplant Subjects|All subjects in this study will receive Myfortic 360mg or 720 mg BID for 90 days.
89201075|NCT01059019|Sham Comparator|Control|Twenty patients labeled as group A (Control Group) will not receive the omega-3 supplement. The Control Group will be treated in the same standard professional way as our normal refractive patients.
89201076|NCT01059019|Experimental|Treatment|20 patients labeled as group B (Treatment group) will be given omega- 3 supplements 1 capsule 3 x a day for 2 weeks pre op and 1 month post op plus the regular post op medications. From these supplements, this will be equivalent to 750 mg of omega 3 fatty acids (both EPH and DHA), 1000 mg of Flaxseed oil, and about 183 IU of vitamin E per day
89201077|NCT00336583|Experimental|Oxaliplatin, response|relapsed or refractory non-Hodgkin's lymphoma
89201078|NCT00336505|Active Comparator|Clarithromycin|
89201079|NCT00336505|Experimental|Cethromycin|
89201080|NCT00357877|Placebo Comparator|Placebo Dental Coating|Dental coating with all ingredients except Chlorhexidine topically applied by dental professional supragingivally to the full dentition
89201081|NCT00357877|Active Comparator|Active Dental Coating|10% w/v chlorhexidine acetate coating FDA IND #45466. Dental coating with all ingredients including Chlorhexidine topically applied by dental professional supragingivally to the full dentition
88938697|NCT01824069|Experimental|Autologous mesenchymal stem cells|Intramuscular injection of a suspension of adult mesenchymal stem cells derived from adipose tissue at doses of 1 million per kilo of weight in a dosis
88938698|NCT01824095|Placebo Comparator|placebo|Acute phase (1st treatment through Week 4): Placebo. 2 capsules 3 x day. Chronic phase (Weeks 5-16): Placebo. 1 capsule 3 x day.
88938699|NCT01824095|Experimental|dietary supplement|"Acute phase (1st treatment through Week 4): Ligaplex 1. Ligaplex 1 supplies nutrients to support connective tissue and reduce inflammation. The protocol is commonly used in chiropractic practice and suggested by Standard Process: 2 capsules 3 x day.~Chronic phase (Weeks 5-16): Glucosamine Synergy. This supplement maintains connective tissue and joint health. The protocol is commonly used in chiropractic practice and suggested by Standard Process: 1 capsule 3 x day."
88938700|NCT01824108|Active Comparator|control group: Lumbar discectomy|Lumbar discectomy alone
89453918|NCT03134079|Experimental|reduced sugar recipe|"Each subject was randomly assigned to one of six possible sequences to taste three recipes of each test item. Oatmeal and tea were served together and tastings occurred over three weeks; tasting of apple crisp occurred over three different weeks. Tastings of the three recipes occurred one week apart. The three recipes were full sugar recipe (FS), reduced sugar recipe (RS) and reduced sugar plus spice recipe (RSS). Each subject was randomly assigned to one of the below sequence schedules for each taste test whereby A, B, and C refer to one of the three recipes (FS, RS, or RSS):~Sequence 1: A, B, C Sequence 2: A, C, B Sequence 3: B, A, C Sequence 4: B, C, A Sequence 5: C, A, B Sequence 6: C, B, A"
88938701|NCT01824108|Experimental|Treatment group: lumbar discectomy + Wallis implant|lumbar discectomy combined with Wallis interspinous dynamic stability system
88938702|NCT01824121|Active Comparator|immediate stem cell therapy|patients will undergo active intervention i.e. they will be given stem cell therapy immediately. After 6 months they will undergo a sham procedure.
89453919|NCT03134079|Experimental|reduced sugar plus spice recipe|"Each subject was randomly assigned to one of six possible sequences to taste three recipes of each test item. Oatmeal and tea were served together and tastings occurred over three weeks; tasting of apple crisp occurred over three different weeks. Tastings of the three recipes occurred one week apart. The three recipes were full sugar recipe (FS), reduced sugar recipe (RS) and reduced sugar plus spice recipe (RSS). Each subject was randomly assigned to one of the below sequence schedules for each taste test whereby A, B, and C refer to one of the three recipes (FS, RS, or RSS):~Sequence 1: A, B, C Sequence 2: A, C, B Sequence 3: B, A, C Sequence 4: B, C, A Sequence 5: C, A, B Sequence 6: C, B, A"
89453920|NCT02447978||PCR-positive pertussis cases|Cases will be all individuals who tested PCR-positive for pertussis and negative for parapertussis during the study period and who received 5 doses of DTaP vaccines (either manufactured by GSK or any brand, depending on study objective) through 84 months of age before testing PCR-positive.
89453921|NCT02447978||PCR-negative pertussis controls|Controls will consist of persons who tested PCR-negative for both pertussis and parapertussis and who received 5 DTaP doses (either manufactured by GSK or any brand, depending on study objective) before testing PCR negative.
89453922|NCT02447978||KPNC-matched controls|Controls will consist of all KPNC members of the same sex, age (year and quarter of birth), race or ethnic group (7 groups; 6 for reported, 1 for imputed), and medical centre as each pertussis case and who were members on the date the case tested PCR-positive (anchor date).
89453923|NCT03962231|Active Comparator|Rotator Cuff Unloading Exercise Program|Patients in this group will perform semi-closed kinetic chain elevation exercises, deltoid re-education exercises, assisted arm elevation and scapula control exercises.
89453924|NCT03962231|Active Comparator|Rotator Cuff Loading Exercise Program|Patients in this group will perform conventional exercises with focus on lateral rotation, medial rotation and arm elevation.
89453925|NCT01909895|Experimental|Anger induction|The participant will be asked to undergo a validated anger induction task.
89453926|NCT01909895|Experimental|Depressed Mood Induction|The participant will be asked to undergo a validated depression/sadness induction task.
89453927|NCT01909895|Experimental|Anxiety Induction|The participant will be asked to undergo a validated anxiety induction task.
89453928|NCT01909895|Other|Neutral emotion task|The participant will be asked to undergo a validated neutral task (i.e. count aloud by ones, starting with one and ending with 100, over and over, until the task period has ended).
89453929|NCT00150813|Experimental|Levetiracetam|Subjects received open-label Levetiracetam.
88938703|NCT01824121|Sham Comparator|delayed stem cell therapy|patients allocated to delayed stem cell therapy will undergo a sham procedure (incannulation of the femoral vein and infusion of saline solution). They will receive stem cell therapy after 6 months
89453930|NCT02712788|Active Comparator|Milrinone|Milrinone will be administered intravenously at an initial rate of 0.75mCg/kg/min and titrated based on symptoms in addition to hyperdynamic therapy and angiographic therapy as indicated per institutional protocol.
89537164|NCT04983303|No Intervention|Standard care provided group as control group|Standard care provided group as the control group
88938704|NCT01824134|Active Comparator|Klean & Klear|aloe vera gel
88938705|NCT01824134|Active Comparator|The Skin Gel|aloe vera gel
88938706|NCT01824147||CABG Patients|Patients undergoing surgery for coronary revascularization.
88938707|NCT01824173|Experimental|Amino Acid Infusion in Lean|Amino Acid Infusion in Lean
88938708|NCT01824173|Experimental|Amino acid Infusion in Obese|Amino acid Infusion in Obese
88938709|NCT01824173|Experimental|Exercise in lean|Exercise in lean
88938710|NCT01824173|Experimental|Exercise in Obese|Exercise in Obese
88938711|NCT01824186|Experimental|SILC|Subjects in this arm were randomized to undergo single-incision laparoscopic cholecystectomy, through a transumbilical incision
88938712|NCT01824186|Active Comparator|LC|Subjects in this arm were randomized to undergo conventional 4-port laparoscopic cholecystectomy. Wound sites at umbilicus, right hypocondrium, epigastrium and right flank
88938713|NCT01824199|Experimental|Omeprazole|Patients will undergo whole blood testing for CYP2C19 genotype and will be started on omeprazole 40 mg once daily in the morning 30 minutes before breakfast. The Mayo Dysphasia Questionnaire 30 day (MDQ-30day) will be used during the study. At the end of 8 weeks, patients will undergo dual probe pH/impedance testing on therapy and a clinically indicated endoscopy to rule out Barrett's esophagus and assess healing. CYP2C19 genotyping will be performed in the Mayo laboratory.
88938714|NCT01824212||ICD-patients|Patients to whom cardiac fibrillation will be induced during the implantation of an implantable cardioverter defibrillator (ICD) or patients with an already implanted ICD, which function needs to be revised and during the revision cardiac defibrillation will be induced.
88938715|NCT01824225|Active Comparator|PRN injection of aflibercept|Intravitreal aflibercept
88938716|NCT01824225|Active Comparator|Two months injection of aflibercept|Intravitreal afilibercept
88938717|NCT01824238|Experimental|Anacetrapib|Participants will receive 100-mg anacetrapib tablet, orally, once-daily for 12 weeks.
88938718|NCT01824238|Placebo Comparator|Placebo|Participants will receive placebo tablet, orally, once daily for 12 weeks.
88938719|NCT01824251|Experimental|NPB-01|Intravenous immunoglobulin
88938720|NCT01824264|Experimental|LIK066 2.5 mg|Patients receive 2.5 mg of LIK066 once daily for 12 weeks
88938721|NCT01824264|Experimental|LIK066 5 mg|Patients receive 5 mg of LIK066 once daily for 12 weeks
88938722|NCT01824264|Experimental|LIK066 10 mg|Patients receive 10 mg of LIK066 once daily for 12 weeks
88938723|NCT01824264|Experimental|LIK066 25 mg|Patients receive 25 mg of LIK066 once daily for 12 weeks
88938724|NCT01824264|Experimental|LIK066 50 mg|Patients receive 50 mg of LIK066 once daily for 12 weeks
88938725|NCT01824264|Experimental|LIK066 100 mg|Patients receive 100 mg of LIK066 once daily for 12 weeks
88938726|NCT01824264|Experimental|LIK066 150 mg|Patients receive 150 mg of LIK066 once daily for 12 weeks
88938727|NCT01824264|Active Comparator|Sitagliptin 100 mg|Patients receive 100 mg sitagliptin once daily for 12 weeks
88938728|NCT01824264|Placebo Comparator|Placebo|Patients receive placebo for 12 weeks
88938729|NCT01824277|No Intervention|Group 1|Group 1 - Standard Pre-operative Diabetes Care
88938730|NCT01824277|Experimental|Group 2|Group 2 - Structured Pre-operative Diabetes Optimization
88938731|NCT01824329|Active Comparator|Prostate capsule sparing cystectomy Group|Prostate capsule sparing cystectomy involves removing the entire bladder.
88938732|NCT01824329|Active Comparator|Nerve sparing cystectomy Group|Nerve sparing cystectomy involves removal of the whole bladder and the entire prostate.
88938733|NCT01824368|Experimental|People with liver transplantation|People with liver transplantation over 2 years following treatment with immunosuppression including cyclosporine or tacrolimus.
88938734|NCT01824381|Experimental|Amniotic membrane in large wounds|
88938735|NCT01824407|Active Comparator|Active device plus standard of care|Active device plus standard of care
88938736|NCT01824407|Sham Comparator|Sham device plus standard of care|dermaPACE device that uses a dummy applicator that does not emit shock waves
88938737|NCT01824420|Experimental|Study group|Tolterodine (Detrusitol) 4mg QD and Oxybutynin (Ditropan) ER 5mg QD
88938738|NCT01824420|Experimental|Control group|Tolterodine (Detrusitol) 4mg QD
88938739|NCT01824433|Active Comparator|venlafaxine|venlafaxine 75-225mg qd
88938740|NCT01824433|Active Comparator|fluoxetine|fluoxetine 20-60mg qd
88938741|NCT01824459|Active Comparator|S-1 + cisplatin(SP)|S-1：40~60mg bid，d1~14 q3W cisplatin：60mg/m2，iv drip ，d1,q3W Number of Cycles: until progression or unacceptable toxicity develops.
88938742|NCT01824459|Experimental|S-1+Oxaliplatin（SOX）|S-1：40~60mg bid，d1~14 q3W oxaliplatin：130mg/m2，iv drip for 2h，d1,q3W Number of Cycles: until progression or unacceptable toxicity develops.
88938743|NCT01824485|Experimental|Group 2|Patients from Group 2 will receive an intra-articular injection of 1 ampoule (2ml) of OSTEONIL®, on a weekly basis, for 3 weeks (total of 3 injections)
88938744|NCT01824485|Experimental|Group 1|Patients from Group 1 will receive a single intra-articular injection of 3 ampoule (6ml) of OSTEONIL®
88938745|NCT01824511|Experimental|Smokers Cease Smoking|Participants are paid to quit smoking without using any medications.
88938746|NCT01824524|Experimental|OROS Hydromorphone|
88938747|NCT01824550|Experimental|home-based exercise training condition|Home based endurance exercise training
88938748|NCT01824550|No Intervention|attention control condition|Attention control condition - home based flexibility training
88938749|NCT01824563||study population|Subjects will need to be standard CI patients acording to national implant criteria and the study criteria.
88938750|NCT01824615|Experimental|Sunitinib|Use Sutent for treatment of recurrent / persisted OCCA
88938751|NCT01824628||• HIV positive subjects receiving antiretroviral regimen|
88938752|NCT01824628||• HIV negative subjects from the pre-admission surgical clinic|
88938753|NCT01824641|Experimental|Eliminate|Eliminate aspiration catheter
88938754|NCT01824641|Active Comparator|Conventional primary angioplasty|Patients treated with conventional primary angioplasty
88938755|NCT01824654|Experimental|Rigid and Elastic registration softwares|
88938756|NCT01824667|Experimental|B-GOS|2.75g daily for 4 weeks
88938757|NCT01824667|Placebo Comparator|Maltodextrin|2.75g daily for 4 weeks
88938758|NCT01824680|Experimental|obesity|
89453931|NCT02712788|Placebo Comparator|Placebo|Placebo (Normal Saline) will be administered intravenously and titrated based on symptoms in addition to hyperdynamic therapy and angiographic therapy as indicated per institutional protocol.
89453932|NCT05218421||Participants|Patients with a carotid artery stenosis ≥50% according to clinically performed imaging (i.e. duplex, computed tomography angiography (CTA), or magnetic resonance angiography (MRA)) that are scheduled for a CEA.
89453933|NCT00035529|Other|1|
89453934|NCT00035529|Active Comparator|2|
89453935|NCT00035529|Active Comparator|3|
88938759|NCT01824706||craniectomy|craniectomy
88938760|NCT01824719||Allergic group|All patients who used Reduning Injection have anaphylaxis.
89453936|NCT03206528||VSMS with ear unit|application of Vital Signs Monitoring System with ear unit for 6-10 days during hospitalization (throughout their admission period)
89453937|NCT03206528||VSMS without ear unit|application of Vital Signs Monitoring System without ear unit for 6-10 days during hospitalization (throughout their admission period)
89453938|NCT02449928|Active Comparator|lactate group,|
89453939|NCT02449928|Active Comparator|control group|
89453940|NCT00356109|Experimental|1|
89453941|NCT00356109|Active Comparator|2|
89453942|NCT02308111|Experimental|Obeticholic Acid (OCA) 5 mg to 10 mg|Obeticholic Acid (OCA) 5 mg for a minimum 3 months and then titrating up to a maximum 10 mg for the remainder of the trial (based on tolerability and CP Score).
89453943|NCT02308111|Placebo Comparator|Placebo|
89453944|NCT03206138|Experimental|GX-188E, GX-I7|GX-188E + GX-I7
89453945|NCT03206138|Experimental|GX-188E, Imiquimod|GX-188E + Imiquimod
89453946|NCT03195842|No Intervention|Usual discharge care|Standard discharge instructions, meaning conversation with physician, usually via interpreter, along with written instructions compiled by the nurse. Written instructions include pre-translated handouts for common languages, and untranslated (English) patient-specific instructions.
88938761|NCT01824719||Control group|All patients who used Reduning Injection don't have anaphylaxis.One allergic group patient should matched four control group patients.
88938762|NCT01824732||Allergic group|All patients who used Tanreqing Injection have anaphylaxis.
88938763|NCT01824732||Control group|All patients who used Tanreqing Injection don't have anaphylaxis.One allergic group patient should matched four control group patients.
88938764|NCT01824758|Experimental|brevibloc (esmolol)|Group E will receive esmolol (1 mg/kg), Group L lidocaine (0.5 mg/kg)and Group C placebo(NaCl 0.9%, 5 mL)
88938765|NCT01824758|Active Comparator|Aritmal (Lidocaine)|Group E: esmolol (1 mg/kg) Group L: lidocaine (0.5 mg/kg) Group C: placebo(NaCl 0.9%, 5 mL)
88938766|NCT01824758|Placebo Comparator|Placebo (NaCl 0.9%, 5 ml)|Group E: esmolol (1 mg/kg) Group L: lidocaine (0.5 mg/kg) Group C: placebo(NaCl 0.9%, 5 mL)
88938767|NCT01824797||Roux-en-Y Gastric Bypass|Changes in bone mineral density will be determined by comparing a peroperative DEXA scan with a one year postoperative DEXA scan on postmenopausal subjects who have already planned to undergo Roux-en-Y gastric bypass or sleeve gastrectomy. Serum will be collected from subjects preoperatively and 12 months postoperatively. The serum will be used at the completion of the study to run enzyme-linked immunosorbent assay (ELISA) to determine biochemical changes in bone metabolism.
89453947|NCT03195842|Experimental|Recordable card|Usual care, as above, plus patient-specific and standard instructions recorded in the patient's preferred language for care and given to them on a card to take home.
89453948|NCT02447900|Other|Treatment|
89453949|NCT02447822|Active Comparator|6.0ATG|Recipients who have 6.0 mg/kg Thymoglobulin as induction therapy
89453950|NCT02447822|Active Comparator|4.5ATG|Recipients who have 4.5 mg/kg Thymoglobulin as induction therapy
89453951|NCT04481945|Active Comparator|bioceramic sealer|pre-mixed bioceramic obturation material. It is dispensed using a syringe in cases of root canal obturation and with either a syringe or as a putty when doing root repair and retrograde fillings.
89453952|NCT04481945|Experimental|bioceramic sealer and silver nanoparticles|silver nanoparticles are antibacterial ions that can interact with multiple targets in the bacterial cell
89453953|NCT04481945|Experimental|bioceramic sealer and chitosan|chitosan has an excellent antibacterial, antiviral and antifungal properties, as an antibacterial, it works better on gram negative than gram positive
89453954|NCT00411801|Experimental|Uniplas|Participants will receive Uniplas intravenously in 4 cycles of 7 to 9 days each for 1 month. The first cycle will consist of 1.5 plasma volume exchanges (= 75 mL/kg) for 3 consecutive days, followed by a minimum of 4 and a maximum of 6 daily single volume plasma exchanges (= 50 mL/kg). Subsequent treatment will depend upon the response of the participant to the first cycle, as assessed by a blinded assessor.
89453955|NCT00411801|Active Comparator|Cryosupernatant plasma|Participants will receive cryosupernatant plasma intravenously in 4 cycles of 7 to 9 days each for 1 month. The first cycle will consist of 1.5 plasma volume exchanges (= 75 mL/kg) for 3 consecutive days, followed by a minimum of 4 and a maximum of 6 daily single volume plasma exchanges (= 50 mL/kg). Subsequent treatment will depend upon the response of the participant to the first cycle, as assessed by a blinded assessor.
88938768|NCT01824797||Sleeve Gastrectomy|Changes in bone mineral density will be determined by comparing a peroperative DEXA scan with a one year postoperative DEXA scan on postmenopausal subjects who have already planned to undergo Roux-en-Y gastric bypass or sleeve gastrectomy. Serum will be collected from subjects preoperatively and 12 months postoperatively. The serum will be used at the completion of the study to run enzyme-linked immunosorbent assay (ELISA) to determine biochemical changes in bone metabolism.
88938769|NCT01824810|Experimental|Intramuscular Stimulation|Participants in this group will receive up to 12 sessions of Intramuscular Stimulation (IMS). Each session may last from 30 to 60 minutes. Primary and secondary outcome measures will be assessed prior to the first treatment, after completion of the last treatment, and 6 months after treatment is complete.
88938770|NCT01824810|Experimental|myoActivation|Participants in this group will receive up to 12 sessions of myoActivation treatment. Each treatment is approximately 15 minutes. Primary and Secondary outcome measures will be assessed prior to treatment, one week after all treatments have been completed, and again 6 months after treatment is complete.
88938771|NCT01824810|Experimental|Neural Prolotherapy|Participants in this group will receive up to 12 sessions of neural prolotherapy. treatment. Each treatment is approximately 30 to 60 minutes minutes. Primary and Secondary outcome measures will be assessed prior to treatment, one week after all treatments have been completed, and again 6 months after treatment is complete.
88938772|NCT01824810|Sham Comparator|Sham Needling Control|Participants in this group will receive up to 12 sessions of sham needle treatment. Each treatment is approximately 15 to 60 minutes. Primary and Secondary outcome measures will be assessed prior to treatment, one week after all treatments have been completed, and again 6 months after treatment is complete.
89453956|NCT03200522|Active Comparator|Prudent diet then Western diet|Participants randomized to this arm will received 6 days of meals consistent with a Prudent diet, followed by a washout period, and then 6 days of meals consistent with a Western diet.
89453957|NCT03200522|Active Comparator|Western diet then Prudent diet|Participants randomized to this arm will received 6 days of meals consistent with a Western diet, followed by a washout period, and then 6 days of meals consistent with a Prudent diet.
88938773|NCT01824849|Experimental|Total arytenoidectomy|Endoscopic total arytenoidectomy was performed on patients.
88938774|NCT01824849|Experimental|Partial arytenoidectomy|Endoscopic partial arytenoidectomy was performed on patients.
89453958|NCT04477265|Experimental|combination of drug and exercise|Participant will be prescribed with oral medication in combination with biofeedback-assisted pelvic floor muscle training (PFMT) during the first month, participant will continue to have biofeedback assisted PFMT for another 2 months
89453959|NCT04477265|Active Comparator|drug only|Participant will be prescribed with oral medication for 3 months
89453960|NCT04477265|Active Comparator|exercise only|Participant will be doing biofeedback-assisted pelvic floor muscle training for 3 months
88938775|NCT01824862||eyes without diabetic retinopathy|eyes of patients with diabetes mellitus type 2 that does not have retinopathy
88938776|NCT01824862||CSME without centre involvement|eyes with CSME without thickening in the 500 µm adjacent to the centre of the macula
89453961|NCT00353457|Experimental|Arm 1|Capecitabine, Oxaliplatin and Cetuximab
89453962|NCT03206294|Other|pharmacist assessment intervention group|St Joseph Hospital pharmacist assess every diabetic patient hospitalized in cardiology service in term of antidiabetic treatment during the hospitalization
89453963|NCT02287701|Experimental|PET/MRI|Patient receives MRI
89453964|NCT02449850|No Intervention|Observation only|Observation only
89453965|NCT02449850|Experimental|Food intervention|Intervention; systematic introduction of egg, milk, wheat and peanut by 4 months of age
89453966|NCT02449850|Experimental|Skin care|Intervention: regular baths with bath-oil 0.5-9 months of age
88938777|NCT01824862||CSME with centre involvement|eyes with CSME with thickening in the 500 µm adjacent to the centre of the macula
88938778|NCT01824888|Active Comparator|Control|Following standard one-minute handwashing, both hands were immersed up to the mid-metacarpals for 5 seconds into a contamination fluid containing E. coli. Handrubs were performed by using 60% propan-2-ol into the cupped hands and rub vigorously for 30 seconds, the procedure was completed by a 5 seconds rinse of the fingers under running tap water and excess water was shaken off.
88938779|NCT01824888|Experimental|JUC solution|Following standard one-minute handwashing, both hands were immersed up to the mid-metacarpals for 5 seconds into a contamination fluid containing E. coli. Handrubs were performed by pouring 1.5 ml of JUC into the cupped hands and rub vigorously for 30 seconds, the procedure was completed by a 5 seconds rinse of the fingers under running tap water and excess water was shaken off.
89453967|NCT02449850|Experimental|Food intervention and skin care|Intervention; systematic introduction of egg, milk, wheat and peanut by 4 months of age Intervention: regular baths with bath-oil 0.5-9 months of age
89453968|NCT01346189|Active Comparator|Physician Incentives|"(with adherence feedback)~Quarterly payments to physician combined based on patient achieving an LDL reduction of at least 10 mg/dl relative to baseline LDL or the last quarter's target LDL with daily patient statin adherence information made available."
89453969|NCT01346189|Active Comparator|Patient Incentives|"(with adherence feedback)~Quarterly payments to patient based on patient achieving an LDL reduction of at least 10 mg/dl relative to baseline LDL or the last quarter's target LDL."
89537165|NCT02633787|Experimental|Study Group|Participants received a booster dose of Menactra vaccine approximately four years earlier
88938780|NCT01824914|Experimental|McGrath Videolaryngoscope|to compare the Cormack-Lehane grade in sedation and anesthesia by McGrath videolaryngoscope
88938781|NCT01824927|Active Comparator|First eye (FE)|Phacoemulsification cataract extraction surgery of first eye
88938782|NCT01824927|Active Comparator|Second eye (SE)|Phacoemulsification cataract extraction surgery of second eye
88938783|NCT01824927|Experimental|Steroids eye drops|Dexamethasone eye drop, 1 drop, qid, for 3 days before surgery
88938784|NCT01824940|Placebo Comparator|Standard of Care|The Standard of Care interventions are the blanket interventions.
88938785|NCT01824940|Active Comparator|WASH|"One of two active interventions to be studied in this 2X2 (two by two) Factorial trial:~Intervention 1: a package of interventions to improve household sanitation and hygiene (WASH)"
89453970|NCT01346189|Active Comparator|Physician and Patient Combined Incentives|"(with adherence feedback)~Quarterly payments shared evenly by physician and patient based on patient achieving an LDL reduction of at least 10 mg/dl relative to baseline LDL or the last quarter's target LDL. Physicians will receive daily information about patients' statin adherence."
89453971|NCT01346189|No Intervention|Usual Care|
89453972|NCT00411099|Experimental|1|
88938786|NCT01824940|Active Comparator|Nutrition|"One of two active interventions to be studied in this 2X2 Factorial trial:~Intervention 2: a package of interventions to improve infant and young child feeding (IYCF)"
88938787|NCT01824940|Active Comparator|WASH and Nutrition|This arm receives a combination of all standard care interventions, all WASH and all IYCF interventions.
88938788|NCT01824953||atrophy-/Hp- group|Subjects without Helicobacter pylori infection and without atrophy
88938789|NCT01824953||atrophy-/Hp+|Subjects with Helicobacter pylori infection and without atrophy
88938790|NCT01824953||atrophy+/Hp+|Subjects with Helicobacter pylori infection and with atrophy
89453973|NCT00411099|Experimental|2|
89453974|NCT00411099|Placebo Comparator|3|
88938791|NCT01824953||atrophy+/Hp-|Subjects without Helicobacter pylori infection and with atrophy
89453975|NCT03206372||Case group|The cases are the first-degree family members of propositi having had an thromboembolic venous disease in hormonal context.
89453976|NCT03206372||Control group|The controls are the first-degree family members of propositi who have never had an thromboembolic venous disease and have identical hormonal exposure
89453977|NCT05218031|Experimental|ACT Intervention|"5-week ACT Group Intervention based on the Self-Help Booklet by the World Health Organization Doing What Matters in Times of Stress: An Illustrated Guide."
89453978|NCT05218031|No Intervention|Control group|Waiting-list
89453979|NCT03195530||Elderly patients|Patients over 65 years, scheduled to general surgery, requiring general anesthesia
89453980|NCT03195452|Experimental|Raltegravir|antiretroviral tritherapy: Raltegravir 600 mg tablet orally (2 tablets QD) and 2 Nucleoside/Nucleotide reverse transcriptase inhibitor (NRTI)
89453981|NCT00406809|Experimental|Phase 1a and 1b|Relapsed or refractory lymphoid malignancies
89453982|NCT00406809|Experimental|Arm A (Phase 2a)|Relapsed or refractory follicular lymphoma
89453983|NCT00406809|Experimental|Arm B (Phase 2a)|Relapsed or refractory mantle cell, peripheral T-cell, cutaneous T-cell lymphoma including mycosis fungoides and Sezary syndrome, or other indolent B-cell lymphomas such as marginal zone lymphoma
89453984|NCT00406809|Experimental|Extension Study|Relapsed or refractory follicular lymphoma or Relapsed or refractory mantle cell, peripheral T-cell, cutaneous T-cell lymphoma including mycosis fungoides and Sezary syndrome, or other indolent B-cell lymphomas such as marginal zone lymphoma
89453985|NCT03200210|Experimental|Treatment with Febuxostat|Febuxostat, starting at dose 20mg/d, once a day. And adjust dose according to serum uric acid at specific visits.
89453986|NCT03200210|Placebo Comparator|Treatment with placebo|Same dose and dose adjustment as the intervention arm.
89453987|NCT00333411|Experimental|BIRT 2584 XX high dose|
89453988|NCT00333411|Experimental|BIRT 2584 XX medium dose|
88938792|NCT01824966||SRC<50%|Adenocarcinoma containing < 50% of signet ring cells
88938793|NCT01824966||SRC>50%|Adenocarcinoma containing > 50% of signet ring cells
88938794|NCT01824992|No Intervention|Observation|subject only got observation
88938795|NCT01824992|Experimental|Drug|subject were treated with Yallaferon®， the recombinant human interferon α-2b gel
89453989|NCT00333411|Experimental|BIRT 2584 XX low dose|
89453990|NCT00333411|Placebo Comparator|Placebo|
88938796|NCT01825005||group 1:surgery|treatment = surgery only
89453991|NCT03199976|Experimental|Tiotropium Bromide & Salbutamol|Inhaled Tiotropium Bromide 5 µg once a day, beginning at the onset of an upper respiratory tract infection and continuing for 7 to 14 days as needed, and inhaled Salbutamol 0.2 mg 4 to 6 times a day as needed for wheeze and shortness of breath
89453992|NCT03199976|Active Comparator|Fluticasone Propionate & Salbutamol|Inhaled Fluticasone Propionate 125 µg twice a day, beginning at the onset of an upper respiratory tract infection and continuing for 7 to 14 days as needed, and inhaled Salbutamol 0.2 mg 4 to 6 times a day as needed for wheeze and shortness of breath
89453993|NCT03199976|Active Comparator|Salbutamol|Inhaled Salbutamol 0.2 mg 4 to 6 times a day as needed for wheeze and shortness of breath
89453994|NCT03675061|Other|Control group|Current care : The management of the preterm delivery risk without biochemical test, with hospitalization of the patient, initiation of tocolysis and a complete corticosteroid treatment.
89453995|NCT03675061|Other|PartoSure group|"Each women have a biochemical test = PartoSure Test.~PartoSure test negative : For a negative test, the patient will be able to benefit from a nifedipine tocolysis, if the uterine contractions require it, then she will return home with a control by a midwife at home twice a week up to 34 weeks of amenorrhea.~PartoSure test positive : For a positive test, the patient will be hospitalized 7 days with a care identical to the control group."
88938797|NCT01825005||group 2: radiotherapy|treatment = radiotherapy only
89453996|NCT00369317|Experimental|Treatment (combination chemotherapy)|"INDUCTION THERAPY COURSE I: Patients receive cytarabine IT on day 1 and cytarabine IV continuously over 96 hours, daunorubicin hydrochloride IV continuously, and oral thioguanine BID on days 1-4. COURSE II: Patients receive high-dose cytarabine IV over 3 hours BID on days 1, 2, 8, and 9 and asparaginase (IM) on days 2 and 9.~COURSE III: Patients receive treatment as in course I. COURSE IV: Patients receive cytarabine IV, daunorubicin hydrochloride IV, and oral thioguanine as in course I~INTENSIFICATION THERAPY: Patients receive cytarabine IV continuously over 168 hours on days 1-7 and etoposide IV over 1 hour on days 1-3. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity."
89453997|NCT03205670|Experimental|Urethroplasty with a tissue-engineered construct|The investigators will take a sample of the buccal mucosa to isolate epithelial cells. Autologous cells will be seeded on a hybrid matrix. Urethroplasty with this tissue-engineered construct will be performed. This is a single arm study with no control. All patients will undergo the surgical operation.
89453998|NCT05725551|Experimental|ShotBlocker group|Pain in intramuscular injection It is a noninvasive, plastic tool used to reduce.
89453999|NCT05725551|Experimental|Finger Puppet group|Finger puppetry is an alternative method of interacting with the child through play while performing an intramuscular injection.
89454000|NCT05725551|Experimental|Balloon group|Balloon inflation method, the child inflating the balloon while performing an intramuscular injection.
89454001|NCT05725551|No Intervention|Control Group|Intramuscular injection without any intervention.
89454002|NCT03205826|Other|Type of sedation used|All patients will undergo two subsequent Chartis measurements. The first measurement will be performed with the patient undergoing conscious sedation and the second measurement with the patient under general anesthesia.
89454003|NCT04470219|Experimental|intervention group|Participants receive rehabilitation as usual and training how to use RemindMe by personnel from the research group and an occupational therapist working at the rehabilitation clinic. The participants will use RemindMe for two months. The participants choose activities that he/she wishes to remember to carry out with support by RemindMe. An individual follow-up session will be conducted once a week by the occupational therapist to evaluate if the chosen activities were performed and discuss strategies for the continued use of RemindMe. After two months the participants decide if he/she wants to continue to use RemindMe.
89454004|NCT04470219|No Intervention|control group|The control group receive treatment as usual by the rehabilitation personnel, for example, occupational therapists give interventions that provide support for memory, it could be a paper calendar or other memory devices or strategies.
89454005|NCT02447666|Experimental|Azacitidine Myelodysplastic Syndrome (MDS)|Azacitidine 75 mg/m2 by Intravenous (IV) or Subcutaneous (SC) administration once daily (QD) on Days 1 to 7 of a 28-day cycle for a minimum of 3 cycles and a maximum of 6 cycles.
89454006|NCT02447666|Experimental|Azacitidine Juvenile Myelomonocytic Leukemia (JMML)|Azacitidine 75 mg/m2 by Intravenous (IV) or Subcutaneous (SC) administration once daily (QD) on Days 1 to 7 of a 28-day cycle for a minimum of 3 cycles and a maximum of 6 cycles.
89454007|NCT04469751|Experimental|patients undergoing neurosurgery|radial artery and dorsalis pedis artery intubated with BD Insyte-W 22G artery puncture needle under local anaesthesia
89454008|NCT03193021|Experimental|Cardiva Mid-Bore VVCS|Cardiva Mid-Bore VVCS will be used to close all femoral venous access sites at the end of the case.
89454009|NCT03193021|Active Comparator|Manual Compression|Direct manual compression to the access sites will be used to close all femoral venous access sites at the end of the case.
89454010|NCT04469829|Experimental|secukinumab|patients with psoriasis and metabolic syndrome candidate for treatment with secukinumab standard doses
89454011|NCT04469829|Active Comparator|methotrexate|patients with psoriasis and metabolic syndrome candidate for treatment with methotrexate dosed 15 mg/week
89454012|NCT05217719|Experimental|the TPO group|Patients in TPO group will be treated with rhTPO at a dose of 15000u/d, subcutaneous injection, for 7 consecutive days.
89454013|NCT05217719|Placebo Comparator|the control group|Patients in the control group will receive the same amount of saline as a placebo, which is injected subcutaneously, for 7 consecutive days.
89454014|NCT04469673|Experimental|JS002|Participants received one of 3 dose regimens of JS002 administered as multiple subcutaneous doses.
89454015|NCT04469673|Placebo Comparator|Placebo|Participants received matching placebo dose regimens by subcutaneous injection.
89454016|NCT03195296||Graves' Orbitopathy|Patients with Graves' Orbitopathy subjected to orbital decompression
88938798|NCT01825005||group 3: RT and CT, and/or hyperthermia|treatment= radiotherapy combined with chemotherapy and/or hyperthermia
88938799|NCT01825005||group 4: stage IVb , any treatment|cervical cancer stage IV b, treatment = any systemic or radiation therapy and supportive care
89454017|NCT03674905|Other|Intra-articular injection|Intra-articular injection at the completion of TAA procedure.
89454018|NCT03674905|Other|Peripheral nerve block|Pre-operative peripheral nerve block.
89454019|NCT05217485|Experimental|Infection and reverted atrial fibrillation|Patients who have developed first-diagnosed atrial fibrillaiton in the context of sepsis or infection
89454020|NCT00405951|Experimental|Obatoclax Mesylate + Docetaxel|Obatoclax Mesylate 250mL in combination with Docetaxel
89454021|NCT03194984|Other|Young Patient|With 18-25 years old. Drug: Hydrogen peroxide 35%. Drug: Hydrogen peroxide 38%
89454022|NCT03194984|Other|Adult Patient|With 40-65 years old. Drug: Hydrogen peroxide 35%. Drug: Hydrogen peroxide 38%
89454023|NCT03669757|Experimental|LEO 134310 Dose A|Once daily application
89454024|NCT03669757|Experimental|LEO 134310 Dose B|Once daily application
89454025|NCT03669757|Experimental|LEO 134310 Dose C|Once daily application
89454026|NCT03669757|Experimental|LEO 134310 Dose D|Once daily application
89454027|NCT03669757|Placebo Comparator|LEO 134310 vehicle|Once daily application
89454028|NCT03669757|Active Comparator|0.1% betamethasone valerate ointment (class III steroid)|Once daily application
89454029|NCT00405327|Experimental|DC vaccine therapy|Tumor lysate-pulsed dendritic cell (DC) vaccine following HSCT
89454030|NCT03199898||34-32 GA|premature infants born <34,6-32,1 weeks of gestational age (GA) receiving different types of non-invasive and invasive respiratory support, and severity of respiratory distress assessed by Silverman-Andersen Retraction Score.
89015749|NCT06215365|Experimental|Adult cancer survivors (until 74 years old) who have completed their heavy treatments|"Adult cancer survivors (until 74 years old) who have completed their heavy treatments (chemotherapy, radio-chemotherapy, …) and that are taking part in the JUMP post-cancer day which is a multidisciplinary evaluation carried out at the end of treatments.~They must not have cognitive disorders that limit their ability to understand and complete the questionnaire. Also, they have to speak, read and write French language.~The study will be presented to the patient who can refuse to participate. The digital version of the questionnaire will be handed out, if the patient does not object after a period of thinking, when he or she comes to the day hospital for his or her JUMP Day. The study will therefore take place at a single point in time, and no pre-inclusion or follow-up visits are planned as part of this protocol.~Completing the questionnaire takes about 15 to 20 minutes. All questions are designed to meet the stated objectives. No personally identifiable data is collected."
89015750|NCT06210906||Sips of water|Patients taking sips of water within 1 hour in preoperative fasting
89015751|NCT06210906||No sips of water|Patients not taking sips of water within 1 hour in preoperative fasting
89015752|NCT06210893|Active Comparator|Conventional simple palpation|The cricoid cartilage is located with simple palpation.
89015753|NCT06210893|Experimental|Upwards laryngeal handshake technique|The cricoid cartilage is located with upwards laryngeal handshake technique.
89454031|NCT03199898||32-28 GA|premature infants born <32-28,1 weeks of gestational age (GA) receiving different types of non-invasive and invasive respiratory support, and severity of respiratory distress assessed by Silverman-Andersen Retraction Score.
89454032|NCT03199898||28-23 GA|premature infants born <28-23,0 weeks of gestational age (GA) receiving different types of non-invasive and invasive respiratory support, and severity of respiratory distress assessed by Silverman-Andersen Retraction Score.
89454033|NCT03913091|Experimental|20 mL 0.5% Bupivacaine HCL|
89454034|NCT03913091|Experimental|Interscalene nerve block with Liposomal + Bupivacaine 0.5%|Administered in an Interscalene block for TSA
89454035|NCT00330369|Placebo Comparator|Darusentan Placebo|Placebo to match darusentan for 2-week placebo run-in period, followed by placebo to match darusentan administered orally once daily for 14 weeks
89454036|NCT00330369|Experimental|Darusentan 50 mg|Placebo to match darusentan for 2-week placebo run-in period, followed by darusentan 50 mg administered orally once daily for 14 weeks
89454037|NCT00330369|Experimental|Darusentan 100 mg|Placebo to match darusentan for 2-week placebo run-in period, followed by darusentan 100 mg administered orally once daily for 14 weeks
89454038|NCT00330369|Experimental|Darusentan 300 mg|Placebo to match darusentan for 2-week placebo run-in period, followed by darusentan 300 mg administered orally once daily for 14 weeks
89454039|NCT03199664|Active Comparator|Group A (NB-UVB)|Intervention: patients will be treated with Narrow band ultra violet rays alone for 6 months
89015754|NCT06210516|Active Comparator|Experimental Group|"Inspiratory muscle training, aerobic training, breathing exercises neurophysiologic rehabilitation will be applied to the experimental group. This treatment program will be applied 5 sessions a week and totally 30 sessions (6 weeks).~Inspiratory muscle training~Aerobic training~Breathing Exercises~Neurophysiological Exercise Program"
89015755|NCT06210516|Active Comparator|Control Group|"The control group will receive aerobic training, breathing exercises and neurophysiological rehabilitation, excluding inspiratory muscle training.~This treatment program will be applied 5 sessions a week and totally 30 sessions (6 weeks)."
89015756|NCT06209034|Other|Optic nerve sheath measurement|Optic nerve sheath diameter (ONSD) was detected 3 mm behind the entry point of the optic nerve into the globe in both eyes in each ultrasonographic measurement. ONSD was measured bilaterally 3 mm posterior to the papilla. Transverse measurements were made for each optic nerve.
89015757|NCT06208215|Placebo Comparator|SoC (Standard-of-Care) + RZ358 (5 mg/kg) or Placebo|Participants ≥1 year old who receive SOC therapy and 5 mg/kg of RZ358 or placebo
89454040|NCT03199664|Active Comparator|Group B ( combined NB-UVB & Tacrolimus)|Intervention: patients will be treated with NB-UVB & Tacrolimus 0.03 % ointment for 6 months
89454041|NCT02447588|Other|Group 1|Intrauterine insemination with sperm donor (IAD) at 36 hours post-hCG. Cases where the IAD is scheduled at 36 hours post-administration of hCG.
89454042|NCT02447588|Experimental|Group 2|Intrauterine insemination with sperm donor (IAD) at 24 hours post-hCG. Cases where the IAD is scheduled at 24 hours post-administration of hCG.
89015758|NCT06208215|Placebo Comparator|SoC + RZ358 (10 mg/kg) or Placebo|Participants ≥1 year old who receive SOC therapy and 10 mg/kg of RZ358 or placebo
89015759|NCT06208215|Experimental|Open Label Arm, SoC + RZ358 (start 5mg/kg and increase to 10 mg/kg per protocol schedule|Infant participants from ≥3 months to <1 year old who receive SOC therapy + RZ358 starting at 5 mg/kg and increasing to 10 mg/kg of RZ358, as needed, per the protocol schedule
89015760|NCT06206148|Experimental|Hand-written pain journal|Post-operative orthopedic surgery patient will be given a pen and journal with chart inside and instructed to fill out the chart with time/date and pain intensity level as frequently as they want.
89015761|NCT06206148|Experimental|Smartphone app|Post-operative orthopedic surgery patient will be given a research smartphone and an app to record their pain and will be instructed to fill out the pain survey as frequently as they want.
89015762|NCT06206148|Experimental|Novel electronic pain recording device|Post-operative orthopedic surgery patient will be given a pain recording device and will be instructed to input their pain using the buttons on the device as frequently as they want.
89454043|NCT02447510|Other|group 1|bone substitute grafting material applied to the defect site control (n=10)
89454044|NCT02447510|Other|group 2|experimental platelet rich growth factor PRGF applied to the defect site (n=10) G2
89454045|NCT02447510|Other|group 3|platelet rich fibrin PRF applied to the defect site (n=10) G3.
89454046|NCT05216471||Mild illness|individuals who have any of the various signs and symptoms of covid-19 (e.g., fever, cough, sore throat, malaise, headache, muscle pain, nausea, vomiting, diarrhea, loss of taste and smell) but who do not have shortness of breath, dyspnea, or abnormal chest imaging findings .
89454047|NCT05216471||Moderate illness|individuals who show evidence of lower respiratory tract disease during clinical assessment or imaging and who have an oxygen saturation (SpO2) ≥94% on room air .
89537166|NCT05635773|Active Comparator|eFONA No Alexa|Arm randomised to performing the procedure without Alexa cognitive aid first
89454048|NCT05216471||Severe illness|individuals who have spO2<94% on room air, a ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (PaO2/FiO2)<300 mm hg, respiratory frequency>30 breaths/min, or lung infiltrate >50%.
89454049|NCT02149537|Experimental|hydroxyurea|500mg of hydroxyurea/day during 6 months
89454050|NCT02149537|No Intervention|No treatment|No hydroxyurea treatment during 6 months
88938800|NCT01825018|Experimental|Social Network Leader Endorsement|Leaders of social networks randomized to this arm will be taught to endorse compliance with medical guidelines, safer behaviors, and effective ways to communicate these concepts to social network members.
88938801|NCT01825018|Active Comparator|Comparison Group|Members of social networks assigned to this group will receive only HIV counseling at the baseline session.
88938802|NCT01825031|Experimental|Antiretroviral Therapy|Raltegravir twice daily for 12 weeks from antiretroviral therapy (ART) initiation in addition to 3 standard ARVs (2NRTIs/1NNRTI) compared with 3 standard ARVs
88938803|NCT01825031|Experimental|Opportunistic Infection (OI) Prophylaxis|Immediate isoniazid/pyridoxine and cotrimoxazole, plus 12 weeks fluconazole, 5 days azithromycin and a single dose of albendazole compared with immediate cotrimoxazole (if not already taking this) in all patients plus (not malawi)isoniazid/pyridoxine after 12 weeks.
88938804|NCT01825031|Experimental|Nutritional Support|Supplementation with Ready to Use Supplementary Food (RUSF) for 12 weeks compared with supplementation for those with severe malnutrition as local practice.
88938805|NCT01825044|Active Comparator|NeuroSTAT 5 mg/kg/day|Intravenous bolus of NeuroSTAT (Ciclosporin) 2.5 mg/kg bodyweight followed by 5 days of 5 mg/kg bodyweight/day continuous infusion
88938806|NCT01825044|Active Comparator|NeuroSTAT 10 mg/kg/day|Intravenous bolus of NeuroSTAT (Ciclosporin) 2.5 mg/kg bodyweight followed by 5 days of 10 mg/kg bodyweight/day continuous infusion
88938807|NCT01825070|Experimental|low dose|Montmorency cherry concentrate, 30 mls
88938808|NCT01825070|Experimental|higher dose|Montmorency cherry concentrate, 60 mls
88938809|NCT01825083|Active Comparator|Ketamine|Ketamine administered 0.5mg/kg followed by an infusion of 1.5mcg/kg/min.
88938810|NCT01825083|Placebo Comparator|Placebo|Saline group will received the same volume in saline as the ketamine dose
88938811|NCT01825096||baseline|No intervention. Participants are scanned at baseline.
89454051|NCT05217407||Rare cancer|Malignancies with an annual incidence of less than 6 cases per 100,000 population; malignancies categorized as rare cancers in the European RARECARE report; malignancies that are difficult to develop treatments; common cancers with rare tissue subtypes; common cancers that can be regarded as rare based on biological demographics such as age or sex; and cancers of unknow primary are eligible for this study.
89501763|NCT02224183|Active Comparator|Yoga|Weekly yoga classes will each be taught by two yoga instructors. Classes will be 75 minutes long. Mats and props will be provided. Yoga participants will be encouraged to practice for 30 minutes on days when they do not have class. They will be provided free of charge with a participant handbook, mat, block, and strap to aid home practice. Yoga home practice videos will be placed online for home practice and the website will track time spent using the videos for home practice. DVDs will be provided for those that do not have consistent access to the internet at home.
89501764|NCT02156297||Induction Group|
88938812|NCT01825109|Experimental|6 weeks RV & normal breast feeding|Administration of Rotarix at 6 and 10 weeks co-administered with oral polio virus vaccine with no intervention in normal breastfeeding practices before and after receiving vaccine.
88938813|NCT01825109|Experimental|6 weeks RV & delayed breastfeeding|Administration of Rotarix at 6 and 10 weeks co-administered with oral polio virus. Breastfeeding will not be permitted 45 minutes prior to vaccine administration and 45 minutes after each vaccine administration.
88938814|NCT01825109|Experimental|14 weeks RV & Normal breastfeeding|Administration of Rotarix at 14 and 18 weeks co-administered with oral polio virus, with no intervention in normal breastfeeding practices before and after receiving vaccine.
88938815|NCT01825109|Experimental|14 weeks RV & delayed breastfeedin|Administration of Rotarix at 14 and 18 weeks co-administered with oral polio virus. Breastfeeding will not be permitted 45 minutes prior to vaccine administration and 45 minutes after each vaccine administration.
88938816|NCT01825135|Experimental|Neuromuscular electrical stimulation|Neuromuscular electrical stimulation (NMES) will be applied to the quadriceps muscles for 30 minutes
88938817|NCT01825135|Sham Comparator|Sham stimulation|Sham stimulation will be applied to the quadriceps for 30 minutes
88938818|NCT01825148||Type 1 Diabetes|patients with long standing T1D
88938819|NCT01825148||Healthy volunteer|healthy volunteers with normal glucose tolerance
88938820|NCT01825174|Active Comparator|Non-overweight children in ball games program|twice a week different ball games 90min
88938821|NCT01825174|Experimental|Overweight children in nutrition counseling program|9 units of 90min each of nutrition counseling
88938822|NCT01825174|Placebo Comparator|Control group overweight children|No intervention during six months
88938823|NCT01825174|Experimental|Overweight children in ball games program|twice a week different ball games 90min
88938824|NCT01825174|Experimental|Overweight children in ball games and nutrition counseling|twice a week different ball games 90min and 9 units of 90min each of nutrition counseling
88938825|NCT01825174|Placebo Comparator|Non-overweight control (no intervention)|
88938826|NCT01825213||Multispectral CT of the liver|Images of lesions and liver will be compared to histology.
88938827|NCT01825226|Experimental|Program participation|Participation in an enhanced-homestead food production program including home gardening and nutrition and health behavior change communication
88938828|NCT01825226|No Intervention|Control|
88938829|NCT01825239|Other|Electrophysiology Study|This is a single arm study, all study participants will be referred for an Electrophysiology Study
88938830|NCT01825252|Experimental|Social Network Intervention|Approximately 20% of people in this condition will be trained to have discussions endorsing less risky behaviors with their social network members.
88938831|NCT01825252|Active Comparator|Counsel, Test, and Treat|People in this arm will only receive standard-of-care counseling, testing, and treatment for HIV and STDs.
88938832|NCT01825304|Active Comparator|esophageal pressure ,titrated setting|
88938833|NCT01825304|Other|ARDSNet recommendations,peep|
88938834|NCT01825317|Active Comparator|NeuroAD|Treatment by the NeuroAD device, real treatment by synchronized TMS+cognitive training
88938835|NCT01825317|Sham Comparator|Sham NeuroAD|Sham TMS+cog, has the same sound and appearance, patients come for the same number of treatments and are exposed to the same procedure.
88938836|NCT01825330|Active Comparator|NeuroAD|NeuroAD treatment, synchronized TMS and cognitive training stimulation
88938837|NCT01825330|Sham Comparator|Sham TMS+Cog|Sham device, has the same appearance and sound as the real device, combined with sham cognitive exercises. Patients come for the same number of sessions, delivers no real stimulation or cognitive training.
88938838|NCT01825369|Experimental|IV L-carnitine|L-carnitine (25, 50, or 100mg/kg IV) will be given, 30-60 minutes prior to the initiation of CPB, and a second dose ~2 hr. following separation from CPB (with a minimum of 4 hrs from initial dose). The first 5 subjects will receive 25 mg/kg, with an escalation of dose after each 5 subjects enrolled. The study drug will be brought to the operating room and administered over 5 minutes by the anesthesiologist after an IV has been placed. Prior to the administration of the study drug, and again 24 and 48 hrs after CPB, 3.0 ml of blood will be collected for determinations of carnitine levels (free, total, and acylcarnitine), mitochondrial function, ROS and bioavailable NO as described in Aim 3A. Additional blood (0.5-1.0 ml) will be obtained to determine carnitine levels before CPB, and then before and 0.5, 1.5, 3, 5, 9, 12, and 24h after the second dose.
88938839|NCT01825382|No Intervention|Accu-chek Meter|Patients receiving the Accu-chek nano meter for use during the study.
88938840|NCT01825382|Experimental|iBGStar meter interventional Arm|Subjects are given iBGstar meter along with iPhone to use as interventional meter.
88938841|NCT01825421|No Intervention|Control (continue antibiotics) group|The antibiotics will be continued for at least another 24h i.e. for 48h, pending blood culture results at 48h, as per standard practice in the NICU.
88938842|NCT01825421|Active Comparator|Study (discontinue antibiotics) group|The intervention is to discontinue antibiotics at 24h, and he/she will be kept under observation in the NICU for at least an additional 24h, pending blood culture results at 48h.
88938843|NCT01825434|Active Comparator|Treatment Group|yogurt containing polydextrose, L. acidophilus NCFM® (ATCC 700396) and B. lactis HN019 (AGAL NM97/09513) 1 time per day, for 30 days.
88938844|NCT01825434|Placebo Comparator|Placebol group|regular yogurt, 1 time per day for 30 days.
88938845|NCT01825447|Placebo Comparator|Treatment A|
88938846|NCT01825447|Experimental|Treatment B|
88938847|NCT01825447|Active Comparator|Treatment C|
88938848|NCT01825460|Experimental|Manual Therapy Protocol|A protocol with five techniques on thoracic area applied twice a week.
88938849|NCT01825460|Active Comparator|Two manual techniques|Two manual therapies on thoracic area applied twice a week.
88938850|NCT01825473|Experimental|Erythromycin|50 mg/kg/day divided every 6 hours oral for 7 days
88938851|NCT01825473|Placebo Comparator|Placebo|Dextrose 5 Water (D5W) equal amount as experimental every 6 hours oral for 7 days
88938852|NCT01825486||accidental falls|
88938853|NCT01824043|Experimental|vitreous hemorrhage group|Patients will be treated monthly: intravitreal ranibizumab (0.5 mg) will be administered in an open-label fashion, using 3 monthly injections (at day 0, day 30 and day 60) followed by an additional post treatment visit, a month after the last injection, for posterior reports
88938854|NCT01825525|Experimental|Cardiac device patients.|Exposure to ScopeGuide - patients with cardiac devices exposed to ScopeGuide as per study protocol
88938855|NCT01825538||COPD, pulmonary fibrosis|observational study, no interventions to be administered
88938856|NCT01825551|Active Comparator|Granulocyte Colony Stimulating Factor|Granulocyte Colony Stimulating Factor 10 microgram/ kg/ day for 5 days subcutaneously
88938857|NCT01825551|Placebo Comparator|Placebo|normal saline 0.01 ml/kg/day for 5 days subcutaneously
88938858|NCT01825590||Subjects undergoing sodium alignment|Dialysate and serum sodium concentration aligned
88938859|NCT01825590||Subjects not undergoing sodium alignment|Dialysate and serum sodium concentration not aligned
88938860|NCT01825616|Experimental|Vitamin D2 mushroom powder|4000 IU/day vitamin D2 mushroom powder
88938861|NCT01825616|Placebo Comparator|Placebo|Mushroom powder without vitamin D2 (not exposed to UV radiation)
89501765|NCT02156297||Consolidation Group|
88938862|NCT01825629|Experimental|Multidisplinary Therapy|The multidisciplinary therapy involves the application of physical therapy, manual therapy and deontology therapy. This multidisciplinary therapy will be administered twice a week for 15 weeks.
88938863|NCT01825629|Placebo Comparator|One technique of myofascial release|"A physiotherapist administered 15 sessions of induction occipital once a week."
88938864|NCT01825642|Active Comparator|Control Group|nerve-sparing radical prostatectomy
88938865|NCT01825642|Active Comparator|Treatment Group|seminal vesicle-sparing radical prostatectomy
88938866|NCT01825668|Experimental|High cholesterol|600 mg cholesterol/day in 240 ml milk shake
88938867|NCT01825668|Experimental|Plant sterols|2.0 g of plant sterols/day in 240 ml milk shake containing 50 mg cholesterol
88938868|NCT01825668|Placebo Comparator|Placebo|50 mg cholesterol/day in 240 ml of milk shake
88938869|NCT01825681|Experimental|positive affect intervention|positive affect intervention
88938870|NCT01825681|No Intervention|wait list control|wait list control
88938871|NCT01825707|Experimental|[14C]-YH4808 200 mg|[14C]-YH4808 200 mg
88938872|NCT01825720|Experimental|(Glucose-Insulin-Potassium)GIK group|infusion of 0.1 IU/kg/hr of insulin and mixture of 30% dextrose water with 80 mmol/l of potassium in the rate of 0.5 ml/kg/hr through out the surgery
88938873|NCT01825720|Active Comparator|normal saline group|same rate of normal saline
88938874|NCT01825733|Experimental|ramosetron|
88938875|NCT01825733|Active Comparator|palonosetron|
88938876|NCT01825746|Active Comparator|Early implementation practices|"9 practices that will initially field the MOHR assessment for up to 6 months. These practices will serve as intervention sites for the effectiveness outcomes measured by the patient experience survey."
89201082|NCT03990337|No Intervention|Control group (CPG, n=65)|cricoid pressure applied by the OR nurse on the cricoid cartilage using finger palpation without ultrasonography
89501766|NCT02156297||Salvage Group|
89501767|NCT02156297||Maintenance Group|
89501768|NCT02156297||Alleviatitive Group|
89537167|NCT05635773|Experimental|eFONA Alexa|Arm randomised to performing the procedure using Alexa cognitive aid first
89015763|NCT06201325|Active Comparator|VR group|VR-based exercise program for half an hour a day, 5 days a week for a total of 3 weeks, in addition to home exercise programs for half an hour a day, 5 days a week for a total of 3 weeks. These individuals will use the Microsoft Kinect for Azure VR system in the virtual environment. They will play the registered games. These games will include purpose-oriented activities such as lying on the shelf and using bilaterally, which are intended to use the upper extremities of individuals with AC in daily life.
89454052|NCT05217407||Cholangiocarcinoma cohort|This study is a part of MASTER KEY Asia study and designed to be conducted on the patients of cholangiocarcinoma only. The primary endpoint is assigned to the frequency of FGFR2 fusion gene positive cholangiocarcinoma detected by fluorescence in situ hybridization (FISH) in Asian countries. The genetic analysis is performed not only by FISH, but also by next generation sequencing (NGS), so that genetic alterations other than the FGFR2 fusion gene in alterations can be confirmed. To improve outcomes, collecting clinical information is very important to study the relationship between genetic alterations and prognosis, effect of treatments, and the incidence of genomic alterations in cholangiocarcinoma to discover more specific and effective treatment.
89454053|NCT05216237|Experimental|Treatment of HER-2 Negative MSS Advanced Gastric|Sintilimab Plus Apatinib and Chemotherapy in Patients with Previously Untreated HER-2 negative MSS Advanced or Metastatic GC or GEJ Cancer
89454054|NCT03205904|Active Comparator|Intervention group|Group that will be receive the diet
89454055|NCT03205904|No Intervention|control|Group that will not receive the diet
89454056|NCT04058977|Experimental|Power training|Randomized to early power training with standardized exercise progression plus standard of care
89454057|NCT04058977|No Intervention|Standard of Care|Standard of care
89454058|NCT03205514||NSTE-ACS with intermediate stenosis and negative FFR|Patients hospitalized because of an acute coronary syndrome without ST segment elevation and with intermediate culprit lesion with negative fractional flow reserve evaluation (>0.80).
89454059|NCT03674749|Active Comparator|Hyperbaric Oxygen|Hyperbaric oxygen treatment with 100% oxygen at 2.0 ATA for 90 min, once daily, five times a week for 8 consecutive weeks
89454060|NCT03674749|Experimental|Meditation with Hyperbaric Oxygen|Meditation session combined with each hyperbaric oxygen treatment with 100% oxygen at 2.0 ATA for 90 min, once daily, five times a week for 8 consecutive weeks,
89454061|NCT02284971|Experimental|Arm A: CDX1127 & SBRT Concurrent|"SBRT will be administered to the primary tumor and/or site of metastatic disease over a period of 5 days (Days 1-5) at a constant dose for 1-4 sites of prostate cancer involvement:30 Gy in 5 fractions of 6 Gy each for prostate gland; 25 Gy in 5 fractions for bone and/or soft tissue metastases).~Subjects will receive four doses of CDX-1127(3 mg/kg) (Days 1, 43, 64, 85). The study drug will be administered intravenously over a 90-minute time period and will be followed by a 2-hour observation period. A subject's dose of CDX-1127 will be calculated based on their actual body weight at the time of screening. A subject's dose of CDX-1127 will remain constant at each time point, unless they experience a greater than 10% change in body weight."
89454062|NCT02284971|Experimental|Arm B: CDX1127 & SBRT Sequential; CDX1127 upfront|"SBRT will be administered to the primary tumor and/or sites of metastatic disease over a period of 5 days (Days 22-26) at a constant dose for 1-4 sites of prostate cancer involvement:30 Gy in 5 fractions of 6 Gy each for prostate gland; 25 Gy in 5 fractions for bone and/or soft tissue metastases).~Subjects will receive four doses of CDX-1127(3 mg/kg) (Days 1, 43, 64, 85). The study drug will be administered intravenously over a 90-minute time period and will be followed by a 2-hour observation period. A subject's dose of CDX-1127 will be calculated based on their actual body weight at the time of screening. A subject's dose of CDX-1127 will remain constant at each time point, unless they experience a greater than 10% change in body weight."
89501769|NCT05718999||With Incisional Hernia|The incisional hernia was defined according to the EHS guidelines as a mass in the abdominal wall with or without a visceral outlet or palpable in the surgical site determined by clinical examination or tomography, this group will present this complication.
89501770|NCT05718999||Without Incisional Hernia|The incisional hernia was defined according to the EHS guidelines as a mass in the abdominal wall with or without a visceral outlet or palpable in the surgical site determined by clinical examination or tomography, this group will not present this complication.
89501771|NCT02156375|Experimental|Ustekinumab 90 mg/mL|
88938877|NCT01825746|Other|Delayed implementation practices|"9 practices that will field the MOHR assessment for up to 6 months but starting 4 months after the early implementation practices. These practices will serve as control sites for the effectiveness outcomes measured by the patient experience survey. However, they will provide intervention data with respect to Reach and cost during the delayed phase."
89454063|NCT02284971|Experimental|Arm C: CDX1127 & SBRT Sequential; SBRT upfront|"SBRT will be administered to the primary tumor and/or sites of metastatic disease over a period of 5 days (Days 1-5) at a constant dose for 1-4 sites of prostate cancer involvement:30 Gy in 5 fractions of 6 Gy each for prostate gland; 25 Gy in 5 fractions for bone and/or soft tissue metastases).~Subjects will receive four doses of CDX-1127(3 mg/kg) (Days 22, 43, 64, 85). The study drug will be administered intravenously over a 90-minute time period and will be followed by a 2-hour observation period. A subject's dose of CDX-1127 will be calculated based on their actual body weight at the time of screening. A subject's dose of CDX-1127 will remain constant at each time point, unless they experience a greater than 10% change in body weight."
89454064|NCT05217329|Experimental|smart phone intervention group|smart phone intervention group stroke subjects completed smart phone App tasks with affected arm or bilateral arm movement
89454065|NCT05217329|Active Comparator|conventional group|stroke subjects receive conventional rehabilitation home program
89454066|NCT03205202|Active Comparator|Cocoa extract + multivitamin|"Dietary Supplement: Cocoa extract (2 capsules each day containing a total of 500 mg cocoa flavanols, including 80 mg (-)-epicatechin, and 50 mg theobromine)~Dietary Supplement: Multivitamin"
89454067|NCT03205202|Active Comparator|Cocoa extract + multivitamin placebo|"Dietary Supplement: Cocoa extract (2 capsules each day containing a total of 500 mg cocoa flavanols, including 80 mg (-)-epicatechin, and 50 mg theobromine)~Dietary Supplement: Multivitamin placebo"
89454068|NCT03205202|Active Comparator|Cocoa extract placebo + multivitamin|"Dietary Supplement: Multivitamin~Dietary Supplement: Cocoa extract placebo"
89454069|NCT03205202|Placebo Comparator|Cocoa extract placebo + multivitamin placebo|"Dietary Supplement: Cocoa extract placebo~Dietary Supplement: Multivitamin placebo"
89454070|NCT00322257|Experimental|A|
89454071|NCT00322257|Active Comparator|B|
89454072|NCT03199742|Active Comparator|PTSD Coach with no Coaching|Participants will receive the PTSD coach mobile app.
89454073|NCT03199742|Experimental|PTSD Coach with Peer Coaching|Participants will receive the PTSD Coach + mobile app which will provide routine, personalized coaching for 8 weeks from a Veteran peer.
89454074|NCT03199742|Experimental|PTSD Coach with Clinician coaching|Participants will receive the PTSD Coach + mobile app which will provide routine, personalized coaching for 8 weeks from a clinical psychologist.
89454075|NCT03199742|Experimental|PTSD Coach with Automated Coaching|Participants will receive the PTSD Coach + mobile app which will provide automated, personalized coaching for 8 weeks.
89454076|NCT05216939|Experimental|Flannel mask with earl loops|Participants will wear a flannel mask with earl loops
89454077|NCT05216939|Experimental|Flannel mask with ties|Participants will wear a flannel mask with earl ties
89454078|NCT05216939|Experimental|Twill mask with ear loops|Participants will wear a twill mask with ear loops
89454079|NCT05216939|Experimental|Twill mask with ties|Participants will wear a twill mask with ties
89454080|NCT03195218|Experimental|HRME examination|HRME will capture images from all areas considered abnormal by VIA (visual inspection with acetic acid) and/or colposcopy. In addition, all four quadrants will be probed with HRME to ensure that any non-acetowhite lesions are also observed
89454081|NCT05216783|Experimental|Experimental|The Personal Information Form, the Traumatic Childbirth Perception Scale (TCPS), and the short-form Childbirth Self-Efficacy Inventory (CBSEI-32) were utilized for the collection of research data. First of all, the TCPS was applied to the pregnant women, and the pregnant women who obtained a score above 53 points (moderate-level traumatic childbirth perception) from the TCPS were invited to the research. Next, the Personal Information Form and the CBSEI-32 were applied to the pregnant women who agreed to participate in the research. The motivational interviews were held with the pregnant women in the experimental group once a week for four weeks. No initiative was applied to the pregnant women in the control group. The TCPS and CBSEI-32 were applied to all participant pregnant women after four weeks following the first application. The application of the measurement tools took 10-15 minutes.
89454082|NCT05216783|No Intervention|Control|The researchers applied no initiative to the control group, and the pregnant women in the control group solely had the routine checks performed at the city hospital. At the end of the study, the questions of pregnant women in the cotrol group about childbirth were answered. Before applying the initiative to the experimental group, the researcher (SB) had had training about motivational interview techniques.
89454083|NCT03627845|Experimental|Experimental|PHP-303, single oral dose, up to 6 ascending dose cohorts
89454084|NCT03627845|Placebo Comparator|Placebo|Placebo, single oral dose, up to 6 ascending dose cohorts
88938878|NCT01825759|Experimental|danshen dripping pill|danshen dripping pill 27mg ten pills by mouth every 8 hours for one year
88938879|NCT01825811|Experimental|TissueGene-C (Low dose)|TissueGene-C (1.0 x 10^6 cells per cm^2 of the cartilage defect) combined with fibrin-glue
89454085|NCT03199586|Experimental|NP-G2-044|capsule
89454086|NCT01918345|No Intervention|Standard Care (Control)|This group will receive a one-on-one counseling session during one visit with a Certified Diabetes Educator (CDE), who will provide standard advice on diabetes prevention and healthy lifestyle. They will receive a booklet on exercise and healthy diet as per current Canadian guidelines for healthy eating. This group will also receive a check-in telephone call from the Study Coordinator, half-way through the study. This group will not receive motivational interviewing, health coaching on low GI diet and/or exercise, or additional telephone follow-up.
89454087|NCT01918345|Experimental|Diet & Physical Activity Program with Health Coach|Participants assigned to this arm will receive a combination of the home-based physical activity program with health coach and the home-based low-GI diet program with health coach, as described in the respective individual arms. The Health Coach for this group will be a CDE.
89501772|NCT02156375|Experimental|Ustekinumab 5 mg/mL|
89501773|NCT02230423|Experimental|Patients receiving nose surgery|"Patients in need of nose surgery, before and after surgery; or only after successful surgery, then with or without Empty Nose Syndrome."
89501774|NCT03542279|Experimental|Early PE group|PE (3-5 times in each course) combined with high-dose glucocorticoid, and IVIG after PE.
89015764|NCT06201325|Active Comparator|Conventional group|Individuals in the second group, who will be included in the traditional exercise group, will be included in the stretching and strengthening exercise program for half an hour a day, 5 days a week for a total of 3 weeks, in addition to home exercise programs for half an hour a day, 5 days a week for a total of 3 weeks. The exercises will be performed by a physiotherapist working in the clinic and blind to the study.
89015765|NCT06201325|Other|Control group|In the third group, who will be included in the home exercise group, exercises will be taught to the patient and will be applied for half an hour a day, 5 days a week for a total of 3 weeks.
89537168|NCT05635695|Active Comparator|Free Museum visit|Free museum visit during 45 to 75 minutes
89537169|NCT05635695|Experimental|Cultural pathways App|Cultural pathways App during 45 to 75 minutes
89015768|NCT06191679|No Intervention|Usual Care|Subjects will have access to their oncology health care providers and other members of the health care team for questions related to cancer and cancer treatment (as per usual).
89015769|NCT06191679|Experimental|DECIDES|Subjects will receive access to DECIDES with an informational handout that includes goals of the decision support intervention and instructions for accessing the application independently.
89015770|NCT06191679|Experimental|DECIDES + coach|Subjects will receive access to DECIDES with live, coach-assisted support.
89015771|NCT06191666|Experimental|Cancer Survivors|Cancer survivors with ow/ob who have completed active treatment will take part in a single-arm 12-week feasibility/acceptability/proof-of-concept study incorporating group nutrition education and discussion, skills development sessions and cooking demonstrations, and 1:1 counseling with a dietitian.
89015772|NCT06191380|Active Comparator|Cycling Alone|Cycling alone, with no virtual reality.
89015773|NCT06191380|Experimental|Cycling with Visually Stimulating VR|Cycling with virtual reality where I only have to look at the environment while I cycle.
89015774|NCT06191380|Experimental|Cycling with Cognitively Stimulating VR|Cycling with virtual reality where I have to complete a thinking task while cycling in the virtual environment.
89015775|NCT06180499|Experimental|T-reg depleted DLI|
89015776|NCT06179472|Experimental|Balloon Arm|Participants who consent to the insertion and the removal of the Balt GOLDBAL2 Balloon.
89015777|NCT06179472|No Intervention|No Treatment|Patients who have been diagnosed with severe CDH at our site but choose not to participate in the study.
89015778|NCT06172907|Other|Young Adults Coping with Cancer Together Intervention|Young adults with cancer and their partner-caregivers will attend dyadic virtual psychotherapy sessions lasting 45-60 minutes on a weekly basis for eight weeks.
89015779|NCT06172699||Subjects successfully implanted with an Abbott Assert-IQ ICM device|Holter monitoring in subjects successfully implanted with an Abbott Assert-IQ ICM device
89015780|NCT06169514||Policy and stakeholder analysis across 6 countries|Policy and stakeholder analysis across 6 countries
89015781|NCT06164132||Normal Weight group|Their BMI ranged from 18.5 to 24.9 kg/m2.
89015782|NCT06164132||Overweight group|Their BMI ranged from 25 to 29.9 kg/m2.
89015783|NCT06164132||Obese group|Their BMI was ≥ 30 kg/m2.
89015784|NCT06163469|Experimental|Arm I|Participants will get bladder instillations of normal saline for three months and then six months of instillations with chlorohexidine gluconate. After the instillation phase the patients will undergo an observational phase with six months of catheter exchanges without the intervention.
89015785|NCT06146621|Active Comparator|Information about free tax-filing support|Basic information about where to find free tax filing support in their community will be provided to all participants by email once upon enrollment.
89015786|NCT06146621|Experimental|Low-touch text messaging|To address families' lack of awareness of the Earned Income Tax Credit (EITC) and the ways they may benefit from filing taxes, one study arm will receive low-touch text messages. These act in part by increasing awareness of programs and eligibility rules and in part as reminders to overcome limited attention to filing. Study participants receiving this intervention will receive behavioral science-informed text messages in English or Spanish from WIC that inform them about the EITC throughout tax season (i.e., January-April) 2024. We will personalize message contents (e.g., EITC benefit size mentioned in message based on participant income, marital status, and number of dependents) due to suggestive evidence that a tailored, individualized text message has the potential to be effective
89015787|NCT06146621|Experimental|Personal tax filing support|Participants randomized to this intervention will be connected with a human assistor who will work with them to ensure they access resources to help them file taxes and apply for the EITC. The English- and Spanish-speaking assistors will be study team staff trained to provide personalized support to help families access resources for which they are eligible. The assistor will be available by text or phone to talk with people if they encounter barriers and will call to follow-up on a mutually agreed upon schedule.
89015788|NCT06146621|Experimental|Financial assistance|Participants randomized to this intervention will receive a $100 cash incentive for tax filing, designed to offset the time, hassle, and resources spent on tax preparation and filing, as well as psychological frictions like inattention that prevent some people from filing. This will be provided to recipients as soon as they show proof of tax filing, to provide a more immediate reward relative to the delays in receiving a federal tax refund. We will test the feasibility of delivering this via gift card, check, or other modalities, in addition to evaluating the framing and incentive amount.
89015789|NCT06139458|Experimental|Cryotherapy|
89015790|NCT06139458|Experimental|Compression with Cryotherapy|
89201083|NCT03990337|Active Comparator|Ultrasound group (USG, n=65)|cricoid pressure applied by the OR nurse on the cricoid cartilage after localization with ultrasonography
89201084|NCT03987529||Sevoflurane+Remifentanil|Using inhalent agent(Sevoflurane), continuous infusion of Remifentanil
89537170|NCT04895553||Cohort Apixaban|"patients who have switched from low molecular weight heparin (LMWH) to apixaban at the recommended dose of the treating physician.~FDA approved dose 10 mg twice daily (BID) for 7 days followed by 5 mg PO BID OR physician prescribed dose"
89454088|NCT01918345|Experimental|Physical Activity Program with Health Coach|Participants will be counseled to follow physical activity recommendations for Canadians, which is at least 150 minutes of moderate physical activity per week. Participants will be asked to participate in aerobic, strength training and stretching activities. Health Coaches will use motivational interviewing, goal-setting and problem solving to assist participants in meeting their physical activity goals. More participants will be randomized to this group and the participants will either have CDE or a Registered Kinesiologist (R. Kin) as their health coach.
89454089|NCT01918345|Experimental|Diet Program with Health Coach|Participants will be counseled to follow recommendations for Canadians on healthy eating (Canada's Food Guide and Space on Your Plate. Low GI education will be layered on top of Canada's Food Guide recommendations. The goal for participants in the diet group is to lower their dietary GI by 8-10 units. Health Coaches will use motivational interviewing, goal-setting and problem solving to assist participants in meeting their dietary and low GI goals. The health coach for this group will be a CDE.
89454090|NCT02285049||Urticaria Control Test|"Evaluation by UAS28, PatGA-LS, PhyGA-LS~Fill the UCT and DLQI questionnaire"
89454091|NCT03674515|Placebo Comparator|placebo|"Smartphone application placebo"
89454092|NCT03674515|Active Comparator|"Bouge"|"Smartphone equipped with the application Bouge"
89454093|NCT03205436|Experimental|Graft|Affinity human amniotic membrane
89454094|NCT03674359||Cohort|Patients hospitalized in intensive care, meeting the inclusion criteria. BDG analysis
88938880|NCT01825811|Experimental|Experimental: TissueGene-C (High dose)|TissueGene-C (3.0 x 10^6 cells per cm^2 of the cartilage defect) combined with fibrin-glue
88938881|NCT01825824|Experimental|Stereotactic ablative radiotherapy|Stereotactic ablative radiotherapy for unresectable hepatocellular carcinoma with size ≤ 5 cm and 3cm apart from gastrointestinal tract after incomplete trans-arterial chemo-embolization
88938882|NCT01825850|Experimental|Gemigliptin|Gemigliptin 50mg q.d. during 7 days
88938883|NCT01825850|Experimental|Irbesartan|Irbesartan 300mg q.d. during 7 days
88938884|NCT01825850|Experimental|Gemiglitin + Irbesartan|Gemigliptin 50mg + Irbesartan 300mg q.d. during 7 days
88938885|NCT01825863|Active Comparator|Active abdominal wall block|60ml ropivacaine 0.375% single shot
88938886|NCT01825863|Placebo Comparator|Placebo abdominal wall block|60ml saline 9% single shot
88938887|NCT01825902|Experimental|Diagnostic (18F-FLT PET, 18F-FDG PET, DW-MRI)|Patients undergo 18F-FLT PET, 18F-FDGPET, and DW-MRI the week prior to induction therapy, within one week after the completion of induction therapy, the week prior to RT (for patients that received surgery), and within 1 week of completion of RT.
88938888|NCT01825915|Active Comparator|Laparoscopic Hysterectomy|Laparoscopic hysterectomy involving removal of both uterine corpus and cervix
88938889|NCT01825915|Active Comparator|Laparoscopic Supracervical Hysterectomy|Laparoscopic hysterectomy involving removal of the uterine corpus alone with conservation of the cervix.
88938890|NCT01825928|Experimental|paliperidone|paliperidone arm,3mg/pill,3mg/day.last84 days.
88938891|NCT01825928|Placebo Comparator|placebo|placebo group,3mg/pill,3mg/day non-forced titration method,last84 days.
89454095|NCT00312975|Experimental|Arm A|
89454096|NCT00312975|Active Comparator|Arm B|
89454097|NCT03199508|Experimental|the 3-day voiding diary group|The 3-day voiding diary group is as the experimental group in which several centers use the 3-day voiding diary by cluster randomization. The 3-day voiding diary is a medical record which need participants to fill in a table about urine volume for 2 days and 3 nights.
89454098|NCT03199508|Active Comparator|the 7-day voiding diary group|The 7-day voiding diary group is as the control group in which several centers use the 7-day voiding diary by cluster randomization. The 7-day voiding diary is a medical record which need participants to fill in a table about urine volume and drinking water volume for 4 days and 7 nights. The 3-day voiding diary group is the experimental group in which several centers use the 3-day voiding diary by cluster randomization.
88938892|NCT01825967||Acute Diverticulitis|We measured C-reactive protein in all the patients diagnosed with acute diverticulitis
88938893|NCT01825993|Experimental|PCA endovenous|1mg/10 min Morphine
88938894|NCT01825993|Active Comparator|PERIDURAL CATHETER|Peridural L-bupivacaine 0.25%
88938895|NCT01825993|Active Comparator|TANSABDOMINAL BLOCK (TAP)|L-BUPIVACAINE im
88938896|NCT01826006|Active Comparator|Excimer laser|After wire crossing, Excimer Laser will be performed. Consequently, intracoronary adenosine will be selectively administered through the guiding catheter.
88938897|NCT01826006|Active Comparator|Manual Thrombus Aspiration|After wire crossing, thrombus aspiration will be performed. The device will removed outside the body, flushed with saline and subsequently reintroduced in the culprit vessel beyond the occlusion site and intracoronary adenosine will be selectively administered.
88938898|NCT01826019|Experimental|Intervention|Intensive CV risk detection, counselling and follow-up program by NPHW; recommended CV medications will include combinations of anti-hypertensive medications (both low and high doses) and a lipid lowering agent (e.g. statin) in accordance with treatment algorithm [precise formulations used may differ in each country]; use of treatment supporters to reinforce adherence.
88938899|NCT01826019|Other|Control - Usual Care|Participants in control communities will be referred to usual care.
89454099|NCT05215301||Occupational Voice Users|Workers who uses voice extensively during work falls under occupational voice users (e.g. singers, actors, radio announcer, teacher, translator, lawyer). The grouping were made based on references from The Union of the European Phoniatricians
89454100|NCT05215301||Non-occupational Voice Users|Those who didn't use voice extensively during work falls under non-occupational voice users (motorcycle drivers, daily labor, administrative workers)
89454101|NCT02285205|Experimental|Lobeglitazone|
89454102|NCT03199820|Active Comparator|Cook Cervical balloon|Cook cervical double balloon catheter
89454103|NCT03199820|Active Comparator|Prostin E2 Vaginal suppository|Prostaglandin E2 sustained release vaginal insert
89454104|NCT03532659|Experimental|Active video game|The adolescents will be submitted to physical activity with active video game for 50 minutes, 3 times a week, for a period of eight weeks. The XBOX360® platform will be used with the Kinect accessory (Microsoft®) and Just Dance will be the selected game. The music used for intervention will be previously selected, including those that can lead to moderate intensity, and assembled in blocks of 10. For each week, a new block and challenges must be elaborated to increase the motivation to carry out the physical activity.
89454105|NCT03532659|No Intervention|control|A follow-up will be done for eight weeks to compare the variables. The adolescents in this group will be interviewed monthly to detect changes in eating habits and lifestyle.
89454106|NCT03243071|Experimental|Intervention Group|The intervention group will have access to culturally tailored website.
89454107|NCT03243071|Active Comparator|Control Group|Participants in the control group will have access to NYU 's standard trial participation website.
89454108|NCT03199430|Placebo Comparator|Placebo|1450mg Corn flour
89454109|NCT03199430|Active Comparator|Epigallocatechin gallate|1450mg Epigallocatechin gallate
89454110|NCT05725473|Experimental|Eso-Flip|Dilatation with Eso-Flip
89454111|NCT03195062|Experimental|Test meal|The subjects will receive a liquid test meal containing glucose and fructose with 13C fructose.
89454112|NCT03532503|Active Comparator|Foley catheter filled with 30 ml|The transcervical placement of the foley catheter will be performed and it will be filled with 30 ml saline. A gentle traction will be applied.
89454113|NCT03532503|Active Comparator|Foley catheter filled with 50 ml|The transcervical placement of the foley catheter will be performed and it will be filled with 50 ml saline. A gentle traction will be applied.
89454114|NCT03118388|Experimental|36 SEI youth|36 homeless youth (ages 16-24) randomized to the SEI intervention
89454115|NCT03118388|Experimental|36 IPS youth|36 homeless youth (ages 16-24) randomized to the IPS intervention
89454116|NCT02287857|Experimental|Domestic Tenofovir Disoproxil Fumarate Tablets|
89454117|NCT02287857|Active Comparator|Tenofovir Disoproxil Fumarate Tablets of Gilead|
89454118|NCT05214677|Experimental|Sequence A|cross-over
89454119|NCT05214677|Experimental|Sequence B|cross-over
89454120|NCT03532347|Experimental|EUS tissue sampling|"Device: EUS-FNA needle (Beacon) 3 passes 25g needle from head of pancreas; 22g needle from neck, body and tail~Device:EUS-FNB needle (Beacon Sharkcore) 3 passes 25g needle from head of pancreas; 22g needle from neck, body and tail"
89454121|NCT03204968|No Intervention|control|
89454122|NCT03204968|Active Comparator|Treated|
89454123|NCT03532269|Experimental|A: 3rd night with acoustic stimulation|Arm A: PSG (3 nights) with Nightly App - acoustic stimulation during the 3rd night.
89201085|NCT03987529||Propofol+Remifentanil|Using continuous infusion of Propofol and Remifentanil
89201086|NCT03990259||Male|The male individuals of the study population
89201087|NCT03990259||Female|The female individuals of the study population
89454124|NCT03532269|Experimental|B: 2nd night with acoustic stimulation|Arm B: PSG (3 nights) with Nightly App - acoustic stimulation during the 2nd night.
89454125|NCT03204890|Experimental|TPTNS|Transcutaneous Posterior Tibial Nerve Stimulation
89454126|NCT00399789|Active Comparator|Perifosine 150 mg qd|A daily dose of 150 mg to be given in one dose at bedtime. If patients experience no grade 2 toxicities during their first month of therapy, the dose will be escalated to 200 mg to be given in one dose at bedtime.
89454127|NCT00399789|Active Comparator|Perifosine 900 mg per week|A weekly dose of 900 mg to be divided into three doses of 300 mg each. If patients experience no grade 2 toxicities during their first month of therapy, the dose will be escalated to 1,200 mg divided into four doses of 300 mg.
89454128|NCT00399789|Active Comparator|Perifosine 50 mg tid|A daily dose of 150 mg to be divided into three doses of 50 mg each. If patients experience no grade 2 toxicities during their first month of therapy, the dose will be escalated to 200 mg divided into four doses of 50 mg.
89454129|NCT03118310|Placebo Comparator|Placebo|Placebo diet
89454130|NCT03118310|Experimental|5:2|5:2 diet
89454131|NCT03118310|Experimental|LCHF|LCHF diet
89454132|NCT01318499|Experimental|Nepafenac 0.3%|Nepafenac Ophthalmic Suspension, 0.3%, one drop in affected eye once daily, for 16 days, beginning one day prior to surgery, continuing on the day of surgery, and for 14 days following surgery. An additional drop was administered between 30-120 minutes prior to surgery.
89454133|NCT01318499|Active Comparator|Nepafenac 0.1%|Nepafenac Ophthalmic Suspension, 0.1%, one drop in affected eye once daily, for 16 days, beginning one day prior to surgery, continuing on the day of surgery, and for 14 days following surgery. An additional drop was administered between 30-120 minutes prior to surgery.
89454134|NCT01318499|Placebo Comparator|Nepafenac Vehicle 0.3%|Nepafenac Vehicle 0.3%, one drop in affected eye once daily, for 16 days, beginning one day prior to surgery, continuing on the day of surgery, and for 14 days following surgery. An additional drop was administered between 30-120 minutes prior to surgery.
89454135|NCT03628079|Experimental|Single arm study|"ReposMBZ 100 mg capsule by mouth followed by 8h PK sampling to decide the initial daily dose.~Treatment: Repos MBZ capsules by mouth twice daily for 16 weeks, daily dose 50mg-4g, based on the serum level of mebendazole."
89454136|NCT03118154||Manual Physical Therapy, retrospective|Endometriosis subjects treated at Clear Passage with follow up to assess changes in pain and overall health in a retrospective chart review.
89454137|NCT03118154||Control, prospective|Endometriosis control subjects not treated at Clear Passage that complete two questionnaires, 30 days apart, to assess changes in their pain levels.
89454138|NCT03204734|Experimental|Capecitabine|Capecitabine by mouth twice per day for 14 days, per 21 days as a cycle, until disease progress or toxicity can not be tolerated.Capecitabine starting dose was the dose used at the end of the combined chemotherapy regimen,eg:1000mg per BSA.
89454139|NCT03204734|Experimental|endocrine therapy|endocrine therapy will been given as a sequential treatment in Metastatic breast cancer patients who are got benefit in capecitabine-base chemotherapy.The medicine will be confirmed by the patient's past-treatment.
89454140|NCT02287935|Active Comparator|Limberg flap|Patients were divided into two groups, group 1 were treated with Limberg flap technique
89454141|NCT02287935|Active Comparator|Karydakis procedure|Patients were divided into two groups, group 2 were treated with Karydakis procedure
89454142|NCT03627689|Experimental|Active air purifier arm|Active portable air purifier for 1 month at bedside
89454143|NCT03627689|Sham Comparator|Sham air purifier arm|Placebo portable air purifier for 1 month at bedside
89454144|NCT00396357|Experimental|vildagliptin + metformin|
89454145|NCT00396357|Active Comparator|Metformin|
89454146|NCT03627611|Active Comparator|T4|
89454147|NCT03627611|Experimental|T3|
89454148|NCT02447042|Experimental|2 ml/Kg|Fluid challenge with crystalloids (2 ml/Kg) infused in 5 minutes Measurment of Pmsf-arm before and after the fluid challenge
89454149|NCT02447042|Experimental|3 ml/Kg|Fluid challenge with crystalloids (3 ml/Kg) infused in 5 minutes Measurment of Pmsf-arm before and after the fluid challenge
89454150|NCT02447042|Experimental|4 ml/kg|Fluid challenge with crystalloids (4 ml/Kg) infused in 5 minutes Measurment of Pmsf-arm before and after the fluid challenge
89454151|NCT02447042|Experimental|5 ml/Kg|Fluid challenge with crystalloids (5 ml/Kg) infused in 5 minutes Measurment of Pmsf-arm before and after the fluid challenge
89454152|NCT00394563|Experimental|1|monoclonal antibody
89454153|NCT00394563|Experimental|2|
89454154|NCT00394563|Experimental|3|
89454155|NCT00394563|Experimental|4|
89454156|NCT00394563|Experimental|5|
89454157|NCT00394563|Placebo Comparator|placebo|
89454158|NCT05194319||1/Children with diparetic cerebral palsy|Children with diparetic cerebral palsy
89454159|NCT05194319||2/Healty control|Children with healty peer ages of cerebral palsy children.
89454160|NCT02449538|Experimental|everolimus|everolimus 10 mg qd daily
89454161|NCT04469361||Ballerinas|Balerina students who have trained at least for 4 years
88938900|NCT01826032|Experimental|CPAP|"Patients with CPAP treatment. Titration will be performed by polysomnography or automatic CPAP to determine the optimal treatment pressure.~This group will also be instructed in hygienic-dietary measures and sleep hygiene counselling."
88938901|NCT01826032|Active Comparator|Standard care for OSA|Sleep hygiene ( regular sleep schedule, avoid sedative drugs, alcohol and tobacco, physical exercise) and dietary counselling
88938902|NCT01826045|Experimental|Poly-gamma Glutamic Acid|Patients with cervical intraepithelial neoplasia 1(CIN1) will be administered Poly-gamma Glutamic Acid for 4 weeks.
88938903|NCT01826045|Placebo Comparator|Placebo|Patients with cervical intraepithelial neoplasia 1(CIN1) will be administered placebo for 4 weeks.
88938904|NCT01826058|Experimental|Stereotactic body radiation therapy|"SBRT in one to four fractions~Irradiated total RT dose to gross tumor volume (GTV) according to fraction size~1 fx: 16 to 24 Gy~2 fx's: 20 to 26 Gy~3 fx's: 21 to 30 Gy~4 fx's: 24 to 36 Gy"
89454162|NCT04469361||Female students|Female students with sedentary lifestyle
89454163|NCT02446652|Experimental|Hydralazine/Magnesium valproate + QT|This group will receive TRANSKRIP® (Hydralazine/Magnesium valproate) + Carboplatin plus Paclitaxel
89454164|NCT02446652|Placebo Comparator|placebo + QT|This group will receive placebo + Carboplatin plus Paclitaxel
89454165|NCT05068427|Experimental|Chidamide + Envafolimab|Patients receive Chidamide 20mg or 30mg orally twice per week and Envafolimab 400mg subcutaneous infusions every 4 weeks untile disease progression or unacceptable toxicity.
89454166|NCT05193695|No Intervention|Control|Patients remained in the supine position for 20 minutes lying on a stretcher after dry needling.
89454167|NCT05193695|Experimental|Treadmill|The patients walked on a treadmill for 20 minutes after dry needling, with an inclination of 5 degrees and at a speed at which the perceived exertion was 5 according to the Borg CR10 scale (Chen et al., 2002).
88938905|NCT01826071|No Intervention|Symptomatic Treatment|
88938906|NCT01826071|Experimental|Static Stretch|Home exercise program with static stretching
88938907|NCT01826071|Experimental|Active Elongation|Home exercise program with active elongation exercises
88938908|NCT01826097|Experimental|Vibration|Whole body vibration applied to a group of 20 bladder cancer patients.
88938909|NCT01826110|Experimental|[11C]PIB|[11C]PIB
88938910|NCT01826123|Active Comparator|Conventional laboratory testing|"After being randomized to the group conventional coagulating testing, hemostatic therapy will be based exclusively on conventional standard coagulation analyses like International normalized ratio (INR), activated prothrombin time (aPTT), fibrinogen and platelet concentration or Activated clotting time (ACT. Analyses will be performed at i) fixed time points (preoperative and at admission to ICU) and ii) variable timepoints depending on the decision of the attending physician. Hemostatic therapy will be based on a specific hemostatic therapy algorithm. Intraoperatively, analyses of ACT (activated clotting time) and INR will be performed following institutional standards using specific POC tests."
89454168|NCT00299325|Experimental|Rimonabant|Rimonabant 20 mg once daily with mild hypocaloric diet
89454169|NCT00299325|Placebo Comparator|Placebo|Placebo (for Rimonabant) once daily with mild hypocaloric diet
89454170|NCT02446808|Experimental|Intraoperative nerve monitoring|Patients for which intraoperative nerve monitoring (electromyography) is used to identify the location of somatic pelvic nerves critical to urinary continence control and erectile function in real time during robotic-assisted laparoscopic prostatectomy surgery
89454171|NCT00391209|Experimental|1|
89454172|NCT00391209|Experimental|2|
89454173|NCT02446574|Experimental|Arm A|"During the Phase I it will administered weekly paclitaxel(dose escalation) and cisplatin with concurrent radiation therapy~During the Phase II it will administered weekly paclitaxel(dose according to phase I) and cisplatin with concurrent radiation therapy"
89015791|NCT06139354|Experimental|decision aid|"A digital, interactive patient-provider HIV PEP decision aid. The decision aid will incorporate five sections of content: 1) key clinical factors input by providers; 2) tailored HIV risk sharing information; 3) standardized multimedia educational messaging regarding the effectiveness, risks, and benefits of HIV PEP; 4) direct comparisons of priorities (e.g., physical well-being - I want to do everything I can to prevent HIV, privacy - I don't want others to know about the exposure, or cost - I can't afford the pills'') completed by patients; and 5) tailored feedback regarding patient priorities for use in shared clinical decision making."
89023560|NCT05153161|Experimental|Persons with ADRD living in a residential care facility|Each consented participant will receive the current Memesto device and will be provided formal and informal training instructions. After consent and screening, a two-week training period with a Memesto device will be followed by ten weeks of data collection. An experienced research assistant will administer the baseline NPI in order to collect the agitation ratings by the family caregiver, and the professional caregiver will be collected by a trained research assistant and captured in an electronic case report form designed using REDCap.14,15 Then, participants will undergo evaluation of the NPI agitation domain at 2 weeks, 4 weeks, 6 weeks, 8 weeks, and 10 weeks. Adverse events related to the device will be collected from the family and professional caregivers. Human centered system designers will work with the operations team to enhance participant engagement and maintain high quality data collection.
89454174|NCT01775813|Experimental|Obese metformin arm|Double-blinded placebo-controlled trial of metformin during puberty, treatment arm Dosage form: Metformin 1000 mg tablets Dosage: 1000 mg by mouth twice daily Duration: From early puberty (Tanner 2-3) until puberty completion (Tanner 5), approximately 3 years
89454175|NCT01775813|Placebo Comparator|Obese placebo arm|Double-blinded placebo-controlled trial of metformin during puberty, placebo arm Dosage form: Placebo stamped to match 1000 mg metformin tablets Placebo comparator: Stamped placebo pill matching metformin dose Dosage: 1000 mg by mouth twice daily Duration: From early puberty (Tanner 2-3) until puberty completion (Tanner 5), approximately 3 years
89454176|NCT01775813|No Intervention|Obese - NT|"Comparator group for the observational comparison of metabolic changes in youth with normal weight and obesity as they progress through puberty.~Duration: From early puberty (Tanner 2-3) until puberty completion (Tanner 5), approximately 3 years"
89454177|NCT01775813|No Intervention|Normal weight|"Comparator group for the observational comparison of metabolic changes in youth with normal weight and obesity as they progress through puberty.~Duration: From early puberty (Tanner 2-3) until puberty completion (Tanner 5), approximately 3 years"
89454178|NCT03204344|Experimental|Intervention group|"For all patients, 2 bottles of oral carbohydrate (Outfast, 710 ml) is provided between 22:00-24:00 on the day before surgery. Subcutaneous insulin is administered before drinking.~For patients who entered operating room before 12:00, 1 bottle of oral carbohydrate (Outfast) is provided at 6:00 on the day of surgery. For patients who enter the operating room after 12:00, another bottle of oral carbohydrate (Outfast) is provided at least 2 hours before entering the operating room. Subcutaneous insulin is administered before drinking."
89454179|NCT03204344|Sham Comparator|Control group|"For all patients, routine fasting (drinking water allowed) begins from 22:00 on the day before surgery， water fasting begins from 6:00 on the day of surgery.~For patients who enter the operating room before 12:00, no oral or intravenoous fluid is provided from 6:00. For patients who enter the operating room after 12:00, 5% glucose (500-1000 ml) is provided by intravenous infusion from 6:00 on the day of surgery. Intravenous insulin is added (glucose:insulin=4-6:1). Electrolytes (such as sodium chloride, potasium chloride, magnesium sulfate) are added when becessary."
89454180|NCT02285517|Active Comparator|modified Meek technique|Intervention: modified Meek skin grafting technique. Patients with third degree of burns without infected wounds are included and the modified Meek results are studied , measured and compared to other group which is operated lesions by mesh technique
89454181|NCT02285517|Active Comparator|mesh technique|Intervention: mesh skin grafting technique. patients with third degree of burns without infected wounds are included and the mesh skin grafting technique results are studied , measured and compared to other group which is operated lesions by modified Meek skin grafting technique
89454182|NCT03204578|Experimental|AB (Midazolam OD/Dormicum)|Subjects with sequence AB will first receive the Intervention OD formulation (Period A, 30 µg Midazolam) and at the second visit the oral solution (Period B, 30 µg Dormicum ).
89454183|NCT03204578|Experimental|BA (Dormicum/midazolam OD)|Subjects with sequence BA will first receive the Intervention oral solution (Period B, 30 µg Dormicum) and at the second visit the OD disintegrating formulation (Period A, 30 µg Midazolam).
89454184|NCT02285595|Other|Sonendo GentleWave™ System|The Sonendo GentleWave System is intended to prepare, clean, and irrigate 1st and 2nd molar teeth indicated for root canal therapy.
89454185|NCT01694069|Active Comparator|Intermittent Infusion piperacillin-tazobactam|Piperacillin-tazobactam administered at a dose of 400 mg/kg/day (maximum of 16 grams), divided in four equal doses, administered over 30 minutes, four times a day
89454186|NCT01694069|Experimental|Continuous infusion piperacillin-tazobactam|Piperacillin-tazobactam administered at a dose of 400 mg/kg/day (maximum of 16 grams) as a continuous infusion over 24 hours, once daily
89454187|NCT03204500|Experimental|Active treatment with dual therapy|This group is composed by 20 ALS subjects under 600mg valproate and 600 mg of litium carbonate per day, during 21 months. The tablets are given orally with meals.
89454188|NCT03204500|Placebo Comparator|placebos|This group is composed by 20 ALS subjects under placebo. Blue tablets ( placebo of VPA) and white tablets (placebo of Li) are administered under the same conditions.
89454189|NCT02449616|Experimental|Study Drug|MST-188
89454190|NCT02285673|Experimental|Umbilical Cord Mesenchymal Stem Cell|
88938911|NCT01826123|Active Comparator|POC testing (ROTEM and Multiplate)|"After being randomized to the group POC testing, hemostatic therapy will be based exclusively on POC measures obtained by i) viscoelastic tests (ROTEM(R), TEM international, Munich, Germany) and aggregometric tests (multiplate, ROCHE AG, Grenzach, Germany). Analyses will be performed at variable timepoints depending on the decision of the attending physician. Hemostatic therapy will be based on a specific hemostatic therapy algorithm. Intraoperatively, analyses of ACT (activated clotting time) and INR will be performed following institutional standards using specific POC tests."
88938912|NCT01826136|Experimental|Acapella|use of the Acapella device postoperatively
88938913|NCT01826136|No Intervention|Control|
88938914|NCT01826149|Experimental|Propofol 1.0mcg|Propofol dosage titration, comparison of the effect of different concentration of propofol to the myocardial performances, namely at 1.0mcg/ml using target controlled infusion.
89201088|NCT00335959|Experimental|Chemotherapy, Chemoradiation, Surgery|"Chemotherapy: Oxaliplatin, 130 mg/m2, 2 hour IV infusion on Days 1 and 22; Capecitabine 850 mg/m2/dose, PO q 12 hours on Days 1-14 and 22-35 Chemoradiation: Capecitabine 650 mg/m2/dose, PO q 12 hours on days 43-77; Radiation therapy 180 cGy/day, 5 days/week beginning on Day 43.~Surgery: Distal subtotal gastrectomy, total gastrectomy, or proximal gastrectomy"
89454191|NCT03204032|Experimental|Tegafur and Temozolomide|
89454192|NCT03204032|Active Comparator|Tegafur and Temozolomide combined with Thalidomide|
89454193|NCT01445327||Markers of Tumor Burden and Radiation Toxicity|Serum, plasma, urine, and stool samples will be collected prior to radiotherapy for participants with gastrointestinal malignancies.
89454194|NCT02285751|Experimental|200mg acetylsalicylic acid per os|"patients with high on treatment platelet reactivity to acetylsalicylic acid are randomized to 3 different groups, one group receives 200mg acetylsalicylic acid per os"
89454195|NCT02285751|Experimental|100mg acetylsalicylic acid intravenous|"patients with high on treatment platelet reactivity to acetylsalicylic acid are randomized to 3 different groups, one group receives 100mg acetylsalicylic acid intravenously."
89454196|NCT02285751|Experimental|81 mg chewable acetylsalicylic acid|"patients with high on treatment platelet reactivity to acetylsalicylic acid are randomized to 3 different groups, one group receives 81mg chewable acetylsalicylic acid"
89454197|NCT02285751|Active Comparator|75mg clopidogrel|"control group for patients with high on treatment platelet reactivity to clopidogrel patients continue with standard treatment 75mg clopidogrel/day"
89454198|NCT02285751|Experimental|60mg prasugrel|"Loading dose of prasugrel for patients who remain tested with high on treatment platelet reactivity in spite of having received an additional loading dose of 600mg clopidogrel"
89454199|NCT02285751|Experimental|600mg clopidogrel|"additional loading dose for 24 patients tested with high on treatment platelet reactivity to clopidogrel"
89454200|NCT02285751|Experimental|180mg ticagrelor|"Loading dose of ticagrelor for patients who remain tested with high on treatment platelet reactivity in spite of having received an additional loading dose of 600mg clopidogrel Loading dose of ticagrelor for patients who remain tested with high on treatment platelet reactivity after being treated with 10mg prasugrel daily"
89454201|NCT02285751|Active Comparator|prasugrel 10mg|patients treated with 10mg prasugrel daily
89454202|NCT02446184|Experimental|Fetal cystoscopy|Fetal cystoscopy will be performed under maternal local anesthesia and fetal anesthesia. The dilated posterior urethra will be directly evaluated. Laser fulguration will be performed in case of posterior urethral valves. However, if a non membrane-like structure is found, even with the fluid injection or the guide-wire, urethral atresia (UA, US or Prune Belly syndrome) will be diagnosed and we will not attempt to perforate this structure. A vesicoamniotic shunting placement will be performed in this situation depending on the patient's consent prior to the surgery.
89454203|NCT02446184|Active Comparator|Vesicoamniotic shunt|The fetal vesicoamniotic shunt is considered the standard prenatal therapy for severe LUTO. Amnioinfusion and vesicoamniotic shunt placement will be performed under ultrasound guidance.
89454204|NCT02446184|No Intervention|No fetal intervention group|Those patients that refuse fetal intervention and do not elect to terminate the pregnancy will be followed as part of the no fetal intervention group.
89454205|NCT03532113|Experimental|Updating|The Updating intervention aims to improve the ability to monitor and quickly add or delete of content of working memory.
89454206|NCT03532113|Experimental|Inhibition|The Inhibition intervention aims to improve the ability to supersede responses that are prepotent or automatic for a given situation.
89454207|NCT03532113|Active Comparator|General Knowledge|The General knowledge intervention allows the learning of information on various topics. It does not involve attentional control but semantic knowledge.
89454208|NCT02449694|Experimental|OCS Liver|OCS Liver will be used to preserve the donor liver
89454209|NCT02446730|Active Comparator|BES with Prasugel 5mg|Biolimus-eluting stent with Prasugrel 5mg once daily MD
89454210|NCT02446730|Active Comparator|BES with Clopidogrel 75mg|Biolimus-eluting stent with Clopidogrel 75mg once daily MD
89454211|NCT03198806|Active Comparator|Control group in supine position|"Intervention:~- Only treadmill aerobic exercise with 60 min recovery in supine position"
89454212|NCT03198806|Experimental|Hydration group in supine position|"Interventions:~Treadmill aerobic exercise with 60 min recovery in supine position~Water intake"
89454213|NCT03198806|Active Comparator|Control group in orthostatic position|"Intervention:~- Only treadmill aerobic exercise with 10 min recovery in orthostatic position"
89454214|NCT03198806|Experimental|Hydration group in orthostatic position|"Interventions:~Treadmill aerobic exercise with 10 min recovery in orthostatic position~Water intake"
89454215|NCT03194828|Active Comparator|Monitoring only|Patients in this arm will be given a real-time medication use monitor to use in dispensing their topical glaucoma medication for 3 months
89454216|NCT03194828|Experimental|Monitoring and reminder|Patients in this arm will be given a real-time medication use monitor to use in dispensing their topical glaucoma medication for 3 months and will receive an automated reminder (text or voice) when a missed dose is determined by the device's system
89201089|NCT01056055||Suture anchor, Bone tunnel|Suture anchor group: patients who underwent the modified Brostrom procedure using suture anchor technique Bone tunnel group: patients who underwent the modified Brostrom procedure using bone tunnel technique
89201090|NCT01056133|Experimental|Omega-3 capsules-Fish Oil|Omega-3 fatty acids in the form of fish oil capsules (2g/d)
89201091|NCT01059097|Active Comparator|High volume surgeons|high volume surgeons performed at least 18 PD/year.
89201092|NCT01059097|Active Comparator|Low volume surgeons|low volume surgeons performed less than 18 PD/year.
89501775|NCT03542279|Active Comparator|Non-early PE group|IVIG (0.4 g/kg/d for each course for 5 d) combined with high-dose glucocorticoid, and PE after IVIG 2 weeks.
89201093|NCT01053091|Experimental|Exercise|exercise
89201094|NCT01053091|No Intervention|Control|control
89201095|NCT03987061|Experimental|MOTIV bioresorbable vascular scaffold|MOTIV bioresorbable vascular scaffold for below-the-knee artery disease
89201096|NCT01053169||Prophylaxis Cohort|Patients with coagulopathy due to liver disease or other condition requiring correction of coagulopathy who require surgical or diagnostic intervention
89201097|NCT01053169||Treatment Cohort|Patients experiencing acute bleeding perioperatively
89201098|NCT01059253|Experimental|Training|15 training sessions
89201099|NCT01059331|Experimental|Pregabalin|
89201100|NCT01059331|Placebo Comparator|Sugar pill|
89201101|NCT03985345|Experimental|EMY Probe|
89201102|NCT01059409|Experimental|Meniscal Allograft|
89201103|NCT01059487|Other|Traditional Chinese Medicine|Assessing efficacy of treating subjects/patients with Traditional Chinese Medicine (TCM) by administering SF-36v2 and PIQ-6 surveys to subjects/patients to create a baseline and then re-assessing quality of life achieved through TCM treatments by administering follow-up SF-12v2 and PIQ-6 surveys every four weeks
89201104|NCT01059721|Experimental|Soft tissue realignment|group cohort label
89201105|NCT03985111||No CVC inserted|Patients undergoing major elective colorectal resection without central venous catheter inserted pre-operatively
89201106|NCT03985111||CVC inserted|Patients undergoing major elective colorectal resection with a central venous catheter inserted pre-operatively
89201107|NCT03742063||Huvos group I|Upon histopathological examination, the tumor response was assessed on the basis of the presence and extent of necrosis, which was assessed by a combination of gross and microscopic observations. Tumor necrosis was graded as per Picci et al. tumor histopathological response grading (Huvos classification), where grade I is 0% to 49%.
89201108|NCT03742063||Huvos group II|Upon histopathological examination, the tumor response was assessed on the basis of the presence and extent of necrosis, which was assessed by a combination of gross and microscopic observations. Tumor necrosis was graded as per Picci et al. tumor histopathological response grading (Huvos classification), where grade II is 50% to 89%.
89201109|NCT03742063||Huvos group III|Upon histopathological examination, the tumor response was assessed on the basis of the presence and extent of necrosis, which was assessed by a combination of gross and microscopic observations. Tumor necrosis was graded as per Picci et al. tumor histopathological response grading (Huvos classification), where grade III is 90% to 99%.
89201110|NCT03742063||Huvos group IV|Upon histopathological examination, the tumor response was assessed on the basis of the presence and extent of necrosis, which was assessed by a combination of gross and microscopic observations. Tumor necrosis was graded as per Picci et al. tumor histopathological response grading (Huvos classification), where grade IV is 100% necrosis.
89201111|NCT03741985|Placebo Comparator|The handgrip exercise|Patients are asked to squeeze a rubber ring 30 times per min for altogether 20 minutes on non-dialysis days.The 20-minute exercise can be divided into 3 parts according to individual circumstances.
89201112|NCT03741985|Experimental|The dumbbell exercise|Patients are asked to hold 6-pound dumbbells to exercise 30 times per min for altogether 20 minutes on non-dialysis days.The 20-minute exercise can be divided into 3 parts according to individual circumstances.
89201113|NCT01059955|Experimental|Active treatment at day 0 and day 7|"Iontophoresis Delivery of Dexamethasone Phosphate (EGP-437) at one of three different iontophoretic doses. One treatment will be given at Day 0 (baseline) and one at Day 7.~The three iontophoresis doses are:~Ocular iontophoresis with EGP-437 1.2 mA-min at 0.4 mA~Ocular iontophoresis with EGP-437 2.5 mA-min at 0.8 mA~Ocular iontophoresis with EGP-437 4.5 mA-min at 1.5 mA"
89201114|NCT01059955|Active Comparator|Active Treatment at Day 0, Sham Treatment at Day 7|"Iontophoresis Delivery of Dexamethasone Phosphate (EGP-437) at one of three different iontophoretic doses. One treatment will be given at Day 0 (baseline) and a sham treatment Day 7.~The three iontophoresis doses are:~Ocular iontophoresis with EGP-437 1.2 mA-min at 0.4 mA~Ocular iontophoresis with EGP-437 2.5 mA-min at 0.8 mA~Ocular iontophoresis with EGP-437 4.5 mA-min at 1.5 mA"
89201115|NCT01060033|Other|Arm 1|"Clinical T1/T2-weighted MRI sequence per standard of care before treatment, during treatment per standard protocol, and at 3 months.~Patients may have one or all of the following sequences in addition to the standard MRI imaging:~MR Spectroscopy~Fat-saturation and Diffusion-Weighted Imaging~Dynamic Contrast Enhancement MRI (MR-DCE)~Diffusion Tensor Imaging (DTI)"
89201116|NCT01060189|Experimental|Ulinastatin|1,000,000 units of ulinastatin in 50ml solution before skin incision; 50ml saline solution after neutralization
89201117|NCT01060189|Experimental|Tranexamic Acid|15mg/kg tranexamic acid in 50ml solution before skin incision; 15mg/kg tranexamic acid in 50ml solution after neutralization
89201118|NCT01060189|Placebo Comparator|Placebo|50ml saline solution before skin incision; 50ml saline solution after neutralization
89201119|NCT03984877||Amyloidosis|TAVI patients with diagnosis of amyloidosis
89201120|NCT03984877||Non-Amyloidosis|TAVI patients without diagnosis of amyloidosis
89201121|NCT01060267|Active Comparator|Erythromycin|The patients in erythromycin group received intravenous bolus infusion of 125 mg of erythromycin lactobionate in 50 ml of normal saline
89201122|NCT01060267|No Intervention|Placebo Group endoscopic therapy|Endoscopic therapy of variceal bleeding.
89201123|NCT01060423|Experimental|hepatic TACE with irinotecan eluting beads and iv cetuximab|Irinotecan drug-eluting beads administered by hepatic chemoembolization with intravenous cetuximab (DEBIRITUX)
89201124|NCT01060423|Active Comparator|iv cetuximab and irinotecan|systemic treatment with intravenous cetuximab and irinotecan
89201125|NCT03984721|Experimental|Amylose typing|Amyloidosis typing by nanoLC-MS/MS in patients diagnosed with Amyloidosis but unable to be typed
89015792|NCT06130670|Other|Group1:Ultrasound-guided quadratus lumborum block technique|"Ultrasound-guided quadratus lumborum block technique:~the patients were placed in the lateral position. Following disinfecting of the site of injection, a convex probe (2-5 HZ, Edge, Sonosite, Seattle, the USA) was positioned in a parasagittal oblique plane at the L3-L4 level, which is approximately 4 cm from the posterior midline. The iliac crest, erector spinae (ES) muscle, QL muscle, and psoas (PM) muscle were identified, and a an 18-gauge Touhy's epidural needle (BBRAUN epidural set) was directed to the anterior part of the QL. Then, the needle tip was located between the QL and PM using the in-plane technique. Normal saline 5 mL was used to identify the plane. After confirmation of the injection site, 20 ml of 0.25% Bupivacaine bolus was injected and 1 μg/kg of dexmedetomidine dissolved in 2 ml normal saline were injected also between the QL and PM muscles divided equally on each side of the abdominal wall before induction general anesthesia."
89015793|NCT06130670|Other|Group2:Lumbar epidural block|"Lumbar epidural block:~Under strict aseptic precautions, lumbar epidural was performed for patients in Group II using a 16-gauge Touhy epidural needle by a median approach. The L3 - L4 interspaces was chosen for the injection. The epidural space identified by the loss of resistance technique. The catheter was advanced 4 cm cephalad. When the aspiration test results for blood and cerebrospinal fluid were negative, a test dose of (3 mL) 2% lidocaine was given after the placement of the epidural catheter.~In the epidural catheter a bolus dose of 15 ml bupivacaine 0.25% and 1 μg/kg of dexmedetomidine dissolved in 2 ml normal saline was injected before induction of general anesthesia."
89015794|NCT06127251|Experimental|PATH Intervention|Insufficiently active adults with obesity will be assigned to the PATH intervention.
89015795|NCT06127251|Other|Control Group|Insufficiently active adults with obesity will be assigned to the attention control group.
89015796|NCT06125054|Experimental|rt-fMRI NFT / Placebo|Participants get real time neurofeedback based on an experimental regions' activity and receive a 0.9% saline solution (i.v.) over 40 minutes.
89015797|NCT06125054|Experimental|rt-fMRI NFT / Ketamine|Participants get real time neurofeedback based on an experimental regions' activity and receive 0.71mg ketamine (i.v.) per kilogram bodyweight.
89015798|NCT06125054|Placebo Comparator|sham NFT / Placebo|Participants get a real time neurofeedback based on a control regions' activity, which serves as a sham region and receive a 0.9% saline solution (i.v.) over 40 minutes.
89015799|NCT06125054|Experimental|sham NFT / Ketamine|Participants get a real time neurofeedback based on a control regions' activity, which serves as a sham region and receive 0.71mg ketamine (i.v.) per kilogram bodyweight.
89454217|NCT05114915|Experimental|Docetaxel for Injection-qw 3/4 regimen|Docetaxel for Injection (Albumin-bound) will be administrated once every week in the first three weeks (Day 1, 8 and 15) in every 28-day cycle, starting at a dose of 30 mg/m^2.
89015800|NCT06123338|Experimental|Participants with Esophagogastric Cancer|Participants will have a diagnosis of resectable HER2+ (IHC 3+ or IHC 2+/FISH ratio >2.0) esophageal, GEJ or gastric cancer.
89015801|NCT06123039||POSITIVE Tidal Volume Challenge|Population with positive result in the tidal volume challenge. That is, an increase in PPV greater than 2% after increasing the tidal volume from 6 ml/kg to 8 ml/kg for 1 minute.
89015802|NCT06123039||NEGATIVE Tidal Volume Challenge|Population with a negative result in the tidal volume challenge. That is, not enough increase in PPV.
89015803|NCT06107452|Experimental|Experimental group|Patient with acute coronary syndrome will be included. According to their initial strength-speed profile, coronary patients will benefit from an individualized cardiac rehabilitation program, with strength or speed training adapted to the autonomic nervous system (ANS).
89454218|NCT05114915|Experimental|Docetaxel for Injection-q2w 2/4 regimen|Docetaxel for Injection (Albumin-bound) will be administrated once every week every other week (Day 1 and 15) in every 28-day cycle, starting at a dose of 50 mg/m^2.
89454219|NCT05114915|Experimental|Docetaxel for Injection-qw 2/3 regimen|Docetaxel for Injection (Albumin-bound) will be administrated once every week in the first two weeks (Day 1 and 8) in every 21-day cycle, starting at a dose of 30 mg/m^2.
89454220|NCT03532035|Experimental|Brincidofovir (BCV)|"Cohort 1: BCV 10 mg twice weekly via IV infusion over 2 hours~Cohort 2: BCV 15 mg twice weekly via IV infusion over 2 hours~Cohort 3: BCV In Cohort 3, the actual dose may be higher or lower than doses administered in previous cohorts; the maximum dose of IV BCV will be ≤ 25 mg."
89454221|NCT03532035|Active Comparator|Standard of Care (SoC)|"Subjects randomized to the SoC in each cohort will be managed per local institutional guidelines and investigator judgement. SoC treatment options may include, but are not limited to, taking a watch and-wait approach, with or without decreased immunosuppression (i.e., no active treatment), or treatment with IV Cidofovir (CDV), ganciclovir, or ribavirin."
89454222|NCT03531879||subject with plaques and without plaques|Subject with plaques and without plaques
89015804|NCT06107452|Active Comparator|Control group|Patient with acute coronary syndrome will be included. According to their initial force-velocity profile, coronary patients will have an individualized cardiac rehabilitation program, either with a training in force or in velocity.
89015805|NCT06107179||Crohns Disease|Patients with Crohns Disease
89015806|NCT06107179||Ulcerative Colitis|Patients with Ulcerative Colitis
89201126|NCT01060501|Active Comparator|5-FU|Standard arm Systemic drug administration of 5-FU (intravenous)
89454223|NCT04950257|Active Comparator|waiting list control group|Participants randomly allocated to this arm will be offered self-help components within a mobile phone app to target worry and rumination after a 6-week wait.
89454224|NCT04950257|Experimental|treatment group|Participants randomly allocated to this arm will be offered self-help components within a mobile phone app to target worry and rumination immediately.
89454225|NCT03531801||Recovered fracture group|The interventions will be conducted on both groups, on two experimental (approximately 45 minutes per session) sessions separated by 24 hours.Pressure algometry consists of measuring pressure pain thresholds at three bilateral muscle sites.Mapping referred pain areas consists of recording on an electronic body chart the area of pain induced by 60s pressure stimulation at 1.2 times the force needed to reach the pressure pain threshold, exerted on the extensor carpi radialis and the infraspinatus muscles.As group-differences can be attenuated at baseline but emerge on a sensitized (exercise-induced soreness) state, these procedures are performed at baseline and 24 hours after evoking exercise-induced muscle soreness. For further clarification see our recent publication PMID:29608510
89454226|NCT03531801||Control group|This group will receive the same intervention than the recovered fracture group
89454227|NCT03198182|Experimental|Module A|BMS-986036 Arm
89454228|NCT03198182|Placebo Comparator|Module B|Placebo Arm
89454229|NCT05037071|Experimental|Upper body compression|An arm compression sleeve with a graduated compression between 18-25 mmHg will be worn on the dominant gaming arm while performing intense gridlock training using an AIM trainer lab. Muscle oxygen saturation of the extensor radialis muscle will be measured using near infrared spectroscopy.
89454230|NCT05037071|No Intervention|No compression|Muscle oxygen saturation of the extensor radialis muscle will be measured using near infrared spectroscopy on the dominant gaming arm while performing intense gridlock training using an AIM trainer lab. .
89454231|NCT03203798|Active Comparator|Training of pelvic floor muscles|
89454232|NCT03203798|Experimental|Hipopressive abdominal gymnastics|
89454233|NCT05724927|Experimental|Animal Assisted İntervention|A total of four study interviews will be held within the scope of animal-supported activities, two days a week, from the elderly individuals in the nursing home to the participants included in the study.
89454234|NCT02446340|Experimental|dalazatide 5ug|8 subjects, 6 given active agent and 2 given placebo
89454235|NCT02446340|Experimental|dalazatide 15ug|8 subjects, 6 given active agent and 2 given placebo
89454236|NCT02446340|Experimental|dalazatide 30ug|8 subjects, 6 given active agent and 2 given placebo
89454237|NCT02446340|Experimental|dalazatide 60ug|8 subjects, 6 given active agent and 2 given placebo
89454238|NCT04669379|Experimental|Intervention group (IG/EXPECT)|
89454239|NCT04669379|No Intervention|Standard of Care (SOC)|
89454240|NCT03531567|Experimental|Virtual Reality Mystic Isle Game|"Subjects in the treatment arm will complete a prescribed 2-month treatment using the virtual reality program Mystic Isle. The OT will follow the Treatment Arm Intervention Protocol, which provides standardized guidelines for grading the intensity, level of challenge, and types of games/activities of the intervention up or down. The OT will complete weekly phone calls with participant to discuss progress, answer any questions, and remotely make updates to the game as necessary. The total time on active treatment for a subject is 8 weeks. The maximum amount of time spent on the intervention will be 7 hours/week. The minimum amount of time spent on the intervention will be 3.5 hours/week."
89501776|NCT03797521|Experimental|SXC-2023 50mg QD|SXC-2023 50mg dosed once daily for 6 weeks
88938915|NCT01826149|Experimental|Propofol 2.0mcg|Propofol dosage titration, comparison of the effect of different concentration of propofol to the myocardial performances, namely at 2.0mcg/ml using target controlled infusion.
89454241|NCT03531567|Active Comparator|Standard Home Exercise Program|"Subjects assigned to the control arm will complete the prescribed 2-month treatment. The OT will follow the Control Arm Intervention Protocol to design and prescribe the home exercise program. The OT will complete weekly phone calls with the participant to check on progress, adherence, and update the exercises as necessary. The total time on active treatment for a subject is 8 weeks. The maximum amount of time spent on the control intervention will be 7 hours/week. The minimum amount of time spent on the control intervention will be 3.5 hours/week."
89201127|NCT01060501|Experimental|5-FU + folinic acid|Experimental arm Systemic drug administration of 5-FU + folinic acid (intravenous)
88938916|NCT01826149|Experimental|Propofol 3.0mcg|Propofol dosage titration, comparison of the effect of different concentration of propofol to the myocardial performances, namely at 3.0mcg/ml using target controlled infusion.
88938917|NCT01826162|Experimental|sigmoidoscopy|2 actetate concentrations and 1 placebo are administered in randomized order after clipping a catheter in the proximal colon (sigmoidoscopy)
88938918|NCT01826162|Experimental|colonoscopy|2 actetate concentrations and 1 placebo are administered in randomized order after clipping a catheter in the distal colon (colonoscopy)
88938919|NCT01826175|Experimental|Ticagrelor|Subjects receive 180 mg of ticagrelor immediately prior to coronary artery stenting and have optical coherence tomography imaging after the stenting procedure.
88938920|NCT01826175|Active Comparator|Clopidogrel|Subjects receive 600 mg of clopidogrel immediately prior to coronary artery stenting and have optical coherence tomography imaging after the stenting procedure.
88938921|NCT01826188|Active Comparator|THC 5 mg/ml and CBD 50 mg/ml.|olive oil containing THC 5 mg/ml and CBD 50 mg/ml. which will be taken twice daily.
88938922|NCT01826188|Placebo Comparator|Placebo|olive oil but without any active ingredients.
88938923|NCT01826240|Experimental|MBCT+SPI|Note: There is only one condition in this study. Mindfulness-Based Cognitive Therapy (MBCT) is combined with Safety Planning Intervention (SPI). All individuals who choose to participate will receive MBCT+SPI.
88938924|NCT01826253||Hypovolemia|Fluid expansion
88938925|NCT01826266|Placebo Comparator|PER977-Dose 1|Dose titration
88938926|NCT01826266|Placebo Comparator|PER977-Dose 2|Dose Titration
88938927|NCT01826266|Placebo Comparator|PER977-Dose 3|Dose Titration
88938928|NCT01826266|Placebo Comparator|PER977-Dose 4|Dose Titration
88938929|NCT01826266|Placebo Comparator|PER977-Dose 5|Dose Titration
88938930|NCT01826266|Placebo Comparator|PER977-Dose 6|Dose Titration
88938931|NCT01826266|Placebo Comparator|PER977-Dose 7|Dose Titration
88938932|NCT01826279|Experimental|Resveratrol|Resveratrol 500mg 3 times daily for 1 month
88938933|NCT01826279|Placebo Comparator|Placebo|Placebo 1 tablet 3 times daily for 1 month
88938934|NCT01826305|Active Comparator|Formal Rehabilitation Therapy|Patients randomized to the formal rehabilitation therapy cohort will receive a prescription for therapy for twelve weeks following their primary knee replacement.
88938935|NCT01826305|Experimental|Independent Exercise Cohort|Patients randomized to the independent exercise cohort will receive online access to a twelve-week protocol of exercises to perform at home to strengthen and improve function of the replaced knee.
88938936|NCT01826318|Experimental|intervention|"Participants received a 10 minute instruction to cope with stress by loudly posing two task-focusing questions (what is the patient's condition?, what immediate action is needed?) when feeling overwhelmed by stress (intervention group)"
88938937|NCT01826318|No Intervention|Control|Students in the control group did not receive any further instructions.
88938938|NCT01826331|No Intervention|Control Group|Participants will be incentivized for assessments only
88938939|NCT01826331|Experimental|Incentives for Participation|Participants will be incentivized for each assessment and for each smoking cessation session they complete
88938940|NCT01826331|Experimental|Incentives for Cessation|Participants will be incentivized for each assessment and biochemically confirmed abstinence at 12 and 24 months
88938941|NCT01826383|Experimental|Active Video|This is a five-minute video that coaches parents about how to soothe their infant post-immunization.
88938942|NCT01826383|Placebo Comparator|Placebo Video|This is a video identical to that of the active video, except no specific instructions regarding how to soothe an infant post-immunization are given.
88938943|NCT01826396|Experimental|high dose irinotecan|high dose irinotecan based on UGT1A1 genotype, 5-fluorouracil, and leucovorin (FOLFIRI) for first-line treatment of locally advanced colon cancer
88938944|NCT01826409|Experimental|Fermented red ginseng|
88938945|NCT01826409|Placebo Comparator|Placebo|
88938946|NCT01826435|Experimental|Electronic Intervention|Over the three months, participants will receive a technology intervention. This will include text or email encounter notifications associated with appropriate mobile or online self-management information for medication adherence and behavior change.
88938947|NCT01826461|Experimental|PDI-192 Foam, 0.1%|topical foam, 0.1% concentration, twice daily
88938948|NCT01826461|Experimental|PDI-192 Foam, 0.15%|topical foam, 0.15% concentration, twice daily
88938949|NCT01826461|Placebo Comparator|Vehicle Foam|topical foam, 0% concentration, twice daily
88938950|NCT01826474|Experimental|PRO045, cohort 1|0.15 mg/kg until dose-titration
88938951|NCT01826474|Experimental|PRO045, cohort 2|1.0 mg/kg until dose-titration
88938952|NCT01826474|Experimental|PRO045, cohort 3|3.0 mg/kg until dose-titration
88938953|NCT01826474|Experimental|PRO045, cohort 4|6.0 mg/kg until dose-titration
89201128|NCT01060501|Experimental|5-FU + Interferon-alpha|Experimental arm Systemic drug administration of 5-FU + interferon-alpha (intravenous)
89201129|NCT01060657||conventional (C) group|
89201130|NCT01060657||low dose (L) groups|
89454242|NCT04797065|Experimental|6-minute then 9-minute withdrawal|"Patients in 6-minute then 9-minute withdrawal group will first be carefully observed in 6 minutes then in 9 minutes during the segmental withdrawal.~At 6-minute withdrawal, the left colon, transverse colon and right colon will take 2 minutes each. Then at 9-minute withdrawal, the observation of the left colon, transverse colon and the right colon will be maintained for 3 minutes each.~A stop watch will be utilized to remind endoscopists the withdrawal time. The time to perform polyp biopsy will not be included."
89454243|NCT04797065|Active Comparator|9-minute then 6-minute withdrawal|"Patients in 9-minute then 6-minute withdrawal group will first be carefully observed in 9 minutes then in 6 minutes during the segmental withdrawal.~At 9-minute withdrawal, the left colon, transverse colon and right colon will take 3 minutes each. Then at 6-minute withdrawal, the observation of the left colon, transverse colon and the right colon will be maintained for 2 minutes each.~A stop watch will be utilized to remind endoscopists the withdrawal time. The time to perform polyp biopsy will not be included."
89454244|NCT03531489|Experimental|Part 1: Feasibility|Patients will perform 6-minute walk test with AIR-AD to allow for observation and real-time feedback.
89454245|NCT03531489|Experimental|Part 2: Crossover|Crossover design where investigator will compare wearing of AIR-AD during exercise to compare distance walked with and without it.
89454246|NCT02712398|Experimental|Phasix™ ST|Subjects treated with Phasix™ ST mesh
89454247|NCT05222945|Other|Single arm composed by 34 HIV-1 infected male subjects|
89454248|NCT02288013|Other|Stratafix Tissue control device|Closure of Uterine incision at C section
89454249|NCT02288013|Other|Vicryl suture|Closure of uterine incision at C section
88938954|NCT01826474|Experimental|PRO045, cohort 5|9.0 mg/kg until move to 48 week treatment phase
88938955|NCT01826474|Experimental|PRO045, cohort 6|48 week treatment phase
88938956|NCT01826500||Patients|"Patients having any of the following criteria:~Patients with embryo transfer fresh or frozen~Patients from an IVF cycle,~Patients supported surgically for endometriosis"
88938957|NCT01826500||Controls|Controls
88938958|NCT01826526|Active Comparator|TauroSept®|"5 ml of TauroSept® will be instilled into the catheter (CVAD) each time after total parenteral nutrition (TPN) has been completed. The frequency of administration depends on the schedule of HPN. It varies between twice per week and once daily.~The duration of TauroSept® administration in this trial will be 12 months."
88938959|NCT01826526|Placebo Comparator|Saline solution 0.9%|"5 ml of saline will be instilled into the catheter (CVAD) each time after total parenteral nutrition (TPN) has been completed. The frequency of administration depends on the schedule of HPN. It varies between twice per week and once daily.~The duration of saline administration in this trial will be 12 months."
88938960|NCT01826539|Other|Innervated finger flap|donor nerve attached with the flap for finger pulp reconstruction
88938961|NCT01826552|Experimental|Orsiro|The Patient group who are treated with Osiro Hybrid Drug-Eluting Stent (Biotronik AG, Bulach, Switzeland)
88938962|NCT01826552|Active Comparator|Resolute Integrity|The Patient group who are treated with ② Resolute Integrity zotarolimus-eluting stent (Medtronic Cardiovascular, CA, Minnesota, USA)
88938963|NCT01826565|No Intervention|Control|i-gel will be inserted without rotation
89454250|NCT05222867|Experimental|Intervention|pregnant women undergoing lower back massage
89454251|NCT05222867|No Intervention|control group|pregnant women given routine care
89454252|NCT00282867|Active Comparator|tight control group|target glucose level 70-110 mg/dL
89454253|NCT00282867|Active Comparator|loose control group|target glucose level 70 - 200 mg/dL
89454254|NCT00282867|Active Comparator|usual care group|target level 70 - 300 mg/dL
89454255|NCT03203720|No Intervention|Standard Care (SC)|Standard Care (SC) in a specialty mood disorders clinic for youth with mood disorders.
89454256|NCT03203720|Experimental|SC + Brief Motivational Intervention|Standard Care (SC) in a specialty mood disorders clinic plus a Brief Motivational Intervention (BMI) targeting medication adherence.
89201131|NCT00670488|Experimental|MK-2206 30 mg QOD|Participants receive 30 mg oral MK-2206 every other day (QOD) in repeating 4-week treatment cycles.
88938964|NCT01826565|Experimental|Rotation|Rotational technique applied
88938965|NCT01826578|Experimental|single port arm|
88938966|NCT01826578|No Intervention|Conventional arm|Using 3-4 port for laparosocpic surgery
88938967|NCT01826617||Prostate Cancer- Indolent type|Patients diagnosed with Indolent type will be classified according to Epstein Criteria on histopathology results and National Comprehensive Cancer Network (NCCN) guideline recommended classification
88938968|NCT01826617||Prostate cancer- aggressive type|Patients diagnosed with aggressive type will be classified according to Epstein criteria on final histopathology findings and NCCN guideline recommended classification
88938969|NCT01826617||Acute Prostatitis|Patient diagnosed with Acute prostatitis- according to histopathology description of Biopsy result
88938970|NCT01826617||Chronic Prostatitis|Patient diagnosed with Chronic prostatitis- according to histopathology description of Biopsy result
88938971|NCT01826617||Benign Prostatic Nodular Hyperplasia|Patient diagnosed with Benign Prostatic Nodular Hyperplasia- according to histopathology description of Biopsy result
88938972|NCT01826630|Active Comparator|CLn BodyWash|CLn BodyWash will be used to wash hands of patients with Hand Atopic Dermatitis
88938973|NCT01826630|Active Comparator|Cetaphil Daily Facial Cleanser|Cetaphil Daily Facial Cleanser will be used to wash hands of patients with Hand Atopic Dermatitis
88938974|NCT01826656|Other|post-menopausal osteoporotic women|Subjects of test group will follow a tooth extraction and they will perform a CBCT scan within 10 days from the extraction and after 3 months (+/-15 days)
88938975|NCT01826656|Active Comparator|non-osteoporotic post-menopausal women|Subjects of the control group will follow a tooth extraction and will perform a CBCT scan within 2 days from the extraction and after 3 months (+/- 2 days)
88938976|NCT01826669|Active Comparator|Stretching|"The respiratory muscle stretching were developed bilaterally as follows:~Upper trapezius: head lateral flexion with a hand therapist supports the the occipital region and his shoulder, promotes the stretching;~Sternocleidomastoid: was stretched with flexion lateral and rotation of the head to the side which hands on the occipital region and in the sternal region;~Scalene: with one hand on the occipital region and the other in the sternum, the two points was stretched;~Pectoralis major: the arm was abducted, flexed the forearm and hand was in the occipital region the therapist hands in the arm and in the side of the upper chest, which was stretched craniocaudal direction;~Intercostal: therapist performs with both hands to mobilize and stretch the ribs in cranial-caudal directions."
88938977|NCT01826669|No Intervention|Rest|COPD patients were not submitted to any intervention, remaining at rest in the same place, position and time period to the treatment group.
88938978|NCT01826682|Placebo Comparator|Medical treatment|29 people are being recruited in order to the inclusion criteria for the study. Placebo controlled.
88938979|NCT01826682|Active Comparator|Physiotherapy program+medical treatment|29 people are recruited in order to the inclusion criteria for the study. Experimental group
88938980|NCT01826695|Placebo Comparator|Placebo group|35 women are recruited in order to the inclusion criteria for the study. Placebo controlled. They received only standard treatment without neurodynamic intervention. They are diagnosed with Fibromyalgia attending to the Fibromyalgia Association of Granada. The study include subjects who can complete the assessment battery of tests at the beginning and end.
88938981|NCT01826695|Active Comparator|Neurodynamic technique group|35 women are recruited, diagnosed with Fibromyalgia attending to the Fibromyalgia Association of Granada. The study include subjects who can complete the assessment battery of tests at the beginning and at the end.
88938982|NCT01826708|No Intervention|Psychomotor retardation syndromic|Psychomotor retardation syndromic by Identification of breakpoints
88938983|NCT01826721|No Intervention|Standard of Care|Patients in the Standard of Care arm receive the usual in-hospital post-transplant medication teaching class led by a transplant pharmacist.
88938984|NCT01826721|Active Comparator|TMITT|Patients in this arm receive the standard of care plus the TMITT educational intervention.
88938985|NCT01826734||Patients with dacryolits|The study population consisted of patients following a dacryolit extraction procedure. The extraction procedure was not a part of this study.
88938986|NCT01826747|Experimental|experimental|Luteal Phase support
88938987|NCT01826747|No Intervention|control|No luteal Phase support
88938988|NCT01826760||acute-on-chronic hepatitis B liver failure, training group|ACHBLF was defined as an acute hepatic insult manifesting as jaundice and coagulopathy, complicated within 4 weeks by ascites and/or encephalopathy in a patient with chronic HBV infection according to consensus recommendations of the Asian Pacific Association for the Study of the Liver in 2009. ACHBLF patients were assigned to a training cohort and a validation cohort randomly. One of the major limitations of ANN is over-training, which can lead to good performance on training sets but poor performance on relatively independent validation sets. To avoid over-training during building ANN, a part of ACHBLF patients were again randomly selected from the training group to train the network and the remaining were used for cross-validation.
89201132|NCT00670488|Experimental|MK-2206 60 mg QOD|Participants receive 60 mg oral MK-2206 QOD in repeating 4-week treatment cycles.
89201133|NCT00670488|Experimental|MK-2206 75 mg QOD|Participants receive 75 mg oral MK-2206 QOD in repeating 4-week treatment cycles.
89454257|NCT05222711|Active Comparator|Monitor used|The device is applied and the GP provides usual care.
89454258|NCT05222711|No Intervention|Usual care|Usual care is provided by the GP.
89454259|NCT03198338|Experimental|TAP group|Drug: 0.25% Bupivacaine, 0.5mL/kg
89454260|NCT03198338|Sham Comparator|Placebo group|Drug: 0.9% Normal Saline, 0.5mL/kg
89501777|NCT03797521|Experimental|SXC-2023 200mg QD|SXC-2023 200mg dosed once daily for 6 weeks
89454261|NCT05222633||Neovascular age-related macular edema|Patients with new-onset and recurrent Neovascular age-related macular edema.
89454262|NCT05222633||Diabetic macula edema|Patients with new-onset and recurrent diabetic macula edema
89454263|NCT05222633||Non-proliferative diabetic retinopathy/proliferative diabetic retinopathy|Patients with new-onset and recurrent non-proliferative diabetic retinopathy/proliferative diabetic retinopathy
89454264|NCT05222633||Retinal vein occlusions|Patients with new-onset and recurrent retinal vein occlusions
89454265|NCT05222633||Choroidal neovascularization|Patients with new-onset and recurrent choroidal neovascularization
89454266|NCT03198260|Experimental|Fascial Manipulation|fascial manipulation is a manual therapy technique were to apply deep frictional massage to the deep fascial structure or point to increase its pliability
89454267|NCT03198260|Active Comparator|Running kinematics|the change in a range of joint angles during different phases of running
89454268|NCT03198104||Liver disease|Paediatric patients (50-60 pts.) with liver disease who are scheduled for an ultrasound-guided liver biopsy as part of their standard care - these patients will be scanned using MRI and fibroscan, then will proceed through standard care pathway to receive blood tests and a liver biopsy. Findings from the fibroscan, blood tests and liver biopsy will be compared to the MRI data to determine it's accuracy in detecting and distinguishing different types of liver disease.
89454269|NCT03198104||Autoimmune Hepatitis Group (AIH)|Paediatric patients who have been diagnosed with autoimmune hepatitis and are about to initiate pharmacological treatment (15-30 pts.) will be scanned using MRI and fibroscan, then proceed through the standard care pathway to receive repeated blood tests and liver biopsies throughout treatment. MRI and fibroscan will be repeated before each liver biopsy. Findings from the fibroscan, blood tests and liver biopsy will be compared to MRI data to determine it's accuracy in monitoring liver disease.
89454270|NCT03198104||Healthy Volunteers|Healthy volunteers (20-30 children) will be scanned using MRI and fibroscan and used as healthy controls.
89454271|NCT05222243|Active Comparator|Calcium Hydroxide (CH)|Calcium Hydroxide is the gold standard for direct pulp capping depends on regeneration
89454272|NCT05222243|Experimental|MTA|Mineral trioxide aggregate used for pulp regeneration
89454273|NCT05222243|Experimental|Formocresol (FC)|composed of formaldehyde, cresol, glycerin and water used for fixation of pulp tissue
89454274|NCT04469283||caffeine efficacy|Collection of preliminary data on caffeine efficacy on movement disorders in patients with ADCY5-related dyskinesia.
89454275|NCT02285829||T4/T1=0.1-0.25|Continuous infusion will commence at the lower dose indicated (0.01mg/kg/min IV for Rocuronium, 0.5 µg/kg/min for Cisatracurium ), and TOF ratios will be monitored every 20 seconds. T4/T1 ratio of quantitative TOF test will be measured, prior pedicle screw stimulation test. When TOF ratio ranges 0.1-0.25, values of pedicle screw stimulation test will be then measured and recorded in milliamps (mA) after TOF test is performed.
89454276|NCT02285829||T4/T1=0.25-0.50|Continuous infusion will commence at the lower dose indicated (0.01mg/kg/min IV for Rocuronium Bromide, 0.5 µg/kg/min for Cisatracurium Besylate ), and TOF ratios will be monitored every 20 seconds. T4/T1 ratio of quantitative TOF test will be measured, prior pedicle screw stimulation test. When TOF ratio ranges 0.25-0.50, values of pedicle screw stimulation test will be then measured and recorded in milliamps (mA) after TOF test is performed.
89454277|NCT02285829||T4/T1=0.50-0.75|Continuous infusion will commence at the lower dose indicated (0.01mg/kg/min IV for Rocuronium Bromide, 0.5 µg/kg/min for Cisatracurium Besylate ), and TOF ratios will be monitored every 20 seconds. T4/T1 ratio of quantitative TOF test will be measured, prior pedicle screw stimulation test. When TOF ratio ranges 0.50-0.75, values of pedicle screw stimulation test will be then measured and recorded in milliamps (mA) after TOF test is performed.
89454278|NCT02285829||T4/T1=0.75-0.90|Continuous infusion will commence at the lower dose indicated (0.01mg/kg/min IV for Rocuronium Bromide, 0.5 µg/kg/min for Cisatracurium Besylate ), and TOF ratios will be monitored every 20 seconds. T4/T1 ratio of quantitative TOF test will be measured, prior pedicle screw stimulation test. When TOF ratio ranges 0.75-0.90, values of pedicle screw stimulation test will be then measured and recorded in milliamps (mA) after TOF test is performed.
89454279|NCT03203408|Experimental|OSTENIL PLUS|A single intra-articular injection of sodium hyaluronate 40 mg/2.0 ml at Day 2, i.e. 2 days post Baseline (Day 0 = Week 0)
89454280|NCT03203408|Active Comparator|SYNVISC-ONE|A single intra-articular injection of hylan G-F 20 48 mg/6 ml at Day 2, i.e. 2 days post Baseline (Day 0 = Week 0)
89454281|NCT02285985|Experimental|Saxagliptin|Saxagliptin (trade-name ONGLYZA™) is used along with diet and exercise to lower blood sugar levels in patients with Type II diabetes (condition in which blood sugar is too high because the body does not produce or use insulin normally). Saxagliptin is in a class of medications called dipeptidyl peptidase-4 (DPP-4) inhibitors. It works by increasing the amount of insulin produced by the body after meals when blood sugar is high As the blood sugar returns towards normal, the medication effect on insulin is decreased.
89454282|NCT02285985|Placebo Comparator|Placebo|Sugar pill
89501778|NCT03797521|Experimental|SXC-2023 800mg QD|SXC-2023 800mg dosed once daily for 6 weeks
89501779|NCT03797521|Placebo Comparator|Matching Placebo QD|Matching Placebo dosed once daily for 6 weeks
88938989|NCT01826760||acute-on-chronic hepatitis B liver failure, testing group|ACHBLF was defined as an acute hepatic insult manifesting as jaundice and coagulopathy, complicated within 4 weeks by ascites and/or encephalopathy in a patient with chronic HBV infection according to consensus recommendations of the Asian Pacific Association for the Study of the Liver in 2009. To avoid over-training during building ANN, a part of ACHBLF patients were again randomly selected from the training group to train the network and the remaining were used for cross-validation.
88938990|NCT01826773|Experimental|Stress only CardioPET™|"Group I will consist of 15-20 patients and will have CardioPET™ imaging performed with a repeat identical stress component at ≥ 48 hours and ≤ 10 days after the initial stress MPI study. There should be no intervention or change in symptoms between the tests, and the patient must have an angiography scheduled to be performed within 30 days.~The analysis of the acquired imaging data will determine if CardioPET™ is suitable for identifying myocardial flow defects that were observed in exercise or pharmacologic stress Tc-99m MPI imaging. The goal for this CardioPET™ imaging group is to measure blood flow at near maximal stress."
88938991|NCT01826773|Experimental|Rest only CardioPET™|"Group II will consist of 15-20 subjects will have undergone either, stress, Tc-99m MPI study or stress-echocardiography indicating ≥2 segments of ischemia. These patients must have been referred and scheduled for coronary angiography. If initial evaluation was performed with stress echocardiography, subjects will have either exercise or pharmacologic stress MPI.~CardioPET™ imaging in these subjects must be performed ≥ 48 hours and ≤ 10 days from the initial stress (stress MPI or echocardiography) at rest only. An angiography must be scheduled to be performed within 30 days."
88938992|NCT01826786|Experimental|JNJ-42165279 (100 mg)|
88938993|NCT01826786|Placebo Comparator|Placebo|
88938994|NCT01826799||adult ICU patients|All adult patients without hearing disabilities and admitted to the ICU more than 48 hours ago, with a Richmond Agitation-Sedation Scale (RASS) of -2 or higher and the capability to understand Dutch are eligible.
88938995|NCT01826864|Experimental|Arm I (sargramostim and sentinel lymph node biopsy)|Patients receive sargramostim SC 3-5 days prior to undergoing sentinel lymph node biopsy.
89454283|NCT02445950|Experimental|Technology-aided counseling|Customers receive intervention via technology-aided phone wellness counseling. The intensive phase lasts 13 weeks and includes 5 phone calls. The customers are able to view their change change needs and choose tasks/goals for the coaching. The independent phase lasts 13 weeks and coaching is done via a digital tool.
88938996|NCT01826864|Active Comparator|Arm II (hypertonic saline and sentinel lymph node biopsy)|Patients receive hypertonic saline SC 3-5 days prior to undergoing sentinel lymph node biopsy.
88938997|NCT01826877|Experimental|Treatment (autologous dendritic cells)|Patients receive AdGMCAIX-transduced autologous dendritic cells ID on days 1, 15, and 29.
89454284|NCT02445950|Active Comparator|Traditional counseling|Customers receive intervention via traditional phone wellness counseling. The intensive phase lasts 13 weeks and includes 5 phone calls. Change needs and goals are set during the phone calls. The independent phase lasts 13 weeks and includes 3 phone calls.
89454285|NCT05222009|Experimental|G-CSF arm1|PD-1 inhibitor resistance regimen+ G-CSF 3mg
88938998|NCT01826890|Experimental|NAVA technology|Following randomisation, a NAVA catheter will be introduced. The Electrical Activity of the Diaphragm (EAdi) will be viewed primarily to ensure a minimum level of diaphragm activation during the weaning phase. NAVA mode suitability/safety assessments will be conducted in all patients prior to the first initiation of the NAVA mode. The NAVA preview function on the Maquet Servo-i ventilators will be used to transfer from the previous mode to the NAVA mode, and the assessment will last for a maximum of 30 minutes. We are recommending the use of the NAVA ventilation mode during the weaning period. Following the commencement of weaning, sedation holds and spontaneous breathing trials will be conducted according to local protocols.
89454286|NCT05222009|Experimental|G-CSF arm2|PD-1 inhibitor resistance regimen+ G-CSF 6mg
89501780|NCT03740789||HBeAg positive|HBeAg positive：group A(ALT≤ULN),group B(ALT 1-2ULN),group C(ALT≥2ULN) and treated subgroup (A1,B1,C1) and untreated subgroup (A2,B2,C2).
89023561|NCT05147571|Active Comparator|Active Group (responsive stimulation ON)|Participants are implanted with the RNS System and are receiving treatment with responsive stimulation.
89454287|NCT02445872|Experimental|Arm A|Aprepitant: 125mg PO on day1, 80mg PO on day2 and day3. Palonosetron (a 5-HT3 receptor antagonist): 0.25 mg IV push on day 1 only. Dexamethasone: 5mg IV push once daily from day 1 to day 3,and 3.75mg PO on days 4-5.
89454288|NCT02445872|Active Comparator|Arm B|Palonosetron: 0.25 mg IV push on day 1 only. Dexamethasone: 5mg IV push once daily from day 1 to day 3,and 7.5mg PO on days 4-5.
89454289|NCT02286063|Active Comparator|ambulatory oxygen cylinders|Subjects randomised to have the intervention of portable oxygen for the first two weeks. Only patients with stable symptoms at the end of the 'run in' period and reproducible 6-minute walk distance on the 6MWT during the baseline visit, as a marker of clinical stability of the disease will be randomized. They will be a portable oxygen cylinder during 2 weeks when they realize activities.
89454290|NCT02286063|No Intervention|no oxygen cylinders|Subjects randomised to be on air for the first two weeks of the treatment period.
89454291|NCT02446106|Active Comparator|Soup with MSG|0.5% MSG incorporated into a soup preload
89454292|NCT02446106|Placebo Comparator|Control Soup|Negative control match for sodium (no MSG + 0.635% salt)
89454293|NCT02288169|Experimental|COPE|The experimental group will receive usual care plus the COPE intervention. This group will receive 3 individual intervention sessions. During the first intervention visit at the cancer center, the COPE group will be taught the COPE intervention in a session focusing on the patient's self-identified most bothersome symptom. Role modeling and additional instruction will be provided via video, and patients will receive the Home Care Guide for Cancer and a copy of the video to take home. Three subsequent visits with the patient during regularly scheduled clinic visits will reinforce the principles of COPE and the use of the Home Care Guide, and will help patients apply this approach to managing other symptoms. In addition they will get 2 phone calls encouraging them to apply COPE.
88938999|NCT01826890|No Intervention|Standard Care|A NAVA catheter will be inserted following randomisation. The NAVA capabilities of the ventilator will be disabled. Patients will be ventilated according to local weaning protocol as per current standard care with either Pressure Support, Synchronised Intermittent Mandatory Ventilation, Volume Controlled Ventilation, Pressure Controlled Ventilation or Pressure Regulated Volume Controlled Ventilation. Following the commencement of weaning, sedation holds and spontaneous breathing trials will be conducted according to local protocols.
88939000|NCT01826903||depressed mother/child dyad - intervention|
88939001|NCT01826903||depressed mother/child dyad - no intervention|
88939002|NCT01826903||non-depressed mother/child dyad|
88939003|NCT01826916|Experimental|5mg/m2 DX-88 IV|5mg/m2 DX-88 (ecallantide)administered intravenously
88939004|NCT01826916|Experimental|10mg/m2 DX-88 IV|10mg/m2 DX-88(ecallantide)administered intravenously
88939005|NCT01826916|Experimental|20mg/m2 DX-88 IV|20mg/m2 DX-88 (ecallantide) administered intravenously
88939006|NCT01826916|Experimental|30 mg DX-88 SC|30mg DX-88(ecallantide)administered subcutaneously
88939007|NCT01826929|Experimental|Therapeutic education|Organized intervention strategy:Informed active patient, shared decision making, appointment planning, primary care doctor-nurse teamwork, actions based on scientific evidence.
88939008|NCT01826929|No Intervention|Usual care model|
88939009|NCT01826942|Experimental|Thin skin|Single fractional CO2 treatment at surgical area closure procedure on thin skin
88939010|NCT01826942|Experimental|Thick skin|Single fractional CO2 treatment at surgical area closure procedure on thick skin
88939011|NCT01826955||Open gastrectomy|patient who undergoing open gastrectomy
89454294|NCT02288169|Sham Comparator|Support|The attention control group will receive supportive visits from the research team at the cancer center and subsequent meetings during clinic visits plus 2 subsequent supportive telephone calls, matched for time with COPE participants.
89454295|NCT02288169|No Intervention|Control|The control group will receive usual care and no additional attention from our interventionists.
88939012|NCT01826955||laparoscopic gastrectomy|patient who undergoing laparoscopic gastrectomy
88939013|NCT01826968|Experimental|Recruitment Group|The investigators used alveolar recruitment maneuver by increasing inspiratory pressure to 20 cmH20 and progressively increasing Positive Expiratory Pressure (PEEP) up to 45 cmH2O maximal (Ppeak) inspiratory pressure. The recruitment maneuver lasted 2 minutes. In this group PEEP was set to 8 cmH2O, after the recruitment maneuver, and was left until the end of the operation.
88939014|NCT01826968|No Intervention|Control Group|We did not used alveolar recruitment maneuver
88939015|NCT01826994|Other|patients|heart type fatty acid binding protein testing
89454296|NCT03203486|Experimental|Meditteranean Diet|NAFLD patients attended appointments with experienced dieticians to receive nutritional guidance based on a traditional Mediterranean Diet for 6 months.
88939016|NCT01827007|Experimental|Study arm, elevation of PEEP|
89454297|NCT05221775|Experimental|experimental arm|
89454298|NCT02288403|Experimental|Aerobic interval training|"Interval exercise at an intensity between 90-95% of maximum heart rate (15x30 s), with recoveries at an equivalent speed to 50-55 % of maximal oxygen consumption at baseline (14x60 s).~24 training sessions, 3x weekly (on alternate days)."
88939017|NCT01827020|Active Comparator|Group L (number of participants=30)|After standard anesthesia induction and before surgery, patients will receive submucosal infiltration of 12 mL lidocaine 2%, 1mg/kg into nasal cavity.
89454299|NCT02288403|Active Comparator|Continuous training|"40 minutes of continuous exercise at an intensity between 65-75% of maximum heart rate.~24 training sessions, 3x weekly (on alternate days)."
89454300|NCT03197792|Experimental|Pulmonary endarterectomy patients|All patients
89454301|NCT05221541|Experimental|Vibration|Vibration (WBV and Tendon vibration) will be applied to participants
89454302|NCT05724459|Experimental|Peer Education Group|Training on stem cell transplantation for a total of 12 hours, two days a week for three weeks, two lesson hours a day (60 min. + 60 min.)
89454303|NCT05724459|No Intervention|Control Group|
88939018|NCT01827020|Active Comparator|Group K (number of participants=30)|After standard anesthesia induction and before surgery, patients will receive submucosal infiltration of 12 mL ketamine 0.5 mg/kg plus lidocaine 2% 1 mg/kg of the intranasal cavity.
88939019|NCT01827020|Placebo Comparator|Group S (number of participants=30)|After standard anesthesia induction and before surgery, patients will receive submucosal infiltration of saline 12 mL into intranasal cavity.
88939020|NCT01827033|Other|meditation training|
88939021|NCT01827059|Active Comparator|Bosentan|Tracleer, 125-mg orange-white, round, biconvex, film-coated tablets
88939022|NCT01827059|Placebo Comparator|Placebo|Placebo tablet
88939023|NCT01827072|Experimental|NPB-01|Intravenous immunoglobulin
88939024|NCT01827085||Macintosh laryngoscope|Patients will be intubated with a conventional Machintosh laryngoscope
88939025|NCT01827085||Videolaryngoscope|Intubation with Stortz video laryngoscope
88939026|NCT01827124|Experimental|carbetocin and placebo|100microgram carbetocin IV and 1cc normal saline(placebo)infusion
88939027|NCT01827124|Experimental|oxytocin and placebo|20Interntional unit oxytocin infusion and 1cc normal saline IV
88939028|NCT01827137|Experimental|vaccine|Galinpepimut-S (GPS) inoculations are started 12-22 d following autologous stem cell transplantation (ASCT). GPS (1.0 ml of emulsion) is given s.c. on weeks 0, 2, 4, 6, 8, & 10 (i.e., x 6). Injection sites are pre-stimulated with Sargramostim (GM-CSF; 70 μg) s.c. on d -2 (± 1 d ) & d 0 of each GPS inoculation. N.B.: during each GPS inoculation, the Sargramostim & GPS are administered to the same anatomical site. Subjects are observed for >/= 30 minutes after vaccination. Non-progressing subjects who are clinically stable (no active infection with fevers & no cardiovascular/respiratory compromise) may receive up to 6 more vaccinations q-month. The use of post-ASCT maintenance therapy with either lenalidomide or bortezomib is allowed starting >/= 3 months after ASCT.
88939029|NCT01827150|Experimental|Redbull, optic nerve|"15 subjects will each be drinking a can of Redbull (250 ml) and an equal amount of water (250 ml) in two different sessions. The order in which they will do so, is determined by randomization.~Intervention: Drug: Redbull, energy drink"
88939030|NCT01827176||Recurrent Acute Rhinosinusitis|Recurrent Acute Rhinosinusitis is defined as acute rhinosinusitis more than 3 times/6 months or more than 4 times/year
88939031|NCT01827189||Comprehensive primary care practices|Comprehensive primary care practices are the intervention group.
88939032|NCT01827189||Comparison practices|Comparison practices are the case-control group--the matched set of practices in a comparison area--whose patients' outcomes will be compared to those of intervention practices.
88939033|NCT01827202|Active Comparator|Aliskiren|After a two-week phase where all RAS blockade is eliminated, patients in this arm will commence taking aliskiren 150 mg once daily for 4 weeks. Thereafter, the dose will be increased to 300 mg once daily for another 4 weeks.
88939034|NCT01827202|Active Comparator|Candesartan|After a two-week phase where all RAS blockade is eliminated, patients in this arm will commence taking candesartan 8 mg once daily for 4 weeks. Thereafter, the dose will be increased to 16 mg once daily for another 4 weeks.
89023562|NCT05147571|Sham Comparator|Sham Group (responsive stimulation OFF)|Participants are implanted with the RNS System and are not receiving treatment with responsive stimulation.
89201134|NCT00670488|Experimental|MK-2206 90 mg QOD|Participants receive 90 mg oral MK-2206 QOD in repeating 4-week treatment cycles.
89501781|NCT03740789||HBeAg negative|HBeAg negative：group A(ALT≤ULN),group B(ALT 1-2ULN),group C(ALT≥2ULN) and treated subgroup (A1,B1,C1) and untreated subgroup (A2,B2,C2).
89501782|NCT02230657|Active Comparator|Same day Discharge|
89501783|NCT02230657|Active Comparator|Next day discharge|
88939035|NCT01827215|Experimental|Intervention (Virtual Patient Advocate)|The Intervention Virtual Patient Advocate (VPA) Group participants will be given a username and secure password to log on to the Gabby site for the 12 months of the intervention. They will be encouraged to log on every two weeks or twice a month, but using the system is voluntary. They will be given the contact information of the Program Manager in the event that they have any issues or questions about the system. The research team will call each intervention participant after 6 and 12 months to conduct a follow-up phone call to collect outcome data. At the end of the intervention period, intervention participants will be invited to participate a focus group session.
88939036|NCT01827215|No Intervention|Control (Letter)|The control group will receive a letter listing the preconception risks identified in the risk assessment and they will be encouraged to see their clinician to discuss them.
89201135|NCT00670488|Experimental|MK-2206 90 mg QW|Participants receive 90 mg oral MK-2206 every week (QW) in repeating 4-week treatment cycles.
89201136|NCT00670488|Experimental|MK-2206 135 mg QW|Participants receive 135 mg oral MK-2206 QW in repeating 4-week treatment cycles.
89454304|NCT02445560|Experimental|Probiotic capsule and Fiber sachet|Participants will be randomly assigned to receive all of the following in random order: a probiotic capsule and fiber sachet daily for 2-weeks, a probiotic capsule and placebo sachet for 2-weeks, a fiber sachet and placebo capsule for 2-weeks, and placebo capsule and placebo sachet for 2-weeks. Each treatment period is separated by a 2-week washout. During each treatment period, in addition to consuming a probiotic capsule or placebo and/or a fiber sachet or placebo sachet participants will be on a controlled higher protein diet.
88939037|NCT01827228|Experimental|Primary Recent infection network tracing|"Subjects: LAg+ recent HIV infection testees & referrals with recent/acute infection; those in social/risk networks of index subjects; people who go to their venues. We'll network trace direct contacts of Index Cases & network/venue members of contacts; and maybe 3rd ring as exploratory part of project. We'll test network/venue members for recent & acute HIV. If they have recent/acute HIV infection, their network/venue contacts will be traced. We'll refer HIV+ Primary arm participants for medical/social evaluation and treatment; those with recent/acute infection on expedited scheduling and case management. We will distribute community alerts to warn people in the social environments of recent/acute infectees to be super-careful in their behaviors for the next 6 months; to tell them how to be safer; and to repeat the importance of assisting rather than stigmatizing anyone they suspect has recently become infected."
88939038|NCT01827228|Active Comparator|Contact tracing of long-term HIV+ people|We will start with 50 subjects in each city who test HIV+ but LAg negative-and who report they have just learned they are HIV+. We will recruit their sexual and injection partners, and other risk environment contacts, for two steps, as in Primary Arm. HIV+ will be referred for treatment; recent/acutes on expedited and assisted basis.
88939039|NCT01827228|Active Comparator|HIV negative comparison arm|This comparison arm will consist of 150 uninfected people in each city whom we screen in the course of testing. The key comparisons here are on two of the central variables: adverse/supportive events and behavior change. This comparison arm will help mitigate social desirability effects that can lead to inaccurate reporting and/or Hawthorne effects and related processes that can lead to behavior changes simply based on the interview. Participants in this arm will be matched on age (within five years), risk group, and gender with an Arm 1 member.
88939040|NCT01827241||Colonoscopy Outcomes|Data collected from endoscopy reports to complete a descriptive analysis of demographics, colonoscopy procedure performance, and assess type of benign colon polyps detected during screening and surveillance from 02/01/2009 - 12/31/2020.
89501784|NCT02230735|Experimental|Bipivacaine 0.5% with epinephrine|Total of 14 ml of bupivacaine hydrochloride 0.5% with epinephrine 1:200,000, 7ml in right uterosacral ligament, 7ml in left uterosacral ligament
89501785|NCT02230735|Placebo Comparator|Normal Saline|Total of 14 ml of normal saline, 7ml into the right uterosacral ligament and 7ml into the left uterosacral ligament
88939041|NCT01827280|Experimental|Metformin|Metformin 850mg/pill will be administered at lunch time and dinner time for 30 days
88939042|NCT01827280|Experimental|Vildagliptina|Vildagliptin 50mg/pill will be administered at 10 AM and at 6 PM also for 30 days.
88939043|NCT01827293|Active Comparator|Promethazine|IV promethazine (25 mg)
88939044|NCT01827293|Active Comparator|lorazepam|IV lorazepam (2 mg)
88939045|NCT01827345|Experimental|Vitamin D|Participants will take the Institute of Medicine's recommended daily dose of vitamin D (800 IU/day) for six months.
88939046|NCT01827397|Experimental|EN41-UGR7C HIV vaccine|Group 1: IM injection of 210 µg UGR7-C in 560 µg of Alum at month 0, 1 and 4
88939047|NCT01827397|Placebo Comparator|NaCl|Group 2: IM injection of 700 µL of 0.9% sodium chloride (NaCl) at month 0, 1 and 4
88939048|NCT01827423|Experimental|Surgical removal of sinonasal papiloma|The study group consisted of patients following a surgical removal of sinonasal papiloma, in which the SCCA blood levels were assessed in pre-defined intervals.
88939049|NCT01827436|Active Comparator|Conventional physical therapy|Includes traditional physical treatment, such as gait and balance training and muscle strengthening.
88939050|NCT01827436|Active Comparator|Asymmetrical gait training|Includes walking on a split-belt treadmill with the belts moving at different speeds under each leg, alternated with overground walking training.
88939051|NCT01827501|Experimental|Group GDT|Goal-directed Management according to pulse contour analysis (PulsioflexTM Monitoring)
88939052|NCT01827501|No Intervention|Group Co|Conventional fluid management
88939053|NCT01827514||People with diagnosed cancer|People wich were diagnosed with one of specific type of cancer: breast, lung, colon, head, neck and lymphoma
88939054|NCT01827540|Experimental|Cenicriviroc + Midazolam, and CVC + DTG|Grp 1: CVC 150mg qd alone from Days 1-10; CVC 150mg qd + DTG 50mg qd from Days 11-20. A single dose of midazolam 5mg administered alone on Day -1 & w/ CVC 150mg on Day 9.
88939055|NCT01827540|Experimental|Dolutegravir , and DTG + CVC|Grp 2: DTG 50 mg qd alone from Days 1-10, DTG 50 mg qd + CVC 150 mg qd from Days 11-20.
88939056|NCT01827566|Active Comparator|gluten|10 grams of gluten in each sachet to be dispersed daily on food for ten days, while maintaining a gluten free diet
88939057|NCT01827566|Placebo Comparator|gluten free flour|10 grams of gluten free flour in each sachet to be dispersed daily on food for ten days, while maintaining a gluten free diet
88939058|NCT01827618|Experimental|Rapamycin|Rapamycin 3mg orally daily x 4weeks prior to radical cystectomy
88939059|NCT01827618|No Intervention|Control|
88939060|NCT01827631|Experimental|GSK1605786 500 mg once daily|GSK1605786 500 mg is given once daily in the morning
88939061|NCT01827631|Experimental|GSK1605786 500 mg twice daily|GSK1605786 500 mg is given twice daily in the morning and in the evening
88939062|NCT01827644|Experimental|Sequence 1|Subjects will receive single doses of AFU HPMC capsule administered in a fasted state, AFU ECT administered in a fasted state, AFU HPMC capsule administered in a fed state and AFU GC administered in a fasted state (sequentially), on Day 1 of Dosing Period 1, 2, 3 and 4 (one treatment per period) respectively, with a minimum 10 Day washout between the doses in each Dosing Period
88939063|NCT01827644|Experimental|Sequence 2|Subjects will receive single doses of AFU ECT administered in a fasted state, AFU ECT administered in a fed state, AFU GC administered in a fasted state and AFU GC administered in a fed state (sequentially), on Day 1 of Dosing Period 1, 2, 3 and 4 (one treatment per period) respectively, with a minimum 10 Day washout between the doses in each Dosing Period.
89201137|NCT00670488|Experimental|MK-2206 200 mg QW|Participants receive 200 mg oral MK-2206 QW in repeating 4-week treatment cycles.
88939064|NCT01827644|Experimental|Sequence 3|Subjects will receive single doses of AFU GC administered in a fasted state, AFU GC administered in a fed state, AFU ECT administered in a fed state and AFU HPMC capsule administered in a fasted state (sequentially), on Day 1 of Dosing Period 1, 2, 3 and 4 (one treatment per period) respectively, with a minimum 10 Day washout between the doses in each Dosing Period.
88939065|NCT01827644|Experimental|Sequence 4|Subjects will receive single doses of AFU GC administered in a fed state, AFU HPMC capsule administered in a fed state, AFU HPMC capsule administered in a fasted state and AFU ECT administered in a fasted state (sequentially), on Day 1 of Dosing Period 1, 2, 3 and 4 (one treatment per period) respectively, with a minimum 10 Day washout between the doses in each Dosing Period
89201138|NCT00670488|Experimental|MK-2206 300 mg QW|Participants receive 300 mg oral MK-2206 QW in repeating 4-week treatment cycles.
89201139|NCT00670488|Experimental|MK-2206 250 mg QW|Participants receive 250 mg oral MK-2206 QW in repeating 4-week treatment cycles.
89201140|NCT00670488|Experimental|MK-2206 150 mg QW|Participants receive 150 mg oral MK-2206 QW in repeating 4-week treatment cycles.
89201141|NCT00671658|Experimental|HYPER-CVAD|Rituximab 375 mg/m^2 intravenous (IV), Cyclophosphamide (CTX) 300 mg/m^2 IV, Doxorubicin 50 mg/m^2 IV, Vincristine 2 mg IV, Dexamethasone 40 mg IV or oral (PO). Methotrexate (MTX) 12 mg intrathecally (6 mg if via Ommaya reservoir) for Courses 1,3,5,7 - 200 mg/m^2 IV followed by 800 mg/m^2 for Courses 2,4,6,8. Cytarabine 100 mg intrathecal for Courses 1,3,5,7 - 3 gm/m^2 IV for Courses 2,4,6,8. G-CSF 10 ug/kg subcutaneous injection. Mesna 600 mg/m2 a day IV, Pegylated asparaginase 2000 International units/m^2 IV. Pegfilgrastim 6 mg (flat dose) within 72 hrs after completion of chemotherapy. Solumedrol 40 mg IV for Courses 2,4,6,8.
89201142|NCT00768378|Experimental|Perceived stimulation|When subjects assigned to the perceived stimulation group increase the intensity of the stimulus, they will feel a tingling sensation on the tongue. The tingling will move on the tongue in relation to where the head/body moves.
89201143|NCT00768378|Experimental|Subliminal stimulation|When subjects assigned to the subliminal stimulation group increase the intensity of the stimulus, the device provides a stimulus that is below their conscious awareness, so they will not be able to perceive it. The stimulus will move on the tongue in relation to where the head/body moves.
89454305|NCT02445560|Experimental|Probiotic capsule and Placebo sachet|Participants will be randomly assigned to receive all of the following in random order: a probiotic capsule and fiber sachet daily for 2-weeks, a probiotic capsule and placebo sachet for 2-weeks, a fiber sachet and placebo capsule for 2-weeks, and placebo capsule and placebo sachet for 2-weeks. Each treatment period is separated by a 2-week washout. During each treatment period, in addition to consuming a probiotic capsule or placebo and/or a fiber sachet or placebo sachet participants will be on a controlled higher protein diet.
89501786|NCT02695329|Active Comparator|Vanguard with KneeAlign 2|Having total knee arthroplasty surgery with the use of a navigation system KneeAlign 2.
89501787|NCT02695329|No Intervention|Vanguard without KneeAlign 2|Having total knee arthroplasty surgery with the use of conventional surgical instruments, and without a navigation system KneeAlign 2.
88939066|NCT01827644|Experimental|Sequence 5|Subjects will receive single doses of AFU ECT administered in a fed state, AFU HPMC capsule administered in a fasted state, AFU GC administered in a fed state and AFU HPMC capsule administered in a fed state (sequentially), on Day 1 of Dosing Period 1, 2, 3 and 4 (one treatment per period) respectively, with a minimum 10 Day washout between the doses in each Dosing Period
88939067|NCT01827644|Experimental|Sequence 6|Subjects will receive single doses of AFU HPMC capsule administered in a fed state, AFU GC administered in a fasted state, AFU ECT administered in a fasted state and AFU ECT administered in a fed state (sequentially), on Day 1 of Dosing Period 1, 2, 3 and 4 (one treatment per period) respectively, with a minimum 10 Day washout between the doses in each Dosing Period
88939068|NCT01827657|Experimental|Part 1 Cohort 1 - Mild hepatic impairment|Subjects with mild hepatic impairment will be enrolled in Cohort 1 and will receive a single dose of 60 mg GSK2336805
88939069|NCT01827657|Experimental|Part 1 Cohort 2 - Moderate hepatic impairment|Subjects with moderate hepatic impairment will be enrolled in Cohort 2 and will receive a single dose of 60 mg GSK2336805
88939070|NCT01827657|Experimental|Part 1 Cohort 3 - Matched healthy volunteers to Cohort 2|Control subjects will be matched for gender, age (+/- 10 years), body mass index (BMI) (+/- 20%), and smoking status to the subjects in the moderate hepatic impairment arm. These healthy volunteers will receive a single dose of 60 mg GSK2336805
88939071|NCT01827657|Experimental|Part 2 Cohort 4 - Severe hepatic impairment|Subjects with severe hepatic impairment will be enrolled in Cohort 2 and will receive a single dose of 60 mg GSK2336805. The decision to move forward into Part 2 (severe hepatic impairment) will be based on a review of the preliminary safety and pharmacokinetic data from subjects with moderate hepatic impairment
88939072|NCT01827657|Experimental|Part 2 Cohort 5 - Matched healthy volunteers to Cohort 4|Based on emerging data from Part 1, the sponsor may decide to enroll matched controls to the severe hepatic group (i.e. in case of a change in dose or the demographics of the severe hepatic group are not well matched with the moderate control data). The subjects in this optional control cohort will be matched for gender, age (+/- 10 years), BMI (+/- 20%), and smoking status to the subjects in the severe hepatic impairment category
88939073|NCT01827683|Active Comparator|Hyperbaric oxygen therapy group|hyperbaric oxygen therapy during the first 2 months
88939074|NCT01827683|Other|Crossed group|no active intervention during the first 2 months.After 2 months will be crossed to HBOT
88939075|NCT01827696|Experimental|Treatment|American Ginseng ingestion
88939076|NCT01827696|Placebo Comparator|Placeobo|non-active ingredient
88939077|NCT01827722|Experimental|Ozurdex Arm|Ozurdex intravitreal injection (combination with monthly sham injection) administered at a 16 week interval beginning on Day 1 and ending at Week 16.
88939078|NCT01827722|Experimental|Ranibizumab Arm|Ranibizumab injection (combination with sham injections beginning on Day 1 and Week 16) administered at monthly intervals beginning Day 1 and ending at Week 20.
89201144|NCT00764712|Active Comparator|Matias protocol|A protocol based on the absolute glucose value - Matias protocol (Matias)
89201145|NCT00764712|Active Comparator|Bath protocol|A protocol based on the relative glucose change - Bath protocol (Bath)
89201146|NCT00764712|Active Comparator|eMPC|a computer-based model predictive control algorithm with variable sampling rate (eMPC)
89201147|NCT00768456|Active Comparator|1|Local infiltration with Ropivacaine
89201148|NCT00768456|Placebo Comparator|2|Local infiltration with Placebo (NaCl)
89201149|NCT00542386|Experimental|1|
89454306|NCT02445560|Experimental|Placebo capsule and Fiber sachet|Participants will be randomly assigned to receive all of the following in random order: a probiotic capsule and fiber sachet daily for 2-weeks, a probiotic capsule and placebo sachet for 2-weeks, a fiber sachet and placebo capsule for 2-weeks, and placebo capsule and placebo sachet for 2-weeks. Each treatment period is separated by a 2-week washout. During each treatment period, in addition to consuming a probiotic capsule or placebo and/or a fiber sachet or placebo sachet participants will be on a controlled higher protein diet.
89454307|NCT02445560|Placebo Comparator|Placebo capsule and Placebo sachet|Participants will be randomly assigned to receive all of the following in random order: a probiotic capsule and fiber sachet daily for 2-weeks, a probiotic capsule and placebo sachet for 2-weeks, a fiber sachet and placebo capsule for 2-weeks, and placebo capsule and placebo sachet for 2-weeks. Each treatment period is separated by a 2-week washout. During each treatment period, in addition to consuming a probiotic capsule or placebo and/or a fiber sachet or placebo sachet participants will be on a controlled higher protein diet.
89454308|NCT02286141||Intervention|Patients receiving care at primary care clinics randomized to receive the supplemental training on stratified care for back pain through the use of the StartBack Tool will be considered to be a part of the intervention group. Randomization is done at the clinic level and not at the individual patient level.
89454309|NCT02286141||Control|Patients receiving care at primary care clinics randomized to receive the standard Group Health training on the updated Guidelines for Back Pain Care will be considered to be a part of the control group. Randomization is done at the clinic level and not at the individual patient level.
89201150|NCT00542386|Placebo Comparator|2|
89201151|NCT00768612|Experimental|1|Lowest dose
89201152|NCT00768612|Experimental|2|Middle dose
89201153|NCT00768612|Experimental|3|Highest dose
89201154|NCT00768612|Active Comparator|4|Positive Control
89201155|NCT00604383|Experimental|Ruboxistaurin|
89201156|NCT00604383|Placebo Comparator|Placebo|
89454310|NCT02445638|Active Comparator|Whole egg|Subjects will be provided with a daily breakfast meal containing the equivalent of 2 whole eggs for 4 weeks.
89015807|NCT06103929||Adults referred to eating disorder services|A cohort of adults referred to a specialist adult eating disorders service will be recruited. A stratified sample of patients will be approached about participating in the study, providing the study inclusion criteria are met, and their responsible clinician does not express concerns about their participation. All study participants will be assessed with the SCAN semi-structured interview (including version 2 of the SCAN, SCANv3s0, SCANv3s1, and SCANv3s9) and will also complete two self-completion measures, the EDE-QS and the SCOFF, randomly ordered. The SCAN items will be asked about in the context of the past 4 weeks and the directly preceding 11 months (i.e., the past year), unless otherwise stated. Additionally, a subset of study participants (n = 25) will be reassessed with the SCANv3s0, SCANv3s1, SCANv3s9, EDE-QS, and SCOFF, for test-retest reliability.
89015808|NCT06102304|Placebo Comparator|Sham Extracorpeal Shock Wave|Control group (GA) Patients in (GA) will be treated by a designed physiotherapy program consisted of Myo-fascial release, stretching exercise, Proprioceptive neuromuscular facilitation (PNF) techniques, Median nerve neural glide techniques, Graduated strengthening exercises for the upper limb in addition to sham shockwave on the upper trapezius.
89015809|NCT06102304|Experimental|Focused Extracorpeal Shock wave|Patients in (GB) will be treated by Focused Extracorpeal shockwave on the trigger points of upper trapezius in addition to the same physiotherapy program as GA.
89015810|NCT06102096|Experimental|Active group|Tailored iCBT for mild to moderate common mental health problems over a period ranging from 6 to 10 weeks.
89015811|NCT06102096|No Intervention|Waiting-list|control group
89015812|NCT06097988|Experimental|ABIO3419|Patients will be included consecutively to receive ABIO3419 by intra-articular injection
89015813|NCT06093126|Experimental|lemborexant|"The study will be an N of 1 trial over 8 weeks were treatment with lemborexant being alternated with a placebo in an ABBABAAB format."
89015814|NCT06091878||Cohort 1|
89015815|NCT06080100|Active Comparator|Main group|patients with high anxiety and stress instability who underwent xenon analgosedation before refractive laser vision correction
89015816|NCT06080100|Other|Control group|patients with high anxiety and stress instability who underwent local anesthesia using standard premedication with hydroxyzine (hydroxyzine) 25 mg.
89015817|NCT06079190|Experimental|GSK4527226 Dose 1|Participants will receive GSK4527226 Dose 1
89015818|NCT06079190|Experimental|GSK4527226 Dose 2|Participants will receive GSK4527226 Dose 2
89015819|NCT06079190|Placebo Comparator|Placebo|Participants will receive placebo.
89454311|NCT02445638|Placebo Comparator|Yolk-free egg|Subjects will be provided with a daily breakfast meal containing the equivalent of 2 yolk-free eggs for 4 weeks.
89454312|NCT04700423|Experimental|A: moxidectin (8 mg) / albendazole (400 mg)|Combination therapy of moxidectin (8 mg using 2 mg tablets) plus albendazole (Zentel®, 400 mg, single tablet) administered orally at day 0
89454313|NCT04700423|Active Comparator|B: ivermectin (200 µg/kg) / albendazole (400 mg)|Combination therapy of ivermectin (Stromectol®, 200 µg/kg using 3 mg tablets) plus albendazole (Zentel®, 400 mg, single tablet) administered orally at day 0
89454314|NCT04700423|Active Comparator|C: albendazole (400 mg)|Monotherapy of albendazole (400 mg) administered orally at day 0 Other names: Zentel®
88939079|NCT01827722|Experimental|Combination Ozurdex with Ranibizumab PRN|"Ozurdex intravitreal injection administered at 16 week intervals beginning on Day 1 and ending at Week 16 with an initial IV Ranibizumab injection administered at Day 1, then treated with Ranibizumab according to reinjection parameters assessed monthly (in combination with sham if reinjection parameters are not met).~Reinjection Parameters:~10 letter drop from best corrected visual acuity or a 100 µm increase in central retinal thickness according to optical coherence tomography (Spectralis HRA + OCT)."
89454315|NCT04700423|Active Comparator|D: ivermectin (200 µg/kg)|Monotherapy of ivermectin ( 200 µg/kg using 3 mg tablets) administered orally at day 0 Other names: Stromectol®
89454316|NCT04700423|Active Comparator|E: moxidectin (8 mg)|Monotherapy of moxidectin (8 mg using 2 mg tablets) administered orally at day 0
88939080|NCT01827748|Experimental|Intraoperative Autorefractor IAR-1|This is a auto refractor mounted on an operating microscope.
88939081|NCT01827748|Active Comparator|Hartmann-Shack Auto Refractor|The Hartmann-Shack type auto refractor used with the subject sitting upright in front of the instrument.
88939082|NCT01827774|Experimental|Surgisis® Soft Tissue Graft|
88939083|NCT01827800|Experimental|eHealth weight loss intervention|The 12-month eHealth behavioral intervention includes interactive self-monitoring and feedback, tailored skills training materials, telephone counseling calls from a study coach, and primary care provider counseling.
88939084|NCT01827800|No Intervention|Usual care|Participants in the usual care arm will receive the usual primary care services offered by their community health center primary care providers.
88939085|NCT01827813|Active Comparator|Saturation biopsy|Saturation biopsy was performed in left lateral decubitus position after application of sedo-analgesia by the anesthesiologists on an outpatient basis. After preparation of the rectal ultrasound probe and assuming an appropriate position, ultrasonographic examination of the prostate was performed on axial and sagittal plane. After injecting 3 cc of prilocaine to each of the right and left lobes in the right and left periprostatic region, prostatic size was measured and changes in the zonal anatomy and ultrasonographic view of the tissue were defined. Next, biopsy procedure was performed with an 18 G, 20 cm tru-cut biopsy needle and an automatic biopsy gun. After passing beyond the rectal mucosa, the needle was advanced until 0.5 cm proximal to the area of interest by tracking the image of the needle on the screen. As a total,24,26 or 28 biopsies were taken depending on prostate volume.
88939086|NCT01827813|Active Comparator|10-12 core biopsy|10-12 core biopsy was performed in left lateral decubitus position without sedo-analgesia on an outpatient basis. After preparation of the probe and assuming an appropriate position, ultrasonographic examination of the prostate was performed on axial and sagittal plane. After injecting 3 cc of prilocaine to each of the right and left lobes in the right and left periprostatic region, prostatic size was measured and changes in the zonal anatomy and ultrasonographic view of the tissue were defined. Next, biopsy procedure was performed with an 18 G, 20 cm tru-cut biopsy needle and an automatic biopsy gun. As a total 10 or 12 core biopsies were taken depending on prostate volume. The biopsies were taken form right base, right mid, right apex, right far-lateral base, right far-lateral mid and left base, left apex, left far-lateral base, and left far-lateral mid in 10 core biopsy, also two additional transitional zone biopsies were taken in 12 core biopsies.
88939087|NCT01827826|Active Comparator|Intervention|Participants assigned to the intervention group worked with the study interventionist over the phone to reduce their risk for developing Diabetes Mellitus, Type 2. The intervention lasted for 24 weeks, with weekly phone calls for the first 12 weeks and 4 maintenance calls over the second 12 weeks. Study measurements were taken at baseline, 12 weeks, 24 weeks, and 52 weeks. After 24 weeks, the investigators randomly divided the intervention group in half. The first group did not receive any more phone calls from the interventionist. The second group continued to receive monthly 20-minute phone calls from the interventionist. At 52 weeks post-baseline participants from both groups had their labs drawn, wore a pedometer for 3 days, and called in with a self-reported weight.
88939088|NCT01827826|No Intervention|Control|Participants randomized into this group did not receive any intervention, although they were encouraged to follow-up with their doctor and follow through with usual clinical care.
88939089|NCT01827852||Cohort|
88939090|NCT01827865|Active Comparator|Etodolac Extended Release Tablets 600mg|Etodolac Extended Release Tablets 600mg of Teva Pharmaceutical Ind. Ltd., USA
88939091|NCT01827865|Experimental|Etodolac Extended Release Tablets USP 600mg|Etodolac Extended Release Tablets USP 600mg of Ipca Laboratories Limited, India
89454317|NCT02286219|Experimental|FS102|Dose escalation of either weekly or Q3W of FS102
89454318|NCT03197948||Health Services Research (electronic patient reported outcome)|Patients complete questionnaires over 15 minutes once a week over 3 months via a smartphone application. Patients rate urinary function, bowel habits, sexual function, hormonal function, and overall satisfaction. Patients with advanced disease also answer questions related to pain, fatigue/lack of energy, weight loss, and worry domains.
89454319|NCT04653467|Experimental|GLPG4399 SAD|Single doses of GLPG4399 at up to 6 dose levels in ascending order
89454320|NCT04653467|Placebo Comparator|Placebo SAD|Single doses of placebo
89454321|NCT04653467|Experimental|GLPG4399 MAD|Multiple ascending doses of GLPG4399
89454322|NCT04653467|Placebo Comparator|Placebo MAD|Multiple doses of placebo
89454323|NCT04653467|Experimental|GLPG4399 FE-rBA|Single dose of GLPG4399 in fed and fasted state
89454324|NCT04653467|Experimental|GLPG4399 FE|Single dose of GLPG4399 in fed and fasted state
89454325|NCT00273351|Experimental|[123I]B-CIT|[123I]B-CIT and SPECT imaging
89454326|NCT02445716|Active Comparator|Testosterone 500 mcg / Biolipid B2|"The arm, is part of a randomized, double-blind, placebo-controlled, parallel group trial.~The arm have 35 women. It consists of a 12-week treatment phase involving three study visits and one telephone contact at week 7 of the treatment."
89454327|NCT02445716|Placebo Comparator|Placebo|"The arm, is part of a randomized, double-blind, placebo-controlled, parallel group trial.~The arm have 35 women. It consists of a 4-week screening period plus a 12-week treatment phase involving three study visits and one telephone contact at week 7 of the treatment.~Participants will be attended at the Federal University of São Paulo / Post Graduation Program in São Paulo, Brazil for their study visits."
89201157|NCT00771108|No Intervention|control|Subjects will serve as controls, continuing current diet and activity levels. Subjects will get monthly weights by the investigator at the research center.
89201158|NCT00771108|Experimental|Exercise|For 16 weeks subjects will exercise from 30-60 minutes five times a week.
89454328|NCT04607369||Groups in General all were done under the wcgIRB, even those that were Practice groups|"Groups 1-3 were practice groups, gathering smartphone app installation, functional and usability feedback in preparation for later phase groups~Groups 4a and 4b Cohort 1 and 2 is the FDA application finalized and submitted study groups~Group 5-6 currently in continuing clinical trial during FDA application process"
89454329|NCT04607369||1-3,5 Developmental team(1), Technician(2) and Non-Clinical Groups(3) 5. Retinal practice|Individuals on the developmental team, staff members and outside clinic people 5 Retinal Practice (to do after FDA approval)
89454330|NCT04607369||4a. Cohort 1. FDA group|Patients in Neuro-Ophthalmology of Texas (NOT) PLLC practice which has referrals from multiple practices including retinal patients.
89454331|NCT04607369||4b. Cohort 2. FDA group|Patients in NOT practice
89454332|NCT04607369||6 At Home use of app in continuing clinical trial during FDA decision|Patients are educated on the app at home via app video clips and brochure, and as necessary, online training with COA (ophthalmic assistants/technicians or other trained educators) in order to do remote physiologic vision monitoring or preclinic near vision check.
89454333|NCT04607369||7a Cohort 1 FDA group responding to AI|Normal patients were tested with standard near vision tests compared with the smartphone app near vision tests. All patients were trained at home with app videos and by COA via telemedicine before coming to clinic.
89454334|NCT04607369||7b Cohort 2 FDA group responding to AI|Normal patients were tested with standard near vision tests compared with the smartphone app near vision tests. All patients were trained at home with app videos and by COA via telemedicine before coming to clinic.
89454335|NCT02286297|Experimental|Endotracheal intubation without chest compressions|Endotracheal intubation of mannikin during resuscitation without chest compressions.
89454336|NCT02286297|Experimental|Endotracheal intubation with uninterrupted chest compressions|Endotracheal intubation of mannikin during resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
88939092|NCT01827878|Active Comparator|Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets|Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets of M/s AstraZeneca Pharmaceuticals LP, USA
89201159|NCT00771186||children with vocal fold immobility|
88939093|NCT01827878|Experimental|Lisinopril and Hydrochlorothiazide Tablets (20+25) mg|Lisinopril and Hydrochlorothiazide Tablets (20+25) mg of M/s Ipca Laboratories Ltd., India
88939094|NCT01827891|Placebo Comparator|control group|Control participants did not experience the procedure of transient upper-limb ischemia.
88939095|NCT01827891|Active Comparator|remote ischemic preconditioning (RIPC) group|Those randomized to RIPC group had a pneumatic medical tourniquet cuff (width , 5 cm ; length , 40 cm) placed around their upper arm at < 2 hours before the PCI procedure. The pneumatic medical cuff was inflated to a pressure of 200 mm Hg for 5 minutes , followed by 5 minutes of deflation to allow reperfusion. This procedure was repeated for 3 times.
88939096|NCT01827917|Experimental|rabies vaccine|When injured by the animal who carries the rabies virus, the patient after standard treatment would survive or die
88939097|NCT01827956||Blood sample|Blood sample for identifying the polymorphism
88939098|NCT01827969|Experimental|ablathermy focused ultrasound|ablathermy focused ultrasound
88939099|NCT01827982|Experimental|Part 1 - Cohort 1: JNJ-54861911 1 mg|Following each dose level the observed safety and tolerability profile will be evaluated. The dose will be escalated only if the observed safety and tolerability profile is acceptable.
88939100|NCT01827982|Experimental|Part 1 - Cohort 2: JNJ-54861911 3 mg|
89201160|NCT00906711||Group I|(G1): 10 - 18 years old
89201161|NCT00906711||Group II|(G2): 20 - 35 years old
89201162|NCT00906711||Group III|(G3): 45 - 60 years old
88939101|NCT01827982|Experimental|Part 1 - Cohort 3: JNJ-54861911 9 mg|
88939102|NCT01827982|Experimental|Part 2 - Cohort 4: JNJ-54861911 9 mg|
88939103|NCT01827982|Experimental|Part 2 - Cohort 5: JNJ-54861911 27 mg|
88939104|NCT01827982|Experimental|Part 2 - Cohort 6: JNJ-54861911 81 mg|
88939105|NCT01827982|Experimental|Part 2 - Cohort 7: JNJ-54861911 160 mg|
88939106|NCT01827982|Experimental|Part 3 - Cohort 8: JNJ-54861911 (dose to be determined [tbd])|
88939107|NCT01827982|Placebo Comparator|Parts 1 through 3 - Placebo|Participants in each cohort will receive matching placebo.
88939108|NCT01827995|Other|Duo test|Self assessment
88939109|NCT01827995|Other|Routine follow up|Follow up in the clinic
88939110|NCT01828047||Elective colorectal surgeries|Patients undergoing elective colorectal procedures with an Enhanced Recovery Program. Orthogonal polarization spectral (OPS) imaging will be used to measure sublingual microcirculation
88939111|NCT01828060|Experimental|Jobelyn™|Dietary supplement Jobelyn™, 500mg daily for 8 weeks Jobelyn is a sorghum bicolor extract marketed as dietary supplement Other Name: Sorghum bicolor extract
88939112|NCT01828060|Placebo Comparator|Placebo|Placebo capsules
89201163|NCT00906711||Group IV|(G4): 65 - 85 years old
89201164|NCT04048200|Other|Control group|Anesthesia will be induced by fentanyl 1 ug/kg, propofol 2 mg/kg, and rocuronium 1 mg/kg to facilitate tracheal intubation. After endotracheal intubation, the patients will be connected to mechanical ventilator with its parameters adjusted to maint5ain etCO2 32-36 mmhg. Anesthesia will be maintained by sevoflurane 2% in a mixture of oxygen: Air 1: 1 to maintain entropy 40-60. The patients in this group will be connected to a syringe pump before induction of anesthesia that was prepared by anesthesia resident not participating in the study and contain normal saline and adjusted at a rate of 1 ml/kg/hr till the end of the surgery.
88939113|NCT01828086|Experimental|CJM112|CJM112 in different doses; single ascending and multiple ascending
88939114|NCT01828086|Placebo Comparator|Placebo|Placebo to match
88939115|NCT01828086|Active Comparator|Secukinumab|Active investigational drug.
89201165|NCT04048200|Experimental|Opioid free anesthesia group|A syringe 50 ml was prepared by anesthesia resident not participating in the study and contain 100 ug of dexmedetomidine (2 ug/ml) and 25 mg ketamine 90.5 mg/ml) and 200 mg lidocaine (4 mg/ml). The syringe will be connected to the patients before induction of anesthesia at a rate of 0.1 ml/kg/hr according to the ideal body weight. Anesthesia will be induced by propofol 2 mg/kg, and rocuronium 1 mg/kg to facilitate tracheal intubation. After endotracheal intubation, the patients will be connected to mechanical ventilator with its parameters adjusted to maint5ain etCO2 32-36 mmhg. Anesthesia will be maintained by sevoflurane 2% in a mixture of oxygen: Air 1: 1 to maintain entropy 40-60. The syringe infusion will be continued till the end of peritoneal manipulation. Patients in this group will receive magnesium sulphate preload at a dose of 40 mg/kg ideal body weight followed by maintenance infusion of 10 mg/kg/hr.
89201166|NCT00985894|Experimental|Teledermatology|Online Telemedicine Group
89201167|NCT00985894|Active Comparator|Usual Care|Conventional in-office care
88939116|NCT01828125|Active Comparator|Hyperinsulinemic hypoglycaemic clamp 1mg glucagon|A 1.0mg glucagon dose will be given during the hyperinsulinemic hypoglycaemic clamp
88939117|NCT01828125|Active Comparator|Hyperinsulinemic hypoglycaemic clamp 0.1 or 0.2mg glucagon|A dose of 0.1mg or 0.2mg will be given during the hyperinsulinemic hypoglycaemic clamp.
88939118|NCT01828138|Other|Preeclampsia|"patients with preeclampsia are given a diet with a fixed content of sodium chloride ( 50-60 mmol/day ) plus a supplement of sodium chloride tablets ( 150-200 mmol/day) OR they are given placebo tablets.~After 5 days they switch their supplement."
89454337|NCT03197636||Malignant melanoma patients|40 patients with metastatic melanoma are included. Patients are admitted to Department of Oncology, Aarhus University Hospital (AUH). The patients are recruited to the study from the outpatient clinic of the Department of Oncology when they are about to begin treatment with pembrolizumab.
88939119|NCT01828138|Other|Controls|"Controls are given a diet with a fixed content of sodium chloride ( 50-60 mmol/day ) plus a supplement of sodium chloride tablets ( 150-200 mmol/day) OR they are given placebo tablets.~After 5 days they switch their supplement"
88939120|NCT01828138|Other|not-pregnant women|"This arm is also a control- group. Controls are given a diet with a fixed content of sodium chloride ( 50-60 mmol/day ) plus a supplement of sodium chloride tablets ( 150-200 mmol/day) OR they are given placebo tablets.~After 5 days they switch their supplement"
88939121|NCT01828151||Developed skin lesions|Patients treated with noninvasive ventilation for an episode of acute respiratory failure
88939122|NCT01828177|Experimental|PDI-320|Foam, twice daily for up to 12 weeks
88939123|NCT01828177|Experimental|PDI-320 Monad #1|Foam, twice daily for up to 12 weeks
88939124|NCT01828177|Experimental|PDI-320 Monad #2|Foam, twice daily for up to 12 weeks
88939125|NCT01828177|Placebo Comparator|Vehicle|Foam, twice daily for up to 12 weeks
88939126|NCT01828203|Experimental|Minocycline|Minocycline twice daily infused over 30 minutes through central venous access as follows 800 mg + 700 mg on Day 1, 600 mg + 500 mg on Day 2, and 400 mg thereafter from Day 3 thru Day 7
88939127|NCT01828203|Placebo Comparator|Placebo|250 ml normal saline and infused over 30 minutes through central venous access twice daily for 7 days
88939128|NCT01828229|Experimental|female inactivity and hypercaloric diet|inactivity and hypercaloric diet in women for two weeks
88939129|NCT01828229|Experimental|inactivity|Inactivity for two weeks
88939130|NCT01828229|Experimental|inactivity and hypercaloric diet|inactivity and hypercaloric diet for two weeks
88939131|NCT01828229|Experimental|normal activity and hypercaloric diet|Normal activity and hypercaloric diet for two weeks
88939132|NCT01828229|Active Comparator|inactivity and iso-caloric diet|inactivity and iso-caloric diet for two weeks
88939133|NCT01828242|Experimental|Empowerment model to Diabetes|Empowerment model to improve dietary intake
88939134|NCT01828242|Active Comparator|Control group following conventional approach|Control group following conventional approach
88939135|NCT01828268||HIV infectors|100 confirmed HIV-1 infected patients who meet inclusion criteria.
89454338|NCT03197636||Healthy controls|20 Healthy volunteers (HV) are included, matched by age and gender.
89454339|NCT04597151|Experimental|Supportive care (diet education)|Patients attend group diet education sessions over 1.5-2 hours every 2 weeks (weeks 1, 3, and 5).
89454340|NCT03194438|Experimental|UZIT arm|Multi-modal components integrative therapy intervention program, Urban Zen Integrative Therapy.
88939136|NCT01828294|Other|Study Population|Study population will include patients (18-80 years old) with non-thymomatous myasthenia gravis MGFA Class II-IV receiving a minimum of 30mg of Prednisone daily and no other immunosuppression and no more 240 mgs per day of Cholinesterase inhibitor. Patients will receive Subcutaneous immunoglobulins weekly for 6 months.
88939137|NCT01828307|Active Comparator|Standard Aftercare Treatment|Standard aftercare treatment consists of once per week group counseling for six months. Aftercare includes the following topics: substance use, high-risk situations, coping and life skills training, focus groups for depression and anxiety, and AIDS education.
88939138|NCT01828307|Experimental|Standard Aftercare Treatment + Exercise Intervention|In addition to attending standard aftercare treatment, participants will receive three 50-minute motivational enhancement therapy sessions focused on exercise, plus 24 weekly contingency management sessions for exercise.
88939139|NCT01828320|Experimental|Treatment 1|Integrates evidence-based treatments derived from basic research on the circadian system
88939140|NCT01828320|Active Comparator|Treatment 2|Psychoeducation on the inter-associations between sleep, diet, exercise and stress.
88939141|NCT01828333||Intravenous artesunate - new routine in DRC|"350 patients to be enrolled~A first study group with the currently used standard for treatment of severe malaria in the DRC, i.v. quinine, was enrolled from 21 October 2012 to 15 January 2013. This study was initially planned as limited scope implementation study with pure observational character (routine diagnosis and treatment, time and motion study, feasibility assessment and costing) and thus not registered. Due to additional publications on i.v. artesunate, non-routine testing for hemoglobin levels before and after treatment plus non-routine follow up was added: Registration of study at this point."
88939142|NCT01828346|Experimental|Treatment|5-Azacitidine plus birinapant
88939143|NCT01828359|Experimental|Amosartan® tab|Amlodipine 5mg /Losartan 100mg
88939144|NCT01828359|Active Comparator|Cozaar® plus pro tab|Losartan 100mg/ HCTZ 12.5mg
88939145|NCT01828372|Other|additional blood withdrawals|"Theoretical anyone with taking a drug of interest (see list of substances and metabolites of interest) can join this trial. But we turn mainly our attention to patient groups who are excluded in modern drug approval studies."
88939146|NCT01828385|Experimental|Group Mg|Magnesium sulfate 40 mg.kg-1 + rocuronium 0.6 mg.kg-1 + sugammadex 2 mg.kg-1
88939147|NCT01828385|Active Comparator|Group C|Saline 100 ml + rocuronium 0.6 mg.kg-1 + sugammadex 2 mg.kg-1
88939148|NCT01828398|Sham Comparator|sham-tDCS + UE robot-assisted therapy|This group will receive the same robot-assisted therapy of the intervention group, in association of sham-tDCS. This consists in a 30 seconds stimulation, with the same instrumentation and electrodes placement. This method of sham stimulation was previously validated.
89015820|NCT06074796||Transgender patients|"Patients included are transgender patients who have had routine consultations as part of the transition process for transgender patients, done in the reproductive medicine department of the regional university hospital centre in Nancy. Exclusion criteria : minors, patients under guardianship or trusteeship.~French laws allow embryo transfer until 45 years for women and sperm reuse up to 60 years for men, so patients older have been excluded."
89454341|NCT03194594|Active Comparator|Group K (n = 31)|will receive a single dose of ketamine 0.5 mg/kg i.v. plus 2 ml normal saline, at 5 minutes after the induction of anesthesia
89454342|NCT03194594|Active Comparator|Group D (n = 31)|will receive dexamethasone 0.5 mg/kg i.v. plus 2 ml normal saline, at 5 minutes after the induction of anesthesia
89454343|NCT03194594|Experimental|Group KD (n = 31)|will receive ketamine 0.5 mg/kg i.v. and dexamethasone 0.5 mg/kg i.v., at 5 minutes after the induction of anesthesia
89454344|NCT04469049|Experimental|Mindfulness-based cognitive therapy (MBCT)|All participants will receive the MBCT intervention, consisting of 8 90-minute weekly group sessions.
89454345|NCT03133533|Active Comparator|laparoscopic|laparoscopic inguinal hernia repair
89454346|NCT03133533|Active Comparator|robot-assisted|robot-assisted inguinal hernia repair
89454347|NCT02450240||Depression and Anxiety Disorders|"350 subjects who screen positive for anxiety or depressive symptoms on the Patient Health Questionnaire (PHQ-9) ≥ 10 and/or Overall Anxiety Severity and Impairment Scale (OASIS) ≥ 8.~Interventions: (1) standardized diagnostic assessment, (2) self-report questionnaires, (3) behavioral tasks, (4) physiological measurements, 5) structural and functional magnetic resonance imaging and EEG, (6) biomarker and microbiome assessments, (h) blood to derive induced pluripotent stem cells, (8) and genetic and epigenetic assessments."
89454348|NCT02450240||Eating Disorders|"350 subjects who screen positive for problems related to eating behavior on the Eating Disorder Screen (SCOFF), score ≥ 2.~Interventions: (1) standardized diagnostic assessment, (2) self-report questionnaires, (3) behavioral tasks, (4) physiological measurements, 5) structural and functional magnetic resonance imaging and EEG, (6) biomarker and microbiome assessments, (h) blood to derive induced pluripotent stem cells, (8) and genetic and epigenetic assessments."
89454349|NCT02450240||Substance Use Disorders|"350 subjects who screen positive for problems related to substance use on the Drug Abuse Screening Test (DAST-10), score > 2.~Interventions: (1) standardized diagnostic assessment, (2) self-report questionnaires, (3) behavioral tasks, (4) physiological measurements, 5) structural and functional magnetic resonance imaging and EEG, (6) biomarker and microbiome assessments, (h) blood to derive induced pluripotent stem cells, (8) and genetic and epigenetic assessments."
89454350|NCT02450240||Healthy Controls|"150 subjects who do not screen positive for anxiety and depression symptoms or problems related to eating behavior and/or substance use.~Interventions: (1) standardized diagnostic assessment, (2) self-report questionnaires, (3) behavioral tasks, (4) physiological measurements, 5) structural and functional magnetic resonance imaging and EEG, (6) biomarker and microbiome assessments, (h) blood to derive induced pluripotent stem cells, (8) and genetic and epigenetic assessments."
89454351|NCT03133455|Other|Patient with Fibromyalgia|
89454352|NCT04407377|Experimental|Tolperisone 200 mg|Study Drug, Tolperisone 200mg TID
89454353|NCT04407377|Experimental|Tolperisone 400 mg|Study Drug, Tolperisone 400mg TID
89454354|NCT04407377|Active Comparator|Cyclobenzaprine|Active Comparator, Cyclobenzaprine 10mg TID
89454355|NCT04407377|Placebo Comparator|Placebo|Placebo, TID
89454356|NCT00272649|Experimental|Single Arm|Single Arm study
89454357|NCT04375085|Other|DESyne X2 Novolimus Eluting Coronary Stent System|
88939149|NCT01828398|Experimental|real-tDCS + UE robot-assisted therapy|"This group will receive continuous stimulation lasting 30 minutes during the session of robot-assisted therapy. The training session, which includes multiplanar, repetitive and target reaching movements, will be given 5 times a week for 2 weeks(REO Therapy System; Motorika, Medical LTD, Israel). Each session will last about 30 minutes.~Transcranial direct current stimulation (tDCS) will be administered as follows. The anode will be placed on the primary motor cortex (M1) of the affected hemisphere and the cathode on the contralateral M1 area. The direct current is transmitted through a pair of sponge electrodes, with a surface of 35 cm2 (7x5), soaked in saline solution and, it is generated by a constant current stimulator, with rechargeable batteries (Brainstim, EMS, Italy). This continuous stimulation lasted 30 minutes, with an intensity of 1mA."
88939150|NCT01828411||Cardiopulmonary bypass group|Patients requiring normothermic (or mild hypothermic) cardiopulmonary bypass.
88939151|NCT01828411||Hypothermic Cardiopulmonary Bypass Group|Patients requiring (deep) hypothermic cardiopulmonary bypass.
88939152|NCT01828437|Experimental|Pyridoxine plus prednisolone|allocated patients receive pyridoxine (30 mg/kg/day) in addition to prednisolone
88939153|NCT01828437|Active Comparator|Prednisolone|allocated patients receive prednisolone alone
88939154|NCT01828463|No Intervention|no treatment|comparrator
88939155|NCT01828463|Experimental|Nitisinone 1mg|interventional
88939156|NCT01828463|Experimental|Nitisinone 2mg|interventional
88939157|NCT01828463|Experimental|Nitisinone 4mg|interventional
88939158|NCT01828463|Experimental|Nitisinone 8mg|interventional
89454358|NCT03203174|Experimental|Split-hand Microneedle Botulinum Toxin A|One palm with microneedle pretreatment prior to application of topical botulinum toxin A
89454359|NCT03203174|Sham Comparator|Split-hand Sham Microneedle Botulinum Toxin A|Contralateral palm with sham microneedle pretreatment prior to application of topical botulinum toxin A
89454360|NCT03531333|Experimental|Ultrasound|ultrasound navigation guided surgery.
89454361|NCT03531333|No Intervention|Non-ultrasound|standard surgery without ultrasound guidance.
89454362|NCT04484480|Experimental|Balance training|Patients included in the study group, who received 3-month proprioception, balance and motor coordination training using the dynamic platform - Biodex Balance System.
89454363|NCT04484480|No Intervention|Control group|Patients included in the control group who did not received any intervention
89015821|NCT06071910|Other|Aortic balloon occulsion|Delivery of ER-REBOA catheter to achieve aortic occlusion during resuscitation for out of hospital cardiac arrest, refractory to conventional advanced life support
88939159|NCT01828489|Active Comparator|Standard arm MEC and ADxE|Standard protocol arm with mitoxantrone in first course (MEC) and standard ADxE treatment in course two
88939160|NCT01828489|Experimental|Experimental DxEC and standard ADxE|Experimental arm with DaunoXome in course one (DxEC) and standard ADxE treatment in course two
88939161|NCT01828489|Experimental|Standard arm MEC and experimental FLADx|Experimental arm with standard MEC in the first course (MEC) and experimental treatment with FLADx in course two
88939162|NCT01828489|Experimental|Experimental DxEC and experimental FLADx|Experimental treatment with DaunoXome in course one (DxEC) and experimental treatment with FLADx in course two
88939163|NCT01828502|Experimental|Active Intervention|Those randomized to the active intervention will receive education about secondhand smoke exposure and feedback using the cotinine test strip.
88939164|NCT01828502|Other|Education only|Those randomized to the education only group will receive only the education about secondhand smoke exposure.
88939165|NCT01828528||NAFLD after SG|26 patients with NAFLD undergoing sleeve gastrectomy (SG).
88939166|NCT01828541|Other|Standard Care|Subjects in this condition will receive our standard care for itch, which includes a stepped based algorithm of medications.
88939167|NCT01828541|Experimental|Hypnosis Condition|Subjects in this condition will receive standard care plus the addition of 4 sessions of hypnosis delivered over a two month period.
88939168|NCT01828580|Experimental|AutoLap|
88939169|NCT01828606|Experimental|Coban 2 system|The two layer system is more stiff and the material is different designed
88939170|NCT01828606|Experimental|coban lite systems|"All centres will perform the pressure measurements with Picopress, Microlab Elettronica, Italy For mobility measurements all centres will be supplied with pedometers. For perometry the centres will use their own equipment~According to protocol the materials are applied to the whole leg and the measuring devices are put in place"
88939171|NCT01828619||modified BuFlu, HSCT, elder/intolerable|The study group is the hematlogic malignant patients that older than 55years and/or with severe concurrent medical conditions, who will undergo HLA-matced allogenic HSCT to cure the disease. The patients will received a modified BuFlu conditioning.
88939172|NCT01828632|Experimental|Respiratory Physical Therapy|Patients assigned to interventional group (Respiratory Physical Therapy) were undergone a program of inspiratory muscular training (IMT) and incentive spirometer for a period of 30 days before the actual date of surgery. PiMAX, PeMAX and spirometry parameters were measured at the randomization day (baseline values)
88939173|NCT01828632|No Intervention|Control|Usual care for the four weeks before surgery. PiMAX, PeMAX and spirometry parameters were measured at the randomization day (baseline values).
88939174|NCT01828645|No Intervention|Control|Patients will be submitted to upper digestive endoscopy in the morning bearing traditional NPO (nil per oral)fast after 11:00PM
88939175|NCT01828645|Experimental|Intervention|The patients belonging to the intervention group will fast from 11:00 PM the night before but will drink 200 mL of a Carbohydrate plus whey protein enriched drink 2h before the exam.
88939176|NCT01828658|No Intervention|Clinical (control)|In the clinical arm, dry weight and ultrafiltration prescription were done exclusively using traditional clinical methods of volume assessment.
88939177|NCT01828658|Active Comparator|Bioimpedance arm|Strict bioimpedance guided dry weight prescription arm. All patients dry weights were permanently maintained in the dry weight interval recommended by the BCM device (+/- 1,1 kg); BCM measurements were performed every 3 months.
88939178|NCT01828671|Active Comparator|Oral Glucose Solution 296 ml|Study Participants will consume oral glucose solution 296 mls. Blood will be sampled via capillary at time-point 0 (before the product is consumed), and 15, 30, 45, 60, 90 and 120 minutes after consumption to determine blood glucose concentrations using a glucometer. Per standard glycemic index testing protocols, this will be repeated at another visit.
88939179|NCT01828671|Active Comparator|Corn Tortilla|Study Participants will consume 2 to 3.5 corn tortillas (12-15 cm in diameter each) with a total serving of 25 grams of available carbohydrate. Blood will be sampled via capillary at time-point 0 (before the product is consumed), and 15, 30, 45, 60, 90 and 120 minutes after consumption to determine blood glucose concentrations using a glucometer.
88939180|NCT01828671|Active Comparator|Low Soy Flour Corn Tortilla|Study Participants will consume 2 to 3.5 tortillas (12-15 cm in diameter each) with a low amount of soy flour that is 25 grams of available carbohydrate. Blood will be sampled via capillary at time-point 0 (before the product is consumed), and 15, 30, 45, 60, 90 and 120 minutes after consumption to determine blood glucose concentrations using a glucometer.
88939181|NCT01828671|Active Comparator|Moderate Soy Flour Corn Tortilla|Study Participants will consume 2 to 3.5 tortillas (12-15 cm in diameter each) with moderate amount of soy flour that has 25 grams of available carbohydrate. Blood will be sampled via capillary at time-point 0 (before the product is consumed), and 15, 30, 45, 60, 90 and 120 minutes after consumption to determine blood glucose concentrations using a glucometer.
88939182|NCT01828671|Active Comparator|High Soy Flour Corn Tortilla|Study Participants will consume 2 to 3.5 tortillas (12-15 cm in diameter each) with a high amount soy flour that has 25 grams of available carbohydrate. Blood will be sampled via capillary at time-point 0 (before the product is consumed), and 15, 30, 45, 60, 90 and 120 minutes after consumption to determine blood glucose concentrations using a glucometer.
88939183|NCT01828684|Experimental|Therapeutic Lens Coating|Subjects will wear a therapeutic lens coating for 2 weeks
88939184|NCT01828684|Sham Comparator|Sham Lens Coating|Subjects will wear a sham lens coating for 2 weeks
88939185|NCT01828723|Experimental|SVF-Enriched Lipoinjection|
88939186|NCT01828736|Active Comparator|Arm A: Platinum + Gemcitabine|"Gemcitabine = 1 000 mg/m2 Day1 and Day8 given every 21 days IV~+ If Creatinin Clearance > 60 ml/min : Cisplatin = Day 1: 70 mg/m² given every 21 days If Creatinin Clearance < 60 ml/min : Carboplatin = Day 1: AUC 5 given every 21 days"
89015822|NCT06062043|Experimental|Brief ACT with CPP Education Group|The Brief Acceptance and Commitment Training (ACT) with Chronic Pelvic Pain (CPP) education Group will attend weekly 90-minute sessions for up to six weeks to learn new ways to respond to their pain and engage in meaningful activities.
89015823|NCT06062043|No Intervention|Enhanced Treatment as Usual|The enhanced treatment as usual (TAU) condition will receive a letter with CPP-specific treatment resources and encouraged to consult with their VHA primary care clinicians for additional education and treatment options.
89015824|NCT06061913|Active Comparator|Breast Pump Suction Pattern 1|
89015825|NCT06061913|Active Comparator|Breast Pump Suction Pattern 2|
89454364|NCT02450162||conventional lateral rectus recession|This is the standard technique for recession with two single-armed sutures.Exposure of the rectus muscle insertion includes freeing the insertion and proximal muscle borders sufficiently to place the sutures. And the needle is passed through the tendon avoiding the anterior ciliary arteries. If the sutures are passed as shown a true knot is formed, and the muscle is detached. Then a caliper measures from the limbus or the original insertion. A passage of the needle through sclera. The recessed muscle is ideally parallel to the old insertion (or nearly so). Conjunctival incision was finally sutured.
89454365|NCT02450162||hang-back lateral rectus recession|"The hang-back recession has been described as a simple, safe alternative to conventional recession. The procedure is said to be less likely to result in scleral perforation because needles are placed through relatively thicker sclera near the insertion site. It is the modified techique for recession with one double-armed sutures."
89454366|NCT04612283|Active Comparator|NGA-01 gel|A formulation with natural ingredients expected to be used for joint pain in Osteoarthritis
89454367|NCT04612283|Placebo Comparator|Placebo gel|Placebo gel with no active ingredient
89454368|NCT04484402|Experimental|mesenchymal stem cells|Patients with inflammatory-dystrophic diseases of the cornea receiving standard treatment plus adipose-derived mesenchymal stem cells
89454369|NCT04484402|Experimental|limbal stem cells|Patients with inflammatory-dystrophic diseases of the cornea receiving standard treatment plus adipose-derived limbal stem cells
89454370|NCT04484402|Active Comparator|control|Patients with inflammatory-dystrophic diseases of the cornea receiving standard treatment
89454371|NCT05220995||100 patients with minimal|In advancing maternal age (AMA) women, minimal stimulation protocol (MSP) with the new combination of human menopausal gonadotrophin (hMG) and clomiphene citrate (CC) were performed for controlled ovarian hyperstimulation is defined for poor ovarian response women.
89015826|NCT06061913|Sham Comparator|Breast Pump Suction Pattern 3|
89015827|NCT06060340|Experimental|class II furcation defects|"Inclusion criteria:~Lower molars with class II furcation defects.~Full mouth plaque score (FMPS )<20% at baseline.~Full mouth bleeding score (FMBS )<10% at baseline.~Systemically healthy.~Cooperative patients.~Exclusion criteria:~Smokers.~Pregnancy and lactation.~Stage 4 Grade C periodontitis."
89454372|NCT05220995||100 patients with recombinant FSH antagonist protocol|In advancing maternal age (AMA) women, flexible antagonist protocol with recombinant FSH were performed for controlled ovarian hyperstimulation is defined for poor ovarian response women.
89454373|NCT00257205|Active Comparator|B|Choice of one or the other Dacarbazine or Temozolomide(CP-675,206) (choice)
89015828|NCT06059118|Experimental|Repeat Sequential DFMO and High dose Testosterone in Sequence with Enzalutamide|Eligible patients will receive 7 days of DFMO (1000 mg PO bid) (days 1-7 of cycle), followed by 56 days of combined testosterone (testosterone cypionate 400 mg IM on day 8 and day 36) and DFMO (1000 mg PO bid) (days 8-63 of cycle), followed by 56 days of enzalutamide (160 mg PO daily) (days 64-119).
89015829|NCT06053281|Experimental|Vitamin D|DRE patients with proved vitamin D deficiency (Serum vitamin D level <30ng/ml). intervention: Daily Cholecalciferol 1000 IU in 24 weeks.
89015830|NCT06053281|Placebo Comparator|Placebo|DRE patients with proved vitamin D deficiency (Serum vitamin D level <30ng/ml). Interventions: Daily Placebo oral (Manufactured to mimic Cholecalciferol) in 24 weeks.
89015831|NCT06052436|Experimental|Phase A: 5.000.000 thyTreg /kg|Allogeneic thyTreg 5.000.000
89015832|NCT06052436|No Intervention|Phase A: standard of care|Standard of care
89015833|NCT06052436|Experimental|Phase B: 10.000.000 thyTreg /kg|Allogeneic thyTreg 10.000.000
89015834|NCT06052436|No Intervention|Phase B: standard of care|Standard of care
89015835|NCT06051435|Active Comparator|Control group|They will receive hot packs and pelvic rocking exercises for one menstrual cycle.
89454374|NCT00257205|Experimental|A|
89454375|NCT05052749|Experimental|High Intensity Resistance Training (HIRT)|In this HIRT group, participants will perform warm-up activity for 15 minutes then high intensity resistance exercises with 120 seconds of rest interval between each set of exercise and between exercises respectively. After that, generalized stretching exercises as a cool down activity will be performed by the participants. Participants will perform exercises twice weekly, 40-50 minutes/session for 12 weeks under supervision.
89015836|NCT06051435|Experimental|Lumbar proprioception group|They will receive the same lumbar proprioception training plus hot packs and pelvic rocking exercises for one menstrual cycle.
89015837|NCT06050395|Experimental|MONITOR group: Monitoring of a Nutrition Intervention to Optimize treatment Response|Participants randomized to the MONITOR arm will be provided dietary coaching biweekly to discuss nutrition concerns, anti-inflammatory diet compliance, and set SMART goals based on their most recent Vioscreen food frequency questionnaires.
89015838|NCT06050395|Active Comparator|Standard Usual Care|Standard Usual Care participants will receive usual nutrition care received in the Moffitt Cancer Center pancreatic clinic, in addition to handouts on diet.
89015839|NCT06047379|Experimental|Phase 2a Safety Run-In - NEO212 and Ipilimumab|"- Unresectable or metastatic melanoma with uncontrolled metastases to the brain.~NEO212 - Starting one dose level under RP2D administered orally on days 1 - 5 of a 28-day treatment cycle, escalated to RP2D per Protocol dose escalation rules.~Ipilimumab - 3 mg/kg administered IV over 90 minutes every 3 weeks for a maximum of 3 doses per package insert."
89201168|NCT04034589|Experimental|Pyrotinib plus fulvestrant|Pyrotinib(400 mg once daily) + fulvestrant (500 mg, administered on days 0, 14 (plus or minus 3 days), 28 (plus or minus 3 days), and every 28 (plus or minus 3 days) days)
89201169|NCT04048434|No Intervention|Standard of care (SOC)|
89201170|NCT04048434|Experimental|Cyotosorb|
89201171|NCT00988312|Experimental|s.c. vaccination|vaccine given subcutaneously
89201172|NCT00988312|Experimental|i.v. vaccination|vaccines are given intravenously
89201173|NCT00906867||Vocal cord dysfunction|Patients with suspicion of VCD
89201174|NCT00768690|Other|1|Healthy volunteers, receiving daily doses of 200 mg ABT-333 or placebo, BID for 10 days; and on Study Day 11 receiving a single dose of 200 mg ABT-333 or placebo + 400 mg ketoconazole
89201175|NCT00768690|Other|2|Healthy volunteers, receiving 400 mg ABT-333 or placebo, BID
89201176|NCT00768690|Other|3|Healthy volunteers, receiving 600mg ABT-333 or placebo, BID
89201177|NCT00768690|Other|4|Healthy volunteers, receiving 1000mg ABT-333 or placebo, BID
89201178|NCT00768690|Other|5|"Healthy volunteers, receiving 1600mg ABT-333 or placebo, BID*~*After review of the data from previous groups, and in accordance with the protocol, this arm was not dosed."
89201179|NCT02538549|Active Comparator|ACE4 and TAU|This group will receive ACE4 as an intervention and treatment as usual.
89201180|NCT02538549|No Intervention|TAU Only|This group will receive only the treatment as usual.
89201181|NCT00775008|Experimental|podcast|
89201182|NCT00775008|Active Comparator|Web group|
89201183|NCT00985972||Intervention|Groups of school intervention that involves a combination of the physical activity and nutrition education in subjects 6 to 18 years of age
89201184|NCT00985972||Control|Groups included in the same school communities that serve as reference for individuals involved in intervention.
89201185|NCT00768768|Active Comparator|1|Iontophoretic Dose Level 1
89201186|NCT00768768|Active Comparator|2|Iontophoretic Dose Level 2
89201187|NCT00768768|Active Comparator|3|Iontophoretic Dose Level 3
89201188|NCT00768768|Active Comparator|4|Iontophoretic Dose Level 4
89201189|NCT00768768|Active Comparator|5|Iontophoretic Dose Level 5
89201190|NCT00988390|Other|Intervention, mothers living with HIV|Mothers living with HIV, Cognitive-behavioral intervention delivered in either English- or Spanish-speaking groups of 5 to 8 mothers living with HIV twice weekly for 1.5 to 2 hours each over eight weeks (n = 16 sessions)
89201191|NCT00988390|No Intervention|Control, mothers living with HIV|Mothers living with HIV, offered intervention at end of study (18 months after recruitment)
89201192|NCT00988390|No Intervention|Control, non-HIV-infected mothers|Neighborhood control mothers not infected with HIV, did not receive any intervention
89201193|NCT00908427|Active Comparator|1|PVP group
89201194|NCT00908427|Active Comparator|2|TURP group
89201195|NCT00988468|Experimental|Manual Therapy|Subjects will receive oscillatory (grade 1 & 2) manual knee mobilization for 15 minutes at various knee range of motion positions.
89201196|NCT00988468|Experimental|Therapeutic Exercise|Subjects will perform 15 minutes of combined resistance exercise and aerobic exercise.
89201197|NCT00988468|Placebo Comparator|Control|Subjects will watch a 15 minute instructional video on a health topic.
89201198|NCT02557854|Experimental|Doxil + MR-HIFU Hyperthermia|Liposomal doxorubicin (Doxil) 50mg IV every 4 weeks followed by Magnetic Resonance High Intensity Focused Ultrasound hyperthermia (MR-HIFU) with Philips Sonalleve System to 42C for 30 minutes every 4 weeks
89201199|NCT00908505|Experimental|physiotherapy|
89201200|NCT00988546|Other|1|exam documentation performed using dictation
89201201|NCT00988546|Experimental|2|exam documentation performed using computer based template
89201202|NCT02557386|Experimental|A Levobupivacaine 5 mL|Adductor canal nerve block with levobupivacaine 0.25% 5 mL and perineural catheter placement, an elastomeric pump with bupivacaine 0.1% at a rate of 5 ml/hr will be placed after surgery for continuous nerve block.
89201203|NCT02557386|Experimental|B Levobupivacaine 10 mL|Adductor canal nerve block with levobupivacaine 0.25% 10 mL and perineural catheter placement, an elastomeric pump with bupivacaine 0.1% at a rate of 5 ml/hr will be placed after surgery for continuous nerve block.
89201204|NCT02557386|Experimental|C Levobupivacaine 15 mL|Adductor canal nerve block with levobupivacaine 0.25% 15 mL and perineural catheter placement, an elastomeric pump with bupivacaine 0.1% at a rate of 5 ml/hr will be placed after surgery for continuous nerve block.
89201205|NCT02557386|Experimental|D Levobupivacaine 20 mL|Adductor canal nerve block with levobupivacaine 0.25% 20 mL and perineural catheter placement, an elastomeric pump with bupivacaine 0.1% at a rate of 5 ml/hr will be placed after surgery for continuous nerve block.
88939187|NCT01828736|Experimental|Arm B: Platinum+Gemcitabine+Trastuzumab|"Trastuzumab: Charging dose = 8mg/kg on day 1; then 6mg/kg every 21 days given IV + Gemcitabine = 1 000 mg/m2 Day1 and Day8 given every 21 days IV~+ If Creatinin Clearance > 60 ml/min : Cisplatin = Day 1: 70 mg/m² given every 21 days If Creatinin Clearance < 60 ml/min : Carboplatin = Day 1: AUC 5 given every 21 days"
89454376|NCT05052749|Active Comparator|Low-moderate Resistance Exercise Training|In this low-moderate resistance training group, participants will perform warm-up activity for 15 minutes then low-moderate intensity resistance exercises with 120 seconds of rest interval between each set of exercise and between exercises respectively. After that, generalized stretching exercises as a cool down activity will be performed by the participants. Participants will perform exercises twice weekly, 40-50 minutes/session for 12 weeks under supervision.
89454377|NCT03627533|Experimental|Electroacupuncture|Electroacupuncture therapy is done at the point of CV3 Zhongji, CV4 Guanyuan, and EXCA-1 Zigong with continuous wave, 2 Hz frequency for 30 minutes. Acupuncture manuals on MA-IC3 endocrine (ear points), GV20 Baihui, ST36 Zusanli, SP6 Sanyinjiao, BL57 Chengsan and KI3 Taixi for 30 minutes.
89454378|NCT03627533|Sham Comparator|Sham electroacupuncture|Sham electroacupuncture are done at same electroacupuncture point location but puncture are not done, also electro stimulator are turned off.
89454379|NCT03197714|Experimental|OPB-111077|Level 1: 200 mg daily Level 2: 250 mg daily
89454380|NCT03194360||delirium group|
89454381|NCT03194360||nondelirium group|
89454382|NCT05220683|Experimental|Verion and Callisto|Alignment axis will be analysed with both, the Verion and the Callisto, digital marking system in the same eye of the same patient
89454383|NCT03194282|Experimental|chronic stroke patient with insole|Poor balance capacity is one of clinical symptoms of stroke patient.Poor balance, or postural stability, is significant predictors the risk of fall.
89454384|NCT03194282|Sham Comparator|chronic stroke patient without insole|Poor balance capacity is one of clinical symptoms of stroke patient.Poor balance, or postural stability, is significant predictors the risk of fall.
89454385|NCT04089527|Experimental|CC-95775|Escalating dose finding part A of study and extension Part B of the study. In Part A, subjects will be treated with oral capsules of CC-95775 with a schedule of 4d on/ 24d off (Q4W) and a starting dose of 100 mg/day on a 28-day cycle. Dose increments between cohorts will not exceed 100% of the dose in previous cohort. Patients in Part B will be treated with a schedule of 4d on/24d off (Q4W) at the Maximum tolerated dose (MTD) established from Part A.
89454386|NCT05724303|Experimental|Training group|8-week neuromuscular training program
89454387|NCT05724303|No Intervention|Control group|
88939188|NCT01828762|Experimental|DC-TC+GM-CSF|
88939189|NCT01828775|Experimental|Arm I (early PCI)|Patients receive part I of the PCI comprising quantitative surveys, comprehensive palliative care assessment by the Research Nurses, and goals of care discussions beginning prior to administration of the first dose of phase I treatment. Patients then receive part II of the PCI comprising recommendations from the interdisciplinary team, patient educational sessions, and supportive care referrals following the first dose of phase I treatment and is completed within one month of the first treatment.
88939190|NCT01828775|Experimental|Arm II (delayed PCI)|Patients receive usual care until 12 weeks post-treatment initiation. Patients then receive both part I and II of the PCI.
88939191|NCT01828788|Experimental|Ropivacaïne|Prospective, controlled, randomised, parallel, single-centre, single-blinded trial, comparing to a control (conventional care with no locoregional anaesthesia) an infusion of ropivacaine through two multihole catheters placed lateral to the sternum. In both groups, postoperative analgesia will be achieved by paracetamol plus titrated then self-administered intravenous morphine.
88939192|NCT01828788|Placebo Comparator|Placebo|Prospective, controlled, randomised, parallel, single-centre, single-blinded trial, comparing to a control (conventional care with no locoregional anaesthesia) an infusion of ropivacaine through two multihole catheters placed lateral to the sternum. In both groups, postoperative analgesia will be achieved by paracetamol plus titrated then self-administered intravenous morphine.
88939193|NCT01828801||Pre-Op|Pre-operative patients who will undergo a total hip replacement.
88939194|NCT01828801||1 year post-op|Patients that underwent a Pinnacle Metal-on-Metal (MoM) total hip replacement (THR) and at the time of enrollment, based on their date of surgery, were 1 year post-operative . Alternatively these are patients who have had their Pinnacle Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
89454388|NCT03194204|Active Comparator|RA patients treated with methotrexate|"Disease activity score(DAS28) matrix metalloproteinase-3(MMP-3) and matrix metalloproteinase-9(MMP-9), Erythrocyte sedimentation rate C- reactive protein Complete blood count Urine analysis Renal and liver function tests Lipid profile, blood glucose level Serum uric acid Rheumatoid factor (RF IgM, U/L) Anti- cyclic citrullinated peptide . Radiological assessment :Plain radiographs of both hands and feet in the postero-anterior views .~Cardiac assessment :By electrocardiogram ( ECG ) and echocardiography , Carotid artery intima-medial thickness (IMT) will be done by colored doppler ultrasound."
89454389|NCT03194204|Active Comparator|RA patients treated with methotrexate plus doxycycline|"Disease activity score(DAS28) Matrix Metalloproteinase-3 (MMP-3) and Matrix Metalloproteinase-9 (MMP-9) Erythrocyte sedimentation rate C- reactive protein Complete blood count Urine analysis Renal and liver function tests Lipid profile, blood glucose level Serum uric acid , Rheumatoid factor (RF IgM(immunoglobulin M), U/L) Anti- cyclic citrullinated peptide. Radiological assessment :Plain radiographs of both hands and feet in the postero-anterior views.~Cardiac assessment :~By electrocardiogram ( ECG ) and echocardiography Carotid artery intima-medial thickness (IMT) will be done by colored doppler ultrasound."
89454390|NCT04441359|Experimental|supplemented formula|Standard formula supplemented with prebiotic inulin-type fructans
89454391|NCT04441359|Placebo Comparator|standard formula|Standard Formula not supplemented with prebiotic inulin-type fructans
89454392|NCT05052047|Experimental|Brisk Walking Group|Brisk walking as training for 4 weeks
89015840|NCT06047379|Experimental|Phase 2a Safety Run-In - NEO212 and Pembrolizumab|"The following primary cancers with uncontrolled metrastases to the brain:~Unresectable or metastatic melanoma.~NSCLC expressing PD-L1, with no EGFR or ALK genomic tumor aberrations.~Metastatic NSCLC whose tumors express PD-L1.~EGFR or ALK genomic tumor aberrations must have disease progression.~SCLC.~Unresectable, recurrent HNSCC whose tumors express PD-L1.~HNSCC on or after platinum-containing chemotherapy.~Urothelial carcinoma whose tumors express PD-L1.~Urothelial carcinoma.~Microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR).~Microsatellite Instability-high or Mismatch Repair Deficient Colorectal Cancer (CRC).~Gastric or gastroesophageal junction adenocarcinoma.~Esophageal or gastroesophageal juncUon (GEJ).~Cervical cancer.~Merkel cell carcinoma.~NEO212 - Same as Arm 1.~Pembrolizumab - 200 mg administered every 3 weeks per package insert."
89015841|NCT06047379|Experimental|Phase 2a Safety Run-In - NEO212 and Nivolumab|"The following primary cancers with uncontrolled metrastases to the brain:~Unresectable or metastatic melanoma.~Metastatic non-small cell lung cancer.~Advanced renal cell carcinoma.~Squamous cell carcinoma of the head and neck.~Urothelial carcinoma.~Microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer.~Unresectable esophageal squamous cell carcinoma (ESCC).~NEO212 - Starting one dose level under RP2D administered orally on days 1 - 5 of a 28-day treatment cycle, escalated to RP2D per Protocol dose escalation rules.~Nivolumab - 240 mg administered every 2 weeks per package insert"
89015842|NCT06047379|Experimental|Phase 2a Safety Run-In - NEO212 and Stivarga (Regorafenib)|"- Colorectal cancer (CRC) with uncontrolled metastases to the brain who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild type, an anU-EGFR therapy.~NEO212 - Starting one dose level under RP2D administered orally on days 1 - 5 of a 28-day treatment cycle, escalated to RP2D per Protocol dose escalation rules.~Stivarga - 160 mg orally, once daily for the first 21 days of each 28-day cycle per package insert"
89201206|NCT02557386|Experimental|E Levobupivacaine 25 mL|Adductor canal nerve block with levobupivacaine 0.25% 25 mL and perineural catheter placement, an elastomeric pump with bupivacaine 0.1% at a rate of 5 ml/hr will be placed after surgery for continuous nerve block.
89454393|NCT05052047|Active Comparator|Conventional Breathing Exercise Group|Conventional Breathing exercise for 4 weeks
89454394|NCT03203018|Experimental|Women participating in HL intervention|Groups of women from disadvantaged communities will participate in a three session health literacy workshop
89454395|NCT05013359||Adolescents Living with Obesity (ALwO)|Recruited from online, general population consumer panels
89454396|NCT05013359||Health Care Providers (HCPs)|HCPs treating adolescents who have obesity
89454397|NCT05013359||Caregivers|A parent or legal guardian of an adolescent with obesity
89454398|NCT03197480|Other|DME treatment group|"All patients will received 4 intravitreal injections of aflibercept.~Based on the OCT outcome they will be classified into 2 groups for assessment of biomarkers:~Less than 20% reduction in CRT on OCT or <5 letter improvement of VA (if VA<6/6 and CRT>=340) Rapid (Mac Dry at M4) Delayed: Persistent fluid at M4, but more than 20% reduction in CRT on OCT"
89454399|NCT00151281|Experimental|Study Treatment Arm|
89454400|NCT03202862|Experimental|ESR1 mutated|ESR1 mutated postmenopausal women with hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer after previous aromatase inhibitor therapy
89454401|NCT03627455||Male, with DM|
89454402|NCT03627455||Male, without DM|
89454403|NCT03627455||Female, with DM|
89454404|NCT03627455||Female, without DM|
89454405|NCT03202940|Experimental|Cobimetinib + Alectinib|Alectinib administered twice daily at pre-determined dosage orally Cobimetinib administered daily at pre-determined dosage orally
89454406|NCT00255099|Active Comparator|001|TMC125 2 x 100 mg tablets b.i.d. / 96 weeks
89454407|NCT00255099|Placebo Comparator|002|Placebo 2 tablets b.i.d. / 96 weeks
89454408|NCT02288481|Experimental|Cohort 1 10 mg TBA-354|
89454409|NCT02288481|Placebo Comparator|Cohort 1 placebo|Placebo Suspension
89454410|NCT02288481|Experimental|Cohort 2 25 mg TBA-354|
89454411|NCT02288481|Placebo Comparator|Cohort 2 placebo|Placebo Suspension
89454412|NCT02288481|Experimental|Cohort 3 60 mg TBA-354|
89454413|NCT02288481|Placebo Comparator|Cohort 3 placebo|Placebo Suspension
89454414|NCT02288481|Experimental|Cohort 4 150 mg TBA-354|
89454415|NCT02288481|Placebo Comparator|Cohort 4 placebo|Placebo Suspension
89454416|NCT02288481|Experimental|Cohort 5 400 mg TBA-354|
89454417|NCT02288481|Placebo Comparator|Cohort 5 placebo|Placebo Suspension
89454418|NCT02288481|Experimental|Cohort 6 1000 mg TBA-354|
89454419|NCT02288481|Placebo Comparator|Cohort 6 placebo|Placebo Suspension
89454420|NCT03197246|Experimental|IVECG and chest X-ray|The patients in this group will be examined with perioperative IVECG for PICC tip placement, as well as standard postoperative chest X-ray.
89454421|NCT03197246|Active Comparator|Standard|Standard method, PICC tip placement confirmed by postoperative chest X-ray .
89454422|NCT05724147|Experimental|Mandala Activity|There will be a total of 5 sessions, including the Mandala activity once a week, meeting (1), working (3) and ending (1).
89454423|NCT03203096|Placebo Comparator|Placebo|identically tasting and looking Placebo
89454424|NCT03203096|Active Comparator|Magnesium|Supplementation with 400 mg Magnesium from Magnesium Citrate / Magnesium Oxide once daily
89454425|NCT00231153|Active Comparator|Povidone-Iodine 10%|
89454426|NCT00231153|Experimental|omiganan 1% gel|
89454427|NCT03202784|Experimental|BCX7353 API in capsule|fasted administration of BCX7353 API in capsule
89454428|NCT03202784|Experimental|BCX7353 blend in capsule|fasted administration of BCX7353 blend in capsule
89454429|NCT03202784|Experimental|BCX7353 blend in capsule with food|administration of BCX7353 blend in capsule following high-fat meal
89454430|NCT05220527|Experimental|Study group|triamcinolone plus hyruan injection
88939195|NCT01828801||2 year post-op|Patients that underwent a Pinnacle Metal-on-Metal (MoM) total hip replacement (THR) and at the time of enrollment, based on their date of surgery, were 2 years post-operative . Alternatively these are patients who have had their Pinnacle Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
88939196|NCT01828801||3 year post-op|Patients that underwent a Pinnacle Metal-on-Metal (MoM) total hip replacement (THR) and at the time of enrollment, based on their date of surgery, were 3 years post-operative . Alternatively these are patients who have had their Pinnacle Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
88939197|NCT01828801||4 year post-op|Patients that underwent a Pinnacle Metal-on-Metal (MoM) total hip replacement (THR) and at the time of enrollment, based on their date of surgery, were 4 years post-operative . Alternatively these are patients who have had their Pinnacle Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
88939198|NCT01828801||5 year post-op|Patients that underwent a Pinnacle Metal-on-Metal (MoM) total hip replacement (THR) and at the time of enrollment, based on their date of surgery, were 5 years post-operative . Alternatively these are patients who have had their Pinnacle Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
88939199|NCT01828801||6 year post-op|Patients that underwent a Pinnacle Metal-on-Metal (MoM) total hip replacement (THR) and at the time of enrollment, based on their date of surgery, were 6 years post-operative . Alternatively these are patients who have had their Pinnacle Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
88939200|NCT01828801||7 year post-op|Patients that underwent a Pinnacle Metal-on-Metal (MoM) total hip replacement (THR) and at the time of enrollment, based on their date of surgery, were 7 years post-operative . Alternatively these are patients who have had their Pinnacle Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
88939201|NCT01828801||8 year post-op|Patients that underwent a Pinnacle Metal-on-Metal (MoM) total hip replacement (THR) and at the time of enrollment, based on their date of surgery, were 8 years post-operative . Alternatively these are patients who have had their Pinnacle Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
88939202|NCT01828814||RUSF (500kcal/day) and cash transfer|Monthly distributions of Ready-to-use Supplementary Food (RUSF) 500kcal per day associated with cash transfer during hunger gap (5 months) then RUSF 500kcal/day for 10 months
88939203|NCT01828814||Super Cereal Plus (SC+)|Monthly distributions of SC+ 800kcal per day during hunger gaps (5 months twice) and SC+ 400kcal per day in-between (5 months)
88939204|NCT01828814||RUSF|Monthly distributions of Ready-to-use Supplementary Food (RUSF) 500kcal per day during hunger gaps (5 months twice) and RUSF 250kcal per day in-between (5 months)
88939205|NCT01828814||RUSF (250kcal/day) and cash transfer|Monthly distributions of Ready-to-use Supplementary Food (RUSF) 250kcal per day associated with cash transfer during hunger gap (5 months) then RUSF 250kcal/day for 10 months
88939206|NCT01828814||SC+ and cash transfer|Monthly distributions of Super Cereal Plus (SC+) 800 kcal per day associated with cash transfer during hunger gap (5 months)
88939207|NCT01828814||SC+ and household ration|Monthly distributions of Super Cereal Plus (SC+) 800 kcal per day associated with food ration for household support during hunger gap (5 months)
88939208|NCT01828814||Cash transfer|Monthly distributions of cash transfer only during hunger gap (5 months)
88939209|NCT01828827|Experimental|Fed 1000 mg PA-824|Each dose will be 1000 mg PA-824 (5 x 200 mg tablets), and will be administered with 240 mL tap water approximately 30 minutes after a high-calorie, high-fat breakfast provided after a minimum 10-hour overnight fast.
88939210|NCT01828827|Experimental|Fasting 1000 mg PA-824|Each dose will be 1000 mg PA-824 (5 x 200 mg tablets), and will be administered with 240 mL tap water after a minimum 10-hour overnight fast.
88939211|NCT01828866|Active Comparator|Community Reinforcement Approach|Treatment as usual, provided in out-patient setting
88939212|NCT01828866|Experimental|Community Reinforcement Approach + EMDR|Treatment as usual + additional sessions of EMDR
88939213|NCT01828879|Experimental|Tacrolimus ointment|Tacrolimus ointment, 0.1 percent will be applied twice daily, in adult population for 4 weeks or until 1 week after the affected areas defined for treatment at baseline are completely cleared, whichever is first.
88939214|NCT01828892|Experimental|PRFG treatment|As described in our previous study, platelet-rich cryoprecipitate and thrombin were obtained from 300-400ml whole blood of each patient enrolled in the PRFG group and then frozen at -20°C for storage. Prior to application, frozen cryoprecipitate and thrombin stored were thawed in a 37°C water bath. Aminomethylbenzoic Acid (1ml: 1mg, Sigma-Aldrich, St Louis, MO) was added into the cryoprecipitate in the volume ratio of 1:10.
88939215|NCT01828892|Sham Comparator|Control|Patients in this group only received standard of care when their fistula output < 200ml/24h.
88939216|NCT01828892|Experimental|Commercial FG|Commercial FG (Zhejiang Puji Porcine fibrin sealant) was applied to close fistulas.
88939217|NCT01828905|Experimental|Cerament|"CERAMENT™|BONE VOID FILLER as bone graft substitute"
88939218|NCT01828905|Active Comparator|Bone graft|Autologous cancellous bone graft (iliac crest)
88939219|NCT01828918|Other|early recurrence|find the postoperative early relapse out
88939220|NCT01828931|Active Comparator|Usual Care|Standard care provided via participants' family physicians, diabetes nurses, and psychiatrists.
88939221|NCT01828931|Experimental|Lifestyle Intervention|A lifestyle intervention based on the Look AHEAD study intervention, involving counselling related to dietary and physical activity habits.
88939222|NCT01828944|Active Comparator|Extra virgin olive oil|Extra virgin olive oil
89454431|NCT05220527|Active Comparator|Experimental|vitagen plus hyruan injection
89454432|NCT05220527|Placebo Comparator|Placebo|normal saline plus hyruan injection
89454433|NCT03197402|Active Comparator|Comparator group|Milk protein gel delivery system supplementation
89454434|NCT03197402|Experimental|Leucine-enriched protein group|Leucine-enriched protein gel delivery system supplementation
89454435|NCT05220449|Active Comparator|Cf-tACS (V1-Alpha_V5-Gamma)|
89454436|NCT05220449|Experimental|Cf-tACS (V1-Gamma_V5-Alpha)|
89015843|NCT06047379|Experimental|Phase 2a Safety Run-In - NEO212 and CarbolaUn (ParaplaUn) + Paclitaxel (Taxol)|"- Colorectal cancer (CRC) with uncontrolled metastases to the brain.~NEO212 - Starting one dose level under RP2D administered orally on days 1 - 5 of a 28-day treatment cycle, escalated to RP2D per Protocol dose escalation rules.~Carboplatin - 300 mg/m2 IV on day 1 every 4 weeks for 6 cycles per package insert.~Paclitaxel - 135mg/m2 IV administered over 24 hours, every 3 weeks per package insert."
89454437|NCT05724069|Other|Sequence A|"Eligible subjects will be treated for 4 periods with either velusetrag (2 periods) or placebo (2 periods), with a wash-out period of 2 weeks between treatment periods.~The progression order of the treatment periods varies in each sequence."
89015844|NCT06047379|Experimental|Phase 2a Safety Run-In - NEO212 and FOLFIRI (Zaltrap) + Bevacizumab (Avastin)|"- Metastatic colorectal cancer (mCRC) with uncontrolled metastases to the brain, that is resistant to or has progressed following an oxaliplatin-containing regimen~NEO212 - Starting one dose level under RP2D administered orally on days 1 - 5 of a 28-day treatment cycle, escalated to RP2D per Protocol dose escalation rules.~FOLFIRI - 4 mg/kg aIV over 1 hour every 2 weeks.~Bevacizumab - 10 mg/kg IV every 2 weeks."
89454438|NCT05724069|Other|Sequence B|"Eligible subjects will be treated for 4 periods with either velusetrag (2 periods) or placebo (2 periods), with a wash-out period of 2 weeks between treatment periods.~The progression order of the treatment periods varies in each sequence."
89015845|NCT06047379|Experimental|Phase 2b efficacy - NEO212 for Astrocytoma IDH-mutant and Glioblastoma IDH-wildtype|"Patients receiving NEO212 alone for treatment of Astrocytoma IDH-mutant and Glioblastoma IDH-wildtype.~NEO212 - Starting one dose level under RP2D administered orally on days 1 - 5 of a 28-day treatment cycle, escalated to RP2D per Protocol dose escalation rules."
89015846|NCT06047379|Experimental|Phase 2b efficacy - NEO212 & SOC for Uncontrolled Metastases to the Brain|"Patients receiving NEO212 in combination with select standard of care treatments for treatment of uncontrolled metastases to the brain.~NEO212 - Starting one dose level under RP2D administered orally on days 1 - 5 of a 28-day treatment cycle, escalated to RP2D per Protocol dose escalation rules.~SOC treatments established to be safe in Phase 2a of the study will be used in this arm of Phase 2b."
89015847|NCT06047353|Experimental|Motivational Enhancement Therapy (MET)|Participants in this group will receive intervention with MET along with PAP therapy. Participants will be in this group for approximately 3 months.
89015848|NCT06047353|Active Comparator|PAP therapy|Participants in this group will receive PAP therapy which is the standard of care. Participants will be in this group for approximately 3 months.
89015849|NCT06046170|Active Comparator|Cognitive Behavioral Therapy|Participants will receive cognitive behavioral therapy that has been adapted for autistic youth with anxiety. These sessions will also include components of exposure. Participants will receive therapy around once a week for 14 weeks.
89015850|NCT06046170|Placebo Comparator|Treatment as Usual|Participants will complete treatment as usual. They will be referred to other community resources, including skills training. Additionally, participants may begin or end therapy and/or medication.
89015851|NCT06045520|Experimental|IBM Educational Training|Intervention group participants will receive IBM skills model on educational training intervention for 8 weeks.
89015852|NCT06045520|No Intervention|Control Group|No intervention was applied to the control group.
89015853|NCT06042855|Experimental|Arm G - Metformin|"Metformin IR tablets will be self-administered orally according to the following dosing schedule:~500 mg on Day 1;~500 mg in the morning and 500 mg in the evening on Day 2 through Day 5; and~500 mg in the morning and 2 x 500 mg (a total of 1000 mg) in the evening on Day 6 through Day 14."
89015854|NCT06042855|Placebo Comparator|Arm G - Placebo|"Placebo - appearance and size matched to active study drug.~Placebo will be self-administered orally by each participant, with number of tablets matched to active study drug dosing."
89015855|NCT06041711|Active Comparator|General anesthesia group|Patients allocated to the general anesthesia group will be subjected to general anesthesia with induction with propofol and will sevoflurane (inhalational agent) used for maintenance. End of the procedure all patients will be extubated and awakened in the operating room. İntravenous morphine patient-controlled analgesia will be used in the postoperative period.
89015856|NCT06041711|Active Comparator|Regional anesthesia group|Patients allocated to the regional anesthesia group will be subjected to combined spinal-epidural anesthesia with heavy bupivacaine or spinal anesthesia with PENG(pericapsular nerve group) block with bupivacaine. If lumbar combined spinal epidural anesthesia is applied epidural patient-controlled analgesia will be used in the postoperative period. If spinal anesthesia and PENG block is applied, intravenous morphine patient-controlled analgesia will be used in the postoperative period.
89454439|NCT05724069|Other|Sequence C|"Eligible subjects will be treated for 4 periods with either velusetrag (2 periods) or placebo (2 periods), with a wash-out period of 2 weeks between treatment periods.~The progression order of the treatment periods varies in each sequence."
89454440|NCT05724069|Other|Sequence D|"Eligible subjects will be treated for 4 periods with either velusetrag (2 periods) or placebo (2 periods), with a wash-out period of 2 weeks between treatment periods.~The progression order of the treatment periods varies in each sequence."
89454441|NCT05723991|Experimental|Vidiximab and Gemcitabine Neoadjuvant therapy|Vidiximab (RC48) 2.0mg/kg, once every two weeks, intravenous drip (60-90 min); Gemcitabine is 1000mg/m2, once every 2 weeks
89454442|NCT05220215|Experimental|Group A: Nordic Hamstring Exercise|"This group includes 15 male participants who will be given 10 minutes of warm and cool down sessions that includes stretching.~Number of sets and repetitions progressively increase i-e: Week 1 - 2 sessions with 2 sets of 5 repetitions each. Week 2 - 2 sessions with 3 set of 5 repetitions each. Week 3 - 2 sessions with 4 set of 6 repetitions each. Week 4 - 2 sessions with 4 set of 8 repetitions each."
88939223|NCT01828944|Experimental|Enriched extra virgin olive oil|Enriched extra virgin olive oil
88939224|NCT01828944|Placebo Comparator|refined olive oil|refined olive oil
88939225|NCT01828957|Experimental|Pneumostem®|A single intratracheal administration of Pneumostem® (1.0 x 10^7 cells/kg)
88939226|NCT01828957|Placebo Comparator|normal saline|A single intratracheal administration of normal saline
88939227|NCT01828970|Experimental|Basal-bolus specific insulin regimen|Basal-bolus detemir-aspart insulin regimen in hemodialyzed diabetic patients
89454443|NCT05220215|Experimental|Group B: Hamstring Curl with Resistance Band|"This group includes 15 male participants who will be given 10 minutes of warm and cool down sessions that includes stretching.~Number of sets progressively increase i-e: Week 1 - 2 sessions with 2 sets of 15 repetitions each. Week 2 - 2 sessions with 3 set of 15 repetitions each. Week 3 - 2 sessions with 4 set of 15 repetitions each. Week 4 - 2 sessions with 4 set of 15 repetitions each."
88939228|NCT01828996|Active Comparator|Shock wave therapy|This group of patient will be treated with the shock wave head in the first 4 sessions then crossover to have the stand-off placebo for another 4 sessions.
88939229|NCT01828996|Placebo Comparator|Placebo|This group of patient will be treated with the stand-off placebo for the first 4 sessions then crossover to have the shock wave head in the other 4 sessions .
88939230|NCT01829009|No Intervention|General Recommendations Group|General information about sarcopenia will be provided to the participants, as well as general recommendations of healthy habits. We will contact the participants weekly by phone to answer questions about sarcopenia, and remind them of their next appointment and about adverse events occured during this period of time. The frequent contact with the participants has also the purpose to prevent losses or rejections for future evaluations
88939231|NCT01829009|Experimental|Resistance Exercise Group|"An individualized resistance exercise program wil be applied twice a week by an expert physiotherapist. Every 2 weeks, intensity will be reassessed by the same physiotherapist. Weekly, participants will be asked about incidents such as the occurrence of falls or hospitalizations during this study period.~Physical performance and functional status will be assessed by the blind investigator at weeks 6,12 and 24"
88939232|NCT01829022||E-NOTES|Embryonic-Natural Orifice Transumbilical Endoscopic Surgery for Myomectomy with Traction of Multidirectional Sutures
88939233|NCT01829035|No Intervention|Arm S|sorafenib 400mg bid daily po until progression
88939234|NCT01829035|Experimental|Arm C|after the first Conventional Transarterial Chemoembolization is completed, sorafenib po and cTACE on demand until progression
88939235|NCT01829061||No Treatment|
88939236|NCT01829087|Experimental|Botox injection|
88939237|NCT01829087|Placebo Comparator|Control|
88939238|NCT01829100|Experimental|Group Behavioral Activation Therapy|Group Behavioral Activation Therapy (GBAT)
88939239|NCT01829100|No Intervention|waitlist|15-week waitlist
88939240|NCT01829126||CCB|Patients receiving calcium channel blockers (CCB)
88939241|NCT01829126||ACEi|Patients receiving angiotensin converting enzyme inhibitors (ACEi)
88939242|NCT01829126||CCB and ACEi|Patients receiving calcium channel blockers (CCB) and angiotensin converting enzyme inhibitors (ACEi)
88939243|NCT01829126||No treatment|Patients not receiving calcium channel blockers (CCB) and/or angiotensin converting enzyme inhibitors (ACEi)
88939244|NCT01829139||Wait-and-see group|After endoscopic clearance of their bile duct stones, this group of patients will be follow up without additional managements
88939245|NCT01829139||Choleretics group|After endoscopic clearance of their bile duct stones, this group of patients receives choleretic agents during 3 months
88939246|NCT01829152|No Intervention|Control|Subjects in the Control Group will receive Heart Failure care as routinely delivered by the SMH HF clinicians according to their standards of care.
88939247|NCT01829152|Experimental|CHM Intervention Group|The Intervention Group subjects will receive Converged Health Management (CHM) in addition to continuing to receive care as routinely delivered by the SMH HF clinicians.
88939248|NCT01829178|Placebo Comparator|Control arm|Placebo 420 mg daily in three divided doses for 65 days as control along with [cisplatin 50-60mg/m2 + fluorouracil 750 mg/m2 +docetaxel 60-80 mg/m2]
88939249|NCT01829178|Active Comparator|Exprimental: Silymarin and chemotherapy|silymarin 420 mg daily in three divided doses for 65 days along with standard chemotherapy [cisplatin 50-60mg/m2 + fluorouracil 750 mg/m2 +docetaxel 60-80 mg/m2 control
88939250|NCT01829256|Experimental|Pharmacist Telehealth Intervention|Will receive a tailored multi-factorial clinical pharmacist-administered telehealth intervention, which includes medication management and behavioral-educational components. The intervention will occur monthly over 3 years.
88939251|NCT01829256|No Intervention|Education Control|Will receive educational material about management of kidney disease
88939252|NCT01829269||Patients with a defibrillator|The study population is that of patients with a defibrillator to have a change of probe.
88939253|NCT01829282|Experimental|Risk Reduction|"The Risk Reduction group will receive the Eban II Intervention upon enrollment. This group will do the following:~Provide HIV and STI test results~First Interview~Attend 8 sessions - 1 session per week~Second interview occurs immediately following the 8th session with HIV and STI tests~Third interview occurs 3 months after the 8th session with HIV and STI tests"
88939254|NCT01829282|Active Comparator|Waitlist|"The Waitlist group will receive the same intervention after waiting for the Risk Reduction group to complete the entire intervention.~Provide HIV and STI test results~First Interview~No sessions for 8 weeks~Second interview and proof of HIV and STI status occurs after the 8 weeks from when you were enrolled~Third interview occurs 3 months after the 8th session with HIV and STI tests The Waitlist Group will then be invited to participate in the Risk Reduction group activities.~Attend 8 sessions - 1 session per week~Fourth interview occurs immediately after the 8th session with HIV and STI tests~Fifth interview occurs 3 months after the 8th session with HIV and STI tests"
88939255|NCT01829308|Experimental|Specialist|The brief interventions are delivered by behavioral health counselors.
88939256|NCT01829308|Active Comparator|Generalist|The brief interventions are delivered by the primary care provider.
88939257|NCT01829321|Experimental|GLPG0974|1 capsule of 200 mg GLPG0974 twice daily
89454444|NCT03531177|Experimental|Intervention|HEAL-D diet and lifestyle education and behavioural change intervention, 7 sessions over 14 weeks.
89454445|NCT03531177|Active Comparator|Control|Usual care.
89454446|NCT05682599|Experimental|A：Azvudine 5 mg|Azvudine 5 mg, QD PO, D1-D7
89454447|NCT05682599|Experimental|B：Azvudine 3 mg|Azvudine 3 mg + placebo 2 mg, QD PO, D1-D7
89454448|NCT05682599|Placebo Comparator|C：placebo|placebo 5 mg, QD PO, D1-D7
89454449|NCT03531021|Experimental|Heart healthy intervention|The intervention group will receive 2 modules (one in in person and one by video conference) and will receive follow-up phone calls/emails by study staff 3 weeks following each visit to review education and strategies for and barriers to reaching goals. Intervention sessions must include teen; parents may attend if they wish. Participants will be placed on teams and encouraged to complete behavioral challenges to earn points towards a cash reward.
89454450|NCT03531021|No Intervention|Attention Control|There will be a delayed intervention for the control group with study handouts after 3 months. The control group will meet with the RAs for demographic and survey completion and receive reminder phone calls/emails in order to match for attention.
89454451|NCT03530553|Experimental|Treatment arm|The treatment arm will receive the HMS as well as standard of care of the weight management program.
89454452|NCT03530553|No Intervention|Control arm|The control arm will not receive the HMS and will receive standard of care.
89454453|NCT05722509|Experimental|"Distal Reduction Flap Group"|A surgical procedure consisting of a tissue reduction flap distal to the second molar prior to the extraction of the third molar will be performed.
89454454|NCT05722509|Active Comparator|"Only Exodontia Group"|Exodontia of the 3rd molar will be performed following the different steps in the simple exodontic technique without performing any other surgical procedure.
89454455|NCT03133689||EPIC-Norfolk|This cohort comprises 25,636 residents of a predefined English healthcare region (11,606 men and 14,030 women). Participants in this cohort study were originally recruited from 35 general practices in Norfolk, England as part of an investigation into diet and cancer, but the study's scope was subsequently widened to include additional outcomes including cardiovascular diseases.
89454456|NCT03133689||GAZEL|This cohort comprises 20,625 employees of French gas and electricity companies (15,011 men and 5,614 women). The cohort commenced data collection in 1989 and follow-up assessments were subsequently completed on an annual basis. The data have undergone linkage to national health administrative datasets.
89454457|NCT03133689||NSHD|This dataset comes from the 1946 National Birth Cohort study, which comprises all persons born in England, Scotland and Wales in one week in March 1946. The cohort comprises 5,362 individuals (2,815 men and 2,547 women). Data have been collected from participants on a regular basis throughout their life, including information on lifestyle and, in combination with administrative datasets, on health outcomes.
89454458|NCT03133689||Twenty-07-1930s|This cohort comprises 1,551 Scottish participants (702 men and 849 women) born around 1932 who were recruited in 1986 as part of a study of health inequalities. The repeated nature of the data collection will enable identification of longitudinal alcohol intake patterns, while linkage to Scottish health system records will enable identification of coronary heart disease onset.
89454459|NCT03133689||Twenty-07-1950s|This cohort comprises 1,444 Scottish participants (656 men and 788 women) born around 1952 who were recruited in 1986, alongside the T-07-1930s' cohort, as part of a study of health inequalities. Participant health was tracked through linkage with national health records.
89454460|NCT03133689||Whitehall II|This cohort comprises 10,308 British civil servants (6,895 men and 3,413 women). The cohort study commenced data collection in 1985 and participants have since undergone questionnaire and clinical assessments across regular intervals. Additional tracking of health outcomes has been performed through linkage with administrative databases. Demographic, behavioural and clinical data will be sourced from this cohort for the purposes of the current study.
89454461|NCT05219747|Experimental|A.Oleracea group|Mucoadhesive film containing Acmella oleracea extract
89454462|NCT05219747|Placebo Comparator|Placebo group|Mucoadhesive film without Acmella oleracea extract
89454463|NCT02288715||SAE|patient who develop encephalopathy in the progress of sepsis
89454464|NCT02288715||non-SAE|patient who do not develop encephalopathy in the progress of sepsis
88939258|NCT01829321|Placebo Comparator|Placebo|1 capsule placebo twice daily
88939259|NCT01829334|Active Comparator|Resin dental sealant|Resin dental sealant placed on pits and fissures of first permanent molars, single-time placement and no replacement
88939260|NCT01829334|Experimental|ART dental sealant|ART dental sealant placed with glass ionomer material using the ART technique on permanent first molar, single-time placement and no replacement
88939261|NCT01829334|Experimental|Sodium fluoride varnish|Topical application of 5% sodium fluoride varnish onto pits and fissures of permanent first molars, repeated every 6 months
88939262|NCT01829334|Experimental|Silver fluoride solution|Topical application of 38% silver fluoride solution onto pits and fissures of permanent first molars, repeated every 12 months
89454465|NCT05219357|Active Comparator|Usual Care Group (UCG)|The usual care control group received care only on hospital wards during episodes
89454466|NCT05219357|Other|Ayu Care Group (ACG)|Multidisciplinary Ayurveda based treatment team aimed to manage acute crises of patients in the community settings or at their home if feasible.
89454467|NCT04873739||20 patients SLE with dry eye|Anterior segment OCT for SLE patients with dry eye
89454468|NCT04873739||30 patients SLE without dry eye|Anterior segment OCT for SLE patients without dry eye
89454469|NCT04873739||50 normal subjects as control group of similar age and gender|Anterior segment OCT for normal subjects
89454470|NCT05723757|Experimental|HS Patients|50 adult subjects suffering from moderate to severe HS, aged 18 to 65, diagnosed for at least 1 year
89454471|NCT01318109|Active Comparator|Alogliptin 12.5 mg QD and metformin 500mg BID or 750mg TID|
89454472|NCT01318109|Active Comparator|Alogliptin 25mg QD and metformin 500mg BID or 750mg TID|
88939263|NCT01829373|Experimental|Vaccine plus oral beta glucan|Vaccine plus oral beta glucan
89454473|NCT01318109|Active Comparator|Metformin 500mg BID or 750mg TID|
89454474|NCT03530475|Active Comparator|placenta previa|cases diagnosed as placenta previa diagnosed by ultrasound and doppler
89454475|NCT03530475|Active Comparator|placenta accreta|placenta previa diagnosed as placenta accreta by ultrasound and doppler
89454476|NCT05201885||laparoscopic surgery|Different surgical methods for rectal cancer resection
89454477|NCT05201885||Transanal endoscopic surgery|Different surgical methods for rectal cancer resection
89454478|NCT05720871|Experimental|Active rTMS + capsaicin 150μM|Each session (5 consecutive days) of active treatment consists of swallowing 10mL capsaicin (150μM) and, just after, of applying focal (alpha D70 coil) rTMS (Magstim Rapid2, UK) over the pharyngeal M1 hotspot of the unaffected hemisphere.
89454479|NCT05720871|Other|sham rTMS + placebo|The same protocol will be applied, swallowing 10mL of placebo (potassium sorbate) but with the coil tilted 90º from the tangent of the skull, as a standard method for sham rTMS application.
89454480|NCT05720871|Experimental|active tDCS + capsaicin 150μM|Active treatment consists of swallowing 10mL capsaicin (150μM) and, just after, of applying 30min of 2.0mA tDCS (DC-Stimulator Plus, NeuroConn, Germany) with the anode placed over the pharyngeal primary motor cortex (M1) of the unaffected hemisphere (3.5cm lateral / 1cm anterior to the vertex) and the cathode over the opposite supraorbital region.
89454481|NCT05720871|Other|sham tDCS + placebo|The same protocol will be applied, swallowing 10mL of placebo (potassium sorbate) but tDCS current is ramped up over 30s in order to simulate the active tDCS and then turned off for 30min23. Setup characteristics otherwise invariable.
89454482|NCT05198453||vaccinated patients with COVID-19|
88939264|NCT01829412|Experimental|DW- MRI|"The patients will perform the DW-MRI, WB-MRI and MRI of the spine in the same session with the following timing:~Patients at first-line treatment for MM:~Within 15 days before the start of the treatment~Within one month after the end of the first-line treatment~Six (6) months after the end of the first-line treatment~Patients at relapse after disease response (CR or PR) lasting at least 6 months~At relapse~Within 15 days after the end of the treatment of relapse~Six (6) months after the end of the treatment of relapse Each DW-MRI, WB-MRI, MRI of the spine and skeletal X-Ray will be independently read and interpreted by two radiologists with proven experience in MM. ."
88939265|NCT01829438|No Intervention|Without music|6MWT without music
88939266|NCT01829438|Experimental|With fast music|6MWT with a fast music
89454483|NCT05198453||unvaccinated patients with COVID-19|
89454484|NCT05720481|Placebo Comparator|Periodontitis quadrant Scaling root planing (SRP)|Each selected subject underwent to quadrant SRP
89454485|NCT05720481|Active Comparator|Periodontitis full mouth scaling root planing (SRP)|Each selected subject underwent to full mouth SRP
88939267|NCT01829438|Experimental|With slow music|6MWT with a slow music
89454486|NCT05636267|Experimental|AK119 + AK112|Subjects will receive AK119 plus AK112 via intravenously (IV) Q3W, up to 2 years.
89454487|NCT05636267|Experimental|AK119 + AK112 + Pemetrexed + Carboplatin|Subjects will receive AK119 and AK112 plus pemetrexed and carboplatin via intravenously (IV) Q3W, up to 4 cycles. Afterward, AK119 and AK112 plus pemetrexed will continue to be treated up to 2 years.
89454488|NCT05636267|Experimental|AK112|Subjects will receive AK112 monotherapy via intravenously (IV) Q3W, up to 2 years.
89454489|NCT02288871|Other|"Sutureless valve"|"Patients who underwent aortic valve replacement with a sutureless aortic valve.~An echocardiogram and a cardiac CT-scan will be conducted."
89454490|NCT02288871|Other|"Sewed-in valve"|"Patients who underwent aortic valve replacement with a sewed-in aortic valve. An echocardiogram and a cardiac CT-scan will be conducted."
88939268|NCT01829438|Experimental|With preferred music|6MWT with the preferred music of the child
88939269|NCT01829451|Experimental|Hyaluronic acid gel|Hyaluronic acid gel is placed into the uterus after endometrial ablation
89454491|NCT05635175|Active Comparator|physiotherapist-supervised pelvic floor muscle training|physiotherapist-supervised pelvic floor muscle (PFM) training (PFMT) and self training PFMT
88939270|NCT01829451|Placebo Comparator|No hyaluronic acid gel|An empty Pipelle device is taken into the uterus after endometrial ablation as an placebo procedure
88939271|NCT01829490|Experimental|Starter Group|The first six volunteers will receive one dose of 5x10^9vp of ChAdOx1 85A intramuscular injection.
88939272|NCT01829490|Experimental|Group A|12 subjects will receive one dose of 2.5x10^10vp of ChAdOx1 85A intramuscular injection.
89454492|NCT05635175|Experimental|hip abductors self training program|physiotherapist-supervised pelvic floor muscle (PFM) training (PFMT) and self training hip abductors self training program
89454493|NCT02288949||Prospective cohort|Stratification of patients admitted into a network of Spanish ICUs.
89454494|NCT05194709|Experimental|Anti-5T4 CAR-NK Cells|
89015857|NCT06024239|Experimental|Part A, ABBV-932|Participants will receive ABBV-932 once daily (QD) for 14 days.
89015858|NCT06024239|Experimental|Part A, Placebo for ABBV-932|Participants will receive placebo for ABBV-932 QD for 14 days.
89454495|NCT03530943|Active Comparator|Academic Stress Management|Students assigned to the Academic Stress Management (ASM) condition will attend a series of once weekly, one hour long workshops over four consecutive weeks during which time they will receive 100% exposure to various evidence-based academic stress management tools.
89015859|NCT06024239|Experimental|Part B, ABBV-932|Participants will receive ABBV-932 QD for 28 days.
89454496|NCT03530943|Experimental|Human Animal Interaction Enhanced|Students assigned to the Human Animal Interaction - Enhanced (HAI-E) condition will attend a series of once weekly, one hour long workshops over four consecutive weeks. This group receives 50% exposure to structured and unstructured animal assisted activities and 50% exposure to various evidence-based academic stress management tools.
89015860|NCT06024239|Experimental|Part B, Placebo for ABBV-932|Participants will receive placebo for ABBV-932 QD for 28 days.
89015861|NCT06024239|Experimental|Part C, ABBV-932|Participants will receive ABBV-932 QD for 28 days.
89015862|NCT06024239|Experimental|Part C, Placebo for ABBV-932|Participants will receive placebo for ABBV-932 QD for 28 days.
89015863|NCT06022510|Experimental|Fetoscopes for Selective Laser Photocoagulation|Single arm study. All patients will undergo selective laser photocoagulation with the use of the fetoscopes in this study.
89015864|NCT06017713|Experimental|tDCS + symptoms provocation|
89015865|NCT06016816|Active Comparator|Endoscopic bilateral sphenopalatine ganglion block|After the induction of general anesthesia, one group (Group: 1) will be administered 8mg dexamethasone and 10mg bupivacaine submucosal,
89015866|NCT06016816|Placebo Comparator|Placebo|Placebo group (group:2) will be administered 4 cc saline. aspects will be evaluated.
89015867|NCT06005558|Active Comparator|Normal saline|30 patients will receive placebo of 100ml 0.9% Nacl over 20 minutes followed by continuous infusion of Nacl for 72 hours.
89015868|NCT06005558|Active Comparator|methylene blue low dose|30 patients will receive a bolus of MB 1mg/kg in 100ml 0.9% Nacl over 20 minutes followed by continuous infusion of 0.25mg/kg/hour for 72 hours.
89015869|NCT06005558|Active Comparator|methylene blue high dose|30 patients will receive a bolus of MB 4mg/kg in 100ml 0.9% Nacl over 20 minutes followed by continuous infusion of 0.25mg/kg/hour for 72 hours.
89015870|NCT05997225|Experimental|Enhanced Treatment|"Opt-out counseling enrollment. individually-tailored biofeedback linked to Chest CT and spirometry results.~Varenicline: Preloading regimen (prior to target quit date): 0.5 mg once a day for days 1-3, 0.5 mg twice a day for days 4-7, and 1 mg twice a day for days 8-28.~1 mg twice day for 12 weeks after target quit date."
89015871|NCT05997225|Active Comparator|Standard Treatment|"Opt-in counseling enrollment. Standard tobacco cessation counseling.~Varenicline: Preloading regimen (prior to target quit date): 0.5 mg once a day for days 1-3, 0.5 mg twice a day for days 4-7, and 1 mg twice a day for days 8-28.~1 mg twice day for 12 weeks after target quit date."
89015872|NCT05995145|Experimental|Experimental group|The hamstring stretching exercises program will be conducted five times a week, 20 min per session, for 8 weeks. The exercises will be supervised by an experienced physiotherapist with five years of clinical experience. The intervention will be divided into two parts. The first part will include exercises with a massage foam roller. The second part will include exercises of active hamstring flexibility exercises with hip flexion mobilization and the development of the habit of correct hip flexion technique, protecting the lower spine.
89201207|NCT02557386|Experimental|F Levobupivacaine 30 mL|Adductor canal nerve block with levobupivacaine 0.25% 30 mL and perineural catheter placement, an elastomeric pump with bupivacaine 0.1% at a rate of 5 ml/hr will be placed after surgery for continuous nerve block.
89201208|NCT00986050|Active Comparator|Bare metal stent (BMS)|
88939273|NCT01829490|Experimental|Group B|12 subjects will receive one dose of 2.5x10^10vp of ChAdOx1 85A by intramuscular injection, followed by a boost dose of 1x10^8pfu of MVA85A by intramuscular injection 56 days later.
88939274|NCT01829490|Experimental|Group C|12 subjects will receive two doses of 2.5x10^10vp of ChAdOx1 85A by intramuscular injection at day 0 and day 28, followed by a boost dose of 1x10^8pfu of MVA85A by intramuscular injection at day 119.
88939275|NCT01829529|Experimental|Amoxicillin|All subjects receive one dose of 2 g Amoxicillin
89454497|NCT03530943|Experimental|Human Animal Interaction only|Students assigned to the Human Animal Interaction - only (HAI-O) condition will attend a series of once weekly, one hour long workshops over four consecutive weeks. This group will be receive 100% exposure to structured and semi-structured animal assisted activities.
88939276|NCT01829542|Active Comparator|319 mg blueberry polyphenols|Freeze-dried blueberry powder dissolved in water
88939277|NCT01829542|Active Comparator|639 mg blueberry polyphenols|Freeze-dried blueberry powder dissolved in water
88939278|NCT01829542|Active Comparator|766 mg blueberry polyphenols|Freeze-dried blueberry powder dissolved in water
89201209|NCT00986050|Active Comparator|Drug eluting stent (DES)|
89454498|NCT03530787|Active Comparator|Acetyl Zingerone Group|This group was given the topical with the active acetyl zingerone agent.
88939279|NCT01829542|Active Comparator|1466 mg blueberry polyphenols|Freeze-dried blueberry powder dissolved in water
88939280|NCT01829542|Active Comparator|1791 mg total blueberry polyphenols|Freeze-dried blueberry powder dissolved in water
88939281|NCT01829542|Placebo Comparator|O mg blueberry polyphenols|Macro- and micronutrient matched control drink
88939282|NCT01829555|Experimental|contingency management|The intervention will provide escalating financial reinforcement for self-monitored blood glucose testing.
88939283|NCT01829581||oral anticoagulation associated intracerebral hemorrhage|
89201210|NCT00986050|Active Comparator|Abciximab|
89454499|NCT03530787|Placebo Comparator|Control Group|This group was given the topical without the active acetyl zingerone agent and just the carrier lotion.
89454500|NCT03873311|Experimental|Azacytidine + HAG Regimen|Azacytidine（75mg/m2 ）+ HAG Regimen（Homoharringtonine(HHT) 1mg/(m2.d) , Cytarabine 10mg/(m2.d), G-CSF 200ug/(m2.d) )
89454501|NCT03873311|Active Comparator|Azacytidine|75mg/m2
88939284|NCT01829594|Experimental|Case Management|
88939285|NCT01829607|Active Comparator|Functional electrical stimulation|Functional electrical stimulation of lower limbs
88939286|NCT01829607|Placebo Comparator|Placebo|
89454502|NCT05641415||General population sample|600 participants aged 40 to 75 years will be randomly selected from a nationally representative general population sample of 9,922 individuals
88939287|NCT01829620|Active Comparator|Treatment as Usual (TAU)|The Treatment as Usual (TAU) control group will reflect current clinical practices for treating suicidal Soldiers and Marines.
88939288|NCT01829620|Experimental|Continuing Contacts via Text (CCVT)+TAU|The intervention group will receive Continuing Contacts via Text (CCVT) in addition to Treatment as Usual (TAU).
88939289|NCT01829633||Rotator cuff tears|Patients who were diagnosed with a symptomatic full-thickness tear of the rotator cuff. Tear examination by sonography and MRI showed a repairable tear. All patients were initially treated conservatively by physiotherapy.
88939290|NCT01829659||AA Ticagrelor|African Americans who present with acute coronary syndrome (ACS) to the cath lab, and receive ticagrelor during their hospital stay.
88939291|NCT01829672|Experimental|Other: pulmonary vascular disease|Dual-energy computed tomography investigation
88939292|NCT01829685|Active Comparator|Group I|oral entecavir 1mg daily and adefovir 10mg daily for 144 weeks
88939293|NCT01829685|Active Comparator|Group II|oral entecavir 0.5mg daily and adefovir 10mg daily for 144 weeks
88939294|NCT01829698|Experimental|tauroursodeoxycholic|tauroursodeoxycholic acid, 750mg , divided into three times, each time 250mg, oral administration, after meal
88939295|NCT01829698|Active Comparator|ursodeoxycholic|control arm: ursodeoxycholic acid, 750mg ,divided into three times, each time 250mg, oral administration, after meal
88939296|NCT01829711|Experimental|Moxetumomab pasudotox 40 µg/kg|Patients will receive Moxetumomab Pasudotox intravenously (IV) over 30 minutes on days 1, 3, 5 of each 28 day cycle for a maximum of 6 cycles or until disease progression, unacceptable toxivity, initiation of alternate therapy or documented CR.
88939297|NCT01829763|Experimental|botox|
88939298|NCT01829776|Experimental|education|Educational intervention
88939299|NCT01829789|Experimental|G-CRT|Group Community Reinforcement Training for parents
88939300|NCT01829789|Active Comparator|I-CRT|Individual Community Reinforcement Training for parents
88939301|NCT01829802|Experimental|RAL+ATA/r|Raltegravir 400 mg BID plus Ritonavir Boosted Atazanavir 300/100 mg QD
88939302|NCT01829802|Active Comparator|TDF/FTC (or 3TC) +ATA/r|TDF/FTC (or 3TC)- Fixed dose combination of Tenofovir 300 mg plus Emtricitabine 200 mg (or Lamivudine 300 mg) QD plus Ritonavir Boosted Atazanavir 300/100 mg QD
88939303|NCT01829815|Experimental|"Parents Make the Difference"|Caregivers are enrolled in the 10-session Parents Make the Difference intervention.
88939304|NCT01829815|Other|Waitlist Control|Caregivers assigned to the control group received the 10-session Parents Make the Difference intervention after the study was completed.
88939305|NCT01829828||Inpatients with cancer pain|Inpatients admitted for cancer pain management
88939306|NCT01829841|Experimental|Famitinib|Famitinib 25 mg qd p.o., 6 weeks per cycle.The treatment continued until disease progression or intolerable toxicity happened or patients withdrawal of consent.
88939307|NCT01829841|Active Comparator|Sunitinib|Sunitinib 50 mg qd p.o., 4 weeks out of 6.The treatment continued until disease progression or intolerable toxicity happened or patients withdrawal of consent.
89454503|NCT02712554|Experimental|Treatment A:CL-108 22.5mg/975mg/37.5mg|CL-108 22.5 mg/975 mg/37.5 mg tablet by mouth
89454504|NCT02712554|Experimental|Treatment B:CL-108 37.5mg/1625mg/62.5mg|CL-108 37.5 mg/1625 mg/62.5 mg tablet by mouth
89454505|NCT02712554|Active Comparator|Treatment C:M366 22.5mg/975mg|M366 22.5 mg/975 mg tablet by mouth
89454506|NCT02712554|Active Comparator|Treatment D: M366 37.5mg/1625mg|M366 37.5 mg/1625 mg tablet by mouth
89454507|NCT02712554|Placebo Comparator|Treatment E: Placebo|Placebo 0 mg tablet by mouth
89454508|NCT03527901||Chronic periodontitis|This groups participant has radiographically moderate alveolar bone loss, CAL > 5 mm and PD >6 mm in several sites of each quadrant
89454509|NCT03527901||Generalized aggressive periodontitis|This demonstrated a generalized pattern of severe breakdown and CAL > 5 mm and PD > 6 mm on 8 > teeth; minimum three of those were other than first incisors or first molars
89454510|NCT03527901||Gingivitis|This group has varying degrees of gingival inflammation, with CAL < 2 mm, without any radiographical bone loss due to periodontitis
89454511|NCT03527901||Implant|Implants classified PD < 5 mm, no bleeding on probing, no suppuration and no radiographic bone loss > 0.5 mm
89454512|NCT03527901||Health|Probing depth (PD) < 3mm, no gingival recession due to periodontal disease, and clinical attachment level (CAL) < 2 mm, BOP in < 10% of full-mouth score examination
89454513|NCT05370261|Experimental|Berberine LipoMicel soft-gel|"Each participant receives their treatment of Berberine LipoMicel soft-gel capsules at a total dose of 500 mg berberine. Treatments are consumed with a glass of water (approx. 200 mL), and standardized breakfast. A standardized lunch is served after the 4hr fasting; standardized dinner after 8hrs. Capillary whole blood samples are collected at time points 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24 hours.~Samples that are not processed the same day are kept frozen at -20°C until further processing and analysis. Processed samples are analyzed by LC-MS within 24 hours after processing.~Participants are asked to arrive after an overnight fast (at least 9hrs). Each participant acts as their own control; there is no separate control group. A washout period of at least 7 days between each treatment will be used.~Adverse events are recorded throughout the study by direct questioning."
89454514|NCT05370261|Experimental|Regular Berberine hard-gel|"Each participant receives their treatment of regular Berberine hard-gel capsules at a total dose of 500 mg berberine. Treatments are consumed with a glass of water (approx. 200 mL), and standardized breakfast. A standardized lunch is served after the 4hr fasting; standardized dinner after 8hrs. Capillary whole blood samples are collected at time points 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24 hours.~Samples that are not processed the same day are kept frozen at -20°C until further processing and analysis. Processed samples are analyzed by LC-MS within 24 hours after processing.~Participants are asked to arrive after an overnight fast (at least 9hrs). Each participant acts as their own control; there is no separate control group. A washout period of at least 7 days between each treatment will be used.~Adverse events are recorded throughout the study by direct questioning."
89454515|NCT03527823||LH supplementation|luteinizing hormone administrated microdose flare up GnRH analog protocol in poor ovarian responders undergoing in vitro fertilization.
89454516|NCT03527823||without LH supplementation|microdose flare up GnRH analog protocol in poor ovarian responders
89454517|NCT03530319|Active Comparator|Azithromycin|Azithromycin (10mg/kg/day) is given to children with mycoplasma pneumonia for 3 days.
89454518|NCT03530319|Experimental|Doxycycline|Doxycycline (2-4mg/kg/day) is given to children with mycoplasma pneumonia for 5-10 days.
89454519|NCT05234372|Experimental|Treatment received intervention at enrollment|Participants received mobile phone delivered intervention at enrollment. The intervention had a duration of 4 weeks. Each week participants received two text messages inviting them to view a short video (Monday) and brief written content (Wed). Each week, the material consisted of a culturally tailored theme related to COVID-19 vaccination. Participants also received information on how to get vaccinated.
89454520|NCT05234372|Other|Control|Wait-list control. No intervention during month 1. Received the intervention at Month 2. Each week, during the first month, participants received a text with a count down of how many days were left to begin the intervention.
89454521|NCT00133497|Experimental|20 mcg CMV gB + MF59|200 subjects will receive vaccine CMV gB + MF59.
89454522|NCT00133497|Placebo Comparator|Saline|200 subjects will receive saline placebo.
89454523|NCT02445170||Below-knee amputees|The present group consists of diabetic below-knee prosthetic user
89454524|NCT02445170||Transmetatarsal amputees|The present group consists of diabetic transmetatarsal amputees
89454525|NCT02445404|Active Comparator|CHOP|cyclophosphamide, 750mg/m² IV day1 doxorubicin, 50 mg/m² IV day1 vincristine, 1.4 mg/m² (max 2 mg) IV day1 prednisone ,40 mg/m² PO day1~5 every 3 weeks
89454526|NCT02445404|Experimental|Fractionated ICED|ifosfamide, 1.67 g/m² IV day1~3 carboplatin, AUC =5 IV day1 etoposide, 100mg/m² IV day1~3 dexamethasone 40 mg PO or IV day1~4 every 3 weeks
89454527|NCT04468269|Experimental|balance training with sensory integration group|Conventional treatment: Static stretching exercises such as trunk rotation, flexion, and extension; hip flexors stretch, standing hamstring stretch; plantar flexors stretch, shoulder, elbow and wrist flexors and supinators stretch. Stretching will be applied for 30-sec hold with 30-sec rest. 3-5 times for each muscle group. For 40 min/day and 3 days/week for 6 weeks to improve balance and postural stability.
89454528|NCT04468269|Experimental|balance training without sensory integration group|Conventional treatment: Static stretching exercises such as trunk rotation, flexion, and extension; hip flexors stretch, standing hamstring stretch; plantar flexors stretch, shoulder, elbow and wrist flexors and supinators stretch. Stretching will be applied for 30-sec hold with 30-sec rest. 3-5 times for each muscle group.For 40 min/day and 3 days/week for 6 weeks to improve balance and postural stability
89454529|NCT02445092|Experimental|Catheter prewashing|"Intervention: prewashing the catheter before IUI.~450 patients randomly included in this group will have their insemination catheter prewashed with the same media used to wash the sperm, prior to performing the insemination using the washed catheter."
89454530|NCT02445092|No Intervention|Control group|450 patients randomly assigned in this group will have their insemination performed routinely, without washing the insemination catheter..
89454531|NCT05726175|Experimental|RC48 and AK105|Disitamab Vedotin(RC48) combined with Penpulimab(AK105) as neoadjuvant therapy
89454532|NCT02444858|Experimental|UCMSC group|Human umbilical cord MSCs are administrated to patients by intravenous injection
89454533|NCT02444858|Other|Control group(Normal saline)|Patients will receive normal saline at the same time points as that in experimental group.
89454534|NCT02444780||elective cardiac surgery patients|consecutive patients who undergo elective cardio-thoracic surgery during a 6 to 8 week period
89454535|NCT05319327|Active Comparator|Control Group|Participants in the control group will be provided with nutritional guidelines to follow a healthy diet based on a Mediterranean diet.
88939308|NCT01829867|Experimental|sNN0031|
88939309|NCT01829880||Chronic heart failure patients|Patients with chronic heart failure who attend to internal medicine outpatient clinic.
88939310|NCT01829893|Active Comparator|Reference arm|Treated with Reference (in combination of 0.2mg tamsulosin and 5mg finasteride) Intervetion: In combination of 0.2mg finasteride and 5mg tamsulosin simultaneously
88939311|NCT01829893|Experimental|Test arm|Treated with Test formulation (single pill combination of 0.2mg finasteride and 5mg tamsulosin) Intervention : GL2701 capsule
89015873|NCT05995145|No Intervention|Control group|Participants assigned to the control group will receive an self-care recommendations book.
89015874|NCT05983939|Experimental|PIPE-791|
89454536|NCT05319327|Experimental|Intervention group|Participants in the intervention group will follow a nutritional intervention program aimed to reduce UPF consumption. Nutritional intervention will not modify basal caloric intake but will record energy intake along the intervention. Nutritional counseling will be based on nutritional educational material such as encouraged and discouraged food items, recipes, menus and food shopping lists based on unprocessed or minimally processed foods.
89454537|NCT03197168|Experimental|Intervention|Intervention to reduce self-stigma among people with mental illness + Usual care
89454538|NCT03197168|Placebo Comparator|Control|Usual care
88939312|NCT01829906|Experimental|Outpatient group|Multidisciplinary outpatient programme including both individual and group-based therapy. During the first visit, every patient will have an individual consultation with the dietician, physiotherapist and psychiatric nurse. After this, the patients will be followed up in groups every month for the first four months and every two months afterwards up to one year. The intervention will focus on nutritional education, healthy eating, increased physical activity levels (aiming initially at 10 minutes/day, then increasing to 30 minutes/day) and cognitive therapy.
88939313|NCT01829906|Experimental|Inpatient group|"Inpatient lifestyle programme offered at a rehabilitation center consisting of a continuous care weight loss program, with three intermittent stays (each with three-week duration) over a one year period."
88939314|NCT01829932|Active Comparator|High Factor Diet|Patients will be on a factor altered diet to see effects on their lactulose breath test and symptoms.
88939315|NCT01829932|Active Comparator|Low Factor Diet|Patients will be on a factor altered diet to assess its effects on symptoms and lactulose breath test.
88939316|NCT01829971|Experimental|MRX34|Single agent MRX34
88939317|NCT01829984||control injection teaching|The first 25 subjects recruited into the study will be that control group. Subjects accrued during the control phase will receive the control injection teaching, which at MSKCC is verbal instruction. To minimize practice variation, the teaching will be provided by the office-practice nurse guided by a verbal script. The consented subjects will complete a questionnaire before the teaching, immediately after the teaching, and after performing the injection the following day. The nurse who administered the teaching will also complete an evaluation immediately following the teaching.
88939318|NCT01829984||intervention group|The subsequent 25 subjects enrolled into the study will be in the intervention group. Subjects accrued during the intervention phase will receive the verbal and written injection teaching, plus demonstration and return demonstration using an injection model. It is anticipated that the intervention teaching will take no longer then 5 additional minutes, however time will be evaluated as a secondary objective as well in both groups. The consented subjects will complete a questionnaire before the teaching, immediately after the teaching, and after performing the injection the following day. The nurse who administered the teaching will also complete an evaluation immediately following the teaching.
88939319|NCT01830010|Experimental|Study Part 1: KRP203|All patients to receive KRP203 for 111days
89015875|NCT05983939|Placebo Comparator|Placebo|
89454539|NCT04441515|Experimental|Music|music supplied by ipod
89454540|NCT04441515|Active Comparator|oral books|Listening to books on ipod
89454541|NCT04441515|Placebo Comparator|usual care|Usual care
89454542|NCT03530085|Experimental|Dec+Flu+Bu Conditioning Regimen|For AML patients older than 60 years in CR, Decitabine+ Fludarabine+Busulfan conditioning regimen was used (Decitabine 20mg/m2/day on days -9 to -7；Fludarabine(Flu) 30mg/m2/day on days -6 to -3；Busulfan (BU) 3.2 mg/kg/day on days -5 to -4).
89454543|NCT03107390|Other|Patients with CD or RCH|
88939320|NCT01830010|Experimental|Study Part 2: lower KRP203 dose|in this treatment arm patients will receive the lower KRP203 dose for 111 days on top of the standard treatment with cyclosporine A and methotrexte for GVHD prophylaxis
88939321|NCT01830010|Experimental|Study Part 2: higher KRP203 dose|in this treatment arm patients will recieve the higher KRP203 dose for 111 days on top of standard treatment with tacrolimus and methotrexate for GVHD prophylaxis
88939322|NCT01830075|No Intervention|Control group|The control group receives care as usual.
88939323|NCT01830075|Experimental|Consultations|An intervention of two consultations with a spiritual counselor supported by an e-application.
88939324|NCT01830153|Experimental|RAD001|RAD001 was given as 10 mg orally once daily, and one cycle was defined as 28 days.
88939325|NCT01830231|Experimental|Cabazitaxel|Cabazitaxel 25 mg/m2 q3w. Cabazitaxel will be given intravenously once every 21 days, starting at a dose of 25 mg/m2 as a 1-hour intravenous infusion
88939326|NCT01830231|Active Comparator|Vinflunine|"• Vinflunine will be given intravenously once every 21 days, starting at a dose of:~320 mg/m2 in patients aged ≤75 years with PS 0 and no prior pelvic radiation~280 mg/m2 in patients aged >75 - ≤80 years, and/or with PS 1 and/or prior pelvic radiation,~250 mg/m2 in patients aged >80 years."
88939327|NCT01830244|Experimental|Nab-Paclitaxel 125mg/m2|"Epirubicin 90 mg/m2 and cyclophosphamide 600mg/m2 IV every 3 weeks for 4 cycles.~Nab paclitaxel 125mg/m2 IV days 1, 8 and 15 for 12 weeks In case of HER2 positive tumour patients will receive trastuzumab in combination with nab-Paclitaxel"
88939328|NCT01830270|Experimental|PET regimen|
88939329|NCT01830504|Experimental|NVP-BKM120 (BKM120) PI3K inhibitor|
88939330|NCT01830530|Experimental|Telmisartan/nifedipine|Subjects treated with telmisartan 80 mg (1 capsule daily in the morning) plus nifedipine slow release 30 mg (1 capsule daily in the morning) combination
88939331|NCT01830530|Placebo Comparator|Placebo|Two tablets containing placebo daily in the morning
88939332|NCT01830673||under SIT|patients completed second or third year of SIT. We include the patients directly after last SIT vaccination.
88939333|NCT01830673||after SIT|Patients completed three years of SIT for at least three years. We included them as a follow up.
88939334|NCT01830673||no SIT|These patients were determined randomly. They have a clinically relevant grass pollen allergy. They never had a SIT.
88939335|NCT01830803||HowRU/HowRwe|All participants will fill out the HowRwe and HowRU questionnaires. Although this questionnaire may be considered an intervention, it is not the goal of this study to investigate the questionnaires as an intervention but to investigate whether they are reliable questionnaires.
88939336|NCT01830907|Active Comparator|Enteral|Enteral nutrition composed of carbohydrates and vitamins
88939337|NCT01830907|Active Comparator|Parenteral|
88939338|NCT01831037||Regression of fibrosis|Group conformed by patients experiencing improvement in the noninvasive markers of fibrosis, Fibrotest/Fibrosure and transient elastography, while enrolled in the study.
88939339|NCT01831037||No regression of fibrosis|Group conformed by patients not showing the predefined improvement in the noninvasive markers of fibrosis, Fibrotest/Fibrosure and transient elastography, while enrolled in the study.
89201211|NCT00986050|No Intervention|No abciximab|
89201212|NCT00986128|Experimental|001|
89454544|NCT03107390|Other|The control population|
89454545|NCT03525639|Experimental|Patients with Acute Myocarditis|Patients undergoing Cardiac Magnetic Resonance at baseline, 2 month, 1 year.
89015876|NCT05979805|Active Comparator|Conventional Oral health Education|Conventional oral health education and nutritional guidelines prior to the placement of fixed appliances, by means of a 5-8 minute video and instructive brochure.
89015877|NCT05979805|Experimental|Motivational interviewing + Conventional Oral health Education|Include the conventional oral health education of the control group and a 30 minute motivational interviewing (MI)
89015878|NCT05974631|Experimental|DBT + DBT PE|This condition combines one year of standard Dialectical Behavior Therapy (DBT) with the DBT Prolonged Exposure (DBT PE) protocol for PTSD.
89015879|NCT05974631|Active Comparator|PE + SRM|This condition provides up to 18 sessions of Prolonged Exposure therapy (PE) for PTSD augmented with suicide risk management (SRM).
89015880|NCT05974267|Experimental|Cohort 1: M5717 (60 mg) + Pyronaridine|Participants will receive single oral dose of M5717 60 milligram (mg) plus pyronaridine tetraphosphate (pyronaridine) 720 mg (Participants >= 65 kilogram [kg]) or pyronaridine 540 mg (Participants >= 45 to < 65 kg) once daily in a single day treatment regimen.
89015881|NCT05974267|Experimental|Cohort 2: M5717 (200 mg) + Pyronaridine|Participants will receive single oral dose of M5717 200 mg plus pyronaridine 720 mg (Participants >= 65 kg) or pyronaridine 540 mg (Participants >= 45 to < 65 kg) once daily in a single day treatment regimen.
89015882|NCT05974267|Experimental|Cohort 3: M5717 (660 mg)+ Pyronaridine|Participants will receive single oral dose of M5717 660 mg plus pyronaridine 720 mg (Participants >= 65 kg) or pyronaridine 540 mg (Participants >= 45 to < 65 kg) once daily in a single day treatment regimen.
89015883|NCT05974267|Experimental|Cohort 4: Atovaquone-proguanil|Participants will receive orally 3 doses of Malarone (fixed-dose combination of atovaquone-proguanil) once daily in a 3-day treatment regimen.
89015884|NCT05967468|Experimental|Family-Based Internet-Based CBT Group (iCBT)|One third of participants will be randomized to receive iCBT. Each week of treatment, the parent will be encouraged to read the corresponding materials on the Baylor College of Medicine (BCM) webpage, complete accompanying worksheets, and guide their child through completing activities in the child-facing materials, with support from a therapist (6 30-minute supportive videoconferencing via Zoom, 6 emails on alternating weeks). One core aspect of treatment will be parents leading their child through graduated exposure. Exposures, a hallmark of CBT for anxiety, are used to gradually and repeatedly confront feared stimuli. For example, exposure therapy for a child fearful of dogs may begin with looking at pictures of dogs and standing across the park from a dog on a leash, to eventually petting a dog. All relevant information regarding parent-led exposures will be detailed in the treatment materials, and therapists will review with parents via email and/or video-conferencing sessions.
89015885|NCT05967468|Experimental|Parent Training Bibliotherapy (SPACE)|One third of participants will be randomized to the SPACE group. Families will receive 4 45-minute supportive video calls with a therapist over the course of 12-14 weeks. Participating families will receive a copy of the book 'Breaking Free of Child Anxiety and OCD' to use at home and in session with the therapist. During each of the video-conferencing sessions, therapists will serve to provide encouragement and support as the parent works through the program independently.
89015886|NCT05967468|Active Comparator|Active Comparator|One third of participants will be randomized to receive a Relaxation and Mentorship. This involves attending 4 45-minute sessions with a therapist over the course of 12-14 weeks. Topics covered include breathing slowly and deeply, coloring activities, and releasing muscle tension to reduce stress levels.
89454546|NCT02444702||CLBP and degenerative lumbar spine|Participants with CLBP (>12 weeks) and degenerative changes of the lumbar spine confirmed by CT imaging who were recommended surgery and chose to undergo surgery will be recruited from the department of Orthopedic Surgery at the Meir Medical Center, Kfar-Saba, Israel. Included participants will be men or women, aged 40-80 years, of any race or ethnic background. Participants' diagnosis may include unstable degenerative spondylolisthesis, radicular pain, or documented stenosis with referred pain.
89454547|NCT02712320|Experimental|LMIS 50 mg|50 mg leuprolide mesylate administered subcutaneously, when given as two separate injections 6 months apart (Month 12 and Month 18 from the initiation of Protocol FP01C-13-001)
89015887|NCT05966727|Experimental|Cholestyramine intake|"1 sachet (4 grams) 3 times a day, corresponding to a daily dose of 12 grams. Preferably taken at mealtimes.~Treatment lasts 4 months."
89015888|NCT05964647|Active Comparator|LSD + ketanserin|
89015889|NCT05964647|Active Comparator|LSD+ olanzapine|
89454548|NCT03527667|Experimental|Short term incentives|usual quit smoking treatment (counseling + medication) plus 6-weeks of payments for proof of smoking abstinence
89454549|NCT03527667|Experimental|Long term incentives|usual quit smoking treatment (counseling + medication) plus 12-weeks of payments for proof of smoking abstinence
89454550|NCT03527667|No Intervention|No incentives|usual quit smoking treatment (counseling + medication)
89454551|NCT03197012|Experimental|Main Study: 90Y-DOTA-TOC|90Y-DOTA-TOC will be administered one time over thirty minutes via the hepatic arterial catheter in the outpatient setting. The injected dose will be 85 to 115 mCi.
89454552|NCT03197012|Experimental|Sub-study: 90Y and 68Ga-DOTA-TOC|"90Y-DOTA-TOC will be administered one time over thirty minutes via the hepatic arterial catheter in the outpatient setting. The injected dose will be 85 to 115 mCi.~Patients enrolled in the correlative sub-study will also receive 111-259 MBq (3-7 mCi) of 68Ga-DOTA-TOC concurrent with 90Y-DOTA-TOC"
89015890|NCT05964647|Active Comparator|LSD+ lorazepam|
89015891|NCT05964647|Active Comparator|LSD + placebo|
89015892|NCT05964647|Placebo Comparator|Placebo + placebo|
89015893|NCT05964192|Experimental|Treatment resistant major depressed inpatients (TRDs)|
89201213|NCT00986128|Experimental|002|
89201214|NCT00771342|Experimental|1|1% gasoue nitric oxide, delivered topically for 40 minutes daily for three consecutive days
88939340|NCT01831050|Experimental|G1: Sanofi bOPV Control|210 infants receiving Bivalent Oral Polio Vaccine (bOPV) at 6, 10 and 14 weeks with Monovalent Oral Polio Vaccine Type 2 (mOPV2) challenge at 18 weeks
88939341|NCT01831050|Experimental|G2: Sanofi bOPV Control|210 infants receiving Bivalent Oral Polio Vaccine (bOPV) at 6, 10 and 14 weeks with Monovalent Oral Polio Vaccine Type 2 (mOPV2) challenge at 40 weeks
88939342|NCT01831050|Experimental|G3: Trivalent OPV Control|100 infants receiving Trivalent Oral Polio Vaccine (tOPV)' at 6, 10 and 14 weeks with Monovalent Oral Polio Vaccine Type 2 (mOPV2) challenge at 18 weeks
88939343|NCT01831050|Experimental|G4: Sanofi bOPV, Sanofi IPV|210 infants receiving Bivalent Oral Polio Vaccine (bOPV) at 6, 10 and 14 weeks and 1 dose of Sanofi-Pasteur IPV (Sanofi IPV) at 14 weeks with Monovalent Oral Polio Vaccine Type 2 (mOPV2) challenge at 18 weeks
88939344|NCT01831050|Experimental|G5: Sanofi bOPV, Sanofi 2 IPV|210 infants receiving Bivalent Oral Polio Vaccine (bOPV) at 6, 10 and 14 weeks and 2 dose of Sanofi-Pasteur IPV (Sanofi IPV) at 14 and 36 weeks with Monovalent Oral Polio Vaccine Type 2 (mOPV2) challenge at 40 weeks
88939345|NCT01831050|Experimental|G6: Sanofi bOPV, GSK IPV|50 infants receiving Bivalent Oral Polio Vaccine (bOPV) at 6, 10 and 14 weeks and 1 dose of Glaxo SmithKline IPV (GSK IPV) at 14 weeks with Monovalent Oral Polio Vaccine Type 2 (mOPV2) challenge at 18 weeks
88939346|NCT01831050|Experimental|G7: Sanofi bOPV, GSK 2 IPV|190 infants receiving Bivalent Oral Polio Vaccine (bOPV) at 6, 10 and 14 weeks and 2 doses of Glaxo SmithKline IPV (GSK IPV) at 14 and 36 weeks with Monovalent Oral Polio Vaccine Type 2 (mOPV2) challenge at 40 weeks
88939347|NCT01831050|Experimental|G8: Sanofi bOPV, SII IPV|50 infants receiving Bivalent Oral Polio Vaccine (bOPV) at 6, 10 and 14 weeks and 1 dose of Serum Institute of India IPV (SII IPV) at 14 weeks with Monovalent Oral Polio Vaccine Type 2 (mOPV2) challenge at 18 weeks
88939348|NCT01831050|Experimental|G9: Sanofi bOPV, SII 2 IPV|190 infants receiving Bivalent Oral Polio Vaccine (bOPV) at 6, 10 and 14 weeks and 2 doses of Serum Institute of India IPV (SII IPV) at 14 and 36 weeks with Monovalent Oral Polio Vaccine Type 2 (mOPV2) challenge at 40 weeks
88939349|NCT01831271|Other|Prescribed physical activity|Prescribed physical activity is a tailored physical activity programme with monitoring of progress and a follow-up. Also includes interview: exploratory talk, commitment/decision, life style change, health promotion, evaluation of readiness for change, reflection, assessment of motivation, patient specific goal assessment, conclusion and plan for follow-up at 14 weeks. Patients are guided by the physiotherapist to increase their overall activity and strength with i.e. walking and other self-mediated activities and exercise.
88939350|NCT01831271|Other|Neck specific training|The active physiotherapy rehabilitation program consists of a standardised and structured physiotherapy program (twice a week) with medical exercise therapy and if needed vestibular rehabilitation. At the start of the intervention motivational interviewing will be included. Additionally once a week during the first 14 weeks of the program the physiotherapist informs the patient about physiology of pain, stress, exercise, breathing, relaxation, coping, pacing and ergonomics. All through the treatment program a cognitive approach from the physiotherapist according to theoretical behaviour change models will be used.
88939351|NCT01831440|Other|medicine combined CBT|Besides clinical routine antidepressant treatment,participants receive CBT weekly for 8 weeks and monthly until the end of the study.
88939352|NCT01831440|Other|medicine (SSRI antidepressants)|clinical routine antidepressant treatment--Selective serotonin reuptake inhibitors（SSRIs）.
88939353|NCT01831648|Experimental|Volonteers|Blood sample
88939354|NCT01831908|Sham Comparator|Lifestyle counseling|These persons will be advised on their cardiovascular status and will receive information on how to improve it.
88939355|NCT01831908|No Intervention|People not seeking attention|Evaluation of cardiovascular health status will be performed in these persons as part of yearly door-to-door survey that will perform in Atahualpa up to the end of the study
88939356|NCT01831986|Experimental|Pregnenolone + L-Theanine|The 60 participating subjects will be randomized into 2 groups: 30 patients will receive PREG (50 mg/day) with L-theanine (400 mg/day) and 30 patients will receive a placebo, each for 8 weeks in a double-blind manner.
88939357|NCT01831986|Placebo Comparator|Sugar caps.|Placebo (4 caps/day)
88939358|NCT01832311|Experimental|senile cataract with NSAID|"15 non-diabetic patients undergoing phacoemulsification combined with IOL implantation.~Subgroup receiving topical nonsteroidal anti-inflammatory drug (NSAID) ketorolac."
88939359|NCT01832311|Experimental|diabetic cataract with NSAID|"17 diabetic patients undergoing phacoemulsification combined with IOL implantation.~Subgroup receiving topical nonsteroidal anti-inflammatory drug (NSAID) ketorolac."
88939360|NCT01832311|No Intervention|senile cataract without NSAID|"17 non-diabetic patients undergoing phacoemulsification combined with IOL implantation.~Subgroup not receiving topical ketorolac."
88939361|NCT01832311|No Intervention|diabetic cataract without NSAID|"12 diabetic patients undergoing phacoemulsification combined with IOL implantation.~Subgroup not receiving topical ketorolac."
88939362|NCT01832350|Experimental|Nuedexta (20/10)|Drug: Nuedexta (20/10) administered orally, two times a day (every 12 hours), during a 26-week period.
88939363|NCT01832389|Active Comparator|Group P|PiCCO-controlled group
88939364|NCT01832389|No Intervention|Group C|control group
89015894|NCT05952934|Active Comparator|Candin vaccine|Seven Candida (Candin). The route of administration is intradermal injection at subject's limbs at 0.5 mL/injection. The schedule is 1 injection every three weeks for the first 4 injections, and then one injection every 3 months until a total of 7 injections has been given.
89201215|NCT00771342|Placebo Comparator|2|Nitrogen gas delivered topically for 40 minutes, daily, for 3 consecutive days
89454553|NCT02449304|Experimental|Endometrial Ablation (4th gen)|A single-centre uncontrolled observational study is proposed. All women presenting to the gynaecology outpatient clinic with heavy menstrual bleeding (HMB) in the absence of recognizable pelvic pathology, as determined by one or all of a normal pelvic ultrasound, hysteroscopy and / or endometrial biopsy, refractory to medical therapy that persists despite treatment with recommended pharmacological agents, who have no desire to preserve their fertility and are willing to have an endometrial ablation will be invited to participate. Eligible women with HMB will undergo RFA G4 endometrial ablation in either an inpatient or outpatient setting according to their preference.
88939365|NCT01832545|Active Comparator|Educational Program|The communitarian PESO program is based on appropriate clinical guidelines and on validated behavior change principles. Implemented by an intervention team with expertise gained from current scientific research in weight control determinants, this program as well PICO, is free of charge for all interested adults who wish to manage their weight and health. It operates since 2005 with the aims to prevent obesity or reduce excess weight, as well as, some of the risks associated with obesity in adults through a change to steady healthy habits, attitudes and behaviors. PESO has 3 months duration and it is structured in 12 sessions of one and a half hour, once a week.
88939366|NCT01832545|Experimental|Aquatic Exetcise|Aquatic Exercise program is organized in 24 sessions distributed over 12 consecutive weeks, with a frequency of twice a week. The duration of each session will be 60 minutes, being that 10 minutes are for patient reception, blood pressure control, pain register or others and the effective time inside the water is 45 minutes. The indoor pool works with an air temperature around 27±1ºC and water temperature is controlled for 30.5±5ºC. Workout is organized in order to have a progressive overload every week or every two sessions, when occurs an introduction of a new stimulus. Water is the main instrument to create resistance and only in the last weeks, according with participants progression and if the self-reported pain controlled, drag equipment will be added.
88939367|NCT01832584|Experimental|RGC1|200 mg of Red Grape Cell (RGC) powder; daily oral dose
88939368|NCT01832584|Experimental|RGC2|1000 mg of Red Grape Cell (RGC) powder; daily oral dose
88939369|NCT01832584|Placebo Comparator|Placebo|1000 mg placebo to Red Grape Cell (RGC) powder; daily oral dose
88939370|NCT01832688||Baseline cohort|The baseline survey will be implemented among pregnant women in randomly selected villages using a continuous enrollment schedule over the period of 18 months
88939371|NCT01832688||Optimization cohort|The programmatic impact of optimized prenatal care services on women's health and behavior will be assessed among pregnant women in randomly selected villages (Programmatic prenatal care optimization)
88939372|NCT01832740|Experimental|0,75 Hz stimulation|slow transcranial oscillating stimulation (~0,75Hz) during periods of Slow Wave Sleep
88939373|NCT01832740|Experimental|SHAM stimulation|SHAM stimulation during periods of Slow Wave Sleep
88939374|NCT01833104|Experimental|Training Cohort 1 (TC1)|"(N = 80) in the order Presence - Affect - Perspective"
88939375|NCT01833104|Experimental|Training Cohort 2 (TC2)|"(N = 81) in the order Presence - Perspective - Affect"
88939376|NCT01833104|No Intervention|Retest Control Cohort 1 (RCC1)|(up to N = 30) this is a non-intervention control group to access measurement effects and will be tested at each timepoint.
88939377|NCT01833104|Active Comparator|Training Cohort 3 (TC3)|"(N = 81) here, the Affect Module only intervention is administered."
88939378|NCT01833104|No Intervention|Retest Control Cohort 2 (RCC2)|(up to N = 60) this is a non-intervention control group to access measurement effects and will be tested at each timepoint.
88939379|NCT01833195||Heart transplant recipients|Heart transplant rejection surveillance including AlloMap testing
88939380|NCT01833221|Experimental|Neurotized facial muscle patients|injection of 1% lidocaine, 2mL for facial nerve block
88939381|NCT01833325|Experimental|Proton radiation|Proton radiation given to a total dose of 24 cobalt gray equivalent (CGE) in 2 treatments
88939382|NCT01833598|Active Comparator|PNT + PRP|percutaneous needle tenotomy with peritendinous platelet-rich plasma injection
88939383|NCT01833598|Active Comparator|PNT alone|percutaneous needle tenotomy alone
88939384|NCT01834131|No Intervention|Usual Care|Clinics assigned to usual care will not receive any of the intervention components. Physicians in these clinics will continue to treat patients using their usual methods. Participants from these clinics will not receive community health worker visits or the mobile health intervention
88939385|NCT01834131|Experimental|Comprehensive Intervention|"Physicians will receive training in the use of treatment algorithms based on hypertension guidelines.~Community health workers (CHW) will be trained in facilitating behavioral change through BP monitoring, medication management, and lifestyle modifications. CHW will serve as a source of education, motivation, and social support, and as facilitators of healthcare utilization for participants. CHW will conduct home visits, schedule appointments with primary care physicians, deliver antihypertensive medications to patients' homes, and provide tailored counseling to address barriers to behavior change.~Individualized text messages to promote lifestyle changes and reminders to reinforce medication adherence will be sent to participants weekly."
88939386|NCT01834300|Experimental|Control|Unsupervised exercise training This group will be given 1 hour lifestyle counseling by the exercise trainer after which they will have no contact with the exercise trainer to the end of the intervention period. The exercise intervention will be offered to the subjects once the post studies are completed.
89201216|NCT00982852||Acute|Patients in acute need for angioplasty or left heart catheterization.
89454554|NCT03196856|Experimental|Yogurt Group|Group will be consuming 200g of Greek Yogurt (Plain, 0%) 3 times daily for 12 weeks
89454555|NCT03196856|Placebo Comparator|Study Designed Supplement Group|Group will consume an isoenergetic, protein void, maltodextrin-based placebo supplement during the same time points for 12 weeks as well. The Placebo contain maltodextrin and pudding powder to mimic the consistency of Greek yogurt.
89454556|NCT03530007|Active Comparator|normal saline|patients received normal saline for prevention of shivering during spinal anesthesia
89454557|NCT03530007|Active Comparator|ondansetron 4MG|patients received 4 mg of ondansetron for prevention of spinal shivering
89454558|NCT03530007|Active Comparator|ondansetron 8MG|patients received 8 mg of ondansetron for prevention of spinal shivering
89454559|NCT03194048|Experimental|Functional Chewing Training|Children with CP and have tongue thrust included this group.
89454560|NCT03194048|Active Comparator|Control|Children with CP and have tongue thrust included this group.
89454561|NCT03202238|Active Comparator|Conventional|Venepuncture without the use of any venepuncture assistive device
89454562|NCT03202238|Active Comparator|Veinlite|Commercial transilluminator device that allows veins to show up as a silhouette among surrounding soft tissue
89454563|NCT03202238|Experimental|TenTaTorch|Transilluminator device that allows veins to show up as a silhouette among surrounding soft tissue
88939387|NCT01834300|Experimental|lifestyle counseling and exercise|Supervised exercise training Four months exercise training intervention will be either gym-based or patients will choose the mode of exercise that suits their lifestyle. Patients will be encouraged to exercise four times per week for 30-45 min at 60-80 % of maximal heart rate, with a 5 min warm-up and warm-down. Participants will be given free access to a variety of affiliated sports centres and will use the Wellness Key system, a software program that enables researchers to remotely track the exercise activity of participants very accurately. To ensure compliance with rest or exercise, all participants of both groups will have their mean physical activity level in 2 non-consecutive weeks evaluated with an ambulatory accelerometer.
89454564|NCT03529929|Experimental|Methylprednisolone|"Methylprednisolone glucocorticoid Medrol Dose Pack~Medrol is supplied as white tablets, of 4mg each. The tablets come in a commercially produced blister pack with instructions for each day of the 6 day dosing on the packaging. Subjects will receive a standard 6-day, graded dosing regimen of methylprednisolone (24mg, 20mg, 16mg, 12mg, 8mg, and 4 mg on days 1 through 6 respectively)."
88939388|NCT01834820|Experimental|Epinephrine and Dexamethasone|First day: One treatment of nebulized dexamethasone 4mg (1ml of dexamethasone 8mg/2ml) + 3ml NS, followed by two treatments of nebulized epinephrine (3 ml of epinephrine in a 1:1000 solution per treatment) with interval 20 minutes. And one treatment of nebulized dexamethasone every 24h for three days.
88939389|NCT01834820|Experimental|Hypertonic Saline 3%|3 treatments of nebulized HS 3% 4ml in first day of treatment with interval 20 minutes And one treatment of nebulized HS 3% 4ml every 24 hours for 3 days
88939390|NCT01834820|Active Comparator|Normal Saline 0.9%|3 treatments of nebulized Normal Saline 0.9% 4ml in first day of treatment with interval 20 minutes. And one treatment of nebulized Normal Saline 0.9% 4ml every 24 hours for 3 days
88939391|NCT01834846|Experimental|no-touch|no-touch technique of harvesting the saphenous vein graft for coronary artery bypass grafting
88939392|NCT01834846|Active Comparator|conventional|conventional technique of harvesting the saphenous vein graft for coronary artery bypass grafting
88939393|NCT01834859|Experimental|Outpatient|Multidisciplinary outpatient program including both individual and group-based therapy. During the first visit, there will be offered an individual consultation with the dietician, physiotherapist and psychiatric nurse. Follow-up will be in groups meeting every month for the first four months and every two months afterwards up to one year. The intervention will focus on nutritional education, healthy eating, increased physical activity levels (aiming initially at 10 minutes/day, then increasing to 30 minutes/day) and cognitive therapy.
88939394|NCT01834859|Experimental|Inpatient|"Inpatient lifestyle program consisting of a continuous care weight loss program offered at a rehabilitation center, with three intermittent stays (each with 3-week duration) over a one year period."
88939395|NCT01835002|Experimental|OkuStim|Electrostimulation Standard Treatment with OkuStim
88939396|NCT01835028||Classical Low-Flow, Low-Gradient AS|"Observational study in patients with Classical Low-Flow, Low-Gradient Aortic Stenosis and Low LV Ejection Fraction undergoing surgical aortic valve replacement, transcatheter aortic valve replacement, or conservative management:~I- Baseline visit: Medical history, physical / functional evaluation, blood biomarkers, resting echocardiography, stress echocardiography, aortic valve calcium scoring by computed tomography, myocardial fibrosis by magnetic resonance imaging II- Follow-up: clinical outcomes, physical / functional evaluation, echocardiography, blood biomarkers"
88939397|NCT01835028||Paradoxical Low-Flow, Low-Gradient AS|"Observational study in patients with Paradoxical Low-Flow, Low-Gradient Aortic Stenosis and Preserved LV Ejection Fraction undergoing surgical aortic valve replacement, transcatheter aortic valve replacement, or conservative management:~I- Baseline visit: Medical history, physical / functional evaluation, blood biomarkers, resting echocardiography, stress echocardiography, aortic valve calcium scoring by computed tomography, myocardial fibrosis by magnetic resonance imaging II- Follow-up: clinical outcomes, physical / functional evaluation, echocardiography, blood biomarkers"
88939398|NCT01835054||Patients with mitral regurgitation|"At study entry, patients have 1) a clinical assessment including metabolic risk profile; 2) a blood sample for analysis of metabolic, cardiac neurohormonal blood biomarkers and DNA collection; 3) a complete rest doppler echocardiography; 4) an exercise stress doppler echocardiography; 5) a cardiopulmonary exercise testing; 6) a magnetic resonance Imaging (MRI); 7) a 24-hour Holter ECG.~At follow-up, patients have 1) a clinical events assessment; 2) a blood sample analysis; 3) a resting echocardiography every year; 4) MRI (at preop. evaluation in the subset of patients undergoing surgery); 5) a 24-hour Holter ECG (at 2-year and postop.)."
89454565|NCT03202394|Active Comparator|Active intervention|Patients will be randomized in a 1:1 ratio to either aerosolized BIO-11006 (125mg in 3mL half normal saline) intervention twice daily plus ventilation for up to 28 days or placebo.
89454566|NCT03202394|Placebo Comparator|Placebo intervention|Patients will be randomized in a 1:1 ratio to either aerosolized placebo (3mL half normal saline) intervention twice daily plus ventilation for up to 28 days or active drug.
89454567|NCT03052751|Experimental|Dosage Regimen 1|Subjects randomized in dosage regimen 1 will receive 3 doses of UCB7655 (dose 1) in dosing period 1 and will then be re-randomized into dosing period 2 to receive 3 doses of UCB7665 (dose 1 or dose 2).
89454568|NCT03052751|Experimental|Dosage Regimen 2|Subjects randomized in dosage regimen 2 will receive 3 doses of placebo in dosing period 1 and will then be re-randomized into dosing period 2 to receive 3 doses of UCB7665 (dose 1 or dose 2).
89201217|NCT00982852||Chronic or non-acute|Patients will planned angioplasty or left heart catheterization.
89201218|NCT00775164|Experimental|pioglitazone|Pioglitazone: 15 mg per day for 4 weeks, then up-titrated to 30 mg per day for 12 weeks
88939399|NCT01835197|Experimental|SAD Cohorts 1-8 Experimental Arm|
89201219|NCT00775164|Active Comparator|Metformin|Metformin XR; 1000 mg once daily for 16 weeks.
89454569|NCT03525561|Active Comparator|acetazolamide arm|This is the arm of the study in which the volunteers will take the acetazolamide (Diamox) pill.
89454570|NCT03525561|Placebo Comparator|placebo arm|This is the arm of the study in which volunteers will take the placebo.
89454571|NCT03202004|Experimental|GSK2894512 1% cream group|Subjects will apply a thin layer of GSK2894512 1% (10 milligrams per gram [mg/g]) topical cream once daily to all psoriasis lesions for 12 weeks. The study staff will instruct subjects on proper topical application of cream.
89454572|NCT03202004|Placebo Comparator|Vehicle cream group|Subjects will apply a thin layer of vehicle cream once daily to all psoriasis lesions for 12 weeks. The study staff will instruct subjects on proper topical application of cream.
89454573|NCT05270265|Experimental|Group 1 (low dose)|8-10 volunteers receiving three doses of 10 µg Pvs25-IMX313 in 50 µg Matrix-M1 on days 0, 28 and 56 via intramuscular injection (IM) in the deltoid region of the arm
89454574|NCT05270265|Experimental|Group 2 (standard dose)|8-10 volunteers receiving three doses of 50 µg Pvs25-IMX313 in 50 µg Matrix-M1 on days 0, 28 and 56 via intramuscular injection (IM) in the deltoid region of the arm
89454575|NCT05270265|Experimental|Group 3 (fractional dose)|8-10 volunteers receiving two doses of 50 µg Pvs25-IMX313 in 50 µg Matrix-M1 on days 0 and 28, followed by one dose of 10 µg Pvs25-IMX313 in 50 µg Matrix-M1 on day 56 via intramuscular injection (IM) in the deltoid region of the arm
89454576|NCT03118700|No Intervention|Non-exercise Control|Subjects will come to the laboratory for 4 hours and their blood pressure will be measured every 10 minutes using the Oscar 2 with SphygmoCor ambulatory blood pressure system, and cardiac output will be measured with 10-second averages using the PhysioFlow. During this time, subjects will remain seated with their body posture maintained constant
89537171|NCT02719691|Experimental|Dose level 1: Alisertib 30mg/MLNO128 1mg|"This group will receive a Dose-Escalation: Combination of MLN0128 and Alisertib using a standard 3 + 3 design. The starting dose of Alisertib is 30 mg given PO twice daily (BID) Days 1-7 repeat every 21 days. The starting dose for MLN0128 is 1 mg given by mouth (PO) once daily with continuous dosing.~Alisertib: Participants will receive Alisertib in the dose-escalation and the dose-expansion part of the study.~MLN0128: Participants will receive MLN0128 in the dose-escalation and the dose-expansion part of the study."
88939400|NCT01835197|Placebo Comparator|SAD Cohorts 1-8 Placebo Arm|
88939401|NCT01835197|Experimental|MAD Cohorts 3 through 5 Experimental Arm|
88939402|NCT01835197|Placebo Comparator|MAD Cohorts 3 through 5 Placebo Arm|
88939403|NCT01835197|Experimental|MAD Cohorts 6 and 7 Experimental Arm|
88939404|NCT01835197|Placebo Comparator|MAD Cohorts 6 and 7 Placebo Arm|
88939405|NCT01835197|Experimental|MAD Cohort 8 Experimental Arm|
88939406|NCT01835197|Placebo Comparator|MAD Cohort 8 Placebo Arm|
88939407|NCT01835197|Experimental|MAD Cohort 9 Experimental Arm|
88939408|NCT01835197|Placebo Comparator|MAD Cohort 9 Placebo Arm|
88939409|NCT01835210||Quality of life|Teenager with acne vulgaris This is an observational study, in which the disease of interest is acne vulgaris.
88939410|NCT01835327||Exposed|Cerebral oximetry desaturation below 65% for a minimum of 3 minutes
88939411|NCT01835327||Not Exposed|Those patients who do not experience a cerebral oxygen desaturation below 65% for a minimum of 3 minutes
88939412|NCT01835418|Experimental|Lisinopril|bedtime administration of lisinopril 20mg
88939413|NCT01835418|Experimental|Amlodipine|Bedtime administration of amlodipine 5mg
88939414|NCT01835444||MD model|Hospital wards at which ward care is provided only by Medical Doctors (MDs)
88939415|NCT01835444||PA/MD model|Hospital wards at which ward care is provided by both Physician Assistants (PAs) and Medical Doctors (MDs)
88939416|NCT01835678|Active Comparator|Linagliptin|Linagliptin
88939417|NCT01835678|Placebo Comparator|Placebo|Placebo
88939418|NCT01835717||Cognitively normal individuals|
88939419|NCT01835808||Fractional Flow Reserve|Coronary artery disease patients submitted to coronary angiography and in which coronary lesions are to be evaluated with pressure-wire (FFR functional evaluation).
88939420|NCT01836055||Clinically Isolated Syndrome|Patients diagnosed with Clinically Isolated Multiple Sclerosis
88939421|NCT01836055||Relapsing Remitting MS|Patients diagnosed with Relapsing Remitting Multiple Sclerosis
89201220|NCT00988624|Experimental|Period 1|
88939422|NCT01836055||Control Subjects|Aged Matched Healthy volunteers
88939423|NCT01836237|Experimental|Alexis group|In experimental group patients, the surgeon will use Alexis - a wound protector during surgery.
88939424|NCT01836237|No Intervention|Control group|In no intervention group patients, the surgeon will not use any wound protector during surgery.
88939425|NCT01836263||Prevention arm: CCB & i.v. iloprost|prevention arm: patients receiving a combination of calcium channel blockers (CCB) and concomitant i.v. iloprost (i.v. iloprost at least in the last three months)
88939426|NCT01836263||Prevention arm: bosentan & sildenafil|prevention arm: patients receiving a combination of the endothelin receptor antagonist bosentan and the Phosphodiesterase-5 inhibitor sildenafil
88939427|NCT01836263||Healing arm: CCB & i.v. iloprost|healing arm: patients receiving a combination of calcium channel blockers (CCB) and concomitant i.v. iloprost (i.v. iloprost at least in the last three months)
89201221|NCT00988624|Experimental|Period 2|
89201222|NCT00988624|Experimental|Period 3|
89201223|NCT00988624|Experimental|Period 4|
89201224|NCT00988624|Experimental|Period 5|
89201225|NCT00771420|Active Comparator|1|0.01mg/kg and 0.03mg/kg CAM-3001
89201226|NCT00771420|Active Comparator|2|0.1mg/kg CAM-3001
89201227|NCT00771420|Active Comparator|3|0.3mg/kg CAM-3001
89201228|NCT00771420|Active Comparator|4|1.0mg/kg CAM-3001
89201229|NCT00771420|Active Comparator|5|3.0mg/kgCAM-3001
89201230|NCT00771420|Active Comparator|6|10.0mg/kg CAM-3001
89201231|NCT00771420|Placebo Comparator|7|Placebo
88939428|NCT01836263||Healing arm: bosentan & sildenafil|healing arm: patients receiving a combination of the endothelin receptor antagonist bosentan and the Phosphodiesterase-5 inhibitor sildenafil
88939429|NCT01836354|Active Comparator|DESERVE education|Intervention group will receive education on stroke preparedness plus risk factor reduction education, and help accessing follow up care with health workers.
88939430|NCT01836354|No Intervention|Usual Care|The usual care group will only receive written preparedness education, which is the standard care for the hospital.
88939431|NCT01836614|Active Comparator|Lidocaine|The treatment group will receive a 1.5mg/kg intravenous lidocaine bolus over 10 minutes. The bolus will be followed by an intravenous lidocaine infusion of 1 mg/kg/hr. The infusion will be stopped after extubation prior to leaving the operating room or after 5 hours from the start of the infusion
88939432|NCT01836614|Placebo Comparator|Saline|The saline will be administered over an infusion pump over 10 minutes and followed by a bolus. The infusion will be stopped after extubation prior to leaving the operating room or after 5 hours from the start of the infusion.
88939433|NCT01836913||Radiotherapy for esophageal cancer|Patients with histology proven esophageal cancer who are planned for high dose radiotherapy with or without chemotherapy with or without surgery.
88939434|NCT01836939|Active Comparator|TSO 2500|TSO 2500: 2500 embryonated, viable TSO/15 mL/day every 2 weeks X 10 weeks
88939435|NCT01836939|Active Comparator|TSO 7500|TSO 7500: 7500 embryonated, viable TSO/15 mL/day every 2 weeks X 10 weeks
88939436|NCT01837134|No Intervention|control (C) group|The control group will remain in routine care for 12 weeks. After 12 weeks they will also be given a weighing machine and a step counter, with automatic transfer into a personalized online portal, which can be monitored from both, the participant and the study centre. During the next 12 weeks they will get care calls from the study centre aiming to discuss measured data and to fix target agreements.
88939437|NCT01837134|Experimental|telemedical (TM) group|Participants in the telemedical (TM) group will get a weighing machine and a step counter, with automatic transfer into a personalized online portal, which can be monitored from both, the participant and the study centre.
88939438|NCT01837134|Experimental|telemedical coaching (TMC) group|Participants in the telemedical coaching (TMC) group will get a weighing machine and a step counter, with automatic transfer into a personalized online portal, which can be monitored from both, the participant and the study centre. Additionally, they will be called once per week for 12 weeks from the study centre aiming to discuss measured data and to fix target agreements. After 12 weeks the care calls be be given once per month for further 9 months.
88939439|NCT01837251|No Intervention|Control Arm|Patients receive bevacizumab 15 mg/kg iv on day 1 followed by gemcitabine 1000mg/m² iv on day 1 & 8 and carboplatin AUC4 iv on day 1 every 3 weeks for up to 6 cycles in the absence of progression disease or unacceptable toxicities. Patients then continue to receive bevacizumab 15 mg/kg iv every 3 weeks until progression disease or unacceptable toxicities.
88939440|NCT01837251|Experimental|Research Arm|Patients receive bevacizumab 10 mg/kg iv on day 1 & 15 followed by PLD 30mg/m² iv on day 1 carboplatin AUC4 iv on day 1 every 4 weeks for up to 6 cycles in the absence of progression disease or unacceptable toxicities. Patients then continue to receive bevacizumab 15 mg/kg iv every 3 weeks until progression disease or unacceptable toxicities.
88939441|NCT01837264|Experimental|Bone Marrow Cell Concentrate|
88939442|NCT01837290|Active Comparator|Group Dexmedetomidine (Group D)|Midazolam 0.02 mg/kg intravenously + 0.5 μg/kg/10 min dexmedetomidine infusion for premedication + Spinal block (Hyperbaric bupivacaine 0.5% 12.5 mg) (n=30)
88939443|NCT01837290|Placebo Comparator|Group Control (Group C)|Midazolam 0.02 mg/kg + saline infusion for premedication; Spinal block (Hyperbaric bupivacaine 0.5% 12.5mg) (n=30)
88939444|NCT01837433|Experimental|Prednisone 1 week|Prednisone 1 week 30mg/day and Celecoxib 400mg in first day, and then 200mg bid in the remaining next week, total 2 weeks.
88939445|NCT01837433|Active Comparator|Prednisone 6 weeks|Oral 30 mg/day of prednisone will be administered as the initial dose for the treatment of SAT in first week,then tapered by 5mg every 1 week,the duration of prednisone will be 6 weeks.
88939446|NCT01837446|Experimental|Morphine mouthwash|The morphine group uses the mouthwash of 2% morphine solution (20 mg morphine sulfate diluted in 100 mL of water), 10 mL every three hours; six times a day. The morphine solution is prepared by the faculty of pharmacy under supervision of the Food and Drug Organization of the local Medical University.
88939447|NCT01837446|Active Comparator|Magic mouthwash|The magic group uses a mouthwash contained a mixture of 240 mL magnesium aluminum hydroxide (Alborz Co., Iran), 25 mL 2% viscous lidocaine (SinaDaru Co., Iran), and 60 mL diphenhydramine (Emad Co., Iran), 10 mL every three hours; six times a day.
88939448|NCT01837472|Experimental|Probiotic|
88939449|NCT01837472|Placebo Comparator|Placebo|
88939450|NCT01838057||painPREMIER cohort|
88939451|NCT01838057||Control cohort|
88939452|NCT01838070||Study Group|Participants that has received AVAXIM 160U vaccine administered under the routine practice according to Summary of Product Characteristics
88939453|NCT01838135|No Intervention|Group-based information sessions|Control group subjects will take part in 6 x 1.5 hour sessions of group-based information sessions facilitated by a trained instructor, consisting of topics on general wheelchair use, transportation, pain and fatigue management, nutrition, and internet resources. The instructor will be trained to not provide any training on wheelchair skills, and will be instructed to divert any wheelchair skills related questions.
89201232|NCT00983008|Experimental|Protected Time Group|Interns working 30 hour shifts every 3rd night and an average of 80 hours per week in a medical intensive care unit.
89015895|NCT05952934|Placebo Comparator|Placebo|Seven placebo injections (sterile 0.9% Normal Saline). The route of administration is intradermal injection at subject's limbs at 0.5 mL/injection. The schedule is 1 injection every three weeks for the first 4 injections, and then one injection every 3 months until a total of 7 injections has been given.
89015896|NCT05942781|Experimental|Vestibular activation training|A cross-over design will be used with group one receiving the training intervention for 7 days, a 6-day washout period, and a 7-day no-training period. Group two will follow the reverse sequence.
89015897|NCT05942781|No Intervention|No training|
89015898|NCT05941039|Experimental|Vestibular Activation Training|
89015899|NCT05941039|No Intervention|No Training|
89015900|NCT05925985||Propel|Patients implanted with Propel model implants
89015901|NCT05925985||Propel Mini|Patients implanted with Propel Mini model implants
89015902|NCT05925985||Propel Contour|Patients implanted with Propel Contour model implants
89015903|NCT05925517|Experimental|Graded Motor Imagery|Each patient in the Graded Motor Imagery group will receive a treatment protocol consisting of Graded Motor Imagery, conventional physiotherapy, and home exercises.
89015904|NCT05925517|Active Comparator|Transcutaneous Electrical Nerve Stimulation (TENS)|Each patient in the Transcutaneous Electrical Nerve Stimulation group will receive a treatment protocol consisting of Transcutaneous Electrical Nerve Stimulation, conventional physiotherapy, and home exercises.
89015905|NCT05923398|Experimental|Experimental Group|During the duration of the study, all participants will use the Digital Intervention Suite (a web-based component, a VR platform, and wearable device) to measure passive and active data, such as: psychological variables (e.g., moral distress, anxiety, and depression) and physiological variables (e.g., heart rate and sleep).
89454577|NCT03118700|Experimental|Aerobic Interval Exercise|Subjects will be equipped with a heart rate (HR) monitor and perform an interval exercise bout on a cycle ergometer. To warm up, subjects will cycle at a work rate associated with 50% HRmax for 10 minutes. Wattage will then increase and subjects will do four 4-minute intervals at a work rate associated with 90%-95% HRmax, separated by 3 minutes of active recovery at a work rate associated with 50% HRmax. Subjects will be given a 5-minute cool-down period at a work rate associated with 50% HRmax. After the exercise, subjects will remain seated in the lab for 4 hours and their blood pressure will be measured every 10 minutes using the Oscar 2 with SphygmoCor ambulatory blood pressure system, and cardiac output will be measured with 10-second averages using the PhysioFlow.
89454578|NCT03118700|Experimental|Continuous Exercise|Subjects will be equipped with a heart rate (HR) monitor and perform an interval exercise bout on a cycle ergometer. To warm up, subjects will cycle at a work rate associated with 50% HRmax for 10 minutes. Wattage will then increase and subjects will perform a 30-minute exercise bout at a HR that elicits 75%-80% of their measured HRmax. Work rate will be adjusted, if needed, to keep HR within this value. Subjects will be given a 5-minute cool-down period at a work rate associated with 50% HRmax. After the exercise, subjects will remain seated in the lab for 4 hours and their blood pressure will be measured every 10 minutes using the Oscar 2 with SphygmoCor ambulatory blood pressure system, and cardiac output will be measured with 10-second averages using the PhysioFlow.
89454579|NCT04760483|Experimental|Transperineal Laser Ablation for BPH|"Ceftriaxone 250 mg IM as antibiotic prophylaxis. Local Anesthesia: perineal skin will be infiltrated with 10 cc of Lidocaine 2% and then each neurovascular bundle will be infiltrated with 5 - 10 cc. Nitrous self-administered anesthesia will be available.~One or two laser fibers from Echolaser x4 will be placed in each of the two prostate lobes using the plan. Treatment will be executed following Echolaser smart Interface planning, needles will follow targeted location using stepper grid under a transperineal approach in a sagittal plane. Ablation with 5 watts power per fiber, a total of ~ 1800 J will be delivered. We will evaluate pain measures and procedure tolerance using visual analog pain scale Upon completion we will measure coagulation zone with TRUS. Before discharge, trial of void will be conducted. Patients with a residual greater than 200 cc will have an indwelling catheter placed and will be discharged with it."
89454580|NCT03525483|Experimental|Patients with ECMO|"Patients with circulatory assistance by ECMO Patients are included 48 hours after ECMO VA or VV therapy and after hemodynamic stabilization defined by blood pressure stability and cardiac output for at least 12 hours without significant changes in amine flow.~When stable they will have an Ultrasound for renal resistivity index measurement"
89454581|NCT03529851|Experimental|PRO intervention|Patients included will weekly fill in a 12 item questionaire via the internet during the 3 week study period.
89015906|NCT05917990|Experimental|Dyadic Text-Messaging Micro-Intervention|The proposed micro-intervention will consist of 4 modules: welcome and overview module, sharing thoughts and feelings module, problem-solving skills module, and meaningful experiences and resources module. Each of the modules contain information and skills relevant to improving dyadic communication and relationship functioning in couples coping with advanced cancer.
89015907|NCT05917990|No Intervention|Waitlist Control|Couples in the waitlist control group will not initially receive any intervention materials; after completing post-assessment, couples in this arm will be offered the dyadic micro-intervention.
89015908|NCT05917301|Experimental|Pre-operative hypofractionated proton therapy|Patients will have 5 fractions of proton therapy prior to surgical resection of their sarcoma.
89015909|NCT05914974||Control Group|Chemotherapy without immunotherapy
89015910|NCT05914974||Experimental Group|Chemotherapy in combination with immunotherapy
89015911|NCT05912647|No Intervention|Usual Care|
89015912|NCT05912647|Experimental|Medication Therapy Management (MTM)|
89015913|NCT05912647|Experimental|Community Health Worker (CHW)|
89015914|NCT05912647|Experimental|MTM + CHW|
89015915|NCT05911113|Experimental|sensory re-education training|the patients will receive sensory re-education training three times a week for six weeks
89015916|NCT05911113|Active Comparator|traditional treatment|the patients will receive traditional treatment three times a week for six weeks
89201233|NCT04767256|Experimental|DD group|co-administered intravenous dexamethasone 10 mg and dexmedetomidine 1 ug/kg
89201234|NCT04767256|Placebo Comparator|D group|intravenous dexmedetomidine 1 ug/kg
89201235|NCT00771498|Other|lopinavir|Patients with HIV/TB co-infection will receive treatment for both infection, and PK of lopinavir 800mg + ritonavir 200mg (PO BID) during 5 months will be performed
89201236|NCT00986206||Biomarker testing|Collect serum for biomarker testing for LAP and HE4 and discovery of new biomarkers.
89015917|NCT05908110|Experimental|Health Communication Message|Parents will review a health communication message (infographic) informing them that their child has OSA symptoms, describing both nighttime and daytime OSA symptoms, and encouraging them to speak to their child's primary care provider at the scheduled visit if they observe symptoms in their child. Primary care providers will receive an alert that the child screened positive for OSA.
89015918|NCT05908110|No Intervention|Usual Care|Like in the intervention group, parents will complete screening items and primary care providers will receive an alert if the child screens positive for OSA. However, parents randomized to this condition will not view the health communication message nor receive any information about OSA or their child's risk for OSA.
89454582|NCT03527355|Experimental|A (Single dose)|"One dose of Vi-DT (Typhoid conjugate vaccine) 25 µg 0.5 mL is administrated intramuscularly at first dost (Day 0).~One dose of FluQuadri™ 0.25mL is administrated intramuscularly at second dose (Week 24).~One booster dose of Vi-DT 0.5 mL is administrated 2 years apart (Week 96). MMR for age group at 9-12 months."
89454583|NCT03527355|Active Comparator|B (Two dose)|"Two doses of Vi-DT (Typhoid conjugate vaccine) 25 µg 0.5 mL is administrated intramuscularly 6 months apart (Day 0 and Day 168 (Week 24)).~MMR for age group at 9-12 months."
89454584|NCT03527355|Placebo Comparator|C (Placebo/Comparator)|"One dose of Placebo (0.9% sodium chloride isotonic solution) 0.5 mL is administrated intramuscularly at first dost (Day 0).~One dose of FluQuadri™ 0.25mL is administrated intramuscularly at second dose (Day 168; Week 24).~MMR for age group at 9-12 months."
89454585|NCT01317797|Experimental|Namilumab 150 mg|Namilumab (MT203) 150 mg (low dose), subcutaneous (SC) injection, on Days 1, 15 and 29.
89454586|NCT01317797|Experimental|Namilumab 300 mg|Namilumab (MT203) 300 mg (high dose), SC injection, on Days 1, 15 and 29.
89015919|NCT05903352|Placebo Comparator|Antibiotic treatment|Antibiotic treatment duration left to the physician's judgment (usual practice: total treatment duration between 5 to 10 days according to French guidelines; more than 7 days of treatment should be justified).
89454587|NCT01317797|Placebo Comparator|Placebo|Namilumab-matching placebo, SC injection, on Days 1, 15 and 29.
89454588|NCT05595395|Placebo Comparator|Intravenous Fluid Arm|"In Group 1 (Standard of practice/intravenous fluid group) no enteral administration of fluid other than enteral nutrition is going to be allowed. Intravenous fluid administration is going to be administered at the discretion of the physician in charge and Elomel isoton is going to be the fluid of choice."
89454589|NCT05595395|Active Comparator|Enteral Fluid Arm|"In Group 2 (Test practice/enteral fluid group) enteral fluid administration is going to be the primary mode of administration. Intravenous fluid administration can be performed by physicians at their own discretion. Primary enteral fluid administered is going to be tap water, intravenous fluid of choice is going to be Elomel isoton."
89454590|NCT03529617||Critically ill patients|Patients admitted on ICU.
89454591|NCT03529617||Hematology patients|Patients admitted on the hematology ward.
89015920|NCT05903352|Experimental|Interruption of treatment|Interruption of treatment based on the patient reaching all of the following stability criteria (body temperature ≤ 37.8°C; heart rate ≤ 100/min; systolic blood pressure > 90mmHg; oxygen saturation ≥ 92%; respiratory rate < 24/min; normal mental status (27)), with a treatment duration no shorter than 48 h.
89015921|NCT05900908|Experimental|surgical tumor removal and GammaTile therapy followed by adjuvant systemic therapy|surgical tumor removal and GammaTile therapy followed by adjuvant systemic therapy
89454592|NCT05707169|Experimental|Two Centimeters from Saphenofemoral Junction|Endogenous Laser Ablation (EVLA) uses a laser fibre, which is inserted into the refluxing vein via skin puncture. Using 1470 nm laser and a radial fibre for less discomfort. The catheter is placed 2-2.5 cm distal to the sapheno-femoral junction. Tumescence with a mixture of 20 mL 2% lidocaine, 1: 200,000 adrenaline and 20 mL 0.5% levobupivacaine in 1 L of 0.9% saline
89454593|NCT05707169|Experimental|Zero point Ablation|The catheter is positioned exactly at the terminal valve of the SFJ (kissing the valve).
89015922|NCT05900908|Active Comparator|surgical tumor removal followed by adjuvant systemic therapy|surgical tumor removal followed by adjuvant systemic therapy
89454594|NCT05707091|Experimental|Low level laser therapy|Patients assigned to experimental group received low level laser therapy and conventional therapy. Treatment frequency was five sessions/week for 4 weeks. . For laser therapy, Omega laser system used with infrared probes of 830 nm wavelength and 100 mW output power, average energy density of 10 J/cm2 , frequency of 1 KHz, and a duty cycle of 80 % in one group. In all cases, the laser was in direct contact with the superficial roots of the facial nerve on the affected side. And was applied for 2 min and 5 s per point for 8 points.
89454595|NCT05707091|Experimental|Conventional therapy|Group B was treated with conventional therapy. The interrupted galvanic electrical impulses with the duration of 3-30 milliseconds, the tolerable intensity was applied over the motor points of each facial muscle. A total of 30-60 electrical twitch induced muscle contractions will be maintained for each muscle. The facial muscles exercise training with mirror-visual feedback was progressed to resisted exercises by self and/or therapist-assistance. All exercises were demonstrated to participants by the therapist's efforts and instructed the participants to continue the exercises twice a day for 10-15 minutes. A pictorial leaflet of facial expressions exercises with appropriate instructions to perform exercises. Treatment frequency was five sessions/week for 4 weeks.
89454596|NCT03525249|Experimental|Comparator Membraflex 500mg|experimental product one dose
89454597|NCT03525249|Experimental|Comparator Membraflex 300mg|experimental product two doses
89454598|NCT03525249|Placebo Comparator|Placebo Comparator|placebo product
89454599|NCT03627221|Experimental|music listening and social network|The intervention group will receive music listening at sleep time and will be invited to join a social network for 12 weeks. But their sleep quality , sleep knowledge, sleep hygiene, daytime fatigue, and daytime sleepy will be collected for 12 months (at baseline, 3 month, 6 month, and the 12th month).
89454600|NCT03627221|No Intervention|Control group|The control group will not receive music listening at sleep time and will not be invited to join a social network for 12 weeks. But their sleep quality, sleep knowledge, sleep hygiene, daytime fatigue, and daytime sleepy will be collected for 12 months (at baseline, 3 month, 6 month, and the 12th month).
89454601|NCT01343693||Anterior cervical discectomy and fusion|Any subject with DDD, tumor, deformity ot trauma to the cervical spine in which the investigator determines the subject will require an ACDF using the MaxAn Plate.
89454602|NCT02712008|Experimental|REGN910-3 (3 mg: 2 mg)|Participants were administered intravitreal injection of REGN910-3 (3 milligram (mg):2 mg) every 4 weeks (Q4) on Day 1, Week 4, and Week 8 for 3 initial doses followed by every Week 8 (Q8) dosing beginning at Week 16 up to Week 32.
88939454|NCT01838135|Experimental|WheelSeeU Training Program|Experimental group subjects will attend 6 x 1.5 hour training sessions (1-2 sessions/week) with a peer-Trainer. The peer-Trainer will facilitate WheelSeeU sessions and will lead participants through practice of wheelchair use goals.
88939455|NCT01838278|Experimental|Vojta physiotherapy Method|Children in the experimental group or Vojta group, received two weekly sessions of sensory-motor stimulation and two weekly sessions of Vojta physiotherapy. Sensory motor stimulation and Vojta physiotherapy sessions lasted 50 minutes each. A guidance programme was also given to parents to carry out at home to promote the overall development of the child and teach the necessary Vojta method exercises, these were to be performed four times a day for 20 minutes.
88939456|NCT01838525||SIRS, SEPSIS|
88939457|NCT01838525||sepsis, severe sepsis, septic shock|
88939458|NCT01838525||health, SIRS, Sepsis|
88939459|NCT01838564|Active Comparator|Routine data collection|Routine collection of patient-reported symptom and Quality of life data using PediQUEST surveys
88939460|NCT01838564|Experimental|Feedback of patient-reported outcomes|Routine collection of QOL and symptom data + feedback
88939461|NCT01838733||Cerebral Desaturation|Patients who suffer an intra-operative cerebral desaturation
88939462|NCT01838850|Experimental|CS8635 20/5/12.5mg and placebo|Participants receiving Olmetec® Plus 20/12.5mg (OM/HCTZ 20/12.5 mg) for the 4-week, Run-in Period but who do not meet their blood pressure goals(Non-responders) could start receiving this triple fixed dose combination therapy (CS8635 20/5/12.5mg (OM/AML/HCTZ 20/5/12.5mg) + placebo) in randomized, 8-week, double-blind Period. The non-responders finishing double-blind treatment could continue the 8-week Open-label Period with CS8635 40/5/12.5mg (OM/AML/HCTZ 40/5/12.5 mg).
88939463|NCT01838850|Active Comparator|Olmetec® Plus 20/12.5mg and placebo|Participants receiving Olmetec® Plus 20/12.5mg (OM/HCTZ 20/12.5 mg) for the 4-week, Run-in Period but who do not meet their blood pressure goals(Non-responders) could start receiving this dual fixed dose combination therapy (Olmetec® Plus 20/12.5mg (OM/HCTZ 20/12.5mg) + Placebo) in randomized, 8-week, double-blind Period. The non-responders finishing double-blind treatment could continue the 8-week Open-label Period with CS8635 20/5/12.5mg (OM/AML/HCTZ 20/5/12.5 mg).
88939464|NCT01839201|Active Comparator|etomidate/sevoflurane|Anesthesia induction: etomidate, maintenance: sevoflurane
88939465|NCT01839201|Active Comparator|propofol/sevoflurane|2.induction: etomidate, maintenance: sevoflurane
88939466|NCT01839201|Active Comparator|propofol/propofol|Anesthesia induction:propofol, maintenance:propofol
88939467|NCT01839227|Experimental|regional cerebral oxygen saturation|
88939468|NCT01839305|Experimental|Hidrotherapy|Patients performed hydrotherapy 2 twice a week, for 16 weeks, to check if there was any effect on the outcome measures for women with fibromyalgia
88939469|NCT01839344|Experimental|Quercetin|Quercetin 250 mg capsules; oral single dose of 2000 mg
89454603|NCT02712008|Experimental|REGN910-3 (6 mg:2 mg)|Participants were administered intravitreal injection of REGN910-3 (6 mg:2 mg) Q4 on Day 1, Week 4 and Week 8 for 3 initial doses up to week 12.
89454604|NCT02712008|Active Comparator|Aflibercept 2 mg|Participants were administered intravitreal injection of Aflibercept (IAI) 2 mg Q4 on Day 1, Week 4 and Week 8 for 3 initial doses up to Week 12.
89454605|NCT02712008|Experimental|REGN910-3 (6 mg:2 mg) Q4 to REGN910-3 (6 mg:2 mg) Q8|Participants were administered intravitreal injection of REGN910-3 (6 mg:2 mg) Q4 on Day 1, Week 4 and Week 8 for 3 initial doses. At Week 12, participants were re-randomized to receive REGN910-3 (6 mg:2 mg) at Week 16 and Q8 through Week 32.
89454606|NCT02712008|Experimental|REGN910-3 (6 mg:2 mg) Q4 to REGN910-3 (6 mg:2 mg) Q12|Participants were administered intravitreal injection of REGN910-3 (6 mg:2 mg) Q4 on Day 1, Week 4 and Week 8 for 3 initial doses. At week 12, participants were re-randomized to receive REGN910-3 (6 mg:2 mg) at Week 20 and Q12 through Week 32.
89454607|NCT02712008|Experimental|Aflibercept 2 mg Q4 to Aflibercept 2 mg Q8|Participants were administered intravitreal injection of Aflibercept (IAI) 2 mg Q4 on Day 1, Week 4 and Week 8 for 3 initial doses up to Week 12. At Week 12, participants were re-randomized to receive IAI at Week16 and Q8 through Week 32.
88939470|NCT01839344|Active Comparator|Acarbose|Acarbose 100 mg tablet; oral single dose of 100 mg
88939471|NCT01839344|Placebo Comparator|Placebo|An oral single dose of a solid, colored empty capsule.
88939472|NCT01839578|Experimental|RCA Group|SHF-CVVHD with regional citrate anticoagulation
88939473|NCT01839578|Experimental|Heparin group|SHF-CVVHD with systemic heparin anticoagulation
88939474|NCT01839669|Active Comparator|Foot Orthoses Only|including Patient Education; Abbreviation: FOO
88939475|NCT01839669|Experimental|Foot Orthoses and Eccentric Exercise|including Patient Education; Abbreviation: FOE
88939476|NCT01839669|Sham Comparator|Sham Foot Orthoses|including Patient Education; Abbreviation: FOS
88939477|NCT01839994|Experimental|CF-CRT combined with BT or SBRT boost|"Conventionally fractionated CRT (IMRT or Rapid Arc) to the TD of 50 Gy, 2.0 Gy d fx, 5 days a week over the period of 5 weeks AND two 10 Gy fractions of real- time HDR brachytherapy OR CRT combined with two stereotactic body radiotherapy boosts of 10 Gy per fraction delivered with dynamic SBRT technique (IMRT or Rapid Arc).~The choice between two ways of delivering radiation dose to the boost volume will be based solely on clinical criteria, decision made by interdisciplinary team, according to the institutional protocol (in non-randomized fashion).~Hormonal treatment: three months of neoadjuvant androgen deprivation (MAB -maximal androgen blockade) in all patients. Long-term (3 years) of adjuvant hormonotherapy (LHRH agonists only) in high risk patients."
88939478|NCT01839994|Active Comparator|CF-CRT alone|"Conventionally fractionated external beam conformal radiotherapy (IMRT or Rapid Arc) to the prostate and seminal vesicles (intermediate risk group) or to the prostate, SV and pelvic lymph nodes (high risk group) to the total dose of 50 Gy in 2.0 Gy per fraction, 5 days a week over the period of 5 weeks, followed by a boost to the prostate (26 or 28 Gy in 2.0 Gy per fraction 5 days a week over the period of 2.5 weeks) to the total dose of 76 or 78 Gy (intermediate or high risk group of patients, respectively).~Hormonal treatment: three months of neoadjuvant androgen deprivation (MAB -maximal androgen blockade) in all patients. Long-term (3 years) of adjuvant hormonotherapy (LHRH agonists only) in high risk patients."
88939479|NCT01840020||Gastric bypass|patients recruited from Central Norway
89454608|NCT02712008|Experimental|Aflibercept 2 mg Q4 to Aflibercept 2 mg Q12|Participants were administered intravitreal injection of Aflibercept (IAI) 2 mg Q4 on Day 1, Week 4 and Week 8 for 3 initial doses up to Week 12. At Week 12, participants were re-randomized to receive IAI at Week 20 and Q12 through Week 32.
89454609|NCT02712008|Experimental|Aflibercept 2 mg Q4 to REGN910-3 (6 mg:2 mg) Q8|Participants were administered intravitreal injection of Aflibercept (IAI) 2 mg Q4 on Day 1, Week 4 and Week 8 for 3 initial doses up to Week 12. At week 12, participants were re-randomized to receive REGN910-3 (6 mg:2 mg) at week 16 and Q8 through week 32.
89454610|NCT03527121|Experimental|R.I.C.E.+ (ESP physiotherapy)|Participants will receive a single session with advice and instructions from an ESP physiotherapist in rest, ice, compression and elevation AND pain guided early weight bearing plus a written home-based exercise program.
89454611|NCT03527121|Active Comparator|R.I.C.E.(Usual care)|A single session with advice and instructions from a physician in rest, ice, compression and elevation.
89454612|NCT05130515|Experimental|Treatment group|Niraparib 200mg po QD day1~21, Anlotinib 10mg po QD day1~14
89454613|NCT03525171|Active Comparator|GHD children|23 prepubertal children with isolated GHD consecutively admitted to the Section of Endocrinology of the University of Palermo during treated with GH for at least 12 months underwent full metabolic evaluation including euglycemic hyperinsulinemic clamp
89454614|NCT03525171|Placebo Comparator|controls|12 prepubertal healthy subjects with short stature recruited among children referred for assessment of short stature as a control group at baseline underwent full metabolic evaluation including euglycemic hyperinsulinemic clamp
89454615|NCT04484324|Experimental|60 seconds|60 seconds stretching group Stretching exercises for upper Trapezius and Levator the examiner will passively place the participant's head into flexion, side-bending away and rotation towards the side to be stretched (for upper trapezius muscle) and flexion, side-bending away and rotation away from the side to be stretched (for levator scapula ). The patient introduces a light resisted effort to take the stabilized shoulder towards the ear and the ear towards the shoulder. The contraction is sustained for 10 seconds and, upon complete relaxation of effort, the therapist gently eases the head/ neck into an increased degree of side-bending and rotation, where it is stabilized, as the shoulder is stretched caudally. The examiner will depress the participant's shoulder with 100 Newton's of force measured with pressure dynamometer. Once the examiner achieved this level of force, he maintains the stretch for 60 seconds . The procedure is repeated three times.
89454616|NCT04484324|Experimental|30 seconds|The same procedures while the therapist will maintain the stretch for 30 seconds.
89454617|NCT04484324|Experimental|15 seconds|The same procedures while the therapist will maintain the stretch for 15 seconds.
89454618|NCT04484324|Placebo Comparator|control|The therapist maintains the same manual contact without stretching force
89454619|NCT04483934|Experimental|Patients treated with dermal fibroblasts|Cultured dermal fibroblasts and LED phototherepy
89454620|NCT03626987||Bacterial identification|Describe the MALDI-TOF spectrum to identify peaks that may be associated with epidemiological and clinical characteristics of bacterial strains
89454621|NCT03201926|Experimental|mealworms|mealworms
88939480|NCT01840020||Gastric sleeve|patients recruited from Central Norway
88939481|NCT01840033|Active Comparator|Group B|After consent, patients will be randomised to PICC Line (group A) or tunnelled nutritional central catheter with cuff (group B). Duration of inclusion will be 24 months. After randomisation, patients will have catheter inserted by a competent radiologist following an echography. Radiologist will have to answer a questionnaire and doctors will note any catheter-related complications.
88939482|NCT01840033|Experimental|Group A|PICC Line (group A) : patients will have catheter inserted by a competent radiologist following an echography. Radiologist will have to answer a questionnaire and doctors will note any catheter-related complications.
88939483|NCT01840059|Experimental|Renal sympathetic denervation|Renal denervation using the Medtronic Symplicity catheter.
89454622|NCT03201926|Placebo Comparator|grain powder|grain powder
89454623|NCT03202082|Experimental|Neuropsychological testing|Participants from this group will be administered a neuropsychological battery in addition to the initial and follow-up surveys
89454624|NCT03202082|No Intervention|Treatment as usual|Participants from this group will be administered the initial and follow-up survey.
89454625|NCT03201692|Active Comparator|Treadmill Training|40' treadmill training walking holding the handrail
89454626|NCT03201692|Experimental|Virtual Reality Treadmill Training|40' treadmill training walking with virtual visual and auditory cues
89454627|NCT02450084|Experimental|Rectus sheath block|Patients of RSB group will be performed ultrasound-guided bilateral RSB after induction of general anesthesia. After draping the needle insertion site, a 22-gauge, 50-mm needle will be inserted medial to the probe by the in-plane technique and advanced in a lateral direction on just lateral to umbilicus. 15 ml of 0.25% ropivacaine will be injected on the posterior border of rectus muscle. This procedure will be performed bilaterally and total 30 ml of 0.25% ropivacaine will be injected. After the surgery, a bandage will be attached on injection site where is same as the incision site of surgery. All patients will use total 100 ml of IV-PCA containing fentanyl 800 µg for 48 hours postoperatively.
89454628|NCT02450084|Sham Comparator|Control|Patients of Control group will be proceeded a surgery scheduled after induction of general anesthesia without any procedure such as placebo injection. After the surgery, a bandage will be attached on the incision site where is same as the block injection site of RSB group. All patients will use total 100 ml of IV-PCA containing fentanyl 800µg for 48 hours postoperatively.
89454629|NCT04467177|Experimental|Glucose group|Neonates will receive 30% oral glucose
89454630|NCT04467177|Placebo Comparator|Placebo group|Neonates will receive sterile water
89454631|NCT03196622|Experimental|Older people|A cross-sectional multicentre study will be performed in hospital and retirement houses on patients ages 75 years old or more.
89454632|NCT05706467|Experimental|non-invasive high-frequency oscillatory ventilation|The day before the test, the patient was titrated with the oxygen concentration under non-invasive ventilation. The non-invasive continuous positive airway pressure ventilation was used, the pressure was set at 8cmH2O, and the oxygen concentration was titrated when the blood oxygen saturation was greater than 92% during non-invasive ventilation, and the oxygen concentration in the respiratory tube was constant after the test. In non-invasive high-frequency oscillatory ventilation mode, maintain the same positive airway pressure setting, and superimpose high-frequency oscillatory airflow with amplitude of 6cmH2O and oscillatory frequency of 10HZ.
89454633|NCT05706467|Active Comparator|continuous positive airway pressure ventilation|The patient was titrated with non-invasive ventilator-related parameters and oxygen uptake concentration the day before the test, and the parameter setting was maintained in the formal experiment.
89454634|NCT03201770|Experimental|Pyramax|Pyronaridine artesunate tablets (180/60mg) and granules (60/20mg)
89454635|NCT03529305|Experimental|Low frequency rTMS|Patients receive low frequency rTMS treatment and physical therapy. rTMS is applied over primary motor (M1) cortex of the unaffected side for two weeks, 5 consecutive days each week.
89454636|NCT03529305|Experimental|High frequency rTMS|Patients receive high frequency rTMS treatment and physical therapy. rTMS is applied over primary motor (M1) cortex of the affected side for two weeks, 5 consecutive days each week.
89454637|NCT03529305|Active Comparator|Physical therapy|Patients receive physical therapy for two weeks.
89454638|NCT02444468|Experimental|IPC and bandage|Pneumatic device and bandage
89454639|NCT02444468|Active Comparator|Bandage only|Bandage only
89454640|NCT03196700|Experimental|Short course radiotherapy|The radiotherapy is delivered over two days with accelerated hypo-fractionation was delivered
89454641|NCT03196544|Experimental|Social Approach Training (5 sessions)|
88939484|NCT01840059|No Intervention|Control|HF-PEF patients who will serve as control.
88939485|NCT01840085|Experimental|0.03% DSC127 topical gel|
88939486|NCT01840098|Active Comparator|control|Isocaloric carbohydrate drink
88939487|NCT01840098|Active Comparator|low leucine content drink|A soy protein drink
88939488|NCT01840098|Active Comparator|high content of leucine drink|A whey protein drink
88939489|NCT01840098|Active Comparator|low leucine content + HMB drink|Soy protein drink added HMB
88939490|NCT01840124|Experimental|Acessa|All women in the trial will be in this group who receive treatment using the Acessa device.
88939491|NCT01840137|Experimental|Prehabilitation|The progressive, pre-operative exercise training program includes 3 supervised exercise sessions per week for 4 weeks. The first week of training will include an acclimation period accomplished via a ramping protocol. Subjects will warm-up on a treadmill for 5-minutes. Subjects will then complete 1 set of 15 repetitions exercising 8 major muscle groups during week one; during week #2 they will complete 2 sets with a goal of at least 12 repetitions; if subjects reach 15 repetitions on the second set, the resistance will be increased by 10% at the next training session to ensure progression. After completion of the resistance training portion of each session, subjects will walk on a treadmill for 30 minutes at a low/moderate intensity followed by a 5 minutes cool-down period.
88939492|NCT01840176|No Intervention|Routine|These women are randomized to receive no McCall culdoplasty at the time of their total laparoscopic hysterectomy.
88939493|NCT01840176|Other|McCall culdoplasty|The women in this arm are those randomized to undergo a McCall culdoplasty at the time of their total laparoscopic hysterectomy.
89201237|NCT00771576||A. Healthy Controls|subjects w/ predicted normal BCM (healthy, normalweight, nondiabetic individuals who have stimulated insulin and cpeptide levels within the normal range);
89454642|NCT03196544|Experimental|Social Approach Training (10 sessions)|
89454643|NCT03196544|No Intervention|Delayed Treatment (Waitlist)|
89454644|NCT04205799|Experimental|CABOZANTINIB|Cabozantinib will be administered at the daily dose of 60 mg given orally in a 4-week cycle. It will be continued without interruption until disease progression or discontinuation for any cause.
89454645|NCT03201614|Experimental|A-CP HA|Patients randomized in this group will be treated with a combination of platelet-rich plasma plus hyaluronic acid prepared with A-CP HA Kit.
89454646|NCT03201614|Active Comparator|ArthroVisc 40|Patients randomized in this group will be treated with hyaluronic acid only (ArthroVisc 40); hyaluronic acid is the same as the one contained in the A-CP HA Kit.
89454647|NCT03201614|Placebo Comparator|Placebo|Patients randomized in this group will be treated with a saline solution.
89454648|NCT03201536|Active Comparator|sutures|zipLine3 device verses conventional sutures
89454649|NCT03201536|Active Comparator|Zip3 Device|
89454650|NCT03856190|Active Comparator|"Fasting and best practice nutrition"|Initial fasting followed by 11 weeks plant-based diet
89454651|NCT03856190|Active Comparator|Standard Nutrition Counselling|12 weeks standard antiinflammatory diet
89454652|NCT04176393|Experimental|Ivosidenib (CS3010) tablet|Ivosidenib (CS3010) tablet
89454653|NCT03525093|Active Comparator|Hypnosis + health education|5 sessions of group hypnosis, each 90 minutes; plus CDs/MP3 recordings to train at home plus health education booklet on coping with stress
89454654|NCT03525093|Other|Health education alone|Patients receive a health education booklet to improve coping with stress
89454655|NCT03193658|Active Comparator|Group T|Will receive bilateral US guided Thoracolumbar Interfascial Plane (TLIP) block at the proposed level of surgery before the start of the surgery
89454656|NCT03193658|Active Comparator|Group O|Will not receive the block and postoperative pain control will be managed by I.V drug based multi-modal approach (Opioid & acetaminophen) only.
89454657|NCT03119246|Experimental|HD patients|
89015923|NCT05900648|Experimental|Regorafenib and XmAb20717|Participants will receive regorafenib and XmAb20717 for up to 6 cycles (6 months). Participants will take regorafenib by mouth on Days 1-21 of each cycle. Participants will rest (not take regorafenib) on Days 21-28 of each cycle. Participants will also receive XmAb20717 by vein on Days 1 and 15 of each cycle. Each infusion should take about 60 minutes.
89454658|NCT03119246|Experimental|Controls|
89454659|NCT03525015|Experimental|A decision aid booklet|A decision aid booklet about cataract surgery choice
89454660|NCT03525015|Active Comparator|An usual booklet|An usual booklet about cataract and cataract surgery
89454661|NCT02449070|Experimental|Nicorandil|Receive nicorandil before primary PCI and thereafter for 6 months along with the standard therapy.
89454662|NCT02449070|No Intervention|Control|Receive primary PCI and the standard therapy.
89454663|NCT03529149|Experimental|Accurate blood pressure control|Implementing accurate blood pressure management under TCD monitoring
89454664|NCT03529149|Active Comparator|Guideline blood pressure control|Control blood pressure according to guidelines
89454665|NCT03618056|Experimental|AIDSVAX® B/E|Participants will receive 600 mcg/mL of AIDSVAX® B/E at Months 0, 1, and 6.
89454666|NCT03526809||Ovarian cancer patients|MRI and FDG-PET imaging
89454667|NCT03524859||Cystic fibrosis|Cystic fibrosis participants without experience on endurance or resistance training will be analyzed through a test battery and lung function test.
88939494|NCT01840202||Control|Healthy volunteers with no family history of glaucoma, an increased or asymmetrical cup/disc ratio or any other optic disc structural change (notching, disc hemorrhage) or an intraocular pressure (IOP) above 21 mmHg that could suggest possible glaucoma suspects.
88939495|NCT01840202||Primary open-angle glaucoma|Patients with a characteristic optic disc damage (based on cup/disc ratio, thinning of neuroretinal rim, notching, disk hemorrhages, etc.) and visual field defects, with at least one measurement of IOP of >21 mmHg required
88939496|NCT01840202||Normal Tension Glaucoma|Patients with a characteristic optic disc damage (based on cup/disc ratio, thinning of neuroretinal rim, notching, disk hemorrhages, etc.) and visual field defects, with at maximum recorded IOP of < 21 mmHg
89454668|NCT03524859||Healthy Subjects|Healthy matched control group without experience on endurance or resistance training will be analyzed through a test battery.
89454669|NCT04101045|Active Comparator|Poorly-controlled T1D|Patients in this group will have poorly-controlled T1D (HbA1c >8.5%).
89454670|NCT04101045|Active Comparator|Controlled T1D|Patients in this group will have T1D and achieve targeted glycemic control (HbA1c <7.5%).
89454671|NCT04101045|Active Comparator|Lean controls|Patients in this group will not have T1D.
89454672|NCT02449382|Active Comparator|continuous venovenous hemofiltration|CVVH was mainly determined by the differences of sodium concentration between serum and replacement fluid. The rate of decline serum sodium could be real-time adjusted using different-sodium-concentration replacement fluid according to the updated serum sodium concentration.
89454673|NCT02449382|Active Comparator|Control group|Treatment of hypernatremia is correction of water deficit.
89454674|NCT03193268|Experimental|High intensity agility group|Exercise therapy
89454675|NCT03193268|Experimental|Non-agility cycling group|Parkinson's Bicycle Group, which takes 1 hour of exercise every day for 5 weeks
89454676|NCT03193268|No Intervention|No-exercise control group|Control Parkinson's disease control group thad will not receive exercise treatment
89454677|NCT03196388|Experimental|Enzalutamide with External|On this study patients will be treated with 6 months of Xtandi (enzalutamide). Approximately one-third of the way through this treatment they will receive EBRT. Starting on Day 1, all patients will ingestenzalutamide 160 mg/day at the same time each day without breaks (except as outlined for toxicity), with or without food, for 6 (28 day +/-3 days) cycles. Dose reduction of enzalutamide to 120 mg/day is allowed with the approval of the Medical Monitor. Patients will be instructed to return all unused capsules at each study visit to assess compliance and will receive study drug every 28 days (+/-3 days) for 6 cycles (25 weeks).
89454678|NCT03526731|Experimental|Group A (original QLB-2):|Local anesthetic will be injected between the quadratus lumborum muscle and the latissimus dorsi muscle guided by ultrasound.
89454679|NCT03526731|Experimental|Group B (trans-muscular OLB-3)|Local anesthetic will be injected between quadratus lumborum and psoas major after passing through the quadratus lumborum muscle guided by ultrasound.
89454680|NCT03193502|Experimental|Portal Vein thrombosis|rivaroxaban
89454681|NCT03526965|Experimental|Yoga Chikitsa|YC group were given traditional combination of yoga therapy including loosening movements, physical postures, breathing, relaxation and yoga counselling.
89454682|NCT03526965|Active Comparator|Usual Care|Usual care were given exercise moves of necks, pain medications prescribed by physicians.
89454683|NCT03193580|Experimental|Anodal Conventional tDCS|The intervention will be anodal conventional tDCS. Anodal tDCS: 30 second ramp up to 1milliamp, 20 minute current hold at 1milliamp, 30 second ramp down to 0 milliamp. Anode positioned over the right primary motor cortex, and the cathode over the contralateral supraorbital area.
89454684|NCT03193580|Experimental|Anodal High Definition tDCS|The intervention will be anodal high definition-tDCS. Anodal HD-tDCS: 30 second ramp up to 1milliamp, 20 minute current hold at 1milliamp, 30 second ramp down to 0milliamp. Anode entered over the right primary motor cortex, and four cathodes placed in a ring formation surrounding the anode.
89454685|NCT03193580|Sham Comparator|Sham tDCS|Sham subjects will undergo exactly the same anodal conventional tDCS protocol as outlined above. This includes the initial stimulation sequence of ramp up of 30 seconds, generating the initial transient scalp sensations identical to the treatment group. The stimulator will be programmed by the technologist after 120 seconds of stimulation to automatically ramp down to 0milliamp over 30 seconds.
89454686|NCT05616429|Experimental|Alcat based personal diet|
89454687|NCT05616429|Sham Comparator|Standard balanced diet|
89454688|NCT04013217|Experimental|Eribulin ORA|To determine the MTD of Eribulin ORA (oral eribulin mesylate and HM30181A) when administered on Day 1 and Day 8 of a 3 weeks cycle.
89454689|NCT03193034|Experimental|ATTUNE Cementless RP TKA|Subjects will receive a cementless, rotating platform total knee arthroplasty.
89454690|NCT05603949||experimental group|
89454691|NCT02711306|Experimental|GMN Diet|In the glucomannan noodle (GMN) diet, the participants received two servings (400 g) of GMN every day to replace their daily carbohydrate intake for 4 weeks, with each serving of glucomannan noodles weighing up to 200 g with 2 g of glucomannan.
89454692|NCT02711306|Placebo Comparator|PN Diet|In the placebo noodle (PN) diet, the participants received the participants received the same amount of noodles without glucomannan.
89454693|NCT03528993|Experimental|Exercise by hippotherapy device group|The experimental group receive conventional rehabilitation for 45 min/day following by use of a hippotherapy device for 15 min/day, 5 times/week for 4 weeks
89454694|NCT03528993|Other|Control group|The control group will receive conventional rehabilitation for 45 min/day, following by postural control exercises 15 min/day 5 times/week for 4 weeks.
89454695|NCT03193112||Study group|The investigators analyze the intraocular pressure changes on patients who have been using Agomelatine for their primary depressive disorder. For the treatment of depression, patients will have been started routinely Agomelatine tablet of 25 mg orally. The investigators measure the eye pressure for one months in those patients receiving standard depression treatment.
89454696|NCT03196154||Metformin|Patients who are on either metformin 2g per day or metformin extended release 2g per day. Subject will be required to fast overnight. Fasting insulin levels and plasma drug levels will be measured.
88939497|NCT01840215||Controls|Patients scheduled for elective ophthalmic surgery with no family history of glaucoma, an increased or asymmetrical cup/disc ratio or any other optic disc structural change (notching, disc hemorrhage) or an intraocular pressure (IOP) above 21 mmHg that could suggest possible glaucoma suspects.
88939498|NCT01840215||Primary open-angle Glaucoma|Patients scheduled for an elective glaucoma surgery that present with a characteristic optic disc damage (based on cup/disc ratio, thinning of neuroretinal rim, notching, disk hemorrhages, etc.) and visual field defects, with at least one measurement of IOP of >21 mmHg required
88939499|NCT01840215||Normal Tension Glaucoma|Patients scheduled for an elective glaucoma surgery that present with a characteristic optic disc damage (based on cup/disc ratio, thinning of neuroretinal rim, notching, disk hemorrhages, etc.) and visual field defects, with at maximum recorded IOP of < 21 mmHg.
88939500|NCT01840241|Experimental|BIVON group|
88939501|NCT01840241|Placebo Comparator|Placebo group|normal saline infusion
88939502|NCT01840254|Experimental|dexmedetomidine|addition of dexmedetomidine to fentanyl-based intravenous patient controlled analgesia (PCA)
88939503|NCT01840254|Placebo Comparator|normal saline|normal saline as a placebo
88939504|NCT01840267||laparoscopic surgery under general anesthesia|pediatric patients undergoing laparoscopic surgery under general anesthesia
88939505|NCT01840280||Carcinoma, Irinotecan onkovis (Irinotecan)|Treatment in mono- or combination therapy with Irinotecan of advanced colorectal carcinoma.
88939506|NCT01840332|Experimental|L-thyroxin|this is one arm study
88939507|NCT01840358|Other|Patients starting pump therapy|
88939508|NCT01840371|Experimental|Propofol based group|
88939509|NCT01840371|Active Comparator|Fentanyl based group|
88939510|NCT01840384|Experimental|Multi-micronutrients|Multi-micronutrients
88939511|NCT01840384|Placebo Comparator|Maltodextrin and Lactose|Placebo contained maltodextrin and lactose
88939512|NCT01840397||Spine surgery|Patients undergoing spine surgery
88939513|NCT01840397||Bone surgery|Patients undergoing bone surgery for fracture treatment other than spine fractures
88939514|NCT01840423|Experimental|ODM-104|Oral capsules dosage 10-800mg once daily for one day or three times daily for 7 days
88939515|NCT01840423|Placebo Comparator|Placebo|Oral capsules given once daily for one day or three times daily for 7 days
88939516|NCT01840423|Active Comparator|entacapone + levodopa/carbidopa|entacapone: oral tablet 200mg given four times daily for one day; levodopa/carbidopa: oral tablet 100/25mg given four times daily for one day
88939517|NCT01840436|Placebo Comparator|Placebo|This arm receives a placebo (saline solution) mouthwash treatment twice a day.
88939518|NCT01840436|Experimental|MUCIPLIQ 0.05 mg/mL|This arm receives MUCIPLIQ mouthwash treatment at a final concentration of 0.05 mg/mL twice a day.
88939519|NCT01840436|Experimental|MUCIPLIQ 0.015 mg/mL|This arm receives MUCIPLIQ mouthwash treatment at a final concentration of 0.015 mg/mL twice a day.
88939520|NCT01840449||Neuroendocrine Tumours|The subject will receive treatment as prescribed by the investigator and in accordance with the current recommendations, routine practice and local regulations.
88939521|NCT01840449||Acromegaly|The subject will receive treatment as prescribed by the investigator and in accordance with the current recommendations, routine practice and local regulations.
88939522|NCT01840462||Subjects naïve to botulinum toxin A (BoNT-A) treatment|Patients naïve to botulinum toxin A treatment
88939523|NCT01840462||Subjects pre-treated with botulinum toxin A (BoNT-A) injection|"Patients pre-treated with botulinum toxin A for at least 2 years.~4 injection cycles, each at 3 to 4 months intervals. Investigators follow their individual injection protocol for the treatment with BoNT-A (modalities of administration in accordance with local Summary of Product Characteristics)."
88939524|NCT01840475||Botulinum toxin type A (BoNT-A) injection (Dysport®) Naïve|Subjects naïve to BoNT-A treatment.
89454697|NCT03196154||Metformin + Gliclazide|Patient who are on both metformin 2g per day or metformin extended release 2g per day and gliclazide 320mg per day or gliclazide modified release 120mg per day. Subject will be required to fast overnight. Fasting insulin levels and plasma drug levels will be measured.
89454698|NCT03996525|Experimental|Electrical Stimulation|"Electrical Stimulation~The patient will receive active electrical stimulation."
89454699|NCT03996525|Placebo Comparator|Sham Treatment|"No Electrical Stimulation~The patient will receive sham electrical stimulation."
89454700|NCT03994497|Other|Patient in need of a kidney transplant|
89454701|NCT03193424|Experimental|Apatinib|
89454702|NCT03193424|Active Comparator|docetaxel|
89454703|NCT03526653|Other|Intervention 1|exercise on an ergometer or motomed in an environment without other visual stimuli
89454704|NCT03526653|Other|Intervention 2|exercise on an ergometer or motomed while watching the National Geografics channel on television
89454705|NCT03526653|Other|Intervention 3|exercise on an ergometer or motomed with the interactive software program MemoRide with which participants can exercise in real life on a virtual manner
89454706|NCT03526653|No Intervention|Control group|Rest during 30 minutes
89454707|NCT03193346|Experimental|BOTOX®|BOTOX® (botulinum toxin Type A) 155U to 195U intramuscular (IM) injections in head/neck areas at Day 0 and Week 12.
89454708|NCT03193346|Placebo Comparator|Placebo|Placebo matching BOTOX® [Sodium chloride 0.9 milligrams (mg)] IM injections in head/neck areas at Day 0 and Week 12.
89454709|NCT03118622||Pentax group|Intubation using Pentax
89454710|NCT03118622||Macintosh group|Intubation using Macintosh
89454711|NCT02448836|Experimental|Active dTMS treatment|In each menstrual cycle, patients will undergo 8 sessions of dTMS active treatment for two weeks (4 sessions every week) with dTMS H-coil system:magstim stimulator rapid2,BrainswayH1coil. The post ovulation phase is the luteal and symptomatic phase of PMDD patients.
88939525|NCT01840475||Botulinum toxin type A (BoNT-A) Pre-treated|"Subjects pre-treated with BoNT-A.~Investigators follow their individual injection protocol for the treatment with BoNT-A (modalities of administration in accordance with local Summary of Product Characteristics [SmPC])."
88939526|NCT01840488|Experimental|Irosustat (BN83495)|Single oral administration of irosustat
89454712|NCT02448836|Sham Comparator|Sham dTMS treatment|In each menstrual cycle, patients will undergo 8 sessions of Sham dTMS treatment for two weeks (4 sessions every week) with dTMS H-coil system:magstim stimulator rapid2,BrainswayH1coil. The post ovulation phase is the luteal and symptomatic phase of PMDD patients.
89454713|NCT03118076|Placebo Comparator|Group R|Nerve blocks were administered with 0.3% ropivacaine without dexmedetomidine.
88939527|NCT01840501|Experimental|Part 1: Panel 1 (0.1 mg JNJ-42721458)|6 participants will receive a single dose of 0.1 mg of JNJ-42721458.
88939528|NCT01840501|Experimental|Part 1: Panel 2 (0.3 mg JNJ-42721458)|6 participants will receive a single dose of 0.3 mg of JNJ-42721458.
89454714|NCT03118076|Experimental|Group RD|Nerve blocks were administered with 0.3% ropivacaine and 50 μg dexmedetomidine.
89454715|NCT03117764|Active Comparator|Acute IV AB for exacerbation at hospital|"The study will compare muscular strength of hospitalised patients who receive specific exercise training, with patients who follow their antibiotherapy at home without specific exercise training.~Interventions: microfet dynamometer, 1 minute sit to stand test, accelerometer."
89454716|NCT03117764|Experimental|Acute IV AB for exacerbation at home|"The study will compare muscular strength of hospitalised patients who receive specific exercise training, with patients who follow their antibiotherapy at home without specific exercise training.~Interventions: microfet dynamometer, 1 minute sit to stand test, accelerometer."
89454717|NCT03528915||Prophylaxis group|Newborns treated with rifamycin eye drops systemically two months before change of practices in delivery room.
89454718|NCT03528915||no-antibiotic group|Newborns not treated with antibiotic prophylaxis in a systemic way, according to the new french guidelines of January 1st, 2015.
89454719|NCT03192878||Naive patients|Patients with corticosteroid- and/or traditional immunosuppressive drug-resistant Takayasu's arteritis with indication of initiating therapy with anti-TNF-alpha
89454720|NCT03192878||Switch patients|Patients with Takayasu's arteritis already in therapy with infliximab originator (Remicade) in whom the originator therapy will be replaced with infliximab biosimilar therapy
89454721|NCT03524703|Experimental|Chewing Gum Group|Patients who receive anterior cervical fusion and have mild or moderate dysphagia postoperatively, will be randomized into two groups. Subjects assigned to the Chewing Gum Group are asked to chew gum four times a day for 5 days (15 minutes each time) after surgery in addition to standard cares. Standard cares include cleaning the wound every 2 days, wearing a collar, pain management, and education.
89454722|NCT03524703|No Intervention|Control Group|Patients who receive anterior cervical fusion and have mild or moderate dysphagia postoperatively, will be randomized into two groups. Subjects assigned to the Control Group receive standard cares and are asked not to chew gum within 5 days after surgery. Standard cares include cleaning the wound every 2 days, wearing a collar, pain management, and education.
89454723|NCT03195920|Experimental|Enhanced Lithotripsy System|Treatment for urinary stones with the Enhanced Lithotripsy System
89454724|NCT04467099||Os Trigonum Excision with Tear|Participants with flexor hallucis tendon tear
89454725|NCT04467099||Os Trigonum Excision without Tear|Participants without flexor hallucis tendon tear
88939529|NCT01840501|Experimental|Part 1: Panel 3 (1.0 mg JNJ-42721458)|6 participants will receive a single dose of 1.0 mg of JNJ-42721458.
88939530|NCT01840501|Experimental|Part 1: Panel 4 (2.5 mg JNJ-42721458)|6 participants will receive a single dose of 2.5 mg of JNJ-42721458.
88939531|NCT01840501|Experimental|Part 1: Panel 5 (5.0 mg JNJ-42721458)|6 participants will receive a single dose of 5.0 mg of JNJ-42721458.
88939532|NCT01840501|Experimental|Part 1: Panel 6 (10.0 mg JNJ-42721458)|6 participants will receive a single dose of 10.0 mg of JNJ-42721458.
88939533|NCT01840501|Experimental|Part 1: Panel 7 (20.0 mg JNJ-42721458)|6 participants will receive a single dose of 20.0 mg of JNJ-42721458.
88939534|NCT01840501|Experimental|Part 1: Panel 8|6 participants will receive a single dose JNJ-42721458, the dose will be determined after completion of panels 1-7 in Part 1.
89454726|NCT00294320|Experimental|1|250mg of Imiquimod cream application once daily 3 times per week.
89454727|NCT00294320|Placebo Comparator|2|250mg vehicle cream for application once daily 3 times per week.
89454728|NCT03526575|Placebo Comparator|10 mg Zolpidem and 10 mg Zaleplon|Experiment 1 will involve N= 14 subjects randomized to placebo , 10 mg zolpidem for males and 10 mg zaleplon in counterbalanced order. Subjects are nested into group.
89454729|NCT03526575|Placebo Comparator|5 mg Zolpidem and 10 mg Zaleplon|Experiment 2, which will involve N=20 subjects randomized to placebo, 5 mg zolpidem and 10 mg zaleplon. All females will be placed in experiment 2. Subjects are nested into group.
89454730|NCT00189254||Imiquimod 5% cream|No investigational treatments were given during this study.
89454731|NCT04978857|Experimental|Virtual reality headset|
89454732|NCT02448524|Experimental|MiStentTM|MiStentTM coronary drug eluting stent (MiStent SES) consists of four parts: a bare-metal stent (BMS), a delivery system, resorbable polymer coating and anti-proliferative drug (sirolimus).
89454733|NCT02448524|Active Comparator|TIVOLI|TIVOLI stent is a mature and fully degradable coating on a cobalt-chromium alloy drug-eluting stent on the market, findings of four years fully demonstrated the efficacy and safety of sirolimus-coated TIVOLI stent.
89454734|NCT02710292|Other|DT1, then TE|Delefilcon A contact lenses worn first, followed by narafilcon A contact lenses. Each product will be worn bilaterally (in both eyes) for at least 7 days in a daily disposable modality.
89454735|NCT02710292|Other|TE, then DT1|Narafilcon A contact lenses worn first, followed by delefilcon A contact lenses. Each product will be worn bilaterally (in both eyes) for at least 7 days in a daily disposable modality.
89454736|NCT03528837||Diagnosed as acute kidney injury|Sure diagnosed as acute kidney injury
89454737|NCT03192644|Experimental|Group A (TAI)|
89454738|NCT03192644|Active Comparator|Group B (TACE)|
89454739|NCT03110055|Experimental|HCV patients with un-resectable HCC|"HCV genotype 1 (a and b) cirrhotic patients (child pugh A compensated cirrhosis) with advanced and un-resectable HCC who are eligible for TACE . The patients will receive Grazoprevir/Elbasvir and Transarterial Chemoembolization.~Their outcomes will be compared to the medical records of patients who underwent Transarterial Chemoembolization only, in the past."
89454740|NCT02444624||not necrotizing enterocolitis group|not necrotizing enterocolitis preterm neonates matched with necrotizing enterocolitis preterm neonates
89454741|NCT02444624||necrotizing enterocolitis group|necrotizing enterocolitis preterm neonates of gestational age less than or equal to 31+6 weeks of amenorrhoea with confirmed NEC diagnosis (Bell stage II or III)
89454742|NCT02448602|Other|Single point group (Shenmen)|Patients will be acupuncture with Shenmen(HT7).
89454743|NCT02448602|Other|Sancai coordinated points group|Patients in Sancai coordinated points group, will be acupuncture with Baihui(DU20), Shenmen(HT7), Sanyinjiao(SP6).
89454744|NCT02448602|Other|Control group|Patients in Control group, will be acupuncture with at the junction of deltoid and biceps.
88939535|NCT01840501|Experimental|Part 1: Panel 9|6 participants will receive a single dose JNJ-42721458, the dose will be determined after completion of panels 1-8 in Part 1.
88939536|NCT01840501|Experimental|Part 1: Panel 10|6 participants will receive a single dose JNJ-42721458, the dose will be determined after completion of panels 1-9 in Part 1.
88939537|NCT01840501|Placebo Comparator|Part 1: Placebo|2 participants from each panel will receive a single dose of placebo.
88939538|NCT01840501|Experimental|Part 2: Panel 1 (5.0 mg JNJ-42721458)|6 participants will receive multiple doses of 5.0 mg of JNJ-42721458.
88939539|NCT01840501|Experimental|Part 2: Panel 2 (10.0 mg JNJ-42721458)|6 participants will receive multiple doses of 10.0 mg of JNJ-42721458.
88939540|NCT01840501|Experimental|Part 2: Panel 3|6 participants will receive multiple doses of JNJ-42721458, the dose will be determined after completion of panels 1-2 in Part 2.
88939541|NCT01840501|Experimental|Part 2: Panel 4|6 participants will receive multiple doses of JNJ-42721458, the dose will be determined after completion of panels 1-3 in Part 2.
88939542|NCT01840501|Experimental|Part 2: Panel 5|6 participants will receive multiple doses of JNJ-42721458, the dose will be determined after completion of panels 1-4 in Part 2.
89454745|NCT03195998||Group A|Gestational Age 23 0/7 - 28 6/7 weeks
88939543|NCT01840501|Experimental|Part 2: Panel 6|6 participants will receive multiple doses of JNJ-42721458, the dose will be determined after completion of panels 1-5 in Part 2.
88939544|NCT01840501|Placebo Comparator|Part 2: Placebo|2 participants from each panel will receive multiple doses of placebo.
88939545|NCT01840527||Group 1|Advanced Melanoma
88939546|NCT01840527||Group 2|Stage II/III Melanoma
88939547|NCT01840540|Experimental|infusion of autologous mesenchymal stem cells|Patients will undergo a subcutaneous fat biopsy for expansion of mesenchymal stromal (stem) cells (MSC) in the Human Cell Therapy Laboratory. Patients will be admitted to the inpatient Clinical Research Unit of the Mayo Clinic Center for 3 days prior to treatment, for pre-infusion tests. Renal angiography will be performed to deliver a single intra-arterial dose of MSC's into one affected kidney. Patients will be observed for 24 hours for acute adverse events. Patients will have remote visits at 1 week, 4 weeks,8 weeks, and 6 months. At 3 months, patients will return for repeat evaluation of kidney function, blood flow and structural alterations within the clinical research unit at St. Mary's Hospital, Rochester, Minnesota. Thereafter, health assessment and blood draws will be repeated at 12 and 24 months with urinary cytology and MRI.
88939548|NCT01840553|Active Comparator|polyethylene glycol|4 Liters of PEG administered split in 2 doses
89454746|NCT03195998||Group B|Gestational Age 29 0/7 weeks - 34 6/7 weeks
89454747|NCT01190852|Experimental|Azelastine, Fluticasone|TEST = MP29-02 = Combination product Azelastine Hydrochloride and Fluticasone Propionate nasal spray
89454748|NCT01190852|Active Comparator|Azelastine mono|REF = AZE mono Azelastine Hydrochloride nasal spray (= essentially combination product formulation without any FLU; US AZE mono formulation as used in pivotal studies)
89454749|NCT01190852|Active Comparator|Azelastine|COMP = Astelin® Nasal Spray = AZE mono Azelastine Hydrochloride nasal spray (= US marketed product)
89454750|NCT02444312|Experimental|Benefit-finding Writing Activity|For two weeks, on six days of their choice, caregivers will be instructed to write about their thoughts and feelings in a diary/ notebook about the benefits of caring.
89454751|NCT02444312|Active Comparator|Neutral Writing activity|For two weeks, on six days of their choice, caregivers will be instructed to write about a neutral topic.
89454752|NCT02444156|Experimental|Exercise training|All participants will receive usual care, including standard advice about diet and physical activity. In addition to usual care, participants will be asked to take part in a 12-week exercise programme. Participants will use an indoor rower (Concept 2, Model E) three times per week at Leicester Diabetes Centre. Each session will be supervised and the investigators will liaise with the participants to arrange convenient times to exercise, including mornings and evenings. The supervisors will teach the participants how to row correctly.
89454753|NCT04917159|Experimental|ACT Group|The ACT intervention was structured to take place over one month on a weekly basis via Tencent's VooV platform. Each roughly 2-hour session will consist of a group-based ACT (1.5 hours) and a brief health education talk on CHF self-management (0.5 hours). Each training session will serve about 4-8 dyads. In addition, each participant will receive one set of session handouts on CHF education, ACT skills, and a homework assignment.
89454754|NCT04917159|Active Comparator|HE group|The participants of the control group will receive four weekly 2-hour sessions of structured health education on CHF self-management over four consecutive weeks via Tencent's VooV platform, delivered by a registered nurse. Each session will includea a review of the previous session (except the first session), a CHF education talk and a Q&A section to evaluate the participant's understanding of the key concepts. Each session will be offered to 4-8 patient-caregiver dyads. In addition, each participant will receive session handouts on the main topic related to CHF self-management and homework assignments.
89454755|NCT04915677|Active Comparator|Subepithelial Connective Tissue Graft (SCTG)|Soft tissue augmentation at edentulous area with subepithelial connective tissue graft harvested from the patient's palate
89454756|NCT04915677|Experimental|Volume Stable Collagen Matrix (VCMX)|Soft tissue augmentation at edentulous area with xenogenic volume stable collagen matrix
89454757|NCT02710214|Experimental|Duavee|1 Tablet of 0.45mg conjugated estrogens/20 mg bazedoxifene daily for 8 weeks
89454758|NCT02710214|Placebo Comparator|Placebo|Placebo pill daily for 8 weeks.
89454759|NCT03524547|Experimental|J-shaped|Endotracheal tube will be molded into a J-shape that is similar to that of Macintosh type blade of a McGrath MAC® videolaryngoscope.
89454760|NCT03524547|Active Comparator|60-degrees|Endotracheal tube will be bent 60 degrees.
89454761|NCT05561205|Experimental|rTMS + methylphenidate|repetitive transcranial magnetic stimulation (rTMS) and methylphenidate
89015924|NCT05894577|Experimental|Arm F - Montelukast|Montelukast will be self-administered orally by each participant at a dose of 10 mg once a day for 14 days.
89015925|NCT05894577|Placebo Comparator|Arm F - Placebo|"Placebo - appearance and size matched to active study drug.~Placebo will be self-administered orally by each participant, with number of tablets matched to active study drug dosing."
89015926|NCT05888727|Experimental|Exercise Training Intervention|
89015927|NCT05888727|Active Comparator|Wellness Control|
89015928|NCT05881759|No Intervention|Usual Practice - ESBA|The control group sites will receive the existing ESBA curriculum which is their usual practice.
89015929|NCT05881759|Experimental|ESBA + Feeding Practices|The intervention site staff will implement the ESBA-FFYF feeding curriculum in classes using standardized implementation protocols.
89454762|NCT05561205|Experimental|rTMS only|repetitive transcranial magnetic stimulation (rTMS) only
89454763|NCT03052517|Experimental|QAW039 150mg|QAW039 Dose 1 once daily
89454764|NCT03052517|Experimental|QAW039 450 mg|QAW039 Dose 2 once daily
89454765|NCT03052517|Placebo Comparator|Placebo|Placebo once daily
89454766|NCT02708498|Experimental|Kronoberg Educational Intervention|The educational intervention is provided to ten nursing homes.
89454767|NCT02708498|No Intervention|Skåne Control|The control group consists of an equal number of nursing homes. This group receives no intervention.
89454768|NCT02708498|Experimental|Skåne Educational Intervention|The educational intervention is provided to ten nursing homes.
89454769|NCT02708498|No Intervention|Kronoberg Control|The control group consists of an equal number of nursing homes. This group receives no intervention.
89454770|NCT03766659|Other|MOSE|EUS-FNB with MOSE
89454771|NCT03766659|Other|ROSE|EUS-FNA with ROSE
89454772|NCT03524391|Experimental|Yoga Counselling Group|Yoga based psychological counselling delivered individually and in group along with conventional care
89015930|NCT05878275|No Intervention|Usual Care Group Receiving an Informational Tummy Time Brochure|Usual care group will receive a brochure on the importance of tummy time and limiting baby gear.
89015931|NCT05878275|Experimental|Parent Informational Session|Parental education session that includes information and a video on avoiding screen time in the first two years of life, the importance and benefits of infants being exposed to tummy time, varying play positions and limiting time in baby gear. Additional information will be provided on the importance of implementing tummy time during the first month of life as well as different ways to implement tummy time and how to increase infant tolerance to tummy time. Parents in the Parent Informational Session can request a Zoom consultation with the Principal Investigator if the parents have questions or need guidance with implementing tummy time.
89015932|NCT05874362|Other|Group with complications at 3 month|Group composed with participants who develop a psychiatric complication (depressive episode or post traumatic stress disorder) 3 month after the death of their loved one.
89015933|NCT05874362|Other|Group without complication at 3 month|Group composed with participants who do not develop a psychiatric complication (depressive episode or post traumatic stress disorder) 3 month after the death of their loved one.
89015934|NCT05873881|Placebo Comparator|Colchicine versus placebo|Randomization to colchicine or placebo
89015935|NCT05873881|Experimental|Thiamine versus no thiamine|Randomization to thiamine or to no thiamine in a PROBE design
89454773|NCT03524391|Active Comparator|Usual Care Group|Usual care provided to patients
89454774|NCT02710136|Experimental|Glycerinated CR Allergenic Extract|"Complete Arm Title: Glycerinated German Cockroach Allergenic Extract.~Cockroach sensitive subjects are exposed to cockroach nasal allergen (NAC) intranasally at at increasing doses per protocol. The NAC aim is pursuit of optimal dose range as determined by tolerability and eliciting a threshold of nasal symptoms."
89015936|NCT05873465|Active Comparator|Non-users|Patients that don't use cannabis and will be submitted to sedation.
89015937|NCT05873465|Experimental|Users that will stop use 72h before the procedure|Patients that use cannabis and will stop using 72 hours before sedation.
89015938|NCT05873465|Experimental|Users that will stop use 12h before the procedure|Patients that use cannabis and will stop using 12 hours before sedation.
89015939|NCT05873062|Experimental|Experimental: AUT00201|Single dose (oral, capsule) of AUT00201
89454775|NCT04441437|Experimental|Splint Group|1-hour task-oriented training with wearing a customized dynamic hand splint, totally 15 times in a duration of one month.
89454776|NCT04441437|Placebo Comparator|No-Splint Group|1-hour task-oriented training without wearing a customized dynamic hand splint, totally 15 times in a duration of one month.
89454777|NCT04467645|Experimental|Reflexology|Reflexology Application: A total of twelve 30-minute reflexology sessions (2 per week)were administered to each patient.
89454778|NCT04467645|No Intervention|No intervention|No intervention was applied to the postmenopausal women in the control group.
89454779|NCT02443844|Active Comparator|First group|Patients taken tamsulosin for benign prostate hyperplasia who have non muscle invasive bladder cancer
89454780|NCT02443844|Active Comparator|Second Group|Patients taken transurethral resection prostatectomy for benign prostate hyperplasia who have non muscle invasive bladder cancer
89454781|NCT03754335|Experimental|Lumbar puncture|Lumbar puncture in addition to a predefined analgesic protocol Patients will be randomized between the 3rd and 5th days following aneurismal rupture.
89454782|NCT03754335|Active Comparator|Sham lumbar puncture|Sham lumbar puncture in addition to a predefined analgesic protocol Patients will be randomized between the 3rd and 5th days following aneurismal rupture.
89454783|NCT02440100|Experimental|Multiple Doses PF-06648671 (Cohort1)|Healthy subjects receive 14-day repeated dose once a day at 4 mg of PF-06648671 or matching placebo
89454784|NCT02440100|Experimental|Multiple Doses PF-06648671 (cohort 2)|Healthy subject receive 14-day repeated dose once a day at 12 mg of PF-06648671 or matching placebo
89454785|NCT02440100|Experimental|Multiple doses PF-06648671 (cohort 3)|Healthy subject receive 14-day repeated dose once a day at 40 mg of PF-06648671 or matching placebo and CSF LP is collected at baseline and steady state predose on day 1 and 14
89454786|NCT02440100|Experimental|Multiple Doses PF-06648671 (cohort 4)|Healthy subject receive 14-day repeated dose once a day at 40 mg of PF-06648671 or matching placebo
89454787|NCT02440100|Experimental|Multiple Doses PF-06648671 (cohort 5)|Healthy subject receive 14-day repeated dose once a day at 100 mg of PF-06648671 or matching placebo, CSF LP is collected at baseline 72 hours prior to day 1 dosing and at steady-state on Day 15, 24 hours after last dosing on day 14
89454788|NCT02440100|Experimental|Multiple Doses in Healthy Elderly (cohort 7)|Healthy Elderly subjects receive 14-day repeated dose once a day at MTD PF-06648671 defined in healthy adult subjects (part 1)
89454789|NCT02440100|Experimental|Multiple Doses PF-06648671 (cohort 8)|Healthy subjects receive 14-day repeated dose once a day at 360 mg of PF-06648671 or matching placebo, CSF LP is collected at baseline 72 hours prior to day 1 dosing and at steady-state on Day 15, 24 hours post last dose
89454790|NCT02440100|Experimental|Midazolam DDI (optional cohort 9)|Healthy Subjects receive single dose of 2 mg midazolam in period 1 followed by 14 days PF-06648671 once a day and coadministration of PF-06648671 and midazolam 2 mg in period 2 (Optional cohort)
89454791|NCT02440100|Experimental|Multiple Doses PF-06648671 (cohort 6)|Healthy subject receive 14-day repeated dose once a day at 200 mg of PF-06648671 or matching placebo, CSF LP is collected at baseline 72 hours prior to day 1 dosing and at steady-state on Day 25, 24 hours after last dosing on day 14
89015940|NCT05873062|Placebo Comparator|Experimental: Placebo|Single dose matching placebo oral capsules
89015941|NCT05867914|Experimental|Inhaled Nitric Oxide (iNO)|"eNOfit an Electric Nitric Oxide (NO) Ambulatory Production and Delivery System, Delivering Nitric Oxide for Inhalation~The treatment period with inhaled Nitric Oxide (iNO) will include start of iNO at a device setting of 2 mg/hr iNO for 2 hours (+15 minutes), device setting escalation to 6 mg/hr iNO for 2 hours (+15 minutes) and then weaning of iNO treatment"
89015942|NCT05867576|Active Comparator|Allocated to treatment|Patients randomly allocated to this arm will receive treatment immediately. They will receive 6-12 sessions of ACT while patients allocated to the waitlist control arm do no receive any treatment.
89015943|NCT05867576|No Intervention|Allocated to waitlist control|Patients randomly allocated to this arm will receive a delay in the treatment they receive. After a 12-week wait they will receive 6-12 sessions of ACT, while patients allocated to the immediate treatment arm receive no treatment for an equal duration.
89454792|NCT02439944|Experimental|Experimental Arm|Escalating nicotine patch dose to satiety over 6 weeks with dosage depending on the number of cigarettes smoked per day and the occurrence of adverse effects
89454793|NCT02439944|Active Comparator|Positive Control Arm|Nicotine patch dose of 21mg coupled with nicotine mouthspray which is to be used as needed.
89454794|NCT03133065|Active Comparator|Group 1: treatment after 6 months post transplantation|53 patients received Sofosbuvir+ribavirin standard of care for treatment of HCV post liver transplantation for 6 months
89454795|NCT03133065|Active Comparator|Group 2: early treatment afer 3 months post transplantation|36 patients received other DAAs regiment for treatment of HCV post liver transplantation for 3- 6 months
89454796|NCT02434250|Experimental|SLT arm|Patient receiving 'Selective Laser Trabeculoplasty' (SLT) due to failed Phacoemulsification Cataract Extraction with Intraocular Lens Implantation combined with Eximer Laser Trabeculectomy (phaco-ELT) in Open Angle Glaucoma and Ocular Hypertension to control intraocular pressure and/or glaucoma progression.
89454797|NCT03803111|Experimental|Initial FCM|Intravenous iron supplementation with FCM, subsequent (after 2 months) exercise training program
89454798|NCT03803111|Experimental|Initial exercise|Exercise training program, subsequent (after 2 months) intravenous iron supplementation with FCM
89454799|NCT03190616|Experimental|drug,apatinib|apatinib 500mg/qd, 28d/cycle
89454800|NCT03702231|Experimental|Chronic Lymphocytic Leukemia Patients That Are Treatment Naive|Chronic Lymphocytic Leukemia Patients That Are Treatment Naive will be followed for 6 months and receive assessment of serologic response 6- months following the first SHINGRIX vaccine dose.
89454801|NCT03702231|Experimental|Chronic Lymphocytic Leukemia Patients Receiving Treatment With Ibrutinib|Chronic Lymphocytic Leukemia Patients Receiving Treatment With Ibrutinib will be followed for 6 months and receive assessment of serologic response 6- months following the first SHINGRIX vaccine dose.
89454802|NCT03702231|Experimental|Chronic Lymphocytic Leukemia Patients Receiving Treatment With Acalabrutinib|Chronic Lymphocytic Leukemia Patients Receiving Treatment With Acalabrutinib will be followed for 6 months and receive assessment of serologic response 6- months following the first SHINGRIX vaccine dose.
89454803|NCT04484090|Experimental|Vertica|Treatment with Vertica RF device for improving erectile function for men with erectile dysfunction
89454804|NCT02443922|Experimental|Glimepiride|Glimepiride 2mg qam
89454805|NCT02443922|Experimental|Sitagliptin|Sitagliptin 100mg qam
89454806|NCT02443922|Active Comparator|Metformin|Metformin as prescribed
89454807|NCT04799847|Experimental|Catumaxomab|In the dose escalation phase, 2 dose levels of catumaxomab will be explored.
89454808|NCT02434562||Medical castration|Patients treated with androgen deprivation therapy (e.g. for hypersexuality, transgender subjects, ...)
89454809|NCT02434562||Male hypogonadism|Patients treated with testosterone replacement therapy (e.g. for late-onset hypogonadism, secondary hypogonadism)
89454810|NCT02434562||Thyroid disorders|Patients treated for hyperthyroidism or hypothyroidism (incl. during treatment for thyroid cancer)
89454811|NCT02434562||Obesity and weight loss|Patients treated for obesity with weight loss interventions (mainly bariatric surgery)
89454812|NCT02434562||Miscellaneous|Various disorders associated with alterations in SHBG, androgens and/or estrogens
89454813|NCT02439866|Placebo Comparator|prescription placebo|control Group consisted of 30 patients who received gelatinous capsules filled with sugar as placebo
89454814|NCT02439866|Active Comparator|prescription Intravenous methylprednisolone|Group 2 or steroid consisted of 30 patients received methylprednisolone (Solu-Medrol, Pharmacia Pharmaceutical Company, Belgium) 500 mg twice a day for 3 days followed by 2 weeks of oral prednisolone 1mg/kg/day
89454815|NCT02439866|Active Comparator|prescription normobaric oxygen with face mask|Thirty patients in group 3 or oxygen received 100% normobaric oxygen with face mask in sitting position, at a flow rate of 5 liters per minute for 1 hour twice a day for two weeks
89454816|NCT02439788|Experimental|GINAKIT Cells plus chemotherapy|Patients receive chemotherapy with Fludarabine and Cyclophosphamide and then an infusion of the GINAKIT cells (iC9-GD2.CD28.OX40.zeta Natural Killer T cells)
89454817|NCT02434796|Experimental|Arm 1 Male Peer Groups (MPG)|Women participate in savings groups and male partners participate in male peer group workshops on gender norms, IPV and HIV prevention. This intervention aims to improve knowledge and attitudes about the harms of IPV on women, men and children; the confidence to internalize positive masculine ideals (e.g. caring for one's family) and to challenge gender stereotypes (e.g. women are not equal to men); and the ability to formulate positive outcome expectations regarding IPV (intolerance of violence perpetrated by themselves or others) and healthy relationships with their spouses and communities.
89454818|NCT02434796|Experimental|Arm 2 MPG & Community Dialogues|This arm will include women participants in savings groups, male peer groups and community dialogues. Village community leaders will engage in community dialogues on gender norms, IPV and HIV prevention.
89454819|NCT04483388|Other|Group AB|After randomization, 6 children composed the AB sequence were initially submitted to experimental training with virtual reality and after a week, a period considered washout, the conventional training.
89454820|NCT04483388|Other|Group BA|After randomization 6 children composed the BA sequence were initially submitted to conventional training and after a week, a period considered washout, the experimental training with virtual reality.
89454821|NCT02443532|Experimental|Structured Group education|Six weekly interactive group sessions of 4 hours each, providing information and developing skills for diabetes self-management, including eating habits, food composition, calculation of bolus insulin, information on physical exercise, blood glucose self-monitoring, management of hypoglycemia.
89454822|NCT02443532|Other|Individual education|Usual care (individual consultations as routinely performed)
89454823|NCT02443454||Patients after kidney transplantation|Short and Long-term results containing first 10 years after KTx.
89454824|NCT02443454||Healthy subjects|Medical staff: medical doctors, nurses
88939549|NCT01840553|Experimental|oral sodium phosphate tablets|oral Sodium Phosphate tablets administered as 32 tablets (20+12) with 2 Liters of liquid
89454825|NCT03188198|Active Comparator|Arm A - R-CHOP|"Patients receive the following treatment:Rituximab 375 mg/m2 IV infusion on Day 1 prior to CHOP chemotherapy.Cyclophosphamide 750 mg/m^2 IV on Day 1.Doxorubicin 50 mg/m^2 IV on Day 1.Vincristine 1.4 mg/m^2 IV (2 mg cap) on Day 1.Prednisone 40 mg/m^2/day PO on Days 1-5.filgrastim or pegfilgrastim as defined in the protocol Required ancillary medications is administered during all cycles as defined in the protocol. Cycles will be repeated every 21 days for 6 treatment cycles. Restaging will occur after Cycles 4 and 6.~Interventions:-Biological: rituximab-Drug: cyclophosphamide-Drug: doxorubicin-Drug: vincristine-Drug: prednisone-Drug: filgrastim-Drug: pegfilgrastim"
89454826|NCT03188198|Experimental|Arm B - DA-EPOCH-R|"Patients receive the following treatment: Cycle 1 Doses:Rituximab 375 mg/m^2 IV infusion on Day 1 prior to EPOCH chemotherapy. Doxorubicin 10 mg/m^2/day CIVI on Days 1-4.Etoposide 50 mg/m^2/day CIVI on Days 1-4. Vincristine 0.4 mg/m^2/day (no cap) CIVI on Days 1-4 (total 1.6 mg/m2 over 96 hours). Cyclophosphamide 750 mg/m^2 IV on Day 5 (following completion of 96 hour infusions). Prednisone 60 mg/m^2 PO BID on Days 1-5 Administer filgrastim 480 mcg subcutaneous daily from Day 6 until ANC > 5000 after the nadir (nadir usually between Days 10-12) Doses for subsequent cycles will be determined by the absolute neutrophil (ANC) or platelet nadir from the previous cycle. Cycles will be repeated every 21 days for a maximum of 6 cycles. Restaging will occur after Cycles 4 and 6.~Interventions:~-Biological: rituximab-Drug: cyclophosphamide-Drug: doxorubicin-Drug: vincristine-Drug: prednisone-Drug: etoposide-Drug: filgrastim"
89454827|NCT03188276|Active Comparator|CHC patients|32 treatment-naive CHC patients treated by Ledipasvir-Sofosbuvir or Daclatasvir-Sofosbuvir.
89454828|NCT03188276|No Intervention|Healthy controls|20 Healthy controls without any treatment
89454829|NCT03187964|No Intervention|PLHIV Centralised Xpert Ultra|Patient sputum specimen collected at Kraaifontein Community Health Centre (KCHC) and sent for centralised Xpert Ultra TB testing at the National Health Laboratory Services (NHLS) facility in Greenpoint, Cape Town, South Africa. Centralised testing uses the established NHLS transportation, testing and report-back to clinic infrastructure according to the national algorithm.
89454830|NCT03187964|Active Comparator|PLHIV Point of Care Xpert Ultra|Patient sputum specimen collected at KCHC and Xpert Ultra TB testing done on site at point of care (POC).
89454831|NCT03187964|No Intervention|PLHIV Centralised Xpert VL|Patient blood specimen collected at Kraaifontein Community Health Centre (KCHC) and sent for centralised viral load testing at the NHLS facility in Tygerberg Hospital, Cape Town, South Africa. Centralised testing uses the established NHLS transportation, testing and report-back to clinic infrastructure according to the national algorithm.
89454832|NCT03187964|Active Comparator|PLHIV Point of Care Xpert VL|Patient blood specimen collected at KCHC and Xpert HIV-1 viral load testing done on site at point of care (POC).
88939550|NCT01840618||Obese PCOS and sleep apnea|"BMI >95%ile AND Polysomnography with AHI >2.5~Will initiate Nasal Continuous positive airway pressure (CPAP)"
88939551|NCT01840618||Obese PCOS without sleep apnea|BMI >95%ile AND Polysomnography with AHI <2.5
88939552|NCT01840618||Normal weight Controls|BMI <85%ile AND regular menses
88939553|NCT01840618||Lean PCOS and sleep apnea|"BMI <85%ile AND Polysomnography with AHI >2.5~Will initiate Nasal Continuous positive airway pressure (CPAP)"
88939554|NCT01840618||Lean PCOS without sleep apnea|BMI <85%ile AND Polysomnography with AHI <2.5
88939555|NCT01840631|Active Comparator|Group nutritional counseling|In this arm, the Nutritionist will conduct the nutritional counseling with numerous patient families as a group
88939556|NCT01840631|Active Comparator|Individual nutritional counseling|In this arm the nutritionist conducts the nutritional counseling with one patient family at a time
88939557|NCT01840644||all participants|Walking on treadmill, different velocities and incline
89015944|NCT05835999|Experimental|Daily Everolimus (0.5 mg/day) and Weekly Placebo|Once daily (0.5 mg) everolimus and once weekly placebo taken orally for 24 weeks
88939558|NCT01840683|Experimental|H.E.L.P. therapy (H.E.L.P. Plasmat Futura System)|A total of 8 apheresis therapies with the H.E.L.P. Plasmat Futura System will be performed over a period of 12 weeks.
89454833|NCT02443376||Hemodialysis patients|Stable end-stage renal disease patients on maintenance conventional hemodialysis received 4-5 hours of treatment thrice weekly. Pulse wave velocity and central aortic pressure was measured before and after the midweek dialysis session.Overhydration Urea distribution volume (V) Total body water, extracellular and intracellular water Lean Tissue Index (LTI) Fat Tissue Index (FTI) Body Cell Mass (BCM) was measured before the midweek dialysis session just after Complior device
89454834|NCT02443376||Healthy subjects|Medical staff: medical doctors, nurses
89454835|NCT03190304|Active Comparator|Enalapril|Enalapril at a dose of 10 mg twice daily for 6 months
89454836|NCT03190304|Experimental|Neprilysin (LCZ696)|LCZ696 at a dose of 200 mg twice daily for 6 months
89454837|NCT03190148|Other|Pregnant women with RYGB-operation|Pregnant women with a history of RYGB-Operation were investigated.
89454838|NCT03190148|Other|Normal weight pregnant women|Normal weight pregnant women were investigated.
89454839|NCT03190148|Other|Obese Pregnant women|Obese pregnant women were investigated.
89454840|NCT03189992|Experimental|CC-GSYXZ|Colon cancer with Chinese medicine syndrome Yin deficiency of liver and kidney and spleen deficiency.Intervented by Bushen-Jianpi Dedoction and cinobufotalin injection
89454841|NCT03189992|Placebo Comparator|CC-WZ|Colon cancer with none Chinese medicine syndrome.Intervented by cinobufotalin injection
89454842|NCT03189992|Experimental|HCC-GSYXZ|Hepatoma cancer with Chinese medicine syndrome Yin deficiency of liver and kidney and spleen deficiency.Intervented by Bushen-Jianpi Dedoction and cinobufotalin injection.
89454843|NCT03189992|Placebo Comparator|HCC-WZ|Hepatoma cancer with none Chinese medicine syndrome.Intervented by cinobufotalin injection
89454844|NCT02439632|Experimental|prulifloxacin|"Prulifloxacin film-coated tablet : 600 mg/tablet, oral administration of a single tablet.~Placebo of levofloxacin hydrochloride tablet without active components."
88939559|NCT01840696|Experimental|Regadenoson|
88939560|NCT01840709|Experimental|Psychotherapy treatment|The experimental group will be treated with Psychoanalytic brief group psychotherapy once a week for 20 consecutive weeks.
88939561|NCT01840709|No Intervention|control group|the patients in this group will be just assessed with the same questionnaires at baseline and after 20 weeks, without psychotherapy.
88939562|NCT01840735|Active Comparator|GS-5737|The GS-5737 85 μg dose is contained in 4 mL of 10 mM citrate buffer, pH 5.0 in 2.8% (w/v) saline.
88939563|NCT01840735|Placebo Comparator|Placebo|The vehicle (placebo) control contains 10 mM citrate buffer, pH 5.0 in 2.8% (w/v) saline in 4 mL.
88939564|NCT01840748||no vasodilator|patients receiving no vasodilator
88939565|NCT01840748||CCB|patients receiving a calcium channel blocker (CCB) for digital vasculopathy
88939566|NCT01840748||i.v. prostanoids or PDE5i or ETRAs|patients treated with i.v. prostanoids or phosphodiesterase-5 inhibitors (PDE5i) or endothelin receptor antagonists (ETRA), regardless of whether a calcium channel blocker is given in addition
88939567|NCT01840761|Experimental|herbal drug|Traditional Chinese herbal drug
88939568|NCT01840761|Placebo Comparator|Placebo|
89454845|NCT02439632|Active Comparator|Levofloxacin|"Levofloxacin hydrochloride tablet 250 mg/tablet, oral administration of a tablet daily for a total of 3 days.~Placebo of prulifloxacin film-coated tablet, without active components."
89454846|NCT02434172||Screening|There are no arms to the study. All participants will undergo screening. Preemptive treatment will only be provided to those who are CrAg positive.
89454847|NCT02439476||Relapsed multiple myeloma patients who are considered eligible|Patients mobilized using G-CSF+Plerixafor according to Plerixafor label in France will be included. Apheresis will be performed according to standard practice and local guidelines. Once the autologous stem cell product becomes available, patients will undergo ASCT conditioned by high dose Melphalan according to standard practice in each centre
88939569|NCT01840774|Active Comparator|Low-dose pain medication|80min IV infusion of a low-dose pain medication
88939570|NCT01840774|Placebo Comparator|saline placebo|80min IV infusion of a saline placebo
88939571|NCT01840787|Experimental|Contralateral lens comfort comparisons|Subjects will be randomized into receiving balafilcon A (8.3), or balafilcon A (8.6), or senofilcon A in one eye, and balafilcon A (8.3), or balafilcon A (8.6), or senofilcon A in the other eye.
88939572|NCT01840800|Active Comparator|Active FEM+ONP|Nerveblock of n. femoralis (FEM) with 10 ml Ropivacaine 7.5 mg/ml and nerveblock of obturator nerveposterior branch (ONP) with 10 ml Ropivacaine 7.5 mg/ml.
89454848|NCT02434874|Experimental|Immediate Activation|Subjects randomized to this group will have the StimGuard Sacral Nerve Stimulator System activated immediately.
89454849|NCT02434874|Other|Delayed Activation|Subjects randomized to this group will have the StimGuard Sacral Nerve Stimulator System activated after 90 days.
89454850|NCT02434094||T1DM Clinicians|Clinicals currently teaching T1DM patients how to use insulin pumps and continuous glucose monitors will be asked to complete the eDAPT on-line training program.
89454851|NCT02434094||T1DM Subjects with DiAs experience|T1DM subjects will prior DiAs experience will be asked to complete the eDAPT on-line training program.
89454852|NCT02434094||T1DM Subjects with no prior DiAs experience|T1DM subjects will no prior DiAs experience will be asked to complete the eDAPT on-line training program.
89454853|NCT03133611|Other|Parkinson's disease|Speech assessment. Routine clinical assessment.
89454854|NCT03133611|Other|REM sleep behaviour disorder|Speech assessment. Routine clinical assessment.
89454855|NCT03133611|Other|Healthy controls|Speech assessment. Routine clinical assessment.
89454856|NCT02439398|Experimental|Allogeneic human cardiac stem cells|After randomization, subjects will received a suspension of allogeneic human cardiac stem cells (35 millions of CSCs - cell medicine) infused into the coronary artery responsible for the ischemic event.
89454857|NCT02439398|Placebo Comparator|Placebo: Human Serum Albumin-HSA 5%|After randomization, subjects will received placebo (which is also the cell medicine diluent). The placebo consists of a final administered volume of human serum albumin 5% in saline solution equivalent to the reconstituted cell medicine (18 mL). The placebo to be used is a marketed product (HSA 5%).
89454858|NCT02442986||Septic Shock or severe sepsis|Septic patients on ICU with severe sepsis or septic shock.
88939573|NCT01840800|Active Comparator|Active SAPH+ONP|Nerveblock of n.saphenous (SAPH) with 5 ml Ropivacaine 7.5 mg/ml and nerveblock of obturator nerve, posterior branch (ONP) with 10 ml Ropivacaine 7.5 mg/ml
88939574|NCT01840800|Placebo Comparator|Placebo|Saline 9 mg/ml
88939575|NCT01840813|Active Comparator|Misoprostol|4 misoprostol tablets (Misotac® 200 micrograms tablet) dissolved in 20 ml of normal saline injected to umbilical vein
88939576|NCT01840813|Placebo Comparator|Normal saline|Normal saline 0.9%, 20 ml was injected in the umbilical vein in cases of retained placenta
88939577|NCT01840826|Experimental|RED-D Care Management|Patients randomized to receive the Intervention work with a RED-D Care Manager post-discharge. The Care Manager meets with the patient in the hospital, prior to discharge, and post-discharge via weekly phone calls. Patients have access to a range of treatment options, overseen by the Care Manager, including: (1) medication; (2) cognitive behavioral therapy (CBT); (3) complementary and alternative medicine (CAM) information and referral; (4) Self-help, such as reading a book, making a change in diet and/or exercise in order to improve mood; (5) active surveillance; and (6) any combination of 1, 2, 3, 4 & 5.
88939578|NCT01840826|No Intervention|RED and Behavioral Health Referral|"Patients randomized to the control group will receive the regular RED intervention, including a follow-up phone call two days post-discharge from the hospital to review and confirm medications, and a referral to behavioral health."
88939579|NCT01840839|Experimental|0,75 Hz stimulation|transcranial slow oscilliating stimulation (tSOS)during periods of SWS
89454859|NCT02442986||Non-Septic, Surgical Patients|Non-septic patients after surgical treatment and anesthesia on ICU.
89454860|NCT02442986||Non-Septic, Non-Surgical Patients|Patients without sepsis criteria treated on ICU, non-surgical patients.
89454861|NCT03187808|Experimental|Group A|Group A is a group of performing single thoracic manipulation at zygapophyseal joint of T6-T7.
89454862|NCT03187808|Experimental|Group B|Group B is a group of performing single thoracic manipulation combined with special massage technique (RT technique).
89454863|NCT02443064|Experimental|MRSA blood stream infection patient|"Intervention:Vancomycin~Dosing:~15-20mg/kg, IV,q 12~8h (or 1 g, IV, q12~8h) for adult patient with normal renal function; Dosage should be adjusted by blood creatinine clearance in patients with impaired renal function; Administration route： 1~2 h/ dosing, IV~Drug combination:~Drug combination is not recommended for patients with simple MRSA infection; Rifampicin can be combined in case of MRSA artificial valve endocarditis; Anti-G- antibacterial agents can be combined in case of concurrent G- bacterial infections.~Duration:~Septicemia: 2~4 weeks Endocarditis: 6~8 weeks"
89454864|NCT02433938|Experimental|Underwent tibial nerve stimulation|Patients that underwent standard postoperative protocol + tibial nerve stimulation for 3 days
89454865|NCT02433938|Sham Comparator|Did not undergo tibial nerve stimulation|Patients that underwent standard postoperative protocol + sham tibial nerve stimulation (standard postoperative protocol+sham tns)
89454866|NCT02741271|Experimental|MF/F MDI 100/10 mcg BID|Eligible participants will be assigned randomly to receive double-blinded MF/F MDI 100/10 mcg BID for 24 weeks.
89454867|NCT02741271|Active Comparator|MF MDI 100 mcg BID|Eligible participants will be assigned randomly to receive double-blinded MF MDI 100 mcg BID for 24 weeks.
89454868|NCT02443142|Experimental|Ibuprofen|Ibuprofen is a nonselective NSAID that inhibits both COX-1 and COX-2 isoenzymes. COX-2 inhibition prevents arachidonic acid from converting to vasoactive prostaglandins and reactive oxygen species in brain cell. The analgesic, antipyretic, and antiinflammatory activity of ibuprofen operates mainly through inhibition of COX-2. The experimental treatment oral doses of either ibuprofen (800 mg three times per day). Subjects will receive the first medication dose in the emergency department and will be given the remaining 5 doses to take over 48 hours as outpatients.
89454869|NCT02443142|Active Comparator|Acetaminophen|Acetaminophen is a poor inhibitor of both COX isoenzymes in the CNS and has significantly weaker antiinflammatory effects than NSAIDs. Acetaminophen does not inhibit COX in peripheral tissues and is less effective in the presence of peroxides. The active comparator treatment is oral doses of acetaminophen (1000 mg three times per day). Subjects will receive the first medication dose in the emergency department and will be given the remaining 5 doses to take over 48 hours as outpatients.
89454870|NCT02442908|Experimental|NF Cachexia|Nutrifriend Cachexia, an Omega-3 enriched fruit juice (non complete dietary formula).
89454871|NCT02442908|Placebo Comparator|Placebo|An isocaloric placebo comparator
89454872|NCT02439008|Experimental|Blood samples collection|"Nine blood samples will be collected in each patient before, during and after radiotherapy treatment.~Interventions :~Blood samples collection before radiotherapy (T0)~Blood samples collection during radiotherapy (T1-T3)~Blood samples collection after radiotherapy (T4-T8)"
89454873|NCT03524079||BrS Group|Ajmaline 17-(Chloroacetate) Monohydrochloride
89454874|NCT03524079||No BrS group|Ajmaline 17-(Chloroacetate) Monohydrochloride
89454875|NCT03528525||Monogenic diseases cases|
89454876|NCT02439086|Experimental|Long Course Radiotherapy|all patients diagnosed with rectal cancer, amenable for neoadjuvant chemoradiotherapy, who agree to participate in this study will undergo 2 PET-CT scans: at baseline and 9 weeks after commencing therapy.
88939580|NCT01840839|Sham Comparator|no stimulation|Sham stimulation during periods of SWS
88939581|NCT01840852||acute uncomplicated diverticulitis|CT-verified acute uncomplicated diverticulitis managed by antibiotics
88939582|NCT01840865|Experimental|SHAM stimulation|SHAM stimulation during periods of Slow Wave Sleep
88939583|NCT01840865|Experimental|0,75 Hz stimulation|slow transcranial oscillating stimulation (~0,75Hz) during periods of Slow Wave Sleep
88939584|NCT01840878||Acute Diverticulitis|CT-verified acute uncomplicated diverticulitis managed by antibiotics
88939585|NCT01840891|Experimental|Noro virus shedder|Lactose H2 breath test (LH2BT)
88939586|NCT01840891|Active Comparator|No norovirus shedding|Lactose H2 breath test (LH2BT)
88939587|NCT01840904||acute uncomplicated diverticulitis|CT-verified acute uncomplicated diverticulitis managed by antibiotics
88939588|NCT01840917||acute uncomplicated diverticulitis|CT-verified acute uncomplicated diverticulitis managed by antibiotics
89454877|NCT02438774|Active Comparator|Routine agriculture extension services|Routine agriculture extension services alone
89454878|NCT02438774|Experimental|Post-harvest intervention package|Post-harvest intervention package and routine agriculture extension services
89454879|NCT02438930|Experimental|Motivational interviewing counseling|"The brief intervention is adapted from the OPTIONS project, which is a brief client-centered risk reduction intervention for HIV-positive patients in clinical care. The OPTIONS intervention content is based upon the IMB model of health behavior change, and uses motivational interviewing techniques to create client-centered discussions in which HIV counselors and patients collaborate to identify patients' HIV transmission risk behaviors and to mutually identify strategies and goals for reducing the patient's risky behavior.~The brief intervention will be facilitated by health care providers (nurses, lab technicians) specifically trained in the intervention protocol and will consist of 2 brief counseling sessions occurring during the same-day rapid HIV-testing procedure"
89454880|NCT02438930|Active Comparator|Standard of care counseling|Participants in this study condition will receive standard-of-care counseling that is usually implemented during HIV testing.
88939589|NCT01840969||CAOD group|Single arm study group
88939590|NCT01840982|Experimental|Giant embryonic brown rice|
88939591|NCT01840982|Experimental|Giant embryonic rice|
88939592|NCT01840982|Active Comparator|White rice|
88939593|NCT01840982|Active Comparator|Glucose solution|
88939594|NCT01840995||stellate ganglion block|Patients receiving stellate ganglion block at our pain management clinic
88939595|NCT01841008|Experimental|Tacrolimus ointment 0.1%|
88939596|NCT01841008|Placebo Comparator|Group Placebo|
88939597|NCT01841086|Active Comparator|Anplag|Sarpogrelate HCl 300mg once a day or 100mg three times a day
88939598|NCT01841086|Experimental|UI03SPG300CT|Sarpogrelate HCl 300mg once a day or 100mg three times a day
88939599|NCT01841099|Experimental|Mesalamine|Mesalamine. Mesalamine granules. 30 mg/kg/day oral for 7 days followed by 50 mg/kg/day oral for 21 days if tolerated.
88939600|NCT01841099|Placebo Comparator|Placebo granules|Placebo granules
88939601|NCT01841112|Placebo Comparator|Placebo (Multiple dose part)|Placebo tablet
88939602|NCT01841112|Experimental|Dose 2, EM, single dose|Extensive Metaboliser (EM), single dose part, medium dose
89454881|NCT03526263|Experimental|Gastric mucosal devitalization arm|"Patients will be enrolled into the study after being scheduled to undergo vertical sleeve gastrectomy as part of routine clinical care at Johns Hopkins Bayview. The cost of the surgery will be covered by the patient's insurance and there will no extra procedural element that would add time to surgery.~The intervention will occur on the excised specimen ex vivo (outside the body) and will involve devitalization of the gastric mucosa using Argon Plasma Coagulation."
89454882|NCT02438852|Experimental|Arm I (ropivacaine hydrochloride)|Patients receive ropivacaine hydrochloride IV continuously over 72 hours after radical cystectomy.
89015945|NCT05835999|Experimental|Daily Placebo and Weekly Everolimus (5mg/week)|Once daily placebo and once weekly (5 mg) everolimus taken orally for 24 weeks
89454883|NCT02438852|Placebo Comparator|Arm II (placebo)|Patients receive normal saline (placebo) IV continuously over 72 hours after radical cystectomy.
89454884|NCT03523845||Test group|Test group (patients diagnosed with early apical peri-implantitis diagnosed)
89015946|NCT05835999|Placebo Comparator|Daily Placebo and Weekly Placebo|Once daily placebo and once weekly placebo taken orally for 24 weeks
89454885|NCT03523845||Control group|Control group (patients whose implants had not developed any inflammatory/infectious process and were osseointegrated)
89015947|NCT05835999|No Intervention|Young Adult Reference Group|Baseline testing only
89015948|NCT05832424|Experimental|UPLIFT Telehealth Intervention|The telehealth group intervention will be delivered using Zoom. Participants will attend facilitated weekly, 1-hour sessions for 8 weeks. The sessions follow a standardized, manualized program based on cognitive-behavioral therapy (CBT) and mindfulness-based practice (MBP)-therapies widely accepted and used by mental health providers for the treatment and prevention of depression and substance use. The study team have tailored this intervention for use in a pregnant population.
89015949|NCT05826392|Experimental|Adolescent/Young Adult Self-Administered Web-Based Single-Session Intervention|Project Personality is a 30- minute, self-administered, web-based single-session intervention that was developed to help adolescents understand what growth mindsets are and provide them with information about self-changing strategies and coping skills (Schleider & Weisz, 2019). Participants learn about how the brain functions (neuroplasticity), how personality is fluid, and read testimonials from other adolescents about how growth mindsets helped them in school and in their personal lives. Participants also have the opportunity to write notes to other youth, providing them with the advantages of using growth mindsets.
89015950|NCT05825560|Active Comparator|Control group|"Analgesia combines paracetamol (1g every 6 to 8 hours according to age and weight recommendations) and remifentanil, adapted according to a tiered administration system depending on the Behavior Pain Scale (BPS) and the theoretical ideal weight. Remifentanil doses are adjusted so that the patient has a BPS score of 4 or less. Reassessment of analgesia will be carried out every 30 minutes until analgesic adaptation is complete, then every 2 hours as is usually done in our department.~If the BPS is less than or equal to 4, the therapeutic de-escalation will be done with a reverse algorithm until the analgesic drugs are stopped.~After the sedation balance phase, the patient's BPS will be assessed every 2 hours."
89201238|NCT00771576||B. Longstanding T1D|subjects with predicted reduced beta cell mass (subjects with established T1DM who have low or not measurable stimulated insulin and c peptide levels);
89454886|NCT02438618|Experimental|Minimally invasive punch technique|New surgical technique for Ponto bone anchored hearing implants
89454887|NCT02438618|Other|Hultcrantz technique|Standard surgical technique for bone anchored hearing implants
89454888|NCT02438696|Experimental|3 BI 1060469 low dose|TF2 followed by iFF followed by TF1
89454889|NCT02438696|Experimental|1 BI 1060469 high dose|TF1 followed by TF2 followed by iFF
89454890|NCT02438696|Experimental|2 BI 1060469 high dose|iFF followed by TF1 followed by TF2
89454891|NCT02438696|Experimental|3 BI 1060469 high dose|TF2 followed by iFF followed by TF1
89454892|NCT02438696|Experimental|1 BI 1060469 low dose|TF1 followed by TF2 followed by iFF
89454893|NCT02438696|Experimental|2 BI 1060469 low dose|iFF followed by TF1 followed by TF2
89454894|NCT03523767|Experimental|Typhoid Vaccine, then Normal Saline|0.5 ml of S.typhi injection, then 0.5 ml of normal saline injection
89454895|NCT03523767|Placebo Comparator|Normal Saline, then Typhoid Vaccine|0.5 ml of normal saline injection, then 0.5 ml of S.typhi injection
89454896|NCT02442596||One Group|This is a prospective observational study, aimed at collecting an adequate dataset on a large cohort of patients admitted to a large number of ICUs.
89454897|NCT05509803|Experimental|PE Audit and Feedback Intervention|Schools in this arm will receive a PE audit and feedback tool delivered by the school district's teacher on special assignment for PE, which will consist of an audit of the school's existing PE program; Feedback on ways to improve the PE program; and technical assistance to help improve the PE program.
89454898|NCT05509803|No Intervention|PE Support as Usual|Schools in this arm will receive district-level support for PE as is typically provided by the school district.
89454899|NCT02442674|Active Comparator|Tolvaptan|Tolvaptan (3.75 mg, 7.5 mg, 15 mg, 30 mg, 60 mg dose daily depending on age and weight)
89454900|NCT02442674|Placebo Comparator|Placebo|Placebo tablet matching active drug
89454901|NCT02442752|Experimental|Regimen A: Dexlansoprazole 10 mg|Dexlansoprazole 10 mg, delayed-release capsules, orally, once daily for 8 weeks.
89454902|NCT02442752|Experimental|Regimen B: Dexlansoprazole 15 mg|Dexlansoprazole 15 mg, delayed-release capsules, orally, once daily for 8 weeks.
89454903|NCT02442752|Experimental|Regimen C: Dexlansoprazole 20 mg|Dexlansoprazole 20 mg, delayed-release capsules, orally, once daily for 8 weeks.
89454904|NCT02442752|Experimental|Regimen D: Dexlansoprazole 30 mg|Dexlansoprazole 30 mg, delayed-release capsules, orally, once daily for 8 weeks.
89454905|NCT03523689||Observational (bronchoscopy, RP-EBUS)|Patients undergo bronchoscopy per standard of care, RP-EBUS of the left and right lungs during bronchoscopy procedure, and RP-imaging over 3-5 minutes at the end of the bronchoscopy procedure.
89454906|NCT02442518||women with placenta praevia|women with placenta previa diagnosed at antenatal ultrasound in the third trimester of pregnancy (lower placental edge within 20 mm from the internal os above 26 week's gestation)
89454907|NCT03523611||lung resection|Patients with suspected lung cancer undergoing lung resection by anatomic lobectomy
89454908|NCT02442362|Active Comparator|TOF Group|"Patients in the TOF group received chemotherapy with paclitaxel+oxaliplatin+fluorouracil"
89454909|NCT02442362|Experimental|SOX Group|The patients in the SOX group received chemotherapy with 'oxaliplatin+S1'
89454910|NCT04440488|Experimental|ARALAST NP 120 mg/kg|Participants will receive 120 mg/kg BW of ARALAST NP intravenous (IV) infusion once in a week for a total of 104 weeks which will be compared with an external placebo arm.
89454911|NCT04440488|Experimental|ARALAST NP 60 mg/kg|Participants will receive 60 mg/kg BW of ARALAST NP IV infusion once in a week for a total of 104 weeks which will be compared with an external placebo arm.
89454912|NCT03187574||Group A|group received Elevate Ant™ single-incision mesh
89454913|NCT03187574||Group B|group received Perigee™ transvaginal mesh
88939603|NCT01841112|Experimental|Dose 3, EM, single dose|Extensive Metaboliser (EM), single dose part, high dose
88939604|NCT01841112|Experimental|Dose 3, PM, single dose|Poor Metaboliser (PM), single dose part, high dose
88939605|NCT01841112|Experimental|Dose 3, PM, multiple dose|Poor Metaboliser (PM), multiple dose part, high dose
88939606|NCT01841112|Placebo Comparator|Placebo (Single dose part)|Placebo tablet
88939607|NCT01841112|Experimental|Dose 1, EM, single dose|Extensive Metaboliser (EM), single dose part, low dose
88939608|NCT01841125|Experimental|escitalopram|escitalopram 15mg
88939609|NCT01841125|Placebo Comparator|Placebo|placebo 15mg
88939610|NCT01841151|Active Comparator|SCP training|Neurofeedback 1 (NF1) Slow Cortical Potential (SCP) training
88939611|NCT01841151|Active Comparator|Live Z-score training|Neurofeedback 2 (NF2) Live Z-score training
88939612|NCT01841151|Active Comparator|WM training|Working Memory training (WMt)
88939613|NCT01841151|No Intervention|Waiting-list|Treatment as usual only
88939614|NCT01841164|Experimental|Montelukast|5 to 7 days of treatment with montelukast 10 mg 2 tablets bid. Efficacy of treatment is evaluated on airway responsiveness to inhaled leukotriene E4.
88939615|NCT01841164|Placebo Comparator|Sugar pill|Placebo for montelukast 5-7 days 2 tablets bid. Efficacy of treatment is evaluated on airway responsiveness to inhaled leukotriene E4.
88939616|NCT01841190||PROCALCITONIN|
88939617|NCT01841190||DELTA SOFA|
88939618|NCT01841203||DPP/RPR-TPHA comparison|The evaluation of T1 (treponemal line) will be conducted by using the T1 positivity identified by naked eye or automated reader to compare with that of TPHA; while the evaluation of T2 (non-treponemal line) will be conducted by using the T2 positivity identified by naked eye, or automatic reader at cut-off value of 20, to compare with the result of RPR.
88939619|NCT01841242|Active Comparator|alcoholic povidone iodine|Betadine Alcoolique 5% One cutaneous application before implant procedure
89454914|NCT04468581||Community sample|We plan to recruit a representative sample of the Singapore population.
89454915|NCT02433860|Experimental|pregnant nicotine users|watch video and tobacco cessation counselling using SCRIPT protocol
89454916|NCT04468503|Active Comparator|1 g per kg body weight per day|"Protein will be receive by patients that is 1g per kg per day, Patients will be assess and according to patient actual dry weight 1 g per kg of that weight protein will provided, energy will be provided according to ASPEN guideline 2016.~Base line characters(BMI, nitrogen Balance, Protein biomarker, LFTs, RFTs, GCS)"
89454917|NCT04468503|Active Comparator|2 g per kg body weight per day|"Protein will be receive by patients that is 2g per kg per day, Patients will be assess and according to patient actual dry weight 1 g per kg of that weight protein will provided, energy will be provided according to ASPEN guideline 2016.~Base line characters(BMI, nitrogen Balance, Protein bio marker, LFTs. , RFTs, GCS)"
89454918|NCT03523455|Placebo Comparator|Sugar Pill|Maltodextrin (matches the weight of the active treatment) Taken once each day after breakfast, but before lunch.
89454919|NCT03523455|Active Comparator|Iron Aid IPS (Iron Protein Succinylate)|IronAid Iron Protein Succinylate 30 mg Taken once each day after breakfast, but before lunch.
88939620|NCT01841242|Experimental|alcoholic chlorhexidine|ChloraPrep 2% One cutaneous application before implant procedure
88939621|NCT01841255|Sham Comparator|Tidal breathing using the facemask|Control
89454920|NCT03189836|Experimental|ACTR707 in combination with rituximab|
89454921|NCT03523299|Experimental|Cryoablation|Participants in this arm will receive cryoablation of their breast tumor two weeks before their routine lumpectomy. They will undergo two blood draws: one before cryoablation (at the time of consent) and one after cryoablation (at the time of surgery).
89454922|NCT03523299|No Intervention|Control|Participants in this arm will undergo a blood draw at the time of consent and then will continue with their scheduled lumpectomy (standard of care).
89454923|NCT03190226|Experimental|L-PRF membranes|"Intra-oral split thickness preparation - apically repositioned to the periosteum.~L-PRF membranes will be used to cover the site. Free Gingival Grafts will be used to cover the site."
89454924|NCT05490927|Experimental|Smoking Deprivation|16 hours of smoking abstinence prior to experimental visit.
89454925|NCT05490927|Experimental|Smoking as Usual|Smoking as usual prior to experimental visit.
89015951|NCT05825560|Experimental|OFA Group|"A fixed combination of nefopam and tramadol will be initiated at daily doses. An initial dose of 50mg tramadol and 20mg nefopam IV over 30 min. will be administered. Reassessment of analgesia will be performed every 30 min. for two hour and then every 2 hours.~If BPS is > 4, administration of ketamine with an initial bolus of 0.15mg/kg followed by continuous administration at a dose of 0.15mg/kg/hour.~If the BPS is < 4, remifentanil is introduced at the minimum effective dose, in a stepwise fashion according to the theoretical ideal weight~In the event of maximum pain requiring the full range of therapies in the algorithm the total dose of tramadol will be 450mg/day and nefopam 120mg/day, in accordance with summaries of product characteristics.~If the BPS < or = 4, the therapeutic de-escalation will be done with a reverse algorithm until the analgesic drugs are stopped, according to the following scheme: remifentanil, ketamine, tramadol and then nefopam."
89454926|NCT03525717|Active Comparator|Routine Dinner|"Participants will be served dinner and a stable isotope of palmitate to measure fat oxidation, at routine dinner time (18:00) followed by a sleep study (23:00). Timing of dinner is the sole intervention distinguishing this arm from late dinner. This arm will cross-over to late dinner in random order."
89454927|NCT03525717|Experimental|Late Dinner|"Participants will be served dinner and a stable isotope of palmitate to measure fat oxidation, at a late dinner time (22:00) followed by a sleep study (23:00). Timing of dinner is the sole intervention distinguishing this arm from routine dinner. This arm will cross-over to routine dinner in random order."
89454928|NCT03187184|Experimental|OneOme RightMed® Test|OneOme RightMed® currently tests for 22 genes that impact over 340 drugs used in multiple fields of medicine, including oncology. The drugs tested for by OneOme RightMed® were generated from practice guidelines and the FDA's guidelines for genotyping, and drugs with published, clinical evidence supporting genotyping. Testing is done using a prepackaged OneOme RightMed® kit to collect a buccal swab. OneOme RightMed® PGx test uses a DNA Genotek ORAcollect OC-100 buccal swab kit to extract DNA, which is then analyzed through polymerase chain reaction (PCR).
89454929|NCT04466943|Experimental|group A|Moderate neuromuscular blockade (NMB) , defined as a 1±2 twitch response to the train-of four (TOF) by stimulation of the ulnar nerve. The device which will be used is neuromuscular transmission monitor (NMT) to test the depth of muscle relaxation after giving rocuronium which is a muscle relaxant during general anesthesia.
89454930|NCT04466943|Experimental|group B|Deep NMB, defined by (0 twitch count in the TOF, 1±2 twitch responses in the post-tetanic count. The device which will be used is neuromuscular transmission monitor (NMT) to test the depth of muscle relaxation after giving rocuronium which is a muscle relaxant during general anesthesia.
89454931|NCT02438462||Group with PE|"The criteria for confirmation of PE are:~PE on spiral computed tomography (CT)~proximal deep vein thrombosis on ultrasound (US)~thromboembolic events objectively confirmed during the follow up"
89454932|NCT02438462||Group without PE|"The criteria for exclusion of PE are:~low or moderate clinical probability and D-dimer ELISA <0.50 µg/mL or <10xage in patients older than 50 years and negative follow up~low and moderate clinical probability and negative CT and negative follow up~high clinical probability and negative CT, US and follow up."
89454933|NCT04466397||3D printed implants reconstruction group|The patients with large bone defects who treated by 3D printed individualized porous implants
89454934|NCT02438150|Experimental|Intervention|Will receive hospital fire video training
89454935|NCT02438150|Placebo Comparator|Control|Will receive non-fire video training
89454936|NCT02438228|Other|Cardiac output measurement|
89454937|NCT03198897||Observation|Patients with a Homozygous familial Hypercholesterolemia or high-grade suspicion for Homozygous familial Hypercholesterolemia
89201239|NCT00771576||C. Obese Subjects|subjects with predicted increased beta cell mass (euglycemic obese subjects with fasting hyperinsulinemia).
89201240|NCT00986284|Experimental|Gefitinib, Neoadjuvant therapy|Patients with EGFR mutation will be recruited and treated with gefitinib.
89454938|NCT02442440|Experimental|anisodamine group|administration of the drug
89454939|NCT02442440|No Intervention|control group|these arm do not use anisodamine, other resuscitation protocol is as usual.
89454940|NCT03528291||Cardiogenic shock treated with medical treatment|Patients with cardiogenic shock treated only by medical treatment
89454941|NCT03528291||Cardiogenic shock treated with transient circulatory support|Patients where transient circulatory support was implanted: veno-arterial extracorporeal circulatory life support (ECLS), Impella
89454942|NCT03187496|Experimental|Single Arm|
89454943|NCT04440969|Experimental|Intervention|Intervention administered is bi-weekly dual-task exercises, small group acitivites and computerised cognitive training for a total of 24 weeks. (Week 1 - 24)
89454944|NCT04440969|Experimental|Wait-list control|Intervention administered is bi-weekly dual-task exercises, small group acitivites and computerised cognitive training for a total of 24 weeks after Intervention Group has completed intervention. (Week 25 - 48)
89454945|NCT03186950|Active Comparator|Restoration with Stainless Steel Crowns|Restoration of the tooth after endodontic treatment using stainless steel crown.
89454946|NCT03186950|Experimental|Restoration using BulkFill CR|Restoration of the tooth after endodontic treatment using bulkfill composite resin
89201241|NCT00768846|Active Comparator|1|Endeavor Resolute Stent
89201242|NCT00768846|Active Comparator|2|Xience V Stent
89201243|NCT00988702|Experimental|Dan Tian Breathing|subjects received one-month's training on the Dan Tian Breathing
89201244|NCT00988702|Active Comparator|Progressive muscle relaxation training|Subjects received one-month's conventional progressive muscle relaxation training
89201245|NCT00768924||1|Spinal fusion patients
89201246|NCT00988780|Experimental|Maraviroc|"Maraviroc 600mg po BID~Background antiretroviral regimen (Efavirenz 600mg QD + Tenofovir 300 mg /Emtricitabine 200 mg QD) plus Maraviroc 600 mg BID"
89201247|NCT00988780|Placebo Comparator|Placebo|"Placebo po BID~Background antiretroviral regimen (Efavirenz 600mg QD + Tenofovir 300 mg /Emtricitabine 200 mg QD plus Placebo po BID"
89201248|NCT00769080||1|Standard Treatment plus PSP
89201249|NCT00769080||2|Standard Treatment
89201250|NCT00775242|Experimental|Estradiol and progesterone injection|Comparison of three different dosages of estradiol and progesterone a) 0.5 mg E/15 mg P; b) 1 mg E/20 mg P; c) 1 mg E/30 mg P
89454947|NCT02438072|Other|Overall population|
88939622|NCT01841255|Experimental|Tidal volume breathing with the UMOXTM, device, no instruction|First experimental measure
89454948|NCT03184311|Experimental|High-intensity interval training (HIT)|A 12-week HIT will be performed 3 times per week on a bicycle ergometer according to the protocol of Wisløff et al. In the first 4 weeks of the program, all sessions will consist of moderate continuous training (MCT) at 60-80% of peak heart rate (HRpeak) for 40 minutes in order that patients get used to exercising. For weeks 4-12, the following HIT protocol is intended: Patients will warm up for 10 minutes at moderate intensity (60-70% of HRpeak, Borg 11-13) before cycling four 4-minute intervals at high intensity (85-95% of HRpeak, Borg 15-17). Each interval will be separated by a 3-minute active pause at 60-70% of HRpeak (Borg 11-13). The training session will end with a 5-minute cool-down at moderate intensity (60-70% of HRpeak). Total exercise time will be 40 minutes.
89454949|NCT03184311|Placebo Comparator|Moderate-intensity continuous training (MCT)|A 12-week MCT will be performed 3 times per week on a bicycle ergometer. All sessions will consist of moderate continuous training (MCT) at 60-70% of peak heart rate (HRpeak) for 47 minutes.
88939623|NCT01841255|Experimental|Tidal volume breathing with the UMOXTM device, instructions|Second experimental measure
88939624|NCT01841255|Experimental|Tidal volume breathing with the UMOXTM, device, nose clip|Third experimental measure
88939625|NCT01841268||Preterm Infants|Infants born prematurely will have their skin, sebum, microbiota, blood, and mother's breast milk analyzed for changes between 0, 2, and 4 weeks of life.
88939626|NCT01841268||Term Infants, Control|Term infants enrolled in the UC Davis Lactation Study (protocol # 216198) will serve as the control group for this study; they will have their skin, sebum, microbiota, and mother's breast milk analyzed for changes between 0, 2, and 4 weeks of life.
88939627|NCT01841294|Experimental|Intravenous Lidocaine|Patients undergoing laparoscopic surgery for resection of colorectal cancer will benefit of an infusion of intravenous lidocaine from the induction of anesthesia untill one hour after PACU admission
88939628|NCT01841294|Placebo Comparator|Placebo|Infusion of normal saline form the induction of anaesthesia untill one hour after PACU admission
88939629|NCT01841307|Experimental|Gastrocrom|4 ingestions (at 2h intervals) of a 200 mL of a 1mg/mL solution of cromolyn sodium (inpatient) OR 2 ingestions (at 4h intervals) of a 200 mL of a 1mg/mL solution of cromolyn sodium (outpatient)
88939630|NCT01841320|Experimental|Intervention|Participants who are assigned to intervention arm will receive ART and methadone maintenance at an integrated methadone and antiretroviral therapy (iMART) clinic and ART adherence support through the use of mobile phone technologies.
88939631|NCT01841320|No Intervention|Standard of Care|Participants will be referred to standard HIV outpatient clinics and methadone maintenance clinics.
88939632|NCT01841346||PCI patients|Patients undergoing PCI for elective or ACS will be enrolled.
88939633|NCT01841372|Active Comparator|Group Phone Conference Call|Group phone clinic will be conducted weekly during the first 9 months and twice/month during the final 9 months (3 to 12 months).
89015952|NCT05825001|Experimental|Arm 1 (active EFT)|Participants receive the active EFT stimulus and use the iCOquit Smokerlyzer carbon monoxide monitor on study.
89201251|NCT00986518|Experimental|adaptive cell immunotherapy|
89015953|NCT05825001|Active Comparator|Arm II (control EFT)|Participants receive the control EFT stimulus and use the iCOquit Smokerlyzer carbon monoxide monitor on study.
89201252|NCT00769158|Experimental|Topiramate + Naltrexone|Combination of Topiramate and Naltrexone
89201253|NCT00769158|Placebo Comparator|Placebo|
89454950|NCT02437994|Experimental|Pulmonary Rehabilitation|The rehabilitation program will be multidisciplinary and will include supervised exercise training (interval exercise and resistance exercises), breathing control and relaxation techniques, methods of clearance of pulmonary secretions, disease education, dietary advice, and psychological support on issues relating to chronic disability.
89454951|NCT02437994|No Intervention|Control|In addition, a control group (Group C) which will not participate in the rehabilitation program (usual care) will be include at the same time as patients in Group A and B so as to be able and independently address study objectives 2 and 3 and 4. Group C will also randomized to those into paper-pencil version and electronic version.
89454952|NCT03522987|Experimental|Epileptologist-Driven Treatment|The intervention will consist of initiating a chronic care management plan in the epilepsy clinic and an initial prescription from the epileptologist for escitalopram 10mg daily. Escitalopram dose adjustment will be made based on biweekly repeated screening of anxiety and depression symptoms, as well as side effects identified on biweekly telephone calls or the 6-week advanced practice provider (APP) follow up visit. Escitalopram dose may be titrated up to a maximum of 20mg daily in 5-10mg increments every 2 weeks for treatment effect, or titrated down to 5mg if needed for adverse effects. If a participant is unable to tolerate escitalopram, then venlafaxine XR 37.5mg will be substituted, to be titrated in a similar manner biweekly based on side effects and anxiety and depression symptoms (with 37.5-75mg increment dose changes and maximum dose of 225mg daily).
89454953|NCT03186872|No Intervention|Care as usual|Participants randomized to this group will continue to see the IBD medical home team as usual
89454954|NCT03186872|Experimental|Digital behavioral program app|Participants randomized to this group will see the IBD medical home team and will utilize the cognitive behavioral app as the intervention.
89454955|NCT03522909||Study|We will be reviewing records of parturients seen at Johns Hopkins Hospital in the Center for Peripartum Optimization (CPO) clinic between January 2017 to January 2018
89454956|NCT03522909||Control|A matched controlled group patients not seen at the CPO clinic
89454957|NCT02433626|Experimental|COTI2|COTI-2 will be self-administered as a single agent, orally, once daily for 5 days followed by 2 treatment-free days each week; 1 cycle will be defined as 4 weeks of treatment as described (5 days on, 2 days off per week). Participants will remain on treatment until they experience a lack of benefit.
89454958|NCT02433626|Experimental|COTI2 + cisplatin|COTI-2 will be self-administered as a single agent, orally, once daily for 5 days followed by 2 treatment-free days each week; 1 cycle will be defined as 3 weeks of treatment as described (5 days on, 2 days off per week). Cisplatin 60 mg/m2 IV will be administered on Day 1 of each 3 week cycle. Participants will remain on treatment until they experience a lack of benefit.
89454959|NCT03392415|Active Comparator|Initial conservative treatment|Optimal medical therapy and option for crossover after 6 months or fulfillment of certain conditions
89454960|NCT03392415|Experimental|initial interventional treatment|CTO PCI attempt as initial strategy with medical optimization simultaneously
89454961|NCT02437448||Idiopathic lung fibrosis|20 IPF patients
89454962|NCT02437448||Controls|20 subjects with no apparent lung disease and normal lung function testing. Matched for gender, age and smoking history.
89454963|NCT02290041|Experimental|Mesenchymal stem cells|Intravenous infusion of 4 doses of allogenic adult mesenchymal stem cells from adipose tissue
89454964|NCT02290041|Placebo Comparator|Placebo|Intravenous infusion of 4 doses of Placebo
89454965|NCT02442128|Active Comparator|Group1|comparison of different dosages of drugs ( Fentanyl / Propofol), fentanyl 2 μg/kg and propofol 2 mg/kg Both test drugs will be made up to 10 ml with saline. fentanyl will be first administered intravenously over 30 s followed by propofol over 20 s.
89454966|NCT02442128|Active Comparator|Group 2|comparison of different dosages of drug ( Fentanyl / Propofol) ,fentanyl 2 μg/kg and propofol 3 mg/kg. Both test drugs will be made up to 10 ml with saline. fentanyl will be first administered intravenously over 30 s followed by propofol over 20 s.
89454967|NCT04465773|Experimental|pupillometry|General anesthesia for scheduled gynecological surgery Propofol target concentration adjusted to maintain bispectral index between 45 and 55 for 10 minutes Remifentanil target concentration 1 ng/ml for 10 minutes Tetanic stimulations of 10-20-30-40-50-60 milliamps (5 seconds per stimulation, 2 minutes between stimulations) Continuous pupillometry VideoAlgesiGraph
89454968|NCT02441972|Experimental|18F-Al-NOTA-PRGD2 PET/CT|Imaging with 18F-Al-NOTA-PRGD2 PET/CT.
89454969|NCT04468191|Experimental|Experimental, then sham|Patients with ALS in the experimental, then sham arm will undergo an expiratory muscle strength training (EMST) session with a device set to 50% of patients with ALS' highest maximum expiratory pressure from their baseline pulmonary function test assessment during their first study visit. Then, during their second study visit, patients with ALS will undergo an EMST session with a device set to 0% resistance.
89454970|NCT04468191|Experimental|Sham, then experimental|Patients with ALS in the sham, then experimental arm will undergo an expiratory muscle strength training (EMST) session with a device set to 0% resistance during their first study visit. Then, during their second study visit, patients with ALS will undergo an EMST session with a device set to 50% of patients with ALS' highest maximum expiratory pressure from their baseline pulmonary function test assessment.
89454971|NCT02290197|Experimental|Hinged External Fixator|Hinged external fixator allows early and aggressive joint mobility in the sagittal plane only. Flexion and extension are permitted, but rotational movements, translations in the anterior-posterior plane, lateral (varus) and medial (valgus) openings are not allowed. Thus protective stability is ensured for ligament reconstruction procedures. Simultaneously we allow immediate joint mobilization, reducing the risk of arthrofibrosis, joint stiffness and postoperative ligament laxity.
89454972|NCT02290197|Active Comparator|Cast Immobilization|In these patients we used cast postoperatively for 3 weeks. After this period we use a removable bracing and initiate rehabilitation with physical therapy.
89454973|NCT02290275|Placebo Comparator|Placebo|The subjects in this arm will receive 20 grams of a placebo (maltodextrin) for 1 week and then 5 grams of placebo (maltodextrin) for 11 weeks in addition to their regular diets.
89454974|NCT02290275|Experimental|Creatine|The subjects in this arm will receive 20 grams of creatine for 1 week and then 5 grams of creatine for 11 weeks in addition to their regular diets.
89201254|NCT00775320||Brain tumor FLT-PET|Those diagnosed with a brain tumor and are to undergo surgery
89201255|NCT00983164|No Intervention|group I|group I - controls
89454975|NCT02290275|Experimental|Walking Exercise|The subjects in this arm will receive a walking exercise program on a motorized treadmill where they will walk for 30 minutes at 3.1 mph, 3 days per week for 12 weeks.
89454976|NCT02709746|Experimental|Vortioxetine 10 mg/day|
89454977|NCT02709746|Experimental|Vortioxetine 20 mg/day|
89454978|NCT02709746|Active Comparator|Fluoxetine 20 mg/day,|
89454979|NCT02709746|Placebo Comparator|Placebo|
89454980|NCT02441894|Experimental|Cabazitaxel|"25 mg/m^2 of cabazitaxel is given intravenously in combination with prednisolone 10 mg orally per day. PEG-G-CSF is administered subcutaneously 24 hours after the completion of cabazitaxel infusion once every 3 weeks.~Antihistamine (dexchlorpheniramine or diphenhydramine), corticosteroids (dexamethasone), and H2 antagonist (ranitidine) premedications will be administered by IV infusion at least 30 minutes prior to each dose of cabazitaxel. A prophylactic antiemetic treatment (metoclopramide, granisetron, or ondansetron) should be given to the patients in all cycles."
88939634|NCT01841372|Experimental|Second Life (2L)|2L group meeting will be conducted weekly during the first 9 months and twice/month during the final 9 months
88939635|NCT01841385|Experimental|Pilates Group|"Sedentary volunteers, but that would begin activities with the Pilates method and evaluated in three months.~Therapeutic intervention in the Pilates method has two regular weekly sessions for 12 weeks, totaling 24 sessions.~For the protocol of Pilates exercises, exercises on soil and equipment, with gradual progression of the load."
88939636|NCT01841385|No Intervention|Control Group|Sedentary volunteers and remain sedentary and evaluated in three months. The volunteers comprised the control group did not perform any physical activity during the study period.
88939637|NCT01841398|Active Comparator|Multimedia Lifestyle Improvement|Includes goal setting, self monitoring and participants will receive regular health messaging using electronic media regarding smoking, dietary habits & physical activity
88939638|NCT01841398|Placebo Comparator|Usual Care|Includes usual advice and no regular health messaging.
88939639|NCT01841411|Experimental|Metronidazole + N-Acetyl cysteine|the second patient group will use NAC sachets containing 200 mg as a vaginal douche once daily plus oral metronidazole 500 mg twice daily for 7 days
88939640|NCT01841411|Experimental|N- Acetyl cysteine|the third patient group will use NAC sachets containing 200 mg as a vaginal douche only without taking metronidazole
88939641|NCT01841411|Active Comparator|Metronidazole|the first group of patients will take oral metronidazole 500 mg twice daily for a week
88939642|NCT01841424|No Intervention|Control|Subjects receive usual care for pregnancy and postpartum.
88939643|NCT01841424|Experimental|Dietary Counseling and Food Diary|Dietary counseling before 16 weeks of pregnancy Maintain food diary during pregnancy
88939644|NCT01841437||iStent|
88939645|NCT01841450|Experimental|iStent|Implantation of one iStent in conjunction with cataract surgery
88939646|NCT01841450|Active Comparator|Cataract surgery|Cataract surgery alone
89201256|NCT00983164|Experimental|group II|group II - patients with hepatitis C without treatment
89454981|NCT01317641|Experimental|ODM-201 Phase I|
89454982|NCT01317641|Experimental|ODM-201 Phase II Dose 1|
88939647|NCT01841463|Experimental|P1446A-05|"The study will be conducted in two phases- Phase I ('Dose escalation' phase), and Extension phase:-~In the 'Dose escalation' phase patients will be co-administered P1446A-05 (150, 250, 350 mg qd) and vemurafenib (720, 960 mg bid) in a cohort of three to six patients on a 28-day cycle, until the occurrence of disease progression or unacceptable toxicity.~In the 'Extension' phase, sixty patients with BRAF V600E/K mutations (forty patients naïve to selective BRAF inhibitor therapy, and twenty progressing on selective BRAF inhibitor therapy) will be treated at the MTD on a 28-day cycle, until the occurrence of disease progression or unacceptable toxicity"
88939648|NCT01841476|Experimental|POL6326|2-hour single intravenous infusion doses of POL6326
88939649|NCT01841489|Experimental|Sequence 1|
88939650|NCT01841489|Experimental|Sequence 2|
88939651|NCT01841489|Experimental|Sequence 3|
88939652|NCT01841489|Experimental|Sequence 4|
88939653|NCT01841502|Active Comparator|paroxetine alone|paroxetine 20 mg tablet once daily oral
88939654|NCT01841502|Experimental|paroxetine + telaprevir|paroxetine 20 mg tablet once daily + telaprevir 1125 mg (3 tablets 375mg) twice daily oral
88939655|NCT01841515|Experimental|Desmopressin|Twenty five patients with chronic kidney disease and who were taking antiplatelet agents and needed an emergent catheter insertion for hemodialysis
88939656|NCT01841528|Experimental|fresh embryo transfer group|rFSH/GnRH antagonist will be administered for ovarian stimulation. Two fresh embryos will be transferred at Day 3. Luteal phase support will last 2 weeks for all subjects in this group. Two weeks after embryo transfer, serum human chorionic gonadotropin (HCG) will be measured to determine pregnant or not. If biochemical pregnancy is achieved, luteal phase support will be continued to 10 weeks gestation. Pregnancy complications and final outcome will be followed up till 6 weeks after delivery.
89015954|NCT05824234|Other|Arm number one (2023)|Arm number one: services formed the first year with the REFOCUS formation Arm number two: services formed the second year with the REFOCUS formation Stepped wedge methodology
89015955|NCT05824234|Other|Arm number two (2024)|Arm number one: services formed the first year with the REFOCUS formation Arm number two: services formed the second year with the REFOCUS formation Stepped wedge methodology
89015956|NCT05821023|No Intervention|Group 1 - control (no exposure)|No message at T1 or T2.
89454983|NCT01317641|Experimental|ODM-201 Phase II Dose 2|
89454984|NCT01317641|Experimental|ODM-201 Phase II Dose 3|
89454985|NCT02433548|Experimental|Fascia iliaca block|Fascia iliaca block (Injection of 30 mLs of bupivacaine 0.5% with epinephrine 5 mcg/mL below the fascia iliaca, Carbostesin®)
89454986|NCT02433548|Sham Comparator|Sham injection|No fascia iliaca block (Sham injection = Subcutaneous injection of 5 cc of normal saline, no intervention)
89454987|NCT02433704|Active Comparator|Intraosseous Administration|Cefazolin 1 gram will be given through an intraosseous cannula, placed into the medial aspect of the proximal tibia, after draping and before skin incision. The cefazolin will be administered as a bolus in 200 mL of normal saline.
89454988|NCT02433704|No Intervention|Systemic Intravenous Administration|Historical controls will be used and will have received systemic dosing of cefazolin within one hour of the incision.
89454989|NCT02437292|Experimental|Ischemic compression with stretching|The participants will receive the ischemic compression with stretching onto the trapezius muscle
89454990|NCT02437292|No Intervention|Control|Rest on the bed
89454991|NCT02433470|Active Comparator|Active tDCS|Active transcranial direct current stimulation
89454992|NCT02433470|Sham Comparator|Sham tDCS|Sham transcranial direct current stimulation
89454993|NCT05453825|Experimental|Combination navicixizumab + paclitaxel|Gastric/GEJ and TNBC cancer patients will be assigned to this treatment arm.
89454994|NCT05453825|Experimental|Combination navicixizumab + irinotecan|CRC patients will be assigned to this treatment arm.
89454995|NCT05453825|Experimental|Navicixizumab monotherapy|CRC,TNBC and ovarian cancer patients will be assigned to this treatment arm.
89454996|NCT03186794|Experimental|Aerobic exercise training (AET)|Participants with systemic lupus erythematosus participated in a 12-week aerobic exercise training program. Exercise was performed on a treadmill, three times a week for 30 minutes at target training intensity of 70 - 80% of heart rate reserve [0.7 to 0.8 * (peak heart rate - resting heart rate) + resting heart rate]
89454997|NCT03189680|Experimental|Exercise therapy|Parkinson's disease group that receive 3 weeks of intensive exercise therapy in a rehabilitation center.
89454998|NCT03189680|No Intervention|Control|Parkinson's disease control group that will not receive exercise treatment.
89454999|NCT03189680|No Intervention|Healthy|A healthy group whose results will be compared with Parkinson's disease groups.
89455000|NCT05024279|Experimental|Intervention Arm|Patients are randomized to receive left bundle branch are pacing due to higher degree AV block
89455001|NCT05024279|Active Comparator|Control Arm|Patients are randomized to receive standard right ventricular pacing due to higher degree AV block.
89455002|NCT02441738|Active Comparator|Hybrid Ablation|Epicardial surgical ablation performed thoracoscopically with occlusion/removal of the LAA combined with percutaneous endocardial ablation (one-stage).
89455003|NCT02441738|Active Comparator|Catheter Ablation|Percutaneous endocardial catheter ablation, with optional repeated catheter ablation(s).
89455004|NCT02441504|Active Comparator|Low intensity exercise|physical inactivity
89455005|NCT02290353|Experimental|Adult (Stroke) group|This includes early intervention and late intervention sub-groups. Intervention: FEATHERS Device
89455006|NCT02290353|Experimental|Teenagers (Cerebral Palsy) group|This includes early intervention and late intervention sub-groups. Intervention: FEATHERS Device
88939657|NCT01841528|Experimental|frozen-thawed embryo transfer group|rFSH/GnRH antagonist will be administered for ovarian stimulation. All embryos will be vitrified in fresh cycle, and at least 2 embryos should be frozen at Day 3. Two months later, two thawed Day 3 embryos will be transferred with hormone replacement therapy (HRT) prepared endometrium. Luteal phase support will last 2 weeks for all subjects in this group. Two weeks after embryo transfer, serum human chorionic gonadotropin (HCG) will be measured to determine pregnant or not. If biochemical pregnancy is achieved, luteal phase support will be continued to 10 weeks gestation. Pregnancy complications and final outcome will be followed up till 6 weeks after delivery.
88939658|NCT01841541|Experimental|Ombda Locality: informal providers|"Ombda locality is located in Western Khartoum and populated with population size of 988,163.~Intervention: 380 unpaid Informal providers trained to recognise TB symptoms and to refer presumptive TB cases to formal health care facilities within the area."
88939659|NCT01841541|No Intervention|Jabal Awlia Locality|The control arm: A locality in south eastern site of Khartoum state populated with 942,429. No intervention took place
88939660|NCT01841658|Experimental|Folic Acid Normal Weight|Folic acid, tablet, 800 mcg, daily, eight weeks. Normal Weight individuals, each will serve as her own control.
88939661|NCT01841658|Experimental|Folic acid Obese|Folic acid, tablet, 800 mcg, daily, eight weeks. Obese individuals, each will serve as her own control.
88939662|NCT01841671|Experimental|IPV/IPV/IPV/Rotarix/mOPV type 2|190 healthy infants due for their first dose of polio vaccines will be receive IPV, IPV, IPV at 8, 16 and 24 weeks of age respectively, Rotarix at 8 and 16 weeks if parents accept (optional), and mOPV type 2 at 28 weeks of age
88939663|NCT01841671|Active Comparator|IPV/IPV/bOPV/Rotarix/mOPV type 2|190 healthy infants due for their first dose of polio vaccines will be receive IPV, IPV, bOPV at 8, 16 and 24 weeks of age respectively and Rotarix at 8 and 16 weeks f age (optional) and mOPV type 2 at 28 weeks of age
89455007|NCT02441816|Other|Eylea Treatment|The intravitreal dose of Eylea will be 2mg (in 0.05ml) per injection. The medication will be supplied in single use vials. Given monthly for 3 months and then every 8 weeks in the first year of treatment before applying a treat and extend paradigm to patient visits in year 2. This is an open-label study.
89455008|NCT02433392|Experimental|CM-BC2|Patients diagnosed with recurrent, surgically resectable glioblastoma multiforme will receive up to 75 mg irinotecan delivered by drug-eluting beads (CM-BC2).
88939664|NCT01841671|Active Comparator|IPV/bOPV/bOPV/Rotarix/mOPV type 2|190 healthy infants due for their first dose of polio vaccines will be receive IPV, bOPV, bOPV at 8, 16 and 24 weeks of age respectively and Rotarix at 8 and 16 weeks of age (optional)and mOPV type 2 at 28 weeks of age
88939665|NCT01841684|Experimental|Anacetrapib|Participants receive anacetrapib 100 mg orally once daily for 12 weeks.
88939666|NCT01841684|Placebo Comparator|Placebo|Participants receive placebo orally once daily for 12 weeks.
88939667|NCT01841710||Women|
88939668|NCT01841749|Other|Surgery|sentinel node biopsy and mastectomy
89455009|NCT02441582|Experimental|Telemetry|In this group, participants will have a prehospital 12 lead ECG taken and sent through to the receiving facility.
89455010|NCT02441582|Other|Non-Telemetry|In this group, participants will have a prehospital 12 lead ECG taken which will not be sent through to the receiving facility.
89455011|NCT02433782|Experimental|Experimental group|Treatment through myofascial therapy for the treatment of pain and restricted mobility in patients with hemophilic arthropathy of the knee and ankle
89455012|NCT02433782|No Intervention|Control group|No myofascial intervention. Patients continue their treatment with FVIII or FIX concentrates, normally
89455013|NCT02290431|Experimental|LBH589 + bortezomib + dexamethasone|Participants were administered LBH589 (panobinostat)in combination with bortezomib and dexamethasone 2 weeks on/1 week off.
89455014|NCT03189758|Experimental|Intervention|Participants will follow a Observational Control Diet (CON) diet followed by an Controlled Dietary Sodium Restriction (INT) diet.
89455015|NCT02433236|Experimental|Fostamatinib Disodium tablet 100 mg|Fostamatinib Disodium tablet 100 milligram (mg) by mouth twice a day for 15 months
89015957|NCT05821023|Other|Group 2 - control (single exposure)|Single clinician message at T1 aimed at reducing over-screening. No message at T2.
89015958|NCT05821023|Experimental|Group 3|T1 - message from media source aimed at reducing over-screening. T2 - message from clinician aimed at reducing over-screening
89015959|NCT05821023|Experimental|Group 4|T1 - message from a close family member aimed at reducing over-screening. T2 - message from clinician aimed at reducing over-screening
89015960|NCT05821023|Experimental|Group 5|T1 - message from media source aimed at supporting continued screening. T2 - message from clinician aimed at reducing over-screening
89015961|NCT05821023|Experimental|Group 6|"T1 - message from a close family member aimed at supporting continued screening.~T2 - message from clinician aimed at reducing over-screening"
89015962|NCT05819801|Active Comparator|Fasting|Patients in the fasting group will be told to avoid any food past midnight the day before their surgery and any liquids 4 hours before their scheduled surgery.
89015963|NCT05819801|Experimental|Not Fasting|The eating group will be told specifically to eat a light meal (equivalent to two slices of toasted bread with butter and jam and one cup of coffee or juice) the morning of their surgery, within two hours of their procedure start time.
89015964|NCT05818332||before and after implementation cohort|"consecutive cohort of 1000 surgical patients (baseline)~consecutive cohort of 1000 surgical patients (after implementation with a multifaceted, tailored implementation strategy to improve adherence to the WHO SSC and routine recording of iAEs)"
89455016|NCT02433236|Experimental|Fostamatinib Disodium tablet 150 mg|Fostamatinib Disodium tablet 150 milligram (mg) by mouth twice a day for 15 months
89015965|NCT05816265|Experimental|IV Iron Infusion Group|Subjects will receive iron infusion 1 week after enrollment. Dosage of iron will be at discretion of physicians
89015966|NCT05816265|No Intervention|Control Group|Subjects will not receive iron replacement infusion.
89455017|NCT02441426||Bangladesh|"Birth cohort study community in Bangladesh is urban, and located in the Mirpur neighborhood of Dhaka.~Case control study is being conducted in the same catchment area. Cases defined as children 6-24 months of age with <-2WAZ (weight for age) score, controls are age and community matched with >-1WAZ."
89015967|NCT05786924|Experimental|Phase 1 Dose Escalation|BDTX-4933 will be administered at escalating dose levels until the maximum tolerated dose (MTD) is reached and the preliminary recommended Phase 2 dose (RP2D) is determined.
89015968|NCT05786924|Experimental|Phase 1 Dose Expansion|BDTX-4933 will be administered at the RP2D.
89015969|NCT05786599|Experimental|methadone|Methadone is a strong opioid that is μ-opioid receptor agonist like other opioids; however, it is additionally a N-methyl-D- aspartate antagonist with serotonin and norepinephrine reuptake inhibition; these attributes enable its efficacy in neuropathic pain and may prevent opioid tolerance over time. It is commonly used to treat opioid use disorder, as well as to treat severe pain. This medication is taken orally every 8 hours when used to treat pain. It has not been studied to treat chemotherapy-induced peripheral neuropathy.
89455018|NCT02441426||Brazil|"Birth cohort study community in Brazil is urban, and located within the Papoco area of Fortaleza.~Case control study is being conducted in the same area as the cohort study. Cases are children 6 - 24 months of age, with <-2 WAZ (weight for age) score, controls are age and community matched children with >-1 WAZ."
89455019|NCT02441426||India|Birth cohort study community in India is urban, and located in the southern state of Tamil Nadu, specifically in Vellore.
89455020|NCT02441426||Nepal|Birth cohort study community in Nepal is semi-urban, and located in Bhaktapur, approximately 25km from Kathmandu.
89455021|NCT02441426||Pakistan|Birth cohort study community in Pakistan is rural, and located in Naushero Feroze, Sindh.
89455022|NCT02441426||Peru|Birth cohort study community in Peru is rural, and located approximately 15km from Iquitos in Loreto.
89455023|NCT02441426||South Africa|Birth cohort study community in South Africa is rural/peri-urban, and comprised of nine settlements within Limpopo Province.
89455024|NCT02441426||Tanzania|Birth cohort study community in Tanzania is rural, and located within Haydom.
89015970|NCT05786599|Active Comparator|duloxetine|Duloxetine is a serotonin and norepinephrine reuptake inhibitor that is commonly used to treat major depressive disorder, generalized anxiety disorder, and neuropathic pain. This medication is taken orally once daily for all of its indications. It is the only well-studied medication that is recommended internationally to treat chemotherapy-induced peripheral neuropathy.
89015971|NCT05774119|Experimental|breakfast with coffee|250 mL of water with 6 mg/caffeine/kg
89015972|NCT05774119|Placebo Comparator|breakfast with water|250 mL of water
89015973|NCT05770622|Experimental|Vancomycin first-dose trough dose adjustment calculation|Participants will have individualised model-based intermittent vancomycin dosing using the Vanc App dosing calculator (as used in VANC APP Part 1, see clinicaltrials.gov ID: NCT04044703). A first-dose trough concentration will be measured for each participant and the clinician will then enter that concentration into the web application ('First-dose trough dose adjustment calculator'). A dose adjustment will be generated by the calculator if the predicted steady-state level is outside of target range. If the predicted steady-state level is within target range (10-20mg/L) the calculator will recommend continuing with the same dose. The vancomycin concentration is then measured at steady state to determine if the target concentration has been achieved.
89455025|NCT02290587|Experimental|Patient|MS diagnosis according to McDonald criteria (Polman et al., 2005). Relapsing-remitting MS (RRMS) according to Lublin et al. (1996);
89015974|NCT05770089|Experimental|AM-APA|The group following the Adapted Physical Activity program via videoconferencing in addition to the outpatient care.
89455026|NCT02290587|Experimental|Control|healthy subject
89455027|NCT02432924|Experimental|Feedback Group|Participants randomised into the intervention group will be invited to return to the university for a one-off 60 minute set-up session once their physical activity monitor has been returned and processed. Within this session the participant will be given detailed instructions on how to use and wear the activity monitor and real time display and upload their data to and navigate the multidimensional feedback web platform (See materials section for details). They will also be introduced to the concept of goal setting and talked through the different aspects of the instantaneous feedback display and how that might benefit them. Following this visit the participant will be given licence to wear and use the physical activity monitoring devices for a 6-week period and encouraged to self-monitor their behaviour using the combined instantaneous and multidimensional feedback.
89455028|NCT02432924|No Intervention|Waiting List Control Group|Participants who have been randomised into the control arm will be put on a 3 month waiting list to receive the intervention described above. They will still attend assessment visits at week 6 and week 12 while they are not receiving any advice or feedback. Following their 12 week assessment, participants in the control arm will be invited to attend the same 60 minute set-up session as received by the intervention group and then provided with the armband monitor and display to then receive the intervention in full. No further post-intervention or follow-up assessments will be taken from these participants.
89455029|NCT02441270|Experimental|Cyclophosphamide|
89455030|NCT03528135|Experimental|Project PRIDE|"Those in the Project PRIDE condition will receive 8 weekly sessions, each lasting 2.5 hours and consisting of approximately 10 men (estimated number given expected attrition). Each session will be co-led by two trained group facilitators. The intervention sessions are described in the Detailed Description section. The will complete a pre-test, post-test, and follow-up assessment."
89455031|NCT03528135|No Intervention|Wait-list|Those in the wait-list arm will wait approximately 5 months before receiving the intervention. They will complete the same pre-test, post-test, and follow-up assessments as those in the PRIDE arm. After they have completed the follow-up assessment, they will be offered the intervention.
89455032|NCT02441192|Experimental|Training resistance|After the baseline tests they were distributed in four randomized groups for the 6 weeks of training: aerobic (AT), resistance (RT), aerobic+resistance (AT+RT) and control (C).
89455033|NCT02441192|Experimental|Training aerobic|After the baseline tests they were distributed in four randomized groups for the 6 weeks of training: aerobic (AT), resistance (RT), aerobic+resistance (AT+RT) and control (C).
89455034|NCT02441192|Experimental|Training resistance+aerobic|After the baseline tests they were distributed in four randomized groups for the 6 weeks of training: aerobic (AT), resistance (RT), aerobic+resistance (AT+RT) and control (C).
89455035|NCT02441348||CTT group|CTT will be initiated in a prospective fashion to study population
89455036|NCT02290665|Experimental|Thermosensitive gel formulation|Thermosensitive gel rectal formulation or saline (control) enema with crossover to the other.
89455037|NCT02290665|Experimental|Saline enema|Thermosensitive gel rectal formulation or saline (control) enema with crossover to the other.
89455038|NCT02436980|Active Comparator|tramadol|1mg/kg of tramadol drop (Contramal® drop, Abdi Ibrahim Ilaç San.,istanbul) was administered orally in 10 mL of cherry juice without particles in preparation room before intervention, Group T who were separated randomly to two premedication groups.
89455039|NCT02436980|Active Comparator|midazolam|0.15 mg/kg of midazolam (Dormicum®, ampoule, Roche Products A.Ş., istanbul) was administered orally in 10 mL of cherry juice without particles in preparation room before intervention, to Group M who were separated randomly to two premedication groups.
89455040|NCT02837523||Observation|Patients with a Cystinosis disease or high-grade suspicion for Cystinosis disease
89455041|NCT02436902|Experimental|TACE|Transarterial chemoembolization (TACE) is performed two to four weeks after hepatic resection.
89455042|NCT02436902|Active Comparator|sorafenib|Patients will receive sorafenib at a dose of 400 mg twice daily after 2 weeks of hepatic resection.
89455043|NCT02436902|Other|TACE plus sorafenib|Patients will receive sorafenib at a dose of 400 mg twice daily after 2 weeks of hepatic resection. At the same time, TACE is performed two to four weeks after hepatic resection.
89455044|NCT02436902|No Intervention|empty control|This group patients will receive best supportive care.
89455045|NCT04009863|Active Comparator|HIFU on NMNG|The patients with non-toxic multinodular goiter are assigned to have high intensity focused ultrasound treatment.
89455046|NCT04009863|Active Comparator|RAI on NMNG|The patients with non-toxic multinodular goiter are assigned to have radioactive iodine (i131) treatment.
89455047|NCT02436746||Neurofibromatosis type I (NF1)|Monozygotic twin pairs with genetically confirmed Neurofibromatosis type I
88939669|NCT01841788|Experimental|Thermal Adhesion Patch|Group of subjects wearing the experimental patch for 8 hour study duration
88939670|NCT01841788|Active Comparator|Marketed Thermal Adhesion Patch|Group of subjects wearing comparative predicate device for 8 hour study duration.
88939671|NCT01841788|Placebo Comparator|Placebo Patch|Group of subjects wearing the placebo patch for 8 hour study duration
88939672|NCT01841801|Active Comparator|Marketed Thermal Adhesive Patch|Group of subjects wearing comparative predicate device for 8 hours daily for 7 days.
88939673|NCT01841801|Experimental|Thermal Adhesive Patch|Group of subjects wearing the experimental patch for 8 hours daily for 7 days.
88939674|NCT01841801|Placebo Comparator|Placebo Patch|Group of subjects wearing the placebo patch for 8 hours daily for 7 days.
88939675|NCT01841814|Experimental|lymphoma|
88939676|NCT01841827|Active Comparator|Cilostazol|Capsule of Cilostazol 200 mg are taken orally on each study day
88939677|NCT01841827|Placebo Comparator|Placebo|A capsule of placebo containing starch are taken orally on each study day.
88939678|NCT01841840|No Intervention|Control|This arm involves not implementing any form of intervention (passive vibration)on the subject during this visit.
88939679|NCT01841840|Experimental|Low-Frequency Pasive Vibration|This arm involves exposing the subject to a 10 minute session of passive vibration set to a frequency of 25Hz and a high amplitude.
88939680|NCT01841840|Experimental|High-Frequency Passive Vibration|This arm involves exposing the subject to a 10 minute session of passive vibration set to a frequency of 40Hz and a low amplitude.
89015975|NCT05770089|No Intervention|AM-T|The group without additional intervention other than the outpatient care.
89455048|NCT02436746||Tuberous Sclerosis Complex (TSC)|Monozygotic twin pairs with genetically confirmed Tuberous Sclerosis Complex
89455049|NCT02436590|Active Comparator|Active PEMF|Subjects have a 2 out of 3 chance to get the active device which emits a Pulsed Electromagnetic Field (PEMF) from the Physio-Stim Model 3315OA device. Double blind randomization
89015976|NCT05769647|Experimental|Virtual Reality Glasses Group|"Volunteer Information and Approval Form will be filled.~Physician request, the name and surname of the individual will be checked.~Patient Information Form and State Anxiety Scale will be filled.~The video containing the nature walk will be watched by virtual reality. 3 minutes after the individual starts watching the video, the IV catheter insertion attempt will be performed while continuing to watch the video.~Visual Pain Scale and State Anxiety Scale will be filled within one minute after intravenous catheter placement is completed."
89455050|NCT02436590|Placebo Comparator|Control/no PEMF|Subjects have a 1 out of 3 chance of getting the control/placebo device which does not emit Pulsed Electromagnetic Field (PEMF) from the Physio-Stim Model 3315A device. Double blind randomization
89455051|NCT02433002||Main study|1300 participants will undergo baseline (month 0) and final (month 36) reference GFR, estimated GFR (eGFR) and urinary albumin-to-creatinine ratio (ACR) tests. Additionally they will provide ACR and eGFR tests at 6-monthly intervals.
89455052|NCT02433002||Sub-study of patterns of progression|A subset of the cohort (n=375) will receive annual reference GFR tests.
89455053|NCT02433002||Biological variability study|In a further sub-study 20 participants will undergo the reference test four times over four weeks.
89455054|NCT02290743|Experimental|Kinesio tape|Kinesio tape on quadriceps femoris
89455055|NCT02290743|No Intervention|Control|No intervention
89455056|NCT02436512|Experimental|Inhaled Nitric Oxide|Active Comparator: Nitric Oxide
89455057|NCT02432768|Active Comparator|Triheptanoin|14 days on Triheptanoin treatment including a 7 days titration period and a 7 days full dose treatment of 1mL/kg/day.
89455058|NCT02432768|Placebo Comparator|Placebo oil|14 days of diet on a placebo oil including 7 days titration period and 7 days full dose treatment of 1mL/kg/day.
89455059|NCT03186716|Experimental|Colostrum|Intervention patients will be received enteral formula and colostrum powder 20 g/kg/day given via nasogastric tube as boluses q 4hrs.
89455060|NCT03186716|Placebo Comparator|Maltodextrin|Control patients will be received enteral formula and maltodextrin mixed in with water and given via nasogastric tube as boluses q 4hrs.
89455061|NCT02436434|Active Comparator|pulsed radiofrequency|Intra-articular pulsed radiofrequency (Neurotherm NT1000, Neurotherm Inc., USA) in treated joint
89455062|NCT02436434|Sham Comparator|Sham pulsed radiofrequency|Sham intra-articular pulsed radiofrequency (Neurotherm NT1000, Neurotherm Inc., USA) in controlled joint
89455063|NCT04466241|Active Comparator|Lopinavir/ritonavir|Lopinavir boosted by ritonavir 200mg/50mg: 2 tablets morning and evening from Day 1 to Day 10
89455064|NCT04466241|Experimental|Lopinavir/ritonavir + telmisartan|"Lopinavir boosted by ritonavir 200mg/50mg: 2 tablets morning and evening from Day 1 to Day 10~Telmisartan 40 mg : 1 tablet daily from Day 1 to Day 10"
89455065|NCT04466241|Experimental|Lopinavir/ritonavir + atorvastatin|"Lopinavir boosted by ritonavir 200mg/50mg: 2 tablets morning and evening from Day 1 to Day 10~Atorvastatin 20 mg : 1 tablet daily from Day 1 to Day 10"
89455066|NCT02440880|Placebo Comparator|CONTROL|TAP block without Dexamethasone neither intravenous nor in combination with the block
89455067|NCT02440880|Experimental|Group 2 (TD8IS)|Dexamethasone in combination with TAP block in dose of 8 mg
89455068|NCT02440880|Experimental|Group 3(TD4IS)|Dexamethasone in addition to TAP block in dose of 4 mg
89455069|NCT02440880|Experimental|Group 4 (TSID8):|Dexamethasone intravenous in addition to TAP block in dose of 8 mg
89455070|NCT02440880|Experimental|Group5(TSID4)|Dexamethasone intravenous 4mg+ TAP block
89455071|NCT04466319|Experimental|intervention arm|The individuals in the intervention group in the rocking chair three times a day, 20 minutes, a total of 60 minutes after the first day after surgery.They did this intervention until they first defecation .
89455072|NCT04466319|No Intervention|Control arm|The individuals in the control group sat in a standard chair in the same time as the intervention group in the non-rocking chair.
89455073|NCT03192098|Experimental|Progressive|Patients will be dilated > 3mm and can be dilated up to 6mm in diameter
89455074|NCT03192098|Active Comparator|Conservative (rule-of-3)|Patients will be dilated according to the rule-of-3 (i.e. dilation of no more than 3mm in diameter)
89455075|NCT02290977|Experimental|Scheduled TACE-RT|RT will be delivered at two weeks after TACE for HCC combined PVTT.
89455076|NCT03186482|Active Comparator|Descovy® (TAF/FTC)|"ATC Code J05AR17. Pharmaceutical form (use standard terms): Film-Coated Tablet Specific paediatric formulation?: No. Maximum duration of treatment of a subject according to the protocol: 56 days.~Maximum dose allowed 200mg/25mg per day. Total dose 200/25mg. Oral Use."
89455077|NCT03186482|Active Comparator|Viread® (TDF)|"ATC Code J05AF07. Pharmaceutical form (use standard terms): Film-Coated Tablet. Specific paediatric formulation?: No. Maximum duration of treatment of a subject according to the protocol 28 days.~Maximum dose allowed: 245mg per day. Total dose: 245mg. Oral Use."
89455078|NCT03186482|Active Comparator|Rifadin® (Rifampicin)|"ATC Code J0AB02 Pharmaceutical form (use standard terms): Capsule, Hard. Specific paediatric formulation?: No. Maximum duration of treatment of a subject according to the protocol 28 days.~Maximum dose allowed: 600mg per day. Total dose: 600mg. Oral Use."
89455079|NCT03522363|Experimental|Monodose group|1 vial with 4E10 CFU/g Total dose treatment: 4E10 CFU
89455080|NCT03522363|Experimental|Multidose group|7 vials with 5,5E09 CFU/g Total dose treatment: 4E10 CFU
89455081|NCT03186092|Active Comparator|Intervention Group|inspiratory muscle training with load
89455082|NCT03186092|Sham Comparator|Control Group|unloaded inspiratory muscle training
89455083|NCT02436278||IPF_MORT|Patients diagnosed with Idiopathic Pulmonary Fibrosis according to NICE guidelines.
89455084|NCT03522207|Experimental|Trazo1|After a baseline polysomnography (PSG), subject will receive 100 mg of trazodone 30 minutes prior to their 2nd PSG and will receive 100mg Placebo 30 minutes prior to their 3rd PSG.
89455085|NCT03522207|Experimental|Trazo2|After a baseline polysomnography (PSG), subject will receive 100 mg of placebo 30 minutes prior to their 2nd PSG and will receive 100mg trazodone 30 minutes prior to their 3rd PSG.
89455086|NCT03186248|Experimental|Short myotomy|Per oral endoscopic myotomy extending from 3 cm cephalad to 3 cm distal to EGJ
89455087|NCT03186248|Active Comparator|Long myotomy|Per oral endoscopic myotomy extending from 6-8cm cephalad to and 3 cm distal to EGJ.
89455088|NCT03528057|Active Comparator|Group 1|Patients undergoing RALPN with the use of HAs by a surgeon.
89455089|NCT03528057|No Intervention|Group 2|Patients undergoing RALPN without the use of HAs by a surgeon
89455090|NCT03527979|Active Comparator|PCOS women with history of LOD before IVF/ICSI|
89455091|NCT03527979|Active Comparator|PCOS women without history of drilling|
89455092|NCT03627377|No Intervention|Control Phase|3-month initial control phase (no intervention, month 1-3)
89455093|NCT03627377|Experimental|Intervention Phase|6-month intervention phase - MIDAS Intervention Delivered. Followed by 6-month follow-up phase (no intervention, months 10-15).
89455094|NCT02707952|Experimental|Arm A|ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) once daily (QD) for 8 weeks in HCV genotype(GT)1 -infected, DAA treatment-naïve participants without cirrhosis.
89455095|NCT02707952|Active Comparator|Arm B|Ombitasvir (25 mg)/paritaprevir (150 mg)/ritonavir (100mg) (OBV/PTV/r) QD for 12 weeks in HCV GT1 infected, DAA treatment-naïve participants without cirrhosis.
89455096|NCT02707952|Experimental|Arm C|ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120mg) QD for 12 weeks in HCV GT1- or GT2-infected participants with compensated cirrhosis, HCV GT3-, 4-, 5- and 6-infected participants (with compensated cirrhosis or without cirrhosis), HCV GT1- and GT2-infected participants who had failed prior DAA treatments (with compensated cirrhosis or without cirrhosis), and HCV GT1- or GT2-infected participants with severe renal impairment and compensated cirrhosis.
88939681|NCT01841853|Experimental|Senior meetings|The intervention will comprise four weekly meetings in small groups (4-6 participants) in addition to an individual follow-up home visit two to three weeks after the last senior meeting.The main purpose of the senior meetings is to give information and facilitate discussion of the ageing process and provide tools and suggest strategies to enable the clients to solve the various problems that may arise at home in order to remain living at home in a safe and secure way. The information will also include what the municipality provides in the form of local meeting places, activities run by local associations, physical training for seniors, walking groups, possibilities of offering or accepting help on a voluntary basis. Furthermore, they will be informed about help and support available in their city district. Identification of risks for, and advice on, how to prevent falls will also be included.
88939682|NCT01841853|No Intervention|Control group|The control group will receive conventional care on their own initiative.
89455097|NCT02707952|Experimental|Arm D|ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 8 weeks in GT1- or GT2-infected participants with severe renal impairment and without cirrhosis.
88939683|NCT01841866|Active Comparator|deep anesthetic state|LMA removal
88939684|NCT01841866|Placebo Comparator|awake|LMA removal
89455098|NCT05706155|Active Comparator|Control|Hypocaloric diet with predominance of animal protein
89455099|NCT05706155|Experimental|Intervention|Hypocaloric diet with predominance of plant protein
89455100|NCT05552573|Experimental|Low-dose vaccine(18-59 years)|3 doses of LYB001 or Recombinant COVID-19 Vaccine (CHO Cell) at the immunization schedule of 0, 28, 56 days. Vaccination or positve-controlled group will be randomly assigned to receive in a 4:1 ratio.
89455101|NCT05552573|Experimental|Low-dose vaccine(60 years old and above)|3 doses of LYB001 or Recombinant COVID-19 Vaccine (CHO Cell) at the immunization schedule of 0, 28, 56 days. Vaccination or positve-controlled group will be randomly assigned to receive in a 4:1 ratio.
89455102|NCT05552573|Experimental|High-dose vaccine(18-59 years)|3 doses of LYB001 or Recombinant COVID-19 Vaccine (CHO Cell) at the immunization schedule of 0, 28, 56 days. Vaccination or positve-controlled group will be randomly assigned to receive in a 4:1 ratio.
89455103|NCT05552573|Experimental|High-dose vaccine(60 years old and above)|3 doses of LYB001 or Recombinant COVID-19 Vaccine (CHO Cell) at the immunization schedule of 0, 28, 56 days. Vaccination or positve-controlled group will be randomly assigned to receive in a 4:1 ratio.
88939685|NCT01841879|Experimental|Intervention Program|Receives the full Healthy, Safe, and Tobacco-Free Worksites intervention
88939686|NCT01841879|Other|Delayed Intervention Control|Receives abbreviated 2-month delayed intervention designed to provide employees with knowledge and skills to quit tobacco after final data collection time point, as well as one non-tobacco event in between data collection points.
88939687|NCT01841892|No Intervention|Usual Care Control|
88939688|NCT01841892|Experimental|Community Therapeutic Workplace|Participants will be enrolled in Phase 1 training for 4 months, and will then be offered to apply for employment with collaborating community employers.
88939689|NCT01841905||Observational Study|Pre-Symptomatic Alzheimers' Disease
88939690|NCT01841918|Experimental|A/17/turkey/Turkey/05/133 (H5N2)|100 participants will be admitted in the isolation ward for 5 days after each immunization mainly for safety assessment. Two doses of live attenuated influenza H5 vaccine candidate strain A/17/turkey/Turkey/05/133 (H5N2) will be given by intranasal route 28 days apart and will be followed for the total of 60 days.
88939691|NCT01841918|Placebo Comparator|Placebo|50 participants will be admitted in the isolation ward for 5 days after each administered placebo mainly for safety assessment. Two doses placebo will be given by intranasal route 28 days apart and will be followed for the total of 60 days.
88939692|NCT01841944|Active Comparator|Pikasol|Pikasol®, 3 capsules (1.8 g EPA+DHA)/day
89455104|NCT03189056||Single cohort|"single cohort for transversal study patients presenting chronic chagas disease for all patients : clinical examination/questionnaires/ quality of life/ blood sample for renal function (creatinina) and Chagas serology control if needed/ uroflowmetry/ ultrasonography~If symptomatic patient at first exploration : urodynamic exploration is proposed (cystomanometry, urethral profile, pressure/flow study). No electromyograma. No video urodynamic procedure."
89455105|NCT03189368||Heart failure patients eligible for CRT|"Adult, consenting patients with any cardiomyopathy type and an existing I/IIa indication for a CRT-D device will receive a device with multi-site pacing capability. Initially, for 6 months, optimal, conventional, resynchronization therapy will be delivered. Following this, all patients will crossover to optimized multi-site pacing, and receive this therapy for 6 more months. Optimization of therapy will be determined based on maximization of cardiac output, i.e. maximization of left ventricular outflow tract velocity-time integral.~Baseline measurements of serum creatinine and ventriculoarterial coupling will also be acquired."
88939693|NCT01841944|Placebo Comparator|Corn oil|3x capsules of corn oil pr day
88939694|NCT01841983|Experimental|Intervention|Be Well Work Well
88939695|NCT01841983|No Intervention|Control|No intervention
88939696|NCT01841996|Experimental|ME1111 solution|
88939697|NCT01841996|Placebo Comparator|Vehicle Solution|
88939698|NCT01842009|Experimental|Active anodal HD-tDCS|Subjects will undergo 20 minutes active HD-tDCS.
88939699|NCT01842022|Other|Better glucose tolerance|Take meals with isomaltulose, sucrose or glucose
88939700|NCT01842022|Other|Better glucose tolerance / Levels fall|Take meals with isomaltulose, sucrose or glucose
88939701|NCT01842022|Other|Poorer tolerance levels remain high|Take meals with isomaltulose, sucrose or glucose
88939702|NCT01842022|Other|Poorer glucose tolerance / Levels fall|Take meals with isomaltulose, sucrose or glucose
88939703|NCT01842048|Experimental|External-beam radiotherapy combine hyperthermia|Hyperthermia 42℃ ± 0.5℃ for 40min, 2 times/week within 2hr after irradiation. Radiation protocol are 3Gy 5 times a week for a total of 30Gy/10fx/2 weeks
88939704|NCT01842048|Active Comparator|External-beam radiotherapy alone|External-beam radiotherapy alone comprising 30Gy/10 fractions, 5 times a week, administered with 2 weeks.
88939705|NCT01842074|Experimental|Bortezomib|Pilot study on the efficacy and safety of bortezomib during desensitization before a living kidney donation
88939706|NCT01842087|Placebo Comparator|Control Foods|For a period of 2 weeks, participants will consume control foods in addition to their usual diets.
88939707|NCT01842087|Experimental|Fiber Fortified Foods|For a period of 4 weeks, participants will consume food fortified with fiber in addition to their usual diets.
88939708|NCT01842100|Active Comparator|Universal antibiotic prophylaxis|In the universal prophylaxis group, all women received doxycycline 100 mg twice daily for 7 days starting on the day of induced abortion. Screening for sexually transmitted diseases was done as baseline but the results were not revealed to the patients.
88939709|NCT01842100|Active Comparator|Screen-and-treat|In the screen-and-treat group, the results of screening for sexually transmitted infections (STI) were revealed to the patients. They would only receive appropriate specific antibiotics treatment only if they were screened positive for any of the STIs. If they were found to have STI, their sexual partners would also be referred to the local social hygiene clinics for contact tracing and treatment. Contraception by barrier methods would also be advised.
88939710|NCT01842113|Active Comparator|Lactulose and Rifaximin Placebo|Standard portal hypertension care, standard nutritional advice, Lactulose 30ml three times a day and Rifaximin (Xifaxan) Placebo twice a day.
88939711|NCT01842113|Active Comparator|Rifaximin and Lactulose Placebo|Rifaximin (Xifaxan) twice a day and Lactulose Placebo three times a day.
88939712|NCT01842126|Experimental|Single Ascending Dose (SAD): BG00010|Up to five cohorts of healthy volunteers will receive a single dose of intravenous (IV) BG00010 followed by a single SC dose of BG00010 2 weeks apart.
88939713|NCT01842126|Experimental|SAD: Placebo|Up to five cohorts of healthy volunteers will receive a single IV dose of placebo followed by a single SC dose of placebo 2 weeks apart.
88939714|NCT01842126|Experimental|Multiple Ascending Dose (MAD): BG00010|Up to 6 cohorts of participants with painful lumbar radiculopathy will receive 3 SC doses of BG00010.
88939715|NCT01842126|Experimental|Multiple Ascending Dose (MAD): Placebo|Up to 6 cohorts of participants with painful lumbar radiculopathy will receive 3 SC doses of placebo.
88939716|NCT01842139|Experimental|Arm A (vaccine with Montanide)|Patients receive WT1 126-134 peptide vaccine emulsified in Montanide ISA 51 VG SC on day 0 and then once every 2 weeks.
88939717|NCT01842139|Experimental|Arm B (vaccine with poly-ICLC)|Patients receive WT1 126-134 peptide vaccine in poly-ICLC SC on day 0 and then once every 2 weeks.
88939718|NCT01842139|Experimental|Arm C (vaccine therapy, monoclonal antibody)|Patients assigned to Arm C receive basiliximab IV over 30 minutes on day -7 and WT1 126-134 peptide vaccine as in Arm A or Arm B, whichever had a superior cellular immune response.
88939719|NCT01842178|Experimental|scratching|"Patients will have an endometrial injury done on purpose, between 18-24 days prior to IVF cycle with a transfer catheter on the surgery outpatient department.~Endometrial Injury~Done between 18-24 days prior to embryo transfer cycle.~Using transfer catheter.~Introduction of the same to the uterine fundus.~Systematic scrapping of the four uterine walls, lengthwise.~Performed by a skilled doctor.~Subsequent ultrasound control"
88939720|NCT01842178|Placebo Comparator|scratching simulation|Patients will come to control visit between day 18-24. A scratching simulation will be done.
88939721|NCT01842191|Experimental|Fish oil|
88939722|NCT01842191|Placebo Comparator|Placebo|
88939723|NCT01842217|Other|Premenopausal women|healthy female subjects: premenopausal
88939724|NCT01842217|Other|Postmenopausal women|healthy female subjects: postmenopausal
88939725|NCT01842230|Experimental|Telmisartan 80mg, S-amlodipine 5mg and Atorvastatin 40mg|
88939726|NCT01842230|Active Comparator|Telmisartan 80mg and S-amlodipine 5mg|
88939727|NCT01842243|Active Comparator|Apical Pacing|Pacemaker programmed to pacing the heart at apex for 9 months.
88939728|NCT01842243|Active Comparator|Septal Pacing|Pacemaker programmed to pacing the heart at the septum for 9 months.
88939729|NCT01842256|Experimental|Telmisartan 80mg, S-amlodipine 5mg and Atorvastatin 40mg|
88939730|NCT01842256|Active Comparator|Atorvastatin 40mg|
89455106|NCT02291211|Experimental|S-1 plus cisplatin HIPEC|8 cycles of hyperthermic intraperitoneal chemotherapy (cisplatin) and S-1(oral) were performed after palliative operation gastric cancer of stage IV limited peritoneal metastasis. HIPEC was conducted in d1 and d3: Normal saline 2000ml-5000ml, Cisplatin 60mg/m^2, 43°C, 60min. every 3 weeks. S-1: 40-60mg/m^2 bid, days 1-14, every 3 weeks.Subjects should be given maximum 8 cycles, or progression/intolerance.
89455107|NCT03189290|Active Comparator|ropivacaine|"Active Comparator: ropivacaine group~- Before general anaesthesia, ultrasound guided Quadratus Lumborum Block (QLB) will be performed with 30 mL 0.33% Ropivacaine"
89455108|NCT03189290|Placebo Comparator|placebo|"Sham Comparator: saline group~- Before general anaesthesia, ultrasound guided Sham Quadratus Lumborum Block (QLB) will be performed with 30 mL saline."
89455109|NCT03627143|Other|Local implementation of AAFF guidelines|The study intervention will support local implementation of the CAEP AAFF Guidelines during the intervention periods of the trial. The investigators will identify behaviour change techniques and organization/system level strategies that could likely address identified barriers or enhance enablers.
89455110|NCT05392101|Experimental|Patient group: 360mg deferasirox|Patient group receiving treatment
89455111|NCT04951739||Achalasia cardia patients - post peroral endoscopic myotomy|All the patients who will undergo peroral endoscopic myotomy for the treatment of achalasia cardia patients.
89455112|NCT02291367|Experimental|Duloxetine Delayed-Release Capsules, 60 mg|
89455113|NCT02291367|Active Comparator|Cymbalta|Cymbalta® 60 mg capsule of Eli Lilly and Company
89455114|NCT03191474|No Intervention|Standard of Care Arm|Participants will receive standard of care HIV risk assessment, PrEP education, and an appointment for a PrEP evaluation visit at an affiliated clinic.
89455115|NCT03191474|Experimental|T-POWr Intervention Arm|Participants will receive the same HIV risk assessment, PrEP education, and appointment for a PrEP evaluation visit as the Control Arm. Participants in the Intervention Arm will also receive a thorough client-centered case management evaluation that will assess needs including access to health insurance, general health care, assessment of current hormone administration, housing, mental health care, domestic violence care, substance use treatment, and other services.
89455116|NCT02440958|Experimental|modified FOLFIRINOX|
89455117|NCT05587283|Experimental|Low dose LABTHERA-001 capsule|Low dose LABTHERA-001 capsule (0.2 x 10^9 CFU), administered intravaginally once a day for 7 consecutive days.
89455118|NCT05587283|Experimental|Medium dose LABTHERA-001 capsule|Medium dose LABTHERA-001 capsule (1 x 10^9 CFU), administered intravaginally once a day for 7 consecutive days.
89455119|NCT05587283|Experimental|High dose LABTHERA-001 capsule|High dose LABTHERA-001 capsule (5 x 10^9 CFU), administered intravaginally once a day for 7 consecutive days.
89455120|NCT05587283|Placebo Comparator|Low dose Placebo capsule|Low dose Placebo (excipients of the study drug) capsule administered intravaginally once a day for 7 consecutive days.
89455121|NCT05587283|Placebo Comparator|Medium dose Placebo capsule|Medium dose Placebo capsule (excipients of the study drug) administered intravaginally once a day for 7 consecutive days.
89455122|NCT05587283|Placebo Comparator|High dose Placebo capsule|High dose Placebo capsule (excipients of the study drug) administered intravaginally once a day for 7 consecutive days.
89455123|NCT03186170|Experimental|SSA|"The investigators propose to assess one method of sperm selection based on the characteristics of spermatozoa recently introduced: Sperm Selection Assay, which used a gradient of concentration of progesterone to act as chemoatractant of spermatozoa of better quality. We will assess in vitro fertilization with two techniques (SSA versus traditional technique of swin up) as well as embryo development.~In this arm, the sperm selection for IVF will be performed by the new proposed technique of Sperm Selection Assay which consist to expose spermatozoa a progesterone quemoatractant Sperm selection via SSA technique"
89455124|NCT03186170|Active Comparator|control|"The investigators propose to assess one method of sperm selection based on the characteristics of spermatozoa recently introduced: Sperm Selection Assay, which used a gradient of concentration of progesterone to act as chemoatractant of spermatozoa of better quality. We will assess in vitro fertilization with two techniques (SSSA versus traditional technique of swin up for sperm selection) as well as embryo development.~In this arm, the sperm selection for IVF will be the traditional swin up technique with different Percoll gradient Sperm selection via traditional swin-up"
89455125|NCT02291757|Active Comparator|NEM brand eggshell membrane|Subjects will be given enough treatment capsules or placebo capsules for 30-days after initial assessment, covering both the 7- and 30-day follow-up visits.
89455126|NCT02291757|Placebo Comparator|Placebo|Subjects will be given enough treatment capsules or placebo capsules for 30-days after initial assessment, covering both the 7- and 30-day follow-up visits. At the 30-day evaluation, patients in the placebo group will cross over to the treatment group for the remainder of the study and all patients will be given a 60-day supply of treatment capsules covering the 90-day follow-up visit.
88939731|NCT01842269|Experimental|My-Rept® Tablet|My-Rept® Tablet, Mycophenolate Mofetil 500mg, orally
89455127|NCT02440802||Gonadoliberin antagonist treatment|Single arm study, all patients are treated the same way. Saliva sample collection for genetic analyses.
89455128|NCT05581277|Active Comparator|Active Comparator: 6 days before intervention|Participants have to complete a pre-treatment assessment (baseline) for 6 days.
89455129|NCT05581277|Active Comparator|Active Comparator: 8 days before intervention|Participants have to complete a pre-treatment assessment (baseline) for 8 days.
88939732|NCT01842269|Active Comparator|My-Rept® Capsule|My-Rept® Capsule, Mycophenolate Mofetil 250mg, orally
88939733|NCT01842295|No Intervention|Bariatric surgery|Obese men with associated co-morbidities selected for bariatric surgery by multidisciplinary team
88939734|NCT01842321|Experimental|Abiraterone Acetate|
88939735|NCT01842347|Experimental|Pediatrics, C. Diff.|Fecal Microbiota Transplantation in children with c. difficile infection
89455130|NCT05581277|Active Comparator|Active Comparator: 10 days before intervention|Participants have to complete a pre-treatment assessment (baseline) for 10 days.
89455131|NCT02440724|Experimental|winged stent group|participants who are assigned to winged-stent group will be treated with deployment of a winged stent(partially covered or uncovered SEMS).
89455132|NCT03117608|Experimental|AUTOLOGOUS MICRO-FRAGMENTED ADIPOSE TISSUE (aMAT)|injection of aMAT obtained with Lipogems® technology.
88939736|NCT01842373|Experimental|LMX4|3 g of LMX4 will be applied to one half of the face for 60 minutes
88939737|NCT01842373|Active Comparator|BLT|3 g of BLT will be applied to half of face for 60 minutes
88939738|NCT01841645|Other|CLA depletion-repletion|
88939739|NCT01842412||claudication|
88939740|NCT01842412||healthy|
88939741|NCT01842477|Experimental|Implantation surgery|All the patients will have the implantation surgery. This trial is a one-arm study.
88939742|NCT01842503|Active Comparator|GET 73|300 mg (3 capsules) tid for 3 days
88939743|NCT01842503|Placebo Comparator|inactive ingredients capsule|3 capsules tid for 3 days
88939744|NCT01842516|Experimental|LCB01-0371 800mg|LCB01-0371 800mg
88939745|NCT01842516|Experimental|LCB01-0371 1200mg|LCB01-0371 1200mg
88939746|NCT01842516|Placebo Comparator|Placebo|Placebo
88939747|NCT01842529|Active Comparator|CABG+ Botulinum toxin|All patients underwent conventional CABG. After the main stage of the surgery botulinum toxin (Xeomin, incobotulinumtoxin A, Merz Pharma GmbH & Co KGaA, Germany; 50 U/1 mL at each fat pad; botulinum toxin group) was injected into the entire four visible area of the major epicardial fat pads. First epicardial left atrial fat pad is located anterior to the right superior pulmonary vein and corresponding to the anterior right GP; second epicardial fat pad is located inferoposterior to the right inferior pulmonary vein and corresponding to the inferior right GP; third fat pad is located anterior to the left superior PV and left inferior PV (between the PVs and LAA), corresponding to the Marshall tract GP and superior left GP; forth fat pad located inferiorly to the left inferior PV and extends posteriorly and corresponding to the inferior left GP.
88939748|NCT01842529|Active Comparator|Control|All patients underwent conventional CABG. After the main stage of the surgery 0.9% normal saline (1 mL at each fat pad; placebo group) was injected into the entire four visible area of the major epicardial fat pads. First epicardial left atrial fat pad is located anterior to the right superior pulmonary vein and corresponding to the anterior right GP; second epicardial fat pad is located inferoposterior to the right inferior pulmonary vein and corresponding to the inferior right GP; third fat pad is located anterior to the left superior PV and left inferior PV (between the PVs and LAA), corresponding to the Marshall tract GP and superior left GP; forth fat pad located inferiorly to the left inferior PV and extends posteriorly and corresponding to the inferior left GP.
88939749|NCT01842542|Experimental|Transcranial Magnetic Stimulation (TMS)|"Patients will receive NeuroStar Transcranial Magnetic Stimulation (TMS) therapy treatments 5 times a week for up to 8 weeks during the acute phase, 3 times during the first week, 2 times during the second week and 1 time during the third week of the taper phase.~Efficacy Assessments will be conducted throughout the acute and taper phase at protocol specific timepoints."
88939750|NCT01842555||PDT registry patients|Any newly diagnosed lung or esophageal cancer that is being being treated with PDT at a participating institution.
88939751|NCT01842659|Experimental|Pregnant women requiring amniocentesis|Pregnant women requiring amniocentesis
88939752|NCT01842685|Experimental|Bladder Thermal Distention|Continuous irrigation of the bladder with warm saline (up to 45 Celsius) using a specific 3 ways catheter. The procedure will last 1 hour. Saline will be irrigated by the PelvixTT system.
88939753|NCT01842698|Experimental|ultrasoundguided paravertebral catheter|ultrasoundguided paravertebral catheter
88939754|NCT01842737|Experimental|Spinal Treatment|Participant receives High Velocity Low Amplitude Spinal Manipulation (HVLA) to the low back only from a doctor of chiropractic. Also receives focused palpation procedures to the low back paired with visual input of these procedures using a tablet computer. During a HVLA treatment, the study doctor will ask the participant to lie on their side on a treatment table. The doctor will make a quick and controlled push with their hand to slightly move joints in the low back. During palpation procedure, the doctor will touch several areas in the low back while asking questions about pain, tenderness and other sensations felt during this procedure. The participant will watch the doctor perform the palpation procedure in real time with a tablet computer.
88939755|NCT01842737|Active Comparator|Foot Massage|The doctor of chiropractic will perform a massage of each foot while the participant lies face up in a relaxed position on a treatment table. The procedure will last approximately 10-20 minutes including massage to the toes, heel, sole, and top of each foot.
88939756|NCT01842750|Experimental|Endorectal Balloon insertion|A cone Beam scan will be performed prior to balloon insertion and then again with balloon in situ. The scans will be compared to see if the organs are stabilised. Questionnaires will be completed by the radiographer and the patient.
88939757|NCT01842802|Experimental|Diode Laser Treatment Before Abdominoplasty|Patient will be treated with Diode Laser prior to abdominoplasty.
88939758|NCT01842802|Experimental|YAG Laser Treatment Before Abdominoplasty|Patients will be treated with YAG prior to abdominoplasty
88939759|NCT01842828|Active Comparator|Standard care plus electronic cigarettes|Standard care for smoking cessation plus electronic cigarettes
88939760|NCT01842828|Other|Standard care|Standard care for smoking cessation
88939761|NCT01842854||Patients with Chagas disease diagnosis|Diagnosis of Chagas disease in both forms: indeterminate and cardiac ones, with and without ventricular dysfunction.
88939762|NCT01842867||Patients with Chagas disease diagnosis|Diagnosis of Chagas disease in both forms: indeterminate and cardiac ones, with and without ventricular dysfunction.
88939763|NCT01842880||Patients with Chagas disease diagnosis|Diagnosis of Chagas disease in both forms: indeterminate and cardiac ones, with and without ventricular dysfunction.
88939764|NCT01842893|Experimental|Fentanyl / Placebo|After an open-label titration to identify an optimal dose, patients were randomized to 1 of 13 prespecified sequences of 9 tablets (6 fentanyl and 3 placebo)
88939765|NCT01842919|Other|Huntington patient|This group will perform Magnetic Resonance Imaging (MRI), kinesthetic test and psychological questionnaires before and after 8 months of dance lessons
88939766|NCT01842919|Other|Assisting Person|This group will perform MRI, kinesthetic test and psychological questionnaires before and after 8 months of dance lessons
88939767|NCT01842919|Other|Pilot subject|Healthy volunteers to set up the kinesthetic test
88939768|NCT01842932|Experimental|Phloroglucin & Placebo|Phloroglucin 20ml before examination & Placebo 1ml before examination
88939769|NCT01842932|Experimental|Cimetropium bromide & Placebo|Cimetropium bromide 1ml before examination & Placebo 20ml before examination
88939770|NCT01842945|No Intervention|Wait-list control|
88939771|NCT01842945|Experimental|Treatment with therapist contact|
88939772|NCT01842945|Experimental|Treatment without therapist contact|
88939773|NCT01842971|Experimental|two stage hepatectomy|the two stage hepatectomy is defined as a two step procedure: first step: hepatotomy with ligature of the right branch of the portal vein second step (one week after the first step): right hepatectomy
88939774|NCT01842984|Experimental|I-SOCIAL intervention|Participants in this group will have up to 10 personal meetings with activities counselors and several group meetings.
88939775|NCT01842984|No Intervention|Control group|Participants in this group will not have meetings with the activities counselors, and will not take part in the group meetings.
88939776|NCT01842997|Experimental|split-virion, non-adjuvanted H1N1 vaccine of 15 μg|split-virion, non-adjuvanted H1N1 vaccine of 15 μg made by Shanghai Institute of Biological Products lot number: 200909008
88939777|NCT01843010|Active Comparator|Parecoxib|Intravenously Parecoxib 40mg at 30min before intubation, 8h and 20h after surgery.
88939778|NCT01843010|Placebo Comparator|Placebo|Normal saline 5ml will be intravenously infused at the same time points., respectively.
89201257|NCT00983164|Experimental|group III|group III - patients with hepatitis C treated weekly with pegylated interferon combined with daily ribavirin
89201258|NCT00769236|Other|1|Patients with crohn disease
89201259|NCT00769236|Other|2|Patients reached by hemorrhagic first side-colitis
89201260|NCT00769236|Other|3|Patients controls
88939779|NCT01843049|Experimental|radiotherapy+chemotherapy|"Radiotherapy:~LEVEL 1: dose given at PTV-G and PTV-C will be 64Gy/32 fractions and 50Gy/25 fractions.~LEVEL 2: dose given at PTV-G and PTV-C will be 63Gy/28 fractions and 50.4Gy/28 fractions.~LEVEL 3: dose given at PTV-GR (with an integrated boost to the 50% SUVmax area of the primary tumor of the pre-treatment 18FDG-PET/CT scan), PTV-G and PTV-C will be 70Gy/28 fractions, 63Gy/28 fractions and 50.4Gy/28 fractions.~LEVEL 4: dose given at PTV-GR (with an integrated boost to the 50% SUVmax area of the primary tumor of the pre-treatment 18FDG-PET/CT scan), PTV-G and PTV-C will be 70Gy/25 fractions, 62.5Gy/25 fractions and 50Gy/25 fractions.~Chemotherapy:~Concurrent chemotherapy: Cisplatin 25mg/m2 IV daily on Days 1-3 and 29-31 plus 5-FU 500mg/m2 IV continuous infusion over 24 hours daily on Days 1-4 and 29-32.~Consolidation chemotherapy: Cisplatin 25mg/m2 IV daily on Days 1-3 plus 5-FU 600mg/m2 IV daily on Days 1-5, cycled every 4 weeks for 2 cycles."
89455133|NCT03117608|Active Comparator|platelet-rich plasma (PRP)|single injection of platelet-rich plasma
89455134|NCT02432534|Experimental|UVB + treatement|The patients will be treated with the combination of oral atorvastatin and NBUVB phototherapy twice a week for 6 months.
89455135|NCT02432534|Other|UVB|The patients will be receiving only NB-UVB phototherapy twice a week for 6 months.
89455136|NCT02432612|Experimental|Sativex|Sativex will be administered by trained, clinical trial personnel, via a pump action oromucosal spray. Sativex will be administered as 2 actuations (sprays) under the tongue or inside the cheeks every 4 minutes until 6 sprays have been administered. Following the administration of the first and second set of 2 actuations, patients will be offered 50 mL water to drink; and following the final set of 2 actuations, 100 mL of water will be offered (i.e., a total of 200 mL water will be offered during the Sativex dosing). There must be a period of at least 2 minutes and no more than 3 minutes between Sativex administration and consumption of water. Patients will not be permitted their regular medication until 2 hours post dose of investigational medicinal product (IMP) to minimize any possible drug interactions.
89455137|NCT02432222|Experimental|Music Training|Music training
89455138|NCT02432222|Experimental|Visual Arts Training|Visual arts training
89455139|NCT02432222|No Intervention|Control|Waitlist control
88939780|NCT01843075|Experimental|Liraglutide|Daily administration of 1.8 mg liraglutide by subcutaneous injection
88939781|NCT01843075|Placebo Comparator|Placebo|Daily administration of matched placebo by subcutaneous injection
88939782|NCT01843088|Experimental|Mannitol cream|cream containing 25% mannitol, applied as often and as much as needed to one leg ( chosen at random), on the day of a 10 km run, following the run and for five days afterwards
88939783|NCT01843088|Placebo Comparator|Placebo cream|Same carrier cream as that containing the active ingredient, mannitol, but without the active ingredient. Placebo cream to be applied to the painful areas of the other leg, chosen at random, on the day of a 10 km or more race, following the race, and as needed for the five days after the race. It is to be noted that, as almost no mannitol is absorbed through the skin, it is highly unlikely that this would involve the pain levels in the placebo leg.
88939784|NCT01843101|Other|Healthy volunteers|10 healthy volunteers
88939785|NCT01843101|Other|Corneal Neovascularisation|5 patients with corneal neovascularisation
88939786|NCT01843101|Other|Keratoconus|5 patients with keratoconus
88939787|NCT01843114|Other|Patients with Type I Diabetes|24 patients with type I diabetes with no or mild non-proliferative retinopathy
88939788|NCT01843114|Other|Healthy subjects|24 healthy age-and sex- matched control subjects
88939789|NCT01843127|Active Comparator|Placebo, Ranolazine, Exenatide|
88939790|NCT01843127|Active Comparator|Ranolazine, Placebo, Exenatide|
88939791|NCT01843153|Other|intermittent|injection of ropivacaine on demand
88939792|NCT01843153|Other|continuous|continuous ropivacaine infusion
88939793|NCT01843166|Active Comparator|Treatment group|These patients will utilize a pessary and be given instructions for use and prescription for Premarin vaginal cream 2g at bedtime twice weekly.
88939794|NCT01843166|Placebo Comparator|Control group|These patients will utilize a pessary with an inactive placebo cream.
88939795|NCT01843179|Experimental|Sulindac Treatment Arm|Induction Chemotherapy followed by treatment with sulindac
88939796|NCT01843218|Other|Register R|Evaluation of erectile dysfunction in the management of localized rectal cancer
88939797|NCT01843231|Experimental|g-Cath EZ Treatment Group|Evaluate the safety and effectiveness of the g-CathTM EZ Suture Anchor Delivery Catheter as an early weight loss intervention
88939798|NCT01843231|Active Comparator|Diet and exercise Control Group|Diet and Exercise only control group
89201261|NCT00988936|Experimental|[F-18]RDG-K5|
89455140|NCT05705843|Active Comparator|Intravenous Vancomycin Administration|Patients will receive the Houston Methodist Hospital orthopedic surgery standard of care pre-operative antibiotic regimen for primary total knee arthroplasty patients. This includes IV antibiotics (typically ancef or cefepime and vancomycin) will be started in the pre-operative period approximately 1 hour prior to incision (vancomycin dose weight-based at approximately 15mg/kg [12,13] generally 1000-1750mg in 500mL NS).
89455141|NCT05705843|Experimental|Intraosseous Vancomycin Administration|"IV antibiotics (per physician's standard of care): Typically ancef or cefepime is started in pre-op within 1 hour of incision. IV Vancomycin will not be administered preoperatively in this group.~IO vancomycin is administered via an intraosseous cannulation device (Arrow EZ-IO; Teleflex, Morrisville, NC) in the OR after sterile prep and draping has occurred prior to skin incision (500mg in 150mL NS).~Injection will take place into the tibial tubercle (within a pre-specified region) immediately prior to incision."
89455142|NCT02435888||Polycystic ovary syndrome|
89455143|NCT02435732|Placebo Comparator|Control group|Standard donor management + vehicle treatment (n=9)- placebo saline solution
89455144|NCT02435732|Experimental|CINRYZE 200 U/Kg IV|Intervention is CINRYZE 200 U/Kg IV single dose
89455145|NCT02435732|Experimental|200 units/kg IV CINRYZE with Heparin 20 U/kg/h IV|CINRYZE 200 units/kg IV single dose with Heparin at 20 units/kg/h IV maintenance until organ recovery
89455146|NCT02435654|Experimental|Treatment group|All EOS patients will receive olanzapine treatment with flexible dose(2.5 to 20 mg/day)according to standard body weight,olanzapine will be initiated at 2.5 or 5 mg/day and the dose could be increased by 2.5 or 5 mg/day dose increments at the investigator's discretion.A effective dose would be titrated in two weeks with no tolerability or safety issues are apparent,the investigator could decrease the dose at any time and in any number of dose decrements if patients experienced an adverse event.
89455147|NCT02435498|Experimental|Interactive website|The interactive website called Online User Centered Home Pain Management for Fractures (OUCH PMF) will cover 4 domains of knowledge: 1. Fracture-related pain 2. Analgesic dosing regimens 3. Indications, risks and safety of analgesia in children 4. Signs and symptoms of pain in children
89455148|NCT02435498|Active Comparator|Video|The online video will contain the same information within the website.
89455149|NCT02435498|Active Comparator|Standard of care|Standard of care includes a pamphlet with cast care instructions and verbal instructions on caring for the child at home.
89455150|NCT02440490|Experimental|Computerised cognitive training|The cognitive training protocol will be run using pre-validated software, HappyNeuronPro, that delivers cognitive training games. The games are designed to be visually interesting and engaging, and are varied so that each session will comprise multiple different games, to avoid boredom. They begin with easy-to-follow instructions and demonstrations, then as the participant progresses, the difficulty is automatically increased in correspondence with their performance, to avoid ceiling or plateau effects. Participants will be assigned a program targeting multiple facets of cognition found to be compromised in chronic pain states, including divided attention, working memory, mentally planning a sequence of items to form a pattern or complete a puzzle, and response inhibition.
89455151|NCT02440490|Active Comparator|Video watching|This group will be provided with a variety of videos to watch, the content of which will be in the style of documentaries on general interest topics such as nature, travel, culture, and history. Each video is followed by multiple-choice questions that participants will answer, to ensure attention was engaged. The videos are visually stimulating and engaging, but involve no increment in difficulty or requirement to improve skills. They may provide some distraction from pain and may be relaxing, interesting and informative.
89455152|NCT03186014|Experimental|Fully covered irradiation stent|A esophageal fully covered segmented irradiation stent loaded with 125I seeds is placed in Patients with malignant dysphagia
89455153|NCT02440412|Experimental|Massage Therapy|A 45 minutes massage therapy (manual) standardized session, based in Swedish techniques.
88939799|NCT01843257||Gastric Bypass longitudinal|Morbidly obese subjects undergoing gastric bypass surgery. Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion before surgery. The two testing sessions will be repeated ~ 9 months after surgery.
89455154|NCT02440412|Placebo Comparator|Rest condition|45 minutes of rest in supine position, listening music with headphones, and warm condition.
89455155|NCT02440412|No Intervention|Control|Normal working condition, as a office workers (secretaries and managements employees)
89455156|NCT05293535||Klotho|"Evaluate the expression of Klotho in gastric adenocarcinoma via immunohistochemistry, find the association between the expression of Klotho in gastric adenocarcinoma and demographic patient data, and clinicopathologic parameters of the patients and investigate the effect of Klotho expression on the prognosis of gastric adenocarcinoma.~Correlate between the Klotho and LRP-6 protein expression."
89455157|NCT05293535||LRP-6|"Evaluate the expression of LRP-6 protein in gastric adenocarcinoma via immunohistochemistry, find the association between the expression of LRP-6 protein in gastric adenocarcinoma and demographic patient data, and clinicopathologic parameters of the patients and investigate the effect of LRP-6 protein expression on the prognosis of gastric adenocarcinoma.~Correlate between the Klotho and LRP-6 protein expression."
89455158|NCT02435420||EMPERION Modular Primary Stem subjects|All subjects have previously been implanted with the EMPERION Modular Primary Stem for primary total hip arthroplasty.
89455159|NCT02435342|Experimental|30ug dalazatide|12 subjects, 10 given active agent and 2 given placebo by subcutaneous injection twice weekly for 4 weeks.
89455160|NCT02435342|Experimental|60ug dalazatide|12 subjects, 10 given active agent and 2 given placebo by subcutaneous injection twice weekly for 4 weeks.
89455161|NCT03185858|Experimental|SINEMA intervention group|The intervention arm will implement the SINEMA model for one year, which consists of a provider-facing intervention aiming to strengthen the capacity of village doctors in delivering stroke secondary prevention, and a stroke survivor-facing intervention aiming to promote medication adherence and physical activity.
88939800|NCT01843257||Gastric Banding longitudinal|Morbidly obese subjects undergoing laparoscopic gastric banding surgery. Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion before surgery. The two testing sessions will be repeated ~ 9 months after surgery.
89455162|NCT03185858|No Intervention|Control group|Villages in the control arm continue their usual practice without the introduction of any of the SINEMA activities described above. People who have hypertension or who are at high-risk of hypertension may receive follow-up visits four times per year as part of the basic public health services required by the government.
89455163|NCT02432066|Active Comparator|GTS-21|Participants in the GTS-21 arm will receive 150 mg/BID GTS-21 over the course of 7 weeks. All participants will receive repeated neurobehavioral testing, laboratory assessment of cardiovascular and liver function, and provide weekly updates regarding smoking behavior, mood states, and side effects.
89201262|NCT00333775|Experimental|Docetaxel 100 mg/m^2 plus placebo|Participants received docetaxel 100 mg/m^2 intravenously on Day 1 of each 3 week cycle for a maximum of 27 weeks (9 cycles). In addition, participants received placebo to bevacizumab intravenously on Day 1 of each 3 week cycle until disease progression, unacceptable toxicity, or participant withdrawal.
89201263|NCT00333775|Experimental|Docetaxel 100 mg/m^2 plus bevacizumab 7.5 mg/kg|Participants received docetaxel 100 mg/m^2 intravenously on Day 1 of each 3 week cycle for a maximum of 27 weeks (9 cycles). In addition, participants received bevacizumab 7.5 mg/kg intravenously on Day 1 of each 3 week cycle until disease progression, unacceptable toxicity, or participant withdrawal.
89201264|NCT00333775|Experimental|Docetaxel 100 mg/m^2 plus bevacizumab 15.0 mg/kg|Participants received docetaxel 100 mg/m^2 intravenously on Day 1 of each 3 week cycle for a maximum of 27 weeks (9 cycles). In addition, participants received bevacizumab 15.0 mg/kg intravenously on Day 1 of each 3 week cycle until disease progression, unacceptable toxicity, or participant withdrawal.
89201265|NCT00771732|Experimental|1|Light therapy
89201266|NCT00771732|Sham Comparator|2|"6 minute session given with machine off"
89201267|NCT03860428|Active Comparator|Rectal ibuprofen|Early treatment of PDA that starts within the first 3 days of life using rectal ibuprofen q24h for 3 days, dosages: 20 mg/kg + 10 mg/kg + 10 mg/kg
89201268|NCT03860428|Active Comparator|Intravenous paracetamol|Early treatment of PDA that starts within the first 3 days of life using intravenous paraceta-mol 15 mg/kg q6h for 3 days
89201269|NCT03860428|Sham Comparator|Expectant Treatment|Expectant PDA management is characterized as 'watchful waiting'. No intervention is initiated with the intention to close a PDA unless defi-nitely needed based of the predefined infant's condition.
89201270|NCT02557074|Experimental|IL2 - Group A|"Patient will received IL2 low doses (1.5 to 3MUI/d) -~IL2 1.5MUI/d SC from day 1 to day 5 for the first course of treatment~IL2 3MUI/d SC from day 1 to day 5 for the 3 following courses"
89201271|NCT02557074|Placebo Comparator|Placebo - Group B|NaCl 9% serum (placebo) NaCl 9% serum SC from day 1 to day 5 for the four courses of treatment
89201272|NCT00771888|Other|1|lanreotide
89201273|NCT00989170|Experimental|Family Program for the Prevention of Weight Gain|Use of an enhanced Family Program on the prevention of weight gain in families with overweight children.
89201274|NCT00989170|Active Comparator|No enhanced Family Program|
89201275|NCT00771966|Placebo Comparator|Standard treatment|
89201276|NCT00771966|Active Comparator|SV maximization|
89201277|NCT00605475|Experimental|Canakinumab|"Eligible participants were assigned to receive canakinumab in one of four cohorts; 1) Single IV infusion of canakinumab 0.3 mg/kg; 2) Singe IV infusion of canakinumab 10 mg/kg; 3) single IV infusion of canakinumab 0.1 mg/kg or 0.3 mg/kg, or 1.5 mg/kg; 4) Single IV injection of canakinumab 0.03 mg/kg.~All participants were required to take a concomitant stable daily dose of metformin during the study."
89201278|NCT00605475|Placebo Comparator|Placebo|"Eligible participants were assigned to receive placebo to canakinumab in one of four cohorts; 1) Single IV infusion of placebo to canakinumab 0.3 mg/kg; 2) Singe IV infusion of placebo to canakinumab 10 mg/kg; 3) single IV infusion of placebo to canakinumab 0.1 mg/kg or 0.3 mg/kg, or 1.5 mg/kg; 4) Single IV injection of placebo to canakinumab 0.03 mg/kg.~All participants were required to take a concomitant stable daily dose of metformin during the study."
89201279|NCT00986596|Active Comparator|vitamin D3|vitamin D3 capsule 4000 IU p.o. daily
89201280|NCT00986596|Placebo Comparator|placebo|microcrystalline cellulose capsule p.o. daily (identical to vitamin D capsule)
89201281|NCT00772044|Active Comparator|Provent|Those receiving the active device
89201282|NCT00772044|Sham Comparator|Sham|Those receiving sham device
89201283|NCT00333619|Experimental|Nonpharmacological sleep intervention|The intervention will combine: 1) structured sleep assessment, 2) environmental interventions (efforts to increase bright light exposure, decrease daytime in-bed time, and provide a structured bedtime routine), and 3) elements of cognitive-behavioral strategies.
89201284|NCT00333619|Active Comparator|Active control|Daily 15-minute social visit from a research assistant. The visits include structured activities to facilitate social interaction (e.g., memory games, current event discussions).
89201285|NCT00986752|Active Comparator|Stenting|Due to randomization one nitinol stent will be implanted after dilation with a conventional balloon.
89201286|NCT00986752|Experimental|Stenting after PEB|Due to randomization one nitinol stent will be implanted after dilation with a Paclitaxel eluting balloon.
89201287|NCT00986752|Experimental|Atherectomy|The third randomization arm is Atherectomy.
89201288|NCT00772122|Experimental|Granulocyte colony stimulating factor|The G-CSF group of 35 women, underwent a daily sub-cutaneous administration of the filgrastim (Neupogen, Dompe', Italy), the recombinant G-CSF, at a dosage of 1 micro gram (100000 IU)/kg/day from the 6th day after ovulation till the occurrence of menstruation or to the end of the 9th week of gestation.
89201289|NCT00772122|Placebo Comparator|placebo (saline solution)|The placebo group consisting of 33 subjects, was given a treatment with saline solution at the 0.2ml/day subcutaneously/, from the 6th day after the ovulation till to the recurrence of menstrual loss or to the end of the 9th week.
89201290|NCT04006678|Experimental|computer guided sandwich osteotomy|segmental sandwich osteotomy will be done for vertically deficient ridges in anterior area of the maxilla. Either using surgical guides (Computer guide segmental sandwich osteotomy technique) for study group and conventional segmental sandwich osteotomy technique for control group.
89201291|NCT04006678|Active Comparator|conventional sandwich osteotomy|:conventional segmental sandwich osteotomy will be done for vertically deficient ridges in anterior area of the maxilla.
89201292|NCT00769470|Active Comparator|Arm I|Patients receive trastuzumab IV over 90 minutes on day in course 1. Patients receive docetaxel IV, carboplatin IV, and trastuzumab IV over 30 minutes on day 1 in course 2-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89455164|NCT02432066|Placebo Comparator|Placebo|Participants in the Placebo arm will receive placebo compound twice daily over the course of 7 weeks. All participants will receive repeated neurobehavioral testing, laboratory assessment of cardiovascular and liver function, and provide weekly updates regarding smoking behavior, mood states, and side effects.
89455165|NCT02435030||NP-C Patients|NPC type 1 or 2 patients aged 2-18 years
89455166|NCT03050801|Experimental|Parietal Cortex rTMS stimulation - 1 day|Experiment 1
89455167|NCT03050801|Experimental|Parietal Cortex rTMS stimulation - 3 days|Experiment 1
89455168|NCT03050801|Experimental|Parietal Cortex rTMS stimulation - 4 days|Experiment 1
89201293|NCT00769470|Experimental|Arm II|Patients receive oral lapatinib ditosylate once daily on days 1-21 in course 1. Patients receive docetaxel IV and carboplatin IV on day 1 and oral lapatinib ditosylate once daily on days 1-21 in courses 2-7.Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89201294|NCT00769470|Experimental|Arm III|Patients receive trastuzumab IV over 90 minutes on day 1 and oral lapatinib ditosylate daily on days 1-21. Starting on day 22, patients receive docetaxel IV, carboplatin IV, and trastuzumab IV three times a week and oral lapatinib ditosylate once daily on days 1-21 in courses 2-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89455169|NCT03050801|Experimental|Experiment 2 - Parietal Cortex rTMS stimulation - 3 days|Experiment 2
89455170|NCT03050801|Experimental|Experiment 2 - Vertex rTMS stimulation - 3 days|Experiment 2
89455171|NCT03050801|Experimental|Experiment 2 - Prefrontal Cortex rTMS stimulation - 3 days|Experiment 2
89455172|NCT03191318|Active Comparator|ERAS pathway|Laparoscopic sleeve gastrectomy with ERAS pathway
89455173|NCT03191318|Active Comparator|Standard pathway|Laparoscopic sleeve gastrectomy with standard pathway
89455174|NCT03190850|Experimental|Intervention|"Intervention: Exercises wih load Device: Powerbreathe"
89455175|NCT03190850|Placebo Comparator|Control|Control: Exercises without load
89455176|NCT03191006|Active Comparator|study group: MEI BIN insoles|Participants in the study group will be prescribed with a pair of customized insoles (MEI BIN) to keep the subtalar joint in neutral position, for 12 weeks.
89455177|NCT03191006|No Intervention|control group: without MEI BIN insoles|Participants in this control group will not receive a pair of customized insoles (MEI BIN) to keep the subtalar joint in neutral position, for 12 weeks.
89455178|NCT02431910|No Intervention|Control group|The control group remains at rest for 10 minutes, which is not applied KT in the RF, VL and VM muscles. The volunteers of this group perform all evaluation without the application of KT
89455179|NCT02431910|Placebo Comparator|Placebo group|The Kinesio Taping (KT) is applied on the vastus lateralis (VL), vastus medialis (VM) and rectus femoris (RF) muscles longitudinally from proximal to the distal. For the RF proximal anchor is applied 5cm below the anterior superior iliac spine and the distal anchor the upper edge of the patella. VL in the proximal and distal anchor will be fixed in greater trochanter of the femur and the lateral edge of the patella. As for the VM muscle proximal anchor will be applied to the middle third from the medial region of the thigh and the distal anchor on the medial edge of the patella. The anchors are applied with 0% tension and therapy area will follow on the belly of the muscles with a 0%.
89455180|NCT02431910|Experimental|Kinesio Taping group|The Kinesio Taping (KT) is applied on the vastus lateralis (VL), vastus medialis (VM) and rectus femoris (RF) muscles longitudinally from proximal to the distal. For the RF proximal anchor is applied 5cm below the anterior superior iliac spine and the distal anchor the upper edge of the patella. VL in the proximal and distal anchor will be fixed in greater trochanter of the femur and the lateral edge of the patella. As for the VM muscle proximal anchor will be applied to the middle third from the medial region of the thigh and the distal anchor on the medial edge of the patella. The anchors are applied with 0% tension and therapy area will follow on the belly of the muscles with a 50%. This application will be held with subjects standing on one foot, with the hip of the non-dominant limb at 0º and knee flexed at 90º.
89455181|NCT05233514|Experimental|Aerobic exercise group (AEM)|The AEM group performed aerobic exercise three times a week for 12 weeks in addition to Metformin treatment.
89455182|NCT05233514|Active Comparator|Metformin group (M)|The M group received Metformin only
89455183|NCT02431832|Experimental|Augmentin tab|
89455184|NCT02435186|Experimental|p53 gene plus chemotherapy|Intraperitoneal p53 gene plus cisplatin, and paclitaxel iv
89455185|NCT02435186|Active Comparator|chemotherapy|Intraperitoneal cisplatin, and paclitaxel iv
89455186|NCT03842657|Other|calcium-free citrate-containing dialysate|Dialysis session will be performed with a non-heparin grafted membrane, a dialysate without calcium (0 mmol/L) and citrate 0.8 mmol/L, a reinjection of a calcium solution (300 mM) according to the ionic dialysance, and no heparin addition
89455187|NCT03842657|Other|heparin-grafted membrane|dialysis session will be performed with a heparin-grafted membrane, a dialysate with calcium (1.65 mmol/L) and citrate 0.8 mmol/L, and no heparin addition
89455188|NCT02435108|Experimental|crizotinib arm|crizotinib medication
89455189|NCT02434952|Experimental|DHA PP plus primaquine, G6PD deficiency|"Standard Dihydroartemisinin piperaquine (DHA PP) dosing according to national guidelines, oral administration of one dose per day for three consecutive days. Target dosing is 2-4 mg/kg for DHA and 20 mg/kg for PP. Children (<30kg) will receive tablets of 20mg DHA and 160mg PP, while adults will receive tablets of 40mg DHA and 320mg PP.~Target dose of 0.25mg/kg primaquine given orally with first dose only of DHA PP, dosing by weight for children <18 years and standard 15mg primaquine dose for all adults ≥18 years. Small children (<25kg) will receive a primaquine suspension, adults receive 7.5mg or 15mg primaquine tablets."
89455190|NCT02434952|Active Comparator|DHA PP plus primaquine, G6PD normal|"Standard Dihydroartemisinin piperaquine (DHA PP) dosing according to national guidelines, oral administration of one dose per day for three consecutive days. Target dosing is 2-4 mg/kg for DHA and 20 mg/kg for PP. Children (<30kg) will receive tablets of 20mg DHA and 160mg PP, while adults will receive tablets of 40mg DHA and 320mg PP.~Target dose of 0.25mg/kg primaquine given orally with first dose only of DHA PP, dosing by weight for children <18 years and standard 15mg primaquine dose for all adults ≥18 years. Small children (<25kg) will receive a primaquine suspension, adults receive 7.5mg or 15mg primaquine tablets."
89455191|NCT02434952|Active Comparator|DHA PP alone, G6PD deficiency|Standard Dihydroartemisinin piperaquine (DHA PP) dosing according to national guidelines, oral administration of one dose per day for three consecutive days. Target dosing is 2-4 mg/kg for DHA and 20 mg/kg for PP. Children (<30kg) will receive tablets of 20mg DHA and 160mg PP, while adults will receive tablets of 40mg DHA and 320mg PP.
89455192|NCT02434952|Active Comparator|DHA PP alone, G6PD normal|Standard Dihydroartemisinin piperaquine (DHA PP) dosing according to national guidelines, oral administration of one dose per day for three consecutive days. Target dosing is 2-4 mg/kg for DHA and 20 mg/kg for PP. Children (<30kg) will receive tablets of 20mg DHA and 160mg PP, while adults will receive tablets of 40mg DHA and 320mg PP.
89455193|NCT03117842|Experimental|Intervention Group|Participants in the intervention group will receive the 3 text or voice messages weekly. The messages will be designed to enhance and increase utilization of existing HIV and SRH services by reminding clients about safe sex methods available to them and providing a conduit for additional support.
89455194|NCT03117842|No Intervention|Control Group|"Those in the control group will get one check-in text or voice message between baseline and midline and another between midline and endline."
89455195|NCT03626753|Active Comparator|Oral Group|"received in post operative period oral analgesia ( nefopam (Acupan) 20mg/6h, piroxicam (piroxan) 40mg/24h, Acetaminophen (paracetamol) 1g/6h)"
89015977|NCT05769647|Experimental|Ball Squeezing Group|"Volunteer Information and Approval Form will be filled.~Physician request, the name and surname of the individual will be checked.~Patient Information Form and State Anxiety Scale will be filled.~Patients will be given a ball and instructed to tighten and loosen with their free hand during IVC placement. The IV catheter insertion attempt will be made while the patient continues to squeeze the ball.~Visual Pain Scale and State Anxiety Scale will be filled within one minute after intravenous catheter placement is completed."
89015978|NCT05769647|No Intervention|Control Group:|"Volunteer Information and Approval Form will be filled.~Physician request, the name and surname of the individual will be checked.~Patient Information Form and State Anxiety Scale will be filled.~An intravenous catheter will be placed.~Visual Pain Scale and State Anxiety Scale will be filled within one minute after intravenous catheter placement is completed."
89015979|NCT05768217|Experimental|Community Resiliency Collective Efficacy Intervention (CRCEI)|Community Resiliency Collective Efficacy Intervention (CRCEI) to engage community members in dialogue on thriving, community leadership, and organizing for social change (9 sessions).
89015980|NCT05768217|Active Comparator|Health Education Sessions|Comparison neighborhoods will receive health education sessions as a control intervention. (9 sessions)
89015981|NCT05766683|Experimental|2mm depth|Subjects will be randomized using computer generated randomization list provided by PHS to receive onabotulinumtoxinA neurotoxin injections in the glabellar complex at depth of 2mm
89455196|NCT03626753|Active Comparator|Intravenous group|"received in post operative period intravenous analgesia ( nefopam (Acupan) 20mg/6h, piroxicam (piroxan) 40mg/24h, Acetaminophen (paracetamol) 1g/6h)"
89455197|NCT03117686||healthy volunteers|10 healthy volunteers climbing Mount Kilimanjaro receiving lung ultrasound
89455198|NCT03117686||patients after lung transplantation|10 patients > 2years after lung transplantation climbing Mount Kilimanjaro receiving lung ultrasound
89455199|NCT02431520|Experimental|Self-collection|Women allocated to this arm will be asked to obtain a specimen of vaginal/cervical by self-collection for Hybrid Capture II (HCII).
89455200|NCT02431520|Active Comparator|Gynecologist collection|Women allocated to this arm will be asked to attend to medical office to have their Pap smear obtained by a gynecologist
89455201|NCT03626675|Other|study group|"They will be subjected to:~Preoperative A-complete ophthalmic examination will be done for every patient; B- Biometric parameters measured with the AS-OCT C- Medical fitness for all patients D- Informed consent will be obtained from all patients after through explanation of operation and its potential benefits and risks.~Surgery combined Phaco trabeculectomy~Post operative:~-Follow-up examinations will be performed for every patient at 1day, 1 week, 1 and 3 months postoperatively.~and biometric parameters measured with the AS-OCT before and after the surgery will be used to collect the data.~-The data will be managed and analysed with confidentiality by scientifically qualified persons"
89455202|NCT02440256|Other|Cluster 1|Cluster 1 is the first OST cluster (with an estimated 15-16 OST sites) to receive the 'Expanded HIV care in Opioid Substitution Treatment' intervention, to be administered during the sixth month of the trial. Cluster 1 will be a 'no intervention' arm in the first 6 months of the study, and will cross-over to an experimental arm for months 6-24.
89455203|NCT02440256|Other|Cluster 2|Cluster 2 is the second OST cluster (with an estimated 15-16 OST sites) to receive the 'Expanded HIV care in Opioid Substitution Treatment' intervention, to be administered during the twelfth month of the trial. Cluster 2 will be a 'no intervention' arm in the first 12 months of the study, and will cross-over to a experimental arm for month 12-24.
89455204|NCT02440256|Other|Cluster 3|Cluster 3 is the final OST cluster (with an estimated 15-16 OST sites) to receive the 'Expanded HIV care in Opioid Substitution Treatment' intervention, to be administered during the 18th month of the trial. As such, Cluster 3 will be a 'no intervention' arm in the first 18 months of the study, and will cross-over to an experimental arm for months 18-24.
89455205|NCT05272085|Active Comparator|Ultrasound Guided Lavage Group|"The physical examination, pain scoring, functional scale, disability scale, special tests, direct radiography findings and ultrasonographic imaging findings of the patients in this group before the treatment and 1 month after the treatment will be evaluated and will be recorded. Size of calcific deposits and Gartner classification will be evaluated on direct radiography. Size, shape, acoustic shadowing, power doppler activity of calcific deposits and other bursitis, tendinitis, ruptures, effusion in the shoulder will be evaluated on ultrasonographic imaging.~Patients in this group will be treated with ultrasound-guided lavage."
89455206|NCT05272085|Active Comparator|Ultrasound Guided Subacromial Bursa Injection Group|"The physical examination, pain scoring, functional scale, disability scale, special tests, direct radiography findings and ultrasonographic imaging findings of the patients in this group before the treatment and 1 month after the treatment will be evaluated and will be recorded. Size of calcific deposits and Gartner classification will be evaluated on direct radiography. Size, shape, acoustic shadowing, power doppler activity of calcific deposits and other bursitis, tendinitis, ruptures, effusion in the shoulder will be evaluated on ultrasonographic imaging.~Patients in this group will be treated with ultrasound-guided subacromial bursa injection with corticosteroid and lidocaine."
89455207|NCT02431442|Active Comparator|Cohort 1: RM-493 SC Infusion 14 Days|Double-blind RM-493 will be administered at a dose of 0.01 mg/kg/24 hours via subcutaneous continuous infusion for 14 days (1 panel, all male subjects)
89455208|NCT02431442|Active Comparator|Cohort 2: RM-493 SC Infusion 28 Days|Double-blind RM-493 will be administered at a dose of 0.01 mg/kg/24 hours via subcutaneous continuous infusion for 28 days (1 panel)
89455209|NCT02431442|Active Comparator|Cohort 3: RM-493 SC Infusion 28 Days|Double-blind RM-493 will be administered at a dose of 0.01 mg/kg/24 hours via subcutaneous continuous infusion for 28 days (1 panel)
89455210|NCT02431442|Active Comparator|Cohort 4: RM-493 SC Infusion 28 Days|Double-blind RM-493 will be administered at a dose of 0.015 mg/kg/24 hours via subcutaneous continuous infusion for 28 days (1 panel)
89455211|NCT02431442|Active Comparator|Cohort 5: RM-493 SC Injection 14 days|Double-blind RM-493 will be administered at a dose of 0.0075 mg/kg every 12 hours via a subcutaneous injection for 14 days (1 panel)
89455212|NCT02431442|Active Comparator|Cohort 6: RM-493 SC Infusion 28 Days|Double-blind RM-493 will be administered at a dose of 0.01 mg/kg/24 hours via subcutaneous continuous infusion for 28 days (1 panel, heterozygous MC4R subjects)
89455213|NCT02431442|Placebo Comparator|Cohort 1: Placebo SC Infusion 14 Days|Double-blind Placebo will be administered via subcutaneous continuous infusion for 14 days (1 panel, all male subject)
89455214|NCT02431442|Placebo Comparator|Cohort 2: Placebo SC Infusion 28 Days|Double-blind Placebo will be via subcutaneous continuous infusion for 14 days (1 panel)
89455215|NCT02431442|Placebo Comparator|Cohort 3: Placebo SC Infusion 28 Days|Double-blind Placebo will be administered via subcutaneous continuous infusion for 28 days (1 panel)
89455216|NCT02431442|Placebo Comparator|Cohort 4: Placebo SC Infusion 28 Days|Double-blind Placebo will be administered via subcutaneous continuous infusion for 28 days (1 panel)
89455217|NCT02431442|Placebo Comparator|Cohort 5: Placebo SC Injection 14 days|Double-blind Placebo will be administered via a subcutaneous injection every 12 hours for 14 days (1 panel)
89455218|NCT02431442|Placebo Comparator|Cohort 6: Placebo SC Infusion 28 Days|Double-blind Placebo will be administered via subcutaneous continuous infusion for 28 days (1 panel, heterozygous MC4R subjects)
89455219|NCT04717271|Experimental|Movement Guidance Group (MVG)|In the MVG Group, the physiotherapist will provide kinesthetic stimuli by assisting manually the participant movements.
89015982|NCT05766683|Experimental|4mm depth|Subjects will be randomized using computer generated randomization list provided by PHS to receive onabotulinumtoxinA neurotoxin injections in the glabellar complex at depth of 4mm
89015983|NCT05765500|Experimental|Arm A: Relugolix|"55 participants will be randomized in a 1:1 fashion to Relugolix and stratified by intent to treat with radiation and will complete study procedures as outlined:~Surveys at baseline and at months 3, 6, 9, and 12.~Medication diary entries.~Cycles 1 - 6:~--Days 1 - 28 of 28 day cycle: Predetermined dose of Relugolix. Participant will self-administer at home.~Follow up visits every 3 months for 12 months."
89455220|NCT04717271|Experimental|No Movement Guidance Group (NO-MVG)|In the NO-MVG, the involvement of the physiotherapist will be restricted to guarantee the safety of the participant.
89455221|NCT02434640|Experimental|BAY1128688 [Dose1]|BAY1128688 dose level 1
89455222|NCT02434640|Experimental|BAY1128688 [Dose2]|BAY1128688 dose level 2
89455223|NCT02434640|Experimental|BAY1128688 [Dose3]|BAY1128688 dose level 3
89015984|NCT05765500|Active Comparator|Arm B: Leuprolide|"55 participants will be randomized in a 1:1 fashion to Leuprolide and stratified by intent to treat with radiation and will complete study procedures as outlined:~Surveys at baseline and at months 3, 6, 9, and 12.~Cycle 1 and Cycle 4:~--Day 1 of 28 day cycle: Predetermined dose of Leuprolide. Injection will be administered in clinic.~Follow up visits every 3 months for 12 months."
89455224|NCT02434640|Experimental|BAY1128688 [Dose4]|BAY1128688 dose level 4
89455225|NCT02434640|Placebo Comparator|Placebo|Placebo to match arm 1,2, 3 and 4
89455226|NCT03185780|Experimental|Treatment|Patients will be treated with acupuncture and/or touch therapies, this in parallel to their chemo-radiation regimen. These treatments will be administered twice-weekly during active chemo-radiation treatment (6 weeks), followed by once-weekly treatment throughout the remainder of the study period (6 months)
89455227|NCT02434484||Symbenda|Subjects who are prescribed with Symbenda per approved prescribing information of Symbenda will be enrolled in the study.
89455228|NCT03185936|Experimental|Optic disc pit maculopathy|pars plana vitrectomy with internal limiting membrane (ILM) peeling, endolaser
89455229|NCT03185624|Experimental|Rifaximin|Prescribed Rifaximin (600mg, twice daily) for 3 months after surgery
89455230|NCT03185624|No Intervention|Blank control|No intervention after surgery
89455231|NCT02434718|Experimental|Cohort 1|IV infusion in cohorts assigned to low dose 1; 1 participant per cohort will receive placebo
89455232|NCT02434718|Experimental|Cohort 2|IV infusion in cohorts assigned to low dose 2; 1 participant per cohort will receive placebo
88939801|NCT01843257||Gastric Bypass (cross-sectional)|Subjects who underwent gastric bypass surgery 1-5 years ago. Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion before surgery.
88939802|NCT01843257||Gastric Banding (cross-sectional)|Subjects who underwent gastric banding surgery 1-5 years ago. Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion before surgery.
88939803|NCT01843257||Sleeve gastrectomy (longitudinal)|Morbidly obese subjects who will undergo sleeve gastrectomy. Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion before surgery. The two testing sessions will be repeated ~ 9 months after surgery.
88939804|NCT01843257||Sleeve gastrectomy (cross-sectional)|Subjects who underwent sleeve gastrectomy 1-5 years ago. Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion before surgery.
88939805|NCT01843257||No bariatric surgery control|"Control group of women with age and BMI similar to those in the cross-sectional arm of the study who have not undergone bariatric surgery.~Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion before surgery."
88939806|NCT01843270|Experimental|ideal body weight|LMA size based on ideal body weight
88939807|NCT01843270|Experimental|actual body weight|LMA size according to actual body weight
88939808|NCT01843283|Experimental|Daily Enhancement Meaningful Activity (DEMA)|The group member will receive Self-management Toolkit and 6 bi-weekly individualized sessions, 2 face-to-face and 4 via telephone delivered by a trained intervener. DEMA will provide autonomy support by helping patients to identify and prioritize activities, classify needs and goals, generalize manageable solutions, engage in self-selected activities under family support, and self-evaluate failure and success or renew problem-solving as needed.
88939809|NCT01843283|Active Comparator|Information Support (IS)|The IS group will receive 2 face-to-face meetings to receive an overview of what will happen in the study and an initial Alzheimer Association, educational brochure. Then they will receive 4 biweekly follow-up phone calls and have the opportunity to ask only questions related to the educational materials.
88939810|NCT01843296|Active Comparator|Magnesium|Patients in group C received a premixed solution of 15 mg hyperbaric bupivacaine 0.5% (3 ml) and 25 µg fentanyl (0.5cc) and 50 mg of magnesium sulfate 50% (0.1 ml) (Pasteur Institute Co, Tehran, Iran) for spinal anesthesia
88939811|NCT01843296|Active Comparator|Fentanyl|Patients in Fentanyl group received a premixed solution of of 15 mg hyperbaric bupivacaine 0.5% (3 ml) and 25 µg fentanyl (0.5cc),plus 0.1 cc preservative free 0.9% normal saline for spinal anesthesia
88939812|NCT01843296|Active Comparator|Bupivacaine|Patients in Bupivacaine group(control) received a premixed solution of 15 mg of hyperbaric bupivacaine 0.5% (3 ml), plus 0.6 cc preservative free 0.9% normal saline for spinal anesthesia
88939813|NCT01843309|Experimental|Spironolactone 200mg|Spironolactone 100 mg twice a day orally
88939814|NCT01843309|Placebo Comparator|Placebo|Placebo twice a day orally
88939815|NCT01843309|Experimental|Spironolactone 100mg|Spironolactone 100mg once a day
88939816|NCT01843322|Experimental|navigation technology|custom made navigation technology integrated in a Siemens angiography suite for feasibility evaluation in endoleak repair procedure
88939817|NCT01843361||acute ischemic stroke|Determing cardiovascular risk factors or medication on clopidogrel response rates after an acute ischemic stroke
88939818|NCT01843387|Experimental|Cohort 1|Mesenchymal Precursor Cells (MPCs) - Dose 1 or Placebo
88939819|NCT01843387|Experimental|Cohort 2|Mesenchymal Precursor Cells (MPCs) - Dose 2 or Placebo
88939820|NCT01843400||Group 1|
88939821|NCT01843426|Experimental|Low-volume, Low-concentration contrast (Visipaque 270) CT scan|An ECG-synchronized, contrast-medium enhanced CT study of the heart for the evaluation of the aortic root complex and general cardiac morphology will be obtained. This is immediately followed by a CT angiographic study of the chest, abdomen, and pelvis (beyond the femoral heads), which utilizes the same contrast bolus that is injected for evaluating the heart. This latter vascular study serves to evaluate the TAVR deployment catheter access route through the femoral, iliac, and aortic vascular stations. In clinical routine, we have been performing this type of study with total contrast media volumes ranging from 40-120 mL of iodinated contrast material.
89015985|NCT05762614||patient on invasive mechanical ventilation able to perform a SBT|
89015986|NCT05761197||Children with history of OPC|Individuals in the non-OPC cohort will be age and sex-matched to individuals in the OPC cohort.
89015987|NCT05761197||Children without history of OPC|Individuals in the OPC cohort will be age and sex-matched to individuals in the non-OPC cohort.
89015988|NCT05741372|Experimental|Group 1: Healthy participants|Every participant receives a cocktail of Rosuvastatin, Digoxin, Metformin hydrochlorid, Furosemide.
89015989|NCT05741372|Experimental|Group 2: F4 Child-Turcotte-Pugh class A (Child-Pugh A) subjects (compensated)|"Every participant receives a cocktail of Rosuvastatin, Digoxin, Metformin hydrochlorid, Furosemide.~Compensated=without any disease symptoms"
89015990|NCT05741372|Experimental|Group 3: F4 Child-Turcotte-Pugh class B (Child-Pugh B) subjects (decompensated)|"Every participant receives a cocktail of Rosuvastatin, Digoxin, Metformin hydrochlorid, Furosemide.~Decompensated= with disease symptoms like aszites, variceal bleeding, hepatic encephalopathy, hepato-renal syndrome"
89455233|NCT02434718|Experimental|Cohort 3|IV infusion in cohorts assigned to high dose; 1 participant per cohort will receive placebo
89455234|NCT02434718|Experimental|Cohort 4|IV infusion in cohorts assigned to mid dose; 1 participant per cohort will receive placebo
89455235|NCT03190772|Experimental|Positive placebo group|Participants receive a placebo nasal spray. However, they are told that it protects from experiencing negative emotions. Participants watch a film sequence that is supposed to induce sadness.
89455236|NCT03190772|Placebo Comparator|Placebo control group|Participants receive a placebo nasal spray and are told that it is a placebo. Participants watch a film sequence that is supposed to induce sadness.
89455237|NCT03190772|Other|No-treatment control group|Participants do not receive the nasal spray. Participants watch a film sequence that is supposed to induce sadness.
89455238|NCT02707640|Placebo Comparator|Matching Placebo|
89455239|NCT02707640|Experimental|N-Acetylcysteine|
89455240|NCT02707640|Other|Pirfenidone|Background therapy
89455241|NCT03190694|Experimental|Dapagliflozin 10mg Tablet|10 mg Green, plain, diamond shaped, film coated tablet (orally)
89455242|NCT03190694|Placebo Comparator|Placebo Matching Dapagliflozin Tablet|Green, plain, diamond shaped, film coated tablet. Does not contain active ingredient
89455243|NCT02430272|Experimental|Anticholinergic premedication|Premedication with 0.005mg/Kg of glycopyrrolate
89455244|NCT02430272|No Intervention|Control group|Same volume of normal saline
89455245|NCT02430506|Placebo Comparator|Placebo|1.0 mL sterile buffer administered by intramuscular (IM) injection to deltoid area on days 0 and 56.
89015991|NCT05741346|Experimental|BCX9930|All subjects receive BCX9930 for 96 weeks
89015992|NCT05739682|Experimental|Antimicrobial Corticosteroid mixture|"Each canal will receive 5 minutes of final irrigation with the antimicrobial-corticosteroid solution of a freshly prepared mixture of:~1 ml of Levofloxacin (Tavanic, Sanofi Aventis, Egypt).~1 ml of Fluconazole (Sunny fungal, Sunny pharmaceuticals, Egypt).~1 ml of Dexamethasone sodium phosphate (Dexamethasone, Amriya, Egypt)."
89455246|NCT02430506|Experimental|AERAS-402|1.0 mL containing 3 x 10^10 vp/mL suspended in 20 mM Tris buffer, 2 mM MgCl2, 25 mM NaCl, 10% w/v sucrose, 0.02% w/v PS-80 (polysorbate-80, non-animal source) and water. Administered intramuscular (IM) injection to deltoid area on days 0 and 56.
89455247|NCT04586855||Healthy persons|Noninvasive ventilation and Cough Assist
89455248|NCT03626597|Active Comparator|CHV-provided post-test counseling & referral|The CHV will provide the woman with the urine pregnancy test and collect baseline information. If the woman desires enrollment in Arm 1 (CHV-provided post-test counseling and referral), the CHV will provide all post-test counseling and referral based on training provided. This may occur at the time of enrollment or at a later time, as preferred by the woman.
89455249|NCT03626597|Active Comparator|Phone-based post-test counseling & referral|The CHV will provide the woman with the urine pregnancy test and collect baseline information. If the woman desires enrollment in Arm 2 (phone-based post-test counseling and referral), the CHV will provide the woman with a phone number which she may call or short message service (SMS) to receive post-test counseling and referral. If the study team does not receive a call or SMS from the woman within one week, our research assistant will phone and/or SMS the participant to provide phone-based post-test counseling and referral.
89455250|NCT03188978|Experimental|Treatment|Atorvastatin 40mg once daily orally for 8 weeks starting 2 weeks before AVF creation
89455251|NCT03188978|Placebo Comparator|Placebo|1 tablet once daily orally for 8 weeks starting 2 weeks before AVF creation
89455252|NCT02431286|Experimental|Aprepitant|patient will receive aprepitant 80 mg per os one hour before surgery; palonosetron and dexamethasone will be intravenously administered during surgery
89455253|NCT02431286|Placebo Comparator|placebo|patient will receive placebo per os one hour before surgery; palonosetron and dexamethasone will be intravenously administered during surgery
89455254|NCT02431208|Experimental|Cohort A: ATZ (Run-In)|Cohort A will involve a safety run-in to evaluate atezolizumab administered as a single agent in participants with relapsed or refractory MM who have received up to 3 lines of prior treatment. NOTE: This cohort has been completed.
89455255|NCT02431208|Experimental|Cohort B1: ATZ + LEN (Dose Escalation)|Cohort B1 will involve a dose escalation to evaluate atezolizumab administered in combination with ascending-dose lenalidomide in participants with relapsed or refractory MM who have received up to 3 lines of prior treatment. NOTE: This cohort has been completed.
89015993|NCT05739682|Active Comparator|Cryotherapy|Each canal will receive final irrigation with 20ml of cold saline (2.5°c) for 5 minutes.
89015994|NCT05738967|Experimental|Transdiagnostic cognitive behavioral therapy|
89015995|NCT05738967|Active Comparator|Treatment as usual|
89015996|NCT05731713|Experimental|Immediate group|Study participants in the immediate group will be randomly assigned to start the intervention immediately at the beginning of the fall trimester.
89015997|NCT05731713|Experimental|Waitlist group|Study participants in the waitlist group will be randomly assigned to start the intervention at the beginning of the winter trimester.
89015998|NCT05730725|Experimental|BMS-986322 Dose 1|
89015999|NCT05730725|Experimental|BMS-986322 Dose 2|
89016000|NCT05730725|Experimental|BMS-986322 Dose 3|
89016001|NCT05730725|Placebo Comparator|Placebo|
89016002|NCT05722353|Other|Collection of clinical parameters, blood and stools samples|Collection of blood samples and feces specimen at inclusion visit; clinical and biological assessment at each visit.
89016003|NCT05722002|Other|NSAID regimen|Surgical teams will elect for one of the medications within the treatment arm to which the patient is randomized.
89016004|NCT05722002|Other|Opioid regimen|
89016005|NCT05716373|Experimental|Experimental:|reiki will be aplicated
89016006|NCT05716373|No Intervention|control|Routine maintenance will be applied.
89016007|NCT05714644|Active Comparator|Mailed FIT Kit|A FIT kit mailed to the patient's home
89016008|NCT05714644|Active Comparator|Cologuard|A Cologuard test mailed to the patient's home
89455256|NCT02431208|Experimental|Cohort C: ATZ + LEN (Post-ASCT):|Cohort C will evaluate atezolizumab administered in combination with lenalidomide in participants with MM who have measureable disease after ASCT. NOTE: This cohort is closed to enrollment.
89455257|NCT02431208|Experimental|Cohort D1: ATZ + DAR (Run-in)|Cohort D1 will involve a safety run-in to evaluate atezolizumab administered in combination with daratumumab in participants with relapsed or refractory MM who have received up to 3 lines of prior treatment.
89455258|NCT02431208|Experimental|Cohort D2: ATZ + DAR (Expansion)|Cohort D2 will involve an expansion to evaluate atezolizumab administered in combination with daratumumab in participants with relapsed or refractory MM who have received 2 but no more than 3 lines of prior treatment that must have included a PI and IMiD and are refractory to the last line of treatment.
89455259|NCT02431208|Experimental|Cohort D3: ATZ + DAR (Progressed)|Cohort D3 will involve an expansion to evaluate atezolizumab in combination with daratumumab in participants with relapsed or refractory MM who have received 2 or more lines of prior treatment and have progressed with an anti-cluster of differentiation (CD) 38 monoclonal antibody, either alone or in combination, and are refractory to both a proteasome inhibitor (PI) and immunomodulatory drug (IMiD).
89455260|NCT02431208|Experimental|Cohort E1: ATZ + DAR + LEN (Dose Escalation)|Cohort E1 will involve a dose escalation to evaluate atezolizumab administered in combination with daratumumab and ascending-dose lenalidomide in participants with relapsed or refractory MM who have received up to 3 lines of prior treatment. NOTE: This cohort is closed to enrollment.
89455261|NCT02431208|Experimental|Cohort E2: ATZ + DAR + LEN (Expansion)|Cohort E2 will involve an expansion to evaluate atezolizumab administered in combination with daratumumab and the maximum tolerated dose (MTD) of lenalidomide determined in Cohort E1 in participants with relapsed or refractory MM who have received up to 3 lines of prior treatment. NOTE: This cohort is closed to enrollment.
89455262|NCT02431208|Experimental|Cohort F1: ATZ + DAR + POM (Dose Escalation)|Cohort F1 will involve a dose escalation to evaluate atezolizumab administered in combination with daratumumab and ascending-dose pomalidomide in participants with relapsed or refractory MM who have received 4 or more lines of prior treatment and are refractory to the last line of treatment. NOTE: This cohort has been completed.
89455263|NCT02431208|Active Comparator|Cohort F2: ATZ + DAR + POM (Expansion)|Cohort F2 will involve an expansion to evaluate atezolizumab administered in combination with daratumumab and the MTD of pomalidomide determined in Cohort F1 in participants with relapsed or refractory MM who have received 4 or more lines of prior treatment and are refractory to the last line of treatment. NOTE: This cohort is randomized.
89016009|NCT05711082|Active Comparator|Dopamine precursor|In the first condition, volunteers will receive a dopamine (DA) precursor (L-dopa, 100mg). L-dopa will be combined with a dose of an Aromatic amino acid decarboxylase inhibitor (Benserazide) 25mg to multiplicate its bioavailability and with a dose of domperidone 10mg (peripheral antagonist of DA) to minimize the risk of side effects.
89016010|NCT05711082|Active Comparator|D2 antagonist|In the second condition, volunteers will receive a D2 antagonist (Sulpiride, 800mg)
89016011|NCT05711082|Placebo Comparator|PLACEBO|In the third condition, volunteers will receive a placebo (lactose)
89016012|NCT05709379|Experimental|Control trial|Sitting from 8 am until 3pm.
89016013|NCT05709379|Experimental|High intensity sedentary breaks|Physical activity on 80-85% of individual VO2max every hour. Modality: Hill walking/jogging on treadmill.
89016014|NCT05709379|Experimental|Low intensity sedentary breaks|Physical activity on 25-30% of individual VO2max every hour. Modality: Hill walking on treadmill.
89016015|NCT05704335||Patients with headache during the course of influenza|Patients with influenza infection who experience new-onset headache during the course of the disease, or a two-fold worsening of a prior headache disorder, according to the International Classification of Headache Disorders
89016016|NCT05704179||Patients who undergo cesarean section|Obstetric comorbidity index will be calculated for all patients, obstetric quality of recovery score will be evaluated in postpartum period( on the first and second day postpartum)
89016017|NCT05703490||Cognitive Impaired Group|older adults (age 50 years and older) with either clinical diagnosis of cognitive impairment or determined to have cognitive impairment based on Montreal Cognitive Assessment (MoCA) Test, score of 26 or lower
89016018|NCT05703490||Cognitive Intact Group|Older adults age matched with Cognitive Impaired Group with MoCA score of greater than 26
89016019|NCT05700695|Experimental|Experiential Arm|Drug: iv Branch Chain Amino Acid + Lactulose Intravenous Branched Chain Amino Acids - 500mL once daily for 3 days plus Lactulose
89016020|NCT05700695|Active Comparator|Comparator Arm|Drug: Lactulose + Placebo
89016021|NCT05693701|Other|Control group (Usual care)|This arm will receive standard notification that is usually provided by Carter describing need to review with donor's primary care physician the presence of high cholesterol
89455264|NCT02431208|Active Comparator|Cohort F3: DAR + POM + Dexamethasone|Cohort F3 is an expansion control arm for cohort F2. Participants will receive daratumumab in combination with pomalidomide at the MTD and dexamethasone. NOTE: This cohort is randomized.
89455265|NCT03107078|Experimental|Group Ia|"I:The increase of fat volume dominates .~a:The weekly protocol was as follows: 0.5 g glucocorticoids weekly for 6 weeks, followed by 0.25 g weekly for 6 weeks."
89455266|NCT03107078|Experimental|Group Ib|"I:The increase of fat volume dominates. b:The qod protocol was as follows: 0.5 g glucocorticoids qod. for 3 interval days per month for 3 months."
89016022|NCT05693701|Experimental|Intervention Group (Implementation strategy bundle)|Along with standard high cholesterol notification from Carter BloodCare, this arm will receive Implementation strategy bundle (educational material regarding high cholesterol levels)
89455267|NCT03107078|Experimental|Group IIa|"II:The increase of extraocular muscles volume dominates .~a:The weekly protocol was as follows: 0.5 g glucocorticoids weekly for 6 weeks, followed by 0.25 g weekly for 6 weeks."
89455268|NCT03107078|Experimental|Group IIb|"II:The increase of extraocular muscles volume dominates . b:The qod protocol was as follows: 0.5 g glucocorticoids qod. for 3 interval days per month for 3 months."
89455269|NCT03188900||preeclampsia|pregnancy with preeclampsia
89455270|NCT03188900||control|pregnancy without preeclampsia
89455271|NCT05693597|No Intervention|Group I (control)|Patients will not receive any prophylactic intervention, as there is no standard of care for prophylaxis to the radiation induced dermatitis (RID).
89455272|NCT05693597|Experimental|Group II (Topical intervention)|Patients will receive Imtenan ® N. sativa oil apply 1.5 mls; twice daily; not sooner than 2 hours before and after radiation therapy; from day 1 of radiation therapy till the end.
89455273|NCT05693597|Experimental|Group III (Oral intervention)|Patients will receive Baraka ® N. sativa gelatin capsules; 40-80 mg/Kg/day; from day 1 of radiation therapy till the end
89455274|NCT02430350|Experimental|Compound Edaravone|Compound Edaravone Injection 37.5mg/dose (Edaravone 30mg, (+)-Borneol 7.5mg), one dose every 12 hours, continue for 14 days
89455275|NCT02430350|Active Comparator|Edaravone|Edaravone Injection 30 mg/dose, one dose every 12 hours, continues for 14 days
89455276|NCT02430038||Acceptability and feasibilty|Where vaginal examinations are best avoided e.g. vaginismus or contraindicated (PPROM) with controls
89016023|NCT05690841|No Intervention|Control: Standard Interventions|Standard interventions for the control cluster will include providing participants with long-lasting insecticide-treated bednets, management of known and possible mosquito breeding sites, passive case detection through detection and diagnosis of symptomatic cases of malaria in health facilities and through community health workers (conducted in villagers with fever), microscopy testing in households of recent index cases to detect asymptomatic malaria cases, and treatment of active cases of malaria (artesunate-mefloquine (AS-MQ) for Plasmodium falciparum and Chloroquine (CQ) (10 mg/kg on days 1 and 2, followed by 5 mg/kg on day 3) + PQ (0.5mg/kg x 7 days).
89455277|NCT02430038||Predictive Model|Nulliparous term labouring women with cephalic presentation
89455278|NCT02430974|No Intervention|Chemotherapy|patients received four cycles of platinum-based doublet chemotherapy (150 mg/m2 paclitaxel plus 80 mg/m2 nedaplatin or 30mg/m2 lobaplatin on day one of a three-week cycle).
89455279|NCT02430974|Experimental|Chemotherapy & Icotinib|patients received four cycles of platinum-based doublet chemotherapy (150 mg/m2 paclitaxel plus 80 mg/m2 nedaplatin or 30mg/m2 lobaplatin on day one of a three-week cycle).Two weeks after chemotherapy completed, patients assigned to the consolidation therapy group began oral icotinib treatment (125 mg, thrice daily). Icotinib treatment continued for four to eight months, or until the occurrence of disease relapse, metastasis or unacceptable icotinib or chemotherapy toxicity.
89455280|NCT02430116|No Intervention|negative control group|The myocardial tissues of the right atrial appendage were obtained at 3 min before CPB was established in the NEG group.
89455281|NCT02430116|Active Comparator|I/R group|The myocardial tissues of the right atrial appendage were obtained at 45 min after opening the aorta in the I/R group.
89455282|NCT02430116|Experimental|I-postC group|The procedure involved 5 min before opening the ascending aorta, aortic unclamping for 30 s, and cross-clamping for 30 s for three cycles, after which the ascending aorta was completely opened.
89455283|NCT02429960|Other|Analgesia monitoring|Remifentanil is increased step-by-step according to the study protocol. After ensuring a steady-state period of remifentanil infusion of at least 5 minutes, the standardized painful stimuli consisting of the intracutaneous pain model and tetanic stimulation for the time period of 30 s with 80 milliampere, 50 Hz are applied. All stimulations are accompanied by the measurement of the analgesic monitoring-devices (PhysioDoloris®, SPI® and AlgiScan®). Moreover the investigators measure and inspect changes in heart rate and blood pressure as well as occurrence of defensive movements of the patients.
89455284|NCT02429804|Experimental|Diagnostic (18F NaF/18F FDG PET/MRI, contrast-enhanced MRI)|Patients receive 18F NaF and 18F FDG IV over 30 seconds-1 minute and then undergo PET/MRI and contrast-enhanced MRI after 45-60 minutes. Patients undergo imaging at baseline, after course 3 (12 weeks), and after course 6 (24 weeks) of treatment with Ra-223.
89455285|NCT03185156|Experimental|propofol group|first dose 0.3mg/Kg propofol, then 1mg/Kg/hr micro-pump
89455286|NCT03185156|Placebo Comparator|control group|first dose 0.03ml/Kg normal saline, then 0.1ml/Kg/hr micro-pump
89455287|NCT03188744||Group 1|Patients with CC with PFMD.
89455288|NCT03188744||Group 2|Patients with CC without PFMD.
89455289|NCT03188744||Group 3|Patients without CC with PFMD.
89455290|NCT03188744||Group 4|Patients without CC without PFMD.
89455291|NCT04483700|Experimental|Filgotinib 200 mg (Main Study - Blinded)|Participants will receive filgotinib 200 mg + placebo to match (PTM) filgotinib 100 mg for up to 16 weeks.
88939822|NCT01843439|Experimental|Intervention|"We designed a intervention study to correct additional risk factors in elderly asthma patients.~We offer following specific interventions simultaneously to intervention arm and will measure the effects of interventions after 1 years.~popularize and educate the asthma action plan~run a emergency call system for acute exacerbation~educate the proper techniques using inhalers~correct the deficiency of magnesium (magnesium 500mg per day)"
88939823|NCT01843452|Experimental|Capecitabine, mitomycin, panitumumab and radiotherapy|"RADIOTHERAPY: daily fraction dose of 1.8Gy , 5 days a week between day 1 and 45 Intensity modulated radiotherapy (IMRT), using a linac based facility or helical tomotherapy, is obligatory.~The first treatment sequence consists of a total dose of 36 Gy in 20 daily fractions of 1.8 Gy on five days a week.~The second treatment sequence consists of a total dose of 23.4 Gy in 13 daily fractions of 1.8 Gy on five days a week.~PANITUMUMAB: 6 mg/kg IV over 60 min infusion on days 1, 15 and 29~MITOMYCIN: 10 mg/m2 IV over 15 min infusion on days 1 and 29~CAPECITABINE: 825 mg/m2 oral twice daily on days 1 to 45"
88939824|NCT01843478|Experimental|HPV Self-Collection|The intervention is a self-collected HPV test, followed by results counseling by phone when the result is available (usually 2-3 weeks). Women are encouraged to have Pap testing.
88939825|NCT01843478|Placebo Comparator|Usual Care|In the usual care arm, women do not receive the HPV test. They are encouraged to have Pap testing. In addition, there is a phone call as an attention control, where women are reminded to make a Pap test appointment about 2-3 weeks after the baseline visit.
88939826|NCT01843491|Experimental|Ad-PfCA|Single injection of Ad-PfCA containing 2 x 10^10 pu total dose in 1 ml of Final Formulation Buffer by intramuscular injection
88939827|NCT01843517||endogenous pain facilitation|Pain facilitation is studied by a simple test of applying over the counter capsaicin cream to the skin for only 30 min, then removing it and heating the skin to a non-noxious temperature.
89455292|NCT04483700|Experimental|Filgotinib 100 mg (Main Study - Blinded)|Participants will receive filgotinib 100 mg + PTM filgotinib 200 mg for up to 16 weeks.
89455293|NCT04483700|Placebo Comparator|Placebo (Main Study - Blinded)|Participants will receive PTM filgotinib 200 mg + PTM filgotinib 100 mg for up to 16 weeks.
89455294|NCT04483700|Experimental|Filgotinib 200 mg (LTE)|"Before study-wide unblinding, participants will receive filgotinib 200 mg + PTM filgotinib 100 mg.~After study-wide unblinding, participants will receive filgotinib 200 mg."
89455295|NCT04483700|Experimental|Filgotinib 100 mg (LTE)|"Before study-wide unblinding, participants will receive filgotinib 100 mg + PTM filgotinib 200 mg.~After study-wide unblinding, participants will receive filgotinib 100 mg."
89455296|NCT02434406|Experimental|Web-based intervention|Participants get access to the web-based intervention and are asked to work through the 8 modules of the intervention within eight weeks. The intervention program sends automated weekly email reminders about the current session. In addition, users are offered weekly optional 30-minute telephone support with a trained intervention coach.
89455297|NCT02434406|No Intervention|Wait-list control|Participants get standard care and will be offered access to the web-based intervention at 8-weeks post-randomization.
89455298|NCT02708966|Experimental|Gymnema Sylvestre|Patients with IGT
89455299|NCT02708966|Placebo Comparator|Placebo|Patients with IGT
89455300|NCT02429726|Experimental|rAdp53|2 x 10^12 viral particles of rAdp53 gene are given in 40 ml of saline by intra-cavity infusion at day of 7, 15 and 21
89455301|NCT02429726|Active Comparator|cisplatin|cisplatin 40 mg in 40 ml of saline are given by intra-cavity infusion at day of 7, 15 and 21
89455302|NCT02429726|Experimental|rAdp53 plus cisplatin|2 x 10^12 viral particles of rAdp53 gene and cisplatin 40 mg in 40 ml of saline are given by intra-cavity infusion at day of 7, 15 and 21
89455303|NCT02429882|Experimental|Brodalumab|
89455304|NCT02429882|Placebo Comparator|Placebo|
89455305|NCT02429648|Active Comparator|PVI performed in Normal Sinus Rhythm|DCC first then PVI
89455306|NCT02429648|Active Comparator|PVI performed in Atrial Fibrillation|PVI then DCC after if patient remains in Atrial Fibrillation
89455307|NCT02425358|Experimental|BMC therapy within 24 hours|Patients with acute myocardial infarction who receive intracoronary infusion of BMC within 24 hours after successful primary PCI.
89455308|NCT02425358|Experimental|BMC therapy within 3-7 days|Patients with acute myocardial infarction who receive intracoronary infusion of BMC within 3-7days after successful primary PCI.
89455309|NCT02425358|Experimental|BMC therapy within 7-30 days|Patients with acute myocardial infarction who receive intracoronary infusion of BMC within 7-30days after successful primary PCI.
89455310|NCT02425358|Active Comparator|PCI only|Patients with acute myocardial infarction who were performed successful primary PCI.
89455311|NCT02425436|Active Comparator|Ginkgo Biloba Extract group|This group received Ginko Biloba, two tablets per day
89455312|NCT02425436|Placebo Comparator|Placebo group|This group received placebo two tablets per day .
89455313|NCT03183050|Experimental|Question Prompt List|This is a single-arm study. Therefore, all participants will receive the prompt list.
89455314|NCT02429492|Experimental|ALS patients|Patients with amyotrophy lateral sclerosis (ALS)
88939828|NCT01843517||endogenous pain inhibition|Pain inhibition is studied by a simple test of mild pain on one area of the body reducing response to a pain stimulus in another area.
89455315|NCT02429492|Experimental|Control subjetcs|Neurologically intact subjects sex and age-matched to ALS patients
89455316|NCT02429180|Experimental|Rehabilitation training|"ReTrain: an exercise-based functional training programme comprising two phases: (1) weekly supervised sessions; (2) monthly drop-in sessions, plus home-based exercise in each phase.~Week 1: one-to-one consultations with trainer to introduce programme, assess individual's concerns and capabilities, introduce and negotiate initial goals~Weeks 2-11: bi-weekly 90 minute group class with group-based activities and one-to-one coaching, based on ongoing goal negotiation review and progression.~Week 12: one-to-one consultations with trainer to review goals and plan ongoing unsupervised exercise programme~Weeks 13-24: monthly drop-in sessions for one-to-one consultation, support and progression."
89455317|NCT02429180|No Intervention|Control|Control: treatment as usual plus receipt of a UK Stroke Association booklet on exercise after stroke.
89455318|NCT03117452|Experimental|visual training condition|Participants in the visual training condition will participate in the visual training (VT) group, during which they will complete computerized visual training that targets low- and mid-level visual processes. Each group will include a maximum of 3 participants and will meet 3 times a week over a period of 12-14 weeks.
89455319|NCT03117452|No Intervention|control condition|Participants assigned to the control condition will receive standard Partial Hospital care without visual training.
89455320|NCT03182816|Experimental|anti-CTLA-4/PD-1 expressing EGFR-CAR-T|This study have only one arm that is anti-CTLA-4/PD-1 expressing EGFR-CAR-T group. All patients with advanced solid tumor will take part in the screening, who matching all the conditions will be chosen for the treatment using CTLA-4 and PD-1 antibodies expressing EGFR-targeted CAR-T cells. New CAR-T cells are cultured from PBMC and returned to the patients by venous transfusion.
89455321|NCT03117374|Experimental|Team Nutriathlon intervention|Participants were invited to participate in the Team Nutriathlon for an 8-week period
89455322|NCT03117374|No Intervention|Control|Participants were invited to follow the regular school curricular for an 8-week period
89455323|NCT02430896||ADHD group|Children and adolescents who met the Diagnostic and Statistical Manual IV Text Revision (DSM-IV-TR) diagnostic criteria for ADHD and needed pharmacotherapy. Subjects will be taking Methylphenidate or Atomoxetine for 52 weeks.
89016024|NCT05690841|Experimental|Focal Mass Drug Administration (fMDA)|Standard interventions in addition to focal mass drug administration. Focal mass drug administration will include using primaquine, chloroquine, and tafenoquine, for high-risk individuals residing in households that are within 200 meters of a Plasmodium vivax (Pv) index case households from the prior 2 years (including individuals in the index case household). Pv index cases include symptomatic cases detected at health facilities or in fever screenings, and asymptomatic cases identified during routine active case detection by health facilities. Households will then be notified regarding their potential to receive two rounds fMDA that cycle. Eligibility to receive medications as part of fMDA will be assessed prior to each administration and include glucose 6 phosphate dehydrogenase (G6PD) testing and counseling if not previously conducted or result is not available on the participant's identification card.
89016025|NCT05681481|Experimental|efgartigimod PH20 SC|participants receiving efgartigimod PH20 SC on top of Prednisone
89016026|NCT05680337|Active Comparator|Active TENS|Active will be performed with using a TENS device with an ear clip attached to the tragus of the left ear (which is innervated by auricular branch of the vagus nerve) at 20 Hz, 200 μs at a current just below discomfort threshold.
89016027|NCT05680337|Sham Comparator|Sham TENS|Sham will be performed with using a TENS device with an ear clip attached to the left earlobe (which is devoid of vegas innervation) at 20 Hz, 200 μs at a current just below discomfort threshold.
89016028|NCT05674357|Experimental|Individualized Evidence-Based Therapy in Cancer (Patients)|"This arm will enroll patient participants receiving evidence-based therapy as part of the protocol.~Participants will complete:~6-16 sessions of therapy 1x/week. Sessions are virtual or in-person at the Massachusetts General Hospital Cancer Center.~Surveys and questionnaires pre- and post-treatment.~At the discretion of the therapist and the supervising therapist, the participant may receive up to 4 booster sessions after completion of the specific treatment protocol."
89016029|NCT05674357|Experimental|Training in Individualized Evidence-Based Therapy in Cancer (Therapists)|This arm will enroll therapist participants as part of the protocol. Therapists participants will enroll in the study and receive training in delivering evidence-based therapy to patients in the cancer center. Therapists will complete pre and post-measures of therapist self-efficacy and competence, as well as a semi-structured exit interview.
89016030|NCT05672524|Experimental|Participant with Rectal Adenocarcinoma|Participants will have HER2-positive locally advanced rectal adenocarcinoma.
89016031|NCT05665465|Placebo Comparator|Placebo|Participants will be administered 2 nasal sprays with a combined nicotine content of 0mg nicotine, 0.1mL
89016032|NCT05665465|Experimental|0.5mg nicotine|Participants will be administered 2 nasal sprays with a combined nicotine content of 0.5 mg nicotine, 0.1mL
89016033|NCT05665465|Experimental|1mg nicotine|Participants will be administered 2 nasal sprays with a combined nicotine content of 1.0 mg nicotine, 0.1mL
89016034|NCT05661695|Other|RT's in ICU|We will collect ventilator pressure, flow, volume, oxygen and breathing pattern data, etc, as well as arterial blood-gas exchange and hemodynamic data of adults attached to ventilators. the RRT's will treat patients as normal without the assistance of the RT Assistant for the pre-intervention phase and will be observed collecting the same data and performing patient care with the assistance of the RT Assistant during the intervention phase. The RRTs will then be given a likert scale questionnaire on the use of the RT Assistant.
89016035|NCT05657678|Experimental|Interventional Arm|a single administration of 750,000 IU of vitamin D3 via the enteral route (through a gastric tube) in ICU patients with severe vitamin D3 deficiency (measured plasma 25(OH)D3 levels ≤12.5 ng/ml) undergoing continuous renal replacement therapy with CVVHDF or CVVHF
89016036|NCT05657678|Active Comparator|Control Arm|a single administration of 500,000 IU of vitamin D3 via the enteral route (through a gastric tube) in ICU patients with severe vitamin D3 deficiency (measured plasma 25(OH)D3 levels ≤12.5 ng/ml) undergoing continuous renal replacement therapy with CVVHDF or CVVHF
89016037|NCT05639933|Experimental|Open-Label PK Cohort|Topical treatment with HT-001 2% Gel unblinded.
89016038|NCT05639933|Placebo Comparator|Randomized, Double Blind Cohort|Topical treatment with HT-001 (2%, 1%, or 0.5%) or placebo (HT-001 vehicle), blinded
89016039|NCT05637723|Experimental|schroth exercise group|Included participants will be included in the Schroth exercise program by a Schroth-trained physiotherapist 3 days a week for 6 weeks, after being evaluated at the start of treatment.
89016040|NCT05637723|Active Comparator|traditional scoliosis exercise group|Included participants will be included in the traditional scoliosis exercise program by a physiotherapist 3 days a week for 6 weeks, after being evaluated at the start of treatment.
89016041|NCT05637723|No Intervention|control group|Any exercise program for scoliosis will not be applied to this group.
89016042|NCT05635734|Experimental|Experimental arm|"Patients will receive azeliragon for up to 2 years or as long as the patient and study investigator feel that a therapeutic benefit is possible.~Patients will receive involved field radiation therapy and temozolomide consisting of fractionated focal irradiation in daily fractions of 2 Gy given 5 days/week for 6 weeks, for a total of 60 Gy, plus concomitant daily temozolomide (TMZ; 75 mg/m2/day, 7 days/week from the first to the last day of radiotherapy), followed by six cycles of adjuvant TMZ (150-200 mg/m2/day for 5 days during each of six 28-day cycles."
89016043|NCT05635643|Experimental|Arm 1a: CHS-114 Dose Escalation|Arm 1 monotherapy dose escalation portion of the study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of CHS-114 as monotherapy in up to 25 participants with advanced solid tumors, to determine the recommended dose for expansion (RDE).
89016044|NCT05635643|Experimental|Arm 1b: CHS-114 Dose Expansion|Arm 1b monotherapy expansion will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of CHS-114 monotherapy at 2 dose levels (potential recommended dose for expansion [RDE]) in up to 5 participants in each dose level with Head and Neck Squamous Cell Carcinoma (HNSCC).
89201295|NCT04854382|Active Comparator|Intervention group|Tailored information about coronavirus using information videos followed by a teach-back procedure
89201296|NCT04854382|No Intervention|Control group|Controls have access to information videos, but do not receive the teach-back procedure (the intervention)
89455324|NCT02430896||Normal control group|Children and adolescents will be recruited by advertisement, and will be assigned to normal group if they do not meet the Diagnostic and Statistical Manual IV Text Revision (DSM-IV-TR) diagnostic criteria for ADHD .
89455325|NCT02425280|Experimental|Narrative Exposure Therapy|For the intervention group receiving Narrative Exposure Therapy treatment, the intervention will last for approximately three months and include 10-12 weekly sessions of 60-90 minutes. The course of the intervention will follow the NET manual (Schauer et al., 2011).
89455326|NCT02425280|Active Comparator|Treatment as Usual|For the TAU control group, participants will receive the usual care for posttraumatic stress symptoms currently offered by each unit.
89455327|NCT03184844|Experimental|thalidomide thalassemia|thalidomide:50mg/d p.o
89455328|NCT02429102|Experimental|Single ascending dose, MT-8554 or Placebo|
89455329|NCT02429102|Experimental|Multiple ascending dose, MT-8554 or Placebo|
89455330|NCT03185390|Other|ERCP guided biopsy or brush cytology|ERCP guided biopsy or brush cytology
89455331|NCT03185312||patients with acne vulgaris|Clinical evaluation including full history taking and dermatological examination will be done for all patients. Assessment of disease severity will be performed using Global acne severity grading for acne vulgaris Skin biopsies will be taken from lesional and non-lesional skin .immunohistochemical staining using specific antibodies for detection of expression of JAK1, JAK2 and JAK3.
89455332|NCT03185312||patients with vitiligo|Clinical evaluation including full history taking and dermatological examination will be done . Assessment of disease severity will be performed using VASI score Skin biopsies will be taken from lesional and non-lesional skin .immunohistochemical staining using specific antibodies for detection of expression of JAK1, JAK2 and JAK3..
89455333|NCT03185312||control|"Skin biopsies will be taken from skin of controls.~. Five micron thick sections will be cut from paraffin blocks for immunohistochemical staining using specific antibodies for detection of expression of JAK1, JAK2 and JAK3."
89455334|NCT02425202|Active Comparator|Ketamine infusion|Ketamine infusion at 0.1 mg/kg/hr up to maximum of 10 mg/hr
89455335|NCT02425202|Placebo Comparator|Saline infusion|Saline infusion
89455336|NCT02425124|Active Comparator|Control|PC101 Enhanced usual primary health care where non-physician clinicians have been equipped with the basic skills to identify stress and depression/anxiety but with limited access to doctors authorized to prescribe antidepressant medication, and with no specific psychosocial interventions.
89455337|NCT02425124|Experimental|Intervention|PC101 + Mental Health Facility-based stepped care intervention combining stress and depression case detection and management by non-physician clinicians and referral pathways for anti-depressant medication and/or group/individual counselling delivered by lay-health workers for patients with depression.
89455338|NCT03185468|Experimental|4SCAR-PSMA|4SCAR PSMA-modified T cells can recognize and kill tumor cells through the recognize of PSMA .This study will evaluate the side effects and effective doses of 4SCAR-PSMA T cells in treating refractory and recurrent solid tumors.
88939829|NCT01843543|Experimental|MBSR participants|Subjects in this arm will participate in an 8 week Mindfulness Based Stress Reduction Course
88939830|NCT01843543|No Intervention|No MBSR Participants|Subjects in this arm will not participate in the Mindfulness Based Stress Reduction Course.
88939831|NCT01843569|Experimental|IVM|All patients registered in this study will undergo natural cycle IVF with In Vitro maturation (IVM) performed on all immature retrieved oocytes.
88939832|NCT01843595|Experimental|REFIT Intervention|This arm will receive the REFIT intervention immediately after randomization.
88939833|NCT01843595|No Intervention|Wait-list control|This arm will receive a modified version of the REFIT program after the 6-month assessment.
88939834|NCT01843608|No Intervention|Control Group|"Patients in this group will be asked to maintain the same activity level until the baseline assessments.~They cannot change physical activity and nutritional habits."
88939835|NCT01843608|Experimental|Physical Intervention Group|"They have to perform two days per week of guide and planned exercise during three months. All classes are composed by different parts: aerobic exercise, to improve cardiovascular capacity, strength, to work muscle mass and flexibility to increase joint movements.~They have to present an attendance above or equal to 80%."
88939836|NCT01843647|Experimental|Icotinib|Patients receive 8-week icotinib induction treatment before surgery and 1-year icotinib adjuvant therapy after surgery.
88939837|NCT01843647|Active Comparator|Chemotherapy|Patients receive 8-week icotinib induction treatment before surgery and 4-cycle adjuvant chemotherapy with vinorelbine/cisplatin regimen after surgery.
88939838|NCT01843686|Experimental|Autologous Platelet Rich Plasma (PRP)|Magellan Autologous Platelet Separator used to extract Platelet Rich Plasma from autologous whole blood. PRP is mixed with calcified thrombin to create a gel, which is place on the excised wound bed prior to application of split thickness autograft.
88939839|NCT01843686|Placebo Comparator|Saline Gel, Standard of Care|Normlgel Saline is placed on the excised wound bed prior to application of split thickness autograft.
88939840|NCT01843699|Experimental|Topiramate|A 12-week topiramate flexible dose administration plus 4 sessions of a manualized cognitive restructuring intervention.
88939841|NCT01843699|Placebo Comparator|Placebo|A 12-week placebo matching tablets plus 4 sessions of a manualized cognitive restructuring intervention.
88939842|NCT01843725|Experimental|Metronomic arm|capecitabine 1100 to 1600 mg/m2/day orally in association with aflibercept 6mg/kg intravenous every 3 weeks
88939843|NCT01843725|Experimental|Intermittent arm|capecitabine 1700 to 2500 mg/m2/day orally 2 weeks out of 3 and aflibercept 6mg/kg intravenous every 3 weeks
88939844|NCT01843738|Experimental|All participants|
88939845|NCT01843764||children with malaria|Tanzanian children between 6-59 months with an uncomplicated P.falciparum monoinfection, followed after arthemeter-lumefantrine treatment according to national treatment guidelines
88939846|NCT01843790|Placebo Comparator|Placebo, saline|Saline, dosed weekly for 8 weeks
88939847|NCT01843790|Experimental|GCS-100 low dose|Low dose of GCS-100 given IV once per week for 8 weeks
88939848|NCT01843790|Experimental|GCS-100 high dose|High dose of GCS-100 given IV once per week for 8 weeks
89201297|NCT00605319|Other|Toviaz (Fesoterodine)|Toviaz 4mg to 8mg
89016045|NCT05635643|Experimental|Arm 2: CHS-114 + toripalimab Dose Expansion|Arm 2 combination dose expansion will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of CHS-114 in combination with toripalimab at 2 dose recommended Phase 2 dose [RDE] levels in up to 6 participants in each dose level with Head and Neck Squamous Cell Carcinoma (HNSCC).
89016046|NCT05627167|Experimental|Daytime Cyclic enteral nutrition|Patients receive continuous isocaloric enteral feeding for 10 hours during the day (e.g. 08:00 to 18:00) via nasal or oro-gastric tube
89016047|NCT05627167|Active Comparator|Continuous enteral nutrition|Patients receive isocaloric enteral feeding continuously 24 hours a day via nasal or oro-gastric tube
89016048|NCT05623189|Experimental|HTD1801|HTD1801,1250 mg, BID
89455339|NCT03185468|Experimental|4SCAR-FRa|4SCAR FRa-modified T cells can recognize and kill tumor cells through the recognize of FRa .This study will evaluate the side effects and effective doses of 4SCAR-FRa T cells in treating refractory and recurrent solid tumors.
89455340|NCT02430662|Experimental|IRE Group|irreversible electroporation for Unresectable Gallbladder Neoplasms
89455341|NCT02430662|No Intervention|Control|The patients without treatment
89016049|NCT05623189|Placebo Comparator|placebo|placebo, BID
89016050|NCT05620914|Experimental|Patritumab deruxtecan|15 participants with surgically-resectable brain metastases from multiple solid tumor primary histologies known to express HER3 will be treated. Patritumab deruxtecan (HER3-DXd) will be administered IV 5.6 mg/kg as a single dose 1-3 days prior to planned craniotomy and resection of BrM. Participants will undergo specimen collection prior to and during the planned craniotomy, including tumor, blood, and cerebrospinal fluid (CSF).
89016051|NCT05618301|Experimental|Motixafortide followed by Motixafortide + Natalizumab|"Consenting and eligible patients will receive a single subcutaneous injection of motixafortide, followed by leukapheresis. Patient will then be followed for 8 weeks for adverse event monitoring.~Following the 8-week monitoring period, patients will receive a single IV infusion natalizumab, then approximately 32 hours later, a single subcutaneous injection of motixafortide, followed by leukapheresis. Patients will then be followed for 8 weeks for adverse event monitoring."
89016052|NCT05613816||Senhance Surgical System|100 patients affected by uterine diseases with indication for hysterectomy undergo treatment with robotically assisted laparoscopic procedures using the Senhance Surgical System
89016053|NCT05612204|Experimental|Biopsy under MRI|
89016054|NCT05609916|Active Comparator|Continued SRI|After post-phase I assessment, participants who are eligible will be randomized to 1) Continued SRI. For these participants, the medication (SRI) will be provided at a consistent dosage.
89016055|NCT05609916|Placebo Comparator|Discontinuation titration to placebo|After post-phase I assessment, participants who are eligible will be randomized to 2) Discontinuation titration to placebo. For these participants, the placebo substitution in an increasing proportion of capsules will be implemented until all drug is withdrawn.
89455342|NCT02706938|Other|Head of bed elevation - Control|Participants will sleep with head of bed raised with standard 20 cm-height wooden blocks during a first period of 6 weeks. After a washout 2 week period, participants will sleep in a bed without inclination for a second period of 6 weeks. During the trial, every patient will receive standard pharmacological treatment with a proton pump inhibitor and/or sodium alginate, according to clinical judgement.
89455343|NCT02706938|Other|Control - Head of bed elevation|Participants will sleep in a bed without inclination during a first period of 6 weeks. After a washout 2 week period, participants will sleep with head of bed raised with standard 20 cm-height wooden blocks for a second period of 6 weeks. During the trial, every patient will receive standard pharmacological treatment with a proton pump inhibitor and/or sodium alginate, according to clinical judgement.
89455344|NCT02428790||ABI Patients|Patients with acquired brain injury.
89455345|NCT03182504|Experimental|Nacubactam Plus Meropenem|Participants will receive a single dose of nacubactam co-administered with meropenem.
89455346|NCT02430428|Experimental|VisuMax lenticule removal|VisuMax femtosecond laser sphere-only or spherocylindrical treatment
89455347|NCT03182348||Optical coherence tomography|As part of the clinical angioplasty procedure the patient will have a coronary guidewire passed down the artery usually from the groin to the heart which is used to position balloons and stents. OCT passes over the wire in the same way. From the patients perspective the procedure may take a small amount of additional time - maximum 10-15 minutes. We would like to be able to pass a second wire down the same coronary artery called a 'buddy wire' which is sometimes required in coronary procedures. This would be used to inflate a balloon at low pressure near the area of interest in the heart in order either to exclude blood or to oppose the OCT catheter to the vessel wall if required.
89455348|NCT02429024|No Intervention|Control|Subjects with type 1 and type 2 diabetes will be provided with the OneTouch Verio® Flex BGM system only over a period of 24 weeks.
89016056|NCT05609916|Other|Open label CBT|During Phase I, all participants will receive open label cognitive-behavioral therapy. Only those who achieve significant benefit will be able to most on to the post-phase I assessment, and then to the random assignment to Continued SRI or Discontinuation titration to placebo arms.
89201298|NCT04006834||MDD with hypersomnia|Patient with a history of MDD and ESS >10
89201299|NCT04006834||MDD without hypersomnia|Patient with a history of MDD and ESS <=10
89201300|NCT00922038|Experimental|High reward|
89201301|NCT00922038|Experimental|Low reward|
89201302|NCT00922038|No Intervention|Control|
89201303|NCT00983320|Experimental|medication|quetiapine
89201304|NCT00983320|Placebo Comparator|placebo|placebo
89455349|NCT02429024|Experimental|Intervention|Subjects with type 1 and type 2 diabetes will be provided with the OneTouch Verio® Flex BGM and the OneTouch Reveal® Mobile APP system over a period of 24 weeks.
89455350|NCT02421458|Active Comparator|arm 1: 6 fractions of radiation|radiation in a 6 fractions scheme and a daily dose of 6 Gy
89016057|NCT05609487|Other|Control group|"Step in control group This stepped wedge study does not use two parallel treatment arms. The stepped wedge design allows each center to be its own control group and then, after implementation of the practice by the research team, to become a intervention group.~The characteristics of these two phases are detailed below. Patients included in the control phase, i.e. without intervention, will be asked not to oppose participation in the research, after having received the presentation of the study and the information notice. The data collection will be similar to the data collection during the intervention period."
89016058|NCT05609487|Other|Protection plan group|"The intervention consists of making the protection plan in a co-constructed process with the care user. This tool is built in 6 steps, is written and takes 20 to 40 minutes to complete.~These 6 steps allow to identify the first signs of a suicidal crisis and to identify different strategies to face it. They are constructed in an ascending order, with the aim of being used by the care user in an autonomous situation."
89016059|NCT05591222|Placebo Comparator|Placebo/Daxdilimab Arm 1|Administration of placebo Q4W from Day 1 through Week 20 and administration of Daxdilimab Q4W from Week 24 through Week 44.
89016060|NCT05591222|Experimental|Daxdilimab Arm 2|Administration of Daxdilimab Q4W from Day 1 through Week 44.
89016061|NCT05591222|Experimental|Daxdilimab Arm 3|Administration of Daxdilimab Q4W from Day 1 through Week 44.
89016062|NCT05584410|Experimental|App-based model of care|"The app-based model of care includes at least one physical visit at the clinic. The majority of the treatment is provided by the app, containing five different sections:~1) My information: specific information regarding osteoarthritis and generic lifestyle advice. 2 & 3) My exercise & My plan: individualized exercises where instructions are given through real-time video or pictures and written descriptions. The patient has access to a calendar and an overview of scheduled rehabilitation/exercises and care meetings. 4) My progress: weekly assessment of pain + every six-month with valid patient reported outcome measures and test of function. 5) My messages (asynchronous chat with the responsible physiotherapist). The app sends automatic and daily reminders and / or motivational notifications."
89016063|NCT05584410|Active Comparator|Web-based model of care|The patient will get access to information about osteoarthritis and generic osteoarthritis exercises program from a web-based platform Individualization of the training can be done by the responsible physiotherapist informing about changes in the training via the message function and / or during physical follow-up visits. An individualized rehabilitation program can be given to the patient, via the platform or at a physical visit at the clinic, in form of a document with pictures and descriptive information. As long as the patient is under treatment (approximately three months), he/she can contact their responsible physiotherapist by sending a message from the platform.
89016064|NCT05584410|Active Comparator|Standard care|Patients who are randomized to standard care receive osteoarthritis specific information at three different group meetings (physical or digital) led by a physiotherapist, an occupational therapist and / or dietitian (each rehab clinic makes its own arrangement). After the theory sessions, the patient is booked for another physical visit to the responsible physiotherapist where an individual training program is tested. The patient is then offered to regularly exercise at the clinic, individually or in a group under supervision from a physiotherapist.
89016065|NCT05582070|Experimental|actigraphy|Patient with nasal obstruction
89016066|NCT05567250|Experimental|Experimental Intervention + Usual Care|Intervention group families will receive usual care and they will be connected via telephone to 211LA.
89016067|NCT05567250|No Intervention|No Intervention: Usual Care|This group will receive usual care
89016068|NCT05558241|Experimental|Combined MRI and micro-ultrasound guided prostate biopsy.|In a single biopsy session, first, a microUS-guided biopsy of regions of interest (ROIs) will be performed. The MRI fusion software will then be turned on, the clinician unblinded to the MRI results, and biopsy cores from within the boundaries of the MRI-fused lesion will be sampled from ROIs. Up to two ROIs identified on microUS or MRI will be targeted with up to 3 cores per ROI. If the MRI ROIs overlap with the microUS ROIs after unblinding, then the cores taken during the microUS-guided biopsy will be counted as both microUS and MRI-guided. Finally, a standard 12-core systematic biopsy will be performed.
89016069|NCT05557370|Active Comparator|Group 1|Patients prior to renal transplant: 9vHPV 0,2,6 months. Immunogenicity test on 0, 7, 12, 24 months.
89016070|NCT05557370|Active Comparator|Group 2|Patients > 6 months from renal transplant: 9vHPV 0,2,6 months. Immunogenicity test on 0, 7, 12, 24 months.
89016071|NCT05554159|Experimental|Actigraph|A device worn on the waist that measures physical activity (such as the number of steps participants walk each day, how long participants spend standing, and how long partticipants spend laying down). Participants should wear the ActiGraph at least 10 hours a day for 7 days.
89016072|NCT05549609|Experimental|XSTEM-VLU|Single topical dose of XSTEM-VLU
89016073|NCT05549609|Placebo Comparator|Vehicle|Single topical dose of CryoStor CS10
89016074|NCT05546385|Active Comparator|Active device|
89016075|NCT05546385|Placebo Comparator|Sham device|
89016076|NCT05544162|Experimental|SeND Home precision nutrition pathway|Oral nutrition supplements (ONS) will be given, at maximum, three times per day throughout hospitalization. Upon discharge, participants will be given 4-weeks' worth of oral supplements to take. Adjustments may be made based on indirect calorimetry (IC) measurements by the clinical dietitian.
89016077|NCT05544162|No Intervention|Control pathway|Standard of care nutrition delivery throughout hospitalization. Upon discharge they will be sent home with standard nutrition information without Indirect Calorimetry (IC) guidance.
89016078|NCT05543642|Active Comparator|Arm 1 (control group, sequential administration)|"Individuals with other chronic conditions and not active rheumatic disease (defined as being treated), who are eligible to receive their tdap booster and hepA vaccines, and receiving a COVID-19 booster vaccination.~This arm will receive sequential administration of both tdap booster and hepA vaccinations."
89016079|NCT05543642|Active Comparator|Arm 2 (co-administration group)|"Individuals with other chronic conditions and not active rheumatic disease (defined as being treated), who are eligible to receive their tdap booster and hepA vaccines, and receiving a COVID-19 booster vaccination.~This arm will receive co-administration of hepA vaccination."
89016080|NCT05543642|Active Comparator|Arm 3 (co-administration group)|"Individuals with other chronic conditions and not active rheumatic disease (defined as being treated), who are eligible to receive their tdap booster and hepA vaccines, and receiving a COVID-19 booster vaccination.~This arm will receive co-administration of tdap booster vaccination."
89016081|NCT05543642|No Intervention|Arm 4 (Inflammatory arthritis patients using DMARDS)|"Individuals with inflammatory arthritis patients using DMARDS, who are eligible to receive their tdap booster and hepA vaccines, and receiving a COVID-19 booster vaccination.~This arm will only receive the standard of care COVID-19 booster vaccination."
89455351|NCT02421458|Active Comparator|arm 2: 16 fractrions of radiation|radiation in a 16 fractions scheme and a daily dose of 3.125 Gy
89016082|NCT05543044|Experimental|TAY receiving peer mentor intervention|Transition age youth with EDs (n=35) will receive a peer mentor delivered transition intervention
89016083|NCT05542238|Active Comparator|CON|Age-and sex-matched healthy controls with exercise intervention
89016084|NCT05542238|Experimental|SCI|Individuals with spinal cord injury
89016085|NCT05540145||SOX plus Paclitaxel with or without antiangiogenesis followed by PD-1 antibody|SOX: Oxaliplatin+S-1
89016086|NCT05536960|Experimental|68Ga-Dotatate PET/CT|These patients will undergo a 68Ga-Dotatate PET/CT scan.
89016087|NCT05525273|Experimental|Dabrafenib and trametinib|Dabrafenib 75 mg twice daily and trametinib 2 mg once daily
89455352|NCT04483310|Experimental|MR therapy|MR therapy is a psychological treatment for SP, comprised of the following steps applied directly during the attack: Step I: Reappraisal of the meaning of the attack; Step II: psychological and emotional distancing; Step III: inward focused-attention meditation; Step IV: Muscle relaxation.
89455353|NCT04483310|Active Comparator|Control intervention|The control intervention was identical, except participants engaged in deep breathing; entailing slow deep breaths, while repeatedly counting from 1-10. This is an active control (breathing-distraction exercise) rather than a placebo.
89455354|NCT02428946|Active Comparator|Morning bromocriptine|Bromocriptine is taken in the morning
89455355|NCT02428946|Active Comparator|Evening bromocriptine|Bromocriptine is taken in te evening
89455356|NCT03182036|Experimental|Study group|Portable pulsed oxygen
89455357|NCT02421848||Cirrhotic Patients With Ascites|Cirrhotic Patients With Ascites
89455358|NCT02422004|Active Comparator|Control|This constitutes the currently accepted regime and is therefore consider the control group (CTRL) with early range of motion and early weight bearing. The control group was allowed to have partial weight-bearing from day 0 and full weight-bearing from week 4. Furthermore, they were instructed in tendon strain exercise identical with the range of motion group.
89455359|NCT02422004|Experimental|Range of motion|Early range of motion and delayed weight bearing (ROM). The range of motion group was restricted completely from weight-bearing until week 6, allowed partial weight-bearing after 6 weeks and full weight-bearing after 8 weeks. In addition to this, the patients were instructed to perform tendon strain exercises, five times a day, from week 2. The exercises were performed by removing the foot from the brace and then perform light dorsal ankle movement, 25 repetitions/time, when sitting on a table.
89455360|NCT02422004|Experimental|Immobilization|Delayed weight-bearing or range of motion (IMMOB). The immobilization group was restricted completely from weight-bearing until week 6, allowed partial weight-bearing after 6 weeks and full weight-bearing after 8 weeks.
89016088|NCT05523401|Experimental|10 mg 2C-B|2C-B (10 mg)
89016089|NCT05523401|Experimental|20 mg 2C-B|2C-B (20 mg)
89016090|NCT05523401|Experimental|30 mg 2C-B|2C-B (30 mg)
89016091|NCT05523401|Active Comparator|125 mg MDMA|MDMA (125 mg)
89016092|NCT05523401|Active Comparator|25 mg Psilocybin|Psilocybin (25 mg)
89016093|NCT05523401|Placebo Comparator|Placebo|Placebo
89016094|NCT05510141|Experimental|Virtual Reality Gaming|
89016095|NCT05510141|Active Comparator|Nitrous Oxide|Standard procedure
89016096|NCT05502341|Experimental|Phase 2: Bictegravir (BIC) 75 mg + Lenacapavir (LEN) 25 mg|"Participants will switch from their stable baseline regimen (SBR) to a regimen of BIC 75 mg + LEN 25 mg. Participants will receive a 2-day loading dose regimen of LEN 600 mg, in addition to the daily doses of BIC 75 mg + LEN 25 mg starting on Day 1 up to the end of randomized treatment (ERT) visit, participants will be treated for at least 24 weeks during the Randomized Period.~Following Randomized Period, the participants will have an option to participate in an Extension Period to receive BIC/LEN 75 mg/50 mg fixed dose combination (FDC)."
89016097|NCT05502341|Experimental|Phase 2: BIC 75 mg + LEN 50 mg|"Participants will switch from their SBR to a regimen of BIC 75 mg + LEN 50 mg. Participants will receive a 2-day loading dose regimen of LEN 600 mg, in addition to the daily doses of BIC 75 mg + LEN 50 mg starting on Day 1 up to the ERT visit, participants will be treated for at least 24 weeks during the Randomized Period.~Following Randomized Period, the participants will have an option to participate in an Extension Period to receive BIC/LEN 75 mg/50 mg FDC."
89016098|NCT05502341|Active Comparator|Phase 2: Stable Baseline Regimen (SBR)|"Participants will continue with their SBR per prescription for up to the ERT visit, participants will be treated for at least 24 weeks during the Randomized Period.~Following Randomized Period, the participants will have an option to participate in an Extension Period to receive BIC/LEN 75 mg/50 mg FDC."
89455361|NCT02428634|Experimental|Program SI! for Elementary 6 levels|The core intervention comprises classroom activities grouped in healthy challenges (about diet, physical activity, human body and heart, and emotions management) distributed across the different levels and implemented by the corresponding teachers. All the materials, formal training and a teaching guide are provided to the school staff by the SHE Foundation. Families receive family-challenges and key messages about their children's health. The school environment is intervened mainly through an annual Healthy Fair. The intervention is implemented during all the elementary levels (PSIE13+PSIE46).
89455362|NCT02428634|No Intervention|Normal curriculum|The schools on the control group keep their normal curriculum and don't join any school program about health until the end of the study.
89201305|NCT00908661|Active Comparator|Prophylactic mesh|All patients will have a permanent ostomy and a randomisation with prophylactic mesh
89201306|NCT00908661|No Intervention|without prophylactic mesh|All patients will have a permanent ostomy and a randomisation without prophylactic mesh
89016099|NCT05502341|Experimental|Phase 3: BIC/LEN 75 mg/50 mg Fixed-dose Combination (FDC)|"Participants will switch from their SBR to a regimen of BIC/LEN 75 mg/50 mg FDC. Participants will receive a 2-day loading dose regimen of LEN 600 mg, in addition to the daily doses of BIC/LEN 75 mg/50 mg FDC starting on Day 1 up to the ERT visit, participants will be treated for at least 48 weeks during the Randomized Period.~Following Randomized Period, the participants will have an option to participate in an Extension Period to receive BIC/LEN 75 mg/50 mg FDC."
89016100|NCT05502341|Active Comparator|Phase 3: Stable Baseline Regimen|"Participants will continue with their SBR per prescription for up to the ERT visit, participants will be treated for at least 48 weeks during the Randomized Period.~Following Randomized Period, the participants will have an option to participate in an Extension Period to receive BIC/LEN 75 mg/50 mg FDC."
89016101|NCT05499013|Experimental|Phase 1 open-label SLN124|SLN124 for subcutaneous (s.c.) injection
89016102|NCT05499013|Experimental|Phase 2 Blinded SLN124|SLN124 for subcutaneous (s.c.) injection
89016103|NCT05499013|Placebo Comparator|Phase 2 Blinded Placebo|Sodium chloride for s.c. injection
89016104|NCT05498181|Experimental|sacubitril/valsartan|Participants will take sacubitril/valsartan, beginning dose of 24/26mg twice daily, with titration to target dose of 97/103 mg twice daily over the first four weeks. Patients will remain on the maximally tolerated dose for the remaining 12 weeks (total on-drug period of 16 weeks) before stopping drug and being followed for a further two weeks (total study time of 18 weeks).
89016105|NCT05498181|Placebo Comparator|placebo|Participants will take equivalent placebo, beginning equivalent dose of 24/26mg twice daily, with titration to target equivalent dose of 97/103 mg twice daily over the first four weeks. Patients will remain on the maximally tolerated dose for the remaining 12 weeks (total on-drug period of 16 weeks) before stopping drug/placebo and being followed for a further two weeks (total study time of 18 weeks).
89016106|NCT05458141|Experimental|Group 1: Usual Education + Weekly Exposure to FYA-003|Students in grades assigned to Group 1 play FYA-003 in the classroom for 30 minutes every week for 12 weeks on a day at a time determined by the school & research team.
89016107|NCT05458141|No Intervention|Group 2: Usual Education + Weekly exposure to non-health related educational mobile games|Students in grades assigned to Group 2 play educational games unrelated to health in the classroom for 30 minutes every week for 12 weeks on a day at a time determined by the school & research team.
89016108|NCT05456620|Experimental|Low Tendon Compression Rehabilitation (LTCR)|A progressive, criteria-based, 4-stage exercise protocol in which the amount of tendon compression is limited (12 weeks).
89455363|NCT02428634|Experimental|Program SI! for Elementary first levels|The core intervention comprises classroom activities grouped in healthy challenges (about diet, physical activity, human body and heart, and emotions management) distributed across the different levels and implemented by the corresponding teachers. All the materials, formal training and a teaching guide are provided to the school staff by the SHE Foundation. Families receive family-challenges and key messages about their children's health. The school environment is intervened mainly through an annual Healthy Fair. To evaluate the effects of different exposures to the program, the intervention is implemented in the first three levels (PSIE13).
89455364|NCT02428634|Experimental|Program SI! for Elementary last levels|The core intervention comprises classroom activities grouped in healthy challenges (about diet, physical activity, human body and heart, and emotions management) distributed across the different levels and implemented by the corresponding teachers. All the materials, formal training and a teaching guide are provided to the school staff by the SHE Foundation. Families receive family-challenges and key messages about their children's health. The school environment is intervened mainly through an annual Healthy Fair. To evaluate the effects of different exposures to the program, the intervention is implemented in the last three levels (PSIE46).
89455365|NCT02421302|No Intervention|Well-nourished HIV+ ART naive|These children aged between 6months-12years will be followed up for 12weeks to look at their nutrition, immune and pharmacological responses. They will receive routine nutritional and ART adherence counseling
89455366|NCT02421302|Active Comparator|Moderately-malnourished HIV+; RUTF|These children aged between 6months - 12years, ART naive or experienced, will be initiating ready-to-use-therapeutic(RUTF) food and will be followed up for 12 weeks to see the effect of nutrition supplementation on immune and pharmacological responses
89455367|NCT02421302|Active Comparator|Severely acute-malnourished HIV+; RUTF|These children aged between 6months - 12years, ART naive or experienced, will be initiating ready-to-use-therapeutic(RUTF) food and will be followed up for 12 weeks to see the effect of nutrition supplementation on immune and pharmacological responses
89455368|NCT02428868|Experimental|Tranexamic acid - intravenous iron|"IV iron (Ferroven®) : 2 vials of 10 mL containing each one 100 mg iron, diluted in 100 mL normal saline over 30 minutes before induction of anesthesia and repeated on day two and three.~IV Tranexamic acid (Exacyl®): 1 gram diluted in 20 mL saline solution, in 30 minutes, five minutes before skin incision and a second 1 gram, 3 hours later."
89455369|NCT02428868|Active Comparator|Tranexamic acid|IV Tranexamic acid (Exacyl®): 1 gram diluted in 20 mL saline solution, in 30 minutes, five minutes before skin incision and a second 1 gram, 3 hours later.
89455370|NCT02428868|Placebo Comparator|Placebo|20 mL saline, in 30 minutes, five minutes before skin incision and 20 ml 3 hours later.
89455371|NCT02428400|Experimental|TG1050|"TG1050 SD cohort, administered SC as a single injection: 9.0 Log [10^9] 10.0 Log [10^10], 11.0 Log [10^11] virus particles~TG1050 MD cohort, administered SC as 3 once weekly injections:9.0 Log [10^9] 10.0 Log [10^10], 11.0 Log [10^11] virus particles~TG1050 Part B cohort, dose(s) and schedule to be determined"
89455372|NCT02428400|Placebo Comparator|Placebo|"Placebo SD cohort, administered SC as a single injection: 9.0 Log [10^9] 10.0 Log [10^10], 11.0 Log [10^11] virus particles~Placebo MD cohort, administered SC as 3 once weekly injections: 9.0 Log [10^9] 10.0 Log [10^10], 11.0 Log [10^11] virus particles~Placebo Part B cohort, dose(s) and schedule to be determined"
89455373|NCT02424890|Active Comparator|Repetitive Sim Group|9 simulation sessions
89455374|NCT02424890|Active Comparator|Control Group|3 simulation sessions
89455375|NCT03181880|Active Comparator|Aclidinium/formoterol|Patients will be randomized to receive either Aclidinium bromide/formoterol fumarate fixed-dose combination
89455376|NCT03181880|Active Comparator|Bronchodilators|The comparator arm consists of SOC.
89455377|NCT02428556|Active Comparator|Facts only|"Scenario describes study results without breakthrough language, promising language, no cautions about conditional approval"
89455378|NCT02428556|Active Comparator|promising language|"study description describes drug as promising; no warning about conditional approval"
89455379|NCT02428556|Active Comparator|"breakthrough with may warning"|"study describes drug as breakthrough; warning that continued approval may be contingent on subsequent verification of clinical benefit in confirmatory trials"
89455380|NCT02428556|Active Comparator|"breakthrough with is warning"|"study describes drug as breakthrough; warning that continued approval may be contingent on subsequent verification of clinical benefit in confirmatory trials"
89455381|NCT02428556|Experimental|breakthrough only|"Scenario describes study results with breakthrough language, no cautions about conditional approval"
89016109|NCT05456620|Active Comparator|High Tendon Compression Rehabilitation (HTCR)|A progressive, criteria-based, 4-stage exercise protocol in which the amount of tendon compression is not limited (12 weeks).
89016110|NCT05453539|Experimental|Healthy volunteers dose level 1|0.53 mL ADx-001 / kg
89016111|NCT05453539|Experimental|Patients dose level 1|0.53 mL ADx-001 / kg
89016112|NCT05453539|Experimental|Patients dose level 2|1 mL ADx-001 / kg
89455382|NCT03178994|Experimental|2% ketoconazole cream|2% ketoconazole cream apply on face twice daily for 10 weeks.
89455383|NCT03178994|Placebo Comparator|Placebo|Hydrophilic cream (in-house preparation) apply on face twice daily for 10 weeks.
89455384|NCT03182114|Placebo Comparator|supine position|the patient will receive spinal anesthesia by Bupivacaine; then she will be placed in supine position
89455385|NCT03182114|Experimental|Left lateral tilted position|the patient will receive spinal anesthesia by Bupivacaine; then she will be placed in left lateral tilted position
89455386|NCT03182270|Experimental|pancreatic cysts|
89455387|NCT02424812|Experimental|Intervention|school based handwashing education programme
89455388|NCT02424812|No Intervention|Control|no intervention
89455389|NCT02428322|Experimental|Intervention|2,000iu vitamin D3 per day for 15 weeks
89455390|NCT02428322|Placebo Comparator|Placebo|An identical placebo capsule daily for 15 weeks.
89455391|NCT02428244|No Intervention|Arm 1, Control|Standard of care intervention: All patients at the University as a standard of care receive informational materials about smoking cessation. They are referred to the patient resource center at our institution. Patients will be provided this, also they will be provided with a smoking cessation Quitline Brochure
89455392|NCT02428244|Experimental|Standard of care + brief counseling|Patients who are randomized into this arm will receive the standard of care (outlined above). Additionally, patients will also receive a smoking education/counseling session. Patients will receive 10-30 minutes of guided discussion regarding the risks and benefits with regards to smoking and the healing of their traumatic injuries. The smoking educators, who will be trained in accordance with the guidelines provided by MdQuit.org will utilize motivational interviewing techniques to enhance interest in quitting. Patients will receive a description of the quitline, and the quitlined will be the recommended resource. If patients elect to enroll in the quitline, they will be consented using the standardized quitline protocols.
89455393|NCT02428244|Experimental|Standard of care + counseling/follow-up|"Patients who are randomized into this arm will receive the same intervention as patients in Arm 2, except when patients arrive for their follow-up, the smoking educator will check-in with their progress for approximately 5 minutes. The techniques utilized during this check-in visit will include repetition of previously described motivational interviewing, at this point patients who elect to be referred to the quitline will be given this opportunity."
89455394|NCT03185078|Experimental|Active Comparator: Low density ESWT Application|ESWT application will be done at energy density of 0.12 mJ/mm2.
89455395|NCT03185078|Experimental|Active Comparator: High density ESWT Application|ESWT application will be done at an energy density of 0.3 mJ/mm2.
89455396|NCT03185078|Sham Comparator|Control|The ESWT application will be executed when the ESWT application is in the off position. During application, pre-recorded sound beats will be played to the treatment group.
89455397|NCT02421068||Preterm neonates|All neonates that receive at least one of the 9 drugs (phenobarbital, paracetamol, levetiracetam, midazolam, sildenafil, fentanyl, doxapram, ibuprofen, fluconazole) are included in the studied cohort
89455398|NCT03178916||Low risk pregnant women|evaluation of the efficacy of breastfeeding Low risk pregnant women
89455399|NCT03178916||high risk pregnant women|evaluation of the efficacy of breastfeeding high risk pregnant women
89455400|NCT03184532||D|diabetic patients
89455401|NCT03184532||ND|non-diabetic patients
89455402|NCT02424500|Experimental|d-Nav Device|"d-Nav Device: daily use to provide insulin dosage updates weekly - or sooner when needed based on analyzes and evaluates the historical blood glucose patterns.~Insulin dosage is adjusted as required"
89455403|NCT02424500|Active Comparator|Blood Glucose Monitoring System|"Patient's personal Over the Counter Blood Glucose Monitoring System (OTC BGMS) for daily glucose testing to determine insulin dosage needed.~Insulin dosage is adjusted as required"
89455404|NCT03106766|Experimental|Acne cream 1x|Twice-daily facial applications of the 1X product (avoiding contact with eyes and all mucous membranes) to the entire face for 6 months.
89455405|NCT03106766|Experimental|Acne cream 2x|Twice-daily facial applications of the 2X product (avoiding contact with eyes and all mucous membranes) to the entire face for 6 months.
89455406|NCT02424266||Healthy subjects|None invasive imaging of the tear film for subjects with no eye disease
89455407|NCT02424266||keratoconjunctivits sicca (KCS) and Dry Eye Syndrome (DES)|None invasive imaging of the tear film for KCS and DES patients as confirmed by a cornea specialist
89455408|NCT03053063|Experimental|SEL 6 mg|"Randomized Phase: SEL 6 mg plus placebo to match SEL 18 mg for up to 240 weeks.~Open-Label (OL) Phase: Participants who experienced a hepatic clinical event during the randomized phase prior to completing the Week 240 visit, will be offered the option to receive OL SEL 18 mg daily for a total treatment duration of 240 weeks inclusive of the Randomized Phase."
89455409|NCT03053063|Experimental|SEL 18 mg|"Randomized Phase: SEL 18 mg plus placebo to match SEL 6 mg for up to 240 weeks.~Open-Label Phase: Participants who experienced a hepatic clinical event during the randomized phase prior to completing the Week 240 visit, will be offered the option to receive OL SEL 18 mg daily for a total treatment duration of 240 weeks inclusive of the Randomized Phase."
89016113|NCT05453539|Experimental|Patients dose level 3|2 mL ADx-001 / kg
89455410|NCT03053063|Placebo Comparator|Placebo|"Randomized Phase: Placebo to match SEL 6 mg plus placebo to match SEL 18 mg for up to 240 weeks.~Open-Label Phase: Participants who experienced a hepatic clinical event during the randomized phase prior to completing the Week 240 visit, will be offered the option to receive OL SEL 18 mg daily for a total treatment duration of 240 weeks inclusive of the Randomized Phase."
89455411|NCT03116906|Experimental|BI 685509|multiple rising doses of BI 685509
89455412|NCT03116906|Placebo Comparator|Placebo|matching placebo
89455413|NCT00702338||corifollitropin alfa + recFSH Mothers|Eligible participants in Stage 1a of base study P05693 (NCT00697255) were administered injection(s) with subcutaneous (SC) corifollitropin alfa (15mcg) and daily SC injections with recFSH (50 IU) when the largest follicle reached a size of ≥12 mm. A bolus injection of hCG (5000 IU) was then administered if at least one follicle was ≥18 mm and in total no more than two follicles ≥15 mm were observed. Eligible mothers in this group with an ongoing pregnancy established in the base study (confirmed at ≥10 weeks after hCG bolus injection) were then to be followed for safety and efficacy on the current follow-up (FU) study (P05713) according to standard practice (no treatment administered).
89455414|NCT00702338||corifollitropin alfa + hCG Mothers|Eligible participants in Stage 1b of base study P05693 (NCT00697255) were administered injection(s) with SC corifollitropin alfa (30 mcg) and daily SC injections with hCG (200 IU) when the largest follicle reached a size of ≥12 mm. A bolus injection of hCG (5000 IU) was then administered if at least one follicle was ≥18 mm and in total no more than two follicles ≥15 mm were observed. Eligible mothers in this group with an ongoing pregnancy established in the base study (confirmed at ≥10 weeks after hCG bolus injection) were then followed for safety and efficacy on the current FU study (P05713) according to standard practice (no treatment administered).
89455415|NCT03184688|Experimental|platelet rich plasma injection|The platelet rich plasma (PRP) is a new and potential treatment for peripheral neuropathy in many animal studies.
89455416|NCT03184688|Placebo Comparator|Normal saline|Normal saline for hydrodissection
89455417|NCT02428010|Experimental|Treatment|TMVR Implant
89455418|NCT02427932||Pregnant/Ampicillin|pregnant participants who will receive Ampicillin for conditions such as Group B Streptococcus
89455419|NCT02427932||Non-pregnant/Ampicillin|non-pregnant participants who will receive Ampicillin for a qualifying hospital admission
89455420|NCT02427932||Pregnant and Non-pregnant/Ampicillin and Gentamicin|pregnant participants who will receive Ampicillin and Gentamicin for conditions such as chorioamnionitis; non-pregnant participants who will receive Ampicillin and Gentamicin for a qualifying hospital admission
89455421|NCT02427932||Non-Pregnant/Gentamicin|non-pregnant participants who will receive Gentamicin for a qualifying hospital admission
89455422|NCT03626519|Experimental|Test with Menthol|Patients will chew a menthol flavored chewing gum 5 minutes before perform one Six-minute Walk Test
89455423|NCT03626519|Placebo Comparator|Test with placebo|Patients will chew a strawberry flavored chewing gum 5 minutes before perform one Six-minute Walk Test
89455424|NCT02427776|Experimental|IMP|
89455425|NCT04576247|Experimental|Combined aerobic and resistance exercise|12 weeks of supervised resistance exercise and unsupervised aerobic exercise.
89455426|NCT03184610||OCT-scanning|Patients with Keratoconus are scanned with an OCT-Prototype
89455427|NCT03184610||OCT-scanning for volunteers|Volunteers with healthy eyes are scanned with an OCT-Prototype
89455428|NCT03184766|Experimental|1|Treatment Order: Test, Comparator 1, Comparator 2
89455429|NCT03184766|Experimental|2|Treatment Order: Test, Comparator 2, Comparator 1
89016114|NCT05453539|Experimental|Patients dose level 4|4 mL ADx-001 / kg
89455430|NCT03184766|Experimental|3|Treatment Order: Comparator 1, Test, Comparator 2
89455431|NCT03184766|Experimental|4|Treatment Order: Comparator 1, Comparator 2, Test
89455432|NCT03184766|Experimental|5|Treatment Order: Comparator 2, Test, Comparator 1
89455433|NCT03184766|Experimental|6|Treatment Order: Comparator 2, Comparator 1, Test
89455434|NCT03184376|Experimental|Prebiotic|Prebiotic oligofructose (Orafti P95, Beneo-Orafti Inc., Tienen, Belgium) taken 8g orally per day for 12 weeks followed by 16g per day for 24 weeks.
89455435|NCT03184376|Placebo Comparator|Placebo|Placebo maltodextrin (isocaloric to prebiotic) taken 3.3g orally per day for 12 weeks followed by 6.6g per day for 24 weeks.
89455436|NCT03181568|Other|Control|This arm group (control) will receive standard wound care of chronic wounds
89455437|NCT03181568|Other|Treatment|The treatment arm of the study will utilize the MolecuLight i:X Imaging Device to guide a clinician to inspect, sample, debride or further evaluate areas within or around a wound where fluorescent bacteria are present
89455438|NCT03181646|No Intervention|control group|newborns with hypoxic ischemic encephalopathy grade 2/3 who will receive only supportive care
89455439|NCT03181646|Experimental|study group|newborns with hypoxic ischemic encephalopathy grade 2/3 who will receive citicoline along with supportive care
89455440|NCT04482998||Steroids only - early|treatment was initiated within 7 days of acoustic trauma.
89455441|NCT04482998||Early combined steroid and hyperbaric oxygen therapy|treatment was initiated within 7 days of acoustic trauma.
89455442|NCT04482998||Delayed combined steroid and hyperbaric oxygen therapy|treatment was initiated after 7 days of acoustic trauma.
89455443|NCT04482998||Early sequential steroid followed by HBO therapy|treatment was initiated within 7 days of acoustic trauma.
89455444|NCT04482998||Delayed sequential steroid followed by HBO therapy|treatment was initiated after 7 days of acoustic trauma.
89455445|NCT04482998||Hyperbaric oxygen therapy only|
89455446|NCT04482998||No treatment|
89016115|NCT05444946|Experimental|Steroid itraconazole|Combination of oral glucocorticoid (prednisolone 0.5 mg/Kg body weight tapered over 4 months) and itraconazole for 12 months
89016116|NCT05444946|Active Comparator|Itraconazole|Oral itraconazole for 12 months
89016117|NCT05436236||Control|People who self-report that they do not use cannabis.
89016118|NCT05436236||Cannabis|People who self-report that they use cannabis.
89455447|NCT04482998||Steroid only - delayed|treatment was initiated after 7 days of acoustic trauma.
89455448|NCT02420834|Experimental|Tear Supplement Hypromellose 0.15%|Preservative free Hypromellose Eye Drops BP 0.15% applied as required for 1 month
89201307|NCT00775398||A|Subjects with anti-topical bovine thrombin antibodies pre-surgery, who received topical THROMBIN-JMI® during the study surgery.
89455449|NCT02420834|Experimental|Tear Supplement Hypromellose 0.4%|Preservative free Hypromellose Eye Drops BP 0.4% applied as required for 1 month
89455450|NCT02420834|Experimental|Tear Supplement Carboxymethylcellulose|Tear Supplement 3: Preservative free 0.25% Carboxymethylcellulose, electrolyte balanced (Theratears) applied as required for 1 month
89016119|NCT05419011|Experimental|Arm I (Tri-Ad5, N-803)|Participants receive Tri-Ad5 SC and N-803 SC at weeks 0, 4, 8, and 52. Participants also undergo SOC colonoscopy with biopsy at baseline and at 52 and 104 weeks. Participants undergo blood sample collection throughout the study.
89455451|NCT02420834|Experimental|Tear Supplement Liposomal spray|Preservative free Phospholipid liposomal spray (Tears Again) applied as required for 1 month
89455452|NCT03184298|Other|Group|Participants receive three interventions: Surveys, Interviews, and Group Workshops
89455453|NCT03184142|Experimental|Simulation|During a suturing class at the simulation center, the students enter a classroom. Although the students are not aware of this, among them is an actor playing the role of a student. One of the two professors is also an actor. As the activity progresses, the professor targets the student played by an actor. The intimidation intensifies until the end. At the end of the activity, there is a debriefing explaining to the students that the bullying professor and the victim were actors.
89455454|NCT03184142|Experimental|Video|During a suturing class at the simulation center, after 55 minutes of suturing, the students will be exposed to a 15-minute video on workplace and hospital intimidation and how to manage it.
89455455|NCT03184142|Placebo Comparator|Control|During a suturing class at the simulation center, the students suture for the entire 70-minute duration of the activity. They are not exposed to intimidation (control group).
89455456|NCT01316939|Placebo Comparator|Placebo|Placebo
89016120|NCT05419011|Placebo Comparator|Arm II (placebo)|Participants receive placebo SC at weeks 0, 4, 8, and 52. Participants also undergo SOC colonoscopy with biopsy at baseline and at 52 and 104 weeks. Participants undergo blood sample collection throughout the study.
89455457|NCT01316939|Experimental|GSK1605786A once daily|500 milligrams once daily
89455458|NCT01316939|Experimental|GSK1605786A twice daily|500 milligrams twice daily
89455459|NCT03183986|Active Comparator|Phototherapy 478 nm|The jaundiced neonates receives phototherapy with blue light from above at wavelength 478 nm. They are treated for 24 hours, which is standard treatment for neonatal jaundice.
89455460|NCT03183986|Active Comparator|Phototherapy 459 nm|The jaundiced neonates receives phototherapy with blue light from above at wavelength 459 nm. They are treated for 24 hours, which is standard treatment for neonatal jaundice.
89455461|NCT03184220|Experimental|EXPERIMENTAL GROUP|"Patients who are pregnant, have pacemaker and those surgically operated cervical spine patients who have been treated with myofascial therapy a month earlier.~Multimodal physical therapy program includes:~Myofascial syndrome cervical therapy treatment."
89455462|NCT03184220|Experimental|CONTROL GROUP|"Multimodal physical therapy program includes:~ultrasound therapy (US),~transcutaneous electric nerve stimulation (TENS)~massage."
89455463|NCT02424110|Experimental|Argon beam coagulator ablation group|In the bipolar left atrial radiofrequency ablation, when the linear ablation was performed through along the lower edge of interatrial groove incision up to the mitral annulus, there is a gap between the ends of the ablation line and the mitral annulus And in the bipolar right atrial radiofrequency ablation, when the linear ablation was performed along the lower edge of the coronary sinus ostium up to the inferoseptal commissure and through the vertical incision on anterior wall of the right atrium up to the tricuspid annulus. There also have gaps between ends of the ablation line and the tricuspid annulus. In the experimental group the investigators plan to use conventional bipolar radiofrequency ablation and use argon beam coagulator to ablate these gaps.
89455464|NCT02424110|Experimental|Bipolar radiofrequency ablation group|Only use conventional bipolar radiofrequency ablation and do not deal with these gaps.
89455465|NCT02424032|Experimental|Exercise and connective tissue massage|Stabilization exercise and connective tissue massage have been applied
89016121|NCT05419011|Experimental|Safety phase I (Tri-Ad5)|Participants receive Tri-Ad5 SC at weeks 0, 4, 8, and 52. Participants also undergo SOC colonoscopy with biopsy at baseline and at 52 weeks and 104 weeks. Participants undergo blood sample collection throughout the study.
89016122|NCT05419011|Experimental|Safety phase II (Tri-Ad5 , N-803)|Participants receive Tri-Ad5 SC and N-803 SC at weeks 0, 4, 8, and 52. Participants also undergo SOC colonoscopy with biopsy at baseline and at 52 weeks and 104 weeks. Participants undergo blood sample collection throughout the study.
89455466|NCT02424032|Active Comparator|Exercise|Only stabilization exercise has been applied
89455467|NCT02423954|Experimental|Arm 1|Temsirolimus 25 mg every 14 days + nivolumab
89455468|NCT02423954|Experimental|Arm 2|Irinotecan 150 mg/m2 every 14 days + nivolumab
89455469|NCT02423954|Experimental|Arm 3|Irinotecan + capecitabine + nivolumab irinotecan 175 mg/m2 on day 1 every 14 days + capecitabine 1000 mg PO BID days 1-5 on, days 6-7 off, each 7 day period
89455470|NCT03626441|Placebo Comparator|Placebo|Two coloured capsules containing 0.5 mg of cornstarch and flavoured with non-active essence of ginger, given 2 hours before the scheduled start of surgery.
89455471|NCT03626441|Experimental|Ginger|Two coloured capsules containing 0.5g ginger powder, flavoured with non-active essence of ginger, given 2 hours before the scheduled start of surgery.
89455472|NCT02427542|Active Comparator|CBT for DP|Six sessions of CBT covering psycho-education, formulation, enhancing coping strategies (including grounding) and cognitive restructuring techniques.
89455473|NCT02427542|Placebo Comparator|Treatment as usual|Participants will continue to receive their normal treatment - in most cases, this will be care coordination/case management delivered through a community mental health team and may include medication.
89455474|NCT03181334|Active Comparator|Branch I|"Condition 1: (Standard Intervention)~Mailed fecal immunochemical test (FIT) kit including the following:~Invitation letter to complete free colorectal cancer (CRC) screening."
89455475|NCT03181334|Experimental|Branch II and Branch III|"Condition 2: (Time Guideline)~Mailed fecal immunochemical test (FIT) kit including the following:~Invitation to complete free colorectal cancer (CRC) screening within a specified time frame:~Branch II - Brief Time (1-week)~Branch III - Extended Time (3-weeks)"
89016123|NCT05413642|Experimental|'Recommended algorithm' cohort|COVID-19 patients treated at home by their family doctors according to the proposed recommendations
89016124|NCT05413642|Active Comparator|Usual care|COVID-19 patients treated at home by their family doctors according to their usual clinical practice expected to be in accordance with AIFA recommendations
89016125|NCT05407025||Observational (questionnaire, biospecimen collection)|Patients complete a risk factor questionnaire over 15 minutes. Patients also undergo collection of blood and urine during pre-operative visit and collection of tissue samples at the time of surgery.
89016126|NCT05406739|Experimental|Spinal Cord Injury Group|Participants who have a spinal cord injury will receive two meals on two separate visits between five to seven days.
89455476|NCT03181334|Experimental|Branch IV and Branch V|"Condition 3: (Time Guideline + Incentive)~Mailed fecal immunochemical test (FIT) kit including the following:~Invitation to complete free colorectal (CRC) screening within a specified time frame with a monetary incentive:~Branch IV - High Incentive~Branch V - Low Incentive"
89455477|NCT03178604|Active Comparator|Classic massage|Classic massage (CM) treatment based on petrissage. It applies: 1 minute of mild effleurage, 5 minutes of deep effleurage with the thumbs, 5 minutes of firm kneading and 1 minute of tapotement (20 minutes in total). This procedure was repeated for each muscle group.
89455478|NCT03178604|Active Comparator|Sham massage|Sham massage (SM). 20 minutes in total soft effleurage was performed. This procedure was repeated for each muscle group.
89455479|NCT03044249|Experimental|MP-101|"Week 0:~Participants received 20 milligrams (mg) MP-101 orally QD (1 x 20-mg caps) and 2 placebo caps.~Week 1:~Participants received 40 mg MP-101 orally QD (2 x 20-mg caps) and 1 placebo caps.~Week 2 through Week 9:~Participants received 60 mg MP-101 orally QD (3 x 20-mg caps )."
89455480|NCT03044249|Placebo Comparator|Placebo|Participants received 3 capsules (caps) of placebo orally once daily (QD) during Week 0, Week 1, and Week 2 through Week 9.
89455481|NCT02427308||miltefosine patients that become pregnant|
89455482|NCT03178292|Active Comparator|Levofloxacin|Levofloxacin 500 mg daily for 5 days
89455483|NCT03178292|Placebo Comparator|Placebo|Placebo tab daily for 5 days
89455484|NCT02427386|Active Comparator|dynamized estrogen in alcohol solution|Dynamized estrogen (17-beta estradiol) in the 12cH, 24cH and 18cH potencies.
89455485|NCT02427386|Placebo Comparator|placebo (alcohol solution)|This arm received alcohol solution during the 24-week study duration.
89455486|NCT05520827|Experimental|Single Rising Dose part: BI 1584862|
89455487|NCT05520827|Placebo Comparator|Single Rising Dose part: Placebo|
89455488|NCT05520827|Experimental|Food effect part: BI 1584862 fed (treatment test, T)/ BI 1584862 fasted (treatment reference, R)|
89455489|NCT05520827|Experimental|Food effect part: BI 1584862 fasted (treatment reference, R)/ BI 1584862 fed (treatment test, T)|
89016127|NCT05406739|Active Comparator|Control Group|Participants without a spinal cord injury will receive two meals on two separate visits between five to seven days.
89016128|NCT05403580|Experimental|Arm I (olanzapine)|Patients receive olanzapine PO every night on days 1-28.
89016129|NCT05403580|Active Comparator|Arm II (placebo, olanzapine)|Patients receive placebo PO every night on days 1-2 and olanzapine PO every night on days 3-28.
89016130|NCT05389189|Active Comparator|CBT Care|"Intervention content~The MITIG.RA program incorporates the following key topics during the 8 weeks of intervention (1st phase):~(i) Psychoeducation on RA, sleep hygiene, exercise, and general nutritional recommendations (promote behavioural change and self-care, boost the sense of self-worth and self-efficacy) (ii) Activity engagement and pacing (iii) The functioning of the mind and its problematic patterns (iv) Focusing on the 'here and now' (mindfulness) (v) Learning new ways of self-relating - self-compassion (vi) Making room for suffering (acceptance); and (vii) Moving towards what matters (identification of valued life directions and promotion of consistent values and goals-directed behaviour).~Booster sessions, at 4 and 12 weeks after completion of the first phase"
89016131|NCT05389189|No Intervention|TAU Care|Usual Care respecting international recommendations for the management of RA.
89016132|NCT05386394|Experimental|Active tDCS + Language Therapy first|Active tDCS will be applied at the beginning of 45 minutes language therapy session and will last for 20 minutes.
89455490|NCT03181802|Experimental|botulinum toxin A|
89455491|NCT03181802|Placebo Comparator|Placebo|
89455492|NCT04518137|Experimental|ATG-008|Enrolled patients will be treated with ATG-008 at an oral fixed milligram (mg) dose of 30 mg QD
89455493|NCT03181178|Active Comparator|KokoPlus and Nutrition Education|Macro-micronutrient complementary food supplement and Nutrition Education
89455494|NCT03181178|Active Comparator|Micronutrient and Nutrition Education|A micronutrient powder and Nutrition Education
89455495|NCT03181178|Active Comparator|Nutrition Education Only|Nutrition Education
89455496|NCT03181178|No Intervention|Growth Monitoring Only|Growth monitoring
89455497|NCT04541537|Experimental|Sorbstar®|Odour sampling : rub hands with Sorbstars® before and post-surgery
89455498|NCT04541537|Experimental|Dog Detection|Odour sampling :sleep over a night with a compress on the affected breast before and after surgery
89455499|NCT02420522|Experimental|Active-first|Participants randomly assigned to this arm will receive one week of active Repetitive Transcranial Magnetic Stimulation prior to one week of Sham Transcranial Magnetic Stimulation, separated by at least one week.
89455500|NCT02420522|Experimental|Sham-first|Participants randomly assigned to this arm will receive one week of Sham Transcranial Magnetic Stimulation prior to one week of active Repetitive Transcranial Magnetic Stimulation, separated by at least one week.
89455501|NCT02420522|Active Comparator|Full-course Active|Participants in this arm will receive three weeks (30 session, twice-daily) of active Repetitive Transcranial Magnetic Stimulation. This arm will not involve random assignment.
89455502|NCT04540757||Surgery|Surgery and systemic anti-cancer therapy (with or without radiotherapy) given in any order
89455503|NCT04540757||No surgery|Radiotherapy and systemic anti-cancer treatment given in any order (with or without adjuvant immunotherapy if indicated).
89455504|NCT02427230|Active Comparator|Pelvic floor muscle training (PFMT)|Pelvic floor muscle training daily during 12 weeks.
89455505|NCT02427230|Active Comparator|PFMT and electrical stimulation|Pelvic floor muscle training and intravaginal neuromuscular electrical stimulation daily during 12 weeks.
89455506|NCT05478551|Experimental|Botulinum toxin|"Biopsy site receiving botulinum toxin~Following the biopsy closures, one of two biopsy sites (left or right) will be selected to receive 30u (0.3cc) of botulinum toxin injected into the suture line at a depth of PPD bleb.~The treatment for each wound site will be randomized (left versus right) and blinded but consistent throughout dosing."
89455507|NCT05478551|Placebo Comparator|Placebo|"Placebo Comparator: Biopsy site receiving placebo~Following the biopsy closures, the other biopsy site will receive 30u (0.3cc) of bacteriostatic normal saline injected into the suture line at a depth of PPD bleb."
89455508|NCT03180788|Active Comparator|Traditional ESD|The patients in this Group will undergo traditional ESD.
89455509|NCT03180788|Experimental|Traction assisted ESD|The patients in this Group will undergo traction assisted ESD
89455510|NCT02420444|Placebo Comparator|BCG SSI prime with Placebo|"All subjects received BCG Vaccine SSI, 2-8 x 10^5 CFU (BCG) on Study Day -42.~Placebo containing 0,8 mL sterile buffer consisting of 10 mmol Tris and 169 mmol NaCl aqueous solution was administered on Study Days 0, 56, and 231."
89455511|NCT02420444|Experimental|BCG SSI prime with Placebo and AERAS-404|"All subjects received BCG Vaccine SSI, 2-8 x 10^5 CFU (BCG) on Study Day -42.~Placebo on Study Day 0 followed by AERAS-404 50/500 on Study Days 56 and 231.~AERAS-404 50/500 was a fixed dose combination of H4 50 mcg and IC31 500 nmol (KLK equivalent). H4 and IC31 adjuvant were supplied as separate single-dose vials containing frozen product as follows:~H4 antigen: 500 mcg/mL (100 mcg/0.2 mL), in 10 mmol/L Tris-HCl, pH 8.3.~IC31 adjuvant: 1250 nmol/mL (1000 nmol/0.8 mL) KLK equivalent, in 10 mmol/L Tris-HCl and 169 mmol/L NaCl."
89455512|NCT02420444|Experimental|BCG SSI prime with AERAS-404|"All subjects received BCG Vaccine SSI, 2-8 x 10^5 CFU (BCG) on Study Day -42.~AERAS-404 50/500 on Study Days 0, 56, and 231.~AERAS-404 50/500 was a fixed dose combination of H4 50 mcg and IC31 500 nmol (KLK equivalent). H4 and IC31 adjuvant were supplied as separate single-dose vials containing frozen product as follows:~H4 antigen: 500 mcg/mL (100 mcg/0.2 mL), in 10 mmol/L Tris-HCl, pH 8.3.~IC31 adjuvant: 1250 nmol/mL (1000 nmol/0.8 mL) KLK equivalent, in 10 mmol/L Tris-HCl and 169 mmol/L NaCl."
89455513|NCT04328909|Experimental|E-Care|Parent-centered care software application (e-Care) to ensure parents of febrile infants are optimally informed and participate in shared decision making in the ED
89455514|NCT04328909|Active Comparator|Control Group|Usual care - No E-Care app will be provided
89455515|NCT03180866|No Intervention|Non-treatment Control|Control arm will not have any intervention
89455516|NCT03180866|Experimental|Luma Light System|The experimental arm will be a combination of an occlusive dressing and NBUVB light.
89455517|NCT03181022|No Intervention|Phase 1a|To develop a measure of MI fidelity to ensure methodological rigor, acceptability and feasibility of administration, and clinical usefulness (Phase 1a). Ratings of 200 recordings of full patient-provider interactions with ratings of thin slices (recording 1 minute every 5 minutes) will be compared.
89455518|NCT03181022|No Intervention|Phase 1b|To conduct evidence-based tailoring of MI training for adolescent HIV care settings (Phase 1b). Coding via sequential analysis will be conducted of the 200 recordings to identify those specific provider communication behaviors that predict subsequent youth motivational statements.
89455519|NCT03181022|No Intervention|Phase 2|To collaboratively develop the implementation intervention with 2 clinic teams associated with the ATN (Phase 2). A formative evaluation will be done to provide local diagnostic data regarding barriers and facilitators to adoption and create development panels - local development teams made up of clinicians and administrators from the site, and study staff to address barriers and facilitators from formative evaluation and draft locally-customized clinical care and multi-level implementation strategies with initial sustainability plans.
89455520|NCT03181022|Experimental|Phase 3|To pilot test the implementation intervention and process/outcome evaluation protocols at two ATN sites in preparation for a full-scale trial.
89455521|NCT03180944|Experimental|1.2% Lugol's solution|This group patients were given concentrations of 1.2% Lugol's solution for chromoendoscopy.
89455522|NCT03180944|Experimental|1.0% Lugol's solution|This group patients were given concentrations of 1.0% Lugol's solution for chromoendoscopy.
89016133|NCT05386394|Sham Comparator|Sham tDCS + Language Therapy first|Sham tDCS will be applied at the beginning of 45 minutes language therapy session.
89016134|NCT05384119|Experimental|Phase 1b: Dose Escalation|Participants will receive up to 3 dose levels of TTI-101 added to palbociclib and AI or fulvestrant to determine the RP2D.
89455523|NCT03180944|Experimental|0.8% Lugol's solution|This group patients were given concentrations of 0.8% Lugol's solution for chromoendoscopy.
88939849|NCT01843816||healthy subjects|18-65 aged healthy subjects who have no disorder that may disturb posture or erect position (inflammatory diseases, kyphosis, scoliosis, joint deformities)
89455524|NCT03180944|Experimental|0.6% Lugol's solution|This group patients were given concentrations of 0.6% Lugol's solution for chromoendoscopy.
89455525|NCT03180944|Experimental|0.4% Lugol's solution|This group patients were given concentrations of 0.4% Lugol's solution for chromoendoscopy.
89455526|NCT03184064|Experimental|Treatment arm 1|Participants will receive the placebo, blackcurrant extract (low dose), blackcurrant extract (high dose), citrus extract (low dose) at 4 separate study visits, in a random order. Visits will be separated by at least 7 days.
89455527|NCT03184064|Experimental|Treatment arm 2|Participants will receive the placebo, citrus extract (low dose), blackcurrant extract (high dose), blackcurrant and citrus extracts (low dose / low dose) at 4 separate study visits, in a random order. Visits will be separated by at least 7 days.
89455528|NCT03184064|Experimental|Treatment arm 3|Participants will receive the placebo, blackcurrant extract (low dose), blackcurrant extract (high dose), blackcurrant and citrus extracts (low dose / low dose) at 4 separate study visits, in a random order. Visits will be separated by at least 7 days.
89455529|NCT03184064|Experimental|Treatment arm 4|Participants will receive the placebo, blackcurrant extract (low dose), citrus extract (low dose), blackcurrant and citrus extracts (low dose / low dose) at 4 separate study visits, in a random order. Visits will be separated by at least 7 days.
89455530|NCT02420288|No Intervention|Control Group|Pregnant women not participating in supervised physical exercise program. The subjects in this group will be monitored during pregnancy to know if they make any kind of exercise on your own, to know which are really sedentary pregnant women.
89455531|NCT02420288|Experimental|Exercise Group|Pregnant women participating in supervised physical exercise program.
89455532|NCT03975491|Experimental|Aerobic Exercise|Moderate-intensity aerobic exercise
89455533|NCT03975491|Sham Comparator|Control|Wait-list control
89455534|NCT03180710|Experimental|BioChaperone® Combo 75/25 at 0.6 U/kg|Single subcutaneous injection of 0.6 U/kg
89455535|NCT03180710|Experimental|BioChaperone® Combo 75/25 at 0.8 U/kg|Single subcutaneous dose of 0.8 U/kg
89455536|NCT03180710|Experimental|BioChaperone® Combo 75/25 at 1.0 U/kg|Single subcutaneous dose of 1.0 U/kg
89455537|NCT03180710|Active Comparator|Humalog® Mix25 at 0.8 U/kg|Single subcutaneous dose of 0.8 U/kg
88939850|NCT01843829|Experimental|Carboplatin and Paclitaxel Arm|"2 cycles OxCap: Oxaliplatin 130mg/m2 Day 1 (IV infusion) Capecitabine 625mg/m2 bd Day 1- 21 (oral)~then CRT: Paclitaxel 50mg/m2 Days 1,8,15,22,29 (IV infusion); Carboplatin AUC 2 Days 1,8,15,22,29 (IV infusion) XRT: 45 Gy in 25 fractions~then surgery.~All drugs will be sourced from local stock"
88939851|NCT01843829|Experimental|Oxaliplatin and Capecitabine Arm|"2 cycles OxCap: Oxaliplatin 130mg/m2 Day 1 (IV infusion) Capecitabine 625mg/m2 bd Day 1- 21 (oral)~then CRT: Oxaliplatin 85mg/m2 Days 1, 15, 29 (IV infusion); Capecitabine 625mg/m2 bd (oral) only on days when receiving RT XRT: 45 Gy in 25 fractions*~then surgery.~All drugs will be sourced from local stock"
88939852|NCT01843855|Experimental|Exendin 9,39|Subjects randomized to this arm will receive an infusion of exendin 9,39 of 300mmol/kg/min for 360 minutes.
88939853|NCT01843855|Placebo Comparator|Placebo|Subjects randomized to this arm will receive a saline infusion for 360 minutes.
88939854|NCT01843868|Other|R-CHOP and standard anti-emetics|"This is a single arm study.~All patients receive R-CHOP every 14 or 21 days for a minimum of 3 cycles. Standard anti-emetics will be used as follows:~5HT3 (5-Hydroxytryptamine 3) antagonists (ondansetron, granisetron or tropisetron) used as the local institutional standard of care will be permitted, although the preferential use of ondansetron or granisetron will be encouraged.~Dexamethasone will not to be used as patients receive hydrocortisone and oral prednisolone in R-CHOP. In this study, the use of oral prednisolone on day 1 will be regarded as equivalent to dexamethasone. Prednisolone will be given PRIOR to the chemotherapy with the 5HT3 antagonist.~Anti-emetics (metoclopramide, prochlorperazine and lorazepam) may be prescribed to be used 'as needed' for breakthrough emesis.~Patients 'failing' the standard Chemotherapy Induced Nausea and Vomiting prophylactic regimen will be eligible to receive aprepitant (Days 1 to 3) for subsequent cycles."
88939855|NCT01843881|Experimental|Exendin 9, 39|Exendin 9, 39 will be infused at 300pmol/kg/min in either first intervention period or second intervention period.
88939856|NCT01843881|Placebo Comparator|Placebo|A saline infusion will be administered in either first intervention period or second intervention period.
88939857|NCT01843894|Placebo Comparator|placebo|In Stage I, each patient will instill 1 drop of placebo into each eye, 6 times a day with at least 2 hours between each dose, for 28 days (4 weeks; a total of 168 doses to each eye). In Stage II, each patient will instill 1 drop into each eye, 6 times a day with at least 2 hours between each dose, for 84 days (12 weeks; a total of 504 doses to each eye).
89455538|NCT04322669|Experimental|Pidotimod|
89455539|NCT04322669|Placebo Comparator|Placebo|
89455540|NCT03180476|Experimental|apatinib|apatinib,500mg,qd，28 day/cycle until the emergence of PD, death, intolerable toxicity
89455541|NCT03180632|Active Comparator|Group A|Patient will receive a single dose of either 0,5mg or 1mg of oral Lorazepam depending on their body weight.
89455542|NCT03180632|Placebo Comparator|Group B|Patient will receive a placebo similar in color, form and size.
89455543|NCT03180632|No Intervention|Group 3|Patient will receive no intervention.
89501788|NCT02230813||Oral antibiotic therapy|Consecutive adult patients attending the study Emergency Departments with cellulitis will be considered eligible for recruitment to the study. Only those patients deemed suitable for oral antibiotic therapy and planned for discharge will be recruited to the study. Oral antibiotic therapy prescribed will be dependent on local institutional prescribing guidelines. For the purposes of the sites enrolling participants, the antibiotic of choice is oral flucloxacillin 500 milligrams four times daily for seven days. We will be assessing the treatment failure rate for this cohort of patients; namely, the number of patients requiring the primary outcome (change from oral to intravenous antibiotic therapy). We will also assess this group of patient for the secondary outcomes listed above.
89455544|NCT03943277||patient with infection|"Acute inflammation is defined as a CRP ≥ 10 mg/l. We will include 2 groups of participants:~A group with an inflammatory syndrome and infection; infection being defined as:~Viral infection confirmed by nasopharynx swab for: influenza, RSV, parainfluenza, rhinovirusses, coronavirusses.~Bacterial infection confirmed with positive blood culture, positive articular punction, positive expectorations, pneumonia on chest radiograph, or infection documented by abdominal imagery (CT or echo), a positive urine culture with a confirmed pyelonephritis with a renal echography or a DMSA scintigraphy or specific clinical symptoms for pyelonephritis and positive hemoculture. A positive urine culture alone is not considered as urine infection because of the high prevalence of asymptomatic bacteriuria in geriatric patients."
88939858|NCT01843894|Experimental|RU-101|In Stage I, each patient will instill 1 drop of RU-101 ophthalmic solution (5%, 10%, or 15%) into each eye, 6 times a day with at least 2 hours between each dose, for 28 days (4 weeks; a total of 168 doses to each eye). In Stage II, each patient will instill 1 drop of RU-101 ophthalmic solution (selected dose from Stage I) into each eye, 6 times a day with at least 2 hours between each dose, for 84 days (12 weeks; a total of 504 doses to each eye).
88939859|NCT01843907|Other|Empowerment|Patients in the intervention group 1 receive a communication report which will also be sent to the physician and home care. In communication report includes the results and interpretation and explanation of the measurements in layman's terms. The report also includes relevant and targeted information on pain management, depression among the elderly, dementia and disability in old age and ways to maintain and improve functional capacity. Links and addresses of relevant, local organizations, and networks are also included. The information material is also included in the report sent to the General Practitioner (GP) and home care.
88939860|NCT01843907|Other|Conversation with Nurse|"Patients in the intervention group 2 gets clarification and follow-up conversation with a nurse anchored in both medical department and municipalities. The nurse is blinded in relation to the patient's screening results. Problems identified in connection therewith are communicated to the GP and home care."
88939861|NCT01843907|No Intervention|Controle Group|Patients in the control group are undergoing the same measurements and records at discharge, as the intervention group, but are otherwise receiving treatment and care as usual without further intervention.
88939862|NCT01843959||Emirati Population|"The individuals enrolled in this study will be divided into children (5-16 years of age) and adults (above 18). The groups will be further divided into BMI categories and glucose tolerance groups.~* Group 1: Underweight (adjusted BMI <10th percentile) and no diabetes~Group 2:~Normal weight (adjusted BMI 10th to 84.9th percentile) and no diabetes~Group 3:~Overweight or obese children (adjusted BMI >= 85th percentile) and no diabetes~Group 4:~Normal weight (adjusted BMI 10th to 84.9th percentile) and T1DM~Group 5:~Overweight or obese children (adjusted BMI ≥ 85th percentile) and T1DM~Group 6:~Normal weight (adjusted BMI 10th to 84.9th percentile) and T2DM~Group 7:~Overweight or obese children (adjusted BMI ≥ 85th percentile) and T2DM"
88939863|NCT01843985||1. Eligible RCT/Elect RCT|Eligible for regular chemotherapy, elects and receives regular chemotherapy
88939864|NCT01843985||2. Eligible RCT/Elect LDC|Eligible for regular chemotherapy, elects and receives low-dose chemotherapy
88939865|NCT01843985||3. Eligible RCT/Elect PCO|Eligible for regular chemotherapy, elects and receives palliative care only
88939866|NCT01843985||4. Ineligible RCT/Elect LDC|Ineligible for regular chemotherapy, elects and receives low-dose chemotherapy
88939867|NCT01843985||5. Ineligible RCT/Elect PCO|Ineligible for regular chemotherapy, elects and receives palliative care only
88939868|NCT01843998|Experimental|Sirolimus 0.1% ointment|Sirolimus 0.1% ointment
88939869|NCT01844011|Experimental|Daily electronic reminders|Women in the intervention arm will be sent either daily text messages on the weekdays on their cell phone or emails on the weekdays reminding them to track kick counts on the chart.
88939870|NCT01844011|No Intervention|Education only|All women enrolled in the trial will receive a paper-based kick count chart, will be educated in the use of the kick count chart, and will be instructed to keep track of their fetal movements on a daily basis.
88939871|NCT01844024|Other|misoprostol by midwife|Women with incomplete abortion is diagnosed and treated with misoprostol by midwife
88939872|NCT01844024|No Intervention|Misoprostol by physician|Women with incomplete abortion is diagnosed and treated with misoprostol by physician
88939873|NCT01844037|Other|Renal denervation|Patients will be treated with the OneShot ablation system
88939874|NCT01844050|Experimental|Chinese herbal medicine|Individualized Treatment with Chinese herbal
88939875|NCT01844050|Placebo Comparator|Placebo|Individualized Treatment with placebo Chinese herbal which Containing 2% of Chinese herbal medicine.
88939876|NCT01844063|Experimental|Conventional treatment|Participants will receive conventional treatment and then be followed until the week 72 study visit.
88939877|NCT01844063|Experimental|Conventional plus BM-MSC treatment|Participants will receive conventional treatment plus a dose of BM-MSC(each subgroups with a different dose ) and then be followed until the week 72 study visit.
88939878|NCT01844063|Experimental|Conventional plus UC-MSC treatment|Participants will receive conventional treatment plus a dose of UC-MSC(each subgroups with a different dose ) and then be followed until the week 72 study visit.
88939879|NCT01844102|Experimental|PrePex|PrePex circumcision procedures will be offered as part of the minimum package of HIV prevention services recommended by the Zambian Ministry of Health (MOH)
88939880|NCT01844128||overweight women with infertility|
88939881|NCT01844141|Experimental|alcohol - clorhexidine|Ingrown toenail irrigated using 70% alcohol - 0.5% clorhexidine
88939882|NCT01844141|Active Comparator|70% alcohol|Ingrown toenail irrigated using 70% alcohol
88939883|NCT01844167|Active Comparator|Physical therapy arm (PT)|"The TENS device used: FDA K071951~Patients will be treated with standard physical therapy, including the electrical stimulation. Manual therapy, cold/heat therapy or exercise will be applied at the discretion of the physical therapist for about 60 minutes in each session. Patient education and self-care instructions will be provided. TENS will also be performed in each session for about 30 minutes based on the typical PT guidelines, which will serve both as a part of the standard of care and as a placebo equivalent. It will typically be set at Normal/Modulate mode and 120 Hertz rate."
88939884|NCT01844167|Experimental|Noxipoint Therapy arm (NT)|"Patients will be treated with TENS following Noxipoint Therapy guidelines as highlighted below:~The TENS device used: FDA K071951~TENS is calibrated to allow for maximum range in the specifications.~A pair of electrode pads is placed at the corresponding pair of Noxipoints of the injured muscle/soft tissue, for about 2- 5 minutes during each application.~The electrical stimulation is set to induce the C-fiber response based on the feedback of the patient.~If the corresponding pain is not eliminated or reduced after a couple of applications on correct Noxipoints, apply an ice pack for about 10-15 minutes on site before and during the next Noxipoint stimulation."
88939885|NCT01844219||Patients who underwent aortic surgery|Patients who underwent aortic surgery in Samsung Medical Center during the period between 2004 and 2010
88939886|NCT01844245|Experimental|Endobiliary RFA group|"Endoscopic retrograde cholangiopancreatography (ERCP) would be performed under standard operating conditions to confirm the biliary malignancy. Subjects will receive endobiliary radiofrequency ablation (Endobiliary RFA) followed by plastic stent(s) placement.~Three months later, subjects will receive the second RFA therapy followed by biliary stents (plastic or SEMS) placement.~During follow-up, if stent occlusion occurs, the patient will undergo endoscopic re-intervention for stent exchange without endobiliary RFA"
88939887|NCT01844245|No Intervention|Control group|"Endoscopic retrograde cholangiopancreatography (ERCP) would be performed under standard operating conditions to confirm the biliary malignancy. Subjects will receive plastic biliary stent(s) placement only.~Three months later, subjects will receive the second endoscopic intervention for stents (plastic or SEMS) exchange.~During follow-up, if stent occlusion occurs, the patient will undergo endoscopic re-intervention for stent exchange without endobiliary RFA"
88939888|NCT01844258|Experimental|Modified technique for I/A group|"In the modified cataract surgery procedure, the size of the capsulorhexis opening will be decreased to 1.0-1.5 mm in diameter.~The capsulorhexis will be located in the peripheral area of the lens instead of the central area.~A 0.9 mm phacoemulsification probe will be used to remove the cataractous lens.~One drop of 0.5% or 1% atropine and an antibiotic/steroid ointment will be placed in the eye, which will then be patched."
88939889|NCT01844258|Active Comparator|Traditional technique for I/A group|• In traditional technique group, the cataractous lens will be removed through an anterior continuous curvilinear capsulorhexis (ACCC) that is about 5-6 mm in diameter.
88939890|NCT01844271|Placebo Comparator|Placebo Low Level Laser|Application of low level laser without any dose (0 Joule) before strenuous exercise. A laser device with a cluster of 5 diodes (810 nm, 200 mW) each diode was used for this study.
88939891|NCT01844271|Experimental|2 Joules Low Level Laser|Application of 2 Joules of Low Level Laser Therapy before strenuous exercise with a cluster of 5 diode (810 nm, 200 mW each diode).
88939892|NCT01844271|Experimental|6 Joules Low Level Laser Therapy|Application of 6 Joules of Low Level Laser Therapy before strenuous exercise with a cluster of 5 diode (810 nm, 200 mW each diode).
88939893|NCT01844271|Experimental|10 Joules Low Level Therapy|Application of 10 Joules of Low Level Laser Therapy before strenuous exercise with a cluster of 5 diode (810 nm, 200 mW each diode).
88939894|NCT01844271|Experimental|Power of 100mW|After assigning ideal dose of application it was delimited two experimental groups which was irradiated with the dose established by the first part of the study and power of 100mW.
88939895|NCT01844271|Experimental|Power of 400mW|After assigning ideal dose of application it was delimited two experimental groups which were irradiated with the dose established by the first part of the study and power of 400mW.
88939896|NCT01844297|Other|TDF+3TC+EFV|
88939897|NCT01844310|Active Comparator|RAL +TDF+ LPV/r|Arm A: RAL +TDF+ KELETRA(LPV/r) Group A will be assigned with RAL+TDF+LPV/r.
88939898|NCT01844310|Active Comparator|3TC+ TDF+LPV/r|Arm B: 3TC+ TDF+KELETRA(LPV/r) Group B will be assigned with 3TC+TDF+LPV/r
88939899|NCT01844323|Active Comparator|Treatment A|treatment A, reference, 20 micron palbociclib and lubrication level 1
88939900|NCT01844323|Active Comparator|Treatment B|treatment B, test, 50 micron palbociclib and lubrication level 1
88939901|NCT01844323|Active Comparator|Treatment C|treatment C, test, 20 micron palbociclib and lubrication level 2
88939902|NCT01844323|Active Comparator|Treatment D|treatment D, test, 20 micron palbociclib and lubrication level 3
88939903|NCT01844336|Experimental|PBASE system 1.1 + CT100 (active treatment)|
88939904|NCT01844336|Placebo Comparator|PBASE system 1.1 + CT100 (placebo treatment)|
88939905|NCT01844401|Experimental|Spiromax/ProAir|Single dose of Albuterol Spiromax® 180 mcg followed by a 4 to 14 day washout period then a single dose of ProAir® HFA 180 mcg
88939906|NCT01844401|Experimental|ProAir/Spiromax|Single dose of ProAir® HFA 180 mcg followed by a 4 to 14 day washout period then a single dose of Albuterol Spiromax® 180 mcg
89201308|NCT00775398||B|Subjects with anti-topical bovine thrombin antibodies pre-surgery, who did not received THROMBIN-JMI® during the study surgery.
89016135|NCT05384119|Experimental|Phase 2: Dose Expansion|Enrollment in Phase 2 may commence with approval from the safety review committee. Participants will be enrolled and treated at the RP2D of TTI-101 added to palbociclib or ribociclib and AI or fulvestrant.
89455545|NCT03943277||patient without infection|"Acute inflammation is defined as a CRP ≥ 10 mg/l. We will include 2 groups of participants:~=> B) A group with inflammatory syndrome and inflammatory diseases without infection: defined as:~Confirmed pulmonary embolism (PE) by CT or ventilation-perfusion scintigraphy~Microcrystalline arthritis diagnosed by articular punction~Crush syndrome or rhabdomyolyses defined by history of a fall and raised creatine kinase in blood sample."
89455546|NCT04483232||Healthy Subjects|
89455547|NCT04483232||Patients with ear infections|
89455548|NCT02420132||Main Study|Decentralized participant recruitment, participant and local ophthalmologist compliance, and use of the mVT mobile medical application in a more geographically diverse, decentralized cohort of participants with DME or nAMD receiving intravitreal ranibizumab therapy as part of standard-of-care treatment.
89455549|NCT02420132||Traditional Substudy|"Subset of participants enrolled through a single investigator who will determine visual acuity and anatomical markers of disease status using clinical gold standard assessments (certified ETDRS protocol visual acuity and macula OCT)."
89455550|NCT03183752|Experimental|Metformin|patients randomized to Metformin group
89455551|NCT03183752|Placebo Comparator|Placebo|patients randomized to placebo group
89455552|NCT02420054|Active Comparator|Intermittent fasting|Intermittent fasting conducted by a group of subjects with type 2 diabetes mellitus and an age- and BMI matched control group.
89455553|NCT02420054|Active Comparator|Time control|A time control period.
89455554|NCT04287179|Experimental|Semaglutide 0.50 mg|Once-weekly semaglutide administered subcutaneously (s.c., under the skin) with or without oral antidiabetics (OADs). Start dose 0.50 mg.
89455555|NCT04287179|Active Comparator|Semaglutide 0.25 mg|Once-weekly semaglutide administered subcutaneously (s.c., under the skin) with or without oral antidiabetics (OADs). Start dose 0.25 mg.
89455556|NCT03183674|Experimental|oxytocin spray|oxytocin nose spray dose 0,4IU/kg, once unique dose
89455557|NCT03183674|Placebo Comparator|placebo|saline nose spray, 0,9 %, once unique dose
89455558|NCT03117530|Experimental|Minocycline|
89455559|NCT03180320|Experimental|BESMILE-HF group|Throughout the study period, all participants will receive typical Western medications for chronic heart failure, according to national guidelines. In addition, patients will receive the BESMILE-HF program.
89455560|NCT03180320|Other|Control|Patients in the control group will receive only the usual medications, since patients typically do not receive exercise-based cardiac rehabilitation in this kind of setting.
89016136|NCT05379179|Active Comparator|Fentanyl|"Drug administration: A single dose of fentanyl 1mcg/kg IV, maximum 100 mcg, over 15 minutes.~Time drug given will be documented Data obtained prior to med administration and then following medication administration at intervals of 15, 30, 60 and 120 minutes~Record vital signs (HR, B/P, resp rate, O2 sat)~Obtain and assess pain response scores~Pain Numerical Rating Score (NRS - 0-10)~Richmond Agitation Sedation Scale (RASS)~Side Effect Rating Scale for Dissociative Anesthesia (SERSDA)~Record any airway interventions required? If yes what? new supplemental O2/BVM/intubation, jaw thrust~Record any rescue meds, dose and time (Rescue medication - Fentanyl):~1 mcg/kg IV fentanyl (0.5 mcg/kg if age >55 yrs)~Defined as rescue if given <30 min post study intervention for pain score >5 or patient requesting additional medication.~Patient pain satisfaction score at discharge"
89455561|NCT03889925|Experimental|Autologous conditioned plasma group|Participants in this group will receive a three-injection series of autologous conditioned plasma over the course of 3 consecutive weeks.
89455562|NCT03889925|Experimental|Autologous conditioned plasma with hyaluronic acid group|Participants in this group will receive a two-injection series of autologous conditioned plasma and hyaluronic acid (Hymovis, Fidia Pharmaceuticals) and a third injection on the third week of autologous conditioned plasma.
89455563|NCT02427152||Lean|body mass index: 18-25 kg/m²
89455564|NCT02427152||Overweight/Obese|body mass index: >25 kg/m²
89455565|NCT02426840|Experimental|High dose vitamin D and calcium|Fixed-dose combination (FDC) of 1,500 mg of calcium carbonate (equivalent to 600 mg of elemental calcium) and 200 IU of vitamin D3, administered orally twice daily plus vitamin D2 (20,000 IU/cap) administered once weekly (a total of 1,200 mg of elemental calcium and 3,200 IU of vitamin D daily)
89455566|NCT02426840|Active Comparator|Normal dose vitamin D and calcium|Fixed-dose combination (FDC) of 1,500 mg of calcium carbonate (equivalent to 600 mg of elemental calcium) and 200 IU of vitamin D3, administered orally twice daily (a total of 1,200 mg of elemental calcium and 400 IU of vitamin D daily)
89455567|NCT04280315||Cases|"Cases are patients with type 1 diabetes in three age strata:~20 participants in the age of 2-10 years~20 participants in the age of 11-20 years~10 participants with more than 30 years of diabetes duration"
89455568|NCT04280315||Controls|Controls are age and sexmatched with the cases and are recruited from the neuropediatric clinic at Herlev Hospital as well as relatives and parents of patients in the whole Pediatric Department
89455569|NCT02427074|Active Comparator|Balloon Compression Rhizotomy|Patients that are submitted to Balloon Compression Rhizotomy
89455570|NCT02427074|Active Comparator|Radiofrequency Thermal Coagulation Rhizotomy|Patients that are submitted to Radiofrequency Thermal Coagulation Rhizotomy
89455571|NCT03178526|Active Comparator|levostatin gel|levostatin gel 1.2% topical gel was put into teh periodontal pocket using an insulin syringe
89455572|NCT03178526|Placebo Comparator|placebo gel|placebo gel 1.2% topical gel was put into the periodontal pocket using an insulin syringe
89455573|NCT02426996|Experimental|Study population|"The patients included have been operated for chronic anterior shoulder instability by a Latarjet-type bone block procedure using the SEM (Science Et Medecine) positioning tool within the past 3 months.~Intervention: Scan of shoulder"
89455574|NCT02423486|Experimental|Electromagnetic stimulation therapy|Electromagnetic stimulation therapy group
89455575|NCT02423486|Experimental|Electromagnetic stimulation therapy with biofeedback|Electromagnetic stimulation therapy with biofeedback group
89016137|NCT05379179|Experimental|Ketamine|"Drug administration: A single dose of ketamine 0.3 mg/kg IV over 15 minutes. Time drug given will be documented Data obtained prior to med administration and then following medication administration at intervals of 15, 30, 60 and 120 minutes~Record vital signs (HR, B/P, resp rate, O2 sat)~Obtain and assess pain response scores~Pain Numerical Rating Score (NRS - 0-10)~Richmond Agitation Sedation Scale (RASS)~Side Effect Rating Scale for Dissociative Anesthesia (SERSDA)~Record any airway interventions required? If yes what? new supplemental O2/BVM/intubation, jaw thrust~Record any rescue meds, dose and time (Rescue medication - Fentanyl):~1 mcg/kg IV fentanyl (0.5 mcg/kg if age >55 yrs)~Defined as rescue if given <30 min post study intervention for pain score >5 or patient requesting additional medication.~Patient pain satisfaction score at discharge"
89016138|NCT05378997|Experimental|Dose group 1|0.15 mL of TCP-25 gel (0.86 mg/mL) or 0.15 mL placebo gel per wound applied as topical treatment on days 1, 2, 3, 5, and 8
89455576|NCT04256369||Primary Cohort|Starting premixed Olimel N9E and follow for electrolyte irregularities.
89455577|NCT02423564|Active Comparator|Healthy Population with Digesta Lac|Digesta Lac is Lactobacillus bulgaricus LB-51 at 2.0 billion cfu with non-medicinal ingredients: cellulose, potato powder, chick pea extract, vitamin c, L-leucine, vegetable capsule (hypromellose)
89455578|NCT02423564|Placebo Comparator|Healthy Population with Placebo|Placebo contains: cellulose, Organic Whole Grain Brown Rice Milk Concentrate, L-Leucine, potato powder, vegetable capsule (hypromellose)
89455579|NCT03180164|Other|chronic lung diseases|bronchiectasis , bronchial asthma and chronic obstructive pulmonary disease assess anxiety and depression by hospital anxiety and depression scale
89455580|NCT02419898||Feasibility Study|Nulliparous women of reproductive age (18-40 years), who are not pregnant but could have a planned or unplanned pregnancy during the duration of the study.
89455581|NCT02423642|Experimental|AKI requring CRRT and use regional citrate anticoagulation|CRRT use regional citrate anticoagulation
89455582|NCT02423642|Experimental|AKI requring CRRT and not use regional citrate anticoagulation|CRRT not use regional citrate anticoagulation
89455583|NCT03180242|Experimental|EG12014|EG12014
89455584|NCT03180242|Active Comparator|EU-sourced Herceptin|EU-sourced Herceptin
89455585|NCT03180242|Active Comparator|US-sourced Herceptin|US-sourced Herceptin
89455586|NCT00709904|Experimental|Semuloparin extension treatment|Extension treatment with Semuloparin sodium 20 mg (10 mg if SRI) for 19-23 days following initial treatment with open-label Semuloparin 20 mg (10 mg if SRI) for 7-10 days.
89455587|NCT00709904|Placebo Comparator|Placebo extension treatment|Extension treatment with placebo (for Semuloparin sodium) for 19-23 days following initial treatment with open-label Semuloparin 20 mg (10 mg if SRI) for 7-10 days
89455588|NCT02426606|Experimental|White bread|
89455589|NCT02426606|Experimental|Lentil 1 + white rice|
89455590|NCT02426606|Experimental|Lentil 2 + white rice|
89455591|NCT02426606|Experimental|Lentil 3 + white rice|
89455592|NCT02426606|Experimental|White rice|
89455593|NCT02426606|Experimental|Lentil 1 + potato|
89455594|NCT02426606|Experimental|Lentil 2 + potato|
89455595|NCT02426606|Experimental|Lentil 3 + potato|
89455596|NCT02426606|Experimental|Potato|
89455597|NCT03183596|Active Comparator|Deep Serratus Anterior Block|"Patients in the deep Serratus Anterior Block (DSAB) group will have 20-60cc of 0.25% bupivacaine and 2-4mg of dexamethasone deposited deep to the serratus. The investigator will then evaluate the difference based on pain scores, opiate consumption, length of hospital stay, as well as nausea and vomiting."
89455598|NCT03183596|Active Comparator|Superficial Serratus Anterior Block|"Patients in the superficial Serratus Anterior Block (SSAB) group will have 20-60cc of 0.25% bupivacaine and 2-4mg of dexamethasone placed between serratus and latissimus dorsi. The investigator will then evaluate the difference based on pain scores, opiate consumption, length of hospital stay, as well as nausea and vomiting."
89455599|NCT03178214|Experimental|Infacort - Yoghurt|One single 5mg dose of Infacort will be sprinkled onto 5mL of yoghurt and swallowed within three minutes. This will be taken with 240mL of water.
89455600|NCT03178214|Experimental|Infacort - Soft Food|One single 5mg dose of Infacort will be sprinkled onto 5mL of soft food (such as applesauce) and swallowed within three minutes. This will be taken with 240mL of water.
89455601|NCT03178214|Active Comparator|Infacort - Dry Granules|One single 5mg dose of Infacort will be administered as dry granules to the back of the tongue and swallowed. This will be taken with 240mL of water.
89455602|NCT03178136||case group|There is no intervention in case group.
89455603|NCT03178136||control group|The control group as the contrast for case group.
89455604|NCT03626051|Active Comparator|rigid tape group|
89455605|NCT03626051|Experimental|fibular tape group|
89455606|NCT03183362|Experimental|Barbed suture ( STRATAFIX™ )|Cesarean section incision is closed using barbed sutures
89455607|NCT03183362|Active Comparator|Conventional suture (VICRYL™)|Cesarean section incision is closed using conventional sutures
89455608|NCT03117062|Experimental|Occlusal Reduction|performing occlusal reduction on functional cusps until abscence of contact was confirmed
89455609|NCT03117062|No Intervention|non-occlusal reduction|occlusal surface left intact
89455610|NCT02704130|Experimental|TAE + MWA combination therapy|In patients randomized to receive the experimental therapy, transarterial embolization (TAE) treatments will be initiated within one week of randomization. Blunt embolization will be performed with LC beads with a maximum size of 700 µm. Microwave ablation (MWA) will be performed up to one month following randomization. The LC beads will be admixed with 8-15 mL of contrast and injected into the arterial branch at a rate of 1-2 mL/min. Treatment may be discontinued if any exclusion criteria develop in the patient or at the patient's request.
89455611|NCT02704130|Active Comparator|MWA monotherapy|Microwave ablation (MWA) will be performed up to one month following randomization. Treatment may be discontinued if any exclusion criteria develop in the patient or at the patient's request. All operative MWAs will be performed in a laparoscopic or robot-assisted laparoscopic setting. All ablations will be guided by intraoperative ultrasound. Ablations will be performed with a 2.45-GHz generator with a 1.8-mm-diameter transcutaneous antenna.
89455612|NCT03180008|Active Comparator|Fit and Strong!|
89455613|NCT03180008|Experimental|Fit and Strong! Plus|
89455614|NCT03594305|Experimental|Educational Intervention Arm|Villages randomized to this arm will receive a one-day educational seminar, which their religious leaders of all denominations will be invited to attend. The seminar will address religious, cultural, and medical aspects of family planning. Leaders who attend will also have the opportunity to participate in mentorship group discussions after the intervention. In addition, both villages will have standard teaching provided by nurses at dispensaries about family planning, and a continual supply of contraceptive options at dispensaries in all villages will be ensured.
89455615|NCT03594305|No Intervention|Control arm|Villages randomized to this arm will not receive the educational seminar. These villages will have standard teaching provided by nurses at dispensaries about family planning, and a continual supply of contraceptive options at dispensaries in all villages will be ensured.
89455616|NCT02426762|Experimental|Sealant skin closure|A quick skin sealant would be applied after laparoscopic surgery. All abdominal wounds are sealed by smearing the quick sealant (skin adhesive) twice. No additional gauges should be appended on wound areas. No further wound care should be applied unless any effusion or bleeding emerged around it.
89455617|NCT04325243|Experimental|study group|50 mg oral sildenafil citrate tablet
89455618|NCT04325243|Placebo Comparator|placebo group|placebo tablets of the same shape, color and size of sildenafil citrate tablets
89455619|NCT03179774|Experimental|Clinical registry-ER and OMT|In clinical registry setting, participants who selected Endovascular revascularization and optimal medical therapy as the treatment for carotid artery occlusion are enrolled.
89455620|NCT03179774|No Intervention|Clinical registry-OMT|In clinical registry setting, participants who selected optimal medical therapy as the treatment for carotid artery occlusion are enrolled.
89455621|NCT03179774|Experimental|RCT-ER and OMT|In randomized control trial setting, participants who are randomized to received endovascular revascularization and optimal medical therapy for carotid artery occlusion are enrolled.
89455622|NCT03179774|No Intervention|RCT-OMT|In randomized control trial setting, participants who are randomized to received optimal medical therapy for carotid artery occlusion are enrolled.
89455623|NCT02419586|Experimental|bubble gum chewing and routine care|Start chewing gum on postoperative day at three times daily with no more than 30 minutes till discharged
89455624|NCT02419586|No Intervention|routine care|Non interventional group will receive existing routine care as usual
89455625|NCT02419820|Experimental|APD791 10mg single dose|APD791 10mg single dose
89455626|NCT02419820|Experimental|APD791 20mg single dose|APD791 20mg single dose
89455627|NCT02419820|Experimental|APD791 40mg single dose|APD791 40mg single dose
89455628|NCT02419820|Experimental|APD791 10mg|APD791 10mg single dose + Aspirin + Clopidogrel
89455629|NCT02419820|Experimental|APD791 20mg|APD791 20mg single dose + Aspirin + Clopidogrel
89455630|NCT02419820|Experimental|APD791 40mg|APD791 40mg single dose + Aspirin + Clopidogrel
89455631|NCT02419820|Experimental|APD791 80mg|APD791 80mg single dose + Aspirin + Clopidogrel
89455632|NCT02419820|Experimental|APD791 160mg|APD791 160mg single dose + Aspirin + Clopidogrel
89455633|NCT02419820|Experimental|APD791 240mg|APD791 240mg single dose + Aspirin + Clopidogrel
89455634|NCT02419820|Experimental|APD791 320mg|APD791 320mg single dose + Aspirin + Clopidogrel
89455635|NCT02419820|Placebo Comparator|APD791 Placebo|APD791 placebo for single dose + Aspirin + Clopidogrel
89455636|NCT02419820|Experimental|APD791 2mg MD|APD791 2mg multiple dose + Aspirin + Clopidogrel
89455637|NCT02419820|Experimental|APD791 5mg MD|APD791 5mg multiple dose + Aspirin + Clopidogrel
89455638|NCT02419820|Experimental|APD791 10mg MD|APD791 10mg multiple dose + Aspirin + Clopidogrel
88939907|NCT01844414|Experimental|Parolee Comprehensive Care + Phone Coach|PCPC Intervention: Eight specialized nurse case managed hepatitis education sessions, the Hepatitis A/B vaccine series and coach-facilitated mentoring.
89455639|NCT02419820|Experimental|APD791 20mg MD|APD791 placebo for multiple dose + Aspirin + Clopidogrel
89455640|NCT02419820|Placebo Comparator|APD791 placebo MD|APD791 placebo for multiple dose + Aspirin + Clopidogrel
89455641|NCT05464511|No Intervention|Patients with Amulet device using non-steerable fixed curve sheath|Patients undergoing left atrial appendage occlusion with the dual mechanism closure Amulet device using non-steerable fixed curve sheath.
89455642|NCT05464511|Active Comparator|Patients with Amulet device using a novel steerable sheath|Patients undergoing left atrial appendage occlusion with the dual mechanism closure Amulet device using a novel steerable sheath.
89455643|NCT02419430|Active Comparator|MBRT ClassRoom and Phone Application|MBRT ClassRoom and Phone Application
89455644|NCT02419430|Active Comparator|Phone application only|Phone application only
89455645|NCT02419430|Active Comparator|Questionnaires|Questionnaires
89455646|NCT03116984|Active Comparator|Transcatheter arterial chemoembolization|TACE group: The frequency of treatment is determined based on the disease condition for patients who are randomly assigned to group of TACE treatment.TACE is performed via an injection into the hepatic artery of agents by puncturing the common femoral artery, and micro-embolization superselective catheterization is preferred.Adriamycin(30 to 60mg) is considered as basic chemotherapy drugs in the process of transcatheter endovascular perfusion.The dose of ultra fluid lipiodol was determined by diameter and blood supply type of HCC,generally 5-20ml, and no more than 30ml once.The boundary is considered whether there are large amounts of lipiodol to deposit in the tumor and tiny branches shadow of portal veins in paracarcinoma under fluoroscopic guidance. Embolizing agents(gelatin sponge particles 350um-560um) are added after lipiodol emulsion embolization.It has a possibility of observeation alone if tumor achieves a complete response after two times TACE.
89455647|NCT03116984|Experimental|External-beam radiotherapy|EBRT group: Patients who were randomized to the external- beam radiotherapy (EBRT) 3-5 weeks after the completion 2 times TACE.Radiotherapy equipment is based on the conditions of the cooperative units. 3-DCRT, IMRT or IGRT will be opted based on hospital. IGRT can also be used via helical tomotherapy, Rapid Arc or VMAT. The target volume should include the visible tumor.
89455648|NCT02426528|Experimental|Cultural and Social exposure A|Cultural and Social exposure
89455649|NCT02426528|No Intervention|Cultural and Social exposure B|Non Intervention (Control Group)
89455650|NCT03380351||SCDIC interventions|Careful detail the intervention components and the implementation strategies (i.e., the mechanisms by which the interventions are being delivered in usual care) being developed by the consortium.
89455651|NCT03380351||SCDIC control groups|Careful detail the control conditions of each of the SCDIC sites for each of the interventions being developed.
89455652|NCT02419352|Active Comparator|Sugammadex|Sugammadex is administered to reverse rocuronium-induced neuromuscular blockade at the end of elective surgery.
89455653|NCT02419352|Active Comparator|Neostigmine/atropine|Neostigmine combined to atropine is administered to reverse rocuronium-induced neuromuscular blockade at the end of elective surgery.
89455654|NCT03858647||Sensorineural hearing loss patients post cochlear implant|Patients who have documented sensorineural hearing loss and have received cochlear implantation (per standard of care).
89455655|NCT02423720|Other|Study Intervention|Audio-based mindfulness intervention A 8-week single arm pilot study will be conducted among Helen Diller Famiily Comprehensive Cancer Center (HDFCCC) patients with metastatic colorectal cancer receiving chemotherapy and their caregivers (44 participants, total). Participants will receive an informational booklet containing a practice log and an MP3 player containing an introductory lecture and guided meditations. Practice reminders will be sent via text messages. Weekly emails will contain practice instructions and links to validated questionnaires.
89455656|NCT03365687|Active Comparator|Vitamin D|Vitamin D supplement (100,000 IU) orally at baseline and at 3.5 months with daily 400 IU vitamin D for 7 months
89455657|NCT03365687|Placebo Comparator|Placebo|Placebo orally at baseline and at 3.5 months with daily placebo during 7 months
89455658|NCT02419118|Experimental|Dara len dex|Daratumumab in combination with lenalidomide and dexamethasone
89455659|NCT02419118|Active Comparator|Len dex|Lenalidomide in combination with dexamethasone
89455660|NCT02426216||Group A|Group A: Subjects who fullfil all eligibility criteria of the MCS-8 protocol and consent to enroll the study.
89455661|NCT02426216||Group B|Group B: Subjects who fullfil the definition of elevated risk for prostate cancer by the MCS-8 protocol but did not sign up for the MCS-8 study.
89455662|NCT05515289|Experimental|Treatment group: mild renal insufficiency|
89455663|NCT05515289|Experimental|Treatment group: moderate renal insufficiency|
89455664|NCT05515289|Experimental|Treatment group: healthy subjects|
89455665|NCT02426294|Experimental|Pioglitazone|Pioglitazone is a Pioglitazone hydrochloride, and white circle-shaped tablet. It is administered once-daily with 15mg, with or without meals. The once-daily administration begins with 15mg, and if need increase, researchers can increase up to 30mg at week 12.
89455666|NCT02426294|Active Comparator|Glimepiride|The generic name of Glimepiride is Glimepiride, and it is a green snowman-shaped tablet. The once-daily administration begins with 2mg, and if need increase, researchers can increase up to 4mg at week 12.
89455667|NCT04051931||stable COPD group|include COPD patients with stable state
89455668|NCT04051931||AECOPD group|include COPD patients with acute exacerbation
89455669|NCT05692661|Experimental|proton plus carbon ion radiotherapy|CTV1: whole breast, proton therapy. CTVboost: Tumor bed, carbon ion dose escalation study with four dose levels.
89455670|NCT02426450|Experimental|RFA+FOLFOX4|"RFA:~RFA was performed by using a commercially available system (RF 2000; Radio-Therapeutics Mountain View, CA), and a needle electrode with a 15 Ga insulated cannula with 10 hook-shaped expandable electrode tines with a diameter of 3.5 cm at expansion (LeVeen; RadioTherapeutics).~Oxaliplatin + 5-Fluorouracil/Leucovorin:~4 weeks after RFA; Drug: Oxaliplatin + 5-Fluorouracil/Leucovorin Day 1: Oxaliplatin 85mg/m² 2h IV infusion, leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m2 22h IV infusion.~Day 2: Leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m² 22h IV infusion.~Repeated every 2 weeks"
89455671|NCT03854123||Old MS patients|"75 to 77 years old MS patients whose disease began at 65 years old or earlier will be retrieved from the Observatoire français de la sclérose en plaques (OFSEP)."
89455672|NCT02423330|Experimental|Strattice-LIFT|
89455673|NCT02419196||abdominal surgery|27 patients undergoing abdominal surgery having an elevated risk for postoperative pulmonary complications will be examined by perioperative pulmonary function tests
88939908|NCT01844414|Experimental|Parolee Brief HBV program + Phone Coach|PBPC Intervention: Eight twenty minute hepatitis education sessions, coach facilitated mentoring and the Hepatitis A/B vaccine series.
88939909|NCT01844414|Active Comparator|Usual Care Group|UC Control Group: One brief general health information program, one-on-one coaching and the Hepatitis A/B vaccine.
88939910|NCT01844427|Active Comparator|Memantine HCl|Memantine administered in capsule form twice daily for 12 weeks and titrated up to a maximum daily dose of 20mg.
88939911|NCT01844427|Placebo Comparator|Placebo|Masked placebo administered in capsule form twice daily for 12 weeks. Placebo titration will be titrated according to the same procedure as active memantine.
88939912|NCT01844440|Experimental|HRM|
88939913|NCT01844453|Experimental|Luteal Phase Arm|Local Endometrial Injury in mid-luteal phase (cycle day 21-26) prior to the treatment cycle.
88939914|NCT01844453|Experimental|Proliferative Phase Arm|Local Endometrial Injury in early proliferative phase of current treatment cycle (cycle day 2-3).
88939915|NCT01844453|No Intervention|Control Arm|No Local Endometrial Injury will be performed. Patients will undergo a routine fresh IVF treatment cycle.
88939916|NCT01844466|Experimental|stroke patients|
88939917|NCT01844492|Active Comparator|ICU Usual Care Control|described below
88939918|NCT01844492|Experimental|The PARTNER Intervention|described below
88939919|NCT01844544||patients after femur neck fracture|
89016139|NCT05378997|Experimental|Dose group 2|0.15 mL of TCP-25 gel (2.9 mg/mL) or 0.15 mL placebo gel per wound applied as topical treatment on days 1, 2, 3, 5, and 8
89016140|NCT05378997|Experimental|Dose group 3|0.15 mL of TCP-25 gel (8.6 mg/mL) or 0.15 mL placebo gel per wound applied as topical treatment on days 1, 2, 3, 5, and 8
89016141|NCT05373537|Experimental|Home-based|home- based CBT-Insomnia intervention
89016142|NCT05373537|Experimental|web-based|web-based CBT-Insomnia intervention
89016143|NCT05370508|Experimental|Cohort 1|10 mg/kg IV SONALA-001 (ALA) and MR-guided Focused Ultrasound (MRgFUS) Energy Level 1
89455674|NCT02419196||limb surgery|27 patients undergoing upper and lower limb surgery having an elevated risk for postoperative pulmonary complications will be examined by perioperative pulmonary function tests
89016144|NCT05370508|Experimental|Cohort 2|10 mg/kg IV SONALA-001 (ALA) and MR-guided Focused Ultrasound (MRgFUS) Energy Level 2
89016145|NCT05370508|Experimental|Cohort 3|10 mg/kg IV SONALA-001 (ALA) and MR-guided Focused Ultrasound (MRgFUS) Energy Level 3
89016146|NCT05370508|Experimental|Cohort 4|10 mg/kg IV SONALA-001 (ALA) and MR-guided Focused Ultrasound (MRgFUS) Energy Level 4
89016147|NCT05370508|Experimental|Cohort 5|Recommended Phase 2 Dose (RP2D) IV SONALA-001 (ALA) and MR-guided Focused Ultrasound (MRgFUS) Energy Level 5
89016148|NCT05366166|Experimental|Single Arm|The participants will receive neoadjuvant and adjuvant pembrolizumab and olaparib combination plus standard of care (chemoradiation therapy) as defined in the protocol.
89016149|NCT05363462|Experimental|Ankle fracture surgical treated plus 1 g of topical vancomycin|A standard surgical treatment of patients with ankle fracture must be carried out. Classified according to Danis Webber classification system. Plus application of 1 g of vancomycin in powder in the surgical site
89016150|NCT05363462|Active Comparator|Ankle fracture surgical treated|A standard surgical treatment of patients with ankle fracture must be carried out. Classified according to Danis Webber classification system
89016151|NCT05360589||Shoulder non-specific pain|68 adult gender-balanced subjects will be enrolled, reporting unilateral, atraumatic, and non-specific shoulder pain68 healthy subjects who regularly perform sports activities (at least one weekly session).
89016152|NCT05360589||Controls|68 healthy subjects who regularly perform sports activities (at least one time/week) without shoulder pain will be recruited.
89016153|NCT05355272|Experimental|Growth Hormone Replacement Therapy|"Patients will be started at a dose of 200-300 mcg/d of daily injections of GHRT. A biweekly titration period of 6 weeks will be performed in increments of 100 mcg/d as needed until IGF-1 levels are between +1 and +2 standard deviation score, up to a maximum dose of 2,000 mcg/d, provided the dose is well tolerated.~The duration of the intervention is 6-months. Participants will complete in-clinic follow-up visits at Days 14, 40, 65, 90, and 180. The primary outcome will be the change in truncal fat mass percentage from baseline to six months measured by dual-energy x-ray absorptiometry (DEXA)."
89455675|NCT02419196||flail chest|10 patients undergoing an operative stabilization of a flail chest will be examined by perioperative pulmonary function tests
89016154|NCT05335421|Experimental|Mindfulness Intervention plus Standard of Care|The Foundations and Awareness modules of the HMP app require a minimum of 133 and 253 minutes, equating to less than 5 and less than 10 minutes per day on average, respectively. Date, duration, and content of usage will be recorded for each participant through the app. Participants will have access to the entire contents of the app for the full duration of the study.
89016155|NCT05335421|No Intervention|Standard of Care|Control group receives standard of care only
89016156|NCT05333978|Experimental|Imaging of Inflammatory region|"Inflammatory regions of patients scheduled for standard of care clinical visits will be imaged using the MSOT device before and after 4 weeks of treatment.~The temperature of their skin prior to and after MSOT imaging will also be measured."
89016157|NCT05332366|Experimental|Delgocitinib - Delgocitinib|Participants will be blinded and randomised to delgocitinib cream treatment for the first 12 weeks, followed by an open label treatment with delgocitinib cream treatment for another 12 weeks.
89455676|NCT02426372|Experimental|QBECO SSI 0.02 mL|0.02 mL administered subcutaneously, every other day for 16 weeks. After completion of the initial 16-week fixed dose treatment period, subjects deemed to be responders will be randomized to one of three maintenance dosing schedules (every second day, weekly, no treatment) for an additional 36 weeks.
89501789|NCT03165903|Experimental|Cue and Implementation-Intention|Families from a school assigned to Cue and Implementation Intention-Based Intervention received an intervention targeting increased levels of healthy snacking and reduced levels of sugar sweetened beverage consumption.
89455677|NCT02426372|Experimental|QBECO SSI 0.05 mL|0.05 mL administered subcutaneously, every other day for 16 weeks. After completion of the initial 16-week fixed dose treatment period, subjects deemed to be responders will be randomized to one of three maintenance dosing schedules (every second day, weekly, no treatment) for an additional 36 weeks.
89455678|NCT02426372|Experimental|QBECO SSI 0.1 mL|0.1 mL administered subcutaneously, every other day for 16 weeks. After completion of the initial 16-week fixed dose treatment period, subjects deemed to be responders will be randomized to one of three maintenance dosing schedules (every second day, weekly, no treatment) for an additional 36 weeks.
89455679|NCT02426060|Experimental|Imrecoxib&Warfarin|
89455680|NCT03761069|Experimental|PTC299|PTC299 will be administered orally once daily (QD) for each 28-day cycle.
89455681|NCT02423174||Total Mesorectal Excision|Patients with an indication for surgical intervention for a total mesorectal excision
89455682|NCT02423252|Experimental|Intervention group|Intervention: Massage, Relaxation, imagery, music. Patients in Intervention group will receive standard care plus massage, relaxation, guided imagery and music listening
89455683|NCT02423252|No Intervention|Control|Patients in control group will receive standard care only. Same records and outcome measures with intervention group will apply for control group as well.
89455684|NCT04051697|No Intervention|Usual Care arm|Participants allocated to the control group will receive their usual care. Healthcare professionals within the designated sites will deliver aftercare treatment as usual, with no changes to the patient's clinical care. Participants in this arm do not receive the self-management intervention (SEA CHANGE).
89455685|NCT04051697|Experimental|Intervention arm|Participants in the intervention group will receive usual care and will be offered access to the self-management intervention (SEA CHANGE). Healthcare professionals within the designated sites will deliver aftercare treatment as usual, with no changes to the patient's clinical care.
88939920|NCT01844557||Group 1(High Accountability-Human Monitoring)|Participants randomly assigned to receive one of three sets of instructions before starting. Instructions for three swallowing exercises as well as an introductory script explaining the purpose of the exercises will be videotaped and shown to participants. Participants perform 3 swallowing exercises while researcher leaves the room. At the end of the testing period, researcher will come back into the room and record the number on participant's tracking device. Participant to tell whether they did as many repetitions as possible and if not, why they were not able to do as many as possible. This portion of the experiment will be videotaped. Participants complete an M.D. Anderson Symptom Inventory for Head and Neck Cancer Patients before procedure as well as a brief 3-page post-session questionnaire.
89455686|NCT02425982||Conservative treatment|Patients who will opt conservative treatment or patients treated conservatively by surgeon decision.
89455687|NCT02425982||Operative treatment|Patients who opt for surgery when offered.
89455688|NCT03749135|Active Comparator|Dupilumab|Dupilumab (anti-IL4Ra), s.c. administration
89455689|NCT03749135|Placebo Comparator|Placebo Comparator|matching Placebo, s.c. administration
89455690|NCT02418962|Experimental|Group 1 (pilot group)|Group 1 will be comprised of 3 volunteers who will be vaccinated first before the rest for demonstration of safety. The safety volunteers will receive 2 escalating doses of PfSPZ vaccine at a two week interval, 1.35x10^5 and 2.7x10^5 PfSPZ.
88939921|NCT01844557||Group 2(Low Accountability-Human Monitoring)|Participants randomly assigned to receive one of three sets of instructions before starting. Instructions for three swallowing exercises as well as an introductory script explaining the purpose of the exercises will be videotaped and shown to participants. Participants perform 3 swallowing exercises while researcher leaves the room. At the end of the testing period, researcher will come back into the room and record the number on participant's tracking device. Participants complete an M.D. Anderson Symptom Inventory for Head and Neck Cancer Patients before procedure as well as a brief 3-page post-session questionnaire.
89016158|NCT05332366|Placebo Comparator|Placebo - Delgocitinib|Participants will be blinded and randomised to placebo cream treatment for the first 12 weeks, followed by an open label treatment with delgocitinib cream treatment for another 12 weeks.
89016159|NCT05332366|No Intervention|No treatment|Participants will not receive any treatment. They will only provide a molecular signature of healthy skin to act as a control.
89455691|NCT02418962|Experimental|Group 2|The second group of 14 - 20 volunteers will receive three vaccinations of 2.7x10^5 PfSPZ Vaccine that will be given at 0, 8 and 16 weeks
89455692|NCT02418962|Placebo Comparator|Group 3|The third group of 7 - 10 volunteers will act as control group for group 2 and will receive three injections of normal saline at 0, 8 and 16 weeks respectively.
89455693|NCT02422784|Placebo Comparator|Control|Participants will be instructed to consume 240 mL of iced-tea daily for 6 weeks. The iced-tea beverages do not contain added sugar or artificial sweeteners. Beverages will be prepared fresh weekly and picked up by participants during their weekly study visits.
89455694|NCT02422784|Active Comparator|Rooibos Tea - Vitamin D3|Participants will be instructed to consume 240 mL of iced-tea fortified with 1000 IU water-soluable vitamin D3 daily for 6 weeks. The iced-tea beverages do not contain added sugar or artificial sweeteners. Beverages will be prepared fresh weekly and picked up by participants during their weekly study visits.
89455695|NCT02422784|Active Comparator|Rooibos Tea- Vitamin D3 & Calcium|Participants will be instructed to consume 240 mL of Rooibos iced-tea fortified with 1000 IU of water-soluable vitamin D3 and 360 mg of calcium daily for 6 weeks. The iced-tea beverages do not contain added sugar or artificial sweeteners. Beverages will be prepared fresh weekly and picked up by participants during their weekly study visits.
89455696|NCT03740009|Experimental|Perimenopausal women, depressed|Participants will take Bazedoxifene/Conjugated Estrogen orally for 3 weeks
89455697|NCT02418806|Experimental|Therapy group with follow up sessions|Weekly psychotherapy groups during 4 months with a monthly follow up period (12 months)
89455698|NCT02418806|Experimental|Therapy group without follow up sessions|Weekly psychotherapy groups during 4 months
89455699|NCT02418806|Active Comparator|Active comparator group|Weekly self-help groups during 4 months with a monthly follow up period (12 months)
89455700|NCT03183440|Experimental|PREBIOTICS|188 pregnant women
89455701|NCT03183440|Placebo Comparator|PLACEBO|188 pregnant women
89455702|NCT05692505||Positive test subjects|Subjects having previous positive tests verified by certified laboratory
89455703|NCT05692505||Control subjects|Subjects having no previous positive tests verified by certified laboratory
89455704|NCT02425670|Experimental|Bone marrow derived stem cells (BMSCs)|BMSCs 30-500 million plus conventional management
89455705|NCT02425670|No Intervention|Control|Control: conventional management
89455706|NCT03710525|Experimental|Own-Price Elasticity|"The price of vegetables will vary (own-price elasticity) while the price of all other foods in the mock grocery store will remain constant."
89455707|NCT03710525|Experimental|Cross-Price Elasticity|"The price of vegetables will remain constant while the price of other foods in the mock grocery store will vary (cross-price elasticity)."
89455708|NCT03183206|Experimental|Group A|In this group, the patients will receive under CT Cryosurgery , IRE surgery or open surgery to control the local tumor
89455709|NCT03183206|Experimental|Group B|In this group, the patients will receive multiple high-activity γδ T cell immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)
89455710|NCT03183206|Experimental|Group C|In this group, the patients will receive multiple high-activity γδ T cell immunotherapies and Cryosurgery, IRE surgery or open surgery
89016160|NCT05329350||muscular ventricular septal defects|patients with muscular ventricular septal defects
89455711|NCT03179696|Experimental|Mobile-assisted CBT|Psychosocial intervention combining in-person and smartphone-based cognitive-behavioral therapy (CBT) for experiential negative symptoms in schizophrenia called, Mobile-assisted Cognitive-Behavioral Therapy for Negative symptoms (mCBTn).
89455712|NCT03179618|Experimental|Qi stagnation and blood stasis|Patients in this group will be treated by Xuefu Zhuyu Decoction at the base of conventional western medicine.
89455713|NCT03179618|Other|Conventional western medicine|Patients in this group will be treated by conventional western medicine, including anti-platelet drugss，lipid regulating drugs, coronary vasodilator, etc.
89455714|NCT03182894|Experimental|Epacadostat + Pembrolizumab + Azacitidine|Oral Epacadostat (INCB024360) (50, 100, or 300 mg twice per day,on days 1-21 of each cycle, every 21 days) in combination with Pembrolizumab (MK-3475) (200 mg IV on days 1 of each cycle, every 21 days) and Azacitidine (VIDAZA) (100 mg SQ daily on days 1-5 of each cycle, every 21 days)
89455715|NCT03649217|Experimental|wearing the iStride device|The training will consist of four weeks of training with three training sessions performed each week. The training sessions will consist of up to thirty minutes of training with the iStride on, with breaks between walking sessions and as needed if the subject requests an additional break. Subjects will place the device on their foot in which they have the shortest step length, as measured during the pre-training gait analysis. This is typically the healthy side foot. There will also be several follow up visits following the final testing session.
89455716|NCT02418650|Experimental|Part 1|A single oral 300 mg tablet of ODM-201 followed by single intravenous 100 microg of 14C-ODM-201 containing not more than 37 kBq (1000 nCi)14C
89455717|NCT02418650|Experimental|Part 2|A single oral solution of 300 mg 14C-ODM-201 containing no more than 6.3 MBq (171 microCi) 14C
89455718|NCT02418728||persons with obesity|
89455719|NCT02418728||lean persons|
89455720|NCT02418884|Other|CAD+DM|Using self controlled study to validate the hypothesis that the treatment of rosuvastatin could increase the score of CAC density in CAD patients with diabetes mellitus.
89455721|NCT05511935|Experimental|exposed to GRIN training|participates in the intervention
89455722|NCT05511935|No Intervention|control/unexposed|no intervention
89455723|NCT03106922|Experimental|PMF104|"The day before the colonoscopy, starting in the mid-late afternoon (4-6 p.m.), by oral route:~2<=Age<6~500 ml in 1-1.5 hours <= to 18 kg~625 ml in 1-1.5 hours >18 kg 6<=Age<12:~750 ml in 1-2 hours <=25 kg~1000 ml in 1-2 hours 25-35 kg~1250 ml in 1-2 hours >35 kg 12>=Age<18 :~1500 ml in 2-3 hours <= 45 kg~1750 ml in 2-3 hours>45 kg.~Rescue dose (if no clear watery stools 3 hours after the entire solution):~250 ml 2 Age <=6;~500 ml 6 <=Age<12; up to a cumulative maximum volume of 2000 ml 12<=Age<18."
89455724|NCT03106922|Active Comparator|Klean- prep|"The day before the colonoscopy, starting in the mid-late afternoon (4-6 p.m.), by oral route:~2<=Age<6:~90 ml/kg in 1-1.5 hours 2<=Age<6~80 ml/kg in 1-1.5 hours 5<=Age<6~2<=Age<6:~80 ml/kg in 1-2 hours 6<=Age<10~70 ml/kg in 1-2 hours 10<=Age<12~12<=Age<18:~70 ml/kg in 2-3 hours. Rescue dose (if no clear watery stools 3 hours after the entire Klean-Prep solution): 50% of the initial dose."
89455725|NCT05692193|Experimental|experimental group|"A 'Patient Pain Education Brochure', which was prepared the day before the surgery, was given, and at the same time, the training was given verbally and in writing for an average of 20-30 minutes in the patient's own room.~Vital sessions and pain assessment were performed during admission to the ward before the training.~Pain was evaluated together with the patient's vital signs at the 15th, 30th, 45th, 60th minutes, 2nd, 4th, 6th, 12th, and 24th hours after the surgery.~Comfort assessment was performed at the 24th hour after surgery."
89455726|NCT05692193|No Intervention|control group|"One day before the operation, vital signs and pain were evaluated during hospitalization.~Pain was evaluated together with the patient's vital signs at the 15th, 30th, 45th, 60th minutes, 2nd, 4th, 6th, 12th, and 24th hours after the surgery.~Comfort assessment was performed at the 24th hour after surgery."
89455727|NCT02423096||Schizophrenia|Patients with schizophrenia will be treated with antipsychotic drugs as routine care (i.e., risperidone, haloperidol, sulpiride, olanzapine, quetiapine).
89455728|NCT02423096||Healthy controls|No special intervention will be provided for healthy controls.
89455729|NCT03629951||Participants with Schizophrenia|Participants will not receive any intervention as a part of this study. Participants with a diagnosis of schizophrenia or schizoaffective disorder receiving oral antipsychotics (OAP) for example, risperidone (1 to 6 milligram [mg] once daily [OD] to twice a day [BID]), olanzapine (5 to 20 mg OD), haloperidol (5 to 20 mg OD to thrice a day [TID]) etc, per their treating physician/clinician instruction will be observed. The primary data source for this study will be the clinical assessments by the treating physician of each participant conducted as a part of routine clinical practice.
89455730|NCT02423018|Active Comparator|Pregabalin|Pregabalin titrated up to, and tapered from, 225mg/day in divided doses for 10 days
89455731|NCT02423018|Placebo Comparator|Placebo|Placebo for 10 days
89455732|NCT03622385||Patients diagnosed with Serous Epithelial Ovarian Cancer|"Discovery Cohort: patients who were diagnosed with serous epithelial ovarian cancer whose tissue specimens were previously collected.~Validation Cohort: patients who are scheduled for a diagnostic laparoscopic biopsy for an undiagnosed pelvic mass that is determined to be cancerous."
89455733|NCT03622385||Normal patients|"Discovery Cohort: patients who were determined to have normal ovarian tissue specimens that were previously collected.~Validation Cohort: patients who are scheduled for a diagnostic laparoscopic biopsy for an undiagnosed pelvic mass that is determined to not be cancerous."
89455734|NCT04483076|Experimental|Arm A|Patients will be pre-enrolled and receive three cycles of SOX. After randomization, patients in Arm A will receive three more cycles of SOX (six cycles of neoadjuvant chemotherapy with SOX in total) followed by D2 gastrectomy.
89455735|NCT04483076|Active Comparator|Arm B|Patients will be pre-enrolled and receive three cycles of SOX. After randomization, patients in Arm B will receive D2 gastrectomy (three cycles of neoadjuvant chemotherapy with SOX in total).
89455736|NCT05692115||case|Coronary Artery Ectasia patients
89455737|NCT05692115||control|Normal coronary artery patients
89455738|NCT02422862|Experimental|UC-TSM|Upper cervical translatoric spinal mobilization (UC-TSM). UC-TSM is a physical therapy technique used to improve range of movement, consisting on a manual stretching of the cervical spine of the patient during 30 minutes.
89455739|NCT02422862|No Intervention|Control|The control group receive no treatment intervention during 30 minutes (a similar time as the UC-TSM group).
89455740|NCT03564353|Experimental|memory task with tDCS location 1|memory task paired with tDCS targeting C2 nerve (anode left c2; cathode right C2)
89455741|NCT03564353|Experimental|memory task with tDCS location 2|memory task paired with tDCS targeting C2 nerve (anode right c2; cathode left C2)
89455742|NCT03564353|Experimental|memory task with tDCS location 3|memory task paired with tDCS targeting C5/6 nerve
88939922|NCT01844557||Group 3(Low Accountability-Technological Monitoring)|Participants randomly assigned to receive one of three sets of instructions before starting. Instructions for three swallowing exercises as well as an introductory script explaining the purpose of the exercises will be videotaped and shown to participants. Participants perform 3 swallowing exercises while researcher leaves the room. At the end of the testing period, researcher will come back into the room and record the number on participant's tracking device. The videocamera will tape participant's session so evaluation can be made as to exercise accuracy. Participants complete an M.D. Anderson Symptom Inventory for Head and Neck Cancer Patients before procedure as well as a brief 3-page post-session questionnaire.
88939923|NCT01844570||Levamlodipine Maleate (Xuanning)|Primary hypertensive patients who take Levamlodipine Maleate (Xuanning) as the only anti-hypertensive medication or one of their medications
88939924|NCT01844570||Amlodipine Besylate (Norvasc)|Primary hypertensive patients who take Amlodipine Besylate (Norvasc) as the only anti-hypertensive medication or one of their medications
88939925|NCT01844596|No Intervention|Usual Care|Usual Care: Community Health Workers (CHW) with standard training on recruitment of individuals.
88939926|NCT01844596|Experimental|behavioral communication strategy|Community Health Workers with an additional tailored behavioral communication strategy.
88939927|NCT01844596|Experimental|Behavioral communication strategy, plus smartphone-based tool|Community Health Workers with a tailored behavioral communication strategy, also equipped with smartphone-based tool linked to the AMPATH Medical Record System (AMRS).
88939928|NCT01844609|Experimental|Self Study Journal Club|25 Chinese Medical Professionals that will be participating in Self Study Journal Club Meetings three times a week for one hour for 8 weeks with interactive questions and answers and discussion of the journal articles.
88939929|NCT01844609|Experimental|Intensive Journal Club|25 Chinese Medical Professionals that will be participating Face to Face Journal Club Meetings three times a week for one hour for 8 weeks along with a native English speaking mentor.
88939930|NCT01844622|Other|Domperidone|Domperidone will be given at 10 mg before each meal and at bedtime. At completion of the study, patients will receive standard medical therapy
88939931|NCT01844635|Experimental|2.5 mg/kg/day of Thymoglobulin for 5 days|2.5 mg/kg/day of Thymoglobulin for 5 days
88939932|NCT01844635|Active Comparator|3.5 mg/kg/day of Thymoglobulin for 5 days|3.5 mg/kg/day of Thymoglobulin for 5 days
89016161|NCT05327803|Experimental|epetraborole + OBR|epetraborole + Optimized Background Regimen
89016162|NCT05327803|Placebo Comparator|placebo + OBR|Placebo + Optimized Background Regimen
89016163|NCT05287451|Other|Risk-Reducing Salpingectomy-RRS|Can help to lower the risk of ovarian cancer with a delayed removal of 1.
89016164|NCT05287451|Other|Risk-Reducing Oophorectomy-RRO|Can help to lower the risk of ovarian cancer removing both fallopian tubes.
89016165|NCT05287451|Other|Risk-Reducing Salpingo-Oophorectomy-RRSO|Can help to lower the risk of ovarian cancer as well as the standard-of-care risk-reducing procedure involving the removal of the fallopian tubes and ovaries (risk-reducing salpingo-oophorectomy-RRSO)
89016166|NCT05283304|Experimental|Injectable Buprenorphine (BUP-inj)|Following successful titration to 16 mg of daily sublingual buprenorphine, the participants will then transition to injectable buprenorphine (300 mg dose) every 4 weeks
89016167|NCT05283304|Placebo Comparator|Injectable Placebo (PBO-inj)|Following successful titration to 16 mg of daily sublingual buprenorphine, the participants will then transition to injectable placebo (300 mg dose) every 4 weeks.
89455743|NCT03564353|Experimental|memory task with tDCS location 4|memory task paired with tDCS targeting trigeminal nerve dermatomes (left and right temple/jaw)
89455744|NCT03179306||Samples|de-identified images and clinical data from NCI studies.
89455745|NCT05691959|Placebo Comparator|Normal Saline|Normal saline 50 ml intravenous piggyback once over 10 minutes
89455746|NCT05691959|Experimental|Calcium chloride|x grams in 50 ml ivpb once over 10 minutes
89455747|NCT02418338|Experimental|dmd children|echocardiography
89016168|NCT05281328|Experimental|CAM2029 once weekly|0.5 mL CAM2029 10 mg, subcutaneous (SC) injection, once weekly
89016169|NCT05281328|Experimental|CAM2029 once every 2 weeks|0.5 mL CAM2029 10 mg, SC injection, every 2 weeks and 0.5 mL placebo, SC injection, once every 2 weeks (alternating with CAM2029 dosing)
89016170|NCT05281328|Placebo Comparator|Placebo|0.5 mL placebo, SC injection, once weekly
89016171|NCT05278039|Experimental|Respiratory-Swallow Phase Training|Participants will be trained to initiate swallowing during expiration.
89016172|NCT05278039|Sham Comparator|Swallow Practice|Participants will practice swallowing, but will not learn the key therapeutic element (i.e., initiating swallowing during expiration).
89016173|NCT05271630||Single Maintenance After Autologous Stem Cell Transplant|Prospectively enrolled cohort of patients receiving single maintenance therapy with an immunomodulatory drug after Autologous Stem Cell Transplant for Multiple Myeloma
89016174|NCT05271630||Double Maintenance After Autologous Stem Cell Transplant|Prospectively enrolled cohort of patients receiving double maintenance therapy with the combination of an immunomodulatory drug and a proteasome inhibitor after Autologous Stem Cell Transplant for Multiple Myeloma.
89201309|NCT00775398||C|Subjects with no anti-topical bovine thrombin antibodies pre-surgery and who did receive THROMBIN-JMI® during the study surgery.
89455748|NCT02418338|Other|healthy children|echocardiography
89455749|NCT02422706|Active Comparator|group I|"Metronidazole(MTZ) 500mg twice daily ,Omeprazole 20 mg twice daily as (Proton Pump Inhibitor (PPI)& Clarithromycin 500 mg twice daily .for 14 days .~40 patients"
89455750|NCT02422706|Experimental|Group II|"Nitazoxanide(NTZ)500 mg twice daily ,PPI 20 mg twice daily & Clarithromycin 500 mg twice daily for 14 days.~40 patients."
89455751|NCT02422706|Experimental|Group III|"Levofloxacin 250 mg once daily,Omeprazole 40mg once daily(PPI),Nitazoxanide (NTZ) 500mg twice daily & Doxicycline 100 mg once daily (LOND).~40 patients"
89455752|NCT03058757|No Intervention|Control arm|No intervention applied.
89455753|NCT03058757|Experimental|Intervention arm|neoadjuvant intravesical mitomycin-C 40mg/20ml instillation
89455754|NCT02418260|Active Comparator|Open reduction and plate osteosynthesis|Open reduction and internal fixation with DCP 4.5mm plate.
89455755|NCT02418260|Experimental|Bridge Plate|Patients will be submitted to closed reduction and anterior bridge plate osteosynthesis (narrow 4.5mm DCP plate will be used)
89455756|NCT02418260|Experimental|Intramedullary nail|Patients will be submitted to closed reduction and locked intramedullary nail osteosynthesis.
89455757|NCT03138889|Experimental|Dose Optimization, Combo of NKTR-214 + Pembrolizumab(KEYTRUDA®)|Cohort 1: NKTR-214 will be combined with pembrolizumab
89455758|NCT03138889|Experimental|Dose Expansion, Combo of NKTR-214 + Pembrolizumab(KEYTRUDA®)|Cohort 2: NKTR-214 will be combined with pembrolizumab
89455759|NCT03138889|Experimental|Dose Expansion, Combo of NKTR-214 + Pembrolizumab (KEYTRUDA®)|Cohort 3: NKTR-214 will be combined with pembrolizumab
89455760|NCT03138889|Experimental|Dose Expansion, NKTR-214 + Pembrolizumab and either Cisplatin, or Carboplatin and Pemetrexed|Cohort 4: NKTR-214 will be dosed in combination with pembrolizumab and either cisplatin, or carboplatin and pemetrexed, per investigator discretion
89455761|NCT03138889|Experimental|Dose Expansion, NKTR-214 + Pembrolizumab and Carboplatin and either Nab-paclitaxel or Paclitaxel|Cohort 5: NKTR-214 will be dosed in combination with pembrolizumab and carboplatin and either nab-paclitaxel or paclitaxel, per investigator discretion
89016175|NCT05270733|Experimental|Treatment|Patients will be treated with ustekinumab (90mg at week 0 and week 4 by subcutaneous injection) for 8 weeks followed by treatment with guselkumab (100mg at week 0 and week 4 by subcutaneous injection) or risankizumab (150mg at week 0 and week 4 by subcutaneous injection)
89016176|NCT05270057|Experimental|Loncastuximab Tesirine Dose Escalation 0.075 mg/kg by IV.|The study uses a classic 3+3 dose-escalation design. Three patients will be enrolled into a cohort receiving 0.075 mg/kg by IV. If there is no dose-limiting toxicity (DLT) seen in any of these participants, the trial will enroll additional participants into the next higher dose cohort, which is 0.12 mg/kg by IV. If one patient experiences a DLT at a specific dose, an additional three individuals will be accrued into that same dose cohort. The third dose level is 0.15 mg/kg by IV. DLTs in two or more at a specific dose level indicates that the MTD has been exceeded; dose escalation will not be pursued, and the prior dose level will be expanded to six patients; if there is no more than one patient who experiences a DLT among those six patients, that dose level is considered the MTD.
89016177|NCT05270057|Experimental|Loncastuximab Tesirine Dose Escalation 0.12 mg/kg by IV.|The study uses a classic 3+3 dose-escalation design. Three patients will be enrolled into a cohort receiving 0.075 mg/kg by IV. If there is no dose-limiting toxicity (DLT) seen in any of these participants, the trial will enroll additional participants into the next higher dose cohort, which is 0.12 mg/kg by IV. If one patient experiences a DLT at a specific dose, an additional three individuals will be accrued into that same dose cohort. The third dose level is 0.15 mg/kg by IV. DLTs in two or more at a specific dose level indicates that the MTD has been exceeded; dose escalation will not be pursued, and the prior dose level will be expanded to six patients; if there is no more than one patient who experiences a DLT among those six patients, that dose level is considered the MTD.
89016178|NCT05270057|Experimental|Loncastuximab Tesirine Dose Escalation 0.15 mg/kg by IV.|The study uses a classic 3+3 dose-escalation design. Three patients will be enrolled into a cohort receiving 0.075 mg/kg by IV. If there is no dose-limiting toxicity (DLT) seen in any of these participants, the trial will enroll additional participants into the next higher dose cohort, which is 0.12 mg/kg by IV. If one patient experiences a DLT at a specific dose, an additional three individuals will be accrued into that same dose cohort. The third dose level is 0.15 mg/kg by IV. DLTs in two or more at a specific dose level indicates that the MTD has been exceeded; dose escalation will not be pursued, and the prior dose level will be expanded to six patients; if there is no more than one patient who experiences a DLT among those six patients, that dose level is considered the MTD.
89016179|NCT05270057|Experimental|Loncastuximab Tesirine Dose Escalation Maximum Tolerated Dose|The study uses a classic 3+3 dose-escalation design. Three patients will be enrolled into a cohort receiving 0.075 mg/kg by IV. If there is no dose-limiting toxicity (DLT) seen in any of these participants, the trial will enroll additional participants into the next higher dose cohort, which is 0.12 mg/kg by IV. If one patient experiences a DLT at a specific dose, an additional three individuals will be accrued into that same dose cohort. The third dose level is 0.15 mg/kg by IV. DLTs in two or more at a specific dose level indicates that the MTD has been exceeded; dose escalation will not be pursued, and the prior dose level will be expanded to six patients; if there is no more than one patient who experiences a DLT among those six patients, that dose level is considered the MTD. This dose will be added to this record when it is determined.
89016180|NCT05270057|Experimental|Dose Expansion Phase|Subjects will receive the recommended phase 2 dose (RP2D) identified from dose-escalation phase. This dose will be added to this record when it is determined.
89016181|NCT05267301|Experimental|AlmgaPL|New consumers of iwi self-elected to start taking 2 capsules a day with 1000 mg of AlmegaPL, containing 250 mg of eicosapentaenoic acid (EPA), 150 mg polar lipids and 15 mg chlorophyll.
89016182|NCT05263648|Other|Virtual Reality Sessions|Patients will undergo at least two VR sessions. One prior to and one during the course of radiation treatment.
89016183|NCT05253833|Active Comparator|Group 1|Allopurinol once daily for 24 weeks
89016184|NCT05253833|Experimental|Group 2|AR882 Dose 1 x 2 weeks, then Dose 2 x 22 weeks
89016185|NCT05253833|Experimental|Group 3|AR882 Dose 1 + Allopurinol for 24 weeks
89455762|NCT03138889|Experimental|Combo of NKTR-214 + Pembrolizumab(KEYTRUDA®) or Atezolizumab (TECENTRIQ®)|Cohort 0 (Before Protocol Amendment 5.0): NKTR-214 will be combined with pembrolizumab or atezolizumab
89455763|NCT02422628||EGFR mutation postive|Blood samples every 3 months till disease progression or intolerable due to side effect.
89016189|NCT05250388||Patient group|"Patients aged 18-40 years with symptomatic unilateral traumatic anterior shoulder instability, following radiographically confirmed or manually reduced dislocation (first-time or recurrent), scheduled for arthroscopic Bankart repair, and with no pathology in the contralateral shoulder.~The study is not interventional but observational, examining biomechanical and proprioceptive conditions in patients' unstable shoulders before and after the surgical procedure."
89016190|NCT05237128|Experimental|Very low-carbohydrate diet|
89016191|NCT05237128|Experimental|Moderate-carbohydrate plate-method diet|
89016192|NCT05234944|Experimental|Intervention|A CDCES trained by the research team will deliver the intervention via HIPAA compliant telehealth/videoconferencing platform. There will be 2 sessions within approximately 6 months. Prior to each session, participants will complete an assessment of T1D-specific health-related quality of life, which will generate a summary report for each person that lists aspects of quality of life that are going well and aspects that are potential areas for improvement. The CDCES will review the reports with the participants, focusing on building on areas of strength and teaching brief behavioral strategies or resources to address aspects of quality of life that could be improved. Strategies may include stress management, problem-solving techniques, goal-setting, strategies to seek social support, or other brief behavioral skills. The CDCES will also offer information about relevant resources and will provide referrals for mental health support as needed.
89016193|NCT05234164|Experimental|EXIST 6F NiTi Stent System FLEX|Stent implantation of lesions in the SFA graded with Fanelli 1 and 2, and lesions in the P1 segment of the proximal popliteal artery.
89016194|NCT05234164|Experimental|EXIST 6F NiTi Stent System PULL|Stent implantation of lesions in the SFA graded with 3 and 4.
89016195|NCT05230992|Experimental|Cryoprobes First|Use of cryoprobes and then conventional forceps during the same operating time.
89016196|NCT05230992|Experimental|Cryoprobes Second|Use of conventional forceps and then cryoprobes during the same operating time.
89201310|NCT00775398||D|Subjects with no anti-topical bovine thrombin antibodies pre-surgery and who did not receive THROMBIN-JMI® during the study surgery.
88939933|NCT01844648|Experimental|NH004 tropicamide|tropicamide 1 mg thin film, twice daily for 7 days
88939934|NCT01844648|Placebo Comparator|NH004 placebo|placebo thin film, twice daily for 7 days
88939935|NCT01844661|Experimental|CELYVIR|Patients will received weekly (n=6) IV infusion of Celyvir.
88939936|NCT01844674|Experimental|Pharmacokinetic Population|All participants will receive a 3-period treatment including single-dose tizanidine on Day 1, twice-daily vemurafenib on Days 2 to 21, and both agents together on Day 22.
88939937|NCT01844713|Experimental|Experimental: Workbook|Distribution of the sun protection educational workbook
88939938|NCT01844713|No Intervention|Control|Distribution of general skin care information
88939939|NCT01844739|Experimental|NVN1000 4% Gel|NVN1000 4% Gel twice daily to the face for 2 weeks
88939940|NCT01844739|Placebo Comparator|Vehicle Gel|Vehicle Gel twice daily to the face for 2 weeks
88939941|NCT01844752|Experimental|NVN1000 1% Gel|NVN1000 1% Gel twice daily
88939942|NCT01844752|Experimental|NVN1000 4% Gel|NVN1000 4% Gel twice daily
88939943|NCT01844752|Placebo Comparator|Vehicle Gel|Vehicle Gel twice daily
88939944|NCT01844791|Experimental|OCZ103-OS, Platinum, Gemcitabine|OCZ103-OS in combination with Platinum-Gemcitabine as standard of care
88939945|NCT01844804|Experimental|A = PF-06438179|
88939946|NCT01844804|Active Comparator|B = Infliximab-EU|
88939947|NCT01844804|Active Comparator|C = Infliximab-US|
88939948|NCT01844843|Experimental|TCD-10023 drug eluting stent|All patients will be treated with the new Drug eluting stent TCD-10023
88939949|NCT01844869|Experimental|omacetaxine mepesuccinate|"Period A: 7-day pharmacokinetic assessment period in which all patients will be administered a single subcutaneous radiolabeled dose of 1.25-mg/m2 omacetaxine.~Period B: omacetaxine will be administered as an sc injection at a dosage of 1.25 mg/m2 twice daily for 7 days (patients with solid tumors) or 14 days (patients with hematologic malignancies) of every 28-day cycle for up to 6 cycles."
88939950|NCT01844882||Chronic Kidney Disease|
88939951|NCT01844908|Experimental|Electroacupuncture|
88939952|NCT01844934|No Intervention|Standard treatment|The no intervention group will receive standard treatment that includes a four hour class pre-surgery consisting of a description of the surgery, what to expect in the hospital and during recovery and some exercises to be done in preparation for surgery.
88939953|NCT01844934|Experimental|Prehabilitation|Prehabilitation:The experimental group will receive a three week prehabilitation program prior to surgery in addition to standard treatment.
88939954|NCT01844947|Experimental|vinflunine + sorafenib|Single arm study.
88939955|NCT01844960|Active Comparator|Multiple Incision Gastric Band Insertion|Current standard surgical approach for laparoscopic gastric band insertion
88939956|NCT01844960|Experimental|Single Incision Gastric Band Insertion|New surgical approach for gastric band insertion
88939957|NCT01844973|Placebo Comparator|Vehicle|
88939958|NCT01844973|Active Comparator|M518101|
88939959|NCT01844999|Other|Usual patient education + standard educational websites|
88939960|NCT01844999|Experimental|Usual patient education + P3P decision support website|
88939961|NCT01845012|Experimental|Daily hemodialysis at low dialysate flow|
88939962|NCT01845038|Experimental|OTX-TPa|OTX-TPa is a hydrogel punctum plug eluting travoprost in sustained release of ~4µg/day over approximately 2 months. For study masking purposes, subjects in this arm will also have natural tears drops administered.
88939963|NCT01845038|Experimental|OTX-TPb|OTX-TPb is a hydrogel punctum plug eluting travoprost in sustained release of ~3µg/day over approximately 3 months. For study masking purposes, subjects in this arm will also have natural tears drops administered.
88939964|NCT01845038|Active Comparator|Timolol|Timolol Maleate (0.5%) ophthalmic solution dosed twice daily (BID). For study masking purposes, subjects in this arm will also have a hydrogel punctum plug with no drug placed for approximately 3 months.
88939965|NCT01845051||Migraine group|Patients diagnosed with migraine
88939966|NCT01845051||Healthy group|Healthy subjects with no migraine as control
89455764|NCT02422628||EGFR mutation wild type|Blood samples before treatment once.
89455765|NCT02422628||Healthy Volunteers|Blood samples once.
89455766|NCT02422472|No Intervention|Standard|Standard of care ultrasound guided peripheral IV placement
89455767|NCT02422472|Experimental|Experimental|Ultrasound guided peripheral IV placement with the use of a guidewire
89455768|NCT02425514|Experimental|Cervios ChronOs|The ACDF surgery will be carried out with Cervios ChronOs(TM), which is the PEEK cage filled with b-TCP.
89455769|NCT02425514|Experimental|NovoMax™|The ACDF surgery will be carried out with NovoMax™, which is the bioactive glass ceramic intervertebral spacer
89455770|NCT02425748|Experimental|Group A|DC-CIK cells will be used against tumor cells.
89455771|NCT02425748|Experimental|Group B|γδ T cells will be used against tumor cells.
89016197|NCT05229952|Experimental|Constant infusion of 13C2-oxalate|Subjects who have passed screening, will consume a low-oxalate, normal calcium controlled diet for 5 days total. On Days 3 and 4, subjects will collect two 24-hour urines. On Day 5, they will receive a carbon 13 oxalate infusion which will occur at a constant rate for 6 hours, in the fasted state, following a priming dose. Hourly urine and twice hourly blood samples will be collected during the 6 hours. Meals will be resumed at the end of the infusion and timed urine collections will take place at home until the next day. A DXA scan will be performed to assess body composition at another date.
89016198|NCT05222594|Other|Epileptic participants undergoing intracranial monitoring|Patients with pharmaco-resistant epilepsy undergoing intracranial monitoring involving the left cerebral hemisphere.
89537172|NCT02719691|Experimental|Dose Level 2: Alisertib 30mg/MLNO128 2 mg|"This group will receive a Dose-Escalation: Combination of MLN0128 and Alisertib using a standard 3 + 3 design. The starting dose of Alisertib is 30 mg given PO twice daily (BID) Days 1-7 repeat every 21 days. The starting dose for MLN0128 is 2 mg given by mouth (PO) once daily with continuous dosing.~Alisertib: Participants will receive Alisertib in the dose-escalation and the dose-expansion part of the study."
89455772|NCT02425748|Experimental|Group C|Combination of γδ T cells/ DC-CIK be used against tumor cells.
89016203|NCT05213442|Other|All inpatients in Vinatier psychiatric Hospital|All hospitalized patients can potentially be recruited. They will benefit from the usual clinical and paraclinical examinations as part of their hospitalization diagnostic work-up. For the determination of biological analyses, a blood sample will be taken following inclusion as well as a Fibroscan examination.
89016204|NCT05201352|Experimental|Experimental arm|trifluridine/tipiracil + XB2001
89016205|NCT05201352|Placebo Comparator|Control arm|trifluridine/tipiracil + placebo
89016206|NCT05189457|Experimental|First Strike then Second Strike|"The first part of the study treatment or first strike involves 12-18 weeks of combined therapy with LHRH analog and one of the new hormonal agents (NHAs). Participants will complete the first strike at week 13 if their PSA has reduced >90%; otherwise they will complete a total of 18 weeks of therapy. The second part of the treatment or second strike involves 4 cycles docetaxel and LHRH analog. The second strike will start immediately after the first strike. MRI guided prostate biopsy will be performed after second strike. For patients with positive prostate biopsy or detectable PSA, the second strike will be consolidated with 4-6 additional cycles of docetaxel plus 6 doses of tislelizumab at 200 mg, given IV once every 3 weeks. For patients with undetectable PSA at year 3 from study enrollment, LHRH analog can be discontinued."
89016207|NCT05184335|Active Comparator|RP5063 15 mg once daily|administered OD for 28 days then flexibly 15-50mg over a period of 52 weeks.
89016208|NCT05184335|Active Comparator|RP5063 (brilaroxazine) 50 mg once daily|administered OD for 28 days, then flexibly 15-50mg over a period of 52 weeks
89016209|NCT05184335|Placebo Comparator|Placebo|administered OD for 28 days.
89016210|NCT05177211|Experimental|Treatment with Fedratinib|Participants will taken Fedratinib by mouth once a day every day of each 28 day cycle.
89016211|NCT05171101|Experimental|MAVEN|
89016212|NCT05171101|No Intervention|Control|Participants enrolled in the control group will receive no mentoring activities but will complete all study measures and assessments.
89455773|NCT03669679|Active Comparator|Group A|"participants undergoing superomedial pedicle breast reduction Hall-Findlay technique"
89455774|NCT03669679|Active Comparator|Group B|"participants undergoing inferior pedicle breast reduction Robbins technique"
89455775|NCT02422394|Experimental|Eltrombopag|"Phase 1: Eltrombopag 50 mg/day for 3 weeks. At the end of these 3 weeks of treatment: platelet count higher than 100 x10e9/L and no spontaneous bleeding, end therapy. In the other cases, treatment with eltrombopag 75 mg/day for 3 additional weeks.~Phase 2: Eltrombopag will be administered for 16 weeks. Eltrombopag will be initially given at 25 mg/day for 4 weeks. Every 4 weeks, the dosage will be modified as follows. (1) Bleeding score (WHO bleeding scale) 0-1 and platelet count between 30 and 100 x10e9/L: continue at the current dose; (2) Bleeding score 0-1 and platelet count higher than 100 x10e9/L: switch to the next lower dose; (3) Bleeding score 2-4 or platelet count lower than 30 x 10e9/L: switch to the next higher dose. The following dosages of eltrombopag are considered: 12.5 mg/day; 25 mg/day; 50 mg/day; 75 mg/day."
89455776|NCT02418494||Observational (ANCHOR HRQoL interview, cognitive interview)|Participants complete the ANCHOR HSIL HRQoL interview over 45-60 minutes, comparing the list of symptoms, concerns, or HRQOL impacts related to HSIL diagnosis and treatment. Some patients also undergo a cognitive interview for up to 3 sessions.
89455777|NCT01881763|Experimental|Ketamine|Participants will be randomized 1:1 to either Ketamine (experimental condition) or Methohexital anesthesia (active comparator)
89455778|NCT01881763|Active Comparator|Methohexital|Participants will be randomized 1:1 to either Ketamine (experimental condition) or Methohexital anesthesia (active comparator)
89455779|NCT03178058||Parturients for CS|"Parturients presenting for Cesarean section will be enrolled preoperatively. Prior to surgery women will be given a questionnaire detailing previous motion sickness, previous history of PONV, emesis during pregnancy, smoking history , itching history, skin atopy and allergies. After surgery details about surgery will be added: intraoperative hypotension, use of phenylepherine, intraoperative nausea and vomiting, exteriorization of uterus, extent of adhesions, need for uterotonic medications, and estimated bleeding.~Parturients will be assessed 1 hour and 24 postoperatively by attending anesthesiologist, PONV incidence will be reported using a three point ordinal scale (0 = none, 1 = nausea, 2 = retching, 3 =vomiting)."
89455780|NCT03137095||Breast Cancer Patient Participants|Female breast cancer patients receiving chemotherapy
89455781|NCT03137095||Healthy, age-matched, female participants|Healthy, female, age-matched participants
89455782|NCT02418416|Experimental|Double activation|The Oocytes in this arm will undergo double activation with Ca ionophore 5 micro mol for 20 min them Strontium chloride 10 micro mol for 60 min.
89455783|NCT02418416|No Intervention|Control arm|The Oocytes will undergo Intracytoplasmic sperm injection only
89455784|NCT02417792||control|group of healthy participants
89455785|NCT02417792||Topical psoriasis treatment|Group of patients who are treated with topical medications for psoriasis
89455786|NCT02417792||Systemic psoriasis treatment|Group of patients who are treated with systematic medications for psoriasis
89455787|NCT03674203|Experimental|Application of platelet-rich plasma|The patients received three sessions of PRP application, at intervals of 15 days between each of them. It was applied by means of a 32G needle to introduce the PRP by means of superficial micro-injections via the mesotherapy technique (approximately 1.5-2.0 mm deep) and it was deposited in the papillary dermis of the rosotro.
89455788|NCT03674125|Experimental|Group 1|GLS-6150 at 2.0 mg DNA/dose (3 dose prime plus boost)
89455789|NCT03674125|Experimental|Group 2|GLS-6150 at 1.0 mg DNA/dose (3 dose prime plus boost)
89455790|NCT03674125|Experimental|Group 3|GLS-6150 at 2.0 mg DNA/dose(3 dose prime plus boost)
89455791|NCT03674125|Experimental|Group 4|GLS-6150 at 2.0 mg DNA/dose(2 dose prime plus boost)
89455792|NCT03669601|Experimental|Continuous AZD6738 & gemcitabine|"Intravenous gemcitabine on days 3, 10 and 17 of a 28 day cycle. Dose range from 500mg/m2 to 1000mg/m2.~Oral tablet AZD6738 once daily for 21 days of a 28 day cycle. Dose range from 40mg to 120mg."
89455793|NCT03669601|Experimental|Intermittent AZD6738 & gemcitabine|"Intravenous gemcitabine on days 3, 10 and 17 of a 28 day cycle. Dose range from 500mg/m2 to 1000mg/m2.~Oral tablet AZD6738 once daily and intermittently for up to 12 days of a 28 day cycle. Dose range from 40mg to 120mg."
89455794|NCT03541499|Experimental|Group 1|800 microliters (10^7 CFU) of B. pertussis vaccine (BPZE1) administered intranasally with the VaxINator device on Day 1, n=15
89455795|NCT03541499|Experimental|Group 2|800 microliters (10^9 CFU) of BPZE1 administered intranasally with the VaxINator device on Day 1, n=15
89455796|NCT03541499|Placebo Comparator|Group 3|800 microliters of Placebo administered intranasally with the VaxINator device on Day 1, n=15
89455797|NCT03541499|Experimental|Group 4|800 microliters (10^9 CFU) of BPZE1 administered intranasally with a needleless tuberculin syringe on Day 1, n=5
89455798|NCT05691881|Experimental|68Ga-NY105|
89455799|NCT02706392|Experimental|Treatment (ROR1 CAR-specific autologous T-lymphocytes)|Patients receive chemotherapy comprising fludarabine phosphate and cyclophosphamide as determined by the referring physician in consultation with the protocol PI. Beginning within 36-96 hours after completion of lymphodepleting chemotherapy, patients receive ROR1 CAR-specific autologous T-lymphocytes IV over 20-30 minutes. Patients may receive a second infusion of ROR1 CAR-specific autologous T-lymphocytes with or without additional cytoreductive therapy at the same (for those that received the highest cell dose) or up to the next highest dose level and there is persistent disease, there were no toxicities attributed to the first infusion, and the patient is at least 21 days from the first T cell infusion.
89455800|NCT02416388|Experimental|R1-IDA|Idarubicin
89455801|NCT02416388|Active Comparator|R1-DAUNO|Daunorubicin
89455802|NCT02416388|Active Comparator|R2-HDAC|High dose cytarabine
89455803|NCT02416388|Experimental|R2-IDAC|Intermediate dose cytarabine
89455804|NCT02416388|Active Comparator|R3-MAC-MTX|Methotrexate and mycophenolic acid
89455805|NCT02416388|Experimental|R3-MAC-MPA|Cyclosporine and mycophenolic acid
89455806|NCT02416388|Active Comparator|R3-RIC-CICLO|Cyclosporine
89455807|NCT02416388|Experimental|R3-RIC-MPA|Cyclosporine and mycophenolic acid
89455808|NCT02416388|Experimental|R4-VOS-IDAC|Intermediate dose cytarabine and vosaroxin
89455809|NCT02416388|Active Comparator|R4-IDAC (without VOS)|Intermediate dose cytarabine alone
89455810|NCT02416388|Experimental|R4-DEX-HDAC|High dose cytarabine and dexamethasone
89455811|NCT02416388|Active Comparator|R4-HDAC (without DEX)|High dose cytarabine alone
89455812|NCT02416388|Experimental|R4-VEN-IDAC|Intermediate dose cytarabine and venetoclax
89455813|NCT02416388|Active Comparator|R4-IDAC (without VEN)|Intermediate dose cytarabine alone
89455814|NCT02417948|Experimental|Arm I (educational brochure, online educational tutorial)|Participants receive a skin cancer educational and preventive brochure distributed by the National Cancer Institute and watch a 30-minute online tutorial video called X-Plain about skin cancer, preventative behaviors, and skin self-examinations.
89455815|NCT02417948|Active Comparator|Arm II (educational brochure)|Participants receive an educational brochure as in Arm I.
89455816|NCT02418104|Experimental|CHS-1701|CHS-1701 followed by CHS-1701
89455817|NCT02418104|Active Comparator|Neulasta|Neulasta followed by Neulasta
89455818|NCT02886065|Experimental|PVX-410 + Citarinostat|"Participants will receive:~6 biweekly doses of PVX-410~6 biweekly doses of Hiltonol~3 monthly cycles of Citarinostat"
89455819|NCT02886065|Experimental|PVX-410 + Citarinostat + Lenalidomide|"Participants will receive:~6 biweekly doses of PVX-410~6 biweekly doses of Hiltonol~3 monthly cycles of Citarinostat~3 monthly cycles of Lenalidomide"
89016213|NCT05168605|Experimental|Home Visit|Participants will receive home visit During the course of the first home visit, patients will receive routine care for diabetes and hypertension management (outcome variables are listed below) and data will be recorded in the EHR for primary outcomes. The resident physician will also assist the patient in completing enrollment in MyChart (if interested), utilizing either the resident's computer or smartphone and an internet hotspot. MyChart is a patient health platform that allows patients to contact their healthcare doctors, log health reminders, see test results, and a list of medications. The resident physician will also review a social determinants of health (SDH) screener (included in the EHR). The research faculty (licensed medical clinician) will collect blood pressure readings during this visit.
89016214|NCT05168605|No Intervention|Standard of care|Participants will receive a standard of care
89016215|NCT05160051|Experimental|68Ga-FAPI-46 PET Scan|A single-center prospective interventional single-arm clinical trial. All eligible subjects undergo FAPI-PET Scan
89455820|NCT02416466|Experimental|anti-CEA CAR-T cells + Sir-Spheres|Three infusions of gene-modified anti-CEA T cells over the course of 6 weeks into the hepatic artery via a percutaneous approach along with low dose IL-2. A single dose of Sir-Spheres will be given 2 weeks following the final T cell dose.
89455821|NCT03496259|Experimental|On-Q Group|Patients in this group will have an On-Q pump placed at the end of the operation
89455822|NCT03496259|Active Comparator|Epidural Group|Patients in this group will have an epidural catheter placed at the end of the operation
89455823|NCT05454215|Active Comparator|Conventional settings first, modified settings second|"The control intervention (CON) is the conventional mode of a commercially available mechanical insufflator/exsufflator. The manoeuvre consists of 5 sets of 5 mechanical insufflations/exsufflations with individual pressure settings.~For the study, the same pressure settings will be used as during daily routine.~The study intervention (MOD) is a modified mode of a commercially available mechanical insufflator/exsufflator in which the active exsufflation of the last breath of each set will be omitted. The manoeuvre consists of 5 sets of 5 mechanical insufflations/exsufflations with individual pressure settings.~For the study, the same pressure settings will be used as during daily routine. This modified mode is already used in daily routine by a minority of subjects with NMD."
89016216|NCT05159830|Experimental|Cannabidiol (CBD)|CBD Group from 20mg x 2/day up to 600mg/day
89016217|NCT05159830|Placebo Comparator|PLACEBO (PCB)|PCB Group from 20mg x 2/day up to 600mg/day
89016218|NCT05150444|Experimental|Cognitive and physical exercise training|"This group will perform combined intradialytic cognitive and physical exercise training. First, they will exercise during dialysis (3 times a week; 12 weeks) for ~30 minutes on a customized ergometer. They will start with a 3-min warm-up, then the resistance will be implied to each individual according to the rate of perceived exertion of 4th to 5th grade on a 10-grade Borg scale. After a break, they will be given tablet computers in order to play brain games on a CogniFit platform (~30 - 45 min)."
89455824|NCT05454215|Experimental|Modified settings first, conventional settings second|"The study intervention (MOD) is a modified mode of a commercially available mechanical insufflator/exsufflator in which the active exsufflation of the last breath of each set will be omitted. The manoeuvre consists of 5 sets of 5 mechanical insufflations/exsufflations with individual pressure settings.~For the study, the same pressure settings will be used as during daily routine. This modified mode is already used in daily routine by a minority of subjects with NMD.~The control intervention (CON) is the conventional mode of a commercially available mechanical insufflator/exsufflator. The manoeuvre consists of 5 sets of 5 mechanical insufflations/exsufflations with individual pressure settings.~For the study, the same pressure settings will be used as during daily routine."
89455825|NCT02416310|Experimental|TEAS group|TEAS are performed by a specific investigator on the specially acupoint.
89455826|NCT02416310|Sham Comparator|Sham group|TEAS are performed by a specific investigator on the non-acupoint.
89016219|NCT05150444|No Intervention|Standard care|This group will receive standard hemodialysis care.
89016220|NCT05147909|Experimental|Sodium Phosphate (NaPO4) then sodium chloride (NaCl)|Participants will be asked to take 2 capsules daily of Sodium Phosphate (containing a total of 500 mg of Pi, 372mg of sodium) ) for 4 weeks during the high Pi phase (total Pi intake 1,200 mg/d). Then, participants will be asked to take 2 capsules of Sodium Chloride (NaCl, containing a total of 372mg of sodium) to match Na content to Sodium Phosphate without extra Pi daily for 4 weeks during the low Pi phase (total Pi intake = 700 mg/d).
89016221|NCT05147909|Experimental|NaCl then NaPO4|Participants will be asked to take 2 capsules daily of Sodium Chloride (NaCl, containing a total of 372mg of sodium) for 4 weeks during the low Pi phase (total Pi intake = 700 mg/d). Then, participants will be asked to take 2 capsules of Sodium Phosphate daily for 4 weeks Sodium Phosphate (containing a total of 500 mg of Pi, 372mg of sodium) for 4 weeks during the high Pi phase (total Pi intake 1,200 mg/d).
89016222|NCT05143489|Active Comparator|Preservative Free Lidocaine Group|The patient will receive a 1mg/kg IV dose of preservative free lidocaine with a max dose of 40mg
89016223|NCT05143489|Active Comparator|Placebo Group|The patient will receive IV normal saline of 1mg/kg with a max of 40mg
89016224|NCT05142059|Experimental|Experimental cohort|Participants will be involved in an evaluation program combining physical tests and self-administered questionnaires. Participants will be followed for 1 year with evaluations taking place at 6 months (occurrence of a fall) and at 1 year (the same evaluation, as initial).
89016225|NCT05141513|Other|Intra Operative Radiation Therapy (IORT) Group|The IORT group is the single arm of this study. Enrolled patients who undergo standard of care treatment will also receive a study treatment of High Dose Rate (HDR) Intra Operative Radiation Therapy.
89455827|NCT02416310|Placebo Comparator|Control group|Only place cutted electrodes but do not give any electrical stimulation.
89016226|NCT05139979|Experimental|Webinar-Based Intervention|Breathing and Wellness Webinar: two yogic breathing practices (Simha Kriya and Naddi Shuddi) and a guided meditation (Isha Kriya).
89016227|NCT05139979|Placebo Comparator|Control|This group will be asked to wait for 3 weeks before being introduced to the Breathing and Wellness Webinar intervention which includes two yogic breathing practices (Simha Kriya and Naddi Shuddi) and a guided meditation (Isha Kriya).
89455828|NCT03392441|Experimental|Insulin Deprivation|Insulin Deprivation in Type 1 Diabetic Patients will be performed for a short time period (4-6 hours). Changes to Age, Sex, and Gender matched controls will be compared.
89455829|NCT03177824|Experimental|S|Sildenafil citrate (25mg)
89455830|NCT03177824|Placebo Comparator|P|placebo oral tablet
89016228|NCT05124665|Experimental|Social Support|"CHWs will offer HIV testing to the individual nominated by the index patient as most likely to test. If this person is not present, CHWs will decide which contact should be offered testing first. CHWs will use a prosocial script for HIV testing: Knowing your status sets a good example for your household. CHWs will follow an opt-out strategy: This test kit is approved by the Ministry of Health and used in KCCA health facilities. I am going to offer you a free HIV test now, is that okay?. If the initial household contact who is offered HIV testing agrees to test, the CHW will ask if he/she is willing to share his/her decision to test with other members of the household: Would you like to share your decision to test with the others? Sharing is completely optional. However, learning that someone else in their household decided to test sometimes gives people the strength to test themselves. Sharing your decision might help another person find the strength to test."
89016229|NCT05124665|No Intervention|Standard of Care|As a control for the socio-behavioral intervention, the control arm will lack the socio-behavioral intervention components. The order of testing invitation will be decided by the CHW; and CHWs will be trained at baseline to provide standard, opt-in framing of test offers, without any mention of asking contacts to share their testing decision with other household contacts. Oral HIV kits will also be used in control households.
89016230|NCT05109780|Experimental|App + Unified Protocol Arm|"Participants at this condition will be daily monitored by the app (My Emi, Emotional Well-being) while they are administered a self-applied online transdiagnostic intervention for their emotional disorders. Alarms will be generated in the face of certain pre-set undesired events.~Therapists will receive pre-set clinical alarms in real time in the presence of relevant clinical events previously determined by the clinical staff (e.g., clinical worsening or no improvement of functionality, mood or psychological mechanisms worked in therapy). This information will be used to make clinical decisions in a short period of time (e.g., call the patient, or send additional therapeutic material by mail or through the app (momentary ecological intervention), or for its implementation during the course of psychological therapy in order to make the therapy more efficient, safe, personalized and adapted to the needs of the patient."
89016231|NCT05093933|Experimental|Vericiguat|Participants receive a starting dose of 2.5 mg of vericiguat taken orally once daily. The vericiguat dose will be titrated to 5 mg and to 10 mg.
89016232|NCT05093933|Placebo Comparator|Placebo|Participants receive a starting matching placebo to vericiguat dose of 2.5 mg taken orally once daily. The matching placebo dose will be sham titrated to 5 mg and to 10 mg.
89016233|NCT05082142|Experimental|TXA intraoperatively|Patients will receive intraoperative 1g TXA during the HoLEP procedure.
89016234|NCT05082142|No Intervention|No TXA intraoperatively|Patients will not receive intraoperative TXA during the HoLEP procedure.
89016235|NCT05073783||Cohort A|Pompe disease patients receiving Myozyme® (alglucosidase alfa) in a home-care setting.
89016236|NCT05073783||Cohort B|MPS I patients receiving Aldurazyme® (laronidase) in a home-care setting.
89016237|NCT05070429|Other|Conventional hearing healthcare group|The conventional hearing healthcare group will have clinic-based visits every 6 months for the duration of the 2-year study. During Year 1, this group will receive clinic-based audiological rehabilitative service delivery and be able to use conventional options to address any unanticipated needs that arise, and then during Year 2, this group will also receive telehealth audiological rehabilitative service delivery and be able to utilize telehealth options, in addition to conventional options, to address any unanticipated needs that arise.
89016238|NCT05070429|Other|Telehealth hearing healthcare group|The telehealth hearing healthcare group will have clinic-based visits every 6 months for the duration of the 2-year study. This group will receive telehealth audiological rehabilitative service delivery and be able to utilize telehealth options, in addition to conventional options, to address any unanticipated needs that arise during both years of the study.
89016242|NCT05052255|Experimental|Part 1: Dose Escalation / Part 2: Cohort Expansion|"Part 1-Dose Escalation: Escalating doses of RVU120, in patients who have progressed from previous therapy.~Part 2-Cohort Expansion and Alternative Schedule Investigation: Recommended dose in patients with tumor types selected from part 1 and escalation for alternative schedule."
89201311|NCT00989248|Experimental|comparation VE/VO2 and VE/VCO2|
89201312|NCT00900861||1|Asthmatic patients above 18 y, treated with ICS or bronchodilators
89455831|NCT02416544|Experimental|Full participation|Participants in this group receive lunch which is calorie-restricted and low-salt during 12 weeks, the total duration of this study.
89455832|NCT02416544|Experimental|Two thirds participation|Participants in this group starts lunch which is calorie-restricted and low-salt after 4 weeks from the beginning of the study and maintain the diet during 8 weeks.
89455833|NCT02416544|Experimental|One thirds participation|Participants in this group starts lunch which is calorie-restricted and low-salt after 8 weeks from the beginning of the study and maintain the diet during 4 weeks.
89455834|NCT04482842|Experimental|Gene-guided Warfarin|
89455835|NCT04482842|Other|Routine use|
89455836|NCT02415920|Experimental|Experimental|These participants will receive 24 international units (IU) of oxytocin via a nasal spray.
89455837|NCT02415920|Placebo Comparator|Control - Placebo|These participants will receive 24 international units (IU) of a saline solution via a nasal spray.
89501790|NCT03165903|Other|Control Arm|Families that were from a school assigned to Control received an intervention on sun safety that consisted of a 10-minute meeting with a trained Health Coach, 2 generic newsletters, an email, and a text message.
89455838|NCT02415764|Other|Pilot test Intervention OnTrack>The Game|"Consumers who have been referred to OnTrackNY sites at Washington Heights Community Service or Mental Health Association Westchester in the past six months will be recruited to participate in a product evaluation of OnTrack>The Game.~Intervention: This is a behavioral/attitudinal intervention, using OnTrack>The Game, which will include each participant sitting down at a computer for approximately one hour (over the course of one week) to complete the prototype game. Users will take on the role of a person who has experienced first-episode psychosis and moves through animated role-playing scenarios, learn practical tips for engaging in care, play mini-games to develop self-advocacy skills, and view stories of hope and recovery (brief video vignettes)."
89455839|NCT02422082|Active Comparator|L. reuteri|Lactobacillus reuteri (L. reuteri) ATCC PTA 6475 at a dose of 5 000 000 000 CFU as a powder in a stick-pack, orally twice daily (morning and evening) yielding a total daily dose of 10 000 000 000 CFU per day, for 12 months.
89455840|NCT02422082|Placebo Comparator|Placebo|Placebo product identical to the active product (L. reuteri) in taste and appearance but without the active component, orally twice daily, for 12 months.
89455841|NCT03389243|Experimental|metamizol|analgesic drug
89455842|NCT03389243|Experimental|paracetamol|analgesic drug
89455843|NCT03389243|Experimental|metamizole & paracetamol|analgesic drugs
89455844|NCT03179150||Oncological patients with extra-thoracic cancer|Patients enrolled into the study performed CT either for staging, restaging or follow-up of extrathoracic malignancies.
89455845|NCT03179228|Experimental|Prostate Embolization|Prostate Embolization with acrylic polymer microspheres impregnated with porcine gelatin
89455846|NCT03042767|Experimental|IMM-124E Group|Participants with nonalcoholic fatty liver disease (NAFLD) will receive 600mg of IMM-124E powder three times daily for twelve weeks.
89455847|NCT03042767|Placebo Comparator|Placebo Group|Participants with nonalcoholic fatty liver disease (NAFLD) will receive placebo powder three times daily for twelve weeks.
89455848|NCT02421770|Experimental|Experimental Chamaemelum Nobile|"Experimental Chamaemelum Nobile 2% gel During the 6-week double-blind phase, all patients will be randomly assigned to receive Chamaemelum Nobile 2% gel twice daily with occlusion on the affected are"
89455849|NCT02421770|Placebo Comparator|Placebo|During the 6-week double-blind phase, all patients will be randomly assigned to receive vehicle ( placebo)twice daily with occlusion on the affected are
89455850|NCT02421692|No Intervention|Usual Care|SNF rehabilitation therapists provide all patients with usual standard of care.
89016243|NCT05046171|Experimental|Arm 1: Pharmacist-led deprescribing intervention|Pharmacists will complete a comprehensive medication assessment with the participant via telemedicine and discuss tailored recommendations for discontinuations of potentially inappropriate medications. The pharmacist will document the evaluation and recommendations and communicate to the participant and care team members. The pharmacist will telephone each participant at least one time after the initial intervention to assess adherence to instructions and recommendations, and to assess any symptoms potentially related to medication discontinuation.
89016244|NCT05046171|Active Comparator|Arm 2: Patient education brochure|Participants will receive a brochure discussing medication appropriateness and deprescribing in general terms
89016245|NCT05043116|Active Comparator|Vitamin D|Dietary supplement: 2000 IU Vitamin D3 daily dose (oral suspension) for one year.
89016246|NCT05043116|Placebo Comparator|Placebo|Oral suspension with no active substance, identical to the active suspension for one year.
89016247|NCT05038839|Experimental|Treatment (cabozantinib, pamiparib)|Patients receive cabozantinib PO QD and pamiparib PO BID. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89455851|NCT02421692|Experimental|Progressive Rehabilitation|SNF rehabilitation therapists have been trained on principles of progressive rehabilitation strategies and will implement to all eligible patients as new standard of care.
89455852|NCT03373253||Participants With Diagnosis of Depression|This study will evaluate participant's socio-demographic, disease-related and treatment-related characteristics along with outcomes in routine clinical practice across the European region. Only data available within clinical practice, through routine therapeutic procedures and diagnostic assessments, will be recorded. Individual participant information will be recorded from participant's medical records or by use of specific questionnaires.
89455853|NCT02421926||IDEAL-E observational group|Subjects who were newly diagnosed as chronic phase chronic myelogenous leukemia, were enrolled to 'IDEAL' study, finished the total study period of 'IDEAL' study or were dropped during the study period.
89455854|NCT02421614|Experimental|high olive oli|A high fat (45%) low carbohydrate (35%) enteral feeding will be administered to acute respiratory failure patients. The percentage of olive oil will be half of total fat.
89455855|NCT02421614|Experimental|high sunflower oil|A high fat (45%) low carbohydrate (35%) enteral feeding will be administered to acute respiratory failure patients. The total fat will be sunflower oil.
89455856|NCT02421614|No Intervention|kitchen formula|A high protein kitchen diet for tube feeding will be administered to acute respiratory failure patients.
89455857|NCT03312881||neuropathic pain|Children with clinical diagnosis of neuropathic pain. Interventions: patient reported outcome measures, quantitative sensory testing, neuroimaging
89455858|NCT03312881||non-neuropathic pain|Children with clinical diagnosis of non-neuropathic pain. Interventions: patient reported outcome measures
89455859|NCT02410616|Experimental|Blended CBT|Internet based blended CBT depression treatment combines individual face-to-face cognitive behavioural therapy (CBT) with CBT delivered through an Internet based treatment platform with mobile phone components. The core components of the CBT treatment are: (1) psychoeducation, (2) behavioural activation, (3) cognitive restructuring, and (4) relapse prevention.
89455860|NCT02410616|Active Comparator|Treatment as usual|Treatment as usual (TAU) is defined as the routine care that subjects receive when they are diagnosed with depression in the secondary care system. The investigators will not interfere with treatment as usual but they will monitor carefully which health care services are utilized by usual care patients using patient records and through self-report.
89455861|NCT05691257|Experimental|Roxadustat group|Roxadustat group: patients with heart failure and chronic kidney disease and anemia treated with roxadustat and other anemia correction drugs.
89016248|NCT05032742|Experimental|mHealth parenting stress app|mHealth parenting stress app intervention to reduce parenting stress and improving youth community-based treatment engagement.
89016249|NCT05032742|No Intervention|Standard of care|Caregiver participants will receive an informational brochure describing ways to support one's adolescent during detention and community reentry and any other usual care.
89016250|NCT05028556|Experimental|Y101D|Y101D in subjects with Metastatic or Locally Advanced Solid Tumors
89016251|NCT05028153|Active Comparator|Antibiotics|Azithromycin (10mg/kg) administered via oral suspension for 3 consecutive days
89016252|NCT05028153|Placebo Comparator|Placebo|Placebo with no active substance administered via oral suspension for 3 consecutive days
89016253|NCT05026541|Sham Comparator|Nap Practitioners|This is an observational arm of regular nappers. Individuals that take naps at least two times a week will be invited to undergo all of the study procedures for one weekend of data collection.
89016254|NCT05026541|Active Comparator|Shoonya Meditators|This is intervention arm. Participants will learn and practice the fifteen minute shoonya meditation - described as a process of conscious non-doing- and shakti chalana kriya, which is a set of breathing exercises designed as a preparatory practice to shoonya meditation. Participants will practice shoonya meditation twice a day for two months. A weekend of data collection will happen at baseline and two months after they learn the practice.
89201313|NCT00983398|Experimental|Treatment (mannitol, melphalan, carboplatin, STS)|Patients receive mannitol IA over 30 seconds, melphalan IA over 10 minutes, and carboplatin IA over 10 minutes. Patients then receive sodium thiosulfate IV over 15 minutes at 4 and 8 hours after carboplatin. Treatment repeats every 4-6 weeks for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
89201314|NCT00333229|Experimental|Zoledronic Acid|Patients randomized into the Zometa arm received a total of 8 study drug infusions which were applied every 3 months. Patients received treatment for 24 months every 3 months.
89201315|NCT00333229|Placebo Comparator|Placebo|Patients randomized into the Placebo Arm received a total of 8 placebo infusions which were applied every 3 months. Patients received treatment for 24 months every 3 months.
89201316|NCT00769548|Experimental|Arm 1|Neoadjuvant total androgen suppression (TAS) given 2 months before and during radiation therapy (RT) to the whole pelvis followed by a prostate boost.
89455862|NCT05691257|Other|Control group|Control group: patients with heart failure and chronic kidney disease and anemia who were treated with other drugs include: Recombinant human eythropoietin (RH-EPO), iron agents (ferrous succinate, polysaccharide iron complex, iron sucrose, etc.)
89455863|NCT02410460|Other|PKA-BIS (intravenous anesthesia)|"Received the following medications:~clonidine 0.1-0.2mg glycopyrrolate 0.2mg propofol infusion titrated to BIS of 60-75 ketamine 50mg + additional ketamine not to exceed 200mg aggregate dosage throughout the case local anesthetic (lidocaine/marcaine mix)"
89455864|NCT02410460|Other|Inhalational anesthesia|"Received the following:~Pre-operatively:~famotidine 20mg scopolamine 1.5mg transdermal patch midazolam 2mg ondansetron 8mg metoclopramide 10mg glycopyrrolate - dose determined by anesthesiologist~During the case, medication choices and dosing were dependent on the anesthesiologist - all general anesthesia cases received inhalational anesthetic (type of anesthetic - desfluorane vs. sevofluorane - also varied based on anesthesiologist's choice)"
89455865|NCT02410226|Active Comparator|Palpation|Double-space combined spinal-epidural anesthesia, Sham ultrasound procedure
89455866|NCT02410226|Experimental|Ultrasound|Double-space combined spinal-epidural anesthesia, Preprocedure spinal ultrasound
89455867|NCT02410070|Experimental|Though Volar Minimal Incision|Patients in group A were treated through a small Incision.
89016255|NCT05026541|No Intervention|Control Meditators|Control subjects will be individuals that have learned the prerequisite meditation to Shoonya meditation. This meditation is called Shambhavi Mahamudra Kriya. Control subjects will not learn Shoonya meditation while they are participating in the study. One weekend of data collection will occur at baseline.
89016256|NCT05023434||Awake Craniotomy|
89016257|NCT05023434||Healthy Volunteers - No Longer Enrolling|
89016258|NCT05012982|Experimental|AirBand followed by uninflated AirBand|The order of study days will be randomized. participants will wear an uninflated AirBand as the control intervention during the session in which BFR is not performed,
89016259|NCT05012982|Experimental|Uninflated Airbnd followed by AirBand|The order of study days will be randomized. participants will wear an uninflated AirBand as the control intervention during the session in which BFR is not performed,
89016260|NCT05011357|Experimental|Phenylephrine|Phenylephrine infusion (0.3 mcg/kg/hr)
89016261|NCT05011357|Placebo Comparator|Control|Saline infusion
89016262|NCT05003310|Experimental|Active Stimulation; Period 1|Active stimulation for 12 weeks in addition to stable dose of csDMARD therapy.
89201317|NCT00769548|Experimental|Arm 2|Neoadjuvant TAS given 2 months before and during RT to the prostate only.
89455868|NCT02410070|Active Comparator|Though Convectional Incision|Patients in group B were treated through the conventional Incision
89455869|NCT03116672|Experimental|ketorolac 10 mg|Administration of one dose Ketorolac 10 mg 15 minutes before treatment
89455870|NCT03116672|Experimental|Diclofenac|Administration of one dose Diclofenac 15 minutes before treatment
89455871|NCT03116672|Experimental|Placebo oral capsule|Administration of Placebo capsule 15 minutes before treatment
89501791|NCT02224339||plaque neovascular and stress echo|After the SE and CEUS examination, patients will be grouped per the result of SE and CEUS as follows: group I: plaque neovascularization and normal wall motion; group II: plaque neovascularization and abnormal wall motion; group III: no plaque neovascularization and abnormal wall motion; group IV: no plaque neovascularization and normal wall motion.
89016263|NCT05003310|Sham Comparator|Sham Stimulation; Period 1|Sham stimulation for 12 weeks in addition to stable dose of csDMARD therapy.
89016264|NCT05003310|Experimental|Open label active stimulation, Period 2|Open label active stimulation for 12 additional weeks in addition to stable dose of csDMARD therapy.
89016265|NCT05003310|Other|Open label RA Drug, Period 2|Open label drug treatment with baricitinib for 12 weeks in addition to stable dose of csDMARD therapy.
89016266|NCT05003310|Experimental|RA drug combined with active stimulation, Period 3|Participants on baricitinib during Period 2 will have active stimulation added for 24 weeks. Participants will also receive a stable dose of csDMARD therapy.
89016267|NCT05003310|Experimental|Active stimulation combined with RA drug, Period 3|Participants on active stimulation during Period 2 will have baricitinib added for 24 weeks. Participants will also receive a stable dose of csDMARD therapy.
89016268|NCT05003310|Other|Long-term Follow-up, Period 4|Standard of care treatments with or without stimulation
89016271|NCT04965311|Experimental|Treatment of POPF (botulinum toxin type A)|Patients receive botulinum toxin type A via endoscopic injection into intraduodenal sphincter of Oddi segment between 7-14 days prior to planned distal pancreas resection.
89016272|NCT04963179|Experimental|Womed Leaf|IUA prevention: The novel intrauterine barrier film (Womed Leaf) is inserted immediately after completion of the hysteroscopic adhesiolysis
89016273|NCT04963179|No Intervention|Control|No IUA prevention - no placebo after adhesiolysis
89455872|NCT02417636|Experimental|Nurse-initiated and monitored ART|This is an experimental task shifting of ART initiation and monitoring from a clinician-led model to a nurse-led model. Participants will be screened for eligibility for ART and the study and then enrolled initiated on ART by a Nursing Officers and then followed and monitored for ART adherence on a monthly basis for 12months. Quarterly, sexual behavior and quality of life questionnaires will be administered. CBC, CD4, HIV-1 Viral load, renal and liver function test will be done biannually. Nursing Officers will be free to consult with clinicians on the management of patients.
89455873|NCT02417636|Active Comparator|Clinician - initiated and monitored ART|This is Standard of Care for the Uganda Ministry of Health to compared with the experimental task shifting. Participants will be screened for eligibility for ART and the study and then enrolled initiated on ART by a Clinicians (Clinical Officer or Medical Officer) and then followed and monitored for ART adherence on a monthly basis for 12months. Quarterly, sexual behavior and quality of life questionnaires will be administered. CBC, CD4, HIV-1 Viral load, renal and liver function test will be done biannually.
89455874|NCT03175094|Experimental|Holistic Health Recovery Program for HIV+ Intervention|
89016274|NCT04959032|Experimental|Lumateperone 42 mg|
89016275|NCT04959032|Placebo Comparator|Placebo|
89016276|NCT04959019|Experimental|Immediate Exercise|immediate participation in 6-week exercise program (intervention)
89016277|NCT04959019|Other|Delayed Exercise|6-week delay (no-intervention control) prior to participating in exercise program
89201318|NCT00769548|Experimental|Arm 3|RT to the whole pelvis followed by a boost to the prostate followed by 4 months of TAS.
89201319|NCT00769548|Experimental|Arm 4|RT to the prostate only followed by 4 months of TAS.
89201320|NCT05277675|Experimental|Neoadjuvant therapy+ RFA|After confirmation of HCC recurrence by imaging exam, subjects will receive neoadjuvant therapy (immune checkpoint inhibitors + targeted therapy) and then RFA
89455875|NCT03175094|No Intervention|Control|
89016278|NCT04955899|Experimental|Active Stimulation|Active stimulation for 12 weeks
89016279|NCT04947085|Active Comparator|IV SDK|intravenous ketamine administration in sub-dissociative doses (SDK) administered at 0.3 mg/kg over 15 minutes to patients presenting to the ED of Maimonides Medical Center with acute and chronic painful conditions.
89016280|NCT04947085|Active Comparator|K-BAN|nebulized ketamine at 0.75mg/kg administered via BAN to patients presenting to the ED of Maimonides Medical Center with acute and chronic painful conditions.
89455876|NCT03174860|Experimental|Diclofenac Potassium 50mg tab|Diclofenac Potassium 50mg (Cataflam) tablet to be administered one hour before treatment.
89455877|NCT03174860|Placebo Comparator|Placebo|Placebo to be administered one hour before treatment.
89455878|NCT02417480|Active Comparator|Vegan arm|A vegan diet is one that does not contain any animal products (no meat, fish, poultry, eggs, or dairy) but emphasizes plant-based foods, such as fruits, vegetables, whole grains, and legumes/beans. Researchers will ask participants on a vegan diet to follow their usual diet and exercise habits consistent for the two week study period.
89455879|NCT02417480|Experimental|Omnivorous arm|A diet containing all food groups. Researchers will ask participants on an omnivorous diet to follow habitual, usual diet and exercise habits for the first week. During the second week, participants will be asked to switch to a vegan diet for one week and to maintain their usual exercise habits.
89201321|NCT05277675|Active Comparator|RFA alone|After confirmation of HCC recurrence by imaging exam, subjects will receive RFA treatment only.
89455880|NCT03174548|Experimental|Fed Tablet period (Test, T)|Sotagliflozin oral in fed conditions
89455881|NCT03174548|Experimental|Fasted Tablet period (Reference, R)|Sotagliflozin oral in fasting conditions
89455882|NCT03174548|Experimental|Oral Solution period (S)|Sotagliflozin oral solution in fasting conditions
89455883|NCT02417558|Experimental|Alterniity Augmented Reality (AAR)|AAR training Participants use the patent pending AAR exercise and gaming (exergaming) platform that combines a physical training component (PTC) and a cognitive training component (CTC) in closed-feedback loop with Personalized Brain Network Activity (PBNA) test from a portable EEG.
89455884|NCT02417558|No Intervention|Passive Control Participants|Passive Control Participants do not receive an intervention serving as passive controls
89455885|NCT02417558|Active Comparator|Active|Active Control Participants receive an alternative cognitive training scheme; software was built on purpose by the Aristotle University of Thessaloniki. The software is called VideoGrade and uses videos from Youtube (YouTube) documentaries (VideoGrade).
89455886|NCT02410148|Active Comparator|Papilledema|non-invasive aICP measurement in patientes with papilledema
89455887|NCT02410148|Active Comparator|open angle glaucoma|non-invasive aICP measurement in patients with glaucoma
89455888|NCT03174470|Experimental|TENS stimulator|Single day Transcutaneous electrical nerve stimulations utilizing a commercial TENS stimulator (TensMed S82 ENRAF-NONIUS)
89455889|NCT02417402|Active Comparator|Untrained Physical Therapists|The patients allocated to the Control group will be treated by physical therapists who did not receive any training about clinical practice guidelines and pain management. These patients will receive the usual care from their physical therapists.
89455890|NCT02417402|Experimental|Trained Physical Therapists|The patients allocated to the Experimental group will be treated by physical therapists who received training about clinical practice guidelines and pain management.
89455891|NCT02409992|Experimental|Parent Training plus Emotion Coaching|This intervention will combine a parent management training program called Helping the Noncompliant Child with elements of an Emotion Coaching parenting intervention.
89455892|NCT02409992|Active Comparator|Parent Training Only|This intervention will consist of a parent management training program called Helping the Noncompliant Child.
89455893|NCT02417090||Metformin therapy|9-year-old children whose mothers used metformin for gestational diabetes
89455894|NCT02417090||Insulin therapy|9-year-old children whose mothers used insulin for gestational diabetes
89455895|NCT00703820|Active Comparator|ADE|"Cytarabine + Daunorubicin + Etoposide~NK cells for infusion are prepared using the CliniMACS System."
89455896|NCT00703820|Active Comparator|Clo/AraC|"Clofarabine + Cytarabine~NK cells for infusion are prepared using the CliniMACS System."
89455897|NCT03177980||Fentanyl|All infants in need of analgesia according to an algorithm based on pain assessment results will receive fentanyl as the first analgesic drug.
89455898|NCT03177980||Fentanyl and Clonidine|Infants in need of further analgesia according to an algorithm based on pain assessment results will receive fentanyl and clonidine as the analgesic drugs.
89455899|NCT02409836|Active Comparator|Crest Cavity Protection|Marketed Dentifrice
89201322|NCT00769626|Experimental|Early Treatment|
89201323|NCT00769626|Active Comparator|Usual Care|
89455900|NCT02409836|Active Comparator|Crest for Kids Hawaiian Punch Paste|Marketed Dentifrice
89455901|NCT02409836|Active Comparator|Crest for Kids Bubble Gum Paste|Marketed Dentifrice
89455902|NCT03174626|Experimental|WLSCC Intervention|Williams LifeSkills framework on stress management and cancer care
89455903|NCT03174626|Other|Usual Care|No intervention is provided
89455904|NCT02417012|Experimental|U-TURN intervention|"The intervention group will receive an intensive lifestyle intervention including partly supervised aerobic and strength exercise, diet plans and counseling by clinical dietitians. All exercise will be supervised initially and the supervision will be reduced gradually across the 12-month intervention. Additionally, the participants will be offered educational classes on implementation of a healthy lifestyle and diabetes education and support by trained nurses.~Participants in this group will have their pharmacological treatment regulated by the study endocrinologists using a standardized pharmacological treatment. The treatment is in accordance with the Danish guidelines."
89455905|NCT02417012|Active Comparator|Standard care|"The reference group will receive diabetes education and support by trained nurses.~Participants in this group will have their pharmacological treatment regulated by the study endocrinologists using a standardized pharmacological treatment. The treatment is in accordance with the Danish guidelines."
89455906|NCT02409758|Active Comparator|VFE voice therapy|Voice therapy: Vocal Function Exercises applied during 6 weeks
89455907|NCT02409758|Experimental|CVRP voice therapy|Voice therapy: Comprehensive Voice Rehabilitation Program applied during 6 weeks
89455908|NCT02409602||Women with BIIAL|Women who underwent bilateral internal iliac artery ligation due to postpartum hemorrhage within last 2 months
89455909|NCT02409602||Healthy puerperal women|Age-matched healthy puerperal women who delivered within last 2 months
89455910|NCT03177668|Experimental|YS110|"Phase 1 part: Administration of 3 different dose cohort~Phase 2 part: Administration of recommended dose determined from result of Phase 1 part"
89455911|NCT03177902||Observational group|Newly diagnosed breast cancer patients undergoing at least four cycles of chemotherapy
89455912|NCT03177902||Control group|Healthy Volunteers
89455913|NCT03177590|Experimental|Recordings of facial and vocal emotional|Recordings of facial and vocal emotional productions during Children are performing three tasks
89455914|NCT03177434|Active Comparator|Dicopeg Junior|"Polyethylene glycols (PEG) - 3350 Dosage form: oral solution sachets Frequency: 2 doses~Dosage:~weight up to 8 kg - 1 sachet per day~weight 8 - 12 kg - 2 sachets a day~weight 12 - 20 kg - 3 sachets a day~weight> 20 kg - 4 sachets per day, Duration: 12 weeks vs Lactulose Dosage form: oral solution Dosage: 2 ml / kg / day Frequency: 2 doses Duration: 12 weeks"
89455915|NCT03177434|Active Comparator|Lactulose|Lactulose Dosage form: oral solution Dosage: 2 ml / kg / day Frequency: 2 doses Duration: 12 weeks
89455916|NCT02415530|Placebo Comparator|Term infant control|term infant without intervention
89455917|NCT02415530|Placebo Comparator|VLBW infant control|very low birth weight infant without intervention
89455918|NCT02415530|Experimental|VLBW infant intervention|Combined home visiting and group intervention for very low birth weight infant
89455919|NCT03045887|Experimental|Part A Cohort 1: Placebo- GSK2292767 (GSK) 200 µg-GSK 1000 µg|Subjects will receive an inhaled single dose of placebo in Period 1, GSK2292767 200 µg in Period 2, and GSK2292767 1000 µg in Period 3. There will be a washout of approximately 4 weeks between doses.
89455920|NCT03045887|Experimental|Part A Cohort 1: GSK 50 µg-Placebo-GSK 1000 µg|Subjects will receive an inhaled single dose of GSK2292767 50 µg in Period 1, placebo in Period 2, and GSK2292767 1000 µg in Period 3. There will be a washout of approximately 4 weeks between doses.
89455921|NCT03045887|Experimental|Part A Cohort 1: GSK 50 µg- GSK 200 µg-Placebo|Subjects will receive an inhaled single dose of GSK2292767 50 µg in Period 1, GSK2292767 200 µg in Period 2, and placebo in Period 3. There will be a washout of approximately 4 weeks between doses.
89455922|NCT03045887|Experimental|Part A Cohort 1: GSK 50 µg-GSK 200 µg-GSK 1000 µg|Subjects will receive an inhaled single dose of GSK2292767 50 µg in Period 1, GSK2292767 200 µg in Period 2, and GSK2292767 1000 µg in Period 3. There will be a washout of approximately 4 weeks between doses.
89455923|NCT03045887|Experimental|Part A Cohort 2: Placebo-GSK 500 µg-GSK 2000 µg|Subjects will receive an inhaled single dose of placebo in Period 1, GSK2292767 500 µg in Period 2, and GSK2292767 2000 µg in Period 3. There will be a washout of approximately 4 weeks between doses.
89455924|NCT03045887|Experimental|Part A Cohort 2: GSK 100 µg-Placebo- GSK 2000 µg|Subjects will receive an inhaled single dose of GSK2292767 100 µg in Period 1, placebo in Period 2, and GSK2292767 2000 µg in Period 3. There will be a washout of approximately 4 weeks between doses.
89455925|NCT03045887|Experimental|Part A Cohort 2: GSK 100 µg-GSK 500 µg-Placebo|Subjects will receive an inhaled single dose of GSK2292767 100 µg in Period 1, GSK2292767 500 µg in Period 2 and placebo in Period 3. There will be a washout of approximately 4 weeks between doses.
89455926|NCT03045887|Experimental|Part A Cohort 2: GSK 100 µg-GSK 500 µg-GSK 2000 µg|Subjects will receive an inhaled single dose of GSK2292767 100 µg in Period 1, GSK2292767 500 µg in Period 2, GSK2292767 2000 µg in Period 3. There will be a washout of approximately 4 weeks between doses.
89455927|NCT03045887|Experimental|Part B: GSK|Subjects will receive inhaled repeat dose of GSK2292767 2000 µg once daily for 14 days.
89455928|NCT03045887|Experimental|Part B: Placebo|Subjects will receive inhaled repeat dose of placebo once daily for 14 days.
89455929|NCT02415374|Placebo Comparator|Low-AVA oat flour cookies|Three low-AVA oat flour cookies
89455930|NCT02415374|Experimental|High-AVA oat flour cookies|Three high-AVA cookies
89455931|NCT02415296||stage 1|French online gamblers.
89455932|NCT02415296||stage 2|Validation of problematic gamblers score on possible problematic gamblers.
89455933|NCT02415296||stage 3|240 problematic gamblers.
89455934|NCT02415452||Acute Coronary Syndrome (ACS) patients|Acute coronary syndrome (ACS) patients who underwent coronary angiography ,drug-eluting stent (DES) implantation, and eye fundus examination.
89455935|NCT02409524|Experimental|Treatment|The treatment schedule of AlloVax includes: (1) Priming segment with ID injections of AlloStim on Days 0, 3, 7 and 10. (2) Vaccination segment with ID injections of AlloStim+CRCL on Days 14, 17, 21 and 24. (3) Activation segment with IV push infusion of AlloStim on Day 28. (4) Booster Segment with monthly (every 28 days) ID injections of CRCL alone beginning on Day 56. These injections will continue until all the vaccine is used or the death of the subject
89455936|NCT03177278|Experimental|Arm 1|
89455937|NCT02587325|Experimental|nab-sirolimus (also known as ABI-009, nab-rapamycin, albumin-bound rapamycin)|
89016286|NCT04921436|Experimental|cardiac surgery patients with preventive treatment|"In addition to standard antibiotic prophylaxis (cefazolin 2 g 60 minutes before skin incision and 2 g 3 times a day after surgery), the following antibiotic regimens will be used perioperatively:~Doxycycline (the day before surgery 200 mg and 100 mg on days 1 and 2 after surgery) or Rimfampicin (150 mg 2 times a day before and after surgery) + Gentamicin (240 mg 3 times a day before and 2 days after surgery) or Clarithromycin (500 mg once daily for up to 2 days after surgery).~The route of administration (oral / intravenous) will depend on the condition of the patient."
89016287|NCT04921436|No Intervention|cardiac surgery patients without preventive treatment|standard antibiotic prophylaxis (cefazolin 2 g 60 minutes before skin incision and 2 g 3 times a day after surgery)
89016288|NCT04920565|Experimental|cardiac surgery patients with multiple organ dysfunction|hemoperfusion procedure with polymyxin B will be performed for 12 hours
89016289|NCT04920565|No Intervention|cardiac surgery patients|without hemoperfusion with polymyxin B
89455938|NCT02409446|Experimental|Anthocyanin|34 patients will receive anthocyanin. We will analyze their blood samples both prior and after taking anthocyanin.
89455939|NCT02409446|No Intervention|Controls|Healthy Controls, 20 persons. Will be giving blood samples at study start and study end.
89016290|NCT04918316|Active Comparator|Corneal gas permeable lens first|"Device: corneal gas permeable contact lenses (RoseK2 corneal Blanchard Contact Lens, Inc. Manchester, NH).~Participants with an odd study ID will be fit with the corneal gas permeable lens first."
89016291|NCT04918316|Active Comparator|Scleral lens first|"Device: scleral lenses (SynergEyes VS (Synergeyes, Inc., Carlsbad CA).~Participants with an even study ID will be fit with the scleral lens first."
89455940|NCT02409056|Experimental|workplace-tailored CDSMP|Group will receive the CDSMP program which has been modified to fit the unique characteristics of the workplace.
89455941|NCT02409056|Active Comparator|CDSMP usual care|Group will receive the standard CDSMP program which is currently being offered in a variety of community settings.
89455942|NCT02409056|No Intervention|control|Group will receive no intervention for the first 6 months (pre / post), then be randomly assigned to one of the above interventions.
89455943|NCT02415218|Experimental|Mucosal cell sheet transplantation|The subjects will have their oral mucosal tissues retrieved for cell sheet preparation. The mucosal cell sheet will be transplanted over the affected cornea.
89455944|NCT02415140||COPD|Spirometry confirmed COPD patients
89455945|NCT02415140||Control|normal geriatric patients without lung disease
89455946|NCT02414906|Experimental|Intervention group|Goal-directed therapy
89455947|NCT02414906|No Intervention|Control group|Control group
89016296|NCT04914208|Active Comparator|Wearing a face mask for 4 hours|Participants are wearing different kinds of face masks for 4 hours each. Masks are worn on different days and the order is randomly assigned.
89016297|NCT04914208|Other|4 hours without wearing a face mask|Participants do not wear any face mask for 4 hours.
89016298|NCT04910945|Experimental|Micro-coring treatment|
89016299|NCT04908397|Experimental|Supplement|Form: 500 mg L-carnitine tablet Dosage: Subjects 50-90kg: 3g/day Subjects <50kg or >90kg: 50mg/kg/day Frequency: twice a day for 2 weeks
89016300|NCT04907526|Experimental|Treatment Arm|Autologous (self) mononuclear cells derived from umbilical cord blood and that meet all release criteria are injected into the surface of the right heart muscle to achieve the target dose of 3 million cells per kilogram of body weight. This is a one time treatment at the time of Stage III Fontan surgery.
89016301|NCT04907526|No Intervention|Control Arm|Control cohort not receiving the cell product, which will be enrolled and followed using the same inclusion/exclusion criteria and follow-up requirements as the treatment arm.
89016302|NCT04906811|Active Comparator|Fat grafting with the AuraGen 1-2-3 with AuraClens System|Patients undergoing an aesthetic fat grafting procedure to the breast without a breast implant. Lipoaspirate processed with the AuraGen 1-2-3 with AuraClens system.
89016303|NCT04906811|Active Comparator|Fat grafting with the Revolve System|Patients undergoing an aesthetic fat grafting procedure to the breast without a breast implant. Lipoaspirate processed with the Revolve System.
89016304|NCT04902469|Experimental|Pleasant Odor|Participants in this condition will sniff the olfactory cue they rate as both pleasant (>5 on the 1-9 scale) and the most intense following cigarette cue exposure. If this odor is the same as their self-reported preferred e-cigarette flavor, we will choose the next most intense odor out of the odors rated as pleasant.
89016305|NCT04902469|Other|Odor Blank|Participants in this condition will sniff a neutral olfactory cue (odor blank) following cigarette cue exposure.
89016306|NCT04902040|Experimental|Arm A (radiation therapy, plinabulin, immunotherapy)|Patients undergo radiation therapy on days 1-3, 1-4, or 1-5 of cycle 1. Patients may undergo additional radiation in cycle 2 at the discretion of treating physician. Patients receive plinabulin IV over 30-60 minutes on days 1 and 4 of cycle 1, days 1 and 4 of cycle 2 (if receiving radiation therapy in cycle 2), and day 1 and or 15 (any day receiving immunotherapy) of subsequent cycles. Patients also receive immunotherapy consisting of either: avelumab IV over 1 hour on days 1 and 15; atezolizumab over 30-60 minutes on day 1; durvalumab IV over 1 hour on days 1 and 15; nivolumab IV over 30-60 min on days 1 and 15; or pembrolizumab IV over 30 min on day 1. Cycles repeat every 21 or 28 days in the absence of disease progression or unacceptable toxicity.
89016307|NCT04902040|Active Comparator|Arm B (radiation therapy, immunotherapy)|Patients undergo radiation therapy on days 1-3, 1-4, or 1-5 of cycle 1. Patients may undergo additional radiation in cycle 2 at the discretion of treating physician. Patients also receive immunotherapy consisting of either: avelumab IV over 1 hour on days 1 and 15; atezolizumab over 30-60 minutes on day 1; durvalumab IV over 1 hour on days 1 and 15; nivolumab IV over 30-60 min on days 1 and 15; or pembrolizumab IV over 30 min on day 1. Cycles repeat every 21 or 28 days in the absence of disease progression or unacceptable toxicity.
89455948|NCT03177356|Experimental|extraction,implant placement,PRF|Extraction of Mandibular first molar and Implant placement followed by Placement of placement of Platelet rich fibrin as space filling material
89455949|NCT03177356|Active Comparator|Exctraction,Implant placement,Bone graft|Extraction of mandibular first molar followed by implant placement and xenogenic bone graft as space filling material
89455950|NCT02414984||Golimumab|Participants with rheumatoid arthritis in Colombia, for whom the treating physician has decided to treat with golimumab prior to enrolment. All participants will be observed for 24 months. Any changes including addition of new medications or dose modifications of existing medications will be entirely according to the treating physician's judgment.
89455951|NCT02415062|Experimental|high dose donepezil (23mg)|Patients with dementia in Parkinson's disease, who are treated with high dose donepezil (23mg)
89016308|NCT04892277|Experimental|Treatment (cyclophosphamide, fludarabine, IC19/1563)|Patients receive cyclophosphamide IV over 60 minutes and fludarabine IV over 30 minutes on days -5, -4, -3, or bendamustine IV over 10 minutes on days -4 and -3, and IC19/1563 IV on day 0. Patients also undergo bone marrow biopsy and aspiration, CT-PET or CT scans, MRI, and collection of blood and tissue samples throughout the trial.
89016309|NCT04874103||EUS guided gallbladder drainage and cholecystoscopy|"EUS-GBD will be performed using LAMS (such as Hot-AxiosTM device). A 10mm x 10mm stent system will be used if the largest gallstone is smaller than 10mm in size and a 15 x 10mm stent will be used if the largest gallstone is larger than 10mm.~Colecystoscopy will be subsequently performed after at least 2 weeks using standard or therapeutic gastroscope. Lithotripsy will be performed using mechanical lithotripsy or laser lithotripsy."
89016310|NCT04865653|Experimental|Oral drinking solution of LSD base|Oral drinking solution of 0.1 mg LSD base in 96% ethanol
89016311|NCT04865653|Experimental|Solid orodispersible film containing LSD base|Solid orodispersible film containing 0.1 mg LSD base
89016312|NCT04865653|Experimental|Oral drinking solution of LSD tartrate|Oral drinking solution of 0.146 mg LSD tartrate in water
89016313|NCT04865653|Experimental|Intravenous administration of LSD tartrate|Intravenous administration of 0.146 mg LSD tartrate in water
89016314|NCT04865653|Placebo Comparator|Placebo|Placebo for all formulations
89016315|NCT04849988|Experimental|ABP-450 - Low Dose|ABP-450 Low Dose - Intramuscular injections into affected neck muscles.
89016316|NCT04849988|Experimental|ABP-450 - Medium Dose|ABP-450 Mid Dose - Intramuscular injections into affected neck muscles.
89016317|NCT04849988|Experimental|ABP-450 - High Dose|ABP-450 High Dose - Intramuscular injections into affected neck muscles.
89016318|NCT04849988|Placebo Comparator|Placebo|Placebo (0.9% saline, sterile, unpreserved, USP/Ph.Eur.) - Intramuscular injections into affected neck muscles.
89016319|NCT04847206|Experimental|MDMA (100 mg MDMA-hydrochloride)|MDMA (100 mg MDMA-hydrochloride; 84.1 mg MDMA free base)
89016320|NCT04847206|Experimental|MDA (93.9 mg MDA-hydrochloride)|MDA (93.9 mg MDA-hydrochloride; 78.0 mg MDA free base)
89016321|NCT04847206|Experimental|lysine-MDMA (171.7mg lysMDMA dihydrochloride|lysine-MDMA (171.7mg lysMDMA dihydrochloride; 84.1 mg MDMA free base)
89016322|NCT04847206|Experimental|lysine-MDA (165.6 mg lysMDA dihydrochloride;|lysine-MDA (165.6 mg lysMDA dihydrochloride; 78.0 mg MDA free base)
89016323|NCT04847206|Placebo Comparator|Placebo|Placebo
89016324|NCT04824417|Active Comparator|Control|Oral itraconazole
89016325|NCT04824417|Experimental|Intervention|Oral voriconazole
89016326|NCT04820829|Active Comparator|High RM, low NSS|Participants in this group will consume nine 3-oz-eq servings of RM per week and 2-oz-eq servings of NSS per week.
89016327|NCT04820829|Active Comparator|Moderate RM, moderate NSS|Participants in this group will consume five 3-oz-eq servings of RM per week and 5-oz-eq servings of NSS per week.
89016328|NCT04820829|Active Comparator|Low RM, high NSS|Participants in this group will consume one 3-oz-eq serving of RM per week and 8-oz-eq servings of NSS per week.
89016329|NCT04814875|Experimental|Part 1 - ACD (Safety)|ATX-101 plus carboplatin and pegylated liposomal doxorubicin (ACD)
89016330|NCT04814875|Experimental|Part 2 - ACD (Efficacy)|ATX-101 plus carboplatin and pegylated liposomal doxorubicin (ACD)
89016331|NCT04809051|No Intervention|Condition 1: Combined Transplant Pictograph|"Participants randomized to baseline (control) arm Condition 1 will view only combined transplant survival outcome information (e.g. transplant survival rate not stratified by number and quality of donor hearts accepted at each center) when making a choice between the two hospitals. The survival following transplant metric is displayed as a survival rate pictograph corresponding to all patients at the center who received transplants."
89016332|NCT04809051|Experimental|Condition 2: Stratified Transplant Pictograph|"Participants randomized to Condition 2 will view only stratified transplant survival outcome information when making a choice between the two hospitals. The survival following transplant metric is displayed as a pair of survival rate pictographs corresponding to two distinct groups of transplant patients at the center: those who received optimal donor organs and those who received adequate donor organs."
89016333|NCT04809051|Experimental|Condition 3: Combined Transplant SRTR|"Participants randomized to Condition 3 will view only combined transplant survival outcome information (e.g. transplant survival rate not stratified by number and quality of donor hearts accepted at each center) when making a choice between the two hospitals. The survival following transplant metric is displayed as a quintile score corresponding to all patients at the center who received transplants."
89016334|NCT04809051|Experimental|Condition 4: Stratified Transplant SRTR|"Participants randomized to Condition 4 will view only stratified transplant survival outcome information when making a choice between the two hospitals. The survival following transplant metric is displayed as a pair of quintile scores corresponding to two distinct groups of transplant patients at the center: those who received optimal donor organs and those who received adequate donor organs."
89016335|NCT04798339|Experimental|Phase 1b: Dose Level 1|Patients will be treated at dose level 1: Canakinumab 150 mg by subcutaneous injection on day 1 of each 28 day cycle. Darbepoetin alfa will be administered subcutaneously at a dose of 300mg on days 1 and 15 of each cycle.
89016336|NCT04798339|Experimental|Phase 1b: Dose Level 2|Patients will be treated at dose level 2: Canakinumab 300 mg by subcutaneous injection on day 1 of each 28 day cycle. Darbepoetin alfa will be administered subcutaneously at a dose of 300mg on days 1 and 15 of each cycle.
89016337|NCT04798339|Experimental|Phase 2: Treatment at Maximum Tolerated Dose|Patients will be treated with Darbepoetin alfa subcutaneously at a dose of 300 mg on days 1 and 15 of each cycle plus the maximum tolerated dose of Canakinumab.
89016338|NCT04785352|No Intervention|Standard well-baby care|Children in this arm (control group), as well as children in the two intervention groups, will receive standard care as outlined in the Essential Package of Health Services by Haiti's Ministry of Public Health and Population (MSPP). This includes a World Health Organization (WHO) immunization schedule of vaccines, high dose vitamin A supplements, and growth monitoring and promotion.
89016339|NCT04785352|Experimental|Nutrition Intervention|Children in this arm will receive one egg per day for six months.
89016340|NCT04785352|Experimental|Grandi Byen|This arm comprises a multicomponent intervention on responsive parenting, nutrition, hygiene, and one egg per day for six months for children.
89016341|NCT04781309|Experimental|NT-I7|480 microgram/kg IM (initial dose)
89016342|NCT04777409|Experimental|Oral semaglutide 14 mg|Participants are given oral semaglutide once daily
89016343|NCT04777409|Placebo Comparator|Placebo (semaglutide)|Participants are given oral placebo once daily
89016344|NCT04773275|Experimental|Aliya PEF treatment|
89016345|NCT04772547|Experimental|Open label|4500 mg of vigabatrin administered enterally
89016346|NCT04771377|Experimental|standard protein supplementation (SPS)|0.8g protein/ IBW/ day
89016347|NCT04771377|Experimental|High protein supplementation (HPS)|1.2g protein/ IBW/ day
89016348|NCT04771377|Experimental|HPS + PA|1.2g protein/ IBW/ day + PA 3 times a week/ 12 weeks
89016349|NCT04768062|Experimental|Viltolarsen|Patients amenable to exon 53 skipping will receive viltolarsen intravenous (IV) infusions, weekly, at 80 mg/kg for up to 96 weeks.
89455952|NCT02415062|Active Comparator|standard dose denepezil (10mg)|Patients with dementia in Parkinson's disease, who are treated with standard dose donepezil (10mg)
89455953|NCT02409212|Experimental|Intervention|12 months of aerobic exercise training with behaviour change support
89455954|NCT02409212|Placebo Comparator|Comparison|Optimal active surveillance according to NICE guidelines and written exercise guidelines from Macmillan cancer
89455955|NCT02416700|Experimental|immediate implant surgery|Immediate implant surgery in one site.
89455956|NCT02416700|Active Comparator|conventional implant surgery|Conventional implant surgery in another site
89455957|NCT02408978|Experimental|OXP005|1g naproxen
89016350|NCT04764474|Experimental|Treatment|All patients will be administered HMPL-306 orally QD
89016351|NCT04756076||Control|age and gender matched controls
89016352|NCT04756076||Pulmonary Hypertension Group|Pulmonary Hypertension Patients with Various Degree of Severity
89455958|NCT02408978|Active Comparator|naproxen|1g naproxen
89455959|NCT02408822|Active Comparator|PBA (Plain Balloon Angioplasty)|"Patient receiving endovascular treatment of a vascular access stenosis by plain balloon angioplasty (mechanical action, without drug)~2-minutes inflation of the plain balloon on pre-dilated stenosis segment, at nominal pressure"
89455960|NCT02408822|Experimental|PTX|(PacliTaXel-coated balloon angioplasty) Patient receiving endovascular treatment of a vascular access stenosis by drug-eluting balloon angioplasty (mechanical action + antiproliferative drug - Paclitaxel) 2-minutes inflation of the drug-eluting balloon on pre-dilated stenosis segment, at nominal pressure
89455961|NCT02414672|Experimental|CareSTEPS|CareSTEPS provides skills training in six domains that are central to the caregiving role: self-care, stress management, symptom management, effective communication, problem-solving, and social support.
89455962|NCT02414672|No Intervention|Usual Medical Care (UMC)|Patients receive standard oncologic and generalist palliative care from their healthcare team.
89016353|NCT04745169|Other|Intervention|Participants will be asked to complete an 8-week home-based exercise intervention
89016354|NCT04741997|Active Comparator|Surveillance|Participants will receive 24 weeks of neoadjuvant encorafenib and binimetinib and then proceed to planned resection. If participants have pathologic complete response they will receive adjuvant treatment for 24 weeks. Imaging will be conducted every 12 weeks for at least one year after surgery, and every 24 weeks for at least two years post-surgery.
89016355|NCT04741997|Experimental|Encorafenib and Binimetinib after Pathologic Complete Response|Participants will receive 24 weeks of neoadjuvant encorafenib and binimetinib and then proceed to planned resection. If participants have pathologic complete response they will continue to receive encorafenib and binimetinib for 24 more weeks. Imaging will be conducted every 12 weeks for at least one year after surgery, and every 24 weeks for at least two years post-surgery.
89016356|NCT04741997|Experimental|Encorafenib and Binimetinib after Non-Pathologic Complete Response|Participants will receive 24 weeks of neoadjuvant encorafenib and binimetinib and then proceed to planned resection. If participants have non-pathologic complete response they will continue to receive encorafenib and binimetinib for 24 more weeks. Imaging will be conducted every 12 weeks for at least one year after surgery, and every 24 weeks for at least two years post-surgery.
89016357|NCT04741997|Experimental|Nivolumab after Non-Pathologic Complete Response|Participants will receive 24 weeks of neoadjuvant encorafenib and binimetinib and then proceed to planned resection. If participants have non-pathologic complete response they will receive nivolumab for 24 weeks. Imaging will be conducted every 12 weeks for at least one year after surgery, and every 24 weeks for at least two years post-surgery.
89016358|NCT04723095||Observational (medical chart review)|Patients' medical records are reviewed retrospectively and prospectively. Patients are followed up by email, telephone, or U.S. mail every 4 months for up to 10 years from date of initial study enrollment. Patients, who are beyond 5 years from their initial diagnosis, are followed up by email, telephone, or U.S. mail annually.
89016359|NCT04706663||Cohort 1|Subjects with histologically confirmed prostate cancer and genomic testing results
89016360|NCT04706663||Cohort 2|Subjects with histologically confirmed prostate cancer who deemed to be an exceptional responder with or without genomic testing results
89455963|NCT03176576|Experimental|Patient Navigator (PN)|Patient Navigator (PN) Intervention Group. In addition to the Baseline Questionnaire and the Follow-up Questionnaire, PN intervention participants will complete a brief Patient Navigator Satisfaction Survey.
89016361|NCT04697589|Experimental|SBRP 300 mg|300 mg standardized botanical blend rich in polyphenols (SBRP) and especially in monomers of flavanols.
89455964|NCT03176576|Other|Usual Care (UC)|Usual Care (UC) Control Group. Control sample of patients not receiving PN intervention will complete a Baseline Questionnaire and the six-week Follow-up Questionnaire. Participants under UC will have access to all services typically provided to Moffitt Cancer Center (MCC) patients. Any baseline distress score greater than three will be reported to the patient's primary oncologist and clinic nurse.
89455965|NCT02408744|Experimental|Pirfenidone|Pirfenidone 1200 mg in the form of prolonged-released tablets, orally administered two times a day (b.i.d.) to yield a daily dose of 2400 mg during three years.
89455966|NCT03176888|Experimental|Exercise|Patients in the Exercise group will follow a fully-supervised exercise routine (Reduced-exertion, high-intensity interval training (REHIT)) with 3 weekly 10-minute training sessions consisting of easy cycling interspersed with 2 brief 'all-out' cycle sprints. Patients in this group will also be offered up to 6 sessions of cognitive behavioral therapy. The duration of the intervention will be the weeks between enrolling in the study and surgery (~1-4 weeks), as well as an additional period of up to 6 weeks following surgery.
89455967|NCT03176888|No Intervention|Standard care|Patients allocated to the Standard Care group will receive the care they would have also received if they would not have participated in the study. They will however undergo the same testing sessions as patients in the Exercise group.
89455968|NCT02414594|Experimental|IONIS-APO(a)-LRx|Drug: IONIS-APO(a)-LRx
89455969|NCT02414594|Placebo Comparator|Placebo (Normal Saline)|Drug: Sterile Normal Saline (0.9% NaCl)
89455970|NCT03176810|Active Comparator|OCT-guided PCI|PCI is performed by OCT guidance.
89455971|NCT03176810|Active Comparator|Angiography-guided PCI|PCI is performed by angiography guidance alone.
89455972|NCT02416778|Experimental|Treatment Arm|Ferric carboxymaltose, Ferinject® 50mg Iron/ml Solution for Injection / Infusion will be administered in patients with COPD
89455973|NCT02408666|Other|Interview|"Interview of epilepsy patients and their family about their experience with epilepsy, EEG registrations and daily life.~Interview of EEG-technologists and neurologists about their experience with EEG registrations and expections when thinking of a ideal EEG-cap."
89455974|NCT02414438|No Intervention|Current Practice Arm|Physicians follow current care procedures
89455975|NCT02414438|Experimental|FirstStep and NextStep Information|Providers receive informational webinar regarding FirstStepDx PLUS and NextStepDx PLUS between rounds and are able to order test results in Round 2
89455976|NCT02414438|Experimental|FirstStep and NextStep Results|Providers receive informational webinar regarding FirstStepDx PLUS and NextStepDx PLUS between rounds and are specifically prompted to order test results in Round 2
89455977|NCT02414516|Experimental|OBP-801|
89455978|NCT03176342|Experimental|patch test arm|Patch test by selected allergens and drawing blood for ELIspot and LTT
89455979|NCT02414360|Experimental|Shortened Format|Shortened format of a systematic review
89455980|NCT02414360|Active Comparator|Control|Full length systematic review
89455981|NCT03171896|Experimental|Intervention|Medical clown
89455982|NCT03171896|Sham Comparator|No Intervention|No clown in the room
89016362|NCT04697589|Experimental|SBRP 600 mg|600 mg standardized botanical blend rich in polyphenols (SBRP) and especially in monomers of flavanols.
89016363|NCT04697589|Placebo Comparator|Placebo|Colored maltodextrin
89016364|NCT04678856|Experimental|Part A and B: Dupilumab|Dupilumab administered every 2 weeks.
89016365|NCT04678856|Placebo Comparator|Part A and B: Matching placebo|Placebo administered every 2 weeks
89455983|NCT02414126|Active Comparator|Children with dilated cardiomyopathy with an ejection fraction|
89455984|NCT02414126|Active Comparator|Children with univentricular congenital heart disease|
89455985|NCT02414126|Active Comparator|Children with left valvulopathy|
89455986|NCT02414282||Experimental F 18 T807|
89455987|NCT03116204||Patients hospitalized in a FRC department|
89455988|NCT03116516|Other|ARM1|"In ARM1, 30 subjects will be assigned and the subjects will be administered telmisartan/amlodipine and rosuvastatin at Day1 and YHP1604 at Day22."
89455989|NCT03116516|Other|ARM2|"In ARM2, 30 subjects will be assigned and the subjects will be administered YHP1604 at Day1 and telmisartan/amlodipine and rosuvastatin at Day22."
89455990|NCT01564537|Experimental|Ixazomib + Lenalidomide + Dexamethasone|Ixazomib 4 mg, capsules, orally, once, on Days 1, 8 and 15; plus lenalidomide 25 mg, orally, once, on Days 1 through 21; and dexamethasone 40 mg, orally, once, on Days 1, 8, 15 and 22 of a 28-day cycle for multiple cycles until progressive disease (PD) or unacceptable toxicity, whichever occurred first up to end of treatment (EOT) up to approximately 42.9 months.
89455991|NCT01564537|Placebo Comparator|Placebo + Lenalidomide + Dexamethasone|Ixazomib placebo-matching capsules, orally, once, on Days 1, 8 and 15; plus lenalidomide 25 mg, orally, once, on Days 1 through 21; and dexamethasone 40 mg, orally, once, on Days 1, 8, 15 and 22 of a 28-day cycle for multiple cycles until PD or unacceptable toxicity, whichever occurred first up to approximately 41 months.
89455992|NCT03116360|Experimental|Single Arm|All patients will undergo traditional xray screening as well as experimental screening with diagnostic ultrasound. All subjects will undergo confirmatory MRI.
89455993|NCT03174236|Experimental|Ceftriaxone|Arm 1 IV Ceftriaxone: Participants in this group receive 80mg/kg IV ceftriaxone once a day for a minimum of 48 hours and a usual maximum of seven days.
89455994|NCT03174236|Active Comparator|Benzyl penicillin plus gentamicin|Arm 2 IV Benzyl penicillin plus gentamicin (usual care): Participants in this group receive 50 000 U/kg IV benzyl penicillin every six hours for a minimum of two days and a maximum of seven days.
89455995|NCT03174236|Experimental|Metronidazole|Arm 1 Metronidazole: Participants receive 10 to 16 mg/kg oral metronidazole twice a day for seven days.
89201324|NCT03984409|Active Comparator|Group 1|Potassium citrate x 7days Off therapy x 7 days 500 mL low calorie orange juice beverage x 7 days 1000 mL low calorie orange juice beverage x 7 days Return to potassium citrate therapy Litholink urine collection to be performed after each 7 days treatment
89455996|NCT03174236|Placebo Comparator|Placebo|Arm 2 Placebo: Participants receive an oral placebo dose to match that for Metronidazole twice a day for seven days.
89455997|NCT03202043|Experimental|High dose vegetable juice|Subject will consume high dose vegetable juice daily for 8 weeks.
89201325|NCT03984409|Active Comparator|Group 2|500 mL low calorie orange juice beverage x 7 days 1000 mL low calorie orange juice beverage x 7 days Off therapy x 7 days Potassium citrate x 7days Continue on potassium citrate therapy Litholink urine collection to be performed after each 7 days treatment
89455998|NCT03202043|Experimental|Medium dose vegetable juice|Subject will consume medium dose vegetable juice daily for 8 weeks.
89455999|NCT03202043|Experimental|Low dose vegetable juice|Subject will consume low dose vegetable juice daily for 8 weeks.
89456000|NCT03202043|Other|Control bottled water|Subject will consume control bottled water daily for 8 weeks.
89201326|NCT00900939|Experimental|Low-fat, vegan diet|
89201327|NCT00900939|Placebo Comparator|Control|
89201328|NCT00775554|Other|traditional hematoma block|people will receive traditional hematoma block for closed forearm fractures
89456001|NCT03172052|Experimental|streptokinase instillation|Chemical adhesiolysis by instillation of streptokinase at a dose of 250,000 I.U dissolved in 40 ml of normal saline will be instil in the pleural cavity through the chest tube. we planning to continue the daily instillation as long as the drained fluid volume is >100 cc with a maximum of 14 doses and to stop further instillation if severe complication occurred and if drained fluid through the tube was <100 cc in 24 h provided that tube is patent and properly positioned.
89456002|NCT03172052|Experimental|instillation of MESNA|Chemical adhesiolysis by instillation of MESNA at a dose of 1800 mg of MESNA i.e. 3 ampoules ( each ampoule contains 3ml and each ml contains 200 mg of MESNA) will be diluted with 20ml of Normal Saline and will be injected into the pleural cavity through the chest tube for three consecutive days.
89456003|NCT03172052|Experimental|Medical thoracoscopy procedure|Medical thoracoscopy procedure will be carried at endoscopy unit at chest department via, semi rigid thoracoscope
89456004|NCT03172052|Experimental|Video assisted thoracoscopy (VATS)|Video assisted thoracoscopy (VATS) at cardiothoracic surgery department.
89456005|NCT03673969|Active Comparator|MGB|Mini gastric bypass
89456006|NCT03673969|Active Comparator|Roux enY gastric bypass|Roux enY gastric bypass
89501792|NCT03167697|Experimental|Synergy|This group will receive the new phenylalanine-free protein substitute daily for 28 days. Patients in this group intervention will be directed to consume one powder sachet (33 g) of daily made up with 100mL of water. The new substitute delivers 414 kJ, 20g protein equivalent and a combination of essential and non-essential amino acids as well a combination of vitamins and minerals.
89501793|NCT03167697|Active Comparator|Routine|This group will continue their usual dietary and/or protein substitute regimen (maximum of 1 protein substitute per day (equal to 20g protein equivalent) control) for 28 days.
89016366|NCT04678661|Experimental|My Dose Coach (Insulin Dosing Support App)|"Phase 1 Titration: Patients receive insulin therapy education from diabetes educator (DE). Plus, DE trains patients to use My Dose Coach (MDC) for titration guidance according to an algorithm prepared by endocrinology provider (EP). Patients are asked to return for a 3-month (mo) follow-up clinic visit. Patients who successfully reach glycemic target are invited to Phase 2. Other patients are invited to continue titrating for another 3 months.~Phase 2 Maintenance: At 3-mo clinic visit, an EP or DE trains patients the MDC Maintenance Module to support proper insulin dosing. Patients are asked to return for follow-up clinic visits at mo 6.~Patients are surveyed (0, 3, 6 mo) to assess changes in behavioral and psychosocial factors that influence diabetes self-management and MDC acceptability."
89016367|NCT04678661|Active Comparator|Usual Care Group|A retrospective comparative group will be selected from eligible patients who previously were treated at the University of Pittsburgh Medical Center (UPMC) Diabetes Outpatient Clinics following standard insulin therapy education. Patients in the usual care group will be identified using data available in the electronic medical record system. Propensity score matching will be used to pair intervention and usual care participants during phase 1 of the study (baseline to 3 months).
89016368|NCT04663802|Active Comparator|Default order set|This arm will have the default order set implementation strategy
89016369|NCT04663802|Active Comparator|Physician-targeted accountable justification|This arm will have the physician-targeted accountable justification implementation strategy
89016370|NCT04663802|Active Comparator|Default order set + physician-targeted accountable justification|This arm will have the default order set and physician-targeted accountable justification
89016371|NCT04663802|Placebo Comparator|Standard of Care|This arm will have no interventions and standard of care practices will be in place.
89016372|NCT04663802|Active Comparator|Physician-targeted accountable justification + RT-targeted accountable justification|This arm will have the default order set and respiratory therapist-targeted accountable justification
89016373|NCT04652518|Experimental|LYT-100|LYT-100 taken orally twice a day (BID) for 91 days
89456007|NCT03673891|No Intervention|Control|After obtaining the consent, the subject will have a bedside ultrasound performed by the study investigator after receiving 500 ml of intravenous fluid bolus. The images will be recorded on ultrasound machine hard drive for future review. If the bedside ultrasound findings determine that the subject is not fluid responsive, subjects will be excluded from the study. If the subject is determined to be fluid responsive, the above listed outcome measures will be collected. Ultrasound will be repeated after every 500 ml bolus if the patient continues to receive IV fluids which will be determined by the treating physician. Ultrasound measurements and other parameters listed above will be collected throughout the ED and hospital stay.
89501794|NCT02224417|Other|Diabetes Educational Program (DEP) only|Participants will receive the Diabetes Educational Program, as required, which is part of usual care at the Polyclinic. They will receive the Fitbit ™, the eCAP, and a glucometer (if they do not already have one).
89016374|NCT04652518|Placebo Comparator|Placebo|Placebo matching LYT-100 taken orally BID for 91 days
89016375|NCT04652518|Other|Open Label Extension LYT-100|Open Label Extension: LYT-100 taken orally BID for 91 days The Open Label Extension (Part B) was terminated after results of the Double Blind Portion.
89016376|NCT04648696|Active Comparator|continuous infusions (CI) group|CI group will have their total daily cumulative dose of vancomycin converted to a 24-hour intravenous infusion upon discharge
89016377|NCT04648696|Active Comparator|Intermittent infusion (II) group|Inpatient study candidates that are randomized to the II group will continue their current intravenous dosing upon discharge
89016378|NCT04639388|Experimental|22q11.2DS|Children aged from 4 to 13 years old with 22q11.2 deletion syndrome
89016379|NCT04639388|Active Comparator|Control Group (Non22q11.2DS)|Children aged from 4 to 13 years old without developmental disease
89016380|NCT04628052|Experimental|Music|
89016381|NCT04628052|No Intervention|No-Music|
89016382|NCT04609904|Experimental|Budesonide, glycopyrronium, and formoterol fumarate (BGF) MDI 320/28.8/9.6 μg|BGF MDI 320/28.8/9.6 μg Budesonide, glycopyrronium, and formoterol fumarate (PT010) Metered Dose Inhaler (MDI)
89016383|NCT04609904|Experimental|BGF MDI 320/14.4/9.6 μg|BGF MDI 320/14.4/9.6 μg Budesonide, glycopyrronium, and formoterol fumarate (PT010) Metered Dose Inhaler (MDI)
89016384|NCT04609904|Active Comparator|Budesonide and formoterol fumarate (BFF) MDI 320/9.6 μg|BFF MDI 320/9.6 μg (Experimental/Comparator) Budesonide and formoterol fumarate (PT009) Metered Dose Inhaler (MDI)
89016385|NCT04609904|Active Comparator|Symbicort®|Budesonide/ formoterol fumarate pressurized metered dose inhaler (pMDI) 320/9 μg
89016386|NCT04607005|Experimental|Participants receiving mepolizumab + Standard of care (SoC)|Participants will receive one dose of 100 mg mepolizumab SC on top of SoC every 4 weeks during the 52-week treatment period.
89016387|NCT04607005|Placebo Comparator|Participants receiving placebo + SoC|Participants will receive one dose of placebo via SC route on top of SoC, every 4 weeks during the 52-week treatment period.
89016388|NCT04599634|Experimental|Experimental treatment: FL dose expansion|Window of magrolimab IV with a 1 mg/kg priming dose followed by 30mg/kg loading and maintenance doses + obinutuzumab IV 1000mg combination for two (2) cycles (28-days each, Cycles -2 and -1), then venetoclax will be added at target dose (dose determined from Arm 1). Triplet combination treatment with magrolimab + obinutuzumab + venetoclax will be 6 cycles (28-days each, Cycles 1-6); further treatment will be response-adapted.
89016389|NCT04599634|Experimental|Experimental treatment: FL Dose-finding|Magrolimab IV with a 1 mg/kg priming dose followed by 30mg/kg loading and maintenance doses + obinutuzumab IV 1000mg + venetoclax 800mg PO combination administered to 6 patients for six (6) cycles (28-days each, Cycles 1-6); further treatment with additional cycles will be response-adapted. Note: DLT assessment of the magrolimab + obinutuzumab + venetoclax triplet will take place during Cycle 1. If =2 patients experience DLT, an additional 6 patients will be enrolled at DL(-1) of venetoclax 600mg with magrolimab and obinutuzumab.
89201329|NCT00775554|Other|ultrasound guided hematoma block|pts. will receive a hematoma block using bedside ultrasound to guide the placement
89016390|NCT04599634|Experimental|Experimental treatment: MZL, MCL, and CLL Dose-finding|Magrolimab IV with a 1 mg/kg priming dose followed by 30mg/kg loading and maintenance doses + obinutuzumab IV 1000mg + venetoclax ramp-up to target dose of 400mg over 5 weeks (35 days, Cycle 1) administered to 6 patients. Triplet combination of magrolimab + obinutuzumab + venetoclax (target dose, no ramp-up) will continue for five (5) additional cycles (28-days each, Cycles 2-6); further treatment with additional cycles will be response-adapted. Note: DLT assessment of the magrolimab + obinutuzumab + venetoclax triplet will take place during Cycle 1. If =2 patients experience DLT, an additional 6 patients will be enrolled at DL(-1) of venetoclax 200mg with magrolimab and obinutuzumab.
89456008|NCT03673891|Experimental|LifeFlow group|LifeFlow device will be used to administer intravenous fluids in this group. LifeFlow is a FDA approved device to administer IV fluids. Subject will have a bedside ultrasound performed by the study investigator after receiving 500 ml of intravenous fluid bolus. The images will be recorded on ultrasound machine hard drive for future review. If the bedside ultrasound findings determine that the subject is not fluid responsive, subjects will be excluded from the study. If the subject is determined to be fluid responsive, the above listed outcome measures will be collected. Ultrasound will be repeated after every 500 ml bolus if the patient continues to receive IV fluids which will be determined by the treating physician. Ultrasound measurements and other parameters listed above will be collected throughout the ED and hospital stay.
89456009|NCT03174392|Experimental|Resistance based training study:|Each training session will begin by determining the treadmill walking speed that an individual will train. The speed of the treadmill will be incrementally increased stepwise and individuals will affirm which speed feels the most comfortable to walk. Thus, the training speed of individuals will not necessarily be fixed over the 8-week study. Heart rate will be monitored and resistive force will be applied stepwise until the heart rate reaches at least 60% heart rate reserve. Individuals will be encouraged to walk at least five minutes and then be allowed to rest. Achieved heart rate reserve and time the spent training at 60-80% heart rate reserve will be quantified for each session. Subjective measures of effort will also be sampled using the Borg Scale.
89456010|NCT03174392|Active Comparator|Speed based training study:|Each training session will begin by determining the fastest walking speed that an individual asserts that they can maintain for five minutes. The training time will then begin. Individuals will be encouraged to walk at least five minutes and then be allowed to rest. Speed will be progressed for each individual every 1-2 weeks at increments between 0.02 m/s and 0.08 m/s. Treadmill inclination will remain at 0°. Participants will be allowed to use the handrail or forearm support while being encouraged to walk without support if possible. Achieved heart rate reserve and the time the spent training at 60-80% heart rate reserve will be quantified for each session. Subjective measures of effort will also be sampled using the Borg Scale.
89456011|NCT02414048|Other|Pimonidazole|All patients will receive Pimonidazole to demarcate hypoxia regions in the tumour
89456012|NCT03171662|Experimental|group study|Imaging and Histopathological examination for Evaluation of Pediatric Appendicitis Score
89456013|NCT03064217|Active Comparator|CLP and 12 weeks waiting|After core build-up and initial tooth preparation, a clinical crown lengthening procedure (CLP) will be performed. Restorative treatments will be initiated 12 weeks after CLPs.
89456014|NCT03064217|Experimental|Digital impression taken at surgery|The final impression will be taken at surgery. The final crown will be delivered at suture removal.
89456015|NCT02413814|Experimental|Anger Reduction Treatment|The treatment consists of eight 30-minute IBM sessions. Participants will be presented with ambiguous scenarios and asked imagine themselves in these situations. In the first task, the scenario will be followed by a benign interpretation of the situation. Participants will answer a comprehension question designed to have participants endorse this benign interpretation. In the second task, participants will be presented with a word denoting an interpretation with either a negative/hostile or positive/benign connotation. Following this word, an ambiguous scenario will appear. Participants will indicate whether the word and the scenario were related. They will receive feedback training them to endorse positive interpretations and reject negative interpretations.
89456016|NCT02413814|Placebo Comparator|Control Condition|Participants assigned to the control condition will complete eight computerized sessions consisting of psychoeducation on healthy behaviors (i.e., topics of exercise, diet, hygiene, social support, healthy activities, and sleep, taken from protocols developed from our ongoing research). These participants will also view relaxing videos consisting of brief guided meditation instructions, pictures of nature scenes, and soft music. These sessions (psychoeducation and relaxing videos) will be matched for time with the active treatment condition, lasting 30 minutes each.
89456017|NCT02408354|Active Comparator|Triheptanoin|"Triheptanoin/ Placebo Randomized to receive active Triheptanoin first for 12 weeks. At cross-over, participants will receive placebo for 12 weeks.~Each drug will be dispensed successively. A one-month wash out period is planned for 4 weeks between triheptanoine and placebo phases."
89456018|NCT02408354|Placebo Comparator|Placebo|"Placebo / Triheptanoin Randomized to receive active Placebo first for 12 weeks. At cross-over, participants will receive Triheptanoin for 12 weeks.~Each drug will be dispensed successively. A one-month wash out period is planned for 4 weeks between placebo and triheptanoin phases."
89456019|NCT02406404|Experimental|spirometer training group|incentive spirometer training group
89456020|NCT02406404|No Intervention|No intervention group|no intervention group
89456021|NCT03176264|Experimental|PDR001|
89456022|NCT02406170|Experimental|Regorafenib+Paclitaxel|Regorafenib tolerability will be tested in a dose escalation scheme with a cytotoxic backbone of paclitaxel 80mg/m2.
89456023|NCT03173768|No Intervention|pre-intervention period|The charts of patients who were prescribed intravenous antibiotics at hospital discharge were reviewed. Appropriateness of intravenous antibiotics was assessed by ID specialists.
89456024|NCT03173768|Experimental|post-intervention period|The intervention is the charts of patients who were prescribed intravenous antibiotics at hospital discharge by the primary team were prospectively reviewed and intervened by ID team (ID specialist approval)
89456025|NCT03173846||Adult children of AD patients|
89456026|NCT02413658|Active Comparator|Control|Dressings of best current clinical practice, sugar solution.
89456027|NCT02413658|Experimental|Phenytoin 1|Dressings using phenytoin solution 20mg/ml
89456028|NCT02413658|Experimental|Phenytoin 2|Dressings using phenytoin solution 40mg/ml
89456029|NCT02406014|Active Comparator|Treatment Group A|Ingenol mebutate gel 0.015%, once daily for 3 consecutive days for the first treatment course. At 8 weeks after treatment initiation, subjects who present with existing AKs or newly emergent AKs in the treatment area will receive one more treatment course of ingenol mebutate gel 0.015%, daily for 3 consecutive days.
89456030|NCT02406014|Active Comparator|Treatment Group B|Diclofenac sodium gel 3%, (0.5 grams), twice daily for 90 days.
89456031|NCT02406092|Experimental|Rituximab|Participants with FL and DLBCL will receive rituximab SC 1400 milligrams (mg) once a month for a minimum of 4 cycles as induction therapy. Participants with FL will continue to receive rituximab once in 2 months for a minimum of 6 cycles as maintenance therapy according to local standards of care. Participants will also receive standard chemotherapy regimen (CHOP [cyclophosphamide+doxorubicin+vincristine+prednisone], CVP [cyclophosphamide+vincristine+prednisone] or FC [fludarabine+cyclophosphamide]) during induction.
89456032|NCT02413268|Placebo Comparator|Placebo|Patient receives an antibiotic ointment with no vasoactive drug as a placebo for comparison.
89456033|NCT02413268|Active Comparator|Nitropaste|Nitroglycerin 2% ointment is applied above the compression surface on the skin, to evaluate its efficacy in reducing radial artery occlusion.
89016391|NCT04599634|Experimental|Experimental treatment: mzl, MCL, CLL dose expansion|Window of magrolimab IV with a 1 mg/kg priming dose followed by 30mg/kg loading and maintenance doses + obinutuzumab IV 1000mg combination for two (2) cycles (28-day cycles, Cycles -2 and -1), then venetoclax safety ramp-up to target dose (dose determined from Arm 2) over 5 weeks (35-days, Cycle 1). Triplet combination treatment with magrolimab + obinutuzumab + venetoclax (target dose, no ramp-up) will continue for 5 additional cycles (28-days each, Cycles 2-6); further treatment will be response-adapted.
89201330|NCT04005820|Experimental|children and young adults supported in one of SFCE's centers|
89201331|NCT02538159|Experimental|Experimental CVC|CVC insertion Non-tunneled Central venous catheter insertion
89456034|NCT03173690|Experimental|Intervention group|Receive medication reconciliation at the ICU, pluss medication reconciliation at the ward
89456035|NCT03173690|Other|Control group|No intervention at the ICU, medication reconciliation at the ward
89456036|NCT02413502|Experimental|Bacillus Calmette-Guérin (BCG)|Tice brand BCG used to vaccinate BCG-Naïve adults.
89456037|NCT02405858|Experimental|Abiraterone Acetate|Participants will receive abiraterone acetate 1000 milligram (mg) (four 250 mg tablets) orally once daily, concomitantly with oral prednisolone 10 mg per day. No food should be consumed for at least 2 hours before the dose of abiraterone acetate is taken and for at least one hour after the dose of abiraterone acetate is taken. A 28-daily dosing cycle will continue until disease progression or unacceptable toxicity is observed up to 2 years.
89456038|NCT03171740|Active Comparator|Dexmedetomidine|Children will receive 1mcg/kg intranasal dexmedetomidine and oral saline, 30 minutes before going to operation theater.
89456039|NCT03171740|Active Comparator|Midazolam oral solution|Children will receive 0,5mg/kg oral midazolam and intranasal saline, 30 minutes before going to operation theater.
89456040|NCT03176186|No Intervention|TH/TTM|Protocol-directed standard of care (including TH/TTM) dictated by the 2015 guidelines for Post-Cardiac Arrest Care from the American Heart Association and the European Resuscitation Council. Mechanical Ventilation delivered by individual site-sanctioned ventilator.
89456041|NCT03176186|Active Comparator|TH/TTM plus Xenon|50% xenon gas in addition to standard of care, including therapeutic hypothermia/targeted temperature management (TH/TTM).
89456042|NCT03175952||PCI|
89456043|NCT02413424|Experimental|Drink Sucralose|Subjects will drink sucralose 10 min before drinking a glucose load
89456044|NCT02413424|Placebo Comparator|Drink Water|Subjects will drink water 10 min before drinking a glucose load
89456045|NCT02413424|Experimental|Taste and spit Sucralose|Subjects will taste and spit up sucralose 10 min before drinking a glucose load
89456046|NCT02413112|Experimental|Training once per week|Subjects train once per week in the University gym. All training sessions are supervised by the researchers.
89456047|NCT02413112|Experimental|Training twice per week|Subjects train twice per week in the University gym. All training sessions are supervised by the researchers.
89456048|NCT02413112|Experimental|Thrice per week|Subjects train three times per week in the University gym. All training sessions are supervised by the researchers.
89456049|NCT02413112|No Intervention|Non-training Control group|Subjects continue with their normal daily lives, just performing measurements
89456050|NCT04482764|Other|cyanotic breath holding spells|drug, valproic acid: 5mg/kg/d for 6 months
89016392|NCT04597411|Experimental|Group A (mCRPC who have received prior ARPI and chemotherapy, but are PSMA RLT naïve)|Men with castrate levels of testosterone that have received prior cytotoxic chemotherapy and a novel androgen axis drugs (e.g., abiraterone or enzalutamide), who HAVE NOT been previously treated with prior 177Lu-PSMA-617 radioligand therapy or 177Lu-PSMA I&T will receive a dose of 225^Ac-PSMA-617 via intravenous injection every 8 weeks (+/- 1 week) for no more than 6 cycles.
89456051|NCT03173378||Narcoleptic Patients|Type 1 and Type 2 narcoleptic adult patients usually followed at the Lyon Sleep Medicine and Respiratory Disease center
89456052|NCT03173378||Control|Adult age-matched family members of the patients
89456053|NCT02408042|Active Comparator|RICE and Pembrolizumab|non-Hodgkin's lymphoma patients requiring 2nd line or beyond therapy and eligible to receive RICE (rituximab, ifosfamide, carboplatin, and etoposide)
89456054|NCT02408042|Active Comparator|ICE and Pembrolizumab|classical Hodgkin's lymphoma requiring 2nd line or beyond therapy and eligible to receive ICE (ifosfamide, carboplatin, and etoposide)
89456055|NCT02408042|Active Comparator|brentuximab vedotin and Pembrolizumab|classical Hodgkin's lymphoma that have progressed after high-dose chemotherapy with autologous stem cell rescue or progressed on at least 2 lines of therapy and are eligible to receive brentuximab vedotin
89456056|NCT03173222|Active Comparator|EA1|
89456057|NCT03173222|Active Comparator|EA2|
89456058|NCT03173222|No Intervention|Control|
89456059|NCT03172988|Experimental|Dexamethasone and flurbiprofen axetil|Dexamethasone 10 mg is administered before anesthesia induction. Flurbiprofen axetil 50 mg is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg/ml sufentanil and 2 mg/ml flurbiprofen axetil, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h.
89016393|NCT04597411|Experimental|Group B (mCRPC who have not had prior ARPI or chemotherapy, and are PSMA RLT naïve)|Men previously treated with luteinizing hormone-releasing hormone (LHRH) agonists or orchiectomy and primary anti-androgen therapy that have not received prior cytotoxic chemotherapy or novel androgen axis drugs (e.g., abiraterone or enzalutamide) will receive a dose of 225Ac-PSMA-617 via intravenous injection every 8 weeks (+/- 1 week) for no more than 6 cycles.
89016394|NCT04597411|Experimental|Group C (mCRPC who have received prior PSMA RLT)|Men with progressive metastatic castration resistant prostate cancer (mCRPC) who HAVE been previously treated with 177Lu-PSMA-617 radioligand therapy or 177Lu-PSMA I&T will receive a dose of 225Ac-PSMA-617 via intravenous injection every 8 weeks (+/- 1 week) for no more than 6 cycles. Prior chemotherapy or novel androgen axis drugs not required.
89201332|NCT02538159|Experimental|Experimental PICC|PICC insertion Peripherally inserted catheter
89456060|NCT03172988|Experimental|Dexamethasone and lipid microsphere|Dexamethasone 10 mg is administered before anesthesia induction. Lipid microsphere 5 ml is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg/ml sufentanil and 20 ml lipid microsphere, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h.
89456061|NCT03172988|Experimental|Normal saline and flurbiprofen axetil|Normal saline 2 ml is administered before anesthesia induction. Flurbiprofen axetil 50 mg is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg/ml sufentanil and 2 mg/ml flurbiprofen axetil, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h.
89456062|NCT03172988|Placebo Comparator|Normal saline and lipid microsphere|Normal saline 2 ml is administered before anesthesia induction. Lipid microsphere 5 ml is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg sufentanil and 20 ml lipid microsphere, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h.
89456063|NCT03042611|Experimental|Rivoceranib Plus BSC|Participants will receive rivoceranib 700 milligrams (mg) orally once per day during each cycle plus BSC. BSC is defined as palliative, non-cancer therapy. Each cycle duration is 28 days.
89456064|NCT03042611|Experimental|Placebo|Participants will receive matching placebo to rivoceranib orally once per day during each cycle plus BSC. BSC is defined as palliative, non-cancer therapy. Each cycle duration is 28 days.
89201333|NCT00983554|No Intervention|Placebo|
89201334|NCT00983554|Experimental|Anastrazole and Testosterone|
89456065|NCT03171350|Experimental|ellume.lab Group A Streptococcus Test|ellume.lab Group A Streptococcus Test
89456066|NCT03171584|Experimental|Terbinafine group|Arm (1) will receive Terbinafine (250mg/day for 6 weeks).
89456067|NCT03171584|Experimental|Fluconazole group|Arm (2) will receive Fluconazole (300mg once weekly for 3monthes).
89201335|NCT00983554|Experimental|Dutasteride and Testosterone|
89201336|NCT00983554|Experimental|Testosterone|
89456068|NCT03171584|Experimental|Itraconazole group|Arm (3) will receive Itraconazole (400mg/day for one week per month followed by 3 free weeks ,, 2 pulses for finger nail)
89456069|NCT02988245|Experimental|Genetically-Guided Treatment for HTN|Using a patient's genetic composition to guide BP prescribing for patients with hypertension, post diagnosis.
89456070|NCT02988245|Active Comparator|JNC-8-Guided Treatment|Using traditional (JNC-8) guidelines for BP prescribing for patients with hypertension, post diagnosis.
89456071|NCT02388659||Brain MRI/MRS Patients|3 Tesla Scanning: MRI/MRS of glioma and non-glioma patients.
89456072|NCT02879825|Experimental|Group A|Mitral valve prolapse without mitral regurgitation
89456073|NCT02879825|Experimental|Group B|Mitral valve prolapse with trivial mitral regurgitation
89456074|NCT02879825|Experimental|Group C|Mitral valve prolapse with moderate or mild mitral regurgitation and asymptomatic
89456075|NCT02879825|Experimental|Group D|Mitral valve prolapse with severe mitral regurgitation or symptomatic
89456076|NCT02349815||Group 1|Women prescribed JAYDESS in Sweden
89456077|NCT03171506|Experimental|Usual care plus ketogenic diet|
89456078|NCT03171506|Placebo Comparator|Usual care plus AND diet|
89456079|NCT02818517||Heart failure|Evaluating the cardio toxicity effect of chemotherapy and radiation and estimating the effect of ACE inhibitors and beta blockers in the prevention of heart failure.
89456080|NCT02699957||Atrial Fibrillation|Those patients with the condition of atrial fibrillation.
89456081|NCT02405546|Experimental|Pre-Rotated Technique (Group R)|90° counterclockwise rotation of bevel of ETT
89456082|NCT02405546|Active Comparator|No rotation|No rotation of bevel of ETT
89456083|NCT02407652|Experimental|cognitive control training|internet-delivered, 2 weeks
89456084|NCT02407652|Active Comparator|low cognitive load training|internet-delivered, 2 weeks
89456085|NCT02407574|Experimental|Spontaneous rhythm first|Stepwise preload increase by repeated administration of 100 mL of fluid during spontaneous rhythm and then stepwise preload reduction by repeated drainage of 100 mL of fluid during atrial pacing.
89456086|NCT02407574|Experimental|Atrial pacing first|Stepwise preload increase by repeated administration of 100 mL of fluid during atrial pacing and then stepwise preload reduction by repeated drainage of 100 mL of fluid during spontaneous rhythm.
89456087|NCT02407496||ADHD|Adults with Attention Deficit Hyperactivity Disorder (ADHD)
89016395|NCT04585191|Experimental|Pre-Visit Conversation Aid|"Patients in the intervention arm will receive a newly developed, 1-page conversation aid/communication tool entitled Talking to Your Doctor about Diabetes: Are My Current Medicines Still Right for Me? prior to a scheduled appointment with their PCP. This document will provide brief education about changing risks and benefits of diabetes treatment as patients age, elicit values and preferences regarding treatment, and help direct next conversation steps."
89456088|NCT02407496||Control|Healthy individuals without ADHD
89456089|NCT02407418|Active Comparator|Spinal Manipulation|In a repeated measures, crossover design, all subjects received spinal manipulation during the second or third session. The selection of spinal manipulation or sham was randomized.
89456090|NCT02407418|Sham Comparator|Sham Manipulation|In a repeated measures, crossover design, all subjects received the sham manipulation during the second or third session. The selection of spinal manipulation or sham was randomized.
89456091|NCT02412800||Acute lung injury|Postoperative acute lung injury was diagnosed according to the latest 2012 Berlin definition of acute respiratory distress syndrome by the PaO2/FiO2< 300 and acute onset of bilateral infiltrates on the chest radiograph that were not fully explained by cardiac failure during postoperative day 1 to postoperative day 3.
89456092|NCT02412410|Experimental|Single|Single arm pilot study analyzing sleep data and calculated efficacy before and after fatigue avoidance education (comparator is same group after intervention)
89456093|NCT04481984|Experimental|Exercise group|The training including isometric and stretching hand exercise was applied once by a physiatrist. A hand exercise ball was used for isometric exercise. Patients performed both stretching exercises and isometric exercises according to the training and printed materials. The home-based exercise program was implemented 7 days per week during an 8-week period. In addition, patients received recommendations such as avoiding cold exposure and trauma.
89456094|NCT04481984|Other|Control group|Patients received care advice including avoiding cold exposure and trauma.
89456095|NCT02405624|Experimental|CPAP training|Patients will be instructed and follow the continuous positive airway pressure (CPAP) training procedure
89456096|NCT02407340|Active Comparator|Oxytocin|intranasal oxytocin - 40 International Units (IU) dose administered 3 times daily for 1 week
89456097|NCT02407340|Placebo Comparator|Placebo|Intranasal placebo administered 3 times daily for 1 week
89201337|NCT03160209||300 esophageal cases|diagnosed with histologically confirmed ESCC
89456098|NCT02701634|Experimental|ENTO|ENTO 400 mg or 200 mg tablet twice daily for 48 weeks
89456099|NCT02701634|Placebo Comparator|Placebo|Placebo to match tablet twice daily for 48 weeks
89456100|NCT02407262|Active Comparator|Treatment|"Black seed oil capsules~1g/day for 4 weeks"
89456101|NCT02407262|Placebo Comparator|Placebo|"Placebo (olive oil) capsules~1g/day for 4 weeks"
89456102|NCT02405468||case|patients with a myocardial infarction within one month to one year before the inclusion
89456103|NCT02405468||control|"patients without history of myocardial infarction, free of coronary disease in the view of one of the following test performed within one year before the inclusion : Effort test Echocardiographic stress test Myocardial perfusion scintigraphy Coronarography with >= 2 major cardiovascular risk factors :~Treated hypertension~Treated dyslipidemia~Current smoking~Diabetes mellitus"
89456104|NCT02407184|No Intervention|Scheduled C-section|Babies that are scheduled to be born in a hospital via standard C-section procedure.
89456105|NCT02407184|No Intervention|Vaginal Delivery|Babies that are born via vaginal delivery, either at home, at a birthing center or hospital. Drugs may be administered during labor.
89456106|NCT02407184|Experimental|Scheduled C-section with Exposure|Babies that are scheduled to be born in a hospital via standard C-section procedure, as well as are swabbed with gauze containing their mother's vaginal microbiota just after delivery. The intervention: Newborn exposure to mother vaginal microbiota.
89456107|NCT02412332|No Intervention|Group 1 - Control|The patients will be followed during the course of 12 months and evaluated regarding disease progression. No interventions will be performed other than conventional (in-course) treatment.
89456108|NCT02412332|Experimental|Group 2 - BMMC|Patients will be submitted to bone marrow harvesting. Bone marrow mononuclear cells (BMMC) will be obtained by Ficoll separation and returned to patients by systemic infusion (1x10^8 BMMC in 30 mL saline). Three patients will be submitted to Lung perfusion scintigraphy with technetium for cell engraftment evaluation.
89456109|NCT02412332|Experimental|Group 3 - ASC|Patients will be submitted to liposuction. The obtained fat tissue will be cultivated by 21 days and adipose-derived stem cell (ASC) will be returned to patients by systemic infusion (1x10^8 ASC in 30 mL saline). Three patients will be submitted to Lung perfusion scintigraphy with technetium for cell engraftment evaluation.
89501795|NCT02224417|Other|DEP + Process Incentive Arm|Participants will receive the Diabetes Educational Program, as required. They will receive the Fitbit ™, the eCAP, and a glucometer (if they do not already have one). They will also have the opportunity to earn financial incentives for meeting specified process goals.
89456110|NCT02412332|Experimental|Group 4 - BMMC + ASC|Patients will be submitted to liposuction and the obtained fat tissue will be cultivated by 21 days and adipose-derived stem cell (ASC) obtained. Patients will be submitted to bone marrow harvesting and bone marrow mononuclear cells (BMMC) will be obtained by Ficoll separation. BMMC and ASC will be returned to patients by systemic infusion (5x10^7 ASC + 5x10^7 BMMC in 30 mL saline). Three patients will be submitted to Lung perfusion scintigraphy with technetium for cell engraftment evaluation.
89456111|NCT02405156|Experimental|letrozole + misoprostol|Women will receive three tablets of letrozole vaginal as a single dose, each tablet 2.5 mg (total dose 7.5 mg per day) for three days and will be followed by 200 mcg vaginal misoprostol or 100mcg vaginal misoprostol (according gestational age) soaked with saline every six hours up to maximum four doses.
89456112|NCT02405156|Placebo Comparator|placebo + misoprostol|Women will receive three tablets of placebo vaginal as a single dose, for three days and will be followed by 200 mcg vaginal misoprostol or 100 mcg vaginal misoprostol (according gestational age) soaked with saline every six hours up to maximum four doses.
89456113|NCT02412254|Active Comparator|Hearing intervention|Best practices hearing rehabilitative treatment
89456114|NCT02412254|Placebo Comparator|Successful aging intervention|Successful aging intervention
89456115|NCT02407106|Experimental|BLIS K12 treatment|Once daily tablet of Streptococcus Salivarius BLIS K 12 to be slowly dissolved orally every evening for six month
89456116|NCT02405312|Experimental|advance care planning|nephrologist empowers social worker to meet with patient and family.
89456117|NCT02412020|Experimental|PA101|PA101, 40 mg administered via inhalation three times daily for 14 days
89456118|NCT02412020|Placebo Comparator|Placebo|Placebo PA101, administered via inhalation three times daily for 14 days
89456119|NCT03171428||TAA|Thoraco-Abdominal Approach: those patients with liver tumors operated with the thoracic-abdominal approach
89456120|NCT03171428||AA|Abdominal Approach: those patients with liver tumors operated with the abdominal approach (without the thoracotomy)
89456121|NCT02412176|Experimental|Pacing site - right ventricular apex|The intervention will be the implantation of the lead into the right ventricular apex
89456122|NCT02412176|Experimental|Pacing site - septum|The intervention will be the implantation of the lead into the septum.
88939967|NCT01845064|Experimental|Part A - SAD in healthy subjects|A randomized, double-blinded, placebo-controlled, single ascending dose (SAD) study in healthy male and/or female subjects. Subjects will receive DM199 subcutaneously (sc).
88939968|NCT01845064|Experimental|Part B - SAD in type 2 diabetic patients|A randomized, partially double-blinded, placebo-controlled, sequential SAD study in male and/or female type 2 diabetes mellitus patients. Subjects will receive DM199 subcutaneously (sc).
88939969|NCT01845064|Experimental|Part C - MAD in healthy subjects|A randomized, double-blinded, placebo-controlled, 14-day multiple ascending dose (MAD) study in healthy male and/or female subjects each. Subjects will receive sequential doses of DM199 sc for 14 days.
88939970|NCT01845064|Experimental|Part D - POC in type 2 diabetes patients|A randomized, double-blinded, placebo-controlled, 28-day multiple-dose proof of concept (POC) study in male and/or female type 2 diabetes mellitus patients. Subjects will receive doses of DM199 sc for 28 days.
89456123|NCT02411942|Experimental|Adapalene Gel 0.3%|Adapalene Gel 0.3% (Taro Pharmaceuticals Inc.)
89456124|NCT02411942|Active Comparator|Differin®|Differin® (adapalene gel 0.3%) (Galderma Laboratories, LP, US)
89456125|NCT02411942|Placebo Comparator|Placebo|Placebo (vehicle of the test product) (Taro Pharmaceuticals Inc.)
89456126|NCT02406950|Experimental|Sitagliptin|All participant will exam brachial artery endothelium-dependent flow-mediated dilatation (FMD). After then, pneumatic cuff wiil be inflated to 200 mmHg for 15 minutes to induce brachial artery ischemia. At the end of ischemia, 15 minutes of reperfusion was performed to induce reperfusion injury. After ischemia-reperfusion (IR) injury, brachial artery FMD will be measured again. After randomization, sitagliptin group will be treated by single dose of sitagliptin (Januvia) 50mg. In 2 hours later, brachial artery FMD measurement, IR injury and brachial artery FMD measurement will be measured again.
89456127|NCT02406950|Placebo Comparator|Placebo|After brachial artery FMD measurement, IR injury for each 15 minutes will be performed, and brachial artery FMD will be measured again. After randomization, placebo group will be treated by nothing. In 2 hours later, brachial artery FMD measurement, IR injury and brachial artery FMD measurement will be measured again.
89456128|NCT02406950|Other|Sitagliptin and glibenclimide|If sitagliptin treatment show preventive effects of IR injury, the investigator will perform additional experiment to explore the mechanism (Protocol 2 study). Additional 15 healthy volunteers will be treated 5 mg of glibenclamide (Euglucon) 1 hour before administration of 50 m g of sitagliptin. In 2 hours after sitagliptin administration, FMD measurement before and after IR injury will be performed as described above.
89456129|NCT02406872|Experimental|Remimazolam Tosilate 1|IV pumping of Remimazolam Tosilate at 6mg/kg/h for anesthesia induction
89016396|NCT04585191|Active Comparator|General Health Education Handout|"Patients in the attention control arm will receive an existing 1-page health education handout entitled Embracing Life as You Age which provides some general advice geared towards older patients such as remaining physically active, limiting sun exposure, and eating well."
89456130|NCT02406872|Experimental|Remimazolam Tosilate 2|intravenous pumping of Remimazolam Tosilate at 12mg/kg/h for anesthesia induction
89456131|NCT02406872|Experimental|Remimazolam Tosilate 3|intravenous pumping of Remimazolam Tosilate at 18mg/kg/h for anesthesia induction
89456132|NCT02406872|Active Comparator|Propofol|single IV bolus of Propofol at 2.0-2.5mg/kg for anesthesia induction
89456133|NCT03171272|Experimental|Experimental Group|
89456134|NCT03171272|Sham Comparator|Control Group|
89456135|NCT02404922|Experimental|CTP-730 Low Dose or Matching Placebo|Capsule, once daily.
89456136|NCT02404922|Experimental|CTP-730 Mid Dose or Matching Placebo|Capsule, once daily
89456137|NCT02404922|Experimental|CTP-730 High Dose or Matching Placebo|Capsule, once daily.
89456138|NCT02406716||HF|Heart failure patients
89456139|NCT02406716||Controls|Healthy donors
89456140|NCT03172832|Active Comparator|Percutaneous Transhepatic Drainage|Subjects randomized to this arm will undergo PTBD as the first drainage intervention.
89201338|NCT03160209||300 patient controls|without a history of esophageal cancer or esophageal squamous dysplasia, a history of other cancer, or upper gastrointestinal diseases
89201339|NCT00908817|Active Comparator|triamcinolone|
89456141|NCT03172832|Active Comparator|Endoscopic Retrograde Cholangiography|Subjects randomized to this arm will undergo ERC as the first drainage intervention.
89456142|NCT03172676|No Intervention|Helicobacter pylori negative patients|chronic immune thrombocytopenic purpura patients who will be diagnosed negative for Helicobacter pylori infection using detection of Helicobacter pylori antigen in stool of these patients.
89201340|NCT00908817|Placebo Comparator|chlorhexidine|
89201341|NCT04005898|Experimental|Experimental: near-infrared cholangiography|Each subject included in the study will be subjected to a fluorescence cholangiography. The control group will be the same patient. The study consists of knowing if fluorescence is able to visualize structures that are not seen with the naked eye. For this purpose the structures are visualized with normal light and then with infrared light of the same patient. During laparoscopic cholecystectomy it will change between normal and infrared light.
89201342|NCT00332839|Active Comparator|Calcineurin Inhibitor (CNI) group|Participants received Cyclosporine A (CsA) plus Enteric Coated Mycophenolate Sodium (EC-MPS) plus corticosteroids, or Tacrolimus A (CsA) plus Enteric Coated Mycophenolate Sodium (EC-MPS) plus corticosteroids.
89456143|NCT03172676|Active Comparator|Helicobacter pylori positive patients with intervention|chronic immune thrombocytopenic purpura patients who will be diagnosed positive for Helicobacter pylori infection using detection of Helicobacter pylori antigen in stool of these patients will receive treatment of Helicobacter pylori: Amoxicillin for 14 days, Clarithromycin for 14 days and Proton pump inhibitor for one month).
89456144|NCT03172676|No Intervention|Helicobacter pylori positive patients without intervention|chronic immune thrombocytopenic purpura patients who will be diagnosed positive for Helicobacter pylori infection using detection of Helicobacter pylori antigen in stool of these patients will not receive treatment of Helicobacter pylori during the study,these patient group will receive treatment of Helicobacter pylori after the end of the study
89456145|NCT03176030||Fortified foods|Fortified foods will be delivered to this group for 3 consecutive days mainly on a mid-meal trolley three times a day (between breakfast and lunch around 10am, between lunch and dinner around 3 pm, and in the evening). However, fortified foods will be available 24 hours and patients will be encouraged to order as many as they like anytime during the day.
89201343|NCT00332839|Experimental|Certican group|Participants were switched in a step-wise fashion from the CNI based regimen to Everolimus (RAD001).
89201344|NCT00983632|Experimental|vagus stimulation|electrical vagus stimulation to X.nerve on neck
89201345|NCT00927147|Experimental|BNCT plus cetuximab|Patients treated with BNCT followed by cetuximab administration
89201346|NCT05712616|Active Comparator|Strontium group|Trial drug given in the form of sachet 2gm/sachet once every day
89201347|NCT05712616|Placebo Comparator|Placebo (Lactose)|Look, smell, taste alike lactose 2gm/sachet in form of sachet
89201348|NCT00907023||SOT|Patients that have had a solid organ transplant
89201349|NCT00927225|Active Comparator|active|subcutaneous wound infiltration with 50 mL ropivacaine 0.2%
89201350|NCT00927225|Placebo Comparator|placebo|subcutaneous wound infiltration with 50 mL saline
89201351|NCT00908973||Good responders|Excess weight loss of > 60% 1 year after gastric bypass surgery
89201352|NCT00908973||Poor responders|Excess weight loss of =< 50% 1 year after gastric bypass surgery
89201353|NCT00908973||Lean controls|Non-gastric bypass operated lean individuals, matched for age and sex
89201354|NCT00983710|Experimental|1|Participants will receive a new patient education program designed to help men manage side-effects related to treatment for localized prostate cancer. The intervention will be targeted to low health literacy men.
89456146|NCT03176030||Baseline|Prior to implementing the intervention, dietary intake among eligible patients offered the standard hospital menu will be measured on the study wards for 24 hours during three days in each of the study wards to estimate the energy and protein intake.
89456147|NCT02404844|Experimental|BKM120 + Tamoxifen|"BKM120 (Buparlisib): 100 mg/day, orally, on a continuous dosing schedule without interruption starting on day 1 in 28 day cycle~Tamoxifen: 20 mg/day, orally, on a continuous dosing schedule without interruption starting on day 1 in 28 day cycle"
89456148|NCT02404766|Experimental|Intervention group|C0-C1 dorsal glide mobilization in the cervical neutral position.
89456149|NCT02404766|Experimental|Intervention group 2|C7-T1 ventral cranial glide mobilization in the cervical neutral position
89456150|NCT02404766|No Intervention|Control group|Not receiving any intervention
89456151|NCT03116594|Experimental|Low potency of NBP608|Single dose 0.5mL of low potency of NBP608 by subcutaneous injection into the outer aspect of the upper arm
89456152|NCT03116594|Experimental|High potency of NBP608|Single dose 0.5mL of high potency of NBP608 by subcutaneous injection into the outer aspect of the upper arm
89456153|NCT03116594|Active Comparator|Zostavax|Single dose 0.65mL Zostavax by subcutaneous injection into the outer aspect of the upper arm
89456154|NCT03175640|Experimental|Implementation intervention|
89456155|NCT04482296|No Intervention|SSRI with placebo|50 patients who will receive placebo with SSRIs for 8 weeks
89456156|NCT04482296|Active Comparator|SSRI with zinc sulfate|50 patients who will receive SSRIs with zinc sulfate for 8 weeks
89456157|NCT03116282|Experimental|Intervention|Conversational therapy via video conference where participants are contacted by an alcohol therapist for the purpose of initiating a course of therapy where participants are not required to show up at a clinic.
89456158|NCT03116282|No Intervention|Control|Treatment as usual where participants receive contact information on their local alcohol treatment facility for the purpose of contacting the facility to initiate a face-to-face course of treatment at the clinic.
89456159|NCT04481906||Women 20 years and older with cystocele|Women 20 years and older with cystocele
89456160|NCT02405000|Experimental|Intraoperative CT imaging|
89456161|NCT03175484||Observation TLX|surgical specialty ( including anesthesia) residents and nurses undergoing High Fidelity Simulation scenarios.
89456162|NCT02406482|Experimental|HIVRR + MF|Four sessions of education and intervention (Behavioral: HIV risk reduction (HIVRR)) followed by financial literacy, micro-savings and vocational training (Behavioral: Microfinance intervention (MF)).
89456163|NCT02406482|Active Comparator|HIVRR only|Four sessions of education and intervention (Behavioral: HIV risk reduction (HIVRR)).
89456164|NCT03171194|Experimental|Drug: Low Dose Mesenchymal Stem Cells ( MSCs)|Participants will receive a single IV infusion of Mesenchymal Stem Cells (MSCs) 1 x 10^6 cells/kg in Plasma-Lyte A solution. All participants will receive the infusion at the Baseline (Day 0) visit. All participants will continue on their standard-of-care therapy during the trial.
89201355|NCT00983710|Active Comparator|2|Usual care, including a booklet on coping with localized prostate cancer. After the 6-month primary outcome data are collected, control group men will be offered the opportunity to cross-over and receive the new educational intervention.
89456165|NCT02442765|Placebo Comparator|Stage 1: Placebo|Participants received matching placebo orally twice daily (BID) for 6 weeks (Days 1-42) in Stage 1. Participants who completed Stage 1 were eligible to Participate in Stage 2.
88939971|NCT01845064|Placebo Comparator|Part A - Healthy subjects SAD placebo|A randomized, double-blinded, placebo-controlled, single ascending dose (SAD) study in healthy male and/or female subjects. Subjects will receive placebo subcutaneously (sc).
89456166|NCT02442765|Experimental|Stage 1: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg)|Participants received AVP-786-18 mg orally once daily (QD) in the morning and placebo orally QD in the evening for the first 7 days, followed by AVP-786-18 mg orally BID for the remaining 5 weeks (Days 8-42). Participants who completed Stage 1 were eligible to participate in Stage 2.
89456167|NCT02442765|Experimental|Stage 1: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg)|Participants received AVP-786-18 mg orally QD in the morning and placebo orally QD in the evening for the first 7 days, followed by AVP-786-18 mg orally BID for 2 weeks (Days 8-21). From Day 22, participants received AVP-786-28 mg orally BID for the remaining 3 weeks. Participants who completed Stage 1 were eligible to participate in Stage 2.
89456168|NCT02442765|Placebo Comparator|Stage 2: Placebo|Participants who received matching placebo orally BID for 6 consecutive weeks in Stage 1 were re-randomized in Stage 2 to receive the study drug or placebo from Day 43 to Day 85.
89456169|NCT02442765|Experimental|Stage 1: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg) to: Stage 2: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg)|Participants who received AVP-786-18 mg in Stage 1 continued to receive AVP-786-18 mg orally BID for the 6 weeks (Days 43-85) in Stage 2..
89456170|NCT02442765|Experimental|Stage 1: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg) to Stage 2: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg)|Participants who received AVP-786-28 mg in Stage 1 continued to receive AVP-786-28 mg orally BID for 6 weeks (Days 43-85) in Stage 2
89456171|NCT02442765|Experimental|Experimental: Stage 1: Placebo to: Stage 2: AVP-786-18 d6-DM 18 mg/Q 4.9 mg|Participants who were placebo responders or non-responders in Stage 1 received AVP-786-18 for 1 week, orally, QD, followed by AVP-786-18 BID for 2 weeks; followed by AVP-786-28 BID for the last 3 weeks.
89456172|NCT02442765|Experimental|Stage 1: Placebo to: Stage 2: AVP-786-28 d6 DM 28 mg/Q 4.9 mg|Participants who were placebo responders or non-responders in Stage 1 received AVP-786-28 for 1 week, orally, QD, followed by AVP-786-28 BID for 2 weeks; followed by AVP-786-28 BID for the last 3 weeks.
89456173|NCT02404454|Experimental|hysteroscopic metroplasty|women undergoing hysteroscopic metroplasty for uterine septum resection
89456174|NCT04964258|Experimental|Part 1: TAK-105-a|TAK-105-a at starting dose of 30 microgram (mcg) or placebo-matching solution, subcutaneously, once on Day 1. Staggered dosing will be done in the first cohort of Part 1 (Cohort 1). Staggered dosing in subsequent Cohorts (Cohorts 2-12) may be used. After the pre-specified first dose, subsequent doses will be determined in the dose escalation meeting based on emerging safety, tolerability, and PK data from the study.
89456175|NCT04964258|Experimental|Part 2: TAK-105-a|TAK-105-a dose to be decided (TBD) or TAK-105-a matching-placebo, subcutaneously, once weekly for 4 weeks. Dose of multiple rising dose (MRD) Cohorts (Cohorts 13-17) of Part 2 will be determined based on emerging safety, immunogenicity, tolerability, and PK data from Part 1 (SRD) determined in the dose escalation meeting.
89456176|NCT04964258|Experimental|Part 3: TAK-105-a|TAK-105-a dose TBD or placebo-matching solution, subcutaneously, once weekly for 2-4 weeks. Dose for the first 2 Cohorts (Cohorts 18-19) of Part 3 will be based on emerging safety, tolerability, and available PK data from Part 1 single rising dose (SRD) and Part 2 (MRD) as determined in the dose escalation meeting. The data from Cohorts 18-19 will further determine additional enrollment of Cohorts 20, 21, 22 and 23. Part 3 will evaluate whether dose titration result in different tolerability in relation with CV observations.
89456177|NCT04964258|Experimental|Part 4: TAK-105-a|TAK-105-a dose TBD or placebo-matching solution, subcutaneously, once a week for 2 weeks, followed by a period of withholding drug and then redosing with a third dose. Part 4 (Cohorts 24 to 27) will provide an exploratory evaluation to assess the safety and CV tolerability profile of redosing with TAK 105.
89456178|NCT04964258|Experimental|Parts 5a and 5b: TAK-105-a|TAK-105-a dose TBD or TAK-105-a placebo-matching solution, subcutaneously, once on Day 1 for the SRD Cohorts (Cohorts 28 to 30), during Part 5a of the study and TAK-105-a dose TBD or TAK-105-a matching-placebo, subcutaneously, once weekly for 4 weeks for the optional MRD Cohorts (Cohorts 31 and 32), during Part 5b of the study. Dose of the SRD and optional MRD Cohorts (28 to 32) will be determined during the dose escalation meeting based on emerging safety, tolerability, and available PK data during the study. The MRD Cohorts in Part 5b will be optional, depending on the PK, safety data observed in Part 2 MRD.
89456179|NCT04964258|Experimental|Part 6: TAK-105-b|TAK-105-b dose TBD or TAK-105-b placebo-matching solution, subcutaneously, once on Day 1. Dose of the SRD Cohorts (33 and 34) will be determined during the dose escalation meeting based on emerging safety, tolerability, and available PK data from Part 1 (SRD).
89456180|NCT03115892|Experimental|intervention arm|Green Tea With Aloe Vera mouthwash twice daily for one week
89456181|NCT03115892|Active Comparator|control arm|Chlorhexidine Mouthwash twice daily for one week
89456182|NCT03116048|Other|Pecs group (study group)|Chronic pain assessment with study questionnaire
89456183|NCT03116048|Other|Control group (placebo group)|Chronic pain assessment with study questionnaire
89456184|NCT02406794|Experimental|Neuromuscular taping|The first group will receive a decalogue of healthy tips (general, to lead an active life) based on the best available evidence, and several strips of neuromuscular bandage will be applied on areas that refer pain (cervical, lumbosacral, both or wrist-forearm).
89456185|NCT02406794|No Intervention|No Kinesio taping|No Kinesio taping
89201356|NCT00927303||Group 1|Intervention 1 Sequence of observers: observer1, observer 2, observer 1, observer 2
89201357|NCT00927303||group 2|intervention 1 sequence of observers: observer 2, observer 1, observer 2, observer 1
89201358|NCT00927303||group 3|intervention 2 sequence of observers: 1,2,1,2
89201359|NCT00927303||group 4|intervention 2 sequence of observers: 2,1,2,1
89201360|NCT00927303||group 5|intervention 1 sequence of observers 1,1,2,2
89201361|NCT00927303||group 6|intervention 1 sequence of observers 2,2,1,1
89201362|NCT00927303||group 7|intervention 2 sequence of observers: 1,1,2,2
89201363|NCT00927303||group 8|intervention 2 sequence of observers: 2,2,1,1
89201364|NCT00983788|Experimental|Bezafibrate|
89201365|NCT00983788|Placebo Comparator|Placebo|
89201366|NCT00983866|Experimental|Tailored Telephone Counseling|
89201367|NCT00983866|No Intervention|Standard Trial Recruitment Procedures|
89201368|NCT00983944|Experimental|Arm I (EPOCH-R)|Patients receive rituximab IV on day 1; etoposide IV, doxorubicin hydrochloride IV, and vincristine sulfate IV continuously over 96 hours on days 1-4; cyclophosphamide IV over 30 minutes on day 5; and oral prednisone twice daily on days 1-5. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
89201369|NCT00983944|Experimental|Arm II (R-VACOP-B)|Patients receive rituximab IV and doxorubicin hydrochloride IV on day 1 of weeks 1, 3, 5, 7, 9, and 11; cyclophosphamide IV over 30 minutes on day 1 of weeks 1, 5, and 9; etoposide IV over 1 hour on day 1 and then orally on days 2 and 3 of weeks 3, 7, and 11; bleomycin sulfate IV and vincristine sulfate IV on day 1 of weeks 2, 4, 6, 8, 10, and 12; and oral prednisone on days 1-7 of week 1 and then every other day in weeks 2-10.
89201370|NCT00927459|Experimental|PRO-040201|PRO-040201 with placebo control in each cohort
89456186|NCT02411786|Experimental|pTVG-AR biweekly|pTVG-AR (dose: 100 µg) alone without rhGM-CSF. Administered at weeks 0, 2, 4, 6, 8, and 10 (biweekly) for 6 doses, then administered at week 12, week 24, week 36, and week 48 (quarterly) for 4 doses, or 10 total doses.
89456187|NCT02411786|Experimental|pTVG-AR staggered biweekly|pTVG-AR (dose: 100 µg) alone without rhGM-CSF. Administered at weeks 0, 2, 12, 14, 24, 26, 36, 38, 48 and 50 (staggered biweekly schedule) for 10 total doses.
89456188|NCT02411786|Experimental|pTVG-AR with rhGM-CSF biweekly|pTVG-AR (dose: 100 µg) with rhGM-CSF (200 µg). Administered at weeks 0, 2, 4, 6, 8, and 10 (biweekly) for 6 doses, then administered at week 12, week 24, week 36, and week 48 (quarterly) for 4 doses, or 10 total doses.
89456189|NCT02411786|Experimental|pTVG-AR with rhGM-CSF staggered biweekly|pTVG-AR (dose: 100 µg) with rhGM-CSF (200 µg). Administered at weeks 0, 2, 12, 14, 24, 26, 36, 38, 48 and 50 (staggered biweekly schedule) for 10 total doses.
89456190|NCT02411708|Experimental|SANGUINATE|320 mg/kg
89456191|NCT02411708|Placebo Comparator|Placebo|Normal saline IV infusion
89456192|NCT02411864||Group 1|Low b=(0,50,150,200)，NEX=(1,3,2,2)
89456193|NCT02411864||Group 2|Low b=(0,30,50,100,200)，NEX=(1,3,3,2,2)
89456194|NCT02411864||Group 3|Low b=(0,30,60,90,120,150,180,200)，NEX=(1,3,3,3,2,2,2,2)
89456195|NCT02411864||Group 4|Low b=(0,30,60,90,120,150,180,200)，NEX=(1,1,1,1,1,1,1,1)
89456196|NCT02411864||Group 5|Low b=(0,20,40,60,80,100,120,140,160,180,200)NEX=(1,3,3,3,3,2,2
89456197|NCT02411552||Intervention schools|These schools were promoting 4 strategies to increase physical activity in students.
89456198|NCT02411552||Control schools|These schools continued with standard programming for activity during year 1, and implemented intervention during years 2 and 3.
89456199|NCT03172442|Experimental|orthodontic removable traction appliance|"Patients in this group will be treated using the orthodontic removable traction appliance (vacuum plate with two hooks between lateral incisor and canine in each side). An rapid maxillary expander will be applied to disarticulate maxillary sutures to allow more efficient forward protraction of the maxilla.~Class III elastic traction from upper first molar to the hook in both side. This appliance will be used full-time with Class III elastics (6- to 8-ounce) traction."
89456200|NCT03172442|No Intervention|Control group|without intervention
89456201|NCT02411474||With or without newly diagnosed chronic GVHD after SCT|The patients developed chronic GVHD after SCT/ The patients did not developed chronic GVHD after SCT
89456202|NCT03524001|Active Comparator|Bifocal stimulation|Active comparator is represented by programming bifocal stimulation (bifocal DDD mode). Every patients will undergo crossover randomization (from bifocal DDD mode to VVI and vice versa).
89456203|NCT03524001|Placebo Comparator|VVI 40|Placebo comparator is represented by programming the device in VVI mode 40/mins. Every patients will undergo crossover randomization (from VVI to bifocal DDD mode and vice versa).
89456204|NCT02404376|Active Comparator|Remote Ischemic Conditioning|Remote Ischemic Conditioning + placebo
89456205|NCT02404376|Active Comparator|Combined treatment|Remote Ischemic Conditioning + exenatide
89456206|NCT02404376|Placebo Comparator|Placebo|Sham Remote Ischemic Conditioning + placebo
89456207|NCT02404376|Active Comparator|Exenatide|Sham Remote Ischemic Conditioning + exenatide
89456208|NCT02383641||Observation|Patients with Wolman disease or high-grade suspicion for Wolman disease
88939972|NCT01845064|Placebo Comparator|Part B - Type 2 diabetic patients SAD placebo|A randomized, partially double-blinded, placebo-controlled, sequential SAD study in male and/or female type 2 diabetes mellitus patients. Subjects will receive placebo subcutaneously (sc).
89456209|NCT02298699||Observation|Patients with Sly disease or high-grade suspicion for Sly disease
89456210|NCT02406560|Experimental|4 tablets of 12.2 mg tafamdis free acid|
89456211|NCT02406560|Experimental|4 tablets of 12.2 mg tafamidis free acid|
89456212|NCT02406560|Experimental|5 tablets of 12.2 mg tafamidis free acid|
89456213|NCT04466085|Experimental|Population I|In population I, there were 150 subjects who injected with 2 doses of low-dose test vaccine into the deltoid muscle of the upper arm according to the 0 and 1 month immunization schedule.
88939973|NCT01845064|Placebo Comparator|Part C - Healthy subjects MAD placebo|A randomized, double-blinded, placebo-controlled, 14-day multiple ascending dose (MAD) study in healthy male and/or female subjects each. Subjects will receive placebo sc for 14 days.
88939974|NCT01845064|Placebo Comparator|Part D - Type 2 diabetic patients POC placebo|A randomized, double-blinded, placebo-controlled, 28-day multiple-dose proof of concept (POC) study in male and/or female type 2 diabetes mellitus patients. Subjects will receive placebo sc for 28 days.
88939975|NCT01845090|Active Comparator|Lanthanum carbonate|Lanthanum carbonate 375mg~750 mg tid for 6 months
88939976|NCT01845090|Active Comparator|Calcium carbonate|Calcium carbonate 500mg~1000 mg tid for 6 months
88939977|NCT01845129|Experimental|anodal tDCS|atDCS will be administered for 20 minutes with 1 milliampere (1 mA) to the left primary hand motor cortex
88939978|NCT01845129|Sham Comparator|sham tDCS|sham tDCS will be administered to the left primary hand motor cortex
88939979|NCT01845142|Active Comparator|intramuscular 100.000 I.U. vitamin D3|intramuscular 100.000 I.U. vitamin D3
88939980|NCT01845142|Placebo Comparator|intramuscular placebo|intramuscular 0.9% sodium chloride
89016397|NCT04584502|Experimental|Intervention as adjunct to Treatment as Usual|Participants will attend via Zoom an 8-session group-based yoga-mindfulness intervention offered over the course of approximately 10 consecutive weeks. Participants will also be asked to use a mobile companion app once a week during the intervention period. All intervention participants also receive treatment as usual for OUD at the partner practice, which includes medication for OUD, individual and/or group counseling, and case management.
89456214|NCT04466085|Experimental|Population II|In population II, there were 150 subjects who injected with 2 doses of high-dose test vaccine in the upper arm deltoid muscle according to the 0 and 1 month immunization schedule.
89456215|NCT04466085|Placebo Comparator|Population Ⅲ|In population Ⅲ, there were 150 subjects who injected with 2 doses of placebo in the upper arm deltoid muscle according to the 0 and 1 month immunization schedule.
89016398|NCT04584502|No Intervention|Treatment as Usual|Participants receive treatment as usual for OUD at the partner practice, which includes medication for OUD, individual and/or group counseling, and case management.
89456216|NCT04466085|Experimental|Population Ⅳ|In population Ⅳ, there were 150 subjects who injected with 3 doses of low-dose test vaccine in the upper arm deltoid muscle according to the 0, 1, and 2 month immunization schedule.
89456217|NCT04466085|Experimental|Population Ⅴ|In population Ⅴ, there were 150 subjects who injected with 3 doses of high-dose test vaccine into the deltoid muscle of the upper arm according to the immunization schedule of 0, 1, and 2 months.
89456218|NCT04466085|Placebo Comparator|Population Ⅵ|In Population Ⅵ, there were 150 subjects who injected with 3 doses of placebo into the deltoid muscle of the upper arm according to the immunization schedule of 0, 1, and 2 months.
89456219|NCT02404298|Experimental|IVIg|
89456220|NCT02217891||participants from existing MSK protocol 12-245|"Participants' responses regarding the benefits and harms of incidental findings arising from tumor genomic profiling will be used to generate novel questionnaire items to assess the construct of perceived personal and clinical utility, which will be tested, along with items designed to assess knowledge about tumor genomic profiling and incidental findings.~Part 2, the investigators will conduct 30-minute cognitive interviews to assess participants' understanding and opinions about the novel items designed to assess perceived personal and clinical utility of incidental findings and knowledge about incidental findings arising from tumor genomic profiling."
89456221|NCT02406638||TVT Group|Women who underwent to stress urinary incontinence surgery using Gynecare TVT 3 years before clinical and 3D pelvic floor ultrasound evaluation.
89456222|NCT02406638||TVT-O Group|Women who underwent to stress urinary incontinence surgery using Gynecare TVT Obturator System, inside-out approach, 3 years before clinical and 3D pelvic floor ultrasound evaluation.
89456223|NCT02406638||TVT-S Group|"Women who underwent to stress urinary incontinence surgery using GynecareTVT-Secur System, in U approach, 3 years before clinical and 3D pelvic floor ultrasound evaluation."
89456224|NCT03517995|Active Comparator|Sulforaphane Plus Surgery|Sulforaphane Administration prior to bladder cancer surgery.
89456225|NCT03517995|Placebo Comparator|Placebo Plus Surgery|Placebo Administration prior to bladder cancer surgery.
89456226|NCT03115658|Experimental|Exercise Intervention|"Participants met with a PhD level psychologist experienced with health behavior change, to set a personalized exercise goal and plan. Participants were told the studies' goal to engage in 150 minutes of moderate intensity or greater physical activity each week, based on the ACSM recommendations, but participants were allowed to set any personal goal. Participants were also instructed on how to self-monitor their physical activity.~After the initial meeting all other intervention components were sent through the mail. The intervention consists of three types of print material that were mailed: stage-matched manuals, tailored feedback report, and tip sheets."
89456227|NCT02411240|Other|Air filtering in the living room|GENANO tubes, GENANO Benelux; Heusen-Zolder, Belgium
89456228|NCT03132987|Experimental|Progressive strengthening program|Subjects identified as having a clinically relevant strength deficit will be asked to participate in physical therapy sessions 3 times per week for 3 weeks. The strengthening program will consist of an individualized, progressive exercise program with an emphasis on increasing lower extremity strength, power, and biomechanics.
89456229|NCT02411630||Interactive Questionnaire System (iQS)|An Interactive Questionnaire System (iQS) will be administered twice. First at study entry (ATN 110/113 week 24 visit) and second at week 24 (ATN 110/113 week 48 visit). The questionnaire will assess adherence as well as how structural (physical settings) and partnership factors affect adherence of YMSM to PrEP with FTC/TDF (Truvada®).
89456230|NCT02411318|Experimental|Cardiovascular Exercise|Participants will ride a stationary bike and maintain their target heart rate (according to the American Heart Association guidelines) for 30 minutes. For example, a 30 year old will have a target heart rate zone of 95-162 beats per minute. A baseline blood sample will be acquired before the participant begins exercising. In the following 30 minutes, participants will ride the exercise bike, and their heart rate and general status will be assessed continuously. Specifically, heart rate will be monitored using a chest strap heart rate monitor. Two additional lancet punctures will be performed after the exercise to measure the changes in neutrophil function: one immediately following the 30 minute exercise period and one 30 minutes after the exercise has been completed.
89456231|NCT02411318|Experimental|Caffeine Consumption|Participants will be exposed to a moderate dose of caffeine (200 mg capsule in one sitting) from a common commercial product. After consent and screening, a baseline blood sample will be acquired using the lancet puncture procedure. The participant will then be instructed to swallow a 200 mg caffeine capsule. Two additional lancet punctures will be performed after the caffeine ingestion: one after 30 minutes post-ingestion and another one after 60 minutes.
89456232|NCT02411318|Experimental|Ethanol Ingestion|Participants will be weighed and their required alcohol dose determined according to the equation used by the Madison Police Department during alcohol training workshops: 1 mL of 80 proof (40%) alcohol per pound of body weight. Participants will be permitted to consume the drink at their own pace, although no slower than one drink per hour. Breath Alcohol Concentration (BAC) will be tested 20 minutes after drinking has ceased in order to clear mouth alcohol that may affect the BAC reading. Participants at 0.05 BAC and above will have blood drawn via lancet puncture. In addition to the lancet puncture done once the alcohol level is reached, an additional lancet puncture will be performed 1 hour later.
89016399|NCT04582149|Experimental|EyeControl Eye-tracking Device|Ventilated ICU patients using the EyeControl wearable, eye-tracking device.
89456233|NCT02411318|Experimental|Glucose Ingestion|After a baseline blood sample is acquired, participants will consume 100 grams of glucose within 5 minutes. Two additional lancet punctures will be performed after the glucose ingestion, one at 30 minutes post-ingestion, and one at 60 minutes post-ingestion.
89456234|NCT02411318|Experimental|Glucose and Caffeine Ingestion|After a baseline blood sample is acquired, participants will swallow 200mg of caffeine in capsule form and consume 100 grams of glucose within 5 minutes. Two additional lancet punctures will be performed after the caffeine and glucose ingestion, one at 30 minutes post-ingestion, and one at 60 minutes post-ingestion.
89456235|NCT03133299|Active Comparator|Glucocorticoid group|Oral prednisolone 0.5 mg/kg/day for four weeks, 0.25 mg/kg/day for four weeks followed by 0.125 mg/kg/day for four weeks. Prednisolone will then be tapered by 5 mg every two weeks and discontinued. The total duration of glucocorticoids will be four months
89456236|NCT03133299|Experimental|Vitamin D plus Glucocorticoid group|Oral vitamin D3 tablet, 60,000 IU weekly for 2 months (8 doses) along with Oral prednisolone 0.5 mg/kg/day for four weeks, 0.25 mg/kg/day for four weeks followed by 0.125 mg/kg/day for four weeks. Prednisolone will then be tapered by 5 mg every two weeks and discontinued. The total duration of glucocorticoids will be four months
89456237|NCT03172598|Experimental|MT-8554 low dose|Patients who meet eligibility criteria will be administered twice daily low dose of MT-8554 during the treatment period.
89456238|NCT03172598|Experimental|MT-8554 middle dose|Patients who meet eligibility criteria will be administered twice daily middle dose of MT-8554 during the treatment period.
89456239|NCT03172598|Experimental|MT-8554 high dose|Patients who meet eligibility criteria will be administered twice daily high dose of MT-8554 during the treatment period.
89456240|NCT03172598|Experimental|MT-8554, then placebo|The study participants will receive MT-8554 (TBD mg) in the first phase, followed by placebo in the second phase
89456241|NCT03172598|Experimental|Placebo, then MT-8554|The study participants will receive placebo in the first phase, followed by MT-8554 (TBD mg) in the second phase
89456242|NCT04465695|Experimental|IFN beta-1b and clofazimine|A 3-day course of 3 doses of subcutaneous injection of interferon β-1b 1mL (0.5mg; 16 million IU) consecutively on day 1 to day 3 and oral clofazimine 100mg twice daily on day 1, then 100mg daily for 2 days plus standard care
89456243|NCT04465695|Active Comparator|Clofazimine|A 3-day course of oral clofazimine 100mg twice daily on day 1, then 100mg daily for 2 days plus standard care
89456244|NCT04465695|No Intervention|Control|Standard care alone
89456245|NCT03115736|Experimental|Switch|Patients are switched from a TDF-containing antiretroviral therapy regimen to a TAF-containing regimen
89456246|NCT02294487||Subjects|Individuals over 50 who are going to get the seasonal flu vaccine, pneumococcal, HIB, and/or meningococcal vaccination and either have multiple myeloma or do not have multiple myeloma.
89456247|NCT03172286|Active Comparator|Patient treated with fake radiofrequencer|
89456248|NCT03172286|Experimental|Patient treated with radiofrequencer|
89456249|NCT04465851|Active Comparator|FS65_Curc|Ferrous Sulphate (65 mg/day elemental iron) and Curcumin 500 mg/day
89456250|NCT04465851|Placebo Comparator|FS65_Plac|Ferrous Sulphate (65 mg/day elemental iron) and Placebo (Curcumin placebo [cellulose])
89456251|NCT04465851|Placebo Comparator|FS0_Plac|Placebo (Ferrous Sulphate placebo [cellulose]) and Placebo (Curcumin placebo [cellulose])
89456252|NCT04465851|Placebo Comparator|FS18_Plac|Ferrous Sulphate (18 mg/day elemental iron) and Placebo (Curcumin placebo [cellulose])
89456253|NCT04465851|Active Comparator|FS18_Curc|Ferrous Sulphate (18 mg/day elemental iron) and Curcumin 500 mg/day
89456254|NCT04465539|Placebo Comparator|control group|received the standard ALP treatment according to TUPTC protocol as follows: patient resuscitation, care of airway, breathing and circulation, gastric decontamination with 2 ampoules sodium bicarbonate (each ampoule 25 ml containing 2.1 gm sodium bicarbonate) followed by activated charcoal in dose of 1 g/Kg orally, adequate hydration, normal saline administration (0.9% Sodium Chloride IV), vasopressors IV infusions, inhalation of 100% oxygen, ranitidine IV, magnesium sulfate IV infusion and other supportive treatment.
89456255|NCT04465539|Experimental|Hydroxyethyl starch group):|Patients will start therapy with Hydroxyethyl starch instead of normal saline (6% hetastarch 600/0.75 in 0.9% sodium chloride) with a dose of 500 cc in 6 hours. Additionally, patient will receive the standard ALP treatment according to TUPTC protocol in the same order of placebo.
89456256|NCT04465539|Experimental|Combined Hydroxyethyl starch and hydrocortisone group|Patients will start therapy with combined Hydroxyethyl starch (Voluven®, fresenius kabi, Germany) and hydrocortisone (SOLU-CORTEF 100 mg ampoule) instead of normal saline of normal saline as follow: Hydroxyethyl starch dose is 6% hetastarch 600/0.75 in 0.9% sodium chloride with a dose of 500 cc in 6 hours. Hydrocortisone dose is 200-300 mg /day intravenously until normalization of blood pressure. Additionally, patient will receive the standard ALP treatment according to TUPTC protocol in the same order of placebo.
89456257|NCT02404142|Placebo Comparator|Control group (saline isotonic solution)|saline isotonic solution
89456258|NCT02404142|Experimental|Curar (Atracurium) group|Curar (Atracurium)
89456259|NCT03172208|Experimental|Group 1: Japanese - Caplacizumab Dose 1 iv (SD)|Single dose (SD) of Caplacizumab Dose 1 administered intravenously (iv) to Japanese participants
89456260|NCT03172208|Placebo Comparator|Group 1: Japanese - Placebo iv (SD)|Single dose (SD) of Placebo administered intravenously (iv) to Japanese participants
89456261|NCT03172208|Experimental|Group 2: Japanese - Caplacizumab Dose 2 iv (SD)|Single dose (SD) of Caplacizumab Dose 2 administered intravenously (iv) to Japanese participants
89456262|NCT03172208|Experimental|Group 2: Japanese - Placebo iv (SD)|Single dose (SD) of Placebo administered intravenously (iv) to Japanese participants
89456263|NCT03172208|Experimental|Group 2: White - Caplacizumab Dose 2 iv (SD)|Single dose (SD) of Caplacizumab Dose 2 administered intravenously (iv) to White participants
89456264|NCT03172208|Placebo Comparator|Group 2: White - Placebo iv (SD)|Single dose (SD) of Placebo administered intravenously (iv) to White participants
89456265|NCT03172208|Experimental|Group 3: Japanese - Caplacizumab Dose 2 sc (SD)|Single dose (SD) of Caplacizumab Dose 2 administered subcutaneously (sc) to Japanese participants
89456266|NCT03172208|Placebo Comparator|Group 3: Japanese - Placebo sc (SD)|Single dose (SD) of Placebo administered subcutaneously (sc) to Japanese participants
89456267|NCT03172208|Experimental|Group 3: White - Caplacizumab Dose 2 sc (SD)|Single dose (SD) of Caplacizumab Dose 2 administered subcutaneously (sc) to White participants
89456268|NCT03172208|Placebo Comparator|Group 3: White - Placebo sc (SD)|Single dose (SD) Placebo administered subcutaneously (sc) to White participants
89456269|NCT03172208|Experimental|Group 4: Japanese - Caplacizumab Dose 2 sc (MD)|Multiple doses (MD) of Caplacizumab Dose 2 administered subcutaneously (sc) to Japanese participants
89456270|NCT03172208|Placebo Comparator|Group 4: Japanese - Placebo sc (MD)|Multiple doses (MD) of Placebo administered subcutaneously (sc) to Japanese participants
89456271|NCT02294565|Other|VST-1001 & 99mTc-labeled sulfur colloid|"VST-1001 (with medical devices) and 99mTc-labeled sulfur colloid are used together during a SLNB procedure in a single subject. Both drugs are evaluated for lymphatic mapping and localization of lymph nodes. The current standard of care for lymphatic mapping and lymph node localization during a SLNB procedure is a combined-modality technique that employs both a radiotracer (99mTc-labeled sulfur colloid is the radiotracer used in this study) and a vital blue dye (a patient receives both drugs). In this study, the vital blue dye is replaced with VST-1001 and companion medical devices.~VST-1001 is excited by a medical device (blue-light LED illuminator) to fluoresce; the surgeon is wearing blue-light filtering eyewear to improve visualization of the relevant tissue structures."
89456272|NCT02410928|Experimental|fiberoptic nasal laringoscopy|the vocal cords ill be visualized with fiberoptic nasal laringoscopy
89456273|NCT02410928|Experimental|ultrasonography|the vocal cords ill be visualized with ultrasonography
89456274|NCT02410928|Active Comparator|Direct laringoscopy|the vocal cords ill be visualized with direct laringoscopy
89456275|NCT02291991|Experimental|Group A|"Drug : GX-E2 - Intravenously injection once day at dose 8 ug/kg Drug : Placebo~(1 subject : GX-E2, 1 subject : Placebo)~Subjects in group A will be injected drug, So we observe safety. After three days, Subject in group B will be injected drug."
89456276|NCT02291991|Experimental|Group B|Drug : GX-E2 - Intravenously injection once day at dose 8 ug/kg Drug : Placebo (7 subjects : GX-E2, 1 subject : Placebo)
89456277|NCT02411162|Experimental|Open Label Arm|In Cohort 1, study medication (Cream A, 1%) will be applied as a thin layer onto a predefined area of the volar region of the forearm that is large enough to image and collect 3 biopsies (4 mm per biopsy). Vehicle will be applied on Day 1 only, onto a symmetrical location on the opposite forearm from Cream A. In cohort 2, subjects will be enrolled to evaluate Cream A (1%) and a different GSK2894512 Cream, Cream B (1%). Cream A, 1% and Cream B, 1% will be applied as a thin layer to the opposite forearms of the subject. Vehicle will be applied only on Day 1 to a separate area (at least 1.3 cm from study drug) of the forearm from where drug is applied. Both Cream A and Cream B will continue to be applied OD to the same area of the same forearm for 7 days.
89456278|NCT03522051|Experimental|Patients with carious teeth|female or male patients with permanent teeth and deep caries will receive pulpotomy treatment and dressing with calcium silicate based material (Neo MTA plus material) followed by restoration.
89456279|NCT02411006|No Intervention|Usual care control|No intervention, just usual care from the insurance company
89456280|NCT02411006|Experimental|Reminder control|Send a reminder to subjects every month
89456281|NCT02411006|Experimental|Anonymous prediction|Ask subjects to anonymously predict their upcoming medication adherence
89456282|NCT02411006|Experimental|Anonymous commitment|Ask subjects to anonymously commit to their upcoming medication adherence
89456283|NCT02411006|Experimental|Identified prediction|Ask subjects to predict their upcoming medication adherence and report it
89456284|NCT02411006|Experimental|Identified commitment|Ask subjects to commit to their upcoming medication adherence and report it
89456285|NCT03521973|Experimental|Group 1- PfSPZ-Vaccine|"Children aged 7-12 years (inclusive) of age will be enrolled in this group.~N=44 will receive PfSPZ Vaccine; three doses of 9x10^6 PfSPZ of PfSPZ Vaccine administered by direct venous inoculation (DVI) given at 0, 7 and 28 day intervals."
89456286|NCT03521973|Placebo Comparator|Group 2|"Children aged 7-12 years (inclusive) of age will be enrolled in this group.~N=22 will receive normal saline; three doses of NS administered by DVI given at 0, 7 and 28 day intervals."
89456287|NCT03521973|Experimental|Group 3|"Children aged 3-6 years (inclusive) of age will be enrolled in this group.~N=44 will receive PfSPZ Vaccine; three doses of 9x10^6 PfSPZ of PfSPZ Vaccine administered by direct venous inoculation (DVI) given at 0, 7 and 28 day intervals; given 2 weeks after the first immunization of Group 1."
89456288|NCT03521973|Placebo Comparator|Group 4|"Children aged 3-6 years (inclusive) of age will be enrolled in this group.~N=22 will receive normal saline; three doses of NS administered by DVI given at 0, 7 and 28 day intervals; given 2 weeks after the first dose of NS of Group 2."
89456289|NCT03521973|Experimental|Group 5|"Children aged 1-2 years (inclusive) of age will be enrolled in this group.~N=44 will receive PfSPZ Vaccine; three doses of 9x10^6 PfSPZ of PfSPZ Vaccine administered by direct venous inoculation (DVI) given at 0, 7 and 28 day intervals; given 2 weeks after the first immunization of Group 3."
89456290|NCT03521973|Placebo Comparator|Group 6|"Children aged 1-2 years (inclusive) of age will be enrolled in this group.~N=22 will receive normal saline; three doses of NS administered by DVI given at 0, 7 and 28 day intervals; given 2 weeks after the first dose of NS of Group 4."
89456291|NCT03171974|Experimental|treatment group|The treatment group will be injected with dexamethasone instracapsular under US according to our built protocol.
89456292|NCT02292069|Experimental|Amlodipine besylate/Atorvastatin calcium tablets 10/80 mg|Amlodipine besylate/Atorvastatin calcium tablets 10/80 mg of Dr. Reddys Laboratories Limited
89456293|NCT02292069|Active Comparator|Caduet|Caduet® 10/80 mg tablets of Pfizer, Ireland
89456294|NCT02404064|Other|Antibiotics perioperative|dose of perioperative antibiotics (cefamezin 1g IV; metronidazole 500 mg IV) This is the standard of care of the department
89456295|NCT02404064|Placebo Comparator|placebo - No Antibiotics perioperative|The intervention is No Antibiotics perioperative
89501796|NCT02224417|Other|DEP + Outcome Incentive Arm|Participants will receive the Diabetes Educational Program, as required. They will receive the Fitbit ™, the eCAP, and a glucometer (if they do not already have one). They will also have the opportunity to earn financial incentives for meeting specified outcome goals.
89501797|NCT03165825|Experimental|Tranforaminal|will receive cervical epidural injection via a transforaminal route with dexamethasone steroid
89501798|NCT03165825|Active Comparator|Interlaminar|will receive cervical epidural injection via an interlaminar route with betamethasone steroid
89501799|NCT03785743|Experimental|TLPD|Total laparoscopic pancreaticoduodenectomy for pancreatic cancer
89501800|NCT03785743|Experimental|OPD|Open pancreaticoduodenectomy for pancreatic cancer
89501801|NCT03167853|Experimental|humanized anti-PD-1 monoclonal antibody|humanized anti-PD-1 monoclonal antibody is to be injected intravenously 3mg/kg per 2 weeks until disease progresses or unacceptable tolerability occurs.
89501802|NCT02690649|Experimental|Health Messaging (Non-Procedural)|"PHR messaging of tailored health education pertinent to non-valvular atrial fibrillation and anticoagulant use.~Training on the use of MyChart and the AdhereTech smart pill bottle, medication adherence monitored with Surescripts e-prescribing software and AdhereTech smart pill bottle use."
89501803|NCT02690649|No Intervention|No Health Messaging|"No PHR messaging of tailored health education pertinent to non-valvular atrial fibrillation and anticoagulant use.~Standard care, training on the use of MyChart and the AdhereTech smart pill bottle, medication adherence monitored with Surescripts e-prescribing software and AdhereTech smart pill bottle use"
89501804|NCT03165357|Experimental|Sodium bicarbonate|"Group taking oral NaHCO3 supplementation in a progressive-dose regimen.~Interventions:~The experimental procedure for each athlete included a 10-day NaHCO3 supplementation in a progressive-dose regimen in order to reduce the likelihood of gastrointestinal side effects (from 37.5 to 150 mg ∙ kg-1). NaHCO3 was administered in the form of unmarked disk-shaped tablets (Alkala T, SANUM, Poland). The tablets were ingested with at least 250 mL of water and could be either swallowed or dissolved in the mouth. On training days the supplements were taken in the morning, in the evening and 1.5 hours before training session. On rest days the supplements were taken in the morning, in the afternoon and in the evening.~Between the 10-day NaHCO3 and PLA or a PLA and NaHCO3 treatments, a 14-day washout period was introduced."
89501805|NCT03165357|Placebo Comparator|Placebo (maltodextrin)|"Group taking oral supplementation with placebo (maltodextrin).~Interventions:~The experimental procedure for each athlete included a 10-day placebo administration. Placebo was ingested with at least 250 mL of water. On training days the supplements were taken in the morning, in the evening and 1.5 hours before training session. On rest days the supplements were taken in the morning, in the afternoon and in the evening.~Between the 10-day NaHCO3 and PLA or a PLA and NaHCO3 treatments, a 14-day washout period was introduced."
89501806|NCT05746221||INSVD Cohort|200 patients with cerebral small vessel disease - 100 recruited from Cambridge, UK; 100 recruited from Nijmegen, Netherlands.
89501807|NCT05746143|Experimental|Zolpidem|
88939981|NCT01845142|Active Comparator|subcutaneous 100.000 I.U. vitamin D3|subcutaneous 100.000 I.U. vitamin D3
89501808|NCT05746143|Placebo Comparator|Placebo|
89501809|NCT03165435|Experimental|CV-MG01|The active targeted immunotherapy candidate, CV-MG01 comprises two short synthetic peptides separately conjugated to a carrier protein for the potential treatment of myasthenia gravis
89501810|NCT03165435|Placebo Comparator|Placebo|Aluminium hydroxide adjuvant alone
88939982|NCT01845142|Placebo Comparator|subcutaneous placebo|subcutaneous 0.9% sodium chloride
88939983|NCT01845168|Active Comparator|Computer-alert|2 arm study active group: 'A computer alert which pops up when the GP prescribes NSAID/ASA to a patient with risk-factors
88939984|NCT01845168|No Intervention|controlgroup, normal procedures|The control-group: GP working in normal procedures
88939985|NCT01845181|Placebo Comparator|Dose Level I - Group A - Placebo|2 capsules of placebo
88939986|NCT01845181|Experimental|Dose Level II - Group B - Active|20 mg: 1 capsule of 20 mg PBF-680
88939987|NCT01845181|Placebo Comparator|Dose Level II - Group B - Placebo|1 capsule of placebo
88939988|NCT01845181|Experimental|Dose Level I - Group A - Active|10 mg: 2 capsules of 5 mg PBF-680
88939989|NCT01845181|Experimental|Dose Level III - Group C - Active|40 mg: 2 capsules of 20 mg PBF-680
88939990|NCT01845181|Placebo Comparator|Dose Level III - Group C - Placebo|2 capsules of placebo
89501811|NCT03165591|Experimental|Experimental|Daily tablet of V3-P given orally for 2 months
89501812|NCT03114813||Clinically indicated primary prophylaxis|"Approach all those who have had a portal pressure measurement (HVPG) as part of their routine clinical care.~At baseline participants will consent to have an additional MRI scan before undergoing clinical screening Endoscopy.~All participants found to have oesophgeal varices that require primary prophylaxis, will be started on Carvedilol 6.25mg.~After 1 week, participants will return for dose optimisation~After 4-12 weeks of treatment, participants will have:~repeat one hour MRI scan~repeat HVPG to evaluate treatment response"
88939991|NCT01845181|Experimental|Dose Level IV - Group D - Active|60 mg: 3 capsules of 20 mg PBF-680
89456296|NCT03171038|Experimental|Telemonitoring group|6 months of telemonitoring (t0-t1), followed by usual care up until common long-term stopping date (t1-t2).
89456297|NCT03171038|No Intervention|Usual care group|Usual care from t0 up until the common stopping date (t2).
89456298|NCT02294643|Active Comparator|aspirin, clopidogrel & sarpogrelate|the triple anti-platelet treatment group will receive aspirin 100mg, clopidogrel 75mg and sarpogrelate (Anplag®, Yuhan Corporation, Seoul, South Korea) 100mg twice daily
89456299|NCT02294643|Placebo Comparator|aspirin, clopidogrel & placebo|the dual anti-platelet group will receive aspirin 100mg and clopidogrel 75mg daily plus placebo twice daily
89456300|NCT02401958|Experimental|Rheumatoid Arthritis Group|Resistance Training
89456301|NCT02401958|Active Comparator|Healthy control Group|Resistance Training
89456302|NCT03520803|Experimental|Experimental|ERAS protocol
88939992|NCT01845181|Placebo Comparator|Dose Level IV - Group D - Palcebo|3 capsules of placebo
88939993|NCT01845194|Experimental|Drug application|"Two treatment periods:~Treatment period 1:~three sequential oral and i.v. doses of 5 mg Metoprolol, 50 mg Talinolol, 2.5 mg Torsemide, 0.2 mg Midazolam and 50 mg Caffeine. At least 1 week of wash out between drug application~Treatment period 2:~combined application of a single oral dose of 2.5 mg Talinolol, 0.25 mg Torsemide, 5 mg Pravastatin, 1 mg Midazolam and 5 mg Codeine.~Treatment period 2 may take place after or before treatment period 1 with a time interval of at least 1 week"
88939994|NCT01845207||Aortic valve replacement|Patients aged ≥70 years referred for surgical or transcatheter aortic valve replacement.
88939995|NCT01845233||Non invasive ventilation|
88939996|NCT01845246|No Intervention|Standard doses of colistin will be used.|Patients will receive the standard doses of colistin without TDM (Therapeutic drug monitoring).
88939997|NCT01845246|Experimental|Prospective TDM (Therapeutic drug monitoring)of colistin arm|CMS dose will be adjusted based on protocol obtained TDM levels.
88939998|NCT01845259|Experimental|Liraglutide|Once a day 1,8 mg subcutaneous injection for 16 weeks
88939999|NCT01845259|Placebo Comparator|Liraglutide placebo|Once a day 1,8 mg subcutaneous injection for 16 weeks
88940000|NCT01845272|Experimental|Part 1|"single administration : candesartan cilexetil 32mg, qd, 10days(oral).~combination administration : candesartan cilexetil 32mg and amlodipine 10mg, qd, 10days(oral)."
88940001|NCT01845272|Experimental|Part 2|"single administration : amlodipine 10mg, qd, 10days(oral).~combination administration : candesartan cilexetil 32mg and amlodipine 10mg, qd, 10days(oral)."
88940002|NCT01845285||aortic valve disease|aortic valve replacement
88940003|NCT01845298|Experimental|HIV-infected subjects|HIV-infected subjects who have not yet initiated highly active antiretroviral therapy (HAART). All enrolled subjects will receive a single dose of rifampicin 600 mg.
88940004|NCT01845324||Diabetes Mellitus in pregnancy|Our cohort will include all consequtive women with Diabetes Mellitus atending our clinic
88940005|NCT01845350|Other|M2 macrophages|M2 macrophage introduction
88940006|NCT01845363|Other|Cefazolin|"Cefazolin used in antimicrobial prophylaxis~Cefazolin administered a first dose of 2g in anesthetic induction, followed by continuous dosage of 1g diluted in 250mL of saline solution for two hours.~Two samples of subcutaneous tissue were collected for analysis: the first soon after the incision, and a second before skin synthesis.~The samples were processed by High Pressure Liquid Chromatography (HPLC)."
88940007|NCT01845376|Experimental|local anesthesia group|In the local anesthesia group, patients will receive local anesthesia similar to that described by Amid et al. except that 1% lidocaine with adrenaline (1:200,000) will be used instead of a mixture of lidocaine and bupivacaine. Surgeons will be taught to do the local anesthetic technique in a standardized manner.
88940008|NCT01845376|Experimental|spinal anesthesia group|In the spinal anesthesia group, patients will be positioned in the lateral position and a Whitacre 25 G needle will be inserted at L3-4 intervertebral space and then heavy bupivacaine 0.5% 15 mg will be injected. Sensory block (T4 and below dermatomes) to cold and pinprick will be tested before starting operation. An incremental dose containing 1 mg of midazolam and 25 mcg of fentanyl will be intravenously given if patients in the LA and SA group require.
89016400|NCT04579666|Experimental|1,080 mg pegcetacoplan (APL-2)|administered subcutaneously twice weekly
89456303|NCT03520803|No Intervention|Control|Standard of care
89456304|NCT02410694|Experimental|Ixazomib-Thalidomide-Dexamethasone|"Combination therapy of:~Ixazomib 4.0mg at days 1, 8, 15, Thalidomide 100mg at days 1 to 28 (50mg in patients aged ≥75 years), Dexamethasone 40mg (20mg in patients aged ≥75 years) at days 1, 8, 15 of a 28-day treatment cycle.~After 8 cycles of ITD therapy, maintenance treatment with 4.0mg ixazomib (3.0mg in patients aged ≥ 75 years at first day of maintenance phase) on days 1, 8, 15 of 28-day cycles will be administered to patients with ≥ MR for a maximum period of 12 months."
88940009|NCT01845376|Experimental|general anesthesia group|In the general anesthesia group, patients will be induced with propofol 2 mg/kg and fentanyl 1.5 µg /kg. They are then allowed to breathe spontaneously with sevoflurane 2% to 2.5% in a mixture of 60% oxygen through a laryngeal mask. End-tidal concentration of sevoflurane will be adjusted to keep end-tidal sevoflurane 1MAC. Supplemental doses of 25 µg of fentanyl will be administered if intraoperative heart rate and blood pressure are greater than 20% of baseline.
89016401|NCT04579666|Placebo Comparator|Placebo administered subcutaneously twice weekly|
89501813|NCT01358864|Active Comparator|Placebo/PegIFN/RBV|patient to receive two capsules identical to those containing BI201335 once a day for 24 weeks and PegIFN/RBV for 48 weeks
88940010|NCT01845389|Experimental|Epidural|epidural anesthesia was administered via a 20-gauge epidural catheter threaded cephalad through an 18 gauge needle identified by the loss of resistance method to air. Bupivacaine 0.5% 5 ml every 5 minutes for T10 sensory level
89016402|NCT04573231|Experimental|18F-DCFPyL PSMA-based PET/CT|"18F-DCFPyL whole body PET/CT scan~Review of relevant imaging and medical record information~Blood draw for circulating tumor cells (CTCs)~Analysis of diagnostic tissue specimens"
89016403|NCT04546685|Other|Usual Care (waitlist)|Participants will continue their usual clinical care.
89016404|NCT04546685|Experimental|1-Session pain relief skills class (online Spanish Empowered Relief)|A 2-hour group intervention that will be delivered by a Spanish-fluent certified instructor to online participant cohorts.
89201371|NCT00927459|Placebo Comparator|Placebo|PRO-040201 with placebo control in each cohort
89456305|NCT02410538||"families that received the list of FAQ"|"The intervention consists of the delivery to the relatives of ICU patients a list of 21 key issues in intensive care during the first 48h period of ICU stay, only for intubated and mechanically ventilated patients A formal interview is scheduled to relatives of ICU patients on D3 of inclusion"
89456306|NCT02410538||families that received information as usual|A formal interview is scheduled relatives of ICU patients on D3 inclusion
89456307|NCT03521895||Treatment naïve wAMD|Treatment naïve patients with wAMD treated with IVT aflibercept from the two underlying studies PERSEUS and RAINBOW
89456308|NCT03171116||CKD-CT|subjects with CKD stages II-V under conservative treatment
89456309|NCT03171116||CKD-HD|subjects with CKD stage V on hemodialysis
89456310|NCT03171116||RTx renal transplant|renal transplant recipients
89456311|NCT03171116||Controls|control subjects
89456312|NCT02401880|Active Comparator|Empagliflozin plus Linagliptin|Linagliptin 5mg to be adminstered for 30 days in T2DM patients on stable metformin and Empagliflozin
88940011|NCT01845389|Active Comparator|Spinal|An18-gauge Tuohy peel-away epidural sheath was introduced into the epidural space by using loss of resistance technique to air. Epidural introducer was removed leaving epidural sheath to be a pathway for Wiley spinal catheter. A flexible, convenience curve 27-gauge atraumatic pencil point tip spinal needle was introduced through the epidural sheath. After CSF flow was confirmed, a 23-gauge flexible cannula was threaded over the spinal needle. Peel-away epidural sheath was removed and flexible cannula was continually advanced over the spinal needle into the intrathecal space cephaled. Bupivacaine 0.5% 0.5 ml every 5 minutes for T10 sensory level.
88940012|NCT01845402||congenital cardiac diseases|blood sample and urine sample.
88940013|NCT01845415|Active Comparator|Social Marketting Only|Two communities receive a social marketing campaign to reduce child falls in the home.
88940014|NCT01845415|No Intervention|No treatment Control|two communities receive no intervention
88940015|NCT01845415|Active Comparator|Social Marketing plus Intervention|Two communities receive the social marketing campaign and additional intervention components
88940016|NCT01845428|Other|pravastatin|All participants will receive pravastatin 20mg daily
88940017|NCT01845454|Active Comparator|Dose 1|The first 15 patients enrolled will receive a dose of 1 application of 20 seconds each of spray cryotherapy using the trūFreeze™ spray cryotherapy device throughout the affected tissue.
88940018|NCT01845454|Active Comparator|Dose 2|If a second cohort of 15 participants is necessary, the next dose will include 1 application of 30 seconds each of spray cryotherapy using the trūFreeze™ spray cryotherapy device throughout the affected tissue.
88940019|NCT01845454|Active Comparator|Dose 3|If an additional cohort of 15 participants is necessary, the next dose will include 2 applications of 20 seconds each of spray cryotherapy using the trūFreeze™ spray cryotherapy device throughout the affected tissue.
88940020|NCT01845454|Active Comparator|Dose 4|If an additional cohort of 15 participants is necessary, the next dose will include 2 applications of 30 seconds each of spray cryotherapy using the trūFreeze™ spray cryotherapy device throughout the affected tissue.
88940021|NCT01845467||Auto-immune pancreatitis, suspected|Patients suspected with auto-immune pancreatitis (AIP) and undergoing secretin assisted MRCP as per the standard of care at our institute.
88940022|NCT01845480|Experimental|Healthful eating phys activity coaching|The healthful eating and physical activity skills coaching intervention is designed to help children set goals and self-monitor healthful eating and physical activity; teach kitchen skills for fruit and vegetable snack preparation; teach children enjoyable physical activities to do at home (e.g., dancing); and provide modeling and social support for physical activity and healthful eating.
88940023|NCT01845480|Active Comparator|Health education coaching|Health education coaching is designed to help children set goals and self-monitor behavior; educate children on a range of relevant health promotion behaviors (e.g., tooth brushing, not smoking, physical activity, etc.); and provide modeling and social support for practicing healthful behavior.
88940024|NCT01845493|Active Comparator|Sulforaphane-rich supplement|Intervention: broccosprout homogenate (rich in Sulforaphane) taken orally daily x 3 days
88940025|NCT01845493|Placebo Comparator|Alfalfa Sprout Homogenate|Placebo: Alfalfa sprout homogenate taken daily x 3 days (poor in sulforaphane)
88940026|NCT01845506|Experimental|Wireless pressure transducer|Following informed consent, each subject will be fitted with a wireless sensor attached to a conventional laptop computer. The sensors fit around the participant's chest and work as transducers.
89456313|NCT02401880|Placebo Comparator|Empagliflozin plus Placebo|Placebo to be adminstered for 30 days in T2DM patients on stable metformin and Empagliflozin
89456314|NCT02401880|Other|Empagliflozin|Empagliflozin 25mg will be adminstered for 30 days in T2DM patients
89456315|NCT03517839|Experimental|Training Group|
89456316|NCT03517839|Sham Comparator|Control Group|
89456317|NCT03170726|Active Comparator|arveles|Ibuprofen 800 mg in normal saline 150 cc and dexketoprofen (50 mg) before operation will be given in 30 minutes
89456318|NCT03170726|Active Comparator|intrafen|intrafen 800 mg in normal saline 150 cc before operation will be given in 30 minutes
89456319|NCT03170726|Placebo Comparator|plasebos|150 cc normal saline will be given in 30 minutes during preoperative period
89456320|NCT03520725|Experimental|No Intervention|This group did not have an intervention
89456321|NCT03520725|Experimental|Intervention pineapple|Daily consumption of 30 g of pineapple snack bar for 4 weeks.
89456322|NCT03520725|Experimental|Intervention mango|Daily consumption of 30 g of mango snack bar for 4 weeks.
89456323|NCT02401802|Experimental|Low-residue diet|The experimental group will receive 4 days of low-residue diet Laxative 4 liters polyethylene glycol 4000 in split fashion.
89456324|NCT02401802|Active Comparator|Usual care|"The control group will receive 3 days of low-residue diet followed by 24 hours of liquid diet.~Laxative 4 liters polyethylene glycol 4000 in split fashion."
89456325|NCT02401724|Active Comparator|Action Training|Training exercise which involves patients lifting up rods of different sizes and shifting their grip if this is too far to one side
89456326|NCT02401724|Experimental|tDCS|A constant 1mA current will be applied to the left (undamaged) side of the scalp with an electrode covered with a damp cotton pad (25 cm2). The current will be applied for 15 minutes per day, with a total of 10 sessions over 3 weeks.
89456327|NCT02401724|Experimental|Action Training + tDCs|This will involve the same procedure as in action training only but with tDCS applied for 15 minutes during the rodlifting.
89456328|NCT02401724|Placebo Comparator|Control training|For the control training, patients will be asked to simply reach for the right hand side of each rod with their right (unaffected) hand and lift it
89456329|NCT02401490|Active Comparator|Human albumin|human albumin in the 24-48 hours after the hospitalization and at 48+/- 24 hours after the first dose.
89456330|NCT02401490|Placebo Comparator|placebo|saline serum 0.9%
89456331|NCT02401646|Experimental|Polygoni Multiflori Radix complex|Participants randomized to the experimental group will take one capsule of Polygoni Multiflori Radix complex extract (250mg) twice a day, 30 minutes after breakfast and dinner for 4 weeks.
89456332|NCT02401646|Placebo Comparator|Starch|Participants randomized to the placebo group will take one capsule of placebo(250mg) twice a day, 30 minutes after breakfast and dinner for 4 weeks.
88940027|NCT01845506|Active Comparator|Cardiorespiratory Monitor|Following informed consent, each subject will be also be fitted with ECG leads (five), and an oxygen saturation monitor. This information as well as blood pressure and temperature will be recorded at 5-minute intervals by a nurse.
88940028|NCT01845519|Experimental|Tailored Group|
88940029|NCT01845519|Active Comparator|Targeted Group|
88940030|NCT01845532|Experimental|TPI group|
88940031|NCT01845532|Active Comparator|ELMA group|
89456333|NCT04481438|Experimental|exercise group|exercise group will receive acupunch exercise
89456334|NCT04481438|No Intervention|control group|control group will maintain the regular activities of their original daily lives
89456335|NCT02294721|Experimental|Without feedback|Participants compress the chest of the manikin without CPR feedback device
89456336|NCT02294721|Experimental|With feedback|Participants compress the chest of the manikin with CPR feedback device.
89456337|NCT03175016|Experimental|DEBIRI|Transcatheter arterial chemoembolization(TACE) with Irinotecan eluting-bead(DEBIRI)
89456338|NCT03175250|Active Comparator|Health Education|This condition included live health education followed by health education videos on HIV risks, testing, and condom use. The videos were presented over laptop.
88940032|NCT01845532|No Intervention|None group|
88940033|NCT01845545|No Intervention|Late intervention|CPSL will support the establishment of self-help groups after 18 months of start of the study.
88940034|NCT01845545|Experimental|Early intervention|CPSL will support the establishment of Women's self-help group. Microfinance will be provided to this group from the first 18 months of the study. The women in these groups will be eligible for emergency loans (up to Rs3000) and general purpose loans, (Rs50-3000) after 3-6 months of starting the self-help groups.
88940035|NCT01845558|Experimental|Wobenzym® plus|Treatment with the licenced drug Wobenzym® plus (3x4 Capsules/ day)
88940036|NCT01845558|Placebo Comparator|Placebo equates Wobenzym® plus but without active ingredients|3x4 capsules/ day
89456339|NCT03175250|Active Comparator|Action Plan|This condition included live health education followed by computerized procedures focusing on action plans for HIV testing and condom use and some of the same health education videos in the Health Education condition.
89456340|NCT03175250|Experimental|Memory Practice|This condition included live health education followed by computerized action plan procedures (as in the Action Plan condition), followed by several memory practice procedures also delivered over laptop. The memory practice procedures were designed to help participants more readily retrieve and use action plans in critical situations.
89456341|NCT03520257|Experimental|Apatinib Plus Radiotherapy|
88940037|NCT01845584|Experimental|NPB-01|Intravenous immunoglobulin
88940038|NCT01845610|Experimental|Fortified fat-based paste with EFAs, DHA, ARA and phytase|Complementary food supplement providing micronutrients and both essential fatty acids, DHA, ARA, phytase and L-lysine, potassium, phosphorous, magnesium and manganese
88940039|NCT01845610|Experimental|Fortified fat-based paste with essential fatty acids|Complementary food supplement providing micronutrients and essential fatty acids (EFAs)
88940040|NCT01845610|No Intervention|Control group|The control group will receive a delayed intervention
88940041|NCT01845623|Experimental|Treatment A|
88940042|NCT01845623|Experimental|Treatment B|
88940043|NCT01845623|Placebo Comparator|Treatment C|
89456342|NCT03520257|Other|Apatinib|
89456343|NCT02292303|Experimental|zinc-enriched yeast|zinc-enriched yeast capsules
89016405|NCT04543539||IN.PACT™ AV Access PAS Primary Cohort|The primary cohort consists of enrolled subjects treated with the IN.PACT™ AV DCB according to labeling requirements who meet the inclusion/exclusion criteria for the primary cohort.
89016406|NCT04543539||IN.PACT™ AV Access PAS Extended Cohort|The extended cohort consists of enrolled subjects who do not meet the eligibility criteria for the primary cohort and receive the IN.PACT™ AV DCB device for treatment of stenosis in the AV circuit.
89016407|NCT04502082|Experimental|ET140203 TCells|ET140203 T Cells
89016408|NCT04492345|Experimental|Experimental|Patient with conventional rehabilitation session and isokinetic reeducation during 7 weeks
89016409|NCT04492345|Other|Control|Patient with conventional rehabilitation session during 7 weeks
89016410|NCT04478123|Experimental|romiplostim|"Patients will be enrolled prior to admission for High-Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT-AHCT), and they will undergo their planned HDT-AHCT for their respective hematologic malignancy as per institutional standards.~Regardless of the conditioning regimen received, all patients will receive romiplostim 3.0 mcg/kg SC on Day +1 and romiplostim 2.0 mcg/kg SC on Day +8 after HDT-AHCT. Beyond Day +8, patients will be treated until platelet count is >50,000/mcL, without any platelet transfusions in the prior 48 hours. All doses after the second romiplostim dose will be titrated as per Table 3, based on weekly CBC/platelet counts. No patient will receive more than six doses of romiplostim, even if platelets have not corrected by Day +42."
89016411|NCT04476472|Experimental|Treatment|All subjects wearing the Omnipod Horizon™ Automated Glucose Control System using the closed-loop algorithm.
89016412|NCT04452500|Experimental|CORT108297|CORT108297- 180mg daily for 7 days
89016413|NCT04452500|Placebo Comparator|Placebo|Placebo- 180mg daily for 7 days
89016414|NCT04448977||Multiple Sclerosis group 1|Individuals with Multiple Sclerosis who are going to be starting Ocrevus as determined by Neurologist as part of clinical care.
89016415|NCT04448977||Multiple Sclerosis group 2|Individuals with Multiple Sclerosis who are going to be starting Copaxone as determined by Neurologist as part of clinical care.
89456344|NCT02292303|Active Comparator|zinc oxide|zinc oxide capsules
89016416|NCT04448977||Healthy Controls|Healthy individuals who are age, gender and education matched to the other groups.
89016417|NCT04432831|Experimental|Faricimab PTI|
89016418|NCT04428372|Experimental|Mannitol|intravenous 20% mannitol, 0.25g/kg/hour (maximum 25g/hour; maximum 75g per session; maximum volume 375mL/session) as a continuous infusion during dialysis
89016419|NCT04428372|Placebo Comparator|Placebo|0.9% saline at a rate of 1.25mL/kg/hour (maximum volume 375mL) as a continuous infusion during dialysis
89456345|NCT02292303|Active Comparator|zinc gluconate|zinc gluconate capsules
89016420|NCT04422002||Surgical treatment|
89016421|NCT04422002||Palliative treatment|
89016422|NCT04407520||Adult patients with intellectual and/or physical disabilities|Adult patients with intellectual and/or physical disabilities requiring dental treatment under general anesthesia
89016423|NCT04402294|Experimental|Optimized TMS frequency, Then Sub-Optimal TMS Frequency|In the first neuromodulation session, participants will receive rTMS using their optimal TMS frequency. After washout period of 1 week (minimum), the participants will start their second neuromodulation session using their sub-optimal TMS frequency instead.
89016424|NCT04402294|Experimental|Sub-Optimal TMS Frequency, Then Optimized TMS frequency|In the first neuromodulation session, participants will receive rTMS using their sub-optimal TMS frequency. After washout period of 1 week (minimum), the participants will start their second neuromodulation session using their optimal TMS frequency instead.
89456346|NCT02397044||Implant loading Immediate|Dental implant surgery with immediate loading
89456347|NCT02397044||Implant Loading Early|Dental implant surgery with delayed loading
89016425|NCT04352777|Active Comparator|Cohort 1|Fulvestrant plus abemaciclib
89016426|NCT04352777|Active Comparator|Cohort 2|Aromatase inhibitor plus abemaciclib (with or without ovarian suppression)
89016427|NCT04343365||Participants Reviewed by ETB|Participants clinical history, available therapeutic options, and outcome expectations will be presented to the Evolutionary Tumor Board (ETB) along with images and pathology. Strategies and models will be presented regarding additional evolutionary ideas that can be applied.
89016428|NCT04329728|Experimental|DLBCL and high-grade B-cell lymphoma|Diffuse Large Cell B-Lymphoma High-grade B-cell Lymphoma
89016429|NCT04329728|Experimental|MCL (Chronic Lymphoid Leukemia)|Chronic Lymphoid Leukemia
89016430|NCT04329728|Experimental|Primary Mediastinal Large B-cell lymphoma|Primary mediastinal large B-cell lymphoma
89016431|NCT04329728|Experimental|Burkitt or Burkitt-like lymphoma/leukemia|Burkitt or Burkitt-like lymphoma/leukemia
89016432|NCT04329728|Experimental|CLL/SLL|Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma
89016433|NCT04329728|Experimental|B- or T-ALL|B-lymphoblastic leukemia/lymphoma, T-lymphoblastic leukemia/lymphoma, acute leukemia/lymphoma, acute leukemias of ambiguous lineage, or natural killer (NK) cell lymphoblastic leukemia/lymphoma
89016434|NCT04312399|Other|oral hormonal therapy|Postmenopausal women who start with oral hormonal therapy (Progesteron + uterogestan) according to standard of care practice. Before the start of the treatment blood will be taken and 6 months after the start of the therapy blood will be taken for analysis. At the 2 study visits the patient will be asked to complete the questionaires (TANGO-SF, ICIQ, Cohen, Pittsburgh sleep quality). Only at the first study visit an MMSE test will be taken, to make sure the patient has no dementia.
89456348|NCT03170570|Experimental|treatment|retreatment using intensity-modulated radiotherapy for cervical cancer patients with in-field recurrence
89456349|NCT02294955|Active Comparator|Catheterablation|Pulmonary vein isolation with Cryo-energy using a Arctic Front™ Cardiac CryoAblation Catheter or an irrigated radiofrequency ablation catheter, with an optional roof line.
89456350|NCT02294955|Active Comparator|Antiarrhythmic drug Class IC or III.|Serial testing of oral antiarrhythmic drugs; amiodarone 600 mg once daily 7-10 days, then 100-200 mg once daily; sotalol: 80-160 mg twice daily; flecainide 100 to 150 mg twice daily or entire dose as slow-release formula once daily; propafenone 300 mg twice daily; disopyramide 250-375mg twice daily, or dronedarone 400 mg twice Daily.
89501814|NCT01358864|Experimental|BI201335 12 weeks|patient to receive two capsules containing BI 201335 once a day for 12 weeks and PegIFN/RBV for 48 weeks
89501815|NCT01358864|Experimental|BI201335 24 weeks|patient to receive two capsules containing BI 201335 once a day for 24 weeks and PegIFN/RBV for 48 weeks
89456351|NCT04481594|Experimental|HPN-01|"Part 1: Including 6 dose cohorts (25 mg, 50 mg, 100 mg, 150 mg, 200 mg and 300 mg). Each dose cohort will receive a single dose of HPN-01. One cohort of Part 1 will receive HPN-01 after a standard high fat/high calorie breakfast (the fed condition) to investigate the effect of food on the pharmacokinetics of HPN-01.~Part 2: Including 3 dose cohorts (50 mg, 100 mg and 200 mg). Each dose cohort will receive HPN-01 once daily for a consecutive 14 days."
89456352|NCT04481594|Placebo Comparator|Placebo|"Part 1: Including 6 dose cohorts (25 mg, 50 mg, 100 mg, 150 mg, 200 mg and 300 mg). Each dose cohort will receive a single dose of HPN-01 placebo.~Part 2: Including 3 dose cohorts (50 mg, 100 mg and 200 mg). Each dose cohort will receive HPN-01 placebo once daily for a consecutive 14 days."
89456353|NCT05416697|Experimental|cannabinoid|Cannabinoid in form of cannabis 2.7 mg THC 2.5 mg twice daily (1 droplet twice daily; 0.73 mg THC and 0.81 mg CBD/drop, 1.46 mg THC and 1.62 CBD/day) for 1 week then titrate up to 2 droplets twice daily if tolerated (2.92 mg THC and 3.24 CBD per day) and continue the treatment until the end of the study
88940044|NCT01845662||surgical or non-surgical management|Patients with non traumatic cause of splenic rupture such as infectious disease (e.g. malaria)and myeloproliferative that have been treated conservatively in one group and operatively in another group.
88940045|NCT01845675|Experimental|temozolomide or dacarbazine-based chemotherapy, endostatin|Endostatin 15mg/d，IV infusion, d1-d14 Temozolomide 150-200mg/m2/d，p.o., d1-d7 or dacarbazine 250mg/m2/d, IV infusion, d1-5, 5-FU 500mg/m2/d, IV infusion d1-5 Repeat every 3 weeks.
89456354|NCT05416697|Placebo Comparator|placeba|Placebo 1 droplet twice daily for 1 week then titrate up to 2 droplets twice daily if tolerated and continue the treatment until the end of the study
89456355|NCT02396888|Experimental|Insulin|Half of the wound surface was treated daily with intermediate insulin. Allocation was randomized.
89456356|NCT02396888|Placebo Comparator|Placebo|Half of the wound surface was treated daily with normal saline. Allocation was randomized.
89456357|NCT02295033|Experimental|Boost irradiation|
88940046|NCT01845701|Experimental|Artesunate-Amodiaquine|As a fixed-dose combination of artesunate-amodiaquine developed by Sanofi-Aventis (France). It has the advantage of being a 3-day regimen usable by all age groups and potentially low cost. tablets are administered per every day at dose of 25mg/67.5mg for those between 4,5kg and 9kg for 48H
88940047|NCT01845701|Experimental|Dihydroartemisinine_Piperaquine|As a fixed-dose combination of dihydroartemisinin-piperaquine which is produced by Fouley (China). It is a potentially low cost 2-day regimen that has been used in children between 5-10kg as half a tablet of 40mg/320mg every day for 48H
88940048|NCT01845701|Active Comparator|Artemeter-Lumefantrine|This is the active comparator as a fixed-dose combination of artemether and lumefantrine which is produced by Novartis (Switzerland). The drug will be used as the comparator because it is the only fixed-dose combination with artemether currently available. Administered in children as tablets containing Artemether-Lumefantrine at (20mg/120mg) for body weights of 5-10kg every 12H within 48H.
88940049|NCT01845714|Active Comparator|Cross Linking Group (CxL group)|Patients that received CXL
88940050|NCT01845714|Active Comparator|Cross Linking with topo-guided PRK (tCxL)|Patients that received tCxL
88940051|NCT01845727|Experimental|Topical Amphotericin B three times per day|Anfoleish applied 3 times per day for 4 weeks (TID group)
88940052|NCT01845727|Experimental|Topical Amphotericin B two times per day|Anfoleish applied 2 times per day for 4 weeks (BID group)
88940053|NCT01845740|Experimental|Milatuzumab SC 250 mg|Milatuzumab 250 mg will be administered subcutaneously once weekly for 4 weeks.
88940054|NCT01845740|Experimental|Milatuzumab 150 mg SC|Milatuzumab 150 mg will be administered subcutaneously once weekly for 4 weeks.
88940055|NCT01845740|Placebo Comparator|Placebo SC|Placebo will be administered subcutaneously once weekly for 4 weeks.
88940056|NCT01845753||All colorectal cancer patients|
88940057|NCT01845766|Experimental|rehabilitation arm|daily standardized exercise rehabilitation during the admission period, and daily standardized self exercise after discharge
88940058|NCT01845766|No Intervention|control arm|
88940059|NCT01845779|Experimental|patients in complete response|
89456358|NCT02295033|No Intervention|No boost irradiation|
89456359|NCT04480580||Hospitalized patients|
89456360|NCT03517683|Experimental|Low speed|Patients will receive intrathecal injection of the anesthetic mixture in a slow speed (1ml in 15 seconds)
89456361|NCT03517683|Active Comparator|High speed|Patients will receive intrathecal injection of the anesthetic mixture in a high speed (1ml in 5 seconds)
88940060|NCT01845844|Experimental|Ranibizumab 0.3mg (12 months)|Intravitreal injection of ranibizumab 0.3mg/0.05cc
88940061|NCT01845844|Active Comparator|Ranibizumab 0.3mg (6 months)|Intravitreal injection of ranibizumab 0.3mg/0.05cc
88940062|NCT01845857|Experimental|Chronic Disease Self-Management Workshop|Longitudinal study of participants who take the CDSMP workshop
88940063|NCT01845870||urinary albumin >300mg/24h|none extra intervention was given by the investigator
88940064|NCT01845870||urinary albumin <30mg/24h|none extra intervention was given by the investigator
88940065|NCT01845870||urinary albumin 30 to 300mg/24h|none extra intervention was given by the investigator
88940066|NCT01845883|Other|Deep Brain Stimulator|Some of our subjects that participate to the study have Deep Brain Stimulation implanted. They will perform the behavioral task twice, with the stimulation ON or OFF.
88940067|NCT01845896|Experimental|Combined exercise|12 weeks combined exercise programme (supervised)
88940068|NCT01845896|Experimental|High intensity interval training|12 weeks high intensity interval exercise programme (supervised)
88940069|NCT01845896|No Intervention|Control|sedentary/habitual lifestyle
88940070|NCT01845909||young adults - Central region of Portugal|
89456362|NCT02401334|Experimental|Hernia Repair|Surgical repair for hernia with implantation of the Cook® Antimicrobial Hernia Repair Device.
89456363|NCT02401568|Other|Normal subjects|"No morphologic changes in carpal ligaments or clinical signs of wrist instability.~Dynamic CT of the wrist will be performed before and after arthrography."
89456364|NCT02401568|Other|Wrist instability|Morphologic ligament changes (e.g. partial or complete rupture) Dynamic CT of the wrist will be performed before and after arthrography.
89456365|NCT02396498|Placebo Comparator|D2 radical gastrectomy+Systemic chemotherapy|8 cycles of systemic chemotherapy were performed for stage Ⅲ patients after D2 gastrectomy .Systemic chemotherapy(SP): Cisplatin: 60mg/m^2, d1 , Intravenous infusion, every 3 weeks. S-1: 40-60mg/m^2 bid, days 1-14, every 3 weeks .Subjects should be given maximum 8 cycles, or progression/intolerance.
89456366|NCT02396498|Experimental|D2 radical gastrectomy+HIPEC|8 cycles of hyperthermic intraperitoneal chemotherapy (cisplatin) and S-1(oral) were performed after D2 radical gastrectomy. HIPEC was conducted in d1 and d3: Normal saline 2000ml-5000ml, Cisplatin 60mg/m^2, 43°C, 60min. every 3 weeks. S-1: 40-60mg/m^2 bid, days 1-14, every 3 weeks.Subjects should be given maximum 8 cycles, or progression/intolerance.
88940071|NCT01845922|Experimental|Low sodium diet|Low sodium diet
88940072|NCT01845922|No Intervention|Control|Standard diet regime
88940073|NCT01845935|Experimental|only one treatment group|Patients presenting inoperable venous vascular malformations in soft tissues with indication of cryoablation.
88940074|NCT01845948|Placebo Comparator|Placebo Control|Parents had no intervention except that an information leaflet for parents on helping children to adapt the new primary school life published by Education Bureau was given to each parent in the control group at the end of data collection.
88940075|NCT01845948|Experimental|parental training programme|The parental training programme was run in small groups of 8 to 12 parents over four consecutive weeks. They consisted of four group sessions, each lasting about two hours. The major focus of the parental intervention included teaching parents: (1) to use more active listening skills, (2) to engage less in harsh parenting practices, (3) to use more praise and encouragement and (4) to set reasonable expectations in the rearing of their children. Each session was started with revision of skills or concepts discussed in previous sessions, therefore, each session built on the previous session.
88940076|NCT01846000|Experimental|Muscles of mastication|This group with TMD will receive low-level laser treatment at masseter and temporal muscles - three points on the masseter (upper, middle and lower) and one point on the anterior temporal
88940077|NCT01846000|Experimental|TMJ and muscles|This group with TMD will receive a mixed application of low-level laser treatment- TMJ and muscles of mastication.
88940078|NCT01846000|Placebo Comparator|Placebo|This group with TMD will receive a low-level laser placebo treatment at TMJ and muscles of mastication. The same equipment will be used with a pen that emits a red guide light and a warning sound, but without the emission of laser
88940079|NCT01846000|Experimental|Tempormandibular Joint|This group with TMD will receive low-level laser treatment in TMJ region - five points around the TMJ.
88940080|NCT01846000|No Intervention|Withou TMD|This will be a follow up group, with volunteers without TMD.
88940081|NCT01846013|Experimental|Stand|
88940082|NCT01846013|Experimental|Move|
88940083|NCT01846013|Experimental|Stand and Move|
89456367|NCT02164643|Experimental|Florbetapir (18F)|
89456368|NCT02164643|Experimental|Flutemetamol (18F)|
89456369|NCT02403908|Experimental|PADN groups (radiofrequency denervation)|An 8-F long sheath will be inserted through the femoral vein and advanced to the main PA (MPA). The nMARQ Circular or Crescent (Biosense Webster) catheter will be advanced along this long sheath. After gently withdrawing the sheath and pushing the PADN catheter, the tip will be released from the sheath. Then, the tip of the catheter will be positioned first at the ostium of the left PA (Level 1 of ablation, <2 mm distal to orifice. After ablation at this level, the catheter tip will be positioned at the ostium of right PA (Level 2 of ablation, <2mm proximal to the bifurcation level). Finally, denervation of main pulmonary artery will be done by pulling the denervation catheter back into Level 3 of ablation (<2 mm proximal to both ostia of right and left PA-s) into main pulmonary artery.
89456370|NCT02403908|No Intervention|SHAM group|non-treated patients (controls)
89456371|NCT02292459|Experimental|PEG 3350|Participants will receive a 17 g oral dose of 1 sachet of PEG 3350 mixed in 120 to 240 mL of water, once a day, for 7 days.
88940084|NCT01846013|No Intervention|General Wellness|
88940085|NCT01846026|Experimental|Vitamin D|"Decristol (cholecalciferol) 20000 IU per capsule~1 capsule per week"
88940086|NCT01846026|Placebo Comparator|Placebo|capsule with peanut oil
89016435|NCT04312399|Other|transdermal hormonal therapy|Postmenopausal women who start with transdermal hormonal (Oestrogel + uterogestan) therapy according to standard of care practice. Before the start of the treatment blood will be taken and 6 months after the start of the therapy blood will be taken for analysis. At the 2 study visits the patient will be asked to complete the questionaires (TANGO-SF, ICIQ, Cohen, Pittsburgh sleep quality). Only at the first study visit an MMSE test will be taken, to make sure the patient has no dementia.
89016436|NCT04312399|Other|oral hormonal therapy + hysterectomy|Postmenopausal women who start with oral hormonal therapy (progesteron) according to standard of care practice and had a hysterectomy in the past. Before the start of the treatment blood will be taken and 6 months after the start of the therapy blood will be taken for analysis. At the 2 study visits the patient will be asked to complete the questionaires (TANGO-SF, ICIQ, Cohen, Pittsburgh sleep quality). Only at the first study visit an MMSE test will be taken, to make sure the patient has no dementia.
89016437|NCT04312399|Other|transdermal hormonal therapy + hysterectomy|Postmenopausal women who start with transdermal hormonal therapy (Oestrogel ) according to standard of care practice and had a hysterectomy in the past. Before the start of the treatment blood will be taken and 6 months after the start of the therapy blood will be taken for analysis. At the 2 study visits the patient will be asked to complete the questionaires (TANGO-SF, ICIQ, Cohen, Pittsburgh sleep quality). Only at the first study visit an MMSE test will be taken, to make sure the patient has no dementia.
89016438|NCT04312399|Other|oral hormonal therapy + IUD|Postmenopausal women who start with oral hormonal therapy (Progynova) according to standard of care practice and have already an intra-uterine device. Before the start of the treatment blood will be taken and 6 months after the start of the therapy blood will be taken for analysis. At the 2 study visits the patient will be asked to complete the questionaires (TANGO-SF, ICIQ, Cohen, Pittsburgh sleep quality). Only at the first study visit an MMSE test will be taken, to make sure the patient has no dementia.
89456372|NCT02292459|Active Comparator|PEG 4000|Participants will receive a 10 to 20 g oral dose of 1 to 2 sachets of PEG 4000 mixed in 120 to 140 mL of water, once a day, for 7 days.
89456373|NCT02396576|No Intervention|Usual Care|NEVHC has two main Department of Mental Health (DMH) contracted clinical partners where the majority of the patients are referred to -these are Child and Family Guidance Center (CFGC) in the San Fernando Valley and Child and Family Center (CFC) in the Santa Clarita Valley.
89456374|NCT02396576|Experimental|Telehealth Intervention|The telehealth model will enhance patient coordination as well as clinician communication via live videoconferencing. Developmental behavioral services will be provided by a Developmental Behavioral Pediatrician (DBP) housed at UCLA from Children's Hospital Los Angeles (CHLA). Mental Health services will be provided by Child Family Center (CFC) and Child Family Guidance Center (CFGC). The location of the telehealth visit will be at the same clinic location as the index PCP visit with a telehealth coordinator facilitating the encounter between patient and clinicians.The clinician communication will be enhanced through monthly telehealth topic-based educational sessions as well as case-based educational sessions for the transfer cases.
89456375|NCT03520023|No Intervention|Standard Care|Standard care with consultant discretion regarding consult of palliative care medicine
89456376|NCT03520023|Experimental|Experimental|Early palliative care consult based upon meeting study inclusion criteria
89456377|NCT02396654||normal pregnant women|Normal pregnant women between 37 and 42 weeks gestation.
89456378|NCT03170336|Experimental|amiloride|Amiloride first for 8 weeks, then for a washout for 4 weeks, and cross over to receive hydrochlorothiazide for another 8 weeks
89456379|NCT03170336|Active Comparator|hydrochlorothiazide|hydrochlorothiazide first for 8 weeks, then for a washout for 4 weeks, and cross over to receive amiloride for another 8 weeks.
89456380|NCT02295111|Active Comparator|EA treatment and TCM health consult|Participants randomized to the EA treatment will receive 2 EA +TCM health consult once a week x 4 weeks (8 total)
89456381|NCT02295111|Experimental|TCM health consult|Participants randomized to TCM health consult will receive 2 TCM health consult once a week x 4 weeks ( 8 total)
89456382|NCT02295111|Active Comparator|Usual care|Participants randomized to usual care will continue with their usual care
89456383|NCT03170102|Other|Building capacity through education|Building capacity process through education - Occupational therapy students participate in online webinars and discussions following completion of readings.
89456384|NCT04465305|Experimental|enraped group|patients with a new treatment of tarlov cysts
89456385|NCT04465305|Active Comparator|plasty group|patients with traditional treatment of tarlov cysts
89456386|NCT03169946|Active Comparator|Test Group|Endodontic treatment using chlorhexidine metronidazole combination as an intracanal medicament along with open flap debridement (RCT with CHX-MTZ,OFD).
89456387|NCT03169946|Active Comparator|Positive Control Group :|Endodontic treatment using chlorhexidine as an intracanal medicament along with surgical periodontal therapy in form of open flap debridement(RCT with CHX,OFD).
89456388|NCT03519789||Post-Traumatic Stress Disorders (PTSD)|30 patients with PTSD (diagnosis based on the standard DSM criteria)
89456389|NCT03519789||Controls|30 healthy controls without any psychiatric or neurological diagnosis
88940087|NCT01846078|Experimental|Mean absolute errors, median absolute errors|
89456390|NCT03517605|Experimental|Exercise for cardiac rehabilitation|Three sessions of exercises will be performed weekly with duration of 30 min to 60 min, divided into heating, aerobic exercise and recovery.
89456391|NCT03517527|No Intervention|Control|
89456392|NCT03517527|Experimental|Intervention|
89456393|NCT02699684|Other|AOHG, then AOA|Lotrafilcon B contact lenses with EOBO-41 worn first, followed by lotrafilcon B contact lenses worn second. Both products worn bilaterally (in both eyes) for 30 days and removed nightly for care using a hydrogen peroxide-based lens care solution.
89456394|NCT02699684|Other|AOA, then AOHG|Lotrafilcon B contact lenses worn first, followed by lotrafilcon B contact lenses with EOBO-41 worn second. Both products worn bilaterally for 30 days and removed nightly for care using a hydrogen peroxide-based lens care solution.
89456395|NCT03169868|Experimental|Enhanced Medication reconciliation|Medication reconciliation with pharmacist using electronic health records, pharmacy dispensing data and Sano Patient Medication Profile(TM)
89456396|NCT03169868|No Intervention|Standard Medication reconciliation|Medication reconciliation with pharmacist using electronic health records and pharmacy dispensing data only
88940088|NCT01846117|Active Comparator|secoisolariciresinol diglucoside|Secoisolariciresinol diglucoside (SDG) supplementation as 1.6g/day of BeneFlax containing 600 mg SDG. 1000 IU vitamin D as standard of care.
88940089|NCT01846117|Placebo Comparator|Whey powder|Natural Factors Whey Factors whey protein (unflavored). An equal volume of measured whey protein (unflavored) to the Beneflax and 1000 IU vitamin D as standard of care.
88940090|NCT01846130|No Intervention|Control|Control bed rest group
88940091|NCT01846130|Experimental|Leucine|Leucine will be administered in mixed meal 3 times a day at 0.06g/kg lean body mass/meal
88940092|NCT01846130|Experimental|Exercise|Daily bouts of low intensity, bed-based exercise for 30 min/day @ 70% of stress test determined maximal heart rate.
88940093|NCT01846130|Experimental|Leucine + Exercise|Leucine (0.06 g/kg lean body mass/meal, 3 meal/day) and exercise daily bouts of low intensity, bed-based exercise for 30 min/day @ 70% of stress test determined maximal heart rate.
89456397|NCT03169400||Theranova treated|We will collect pool of human sera from HD patients treated with regular bicarbonate dialysis membrane (baseline). Then, patients will be treated for 3 months with Theranove dialyzer, and sera will be collected at 1, 2, and 3 months. We will create a serum pool.
89456398|NCT03169400||Standard treated|We will collect pool of human sera from HD patients treated with regular bicarbonate dialysis membrane (baseline). Then, patients will be treated for 3 months with Theranove dialyzer, and sera will be collected at 1, 2, and 3 months. We will create a serum pool.
88940094|NCT01846130|Experimental|Whey protein|22 g of whey isolate 3x a day (with meals)
88940095|NCT01846130|Experimental|Whey protein + exercise|22 g whey isolate 3x day (with meals) and daily bouts of low intensity, bed-based exercise for 30 min/day @ 70% of stress test determined maximal heart rate
88940096|NCT01846130|No Intervention|Skewed|Protein intake is distributed similar to typical American diet with low protein intake at breakfast, intermediate at lunch and high at dinner.
88940097|NCT01846143|Experimental|Arm A: pBCAR3-phosphopeptide + tet vaccine plus polyICLC|"pBCAR3-phosphopeptide + tet vaccine plus polyICLC~The vaccines will be administered in two treatment cycles. During cycle one, three vaccines will be administered over a 3-week period on days 1, 8, and 15. During cycle two, three vaccines will be administered over a 9-week period on days 36, 57, 78. Participants will be vaccinated with 100 mcg each of the phosphopeptides and 200 mcg of the tetanus peptide (Peptide-tet). The peptides will be administered subcutaneously (0.5 ml) and intradermally (0.5 ml) in Montanide ISA-51 VG adjuvant at six separate vaccine sites in a minimum of two separate extremities.~Poly ICLC: PolyICLC will be administered by a separate 0.5 ml injection (0.25 ml subcutaneously and 0.25 ml intradermally), immediately after, and directly into the precise site where the peptide emulsion was given. We will administer 1 mg per vaccine."
89456399|NCT02292615||cervical cancer|Group 1: Patients with newly diagnosed gynecologic cancers (including cervical, endometrial, and ovarian cancers).
89456400|NCT02292615||endometrial cancer|Group 2: Patients with suspicious recurrent gynecologic cancers (including cervical, endometrial, and ovarian cancers).
89456401|NCT02292615||ovarian cancer|Group 3: Patients with ovarian cancer who had debulking surgery and are going to receive adjuvant chemotherapy.
89456402|NCT03169478|No Intervention|multiple myoma control group|The control group will not have any balloon therapy. A second-look hysteroscopy will be carried out 6 weeks after the surgery.
89456403|NCT03169478|Experimental|multiple myoma IUB dilatation group|The multiple myoma study group will have Foley-catheter intrauterine balloon dilatation therapy 2 weeks and 4 weeks after hysteroscopic myomectomy. A second-look hysteroscopy will be carried out 6 weeks after the surgery.
89456404|NCT02295189|Active Comparator|Visual analogue scale|visual analogue scale versus triamcinolone acetonide visual analogue scale versus ketorolac tromethamine
89456405|NCT02295189|Active Comparator|Treatment|visual analogue scale versus triamcinolone acetonide visual analogue scale versus ketorolac tromethamine
89456406|NCT03169322|Active Comparator|Test Group|patients having chronic periodontitis with mouth breathing habit will receive scaling and root planing (SRP)
89456407|NCT03169322|Active Comparator|Control Group|Nose breathers having chronic periodontitis will receive scaling and root planing (SRP)
89456408|NCT02292693|Experimental|intubation with immobilized cervical spine|endotracheal intubation with immobilized cervical spine
89456409|NCT03169556|Experimental|video-laryngoscope guided lightwand|
89456410|NCT03169556|Active Comparator|lightwand|
89456411|NCT02295267|Experimental|walnut allergy provocation|inclusion of walnut allergic patients, food provocation with walnut
89456412|NCT02396264|Experimental|Mediterranean Diet|The diet programme will be characterized by carbohydrates (60 %); proteins (20 %, half comprised of vegetable proteins); total fat (20 %; saturated fat < 10 %). After calculating the patient's energy need, the amount of calories will be successively adjusted to mantain the same weight of the time of recruitment
89456413|NCT02396264|Active Comparator|normocaloric diet|50% carbohydrates, 30% total lipids and 20% proteins. After calculating the patient's energy need, the amount of calories will be successively adjusted to mantain the same weight of the time of recruitment
89456414|NCT03519633|Experimental|SUG|
89456415|NCT03519633|Active Comparator|NEO|
89456416|NCT02289027|Experimental|Deployed volunteers - Group 1|Low dose cAd3-EBOZ (2.5x10e10 vp)
89456417|NCT02289027|Experimental|Deployed volunteers - Group 2|High dose cAd3-EBOZ (5x10e10 vp)
89456418|NCT02289027|Experimental|Not deployed volunteers - Group 3|Low dose cAd3-EBOZ (2.5x10e10 vp)
89456419|NCT02289027|Experimental|Not deployed volunteers - Group 4|High dose cAd3-EBOZ (5x10e10 vp)
89456420|NCT02289027|Placebo Comparator|Not deployed volunteers - Group 5|
89456421|NCT02396030|Active Comparator|Magnesium sulfate 50% - 1g/h|After loading dose of 6g of magnesium sulfate, patients will receive the maintenance dose of 1g/hour of intravenous magnesium sulfate, for 24 hours
89456422|NCT02396030|Experimental|Magnesium sulfate 50% - 2g/h|After loading dose of 6g of magnesium sulfate, patients will receive the maintenance dose of 2g/hour of intravenous magnesium sulfate, for 24 hours
89456423|NCT02289183|Experimental|Totally laparoscopic distal gastrectomy|The totally laparoscopic distal gastrectomy with modified delta-shaped gastroduodenostomy will be performed for the treatment of patients with distal gastric cancer assigned to this group.
89456424|NCT02289183|Active Comparator|Laparoscopy-assisted distal gastrectomy|The laparoscopy-assisted distal gastrectomy with Billroth-I anastomosis will be performed for the treatment of patients with distal gastric cancer assigned to this group.
89456425|NCT03168152|Experimental|MWA|MWA will typically be administered in one ablation session during which time up to 2 tumors are treated.
89456426|NCT03168152|Experimental|SBRT|SBRT will be administered in five fractions of up to 10 Gy per fraction. SBRT will be administered 5-15 days per tumor.
89456427|NCT03168230||PVE|Patients who required PVE prior to the attempt of liver resection.
89456428|NCT03168230||No-PVE|Patients who received upfront surgery (no PVE prior to the intervention)
89456429|NCT02289261|Active Comparator|Control|Morphine, 0.02 mg/kg PCA bolus dose with 10 minutes lock-out interval
89456430|NCT02289261|Active Comparator|Morphine plus dexmedetomidine|Morphine 0.02 mg/kg plus dexmedetomidine 0.1 microgram/kg PCA bolus dose with 10 minutes lock-out interval
89456431|NCT03168074|Experimental|lenvatinib|Eligible patients will be treated with approximately 2 weeks of single agent lenvatinib (range 10-28 days, depending on the date of breast cancer surgery; last dose of lenvatinib to be administered no later than 48 hours before surgery in patients who are planned to receive ≤14 days lenvatinib, and no later than 120 hours before surgery in patients who are planned to receive 15-28 days lenvatinib).
89456432|NCT02295345|Experimental|CBT for Insomnia|Participants attend 5 weekly sessions of Cognitive Behavioural Therapy for Insomnia for pregnant women, administered by licensed clinical psychologist.
89456433|NCT02403752|Experimental|exercise intervention|"Exercise protocol based on the PLIÉ protocol, developed in consultation with experts worldwide, incl. traditional strength-building exercises, yoga, Tai Chi and Feldenkrais, that engage the muscles most needed to maintain independence--including lower body strength, balance, upper body strength, fine motor exercises , and pelvic floor exercises- combined them into a unique integrative exercise program, to be purposeful and to build procedural ('muscle') memory.~To be practiced at home in dyads of affected individuals and caregivers, called Paired PLIE Program."
88940098|NCT01846143|Experimental|Arm B: pIRS2-phosphopeptide + tet vaccine plus polyICLC|"The vaccines will be administered in two treatment cycles. During cycle one, three vaccines will be administered over a 3-week period on days 1, 8, and 15. During cycle two, three vaccines will be administered over a 9-week period on days 36, 57, 78. Participants will be vaccinated with 100 mcg each of the phosphopeptides and 200 mcg of the tetanus peptide (Peptide-tet). The peptides will be administered subcutaneously (0.5 ml) and intradermally (0.5 ml) in Montanide ISA-51 VG adjuvant at six separate vaccine sites in a minimum of two separate extremities.~Poly ICLC: PolyICLC will be administered by a separate 0.5 ml injection (0.25 ml subcutaneously and 0.25 ml intradermally), immediately after, and directly into the precise site where the peptide emulsion was given. We will administer 1 mg per vaccine."
88940099|NCT01846143|Experimental|Arm C: 2-MpP+ tet vaccine plus polyICLC|"The vaccines will be administered in two treatment cycles. During cycle one, three vaccines will be administered over a 3-week period on days 1, 8, and 15. During cycle two, three vaccines will be administered over a 9-week period on days 36, 57, 78. Participants will be vaccinated with 100 mcg each of the phosphopeptides and 200 mcg of the tetanus peptide (Peptide-tet). The peptides will be administered subcutaneously (0.5 ml) and intradermally (0.5 ml) in Montanide ISA-51 VG adjuvant at six separate vaccine sites in a minimum of two separate extremities.~Poly ICLC: PolyICLC will be administered by a separate 0.5 ml injection (0.25 ml subcutaneously and 0.25 ml intradermally), immediately after, and directly into the precise site where the peptide emulsion was given. We will administer 1 mg per vaccine."
88940100|NCT01846156|Experimental|Abrreviated MgSO4 protocol|- Category B : 80 patients given abbreviated doses of MgSO4 (4 grams of MgSO4 on 250 ml ringer solution over 4 hours every 4 hours by IV drip only for 12 hours) in the postpartum period.
88940101|NCT01846156|Experimental|No maintenance protocol|- Category C : 80 patients who will take only loading dose of MgSO4 (6 grams of MgSO4 on 250 ml ringer solutions over 20 minutes) with no postpartum maintenance sulfate
88940102|NCT01846156|Active Comparator|standard MgSO4 protocol|- Category A : 80 patients given full dose of maintenance MgSO4 (4 grams of MgSO4 on 250 ml ringer solution over 4 hours every 4 hours by IV drip for 24 hours) in the postpartum period.
88940103|NCT01846169|Experimental|food deliveries|After baseline screening, participants receive weekly or bi-weekly food deliveries and brief nutrition education.
88940104|NCT01846234||MS patients|MS patients
88940105|NCT01846247|Placebo Comparator|Standard Care|Standard stroke unit rehabilitation care
88940106|NCT01846247|Experimental|Standard Care + VEM|Standard stroke unit rehabilitation care in addition to a very early rehabilitation protocol
88940107|NCT01846273|Experimental|Ranibizumab + vPDT|Treatment initiation with Ranibizumab and verteporfin PDT (vPDT), with re-treatment need (either Ranibizumab alone or combined with vPDT) determined at monthly visits based on defined retreatment criteria
88940108|NCT01846273|Active Comparator|Ranibizumab monotherapy|Treatment initiation with Ranibizumab and Sham PDT, with re-treatment need (either Ranibizumab alone or combined with Sham PDT) determined at monthly visits based on defined retreatment criteria
88940109|NCT01846312||All participants|
88940110|NCT01846325|Experimental|DHA plus vitamin E|Cap DHA 460mg plus vitamin E 600mg per day
88940111|NCT01846325|Active Comparator|VitaminE plus placebo|vitamin E 600 mg plus placebo
88940112|NCT01846325|Placebo Comparator|placebo plus placebo|DHA shaped placebo plus vitamin E shaped placebo
88940113|NCT01846325|Active Comparator|DHA plus placebo|460 mg DHA plus placebo
88940114|NCT01846338|Experimental|green tea extract EGCG|experimental: green tea extract EGCG, 500mg , tid, 4 weeks
88940115|NCT01846338|Placebo Comparator|cellulose|Placebo Comparator: cellulose, 500 mg tid, 4 weeks
88940116|NCT01846364|Experimental|A|Subjects with proliferative thyroid disease
88940117|NCT01846377|Experimental|G4H-Diab-Nano|Intervention - play two videogames Diab and Nanoswarm (9 sessions each, 18 total sessions) over a 12-week time period.
88940118|NCT01846377|No Intervention|Wait List Control|5-months after baseline assessment they will receive the two video games: 1) Diab and 2) Nanoswarm.
88940119|NCT01846403|Other|Semi-quantitative pregnancy test|Semi-quantitative urine pregnancy test (dBest One Step hCG Panel Test Kit)
89456434|NCT03517215|Experimental|Enhanced CB-ASP|If a site is randomized to the enhanced CB-ASP, prescribers at that site will be required to attend an education session. In the four months following the initial session, prescribers will be asked to complete one on-line eModule for each target condition (acute sinusitis, sore throat, acute bronchitis and acute uncomplicated cystitis) each month. Each module will take approximately 15 minutes to complete. Two audit and feedback reports (every 3 months) of their clinic's prescriptions for these conditions will be provided where they will be asked to review and discuss with their colleagues and study staff.
89016439|NCT04312399|Other|transdermal hormonal therapy + IUD|Postmenopausal women who start with transdermal hormonal therapy (Oestrogel ) according to standard of care practice and have an intra-uterine device. Before the start of the treatment blood will be taken and 6 months after the start of the therapy blood will be taken for analysis. At the 2 study visits the patient will be asked to complete the questionaires (TANGO-SF, ICIQ, Cohen, Pittsburgh sleep quality). Only at the first study visit an MMSE test will be taken, to make sure the patient has no dementia.
89456435|NCT03517215|Active Comparator|Standard CB-ASP|If a site is randomized to the standard CB-ASP strategy arm, prescribers will be offered the opportunity to attend the 1 hour introductory seminar by a web-link, provided with access to the short e-learning modules each month by email, and sent their clinic's audit and feedback reports by email for review two times during the study.
89456436|NCT03517215|No Intervention|Control|If a site is randomized to the control arm, the site will not receive any active interventions. Prescribers at the site will be offered access to the eModules at the completion of the study and provided with one audit and feedback report of their clinic's antibiotic prescribing patterns for local quality improvement needs as desired.
89456437|NCT02396108|Experimental|Paclitaxel + Carboplatin + ASLAN001|"Phase I:~A modified 3+3 study de-escalating dose design will be employed for dose determination. Subjects will receive treatment in 21-day cycles until disease progression, intolerable toxicities or withdraws consent. In the presence of intolerable toxicities to one or more of the drugs in the regimen (but not all 3), the drug in question may be discontinued and the other drugs continued with the patient remaining in the study, if the patient is deemed to be benefiting, after discussion with the Principal Investigator.~Phase II:~Patients with stage I-III HER2-positive breast cancer with a primary breast tumour of 2cm or greater will receive up to 4 cycles of pre-operative ASLAN001 and weekly paclitaxel/ carboplatin delivered in 21-day cycles. Prior to administration of chemotherapy, there will be lead-in dosing of single-agent ASLAN001 administered daily for 2 weeks at the recommended phase II dose."
89456438|NCT02293083|Experimental|Lidocaine|Group L received trigger point injection with a 3.2 ml of a 1:1 mixture of 1% lidocaine and 0.9% normal saline
89456439|NCT02293083|Experimental|Hyaluronidase|Group H received trigger point injection with the same volume of solution supplemented with hyaluronidase (H-LASE®, 1500 iu, L&H Pharm., Seoul, Korea) 600 iu/ml
89456440|NCT03519477|Experimental|Heart failure care with Sano test|Scheduled outpatient care for patients at high risk of admission for heart failure, supplemented with the Sano Patient Medication Profile
89456441|NCT03519477|No Intervention|Heart failure care as-usual|Scheduled outpatient care for patients at high risk of admission for heart failure, care as-usual (i.e. without the Sano Patient Medication Profile).
89456442|NCT02401178||Well baby|"For cross-sectional study design:~The dependent variables are LCPUFA composition from buccal. The independent variables are 17 SNP from FADS genes.~For extended cross-sectional study design:~The dependent variable is atopic dermatitis, while independent variables are:~17 SNP; LCPUFA and FLG gene mutation"
89456443|NCT03521661||Kyphoplasty|Patients underwent kyphoplasty with an intravertebral expander
89456444|NCT02395718|Experimental|QDU|Patients will undergo a fast track model for diagnostics and treatment with a goal of accomplishing a short-term hospitalisation. Patients will have immediate access to all diagnostic tests and treatments that will be carried out all day (24 hours) on demand from the responsible physician. The QDU is both organisationally and physically integrated in the ED. Point of care ultrasonography can be performed round the clock. Additionally the Department of Radiology provides the QDU with more advanced diagnostic procedures such as e.g. CT scans or MRI scans on a fast track basis. There is access to additional specialist evaluations from the ED staff or from various in house specialists, when needed. Simultaneously to the medical treatment, physical therapists and occupational therapists train and optimise patients' level of functioning, including prevention of loss of function.
89456445|NCT02395718|Active Comparator|DIM|Patients in the control group are treated as conventionally at one of seven wards at the DIM. After initial admission including initial diagnostics and treatment have been carried out in the ED, patients are transferred to the DIM. Usually patients are seen primarily by the on-call physician for evaluation of acute symptoms. The following day, a Chief physician will work out a plan for further diagnostics and treatment. Treatment by physiotherapists and occupational therapists is available on request from a physician. Analyses of blood samples are performed at the central laboratory and radiological procedures at the Department of Radiology.
89456446|NCT02289339||TAVI patients|all patients undergoing transcatheter aortic valve prostheses implantation
89456447|NCT02403518|Active Comparator|Back Pain Only|Pain localized to the low back or buttocks.
89456448|NCT02403518|Active Comparator|Leg Pain Only|Pain localized to unilateral pain of the leg (thigh, knee, calf, or foot).
89456449|NCT02403518|Active Comparator|Back and Leg Pain|Pain localized to both the low back and legs (back, buttocks, thigh, knee, calf, or foot).
88940120|NCT01846429|Experimental|Sodium Bicarbonate Treatment|A 3+3 design for Phase I component and a two staged design for Phase II were to be used. Treatment: Sodium Bicarbonate Capsules (900 mg).
88940121|NCT01846468|Experimental|Stage 1 : LHW090, Healthy Volunteers|Healthy Volunteers will receive single dose of LHW090 on Day 1.
89456450|NCT03519399||Cases and Controls|"Cases - Pregnant women with ICP defined as pruritus in pregnancy in association with raised serum bile acids (using hospital threshold for diagnosis), and in the absence of an alternative cause.~Controls - Pregnant women not affected by ICP, or other liver, cardiac or hypertensive disorders."
89456451|NCT02403596|Experimental|Group 1: Exacyl®: Standard treatment|Intravenous use. 1g Exacyl® at H0 (Hour = 0 in other term at the time of incision) then 1g Exacyl® at H+3 then 1g Exacyl® placebo at H+7 and H+11
89456452|NCT02403596|Experimental|Group 2: Exacyl®: Extended treatment|Intravenous use. 1g Exacyl® at H0 (Hour = 0 in other term at the time of incision) then 1g Exacyl® at H+3 / H+7 and H+11
89456453|NCT02403596|Placebo Comparator|Group 3: Placebo|This group will receive a placebo of Exacyl®: 1g placebo of Exacyl® at H0 (Hour = 0 in other term at the time of incision) then 1g placebo of Exacyl® at H+3 / H+7 and H+11
89456454|NCT02700698||Healthy lean|Healthy lean women, 25-35 years
89456455|NCT02700698||Overweight/obese with/without IR|Overweight/obese with/without insulin resistant women, 25-35 years
88940122|NCT01846468|Experimental|Stage 2: LHW090, Healthy Volunteer|Healthy Volunteers across 7 single ascending dose cohorts will be administered LHW090 or matching placebo day 1
89456456|NCT02293161|Experimental|Cohort A GSK2618960|Subjects will receive GSK2618960 0.6 milligram per kilogram (mg/kg)
89456457|NCT02293161|Placebo Comparator|Cohort A Placebo|Subjects will receive Sodium Chloride Intravenous as placebo
89456458|NCT02293161|Experimental|Cohort B GSK2618960|Subjects will receive GSK2618960,planned dose being 2mg/kg. However, actual dose level for Cohort B may be adjusted based on the emerging data on safety, tolerability, PK and RO from Cohort A. The maximum dose will not exceed 2.4 mg/kg (i.e. a 4-fold dose escalation from 0.6 mg/kg)
89456459|NCT02293161|Placebo Comparator|Cohort B Placebo|Subjects will receive Sodium Chloride Intravenous as placebo
89456460|NCT04480112|Experimental|Group A Intervention|Participants in Group A will receive an intervention designed to provide participants with more social interaction during a time of social distancing and highly limited in-person social interactions
89456461|NCT04480112|Active Comparator|Group B Control|Participants in Group B will not receive any new interventions.
89456462|NCT03517059||PD patients|30 PD patients in ON and OFF levodopa conditions
89456463|NCT03517059||Healthy control subjects|30 age matched healthy control subjects
89456464|NCT03517059||Neurological control subjects|10 patients with defined supra nuclear palsy
89456465|NCT03167762|Experimental|Study group|
89456466|NCT03519321|Experimental|Treatment|MID-C EOS implant will be implanted for the correction of the spine deformity in children found eligible for the study
89456467|NCT03169088|Experimental|Coaching procedure|Volunteers will received Updated National Dietary Guidelines about food and physical activity with a one-year follow-up, plus connected coaching.
89456468|NCT04464681|Experimental|M201-A Injection|Active Substance: M201-A Route of administration: continuous intravenous injection
89456469|NCT04464681|Placebo Comparator|Placebo|Placebo: M201-A Placebo Route of administration: continuous intravenous injection
89456470|NCT02289495|Experimental|GSK2838232 without RTV|Subjects will receive 20 mg of GSK2838232/ placebo (3:1) in cohort 1 and 50 mg of GSK2838232/ placebo (3:1) in cohort 2, administered QD for 8 days. There will be a minimum period of 7 days between successive cohorts to establish safety and PK for dose escalation; enrollment into a cohort will commence following review of interim PK and safety data from at least 4 subjects in the preceding cohort
89456471|NCT02289495|Experimental|GSK2838232 with RTV|Subjects will receive 10 mg of GSK2838232/ placebo (3:1) in cohort 3, 20 mg of GSK2838232/ placebo (3:1) in cohort 4 and 50 mg of GSK2838232/ placebo (3:1) in cohort 5, co administered with RTV 100 mg, QD for 11 days. There will be a minimum period of 7 days between successive cohorts to establish safety and PK for dose escalation; enrollment into a cohort will commence following review of interim PK and safety data from at least 4 subjects in the preceding cohort
89456472|NCT03168776|Experimental|BuMA Supreme Coronary Stent System|
89456473|NCT03168776|Active Comparator|Xience or Promus Everolimus Stent System|
89456474|NCT03519165|No Intervention|Control group (Group C)|"Conventional Fluid therapy guided by clinical parameter~Intraoperative fluid therapy will include maintenance fluid and replacement of the surgical loss. Aim to maintain MAP > 65 mmHg, CVP 8-12 cm H2O and urine output > 0.5 ml/kg/h."
89456475|NCT03519165|Active Comparator|Goal directed group (Group G)|"Intervention: Machine guided fluid therapy using EV1000 (FloTrac System 4.0 Edward Lifesciences, Irvine, CA, USA)~Intraoperative fluid therapy will be targeted to SVV <13%, SVI > 35ml/m2/ beat, SVRI more than equal to 1900 dynes-sec/cm-5/m2 using EV1000 floTrac monitor in addition to clinical parameters like MAP, CVP and urine output"
89456476|NCT01774721|Experimental|Dacomitinib (PF-00299804)|Dacomitinib (PF-00299804) is provided as 45 mg tablets, continuous oral daily dosing.
89456477|NCT01774721|Active Comparator|gefitinib|Gefitinib is provided as 250 mg tablets, continuous oral daily dosing.
89456478|NCT02293239|No Intervention|Control Group|"usual care control group receives individualized nutritional support (dietary advices: daily protein intake > 1.0 g/kg bodyweight)"
89456479|NCT02293239|Experimental|WB-EMS group|"physical exercise group regular WB-EMS training (2 EMS trainings per week; each session for 20 min)~+ individualized nutritional support (dietary advices: daily protein intake > 1.0 g/kg bodyweight)"
89456480|NCT02395796|Experimental|Epidural Pressure Waveform|"Study Population:~Term pregnancy~in labour~18 years of age or older."
89456481|NCT02289573|Experimental|neurally adjusted ventilatory assist|
89456482|NCT02289573|Sham Comparator|pressure support ventilation|
89456483|NCT03170492|Experimental|Computerized Cognitive Training|RehaCom for 480 minutes over 12 weeks.
89456484|NCT03170492|Active Comparator|Pencil-and-Paper Cognitive Training|Table-top based activities for 480 minutes over 12 weeks.
89016440|NCT04312399|Other|selective oestrogenreceptor modulators|Postmenopausal women who start with hormonal therapy according to standard of care practice and take selective oestrogenreceptor modulators (Nolvadex) because of their cancer in their medical history. Before the start of the treatment blood will be taken and 6 months after the start of the therapy blood will be taken for analysis. At the 2 study visits the patient will be asked to complete the questionaires (TANGO-SF, ICIQ, Cohen, Pittsburgh sleep quality). Only at the first study visit an MMSE test will be taken, to make sure the patient has no dementia.
89016441|NCT04312399|Other|aromatase inhibitors|Postmenopausal women who start with hormonal therapy according to standard of care practice and who taken aromatase inhibitors (Femara) because of their cancer in their medical history. Before the start of the treatment blood will be taken and 6 months after the start of the therapy blood will be taken for analysis. At the 2 study visits the patient will be asked to complete the questionaires (TANGO-SF, ICIQ, Cohen, Pittsburgh sleep quality). Only at the first study visit an MMSE test will be taken, to make sure the patient has no dementia.
89016442|NCT04312399|Other|Duavive|Postmenopausal women who start with hormonal therapy according to standard of care practice and who take duavive because of their cancer in their medical history. Before the start of the treatment blood will be taken and 6 months after the start of the therapy blood will be taken for analysis. At the 2 study visits the patient will be asked to complete the questionaires (TANGO-SF, ICIQ, Cohen, Pittsburgh sleep quality). Only at the first study visit an MMSE test will be taken, to make sure the patient has no dementia.
89016443|NCT04312399|Other|Control|Postmenopausal women who don't start with hormonal therapy according to standard of care practice. At the first study visit blood will be taken and 6 months after the start of the therapy blood will be taken for analysis. At the 2 study visits the patient will be asked to complete the questionaires (TANGO-SF, ICIQ, Cohen, Pittsburgh sleep quality). Only at the first study visit an MMSE test will be taken, to make sure the patient has no dementia.
89016444|NCT04300647|Experimental|Tiragolumab plus Atezolizumab|Participants will receive tiragolumab and atezolizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
89456485|NCT03518931|No Intervention|Control|This arm included individuals randomized to receiving fitness information only.
89456486|NCT03518931|Experimental|Intervention|This arm included individuals randomized to having fitness assessments performed.
89456487|NCT02395952|Active Comparator|Lubrication|
89016445|NCT04300647|Experimental|Atezolizumab|Participants will receive atezolizumab monotherapy until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
89016446|NCT04291599|Experimental|Experimental Arm - Ketorolac (Opioid-Sparing)|Patients assigned to this arm of the study will follow the standardized step-up approach to pain management per the hospital Evidenced Based Guideline (EBG). If analgesia is not obtained with first-line medications such as acetaminophen, the patient will be given the NSAID ketorolac intravenously every 6 hours at the standard weight-based dose throughout hospitalization. If the patient experiences continued pain, they (or their guardian/ caregiver) may request a rescue medication in the form of low-dose morphine (or an alternative opioid if allergic to morphine) at 0.025 mg/kg/dose every 4 hours.
89016447|NCT04291599|Active Comparator|Control Arm - Conventional Treatment/Standard of Hospital Care|Patients assigned to this arm of the study will be treated per institutional policy and procedural care as dictated by established hospital order sets and at the discretion of the provider. This may involve the step-up approach per the hospital EBG utilizing acetaminophen or ibuprofen as first-line agents; however, it remains at the discretion of the treating provider. The current standard of care for children presenting to the ED is based on prescribing order sets within the electronic medical record (EMR). Physicians in the BCH emergency department choose in an intermittently-prescribed manner, standard doses of analgesia including acetaminophen (Tylenol) or ibuprofen per the hospital EBG, as well as opioids (morphine, hydromorphone).
89016448|NCT04275973|Other|Healthy controls|The Control participants are for methods development and do not constitute a formal study group
89016449|NCT04275973|Experimental|Prosthesis user with transtibial or transfemoral amputation|Experiments will use standard commercially available prostheses for participants with lower-limb amputation. Specific prostheses will be determined at the time of the study, but they will include prostheses that are fully passive such as energy storage-and-return (ESR) feet, ESR feet with mobilized ankles such as passive hydraulic ankles (PHA), and ESR feet with microprocessor-controlled ankles (MPA).
89016450|NCT04275973|Experimental|Orthoses user with drop-foot|"This arm will consists of participants with drop-foot. A subset of the drop-foot population will be persons with Multiple Sclerosis and currently drop-foot.~For participants in this arm, standard commercially-available orthoses or standard-of-care custom orthoses will be used, as well as standard commercially-available electrical stimulation neuro-orthoses."
89016451|NCT04274790||Metastatic colon cancer|Patient with metastatic colon cancer operated on and followed up at the Centre Leon Berard for liver metastasis.
89016452|NCT04274660|Experimental|DWELL Intervention|People with type 2 diabetes participating in the 12-week DWELL (Diabetes and WELLbeing) Programme
89016453|NCT04274660|No Intervention|DWELL non-intervention/Control|People with type 2 diabetes who are receiving routine care from their GP and healthcare team. People with type 2 diabetes will continue to receive routine standard care. Routine care in this respect constitutes usual health and social care or any other nationally or locally commissioned education programmes
89016454|NCT04267393|Experimental|Dose A BMS-986263|
89016455|NCT04267393|Experimental|Dose B BMS-986263|
89016456|NCT04267393|Placebo Comparator|Placebo|
89456488|NCT02395952|Active Comparator|Bandage Contact Lens|Acuvue Oasys Contact Lens
89456489|NCT02395952|Active Comparator|Prokera|Wet amniotic membrane mounted on plastic retaining ring
89456490|NCT02395952|Active Comparator|Ambiodisk|Freeze dried amniotic membrane
89456491|NCT03516903|Active Comparator|Methotrexate & Folic acid|ddMTX-LDE 40mg/m2 (100mL total volume) IV and Folic acid 5mg by mouth (the day after ddMTX-LDE) weekly for 6 weeks
89456492|NCT03516903|Placebo Comparator|Placebo & folic acid|Placebo-LDE IV 100mL and Folic acid 5mg by mouth (the day after Placedo-LDE) weekly for 6 weeks
89456493|NCT05693285||Preterm birth|Women with spontaneous preterm birth in first pregnancy
89456494|NCT05693285||Controls|Matched controls with spontaneous delivery in normal time in first pregnancy
89456495|NCT02292381||Glaucoma Patients|Patients with primary open angle glaucoma
89456496|NCT02292381||Healthy controls|age- and sex matched controls
89456497|NCT05693207|Experimental|People with iPD with freezing of gait|
89456498|NCT05693207|Other|People with iPD without freezing of gait|control group
89456499|NCT02289651|Experimental|Intubation without chest compressions|Endotracheal intubation of pediatric mannikin during resuscitation without chest compressions.
89456500|NCT02289651|Experimental|Intubation with uninterrupted chest compressions|Endotracheal intubation of pediatric mannikin during resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
89456501|NCT02293317|Experimental|M-001 0.5mg & TIV|M-001 (0.5mg) administered intramuscular 3 times at 21 days intervals followed by vaccination with Trivalent Influenza Vaccine (TIV)
89456502|NCT02293317|Experimental|M-001 1.0mg & TIV|M-001 (1.0mg) administered intramuscular 3 times at 21 days intervals followed by vaccination with Trivalent Influenza Vaccine (TIV)
89456503|NCT02293317|Placebo Comparator|Placebo & TIV|0.3ml Saline administered Intramuscular 3 times at 21 days intervals followed by vaccination with Trivalent Influenza Vaccine (TIV)
89456504|NCT03516825|Experimental|Musical Neglect Training (MNT)|A single-subject design was used. All participants took Musical Neglect Training.
89456505|NCT02295501|Experimental|EBOV convalescent donors|EBOV convalescent donors for passive immune therapy in subjects with acute EVD
89456506|NCT02295657|Experimental|ETI intubation|endotracheal intubation in manikin
89456507|NCT03516747|Experimental|investigation group|participants that suffer hypercalcemia due to primary hyperparathyroidism. include all participants in the trial
89456508|NCT03516669|Other|Intraluminal Clarithromycin eradication|20 Patients receive intraluminal Clarithromycin eradication of H. pylori.
89456509|NCT03516669|Other|Oral standard triple therapy|Patients fail to achieve intraluminal eradication of H. pylori will be assigned to the oral antibiotic rescue therapies with triple therapy which contains a proton pump inhibitor and two antibiotics ( amoxicillin, and clarithromycin) for 14 days.
89456510|NCT03521427|Experimental|Intensive bimanual therapy|Ninety hours of intensive bimanual therapy
89016457|NCT04264949|Experimental|group application (GA)|"benefit from conventional care in a rehabilitation center, therapeutic education program and education in the use of the smartphone application mon coach dos"
89016458|NCT04264949|Active Comparator|Groupe conventional care (GCC)|benefit from conventional care in a rehabilitation center and therapeutic education program
89016459|NCT04259229|Experimental|Mushroom intervention|Subjects will be randomized and assigned to consume the Mediterranean Diet with mushrooms for eight weeks.
89016460|NCT04259229|Active Comparator|Control|Subjects will be randomized and assigned to consume the Mediterranean Diet without mushrooms for eight weeks.
89016461|NCT04257045||Observational (interview, survey)|"STEP I: Patients and first degree relatives participate in semi-structure, in-depth interviews about genetic testing over 45-60 minutes.~STEP II: Patients and first degree relatives complete survey questionnaires over 20 minutes."
89016462|NCT04231500||patients with GVHD after allo-HSCT|Exploration of the skin-microbiota in patients with GVHD after allo-HSCT by sampling of skin swabs and a skin punch biopsy before conditioning procedure and additional skin biopsies from affected and healthy skin sites in case of GVHD
89456511|NCT03521427|Active Comparator|Neurodevelopmental treatment|Ninety hours of intensive neurodevelopmental therapy
89456512|NCT02289807|Experimental|RT group|intensity modulated-radiotherapy (IMRT) alone Patients receive intensity modulated-radiotherapy (IMRT) alone
89456513|NCT02289807|Active Comparator|CCRT group|IMRT and concurrent cisplatin Patients receive intensity modulated-radiotherapy (IMRT), concurrently with cisplatin 100 mg/m² every 3 weeks for 3 cycles
89456514|NCT03521349|Placebo Comparator|Egg White Snacks|Egg white-based snacks
89456515|NCT03521349|Experimental|Whole Egg Snacks|Whole egg-based snacks
89456516|NCT02289885|Experimental|normal model patient|Images of the ultrasound window were captured to disk and later evaluated by an expert in emergency medicine. In this study, the FAST examination was measured to the perihepatic space (also called Morison's pouch or the hepatorenal recess), perisplenic space, pericardium, and the pelvis.
89456517|NCT02289885|Experimental|ascites positive model patient|Images of the ultrasound window were captured to disk and later evaluated by an expert in emergency medicine. In this study, the FAST examination was measured to the perihepatic space (also called Morison's pouch or the hepatorenal recess), perisplenic space, pericardium, and the pelvis.
89456518|NCT02298153|Experimental|atezolizumab (MPDL3280A) + epacadostat (INCB024360)|atezolizumab (MPDL3280A) 1200 mg given every 3 weeks + epacadostat (INCB024360) 25 mg BID as starting dose, followed by dose escalations until MTD or PAD is identified
89016463|NCT04231500||patients without GVHD after allo-HSCT|Exploration of the skin-microbiota in patients without GVHD after allo-HSCT by sampling of skin swabs and a skin punch biopsy before conditioning procedure
89456519|NCT03514797|Experimental|Combined technique|A single session of in-office tooth bleaching will be performed with 35% hydrogen peroxide for 45 minutes. Following, the teeth will be further bleached with customized trays filled with 10% carbamide peroxide and used for 1h per day.
89456520|NCT03514797|Active Comparator|At-home bleaching|The teeth will be bleached only with customized trays filled with 10% carbamide peroxide and used for 1h per day.
89456521|NCT02298231|Experimental|Group 1|Standard of Care Balance (SCB) Treatment
89456522|NCT02298231|Experimental|Group 2|Mystic Isle (MI) Balance Training
89456523|NCT02298231|Experimental|Group 3|Mystic Isle (MI) Dual Task Training
88940123|NCT01846468|Experimental|Stage 3: LHW090, Healthy Volunteer|Healthy Volunteers across 6 multiple ascending dose cohorts will be administered LHW090 or matching placebo for 14 days.
88940124|NCT01846468|Experimental|Stage 4: LHW090, Patients|Subjects with Chronic Renal Insufficiency across 3 cohorts will be administered a single dose of LHW090 in Day 1.
88940125|NCT01846520|Experimental|Arm I (FCPCI)|Participants receive FCPCI with an APN, comprising 4 home education sessions once weekly followed by 4 telephone support sessions for 30 minutes once monthly and 24 hour telephone support available for 6 months.
88940126|NCT01846520|No Intervention|Arm II (usual care)|Participants receive usual care.
88940127|NCT01846546||Severe Traumatic Brain Injury|Patients with severe TBI (Glasgow Coma Scale GCS score of 8 or less) requiring continuous lumbar drainage of CSF
88940128|NCT01846559|Experimental|Clopidogrel & Endotoxin|"Clopidogrel (tablet) over 8 days Day 1: 300 mg loading dose Day 2-7: 75 mg orally once daily~E.coli Endotoxin Day 7 - 2 ng/kg"
88940129|NCT01846559|Placebo Comparator|No antiplatelet medication & Endotoxin|"No antiplatelet medication~E.coli Endotoxin Day 7 - 2 ng/kg"
88940130|NCT01846559|Experimental|Ticagrelor & Endotoxin|"Ticagrelor over 8 days (tablet) Day 1: 180 mg loading dose Day 2-7: 90 mg orally twice daily~E.coli Endotoxin Day 7 - 2 ng/kg"
88940131|NCT01846585|Other|ABTI|Arousal Based Therapy for Insomnia
88940132|NCT01846585|Other|CBTI|Cognitive Behavioral Therapy for Insomnia
88940133|NCT01846637|Experimental|2 cm from pylorus|at laparoscopic sleeve gastrectomy the distal point of gastric division is 2 cm from the pylorus.
88940134|NCT01846637|Active Comparator|6 cm from pylorus|at laparoscopic sleeve gastrectomy the distal point of gastric division is 6 cm from the pylorus
88940135|NCT01846650|Experimental|Capecitabine tablets|Single oral Capecitabine tablets 2000mg qd
88940136|NCT01846650|Active Comparator|XELODA|Single oral XELODA 2000mg qd
88940137|NCT01846676|Active Comparator|Program counseling|Active branch, subject to the rehabilitation program
88940138|NCT01846676|Placebo Comparator|No counseling|Passive branch, which was control, with usual management (no intervention).
88940139|NCT01846689|Experimental|ESS|Prescription medical food erythropoietin stimulating system
88940140|NCT01846715|Experimental|NKA Treatment|Patients will receive an implantation of autologous selected renal cells (SRC).
88940141|NCT01846754||Hemodialysis patients|
88940142|NCT01846767|Experimental|Type 2 diabetes|Diabetic patients Oral glucose breath test
88940143|NCT01846767|Experimental|Healthy controls|non-diabetic Oral glucose breath test
88940144|NCT01846780||Venous outflow obstruction lower limb|Patients with unilateral post-thrombotic iliac vein/common femoral vein obstruction undergoing PTA & stenting (possibly with additional endophlebectomy and AV-fistula)
88940145|NCT01846806|Experimental|Rifaximin|Participants in Phase B will be administered 550 mg of Rifaximin two times a day for 14 days.
88940146|NCT01846819||Ambulatory cirrhotic patients|"Severity of liver disease will be assessed through a detailed clinical examination of ascites grade, history of complications from cirrhosis (hepatic coma, spontaneous bacterial peritonitis, gastrointestinal bleeding), laboratory tests (TBili, Albumin, INR, hemoglobin).~Depression will be assessed with the following questionnaires: Beck Depression Inventory (BDI), EQ-5D, Psychological General Well-Being Index (PGWBI), LDQOL.~Fatigue will be assessed with the FIS and 6 Minute Walk Test.~Hepatic Encephalopathy will be assessed with the number connection, digit-symbol coding and inhibitory control test."
88940147|NCT01846832|Experimental|TMC435 + PegIFNα-2a + RBV|TMC435 will be administered as triple therapy with pegylated interferon alfa-2a (PegIFNα-2a) and ribavirin (RBV).
88940148|NCT01846845|Active Comparator|Conventional TF Socket System|Conventional Prosthetic Transfemoral Socket System
88940149|NCT01846845|Experimental|Novel TF Socket System|Novel Prosthetic Transfemoral Socket System
88940150|NCT01846858||CO2 Laser|
88940151|NCT01846858||Monopolar energy|
88940152|NCT01846910|Active Comparator|Motivational Counseling|The extended counseling group will receive one to three, 45-minute individual motivational counseling sessions using a motivational interviewing approach to Express empathy, Develop discrepancy, Roll with resistance, and Support self-efficacy.
88940153|NCT01846910|Experimental|Tooth Whitening Incentive|The tooth whitening group will receive all of the interventions previously described for the Motivational Counseling Group, and as an extra incentive against relapse, will also be offered complimentary tooth whitening procedures if biochemically verified as tobacco-free by Carbon Monoxide monitor (bleaching at 3-weeks, whitening strips at 3-months, and whitening touch-up at 1 year).
88940154|NCT01846923|Experimental|PCV13|
89456524|NCT03518775||Normal Eyes|Eyes with best-corrected visual acuity of 20/20 or better, and lens opacities of 1.0 or less in the study eye using the LOCS III system, and no prior Laser Vision Correction.
89456525|NCT03518775||Cataract Eyes|Cataract in the study eye greater than Grade 1 using the LOCS III system for one or more: nuclear opacity, nuclear color, cortical opacity, or PSC.
89456526|NCT03518775||Post LVC Eyes|History of Laser Vision Correction (LVC)
89456527|NCT03518697|Experimental|Exercise Group|"First 6 months supervised exercise program with telephone contact every two weeks~Second 6 months exercise program without telephone contact~Patients should increase habitual daily physical activity for 10-20 minutes per day 5 times per week~Activities were chosen according to the preferences, interests, and severity of disease of the patients~Activites should improve endurance, strength, coordination and flexibility~Every three month regular vistit at the CF care center (medical examination, lung function, exercise testing, counselling and evaluation of activities by acceleometry and if appropirate adaption of exercise program)"
88940155|NCT01846936|Experimental|DLT with conventional technique|"The double lumen tube is introduced into the glottis under direct laryngoscopy. After the bronchial cuff had passes the vocal cords, the tube is rotated counterclockwise 90° and advanced until a slight resistance was encountered.~One lung ventilation is initiated after the lumen of operative lung is clamped and opened."
88940156|NCT01846936|Active Comparator|BB with conventional technique|"The brochial blocker (BB) is introduced through the endotracheal tube to the desired bronchus under fiberoptic bronchoscopy (FOB) vision by turning the device's steering wheel.~The BB cuff is inflated with air under FOB vision with the volume necessary to seal the bronchus and initiate one lung ventilation. And then, dependent lung is ventilated."
89456528|NCT03518697|No Intervention|Control-Group|"12 months usual routine care and habitual exercise in daily life.~At start and after 12 month assessment of habitual exercise with accelerometry (Actigraph GTX3)"
88940157|NCT01846936|Active Comparator|Disconnection technique|Disconnection technique; 1) before initiating OLV, we turned-off the ventilator and fully opened the adjustable pressure limiting valve allowing both lungs to collapse, and 2) after loss of the carbon dioxide trace on the capnograph, 3) inflated the BB cuff with air, and 4) turned-on the ventilator allowing only dependent-lung reventilation.
89456529|NCT02293473|Experimental|Protocol Group|"Using multimodal monitoring to optimise the patients' haemodynamic status, namely, the use of LiDCO Rapid, BIS-Bispectral Index Monitor and INVOS-Cerebral Oxygenation Monitor monitors to assess and fine tune the patient, as described in the study protocol in detail."
89456530|NCT02293473|Active Comparator|Control Group|Using current standard of care
89456531|NCT02298309|No Intervention|Usual Care|Patients in the usual care arm will be screened for tuberculosis (TB) on a mobile unit and referred for treatment according to the current standard of care in South Africa
89456532|NCT02298309|Active Comparator|Test-and-Treat Intervention|Patients in the intervention arm will partake in a Test-and-Treat TB strategy involving mobile GeneXpert MTB/RIF testing, facilitated TB treatment initiation, SMS reminders for clinic visits, and cashless incentives.
89456533|NCT02298387|Experimental|OMP-305B83|The dose levels of OMP-305B83 will be 0.5, 1.0, 2.5, 5 and 10 mg/kg administered IV once every 3 weeks.
89456534|NCT02295813|Experimental|FBF001|"FBF001 must be administered by intravenous route during 1 hour. The dose must be calculated according to the body weight of the subject and diluted in sodium chloride 0.9%.~FBF001 is administered once during 1 day or once per day during 5 days."
89456535|NCT02295813|Placebo Comparator|Placebo|The placebo must be administered by intravenous route during 1 hour. It administered once during 1 day or once per day during 5 days.
88940158|NCT01846962|Experimental|six-foods elimination diet|six-foods elimination diet. The standard panel of foods tested included the 6 most common allergenic foods in childhood (cow's milk, egg, soy, wheat, peanuts, fish), plus foods that were suspiciously implicated in triggering an allergic reaction referred by patients or their parents. Both perennial (dust mite, Parietaria, Alternaria, cat and dog dander) and seasonal (grass pollen including Graminaceae, Olea europea, Platanus) aeroallergens have been tested.
88940159|NCT01846962|Experimental|fluticasone|The administered dose of topical steroid was 440mcg or 880mcg/day (<150 cm or >150 cm). Patients were trained to swallow puffs and to non eat or drink fo 30 minutes after ingestion. Patients noncompliant with therapy, monthly assessed by Pediatric Allergologists, were withdrawn from the study.
88940160|NCT01846962|Experimental|Budesonide|The administered dose of topical steroid was 400mcg/day or 800 mcg/day (<150 cm or >150 cm). Patients were trained to swallow puffs and to non eat or drink fo 30 minutes after ingestion. Patients noncompliant with therapy, monthly assessed by Pediatric Allergologists, were withdrawn from the study.
88940161|NCT01846962|Experimental|Oral Viscous Budesonide (OVB)|The administered dose of topical steroid was 1 or mg/day (<150 cm or >150 cm). Patients were trained to prepare a homemade suspension of OVB prepared by mixing inhaled budesonide with viscous solutions of sodium alginate and to non eat or drink fo 30 minutes after ingestion. Patients noncompliant with therapy, monthly assessed by Pediatric Allergologists, were withdrawn from the study.
88940162|NCT01846975|Experimental|Switch from SC to IV Abatacept and back|Transition from weekly SC- to a single IV-Abatacept but also the return to weekly SC treatments after a 4 week break.
88940163|NCT01847040||TBI while Deployed|Active duty service members returning from Afghanistan or Iraq who were screened positive for Mild TBI
88940164|NCT01847040||No TBI while Deployed|Active duty service members returning from Afghanistan or Iraq who screened negative for mild TBI.
88940165|NCT01847053|Placebo Comparator|Oatmeal control|Oatmeal control, around 70g; without cinnamon
88940166|NCT01847053|Active Comparator|Ground cinnamon, 3g|3 g ground cinnamon in Oatmeal (~70 g)
88940167|NCT01847053|Active Comparator|Cinnamon extract, 3 g|3 g cinnamon extract in Oatmeal (~70 g)
89456536|NCT02293551|Experimental|Part A: Lispro (A)|Formulation A: Single dose of lispro administered subcutaneously (SC) in one of five periods.
89456537|NCT02293551|Experimental|Part A: Lispro (B)|Formulation B: Single dose of lispro administered SC in one of five periods.
89456538|NCT02293551|Experimental|Part A: Lispro (C)|Formulation C: Single dose of lispro administered SC in one of five periods.
89456539|NCT02293551|Experimental|Part A: Lispro (D)|Formulation D: Single dose of lispro administered SC in one of five periods.
89456540|NCT02293551|Experimental|Part A: Lispro (Reference)|Reference formulation: Single dose of lispro administered SC in one of five periods.
89456541|NCT02293551|Experimental|Part B: Lispro|Formulation selected from Part A. Single dose of lispro administered SC in one of four periods.
89456542|NCT03518541|Active Comparator|Goniometer|FDO: classic procedure with goniometer controlled derotation
89456543|NCT03518541|Experimental|EMT|FDO: procedure with electromagnetic tracking (EMT) controlling derotation
89456544|NCT02298543||coronary spasm|
88940168|NCT01847053|Active Comparator|Cinnamon extract, 6 g|6 g cinnamon extract in Oatmeal (~70 g)
88940169|NCT01847066|Active Comparator|Erbium plus cosmetics plus Impact|Erbium 2940 plus cosmetics plus Impact Patient shall be treated with erbium 2940nm laser, cosmetics and the Impact.
88940170|NCT01847066|Active Comparator|Erbium 2940 plus cosmetics|Erbium 2940 plus cosmetics Patient shall be treated with erbium 2940nm laser, cosmetics
89456545|NCT03518463|Experimental|Intervention|"ERAS arm received;~Preoperative:1. Intravenous (IV) cefazoline 1g 2. IV metoclopromide 10mg, dexamethasone 8mg, ranitidine 150mg~Intraoperative: 1. Hyperbaric bupivacaine 10-15mg plus intrathecal morphine 100mcg 2. Adrenaline 100mcg in 500ml of ringers lactate 3. Individualized goal directed fluid therapy 4. Reinforced counseling and education 5. wound infiltration with isobaric bupivacaine 2mg/kg 6. Rectal diclofenac 100mg and misoprostol 400mcg stat~Postoperative:~Feeding within 1 hour~urethral catheter removal at 6-8 hours~Mobilization at 8-10 hours~A single fixed dose combination of ibuprofen 400 mg and paracetamol 500 mg 8 hourly~Tablets Amoxicillin-clavulunate 850mg 12 hourly"
89456546|NCT03518463|Active Comparator|Control|"Standard care arm received;~IV ceftriaxone 2g or ampiclox 2g~Anesthetists administered IV fluids, vasopressors, and managed hypothermia based on their clinical impressions.~Oral feeding and breastfeeding were allowed any time after transfer to postnatal ward.~Urethral catheters were removed between 12-24 hours after surgery.~Ward nurses and obstetricians made decisions regarding treatment without study staff input or oversight."
88940171|NCT01847066|Active Comparator|Erbium 2940 plus cosmetics plus Impact|Patient shall be treated with erbium 2940nm laser, cosmetics and the Impact.
89456547|NCT02298621|Experimental|pomegranate juice|pomegranate juice: 500 ml
89456548|NCT02298621|Placebo Comparator|placebo|sugar + aroma+ color: 500ml
89456549|NCT02293629|Placebo Comparator|A1: BMS-986147 or Placebo matching BMS-986147|Single oral dose as specified
88940172|NCT01847066|Active Comparator|Erbium 2940nm plus cosmetics|Patients shall be treated with Erbium 2940nm laser plus cosmetics only.
88940173|NCT01847079|Other|Intervention group, procalcitonin|procalcitonin to guid obtaining bloodcultures in the ICU
89456550|NCT02293629|Placebo Comparator|A2: BMS-986147 or Placebo matching BMS-986147|Single oral dose as specified
89456551|NCT02293629|Placebo Comparator|A3: BMS-986147 or Placebo matching BMS-986147|Single oral dose as specified
89456552|NCT02293629|Active Comparator|B1: BMS-986147 or Placebo matching BMS-986147|Daily oral dose as specified
89456553|NCT02293629|Active Comparator|B2: BMS-986147 or Placebo matching BMS-986147|Daily oral dose as specified
89456554|NCT04465149|Experimental|Patients|Patients who required germectomy of mandibular third molars. Each patient received local anaesthesia on one side with articaine inoculated with plexus technique while on the other side with mepivacaine using inferior alveolar nerve block technique.
88940174|NCT01847079|No Intervention|Control group, ICIS, procalcitonin|Measurement of PCT and ICIS.
88940175|NCT01847105|Experimental|RevitaLens|AMO's RevitaLens contact lens solution
88940176|NCT01847118|Experimental|Sevacizumab|2mg/kg、5mg/kg、7.5mg/kg、10mg/kg、12.5mg/kg、or 15mg/kg. d1, d29, d43, d57
89016464|NCT04208802||Smokers|Volunteers smoking at least 10 cigarettes per day
89456555|NCT03516435|Experimental|Parasacral transcutaneous ES|20min./session, 2 sessions/week ,12 sessions of Parasacral transcutaneous electrical stimulation.
89456556|NCT03516435|Active Comparator|Intravaginal electrical stimulation|20min./session, 2 sessions/week ,12 sessions of Intravaginal electrical stimulation.
89456557|NCT02298855|No Intervention|Conventional follow-up|Treatment as usual will involve: one post treatment appointment then 3 monthly appointments with a Dr. At appointments: medical history; investigations to monitor disease progression including CA125 tumour marker blood test if this were raised at diagnosis. A physical examination may be performed.
89501816|NCT02750761|Experimental|Group 1 Cohort 1: Tedizolid IV 5 mg/kg (6 to <12 years)|Participants 6 to <12 years of age received a single intravenous infusion of tedizolid phosphate dosed at 5 mg/kg of total body weight. Maximum dose is 200 mg of tedizolid phosphate.
88940177|NCT01847144|Active Comparator|Gliclazide - Sitagliptin|Gliclazide 80mg OD and Sitagliptin 100mg OD
88940178|NCT01847144|Active Comparator|Sitagliptin - Gliclazide|Gliclazide 80mg OD and Sitagliptin 100mg OD
89016465|NCT04208802||Non-smokers|Non-smoking volunteers
89016466|NCT04207086|Experimental|6 wk pembrolizumab & lenvatinib, surgery, 46 wk pembrolizumab|Neoadjuvant pembrolizumab & lenvatinib for 6 weeks followed by definitive surgery then adjuvant pembrolizumab alone for 46 weeks.
89456558|NCT02298855|Experimental|Individualised follow-up|Follow-up is delivered by a nurse and frequency and type (telephone or face-to-face) is negotiated to suit their individual situation. Assessment by holistic guide. The intervention is informed by a model of health promoting interactions oriented towards improving self-efficacy. The nurses will provide information and support to help patients manage symptoms and psychological discomfort.
88940179|NCT01847157|Experimental|tDCS & epidermis anesthesia & repeated passive movement|"The patients in the experiment group will receive multi-strategy combination treatment mode- combined tDCS and sensory input regulation treatment mode, including bilateral tDCS , epidermis anesthesia in the proximal hand of affected side and in the distal hand of unaffected side , and repeated passive movement training for the hand of affected side.~Treatment modes are 3 times a week, 30 minutes each time, lasting for 8 weeks, and totally 24 trainings. The treatment content of each strategy is separately described in the following."
89456559|NCT03518385||Patients with intracavitary fluid|to evaluate the correlation between the presence of intracavitary fluid during hormonal stimulation for IVF depending on the position of C-section-scar and the presence of an isthmocele, this group patients will have intracavitary fluid.
89456560|NCT03518385||Patients without intracavitary fluid|to evaluate the correlation between the presence of intracavitary fluid during hormonal stimulation for IVF depending on the position of C-section-scar and the presence of an isthmocele, in this group patients will not have intracavitary fluid.
89456561|NCT02299011|Experimental|Orsiro drug eluting stent|Orsiro drug eluting stent
89456562|NCT02299011|Active Comparator|Biomatrix drug eluting stent|Biomatrix drug eluting stent
89456563|NCT02296047|Experimental|Group A|The medication order: subjects inhaled placebo,ipratropium bromide 80μg, salbutamol 400μg in sequence.
89456564|NCT02296047|Experimental|Group B|The medication order: subjects inhaled placebo, salbutamol 400μg, ipratropium 80μg in sequence.
89456565|NCT02293707|Experimental|GX301 Regimen A (8 administrations)|Administration time frame: Day 1 to Day 63.
89456566|NCT02293707|Experimental|GX301 Regimen B (4 administrations)|Administration time frame: Day 1 to Day 63.
89456567|NCT02293707|Experimental|GX301 Regimen C (2 administrations)|Administration time frame: Day 1 to Day 63.
89456568|NCT03514407|Experimental|INCB059872|INCB059872
89456569|NCT03516357||low myopia|-3.00D < spherical equivalent refractive error < -0.50D
89456570|NCT03516357||moderate myopia|-6.00D < spherical equivalent refractive error ≤ -3.0D
89456571|NCT03516357||high myopia|spherical equivalent refractive error ≤ -6.0D
88940180|NCT01847157|Sham Comparator|Shame tDCS & sham anesthesia & repeated passive movement|"the control group is repeated passive movement stimulation, including sham bilateral tDCS, sham epidermis anesthesia in the proximal hand of affected side and in the distal hand of unaffected side, and repeated passive movement training for the hand of affected side.~Treatment modes are 3 times a week, 30 minutes each time, lasting for 8 weeks, and totally 24 trainings. The treatment content of each strategy is separately described in the following."
88940181|NCT01847170|Experimental|Fecal Microbial Transplantation|
88940182|NCT01847183|Experimental|Click City®: Alcohol|Receive the Click City®: Alcohol program as part of their school curriculum.
88940183|NCT01847183|No Intervention|Usual Curriculum|Students receive their usual alcohol curriculum
88940184|NCT01847222|Experimental|SANGUINATE™|PEG-bHb-CO
88940185|NCT01847222|Placebo Comparator|Normal Saline Solution|Saline Solution
88940186|NCT01847235|Experimental|Temozolomide|Temozolomide 200 mg/m2/d in a fasting state for 5 consecutive days
88940187|NCT01847248||sepsis|Patients with sepsis but not severe sepsis
88940188|NCT01847248||Severe sepsis|Patients with severe sepsis
88940189|NCT01847248||SIRS|Patients with SIRS after major orthopedics surgery
88940190|NCT01847248||Control|Healthy volunteers
88940191|NCT01847261|Experimental|Soy Dairy Protein Blend|30 grams of Soy Dairy Protein Blend given as a single beverage following leg resistance exercise
88940192|NCT01847261|Active Comparator|Positive Control (Dairy Whey Protein)|30 grams of Dairy Whey Protein will be given as a single beverage following leg resistance exercise
88940193|NCT01847287||Tysabri|All subjects took Tysabri and also had an MRI which we use for the baseline evaluation. Over 5 years, some patients remained on Tysabri, some started another drug and others were off Tysabri for a time but then restarted.
88940194|NCT01847300|Experimental|cSBI-M|Participants in this group will complete the cSBI-M screening and brief intervention program
88940195|NCT01847300|No Intervention|Treatment as Usual|Participants in this group will receive treatment as usual.
88940196|NCT01847339|Experimental|bupivacaine soaked sponges|Patients will be randomized using a reproducible set of computer-generated random numbers. In study group a 1 square centimeter piece of absorbable gelatin sponge will be soaked in the bupivacaine solution %0.25 and then will be placed by the surgeon in the epidural space before final closure
88940197|NCT01847339|Placebo Comparator|saline soaked sponges|Patients will be randomized using a reproducible set of computer-generated random numbers. In study group a 1 square centimeter piece of absorbable gelatin sponge will be soaked in saline solution and then will be placed by the surgeon in the epidural space before final closure.
89456572|NCT01162109|Placebo Comparator|Severe sepsis without zinc|Mechanically ventilated patients with severe sepsis will be randomized to receive IV zinc or placebo
89456573|NCT01162109|Experimental|Zinc in severe sepsis|Mechanically ventilated patients with severe sepsis will be randomized to receive IV zinc or placebo
89016467|NCT04191135|Experimental|Pembrolizumab + Olaparib|This arm includes participants who randomized following completion of the induction period. After the induction period, participants received pembrolizumab 200 mg intravenously on Day 1 of each 21-day cycle plus olaparib 300 mg orally twice daily during the post-induction period.
89016468|NCT04191135|Experimental|Pembrolizumab + Carboplatin + Gemcitabine|This arm includes participants who randomized following completion of the induction period. Participants continued to receive both carboplatin AUC 2 with gemcitabine 1000 mg/m^2 intravenously on Days 1 and 8 of each 21-day cycle in addition to pembrolizumab 200 mg intravenously on Day 1 of each 21-day cycle in the post-induction period.
89016469|NCT04189770||Observational (questionnaire, accelerometer, EMA, survey)|Patients and partners complete questionnaires over 60 minutes about demographic information, stress, coping, and lifestyle behaviors at baseline and end of study. Patients and partners also receive an accelerometer and complete EMA questionnaire on stress, coping, physical activity, and eating behaviors over 5-10 minutes QID (7:30 am, 11:30 am, 3:30 pm, and 7:30 pm) via an smartphone app for 14 days. Patients and partners also complete a survey on nutrition BIW for a total of 4 surveys.
89016470|NCT04169217|No Intervention|Control arm|This arm will not be in the prehabilitation group- as is current standard practice
89456574|NCT01162109|Experimental|Healthy Volunteers receiving zinc|Cohort of healthy volunteers will receive a single dose of 500 mcg/kg IBW IV zinc and pharmacokinetics will be measured for 8 hours. PK in sepsis patients and healthy volunteers will be compared.
89456575|NCT02296203|Experimental|cetuximab and irinotecan|
89456576|NCT03626207||Retinitis pigmentosa|Retinitis pigmentosa patients with severe visual impairment
89456577|NCT03514251|No Intervention|Control group|Routine thyroidectomy and central lymph node dissection
89456578|NCT03514251|Experimental|Parathyroid marker group|When the lower parathyroid gland is first seen, the parathyroid gland is sutured with a suture during the operation, and then during this subsequent cleaning, rapid parathyroid localization and parathyroid glands are performed through this marker.
89456579|NCT03518229|Experimental|Intervention|Microsoft Band 2 application with UV messaging activated
89456580|NCT03518229|Active Comparator|Control|Microsoft Band 2 application (UV messaging not active)
89456581|NCT05504525|Active Comparator|Fascia iliaca block for postoperative pain management in hip arthroplasty|
89456582|NCT05504525|Active Comparator|Quadratus lumborum block for postoperative pain management in hip arthroplasty|
89456583|NCT03518151|Experimental|Intervention|The intervention includes 3 components: i) creation of a new fresh fruit and vegetable section at store entrance; ii) placing frozen fruit and vegetables in the first aisle and iii) removal of all cakes, confectionary and sugar sweetened beverages from checkouts (replaced with non-food items, fruit and bottled water).
89456584|NCT03518151|Sham Comparator|Control|The control condition is provision of a limited range of fresh fruit and vegetables, all placed at the back of the store, frozen vegetables in a middle aisle and confectionery sold at checkouts.
89456585|NCT03514095|No Intervention|Control Group|The control group shall participate in the usual home-based care provided by their carer.
89456586|NCT03514095|Experimental|Individual Cognitive Stimulation Therapy|The experimental group shall participate in the Making a Difference 3 program (Yates et al., 2015) is aimed at elderly people with mild or major neurocognitive disorder, where informal caregiver (family, friend or neighbour) assume a partnering role in an one-to-one approach. The program is composed by a range of stimulating activities (sessions), each with two levels of difficulty. The carers are introduced to a set of key principles that guides them during individual cognitive stimulation sessions, tailoring the interventions to the needs and reality of the elderly participants.
89456587|NCT03516201||obese patients after bariatric surgery|obese adults (≥ 18 years) who underwent bariatric surgery
89456588|NCT03516201||obese adultes without bariatric surgery|obese adults (≥ 18 years) who did not underwent bariatric surgery at the time of the examination
89016471|NCT04169217|Active Comparator|Group 2|This arm will be subject to a one off prehabilitation workshop and provided with a prehab booklet
89016472|NCT04169217|Experimental|Group 3- Mentored group|This arm will be subject to a one off workshop and provided with a prehab booklet- and additional mentoring by means of 1. an educational app, 2. push notifications,3. weekly communication with physiotherapy team member.
89016473|NCT04164173|Experimental|EzPAP|The patient will have EzPAP postoperative respiratory therapy as 3 x 10 breaths at a 1:4 ratio four times daily
89016474|NCT04164173|Experimental|Metaneb|The patient will have Metaneb postoperative respiratory therapy as 10 minutes Continuous Positive End Expiratory Pressure (CPEP) four times daily
89456589|NCT02294097|No Intervention|Non-biopsy|Population in this arm will be adjusted immunosuppressive drug only from the result of tough level.
89456590|NCT02294097|Experimental|Protocol biopsy|Population in this arm will be adjusted immunosuppressive drug upon both pathological findings and the result of tough level.
89456591|NCT02302443|Experimental|Cohort 1|Very low dose of HM12470 (single dose, subcutaneous injection)
89456592|NCT02302443|Experimental|Cohort 2|Low dose of HM12470 (single dose, subcutaneous injection)
89456593|NCT02302443|Experimental|Cohort 3|Intermediate dose of HM12470 (single dose, subcutaneous injection)
89016475|NCT04164173|Experimental|Intermittent Positive Pressure Breathing (IPPB)|The patient will have Intermittent positive pressure breathing (IPPB) postoperatively for 10 minutes four times daily
89456594|NCT02302443|Experimental|Cohort 4|High dose of HM12470 (single dose, subcutaneous injection)
89456595|NCT02302443|Experimental|Cohort 5|Active comparator and a selected dose of HM12470 (single dose, subcutaneous injection)
89456596|NCT02302443|Experimental|Cohort 6|Active comparator and a selected dose of HM12470 (single dose, subcutaneous injection)
89456597|NCT03516123|Experimental|CS3006|Participants will receive CS3006 orally at specified dose on specified days
89456598|NCT03132597|Experimental|Early Mindfulness exposure|six weeks of 2 hours class of mindfulness training and orientations for home training at the beginning of the first semester
89456599|NCT03132597|Experimental|Late Mindfulness exposure|six weeks of 2 hours class of mindfulness training and orientations for home training at the second half of the first semester
89456600|NCT03132597|No Intervention|Control (not exposed)|Students not exposed to the mindfulness mandatory course (not exposed to the intervention)
89456601|NCT02296281|Experimental|treatment group|
89456602|NCT03513861|Experimental|Aim 1: Parental FASTER tool training|The goal is to see whether the child's parent/ guardian can be trained in overall severity of illness assessment using the FASTER Tool, to match the performance of a professional.
89456603|NCT03513861|Active Comparator|Aim 2: Intervention group|The intervention group parents will be taught the FASTER assessment tool. Intervention group parents will each be asked to monitor their own hospitalized child hourly using the FASTER assessment tool, and put up color-coded flags indicating severity of illness to the healthcare team. Parents will record the frequency of healthcare provider assessments of their child over the 24 hour intervention period.
89456604|NCT03513861|No Intervention|Aim 2: Control Group|The control group parents will not be taught the FASTER assessment tool. Hence they will not be involved in monitoring their child, nor signaling severity of their child's illness per color-coded flag system. Control group parents will record the frequency of healthcare provider assessments of their child over the 24 hrs enrollment period.
89456605|NCT02299245|Experimental|randomised to rosuvastatin (20mg/d)|randomised to rosuvastatin (20mg/d)
89456606|NCT02299245|Active Comparator|randomised to rosuvastatin (10mg/d)|randomised to rosuvastatin (10mg/d)
89456607|NCT02302521||Healthy Younger Adults|Age: 20-30. Gender: male or female. No neurological conditions.
89456608|NCT02302521||Healthy Older Adults|Age: 50-70. Gender: male or female. No neurological conditions.
88940198|NCT01847352|Other|Iron-deficient|Healthy volunteers meeting iron-deficient entry criteria; Intravenous administration of ferric carboxymaltose; Subacute hypoxic exposures
88940199|NCT01847352|Other|Iron-replete|Healthy volunteers meeting iron-replete entry criteria; Intravenous administration of ferric carboxymaltose; Subacute hypoxic exposures
88940200|NCT01847365|Experimental|Retinitis Pigmentosa|Transcorneal electrical stimulation (TES) administered to one eye for 6 months, followed by monitoring period without treatment for 6 months.
88940201|NCT01847378||Catheter ablation|Patients with chronic chagasic disease and documented monomorphic ventricular tachycardia
88940202|NCT01847391|Experimental|Cohort 1|Randomized to 6 mg once daily (Days 1-7) followed by 3 mg once daily (Days 8-21) of GS-6615 or matching placebo
88940203|NCT01847391|Experimental|Cohort 2|Randomized to 12 mg once daily (Days 1-7) followed by 6 mg once daily (Days 8-21) of GS-6615 or matching placebo
88940204|NCT01847391|Experimental|Cohort 3|Randomized to 20 mg once daily (Days 1-7) followed by 9 mg once daily (Days 8-21) of GS-6615 or matching placebo
88940205|NCT01847404|Experimental|Overall Study Arm|All the subjects in this study will take part in 3 treatment periods with one of the following treatments in each period. Subjects will receive all three treatments (one per period) in a random order after an overnight fasting of at least 10 hours fast in each period. Test 1= Fixed dose combination (FDC) formulation one of a capsule containing ASA 100 mg and pantoprazole 20 mg. Test 2= FDC formulation two of a capsule containing ASA 100 mg and pantoprazole 20 mg. Reference= ASA 100 mg tablet + pantoprazole 20 mg gastro-resistant tablet
88940206|NCT01847417|Experimental|Overall Study Arm|"All the subjects in this study will take part in 3 treatment periods with one of the following treatments in each period. Subjects will receive all three treatments (one per period) in a random order in fed condition.~Test 1= Fixed dose combination (FDC) formulation one of a capsule containing ASA 100 mg and pantoprazole 20 mg. Test 2= FDC formulation two of a capsule containing ASA 100 mg and pantoprazole 20 mg. Reference= ASA 100 mg tablet + pantoprazole 20 mg gastro-resistant tablet"
88940207|NCT01847456|Experimental|insulin nasal spray|160 Units of human insulin as nasal spray
89456609|NCT02302521||Parkinson's disease|Gender: male or female. Tremor dominant Parkinson's disease.
89456610|NCT02302521||Healthy Children|Age: 4-8. Gender:male or female. No neurological conditions.
89456611|NCT02296359||Asthma Discordant Monozygotic Twins|This is a group where one of the monozygotic twins has asthma and the other is non-asthmatic. Influenza Vaccination will be performed for both cohorts.
89456612|NCT02296359||Non-Asthma Concordant Monozygotic Twins|This is a group where both of the monozygotic twins are non-asthmatic. Influenza Vaccination will be performed for both cohorts.
89456613|NCT02302599|Experimental|Umbilical cord mesenchymal stem cells|Patients receive Umbilical cord mesenchymal stem cells intravenous infusion for three times with an interval of 4 weeks in the absence of disease progression or unacceptable toxicity
89456614|NCT02302599|Experimental|Controlled suspension liquid|Patients receive Controlled suspension liquid
89456615|NCT03513627||Implant|Post-occlusive reactive hyperaemia test (PORH test) in the gingiva at a dental implant born crown in the front region of the jaw
89456616|NCT03513627||Tooth|Post-occlusive reactive hyperaemia test (PORH test) in the gingiva at the contralateral natural tooth
89456617|NCT03513549||Loxapine 10 MG|ADASUVE (loxapine) inhalation powder in a 10-milligram (mg) single-use oral inhaler. One dose in a 24-hour period.
89456618|NCT03513471|Experimental|Anakinra then Placebo Treatment|Subjects randomized to this arm will receive the experimental treatment of Anakinra on their first exposure to the Dermatophagoides Farinae (dust mite) allergen challenge, followed by the Anakinra matching placebo on their second exposure.
88940208|NCT01847456|Placebo Comparator|Placebo nasal spray|Nasalspray containing placebo solution
88940209|NCT01847482|Experimental|Therapeutic Hypothermia|
88940210|NCT01847495|Experimental|Low-Dose Irinotecan & CyberKnife SBRT|Irinotecan 40mg/m2 x 3-5 days + CyberKnife SBRT 45-60Gy x 3-5 fractions
88940211|NCT01847508|Active Comparator|PHILOS +|Proximal Humeral Internal Locking System with screw tip augmentation (PHILOS+) with high viscous polymethylmethacrylate (PMMA) cement (Traumacem V+).
88940212|NCT01847508|Active Comparator|PHILOS|Proximal Humeral Internal Locking System (PHILOS)
88940213|NCT01847521|Experimental|Capsule containing Luteolin, Quercetin, and Rutin|One capsule containing Luteolin (100 mg/capsule), Quercetin (70 mg/capsule), and Rutin (30 mg/capsule). 1 capsule per 10 kg weight per day with food
88940214|NCT01847534|Other|Standard Care|Standard care: Nutrition will be managed as per best practice and local policy including the use of small bowel feeding tubes, prokinetics and PN if required to meet nutrition needs.
88940215|NCT01847534|Experimental|Supplemental PN|"Supplemental PN to complete inadequate EN provision~Patients allocated to the supplemental PN (intervention) group will have PN commenced within 2 hours of randomisation. The starting dose of PN will be determined by the amount of energy received in the 24 hours prior to randomisation.~EN will be managed as per local protocol however EN must not be reduced based on the supplemental PN being administered.~The adequacy of nutrition provision from both PN and EN will be assessed at midday each day for 7 days or until ICU discharge. The dose of PN will be adjusted according to a prespecified schedule."
88940216|NCT01847586|Experimental|Alzheimer's disease-rPAS|The intervention procedure will done in this group is r-Paired Associative Stimulation. This involves the repetitive pairing of electrical stimulation of the median nerve with - 25 ms later - transcranial magnetic stimulation (TMS) of the contralateral DLPFC
88940217|NCT01847586|Placebo Comparator|Alzheimer's disease-rPAS-C|The intervention procedure being done with this group is PAS-C. This is a control Paired Associative Stimulation paradigm in which TMS to the left DLPFC follows the electrical stimulation of the right median nerve by 100 ms, and, thus, does not result in contemporaneous occurrence of the two stimulations in the cortex and consequently no LTP.
89456619|NCT03513471|Experimental|Placebo then Anakinra Treatment|Subjects randomized to this arm will receive the inactive placebo on their first exposure to the Dust Mite Allergen challenge, followed by the experimental treatment of Anakinra on their second exposure.
88940218|NCT01847586|Other|Control|Controls will have a one time Paired Associative Stimulation-Control (PAS-C) paradigm intervention in which TMS to the left DLPFC follows the electrical stimulation of the right median nerve by 100 ms, and, thus, does not result in contemporaneous occurrence of the two stimulations in the cortex and consequently no LTP.
88940219|NCT01847599|Other|capecitabine|patients treated by capecitabine alone (n=100)
88940220|NCT01847599|Other|capecitabine + lapatinib|patients treated by capecitabine and lapatinib (n=100)
88940221|NCT01847612|Experimental|indocyanine green fluorescent cholangiography|use of indocyanine green fluorescent cholangiography in the patients of this arm, an indocyanine green fluorescent cholangiography is performed
88940222|NCT01847612|Active Comparator|methylene blue|injection of methylene blue during the surgery
89456620|NCT02296437|Experimental|tDCS + CT|
89456621|NCT03516045|Experimental|18F-AlF-NOTA-neurotensin PET/CT|One injection of the radioligand 18F-AlF-NOTA-neurotensin Device: PET/CT Following injection of 18F-AlF-NOTA-neurotensin the participants will be subjected to whole body PET/CT
89456622|NCT03515967|Experimental|Injured Athletes|Athletes tested for mild traumatic brain injury (mTBI) after injury using the I-PAS goggles
89456623|NCT03515967|Active Comparator|Non-Injured Athletes|Athletes tested for mild traumatic brain injury (mTBI) with no injury using the I-PAS goggles
89456624|NCT02302755|Experimental|Screening/ Active Treatment Arm|"Screening Period: This includes diagnosis confirmation, consent, required tests and vaccinations.~Treatment Period: All patients will be enrolled through the University of Iowa. This study will follow a patient-specific TP10 dose-escalation scheme during the Induction Period and subsequent dose adjustments based on complement levels during the Maintenance Period"
89456625|NCT03513393|Experimental|A: Epclusa + omeprazole + Coca Cola (test 1)|Day 1 - 6 40mg omeprazole QD; on Day 5 a single-dose of SOF/VEL with 250 mL of Coca Cola Classic is administered (test 1).
89456626|NCT03513393|Experimental|B: Epclusa + omeprazole + water (test 2)|Day 8 - 13: 40mg omeprazole QD; on Day 12 a single-dose of SOF/VEL is administered (test 2).
89456627|NCT03513393|Active Comparator|C: Epclusa + water (Reference)|Day 15 - 21: no treatment with omeprazole; on Day 19 a single-dose of SOF/VEL is administered (reference).
89456628|NCT02302911||Early intensive behavioral intervention|Children with a diagnosis of Autism Spectrum Disorder under the age of 5 years that are receiving early intensive behavioral Intervention at one of the participating centres.
89456629|NCT02302911||Early intensive eclectic intervention|Children with a diagnosis of Autism Spectrum Disorder under the age of 5 years that are receiving early intensive eclectic Intervention at the participating centre.
89456630|NCT02302911||Control group|Children with a diagnosis of Autism Spectrum Disorder under the age of 5 years that are receiving treatment as usual or no treatment at all.
89456631|NCT02299401|Experimental|Buccal|Women randomized to receive three 800 mcg doses of misoprostol taken buccally in three hour intervals. All women receive a semi-quantitative pregnancy test for at-home follow up.
89456632|NCT02299401|Experimental|Sublingual|Women randomized to receive three 800 mcg doses of misoprostol taken sublingually in three hour intervals. All women receive a semi-quantitative pregnancy test for at-home follow up.
89456633|NCT03513315|Experimental|Intervention Community Clusters|For the community-based arm of the study, 16 clusters will be randomized into intervention and control groups. Those in the intervention group will receive implementation of community-based Home Heat Bundle. This Bundle includes education from community health workers on the signs and symptoms of heat-related illness, how to prevent the illness, and when to seek treatment. In addition, the intervention group will receive SMS messaging with information about heatwaves. The education and Short Message Service (SMS) messaging will occur in March and April via meetings in households and in public spaces. There will be a total of 40 activities, each lasting approximately two hours.
89456634|NCT03513315|Experimental|Control Community Clusters|Eight community clusters of 1000 population each where regular community-based healthcare services will be provided without focused interventions on identification and management of heat-related illnesses. These clusters will receive regular community healthcare provision.
89456635|NCT02699450|Active Comparator|Arm A: 0.3 mg Ranibizumab|Participants will receive 0.3 milligrams (mg) ranibizumab every fourth week up to Week 20, for a total of 6 administrations, followed by an observational period up to Week 36. If a participant meets pre-specified criteria the participant will receive a single dose of 0.3 mg ranibizumab and exit the study.
89456636|NCT02699450|Experimental|Arm B: 1.5 mg Faricimab|Participants will receive 1.5 mg faricimab every fourth week up to Week 20, for a total of 6 administrations, followed by an observational period up to Week 36. If a participant meets pre-specified criteria the participant will receive a single dose of 0.3 mg ranibizumab and exit the study.
88940223|NCT01847651|Active Comparator|LOLA|"Other Names:~Hepa-Merz Granulat 3000 Hepa-Merz granules 3g (Each 5g sachet contains 3g of L-ornithine L-aspartate) L-ornithine L-aspartate LOLA~Randomised to a daily dose 18g per day, two sachets of Hepa-Merz granules three times a day (or placebo)"
88940224|NCT01847651|Placebo Comparator|Placebo|
88940225|NCT01847664|Experimental|Rifamycin SV-MMX® 400 mg b.i.d.|Rifamycin SV-MMX® 800 mg
88940226|NCT01847664|Experimental|Rifamycin SV-MMX® 600 mg t.i.d.|Rifamycin SV-MMX® 1800 mg
88940227|NCT01847664|Placebo Comparator|Rifamycin SV-MMX® Placebo|Rifamycin SV-MMX® placebo
88940228|NCT01847677|Active Comparator|Paclitaxel & Carboplatin|"Preoperative treatment Cycle 1 to 4 (4 cycles every 3 weeks of chemotherapy pre-surgery)~Carboplatin AUC 6 i.v. first day~Paclitaxel 175 mg/m2 i.v. first day~Surgery~Post-Operative treatment~Cycle 5 to 7 (3 cycles every 3 weeks of chemotherapy post-surgery):~Carboplatin AUC 6 i.v. first day~Paclitaxel 175 mg/m2 i.v. first day~Bevacizumab 15 mg/Kg i.v. first day1~When the chemotherapy treatment is completed, the patient will continue with maintenance bevacizumab until 15 months length treatment."
88940229|NCT01847677|Experimental|Paclitaxel & Carboplatin & Bevacizumab|"4 cycles every 3 weeks (at least 3 Bevacizumab neoadjuvant cycles): Carboplatin AUC 6 i.v. first day Paclitaxel 175 mg/m2 i.v. first day Bevacizumab 15 mg/Kg i.v. first day.~b) Surgery Ovarian cancer surgery should be performed according to FIGO guidelines.~c) Postoperative treatment~Both arms:~Cycle 5 to 7 (3 cycles every 3 weeks of chemotherapy post-surgery):~Carboplatin AUC 6 i.v. first day Paclitaxel 175 mg/m2 i.v. first day Bevacizumab 15 mg/Kg i.v. first day.~When the chemotherapy treatment is completed, the patient will continue with maintenance bevacizumab until 15 months length treatment."
88940230|NCT01847690|Placebo Comparator|Placebo|Treatment B is placebo (2 placebo tablets).
88940231|NCT01847690|Active Comparator|Hydrocortisone|Treatment A is 10 mg hydrocortisone (2 tablets Cortef, 5 mg each),Stress-dose will be taken per os one time 2 tablets 10 mg of Cortef 60 min before start of exercise. Cortef tablets 5 mg produced by Pharmacia and Upjohn . One day.
88940232|NCT01847703|Experimental|Robotic surgery|Experimental method, to be compared with standard care
88940233|NCT01847703|Active Comparator|Abdominal surgery|Conventional open surgery (laparotomy)
88940234|NCT01847716||PH with wasting|This group of patients with idiopathic pulmonary arterial hypertension exhibit quadriceps wasting
89456637|NCT02699450|Experimental|Arm C: 6 mg Faricimab|Participants will receive 6 mg faricimab every fourth week up to Week 20, for a total of 6 administrations, followed by an observational period up to Week 36. If a participant meets pre-specified criteria the participant will receive a single dose of 0.3 mg ranibizumab and exit the study.
89456638|NCT02299557|Experimental|Treatment|Intra-anal Oxymetazoline gel once daily
89456639|NCT02299557|Placebo Comparator|Placebo|Intra-anal Placebo gel once daily
88940235|NCT01847716||PH no wasting|This groups of patients with idiopathic pulmonary arterial hypertension exhibit no evidence of muscle wasting
88940236|NCT01847716||Controls|This group of volunteers does not have pulmonary arterial hypertension and would not be expected to have muscle wasting
89016476|NCT04152772|Active Comparator|Active during extinction learning / Sham during consolidation|Active tDCS stimulation will be applied during the extinction learning phase. Sham tDCS stimulation will be applied during the consolidation phase.
89016477|NCT04152772|Active Comparator|Sham during extinction learning / Active during consolidation|Sham tDCS stimulation will be applied during the extinction learning phase. Active tDCS stimulation will be applied during the consolidation phase
89016478|NCT04152772|Sham Comparator|Sham during extinction learning / Sham during consolidation|Sham tDCS stimulation will be applied during both the extinction learning phase and the consolidation phase.
89456640|NCT02302989|No Intervention|Observation|No treatment. Observation only
89456641|NCT02302989|Active Comparator|Quarterly Ranibizumab 0.5|Quarterly intravitreal injection of 0.5mg Ranibizumab Intervention: Drug: Ranibizumab 0.5mg
89456642|NCT02299713|Sham Comparator|placebo/sham acupuncture|There are different types of controls used in acupuncture trials. We used the control described as sham and by some as minimal acupuncture. This group had the same schedule as the electro-acupuncture group. Sham acupuncture was administered, with the same duration and frequency and by the same specialist who performed the non-sham acupuncture. Retractable needles were placed into small adhesive cylinders, so that the needles were supported but did not perforate the skin. The acupuncturist placed the needles at the same points as the non-sham group and used the same pairs of electrodes to simulate the electrical connection.
89456643|NCT02299713|Active Comparator|Electroacupuncture|The electro-acupuncture device was a biphasic pulse generator. It was used with maximum tolerable intensity of current and a frequency of 3 Hz. The points were selected according to the Traditional Chinese Medicine meridian theory to treat knee pain. The points selected were local points St 34, St 35, St 36,Liv 8, Sp 10. One distal point St 44.A total of six needles were inserted into each leg by the acupuncturist (the out come measures were not specifically targeted to whether the patient had one or both knees involved). All patients belonging to this group experienced a De Qi sensation, which is a tingling and numbness sensation upon needling of specific points.
89016479|NCT04145388|Other|Comparator 1|Participants will have their cancer risk assessed via usual care. Usual Care is defined as provider capture of family history during a clinical encounter and its entry into the electronic health record (EHR). Participants will take the a patient reported outcomes (PRO) survey once to assess participants experience, perspectives and thoughts on cancer, cancer risk, and cancer risk assessments.
89016480|NCT04145388|Experimental|Comparator 2|Participants will have their cancer risk assessed using a short, standardized web-based questionnaire that will populate validated cancer risk models (such as Breast Cancer Risk Assessment Tool/Gail model 2, PREMM and/or MMRpro) which will take 5-10 minutes to complete. Following the cancer risk assessment, participants will be asked to take a PRO survey. PRO surveys will also be administered at the time of the cancer risk assessment and then 6 and 12 months following.
89016481|NCT04145388|Experimental|Comparator 3|Participants will have their cancer risk assessed using a more detailed, full version of the family history survey than the one comparator 2 participants take. This version is a full pedigree assessment, which entails family health history for all 1st, 2nd, and 3rd-degree relatives. Time needed for completion is 15-25 minutes, depending on family size and cancer risk. Participants will also be asked to take the PRO survey following the full cancer risk assessment and also at 6 and 12 months.
89016482|NCT04111874|Experimental|Low-Intensity Therapist Assistance (LTA)|Parents will receive four 30-minute supportive video calls with a therapist over the 12 weeks of treatment.
89016483|NCT04111874|Active Comparator|Standard Therapist Assistance (STA)|Parents will receive ten 60-minute supportive video calls with a therapist over the 12 weeks of treatment.
89016484|NCT04109638|Active Comparator|Active PEMF Group|Participants will have a 1 in 2 chance to get the active treatment device post-operatively. The device will be attached to the post-operative dressing. The device is an Endonovo SofPulse that emits a pulsed electromagnetic field (PEMF). Single blind randomization.
89456644|NCT02296671|Experimental|PEMOX|"Pemetrexed will be given intravenously (IV) on an outpatient basis on Day 1 of each 14-day cycle over 10 minutes. Oxaliplatin will be given (IV) on an outpatient basis on Day 1 of each 14-day cycle at a dose over 120 minutes. Drugs may be given in either order.~-Oxaliplatin will be administered on Day 2 for Cycle 1 only. **"
89016485|NCT04109638|Sham Comparator|Placebo PEMF Group|Participants will have a 1 in 2 chance to get the placebo treatment device post-operatively. The device will be attached to the post-operative dressing. The Endonovo SofPulse placebo device does not emit a pulsed electromagnetic field (PEMF). Single blind randomization.
89016486|NCT04107298|Experimental|SUNDANCE™ Drug Coated Balloon|SUNDANCE™ Drug Coated Balloon
89016487|NCT04104139|Experimental|Treatment (TAS-102, IMRT, 3D-CRT)|Patients receive TAS-102 PO BID Monday-Friday on weeks 1, 3, and 5. Patients also undergo IMRT or 3D-CRT 5 days per week on weeks 1-5. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care FOLFOX or CAPOX.
89016488|NCT04089579|Experimental|MSC|One dose of 6x10e6 cells/kg administered intravenously.
89456645|NCT02296671|Experimental|FOLFOX|"The modified FOLFOX-6 regimen is the following drugs given every 14 days:~Oxaliplatin on Day 1 of each cycle~Leucovorin over 120 minutes on Day 1 of each cycle~5-FU bolus and continuous infusion over 46 hours beginning on Day 1 of each cycle~Oxaliplatin will be administered on Day 2 for Cycle 1 only and the 5-FU infusion will be interrupted at 20 hours so that the FLT-PET scan can be performed (only for FLT-PET scan eligible patients)."
89456646|NCT02296749|Experimental|Sirolimus tablets 2 mg|Sirolimus tablets 2 mg of Dr. Reddys Laboratories Limited
89456647|NCT02296749|Active Comparator|Rapamune|Rapamune® 2 mg tablets of Wyeth Laboratories, Philadelphia
89016489|NCT04089579|Placebo Comparator|Placebo Infusion|Placebo infusion
89016490|NCT04086953|Experimental|Chronic Respiratory Disease Group|"Each patient receive the same intervention : 4 visits with different exercise tests.~Visit 1: Inclusion Visit, Functional Assessment and TTLM Speed Determination (6-minute walk test x2, cardiopulmonary exercise testing on ergocycle, questionnaires and accelerometer)~Visit 2 : Functional Evaluation and Shuttle Tests (ISWT, ESWT, Speed tests on 4m, Quadriceps muscle strength)~Visit 3 : Feasibility of the WTLT (WTLT x2 or 3)~Visit 4 : Reproducibility of the WTLT (WTLT x2) Specific measures for COPD subjects : Respiratory Functional Assessment and Dyspnea questionnaire"
89016491|NCT04086953|Experimental|Cardiovascular diseases Group|"Each patient receive the same intervention : 4 visits with different tests.~Visit 1: Inclusion Visit, Functional Assessment and TTLM Speed Determination (6-minute walk test x2, cardiopulmonary exercise testing on ergocycle,, questionnaires and accelerometer)~Visit 2 : Functional Evaluation and Shuttle Tests (ISWT, ESWT, Speed tests on 4m, Quadriceps muscle strength)~Visit 3 : Feasibility of the WTLT (WTLT x2 or 3)~Visit 4 : Reproducibility of the WTLT (WTLT x2)"
89016492|NCT04069520|Experimental|aNMT Biofeedback|Participants randomized to receive a neuromuscular training intervention that incorporates biofeedback training.
89016493|NCT04069520|Sham Comparator|Sham Biofeedback|Participants randomized to receive a neuromuscular training intervention with sham feedback training.
89206148|NCT00824694|Active Comparator|Intervention|The intervention will consist of targeted SMBG, provider training and patient education-all of which are focused on normalizing the most significant glucose abnormalities at any given time. SMBG will alternate between 2 strategies: glucose profiling and target monitoring. Intervention PCP's will use 380 View to identify a patient's most significant glucose elevations(s) and devise a treatment plan that includes drug type, dose increases, monitoring times, goal for the target, and stop criteria.
89456648|NCT02303145||Breast cancer survivor Group|Breast Cancer Survivor Group includes: women between the ages of 18 to 69 who have received a stage I-III diagnosis of breast cancer in the past and completed primary treatment and finished with treatment for at least 6 months; currently employed working part-time or full-time at the time of assessment. Participants working between 1 to 34 hours a week will be considered part-time employees.
89456649|NCT02303145||Control Group|Control Group includes: women between the ages of 18 to 60 who are healthy with no diagnosis of cancer, currently employed working part-time or full-time at the time of assessment. Participants working between 1 to 34 hours a week will be considered part-time employees.
89456650|NCT04481750|Experimental|A single dose MT-1186 (Part 1, Cohort S1)|Healthy Japanese male subjects receive a single dose of MT-1186 or matching placebo.
89456651|NCT04481750|Experimental|A single dose MT-1186 (Part 1, Cohort S2)|Healthy Japanese male subjects receive a single dose of MT-1186 or matching placebo.
89456652|NCT04481750|Experimental|A single dose MT-1186 (Part 1, Cohort S3-1)|Healthy Japanese male subjects receive doses of MT-1186 or matching placebo.
89456653|NCT04481750|Experimental|A single dose MT-1186 (Part 1, Cohort S3-2)|Healthy Japanese male subjects receive doses of MT-1186 or matching placebo.
89456654|NCT04481750|Experimental|A single dose MT-1186 (Part 1, Cohort S4)|Healthy Japanese male subjects receive a single dose of MT-1186 or matching placebo.
89016494|NCT04067726|Experimental|Denosumab|"Subcutaneous injection of denosumab at a dose of 60 mg at two time points: baseline and 6 months~Participants will also be instructed to take calcium and vitamin D supplements daily for 12 months between baseline examination and 12-month mammographic breast density examination.~Mammographic breast density will be assessed at three time points in all participants: baseline, 12 months, and 24 months. A 36-month optional assessment may also occur.~Biopsies and blood draws will occur for research purposes at baseline and 12 months."
89016495|NCT04067726|Placebo Comparator|Placebo|"Subcutaneous injection of the placebo at a dose of 60 mg at two time points: baseline and 6 months~Participants will also be instructed to take calcium and vitamin D supplements daily for 12 months between baseline examination and 12 month mammographic breast density examination~Mammographic breast density will be assessed at three time points in all participants: baseline, 12 months, and 24 months. A 36 month optional assessment may also occur.~Biopsies and blood draws will occur for research purposes at baseline and 12 months."
89016496|NCT04054596|Experimental|STEM|The treatment group (TX) will complete 8 sessions of STEM (2 sessions per week for 4 weeks), Sessions are approximately 30-45 minutes long.
89016497|NCT04054596|No Intervention|Controlled|During weeks 2-5, one group will undergo a memory enhancement protocol, used to improve memory functioning in individuals with neurological injuries. The other group will serve as a control group and complete memory exercises with the researcher.
89456655|NCT04481750|Experimental|A single dose MT-1186 (Part 1, Cohort S5)|Healthy Japanese male subjects receive a single dose of MT-1186 or matching placebo.
89456656|NCT04481750|Experimental|A single dose MT-1186 (Part 1, Cohort S6)|Healthy Japanese male subjects receive a single dose of MT-1186 or matching placebo.
89456657|NCT04481750|Experimental|A single dose MT-1186 (Part 1, Cohort S7)|Healthy Caucasian male subjects receive a single dose of MT-1186 or matching placebo.
89016498|NCT04045795|Experimental|Dose regimen 1|Isatuximab SC administration dose level 1 once weekly for 4 weeks (Cycle 1) and on Day 1 and Day 15 of each subsequent cycle
89456658|NCT04481750|Experimental|Multiple doses MT-1186 (Part 2, Cohort M1)|Healthy Japanese male subjects receive multiple doses of MT-1186 or matching placebo.
89456659|NCT04481750|Experimental|Multiple doses MT-1186 (Part 2, Cohort M2)|Healthy Japanese male subjects receive multiple doses of MT-1186 or matching placebo
89456660|NCT02303223|Other|Propofol|Single intravenous bolus dose of Propofol 2.5mg/kg for induction of anesthesia
89016499|NCT04045795|Experimental|Dose regimen 2|Isatuximab SC administration dose level 2 once weekly for 4 weeks (Cycle 1) and on Day 1 and Day 15 of each subsequent cycle
89456661|NCT03168620|Active Comparator|ITR group|In ITR group after partial caries removal(PCR), interim therapeutic restoration of glass ionomer cement (GIC) Ketac molar was placed for one month before definitive adhesive restoration
89016500|NCT04045795|Experimental|Dose regimen 3|Isatuximab SC administration dose level 3 using the investigational injector device once weekly for 4 weeks (Cycle 1) and on Day 1 and Day 15 of each subsequent cycle
89456662|NCT03168620|Active Comparator|Non ITR group|In NON-ITR group, cavity preparation was similar to ITR group, but definitive restoration was done in the same visit
89456663|NCT03515889|Experimental|Ideal Protein Weight Loss Protocol|This arm will follow the Ideal Protein method as documented in the Ideal Protein Clinic Manual and in the Ideal Protein Coaches Manual.
89456664|NCT03515889|Active Comparator|Standard Weight Loss|This arm utilizes evidence-based, low fat, low calorie strategies that have been shown to be effective for long-term weight loss and weight loss maintenance.
89016501|NCT04045795|Experimental|Dose regimen 4|Isatuximab IV administration once weekly for 4 weeks (Cycle 1) and on Day 1 and Day 15 of each subsequent cycle
89016502|NCT04045795|Experimental|Dose regimen 5|Isatuximab IV administration once weekly for 4 weeks (Cycle 1) and on Day 1 and Day 15 of each subsequent cycle
89016503|NCT04035486|Active Comparator|Osimertinib 80mg QD|"Osimertinib (AZD9291) 80mg QD.~All patients randomized into this will only receive Osimertinib 80mg.~Dose may be reduced to allow for the management of IP related toxicity."
89456665|NCT02395874|Experimental|verum-tDCS|verum-tDCS+ speech therapy
89456666|NCT02395874|Sham Comparator|sham-tDCS|sham-tDCS + speech therapy
89456667|NCT02299947|Experimental|Haemocomplettan P|Study patients that receive Haemocomplettan P
89456668|NCT02299947|Placebo Comparator|NaCl 0.9%|Study patients that receive NaCl 0.9%
89456669|NCT05692817|Experimental|one- weeks group|
89016504|NCT04035486|Experimental|Osimertinib 80 mg QD and platinum-based chemotherapy|"Osimertinib 80 mg in combination with pemetrexed (500 mg/m2) plus cisplatin (75 mg/m2) or carboplatin (AUC5) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by Osimertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.~Dose may be reduced to allow for the management of IP related toxicity."
89016505|NCT04033978|Experimental|Cognitive remediation arm|Participants will be enrolled in a cognitive remediation group. The program will last 10 weeks and be composed of 10 participants. This program is based on strategy learning and its aim is to reduce the jumping to conclusion phenomenon.
89456670|NCT05692817|Experimental|three-weeks group|
89456671|NCT03510585|Experimental|saline and sniffing|This RRC is the combination of positioning (laying down), sniffing (only one side), throat vibration and saline instillation. And then the other side.
89456672|NCT03510585|Placebo Comparator|sniffing|Pacient will be in a lay down condition and will perform sniffing with throat vibration several times each side (but with no saline instillation)
89456673|NCT05364983|Experimental|Investigational IOL|Juvene® IOL
89456674|NCT05364983|Active Comparator|Control IOL|Tecnis® Monofocal (ZCB00, PCB00 or DCB00)
89456675|NCT03168854|Experimental|GAP Arm 1|10 subjects will receive 5 vaccinations: the GAP3KO vaccine administered by the bite of approximately 200 infected A. Stephensi mosquitoes at weeks 0, 4, 8, 12, and 20 for a maximum cumulative dose of 1000 GAP3KO bites per subject
89456676|NCT03168854|Experimental|GAP Arm 2|6 subjects will receive 3 vaccinations: the GAP3KO vaccine administered by the bite of approximately 200 infected A. Stephensi mosquitoes at weeks 8, 12, and 20 for a maximum cumulative dose of 600 GAP3KO bites per subject
89456677|NCT03168854|Active Comparator|Malaria-naive Infectivity Control Arm|6 healthy volunteers will receive challenge with wild type Plasmodium falciparum NF54 sporozoites through the bites of five infectious A. stephensi moquitoes using standard CHMI procedures
89456678|NCT02300181|Placebo Comparator|Placebo (flour)|5 placebo capsules for each test (4.88 kcal/5 cap)
89456679|NCT02300181|Experimental|Bacillus subtilis var natto DC-15|5 experimental capsules for each test (4.96 kcal/5 cap) Extract powder of the flour fermented with Bacillus subtilis var natto DC-15
89456680|NCT02699996|Experimental|self-management + peer mentoring|Participants complete the self-management + peer mentoring intervention comprising 5 online educational modules and 6 videoconference or phone calls with the peer mentor.
89456681|NCT03510429|Active Comparator|Routine post-op care|Routine post-op care (N=20)
89456682|NCT03510429|Experimental|Routine post-op care with Nutritional supplement|Routine post-op care + Nutritional supplement by specific product (N=20)
89456683|NCT02403362|Experimental|EPO-018B 0.025 mg/kg|EPO-018B starting dose of 0.025 milligram per kilogram (mg/kg) administered subcutaneously (SC) once every 4 weeks (Q4W) for a total of 6 doses
89456684|NCT02403362|Experimental|EPO-018B 0.05 mg/kg|EPO-018B starting dose of 0.05 milligram per kilogram (mg/kg) administered subcutaneously (SC) once every 4 weeks (Q4W) for a total of 6 doses
89456685|NCT02403362|Experimental|EPO-018B 0.08 mg/kg|EPO-018B starting dose of 0.08 milligram per kilogram (mg/kg) administered subcutaneously (SC) once every 4 weeks (Q4W) for a total of 6 doses
89456686|NCT03513159|Experimental|Pathfinder support|Pathfinder support with development of an individual care plan for the intervention patients and their informal caregivers, with the hospital physicians already inside the hospital setting. This will then be developed and improved further during up to twelve months after hospital release with the primary physician. The pathfinders will coordinate the ambulatory care team services and closely involve the primary physicians. The patients and their informal caregivers will be empowered and educated to achieve a stabilization or improvement in functionality, independence, quality of life, coping with disease, nutritional status and wound healing process. In the regular assessments they will be tested for functionality and nutritional parameters, quality of life and stress scores.
89456687|NCT03513159|No Intervention|Control without pathfinder support|Control patients will not be supported by pathfinders. In regular assessments they will be tested for functionality and nutritional parameters, quality of life and stress scores.
89456688|NCT03168698|Active Comparator|Carbetocin 20mcg|Carbetocin 20mcg, administered intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby.
89456689|NCT03168698|Active Comparator|Carbetocin 100mcg|Carbetocin 100mcg, administered intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby.
89456690|NCT03168698|Active Comparator|Oxytocin 0.5IU|Oxytocin 0.5IU, administered intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby.
89456691|NCT03168698|Active Comparator|Oxytocin 5IU|Oxytocin 5IU, administered intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby.
89456692|NCT02303301|Active Comparator|Probiotics|Patients gurgle twice a day with a suspension of two probiotic strains of bacteria- Contains also a filling material - maltodextrin
89456693|NCT02303301|Placebo Comparator|Control|Patients gurgle twice a day with a suspension of the filling material - maltodextrin
89016506|NCT04033978|Active Comparator|Control group|Participants will be enrolled in an information control group. They will receive information about psychosocial rehabilitation and recovery process. The program lasts 10 weeks.
89016507|NCT04025905|Experimental|Social Cognition Training Program|This program is taken from two validated cognitive remediation programs: the SCIT program and the RC2S program : perception of social situations - emotional processes and social perception;interpretation of social situations - theory of mind and attributions;acting in social situations - social skills training
89016508|NCT04025905|Sham Comparator|Informations program|Educational team Information will be given to participants about work environment, social environment, stress management, sleep management, treatments. It will also include socialization sessions with board games or cultural activities.
89456694|NCT02395406|Active Comparator|Totaltrack|OTI with Totaltrack
89456695|NCT02395406|Active Comparator|Airtraq|OTI with Airtraq
89456696|NCT02296905|Experimental|Group I|Subjects with mild hepatic impairment
89456697|NCT02296905|Experimental|Group II|Subjects with moderate hepatic impairment
89456698|NCT02296905|Experimental|Group III|Subjects with severe hepatic impairment
89016509|NCT04025398|Experimental|REHABILITUS|Réhabilitus is a cognitive remediation program focused on the functions of attention and visuospatial that is to say that can move in space, to perceive objects of our environment and organize them, to mentally imagine a physically absent operation object very involved in social behavior, in order to limit the presence of behavioral disorders among adults with intellectual disabilities.
89456699|NCT02296905|Experimental|Group IV|Subjects with normal hepatic function
89456700|NCT02395484||constipation|collect stool samples from constipation patients
89456701|NCT02395484||healthy controls|collect stool samples from healthy controls patients
89456702|NCT04464447|Other|Group-based Acceptance and Commitment Therapy|Group-based Acceptance and Commitment Therapy (ACT) for adolescents presenting with multiple functional somatic syndromes.
89456703|NCT02395562||OTR and viral reactivation|Organ transplant recipients with and without viral reactivation and skin cancer
89456704|NCT04464135|Experimental|WE+AA group|Water containing 1% of AA was used during insertion of colonoscopy using water exchange method.
89456705|NCT04464135|Active Comparator|WE group|Water exchange colonoscopy was used for standard screening or surveillance colonoscopy.
89456706|NCT02403440|Experimental|Hetrombopag Olamine|Hetrombopag Olamine 2.5mg, 5mg and 7.5mg
89016510|NCT04025398|Active Comparator|CONTROL GROUP|The control group involves manual activities and research computer information.
89016511|NCT04021368|Experimental|RVU120(SEL120)|The first part of the study consists of dose-escalation cohorts where patients will receive ascending doses of RVU120(SEL120) to determine the recommended dose (RD) for further clinical development. The second part of the study is an enrichment cohort where additional 6 to 20 patients will be treated with RVU120(SEL120) to support the evaluation of the RD.
89456707|NCT02395328|Experimental|Care worker home visitation|Care Workers provide biweekly home visits and offer residing caregivers and children information and psychosocial support, and encourage their awareness and accessing of external health and social services.
89456708|NCT02395328|No Intervention|Wait List|Access to homework classes are made available to all participants' children at schools supported by the implementing organization.
89456709|NCT03513003|Experimental|Functional pacifier|Swap from the habitual pacifier to a functional pacifier
89456710|NCT03513003|Active Comparator|Stop habit|Stop the use of the habitual pacifier and or baby bottle
89456711|NCT03510351||Treated subjects|All patients with Pseudomonas infections treated with ceftolozane-taezobactam who meet the inclusion criteria
89456712|NCT02400632|Experimental|MAGIC-TOUCH Drug-eluting balloon|in-stent restenosis treated with drug-eluting balloon
89456713|NCT03512925|Experimental|Standardized post-coercion review|Intervention: Standardized post-coercion review session. Patients allocated to this arm receive a standardized post-coercion review of the coercive measure they experienced using the developed guidelines.
89456714|NCT03512925|No Intervention|Control group|Patients allocated to this arm are treated following usual standards and routine. This might include some form of post-coercion review that doesn't follow the developed standardized guidelines.
89456715|NCT02395250|Experimental|anti-GPC3 CAR T|
89456716|NCT02296983|Experimental|Low dose arm|The low dose cohort will receive an intramuscular (deltoid) injection of 3x106 pfu of VSV-ZEBOV vaccine.
89456717|NCT02296983|Experimental|Full dose arm|The full dose cohort will receive an intramuscular (deltoid) injection1x107 pfu of VSV-ZEBOV vaccine.
89016512|NCT04015921||Inpatients|Patients admitted with various psychiatric disorders
89456718|NCT02403284|Experimental|Liraglutide|Liraglutide titration up to 1.8 mg/d over approximately 3 weeks
89456719|NCT02403284|Placebo Comparator|Sugar pill|matching placebo and titration
89456720|NCT02400866|Placebo Comparator|Control|palonosetron + dexamethasone + placebo
89016513|NCT04015921||Age-matched control group|
89016514|NCT04010435|Active Comparator|Group A (r TMS group)|Twenty randomly assigned patients with unilateral peripheral vestibular disorders will undergo 10 Hz rTMS to the dorsolateral prefrontal cortex of their dominant hemisphere; in addition to designed vestibular rehabilitation exercises.
89016515|NCT04010435|Active Comparator|Group B (Galvanic stimulation)|Twenty randomly assigned patients with unilateral peripheral vestibular disorders will undergo galvanic vestibular stimulation; in addition to designed vestibular rehabilitation exercises.
89016516|NCT04010435|No Intervention|Control (Group C)|Twenty randomly assigned patients with unilateral peripheral vestibular disorders will undergo designed vestibular rehabilitation exercises.
89016517|NCT04010266|Active Comparator|Standard of care group|Receive standard of care for pain management, do not receive RelieVRx headset
89456721|NCT02400866|Experimental|Experimental|palonosetron + dexamethasone + olanzapine
89456722|NCT02400788|Experimental|Resminostat + Sorafenib|oral administration
89456723|NCT02400788|Active Comparator|Sorafenib|oral administration
89456724|NCT02297061||TEG group|200 consecutive hip fracture patients, Thrombelastography is performed on admission.
89456725|NCT02403128|Experimental|Patients with macular edema from RAM|Intravitreal aflibercept 2.0 mg injection for eyes meeting eligibility criteria will be administered at baseline. Reinjection of the drug for protocol-defined criteria at least two months after previous injection.
89456726|NCT02297217|Experimental|Chemotherapy with Concurrent Radiation|Carboplatin and paclitaxel will be administered intravenously on Days 1 and 8 while radiation therapy is administered
89456727|NCT03512691|Experimental|Information on CVD risk|Respondents will receive information on the predicted probability of having a heart attack or stroke within 10 years. The predictions will be obtained from the Globorisk tool (www.globorisk.org). All information will be provided within a risk perceptions module of the baseline survey. Only this module will differ across the two treatment groups (information and lottery) and the control group. Information obtained from earlier modules will be retrieved automatically and used to make predictions of CVD risk consistent with the risk factor profile of the respondent.
89456728|NCT03512691|Experimental|Lottery Incentive|Respondents will be offered a ticket for a lottery with a money prize on condition that they visit a specific public health clinic for a checkup. There will be one prize per barangay giving each respondent a one in ten chance of winning P5000 (US$100). The prize is equivalent to approximately 14 days earnings at the regional minimum wage.
89456729|NCT03512691|No Intervention|Control|No intervention will be introduced to the participants in this arm.
89456730|NCT02300337|Experimental|Reduce Cuff Pressure|Cuff Pressure difference between inspiration and expiration is measured.
89456731|NCT02300415||patient with sepsis|Patients admitted to the emergency department and with criteria of sepsis.
89456732|NCT03510039|Active Comparator|"Before Group"|35 Thirds benefiting from the usual care
89456733|NCT03510039|Experimental|"After Group"|"Recruit 35 Thirds for the phase phase After : Early device / Follow up by nurses"
89456734|NCT03515577|Experimental|Diagnostic ([68]Ga-PSMA-11 PET/CT, Axumin PET/CT)|Participants receive (68)Ga-PSMA-11 IV and 60-90 minutes later, undergo PET/CT imaging over 3 hours. Participants also undergo best standard of care Axumin PET/CT within 2 weeks before or after (68)Ga-PSMA-11 PET/CT.
89456735|NCT02303379|Active Comparator|Continuous Endurance training|Endurance training with constant work load 31min at 65-75% maximal heart rate (HRmax)
89456736|NCT02303379|Experimental|Pyramid Training|One pyramid consists of 8 one-minute blocks. Those are grouped starting with one block of 70-75% HRmax, followed by one block at 75-80% HRmax and another one at 80-85% HRmax. The top of the pyramid are 2 blocks of 85-90% HRmax. Intensity is lowered afterwards with one block of 80-85% HRmax, followed by one block at 75-80% HRmax and last one at 70-75% HRmax. Two more pyramids follow, each divided by 2min of active recovery at 65-70% HRmax, making it a total of 28min.
89456737|NCT02303379|Experimental|High-intensity intervall training|HIT: 4x4 min intervals at85-95% HRmax divided by 3x3min of active recovery at 60-70% HRmax, making it a total of 25min.
89456738|NCT03509961|Other|Observational Arm|"Patients are enrolled to the observational arm to proceed with NGS-MRD testing pre-HCT. If NGS-MRD negative, eligible patients may be considered for the Treatment Arm to receive a myeloablative non-TBI conditioning regimen prior to HCT.~If NGS-MRD positive, patients may continue in the observational arm and receive HCT under the direction of their transplant physician and followed on the study for outcome."
89456739|NCT03509961|Other|Treatment Arm|Patients enrolled to the observational arm that are NGS-MRD pre-HCT are considered for the Treatment Arm. Patients will receive a myeloablative non-TBI conditioning regimen prior to the transplant consisting on busulfan, fludarabine and thiotepa. Patients will be followed for outcome for up to 5 years.
89456740|NCT03515499|Active Comparator|Control|The control arm will have medication monitoring sensors placed on their asthma medications. They will have reminders to take their medicines and access to a mobile app that will show them trends in their medication use.
89456741|NCT03515499|Experimental|Treatment arm|The treatment arm will have medication monitoring sensors placed on their asthma medications. They will have reminders to take their medicines and access to a mobile app that will show them trends in their medication use. Additionally, they will be paid up to $1 per day for perfect medication adherence.
89456742|NCT03509805|Experimental|OSA in obese patient during pregnancy|OSA in polysomnography
89456743|NCT03509805|Experimental|no OSA in obese patient during pregnancy|no OSA in polysomnography
89456744|NCT03512535||Stage 1|Samples from up to 20 participants will be used to finalise the analytical methods
89456745|NCT03512535||Stage 2|Samples from up to 200 participants will be used to then validate the normal ranges of these markers across different age ranges in both genders
89456746|NCT02297295|Experimental|Physiotherapy|Comparing the patients to themselves (spontaneus evolution) before intervention.
89016518|NCT04010266|Experimental|Standard of care + RelieVRx group|Receive standard of care for pain management, plus RelieVRx headset
89456747|NCT02303457|Experimental|CO2 laser surgery|CO2 Laser surgery for T1N0 Glottic Squamous Cell Carcinoma With Anterior Commissure Involved. All patients, under general anesthesia, underwent endoscopic excision of the lesion using a carbon dioxide (CO2) laser (Sharplan 100) coupled with a microscope (Zeiss) set to an output power of between 5 and 12 W in superpulse mode. The lesion's resection was accomplished in a radical fashion, with a free margin of 2 mm. For lesions which involved the anterior commissure, the excision plane always uncovered the cartilage.
89456748|NCT02303457|Other|Open surgery|"Open Surgery for T1N0 Glottic Squamous Cell Carcinoma With Anterior Commissure Involved.~open surgery :Frontolateral Vertical Partial Laryngectomy or laryngofissure with cordectomy was accomplished in a radical fashion, with a free margin of 2 mm."
89456749|NCT02300649|Experimental|Dexmedetomidine group|Dexmedetomidine will be infused at a rate of 6 mcg/kg/hr for 10 minutes; resulting in a loading dose of 1 mcg/kg, followed by an infusion of 0.5 μg/kg/hr for 50 minutes.
89456750|NCT02300649|Placebo Comparator|Control group|Saline will be infused at a rate of 6 mcg/kg/hr for 10 minutes; resulting in a loading dose of 1 mcg/kg, followed by an infusion of 0.5 μg/kg/hr for 50 minutes.
89456751|NCT03512379|Experimental|Robot assisted surgery group|Spinal surgery using TIANJI Robot system.
89456752|NCT03512379|Active Comparator|Free hand surgery group|Spinal surgery using fluoroscopy-based free hand technique
89456753|NCT03512379|Active Comparator|Navigation-assisted surgery group|Spinal surgery using Navigation-assisted technique
89016519|NCT04004442|Experimental|Avelumab + AVB-S6-500|
89201372|NCT00356863|Experimental|Explanation on cardiac rehabilitation|Intervention: Increasing awareness to cardiac rehabilitation programs: Patients received a written and oral short explanation on the importance and benefits of cardiac rehabilitation (CR) participation, and information on available programs. They were telephoned 2 weeks after hospital discharge to encourage them to enroll at a cardiac rehabilitation program (CRP). In addition, physicians and nurses at the cardiothoracic units participated in a 1-hour seminar on CR. A recommendation to the general physician to refer the patient to CRP was added to the letter of discharge from hospital.
89201373|NCT00356863|No Intervention|Usual care with no intervention|Patients recruited to the study received the usual care without any additional explanation on cardiac rehabilitation, and no effort to increase their awareness or the ward's awareness to cardiac rehabilitation was done.
89201374|NCT00927537||Group 1|
89201375|NCT00927537||Group 2|
89201376|NCT00987064|Active Comparator|Temperature controlled Laminar Airflow|Active treatment with Temperature controlled Laminar Airflow (TLA)
89201377|NCT00987064|Placebo Comparator|Placebo TLA|Placebo treatment with TLA (no filtration function)
89201378|NCT02538003|Experimental|Group 1(RT):LCB01-0371 Tablet 800mg|"Period:LCB01-0371 Tablet 800mg(Reference: Taken drug before meal)~Period: LCB01-0371 Tablet 800 mg(Test: Taken drug after meal)"
89201379|NCT02538003|Experimental|Group 2(TR):LCB01-0371 Tablet 800mg|"Period:LCB01-0371 Tablet 800mg(Test:taken drug after meal)~Period: LCB01-0371 Tablet 800 mg(Reference:taken drug before meal)"
89201380|NCT02533609||Piperacillin/Tazobactam|Patients undergoing continuous veno-venous renal replacement therapy and treated with this antibiotics
89201381|NCT02533609||Imipenem/Cilastatin|Patients undergoing continuous veno-venous renal replacement therapy and treated with this antibiotics
89201382|NCT00909129|Experimental|HIV-1 HCV coinfected patients|HIV-1 HCV coinfected patients undergoing HCV therapy
89201383|NCT01053325|Experimental|CTX in HIV-negative women|CTX daily prophylaxis in HIV-negative pregnant women
89201384|NCT01053325|Experimental|CTX in HIV-positive women|CTX daily prophylaxis in pregnant women who are infected with HIV
89201385|NCT01053325|Active Comparator|SP IPT in HIV-negative women|Intermittent Preventive Treatment with SP in HIV-negative pregnant women
89201386|NCT01053325|Active Comparator|IPT SP in HIV-positive women|Intermittent Preventive Treatment with SP in HIV-positive pregnant women
89201387|NCT01053325|Active Comparator|CTX in HIV-positive pregnant women with CD4<350|Daily prophylaxis with cotrimoxazole in HIV-positive pregnant women with CD4<350
89201388|NCT04733404|Experimental|Dragonfly Mitral Valve Repair System|The experimental group is allocated to use a novel mitral valve repair system for edge-to-edge repair manufactured by Hangzhou Valgen Medtech Co., Ltd.
89201389|NCT05277363||Prospective cohort|Parents/caregivers of participants with SURF1 deficiency will provide information regarding diagnosis, onset of symptoms, and course of the disease and participants will be assessed prospectively over time using standardized qualitative and quantitative tools.
89201390|NCT03990181|Experimental|Meal & natural polyphenol supplement (NPPS)|A meal, labelled with stable iron isotope as ferrous sulphate, consumed with the natural polyphenol supplement
89201391|NCT03990181|Experimental|Drink & natural polyphenol supplement|A drink, labelled with stable iron isotope as ferrous sulphate, consumed with the natural polyphenol supplement
89201392|NCT03990181|Placebo Comparator|Meal & control supplement (CS)|A meal, labelled with stable iron isotope as ferrous sulphate, consumed with a control supplement
89201393|NCT03990181|Placebo Comparator|Drink & control supplement|A drink, labelled with stable iron isotope as ferrous sulphate, consumed with a control supplement
89201394|NCT05712148|Experimental|Retinitis Pigmentosa patients|Suprachoroidal mesenchymal stem cell implanted Retinitis pigmentosa patients
89201395|NCT00909207||Interview|Review list of 25 cancer symptoms, 20-30 minute audio-taped personal interview and 15-20 minute questionnaire.
89201396|NCT01053403|Active Comparator|MDMA|
89201397|NCT00987142|Experimental|CX501|Cultured chimeric skin
89201398|NCT00987142|Active Comparator|Non adherent dressing|Occlusive non adherent dressing
89201399|NCT00927615|Experimental|intracoronary abciximab|intracoronary administration of abciximab (0.25 mg/kg body weight)
89201400|NCT00927615|Active Comparator|intravenous abciximab|intravenous administration of abciximab (0.25 mg/kg body weight)
89201401|NCT03990103|Experimental|Experimental arm|S1+Paclitaxel (IV&IP)+Bevacizumab (IP)
89201402|NCT03990103|Active Comparator|Control arm|S1+Oxaliplatin (IV)
89201403|NCT00927693|Experimental|Scan group|"Scan group undergoes complete cardiac risk assessment and CAC scanning at baseline."
89201404|NCT00927693|No Intervention|No scan group|"No scan group undergoes only complete cardiac risk assessment (without CAC scan) at baseline."
89201405|NCT00987220||Placebo|
89201406|NCT00987220||donepezil (Aricept)|
89201407|NCT01581151|Active Comparator|Monthly Ranibizumab|"• Patients will receive a ranibizumab intravitreal injection on day 0. During each other visit, patients will receive a ranibizumab intravitreal injection. The protocol will use the term monthly to represent a 30 day interval between treatments."
89456754|NCT02297451|No Intervention|Brachial artery inflow|Elbow fistula created with brachial artery as inflow (ie. either brachiocephalic or brachiobasilic fistulas)
89456755|NCT02297451|Active Comparator|Proximal radial/ulnar artery as inflow|Elbow fistula created with either proximal radial or ulnar artery as inflow
89456756|NCT02303535||Congenital|"All patients with congential and acquired heart disease treated by cardiac surgery and therapeutic cardiac catheterisations procedures .~For acquired heart disease, the audit covers all arrhythmias & cardiomyopathies in patients less than 16 years old only.~For congenital heart disease, the audit collects data on both children and adult patients."
89501817|NCT02750761|Experimental|Group 1 Cohort 2: Tedizolid IV 4 mg/kg (6 to <12 years)|Participants 6 to <12 years of age received a single intravenous infusion of tedizolid phosphate dosed at 4 mg/kg of total body weight. Maximum dose is 200 mg of tedizolid phosphate.
88940237|NCT01847729||Patients on OST prescribed to treat opiate dependence|Collecting socio-demographic data, data concerning opiate dependence, data about other substance use disorder, data regarding gambling practice, psychopathological data.
88940238|NCT01847742|Experimental|EMDR intervention|40 participants with trauma symptoms will be randomly assigned to treatment group and receive EMDR intervention for trauma symptoms.EMDR is a trauma focused therapy starts with resource development and continue with bilateral stimulation while working on the most troubling traumatic memory.
88940239|NCT01847742|No Intervention|Waiting List|40 participants with trauma symptoms will be randomly assigned to waiting list as the control group.
88940240|NCT01847768|Experimental|Asthmatic Group|"Subjects with well-controlled, mild-moderate allergic asthma.Subjects will be inoculated with a total dose of 1000 TCID50 of HRV- 39.~The inoculum is diluted, as appropriate, in lactated Ringer's solution and delivered via the following procedure: 0.5 ml per nostril is administered by pipette while the subject tilts their head back."
88940241|NCT01847768|Active Comparator|Healthy Non-Asthmatic Control Group|"Healthy volunteers. Subjects will be inoculated with a total dose of 1000 TCID50 of HRV- 39.~The inoculum is diluted, as appropriate, in lactated Ringer's solution and delivered via the following procedure: 0.5 ml per nostril is administered by pipette while the subject tilts their head back."
88940242|NCT01847781|Active Comparator|IgG-deficient patients|Prevenar13
88940243|NCT01847781|Active Comparator|Healthy controls|Prevenar13
88940244|NCT01847794|Experimental|chemotheropy|
88940245|NCT01847807|Active Comparator|High-dose Astragalus group|treatment with 10 gram astragalus
88940246|NCT01847807|Active Comparator|Low-dose Astragalus group|treatment with 5 gram astragalus
88940247|NCT01847807|No Intervention|MS control|
88940248|NCT01847820||Symptomatic|Individuals with signs, symptoms or suspicion of membrane rupture at 11 to 42 weeks gestation that will receive the AmniSure ROM test.
88940249|NCT01847833||Patients with brain tumors|
88940250|NCT01847846|Experimental|Prototype mask|Participants will be randomised to trial the new prototype mask for 4 and 8 weeks. The prototype mask will be used in conjunction with the participant's home CPAP machine. The participant's will be instructed to use the prototype mask every night until the completion of the trial. No changes will be made to the participant's prescribed CPAP settings.
88940251|NCT01847872|Experimental|IPV IM (Visit 1)|IM IPV vaccine using syringe and needle pair is given at visit 1 followed by MR vaccine at visit 2 and YF vaccine at visit 3
88940252|NCT01847872|Experimental|IPV IM (Visit 2)|MR vaccine at visit 1 followed by IM IPV vaccine using syringe and needle pair at visit 2, then YF vaccine at visit 3
88940253|NCT01847872|Experimental|IPV IM (Device - Visit 2)|YF vaccine at visit 1 followed by IPV given IM using a Jet injector device at visit 2 and MR vaccine at visit 3
88940254|NCT01847872|Experimental|IPV IM and MR (Visit1)|IM IPV using syringe and needle pair is given alongside MR at visit 1 followed by YF vaccine at visit 2
88940255|NCT01847872|Experimental|IPV IM and YF (Visit 1)|IM IPV using syringe and needle pair is given alongside YF vaccine at visit 1 followed by MR at visit 2
88940256|NCT01847872|Experimental|IPV ID (Visit 2)|MR and YF vaccines are co-administered at visit 1 followed by ID IPV using syringe and needle pair is given at visit 2
88940257|NCT01847872|Experimental|IPV IM and MR and YF (Visit 1)|IM IPV using syringe and needle pair is given alongside YF vaccine and MR vaccine at visit 1
88940258|NCT01847872|Experimental|IPV (ID Device Visit 2)|MR vaccine is given at visit 1 followed by IPV vaccine by ID Jet injector device at visit 2 and YF vaccine at visit 3
88940259|NCT01847898|Experimental|Vertebral Body Stenting (VBS)|
88940260|NCT01847898|Experimental|Balloon Kyphoplasty|
88940261|NCT01847911|Experimental|Self instructed video learning|A complete video lesson of neonatal resuscitation including initial resuscitative maneuvers and administration of ventilation with a SIB and a T-piece resuscitator presented in the primary language of the participating center or university (Spanish or English). A portable kit with a newborn mannequin will be provided for independent video guided practice during the session.
88940262|NCT01847911|Active Comparator|instructor training|A standard hands-on training with a face-to-face instructor following a pre-validated OSCE program guidelines.
88940263|NCT01847924|Active Comparator|MLC901|Brand: Neuroaid II. Dosage: 2 capsules 3 times a a day
88940264|NCT01847924|Placebo Comparator|placebo|MLC901 matching placebo made by the same manufacturer for this study dosage: 2 capsules 3 times a day.
88940265|NCT01847937||Diabetics Type I non-neuropathic|Diabetics with type 1 diabetes and without neuropathy
88940266|NCT01847937||Diabetics Type II non-neuropathic|Diabetics with type 2 diabetes without neuropathy
88940267|NCT01847937||Diabetics Type I neuropathic|Diabetics with type 1 diabetes and neuropathy
88940268|NCT01847937||Diabetics Type II neuropathic|Diabetics with type 2 diabetes and neuropathy
88940269|NCT01847937||Hereditary axonal neuropathic|
88940270|NCT01847937||Hereditary demyelinated neuropathic|This will mainly be patients with Chronic inflammatory demyelinating polyneuropathy (CIDP).
88940271|NCT01847950|Experimental|short-chain fructo-oligosaccharides|Short-chain fructo-oligosaccharides are consummed at 5g/day for 6 weeks
88940272|NCT01847950|Placebo Comparator|Maltodextrin|maltodextrins are consummed at 5g/day for 6 weeks
88940273|NCT01847963|Experimental|Sindhuvallathy mezhugu|Sindhuvallathy mezhugu (SVM) 500 mg Twice daily per Oral 45 days duration
88940274|NCT01847963|Experimental|Kalladaippu Kudineer|Kalladaippu Kudineer (KK) 130 ml decoction Twice daily Per oral 45 days Duration
88940275|NCT01847963|Experimental|Sindhuvallathy + Kalladaippu Kudineer|Sindhuvallathy mezhu -500 mg capsules twice daily + Kalladaippu kudineer -130 ml decoction twice daily-per oral for 45 days.
88940276|NCT01847976|Experimental|Doxycycline|100 mg of Doxycycline orally twice a day for 12 weeks.
89456757|NCT02739321|Experimental|Mattress Technology On then Off|"Intervention: Sound to Sleep System will be turned on for the first two weeks of the study allowing the participant sleeping atop the mattress to feel the vibrations synced to the audio input. Sound to sleep system will be turned on during this phase of the study. The sound to sleep system will sync an audio input with the vibrations of the mattress technology and allow the user to control the intensity of the vibration.~No intervention: The mattress technology will be turned off for the second two weeks of the study. During this time, there will be no intervention."
89456758|NCT02739321|Experimental|Mattress Technology Turned Off then On|"No intervention: For the first two weeks of the study, the mattress technology will not be turned off. There will be no intervention during this time.~Intervention: Sound to Sleep System will be turned on for the second two weeks of the study allowing the participant sleeping atop the mattress to feel the vibrations synced to the audio input. Sound to sleep system will be turned on during this phase of the study. The sound to sleep system will sync an audio input with the vibrations of the mattress technology and allow the user to control the intensity of the vibration."
88940277|NCT01847989|Experimental|rFXIII|
89456759|NCT02449161|Experimental|MPA|medroxyprogesterone acetate, 10 mg/day, for 90 days, following endometrial ablation
89456760|NCT02449161|Placebo Comparator|placebo|1 placebo/day, for 90 days, following endometrial ablation
89456761|NCT02303691|Experimental|Computerized Attention Bias Modification|
89456762|NCT02303691|Sham Comparator|Computerized Neutral Training|
88940278|NCT01847989|Placebo Comparator|Placebo|
89456763|NCT03515421|Experimental|Blood Glucose monitoring System (BGMS)|"Intervention: Blood Glucose monitoring Systems (BGMSs): Frazier 3 Verio and Frazier 3 UltraPLus.~Results obtained from the BGMS for UP and SA are compared to a reference instrument (YSI)"
89456764|NCT02303769|Active Comparator|Tamsulosin HCL 0.2mg|Harnal-D tablet (Tamsulosin HCL 0.2mg)
89456765|NCT02303769|Experimental|Tamsulosin HCL 0.4mg|GL2702 GLARS-NF1 tablet (Tamsulosin HCL 0.4mg)
89456766|NCT04464525|Experimental|Omecamtiv mecarbil|All subjects will be assigned to OM
89456767|NCT03509649|Experimental|Experienced - Positive|Participants will receive cervical spine manipulation after being given a positive description of the technique from an experienced clinician
89456768|NCT03509649|Experimental|Experienced - Negative|Participants will receive cervical spine manipulation after being given a negative description of the technique from an experienced clinician
89456769|NCT03509649|Active Comparator|Novice - Positive|Participants will receive cervical spine manipulation after being given a positive description of the technique from a novice clinician
89456770|NCT03509649|Active Comparator|Novice - Negative|Participants will receive cervical spine manipulation after being given a negative description of the technique from a novice clinician
89456771|NCT02303847|Active Comparator|Active Drug|ketamine 16 mg in flavored syrup by mouth twice daily for 1 week, then ketaming 32 mg in flavored syrup by mouth twice daily for 1 week
89456772|NCT02303847|Placebo Comparator|Placebo|Flavored syrup (without ketamine) by mouth twice daily for 2 weeks
89456773|NCT03509493||Patients without structural heart disease|
89456774|NCT03509493||Patients with structural heart disease|
89456775|NCT03509493||Patients with high risk parameters for AF development|
89456776|NCT03509493||Patients post-cryptogenic stroke|
89456777|NCT03509493||Patients post-cardioversion therapy|
89456778|NCT03509493||Patients post-ablation therapy|
89456779|NCT03512145|Experimental|VIPUN Balloon Catheter|Recording of gastric motility with the investigational medical device. Gastric emptying rate of a liquid meal is assessed with the 13C-octanoate breath test.
89456780|NCT02297607|Experimental|Tube Feeding|Study subjects will continue to receive tube feedings (for at least 50% of caloric need) for 1-month post-operatively.
88940279|NCT01848002|Experimental|rFXIII|
88940280|NCT01848002|Placebo Comparator|Placebo|
88940281|NCT01848015||CTCs positive|
88940282|NCT01848080|Experimental|Tai chi program via Telerehabilitation|An individualized exercise program, based on Tai Chi, was developed by our team for previous studies aiming to improve balance in elderly, diabetic individuals and in frail, elderly individuals with balance problems. The exercise program consists of movements based on a combination of alignments and body-specific orientations, weight transfers and changes in direction inspired by Tai Chi. This group will receive this program via telerehabilitation.
88940283|NCT01848080|Active Comparator|Tai chi program via home visits|An individualized exercise program, based on Tai Chi, was developed by our team for previous studies aiming to improve balance in elderly, diabetic individuals and in frail, elderly individuals with balance problems. The exercise program consists of movements based on a combination of alignments and body-specific orientations, weight transfers and changes in direction inspired by Tai Chi. This group will receive this program via home visits.
89456781|NCT02297607|No Intervention|Standard of Care|Tube feeding to continue in the hospital until the patient is taking adequate nutrition by mouth at post-op day #8, or upon discharge,
89456782|NCT02297685|Sham Comparator|Sham Transcutaneous nerve stimulation|The group with sham TENS did not receive any current. Four surface electrodes (5×5 cm Prim-Trode®, Spain) were symmetrically placed over the L1 and L5 transverse processes with respect to the spine. The patients were informed that they may or may not feel any sensation at the application site of the electrodes.
89456783|NCT02297685|Experimental|Transcutaneous nerve stimulation|The group with TENS received current at a frequency of 80 Hz and with a pulse width of 150 μs with two channels, for 30 minutes over a period of 4 weeks, including a total of 12 sessions.
89456784|NCT02297685|Experimental|Interferential currents|The group with IC received a base frequency of 4000 Hz with AMF = 65 Hz, sweep = 95 Hz and slope of 1/1 in tetrapolar mode, for 30 minutes over a period of 4 weeks, including a total of 12 sessions.
89456785|NCT02297763|Active Comparator|quetiapine|quetiapine 12.5mg (bwt <50kg ) or 25mg (bwt>= 50kg) study medicine is pulverized to power and melted in 10cc tepid water. The study medicine(quetiapine) will be provided as liquid form.
89456786|NCT02297763|Placebo Comparator|placebo|The placebo is made of 100mg of corn starch which is melted in 10cc water.
89456787|NCT03511989|Active Comparator|Bone Borne distractor|The device being investigated, Boneborne distraction appliance
89456788|NCT03511989|Other|Tooth borne distractor|The control device Toothborne distraction appliance
89456789|NCT03511989|No Intervention|Segmental LF1 osteotomy group 1|Control Group, no stabilization of palatal vault
89456790|NCT03511989|Active Comparator|Segmental LF1 osteotomy group 2|Testgroup, biodegradable plate at osteotomy site in palate
89456791|NCT03511989|Active Comparator|Segmental LF1 osteotomy group 3|Testgroup, autologous bonegraft at palatal osteotomy site
89456792|NCT03511911|Experimental|GROUP A1|In GROUP A1, participants are all healthy women.A gynecological physician evaluates the participant's pelvic floor muscle strength by vaginal palpation based on modified Oxford Grading Scale(MOS) and Levator ani testing(LAT) without telling the participant her result, and records it on a unique paper other than in the Case Report Form.Then inspector A will test them twice using the PHENIX instrument with a 5 minutes' interval at the same day.After three days,participants in group A1 will be tested by inspector B twice in the same way as what they have done the first day.
89456793|NCT03511911|Experimental|GROUP A2|In GROUP A2,participants are all healthy women.A gynecological physician evaluates participant's pelvic floor muscle strength by vaginal palpation without telling the participant her result, and records it on a unique paper other than in the Case Report Form as what GROUP A1 do.Then it is inspector B who will test them twice using the PHENIX instrument with a 5 minutes' interval at the same day.Three days later,participants in group A2 will be tested by inspector A twice in the same way as what they have done the first day.
89456794|NCT03511911|Experimental|GROUP B1|In GROUP B1,patients are all with pelvic floor disorders.A gynecological physician evaluates the patient's pelvic floor muscle strength by vaginal palpation based on modified Oxford Grading Scale(MOS) and Levator ani testing(LAT) without telling the patient her result, and records it on a unique paper other than in the Case Report Form.Then inspector A will test them twice using the PHENIX instrument with a 5 minutes' interval at the same day.After three days,patients in group B1 will be tested by inspector B twice in the same way as what they have done the first day.
89456795|NCT03511911|Experimental|GROUP B2|In GROUP B2,patients are all with pelvic floor disorders.A gynecological physician evaluates the patient's pelvic floor muscle strength by vaginal palpation without telling patient her result, and records it on a unique paper other than in the Case Report Form as what GROUP B1 do.Then it is inspector B who will test them twice using the PHENIX instrument with a 5 minutes' interval at the same day.Three days later,patients in group B2 will be tested by inspector A twice in the same way as what they have done the first day.
89456796|NCT03511911|Experimental|GROUP C1|In GROUP C1,participants are all female who give birth to a child within a year(compliance and twice assessment are guaranteed,but PFMT are not allowed during the interval).A gynecological physician evaluates the participant's pelvic floor muscle strength by vaginal palpation based on modified Oxford Grading Scale(MOS) and Levator ani testing(LAT) without telling the participant her result, and records it on a unique paper other than in the Case Report Form.Then inspector A will test them twice using the PHENIX instrument with a 5 minutes' interval at the same day.After three days,participants in group C1 will be tested by inspector B twice in the same way as what they have done the first day.
89456797|NCT03511911|Experimental|GROUP C2|In GROUP C2,participants are all female who give birth to a child within a year(compliance and twice assessment are guaranteed,but PFMT are not allowed during the interval).A gynecological physician evaluates the participant's pelvic floor muscle strength by vaginal palpation without telling patient her result, and records it on a unique paper other than in the Case Report Form as what GROUP C1 do.Then it is inspector B who will test them twice using the PHENIX instrument with a 5 minutes' interval at the same day.Three days later,participants in group C2 will be tested by inspector A twice in the same way as what they have done the first day.
89456798|NCT02303925|Experimental|coils|
89456799|NCT02304003|Experimental|Structured Physiotherapy regimen|Heavy-slow resistance training of rotator cuff . Scapular exercises. Manual mobilisation of glenohumeral joint . Stretching. Low Level Laser therapy
89456800|NCT02304003|Other|Standard care|Standard care offered in primary care while waiting for surgery , this may be but are not limited to : Wait and see, Drugs ( NSAIDS ), Corticosteroid injections, physiotherapy or other conservative treatment options.
89456801|NCT03511833|Active Comparator|Morphine group|Morphine group will receive IV medication and IN saline.
89456802|NCT03511833|Experimental|Ketamine group|Ketamine group will receive IV saline and IN medication.
89456803|NCT03515343||Optical diagnosis with Optivista|Participants for which the optical diagnosis of detected colorectal polyps will be done with the new technique Pentax Optivista.
89456804|NCT03515343||Optical diagnosis with iScan|Participants for which the optical diagnosis of detected colorectal polyps will be done with the oldest technique Pentax iScan.
89456805|NCT03511755|Experimental|TEN 1-11 kHz|Transdermal Electrical Neuromodulator (TEN) waveform pulsed biphasic current (1-11 kHz)
88940284|NCT01848093||COPD exacerbation|"COPD Stadium 2 and 3 during pulmonary exacerbation~sputum collection"
88940285|NCT01848106|Active Comparator|Bivalirudin|Bivalirudin bolus and infusion
89456806|NCT03511755|Active Comparator|TEN 1-3 kHz|Transdermal Electrical Neuromodulator (TEN) waveform pulsed biphasic current (1-3 kHz)
89456807|NCT02696798|Experimental|Q2W Ixekizumab|"Double Blind Period: Starting dose of 80 or 160 milligrams (mg) ixekizumab given subcutaneously (SC) at baseline followed by 80 mg ixekizumab given SC every two weeks (Q2W) to week 14.~Extended Treatment Period: 80 mg ixekizumab given SC Q2W from week 16 to week 52."
89456808|NCT02696798|Experimental|Q4W Ixekizumab|"Double Blind Period: Starting dose of 80 or 160 mg ixekizumab given SC at baseline followed by 80 mg ixekizumab given SC every four weeks (Q4W) to week 14.~Extended Treatment Period: 80 mg ixekizumab given SC Q4W from week 16 to week 52."
89456809|NCT02696798|Placebo Comparator|Placebo|"Double Blind Period: Placebo given SC Q2W to week 14.~Extended Treatment Period: Starting dose of 160 mg ixekizumab given SC at week 16 followed by 80 mg ixekizumab given SC Q2W or Q4W from week 16 to week 52."
89456810|NCT02304081|Active Comparator|Saxagliptin|Metformin and Dapagliflozin background therapy
89456811|NCT02304081|Placebo Comparator|Placebo|Metformin and Dapagliflozin background therapy
89201408|NCT01581151|Experimental|Dexamethasone intravitreal implant|"Patients will receive a dexamethasone intravitreal implant injection at day 0.~During monthly visits 1,2,3, and 5, patients will receive a ranibizumab intravitreal injection if the macula SD-OCT during that visit shows mean central foveal thickness ≥ 250 μm or the best-corrected visual acuity is 20/40 or worse. The injection procedure is described in the next section.~During monthly visit 4, patients will receive a dexamethasone intravitreal implant injection if the macula SD-OCT during that visit shows mean central foveal thickness ≥ 250 μm or the best-corrected visual acuity is 20/40 or worse."
89456812|NCT03511677|Experimental|Intervention Group|Customized insole with metatarsal support
89456813|NCT03511677|Placebo Comparator|Control Group|Placebo flat insole
89456814|NCT03515265|Experimental|Fiber resin composite|Fiber reinforced resin composite restoration used as dentin substitute covered by conventional resin composite
89456815|NCT03515265|Active Comparator|Microhybrid resin composite|Microhybrid resin composite restoration with lower strength compared to Fiber reinforced resin composite restoration
89456816|NCT02304237|Experimental|Vaginal progesterone|Vaginal progesterone(Utrogestan)200mg/day, during 14~21 weeks.
89456817|NCT02304237|Active Comparator|Intramuscular progesterone|Intramuscular progesterone(Progesterone Depot Jenapharm Injection)250mg/week, during 14~21 weeks.
89456818|NCT03515187|Experimental|A1 Medicine treatment group|0.3%sodium hyaluronate ophthalmic solution + 0.1 sodium bromide solution, 28 days
89456819|NCT03515187|Experimental|A2 Combined treatment group|0.3%sodium hyaluronate ophthalmic solution + 0.1 sodium bromide solution，with meibomian gland massage , 28 days
89456820|NCT03515187|Placebo Comparator|B1 Control group|Placebo
89456821|NCT03515187|Experimental|B2 Experiment group|0.3%sodium hyaluronate ophthalmic solution, 12 months
89456822|NCT02301117|Experimental|Mild Renal Impairment|35 mg/m2/dose of TAS-102 orally, twice daily on days 1-5 and days 8-12 of each 28 day cycle. Number of cycles: approximately 4 or until discontinuation criteria is met.
89201409|NCT00909285|Experimental|Treatment Group (#1)|
89456823|NCT02301117|Experimental|Moderate Renal Impairment|35 mg/m2/dose of TAS-102 orally, twice daily on days 1-5 and days 8-12 of each 28 day cycle. Number of cycles: approximately 4 or until discontinuation criteria is met.
89456824|NCT02301117|Experimental|Severe Renal Impairment|"35 mg/m2/dose of TAS-102 orally, twice daily on days 1-5 and days 8-12 of each 28 day cycle. Number of cycles: approximately 4 or until discontinuation criteria is met.~The dose level of severe cohort will be determined based on the Interim Assessment of mild and moderate cohorts"
88940286|NCT01848106|Experimental|Reg 1 (pegnivacogin/anivamersen)|Bolus pegnivacogin plus anivamersen active control agent
88940287|NCT01848119|Active Comparator|Gabapentin|Gabapentin 600mg, 1 dose preoperatively, followed by Gabapentin 200mg tid for 5 doses.
89456825|NCT02301117|Experimental|Normal Renal Function|35 mg/m2/dose of TAS-102 orally, twice daily on days 1-5 and days 8-12 of each 28 day cycle. Number of cycles: approximately 4 or until discontinuation criteria is met.
89456826|NCT02394938|Experimental|MUSIC|In addition to the standard care, heart failure patients assigned to the music group will listen recorded classical music.
89456827|NCT02394938|No Intervention|CONTROL|Heart Failure patients assigned to the control group will receive standard care only. The standard care will consist in nursing and medical counselling, self-care education and medication.
89456828|NCT02301195|Experimental|Therapeutic Horseback Riding|Ten-weekly one-hour manualized small group Therapeutic Horseback Riding intervention led by certified THR instructor.THR intervention taught riding and horsemanship skills.
89456829|NCT02301195|Active Comparator|Barn Activity Intervention|Ten-weekly one-hour manualized small group Barn Activity Intervention led by THR instructor, teaching horsemanship skills without horses present.
89456830|NCT02395094|No Intervention|Group 1 (Standard Procedure)|Group 1 (Standard Procedure) will receive BCCH standard care, which consists of topical anesthetic cream, waiting with parents in the playroom in the surgical daycare unit preoperatively, parental presence in the OR, the BCCH 'parent hug' and standard distraction techniques
89456831|NCT02395094|Experimental|Group 2 (Child Life)|Group 2 (Child Life) will receive Child Life intervention applicable to the individual patient, on the day of surgery in addition to standard practices
89201410|NCT00909285|Sham Comparator|Control group (#2)|
89201411|NCT01053481|Experimental|Vitamin D|Vitamin D supplement
89201412|NCT05712070|Experimental|smart group|Smartphone App-based healthcare
89201413|NCT05712070|Active Comparator|control group|a book-based self-education
89201414|NCT00927771|Experimental|Azelaic Acid|
89201415|NCT00927771|Active Comparator|Hydroquinone|
89456832|NCT02304315|Experimental|GC1102 50,000 IU|Anhepatic phase: 50,000 IU intravenous during surgery, Post-transplantation(1st week): 50,000 IU intravenous every day, Post-transplantation(2nd-4th weeks): 50,000 IU intravenous every weeks, Post-transplantation(8th weeks and till 24 weeks): 50,000 IU intravenous every 4 weeks.
89456833|NCT02304315|Experimental|GC1102 80,000 IU|Anhepatic phase: 80,000 IU intravenous during surgery, Post-transplantation(1st week): 80,000 IU intravenous every day, Post-transplantation(2nd-4th weeks): 80,000 IU intravenous every weeks, Post-transplantation(8th weeks and till 24 weeks): 80,000 IU intravenous every 4 weeks.
89456834|NCT02400320|Active Comparator|Topical Spray|Topical spray containing Diclofenac 1.16%, Linseed Oil 3%, Menthol 5%, Methyl salicylate 10%.
89456835|NCT02400320|Experimental|Topical Gel|Topical gel containing Diclofenac 1.16%, Menthol 5%, Methyl salicylate 10%
89456836|NCT02400320|Other|Saline|Saline
88940288|NCT01848119|Placebo Comparator|Placebo|lactose capsules
89456837|NCT03511443|Other|Diagnostic performance of hsRDT|Comparing diagnostic power of two diagnostics
89456838|NCT03511365|Experimental|Probiotic administration|After baseline collection of serum and fecal microbiota, each subject will be administered the probiotic formulation VSL#3 450 Billion CFU Twice daily for 8 weeks. Serum and fecal microbiota will again be collected at the end of the intervention and compared with baseline with each subject serving as his or her own control.
89456839|NCT02297919|Experimental|web based intervention|Web based intervention: Students will have access to the educational content through the learning management system on the web site (genc-e-saglik) created for this project.
89456840|NCT02297919|Active Comparator|classic preprepared lesson|Training at the control group,lectures will be presented on the basis of the classic preprepared lesson by educator and at the end of the training, will be answered student's questions.
89456841|NCT02297997|Experimental|1.5mg Cetylpyridinium Chloride|Cetylpyridinium chloride of 1.5mg will be taken daily for two weeks.
89456842|NCT02297997|Experimental|3mg Cetylpyridinium Chloride|Cetylpyridinium chloride of 3mg will be taken daily for two weeks.
89456843|NCT02297997|Experimental|4.5mg Cetylpyridinium Chloride|Cetylpyridinium chloride of 4.5mg will be taken daily for two weeks.
89456844|NCT02297997|Experimental|6mg Cetylpyridinium Chloride|Cetylpyridinium chloride of 6mg will be taken daily for two weeks.
89456845|NCT02297997|Placebo Comparator|Control|Placebo will be taken daily for two weeks.
88940289|NCT01848132|Active Comparator|R-CHOP|"6 cycles every 21 days.~Rituximab: intravenous, 375 mg/m2, day 1~Cyclophosphamide: intravenous, 750 mg/m2, day 1~Doxorubicin: intravenous, 50 mg/m2, day 1~Vincristine: intravenous, 1,4 mg/m2, day 1~Prednisone: oral, 100 mg, days 1-5"
89456846|NCT03509259||Asthma|"If the doctor has been diagnosed with asthma and one or more of the following criteria is met;~FEV1 (Forced expiratory volume in 1 second) increased more than 12% & 200 mL after 10-20 minutes of inhalation of short-acting bronchodilator (200-400 mg salbutamol)~Positive bronchial provocation tests (methacholine, mannitol, exercise, aspirin, etc.)~FEV1 Increased more than 12% & 200 mL from baseline FEV1 after anti-inflammatory treatment for 4 weeks or longer.~They can have concomittent COPD or not"
89456847|NCT03509259||Healthy control|Subjects who performed coronary artery calcium scoring CT for health checkup purpose.(retrospective group = historical control group)
89456848|NCT03511287|Experimental|IMT group|"Group intervention: home-based interval inspiratory muscle training:~during 8 weeks (two sessions per day, daily)~two times 30 breaths with one-minute rest between them in each session~training resistance set to the highest tolerable load according to scores pointed by the patient on the Borg score (between 4 and 6) aiming 50% of actual pimax or higher adjusted in the supervised weekly session"
88940290|NCT01848132|Experimental|B-R-CAP|"6 cycles every 21 days~Bortezomib: subcutaneous, 1,3 mg/m2, day 1, 8, 15~Rituximab: intravenous, 375 mg/m2, day 1~Cyclophosphamide: intravenous, 750 mg/m2, day 1~Doxorubicin: intravenous, 50 mg/m2, day 1~Prednisone: oral, 100 mg, days 1-5"
88940291|NCT01848197|Experimental|EC-P2|all patients first received 4 cycles of intravenous epirubicin and cyclophosphamide at 3-week intervals and were then intravenous paclitaxel 2-week intervals for 4 cycles.
88940292|NCT01848197|Active Comparator|EC-P1|all patients first received 4 cycles of intravenous epirubicin and cyclophosphamide at 3-week intervals and were then intravenous paclitaxel 1-week intervals for 12 cycles.
88940293|NCT01848223||late menopause|
88940294|NCT01848236|Experimental|Vitamin D2|Total of 500,000 IU vitamin D2 (50,000 IU twice weekly for 5 weeks)
88940295|NCT01848236|Experimental|Vitamin D3|Total of 500,000 IU vitamin D3 (50,000 IU twice weekly for 5 weeks)
88940296|NCT01848249||Deceased-Donor Cohort|We will collect urine samples from approximately 1600 deceased donors and approximately 600 perfusate samples from machine-pumped kidneys from participating organ procurement organizations (OPOs).
88940297|NCT01848249||Recipient Cohort (Overall and Detailed)|No samples will be collected from the recipients. Only clinical data and outcomes will be collected from the recipients.
88940298|NCT01848262|Active Comparator|ECALMIST|ECALMIST will be used in preterm infants between 24 weeks to 31 weeks in the 1st day of life with RDS and spontaneously breathing with decision to give surfactant
89456849|NCT03509103|Experimental|Electronic partograph|"The electronic version of the partograph was a state-of-the-art application that is accessed through smart phone or tablet pc or computer device. The application's user interface (UI) is segmented; users will have to concentrate only on a single portion at a time that would lessen the existing complexity of using paper-based partograph.~e-partograph application's user interface in Android programming language for smart tabs, and in ASP.net with C# language for personal computers. The application has options to save the data in local storage and in a remote central database storage concurrently. Local storage contains data for temporarility; the remote server contains the data permanently which makes the partograph information searchable at any time and place. This application allows partograph data to be monitored remotely."
89456850|NCT03509103|Active Comparator|Paper Partograph|An standard training on how to use and fill out partograph was conducted
88940299|NCT01848262|Experimental|InSurE|InSurE will be used in preterm infants between 24 weeks to 31 weeks in the 1st day of life with RDS and spontaneously breathing with decision to give surfactant
88940300|NCT01848275|Active Comparator|Group 1|Group 1 received ablation from distal to ostial of bilateral renal arteries
88940301|NCT01848275|Experimental|Group 2|group 2 received ablation at proximal of bilateral renal arteries
89016520|NCT03996096||Group with the TKI withdrawal syndrome|There is no intervention. Patients will stop their tyrosine kinase inhibitor yielding to 2 subsets: patients with or without the TKI withdrawal syndrome.
89016521|NCT03996096||Group without the TKI withdrawal syndrome|As abovementioned.
89016522|NCT03991728||Alloplastic total TMJ replacement|All treatments will remain the standard (routine) care procedures based on individual clinician's judgment and the patient characteristics. The registry does not dictate any specific treatment.
89016523|NCT03966651|Experimental|PRRT with 177Lu-DOTATATE|
89016524|NCT03932409|Experimental|Pembrolizumab + Radiation Therapy + Pembrolizumab/Chemotherapy|Pembrolizumab given 7 days prior to radiation therapy (e.g., vaginal cuff brachytherapy) followed by three cycles pembrolizumab combined with Carboplatin/Paclitaxel chemotherapy
89016525|NCT03892642|Experimental|BCG + Avelumab|Combination of avelumab and intravesical BCG. One cycle = 12 weeks (84 days). A standard maintenance therapy regimen will be provided with BCG occurring at Month 3, 6, and 12. Avelumab treatment ends at the conclusion of Month 12 maintenance therapy.
89016526|NCT03872752|Experimental|Lay leader training in FL intervention|Community lay leaders from pre-existing community frameworks will undergo training in a manualized program that enables lay leaders to effectively disseminate food literacy skills through engaging visual and game-based tools in a food literacy workshop. Post training, lay leaders will implement the food literacy workshop in their communities.
89016527|NCT03828773|Other|high-risk PTX3 SNPs|risk predicted by genotyping two PTX3 single nucleotide polymorphisms (SNPs): homozygous for rs230561 and/or rs381652
89456851|NCT02301273|Active Comparator|Usual Physiotherapy|Patients will receive the usual physiotherapy treatment in ICU in Iceland from day 5 after intubation, which adheres to international standards of practice, including the potential for no treatment. Usual physiotherapy once daily for 20 minutes.
89016528|NCT03828773|Other|low-risk PTX3 SNPs|risk predicted by genotyping two PTX3 single nucleotide polymorphisms (SNPs): other than homozygous for rs230561 and/or rs381652
89016529|NCT03824639|Experimental|Exercise group|Structured exercise
89016530|NCT03824639|Active Comparator|Control group|Health education
89016531|NCT03807973|Experimental|Fibromyalgia|
89456852|NCT02301273|Experimental|Enhanced Physiotherapy|Patients will receive the intervention physiotherapy treatment consisting of exercises and a progressive upright positioning and mobilization (20 minutes) twice daily from day 3 (>48 hours) after intubation including the potential for no treatment, if they are stable, even though they are not completely alert, Total treatment time of 40 minutes.
89016532|NCT03807973|Experimental|Chronic Fatigue Syndrome|
89016533|NCT03807973|Experimental|Multiple Sclerosis|
89016534|NCT03807973|Experimental|Healthy Controls|
89016535|NCT03805789|Experimental|AAT (low dose)|Open label. Alpha-1 antitrypsin (AAT) is a lyophilized product for intravenous administration
89016536|NCT03805789|Experimental|AAT (medium dose)|Open label. AAT is a lyophilized product for intravenous administration
89016537|NCT03805789|Experimental|AAT (high dose)|Open label. AAT is a lyophilized product for intravenous administration
89016538|NCT03805789|Experimental|AAT (selected dose from open-label)|Double-blind. AAT is a lyophilized product for intravenous administration
89016539|NCT03805789|Placebo Comparator|Placebo|Albumin solution administered intravenously
89016540|NCT03781128|Other|LSD, Placebo|Lysergic acid diethylamide (3 x 100 µg LSD in three weeks, per os) followed by Placebo
89016541|NCT03781128|Other|Placebo, LSD|Placebo (3 x 1 vial looking like LSD in three weeks, per os) followed by Lysergic acid diethylamide
89016542|NCT03761017|Experimental|Cohort 1|0.03 mg/kg administered IV every 3 weeks.
89016543|NCT03761017|Experimental|Cohort 2|0.1 mg/kg administered IV every 3 weeks.
89016544|NCT03761017|Experimental|Cohort 3|0.3 mg/kg administered IV every 3 weeks.
89016545|NCT03761017|Experimental|Cohort 4|1.0 mg/kg administered IV every 3 weeks.
89016546|NCT03761017|Experimental|Cohort 5|30. mg/kg administered IV every 3 weeks.
89016547|NCT03761017|Experimental|Cohort 6|6.0 mg/kg administered IV every 3 weeks.
89016548|NCT03761017|Experimental|Cohort 7|10.0 mg/kg administered IV every 3 weeks.
89016549|NCT03752203|Experimental|Sodium-Fluorescein Resection|This study will employ the use of sodium fluorescein and an FDA approved operative microscope equipped with excitation and barrier filters for monitoring with sufficient fluorescent enhancement and contrast.
89016550|NCT03748342|No Intervention|Standard Endotracheal Tube|
89016551|NCT03748342|Active Comparator|Second-Generation LMA|
89016552|NCT03740334|Experimental|Ribociclib (RIBO) + Dexamethasone (DEX)|"Ribociclib administered daily for 21 consecutive days~Dexamethasone administered intravenously on days 1-5 and again on days 11-15"
89016553|NCT03740334|Experimental|RIBO + Everolimus (EVE) + DEX|"Ribociclib administered daily for 21 consecutive days~Dexamethasone administered intravenously on days 1-5 and again on days 11-15~Everolimus administered daily for 21 consecutive days"
89016554|NCT03740334|Experimental|RIBO + EVE+ DEX (dose expansion)|"Ribociclib administered daily for 21 consecutive days. Dosing at RDE~Dexamethasone administered intravenously on days 1-5 and again on days 11-15~Everolimus administered daily for 21 consecutive days. Dosing at RDE"
89016555|NCT03737266|Experimental|Sonographically assisted breast surgery|Sonography assisted breast surgery
89016556|NCT03737266|Active Comparator|Conventional breast surgery|Conventional breast surgery
89016557|NCT03732417||Stroke patients|Control group included people with ischemic or haemorragic stroke in Terres de l'Ebre, Spain.
89016558|NCT03732417||Telematic model treatment of patients with Stroke|The intervention group included control and education for the patient's health to promote self-care and empowerment, and enhance pharmacological compliance. The telematic model has been developed through clinical practice guides of primary care and the most recent publications on the subject referenced.
89456853|NCT02395016|Experimental|Nimotuzumab and Gemcitabine|"nimotuzumab,400mg/w，Intravenous infusion over 60 minutes,Until disease progression or intolerable toxicity or subjects ask to leave the test.~Gemcitabine，1000mg/m2，Intravenous infusion over 30 minutes,Once every three weeks, rest one week (d1,8,15; q28d), Every 4 weeks for a period,Until disease progression or intolerable toxicity or subjects ask to leave the test."
89456854|NCT02395016|Placebo Comparator|Placebo and Gemcitabine|"placebo,400mg/w，Intravenous infusion over 60 minutes,Until disease progression or intolerable toxicity or subjects ask to leave the test.~Gemcitabine，1000mg/m2，Intravenous infusion over 30 minutes,Once every three weeks, rest one week (d1,8,15; q28d), Every 4 weeks for a period,Until disease progression or intolerable toxicity or subjects ask to leave the test."
88940302|NCT01848301|Experimental|Single arm|All subjects will undergo a Brachial Artery Flow Medicated Dilation prior to heart catheterization. After routine heart catheterization, images of their coronary artery will be recorded by Optical Coherence Tomography (OCT) during infusion of Acetylcholine.
88940303|NCT01848314|Experimental|Patients undergoing renal denervation|patients diagnosed with resistant hypertension, eligible to undergo renal denervation
88940304|NCT01848327|Experimental|Caprylic Triglyceride|Caprylic Triglyceride (40 gram packet orally once a day for 90 days)
88940305|NCT01848327|Placebo Comparator|Placebo|Placebo (40 gram packet orally once a day for 90 days)
88940306|NCT01848340|Experimental|Part A: 14C-GSK1265744 Arm|Each subject will receive a single 30 mg oral solution dose of GSK1265744 containing 14C-GSK1265744 of approximately 70 mcgCi (0.96 MSv) of radioactivity.
88940307|NCT01848340|Experimental|Part B: GSK1265744 Arm|In Part B - 8 subjects will be randomised to receive a single dose of GSK1265744 150 mg
88940308|NCT01848340|Placebo Comparator|Part B: Placebo Arm|In Part B - 2 subjects will be randomised to receive a single dose of placebo
88940309|NCT01848379|Experimental|Antidiabetic Therapy(ADT)+Full Mouth Decontamination(FD)|"ADT:~(Par-)enteral, anti-diabetic medication, diet and dietetic supervision, physiotherapy and physical exercises~FD:~The oral use of topical antiseptics prior and after mechanical tooth debridement, tooth as well as root surface planing and soft tissue decontamination in combination with systemic antibiotics (a combination of amoxicillin and metronidazole - if no microbial resistances were detected)"
88940310|NCT01848379|Active Comparator|Full Mouth Deconatamination(FD)|"FD:~The oral use of topical antiseptics prior and after mechanical tooth debridement, tooth as well as root surface planing and soft tissue decontamination in combination with systemic antibiotics (a combination of amoxicillin and metronidazole - if no microbial resistances were detected)"
88940311|NCT01848379|No Intervention|No Treatment|Healthy individuals to be monitored cross-sectional
88940312|NCT01848392||physical activity CF cohort|adult patients with CF at time of their yearly assessment at Cochin adult CF centre
88940313|NCT01848431||anaemia group|no blood transfusions will be given until hct falls under 25%
88940314|NCT01848431||normal hct group|patients in group 2 will receive transfusions as is currently standard protocol outside the study
88940315|NCT01848444||Lactating women who give her breastmilk to a milkbank|180 women will be included in 6 milk banks in France during 18 months
88940316|NCT01848470|Experimental|E1. CG400549 640mg|CG400549 640mg BID on Day 1-5 and QD on Day 6 in the fed-state
88940317|NCT01848470|Experimental|E2: CG400549 320mg|CG400549 320mg QD on Day 1-5 in the fed-state.
88940318|NCT01848470|Experimental|E3: CG400549 640mg|CG400549 640mg QD on Day 1-5 in the fed-state.
88940319|NCT01848470|Experimental|E4: CG400549 960mg|CG400549 960mg QD on Day 1-5 in the fed-state.
88940320|NCT01848470|Placebo Comparator|P1 Placebo|Placebo 640mg BID on Day 1-5 and QD on Day 6 in the fed-state
88940321|NCT01848470|Placebo Comparator|P2: Placebo 320mg|Placebo 320mg QD on Day 1-5 in the fed-state
88940322|NCT01848470|Placebo Comparator|P3 Placebo 640mg|Placebo 640mg QD on Day 1-5 in the fed-state.
88940323|NCT01848470|Placebo Comparator|P4: Placebo 960mg|Placebo 960mg QD on Day 1-5 in the fed-state.
88940324|NCT01848496|Experimental|Cordless technique|This technique does not employ a gingival cord to obtain gingival displacement.
88940325|NCT01848496|Active Comparator|Conventional technique|This technique employ a gingival cord to obtain gingival displacement.
88940326|NCT01848509|No Intervention|Without telemonitoring|Without teletransmission of alerts
88940327|NCT01848509|Experimental|With telemonitoring|With teletransmission of alerts
89456855|NCT03515109|Active Comparator|group A|Altis tape surgical placement
88940328|NCT01848535|Placebo Comparator|GOS addition|All subjects will receive amoxicillin (375 mg 3x per day) for 5 days. Group 1 receives a drink with GOS (2,5 g 3x per day) simultaneously to the antibiotic for 5 days and after the antibiotic treatment for another 7 days. The intervention products should be consumed at breakfast/lunch/dinner.
89201416|NCT01053559|Other|certolizumab pegol|Subjects will receive FDA approved Cimzia injections as indicated on the product label. Subjects will undergo 3 wireless capsule endoscopies, one at screening,Day 84 and Day 168 as well as monthly bloodwork.
89456856|NCT03515109|Placebo Comparator|group B|TVT transobturator tape placement
89456857|NCT02403050||Fiducial Markers Prospective cohort|2 fiducial markers (Visicoils) to be placed in the tumor area at the routine endoscopic ultrasound (EUS) appointment.
88940329|NCT01848535|Placebo Comparator|placebo (maltodextrine)|All subjects will receive amoxicillin (375 mg 3x per day) for 5 days. Group 2 receives a drink with placebo, maltodextrin(2,5 g 3x per day) simultaneously to the antibiotic for 5 days and after the antibiotic treatment for another 7 days. The intervention products should be consumed at breakfast/lunch/dinner.
88940330|NCT01848548||Assessment of Superior Laryngeal Nerve Block Technique|
88940331|NCT01848574|No Intervention|Usual procedure|Investigators will give medical information to their patients as usual.
88940332|NCT01848574|Experimental|Experimental procedure|"You must use the standardized patient information. The final Information of the patient before the final output should be clear and concise in the presence of trustworthy people if the patient wishes.~Deliver the following information in the orde of the items below:~Decline your identity and function Provide a final diagnosis, indicating the affected organ and Inform prognosis (any severity), and the potential duration of affection~Briefly additional tests:~Radio show~Explain the main abnormalities Explain treatment modalities and setpoint monitoring Finish with an open question: Do you have questions? If you think the state anxiety or depression alters the patient's understanding, still deliver all the information listed above."
88940333|NCT01848587|Experimental|acupuncture|5 acupuncture sessions over a 4 week period plus standard treatment
88940334|NCT01848587|Active Comparator|usual care|standard treatment (pregnancy belt, behavioral recommendations, exercises, pain killers as prescribed by usual health care professional)
88940335|NCT01848600|Experimental|abstract without limitation section|the experimental arm is abstract without the limitation section
88940336|NCT01848600|Other|abstract with limitation section|the control arm is abstract with the original limitation section
88940337|NCT01848613|Experimental|Arm A|•Arm A: first cycle of IV vinorelbine (30 mg/m2) and second cycle of PO vinorelbine (60mg/m2)
88940338|NCT01848613|Experimental|Arm B|• Arm B: first cycle with PO vinorelbine (60mg/m2) followed by a second cycle of IV vinorelbine (30mg/m2)
88940339|NCT01848652|Experimental|MYOCET|
89201417|NCT00987298||Visceral fat mass|The study population will include adult men and women, ages 18 to 90 years. All subjects will be recruited at Oregon Health and Science University (OHSU). Subjects will represent a wide range of BMI values (18.5 - 40 kg/m2).
89201418|NCT00909441|Experimental|SNB + ALND|Intervention: Sentinel Lymph Node Biopsy followed by Axillary Node Dissection.
89456858|NCT02403050||Retrospective cohort|Images and clinical data from a retrospective group of patients without fiducial markers
88940340|NCT01848665|Experimental|Drug|Indomethacin, 1.2 mg kg 1 dose
88940341|NCT01848665|Placebo Comparator|Placebo|generic flour placebo capsule
88940342|NCT01848691|Experimental|Sickle Cell|This arm will include 20 children with sickle cell anemia
88940343|NCT01848691|Active Comparator|Control|This arm will include 20 children without sickle cell anemia
88940344|NCT01848704|Active Comparator|abstract with spin|30 abstracts of 2 parallel arms negative RCTs (ie, non-statistically significant primary outcome) evaluating treatment in the field of cancer and having spin in the abstract conclusion according to a classification developed previously
89201419|NCT00984100|Experimental|Notes Transvaginal Cholecystectomy|Patients who undergo a NOTES Transvaginal cholescystectomy.
89201420|NCT01053637|Experimental|Hydrocodone/acetaminophen|Patients will receive 0.17 mg/kg hydrocodone component to a max of 10 mg hydrocodone.
89456859|NCT03508947|Experimental|WVE-210201 (Dose A) or placebo|
89456860|NCT03508947|Experimental|WVE-210201 (Dose B) or placebo|
89456861|NCT03508947|Experimental|WVE-210201 (Dose C) or placebo|
89456862|NCT03508947|Experimental|WVE-210201 (Dose D) or placebo|
89456863|NCT03508947|Experimental|WVE-210201 (Dose E) or placebo|
89456864|NCT02394782||Relapsing-remitting Multiple Sclerosis|
89456865|NCT03514953|Experimental|Reduced Physical Activity|Participants will reduce their physical activity level by >5000 steps per day for two weeks.
89456866|NCT02400398||Tube feeding with peptide-base formula|The peptide-based formula (Peptamen) will be administered through a gastrojejunal or jejunal feeding tube and dosing will be calculated using the Mifflin St. Jeor equation. It will be administered for three 28-day cycles.
89456867|NCT02301351|Other|Graphic Warning Label|Days 5-50: Participants will receive cigarette packs as per the study randomization schema (e.g. three15-day periods of red, gold, and plain packs; order counterbalanced within subject) with FDA-approved graphic warning labels.
89456868|NCT02301351|Other|Text Warning Label|Days 5-50: Participants will receive cigarette packs as per the study randomization schema (e.g. three15-day periods of red, gold, and plain packs; order counterbalanced within subject) with standard text warning labels.
89456869|NCT02400164|Experimental|alfapump system|The Sequana Medical alfapump system is an implanted subcutaneous device with a rechargeable battery that moves ascitic fluid from the peritoneal cavity to the urinary bladder where it is eliminated by spontaneous diuresis.
89456870|NCT03510975|Sham Comparator|Verbal Behavioral Therapy|All children and their parents were instructed only a verbal behavioral therapy
89456871|NCT03510975|Experimental|Check-list|All participants were instructed a behavioral therapy with a written formed check-list for parents to complete
89456872|NCT03510975|Active Comparator|Desmopressin plus verbal therapy|All children in Group III received desmopressin melt form 120 μg (Minirin, Ferring International center, Switzerland) plus verbal behavioral therapy.
89456873|NCT02301507|Experimental|SMS (texting) Arm|texts received
89456874|NCT03169790|Experimental|Nant NHL Vaccine|avelumab, bevacizumab, capecitabine, cyclophosphamide, 5-fluorouracil, leucovorin, nab-paclitaxel, lovaza, oxaliplatin, rituximab, stereotactic body radiation therapy, ALT-803,ETBX-061, and haNK.
89456875|NCT02301585|Experimental|Passive Leg Raising|Before decision on fluid administration a passive leg raising test is performed. If the test indicates fluid irresponsiveness optimization of circulation will be done with vasopressors or inotropes.
89456876|NCT02301585|Active Comparator|Standard of care|Patients are treated according to Surviving Sepsis Guidelines. Fluid is administered according to the choice of the clinician.
89456877|NCT02304393|Experimental|Part IA: Selicrelumab (IV) + Atezolizumab|Selicrelumab at a dose of 16 milligrams (mg) will be administered intravenously (IV) on Day 1 of Cycle 1 (first cycle in this group was of 42 days, and subsequent 21-day cycles); and atezolizumab 1200 mg will be administered IV after 6 weeks on Day 1 of Cycle 2, followed by every 3 weeks during Part IA until disease progression, death, loss of follow-up, or withdrawal of consent.
89456878|NCT02304393|Experimental|Part IA: Selicrelumab(SC) + Atezolizumab|Selicrelumab at a starting dose of 1 mg will be administered subcutaneously (SC) on Day 1 of Cycle 1 (21-day cycle) which will follow escalation in sequential cohorts; and atezolizumab 1200 mg will be administered IV on Day 1 of Cycle 2, and followed by every 3 weeks during Part IA as long as the participant experiences clinical benefit in the opinion of the investigator or until unacceptable toxicity.
89456879|NCT02304393|Experimental|Part IB: Selicrelumab + Atezolizumab|Selicrelumab will be administered at a starting dose of 1 mg SC on Day 2 of Cycle 1 (21-day cycle) which will follow escalation in sequential cohorts; and atezolizumab 1200 mg will be administered IV on Day 1 of Cycle 1, and followed by every 3 weeks during Part IB as long as the participant experiences clinical benefit in the opinion of the investigator or until unacceptable toxicity.
89456880|NCT02304393|Experimental|Part II: Selicrelumab + Atezolizumab|Atezolizumab 1200 mg will be administered IV on Day 1 of Cycle 1, and followed by every 3 weeks; and Selicrelumab will be administered at the dose defined in Part IB (not exceeding 80 mg SC [unless IV administration in Part IB demonstrates better benefit/risk ratio]) on Day 2 (1 day after atezolizumab administration) of every second cycle from Cycles 1 to 7, and every fourth cycle thereafter during Part II as long as the participant experiences clinical benefit in the opinion of the investigator or until unacceptable toxicity.
89456881|NCT02304471||Control|healthy subjects
89456882|NCT02304471||CKD|chronic kidney disease
89456883|NCT02304471||ESRD|end-stage renal disease
88940345|NCT01848704|Experimental|abstract without spin|The abstracts with spin were systematically rewritten without spin
88940346|NCT01848717|Experimental|Lift thread|
89456884|NCT02402972|Experimental|IPC plus AC|"patients treated with intraoperative intraportal chemotherapy (IPC) plus adjuvant chemotherapy (AC; mFOLFOX6).; IPC: During the operation, one dose of fluorodeoxyuridine (FUDR) 1000 mg and oxaliplatin 100 mg were administered as a bolus into the regional vein within 5 minutes just before ligation.~AC: All patients received mFOLFOX6 adjuvant chemotherapy, consisting of a 2-h infusion of 85 mg/m2 oxaliplatin given simultaneously with a 2-h infusion of 400 mg/m2 LV, followed by a bolus of 400 mg/m2 5-FU, and then a continuous infusion of 2000 mg/m2 5-FU given on 2 consecutive days by intravenous pumping every 14 days for 12 cycles.[1] Adverse events were categorized according to National Cancer Institute Common Toxicity Criteria, version 3.0."
89456885|NCT02402972|Active Comparator|AC|patients treated with adjuvant chemotherapy (AC; mFOLFOX6) alone after surgery; Adjuvant chemotherapy (AC): All patients received mFOLFOX6 adjuvant chemotherapy, consisting of a 2-h infusion of 85 mg/m2 oxaliplatin given simultaneously with a 2-h infusion of 400 mg/m2 LV, followed by a bolus of 400 mg/m2 5-FU, and then a continuous infusion of 2000 mg/m2 5-FU given on 2 consecutive days by intravenous pumping every 14 days for 12 cycles.[1] Adverse events were categorized according to National Cancer Institute Common Toxicity Criteria, version 3.0.
89456886|NCT04464369|Placebo Comparator|Placebo|Placebo t.i.d.
89456887|NCT04464369|Active Comparator|Itopride|Itopride co 100 mg t.i.d.
89456888|NCT02304549||patients with BPH undergoing TUV-P|patients with Benign Prostatic Hyperplasia undergoing TUV-P
88940347|NCT01848730|Experimental|CNV2197944|CNV2197944 75mg tid 21 days
88940348|NCT01848730|Placebo Comparator|Placebo|Placebo tid 21 days
88940349|NCT01848743|Active Comparator|Tenofovir|All enrolled patients are randomized to tenofovir arm who receives tenofovir 300 mg qd for 36 months
88940350|NCT01848743|Placebo Comparator|lamivudine|All enrolled patients are randomized to lamivudine arm who received lamivudine 100 mg qd for 6 months, followed by tenofovir for another 30 months.
89201421|NCT01053637|Placebo Comparator|Sugar water|Placebo
88940351|NCT01848769|Experimental|CHF1535 pMDI + AC Plus|Fixed combination of Beclomethasone Dipropionate and Formoterol 50/6 mcg with Aerochamber Plus spacer device
88940352|NCT01848769|Active Comparator|BDP and Formoterol + AC Plus|Beclomethasone Dipropionate 50 mcg and Formoterol 6 mcg with Aerochamber Plus spacer device
88940353|NCT01848782|Experimental|abstract with limitation section added|we add a limitation section in each selected abstract, the limitation section will focus on the quality of included studies.
88940354|NCT01848782|Active Comparator|abstract without limitation section|We selected 30 abstracts with a conclusion in favour the experimental treatment from a sample of systematic reviews that evaluate the effect of health care intervention.
88940355|NCT01848795|Experimental|EndoBarrier Gastrointestinal Liner|The treatment in this arm is the endoscopic positioning of the EndoBarrier Gastrointestinal Liner and follow up.
88940356|NCT01848795|Active Comparator|Intragastric Balloon|The treatment in this arm is the endoscopic positioning of the intragastric balloon (Easy life balloon) as a comparator and follow up.
88940357|NCT01848808|Experimental|Wobenzym PS|During the 4-week of the Wobenzym supplementation, participants will take 6 tablets of Wobenzym: 2 tablets 3 times daily at least 45 minutes before meal.
88940358|NCT01848808|Placebo Comparator|Placebo|During the 4-week of placebo phase, participants will take 6 tablets of placebo: 2 tablets 3 times daily at least 45 minutes before meal.
88940359|NCT01848860|Sham Comparator|Control group|In this group, only thoracoscopic bullectomy and pleural abrasion will be done.
88940360|NCT01848860|Experimental|Mesh group|In this group, absorbable mesh coverage of the staple line will be performed after thoracoscopic bullectomy and pleural abrasion.
88940361|NCT01848873|Experimental|amlodipine-FA tablet, low dose group|5mg amlodipine combined with 0.4 mg of folic acid (FA),once daily for 8 weeks.
88940362|NCT01848873|Experimental|amlodipine-FA tablet ,high dose group|5mg amlodipine combined with 0.8 mg of folic acid (FA), once daily for 8 weeks.
88940363|NCT01848873|Active Comparator|amolodipine|5 mg amlodipine, once daily for 8 weeks.
88940364|NCT01848886|Other|Grp 1: ERAH, Mammarioradial (Y-graft)|Endoscopic radial artery harvest Mammarioradial graft (Y-graft) In this group the radial artery is harvested as an endoscopic procedure and positioned on the heart as an composite graft (Y-graft).
89201422|NCT00928005|Active Comparator|Weight loss diet|Participants will follow a low-calorie, low-fat weight loss diet for 6 months.
89201423|NCT00928005|Active Comparator|Weight loss diet plus exercise|Participants will follow a low-calorie, low-fat weight loss diet plus participate in a supervised exercise training program for 6 months.
89201424|NCT00928161|No Intervention|Group 1|Patients with no acid reflux.
89201425|NCT00928161|Active Comparator|Group 2|Patients with acid reflux.
89201426|NCT00909519|Active Comparator|naproxen|
89201427|NCT00909519|Experimental|naproxcinod|
89201428|NCT00909519|Placebo Comparator|placebo|
88940365|NCT01848886|Other|Grp 2: ERAH, Aortoradial (Free RA)|Endoscopic radial artery harvest Aortooradial (free RA) In this group the radial artery is harvested as an endoscopic procedure and positioned on the heart as an free RA graft.
88940366|NCT01848886|Other|Grp 3: ORAH, Mammarioradial (Y-graft)|Open radial artery harvest Mammarioradial graft (Y-graft) In this group the radial artery is harvested as an open procedure and positioned on the heart as an composite graft (Y-graft).
89201429|NCT00928239|Experimental|1|Arm1: Laparoscopic repair of vaginal vault prolapse. Laparoscopic sacropexy procedure as described in previous publication(Sarlos D, Brandner S, Kots L, Gygax N, Schaer G. Laparoscopic sacrocolpopexy for uterine and post-hysterectomy prolapse: anatomical results, quality of life and perioperative outcome-a prospective study with 101 cases. Int Urogynecol JPelvic Floor Dysfunct. 2008 Oct;19(10):1415-22. Epub 2008 Jun 7. PubMed PMID: 18536861) with attachment to the caudal part of the vagina and the apex.
89201430|NCT00928239|Active Comparator|2|Arm 2: Laparoscopic repair of vaginal vault prolapse. Laparoscopic sacropexy procedure as described in previous publication(Sarlos D, Brandner S, Kots L, Gygax N, Schaer G. Laparoscopic sacrocolpopexy for uterine and post-hysterectomy prolapse: anatomical results, quality of life and perioperative outcome-a prospective study with 101 cases. Int Urogynecol JPelvic Floor Dysfunct. 2008 Oct;19(10):1415-22. Epub 2008 Jun 7. PubMed PMID: 18536861) with attachment of the dorsal mesh at distal end of vagina at dorsal vaginal wall
89201431|NCT00928317|Experimental|ART621 A|ART621 0.75mg/kg per week
89201432|NCT00928317|Experimental|ART621 B|ART621 1.5 mg/kg per week
89201433|NCT00928317|Experimental|ART621 C|ART621 3.0mg/kg per week
89201434|NCT00928317|Placebo Comparator|Placebo arm|
89201435|NCT00355615|Active Comparator|rosuva 5|rosuvastatin 5 mg
89201436|NCT00355615|Active Comparator|rosuva 10|rosuvastatin 10 mg
89201437|NCT00355615|Active Comparator|rosuva 20|rosuvastatin 20 mg
89201438|NCT00355615|Placebo Comparator|Placebo|Placebo
89201439|NCT00355615|Other|rosuva ol|rosuvastatin open label
89201440|NCT00907179|Experimental|Dose escalation|"Phase I: Determine the highest and safest dosage of LBH589 (15 mg, 20 mg, and 30 mg). If the 15 mg dosage causes too many side effects, a back-up dosage of 10 mg will be used instead of the 15 mg.~Pemetrexed 500mg/m2 IV, day 1, every 21 days, on the first day of the week LBH589 is given"
88940367|NCT01848886|Other|Grp 4: ORAH, Aortoradial graft (Free RA)|Aortooradial graft (free RA) Open radial artery harvest In this group the radial artery is harvested as an open procedure and positioned on the heart as an free RA graft.
88940368|NCT01848925|Experimental|SANGUINATE™|PEG-bHb-CO
88940369|NCT01848925|Active Comparator|Hydroxyurea|Standard of care for Sickle Cell treatment, 15 mg/kg.
88940370|NCT01848964|Experimental|Evaluation|"First, the assessment will be performed to evaluate the relationship between pressure repartition pattern, clinical evaluation and motor capabilities. All the patients and volunteers will be concerned by this first part.~A second part will be conducted in 15 amputees within the 40 patients. Assessments of pressure pattern during gait and standing will be repeated two times: by the same investigator and by a different investigator, in order to test intra- and inter-evaluator reproducibility.~After the first assessment, the prosthesis may be modified in order to solve clinical problems. In that case, a new assessment will be proposed 2 to 8 weeks after in order to test the effect of the prosthesis modification on pressure pattern, gait, posture and clinical parameters."
88940371|NCT01849003|Experimental|Cohort 1|Participants will receive a single 10 mg dose of GS-6615.
89456889|NCT02402816|Experimental|MPP ON|Patients will be randomized to the MPP-ON Arm vs Standard ICD
89456890|NCT02402816|Active Comparator|Standard ICD|Patients will be randomized to the MPP-ON Arm vs Standard ICD
89456891|NCT02394470|Other|Acute heart failure HF,Chronic HF,Advanced chronic HF|patient admitted to the hospital for acute heart failure (de-novo or exacerbation of chronic heart failure), for Chronic HF and for Advanced chronic heart failure
89456892|NCT02394236|Experimental|Continuous exercise training|The continuous exercise training was performed on a treadmill with a 50-minutes duration and intensity at ventilatory anaerobic threshold.
88940372|NCT01849003|Experimental|Cohort 2|Participants will receive a single 20 mg dose of GS-6615.
88940373|NCT01849003|Experimental|Cohort 3|Participants will receive a single 30 mg dose of GS-6615.
89456893|NCT02394236|Experimental|interval exercise training|The interval exercise training consisted of 7 sets of 3 minutes at respiratory compensation point and 7 sets of 3 minutes of exercise at moderate intensity corresponding to the ventilatory anaerobic threshold totaling 42 minutes
89456894|NCT02304627|Experimental|Eating meal immediately after dosing|
89456895|NCT02304627|Experimental|Eating meal 30 min after dosing|
89456896|NCT02304627|Experimental|Eating meal 1 hour after dosing|
89456897|NCT02304627|Experimental|Eating meal 6 hour after dosing|
89456898|NCT02402738|Experimental|Interpersonal and Social Rhythm Therapy|Participants may be randomized to receive up to 20 outpatient sessions of Interpersonal and Social Rhythm Therapy, provided as an adjunct to community treatment as usual. Intervention sessions begin during pregnancy and continue through 8 weeks postpartum.
89456899|NCT02402738|Active Comparator|Enhanced Treatment as Usual|Those randomized to the Enhanced Treatment as Usual arm will follow their usual treatment plans in the community, with enhanced monitoring of symptoms and functioning through regular study assessments. With a release of information, we will provide community clinicians with a monthly standardized report that summarizes level of symptom severity and risk, designed to aid in continuity of care.
88940374|NCT01849003|Experimental|Cohort 4|Participants will receive a single 60 mg dose of GS-6615.
88940375|NCT01849003|Experimental|Cohort 5|"Participants will receive single doses of GS-6615 as follows:~Day 1: 20 mg (loading dose)~Day 2: 40 mg (loading dose)~Days 3-7: 6 mg (maintenance dose) once daily~If a participant has a QTcF value of ≤ 420 msec on 2 consecutive time points after the 20 mg dose on Day 1, the participant will receive the maintenance dose of 6 mg on Day 2."
88940376|NCT01849003|Experimental|Cohort 6|"Participants will receive single doses of GS-6615 as follows:~Day 1: 50 mg (loading dose)~Day 2-3: 10 mg once daily~Days 4-7: 20 mg once daily"
88940377|NCT01849016|Experimental|N-Acetylcysteine|N-Acetylcysteine 600mg 1 oral tablet twice daily during 6 months
88940378|NCT01849016|Placebo Comparator|Placebo|Placebo 1 oral tablet twice daily during 6 months
88940379|NCT01849029|Experimental|Cognitive Processing Theapy-Cognitive|Immediate group receives Cognitive Processing Therapy-Cognitive CPT-C intervention within one week of being consented into the study
89456900|NCT02301741|Experimental|Game Condition|Participants in the GAME condition will complete laboratory sessions on five consecutive days. Session 1 (baseline) and Session 5 (post-test) will be used to assess lumbar spine motion and expectations of pain and harm during standardized reaching tasks. In sessions 2 through 4 they will play the virtual dodge ball game.
89456901|NCT02301741|No Intervention|Control Condition|Participants in the CONTROL condition will complete baseline and post-test standardized reaching tasks, but will not play the game in the intervening three days.
89456902|NCT03508791|Active Comparator|Trendelenburg group|Arterial, end-tidal, and transcutaneous carbon dioxide partial pressure are monitored in the Trendelenberg position
88940380|NCT01849029|Other|Cognitive Processing Threapy-Cognitive|Wait list group: waits 6 weeks before receiving the Cognitive Processing Therapy-Cognitive (CPT-C) intervention. During this period no intervention is received
89456903|NCT03508791|Active Comparator|reverse Trendelenburg group|Arterial, end-tidal, and transcutaneous carbon dioxide partial pressure are monitored in the reverse Trendelenberg position
89456904|NCT02306421|Active Comparator|RPH with the simplified Milligan-Morgan|RPH is a new therapy for hemorrhoid following the improvement of rubber band ligation. The treatment principle is: shrinkage of mucous membrane after the ligation, lift of anal cushion, the local inflammatory response resulting in adhesion of mucosa and submucosa and shallow muscle layer, anal cushion fixing to a higher position, at the same time by using the elastic contraction of automatic elastic line partly blocking blood supply of Internal hemorrhoids or reducing venous stasis, decreasing congestion hypertrophy of hemorrhoids. Simplified Milligan-Morgan is a surgical option which was improved and developed by Professor He,well-known traditional Chinese doctor from Hunan province, based on Milligan-Morgan in 1971.The operation method is simple, the operation time is shortened.
88940381|NCT01849042|Other|donepezil maintain group|continue already taking same dose (5mg or 10mg per day) of donepezil who assigned donepezil group
88940382|NCT01849042|Active Comparator|add-on Ebixa oral pump group|Ebixa dosage titration (5mg per day for 1week, then 10mg per day for 1week, then 15mg per day for 1week, then up to 20mg per day) add-on already taking donepezil (5mg or 10mg per day)
89456905|NCT02306421|Active Comparator|PPH with the simplified Milligan-Morgan|According to anal cushion down theory of the formation of hemorrhoids, the Italy scholar Longo pioneered a new method for the treatment of circular prolapsed internal hemorrhoids In 1998.Its principle is resection of lower rectal mucosa and submucosa of the intestinal wall tissue in the ring above the hemorrhoids through surgical staples,anastomosis of the proximal and distal mucosa , lifting and fixing down anal cushion, recovering to the normal anatomical position.Simplified Milligan-Morgan is a surgical option which was improved and developed by Professor He,well-known traditional Chinese doctor from Hunan province, based on Milligan-Morgan in 1971.The operation method is simple, the operation time is shortened.
89456906|NCT02306421|Active Comparator|R P H|RPH is a new therapy for hemorrhoid following the improvement of rubber band ligation.The treatment principle is: shrinkage of mucous membrane after the ligation, lift of anal cushion, the local inflammatory response resulting in adhesion of mucosa and submucosa and shallow muscle layer , anal cushion fixing to a higher position, at the same time by using the elastic contraction of automatic elastic line partly blocking blood supply of Internal hemorrhoids or reducing venous stasis, decreasing congestion hypertrophy of hemorrhoids , making hemorrhoidal lump shrink, thus eliminating bleeding and prolapse symptoms of hemorrhoid.It is suitable for internal hemorrhoids in every period and internal hemorrhoids part of mixed hemorrhoid.
89456907|NCT02306421|Active Comparator|P P H|According to anal cushion down theory of the formation of hemorrhoids, the Italy scholar Longo pioneered a new method for the treatment of circular prolapsed internal hemorrhoids-PPH.In 1998.Its principle is resection of lower rectal mucosa and submucosa of the intestinal wall tissue in the ring above the hemorrhoids through surgical staples,anastomosis of the proximal and distal mucosa , lifting and fixing down anal cushion, recovering to the normal anatomical position
88940383|NCT01849081|Experimental|CPAP|Subjects in this arm with receive treatment with CPAP for fatty liver disease.
88940384|NCT01849081|Active Comparator|Lifestyle Intervention|Subjects in the lifestyle arm will undergo 12 weeks of dietary counseling.
88940385|NCT01849094|Experimental|Milrinone 6mg|"single oral dose of 6mg ER milrinone tablet (Part A).~1. single intravenous infusion of milrinone (per Alfred Hospital protocol. 50ug/kg loading dose over 15 mins followed by infusion at 0.375 ug/kg/min for 6 hrs) - Part B."
88940386|NCT01849094|Active Comparator|Milrinone 10mg ER|single oral dose of 10 mg ER milrinone tablet (Part A) single oral dose of 10 mg ER milrinone tablet (Part B)
88940387|NCT01849094|Active Comparator|Milrinone 14mg|single oral dose of 14 mg ER milrinone tablet (Part A) single dose of 14 mg ER milrinone tablet 4. single oral dose of 18 mg ER milrinone tablet (if the group average plasma milrinone levels is less than 150 ug/L with 15 mg dose) - (Part B)
88940388|NCT01849107|Experimental|Plasma citrulline|
88940389|NCT01849120||Near-infrared spectroscopy (NIRS)|After cardiac surgery, all subjects will have EQUANOX Advance 8004CB sensors applied to peripheral sites (left and right calf and side of abdomen).
88940390|NCT01849133|Experimental|ELIOT|intraoperative radiotherapy
88940391|NCT01849133|Active Comparator|EXTERNAL RT|external fractionated radiotherapy
89456908|NCT02306421|Active Comparator|Milligan-Morgan|Milligan-Morgan surgery ,created in 1937 by Milligan etc,whose essence is to excise hemorrhoids of increasing prolapse in anatomy has good curative effect, low recurrence.It is currently the most common clinical surgery.
88940392|NCT01849159|Active Comparator|MSC group|Intravenous infusion of MSC suspension, pre-conditioned under 1% oxygen, in the amount of 200 mln. cells per 400 mL of sodium chloride physiological solution. Infusions will be performed every 2 months for 1 year
88940393|NCT01849159|Placebo Comparator|Control Group|400 mL of 0.9% NaCl solution. Infusions will be performed every 2 months for 1 year
88940394|NCT01849185|Active Comparator|BIO 25 (food supplements)twice a day for 8 weeks|BIO 25 - Innovative Formula contains 11 different strains of probiotic bacteria patents and more than 25 billion active bacteria in each capsule.
88940395|NCT01849185|Placebo Comparator|Placebo twice a day for 8 weeks|Placebo twice a day for 8 weeks
88940396|NCT01849198|Other|Group trapezius|Assessment of intubation conditions after onset of the neuromuscular block at the m. trapezius
88940397|NCT01849198|Other|group adductor pollicis|assessment of intubation conditions after onset of the neuromuscular block at the m. adductor pollicis
88940398|NCT01849211|Other|neuromuscular block|
88940399|NCT01849224|Experimental|Pelvic and lower extremity exercise|Experimental arm will be educated the guidelines for prevention and early detection of lower extremity edema. Additionally, pelvic and lower extremity exercise will be educated and participants will continue exercise for 1 year at home.
89201441|NCT00347269|Experimental|CALM Intervention|"Participant choice of:~Cognitive Behavioral Therapy (CBT) Psychotropic (anti-anxiety) medication optimization"
89201442|NCT00347269|Active Comparator|Treatment as Usual (TAU)|Participants assigned to TAU with their primary care provider (PCP)
89456909|NCT02400008|Experimental|Patient with bilateral vocal fold paralysis|Patient with bilateral vocal fold paralysis in a closure position between 6 months to 36 months before et who has been treated by endoscopic treatment without satisfying result (voice or breathing).
89456910|NCT02394314|Placebo Comparator|Placebo|Placebo administered subcutaneously
89456911|NCT02394314|Experimental|MEDI0382|MEDI0382 administered subcutaneously
89456912|NCT03508713||early RA patients|patients must fulfill the 1987 ACR classification criteria for rheumatoid arthritis or 2010 Rheumatoid arthritis classification criteria of ACR/EULAR, and meet the condition that the course of disease was no more than 6 months. If enrolled, patients will be treated with disease modified antirheumatic drugs or biological agents.
89456913|NCT04481828||open gastrectomy|The first group (Group 1; n: 30) consisted of patients who underwent open surgery
89456914|NCT04481828||laparoscopic gastrectomy|The second group (group 2; n:30) consisted of patients who underwent laparoscopic gastrectomy
89456915|NCT03510897|Active Comparator|QPI-1002|QPI-1002 Injection, Single dose
88940400|NCT01849224|No Intervention|Control|Control group will be educated the guidelines for prevention and early detection of lower extremity edema
88940401|NCT01849237|Active Comparator|Standard therapy of septic shock|according to Surviving Sepsis Campaign 2012 Antibiotic therapy Fluid therapy Vasopressors Inotropic therapy Steroids
88940402|NCT01849237|Experimental|Mesenchymal stromal cells+ standard therapy of septic shock|"MSCs intravenous infusion of 1-2 millions/kg/day will be performed not more than 10 hs after onset of septic shock in patients with severe neutropenia(≤ 1x10^9/l).~according to Surviving Sepsis Campaign 2012: Antibiotic therapy Fluid therapy Vasopressors Inotropic therapy Steroids"
88940403|NCT01849302|Experimental|High protein/ High fat beverage|"Beverage based on milk protein: 1.8 MJ, 40 E% Protein, 42 E% fat~Acute effect of beverages varying in macronutrient content on appetite and energy intake"
88940404|NCT01849302|Experimental|High protein/ Normal CHO beverage|"Beverage based on milk protein: 1.8 MJ, 40 E% Protein, 47 E% CHO~Acute effect of beverages varying in macronutrient content on appetite and energy intake"
88940405|NCT01849302|Experimental|Low protein/ High fat beverage|"Beverage based on milk protein: 1.8 MJ, 9 E% Protein, 63 E% fat~Acute effect of beverages varying in macronutrient content on appetite and energy intake"
88940406|NCT01849302|Experimental|Low protein/ High CHO beverage|"Beverage based on milk protein: 1.8 MJ, 9 E% Protein, 71 E% CHO~Acute effect of beverages varying in macronutrient content on appetite and energy intake"
88940407|NCT01849302|Experimental|Normal protein/ Normal CHO beverage 1|"Beverage based on milk protein: 1.8 MJ, 24 E% Protein, 50 E% CHO~Acute effect of beverages varying in macronutrient content on appetite and energy intake"
88940408|NCT01849302|Experimental|Normal protein/Normal CHO beverage 2|"Beverage based on milk protein: 1.8 MJ, 24 E% Protein, 50 E% CHO~Acute effect of beverages varying in macronutrient content on appetite and energy intake"
88940409|NCT01849302|Experimental|Normal protein/Normal CHO beverage 3|"Beverage based on milk protein: 1.8 MJ, 24 E% Protein, 50 E% CHO~Acute effect of beverages varying in macronutrient content on appetite and energy intake"
89201443|NCT00928473|Experimental|Lifestyle counseling|The obese children will start a treatment for obesity in the Children's Obesity Clinic. This treatment includes lifestyle counseling, objective examination, weight-controls, visiting a psychologist, visiting a dietician and blood samples, DXA-scan, eventually MRI.
89201444|NCT01053793|Active Comparator|Glucose Standard|
89456916|NCT03510897|Placebo Comparator|Placebo|isotonic saline
89456917|NCT02394158|Active Comparator|Intervention arm Metformin|Metformin (500mg tablets) to start at a dose of 500mg once daily with an increase of 500mg every five days until the maximum dose of 1000mg twice daily is reached.
89456918|NCT02394158|Placebo Comparator|Control arm placebo|Matched placebo tablets (500mg) to start at a dose of 500mg once daily with an increase of 500mg every five days until the maximum dose of 1000mg twice daily is reached.
88940410|NCT01849315|Placebo Comparator|Control|Sedentary intervention
88940411|NCT01849315|Active Comparator|AKIDS II|Physically active group
88940412|NCT01849328||Breast Cancer|
88940413|NCT01849328||Healthy|
89456919|NCT02698826|Experimental|Adult patients resuscitated from cardiac arrest|Rapid FiO2 optimization protocol
89456920|NCT03508635|Experimental|SAD Cohorts 1 through 6|Participants will receive single doses of 5 mg up to 400 mg of CORT125134 (capsule) in a dose escalation format. The doses selected will be subject to amendment based on emerging data.
89456921|NCT03508635|Placebo Comparator|SAD Cohorts 1 through 6 Placebo|Participants will receive single doses of Matching Placebo of CORT125134 (capsule).
89456922|NCT03508635|Experimental|Food Effect Cohort 7|Participants will receive a single dose of CORT125134 (capsule) with a standard high fat breakfast. The dose will be chosen such that it has been previously administered in a prior SAD cohort.
88940414|NCT01849341|Experimental|Roflumilast alternated days|Intervention: 500 mcg per day on alternate days (roflumilast 500μg eod) for 2 weeks
88940415|NCT01849341|Active Comparator|Roflumilast 500 mcg per day|Roflumilast 500μg standard dosage
88940416|NCT01849354||Endometriosis patients|Endometriosis patients to be operated in Turku university hospital 2013-2015
89201445|NCT01053793|Experimental|Potato Variety|
89201446|NCT01056211|Active Comparator|hypopigmented scars treated with laser|patients with hypopigmented scars treated with Starlux 300 Lux 1540nm Fractional laser hand piece
89201447|NCT01056211|Placebo Comparator|hypopigmented scars treated without laser|patients with hypopigmented scars treated without laser
89201448|NCT01056211|Active Comparator|hypertrophic scars treated with laser|
89201449|NCT01056211|Placebo Comparator|hypertrophic scars not treated with laser|
88940417|NCT01849354||Control patients|Patients who will be operated because of an adnexal finding other than endometriosis, for example ovarian cyst. Also patients with laparoscopic sterilization will be recruited to the control group.
88940418|NCT01849367|Experimental|Active tDCS (1)|
88940419|NCT01849367|Active Comparator|Active tDCS (2)|
88940420|NCT01849380|Experimental|Epirubicin-cyclophosphamide-S-1( ECS)|S-1(SuLi,QILU Pharmaceutical co.ltd ) was given at a standard dose of 40 mg/m2 twice daily in cycles of 14-day consecutive administration followed by a 14-day rest, combined with by epirubicin(80mg/m2, d1 and d8 respectively) and cyclophosphamide(500mg/m2, d1, infusion). The chemotherapy was applicated 4 cycles 4-weekly.
88940421|NCT01849380|Active Comparator|Epirubicin-cyclophosphamide-5-FU (ECF)|5-FU was given at a standard dose of 500mg/m2 (infusion, d1, d8 respectively), combined with by epirubicin(80mg/m2, d1 and d8 respectively) and cyclophosphamide(500mg/m2, d1, infusion). The chemotherapy was applicated 4 cycles 4-weekly.
88940422|NCT01849393||Study Population|Participants must meet the eligibility requirements will complete a questionnaire on the computer.
88940423|NCT01849406|Active Comparator|Nasal spray Budesonide|one week therapy of nasal budesonide (twice per day)
88940424|NCT01849406|Placebo Comparator|Nasal spray Normal Saline|one week therapy of nasal normal saline (twice per day)
88940425|NCT01849432||Control|Healthy Controls
88940426|NCT01849432||Posttraumatic Stress Disorder|Participants with Posttraumatic Stress Disorder
88940427|NCT01849432||Panic Disorder|Participants with Panic Disorder
88940428|NCT01849432||Specific Phobia|Participants who have specific phobias
88940429|NCT01849445|Active Comparator|Intensive physiotherapy|Participants will visit hospital for physiotherapy sessions once a week for 6 weeks in addition to completing prescribed exercises twice a week at home on their own.
88940430|NCT01849445|Active Comparator|Home physiotherapy excercises|Patients will be asked to complete prescribed exercises at home on their own 3 times a week for 6 weeks.
88940431|NCT01849471||patients with prostate cancer|questionnaires
88940432|NCT01849484|Experimental|hippocampal sparing radiotherapy|Radiation according to indication with hippocampal sparing
88940433|NCT01849484|Active Comparator|Control|Radiation according to indication without hippocampal sparing
88940434|NCT01849510|Experimental|dose intensified|hypofractionated 12x3 Gy + integrated boost 12x4 Gy
88940435|NCT01849510|Active Comparator|standard|hypofractionated 10x3 Gy
88940436|NCT01849523|Experimental|Web-based information and support|Web-based tailored information and support
88940437|NCT01849523|No Intervention|Standard care|Standard care
88940438|NCT01849536|Experimental|SENSIMED Triggerfish®|SENSIMED Triggerfish®
88940439|NCT01849549|Experimental|brain damaged subjects|patients with circumscribed brain injury, selective disorders of cognitive development or degenerative disorders responsible for focal troubles
88940440|NCT01849549|Sham Comparator|healthy volunteers|healthy controls
88940441|NCT01849601|Experimental|PTA catheter|
88940442|NCT01849614||Patient group|Women with left-sided breast cancer
88940443|NCT01849640|Active Comparator|DHA-piperaquine with Primaquine|3-day treatment course of DHA-piperaquine with 45mg single dose primaquine
88940444|NCT01849640|Active Comparator|DHA-piperaquine without Primaquine|3-day treatment course of DHA-piperaquine
88940445|NCT01849653||Women - Upcoming routine clinic visit|This group of women will self-obtain vaginal swabs at home on the day of their medical appointment and bring the specimens to the clinic. Subjects will then self-obtain another set of vaginal swabs at the clinic. Clinician/nurse will obtain another set of vaginal swabs from the subject at the clinic.
88940446|NCT01849653||Women - Recruited while at the clinic|This group of women will self-obtain vaginal swabs at the clinic. Clinician/nurse will obtain another set of vaginal swabs from the subject at the clinic. Within 24 hours of their clinic visit, subjects will self-obtain another set of vaginal swabs at their home and mail them to the laboratory.
88940447|NCT01849666|Active Comparator|A: phenprocoumon single dose|
88940448|NCT01849666|Experimental|B: vemurafenib + phenprocoumon single dose|
88940449|NCT01849679||Post-Extubation Subjects|
88940450|NCT01849705||All subjects|No intervention
89201450|NCT01056211|Active Comparator|scars due to grafts and reconstructions treated with laser|scars due to grafts and reconstructions in the head and neck region
89456923|NCT03508635|Experimental|Pharmacological Effect Cohort 8|Participants will receive a single dose of 25 mg of prednisone on Day -19; a single dose of 25 mg prednisone and 600 mg of mifepristone on Day -12; and a single dose of 25 mg prednisone and a single dose of CORT125134 on Day 1. The dose of CORT125134 will be chosen such that it has been previously administered in a prior SAD cohort.
89456924|NCT03508635|Experimental|Proof of Concept (POC) Cohort 9|Participants will receive a single dose of 25 mg of prednisone on Day -19; a single dose of 25 mg of prednisone and 600 mg of mifepristone on Day -12; and a single dose of 25 mg prednisone and a single dose of CORT125134 on Day 1. An oral glucose tolerance test will be administered on each study day. The dose of CORT125134 will be chosen such that it has been previously administered in a prior SAD cohort.
89456925|NCT03508635|Experimental|MAD Cohorts 10 and 11|Participants will receive the selected dose of CORT125134 (capsule) following receipt of data from Cohorts 1-9 up to a maximum frequency of twice a day for a total of 14 days.
89456926|NCT03508635|Placebo Comparator|MAD Cohorts 10 and 11 Placebo|Participants will receive Matching Placebo of CORT125134 (capsule) up to a maximum frequency of twice a day for a total of 14 days.
89456927|NCT03508635|Experimental|MAD of PoPE Cohorts 12 and 13|Proof of Pharmacological Effect (PoPE+POC). Participants will receive 25 mg of prednisone (both cohorts) and an oral glucose tolerance test (Cohort 13 only) on Day -5. Participants will then receive the selected dose of CORT125134 (capsule) for a total of 13 days. Participants may either receive a higher dose level than previously administered or a repeat of a dose level given in 1 of the previous 2 MAD Cohorts. Participants will then receive 25 mg of prednisone (both cohorts) and an oral glucose tolerance test (Cohort 13 only) on Day 14.
89456928|NCT03508635|Placebo Comparator|MAD of PoPE Cohort 12 and 13 Placebo|Participants will receive 25 mg of prednisone (both cohorts) and an oral glucose tolerance test (Cohort 13 only) on Day -5. Participants will then receive the Matching Placebo of CORT125134 (capsule) for a total of 13 days. Participants will then receive 25 mg of prednisone (both cohorts) and an oral glucose tolerance test (Cohort 13 only) on Day 14.
89456929|NCT02399774|Experimental|Post-partum primi and multiparous women|"Post-partum primipara and multiparous women whom are interested in breastfeeding and have not begun yet. This arm will be randomized into 2 groups~Intervention group: participants will receive the dental device and be instructed to use it during breastfeeding.~Control group: participants will not receive any device for breastfeeding pain control"
89456930|NCT02399774|Experimental|Post-partum women that have already begun breast feeding|2. Post-partum women that have already begun breast feeding, will receive the dental device and each woman will be serve as her own control (breastfeeding before and after the use of the dental device.
89456931|NCT04481282|Experimental|Terbutaline plus Danazol group|Terbutaline 2.5mg tid po plus danazol 200mg bid po for 12weeks
89456932|NCT02541604|Experimental|Atezolizumab|Participants received intravenous (IV) infusion of atezolizumab (maximum 1200 milligrams [mg]) on Day 1 of each 21-day cycle.
89456933|NCT02302053|Active Comparator|New Viviscal Professional Supplement|New Viviscal Professional Strength Supplements. One tablet taken by mouth in the morning and one tablet in the evening with food for 180 days.
89456934|NCT02302053|Placebo Comparator|Placebo Tablet|Placebo tablets. One tablet taken by mouth in the morning and one tablet in the evening with food for 180 days.
89456935|NCT02399540|Sham Comparator|Sham|Day 1: sham stimulation Day 2: sham stimulation
89456936|NCT02399540|Active Comparator|Conventional Paired tDCS|Day 1: sham stimulation Day 2: conventional tDCS
89456937|NCT02399540|Active Comparator|Conventional Unpaired tDCS|Day 1: conventional tDCS Day 2: sham stimulation
89456938|NCT02399540|Experimental|Late LTP-like Plasticity tDCS|Day 1: late LTP-like Plasticity tDCS Day 2: sham stimulation
89456939|NCT02304861|Active Comparator|Viscoat group|Patients operated using Viscoat OVD
89456940|NCT02304861|Active Comparator|Visthesia group|Patients operated using Visthesia OVD
89456941|NCT02302131||pulmonary valve replacement|SAPIEN XT Transcatheter Heart Valve in the pulmonic position at the time of data collection
88940451|NCT01849718||CBT - Cognitive Behavioural Therapy|"40 participants will receive cognitive behavioural therapy in a clinical setting.~The duration of the individual sessions are one hour, and there are 1-2 sessions per. week, totaling 20 hours, incl. 4 hours of transition conversations.~The conversations will be exclusively CBT-based. Number of hours for conversational therapy: 20 hours of individual psychotherapy"
88940452|NCT01849718||Nacadia Therapy|"40 participants will receive garden therapy in a designed, natural environment.~The individual sessions last three hours with two sessions per week the first and last week and three sessions per week in week 2-9. This gives a total of 96 hours, including 4 x 3 hours transition conversation and 10 x ½ hour individual interviews.~Experiences and activities related to the garden environment are integrated with mindfulness exercises. The individual conversations in the Nacadia-therapy will be mindfulness-based CBT.~10 x ½ an hour of individual psychotherapy."
88940453|NCT01849731|Experimental|Intervention A|Face-to face intervention
88940454|NCT01849731|Experimental|Intervention B|Face-to-face intervention plus telephone reinforcement
88940455|NCT01849731|No Intervention|Control Group|
88940456|NCT01849744|Experimental|VS-4718|Oral VS-4718 administered BID (QD during first cohort) during a 28 day cycle.
88940457|NCT01849757|Active Comparator|Human Albumin|Human albumin solution used as part of the priming volume for the cardiopulmonary bypass circuit.
88940458|NCT01849757|Active Comparator|Voluven or hydroethylstarch HES 130/0.4|Hydroethylstarch HES 130/0.4 used as part of the priming volume for the cardiopulmonary bypass circuit.
88940459|NCT01849757|Placebo Comparator|Crystalloid|Crystalloid will be used to prime the cardiopulmonary bypass circuit
88940460|NCT01849796|Active Comparator|Group A: Anodal tDCS|Group A will receive one block of real excitatory anodal tDCS over the motor cortex and one block of sham.
88940461|NCT01849796|Sham Comparator|Arm B: Cathodal tDCS|Group B will receive one block of inhibitory cathodal tDCS over the somatosensory cortex and one block of sham.
88940462|NCT01849809|Experimental|Gamma Ventral Capsulotomy|
88940463|NCT01849835|Experimental|trans-rectal|trans-rectal to perform the prostate biopsy
88940464|NCT01849835|Experimental|trans-perineal|trans-perineal to perform the prostate biopsy
89456942|NCT02393846|Experimental|ketoprofen|Topical ketoprofen (gel) is the experimental drug that is applied to the ankle in a dose of 2 gr.
89456943|NCT02393846|Placebo Comparator|Placebo|Topical placebo (gel) is identical in colour, form and smell with the ketoprofen gel.
88940465|NCT01849861|Experimental|Methimazole,|"Patients with serum TSH initially on the 1st. Quartile (TSH: 0.4 to 1.0 mIU / ml) will receive treatment with Methimazole (initial dose of 5mg/day) with the goal of raising the TSH values to range between 2.0 and 4.0 mIU / ml (the half upper range of normal).~After six months with TSH in the target range (2.0 and 4.0 mIU / ml), these patients will be subjected to the same examination protocol performed at baseline and assessed to the effects of treatment on outcome variables.~Variables considered in this study:~TSH and FT4~Questionnaire of Quality of life for older adults (WHOQOL-OLD)~Mini-Mental State Examination~Geriatric Depression Scale~Cardiopulmonary exercise testing - cardiopulmonary capacity"
88940466|NCT01849887|Active Comparator|mesenchymal stem cells|bone marrow-derived mesenchymal stem cells
88940467|NCT01849887|Placebo Comparator|Placebo|Placebo
89456944|NCT02302209|Experimental|Oxytocin|40 IU Oxytocin Intranasal
89456945|NCT02302209|Placebo Comparator|Placebo|Saline Nasal Spray
89456946|NCT02302287|Experimental|Group A|"Free diet for 3 months: protein 1 g/body weight/day (animal protein 50-70 g/day, plant protein 15-20 g/day); energy 30-35 kcal/bw/day; Calcium 1,1-1,3 g, phosphate 1,2-1,5 g/day; sodium 6 g/day, potassium 2-4 g/day;~Ketoacids diet for 6 months: protein 0,3-0,5 g/bw/day (animal protein 0 g/day, plant protein 30-40 g/day); energy 30-35 kcal/bw/day; Calcium 1,1-1,3 g, phosphate 0,6-0,8 g/day; sodium 6 g/day, potassium 2-4 g/day; mixture of essential aminoacids and ketoacids 0,05 g/kg ideal bw/day~Mediterranean diet for 6 months: protein 0,7-0,8 g/bw/day (animal protein 30-40 g/day, plant protein 40-50 g/day); energy 30-35 kcal/bw/day; Calcium 1,1-1,3 g, phosphate 1,2-1,5 g/day; sodium 2,5-3 g/day, potassium 2-4 g/day~Mediterranean diet and ketoacids for 6 months"
89456947|NCT02302287|Experimental|Group B|"Free diet for 3 months: protein 1 g/body weight/day (animal protein 50-70 g/day, plant protein 15-20 g/day); energy 30-35 kcal/bw/day; Calcium 1,1-1,3 g, phosphate 1,2-1,5 g/day; sodium 6 g/day, potassium 2-4 g/day;~Mediterranean diet for 6 months: protein 0,7-0,8 g/bw/day (animal protein 30-40 g/day, plant protein 40-50 g/day); energy 30-35 kcal/bw/day; Calcium 1,1-1,3 g, phosphate 1,2-1,5 g/day; sodium 2,5-3 g/day, potassium 2-4 g/day;~Ketoacids diet for 6 months: protein 0,3-0,5 g/bw/day (animal protein 0 g/day, plant protein 30-40 g/day); energy 30-35 kcal/bw/day; Calcium 1,1-1,3 g, phosphate 0,6-0,8 g/day; sodium 6 g/day, potassium 2-4 g/day; mixture of essential aminoacids and ketoacids 0,05 g/kg ideal bw/day~Mediterranean diet and ketoacids for 6 months"
89456948|NCT02302287|Other|Group control|Free diet: protein 1 g/body weight/day (animal protein 50-70 g/day, plant protein 15-20 g/day); energy 30-35 kcal/bw/day; Calcium 1,1-1,3 g, phosphate 1,2-1,5 g/day; sodium 6 g/day, potassium 2-4 g/day
89456949|NCT04481360||patients with covid 19 pneumonia|clinical presentation & outcome of covid 19 pneumonia
89456950|NCT02399618|Experimental|Capsulized freeze-dried FMT|Reconstitution of normal flora with capsulized freeze-dried fecal inoculum
89456951|NCT02306499|Experimental|ICSI WITH CRYOPRESERVED SPERM FROM NOA WITH VARICOCELE|ICSI cases using cryopreserved testicular sperm from infertile azoospermic men, with proven diagnosis of varicocele (clinical & sonographic), which will be used for ICSI in an ART program
89456952|NCT02306499|Experimental|ICSI WITH CRYOPRESERVED SPERM FROM NOA WITH NO VARICOCELE|ICSI cases using cryopreserved testicular sperms from infertile azoospermic men due to etiologies other than varicocele
89456953|NCT02394002|Experimental|Brain surgery|Somatosensory evoked potentials in relation to anasthesia (Propofol bolus) induced burst and suppression periods in electroencephalography
89456954|NCT02394002|Experimental|Spine surgery|Somatosensory evoked potentials in relation to anasthesia (Propofol bolus) induced burst and suppression periods in electroencephalography
88940468|NCT01849900|Other|Healthy Lifestyle|60 women randomly assigned to the control group
88940469|NCT01849900|Other|Knowing your body|60 women randomly assigned to intervention group
88940470|NCT01849913|Experimental|Group B & Group C|Group B equal to low-level laser therapy dosis 5,9 j per point Group C equal to Placebo group
88940471|NCT01849913|No Intervention|Group A & Group C|Group A equal to Control (no intervention) Group C equal to Placebo group
89456955|NCT02394002|Active Comparator|General surgery|Somatosensory evoked potentials in relation to anasthesia (Propofol bolus) induced burst and suppression periods in electroencephalography
89456956|NCT02306577||Vancouver|HIV infected people who are current of recent illicit drug users and receive Stribild for their HIV treatment at Vancouver Infectious Diseases Centre and Regina General Hospital.
89456957|NCT05454982|Experimental|Low pressure|Participants will wear the cryocompression device for 30 minutes while ice-water at a temperature of 8℃ and a static pressure of 25 mmHg is applied to the lower limb by the cuff.
89456958|NCT05454982|Experimental|Medium pressure|Participants will wear the cryocompression device for 30 minutes while ice-water at a temperature of 8℃ and an intermittent pressure of 25-50 mmHg is applied to the lower limb by the cuff.
89456959|NCT05454982|Experimental|High pressure|Participants will wear the cryocompression device for 30 minutes while ice-water at a temperature of 8℃ and an intermittent pressure of 25-75 mmHg is applied to the lower limb by the cuff.
89456960|NCT02402348|Experimental|Metformin|Metformin 850 mg orally once a day for 3 days, then 850 mg orally twice daily starting day 4 until 24hrs before surgery.
89456961|NCT02304939|Active Comparator|Quick change|"For this changeover : When the syringe of norepinephrine stops (pre alarm), start the second syringe pumps at the same speed of the first, wait for a first drop at the end of the tubing.~Close the first syringe, disconnect it and connect the second syringe, open the valve on and stop the first syringe."
89456962|NCT02304939|Experimental|Double Pumping|"For this changeover : When the syringe of norepinephrine stops (pre alarm), start the second syringe pumps, open the second syringe while leaving the first syringe open. Wait until the blood pressure rises 5 mmHg (SBP, DBP or MAP).~Once the blood pressure increased or 2 minutes from the start of the relay if no increase in blood pressure is observed, close the first syringe."
89456963|NCT02304939|Experimental|Smart infusion pump|For this automatic changeover : When the syringe of norepinephrine stops (pre alarm), oversee the progress of the automatic relay.
89456964|NCT04423666|Experimental|Intervention|"Will receive:~education~a wireless pedometer with set up~nurse coaching via text message, email or telephone based on participant preference and at frequency determined by the participant"
89456965|NCT04423666|Experimental|Control|"Will receive:~education~a wireless pedometer with set up"
89456966|NCT02393768||patients|patients with documented atherosclerosis on a CCTA
89456967|NCT02393768||controls|patients without atherosclerosis on a CCTA
89201451|NCT01056211|Placebo Comparator|grafts and reconstructions scars not treated with laser|scars due to grafts and reconstructions in the head and neck region
89456968|NCT03505125||PKU Patients|Adults with PKU will be interviewed about the symptoms and impacts of PKU.
89456969|NCT03505125||Observers|Close friends and family members of adults with PKU will be interviewed about the behaviors they have observed in adults with PKU
89456970|NCT03505125||Clinical Experts|Experienced, practicing clinicians currently treating adults with PKU will be interviewed about the symptoms and impacts of PKU on their patients.
89456971|NCT02399696|Experimental|Primary Care-Brief Mindfulness Program|A 4-week group program adapted from the 8-week Mindfulness Based Stress Reduction (MBSR) curriculum.
89456972|NCT02399696|Active Comparator|Primary Care-Treatment as Usual|Typical VA primary care treatment, including mental health services delivered by primary care staff.
89456973|NCT02399462|Experimental|Study Drug Arm|Acthar SC injections
88940472|NCT01849926|Active Comparator|Ibuprofen|Tablet, over capsulated, 600mg three times a day for three days.
89456974|NCT03505047|Experimental|Immediate group:|The Copper Intrauterine device will be inserted within 24 hours of the expulsion of the fetus and placenta or after surgical evacuation for placental remains, and prior to discharge from the facility.
89456975|NCT03505047|No Intervention|Delayed Group|The Copper Intrauterine device will be inserted at a local community health centre 14-28 days after discharge.
89456976|NCT02402114|Experimental|Intervention|Subject randomized to this group receives 1 oral dose of Hydrocortisone 120 mg
89456977|NCT02402114|Placebo Comparator|Placebo|Subject randomized to this group will receive an oral sugar/placebo pill that looks similar to the Hydrocortisone pill.
89456978|NCT02311413|Experimental|Cat-PAD|Subjects will be treated with four monthly doses of Cat-PAD, a peptide immunotherapy product consisting of Fel d 1 synthetic peptide immunoregulatory epitopes (SPIRE).
89456979|NCT02311413|Placebo Comparator|Placebo|Subjects will be treated with 4 monthly doses of Placebo.
89456980|NCT02311491|Experimental|Ceramic Coated Orthodontic Archwire|Ceramic coated orthodontic archwires will be evaluated in a limited clinical study at the university of North Carolina to test their efficacy in early and intermediate stages of tooth straightening in orthodontic patients.
89456981|NCT02311491|No Intervention|Control|The patients will receive the ordinary archwires. There is no intervention to the standard treatment.
89456982|NCT05745896|Active Comparator|Usual Care|Pregnants at usual care attending appointments in-person.
89456983|NCT05745896|Experimental|Telemedicine Prenatal Care|Pregnants under telemedicine based group attending at least 6 in-person outpatient clinic appointments and the remaining ones (i.e., 3) online.
89456984|NCT03507621||Propofol Group|1- Propofol Group: Propofol group will use 1 mg / kg propofol for the patient.Preoperative blood will be taken from the patients and cortisol, acth, glucagon, aldosterone, adrenalin, noradrenalin, PGE2, CRH will be studied. During the operation, the patient's systolic blood pressure, diastolic blood pressure, mean arterial pressure, heart rate, oxygen saturation will be followed. Analgesia will be provided according to the body movements of the patient and VAS measurement will be performed. Remifentanyl will be used as a anelgesic 0.5 mcg/ kg during operation. The patient's pain will be assessed by the VAS (Visuel Analogue Scale) scoring system and during the first hour postoperatively after the patient's consciousness is complete .
89456985|NCT03507621||Sevoflurane Group|1- Sevofluran Group: sevoflurane was administered at one minimum alveolar concentration (MAC) to end-tidal concentrations of 3% to 5%.Preoperative blood will be taken from the patients and cortisol, acth, glucagon, aldosterone, adrenalin, noradrenalin, PGE2, CRH will be studied. During the operation, the patient's systolic blood pressure, diastolic blood pressure, mean arterial pressure, heart rate, oxygen saturation will be followed. Analgesia will be provided according to the body movements of the patient and VAS measurement will be performed. Remifentanyl will be used as a anelgesic 0.5 mcg/ kg during operation. The patient's pain will be assessed by the VAS (Visuel Analogue Scale) scoring system and during the first hour postoperatively after the patient's consciousness is complete.
89456986|NCT02394080|Experimental|Photodynamic Bone Stabilization System (PBSS)|The PBSS is comprised of an inflatable, thin walled polyethylene terephthalate (PET; Dacron™) balloon mounted on an insertion catheter. This balloon catheter system is designed to deliver the monomer cement to the fracture site via the medullary canal of the bone.
89456987|NCT02546674|Experimental|Nilotinib|Participants with newly diagnosed CML in chronic phase received nilotinib 300 mg BID for 24 months
89456988|NCT02393534|No Intervention|Usual Care|Eligible patients that are randomized to the usual care arm will have a standard in-person clinic visit with their primary care provider.
89456989|NCT02393534|Experimental|Telephone visit|Eligible patients that are randomized to the telephone follow-up arm will have their next medical visit with their primary care provider via a telephone call.
89456990|NCT04463355|No Intervention|Control group: usual verbal instructions|In this group, caregivers receive, after completing the test and prior to discharge, the usual verbal information and recommendations about AGE following the guidelines of the Spanish Society of Pediatric Emergencies. The instructions are always given by one of the main investigators to provide homogeneity in the information
88940473|NCT01849926|Active Comparator|Mecillinam|Tablet, over capsulated, 200mg three times a day for three days.
88940474|NCT01849939|Experimental|Fludarabin|
88940475|NCT01849965|Active Comparator|DSC127|DSC127 0.03% in a vehicle gel (hydroxyethyl cellulose (HEC) with parabens)
88940476|NCT01849965|Placebo Comparator|Vehicle gel|Vehicle gel comprising HEC with parabens
88940477|NCT01849965|Placebo Comparator|Standard of Care gel|Aquasite gel, as standard of care gel
88940478|NCT01849978|Active Comparator|Control arm|"Participants in this arm will receive the newsletter about their reported minutes of physical activity and the benefits of physical activity specific to breast cancer survivors, and the brochure Changing your habits, developed by the NIH."
88940479|NCT01849978|Active Comparator|Habit Formation Arm|Participants in this arm will receive all of the intervention materials.
88940480|NCT01849991|Active Comparator|Lactobacillus reuteri|The first arm of the cohort will include 30 patients on LR (5x10^8 cfu's orally once daily.)
88940481|NCT01849991|Placebo Comparator|Sunflower Oil|The second arm includes 15 subjects on placebo (sunflower oil.)
88940482|NCT01850017|Experimental|Methadone and dexmedetomidine|"Standard American Society of Anesthesiology monitors. Midazolam 1-2 mg for pre-operative sedation. Lidocaine 0.5-1 mg/kg with induction. Propofol 1-2 mg/kg with induction. Fentanyl 0.5-1 mcg/kg with induction. Rocuronium 0.5 -1 mg/kg with induction. Total intravenous anesthesia with propofol for maintainence of anesthesia. Titrated to maintain BIS (bispectral index) between 30-60.~Methadone 0.2 mg/kg ideal body weight and dexmedetomidine 1 mcg/kg load over 20 minutes followed by a continuous infusion of 0.5 mcg/kg/h for the duration of the procedure."
89201452|NCT00924105|Experimental|1|
89201453|NCT00924105|Placebo Comparator|2|
89201454|NCT00544648|Experimental|Treatment|nab-paclitaxel+ carboplatin + radiation
89456991|NCT04463355|Experimental|Intervention group: video discharge instructions|Additionally to the verbal information, patients are shown a short 2-minute video providing the same information about AGE that would be given by verbal information.
89456992|NCT02399150||Acute Abdominal Pain|patients presenting to the ED with acute abdomen
89016559|NCT03720795|Other|Stepped Care CBT|Stepped Care CBT consists of two main steps. Step One involves 4 parent-led, therapist-assisted treatment sessions, up to 45 minutes each, over an 8-week period. Participants who do not show significant improvement in symptom severity at the end of Step One, are then 'stepped up' to receive Step Two, which involves 12 weekly, therapist-led, parent-assisted treatment sessions, up to 60 minutes each.
89016560|NCT03708341|Experimental|Melatonin|Patients will be administered melatonin 5 mg at a fixed time every day during their ICU stay (from day of admission till day of discharge from ICU)
89016561|NCT03708341|Placebo Comparator|Placebo|Patients will be administered a placebo pill that is identical in shape and color to the melatonin pill, at a fixed time every day during their ICU stay
89456993|NCT02305407|Experimental|surgical revascularization|Patients will be assigned to either surgical or conservative treatment depending on their clinical symptoms and radiological assessment.
89456994|NCT02305407|Experimental|conservative treatment|Normal conservative treatment without surgical intervention.
89456995|NCT02399384||HIV+/CAD+|HIV+/CAD+
89016562|NCT03683069|Experimental|Epleronone Arm|
89016563|NCT03683069|Experimental|Amlodipine Arm|
89016564|NCT03682848|Experimental|Participants receiving DTG + 3TC FDC|Eligible participants will receive FDC of DTG + 3TC 50/300 milligrams, tablets, given orally once daily.
89016565|NCT03670056|Experimental|Nivolumab and Ipilimumab|Patients will be treated with nivolumab 1 mg/kg and ipilimumab 3 mg/kg, starting on Day 1. Patients will receive 4 doses of each nivolumab and ipilimumab and then will receive nivolumab 240 mg starting week 13 (day 85) every 2 weeks until progression, unacceptable toxicity, withdrawal of consent, or the study ends, whichever occurs first.
89016566|NCT03653091|Active Comparator|Duodenal Mucosal Resurfacing (DMR)|Duodenal Mucosal Resurfacing (DMR) treatment will include hydrothermal ablation of the duodenal mucosa in an upper endoscopic procedure in patients with type 2 diabetes.
89016567|NCT03653091|Sham Comparator|Duodenal Mucosal Resurfacing Sham (Sham)|Duodenal Mucosal Resurfacing Sham (Sham) treatment will include an upper endoscopic procedure similar to DMR treatment without hydrothermal ablation of the duodenal mucosa in patients with type 2 diabetes.
89456996|NCT02399384||HIV+/CAD-|HIV+/CAD-
89016568|NCT03633955|Active Comparator|Standard therapy - Acute leukemia cohort|The Arm will accrue patients receiving standard therapy from the high-risk acute leukemia cohort (18 patients).
89016569|NCT03633955|Experimental|Immunotherapy - Acute leukemia cohort|The Arm will accrue patients receiving immunotherapy from the high-risk acute leukemia cohort (18 patients).
89016570|NCT03633955|Active Comparator|Standard therapy - Myeloma cohort|The Arm will accrue patients receiving standard therapy from the myeloma cohort (9 patients).
89016571|NCT03633955|Experimental|Immunotherapy - Myeloma cohort|The Arm will accrue patients receiving immunotherapy from the myeloma cohort (9 patients).
89016572|NCT03624712||uterine neoplasms|Women with operable and inoperable uterine malignomas (cervical cancer, endometrial cancer, uterine sarcoma)
89016573|NCT03622788|Experimental|Treatment (chemotherapy, PBSCT, cytokine-treated veto cells)|"CONDITIONING REGIMEN: Patients receive ATG IV over 4 hours on days -9 to -7, and fludarabine IV over 1 hour on days -6 to -3, then undergo TBI on day -1.~TRANSPLANT: Patients undergo PBSCT IV over 30-60 minutes on day 0.~GVHD PROPHYLAXIS: Patients receive cyclophosphamide IV over 3 hours on days +3 and +4 and cytokine-treated veto cells IV over 30-60 minutes on day +7."
89456997|NCT02399384||HIV-/CAD+|HIV-/CAD+
89456998|NCT03507543|Experimental|IMP4297|
89456999|NCT04487782||High SES / African-American Women|Semi-structured focus groups of 6 to 8 women per group will be conducted. Women in these groups will be of higher socioeconomic status (SES) and will be African-American/Black.
89457000|NCT04487782||High SES / Caucasian Women|Semi-structured focus groups of 6 to 8 women per group will be conducted. Women in these groups will be of higher socioeconomic status (SES) and will be Caucasian/White.
89457001|NCT04487782||Low SES / African-American Women|Semi-structured focus groups of 6 to 8 women per group will be conducted. Women in these groups will be of lower socioeconomic status (SES) and will be African-American/Black.
89457002|NCT04487782||Low SES / Caucasian Women|Semi-structured focus groups of 6 to 8 women per group will be conducted. Women in these groups will be of lower socioeconomic status (SES) and will be Caucasian/White.
89457003|NCT03167684|Experimental|Oral appliance therapy|Oral appliance (SomnoMed) worn nightly
89457004|NCT03167684|No Intervention|Control|Sham oral appliance device
89457005|NCT05454904|Active Comparator|Low fat diet|The low fat diet group will be counseled to consume a dietary pattern with fat restriction including food intake based in the pre-specified nutritional criteria.
89457006|NCT05454904|Active Comparator|Mediterranean diet alone|The Mediterranean group will receive indications to consume a locally adapted and feasible dietary pattern including characteristic Mediterranean foods based on Chilean food availability.
89501818|NCT02750761|Experimental|Group 2 Cohort 1: Tedizolid IV 6 mg/kg (2 to <6 years)|Participants 2 to <6 years of age received a single intravenous infusion of tedizolid phosphate dosed at 6 mg/kg of total body weight. Maximum dose is 200 mg of tedizolid phosphate.
88940483|NCT01850017|No Intervention|Methadone and placebo|"Standard American Society of Anesthesiology monitors. Midazolam 1-2 mg for pre-operative sedation. Lidocaine 0.5-1 mg/kg with induction. Propofol 1-2 mg/kg with induction. Fentanyl 0.5-1 mcg/kg with induction. Rocuronium 0.5 -1 mg/kg with induction. Total intravenous anesthesia with propofol for maintainence of anesthesia. Titrated to maintain BIS (bispectral index) between 30-60.~Methadone 0.2 mg/kg ideal body weight and placebo (normal saline) 1 mcg/kg load over 20 minutes followed by a continuous infusion of 0.5 mcg/kg/h for the duration of the procedure"
88940484|NCT01850043||Military Conscripts|A term of whole military conscripts per year in one Reserve Force Battalion. Military conscripts gather from all around area in Korea randomly
88940485|NCT01850056|Experimental|drug eluting balloon catheter|use drug eluting balloon catheter to inflate the stenosis or occlusion in superficial femoral artery(SFA) and/or popliteal artery
88940486|NCT01850056|Active Comparator|common balloon catheter(uncoated drug)|use common balloon catheter to inflate stenosis or occlusion in SFA and/or popliteal artery
88940487|NCT01850069||Intracranial hypertension|Patients with raised intracranial pressure
88940488|NCT01850095|Active Comparator|treatment 1|topical acid azelaic, used 2 times a day for 6 months
88940489|NCT01850095|Active Comparator|treatment 2|contraceptive with drospirenone/ethinyl estradiol used for 6 months
88940490|NCT01850095|No Intervention|control|control group ( only take biopsies and blood samples )
88940491|NCT01850121||Infliximab|Patients with active AS defined as BASDAI score above 4 and no exclusion criteria were consecutively included in this single-armed unblinded trial.
88940492|NCT01850134|Placebo Comparator|Control Study Product|1 serving of control beverage.
88940493|NCT01850134|Experimental|Experimental Study Product|1 serving of a nutritional supplement for people with diabetes.
88940494|NCT01850147|Experimental|Sunitinib|
88940495|NCT01850160|Experimental|GROUP A: Valsartan plus Chlorthalidone|GROUP A: Combination therapy of Valsartan plus Chlorthalidone. Valsartan 80 mg/Chlorthalidone 12,5 mg. Once daily during 12 weeks.
88940496|NCT01850160|Experimental|GROUP B: Valsartan|GROUP B: Treatment with Monotherapy. Valsartan 80 mg. Once daily during 12 weeks.
88940497|NCT01850160|Experimental|GROUP C: Chlorthalidone|GROUP C: Treatment with Monotherapy. Chlorthalidone 12,5 mg. Once daily during 12 weeks.
88940498|NCT01850173|Experimental|static work with a vertical vibration platform|The training was designed to perform static work of the lower limbs. Patients worked in a squatting position, with 30º of hip flexion and 55º of knee flexion, holding onto the bars of the WBV platform.
88940499|NCT01850173|No Intervention|Control group|general recommendations about physical activity and lifestyle
88940500|NCT01850186|Experimental|Dual yellow Laser|Patients will receive treatment by stabilized kilnman trio for four weeks (one application per day). Patient will receive 4 treatments by Dual yellow Laser on the hemi-face (side determinated by randomisation, split body study) at weeks 4, 6, 9 and 12.
88940501|NCT01850186|Placebo Comparator|Stabilized kilnman trio|Patients will receive treatment by stabilized kilnman trio for four weeks on all the face (one application per day). At the beginning of week 5, Patient will receive stabilized kilnman trio on the hemi-face during three months (side not treated by dual yellow laser, split body study). The stabilized kilnman trio will be prescribed for one month at inclusion (applied all over the face), and on the half of the face not treated by laser at weeks 4, 8 and 12.
88940502|NCT01850199|Active Comparator|Usual management (presential visits)|Patient will follow the usual care program, which includes in-person appointment (weekly/biweekly)
88940503|NCT01850199|Experimental|Smart telemedicine remote monitoring for gestational diabetes|After receiving an structured education on the matter, patients will be followed remotely by analysing glucose and diet/physical activity/other events data with a periodicity no longer than 48 hours
88940504|NCT01850212||Male (≥ 50 years), TDF|Male (≥ 50 years of age) on regimens containing tenofovir disoproxil fumarate (TDF)
88940505|NCT01850212||Male (≥ 50 years of age), Non-TDF|Male (≥ 50 years of age) on non-TDF (tenofovir disoproxil fumarate) based nucleoside reverse transcriptase inhibitors (NRTIs)
88940506|NCT01850212||Female (Postmenopausal), TDF|Female (postmenopausal) on regimens containing tenofovir disoproxil fumarate (TDF)
88940507|NCT01850212||Female (Postmenopausal), Non-TDF|Female (postmenopausal) on non-TDF (tenofovir disoproxil fumarate) based NRTIs
88940508|NCT01850225|Experimental|Device implantation|Implantation of device
89016574|NCT03620578|Experimental|DA-EPOCH-R followed by Nivolumab|5 cycles of DA-EPOCH-R protocol induction, followed with one year Nivolumab consolidation for end-of-induction patients who are in complete metabolic response
89457007|NCT05454904|Active Comparator|Mediterranean diet plus psychological well-being support|The Mediterranean diet + well-being intervention group will be subject to intake a locally adapted and feasible pattern of Mediterranean foods available in Chile in combination with a psychological well-being theory-based intervention.
89016575|NCT03608137|Experimental|Cannabis users|Subjects of this group have to meet the DSM-5 criteria for schizophrenia and smoke cannabis at least two days per week for every week of the past month. They have to exhibit negative urine screen for any substance except benzodiazepines and cannabis.
89201455|NCT00924183||Treatment-as-usual|All patients will receive treatment as usual: antidepressant medication and/or cognitive behavioral therapy (CBT). Patients' results will be compare to their own baseline measurements.
89201456|NCT00346333|Experimental|Lutein plus 15,000 IU/d Vitamin A|Daily intake of 12mg of Lutein plus 15,000 IU/d of Vitamin A palmitate
89457008|NCT02305485|Experimental|NeoVas|"The NeoVas sirolimus-eluting bioresorbable coronary scaffold system is a PLLA- based polymer scaffold and contains the antiproliferative drug sirolimus.~Intervention: Device: NeoVas BCS"
89457009|NCT02305485|Active Comparator|XIENCE PRIME|XIENCE PRIME Everolimus Eluting Coronary Stent System is a balloon expandable metallic platform stent manufactured from a flexible cobalt chromium alloy with a multicellular design and coated with a thin nonadhesive, durable, biocompatible acrylic, and fluorinated everolimus-releasing copolymer. Intervention: Device: XIENCE PRIME EECSS
89457010|NCT02399072||Geographic Atrophy Participants|Participants with unilateral GA or GA in one eye and choroidal neovascularization (CNV; active or treated) with or without GA, in the contralateral eye, will be evaluated for the progression of GA for up to approximately 60 months.
89457011|NCT04480762|Experimental|SHR-1703-Subcutaneous administration of Dose 1|A single subcutaneous injection of SHR-1703 (Dose 1) or Placebo
89457012|NCT04480762|Experimental|SHR-1703-Subcutaneous administration of Dose 2|A single subcutaneous injection of SHR-1703 (Dose 2) or Placebo
89457013|NCT04480762|Experimental|SHR-1703-Subcutaneous administration of Dose 3|A single subcutaneous injection of SHR-1703 (Dose 3) or Placebo
89457014|NCT04480762|Experimental|SHR-1703-Subcutaneous administration of Dose 4|A single subcutaneous injection of SHR-1703 (Dose 4) or Placebo
89457015|NCT04480762|Experimental|SHR-1703-Subcutaneous administration of Dose 5|A single subcutaneous injection of SHR-1703 (Dose 5) or Placebo
89457016|NCT02311569|Experimental|Arm Mirabegron|Mirabegron treatment of at least 24 weeks with an initial dose of 25 mg daily during the first week followed by 50 mg Mirabegron daily during the remaining treatment period.
89457017|NCT02399306|Experimental|Arm A|chemoradiotherapy with Enteral Nutrition intervention
89457018|NCT02399306|Placebo Comparator|Arm B|chemoradiotherapy
89457019|NCT02305719||Epidural anesthesia|Patients receiving thoracic epidural anesthesia for thoracoscopic surgery. Standard regimen with 8-20 ml Ropivacaine 0,5% in the epidural catheter. Postopertive Ropivacaine 0,2% 6 ml/h via catheter were administered.
89457020|NCT02305719||Serratus-anterior-plane-Block|"Patients receiving (ultrasound-guided) Serratus-anterior-plane-Block for thoracoscopic surgery.~Standard regimen up to 20 ml Ropivacaine 0,5%, were installed. Postopertive Ropivacaine 0,2% 6 ml/h via catheter were administered."
89457021|NCT02305719||Local infiltration|Patients receiving local infiltration with up to 20 ml Ropivacaine 0,5% for thoracoscopic surgery (at the site of thoracoscopy)
89457022|NCT02311647||Post Tamoxifen exposure group|Breast cancer patients receiving or formerly received Tamoxifen for at least 1 year.
89457023|NCT02311647||Control group|Breast cancer patients who did not receive endocrine treatment
89457024|NCT02393456|Experimental|Intranasal oxytocin|Participants will self-administer 24 IU oxytocin (Syntocinon, Novartis Pharmaceuticals). 5 puffs per nostril (1 puff = 2.4 IU oxytocin).
89457025|NCT02393456|Placebo Comparator|Intranasal placebo|2 mls Glycerine and 3 mls purified water (methylparaben and propylparaben mixed according to purified water formula) for a total of 5 ml, which will be filtered with a 5mu filter. Participants will self-administer 5 puffs per nostril.
89457026|NCT02393612|Experimental|DP-R202|Patients administrate DP-R202 (Sarpogrelate 300mg) once a day for 12 weeks
89457027|NCT02393612|Active Comparator|Anplag tab|Patients administrate Anplag tab (Sarpogrelate 100mg) 3 times a day for 12 weeks
89457028|NCT02311803|Experimental|Preservation of Denonvilliers Fascia|Preservation of Denonvilliers Fascia in Laparoscopy-assisted pelvic autonomic nerve preservation surgery for male mid-low rectal cancer patients
89457029|NCT02311803|Active Comparator|Excision of Denonvilliers Fascia|Excision of Denonvilliers Fascia in Laparoscopy-assisted pelvic autonomic nerve preservation surgery for male mid-low rectal cancer patients
89457030|NCT02546362|Experimental|Cefaly active device|12 weeks of treatment using Cefaly twice a day (treatment session of 20 minutes)
89457031|NCT03167840|Experimental|Physical training alone (PT)|Physical Training (flexibility, endurance, strengthening, and balance training) for 60-90 minutes 3x/week over 12 weeks of moderate intensity.
89457032|NCT03167840|Experimental|Cognitive training alone (CT)|Cognitive training with a focus on orientation, memory, attention and executive functioning for 60-90 minutes per session, once per week for 12 weeks.
89457033|NCT03167840|Experimental|Physical and cognitive training (PACT)|Integrated cognitive training in physical exercise for 60-90 minutes per session, 3x/week over 12 weeks.
89457034|NCT03167840|No Intervention|Wait-list group (WG)|The control group on wait-list. They will be instructed to go on with their usual activities and will receive the intervention, combined physical and cognitive training, at a later date.
89457035|NCT03504891|Experimental|MRI Prior to CRT for Upgrades|MRI will be performed prior to CRT upgrade.
89457036|NCT03504891|Active Comparator|MRI Prior to de novo CRT Implants|MRI will be performed prior to de novo CRT implants.
89457037|NCT02306733|Active Comparator|Ergometrine|100 women with atonic PPH will receive Ergometrine 400µgm (Methergin® Novartis, Switzerland) slowly intravenous (iv)
89457038|NCT02306733|Active Comparator|Oxytocin|100 women with atonic PPH will receive oxytocin 10 IU (Syntocinon® Novartis, Switzerland) slowly intravenous.
89457039|NCT05454436|Experimental|Healing rate of intra oral sinus tract in single visit by SCT with bioceramic sealer|When a patient comes with intra oral sinus tract will treat in a single visit. The treatment protocol will be: cleaning and shaping by NITI file ( pro taper gold ) with Naocl 5.25%, EDTA 17% and saline then the canal will be obturate by single cone technique with bioceramic sealer.
89457040|NCT05454436|Experimental|Healing rate of intra oral sinus tract in multi visit by SCT with bioceramic sealer|When a patient comes with intra-oral sinus tract will treat in a multi-visit. The treatment protocol will : cleaning and shaping by NITI file ( pro taper gold ) with Naocl 5.25%, EDTA 17%, and saline then ca(oh)2 use as Intracanal medication the after disappear the sinus tract the canal will obturate by single cone technique with bioceramic sealer.
89457041|NCT02698436|Experimental|Acne Mask|"The light therapy acne device is applied to the face once in the evening for a duration of 10 minutes. The cleanser is used twice daily, once in the morning and once in the evening.~Other Names: Cleanser is marketed while the device is not marketed"
89457042|NCT02698436|Active Comparator|2.5% Benzoyl Peroxide Treatment|"Cleanser and 2.5% Benzoyl Peroxide Treatment Both the cleanser and the 2.5% Benzoyl Peroxide Treatment are applied twice daily, once in the morning and once in the evening.~Other names: Both products are marketed"
89457043|NCT03507465|Experimental|Letrozole Plus Low-Dose Metronomic Capecitabine|
89457044|NCT03507465|Active Comparator|EC-T|
89457045|NCT05476042|Active Comparator|Prescribe Erythropoieti|
89457046|NCT05476042|Placebo Comparator|Prescribe placebo|
89457047|NCT03507387|Experimental|Intramuscular phenylephrine group|Patients in intramuscular phenylephrine group will receive spinal anesthesia with bupivacaine. 5 mg (1ml) phenylephrine intramuscular injection will be given into the gluteus maximus muscle before anesthesia.1ml of 0.9% normal saline intravenous injection will be given after the subarachnoid injection is completed.
89457048|NCT03507387|Active Comparator|Intravenous phenylephrine group|Patients in intravenous phenylephrine group will receive spinal anesthesia with bupivacaine. 1ml of 0.9% normal saline intramuscular injection will be given into the gluteus maximus muscle before anesthesia.100ug (1ml) phenylephrine intravenous injection will be given after the subarachnoid injection is completed.
89457049|NCT03507387|Placebo Comparator|Placebo group|Patients in intravenous phenylephrine group will receive spinal anesthesia with bupivacaine. 1ml of 0.9% normal saline intramuscular injection will be given into the gluteus maximus muscle before anesthesia. 1ml of 0.9% normal saline intravenous injection will be given after the subarachnoid injection is completed.
89457050|NCT03508401|Experimental|ICU intubated patients|"After inclusion, Echo-Doppler measurements are performed with Vivid S6 model (GE Healthcare France, Lyon, France). The left ventricular outflow tract velocity time index (LVOT TVI) will be measured with this device. Then, a passive leg raising (PLR) will be performed and finally LVOT VTI will be measured again after PLR~Patients will be classified in two groups according to the hemodynamic response to PLR :~Patients are responders if LVOT VTI increases of at least 10% after PLR~patients are non-responders if LVOT VTI does not increase or increase of less than 10% after PLR."
89457051|NCT03504813|Experimental|Urinary Incontinence|"The involuntary loss of urine through the urethra, objectively demonstrable and constituting for the person who suffers it a social and hygienic problem.~In this arm, participants will receive the following interventions: physical activities program, training of the pelvic floor and counseling about occupational performance"
89457052|NCT03504813|Experimental|Insomnia|"A condition characterized by an unsatisfactory amount or quality of sleep which persists for a considerable period. This disorder includes difficulties for the falling and/or staying asleep and early awakening in the final phase of sleep.~In this arm, participants will receive the following interventions: physical activities program, relaxation training and counseling about occupational performance."
89457053|NCT03504813|Experimental|Risk of falls|"Involuntary events that cause people to lose balance and find themselves on the ground or other firm surfaces. The factor of falls can be intrinsic (related to the person) or extrinsic (derived from the activity or environment of the individual).~In this arm, participants will receive the following interventions: physical activities program, and counseling about occupational performance"
88940509|NCT01850238|Placebo Comparator|Placebo (adjuvant in saline solution)|"Placebo patients will receive 1 dose of placebo per month over 3 months, for a total of 3 administrations.~Placebo consists of vaccine adjuvant in saline solution. Placebo is administered subcutaneously."
88940510|NCT01850238|Experimental|AADvac1|"AADvac1 patients will receive 1 dose of AADvac1 per month over 3 months, for a total of 3 administrations.~AADvac1 is a vaccine (single-use vials with solution ready for injection) AADvac1 is administered subcutaneously."
88940511|NCT01850251|Experimental|Supplement with HMB and vitamin D|Oral administration of 440 mL (2 bottles) of nutritional supplement with HMB and vitamin D each day during 8 weeks.
88940512|NCT01850251|Active Comparator|Standard nutritional supplement|Oral administration of 440 mL (2 bottles) of standard nutritional supplement each day during 8 weeks.
88940513|NCT01850264|Active Comparator|Quadripolar LV electrode|Application of a quadripolar LV electrode
88940514|NCT01850264|Active Comparator|Bipolar LV electrode|Application of a bipolar LV electrode
89016576|NCT03608137|Active Comparator|Non- cannabis users (control group)|Subjects of this group have to meet the DSM-5 criteria for schizophrenia and have to report no cannabis use over the previous month, and exhibit negative urine screen for any substance except benzodiazepines.
89016577|NCT03604406|Experimental|Varicella Zoster Vaccine (Zostavax)|Live zoster vaccine injection will be administered as a single 0.65-mL dose subcutaneously in the deltoid region of the upper arm at the baseline visit
89457054|NCT02694536|Experimental|Erlotinib + Gemcitabine|Participants will receive erlotinib in combination with standard of care chemotherapy (gemcitabine) until disease progression, unacceptable toxicity, or withdrawal for any reason.
89457055|NCT01661686|Active Comparator|Insertion of a partially covered SEMS|
89457056|NCT01661686|Active Comparator|Insertion of a Fully covered SEMS|
89457057|NCT03167918|Experimental|Calcium dobesilate|gave each patient metformin (1000 mg, bid, PO), Mecobalamin Tablets, (0.5 mg bid, PO) and Calcium dobesilate 0.5 g bid, PO
89457058|NCT03167918|Experimental|Xuefuzhuyu Decoction|gave each patient metformin (1000 mg, bid, PO), Mecobalamin Tablets, (0.5 mg bid, PO) and Xuefuzhuyu Decoction 100 ml bid，po
89457059|NCT03167918|Experimental|Xuefuzhuyu Decoction &Calcium dobesilate|gave each patient metformin (1000 mg, bid, PO), Mecobalamin Tablets, (0.5 mg bid, PO) and Calcium dobesilate (0.5 g bid, PO)& Xuefuzhuyu Decoction（100 ml bid，po)
89457060|NCT05745818||colchicine group|
89457061|NCT05745818||control group|
89457062|NCT05475964|Other|patients with undiagnosed bile duct dilatation|patients with bile duct dilation detected by imaging studies without revealing definite cause of obstruction
89457063|NCT02393300|Placebo Comparator|Group1|60 Milliliters（ml）Normal saline (0.9% sodium chloride) will be applied by soaking the knee cavity for at least 3 minutes before wound closure and then sucked away.
89457064|NCT02393300|Experimental|Group2|two-dose intravenous tranexamic acid will be applied as follow: 10mg/kg of Tranexamic Acid in 100 Milliliters（ml) normal saline (0.9% sodium chloride),the first dose 15' before the tourniquet deflation and the second dose at 180' after the first dosage
89457065|NCT02393300|Experimental|Group 3|3g Tranexamic Acid diluted to 60 Milliliters（ml） with normal saline (0.9% sodium chloride) will be applied by soaking the knee cavity for at least 3 minutes before wound closure and then sucked away.
89457066|NCT02305875|Experimental|MCN scoring|Scoring of the mcn nerve's position in the axillary sheat using MRI
89457067|NCT03106610|Experimental|Nivolumab|"Participants receive Nivolumab by vein over about 60 minutes on Day 1 of Cycles 1-3 before scheduled surgery. Each study cycle is 14 days (2 weeks).~Questionnaires completed on Day 1 of Cycles 1-3, at the visit before surgery, and 4 weeks after surgery."
89457068|NCT03504735|Placebo Comparator|Therapeutic Lifestyle Change+Placebo|Therapeutic Life-style change intervention with Placebo pills.
89457069|NCT03504735|Active Comparator|Therapeutic Lifestyle Change+Caduet|Therapeutic Lifestyle Change intervention with Caduet pills.
89457070|NCT03167450||Adults|Adults have sickle cell disease
89457071|NCT03167450||Parents|Parents with children/adults who have sickle cell disease
89457072|NCT03167450||Physicians|Physicians who have delivered healthcare to individuals living with sickle cell disease for at least a year
89457073|NCT02312115|Active Comparator|Furosemide|Patients assigned to the furosemide infusion group will receive furosemide infusions, as outlined in figure 2. This has been adapted from Ostermann et al. (2007) and the SPARK study protocol (Bagshaw et al. 2010). Furosemide will be prepared in bags that contain 1000 mg of furosemide per 250 mL of saline reaching a concentration of 4 mg/mL. All medication and placebo bags will have no identifiers that show what type of drug is being administered, for blinding purposes. Medication and placebo bags will have randomly generated study identifier numbers. The protocol in figure 2 will be followed to achieve a total urine output of 1mL/kg/h. The furosemide infusion rate will not exceed 4mg/min IV as this is the maximum set by the manufacturer.
89457074|NCT02312115|Placebo Comparator|Saline|All patients assigned to the saline group will receive saline that is equal in volume as compared to the treatment group. The amount of saline given to the patients in the placebo arm is so small that its effect on these patients is negligible. All other aspects of care for the enrolled patient will be managed per primary team and any consultants.
89457075|NCT03106532|Experimental|PHP-201 0.25% ophthalmic solution|PHP-201 0.25% ophthalmic solution, TID
88940515|NCT01850277|Experimental|Rhythm control|"In this group a strategy to restore and maintain SR, including amiodarone and an external electrical cardioversion (EEC), is implemented. A procedure of AF ablation is possible but not obligatory.~At baseline, patients assigned to the group undergo a standard 12-lead ECG, a 6-minute walk test (6MWT), a cardiopulmonary exercise test(CPX), an echocardiography(ECHO), a standard device control; a serum thyroid -stimulating hormone (TSH) level is assessed and patients fill the Minnesota Living With Heart Failure Questionnaire (MLHFQ). Control visits are performed every 3 months including a 12-lead ECG measurement and a device control. On the visits in the 3rd and 12th month an ECHO, a CPX, a 6MWT are performed and a MLHFQ is filled; control TSH levels are assessed every 6 months."
88940516|NCT01850277|Active Comparator|Rate control|"In the latter group a pharmacotherapy to slow and control ventricular rate by means of pharmacotherapy and an atrio-ventricular junction ablation (AVJA) is implemented.~At baseline, each patient assigned to the rate control group undergoes a standard 12-lead ECG, a 6MWT, a CPX, an ECHO, a standard device control and a serum TSH level assessed. Moreover, the patient fills the Minnesota Living With Heart Failure Questionaire (MLHFQ). The control visits are performed for one year, every 3 months including a standard 12-lead ECG measurement and standard control of the device. On the visits in the 3rd and 12th month additionally an ECHO, a CPX, a 6MWT are performed and a MLHFQ is filled. The control TSH levels are assessed every 6 months."
88940517|NCT01850290||Dopamine Imaging|
88940518|NCT01850316|Experimental|Stereotactic Ablative Radiotherapy|Preferred target coverage of 40 Gy: coverage and total dose determined by irradiated liver volume NTCP (normal tissue complication probability) nomogram and OAR dose limits
88940519|NCT01850329|No Intervention|control|No computed-assisted information program will be administered.
88940520|NCT01850329|Experimental|intervention|computed-assisted information program will be administered.
88940521|NCT01850342|Experimental|Fat micrograft enhanced with ADRC|
88940522|NCT01850368|Experimental|Stereotactic ablative radiotherapy|Stereotactic ablative radiotherapy for HCC patients with major portal vein tumor thrombosis (tumor thrombosis in the main portal vein or 1st branch of portal vein)
89457076|NCT03106532|Experimental|PHP-201 0.5% ophthalmic solution|PHP-201 0.5% ophthalmic solution, TID
89457077|NCT03106532|Placebo Comparator|Placebo ophthalmic solution|Placebo ophthalmic solution, TID
89457078|NCT03504657|Experimental|Drug-coated balloon angioplasty|
89457079|NCT03504657|Active Comparator|stenting angioplasty|
89457080|NCT03026140|Experimental|group 1|drug: ipilimumab 1 mg/kg day 1 (IV) drug: nivolumab 3 mg/kg on day 1 and day 15 (IV)
88940523|NCT01850407|No Intervention|Education Counseling|Education of caregivers to counter lack of Preparedness for Children Undergoing Sexual Abuse Medical Examination
88940524|NCT01850420|Experimental|IMC-1|Experimental intervention
88940525|NCT01850420|Placebo Comparator|Matching placebo|
88940526|NCT01850433|Experimental|Internet CBT|
88940527|NCT01850459||Autism Spectrum Disorder group|Diagnosis of autistic disorder as confirmed by a clinical interview, utilizing the DSM-V
88940528|NCT01850459||IQ-Matched Control Subjects|
88940529|NCT01850459||Age-Matched Neurotypical Controls|
88940530|NCT01850459||Shipped Biomarker Control Group Subjects|These subjects provide a blood sample only that serves as a shipping control that is shipped along with all blood samples from Autistic Disorder Subjects, IQ-Matched Control Subjects or Age-Matched Neurotypical Control Subjects. For these shipping control samples, blood samples will also be drawn from the subjects.
88940531|NCT01850472||Healthy controls|Individuals with no psychiatric diagnosis as determined by structured clinical interview for DSM-IV (SCID) at time of enrollment. There is no intervention administered in this study.
88940532|NCT01850498||Partial seizures|Partial seizures with secondary generalization which results in visible clonic or tonic-clonic motor behavior
88940533|NCT01850498||Generalized seizures|Primarily generalized seizures (in patients with either primary [idiopathic] or secondary [symptomatic] generalized epilepsy), which may involve the following depending on the motor manifestation observed: myoclonic seizures, clonic seizures, tonic-clonic seizures, or atonic seizures.
88940534|NCT01850511|Experimental|Vibrissae trimming|Patients will serve as their own control, with assessment of primary outcomes pre- and post-trimming of vibrissae.
88940535|NCT01850537|Experimental|single arm study|treatment of degenerative disc disease using the PROW LIF
88940536|NCT01850576|Experimental|Intervention|Those randomized to the intervention group will be invited to attend the risk reduction intervention.
88940537|NCT01850576|No Intervention|Control|The control group will receive usual care. Both treatment and control groups will have received the video-based risk reduction intervention.
88940538|NCT01850628||Paclitaxel plus trastuzumab or trastuzumab/pertuzumab|Patient received paclitaxel plus trastuzumab or a trastuzumab/pertuzumab-based combination administered per investigators discretion
88940539|NCT01850654|Other|Probands|Participants with colorectal or endometrial cancer.
88940540|NCT01850654|Other|First-degree relatives of the participants with CRC|The first-degree relatives of the CRC probands (participants with colorectal cancer).
88940541|NCT01850654|Other|At-risk relatives|The relatives of the participants found to have Lynch syndrome.
88940542|NCT01850667|Experimental|Stereotactic body radiotherapy|Stereotactic body radiotherapy for unresectable hepatocellular carcinoma after incomplete trans-arterial chemo-embolization
88940543|NCT01850680|Experimental|Sarilumab (SAR153191, REGN88) Dose 1|First dose of Sarilumab in a single SC injection. Methotrexate (stable dose) and folic acid are continued as background therapy
88940544|NCT01850680|Experimental|Sarilumab (SAR153191, REGN88) Dose 2|Second dose of Sarilumab in a single SC injection. Methotrexate (stable dose) and folic acid are continued as background therapy
88940545|NCT01850680|Experimental|Sarilumab (SAR153191, REGN88) Dose 3|Third dose of Sarilumab in a single SC injection. Methotrexate (stable dose) and folic acid are continued as background therapy
88940546|NCT01850680|Experimental|Sarilumab (SAR153191, REGN88) Dose 4|Fourth dose of Sarilumab in a single SC injection. Methotrexate (stable dose) and folic acid are continued as background therapy
88940547|NCT01850680|Placebo Comparator|Placebo Dose 5|Placebo to match Sarilumab (SAR153191, REGN88) in a single SC injection. Methotrexate (stable dose) and folic acid are continued as background therapy
88940548|NCT01850693||Coronary artery disease, Stroke|Coronary artery disease, stroke, coronary CT angiography
88940549|NCT01850719|Experimental|Arthroscopic Partial Meniscectomy|
88940550|NCT01850719|Active Comparator|Physical Therapy|
88940551|NCT01850732|Other|ultrasound of aorta|
88940552|NCT01850771|Active Comparator|Regenexx PL-Disc|Injection of Regenexx PL-Disc into the epidural space once a week for two weeks.
88940553|NCT01850771|Active Comparator|Steroid Epidural|Injection of steroid into the epidural space once a week for two weeks
88940554|NCT01850784|Active Comparator|High energy formula|High energy formula (Similac)
88940555|NCT01850784|Active Comparator|Standard formula|Standard formula
88940556|NCT01850797||NOAC|Patients receiving NOAC and suffering from ischemic stroke or intracranial bleeding.
88940557|NCT01850810|Experimental|Experimental Study Product|1 serving of a nutritional product for people with diabetes.
88940558|NCT01850810|Placebo Comparator|Control Study Product|1 serving of control beverage.
88940559|NCT01850836|Active Comparator|Real rTMS|19 subacute stroke pts with aphasia received 10 rTMS (5sessions/week) for 2 successive weeks
88940560|NCT01850836|Sham Comparator|Sham rTMS|10 patients received sham rTMS stimulation (5 sessions/week) for 2 successive weeks
88940561|NCT01850849|Experimental|LEO 39652 cream|Active drug
88940562|NCT01850849|Placebo Comparator|LEO 39652 cream vehicle|Placebo drug
88940563|NCT01850862|Experimental|Collective group exercise program in patients with KOA|Collective exercises program for patients with osteoarthritis and orientation about this disease
88940564|NCT01850862|Active Comparator|Control group (without exercise)|Orientation about osteoarthritis disease but without any exercise program
88940565|NCT01850875|Experimental|Eye-Movement-Desensitization-Reprocessing|Eye-Movement-Desensitization-Reprocessing
88940566|NCT01850875|No Intervention|Treatment as usual (control group)|treatment as usual
88940567|NCT01850901|Experimental|Renal sympathetic denervation|Catheter-based renal nerve ablation
88940568|NCT01850901|No Intervention|Usual care|Antihypertensive treatment according to guidelines
88940569|NCT01850914||Shunted patients with INPH|Cases: Patients with normal pressure hydrocephalus who have underwent surgery. Controls: Sex- and age-matched community based controls.
88940570|NCT01850914||Populationbased elderly.|A group of populationbased elderly, matched according to age and sex to the patients with INPH. Vascular risk factors studied.
88940571|NCT01850927|Active Comparator|Intervention|Patients will receive remote ischaemic preconditioning prior to surgery. After the induction of anaesthesia, a blood pressure cuff will be placed on an upper arm and inflated to 200mmHg for 5 minutes, then deflated for 5 minutes, repeated for a total of 3 inflation-deflation cycles.
88940572|NCT01850927|Sham Comparator|Control|Patients will have the same procedure as for the intervention group, however the blood pressure cuff valve will be left open throughout the 30 minute treatment. Patients will be kept under anaesthesia for this additional time.
88940573|NCT01850940||Tolvaptan Group|Tolvaptan,qd, po
88940574|NCT01850940||Conventional therapy|control group:Conventional therapy without tolvaptan
88940575|NCT01850953|Placebo Comparator|Sugar Pill|This is a sugar pill that will be used as a placebo comparator.
88940576|NCT01850953|Active Comparator|Varenicline|Varenicline will be titrated to steady-state levels of 2mg/day over 4 days (0.5mg BID for day 1 and 1.0mg BID for days 2-4) before testing at 2mg/day on days 5 and 6.
88940577|NCT01850966||Iguratimod|
88940578|NCT01850979|Active Comparator|tacrolimus|tacrolimus 0,03% eye drops (olive oil as vehicle) every 12/12 hours for 3 months placebo as olive oil eye drops every 12/12h hours for 3 months
89201457|NCT00346333|Placebo Comparator|Control plus 15,000 IU/d Vitamin A|Daily intake of cornstarch control plus 15,000 IU/d Vitamin A palmitate
88940579|NCT01850979|Placebo Comparator|Olive Oil|All patients in this groups receive eye drops containing olive oil (vehicle of tacrolimus eye drops) twice a day (every 12 hours) for 90 days.
88940580|NCT01850992|Active Comparator|ACtive CPAP|Continuous positive airway pressure (CPAP) to treat obstructive Sleep Apnea
89457081|NCT03026140|Experimental|group 2|drug: ipilimumab 1 mg/kg day 1 (IV) drug: nivolumab 3 mg/kg on day 1 and day 15 (IV) drug: celecoxib 200 mg daily (oral)
88940581|NCT01850992|Placebo Comparator|Sham CPAP|This is placebo CPAP
89457082|NCT03026140|Experimental|Anti-IL8 cohort 4 (pMMR/MSS tumors)|drug: nivolumab 3 mg/kg day 1 and day 15 (IV) drug: BMS-986253 (anti-IL8) 2400mg on day 1 and day 15 (IV)
88940582|NCT01851005|Placebo Comparator|Group 1|General anesthesia with sevoflurane. Infusion of normal saline during surgery. Administer rocuronium 0.8 mg/kg for induction.
88940583|NCT01851005|Placebo Comparator|Group 2|General anesthesia with propofol and remifentanil. (Total intravenous anesthesia) Infusion of normal saline during surgery. Administer rocuronium 0.8 mg/kg for induction.
88940584|NCT01851005|Experimental|Group 3|General anesthesia with sevoflurane. Infusion of dexmedetomidine (0.4 ug/kg/hr) during anesthesia. Administer rocuronium 0.8 mg/kg for induction.
88940585|NCT01851005|Experimental|Group 4|General anesthesia with propofol and remifentanil. (Total intravenous anesthesia) Infusion of dexmedetomidine (0.4 ug/kg/hr) during surgery. Administer rocuronium 0.8 mg/kg for induction.
88940586|NCT01851031|Experimental|the minor approach group|Thirty-six patients (the minor parotid anterior approach group) were treated with minor parotid anterior approach
88940587|NCT01851031|Other|control group|24 patients (control group) were treated with the retromandibular approach
88940588|NCT01851044|Placebo Comparator|Vehicle (Saline)|2 ml of saline is injected to the proximal insertion of extensor carpi radialis brevis (ECRB) muscle.
88940589|NCT01851044|Active Comparator|Whole Blood|2 ml of patient own venous blood is injected to the proximal insertion of ECRB.
88940590|NCT01851044|Experimental|Platelet Rich Plasma|9 ml of patient own venous blood is centrifuged using The Arthrex ACP® Double Syringe System and 2 ml of platelet rich plasma is injected to the proximal insertion of ECRB.
88940591|NCT01851057|Active Comparator|Education Only|Education only arm (8 total sessions)
88940592|NCT01851057|Experimental|STAR: Education and Problem Solving|Problem-solving and education intervention (8 total sessions)
88940593|NCT01851070|Placebo Comparator|Normal Saline Placebo|Placebo will be delivered in 100 mL normal saline administered intravenously over approximately 45 minutes.
88940594|NCT01851070|Active Comparator|Allogeneic Mesenchymal Precursor Cells|Mesenchymal Precursor Cells (MPCs), either 1.0 or 2.0 million cells/kg, will be delivered in 100 mL normal saline administered intravenously over approximately 45 minutes.
88940595|NCT01851096|Experimental|SNX-5422|Open label administration of SNX-5422 tablets every other day for 21 days on a 28 day cycle. Dose escalation of SNX-5422 based on safety outcomes
88940596|NCT01851109|No Intervention|Control|
88940597|NCT01851109|Experimental|Genetic counseling|After randomization the participant is offered a referral to a genetic counselor.
88940598|NCT01851135|Experimental|Patients with NF1|
88940599|NCT01851135|Other|Healthy controls|
89457083|NCT03026140|Experimental|Relatlimab cohort 5 (pMMR/MSS tumors)|drug: nivolumab 240mg IV on day 1 and day 15 drug: relatlimab 240mg IV on day 1 and day 15
89457084|NCT03026140|Experimental|Relatlimab cohort 6 (dMMR/MSI tumors)|drug: nivolumab 480mg IV on day 1 and day 29 drug: relatlimab 480mg IV on day 1 and day 29
89457085|NCT02398994|Active Comparator|Intravenous Methylprednisolone|"Paediatric patients - 30mg/kg or 500mg/m2 up to a maximum daily dose of 1g/day for 5 days.~Adult patients - 1g/day for 5 days."
88940600|NCT01851148|Sham Comparator|sham therapy|subtracting serial sevel (McPartland 2003)
88940601|NCT01851148|Other|usual care|triptans treatment only
88940602|NCT01851148|Experimental|OMT|8 sessions of osteopathic manipulative treatment
88940603|NCT01851161||Diagnostic (CT and 4D CT in supine and prone positioning)|Patients undergo conventional CT scan and 4D CT scan in both supine and prone positioning before undergoing radiation therapy.
88940604|NCT01851187|Experimental|emotional management (EM) group|emotional management (EM) group received antenatal psychological intervention
88940605|NCT01851187|Active Comparator|the usual care (UC) group|the usual care (UC) group was given routine prenatal care only
88940606|NCT01851200|Experimental|Brentuximab Vedotin|Intravenous Brentuximab Vedotin at the dose of 1.8 mg/Kg every 3 weeks until disease progression or onset of unacceptable toxicity
88940607|NCT01851213||FoundationOne™ Test Ordered|Patients for whom a FoundationOne™ test was ordered and a report is delivered.
89201458|NCT00924261|Experimental|Hip Stretching|Kneeling Hip flexor stretch - 3 minutes a day, daily, for 10 weeks
89016578|NCT03604406|Placebo Comparator|Placebo Injection (Zostavax Comparator)|Saline injection will be administered as a single 0.65-mL dose subcutaneously in the deltoid region of the upper arm at the baseline visit
89016579|NCT03604406|Experimental|Varicella Zoster Vaccine (Shingrix)|Non-live zoster vaccine injection will be administered twice, 8 weeks apart, as a single 0.65-mL dose subcutaneously in the deltoid region of the upper arm at the baseline visit
89016580|NCT03604406|Placebo Comparator|Placebo Injection (Shingrix Comparator)|Saline injection will be administered twice, 8 weeks apart, as a single 0.65-mL dose subcutaneously in the deltoid region of the upper arm at the baseline visit
89016581|NCT03577028|Experimental|Fixed IV|HPN424 administered once weekly via IV infusion in doses ranging from 1.3 to 150 ng/kg
89457086|NCT02398994|Experimental|Intravenous Immunoglobulin|"Paediatric patients <41.2kg - total dose of 2g/kg in divided doses over 2 days.~All other patients - total dose of 2g/kg in divided doses over 5 days.~PLUS Intravenous Methylprednisolone~Pediatric patients - 30mg/kg or 500mg/m2 up to a maximum daily dose of 1g/day for 5 days.~Adult patients - 1g/day for 5 days."
89457087|NCT02306889|Experimental|Test|Fenofibrate Capsules, USP 130 mg
89457088|NCT02306889|Active Comparator|Reference|ANTARA® (fenofibrate) Capsules 130 mg
89457089|NCT02305953||Frozen serum|The cohort consists of original subjects from the Inno-6025 Trial who previously consented to measuring protein in the blood involved in skin inflammation.
89457090|NCT02393144|Other|Spontaneous labor arm|Women with term pregnancies whose labor started spontaneously. Spontaneous labor is determined by either spontaneous rupture of membranes at term and/or powerful, regular uterine contractions that cause cervical change. Women will be admitted to labor ward after initial assessment via transperineal ultrasonography. Labor augmentation will be performed for women with inadequate uterine contractions, i.e. contractions measuring less than Montevideo units, irregular weak uterine contractions. Analgesia will be provided via administration of 50 mg intramuscular meperidine at 2 hour intervals as required. Amniotomy will be performed for women with adequate cervical dilatation and fetal head-descent. Transperineal ultrasonography will be performed at irregular intervals to assess cervical dilatation, angle of progression and fetal head position. After birth, birth time, birth weight, APGAR scores, degree of perineal trauma, episiotomy use will be recorded.
89457091|NCT02393144|Other|Induced labor arm|Women with term pregnancies who are induced for birth before the onset of spontaneous labor. Labor will be induced with either oxytocin infusion for women with high Bishop score, or labor will be induced with dinoprostone pessary for women requiring cervical ripening, i.e. poor. Women will be admitted to labor ward after initial assessment via transperineal ultrasonography. Analgesia will be provided via administration of 50 mg intramuscular meperidine at 2 hour intervals as required. Amniotomy will be performed for women with adequate cervical dilatation and fetal head-descent. Transperineal ultrasonography will be performed at irregular intervals to assess cervical dilatation, angle of progression and fetal head position. After birth, birth time, birth weight, APGAR scores, degree of perineal trauma, episiotomy use will be recorded.
89457092|NCT02306967|Active Comparator|Standard Resection|Oral resection will be guided by usual practice. This involves identifying the tumour with white light and then marking surgical margins and resection the primary cancer.
89457093|NCT02306967|Experimental|FV Guided Resection|The oral resection will be guided by fluorescent visualization (FV).
89457094|NCT02393222||Patients with ESRD on HD|Adult patients with ESRD on HD. Observing the effect of a single HD session on cerebral blood flow (assessed by transcranial doppler) and cognitive function (assessed by neurocognitive questionnaires). Subgroup to undergo brain MRI.
89457095|NCT02306031|Placebo Comparator|placebo (ARTIFICIAL TEAR)|control group received artificial tear (Sina Darou Laboratories Company, Tehran, Iran) as a placebo every 6 hours. Theses drops continued up to 6 weeks with the same dose after operations.
89457096|NCT02306031|Active Comparator|diclofenac sodium drop|case group received diclofenac sodium drop 0.1% (Sina Darou Laboratories Company, Tehran, Iran) every 6 hours.. Theses drops continued up to 6 weeks with the same dose after operations.
89457097|NCT02392910|Other|Group A|Placebo
89016582|NCT03577028|Experimental|1 Prime Step IV 36 ng/kg Target|Step-dosing IV cohort who received a single Prime Dose followed by the Target Dose (12/36 ng/kg)
89016583|NCT03577028|Experimental|1 Prime Step IV 225-300 ng/kg Target|Step-dosing IV cohorts who received a single Prime Dose followed by the Target Dose (100/300 ng/kg and 75/225 ng/kg]
89016584|NCT03577028|Experimental|2 Prime Step IV 300 ng/kg Target|Step-dosing IV cohorts who received 2 Prime Doses followed by the Target Dose (50/150/300 ng/kg with prior chemotherapy and 50/150/300 ng/kg no prior chemotherapy)
89016585|NCT03577028|Experimental|2 Prime Step IV 450 ng/kg Target|Step-dosing IV cohorts who received 2 Prime Doses followed by the Target Dose (100/300/450 ng/kg and 50/150/450 ng/kg)
89457098|NCT02392910|Other|Group B|Iron Sucrose
89457099|NCT02307045|Active Comparator|varenicline|Stimulation of nicotinic receptors by varenicline (Champix) 1,0 mg po
89016586|NCT03577028|Experimental|Fixed SC|Fixed subcutaneous dose (120 ng/kg)
89016587|NCT03574597|Experimental|Semaglutide|Participants will receive semaglutide as an adjunct to standard-of-care. Estimated trial duration for an individual subject is from 31 to 59 months.
89016588|NCT03574597|Placebo Comparator|Placebo (semaglutide)|Participants will receive placebo (semaglutide) as an adjunct to standard-of-care. Estimated trial duration for an individual subject is from 31 to 59 months.
89023563|NCT05142202|Experimental|Doubly Accelerated Partial Breast Irradiation after Breast-Conserving Surgery|"All recruited participants will be treated with adjuvant to breast-conserving surgery accelerated partial breast irradiation with multicatheter interstitial brachytherapy technique and prescribed five times 5,4 Gy delivered in 3 consecutive days (6 hours minimum gap between the fractions). Treatment starts not later than 12 weeks after surgery (optimally 4-8 weeks), after wound healing, and obtaining the final pathological report with full immunohistochemistry and proper risk group assignment.~The control group consists of standard adjuvant APBI with multicatheter interstitial brachytherapy technique 8 x 4 Gy in 5 consecutive days or 7 x 4,3 Gy in 4 consecutive days (6 hours minimum gap between the fractions)."
89457100|NCT02307045|Active Comparator|nicotine|Nicotine replacement therapy with transdermal patches and/or chewing gums
89501819|NCT02750761|Experimental|Group 2 Cohort 2: Tedizolid IV 3 mg/kg (2 to <6 years)|Participants 2 to <6 years of age received a single intravenous infusion of tedizolid phosphate dosed at 3 mg/kg of total body weight. Maximum dose is 200 mg of tedizolid phosphate.
88940608|NCT01851226|Experimental|5 minutes group|The time limit of attempt selective cannulation by trainees is limited to 5 minutes. If the trainees failed to enter the targeted duct within 5 minutes, the senior endoscopist would take over the duodenoscope and continue the following procedure of cannulation.
88940609|NCT01851226|Experimental|10 minutes group|The time limit of attempt selective cannulation by trainees is limited to 10 minutes. If the trainees failed to enter the targeted duct within 10 minutes, the senior endoscopist would take over the duodenoscope and continue the following procedure of cannulation.
89016589|NCT03567642|Experimental|Osimertinib, Platinum (cisplatin or carboplatin) and Etoposide|Initially, 6 patients will be enrolled and will begin treatment with osimertinib 80mg orally daily (3 who will be receiving cisplatin and 3 who will be receiving carboplatin). Cisplatin or carboplatin treatment will be decided by the treating physician prior to study registration. After 9 weeks (+/- 1 week)( 3 cycles) on osimertinib alone, carboplatin or cisplatin and etoposide will be added. Carboplatin is doses at an AUC of 5 or cisplatin at 60mg/m2 will be given on C4D1. Etoposide is dosed at 100mg/m2 given on Days 1-3 of C4. Only patients on osimertinib 80mg orally daily at the start of cycle 4 will be included in the 3+3 dose de-escalation portion of the study. Chemotherapy and osimertinib will be administered concurrently during cycles 4-7, and from cycle 8 onward, osimertinib monotherapy will be continued. Patients will present every 2 cycles post-chemo (Cycles 8, 10, 12, etc.)
89016590|NCT03558828|Experimental|Step1: Initial Treatment|Participants will be randomly assigned to one of the two initial treatment components: a) enhanced physical activity monitor only (physical activity monitor with goal setting and a physical activity prescription) treatment, or b) enhanced physical activity monitor+ motivational text messaging treatment for 8 weeks (early adoption phase). All participants will be given a physical activity step goal The initial treatment time period is from Weeks 1-8.
89023564|NCT05141227|Experimental|two stage ORIF|Two-stage Open reduction and internal fixation
89023565|NCT05141227|Experimental|single stage Ex. Fix|Single-stage external fixation with minimal internal fixation if needed
89457101|NCT02398604|Experimental|Group A - Allo-hMSCs|Group A: Fifteen (20) patients will be treated with Allogenic human mesenchymal stem cells (Allo-hMSCs): A concentration of 5 million cells/ml delivered in a dose of 2.5 x 10^5 cells per kg of recipient (5 million/20kg) Allo-hMSCs. The entire dose of the cells will be divided and delivered in 6-10 open intramyocardial injections during the BDCPA operation.
89457102|NCT02398604|Placebo Comparator|Group B|Group B: Fifteen (10) patients will be treated with a placebo comparator. The placebo will be divided and delivered in 6-10 open intramyocardial injections during the BDCPA operation.
89457103|NCT04464291|Experimental|Patients with pneumococcal infection|There will be assessing the prevalence of Streptococcus pneumoniae serotypes in the nasopharynx in healthy people; in middle ear liquid in patients with acute otitis media; in sputum and epithelial lining fluid in patients with community-acquired pneumonia; in spinal fluid in patients with invasive pneumococcal indection
89457104|NCT03167372|Experimental|Bright white light vs dim red light|"A balanced sequence (ABBA) over a 12 week period of bright white light and dim red light; alternating bright white and dim red light every 3 weeks.~Subjects will receive 2 Litebook® Advantage lightboxes - 1 bright white and 1 dim red. Information such as mood, fatigue, sleep and light therapy side effects will be self-reported using a smartphone diary; physical activity and sleep will also be reported using a Fitbit Flex2 TM. Data visualization at 12 weeks."
89457105|NCT03167372|Active Comparator|Dim white light vs dim red light|"A balanced sequence (ABBA) over a 12 week period of dim white light and dim red light; alternating dim white and dim red light every 3 weeks.~Subjects will receive 2 Litebook® Advantage lightboxes - 1 dim white and 1 dim red. Information such as mood, fatigue, sleep and light therapy side effects will be self-reported using a smartphone diary; physical activity and sleep will also be reported using a Fitbit Flex2 TM. Data visualization at 12 weeks."
89457106|NCT02312271||enterally fed adults|adult subjects with established enteral access receiving standard tube feeding formula
89457107|NCT02306109|Active Comparator|Standard motor rehabilitation treatment|
89457108|NCT02306109|Experimental|Intensive motor rehabilitation treatment|
89457109|NCT03167294|Other|Single Arm|AquaBeam System for resection and removal of prostatic tissue in males suffering from BPH
89457110|NCT03504345|Active Comparator|Control Group|This arm of the study will have their frozen-thawed embryo transfer take place on the sixth day of progesterone supplementation (Prometrium), which is the standard protocol in our clinic.
89457111|NCT03504345|Experimental|Experimental Group|This arm of the study will have their frozen-thawed embryo transfer take place on the seventh day of progesterone supplementation (Prometrium).
89457112|NCT02398760|Experimental|Motor Control Exercises|(Costa LOP et al. 2009; Hodges PW et al. 2009)
89457113|NCT03507309||To be specified by Steering Committee.|
89457114|NCT02392988|Placebo Comparator|Group receives sham treatment|Sham treatment will be given on points on the back, points that are not acupuncture points, so that the patient will not be able to know whether she is receiving sham treatment or a real treatment. The treatment will be every 48-72 hours, a maximum of three treatments.
89457115|NCT02392988|Experimental|Group receives acupuncture treatment|The women in this group will receive acupuncture treatment every 48-72 hours, a maximum of three treatments.
89457116|NCT02392988|No Intervention|Group doesn't receive any treatment|The women in this group will come for a follow-up check a week later, unless a spontaneous birth will develop.
89457117|NCT02307201|Experimental|Postpartum Magnesium sulfate|The patient will receive magnesium sulfate as usual for 24 hours postpartum
89457118|NCT02307201|No Intervention|No postpartum treatment|The patient did not receive postpartum magnesium sulfate or other anticonvulsant during 24 hours postpartum
89457119|NCT03167528|Experimental|Lung transplant|"Patients who must undergo a lung transplant at the FOCH hospital.~Before and after transplantation, patients benefits of learning and realization sessions of complementary techniques:~Relaxation,~Hypnosis,~Holistic gymnastics,~Transcutaneous electrical nerve stimulation (TENS),~Sophrology."
89457120|NCT02306187|Experimental|Non-Alfacaocidol|Ahead of Eldecalcitol treatment, this group has not taken Alfacaocidol before. Eldecalcitol: the commercial name is Edirol We prescribe Edirol 0.5 or 0.75ug per day into each patient.
89457121|NCT02306187|Experimental|Alfacalcidol|Ahead of Eldecalcitol treatment, this group has taken Alfacaocidol before. Eldecalcitol: the commercial name is Edirol We prescribe Edirol 0.5 or 0.75ug per day into each patient.
89457122|NCT03167216|Experimental|Treatment arm|Treated arm with cromolyn sodium and cetirizine hydrochloride
88940610|NCT01851226|Experimental|15 minutes group|The time limit of attempt selective cannulation by trainees is limited to 15 minutes. If the trainees failed to enter the targeted duct within 15 minutes, the senior endoscopist would take over the duodenoscope and continue the following procedure of cannulation.
88940611|NCT01851239||medical ICU inpatients|
88940612|NCT01851239||surgical ICU inpatients|
88940613|NCT01851265|Other|Fasted|Olaparib capsules following no breakfast
88940614|NCT01851265|Other|Standard meal|Olaparib capsules after standard breakfast
88940615|NCT01851265|Other|High Fat|Olaparib capsules after high fat breakfast
88940616|NCT01851278|Active Comparator|high dose|intraarticular wrist injection of 40mg, 2ml
88940617|NCT01851278|Active Comparator|low dose|intraarticular wrist injection of 20mg, 1ml.
88940618|NCT01851304|Placebo Comparator|Control Bread|A 100 g portion of Control Bread with no extra fiber added. The control bread will be consumed in the intervention Satiety of breads
88940619|NCT01851304|Experimental|Bread Crust Bread|A 100 g portion of Bread Crust Bread with 3 g bread crust per 100 g portion of control bread. The bread crust bread will be consumed in the intervention Satiety of breads.
88940620|NCT01851304|Experimental|Coffee Melanoidins Bread|A 100 g portion of Coffee Melanoidins Bread with 3 g of isolated coffee melanoidins per 100 g portion of control bread. The coffee melanoidins bread will be consumed in the intervention Satiety of breads.
88940621|NCT01851304|Experimental|beta-Glucans Bread|A 100 g portion of beta-Glucans Bread with 3 g of barley beta-glucans per 100 g portion of control bread. The beta-glucans bread will be consumed in the intervention Satiety of breads.
89457123|NCT03508167|Experimental|Thermal Band plus Dorilax®|
89457124|NCT03508167|Other|Thermal Band plus Placebo|
89457125|NCT03507231|Active Comparator|Control|Participants will receive an E-mail Message encouraging them to get vaccinated, and asking them to indicate if they intend to do so and to complete a brief questionnaire after vaccination.
89457126|NCT03507231|Experimental|Direct Incentive|Participants will receive an E-mail Message encouraging them to get vaccinated, and asking them to indicate if they intend to do so and to complete a brief questionnaire after vaccination. They are offered an Incentive for Vaccination ($5 Amazon Gift Card).
89457127|NCT03507231|Experimental|Indirect Incentive|Participants will receive an E-mail Message encouraging them to get vaccinated, and asking them to indicate if they intend to do so and to complete a brief questionnaire after vaccination. They are offered an Incentive for completing a short survey ($5 Amazon Gift Card).
89457128|NCT02392832|Experimental|Intervention arm|Fourstar® granule formulation, 90day and 180 day briquettes Bti/Bs in larval habitats of malaria vectors.
89457129|NCT02392832|No Intervention|Control arm|No larvicide application.
89457130|NCT03507153|Active Comparator|Bre-fllex group|Maxillary class III modification I edentulous patients that will recieve Bre-flex partial denture
89457131|NCT03507153|Experimental|PEEK group|Maxillary class III modification I edentulous patients that will recieve PEEK partial denture
89457132|NCT02393066|Active Comparator|propofol|these patients are sedated with propofol infusion during ICU admission
89457133|NCT02393066|Active Comparator|dexmedetomidine|these patients are sedated with dexmedetomidine infusion during ICU admission
89457134|NCT03504267|Experimental|Physical Activity Group|The PAG (physical activity) group will receive evidence-based educational information as well as a list of local resources for pursuing physical activity.
89457135|NCT03504267|No Intervention|Standard of Care Group|The SOC (standard of care) group will receive no additional information beyond standard-of-care brochures and information
89457136|NCT02392754|Experimental|Screening|The intervention group receives AF screening with a 2-week ambulatory ECG patch monitor (ZIO XT Patch) worn at baseline and again at 3 months, in addition to standard care for 6 months. The intervention group also receives a home BP monitor with automatic AF detection capability to be used twice daily for 2 weeks during the ECG monitoring periods.
88940622|NCT01851304|Placebo Comparator|Control Pudding|A 150 g portion of Control Pudding without the addition of any extracts. The control pudding will be consumed in the intervention Satiety of puddings.
88940623|NCT01851304|Experimental|Gentian extract pudding|A 150 g portion of Gentian Pudding with the addition of 1 g Gentian extract per 100 g pudding. The Gentian extract pudding will be consumed in the intervention Satiety of puddings.
88940624|NCT01851304|Experimental|Encapsulated Gentian Extract Pudding|A 150 g portion of Microencapsulated Gentian extract pudding with the addition of 1 g of a microencapsulated Gentian extract per 100 g pudding. The Microencapsulated Gentian extract pudding will be consumed in the intervention Satiety of puddings.
88940625|NCT01851343|Experimental|1|All patients will receive the same treatment
88940626|NCT01851408|Experimental|Temsirolimus + Sorafenib|Temsirolimus intravenous (IV) over 30 minutes on days 1, 8,15, and 22 and oral sorafenib once or twice daily on days 1-28.
89457137|NCT02392754|No Intervention|Control|The control group receives standard care for 6 months (including a pulse check and heart auscultation by a physician at 6 months).
89457138|NCT03504111|Active Comparator|Needle Tenotomy|1 group will be assigned to get the standard treatment for chronic tendinopathy, percutaneous needle tenotomy (PNT). It is currently considered a standard treatment option. Ultrasound guided PNT with approximately 25 passes through the tendon and enthesis with approximately an 18 gauge needle with adequate amount of anesthetic (lidocaine) for effective anesthesia. Investigators will keep track of the number of passes through the tendon. Investigators will keep track of the amount and type of anesthetic used
88940627|NCT01851421||Double-Variant MC3R|Volunteers with homozygous polymorphisms causing protein changes to T6K and V81I.
88940628|NCT01851421||Wild Type MC3R|Volunteers with no polymorphisms in MC3R gene.
88940629|NCT01851460|Experimental|RFA|All subjects enrolled onto this study will receive treatment of their liver abscess (es) by RFA ablation
88940630|NCT01851486|Active Comparator|Clonidine+ Saline|Clonidine 0.15 mg and saline 0.15 mg/kg
88940631|NCT01851486|Active Comparator|Clonidine + Naloxone|Clonidine 0.15 mg and Naloxone 0.15 mg/kg
88940632|NCT01851486|Active Comparator|Placebo +Naloxone|Placebo 0.15 mg+ naloxone 0.15 mg/kg
88940633|NCT01851486|Placebo Comparator|Placebo +saline|Placebo 0.15 mg+ saline 0.15 mg/kg
88940634|NCT01851499|Experimental|Ultramicronized PEA (Normast)|"Normast is ultramicronized Palmitoylethanolamide (PEA) classified as Dietary foods for special medical purposes."
88940635|NCT01851499|Placebo Comparator|Microgranules|Same as Normast, without active component.
88940636|NCT01851512|Experimental|T-R (Test-Reference drug)|DA-3803 Injection is injected first and Ovidrel liquid injection is injected after 3-week period
88940637|NCT01851512|Experimental|R-T (Reference-Test drug)|Ovidrel liquid injection is injected first and DA-3803 Injection is injected after 3-week period
88940638|NCT01851525|Active Comparator|Contact Force Sensing (CFS) Blinded|Contact Force Sensing (CFS) Blinded: Operator will be blinded to data provided by the integrated force sensor in the ablation catheter (ThermoCoolSmartTouch ablation catheter)
88940639|NCT01851525|Active Comparator|Contact Force Sensing (CFS) Guided|Contact Force Sensing (CFS) Guided: Operator will be guided by integrated force sensor in the ablation catheter (ThermoCoolSmartTouch ablation catheter)
88940640|NCT01851538||Chronic heart failure patients visiting the outpatient clinic|
88940641|NCT01851551|Experimental|VSLI plus rituximab|VSLI (vincristine sulfate liposome injection) plus rituximab
88940642|NCT01851564|Experimental|SEMS for primary variceal haemorrhage|Use of the Self-expanding mesh-metal oesophageal stent (SEMS) as primary therapy for Acute Variceal Haemorrhage.
88940643|NCT01851564|Active Comparator|Standard Therapy - Primary Haemorrhage|Use of standard medical and endoscopic therapy for the treatment of primary variceal haemorrhage.
88940644|NCT01851564|Experimental|SEMS for Failure to Control Bleeding|Use of the self expanding mesh-metal stent for failure of standard therapy in oesophageal variceal haemorrhage.
89023566|NCT05139875|Experimental|Betamethasone (Diprospan)|Participant received single intra-articular Betamethasone Dipropionate / Betamethasone Sodium Phosphate 1 ml
89501820|NCT02750761|Experimental|Group 3: Tedizolid oral 4 mg/kg (6 to <12 years)|Participants 6 to <12 years of age received a single dose of tedizolid phosphate oral suspension dosed at 4 mg/kg of total body weight. Maximum dose is 200 mg of tedizolid phosphate.
88940645|NCT01851564|Active Comparator|Standard Therapy - Failure of Control|Use of standard medical and endoscopic therapy for failure of standard therapy in oesophageal variceal haemorrhage.
89457139|NCT03504111|Active Comparator|Platelet Rich Plasma|1 group will be assigned to the PRP arm. Investigators will have a trained provider draw the blood, and prepare the PRP according to manufacturer and departmental (KP) protocol. Ultrasound guided injection of this PRP using approximately an 18 gauge needle with a single pass through the tendon into affected area as demonstrated on ultrasound. Adequate amount of anesthetic will be given in a separate syringe with adequate amount of anesthetic (lidocaine) for effective anesthesia. Investigators will keep track of amount and type of anesthetic used. The amount of anesthesia will be the same in both arms of the study
89457140|NCT02398838|Experimental|Home administration of mifepristone|Home administration of 200 mg mifepristone. Choice of home or clinic administration of 400 mcg buccal misoprostol.
89457141|NCT02398838|Active Comparator|Clinic administration of mifepristone|Clinic administration of 200 mg mifepristone. Choice of home or clinic administration of 400 mcg buccal misoprostol.
89457142|NCT02398682|Experimental|After study Intervention arm Heartlands|"The trial has 4 arms in a Before and After design:~Arm 3. After/Heartlands area patients receiving the experimental intervention~Patients who have AKI and are either inpatients in the Intervention hospital or living within the surrounding catchment area are eligible. The intervention will be in the form of a telephone call to the primary clinician or visit to the patient. The intervention will include:~Rapid diagnosis of AKI cause; Rapid treatment of AKI cause; Stopping 'nephrotoxic' drugs; Early nephrology followup for stage 3 AKI survivors; and preventing recurrent AKI."
89457143|NCT02398682|Active Comparator|After study Control arm Good Hope|"The trial has 4 arms in a Before and After design:~Arm 4. After/Good Hope area patients observed whilst receiving active comparator~Patients who have AKI, as shown by having an Alert for such, and are either inpatients in Good Hope Hospital or living within the surrounding catchment area. These patients will receive good standard care (active comparator), but none of the interventions listed for the Intervention group."
89457144|NCT02398682|Active Comparator|Before study Heartlands area|"The trial has 4 arms in a Before and After design:~Arm 1. Before/Heartlands area patients observed whilst receiving active comparator~Patients who have AKI, as shown by having an Alert for such, and are either inpatients in Heartlands Hospital or living within the surrounding catchment area. These patients will receive good standard care (active comparator), but none of the interventions listed for the Intervention group."
89457145|NCT02398682|Active Comparator|Before study Good Hope area|"The trial has 4 arms in a Before and After design:~Arm 2. Before/Good Hope area patients observed whilst receiving active comparator~Patients who have AKI, as shown by having an Alert for such, and are either inpatients in Good Hope Hospital or living within the surrounding catchment area. These patients will receive good standard care (active comparator), but none of the interventions listed for the Intervention group."
89457146|NCT03508089|Other|Control Arm|
89457147|NCT03508089|Active Comparator|Multiple Sclerosis Arm|
89457148|NCT02312427|Experimental|Outpatient arm|After baseline data collection, DPP-4 inhibitor will be suspended for one month and serum BNP will be measured. The DPP-4 inhibitor will be resumed and after another month, serum BNP will be measured again.
89457149|NCT02312427|Experimental|Hospitalization arm 1|After hospitalization, medication for diabetes will be suspended. During the treatment for heart failure, drugs other than DPP-4 inhibitor will be resumed when required. After the stabilization of heart failure, DPP-4 inhibitor will be resumed (or administered if it was not prescribed before hospitalization) and serum BNP before and after the initiation of DPP-4 inhibitor will be measured.
89457150|NCT02312427|Experimental|Hospitalization arm 2|After hospitalization, medication for diabetes may be suspended or continued. During the treatment for heart failure, drugs including DPP-4 inhibitor will be resumed when required. After the stabilization of heart failure, DPP-4 inhibitor will be suspended and serum BNP before and after the suspension of DPP-4 inhibitor will be measured.
89457151|NCT02398916|Experimental|Music|"Listening to relaxing music for the entire period starting from waiting period in the surgical waiting area until the end of the LEEP procedure~Undergoing LEEP according to the usual protocol"
89457152|NCT02398916|No Intervention|Control|- Undergoing LEEP according to the usual protocol without listening to music
89457153|NCT02312505|Other|COPFX|cardiac output by PulsioFlex® Monitoring system (COPFX)
89457154|NCT03115346|Experimental|decision aid|the experimental group will receive the decision aid
89457155|NCT03115346|No Intervention|control|the control group will only receive the survey
89457156|NCT03504033|Experimental|Xenon|Xenon concentration of 50-60 % will be used for maintenance of general anesthesia and will be adjusted to maintain Bispectral index (BIS) value between 40 and 60.
88940646|NCT01851577|Experimental|Family Foundations coparenting program|Family Foundations is a coparenting prevention program that will be administered concurrently with ongoing home visiting.
88940647|NCT01851577|Active Comparator|Home visiting|"Home visiting as usual will be provided without the added Family Foundations coparenting prevention program."
88940648|NCT01851603|Experimental|AVL-3288|Oral administration of AVL-3288
88940649|NCT01851603|Placebo Comparator|Sugar pill|Placebo
88940650|NCT01851616|Active Comparator|Glucose 25g|25g of glucose in 200ml tap water, given orally (plus 50 mg 13C-sodium acetate)
88940651|NCT01851616|Active Comparator|Glucose 10g|10g Glucose in 200ml tap water given orally (plus 50 mg 13C-sodium acetate)
88940652|NCT01851629|Experimental|ADAPT Locomotor Training|Individuals receive 15 sessions of ADAPT-locomotor training for 3 weeks. During ADAPT-locomotor training, stepping in response to obstacles and walking challenges are practiced on a treadmill and overground.
88940653|NCT01851629|Active Comparator|Basic Locomotor Training|Individuals will receive 15sessions of the traditional form of basic locomotor training for 3 weeks. Repetitive stepping patterns are practiced on the treadmill and overground.
88940654|NCT01851629|Other|Cross-Sectional Testing|Individuals with and without spinal cord injury will be evaluated to develop protocols within our laboratory to assess reflexes (spinal tract integrity), walking ability, and whether mirror images during walking enhance or disrupt motor responses during walking.
88940655|NCT01851668||Preterm inter-hospital transfers|preterm infants <31 weeks gestation and <=day 3 of life
88940656|NCT01851668||Preterm infants inborn|Preterm infants <31 weeks gestation and <=3 days old born and remaining at same hospital.
88940657|NCT01851668||Ex-preterm infants back transfered|Mature ex-preterm infants transferred back to referring hospital
89457157|NCT03504033|Active Comparator|Desflurane|Desflurane concentrations of 4-5%/0.8 minimum alveolar concentration (MAC) respectively will be used for maintenance of general anesthesia and will be adjusted to maintain BIS index value between 40 and 60.
88940658|NCT01851681|Active Comparator|Amoxicillin taken 2 g preoperatively|2 g amoxicillin 1h preop then placebo tid x 7 days
88940659|NCT01851681|Active Comparator|Amoxicillin 2g taken preoperatively and 500mg tid x 7 days|2g amoxicillin 1h preop then tid x 7 days
88940660|NCT01851707|Experimental|IPI-145, low dose BID|
88940661|NCT01851707|Experimental|IPI-145, medium dose BID|
88940662|NCT01851707|Experimental|IPI-145, high dose BID|
88940663|NCT01851707|Placebo Comparator|Placebo BID|
88940664|NCT01851733|Experimental|Arm B: (MLA, doxorubicin hydrochloride at 6-8 weeks)|"Patients undergo MLA (MRI-guided laser heat ablation). A subset of patients will have a biopsy at time of MLA.~Beginning 6-8 weeks later, patients receive doxorubicin hydrochloride 20 mg/m2 intravenously (IV) over 5 minutes once weekly for 6 weeks.~Biomarker blood draws will be drawn at different time points.~DSC-MRI: no more than 2 weeks prior to MLA, within approximately 3 days after MLA, 2/4/6 weeks after MLA, 10 weeks after MLA only if 6-week scan shows prolonged disruption of the blood brain barrier, 14 weeks after MLA only if week 10 MRI shows contined blood brain barrier disruption, and every 8 weeks until disease progression (these scans do not have to be DSC-MRI)"
88940665|NCT01851733|Experimental|Arm C: (MLA, doxorubicin hydrochloride at 72 hours)|"Patients undergo MLA (MRI-guided laser heat ablation).~Beginning within 72 hours later, patients receive doxorubicin hydrochloride 20 mg/m2 IV over 5 minutes once weekly for 6 weeks.~DSC-MRI: no more than 2 weeks prior to MLA, within approximately 3 days after MLA, 2/4/6 weeks after MLA, 10 weeks after MLA only if 6-week scan shows prolonged disruption of the blood brain barrier, 14 weeks after MLA only if week 10 MRI shows contined blood brain barrier disruption, and every 8 weeks until disease progression (these scans do not have to be DSC-MRI)"
88940666|NCT01851759|Experimental|Cinepazide, Stroke, Injection|Test drug：Methanesulfonic acid cinepazide injection（5ml/125mg）
88940667|NCT01851759|Placebo Comparator|palcebo,Stroke,Injection|Placebo：simulation agent of Methanesulfonic acid cinepazide injection（5ml sterile water for injection）
89457158|NCT03132519|Experimental|Sevo-2.0|This group will maintain remifentanil infusion by TCI to 2 ng/ml during emergence and extubation after have received sevoflurane during procedure.
89457159|NCT03132519|Experimental|Sevo-2.5|This group will maintain the remifentanil infusion by TCI to 2.5 ng/ml during emergence and tracheal extubation after have received sevoflurane during surgical procedure.
89457160|NCT03132519|Experimental|Des-2.0|This group will maintain the remifentanil infusion by TCI to 2.0 ng/ml during emergence and tracheal extubation after have received desflurane during surgical procedure.
89457161|NCT03132519|Experimental|Des-2.5|This group will maintain the remifentanil infusion by TCI to 2.5 ng/ml during emergence and tracheal extubation after have received desflurane during surgical procedure.
89457162|NCT03132519|Active Comparator|Sevo-Control|This group will maintain the remifentanil infusion by TCI to 1.0 ng/ml during emergence and tracheal extubation after have received sevoflurane during surgical procedure.
88940668|NCT01851785|No Intervention|Attention control|Subjects randomized to the attention control arm will receive an educational program (an NIH-developed booklet) that summarizes how to live with knee OA but does not specifically mention joint replacement. This booklet provides information about OA, examples of exercises one could do to improve pain and reduce stiffness, types of non-drug pain relief such as massage, and information about various medications. The interventionist will give the participant the booklet and describe what can be found inside. They are also encouraged to ask their doctor any questions they may have about the information in the booklet or questions they may have about their OA. The purpose of this educational program is to provide a tangible clinical incentive to the control group for participating in this additional component of the study.
88940669|NCT01851785|Experimental|Decision Aid (DA) Intervention|"Patients randomized to the DA Intervention will watch a Knee OA Decision Aid (DA) developed by the Foundation for Informed Medical Decision Making and then receive a brief counseling session called AskMe3. The DA is a video that provides viewers with information about OA, treatment choices such as lifestyle changes, non-drug treatments, medication, injections, complementary therapies, and surgery, as well as the pros and cons of each type of treatment. The AskMe3 is a communication, skill-building intervention, which instructs patients to ask 3 questions to the doctor: 1) What is my main problem? 2) What do I need to do? 3) Why is it important for me to do this?"
88940670|NCT01851798||ambulatory orthopedic surgery patients with OSA|ambulatory orthopedic surgery patients with home sleep test preoperative AHI => 5
88940671|NCT01851798||ambulatory orthopedic surgery patients without OSA|ambulatory orthopedic surgery patients with home sleep test preoperative AHI < 5
88940672|NCT01851824|Experimental|Acenocoumarol + Vemurafenib|
88940673|NCT01851837|Active Comparator|Group I|Study group I (57 participants) received the continuous training of exercise time.
88940674|NCT01851837|Active Comparator|Group II|Study group II (58 participants) received the interval training of exercise time.
88940675|NCT01851850|Experimental|Drug|
88940676|NCT01851889||CF-LVAD pump speed.|
88940677|NCT01851902||CHA2DS2-VASc Score 2 - 4|Physicians estimate the risk of stroke in AF patients using either the CHADS2 or CHA2DS2-VASc scoring; this is a low risk cohort.
88940678|NCT01851902||CHA2DS2-VASc Score 5 - 6|Physicians estimate the risk of stroke in AF patients using either the CHADS2 or CHA2DS2-VASc scoring; this is a medium risk cohort.
88940679|NCT01851902||CHA2DS2-VASc Score 7 - 9|Physicians estimate the risk of stroke in AF patients using either the CHADS2 or CHA2DS2-VASc scoring; this is a high risk cohort.
88940680|NCT01851915|Active Comparator|Cognitive Behavioral therapy (CBT)|Short term therapy for treatment of depression
88940681|NCT01851915|Experimental|Interpersonal Psychotherapy (IPT)|Interpersonal short term therapy for treatment of depression
89201459|NCT00924261|Experimental|Shoulder Stretch|Shoulder Stretch - 3 minutes daily for 10 weeks
88940682|NCT01851941|Experimental|mFOLFOX6|Modified FOLFOX6 regimen consists of oxaliplatin 100 mg/m2 and FA 100 mg/m2 given as a 2 hour intravenous infusion, followed by 5-FU 2.4 g/m2 given as a continuous infusion over 46 hour, which is repeated every 2 weeks. Patients receive 4 cycles of neoadjuvant modified FOLFOX6 followed by curative radical surgery with D2 dissection and 4 cycles of adjuvant modified FOLFOX6.
88940683|NCT01851954|Experimental|clarithromycin|Population PK
88940684|NCT01851967|Experimental|MoodGYM|This study is a single-arm intervnetion. All subjects will be assigned to receive six weeks of online CBT through MoodGYM.
88940685|NCT01851980|Experimental|CWS+Furosemide (40 mg)|Chest wall strapping to reduce vital capacity by 20% of its baseline value + single-dose inhalation of furosemide (40 mg)
88940686|NCT01851980|Placebo Comparator|CWS+0.9% saline placebo|Chest wall strapping to reduce vital capacity by 20% of its baseline value + single-dose inhalation of 0.9% saline placebo
88940687|NCT01851980|Experimental|CWS+Furosemide (120 mg)|Chest wall strapping to reduce vital capacity by 20% of its baseline value + single-dose inhalation of furosemide (120 mg)
88940688|NCT01851993|Experimental|Inhaled Ondansetron (8 mg)|Single-dose inhalation of nebulized ondansetron (8 mg)
88940689|NCT01851993|Placebo Comparator|Inhaled 0.9% saline placebo|Single-dose inhalation of 0.9% saline placebo
88940690|NCT01852006|Experimental|COPD AB ON|"Abdominal Binder ON"
88940691|NCT01852006|No Intervention|COPD AB OFF|"Abdominal Binder OFF (control)"
88940692|NCT01852097|Experimental|CBT based online intervention|CBT based online intervention to elicit and address perceptual and practical barriers to taking medication.
88940693|NCT01852097|No Intervention|Control group|Care as Usual. Participants in the control group will be able to access the online intervention after they complete their last follow-up questionnaire.
88940694|NCT01852123|Other|Early implementation|The high-sensitivity troponin I assay will be implemented after a 6 month validation phase
88940695|NCT01852123|Other|Late implementation|The high-sensitivity troponin I assay will be implemented after a 12 month validation phase
89016591|NCT03558828|Experimental|Step 2: Augmented Treatment|"At Week 8, it will be determined if a women has met her physical activity step goal. If she has, then she will be classified as a responder, and will continue with the same initial treatment component for weeks 9-34 (later adoption).~If a woman has not met her physical activity step goal she will be classified as a non-responder. In addition to the initial treatment component non-responders to initial treatments will be randomly assigned to one of two augmented treatment components: a) personal calls, or b) group meetings for Weeks 9-34 (later adoption phase)."
89201460|NCT00928551|Experimental|1|
89201461|NCT01053871|Experimental|1|sedation using propofol
89201462|NCT01053871|Experimental|2|sedation using midazolam with fentanyl
89457163|NCT03132519|Active Comparator|Des-Control|This group will maintain the remifentanil infusion by TCI to 1.0 ng/ml during emergence and tracheal extubation after have received desflurane during surgical procedure.
88940696|NCT01852136||NEXT 31G x 5mm|Subjects will use their current pen needle or the BD NEXT 31G x 5mm pen needle for approximately one week (Period 1). The alternate pen needle will be used for one week in Period 2.
88940697|NCT01852136||NEXT 31G x 8mm|Subjects will use their current pen needle or the BD NEXT 31G x 8mm pen needle for approximately one week (Period 1). The alternate pen needle will be used for one week in Period 2.
88940698|NCT01852136||NEXT 32G x 4mm|Subjects will use their current pen needle or the BD NEXT 32G x 4mm pen needle for approximately one week (Period 1). The alternate pen needle will be used for one week in Period 2.
88940699|NCT01852149|Experimental|MPAS Implant|MPAS Implant
88940700|NCT01852188|Other|Nonsterile|Patients will be randomized to either sterile or clean gloves during intrapartum vaginal exams.
88940701|NCT01852188|Other|Sterile|Patients will be randomized to either sterile or clean gloves during intrapartum vaginal exams.
88940702|NCT01852240||erectile dysfunction|"Inclusion criteria:~male patients with ED defined by an IIEF-5 score of ≤ 21~age between 18-45a~Exclusion criteria:~systemic diseases (e.g. diabetes mellitus, heart disease, hypertension, neurological disorders etc.)~pure psychogenic (non-organic) ED with good spontaneous / nightly erections~periodontal treatment within the last 3 months~antibiotic intake within the last 3 months"
88940703|NCT01852253|Active Comparator|2% chlorhexidine|Implants with peri-implantitis lesions will be surgically exposed, followed by a mechanical cleansing using curettes and gauzes and cotton pellets soaked in saline and 1 minute of local application of a 2 % chlorhexidine solution. After 1 minute of saline rinsing the gingival flap will be returned slightly apical (in order to reduce pockets) and will be firmly sutured. The surgery is followed by 2 weeks of rinsing with 0.12% chlorhexidine + 0.05% cetylpyridinium chloride without alcohol twice daily during 30 seconds.
89016592|NCT03558828|Experimental|Step 3: Maintenance|At Weeks 35-50 (maintenance phase) all participants in the study return to an enhanced physical activity monitor only treatment component.
89201463|NCT00984178|No Intervention|Control group|standard treatment
89201464|NCT00984178|Experimental|Bone marrow mononuclear progenitors|intracoronary transplantation of bone-marrow mononuclear progenitor cells
89201465|NCT00984178|Experimental|GCSF|progenitor cells mobilization through Granulocite- Colony Stimulating Factor treatment (G-CSF)
89457164|NCT03115970||Trauma patients|All patients having / suspected to have severe trauma injuries
89457165|NCT02306343|Experimental|Test (with the InsuPad device)|"In the Meal Tolerance Test protocol - After overnight fast followed by a pre-study stabilization period, the InsuPad device was placed on the abdomen of the subject. The InsuPad device was activated and insulin bolus (0.2 units/kg body weight) was injected right before study start. The injection was given to the subject's abdomen through the injection window of the InsuPad device. Immediately afterwards the subject was asked to drink a standardized liquid meal within 10 minutes. Blood glucose measurements were taken from a peripheral venous line at a pre-determined time points. Total follow up time was 5 hours post meal.~In the daily life setting - Up to 12 months with the device (test). Subjects were asked to perform at least 3 blood glucose measurements during the day."
89457166|NCT02306343|No Intervention|Control (without the InsuPad device)|"In the Meal Tolerance Test protocol - After overnight fast followed by a pre-study stabilization period, insulin bolus (0.2 units/kg body weight) was injected to the abdomen right before study start. Immediately afterwards the subject was asked to drink a standardized liquid meal within 10 minutes. Blood glucose measurements were taken from a peripheral venous line at a pre-determined time points. Total follow up time was 5 hours post meal.~In the daily life setting - Up to 12 months without the device (control). Subjects were asked to perform at least 3 blood glucose measurements during the day."
89457167|NCT02398448|Experimental|Zyloprim® 300 mg and three dissolution test formulations|Regimen A: Zyloprim® 300 mg; Regimen B: Allopurinol 300 mg; undergranulated, high hardness condition; Regimen C: Allopurinol 300 mg; alternative condition 2; Regimen D: Allopurinol 300 mg; alternative condition 3
89016593|NCT03555058|Other|High risk- TDM|Treatment escalation per TDM and physician's decision.
89016594|NCT03555058|No Intervention|High risk- Follow Up|Patients randomized to this arm will keep with the follow-up regime. Treatment escalation will occur only upon worsening of symptoms.
89016595|NCT03555058|No Intervention|Low risk|Control group. Patients will be assigned to this group based on VCE results and will not undergo randomization.
89016596|NCT03552978|Experimental|Tech-facilitated IC intervention|After completing an initial 2-hour screening visit that includes a series of questionnaires assessing eligibility criteria and meeting with the study physician to review medical history, participants will be offered nicotine replacement therapy (NRT) at baseline (Week 0), per VA prescribing guidelines, nicotine dependence levels, and participant preference. Participants will then receive 8 counseling sessions (video or telephone). The first session lasts 45-60 min, and the remaining 7 sessions last 20-30 min. Participants will be asked to use the Stay Quit Coach (SQC) app between sessions, and the iCO® Smokerlyzer®
89023567|NCT05139875|Active Comparator|Triamcinolone acetonide|Participant received single intra-articular Triamcinolone acetonide 40 mg
89023568|NCT05139810|Experimental|Donidalorsen: Cohort A|Participants will be administered donidalorsen by subcutaneous (SC) injection for up to 25 weeks.
89457168|NCT03508011|Experimental|IMP4297|
89457169|NCT02398370|Experimental|Injection of PMD-MSCs into the penis|Subjects will receive an initial injection of 1.0cc of Placental Matrix-Derived Mesenchymal Stem Cells (PMD-MSCs). Subjects will be eligible for re-injection at 3 months and/or 6 months as determined by the clinician based patient reported treatment satisfaction.
89457170|NCT03503955|Experimental|study group|fine motor skills activities and Leap-Motion virtual reality games
89457171|NCT03503955|Experimental|control group|fine motor skills activities
89457172|NCT02392520|Experimental|Antagonist|0.25 mg GnRH antagonist cetrorelix will be administered once daily for 4 days, starting on the day of severe early OHSS diagnosis
89457173|NCT02392520|Placebo Comparator|Conventional|Women with severe early OHSS will be treated with conventional treatment, such as intravenous albumin administration, paracentesis of ascitic fluid, either on an outpatient or inpatient basis.
89457174|NCT02312583|Sham Comparator|Psychoeducational online information|Psychoeducational online information. During 7 weeks as a complement to the usual treatment.
89457175|NCT02312583|Experimental|iFightDepression online programme.|iFightDepression online programme. During 7 weeks as a complement to the usual treatment.
89457176|NCT02316249|Active Comparator|Gellhorn Pessary|Patients who are fitted with a Gellhorn pessary for reduction of pelvic organ prolapse. Patients will then be randomized based on pessary to either Estradiol vaginal cream or Placebo vaginal cream. Patients will be instructed to digitally apply 0.5mg of cream inside vagina every night for 2 weeks. After 2 weeks they will switch to 2 nights weekly.
89457177|NCT02316249|Active Comparator|Ring with Support Pessary|Patients who are fitted with a Ring with Support Pessary for reduction of pelvic organ prolapse. Patients will then be randomized based on pessary to either Estradiol vaginal cream or Placebo vaginal cream. Patients will be instructed to digitally apply 0.5mg of cream inside vagina every night for 2 weeks. After 2 weeks they will switch to 2 nights weekly.
89457178|NCT03115268|Experimental|Immediate|Participants allocated to the immediate arm will receive 6 months of Social support groups delivered in EVA Park immediately after randomisation. They will be re-assessed in Month 7, then receive 6 months of usual care, followed by reassessment in month 14.
89457179|NCT03115268|Active Comparator|Wait list control|Participants allocated to the wait list control arm will receive 6 months of usual care after randomisation. They will be re-assessed in month 7, and will then receive 6 months of social support groups delivered in EVA Park, with reassessment in month 14.
89457180|NCT02307357|Experimental|newcomball players|active newcomball women players will perform physical fitness tests
89457181|NCT02307357|Experimental|control|not physically active women will perform physical fitness tests
88940704|NCT01852253|Sham Comparator|0.12% chlorhexidine|Implants with peri-implantitis lesions will be surgically exposed, followed by a mechanical cleansing using curettes and gauzes and cotton pellets soaked in saline and 1 minute of local application of a 0.12 % chlorhexidine solution. After 1 minute of saline rinsing the gingival flap will be returned slightly apical (in order to reduce pockets) and will be firmly sutured. The surgery is followed by 2 weeks of rinsing with 0.12% chlorhexidine + 0.05% cetylpyridinium chloride without alcohol twice daily during 30 seconds.
89457182|NCT02307435|Experimental|implantation group|implantation group will receive MSC and HA-CaSo4
89457183|NCT02696096|Other|All Participants|FMRI Suboxone
89457184|NCT02316327|Experimental|gemcitabine, cisplatin and bevacizumab|"Bevacizumab will be given by I.V infusion at the dose of 7.5 mg/kg on days 1 every 21 days~Cisplatin 80 mg/m2 I.V on day 1~Gemcitabine 1250 mg/m2 I.V on day 1 & 8~Treatment cycles will be repeated every three weeks up to 6 cycles~Bevacizumab monotherapy as maintenance allowed in non-progressive tumors"
89457185|NCT04480346|Experimental|CHP treatment|Participants assigned to this arm received the treatment described in another section.
89457186|NCT04480346|No Intervention|Community Care|Participants randomly assigned to this condition received information about service providers in the community, but no services from the investigators.
89457187|NCT03132441|Experimental|Cardiac Rehabilitation|"Strength Training for Frailty:~All patients enrolled will be enrolled in 6 weeks of cardiac rehabilitation for the pilot study."
89457188|NCT03503721|Experimental|BipolEP|includes all patients undergoing BipolEP surgery
89457189|NCT03503721|Active Comparator|TURP|includes all patients undergoing TURP surgery
89457190|NCT02316405|Experimental|Test Group|5 weeks of arm and leg cycling, 3 times per week for 30 minute of total exercise per session
89457191|NCT02392364|Active Comparator|Variable Treatment Dosing Arm|Group 1 will receive injections every 4 weeks until diabetic macular edema on the OCT is decreased and stable. At that point, the length of time between injections may increase, depending on how the study eye is doing. The interval between study eye treatments may maintain, increase, or decrease once the variable treatment dosing has begun. This will be determined by an algorithm designed into a computer program
89457192|NCT02392364|Active Comparator|Monthly Treatment Arm|Group 2 will receive 5 intravitreal injections, monthly, for the first 5 months of the study. After those initial injections, visits/treatment will be every 8 weeks.
89457193|NCT02316483||Group I: T2D and Charcot foot|Individuals with confirmed diagnosis of type 2 diabetes, using the American Diabetes Association guidelines and confirmed diagnosis of Charcot foot, based on clinical and radiological evidence of Charcot foot.
89457194|NCT02316483||Group II: T2D neuropathy, no charcot|Individuals with type 2 diabetes and presence of neuropathy but the absence of Charcot foot.
88940705|NCT01852266|Experimental|RSV cps2 Vaccine|Participants will receive one dose of the RSV cps2 vaccine administered as nose drops at study entry.
88940706|NCT01852266|Placebo Comparator|Placebo|Participants will receive one dose of placebo administered as nose drops at study entry.
88940707|NCT01852279|Experimental|Active muscle stimulation|Muscle stimulation delivered by Brain Computer Interface
88940708|NCT01852279|Active Comparator|Passive muscle stimulation|FES will be delivered by therapist
88940709|NCT01852305|Experimental|Lab Sleep Study (group 1)|The patients in the Sleep Study group will be referred to a sleep medicine specialist who is part of the Bariatric Surgery Psychosocial Program. In the Sleep Study group, patients will undergo sleep studies overnight in a sleep laboratory. At the same time, they will also wear the oximeter wristwatch to measure overnight oximetry.
89457195|NCT02316483||Group III: Control, non-diabetic|Individuals without history of type 2 diabetes.
89457196|NCT02392676|Experimental|1/OLAPARIB|olaparib 300 mg oral tablets; twice daily
89457197|NCT02392676|Placebo Comparator|2/PLACEBO|placebo matching olaparib 300 mg oral tablets; twice daily
89457198|NCT03503487|No Intervention|Control|Patients receiving standard informed consent procedure before intervention
88940710|NCT01852305|Active Comparator|Oximetry group (group 2)|The patients in the Oximetry group will undergo overnight pulse oximetry. The patients with ODI>10 events/hour will be referred to the sleep medicine specialist.A split- night polysomnography(PSG) will be employed to confirm obstructive sleep apnea OSA) diagnosis. The 1st part of the night will be a sleep study and depending on AHI, CPAP titration will be done for the 2nd part of the night.
88940711|NCT01852318|Experimental|Pregabalin|pregabalin 75mg daily for 12 weeks
88940712|NCT01852318|Active Comparator|fexofenadine|fexofenadine 60 mg daily for 12 weeks
88940713|NCT01852318|Placebo Comparator|Placebo|placebo 75 mg for 12 weeks
89457199|NCT03503487|Experimental|Planner 1|Patients receiving 3D informed consent procedure before intervention with Surgical Theater
89457200|NCT03503487|Experimental|Planner 2|Patients receiving 3D informed consent procedure before intervention with Vesalius
88940714|NCT01852331|Active Comparator|PGD granules|While continuing current antipsychotic medications, subjects will receive adjunctive Peony-Glycyrrhiza Decoction (PGD) granules (equivalent to 45 g raw materials in total per day). They need to take the granules two times a day, each time one sachet (aluminum foil pack of 9g, tear open and empty contents into a cup, add 200ml hot water, stir until dissolute completely, and drink the preparation when warm), for a consecutive of 16 weeks.
89016597|NCT03552978|Active Comparator|VA Quitline|After completing an initial 2-hour screening visit that includes a series of questionnaires assessing eligibility criteria and meeting with the study physician to review medical history, participants will be offered nicotine replacement therapy (NRT) at baseline (Week 0), per VA prescribing guidelines, nicotine dependence levels, and participant preference. Participants will also receive weekly proactive telephone sessions through the VA Quitline, a standard of care, proactive telephone quitline available to all veterans for up to eight weeks. Participants will initiate the first call and subsequent calls will be made by the Quitline counselor.
89016598|NCT03543839|Active Comparator|Belimumab|Subjects in this arm will receive 200mg belimumab for self administration subcutaneously weekly for 2 years
89457201|NCT03167996|Experimental|Group B/ HealthPals|"Group B have access to HealthPals app where they will coordinate with a trained health coach Group B patients will only come into SSATHI clinic to see their doctor for an initial visit and 6 month follow up, and they will have a telephone visit with their doctor at 3 months instead of an in-clinic visit~Lab testing is the same for both Group A/ control and Group B patients"
89457202|NCT03167996|No Intervention|Group A/ Control|"Group B will not have access to HealthPals app~Group A patients will come into SSATHI clinic to see their doctor for an initial visit, a 3 month follow up, and a 6 month follow up~Lab testing is the same for both Group A/ control and Group B patients"
89457203|NCT03507075|Active Comparator|Contingent|The Contingent group will receive nearly immediate monetary payments over the internet each day they remotely provide negative breathalyzer samples, but will not receive the payments if they provide positive samples or fail to provide samples in a timely manner.
89457204|NCT03507075|Sham Comparator|Noncontingent|The Noncontingent group will receive payments each day they successfully provide samples independent of the alcohol content of those samples.
89457205|NCT03106298||Iron Sucrose Treatment|All patients with iron deficiency anemia (those without CKD or HF, those with CKD only, those with HF only, and those with CKD/HF) will be given 5 weekly doses of 200 mg of intravenous iron sucrose.
89457206|NCT02316561|Experimental|Single dose ablative radiotherapy|Eligible patients for single dose ablative radiotherapy according to inclusion and exclusion criteria
89457207|NCT02398292|Other|M3 Program|Non-randomized experimental group. The program is a six-week multi-modal intervention, including nutrition education and cooking classes, physical activity, and mindfulness. Outcomes will be compared to a non-randomized control group.
89457208|NCT02398292|Other|Control|Non-randomized control group. Outcomes will be compared at same time points (baseline, 6 weeks, 12 weeks).
89016599|NCT03543839|Experimental|Belimumab/Placebo|Subjects in this arm will receive 200mg belimumab for self administration subcutaneously weekly for 1 year and then placebo injections subcutaneously for 1 year.
89016600|NCT03543839|Placebo Comparator|Placebo|Subjects in this arm will receive placebo for self administration subcutaneously weekly for 2 years
89501821|NCT02750761|Experimental|Group 4: Tedizolid oral 3 mg/kg (2 to <6 years)|Participants 2 to <6 years of age received a single dose of tedizolid phosphate oral suspension dosed at 3 mg/kg of total body weight. Maximum dose is 200 mg of tedizolid phosphate.
89501822|NCT03165669|Experimental|Cervical pillow|"The cervical pillow is known as the Viscospring PostuRite - medium model, made by SOFF-ART S.r.l. - Via Maestri del Lavoro 49 - 05100 Terni, Italy. The Viscospring PostuRite pillow is externally made of viscoelastic polyurethane and internally 60 independent, individually coated harmonic phosphate-coated steel springs, are thought to promote correct posture of the cervical spine, due to the adaptation of the pillow to the shape and movements of the head.~Each intervention will be supported by a 30-minutes informative session delivered by a physical therapist, and will be completed by the delivery of an informative brochure."
89201466|NCT00984178|Experimental|GCSF plus bone marrow mononuclear cells|combined treatment (intracoronary transplantation plus cell mobilization with G-CSF).
89457209|NCT02307591|Active Comparator|Best Supportive Care|Dehydration Ringer's lactate solution or normal saline intravenously Electrolytes should be monitored at regular intervals and corrected as long as vomiting and/or diarrhoea persist Fever intravenous Paracetamol Antimicrobial treatment Prophylactic 5-days course with Ampicillin should be used Pain Paracetamol,Tramadol or Pentazocine Central nervous system disturbances If a patient is restless or confused, prescribe a light sedation utilizing Midazolam, Propofol or Ketamine, preferably in association with Diazepam or Midazolam Seizures Diazepam Vomiting antiemetic medications may provide some relief and facilitate the rehydration Dyspepsia in adults, Omeprazole Diarrhoea in adults, Loperamide Acute bleeding leading to signs of haemorrhagic shock should be treated with whole blood transfusion and supportive care. Patients haemodynamically stable should not be transfused if the Hb level is >7 mg% Septic shock intensive support care Malaria in case of positive initial test, Artesunate
89457210|NCT02307591|Experimental|Best Supportive Care + Amiodarone|"This treatment will be provided to patients in the experimental arm only in addition to best supportive care scheme .~During the first 3 days of treatment, the drug must be administered in Glucose 5% solution. Deliver through the largest possible vein inserting a long catheter (if possible a CVP line).~Day 1. Dose: 20 mg/kg/die i.v. deliver a loading dose of 5mg/kg in the 1st hour, followed by continuous infusion during the remaining 23 hours.~Example: 20 mg /kg of Amiodarone in 500 cc of Glucose 5%. Deliver 125 ml during the 1st hour followed by 16 ml/hour for the remaining 23 hours.~Day 2 - Day 3. Dose: 20 mg/kg/die i.v. Continuous infusion over 24 hrs. Example: Glucose 5% 500 ml containing 20 mg/kg of Amiodarone (infusion speed = 21 ml/hour).~Day 4 to Day 10. If no significant diarrhea and/or vomiting, shift to oral intake of Amiodarone as follows:~Adults: 200 mg tablets, 3 times a day, according to the body weight (30mg/Kg)~Children < 29 kg: 5 mg/kg 3 times a day"
89457211|NCT02316639|Experimental|Neuromuscular Training - No Exercise|Subjects will participate in 5 weeks of neuromuscular training followed by 5 weeks of no exercise intervention
88940715|NCT01852331|Placebo Comparator|Placebo|While continuing current antipsychotic medications, subjects will receive adjunctive treatment with placebo granules. They need to take the placebo granules two times a day, each time one sachet (aluminum foil pack of 9g, tear open and empty contents into a cup, add 200ml hot water, stir until dissolute completely, and drink the preparation when warm), for a consecutive of 16 weeks.
88940716|NCT01852357|Sham Comparator|Sham control|This group will receive 12 sham neurofeedback sessions in which the feedback is based on pre-recorded data.
88940717|NCT01852357|Experimental|Neurofeedback|The intervention will be 24 sessions of beta/SMR neurofeedback.
88940718|NCT01852396|Experimental|Regional anesthesia|Recruit 50 patient having elbow, forearm, wrist or hand surgery and block brachial plexus using the novel retroclavicular approach
88940719|NCT01852409|Experimental|bevacizumab|The study evaluate 4 dose level of bevacizumab:2.5mg /kg;5 mg /kg;7.5mg /kg; 1.25mg /kg;
88940720|NCT01852435|Active Comparator|R-CHOP-50|R-CHOP-50 (Rituximab 375 mg/m2 d1+Cyclophosphomide 750mg/m2 d2+Adriamycin 50mg/m2 d2+vincristine 1.4mg/m2 d2+Prednisone 60 mg/m2 d2-6) every 21 days for 6 cycles, followed by Rituximab 375 mg/m2 every 21 days for 2 cycles.
88940721|NCT01852435|Experimental|R-CEOP-70|R-CEOP-70 (Rituximab 375 mg/m2 d1+Cyclophosphomide 750mg/m2 d2+Adriamycin 70mg/m2 d2+vincristine 1.4mg/m2 d2+Prednisone 60 mg/m2 d2-6) every 21 days for 6 cycles, followed by Rituximab 375 mg/m2 every 21 days for 2 cycles.
88940722|NCT01852435|Experimental|R-CEOP-90|R-CEOP-90 (Rituximab 375 mg/m2 d1+Cyclophosphomide 750mg/m2 d2+Adriamycin 90mg/m2 d2+vincristine 1.4mg/m2 d2+Prednisone 60 mg/m2 d2-6) every 21 days for 6 cycles, followed by Rituximab 375 mg/m2 every 21 days for 2 cycles.
88940723|NCT01852461|Active Comparator|Beractant|Beractant;bovine lung extract; both initial and subsequent dosing is 100 mg/kg (4 mL/kg), which may be given every 6 hours up to four total doses
88940724|NCT01852461|Active Comparator|Poractant alfa|Poractant alfa; porcine lung extract; initial dosing is 200 mg/kg (2.5 mL/kg) and repeated dosing is given at 100 mg/kg (1.25 mL/kg) every 12 hours, up to maximum of two additional doses when indicated
88940725|NCT01852474|Experimental|Active tDCS|Subjects will receive active tDCS stimulation for 5 sessions (20m/each) over one week.
88940726|NCT01852487|Active Comparator|Pumpkin Seed Oil|400mg/ day during 6 months
88940727|NCT01852487|Placebo Comparator|sweet potato starch|400mg/day during 6months
88940728|NCT01852500|Experimental|Sham OMT|patients under standard medical care plus sham OMT
88940729|NCT01852500|Other|Control|patients under standard medical care plus only osteopathic evaluation
88940730|NCT01852526|Experimental|hybrid system|hybrid system (PLIF + flexible pedicle screw system above the fusion) (Dynamic Rod®: AESCULAP AG, Tuttlingen: Germany
88940731|NCT01852526|Active Comparator|Plif posterior lumbar intervertebral fusion|Conventional monosegmental posterior lumbar intervertebral fusion (PLIF) (Fixateur: S4®: AESCULAP AG, Cage: Wave® Cage, Fa. AMT®)
88940732|NCT01852539|Experimental|dexmedetomidine|After intravenous infusion of dexmedetomidine for 2 min, propofol 2.0 mg/kg was administrated. And laryngeal mask airway device was inserted(LMA # 3,4).
88940733|NCT01852552||Transcatheter aortic valve implantation|All consecutive patients undergoing TAVI at participating centres during study period
88940734|NCT01852552||Aortic Valve Replacement|All consecutive patients aged ≥ 80 years or with Logistic Euroscore≥ 15% undergoing AVR for AS at participating centers during the period of enrollment
88940735|NCT01852565|Experimental|Darapladib+Diltizem Arm|Each subject will receive darapladib EC tablet 160 mg once daily for 10 days followed by darapladib EC tablet 160 mg once daily + diltiazem 240mg once daily for 14 days and then diltiazem 240mg once daily alone for three days
88940736|NCT01852578|Experimental|1|
88940737|NCT01852604|Experimental|Part A: GT 1b, 4 - samatasvir 50/simeprevir/RBV|Part A: Participants with genotype 1b or 4 received samatasvir 50 mg and samatasvir matching placebo once daily, plus simeprevir 150 mg capsule once daily, plus RBV (dosing weight-based, according to product label) twice daily for 12 weeks
88940738|NCT01852604|Experimental|Part A: GT 1b, 4 - samatasvir 100/simeprevir/RBV|Part A: Participants with genotype 1b or 4 received samatasvir 100 mg and samatasvir matching placebo once daily, plus simeprevir 150 mg capsule once daily, plus RBV (dosing weight-based, according to product label) twice daily for 12 weeks
89457212|NCT02316639|Experimental|No Exercise - Neuromuscular Training|No exercises will be administered for 5 weeks, followed by 5 weeks of neuromuscular Training.
89457213|NCT02397980|No Intervention|Control|Basic information about dementia
89457214|NCT02397980|Active Comparator|Behavioral intervention|"Individual, 90 min a day, with an interval of 2 weeks~Education about dementia~psychological counselling~cognitive behavioral therapy"
89457215|NCT03506997|Experimental|Pembrolizumab|Pembrolizumab will be given at a dose of 200mg IV every 3 weeks for a maximum of two years
89457216|NCT02398136|Experimental|Ketamine|Intranasal ketamine up to 75 mg, delivered over 20 minutes, frequency: 3x/week for 4 weeks.
89457217|NCT02398136|Active Comparator|Midazolam|Intranasal midazolam 3.75mg, delivered over 20 minutes, frequency: 3x/week for 4 weeks.
89457218|NCT03503253|Other|Single-arm|LAA leak closure using detachable coils; Interlock-35 Fibered IDC Occlusion System, Concerto Helix Detachable Coil System
89457219|NCT05745584|Experimental|Experimental|8 weeks of mirabegron treatment==> 8 weeks of anticholinergics treatment
89457220|NCT02312661|Experimental|Carboplatin / paclitaxel /metformin|Three-weekly cycles of carboplatin/paclitaxel chemotherapy in combination with metformin treatment
89457221|NCT05745506||CRD|patients whose PSQI score>5
89457222|NCT05745506||non-CRD|patients whose PSQI score ≦ 5
89457223|NCT03501771|Experimental|Acupuncture|Acupuncture needle will be administered.
89457224|NCT02397902|Experimental|Dairy|Add 4 daily servings of high fat dairy to diet for a period of 4 weeks
89457225|NCT02397902|Active Comparator|Plant-based|Add 4 daily servings of fruit to diet and/or plant-based milk, remove all dairy from diet for a period of 4 weeks
89457226|NCT02307669|Placebo Comparator|Routine inhaler adherence care|"Normal Care group This management is based on the inhaler training recommendations of the BTS/SIGN group (http://www.brit-thoracic.org.uk/Portals/0/Guidelines/AsthmaGuidelines/sign101%20Jan%202012.pdf) and medication management of the GINA management strategy.~The core features of the usual care group are:~The patient's inhaler technique will be checked using a checklist, at each visit. If there are errors these will be corrected using teach-to-goal principals.~Adherence will be discussed and barriers to adherence addressed, using motivational interview techniques.~Written action plans for managing asthma, based on changes in PEF and symptoms will be given.~In follow up, medication changes in response to the above will be directed by these, as suggested by GINA management guidelines using a standardised digital script."
89457227|NCT02307669|Active Comparator|INCA feedback|"The patient's treatment goal is established and used as the focus of the conversation.~Data from the INCA device including (1) time of use, (2) handling proficiency and (3) inhalation flow rates are discussed, with three graphs as shown in the appendix and derived as discussed. These are aimed to enhance the value of the inhaler.~Data from the electronic PEF and AQLQ are correlated with digitally recorded adherence so that these can be used to account for improvements or declines in these measures.~In follow up, medication changes in response to the above (adherence, PEF, ACT and exacerbations) are made using a standardised digital script."
89457228|NCT02398058|Experimental|Trabectedin plus olaparib|"All patients will be treated with trabectedin and olaparib in an open-label fashion.~The dosage of the drugs at which each patient is treated depends on the dose level reached at the time of enrollment."
89457229|NCT03503175|Experimental|Novel urinary access system|Participants randomized to this arm will receive the novel urinary access system (CystoSureTM).
89457230|NCT03503175|Active Comparator|Standard Foley catheter|Participants randomized to this arm will receive a standard Foley catheter and rigid cystoscopy.
88940739|NCT01852604|Experimental|Part A: GT 1b, 4 - samatasvir 150/simeprevir/RBV|Part A: Participants with genotype 1b or 4 received samatasvir 150 mg once daily, plus simeprevir 150 mg capsule once daily, plus RBV (dosing weight-based, according to product label) twice daily for 12 weeks
88940740|NCT01852604|Experimental|Part B: GT 1b, 4 - samatasvir 25/simeprevir/RBV|Part B: Participants with genotype 1b or 4 received samatasvir 25 mg once daily, plus simeprevir 150 mg capsule once daily, plus RBV (dosing weight-based, according to product label) twice daily for 12 weeks
88940741|NCT01852604|Experimental|Part B: GT 1b, 4 - samatasvir 100/simeprevir/RBV|Part B: Participants with genotype 1b or 4 received samatasvir 100 mg once daily, plus simeprevir 150 mg capsule once daily, plus RBV (dosing weight-based, according to product label) twice daily for 12 weeks
88940742|NCT01852604|Experimental|Part B: GT 6 - samatasvir 100/simeprevir/RBV|Part B: Participants with Genotype 6 received samatasvir 100 mg once daily, plus simeprevir 150 mg capsule once daily, plus RBV (dosing weight-based, according to product label) twice daily for 12 weeks
88940743|NCT01852604|Experimental|Part C: GT 1a, 1b - samatasvir 50/simeprevir/TCM647055/RTV|Part C: Participants with Genotype 1a or 1b received samatasvir 50 mg once daily, plus simeprevir 75 mg capsule once daily, plus TMC647055 450 mg once daily plus RTV 30 mg once daily for 12 weeks
89457231|NCT02312817|No Intervention|Group 1|Individuals randomized to Group 1 will receive usual medical care and will not be directly contacted at any point of the trial. Study data and outcomes will be abstracted from the EMR.
89023569|NCT05139810|Experimental|Donidalorsen: Cohort B|Participants will be administered donidalorsen by subcutaneous (SC) injection for up to 25 weeks.
89457232|NCT02312817|Experimental|Group 2|Individuals randomized to Group 2 will receive mailed outreach invitation.
89457233|NCT02312817|Experimental|Group 3|Individuals randomized to Group 3 will receive mailed outreach invitation and patient navigation.
89457234|NCT02693834|Experimental|PLS AFO first then DA AFO|Participants will be assigned to practice with Posterior Leaf spring AFO for a week, then they will be assigned to practice with Double adjustable AFO for another week.
89457235|NCT02693834|Experimental|DA AFO first then PLS AFO|Participants will be assigned to practice with Double adjustable AFO for a week, then they will be assigned to practice with Posterior Leaf spring AFO for another week
89457236|NCT02312895|Experimental|Dry Needling|A total of 30 subjects will be randomized to this experimental arm. If randomized to this arm, subjects will receive dry needling, patient education, and a home exercise program.
89457237|NCT02312895|Experimental|Manual Therapy|A total of 30 subjects will be randomized to this experimental arm. If randomized to this arm, subjects will receive manual therapy, patient education, and a home exercise program.
89201467|NCT04034277|Experimental|Lee Silverman Voice Therapy|LSVT LOUD® is a therapy program which requires four sessions per week for 4 weeks by a speech and language therapists with a certification in Lee Silverman Voice Therapy. Each session lasted 50-60 min.
89457238|NCT02312973|Experimental|Arm 1|Single oral dose of 75 mg molidustat (fasted) in subjects on hemodialysis (at start of hemodialysis and on a hemodialysis free day,respectively)
89457239|NCT02312973|Experimental|Arm 2|Single oral dose of 75 mg molidustat (fasted) in subjects on peritoneal dialysis (after start of peritoneal dialysis intervall and, optionally, after the start of a peritoneal dialysis-free intervall,respectively)
89457240|NCT02312973|Experimental|Arm 3|Single oral dose of 75 mg molidustat (fasted) in healthy subjects
89457241|NCT03506919|Experimental|Arthitec 1|
89457242|NCT03506919|Experimental|Arthitec 2|
89457243|NCT02545504|Experimental|Andecaliximab|Andecaliximab plus mFOLFOX6 (LV+5-FU+OXA) during Cycles 1-6, followed by andecaliximab plus LV+5-FU during subsequent cycles
89457244|NCT02545504|Placebo Comparator|Placebo|Placebo plus mFOLFOX6 (LV+5-FU+OXA) during Cycles 1-6, followed by placebo plus LV+5-FU during subsequent cycles
89457245|NCT03506841|Active Comparator|Cerbrolysin|Preterm infants with gestational age less than 32 weeks at birth will receive once weekly Cerebrolysin injections of 0.1 mL/kg body weight for 3 months (total of twelve injections) starting at the corrected postnatal age of 5 months.
89457246|NCT03506841|No Intervention|Control|Preterm infants with gestational age less than 32 weeks at birth will receive routine care.
89457247|NCT02316795|Experimental|SLN biopsy with ICG injection|"During the SLN biopsy, the patient will undergo injection of ICG around the breast tumor or melanoma per standard techniques. 1.6 mL of 500 micro-molar ICG will be injected periareolarly (for breast cancer) or peri-tumorly (for melanoma). This will be performed after standard of care technetium-colloid injection. Patients will then undergo the standard SLN biopsy procedure.~After gamma-probe identification of the SLN, the surgeon will put on the goggle system to attempt to identify the SLN using fluorescence guidance. After this is performed, the goggle system will be removed and the SLN biopsy will be completed per standard techniques. Findings with the goggles will be recorded but will not change how the SLN biopsy is performed."
89457248|NCT02397512|Experimental|Lactulose group|Subjects will ingest 50g of lactulose once
89457249|NCT02397512|Placebo Comparator|Control group|Subjects will ingest 50g of sucrose once
89457250|NCT02313051|Experimental|Everolimus arm|Everolimus+letrozole
89457251|NCT02313051|Active Comparator|Controll arm|letrozole alone, and when progress, followed by everolimus
89457252|NCT03501537|Experimental|Surgical treatment with free gingival graft|Free gingival graft harvested from the palate will be placed around the diseased implant
88940744|NCT01852604|Experimental|Part C: GT 1a, 1b - samatasvir 50/simeprivir/TCM647055/RTV/RBV|Part C: Participants with Genotype 1a or 1b received samatasvir 50 mg once daily, plus simeprevir 75 mg capsule once daily, plus TMC647055 450 mg once daily, plus RTV 30 mg once daily, plus RBV (dosing weight-based, according to product label) twice daily for 12 weeks
88940745|NCT01852617|Experimental|Implementation of intervention|"Midwife facilitators in the intervention clinics will be identified and trained to deliver the 5 A's to pregnant women and will then disseminate and implement the program. The 5 A's (Ask, Advise, Assess, Assist, Arrange) is a strategy consisting of a brief cessation counseling session of 5-15 minutes delivered by a trained provider, which is considered the standard of care worldwide"
88940746|NCT01852617|No Intervention|No implementation of the intervention|Standard in-service activities
89457253|NCT02397590|Other|A Group|Fimasartan (7 days) → wash out (7days) → Atorvastatin (7 days) → wash out (7days) → Fimasartan+Atorvastatin (7 days)
89457254|NCT02397590|Other|B Group|Fimasartan (7 days) → wash out (7days) → Fimasartan+Atorvastatin (7 days) → wash out (7days) → Atorvastatin (7 days)
88940747|NCT01852630|Experimental|cefepime + Albumin|cefepime 1g iv 8 hourly + Albumin will be given for 2 days.
88940748|NCT01852630|Active Comparator|Imipenem + Albumin|Imipenem 1g iv 8 hourly + Albumin will be given for 2 days.
88940749|NCT01852643|Active Comparator|Spreader graft|
89457255|NCT02397590|Other|C Group|Atorvastatin (7 days) → wash out (7days) → Fimasartan+Atorvastatin (7 days) → wash out (7days) → Fimasartan (7 days)
89457256|NCT02397590|Other|D Group|Atorvastatin (7 days) → wash out (7days) → Atorvastatin (7 days) → wash out (7days) → Fimasartan+Atorvastatin (7 days)
89457257|NCT02397590|Other|E Group|Fimasartan+Atorvastatin (7 days) → wash out (7days) → Fimasartan (7 days) → wash out (7days) → Atorvastatin (7 days)
89457258|NCT02397590|Other|F Group|Fimasartan+Atorvastatin (7 days) → wash out (7days) → Atorvastatin (7 days) → wash out (7days) → Fimasartan (7 days)
89457259|NCT02313129||Rheumatoid Arthritis|This group will complete questionnaires related to prior pregnancies, intentions and goals for childbearing, fertility history and detailed menstrual history. They will also have a physical exam and blood tests.
89457260|NCT02313129||Healthy Controls|This group will complete questionnaires related to prior pregnancies, intentions and goals for childbearing, fertility history detailed menstrual history, and blood tests.
89457261|NCT02545270|Experimental|Group 1: 12-9-6 mmHg|Elective laparoscopic inguinal hernia procedures will be used to make three video-recordings (lasting 20-30 seconds) under different levels of pneumoperitoneum (12-9-6 mmHg) during desufflation after surgery is completed.
89457262|NCT02545270|Experimental|Group 2: 11-8-5 mmHg|Elective laparoscopic inguinal hernia procedures will be used to make three video-recordings (lasting 20-30 seconds) under different levels of pneumoperitoneum (11-8-5 mmHg) during desufflation after surgery is completed.
88940750|NCT01852643|Active Comparator|Lateral crural overlay|
88940751|NCT01852656|Active Comparator|Postcard Only Reminder Group|In the postcard reminder intervention, the member will receive a single postcard, addressed to the member with asthma or COPD.
88940752|NCT01852656|Active Comparator|IVR Only Reminder Group|In the IVR reminder intervention, targeted members will be contacted by the interactive voice response system
89457263|NCT02545270|Experimental|Group 3: 10-7-4 mmHg|Elective laparoscopic inguinal hernia procedures will be used to make three video-recordings (lasting 20-30 seconds) under different levels of pneumoperitoneum (10-7-4 mmHg) during desufflation after surgery is completed.
89457264|NCT02397356|Experimental|Ketamine first AB|Patients in this group will first receive a dose of ketamine in the nebulised form when they ask for pain relief. The second time they ask for pain relief, they will receive physiological salt in the nebulised form.
89457265|NCT02397356|Active Comparator|Placebo first BA|Patients in this group will first receive physiological salt in the nebulised form form when they ask for pain relief. The second time they ask for pain relief, they will receive a dose of ketamine in the nebulised.
89457266|NCT02316873|Experimental|Music training|twice a week one hour for 30 weeks, music training
89457267|NCT02316873|Active Comparator|Visual arts|twice a week one hour for 30 weeks, visual arts training
89457268|NCT05453344|Other|Intervention - DexCom one|Provision of DexCom one for glucose monitoring
89457269|NCT02317029|Experimental|"1 (Standard: Oxygen / LIFEPAK 20)"|"Intervention: Cardioversion with a biphasic truncated exponential waveform~Intervention: Hyperoxia during cardioversion"
88940753|NCT01852656|Active Comparator|Postcard and IVR Reminder Group|In this group, individuals will receive both a postcard reminder and an IVR reminder.
88940754|NCT01852682|Experimental|PA21|
88940755|NCT01852695|Experimental|Family Integrated Care Arm|Parents are integrated into the care of their infants in the NICU. Parents consent to spending up to eight hours a day with their infant, attend special education sessions, participate in daily medical rounds, and do basic infant charting. This will enable parents to provide care for infants with nursing supervision in the areas of feeding, bathing, dressing and holding skin to skin.
88940756|NCT01852695|No Intervention|Control Arm|Regular care by nurse will be provided to patients admitted to control sites.
88940757|NCT01852708||Pregnant Women|Women and their partners (presumed biological father of the fetus) who are currently pregnant and carrying a fetus that has been diagnosed with a microdeletion/duplication syndrome, aneuploidy or another genetic disorder (positive karyotype result or positive result on microarray test).
88940758|NCT01852721|Experimental|Men and Mediterranean diet|The 12-week nutritional education program will include 3 group sessions with 8-12 participants per group, 3 individual counseling sessions, and 4 telephone interviews. The registered dietitian will encourage participants to make their own decision about dietary changes while promoting their autonomy and competence, and will accept participants' choices, avoiding pressuring them to perform a specific change.
88940759|NCT01852721|Experimental|Women and Mediterranean diet|The 12-week nutritional education program will include 3 group sessions with 8-12 participants per group, 3 individual counseling sessions, and 4 telephone interviews. The registered dietitian will encourage participants to make their own decision about dietary changes while promoting their autonomy and competence, and will accept participants' choices, avoiding pressuring them to perform a specific change.
88940760|NCT01852734|Other|embolizations, uterine fibroid|embolization interventions with microspheres
88940761|NCT01852747|Experimental|Multilevel Spinal Fusion w/ Actifuse ABX®|An osteostimulatory,phase pure,porous,silicate substituted calcium phosphate bone graft substitute used during multilevel spinal fusion.
88940762|NCT01852747|No Intervention|Multilevel Spinal Fusion|Multilevel spinal fusion without Actifuse ABX.
88940763|NCT01852760||UC in Remission|Patients with UC in remission
88940764|NCT01852760||UC Mild Disease|Patients with mild UC disease activity based on partial Mayo Score
88940765|NCT01852760||UC Moderate to severe|Patients with ulcerative colitis with moderate to severe disease activity based on partial Mayo score
88940766|NCT01852773||Blunt Aortic Injury Patients|Trauma patients with blunt aortic injury. This Cohort of trauma patients will require management with one of two interventions. They will require either; Open repair of thoracic aorta injury (Intervention #1) or TEVAR (Intervention #2). As of yet the short term and long term outcomes of these two treatments have not been directly compared.
88940767|NCT01852786||Contraceptives, Oral, Combined|The women, presenting for hormonal contraception use and with no contraindications for hormonal therapy.
88940768|NCT01852786||Controls|The women, presenting for non- hormonal contraception- barrier contraception methods -BCM- or natural family planning methods- NFPM.
88940769|NCT01852838||Lung cancer patients, pre treatment|Patients who have diagnosed with lung cancer before treatment
88940770|NCT01852838||High risk patients for lung cancer|high risk patients who are age and co-morbidity matched controls without proof of lung cancer.
88940771|NCT01852864|Experimental|Degarelix treated group|240mg degarelix s.c. injection to be administered 7 days prior to radical prostatectomy for high/intermediate risk prostate cancer.
88940772|NCT01852877||Jail: HIV testing, corrections case mgt|For all jail detainees regardless of HIV status, we observed the uptake of opt-out and opt-in HIV testing. For HIV-positive jail detainees leaving jail, we observed 1) health outcomes for corrections case management versus other than corrections case management, 2) the impact of an incentive to visit an HIV service organization after release from jail
88940773|NCT01852877||Prison: telemed, corrections case mgt|We compared outcomes for for HIV-positive prisoners before and after the implementation of telemedicine to deliver HIV medical care. For HIV-positive prisoners released from prison and returning to Chicago, we observed health outcomes for those enrolled in corrections case management those not enrolled in corrections case management.
88940774|NCT01852903|Experimental|calcium ascorbate|
88940775|NCT01852903|Active Comparator|ascorbic acid|
88940776|NCT01852903|Placebo Comparator|placebo|
88940777|NCT01852916|Active Comparator|Nasal CPAP|Nasal CPAP using Infant flow
89457270|NCT02317029|Active Comparator|2 (room air / LIFEPAK 20)|"Intervention: Cardioversion with a biphasic truncated exponential waveform~Intervention: Normoxia during cardioversion"
89457271|NCT02317029|Active Comparator|3 (Oxygen / Schiller Defigard 5000)|"Intervention: Cardioversion with a pulsed biphasic waveform~Intervention: Hyperoxia during cardioversion"
89457272|NCT02317029|Active Comparator|4 (Room air / Schiller Defigard 5000)|"Intervention: Cardioversion with a pulsed biphasic waveform~Intervention: Normoxia during cardioversion"
89457273|NCT05453110|Experimental|Cautionary|The group will receive a message regarding potential risk for spine injury before the tested task.
89457274|NCT05453110|Experimental|Reassuring|This group will receive a message regarding spine resiliency before the tested task.
89457275|NCT05453110|No Intervention|Control|This group will not receive education before the tested task.
89457276|NCT02307825|Active Comparator|Azithromycin|Patients will receive the active study drug, azithromycin, as well as sinus irrigations with budesonide.
88940778|NCT01852916|Experimental|NHFOV|Nasal High Frequency Oscillatory Ventilation using Dräger Babylog® VN500 ventilator machine
88940779|NCT01852929|Other|Apnea patients on and off PAP in order A|Subject using usual positive airway pressure therapy while sleeping for one night, then crossing over to not using usual apnea therapy while sleeping for another night.
88940780|NCT01852929|Other|Apnea patients on and off PAP in order B|Subject not using apnea therapy while sleeping for one night, then crossing over and subject using usual positive airway pressure therapy while sleeping for one night.
88940781|NCT01852981|Experimental|Lifestyle counseling|Physical activity promotion using methods based on health education.
89457277|NCT02307825|Placebo Comparator|Placebo|Patients will receive a placebo as well as sinus irrigations with budesonide.
88940782|NCT01852981|Experimental|Supervised exercise|Supervised sessions of aerobic, strength, and stretching exercises, drawn up in accordance to the American College of Sports Medicine recommendations.
88940783|NCT01852981|No Intervention|Control|Control group.
88940784|NCT01852994|Other|Exercise training|Aerobic and strength exercise training
88940785|NCT01852994|Other|Testosterone replacement|Testosterone replacement will be done quarterly
88940786|NCT01852994|Other|Testosterone replacement+Exercise|Both Testosterone replacement and Exercise will done
88940787|NCT01853007|No Intervention|Usual care|Patients in this arm will receive only the education offered by the transplant center, as required by Medicaid. Upon completion of all data collection activities, patients in this arm will be offered the program.
88940788|NCT01853007|Experimental|COACH Program|Participants randomized to the intervention condition will attend a COACH session held in a small group format. The session provides information on living and deceased donor transplantation (i.e., the processes, risks and benefits) and on the key communication skills needed to effectively initiate and maintain conversations about transplantation.
88940789|NCT01853033|Experimental|Group 1|Randomized 6 drug/2 placebo by group
88940790|NCT01853033|Experimental|Group 2|Randomized 6 drug/2 placebo by group
88940791|NCT01853033|Experimental|Group 3|Randomized 6 drug/2 placebo by group
88940792|NCT01853059||IMRT|Prospective longitudinal assessment of patients receiving intensity-modulated radiation therapy for anal cancer
88940793|NCT01853059||Conventional|Cross-sectional analysis of patients receiving conventional radiotherapy
88940794|NCT01853098|Experimental|Positive Affect Training (PAT)|The intervention will be conducted in groups with 6-8 participants and 2 facilitators/therapists per group. The groups will meet once a week for 12 successive weeks and each session will be approximately 60 minutes long.
88940795|NCT01853111|Experimental|Interleukin 2|Subjects who receive a tolerogenic drug protocol
88940796|NCT01853124|Experimental|Lacidofil|Lacidofil sachet containing active ingredients
88940797|NCT01853124|Placebo Comparator|Placebo|Placebo sachet containing inactive ingredients
88940798|NCT01853150|Experimental|rTMS Motor cortex|rTMS will be applied over the motor cortex
88940799|NCT01853150|Active Comparator|rTMS Supplementary motor area|rTMS will be applied over the supplementary motor area
88940800|NCT01853189|Other|OMT + Usual Care|
88940801|NCT01853189|Other|Usual Care|
88940802|NCT01853202|Experimental|Group 1 - Supervised aerobic exercise training|This group will participate in 3 supervised exercise sessions/week at an intensity of 50%-70% of the individually determined VO2max between 30-45 min/session for 12 weeks. The aerobic training intervention will closely mimic the standard exercise-based guidelines adopted in cardiac rehabilitation. All intervention sessions will be performed in a supervised setting with one-on-one supervision by an American College of Sports Medicine-certified exercise physiologist. Aerobic exercise training will be prescribed based on the guiding ACSM principles with the aim of improving VO2max. Walking was chosen because it is the preferred mode of exercise training in cancer patients.
88940803|NCT01853202|No Intervention|Group 2|The 12-week program will consist of monthly phone contacts to check in with patient and review their exercise log entries for that month in order to capture physical activity done outside of the intervention setting.
88940804|NCT01853241||Single balloon|Single Balloon Enteroscopy
88940805|NCT01853241||Spirus|Spirus Enteroscopy
88940806|NCT01853267|Active Comparator|Control group (Packing)|The perianal abscess cavity will continue to be packed after discharge until healing is complete
88940807|NCT01853267|Experimental|Intervention Group (Non-Packing)|The cavity will be allowed to heal by secondary intention without packing.
88940808|NCT01853293|Active Comparator|Kudzu extract|Participants will take two 500-mg capsules of Kudzu extract, t.i.d. (morning, 6:00 to 8:30 a.m.; afternoon, 2:00 to 4:30 p.m.; evening, 9:00 to 11:30 p.m.).
88940809|NCT01853293|Placebo Comparator|Placebo|Placebo capsule contains sugar beet filler. Participants will take two 500-mg capsules, t.i.d. (morning, 6:00 to 8:30 a.m.; afternoon, 2:00 to 4:30 p.m.; evening, 9:00 to 11:30 p.m.).
88940810|NCT01853306|Experimental|Veliparib formulation A|veliparib formulation A
88940811|NCT01853306|Experimental|Veliparib formulation B|Veliparib formulation B
88940812|NCT01853306|Experimental|Veliparib formulation C|veliparib formulation C
88940813|NCT01853319|Experimental|Regorafenib|Regorafenib, 40 mg tablets
88940814|NCT01853345||Refractory/Recurrent/High Risk Solid Tumors|
89457278|NCT02540668|Experimental|Warfarin|Single oral dose of 15 mg warfarin on Day 1.
89457279|NCT02540668|Experimental|Lanabecestat + Warfarin|Lanabecestat administered orally once daily on Days 8 to 27, with a single oral dose of 15 mg warfarin co-administered on Day 22.
89457280|NCT03506763|Placebo Comparator|Placebo Oral + Placebo Oral|Placebo Oral + Placebo Oral
89457281|NCT03506763|Active Comparator|Diclofenac oral + Placebo Oral|Diclofenac oral + Placebo Oral
89457282|NCT03506763|Active Comparator|Diclofenac oral + scopolamina oral|Diclofenac oral + scopolamina oral
89457283|NCT02441439|Other|Iron sucrose 200 mg|first arm will be treated with iron sucrose 200 mg 2-3 times a week
89457284|NCT02441439|Active Comparator|Iron sucrose 500 mg|Second arm will be treated with iron sucrose 500 mg once a week
89457285|NCT02669992|Experimental|Stapled anastomosis|Stapled anastomosis by the use of commercially available linear stapler device
89457286|NCT02669992|Active Comparator|Hand-sewn anastomosis|Hand-sewn by the use of a resorbable monofilament suture
89457287|NCT02669992|Experimental|Abdominal wall mesh closure|Closure by the use of a mesh low-weight net device
89457288|NCT02669992|Active Comparator|Abdominal wall suture closure|Closure by the use of slowly absorbing monofilament suture
89457289|NCT02317107||Concussion|Individuals who report to the Division of Sports Medicine at Boston Children's Hospital will be identified for inclusion in the study if they receive a diagnosis of concussion, defined as a complex pathophysiological process affecting the brain, induced by biomechanical forces. If they agree to participate, they will be placed in the concussion group and assessed at each visit to the clinic. No intervention will be administered.
89457290|NCT02317107||Control|Individuals who report to the Division of Sports Medicine at Boston Children's Hospital will be identified for inclusion in the study if they come to the clinic for an injury unrelated to brain function or a lower extremity function (which may affect normal gait patterns). If they agree to participate, they will be placed in the control group and assessed at each visit to the clinic. No intervention will be administered.
89457291|NCT05475652|Sham Comparator|Sham (ligth touch)|Placebo intervention composed of light touch treatment on the cervical spine.
88940815|NCT01853358|Experimental|NK Cell infusion|"Cell collection~o Lymphocytes will be harvest from the original and consenting donor as soon as possible around day 60 post transplantation~NK Cell selection~o Cells will be obtained after double selection: CD3+ depletion followed by CD56+ selection using an european approved device (Miltenyi corporation)~NK Cell ex-vivo activation~o ex-vivo activation: interleukin-2 according to a classical procedure (7 days at 37°C with RPMI clinical grade medium supplemented with 10% of foetal calf serum, 0.5 x 106 cellules / ml, 1000 U/ml d'IL-2 (interleukin, proleukin)~NK Cell infusion (60 to 90 days after transplantation)"
89457292|NCT05475652|Experimental|Manual therapy|Manual therapy applied to the cervical spine.
89457293|NCT04463199|Experimental|Experimental|Experimental group received craniocervical flexion training for 4 weeks and postural advice
89457294|NCT04463199|No Intervention|Control Group|Control group received only postural advice
89457295|NCT03503019||Diabetic|
89457296|NCT03503019||Non-diabetic|
89457297|NCT02307903||End-stage renal failure (ESRF)|end-stage renal failure (ESRF)
89457298|NCT02307981||Visual field defect with vision teacher|Patients With occipital ischemic stroke and Visual Field defect that live in a geographical region where training With vision teacher is an available service (vision Teachers are a Limited Resource in Norway)
89457299|NCT02307981||Visual field defect without vision teacher|Patients With occipital ischemic stroke and a Visual Field defect, who live in a geographical area where training With vision teacher is not an available service.
89457300|NCT02308059||Patients with diabetes mellitus|Group I; the patients with diabetes mellitus who had peripheral neuropathy as diagnosed.
89457301|NCT02308059||Control|Group II; healthy volunteers
89457302|NCT02308137|Experimental|Domperidone|Treatment: Oral domperidone four times daily Target dose: 40mg per day Duration: 1 year
88940816|NCT01853410|Experimental|gekoTM device application|Single arm study. Application of gekoTM device as described above with assessment of effect on coronary flow and endothelial function.
88940817|NCT01853423|Experimental|Rapamune|Small amount of 0.1% rapamune ointment applied topically to affected facial areas twice daily for the first two weeks, then once daily.
88940818|NCT01853436|Experimental|Single stage reconstructions|as defined for use in the Experimental arm
88940819|NCT01853436|Other|Two stage breast reconstructions|CONTROL: standard two stage breast reconstructions without Acellular dermal matrices (ADM), in patients who are clinically suitable candidates for reconstruction with Acellular dermal matrices(ADM)based single stage reconstruction technique. Reconstructions with Strattice™ Reconstructive Tissue Matrix
88940820|NCT01853449|Experimental|CWS+Fentanyl Citrate (250 mcg)|Chest wall strapping to reduce vital capacity by 20% of its baseline value + single-dose inhalation of nebulized fentanyl citrate (250 mcg)
88940821|NCT01853449|Placebo Comparator|CWS+0.9% saline placebo|Chest wall strapping to reduce vital capacity by 20% of its baseline value + single-dose inhalation of 0.9% saline placebo
88940822|NCT01853449|Active Comparator|No CWS+Fentanyl Citrate (250 mcg)|No chest wall strapping (unloaded control) + single-dose inhalation of nebulized fentanyl citrate (250 mcg)
88940823|NCT01853449|Placebo Comparator|No CWS+0.9% saline placebo|No chest wall strapping (unloaded control) + single-dose inhalation of 0.9% saline placebo
89457303|NCT02313363|Experimental|PSDCS|using the patient-centered smartphone-based diabetes care system (PSDCS) for 12 weeks
89457304|NCT03502863|Experimental|Digital refraction|Web-based application for obtaining the refractive error and visual acuity of each eye, using a computer and a smart phone
89457305|NCT03502863|Active Comparator|Manual Refraction|Manual manifest refraction is performed by an eyesore specialist using a phoropter.
89457306|NCT03501459|Experimental|Rituximab|
89457307|NCT02308293|Experimental|High intensity exercise|Subjects will preform a high intensity training exercise (3* 30 seconds all out sprint on a cycle ergometer) to raise plasma lactate levels
89457308|NCT02308293|Sham Comparator|Lay down comfortably|As a control conditions, subjects wil lay down comfortably and rest
89457309|NCT02317263|Active Comparator|Testosterone gel|Apply gel once a day for 96 weeks
89457310|NCT02317263|Placebo Comparator|Placebo gel|Apply gel once a day for 96 weeks
89457311|NCT03506685|No Intervention|control group Standard ACL protocol|This group will receive the standard ACL protocol rehab
89457312|NCT03506685|Experimental|Dry needling and STM group|This group will also receive the standard ACL protocol in addition to STM and DN
89457313|NCT03502629|Experimental|GB226 3mg/kg every 2 weeks|Geptanolimab Injection, 3mg/kg every 2 weeks
89457314|NCT02317341|Experimental|1|Single intravenous dose given over 40 minutes
89457315|NCT02317341|Active Comparator|2|Single intravenous dose goven over 40 minutes
89457316|NCT02317419|Experimental|Part A MAD Phase RO6927005 Monotherapy|RO6927005 given as a single agent in participants with tumors known to be mesothelin expressing and with mesothelin-positive tumors. MAD = multiple ascending dose.
89457317|NCT02317419|Experimental|Part A Extension Phase Group 1|RO6927005 given as a single agent in participants with mesothelin-positive refractory/recurrent solid tumors, other than malignant pleural mesothelioma (MPM) and pancreatic ductal adenocarcinoma (PDA)
89457318|NCT02317419|Experimental|Part A Extension Phase Group 2|RO6927005 given as a single agent in participants with mesothelin-positive metastatic and/or advanced PDA
89457319|NCT02317419|Experimental|Part B MAD Phase|RO6927005 with gemcitabine/nab-paclitaxel in participants with mesothelin-positive metastatic and/or advanced PDA
89457320|NCT02317419|Experimental|Part B Extension Phase|RO6927005 with gemcitabine/nab-paclitaxel in participants with PDA
89457321|NCT02313441|Active Comparator|RIPC (Remote Ischemic Pre-Conditioning)|Patients used RIPC had a blood pressure cuff placed around their upper arm at < 2 hours before the PCI procedure. The blood pressure cuff was inflated to for 5 minutes, followed by 5 minutes of deflation. This procedure was repeated 3 times
89457322|NCT02313441|Placebo Comparator|Control|Control participants did not experience this procedure of transient upper-limb ischemia.
89457323|NCT02313519|Placebo Comparator|Placebo|Capsules of powdered glucose polymer given one capsule every 12 hours for 15 days
89457324|NCT02313519|Active Comparator|Probiotics|Capsules containing Lactobacillus acidophilus LA-5 [1.75x10^9 cfu], Lactobacillus plantarum [0.5x10^9 cfu], Bifidobacterium lactis BB-12 [1.75x10^9cfu], and Saccharomyces boulardii [1.5x10^9] per capsule. One capsule is given every 12 hours for 15 days
89457325|NCT02308605||Suspected stroke patients and subset|"Blood samples taken on admission and at 24 hours, MRI scan between 24 and 48 hours~Subset: Blood samples repeated once per hour for six hours"
89457326|NCT02308605||Control participants (relatives)|To donate blood on two occasions, 24 hours apart, to draw comparison with stroke patients
89457327|NCT02308605||Feeding control participants|To donate a baseline blood sample, eat a simple purine rich meal (meat sandwich), then donate 4 more blood samples at 10, 30, 60 and 120 minutes following the meal
89457328|NCT03501225|Experimental|ozone|tooth extraction under irrigation with ozonated water
89457329|NCT03501225|Experimental|water|tooth extraction under irrigation with ozonated water or doubly distilled water
89457330|NCT02313753|Active Comparator|SAFE|Safety Assessment and Follow-up Evaluation Protocol
89457331|NCT02313753|Experimental|CLASP|Coping Long Term with Active Suicide Program Protocol
89457332|NCT05452330|Experimental|Group 1|Connective tissue massage
89457333|NCT05452330|Experimental|Group 2|Classical massage
89457334|NCT02317497|Experimental|Moderate sedation (M)|1. Moderate sedation defined by target RASS of >= -3. The intervention (M) is sedation by use of any sedative and/or analgesic medication(s) left at the discretion of the treating physicians targeted at a RASS of >= -3 (patient responds to verbal stimulus) from randomization for the next 72h. RASS will be assessed once every 8 h (at he beginning of each shift) and measures undertaken to achieve the target level. If safety-limits are violated, sedation may have to be deepened below the target level for 8h and re-assessed at the beginning of the next shift with the aim to approach the target level of the intervention group again.
89016601|NCT03541889|Experimental|Cord and haplo imaging cohort|For all pediatric and adult patients undergoing cord blood HSCT, FLT PET/CT imaging will occur one day prior to HSCT and on days 9 and 28 after HSCT. For recipients of haplo-HSCT, FLT PET/CT imaging will occur one day prior to HSCT and on days 5 and 28 after HSCT.
89457335|NCT02317497|Active Comparator|Deep sedation (D)|2. Deep sedation defined by target RASS of < -3. The control (D) is sedation by use of any sedative and/or analgesic medication(s) left at the discretion of the treating physicians targeted at a RASS of < -3 (patient does not respond to verbal stimulus) from randomization for the next 72h. RASS will be assessed once every 8 h (at he beginning of each shift) and measures undertaken to achieve the target level. If safety-limits are violated, sedation may have to be reduced above the target level for 8h and re-assessed at the beginning of the next shift with the aim to approach the target level of the control group again.
89457336|NCT02313831|Experimental|Exercise training|Patients of this group will be submitted to an interval training
89457337|NCT03501147|Experimental|Intervention|15 minutes of resistance training at the work place every day
89457338|NCT03501147|No Intervention|Control|Usual work
89457339|NCT02317653||Overweight/Obese|Archive blood, archive breast milk, and clinical assessment data from 15 participants who were considered overweight or obese at enrollment in the Expecting Success study conducted at Pennington Biomedical Research Center (NCT01610752) will be used to represent the overweight and obese sample for study investigations.
89457340|NCT02317653||Normal Weight|Up to 20 pregnant women who were considered normal weight (18.5 ≤ BMI ≤ 24.9 kg/m2) prior to pregnancy will be enrolled in the study.
89457341|NCT02313987||A-Usual care- Standard care for NOCAD|"Subjects with non obstructive CAD (20-70% luminal diameter stenosis) and normal Endothelial function as defined by EndoScore.~These subjects will receive the standard care usually provided in each facility for patients with NOCAD"
89457342|NCT02313987||B1-Usual Care-Standard care for NOCAD|"Subjects with non obstructive CAD (20-70% luminal diameter stenosis ) and abnormal Endothelial function as defined by EndoScore.~These subjects will receive the standard care usually provided in each facility for patients with NOCAD. (Same care as Group A)"
89457343|NCT02313987||B2- Endothelial function guid care|"Subjects with non obstructive CAD and abnormal Endothelial function as defined by EndoScore.~These subjects will receive the an Endothelial Function-guided Therapy."
89457344|NCT02314065|Experimental|Conventional CBT|Cognitive Behavioural Therapy delivered in a conventional manner
89457345|NCT02314065|Experimental|Internet-delivered CBT|Cognitive Behavioural Therapy delivered via the Internet
89457346|NCT02314221|Experimental|Exoskeletal-Assisted Walking (WALK)|WALK first for 12 weeks (36 sessions)
89457347|NCT02314221|No Intervention|Usual Activities (UA)|Usual activities first for 12 weeks
89016602|NCT03541889|Experimental|Nonengrafted cohort|Pediatric and adult patients who have not engrafted by day 24 after cord or haplo-identical HSCT will undergo a single FLT PET/CT image within one week to determine if this scan can identify graft failure versus delayed engraftment.
89016603|NCT03534947|Experimental|Sonidegib followed by imiquimod|Sonidegib 200mg taken orally once a day for 12 weeks. COMPLETE OR PARTIAL RESPONSE WITH SUPERFICAL REMNANT LESION For patients with a complete response or a partial response resulting in a superficial lesion, treatment with topical imiquimod for 5 days a week for 6 weeks will be prescribed.
89016604|NCT03534947|Experimental|Sonidegib followed by surgery|Sonidegib 200mg taken orally once a day for 12 weeks. PARTIAL RESPONSE WITH REMNANT INVASIVE LESION For patients with a no change on BCC size / depth or patients with a partial response but a remaining invasive lesion, will have surgical excscion of the remaining lesion.
89016605|NCT03534947|Other|Sonidegib then best supportive care|Sonidegib 200mg taken orally once a day for 12 weeks. PROGRESSIVE DISEASE Patients with lesions that have progressed in size and/or depth will receive the best supportive care deemed appropriate by the treating clinician. This may be surgery, imiquimod, a clinical trial treatment, radiotherapy or any combination of these interventions.
89016606|NCT03530124|Other|Vaccinated|In the study arm, infants will receive PCV13, DTaP, HBV, IPV, and Hib vaccines within 12 hours of randomization. Infants will be monitored from time of vaccination to 48 hours post-vaccination for the occurrence of apnea, bradycardia and desaturation.
89016607|NCT03530124|No Intervention|Unvaccinated|In the study arm, infants will not receive PCV13, DTaP, HBV, IPV, and Hib vaccines during the study. Infants will be monitored from randomization to 48 hours post-randomization for the occurrence of apnea, bradycardia and desaturation.
89016608|NCT03522168||Risperidone group|Risperidone, n=350, including 30 children 3 - <6 years old and 320 children 6 - <18 years old. ~50% - ~80% of the entire group will have <90 days of prior treatment with any antipsychotic.
89023570|NCT05139810|Placebo Comparator|Placebo: Cohort A|Participants will be administered donidalorsen-matching placebo by subcutaneous (SC) injection for up to 25 weeks.
89457348|NCT02308683|Experimental|hsCRP, Hgba1c|Pre treatment hsCRP and hgba1c will be initially measured After 12 weeks supplementation of Moringa oleifera, post treatment hsCRP and Hgba1c will be measured
89457349|NCT03943888|Experimental|Sugammadex 2mg|Administer 2mg/kg of sugammadex 15 minutes after rocuronium administration
89457350|NCT03943888|Experimental|Sugammadex 4mg|Administer 4mg/kg of sugammadex 15 minutes after rocuronium administration
89457351|NCT03943888|Experimental|Sugammadex 8mg|Administer 8mg/kg of sugammadex 15 minutes after rocuronium administration
89457352|NCT03943888|Active Comparator|Conventional reversal|Administer conventional neuromuscular reversal agent (0.02mg/kg of atropine and 0.03mg/kg of neostigmine) 15 minutes after rocuronium administration
89457353|NCT02308761|Experimental|RO6870810|Participants with RR-AML and HMA-refractory MDS will receive RO6870810, as per schedule described in intervention description.
89457354|NCT03506607|Experimental|Exercise in hypoxia 1500m|During this visit, subjects will perform a 6-min treadmill exercise wearing an oronasal mask connected (through a hose) with a three-way valve to an altitude simulation device (Altitrainer; SMTech, Nyon, Switzerland). The ambient air will be mixed with nitrogen and inspired oxygen fraction will be reduced to 16%.
89457355|NCT03506607|Experimental|Exercise in hypoxia 2500m|During this visit, subjects will perform a 6-min treadmill exercise wearing an oronasal mask connected (through a hose) with a three-way valve to an altitude simulation device (Altitrainer; SMTech, Nyon, Switzerland). The ambient air will be mixed with nitrogen and inspired oxygen fraction will be reduced to 14%.
89016609|NCT03522168||Aripiprazole group|Aripiprazole group, n=350, including 30 children 3 - <6 years old and 320 children 6 - <18 years old. ~50% - ~80% of the entire group will have ≤90 days of prior treatment with any antipsychotic.
89016610|NCT03514017|Experimental|Pembrolizumab and Ibrutinib|"Treatment with pembrolizumab and ibrutinib and follow-up period of up to 24 months.~Pembrolizumab is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2.~Ibrutinib is an inhibitor of Bruton's tyrosine kinase (BTK). Ibrutinib is a small-molecule inhibitor of BTK."
89016611|NCT03500315|Experimental|HIV D+/R+|HIV-infected individuals that accept an organ from an HIV-infected deceased donor - enrollment 80
89457356|NCT03506607|Placebo Comparator|Exercise in normoxia|During this visit, subjects will perform a 6-min treadmill exercise wearing an oronasal mask connected (through a hose) with a three-way valve to an altitude simulation device (Altitrainer; SMTech, Nyon, Switzerland). For the exercise performed in normoxia conditions, subjects will breathe room air.
89457357|NCT03942718|No Intervention|Control group|Participants will obtain no exercise program. After 12 weeks, the patients in the control group will be invited to participate in the training group.
89457358|NCT03942718|Experimental|Aerobic exercise group|Participants will obtain aerobic exercise only.
89457359|NCT03942718|Experimental|Anaerobic exercise group|Participants will obtain aerobic and anaerobic exercise respectively
89457360|NCT02317731|No Intervention|Routine|Subjects will ingest the bowel preparation from a cup
89457361|NCT02317731|Experimental|Straw|Subjects will ingest the bowel preparation with a straw
89457362|NCT03502551|Experimental|Treatment with Ketamine|In this arm an IV infusion of 0.5 mg/kg of ketamine will be administered over 40 minutes.
89457363|NCT02314377|Experimental|AVM treatment with Bevacizumab|Bevacizumab infusion dose of 5mg/kg q 2 weeks for 12 weeks (2.5 mg/week).
89457364|NCT03502473|Experimental|One pass/no treatment arm|One random flank will be treated with UltraShape Power device with one pass or remained as a control (no treatment)
89457365|NCT03502473|Experimental|Multiple passes treatment arm|Second flank will be treated with UltraShape Power device with multiple passes.
89457366|NCT02398214|Experimental|Sleep hygiene & standard care|Participants receive a light, activity, and sleep training (LAST) intervention consists of behavioral and educational strategies for increasing light exposure and physical activity to minimize sleep disturbance.
89457367|NCT02398214|No Intervention|Standard care|Participants receive usual care.
89457368|NCT02314455|Experimental|D-xylose, water, honey|"25 grams of D-xylose~10 cc of water~2 teaspoons of honey"
89457369|NCT02535364|Experimental|JCAR015 (CD19-targeted CAR T cells)|JCAR015 was administered as two intravenous (IV) infusions separated by 14 to 28 days.
89016612|NCT03500315|No Intervention|HIV D-/R+|HIV-infected individuals that accept an organ from an HIV-uninfected deceased donor -enrollment 80
89016613|NCT03500315|No Intervention|HIV D-/R+ (observational)|HIV-infected individuals that accept an organ from an HIV-uninfected deceased donor and randomized to observational group - enrollment 200
89016614|NCT03451409|Active Comparator|OCD Proband|Healthy controls (HC, n=50) without a family history of OCD will be matched to SIB.
89457370|NCT05464576|Other|Comparison between MRI versus anatomopathology report in bladder cancer|Comparison of MRI and anatomopathology on urinary bladder tumour after transurethral resection of the bladder or cystectomy (for patients with an invasive bladder cancer.
89016615|NCT03451409|Active Comparator|OCD Siblings|Healthy controls (HC, n=50) without a family history of OCD will be matched to SIB.
89457371|NCT02942290|Experimental|Venetoclax + Azacitidine|
89457372|NCT02540356|Experimental|Single-Route Arm|BAX69 administered weekly by intraperitoneal (IP) infusion only
89016616|NCT03451409|Active Comparator|Healthy Controls|Healthy controls (HC, n=50) without a family history of OCD will be matched to SIB.
89023571|NCT05139810|Placebo Comparator|Placebo: Cohort B|Participants will be administered donidalorsen-matching placebo by subcutaneous (SC) injection for up to 25 weeks.
89457373|NCT02540356|Experimental|Double-Route Arm|BAX69 administered weekly by intravenous (IV) infusion + intraperitoneal (IP) infusion
89457374|NCT05433064|Experimental|Epidural Stimulator|Subjects will be implanted with 16-electrode epidural array in the T11-L1 area of the spinal cord. After 2 weeks recovery,patients will undergo a structured program of physical rehabilitation and electrical stimulation.
89457375|NCT05431816|Experimental|dietary fiber intervention|Participants take a certain amount of dietary fiber per day.
89457376|NCT05431816|Placebo Comparator|Placebo|Participants take a certain amount of placebo (Maltodextrin) per day.
89457377|NCT05463094|Experimental|First Test GXR RM (Fasted), Then Reference GXR RM (Fasted)|Participants will receive a single dose of Test Glucophage Extended Release Reduced Mass (GXR RM) tablet on Day 1 in treatment period 1 followed by a single dose of Reference GXR RM tablet on Day 8 in treatment period 2 under fasted condition. There will be separate washout period of 7 days between each treatment period.
89457378|NCT05463094|Experimental|First Reference GXR RM (Fasted), Then Test GXR RM (Fasted)|Participants will receive a single dose of Reference GXR RM tablet on Day 1 in treatment period 1 followed by a single dose of Test GXR RM tablet on Day 8 in treatment period 2 under fasted condition. There will be separate washout period of 7 days between each treatment period.
89457379|NCT05463094|Experimental|First Test GXR RM (Fed), Then Reference GXR RM (Fed)|Participants will receive a single dose of Test GXR RM tablet on Day 1 in treatment period 1 followed by a single dose of Reference GXR RM tablet on Day 8 in treatment period 2 under fed condition. There will be separate washout period of 7 days between each treatment period.
89457380|NCT05463094|Experimental|First Reference GXR RM (Fed), Then Test GXR RM (Fed)|Participants will receive a single dose of Reference GXR RM tablet on Day 1 in treatment period 1 followed by a single dose of Test GXR RM tablet on Day 8 in treatment period 2 under fed condition. There will be separate washout period of 7 days between each treatment period.
89457381|NCT05463016|Experimental|Color Vision Deficient with Color Correcting Lenses|10 subjects confirmed to have hereditary color vision deficiency randomly assigned to experimental group 1 which includes baseline testing with and without color correcting lenses, followed by 7 days of wear, minimum 3 hours/day, followed by retesting with and without color correcting lenses.
89457382|NCT05463016|Placebo Comparator|Color Vision Deficient with Placebo Lenses|10 subjects confirmed to have hereditary color vision deficiency randomly assigned to Placebo Group 1 which includes baseline testing with and without placebo lenses, followed by 7 days of wear, minimum 3 hours/day, followed by retesting with and without placebo lenses.
89457383|NCT05463016|Experimental|Crossover: Placebo to Experimental|Placebo Group 1 crosses over to become Experimental Group 2 which includes baseline testing with and without color correcting lenses, followed by 7 days of wear, minimum 3 hours/day, followed by retesting with and without color correcting lenses.
89457384|NCT05463016|Placebo Comparator|Crossover: Experimental to Placebo|Experimental Group 1 crosses over to become Placebo Group 2 which includes baseline testing with and without placebo lenses, followed by 7 days of wear, minimum 3 hours/day, followed by retesting with and without placebo lenses.
89457385|NCT05463016|Active Comparator|Control Group: Subjects with Normal Color Vision|Fifteen subjects confirmed to have normal color vision will be tested in a single session to determine whether color correcting lenses affect color vision in color vision normal subjects and to provided normative data for several unique measures of color vision performance
89457386|NCT05431660|Experimental|tele-rehabilitation group|1st group within the scope of diabetic foot school, and an exercise program aiming to increase the mobility and strength of the foot will be implemented through video calls twice a week, face-to-face once a week for 8 weeks.
89457387|NCT05431660|Active Comparator|face to face training group|The 2nd group will be given a booklet covering this training and they will be followed up with video calls 1 day a week for 8 weeks.
89457388|NCT05431348||patients with glioblastoma treated with STUPP schema|
89457389|NCT05450068|Active Comparator|Group A-Combined Group|Participants in this group will receive both Mulligan's mobilization with movement and Spencer's muscle energy technique along with conventional therapy and home exercise plan. 3 sessions per week will be given for 4 weeks.
89457390|NCT05450068|Active Comparator|Group B-Mulligan Group|Participants in this group will receive Mulligan's mobilization with movement along with conventional therapy and home exercise plan. 3 sessions per week will be given for 4 weeks.
89457391|NCT05450068|Active Comparator|Group C-Spencer Group|Participants in this group will receive Spencer's muscle energy technique along with conventional therapy and home exercise plan. 3 sessions per week will be given for 4 weeks.
89457392|NCT05450068|Active Comparator|Group D-Conventional Group|Participants in this group will receive conventional therapy alone in hospital with home exercise plan. 3 sessions per week will be given for 4 weeks.
88940824|NCT01853501|Experimental|POF,treatment,ADSC|Fat from POF patients undergo Autologous fat grafting operation were separated, from which Adipose Derived Stem Cell were then purified and injected into the both ovaries of patients.
89457393|NCT05449678|No Intervention|Control diet|Usual diet (45% of daily energy intake from CHO)
89457394|NCT05449678|Experimental|Low carb diet|Low-carb diet (25% of daily energy intake from CHO)
89457395|NCT05449600|Experimental|Participant|Tegaderm™ tape, Kind™ removal tape, and Thermotape will be applied to both of the participant's forearms.
89457396|NCT05449600|No Intervention|Researcher|
89457397|NCT05430724|Active Comparator|Grup E|Patients given esmolol infusion
89457398|NCT05430724|Active Comparator|Grup N|Patients given nicardipine infusion
89457399|NCT02534896|Experimental|Treatment 1: Sunpharma1505 (Low dose) and Placebo|
89457400|NCT02534896|Experimental|Treatment II: Sunpharma1505 (High Dose) and Placebo|
88940825|NCT01853514||Low income|Income level equal or less than 250% above the poverty level
89457401|NCT02534896|Active Comparator|Treatment III: Reference1505 and Placebo|
89457402|NCT02697734|Experimental|osilodrostat Group|Participants in this arm were randomized to receive the study drug, osilodrostat followed after Week 12 by open-label osilodrostat at the starting dose (with a second dose titration)
89457403|NCT02697734|Placebo Comparator|osilodrostat Placebo Group|Participants in this arm were randomized to receive osilodrostat placebo followed after Week 12 by open-label osilodrostat at the starting dose (with a dose titration)
89457404|NCT05447494|Experimental|Low-dose CAN103|Low dose intravenous infusion of CAN103 every other week for 37 weeks
89457405|NCT05447494|Experimental|High-dose CAN103|High dose intravenous infusion of CAN103 every other week for 37 weeks
89457406|NCT02392130|Active Comparator|Active Drug|Clobetasol propionate 0.05% ointment
89457407|NCT02392130|Experimental|Experimental Drug|LEO 130852A gel 1%
89457408|NCT02392130|Placebo Comparator|Placebo Drug|LEO 130852A placebo gel
89457409|NCT02392052|Experimental|Reinvention Protocol Participants|This group will receive 6 instructor-led 2 hour long didactic presentations regarding 8 key principles of self-efficacy and experiential exercises, including goal setting and problem solving with extensive group discussion. At the end of each session, tasks are assigned to participants to be completed outside the group during the week between sessions. Experiences from these activities and practice implementing the intervention principles will be shared and discussed each week, providing additional opportunities for problem solving and positive feedback.
88940826|NCT01853527||Angina pectoris, non-obstructive CAD|Contrast stress echocardiography will be performed in patients with angina pectoris and non-obstructive CAD on CT-angiography to detect presence of myocardial ischemia
89457410|NCT02392052|Other|Waitlist Group|This group will include individuals randomized to receive no treatment for the 18 weeks during which the interventional group will receive the active treatment and have their progress tracked.
89457411|NCT02391974|Experimental|PERIOSYAL FILL|n=15
89457412|NCT02391974|No Intervention|No treatment (untreated control)|n=15
89457413|NCT02692586|Experimental|FlowTriever System|
89457414|NCT02391896|Other|Digital Tomosynthesis|Patient will get tomosynthesis scan
89457415|NCT02391896|Other|Dual energy|Patient will get dual energy scan
88940827|NCT01853566|Experimental|growth hormone|GH group received an initial dose of 0.5 units (UI)/day (0.2 mg/day), with readjustments to 1.0 UI/day (0.4 mg/day) and 1.5 UI/day (0.6 mg/day) after 1 and 2 months of treatment, respectively. The last GH dose will be maintained until the end of the study (6 months).
88940828|NCT01853579|Experimental|1|Experimental: Drug: Levothyroxine The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects <50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is <0.4 mU/L, dose will be reduced by 25 mcg; TSH >=0.4 and <4.6 mU/L, no change to dose; TSH >=4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
88940829|NCT01853579|Placebo Comparator|2|"Placebo Comparator: Drug: Placebo Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug.~Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg."
88940830|NCT01853657|Active Comparator|Virological monitoring|In addition to routine clinical and immunological monitoring with CD4 counts
88940831|NCT01853657|No Intervention|Routine monitoring|Immunological and clinical monitoring
88940832|NCT01853670|Experimental|definitive radiation + concomitant chemo|"Concurrent chemo + IGRT:~These patients will have chemotherapy during the time of radiation treatment"
88940833|NCT01853670|Experimental|neoadjuvant chemo|"Neoadjuvant chemo + IGRT:~These patients will have chemotherapy prior to other radiation treatment."
88940834|NCT01853683|Experimental|Conservative Management|Children randomized to conservative management will be seen in the clinic 6-10 weeks after discharge and phoned to follow up every 3 month for a total follow-up of a year. Family will be instructed to come back to the hospital or call the treating physician if the child develops any abdominal pain or fever.
88940835|NCT01853683|Active Comparator|Operative Management|Children randomized to IA will be scheduled for an interval appendectomy 6-10 weeks after discharge, and will be seen in the clinic 6-8 weeks following the interval appendectomy and phoned for follow-up every 3 month for a total of one year.
88940836|NCT01853709|Experimental|Multidisciplinary approach|"The multidisciplinary approach will include:~Education Fiber free diet Bisacodyl: 10 mg 2 days before the procedure, 20 mg the day before the procedure and 10 mg 3 hours before the procedure Adjuvants: Olive Oil:60 mL/Apple Juice: 200 mL PEG: 1 L the night before the procedure and 1 L 3 hours before the procedure"
88940837|NCT01853709|Active Comparator|Conventional approach|"The conventional approach will include:~Education Fiber free diet Polyethylene glycol (PEG): 2 L the night before the procedure, 2 L 3 hours before the procedure"
88940838|NCT01853761|Experimental|Exercise after, Transcutaneos, 25-10Hz|Experimental group 1 performed aerobic exercise just after microcurrent in the abdominal region with four transcutaneous electrodes in a parallel position, intensity below the sensivity threshold and a maximum of 1 mA. Every 15 minutes changed from 25Hz to 10 Hz.
88940839|NCT01853761|Experimental|25-50Hz microcurrent|Experimental group 2 performed aerobic exercise just after microcurrent in the abdominal region with four transcutaneous electrodes in a parallel position, intensity below the sensivity threshold and a maximum of 1 mA. Every 15 minutes changed from 25Hz to 50Hz.
88940840|NCT01853761|Experimental|percutaneous microcurrent|Experimental group 3 performed aerobic exercise just after microcurrent in the abdominal region with four percutaneous electrodes in a parallel position, intensity below the sensivity threshold and a maximum of 1 mA. Every 15 minutes changed from 25Hz to 10 Hz.
88940841|NCT01853761|Experimental|Exercise at same time|Experimental group 4 performed aerobic exercise at the same time microcurrent in the abdominal region with four transcutaneous electrodes in a parallel position, intensity below the sensivity threshold and a maximum of 1 mA. Every 15 minutes changed from 25Hz to 10 Hz.
89457416|NCT05744882|Placebo Comparator|Control Group|no further treatment provided after coronectomy
89457417|NCT05744882|Active Comparator|Experimental Group|root canal treatment provided after the coronectomy procedure
89457418|NCT02391818||Breast Cancer Patients receiving ACT|Adraimycin/Cytoxan/Taxol
89457419|NCT02391818||Breast Cancer patients receiving RT only|radiation therapy
89457420|NCT02534350|Experimental|Presatovir|Presatovir 200 mg (4 x 50 mg) on Day 1, followed by 100 mg (2 x 50 mg) from Day 2 to Day 14
89457421|NCT02534350|Placebo Comparator|Placebo|Placebo tablets for a total of 14 days
89457422|NCT03165422||Adult patients with melanoma|Adult patients with melanoma at participating centers in Japan
89457423|NCT03166904|Experimental|AZD2014|Vistusertib(AZD2014) 50mg BD continuous schedule of a 28 day cycle
89201468|NCT04034277|Active Comparator|Conventional Treatment|The content and dose of standard SLT is poorly defined within the published literature. For this reason, the standard therapy intervention will encompass all SLT techniques that are not LSVT®. Treatment will be individualized and may include any of the following: exercises targeting respiration, phonation, articulation, behavioral strategies to reduce prosodic abnormality
89457424|NCT05385497|Experimental|Combined Aerobic Exercise (AE) and Virtual Reality (VR)-based program|Individuals diagnosed with PD will participate in AE and VR.
89457425|NCT05356091|Active Comparator|Sevoflurane|General anesthesia using sevoflurane
89457426|NCT05356091|Experimental|Remimazolam|General anesthesia using remimazolam
89457427|NCT05196971|Experimental|HS-10345 84mg|Participants will self-administer intranasal HS-10345 84mg on Days 1, 4, 8, and 11 during the double-blind phase
89457428|NCT05196971|Placebo Comparator|Placebo|Participants will be self-administered on Days 1, 4, 8, and 11 during the double-blind phase
89457429|NCT05351021|Experimental|Group I (metformin group)|who will receive adjuvant paclitaxel in addition to metformin tablets (1700 mg daily) during the chemotherapy treatment duration.
89457430|NCT05351021|Placebo Comparator|Group II (control group)|who will receive adjuvant weekly paclitaxel.
89457431|NCT05309291|Experimental|Theranova 400 Dialyzer|1 week, 1 session in mid-week HD therapy. Pre dialysis blood samples taken from fistula needle or central venous catheter. Post dialysis blood samples taken from arterial sampling port of bloodline
89457432|NCT05309291|Active Comparator|FX 800 Dialyzer|1 week, 1 session in mid-week HDF therapy. Pre dialysis blood samples taken from fistula needle or central venous catheter. Post dialysis blood samples taken from arterial sampling port of bloodline
89457433|NCT03625817|No Intervention|Urban setting|The participants will be staying in their permanent house in an urban area in Cyprus for at least 7 days. On the 7th day, they will be wearing 2 temperature sensors, for skin and air temperature. They will also collect the urine samples of the day and note in an activity diary, the names and times of activities.
89457434|NCT03625817|Experimental|Mountainous setting|The intervention is the short stay in the mountainous area of Troodos for atleast 7 consecutive days. The participants will be staying in their holiday house in the mountainous-rural area of Troodos, Cyprus for at least 7 days. On the 7th day, they will wear 2 temperature sensors, for skin and personal air temperature monitoring (every minute data points). They will also collect the urine samples of the day and note in an activity diary, the names and times of activities.
89457435|NCT02688764|Experimental|PA21 (Velphoro®)|"PA21 (Velphoro®), chewable tablets 500 mg iron~PA21 (Velphoro®), chewable tablets 250 mg iron~PA21 (Velphoro®), powder for oral suspension 500 mg iron~PA21 (Velphoro®), powder for oral suspension 250 mg iron~PA21 (Velphoro®), powder for oral suspension 125 mg iron"
89457436|NCT02688764|Active Comparator|Calcium Acetate (Phoslyra®)|Calcium Acetate (Phoslyra®) - Oral Solution: 667 mg calcium acetate per 5 mL.
89457437|NCT02688608|Experimental|Pembrolizumab|200 milligrams of Pembrolizumab will be given intravenously every 3 weeks.
89457438|NCT02688530|Placebo Comparator|0mg IV Dexamethasone|0mg IV Dexamethasone
89457439|NCT02688530|Experimental|4mg IV Dexamethasone|4mg IV Dexamethasone
89457440|NCT02688530|Experimental|6mg IV Dexamethasone|6mg IV Dexamethasone
89457441|NCT02688530|Experimental|8mg IV Dexamethasone|8mg IV Dexamethasone
89457442|NCT03167060|Active Comparator|Active Rhinochill|Intranasal cooling device , using nasal cannula
89457443|NCT03167060|Sham Comparator|Control Rhinochill|Intranasal cooling device , using nasal cannula (difference with active device not disclosed to maintain blindness)
89457444|NCT05744804|Active Comparator|-group of patients(75 patients) will receive low dose rivaroxaban|-group of patients(75 patients) will receive low dose rivaroxaban (rivaroxaban 2.5 mg twice daily orally) for 1 month after anterior ST-segment myocardial infarction plus dual antiplatelet therapy (acetylsalicylic acid 75 mg once daily orally and cloppe
89457445|NCT05744804|Active Comparator|control group of patients:|control group of patients: 75 Patients of anterior ST-segment myocardial infarction on dual antiplatelet therapy only
89457446|NCT03166748|Active Comparator|MTA pulpotomy|mineral trioxide aggregates (MTA) is accepted as an optimum material for use in vital pulp therapy of permanent teeth
89457447|NCT03166748|Experimental|Potassium Nitrate in Polycarboxylate cement|Potassium nitrate (KNO3) is a superior desensitizer for hypersensitive teeth. Used with polycarboxylate cement, it serves as an effective liner for deep carious lesions. Also when placed under deep restorations with less than 1 mm of protective dentin remaining, it was effective in preserving pulpal vitality and it diminished the incidence and severity of post-restoration pain. As temporary cement (Kno3/zinc oxide eugenol [ZOE]) It reduced pain following full crown preparation.
89457448|NCT05744726|Experimental|A-PRF|Advance Platelet-Rich Fibrin
89457449|NCT05744726|Active Comparator|Bone-wax|
89457450|NCT05744726|No Intervention|Conventional Dental Extraction protocol|Control Group
89457451|NCT03166670||study group|children with acute secretory diarrhea
89457452|NCT03166670||Control group|normal healthy children
89457453|NCT05083559|Experimental|MPC AP system|Participants will use the MPC AP system for automated insulin delivery for a 9 hour study visit.
89457454|NCT05083559|Experimental|Robust R-AP system|Participants will use the Robust R-AP system for automated insulin delivery for a 9 hour study visit.
89457455|NCT03166982|Experimental|laparoscopy|the tubo-ovarian abscess should be drained by interventional radiology, preferably by transvaginal or laparoscopic
89201469|NCT01053949|Active Comparator|Drug on 21 days per 28 days cycle|Pomalidomide 4 mg continuous daily oral route on 21 days per 28 days cycle. The proposed dose of dexamethasone is considered standard, 40mg/day once a week.
89201470|NCT01053949|Active Comparator|Drug on 28 days per 28 days cycle|Pomalidomide 4 mg continuous daily oral route on 28 days of a 28 days cycle The proposed dose of dexamethasone is considered standard, 40mg/day once a week.
89457456|NCT03166982|Experimental|ultrasound-guided puncture|The transvaginal echo guided puncture to replace the first laparoscopy because of its less invasive nature, this is a simple act, fast, possible under mild sedation, the cost is still lower than laparoscopy
89457457|NCT05150795|Active Comparator|Group Pregabalin|Patients will receive oral pregabalin capsule (150 mg) 90 min before induction of anesthesia, and will receive a bolus injection of 10 ml saline at induction of anesthesia
89457458|NCT05150795|Active Comparator|Group Fentanyl|Patients will receive oral placebo capsule identical to the trial drug in size, shape and color, 90 min before induction of anesthesia and will receive a bolus injection of 10 ml of 1µg /kg fentanyl at induction of anesthesia
89457459|NCT02400658|Experimental|IORT with CT-Guided HDR Brachytherapy|Patients will receive IORT with CT-guided HDR brachytherapy at the time of breast surgery.
89457460|NCT03167138|Experimental|Autologous micro-fragmented adipose tissue|Injection (under ultrasound guidance) of autologous micro-fragmented adipose tissue obtained from abdominal region or thighs using the Lipogems® system.
89457461|NCT05027087|Experimental|Treatment|Participants receive the blueberry gummy supplement
89457462|NCT05027087|Placebo Comparator|Placebo|Participant receive the placebo gummy supplement
89457463|NCT03166280||hepatitisC-pre-ttt|Naïve HCV Patients (>18Y) coming to National Committee for control of viral hepatitis before receiving their treatment
89457464|NCT03166280||hepatitis C-ttt|Naïve HCV Patients (>18Y) coming to National Committee for control of viral hepatitis- 12 weeks after stoppage their treatment of sofosbuvir 400 mg/day plus Daclatasvir 60 mg/day for 12 weeks.
89457465|NCT05427994||Patients with age-related macular degeneration|Patients with age-related macular degeneration who fill out the quality of life questionnaire, and answer questions about social support and reliability of social support
89457466|NCT04440254|Other|ONE|One single group of patients
89457467|NCT03037307|Experimental|Test product|Participants will topically apply the test product to clean wet denture (upper denture) fit surface in a pattern consistent with product label and application instructions.
89457468|NCT03037307|Active Comparator|Positive Control|Participants will topically apply the positive control to clean wet denture (upper denture) fit surface in a pattern consistent with product label and application instructions.
89457469|NCT03037307|Other|Negative Control|Participants of this group will not be assigned to any treatment.
89457470|NCT05746052|Other|atrophic acne scar in face|
89457471|NCT02428049||Lung cancer patients|Lung cancer patients in stages IA-IIIA destined to have stereotactic radiotherapy or conventional radiotherapy and chemotherapy in curative intent
89457472|NCT05427526|Active Comparator|group 1: LARA IOL implanted in combination with vitrectomy.|intraocular lens implantation in combination with vitrectomy
89457473|NCT05427526|Active Comparator|group 2: LARA IOL implanted in during surgery for cataract secondary to vitrectomy|intraocular lens implantation during surgery for cataract secondary to vitrectomy
89457474|NCT05410054||good prognosis|Patients with higher Fugl-Meyer motor function scale (upper limb part) and higher Action Research Arm Test (ARAT) score.
89457475|NCT05410054||poor prognosis|Patients with lower Fugl-Meyer motor function scale (upper limb part) and lower Action Research Arm Test (ARAT) score.
89457476|NCT03669887|Experimental|Lifestyle Modification Program|Women randomised into the intervention group received the 1-year lifestyle modification program.
89457477|NCT03669887|No Intervention|Control|Women randomised into the control arm received standard postnatal care.
89457478|NCT02538094|Sham Comparator|Sham Stimulation First|Transcranial direct current stimulation (tDCS) that is ramped up and ramped down providing the sensation of tDCS without delivering the full amount of tDCS first and then Anodal Stimulation second.
89457479|NCT02538094|Experimental|Anodal Stimulation First|Transcranial direct current stimulation using Anodal stimulation first over the area of interest and then Sham Stimulation second.
89457480|NCT02686034|Active Comparator|gammaCore-S|Treatment of up to 5 migraine attacks with the Active gammaCore-S non-invasive vagus nerve stimulator device which delivers a mild electrical signal in the vicinity of the vagus nerve
88940842|NCT01853761|Placebo Comparator|Control Group|Control group performed aerobic exercise just after microcurrent in the abdominal region with four transcutaneous electrodes in a parallel position, but microcurrent device was switched off.
88940843|NCT01853787|Experimental|Formoterol Fumarate|At study day n°1 the patients will be randomized to take either Salmeterol or Formoterol in a double blind way.
88940844|NCT01853787|Active Comparator|Salmeterol|The second study arm represents the crossing over arm. Every patient, at study day number 2 will take a different medication (Salmeterol 50 mcg or Formoterol 12 mcg) from that taken at the study day n° 1.
88940845|NCT01853800|Experimental|Rivaroxaban (Treatment A) suspension (BN03501), fasted|Subjects received single oral dose of Rivaroxaban suspension 10 mg (Treatment A, Batch number BN03501) under fasting conditions in any intervention period.
88940846|NCT01853800|Experimental|Rivaroxaban (Treatment B) suspension (BN03501), fed|Subjects received single oral dose of Rivaroxaban suspension 20 mg (Treatment B, Batch number BN03501) under fed conditions in any intervention period.
88940847|NCT01853800|Experimental|Rivaroxaban (Treatment C) suspension (BR05701), fasted|Subjects received single oral dose of Rivaroxaban suspension 10 mg (Treatment C, Batch number BR05701) under fasting conditions in any intervention period.
88940848|NCT01853800|Experimental|Rivaroxaban (Treatment D) IR tablet, fasted|Subjects received single oral dose of Rivaroxaban IR tablet 10 mg (Treatment D) under fasting conditions in any intervention period.
88940849|NCT01853813|Other|Bevacizumab and FOLFIRI|Bevacizumab 5 mg/kg d1 q14 in combination with FOLFIRI (Irinotecan, leucovorin, 5FU I.V.bolus and 5FU I.V. c.i.)
88940850|NCT01853852|Experimental|50 mg|GR181413A/AT1001
88940851|NCT01853852|Experimental|150 mg|GR181413A/AT1001
88940852|NCT01853852|Experimental|450 mg|GR181413A/AT1001
89457481|NCT02686034|Sham Comparator|gammaCore-S Sham|Treatment of up to 5 migraine attacks with the Sham gammaCore-S non-invasive vagus nerve stimulator device which delivers a mild electrical signal in the vicinity of the vagus nerve
89457482|NCT02685488|Active Comparator|Transcranial Ultrasound Power|Transcranial Ultrasound Power
89457483|NCT02685488|Sham Comparator|Transcranial Ultrasound Sham|Transcranial Ultrasound Sham. Unknown to both participants and experimenters, the ultrasound will not stimulate.
89457484|NCT03165032||High altitude pulmonary hypertension|Highlanders with high altitude pulmonary hypertension living above 2500 m.
89457485|NCT03165032||High altitude control|Healthy highlanders living above 2500 m.
89457486|NCT03165032||Low altitude control|Healthy lowlanders living below 1000 m.
89457487|NCT03166514|Experimental|Commercially Available Food Bar|62 g. Fitjoy Bar
89457488|NCT03166514|Placebo Comparator|Placebo|25 g. Dextrose
89457489|NCT04479800|Experimental|Treatment A - Fasting|No food prior to dosing
89457490|NCT04479800|Experimental|Treatment B - Fed|High-fat/high-calorie meal prior to dosing
89457491|NCT04479800|Experimental|Treatment C - Fed|Low-fat/low-calorie meal prior to dosing
89457492|NCT02533570|Experimental|Brentuximab vedotin|4 dose groups
89457493|NCT02533570|Placebo Comparator|Placebo|Matching placebo
89457494|NCT03106220|Active Comparator|home exercise|participate in home exercise program
89457495|NCT03106220|Placebo Comparator|standard care|encouraged to join physical therapy and walking goals
89201471|NCT00928629|Other|All Subjects|ABI Screening Test Population: Subjects of either sex, any race, with at least two of the specified CVD risk factors, with no overt cardiovascular disease.
89201472|NCT04005508||OSA (Watch PAT AHI >/= 15 events per hour)|Patients found to have OSA by an overnight sleep study
89457496|NCT02268448|Experimental|Clonidine|Clonidine will be given orally as a starting dose of 0.1 mg daily. The drug will be administered orally by the subject at bedtime daily for four weeks.
89457497|NCT02268448|Experimental|Naltrexone|Naltrexone will be given to each subject at an oral dose of 50 mg daily. Subjects will self-administer the drug at bedtime.
89457498|NCT05744570||Male anesthesiologist|The anesthesiologist gender defined by first name
89457499|NCT05744570||Female anesthesiologist|The anesthesiologist gender defined by first name
89457500|NCT03106064|Placebo Comparator|Usual Care Group|Intervention: Usual care
89457501|NCT03106064|Experimental|Intervention Group|Intervention:Promoting independence in self-care
89457502|NCT03106142|Other|Academic detailing visit arm|The GPs will receive an academic detailing visit by a medical visitor. GPs will receive information on the conservative evidence-based management of knee osteoarthritis with physiotherapy. The information will be summarized on a flyer for the GPs.
89457503|NCT03106142|No Intervention|control group|The two case vignettes will also be presented to GP who did not received the intervention.
89201473|NCT04005508||Non-OSA (Watch PAT AHI < 15 events per hour)|Patients found NOT to have OSA by an overnight sleep study
89201474|NCT00987376|Experimental|1|Prostate cancer patients
89201475|NCT00924339|Placebo Comparator|Rapeseed oil|Control-Group (n = 15) : Diet reduced in SFA, modified in fatty acid pattern. Only rapeseed oil should to be used for preparation of the meals (baking, frying, in salad, and as spread.
89457504|NCT03105908|Other|Treatment|Internet delivered Acceptance and Commitment therapy, supported by a psychologist/psychology student under supervision.
89457505|NCT03105908|Other|Waiting list control condition|Participants receive no treatment for ten weeks, i.e. waiting list condition. Following post-assessment, the control condition receive unguided iACT (i.e. the same content and structure as iACT but without systematic therapist communication).
89457506|NCT03036839|Experimental|LDV/SOF for 8 weeks|Treatment-naive participants with genotype 1 without cirrhosis will receive LDV/SOF for 8 weeks
89457507|NCT03036839|Experimental|LDV/SOF for 12 weeks|Treatment-experienced participants with genotype 1 and treatment-naive or treatment-experienced participants with genotype 2 (Taiwan only), 4, 5 and 6 without cirrhosis will receive LDV/SOF for 12 weeks
89457508|NCT03036839|Experimental|LDV/SOF for 24 weeks|Participants with compensated cirrhosis will receive LDV/SOF for 24 weeks
89457509|NCT05317871||Lewy Body Spectrum Diseases|
89457510|NCT05317871||Progressive Supranuclear Palsy|
89457511|NCT05317871||Corticobasal Syndrome|
89457512|NCT05317871||Frontotemporal Degeneration|
89457513|NCT03619421|Experimental|Supplement with food|Zinc supplement to be taken at time of breakfast consumption
89457514|NCT03619421|Experimental|supplement prior to food|Zinc supplement to be taken 30-min before breakfast consumption
89457515|NCT05123885||Experimental:|Adult patients who benefited, between the start of 2015 and January 1, 2021, from a LifeVest after a myocardial infarction, followed by the implantation of an ICD before March 1, 2021.
89457516|NCT03904199|Experimental|Basal-Prandial-Correctional Insulin Regimen|Participants hospitalized in the medical, hematologic, or bone marrow transplant units will begin with basal long-acting insulin glargine with correctional and prandial rapid-acting insulin that is personalized and precise, to achieve target blood glucose levels with daily assessments during hospitalization. Adjustments will be made in real time to reach the target range.
89457517|NCT03904199|Active Comparator|Standard of Care Insulin Regimen|Participants hospitalized in the medical, hematologic, or bone marrow transplant units' blood sugar levels will be managed with sliding scale insulin or a combination of long- and short-acting insulin as per standard of care.
89457518|NCT05654987||pregnat women|refugee internal or external pregnant women from Ukraine
89457519|NCT05654987||Post partum women|refugee internal or external women during postpartum period (one year after give birth) from Ukranie
89457520|NCT05022173|Experimental|Helmet NIV|Patients randomized to the intervention arm will receive NIV through a phthalate free helmet (CaStar, STARMED) via an ICU ventilator in pressure support (PS) mode.
89457521|NCT05022173|Active Comparator|Facemask NIV|Patients in the control arm will be randomized to the traditional facemask interface. The facemask group will use the same ICU ventilator being used for the helmet group.
89201476|NCT00924339|Experimental|Soy protein diet|Intervention-Group (n = 15): Fat- modified dietary regime and a minimum amount of soy protein: 0,25 g/ kg BW/d
88940853|NCT01853852|Placebo Comparator|Placebo|placebo
88940854|NCT01853865|No Intervention|Follow-up|Patients in this arm attend regular follow-up examinations, as is the current standard, at the department of gynecology following surgery.
88940855|NCT01853865|Experimental|Self-referral|Instead of regular follow-up examinations, this group is carefully instructed in alarm symptoms that require contact with a physician.
89457522|NCT01286207|Experimental|Rizatriptan 5 mg|Rizatriptan 5 mg orally once for treatment of index migraine attack, followed by two additional doses within 24 hours of the initial dose for migraine recurrence(s)
89457523|NCT01286207|Experimental|Rizatriptan 10 mg|Rizatriptan 10 mg orally once for treatment of index migraine attack, followed by two additional doses within 24 hours of the initial dose for migraine recurrence(s)
89457524|NCT01286207|Active Comparator|Standard Care|Standard care at onset of migraine attack
89457525|NCT02236000|Experimental|Neratinib and T-DM1|
89457526|NCT04460014|Experimental|Simple cognitive task intervention|"Session 1: A memory cue followed by playing the computer game Tetris (e.g. on own smartphone) with mental rotation instructions.~Options to engage in self-administered/guided booster sessions per intrusive memory."
89457527|NCT04460014|Placebo Comparator|Attention placebo|Session 1: Digital activity for same amount of time (e.g. listening to podcast on own smartphone).
89457528|NCT05408026|Experimental|Combination of Pomalidomide, Bortezomib, Low-Dose Dexamethasone, and Daratumumab|Combination of Pomalidomide, Bortezomib, Low-Dose Dexamethasone, and Daratumumab
89457529|NCT04423510||Recurrent pilonidal sinus|Postoperative recurrent pilonidal sinus disease
89457530|NCT00968201|Experimental|1|Montelukast
88940856|NCT01853891|No Intervention|usual condition|sleep in usual room light condition for 5 nights
88940857|NCT01853891|Experimental|dLAN|sleep with dim light at night for 5 nights
88940858|NCT01853904|Other|Channel Suction first|This arm is for patients who will receive channel suction first to obtain the specimen then syringe suction to obtain the specimen.
88940859|NCT01853904|Other|Syringe Suction first|This arm is for patients who will receive syringe suction first to obtain the specimen then channel suction to obtain the specimen.
89201477|NCT00987454|Active Comparator|Erythropoietin|Epoetin alfa 40,000 international units will be given by subcutaneous injection to eligible patients, allocated to the treatment arm, on Study Days 1; 8 and15 during the intensive care unit stay.
89201478|NCT00987454|Placebo Comparator|Placebo|Sodium Chloride 0.9% in m/L will be given by subcutaneous injection to eligible patients, allocated to the placebo arm, on Study Days 1; 8 and15 during the intensive care unit stay.
88940860|NCT01853917||questionaires and structured interview|HIV infected women who are pregnant and receiving care in Harris County Hospital District single arm study Single arm study
88940861|NCT01853943||Patent radial artery|Patient with patent radial artery after the percutaneous coronary procedure
88940862|NCT01853943||Occluded radial artery|Patients with occluded radial artery after the procedure
88940863|NCT01853956|Experimental|A (reference)/ B (test)|initial administration of reference and cross-over to test
88940864|NCT01853956|Experimental|B (test)/ A (reference)|initial administration of test and cross-over to reference
88940865|NCT01853969||Patients who have carpal tunnel release surgery|
88940866|NCT01854008|Experimental|rehabilitation program more the urban circuit|One group, the urban circuit group (UCG), received a triptych that included urban walking circuits,the remaining patients formed the non circuit group (NCG).These circuits can be obtained on the website http://www.mataro.cat/web/portal/ca/salut/salut_publica/itineraris/index
89457531|NCT00968201|Placebo Comparator|2|Placebo
89457532|NCT00967577|Experimental|J591|
89457533|NCT00943397|Experimental|1|Montelukast
89457534|NCT00943397|Active Comparator|2|Usual Care
89457535|NCT00935519|Other|ceramic bearing|Survival rate of THA with use of the new alumina-zirconia(4th generation ceramic bearing) composite ceramic bearing at a minimum of 10 years follow-up.
89457536|NCT00817817|Experimental|Group 1|
89457537|NCT00817817|Experimental|Group 2|
89457538|NCT05303675|Experimental|Intervention Group|"Preoperative: An introductory information form will be filled out, and a lymphedema self-care and exercise booklet will be given.~Postoperative: Patients will be applied Progressive Upper Limb Exercises and Muscle Relaxation Training (PULE-MRT), lymphedema upper extremity circumference measurement, and symptom alert model until discharge, and Muscle Relaxation Training will continue until discharge.~Post-Discharge: They will be asked to record a diary at home. PULE-MRT will continue until day 15. The 15-day exercise program will continue for up to 3 months. Follow-up will be made by telephone according to the symptom alert model at the 1st, 2nd, and 3rd months, and at the end of the 3rd month, the breast cancer-related lymphedema self-care scale will be administered."
89457539|NCT05303675|No Intervention|Control Group|"Preoperative: Introductory information form will be filled out. Postoperative: Standard nursing care will be applied to the patients, lymphedema upper extremity circumference measurement and symptom alert model follow-up form will be applied.~Post-Discharge: Lymphedema upper extremity circumference measurement will be explained to the patients before discharge, and they will be asked to record the 1st, 2nd, and 3rd months at home. Patients will be followed up by telephone according to the symptom alert model at the 1st, 2nd, and 3rd months, and at the end of the 3rd month, the breast cancer-related lymphedema self-care scale will be administered."
89457540|NCT00702845|Experimental|corifollitropin alfa 100 µg|Participants received a single subcutaneous (SC) injection of corifollitropin alfa 100 μg (Org 36286) on Day 2 or 3 of the menstrual cycle and daily placebo-recombinant Follicle Stimulating Hormone (recFSH) injections (7 total) from Stimulation Day 1 up to and including Stimulation Day 7. Participants also received open-label recFSH (up to 200 IU/day) from Stimulation Day 8 onwards, up to and including Day of Human Chorion Gonadotropin (hCG) administration. Participants also received Gonadotropin Releasing Hormone (GnRH) antagonist ganirelix (0.25 mg) once daily SC starting on Stimulation Day 5 up to and including the Day of hCG (10,000 or 5,000 IU/USP). Participants also received progesterone (at least 600 mg/day vaginally or 50 mg/day by intramuscular [IM] injection), starting on day of oocyte pick-up (OPU) and continuing for at least 6 weeks or up to menses.
89457541|NCT00702845|Active Comparator|recFSH 150 IU|Participants in the reference group received a single SC injection of placebo-corifollitropin alfa administered on Day 2 or 3 of the menstrual cycle and daily SC recFSH 150 IU injections (7 total) from Stimulation Day 1 up to and including Stimulation Day 7. Participants also received open-label recFSH (up to 200 IU/day) from Stimulation Day 8 onwards, up to and including the day of hCG (10,000 or 5,000 IU/USP) administration. Participants also received the GnRH antagonist ganirelix (0.25 mg) once daily SC starting on Stimulation Day 5 up to and including the Day of hCG. Participants also received progesterone (at least 600 mg/day vaginally or 50 mg/day IM), starting on the day of OPU and continuing for at least 6 weeks or up to menses.
89457542|NCT00647933|Experimental|Org 36286 15 μg + Lyndiol®|After a pill-free period of 7 days, participants took 1 oral tablet of Lyndiol® (50 μg ethinylestradiol + 2.5 mg lynestrenol) daily for a total period of at least 6 weeks to suppress endogenous gonadotropin secretion. After 3 weeks of Lyndiol® intake, participants received a single subcutaneous dose of Org 36286 15 μg.
89457543|NCT00647933|Experimental|Org 36286 30 μg + Lyndiol®|After a pill-free period of 7 days, participants took 1 oral tablet of Lyndiol® (50 μg ethinylestradiol + 2.5 mg lynestrenol) daily for a total period of at least 6 weeks to suppress endogenous gonadotropin secretion. After 3 weeks of Lyndiol® intake, participants received a single subcutaneous dose of Org 36286 30 μg.
89457544|NCT00647933|Experimental|Org 36286 60 μg + Lyndiol®|After a pill-free period of 7 days, participants took 1 oral tablet of Lyndiol® (50 μg ethinylestradiol + 2.5 mg lynestrenol) daily for a total period of at least 6 weeks to suppress endogenous gonadotropin secretion. After 3 weeks of Lyndiol® intake, participants received a single subcutaneous dose of Org 36286 60 μg.
89457545|NCT00647933|Experimental|Org 36286 120 μg + Lyndiol®|After a pill-free period of 7 days, participants took 1 oral tablet of Lyndiol® (50 μg ethinylestradiol + 2.5 mg lynestrenol) daily for a total period of at least 6 weeks to suppress endogenous gonadotropin secretion. After 3 weeks of Lyndiol® intake, participants received a single subcutaneous dose of Org 36286 120 μg.
89457546|NCT00641771|Experimental|1|MK0217A
89457547|NCT00641771|Placebo Comparator|2|Placebo
89457548|NCT05008445|Experimental|LM-102 Dose Escalation Level 1, 3mg/kg|"The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.~first dose: 3mg/kg, Q3W;"
89457549|NCT05008445|Experimental|LM-102 Dose Escalation Level 2, 10mg/kg|"The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.~Second dose: 10mg/kg, Q3W;"
89457550|NCT05008445|Experimental|LM-102 Dose Escalation Level 3, 20mg/kg|"The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.~Third dose: 20mg/kg, Q3W;"
89016617|NCT03435003|Experimental|Intervention Arm|"A) Pre-operatively: aprepitant 80 mg oral capsule and scopolamine transdermal patch.~B) Intra-operatively: total intravenous anesthesia (TIVA) will be maintained with IV infusions of propofol, and dexmedetomidine infusion or intermittent bolus dosing of fentanyl after induction. Sugammadex (2-4 mg/Kg IV) will be used for reversal of neuromuscular blockade in both groups. A single dose of dexamethasone 8 mg IV will be administered after induction, and a single dose of ondansetron 4 mg IV will be administered approximately 20 minutes prior to the end of operation.~C) Post-operatively: Scheduled ondansetron and Raglan every 6 hours, using Compazine as a rescue medication."
89016618|NCT03435003|Active Comparator|Control Arm|"A) Pre-operatively: No intervention~B) Intra-operatively: inhalation anesthetics (sevoflurane or desflurane) and intermittent opioid boluses will be used for maintenance of anesthesia, as standard practice in the institution of the investigators and across the country. PONV prevention measures in the control group will be limited to dexamethasone 8 mg and ondansetron 4 mg.~C) Post-operatively: Scheduled ondansetron and Raglan every 6 hours, using Compazine as a rescue medication."
89457551|NCT05008445|Experimental|LM-102 Dose Escalation Level 4, 30mg/kg|"The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.~Four dose: 30mg/kg, Q3W;"
89201479|NCT03986983|Experimental|Experimental group of Aerobic exercise|The participants perform the Aerobic exercise protocol - The entire protocol was monitored through the Polar® brand heart rate monitor and watch.
89457552|NCT05008445|Experimental|LM-102 Dose Escalation Level 5, 40mg/kg|"The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.~Five dose: 40mg/kg, Q3W;"
89016621|NCT03377088|Placebo Comparator|Almond Oil|Patients will be given Almond Oil for inhalation on cotton balls as a control. Almond Oil has been shown to act as a placebo when compared to our variable, Rosa Damascena oil. To ensure blinding, this arm will act to always deliver a scent to a patient, blinding them to whether they are receiving a known aromatherapy or a common scent.
89457553|NCT05008445|Experimental|LM-102 (RP2D-1) combined with SOC Dose Escalation|During the dose escalation of LM-102 combined with SOC,the next lower dose groups (RP2D-1) of LM-102 monotherapy's RP2D will be adopted as the starting dose.
89016622|NCT03377088|Experimental|Rose Oil|Patients will be given Rosa Damascena oil on cottons balls as a variable. This oil has been shown to significantly lower acute pain levels on the visual analog pain scale when compared to placebo of distilled water or Almond Oil.
89016623|NCT03367546|Experimental|rATG, FLU/CY/TBI, & Thiotepa|Anti-Thymocyte Globulin - Rabbit (rATG), Fludarabine (Fludara), Cyclophosphamide (Cytoxan, Neosar), Total Body Irradiation (TBI), & Thiotepa
89016624|NCT03365362|Experimental|Long-Term Varenicline|Participants will receive 24 weeks of varenicline at standard doses (0.5 mg/day for days 1 to 3, 0.5 mg twice daily for days 4 to 7, then 1 mg twice daily)
89016625|NCT03365362|Active Comparator|Short-Term Varenicline|Participants will receive 12 weeks of varenicline at standard doses (0.5 mg/day for days 1 to 3, 0.5 mg twice daily for days 4 to 7, then 1 mg twice daily), followed by matching placebo twice daily through week 24.
89016626|NCT03365362|Experimental|Directly Observed Therapy|Participants receiving directly observed therapy (DOT) will receive varenicline from opioid treatment program nurses at the same time as they receive methadone, as well as individually packaged take-home doses for self administration on evenings/weekends.
89016627|NCT03365362|Active Comparator|Self Administered Therapy|Patients receiving varenicline self administered therapy (SAT) will self-administer all varenicline doses.
89016628|NCT03329404|Experimental|Mirasol Red Blood Cells (MIR RBCs)|MIR RBCs: RBCs will be derived from WB collected in CPD solution, treated with the Mirasol System for WB, LR, and stored in AS-3 for ≤ 21 days at 1-6°C
89016629|NCT03329404|Active Comparator|Reference Red Blood Cells (REF RBCs)|Reference Red Blood Cells (REF RBCs); LR apheresis RBCs or WB-derived RBCs will be per site standard inventory
89016630|NCT03311633|Experimental|3 week percutaneous pinning group|Percutaneous pinning time will be for three weeks and short cast immobilization for six weeks.
89016631|NCT03311633|Active Comparator|6 week percutaneous pinning group|Percutaneous pinning time will be for six weeks and also short cast immobilization.
89457554|NCT05008445|Experimental|LM-102 (RP2D) combined with SOC Dose Escalation|During the dose escalation of LM-102 combined with SOC,(If applicable) LM-102 monotherapy's RP2D will be adopted as the starting dose.
89457555|NCT03821831||Continuous Positive Airway Pressure|This group consists of consenting patients and their parents who choose Continuous Positive Airway Pressure (CPAP). The CPAP is a type of therapy that applies mild air pressure to a person's upper airway to keep their airway open so that they can breathe normally while they sleep.
89457556|NCT03821831||Orthodontic Intervention|This group consists of consenting patients and their parents who choose orthodontic intervention will be seen by participating orthodontists who will determine types of orthodontic intervention; mandibular advancement devices or rapid maxillary expansion devices, or Class III mid face advancement with skeletal anchored headgear. In this group, the patients will also receive a biometric shirt to use once every two weeks, to monitor their sleep during the study.
89016632|NCT03288220||Healthy volunteers|Healthy volunteers age 50 and older
89016633|NCT03288220||Stroke patients|Stroke patients aged 18 and older
89016634|NCT03283917|Experimental|Treatment (daratumumab, ixazomib, dexamethasone)|Participants receive daratumumab IV over 3.5-6.5 hours on days 1, 8, 15, and 22 of courses 1-2, on days 1 and 15 of courses 3-6, and on day 1 of courses 7-12. Participants also receive ixazomib PO on days 1, 8, and 15, and dexamethasone IV over 15 minutes or PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unaccepted toxicity.
89016635|NCT03275064|Experimental|LNA043 40 mg Part B|LNA043 40 mg Part B
89016636|NCT03275064|Experimental|LNA043 20 mg Part B|LNA043 20 mg Part B
89016637|NCT03275064|Experimental|LNA043 20 mg Part A|LNA043 20 mg Part A
89016638|NCT03275064|Placebo Comparator|Placebo Part A|Placebo Part A
89016639|NCT03275064|Placebo Comparator|Placebo Part B|Placebo Part B
89016640|NCT03271762|Experimental|MITRACLIP NT, MITRACLIP NTR/XTR, MITRACLIP G4NT/XT, MITRACLIP G4NTW/XTW Device|MitraClip NT System includes a MitraClip device, a steerable guide catheter and a MitraClip delivery system
89016641|NCT03271762|Active Comparator|cardiac surgery|mitral valve repair in first intervention, valve replacement if repair not feasible
89016642|NCT03252795|Experimental|Uterus transplantation|
89016643|NCT03238248|Experimental|Pevonedistat and Azacitidine|"Participants will receive Azacitidine (via an injection under the skin, or via an intravenous infusion (IV bag) on days 1, 2, 3, 4 and 5 of each 28-day cycle.~Participants will receive Pevonedistat (through a vein in the arm) on Days 1, 3 and 5 of each 28-day cycle."
89457557|NCT03821831||Control|This group consists of consenting patients and their parents who choose to remain untreated. In this group, the patients will also receive a biometric shirt to use once every two weeks, to monitor their sleep during the study.
89457558|NCT05096585|Placebo Comparator|normal sleep|Subjects will go to sleep at their normal bedtime and normal sleep duration (7-9 hr)
89457559|NCT05096585|Experimental|delayed bedtime sleep restriction|Subjects will go to sleep at 2 hr later than their normal bedtime
89457560|NCT05096585|Experimental|early waking sleep restriction|Subjects will wake up 2 hr earlier than their normal wake time
89457561|NCT00519857|Active Comparator|1|Tibolone
89457562|NCT00519857|Placebo Comparator|2|Placebo
89457563|NCT00431093|Experimental|1|tibolone
89457564|NCT00431093|Active Comparator|2|low-dose estradiol/noresterone
89457565|NCT04051385|Active Comparator|stage II grade B periodontitis|"GCF and serum samples were taken before and after treatment from stage II grade B periodontitis patients.~Intervention: Non- surgical periodontal treatment (SRP and oral hygiene instructions)"
89457566|NCT04051385|Active Comparator|stage III grade B periodontitis|"GCF and serum samples were taken before and after treatment from stage III grade B periodontitis patients.~Intervention: Non- surgical periodontal treatment (SRP and oral hygiene instructions)"
89457567|NCT04051385|Active Comparator|gingivitis|"GCF and serum samples were taken before and after treatment from gingivitis patients.~Intervention: Non- surgical periodontal treatment (Scaling and oral hygiene instructions)"
88940867|NCT01854008|Experimental|rehabilitation program non circuit group .|One group, the urban circuit group (UCG), received a triptych that included urban walking circuits,the remaining patients formed the non circuit group (NCG)
88940868|NCT01854021|Experimental|inhalational anesthesia|inhalational anesthesia
88940869|NCT01854021|Experimental|combined intravenous-inhalational anesthesia|combined intravenous-inhalational anesthesia
88940870|NCT01854021|Experimental|intravenous anesthesia|intravenous anesthesia
88940871|NCT01854060||irritable bowel syndrome|All new cases of clinical diagnosis of irritable bowel syndrome
88940872|NCT01854073|Active Comparator|Group A|Group A, will receive injection Hyoscine butyl bromide 20 mg first dose at the time of amniotomy, and second dose 2 hours after.
88940873|NCT01854073|Placebo Comparator|Group B|Group B, will receive normal saline same volume first dose at the time of amniotomy, and second dose 2 hours after.
89457568|NCT04051385|Placebo Comparator|periodontally healthy|GCF and serum samples were taken at baseline from periodontally healthy individuals.
89457569|NCT05283941|Experimental|Pistachio Group|The pistachio group will receive pistachio nuts in 2-ounce packs. This group will consume one pack every day over the course of the 12-week study.
89457570|NCT05283941|No Intervention|Control (Usual Diet) Group|The control group will not receive pistachio nuts. They will be asked to make no changes and continue to eat their regular diet.
89457571|NCT01302847|Experimental|Cohort I|Adolescents 12 to younger than 18 years of age who received DTG film-coated tablets
89457572|NCT01302847|Experimental|Cohort IIA|Children 6 to younger than 12 years of age who received DTG film-coated tablets
88940874|NCT01854086||Postmenopausal women|Postmenopausal women treated with bisphosphonates
88940875|NCT01854099|Active Comparator|5 Day TMZ with PEP-CMV on Day 6-8|Standard TMZ (200 mg/m2/day x 5 days) with PEP-CMV vaccination on Day 6-8 of each monthly TMZ cycle
88940876|NCT01854099|Active Comparator|5 day TMZ with vaccine on day 22-24|Standard TMZ (200 mg/m2/day x 5 days) with vaccination on Day 22-24 of each monthly TMZ cycle
88940877|NCT01854099|Active Comparator|21 day TMZ wtih vaccine on day 22-24|Dose-intensified TMZ (100 mg/m2/day x 21 days) with vaccination on day 22-24 of each monthly TMZ cycle
88940878|NCT01854112||T-cell lymphoma|
88940879|NCT01854125|Active Comparator|autologous bone marrow mesenchymal stem cells transplantation|Every patient is given 1x106 MSCs per kg infused via liver artery
88940880|NCT01854125|Active Comparator|mesenchymal stem cells transplantation|autologous bone marrow mesenchymal stem cells transplantation
88940881|NCT01854125|Experimental|stem cells transplantation|autologous bone marrow mesenchymal stem cells transplantation
88940882|NCT01854164|Experimental|HGE(hydrolyzed ginseng extract)|HGE capsules(2cap/d, 960mg/d) for 8 weeks.
88940883|NCT01854164|Placebo Comparator|Placebo|Placebo for 8 weeks
88940884|NCT01854190||Resistant hypertension|"Patients with uncontrolled blood pressure despite 3 medications, including diuretic.~Endothelial function assessed by peripheral arterial tonometry (PAT) by EndoPAT and the OSA diagnosis also through PAT, using the portable device WatchPAT."
88940885|NCT01854190||Controlled hypertension|Patients with controlled blood pressure by medications. These drugs are the same used in both groups.
88940886|NCT01854203|Experimental|IInductive chemotherapy + concurrent cisplatin and IMRT|Patients receive Gemcitabine (800mg/m2 on day 1,8) and cisplatin (80mg/m2 on day 1)of a 21 day cycle, patients received four cycles chemotherapy before the radiotherapy, then receive radical radiotherapy with IMRT and cisplatin (30 mg/m2，on day 1) repeated every weeks for 6 cycles during radiotherapy.
88940887|NCT01854203|Experimental|Inductive chemotherapy + IMRT|Patients receive Gemcitabine (800mg/m2 on day 1,8) and cisplatin (80mg/m2 on day 1)of a 21 day cycle, patients received four cycles chemotherapy before the radiotherapy, then receive radical radiotherapy with IMRT.
88940888|NCT01854216|Experimental|Rotigotine in Japanese subjects|Repeated-Dose application of 1,2, and 4 mg / 24 hours Rotigotine in healthy Japanese subjects; Transdermal patch over 24 hours
88940889|NCT01854216|Experimental|Rotigotine in Caucasian subjects|Multiple-Dose application of 1, 2, and 4 mg / 24 hours Rotigotine in healthy Caucasian subjects; Transdermal patch over 24 hours
88940890|NCT01854307|Experimental|Pneumoperitoneum and SVV/PPV|
88940891|NCT01854320|Experimental|Acceptance-based treatment|Behavioral therapy for weight loss focusing on acceptance-based cognitive strategies and techniques.
88940892|NCT01854320|Active Comparator|Standard behavioral treatment|"Standard behavioral therapy for weight loss, the gold standard treatment."
88940893|NCT01854333|Other|ADOS module 1-4, ADI-R|Individuals recruited within clinical services in child psychiatry and child medicine in Stockholm county and Lund for whom assessments with ADOS module 1-4 or ADI-R are appropriate.
88940894|NCT01854346|Experimental|Social skills group training KONTAKT|N= 144 participants are offered group training KONTAKT. The intervention includes 12 (brief intervention) and 24 (long intervention) sessions.
88940895|NCT01854346|No Intervention|Control group (TAU), the usual intervention / treatment|N = 144 participants are received treatment as usual (pharmacological therapy, family therapy, Cognitive behavioral therapy etc).
89457573|NCT01302847|Experimental|Cohort IIB|Children 6 to younger than 12 years of age who received DTG granules for suspension
89457574|NCT01302847|Experimental|Cohort III|Children 2 to younger than 6 years of age who received DTG granules for suspension
89457575|NCT01302847|Experimental|Cohort IV|Children 6 months to younger than 2 years of age who received DTG granules for suspension
89457576|NCT01302847|Experimental|Cohort III-DT|Children 2 to younger than 6 years of age who received DTG dispersible tablets
89457577|NCT01302847|Experimental|Cohort IV-DT|Children 6 months to younger than 2 years of age who received DTG dispersible tablets
89457578|NCT01302847|Experimental|Cohort V-DT|Infants 4 weeks to younger than 6 months of age who received DTG dispersible tablets
89457579|NCT03619577|Experimental|Sequential training-high frequency|The participants of HF will receive a total of 36 training sessions, and each session will contain 90-105 minutes of training. The participants in this group will first perform 45-55 minutes of physical exercise followed by 45-50 minutes of cognitive training. The participants in this group participate in multimodel exercise programs including aerobic exercise, balance, and strength training. The entire program will contain 5-10 minutes of warm-up, 35-40 minutes of physical exercise, and 5 minutes of cool-down. Then, the participants will practice tasks that involve the abilities of visuospatial processing, attention, memory, language, and/or executive functions for 45-50 minutes.
89457580|NCT03619577|Experimental|Sequential training-low frequency|The participants of LF will receive a total of 12 training sessions, and each session will contain 90-105 minutes of training. The participants in this group will first perform 45-55 minutes of physical exercise followed by 45-50 minutes of cognitive training. The participants in this group participate in multimodel exercise programs including aerobic exercise, balance, and strength training. The entire program will contain 5-10 minutes of warm-up, 35-40 minutes of physical exercise, and 5 minutes of cool-down. Then, the participants will practice tasks that involve the abilities of visuospatial processing, attention, memory, language, and/or executive functions for 45-50 minutes.
89457581|NCT03039569|Experimental|Text messaging|Participants will receive 3 messages weekly consisting of nutrition education and diabetes self-management information and skills for 3 months (12 weeks).
89457582|NCT03039569|No Intervention|Control|Participants will not receive text message intervention. This is the measurement-only group
89457583|NCT03673735|Experimental|Experimental Arm|Patients will receive 1 infusion of 1500 mg Durvalumab within 1 week prior to concurrent chemoradiotherapy. Chemoradiation should start within 6 weeks after surgery and within 1 week maximum of the induction phase. Radiation will consist of 33 fractions over 6 weeks for a total of 66 Gy. Chemotherapy will consist of cisplatin 100 mg/m2 given on days 1, 22 and 43 of radiotherapy. Maintenance phase with Durvalumab will begin within 1 to 28 days maximum after the end of radiotherapy and will consist of 6 doses administered every 4 weeks.
89457584|NCT03673735|Placebo Comparator|Control arm|Patients will receive 1 infusion of placebo within 1 week prior to concurrent chemoradiotherapy. Chemoradiation should start within 6 weeks after surgery and within 1 week maximum of the induction phase. Radiation will consist of 33 fractions over 6 weeks for a total of 66 Gy. Chemotherapy will consist of cisplatin 100 mg/m2 given on days 1, 22 and 43 of radiotherapy. Maintenance phase with placebo will begin within 1 to 28 days maximum after the end of radiotherapy and will consist of 6 doses administered every 4 weeks.
89457585|NCT02738775|Experimental|Cohort 1|Participant received intravenous (IV) infusion of ublituximab 150 milligrams (mg)/4 hour (hr) on Day 1, 450 mg/3 hr on Day 15 and 450 mg/1.5 hr on Week 24. Some participants initially received placebo IV infusion /4 hr on Day 1 and /3 hr on Day 15 before receiving ublituximab.
89457586|NCT02738775|Experimental|Cohort 2|Participant received IV infusion of ublituximab 150 mg/4 hr on Day 1, 450 mg/1.5 hr on Day 15 and 450 mg/1 hr on Week 24. Some participants initially received placebo IV infusion /4 hr on Day 1 and /1.5 hr on Day 15 before receiving ublituximab.
89457587|NCT02738775|Experimental|Cohort 3|Participant received IV infusion of ublituximab 150 mg/4 hr on Day 1, 450 mg/1 hr on Day 15 and 600 mg/1 hr on Week 24. Some participants initially received placebo IV infusion /4 hr on Day 1 and /1 hr on Day 15 before receiving ublituximab.
89457588|NCT02738775|Experimental|Cohort 4|Participant received IV infusion of ublituximab 150 mg/3 hr on Day 1, 600 mg/1 hr on Day 15 and 600 mg/1 hr on Week 24. Some participants initially received placebo IV infusion /3 hr on Day 1 and /1 hr on Day 15 before receiving ublituximab.
89457589|NCT02738775|Experimental|Cohort 5|Participant received IV infusion of ublituximab 150 mg/2 hr on Day 1, 600 mg/1 hr on Day 15 and 600 mg/1 hr on Week 24. Some participants initially received placebo IV infusion /2 hr on Day 1 and /1 hr on Day 15 before receiving ublituximab.
89016644|NCT03214510|Experimental|Arm I (TAE)|Patients undergo placement of thoracic epidural catheter before surgery. Patients receive hydromorphone hydrochloride and bupivacaine via thoracic epidural catheter every 10 minutes or 3 hours as needed. Patients may receive fentanyl and bupivacaine or plain bupivacaine via thoracic epidural catheter.
88940896|NCT01854372|Experimental|R-HCVAD and R-MC Chemotherapy|"R-HCVAD - Rituximab (375 mg/m2), Cyclophosphamide (300 mg/m2), Mesna (600 mg/m2), Doxorubicin (50 mg/m2), Vincristine (2 mg total), Dexamethasone (40 mg total), Methotrexate (12 mg), Cytarabine (100mg).~R-MC -Rituximab (375 mg/m2),Methotrexate (200 mg/m2 - 800mg/m2), Cytarabine (3000mg/m2), Leucovorin (15mg - 50mg)."
88940897|NCT01854398|Experimental|CPAP group|
88940898|NCT01854398|Sham Comparator|sham-CPAP group|
88940899|NCT01854411||analgesic dose measure|breastfeeding mother who will take analgesics
89457590|NCT02738775|Experimental|Cohort 6|Participant received IV infusion of ublituximab 150 mg/1 hr on Day 1, 600 mg/1 hr on Day 15 and 600 mg/1 hr on Week 24. Some participants initially received placebo IV infusion /1 hr on Day 1 and /1 hr on Day 15 before receiving ublituximab.
88940900|NCT01854424||ARDS|Ventilated patients with ARDS criteria (Berlin criteria) will be recruited in 3 ICU (2 from Bichat Hospital and 1 from Tenon Hospital, Paris) during the first 48 hours of their evolution. The patients will considered in 2 groups during analysis by taking into account their vital status at day-28 of inclusion.
88940901|NCT01854437||Mg Oxide|Mg Oxide (Mg®, 21st Century®) 250 mg orally for 4 weeks
88940902|NCT01854437||placebo|placebo 1 tab TDS
88940903|NCT01854450|Experimental|Asymmetrical Lateral Decubitus|Women in labor are postured in pronounced lateral decubitus (side opposite to the back of the fetus), with the inferior leg in extension, and the superior leg in hyperflexion
88940904|NCT01854450|Other|control|usual obstetrical care
88940905|NCT01854463|Experimental|Vitamin D3|25-hydroxy vitamin d 2000 IU and elemeental calcium 200mg daily for 24 weeks
88940906|NCT01854463|Placebo Comparator|placebo|administered elemental calcium 200mg daily for 24 weeks
88940907|NCT01854476|Experimental|Tranexamic acid|pad-gauze with tranexamic acid (Hemostopan™)
88940908|NCT01854476|Placebo Comparator|Pad gauze|Pad gauze with no tranexamic acid
89457591|NCT02314533|Experimental|fenofibrate|Fenofibrate 200mg capsule will be administered orally with breakfast once daily according to the Chinese prescription information of Lipanthyl, while previous type and dose of statin will be administered in the evening.
89457592|NCT02317965||Pregnant Women|"Pregnant women who are scheduled to undergo an amniocentesis or chorionic villus sampling (CVS) procedure~Intervention: Single Maternal blood draw of 20mL"
89457593|NCT03502395|Active Comparator|Group I|Patients were received intravenous 1 mg/kg of 2 % lidocaine as a loading dose (just before induction of anesthesia) then received 2mg/kg /h lidocaine as maintenance dose (with maximum of 200 mg/h) till the end of the operation (skin closure).
89457594|NCT03502395|Placebo Comparator|Group II|A standardized equal volume of intravenous bolus dose of normal saline was given as loading dose then normal saline was administered on an equal rate of infusion.
89457595|NCT02308995|Experimental|Cystectomy using barbed sutures|Endometrioma bed is sutured with barbed sutures
89457596|NCT02308995|Active Comparator|Cystectomy using conventional sutures|Endometrioma bed is sutured with conventional sutures
89457597|NCT02318043|Active Comparator|AMP-BPT|Methods of AMP-BPT, by applying dosimeters, resembled that reported previously [see references 21-25]. Briefly, dilutions were delivered via nebulizers (output: 160 μl/min) using automated APS pro system (JAEGER, Hochburg, Germany). Inhalation challenge with normal saline served as control step. Challenge steps were proceeded if FEV1 fall <15% and restored to <10% within 1 minute. Subsequent inhalation challenges were performed at 1-minute intervals, and ceased when FEV1 fell by ≥20%. Salbutamol was administered via spacer (Volumatic, Allen & Hanbury's, UK). Spirometry was reexamined at minutes 3, 5, 10 and thereafter, to ensure safety, before discharge.
89457598|NCT02318043|Active Comparator|His-BPT|Methods of His-BPT, by applying dosimeters, resembled that reported previously [see references 21-25]. Briefly, dilutions were delivered via nebulizers (output: 160 μl/min) using automated APS pro system (JAEGER, Hochburg, Germany). Inhalation challenge with normal saline served as control step. Challenge steps were proceeded if FEV1 fall <15% and restored to <10% within 1 minute. Subsequent inhalation challenges were performed at 1-minute intervals, and ceased when FEV1 fell by ≥20%. Salbutamol was administered via spacer (Volumatic, Allen & Hanbury's, UK). Spirometry was reexamined at minutes 3, 5, 10 and thereafter, to ensure safety, before discharge.
89457599|NCT02309073||women with a regular indication for ART|In the present proposal we are aiming to include all normo-ovulatory women with a regular indication for ART.
89457600|NCT02309073||women undergoing donor insemination treatment|potential normal fertile control group
89457601|NCT05277545|Experimental|The effect of teknology addiction training on the experimental group|The arm explanations for which the analyzes of the research have not been completed yet cannot be made.
89457602|NCT05277545|Active Comparator|Comparison of the experimental group and control group on technology addiction|The arm explanations for which the analyzes of the research have not been completed yet cannot be made.
89457603|NCT03502317|Experimental|Prehabilitation Study Arm|Patients will participate in a two-pronged prehabilitation strategy - physical prehabilitation and psychological prehabilitation. Prehabilitation will last from a minimum of 21 days to a maximum of 42 days before a patient's clinically indicated surgery.
89457604|NCT03502317|No Intervention|Usual Care Study Arm|No specific exercises or stress reduction techniques are prescribed and the patient will be counseled to continue their current level of activity, and will be given the information on exercise as outlined in the Cancer Care Ontario guidelines. Patients in the Usual Care arm will also be given the same Fitbit activity tracker as patients in the Prehabilitation arm in order to eliminate the activity tracker as an intervention itself and to be able to track the activity (steps) for comparison. Patients in the Usual Care arm will be required to wear their Fitbit activity tracker from the day of randomization to 90 days post-surgery. Patients will record their steps in the diary provided.
89457605|NCT03433313|Experimental|EG12014|Epirubicin and cyclophosphamide followed by EG12014 plus paclitaxel. All patients will be scheduled for surgery (breast and axillary lymph nodes) at 3 to 6 weeks after completion of neoadjuvant chemotherapy.
89457606|NCT03433313|Active Comparator|Herceptin|Epirubicin and cyclophosphamide followed by Herceptin plus paclitaxel. All patients will be scheduled for surgery (breast and axillary lymph nodes) at 3 to 6 weeks after completion of neoadjuvant chemotherapy.
89457607|NCT02314767|Active Comparator|Interpersonal Psychotherapy|Interpersonal Psychotherapy treatment for MDD patients was implemented with antidepressant pharmacotherapy by national Quidelines for the treatment of Patients with depression. Intervention:Interpersonal psychotherapy as ADD-on method. Outcome was compared with patients in treatment as usual group.
89457608|NCT02314767|Active Comparator|Psychoeducational Group Therapy|Psychoeducational Group Therapy arm for MDD patients with antidepressant pharmacotherapy by national Quidelines for the treatment of Patients with depression. Intervention: Psychoeducational Group Treatment as ADD-on method.
89457609|NCT02314767|No Intervention|Treatment as Usual|Treatment as usual ( consisting of supportive psychodynamic-oriented treatment) with antidepressant pharmacotherapy by national Quidelines for the treatment of Patients with depression
89457610|NCT02318121|Active Comparator|Amniotomy first|Will be done with sterile gloves after insurance that is the baby's head fits in the pelvis ( 3\5 or less of fetal head felt by first pelvic grip ) and by vaginal examination the head at station zero . The membranes are then punctured using an a hook during uterine contractions.
89457611|NCT02318121|Active Comparator|Oxytocin first|The starting dose will be the low dose rate equal or less than 4 m unit\minute (4 drops\minute doubled every 15 minutes up to 40 drops \minute) as intravenous drip on dextrose ,Ringer's lactate or saline solution.
89457612|NCT02318121|Active Comparator|Amniotomy and oxytocin|Amniotomy will be done (as explained above) and oxytocin (the same regimen mentioned above) at the same time.
88940909|NCT01854489|Active Comparator|Rifampicin|The volunteers will be given oral rifampicin (Rimapen, Orion, Finland) 600 mg as a single daily dose at 20.00 for 7 days
88940910|NCT01854489|Placebo Comparator|Placebo|The volunteers will be given oral placebo at 20.00 for 7 days
88940911|NCT01854489|Active Comparator|Buprenorphine|The volunteers will be given single dose of 0,4 mg intra venous buprenorphine or 0,6 mg sublingual buprenorphine on day 5.
88940912|NCT01854502|Experimental|Oral hygiene and fluoride use|Parents of young children were given counseling of their own oral hygiene and the use of fluoride on their child's visit to public dental service. The child was given multi-faceted counseling for good oral health habits.
88940913|NCT01854502|No Intervention|Control|"Control, The parents were not given any intervention on their child's visit to public dental service.~The child was given multi-faceted counseling for good oral health habits."
88940914|NCT01854502|Experimental|Diet and use of xylitol|Parents of young children were given counseling of their own diet and the use of xylitol on their child's visit to public dental service. The child was given multi-faceted counseling for good oral health habits.
88940915|NCT01854515|Active Comparator|Budesonide|1 mg diluted in 4 cc of sterile water for 20 minutes, one hour preceding extubation. After extubation patients received nebulizing Budesonide via oxygen mask at the same dose every 12 h. for 48 h.
88940916|NCT01854515|Experimental|Dexamethasone|0.15 mg/kg before extubation. After extubation, the administration of intravenous Dexamethasone continued at the same dose every 12 h. for 48 h.
88940917|NCT01854541||Radiotherapy|All patients receiving radiotherapy
88940918|NCT01854567|Experimental|Active|Infusion of one MPC expanded cord unit and one unexpanded cord unit.
88940919|NCT01854567|Active Comparator|Control|Infusion of two unexpanded cord blood units.
88940920|NCT01854580||Integrated care|Insured people in the Techniker Krankenkasse that are registered in the integrated care project.
88940921|NCT01854580||Control group|Insured people in the Techniker Krankenkasse that are not registered in the integrated care project.
88940922|NCT01854606|Experimental|AEB071 and EVEROLIMUS|AEB071 and EVEROLIMUS will be taken together in this open-label non-randomized study
88940923|NCT01854619|Active Comparator|Saline irrigation|Saline irrigation via syringe will be administered using a sinus irrigation catheter under endoscopic control.
88940924|NCT01854619|Active Comparator|Double photodisinfection treatment|Patients in the double treatment arm will receive a second photodisinfection treatment 4 weeks following the first treatment with regular follow-up visits
88940925|NCT01854619|Active Comparator|Single photodisinfection treatment|The single-treatment group will receive a single photodisinfection treatment of all involved paranasal sinuses with multiple follow-up visits.
88940926|NCT01854671|No Intervention|standard care|
88940927|NCT01854671|Experimental|family planning counseling led by community health worker|The family planning counseling sessions led by community health workers will present advantages of birth spacing, available methods of postpartum contraception, contraindications (if any) for the method, when each method can be safely started postpartum, where each method can be obtained, and importance of 6 week postpartum clinic follow-up. There will also be a take-home contraceptive method brochure given at conclusion of information session -primarily pictorial and in Arabic, to facilitate discussion at home with husbands and family members.
88940928|NCT01854723|Experimental|Switching to NPH insulin|Patients in this arm will be transitioned from insulin glargine to NPH insulin with subsequent titration according to algorithm within protocol. If needed, meal-time insulin will be added during study period.
88940929|NCT01854723|Active Comparator|Continuation of insulin glargine|Patients in this arm will continue on insulin glargine and serve as a control group.
88940930|NCT01854736|Active Comparator|GRAZAX|Tablet 75.000SQ-T once daily
88940931|NCT01854736|Placebo Comparator|Placebo|Tablet with no active grass component
88940932|NCT01854749|Experimental|S1 combined with cisplatin|
88940933|NCT01854762|Experimental|Raltegravir|Use of Raltegravir plus backbone treatment for pregnant women
88940934|NCT01854762|Active Comparator|Lopinavir/Ritonavir|Use of standard PI treatment (Lopinavir/r) plus backbone treatment for pregnant women
88940935|NCT01854788|Active Comparator|Autogenic drainage|All patients performed all interventions in a randomized order. Each technique was applied in 3 non consecutively sessions during one week. The time spent during the session was 40 minutes
88940936|NCT01854788|Active Comparator|Slow expiration with glottis opened in lateral posture|All patients performed all interventions in a randomized order.Each technique was applied in 3 non consecutively sessions during one week. The time spent during the session was 40 minutes
88940937|NCT01854788|Active Comparator|Temporary-Positive Expiratory Pressure|All patients performed all interventions in a randomized order. Each technique was applied in 3 non consecutively sessions during one week. The time spent during the session was 40 minutes
88940938|NCT01854801|Experimental|Experimental|Patients who declare themselves to be intolerant to electromagnetic fields benefit from medical care in occupational and environmental diseases centers and from a measurement of individual electromagnetic exposures and symptoms episodes. Each patient is his own control.
88940939|NCT01854840||Celesten in prevention of hyaline membrane disease.|Pregnant women that received at least a first injection of Celesten in the prevention of hyaline membrane disease.
88940940|NCT01854853|Experimental|STYLE Brazil|STYLE-BRazil Multifamily Group HIV/STI Prevention intervention
88940941|NCT01854853|Active Comparator|Health Promotion|Health Promotion Intervention - Adolescents only
88940942|NCT01854866|Experimental|Drug-packaging Microparticles|Drug-packaging microparticles are perfused to the pleural or peritoneal cavity of patients with four times per week.
88940943|NCT01854892|Experimental|Manipulation|Spinal manipulation
88940944|NCT01854892|Experimental|Mobilization|Spinal mobilization
88940945|NCT01854892|Experimental|Laser Therapy|Cold laser therapy
88940946|NCT01854931|Other|Tai Ji Quan|Single aim intervention - 2 twice per week for 48 weeks
89457613|NCT02318199||Agitation group|Patient is evaluated by the sedation-agitation scale (SAS) during the anesthesia recovery after intracranial surgery under general anesthesia. SAS equals to 5-7 during the first 12 hours after surgery.
89457614|NCT02318199||Non-agitation group|Patient is evaluated by the sedation-agitation scale (SAS) during the anesthesia recovery after intracranial surgery under general anesthesia. SAS equals to 1-4 during the first 12 hours after surgery.
89457615|NCT05225597|Active Comparator|epinephrine|In the epinephrine group, 0.2 mL of epinephrine (1:5000 solution) was used immediately after making the clear corneal incision during cataract surgery
89457616|NCT05225597|Active Comparator|carbachol|In the carbachol group, a 0.5 ml dose of 0.01% carbachol solution (Miostat®, Alcon Laboratories, Inc., Fort Worth, TX) was given intracamerally immediately after viscoelastic matter removal following IOL implantation
88940947|NCT01854957|Experimental|Autologous Mesenchymal Stem Cells|At week 0 a single infusion of either ex-vivo expanded autologous MSC or suspension media will be administered intravenously at a dose of 1-2 x 1000000 MSC/Kg body weight. At week 24, another infusion will be performed for cross-over re-treatment: at week 24 treatments will be reversed compared to week 0
88940948|NCT01854957|Placebo Comparator|Suspension media|At week 0 a single infusion of either ex-vivo expanded autologous MSC or suspension media will be administered intravenously at a dose of 1-2 x 1000000 MSC/Kg body weight. At week 24, another infusion will be performed for cross-over re-treatment: at week 24 treatments will be reversed compared to week 0
88940949|NCT01854970|Experimental|Patient|
88940950|NCT01854996|Experimental|Oral disperion fasted|A single dose of 450 mg PF-05089771 TS oral dispersion in fasted conditions.
88940951|NCT01854996|Experimental|Capsule fasted|single dose of 450 mg PF-05089771 TS as 3 x 150 mg capsules in fasted conditions
88940952|NCT01854996|Experimental|Capsule fed|single dose of 450 mg PF-05089771 TS as 3 x 150 mg capsules in fed conditions
88940953|NCT01855009|Active Comparator|MannaBears|Subjects will take 4 MannaBears daily
88940954|NCT01855009|Active Comparator|MannaBears, AlgaeCal Calcium, Vitamin D3|Subjects will take 4 MannaBears daily and 3 Calcium/Vit D capsules (2 with breakfast and 1 with dinner or vice-versa) daily
88940955|NCT01855009|Active Comparator|MannaBears, Calcium Carbonate, Vitamin D3|Subjects will take 4 MannaBears daily and 3 Calcium/Vit D capsules (2 with breakfast and 1 with dinner or vice-versa) daily
88940956|NCT01855022|Experimental|MI + IVR|90 days of motivational interviewing and 30 days of interactive voice response monitoring
88940957|NCT01855022|No Intervention|Usual Care|Usual care that a patient would receive absent the intervention
88940958|NCT01855035|Experimental|prolonged ECG monitoring|Prolonged ECG monitoring: 10-day Holter ECG at months 0, 3 and 6
88940959|NCT01855035|Other|standard care|Usual care according to current guidelines (minimum of 24 hours of cardiac monitoring).
89016645|NCT03214510|Experimental|Arm II (TAP)|Patients undergo placement of ultrasound-guided, four-quadrant transversus abdominus plane block. Patients receive plain bupivacaine and liposomal bupivacaine via TAP block.
89457617|NCT05225597|No Intervention|control|The control group was given neither epinephrine nor carbachol. Standard cataract surgery was performed
89016646|NCT03211546||Femoral shaft fracture|Patients (children up to 16 years old) diagnosis of isolated closed femur shaft fracture (3.2-D) and open distal physis. Treatment strategies will follow standard of care (routine) procedures, either conservative (non-surgical) treatment or surgical treatment.
89016647|NCT03183102|No Intervention|Estrogen suppression no flax|Control subjects will not consume flaxseed, but will receive GnRH suppression
89016648|NCT03183102|Experimental|Estrogen suppression with flax|Flax subjects will consume flaxseed for 2 months in addition to GnRH suppression
89457618|NCT02314845|Experimental|Optimal PEEP|"Patients submitted to general anesthesia and abdominal laparoscopic surgery (number=10) or open surgery (number=10) will be submitted to a recruitment maneuver followed by a PEEP titration procedure using Electrical Impedance Tomography (EIT). Patients will be mechanically ventilated during intraoperative period using Optimal PEEP determined by Electrical Impedance and FIO2 of 0.5."
89457619|NCT02314845|Other|Low PEEP|"Patients submitted to general anesthesia and abdominal laparoscopic surgery (number=10) or open surgery (number=10) will be submitted to a recruitment maneuver followed by a PEEP titration procedure EIT. In this arm, the ventilator will be set with a PEEP=4 cmH2O (Low PEEP) and FIO2 of 0.5 during intraoperative period."
89457620|NCT05225519|Experimental|Experimental arm|Usage of a long-sleeved white shirt impregnated with a long-infrared irradiating bioceramic for a period of 12 weeks.
89457621|NCT05225519|Placebo Comparator|Placebo arm|Usage of a long-sleeve white shirt (similar to the one in the experimental arm) but with no long-infrared technology for a period of 12 weeks.
89457622|NCT04051307|Experimental|intervention|"Vaccination with:~PD-L1 peptide:~PD-L1 Long(19-27) Peptide sequence: FMTYWHLLNAFTVTVPKDL Dose: 100 µg PD-L1 long1 dissolved in DMSO/water - Total volume: 0,5 ml.~Arginase1 peptide:~ArgLong2(169-206) Peptide sequence ISAKDIVYIGLRDVDPGEHYILKTLGIKYFSMTEVDRL Dose: 200 µg ARGLong2 dissolved in DMSO/water - Total volume: 0,5 ml.~Both vaccines are given at a treatment. Adjuvant Montanide ISA 51 0,5ml is mixed with the peptides before treatment To be administered every second week - a total of twelve times, with a possibility of additional six treatments."
89457623|NCT05225285|Experimental|VACC|This group will receive the inactivated Coronavac/Butantan vaccine.
89457624|NCT05225285|Active Comparator|BNTC|This group will receive the immunizing BNT162b2 (Pfizer).
89457625|NCT05225285|Active Comparator|ADU|This group of adults participants will receive the inactivated Coronavac/Butantan vaccine.
89457626|NCT03673579|Experimental|NICU Dashboard: Parent|"The parental intervention group will have access to the parent application on the NICU Dashboard. Parents will be able to view basic information about their baby's condition, educational material, and track core measures and developmental milestones.~Parents of NICU babies will be asked to complete questionnaires at baseline and within 48 hours of NICU discharge."
89457627|NCT03673579|No Intervention|Standard Care: Parent|The Parental Control group will receive standard of care without any study devices.
89457628|NCT03673579|Experimental|NICU Dashboard: Clinician|"The Clinician group will have access to the NICU Dashboard, which presents information from the EHR, bedside monitoring, and other systems of record through a pre-released FDA Class 2 clinical decision support rule-based system, to assist the appropriate evidence-based guidelines be integrated with team workflows. Caregivers educate and coach parents to facilitate integrating them into their infant's care.~NICU clinicians will be asked to complete questionnaires 1) prior to clinical go-live of the intervention (baseline), 2) at the study mid-way point, and 3) upon completion of parent recruitment."
89457629|NCT00543127|Experimental|Fulvestrant + Anastrozole|Fulvestrant loading dose regimen will consist of two 5 ml intramuscular injections on day 0 (500 mg), 250 mg single injection on days 14 and 28, and 250 mg single injection every 28 days thereafter for 3 years plus Anastrozole 1 mg PO once daily for 5 years
89457630|NCT00543127|Active Comparator|Anastrozole|Anastrozole 1 mg will be administered orally as one tablet daily for 5 years.
89457631|NCT02314923|Experimental|3x10^3 pfu Vaccine Cohort 1|Participants will receive a 1-mL intramuscular injection of V920 3x10^3 pfu in the deltoid on Day 0.
89457632|NCT02314923|Experimental|3x10^4 pfu Vaccine Cohort 1|Participants will receive a 1-mL intramuscular injection of V920 3x10^4 pfu in the deltoid on Day 0.
89457633|NCT02314923|Experimental|3x10^5 pfu Vaccine Cohort 1|Participants will receive a 1-mL intramuscular injection of V920 3x10^5 pfu in the deltoid on Day 0.
89016649|NCT03179995|Experimental|Octreotide treatment arm|Octreotide will be administered post-operatively until day 5
89457634|NCT02314923|Experimental|3x10^6 pfu Vaccine Cohort 1|Participants will receive a 1-mL intramuscular injection of V920 3x10^6 pfu in the deltoid on Day 0.
89016650|NCT03179995|Placebo Comparator|Placebo Arm|Normal saline will be administered post-operatively until day 5
89457635|NCT02314923|Experimental|9x10^6 pfu Vaccine Cohort 2|Participants will receive a 1-mL intramuscular injection of V920 9x10^6 pfu in the deltoid on Day 0.
89457636|NCT02314923|Experimental|2x10^7 pfu Vaccine Cohort 2|Participants will receive a 1-mL intramuscular injection of V920 2x10^7 pfu in the deltoid on Day 0.
89457637|NCT02314923|Experimental|1x10^8 pfu Vaccine Cohort 2|Participants will receive a 1-mL intramuscular injection of V920 1x10^8 pfu in the deltoid on Day 0.
89016651|NCT03148418|Experimental|Atezolizumab Monotherapy|Participants will continue to receive atezolizumab monotherapy in a Genentech or Roche-sponsored study (the parent study) in accordance with local prescribing information till the participant continues to derive clinical benefit or until death, withdrawal of study consent, unacceptable toxicity, pregnancy, participant non-compliance, or study termination by the Sponsor, whichever occurs first.
89023572|NCT05133336|Experimental|Saroglitazar Magnesium 2 mg|Saroglitazar Magnesium 2 mg tablet orally administered once daily in the morning before breakfast without food, for the duration of treatment (52 weeks).
89457638|NCT02314923|Placebo Comparator|Placebo Cohort 1|Participants will receive a 1-mL intramuscular injection of placebo in the deltoid on Day 0.
89457639|NCT02314923|Experimental|3x10^6 pfu Vaccine Cohort 2|Participants will receive a 1-mL intramuscular injection of V920 3x10^3 pfu in the deltoid on Day 0.
89457640|NCT02314923|Placebo Comparator|Placebo Cohort 2|Participants will receive a 1-mL intramuscular injection of placebo in the deltoid on Day 0.
89457641|NCT02309229||Cystic fibrosis patients|patients with cystic fibrosis
89457642|NCT02309307|Experimental|Arm 1 Tissue Repair Device|Tissue Repair Device
89457643|NCT03500601|Experimental|Active treatment|Nut components
89457644|NCT03500601|Placebo Comparator|Placebo|Placebo
89457645|NCT02309385|Experimental|8% DSP-Visulex|8% dexamethasone sodium phosphate - Visulex (DSP- Visulex) and placebo eye drops in the affected eye.
89457646|NCT02309385|Experimental|15% DSP-Visulex|15% dexamethasone sodium phosphate - Visulex (DSP- Visulex) and placebo eye drops in the affected eye.
89457647|NCT02309385|Active Comparator|Pred Forte|Prednisolone acetate (1%) eye drops and vehicle - Visulex in the affected eye.
89457648|NCT03463785||Chinese|Chinese mild or moderate OSA patients
89457649|NCT03463785||Dutch|Dutch mild or moderate OSA patients
89457650|NCT03023137|Active Comparator|Walking & dietary modification (W&D)|W&D should begin when participants wish to conceive. The intervention was standardized by training of research staff. Careful instructions about walking speed and diet would be given to participants assigned to W&D at enrolment and at each consultation.
89457651|NCT03023137|No Intervention|Controls|No recommendations regarding diet or physical activity were given to controls. Antiemetics such as ondansetron would be given to controls complaining of vomiting.
89457652|NCT03502239|Experimental|Treatment group|Subjects randomly assigned to this arm will train on the Mega Team video game.
89457653|NCT03502239|No Intervention|Control- wait list group|Subjects randomly assigned to this arm will be the wait-list group. They are allowed to play the video games that they usually play.
89016652|NCT03148418|Experimental|Combined Agents with Atezolizumab|Participants will receive treatment of atezolizumab with combined agent(s) as directed per the parent study. Participants will receive agent(s) in combination with atezolizumab at the same dose and schedule, and with the same administration guidelines that were in effect at the time of participant discontinuation from the parent study.
89016653|NCT03148418|Active Comparator|Comparator Treatment|Participants will receive comparator treatment administration as directed per the parent study. Participants will receive comparator treatment at the same dose and schedule, and with the same administration guidelines that were in effect at the time of participant discontinuation from the parent study.
89457654|NCT02315001|Active Comparator|Liraglutide|"Week 1 Run-In Phase = 0.6 mg (0.1 ml) Liraglutide once daily via subcutaneous injection~Week 2 Low-Dose Phase = 1.2 mg (0.2 ml) Liraglutide once daily via subcutaneous injection~Week 3 High-Dose Phase = 1.8 mg (0.3 ml) Liraglutide once daily via subcutaneous injection"
89457655|NCT02315001|Placebo Comparator|Saline Placebo|"Week 1 Run-In Phase = 0.1 ml normal saline once daily via subcutaneous injection~Week 2 Low-Dose Phase = 0.2 ml normal saline once daily via subcutaneous injection~Week 3 High-Dose Phase = 0.3 ml normal saline once daily via subcutaneous injection"
89457656|NCT03049813|Experimental|Virtual Reality Job Interview Training|Virtual Reality Job Interview Training
89457657|NCT03049813|Other|Supported Employment (Services as Usual)|Supported Employment (Services as Usual)
89457658|NCT03502161||All subjects|Those receiving a SOT and coming off either 3 months or 6 months of antiviral prophylaxis.
89457659|NCT02445885|Experimental|Acute PCI|Acute re-opening of the occluded coronary artery including premedication as for primary PCI within 12 hours
89457660|NCT02445885|Active Comparator|Subacute PCI|Standard subacute re-opening of the occluded coronary artery including premedication as for subacute PCI within 72 hours
89457661|NCT03673267|Experimental|Nutricity|
89457662|NCT03669913|Experimental|Intervention|Intervention arm will receive a pre evaluation survey, 11 lessons on CSE sequentially in a period of one year and a post evaluation survey
89457663|NCT03669913|No Intervention|Control arm|This is a control arm that receives no intervention but will have and pre and post evaluation in one year
89457664|NCT02315079||Eye inflammation|This group will have a regular eye exam with the collection of tears. In addition, a the Ocular Surface Disability Index Survey of National Eye Institute Visual Functioning Questionnaire- 25 may be administered.
89457665|NCT02315079||Without eye inflammation|This group will have a regular eye exam with the collection of tears.
89457666|NCT03500523|Experimental|1-study group|study group: pregnant women
89457667|NCT03500523|Experimental|2-control group|control group: healthy non pregnant women
89457668|NCT03673111|Experimental|1.0 mg|Y14 single dose, subcutaneous
89457669|NCT03673111|Experimental|2.0 mg|Y14 single dose, subcutaneous
89457670|NCT03673111|Experimental|6.0 mg|Y14 single dose, subcutaneous
89457671|NCT03673111|Experimental|9.0 mg|Y14 single dose, subcutaneous
89457672|NCT03673111|Experimental|18.0 mg|Y14 single dose, subcutaneous
89457673|NCT03673111|Experimental|36.0 mg|Y14 single dose, subcutaneous
89457674|NCT03673111|Placebo Comparator|Placebo|0.9% saline
89457675|NCT03673111|Experimental|26.0 mg (B1)|Y14 multiple dose, subcutaneous 5 doses over a 4 week treatment period: 9mg on day 1, 12mg on day 8, 16mg on day 15, 20mg on day 22 and 26mg on day 29.
88940960|NCT01855061||Irinotecan|"Patients will be subjected to a their metastatic solid tumor. Radiological response will be evaluated after each 2 cycles: 1. percentage change in radiological volume of the index lesion (radiological measurable lesion that underwent biopsy) after the first two cycles of irinotecan; 2. radiological response according to RECIST 1.1 after each 2 cycles. Patients are intended to receive irinotecan until progressive disease or unacceptable toxicity. Patients will be subjected to another biopsy of the index lesion at definitive discontinuation of irinotecan. Patients will also be subjected to blood draws for determining patient's genetic background variation.~Side studies include:~pharmacogenetics~pharmacokinetics of SN-38~carboxylesterase activity in the index lesion~midazolam clearance test (only in Rotterdam patients)"
88940961|NCT01855100||Rivaroxaban|
88940962|NCT01855113||INVISALIGN®|those with an Invisalign® Treatment for orthodontic correction
88940963|NCT01855113||braces|those with braces for orthodontic correction.
88940964|NCT01855139||Rivaroxaban|
88940965|NCT01855152|Experimental|Optimised WHELD intervention|The optimised WHELD intervention combining person centred care, promoting person centred activities and interactions and provide care home staff and general practitioners with updated knowledge regarding the optimal use of psychotropic medications for persons with dementia in care homes, is more effective in improving the quality of life and mental health, than usual care for people with dementia living in nursing homes.
88940966|NCT01855152|Experimental|Treatment as usual|Treatments delivered as usual
89457676|NCT03673111|Experimental|36mg (B2)|Y14 multiple dose, subcutaneous 5 doses over a 4 week treatment period: 9mg on day 1, 24mg on day 8, 36mg on day 15, no dose on day 22 and 36mg on day 29.
89457677|NCT03673111|Experimental|36mg (B3)|Y14 multiple dose, subcutaneous 5 doses over a 4 week treatment period: 12mg on day 1, 24mg on day 8, 36mg on day 15, no dose on day 22 and 36mg on day 29.
89457678|NCT04463277|Experimental|Calorie Restriction|
89457679|NCT04463277|Experimental|Time Restricted Feeding|
89457680|NCT04463277|Experimental|Time Restricted Feeding with Calorie Restriction|
89457681|NCT04463277|No Intervention|Control|
89457682|NCT03506217||mitral valve prolaps|Hemodynamic recovery and anesthesia revealed by invasive arterial cardiac output (CO) measurement (Vigileo Flo-trac device) in 13 cases who underwent mitral valve (MV) repair with the transapical off-pump minimally invasive method in our clinic.
89457683|NCT03500367|Experimental|rapamycin|rapamycin, 2 mg a day, orally ,for 3months
89457684|NCT02318433|Experimental|Dexamethasone|Subjects receive dexamethasone (4 mg) injection within the radiocarpal joint either in clinic or in the OR.
89457685|NCT02318433|Placebo Comparator|Saline|Subjects receive sterile saline (4 mg) injection within the radiocarpal joint either in clinic or in the OR.
89457686|NCT02315235|Active Comparator|control|The operator inject normal saline(control) to thirty site of the other side leg of active comparator. The volume of one site injection is 0.5 ml. The depth of needle injection would be 1.5cm.
89457687|NCT02315235|Active Comparator|stem cell (mononuclear cell)|The stem cell (mononuclear cell) is injected to thirty site of one side leg in operating room after general anesthesia. The volume of one site injection is 0.5 to 1.0 ml. The depth of needle injection would be 1.5cm.
89457688|NCT02315313||group1|RHR≤60bpm
89457689|NCT02315313||group2|RHR 61-70bpm
89457690|NCT02315313||group3|RHR 71-80bpm
89457691|NCT02315313||group4|RHR >80bpm
89457692|NCT03506139|Experimental|Radiation Therapy|External beam radiation therapy delivered to target volume.
89457693|NCT02318511|Experimental|ReNu amniotic allograft|Knee injection with ReNu. ReNu is an allograft tissue composed of particularized amniotic membrane and cell from the amniotic fluid.
89457694|NCT02318511|Placebo Comparator|Saline|Knee injection with saline. Injectable saline will be used as the placebo control.
89457695|NCT02318511|Active Comparator|HA injection|Knee injection with HA. HA will be used as a viscosupplementation injection consisting of cross linked HA.
89457696|NCT02315391|Experimental|20g isolated whey protein + 30g carb, 8,5g fat, 15g glycine|20g isolated whey protein + 30g carb, 8,5g fat, 15g glycine
89457697|NCT02315391|Experimental|20g micellar whey protein + 30g carb, 8.5g fat, 15g glycine|20g micellar whey protein + 30g carb, 8.5g fat, 15g glycine
89016654|NCT03138278|No Intervention|Usual care|ICU with ordinary care for elderly ICU survivors and their care-givers
89457698|NCT02315391|Experimental|20g micellar whey protein + 30g carb, 8.5g fat, 5g citrulline|20g micellar whey protein + 30g carb, 8.5g fat, 5g citrulline
89457699|NCT02318745|Experimental|Culturally Informed Family Treatment for Adolescents|CIFTA focuses on improving parenting practices, parent-adolescent attachment, adolescent ability to meet developmental challenges, increasing family support and decreasing family conflict/negativity, increasing knowledge of drug effects and triggers to use. Parents are taught general parenting and how to help a son or daughter with depression, conduct problems, and/or ADHD. Psycho-educational modules complement the family therapy and culturally relevant information is infused throughout the treatment. In family therapy sessions family members practice the skills and psycho-educational material they have learned. Treatment last approximately 4 months and includes approximately 6 session per month. Session may be family therapy sessions, individual sessions, or psycho-educational modules.
89457700|NCT02318745|Active Comparator|Individual Treatment As Usual|The active comparison condition reflects the typical individually-oriented services that behavior problem youth receive in the community. It was designed to isolate the effects of the CIFTA family interventions. A community agency helped us to standardize the individually-oriented services that were normally provided and a therapist trained by that agency was hired to work on the study to provide continuity to the services. The adolescent individual sessions addressed depression, ADHD, and/or conduct disorder through Cognitive Behavior Therapy, Interpersonal psychotherapy, social skills training, anger control training, problem solving skills, and assertiveness training. The ITAU therapists were expected to hold 6 sessions per month with the youth.
89457701|NCT03022981|Experimental|12 to < 18 Years Old|"PK Lead-in Phase: Sofosbuvir/Velpatasvir (SOF/VEL) 400/100 mg once daily for 7 days. Participants who complete the PK lead-in phase, continue into the treatment phase with no interruption of study drug administration and additional participants will be enrolled into the treatment phase once the appropriateness of the dose is confirmed by PK results from the PK lead-in phase.~Treatment Phase: SOF/VEL 400/100 mg once daily for 12 weeks."
89457702|NCT03022981|Experimental|6 to < 12 Years Old|"PK Lead-in Phase: SOF/VEL 200/50 mg once daily for 7 days. Participants who complete the PK lead-in phase, continue into the treatment phase with no interruption of study drug administration and additional participants will be enrolled into the treatment phase once the appropriateness of the dose is confirmed by PK results from the PK lead-in phase.~Treatment Phase: SOF/VEL 200/50 mg once daily for 12 weeks."
89457703|NCT03022981|Experimental|3 to < 6 Years Old|"PK Lead-in Phase: SOF/VEL 200/50 mg once daily for 7 days for participants who weigh ≥ 17 kg. SOF/VEL 150/37.5 mg once daily for 7 days for participants who weigh < 17 kg. Participants who complete the PK lead-in phase, continue into the treatment phase with no interruption of study drug administration and additional participants will be enrolled into the treatment phase once the appropriateness of the dose is confirmed by PK results from the PK lead-in phase.~Treatment Phase: SOF/VEL 200/50 mg once daily for 12 weeks for participants who weigh ≥ 17 kg. SOF/VEL 150/37.5 mg once daily for 12 weeks for participants who weigh < 17 kg."
89457704|NCT03164967|Other|Active Drug|All subjects will receive Bivigam based on their prior dosing to be adjusted as clinically necessary.
89457705|NCT03502005|Experimental|BIKTARVY®|initiation of single pill once daily bictegravir/emtricitabine/tenofovir alafenamide from prior efavirenz/emtricitabine/tenofovir DF
89457706|NCT03501927|Active Comparator|FOCUS (focused cardiac ultrasound)|Patients allocated to FOCUS will receive a preoperative FOCUS examination in conjunction with a standard anesthetic preoperative evaluation.
89016655|NCT03138278|Active Comparator|Telephone support|ICU with day-time telephone support to care-givers
89016656|NCT03119584|Active Comparator|1)28days of linaclotide or placebo|patient will be randomized and allocated to one of the treatment arms using computerized generated simple random number in a double-blinded fashion for 28 days of therapy with the study drug, linaclotide or placebo. Patients, and trial personnel involve (other than biostatistician) in this study will not be aware of the group assignments. Patients, treatment providers and staffs will be kept blinded in this study.
89016657|NCT03119584|Active Comparator|2)28days of linaclotide or placebo|patient will be randomized and allocated to one of the treatment arms using computerized generated simple random number in a double-blinded fashion for 28 days of therapy with the study drug, linaclotide or placebo. Patients, and trial personnel involve (other than biostatistician) in this study will not be aware of the group assignments. Patients, treatment providers and staffs will be kept blinded in this study.
89016658|NCT03112980|Experimental|Transcatheter aortic valve implantation|Transcatheter aortic valve implantation (TAVI) using the most appropriate CE (Conformité Européene)-marked device available, with a minimum demand of experience of 30 implanted devices/type per center.
89016659|NCT03112980|Active Comparator|Surgical aortic valve replacement|Surgical aortic valve replacement (SAVR) with free choice of surgical bioprosthesis and free choice of surgical access according to the surgeon's preference.
89016660|NCT03090789||Study Participant|Study participants can be individuals with either a clinical diagnosis or genetic confirmation of Friedreich ataxia. In addition, this study enrolls Friedreich ataxia carriers and unaffected controls.
89016661|NCT03088605|Experimental|Active|TOP1630 Ophthalmic Solution
89016662|NCT03088605|Placebo Comparator|Placebo|Placebo (Vehicle) Ophthalmic Solution
89457707|NCT03501927|No Intervention|Control|Patients allocated til control arm will receive a standard anesthetic preoperative evaluation according to hospitals' standards.
89457708|NCT04058821|Experimental|Adults with traumatic brachial plexus injuries|Participants will have two MRI scans before surgery (to find out the best time to scan), then two after surgery (at 6 and 12 months).
89457709|NCT02315547|Other|Antibiotics|Patients will be given antibiotics based on sputum microbiology during steady-state bronchiectasis. The methodology has been described in the British Thoracic Society guideline [16]. Briefly, for first-line therapy, patients isolated with Hemophilus influenzae, Hemophilus parainfluenzae, Streptoccus pneumoniae and Moraxella catarrhalis at baseline will be treated with amoxicillin clavulanate potassium (625mg bid); patients isolated with Klebsela pneumonae or Pseudomonas aeruginosa at baseline will be treated with fluoroquinolones. Levofloxacin (500mg qd) will be empirically employed for antibiotic treatment in those who tested negative to sputum microbiology. Severe BEs could be prescribed with intravenous antibiotics therapy at the discretion of study investigators, either in the out-patient department or hospitalized for intensive systemic treatment. Hospitalized patients will not be included in the exacerbation cohort.
89457710|NCT02309541|Experimental|Firmware N|New feedback canceller algorithm
89457711|NCT02309541|Active Comparator|Firmware R|Current feedback canceller algorithm (reference)
89457712|NCT03669445|Experimental|four drugs combination|21-day cycles induction, then 28-day cycles consolidation and maintenance with Lenalidomide, Ixazomib, and Dexamethasone Plus Daratumumab
89457713|NCT02309619|Experimental|trans-substernal group|Patients who undergo esophagectomy with the gastric tube lifting to the neck through trans-substernal path.
89457714|NCT02309619|Experimental|trans-esophageal bed group|Patients who undergo esophagectomy with the gastric tube lifting to the neck through trans-esophageal bed path.
89457715|NCT03669835|Experimental|Dietary supplement and standard therapy.|Participants will take a supplement of 1 sachet (20 mg) 3 times/day accompanied with the standard therapy for 1 month.
89457716|NCT03669835|Other|Standard therapy only.|Patients would be given standard treatment for 1 month.
89457717|NCT03501849|Experimental|Polypectomy using a cold snare|Polypectomy by cold-snare technique
89457718|NCT02315781|Active Comparator|Active tDCS|active tDCS will be used on half of the study participants
89457719|NCT02315781|Sham Comparator|Sham tDCS|Sham tDCS will be used on half of the study participants
89457720|NCT02316015|Experimental|Intervention group|Children in the intervention group will receive a protein-energy enriched milk (Infatrini®, or in the case of children on a partial or fully hydrolized milk Infatrini Peptisorb®). The volume of milk offered will be the same quantity as they usually drink at home (within the limits of 120-170 ml/kg/day). The intervention will be carried out during the first 7 days of hospitalisation, or until the day of discharge (if hospitalized for less than 7 days).
89457721|NCT02316015|No Intervention|Control group|Children in the control group will receive their regular milk. The volume of milk offered will be the same quantity as they usually drink at home (within the limits of 120-170 ml/kg/day).
89457722|NCT02316093||obese-chronic periodontitis patients|
89457723|NCT02316093||obese-gingivitis patients|
89457724|NCT02316093||obese-periodontally healthy controls|
89457725|NCT02316093||normal weight-chronic periodontitis patients|
89457726|NCT02316093||normal weight-gingivitis patients|
89457727|NCT02316093||normal weight-periodontally healthy controls|
89457728|NCT04462653|Experimental|use two kinds of device successively|the same participant use a Wearable Dynamic ECG Recorder and 12-lead ECG to record heart rate and atrial fibrillation
89457729|NCT04462809|Experimental|Cohort A, Malignant pleural mesothelioma|Malignant pleural mesothelioma
89457730|NCT04462809|Experimental|Cohort B1:Malignant peritoneal mesothelioma non-resected|Malignant peritoneal mesothelioma with non-resected or incompletely resected disease
89457731|NCT04462809|Experimental|Cohort B2:Malignant peritoneal mesothelioma (resected)|Malignant peritoneal mesothelioma with completely resected disease.
89457732|NCT04462575|Experimental|Onlay bone block covered using collagen membrane|The onlay bone block (harvested from mandibular intra oral sites) on top of a mixture of particulate autogenous bone and particulate xenogenic bone (assembly going to be fixed by at least 2 micro screws of diameter 1.5 mms and length 13 mms, to avoid micro movements of onlay bone block) covered by collagen membrane, stabilized by resorbable suture and fixed by tacs.
89457733|NCT04462575|Active Comparator|Onlay bone block without collagen membrane|The onlay bone block (harvested from mandibular intra oral sites) on top of a mixture of particulate autogenous bone and particulate xenogenic bone (assembly going to be fixed by at least 2 micro screws of diameter 1.5 mms and length 13 mms, to avoid micro movements of onlay bone block).
89457734|NCT02320773||1. OAB patients taking Betmiga®|OAB patients whose physician has made the decision to prescribe Betmiga® as part of routine clinical practice and who are about to start treatment
89457735|NCT03498651|Experimental|CBM-I, low attrition|Computer- or phone-based Cognitive Bias Modification - Interpretation training
89457736|NCT03498651|Experimental|CBM-I, high attrition, coach|Computer- or phone-based Cognitive Bias Modification - Interpretation training + Coaching
89457737|NCT03498651|Experimental|CBM-I, high attrition, no coach|Computer- or phone-based Cognitive Bias Modification - Interpretation training
89457738|NCT03498651|Active Comparator|Psychoeducation|Online psychoeducation about anxiety
89457739|NCT02320851|Experimental|SVD-tailored Integrative Psychotherapy (IPT)|IPT is a short-term psychotherapy aiming to ameliorate both physical and psychosocial distress. It emanates from a multidirectional and dynamic relationship among body, mind, and environment irrespective of causality. In a multi-component approach, other elements are integrated into it, such as cognitive-behavioral and psychodynamic techniques, psychoeducation and body-oriented techniques. The IPT intervention tailored to SVD will be delivered for 16 weeks in a manualised setting with one group session per week (à 90 minutes) and one additional booster session three months after the end of the therapy. The group psychotherapy is on a 6-8:1 basis and will be conducted by a psychotherapist trained on the basis of the manual and under regular clinical supervision.
89457740|NCT02320851|Active Comparator|Self-help group (SHG)|The experimental condition will be compared to moderated self-help groups without the implementation of additional therapeutic interventions. Those can be classified as low-level non-placebo control. Treatment will consist of 16 weekly moderated SHG sessions (one weekly session à 90 minutes) and one additional booster-session at three months after the end of the control intervention to be delivered on a 6-8:1 basis by a trained SHG moderator under clinical supervision.
89457741|NCT02309697||Full Term|Children born at full term on or after Jan 1, 2011
89016663|NCT03051282|Active Comparator|non-carrier control group|Subjects who do not carry the CES1 variant G143E (rs71647871) will receive 10 mg Enalapril orally once daily for 7 consecutive days.
89016664|NCT03051282|Active Comparator|G143E carriers group|Subjects who carry the CES1 variant G143E (rs71647871) will receive 10 mg Enalapril orally once daily for 7 consecutive days.
89016665|NCT03037684||chronic pain|individuals suffering from chronic pain
89016666|NCT03037684||neuropathic pain|individuals suffering from neuropathic pain
89016667|NCT02964013|Experimental|vibostolimab|During an initial dose evaluation phase, participants will receive Dose A, B, C, D, E, or F of vibostolimab on Day 1 of each 21-day infusion cycle (for a maximum of 35 cycles) until the RPTD has been established. The RPTD will be established based on the number of dose limiting toxicities (DLTs) at each dose level. Once the RPTD is established, participants will continue receiving the RPTD of vibostolimab on Day 1 of each 21-day infusion cycle until the 35-cycle limit is reached.
89457742|NCT02309697||PreTerm|Children born preterm on or after Jan 1, 2011
89457743|NCT02309775|Active Comparator|Auriculotherapy Group|The placement, points according to Souza (1997), will be: Shen Men, Sympathetic, Kidney, Subcortex, Adrenal and Cerebral. The point descriptions are: Shen Men, is located in the vertex of the angle formed by the lower root and the upper root of the antihelix; the Sympathetic is situated in the middle of the lower root below the Helix membrane (located at the lower end of the Lobe); the Kidney point is situated in cymba concha, near its junction with the lower root of the antihelix, in the same line as the Shen Men point; the Subcortex is situated on upward curve towards the apex of the antitragus, on the upper edge of the concha; the Adrenal is located at the apex of the tragus, on its projection towards the concha cava; the Cerebral point is situated above the edge of the antitragus. As sessions will held twice a week for a total of 10 sessions.
89457744|NCT02309775|Placebo Comparator|Placebo Grup|The point stimulated will be the Trachea, which is one millimeter in the direction of the auditory meatus. This point does not cause risk to the research participant. As sessions will held twice a week for a total of 10 sessions.
89457745|NCT03377699|Experimental|Insulin Degludec|Insulin Degludec once daily and Insulin Aspart 2-4 times daily
89457746|NCT03377699|Active Comparator|Insulin Determir|Insulin Determir once daily or twice daily and Insulin Aspart 2-4 times daily
89457747|NCT04463901|Active Comparator|Group CAG|After pterygium excision, intraoperative mitomycin c (0.02%) for 5 minutes will be applied topically onto the exposed surgical area and then conjunctival autograft without limbal tissue will be used to cover the bare sclera.
89457748|NCT04463901|Active Comparator|Group LCAG|After pterygium excision, intraoperative mitomycin c (0.02%) for 5 minutes will be applied topically onto the exposed surgical area and then limbal conjunctival autograft will be used to cover the bare sclera.
89016668|NCT02964013|Experimental|vibostolimab + pembrolizumab|During an initial dose evaluation phase, participants will receive Dose A, B, C, D, E, or F of vibostolimab in combination with 200 mg pembrolizumab on Day 1 of each 21-day infusion cycle (for a maximum of 35 cycles) until the RPTD of vibostolimab has been established. The RPTD will be established based on the number of DLTs at each dose level. Once the RPTD of vibostolimab is established, participants will continue receiving the RPTD of vibostolimab in combination with 200 mg pembrolizumab on Day 1 of each 21-day infusion cycle until the 35-cycle limit is reached.
89016669|NCT02964013|Experimental|Advanced solid tumor cohort|Participants will receive the RPTD of vibostolimab monotherapy or the RPTD of vibostolimab in combination with 200 mg pembrolizumab on Day 1 of each 21-day infusion cycle until the 35-cycle limit is reached.
89016670|NCT02964013|Experimental|Randomized dose 1 comparison cohort|Participants will be randomized to receive a fixed dose (Dose 1) of vibostolimab in combination with 200 mg pembrolizumab on Day 1 of each 21-day infusion cycle until the 35-cycle limit is reached.
89016671|NCT02964013|Experimental|Randomized dose 2 comparison cohort|Participants will be randomized to receive a fixed dose (Dose 2) of vibostolimab in combination with 200 mg pembrolizumab on Day 1 of each 21-day infusion cycle until the 35-cycle limit is reached.
89023573|NCT05133336|Experimental|Saroglitazar Magnesium 1 mg|Saroglitazar Magnesium 1 mg tablet orally administered once daily in the morning before breakfast without food, for the duration of treatment (52 weeks).
89457749|NCT04463745||Liver Transplant Recipients|adult patients undergoing liver transplantation
89457750|NCT02309853|Experimental|Visual and tactile scanning training|20 Sessions of 30 minutes with a visual and tactile scanning training in the personal, peripersonal and extrapersonal space combined with trunk rotation
89457751|NCT02309853|Active Comparator|Unimodal visual scanning training|20 sessions of 30 minutes with traditional uni-modal visual scanning training
89457752|NCT03505827||TECNIS Monofocal|This group of patients has chosen to undergo implantation of a TECNIS monofocal ZCB00 lens during cataract surgery. This decision was made prior to enrolment in the study. This group of patients will receive standard of care cataract surgery, as any other patient would. The sole intervention we will be undertaking is a 24-2 Humphrey visual field test prior to surgery, and a 24-2 SITA standard Humphrey visual field test after surgery at 1 month post-operatively.
89457753|NCT03505827||TECNIS Symfony|This group of patients has chosen to undergo implantation of a TECNIS Symfony extended depth of focus lens during cataract surgery. This decision was made prior to enrolment in the study. This group of patients will receive standard of care cataract surgery, as any other patient would. The sole intervention we will be undertaking is a 24-2 SITA standard Humphrey visual field test prior to surgery, and a 24-2 Humphrey visual field test after surgery at 1 month post-operatively.
89457754|NCT03500055|Experimental|Abdominal Closure Bundle|Surgeons will re-scrub, change gown and gloves prior to closure of fascia. Will also use new instruments, bovie tip, suction tip, and light handles, for closure of fascia, subcutaneous tissue, and skin.
89457755|NCT03500055|No Intervention|Control|Normal operative procedure. The abdominal closure bundle will not be used.
89457756|NCT04752449|Experimental|Virtual Cognitive Behavioural Therapy for Psychosis|CBT will be delivered according to an established manual that the PI has previously used successfully for in-person treatment. Treatment will consist of individual sessions with a psychologist employed by the University of Toronto for 1-hour per week for 6-months, or by one of the listed clinical graduate students under his supervision. All treatment will be delivered virtually in the participant's home using the online platform Zoom which is PHIPA/PIPEDA compliant. If participants do not have the technology required for virtual sessions, then a tablet will be loaned to them for the duration of treatment. This treatment will be delivered in addition to usual care and no changes to usual care will be required.
89016672|NCT02964013|Experimental|vibostolimab +pembrolizumab+pemetrexed+carboplatin|Participants will receive a fixed dose of vibostolimab in combination with 200 mg pembrolizumab, 500 mg/m^2 pemetrexed, and Area Under Curve (AUC) 5 mg/mL/min carboplatin on Day 1 of each 21-day infusion cycle for up to 4 cycles followed by maintenance therapy with a fixed dose of vibostolimab in combination with 200 mg pembrolizumab and 500 mg/m^2 pemetrexed on Day 1 of each 21-day infusion cycle for up to an additional 31 cycles.
89016673|NCT02964013|Experimental|vibostolimab Dose 1 Japanese cohort|Japanese participants will be randomized to receive a fixed dose (Dose 1) of vibostolimab in combination with 200 mg pembrolizumab on Day 1 of each 21-day infusion cycle until the 35-cycle limit is reached.
89016674|NCT02964013|Experimental|vibostolimab Dose 2 Japanese cohort|Japanese participants will be randomized to receive a fixed dose (Dose 2) of vibostolimab in combination with 200 mg pembrolizumab on Day 1 of each 21-day infusion cycle until the 35-cycle limit is reached.
89457757|NCT04752449|No Intervention|Treatment as Usual|Participants continue with their regular standard of care without the addition of virtual Cognitive Behavioural Therapy for Psychosis.
89457758|NCT02318823|Other|Beer (alcoholic) followed by placebo (non-alcoholic)|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has two treatment conditions in the same subject.
89457759|NCT02318823|Other|Placebo (non-acoholic beer) followed by Beer (alcoholic)|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has two treatment conditions in the same subject.
89457760|NCT02319057|Experimental|Panel 1|Adaptive design: Each subject will receive 1-4 single doses of ORM-12741 including various dose levels of ORM-12741 MR A, ORM-12741 MR B, ORM-12741 IR or combination of these
89457761|NCT02319057|Experimental|Panel 2|Adaptive design: Each subject will receive 1-4 single doses of ORM-12741 including various dose levels of ORM-12741 MR A, ORM-12741 MR B, ORM-12741 IR or combination of these
89016675|NCT02964013|Experimental|pembrolizumab/vibostolimab coformulation|Participants will receive a fixed dose of pembrolizumab/vibostolimab coformulation, consisting of 200 mg of pembrolizumab + 200 mg vibostolimab, on Day 1 of each 21-day infusion cycle for up to 35 cycles.
89016676|NCT02964013|Experimental|vibostolimab+pembrolizumab+carboplatin OR cisplatin+etoposide|Participants will receive 200 mg vibostolimab in combination with 200 mg pembrolizumab, plus the investigator's choice of Area Under Curve (AUC) 5 mg/mL/min carboplatin OR 75 mg/m^2 cisplatin on Day 1 of each 21-day cycle plus 100 mg/m^2/day etoposide on Days 1-3 of each 21-day cycle for up to 4 cycles. Maintenance therapy with 200 mg vibostolimab in combination with 200 mg pembrolizumab on Day 1 of each 21-day cycle will continue for up to an additional 31 cycles. A participant will be allowed to switch from cisplatin to carboplatin in the event of an adverse event (AE), ineligibility for further cisplatin therapy, and/or the investigator considers switching to carboplatin to be in the best interest of the participant.
89016677|NCT02964013|Experimental|pembrolizumab/vibostolimab coformulation China cohort|Participants from mainland China will receive a fixed dose of pembrolizumab/vibostolimab coformulation, consisting of 200 mg of pembrolizumab + 200 mg vibostolimab, on Day 1 of each 21-day infusion cycle for up to 35 cycles.
89016678|NCT02959463|Experimental|Cohort 1 (hemithoracic radiation therapy, pembrolizumab)|Patients undergo hemithoracic radiation therapy. After radiation therapy, patients receive pembrolizumab IV over about 30 minutes on day 1. Courses repeat every 3 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
89016679|NCT02959463|Experimental|Cohort 2 (palliative radiation therapy, pembrolizumab)|Patients undergo palliative radiation therapy over 1-3 weeks to only the region of palliation (a region that does not include the entire side of the chest or thorax). After radiation therapy, patients receive pembrolizumab IV over about 30 minutes on day 1. Courses repeat every 3 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
89457762|NCT02319057|Experimental|Panel 3|Adaptive design: Each subject will receive 1-4 single doses of ORM-12741 including various dose levels of ORM-12741 MR A, ORM-12741 MR B, ORM-12741 IR or combination of these
89457763|NCT02319057|Experimental|Panel 4|Adaptive design: Each subject will receive 1-4 single doses of ORM-12741 including various dose levels of ORM-12741 MR A, ORM-12741 MR B, ORM-12741 IR or combination of these
89457764|NCT02319057|Experimental|Panel 5|Adaptive design: Each subject will receive 1-4 single doses of ORM-12741 including various dose levels of ORM-12741 MR A, ORM-12741 MR B, ORM-12741 IR or combination of these
89457765|NCT02319057|Experimental|Panel 6|Adaptive design: Each subject will receive 1-4 single doses of ORM-12741 including various dose levels of ORM-12741 MR A, ORM-12741 MR B, ORM-12741 IR or combination of these
89457766|NCT01314443|Experimental|Placebo + Smoking Cessation|Individuals will quit smoking without use of nicotine replacement therapy (NRT) and ingest a placebo for 7 days
89457767|NCT01314443|Experimental|Supplement + Smoking Cessation|Individuals will quit smoking without the use of nicotine replacement therapy (NRT) and ingest a gamma-tocopherol supplement for 7 days
89457768|NCT01314443|Experimental|Placebo + Nicotine Replacement Therapy|Individuals will quit smoking with the use of nicotine replacement therapy (NRT) and ingest a placebo for 7 days
89457769|NCT01314443|Experimental|Supplement+Nicotine Replacement Therapy|Individuals will quit smoking with the use of nicotine replacement therapy (NRT) and ingest a gamma-tocopherol supplement for 7 days
89457770|NCT02310009|Experimental|Control (CON)|Placebo will be administered as a subcutaneous injectable bolus, the day prior to the repeated measurement of beta-cell function.
89457771|NCT02310009|Experimental|Anakinra (AN)|100 mg of Kineret (Anakinra) will be administered as a subcutaneous injectable bolus, the day prior to the repeated measurement of beta-cell function.
89457772|NCT02310009|Experimental|Exercise (EX)|1 hour of cycling exercise will be performed at 75% VO2max, the day prior to the repeated measurement of beta-cell function.
88940967|NCT01855165|Experimental|Advice on DDIs|Attending physician will be randomly assigned to intervention arm care as usual; in the intervention arm, he/she will receive advice about DDIs between medications prescribed to patients on top of general heart failure advice.
88940968|NCT01855165|No Intervention|General advice|
88940969|NCT01855191||Standard|
88940970|NCT01855191||Standard + saliva collection|
88940971|NCT01855204|Active Comparator|Conventional|Computed tomographic urography was done with conventional protocols.
88940972|NCT01855204|Experimental|Reduced|Computed tomographic urography was done with the protocols of low voltage and low iodine concentration.
88940973|NCT01855217|Active Comparator|Sugammadex total body weight|1 mg/kg total body weight
88940974|NCT01855217|Active Comparator|Sugammadex ideal body weight|1 mg /kg ideal body weight
88940975|NCT01855217|Placebo Comparator|placebo|placebo 0,9% NaCl
88940976|NCT01855230|Experimental|ASM-024|Dry Powder for Inhalation, b.i.d., 14 days
88940977|NCT01855230|Placebo Comparator|Placebo|Dry Powder for Inhalation, b.i.d., 14 days
88940978|NCT01855256|Experimental|oxybutynin|Oxybutynin was done at 2.5 mg/day from day 1 to day 4, then at 5 mg/day from day 5 to day 7 and at 7.5 mg/day from day 8 to the end of the 6 weeks.
88940979|NCT01855256|Placebo Comparator|Placebo|Placebo was done at 2.5 mg/day from day 1 to day 4, then at 5 mg/day from day 5 to day 7 and at 7.5 mg/day from day 8 to the end of the 6 weeks.
88940980|NCT01855269|Active Comparator|Lactobacillus reuteri|Lactobacillus reuteri (BioGaia, Stockholm, Sweden):at a dose of 100 million colony forming unit in 5 drops, 30 minutes after feeding, once per day for 3 weeks
88940981|NCT01855269|Active Comparator|Herbal drop|Herbal drop containing sodium bicarbonate, Pimpinella anisum oil, foeniculum vulgare oil, Mentha piperita (Babs, Berko, Istanbul, Turkey):5 drops 30 minutes after feeding, once per day for 3 weeks
88940982|NCT01855269|Placebo Comparator|Sterile water|Sterile water: 5 drops, 30 minutes after feeding, once per day for 3 weeks
88940983|NCT01855282|Experimental|Behavioral intervention|Behavioral intervention consisting of 10 educational sessions promoting healthy diet and increased physical activity.
89457773|NCT02310009|Experimental|Anakinra + Exercise (ANEX)|100 mg of Kineret (Anakinra) will be administered as a subcutaneous injectable bolus followed by 1 hour of cycling exercise at 75% VO2max, the day prior to the repeated measurement of beta-cell function.
89457774|NCT03498573|Experimental|tunneling surgical technique|
89457775|NCT05655065|Active Comparator|Increase of MAP at low target 65-70 mmHg (with catecholamines or volemic expansion)|Target of mean arterial pressure (MAP) at 65-70 mmHg The therapeutic means used to obtain the MAP objectives within each group (increase in catecholamines and / or volume expansion) are left to the discretion of the clinician, in accordance with the recommendations.
89457776|NCT05655065|Experimental|Increase of MAP at high target 80-85 mmHg (with catecholamines or volemic expansion)|Target of mean arterial pressure (MAP) at 80-85 mmHg The therapeutic means used to obtain the MAP objectives within each group (increase in catecholamines and / or volume expansion) are left to the discretion of the clinician, in accordance with the recommendations.
89457777|NCT03498417||Graves' diseases|Patients with Graves' disease. No interventions foreseen
89457778|NCT03498417||Autoimmune thyroiditis|Patients with autoimmune thyroiditis. No interventions foreseen
88940984|NCT01855282|Active Comparator|Control|Control arm received no behavioral intervention
88940985|NCT01855295|Experimental|Protein Supplementation|Hemodialysis patients with inflammation and low body mas index to receive protein dietary advice and protein supplements while on dialysis
88940986|NCT01855308||Single site robotic chole|Cholecystectomy performed through a single incision with the robot.
89023574|NCT05133336|Placebo Comparator|Placebo|Placebo tablet orally administered once daily in the morning before breakfast without food, for the duration of treatment (52 weeks).
89023575|NCT05132790|Experimental|TNBC|
89457779|NCT03498417||Healthy Subjects|Normal healthy subjects. No interventions foreseen
89457780|NCT03212651|Experimental|Patients with MIBC (Muscle Invasive Bladder Cancer)|Cisplatinum-ineligible patients with muscle-invasive bladder cancer
89457781|NCT03499977|Experimental|Sitting|The participant will be asked to sit for 10 min (not increasing their heart rate) then do the anti-saccade task
89457782|NCT03499977|Experimental|Low-Intensity Cycling|Participant will be asked to cycle for 10 min (<40% VO2R) and then perform the anti-saccade task
89457783|NCT03499977|Experimental|Moderate-Intensity Cycling|The participant will be asked to do 10 min of cycling (40-59% VO2R) followed but the anti-saccade task
89457784|NCT03499977|Experimental|High-Intensity Cycling|The participant will be asked to do 10 min of cycling (60%-84% VO2R) followed but the anti-saccade task
89457785|NCT02319135|Active Comparator|fludarabine cytarabine|"Priming with daily administration of subcutaneous G-CSF (lenograstim or filgrastim 5 mcg /kg / day, days -1, 1 and 2) (not given if hyperleukocytosis> 25 x 109/l), followed by:~Oral fludarabine (40 mg/m2/day, days 1 to 5) and subcutaneous cytarabine (75mg/m2/day, days 1 to 5) (FLUGA scheme) (fludarabine and cytarabine only days 1 to 4 if age ≥75 years), OR~Fludarabine (25 mg/m2/day) and cytarabine (75 mg/m2/day infusion of 6 hours) on their intravenous formulations if the patient is hospitalized (patients with hyperleukocytosis or other unfavourable conditions).~Treatment cycles every 28 days"
89457786|NCT02319135|Experimental|Azacitidine|Subcutaneous Azacitidine 75 mg/m2/day, days 1 to 7. Treatment cycles every 28 days.
89457787|NCT05242991|Active Comparator|Intraoral photobiomodulation protocol|Patients will receive the PBMT from the first day of RT, 5 times a week (Monday to Friday), for 6 to 7 weeks, or until there are no more mucositis lesions, just before the RT session. Intraoral protocol will utilize a low-level laser device (MMOptics Ltda, Sao Carlos, Sao Paulo, Brazil) with wavelength 660nm, power 100 mW, spot 0.03 cm², dose 10 J/cm², and time 3 seconds. The irradiations will be punctual and in a contact form, with 1 cm between the points, perpendicular to the oral mucosa, avoiding the tumor site and will be performed: 6 points on the labial mucosa (3 in the upper and 3 in the lower), 2 points on the labial commissure (1 on the right and 1 on the left), 8 points on the jugal mucosa (4 on the right and 4 on the left), 8 points on the lateral border of the tongue (4 on the right and 4 on the left), 5 points on the ventral tongue (2 on the right, 2 on the left side and 1 point on the apex), 4 points on the oral floor (2 on the right and 2 on the left side).
89457788|NCT05242991|Active Comparator|Extraoral photobiomodulation protocol|"Patients will receive the PBMT from the first day of RT, 5 times a week (Monday to Friday), for 6 to 7 weeks, or until there are no more mucositis lesions, just before the RT session.~Extraoral protocol will utilize a defocused high-level laser device (Gemini® Diode Laser - UltraDent) with wavelength 810 + 980 nm, power 1 W, spot 4.91 cm², dose 6.11 J/cm², and time 30 seconds.~The irradiations will be punctual and in a contact form, perpendicular to the skin, avoiding the tumor site and will be performed:~5 points on the face (2 on both right and left cheeks, 2 points on both right and left parotid gland region and 1 on the lip);~5 points on the neck area (1 point on the sublingual gland region, 2 points on the right and left submandibular spaces and 2 points on the neck nearby lymphatic chain)."
89457789|NCT03505515||Lung Cancer Patricipants in China|Participants with advanced/metastatic lung cancer (advanced NSCLC (IIIB/IV) and extensive disease SCLC) in China
89457790|NCT02319213|No Intervention|Group C|The control group (Group C) was not subjected to laparoscopic intervention
89457791|NCT02319213|Experimental|Group L|Intraocular pressure measurement with 9 mmHg insufflation
88940987|NCT01855321|Active Comparator|Vitamin D|the cholecalciferol capsule with respect to size and shape and 2) the intervention group will take 1 oral capsule of cholecalciferol 50,000 IU (Bio-Tech Pharmacal, Fayetteville, AR USA) once weekly for 8 weeks followed by 50,000 IU once monthly for 4 months.
88940988|NCT01855321|Placebo Comparator|Placebo|The placebo capsule is to be identical to the cholecalciferol capsule with respect to size and shape and 2) the intervention group will take 1 oral capsule of cholecalciferol 50,000 IU (Bio-Tech Pharmacal, Fayetteville, AR USA) once weekly for 8 weeks followed by 50,000 IU once monthly for 4 months.
88940989|NCT01855334|Experimental|Spironolactone + Placebo|Spironolactone 25 mg by mouth daily + Placebo L-arginine-liquid formulation by mouth 3 times daily
88940990|NCT01855334|Placebo Comparator|Double Placebo|Placebo spironolactone-1 tablet by mouth daily + Placebo L-arginine liquid formulation by mouth 3 times daily
88940991|NCT01855334|Experimental|Spironolactone + L-arginine|Spironolactone 25 mg daily + L-arginine 3 grams orally 3 times daily
88940992|NCT01855334|Experimental|L-arginine + Placebo|L-arginine 3 grams by mouth 3 times daily + Placebo spironolactone 1 tablet by mouth daily
88940993|NCT01855347||Preterm infants|Preterm infants (32 to 36 weeks of postmenstrual age) will be evaluated with a Near infrared Spectroscopy monitor device.
88940994|NCT01855373|Other|Placebo|No active ingredient
88940995|NCT01855373|Active Comparator|PEAK ATP® with GlycoCarn®|Adenosine 5'-Triphosphate Disodium Salt (100mg/capsule)and Glycine Propionyl-L-Carnitine Hydrochloride, USP (500mg/capsule)
88940996|NCT01855373|Active Comparator|PEAK ATP®|Adenosine 5'-Triphosphate Disodium Salt (100mg/capsule)
88940997|NCT01855373|Active Comparator|GlycoCarn®|Glycine Propionyl-L-Carnitine Hydrochloride, USP (500mg/capsule)
88940998|NCT01855386||Subjects with Gestational Diabetes|Subjects with a history of Gestational Diabetes will provide blood samples, blood pressure measured with a blood pressure cuff, pulse, height, weight, and ultrasound of the liver at the 6 week postpartum and 6 month postpartum visits.
88940999|NCT01855386||Controls without Gestational Diabetes|Matched control subjects without Gestational Diabetes will provide blood samples, blood pressure measured with a blood pressure cuff, pulse, height, weight, and ultrasound of the liver at the 6 week postpartum and 6 month postpartum visits.
88941000|NCT01855438|No Intervention|Usual Care|Kidney transplant candidates randomized to this arm will receive only the education provided by the transplant center. After data collection activities have concluded, transplant candidates in this arm will be offered the opportunity to attend a program session.
88941001|NCT01855438|Experimental|Living Donor Transplant Education 1|Participants randomized to Living Donor Transplant Education 1 will receive education on living donor kidney transplantation and its discussion.
88941002|NCT01855438|Experimental|Living Donor Transplant Education 2|Participants randomized to Living Donor Transplant Education 2 will receive education on living donor kidney transplantation and its discussion; they will also have the opportunity to practice discussing living kidney transplantation with simulated patients portraying participants' conversational partners.
89023576|NCT05132790|Experimental|HER2-/HR+BC|
89457792|NCT02319213|Experimental|Group M|Intraocular pressure measurement with 12 mmHg insufflation
89457793|NCT02319213|Experimental|Group H|Intraocular pressure measurement with 15 mmHg insufflation
89457794|NCT03498183|Experimental|ARM experimental|All the patients will have MIBI-Tc99m/Iodine-123 . Following the injections they will have a scintigraphy.
89457795|NCT03499743|Experimental|group1 (hyoscine Butyl-bromide group)|group1 will receive hyoscine butyl bromide 10 mg (BUSCOPAN tablets, produced by Chemical Industries Development (CID), Giza - A.R.E. under licence of Boehringer Ingelheim International GmbH - Germany) orally in addition to a placebo similar to Celecoxib 2 hours before IUD insertion.
89457796|NCT03499743|Placebo Comparator|group 3 (PLACEBO GROUP)|will receive a placebo similar to hyoscine butyl bromide in addition to a placebo similar to Celecoxib 2 hours before IUD insertion.
88941003|NCT01855490|Experimental|Single-arm treatment with Exenatide|Exenatide 5 mcg sc. injection 15 minutes prior to a MMTT and IVGTT
89457797|NCT03499743|Experimental|group 2(celecoxib group)|group 2 will receive Celecoxib 200mg (Celebrex® 200, Pfizer, USA) in addition to a placebo similar to hyoscine butyl bromide 2 hours before IUD insertion.
89457798|NCT03498027||Data Collection|
88941004|NCT01855503||Metastatic Breast Cancer|
88941005|NCT01855516|Active Comparator|UFH 5000 U three times a day|Study subjects will be randomized to receive heparin 5000 U subcutaneous three times a day.
88941006|NCT01855516|Active Comparator|UFH 5000 U two times a day|Study subjects will be randomized to receive heparin 5000 U subcutaneous two times a day.
88941007|NCT01855529|Experimental|Ropivacaine arm|Ropivacaïne 2 mg/ml 10ml/h
88941008|NCT01855529|Placebo Comparator|NaCl arm|NaCl 0,9% 250ml 10 ml/h
88941009|NCT01855542|Experimental|0.9% saline|In each group, patients received either 0.9% normal saline or plasmalyte solution until end of surgery.
88941010|NCT01855542|Active Comparator|plasmalyte|In each group, patients received either 0.9% normal saline or plasmalyte solution until end of surgery.
88941011|NCT01855555||sedation group|Children requiring sedation for MRI/CT
88941012|NCT01855568|Experimental|Single-dose methotrexate protocol|"Participants in the single-dose protocol group received intramuscular methotrexate at single dose of 50 mg/m2 on day 0 (the initial day of treatment). The β-hCG levels were then measured on day 4 and 7. If there was at least 15% β-hCG drop between day 4 and 7, the treatment was deemed successful and the participants were then followed with weekly β-hCG measurements until the results was negative. If a 15% drop on day 4 and 7 did not occur, a second dose was administrated on day 7 and β-hCG levels were then measured on day 11 and 14. Participants were referred for surgical treatment if β-hCG levels fell <15% between day 11 and 14."
88941013|NCT01855568|Experimental|Two-dose methotrexate protocol|"Participants in the two-dose protocol group received intramuscular methotrexate twice at dose of 50 mg/m2 on day 0 and 4. A third dose of methotrexate was given on day 7 if β-hCG levels did not fall 15% between day 4 and 7 after two-dosing. A fourth dose was administered on day 11 if β-hCG levels fell <15% between day 7 and 11. Then, a final β-hCG level was checked on day 14. If a 15% drop was not seen, the medical treatment was deemed refractory and the patients were referred for surgical treatment."
88941014|NCT01855581||sedation group|Children requiring sedation for MRI/CT
88941015|NCT01855594|Experimental|Lithium treatment group|Lithium carbonate, 250mg/tablet. The dose starts with three times a day and one tablet each time for a week. The daily dose will then be adjusted according to serum lithium level and clinical finding. Target serum lithium level is 0.6 - 1.2mmol/L.
89457799|NCT02310087|Active Comparator|astaxanthin with vitamin E|The participants in the study group will be given perorally four tablets of 4 mg astaxanthin with 10 mg vitamin E (Astasan, Sensilab, Slovenia) daily, taken in single daily dose. The total daily dose will be 16 mg astaxanthin with 40 mg vitamin E. The product will be taken for three months continuously.
89457800|NCT02310087|Placebo Comparator|placebo|The participants in the control group will be given perorally four tablets of placebo daily taken in single daily dose. The placebo tablets are of the same size and colour as the study tablets and were produced by manufacturer of Astasan, Sensilab, Slovenia. The placebo will be taken for three months continuously.
89457801|NCT02310165|Other|Z-tract Insertion Technique|For this technique, the skin is pulled 2 cm downward before the paracentesis needle is inserted and advanced.
89457802|NCT02310165|Other|Coaxial Insertion Technique|For this technique, the needle is directly inserted to minimize the distance between he cutaneous tissue and ascites
89457803|NCT02923921|Experimental|Pegilodecakin + FOLFOX|Pegilodecakin 5 microgram per kilogram (μg/kg) dosed as one of the following 2 fixed doses: 0.4 milligram (mg) for participants weighing ≤80 kg or 0.8 mg for participants weighing>80 kg on Days 1-5 and Days 8-12 subcutaneously (SC) plus FOLFOX [dl-Leucovorin (dl-LV) 400 milligram per meter square (mg/m2) and oxaliplatin 85 mg/m2 followed by bolus 5-fluorouracil (5-FU) 400 mg/m2 and a 46 to 48 hour infusion of 5- FU 2400 mg/m2] initiated on Day 1 of a 14-day cycles for up to 12 cycles or until disease progression. After discontinuation of FOLFOX in the absence of tumor progression [that is (i.e., completion of the planned 12 cycles or unacceptable FOLFOX related toxicity], Pegilodecakin 10µg/kg maintenance treatment administered as one of the 2 fixed doses, either 0.8 mg for participants weighing ≤80 kg or 1.6 mg for participants weighing>80 kg.
89457804|NCT02923921|Active Comparator|FOLFOX|FOLFOX (dl-LV 400 mg/m2 and oxaliplatin 85 mg/m2 followed by bolus 5-FU 400 mg/m2 and a 46-hour infusion of 5-FU 2400 mg/m2) initiated on Day 1 of a 14-day cycles for up to 12 cycles or until disease progression.
89457805|NCT02310243|Experimental|Palbociclib|"Phase1b: 125 mg palbociclib once daily for 21 days followed by 7 days of rest; this regimen will be chosen for the first dose to be evaluated.~phase IIa: single-agent palbociclib using the tolerable dose defined in the phase Ib part of the study is administered once daily for 21 days followed by 7 days of rest."
88941016|NCT01855594|Placebo Comparator|Control group|The dose of the placebo will be adjusted according to the dummy serum level report.
88941017|NCT01855659||COPD patients|Patients who are stratified in the subgroups of COPD based on the severity: stages II, III, IV
88941018|NCT01855672|Active Comparator|Perceivable Stimulation|Stimulation of the occipital nerves.
88941019|NCT01855672|Active Comparator|Non-Perceivable|Stimulation of the occipital nerves.
88941020|NCT01855698||All patients registered|
88941021|NCT01855711|Experimental|GR68755 (Alosetron hydrochrolide) group|GR68755 1 mg tablets QD in the morning every day for 28 days
88941022|NCT01855724|Experimental|Gemcitabine-Pazopanib|"Gemcitabine 1000 mg/m2 administered intravenously on days 1 and 8 and Pazopanib 800 mg administered per os on days 1 to 21 every 21 days.~Treatment with gemcitabine/pazopanib combination will continue until disease progression, appearance of significant toxicity, completion of 8 cycles or informed consent withdrawal.~Upon completion of 8 treatment cycles with the combination, and in the absence of disease progression, administration of pazopanib monotherapy as maintenance treatment will be continued until disease progression, appearance of significant toxicity or informed consent withdrawal."
88941023|NCT01855737||Warfarin Using Group|
88941024|NCT01855763|Experimental|metformin|group A1:Consists of patients with GDM who were given drug metformin as treatment group B1:Consists of patients with type 2 diabetes in pregnancy were given the drug metformin as treatment intervention with drug metformin is given for control of diabetes in esclation dose of 500mg /day upto 2.5 grams per day in two to three divided doses till delivery
88941025|NCT01855763|Active Comparator|insulin|GroupA2:gestational diabetes on insulin treatment Group B2:type 2 diabetes on insulin treatment intervention:insulin treatment till delivery
89016680|NCT02951052|Experimental|CAB LA + RPV LA every 4 weeks|Eligible subjects receive Oral CAB 30 mg + RPV 25 mg once daily for four weeks, IM CAB LA 600 mg and RPV LA 900 mg for the first injection, and Week 4 onwards subjects will receive CAB LA (400 mg) + RPV LA (600 mg) injections every 4 weeks until withdrawal.
89457806|NCT05223569|Experimental|Home OCT monitoring model|"Participants will receive a home monitoring set, which includes a self-administrated OCT, and a self-administrated smartphone-based visual acuity tester. For each home service, participants will undergo the following:~Smartphone-assisted online instruction provided by a virtual specialist~Visual acuity self test using a smartphone~Self-testing OCT imaging"
89457807|NCT05223569|Active Comparator|Hospital-based monitoring with a staff-administrated OCT|Participants will be instructed to come back to the clinic to receive traditional OCT and VA examinations operated by the study coordinators every month.
89457808|NCT02989571|Placebo Comparator|Group 1 - Placebo Arm|Intravenous normal saline administered at 125ml/hr
89457809|NCT02989571|Active Comparator|Group 2 - Intervention Arm|Intravenous normal saline administered at 250ml/hr
89457810|NCT03497793|Experimental|Skin-to-skin care with SNUBY|Mothers providing skin-to-skin care with the use of SNUBY
89457811|NCT02319447|No Intervention|Usual Care|After randomization, these study participants will receive the Usual Care received by all listed kidney transplant candidates at our center.
89457812|NCT02319447|Experimental|Additional education|These study participants will be invited to attend a 60-90 minute educational seminar, entitled Destination: Transplant, delivered in a group setting. They will also receive monthly mailings for 9 months and a follow-up phone call from a transplant educator.
89457813|NCT02321085|Active Comparator|Sinus Rhythm Control group|"Start AAD right after evaluating for LA size, EF, LA thrombus, and presence of CAD during anticoagulation~Cardioversion after 1 month~Rhythm FU schedule (2012 ACC/AHA/ESC guidelines)~If AF recur, RFCA"
89457814|NCT02321085|Active Comparator|Pulse Rate Control Group|"No AAD, just anticoagulation~HR control between 60~110bpm (with beta blocker, calcium channel blocker, digoxin)~Without the treatment about antiarrhythmia and rhythm control, diffraction of rate control, the subject will be drop out for study."
89457815|NCT03625661|Experimental|Arm with Ferinject|Ferinject will be administered once at inclusion
89457816|NCT03497715|Experimental|Experimental 1|Treatment order: Ibuprofen liquid capsules, Ibuprofen sodium, Ibuprofen (Nurofen), Ibuprofen lysine, Ibuprofen (Wockhardt)
88941026|NCT01855776|Other|Control Group|"The control group will receive a usual care educational programme at baseline created by the Singapore Health Promotion Board. This guide describes the importance of physical activity and illustrates one possible physical activity programme. It also discusses strategies for adopting a healthy lifestyle. They will not receive the Fitbit Zip wireless pedometer from the study team. However, they will receive $4 per week, regardless of physical activity levels."
88941027|NCT01855776|Experimental|Programme Only Group|This group receives the Fitbit Zip, and access to the Fitbit website. Fitbit Zip counts the number of steps walked, calories burned, and distance travelled. Participants can set goals for their physical activity levels, and will have access to personalised feedback from Fitbit. This group will also receive $4 per week, regardless of physical activity levels.
88941028|NCT01855776|Experimental|Cash Incentive Group|"This group receives the Fitbit Zip and the opportunity to earn money each week based on the number of steps logged on the pedometer during that week. We will offer the following incentive schedule:~$0 SGD for less than 50,000 steps during the week~$15 SGD for 50,000 - 69,999 steps during the week (max of 20,000 steps per day)~$30 SGD for 70,000 or more steps during the week (max of 20,000 steps per day) Participants will receive monthly payments in cash after their physical activity is confirmed. The incentive will be calculated separately for each week of the 6-month incentive programme."
88941029|NCT01855776|Experimental|Charitable Incentive Group|This group is identical to the cash incentive group except that incentive payments will be donated directly to a tax-exempt nonprofit charity of the participant's choice. The charity will be selected at the start of the programme but will be limited to the most common tax-exempt nonprofit charities operating in Singapore. As a motivational feedback component of the programme, participants will receive a thank-you email or letter from the charity.
88941030|NCT01855841|Active Comparator|Hemin|A peripheral perfusion of 4mg/kg of hemin (Normosang) diluted in 100mL NaCL (sodium chloride) 0.9% will be administered in 30-60minutes as soon as possible after the end of the ERCP, followed by 100mL of NacL 0.9% to flush the vein
88941031|NCT01855841|Placebo Comparator|Placebo|The same amount of NaCl 0.9% (100 ML followed by a flushing perfusion of 100mL) will be perfused to the patient as soon as possible after the end of the ERCP
88941032|NCT01855854|Experimental|Icotinib|Icotinib: 250 mg is administered orally three times per day, until disease progression or unacceptable toxicity.
88941033|NCT01855893|Experimental|Auto-acupressure|Patients will receive instructions about how to apply auto-acupressure once in a day during one week by their health care professionals.This technique will be complementary to the conventional treatment.
88941034|NCT01855893|Other|Conventional treatment|Conventional treatment consist of: 7 days with paracetamol 1g /8 hours and/ or ibuprofen 400mg/ 8 hours, and tetrazepam 50 mg/ 12 hours
88941035|NCT01855906|Active Comparator|Gap balanced surgical technique|Study patients in this arm of the study will have their knee replacement done using the gap balanced technique. Gap balancing adjusts the bony cuts for femoral rotation to balance the soft tissues of the knee in flexion.
89457817|NCT03497715|Experimental|Experimental 2|Treatment order: Ibuprofen lysine, Ibuprofen (Wockhardt), Ibuprofen sodium, Ibuprofen (Nurofen), Ibuprofen liquid capsules
89457818|NCT03497715|Experimental|Experimental 3|Treatment order: Ibuprofen liquid capsules, Ibuprofen (Nurofen)1, Ibuprofen sodium, Ibuprofen (Wockhardt), Ibuprofen lysine
89457819|NCT03497715|Experimental|Experimental 4|Treatment order: Ibuprofen (Wockhardt), Ibuprofen (Nurofen), Ibuprofen lysine, Ibuprofen liquid capsules, Ibuprofen sodium
89457820|NCT03625583||chronic myeloid leukaemia|chronic myeloid leukaemia diagnosed from 2007 - 2017
89457821|NCT02321163|Experimental|NMES new paradigm|For the NMES new paradigm, A portable electrical stimulator will be used to produce simultaneous stimulation to both the quadriceps and calf muscles. The stimulator delivers a biphasic, asymmetrical square wave at a pulse width of 250 μs and duty cycle 5:10 sec with 2 Hz frequencies of stimulation. To disperse current intensity and enhance the comfort of the stimulation, large rectangular electrodes (80 × 100 mm) will be positioned at the best motor points of the quadriceps and calf muscles. The electrodes will be secured by tight short and sock at the respective positions. The stimulation intensity will be set to just visible muscle contractions. Stimuli will be applied twice a day for 3 h (with a 2 h rest between treatments), 5 days a week for 8 weeks.
89457822|NCT02321163|Active Comparator|NMES conventional|For NMES conventional, the experimental protocol will be the conventional electrical stimulation protocol i.e frequency: 50 Hz; intensity: maximum intensity tolerated by the subject; duration: 30 min.
88941036|NCT01855906|Active Comparator|Measured resection surgical technique|Study patients in this arm of the study will have their knee replacement done using the measured resection surgical technique. Pre-determined bony cuts are made and appropriate balance is obtained by judicious soft tissue releases as required.
89457823|NCT02321163|Sham Comparator|Placebo|For placebo, electrodes will be applied and all conditions will be similar to those in the NMES group, except that the amplitude will be set to 0 mA so that no muscle stimulation occurs.
89457824|NCT04462887|Experimental|Nursing intervention program|The nursing intervention program consisting of 3 parts: (1) Structural Informational (SI) booklet, (2) Nursing Telephone Support (NTS) protocol, and (3) Nurse Pager 24/7.
89457825|NCT04462887|No Intervention|Usual Care Group|Usual care participants received treatment as usual from their health care providers.
89457826|NCT02321241||Group 1|According to the recommendations of the Summary of Products Characteristics (SmPC) Administration by intravitreal injection
89457827|NCT03583307|Experimental|Sirolimus|
89457828|NCT02449551|Experimental|Volitinib|Volitinib 800 mg will be administered orally once a day for 21 days as one cycle.
89457829|NCT03499665|Experimental|PNF, Myofascial Releasing Maneuvers, Home Exercise Group|This group of patients received patients with bruxism. It was applied proprioceptive neuromuscular facilitation (PNF), myofascial releasing maneuvers and home exercises.
89457830|NCT03499665|Active Comparator|Myofascial Releasing Maneuvers and Home Exercises Group|This group of patients received patient with bruxism. It was applied myofascial releasing maneuvers and home exercises.
89457831|NCT03499665|Active Comparator|Control Group|This group of patients received patient with bruxism. It was applied conventional treatment and no myofascial releasing or Proprioceptive Neuromuscular Facilitation exercises were applied.
89457832|NCT03039023|Experimental|Whole Hardboiled Eggs|Subjects will consume four (4) pre-cooked, pre-peeled whole hardboiled eggs per day for 28 days.
88941037|NCT01855932|Experimental|Technology Supported|
88941038|NCT01855971|Active Comparator|Fragile X syndrome experimental group|"Administration of 400 mg/day of epigallocatechin-3-gallate (EGCG). Life Extension, Mega Green Tea Extract Decaffeinated, a dietary supplement containing EGCG extract (45% EGCGC).~Dosage form: capsules of 200mg Route of administration: orally Dosage: 2 capsules per day (400 mg EGCG/day) Frequency: one capsule in the morning (fasting state) and a second capsule in the afternoon (before dinner).~Treatment period: 3 months (from month 1 to month 4)~Cognitive training: non-pharmacological cognitive training 3 sessions per week (1 hour per session) by using the Feskits program."
88941039|NCT01855971|Placebo Comparator|Fragile X syndrome control group|"Placebo administration. Placebo consists in capsules containing rice flour. Dosage form: capsules Route of administration: orally Dosage: 2 capsules per day Frequency: one capsule in the morning (fasting state) and a second capsule in the afternoon (before dinner).~Cognitive training: non-pharmacological cognitive training 3 sessions per week (1 hour per session) by using the Feskits program."
88941040|NCT01855984|Experimental|Oral mixed tocotrienols|2 capsules containing 100mg mixed tocotrienols per capsule taken orally once a day for 6 months
88941041|NCT01855984|Placebo Comparator|Placebo|2 capsules containing soya bean oil taken orally once a day for 6 months
88941042|NCT01855620||Normal weight women|Women with implant for more than twelve months who have BMI <25.
89457833|NCT03039023|Experimental|Choline Bitartrate Tablets|Subjects will consume two (2) 500mg choline bitartrate tablets per day for 28 days.
89457834|NCT03039023|Experimental|Hardboiled Eggs + Choline Bitartrate Tablets|Subjects will consume both four (4) whole, pre-cooked, pre-peeled hardboiled eggs and two (2) 500mg choline bitartrate tablets per day for 28 days.
89457835|NCT03039023|Experimental|Egg Whites + Choline Bitartrate Tablets|Subjects will consume both the egg whites (no yolks) of four (4) pre-cooked, pre-peeled hardboiled eggs and two (2) 500mg choline bitartrate tablets per day for 28 days.
89457836|NCT03039023|Experimental|Phosphatidylcholine Capsules|Subjects will consume six (6) 420 mg phosphatidylcholine capsules by mouth per day for 28 days.
89457837|NCT02310555|Active Comparator|Gastric bypass|classic Gastric bypass
89457838|NCT02310555|Active Comparator|Modified gastric bypass.|Modified gastric bypass. Resection body and fundus gastric
89457839|NCT02310555|Active Comparator|Slevee Gastrectomy|Slevee Gastrectomy
89457840|NCT03708263|Active Comparator|532nm KTP Laser|Cutera® Excel V 532 nm Application of light spots 5 to 7 mm for a pulse duration of 8 to 20 ms and a fluence of 7.4 to 10 J / cm2.
89457841|NCT03708263|Experimental|585 nm yellow laser|PHOTOLASE PLV 585 nm Application of light spots 1.4mm for a pulse duration of 10 to 100 ms and a fluence of 0 to 65 J / cm2.
89457842|NCT03022045|Experimental|Risankizumab 75 mg|Participants randomized to receive risankizumab 75 mg at Week 0, Week 4, and every 12 weeks up to Week 172.
89457843|NCT03022045|Experimental|Risankizumab 150 mg|Participants randomized to receive risankizumab 150 mg at Week 0, Week 4, and every 12 weeks up to Week 172.
89457844|NCT04462263|Experimental|Single Dose HTL0014242|The study consists of up to 5 dosing groups, with 2 to 3 subjects per dosing group. Each subject will receive a single oral dose of HTL0014242 in the form of solid suspension capsules (1, 5, 10, and 30mg) as required. HTL0014242 will be administered in up to 5 single dose groups, with 120mg administered in the first dosing group.
89457845|NCT04462341|Active Comparator|Manual brushing only|Participants brushed with a manual toothbrush and fluoridated toothpaste twice a day for 6 weeks
89457846|NCT04462341|Experimental|Manual brushing + water flossing|Participants brush twice a day and water flossed once a day for 6 weeks.
89457847|NCT02321397|Experimental|OXN PR HST|Prolonged release oxycodone/naloxone higher strength tablets
89457848|NCT02321397|Active Comparator|OXN PR LST|Prolonged release oxycodone/naloxone lower strength tablets
89457849|NCT02319603|Active Comparator|Low dose WenXin keli|"Low dose group (the original quantity Wenxin keli): specification 10g /bag, Wenxin keli (no sugar) 5 g+ Wenxin keli simulation agent 5g.~Oral ,1 bag each time, 3 times a day, 4 weeks for 1 course of treatment."
89457850|NCT02319603|Experimental|High dose WenXin keli|"High dose group(2 times the amount of Wenxin keli): specification 10g /bag, Wenxin keli (no sugar) 10 g.~Oral ,1 bag each time, 3 times a day, 4 weeks for 1 course of treatment."
89457851|NCT02673671||Subjects with unknown POI status consented pre-surgery|Up to 100 subjects may be consented prior to surgery who are planned to undergo gastrointestinal surgery or a planned surgery that does not involve the abdominal cavity. The investigator does not change the routine medical care of study participants.
89457852|NCT02673671||Subjects with known/unknown POI status consented post-surgery|Up to 50 subjects who have undergone gastrointestinal surgery or surgery not involving the abdominal cavity may be consented post- operatively during their hospital stay for this study.The investigator does not change the routine medical care of study participants.
89457853|NCT03499275|Sham Comparator|Sham NMES|Sham neuromuscular electrical stimulation plus home exercise programme and advice on breathlessness management
89457854|NCT03499275|Experimental|Active NMES|Neuromuscular electrical stimulation plus home exercise programme and advice on breathlessness management
89457855|NCT03497559|Experimental|Music|Patients will received 30 minutes of classical music 3 times per day . Music will be delivered with noise cancellation headphones.
89457856|NCT03497559|Sham Comparator|Noise cancellation|Patients will received 30 minutes of silent recording 3 times per day . Music will be delivered with noise cancellation headphones.
89457857|NCT03497559|No Intervention|Control|Patients will receive standard of care.
88941043|NCT01855620||Overweight women|Women with implant for more than twelve months who have BMI > or = 25 and <30.
88941044|NCT01855620||Obese women|Women with implant for more than twelve months who have BMI > or = 30.
89457858|NCT02310945||Knee osteoarthritis|People with moderate/severe symptomatic knee osteoarthritis referred for physiotherapy
88941045|NCT01856010||ECT Treatment|Those who were referred for ECT treatment for behavior refractory to standard care and who opted to undergo ECT treatment
89457859|NCT05209451|Active Comparator|Control Condition - No additional study intervention|Subjects will receive a 12-week, digital, evidence-based behavioral health program for smoking cessation delivered through the patient portal and a written guide on existing digital access resources along with any other necessary material.
89457860|NCT05209451|Experimental|Loaner Digital Device|Subjects will receive a 12-week, digital, evidence-based behavioral health program for smoking cessation delivered through the patient portal and a written guide on existing digital access resources along with any other necessary material. Participants in this group will also receive a loaned Bluetooth enabled iPad with data plan coverage for the study duration.
89457861|NCT05209451|Experimental|Loaner Digital Device + Coaching Support|Subjects will receive a 12-week, digital, evidence-based behavioral health program for smoking cessation delivered through the patient portal and a written guide on existing digital access resources along with any other necessary material. Participants in this group will also receive a loaned Bluetooth enabled iPad with data plan coverage for the study duration plus up to six coaching call, 15-20 minutes in duration.
89457862|NCT02319681|Experimental|Simple Reminiscence (SR) caregiver|Subjects are caregivers for a persons with EAD and will be administered SR intervention and an attention control treatment four times
89457863|NCT02319681|Experimental|Simple Reminiscence (SR) EAD|Subjects are persons with EAD and will be administered SR intervention and an attention control treatment four times
89457864|NCT02321475||Psycho-emotional symptoms, added to cognitive disorders|Patients of middle age and younger with psycho-emotional symptoms, added to cognitive disorders.
89457865|NCT02321553|Experimental|Brown Rice|Eat 100g of brown rice cake (3 packets) per day for 5 weeks
89016681|NCT02951052|Active Comparator|Current antiretroviral regimen|Eligible subjects will continue their current anti-retroviral regimen (2 NRTIs plus an INI, NNRTI, or a PI) for 52 weeks. After 52 weeks subjects have the option to continue study participation by switching to CAB LA + RPV LA in the Extension Phase where they will follow the procedure of CAB LA + RPV LA arm.
89016682|NCT02888600|Active Comparator|Mindfulness Training|The Mindfulness Meditation Program consists of eight weekly 2- 2.5 hour group sessions, a day-long retreat in the sixth week, and daily mindfulness meditation homework.
89016683|NCT02888600|Active Comparator|Health Education|The Health Education Program also consists of eight weekly 2- 2.5 hour group sessions, a day-long retreat in the sixth week, and daily health practice homework
89016684|NCT02879383|Experimental|DMR Procedure|Subjects randomized to the DMR procedure are unblinded at 24 weeks and followed for an additional 24 weeks.
89016685|NCT02879383|Sham Comparator|Sham Procedure|Subjects are unblinded at 24 Weeks. Sham subjects to cross over to receive DMR treatment at 24 Weeks and followed up for additional 24 weeks.
89016686|NCT02848040|Experimental|Single Arm|All patients will receive the same interventions. Single are only
89016687|NCT02841540|Experimental|H3B-8800 (RVT-2001) Dose Escalation|H3B-8800 Acute Myeloid Leukemia or High Risk Myelodysplastic Syndromes/ Low Risk Myelodysplastic Syndromes/ Chronic Myelomonocytic Leukemia.
89016688|NCT02841540|Experimental|H3B-8800 (RVT-2001) MDS Expansion|Transfusion-dependent, lower-risk MDS subjects (very-low to intermediate risk categorization per IPSS-R) with missense mutations in SF3B1.
89016689|NCT02841540|Experimental|H3B-8800 (RVT-2001) Dose Optimization|Transfusion-dependent, lower-risk MDS subjects (very-low to intermediate risk categorization per IPSS-R) with missense mutations in SF3B1, and who have not been exposed to HMA's or lenalidomide in a prior line of therapy.
89016690|NCT02814383||ELBW Infants|This study seeks to collect data on premature ELBW infants (less than or equal to 2.2 lbs) at high risk of developing brain injury.
89016691|NCT02780973||Females|Female volunteers
89457866|NCT02321553|Experimental|White Rice|Eat 100g of white rice cake (3 packets) per day for 5 weeks
89457867|NCT02321631|Experimental|EPA-enriched supplement|EPA-enriched supplement is given to the patients for 3 weeks (1 week prior to surgery and 2 weeks post surgery). The supplement composes of 2.2 gm of EPA and 630 kcal daily.
89457868|NCT02321631|Placebo Comparator|standard formula supplement|The standard formula supplement is given to the patients for 3 weeks (1 week prior to surgery and 2 weeks post surgery). The supplement is 630 kcal daily without EPA.
89457869|NCT02321709|Experimental|SAR113244 cohort 1|Two administrations of dosage 1 SAR113244 or placebo subcutaneous dose (Q4 weeks)
89457870|NCT02321709|Experimental|SAR113244 cohort 2|Two administrations of dosage 2 SAR113244 or placebo subcutaneous dose (Q4 weeks)
89457871|NCT02321709|Experimental|SAR113244 cohort 3|Two administrations of dosage 3 SAR113244 or placebo subcutaneous dose (Q4 weeks)
89457872|NCT03037619|Experimental|Fitbit|Participants randomized to Fitbit will be mailed a Fitbit and encouraged to wear it over the next 4 months.
89016692|NCT02780973||Males|Male volunteers
89016693|NCT02724878|Experimental|Bevacizumab And Atezolizumab Combination|"1200 mg of Atezolizumab intravenously x 3 weeks~15 mg/kg of Bevacizumab intravenously x 3 weeks.~One cycle will be 3 weeks in duration."
89016694|NCT02723331|Experimental|Nab-paclitaxel and Gemcitabine for R-PDAC|Nab-paclitaxel and gemcitabine, for R-PDAC patients enrolled in this trial, will be given in combination as neoadjuvant combination chemotherapy, followed by SBRT. This is will be followed up by surgical resection and an additional combination chemotherapy of nab-paclitaxel and gemcitabine as adjuvant chemotherapy.
89016695|NCT02723331|Experimental|Nab-paclitaxel and Gemcitabine for BR-PDAC|Nab-paclitaxel and gemcitabine, for BR-PDAC patients enrolled in this trial, will be given in combination as neoadjuvant combination chemotherapy, followed by SBRT. This is will be followed up by surgical resection and an additional combination chemotherapy of nab-paclitaxel and gemcitabine as adjuvant chemotherapy.
89016696|NCT02723240|Experimental|Part 1 (weekly administration) NUC-3373 125mg/m2|"NUC-3373 125mg/m2 solution for injection/infusion IV Infusion on Day 1, Day 8, Day 15, Day 22 (28 day cycle).~Participants can remain on study and receive treatment until disease progression or unacceptable toxicity occurs."
89016697|NCT02723240|Experimental|Part 1 (weekly administration) NUC-3373 250mg/m2|"NUC-3373 250mg/m2 solution for injection/infusion IV Infusion on Day 1, Day 8, Day 15, Day 22 (28 day cycle).~Participants can remain on study and receive treatment until disease progression or unacceptable toxicity occurs."
89016698|NCT02723240|Experimental|Part 1 (weekly administration) NUC-3373 500mg/m2|"NUC-3373 500mg/m2 solution for injection/infusion IV Infusion on Day 1, Day 8, Day 15, Day 22 (28 day cycle).~Participants can remain on study and receive treatment until disease progression or unacceptable toxicity occurs."
89016699|NCT02723240|Experimental|Part 1 (weekly administration) NUC-3373 750mg/m2|"NUC-3373 750mg/m2 solution for injection/infusion IV Infusion on Day 1, Day 8, Day 15, Day 22 (28 day cycle).~Participants can remain on study and receive treatment until disease progression or unacceptable toxicity occurs."
89016700|NCT02723240|Experimental|Part 1 (weekly administration) NUC-3373 1125mg/m2|"NUC-3373 1125mg/m2 solution for injection/infusion IV Infusion on Day 1, Day 8, Day 15, Day 22 (28 day cycle).~Participants can remain on study and receive treatment until disease progression or unacceptable toxicity occurs."
89457873|NCT03037619|Experimental|Fitbit+Support|"Participants will identify a Buddy and both the participant and Buddy will be mailed a Fitbit. Both participant and Buddy will be asked to Friend each other on Fitbit and encouraged to wear the monitor over the next 4 months."
89457874|NCT03497403|Active Comparator|Control|Socket preservation control. After tooth extraction, bone graft is applied to socket and a non-cross-linked membrane is used in primary intentional healing.
89457875|NCT03497403|Experimental|Experimental|Socket preservation experimental. After tooth extraction, bone graft is applied to socket and a cross-linked membrane is used in secondary intention healing.
89457876|NCT04463433|Experimental|Parent-child Relationship Intervention|The intervention involves five 2h weekly group sessions in which exercises in mindfulness are practiced and associated ABCDE theory is taught to improve emotional regulation and parent-child communication under COVID-2019.
89457877|NCT04463433|Experimental|Couple Relationship Intervention|The intervention involves four 2h weekly group sessions in which express feelings and wants clearly are practiced and associated Satir communication model is taught to improve couple conflict resolution and communication under COVID-2019.
89457878|NCT02319915|Experimental|Tranexamic acid|Study of the pharmacokinetic profile of the plasmatic resorption of tranexamic acid after an intra-articular injection.
89457879|NCT02319915|Active Comparator|Tranexamic acid + adrenalin|Study of the pharmacokinetic profile of the plasmatic resorption of tranexamic acid after an intra-articular injection of tranexamic acid with adrenalin 1/200 000.
89457880|NCT04898309|Experimental|Study stage 1: GNR-038, 50 МЕ/ kg|Recombinant C1 esterase inhibitor
89457881|NCT04898309|Experimental|Study stage 1: GNR-038, 100 МЕ/ kg|Recombinant C1 esterase inhibitor
89457882|NCT04898309|Experimental|Study stage 1: Berinert®, 20 МЕ/ kg|Human C1 esterase inhibitor
88941046|NCT01856010||Standard Care (Non-ECT Group)|Those who were referred for ECT treatment for behavior refractory to standard care, but who opted to not undergo ECT treatment and continue with standard care.
89457883|NCT04898309|Experimental|Study stage 1: Placebo|Placebo
89457884|NCT04898309|Experimental|Study stage 2: GNR-038 in selected dose|Recombinant C1 esterase inhibitor
89457885|NCT04898309|Experimental|Study stage 2: Berinert®, 20 МЕ/ kg|Human C1 esterase inhibitor
89457886|NCT02311023|Experimental|Intermittent fasting|Patients consume their normal diet for 5 days in the week. On 2 days they only consume 500 Cals if female and 600 Cals if male.
89457887|NCT03694457|Active Comparator|deltopectoral approach|the patients are treated with deltopectoral approach surgery
89457888|NCT03694457|Other|lateral approach|the patients are treated with a lateral approach surgery
89457889|NCT03505437|Experimental|Stress + Exposure|Stress Condition: Cold water condition of the socially evaluated cold pressor test (SECPT; Schwabe et al, 2008).
89457890|NCT03505437|Active Comparator|Control + Exposure|Control condition: Warm water condition of the SECPT.
89457891|NCT03497325|Experimental|PRP|55 participant unergoing prelabor primary CS will receive intramyometrial injection of PRP after closure of uterine incision
89457892|NCT03497325|Placebo Comparator|placebo|55 participant unergoing prelabor primary CS will receive intramyometrial injection of normal saline after closure of uterine incision
89457893|NCT02321787|No Intervention|Traditional Methods of Assessment|The caudal block will be done using traditional means of assessment, not confirmed by ultrasound.
89457894|NCT02321787|Experimental|Ultrasound for Confirmation|The caudal block will be performed utilizing ultrasound as an additional method of assessment for successful block (in addition to all traditional means of assessment).
89457895|NCT03497247|Experimental|Mindfulness-Based Cognitive-Behavioral Therapy|
89457896|NCT03497247|Active Comparator|Cognitive-Behavioral Therapy|
89457897|NCT03499041|Experimental|LY3314814 Control|LY3314814 administered orally to participants with normal hepatic function
89457898|NCT03499041|Experimental|LY3314814 Mild|LY3314814 administered orally to participants with mild hepatic impairment
89457899|NCT03499041|Experimental|LY3314814 Moderate|LY3314814 administered orally to participants with moderate hepatic impairment
89457900|NCT03499041|Experimental|LY3314814 Severe|LY3314814 administered orally to participants with severe hepatic impairment
88941047|NCT01856036|Experimental|Cryoablation|Cryoablation of breast cancer will be performed using a freeze-thaw technique and an IceCure probe. Cryoablation cycles will be determined by IceCure software programmed by the treating surgeon.
88941048|NCT01856062|Experimental|Clomiphene plus dexamethasone|Oral dexamethasone will be added to clomiphene citrate
88941049|NCT01856062|Placebo Comparator|Clomiphene plus placebo|A placebo of dexamethasone will be given with clomiphene citrate
88941050|NCT01856075||Patients treated with dronedarone|Patients treated with dronedarone at inclusion
89457901|NCT03498963|Other|bronchoalveolar lavage|
89457902|NCT02321865|Experimental|NPC-02|
89457903|NCT03505359|Experimental|Experimental group|Group treated by the new protocol with partial knee immobilization
89457904|NCT03505359|Active Comparator|Control group|Group treated by a standard protocol for ACL reconstruction.
89457905|NCT03498885|Experimental|Low ligation|Left colic artery (LCA) is identified, tie the sigmoid artery and superior rectal artery,Apical lymph node dissection with the left colic artery preservation is performed.
89457906|NCT03498885|Active Comparator|High ligation|The IMA is ligated and divided at 2 cm from its origin. Apical lymph nodes dissection is performed.
89457907|NCT05027399|Active Comparator|Intervention Group|Consultations will be carried out via video call, every 15 days for a period of 3 months, with a total of 6 telephone consultations that will have in order to clarify doubts about the CI, the monitoring of possible clinical signs of instability and help in adapting or creating strategies for better adherence to therapy.
89457908|NCT05027399|No Intervention|Control Group|Will be composed by the participants who will have no intervention and will continue to monitor according to the institution's routine.
89457909|NCT02311101|Experimental|Therapy Group MMC 10/BCG Half|"Intravesical Mitomycin C and intravesical BCG~First intravesical mitomycin C (10 mg) is instilled for 30 minutes. Then the mitomycin is removed and the bladder is gently hand-irrigated with sterile water for 15 minutes in order to facilitate removal of mitomycin C. Then, intravesical BCG (half dose) is instilled for 2 hours under usual conditions. Full dose BCG corresponds to 1 to 8x10^8 colony-forming units of BCG. This study targets patients with BCG-naive or BCG-refractory high-risk non-muscle invasive bladder cancer. The first 3 participants received 10mg of MMC and half dose of BCG. The dose was assigned in order of enrollment."
89457910|NCT02311101|Experimental|Therapy Group MMC 10/BCG Full|First intravesical mitomycin C (10 mg) is instilled for 30 minutes. Then the mitomycin is removed and the bladder is gently hand-irrigated with sterile water for 15 minutes in order to facilitate removal of mitomycin C. Then, intravesical BCG (full dose) is instilled for 2 hours under usual conditions. Full dose BCG corresponds to 1 to 8x10^8 colony-forming units of BCG. This study targets patients with BCG-naive or BCG-refractory high-risk non-muscle invasive bladder cancer. The following 3 participants received 10mg of MMC and full dose BCG. Dose was assigned in order of enrollment.
89016701|NCT02723240|Experimental|Part 1 (weekly administration) NUC-3373 1500mg/m2|"NUC-3373 1500mg/m2 solution for injection/infusion IV Infusion on Day 1, Day 8, Day 15, Day 22 (28 day cycle).~Participants can remain on study and receive treatment until disease progression or unacceptable toxicity occurs."
89016702|NCT02723240|Experimental|Part 1 (weekly administration) NUC-3373 1875mg/m2|"NUC-3373 1875mg/m2 solution for injection/infusion IV Infusion on Day 1, Day 8, Day 15, Day 22 (28 day cycle).~Participants can remain on study and receive treatment until disease progression or unacceptable toxicity occurs."
89016703|NCT02723240|Experimental|Part 1 (weekly administration) NUC-3373 2500mg/m2|"NUC-3373 2500mg/m2 solution for injection/infusion IV Infusion on Day 1, Day 8, Day 15, Day 22 (28 day cycle).~Participants can remain on study and receive treatment until disease progression or unacceptable toxicity occurs."
89457911|NCT02311101|Experimental|Therapy Group MMC 20/BCG Full|First intravesical mitomycin C (20 mg) is instilled for 30 minutes. Then the mitomycin is removed and the bladder is gently hand-irrigated with sterile water for 15 minutes in order to facilitate removal of mitomycin C. Then, intravesical BCG (full dose) is instilled for 2 hours under usual conditions. Full dose BCG corresponds to 1 to 8x10^8 colony-forming units of BCG. This study targets patients with BCG-naive or BCG-refractory high-risk non-muscle invasive bladder cancer. The next 3 participants enrolled received 20mg of MMC and full dose BCG. Dose was assigned in order of enrollment.
89457912|NCT02311101|Experimental|Therapy Group MMC 40/BCG Full|First intravesical mitomycin C (40 mg) is instilled for 30 minutes. Then the mitomycin is removed and the bladder is gently hand-irrigated with sterile water for 15 minutes in order to facilitate removal of mitomycin C. Then, intravesical BCG (full dose) is instilled for 2 hours under usual conditions. Full dose BCG corresponds to 1 to 8x10^8 colony-forming units of BCG. This study targets patients with BCG-naive or BCG-refractory high-risk non-muscle invasive bladder cancer. The last 3 participants received 40mg of MMC and full dose BCG. Dose was assigned in order of enrollment.
89457913|NCT03619499|Experimental|non invasive|infants who fulfill criteria of severe bronchiolitis will be connected to non invasive ventilation
89457914|NCT03619499|No Intervention|invasive|infants who were connected to invasive mechanical ventilation
89457915|NCT04058119|Experimental|Mind-body therapies|Sessions of body-mind therapies (yoga, qigong and pilates)
89457916|NCT04058119|No Intervention|Waiting list control group|Participants will not participate in any specific intervention, but will receive the Functional Training Program after the experimental period (6 months).
89457917|NCT02321943||Follow-Up Group|"An earlier investigated cohort with first episode psychosis patients from two Norwegian counties. Being between 18 - 65 years old and being consecutive in- or outpatient referred to first adequate treatment for a DSM-IV diagnosis of schizophrenia, bipolar disorder, or other psychosis."
89457918|NCT04925765|Experimental|Virtual Reality Session|All participants in this study will complete a 1 hour virtual reality session.
89016704|NCT02723240|Experimental|Part 1 (weekly administration) NUC-3373 3250mg/m2|"NUC-3373 3250mg/m2 solution for injection/infusion IV Infusion on Day 1, Day 8, Day 15, Day 22 (28 day cycle).~Participants can remain on study and receive treatment until disease progression or unacceptable toxicity occurs."
89457919|NCT04058275||Control|Deployed to 1990-1991 Persian Gulf War Do not meet Kansas Criteria for Gulf War Illness [Steele L. Prevalence and patterns of Gulf War illness in Kansas veterans: association of symptoms with characteristics of person, place, and time of military service. Am J Epidemiol. 2000 Nov 15; 152:992-1002. PubMed PMID: 11092441.] Good general medical and psychiatric health
89457920|NCT04058275||Gulf War Illness|Deployed to 1990-1991 Persian Gulf War Meet Kansas Criteria for Gulf War Illness [Steele L. Prevalence and patterns of Gulf War illness in Kansas veterans: association of symptoms with characteristics of person, place, and time of military service. Am J Epidemiol. 2000 Nov 15; 152:992-1002. PubMed PMID: 11092441.] plus Center for Disease Control criteria for Chronic Multisymptom Illness (CMI) [Fukuda K, Nisenbaum R, Stewart G, Thompson WW, Robin L, Washko RM, Noah DL, Barrett DH, Randall B, Herwaldt BL, Mawle AC, Reeves WC. Chronic multisymptom illness affecting Air Force veterans of the Gulf War. JAMA. 1998 Sep 16;280(11):981-8. PubMed PMID: 9749480.]
89457921|NCT03498807|Experimental|Control group_Use Ventilator P/V tool|Use the Pressure/Volume Loop
89457922|NCT03498807|Active Comparator|Study group_Use EIT|Use the Electrical Impedance Tomography
89457923|NCT03668899|Experimental|Chitosan NPs group|irrigation with Chitosan nanoparticles (final flush)
89457924|NCT03668899|Experimental|Chlorhexidine group|irrigation with CHX (final flush)
89457925|NCT03668899|Experimental|Combination group|irrigation with CHX/ nano Chitosan combination (final flush)
89457926|NCT03668899|Active Comparator|Hypochlorite group|irrigation with NaOCL (final flush)
89016705|NCT02723240|Experimental|Part 2 (two weekly administration) NUC-3373 1500mg/m2|"NUC-3373 1500mg/m2 solution for injection/infusion IV Infusion on Day 1, Day 15 (28 day cycle).~Participants can remain on study and receive treatment until disease progression or unacceptable toxicity occurs."
89016706|NCT02723240|Experimental|Part 2 (two weekly administration) NUC-3373 1875mg/m2|"NUC-3373 1875mg/m2 solution for injection/infusion IV Infusion on Day 1, Day 15 (28 day cycle).~Participants can remain on study and receive treatment until disease progression or unacceptable toxicity occurs."
89457927|NCT02319993|Experimental|TIAN WANG BU XIN DAN|"Drug:TIAN WANG BU XIN DAN CONCENRATED GRANULES CHUANG SONG ZONG"
89457928|NCT02319993|Experimental|Suan Tzao Ren Tang|"Drug:Suan Tzao Ren Tang Granula Subtilae CHUANG SONG ZONG"
89457929|NCT02319993|Placebo Comparator|Placebo|Drug:1/10 TIAN WANG BU XIN DAN
89457930|NCT02322255||All Subjects|All subjects enrolled in the study.
89457931|NCT03669211|Experimental|Cardiac stress test|
89457932|NCT04771013|Experimental|Daily oral dose of thymic peptides|Patients will receive a daily oral dose of 250 mg of lyophilized thymic peptides dissolved in 50 mL of water (one hour before or two hours after a meal) in addition to the standard treatment, for up to 20 days or until medical discharge.
89457933|NCT02320071||Patients with incisional hernia|Patients with one or more incisional hernias, combined horizontal fascial defect 3-8 cm, planned for laparoscopic mesh repair. Patients are examined before and one and three months postoperative in regard to abdominal wall function, pain, discomfort, hernia-related quality of life and physical activity level.
89457934|NCT03623191||Patients with erosive pustular dermatosis of the leg|
89457935|NCT04760561|No Intervention|Control group (conventional care)|Patients randomized to this arm will receive the conventional positioning interventions provided by the critical care nurses, which will not include self-prone positioning.
89457936|NCT04760561|Experimental|Intervention group (prone position group)|Patients randomized to this arm will receive self-prone positioning.
89457937|NCT04620187|Experimental|Standard of Care + T-DM1 in HER2-Positive Salivary Gland Cancer|"Participants will undergo standard of care surgery followed by standard of care radiation and chemotherapy with the addition of T-DM1.~Study cycles are 21 days (3 weeks):~Participants will be given the study treatment T-DM1 at a predetermined dose (3.6 mg/kg) intravenously once (1x) every 3 weeks for up to 52 weeks (or about 1 year).~Participants will be given standard of care radiation and chemotherapy~Radiation will be given on Cycle 1 Day 8, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 2 Day 8, Cycle 2 Day 15, and Cycle 3 Day 1~Chemotherapy (cisplatin 40 mg/m2 intravenously or carboplatin AUC 2 intravenously) will be given on Cycle 1 Day 8, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 2 Day 8, Cycle 2 Day 15, and Cycle 3 Day 1~Participants will be followed for 3 years."
89457938|NCT02320305|Experimental|Arm I (MART-1 antigen and TLR4 antagonist GLA-SE)|Patients receive MART-1 antigen and TLR4 antagonist GLA-SE IM on day 1. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
89457939|NCT02320305|Experimental|Arm II (MART-1 antigen)|Patients receive MART-1 antigen IM on day 1. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
89457940|NCT04599725||Pregnant people|
89457941|NCT03625271|No Intervention|Control|All subjects will undergo same study procedures. Subjects in the Control Arm will receive treatment as usual by the prescribing clinician/investigator. The prescribing clinician/investigator will not receive the PEER Report of probable medication response for a control arm subject.
89457942|NCT03625271|Experimental|Experimental|All subjects will undergo same study procedures. Subjects in the Experimental Arm will receive treatment as usual by the prescribing clinician/investigator. However, the prescribing clinician/investigator will receive the PEER Report of probable medication response for an experimental arm subject. The report will provide additional data/information regarding probable medication response for an experimental arm subject to the prescriber .
89457943|NCT03497091||Enteral Tube fed children|Enteral Formula
89457944|NCT03668665|Active Comparator|Conventionell Treatment|"After split skin removal, the wound is divided into 2 parts (=2 arms):~1st half: conventional treatment with moist dressings (mepilex and fixomull)"
89457945|NCT03668665|Experimental|Treatment with Ready Medical Post Treatment|"After split skin removal, the wound is divided into 2 parts (=2 arms):~2nd half: conventional treatment with moist dressings (mepilex and fixomull) and additional treatment with ready medical post treatment"
89457946|NCT02322489|Sham Comparator|Sham microcurrent therapy|The participant is lying on an examination table for one hour; several electrodes are placed over the muscles involved in the provocative task. The microcurrent therapy is then started but it lasts only for 5 seconds.
89457947|NCT02322489|Experimental|Microcurrent Group|The participant is lying on an examination table for one hour; several electrodes are placed over the muscles involved in the provocative task. The microcurrent therapy is then started.
89457948|NCT04058509|Experimental|focused shockwave therapy|3 sessions of shock wave treatment.(Focused Shockwave Therapy).
89457949|NCT02320383|Experimental|B + GA101|"Induction:~Bendamustine + GA101; a maximum of 6 cycles of BG will be administered; each cycle with a duration of 28 days~Maintenance:~GA101 i.v. 1000 mg (flat dose): every 84 days starting on final restaging continued until progression or to a maximum of 2 years"
89457950|NCT03668509|Experimental|Cohort 1|oral adminstration of SHR1459, dose 1
89457951|NCT03668509|Experimental|Cohort 2|oral adminstration of SHR1459, dose 2
89457952|NCT03668509|Experimental|Cohort 3|oral adminstration of SHR1459, dose 3
89457953|NCT03494595||Thrombosis|Patients who will develop thrombosis perioperatively
89457954|NCT03494595||No thrombosis|Patients who will not develop thrombosis perioperatively
89457955|NCT03021265||T80/A5/H12.5 FDC|Patients with hypertension
89457956|NCT02322567||LV diastolic dysfunction|
89457957|NCT02322567||No LV diastolic dysfunction|
89457958|NCT03704987|Active Comparator|Klinefelter|Male patients followed with the diagnosis of klinefelter
89457959|NCT03704987|Active Comparator|Control|healthy male subjects
89457960|NCT03669289|Experimental|Enhanced model of primary care|
89457961|NCT04461951||Community dwelling seniors|Participants are visited at the research facility in their residence town by a trained team. Informed consent form is completed at the research facility prior to data collection. In those individuals without capacity to give full informed consent, proxy consent is collected from relatives or caregivers. This 2-hours interview includes a face-to-face administration of a neuropsychological battery of tests and questionnaires to inquire about socio-demographic, occupational, and social-economic data, education, medical conditions and drug use, lifestyle habits, functional status, and dietary behaviours.
89457962|NCT03668353|Experimental|treatment 1|Recombinant SeV-hFGF2/dF Injection 2×10 8CIU
89457963|NCT03668353|Experimental|treatment 2|Recombinant SeV-hFGF2/dF Injection 1×10 9CIU
89457964|NCT03668353|Experimental|treatment 3|Recombinant SeV-hFGF2/dF Injection 5×10 9CIU
89457965|NCT03668353|Experimental|treatment 4|Recombinant SeV-hFGF2/dF Injection 1×10 10CIU
89457966|NCT03704909|Active Comparator|Group Adrenaline: Group A|All parturients received a prophylactic i.v bolus of Epinephrine 0.15µg/Kg at time of SA. In this group, rescue boluses of Epinephrine 0.15µg/Kg, will be given if maternal BP decreased more than 20% from the baseline value.
89457967|NCT03704909|Active Comparator|Group Ephedrine: Group E|All parturients received a prophylactic i.v bolus of Ephedrine 0.1mg/Kg at time of SA. In this group, rescue boluses of Ephedrine 0.1mg/Kg, will be given if maternal BP decreased more than 20% from the baseline value.E
89457968|NCT02320539||SAH with DCI|After 21 days from ictus the patients with subarachnoid hemorrhage are stratified to group 1 or 2 depending on their development of delayed cerebral ischemia.
89457969|NCT02320539||SAH without DCI|After 21 days from ictus the patients with subarachnoid hemorrhage are stratified to group 1 or 2 depending on their development of delayed cerebral ischemia.
89457970|NCT02320539||SAH good grade|SAH without external ventricular drainage
89457971|NCT02320539||Healthy controls|Blood sample in healthy donors registered in the National Donor Registry.
89016707|NCT02723240|Experimental|Part 2 (two weekly administration) NUC-3373 2500mg/m2|"NUC-3373 2500mg/m2 solution for injection/infusion IV Infusion on Day 1, Day 15 (28 day cycle).~Participants can remain on study and receive treatment until disease progression or unacceptable toxicity occurs."
89457972|NCT03704831||IPACK group|IPACK group
89016708|NCT02717624|Experimental|Part 1: Acalabrutinib+BR in TN patients|Part 1: Acalabrutinib in combination with drugs bendamustine and rituximab (BR) in treatment naive patients
89457973|NCT03704831||Surgical infiltration group|Surgical infiltration group
89457974|NCT04462029|Other|sequence 1|"A total of 18 subjects will be randomized into 6 sequence groups. The investigational products (IPs) will be administered according to the treatment groups (R, T1, and T2) assigned to each sequence group in Period 1, Period 2, and Period 3. In between each period, there will be a washout period (28 days) long enough for the administered IP to be metabolized and eliminated.~R(Reference): BR4002-1 (oral intake) 5mg single-dose~T1(Test1): BR4002 (patch) 5mg single-dose (using the applicator)~T2(Test2): BR4002 (patch) 5mg single-dose (not using the applicator)~sequence 1: R - T1 - T2"
89457975|NCT04462029|Other|sequence 2|"A total of 18 subjects will be randomized into 6 sequence groups. The investigational products (IPs) will be administered according to the treatment groups (R, T1, and T2) assigned to each sequence group in Period 1, Period 2, and Period 3. In between each period, there will be a washout period (28 days) long enough for the administered IP to be metabolized and eliminated.~R(Reference): BR4002-1 (oral intake) 5mg single-dose~T1(Test1): BR4002 (patch) 5mg single-dose (using the applicator)~T2(Test2): BR4002 (patch) 5mg single-dose (not using the applicator)~sequence 2: R - T2 - T1"
89457976|NCT04462029|Other|sequence 3|"A total of 18 subjects will be randomized into 6 sequence groups. The investigational products (IPs) will be administered according to the treatment groups (R, T1, and T2) assigned to each sequence group in Period 1, Period 2, and Period 3. In between each period, there will be a washout period (28 days) long enough for the administered IP to be metabolized and eliminated.~R(Reference): BR4002-1 (oral intake) 5mg single-dose~T1(Test1): BR4002 (patch) 5mg single-dose (using the applicator)~T2(Test2): BR4002 (patch) 5mg single-dose (not using the applicator)~sequence 3: T1 - R - T2"
89457977|NCT04462029|Other|sequence 4|"A total of 18 subjects will be randomized into 6 sequence groups. The investigational products (IPs) will be administered according to the treatment groups (R, T1, and T2) assigned to each sequence group in Period 1, Period 2, and Period 3. In between each period, there will be a washout period (28 days) long enough for the administered IP to be metabolized and eliminated.~R(Reference): BR4002-1 (oral intake) 5mg single-dose~T1(Test1): BR4002 (patch) 5mg single-dose (using the applicator)~T2(Test2): BR4002 (patch) 5mg single-dose (not using the applicator)~sequence 4: T1 - T2 - R"
89457978|NCT04462029|Other|sequence 5|"A total of 18 subjects will be randomized into 6 sequence groups. The investigational products (IPs) will be administered according to the treatment groups (R, T1, and T2) assigned to each sequence group in Period 1, Period 2, and Period 3. In between each period, there will be a washout period (28 days) long enough for the administered IP to be metabolized and eliminated.~R(Reference): BR4002-1 (oral intake) 5mg single-dose~T1(Test1): BR4002 (patch) 5mg single-dose (using the applicator)~T2(Test2): BR4002 (patch) 5mg single-dose (not using the applicator)~sequence 5: T2 - R - T1"
89457979|NCT04462029|Other|sequence 6|"A total of 18 subjects will be randomized into 6 sequence groups. The investigational products (IPs) will be administered according to the treatment groups (R, T1, and T2) assigned to each sequence group in Period 1, Period 2, and Period 3. In between each period, there will be a washout period (28 days) long enough for the administered IP to be metabolized and eliminated.~R(Reference): BR4002-1 (oral intake) 5mg single-dose~T1(Test1): BR4002 (patch) 5mg single-dose (using the applicator)~T2(Test2): BR4002 (patch) 5mg single-dose (not using the applicator)~sequence 6: T2 - T1 - R"
89457980|NCT03669055|Experimental|Pre-operative and post operative Magnetic Resonance Imaging|Realization of an angio-MRI with 4D phase contrast sequence before and after the endovascular treatment of the aortic dissection
89457981|NCT03704675|Experimental|Group I (Fasted->Fed)|Group 1 received a single oral dose in a fasting condition in Period 1, followed by a single oral dose after a high-fat diet in Period 2
89457982|NCT03704675|Experimental|Group II(Fed->Fasted)|Group 2 received a single oral dose after a high-fat diet in Period 1, followed by a single oral in a fasting condition in Period 2
89457983|NCT03494517||Preeclampsia|"Women aged 18-45 years~Confirmed pregnancy > 30 weeks of gestation~Singleton or multiple pregnancies~Admission in maternity of the Women's hospital with clinically suspected signs of severe preeclampsia:~Systolic blood pressure >140 mmHg or diastolic pressure > 90 mmHg and~Proteinuria > 0.3 grams in a 24-hour urine or protein:creatinine ratio >0.3 or~Signs of end-organ dysfunction (platelet count < 100'000G/l, serum creatinine >110 mg/l, or doubling of the serum creatinine, elevated serum transaminases to twice normal concentration)"
89457984|NCT04461873|Experimental|Reiki|Reiki was applied to this arm by the researcher who completed her second level education according to the Usui method, for 45 minutes once a week for 6 weeks and by touching the 9 main points in line. A saliva sample was taken from the participants in order to determine the stress level through cortisol and Caregiver Stress Scale (CSS) was applied in the first week of Reiki application. Systolic and diastolic blood pressures and pulse rates were measured for six weeks before and after each application. At the end of six weeks, saliva samples were collected and CSS was applied again. After the 6-week Reiki application, all the caregivers of the intervention group were asked about their experience and opinions regarding the application by the individual in-depth interview method during the home visit.
89457985|NCT04461873|Placebo Comparator|Sham Reiki|Four student nurses who did not receive Reiki training and were trained about application by the investigator applied sham by gesturing and mimic imitation through touching 9 points for 45 minutes/week for 6 weeks in line. A saliva sample was taken from the participants in order to determine the stress level through cortisol and Caregiver Stress Scale (CSS) was applied in the first week of Reiki application. Systolic and diastolic blood pressures and pulse rates were measured for six weeks before and after each application. At the end of six weeks, saliva samples were collected and CSS was applied again.
89457986|NCT04177901|Active Comparator|Brachial plexus blockage group|
89016709|NCT02717624|Experimental|Part 1: Acalabrutinib+BR in RR patients|Part 1: Acalabrutinib in combination with bendamustine and rituximab (BR) in relapse refractory patients
89016710|NCT02717624|Experimental|Part 2: Acalabrutinib+VR in TN patients|Part 2: Acalabrutinib in combination with venetoclax and rituximab (VR) in treatment naive patients
89457987|NCT04177901|Active Comparator|local anesthesia group|
89457988|NCT02320617|Experimental|DW-MRI group|To evaluate the efficacy of chemoradiotherapy in lung cancer patients by DW-MRI when compared with conventional imaging modalities(CT, ultrasound et al.)
89457989|NCT03491865|Experimental|REAL media Plus|Participants in this group will be assigned to use the REAL media Plus curriculum.
89457990|NCT03491865|No Intervention|programming as usual|Participants in this group will participate in their usual school curriculum. They will have the opportunity to use the REAL media Plus curriculum at the conclusion of the study.
89457991|NCT02324517||Hemophilia|Patients with Hemophilia A OR B
89457992|NCT02324517||inhibitor patients|Hemophilia or FXI def with inhibitors
89457993|NCT02324517||anticoagulants|patients under therapy with various anticoagulant drugs
89457994|NCT02324517||thrombocytopenia|patients with ITP, chronic thrombocytopenia, chemotherapy induced thrombocytopenia
89457995|NCT02324517||platelet function disorders|Glanzmann, Bernard Soulier, antiplatelet therapy
89457996|NCT02324517||Fibrinogen disordsers|hyperfibrinogenemia, hypofibrinogenemia, dysfibrinogenemia
89457997|NCT02324517||acquired hemophilia|patients with autoimmune Ab's to FVIII
89457998|NCT02324517||RBD|FXIII DEF, FV+FVIII DEF, FVII DEF, FV DEF
89457999|NCT02324517||THROMBOLYTICS|Patients treated by thrombolytic agents
89458000|NCT02324517||Hypercoag|thrombophilias, thrombosis- inc under therapy, acquired high thrombotic risk (eg: cancer)
89458001|NCT03496935|Active Comparator|Tunneled dialysis catheter|In this arm, patients will be randomized to undergo tunneled dialysis catheter insertion.
89458002|NCT03496935|Active Comparator|Non-tunneled dialysis catheter|In this arm, patients will be randomized to undergo non-tunneled dialysis catheter insertion.
89458003|NCT04050839|Experimental|Neuroscience pain education group|Pain neuroscience education in addition medical treatment
89458004|NCT04050839|Active Comparator|Control group|Medical treatment only
89458005|NCT02322645|Experimental|Eszopiclone Tablets|Eszopiclone Tablets 3 mg of Dr. Reddy's Laboratories Limited
89458006|NCT02322645|Active Comparator|Lunesta|Lunesta Tablets 3 mg of Sepracor Inc.
89458007|NCT04050761||Monotherapy|Participants diagnosed with recurrent or metastatic squamous cell carcinoma of the Head and Neck and whose physician has decided to initiate a treatment with Nivolumab for the first time for the treatment of SCCHN.
89458008|NCT03496857|Experimental|Photobiomodulation analgesia|"LED therapy sessions will be held in the pre-labor room. The patient who will undergo analgesia and the professional responsible for placing the LED plate on the patient's back, between T10 and L2, will be present at the time of the intervention. The LED plate will be covered with clear disposable plastic (PVC) to avoid cross-contamination and ensure hygiene. During the interventions, the patient will be allowed to choose the position that is the most comfortable for her.~Three 10-min LED applications will be performed when the patient has a cervical dilatation of 4-5, 6-7, and 8-9 cm. Data on the level of pain, characteristics of the membrane (intact or damaged), heart rate, cardiotocography, and uterine dynamics will be collected after each intervention."
89458009|NCT03496857|Active Comparator|bath therapy|The method of analgesia with the bath therapy will be performed using a hot shower at 37°C for 10 min. After showering the entire body or the back for 5 min, the participants will be allowed to direct the water flow to any area of the body that feels the most comfortable and to adjust the temperature themselves for improved comfort. Bath therapy will be performed at three time points during labor: at cervical dilatation of 4-5 cm, 6-7 cm, and 8-9 cm. Data on the level of pain, membrane characteristics (intact or damaged), heart rate, cardiotocography, and uterine dynamics will be collected after the bath therapy by performing the same measurements used in the intervention group.
89458010|NCT05130021|Experimental|Part 1;50mg|
89458011|NCT05130021|Experimental|Part 1;70mg|
89458012|NCT05130021|Experimental|Part 2;MAX-40279-01|
89458013|NCT05130021|Experimental|Part 2;regorafenib|
89458014|NCT02322723||Moderately to severely active RA patients|Moderately to severely active RA patients aged 18 years or older, both male and female
89458015|NCT02322801||Cohort|
89458016|NCT02324595|Experimental|Laparoscopic Interval Debulking Surgery|Patients affected by advanced epithelial ovarian cancer already submitted to neoadjuvant chemotherapy with evidence of complete/partial response
89458017|NCT03491787||Ultrasound guidance|The ultrasound guidance was used to establish intraosseous access
89458018|NCT03491787||Not ultrasound guidance|The ultrasound guidance was not used to obtain intraosseous access
89458019|NCT05099757|Experimental|20 µg at month 0, months 0, 1 or 0, 1, and 6|20 µg recombinant hepatitis B vaccine with one, two or three injections at month 0, months 0, 1 or 0, 1, and 6
89458020|NCT03494361||Young normal group|normal participants below 60 years
89458021|NCT03494361||Old normal group|normal participants above 60 years
89458022|NCT03494283||CrossFit injuries|
89458023|NCT02322957|Experimental|Treatment Regimen A|FV-100 400mg OD as a single dose fasted (>/= 8 hours)
89458024|NCT02322957|Experimental|Treatment Regimen B|FV-100 400 mg OD as a single dose with ritonavir 200mg OD as a single fasted dose (>/= 8 hours)
89458025|NCT04785261|Active Comparator|conventional treatment|Patients in this group will be given conventional treatment including Artelac® Eye Drops (1-2 drips each time, every 4 hours) and Vidisic® Gel (1 drip each time, at bedtime) for 12 weeks.
89458026|NCT04785261|Experimental|conventional treatment + TCM|Patients in this group will be given conventional treatment and traditional Chinese medicine (6.0g twice daily) for 12 weeks.
89458027|NCT04611789|Experimental|LY3832479|Participants received single subcutaneous dose of 350 milligrams (mg) and 1000 mg LY3832479.
89458028|NCT04611789|Placebo Comparator|Placebo|Participants received single subcutaneous dose of Placebo.
89458029|NCT03496389|Experimental|Gabapentin + panadol|
89458030|NCT03496389|Active Comparator|Tramadol + panadol|
89458031|NCT02324829||Total joint replacement|Patients who has undergone lower body total joint replacement surgery.
89458032|NCT03496311||Pregnant Women|Pregnant women with gestational age > 35 weeks undergoing spinal anesthesia for elective cesarean section.
89458033|NCT03496311||Control Group|Fertile, non-pregnant women undergoing spinal anesthesia for elective surgery.
89458034|NCT02323035|Experimental|Headgear|Investigative Headgear with CPAP Mask.
89458035|NCT03496155|Experimental|Intervention Group (Arm 1- Main)|"Will receive the Build Your Teen's Strengths educational pamphlet, health coaching sessions, and provider endorsement."
89458036|NCT03496155|No Intervention|Control Group (Arm 1- Main)|Will receive usual care at well-child visit.
89458037|NCT03496155|Experimental|Intervention Group (Arm 1-asthma subgroup)|"Will receive the Build Your Teen's Strengths educational pamphlet, health coaching sessions, and provider endorsement."
89458038|NCT03496155|No Intervention|Control Group (Arm 1-asthma subgroup)|Will receive usual care at well-child visit.
89458039|NCT03496155|No Intervention|Control Group (Arm 2)|Convenience sample used for a post-hoc, exploratory analysis. Will receive usual care at well-child visit.
89458040|NCT04414527|Other|Standard counseling|Pregnant women in the control group will receive the standard education package as per the Ethiopian guidelines. In the standard health care, pregnant women receive a minimum of four ante-natal care visits at the health centers during which they also receive iron and folic acid supplementation. They participate in monthly forums facilitated by nurses to answer questions and concerns regarding nutritional care.
89458041|NCT04414527|Experimental|Health-Video|Women in the Health-Video group will receive home visits for delivery of healthy nutrition messages using prepared video-based messages every two weeks. They will also participate in monthly forums facilitated by nurses using also videos for demonstration of nutritional care. During the monthly forums (six in total during the pregnancy and the post-partum periods), the messages will all be given as a video show coordinated by a nurse/ health professional for any questions. During postnatal period, two counseling sessions will be delivered within two weeks of birth, and 12 sessions or twice every month till 6 months.
89458042|NCT03491709|Experimental|anti-EGFR monoclonal antibody|Recombinant anti-EGFR human mouse chimeric monoclonal antibody injection 250mg/m2 single administration
89458043|NCT03491709|Active Comparator|Cetuximab injection|Cetuximab,Erbitux 250mg/m2 single administration
89458044|NCT02325063|Experimental|PRP-L Group|"Patients randomized to this group will be treated with an injection of Leukocyte and Platelet Rich Plasma (PRP-L).~Intervention: PRP-L Injection"
89458045|NCT02325063|Active Comparator|Botox Group|"Patients randomized to this group will be treated with an injection of Type A Botulinum Toxin (Xeomin®, MERZ).~Intervention: Botox injection"
89023577|NCT05124210|Experimental|Cohort A: Sotrovimab Intravenous (IV) (6 to less than [<] 12 years)|Participants in the age group 6 to < 12 years received up to a maximum of 500 milligram (mg) sotrovimab based on the body weight through Intravenous administration on Day 1
89458046|NCT02325063|Active Comparator|Corticoid Group|"Patients randomized to this group will be treated with an injection of Corticoids.~Intervention: Corticoid injection"
89458047|NCT04086693|Active Comparator|Standard IV dressing|Polyurethane dressing with clear tape
89458048|NCT04086693|Experimental|Standard IV dressing plus Adhezion SecurePortIV|Polyurethane dressing with clear tape plus Adhezion Biomedical SecurePortIV (a tissue adhesive peripheral IV securement device).
89458049|NCT02325141|Active Comparator|LSG|patients undergoing laparoscopic sleeve gastrectomy without BTX-A injection into the pyloric sphincter
89458050|NCT02325141|Active Comparator|BTX-LSG|patients undergoing laparoscopic sleeve gastrectomy with BTX-A injection into the pyloric sphincter
89458051|NCT03495999||Normouricemia|Serum uric of 7mg/dl or less in men or 6mg/dl or less in women
89458052|NCT03495999||Hyperuricemia|Serum uric of 7mg/dl or more in men or 6mg/dl or more in women
89458053|NCT02323191|Experimental|Part 1 (Dose-finding): Emactuzumab + Atezolizumab|Participants will receive escalating doses of emactuzumab along with atezolizumab every 3 weeks (q3w).
89458054|NCT02323191|Experimental|Part 2 (Expansion): Emactuzumab + Atezolizumab|Participants will receive emactuzumab at or below the MTDs for the combination treatments that are determined during Part 1 along with atezolizumab.
89458055|NCT02323269||Treatment naive to dimethyl fumarate|Participants who are prescribed dimethyl fumarate as their initial therapy will receive 120 mg tablet administered orally twice a day for 7 days, then switch to maintenance dose of 240 mg tablet twice daily.
89458056|NCT02323269||Switch to dimethyl fumarate|Participants who are prescribed dimethyl fumarate after suboptimal response to IFN or GA will receive 120 mg tablet administered orally twice a day for 7 days, then switch to maintenance dose of 240 mg tablet twice daily.
89023578|NCT05124210|Experimental|Cohort A: Sotrovimab Intravenous (IV) (12 to less than [<] 18 years)|Participants in the age group 12 to < 18 years received up to a maximum of 500 milligram (mg) sotrovimab based on the body weight through Intravenous administration on Day 1
89458057|NCT04070313|Experimental|S-1|single-arm
89458058|NCT03763149|Experimental|IBI188|"Part 1: Accelerated Titration Phase 0.1 mg/kg IV; QW 0.3 mg/kg IV QW; 1 mg/kg IV QW~Part 2 : Dose Escalation Phase with initial fixed priming dose Priming dose of 1mg/kg on C1D1 followed by 3 mg/kg IV QW; 10 mg/kg IV QW; 20 mg/kg IV QW; 30 mg/kg IV QW."
89458059|NCT03495765|Active Comparator|Well controlled|Eligibile people with diabetic macular oedema and HBA1C < 7.5
89458060|NCT03495765|Active Comparator|Poorly controlled|eligible people with Diabetic macular oedema and HBAIC >10.0
89458061|NCT03495531|No Intervention|Standard of Care|Standard of Care
89458062|NCT03495531|Experimental|VR Use|Obstetrics patients who use virtual reality
89458063|NCT02325297|Experimental|Letter of condolence|Letter of condolence 15 days after the death of the relative.
89458064|NCT02325297|No Intervention|No letter of condolence|No letter of condolence
89458065|NCT02325375||ALS newly diagnosed|
89458066|NCT02325375||ALS treated|
89458067|NCT02325375||controls|
89458068|NCT03491475||Negative Ajmaline test|No appearance of a type 1 ECG during Ajmaline test
89458069|NCT03491475||Positive Ajmaline test|Appearance of a type 1 ECG during Ajmaline test
89458070|NCT02325453||Robotic Surgery|Patients underwent gastric surgery through the use of a robotic system.
89458071|NCT02325453||Laparoscopic Surgery|Patients underwent gastric surgery with laparoscopic procedures.
89458072|NCT02325453||Open Surgery|Patients underwent gastric surgery with open approach.
89501823|NCT03165669|Active Comparator|Education|The educational intervention will be conducted by a physical therapist and will consist of a advice on positions, movements and activities recommended or not recommended for people with chronic neck pain, both in the workplace and in leisure time, including nighttime postures. Each educational intervention will be carried out individually, will last half an hour and will be supported by the delivery of an informative brochure.
88941051|NCT01856075||Patients treated with other antiarrhythmic drugs of interest|"The antiarrhythmic drugs of interest to which dronedarone will be compared are:~Class 1a/1c antiarrhythmics~Sotalol~Amiodarone"
88941052|NCT01856088|Experimental|Inspiron Stent|Stent Inspiron with Sirolimus
88941053|NCT01856088|Active Comparator|Biomatrix Flex Stent|Stent Biomatrix Flex with biolimus
88941054|NCT01856101|Experimental|BEZ235, powder|"Group 1: patients without PI3K pathway activation; no loss of PTEN and no activating PIK3CA mutation.~Group 2: patients with PI3K pathway activation as defined by PIK3CA mutation and/or PTEN loss"
88941055|NCT01856127|Experimental|Vilazodone|Vilazodone
88941056|NCT01856127|Active Comparator|Sertraline|Sertraline
88941057|NCT01856153|Other|Before meal|Strawberry-Placebo-Placebo
88941058|NCT01856153|Other|With Meal|Placebo-Strawberry-Placebo
88941059|NCT01856153|Other|After Meal|Placebo-Placebo-Strawberry
88941060|NCT01856166|Active Comparator|CEI-PCEA|Continuous Epidural Infusion coupled with Patient Controlled Epidural Analgesia
88941061|NCT01856166|Experimental|PIEB-PCEA|Programmed Intermittent Epidural Bolus coupled with Patient Controlled Epidural Analgesia
88941062|NCT01856179|Experimental|Echium oil young|"BMI<25,~age 20-30"
88941063|NCT01856179|Experimental|Echium oil older|age 40-70 BMI <25
88941064|NCT01856179|Experimental|Echium oil older, overweight|age 40-70 BMI >25
88941065|NCT01856205|Placebo Comparator|IVIG in JE (JE-positive)|We randomly allocated patients to treatment with IVIG or placebo. Children received either saline or intravenous immunoglobulin (IVIG) [ImmunoRel™ (batch 20081217)] at a dose of 400mg/kg/day for 5 days or an equivalent volume of 0.9% normal saline given intravenous at the rate of 0.01 to 0.02 ml/kg body weight/minute. All investigators, care providers and participants were blinded of the study drug. A second sealed envelope was kept with the patient's notes in case a physician urgently needed to know which drug a patient had received.
88941066|NCT01856205|Placebo Comparator|IVIG in Non-JE(JE-negative)|We randomly allocated patients to treatment with IVIG or placebo. Children received either saline or intravenous immunoglobulin (IVIG) [ImmunoRel™ (batch 20081217)] at a dose of 400mg/kg/day for 5 days or an equivalent volume of 0.9% normal saline given intravenous at the rate of 0.01 to 0.02 ml/kg body weight/minute. All investigators, care providers and participants were blinded of the study drug. A second sealed envelope was kept with the patient's notes in case a physician urgently needed to know which drug a patient had received.
88941067|NCT01856231|Experimental|8 week group|Lifestyle physical activity self-efficacy
88941068|NCT01856244|Experimental|sensorimotor treadmill training|specific treadmill control using oscillating platform
88941069|NCT01856244|Active Comparator|conventional treadmill training|conventional treadmill control
88941070|NCT01856283|Experimental|Nilotinib|study of nilotinib 300 mg BID
88941071|NCT01856296|Experimental|Arm A|ARM A patients with an identified oncogenic driver mutations/amplifications/translocations), who will potentially benefit from targeted therapies, either on the market or in clinical trials according to existing knowledge of matching oncogenic events with actionable drugs. This will be detected through Next Generation Sequencing (NGS) performed by Foundation Medicine, CLIA certified.
88941072|NCT01856296|Experimental|Arm B|patients negative for oncogene events (which remains the majority), for whom genome based relevant information will be obtained through functional genomics (micro arrays and gene expression profiling) performed by Institut Gustave Roussy, and innovative computational methods enabling a rational choice of therapies. For such patients we will apply a new prediction model of efficacy of existing and under clinical trial drugs, based on differences in gene expression profiling between tumor and normal biopsies to be matched with relevant genes that are related to drug activities.
88941073|NCT01856348|Experimental|1, 25 dihydroxyvitamin D3 intake|This is a single arm study.
88941074|NCT01856374|Active Comparator|Cypher group|
88941075|NCT01856374|Experimental|Xience group|
88941076|NCT01856374|Active Comparator|Pravastatin group|
89458073|NCT03561597|Experimental|Mobile health application|Participants will undergo Kurbo program, a Mobile health application, for more detailed dietary and physical activity recommendations and implementation of behavioural changes. The patient's progress will be reviewed by the nurse clinician at one month post intervention to determine whether the BMI percentile has shown a reduction through the Kurbo Program. Patients that declined Kurbo intervention, has a BMI of more than 99th percentile or continue to have increase in their BMI percentile in Kurbo program, will be offered the high risk weight management clinic appointment for a more detailed multidisciplinary evaluation for targeted intervention. Patients that are able to engage with Kurbo intervention and showed a decrease in BMI percentile over 4 sessions of Kurbo will be offered the low risk weight management clinic (WMC). There will be a month 3 and month 6 visit for study measurements in this study.
89458074|NCT02323425|Experimental|Remote Ischemic Postconditioning|remote ischemic postconditioning（RIPC） treatment was performed by the inflating a cuff around bilateral arms to 180 mmHg with 5 cycles of 3 min inflation and 5 min relax alternation twice a day for the total of 180 consecutive days.
89458075|NCT02323425|No Intervention|Control|Patients in control group will receive foundation treatment. Foundation treatment: including blood vessel expansion、free radical elimination etc during acute phase and aspirin (100-300 mg/d), and atorvastatin (20 mg/d) till the end of the study (180 consecutive days).
89458076|NCT03132207||Pregnant women|Pregnant women attending hospital during pregnancy monitoring and / or being hospitalized in one of the maternity wards associated with the project.
89458077|NCT03132207||Professional|health professionals in charge of the follow-up of these pregnant women and their childbirth.
89458078|NCT03328845|Other|Tresiba & NovoRapid|Patients treated with Tresiba insulin and NovoRapid insulin
89458079|NCT03328845|Other|Toujeo SoloStar & NovoRapid|Patients treated with Toujeo SoloStar insulin and NovoRapid insulin
89458080|NCT03328845|Other|Tresiba & Humalog Kwikpen|Patients treated with Tresiba insulin and Humalog kwikpen insulin
89458081|NCT03328845|Other|Toujeo SoloStar & Humalog Kwikpen|Patients treated with Toujeo SoloStar insulin and Humalog kwikpen insulin
89458082|NCT03328845|Other|Tresiba & Apidra|Patients treated with Tresiba insulin and Apidra insulin
89458083|NCT03328845|Other|Toujeo SoloStar & Apidra|Patients treated with Toujeo SoloStar insulin and Apidra insulin
89458084|NCT03495297|No Intervention|S-ICD Implant with defibrillation test|Patients undergoing de novo S-ICD implantation including induction of VF and defibrillation testing post-implant
89458085|NCT03495297|Experimental|S-ICD Implant without defibrillation test|Patients undergoing de novo S-ICD implantation without induction of VF and defibrillation testing post-implant
89458086|NCT03291171|Experimental|Intervention group|Participants will receive the e- and mHealth intervention 'MyPlan 2.0'.
88941077|NCT01856374|Experimental|Atorvastatin group|
88941078|NCT01856387||normal pregnancy outcomes|do not expect poor pregnancy outcomes on normal patients
88941079|NCT01856387||adverse pregnancy outcome|high ratio of Neutrophil / lymphocyte ratio may predict preeclampsia eclampsia
88941080|NCT01856413|Experimental|Zutectra|Subcutaneous injections of Zutectra up to 1,000 IU (2 ml) per week.
88941081|NCT01856426|Experimental|1- EDP239|EDP239 given once a day.
88941082|NCT01856426|Placebo Comparator|Placebo|1 treatment arm will be placebo, dose given once a day.
88941083|NCT01856426|Experimental|2- EDP239|EDP239 given once a day.
89458087|NCT03291171|No Intervention|Waiting-list control group|Participants will not receive the e- and mHealth intervention 'MyPlan 2.0', but will be given access to the intervention after all testing phases.
89458088|NCT02323737|Active Comparator|Irinotecan and cisplatin|The IP regimen consisted of at most 6 cycles of irinotecan 65 mg/m2 of body-surface area on days 1, 8 and cisplatin 75mg/m2 of body-surface area on day 1.
89458089|NCT02323737|Active Comparator|Etoposide and Cisplatin|The EP regimen consisted of at most 6 cycles of etoposide 100 mg/m2 of body-surface area from day 1 to 3 and cisplatin 75mg/m2 of body-surface area on day 1.
89458090|NCT03491319|Placebo Comparator|Group C Control|spinal anaesthesia was given with table in neutral positon. Same position was maintained after spinal anaesthesia
89458091|NCT03491319|Active Comparator|Group X|spinal anaesthesia was given with table in neutral positon. 10 degree head low position was maintained for 10 minutes following spinal
88941084|NCT01856426|Experimental|3-EDP239|EDP239 given once a day.
88941085|NCT01856426|Experimental|4-EDP239|EDP239 given once a day.
88941086|NCT01856452|Active Comparator|radioisotope|sentinel lymph node operation using radioisotope in the breast cancer patients
88941087|NCT01856452|Experimental|the mixture including indocyanine green|sentinel lymph node operation using the mixture of indocyanine green, blue dye and radioisotope in the breast cancer patients
88941088|NCT01856465||Bariatric surgery of morbid obese|Morbid obese patient who undergo Bariatric surgery with NAFLD (NASH or SS) status
88941089|NCT01856504||CCTA Patient|"Consenting adult patients ≥18 years of age;~Suspected but without known prior history of CAD~Not actively taking heart rate lowering agents at least 48 hours prior to study (e.g., AV nodal blockers such as beta blockers, calcium channel blockers or digoxin)~Glomerular filtration rate >60 ml/min~CCTA and ICA within 1 week of each other with no interscan event (e.g., myocardial infarction or coronary revascularization)"
88941090|NCT01856517|Placebo Comparator|placebo|saline administration over 24 h following full optimization of patient according to current guidelines
88941091|NCT01856517|Active Comparator|clonidine|clonidine 1 mcg.kg-1.h-1 over 24 h following full optimization of the patient according to current guidelines
89458092|NCT03491319|Active Comparator|Group Y|the table was put in 10 degree head low position before proceeding to give spinal anaesthesia. Head low position was maintained for 10 minutes following spinal
89458093|NCT03037359||Bivigam|Patients with primary immunodeficiency disease treated with Bivigam™
89458094|NCT03037359||Other IGIV|Patients with primary immunodeficiency disease treated with other IGIVs
89458095|NCT03491241|Experimental|pre-diabetics obese patients|These pre-diabetic obese patients will be treated by hypocaloric diet therapy. these patients were under metformine therapy at enrollment.
89458096|NCT03491241|Placebo Comparator|pre-diabetics patients|These pre-diabetic patients will be treated by hypocaloric diet therapy alone.
89458097|NCT03491241|Active Comparator|obese patients|These obese patients will be treated by hypocaloric diet therapy.
89458098|NCT03495219||Esophageal Manometry|Esophageal manometry is a test to assess motor function of the upper esophageal sphincter, esophageal body and lower esophageal sphincter
89458099|NCT03491163||Patients|Syndecan-1 concentration evaluation
89458100|NCT02323815|Active Comparator|Control|Behavior change communication (BCC) on Essential Nutrition Actions (ENA), Infant and Young Child Feeding (IYCF) and Water, sanitation and hygiene (WASH) is provided during monthly meetings for children 6-23 months of age
89458101|NCT02323815|Experimental|PROMIS intervention|"Behavior change communication (BCC) on Essential Nutrition Actions (ENA), Infant and Young Child Feeding (IYCF) and Water, sanitation and hygiene (WASH) is provided during monthly meetings for children 6-23 months of age~Caregivers with children 6-23 months of age that attend Counselling meetings will be provided with a monthly dose of SQ-LNS (20g/day)"
89458102|NCT03491085|Active Comparator|tonsillictomy with antibiotics|
89458103|NCT03491085|No Intervention|tonsillictomy Without Antibiotics|
89458104|NCT02323893|Experimental|18F-FAraG|A single dose intravenous injection of 18F-FAraG followed by PET scanning.
89458105|NCT03490851|Experimental|Oatmeal + OatWell28XF Intervention 1|2g β-glucan
89458106|NCT03490851|Experimental|Oatmeal + OatWell28XF Intervention 2|4g β-glucan
89458107|NCT03490851|Experimental|Oatmeal + OatWell28XF Intervention 3|4g β-glucan plus β-glucanase
89458108|NCT03490851|Placebo Comparator|Cream of Rice|27 grams of cream of rice
89458109|NCT04461717||MicroNet covered stenting (interventional)|MicroNet covered stent implantation for increased risk arterial lesions beyond the carotid bifurcation
89458110|NCT02325765||category of RACHS-2 for cardiac surgery|ASD & VSD repair; VSD repair; Tetralogy repair; Tetralogy repair
89458111|NCT02325765||category of RACHS-3 for cardiac surgery|DORV repair with or without RV obstruction; AVSD (complete or transitional) repair with or without valve replacement; Coarctation & VSD repair
89458112|NCT03148899|Experimental|Visit 1 Randomization|At visit 1 (PSG 1) subjects will receive one of two interventions: either Oxytocin Intranasal Spray (40 IU) or Placebo Intranasal Spray. Subjects will be blinded as to which drug they are receiving.
89458113|NCT03148899|Experimental|Visit 2: Crossover Randomization|At visit 2 (PSG 2) subjects will receive the opposite intervention from the one they received at visit 1: either Oxytocin Intranasal Spray (40 IU) or Placebo Intranasal Spray. Subjects will be blinded as to which drug they are receiving.
89458114|NCT03493893||Affixus|To compare Affixus to PFNA and TFNA
89458115|NCT03493893||PFNA|To compare PFNA to Affixus and TFNA
89458116|NCT03493893||TFNA|To compare TFNA toPFNA and Affixus
89458117|NCT03495063|Experimental|Natural Caffeine|Subjects will be their own control and will have repeated measures after the consumption of a drink with 400mg of natural caffeine. Blood pressure measurements will be taken at baseline, then hourly for four hours.
89458118|NCT03495063|Experimental|Synthetic Caffeine|Subjects will be their own control and will have repeated measures after the consumption of a drink with 400mg of synthetic caffeine. Blood pressure measurements will be taken at baseline, then hourly for four hours.
88941092|NCT01856556|Experimental|NRX-1074, 1 mg|1 mg IV
88941093|NCT01856556|Placebo Comparator|Placebo|Saline
88941094|NCT01856556|Experimental|NRX-1074, 5 mg|5 mg IV
88941095|NCT01856556|Experimental|NRX-1074, 10 mg IV|10 mg
88941096|NCT01856556|Experimental|NRX-1074, 50 mg IV|50 mg
88941097|NCT01856556|Experimental|NRX-1074, 25 mg PO|25 mg
88941098|NCT01856556|Experimental|NRX-1074, 125 mg PO|125 mg
88941099|NCT01856621|Active Comparator|Seretide Diskus and charcoal|Single-dose of Seretide Diskus (50/500 mcg/inhalation) and charcoal
88941100|NCT01856621|Active Comparator|Seretide Diskus|Single-dose of Seretide Diskus (50/500 mcg/inhalation)
88941101|NCT01856621|Experimental|SF Easyhaler and charcoal|Salmeterol/fluticasone Easyhaler (50/500 mcg/inhalation) with charcoal
88941102|NCT01856621|Experimental|SF Easyhaler|Salmeterol/fluticasone Easyhaler (50/500 mcg/inhalation)
88941103|NCT01856634|Experimental|Group 1: 12 to 17 years of age|Group 1: 100 mg Delamanid BID for 10 days + OBR
88941104|NCT01856634|Experimental|Group 2: 6 to 11 years of age|50 mg Delamanid BID for 10 days + OBR
88941105|NCT01856634|Experimental|Group 3: 3 to 5 years of age|25 mg Pediatric Formulation Delamanid BID for 10 days + OBR
88941106|NCT01856634|Experimental|Group 4: Birth to 2 years of age|"Delamanid Pediatric Formulation (DPF) for 10 days + OBR. DPF dose based on patient's body weight during baseline visit:~Patient's > 10 kg will receive DPF 10 mg BID + OBR~Patient's > 8 kg and ≤ 10 kg will receive DPF 5 mg BID + OBR~Patients ≤ 8 kg will receive DPF 5 mg QD + OBR"
89458119|NCT02324127|Experimental|liver cancer|Detect plasma Hsp90α concentration of liver cancer patients
89458120|NCT03036267|Experimental|BREATHE|7-minute brief shared decision-making intervention using a 4-step motivational interviewing approach
89458121|NCT03036267|Active Comparator|Attention Control Condition|7-minute diet and exercise discussion
89458122|NCT03132285|Other|PrePex Day 0 foreskin removal|Day 0 foreskin removal
89458123|NCT02325843|Experimental|human bone marrow MSC|5×106/0.5ml MSC was injected subconjunctival at the inferior fornix.If persistent epithelial defect was noted thereafter, a second AMT and MSC injection was performed.
89458124|NCT02325921||Renal tumor.|Patients >18 years of age with histopathologically confirmed renal tumor diagnosis.
89458125|NCT03490617|Active Comparator|Vaginal Misoprostol Group|Vaginal misoprostol (400 μg) 4 hours prior to IUD insertion
89458126|NCT03490617|Placebo Comparator|Placebo group|Vaginal placebo tablets 4 hours prior to IUD insertion
89458127|NCT03494907|Experimental|Seltorexant (Low and high dose)|Participants will receive seltorexant tablets orally in 2 of 4 treatment arms (A,B,C,D) in a cross-over design, with 7 days wash-out phase between each treatment period.
89458128|NCT03494907|Experimental|Moxifloxacin|Participants will receive moxifloxacin tablets orally in 1 of 4 treatment arms (A,B,C,D) in a cross-over design, with 7 days wash-out phase between each treatment period.
89458129|NCT03494907|Experimental|Placebo Matched to Seltorexant|Participants will receive seltorexant placebo tablets orally in 3 of 4 treatment arms (A,B,C,D) in a cross-over design, with 7 days wash-out phase between each treatment period.
89458130|NCT03494907|Experimental|Placebo Matched to Moxifloxacin|Participants will receive moxifloxacin placebo tablets orally in 3 of 4 treatment arms (A,B,C,D) in a cross-over design, with 7 days wash-out phase between each treatment period.
89458131|NCT03490539||azathioprine (AZT)|Patients with MG who are receiving azathioprine as part of routine clinical care
89458132|NCT03490539||mycophenolate mofetil (MMF)|Patients with MG who are receiving mycophenolate mofetil as part of routine clinical care
89458133|NCT03494751|Experimental|Heart Monitor|We used the device (heart monitor) in the patients with myocardial infarction.
89458134|NCT03494751|Active Comparator|No Heart Monitor|No heart monitor device in the patients with myocardial infarction (control).
89458135|NCT03494673||Control|Normal controls without headaches will undergo BOLD MRI with prospective CO2 targeting
88941107|NCT01856647||lean (BMI≤ 24.9 Kg/m2)|Adipose tissue biopsy (fat biopsy) in 9 lean (BMI≤ 24.9 Kg/m2)
88941108|NCT01856647||obese (BMI= 30-40 Kg/m2)|9 obese (BMI= 30-40 Kg/m2)
88941109|NCT01856647||psoriatic lean|9 psoriatic lean
88941110|NCT01856647||psoriatic obese|9 psoriatic obese
88941111|NCT01856660|Experimental|Low-Fat Diet|Participants are provided with a 6-month standard lifestyle intervention. They will follow an energy restricted, low-fat diet where the daily energy consumption target is 1,200- 1,500 kilocalories/d. The fat intake target is 28% or less of daily kilocalories. Gradual increase in physical activity until participants are active at least 40 min per day, 5 times/week.
88941112|NCT01856660|Experimental|Low-Carbohydrate Diet|Participants are provided with a 6-month standard lifestyle intervention. They will follow a low-carbohydrate diet where the daily carbohydrate target is 50g/d. There is no energy restriction. Gradual increase in physical activity until participants are active at least 40 min per day, 5 times/week.
88941113|NCT01856699||Study Group|Patients with cortical superficial siderosis and possible or probable cerebral amyloid angiopathy meeting the modified Boston criteria.
88941114|NCT01856699||Control Group|Patients with possible or probable cerebral amyloid angiopathy meeting the classic Boston criteria but without any cortical superficial siderosis.
88941115|NCT01856725|Active Comparator|MultiPoint Pacing programming based on hemodynamics|"CRT device implant with MultiPoint Pacing~Hemodynamic measurements for CRT device programming"
88941116|NCT01856725|Experimental|MultiPoint Pacing programming without hemodynamics|"CRT device implant with MultiPoint Pacing~CRT device programming without hemodynamics"
88941117|NCT01856738|Placebo Comparator|Placebo|placebo capsule for oral use 6,0 mg BID during 24 months of follow-up
88941118|NCT01856738|Experimental|Rivastigmine|rivastigmine capsule for oral use 6,0 mg BID during 24 months of follow-up
88941119|NCT01856751||haemophilia|Patients with acquired haemophilia. Patients with haemophilia A with inhibitor.
88941120|NCT01856777|Other|High sensitivity urine pregnancy test|Standard medical care and high sensitivity urine pregnancy test
88941121|NCT01856777|Other|Semi-quantitative panel test|Standard medical care and semi-quantitative panel test
88941122|NCT01856803|Active Comparator|routine prophylaxis|In this group, CSA plus MMF and MTX adopted as prevention of GVHD.
88941123|NCT01856803|Experimental|ATG prophylaxis|In this group,ATG+MMF+CsA+MTX was adopted as prevention of GVHD
88941124|NCT01856816|Experimental|Meal Pattern Treatment A|A large vegetable salad (262g) and with a moderate amount of canola oil (8g) was consumed over a two meal period as designated by treatment group A.
88941125|NCT01856816|Experimental|Meal Pattern Treatment B|A large vegetable salad (262g) and with a moderate amount of canola oil (8g) was consumed over a two meal period as designated by treatment group B.
88941126|NCT01856816|Other|Treatment Group C|A large vegetable salad (262g) and with a moderate amount of canola oil (8g) was consumed over a two meal period as designated by treatment group C.
88941127|NCT01856829|Placebo Comparator|Control|Control participants will take placebo capsules daily for 4 weeks before and for the duration of the test. At week 4, participants will undergo a training protocol consists of a series of five sessions consecutively performed at intervals of 3 to 7 days. Taking products will be made more specifically 30 minutes before the start of the sessions.
88941128|NCT01856829|Experimental|Omega-3|Omega-3 participants will take capsules daily for 4 weeks before and for the duration of the test. At week 4, participants will undergo a training protocol consists of a series of five sessions consecutively performed at intervals of 3 to 7 days. Taking products will be made more specifically 30 minutes before the start of the sessions.
88941129|NCT01856842|Active Comparator|Interlock fibered IDC Occlusion System|Pulmonary angiography and embolotherapy technique using Interlock (TM) fibered IDC Occlusion System(TM)
88941130|NCT01856842|Active Comparator|Nestor Coil|Pulmonary angiography and embolotherapy technique using Nestor coils
88941131|NCT01856881|Active Comparator|AMG 876|
88941132|NCT01856881|Placebo Comparator|Placebo|
88941133|NCT01856920|Experimental|A|GI-6207 for 1 year
88941134|NCT01856920|Experimental|B|6 months of surveillance followed by GI-6207 for 1 year
88941135|NCT01856946|Experimental|4,000 IU Vitamin D3|two 2,000 IU vitamin D3 pills (total 4,000 IU) daily for six months.
88941136|NCT01856959|Experimental|nebulized magnesium sulfate|nebulized magnesium sulfate 150mg and consisted about 5 min,which used only once
89458136|NCT03494673||Migraineurs|Patients diagnosed with migraine based on the ICHD-3 beta will undergo BOLD MRI with prospective CO2 targeting
89458137|NCT03490461||Statin group|Statin therapy was defined as the administration of statins for more than 30 days after liver transplantation
89458138|NCT03490461||Non-statin group|the administration of statins for less than 30 days after liver transplantation
89458139|NCT03489135|Experimental|Intervention using the ReVene Thrombectomy Catheter|Open label, prospective, non-randomised, multi-centre first-in-human evaluation of the Vetex ReVene Thrombectomy Catheter for treatment of acute iliofemoral deep vein thrombosis (DVT).
89458140|NCT03493737||HaH (Hospital-at-Home)|Bortezomib is injected at Outpatient hospital at day 1 and at Home at further day of cycles
89458141|NCT03493737||OH (Outpatient Hospital)|Bortezomib is always injected at Outpatient hospital
89458142|NCT03490305||Combatants|Men 16-50 years old or combatants by own admission.
89458143|NCT03490305||Civilians|Children <16 years, all women and men ≥50 years.
89458144|NCT03493659|No Intervention|Sit-Sit|The participants will sit during the tutorials, and sit during the concept tests given to measure their learning.
89458145|NCT03493659|Active Comparator|Sit-Stand|The participants will sit during the tutorials. Intervention: Behavioral: Standing during Concept Test will be administered
88941137|NCT01856959|Experimental|nebulized magnesium sulfate & albuterol|nebulized magnesium sulfate 150mg & albuterol 2.5mg and consisted about 5 min,which used only once
89458146|NCT03493659|Active Comparator|Stand-Stand|The participants will stand during the tutorials, and stand during the concept tests given to measure their learning. Intervention: Behavioral: Standing during Concept Test and regular tutorial session will be administered.
89458147|NCT03493659|Active Comparator|Stand-Sit|"The participants will stand during the tutorials. Intervention: Behavioral: Standing during regular tutorial session will be administered.~However, participants will sit during the concept tests given to measure their learning."
89458148|NCT03496077|Experimental|Flavored LCCs|Half of the group will start with a flavored little cigar/cigarillo (LCC) and cross over to unflavored LCC. The LCCs will be a popular brand already available for sale on the market.
89458149|NCT03496077|Experimental|Unflavored LCCs|Half of the group will start with an unflavored little cigar/cigarillo (LCC) and cross over to flavored LCC. The LCCs will be a popular brand already available for sale on the market.
89458150|NCT02586519|Experimental|Active SurroSense Rx System + RCW|Patients randomized to the experimental group will be fitted with an active (alerting) version of the SurroSense R® smart insole System. This device will be placed in the RCW, underneath the liner. The device tab will be fed up the instep, through a hole in the liner, and affixed to the dorsum of the RCW by way of a tie.
89458151|NCT02586519|Sham Comparator|Inactive SurroSense Rx System + RCW|Patients randomized to this group will be fitted with an inactive (non-alerting) version of the device in an identical fashion.
89458152|NCT02586519|Sham Comparator|Inactive SurroSense Rx System + iTCC|Patients in this group will be fitted with an inactive (non-alerting) version of the device in an identical fashion. The RCW will be further secured using a device specific tie such that it acts as an iTCC.
89458153|NCT02516553|Experimental|arm A|once daily continuous oral intake in 3-week cycles
89458154|NCT02516553|Experimental|arm B|once daily intermittent oral intake with two weeks on treatment followed by one week off in 3-week cycles
89458155|NCT02516553|Experimental|arm C|one week on followed by one week off treatment, repeated every two weeks in 4-week cycles
89458156|NCT03034967|Experimental|Danirixin 5 mg|Eligible participants will receive danirixin 5 mg tablet with food twice daily along with standard care of treatment for 24 weeks.
89458157|NCT03034967|Experimental|Danirixin 10 mg|Eligible participants will receive danirixin 10 mg tablet with food twice daily along with standard care of treatment for 24 weeks.
89458158|NCT03034967|Experimental|Danirixin 25 mg|Eligible participants will receive danirixin 25 mg tablet with food twice daily along with standard care of treatment for 24 weeks.
89458159|NCT03034967|Experimental|Danirixin 35 mg|Eligible participants will receive danirixin 35 mg tablet with food twice daily along with standard care of treatment for 24 weeks.
89458160|NCT03034967|Experimental|Danirixin 50 mg|Eligible participants will receive danirixin 50 mg tablet with food twice daily along with standard care of treatment for 24 weeks.
89458161|NCT03034967|Placebo Comparator|Placebo|Eligible participants will receive placebo tablet with food twice daily along with standard care of treatment for 24 weeks.
89458162|NCT03021187|Experimental|Semaglutide 3 mg|
89458163|NCT03021187|Experimental|Semaglutide 3 mg + 7 mg|
89458164|NCT03021187|Experimental|Semaglutide 3 mg + 7 mg + 14 mg|
89458165|NCT03021187|Placebo Comparator|Placebo|
89458166|NCT03493503|Experimental|Salbutamol loading dose|Salbutamol loading dose of 15 mcg/kg in 10 minutes, with a maximum of 750 mcg.
88941138|NCT01856959|Active Comparator|nebulized albuterol|nebulized albuterol 2.5mg and consisted about 5 min,which used only once
88941139|NCT01856972|Experimental|Instrument Assisted Soft Tissue Mobilization|Subjects randomized into this treatment arm will receive Instrument Assisted Soft Tissue Mobilization to the Gastrocnemius/Soleus complex, as well as a standard stretching/ROM protocol
88941140|NCT01856972|Experimental|Rearfoot joint mobilization|Subjects randomized into this treatment arm will receive a rear-foot joint mobilization as well as a standard stretching/ROM protocol
88941141|NCT01856972|Active Comparator|Static stretching/ROM exercises|This is the control group consisting of Static stretching/ROM exercises. No manual intervention is performed with the group. The subjects will perform the standard stretching and ROM protocol
89023579|NCT05119309||patient group|Renal biopsy diagnosis of MGRS or disease linked to multiple myeloma and B cell lymphoma
89458167|NCT03493503|Placebo Comparator|Sodium Chloride 0.9%|10 ml of Sodium Chloride 0.9% in 10 minutes.
89458168|NCT03490149||ECT|
89458169|NCT03490149||Medication - Treatment as usual|
89458170|NCT03490149||Healthy controls|
89458171|NCT03131739||Community Level Assessment|65 communities will undergo assessment of community / structural variables through review of public records and 3-5 key community interviewees per community.
89458172|NCT03131739||Individual Level Assessment|A subset of 6 communities will be elected through a stratification process. Youth will complete a set of protective factors measures and outcomes. Adults will complete a section of the Neighborhood Matters survey.
89016711|NCT02695225|Other|Lay-led tobacco abstinence|Each intervention visit, which lasts an average of 30 minutes, will be delivered face-to-face in a mutually agreed upon convenient location (e.g. participant's home, county extension office). All behavioral and pharmacological intervention strategies will be delivered by the lay educator, with supervision by the county nurse (assigned by county with no overlap between conditions). As recommended by the USPHS guideline, all participants will set a 'quit date' and receive identical behavioral and pharmacological treatment throughout the intervention.
89016712|NCT02695225|Other|Lay-led promotion of Ohio Quit Line|Each participant will be given print information about the Ohio Tobacco QUIT LINE (1-800-QUIT-NOW) and encouraged to call for proactive telephone counseling and free NRT. Proactive telephone counseling and NRT administration will be provided by a QUIT LINE counselor, using their standard protocol.
89458173|NCT02366559|Active Comparator|electrocautery|Blocks of subjects' lesions will be randomized 1:1 to receive electrocautery or 532 nm Nd:YAG laser. Prior to treatment with either electrocautery or 532nm Q-switched Nd:YAG laser, a topical EMLA cream will be applied to the lesions for at least 60 minutes under occlusion at the area of treatment.
89458174|NCT02366559|Active Comparator|532 nm Nd:YAG laser|Blocks of subjects' lesions will be randomized 1:1 to receive electrocautery or 532 nm Nd:YAG laser. Prior to treatment with either electrocautery or 532nm Q-switched Nd:YAG laser, a topical EMLA cream will be applied to the lesions for at least 60 minutes under occlusion at the area of treatment.
89458175|NCT05150145|Experimental|Radiotherpy will be performed to thoracic and liver metastasis.|Radiotherapy for liver metastases and thoracic will be performed in paticipants with liver metastasis who achieved CR or PR after chemotherapy.
89458176|NCT05150145|No Intervention|Radiotherpy will be performed to thoracic.|Radiotherapy performed only on the thoracic after chemotherapy of paticipants with liver metastasis who achieved CR or PR.
89458177|NCT03493347|Experimental|Equine-assisted Occupational Therapy|All children will receive the Equine-assisted Occupational Therapy (EAOT) intervention, which includes occupational therapy administered in an equine environment. Common intervention activities include grooming, tacking, mounting, and riding the horse.
89458178|NCT03668275|Experimental|Intervention|(partial) oncological home-hospitalization
89458179|NCT03668275|No Intervention|Control|standard oncological ambulatory hospital care
89458180|NCT03489915||Patients with macular edema due to RVO|assessment of visual acuity using Landolt chart and follow up of macular edema using OCT
89458181|NCT03667963|Other|Low Salivary Amylase Activity|Glucose Glucose plus lactulose Hot Rice Cold Rice
89458182|NCT03667963|Other|High Salivary Amylase Activity|Glucose Glucose plus lactulose Hot Rice Cold Rice
89458183|NCT03488901||methotrexate sensitive|patients with gestational choriocarcinoma cured with methotrexate alone
89458184|NCT03488901||methotrexate resistant|patients with gestational choriocarcinoma not cured with methotrexate alone
89458185|NCT03488901||polychemotherapy sensitive|patients with gestational choriocarcinoma cured with polychemotherapy
89016713|NCT02694965||Stage IV/Unresectable Stage III Melanoma|Observational - Eligible patients with stage IV/unresectable stage III melanoma selected to undergo treatment with an anti-CTLA-4 antibody, an anti-PD-1 antibody, an anti-PD-L1 antibody, or a combination of an anti-CTLA-4 antibody/anti-PD-1 antibody will be asked to participate in the study by the Principal Investigator, co-Investigators, or clinical staff.
89458186|NCT03488901||polychemotherapy resistant|patients with gestational choriocarcinoma not cured with polychemotherapy
89458187|NCT03488901||hydatidiform moles without malignant transformation|patients treated for hydatidiform moles but who did not turn into trophoblastic tumors (=controls)
89458188|NCT03488901||placental site trophoblastic tumors|patients with placental site trophoblastic tumors not cured with polychemotherapy
89458189|NCT03667885||Small renal Masses|patients with a renal mass of 4 cm or less. Typically incidentally found. Blood and urine samples will be collected from each patient at baseline before a biopsy of the tumor is collected and 14 days later. In addition, all patients will be offered a Multi planar MRI before the biopsy. Patients elected for curative treatment for malignant tumors will have another set of blood and urine samples collected at 1 month and 6 months after the intervention.
89458190|NCT03704597|Active Comparator|7-hour cryotherapy|Standard of care
89458191|NCT03704597|Experimental|2-hour cryotherapy|Experimental treatment
89458192|NCT05149521||Patients who have received radiotherapy|This is a consensus study with no interventions Patients who previously participated in COMFORT study interviews (NCT03984435)
89458193|NCT05149521||Therapeutic radiographers who deliver radiotherapy|This is a consensus study with no interventions Therapeutic radiographers who previously participated in COMFORT study interviews (NCT03984435)
89458194|NCT03489837|Experimental|Levotuss CR tab|oral taken
89458195|NCT03489837|Active Comparator|Levotuss syrup|oral taken
89458196|NCT03488823|Experimental|Young with Flavanol|Young patients (< 45 years) will get twice daily from1 week vor catheterisation till one week after catheterisation drink with flavanols ( 2x400 mg Flavanols).
89458197|NCT03488823|Placebo Comparator|Young without Flavanol|Young patients (< 45 years) will get twice daily from1 week vor catheterisation till one week after catheterisation drink without flavanols .
89458198|NCT03488823|Experimental|Old with Flavanol|Old patients (>60 years) will get twice daily from1 week vor catheterisation till one week after catheterisation drink with flavanols ( 2x400 mg Flavanols).
89458199|NCT03488823|Placebo Comparator|Old without Flavanol|Young patients (>60 years) will get twice daily from1 week vor catheterisation till one week after catheterisation drink without flavanols.
89458200|NCT03488745|Experimental|IntelliCare + Phone Coaching|Participants will receive IntelliCare apps with phone coaching for 7 weeks. In this arm, participants will pick two IntelliCare apps to use every week. Participants will receive a phone coaching call before they use the apps, for approximately 30 minutes, as well as 3 weeks after initiating app use (10 minute call).
89458201|NCT03625505|Experimental|Dose Escalation Venetoclax + Gilteritinib|Different combinations of dose levels for venetoclax in combination with gilteritinib will be administered to determine the recommended phase 2 dose (RPTD).
89458202|NCT03625505|Experimental|Dose Expansion Venetoclax + Gilteritinib|Participants will receive venetoclax in combination with gilteritinib at the dose determined in dose escalation portion.
89458203|NCT03493269|Experimental|BAY1834845|"Part 1 in healthy male subjects:~Dose Groups 1-4 : orally administered multiple ascending doses. The treatment will last 10 consecutive days (treatment period1) and 1 day (treatment period 2) Dose Group 5: The treatment will last 1 day (treatment period 1) and 10 consecutive days (treatment period 2)"
89458204|NCT03493269|Placebo Comparator|Matching Placebo|Part 1: Matching placebo in healthy male subjects.
89458205|NCT03493269|Experimental|Chosen dose of BAY1834845|Part 2: This dose level will be adminstered in female and male patients with psoriasis
89458206|NCT03493269|Placebo Comparator|Placebo|Part 2: The placebo will be adminstered in female and male patients with psoriasis
89458207|NCT04257682|Active Comparator|Bupivacaine|The participant will receive Bupivacaine as anesthesia during his or her planned total hip or knee replacement surgery.
89458208|NCT04257682|Active Comparator|Ropivacaine|The participant will receive Ropivacaine as anesthesia during his or her planned total hip or knee replacement surgery.
89458209|NCT04257682|Active Comparator|Mepivacaine|The participant will receive Mepivacaine as anesthesia during his or her planned total hip or knee replacement surgery.
89458210|NCT03704519|Experimental|Men_EPD|Healthy male participants receive drugs in order Enzalutamide, Placebo and Darolutamide.
89016714|NCT02694965||Stage III/IV Adjuvant Melanoma|Observational - 1) Patients either undergoing resection of stage III or stage IV melanoma or have previously undergone resection and who are considered candidates for adjuvant anti-PD-1 antibody immunotherapy. 2) Patients who previously underwent resection of stage III or stage IV melanoma and received prior adjuvant anti-PD-1 antibody immunotherapy and have subsequently developed recurrent melanoma.
89458211|NCT03704519|Experimental|Men_DEP|Healthy male participants receive drugs in order Darolutamide, Enzalutamide and Placebo.
89458212|NCT03704519|Experimental|Men_PDE|Healthy male participants receive drugs in order Placebo, Darolutamide and Enzalutamide.
89016715|NCT02664870||Shoulder Patients|Patients (1) without evidence of cartilage damage, (2) with molecular change, (3) physiologic change, or (4) with end-stage osteoarthritis, who require arthroscopy or arthroplasty
89016716|NCT02664870||Hip Patients|Patients (1) without evidence of cartilage damage, (2) with molecular change, (3) physiologic change, or (4) with end-stage osteoarthritis, who require arthroscopy (with or without periacetabular osteotomy (PAO)) or arthroplasty
89016717|NCT02664870||Knee Patients|Patients (1) without evidence of cartilage damage, (2) with molecular change, (3) physiologic change, or (4) with end-stage osteoarthritis, who require arthroscopy or arthroplasty
89458213|NCT03704519|Experimental|Men_DPE|Healthy male participants receive drugs in order Darolutamide, Placebo and Enzalutamide.
89458214|NCT03704519|Experimental|Men_EDP|Healthy male participants receive drugs in order Enzalutamide, Darolutamide and Placebo.
89458215|NCT03704519|Experimental|Men_PED|Healthy male participants receive drugs in order Placebo, Enzalutamide and Darolutamide.
89016718|NCT02653768|Experimental|STEP-KOA|This is a stepped exercise program. It begins with an internet-based exercise training program (STEP 1). After three months, participants are assessed to see if they have achieved clinically meaningful improvement in key osteoarthritis outcomes. If so, they remain at STEP 1. If not, they move on to STEP 2, which adds telephone-based coaching. Participants are assessed again three months later. Those that still have not achieved clinically relevant improvement move on to STEP 3, which adds a series of in-person physical therapy visits.
89458216|NCT01735929|Experimental|Neck Liposuction and Ultrasound Treatment|Subject will receive neck liposuction and ultrasound treatment.
89458217|NCT01735929|Sham Comparator|Sham|Subject will receive sham treatment
89458218|NCT03489759|Experimental|ViE15-A|The patients were randomly allocated to two groups by using computer-generated numbers. The renal replacement therapy will be started using ViE15-A hemofilter
89458219|NCT03489759|Active Comparator|REXEED-15A|TThe patients were randomly allocated to two groups by using computer-generated numbers. The renal replacement therapy will be started using REXEED-15A
89458220|NCT03667183|Experimental|Pilates Group|Female adolescents with eating disorders who receive Pilates for 10 weeks.
89458221|NCT05424952|No Intervention|Control|Eligible adults with unvaccinated senior parents/grandparents or children.
89016719|NCT02653768|Active Comparator|Arthritis Education (AE)|"Participants in the AE control group will receive low literacy educational materials via mail every two weeks. Because STEP-KOA is a multi-component intervention, with participants receiving different numbers of Steps, it is not possible to implement a control condition that will mirror the exact intervention dose received by all participants in the STEP-KOA group. However, AE will achieve the goal of providing an active, OA-related control condition."
89016720|NCT02638090|Experimental|Phase I Dose Escalation|"Level 1: Vorinostat 200mg by mouth (PO) Daily; Pembrolizumab 200 mg intravenously (IV) every (Q) 3 weeks.~Level 2: Vorinostat 400 mg PO Daily; Pembrolizumab 200 mg IV Q3 weeks"
89016721|NCT02638090|Experimental|Phase Ib Expansion|"Pembrolizumab plus Vorinostat.~Level 1: Maximum Tolerated Dose (MTD)"
89016722|NCT02638090|Active Comparator|Arm A: Pembrolizumab|"Pembrolizumab treatment only.~Level 1: Pembrolizumab 200 mg Q3 wks"
89458222|NCT05424952|Experimental|Intervention|Eligible adults with unvaccinated senior parents/grandparents or children.
89458223|NCT04766333|Active Comparator|Healthcare Worker Focused Outreach Intervention Strategy|Healthcare Worker Focused Outreach Intervention Strategy
89458224|NCT04766333|Active Comparator|Community Organization Led Outreach|Community Organization Led Outreach
89458225|NCT05405530|Experimental|nasal mask oxygen group|In this group, patients use the nasal mask oxygen kit for oxygenation.
89458226|NCT05405530|Active Comparator|regular nasal cannula group|In this group, patients use the regular nasal cannula for oxygenation.
89458227|NCT03020641|Experimental|Low pneumoperitoneum pressure.|Pneumoperitoneum pressure at 8 mmHg or lower.
89458228|NCT03020641|Active Comparator|standard pneumoperitoneum pressure|Pneumoperitoneum pressure at 12 mmHG or higher
89458229|NCT05405140|Experimental|Shock wave therapy with multiphasic neuroplasticity based training protocol|Shock wave therapy with multiphasic neuroplasticity based training protocol based on motor relearning program and task oriented approach
89458230|NCT05405140|Active Comparator|Conventional physical therapy|Stretching and strengthing and motor sensory motor training of effected side
89458231|NCT05404906|Experimental|Treatment (azacytidine+venetoclax)|Participants will receive azacytidine QD, on Days 1-5 and venetoclax QD, on Days 1-14 of each 28-day cycle for 8 cycles.
89016723|NCT02638090|Active Comparator|Arm B: Pembrolizumab plus Vorinostat|"Pembrolizumab plus Vorinostat treatment.~Level 1: MTD"
89458232|NCT05404906|Experimental|Comparator ( best supportive care)|Participants will receive observation and supportive care during remission.
89458233|NCT03020407|Experimental|IVC Ultrasound-guided|The treating physician will promptly assess the IVC diameter to obtain the collapsibility index (IVCCI) (or distensibility index, IVCDI) of an eligible patient. A previous study showed that IVCCI > 40% were strongly associated with fluid responsiveness. Accordingly, the patient will be given 10 ml/kg of bolus of 0.9% normal saline solution (NSS) each time when the IVCCI > 40% is discovered and serial measurements will be done after each intravenous bolus is achieved until the IVCCI < 40 % during our protocol. Prompt empirical antibiotics will be given to the patients within one hour before the treatment allocation.
89458234|NCT03020407|No Intervention|Usual care|Patients will be promptly and empirically treated by 30 ml/kg loading of NSS in this treatment arm. After the NSS bolus, treatment with either the additional intravenous fluid or a vasopressor is given depended on physicians' discretion during the 6-hour study period. Prompt empirical antibiotics will be given to the patients within one hour before the treatment allocation.
89458235|NCT01444222||Pulmonary Hypertension|
89016724|NCT02606305|Experimental|Regimen A (Mirvetuximab soravtansine + Bevacizumab)|Mirvetuximab soravtansine + Bevacizumab administered on Day 1 of each 21-day cycle in Dose Escalation and Dose Expansion phase.
89016725|NCT02606305|Experimental|Regimen B (Mirvetuximab soravtansine + Carboplatin)|Mirvetuximab soravtansine + Carboplatin administered on Day 1 of each 21-day cycle in Dose Escalation phase.
89016726|NCT02606305|Experimental|Regimen C (Mirvetuximab soravtansine + Pegylated liposomal doxorubicin)|Mirvetuximab soravtansine + Pegylated liposomal doxorubicin administered on Day 1 of each 28-day cycle in Dose Escalation Phase.
89016727|NCT02606305|Experimental|Regimen D (Mirvetuximab soravtansine + Pembrolizumab)|Mirvetuximab soravtansine + Pembrolizumab administered on Day 1 of each 21-day cycle in Dose Escalation and Dose Expansion phase.
89016728|NCT02606305|Experimental|Regimen E (Mirvetuximab soravtansine + Bevacizumab + Carboplatin)|Mirvetuximab soravtansine + Bevacizumab + Carboplatin administered on Day 1 of each 21-day cycle in Dose Expansion phase.
89016729|NCT02597348|Experimental|Liver Transplantation|Arm LT+C: patients will be treated by experimental liver transplantation preceding the non experimental standard chemotherapy (according to usual practices).
89016730|NCT02597348|No Intervention|No intervention|Arm C: patients will receive non experimental standard chemotherapy according to usual practices in the context of definitively unresectable CLM.
89016731|NCT02588079|Experimental|Internet-based cognitive behavioral therapy|The treatment program consists of 12 modules that are offered during 12 weeks on Internet. Modules consist of parental education, psycho-education for the children, exposure, cognitive restructuring and home exercises. A psychologist guides parents and children through the treatment with continuous contact using the message function on the Internet platform that is used.
89016732|NCT02588079|No Intervention|Wait list|Participants are not offered any active controlled psychological interventions but have free access to dental health services, which could involve exposure and other behavioral strategies applied by dental staff.
89016733|NCT02560805|Experimental|Veterans|Subjects with post-traumatic stress disorder (PTSD) will be evaluated using microneurography, static handgrip exercise, cold pressor test, combat virtual reality video clip, and baroreflex sensitivity using sodium nitroprusside and phenylephrine. For the second phase, they will be randomized to either losartan or atenolol.
89016734|NCT02560805|Experimental|Control|Healthy controls will be evaluated using microneurography, static handgrip exercise, cold pressor test, combat virtual reality video clip, and baroreflex sensitivity using sodium nitroprusside and phenylephrine.
89016735|NCT02542293|Experimental|Combination Therapy|Durvalumab (PD-L1 monoclonal antibody) + Tremelimumab (monoclonal antibody directed against CTLA-4)
89016736|NCT02542293|Active Comparator|Standard of Care|Standard of Care chemotherapy treatment
89016737|NCT02530463|Experimental|Cohort I (nivolumab)|Patients receive nivolumab IV over 30 minutes on days 1 and 15. Treatment repeats every 4 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with disease progression may receive nivolumab and azacitidine at the discretion of the treating physician.
89016738|NCT02530463|Experimental|Cohort II (ipilimumab)|Patients receive ipilimumab IV over 30 minutes on day 1. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients with disease progression may receive ipilimumab and azacitidine at the discretion of the treating physician.
89023580|NCT05119309||control patient group|Renal biopsy diagnosis of nephropathy linked to onco-haematological pathology with full clinical expression (Multiple Myeloma, B-cell Lymphoma)
89458236|NCT01444222||pulmonic valve stenosis|
89458237|NCT01444222||pulmonic valve homograft|
89458238|NCT01444222||pulmonic valve insufficiency|
89458239|NCT01444222||atrial septum defect|
89458240|NCT01444222||Ebstein's anomaly|
89458241|NCT01444222||transvalvular right ventricular lead|
89458242|NCT01444222||control|
89458243|NCT03667729|Experimental|progressive muscle relaxation|The experimental group received PMR once a week for a total of 12 weeks. Subjects completed measures at baseline, 3-month, and 3-month follow-up.
89458244|NCT03667729|No Intervention|Control group|treatment-as-usual(TAU)
89501824|NCT02814019|Experimental|idebenone 150 mg film-coated tablets|900 mg idebenone/day (2 tablets to be taken 3 times a day with meals)
89458245|NCT03625193||Ambulatory patients with SCI|"Age at least 18 years~Body mass index (BMI) between 18.5 - 29.9 kg/m2~Having an incomplete SCI from traumatic or non-traumatic causes~Ability of independent standing up from a chair with or without hand support~Ability of independent walking with or without walking device over at least 10 meters continuously.~Ability to follow commands used in the studies"
89458246|NCT03624959|Experimental|Treatment Group A - Ozanimod 0.46mg|A single dose of ozanimod 0.46 mg on Day 1
88941142|NCT01856985|Experimental|Misoprostol at clinic|"Eligible women will receive 200 mg mifepristone to be administered at home or at the clinic and will receive either 800 µg misoprostol buccally (study 1) or 800 µg misoprostol sublingually (study 2) to self administer at home.~Participants will be asked to return to the hospital 14 days later for a follow-up visit."
88941143|NCT01856998|Active Comparator|Diprivan® 20 mg/mL (AstraZeneca)|"Dosage form: lipid emulsion~Dosage: Initial effect-site target concentration: 5 μg/mL, if necessary increased by 1 μg/mL every 60 seconds until LOER~Frequency: continuously (will be adjusted to keep Bispectral Index (BIS) between 40 and 60, however maintenance target concentration can be increased if a patient needs a BIS <40 with regard to individual condition and the respective surgery)~Duration: Until end of surgery"
89458247|NCT03624959|Experimental|Treatment Group B - Ozanimod plus Gemfibrozil|Gemfibrozil 600 mg twice daily (BID) on Days 1 through 17. On Day 4, a single dose of ozanimod 0.46 mg will be coadministered with the morning dose of gemfibrozil.
89458248|NCT03624959|Experimental|Treatment Group C - Ozanimod 0.92mg|A single dose of ozanimod 0.92 mg on Day 1.
89458249|NCT03624959|Experimental|Treatment Group D - Ozanimod plus Itraconazole|Itraconazole 200 mg once daily (QD) on Days 1 through 17. On Day 4, a single dose of ozanimod 0.92 mg will be co-administered with itraconazole.
89458250|NCT03624959|Experimental|Treatment Group E - Ozanimod plus Rifampin|Rifampin 600 mg QD on Days 1 through 21. On Day 8, a single dose of ozanimod 0.92 mg will be coadministered with rifampin
89458251|NCT03667105|Experimental|CAF+XDM|CAF treatment will be performed by starting with two divergent releasing incisions lateral to the recessed area. A sulcular incision will be made to unite the releasing incisions and the flap will be raised beyond the mucogingival junction (MGJ) in split-full-split thickness. Additionally, this group will receive the xenogenous dermal collagen matrix graft (AXDM - Mucoderm®, Botiss,) on the recessed area before the sutures. Then, the flap will be coronally positioned and sutured to completely cover the graft.
89501825|NCT02814019|Placebo Comparator|placebo|matching placebo tablets
88941144|NCT01856998|Experimental|Propofol 2% (20 mg/mL) MCT Fresenius|"Dosage form: lipid emulsion~Dosage: Initial effect-site target concentration: 5 μg/mL, if necessary increased by 1 μg/mL every 60 seconds until LOER~Frequency: continuously (will be adjusted to keep Bispectral Index (BIS) between 40 and 60, however maintenance target concentration can be increased if a patient needs a BIS <40 with regard to individual condition and the respective surgery)~Duration: Until end of surgery"
88941145|NCT01857011|Experimental|IV Iron|Intravenous Iron Sucrose 200 mg in the immediate postoperative period and first day postop.
88941146|NCT01857011|Active Comparator|Oral Iron|Oral iron(III)-hydroxide polymaltose complex 100 mg twice daily in the fist 8 postoperative weeks.
88941147|NCT01857037|Other|Single arm|Single arm
89501826|NCT02224495|Placebo Comparator|Control|Standard of care
88941148|NCT01857076|Active Comparator|Clinical|Subject submitted to clinical obesity treatment
88941149|NCT01857076|Active Comparator|Gastric bypass surgery|Subjects submitted to Gastric Bypass Surgery
88941150|NCT01857076|Active Comparator|Surgical ileal transposition with sleeve|Subjects submitted to surgical ileal transposition with sleeve
88941151|NCT01857089|Experimental|Pressure Measurement|
88941152|NCT01857128|Experimental|Drawtex Hydroconductive Dressing|Gauze-like dressing placed onto wound
88941153|NCT01857128|Active Comparator|Negative Pressure Wound Therapy|Usual care including vacuum and canister
88941154|NCT01857141|Experimental|dexmedetomidine|
89016739|NCT02530463|Experimental|Cohort III (nivolumab, ipilimumab)|Patients receive nivolumab IV over 30 minutes on days 1 and 15 and ipilimumab IV over 30 minutes on day 1. Treatment repeats every 4 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive nivolumab IV over 30 minutes every 2 weeks (or every 4 weeks if patients receive azacitidine) in the absence of disease progression or unacceptable toxicity. Patients with disease progression may receive ipilimumab, nivolumab, and azacitidine at the discretion of the treating physician.
89016740|NCT02530463|Experimental|Cohort IV (azacitidine, nivolumab)|Patients receive azacitidine IV over 10-40 minutes on days 1-5 and nivolumab IV over 30 minutes on days 6 and 20. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
89016741|NCT02530463|Experimental|Cohort V (azacitidine, ipilimumab)|Patients receive azacitidine IV over 10-40 minutes on days 1-5 and ipilimumab IV over 30 minutes on day 6. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
89458252|NCT03667105|Experimental|CAF+MC|CAF treatment will be performed by starting with two divergent releasing incisions lateral to the recessed area. A sulcular incision will be made to unite the releasing incisions and the flap will be raised beyond the mucogingival junction (MGJ) in split-full-split thickness. Additionally, this group will receive the xenogenous collagen matrix graft (Mucograft®, Geistlich Pharma) on the recessed area before the sutures. Then, the flap will be coronally positioned and sutured to completely cover the graft.
89016742|NCT02530463|Experimental|Cohort VI (azacitidine, nivolumab, ipilimumab)|Patients receive azacitidine IV over 10-40 minutes on days 1-5 and nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 6. Treatment with ipilimumab repeats every 4 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity. Cycles with nivolumab and azacitidine repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
89458253|NCT03667105|Active Comparator|CAF|CAF treatment will be performed by starting with two divergent releasing incisions lateral to the recessed area. A sulcular incision will be made to unite the releasing incisions and the flap will be raised beyond the mucogingival junction (MGJ) in split-full-split thickness. Then, the flap will be coronally positioned and sutured to completely cover the graft. This group will be the control group.
89458254|NCT04888637||All Subjects|MEG baseline session Receptive Language Task Memory Task
89458255|NCT04579315|Active Comparator|Intervention group, NNRD group|"Main principles of the interventional whole food approach are:~Maximum of 850 mg phosphorous/day~Protein: 0.8 g/kg/day~80% vegetable products; 20% animal products~Maximum of 5-7 g NaCl/day (table salt)~Fresh raw products~Seasonal oriented~Fish: At least once a week~Vegetarian: At least once a week~Wide range of fruit and vegetables~Easy to follow in daily practice~Rich in flavors~Sufficient content of micro- and macronutrients"
89458256|NCT04579315|No Intervention|Control group|There is no intervention, patients are following their habitual diet
89458257|NCT03667495||Relapse|Patients who suffered colorectal cancer or adenoma relapse after curative surgery
89458258|NCT03667495||Remission|Patients who get remission after curative surgery
89458259|NCT02536846|Experimental|Second Generation Antipsychotic Drug|Olanzapine; a single 2.5 mg dose PO daily followed by 5 mg dose PO daily for 14 days
89458260|NCT03554057||Intervention Group|All low-risk patients referred for invasive coronary angiography through the Hamilton General Hospital's Heart Investigation Unit Triage will be potentially eligible to receive the intervention over a 12-month period. The intervention will include risk stratification with CCTA at HHS and NHS as an alternative to upfront invasive angiography.
89458261|NCT03554057||Control Group|Intervention sites will act as their own controls: outcomes of all eligible patients in the 24-months prior to the implementation of the intervention will be assessed from a routinely collected health administrative database. Eligible patients not undergoing CCTA (patient or physician refusal, or CCTA not available) will be captured and included in the control group as part of a sensitivity analysis during the intervention period
89458262|NCT03014011|Other|Hypoglycaemic clamp first, then euglyceamic clamp|First intervention with a hypoglycaemic clamp (one examination day of approximately 5 hours), there after a wash out period of 21-42 days, then second and final intervention day with an euglycaemic clamp (approximately 5 hours).
89458263|NCT03014011|Other|Euglycaemic clamp first, then hypoglycaemic clamp|First intervention with an euglycaemic clamp (one examination day of approximately 5 hours), there after a wash out period of 21-42 days, then second and final intervention day with a hypoglycaemic clamp (approximately 5 hours).
89016743|NCT02529189|Active Comparator|Nitrate-rich beetroot juice|70 ml of a beetroot juice concentrate containing ~5 mmol nitrate
89016744|NCT02529189|Placebo Comparator|Nitrate-deplete beetroot juice|70 ml of a beetroot juice concentrate that is nitrate-depleted
89458264|NCT03012841|Experimental|Treatment Arm|Subjects enrolled and treated with Arctic Front Advance Cardiac CryoAblation Catheter
89458265|NCT03704129|Experimental|"Tutor group"|"After a theoretical part through the administration of a video-tutorial, a 10-point questionnaire will be administered to evaluate the level of learning for each participant. Every single participant will pass the test if he/she correctly answer to >70% of the questions. Those passing the test, will be randomized to two groups.~The interventional group will access the practical training, during which each participant will be followed by a tutor who will interactively explain, using a healthy volunteer, how to perform the ultrasound scan of the diaphragm. The ultrasound will be performed on a healthy volunteer first by the tutor and then by the participants. During the exercise, each individual learner will be supervised by the tutor himself."
89458266|NCT03704129|No Intervention|"No tutor group"|This control group will directly perform the ultrasound examination of the diaphragm. The expert tutor will only show the learners how to use the various functions of the ultrasound, the linear and convex probes both in two-dimensional and in M-mode.
89458267|NCT02359864|Experimental|Cohort One|An initial 15 patients will be enrolled in the first treatment scheme (5 daily fractions of 2 Gy) and will be followed for 12 months after completion of treatment to assess safety and any toxicity/adverse events associated with treatment. 15 patients will be enrolled and each will be followed for 12 months to assess safety and toxicity/adverse events.
89458268|NCT02359864|Experimental|Cohort Two|"The second treatment arm will not be used until the last patient in the first dose arm has completed all follow up. At that point patients~#16-30 will be enrolled in the second dose arm (10 daily fractions of 2 Gy). 15 patients will be enrolled and each will be followed for 12 months to assess safety and toxicity/adverse events."
89458269|NCT03703973||study group|1000 Male and female patients undergoing non-cardiac surgery at the Affiliated Hospital of Xuzhou Medical University [Jiangsu China]. We do the neuropsychological tests, Mini-Mental score examination (MMSE) and olfaction test 1 day before (baseline) and 1 week,3 months,1 year and 3 years after surgery without safety issue.We also measure their preoperative leukocyte telomere length.
89458270|NCT03703973||control group|We enroll 50 healthy volunteers and do the neuropsychological tests, Mini-Mental score examination (MMSE) and olfaction test at 1 day (baseline), 1 week, 3 months, 1 year and 3 years without safety issue.
89458271|NCT03703739|Active Comparator|Reference meal 1|50 g of Commercial Rice (Jasmin Rice) (dry weight) was cooked and 4 mg iron from Ferrous sulfate was added Prior to give to participants. Rice meal consumed with mixed vegetable Sauce.
89016745|NCT02522715|Experimental|Treatment (cabazitaxel, enzalutamide)|Patients receive cabazitaxel IV over 1 hour on day 1 and enzalutamide PO QD on days 1-21 (days 2-21 of cycle 1). Patients also receive prednisone PO BID as standard of care with cabazitaxel. Cycles repeat every 21 days for 6-10 cycles in the absence of disease progression or unacceptable toxicity. Patients may continue enzalutamide PO QD on days 1-28 in the absence of disease progression or unacceptable toxicity.
89458272|NCT03703739|Active Comparator|Reference 2|50 g of Commercial Rice (Jasmin Rice) (dry weight) was cooked and 4 mg iron from Ferrous sulfate was added Prior to give to participants. Rice meal consumed with bean sauce.
89458273|NCT03703739|Experimental|Test meal A|Commercial Rice (Jasmin Rice) was mixed with iron fortified extuded rice cofortified with zinc oxide and ethylenediaminetetraacetic acid (mixing ratio 100:1), Rice meal consumed with mixed vegetable Sauce.
89458274|NCT03703739|Experimental|Test meal B|Commercial Rice (Jasmin Rice) was mixed with iron fortified extuded rice co-fortified with zinc sulfate and ethylenediaminetetraacetic acid (mixing ratio 100:1), Rice meal consumed with mixed vegetable Sauce.
89458275|NCT03703739|Experimental|Test meal C|Commercial Rice (Jasmin Rice) was mixed with iron fortified extuded rice co-fortified with zinc sulfate, citric acid and trisodium citrate (mixing ratio 100:1), Rice meal consumed with mixed vegetable Sauce.
89458276|NCT03703739|Experimental|Test meal D|Commercial Rice (Jasmin Rice) was mixed with iron fortified extuded rice co-fortified with zinc sulfafe and sodium pyrophosphate (mixing ratio 100:1), Rice meal consumed with mixed vegetable Sauce.
89458277|NCT03703739|Experimental|Test meal E|Commercial Rice (Jasmin Rice) was mixed with iron fortified extuded rice co-fortified with zinc sulfate, citric acid and trisodium citrate (mixing ratio 100:1), Rice meal consumed with bean Sauce.
88941155|NCT01857141|Placebo Comparator|normal saline|
88941156|NCT01857154|Active Comparator|Bisphosphonates/Micronized Calcium Carbonate/Vitamin D3|Subjects currently being treated with Bisphosphonates will replace any calcium they are currently taking with four Capsules/Day containing a total amount of 500 mg of Micronized Calcium Carbonate and 800 IU Vitamin D3
89458278|NCT05441176|Experimental|Patients with suspicion of TOS|Patients coming for a visit to diagnostic TOS and submitted TULIP and MASC questionnaires
89458279|NCT05402254|Experimental|Pharmacovigilance Program|Intensive nursing intervention is carried out for the identification and notification of ADE
89458280|NCT05402254|No Intervention|Control|The Usual practice of the nursing care process
89458281|NCT04423042|Experimental|Tocilizumab Arm|Tocilizumab 8 mg/kg IV up to a maximum of 800 mg with possible repetition of the same dosage within 28 hours (the optional second dose after 12 hours but before 28 hours following the first dose), based on the clinical judgement of the attending physician in consultation with the COVID-inflammation team.
89458282|NCT04423042|No Intervention|No Intervention Arm|No intervention arm patients will be identified from medical records, as being COVID-19 positive patients with hyperinflammation who did not receive any interleukin antagonist treatment.
89458283|NCT05440006|Experimental|Fed+ Fasted|The first cycle with high-fat meal, the second cycle under fasting.
89458284|NCT05440006|Experimental|Fasted + Fed|The first cycle under fasting, the second cycle with high-fat meal.
89458285|NCT05439460|Experimental|Phenylephrine|Phenylephrine will be administered once the child is under anesthesia and the interventional cardiologist has measured the pressures in the pulmonary artery.
89458286|NCT05439460|Experimental|Epinephrine|Epinephrine will be administered once the child is under anesthesia and the interventional cardiologist has measured the pressures in the pulmonary artery.
89458287|NCT05439460|Experimental|Arginine Vasopressin|Arginine Vasopressin will be administered once the child is under anesthesia and the interventional cardiologist has measured the pressures in the pulmonary artery.
88941157|NCT01857154|Active Comparator|Bisphosphonates/Non-Micronized Calcium Carbonate/Vitamin D3|Subjects currently being treated with Bisphosphonates will replace any calcium they are currently taking with four Capsules/Day containing a total amount of 1000 mg of Non-Micronized Calcium Carbonate and 800 IU Vitamin D3.
88941158|NCT01857154|Active Comparator|Non-Micronized Calcium Carbonate/Vitamin D3|Subjects who are not currently being treated with Bisphosphonates will replace any calcium they are currently taking with four Capsules/Day containing a total of 1000 mg of Non-Micronized Calcium Carbonate and 800 IU Vitamin D3.
89016746|NCT02483481|Other|Shear Wave Ultrasound Elastography|
89016747|NCT02447029|Experimental|Active Comparator|Drug: vaginal 2% Xylocaine
89016748|NCT02447029|Other|standard lidocaine paracervical block|standard lidocaine paracervical block
89458288|NCT03019627|Experimental|rhNGF 20μg/mL|Recombinant Human Nerve Growth Factor (rhNGF) at 20 μg/mL eye drops six times daily
89458289|NCT03019627|Placebo Comparator|Vehicle|vehicle eye drops six times daily
89501827|NCT02224495|Experimental|Structured exercise training|8-week outpatient exercise-training program, encompassing 3 sessions per week, including endurance and resistance training
89458290|NCT01661140|Experimental|Methotrexate (MTX) Tapering Dosage|At Week 0 participants will start open-label tocilizumab and open-label MTX for 24 weeks. At Week 24, participants achieving a good/moderate European League Against Rheumatism (EULAR) disease response will be randomized to the MTX Tapering group or MTX Maintenance group. In this arm participants will receive a double-blind MTX dose according to the MTX tapering scheme between Week 24 and Week 56. Participants will also continue to receive open-label tocilizumab between Week 24 and Week 56. From Week 56 to Week 72 participants will receive tocilizumab monotherapy.
89458291|NCT01661140|Active Comparator|Methotrexate (MTX) Maintenance Dosage|At Week 0 participants will start open-label tocilizumab and open-label MTX for 24 weeks. At Week 24, participants achieving a good/moderate European League Against Rheumatism (EULAR) disease response will be randomized to the MTX Tapering group or MTX Maintenance group. In this arm participants will continue to be administered a stable dose of MTX in a double-blind fashion between Week 24 and Week 56. Participants will also continue to receive open-label tocilizumab between Week 24 and Week 56. From Week 56 to Week 72 participants will receive tocilizumab monotherapy.
89458292|NCT03019549|Experimental|Rosuvastatin|Period 1: 20 mg rosuvastatin administered once orally (PO)
89458293|NCT03019549|Experimental|Lanabecestat + Rosuvastatin|Period 2: 50 mg Lanabecestat (LY3314814) administered orally (PO) Day 1 to Day 12 Rosuvastatin: 20 mg co-administered PO on Day 8
89458294|NCT05400850|Experimental|YOGA|sEMG values will record during different 5 YOGA Asana's
89458295|NCT05423314||control|patients operated for ACLR
89458296|NCT05423314||cold therapy|"patients operated for ACLR, and received a knee brace cold therapy to use it in the post op recovery rehabilitation, sent to patient's home directly during pre-op phase."
89458297|NCT01661062|Experimental|Cone Beam CT|All patients will be included in the treatment arm of this study. For the purposes of this study patients will get CT scans every day for the length of their radiation therapy (in order to assess if CT every day provides additional information compared with CT scans performed less frequently). Although the exact amount of radiation patients get will be determined by their doctor, it is expected that they will get approximately 7 weeks, approximately 35 total cone beam CT scans.
89458298|NCT04260958|Experimental|Intervention center|Patients at intervention centers will be offered remote video exCR (first-hand option), usual care centre-based exCR or a combination. The exercise program (remote/centre-based) will be standardized and performed for totally 60 minutes, 2 times a week for 3 months. Exercise will be individually prescribed and progressed by physiotherapists in accordance with guidelines. Patients will also be asked to perform one additional session of at least 30 min aerobic exercise per week, at intensity level 13-15 according to Borg RPE-scale.
89458299|NCT04260958|No Intervention|Control|At control centers, patients will be offered usual care centre-based exCR only. Patients will also be asked to perform one additional session of at least 30 min aerobic exercise per week, at intensity level 13-15 according to Borg RPE-scale.
89458300|NCT05436886|Experimental|Test Group (Neurogabin-M 400 mg) Capsules|A single dose consisting of one capsule of Test Drug (Neurogabin 400 mg capsule) will be administered to each of the subjects in both Periods in fasting conditions with 240 mL ambient temperature water.
89458301|NCT05436886|Active Comparator|Reference Group (Parketin 400 mg) Capsules|A single dose consisting of one capsule of Reference Drug (Parketin 400 mg capsule) will be administered to each of the subjects in both Periods under fasting conditions with 240 mL ambient temperature water.
89458302|NCT01373151|Placebo Comparator|Arm 1|BMS-945429 Placebo/BMS-945429+Methotrexate+Adalimumab Placebo
89458303|NCT01373151|Experimental|Arm 2|BMS-945429 + Methotrexate + Adalimumab Placebo
89458304|NCT01373151|Experimental|Arm 3|BMS-945429 + Methotrexate + Adalimumab Placebo
89458305|NCT01373151|Experimental|Arm 4|BMS-945429 + Methotrexate + Adalimumab Placebo
89458306|NCT01373151|Experimental|Arm 5|BMS-945429 + Methotrexate/Methotrexate Placebo + Adalimumab Placebo
89458307|NCT01373151|Experimental|Arm 6|BMS-945429 + Methotrexate/Methotrexate Placebo+Adalimumab Placebo
89458308|NCT01373151|Active Comparator|Arm 7|Adalimumab + Methotrexate
89458309|NCT05435716|Experimental|Peripheral seismic catheterization system (IVL) + drug-coated balloon (DCB) and/or stent|
89458310|NCT05435716|Other|PTA + DRUG-coated balloon (DCB) and/or stent|
89458311|NCT05419882||colorectal surgery patients|In patients undergoing colorectal surgery, blood samples will be collected at 5 times: preoperatively, and at 2, 6, 24 and 48 hours after finishing surgery, respectively.
89458312|NCT05148897||All Women can participate|among 500 women, over 6 months by random selection and they will be asked to answer the questions of prepared and copied questionnaire sheet.
89458313|NCT03488511|Experimental|Intervention group|The intervention group will receive meals from FoodforCare at Home. The FoodforCare at Home concept consists of six small protein and energy enriched meals and snacks that will be delivered twice a week. After an individual intake, the composition of the dishes will be tailored to the needs of the patient in terms of composition, diet, taste, flavor and portion size. Besides the meals, patients in the intervention group will also receive an information leaflet about the importance of protein during treatment and how to reach their protein requirements.
89458314|NCT03488511|No Intervention|Control group|The control group will continue their usual diet for 3 weeks and have no restrictions to their diet.
89458315|NCT01660906|Experimental|Dasatinib (100 mg)|
89458316|NCT03488979||Educational Interventional Group|Primary outcome measure: Difference in MOSSAS-3HF score between intervention group and control group, administered 4 weeks after discharge.
89458317|NCT03488979||Attention Control Group|Primary outcome measure: Difference in MOSSAS-3HF score between intervention group and control group, administered 4 weeks after discharge.
89458318|NCT01285947|Other|Naive Subjects|Subjects who have not previously undergone energy-based dermatologic procedures in the past.
89501828|NCT03364244||Sildenafil|Pediatric patients receiving Revatio
89458319|NCT01285947|Other|Non-Naive Subjects|Subjects who have previously undergone energy-based dermatologic procedures in the past.
89458320|NCT03015181|Experimental|Group 1: 1 mg/kg IV Single Dose|Group 1 subjects received a single IV infusion of VRC07-523LS (VRC-HIVMAB075-00-AB) on Day 0 at a dose of 1 mg/kg.
89458321|NCT03015181|Experimental|Group 2: 5 mg/kg IV Single Dose|Group 2 subjects received a single IV infusion of VRC07-523LS (VRC-HIVMAB075-00-AB) on Day 0 at a dose of 5 mg/kg.
89458322|NCT03015181|Experimental|Group 3: 5 mg/kg SC Single Dose|Group 3 subjects received a single SC injection of VRC07-523LS (VRC-HIVMAB075-00-AB) on Day 0 at a dose of 5 mg/kg.
89458323|NCT03015181|Experimental|Group 4: 20 mg/kg IV Single Dose|Group 4 subjects received a single IV infusion of VRC07-523LS (VRC-HIVMAB075-00-AB) on Day 0 at a dose of 20 mg/kg.
89458324|NCT03015181|Experimental|Group 5: 40 mg/kg IV Single Dose|Group 5 subjects received a single IV infusion of VRC07-523LS (VRC-HIVMAB075-00-AB) on Day 0 at a dose of 40 mg/kg.
89458325|NCT03015181|Experimental|Group 6: 5 mg/kg SC Multiple Doses|Group 6 subjects received a SC injection of VRC07-523LS (VRC-HIVMAB075-00-AB) on Day 0, Week 12 and Week 24 at a dose of 5 mg/kg.
89458326|NCT03015181|Experimental|Group 7: 20 mg/kg IV Multiple Doses|Group 7 subjects received an IV infusion of VRC07-523LS (VRC-HIVMAB075-00-AB) on Day 0, Week 12 and Week 24 at a dose of 20 mg/kg.
89458327|NCT03493191|Experimental|0.5 μg/kg SHR0410|8 subjects will be randomized in a 3:1 ratio to receive a single dose of either 0.5μg/kg SHR0410 (n=6) or placebo (n=2)
89458328|NCT03493191|Experimental|1 μg/kg SHR0410|8 subjects will be randomized in a 3:1 ratio to receive a single dose of either 1μg/kg SHR0410 (n=6) or placebo (n=2)
89458329|NCT03493191|Experimental|2 μg/kg SHR0410|8 subjects will be randomized in a 3:1 ratio to receive a single dose of either 2μg/kg SHR0410 (n=6) or placebo (n=2)
89458330|NCT03493191|Experimental|5 μg/kg SHR0410|8 subjects will be randomized in a 3:1 ratio to receive a single dose of either 5μg/kg SHR0410 (n=6) or placebo (n=2)
89458331|NCT03493191|Experimental|10 μg/kg SHR0410|8 subjects will be randomized in a 3:1 ratio to receive a single dose of either 10μg/kg SHR0410 (n=6) or placebo (n=2)
89016749|NCT02445781|Experimental|90 mg/dl glucose clamp|Glucose clamp intervention of 90 mg/dl maintained for 90 minutes.
89016750|NCT02445781|Experimental|70 mg/dl glucose clamp|Glucose clamp intervention of 70 mg/dl maintained for 90 minutes.
89016751|NCT02445781|Experimental|60 mg/dl glucose clamp|Glucose clamp intervention of 60 mg/dl maintained for 90 minutes.
89458332|NCT03493191|Experimental|20 μg/kg SHR0410|8 subjects will be randomized in a 3:1 ratio to receive a single dose of either 10μg/kg SHR0410 (n=6) or placebo (n=2)
89458333|NCT03666949|Other|All General anesthesia|"Use of a hypnotic(propofol 2.5mg/kg), morphine(remifentanil1yg/kg) and curare(atracurium0.5mg/kg), with the support of orotracheal intubation and mechanical ventilation"
89016752|NCT02445781|Experimental|50 mg/dl glucose clamp|Glucose clamp intervention of 50 mg/dl maintained for 90 minutes.
89016753|NCT02420977|Experimental|DCFPyL PET-MRI fusion or PET/MRI|"Pelvic DCFPyL PET-MRI fusion or PET/MRI compared before and after 2-3 months of ADT~Pelvic DCFPyL PET-MRI fusion or PET/MRI compared before and after 2-3 months"
89016754|NCT02413567|Experimental|DMR Procedure|Subjects receive the endoscopic DMR procedure in this arm
89016755|NCT02386709|Experimental|Experimental Arm|"Diagnostic~PET1 : before the neoadjuvant treatment~start neoadjuvant treatment~PET2: two weeks after the start of the first course of chemotherapy~surgery"
89016756|NCT02328872|Experimental|Intervention (HPV Arm)|"Molecular testing for HPV with partial genotyping for types 16/18, with referral of the HPV16/18-positive group for diagnostic evaluation, and secondary randomisation of women testing positive for other oncogenic HPV infection (not 16/18), to either image-read cytology screening or dual-stained (DS) cytology testing with p16/Ki67 - the HPV arm. Screening performed 5 yearly."
89016757|NCT02328872|Active Comparator|Control (LBC Arm)|"Image-read liquid based cytology (LBC) screening with reflex HPV triage testing for low grade smears, the LBC arm. Screening performed 2.5 yearly."
89458334|NCT03666949|Other|All Locoregional anesthesia|"Use of a local anesthetic( xylocaine 1%) for the realization of scalp nerve block"
89458335|NCT05396404||observation|all subject data were retrieved from databank which is stored in the e-medical chart system.
89458336|NCT00886691|Experimental|Arm I (bevacizumab and everolimus)|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15 and everolimus PO QD on days 1-28.
89458337|NCT00886691|Experimental|Arm II (bevacizumab and placebo)|Patients receive bevacizumab as in Arm I and placebo PO QD on days 1-28.
89458338|NCT03667417||subjects carrying a BRCA gene mutation|subjects carrying a BRCA gene mutation
89458339|NCT00960297|Experimental|Carboplatin/Paclitaxel/Bevacizumab|Preoperative chemotherapy and bevacizumab
89458340|NCT03488433|Active Comparator|Antirotation sling|Patients who undergo reverse shoulder arthroplasty or rotator cuff repair will be randomly assigned to this group.
89501829|NCT02224651|Experimental|(1-1000mg) Immediate Release formulation|
89458341|NCT03488433|Active Comparator|abduction brace|Patients who undergo reverse shoulder arthroplasty or rotator cuff repair will be randomly assigned to this group.
89458342|NCT00518037||1|nonmelanoma skin cancer patients
89458343|NCT04423354|Experimental|Research group|Patients diagnosed with Siewert Ⅱ adenocarcinoma of esophagogastric junction and met the inclusion criteria will be assigned to the research group and carry out transthoracic single-hole assisted laparoscopic radical gastrectomy.
89458344|NCT03018691|Experimental|0.3% OPA-15406 Ointments|Subjects were treated with assigned 0.3% OPA-15406 ointment twice daily.
89458345|NCT03018691|Experimental|1% OPA-15406 Ointments|Subjects were treated with assigned 1% OPA-15406 ointment twice daily.
89458346|NCT03018691|Placebo Comparator|Placebo Ointments|Subjects were treated with assigned 0% OPA-15406 ointment twice daily.
89458347|NCT05112861|Experimental|Biological: bevacizumab|
89458348|NCT04423198||Target Condition|Subjects presenting to the Emergency Department (ED) or Urgent Care (UC) with a blunt head trauma
88941159|NCT01857154|Active Comparator|Micronized Calcium Carbonate/Vitamin D3|Subjects who are not currently being treated with Bisphosphonates will replace any calcium they are currently taking with four Capsules/Day containing a total of 500 mg of Micronized Calcium Carbonate and 800 IU Vitamin D3
89458349|NCT04423198||Trauma Control|Subjects presenting to the ED or UC requiring an Xray but do not have a head trauma
89458350|NCT04423198||Healthy Control|Subjects that are healthy and not taking any prescription medications
89458351|NCT03667261|Active Comparator|cover screw|extraction of hopeless mandibular molars followed by immediate implants that will be covered using cover screw
89458352|NCT03667261|Experimental|sealing socket abutment|extraction of hopeless mandibular molars followed by immediate implants that will be covered using sealing socket abutment
89458353|NCT03493035||MCA aneurysm group|All patients with unruptured MCA aneurysm diagnosed on three-dimensional computed tomography angiography (3D CTA) and transcranial color-coded sonography (TCCS) .
89458354|NCT03493035||non-MCA aneurysm group|All patients with no evidence of intracranial pathologies on 3D CTA and diagnosed on transcranial color-coded sonography (TCCS).
89458355|NCT05418400|Active Comparator|bulkfill composites|sonic fill 3 & PALFIQUE bulk flow bulk fill composite
89458356|NCT05418400|Active Comparator|incremental composites|Neo spectra & Clear fill AP-X incremental composites
88941160|NCT01857167|Experimental|Fish Oil Supplementation|Patients will receive fish oil capsules, at a dose of 4g/day. Each 1g capsule will contain 300mg of EPA and 200mg of DHA.
88941161|NCT01857167|Experimental|Flaxseed Oil Supplementation|Patients will receive flaxseed oil capsule, at a dose of 4g/day. Each 1g capsule will contain 630mg of ALA
89458357|NCT01790776|Active Comparator|Conventional urethrography|Current golden standard.
88941162|NCT01857167|Placebo Comparator|Placebo Supplementation|Patients will receive corn oil in the capsules at the same dose as fish oil. The corn oil will appear identical in size and color to the fish oil.
88941163|NCT01857180|Experimental|Curriculum|Participants in the curriculum group took part in a structured, comprehensive curriculum consisting of a 1 hour didactic cognitive component, a 1 hour didactic non-technical (team-based skills) component, and 6 hours of structured technical skills practice in peg transfer, intracorporeal suture, and VR simulator tasks. Participants had the opportunity to ask questions and engage in discussion with experts after the didactic sessions, and received subjective feedback from circulating residents in addition to objective feedback in the technical skills tasks.
88941164|NCT01857180|No Intervention|Self-directed|Participants in the control (self-directed) group took part in 8 hours of self-directed learning with written materials for cognitive and non-technical skills components and unstructured surgical simulation practice of technical skills with only objective feedback from the simulator for the VR tasks or time for the peg transfer and intracorporeal suture tasks.
88941165|NCT01857193|Experimental|L-R-E arm|Participants who took ribociclib (LEE011), everolimus (RAD001) and exemestane triple combination
88941166|NCT01857193|Experimental|L-E arm|Participants who ribociclib (LEE011) and exemestane double combination
89201480|NCT03986983|Experimental|Experimental group of Shockwave therapy and Aerobic Exercise|"The participants do the Shockwave therapy protocol - The shockwave therapy protocol was performed in the prone position.~In addition, the participants also perform the Aerobic exercise protocol - The entire protocol was monitored through the Polar® brand heart rate monitor and watch."
89201481|NCT03986983|No Intervention|Control group|The participants do not perform any type of intervention.
89458358|NCT01790776|Experimental|Sono-urethrography|Experimental urethrography, which could be followed by conventional urethrography if the results are inconclusive.
89458359|NCT05148585|Active Comparator|group 1|"group 1 (get only physiotherapy) After flexor tendon repair patients start getting physiotherapy. They use static dorsal splint.~exercises are progressive according to the healing process. Physiotherapy lasts 12 weeks. Then follow-up sixth months."
89458360|NCT05148585|Experimental|group 2|"group 2 (get both physiotherapy and activity-based therapy) After flexor tendon repair patients start getting physiotherapy. They use a static dorsal splint.~Exercises are progressive according to the healing process. Physiotherapy lasts 12 weeks. then follow-up sixth month. Additionally, group 2 gets activity-based therapy once a week about an hour. activities are also progressive according to the patients needs."
89458361|NCT05130333||Non-cardiac surgery patients under general anesthesia|> 18y/o patients undergoing noncardiac surgery with BIS monitoring under general anesthesia.
89016758|NCT02312557|Experimental|Treatment (pembrolizumab)|"INITIAL TREATMENT PHASE: Patients who are progressing on enzalutamide will receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Patients continue to receive standard of care enzalutamide PO daily.~MONITORING PHASE: After completion of the initial treatment phase, patients continue to receive standard of care enzalutamide PO daily for the duration of the trial.~RETREATMENT PHASE: Patients with disease response or stability after the initial treatment phase will receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for an additional 4 courses in the absence of disease progression or unacceptable toxicity. Patients continue to receive standard of care enzalutamide PO daily for the duration of the trial."
89016759|NCT02279693|Other|CBCT|cone beam computed tomography (CBCT) repositioning
89016760|NCT02279693|Other|fiducial markers|kV imaging of fiducial marker repositioning
89016761|NCT02269527|Other|Live music|1-hour live music 5 days/week
89016762|NCT02206984|Active Comparator|tamoxifen|Tamoxifen is administered orally, at a dose of 20 mg,daily, for 21 days
89016763|NCT02206984|Active Comparator|Anastrozole|1mg given orally daily for 21 days
89016764|NCT02206984|Active Comparator|fulvestrant|500 mg, administered as two 250 mg IM injections, given on days 1 and 14
89016765|NCT02200705|Other|single arm, open label|Early stage Breast cancers up to 1.5cm
89016766|NCT02055248||Subjects with Moebius or related syndromes and their family me|Subjects with Moebius or related syndromes and their family members and healthy volunteers.
89016767|NCT01976182|Active Comparator|METHOTREXATE|"In step 1, 55 patients will receive methotrexate 10mg / m² orally once a week, (at split doses of 5 mg/m2 in the morning and 5 mg/m2 at night), that is to say 2 tablets of 2.5 mg at each take~In step 2, responders at Month 4 (CR or PR) will be treated during 8 additional months with methotrexate at the same dosage.~Non responders at Month 4 will be randomized and treated either by:~Cyclophosphamide delivered at 100 mg orally once daily, that is to say 2 tablets of 50 mg at each take between Month 5 and Month 8, decreased to 50 mg orally once daily beyond Month 8 for responders at Month 8;~Ciclosporine A delivered at 3 mg/kg per day (at split doses of 1.5 mg/kg in the morning and 1.5 mg/kg at night) orally administered."
89201482|NCT00924417|Experimental|Distraction|"Parent given brief teaching session on concept of distraction, and parent and child given 3 distraction toys/tools to assist with peripheral intravenous line placement."
89201483|NCT00924417|Other|Routine care|Patient managed as routine care.
89201484|NCT04015245|Experimental|SNMC|
89201485|NCT04015245|No Intervention|non-SNMC|
89458362|NCT04746911|Experimental|ARQ-151 cream 0.3%|Open label study of ARQ-151 cream 0.3% applied once daily for 4 weeks
89458363|NCT04460859||Intubated mechanically ventilated ARDS patients|Intubated mechanically ventilated patients with moderate to severe ARDS according to the Berlin definition
89458364|NCT03012061|Placebo Comparator|Placebo|Subjects will be administered placebo once daily via the ELLIPTA® dry powder inhaler (DPI) for 24 weeks. Subjects will also receive FF 100 mcg once daily, in the morning for 24 weeks. ELLIPTA is a registered trademark of the GSK group of companies.
89458365|NCT03012061|Experimental|UMEC 62.5 mcg|Subjects will be administered UMEC 62.5 mcg once daily via the ELLIPTA dry powder inhaler (DPI) for 24 weeks. Subjects will also receive FF 100 mcg once daily, in the morning for 24 weeks.
89458366|NCT03012061|Experimental|UMEC 31.25 mcg|Subjects will be administered UMEC 31.25 mcg once daily via the ELLIPTA dry powder inhaler (DPI) for 24 weeks. Subjects will also receive FF 100 mcg once daily, in the morning for 24 weeks.
89458367|NCT04953065||interventional|Single arm, interventional. All participants will be contacted over the phone to answer questions from a COVID-19 vaccine hesitancy and acceptance survey.
89458368|NCT00408863|Active Comparator|Tibolone|Tibolone 2.5 mg/day
89458369|NCT00408863|Placebo Comparator|Placebo|Placebo
89458370|NCT05378074|Experimental|MaxiPost|A time- and volume-controlled infusion pump is used to administer MaxiPost by intravenous infusion over 20 minutes.
89458371|NCT05378074|Placebo Comparator|Placebo (isotonic saline)|A time- and volume-controlled infusion pump is used to administer placebo (isotonic saline) by intravenous infusion over 20 minutes.
89458372|NCT05113719|Experimental|Bridge exercise at knee angle 45 degree|The group will perform the bridge exercise at a 45-degree knee flexion angle.
89458373|NCT05113719|Experimental|Bridge exercise at knee angle 60 degree|The group will perform the bridge exercise at a 60-degree knee flexion angle.
89458374|NCT05113719|Experimental|Bridge exercise at knee angle 90 degree|The group will perform the bridge exercise at a 90-degree knee flexion angle.
89458375|NCT03666793|No Intervention|Control|Standard healthcare procedures
89458376|NCT03666793|Experimental|experimental: Reconciliation group|medical reconciliation at admission, multidisciplinary medication review, medical reconciliation at discharge of the hospital
89458377|NCT03488277|Experimental|LE: leg elevation group|the patients of this group will be positionned in supine with 15° left tilt and will have a leg elevation with a 30 cm pillow positionned under the heels. this position will be hold immediately after spinal anesthesia until fetal extraction
89458378|NCT03488277|No Intervention|CG: Control group|The patients of this group will be positiooned in supine with 15° left tlit after spinal anesthesia. no leg elevation
89016768|NCT01976182|Active Comparator|CYCLOPHOSPHAMIDE|"In step 1, 55 patients will receive cyclophosphamide 100 mg orally once daily, that is to say 2 tablets of 50 mg at each take.~In step 2, responders at Month 4 (CR or PR) will be treated during 8 additional months with cyclophosphamide (at 50 mg orally once daily);~Non responders at Month 4 will be randomized and treated either by:~Methotrexate administered at 10 mg/m2 orally once a week (at split doses of 5 mg/m2 in the morning and 5 mg/m2 at night), that is to say 2 tablets of 2.5 mg at each take;~Ciclosporine A delivered at 3 mg/kg per day (at split doses of 1.5 mg/kg in the morning and 1.5 mg/kg at night) orally administered."
89016769|NCT01940094|Experimental|5 mg Prednisone|Subjects will be randomized to a prednisone dose of 5 mg per day for a 6 month period.
89016770|NCT01940094|Experimental|0 mg Prednisone|Subjects will be randomized to taper their prednisone dose from 5 mg per day to 0 mg per day for a 6 month period.
89458379|NCT03665389|Other|Single Arm|Among patients who undergo TAVR at the kobe university hospital, those who are found to have moderate or severe stenosis on cCTA performed before surgery and judged to clinically require ischemia evaluation will be included in this study.
89458380|NCT03703661|Other|Control|primary closure with gauze and adhesive/occlusive dressing
89458381|NCT03703661|Experimental|Negative Pressure|primary closure with gauze and adhesive/occlusive dressing under negative pressure
89458382|NCT04941339|Experimental|MRG002|All patients in Phase Ia (dose escalation) and Phase Ib (dose expansion) will be administrated MRG002 on Day 1 of every 3 weeks (21-day cycle).
89458383|NCT03666715||Participants with Schizophrenia|Participants diagnosed with schizophrenia who switched from oral antipsychotics (OAPs) to Paliperidone Palmitate 1-month formulation (PP1M), with available information concerning the annual schizophrenia-related hospitalizations before and after initiation of PP1M treatment, and who switched to PP1M at least 6-months after it was available for reimbursement in Portugal will be observed. The primary data source for this study will be the medical records of each participant.
89016771|NCT01927562|Experimental|Duodenal Treatment|The Duodenal Remodeling procedure utilizes both a trans-oral over the wire and endoscopic approach to minimally invasively ablating and remodeling the duodenum.
89016772|NCT01862991|Placebo Comparator|Dilapan-Placebo|The clinician will place 4 or 5 osmotic cervical dilators (Dilapan-S)(4mm x 65mm). The patient will be administered a placebo pill orally with juice or water by the clinician or study investigator. Patients that are over 22 weeks gestation will receive 1mg of intra-amniotic digoxin the day prior to the procedure.
89016773|NCT01862991|Active Comparator|Dilapan-Mifepristone|The clinician will place 4 or 5 osmotic cervical dilators (Dilapan-S) (4mm x 65mm). The patient will be administered mifepristone (200mg) orally with juice or water by the clinician or study investigator.Patients that are over 22 weeks gestation will receive 1mg of intra-amniotic digoxin the day prior to the procedure.
89016774|NCT01862991|Experimental|Mifepristone|The patient will be administered mifepristone (200mg) orally with juice or water by the clinician or study investigator. Patients that are over 22 weeks gestation will receive 1mg of intra-amniotic digoxin the day prior to the procedure.
89458384|NCT04920435||training population|patients from which we will develop the prediction model
89458385|NCT04920435||testing population|patients on whom we will test the prediction model
89458386|NCT03665311|Placebo Comparator|Normal Saline|100 mL 0.9% Normal Saline at the initiation of SLED and another 100 mL 0.9% Normal Saline after 4 hours of treatment
89458387|NCT03665311|Active Comparator|25% Albumin fluid|100 mL 25% Albumin fluid at the initiation of SLED and another 100 mL 25% Albumin fluid after 4 hours of treatment
89458388|NCT04830033|Experimental|ENO Breathe group|Participation in the online ENO Breathe programme for 6 weeks.
89458389|NCT04830033|No Intervention|Usual Care Group|Participants continue with usual care.
89458390|NCT03488199|Active Comparator|Stent Acculink™ (RX ACCULINK CAROTID STENT SYSTEM)|50 Carotid stenting (RX ACCULINK CAROTID STENT SYSTEM)
89458391|NCT03488199|Experimental|Stent CGuard™ (The CGuardTM Embolic Prevention System (EPS))|50 Carotid stenting (The CGuardTM Embolic Prevention System (EPS))
89201486|NCT03983785|Experimental|Pilates|
89458392|NCT03010501|Experimental|100% Food Energy Density|Baseline Food Energy Density
89458393|NCT03010501|Experimental|80% Food Energy Density|Lower Food Energy Density
89458394|NCT03010501|Experimental|120% Food Energy Density|Higher Food Energy Density
89201487|NCT03983785|Experimental|Elastic Taping|
89201488|NCT03983785|No Intervention|Wait List Control|
89201489|NCT00924495|Active Comparator|Cortical function|Activity/inhibition of the cortex
89201490|NCT00924495|Active Comparator|Cortical regulation|
89458395|NCT03489681|Experimental|Acupuncture, low dosage|treat as six acupoints
89016775|NCT01821690|Experimental|Buspirone Treatment|starting at 15 mg/day and ending at 60 mg/day as prescribed
89458396|NCT03489681|Experimental|Acupuncture, high dosage|treat as 18 acupoints
89458397|NCT03489681|No Intervention|Control group|no acupuncture treatment, healthy control
89458398|NCT03666481|Experimental|MPAI group|Patients in this group participated in a 6-months Motivational Physical Activity Intervention (MPAI) to explore its effects on different variables related to PA levels and psychosocial aspects of life of bariatric patients. Concretely, the fundamental goals of the MPAI group were three: to increase the self-determined forms of motivation of the patients towards exercise or reduce those related to non-self-determined motivation; to improve post-operative levels of PA with respect to pre-operative levels, and; transfer the benefits of the intervention on different variables related to the perceived health-related quality of life.
89458399|NCT03666481|No Intervention|Control group|Patients in this group did not participate in any intervention, but the same measurements were made in them as in the MPAI group in the same temporal spaces.
89016776|NCT01821690|Placebo Comparator|Buspirone Placebo|placebo tablets as prescribed
89201491|NCT04005664|No Intervention|Bolus group|Hypotension occurring under spinal anaesthesia (SBP < 90mmHg) requires pharmacological treatment. The pharmacological management of hypotension, once diagnosed, will be the same regardless of the protocol being used. If the heart rate is greater than 70 beats per minute, phenylephrine will be administered in a dose of 50-100 mcg as an intravenous bolus. If the heart rate is less than 70 beats per minute, ephedrine will be administered in a dose of 5-10 mg. The dose within this range will be decided by the attending anaesthetist. In both arms, Ringers Lactate fluid should run fast if hypotension occurs.
89201492|NCT04005664|Active Comparator|Phenylephrine coload group|Phenylephrine 500ug will be added to the first litre of ringer's lactate infused on initiation of spinal anaesthesia. If the phenylephrine infusion protocol is being used, and the mean arterial pressure (MAP) rises to greater than 20% of the initial MAP, and where this rise in MAP is not due to a recent bolus of either phenylephrine or ephedrine (within 2 minutes), the Ringers Lactate infusion will be switched off. The pharmacological management of hypotension, once diagnosed, will be the same regardless of the protocol being used. If the heart rate is greater than 70 beats per minute, phenylephrine will be administered in a dose of 50-100 mcg as an intravenous bolus. If the heart rate is less than 70 beats per minute, ephedrine will be administered in a dose of 5-10 mg. In both arms, Ringers Lactate fluid should run fast if hypotension occurs.
89201493|NCT00928785|Experimental|REPEVAX|
89201494|NCT00928785|Active Comparator|Monovalent tetanus vaccine|
89201495|NCT00330967||Group 1|healthy subjects
89201496|NCT00330967||Group 2|healthy subjects different from group 1
89201497|NCT00928863||Haemorrhagia post partum|Women with a high risk for haemorrhagia post partum.
89201498|NCT03983629||CDA patients|
89201499|NCT00987610|Active Comparator|slender guidewire|Percutaneous coronary intervention (PCI) using guidewires with small distal tip equal to 0.010 inch or less
89458400|NCT03131973|Experimental|Methotrexate|Methotrexate single oral dose followed by leucovorin single oral dose on specified days followed by BMS-986195 coadministered with methotrexate single oral dose followed by leucovorin single oral dose on specified days
89458401|NCT03131973|Experimental|Cytochrome P450 and Transporter Substrates|Caffeine, montelukast, flurbiprofen, omeprazole, midazolam, digoxin, and pravastatin single oral dose on specified days, BMS-986195 multiple oral dose administration on specified days, and BMS-986195 coadministered with caffeine, montelukast, flurbiprofen, omeprazole, midazolam, digoxin, and pravastatin single oral dose on specified days.
89458402|NCT03666013||Young healthy subjects|20-30 years old, max 1h of exercise per week
89458403|NCT03666013||Elderly with a normal physical function|65-80 years old, max 1h of exercise per week
89458404|NCT03666013||Elderly with a decreased physical function|65-80 years old, max 1h of exercise per week, SPPB under 9 or frailty score lower then 10
89458405|NCT03666013||Active elderly|65-80 years old, minimal 3h of exercise per week
89458406|NCT03665233|Sham Comparator|Sh-group|The patients in this arm get standard treatment, together with a sham version of a VR session.
89458407|NCT03665233|Active Comparator|VR-group|These patients get a VR session with the standard treatment
89458408|NCT05078931|Experimental|Pembrolizumab + Lenvatinib in PD-L1 Positive TKI resistant NSCLC patients|The PD-L1 positive patients with TKI-resistant EGFR-mutated advanced NSCLC will receive the combination of pembrolizumab and lenvatinib.
89458409|NCT05579873||Single plating technique|Choice of implant used for single plating left at descretion of treating surgeon.
89458410|NCT05579873||Double plating technique|Double plating consist of one VariAx 2.0mm plate positioned on the superior aspect of the clavicula and a second VariAx 2.4mm or 2.7 mm on the anterior side. Use of this implant will be according to the device's cleared indications of use.
89458411|NCT03492957|Experimental|Physical activity|A tailored, person-centred, 12-week, chair-based exercise intervention to increase physical activity and fitness. Dose: one face-face session with a qualified physiotherapist plus two independent sessions per week. This is combined with education on self-management, self-efficacy and lifestyle change. There is no control group ion this feasibility study.
89458412|NCT03002623|Experimental|Group|CUDC-907 for thyroid cancer
89458413|NCT04825197|Experimental|LRS Group|This arm will receive up to 4 doses (100 mg Kg) of Poractant alfa (Curosurf, Chiesi) every 12 hours; each dose preceded by a recruitment manoeuvre in HFOV. Optimal recruitment is defined as adequate oxygenation using a fraction of inspired oxygen (FiO2) of 0.30 or less. The continuous distending pressure (CDP) will be increased stepwise (1 cmH2O every 2-3 min) as long as pulse oximetry (SpO2) improves. The FiO2 will be reduced stepwise, keeping SpO2 within the target range (87-94 %). The recruitment procedure will be stopped if oxygenation no longer improves or if the FiO2 is equal to or less than 0.30. The corresponding CDP will be called the opening pressure (CDPO). Next, the CDP will be reduced stepwise (1-2 cmH2O every 2-3 min) until the SpO2 deteriorates (by at least 2-3 points). The corresponding CDP will be called the closing pressure (CDPC). After a second recruitment maneuver at CDPO for 5 min, the optimal CDP (CDPOPT) will be set 2 cmH2O above the CDPC for at least 3 min.
89458414|NCT04825197|No Intervention|Standard Group|This arm will be managed following the ward standard ventilatory protocol which does not contemplate neither surfactant administration nor recruitment manoeuvre.
89458415|NCT04728191|Experimental|+ asthma + intervention|35 participants with asthma aged 10-17 years, randomized to physiotherapy. The intervention consists of 4 instruction lessons spread over 6 weeks. The participants are instructed in a daily ten-minute-program of breathing exercizes.
89501830|NCT02224651|Placebo Comparator|Immediate Release Placebo arm|
89501831|NCT02224651|Experimental|(10-500) mg Modified Release formulation|
88941167|NCT01857219|Experimental|Role of Tai Chi in Fibromyalgia|"Each Tai Chi session will last 60 minutes and will continue twice a week for 12 weeks. Our instructors, who have extensive experience conducting Tai Chi training programs, will follow the standardized Tai Chi protocol. We will also provide the participants with printed materials on FM and the Tai Chi Mind-Body program, including Tai Chi principles, practicing techniques, and safety precautions for participants with FM.~In the first session, the Tai Chi instructors will explain exercise theory and procedures of Tai Chi. For the remaining sessions, the subjects will practice Tai Chi under the instruction of one of the Tai Chi instructors. Every session will include the following components: (1) warm-up and self-massage and a review of Tai Chi principles; (2) Tai Chi movement; (3) breathing techniques; (4) relaxation. Each component of the program derives from classical Yang style Tai Chi 108 posture.30"
88941168|NCT01857245|Experimental|Modified Directly Observed Therapy (mDOT)|In our mDOT model, pegylated interferon is administered once weekly, and one daily dose of oral medication is administered at the methadone window.
88941169|NCT01857245|Experimental|Concurrent Group Treatment (CGT)|In our CGT model, patients initiate HCV treatment within a once weekly treatment group which provides social support to mitigate fears of side effects, promote efficient education, and deliver weekly injections.
88941170|NCT01857245|Active Comparator|Treatment as Usual|In the TAU arm, subjects will receive all medications monthly (or more often as needed) at the clinic.
89016777|NCT01778296|Experimental|Surgical flap|The neurocutaneous island flap is based on the dorsal branch of the digital nerve
88941171|NCT01857284|Experimental|Group 1|Tauroursodeoxycholic Acid Capsules,250mg,tid.
88941172|NCT01857284|Active Comparator|Group 2|Ursodeoxycholate acid capsules, 250mg,tid,
89458416|NCT04728191|Active Comparator|+ asthma - intervention|35 participants with asthma aged 10-17 years, randomized to standard care. Participants are getting advice about dysfunctional breathing by a physician or nurse in the outpatient clinic.
89458417|NCT04728191|Experimental|- asthma + intervention|35 participants without asthma aged 10-17 years, randomized to physiotherapy. The intervention consists of 4 instruction lessons spread over 6 weeks. The participants are instructed in a daily ten-minute-program of breathing exercizes.
89458418|NCT04728191|Active Comparator|- asthma - intervention|35 participants without asthma, which are randomized to standard care. Participants are getting advise about dysfunctional breathing by a physician or nurse in the outpatient clinic.
89458419|NCT04737135||Patients|Patients with Tetralogy of Fallot
89458420|NCT03665857|Experimental|multicomponent intervention|"Schools in the intervention arm will receive a multicomponent intervention at the school-, parent- and student-level, with a mobile application to promote the collaboration between investigators, school teachers, parents and students.~The school-level intervention elements will include school policies and health education for teachers.~The parent-level intervention elements will include health education for parents and promoting students' physical activity at home.~The student-level intervention elements will include health education for students, promoting students' physical activity in school and monthly monitoring of weight and height."
89458421|NCT03665857|No Intervention|usual-care control|Schools assigned to the control group will have usual education provision throughout their participation in the trial, and after finishing the study they will be offered the health education package, policy suggestion and materials as the schools in the multicomponent intervention group.
89458422|NCT04703361|Experimental|Niacin|12 patients with Heart failure with reduced ejection fraction (HFrEF) investigated with echocardiography and right heart catheterization.
89458423|NCT04703361|Experimental|Na-3-OHB|"12 patients with Heart failure with reduced ejection fraction (HFrEF) investigated with echocardiography and right heart catheterization.~All patients will receive Aspirin before intervention and randomization."
89458424|NCT03010423|Experimental|Nicorandil|
89458425|NCT05576597|Experimental|butyrate supplement|2 capsules butyrate supplement (containing 1200 mg of sodium butyrate ) once a day for 12 weeks Drug: sodium butyrate
89458426|NCT04727099|Experimental|Benign Pigmented Lesions|Up to six (6) treatments with PicoWay laser for treatment of benign pigmented lesions
89458427|NCT04727099|Experimental|Wrinkles|Up to six (6) treatments with PicoWay laser for treatment of wrinkles
89458428|NCT03492879|Experimental|Biopsy: Routine tests & EIT Technology|The patients will undergo a routine liver biopsy and also routine liver Ultrasonography, Shear wave elastography and Electrical Impedance Technology (EIT).
89458429|NCT03492879|Experimental|Routine tests & EIT Technology|The patients will undergo a routine liver Ultrasonography, Shear wave elastography and Electrical Impedance Technology (EIT).
89458430|NCT03492879|Experimental|NASH : Routine tests & EIT Technology|The patients will undergo a routine liver Ultrasonography, Shear wave elastography and quantification of liver steatosis using the Electrical Impedance Technology (EIT).
89458431|NCT03002311|No Intervention|Control|Receiving current standard of care as designated by emergency department (ED) standard operating practice.
89458432|NCT03002311|Experimental|Epharmix/CareSignal eHealth Intervention|After randomization, participants receive text reminders to have a follow-up visit. The participant can respond to these messages via numerical or binary answers (Y/N).
89458433|NCT05034471|Experimental|Mitral Valve Repair with Novel Device Technologies|All study participants will undergo mitral valve repair by replacing the chordae tendinea with ePTFE single loop sutures using novel suturing devices.
89458434|NCT03488043||Retrospective cohort|All patients having a CT-guided transthoracic biopsy from September 2012 and September 2017.
89458435|NCT03488043||Prospective cohort|All patients having a CT-guided transthoracic biopsy from April 2018.
88941173|NCT01857336|Experimental|infusion group|Patients with PGF were planed to infusion peripheral harvest. The peripheral cell harvest was aphaeresis on the fourth or fifth day after mobilization with recombinant human granulocyte colony stimulating factor.
88941174|NCT01857349|Active Comparator|Chlora Prep|Food and Drug Administration (FDA)-approved, surgical skin preparation solution: ChloraPrep (2% chlorhexidine gluconate and 70% isopropyl alcohol; Enturia, El Paso, Texas)
88941175|NCT01857349|Active Comparator|Dura Prep|Food and Drug Administration (FDA)-approved, surgical skin preparation solution:DuraPrep (0.7% available iodine and 74% isopropyl alcohol; 3MHealthcare, St. Paul, Minnesota).
88941176|NCT01857375||Group receiving insulin via vial/syringe|This group will receive their insulin via vial/syringe
88941177|NCT01857375||Insulin Pen|Patients receiving insulin via insulin pen
88941178|NCT01857388|Experimental|ParentCorps|Teachers from Intervention schools will receive ParentCorps training and support.
88941179|NCT01857388|No Intervention|Wait List Control|Teachers from control schools will not receive training and support in Year 1, but will receive training and support in Year 2.
88941180|NCT01857401||Observational study|Blood draw only, observational study
88941181|NCT01857440||Subjects with glaucoma (Cases)|This group will consist of patients with glaucoma who are under care at the Ohio State University Havener Eye Institute.
88941182|NCT01857440||Subjects without glaucoma (Controls)|This group will consist of matched controls who are free of glaucoma and other complications, and who received a comprehensive eye examination at the Ohio State University College of Optometry.
88941183|NCT01857453|Experimental|teatment arm|carboplatine + etoposide based chemotherapy followed by radiation therapy with 24 Gy on the in toto neuro axis and 54 Gy on the post operative bed
89016778|NCT01701674|Experimental|Combination Therapy|The combination of ipilimumab followed by lymphodepletion with chemotherapy, TIL infusion, and high dose IL-2.
89458436|NCT03002077|Experimental|Rapastinel|Rapastinel 450 milligrams (mg) intravenous (IV) open label weekly or every two weeks, based on investigator's discretion for 52 Weeks.
89458437|NCT03487965|Experimental|Low dose Polyphenol|130 mg of Aronia Extract with 120 mg of licorice root combination blend provided to subjects once per day for 16 weeks.
89501832|NCT02224651|Placebo Comparator|Modified Release Placebo arm|
89016779|NCT01672255|Active Comparator|Trial 1-SSRI|90 minute exercise baseline with 6 weeks treatment with SSRI (Prozac). Repeat 90 minute exercise after 6 week treatment.
89016780|NCT01672255|Placebo Comparator|Trial 2-Placebo|90 minute exercise at baseline with 6 weeks treatment with placebo. Repeat 90 minute exercise after 6 weeks treatment of placebo.
89016781|NCT01588431|Experimental|(TPE-A) Followed by Concurrent RT(XPE-A), surgery|Docetaxel, Cisplatin, Cetuximab and Bevacizumab (TPE-A) Followed by Concurrent Radiation, Cisplatin, Cetuximab and Bevacizumab (XPE-A), surgery
89016782|NCT01377805||Multiple Sclerosis patients|Multiple sclerosis patients
89016783|NCT01367977||Ehlers-Danlos patients|Patients with diagnosed or suspected Classic or Hypermobile Ehlers-Danlos Syndrome
89016784|NCT01330446|Experimental|Armodafinil|50 mg the first 3 days, 100 mg the next 4 days, and 150 mg for the remaining treatment period.
89016785|NCT01330446|Placebo Comparator|Placebo|1 Placebo by mouth every morning for a 28 day cycle.
89016786|NCT01323374|Experimental|Droxidopa 200mg TID|
89016787|NCT01323374|Experimental|Droxidopa 400mg TID|
89458438|NCT03487965|Experimental|High dose Polyphenol|200 mg of Aronia extract provided to subjects once per day for 16 weeks
89458439|NCT03487965|Placebo Comparator|Placebo control|Inert tablet provided to subjects once per day for 16 weeks
89458440|NCT03665779|Experimental|isosorbide mono-nitrate group|70 pregnant females, induction of labor will be done by Intra vaginal isosorbide mono nitrate (Effox 40 mg MINAPHARM)
89458441|NCT03665779|Placebo Comparator|placebo group|70 pregnant females, induction will be done by placebo (pyridoxine) administered in the posterior vaginal fornix.
89458442|NCT03664999||Parturients physiologic pregnancy|Parturients undergoing caesarean delivery with physiologic pregnancy
89458443|NCT03664999||Parturients with risk pregnancy|Parturients undergoing caesarean with risk of complications (pre-eclampsia, HELLP syndrom, placenta praevia, placental abruption, IUGR, previous post partum hypotony).
89458444|NCT03703505|Experimental|AG-348|On Day 1, participants fasting for at least 10 hours the night before will receive oral AG-348 followed by intravenous (IV) [13C6]AG-348, 1 hour post-oral dose.
89458445|NCT04947293|Experimental|Yoga Exercise|Subjects in the experimental group will be invited to participate in 60-minute yoga sessions twice a week for 12 weeks. Each session will include postural (asanas), breathing (pranayama), and meditative exercises. They will be adapted to the physical possibilities of the patients with the help of accessories such as chairs, straps, blankets, blocks. One additional session (60 minutes) per week, in autonomy, at home, will be recommended and accompanied by a video support.
89458446|NCT04947293|Active Comparator|Fitness and mobility exercise|Subjects in the control group will be invited to participate in more conventional exercise sessions, based on a fitness and mobility exercise (FAME) program, 60-minute per sessions twice a week for 12 weeks. One additional session (60 minutes) per week, in autonomy, at home, will be recommended and accompanied by a video support. The effectiveness of this program has already been demonstrated in previous studies.
89458447|NCT04946435|Experimental|Drug: Antibiotic Irrigation, and Procedure/Surgery: Nasal Packing|Experimental group will receive nasal packing with antibiotic irrigation.
88941184|NCT01857466|Experimental|Floseal|In the Floseal group, the sites of bleeding were covered with Floseal under direct vision with a laparoscopic applicator and ovarian cortex was closed on itself and waited for 2 minutes for Floseal to act. Then, subsequently bleeding sites were reexamined with irrigation.
88941185|NCT01857466|Active Comparator|Bipolar coagulation|In the bipolar group, hemostasis of the ovarian parenchyma was achieved with selective minimal (20-30 watt current) bipolar coagulation without excessive coagulation of surgical defect to avoid damaging the ovary.
88941186|NCT01857479|Active Comparator|Inhaled budesonide|Nebulized budesonide 1 mg b.i.d. thrice a week for four months. Patients will also receive a metered dose inhaler of formoterol/budesonide (6/200) at a dose of 2 puffs b.i.d. and as and when required [max 10 puff/day]
88941187|NCT01857479|Experimental|Inhaled budesonide plus amphotericin|"Amphotericin B deoxycholate (50 mg) will be dissolved in 10 mL sterile water for injection (5 mg/mL). The solution remains stable for at least 7 days at 2°C to 8°C. Ten milligrams of the drug (2 mL) will be nebulized over 10-15 minutes twice in a day for three times a week (Effective dose: 10 mg b.i.d. thrice a week) using a jet nebulizer. Nebulized budesonide will be administered at a dose of 1 mg b.i.d. thrice a week after nebulization with amphotericin B. The total duration of therapy would last 4 months. Patients will also receive a metered dose inhaler of formoterol/budesonide (6/200) at a dose of 2 puffs b.i.d. and as and when required [max 10 puff/day].~The first dose will be administered under direct supervision."
88941188|NCT01857492|Sham Comparator|SHAM|We will apply sham tDCS on the primary motor cortex. We will use the same montage and parameters of active tDCS. However the current will be applied for 30 seconds in the beginning of the procedure and after that the current is turned off. This parameter for sham stimulation was chosen based on previous studies that have shown that perceived sensations on the scalp such as tingling usually fade out in the first 30 seconds of tDCS. It should be noted that less than 3 minutes of tDCS induces no effects on cortical excitability [29] and also using 30 seconds of sham is a reliable method of blinding as shown by a randomized controlled study [30]. Subjects will also meditate while receiving stimulation
89016788|NCT01323374|Experimental|Droxidopa 600mg TID|
89016789|NCT01323374|Active Comparator|Carbidopa 25mg TID|
89016790|NCT01323374|Active Comparator|Carbidopa 50 mg TID|
89016791|NCT01323374|Experimental|Droxidopa/carbidopa 200mg/25mg TID|
89016792|NCT01323374|Experimental|Droxidopa/carbidopa 400mg/25mg TID|
89458448|NCT04946435|Active Comparator|Procedure/Surgery: Nasal Packing|Patients will be assigned to the control group to collect data on common nasal packing colonization and appropriate antibiotic selection for the experimental group.
89458449|NCT03666403|Experimental|Patients|This prospective one-year study enrolled consecutive 30 children of ≤3 years-old with suspected major airway diseases and therefore scheduled for diagnostic FB. During FB, PIP measurements and associated lumen images were obtained at six airway locations using three studied NIV modes, including 1) NIV rate: 0/min, 2) NIV rate: 10-20/min, 3) NIV rate: 5-10/min.
89458450|NCT03622957||Type 2 diabetes subjects|Type 2 diabetes subjects consecutively referring to Santa Chiara, Pisa diabetes outpatients clinic
89458451|NCT03686891|Experimental|Experimental|Skin prick tests with four native legumes
89458452|NCT03664843||The chemotherapy cohort|Blood samples for ctDNA and biomarkers analysis are collected at before chemotherapy and at a series of scheduled time-points after chemotherapy , with serial two-weekly blood samples collected from a subset of patients. Meanwhile, imaging technology such as CT scan detection would be performed.
89458453|NCT03664843||The radiotherapy cohort|Blood samples for ctDNA and biomarkers analysis are collected at before radiotherapy and at a series of scheduled time-points after radiotherapy, with serial two-weekly blood samples collected from a subset of patients. Meanwhile, imaging technology such as CT scan detection would be performed.
89458454|NCT03664843||The targeted therapy cohort|Blood samples for ctDNA and biomarkers analysis are collected at before targeted therapy and at a series of scheduled time-points after targeted therapy, with serial two-weekly blood samples collected from a subset of patients. Meanwhile, imaging technology such as CT scan detection would be performed.
89458455|NCT03703427|Experimental|Capecitabine|
89458456|NCT03703427|Experimental|Vinorelbine|
89458457|NCT03703349|Experimental|Preoperative oral Magnesium|Magnesium sulfate 8 tablets (8 x 0.4 g) per day, PO, for the 3 days preceding the surgical intervention
89201500|NCT00987610|Active Comparator|normal guidewire|Percutaneous coronary intervention (PCI) using guidewires with normal distal tip equal to 0.014 inch
89458458|NCT03703349|Placebo Comparator|Control|Placebo oral tablet, for Magnesium Sulfate tablets, PO, for the 3 days preceding the surgical intervention
89458459|NCT03008005|Placebo Comparator|Placebo Oral Capsule|"In a randomized, double-blind, placebo-controlled, between-subjects design, we will administer a one-time oral dose of dronabinol (5mg or 10mg) or placebo (PBO) approximately two hours prior to MR scanning and task performance in 78 patients with PTSD.~One-third of the participants will receive 5mg dronabinol (n=26) , one-third of the participants will receive 10mg dronabinol (n=26), and the remaining one-third of the participants will receive placebo (n=26)."
89458460|NCT03008005|Experimental|Dronabinol Cap 5 milligrams (MG)|"In a randomized, double-blind, placebo-controlled, between-subjects design, we will administer a one-time oral dose of dronabinol (5mg or 10mg) or placebo (PBO) approximately two hours prior to MR scanning and task performance in 78 patients with PTSD.~One-third of the participants will receive 5mg dronabinol (n=26) , one-third of the participants will receive 10mg dronabinol (n=26), and the remaining one-third of the participants will receive placebo (n=26)."
89458461|NCT03008005|Experimental|Dronabinol Cap 10 milligrams (MG)|"In a randomized, double-blind, placebo-controlled, between-subjects design, we will administer a one-time oral dose of dronabinol (5mg or 10mg) or placebo (PBO) approximately two hours prior to MR scanning and task performance in 78 patients with PTSD.~One-third of the participants will receive 5mg dronabinol (n=26) , one-third of the participants will receive 10mg dronabinol (n=26), and the remaining one-third of the participants will receive placebo (n=26)."
89458462|NCT03666325|Experimental|Pembrolizumab|Pembrolizumab 200 mg, IV infusion on Day 1 of each 3 week cycle. After 3 cycles patient will be evaluated. In case of disease control (SD, PR, CR) the patient will continue to receive pembrolizumab. In case of progression the patient will receive also Cetuximab (250 mg/m2 after loading dose of 400mg/m2 IV infusion every week.
89458463|NCT03394781|Experimental|DUR-928 10 mg|10 mg oral suspension
89458464|NCT03394781|Experimental|DUR-928 50 mg|50 mg oral suspension
89501833|NCT03165513|Experimental|Experimental arm|mhGAP-IG psychosocial intervention
88941189|NCT01857492|Active Comparator|ACTIVE|"A 1x1 Low-intensity DC Stimulator such as the Soterix Medical Inc. (Model 1224-B New York, NY, USA) or an equivalent device will be used to deliver direct current through 35cm² saline-soaked electrodes. The anodal electrode will be placed over the left primary motor cortex (M1) while the cathodal electrode will be placed over the contralateral supra-orbital area. Primary motor cortex will be localized using the 10/20 EEG system (C3 or C4) and this is a reliable method for the technique of tDCS [5]. During active tDCS, a 2mA constant current will be delivered for 20 minutes while the subject meditates. The primary motor cortex is a reliable entry port to modulate dysfunctional activity in pain-related neural networks."
89016793|NCT01323374|Experimental|Droxidopa/carbidopa 600mg/25mg TID|
89016794|NCT01323374|Experimental|Droxidopa/carbidopa 200mg/50mg TID|
89201501|NCT00924573|Experimental|1|"Metformin on top of glimepiride~Twice a day with 2-6 mg of daily dose for glimepiride and 500-750mg of daily dose for metformin for 24 weeks"
89201502|NCT00924573|Placebo Comparator|2|"Placebo on top of glimepiride~Twice a day with 2-6 mg of daily dose for glimepiride and 2-3 tablets of placebo for 24 weeks"
89201503|NCT01054027|Experimental|0 Drop|Left eye dose
89201504|NCT01054027|Experimental|1 Drop|Left eye dose
89201505|NCT01054027|Experimental|2 drop|Left eye dose
89201506|NCT01054027|Active Comparator|3 drops|Right eye dose for all groups
89458465|NCT03666247|Experimental|HealthMindr Application|Participants in this study arm will have access to the mobile messaging platform (HealthMindr) for 3 months.
89458466|NCT03666247|Other|Waitlist|Participants in this study arm will not have access to the mobile messaging application during the course of the study. After the Month 9 follow up assessment participants in this study arm will be offered access to HealthMindr.
89458467|NCT03703193|Experimental|Dry needling|The experimental group will receive a single session of modulatory interventions combined with a single session of dry needling into the shoulder muscles which active trigger points will reproduce the shoulder pain symptoms.
89458468|NCT03703193|Active Comparator|Physical Therapy|This group will receive a single session of modulatory interventions targeting modulation of central nervous system.
89458469|NCT03665701|Experimental|Inhibitory effects of Fevipiprant|in vitro experiments: The reaction of the innate lymphoid cells by cytokine secretion in response to the stimulation by Prostagalandin D2 metabolites and the measurement of a potential suppressive effect of Fevipiprant will be assessed.
89458470|NCT03255863|Other|Questionnaire|Auto and hetero questionnaire
89458471|NCT02440425|Experimental|Combination Therapy|Combination Therapy: Pembrolizumab (experimental use) and Paclitaxel (standard use). All trial treatments will be administered on an outpatient basis. One cycle equals 21 days. The first cycle is 28 days with Pembrolizumab given on day 8 in order to determine paclitaxel tolerance.
89458472|NCT04054141|Experimental|rTMS arm|"Each patient's participation will last a maximum of 12 weeks and involves 2 sessions of neurophysiological testing (TMS) sessions and 15 neurophysiological treatment sessions (rTMS).~Patients will have a neurophysiological testing session (TMS) at the screening visit (week 0). Patients will then return for 15 neurophysiological treatment sessions (rTMS) within 14 days of screening. Patients must complete three neurophysiological treatment sessions (rTMS) during weeks 1, 2, 3, 4 and 5. The second neurophysiological testing session will be done at the final visit (week 5). Follow-up visits will be scheduled at weeks 7 and 10 (+/- 3 days). That is, the follow-up visits will occur two and five weeks after the final rTMS session which occurs on day 15."
89458473|NCT03199079||Group 1: Non-pregnant women|Non-pregnant women with normal pelvic floor
89458474|NCT03199079||Group 2: Pregnant women|Pregnant women; 22-29 weeks of pregnancy
89458475|NCT04050917|Experimental|Real stimulation|The smartwatch produces vibration stimulation.
89458476|NCT04050917|Sham Comparator|No stimulation|The smartwatch produces no vibration.
89458477|NCT03109743|Experimental|Sisters-GPS: Group Clinical Visits|Those randomized to the Sisters-GPS arm will be expected to attend a total of seven group clinical visits, once a week for ~1.5 hours. Groups visits will include education, self-management skills development, and a clinical assessment by a medical provider with a focus on HIV treatment and adherence. Additionally, Sisters-GPS participants will be encouraged to participate in a private social media site specifically designed for the study, where participants will be able communicate with one another and with research staff. Group size will be 8-10 participants.
89458478|NCT03109743|Active Comparator|Control: One-on-one Adherence Counseling|Those randomized to the control condition will receive an appointment with a HIV treatment adherence counselor and will be expected to attend a minimum of three adherence counseling visits. .
89458479|NCT04182321|Experimental|Combination Therapy|Metformin as add-on to entecavir therapy in patients with chronic hepatitis B
89458480|NCT04182321|Placebo Comparator|Standard Therapy|Entecavir monotherapy in patients with chronic hepatitis B
89458481|NCT03703037||Cohort|"This will be a nested case-control study. Women with low risk pregnancies at or beyond 41 weeks, who will be referred to our Maternal-fetal unit and admitted 1 to 2 days prior to induction of labour according institutional protocol will constitute the cohort.~Then women with intrapartum abnormal fetal heart rate tracings (cases) will be identified and match with controls. The primary outcome will be to obtain odds ratios for the Doppler ultrasound parameters (middle cerebral artery pulsatility index, mean uterine artery pulsatility index and Middle cerebral artery pulsatility index to mean uterine artery pulsatility index ratio) and Ultrasound assessment of amniotic fluid index that would be associated with intrapartum category III fetal heart rate tracing."
89458482|NCT03703037||Cases|"Cases will be patients with abnormal intrapartum cardiotocogram (category III fetal heart rate tracing).~Intervention: Ultrasound and Doppler ultrasound"
89458483|NCT03703037||Controls|"Those will be patients with normal intrapartum cardiotocogram (category I fetal heart rate tracing) or category II that converted into category I after intrauterine resuscitation methods.~Intervention: Ultrasound and Doppler ultrasound"
89458484|NCT04461405|Experimental|Intervention Arm|INTEGRATE-D is a step-by-step blueprint that will assist practices with employing American Diabetes Association recommendations for integrating medical and psychosocial care. INTEGRATE-D consists of a set of implementation strategies that enable clinical teams to put evidence-based care in place. The intervention consists of training and education; audit and feedback materials; a facilitation implementation protocol; and health information technology support materials.
89458485|NCT04461405|No Intervention|Control Arm|Usual care
89458486|NCT03702959||Betamethasone group 1|Betamethasone Group 1 (5am-11am)
89458487|NCT03702959||Betamethasone Group 2|Betamethasone Group 2 (11am-5pm)
89016795|NCT01323374|Experimental|Droxidopa/carbidopa 400mg/50mg TID|
89016796|NCT01323374|Experimental|Droxidopa/carbidopa 600mg/50mg TID|
89458488|NCT03702959||Betamethasone Group 3|Betamethasone Group 3 (5pm-11pm)
89458489|NCT03702959||Betamethasone Group 4|Betamethasone Group 4 (11pm-5am).
89458490|NCT03702881|Experimental|Bonded Spurs associated with posterior build-ups Group|The experimental group will consist of 25 patients treated with bonded spurs associated with build-ups.
89458491|NCT03702881|Active Comparator|Conventional bonded spurs Group|Active comparator group will consist of 25 patients treated with conventional bonded spurs
89458492|NCT03001219|Placebo Comparator|Part 1: Placebo|Participants will receive placebo (matched to RO7123520) on Days 1, 14, 28, and 56 with pre-trial anti-TNF-alpha and methotrexate.
89458493|NCT03001219|Experimental|Part 1: RO7123520|Participants will receive RO7123520 on Days 1, 14, 28, and 56 with pre-trial anti-TNF-alpha and methotrexate.
89458494|NCT03001219|Placebo Comparator|Part 2: Placebo|Participants will receive placebo (matched to RO7123520) on Days 1, 14, 28, and 56 with pre-trial anti-TNF-alpha and methotrexate.
89458495|NCT03001219|Experimental|Part 2: RO7123520|Participants will receive RO7123520 on Days 1, 14, 28, and 56 with pre-trial anti-TNF-alpha and methotrexate.
89458496|NCT03001219|Placebo Comparator|Part 3: Placebo|"Participants will receive placebo (matched to RO7123520) on Days 1, 14, 28, and 56 with pre-trial anti-TNF-alpha and methotrexate.~NOTE: Part 3 was not conducted."
89458497|NCT03001219|Experimental|Part 3: RO7123520|"Participants will receive RO7123520 on Days 1, 14, 28, and 56 with pre-trial anti-TNF-alpha and methotrexate.~NOTE: Part 3 was not conducted."
89458498|NCT03492723|Experimental|garlic groupe|Concentrated Aged Garlic Extract Microcrystalline Cellulose 133 mg Carboxymethylcellulose Calcium 6 mg Agar Powder 35 mg Silicon Dioxide 3.5 mg Calcium Stearate 3.5 mg Total Weight 307 mg
89458499|NCT03492723|Placebo Comparator|placebo groupe|Microcrystalline Cellulose 258.55 mg Carboxymethylcellulose Calcium 6 mg Agar Powder 35 mg Coloring Agent 0.45 mg Details: Gardenia Extractive 44.5%, Corn Syrup 55% Potassium pyrophosphate 0.5% Silicon Dioxide 3.5 mg Calcium Stearate 3.5 mg Total Weight 307 mg
89458500|NCT05477849|Experimental|3+3 design|This is an open label, single-arm trial using standard 3+3 design, in up to 30 HSV seropositive subjects. This rule-based design proceeds with cohorts of three patients
89458501|NCT04461093|Experimental|Group I|"Group I (n=45)~Acupressure wristband~IV Dexamethasone 8mg~IV Ondansetron 4mg"
88941190|NCT01857505||Direct Anterior Approach hip replacement|Single surgeon series of 105 consecutive patients who underwent hip replacement via the direct anterior approach on a fracture table
88941191|NCT01857505||Posterior Approach Hip Replacement|105 consecutive patients previously operated on by a less invasive posterior approach at the same institution. These surgeries occurred prior to March, 2010.
88941192|NCT01857518|Other|Depressed adolescents Group|Adolescents with a major depressive episode diagnosis
88941193|NCT01857518|Other|Healthy adolescent control Group|Healthy adolescents recruited from general population
88941194|NCT01857544|Experimental|Aflibercept 2.0mg|Single arm - Intravitreal Aflibercept 2.0mg, 0.05 milliliters, monthly for 6 months.
89458502|NCT04461093|Active Comparator|Group II|"Group II (n=45)~1. IV Palonosetron 0.075mg"
89458503|NCT03702803|Experimental|Galphimia glauca standardized extract|Patients with a clinical diagnosis of GAD (with a score of 18 points or more on the Hamilton anxiety scale) that will be included in the experimental group and will be assigned the treatment consisting of hard gelatin capsules with a pharmaceutical formulation prepared with a standardized extract from G. glauca, which will be administered once a day.
89458504|NCT03702803|Active Comparator|alprazolam 1mg|Patients with a clinical diagnosis of GAD (with a score of 18 points or more on the Hamilton anxiety scale) that will be included in the control group and will be assigned the treatment consisting of hard gelatin capsules with the drug Alprazolam (1 mg ), which will be administered once a day.
89458505|NCT03543943|Experimental|Individualized treatment|The ruptured achilles tendon is examined by ultrasonography. If the overlap of the tendon ends is less than 25 % or the tendon is elongated 7 % or more the patient receives conventional open operative treatment. The tendon is sutured with double fiberwire size 2 a.m. Kessler under prophylactic Dicloxacillin 2 g and in local anesthesia or alternatively popliteal or spinal block. The injured leg is placed in a circulated below the knee cast after surgery. The ankle is held at maximal plantar flexion. Weight bearing is not allowed. After 3 weeks the cast is removed and the injured leg is transferred to a functional brace with 3 heel wedges. The patient will follow standard functional rehabilitation and the follow-up evaluations.
89458506|NCT03543943|Active Comparator|Control group 1|For the patients allocated to non-operative treatment the injured leg is placed in a circulated below the knee cast from the time of the first appointment in the Outpatients Department. The ankle is held at maximal, unforced plantar flexion. Weight bearing is not allowed and the patient should walk with the aid of crutches. After 3 weeks from initiated treatment in the Emergency Department the cast is removed in the Outpatients Department and the injured leg is transferred to a functional brace (Walker boot) with 3 heel wedges promoting 20 degrees plantar flexion over the ankle. The patient will follow standard functional rehabilitation and the follow-up evaluations.
89458507|NCT03543943|Active Comparator|Control group 2|The tendon is sutured with double fiberwire size 2 a.m. Kessler under prophylactic Dicloxacillin 2 g and in local anesthesia or alternatively popliteal or spinal block. The injured leg is placed in a circulated below the knee cast from the time of the first appointment in the Outpatients Department. The ankle is held at maximal, unforced plantar flexion. Weight bearing is not allowed and the patient should walk with the aid of crutches. After 3 weeks from initiated treatment in the Emergency Department the cast is removed in the Outpatients Department and the injured leg is transferred to a functional brace (Walker boot) with 3 heel wedges promoting 20 degrees plantar flexion over the ankle. The patient will follow standard functional rehabilitation and the follow-up evaluations.
88941195|NCT01857557|Experimental|Aerobic Exercise|Fitness program for migraine patients in addition to usual headache care.
88941196|NCT01857557|No Intervention|Control Group|Patients receiving usual headache care but no exercise program
88941197|NCT01857570||Adult, clinical suspicion fractures wrist or carpus|- Patients (18 years and older) who are referred to our hospital for conventional radiography of the wrist and carpus
88941198|NCT01857596|Experimental|Bupropion -> Lorexys LO -> Lorexys HI|Crossover with all on positive comparator,lower-dose Lorexys,higher-dose Lorexys
89458508|NCT03702647|Experimental|Ropivacaine|30mL of 0.2% Ropivacaine placed in the POEM tunnel
89458509|NCT03702647|Placebo Comparator|Normal Saline|30mL of normal saline placed in the POEM tunnel
89458510|NCT03489447||Sepsis group|All adult (>= 18 years) patients with a diagnosis of sepsis included in the Swedish ICU Registry between 2008-01-01 and 2016-10-18
89458511|NCT03489447||Non-sepsis group|All adult (>=18 years) patients without a diagnosis of sepsis included in the Swedish ICU Registry between 2008-01-01 and 2016-10-18
89458512|NCT04583787|Experimental|Patients with suspected CAD|
89458513|NCT03000673|Active Comparator|Dose Sequence 1|UFH, BMS-986177 - dose 1, BMS-986177 - dose 2, Enoxaparin
89458514|NCT03000673|Active Comparator|Dose Sequence 2|BMS-986177 - dose 1, Enoxaparin, UFH, BMS-986177 - dose 2
89458515|NCT03000673|Active Comparator|Dose Sequence 3|BMS-986177 - dose 2, UFH, Enoxaparin, BMS-986177 - dose 1
89458516|NCT03000673|Active Comparator|Dose Sequence 4|Enoxaparin, BMS-986177 - dose 2, BMS-986177 - dose 1, UFH
89458517|NCT03487731|Placebo Comparator|Group 1 - Placebo|Group 1 - Five (5) subjects will be treated with a single administration of 1 cc of 1% lidocaine with 1 cc of 2% Ropivicaine and 0.5 cc of betamethasone soluspan (celestone) solution delivered via intra-facet injection. These subjects will be part of the control (Standard care) group.
89458518|NCT03487731|Experimental|Group 2 - Allogeneic Human Mesenchymal Stem Cells (hMSCs)|Group 2 - Five (5) subjects will be treated with a single administration of 20 million allogeneic mesenchymal stem cell delivered intra-facet via 6 injections of 1.5 mL per injection, total of 9 to 12ml. These subjects will be part of the experimental group.
89458519|NCT03487731|Experimental|Group A - Allogeneic Human Mesenchymal Stem Cells (hMSCs)|Group A will consist of 15 subjects that will receive 20 million Allogeneic hMSCs delivered via lumbar level injection based on pain originator.
89458520|NCT03487731|Placebo Comparator|Group B - Placebo|Group B will consist of 15 subjects who will receive 2% Ropivicaine and 0.5 cc of betamethasone soluspan (celestone) solution via lumbar level injection based on pain originator.
89458521|NCT05423249|Experimental|Treatment Group|The treatment group will receive oral ferrous sulfate 325mg (containing 65 mg of elemental iron) once daily, an oral prenatal vitamin once daily, oral ascorbic acid 500mg once daily, and oral docusate sodium 100mg twice daily as needed.
89458522|NCT05423249|Placebo Comparator|Placebo Group|The placebo group will receive a placebo bill, the same oral prenatal vitamin, and oral docusate sodium 100mg twice daily as needed.
89458523|NCT04334577|Experimental|Attenuated Zoster Vaccine, Live|One shot of the vaccine (with live viruses titer >=4.3 LgPFU per dose)
88941199|NCT01857609|Experimental|Metformin only|metformin 750mg(D-1), metformin 500mg (D1)
88941200|NCT01857609|Experimental|Metformin and Pantoprazole|pantoprazole 40mg(D-2)/ metformin 750mg + pantoprazole 40mg(D-1)/metformin 500mg + pantoprazole 40mg(D1)
88941201|NCT01857609|Experimental|Metformin and Rabeprazole|rabeprazole 20mg(D-2)/metformin 750mg+rabeprazole 20mg(D-1)/metformin 500mg+rabeprazole 20mg(D1)
88941202|NCT01857648|Experimental|Physical activity counseling|Home visits including physical activity promotion by the trained Community Health Workers.
88941203|NCT01857648|No Intervention|Control|Control group.
88941204|NCT01857661|Other|control|hearing aid without an integrated sound generator
88941205|NCT01857661|Experimental|sound generator|hearing aid with an integrated sound generator
88941206|NCT01857687||patients with coronary artery stenosis|
88941207|NCT01857700|Experimental|Conditional economic compensation|A scratch off card will be used to randomly determine which of the compensations will be offered: compensation for transport cost, compensation for lost wages, or compensation for transport cost and lost wages
88941208|NCT01857700|Placebo Comparator|Standard of Care|
89458524|NCT04334577|Placebo Comparator|Placebo|one shot of placebo with no live virus
88941209|NCT01857726|Experimental|The TACE/TACI combination group|Transarterial chemoembolization with doxorubicin/transarterial chemoinfusion with cisplatin combination
88941210|NCT01857726|Active Comparator|The TACE-only group|Transarterial chemoembolization with doxorubicin
88941211|NCT01857752|Experimental|temozolomide|
88941212|NCT01857765|Active Comparator|Standard of Care|
88941213|NCT01857765|Experimental|Rehabilitation|
89458525|NCT02912455|Active Comparator|Study Drug (canagliflozin)|Subjects randomized to study drug will be assigned a six month course starting on canagliflozin 100 mg for two weeks titrated up to 300 mg daily (n= 24).
89458526|NCT02912455|Placebo Comparator|Placebo|Subjects randomized to placebo will be assigned a six month course of one placebo pill daily (n =12).
89458527|NCT03492645|Active Comparator|Office Group|
89458528|NCT03492645|Experimental|Telephone Group|
89458529|NCT03492567|Experimental|Blood monocyte precursors/osteoclasts|Blood test
89458530|NCT03666169||Whole Cohort|UK Citizens, aged 18-65 years
89458531|NCT03702491|Experimental|Apatinib with SOX(Tegafur,Oxaliplatin)|Patients 3-4 weeks after surgery, the SOX regimen was given palliative adjuvant chemotherapy for 6-8 cycles, then followed by the second cycle combined with the treatment of apatinib mesylate and the monotherapy maintenance of apatinib mesylate
89458532|NCT03702491|Active Comparator|SOX( Tegafur,Oxaliplatin)|3-4 weeks after operation, 6-8 cycles of adjuvant chemotherapy with simple SOX protocol were given.
89458533|NCT03663751|Experimental|Treatment|The peripheral and bone marrow T cell and mono nucleated cell chimerism will be closely followed-up. In case of decreasing donor chimerism, patients will receive low-dose decitabine with 5mg/m2 daily for 5 days every 6-8 weeks until the chimerism recovered to full donor type (>98%).
89458534|NCT04054687|Experimental|TXA|Research participants in the experimental group will receive one dose of 100mg/mL TXA soaked in a cotton pledget in the bleeding nare for a total of 15 minutes.
88941214|NCT01857778||Lactating Women|
88941215|NCT01857791|Experimental|multidisciplinary, behavior modification|
89458535|NCT04054687|Placebo Comparator|Saline|Research participants in the placebo group will receive one dose of normal saline (0.9%) soaked in a cotton pledget in the bleeding nare for a total of 15 minutes.
89458536|NCT04524507|Experimental|High-Titer (CCP1)|Within 8 days of COVID symptom onset and no more than 48 hours following hospitalization, participants will be randomized to and receive high-titer ABO-compatible convalescent COVID-19 plasma (CCP1) within 24 hours following random assignment.
89458537|NCT04524507|Active Comparator|Standard-Titer (CCP2)|Within 8 days of COVID symptom onset and no more than 48 hours following hospitalization, participants will be randomized to and receive standard-titer ABO-compatible convalescent COVID-19 plasma (CCP2) within 24 hours following random assignment.
89458538|NCT02999191|Experimental|BI 1467335 (Treatment A)|Tablet under fasted conditions
89458539|NCT02999191|Experimental|BI 1467335 (Treatment B)|Oral solution under fasted conditions
89458540|NCT02999191|Experimental|BI 1467335 (Treatment C)|Tablet under fed conditions
89458541|NCT03837639|Experimental|Arm crank ergometer|Arm-crank exercise group will be performed twice a week for 12 weeks. In the first weeks of training, each session will consist of 15 bouts, two active minutes and two minutes of passive interval, consisting of 60 minutes of session (30 minutes of active exercise). After the first three weeks of training, the exercise time will progressively increase by one minute every 3 weeks and the recovery period will be decreased, completing, at the end, a maximum volume of 10 bouts of five minutes of exercise and one minute of passive interval. The intensity of the exercise will be determined by the load equivalent to the range of 13 - 15 of The Borg Rating of Perceived Exertion, considered as somewhat hard to hard.
89458542|NCT03837639|Experimental|Treadmill ergometer|Walking exercise group will be performed twice a week for 12 weeks. In the first weeks of training, each session will consist of 15 bouts, two active minutes and two minutes of passive interval, consisting of 60 minutes of session (30 minutes of active exercise). After the first three weeks of training, the exercise time will progressively increase by one minute every 3 weeks and the recovery period will be decreased, completing, at the end, a maximum volume of 10 bouts of five minutes of exercise and one minute of passive interval. The intensity of the exercise will be determined by the load equivalent to the range of 13 - 15 of The Borg Rating of Perceived Exertion, considered as somewhat hard to hard.
89458543|NCT03837639|Other|Control group|Patients randomized to control group will attend to meetings with the researcher team twice a week during the 12 weeks. At these meetings, patients will perform manual tasks, with or without the use of artistic materials, cultural programs, cooking classes and home care, without any exercise component. This CG practice will be performed in order to minimize the effects of the patient's bi- weekly commitment and displacement to the training site, to minimize the influence of the patient- researcher contact and also minimize the convivial effect among the patients themselves, which will occur in the other two groups.
88941216|NCT01857804|Experimental|antibiotics and local antiseptics|systemic antibiotics (2 x 750mg amoxicillin/day) + implant surface decontamination with chlorhexidine gluconate 0,2%
88941217|NCT01857804|Experimental|antibiotics without local antiseptics|systemic antibiotics (2 x 750mg amoxicillin/day) + implant surface decontamination with saline
88941218|NCT01857804|Experimental|local antiseptics no antibiotics|no systemic antibiotics + implant surface decontamination with chlorhexidine gluconate 0,2%
88941219|NCT01857804|Placebo Comparator|no antibiotics and no local antiseptics|no systemic antibiotics + implant surface decontamination with saline
88941220|NCT01857817|Experimental|VT-122 with physician's choice therapy|Participants will receive oral doses of 66 mg propranolol and 680 mg etodolac daily. Propranolol will be administered 44 mg with breakfast and 22 mg in the mid-afternoon (3PM). Etodolac will be administered 340 mg with breakfast and 340 mg with dinner.
88941221|NCT01857817|Placebo Comparator|Placebo with physician's choice therapy|Participants will receive physician's choice therapy as the standard of care as well as the placebo capsules that are of the same weight as propranolol and etodolac.
88941222|NCT01857830|Experimental|Meditation Retreat Group|Participants in this group will participate in a 6 day meditation retreat at the La Costa Resort and Spa in Carlsbad, CA. They will be self-selected to participate in the retreat or are novice meditators randomized into this retreat.
88941223|NCT01857830|Active Comparator|Relaxation/Control Group|Participants in this group will stay at La Costa Resort and spa for a 6 day period and will participate in the Active Comparator Relaxation Group activities (i.e. series of lectures on longevity and health, shared meals, and other leisure activities).
88941224|NCT01857843|Experimental|ZES group|
88941225|NCT01857843|Active Comparator|EES group|
88941226|NCT01857843|Experimental|Vytorin group|
88941227|NCT01857843|Active Comparator|Mevalotin group|
89458544|NCT04050397|Experimental|Supervised exercise arm|Informational initiation lecture and supervised exercise twice a week for 12 weeks followed by 12 weeks of non-supervised exercise.
89458545|NCT04050397|Active Comparator|Non-supervised exercise arm|Informational initiation lecture and only non-supervised exercise
89458546|NCT03492411|Experimental|eHealth Intervention|This group will receive information about an eHealth breastfeeding co-parenting resource. They will have a short demonstration of the site and will receive weekly emails for 6 weeks reminding them about the resource and their participation in the study.
89458547|NCT03492411|No Intervention|Usual Care|This group will not receive any intervention. They will receive emails for 6 weeks reminding them that they are in the study.
89458548|NCT02531698|Experimental|Bivalent rLP2086|Bivalent rLP2086 (containing 60 μg each of a purified subfamily A and subfamily B rLP2086 protein, adsorbed to aluminum in a sterile buffered isotonic suspension) in a 0.5-mL dose for injection.
89458549|NCT02531698|Other|Licensed pediatric hepatitis A vaccine|
89458550|NCT04308837|Experimental|Patients With Local Regional Advanced Gastric Cancer|Patients with local regional advanced gastric cancer after at least 4 weeks post diagnostic laparoscopy and HIPEC, will receive all of the treatments described in the study protocol.
89458551|NCT02998021|Experimental|Resistance Training - Vibrating Dumbbell|Study participants who are randomized into the vibration exercise group will complete an in-home exercise program using a vibrating dumbbell.
89458552|NCT02998021|Active Comparator|Resistance Training - Standard Dumbbell|Study participants who are randomized into the control exercise group will complete an in-home exercise program using standard dumbbells.
89458553|NCT03487497||Patients|Patients who underwent lateral column lengthening osteotomy
89458554|NCT03487497||Healthy subjects|Healthy subjects without intervention
89458555|NCT03664375|Experimental|Experimental Group|The experimental group received botulinum toxin type A. After one week of Botox administration, a specially made task specific training program was started for these patients. It was provided for a duration of one hour and for three times per week for a total of 12 weeks by a trained physiotherapist.
89458556|NCT03664375|Placebo Comparator|Control Group|The control group received only task specific training program with the same protocol as for the experimental group; for a duration of one hour and for three times per week up to a total of 12 weeks by a trained physiotherapist
89458557|NCT03487419||patients develop atrial fibrillation|patients post coronary artery bypass grafting who develop atrial fibrillation post operative
89458558|NCT03487419||patients who not develop atrial fibrillation|patients post coronary artery bypass grafting who don't develop atrial fibrillation post operative
89458559|NCT03731247|Experimental|OCTAV Patient|The patients who will have a biopsy of skin suspected to be a melanoma, basal cell carcinoma or squamous cell carcinoma will have a skin imaging with a new Microscopy Optical Coherence (OCTAV)
88941228|NCT01857856|No Intervention|No treatment|no medical treatment
88941229|NCT01857856|Active Comparator|Eplerenone|Eplerenone (Inspra, 50 mg for 3 years once daily) oral, film-coated tablet 50 mg for 3 years once daily
89458560|NCT03731247|Experimental|OCTAV Control group|Control group (patients without skin cancer) will have a skin imaging with a new Microscopy Optical Coherence (OCTAV)
89458561|NCT03434301|Active Comparator|Mesh with absorbable tack fixation|Mesh with absorbable tack (ReliaTack™) fixation
89458562|NCT03434301|Active Comparator|Mesh with non-absorbable fixation|Mesh with non-absorbable (Protack™) fixation
89458563|NCT03492333|Experimental|Gluten free diet|Single arm
89458564|NCT00403793|Active Comparator|Arm 1|etonogestrel with testosterone undecanoate
89458565|NCT00403793|Placebo Comparator|Arm 2|Placebo
89458566|NCT03419871||monitoring sleep effects on toddlers|Monitoring the sleep characteristics of toddlers living in economically stressed communities.
89458567|NCT03702335|Experimental|Dietary Counselling|Each subject will receive a comprehensive dietary counselling for the first 12-weeks of the study, which will be followed by another 12-weeks without dietary counselling.
89458568|NCT03702335|No Intervention|No Dietary Counselling|Subjects in the control group will be followed for 24-weeks without any dietary counselling.
89458569|NCT03489213|Active Comparator|Arm I (DGA/AICR)|Patients receive DGA/AICR-based dietary intervention for 6 months consisting of 12 education sessions (60 minutes each) every other week. Lectures will take place in an urban garden where fruit, vegetable, and herb harvesting 1-2 times per week is encouraged. All participants will be given a FitBit and regular physical activity will be encouraged. Finally, remote health coaching is offered to all study subjects for the duration of the intervention (12 weeks).
89458570|NCT03489213|Experimental|Arm II (DGA/AICR plus Beef)|Patients receive the same intervention as in Arm I with the addition of 18 ounces of lean beef provided by the study to each subject. Subjects will be encouraged to consume the lean beef and lectures will incorporate healthy beef consumption into each lesson and cooking demonstration.
89458571|NCT04441125||case group|The mothers in the case group will receive oxytocin induction before and after delivery(n:44).
89458572|NCT04441125||control group|The mothers in the control group will not receive any oxytocin induction before delivery, and will receive oxytocin induction in the end of delivery(n:44)
89458573|NCT04387773|Experimental|GOCOVRI Treatment|All participants will have gait, balance, dyskinesia assessed before and after receiving GOCOVRI (274 mg/day).
89458574|NCT03034577|Active Comparator|ModNMB|"Moderate Neuromuscular block: participants will receive moderate neuromuscular blockade with rocuronium aiming for TOF 0-2 twitches, with neostigmine reversal when the TOF at least 3 twitches. The depth of neuromuscular block may be reduced after completion of the majority of surgical excision to TOF 3 or more~Neostigmine"
89458575|NCT03034577|Active Comparator|DeepNB|Deep Neuromuscular block: participants will receive DNB aiming for a post tetanic count of 1-2, which will be maintained until removal of the laparoscopic ports, with reversal using sugammadex
89458576|NCT03487341|Active Comparator|Cord drainage|
89458577|NCT03487341|Active Comparator|Cord clamping|
89458578|NCT05377060|Experimental|Plasma p-tau Disclosure|To receive risk estimate based on plasma p-tau results in addition to age, sex, and cognitive screening score.
89458579|NCT05377060|Active Comparator|Standard Disclosure|To receive risk estimate based on age, sex, and cognitive screening score.
89458580|NCT04384497|Experimental|Convalescent plasma treatment|Participants will receive 200 ml convalescent plasma daily until SARS-CoV-2 is no longer detectable in the blood up to a maximum of 7 CP infusions. CP will be given as a slow infusion over 1 hour. Patients will be monitored for adverse events, especially allergic reactions.
89458581|NCT03705455|Active Comparator|ISAP SMS|ISAP SMS will be sent to enrolled caregivers
89458582|NCT03705455|No Intervention|No ISAP SMS|No ISAP SMS will be sent to enrolled caregivers
89458583|NCT03092427|Experimental|Probiotic VSL#3|
89458584|NCT03092427|Placebo Comparator|Placebo|
88941230|NCT01857895|Experimental|Exenatide infusion in Part A|Subjects in Part A will receive exenatide as a subcutaneous infusion at a constant rate for 24 hours.
89458585|NCT04364997|Experimental|Desvenlafaxine Succinate Sustained-Release|
89458586|NCT04364997|Active Comparator|Duloxetine Hydrochloride Enteric-coated|
89458587|NCT05376982|Experimental|Neurodevelopmental Treatment|Using Neurodevelopmental Treatment Method
89458588|NCT05376982|Experimental|Body weight supported treadmill training along with conventional therapy|Using Body weight supported treadmill training along with conventional therapy Method
89458589|NCT04820075|Other|Process about performance of the preoperative shower|Implementation of a process aimed at improving the preoperative shower in programmed surgery
89458590|NCT03034629|Experimental|Short-term aerobic exercise|One bout of moderate intensity exercise (75% of maximal predicated heart rate).
89458591|NCT03705377||Head Start children and families|children (2,400), parents (2,400), classrooms/teachers (720), program directors (180), center directors (360), family service staff (168)
89458592|NCT01717924|Active Comparator|peri-operative chemotherapy|Neoadjuvant chemotherapy with 3 cycles of Epirubicin/Cisplatin/5 fluoro-uracil (oral or intra-veinous) Surgery within 3 and 6 weeks after the end of neoadjuvant chemotherapy Adjuvant chemotherapy with 3 cycles of the same chemotherapy within 6 and 12 weeks after surgery
89458593|NCT01717924|Experimental|surgery first with adjuvant chemotherapy|Surgery first Adjuvant chemotherapy with 3 cycles of Epirubicin/Cisplatin/5FU within 6 and 12 weeks after surgery No neoadjuvant chemotherapy
89458594|NCT04289493|Experimental|Group 1: first to receive therapy|27 patients that will receive study specific speech therapy in the first 3 months since study inclusion. From months 3-6 they will be group 2 controls.
88941231|NCT01857895|Experimental|Exenatide infusion in Part B|Subjects in Part B will receive exenatide with daily increases in the infusion rate.
88941232|NCT01857908||Abiraterone acetate|All patients will be receiving abiraterone acetate as per standard of care
88941233|NCT01857921|Active Comparator|Pravastatin group|
88941234|NCT01857921|Experimental|Combination of Atorvastatin and trimetazidine group|
88941235|NCT01857947|No Intervention|AECOPD Mr proADM|Patients involved in this study will have a simple blood sample collected for Mr proADM assessment at the end of study
88941236|NCT01857960||Adolescents|Acne survey among Mexican adolescents
88941237|NCT01857999|Experimental|Losartan|Losartan 50 mg bid orally
89458595|NCT04289493|Experimental|Group 2: second to receive therapy|27 patients that will receive study specific speech therapy during months 3-6 since study inclusion. During the first 3 months of the study period, they will be group 1 controls.
89458596|NCT03701867|Experimental|Metabolic Flexibility Tests Group|
89458597|NCT03750279|Active Comparator|Exercise therapy + LLLT|"Exercise therapy 3 times per week for 8 weeks from baseline.~LLLT applied to the knee 3 times per week for 3 weeks from baseline."
89458598|NCT03750279|Placebo Comparator|Exercise therapy + sham LLLT|"Exercise therapy 3 times per week for 8 weeks from baseline.~Sham LLLT applied to the knee 3 times per week for 3 weeks from baseline."
88941238|NCT01857999|Placebo Comparator|Placebo|Placebo 1 pill bid orally
88941239|NCT01858025|Experimental|Pencil Beam Scanning Radiation|Pencil Beam Radiation daily, Monday-Friday, for 5-6 weeks Mitomycin-C via IV on Days 1 and 29 5-Fluorouracil via infusion pump over 4 days, starting Day 1 and 29 of chemotherapy
89016797|NCT01323374|Placebo Comparator|Placebo TID|
89458599|NCT03701789|Other|Patients with Rheumatoid Arthritis|In-label treatment with Baricitinib
89458600|NCT05417386|Experimental|Safety Run-In|Following a 3 + 3 dose escalation design 6-18 participants will receive NIS793 and FOLFIRINOX on day 1 of each 14 day cycle for 3+ cycles until recommended phase 2 dose is determined.
89458601|NCT05417386|Experimental|FOLFIRINOX|"Participants will be randomly assigned to receive:~FOLFIRINOX on day 1 of each 14 day cycle for cycles 1-8~Cycles 9+: Chemoradiation (CRT) and surgery"
89458602|NCT05417386|Experimental|FOLFIRINOX + NIS793|"Participants will be randomly assigned to receive:~FOLFIRINOX FOLFIRINOX + NIS793 on day 1 of each 14 day cycle for cycles 1-8~Cycles 9+: Chemoradiation (CRT) with NIS793, Surgery, NIS793"
89458603|NCT03487263|Experimental|IC14 dose level 1|For the initial 3 patients: intravenous IC14 at a dosage of 2 mg/kg on Study Day 1, then 1 mg/kg once daily on Study Days 3-5 for 4 total doses
89458604|NCT03487263|Experimental|IC14 dose level 2|For the subsequent 7 patients: intravenous IC14 at a dosage of 4 mg/kg/day on Day 1, followed by IC14 2 mg/kg/day on Days 2-4
89458605|NCT03702101||Orofacial pain group|Patients in this group will receive auricular point detection which is accomplished by the novel auricular point detector device. There is no addition to the patient's routine care.
89458606|NCT03702101||Control group|This group includes healthy subject, for whom no treatment will be performed. Only auricular point detection by the auricular point detector will be conducted.
89458607|NCT04005729|Experimental|Cangrelor + Ticagrelor|Bolus of cangrelor (30 mcg/kg) and immediately afterwards a continuous intravenous infusion of 4 mcg/kg/min at the start of the primary percutaneous coronary intervention. Crushed and dissolved ticagrelor tablets (180 mg) will be given via inserted enteral tube.
89458608|NCT04005729|No Intervention|Ticagrelor|Crushed and dissolved ticagrelor tablets (180 mg) will be given via enteral tube (standard care).
89458609|NCT03486015|Experimental|30% glucose|This group will be given 2 ml of 30% glucose in the mouth before the physical examination of the infant.
89458610|NCT03486015|Placebo Comparator|Sterile water|This group will be given 2 ml of sterile water in the mouth before the physical examination of the infant.
89458611|NCT04599023||MS patients including CIS|Patients with a diagnosis of MS, including Clinically Isolated Syndrome (CIS), who have the ability to understand the audio and visual instructions for the MSPT modules and whose visual function that does not preclude an ability to see the screen of the MSPT tool.
89458612|NCT01659736|Experimental|TMS Therapy|TMS treatment
89458613|NCT01659736|Sham Comparator|TMS-Sham|This is a sham TMS condition
89458614|NCT03487107|Experimental|SOF 400 mg+DAG181 100 mg|Patients with genotype 1 HCV infection without cirrhosis will receive SOF 400 mg+DAG181 100 mg for 12 weeks.
89458615|NCT03705299|Experimental|NeuMeDex NICVP (Non-Invasive CVP) vs Standard CVP|Three pressure readings recorded for both NeuMeDex NICVP and central line pressure catheter over a 10 minute period.
89016798|NCT01233297|Active Comparator|Antibiotics|Azithromycin (10 mg/kg once a day for 3 days)
89458616|NCT03705221|Experimental|Group programme|Healthy Parent Carers group programme: A group-based peer led manualised programme called Healthy Parent Carers. The programme content is organised into 12 modules, which can be delivered over six longer (4-hour) sessions or 12 shorter (2-hour) sessions.
89458617|NCT03705221|Active Comparator|Online resources|Healthy Parent Carers online resources: Online resources from the Healthy Parent Carers programme, including materials for 12 modules and related videos and audio files to illustrate the content.
89458618|NCT03485937|Experimental|Pre-Operative Videos + verbal/written instructions|This video contains the same instructions that the patient receives when they arrive at the clinic, as well as a video walk through of the clinic/patient room. Videos will be created by the study team to ensure that the content coincides with what is delivered in the standard-of-care verbal and written instructions.
89458619|NCT03485937|Active Comparator|verbal/written instructions|This arm will receive the standard-of-care verbal/written instructions and the pre-operative video explanation. These instructions contain the same content as in the pre-operative videos
89458620|NCT05591716|Active Comparator|Unilateral flexible ureteroscopy|Transurethral removal of kidney stones
89458621|NCT05591716|Active Comparator|Bilateral flexible ureteroscopy|Transurethral removal of kidney stones
89458622|NCT03485859|Experimental|Experimental group|In subjects allocated to the abdominal binder group, the abdomen binder with a standard height of 22 cm (Sejung Korea, Seoul, Republic of Korea) was applied before leaving the operating room. The binder was placed on the abdomen across the laparoscopic incision, with the upper border not higher than the lower margin of the rib cage, ensuring minimal restriction of lateral costal expansion and diaphragmatic excursion. Subjects were carefully instructed to use the abdominal binder during at least the first 2 consecutive days and night, and to reposition the abdominal binder correctly when needed.
89458623|NCT03485859|Placebo Comparator|Control group|In subjects allocated in the control group, subjects were not given any opportunity to ware an abdominal binder.
89458624|NCT03705143|Placebo Comparator|Treatment as Usual|Participants will receive no additional intervention besides the services they are currently receiving at the MMT clinic.
89458625|NCT03705143|Experimental|Chinese translated LETS ACT|In addition to services participants are currently receiving at the MMT clinic, individuals will attend six group-based one-hour behavioral activation treatment sessions.
89458626|NCT02997163|Experimental|Group A (control, normal renal function)|
89458627|NCT02997163|Experimental|Group B (mild renal impairment)|
89458628|NCT02997163|Experimental|Group C (moderate renal impairment)|
89458629|NCT02997163|Experimental|Group D (severe renal impairment)|
89458630|NCT03705065|Experimental|Treatment Group 1|Bupivacaine HCI by instillation into each pectoral pocket.
89458631|NCT03705065|Experimental|Treatment Group 2|Bupivacaine HCI by injection into each pectoral pocket.
89458632|NCT03702023|Active Comparator|Intervention Group|Patients in the intervention group with receive the study medication 1000mg acetaminophen orally one time prior to their scheduled electrophysiology procedure.
89458633|NCT03702023|Placebo Comparator|Placebo Oral Tablet|Patients in the control group will receive a placebo orally one time prior to their scheduled electrophysiology procedure.
89458634|NCT05391880|Experimental|Drug:BEBT-503|BEBT-503
89458635|NCT05391880|Placebo Comparator|Drug: Placebo|Placebo
89458636|NCT04649255|Experimental|Lava LES|
89458637|NCT04532827|Experimental|Case formulation with web-program|"The intervention will start with two video meetings with a psychologist to build up and present an individual case formulation, based on behavioural analysis, and to build up a shared decision of individual goals for the web program. The intervention continues with a web program consisting of ten manualized web-based modules, each at one-week intervals based on relational frame theory (RFT) and acceptance and commitment therapy (ACT). The pilot programme included six two-weeks modules and it was in use until 5/2021. The programme is in Finnish.~Both participants in the intervention arm and in the treatment as the usual arm will receive usual care, meaning that TAU will be enhanced with the study intervention in the intervention arm. In addition to TAU, all participants will be given self-help and educational leaflet based on scientific knowledge related to their condition."
89458638|NCT04532827|No Intervention|Treatment as usual|"Treatment as usual includes all the routine care that individual receives when he or she is presenting his or her symptoms at the primary or the occupational health care unit (corresponds primary care level treatment) or other unit that recommends the study for the participant. In practice, TAU may vary between the study participants based on their individual needs e.g. treatments for co-morbid somatic diseases or psychiatric disorders that this study will not interfere.~Both participants in the intervention arm and in the treatment as usual arm will receive usual care, meaning that TAU will be enhanced with the study intervention in the intervention arm. In addition to TAU all participants will be given self-help and educational leaflet based on scientific knowledge related to their condition."
89458639|NCT03698513|Experimental|BMS-986177 + Aspirin + Clopidogrel (Part 1)|BMS-986177 200 mg capsule twice daily (days 1-5) + Aspirin 325 mg tablet once daily (days 1-5) + Clopidogrel 300 mg tablet once daily (day 1) then 75 mg tablet once daily (days 2-5)
89458640|NCT03698513|Experimental|BMS-986177 (Part 1)|BMS-986177 200 mg capsule twice daily (days 1-5)
89458641|NCT03698513|Placebo Comparator|BMS-986177 placebo + Aspirin + Clopidogrel (Part 1)|BMS-986177 placebo match capsule twice daily (days 1-5) + Aspirin 325 mg tablet once daily (days 1-5) + Clopidogrel 300 mg once daily (day 1) then 75 mg tablet once daily (days 2-5)
89458642|NCT03698513|Experimental|BMS-986177 (Part 2)|BMS-986177 200 mg capsule twice daily (days 1-5)
89458643|NCT03698513|Placebo Comparator|BMS-986177 placebo + Clopidogrel (Part 2)|BMS-986177 placebo match capsule twice daily (days 1-5) + Clopidogrel 300 mg tablet once daily (day 1) then 75 mg tablet once daily (days 2-5)
89458644|NCT03698513|Experimental|BMS-986177 + Clopidogrel (Part 2)|BMS-986177 200 mg capsule twice daily (days 1-5) + Clopidogrel 300 mg tablet once daily (day 1) then 75 mg tablet once daily (days 2-5)
89458645|NCT03698513|Experimental|BMS-986177 (Part 3)|BMS-986177 200 mg capsule twice daily (days 1-5)
89458646|NCT03698513|Placebo Comparator|BMS-986177 placebo + Aspirin (Part 3)|BMS-986177 placebo match capsule twice daily (days 1-5) + Aspirin 325 mg tablet once daily (days 1-5)
89458647|NCT03698513|Experimental|BMS-986177 + Aspirin (Part 3)|BMS-986177 200 mg capsule twice daily (days 1-5) + Aspirin 325 mg tablet once daily (days 1-5)
89458648|NCT05416294|Experimental|Active Device|Participants in this arm will receive an active Primary Relief device placed following the total knee replacement surgery.
89458649|NCT05416294|Sham Comparator|Placebo Device|Participants in this arm will receive an inactive (sham) Primary Relief device placed following the total knee replacement surgery.
89458650|NCT03698435||Prophylaxis|Patients who receive (val)ganciclovir for prophylaxis of cytomegalovirus
89458651|NCT03698435||Treatment|Patients who receive (val)ganciclovir for treatment of cytomegalovirus
89458652|NCT03698357|Experimental|Interactive video balance-based exercise|Fifteen participants in group A will undergo 30 minutes a day and 3 days a week interactive video balance-based exercise intervention for four weeks.
89458653|NCT03698357|Active Comparator|Conventional physiotherapy|Another 15 participants allocated to the group B will receive 30 minutes a day and 3 days a week conventional rehabilitation for four weeks.
89458654|NCT05389072|Experimental|Control Lens|
89458655|NCT03701633||Prior to breastfeeding - cross section|Measurements of the UtA doppler postpartum ultrasound will be carried out twice for each eligible woman on the second day postpartum. The first measurement will take place just prior to a planned breastfeeding. The second measurement will be followed immediately (within 10 min) after the breastfeeding session.
89458656|NCT03701633||After breastfeeding - cross section|Measurements of the UtA doppler postpartum ultrasound will be carried out twice for each eligible woman on the second day postpartum. The first measurement will take place just prior to a planned breastfeeding. The second measurement will be followed immediately (within 10 min) after the breastfeeding session.
89458657|NCT04641065|Experimental|Music Intervention Group|The music intervention group will be listened to Traditional Turkish Military music by the researchers for the duration of 15 minutes before the procedure as well as the standard care.
89458658|NCT04641065|No Intervention|No Intervention Group|The control group patients will receive standard care only
89458659|NCT03701945|Experimental|Pulmonary rehabilitation|Pulmonary rehabilitation will be provided to every patient that accepts the intervention and presents an acute exacerbation
89458660|NCT03698045|Experimental|PRO-143 Ophthalmic Solution|PRO-143 Ophthalmic Solution applied four times per day (c/6 hours) during 10 days.
89458661|NCT03701477|Experimental|Trans-diagnostic approach|Trans-diagnostic cognitive-behavioral therapy In this arm, patients will participate in 10 sessions of therapy. During each session, specific topics will be discussed and participants will need to complete their homework for the next session. Each session lasts for 120 minutes. Sessions will be held in groups of 5-10 subjects weekly, except the last session that will be held after a two-week interval.
89458662|NCT03701477|Sham Comparator|Control|General relaxation/stress management therapeutic session In this arm, patients will attend a 3-hour meeting in which basic techniques of relaxation and overcoming stress and anxiety will be discussed.
88941240|NCT01858038|No Intervention|Control|The scar will be randomized and demarcated as the following: (1) treatment site and (2) control site (no treatment, no intervention) The treatment condition assigned for each site will be kept the same for all following treatment sessions
88941241|NCT01858038|Experimental|Intervention Fractional Laser treatment|Intervention: An FDA-approved Fractional 10,600 nm laser source will be used for laser exposures performed 2 months prior to biopsies of treated sites
88941242|NCT01858051|Active Comparator|Cholecalciferol Bolus Dose|70 patients will receive a bolus pre-operative oral dose of 150,000 IU cholecalciferol 3-7 days before surgery
88941243|NCT01858051|Active Comparator|Cholecalciferol Divided Dose|70 patients will receive an oral 100,000 IU cholecalciferol dose 3-7 days before surgery and an additional oral 50,000 IU cholecalciferol dose on post-operative day 1
88941244|NCT01858051|Placebo Comparator|Sugar Pill|35 patients will receive a placebo pill orally 3-7 days before surgery
88941245|NCT01858064|Experimental|OROS-MPH|OROS-MPH is administered in capsule form daily, beginning at 36 mg/day and titrated on a weekly basis for 3 weeks in increments of 18-36 mg/day to a maximum daily dose of 90mg/day.
88941246|NCT01858077|Active Comparator|ABSORB BVS™|Abbott Vascular ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold System
88941247|NCT01858077|Active Comparator|XIENCE™|XIENCE PRIME everolimus eluting coronary stent system and the XIENCE Xpedition everolimus eluting coronary stent system
89458663|NCT03697889|Experimental|Treatment Sequence AB|Participants will receive Treatment A (test product Naproxen sodium tablet, 1 x 275 mg) at dosing period 1 followed by Treatment B (reference product Nalgesin, 1 x 275 mg) dosing period 2. There is a wash-out period of 7 days between the two dosing periods.
89458664|NCT03697889|Experimental|Treatment Sequence BA|Participants will receive Treatment B (reference product Nalgesin, 1 x 275 mg) at dosing period 1 followed by Treatment A (test product Naproxen sodium tablet, 1 x 275 mg) at dosing period 2. There is a wash-out period of 7 days between the two dosing periods.
89458665|NCT03692819|Active Comparator|placebo|Periodontal debridement treatment will be performed in a single session after the therapy will be administered the Placebo Oral Tablet twice a day for 21 days.
89458666|NCT03692819|Experimental|Metronidazole and Amoxicillin|Periodontal debridement treatment in a single session Metronidazole 400mg + Amoxicillin 500mg every 8 hours for 7 days.
89458667|NCT03692819|Experimental|Lactobacillus reuteri|Periodontal debridement treatment in a single session Lactobacillus reuteri Oral Drops twice a day for 21 days.
89458668|NCT00458536|Experimental|Cohort 1|Patients treated with DC/RCC vaccine to evaluate for treatment-limiting toxicity
88941248|NCT01858090|Placebo Comparator|Control Group|Control Group, Group C: Spinal anesthesia with levobupivacaine %0.5 (2.2±0.2 ml)+ Serum saline
88941249|NCT01858090|Active Comparator|Group Fentanyl|Group Fentanyl, Group F: Spinal anesthesia with levobupivacaine %0.5 (2.2±0.2 ml+fentanyl (10 µg)
89458669|NCT00458536|Experimental|Cohort 2|Patients treated with DC/RCC vaccine to evaluate response
89458670|NCT03697733|Experimental|Oral Etoricoxib group|Subjects will receive oral Etoricoxib120 mg 30 minutes before fractional curettage then added intravenous Propofol 2 mg/kg when start the procedure
88941250|NCT01858090|Active Comparator|Group sufentanil|Group sufentanil, Group S: spinal anesthesia with levobupivacaine %0.5 (2.2±0.2 ml)+ sufentanil (2.5 µg)
88941251|NCT01858116|Experimental|[68Ga]ABY-025|
88941252|NCT01858129|Experimental|Inhaled steroids (Budicort)|Inhaled Budicort
89458671|NCT03697733|Placebo Comparator|Intravenous Fentanyl group|Subjects will receive oral placebo [folic acid] 1 tab 30 minutes before the procedure then added intravenous Propofol 2 mg/kg and Intravenous Fentanyl 1 microgram/kg when start the procedure
89458672|NCT05373394||Case|patients with a history of surgical removal of diffuse low grade glioma located in the supplementary motor area
89458673|NCT05373394||Control|patients with a history of surgical removal of diffuse low-grade glioma located in another brain area
89458674|NCT03697655|Experimental|PREDATOR-BR Cohort A|n=46, Daratumumab 20 MG/ML [Darzalex], 16 mg/kg body weight administered as an intravenous infusion
89458675|NCT03697655|No Intervention|PREDATOR-BR Cohort B|n=46, Control Group, Observation (no treatment)
89458676|NCT03697655|Experimental|PREDATOR-MRD Cohort A|n=59, Daratumumab 20 MG/ML [Darzalex], 16 mg/kg body weight administered as an intravenous infusion
89458677|NCT03697655|No Intervention|PREDATOR-MRD Cohort B|n=59, Control Group, Observation (no treatment)
89458678|NCT05373160||Healthy young group|Individuals who are 18-35 years, did not diagnosed with musculoskeletal disorder, and volunteers
89458679|NCT02526550|Experimental|Imojev|Live attenuated chimeric Japanese Encephalitis vaccine, 0.5 mL dose containing ≥ 4.0 log10 plaque forming units (PFU) administered via the subcutaneous route into the left thigh and Simultaneous administration of Inactivated Hepatitis A vaccine, 0.5 mL liquid dose for intramuscular injection administered via the intramuscular route into the right thigh
89458680|NCT05565352||Major Depressive Disorder|Patients must have a Diagnostic and Statistical Manual 5 (DSM-5) diagnosis of Major Depressive Disorder (MDD), as determined by a psychiatrist.
89458681|NCT05565352||Obsessive Compulsive Disorder|Patients must have a Diagnostic and Statistical Manual 5 (DSM-5) diagnosis of Obsessive Compulsive Disorder (OCD) as determined by a psychiatrist.
89458682|NCT05565352||Post traumatic Stress Disorder|Patients must have a Diagnostic and Statistical Manual 5 (DSM-5) diagnosis of Post-Traumatic Stress Disorder (PTSD) as determined by a psychiatrist.
89458683|NCT05565352||Somatoform Disorder|Patients must have a Diagnostic and Statistical Manual 5 (DSM-5) diagnosis of Somatoform Disorder as determined by a psychiatrist.
89458684|NCT05565352||Anxiety Disorder|Patients must have a Diagnostic and Statistical Manual 5 (DSM-5) diagnosis of Anxiety Disorder as determined by a psychiatrist.
89458685|NCT05565352||Dissociative Disorder|Patients must have a Diagnostic and Statistical Manual 5 (DSM-5) diagnosis of Dissociative Disorder as determined by a psychiatrist.
89458686|NCT05565352||Bipolar Disorder|Patients must have a Diagnostic and Statistical Manual 5 (DSM-5) diagnosis of Bipolar Disorder as determined by a psychiatrist.
89458687|NCT00246454||1|People with delayed sleep phase syndrome (DSPS).
89458688|NCT00246454||2|People with advanced sleep phase syndrome (ASPS).
89458689|NCT00246454||3|Control group (people with intermediate sleep patterns).
89458690|NCT04423276|Placebo Comparator|Control|
89458691|NCT04423276|Experimental|Donepezil|
89458692|NCT03701243|Experimental|mNT-BBAVF|These patients will receive a modified non-transposed brachiobasilic arteriovenous fistula (mNT-BBAVF) at elbow for hemodialysis acess.
89458693|NCT03701243|Active Comparator|RCAVF|These patients will receive a radiocephalic arteriovenous fistula (RCAVF) at wrist for hemodialysis acess.
89458694|NCT03697499|Experimental|fish oil and acute ozone exposure|The participants will take fish oil (2.2 g/day, two 1.1-g capsules daily) in divided doses. Two hour ozone exposure (200 ppb ozone) will be conducted in a chamber after four weeks of supplementation.
89458695|NCT03697499|Sham Comparator|fish oil and shame exposure|The participants will take fish oil (2.2 g/day, two 1.1-g capsules daily) in divided doses. Two hour shame exposure (0 ppb ozone) will be conducted in a chamber after four weeks of supplementation.
89458696|NCT03697499|Placebo Comparator|soy oil and acute ozone exposure|The participants will take soy oil (2.2 g/day, two 1.1-g capsules daily) in divided doses. Two hour ozone exposure (200 ppb ozone) will be conducted in a chamber after four weeks of supplementation.
89458697|NCT03697499|Other|soy oil and shame exposure|The participants will take soy oil (2.2 g/day, two 1.1-g capsules daily) in divided doses. Two hour shame exposure (0 ppb ozone) will be conducted in a chamber after four weeks of supplementation.
89458698|NCT05371210|Experimental|SAIF|After completion of baseline assessment, participants were required to interact with the SAIF system for 4 months. They were followed up at 2-month (mid-way of intervention), 4-month (end of intervention), and 7-month (3 months post-intervention).
89458699|NCT05371210|No Intervention|Control|Participants received a one-time health pamphlet after completing baseline assessment. They were followed up at 2-month, 4-month and 7-month thereafter.
89458700|NCT04423432|Active Comparator|Control|
89458701|NCT04423432|Experimental|Creatine Supplementation|
89458702|NCT04423432|Experimental|Glucoseamine/ Chondritin Sulfate Supplementation|
89458703|NCT05370586|Experimental|PENG block: Study group|Patients enrolled in the study group will receive a PENG block with 20 mL of 0,375% levobupivacaine with 4 mg of dexamethasone. The block will be performed with the patient in a supine position using an 18-gauge, 90 mm needle, inserted with an in-plane lateral to medial approach. Operators will use the original technique described by Girón-Arango L et al. The aim of this block is to inject the local anaesthetic between the psoas tendon and the iliopubic eminence. We will instruct operators to routinely use a curvilinear probe (2-6 MHz) or a linear probe (4-16 MHz) in particularly lean or cachectic patients.
89458704|NCT05370586|Other|Infrainguinal fascia iliaca block: Control group|"Patients allocated in the control group will receive an infrainguinal fascia iliaca block with 30 mL of 0,25 % levobupivacaine with 4 mg of dexamethasone, using an 18-gauge, 90 mm needle, inserted with an in-plane lateral to medial approach.~The probe (linear 4-16 MHz) is placed transversely at the inguinal crease to identify the femoral artery, femoral nerve, iliopsoas muscle and the fascia iliaca over the psoas muscle. Moving the probe laterally the sartorius muscle and the anterior inferior iliac spine (AIIS) can be identified. After skin disinfection the needle is inserted placing the tip beneath the fascia iliaca at the lateral third of a line between the AIIS and pubic tubercle. Correct needle placement is confirmed by separation of the fascia iliaca from the iliopsoas muscle upon injection, with local anaesthetic spreading towards the FN medially and the iliac crest laterally."
89458705|NCT03701087|No Intervention|normal serum vitamin D|normal serum vitamin D
89458706|NCT03701087|Experimental|low serum level of vitamin D|this arm will intake vitamin D 2800 IU daily
89458707|NCT03701087|Placebo Comparator|low serum vitamin D|this arm will intake placebo omega 3
89458708|NCT03701009|Other|Stone removal (Saline 50ml each time)|After CBD stone removal via lithotripsy, and the cholangiogram showed normal, residual CBD stones were detected by SpyGlass in the first round, if CBD not clean, sterile saline 50ml were intermittently irrigated into the CBD. After that, if bile duct clearance was not achieved, another 50ml saline will be irrigated into CBD again until the clear bile duct determined by SpyGlass.
89458709|NCT03697265|Experimental|Sepranolone (UC1010) low dose|Sepranolone (UC1010) low dose administered subcutaneously (SC) during the luteal phase
89458710|NCT03697265|Experimental|Sepranolone (UC1010) high dose|Sepranolone (UC1010) high dose administered subcutaneously (SC) during the luteal phase
89458711|NCT03697265|Placebo Comparator|Placebo|Placebo administered subcutaneously (SC) during the luteal phase
89458712|NCT05415046||Sacral ESPB|Sacral erector spinae plane block performed with 0,25% bupivacaine (1 mL/kg-max 20mL), under general anesthesia before the start of the surgery.
89458713|NCT03697187||Hereditary Angioedema|Patients with Hereditary Angioedema who are receiving treatment with Ruconest (rhC1INH).
89458714|NCT03692507|Experimental|HMB only|Taking HMB supplements three times a day
89458715|NCT03692507|Experimental|Protein and HMB|Drinking Ensure Enlive shakes
89458716|NCT03692507|Experimental|Current ERAS (High Protein)|Drinking Ensure surgery shakes + Ensure pre-surgery
89458717|NCT05610748|Experimental|Sub-Periosteal Peri-implant Augmented Layer (SPAL) technique simultaneous to implant placement|In patients assigned to the SPAL group, the management of the soft tissues will be performed according to the SPAL technique as originally described by Trombelli et al. (2018). Implant site preparation will be performed using a set of calibrated guided surgery steel burs under copious sterile saline irrigation. Implants will be placed, and a healing abutment will be positioned and screwed. The space underneath the periosteal layer will be then filled with a deproteinized bovine bone mineral (DBBM) graft. A sterile viscoelastic gel (SVG) based on polynucleotides and hyaluronic acid (REGENFAST®, Mastelli Srl, Sanremo, Italia) will be combined with the bone graft. The periosteal layer will be then secured to the oral flap by mean of 6/0 resorbable internal mattress sutures. SVG wil be placed underneath the mucosal layer and the latter will be coronally advanced and stabilized a using 6/0 resorbable internal mattress and sling sutures.
89458718|NCT05610748|Active Comparator|Soft Tissue Augmentation (STA) simultaneous to implant placement|In patients assigned to the STA group, flap management will be performed as described by Stefanini et al. (2016). Implant site preparation will be performed according to the same procedures described for the SPAL group. SVG will be placed underneath the buccal flap and the latter will be then released from tension by means of periosteal and muscular incisions, and will be coronally advanced and adapted to the healing abutment with a 6/0 resorbable sling suture. Interrupted sutures will be used to accomplish primary intention closure in the interproximal areas.
89458719|NCT05369338|Experimental|Low Level Light Therapy|"The application of LLL is applied for 12 minutes using Repuls 7 (Repuls Lichtmedizintechnik GmbH, Vienna). This is a class IIb medical device. It applies pulsed red light of a frequency of 640nm. The intensity is 175 mWcm-2, which corresponds to a power density of 4,100 mW. The pulse frequency is set to 2.5 hz.~The device is positioned 7cm from the skin using a distance ring."
88941253|NCT01858129|Placebo Comparator|Control|Inhaled NS 0.9%
88941254|NCT01858142|Experimental|Preparation intervention|The parental presence decision tool will be delivered as an App shown to families using an iPAD and a set of headphones. This App will include information on what to expect in the operating room as well as the role of the parents. The App incorporates the basic principles of other effective perioperative preparation interventions (e.g., providing both sensory and procedural information) and is tailored to the local context. In addition to preparatory information, the App will also inform parents of the role of parent anxiety on children's outcomes in the operating room.
88941255|NCT01858142|Placebo Comparator|Standard preparation|In standard preparation condition, treating nurses and anesthesiologists will provide information to parents as they standardly do when parents are present at induction; this includes information on logistical issues and safety in the operating room (e.g., where to stand, how to put on gown) and risks of anesthesia induction. Additionally, parents in the standard preparation condition will view a summary of this standard information as text on an iPAD.
88941256|NCT01858155|Experimental|Melatonin|
88941257|NCT01858181|Experimental|Cohort 1|SC ocaratuzumab 40 mg weekly x 4 doses
88941258|NCT01858181|Experimental|Cohort 2|SC ocaratuzumab 80 mg weekly x 4 doses
88941259|NCT01858181|Experimental|Cohort 3|SC ocaratuzumab 80 mg weekly x 8 doses
88941260|NCT01858207|Active Comparator|TACE+ RFA|"This arm will be conventional TACE(Transcatheter Arterial Chemoembolization) plus RFA(radiofrequency ablation.~use intra-injection of lipiodol mized with doxorubicin when the catheter was placed in the superselective location very close to the tumor."
88941261|NCT01858207|Active Comparator|RFA|Recent advances in local ablation are aimed to expand the ablation size (> 3cm in diameter) in a minimal session by utilizing the switching RF controller and simultaneous 2 or 3 RF electrodes placement. The procedure of RFA was according to manufacture algorithm. RFA was performed within 7 days after TACE because the embolization effect in reducing blood flow will be not evident afterwards.
88941262|NCT01858220||Video capsule examinee|Every subject having capsule endoscopy for any indication
89501834|NCT03165123|Placebo Comparator|placebo group|The patients will receive oral placebo tablet, one hour before induction of anesthesia and 5 mg Intra-venous dexamethasone within 1-2 minutes after the umbilical cord is clamped.
88941263|NCT01858233|Experimental|Intensive Behavioral Modification|intensive dietary counseling, increased activity, lactation consult
88941264|NCT01858233|No Intervention|Routine care|standard dietary counseling
88941265|NCT01858246|Active Comparator|Bonebridge|Implantation with a Bonebridge
89458720|NCT05369338|Sham Comparator|Sham controll|"The application of LLL is applied for 12 minutes using Repuls 7 (Repuls Lichtmedizintechnik GmbH, Vienna). This is a class IIb medical device. It applies pulsed red light of a frequency of 640nm. The intensity is 175 mWcm-2, which corresponds to a power density of 4,100 mW. The pulse frequency is set to 2.5 hz.~The device is positioned 7cm from the skin using a distance ring. The sham treatment is performed with the same device and the same distance ring without activating it."
88941266|NCT01858246|Active Comparator|Bone Anchored Hearing Aid|Implantation with a Bone Anchored Hearing Aid
89458721|NCT03696875|Experimental|Multilevel Guided Discharge Planning|
89458722|NCT03696875|Active Comparator|Standard of care|
89458723|NCT03692429|Experimental|CYAD-101 with FOLFOX|Infusion after standard FOLFOX chemotherapy
89458724|NCT03692429|Experimental|CYAD-101 with FOLFIRI|Infusion after standard FOLFIRI chemotherapy
89458725|NCT04523129|Experimental|CyclASol Ophthalmic Solution|Cyclosporine A solution in vehicle
89458726|NCT04523129|Placebo Comparator|Vehicle Ophthalmic solution|Vehicle only
89458727|NCT03700775|Experimental|Telemonitoring intervention|
88941267|NCT01858259||cyclophosphamide|Patients receiving cyclophosphamide
88941268|NCT01858259||azathioprine|Patients receiving azathioprine
88941269|NCT01858259||mycophenolate mofetil|Patients receiving mycophenolate mofetil
88941270|NCT01858259||methotrexate|Patients receiving methotrexate
88941271|NCT01858259||no therapy|Patients receiving no immunosuppressive therapy
88941272|NCT01858272|Experimental|H5.020CMV.PDGF-b and limb compression bandage|This study will use a standard, three-six Phase I dose escalation scheme. Three subjects will be treated at the lowest dose. If zero of three experience dose limiting toxicity (DLT), three new subjects will be treated at the next higher dose. If one of three of the subjects at the lowest dose had experienced DLT, then three more for a total of six will receive the lowest dose. Of the six subjects who received the lowest dose, if only one of six experience DLT, then the dose will be escalated to the next higher dose. However, if more than one of six experiences DLT (i.e., any of the additional subjects), then the MTD will be declared and the next lower dose will be the recommended dose for future trials.
88941273|NCT01858298|Experimental|pulpectomy|The technique of pulpectomy will be performed in one appointment according to clinical guidelines and followed by a composite resin crown.
88941274|NCT01858298|Experimental|tooth extraction|The technique of tooth extraction of primary teeth will be performed according to clinical guidelines
88941275|NCT01858311||Placebo vehicle|(2) placebo capsules following AM meal and (2) placebo capsules following PM meal.
88941276|NCT01858311||Tocotrienol capsules (400 mg)|(2) 100mg TCT capsules following AM meal and (2) 100mg TCT capsules following PM meal.
88941277|NCT01858311||Tocotrienol Capsules (800 mg)|(2) 200mg TCT capsules following AM meal and (2) 200mg TCT capsules following PM meal.
88941278|NCT01858324|Experimental|educational tools|Subjects will receive at time 0 the educational tools (pamphlet-including a graphic-based summary, a magnet and a 12 minutes video). They will then have to answer a questionnaire 1 month later about knowledge, anxiety and satisfaction.
88941279|NCT01858324|No Intervention|Usual antenatal care|Subjects in this group will not receive any more educational tools that what is generally offered in routine antenatal care.
88941280|NCT01858337|Experimental|green beans group,|1 of the 2 vegetable groups. The infants were weaned only with vegetables. With green beans every other day and another vegetable on the days in between.
88941281|NCT01858337|Experimental|Artichoke group|1 of the 2 vegetable groups. The infants were weaned only with vegetables. With Artichoke every other day and another vegetable on the days in between
88941282|NCT01858337|Active Comparator|Apple group|1 of the 2 fruit groups. The infants were weaned only with fruits. With Apple every other day and other fruits on the days in between
88941283|NCT01858337|Active Comparator|Plums group|1 of the 2 fruit groups. The infants were weaned only with vegetables. With Plums every other day and other fruits on the days in between
88941284|NCT01858350|Other|Active Music Therapy|Active Music Therapy: A music therapist plays music to patients for 15 minutes
88941285|NCT01858350|Other|Passive Music Therapy|Passive Music Therapy: A music therapist plays a compact disc (CD) to patients for 15 minutes
88941286|NCT01858350|No Intervention|No intervention|
88941287|NCT01858350|Other|Distraction Therapy|Distraction Therapy: A child life specialist plays with patients for 15 minutes
88941288|NCT01858402|Active Comparator|Paracetamol|15 mg/kg paracetamol, IV (in the vein)(premixed with 0.9% sodium chloride to a total of 50 ml)single dose
88941289|NCT01858402|Active Comparator|Dipyrone|15 mg/kg IV (in the vein)dipyrone received (premixed with 0.9% sodium chloride to a total of 50 ml), single dose
89458728|NCT03692351|Active Comparator|Cup with screw holes|Uncemented Trilogy cup (Zimmer, Warzaw, IN, US), screw fixation (2 or 3 screws)
89458729|NCT03692351|Experimental|Cup without screw holes|Uncemented Trilogy cup (Zimmer, Warzaw, IN, US) without screw holes, press-fit fixation
89458730|NCT03700697|Experimental|Family Stress Module Intervention|Primary care clinicians will use the CHADIS Family Stress Module including the reviewing ACE, Positive Childhood Experiences, and FASS Plus questionnaires at designated child ages; address family stressors revealed using the motivational interviewing teleprompter and refer parents with stressors as indicated using the care coordination functionality.
89458731|NCT03700697|No Intervention|Controls|Control primary care providers will provide care as usual.
89458732|NCT04519229||Children in fostercare in CPP-treatment|Children in foster care taking part in Child-Parent Psychotherapy
89458733|NCT04346849|Experimental|MTA pulpotomy|Teeth receiving pulpotomy using MTA
89458734|NCT04346849|Experimental|Biodentine pulpotomy|Teeth receiving pulpotomy using Biodentine
89458735|NCT04346849|Experimental|Bioceramic pulpotomy|Teeth receiving pulpotomy using Bioceramic
88941290|NCT01858415|Experimental|Single arm|
88941291|NCT01858441|Other|Abiraterone Acetate|
88941292|NCT01858454|Experimental|HALS for myomectomy|Hand-assisted laparoscopic surgery for myomectomy
88941293|NCT01858454|Active Comparator|Open myomectomy|Open surgery for myomectomy
89016799|NCT01233297|Placebo Comparator|Placebo|Placebo mixture (once a day for 3 days)
89016800|NCT00960414|Experimental|SHINE A|Mindfulness training added to diet-exercise education.
88941294|NCT01858467|Experimental|Supreme Laryngeal Mask Airway|Supreme Laryngeal Mask Airway (Airway Device) with gastric tube. Preoxygenation, rapid sequence induction and cricoid pressure. Propofol 2 to 3mg/kg with 100mg succinylcholine. General anaesthesia with sevoflurane.
88941295|NCT01858467|Active Comparator|Endotracheal Intubation|Endotracheal intubation (Airway Device) using Macintosh Laryngoscope with tracheal tube with gastric tube insertion after placement. Preoxygenation, rapid sequence induction and cricoid pressure. Propofol 2 to 3mg/kg with 100mg succinylcholine. General anaesthesia with sevoflurane.
88941296|NCT01858480|Active Comparator|D-ribose|D-ribose administered via peripheral intravenous for 24 hours followed by oral D ribose dosing for 3 months versus placebo in subjects with CHF who have been stabilized following hospitalization for acute decompensation.
88941297|NCT01858480|Placebo Comparator|Placebo|Placebo dosage form designed to mock active.
88941298|NCT01858493|Experimental|Continence promotion group education|A single 1-hour continence promotion group education workshop, facilitated by the research coordinator, aimed at changing knowledge and beliefs about urinary incontinence and different treatment options. An evidence-based self-management tool will be distributed at the end of the workshop.
88941299|NCT01858493|Sham Comparator|Sham health lecture|A single 1-hour group education workshop on other health topics of concern to older women such as memory, hearing, insomnia
88941300|NCT01858506|Experimental|I-ACE intervention arm|lifestyle counselling using the interactive assessment, counselling and education (I-ACE)-based method.
88941301|NCT01858506|Active Comparator|Standard lifestyle advice arm|lifestyle counselling using the standard lifestyle advice (SLA) program currently provided to Clalit Health Services patients.
88941302|NCT01858519||CF patients receiving PERT|Cystic fibrosis (CF) patients receiving pancreatic enzyme replacement therapy (PERT)
88941303|NCT01858519||Matched control patients unexposed to PERT|Patients unexposed to pancreatic enzyme replacement therapy (PERT); matched on age and location of residence to PERT-exposed CF patients with chronic disease.
88941304|NCT01858571|Experimental|Low dose chemotherapy|"Alternating cycles of Cycle A and B (Each cycle includes 3 weeks of drug administration) with each drug rounded off to the nearest tablet/capsule size.~Cycle A~Daily oral Thalidomide (at 3mg/kg)~Daily oral Celecoxib (100 mg BID for patients < 20 kg, 200 mg BID for patients 20-50 kg, and 400 mg BID for patients > 50 kg)~Daily oral Etoposide (50 mg/m2/d)~Cycle B~Daily oral Thalidomide (at 3mg/kg)~Daily oral Celecoxib (100 mg BID for patients < 20 kg, 200 mg BID for patients 20-50 kg, and 400 mg BID for patients > 50 kg)~Daily oral Cyclophosphamide (2.5 mg/kg/d to a maximum of 100 mg/d) every 21 days"
88941305|NCT01858571|Placebo Comparator|Best supportive care|"Placebo: Alternating cycles of Cycle A and B (Each cycle includes 3 weeks of drug administration)~Capsules of same size and color as used in metronomic therapy Best supportive care~Management of pain as per WHO standard for pain management"
88941306|NCT01858584|Experimental|Gastrotuss|"Gastrotuss baby: syrup based on alginate consisting of: magnesium alginate, simethicone, fructose, xanthan gum, honey, D-panthenol, fluid extracts of Althaea officinalis, Papaver rhoeas, zinc oxide, sodium bicarbonate, sodium hydroxide, p-hydroxybenzoate of methyl-sodium, sodium propyl p-hydroxybenzoate, natural flavors, erythrosine (E127), purified water.~dosage:~Infants weighing <5 kg in 2.5 ml 5-10 min after feeding. In case of regurgitation after administration, 1 ml additional~Infants weighing> 5 kg per 5 ml dose after the meal and the evening before putting the baby to sleep The administration should be maximum 3 times per day"
88941307|NCT01858584|Active Comparator|Thickened Formula|Milk thickened (formulat AR): contains a special thickener derived from corn starch waxy, that maintains its fluidity into the bottle and thickens just inside the stomach of the child, and this makes it easy to use in breastfeeding , as it is usable with a common teat.
88941308|NCT01858584|No Intervention|control group|
88941309|NCT01858610|Other|Irbesartan alone|Irbesartan 300 mg alone
88941310|NCT01858610|Other|Hydrochlorothiazide 25 mg alone|Hydrochlorothiazide 25 mg alone
88941311|NCT01858610|Other|Irbesartan 300 mg + Hydrochlorothiazide 25 mg|Irbesartan 300 mg + Hydrochlorothiazide 25 fixed dose combination
88941312|NCT01858623|Other|Losartan / Hydrochlorothiazide100 mg/25mg|Losartan / Hydrochlorothiazide100 mg/25mg fixed dose combination
88941313|NCT01858623|Other|Losartan 100 mg|Losartan 100 mg alone
88941314|NCT01858623|Other|hydrochlorothiazide 25 mg|hydrochlorothiazide 25 mg alone
88941315|NCT01858649|Active Comparator|Folfox: oxaliplatin +leucovorin+ 5FU|FOLFOX (oxaliplatin +leucovorin+ 5FU) +bevacizumab+ metastases resection
88941316|NCT01858649|Active Comparator|FOLFIRI: irinotecan+leucovorin+5FU|FOLFIRI (irinotecan+leucovorin+5FU) +bevacizumab +metastases resection
88941317|NCT01858662|Active Comparator|oxaliplatin +leucovorin L+5FU+ cetuximab|oxaliplatin +leucovorinL+5-Fluorouracile +cetuximab+'Metastases Resection ( multiple steep surgery possible)
89016801|NCT00960414|Active Comparator|SHINE B|Diet-exercise education.
88941318|NCT01858662|Active Comparator|Irinotecan+ + leucovorinL +5-Fluorouracil +cetuximab|Irinotecan+ + leucovorinL +5-Fluorouracile + cetuximab +'Metastases Resection ( multiple steep surgery possible)
88941319|NCT01858675|Experimental|Biomarkers, total blood volume|
88941320|NCT01858714|Active Comparator|Behavior Therapy (BT)|"Active Comparator: Behavior Therapy~Behavioral treatment strategies will be utilized to facilitate adherence to the treatment goals in all three treatments. Participants in the BT condition will receive only the BT intervention. Strategies that will be emphasized are listed below:~Self monitoring Stimulus control Changing eating behaviors Goal setting Problem solving Social support Cognitive restructuring Relapse prevention"
88941321|NCT01858714|Experimental|Behavior Therapy + Environment|Participants will receive standard behavioral therapy with an emphasis on environmental strategies.
88941322|NCT01858714|Experimental|Acceptance-based BT + Environment|Participants will receive acceptance-based behavioral therapy with an emphasis on environmental strategies.
88941323|NCT01858727|Active Comparator|forced air warming group|30 minutes before the preoperative will use forced air warming.
88941324|NCT01858727|No Intervention|control group|do not active heating group
89458736|NCT03696719|Active Comparator|Undergoing surgery under general anesthesia|Patients will undergo the surgery under general anesthesia, anesthetic regime will be according to standard clinical practice.
89016802|NCT00798226|Active Comparator|1|n-3 fatty acid
89016803|NCT00798226|Placebo Comparator|2|Olive oil
89458737|NCT03696719|Active Comparator|Undergoing surgery under regional anesthesia|Patients will undergo the surgery under neuroaxial anesthesia.
89458738|NCT04336943|Experimental|Treatment (durvalumab, olaparib)|All patients receive durvalumab IV over 1 hour on day 1 of each cycle. Patients with CDK12 mutation and MMRd/MSI-high also receive olaparib PO BID on days 1- 28 of cycles 3-6. Patients with homologous recombination mutation also receive olaparib PO BID on days 1-28 of cycles 1-6. Cycles repeat every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity.
89458739|NCT03030989|Active Comparator|Chlorhexidine Gluconate 2% Wipe|
89458740|NCT03030989|Placebo Comparator|Placebo wipe|
89458741|NCT03030599|Placebo Comparator|Placebo|Placebo
89458742|NCT03030599|Experimental|JZP-258|JZP-258
89458743|NCT04512521||eosinophilic asthma|
89458744|NCT03692195|Experimental|Week WHOOP is worn|Participants will wear the WHOOP strap 2.0 either 7 days prior to or 7 days after their sleep study.
89458745|NCT03692195|Placebo Comparator|Week WHOOP is not worn|Participants will not wear the WHOOP strap 2.0 either 7 days prior to or 7 days after their sleep study.
89458746|NCT04499807|Other|Smart Watch|The patients will wear the Smart Watch to generate data to assess their rhythm as confirmed by the ILR done during the same time.
89458747|NCT03696641|Active Comparator|glazed IPS e.max|lithium disilicate glazed crowns that proved to have a good color stability
89458748|NCT03696641|Experimental|polished IPS e.max|polished lithium disilicate crowns with the polishing kit
89458749|NCT03696563|Active Comparator|Control group|In this group, the - usual care based upon BLS-PCS with manual titration of oxygen. In this group the SpO2 was recorded any time with FreeO2 device - recording mode.
89458750|NCT03696563|Experimental|FreeO2 group|The adjustment of the oxygen flow will be made by the FreeO2 system, an automated titration to reach the SpO2 target set by paramedic.
89458751|NCT03624647|Experimental|Power toothbrush|
89458752|NCT03624647|Placebo Comparator|Manual toothbrush|
89458753|NCT03624257|Experimental|Scaling and root planning + Laser treatment|
89458754|NCT03624257|Active Comparator|Mucosal flap surgery|
89458755|NCT03624569|Sham Comparator|Bagel diet|Bagel consumed daily for 2 weeks
89458756|NCT03624569|Experimental|Potato diet|Potato consumed daily for 2 weeks
89458757|NCT03700307|Experimental|pulmonary vein isolation|patients will receive circumferential pulmonary vein isolation using cryoballoon ablation
89458758|NCT03700307|Experimental|pulmonary vein and left atrial roof linear isol|patients will receive circumferential pulmonary vein and left atrial roof linear isolation using cryoballoon ablation
89458759|NCT03696329|Experimental|Tetrabenazine Tablets|Tetrabenazine Tablets 25 mg of Dr. Reddy's Laboratories Limited
89458760|NCT03696329|Active Comparator|Xenazine|Xenazine Tablets 25 mg of Lundbeck Inc.
89458761|NCT03696251||master's nursing program|the graduates of master's nursing program in recent three years in Taiwan
89458762|NCT03696173||Participants taking abatacept|
89458763|NCT03696173||Participants taking abatacept with methotrexate|
89458764|NCT03696095|Active Comparator|Continous infusion ropivacaine|Continuous infusion via peri-neural femoral nerve catheter of Ropivacaine Hcl 0.2% Inj Bag 200Ml (CI mode) at rate of 6ml/h + patient controlled bolus of 3ml ...
89458765|NCT03696095|Experimental|PIB ropivacaine|Programmed intermittent bolus of Ropivacaine Hcl 0.2% Inj Bag 200Ml (PIB mode) : 6ml each 60min + patient controlled bolus 3ml ...
89458766|NCT03700229|Experimental|Bortezomib +Rituximab|Bortezomib +Rituximab
89458767|NCT03700151|Experimental|Children with SSD|Participants will receive a piloted treatment programme for children with severe speech sound disorders, especially childhood apraxia of speech.
89458768|NCT03619343|Experimental|No ETOIMS arm|When the abdominal wound is closed, the operator performs needle insertion at 14 sites near the incision site under the guidance of ultrasonography.
89458769|NCT03619343|Active Comparator|ETOIMS arm|When the abdominal wound is closed, the operator performs needle insertion at 14 sites near the incision site under the guidance of ultrasonography. When the needle is in the abdominal muscle, the operator performs muscle stimulation for about 10 seconds per needle insertion.
89458770|NCT03700073|Experimental|Walk training plus virtual reality|Experimental group (GTVR): The intervention consisted of treatment with the robotic CL1Walker gait training system in combination with virtual reality
89458771|NCT03700073|Active Comparator|Walk training|Control group (GT): The intervention consisted of treatment with the robotic CL1Walker gait training system
89458772|NCT03692039|Experimental|M-pro files|Instrumentation using M-pro files in rotating motion
89458773|NCT03692039|Active Comparator|ProTaper Next files|Instrumentation using ProTaper Next files in rotating motion
89016804|NCT00692939|Experimental|1|High-dose immunotherapy followed by infusion of autologous CD34-selected peripheral blood stem cells (PBSC)
89016805|NCT00577200|No Intervention|Control|Control group subjects are not undergoing any surgical procedures and will not be randomized to any anesthetic drug group.
89016806|NCT00577200|Experimental|Midazolam + Sufentanil + Propofol|"Midazolam 0.03 mg/kg + Sufentanil 0.1 µg/kg + Propofol bolus of 300 µg/kg + infusion at 75 µg/kg/min.~For subjects who are chronic pain patients undergoing minor surgical procedures."
89458774|NCT03695861|Experimental|Whole-body 18F-FDG PET-CT scan|
89458775|NCT04311749||Fetal growth restriction|
89458776|NCT04311749||Severe preeclampsia|
89458777|NCT04311749||Low PAPP-A|
89458778|NCT04311749||Healthy control|
89458779|NCT03695705|Other|Primary prophylaxis arm|28 Patients with decompensated cirrhosis without past history of SBP were randomised to receive Rifaximin at dose 550 mg twice daily.29 Patients with decompensated cirrhosis without past history of SBP were randomized to receive Norfloxacin at dose 400 mg once daily
89458780|NCT03695705|Other|Secondary prophylaxis arm|26 Patients with decompensated cirrhosis with past history of SBP were randomized to receive Rifaximin at dose 550 mg twice daily.33 Patients with decompensated cirrhosis with past history of SBP were randomized to receive Norfloxacin at dose 400 mg once daily
89458781|NCT03695627|Experimental|Meditation Group|Participants in the meditation group will use a digitally-based mindfulness intervention Headspace app (Basics + Stress packs) will be used for 10 minutes a day over the course of 8 weeks
89458782|NCT03695627|No Intervention|Control Group|Control group participants will continue their normal activities and not add any form of meditation during the study period.
89458783|NCT03699839|Experimental|High dose influenza vaccine|Administration of high-dose influenza vaccine
89458784|NCT03699839|Experimental|MF59-adjuvanted influenza vaccine|Administration of MF59-adjuvanted vaccine
89458785|NCT03699839|Active Comparator|Standard influenza vaccine|Administration of standard intramuscular influenza vaccine
89458786|NCT04050215|Experimental|Diagnostic (68Ga-PSMA-11 PET/CT)|Patients receive 68Ga-PSMA-11 IV and undergo PET/CT scan over 3 hours. Patients may be reenrolled in the study, if 68Ga-PSMA-11 PET/CT is performed for subsequent management decision.
89458787|NCT03699683|Experimental|Physical Combined Activity Program|Before and after a 6-months supervised and individualized program that combined aerobic and resistance training were performed in post bariatric patients. Body composition, physical fitness and cardiovascular risk factors were measured before, after the physical activity program and 6 months later (13 months sinde the program started)
89458788|NCT03691805|Active Comparator|anodal tDCS over rDLPFC|Participants will receive anodal tDCS (transcranial direct current stimulation) of the right dorsolateral prefrontal Cortex (DLPFC).
88941325|NCT01858779||Study-cohort|"Patients after ischemic stroke without a history of atrial fibrillation will perform measurements of peripheral pulse three times daily and in case of symptomatic arrhythmic episodes. Results will be entered into a diary which will be send to the center every month. In parallel to the measurements, patients will transmit ECGs via a mobile ECG recorder to the study center.~At 3 and 6 months after inclusion patients will be evaluated using 72h holter ECG. During the whole study period AEs as well as SAEs and changes in medications are recorded."
88941326|NCT01858792||Baseline Health-Related Quality of Life (HRQOL)|Quality of life assessment tools were similar across the treatment groups and indicated that there was impairment in quality of life of subjects in the Low C+anti-dsDNA Population
88941327|NCT01858792||SLE Medication Usage at Baseline|All subjects in the Low C+anti-dsDNA Population
88941328|NCT01858805||detection of circulating tumors cells|This prospective, single-institution study conducted at the University Hospital Hamburg-Eppendorf (Hamburg, Germany) enrolled 123 patients with ECs that were initially considered resectable. Only patients with histologically proven EC were included. Peripheral blood samples for CTC analysis were collected immediately before surgery.
88941329|NCT01858818||healthy 18 year old males|
88941330|NCT01858831|Experimental|Atovaquone/proguanil HCL|Atovaquone/proguanil HCL
88941331|NCT01858831|Active Comparator|Atovaquone 750 mg|Atovaquone 750 mg
88941332|NCT01858831|Active Comparator|Atovaquone 1500 mg|Atovaquone 1500 mg
89016807|NCT00577200|Experimental|Midazolam and Sufenatnil|"Midazolam 1-5 mg in holding area + Sufentanil 5-10 mcg.~For subjects who are chronic pain patients undergoing minor surgical procedures."
89016808|NCT00520559||Thalassemia|
89458789|NCT03691805|Sham Comparator|sham tDCS|Participants will receive sham tDCS (transcranial direct current stimulation) of the DLPFC.
89501835|NCT03165123|Active Comparator|Azithromycin group|The patients will receive 250 mg oral Azithromycin tablet, one hour before induction of anesthesia and 5 mg Intra-venous dexamethasone within 1-2 minutes after the umbilical cord is clamped.
89501836|NCT03167931|Experimental|18-49 years group|Participants undergo 2 sessions of MRI + transcranial Magnetic Stimulation or transcranial electric stimulation + electroencephalogram. The 2 sessions are performed with an interval of 3 to 7 days.
89458790|NCT03699605|Experimental|VESMP|"Participants used VESMP at least half hour session thrice a week over an average of 4 months. The instruction before every domain included using it independently on the participant's own smart phone, or with a trained person either in the clinic or on their phone brought to the participant's home.~Total 25 patients with diagnosis of severe non-fluent aphasia included, ages 40+, at least 3 months post-onset of single unilateral CVA affecting the language dominant hemisphere at the time of baseline testing also including, Participant demographics, aphasia classification and severity. All subjects participated in an intensive 2-week VESMP treatment program prior to beginning the individualized programs."
89458791|NCT03699605|Active Comparator|Traditional Therapy|Control group received traditional therapy total 25 patients with diagnosis of severe non-fluent aphasia included, All subjects participated in an traditional therapy group in routine and received language therapy for 4 months of periods with three sessions per week.
89016809|NCT00299559|Other|1|cross over application of both specimen
89201507|NCT00928941|Experimental|Arm 1|A cognitive training program (Posit Science) or an active control (video game) will be implemented for at least 3-4 hours a week for 40 training units.
89201508|NCT00928941|Active Comparator|Arm 2|A computer game control condition will be implemented for 3-4 training exercises a week for 40 hours.
89458792|NCT03695549|Active Comparator|intervention|CAF+ APRF
89458793|NCT03695549|Active Comparator|control|CAF+SCTG
89458794|NCT03699449|Experimental|olaparib + cediranib|olaparib+cediranib combination therapy
89201509|NCT01054105||Step I: BMPR-2 gene analysis|BMPR-2 gene analysis on 100 IPAH or heritable PAH Patients
89458795|NCT03699449|Experimental|durvalumab + olaparib|durvalumab + olaparib combination therapy
89458796|NCT03699449|Experimental|durvalumab + chemotherapy|durvalumab +chemotherapy
89458797|NCT03699449|Experimental|durvalumab + tremelimumab + chemotherapy|durvalumab + tremelimumab + chemotherapy
89458798|NCT03699449|Experimental|durvalumab + tremelimumab + paclitaxel|durvalumab + tremelimumab + paclitaxel
89458799|NCT03699449|Experimental|durvalumab +chemotherapy|durvalumab +chemotherapy
89458800|NCT03028415|Experimental|AMPLEX|
89458801|NCT03028415|Active Comparator|Autogenous Bone Graft (ABG)|
89458802|NCT04477577|Experimental|New Parent Intervention|
89458803|NCT04477577|Active Comparator|Safety Control|
89458804|NCT03699371|Experimental|Early Supplemental Parenteral Nutrition|Intervention group: would receive EN reaching up to 20 % of daily nutritional requirements and early (on first day of stay in ICU) provision (of up to 80%) of protein (2 g/kg/ day or in case of continuous renal replacement therapy (CRRT) 2,5 g/kg/ day) and caloric (15-20 kcal/kg/day) needs in SPN that would be continued until 7th day of stay in ICU for the purpose of the study.
89458805|NCT03699371|No Intervention|Late Supplemental Parenteral Nutrition|Control group: would receive EN reaching up to 20 % of daily nutritional requirements and late (of up to 80%) of protein (2 g/kg/ day or in case of CRRT 2,5 g/kg/ day) and caloric (15-20 kcal/kg/day ) in SPN on 7th day of stay in ICU if it is not already met via enteral route.
89458806|NCT04475081|Experimental|MMR vaccination|Subjects will be randomized to receive the MMR Vaccine subcutaneously
89201510|NCT01054105||Step-II: Iloprost and Exercise Echo|Illoprost inhalation for 3 months & Check-up before and after treatment; WHO functional classification Assessment of exercise capacity (6M walk test) Cardiopulmonary exercise echocardiography NT-proBNP
89458807|NCT04475081|Placebo Comparator|Placebo control|Subjects will be randomized to receive sterile saline given subcutaneously
89458808|NCT03699293|Active Comparator|ASA and Celecoxib|Take celecoxib 200mg capsule twice a day and aspirin 81mg tablet once a day for 4 weeks (after completion of the run-in period)
89458809|NCT03699293|Active Comparator|ASA and Naproxen|Take naproxen sodium 550mg tablet twice a day and aspirin 81mg tablet once a day (after completion of the run-in period)
89458810|NCT03695003|Active Comparator|600 mg sage/polyphenol combination|600 mg of this sage/polyphenol combination will be consumed, via capsule, per day for 29 days.
89458811|NCT03695003|Placebo Comparator|Placebo|The same number of aesthetically similar capsules will be consumed per day for 29 days.
89458812|NCT02692040|Experimental|12-24 mg (B1) dose of G3215|"G3215 multiple dose, subcutaneous injection:~5 doses over a 4 week treatment period at escalating doses to a max of 24 mg."
89458813|NCT02692040|Experimental|6-10 mg (B2) dose of G3215|"G3215 multiple dose, subcutaneous injection:~5 doses over a 4 week treatment period at escalating doses to a max of 10 mg."
89458814|NCT02692040|Experimental|5-16 mg (B3) dose of G3215|"G3215 multiple dose, subcutaneous injection:~5 doses over a 4 week treatment period at escalating doses to a max of 16 mg."
89458815|NCT02692040|Experimental|3.2mg (C) infusion pump dose of G3215|G3215 subcutaneous infusion over a 4 day treatment period at escalating doses to a max of 3.2 mg (with either the first or last day administering infusion of placebo [saline]).
89201511|NCT00987688|Experimental|Hypothermia|Early and sustained hypothermia.
89458816|NCT02692040|Placebo Comparator|Placebo (B) - saline|5 subcutaneous injections of 0.9% saline, over a 4 week treatment period
89458817|NCT02692040|Placebo Comparator|Placebo (A) - saline|Single subcutaneous injection of 0.9% saline
89458818|NCT02692040|Experimental|0.1 mg dose G3215 (A1)|0.1 mg G3215 single dose, subcutaneous injection
89458819|NCT02692040|Experimental|0.5 mg dose G3215 (A1)|0.5 mg G3215 single dose, subcutaneous injection
89458820|NCT02692040|Experimental|1.5 mg dose G3215 (A1)|1.5 mg G3215 single dose, subcutaneous injection
89458821|NCT02692040|Experimental|4 mg dose G3215 (A2) with varied formulation|4 mg G3215 single dose, subcutaneous injection
89458822|NCT02692040|Experimental|4 mg dose G3215 (A3) with varied formulation|4 mg G3215 single dose, subcutaneous injection
89458823|NCT02692040|Experimental|4 mg dose G3215 (A4) with varied formulation|4 mg G3215 single dose, subcutaneous injection
89458824|NCT02692040|Experimental|4 mg dose G3215 (A5) with varied formulation|4 mg G3215 single dose, subcutaneous injection
89458825|NCT02692040|Experimental|8 mg dose G3215 (A7)|8 mg G3215 single dose, subcutaneous injection
89458826|NCT02692040|Experimental|10 mg dose G3215 (A6)|10 mg G3215 single dose, subcutaneous injection
89458827|NCT02692040|Experimental|12 mg dose G3215 (A8)|12 mg G3215 single dose, subcutaneous injection
89458828|NCT02692040|Experimental|16 mg dose G3215 (A9)|16 mg G3215 single dose, subcutaneous injection
89458829|NCT02692040|Experimental|32 mg dose G3215 (A10)|32 mg G3215 single dose, subcutaneous injection
89458830|NCT02692040|Experimental|48 mg dose G3215 (A11)|48 mg G3215 single dose, subcutaneous injection
89458831|NCT03694847||Asthma with CRSwNP|Asthmatic patients with a diagnosis of CRSwNP
89458832|NCT03694847||Asthma without CRSwNP|Asthmatic patients without a diagnosis of CRSwNP
89458833|NCT05610670|Other|Patients who underwent a kidney/pulmonary transplant before the age of 40|The questionnaire will allow us to complete the information not obtained from the patients' files on the one hand, and to collect their experiences regarding the desire and/or achievement of a pregnancy, but also their gynecological follow-up in the broad sense, on the other hand.
89458834|NCT03029819|Active Comparator|Mindfulness-based Addiction Treatment (MBAT)|Nicotine patch; self-help guide; MBAT
89458835|NCT03029819|Experimental|iQuit Mindfully|Nicotine patch; self-help guide; MBAT; text messaging
89458836|NCT03105830|Experimental|intervention and data collection|pain management by iv paracetamol
89458837|NCT03694769||All participants|Semi-structured interview and drop attack diary
89458838|NCT04465409|Experimental|Presbyopic adults|"Presbyopic adults, male or female between 40-65 years of age who need from +1.25 D to +3.50 D of reading addition in the non-dominant eye to improve near visual acuity by at least one line or more.~In this investigation, CorVision® will be implanted in the non-dominant eye to improve near vision and the dominant eye is left intact or corrected by a standard refractive surgery to emmetropia. In brief, subjects will undergo laser corneal surgery on their non-dominant eye to create an anterior stromal pocket into which the investigational device will be implanted."
89458839|NCT04440020|Experimental|Beverage of Olive Oil Leaves|50 patients Beverage of Olive Oil Leaves
89458840|NCT04440020|Active Comparator|Mediterranean dietary protocol Intervention|50 patients Dietary Supplement: Dietary Supplement:Mediterranean Diet
89458841|NCT03691415||BELKYRA Inj.|Each patient will be administered BELKYRA Inj. at least once and the interval between treatments not less than 1 month apart and follow-up within 3 months of the last treatment session.
89458842|NCT03699215|Placebo Comparator|placebo|solution for intravenous infusion, with similar organoleptic characteristics than active treatment.
89458843|NCT03699215|Experimental|levosimendan|Concentrate for solution for perfusion. Pack with a 5 ml vial
89458844|NCT03166436|Experimental|RFA plus stenting|Endoluminal radiofrequency ablation followed by biliary stenting
88941333|NCT01858844|Active Comparator|CHEST COMPRESSION TECHNIQUE 2|The CCT was held only once. Prior to the start of data collection the patients were placed in supine position, with the slope of the headboard of the bed in 30 degrees for collection of signs of respiratory distress (runs), RR(respiratory rate)(timer for 1 minute); HR (heart rate) and SpO2(oxygen saturation) through pulse oximetry in infants without atelectasis.
88941334|NCT01858844|Experimental|CHEST COMPRESSION TECHNIQUE|The CCT was held only once. Prior to the start of data collection the patients were placed in supine position, with the slope of the headboard of the bed in 30 degrees for collection of signs of respiratory distress (runs), RR (timer for 1 minute); HR and SpO2 through pulse oximetry in infants with atelectasis.
88941335|NCT01858857||Geriatric psychiatric in patients|
88941336|NCT01858870||Lacosamide|patients with Partial Crisis of epilepsy treated with Lacosamide for at least 12 months
88941337|NCT01858909|Placebo Comparator|Control|saline every 12 hours for 28 days
88941338|NCT01858909|Experimental|Melatonin|Oral 30mg/12hours melatonin 28 days
88941339|NCT01858935|Experimental|ND-L02-s0201 Injection 0.03 mg/kg|
88941340|NCT01858935|Experimental|ND-L02-s0201 Injection 0.1 mg/kg|
88941341|NCT01858935|Experimental|ND-L02-s0201 Injection 0.2 mg/kg|
88941342|NCT01858935|Experimental|ND-L02-s0201 Injection 0.4 mg/kg|
88941343|NCT01858935|Experimental|ND-L02-s0201 Injection 0.5 mg/kg|
88941344|NCT01858935|Experimental|ND-L02-s0201 Injection 0.6 mg/kg|
88941345|NCT01858935|Experimental|ND-L02-s0201 Injection 0.8 mg/kg|
88941346|NCT01858935|Placebo Comparator|Placebo|
88941347|NCT01858961|Experimental|Group 1|BI 201335 in combination with BI 207127 and ribavirin for 24 weeks
88941348|NCT01858961|Experimental|Group 2|Telaprevir in combination with PegIFN and ribavirin for 24 weeks or 48 weeks
88941349|NCT01858987|Active Comparator|Stapler hepatectomy|Liver resection using vascular stapler for transection of the parenchyma
88941350|NCT01858987|Experimental|LigaSure Hepatectomy|Liver resection using LigaSure for transection of the parenchyma
88941351|NCT01859000|Experimental|Multidimensional Family Therapy|MDFT is a multi-systems family-based approach (Liddle, 2002a) designed to address the multiple developmental disruptions and symptoms that result from interacting individual, family, peer, and community risk factors (Liddle, 2002a). MDFT assesses and intervenes at multiple levels and in multiple domains of the adolescent's life -- individual, familial and extrafamilial.
88941352|NCT01859000|Other|Group CBT|The group treatment employed in the proposed study is a state-of-the-art peer group-based CBT model. The treatment will be based on established guidelines for CBT therapy for teen substance abuse (CSAT, 1999; Waldron & Kaminer, 2004) as well as trauma (La Greca & Silverman, in press). The treatment adopts a risk and protective factor framework, seeking to reduce substance use both by targeting cognitions about use directly and by focusing on accompanying problem behaviors such as poor academic performance and limited social skills (Hawkins et al, 1992).
88941353|NCT01859039||Egg allergic children|Administration of Live attenuated influenza vaccine
88941354|NCT01859052|Other|Obese migraineurs|Low carbohydrate diet
88941355|NCT01859052|Other|low-fat diet|Obese Migraineurs
88941356|NCT01859052|Other|Controls|Controls receiving AHA diet recommendations
88941357|NCT01859065|Placebo Comparator|Control|Mothers receive routine anticipatory guidance
88941358|NCT01859065|Experimental|Intervention|Mothers receive video-based and handout-based anticipatory guidance regarding non-urgent problems in addition to the routine anticipatory guidance
88941359|NCT01859091|Experimental|Fat Reduction|
88941360|NCT01859104|Other|Smartphone Arm|This is a feasibility trial and thus all participants in the study will be provided a smartphone app to assist them in making lifestyle modifications
88941361|NCT01859117|Experimental|3 x 10^6 cells|3 x 10^6 Human Placenta Derived cells (PDA-002) administered intramuscularly on Study Days 1 and 8
88941362|NCT01859117|Experimental|10 x 10^6 cells|10 x 10^6 Human Placenta Derived cells (PDA-002) administered intramuscularly on Study Days 1 and 8
88941363|NCT01859117|Experimental|30 x 10^6 cells|30 x 10^6 Human Placenta Derived cells (PDA-002) administered intramuscularly on Study Days 1 and 8
88941364|NCT01859117|Experimental|100 x 10^6 cells|100 x 10^6 Human Placenta Derived cells (PDA-002) administered intramuscularly on Study Days 1 and 8
88941365|NCT01859156||Carbon Monoxide Exposure|
88941366|NCT01859169||Control Group|Group that be administrated biliary drainage only
88941367|NCT01859169||PDT Group|Group that be administrated photodynamic therapy and biliary drainage
89016810|NCT00263081|Experimental|Lapaquistat Acetate QD|(and current lipid-lowering treatment)
89016811|NCT00263081|Placebo Comparator|Current lipid-lowering treatment|
89458845|NCT03166436|Active Comparator|Stenting alone|Biliary stenting alone
89458846|NCT03699137||Cases with confirmed ACS|Cases with confirmed diagnosis of acute coronary syndrome in the MINAP database (national registry of ACS patients). No interventions apply to this group as this is an observational study.
89458847|NCT03699137||EMS personnel|Emergency Medical Service (EMS) personnel will take part in the focus group. No intervention applies to this group in this qualitative component of the study.
89458848|NCT03166358|Experimental|hatha yoga intervention|Participants randomized to the intervention are asked to attend 8 hatha yoga classes delivered in a group format.
89458849|NCT03166358|No Intervention|waitlist control|Participants randomized to the waitlist control condition complete assessments while the intervention group completes the yoga intervention. They are given the option to complete 8 hatha yoga classes delivered in group format once the waitlist period is finished.
89458850|NCT04479956|Experimental|Surgical Ligation|Conventional surgical procedures will carried out through a 3-4 cm incision in the groin. The trunk of GSV and the tributaries will be ligated and divided.
89458851|NCT04479956|Experimental|Microwave group|The microwave treating wire (Microwave Intracavity Coagulation System; Shanghai Medical Electronics, Shanghai, China) will be inserted into the GSV until it reached the medial aspect of ankle, guided by a light that illuminated the tip of the wire. Then, GSV will be ablated using pulse mode at 20-30 W. The treating wire will be withdrawn at 2-4 mm/s, with the ablation time lasting 2 s (energy delivery to the GSV was estimated at around 80 J/cm); the treatment parameters will be based on a previous report. Tumescence will be used in all patients with 0.9% saline containing 20 mL 2% lidocaine with 1: 200,000 adrenaline and 20 mL 0.5% levobupivacaine in 1 L 0.9% saline.
89458852|NCT04479956|Experimental|Laser ablation group|"Endovenous Laser Ablation (EVLA) uses a laser Fiber, which is inserted into the abnormal vein via a small skin puncture.using 1470 nm laser and a radial fiber for less discomfort. Two weeks later the branch vessels have reduced in size"
89458853|NCT04479956|Experimental|Radiofrequency ablation group|inserts a small catheter into the diseased vein through a small incision, using ultrasound guidance for an accurate and live view. Consistent and uniform heat is delivered to contract the collagen in the vein walls, causing them to collapse and close. After the vein is closed the treated vein is gradually absorbed into surrounding tissue.
89458854|NCT04457843||COPD patients|
89458855|NCT03699059|Other|Health Care Professionals|A purposeful sample of 5 HCP's from the transplant team will test the online intervention and be interviewed using qualitative methods. This data will be analysed and used to plan a second study (feasibility RCT).
89458856|NCT03699059|Other|Kidney Transplant Patients|A purposeful sample of 10 kidney transplant patients will test the online intervention and be interviewed using qualitative methods. This data will be analysed and used to plan a second study (feasibility RCT).
89458857|NCT03694535|Experimental|Bladder wall thermochemotherapy|Mitomycin-C application with bladder wall thermochemotherapy system after TUR bladder tumor in intermediate and high risk non muscle invasive bladder cancer
88941368|NCT01859182|Experimental|Treatment (selumetinib, Akt inhibitor MK2206)|Patients receive Akt inhibitor MK-2206 PO on days 1, 8, 15, and 22 (days 8, 15, and 22 of course 1) and selumetinib PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89458858|NCT03694379|Experimental|Apneic Oxygenation|Participants receiving apneic oxygenation
89458859|NCT03694379|No Intervention|No Apneic Oxygenation|Participants not receiving apneic oxygenation
89458860|NCT03115034|Active Comparator|CEA with melatonin|Patients under CEA with melatonin taken during perioperative period.
89458861|NCT03115034|Placebo Comparator|CEA with placebo|Patients under CEA with placebo taken during perioperative period.
89458862|NCT03115034|Sham Comparator|CEA with blank control|Patients under CEA with nothing unnecessary taken during perioperative period.
88941369|NCT01859234|Experimental|89Zr-bevacizumab PET scan|all patients included in the study will have a 89Zr-bevacizumab PET scan
89458863|NCT03161990||Transgluteal approach to the hip joint|Patients who have been revised once for an infected total hip replacement with debridement and implant retention and in whom both the primary hip arthroplasty and the revision procedure were performed through a transgluteal approach.
89458864|NCT03161990||Posterior approach to the hip joint|Patients who have been revised once for an infected total hip replacement with debridement and implant retention and in whom both the primary hip arthroplasty and the revision procedure were performed through a posterior approach.
89458865|NCT03694223|Experimental|Booklets|Health education delivery method: Booklet. Patients will be given 2 leaflets on the low FOMDAP diet produced by the Department of Nutrition and Dietetic in Guy's & St Thomas' NHS Foundation Trust, and the Diabetes and Nutritional Sciences Division at King's College London. These booklets have been produced by dietitians and are commonly used in clinical practice across the UK.
89458866|NCT03694223|Experimental|Mobile application|Health education delivery method: Mobile application. Patients will be asked to download an application on their mobile phones or tablets. This application has been produced by dietitians from the Department of Nutrition and Dietetic in Guy's & St Thomas' NHS Foundation Trust, and the Diabetes and Nutritional Sciences Division at King's College London.
89458867|NCT03694223|Active Comparator|One to one consultation with dietitian|Health education delivery method:One-to-one consultation with dietitian. Patients will attend a clinic visit for a one-to-one consultation with a dietitian. As per current clinical practice, the initial visit will last for 1 hour. During the visit, tailored information on the low FOMDAP diet will be given to match patients' individual needs. During the visit, either the leaflets (used in group 1) or the application (used in group 2) will be used to facilitate the visit. The choice of using the leaflets or the app during the visit will be based on the dietitian's judgment based on the patients' needs.
89458868|NCT03691259|Experimental|Dance Group|Dance group will participate in one-hour ballet classes twice per week for 10 weeks
89458869|NCT03691259|No Intervention|Control Group|The control group will not participate in the ballet classes
88941370|NCT01859260|No Intervention|Control|
88941371|NCT01859260|Experimental|Intervention|CPAP/autopap
88941372|NCT01859273|No Intervention|Standard Care|Standard Care after kidney transplantation
88941373|NCT01859273|Experimental|mHealth|subjects provided with electronic medication tray, electronic blood pressure cuff, and a smart phone.
88941374|NCT01859286||regular sign out process|
88941375|NCT01859338||MRI, CBCT, FBCT|Patients undergo MRI and fan beam CT (FBCT) at baseline, within the first 3 weeks of radiotherapy and between week 4 and 6 of radiotherapy. Patients with lung cancer may undergo 4D cone beam x-ray CT (CBCT) on the same day as the second and third MRI and FBCT.
88941376|NCT01859351|Experimental|WX-037|PI3K inhibitor
88941377|NCT01859351|Experimental|WX-037 in combination with WX-554|PI3K inhibitor in combination with MEK inhibitor
88941378|NCT01859377|Other|Sequence 1|Test Drug (V0498 - A mg) - Reference (Ibuprofen)
88941379|NCT01859377|Other|Sequence 2|Reference (Ibuprofen) - Test drug(V0498 - A mg)
88941380|NCT01859416|Experimental|Oral nutritional supplement|2 * 125 mL low volume, energy and nutrient dense ONS per day (2 * 300 kcal) in addition to usual nutritional care
88941381|NCT01859416|No Intervention|Control|Usual nutritional care
88941382|NCT01859429|Experimental|Stepped Care|Structured stepped requirement of psychosocial support
88941383|NCT01859429|No Intervention|Care as usual|Unstructured requirement of psychosocial support
89501837|NCT03167931|Experimental|50-85 years group|Participants undergo 2 sessions of MRI + transcranial Magnetic Stimulation or transcranial electric stimulation + electroencephalogram. The 2 sessions are performed with an interval of 3 to 7 days.
88941384|NCT01859442|Active Comparator|Exercise group|6 week structured responsive interval exercise training programme
88941385|NCT01859442|Sham Comparator|Control group|Negative, unsupervised, out of hospital control group
88941386|NCT01859455|Experimental|Patient: LGT209 50 mg|50 mg LGT209 subcutaneous (SC) (1 mL injection x 1 site) in statin patients
89201512|NCT00987688|No Intervention|Normothermia|Standard management
88941387|NCT01859455|Experimental|Patient: LGT209 300 mg|300 mg LGT209 subcutaneous (SC) (1 mL injection x 2 sites) in statin patients
88941388|NCT01859455|Experimental|Healthy Volunteers: LGT209 300 mg|300 mg LGT209 or placebo subcutaneous (SC) (1 mL injection x 2 sites) in healthy volunteers
88941389|NCT01859455|Placebo Comparator|Patient: Placebo|matching placebo subcutaneous (SC) of LGT209 50 mg or 300 mg in statin patients
88941390|NCT01859455|Placebo Comparator|Healthy volunteers: Placebo|matching placebo subcutaneous (SC) of LGT209 300 mg in healthy volunteers
88941391|NCT01859468|Experimental|Amorphous calcium carbonate|200 mg elemental calcium tablets, 2 in the morning and 2 in the evening, after a meal
88941392|NCT01859468|Placebo Comparator|StarLac|Tablets containing 300 mg StarLac (starch cellulose and lactose blend) to be used as placebo, 2 tablets in the morning and 2 tablets in the evening, after a meal.
88941393|NCT01859481|Placebo Comparator|Placebo|
88941394|NCT01859481|Experimental|Eletriptan HBr 40 mg|
88941395|NCT01859481|Experimental|Eletriptan HBr 80 mg|
88941396|NCT01859520|Experimental|Swim up, density gradient|swim-up and density gradient sperm preparation techniques in male factor infertility and unexplained infertility groups
88941397|NCT01859533|Experimental|Neopuff group|includes 34 newborns showing signs of TTN who received CPAP (5 cm of H2O) via T- piece (Neopuff; Fisher and Paykel Healthcare, Auckland, New Zealand).
88941398|NCT01859533|No Intervention|Control group|includes 30 newborns who will receive nasal prong oxygen treatment; standard care according to Siva Subramanian et al. (2010).
89458870|NCT02678390|Experimental|Healthy women|"Arm: Evaluation of MCT, aerobic exercise alone and MCT+ aerobic exercise on glucose/ketone/lipid/insulin metabolism in 4-hour visits with repeated blood sampling.~Interventions:~A control day with no MCT and no aerobic exercise.~A 5 day consecutive MCT intake of 30 g/day.~30 minutes of aerobic exercise at 70% to 80% HRR of intensity.~A 5 day consecutive MCT intake of 30 g/day in combination with 30 minutes of aerobic exercise (70% to 80% HRR)/ day for the five days."
89458871|NCT02678390|Experimental|Women with prediabetes|"Arm: Evaluation of MCT, aerobic exercise alone and MCT+ aerobic exercise on glucose/ketone/lipid/insulin metabolism in 4-hour visits with repeated blood sampling.~Interventions:~A control day with no MCT and no aerobic exercise.~A 5 day consecutive MCT intake of 30 g/day.~30 minutes of aerobic exercise at 70% to 80% HRR of intensity.~A 5 day consecutive MCT intake of 30 g/day in combination with 30 minutes of aerobic exercise (70% to 80% HRR)/ day for the five days."
89458872|NCT03694067||Androgenetic alopecia patients|Two 1 mm scalp punch skin biopsy will be taken per patient
89458873|NCT05553236|Experimental|Sequencing Intervention in addition to standard of care|Batched targeted deep sequencing in addition to the locally accepted standard of care drug susceptibility determination of multidrug/extensively drug-resistant tuberculosis (M/XDR-TB)
89458874|NCT05553236|No Intervention|Standard of Care|Locally accepted standard of care which is consistent with the WHO recommendations for the drug susceptibility determination of M/XDR-TB
89458875|NCT03698981|Experimental|Mothers Moving towards Empowerment (MME)|The MME intervention arm will complete our 8-session intervention, weekly for 60-70 minutes per session. Homework will be assigned each week and reviewed the next session. Certificates will be issued to participants who complete the intervention. Fidelity assessments for each session will be evaluated by local research personnel.
89458876|NCT03698981|No Intervention|Treatment As Usual (TAU)|Control condition participants will receive Treatment as usual (TAU), including using free ART and antenatal services as they wish. Control condition participants are assessed on all 'Primary outcomes' at the same time points as the MME intervention group.
89458877|NCT03027557|Experimental|Combined treatment.|20 subjects will be treated with combined 60mg denosumab bi-annually , 30 mg cinacalcet daily and 50 micrograms vitamin-D daily.
89458878|NCT03027557|Active Comparator|Monotherapy|20 subjects will receive 60mg denosumab bi-annually, placebo and 50 micrograms vitamin-D daily.
89458879|NCT03027557|Placebo Comparator|Placebo|20 subjects will receive a saline injection bi-annually (blinded), placebo-tablets and 50 micrograms vitamin-D daily.
89458880|NCT03162068||Control group|Cases are recruited thanks to advertisement within CHU.
89458881|NCT03162068||Post menopausal women|Post-menopausal women are recruited within rheumatology service.
89458882|NCT03162068||Cushing' syndrome group|Cushing' syndrome patients are recruited during hospitalisation in endocrinology service
89458883|NCT03162146||Patient admitted to intensive care unit|All patients requiring intensive care unit stay
89458884|NCT03698903|Experimental|Take a STAND 4 Health: Immediate|Receives the coaching calls + mHealth intervention first, then receives only the mHealth intervention after the 4 week assessment.
89458885|NCT03698903|Active Comparator|Take a STAND 4 Health: Delayed|Will receive no intervention for the first 4 weeks but then after assessment will be provided the opportunity to receive the full coaching calls + mHealth intervention.
89458886|NCT03698825|Experimental|Dose Escalation of TEW-7197|TEW-7191 will be given twice daily (BID) for 5 days followed by 2 days off with a cycle of 4 weeks
89201513|NCT05277597|Experimental|The group (ET+S )|Participants exercised 60 minutes, 3 times per week, on a bicycle ergometer followed by a 30-minute dry Finish sauna treatment.
89458887|NCT03691181|Experimental|Open Ambulatory Ventilation|"monitoring with the use of the Life2000 Open Ventilation System for a period of six months with measures of nutrition, feeling of breathlessness, exercise tolerance, and quality of life.~BODE Index B - BMI - BMI stands for body mass index, a calculation made by comparing height vs weight.~O - Airway obstruction - Airway obstruction is measured by evaluating FEV1 - the amount of air that can be forcefully exhaled in 1 second after a deep breath.~D - Dyspnea - Dyspnea refers to the degree of breathlessness someone experiences while living with COPD.~E - Exercise tolerance - Exercise testing refers to how well some does on a 6-minute walk test.~Modified Medical Research Council Dyspnea Scale"
89458888|NCT03029585|Experimental|NanoPac® 100 mg/m2|Intraperitoneal NanoPac® 100 mg/m2 applied immediately post-cytoreductive surgery, followed by standard of care intravenous chemotherapy.
89458889|NCT03029585|Experimental|NanoPac® 200 mg/m2|Intraperitoneal NanoPac® 200 mg/m2 applied immediately post-cytoreductive surgery, followed by standard of care intravenous chemotherapy.
89458890|NCT03029585|Experimental|NanoPac® 300 mg/m2|Intraperitoneal NanoPac® 300 mg/m2 applied immediately post-cytoreductive surgery, followed by standard of care intravenous chemotherapy.
89458891|NCT03029585|Experimental|NanoPac® 400 mg/m2|Intraperitoneal NanoPac® 400 mg/m2 applied immediately post-cytoreductive surgery, followed by standard of care intravenous chemotherapy.
89458892|NCT03029585|Active Comparator|Standard of Care Intravenous Chemotherapy|Standard of care intravenous chemotherapy (with platinum and taxane agents) administered per institutional standards.
89458893|NCT04295135|Experimental|OneSheet access|Clinics or providers who receive access to, and training in the Chronic Pain OneSheet, and use it while caring for patients with chronic pain.
89458894|NCT04295135|No Intervention|Normal practice|Clinics or providers who do not receive access to, or training in the Chronic Pain OneSheet, and care for patients with chronic pain as they would normally.
89458895|NCT03691025||RALPD|
89458896|NCT03624179||Rheumatoid arthritis patients|complete blood count, Erythrocyte sedimentation rate, C reactive protien ,rheumatoid factor,Anti cyclic citrullinated peptide antibody
88941399|NCT01859546|No Intervention|One time standard verbal counseling|The control group will receive one time standard verbal counseling at the time of initial visit related to EPI vaccination
88941400|NCT01859546|Experimental|SMS Reminders|Short message service (SMS) - SMS reminders for EPI vaccination at 6, 10 and 14 weeks of life sent in the week that these vaccines are due
88941401|NCT01859559|Experimental|Easy Access|This arm will included emergency department patients that are judged to have easy intravenous access in at least one of the upper extremities by the ED technician.
88941402|NCT01859559|Experimental|Difficult Access By Clinician Judgment|This arm will include patients that at least one vein is visible or palpable in one of the upper extremities but either the ED technician and/or ED nurse judges the patient to have difficult intravenous access.
88941403|NCT01859559|Experimental|Non visible and Non palpable|This arm will include patients for whom neither the ED technician nor an ED nurse can identify a visible or palpable vein that is suitable for an intravenous access line in either upper extremity.
89458897|NCT03624179||healthy control|complete blood count, Erythrocyte sedimentation rate, C reactive protien ,rheumatoid factor,Anti cyclic citrullinated peptide antibody
89458898|NCT03698747||mTBI Study Group with McDESPOT sequence|Study group (30 subjects) of football players diagnosed with mTBI (scan at diagnosis, 3-month follow-up scan, genetic screening, concussion assessment at both interaction)
89458899|NCT03698747||Control Group|Control group (30 subjects) of age match non-contact sport players (scan, genetic testing, concussion assessment)
88941404|NCT01859585|Experimental|Parecoxib|Parecoxib
88941405|NCT01859585|Experimental|Ketorolac|Ketorolac
88941406|NCT01859585|No Intervention|No medication|No medication
88941407|NCT01859624|Experimental|Albuterol|This study includes the off-label administration of oral albuterol (4 mg pill) and tracking the effect of motor function at two additional visits, 6 and 12 weeks following the initiation of the study drug. The initial dose of albuterol will be a 4 mg daily for the first 6 weeks. If the 4 mg is well tolerated, the dose will be increased to 8 mg at the 6 week visit.
88941408|NCT01859650||NSCLC patients undergoing RT|
88941409|NCT01859689|Experimental|Treatment (image-guided HDR brachytherapy)|Patients undergo 3 fractions of image-guided HDR brachytherapy over 2 days.
89201514|NCT05277597|Active Comparator|The group (ET)|Participants exercised 60 minutes, 3 times per week
89458900|NCT02678000|Experimental|LHW090|"For Part 1, patients will receive 3 doses of LHW090 once daily with escalating doses every 4 days for a total 12 days of treatment.~For Part 2, patients will receive LHW090 once daily for 4 weeks."
89458901|NCT02678000|Placebo Comparator|Placebo|For Part 1, patients will receive matching placebo once daily for 12 days. For Part 2, patients will receive matching placebo once daily for 4 weeks.
89458902|NCT05495438||ICU Clinicians|
89458903|NCT02691572|Active Comparator|Wound Infiltration|Cesarean delivery performed under spinal anesthesia (intrathecal bupivacaine 12.5 mg and intrathecal fentanyl 15 µg). At the end of surgery, 30 mL bupivacaine 0.25% will be injected subcutaneously in the surgical wound (15 mL on the upper and lower sides) by the obstetrician before skin suturing. Sham procedure will be performed after surgery. Standard analgesia (ketorolac and paracetamol) and fentanyl patient-controlled analgesia will be administered postoperatively.
89458904|NCT02691572|Experimental|Transversus abdominis plane block|Cesarean delivery performed under spinal anesthesia (intrathecal bupivacaine 12.5 mg and intrathecal fentanyl 15 µg). After completion of surgery, bilateral ultrasound-guided TAP block will be performed using 20 mL bupivacaine 0.25% on each side. Standard analgesia (ketorolac and paracetamol) and fentanyl patient-controlled analgesia will be administered postoperatively.
89458905|NCT03688217|Experimental|Philani Intervention Model+MOVIE (PIM+M)|Participants will receive the standard PIM perinatal home visiting program together with the MOVIE intervention (13 entertainment-education videos about infant feeding). The PIM is a structured program of antenatal and postnatal home-visits covering foundational health promotion topics including nutrition in pregnancy, infant feeding, newborn care and maternal mental health among others. The MOVIE videos will be integrated into the regular home visiting program.
89458906|NCT03688217|Active Comparator|Philani Intervention Model (PIM)|Participants will receive the standard PIM perinatal home visiting program, which is a structured program of antenatal and postnatal home-visits covering foundational health promotion topics including nutrition in pregnancy, infant feeding, newborn care and maternal mental health among others.
89458907|NCT05320172|Experimental|Treatment group|Participants with persistent epithelial defects will be treated with autologous platelet rich plasma eye drops.
89458908|NCT03693911|Experimental|Prevention group|AcceptME- digital gamified Acceptance and Commitment Therapy prevention program
89458909|NCT03693911|No Intervention|Waitlist control|Waitlist control group
89458910|NCT03693833|Experimental|Intervention|10mg Cannabidiol (CBD) tablets once daily for the first two weeks increasing to twice daily for week 3 and 4 if adequate analgesic effect is not attained at week 5 then the dose can be increased to 10mg thrice daily from week 5 and onward.
89458911|NCT03693833|Placebo Comparator|Placebo|10mg Placebo Oral tablets once daily for the first two weeks increasing to twice daily for week 3 and 4 if adequate analgesic effect is not attained at week 5 then the dose can be increased to 10mg thrice daily from week 5 and onward.
89458912|NCT03693755|Active Comparator|In-plane Group|In this Group the femoral nerve catheter will be placed with the in-plane technique.
89458913|NCT03693755|Active Comparator|Out-of-plane Group|In this Group the femoral nerve catheter will be placed with the out-of-plane technique.
89458914|NCT03693599|Experimental|carbetocin|600 women received single 100 µg IV dose of carbetocin diluted in 10 ml of Ringer's lactate solution (Pabal, Ferring Pharmaceuticals Ltd, West Drayton, UK).
89458915|NCT03693599|Active Comparator|Syntometrine|600 women received one ampoule of syntometrine (Novartis, Basel, Switzerland), which consisted of 5 IU of oxytocin and 500 micrograms of ergometrine diluted in 10 ml of Ringer's lactate solution and was administered intravenously over 2 minutes
89458916|NCT04277663|Experimental|IBI310 + IBI308|Participants will be treated with IBI310 in combination with IBI308
88941410|NCT01859728|Experimental|IP (irinotecan and cisplatin)|Irinotecan 65mg/m² D1 and D8 q21 days plus Cisplatin 60mg/m² D1 q 21 days, until disease progression or unacceptable toxicity, with standard hydration and antiemetics.
89201515|NCT00907413|Experimental|ERCP and PDT|Endoscopic Retrograde Cholangio Pancreatography (ERCP) and stenting combined with Photodynamic Dynamic Therapy ERCP and PDT
89458917|NCT04277663|Experimental|IBI308|Participants will be treated with IBI308
89458918|NCT04277663|Active Comparator|high-dose recombinant interferon a-2B|Participants will be treated with recombinant interferon a-2B
89458919|NCT03693209|Experimental|General trigger|"VHS with one general trigger: If I am getting angry... and 10 strategies (e.g. Then I will take deep breaths). Participants are instructed to link trigger with strategies."
89458920|NCT03693209|Experimental|Specific triggers|"VHS with a list of 10 specific situations that can act as anger triggers (e.g. If I am getting angry when people act like they know it all) and 10 strategies. Participants are instructed to link triggers with strategies."
89458921|NCT03693209|No Intervention|Control|List of 10 specific situations that can act as anger triggers and 10 strategies. Participants are instructed to select most encountered triggers and most useful strategies.
89458922|NCT04270643|Experimental|Vitamin D|Two oral doses of 5 mg (200,000 international units) vitamin D3 in 1 ml ethyl oleate, given at baseline and two weeks thereafter
89458923|NCT04270643|Placebo Comparator|Placebo|Two oral doses of 1 ml ethyl oleate
89458924|NCT03693131|Experimental|MND-2119 2 g|MND-2119 2 g, orally, once daily after breakfast for 12 weeks.
88941411|NCT01859728|Active Comparator|GC (gemcitabine and cisplatin)|Gemcitabine 1000mg/m² D1 and D8 every 21 days plus cisplatin 25mg/m² D1 and D8 every 21 days, until disease progression or unacceptable toxicity, with standard hydration and antiemetics.
88941412|NCT01859754||Octagam 5%|Primary Immune Deficiency Syndrome patients receiving Octagam 5% by infusion who have been treated with a marketed IVIG product for at least 6 months.
88941413|NCT01859754||Other marketed IVIG product|Primary Immune Deficiency Syndrome patients receiving marketed IVIG product other than Octagam 5% by infusion as treatment for at least 6 months.
88941414|NCT01859767|Experimental|[123I]MNI-672 SPECT|[123I]MNI-672 single photon emission tomography (SPECT)imaging
88941415|NCT01859780|Experimental|Prescription packages (vials and blisters)|"Stage I Prescription vials and wallets (packaging) with three levels of distractor placement (hidden, absent and obvious) will be tested for an effect of placement on selection behavior and time to package selection.~Stage II Prescription vials and wallets (packaging) with and without distractors will be tested for an effect on time to open and number of successful openings."
89458925|NCT03693131|Experimental|MND-2119 4 g|MND-2119 4 g, orally, once daily after breakfast for 12 weeks.
89458926|NCT03693131|Active Comparator|EPADEL CAPSULES 300 1.8 g|EPADEL CAPSULES 300 0.9 g, orally, twice daily after breakfast and dinner for 12 weeks.
89458927|NCT03693131|Active Comparator|EPADEL CAPSULES 300 2.7 g|EPADEL CAPSULES 300 0.9 g, orally, three-times daily after each meal for 12 weeks.
89458928|NCT03687983|Experimental|Intervention arm|Participants will be treated with GoldenFlow Peripheral Stent System.
89458929|NCT02677844|Experimental|Abemaciclib|200 - 600 mg single increasing oral dose of abemaciclib on Day 1 of up to 3 study periods.
89458930|NCT02677844|Placebo Comparator|Placebo|Single oral dose of placebo on Day 1 of 1 study period.
89458931|NCT02677844|Active Comparator|Loperamide|Cohort 2, only. 8 mg Loperamide given orally once in 1 of 4 study periods.
89458932|NCT02677844|Experimental|Loperamide + Abemaciclib|Cohort 2, only. 8 mg Loperamide co-administered with abemaciclib given orally once in up to 1 of 4 study periods.
89458933|NCT02677844|Active Comparator|Loperamide + Placebo|Cohort 2, only. 8 mg Loperamide co-administered with placebo given orally once in up to 1 of 4 study periods.
89458934|NCT03687905||Lupus nephritis III or IV/chloroquine|receiving chloroquine with daily dose 5 mg/kg
89458935|NCT03687905||Lupus nephritis III or IV/hydroxychloroquine|receiving hydroxycholorquine with daily dose 5 mg/kg
89458936|NCT03687905||Systemic lupus erythematosus|not received hydroxychloroquine nor chloroquine .
89458937|NCT03687749||Women with breast cancer-related lymphedema|Individuals with upper limb lymphedema developed after breast cancer treatment
89458938|NCT03687749||Healthy control subjects|Healthy individuals without breast cancer-related lymphoedema.
89458939|NCT03687515|Experimental|budesonide inhalation suspension|
89458940|NCT03687515|Active Comparator|budesonide aqueous nasal spray|
89458941|NCT03687515|Active Comparator|oral steroids|
89458942|NCT03164876|Experimental|Dose AUT00206 800 mg BD|AUT00206 800mg twice daily for 28 days
89458943|NCT03164876|Placebo Comparator|Placebo|Placebo to match AUT00206 twice daily for 28 days
89458944|NCT03690713||Patient and Vessels underwent physiologic evaluation|The total 1397 patients (1694 vessels) which evaluated using pressure-temperature sensor wire and measured FFR, CFR, and IMR.
89458945|NCT03687281||Male patients living with HIV and having sex with men|Male patients living with HIV and having sex with men followed at Universitary Hospital Center of Reunion Island
89458946|NCT03682913|Experimental|P-CIT protocol|OCD patients who receive the P-CIT intervention.
89458947|NCT03682913|Placebo Comparator|Placebo|OCD patients who don't receive the P-CIT intervention.
89458948|NCT03682835|Placebo Comparator|Placebo treatment arm|Placebo: 2 capsules per dose, 2 doses per study day.
89458949|NCT03682835|Experimental|POCO treatment arm|FDGard Capsule containing a combination of peppermint oil (41,5mg) and caraway oil (50mg); 2 capsules per dose, 2 doses per study day.
89458950|NCT02691494|Placebo Comparator|Placebo|Placebo for both elagolix twice daily (BID) and norethindrone acetate (E2/ NETA) once daily (QD)
89458951|NCT02691494|Experimental|Elagolix|Elagolix 300 mg BID and placebo for E2/NETA (estradiol 1.0 mg/norethindrone acetate 0.5 mg) QD
89458952|NCT02691494|Experimental|Elagolix + E2/NETA|Elagolix 300 mg BID and E2/NETA (estradiol 1.0 mg/norethindrone acetate 0.5 mg) QD
89458953|NCT03624335|Experimental|Group 1: ECC|"In the ECC group, the cord was clamped immediately after delivery, before the first minute of life.~Blood test 6hours after clamping Blood test 24hours after clamping Blood test 48hours after clamping Blood test 28days after clamping"
89458954|NCT03624335|Experimental|Group 2: DCC|In the DCC group, the cord was clamped when it stops beating. Blood test 6hours after clamping Blood test 24hours after clamping Blood test 48hours after clamping Blood test 28days after clamping
89458955|NCT02677220|Experimental|Surgical|Subjects to be implanted with the CI532 cochlear implant in one ear
89458956|NCT03972449|Experimental|Beatboxing: BEAT-Speech|
89458957|NCT03972449|Experimental|Traditional Articulation Approach|
89458958|NCT02682602||Diseased Hip|Subjects will have a diseased hip which requires replacement, which will be implanted with either DePuy Synthes Summit/Pinnacle total hip arthroplasty (THA) or the Corail/Pinnacle THA.
89458959|NCT02682602||Normal Hip|Subjects will have a normal hip.
89458960|NCT02682602||Implanted Group|All subjects from the Diseased Hip group were implanted with either DePuy Synthes Summit/Pinnacle total hip arthroplasty (THA) or the Corail/Pinnacle THA
89458961|NCT03959111|Experimental|Ear stimulation (Location 1)|
89458962|NCT03959111|Experimental|Ear stimulation (Location 2)|
89458963|NCT03803657||Neonates|Neonates 0-28 days
89458964|NCT03803657||Infant|29 days to 1 year
89458965|NCT03803657||Child|>1 year and <10 kg
89458966|NCT03690635|Experimental|VISTA technique|evolution of a newer approach known as Vestibular Incision Subperiosteal Tunnel Access (VISTA) was proposed to avoid some of the potential complications occurring with other intrasulcular tunneling techniques
89458967|NCT03690635|Active Comparator|tunneling technique|Several modifications of tunnel technique have been described in order to preserve esthetics, avoid relapse of gingival recession and maintain papillary integrity. These modifications also attend to avoid scar formation and delayed healing related to vertical releasing incision
89458968|NCT03691337|Active Comparator|Low dosis bupivacaine|Preoperative fascia iliaca block with Marcaine 0.25% (0.11 mL x subject height)
89458969|NCT03691337|Active Comparator|High dosis bupivacaine|Preoperative fascia iliaca block with Marcaine 0.25% (0.22 mL x subject height)
89458970|NCT03691337|Placebo Comparator|Placebo|Preoperative fascia iliaca block with Sodium Chloride 0.9% (0.11 mL x subject height)
89458971|NCT03682445|Active Comparator|High intensity interval exercise|Participants with type 2 Diabetes mellitus in High intensity interval exercise (HIIE) group will make aerobic exercise using bicycle at high intensity followed by low intensity periods under observation in the hospital.
89458972|NCT03682445|Active Comparator|Moderate intensity continuous exercise|Participants with type 2 Diabetes mellitus in Moderate intensity continuous exercise (MIC) group will make aerobic exercise using bicycle at moderate intensity during the session under observation in the hospital.
89458973|NCT03682445|No Intervention|Control group|The participants in the control group will make stretching exercise at home
89458974|NCT03164642|Experimental|LENA with Feedback|Mothers who will run the LENA system with their young children, AND who will receive feedback from their service providers on how to enhance the language the home language environment.
89458975|NCT03164642|Placebo Comparator|LENA no feedback|Mothers who will only run the LENA system with their young children. These mothers will NOT receive feedback from their service providers on how to enhance the language the home language environment.
89458976|NCT03690479|Active Comparator|Ball Tip Probe|One half (upper or lower jaw) of the mouth will be probed using the new trial tip (ball-end probe, 0.6mm diameter).
89458977|NCT03690479|Active Comparator|Florida Probe Straight Tip Probe|One half (upper or lower jaw) of the mouth will be probed using the current, standard probe tip (straight-end probe, 0.45mm diameter).
89458978|NCT02681510|Experimental|Three drug intervention|varenicline, nicotine patch and nicotine lozenge for 12 weeks
89458979|NCT03690323|Experimental|RFA|"RFA: laparotomy is performed followed by radiofrequency ablation of the tumor.~After recovery of the RFA patients will continue chemotherapy:~FOLFIRINOX or nab-paclitaxel + gemcitabine or gemcitabine monotherapy"
89458980|NCT03690323|Active Comparator|Chemotherapy|"Patients will continue chemotherapy:~FOLFIRINOX or nab-paclitaxel plus gemcitabine or gemcitabine monotherapy"
88941416|NCT01859806|Active Comparator|Pancreaticogastrostomy group|Standard PD with regional lymphadenectomy was performed. PG was done between pancreatic stump and posterior surface of the stomach with 2 layer interrupted anastomosis,and duct to mucosa.
89458981|NCT03682211|Experimental|Active Intranasal Fentanyl|Subjects will receive 50 μg/ml intranasal fentanyl citrate and a placebo matched to intravenous morphine (1 ml water for injection) at time 0
89458982|NCT03682211|Active Comparator|Active IV Morphine|Subjects will receive 10 mg/ml intravenous morphine sulphate and a placebo matched to intranasal fentanyl (2 ml water)
89458983|NCT03690245|Active Comparator|Control|Infants will have immediate cord clamping and respiratory support afterwards
89201516|NCT00907413|Active Comparator|ERCP alone|Endoscopic Retrograde Cholangio Pancreatography (ERCP) with stenting alone
89458984|NCT03690245|Experimental|Initiation of Resuscitation While Attached to the Cord|Infants will receive respiratory support for 120 seconds while attached to the cord.
89458985|NCT03686735||Satisfaction measure 1|25% of the cohort
89458986|NCT03686735||Satisfaction measure 2|25% of the cohort
89458987|NCT03686735||Satisfaction measure 3|25% of the cohort
89458988|NCT03686735||Satisfaction measure 4|25% of the cohort
89458989|NCT03682133||Prehabilitation|The care as given in a participating hospital is according to the local guideline and will not be changed for this study. Whether prehabilitation is applied in a participating hospital is based on a predefined definition of oncological surgical prehabilitation.
89458990|NCT03682133||Usual care|Guideline based colon cancer surgery, without prehabilitation.
89458991|NCT03681899||Subjects aged of 65 years or older|Subjects aged of 65 years or older, taking at least one oral medication for two weeks or more.
89458992|NCT02690714|Experimental|6.6 mg/kg Plasminogen (Human) Intravenous|6.6 mg/kg Plasminogen (Human) Intravenous given every 2 to 4 days by a 10- to 30-minute intravenous infusion
89458993|NCT04769726|Experimental|treatment|premeal load of almonds
89458994|NCT04769726|No Intervention|control|standard diet
89458995|NCT03165812|Experimental|SADJB-SG group|Patients in this group will undergo bariatric surgery. There are two parts to this procedure. One is the restrictive type of weight loss surgery, which reduces the stomach size. The other type prevents the body from absorbing fats and sugar properly, as the small intestine will be attached to the small stomach, bypassing most of the stomach and upper part of the small intestine. This surgery will be performed using a minimally invasive technique known as laparoscopic keyhole surgery.
89458996|NCT03165812|Experimental|IMT group|Patients in this group will be subjected to strict adherence to diet, optimisation of diabetic medications and close monitoring of blood glucose and HbA1c.
89458997|NCT03690167|Active Comparator|Concentrated Growth Factor (CGF)|Participants with impacted lower third molar
89458998|NCT03690167|Active Comparator|Advanced Platelet Rich Fibrin (A-PRF)|Participants with impacted lower third molar
89458999|NCT03690167|Sham Comparator|Control|Participants with impacted lower third molar
88941417|NCT01859806|Active Comparator|Isolated Roux PJ group|Isolated Roux PJ group, reconstruction was begun using the transected jejunum and ,which was anastomosed in end to side fashion. A separate Roux loop was performed for HJ, by dividing the jejunum about 40 cm beyond the pancreatic anastomosis and GJ was done in this loop (30 cm caudally from HJ). The PJ loop was anastomosed to the main loop (20 cm caudal to GJ).
89201517|NCT00330343|Experimental|Naloxone|continuous infusion of naloxone administered in escalating dosing from 0.05 mcg/kg/hr to 1.65 mcg/kg/hour
89201518|NCT00987766|Experimental|Treatment|Gemcitabine + Oxaliplatin + Erlotinib
89459000|NCT03686579||chest trauma|"Early detection and diagnosis of associated thoracic injuries .~decrease of costs required for investigations . 3- sensitivity and specificity of the investigations"
89459001|NCT03686501|Experimental|PF-06412562|To assess the D1 receptor occupancy (D1 RO) in striatum after a single oral administration of PF-06412562.
89459002|NCT03681821|Experimental|The intervention group|Patients in the intervention group receiving the follow-up TTM-based intervention sessions.
89459003|NCT03681821|No Intervention|The control group|No interventions except conventional care were performed for the control group.
89459004|NCT03164330|No Intervention|Control|The control group takes a baseline survey, and thereafter has minimal interaction with the project, until a follow-up biometric screening is conducted during the one-year follow-up.
89459005|NCT03164330|Experimental|A25|"Group A25 is offered no compensation for completing a biometric screening and HRA, and low compensation for each completed wellness course in the fall or spring of the study.~Interventions: Workplace Wellness Program, Biometric Screening/HRA - No compensation, Wellness Activities - low compensation"
89201519|NCT00984412|Experimental|AATT|
89201520|NCT00330187|Experimental|Bupropion SR + Contingency Management|Bupropion SR capsules, with goal dose of 300 mg/day, for 6 weeks of treatment. Contingency Management, with escalating rewards for abstinence (and re-sets for non-abstinence) at twice-weekly visits.
89201521|NCT00330187|Active Comparator|Placebo + Contingency Management|Placebo capsules, matched in appearance to Bupropion SR capsules, for 6 weeks of treatment. Contingency Management, with escalating rewards for abstinence (and re-sets for non-abstinence) at twice-weekly visits.
89459006|NCT03164330|Experimental|A75|"Group A75 is offered no compensation for completing a biometric screening and HRA, and high compensation for each completed wellness course in the fall or spring of the study.~Interventions: Workplace Wellness Program, Biometric Screening/HRA - No compensation, Wellness Activities - high compensation"
89459007|NCT03164330|Experimental|B25|"Group B25 is offered moderate compensation for completing a biometric screening and HRA, and low compensation for each completed wellness course in the fall or spring of the study.~Interventions: Workplace Wellness Program, Biometric Screening/HRA - moderate compensation, Wellness Activities - high compensation"
89459008|NCT03164330|Experimental|B75|"Group B75 is offered moderate compensation for completing a biometric screening and HRA, and high compensation for each completed wellness course in the fall or spring of the study.~Interventions: Workplace Wellness Program, Biometric Screening/HRA - moderate compensation, Wellness Activities - high compensation"
89501838|NCT05497622|Experimental|Healthy participants|Non-invasive quantitative ultrasound (B-mode image, ultrasound elastography), EMG, and osteopathic assessment (TART assessments) will be performed on the upper trapezius muscle in healthy participants one time at the time of the enrollment.
89459009|NCT03164330|Experimental|C25|"Group C25 is offered high compensation for completing a biometric screening and HRA, and low compensation for each completed wellness course in the fall or spring of the study.~Interventions: Workplace Wellness Program, Biometric Screening/HRA - high compensation, Wellness Activities - high compensation"
89459010|NCT03164330|Experimental|C75|"Group C75 is offered high compensation for completing a biometric screening and HRA, and high compensation for each completed wellness course in the fall or spring of the study.~Interventions: Workplace Wellness Program, Biometric Screening/HRA - high compensation Wellness Activities - high compensation"
89459011|NCT03681743|Experimental|Virtual Reality|Participants are distracted by wearing the virtual reality headset and watching a roller coaster app during an IV start.
89459012|NCT03681743|No Intervention|Control (Standard-of-Care)|Participants are distracted with Standard-of-Care by doctors and/or parents.
89459013|NCT03681665||Abscess|Patients group with abdominal abscess
89459014|NCT03165890|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m
89459015|NCT03165890|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m.
89459016|NCT03689933|Experimental|root analog implant|The tooth indicated for extraction will be extracted atraumatically using periotome, socket preservation using Iodoform packing strips, and then optical scanning of the remaining tooth structure with optical scanner will be made to obtain a 3D virtual model, this model will be modified by addition of macro-retentions strictly to the interdental area to avoid any fracture in thin cortical bone, the cervical portion of implant circumference will be decreased by 0.1 to 0.2 mm to avoid pressure resorption of alveolar crest of bone and addition of prepared crown stump for the future crown to be placed.
89459017|NCT03689933|Active Comparator|conventional stock root-form titanium implant|Using a conventional implant as a comparator as it's the gold stander in restoring the non-restorable teeth.
89459018|NCT05228990|Experimental|Warm acupuncture - observation group|"Sequence A: Participants will receive warm acupuncture for 20 minutes twice a week for eight weeks.~Sequence B: Patients will be observed without any intervention for eight weeks."
89459019|NCT05228990|Experimental|Observation - warm acupuncture group|Sequence A: Patients will be observed without any intervention for eight weeks. Sequence B: Participants will receive warm acupuncture for 20 minutes twice a week for eight weeks.
89459020|NCT03115190|Other|General practitioner diagnosis with Heart score|Patients with chest pain who are reviewed by the general practitioner (GP) at the GP cooperation will be evaluated with the Heart score to support the GP with the diagnosis.
89459021|NCT03115190|No Intervention|Triage Nurse education|The general practitioner cooperation employs nurses for (telephone) triage. They are aided by a computer based triage system, the Netherlands triage system (NTS), a 6-level urgency triage system. With this study we aim to educate the nurses in the signs and symptoms of chest pain patients. The training program will aim to educate the triage nurses in acute coronary syndrome, including pathophysiology, symptoms and risk factors. The NTS will be incorporated within the training. The triage nurses will receive a training session by Cardiologists with information about acute coronary syndrome, the symptoms and the risks.
89459022|NCT03115190|No Intervention|Baseline registry as comparison|"All patients referred to the emergency department (ED) with suspected acute coronary syndrome (ACS) will be evaluated. They will receive a questionnaire to evaluate the accuracy of referral and the delays of ACS patients. This will be compared to the registry at baseline. Some patients will either have not contacted the general practitioner cooperation (GPC) at all, or will have been referred to the ED directly through the GPC nurse triage.~The 30 day, 6 months and one year follow-up of all patients will be via medical records, or in case of no or not enough information, by telephone."
89459023|NCT03114800|Experimental|E-Scale|Weight monitoring
89459024|NCT03114956|Experimental|Group A|Implant surface will be wiped with sterile gauze soaked alternatively in sterile saline and CHX (5 times)
89459025|NCT03114956|Experimental|Group B|Titanium brush: Titanium brush (TiBrush, Straumann, Switzerland) mounted on an oscillating hand piece will be used for 1 minute.
89459026|NCT03114956|Experimental|Group C|Air powder abrasion: One minute of air powder abrasion using Glycine prophy powder (Prophy Jet, Dentsply, USA) with overlapping passes form apical to coronal direction for 1 minute.
89459027|NCT03114956|Experimental|Group D|A comprehensive treatment including the use of titanium brush and air powder abrasion (as described above) and 30 seconds etching with 9.6% HF acid gel (Premier, USA) applied with a micro-applicator tip (Unipack Medical, USA), followed by copious irrigation with sterile saline.
89459028|NCT03166046|Active Comparator|Study Group|Subjects will use the active pulsed shortwave therapy device (ActiPatch) as a prophylactic treatment for episodic migraine
89459029|NCT03166046|Placebo Comparator|Control Group|Subjects will use the placebo pulsed shortwave therapy device (Placebo ActiPatch) as a prophylactic treatment for episodic migraine
89459030|NCT03161366|Experimental|Single arm|Vaccination of contacts and contacts of contacts of a confirmed Ebola Zaire case with one dose of rVSVΔG-ZEBOV-GP (≥ 2x10^7 PFU)
89016812|NCT00263198|Experimental|Letrozole + PTK787/ZK222584|"Letrozole 2.5 mg PO daily for 28 days (patients who have already been treated with letrozole for at least 28 days can skip this part)~Start cycle 1 with:~Letrozole 2.5 mg PO once daily~PTK787/ZK222584 250 mg BID PO for 1 week, then 500 mg BID PO for the 2nd week followed by 500 mg qAM and 750 mg QPM PO for the subsequent 2 weeks.~Subsequent cycles:~PTK787/ZK222584 500 mg qAM and 750 mg qPM PO daily~Letrozole 2.5 mg PO once daily"
89016813|NCT00294099|Experimental|2|120 subjects to receive 45 mcg of inactivated influenza A/H5N1 vaccine without aluminum hydroxide.
89459031|NCT03161288|Experimental|Cohorts 1-3|Healthy volunteers will receive single rising doses of KY1005 or placebo
89459032|NCT03161288|Experimental|Cohorts 4-8|Healthy volunteers will receive multiple rising doses of KY1005 or placebo
88941418|NCT01859832||Enrolled participants|"All participants enrolled in this study will have been previously consented to the study entitled, A Comparison of Effects of Standard Dose vs Low Dose Advagraf with Il-2 Receptor Antibody Induction, MMF and Steroids, With or Without ACEi/ARB-based Antihypertensive Therapy on Renal Allograft Histology, Function, and Immune Response. This is an observational study with only one group/cohort in which all participants have bloodwork collected pre-transplant and at various time points post-transplant and these samples are analyzed using the Cylex ImmuKnow Assay."
88941419|NCT01859845|No Intervention|Control Study Arm|The control participants will first interact with the simulated melanoma back model to learn clinical unaided visual inspection skills and then view a passive image projected onto a screen for dermoscopy learning. Remediation of inappropriate clinical decisions will be carried out by the research coordinator and is based on predefined feedback consistent across both arms of the study. Along with the projected images, the coordinator will provide each control participant with worksheets for the clinical Asymmetry, Border, Color, Diameter (ABCD) and Dermoscopy 3-point check list. A copy of the completed worksheet will be made at the end of the workshop.
88941420|NCT01859845|Experimental|smartphone|Each participant in the educational intervention arm will have access to a smartphone with a preloaded android software package. The smartphone software allows the participant to visualize a dermoscopic image of the pigmented lesion at the surface of the simulated melanoma model. Participants are given the freedom to navigate through the program via the smartphone to learn at their own pace with reinforcement of correct clinical management decisions and correction of weaknesses. The software content is limited to the dermoscopy information available to the positive control arm through the coordinator and the dermoscopic images projected onto the screen, thus a comparison of retention rates across both arms is possible.
88941421|NCT01859871|No Intervention|Control Arm|Study participants will take the self-administered pre-test and receive the standard of care. After taking the pre-test, control arm participants will be done with study participation for that day and will attend the transplant center's education sessions. All participants will receive a letter and follow-up call at about two weeks later to schedule the final survey. They will take a final survey via telephone about 3 weeks later. The final survey includes the same topics as the pre-test. They will receive a thank you letter and gift card by mail after completing the final survey.
89201522|NCT00330187|Active Comparator|Bupropion SR + No Contingency Management|Bupropion SR capsules, with goal dose of 300 mg/day, for 6 weeks of treatment. Contingency Management is not provided in this arm.
88941422|NCT01859871|Experimental|Website Intervention|Navigate website plus standard of care
88941423|NCT01859884|Experimental|Inform Me: web-based education tool|Intervention will receive the standard of care, the Inform Me intervention, a post-test evaluation, and 1 week recall test.
88941424|NCT01859884|No Intervention|Control Standard of Care|This group receives standard of care with a post test.
88941425|NCT01859897||Optimal therapy|All subjects will be treated by optimal medical therapy and lifestyle modification.
88941426|NCT01859910|Experimental|compression|compression and scrub of lid margin for 5 circles before cataract surgery
88941427|NCT01859910|Active Comparator|control|no compression or scrub of lid margin
88941428|NCT01859936|Experimental|preoperative breast MRI|The intervention is that preoperative MRI breast will be performed in women under 56 years with newly diagnosed breast cancer
88941429|NCT01859936|No Intervention|no MRI breast|The arm type description implies that no MRI breast will be performed to women under 56 years with newly diagnosed breast cancer
88941430|NCT01860014|Active Comparator|Beractant|Beractant (Survanta): 100 mg/kg-intratracheal, just after pulmonary hemorrhage
88941431|NCT01860014|Active Comparator|Poractant alfa|Poractant alfa (Curosurf): 100 mg/kg-intratracheal, just after pulmonary hemorrhage
88941432|NCT01860053|Experimental|behavioral intervention|
88941433|NCT01860053|No Intervention|no treatment control|
88941434|NCT01860066|Experimental|QVA149|QVA149 study medication kit will contain blister strips and a unique inhaler. Patients will be instructed to inhale their medication twice a day for 12 weeks.
88941435|NCT01860066|Active Comparator|fluticasone/salmeterol|Fluticasone/salmeterol study medication kit will contain an inhaler in the manufacturer's device. Patients will be instructed to inhale their medication twice a day for 12 weeks.
88941436|NCT01860105|Active Comparator|75mg MDCO-157|iv
88941437|NCT01860105|Active Comparator|150mg MDCO-157|iv
88941438|NCT01860105|Active Comparator|300mg MDCO-157|iv
88941439|NCT01860105|Active Comparator|300mg PLAVIX|oral
88941440|NCT01860118||Parkinson's Disease|1) the presence of bradykinesia and either rest tremor or rigidity; 2) asymmetric onset; 3) progressive motor symptoms 4) age at onset 21-99 years.
88941441|NCT01860118||Healthy Control|Healthy controls between ages of 21-99 years and a lack of PD in first-degree blood relatives
88941442|NCT01860131|Active Comparator|Weight Wise Community Modules: Workshops|Groups workshops (10 in total) designed to improve weight management skills and enhance self-efficacy, delivered over 3 months, prior to entering a multidisciplinary bariatric care.
88941443|NCT01860131|Active Comparator|Weight Wise Community Modules: Online|Online modules (13 in total) designed to improve weight management skills and enhance self-efficacy, delivered over 3 months, prior to entering a multidisciplinary bariatric care.
88941444|NCT01860131|No Intervention|Educational Written Materials|"Educational pamphlets about healthy living and tips on self-management strategies.~Delivered by mail 3 months prior to entering a multidisciplinary bariatric care.~This is minimal intervention and considered the control arm."
88941445|NCT01860144||bevacizumab|Patients with metastatic colorectal cancer who accept treatment with chemotherapy and bevacizumab
88941446|NCT01860157|Sham Comparator|Sham H1 Coil|deep rTMS sham treatment
89201523|NCT00330187|Placebo Comparator|Placebo + No Contingency Management|Placebo capsules, matched in appearance to Bupropion SR capsules, for 6 weeks of treatment. Contingency Management is not provided in this arm.
89459033|NCT03681509|Experimental|Pramipexole|Maximum daily dose: 1.0 mg of pramipexole salt
89459034|NCT03681509|Placebo Comparator|Placebo|Lactose
89459035|NCT03686267|Experimental|intervention (I1)|Lithium disilicate crowns over titanium abutments covered by a layer of opaque porcelain
89459036|NCT03686267|Experimental|Intervention (I2)|Lithium disilicate crowns over titanium abutments covered by lithium disilicate (high opacity) coping
89459037|NCT03686267|Active Comparator|Lithium disilicate crowns over uncovered titanium abutments|Lithium disilicate crowns over uncovered titanium abutments directly without masking
89459038|NCT03686189|Experimental|Intervention arm|Participants will be treated with Iliac Bifurcation Stent Graft System
89459039|NCT03686111||infertile patientes with medical assistance to procreation|
89459040|NCT03686111||Infertile patientes with induction of ovulation to give their|
89459041|NCT03685955||Genitourinary Reconstruction with Amniotic Membranes|Patients who undergo genitourinary reconstruction with amniotic membranes
89459042|NCT03164252|Active Comparator|Grupo I- Lower laser fluency|20 patients received 660 nm red laser diode laser therapy, 30 mW power and 10 J / cm2 fluency, in the immediate period after surgical period of the third molar third molar extraction / impacted by the intraoral region
89459043|NCT03164252|Active Comparator|Grupo II- Greater laser fluency|20 patients received 660 nm red laser diode laser therapy, 30 mW power and 30J / cm2 fluency, in the immediate period after surgical of the third molar third molar extraction / impacted by the intraoral region
89459044|NCT03164252|Placebo Comparator|Grupo III- Laser sham|Application of laser sham, the handpiece of the device will be positioned intraorally and activated. However, the tip of the applicator will be covered by an opaque material that prevents radiation from passing through.
89459045|NCT03161210|Experimental|Dextrose Prolotherapy|
89459046|NCT03161210|Active Comparator|Local Anaesthetic|
89459047|NCT03161210|Placebo Comparator|Saline|
89459048|NCT03160976|No Intervention|Control Group|Subjects will only receive the Evaluation Protocol and will be followed for 90 days.
89459049|NCT03160976|Active Comparator|Intervention Group|A single 50 minutes session of cold exposure with a cryolipolysis device. The parameters will be: temperature -10°C and vacuum between 60 Kpas (at beginning) and 40 Kpas (until the end).
88941447|NCT01860157|Active Comparator|Active H1|deep rTMS active treatment
88941448|NCT01860183|Experimental|MMF 3g daily|
88941449|NCT01860183|Active Comparator|MMF 2 g daily|
88941450|NCT01860196|Active Comparator|Treatment-Placebo Group|Treatment on 0 day Placebo at 5th week
88941451|NCT01860196|Active Comparator|Placebo-Treatment Group|Placebo on 0 day Treatment at 5th week
89016814|NCT00294099|Experimental|3|60 subjects to receive 15 mcg of inactivated influenza A/H5N1 vaccine with aluminum hydroxide.
89201524|NCT01056445|Active Comparator|carotid stenting and hemodynamic instability|27 patients undergone carotid stenting
89201525|NCT01056445|Active Comparator|carotid stenting without hemodynamic instability|no hemodynamic instability after carotid stenting
89459050|NCT03164096|Experimental|intrathecal bupivacaine|intrathecal bupivacaine hydrochloride 0.5%,12.5mg
89459051|NCT04480034||Group Pisa|All the bariatric cases (all laparoscopic bariatric procedures) performed during the period July/December 2020 in the unit UOC Chirurgia Bariatrica, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy (Head Prof. Marco Anselmino) will be collected in a prospective database, to monitor the postoperative course.
89459052|NCT04480034||Group Padova|All the bariatric cases (all laparoscopic bariatric procedures) performed during the period July/December 2020 in the unit UOSD Week Surgery, Azienda Ospedaliera, Università di Padova, Italy (Head Dr. Mirto Foletto) will be collected in a prospective database, to monitor the postoperative course.
89459053|NCT04480034||Group Bologna|All the bariatric cases (all laparoscopic bariatric procedures) performed during the period July/December 2020 in the unit Chirurgia Bariatrica, Azienda Ospedaliera Universitaria di Bologna, Italy (Head Dr. Paolo Bernante) will be collected in a prospective database, to monitor the postoperative course.
89459054|NCT04480034||Group Bergamo|All the bariatric cases (all laparoscopic bariatric procedures) performed during the period July/December 2020 in the unit UOC Chirurgia Generale e Oncologica, Policlinico San Marco di Zingonia, Bergamo, Italy (Head Prof. Stefano Olmi) will be collected in a prospective database, to monitor the postoperative course.
89459055|NCT04480034||Group Tor Vergata|All the bariatric cases (all laparoscopic bariatric procedures) performed during the period July/December 2020 in the unit U.O.S.D. Chirurgia Mininvasiva e dell'Apparato Digerente, Università Tor Vergata, Rome, Italy (Head Prof. Paolo Gentileschi) will be collected in a prospective database, to monitor the postoperative course.
89459056|NCT04480034||Group Torino|All the bariatric cases (all laparoscopic bariatric procedures) performed during the period July/December 2020 in the unit Dipartimento di Scienze Chirurgiche, Azienda Ospedaliera Universitaria Citta della Salute e della Scienza, Università di Torino, Italy (Head Prof. Mario Morino) will be collected in a prospective database, to monitor the postoperative course.
88941452|NCT01860209|Experimental|Group A|the first polysomnography (PSG) is performed before hemodialysis (HD), followed by a post-HD PSG on the subsequent night
88941453|NCT01860209|Experimental|Group B|the first PSG is performed after hemodialysis (HD), followed by a pre-HD PSG, on the subsequent night
88941454|NCT01860222|Active Comparator|SR|
88941455|NCT01860222|Experimental|PLAT|
88941456|NCT01860235|Experimental|sextant 1|Treatment with subgingival scaling and root planing was done in 6 weekly sessions, being the sextant 1 in the randomization for experimental procedures (EMLA)
88941457|NCT01860235|Active Comparator|sextant 2|Treatment with subgingival scaling and root planing was done in 6 weekly sessions, being the sextant 1 in the randomization for experimental procedures (Injectable anesthesia)
88941458|NCT01860235|Active Comparator|sextant 3|Treatment with subgingival scaling and root planing was done in 6 weekly sessions, being the sextant 1 in the randomization for experimental procedures (2% Benzocaine)
89201526|NCT04006132|Experimental|Ponto 3 SuperPower sound processor|All patients will be fitted with two bone-anchored sound processors (Ponto 3 SuperPower), unilaterally and bilaterally.
89201527|NCT03986905|Experimental|Scopolamine Nasal Gel|DPI-386 Nasal Gel + placebo patch
89201528|NCT03986905|Placebo Comparator|Placebo|placebo nasal gel + placebo patch
89016815|NCT00294099|Experimental|4|60 subjects to receive 15 mcg of inactivated influenza A/H5N1 vaccine without aluminum hydroxide.
89459057|NCT04480034||Group Milano|All the bariatric cases (all laparoscopic bariatric procedures) performed during the period July/December 2020 in the unit UO di Chirurgia Bariatrica, Humanitas Research Hospital, Rozzano, Milano, Italy (Head Dr. Giuseppe Marinari) will be collected in a prospective database, to monitor the postoperative course.
89459058|NCT04480034||Group Rome|All the bariatric cases (all laparoscopic bariatric procedures) performed during the period July/December 2020 in the unit UOC Chirurgia Generale & Bariatric Center of Excellence IFSO-EC, University La Sapienza of Rome, Italy (Head Prof. Gianfranco Silecchia) will be collected in a prospective database, to monitor the postoperative course.
89459059|NCT03689777|Active Comparator|Glomerular Filtration Rate|
89459060|NCT03163784|Placebo Comparator|Arm A|Weekly placebo (for Fecal Inoculum Capsule) treatment with placebo pre-treatment.
89459061|NCT03163784|Experimental|Arm B|Weekly Fecal Inoculum Capsule treatment with placebo pre-treatment.
89459062|NCT03163784|Experimental|Arm C|Weekly Fecal Inoculum Capsule treatment with antibiotic pre-treatment.
89459063|NCT01791543|Experimental|Intramural Needle Catheter Ablation|Ablation of Ventricular Tachycardia with Intramural Needle Ablation Catheter
89459064|NCT03681431|Experimental|Ceftriaxone 4g/ 24h|Single intravenous dose of Ceftriaxone 4g/ 24h
89459065|NCT03681431|Active Comparator|Ceftriaxone 2g/ 12h|Two intravenous doses of Ceftriaxone 2g/ 12h
89459066|NCT02925455|Experimental|Stimulation + Video Games|Contralaterally-controlled functional electrical stimulation (CCFES) enables patients with upper extremity hemiplegia to open their paretic hand by stimulating finger and thumb extensors with surface electrodes. CCFES is used during functional task practice and hand therapy video games to link motor intent with execution. Four intuitive and engaging games were developed to provide goal-oriented motor skill training, impairment-appropriate difficulty, and performance feedback that motivates iterative play and skill improvement.
89459067|NCT02925455|Active Comparator|Video Games (no stimulation)|Participants receive duration-matched, identical hand therapy video games and task practice therapy as the experiment arm, but do not receive CCFES to assist hand opening.
89459068|NCT01563783|Active Comparator|Woman Suitable for Myomectomy or GFA|This group will consist of women who desire uterine preservation. Women will be randomized 1:1 to GFA or Myomectomy (laparoscopic or abdominal).
89459069|NCT01563783|Active Comparator|Woman Suitable for UAE or GFA|This group will consist of women who desire uterine preservation. Women will be randomized 1:1 to GFA or uterine artery embolization (UAE).
89459070|NCT03689621|Active Comparator|Transcutaneous vagal nerve stimulation (tVNS)|tVNS administered for 4 hours each day and behaviour is recorded.
89459071|NCT03689621|Placebo Comparator|Baseline|tVNS worn but not switched on whilst collecting behavioural data.
89459072|NCT03681197|Active Comparator|Metformin Group|Will receive metformin plus clomiphene citrate
89459073|NCT03681197|Placebo Comparator|Placebo|Will receive placebo plus clomiphene citrate.
89459074|NCT03485703|Experimental|azithromycin group|A control group composed of 40 newborns receiving azithromycin
89459075|NCT03485703|Placebo Comparator|placebo group|comparative group composed of 40 newborns who would receive saline 0.9%
89459076|NCT03165344|Experimental|hydrocortisone group|
89459077|NCT03165344|Placebo Comparator|prednisone grope|
89016816|NCT00294099|Experimental|8|60 subjects to receive 3.75 mcg of inactivated influenza A/H5N1 vaccine without aluminum hydroxide.
89016817|NCT00294099|Experimental|7|60 subjects to receive 3.75 mcg of inactivated influenza A/H5N1 vaccine with aluminum hydroxide.
89016818|NCT00294099|Experimental|1|120 subjects to receive 45 mcg of inactivated influenza A/H5N1 vaccine with aluminum hydroxide.
89016819|NCT00294099|Experimental|5|60 subjects to receive 7.5 mcg of inactivated influenza A/H5N1 vaccine with aluminum hydroxide.
89016820|NCT00294099|Experimental|6|60 subjects to receive 7.5 mcg of inactivated influenza A/H5N1 vaccine without aluminum hydroxide.
89016821|NCT00299676||001|Galantamine (Reminyl) Use of Reminyl according to approved NZ data sheet
89016822|NCT00263276|Experimental|Arm 1|
89016823|NCT00263276|Experimental|Arm 2|
89016824|NCT00263276|Experimental|Arm 3|
89016825|NCT00263276|Experimental|Arm 4|
89016826|NCT00263276|Experimental|Arm 5|
89016827|NCT00263276|Placebo Comparator|Arm 6|
89016828|NCT00263276|Active Comparator|Arm 7|
89016829|NCT00417807|Experimental|Gleevec/Glivec|
89016830|NCT00263393|Other|Algorithm-based care|An algorithm based approach to increase the identification of high-risk individuals in the community through encouraging opportunistic screening, and to increase the use of appropriate evidence based prevention strategies.
89459078|NCT03487029|Experimental|short duration group|30sn %100 Wmax 120sn %25 Wmax 3 sessions/week total 8 weeks
89459079|NCT03487029|Experimental|long duration group|4dk %85 Wmax 120sn %25 Wmax 3 sessions/week total 8 weeks
89459080|NCT03165578|Experimental|Neurofeedback|Neurofeedback training.
89459081|NCT03165578|Sham Comparator|Sham Feedback|Sham controlled neurofeedback training. Subjects in the sham control group will undergo the same procedure as subjects in the experimental group, but instead of being shown feedback derived from their own brain activity, they will be shown replayed feedback values from a randomly chosen subject of the experimental group.
89459082|NCT03114878|Active Comparator|TRT / EMDR|Tinnitus Retraining Therapy / Eye Movement Desensitization Reprocessing
89459083|NCT03114878|Active Comparator|TRT / CBT|Tinnitus Retraining Therapy / Cognitive Behavioral Therapy
89459084|NCT03689465|Active Comparator|PTCy-ATG group|PTCy-ATG group refers to treatment with PTCy-ATG protocol as GVHD prophylaxis at a total dose of 4.5mg/kg ATG, a dose of 50mg/kg/d cyclophosphamide (CTX), a dose of 2.5mg/kg/d Ciclosporin A （CsA）, and a dose of 1.0g/d Mycophenolate Mofetil(MMF).
89459085|NCT03689465|Active Comparator|ATG group|ATG group refers to treatment with ATG protocol as GVHD prophylaxis at a total dose of 7.5mg/kg ATG, a dose of 2.5mg/kg/d Ciclosporin A （CsA）, a dose of 1.0g/d Mycophenolate Mofetil(MMF) and methotrexate (MTX, on days +1, +3 and +6).
89459086|NCT03485625|Experimental|Lidocaine|Patients in group C will receive 3 mg/kg of lidocaine 2% diluted with saline to a total volume of 40 ml.
89201529|NCT03986905|Active Comparator|TDS Patch|placebo nasal gel + TDS patch
89201530|NCT00987922|Experimental|Hypothermia|
89201531|NCT00987922|No Intervention|Control|
89201532|NCT03595774|Placebo Comparator|Placebo|3.3 mL/kg concentrated beet root juice *depleted of nitrate* Other names: Beet It Sport Nitrate 400 placebo
89201533|NCT03595774|Active Comparator|low nitrate|"1.55 mL/kg concentrated beet root juice depleted of nitrate + 1.55 mL/kg concentrated beet root juice *depleted of nitrate*~Other names: Beet It Sport Nitrate 400 placebo + Beet It Sport Nitrate 400"
89201534|NCT03595774|Active Comparator|high nitrate|"3.3 mL/kg concentrated beet root juice containing nitrate~Other names:Beet It Sport Nitrate 400"
89201535|NCT03914950|Other|PET/CT results with TOF/without TOF|"Diagnostic CT of the abdomen or upper abdomen (in case of already performed diagnostic CT of the abdomen < 2 weeks ago) with 2 phases, 1 - 4 mSv, ca. 20 sec., 1 x~Contrast medium (Iodixanol 550 mg/ml) 1 x 1.4 ml/kg body weight i.v. for 40 sec, 1 x if creatinine, GFR, and TSH levels are within the normal range~1 x 500 ml water oral, 1 x~Biopsy or FNA (fine-needle aspiration) or operation of the pancreas"
89201536|NCT00329797|Experimental|Zoledronic Acid|Zoledronic acid q 6 months plus Vitamin D and calcium supplement for 3 years in addition to concurrent radiation therapy and LHRH therapy.
89201537|NCT00329797|Active Comparator|Control|Vitamin D and calcium supplement everyday for 3 years in addition to concurrent radiation therapy and LHRH therapy.
89201538|NCT00541450|Experimental|Sita/Met FDC|"In Phase A (Treatment Day 1 to Week 12), participants were administered 100 mg once daily (q.d.) of sitagliptin and matching placebo to 15 mg pioglitazone q.d. for 6 weeks followed by matching placebo to 30 mg pioglitazone for the next 6 weeks.~In Phase B (Treatment Week 12-Week 40), participants were switched to the Sita/Met Fixed-Dose Combination (FDC) at a dose of 50/500 mg twice a day (b.i.d.), which was increased to 50/1000 mg b.i.d. over a period of 4 weeks; as well as matching placebo to 45 mg pioglitazone."
89016831|NCT00263393|Other|Health-promotion|The health promotion arm has been designed to increase knowledge of the causes of cardiovascular disease and enhance use of preventive behaviours in the general population
89201539|NCT00541450|Active Comparator|Pioglitazone|"In Phase A (Treatment Day 1 up to Week 12), randomized participants in the pioglitazone group were administered 15 mg q.d. of pioglitazone and matching placebo to sitagliptin. At Week 6, participants were up-titrated to 30 mg pioglitazone q.d.~In Phase B (Treatment Week 12 to Week 40), participants were administered 45 mg pioglitazone q.d.; as well as matching placebo to Sita/Met FDC (50/500 increased to 50/1000 b.i.d. after 4 weeks)."
89201540|NCT03989635|Experimental|QAW039|QAW039 450mg
89201541|NCT03989635|Placebo Comparator|Placebo|Placebo to QAW039
89201542|NCT03986827|Experimental|Cool Kids Anxiety Program - Social Enhanced (CK-E)|CK-E is a G-CBT treatment developed specifically for treatment of youth SAD. The program consists of 10 2-h group sessions with four to five adolescents and their parents in each group. 9 sessions with the adolescents and parents together and one parents-only session (session 5). Three months after ending treatment participant will be offered a 1-h booster group session.
89201543|NCT03986827|Active Comparator|Cool Kids Anxiety Program (CK)|"The standard Cool Kids Anxiety Program is a treatment program based on generic CBT techniques such as cognitive restructuring and gradual exposure.~The program consists of 10 2-h group sessions with four to five adolescents and their parents in each group. 9 sessions with the adolescents and parents together and one parents-only session (session 5). Three months after ending treatment participant will be offered a 1-h booster group session."
89201544|NCT01054261|Other|Normal|Normal renal function
89201545|NCT01054261|Other|Mild|Mild renal impairment
89201546|NCT01054261|Other|Moderate|Moderate renal impairment
89201547|NCT01056679|Experimental|AVD-Rev|Patients with intermediate stage HL receive 4 cycles of AVD-Rev followed by 30 Gy IF-RT Patientes with advanced stage HL receive 6 to 8 cycles of AVD-Rev followed by 30 GY IF-RT depending on the FDG-PET results
89201548|NCT03989791|Active Comparator|Absolute diet|
89201549|NCT03989791|Experimental|Normal diet|
89201550|NCT00355147|Experimental|Arm 1 Secondary Risk Factor Management|Patient Secondary Stroke Risk Factor Program including Stroke Self Management and Stroke Peer Support and Physician Stroke Guideline Adherence
89201551|NCT00355147|Placebo Comparator|Attention Control Group|Received Phone Calls from Staff to Control for Attention
89459087|NCT03485625|Experimental|Lidocaine+ Ketorolac|Patients in group K receive 3 mg/kg of lidocaine 2% + 20 mg ketorolac diluted with saline to a total volume of 40 ml.
89201552|NCT05711368|Active Comparator|interventional group|Nursing students who participated in distress tolerance training session
89201553|NCT05711368|No Intervention|control group|Nursing students not participating in distress tolerance training session
89201554|NCT03983551|Experimental|Dipeptidyl peptidase 4 inhibitors|Vildagliptin 50 milligrams twice daily in addition to metformin 1000 milligrams once daily
89201555|NCT03983551|Active Comparator|Sulfonylureas|Glimepiride 2 milligrams twice daily in addition to metformin 1000 milligrams once daily
89459088|NCT03485625|Experimental|Lidocaine+Paracetamol|Patients in group P will receive 3 mg/kg of lidocaine 2% + 300 mg paracetamol diluted with saline to a total volume of 40 ml.
89459089|NCT03685799||DHG on Barrett's esophagus|patients with DHG on Barrett's esophagus on endoscopic biopsies followed by endoscopic resection
89459090|NCT03114332|Experimental|Study Group|Patients for whom a subcutaneous drain was used
89459091|NCT03114332|No Intervention|Control group|No drain group
89459092|NCT03680885|Active Comparator|Reports getting numb at dentist|Subjects will be tested twice with lidocaine gel, twice with a Placebo and once with Injected Lidocaine to assess effectiveness of lidocaine. Each assessment will be on a different day.
89459093|NCT03680885|Active Comparator|Reports trouble getting numb at dentist|Subjects will be tested twice with lidocaine gel, twice with a Placebo and once with Injected Lidocaine to assess effectiveness of lidocaine. Each assessment will be on a different day.
89459094|NCT03114566||Consenting healthy donor|Transplant and healthy HLA typed donors
89459095|NCT03689309|No Intervention|1. Classic SBT (C-SBT)|The patient is disconnected from the ventilator and remains 30 minutes without support but oxygen delivered through a heat humidifier filter that is usually connected on tracheotomy.
89459096|NCT03689309|Experimental|2. High Flow Oxygen SBT (HFO-SBT)|The patient is disconnected from the ventilator and remains 30 minutes without support but high flow oxygen delivered through a dedicated piece that is usually connected on tracheotomy.
89459097|NCT03680807||Older adults with knee osteoarthritis (>50 years)|
89459098|NCT03680807||Healthy older adults (> 50 years)|
88941459|NCT01860235|Placebo Comparator|sextant 4|Treatment with subgingival scaling and root planing was done in 6 weekly sessions, being the sextant 1 in the randomization for experimental procedures (Placebo)
88941460|NCT01860248|Experimental|Vapocoolant spray|Vapocoolant is administered in 20 centimeters distance for 20 seconds to the patients as anesthetic before ABG.
89459099|NCT03163862|Placebo Comparator|Placebo|Patients treated with infusion of PLACEBO (saline solution) from the day of embryo transfer through the day of beta hCG test
89459100|NCT03163862|Experimental|G-CSF group|"Patients treated with G-CSF if the biopsy adhesive score 1-3 only, by Endometrial scratching and adhesive factor scoring on day 21-24 cycle prior to IVF//or day 3 of IVF cycle not planned before.~The dose of G-CSF is 300 µg by trans cervical intrauterine route administered at the oocyte retrieval day, Ans subcutaneous 300µg G-CSF on the day of embryo transfer"
89459101|NCT03163862|Sham Comparator|Comparative group|patients not treated with G-CSF after scratching if the biopsy adhesive score 4 only
89459102|NCT03685565|Experimental|Dermabond with underlying steristrips|
89459103|NCT03685565|Active Comparator|Dermabond|
89459104|NCT03163706|Experimental|Schizophrenia patients|Patients with DSM-5 criteria of schizophrenia
89459105|NCT03163706|Other|Control group|Control, no schizophrenia
89459106|NCT03033069|Experimental|Brexpiprazole + Sertraline|Participants were administered oral brexpiprazole initial dose of 0.5 milligram (mg)/day plus sertraline initial dose of 50 mg/day. The dose was up titrated to brexpiprazole maximum dose of 3 mg/day and sertraline maximum dose of 200 mg/day and continued thereafter up to Week 12 based on efficacy and tolerability. No dose reductions were allowed after Week 6 and no dose increments were allowed after Week 4. Participants also received sertraline matching placebo based on dose titration/adjustment up to Week 12.
89459107|NCT03033069|Experimental|Brexpiprazole|Participants were administered oral brexpiprazole initial dose of 0.5 mg/day The dose was up titrated to brexpiprazole maximum dose of 3 mg/day and continued thereafter up to Week 12 based on efficacy and tolerability. No dose reductions were allowed after Week 6 and no dose increments were allowed after Week 4. Participants also received sertraline matching placebo up to Week 12.
89459108|NCT03033069|Active Comparator|Sertraline|Participants were administered oral sertraline initial dose of 50 mg/day. The dose was up titrated to sertraline maximum dose of 200 mg/day and continued thereafter up to Week 12 based on efficacy and tolerability. No dose reductions were allowed after Week 6 and no dose increments were allowed after Week 4. Participants also received brexpiprazole matching placebo and sertraline matching placebo based on dose titration/adjustment up to Week 12.
89459109|NCT03033069|Placebo Comparator|Placebo|Participants received oral brexpiprazole matching placebo tablet and oral sertraline matching placebo capsules up to Week 12.
89459110|NCT03163628|Experimental|7 biomarkers combination|
89459111|NCT03685409|Active Comparator|Metformin-Group|Metformin hydrochloride tablets 500 mg taken orally once daily for 3 months
89459112|NCT03685409|Placebo Comparator|Placebo-Group|Starch placebo tablets taken orally once daily for 3 months
89459113|NCT05147948|Experimental|Treatment|Internet delivered Acceptance and Commitment Therapy for PTSD and Chronic Pain, supported by a psychologist
89459114|NCT05147948|No Intervention|Waitlist|Waitlist for 12 weeks.
89459115|NCT05146544||No limitation of exercise performance capacities|normal maximal oxygen uptake (greater than or equal to 80% of the reference value)
89459116|NCT05146544||Limitation of exercise performance capacities|reduced maximal oxygen uptake (less than 80% of the reference value).
89459117|NCT03486795|Experimental|Dual stimulation|"anodal stimulation on right primary motor cortex and cathodal stimulation on left primary motor cortex~anodal stimulation on right premotor cortex and cathodal stimulation on left supraorbital area"
89459118|NCT03486795|Experimental|M1 stimulation|anodal stimulation on right primary motor cortex and cathodal stimulation on left primary motor cortex
88941461|NCT01860248|Placebo Comparator|Water spray|The Patients in this arm will receive water spray as anesthetic before ABG.
88941462|NCT01860274|Experimental|External Mesh|
88941463|NCT01860300|Experimental|Antibiotic|Amoxicillin-Potassium Clavulanate Combination
88941464|NCT01860300|Placebo Comparator|Placebo|Placebo
88941465|NCT01860313|Experimental|Web-based interactive educational group|This group was submited to the web-based interactive education created for train teachers in child mental health, how to identify mental health problems in children and to know how to deal with problematic children in class.
88941466|NCT01860313|Experimental|Text and Video-based education|This group received the material that composed the web-based education environment without any kind of interactivity. This material was composed by some videos about children mental health and a support text.
88941467|NCT01860313|No Intervention|Waiting List group|This group was used as control group and did not receive any intervention.
88941468|NCT01860326|Experimental|Alisporivir|Single 200 mg oral dose
88941469|NCT01860352|Other|Fish Oil|
88941470|NCT01860378|Active Comparator|No Video: Full price & $5 off|Participants will not view the pertussis video
88941471|NCT01860378|Experimental|Video: Full price & $5 off|Participants will watch a brief (~ 1 minute) video about Tdap vaccination
88941472|NCT01860391|Experimental|Application of Diammine SIlver Fluoride|"GROUP A (6 TEETH): 18 mcL will be expressed from a Hamilton syringe into a dappen dish, and then a single preweighed microbrush will be used to apply the material to the tooth surface after drying with cotton gauze. The 6 teeth will be treated consecutively until all the material in the dappen dish will be used. Then the brush will be reweighed to establish the non-applied amount.~GROUP B (28 TEETH) Measure out 3 mcL X number of teeth present into dappen dish. Procedure is the same."
88941473|NCT01860417|Experimental|Allogenic Mesenchymal Stromal Cells|Mesenchymal stem cells (MSC) prepared from bone marrow from healthy donor expanded ex vivo for 3-4 weeks. Intradiscal injection of 25 millions MSC in 2 ml of saline
88941474|NCT01860417|Active Comparator|Mepivacaine|Infiltration of paravertebral musculature close to the affected disc(s) with 2 ml of 1% Mepivacaine
88941475|NCT01860443|Experimental|Telepsychiatry collaborative program|"Online training on the diagnosis and management of adolescent depression for health professionals from primary care clinics participating in active branch.~Clinical management of depression by primary care professionals, according to algorithms based on the Clinical Guidelines of the Chilean Ministry of Health (MINSAL).~Supervision of primary care professionals through an internet site run by a team of specialists.~Telephone monitoring of patients by personnel trained on clinical progress, treatment adherence, and side effects (applicable for patients taking drugs)."
88941476|NCT01860443|Active Comparator|Usual care|"Online training on the diagnosis and management of adolescent depression for health professionals from primary care centers participating in active branch.~Clinical management of depression by primary care professionals, according to algorithms based on the Clinical Guidelines of the Chilean Ministry of Health (MINSAL)."
88941477|NCT01860469|Active Comparator|plain mesh|standard practice of using plain mesh (non vancomycin-soaked) for open hernia repair
88941478|NCT01860469|Experimental|vancomycin-soaked mesh|use of vancomycin-soaked mesh for open hernia repair
88941479|NCT01860482|Experimental|Newrabell single arm|Newrabell® Tablet 10mg b.i.d PO during 8 weeks
88941480|NCT01860495||perforated membrane group|perforated membrane group (G1- 15 sites)
88941481|NCT01860495||occlusive membrane group|occlusive collagen membrane that are tradetionally used in guided tissue regeneration , control occlusive group (G2-15 sites)
88941482|NCT01860508|Experimental|pemetrexed|
88941483|NCT01860547|Experimental|bilberry|
88941484|NCT01860547|Experimental|sea buckthorn berry|
88941485|NCT01860547|Experimental|sea buckthorn phenolic extract|
89201556|NCT05706142|No Intervention|Control group|No motor imagery will be shown to these students. The same massage will only be shown as practically at class.
88941486|NCT01860547|Experimental|sea buckthorn oil|
88941487|NCT01860599|Other|Prediabetes with exercise|150 minutes of moderate exercise per week
88941488|NCT01860599|Other|Prediabetes without exercise|Pre-study activity level (i.e. no exercise)
88941489|NCT01860625|Experimental|1(12.5㎠)|"drug : 9 people, 43.75mg/12.5㎠~placebo : 3 people, 12.5㎠"
89016832|NCT00263627|Placebo Comparator|Placebo|Sterile aluminium hydroxide suspension for subcutaneous injection were applied in the upper arm. Vials with strength A contained 0.0125 mg/mL and with strength B 0.125 mg/mL histamine-dihydrochloride and strength 0 was produced by dilution of strength A. The vials containing the placebo solution were identical in their outer appearance with the active study preparation of the birch pollen allergoids.
89201557|NCT05706142|Experimental|Intervention Group|"Within the scope of motor imagery training, a presentation will be made to the students of pediatric rehabilitation lecture in the intervention group about what motor imagery is. PETTLEP model will be used for imagery training. In this model, imagery training will be prepared in accordance with our purpose, taking into account the physical, environmental, time, task, learning, emotion and personal subheadings. In the training sessions, relaxation exercises will be given for 5 minutes first. After the relaxation exercises, special colic massage imagery training will be given to newborns for 10 minutes. The massage will also be shown as practically at class."
89201558|NCT04697212|Experimental|Healthcare team- + patient-directed intervention|Team education and patient tool
89201559|NCT04697212|Active Comparator|Healthcare team-directed intervention|Team education
89201560|NCT00540124|Experimental|Tadalafil|
89201561|NCT00540124|Placebo Comparator|Placebo|
89459119|NCT03486795|Experimental|PMC stimulation|anodal stimulation on right premotor cortex and cathodal stimulation on left supraorbital area
89459120|NCT03486795|Sham Comparator|Sham stimulation|Sham stimulation
89459121|NCT02917265|Experimental|TENS for vagus stimulation|A transcutaneous electrical nerve stimulation (TENS) unit is applied to an area of the external ear that is innervated by the auricular branch of the vagus nerve.
89459122|NCT02917265|Sham Comparator|TENS for sham stimulation|A TENS unit is applied to an area of the external ear that is devoid of vagus innervation.
88941490|NCT01860625|Experimental|2(25㎠)|"drug : 9 people, 87.5mg/25㎠~placebo : 3 people, 25㎠"
88941491|NCT01860625|Experimental|3(50㎠)|"drug : 9 people, 175mg/50㎠~placebo : 3 people, 50㎠"
88941492|NCT01860638|Experimental|First-Line Bevacizumab followed by Bevacizumab + Lomustine/SOC|Participants will receive first-line treatment with radiotherapy, temozolomide, and bevacizumab. All three treatments will be given concurrently for the first 6 weeks, followed by 6 cycles (28 days each) of temozolomide plus bevacizumab, followed by bevacizumab monotherapy until PD1 or unacceptable toxicity. At PD1, participants randomized to bevacizumab will receive bevacizumab plus lomustine until PD2. Following PD2, participants will continue with blinded bevacizumab with the addition of appropriate SOC. Following PD3, for subsequent treatment lines blinded bevacizumab may continue or open-label bevacizumab may be given at the discretion of the investigator and the participant.
89201562|NCT00540124|Active Comparator|Tamsulosin|
89201563|NCT00540046|Active Comparator|A/Immediate|The patients in the immediate arm will have the Copper T 380A IUD inserted within 15 minutes after delivery of the placenta immediately following procedure
89201564|NCT00540046|Active Comparator|B/Delayed|The delayed group will have the Copper T 380A IUD inserted at the post-operative visit within 2-4 weeks following the procedure.
89201565|NCT04613830|Active Comparator|Erector spinae group|patient will be placed in a sitting position under complete aseptic condition and a cover sheath will be used for the ultrasound probe with an appropriate amount of lubricating gel applied on the probe, a high-frequency linear ultrasound transducer will be placed in a longitudinal orientation 3 cm lateral to the L3 spinous process. This should reveal three muscles superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae.
89459123|NCT03486717|Experimental|Control|Study group that does not wear the virtual reality goggles. This group will serve as a control.
88941493|NCT01860638|Placebo Comparator|First-Line Bevacizumab followed by Placebo + Lomustine/SOC|Participants will receive first-line treatment with radiotherapy, temozolomide, and bevacizumab. All three treatments will be given concurrently for the first 6 weeks, followed by 6 cycles (28 days each) of temozolomide plus bevacizumab, followed by bevacizumab monotherapy until PD1 or unacceptable toxicity. At PD1, participants randomized to placebo will receive placebo plus lomustine until PD2. Following PD2, participants will continue with blinded placebo with the addition of appropriate SOC. Following PD3, for subsequent treatment lines blinded bevacizumab may continue or open-label bevacizumab may be given at the discretion of the investigator and the participant.
88941494|NCT01860664|Experimental|hydrocortisone ophthalmic ointment 0.5%|Topical ophthalmic corticosteroid ointment, is produced in a concentration of 0.5% of hydrocortisone Acetate in a vehicle composed of mineral oil and white petrolatum
88941495|NCT01860664|Placebo Comparator|Placebo|mineral oil and white petrolatum
88941496|NCT01860690|Experimental|MTX , treatment outcome|patient receiving MTX. in a dosage of 50 mg/m^2 , IM , in single dose
88941497|NCT01860716|Placebo Comparator|Solution for infusion|Solution for infusion administrated via nasogastric tube
88941498|NCT01860716|Experimental|Melatonin|30 mg melatonin administrated via nasogastric tube in the Intensive Care Unit when included in the study and 30 mg melatonin 60 minutes before transfer to the operating room.
88941499|NCT01860729|Experimental|Anacetrapib|100 mg tablet, oral, once daily for 24 weeks
88941500|NCT01860729|Placebo Comparator|Placebo|Matching tablet to Anacetrapib 100 mg, oral, once daily for 24 weeks
88941501|NCT01860742|Active Comparator|Interferon alpha-2b|Interferon α-2b in a dose of 5000000 Units administered subcutaneously every second day until progression or unacceptable adverse event from a clinical or a patient point of view.
88941502|NCT01860742|Active Comparator|177Lu-DOTATATE|intravenous injection of 177Lu-octreotate with simultaneous infusion of an aminoacid solution
88941503|NCT01860755|Experimental|Physiotherapy|Physiotherapy: including vestibular rehabilitation and multimodal treatment for the cervical spine, once weekly with the study physiotherapist for 8 weeks or until time of medical clearance to return to sport. This group also received the control intervention.
88941504|NCT01860755|Active Comparator|Control|Control: postural education, general range of motion and strengthening in addition to the standard of care rest followed by graded exertion. Individuals were seen once weekly for eight weeks or until time of medical clearance to return to sport.
88941505|NCT01860768||acute aortic dissectin patients|definite diagnosis by computed tomography arteriography (CTA).
88941506|NCT01860768||acute chest pain patients|aortic dissection is exclude by aorta CTA
88941507|NCT01860781|Experimental|paliperidone palmitate|paliperidone palmitate
88941508|NCT01860794|Other|Mesencephalic Neuronal Precursor Cells|
88941509|NCT01860820|No Intervention|Best Medical Therapy|Participants will follow standard post-transplant protocols with IPC
88941510|NCT01860820|Active Comparator|Geko device|Participants will be fitted with the device to ensure that it functions according to the manufacturer's instructions by a trained technician. This device will be changed every 24 hours. The device is worn on both legs and is worn for 24 hours a day. The device will first be put on the first day following the day of surgery and will then be changed the following day at the same time for a total of 7 days after surgery.
88941511|NCT01860833|Active Comparator|diclofenac 75 mg/day|diclofenac 75 mg once day slow release
88941512|NCT01860833|Active Comparator|diclofenac 150 mg/day|diclofenac 75 mg bid
88941513|NCT01860833|Active Comparator|ibuprofen 1200 mg/day|ibuprofen 600 mg bid
88941514|NCT01860833|Active Comparator|ibuprofen 1800 mg/day|ibuprofen 600 mg tid
88941515|NCT01860833|Active Comparator|celecoxib 200 mg/day|celecoxib 200 mg once day
88941516|NCT01860833|Active Comparator|celecoxib 400 mg/day|celecoxib 200 mg bid
88941517|NCT01860859|Other|Unlocked double layer|Double layer closure with a first continuous unlocked suture of the deep portion of the myometrium avoiding the inclusion of the decidua and a second unlocked continuous suture that approximate the upper portion of the myometrium.
88941518|NCT01860859|Other|Locked single layer closure|As reported in Williams Obstetrics textbook
88941519|NCT01860859|Other|Locked double layer|Double layer closure with a first continuous locked suture and a second imbricating continuous suture.
89459124|NCT03163940|Experimental|Laughter Yoga (LY) Group|The LY session will be offered twice weekly, for 45 minutes each time. Each participant will be asked to attend a total of 8 groups (over 4 weeks).
88941520|NCT01860872||CF Group|Cystic Fibrosis group with MRI and CT of chest
88941521|NCT01860872||Control group|Non-CF controls will have MRI and no CT of chest
88941522|NCT01860872||Combined Group|MRI Quality & Image Relatedness
88941523|NCT01860885||Patients requiring naloxone for respiratory depression|
88941524|NCT01860911|Experimental|Insulin-Sensitive|One group consists of insulin sensitive volunteers.
88941525|NCT01860911|Experimental|Insulin-Resistant|One group consists of insulin resistant volunteers.
88941526|NCT01860924|Active Comparator|health education|health education control
88941527|NCT01860924|Experimental|exercise|vigorous supervised exercise
88941528|NCT01860963|Active Comparator|IBD patients on immunosuppression|Patients on azathioprine/6-mercaptopurine (6MP), prednisone, methotrexate, infliximab, adalimumab, certolizumab, natalizumab, and etanercept are included.
88941529|NCT01860963|Active Comparator|IBD patients off immunosuppressants|Patients off immunosuppressants, on 5-aminosalicylic acid (5-ASA) agents, antibiotics, or no treatment for IBD are included.
89201566|NCT04613830|Placebo Comparator|Opioid GROUP|Patient in group T will intravenously administrate dose of 1 mg/kg/8hr tramal ( opioid) to be increased upon patient needs up to 2mg/kg/6hr as rescue analgesic.
89459125|NCT03163940|No Intervention|Treatment-as-usual (TAU)|The TAU will receive their usual routine community mental health care (including medications) and attend medical outpatient appointments as determined by their individual needs.
89459126|NCT03486639||Patients undergoing urodynamic|All patients older than 18 who are refered for Urodynamics examination
89459127|NCT03165500|Active Comparator|Diazepam|Sedation of the anxious patient with diazepam 5 mg for measuring vital signs (blood pressure, heart rate, oxygen saturation) in the pre, trans and postoperative periods of third molar extraction.
89459128|NCT03165500|Active Comparator|Midazolam|Sedation of the anxious patient with midazolam 7.5 mg for measurement of vital signs (blood pressure, heart rate, oxygen saturation) in the pre, trans and postoperative periods of third molar extraction.
89459129|NCT03165500|Active Comparator|Nitrous Oxide + Oxygen Gas|Inhaled sedation of the mixture of 40% of nitrous oxide and 60% of oxygen gas for measurement of vital signs (blood pressure, heart rate, oxygen saturation) in the pre, trans and postoperative periods of third molar extraction.
89459130|NCT03163238|Active Comparator|Group D|One syringe contain dexmedetomidine 0.5 mcg/kg diluted with normal saline in Dexmedetomidine group. Second syringe (50 ml) will contain normal saline (0.9%) in addition to Dexmedetomidine in addition to normal saline in Dexmedetomidine group. Concentration of Dexmedetomidine will be diluted according to the body weight so that we will fix the rate of infusion (1 ml/kg) to achieve a concentration of 0.5 mcg/kg/h in Dexmedetomidine group.
89459131|NCT03163238|Placebo Comparator|Group S|One syringe contain normal saline in 5 ml in Saline group. Second syringe (50 ml) will contain normal saline (0.9%) alone in rate of infusion (1 ml/kg) in Saline group
89459132|NCT05150379||Dominant side shoulder surgery patients|
89459133|NCT05150379||Patients operated on the shoulder on the non-dominant side|
89459134|NCT05150379||Healthy volunteers|
89459135|NCT04461561|Experimental|ELNEC-PPC WBT pluss usual care|The End-of-Life Nursing Education Consortium (ELNEC) project is a national education initiative to improve nursing education on end-of-life care. The project is administered by the American Association of Colleges of Nursing and City of Hope National Medical Center. The intervention group received training through the Relais Academy website
89459136|NCT04461561|No Intervention|Usual care only|Participants nurses deliver usual care as his/her role appropriate to neonates, infants, toddlers, preschoolers, school age, also to adolescents in selected unit of perinatal, neonatal, and settings which can be pediatric.
89459137|NCT04059341|Experimental|Active LI-ESWT|Active group receives five sessions of low intensity extracorporeal shockwave treatment, once per week for five consecutive weeks. Treatment is initiated three weeks after radical prostatectomy and is given using DUOLITH® SD1 manufactured by STORZ MEDICAL AG.
89459138|NCT04059341|Sham Comparator|Sham|Sham group receives five sessions of sham low intensity extracorporeal shockwave treatment, once per week for five consecutive weeks. Treatment is initiated three weeks after radical prostatectomy and is given using DUOLITH® SD1 manufactured by STORZ MEDICAL AG with a shockwave absorbing adapter.
89459139|NCT03165656||High altitude pulmonary hypertension|Highlanders with high altitude pulmonary hypertension living above 2500 m.
89459140|NCT03165656||High altitude control|Healthy highlanders living above 2500 m.
89459141|NCT03165656||Low altitude control|Healthy lowlanders living below 1000 m.
89459142|NCT03486561|Other|Ranolazine|Ranolazine was approved by the U.S. Food and Drug Administration in 2006 in 500 mg and 1000 mg extended-release doses, advising 500 mg BID as a starting dose and 1000 mg BID as maximum dose
89459143|NCT03689153|Experimental|Cohort 1: JNJ-63733657 or Placebo|Participants will receive a single intravenous (IV) low dose of JNJ-63733657 or matching placebo.
89459144|NCT03689153|Experimental|Cohort 2: JNJ-63733657 or Placebo|Participants will receive a single IV middle dose of JNJ-63733657 or matching placebo.
89459145|NCT03689153|Experimental|Cohort 3: JNJ-63733657 or Placebo|Participants will receive a single IV high dose of JNJ-63733657 or matching placebo.
89459146|NCT03685097||Cardiac surgery patients|Patients undergoing elective cardiac surgery requiring cardiopulmonary bypass.
89459147|NCT02533713|Experimental|Immediate gait training|Participants assigned to this arm will begin Exoskeleton assisted gait training right away and will continue training for the first 6 months of the study.
89459148|NCT02533713|Other|Delayed gait training|Participants assigned to this arm will not gait train for 6 months. They will engage in Exoskeleton assisted gait training for the last 6 months of the study.
89459149|NCT03680573|Active Comparator|Control- Lactated Ringers|This site will serve as the control site and will receive lactated Ringer's (saline solution) at an infusion rate of 2 µl/min.
89459150|NCT03680573|Experimental|Apocynin (1-(4-Hydroxy-3-methoxyphenyl)ethanone)|This site will receive 100 µM apocynin (1-(4-Hydroxy-3-methoxyphenyl)ethanone) at an infusion rate of 2 µl/min.
89459151|NCT03680573|Experimental|Allopurinol (1H-pyrazolo[3,4-d]pyrimidin-4(2H)-one)|This site will receive 10 µM allopurinol (1H-pyrazolo[3,4-d]pyrimidin-4(2H)-one)at an infusion rate of 2 µl/min.
89459152|NCT03680573|Experimental|BH4 ((6R)-5,6,7,8-Tetrahydrobiopterin dihydrochloride)|This site will receive 10 mM (6R)-5,6,7,8-Tetrahydrobiopterin dihydrochloride (BH4) at an infusion rate of 2 µl/min.
89459153|NCT03689075|No Intervention|Immediate release tacrolimus|Patients will continue on immediate release tacrolimus
89459154|NCT03689075|Active Comparator|Extended release tacrolimus|
89459155|NCT05015127|Experimental|HBM9161 680 mg qw by q2w from week 13|Subcutaneous injection; HBM9161 680 mg qw from week 13
88941530|NCT01860963|Active Comparator|Healthy controls|Age-matched healthy controls enrolled from the hospital, outpatient clinics, and from the general public via flyers and online advertisements.
88941531|NCT01861015|Experimental|Epinephrine|In the epinephrine group, we used a dilute epinephrine, 0.5 mg of epinephrine ([1/2] vial of 1mg/mL) in 50 mL of saline solution, taking care to use no more than 20 mL of solution per a subject.
88941532|NCT01861015|Active Comparator|Vasopressin|In the vasopressin group, a dilute vasopressin, 5 units in 50 mL of saline solution, taking care to use no more than 20 mL of solution per a subject was injected.
89459156|NCT05015127|Experimental|HBM9161 680 mg qw by q2w from week 7|Subcutaneous injection; HBM9161 680 mg qw by q2w from week 7
89459157|NCT05015127|Experimental|Placebo|Subcutaneous injection; Placebo
89459158|NCT05015127|Experimental|Placebo qw by HBM9161 680mg qw from week 12|Placebo qw by HBM9161 680mg qw from week 12
89459159|NCT03680495||AECOPD with Respiratory Failure|The AECOPD cohort will be hospitalized for an acute exacerbation of chronic obstructive pulmonary disease (AECOPD) with respiratory failure requiring invasive or non-invasive mechanical ventilation. We will be following patients from admission through to discharge, and during a follow-up visit (~2 months from discharge). During the follow-up visit we will be administering 60mg of methylprednisolone once to study possible steroid resistance.
89459160|NCT03680495||Stable COPD|The Stable COPD cohort will not have had an AECOPD within the past 6 months and will be frequency matched to the AECOPD cohort. The Stable COPD cohort will have one research visit where we will administer 60mg of methylprednisolone once to study possible steroid resistance.
89459161|NCT02328885|Experimental|Experimental|DLI of the 20 fraction of the UCBT
89459162|NCT02178345||Surgical patients|The patients will undergo DW-MRI and (if patient is eligible and agrees) DCE-MRI study prior to surgery. The maximum time interval allowed between the MRI study and surgery will be six months.
89459163|NCT02178345||surveillance management patients|The patients will undergo DW-MRI and (if patient is eligible and agrees) DCE-MRI study while being on active surveillance.These patients can also receive the same DW and DCE MRI as a followup a year after the first.
89459164|NCT03685019|Experimental|Valgus stress - lateral compartment|Valgus stress radiograph. Joint space width measured in lateral compartment.
89459165|NCT03685019|Experimental|Varus stress - medial compartment|Varus stress radiograph. Joint space width measured in medial compartment.
89459166|NCT03685019|Experimental|0 degree flexion - medial compartment|0 degree flexion radiograph. Joint space width measured in medial compartment.
89459167|NCT03685019|Experimental|0 degree flexion - lateral compartment|0 degree flexion radiograph. Joint space width measured in medial compartment.
88941533|NCT01861041|Experimental|Heavy Bupivacain, Local anesthetic, Amp|Heavy bupivacaine 7.5 mg (1.5 ml), 20 microgram fentanyl(0.4 ml), 1.1 ml saline , Total 3 ml
88941534|NCT01861041|Active Comparator|Isobaric spinal, Local anesthetic, Amp|7,5 mg isobaric bupivacaine, 20 microgram (0.4 ml)fentanyl, 1.1 ml saline, Total 3 ml
88941535|NCT01861067|Experimental|LESS-TLH|laparoendoscopic single-site (LESS) total laparoscopic hysterectomy (TLH)
89459168|NCT03685019|Experimental|20 degree flexion - medial compartment|20 degree flexion radiograph. Joint space width measured in medial compartment.
89459169|NCT03685019|Experimental|20 degree flexion - lateral compartment|20 degree flexion radiograph. Joint space width measured in lateral compartment.
89459170|NCT03685019|Experimental|45 degree flexion - medial compartment|45 degree flexion radiograph. Joint space width measured in medial compartment.
89459171|NCT03685019|Experimental|45 degree flexion - lateral compartment|45 degree flexion radiograph. Joint space width measured in lateral compartment.
89459172|NCT01997697|Experimental|Patients with obesity|behavior change program among patients with obesity
89459173|NCT03688997|Experimental|Experts|"For the novice group, the investigators recruited 30 residents within their first year of surgical residency (Post-Graduate Year [PGY]-1) in general surgery, vascular surgery, plastic surgery, orthopedic surgery, cardio-thoracic surgery, gynecology and urology.~The intervention administered was the use of a simulator by the participants."
89459174|NCT03688997|Experimental|Novice|"The expert's group included 15 attending surgical faculty members in the general surgery, vascular surgery, cardio-thoracic surgery and gynecology services.~The intervention administered was the use of a simulator by the participants."
88941536|NCT01861067|Active Comparator|LESS-LAVH|laparoendoscopic single-site (LESS) laparoscopically-assisted vaginal hysterectomy (LAVH)
88941537|NCT01861080||incident hypertensives|"Inclusion Criteria:~age≧30years~primary incident hypertension~signed informed consent"
89459175|NCT03492255|Active Comparator|Eurolupus: Cyclophosphamide + Methylprednisolone + oral GC|The EUROLUPUS group will receive Cyclophosphamide (6 doses of 500 mg / fortnightly) + 3 doses of Methylprednisolone (750 mg) initial + oral glucocorticoid (GC) (prednisone) ≤ 30 mg/day with a gradual reduction of 5 mg/month (EUROLUPUS). From the 3rd month, the group will receive oral mycophenolate mofetil (MMF) (2-3 g) until 6 months with gradual reduction of GC from 5 mg/month until the minimum dose of 5 mg/month.
89459176|NCT03492255|Experimental|Cyclones Group: Cyclophosphamide+Methylprednisolone no oral GC|CYCLONES Group will receive for 3 months Cyclophosphamide (6 doses of 500mg / fortnightly) + Methylprednisolone [500 mg (day 0 and day 15), 250 mg (day 30 and day 45) and 125 mg (day 60 and day 75)] without oral glucocorticoid (GC). From the third month, the group will receive only oral MMF (2-3 g) until the 6th month. Patients using GC ≤ 20 mg/day may enter the protocol with immediate reduction to 15 mg/day with a reduction of 5mg/month until complete withdrawal.
89459177|NCT03684941|Experimental|Treatment Period One|LoFric, hydrophilic urinary catheter for single use. The study device is based on commercially available hydrophilic urinary catheters for intermittent catheterization, but with a different coating process than the comparator. Treatment Period One will last 1 week.
89459178|NCT03684941|Active Comparator|Treatment Period Two|CE-marked LoFric®, hydrophilic urinary catheter for single use. The comparator product is today commercially available and produced by WHC. Treatment Period Two will last 1 week.
89459179|NCT03684863|No Intervention|Standard therapy|
89459180|NCT03684863|Experimental|capecitabine|
89459181|NCT04715997|Experimental|GX-19: Dose A|Dose A of GX-19N will be intramusculary administered via EP on day 1 and day 29.
89459182|NCT04715997|Placebo Comparator|Placebo: Normal saline|Placebo will be intramusculary administered via EP on day 1 and day 29.
89459183|NCT03680417|Active Comparator|Safety Study (Measles-Rubella vaccine)|open labeled, prospective intervention study, only assess the safety outcome. The Measles-Rubella vaccine is administered in infants age 9-12 months or 18 - 47 months. This study group only assessed for safety profile of the Measles-Rubella vaccine.
89459184|NCT03680417|Active Comparator|Sub Study (Measles-Rubella vaccine)|open labeled, prospective intervention study, assess the safety and immunogenicity outcome. The Measles-Rubella vaccine is administered in infants age 9-12 months or 18 - 47 months. For Sub study, pre- and post immunization sera will be obtained from 200 infants and/or children. Safety assessment also evaluated for 28 days after immunization.
89459185|NCT05388513||Colon|The patients who are operated with colon cancer
89459186|NCT05388513||Rectum|The patients who are operated with rectum cancer
89459187|NCT03680339|Active Comparator|Routine ecbolic group|100 patients will receive routine ecbolics ( oxytocin) after delivery of baby
89459188|NCT03680339|Active Comparator|Misoprostol group|The 100 patients will receive routine ecbolics (oxytocin) after delivery of baby plus 400 microgram misoprostol rectally with catheterization and another 400 microgram rectally after closure of abdomen
89459189|NCT04100057|Experimental|Cognitive Behavioral Therapy for Insomina (CBT-I)|CBT-I improves sleep through a combination of behavioral interventions (stimulus control (SC), sleep restriction (SR)), cognitive therapy (CT) as well as additional components such as mindfulness training and sleep hygiene education. SC is an intervention that re-establishes the connection between the bed/bedroom with sleep to help develop a more consistent sleep/wake pattern. SR leads to higher quality sleep by reducing excessive time spent in bed to the actual amount of sleep, thereby creating mild sleep deprivation and increasing the homeostatic sleep drive. Like CT for other disorders, CT for insomnia targets maladaptive thoughts and cognitions that may interfere with sleep.
89459190|NCT04100057|Active Comparator|Desensitization Therapy for Insomnia (DT-I)|"DT-I is a quasidesensitization treatment presented as a means of eliminating the conditioned arousal, which prolongs nocturnal awakenings. DT-I has been validated as an active-placebo control condition. Therapists help each DT-I recipient develop a chronological 12-item hierarchy of common activities he/she does on awakening at night (e.g., opening eyes, clock watching). Therapists also help them develop 6 imaginal scenes of themselves engaged in neutral activities (e.g., reading the newspaper). Each session, DT-I recipients are taught to pair neutral scenes with items on the 12-item hierarchy so, by the end of the sixth session, all hierarchy items have been practiced with therapist assistance. Each session, the exercise is tape recorded and the patient is given this tape locked in a player. The patients are told to practice their exercises at home once each day, no less than 2 hours before bedtime, but to avoid using the tape or exercise during sleep periods."
89459191|NCT03680261|Experimental|Adjuvant chemoradiotherapy group|Adjuvant chemoradiotherapy (1 cycle CT: Oxaliplatin plus capecitabine (Xelox) or S-1 plus oxaliplatin (SOX), Q21d×1, Followed by RT: 45 Gray (Gy), 5d/week×5 with capecitabine or S1, Followed by 3 cycles CT: Xelox or SOX, Q21d×3) for patients enrolled in this group.
89459192|NCT03680261|Active Comparator|Adjuvant chemotherapy group|Adjuvant chemotherapy (6 cycles CT: Xelox or SOX, Q21d×3) for patients enrolled in this group.
88941538|NCT01861119|Experimental|Silicone gel|Silicone gel (Kelo-cort™; Advanced Bio-Technologies, Silverdale, WA, USA) From the day of suture removal, the treatment was applied three times daily for 3 months.
88941539|NCT01861119|Active Comparator|Onion extract gel|Onion extract gel (Contractubex™; Merz Pharma, Frankfurt, Germany) From the day of suture removal, the treatment was applied three times daily for 3 months.
88941540|NCT01861119|No Intervention|No treatment|Subjects who assigned In the no treatment group did not receive any topical scar emollients.
88941541|NCT01861132||Healthy pregnant women|Healthy pregnant women for C-section under spinal anesthesia
88941542|NCT01861145|Active Comparator|Bed Alarm|Patients in the control arm will use only the bed alarm for treatment of their enuresis
89459193|NCT03680183||Pre-exposure|Entecavir 1Mg Oral Tablet
88941543|NCT01861145|Experimental|Bed alarm + intranasal steroids|"Intervention: Nasonex (Mometasone furoate aqueous nasal spray) Children 5-11: 50 mcg/metered spray, 1 sprays in each nostril daily for 3 months in conjunction with nightly use of the bed alarm.~Children ≥ 12: 50 mcg/metered spray, 2 sprays in each nostril daily for 3 months in conjunction with nightly use of the bed alarm."
88941544|NCT01861158|Experimental|Parenting Wisely|Immediate access to the online Parenting Wisely program
88941545|NCT01861158|Active Comparator|Parenting Wisely + Community Forum|Immediate access to the online Parenting Wisely program, as well as access to a community form where parents can receive social support from other online users of the program and a moderator
88941546|NCT01861158|No Intervention|Delayed Parenting Wisely|Delayed (6-month) access to the Parenting Wisely program. Parents will receive access to PW after the final, 6-month, follow-up assessment.
88941547|NCT01861171|Placebo Comparator|Placebo|Crossover randomized controlled double-blinded trial. Twenty women with obesity and pre-hypertension, aged 28-59 years, with stable body weight were randomized to receive a daily supplement of 3 capsules that contained either 500mg of green tea extract (GTE) or a matching placebo for 4 weeks, with a washout period of 2 weeks between the treatments.
88941548|NCT01861171|Active Comparator|Green Tea|Crossover randomized controlled double-blinded trial. Twenty women with obesity and pre-hypertension, aged 28-59 years, with stable body weight were randomized to receive a daily supplement of 3 capsules that contained either 500mg of green tea extract (GTE) or a matching placebo for 4 weeks, with a washout period of 2 weeks between the treatments.
88941549|NCT01861197|Experimental|Dovitinib monotherapy|
88941550|NCT01861210|Experimental|Couples Counseling and Testing|Couples Voluntary HIV Counseling and Testing, adapted for use with male couples from the standard African couples testing service.
88941551|NCT01861210|Active Comparator|Individudal Counseling and Testing|"Individual Voluntary Counseling and Testing involves HIV testing and individual, client-centered HIV prevention counseling. This service is provided by counselors trained in Centers for Disease Control and Prevention's Fundamentals of HIV Prevention Counseling training."
88941552|NCT01861223|Experimental|afatinib + nimotuzumab|
88941553|NCT01861236||Advanced Prostate Cancer|Advanced Prostate Cancer that receive Firmagon therapy in the context of usual clinical practice
88941554|NCT01861262|Experimental|Measurement of StO2|The procedure is a measurement and non-invasive monitoring system of percentage of oxygen saturation of haemoglobin in tissues using infrared technology. The system used in the study is the tissue oxygenation monitor InSpectraTM StO2 Spot Check, Model 300 consisting of a clamp applied to the base of the thumb of the patient.
88941555|NCT01861275||Nasal CPAP|We want to study the nasal-cpap treatment and it's compliance in sleep apnea patients with ischaemic stroke.
88941556|NCT01861275||no Nasal CPAP|No nasal-cpap in sleep apnea patients with ischaemic stroke.
88941557|NCT01861288||Adults and children with and without IBD|"The study includes adult and pediatric patients with and without IBD who, as part of an ongoing investigation or treatment, have to undergo a sigmoidoscopy (for children: colonoscopy).~Inclusion of adult patients, age 15-67 years: 50 patients with UC in remission, 50 patients with active UC, 50 patients without IBD~Inclusion of pediatric patients, <15 years: We expect to include: 10 UC / CD patients in remission,10 UC / CD patients in relapse,10 non-IBD patients."
88941558|NCT01861327|Experimental|lower limb angioplasty with CO2|lower limb angioplasty made with carbon dioxide as contrast media
88941559|NCT01861327|Active Comparator|lower limb angioplasty with Iodine|lower limb angioplasty made with Iodine as contrast media
88941560|NCT01861327|Experimental|aorto-iliac angioplasty with CO2|aorto-iliac angioplasty made with carbon dioxide as contrast media
88941561|NCT01861327|Active Comparator|aorto-iliac angioplasty with Iodine|aorto-iliac angioplasty made with Iodine as contrast media
88941562|NCT01861327|Experimental|endovascular AAA correction with CO2|endovascular abdominal aortic aneurysm (AAA) correction made with carbon dioxide as contrast media
88941563|NCT01861327|Active Comparator|endovascular AAA correction with Iodine|endovascular abdominal aortic aneurysm (AAA) correction made with Iodine as contrast media
88941564|NCT01861340|Experimental|Lenalidomide, Dexamethasone, and MEDI-551|Eligible patients will receive Lenalidomide and dexamethasone as per standard of care guidelines for 2 cycles. Patients with a clinical response to lenalidomide and dexamethasone after 2 cycles will proceed to get MEDI-551 for 2 cycles. MEDI-551 will be dosed at 4mg/kg IV on days 1 and 8 of cycle 3 and 4mg/kg IV on day 1 of cycle 4.
88941565|NCT01861366|Experimental|External facilitator|The external facilitation is a one year multifaceted intervention, including support, guidance, practice audit and feedback, training targeted to a team of practitioners involving the unit manager, the nurses and diet aides at the nursing home. The facilitator is a researcher and dietician.
88941566|NCT01861366|Active Comparator|Educational outreach visit|The outreach visit is a three hour lecture about the nutritional guidelines targeted to a team of practitioners including the unit manager, the nurses and diet aides at the nursing home. The trained person giving the lecture is a researcher and dietician.
88941567|NCT01861379|Experimental|Ghost Ileostomy|The patients were subjected to laparoscopic anterior rectal resection with performance of ghost ileostomy
88941568|NCT01861379|Placebo Comparator|No protective stoma|The patients were subjected to laparoscopic anterior rectal resection without simultaneous construction of any protective stoma.
89459194|NCT03680183||Post-exposure|Entecavir 1Mg Oral Tablet
89459195|NCT02136069|Experimental|Etrolizumab + Placebo (IV)|Participants will receive ertolizumab (SC) Q4W until Week 52 along with placebo matched to infliximab as IV infusion until Week 46.
89459196|NCT02136069|Active Comparator|Infliximab + Placebo (Injection)|Participants will receive IV infusion of infliximab at Weeks 0,2, and 6, then every 8 weeks until Week 46 partnered with placebo matched to etrolizumab by SC injection Q4W until Week 52.
89459197|NCT02917031|Active Comparator|Saxagliptin|one tablet of saxagliptin 5 mg or 2.5 mg + one placebo capsule matching sitagliptin
89459198|NCT02917031|Active Comparator|Sitagliptin|one capsule of sitagliptin 100 mg or 50 mg + one placebo tablet matching saxagliptin
89459199|NCT02917031|Placebo Comparator|Placebo|one placebo tablet matching saxagliptin + one placebo capsule matching sitagliptin
89459200|NCT03485235|Experimental|D&C|
89459201|NCT03485235|Other|No D&C|
89201567|NCT05676892|Experimental|The experimental group in benign gallbladder disease|"inclusion criteria~Patients who underwent elective gallbladder surgery (cholelithiasis, chronic cholecystitis, gallbladder polyps, gallbladder adenomyomatosis) ② Patients between the ages of 19 and 65 ③ A person who voluntarily signed a written consent form after hearing and understanding the explanation of this clinical trial~intravenous ibuprofen 800mg/8ml was used after surgery."
88941569|NCT01861392|Active Comparator|sensory-motor training|Guidelines + sensory-motor training.Evaluation Biomechanical data will be collected (balance, baropodometry, electromyography strength and joint position sense), as well as questionnaires ADDQoL and BESTest. The intervention will be twice a week for 45 minutes for 12 weeks, divided into three phases: heating, sensory-motor training and cool-down, with monitoring of blood pressure and blood glucose.
88941570|NCT01861392|Active Comparator|guidelines|receive the same guidelines and reviews that group orientation and training sensorineural engine and will be guided home exercises for postural twice a week 45 minutes for 12 weeks.
88941571|NCT01861405||Cerebral metastases subjects|Prior to each subject's radiation treatment (either whole brain radiation therapy or stereotactic radiosurgery), he/she will have fMRI scanning and neuropsychological testing and conduct a quality of life assessment. Each subject will then have standard of care WBRT or SRS treatment. Following WBRT or SRS treatment, subjects will have 4 month follow up fMRI scanning, and have neuropsychological testing and a quality of life assessment 4 months and 12 months post treatment.
88941572|NCT01861405||Healthy participants|Healthy control subjects will be matched by age, gender, education, ect. to cerebral metastases subjects. Each will have fMRI scannings (3 total), neuropsychological testings (3 total), and quality of life assessments (3 total) at the same time points as their matched cerebral metastases subject.
88941573|NCT01861418|Placebo Comparator|Sham manipulation|Each participant will lie in a supine position. The treating investigator (TI) will stand on the opposite side of the low back pain. Then, the participant will be asked to clasp his/her hand behind the neck. The TI will side bend the participant's spine towards the non-painful side, reach through the participant's hands and perform a spinal rotation away from the painful side. The TIs other hand will be placed over the anterior superior iliac spine (ASIS) of the painful side. Lastly, the TI will take up the slack and maintain the pressure on the ASIS for 5-10 seconds and ask the participant whether he/she can tolerate the pressure. If the participant can tolerate the pressure for at least 5 seconds. Then, the subjects will be re-positioned to the starting position.
88941574|NCT01861418|Experimental|Lumbopelvic Manipulation, Chicago|Each participant will lie in supine position. The treating investigator (TI) will stand opposite of the low back pain. Participant will clasp his/her hand behind the neck. TI will side bend the participant's spine toward non-painful side, reach through participant's hands and perform a spinal rotation away from the painful side. TI's other hand will be placed over the anterior superior iliac spine (ASIS) of the painful side. The TI will take up the slack and maintain pressure on the ASIS for 5-10 seconds and ask participant whether he/she can tolerate the pressure. If participant can tolerate the pressure for at least 5 seconds, verbal permission will be obtained from the participant and the TI will proceed and apply a high-velocity low-amplitude posterior thrust force over the ASIS.
88941575|NCT01861431|Active Comparator|HIVSRR|4 sessions of HIV sexual risk reduction
88941576|NCT01861431|Experimental|HIVSRR + Microfinance|4 sessions of sexual risk reduction plus 12 sessions of financial literacy, 12 sessions of business development training, 10 sessions of business mentorship; matched savings throughout course of intervention
88941577|NCT01861444||Cohort|
88941578|NCT01861470||Preterm infants|all <32 weeks
88941579|NCT01861509|Experimental|BP-C1 IM Injections|BP-C1 given in daily intramuscular doses of 0.035 mg/kg bodyweight in one syringe per day during a total treatment of 32 days.
88941580|NCT01861535|Experimental|Primary Imiquimod|Treatment with imiquimod will be patient self-administered for a period of 4 months with possible extension to 6 months. A thin layer of imiquimod cream should be applied to the lesion and remain overnight without a cover. Application will be once a week for 2 weeks, then twice a week the following 2 weeks and, if tolerated, 3 times a week for the last weeks. In case of severe side-effects the number of applications can be reduced; a treatment-free period of no more than 1 week is permitted
88941581|NCT01861535|Active Comparator|Primary surgery|The type of surgery (excision or ablation) will be based on clinical findings and surgeon's judgement. After excision the specimen will be histologically analyzed to assess resection margins and rule out invasion.
89201568|NCT05676892|Experimental|The controled group in benign gallbladder disease|"inclusion criteria~Patients who underwent elective gallbladder surgery (cholelithiasis, chronic cholecystitis, gallbladder polyps, gallbladder adenomyomatosis) ② Patients between the ages of 19 and 65 ③ A person who voluntarily signed a written consent form after hearing and understanding the explanation of this clinical trial~normal saline (Isotonic Sodium Chloride Injection Daihan(50mL/bag)) was used after surgery."
89201569|NCT00689936|Experimental|Lenalidomide / Dexamethasone until disease progression|Lenalidomide plus low-dose dexamethasone given until disease progression
89201570|NCT00689936|Experimental|Lenalidomide / Dexamethasone for 18 cycles|Lenalidomide plus low-dose dexamethasone given for 18 four-week cycles
89201571|NCT00689936|Active Comparator|Melphalan, Prednisone, and Thalidomide (MPT) for 12 cycles|Combination of Melphalan, Prednisone and Thalidomide given for 12 six-week cycles
89201572|NCT04528576|Experimental|DragonFly-M|Experimental group is allocated to use novel mitral valve repair system manufactured by Hangzhou Valgen Meditech Co., Ltd
89201573|NCT05279170|Experimental|children|"Compression of adjacent vessels (jugular vein and carotid artery), near the left paratracheal area. The risk of compression of the vessels will be assessed before performing the maneuver.~At the screening time before the intervention, we will perfom an ultrasonography measurement while we applied the maneuver in order to eliminate a risk of compression of the vessels, defined as a reduction in diameter of 50%."
89201574|NCT01563718|Experimental|PRE-release XR-NTX|Participants randomly assigned to the pre-release condition will receive one injection of XR-NTX 1-2 weeks prior to prison release plus up to five additional injections of XR-NTX in the community after release
89459202|NCT04460547||Completed Interventional studies|Interventional studies in the WHO-compliant registries database which are registered and completed before 11th March 2020.
89459203|NCT04460547||Completed Observational studies|Observational studies in the WHO-compliant registries database which are registered and completed before 11th March 2020.
89459204|NCT03132051|Experimental|steroid injection|ultrasound-guided steroid injection using 1ml of 10 mg (10mg/ml) triamcinolone acetonide
89459205|NCT03684707|Active Comparator|Metformin Hcl 500Mg 24Hr Sa Tab|Metformin Hcl 500Mg 24Hr Sa Tab drug is given to the patient
89459206|NCT03684707|Placebo Comparator|control|starch tablets
89459207|NCT03688841|Experimental|Bridged V.A.C.® with compression therapy|A vacuum assisted closure device will be placed on the ulcer. A compression dressing will be placed over the V.A.C.® device
89459208|NCT03688841|Active Comparator|Conventional compression therapy|A Coban™ Lite compression dressings with underlying non-adherent wound contact layer (WCL) dressings will be applied and changed once to three times per week (dependant on exudate).
89201575|NCT01563718|Active Comparator|POST-release XR-NTX|Participant randomly assigned to the post-release group will be referred to Rhode Island Hospital to receive up to six injections of XR-NTX immediately after release from prison
89459209|NCT03684551|Active Comparator|No dashboard supervision tool|CHWs received monthly individual supervision from a dedicated CHW supervisor. The supervisory feedback session for CHWs in the control arm was not facilitated by a visual Dashboard tool or any personalised quantitative feedback on quantity, speed, or quality of care. CHW supervisors were instructed to continue providing CHWs in the control arm with feedback informed by patient perspectives and direct observation during the individual supervision visit.
89459210|NCT03684551|Experimental|Dashboard supervision tool|CHWs received monthly individual supervision from a dedicated CHW supervisor. For CHWs randomised to the intervention arm, a visual feedback tool, the CHW Performance Dashboard, was employed during individual supervision, starting in January 2016. During the individual supervisory feedback session, this personalised and relative (to the highest performer) quantitative performance feedback helped orient the discussion of strengths and weaknesses, and allowed the CHW to see quantitatively and visually how his/her performance fared the previous month. The feedback provided to CHWs in the intervention arm, therefore, was both quantitative, informed by the Dashboard, and qualitative, informed by patient perspectives and direct observation of CHW service provision during the individual supervision visit.
89459211|NCT03680027|No Intervention|Control Group|In 'Control group' participants had 6 week follow-up without any intervention.
89459212|NCT03680027|Experimental|Interventional Group|In 'Interventional group' participants had 6 week follow-up and during that period of time, they were asked to consume 40g/day walnut. Participants in intervention group was ensured to consume all 40g of walnut every day, during their snack times for 6 weeks.
89459213|NCT01018563|Experimental|MORAb-003|Maintenance infusions of MORAb-003 every 3 weeks
89459214|NCT03679871|Other|Questionnaire validation|"22-items questionnaire Spiritual Resources and Distress"
89459215|NCT02528188|Active Comparator|NSAID|Subcutaneous injection of placebo for tanezumab every 8 weeks plus oral NSAID (naproxen 500 mg, celecoxib 100 mg or diclofenac 75 mg) twice daily for 56 weeks
89459216|NCT02528188|Experimental|Tanezumab 2.5 mg|Subcutaneous injection of tanezumab 2.5 mg every 8 weeks plus oral placebo for NSAID (naproxen, celecoxib or diclofenac ER) twice daily for 56 weeks
89459217|NCT02528188|Experimental|Tanezumab 5 mg|Subcutaneous injection of tanezumab 5 mg every 8 weeks plus oral placebo for NSAID (naproxen, celecoxib or diclofenac) twice daily for 56 weeks
89459218|NCT03684395||DOACs (Direct Oral Anticoagulants)|
89459219|NCT03684395||Standard of care|
89459220|NCT04050137|Experimental|Exercise group|Exercise programme 3 times/week.
89459221|NCT04460391|Experimental|experimental group|Early standing training and routine rehabilitation
89459222|NCT04460391|Active Comparator|control group|Conventional rehabilitation，Muscle training and breathing training
89016833|NCT00263627|Experimental|Specific Immunotherapy|Subcutaneous injections with birch pollen allergoid were applied in the upper arm. Vials with three different concentrations were used: Strength A (1000 TU/mL), strength B (10 000 TU/mL) and strength 0 (100 TU/mL) by dilution of strength A.
89459223|NCT04059497|Experimental|Exercise group|The exercise group will receive a 10-minute exercise intervention.
89459224|NCT04059497|Experimental|Healthy diet group|The healthy diet group (control) will receive a 10-minute healthy-diet intervention.
89459225|NCT04460001|Active Comparator|Ranibizumab|intravetreal injection of Ranibizumab alone for treatment of patients with macular oedema after CRVO once per month and follow up
89459226|NCT04460001|Active Comparator|Ranibizumab and triamcinolone acetate|intravetreal injection of Ranibizumab and triamcinolone acetate for treatment of patients with macular oedema after CRVO once per month and follow up
89459227|NCT03486483|Experimental|Supervised Slackline Training|Supervised Slackline training in children and teenagers with spastic cerebral palsy (grade I and II of the Gross Motor Function Classification System). Intervention included 18 slackline rehabilitation sessions for 6 weeks: 3 sessions per week on non-consecutive days, 30 min each one.
89459228|NCT03486483|No Intervention|Physical Activity|The control group followed its usual weekly physical activity routine.
89501839|NCT05497622|Experimental|Patients with chronic neck pain|Non-invasive quantitative ultrasound (B-mode ultrasound, ultrasound elastography), EMG, osteopathic assessment, and osteopathic manipulative treatment (OMT) of the upper trapezius muscle will be performed on participants with chronic neck pain 3 times. All ultrasound, EMG biomarkers and TART assessments will be collected before and after OMT.
89501840|NCT04601870|Experimental|No Financial Incentive|N=180 participants randomized to not be offered monetary incentive to participate in an intervention to quit smoking.
89501841|NCT04601870|Experimental|Financial Incentive (100 dollars)|N=180 randomized participants will be offered a 100 dollar incentive to participate in an intervention to quit smoking.
89016834|NCT00294255|Experimental|Risperidone|patients will receive risperidone for up to 20 weeks
89201576|NCT05485714||Patient with non-alcoholic fatty liver with advanced liver fibrosis|Patient with non-alcoholic fatty liver with advanced liver fibrosis with F3 or F4 stage on Fibroscan without any evidence of previous decompensation like ascites, jaundice or encephalopathy
89459229|NCT03896165|Experimental|Teaching Reiki|Parent-adolescent pairs will be in the study for a total of nine weeks from enrollment to the follow up visit. During Week 1, the parent will receive Reiki training, a poster with suggested hand positions and a commercially-available book about Reiki in the home. During Week 2 the parent will receive a Reiki booster session with a repeat of the training and may ask questions in the home. At the end of Week 4, measures will be repeated either in person or by phone. During Week 8, measures will be repeated, another hair sample obtained and the parent will participate in a qualitative interview. The qualitative interview will be administered in person by trained Ohio State University College of Nursing study staff as part of the interview session. Interviews will be audio recorded using a hand-held audio recording device. Audio recording is voluntary and participants can choose to not have their interview recorded and still be a part of the study.
89459230|NCT04459923|Active Comparator|Epidural Catheter Group|Patients will be applied with epidural catheter at T 5-6 level and the patient will be injected with an epidural solution containing 15 ml 0.125% bupivacaine through this epidural catheter
89459231|NCT04459923|Active Comparator|Erector Spina Block Catheter Groups|Patients will be applied with an erector spina plane block catheter at the T 5-6 level, erector spina plane block will be applied by ultrasound guidance and when the first local anaesthetic dosage block needle is identified under the erector spina muscle 30 ml 0.25% bupivacaine (15 ml bupivacain + 15 ml saline) will be injected.
89459232|NCT03679793|Active Comparator|Open Release Group|Open surgical release of the A1 pulley is the gold standard of treating symptomatic trigger finger.
89459233|NCT03679793|Experimental|Percutaneous Release Group|Percutaneous release is a minimal invasive alternative surgical procedure
89459234|NCT03679715|Experimental|Intervention group|The participants in the Intervention group will be participants of the museum participatory art-based activity.
89459235|NCT03679715|No Intervention|Control Group|The Control arm will be composed of older community dwellers matched on age and sex compared to the Intervention group but who will not be participants at the museum participatory art-based activity.
89459236|NCT03486405|Experimental|Intervention group|The experimental group will have no in person education by researchers. All education and running modification will be performed via video. Education on running form, a home exercise program, and a 4 week return to run program will be provided to the subjects through e-mail. They will also receive the same in person video analysis performed at weeks 0 (initial), 10 and 6 months to assess running kinematics.
89459237|NCT03486405|Active Comparator|Control group|This group will have the same 4 week return to run program, home exercise program, and video analysis performed at weeks 0 (initial), 10 and 6 months to assess running kinematics.
89459238|NCT03679637|Experimental|Intervention group|Each participant will receive a tablet-based aphasia therapy
88941582|NCT01861548||Children (up to 24 months after birth)|Investigators include into the study children delivered from women observed starting from between 8-12 weeks of single pregnancy, not assisted with reproductive technology, and not expected to be finished as spontaneous abor-tion. All women with the serious chronic diseases specified in study protocol such as diabetes, hypertension, nephrop-athy, epilepsy and cancer are excluded from the study. The same refers to suspicion of serious child malformations known to exist at the inclusion into the study.
89459239|NCT03485001|Sham Comparator|Sham of Argon Laser Treatment|Slit lamp light exposure
89459240|NCT03485001|Experimental|Argon Laser Treatment|Argon Laser Treatment
89459241|NCT03484845|Active Comparator|Oral lactoferrin|women who take oral lactoferrin sachets 100 mg twice daily for one month.
89459242|NCT03484845|Active Comparator|Oral ferrous fumarate|women who take oral ferrous fumarate tablet 30 mg elemental iron twice daily for one month.
89459243|NCT03484845|Active Comparator|Combined lactoferrin & ferrous fumarate|women who take lactoferrin sachets 100 mg and ferrous fumarate tablet 30 mg elemental iron once daily for one month.
89459244|NCT03688607||POKE|All babies in NICU at Intermountain Healthcare hospitals
89459245|NCT03679481|Experimental|Tranexamic acid (TXA)|Following induction of anesthesia and prior to surgical incision, patients will receive 1 gram of intravenous TXA mixed in 100cc of normal saline.
89459246|NCT03679481|Placebo Comparator|Normal saline|Following induction of anesthesia and prior to surgical incision, patients will receive 100cc of normal saline.
89459247|NCT03484767||Methylmalonic Acidemia Participants|Individuals with isolated MMA (mut0 and mut-)
89459248|NCT03484767||Propionic Acidemia Participants|Individuals with isolated PA
89459249|NCT03679403||ADHD Probands|Subjects with DSM-IV ADHD who received the same MRI and CANTAB+CPT assessments during 2010.8-2015.7(NCT00916851, NCT01682915) at their age of 8-17 will be reassessed at the estimated age of 15-25.
89459250|NCT03679403||Unaffected siblings of ADHD|The unaffected siblings received the MRI and CANTAB+CPT assessments during 2013.8-2015.7 (NCT01682915) will be recruited and assessed.
89459251|NCT03679403||Neurotypicals Follow-up|Subjects without any lifetime diagnosis of DSM-IV ADHD or other psychiatric disorders as the control group of the ADHDFU group around 4-8 years ago when they received the same MRI and neuropsychological assessments during 2010.8-2015.7(NCT00916851, NCT01682915) at their age of 8-17 will be reassessed at their estimated age of 15-25.
89459252|NCT05151783|Active Comparator|conventional physiotherapy|routine physical therapy for adhesive capsulitis
89459253|NCT05151783|Experimental|PNF techniques|PNF techniques along with conventional physiotherapy
89459254|NCT03484689|Other|MBCT arm|8-week MBCT program
89459255|NCT05151705|Experimental|Treatment group A: HR17031 injection|
89459256|NCT05151705|Experimental|Treatment group B: HR17031 injection|
89459257|NCT05151705|Experimental|Treatment group C: HR17031 injection|
89459258|NCT05151627|Experimental|KINESIO TAPING AND CONVENTIONAL PHYSICAL THERAPY|Application of Kinesio taping following Transcutaneous Electrical Nerve Stimulation and Knee Exercises
89459259|NCT05151627|Experimental|CONVENTIONAL PHYSICAL THERAPY|Application of Transcutaneous Electrical Nerve Stimulation and Knee Exercises
89459260|NCT04461249||Latanoprost group|Latanoprost 0.005 % eye drops was given once by night for 3 months for newly diagnosed primary open-angle glaucoma patients.
89459261|NCT04461249||Travoprost group|Travoprost 0.004 % eye drops was given once by night for 3 months for newly diagnosed primary open-angle glaucoma patients.
89459262|NCT04461249||Tafluprost group|Tafluprost 0.0015 % eye drops was given once by night for 3 months for newly diagnosed primary open-angle glaucoma patients.
89459263|NCT05151549|Experimental|Camrelizumab , Cisplatin or Carboplatin|Participants will be given intravenous administration of Camrelizumab (200mg) ,Cisplatin(40mg/m²) or Carboplatin(AUC 2) and Radiotherapy. After completing 17 cycles of concurrent chemoradiation, the Participants will continue to use camrelizumab as maintenance therapy until one year.
89459264|NCT05151393||Cases|Cases with uterine leiomyoma
89459265|NCT05151393||Controls|Cases free of uterine leiomyoma
89459266|NCT03484611|Active Comparator|AMH < 0.3 ng/ml|Poor ovarian responders according to ESHRE consensus with serum AMH < 0,3 ng/ml
88941583|NCT01861561|Experimental|Low-dose intravenous cyclophosphamide|Low-dose intravenous cyclophosphamide 500 mg/m2/dose every 4 weeks/months for 7 doses. Total duration is 6 months for the induction treatment.
88941584|NCT01861561|Active Comparator|High-dose intravenous cyclophosphamide|High-dose intravenous cyclophosphamide 1,000 mg/m2/dose, the first dose will be started with 500 mg/m2/dose and steped up to 750 mg/m2/dose for the second dose. Then the dosage will be increased to 1,000 mg/m2/dose for the third dose and continued the dosage through the seventh dose. Total duration is 6 months for the induction treatment.
89459267|NCT03484611|Active Comparator|AMH 0.3 to 0.7 ng/ml|Poor ovarian responders according to ESHRE consensus with serum AMH 0.3 to 0.7 ng/ml
89459268|NCT03484611|Active Comparator|AMH > 0.7 to 1 ng/ml|Poor ovarian responders according to ESHRE consensus with serum AMH 0.7 to 1 ng/ml
89459269|NCT05151081||Enuresis, Non-Enuresis|Patients were divided into two gruops according to whether having NE or not during childhood
89459270|NCT03486249|Experimental|Patient difficult to wean|Repetition of medical examinations performed as part of the care. All patients will have a cardiac echo examination and diaphragm function assessment before the spontaneous breathing trial.
89459271|NCT03491943|Experimental|Midline group|Preprocedural ultrasound-assisted midline approach of spinal anesthesia will be performed. 0.5% heavy bupivacaine will be injected to intrathecal space for spinal anesthesia.
89459272|NCT03491943|Active Comparator|Paramedian group|Preprocedural ultrasound-assisted paramedian approach of spinal anesthesia will be performed. 0.5% heavy bupivacaine will be injected to intrathecal space for spinal anesthesia.
89459273|NCT02447133||Subjects Presenting With Normal Eyes|Subjects with no known ocular diseases will be scanned on the Maestro device
89459274|NCT03679325|Active Comparator|vitamine D|a dose once a week
89459275|NCT03679325|Placebo Comparator|vitamine D placebo|a dose once a week
89459276|NCT03684239|Experimental|G-CBT group|G-CBT group has 40 patients, maybe will be divided them into 4 groups. Every group has 8-10 patients. Every group receive 10 times CBT group therapy and 1 times a week for 120 minutes each time.
89459277|NCT03684239|Active Comparator|Conventional treatment group|Conventional treatment group has 40 patients, received routine outpatient treatment. Once every two weeks for 45 minutes each time, including nutritional advice, encouragement, and routine treatment by a psychiatrist with work experience with eating disorders.
89459278|NCT03684161||Surgically closed VSDs|Patients born with a ventricular septal defect, which have been closed in early childhood.
89459279|NCT03684161||Small, persistent VSDs|Patients born with a small, hemodynamically insignificant ventricular septal defect.
89459280|NCT03684161||Healthy controls|Healthy control subjects.
89459281|NCT03131661||SpA with DMARDs|Participants with first diagnosis or confirmed diagnosis of Spondyloarthritis (SpA) and naïve to conventional, targeted or biological Disease modifying anti-rheumatic drugs (DMARDs) will be observed in order to describe SpA characteristics and pattern of clinical presentation.
89459282|NCT03684083||Case|patients having received heterologous stem cell transplantation (HSCT)
89459283|NCT03684083||Control|patients without HSCT
89459284|NCT03878927|Experimental|Cohort A|"CPX-351 : Daunorubicin 44mg/m^2 and cytarabine 100mg/m^2/day on Days 1,3 and 5 (90 minute IV infusion)~Gemtuzumab ozogamicin: 3mg/m^2/day on Day 1 (2 hour IV infusion)"
89459285|NCT03878927|Experimental|Cohort B|"CPX-351: Daunorubicin 44mg/m^2 and cytarabine 100mg/m^2 on Days 1, 3 and 5 (90 minute IV infusion)~Gemtuzumab ozogamicin: 3mg/m^2 on Days 1, 4 (2 hour IV infusion)"
89459286|NCT03878927|Experimental|Cohort C|"CPX-351: Daunorubicin 44mg/m^2 and cytarabine 100mg/m^2 on Days 1, 3, and 5 (90 minute IV infusion)~Gemtuzumab ozogamicin: 3mg/m^2 on Days 1, 4 and 7 (2 hour IV infusion)"
89459287|NCT03684005|Other|Single-Arm Smartphone App Use|All patients in this single-arm study will use a smartphone-based app, MyPatientPal, to enter symptoms and track medications related to their cancer treatment. No drugs will be administered for the purposes of this behavioral study.
89459288|NCT03679169|Experimental|Group RAMPS|Radical antegrade modular pancreatosplenectomy
89459289|NCT03679169|Active Comparator|Group SPS|standard pancreatosplenectomy
89459290|NCT03623555||E-IPV|"Women who have been exposed to intimate partner violence. Half of this group will also have a history of childhood maltreatment.~Women will be assessed for behavioral performance during the Trier Social Stress Test, and salivary cortisol will be collected."
89459291|NCT03623555||NE-IPV|"Women who have never been exposed to intimate partner violence. Half of this group will also present a diagnosis of Major Depressive Disorder.~Women will be assessed for behavioral performance during the Trier Social Stress Test, and salivary cortisol will be collected."
88941585|NCT01861600|Experimental|Experimental (EF) 1|For 8 weeks, infants will consume ad libitum per day S-26 Gold EF1
88941586|NCT01861600|Active Comparator|Standard Formula|For 8 weeks, infants will consume ad libitum per day. S-26 Gold
89459292|NCT03842267|Active Comparator|Gemigliptin 50mg|
89459293|NCT03842267|Placebo Comparator|Gemigliptin Placebo|
89459294|NCT03688373|Experimental|Exposure-in-big-steps|In the big steps exposure sessions the adolescent moves in three a set pace of big steps from bottom to top (1-5-10) in their fear hierarchy. From 0-5 in the first session and from 5-10 in the second session.
89459295|NCT03688373|Experimental|Exposure-in-small-steps|In the small steps exposure sessions the adolescent moves in a step-by-step pace of their own choice from bottom to top in their fear hierarchy, for example from 1 to 2 to 3 to in the first session and from 4 to 5 to 6 etc. in the second session.
89459296|NCT04060511|Experimental|HS-10342|Each subject will receive a single dose(C0) of HS-10342 and then repeat doses(C1, C2…) for 28-day cycles. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criteria is met.
89459297|NCT03623711|Experimental|Escitalopram group|including 50 patients, dosage:start 10mg/day and last 2 weeks,we assess the HAMD score at the end of 2 weeks, if the reduction rate of HAMD less than 20% relative to baseline, the dosage add to 20mg/day and last to the end of 12 week. but if the reduction rate of HAMD more than 20% relative to baseline, the investigators will continue to use current dosage until the end of 12 week.
88941587|NCT01861600|Experimental|Experimental 2 (EF2) S-26 Gold|For 8 weeks, infants will consume ad libitum per day. S-26 Gold EF2
89459298|NCT03623711|Experimental|Duloxetine group|including 50 patients, dosage:start 30mg/day and last 2 weeks,we assess the HAMD score at the end of 2 weeks, if the reduction rate of HAMD less than 20% relative to baseline, the dosage add to 60mg/day and last to the end of 12 week. but if the reduction rate of HAMD more than 20% relative to baseline,the investigators will continue to use current dosage until the end of 12 week.
89459299|NCT03623711|Experimental|Bupropion group|including 50 patients, dosage:start 75mg/day and last 2 weeks,we assess the HAMD score at the end of 2 weeks, if the reduction rate of HAMD more than 20% relative to baseline, the investigators will continue to use current dosage until the end of 12 week.if the reduction rate of HAMD less than 20% relative to baseline, the dosage add to 150mg/day and last 2 weeks, the investigators assess the HAMD score again, if the reduction rate of HAMD more than 20% relative to baseline, the investigators will continue to use current dosage until the end of 12 week, but if the reduction rate of HAMD still less than 20% relative to baseline, the participants would withdraw.
89459300|NCT03623711|Placebo Comparator|Healthy control|50 age-, gender-,education level- and handedness matched healthy control would recruit by an advertisement in the local community and school, and excluding ① with a severe physical disease and/or neurological disease, ②with substance abuse, ③ with a history of brain injury, ④ inability to undergo a MRI scan.
89459301|NCT03677609|Experimental|Intervention|Physicians will receive a training or trainings to improve their communication and interaction with patients. The primary trainings will involve teaching physicians how to understand and leverage patient psychology as part of clinical care. Impact on patient health will then be assessed.
89459302|NCT03677609|No Intervention|Control|
89459303|NCT03683927|Experimental|Probiotics|Probiotics consist on Bacillus clausii in a plastic vial that will be administered to the infant 4 times a week
89459304|NCT03683927|Placebo Comparator|Placebo group|Sterile water contained in a plastic vial will be administered to the infant 4 times a week
89459305|NCT03683849|Experimental|Dancing group|Dance intervention group, inspired by the rhythm of Salsa. Training will be administered for an hour twice a week, for six months.
89459306|NCT03683849|Active Comparator|Strength training group|Strength training group. Training will be administered for an hour twice a week, for six months.
89459307|NCT03683849|No Intervention|Control|Control group
89459308|NCT03563261|Active Comparator|Collagen supplement group|Participants assigned in the collagen supplement group will drink the active product every morning before breakfast.
89459309|NCT03563261|Placebo Comparator|Placebo supplement group|Participants assigned in the placebo supplement group will drink the placebo every morning before breakfast.
89459310|NCT03677531|Experimental|Other (radiation therapy, videos)|Participants undergo daily radiation therapy and watch videos/movies of their choice during treatments.
89459311|NCT05610592||Rectal cancer|patients underwent curative surgery
89459312|NCT03678857|Experimental|Creatine Before|Receives Creatine before and placebo after training.
89459313|NCT03678857|Experimental|Creatine After|Receives creatine after and placebo before training.
89459314|NCT03683693|No Intervention|Standard of Care group|Historical Group = Standard of Care group. Decision for stopping antibiotics taken by ICU physician: assessment on the basis of the clinical picture and traditional inflammatory biomarkers such as crp and leucocytosis
89459315|NCT03683693|Experimental|Procalcitonin group|ICU physician gets on regular base PCT value, what can be used as additive tool in the decision-making for stopping antibiotics.
89459316|NCT04994080|Experimental|Treatment group A/B|
89459317|NCT04994080|Placebo Comparator|Treatment group C|
89459318|NCT05412316|Experimental|Healthy Volunteers|Healthy volunteers that fulfill the inclusion criteria. Intervention: Short-wave diathermy (Radiation)
88941588|NCT01861600|Other|Human milk (HM)|For 8 weeks, infants will consume ad libitum per day. Human Milk
89459319|NCT05363878|Experimental|Native HEALTH Condition|
88941589|NCT01861600|Experimental|Experimental formula (EF) 3|For 8 weeks, infants will consume ad libitum per day. S-26 Gold EF3
88941590|NCT01861613|Experimental|HBV vaccine|HBV vaccine (Engerix-B, recombinant hepatitis B surface antigen, 20µg/mL/vial, GlaxoSmithKline, Belgium)
89459320|NCT05363878|No Intervention|Wait-List Control|
88941591|NCT01861626|Other|sequence 1 : Test drug - Reference|
88941592|NCT01861626|Other|Sequence 2 : Reference - Test drug|
88941593|NCT01861639|Experimental|ineffective rTMS - Active TBS - fMRI|
88941594|NCT01861639|Experimental|Effective rTMS - Active TBS - fMRI|
88941595|NCT01861639|Sham Comparator|ineffective rTMS - Sham TBS - fMRI|
88941596|NCT01861639|Sham Comparator|Effective rTMS - Sham TBS - fMRI|
89016835|NCT00263705|Experimental|capecitabine|capecitabine 2000 mg/m² daily
89016836|NCT00263744|Experimental|1|MEDI517
89016837|NCT00263744|Active Comparator|2|Aluminum hydroxide
89016838|NCT00263783|Experimental|1|MEDI-522
89016839|NCT00263939|Experimental|1 - In home intervention|In home (face to face) delivery of the study intervention, Homing in on Health
89016840|NCT00263939|Experimental|2 - Telephone intervention|Telephone delivery of the study intervention, Homing in on Health
89016841|NCT00263939|No Intervention|3 - Usual care|Patients receiving the care their usual health providers supply, without an study intervention
89459321|NCT05363800|Experimental|HRS-3738|"In dose Escalation:~HRS-3738 will be taken in oral. Seven dose levels are preset.~In dose Expansion:~2 to 3 dose cohorts will be selected for dose expansion stage.~In indication Expansion:~Indications will be selected to evaluate preliminary efficacy."
89459322|NCT05382052||Study group|The study is based on a blood sample analysis in stage IIIA non-small lung cancer patients that are going to receive neoadjuvant treatment in the real world. The patients participating in this non-interventional study will not receive treatment in relation to the study. Prospective information about treatment after neoadjuvant treatment and after the last blood extraction will not be collected.
89016842|NCT00300261|No Intervention|1|receives home care
89459323|NCT05362474|Experimental|montelukast|montelukast 10mg orally once a day
89016843|NCT00300261|Experimental|2|receives telehealth monitoring in addition to home care
89016844|NCT00300300|No Intervention|1|applying a patellar graft using conventional surgical technique.
89016845|NCT00300300|No Intervention|2|applying a hamstring graft using conventional surgical technique.
89016846|NCT00300300|Experimental|3|applying a patellar graft using a computer-assisted surgy technique.
89016847|NCT00300300|Experimental|4|hamstring graft CAOS
89016848|NCT00264095||001|
89016849|NCT00294567|Active Comparator|1|Amlodipine
89016850|NCT00294567|Active Comparator|2|Azelnidipine
89016851|NCT04708925||group A- conservative therpay|hypertriglyceridemia-induced acute pancreatitis patients who recieved conservative therapy
89016852|NCT04708925||group B- plasmapharesis therapy|hypertriglyceridemia-induced acute pancreatitis patients who recieved plasmapharesis therapy
89016853|NCT00300534|No Intervention|Abbott Laboratories Determine test for syphilis|Abbott Laboratories Determine rapid test for syphilis
89016854|NCT04708964|Active Comparator|Flurbiprofen|5 ml of flurbiprofen solution 0.25% will be administered, through the subglottic intake door of the endotracheal tube. The solution will be left in place for 1 minute
89016855|NCT04708964|Placebo Comparator|Placebo|5 ml of saline solution 0.9% will be administered, through the subglottic intake door of the endotracheal tube. The solution will be left in place for 1 minute
89016856|NCT00300573|Experimental|Dexelvucitabine (DFC)|200 mg once daily
89016857|NCT00300573|Active Comparator|lamivudine (3TC)|300 mg once daily
89016858|NCT00300612|Experimental|vaccine group|
89016859|NCT00264563||Behavioral|The intervention is basically by letting the care givers to be aware that there is active recording of iatrogenesis
89016860|NCT00294918|Experimental|Serostim® (1 mg)|
89016861|NCT00294918|Experimental|Serostim® (2 mg)|
89016862|NCT00294918|Experimental|Serostim® (4 mg)|
89016863|NCT00300729|Active Comparator|Celecoxib|Four cycles of combination chemotherapy, usually with carboplatin + gemcitabine or carboplatin + vinorelbine, plus celecoxib 400 mg b.i.d. Treatment with celecoxib is continued after completion of chemotherapy. Maximum treatment duration is one year.
89016864|NCT00300729|Placebo Comparator|Placebo|Chemotherapy as in arm 1 plus placebo capsules, b.i.d.
89016865|NCT00264719|Active Comparator|A|Mothers with pre-term deliveries will receive metoclopramide 10 mg three times a day for the first 7 days and 2 times a day for the 8th to 10th day, and once a day for the 11th to 12th day
89016866|NCT00264719|Placebo Comparator|B|Mothers with pre-term deliveries will receive metoclopramide 10 mg 3 times a day, 2 times a day from 8th to 10th day and once a day from 11th to 12th day
89016867|NCT00264719|Active Comparator|C|Mothers with full term deliveries will receive 10 mg metoclopramide, 3 times a day for the first 7 days, 2 times a day from 8th to 10th day, and once a day for day 11 to 12
89016868|NCT00264719|Placebo Comparator|D|Mothers with full term deliveries will receive the placebo 10 mg three times a day, for 7 days, and two times a day from day 8 to day 10, and once a day from 11th to 12th day
89459324|NCT05362396|Experimental|Inspiratory muscle training|Inspiratory muscle training with Powerbreath IMT device, for a duration of 8 weeks. Treatment as usual
89459325|NCT05362396|No Intervention|No training program|Without inspiratory muscle training. Treatment asusual.
89459326|NCT05610202|Experimental|TQB3702 tablets|TQB3702 tablets were administered orally, 28 days as a treatment cycle until the progressive diseases or the investigator judges that it is not suitable for subject to continue to take this medicine.
89459327|NCT05361304|Experimental|TEST Lens|Eligible subjects who are habitual soft contact lens wearers will be randomized into the TEST Lens for the duration of the study.
89459328|NCT05361304|Experimental|CONTROL Lens|Eligible subjects who are habitual soft contact lens wearers will be randomized into the CONTROL Lens for the duration of the study.
89459329|NCT05540002|Active Comparator|High Intensity Stimulation|Patients will be randomly assigned to the High Intensity Quell group and will receive higher intensity stimulation every day for 12 weeks.
89201577|NCT04500418|Active Comparator|Cenicriviroc (CVC)|Approximately 122 patients. Day 1: CVC 450 mg (300 mg AM; 150 mg PM; if patients receive their first dose on Day 1 past 2 PM, then their evening dose will be 300 mg and their next dose will be the following AM.) Days 2-28: CVC BID 150 mg (AM/PM). Every dose should be taken with food (within 30 min).
89459330|NCT05540002|Sham Comparator|Low Intensity Stimulation|Patients will be randomly assigned to the Low intensity Quell group and will receive lower intensity stimulation every day for 12 weeks.
89016869|NCT00264758|Active Comparator|Conventional hemodialysis|Three times per week in-center hemodialysis
89016870|NCT00264758|Experimental|Frequent hemodialysis|Six times per week in-center hemodialysis
89016871|NCT00264953|Active Comparator|A|4x ABVD plus 30Gy IF-RT
89016872|NCT00264953|Experimental|C|4x BEACOPP baseline plus 30Gy IF-RT
89459331|NCT05359510|Experimental|patient with various abdominal incisions to be operated|patients with various abdominal incisions for closure either by primary suturing or by mesh
89016873|NCT00264953|Experimental|B|4x ABVD plus 20Gy IF-RT
89201578|NCT04500418|Placebo Comparator|Placebo|Approximately 61 patients. A matching placebo will be given to the patients in the Placebo group at an equal volume and at the same schedule.
89459332|NCT05359120||cohort A|new brain metastases directly treated with pyrotinib combined with capecitabine
89459333|NCT05359120||cohort B|whole brain radiotherapy or stereotactic radiotherapy concurrently (≤3 months before and after radiotherapy) with pyrotinib combined with capecitabine
89201579|NCT05473156|Experimental|Dose-Escalation|
89459334|NCT05359120||cohort C|after whole brain radiotherapy or stereotactic radiotherapy (more than 3 months after radiotherapy) treated with pyrotinib combined with capecitabine
89016874|NCT00264953|Experimental|D|4x BEACOPP baseline plus 20Gy IF-RT
89016875|NCT00300846|Active Comparator|A1|
89016876|NCT00300846|Placebo Comparator|A2|
89016877|NCT02960945|Experimental|CTP-543|Tablet, single oral dose
89016878|NCT02960945|Active Comparator|Jakafi|Tablet, single oral dose
89016879|NCT00265226|Experimental|1|In one arm the patient will receive intradermal Mycobacterium W Vaccine along with Category II ATT according to RNTCP guidelines
89016880|NCT00265226|Placebo Comparator|2|In this Arm patient will receive Placebo along with Category II ATT drugs according to RNTCP guidelines
89016881|NCT00295191|Active Comparator|1|high-flux dialyser
89016882|NCT00295191|Active Comparator|2|low-flux dialyser
89016883|NCT00295191|Active Comparator|3|conventional dialysate
89016884|NCT00295191|Active Comparator|4|ultrapure dialysate
89201580|NCT05473156|Experimental|Dose-Expansion (Non Small Cell Lung Cancer, NSCLC)|
89201581|NCT05473156|Experimental|Dose-Expansion (Head and Neck Squamous Cell Carcinoma, HNSCC)|
89201582|NCT05473156|Experimental|Dose-Expansion (Esophageal Squamous Cell Carcinoma, ESCC)|
89459335|NCT05601622|Experimental|Study group|Fluid loading, Stroke volume index measurement via transthoracic echocardiography, measurement of pleth variability index and Rainbow pleth variability index, change of tidal volume under mechanical ventilation
89459336|NCT05599516|Experimental|Cohort 1 LIBP-Rec-Vaccine Group|Subject vaccinated with ≥2 doses of inactivated COVID-19 vaccine for ≥6 months
89459337|NCT05599516|Experimental|Cohort 1 BIBP-Rec-Vaccine Group|Subject vaccinated with ≥2 doses of inactivated COVID-19 vaccine for ≥6 months
89459338|NCT05599516|Placebo Comparator|Cohort 1 placebo control group|Subject vaccinated with ≥2 doses of inactivated COVID-19 vaccine for ≥6 months
89459339|NCT05599516|Experimental|Cohort 2 LIBP-Rec-Vaccine Group|Subject vaccinated with ≥2 doses of mRNA COVID-19 vaccine for ≥6 months
89459340|NCT05599516|Experimental|Cohort 2 BIBP-Rec-Vaccine Group|Subject vaccinated with ≥2 doses of mRNA COVID-19 vaccine for ≥6 months
89459341|NCT05598970|No Intervention|Control|This group will serve as the Control group (81 HDs, 81 communities, 810 households) to identify the effects of a Parenting only, Unconditional Cash Transfer (UCT) only, and Parenting+UCT interventions. Caregivers will continue benefiting from a traditional government CHW home visit program, focusing on maternal and child health and nutrition, which is currently in practice in Tanzania.
89459342|NCT05598970|Experimental|Parenting only|88 HDs, 77 communities, 770 households. Existing CHWs will be trained to use an innovative digital application for the delivery of integrated ECD services to mothers who are at least 20 weeks pregnant and less than 32 weeks pregnant for a period of 15 months. CHWs will provide tailored ECD services (e.g., prompting messages tailored to child age and triggering follow-up visits conditional on changing conditions), covering all aspects of the Nurturing Care Framework (Health, Nutrition, Responsive Caregiving, Early Learning, Safety and Security (WHO, UNICEF, World Bank Group, 2018)). Real time data will be recorded by the CHWs in each visit using the application. Data will include information on visit attendance, activities conducted, home environment, caregiver practices, and CHW observations. From when the target child is 6 months old, group sessions will be organised by CHWs, focusing on caregiver-child interaction and stimulation activities.
89459343|NCT05598970|Experimental|Parenting+Unconditional Cash Transfer|88 HDs, 77 communities, 770 households. In addition to the Parenting Intervention, pregnant women in the study sample will receive a bi-monthly unconditional mobile money transfer of 77,000 TZS (33 USD) from 5-7 months pregnancy over a period of 15 months (7 transfers in total).
89459344|NCT05598970|Experimental|Unconditional Cash Transfer only fixed amount|89 HDs, 80 communities, 800 households. Households, in addition to the CHWs delivering health and nutrition services as usual, will receive a fixed bi-monthly unconditional mobile money transfer each of 109,000 TZS (47USD) from 5-7 months pregnancy over a period of 15 months (7 transfers in total). The transfer will be randomly assigned between mothers and fathers/spouses within each community, where in half of the eligible households, mothers will receive the transfer and in the other half, fathers/spouses (or household head where the father/spouse is not available) will receive the transfer.
89459345|NCT05598970|Experimental|Unconditional Cash Transfer only vary amount|89 HDs, 75 communities, 375 households. In addition to the previous four main treatment arms, there is another UCT only treatment study group where the level of the cash amount varies across communities. Communities, in addition to the CHWs delivering health and nutrition services as usual, in this group will be randomised to receive one of the bi-monthly unconditional mobile money transfer amounts: 32,000 TZS (14USD), 77,000 TZS (33USD), 109,000 TZS (47USD) from 5-7 months pregnancy over a period of 15 months (7 transfers in total). The transfers will be randomly assigned between mothers and fathers/spouses within each community, where in half of the eligible households, mothers will receive the transfer and in the other half, fathers/spouses (or household head where the father/spouse is not available) will receive the transfer.
89459346|NCT05380024|Experimental|Ensaritinib|
89459347|NCT05342740||Case group-CWD|diabetic patients with chronic wounds (CWD)
89459348|NCT05342740||Control group 1-ND|patients without diabetes (ND)
89459349|NCT05342740||Control group 2-NWD|diabetic patients without newly identified wound (NWD)
89459350|NCT05342194|Experimental|Toripalimab, lenvatinib, and gemcitabine-based chemotherapy-Arm A|Toripalimab plus lenvatinib and GEMOX (Gemcitabine hydrochloride and Oxaliplatin for injection ) or GC (Gemcitabine hydrochloride and Cisplatin)
89459351|NCT05342194|Experimental|Toripalimab, oral placebo, and gemcitabine-based chemotherapy -Arm B|Toripalimab plus lenvatinib placebo and GEMOX (Gemcitabine hydrochloride and Oxaliplatin for injection ) or GC (Gemcitabine hydrochloride and Cisplatin)
89459352|NCT05342194|Active Comparator|Intravenous placebo, oral placebo, and gemcitabine-based chemotherapy-Arm C|Toripalimab placebo plus lenvatinib placebo and GEMOX (Gemcitabine hydrochloride and Oxaliplatin for injection ) or GC (Gemcitabine hydrochloride and Cisplatin)
89459353|NCT04422496|Experimental|HEC96719 tablets|part A: There will be a total of 6 dose cohorts: 0.2 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg part B: There will be a total of 3 dose cohorts: 0.5 mg, 1 mg, 2 mg
89459354|NCT04422496|Placebo Comparator|placebo tablets|part A: There will be a total of 6 dose cohorts: 0.2 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg part B:There will be a total of 3 dose cohorts: 0.5 mg, 1 mg, 2 mg
89459355|NCT05341804|Experimental|the cognitive and balance dual task training group|It is performed using the CogBals software, emphasizing the completion of cognitive tasks while performing balance/strength training during the training process.
89459356|NCT05341804|Experimental|the balance training group|Balance/strength training without cognitive challenges.
88941597|NCT01861639|Experimental|ineffective rTMS - Active TBS - EEG|
88941598|NCT01861639|Experimental|Effective rTMS - Active TBS - EEG|
88941599|NCT01861639|Sham Comparator|ineffective rTMS - Sham TBS - EEG|
88941600|NCT01861639|Sham Comparator|Effective rTMS - Sham TBS - EEG|
88941601|NCT01861652|Experimental|Venous health systems Vasculaire leg compression device|Vasculaire leg compression device
88941602|NCT01861678|Active Comparator|High tie of IMA|In High tie group, IMA was transected at its origin from the abdominal aorta.
88941603|NCT01861678|Experimental|Low tie of IMA|In the low tie of the IMA, IMA was separated after branching to the left colic artery. The lymph node dissection around the IMA at its origin was performed.
88941604|NCT01861691|Active Comparator|Open surgery|Open colectomy
88941605|NCT01861691|Experimental|Laparoscopic surgery|Laparoscopic colectomy
88941606|NCT01861730|Experimental|Cohort 1 Aeras404 (5ug H4/100nmol IC31) or Placebo|1 Dose; Subject ≥ 168 to ≤ 196 days of age
88941607|NCT01861730|Experimental|Cohort 2 AERAS-404 (5ug H4/500nmol IC31) or Placebo|1 Dose; Subject ≥ 168 to ≤ 196 days of age
89459357|NCT05341804|No Intervention|the treatment as usual group|Maintain usual rehabilitation activities.
89459358|NCT05341258|Other|Critical Care Patients whom intubated last 24 hours|Critical Care Patients whom intubated last 24 hours
89459359|NCT03623789|Active Comparator|Group I|Primary total hip replacement with application of Floseal hemostatic matrix on potential bleeding sites after prosthesis implantation, and intravenous application of tranexamic acid1 g TXA before incision, followed by two boluses (1g TXA) three hours later and six hours later
89459360|NCT03623789|Active Comparator|Group II|Primary total hip replacement with intravenous application of tranexamic acid1 g TXA before incision, followed by two boluses (1g TXA) three hours later and six hours later
89459361|NCT03623789|Placebo Comparator|Group III|Control group, neither TXA nor Floseal® will be used. Equivalent volume of normal saline injection pre- and post-operatively
89459362|NCT05307406|Experimental|XAB05|Single ascending dose from 0.25 mg/kg up to 20mg/kg IV infusion
89459363|NCT05307406|Placebo Comparator|Placebo|Single IV infusion
88941608|NCT01861730|Experimental|Cohort 3A AERAS-404 (5ug H4/500nmol IC31) or Placebo|2 Doses; Subject ≥ 168 to ≤ 189 days of age
89459364|NCT05341024|Experimental|Intervention Group|16 weeks home-based PFM training program with weekly follow-up by a physiotherapist
88941609|NCT01861730|Experimental|Cohort 3B AERAS-404 (15ug H4/500nmol IC31) or Placebo|2 Doses; Subject ≥ 168 to ≤ 189 days of age
88941610|NCT01861730|Experimental|Cohort 4 AERAS-404 (15ug H4/500nmol IC31) or Placebo|3 Doses; Subject ≥ 84 to ≤ 98 days of age
89459365|NCT05341024|No Intervention|Control Group|No intervention
89459366|NCT05306470|Experimental|Ethyl chloride|Pre cooling done by the application of single spray ethyl chloride on a cotton pellet and placed for 30 seconds at the injection site for numbing effect
88941611|NCT01861730|Experimental|Cohort 5 AERAS-404 (50ug H4/500nmol IC31) or Placebo|3 Doses; Subject ≥ 84 to ≤ 98 days of age
89459367|NCT05306470|Experimental|5% lidocaine gel|5% lidocaine gel 2ml applied on a cotton pallet for 30 seconds on the oral mucosa at the site of injection for the numbing effect
89459368|NCT05306470|No Intervention|control|Local anesthesia infiltration is administrated without using any numbing agent
89459369|NCT05340010|Experimental|HCG group|n Group 1 (hCG): participants will receive endometrial preparation with estrogen and an intramuscular hCG injection will before progesterone supplementation
88941612|NCT01861730|Experimental|Cohort 6 AERAS-404 (dose level pending) or Placebo|3 Doses; Subject ≥ 64 to ≤ 83 days of age
88941613|NCT01861743|Experimental|Multimodal analgesia|multiple analgesic medications utilized in a synergistic manner to control pain while minimizing side-effects of individual drugs due to decreased doses. This includes pre-operative patient education, intra-operative pain management and post-operative pain protocols.
88941614|NCT01861743|Active Comparator|Patient Controlled analgesia|Pain management using patient controlled narcotic analgesia.
88941615|NCT01861769|Experimental|Technology-enhanced Teleconsultation|Technology-enhanced Group Tele-consultation. This consultation method requires that participants be prepared to review and receive feedback on audiorecorded CPT sessions in a group format. The CPT expert randomly selects two clinician sessions each week that have been audiorecorded to use for feedback and discussion in group teleconference based on procedures used in previous training initiatives (Stirman, Bhar, et al., 2010). Five- to twenty-minute segments of the two sessions will be shared within the group consultation. The CPT expert will provide feedback on the sessions with an emphasis on review of key learning points. These consultation group sessions will be facilitated with collaborative meeting software that includes audio file uploading.
88941616|NCT01861769|Experimental|Standard Teleconsultation|Standard Tele-consultation Group. The CPT expert will randomly select clinicians for case presentation each week. Each clinician will be responsible for verbally presenting on their CPT cases throughout the 6-month period of consultation course. No audiorecorded content will be reviewed within the calls. All other procedures used in the above condition will be used here.
88941617|NCT01861769|No Intervention|No consultation|No Consultation/Fidelity Monitoring Only. Participants assigned to this condition will receive no post-workshop expert consultation, but will be subject to the same audiorecorded session-uploading and client-outcome reporting as the other conditions. This condition allows us to assess the effect of clinicians knowing that their sessions are subject to fidelity assessment.
89459370|NCT05340010|No Intervention|control group|Group 2 (control): participants will receive the conventional endometrial preparation with estrogen followed by progesterone supplementation
88941618|NCT01861782|Experimental|Dead Sea Solar and Water Treatment|Dead Sea Solar and Water Treatment
89459371|NCT05339386||Initiating Therapy|PAH patients who are newly initiating background therapy to treat pulmonary arterial hypertension.
89459372|NCT05339386||Stable|PAH patients who are stable on therapy (On stable doses of background PAH therapy and diuretics for at least 90 days prior to screening).
89459373|NCT05339074|Experimental|Ketamine|Open-label ketamine infusions will be provided on a flexible schedule (every 2-4 weeks) with flexible dosing (0.5-1.0mg/kg over 40 minutes) titrated to optimize benefits, while minimizing the dosage and frequency over a 12-week extension period
89459374|NCT05338996|Experimental|iENGAGE for PrEP|We will conduct an exploratory pilot of the PrEP intervention, using a quasi-experimental design, among 80 multi-ethnic WOC in Miami-Dade, Broward, and Palm Beach counties to evaluate feasibility, acceptability, and fidelity. PrEP uptake, adherence, and retention in care will be measured over a 4-month period, including biomarkers of adherence.
89459375|NCT05352490||HF-group|patients with AECOPD and acute heart failure
89459376|NCT05352490||non HF-group|patients with AECOPD without acute heart failure
89459377|NCT05560282|Experimental|Fenfluramine|"Fenfluramine, oral,~starting at 0.1mg/kg twice daily, maximum 26mg/day in patients not taking concomitant stiripentol~starting at 0.1mg/kg twice daily, maximum 17mg/day in patients taking concomitant stiripentol"
89459378|NCT03683615|Other|patients with traumatic recent orbital blow out fractures|
89501842|NCT04601870|Experimental|Financial Incentive (50 dollars)|N=180 randomized participants will be offered a 50 dollar incentive to participant in an intervention to quit smoking.
89459379|NCT05338762||Current COVID-19 symptoms or SARS-CoV-2 in the last 30 days with a positive RT-PCR test|"75 subjects will be enrolled who were diagnosed as SARS-CoV-2 with a positive RT-PCR nasal pharangeal test or are suspected of having a COVID-19 infection with symptom onset in the last 30 days. (Symptom onset 0-30 days)~This group of subjects will receive:~a fingerstick blood sample for a rapid test neutralizing antibody test to be done in the office with the TekiTrust SARS-CoV-2 Neutralizing Antibody Detection Rapid Test~a blood draw which will be sent to the lab for neutralizing antibody testing with the TekiTrust SARS-CoV-2 Nuetralizing Antibody Detection ELISA Kit and the standard Plaque Reduction Neutralization Test (PRNT)~a nasal-pharangeal RT-PCR test"
88941619|NCT01861782|Experimental|Sulfur Pool & Medicinal Mud|Sulfur Pool & Medicinal Mud
89459380|NCT05338762||Diagnosed with SARS-CoV-2 (COVID-19) in the past 3 months with a positive RT-PCR test|"30 subjects will be enrolled who have been diagnosed with COVID-19 in the past 3 months and had a prior positive RT-PCR nasal pharangeal test. (Symptom onsent 31-90 days)~This group of subjects will receive:~a fingerstick blood sample for a rapid test neutralizing antibody test to be done in the office with the TekiTrust SARS-CoV-2 Neutralizing Antibody Detection Rapid Test~a blood draw which will be sent to the lab for neutralizing antibody testing with the TekiTrust SARS-CoV-2 Nuetralizing Antibody Detection ELISA Kit and the standard Plaque Reduction Neutralization Test (PRNT)"
89459381|NCT03678779|Experimental|Incentive|Each week parents received one $5 grocery store gift card per child in the household, intended for the purchase of healthy snacks, donated to the study by a partnering grocery store
89459382|NCT03678779|Experimental|Education|Parents received brief weekly nutrition education videos (approximately one minute in length, uploaded on YouTube and viewable on most operating systems and on mobile devices
89459383|NCT03678779|Experimental|Combined|Parents received both the Incentive and Education arm interventions
89459384|NCT03677453|Active Comparator|IPTP|Patients will have access to the web-based interactive teaching tool.
89459385|NCT03677453|No Intervention|Non-IPTP|Patients will not have access to the web-based interactive teaching tool.
89459386|NCT03678701|Experimental|Protein group|The protein group will consume 30g of 100% whey protein shake 1 hour before lunch and before dinner, for 12 weeks
89459387|NCT03678701|No Intervention|Control group|Control group will not consume any protein supplements. They will continue the usual feeding habits
89459388|NCT05338450|Experimental|Clemastine Fumarate|
89459389|NCT05338450|Placebo Comparator|Placebo|
89459390|NCT03678623||Office-based workers|Individuals working in an office environment with their main tasks involving use of a computer, reading, phoning, making presentations and participating in meetings, who perform more than 30 hours per week mostly sitting at a computer.
89459391|NCT03683537||Delayed Neurocognitive decline|Patients in whom there is Delayed Neurocognitive Recovery (DNR) after surgery, based on neuropsychological tests or clinically. DNR is defined as follow: 1)decrease of scores of neuropsychological test scores for more than 1 standard deviation (SD) of these tests; 2)clinically - inability of patient to perform test after surgery because of neurocognitive impairment.
89459392|NCT03683537||Normal postop neurocognitive function|Patients in whom there is no clinical signs of DNR, defined as in previous group.
89016885|NCT00265733|Experimental|paclitaxel + capecitabine|"Patients receive paclitaxel poliglumex IV (CT-2103; Xyotax™) over 10-20 minutes on day 1 and oral capecitabine twice daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~After completion of study treatment, patients are followed every 6 months for up to 5 years."
89016886|NCT00265811|Experimental|Folfox+Cetuximab|FOLFOX-4 Cetuximab alone every 2 weeks
89016887|NCT00265811|Active Comparator|Folfox|FOLFOX-4 alone every 2 weeks
89016888|NCT00295308|Experimental|Arm 1|
89016889|NCT00295308|Placebo Comparator|Arm 2|
89016890|NCT00265967|Experimental|1|Irbesartan
89016891|NCT00415766|Active Comparator|rHCG 250 ug|Injection of 250 ug Ovitrelle to trigger final oocyte maturation
89016892|NCT00415766|Active Comparator|uHCG 5000 IU|Injection of 5000 IU Pregnyl to trigger final oocyte maturation
89016893|NCT00415766|Active Comparator|uHCG 7500 IU|Injection of 7500 IU Pregnyl to trigger final oocyte maturation
89016894|NCT00301392|Other|Pitavastatin|Administration of Pitavastatin
89016895|NCT00266240|Experimental|1|
89016896|NCT00266240|Experimental|2|
89016897|NCT00266240|Experimental|3|
89016898|NCT00266240|Experimental|4|
89016899|NCT00266240|Placebo Comparator|5|
89016900|NCT00295542|Active Comparator|1|Treatment on awakening
89016901|NCT00295542|Active Comparator|2|Treatment at bedtime
89016902|NCT04719026||Cases|Patients for the case study group will be recruited from those hospitalized for acute myocardial infarction on the Cardiology Ward and Coronary Care Unit at Aberdeen Royal Infirmary. All patients will be diagnosed using current clinical criteria for type-1 myocardial infarction according to the ESC guidelines10 and recruited within 3 days of admission. Recruitment of this arm is now complete.
89016903|NCT04719026||Controls|A control group of dental patients matched for age (±3 years), gender, and risk factors for CAD (hypertension, obesity, diabetes, smoking, hypercholesterolaemia and family history) but with no history of myocardial infarction will be selected at Aberdeen Dental School or from the SHARE register or via the NHS Research Scotland Primary Care Network on an invitation basis. Thr recruitment of this arm of the study is ongoing.
89016904|NCT00266396|Experimental|weight-bearing recommendation|Weight-bearing recommendation after THA and TKA
89016905|NCT00266474||Cross sectional CF study|Multicentric study, including 187 CF patients of all age groupr in 5 CF centres.
89459393|NCT03677297|Experimental|ROSUVASTATIN|1.2% Rosuvastatin Gel. Insertion in infrabony defects once
89459394|NCT03677297|Placebo Comparator|placebo|No intervention used on control site
89459395|NCT03683459|Experimental|interventional arm|Participants will be treated with FemFlow Drug-Eluting Peripheral Balloon Catheter.
89459396|NCT05303584|Experimental|Group A|Approximately 70 subjects recruited from the prior clinical trial and newly enrolled 50 subjects will receive a booster dose of aerosolized Ad5-nCoV after three-dose priming with ICV
89459397|NCT05303584|Experimental|Group B|Approximately 70 subjects recruited from the prior clinical trial and newly enrolled 50 subjects will receive a booster dose of intramuscular Ad5-nCoV after three-dose priming with CoronaVac
89459398|NCT05303584|Experimental|Group C|Approximately 70 subjects recruited from the prior clinical trial and newly enrolled 50 subjects will receive homologous fourth dose of CoronaVac.
89459399|NCT03677219|No Intervention|Control|Parents in this arm receive the standard lumbar puncture consent discussion and answer a survey about their concerns, and do not view an educational video.
89016906|NCT04719299|Experimental|smart phone application|Behavior modification of patients will be done by showing them smartphone application game. The game demonstrates the use of common dental equipment like mirrors, ultrasonic scalers, handpieces and suction tips, etc. in the form of animated pictures with visual and sound effects. The dentist will play the game to show the child the dental procedure that will be performed on him later.
89016907|NCT04719299|Active Comparator|traditional behavior management technique|Using traditional behavior management techniques (Tell-Show-Do) which will be applied prior to local anesthesia administration
89459400|NCT03677219|Experimental|Video|Parents in this arm receive the standard lumbar puncture consent discussion and answer a survey about their concerns, then view a 2 minute educational video and respond to a second survey.
89459401|NCT03683303|Experimental|mobile applications (APP)|"A total of 70 participants were randomized to each group for 35 people, the control group receiving the oral patient education and the experimental group receiving patient education using mobile applications. Both groups collected data using Wound Care Knowledge Scale, Wound Care Skills Scale, State Trait Anxiety Inventory and Heart Rate Variability at three phases, including before the intervention (T1), after 3 times of intervention (T2), and before discharge from hospital (T3)."
89459402|NCT03683303|Active Comparator|oral education|"A total of 70 participants were randomized to each group for 35 people, the control group receiving the oral patient education and the experimental group receiving patient education using mobile applications. Both groups collected data using Wound Care Knowledge Scale, Wound Care Skills Scale, State Trait Anxiety Inventory and Heart Rate Variability at three phases, including before the intervention (T1), after 3 times of intervention (T2), and before discharge from hospital (T3)."
89459403|NCT03676985|Experimental|ZKAB001 5 mg/kg/time|Three or six patients will treated with the dose of 5 mg/kg/time of ZKAB001 IV bi-weekly. DLT was observed within 28 days after administration.
89016908|NCT00266786|Experimental|Intranasal Ketorolac Tromethamine|
89016909|NCT00266786|Placebo Comparator|Intranasal Placebo|
89016910|NCT00295815|Experimental|A|
89016911|NCT00295815|Active Comparator|B|
89016912|NCT00295971|Experimental|Single arm of transplant|Receiving haplocompatible T cell depleted peripheral blood stem cell transplant
89016913|NCT00296010|Experimental|CASA-nil PLD|Adjuvant pegylated liposomal doxorubicin (PLD) for 16 weeks
89016914|NCT00296010|Active Comparator|CASA-Nil|No adjuvant therapy
89016915|NCT00296010|Experimental|CASA-CM PLD|Adjuvant pegylated liposomal doxorubicin (PLD) for 16 weeks
89016916|NCT00296010|Active Comparator|CASA-CM CM|Low-dose, metronomic cyclophosphamide and methotrexate (CM) for 16 weeks
89016917|NCT00296049|Active Comparator|vancomycin|
89016918|NCT00296049|Experimental|daptomycin|
89016919|NCT04718649|Experimental|Celebrex + Joins|"The experimental group will receive 12 weeks of Celebrex 200mg tab (taken once a day) and Joins (taken 3 times a day) at the clinical pharmacy at the first visit, and will be prescribed only Joins (taken 3 times a day) at week 12. They will only take Joins for another 24 weeks until the 36th week.~The subject's oral medication is received at the clinical pharmacy twice at the time of first visit and at week 12. The follow-up period of the study will be 36 weeks."
89459404|NCT03676985|Experimental|ZKAB001 10 mg/kg/time|Three or six patients will treated with the dose of 10 mg/kg/time of ZKAB001 IV bi-weekly. DLT was observed within 28 days after administration.
89459405|NCT03676985|Experimental|ZKAB001 15 mg/kg/time|Three or six patients will treated with the dose of 15 mg/kg/time of ZKAB001 IV bi-weekly. DLT was observed within 28 days after administration.
89459406|NCT05348824|Experimental|Moringa oleifera|
89459407|NCT05348824|Active Comparator|Sodium hypochlorite|
89016920|NCT04718649|Placebo Comparator|Celebrex + Placebo|"The control group will receive 12 weeks of Celebrex 200mg tab (taken once a day) and placebo (taken 3 times a day) at the clinical pharmacy at the first visit, and will be prescribed only placebo (taken 3 times a day) at week 12. They will only take Joins placebo for another 24 weeks until the 36th week.~The subject's oral medication is received at the clinical pharmacy twice at the time of first visit and at week 12. The follow-up period of the study will be 36 weeks."
89016921|NCT00267566|Experimental|Treatment|50% random assignment to receive Family Help Anxiety Treatment
89016922|NCT00267566|Experimental|Control|50% random assignment to control group to receive usual/standard care for anxiety
89016923|NCT00267605|Experimental|Treatment|FHPADHD 50% randomized to receive Strongest Families (formerly Family Help Program): behavioural distance intervention
89016924|NCT00267605|Active Comparator|Control|ADHD Standard Care 50% randomized to receive standard/usual care for ADHD
89016925|NCT00301938|Experimental|Arm I (enzyme inhibitor, chemotherapy)|Patients receive a loading dose of oral perifosine every 6 hours on day 1 followed by a maintenance dose once daily on days 2-28 of course 1 and then once daily on days 1-28 in all subsequent courses. Patients also receive 7-hydroxystaurosporine IV over 3 hours on day 4. Cohorts of 3-6 patients receive escalating doses of 7-hydroxystaurosporine until the MTD is determined.
89016926|NCT00301938|Experimental|Arm 2 (enzyme inhibitor, chemotherapy)|Patients receive 7-hydroxystaurosporine IV over 3 hours on day 1 at the MTD determined in group I. Patients also receive oral perifosine as a loading dose every 6 hours on day 4 followed by a maintenance dose once daily on days 5-28 of course 1 and then once daily on days 1-28 in all subsequent courses.
89016927|NCT00296361|Active Comparator|1|
89016928|NCT00296361|Experimental|2|
89459408|NCT03678155|Active Comparator|Treatment as usual + app (without alarm)|Participants at this condition will receive the usual medical treatment for their pain but also they will be monitored daily using the Pain Monitor app. Because alarms will not be generated, physicians will not know if an undesired event is occuring despite the app is actually collecting data.
89459409|NCT03678155|Experimental|Treatment as usual + app (with alarm)|Participants at this condition will receive the usual medical treatment for their pain but also they will be monitored daily using the Pain Monitor app. Alarms will be generated in the face of certain preestablished events. Physicians will be asked to call patients and change/stop treatment if an alarm is received.
89459410|NCT03678077||Mild traumatic brain injury|"Patients between 18-60 years, who were hospital admitted, emergency or outpatient treated with mild traumatic brain injury (ICD-10 S06.0). Data were extracted from the Danish national patient register from January 2003 - December 2007.~Patients who were not resident in Denmark 5 years before and during the inclusion period were excluded (1998-2007)."
89016929|NCT00415961|Experimental|1|CoStar Paclitaxel drug eluting stent
89016930|NCT00416039|Experimental|1|Midazolam and morphine
89016931|NCT00416039|Placebo Comparator|2|placebo, Nacl 0.9 %, morphine 0.5 mg/kg
89016932|NCT00296478|Experimental|1|Endometrin 100mg BID
89016933|NCT00296478|Experimental|2|Endometrin 100mg TID
89016934|NCT00296478|Active Comparator|3|Crinone
89016935|NCT00302172|Experimental|ARQ 197|
89016936|NCT00268307|Experimental|Cell therapy|Intracoronary, one time infusion of autologous, unfractionated bone marrow mononuclear cells.
89016937|NCT00296595|Placebo Comparator|Placebo|Placebo capsules + 500 mL/day of placebo juice
89016938|NCT00296595|Experimental|Cranberry Juice|Placebo capsules + 500 mL/day of cranberry juice
89016939|NCT00296595|Experimental|Fish Oil|2 g/day of fish oil + 500 mL/day of placebo juice
89016940|NCT00296595|Experimental|Cranberry Juice + Fish Oil|2 g/day of fish oil + 500 mL/day of cranberry juice
89016941|NCT00296634|Experimental|1|45 microgram dose Hemagglutinin (HA), 120 subjects receiving Aluminum hydroxide and 120 not receiving Aluminum hydroxide.
89459411|NCT03678077||Matching controls|"Matching controls without concussion of the same age, from the same municipality and of same gender as the included cases. Controls were included during 2003 - 2007. Data were extracted from the population register.~Controls who were not resident in Denmark 5 years before and during the inclusion period were excluded (1998-2007)."
89459412|NCT05301088|Experimental|Chocolate Scent|
89459413|NCT05301088|Experimental|Stress Ball|
89016942|NCT00296634|Experimental|2|15 microgram dose HA, 60 subjects receiving Aluminum hydroxide and 60 not receiving Aluminum hydroxide.
89016943|NCT00296634|Experimental|4|3.75 microgram dose HA, 60 subjects receiving Aluminum hydroxide and 60 not receiving Aluminum hydroxide.
89016944|NCT00296634|Experimental|3|7.5 microgram dose HA, 60 subjects receiving Aluminum hydroxide and 60 not receiving Aluminum hydroxide.
89016945|NCT00268580|Experimental|Intervention|Asthma care provided using care pathway
89016946|NCT00268580|No Intervention|Control|Standard of care provided
89016947|NCT00296712|Experimental|escitalopram + bupropion|patients begin on escitalopram 10 mg/d, then bupropion 150 mg/d is added and each is alternately increased as tolerated to maximal dose of escitalopram of 40 mg/d and of bupropion of 450 mg/d
89016948|NCT00268697|Experimental|Lapaquistat Acetate 100 mg QD|
89016949|NCT00268697|Experimental|Lapaquistat Acetate 100 mg QD + Ezetimibe|
89016950|NCT00268697|Active Comparator|Ezetimibe|
89016951|NCT02961023|Active Comparator|Training|15 patients are randomised to receive 15 weeks exercise therapy as per study protocol at point of study entry.
89016952|NCT02961023|Other|Control|15 patients are randomised to receive 15 weeks of standard care, acting as a control arm, followed by 15 weeks of exercise therapy.
89016953|NCT00268814|Experimental|MTF, Psycho-education, Heroin|Stratum: Methadone treatment failures (MTF) Intervention: Psycho-education and Counselling, Drug: Diacetylmorphine (i.v.)
89016954|NCT00268814|Experimental|MTF, Case management, Heroin|Stratum: Methadone treatment failures (MTF) Intervention: Case Management and Motivational Interviewing, Drug: Diacetylmorphine (i.v.)
89016955|NCT00268814|Active Comparator|MTF, Psycho-education, Methadone|Stratum: Methadone treatment failures (MTF) Intervention: Psycho-education and Counselling, Drug: Methadone (p.o.)
89459414|NCT05301088|No Intervention|Control|
89459415|NCT02988401|Experimental|Intranasal insulin 20 international units|Subjects will administer 20 I.U. of insulin in the nostrils using a ViaNaseTM controlled particle dispersion nasal device two times/day (BID) for 24 weeks.
89459416|NCT02988401|Experimental|Intranasal insulin 10 international units|Subjects will administer 10 I.U. of insulin in the nostrils using a ViaNaseTM controlled particle dispersion nasal device two times/day (BID) for 24 weeks.
89016956|NCT00268814|Active Comparator|MTF, Case management, Methadone|Stratum: Methadone treatment failures (MTF) Intervention: Case Management and Motivational Interviewing, Drug: Methadone (p.o.)
89016957|NCT00268814|Experimental|NIT, Psycho-education, Heroin|Stratum: Not in treatment (NIT) Intervention: Psycho-education and Counselling, Drug: Diacetylmorphine (i.v.)
89016958|NCT00268814|Experimental|NIT, Case management, Heroin|Stratum: Not in treatment (NIT) Intervention: Case Management and Motivational Interviewing, Drug: Diacetylmorphine (i.v.)
89016959|NCT00268814|Active Comparator|NIT, Psycho-education, Methadone|Stratum: Not in treatment (NIT) Intervention: Psycho-education and Counselling, Drug: Methadone (p.o.)
89016960|NCT00268814|Active Comparator|NIT, Case management, Methadone|Stratum: Not in treatment (NIT) Intervention: Case Management and Motivational Interviewing, Drug: Methadone (p.o.)
89016961|NCT00268853|Experimental|1|
89016962|NCT00268853|Active Comparator|2|
89016963|NCT00268931|No Intervention|True Control|This group is being enrolled as a true control group. This group will not participate in the movement training or social training however, they will be evaluated in the same way.
89016964|NCT00268931|Experimental|Social Training|This group underwent specific social interactions two times each day with their parents.
89016965|NCT00268931|Experimental|Movement Training|This group of preterm infants underwent movement training two times per day with their parents.
89016966|NCT00296907|Experimental|Psychological Intervention|2-session psychological intervention
89016967|NCT00269048|Experimental|Arm 1|SB-480848
89016968|NCT00269048|Placebo Comparator|Arm 2|placebo
89016969|NCT00302523|Active Comparator|FK506|
89016970|NCT02960412|Experimental|furosemide|furosemide 10mg (1mL) IV push for one dose
89459417|NCT02988401|Placebo Comparator|Intranasal saline|Subjects will administer a sterile diluent containing inactive ingredients in the nostrils using a ViaNaseTM controlled particle dispersion nasal device two times/day (BID) for 24 weeks.
89459418|NCT05299060|Active Comparator|Control|After cannulation of a midline catheter or peripherally inserted central venous catheter with modified micro-Seldinger technique, the control group underwent standard care.
89459419|NCT05299060|Experimental|Intervention|After cannulation of a midline catheter or peripherally inserted central venous catheter with a modified micro-Seldinger technique, the intervention group underwent the standard treatment plus application of cyanoacrylate tissue adhesive (SecurePortIV®) at the puncture site.
89459420|NCT05268874|Active Comparator|Group Clavipectoral = Clavipectoral block group|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by a pain nurse blinded to the procedure. Tramodol will be performed for rescue analgesia.
89459421|NCT05268874|No Intervention|Group Control = Control group|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by a pain nurse blinded to the procedure. Tramodol will be performed for rescue analgesia.
89459422|NCT04246528|Experimental|Intervention group|Access to the online SPIN-SELF program
89459423|NCT04246528|No Intervention|Control group|Usual care, no access to the online SPIN-SELF program
89459424|NCT05329246|Experimental|Experimental Intervention Group|AI-assisted interpretation of the ECG including the predicted ECG diagnoses, disease-specific anamnestic questions, and patient management recommendations for referral to secondary care, including suggestions for procedures and further diagnostic tests
89459425|NCT05329246|No Intervention|Control Group|The usual standard of care, with NO AI-based diagnosis or treatment recommendation available.
89459426|NCT05501470|Experimental|Vivomixx|Participant in the treatment arm will receive a daily dose of the probiotic Vivomixx for 8 weeks.
88941620|NCT01861795||Preterm Neonates|Preterm neonates born at or above 27+0 weeks of gestational age sufficiently stable on nasal continuous positive airway pressure (CPAP) will be treated by standard of care.
88941621|NCT01861808|Other|lumbar puncture|That's not really an arm label because the only intervention on the patients is the lumbar puncture
88941622|NCT01861821|Active Comparator|Multiport flexible catheter|Multiport flexible catheter has three ports for the delivery of epidural medication for labor analgesia
88941623|NCT01861821|Active Comparator|Uniport flexible catheter|Uniport flexible catheter has one port for the delivery of epidural medication for labor analgesia
89459427|NCT05501470|Placebo Comparator|Placebo|Participant in the control arm will receive a daily dose of a placebo (microcrystalline cellulose) for 8 weeks.
89459428|NCT05266456|Experimental|Group 1|Participants will receive a single dose of VAX-24 administered as an intramuscular injection on Day 1 at one of three dose levels.
89459429|NCT05266456|Experimental|Group 2|Participants will receive a single dose of VAX-24 administered as an intramuscular injection on Day 1 at one of three dose levels.
89459430|NCT05266456|Experimental|Group 3|Participants will receive a single dose of VAX-24 administered as an intramuscular injection on Day 1 at one of three dose levels.
89459431|NCT05266456|Active Comparator|Group 4|Participants will receive a single intramuscular injection of the standard dose of PCV20 on Day 1.
88941624|NCT01861860|Experimental|New OPERA Criteria|TAXUS™ Element long stent
88941625|NCT01861873|Other|liver metastases|measuring liver function by PET/CT at patients where SBRT is planned for liver metastases
88941626|NCT01861886|Experimental|ESS505|Bilateral hysteroscopic placement of the permanent birth control system, Model ESS505 in the proximal portion of the fallopian tubes using a transvaginal approach. Subsequent transvaginal ultrasound (TVU) or hysterosalpingogram (HSG) was performed approximately ≤ 3 hours and 90 days following insert placement.
88941627|NCT01861899||SI-Joint Dysfunction|Device- SI-LOK
88941628|NCT01861912|Active Comparator|Arsenic trioxide TACE|Arsenic trioxide TACE: arsenic trioxide powder 20mg dissolved in lipiodol(the dosage of lipiodol is decided according to the volume of the target lesion)is used for transcatheter arterial chemoembolization(TACE). TACE will be repeated after 4~6 weeks if it is necessary according to the assessment from imaging modalities.
89016971|NCT02960412|Placebo Comparator|placebo|normal saline 1mL IV push for one dose
89016972|NCT04717947||Short interval group|≤ 8weeks between the end of neoadjuvant therapy and surgery
89016973|NCT04717947||Intermediate interval group|> 8 and ≤ 12 weeks between the end of neoadjuvant therapy and surgery
89016974|NCT04717947||Long interval group|> 12 weeks between the end of neoadjuvant therapy and surgery
89459432|NCT05329012||DUL treatment group|Patients with unstable ulna fractures will be operated and treated with the Distal Ulna locking plate (I.T.S. company) according to clinical routinal indication.
89201583|NCT00671034|Experimental|Arm I (combination chemotherapy)|Patients receive calaspargase pegol together with combination chemotherapy. Patients receive chemotherapy PO, IV, SC, and IT. Some patients also undergo radiation therapy to the head. Treatment may continue for up to 4 years.
89201584|NCT00671034|Active Comparator|Arm II (combination chemotherapy)|Patients receive pegaspargase together with combination chemotherapy. Patients receive chemotherapy PO, IV, SC, and IT. Some patients also undergo RT to the head. Treatment may continue for up to 4 years.
89201585|NCT04483648|Experimental|Exercise Group|A progressive home-based cervical stabilization exercise program was delivered by sending messages and video instructions via a freeware and cross-platform messaging service (WhatsApp Messenger) in a weekly basis.
89201586|NCT04483648|No Intervention|Control Group|Patients in control group did not receive any exercise intervention.
89201587|NCT04432792||Clinical Records Review|We will receive clinical chart data from the telehealth providers on 3,000 patients (which could include the survey study participants, but we will not know their identities) which will include date of birth, zip code, and dates of service - but will otherwise be de-identified.
89201588|NCT04432792||Study Survey Participants|We aim to enroll at least 3,000 participants to complete the study surveys.
89201589|NCT00743522||Control|PROVE Trial settings
89201590|NCT00743522||Experimental|Pre-selected settings
89201591|NCT05623462|Active Comparator|Control Group|"Participants in the control group will receive conventional gait training (conventional physical therapy program) for one hour as the following.~Part (1) Treadmill gait training without virtual reality. (for 30 minutes)~Rest for 15 minutes between the first part and the second part.~Part (2) Indoor open environment gait training exercises(over-ground gait training exercises.). (for 30 minutes)"
89201592|NCT05623462|Experimental|Experimental Group|"Participants in the experimental group will receive a treatment program that is comprised of two parts.~The first part included training, for (30 minutes), on The C-Mill virtual reality treadmill. The C-Mill is an instrumented treadmill with interactive virtual reality games and applications. The C-Mill applies an augmented virtual reality environment, obstacle avoidance games, and a variety of balance challenges in a safe and controlled environment to increase walking adaptability and performance in everyday life.~There will be 15 minutes rest between parts one and two of the training program~The second part (conventional training program) (30 minutes) will include: Indoor open environment gait training exercises (over-ground gait training exercises.). (30 minutes)"
89201593|NCT00743600|Experimental|1|Patients with shoulder pain who were clinically referred to Ultrasound for evaluation
89201594|NCT00743600|Active Comparator|2|healthy volunteers who do not have shoulder pain
89201595|NCT04425070|Experimental|ATG-010 + ICE|ATG-010 60 mg/once,total twice in each cycle; on Days 4 and 11
89201596|NCT04425070|Experimental|ATG-010 + GEMOX|ATG-010 60 mg/once,total twice in each cycle; on Days 2 and 9
89201597|NCT04425070|Experimental|ATG-010 + Tislelizumab|ATG 010 40mg/once, will be given on Days 1, 8, and 15 of each cycle
89201598|NCT00743678|Experimental|NEO|NEO : Neoadjuvant therapy with FOLFOX6 plus cetuximab
89201599|NCT00743756|Experimental|1|A total of 20 African-American patients with type 2 diabetes will be randomized to receive home-delivered meals for twelve consecutive months. In addition, the subjects received diabetes education at every visit (8 clinic visits and 8 phone calls)
89201600|NCT00743756|Experimental|2|A total of 20 African-American patients with type 2 diabetes will be randomized to receive home-delivered meals for six consecutive months. In addition, the subjects received diabetes education for up to twelve months(8 clinic visits and 8 phone calls)
89201601|NCT00743756|Other|3|20 subjects received 12 months of diabetes education (8 clinic visits and 8 phone calls)
89201602|NCT00772278|Active Comparator|CAS|carotid artery stenting
89201603|NCT00772278|Active Comparator|CEA|carotid endarterectomy
89459433|NCT05328466|Experimental|video game in CP children|Children in this arm will play the computer game which was developed by the researcher team 3 session/weeks for 5 weeks. Each session will last for 40 minutes.
89459434|NCT05328466|No Intervention|Conventional therapy|children in this arm will receive a conventional program by occupational therapists 3 times/week for 5 weeks. Each session will last for 40 minutes.
89016975|NCT00297024|Experimental|MRI for brain mets|
89201604|NCT02679508|Experimental|Vonoprazan group|Vonoprazan 20 mg administered orally once daily in the healing phase + vonoprazan 10 mg (as the initial dose and adjusted to vonoprazan 10 mg or 20 mg) administered orally once daily in the maintenance phase
89201605|NCT02679508|Active Comparator|Lansoprazole group|Lansoprazole 30 mg administered orally once daily in the healing phase + lansoprazole 15 mg (as the initial dose and adjusted to lansoprazole 15 mg or 30 mg) administered orally once daily in the maintenance phase
89459435|NCT05295550|Experimental|Flexicurve-Smartphone İnclinometer Application|Measurement of thoracic kyphosis
89459436|NCT02269917|Experimental|Experimental Treatment Regimen|Participants will receive a single fixed dose combination (FDC) tablet containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg (D/C/F/TAF tablet), orally once daily, up to Week 48. After Week 48, all participants will continue to receive the D/C/F/TAF tablet in a 48 week extension phase (up to Week 96).
89459437|NCT02269917|Active Comparator|Current Treatment Regimen|Participants will receive a boosted protease inhibitor (bPI) (limited to darunavir [DRV] or atazanavir with low-dose ritonavir [rtv] or cobicistat [COBI], or lopinavir with rtv) combined with emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) up to Week 52. After Week 52, all participants will receive the D/C/F/TAF tablet in a 44 week extension phase (up to Week 96).
89459438|NCT02522494|Active Comparator|Intervention|Patients randomized to the intervention will view the video
89459439|NCT02522494|Other|Pamphlet alone|Patients randomized to the pamphlet alone will only receive the pamphlet
89459440|NCT05263570||Stage II-III HR+/HER2+ Early Breast Cancer|Stage II-III HR+/HER2+ Early Breast Cancer
89459441|NCT05326828||ICM group|Patients eligible for ICM implantation for screening of atrial fibrillation
89459442|NCT05326828||Non-ICM group|Patients ineligible for ICM implantation due to 1) refusal, 2) contraindication, or 3) clear underlying cause of MINOCA before ICM implantation.
89459443|NCT03484377|Experimental|Anodal tDCS|The anodal tDCS electrode will be placed over the area corresponding to the right DLPFC (F4 of the EEG10-20 international system). The anodal tDCS condition will use a constant current of 2mA, delivered via gradual increase and decrease over 10 seconds at the onset and offset of stimulation (current ramps), respectively.
89459444|NCT03484377|Sham Comparator|Sham tDCS|The sham (cathodal) electrode will be placed over the left supraorbital ridge. The current will be delivered only in the first 10 seconds, after which the stimulation will cease but with the electrodes still in place throughout the session.
88941629|NCT01861912|Experimental|Arsenic trioxide TACE+IV|"Arsenic trioxide TACE: arsenic trioxide powder 20mg dissolved in lipiodol(the dosage of lipiodol is decided according to the volume of the target lesion)is used for transcatheter arterial chemoembolization(TACE). TACE will be repeated after 4~6 weeks if it is necessary according to the assessment from imaging modalities.~Arsenic trioxide intravenous infusion: arsenic trioxide powder 0.15mg/Kg/d(maxim 10mg/d) dissolved in 250ml 0.9% sodium chloride solution is used for intravenous infusion.Every course will last for 3 weeks and the next course will be continued after 1 week suspension.Intravenous infusion will be suspended 3 days before and 7~14 days after TACE."
89459445|NCT05261308|Experimental|prosthesis|The polyamide prosthesis
88941630|NCT01861938|Experimental|Melanoma vaccine|
88941631|NCT01861951|Experimental|Pazopanib|"Pazopanib 800 mg, p.o., daily~Duration of treatment:~Until disease progression, treatment failure, or death due to any cause, whichever occurs first"
88941632|NCT01861951|Active Comparator|Doxorubicin|"Doxorubicin 75 mg/m² BSA, d1, q3wk, i.v.~Duration of treatment:~Six cycles (approximately 18 weeks) or until disease progression, treatment failure, or death due to any cause, whichever occurs first"
88941633|NCT01861964|Placebo Comparator|Sugar Pill|
88941634|NCT01861964|Active Comparator|Xylooligosarcharide 2.8g|Xylooligosarcharide 2.8grams
88941635|NCT01861964|Active Comparator|Xylooligosarcharide 1.4g|
88941636|NCT01861990|Experimental|Treatment arm|All participants will be enrolled on to one, open-label arm. Participants will be treated with valproic acid in addition to standard of care therapy.
88941637|NCT01862003|Experimental|Arm 1|AZD8931 160 mg bd, on days 1-4, + FOLFIRI in a 2 weekly schedule
88941638|NCT01862016|Active Comparator|VAC mode, Controlled ventilation|From randomization, patients are put under controlled ventilation with specific settings
88941639|NCT01862016|Experimental|APRV mode, Spontaneous breathing|During 1 to 3 hours after randomization, patients are put under controlled ventilation with specific settings for baseline data. After that, they are placed under APRV mode with specific settings
88941640|NCT01862042|Other|Supportive and Palliative care|A follow-up diary will be completed by the families and the different practitioners working with the patient. One year after the death of the patient, a questionnaire will be proposed to the parents of the child by a psychologist.
88941641|NCT01862055||SAS cohort|Consecutive patients undergoing planned cesarean section under spinal anesthesia
88941642|NCT01862068||GPA patients|GPA patients with an active disease at inclusion
88941643|NCT01862068||MPA patients|
88941644|NCT01862068||Healthy Blood Donors|
88941645|NCT01862068||Atherosclerotic patients|
88941646|NCT01862068||EGPA (Eosinophilic Granulomatosis With Polyangiitis)|
88941647|NCT01862081|Experimental|Arm A: GDC-0032 + Docetaxel|Participants will receive GDC-0032 once daily for 21 consecutive days (beginning from Day 1) in each 21-day cycle along with Docetaxel on Day 1 of each 21-day cycle.
88941648|NCT01862081|Experimental|Arm B: GDC-0032 + Paclitaxel|Participants will receive GDC-0032 once daily for 28 consecutive days (beginning from Day 1) in each 28-day cycle along with Paclitaxel on Days 1, 8, 15 and 22 of each 28-day cycle.
88941649|NCT01862081|Experimental|Arm C: GDC-0032 + Docetaxel|Participants will receive GDC-0032 once daily on Day 1 and Days 8-14 of each 21-day cycle along with Docetaxel on Day 1 of each 21-day cycle.
89459446|NCT05259514|Experimental|CytoSorb|Phase 2: 40 (20 each in treatment and control group). The Study Product is CytoSorb. Patients included will receive a CytoSorb filter. The device has a CE-mark and is used in accordance with its CE-Certification. Patients are installed as early as possible after exclusion of the bleeding source and are treated with the CytoSorb Adsorber for 48 hours. Blood flow will be set at least 200 ml/min.
89459447|NCT05259514|No Intervention|Standard of Care|Only routine treatment
89459448|NCT03486093|Experimental|CVC managed by healthcare workers|Patients with CVC managed by healthcare workers trained/retrained to GAVECELT recommendations.
89459449|NCT03486093|Experimental|CVC managed by healthcare workers plus port protector|Patients with CVC managed by healthcare workers trained/retrained to GAVECELT recommendations with the aid of port protector devices.
89459450|NCT03484221|Experimental|FOLFOXIRI+short-course radiation+XELOX|Firstly, 4 cycles of neoadjuvant FOLFOXIRI chemotherapy were administered. Subsequently, a short-course radiation therapy (5Gy*5) will be performed. After that, 4 cycles of XELOX chemotherapy will be administered followed by surgery.
89016976|NCT00297141|Experimental|single arm (radiochemotherapy)|single arm study (capecitabine, oxaliplatin)
89459451|NCT03481491|Sham Comparator|Sham cerebellar stimulation|Participants will receive a Sham stimulation (inefficient probe) applied over the cerebellum.
89459452|NCT03481491|Active Comparator|Real cerebellar stimulation|Participants will receive a real continuous theta burst stimulation (cTBS) applied over the cerebellum.
89459453|NCT03857139|Experimental|NRT smoking Cessation Intervention|All participants will be provided with the Nicotine Patch as an intervention
89459454|NCT03481335|Experimental|Intervention Community|Intervention communities (barangays) will receive the intervention (CHAP-P sessions).
89459455|NCT03481335|No Intervention|Control Community|Control communities (barangays) will receive care as usual.
88941650|NCT01862081|Experimental|Arm D: GDC-0032 + Docetaxel|Participants will receive GDC-0032 once daily on Days 2-14 of each 21-day cycle along with Docetaxel on Day 1 of each 21-day cycle.
88941651|NCT01862081|Experimental|Arm E: GDC-0032 + Docetaxel|Participants will receive GDC-0032 once daily on Days 1-14 of each 21-day cycle along with Docetaxel on Day 1 of each 21-day cycle.
88941652|NCT01862081|Experimental|Arm F: GDC-0032 + Paclitaxel|Participants will receive GDC-0032 once daily on a 5-days on, 2-days off schedule in each 28-day cycle along with Paclitaxel on Days 1, 8, 5 and 22 of each 28-day cycle.
88941653|NCT01862081|Experimental|Arm G: GDC-0032 + Paclitaxel|Participants will receive GDC-0032 once daily on a 3-days on, 4-days off schedule in each 28-day cycle along with Paclitaxel on Days 1, 8, 5 and 22 of each 28-day cycle.
88941654|NCT01862120|Experimental|interleukin-2|Dose D1 of interleukin-2
88941655|NCT01862120|Experimental|Dose D2 of interleukin-2|Dose D2 of interleukin-2
88941656|NCT01862120|Experimental|Dose D3 of interleukin-2|Dose D3 of interleukin-2
88941657|NCT01862120|Placebo Comparator|placebo|placebo
88941658|NCT01862146||Current Smoker underwent TCA|subjects who smokes daily
88941659|NCT01862146||Former Smokers underwent TCA|subjects who do not smoke since 7 years
88941660|NCT01862172|Other|additional MRI|
88941661|NCT01862185|Experimental|semi-quantitative procalcitonin|patients whom checked semi-quantitative procalcitonin examination
88941662|NCT01862185|No Intervention|control|patients whom do not checked semi-quantitative procalcitonin examination
88941663|NCT01862198|Experimental|hybrid metallic stent|Patients group who were inserted a hybrid metallic stent
88941664|NCT01862211|Experimental|members of family of children with a DA1AT|
88941665|NCT01862211|Experimental|children with a DA1AT|
88941666|NCT01862237|Experimental|Patients with type II diabetes|Type II diabetes patients with aortic valve stenosis referred for aortic valve replacement.
88941667|NCT01862237|Experimental|Patients without type II diabetes|No type II diabetes patients with aortic valve stenosis referred for aortic valve replacement.
88941668|NCT01862263|Experimental|Vildagliptin|Vildagliptin 50 mg twice daily (bid) + Insulin 20 to 40 IU/day
88941669|NCT01862263|Placebo Comparator|Placebo|Insulin 20 to 40 IU/day + Vildagliptin Placebo twice daily (bid)
88941670|NCT01862289|Experimental|Severe uncontrolled asthma|Asthmatics patients with uncontrolled symptoms despite a daily treatment by high doses of inhaled steroids and LABA. Diagnostic of chronic hyperventilation syndrome.
88941671|NCT01862302|Active Comparator|Haloperidol|Haloperidol 1mg the night before and 1mg the morning of surgery; OR Haloperidol 2mg the morning of surgery
88941672|NCT01862302|Placebo Comparator|Placebo|1 dose the night before and 1 dose the morning of surgery; OR 2 doses the morning of surgery
88941673|NCT01862341|Experimental|Milk powder|ANMUM In-Shape Nutritional Milk Powder for Active Mothers. The dose of the milk powder is 40g added to 200ml of drinkable water and will be taken twice a day.
88941674|NCT01862354|Active Comparator|Group TAP block|Patients in this group received a transverse abdominal plan block with local anesthetics and clonidine as postoperative analgesia.
88941675|NCT01862354|Active Comparator|Group : Continuous wound infusion|Patients in this group received continuous wound infusion with local anesthetics and clonidine as postoperative analgesia.
88941676|NCT01862367||rFXIII|
88941677|NCT01862380|Experimental|Cases|Functional explorations of cortisol and aldosterone production during stimulation by ITT and sodium depletion respectively in female patients with non classical 21-hydroxylase deficiency.
88941678|NCT01862380|Experimental|Control|Functional explorations of cortisol and aldosterone production during stimulation by ITT and sodium depletion respectively in healthy female controls.
88941679|NCT01862393|Experimental|400 microseconds|Electrically-induced torque generated with stimulus phase duration set at 400 microseconds.
89459456|NCT01658020|Experimental|DW224|Zabofloxacin 367mg tablet P.O. once daily for 5days and then Placebo P.O. once daily for 2days
89459457|NCT01658020|Active Comparator|Avelox|Moxifloxacin 400mg tablet P.O. once daily for 7days
89459458|NCT03481257||Ticagrelor|ACS patients treated with aspirin (100mg/d) and ticagrelor (90mg bid)
89459459|NCT03481257||Clopidogrel + very low dose rivaroxaban|ACS patients treated with aspirin (100mg/d), clopidogrel(75mg/d) and very low dose rivaroxaban (2.5mg bid)
89459460|NCT03481179|Experimental|Experimental: hf rTMS and Physical therapy|High frequency TMS will be applied with an eight shaped coil angled at 45 degrees from the sagittal axis and positioned at the C3 or C4 in accordance with the international 10-20 marking system (JASPER, 1958), which corresponds to the right or left primary motor cortex (M1) injured. Forty stimulus trains will be provide at 10Hz over the injured hemisphere, at 10 Hz for five seconds each. The interval between the trains will be 25 seconds, totaling 2000 pulses for approximately 20 minutes, with 120% of resting motor threshold (RMT). After TMS, patients will be submitted to 50 minutes of physical therapy protocol.
88941680|NCT01862393|Experimental|700 microseconds|Electrically-induced torque generated with stimulus phase duration set at 700 microseconds.
88941681|NCT01862393|Experimental|1000 microseconds|Electrically-induced torque generated with stimulus phase duration set at 1000 microseconds.
88941682|NCT01862406|Experimental|Generic Label|Purportedly generic version of the analgesic presented
88941683|NCT01862406|Active Comparator|Brand-name Label|actual brand-name analgesic presented
88941684|NCT01862432|Experimental|immediate skin-to-skin|
88941685|NCT01862432|No Intervention|control|
89459461|NCT03481179|Sham Comparator|Control: Sham hf rTMS and Physical theraphy|In this group, the volunteer will start with sham TMS, will be the same parameters was used in experimental group, however, it will be performed using two coils, one connected to the magnetic stimulator, away from the patient's scalp and another uncoupled from the stimulator and positioned in the same way as in real stimulation. After, the volunteer will be submitted to 50 minutes of physical therapy protocol.
88941686|NCT01862445||Study group|Patients receiving Chlorambucil plus Rituximab
88941687|NCT01862458|Active Comparator|tPA alone|tPA alone used to treat empyema
88941688|NCT01862458|Experimental|tPA plus dornase|tPA plus dornase used to treat empyema
88941689|NCT01862471|Experimental|DVT prophylaxis|"Neuromuscular electrical stimulation using a custom-built, two-channel stimulator (Duo-STIM (stimulator), Bioelectronics Research Cluster, National University of Ireland, Galway) with a frequency of 36 Hz, a balanced biphasic waveform with a pulse width of 350μs, a ramp up time of 500ms, a contraction time of 1s and a ramp down time of 500ms. Stimulation was applied every 20 seconds over a period of 5 minutes.~Intermittent pneumatic compression using the Novamedix A-V Impulse System Model 6000 (Novamedix distribution Limited, England), programmed to deliver compression every 20 seconds at a pressure of 130 mmHg for a 1 second duration over a period of 5 minutes."
88941690|NCT01862497||Carvedilol (for Aim 3 only)|"Eligible case subjects from aims 1-2 will participate in a randomized crossover study where each subject will receive carvedilol and prazosin for 8 weeks each(under randomized treatment sequence) with a 1 week washout period included in between treatments.~The first arm will include subjects that are assigned to the randomization sequence: Carvedilol x 8 weeks (titrated up to 50 mg po bid), washout x 1 week, Prazosin x 8 weeks (titrated up to 16 mg daily)"
88941691|NCT01862497||Prazosin (for Aim 3 only)|"Eligible case subjects from aims 1-2 will participate in a randomized crossover study where each subject will receive carvedilol and prazosin for 8 weeks each(under randomized treatment sequence) with a 1 week washout period included in between treatments.~The first arm will include subjects that are assigned to the randomization sequence: Prazosin x 8 weeks, washout x 1 week, Carvedilol x 8 weeks"
88941692|NCT01862523|Placebo Comparator|diluent|diluent
88941693|NCT01862523|Experimental|capsaicin|capsaicin
88941694|NCT01862523|No Intervention|control healthy volunteers|control healthy volunteers
88941695|NCT01862549|Experimental|DBT for children|Dialectical Behavior Therapy for children is a 32 session intervention (it consists of 2 pre-treatment sessions and 30 treatment sessions; treatment sessions are to be delivered in 32 weeks total) with once per week meetings, including 30 min. individual child therapy, 20 min. meeting with a caregiver and 40 min. of skills training with both.
88941696|NCT01862549|Active Comparator|Treatment as Usual|Children in active comparison conditions will receive Treatment as Usual (TAU) that primarily consists of 32 weekly sessions of supportive individual psychotherapy and adjunctive family interventions. Individual therapy included cognitive behavioral skills training (e.g., psychoeducation, cognitive modifications, thought blocking) and non-directive supportive therapy. Family therapy includes parenting skills training (e.g., limit setting, reinforcement techniques), structuring household environment, and safety planning.
88941697|NCT01862562|Active Comparator|Open surgery|Conventional procedure
88941698|NCT01862562|Experimental|Laparoscopic surgery|Minimum invasive procedure
88941699|NCT01862601|Experimental|JetTouch injections|
88941700|NCT01862627||Macular retinoschisis and detachment|
88941701|NCT01862653|Experimental|Auricular Acupuncture|An insomnia auricular acupuncture protocol will be administered for 30 minutes, three times per week, for three weeks in the intervention group.
88941702|NCT01862653|No Intervention|Control|The control group is a wait-list control group and will be offered the auricular acupuncture intervention after the study is complete. No intervention will be performed on control group.
88941703|NCT01862679|Experimental|8 weeks HF haemodialysis / 8 weeks HD-filtration|8 weeks high-flux haemodialysis followed by 8 weeks haemodiafiltration
88941704|NCT01862679|Experimental|8 weeks HD-filtration /8 weeks HF haemodialysis|8 weeks haemodiafiltration followed by 8 weeks high-flux haemodialysis
88941705|NCT01862692|Active Comparator|Developmental Awareness Skils|
88941706|NCT01862692|Experimental|Baby-Net condition|
88941707|NCT01862705|Experimental|Thoracic spine manipulation thrust|Thoracic spine manipulation thrust
88941708|NCT01862705|Sham Comparator|Thoracic spine manipulation non-thrust|Thoracic spine manipulation non-thrust
88941709|NCT01862809||cases|smokers
88941710|NCT01862809||controls|non-smokers
88941711|NCT01862822|Experimental|upright position|Upright position during urine bag collection
88941712|NCT01862822|No Intervention|usual position|
88941713|NCT01862835|Experimental|Degarelix/Te/placebo/ placebo|Degarelix 80 mg (given as two s.c. injections of 60 mg) once [called day 1]; Te enanthate 100 mg i.m. given on day 1, 8 and 15; Oral placebo once daily x 22 days; and no patch beginning on day 1 and changed every 3 days through day 22.
88941714|NCT01862835|Experimental|degarelix/Te/anastrozole/ placebo|degarelix 80 mg (given as two s.c. injections of 60 mg) once [called day 1]; Te enanthate 100 mg i.m. given on day 1, 8 and 15; Oral anastrozole 2.0 mg once daily x 22 days; and no patch beginning on day 1 and changed every 3 days through day 22.
88941715|NCT01862835|Experimental|degarelix/Te/ anastrozole/E2 patch|degarelix 80 mg (given as two s.c. injections of 60 mg) once [called day 1]; Te enanthate 100 mg i.m. given on day 1, 8 and 15; Oral anastrozole 2.0 mg once daily x 22 days; and an E2 patch calibrated to deliver 0.05 mg/day E2 beginning on day 1 and changed every 3 days through day 22.
88941716|NCT01862835|Experimental|degarelix/ placebo/placebo/no patch|degarelix 80 mg (given as two s.c. injections of 60 mg) once [called day 1]; placebo i.m. given on day 1, 8 and 15; Oral placebo once daily x 22 days; and no patch beginning on day 1 and changed every 3 days through day 22.
88941717|NCT01862861||Peri or post-menopausal women.|Women with peri or post-menopausal vasomotor symptoms between 30 and 60 years of age.
88941718|NCT01862887|Experimental|PH-797804|Subjects will receive a single 24 mg dose in the fed state
88941719|NCT01862887|Experimental|Moxifloxacin|Subjects will receive a single 400 mg dose in the fed state
88941720|NCT01862887|Experimental|Placebo|Subjects will receive a single placebo dose
88941721|NCT01862900|Experimental|15 Gy|Patients receive a radiation dose of 15 Gy to their liver or lung metastases. Patients receive a dose of MEDI6469 following radiation and on Days 3, and 5.
88941722|NCT01862900|Experimental|20 Gy|Patients receive a radiation dose of 20 Gy to their liver or lung metastases. Patients receive a dose of MEDI6469 following radiation and on Days 3, and 5.
88941723|NCT01862900|Experimental|25 Gy|Patients receive a radiation dose of 25 Gy to their liver or lung metastases. Patients receive a dose of MEDI6469 following radiation and on Days 3, and 5.
88941724|NCT01862913|Experimental|Computer-assisted CBT|"Usual medical treatment in accordance with a decision algorithm based on the Clinical Guidelines for the Treatment of Depression of the Ministry of Health of Chile.~Eight sessions of a computer-assisted cognitive-behavioral therapy. Trained psychologists administer this program in face to face meetings."
88941725|NCT01862913|Active Comparator|Usual care treatment|"- Usual psychological and medical treatment in accordance with a decision algorithm based on the Clinical Guidelines for the Treatment of Depression of the Ministry of Health of Chile."
88941726|NCT01862926|Experimental|Rituximab|1g given at baseline and two weeks.
88941727|NCT01862926|Active Comparator|Cyclophosphamide|Intravenous dose of 600 mg/m2 body surface area. 6 doses given 4 weekly.
88941728|NCT01862939|Experimental|part 1 DS-7309 ascending dose|1, 2.5, 5, 10, 20 mg blinded DS-7309 powder in bottle.
88941729|NCT01862939|Experimental|part 2 DS-7309|1, 2.5, 5, and 15mg DS-7309 powder in bottle for oral solution.
88941730|NCT01862939|Placebo Comparator|part 2 placebo|placebo to match part 2 DS-7309
88941731|NCT01862965|Experimental|PredEver|Prednisone and Everolimus
88941732|NCT01862978|Experimental|Heparin|Patient receiving Heparin
88941733|NCT01862978|Experimental|Nadroparin|Patient receiving nadroparin
88941734|NCT01862978|Placebo Comparator|Placebo|Patients receiving placebo
88941735|NCT01863004|Experimental|Bortezomib (Velcade®)|"This study tests whether salvage of mis-sense mutated dysferlin through proteasomal inhibition seen in cultured muscle cells can be translated into patients harboring dysferlin mis-sense mutations. The proteasomal inhibitor Bortezomib (Velcade®) is already approved as a medication for the treatment of multiple myeloma in Switzerland and in other countries.~Following an administration of a single dose of Bortezomib repeated needle muscle biopsies and blood draws will be performed to assess dysferlin levels in skeletal muscle and blood monocytes over a five day period."
88941736|NCT01863082|Experimental|exercise|the patients will be submitted to an exercise protocol
88941737|NCT01863095|Experimental|Lifestyle counseling|MJ users assigned to this condition will participate in 4 individualized intervention sessions that are based on Motivational Interviewing principles. They will receive personalized feedback on their MJ use and will be provided a smart phone app on which they report their MJ use episodes, which also is designed to promote the use of exercise/physical activity as an alternative to MJ use. Level of Physical activity will be measured using accelerometers.
88941738|NCT01863095|Active Comparator|Personalized Feedback only|MJ users assigned to this condition will participate in 4 individualized intervention sessions that are based on Motivational Interviewing principles. They will only receive personalized feedback on their MJ use.
88941739|NCT01863108|Experimental|GeniusVac-Mel4|Sub-cutaneous injections of GeniusVac-Mel4 in patients with melanoma.
88941740|NCT01863121||Cirrhotic Patients|Patients of cirrhosis
88941741|NCT01863147|Experimental|Sitagliptin|Sitagliptin 0.1 daily for 1 year
88941742|NCT01863147|Active Comparator|acarbose|acarbose 150mg daily for 1 year
88941743|NCT01863160|Other|0.1% ZEP-3 cream|250 mg of ZEP-3 Cream 0.1% is applied on the right ventral forearm and 250 mg placebo is applied on the left ventral forearm 4 times daily
88941744|NCT01863160|Other|placebo|250 mg of ZEP-3 Cream 1.0% is applied on the right ventral forearm and 250 mg placebo is applied on the left ventral forearm 4 times daily
88941745|NCT01863173|Active Comparator|metoprolol|patient or intervention group
88941746|NCT01863173|Active Comparator|placebo group|control group
88941747|NCT01863199|Active Comparator|Lucentis every 4 weeks|Lucentis 0.5mg administered intravitreally every four weeks for 12 months
88941748|NCT01863199|Active Comparator|Lucentis every 12 weeks|Lucentis 0.5mg administered intravitreally every 12 weeks
88941749|NCT01863199|Experimental|Treat and extend|Lucentis 0.5mg will be administered on an as needed basis after a loading dose using a treatment extending protocol and home monitoring.
88941750|NCT01863212|Experimental|Risk allele carriers|Individuals homozygous for the risk allele (A/A) The interventions administrated to this group: 'Blood sampling for genetic analyse', 'Stroop test', 'fMRI'
88941751|NCT01863212|Experimental|Non risk allele carriers|Individuals homozygous for the non-risk allele (T/T) The interventions administrated to this group: 'Blood sampling for genetic analyse', 'Stroop test', 'fMRI'
88941752|NCT01863225|Experimental|Group A|RVX000222 200 mg (100 mg b.i.d.) + Atorvastatin 40 mg
88941753|NCT01863225|Experimental|Group B|RVX000222 200 mg (100 mg b.i.d.) + Rosuvastatin 20 mg
88941754|NCT01863225|Experimental|Group C|RVX000222 200 mg (100 mg b.i.d.) + Atorvastatin 80 mg
88941755|NCT01863225|Experimental|Group D|RVX000222 200 mg (100 mg b.i.d.) + Rosuvastatin 40 mg
88941756|NCT01863238||Ivacaftor Treated|
88941757|NCT01863251|Experimental|Atomoxetine|Patients assigned to atomoxetine will receive atomoxetine 40 mg daily, beginning on Day 5. Atomoxetine dose will be increased to 80 mg daily for all patients beginning on Day 12. Atomoxetine will be increased to 120 mg daily for patients with persistent ATS use after 4 weeks of treatment.
88941758|NCT01863251|Placebo Comparator|Placebo|Placebo inactive medication
88941759|NCT01863264|Experimental|Cold Thin Liquid Barium|"Poland Spring Natural Spring Water will be placed in a refrigerator set to 36 °F, this will allow the water to cool to approximately 4-9 °C. As described by several authors, these waters will be used to mix the barium powder (Varibar® Thin Liquid Barium Sulfate for Suspension) to create a thin liquid consistency, with 50% dilution, which is found to be most similar to human milk and infant formula.~the infant will be required to swallow 5 boluses of this cold liquid barium while bottle feeding."
88941760|NCT01863277|Active Comparator|Melatonin|Melatonin 14mg/daily given over 14 days
88941761|NCT01863277|Placebo Comparator|sugar pill|sugar pill given over 14 days
88941762|NCT01863290||Former inmates|Former inmates with a chronic disease condition or aged 50 years and above engaged into primary care through an innovative primary care redesign model of the Transitions Clinic Network.
88941763|NCT01863316|Experimental|1) I gel group|using supraglottic airway I gel
88941764|NCT01863316|Active Comparator|2) LMA Supreme group|using supraglottic airway LMA Supreme
88941765|NCT01863329||both optic nerve sheath diameter|both optic nerve sheath diameter (the posterior 3mm of the papilla), 5 individual measurement
88941766|NCT01863342||CSI score < 40|CSI cutoff value<40
88941767|NCT01863342||Group 2: CSI score ≥ 40|CSI cutoff value≥40
88941768|NCT01863355|Experimental|B0|(basal rate 0cc/hr, bolus 3cc, lockout time 10min)
88941769|NCT01863355|Active Comparator|BL|(basal rate 1cc/hr, bolus 2cc, lockout time 10min)
88941770|NCT01863355|Active Comparator|BH|(basal rate 2cc/hr, bolus 1cc, lockout time 10min)
88941771|NCT01863381|Experimental|Hydrocephalus/Pseudotumor|Patients between the ages of 18-65 years with suspected hydrocephalus or idiopathic intracranial hypertension (IIH), also known as pseudotumor cerebri, who are recommended by their doctor based on standard clinical criteria to undergo intracranial pressure monitoring. The interventions include tympanic membrane displacement (TMD) and DPOAE.
88941772|NCT01863394|Active Comparator|Screening by community health workers|"One Community Health Worker (CHW) will be trained per village in the comparator arm. The training the CHWs receive will be identical to that delivered in the Community Management of Acute Malnutrition program run by ALIMA/BEFEN (Bien Être de la Femme et l'Enfant Niger) over the last 3 years. This involves 6 hours theoretical training and a practical session in the health centre.~CHWs will screen children 06-59 months in their village once a month"
88941773|NCT01863394|Experimental|Screening by mothers|"Mothers in the intervention health district will be trained in small womens' groups in their village. Training will have a theoretical component and a practical demonstration component on children in the village~During the first baseline door to door mass screening campaign, mothers will also receive individual training on conducting a Mid Upper Arm Circumference (MUAC) classification and looking for pedal oedema. they will receive a brief recap during the three monthly door-to-door mass screening campaigns~Mothers will be asked to check their child's MUAC and look for pedal oedema~whenever the child does not seem to be in 'good health' to the mother~whenever the mother feels that the child is 'unwell' or 'sick'~whenever it seems to the mother that her child has lost weight~whenever the mother thinks that it is necessary to do so"
88941774|NCT01863407|Experimental|DAM Solution|Preheated to a temperature level, mixed the DAM Solution 2ml and Normal Saline 250ml, poured into abdominal cavity and infiltrate the operative field before the abdominal closure
88941775|NCT01863407|Placebo Comparator|Normal Saline|Preheated the Normal Saline 250ml to a temperature level, poured into abdominal cavity and infiltrate the operative field before the abdominal closure
88941776|NCT01863420||Rectal cancer patients|For rectal cancer patients before surgery, IMRT is given with 5000 cGy in 25 fractions (5 weeks). Concurrent chemotherapy consists of oxaliplatin (50 mg/m2 ) intravenously over 2 h on days 1, 8, 15, 22 and 29, and capecitabine (825 mg/m2 twice day) was given orally on each day of radiation.The dose constraints for active bone marrow are V5<95%, V10<88%,V20<80%,V30<65%, V40<45%.
88941777|NCT01863420||Gastric cancer patients|For gastric cancer patients after surgery and chemotherapy,the 4500 cGy of radiation was delivered in 25 fractions, five days per week. Concurrent chemotherapy regimen is monotherapy with capecitabine 1600mg∙m2 twice a day (b.i.d.).The dose constraints for active bone marrow are V5<90%, V10<80%,V20<70%,V30<55%, V40<35%.
89016977|NCT04718064|Experimental|fingolimod with standard therapy|Patients will be treated with intravascular therapy and fingomod.
89016978|NCT04718064|Placebo Comparator|Placebo with standard therapy|Patients will be treated with intravascular therapy and placebo.
89201606|NCT00775632|Active Comparator|Standard of Care|The current standard of care for GVHD prophylaxis at Princess Margaret Hospital is cyclosporine and Mycophenolate or cyclosporine and methotrexate.
89016979|NCT00302601|Other|None relevant|Not relevant
89016980|NCT00269282|Active Comparator|1|Self-Management (SM) (Standard Care Group)
89016981|NCT00269282|Experimental|2|Motivational Interviewing plus Self-Management Training (MI+SM)
89016982|NCT00297219|Active Comparator|2|high dialysate calcium
89016983|NCT00297219|Active Comparator|1|low dialysate calcium
89016984|NCT00269321|Experimental|1|
89201607|NCT00775632|Experimental|Cyclosporine and Campath|The efficacy of experimental arm will be tested against standard of care for prevention of Chronic extensive GVHD.
89201608|NCT04047654||Non vitamin K oral anticoagulants (NOACs)|Patients who were prescribed with apixaban, dabigatran, edoxaban, or rivaroxaban for stroke secondary prevention.
89201609|NCT04047654||Warfarin|Patients who were prescribed with warfarin for stroke secondary prevention.
89201610|NCT04404478|Experimental|B-SWELL|Participants in the B-SWELL intervention will receive information about stress and goal setting in addition to healthy lifestyle behaviors. The intervention will take place weekly for eight weeks in groups of 11 to 13 midlife Black women for peer support. Outcome measures will include perceived general health, depressive symptoms, life's simple 7 (LS7) score, and number of unhealthy days. Data collections will occur at baseline, 8 weeks, and 12 weeks.
89201611|NCT04404478|Active Comparator|WE|The attention control group (WE), will include education about healthy lifestyle behaviors and peer support. The attention control groups will also have weekly sessions for eight weeks in groups of 11 to 13 midlife Black women. Outcome measures will include perceived general health, depressive symptoms, life's simple 7 (LS7) score, and number of unhealthy days. Data collections will occur at baseline, 8 weeks, and 12 weeks.
89201612|NCT00772356|Experimental|A|
89201613|NCT00772356|Active Comparator|B|
89016985|NCT00269321|Experimental|2|
89016986|NCT00269321|Active Comparator|3|
89016987|NCT00302640|Active Comparator|Nitazoxanide|7.5mg/kg (age under 12 months), 5 mL (100mg nitazoxanide; age 1-3 years), 10 mL (200mg nitazoxanide; age 4-11 years) twice daily x 3 days
89016988|NCT00302640|Placebo Comparator|Placebo|7.5mg/kg (age under 12 months), 5 mL (100mg nitazoxanide; age 1-3 years), 10 mL (200mg nitazoxanide; age 4-11 years) twice daily x 3 days
89016989|NCT00269360|Experimental|1|
89016990|NCT00269360|Experimental|2|
89016991|NCT00269360|Active Comparator|3|
89016992|NCT00269516|Experimental|1|
89016993|NCT00269516|Experimental|2|
89016994|NCT00269516|Experimental|3|
89016995|NCT00269516|Placebo Comparator|4|
89016996|NCT00418392|Experimental|Minocycline group|After successful simple aspiration, minocycline pleurodesis will be performed.
89016997|NCT00418392|Placebo Comparator|Control group|After successful simple aspiration, nothing will be performed.
89016998|NCT00418470|Experimental|A|Higher concentration of antibiotic in NS
89201614|NCT04360096|Experimental|Severe COVID-19 ZYESAMI™|Patients with Severe COVID-19 to be treated with inhaled ZYESAMI™ (aviptadil) by mesh nebulizer 100μg 3x daily
89201615|NCT04360096|Experimental|Severe COVID-19 Placebo|Patients with Severe COVID-19 to be treated with inhaled placebo 3x daily
89201616|NCT04005118||preoperative preparation on microbiome composition|Mechanical Bowel Preparation + oral antibiotics group: receiving mechanical bowel preparation only MBP will be prepared with 4 liters of Polyethylene glycol (PEG) solution to be started 24 hours before the planned surgery. 500mg of Metronidazole will be administrated 3 times one day before the surgery at 2 pm, 3 pm and 10 pm.
89201617|NCT04005040|Active Comparator|Mobile X-ray|Intervention: X-ray examination in the patients own home
89201618|NCT04005040|Placebo Comparator|X-ray at the Hospital|Control: X-ray at the hospital
89201619|NCT04048044|Active Comparator|Telomere length, GigaHz exposure|Measurement of white blood cell telomeres before and yearly for 5 years
89016999|NCT00418470|Experimental|B|Lower concentration of antibiotic in NS
89017000|NCT00302796|Experimental|Group A, Antibiotic|1 antibiotic tablet 45 patients Group
89017001|NCT00302796|Placebo Comparator|Group B: 1 placebo|1 placebo tablet
89459462|NCT05485948|Experimental|Treatment with P1101|Subjects who meet all the inclusion criteria and do not meet any of the exclusion criteria will start treatment with P1101. The study drug will be subcutaneously injected once every 2 weeks, with the target dose being 500 µg. Subjects will receive an initial dose of 250 µg at Week 0, a medium dose of 350 µg at Week 2, a target dose of 500 µg at Week 4, and a maintenance dose of 500 µg from the subsequent week until Week 52. If the dose needs to be adjusted due to safety or tolerability consideration, it is allowed to be adjusted to the previous dose, but the target dose is preferred to be maintained during the treatment period.
89459463|NCT03477123|Experimental|Intervention|Walking therapy with Exo-H2 exoskeleton
89459464|NCT03477123|No Intervention|Control|Group receiving conventional walking therapy without robotic exoskeleton
89459465|NCT05291494|Experimental|WeChat group|The patients in this group will be first assessed by a researcher on admission about anxiety and sleep (base on the State-Trait Anxiety Inventory (STAI) scale and the sleep quality scale (SQS)). Once the assessment completed, the patients are required to follow the WeChat public platform to watch the education videos when they are free. The content of the videos covers all aspects of surgery, anesthesia, and perioperative care. The videos are presented in an easy-to-understand pattern to ensure participants of all ages and levels of education comfortably understand the content.
89459466|NCT05291494|Placebo Comparator|Regular group|Patients in this group were also assessed by the same researcher on admission for anxiety and sleep (base on State-Trait Anxiety Inventory (STAI) scale; sleep quality scale (SQS) scale). Upon completion of the assessment, they received oral instruction from the ward nurse covering the same contents as above instead of the education video.
89459467|NCT03476967||Pretreatment x Posttreatment|The group was evaluated through non-invasive complementary examinations before laser therapy and at the 1-year follow-up visit to analyze possible optical disc alterations that may occur after retinal panretinal photocoagulation in patients with proliferative diabetic retinopathy.
89459468|NCT03476889|Experimental|Intervention|Cows milk based infant formula containing fermented infant formula and prebiotic oligosaccharides
89459469|NCT03476889|Active Comparator|Control|Cows milk based infant formula containing prebiotic oligosaccharides (commercially available Aptamil ProNutra)
89459470|NCT03476889|No Intervention|Breastfed reference|Exclusively breastfed from birth to study completion
89459471|NCT04968028|Experimental|ACAF|Participants underwent anterior decompression of Anterior Controllable Antedisplacement and Fusion
89459472|NCT04968028|Experimental|Laminoplasty|Participants underwent posterior decompression of Laminoplasty
89459473|NCT03476733||patient with drug related problem|patient with drug related problem
89459474|NCT03476733||patient without drug related problem|patient without drug related problem
89459475|NCT04713267|Other|ISABel Bed 1 or ISABel Bed 2|The study has a within-subject repeated measures-design. After a baseline measurement, participants will be allocated to either a first experimental night in automated bed 1 (ISABel Bed 1) and a second one in automated bed 2 (ISABel Bed 2) or a first experimental night in bed 2 and a second one in bed 1. Afterwards, the results of each polysomnographic measurement carried out during the intervention will be compared to the off-treatment baseline measurement.
89459476|NCT05255770|Experimental|Test condom A (NRL condom with 5% benzocaine paste)|Following randomisation each subject will be given one set of 8 condoms as per randomisation schedule. After reporting at least 4 duration records (from vaginal entry to ejaculation), subjects will return to the clinical site for collection of their next set of condoms.
89459477|NCT05255770|Experimental|Test condom B (NRL condom with 3% benzocaine paste)|Following randomisation each subject will be given one set of 8 condoms as per randomisation schedule. After reporting at least 4 duration records (from vaginal entry to ejaculation), subjects will return to the clinical site for collection of their next set of condoms.
89459478|NCT05255770|Active Comparator|Control NRL condom|Following randomisation each subject will be given one set of 8 condoms as per randomisation schedule. After reporting at least 4 duration records (from vaginal entry to ejaculation), subjects will return to the clinical site for collection of their next set of condoms.
89459479|NCT04635579|Experimental|Anterior cruciate ligament reconstruction group|Single session blood flow restriction of lower limb to individuals who have undergone anterior ligament reconstruction surgery
89459480|NCT04635579|Active Comparator|Control group|Single session blood flow restriction of lower limb to individuals who have no musculoskeletal injuries
89459481|NCT05322538|Other|Controls|Healthy controls with no known vestibular disease
89017002|NCT00302796|Experimental|Group C: Antibiotics|2 antibiotic tablets 45 patients
89017003|NCT00302796|Placebo Comparator|Group D, Placebo|2 placebo tablets 36 patients
89017004|NCT00269789|Experimental|001|OROS Methylphenidate HCl
89017005|NCT00269789|Active Comparator|002|Ritalin
89017006|NCT00269789|Placebo Comparator|003|Placebo
89017007|NCT00269867|Placebo Comparator|Placebo|Matching placebo will be adminstered at Week 0, 2, 6 and every 4 weeks up to Week 54.
89017008|NCT00269867|Experimental|Infliximab 3 mg/kg every 8 weeks|Infliximab 3 milligram per kilogram (mg/kg) will be administered as infusion at Week 0, 2, 6 and every 8 weeks up to Week 52.
89017009|NCT00269867|Experimental|Infliximab 3 mg/kg every 4 weeks|Infliximab 3 mg/kg will be administered as infusion at Week 0, 2, 6 and every 4 weeks up to Week 52.
89017010|NCT00269867|Experimental|Infliximab 10 mg/kg every 8 weeks|Infliximab 10 mg/kg will be administered as infusion at Week 0, 2, 6 and every 8 weeks up to Week 52.
89459482|NCT05322538|Experimental|Definite Meniere's disease|Patients with Definite Meniere's disease
89459483|NCT03476655||Participants with Chronic Lymphocytic Leukemia (CLL)|This study will collect retrospective data on effectiveness and outcome parameters for participants of CLL being managed with ibrutinib in the clinical practice. The primary data source for this observational study will be the medical records of each enrolled participant.
89459484|NCT03476655||Participants with Mantle Cell Lymphoma (MCL)|This study will collect retrospective data on effectiveness and outcome parameters for participants of MCL being managed with ibrutinib in the clinical practice. The primary data source for this observational study will be the medical records of each enrolled participant.
89459485|NCT04593537||MDD group|Participants with current major depressive disorder (MDD)
89459486|NCT04593537||Control group|Participants without a family and personal history of a mood disorder, schizophrenia or substance/alcohol abuse but other disorders often co-morbid with MDD are allowed such as anxiety disorders
89459487|NCT03484065||Afibrinogenemia|
89459488|NCT04376385|Experimental|Treatment condition - 9 days wait|Internet-based Self Applied Treatment Program. Main components: Motivation for change, Psychoeducation, Behavioral activation, Exposure, Mindfulness and compassion strategies, integration of loss, restoration and reconstruction of meaning, Cognitive reappraisal and Relapse prevention
89459489|NCT04376385|Experimental|Treatment condition - 12 days wait|Internet-based Self Applied Treatment Program. Main components: Motivation for change, Psychoeducation, Behavioral activation, Exposure, Mindfulness and compassion strategies, integration of loss, restoration and reconstruction of meaning, Cognitive reappraisal and Relapse prevention
89459490|NCT04376385|Experimental|Treatment condition - 17 days wait|Internet-based Self Applied Treatment Program. Main components: Motivation for change, Psychoeducation, Behavioral activation, Exposure, Mindfulness and compassion strategies, integration of loss, restoration and reconstruction of meaning, Cognitive reappraisal and Relapse prevention
89459491|NCT04376385|Experimental|Treatment condition - 19 days wait|Internet-based Self Applied Treatment Program. Main components: Motivation for change, Psychoeducation, Behavioral activation, Exposure, Mindfulness and compassion strategies, integration of loss, restoration and reconstruction of meaning, Cognitive reappraisal and Relapse prevention
89459492|NCT04376385|Experimental|Treatment condition - 33 days wait|Internet-based Self Applied Treatment Program. Main components: Motivation for change, Psychoeducation, Behavioral activation, Exposure, Mindfulness and compassion strategies, integration of loss, restoration and reconstruction of meaning, Cognitive reappraisal and Relapse prevention
89459493|NCT04459767|Experimental|Vupanorsen 80 milligram (mg)|Participants will receive one, 0.8 milliliter (mL) subcutaneous injection with vupanorsen 100 mg/mL solution
89459494|NCT04459767|Experimental|Vupanorsen 160 mg|Participants will receive two, 0.8 mL subcutaneous injections with vupanorsen 100 mg/mL solution
89459495|NCT04459767|Placebo Comparator|Placebo|"Participants in Cohort 1 (vupanorsen 80 mg) will receive one 0.8 mL subcutaneous injection with 0.9% sodium chloride in water.~Participants in Cohort 2 (vupanorsen 160 mg) will receive two 0.8 mL subcutaneous injections with 0.9% sodium chloride in water."
89459496|NCT03481101|Other|All patients|Both patients receiving chemotherapy and immunotherapy are observed during the same intervention with PET/CT and liquid biopsy. No primary comparison are made between the groups.
89459497|NCT04245670|Experimental|Stereotactic Ablative Body Radiotherapy (SABR) 35-50 Gy/5|Stereotactic Ablative Body Radiotherapy (SABR) given in 5 weekly fractions. Simultaneously treating the pelvic lymph nodes, prostate and MRI-nodule to a total dose of 25 Gy, 35 Gy and up to 50 Gy, respectively. The radiation will be given with 6-18 months of ADT.
89459498|NCT02523573||Study population|Adult ARF ICU patients needing BAL with HFNC
89459499|NCT04965220|Experimental|ATC|HLX208 (dose of RP2D) and trametinib 2mg qd ,orally,Continuation of treatment until progression, withdrawal of informed consent, intolerant toxicity (whichever occurs first)
89459500|NCT04965220|Experimental|Primary brain tumor|HLX208 (dose of RP2D) and trametinib 2mg qd ,orally,Continuation of treatment until progression, withdrawal of informed consent, intolerant toxicity (whichever occurs first)
89459501|NCT04965220|Experimental|CRC(KRAS mutant)|HLX208 (dose of RP2D) and trametinib 2mg qd ,orally,Continuation of treatment until progression, withdrawal of informed consent, intolerant toxicity (whichever occurs first)
89459502|NCT04965220|Experimental|other solid tumor|HLX208 (dose of RP2D) and trametinib 2mg qd ,orally,Continuation of treatment until progression, withdrawal of informed consent, intolerant toxicity (whichever occurs first)
89459503|NCT03483987|Experimental|Sof+Ledi+R arm|"Participants with HCV genotype 1,4, 5 or 6 and relapsed with following regimens will be treated with sofosbuvir, ledipasvir and ribavirin combination~Sofosbuvir plus velpatasvir with or without ribavirin for 12 weeks~Sofosbuvir plus ribavirin with or without pegylated interferon for 12 or 24 weeks~Sofosbuvir plus velpatasvir with or without ribavirin for 24 weeks and are not eligible for pegylated interferon"
89017011|NCT00269867|Experimental|Infliximab 10 mg/kg every 4 weeks|Infliximab 3 mg/kg will be administered as infusion at Week 0, 2, 6 and every 4 weeks up to Week 52.
89017012|NCT00303030|Active Comparator|1. Anal injection|
89459504|NCT03483987|Experimental|Sof+Ledi+R+Peg-IFN arm|Participants with HCV genotype 1,4, 5 or 6, who have relapsed after a 24 weeks treatment regimen of sofosbuvir plus velpatasvir with or without ribavirin combination and are eligible for pegylated interferon, will be treated with a combination of sofosbuvir, ledipasvir, ribavirin plus pegylated interferon
89459505|NCT03483987|Experimental|Sof+Dacla+R arm|"Participants with HCV genotype 2 or 3 and relapsed with following regimens will be treated with a combination of sofosbuvir, daclatasvir and ribavirin~Sofosbuvir plus velpatasvir with or without ribavirin for 12 weeks~Sofosbuvir plus ribavirin with or without pegylated interferon for 12 or 24 weeks~Sofosbuvir plus velpatasvir with or without ribavirin for 24 weeks and are not eligible for pegylated interferon"
89459506|NCT03483987|Experimental|Sof+Dacla+R+Peg-IFN arm|Participants with HCV genotype 2 or 3, who have relapsed after a 24 weeks treatment regimen of sofosbuvir plus velpatasvir with or without ribavirin combination and are eligible for pegylated interferon, will be treated with a combination of sofosbuvir, ledipasvir, ribavirin plus pegylated interferon
89017013|NCT00303030|Active Comparator|2. Biofeedback|
89017014|NCT00269906|Experimental|Abciximab (c7E3 Fab)|Participants will receive 0.25 milligram per kilogram (mg/kg) of body weight abciximab as bolus intravenous injection followed by continuous infusion of abciximab at rate of 10 microgram per minute for at least 18 hours but not longer than 26 hours.
88941778|NCT01863459|Experimental|Lidexamfetamine Dimesylate|"Lisdexamfetamine dimesylate (Vyvanse) is a central nervous system (CNS) stimulant, approved for the treatment of ADHD Lisdexamfetamine dimesylate is to be started at a dose of 30 mg/day for one week, increased to 50 mg/day for week 2 and to 70 mg/day for week 3. Doses are increased to the maximally tolerated/efficacious dose. Thirty milligrams of Lisdexamfetamine dimesylate per day, is the minimum dose that must be achieved.~Duration of treatment in this arm is 8 weeks; tablet is taken once per day"
89201620|NCT00775710|Active Comparator|1|Non-invasive ventilation is maintained during three nights after recovery of an episode of hypercapnic respiratory failure.
89459507|NCT03483987|Experimental|Sof+Velpa+R arm|"Following group of participants will be treated with sofosbuvir, velpatasvir and ribavirin combination~who were treated earlier with 12 week treatment regimen of either sofosbuvir plus daclatasvir or sofosbuvir plus ledipasvir with or without ribavirin or~who were earlier treated with a 24 treatment regimen of either sofosbuvir plus daclatasvir or sofosbuvir plus ledipasvir with or without ribavirin and are not eligible for pegylated interferon"
89459508|NCT03483987|Experimental|Sof+Velpa+R+Peg-IFN arm|Participants, who have relapsed after a 24 week treatment regimen of either sofosbuvir plus daclatasvir or sofosbuvir plus ledipasvir with or without ribavirin and are eligible for pegylated interferon will be treated with sofosbuvir, velpatasvir, ribavirin and pegylated interferon combination
89459509|NCT02523729|No Intervention|control|subjects drunk no Anke Malz product.
89459510|NCT02523729|Experimental|intervention one|subjects drunk one can Anke Malz product.
89459511|NCT02523729|Experimental|intervention two|subjects drunk two cans Anke Malz product.
89459512|NCT03476499|Experimental|Planned skin flap procedure|"Inclusion Criteria: i. Planned skin flap procedure, ii. SpO2 above 96% and iii: Written informed consent.~Exclusion criteria: Use of epinephrine, patent blue V or methelyne blue during procedure.~The near infrared imaging NIR device is experimental. Experimental means that the NIR imaging is not used routinely in patients' care.~The research will require no extra study visits. Images will be taken at 3 - 4 time points and a separate photo consent will be obtained prior to imaging.~One set of pre-procedure images, NIR images will be taken prior to the start of the breast surgery.~One set of intra-operative Images that will be taken intra-operatively following the mastectomy.~One to two follow-up sets of NIR images will be taken at the standard post-op follow-up visits at 1 to 2 weeks post-op for up to 30 days post-op. Follow-up visits will be scheduled as per the standard of care."
89459513|NCT04459533||TOF group|COVID-19 patients admitted to the ICU, receiving mechanical ventilation and NMB agents, for whom a NMB monitor use (TOF) was reported in the electronic health records (EHR).
89459514|NCT04459533||Control group|COVID-19 patients admitted to the ICU, receiving mechanical ventilation and NMB agents, with no NMB monitor use reported in the EHR
89459515|NCT03483909|Experimental|left IFG iTBS|intermittent theta burst stimulation over the left inferior frontal gyrus
89459516|NCT03483909|Active Comparator|right IPL cTBS|continuous theta burst stimulation over the right inferior parietal cortex
89459517|NCT03483909|Placebo Comparator|placebo|Placebo TMS stimulation over the left inferior parietal cortex
89459518|NCT04459455|Experimental|Contain COVID Anxiety SSI|Participants first receive normalizing scientific information (including neuroscience findings) that help explain why increased anxiety during the COVID-19 is a typical response. They then read testimonials from three other people from the US who have applied a 3-step action plan for coping more effectively with their anxiety. The entire intervention takes approximately 8 minutes and is completely entirely within the Qualtrics survey platform.
89459519|NCT04459455|Placebo Comparator|Remain COVID Free SSI|This placebo SSI was developed to mirror the structure of the Contain COVID Anxiety SSI, discuss COVID-19 related content, and do so without as many of the potential active ingredients of effective SSIs. Participants will receive scientific information about how soap kills the COVID-19 virus, but no neuroscience information related to behaviors or behavior change.
89459520|NCT03476421||R0 hepatectomy|Those HCC patients operated with standard R0 hepatectomy
89459521|NCT03476421||R1par hepatectomy|Those HCC patients operated with R1par hepatectomy
88941779|NCT01863459|Placebo Comparator|Placebo|"Placebo will be dosed in the same fashion as the active intervention - 3 potential dose levels.~Placebo is taken once per day for 8 weeks"
88941780|NCT01863472|Active Comparator|HeartLight(TM) Laser Balloon|Safety and efficacy of pulmonary vein isolation using the HeartLight(TM) Laser Balloon (endoscopically guided ablation)
88941781|NCT01863472|Active Comparator|irrigated radiofrequency current ablation|Safety and efficacy of pulmonary vein isolation using the irrigated radiofrequency current ablation
88941782|NCT01863485|Experimental|CM082|CM082 tablet
88941783|NCT01863511|Active Comparator|usual care|IV loop diuretics
88941784|NCT01863511|Active Comparator|Usual care plus tolvaptan|IV loop diuretic plus Tolvaptan 30 mg orally once daily
88941785|NCT01863511|Active Comparator|ultrafiltration|Volume removal through a brachial line extended length catheter or a quad lumen catheter via the internal jugular vein
88941786|NCT01863537|Experimental|Intervention|Multimedia Connect and the Multimedia facilitator training curriculum with a 4-day, face-to-face structured orientation and training for implementation, and planned, investigative team initiated telephone consultations with CBO staff to provide technical assistance at 2 and 4 months following the training workshop;
88941787|NCT01863537|Active Comparator|Traditional Connect|The original, manualized version of Connect (CDC DEBI)and manualized facilitator training curriculum with a 4-day, face-to-face structured orientation and training for implementation, and planned, investigative team initiated telephone consultation with CBO staff to provide technical assistance at 2 and 4 months following the training workshop.
88941788|NCT01863576|Active Comparator|Omega-3|This group is receiving omega-3 supplement.
88941789|NCT01863576|Placebo Comparator|Oil Corn|This group is receiving the placebo comparator.
89201621|NCT00775710|No Intervention|2|Discontinuation of NIV after the recovery of hypercapnic respiratory failure, without prolong it during night.
89201622|NCT04397536||Cohort|Patients diagnosed with MDR-TB
89459522|NCT03476421||R1vasc hepatectomy|Those HCC patients operated with R1vasc hepatectomy
89459523|NCT03476421||R1par+R1vasc hepatectomy|Those HCC patients operated with both R1par and R1vasc hepatectomy
89459524|NCT03483831|Experimental|Intervention group|Students of 5 secondary school classes aged 12-14
89459525|NCT03483831|No Intervention|Control group|Students of 5 secondary school classes aged 12-14
89459526|NCT03476265|Experimental|Ineffective Esophageal Motility and GERD|Patients with gastroesophageal reflux disease (GERD) refractory to proton pump inhibitors (PPI) and ineffective esophageal motility (IEM) according to the Chicago classification v3.0.
89459527|NCT05153577|Active Comparator|Group A: Free produce box|Participants receive free weekly produce boxes for the first 4 weeks of the study and are then randomized to pay $5 per box (with continued free weekly delivery) for the remaining 4 weeks of the study.
89459528|NCT05153577|Active Comparator|Group B: Free produce box|Participants receive free weekly produce boxes for the first 4 weeks of the study and are then randomized to pay $10 per box (with continued free weekly delivery) for the remaining 4 weeks of the study.
89459529|NCT05153187||Patients with HR+/HER2- advanced breast cancer|
89459530|NCT03672617||Children and adolescents|Children and adolescents, who administer growth hormone (GH) themselves (self-injections) will be asked to complete the questionnaire.
89459531|NCT03672617||Parents/legal guardians|Parents/legal guardians who administer the GH to their child will be asked to complete the questionnaire.
89459532|NCT05153109||Community sample|Participants will be recruited from families in Bochum who take part in experiments and studies at the department of delevopmental psychology at the Ruhr-University. The department of developmental psychology organizes a panel every year inviting all parents of newborn babies in Bochum to register if they want to participate in research.
89459533|NCT05153109||Clinical sample|Participants will be recruited from families in Bochum and Munich who seek treatment in the outpatient treatment centers at both sites. Both study sites offer special counselling for parents who experience difficulties with a child from zero to five years of age.
89459534|NCT03677921|Experimental|Investigational Group- Bio-Germanium|"Ingredient: Bio-Germanium~Type: HPMC capsule~Weight: 300mg/capsule~Directions: 2 capsules, twice a day (1.2g/day of Bio-Germanium)~Duration of use: 8 weeks"
89459535|NCT03677921|Placebo Comparator|Control Group - Placebo Product|"Ingredient: Corn starch~Type: HPMC capsule~Weight: 300mg/capsule~Directions: 2 capsules, twice a day~Duration of use: 8 weeks"
89459536|NCT05153031||lithiasic acute cholecystitis|Acute cholecystitis with the presence of one or more calculi (gallstones) in the gallbladder.
89459537|NCT05153031||alithiasic acute cholecystitis|Acute cholecystitis without the presence of one or more calculi (gallstones) in the gallbladder.
89459538|NCT05153031||elective cholecystectomy|Elective surgery is surgery that is scheduled in advance because it does not involve a medical emergency.
89459539|NCT05153031||emergency cholecystectomy|Emergence surgery
89459540|NCT05153031||management with percutaneous cholecystostomy alone|Patients that didnt recieve cholecystectomy during de whole study
89459541|NCT05153031||managemente with surgery|Patients that recieve cholecystectomy during de whole study
89459542|NCT03677765|Active Comparator|Infraclavicular group|In the infraclavicular group, subclavian venous catheterization using ultrasonography is performed beneath the clavicle.
89459543|NCT03677765|Active Comparator|Supraclavicular group|In the supraclavicular group, subclavian venous catheterization using ultrasonography is performed over the clavicle.
88941790|NCT01863589||Subjects prescribed adefovir tablets|Subjects with chronic hepatitis B or hepatic cirrhosis B to whom adefovir tablets are administered
88941791|NCT01863602||Subjects prescribed lamotrigine tablets|Subjects with epilepsy with partial seizures, tonic-clonic seizuresm or generalized seizures of Lennox-Gastaut syndrome to whom lamotrigine tablets are administered.
88941792|NCT01863615|Experimental|A(reference)/B(test)|initial administration of reference and cross-over to test
88941793|NCT01863615|Experimental|B(test)/A(reference)|initial administration of test and cross-over to reference
88941794|NCT01863628|Placebo Comparator|psychoeducation|including delivering knowledge on symptoms, discussion of suffering mental difficulties, and general coping techniques
88941795|NCT01863628|Experimental|aerobic exercise|The aerobic exercise would include cycling, jogging, table tennis,and playing badminton for 40 mins at least 3 times per week for 3 months. In each exercise, participants are supposed to exercise to the extent of getting sweaty
88941796|NCT01863641|Experimental|treatment group|Patients will receive calcitriol at a fixed dose daily.
88941797|NCT01863641|Active Comparator|control group|Patients will receive placebo daily.
88941798|NCT01863654|Experimental|A(reference)/B(test)|initial administration of reference and cross-over to test
88941799|NCT01863654|Experimental|B(test)/A(reference)|initial administration of test and cross-over to reference
88941800|NCT01863693||Cohort|
88941801|NCT01863706|Experimental|Misoprostol|400µg oral misoprostol
88941802|NCT01863706|Active Comparator|Oxytocin|20 IU oxytocin
88941803|NCT01863719|Experimental|Cohort 1|9 Subjects
88941804|NCT01863719|Experimental|Cohort 2|9 Subjects
88941805|NCT01863719|Experimental|Cohort 3|9 Subjects
89459544|NCT03623477|Active Comparator|Cognitive Remediation (CRT)|Participants assigned to CRT alone will complete 24 hours of neurocognitive training activities and 12 hours of control computer activities.
88941806|NCT01863719|Experimental|Cohort 4|12 Subjects
88941807|NCT01863784|Experimental|JNJ-38518168|
88941808|NCT01863797|Active Comparator|Early induction|"Induction was performed if membranes were still intact and cervical dilation was less than four centimetres five hours after medication for therapeutic rest. For participants with an unripe cervix intravaginal prostaglandin E2 (PgE2, dinoproston) was used. A transcervical catheter (BARD) was inserted if this procedure was possible 19 and if cervical dilatation permitted, amniotomy was performed. The physician in charge performed all assessments and procedures except amniotomy.~When the participants reached the active phase they were monitored according to the clinical guidelines."
88941809|NCT01863797|Experimental|expectant management|The participants in the control group awaited spontaneous onset of labour as long as possible (expectant management). If contractions had ceased or subsided after the therapeutic rest women could be discharged from hospital, but were still included in the study. When reaching the active phase of labour women were monitored according to the clinical guidelines.
88941810|NCT01863810|Experimental|KW21052|This arm will be pre-treated with Lyrica 150mg (75mg bid) for titration period of 1 week and then be treated with KW21052 300mg and Placebo of Lyrica for intervention period of 8 weeks.
88941811|NCT01863810|Active Comparator|LYRICA|This arm will be pre-treated with Lyrica 150mg (75mg bid) for titration period of 1 week and then be treated with Lyrica 300mg (150mg bid) and Placebo of KW21052 300mg for intervention period of 8 weeks.
88941812|NCT01863823|Other|Amoxicillin and Tetracyclines|drug treatment
88941813|NCT01863823|Other|Mouth washing|Mouth washing
88941814|NCT01863836|Experimental|Fluoroscopy|Patients will undergo bronchoscopy and radial endobronchial ultrasound-guided biopsy of a peripheral lung lesion like patients in the other group. However, single-plane fluoroscopy will be used to help locate the lesion (with the help of a steerable curette) in case of failure to locate the lesion, and it will also be used to guide tissue sampling and ensure appropriate sampling tool function. Transbronchial biopsies, transbronchial needle aspiration, brushings, and bronchoalveolar lavage will be performed for each lesion.
88941815|NCT01863836|Active Comparator|No fluoroscopy|Patients will undergo biopsy of peripheral lung lesions using radial endobronchial ultrasound guidance only, without the use of fluoroscopy. Transbronchial biopsies, transbronchial needle aspiration, brushings, and bronchoalveolar lavage will be performed for each lesion.
88941816|NCT01863862|Experimental|Clinical complete responders.|Patients with complete clinical response obtained 8 weeks after chemoradiation or 10 weeks after short-course radiation.
88941817|NCT01863875||Childhood cochlear implant recipients|The sample includes all childhood cochlear implant (CI) recipients at Oslo University Hospital in Norway from 1988-2012. The participant must have at least one year of CI-user time. Possible sample size is 530 children. The age span is from 1 to 50 years.
88941818|NCT01863875||Normal hearing people|Reference group: A group of normal hearing people matching the target group on gender and age.
88941819|NCT01863888|Experimental|teriflunomide (HMR1726)|Participants administered 14mg Teriflunomide once daily, oral. For participants who permanently discontinue Teriflunomide, an accelerated elimination procedure with either cholestyramine or charcoal will be administered.
88941820|NCT01863888|No Intervention|Reference population|Untreated healthy subjects
88941821|NCT01863914|Placebo Comparator|Placebo|Placebo tablet contains only inactive ingredient. The placebo tablets will be taken once daily for 4 weeks (1 week before operation and 3 weeks after creation of AV fistula)
88941822|NCT01863914|Active Comparator|Rosuvastatin|Rosuvastatin (CrestorÒ, Astrazeneca) 5mg once daily for 4 weeks (1 week before operation and 3 weeks after creation of AV fistula)
88941823|NCT01863927|Experimental|Research arm|Each of the participants will be randomly exposed to 4 conditions during four separate consecutive days.
88941824|NCT01863966|Experimental|Hot water drinking therapy|Hot water drinking before,after meal and before sleep
88941825|NCT01863966|Active Comparator|Pneumatic dilation|Patients who are unsatisfied with hot water drinking therapy are to receive standard pneumatic dilation
88941826|NCT01863979||Acute Atrial Fibrillation|
88941827|NCT01864057|Active Comparator|Cambodian mothers|thiamine hydrochloride 100 mg orally daily for 5 days
88941828|NCT01864057|No Intervention|American mothers|Baseline blood and breast milk sample collection
89459545|NCT03623477|Experimental|CRT+ Social Cognition Training|Participants assigned to the combination of CRT and SCT will complete 24 hours of computerized neurocognitive training in memory, attention, and processing speed, and 12 hours of computerized social cognition training focused on improving emotion recognition, social perspective taking, and mentalizing abilities.
89459546|NCT05152797|Experimental|TILs infusion|Enrolled patients will be infused with their autologous TILs followed by IL-2 administration after post- NMA lymphodepletion
89459547|NCT03677687|Experimental|Mindfulness for Physical Activity|A 6-week mindfulness programme (2 hours per week) aimed at increasing physical activity in underactive participants.
89459548|NCT03476031||study group|patients with hepatitis c nephropathy detected by lab and renal biopsy
89459549|NCT03483519|Experimental|Prehabilitation|Patients in the Prehabilitation Group and are randomized to the Experimental Group will undergo a 6 Week Exercise Program plus Standard of Care
89459550|NCT03483519|Active Comparator|Standard of Care|Patients in the Standard of Care will not receive an additional an exercise program, patients will receive the usual care received by all orthopaedic patients.
89459551|NCT03672383|Experimental|BAY987534 (Treated Arm)|Subjects with quiescent atopic dermatitis. Right or left volar forearm with test product applied.
89459552|NCT03672383|No Intervention|Untreated Arm|Subjects with quiescent atopic dermatitis. Right or left volar forearm without test product applied.
89459553|NCT04154163||Stage 1 Participants|"Blood test Day 1 DBS and venous blood~Blood test Day 2 DBS (+/- and venous blood)~Blood test Day 15 DBS only~Blood test Day 16 DBS only"
89459554|NCT04154163||Stage 2 Participants|"Non-drug naive participants:~Blood test Day 1 DBS~Blood test Day 2 DBS~Blood test Day 15 DBS~Blood test Day 16 DBS~Drug naive participants:~Blood test Day 1 DBS~Blood test Day 2 DBS~Blood test Day 3, 4, or 5 DBS~Blood test Day 4, 5 or 6 DBS~Blood test Day 15 DBS~Blood test Day 16 DBS"
89459555|NCT03672305|Other|c-Met/PD-L1 CAR-T cells treating group|Intervention Name:c-Met/PD-L1 CAR-T cell injection dosage form: injection dosage:The backtransfusion dose (recommended dose: 2 * 10^6/kg) was determined by the investigator based on the subject's own/disease condition and in vitro preparation.
89459556|NCT02523807||Patients with Parkinson's Disease|Patients with tremor due to Parkinson Disease
89459557|NCT02523807||Patients with Essential tremor|Patients with tremor due to Essential tremor
89459558|NCT02680574|Experimental|Vadadustat|
89459559|NCT02680574|Active Comparator|Darbepoetin alfa|
89459560|NCT03676829|Experimental|Arterial Embolization of the Shoulder (AES)|Patients in this study will receive the arterial embolization of the shoulder (AES) procedure. The primary aims will be to determine if arterial embolization of the shoulder (AES) will reduce pain and improve range of motion (ROM) caused by adhesive capsulitis.
89459561|NCT02523963|Experimental|study group|"children with developmental delays participated 6 sessions of family work shop~The family work shop has 5 courses, with 6 families in one course.~Intervention of one course: 2-3 hours per session, one time per week, for a total of 6 weeks."
88941829|NCT01864070|Experimental|TheraSphere + Everolimus|"Each cycle is 28 days. Target dose of TheraSphere is fixed at 120 Gy to entire tumor bearing portion of liver given at a single session on Cycle 1 Day 15. The dose of everolimus will be escalated in 2 sequential cohorts of 6 TheraSphere-treated patients each. Starting dose of everolimus is 5 mg by mouth daily for cycles 1 and 2. Patients will receive standard dose of Everolimus at 10 mg PO daily starting cycle 3 day 1.~Once DLT is defined or dose level 2 has been completed, a dose expansion cohort of 10 patients with advanced low to intermediate grade neuroendocrine tumor will be enrolled.~At least 1 time a week by phone or at the clinic for up to 30 days after last everolimus dose, study staff will follow up. Patient asked about any side effects they may have had."
88941830|NCT01864083|Experimental|Local staging patients|Breast MR and FACBC PET/PEM will be scheduled within one week of each other. Breast MR is a standard clinical examination and will be performed as standard.
89459562|NCT02523963|No Intervention|control|children with normal development not participate the work shop followed up at before, and 6 weeks later
89459563|NCT03672149|Other|Infection needing cefazolin|a) If a patient requires antimicrobial therapy for a proven or suspected infection at the time of CRRT initiation or at any time receiving CRRT, they are eligible for inclusion. If cefazolin is part of the empiric or definitive treatment regimen, it will be mixed in the CRRT solution(s) and administered via a continuous infusion to obtain pharmacokinetic and safety data of administering cefazolin via the CRRT solution and infection treatment related data. For this indication, pharmacokinetic and safety data will be obtained for the duration the patient receives cefazolin via the CRRT solution(s) for the proven or suspected infection as dictated by the primary team caring for the patient.
89459564|NCT03672149|Other|Infection not needing cefazolin|b) If a patient is deemed a candidate for CRRT and requires therapy with any anti-microbial for a proven or suspected infection not requiring cefazolin as part of the anti-microbial drug regimen, administration of cefazolin via the CRRT solution(s) will occur to solely obtain pharmacokinetic and safety data. For this indication, pharmacokinetic and safety data will be obtained for a 72-96-hour duration.
89459565|NCT03672149|Other|No infection|c) If a patient is deemed a candidate for CRRT and does not require any anti-microbial therapy, administration of cefazolin via the CRRT solution(s) will occur to solely obtain pharmacokinetic and safety data. For this indication, pharmacokinetic and safety data will be obtained for a 72-96-hour duration.
89501843|NCT01131169|Experimental|relapsed multiple myeloma|This is a two arm phase II trial to assess the progression-free and overall survival as well as the safety and efficacy of allogeneic hematopoietic stem cell transplantation using a preparative regimen with busulfan, melphalan, fludarabine, and anti-thymocyte globulin (ATG), and a T cell depleted stem cell transplant from a histocompatible related or unrelated donor in patients with relapsed or high-risk multiple myeloma.
89459566|NCT05152719|Experimental|Sprint Interval Training (SIT) Protocol|"Participants in the SIT group will start with a 5 minute warm-up jogging at around 70-80% of their heart rate max. The SIT protocol consists of 30 second intervals of all out shuttle runs, seperated by 2 minutes of low pace walking active rest. This will be repeated between 4 times during the first 2 weeks, 5 times during the second 2 weeks, and 6 times during the third 2 weeks. Participants will be instructed to sprint the greatest possible distance in 30 seconds, starting by running to the 5m marker and back, then to the 10m marker and back, then to the 15m marker etc. The SIT session will finish with 2 minutes walking at a pace 50% of their heart rate max."
89459567|NCT05152719|Active Comparator|Time Restricted Eating (TRE) Protocol|Participants will be asked to limit their food intake to the hours between 12pm to 8pm, and fast outside of these hours. During the fast, participants may consume zero calorie beverages with no caffeine or artificial sweetener. Participants are instructed to maintain their diet, with no restrictions on the type or amount of food consumed in the feeding window.
89459568|NCT05152719|Active Comparator|Combined Sprint Interval Training (SIT) and Time Restricted Eating (TRE) Protocol|Participants will be asked to abide by the same eating regimen as the Time Restricted Eating Protocol Arm. Additionally, participants in this arm will perform the SIT protocol, in the fasted state. The SIT protocol will be identical to that listed in the Sprint Interval Training Protocol Arm.
89459569|NCT03672071|Other|Group E|If a 20% decrease in any parameter compared to their baseline levels is sustained, necessary interventions 5 mg Ephedrine i.v. will be administered to patient will be performed. In the case of hypotension,
89459570|NCT03672071|Other|Group NE|.If a 20% decrease in any parameter compared to their baseline levels is sustained, necessary interventions 5 mg Noradrenaline, i.v. will be administered to patient will be performed. In the case of hypotension,
89459571|NCT03672071|Other|Group N|. If a 20% decrease in parameter compared to their baseline levels is sustained, necessary interventions mg Ephedrine + 2.5 mg Noradrenaline i.v. will be administered to patient will be performed. In the case of hypotension,
89459572|NCT04010565|Experimental|Extract of aged black garlic|Participants will consume a tablet of 550 mg daily with 250 mg of aged black garlic extract and 300 mg of excipients (microcrystaline cellulose 90 mg; dicalcium phosphate 157 mg; crosscamellose sodium 10 mg; magnesium stearate 7 mg; sodium alignate 3.06 mg; stearic acid 0.03 mg; oleic acid 1.54 mg; medium chain triglycerides 2.80 mg; ethylcellulose 13.17 mg; hydroxypropylcellulose 4.86 mg; hydroxypropylmethylcellulose 4.86 mg; talcum 2.88 mg; titanium dioxide 1.80 mg; vanilla aroma 1.00 mg) .
89459573|NCT04010565|Placebo Comparator|Placebo|Participants will consume a tablet of 550 mg daily with 550 mg of excipients (microcrystaline cellulose 342.5 mg; dicalcium phosphate 154.5 mg; crosscamellose sodium 10 mg; magnesium stearate 7 mg; sodium alignate 3.06 mg; stearic acid 0.03 mg; oleic acid 1.54 mg; medium chain triglycerides 2.80 mg; ethylcellulose 13.17 mg; hydroxypropylcellulose 4.86 mg; hydroxypropylmethylcellulose 4.86 mg; talcum 2.88 mg; titanium dioxide 1.80 mg; vanilla aroma 1.00 mg).
89459574|NCT03671993|Experimental|EPNS group|Electrical pudendal nerve stimulation (EPNS) is a type of conservative treatment which can directly modulate the pudendal nerve and produce a regulation effects on both the sensory fibers and the motor fibers of pudendal nerve.
89459575|NCT03671993|Active Comparator|II group|Intravesical instillation (II) are mixture solution administered due to poor oral bio-availability establishing high drug concentrations within the bladder, with few systemic side-effects.
89459576|NCT03475797|Experimental|Occipital Nerve Stimulation (ONS)|Occipital nerve stimulation with percutaneous or surgical lead plus optimal medical management
89459577|NCT03475797|Active Comparator|Optimal Medical Management (OMM)|Optimal Medical Management according to what is done in routine clinical practice
89459578|NCT03483285|Active Comparator|heart rate|Effects of İntubation with Airtraq or Storz to heart rate
89459579|NCT03483285|Active Comparator|mean arterial pressure|Effect of intubation with Airtraq or Storz to mean arterial pressure
89459580|NCT03475719|Active Comparator|HUG186-B and HUG186-D|Bazedoxifene acetate 22.6mg, Cholecalciferol 8.0mg(=800IU)
89459581|NCT03475719|Experimental|HUG186|Combination of Bazedoxifene acetate 22.6mg and Cholecalciferol 8.0mg(=800IU)
89201623|NCT04047888||Intervention Group|Mothers and children in this group will have measurements, questionnaire administration. The children will have routine child care at their health center and mothers will have a 60 minute nutrition-based and non-nutrition based educational message
89201624|NCT04047888||Control Group|Mothers and babies will have measurements and questionnaire administration and children will receive routine child care at their health centers. These mothers will receive a non-nutrition based educational message only.
89459582|NCT03475563||Patients with coronary artery disease|(coronary artery disease)
89459583|NCT03483207|Experimental|MVT with anticoagulation therapy(heparin &warfarin)|patients with confirmed diagnosis of acute MVT on CT scan but having no signs of peritonitis or established CT signs of gangrene will be treated conservatively with anticoagulation(heparin &warfarin) while other cases will be for surgical management and not included in the study.
89459584|NCT03483207|Experimental|MVT with failure of anticoagulation therapy(heparin &warfarin)|patients who underwent conservative therapy with anticoagulation (heparin &warfarin) but showed no improvement .
88941831|NCT01864083|Experimental|Neoadjuvant chemotherapy patients|Baseline FACBC PET/PEM will be scheduled within 1 week of beginning neoadjuvant therapy. A repeat FACBC PET/PEM will be scheduled after the conclusion of neoadjuvant therapy, and before definitive surgical management.
88941832|NCT01864135|Experimental|MRI|Comparison of targeted transrectal ultrasound guided prostate biopsies based on 3T multiparametric MRI findings to systematic non-targeted transrectal ultrasound guided prostate biopsies
88941833|NCT01864161|Experimental|oral liposomal iron|patients receive a dose of liposomal 30 mg/die iron (equivalent to 1 cp Sideral forte).
89459585|NCT05132985|Experimental|Icotinib+chemotherapy|"Neoadjuvant chemotherapy (pemetrexed + carboplatin/cisplatin ) will start within 1-3 days from enrollment at 21-day (+/-3 days) intervals (Q3W) prior to surgery. Before surgery a tumor assessment will be done to exclude evidence of progression. Patients with radiographically stable disease or partial response may be considered for operation.~Icotinib will be given as a neoadjuvant therapy before surgical resection. The recommended dose of Icotinib is 125mg 1tt(Take 1 tablet 3 times a day) orally.~Surgery: Surgery must be done within the 3rd to 4th week (+7 days) from day 21 cycle 2 of neoadjuvant treatment.~Adjuvant treatment: Patients receive additional 2 cycles of platinum-based doublet chemotherapy(Researcher decide) on day 1 with intercalated icotinib (D8-15) every 3 weeks, and continued icotinib for 2 years or until the occurrence of disease relapse, metastasis or unacceptable icotinib or chemotherapy toxicity"
89459586|NCT03483129|Experimental|Consultation|The consultation will provide the participant with one to one information regarding the benefits of physical activity and healthy eating. Emphasis will placed on the importance of achieving at least 150 minutes of moderate physical activity each week as well as adhering to healthy dietary habits, based on the NHS Eatwell Guide (Eatwell Guide, 2016). Furthermore, participants will have the opportunity to discuss pre-diabetes with a trained practice nurse and ask any questions they may have.
89459587|NCT03483129|No Intervention|Control|All participants will receive an information leaflet detailing pre-diabetes, the associated risks and steps that can be taken to avoid developing diabetes.
89459588|NCT05676320|Experimental|V-Flex|Bone cement including Inossia Cement Softener
89459589|NCT05676320|Active Comparator|V-Steady|Bone Cement alone
89459590|NCT05091723|Experimental|Administration Scenario A|Single dose of TD-0903 at Dose A on Day 1, Period 1 delivered by nasal inhalation via nebulizer device with a high-flow nasal cannula delivering supplemental oxygen
89459591|NCT05091723|Experimental|Administration Scenario B|Single dose of TD-0903 at Dose A on Day 1, Period 2 delivered by oral inhalation via nebulizer device with supplemental oxygen delivery via low-flow nasal cannula
89459592|NCT05091723|Experimental|Administration Scenario C|Single dose of TD-0903 at Dose A on Day 1, Period 3 delivered by oral inhalation via nebulizer device with supplemental oxygen delivery via high-flow nasal cannula
89459593|NCT05091723|Experimental|Administration Scenario D|Single dose of TD-0903 at Dose B on Day 1, Period 4 delivered by a route to-be-determined based on data from Scenarios A, B and C.
89459594|NCT03163316||Breast cancer patients|Patients will undergo unenhanced magnetic resonance imaging on both axillae.
89459595|NCT05079633|Active Comparator|Moderna COVID-19 vaccine (mRNA 1273)|110 participants will be randomly assigned to Moderna COVID 19
89459596|NCT05079633|Experimental|Medigen COVID-19 vaccine (MVC COV1901)|110 participants will be randomly assigned to Medigen COVID 19 vaccine
89459597|NCT02522884|Experimental|Tack Implant|Implantation of a Tack using the Intact Vascular Tack Endovascular System for the repair of post angioplasty dissections.
89459598|NCT03739593|Experimental|AR-1105-CF1|Single dose of AR-1105-CF1 (dexamethasone, targeted dose of 340 mcg) administered as an intravitreal implant into a single eye of up to 20 subjects who will be followed for 6 months
89459599|NCT03739593|Experimental|AR-1105-CF2|Single dose of AR-1105-CF2 (dexamethasone, targeted dose of 340 mcg) administered as an intravitreal implant into a single eye of up to 20 subjects who will be followed for 6 months
89459600|NCT03475485|Experimental|ID-Capsules- Active|"Randomly-assigned ingestions of ID-Capsules containing ingestible sensors (ID-Capsule- Active) while wearing the ID-Cap Reader (Wearable Sensor) under direct observation~• Subjects will ingest ID-Capsules containing the ingestible sensor which emits a signal from within the subject's stomach. This signal is detected by the wearable Reader, and the ingestion event is recorded."
89459601|NCT03475485|Placebo Comparator|ID-Capsules- Inactive|"Randomly-assigned ingestions of ID-Capsules containing no ingestible sensors while wearing the ID-Cap Reader under direct observation~• Subjects will also ingest empty placebo capsules that do not contain ingestible sensors. In the absence of an ingested sensor, no signal is received by the Reader after the capsule is ingested, and the ingestion event is not recorded."
89459602|NCT05676164|Active Comparator|Control group|Oral Contrast Agent for Sonography from Huzhou East Asia Medical Supplies Co., LTD
89459603|NCT05676164|Experimental|Experimental group|Oral Contrast Agent for Sonography from Shandong branden Medical Device Co., LTD
89459604|NCT03480867|Experimental|Pre-operative RT and TMZ|Single Arm: Pre-operative Radiation +Temozolomide followed by Surgery plus six cycles of Temozolomide
89459605|NCT05254912|Active Comparator|6% BEMT in sunscreen oil (SU E 101413 85)|"Assess the photoallergic potential of Sunscreen oil with 6% BEMT (PARSOL® Shield) and 10% ethanol as penetration enhancer a test material (formulation: SU E 101413 85).~Approximately 0.15 g or 0.15 ml of each product and vehicle control will be applied. Two doses (one irradiated and one non- irradiated) of the investigational products and two doses (one irradiated and one non- irradiated) of the vehicle controls will be applied to back of each subject once on Day 1 under occlusive patches. Patches will remain in place for approximately 24 hours and will be removed by clinical study staff on Day 2. During the challenge phase, two undosed negative control occlusive patches will also be also applied. Subjects will return to the laboratory 24 hours and 48 hours post-irradiation for dermal evaluations. Dermal scores obtained during the challenge phase will be reported for each site."
89501844|NCT01131169|Experimental|high-risk multiple myeloma|This is a two arm phase II trial to assess the progression-free and overall survival as well as the safety and efficacy of allogeneic hematopoietic stem cell transplantation using a preparative regimen with busulfan, melphalan, fludarabine, and anti-thymocyte globulin (ATG), and a T cell depleted stem cell transplant from a histocompatible related or unrelated donor in patients with relapsed or high-risk multiple myeloma.
89459606|NCT05254912|Other|Sunscreen oil Vehicle (SU E 101413 91)|"Vehicle Control: Assess the photoallergenic potential of sunscreen oil vehicle with 10% ethanol as penetration enhancer without BEMT.~Approximately 0.15 g or 0.15 ml of each product and vehicle control will be applied. Two doses (one irradiated and one non- irradiated) of the investigational products and two doses (one irradiated and one non- irradiated) of the vehicle controls will be applied to back of each subject once on Day 1 under occlusive patches. Patches will remain in place for approximately 24 hours and will be removed by clinical study staff on Day 2. During the challenge phase, two undosed negative control occlusive patches will also be also applied. Subjects will return to the laboratory 24 hours and 48 hours post-irradiation for dermal evaluations. Dermal scores obtained during the challenge phase will be reported for each site."
89459607|NCT05254912|Active Comparator|6% BEMT in petrolatum (SU E 101413 82)|"Assess the photoallergenic potential of a dispersion of 6% BEMT (PARSOL® Shield) in petrolatum~Approximately 0.15 g or 0.15 ml of each product and vehicle control will be applied. Two doses (one irradiated and one non- irradiated) of the investigational products and two doses (one irradiated and one non- irradiated) of the vehicle controls will be applied to back of each subject once on Day 1 under occlusive patches. Patches will remain in place for approximately 24 hours and will be removed by clinical study staff on Day 2. During the challenge phase, two undosed negative control occlusive patches will also be also applied. Subjects will return to the laboratory 24 hours and 48 hours post-irradiation for dermal evaluations. Dermal scores obtained during the challenge phase will be reported for each site."
89459608|NCT03482895||Patient: Blood sampling & Feces sampling|"Blood samplings at different times after a meal test: 0, 15, 30, 60, 90 and 120 minutes.~Feces sampling: collection during 24 hours"
89459609|NCT03480789|Experimental|eye patch|wearing the eye patch from 22:00 to 6:00 of the next day
89459610|NCT03480789|Experimental|Dexmedetomidine|given dexmedetomidine to meet RASS -1 from 22:00 to 6:00 of the next day
89459611|NCT03480789|Experimental|eye patch + DEX|given dexmedetomidine to meet RASS -1 and wearing the eye patch from 22:00 to 6:00 of the next day
89459612|NCT03480789|No Intervention|usual treatment|treatment as usual
89459613|NCT03480711|Experimental|Group (A)|20 eyes of 20 patients of uncontrolled POAG administrated intervention will be subscleral trabeculectomy (SST) single surgeon, using retrobulbar anaesthesia with 2% lidocaine, will be performed in all surgeries. Following insertion of a lid speculum, a 10/0 silk bridle suture is inserted at superior limbus if required. In group (A) a conjunctival incision is made at the limbus to create a fornix-based conjunctival flap. A half thickness scleral flap (4 × 4 mm) are created and dissected into the clear cornea. A cellulose microsponge soaked in 0.3 mg/ml MMC solution (Mitomycin-C) is applied to the under surface of the scleral flap over a wide posterior area for 2 ml
89459614|NCT03480711|Experimental|group (B)|20 eyes of 20 patients of uncontrolled POAG d Administrated intervention will be ESST another longitudinal scleral groove will be created in the center of the deep scleral bed area measured about 1.5 × 6 mm.In both groups, standard trabeculectomy of equal size (two bites aside) is created by a Kelly punch ( 1 mm)
88941834|NCT01864161|Active Comparator|endovenous iron|patients receive a total dose 1000 mg of intravenous iron gluconate divided into administrations of 125 mg diluted in 250 mL normal saline infused weekly for 3 months
88941835|NCT01864187|Experimental|Dexmedetomidine|Each team will be administered for 1μg/kg of dexmedetomidine eace one.
88941836|NCT01864213|Experimental|Ametop cream|
88941837|NCT01864226|Placebo Comparator|Placebo|
88941838|NCT01864226|Experimental|RO5545965|
88941839|NCT01864239|Experimental|Patient-centred tailored intervention|Medicines Advice Service
88941840|NCT01864239|No Intervention|Control|Usual care
88941841|NCT01864252|Sham Comparator|Group 1 Control (65 patients)|Sham Remote ischaemic preconditioning with IV normal saline 2-5ml/hour.
88941842|NCT01864252|Active Comparator|Group 2 (65 patients)|Patients administered a Remote Ischaemic preconditioning protocol (three-5 min cycles of simultaneous inflation to cuffs placed on upper arm and thigh) prior to surgery and IV normal saline 2-5 mL/h during surgery.
88941843|NCT01864252|Experimental|Group 3 GTN (65 patients):|Patients administered sham simulated Remote Ischaemic Preconditioning protocol prior to surgery and IV Glyceryl Trinitrate 2-5ml/h during surgery.
88941844|NCT01864252|Experimental|• Group 4 RIPC+GTN (65 patients):|Patients administered Remote Ischaemic Preconditioning protocol and IV Glyceryl Trinitrate during surgery
88941845|NCT01864265|Active Comparator|Certolizumab Pegol|
88941846|NCT01864265|Placebo Comparator|Placebo|
88941847|NCT01864278||Lutonix Drug Coated Balloon|Paclitaxel coated ballooncatheter
88941848|NCT01864304||Williams Syndrome|Children and adults with Williams Syndrome
88941849|NCT01864304||Control Group|Controls will be recruited in 2 ways: 1) a gender matched and age- and BMI-similar control for each WS patient, and, 2) sibling controls when available
88941850|NCT01864317|Experimental|Primary Open Angle Glaucoma|30 patients with primary open angle glaucoma
88941851|NCT01864317|Experimental|Normal Tension Glaucoma|30 patients with normal tension glaucoma
89459615|NCT03475407|Experimental|Treatment Group|Ozurdex intravitreal injection
89459616|NCT03475329||adenoidectomy with bilateral partial tonsillectomy|
89459617|NCT03475329||adenoidectomy with complete unilateral tonsillectomy|
89459618|NCT05285956|Experimental|Intervention|Participants (n=90) will be provided free access to and asked to register for the consumer-based mobile meditation app, Calm, on their phone. Participants will then receive an email containing one year of free access to Calm. Participants will be asked to use Calm at least 10 minutes per day for 8 weeks. Women will be asked to use 10 sessions of specific pregnancy content for the first four weeks and then will have autonomy to use the app how they prefer for the remainder of the study period (with continued encouragement to use the pregnancy meditations)
89459619|NCT05285956|No Intervention|Control|Participants (n=90) will be asked to continue with usual care and complete survey measures at each time point.
89459620|NCT03482817|Experimental|Probe drug cocktail / Ze 117|One-sequence, Probe drug cocktail alone and in combination with Ze 117.
89459621|NCT03655197|No Intervention|Healthy Subjects|Healthy subjects will receive no intervention and will have samples collected only at one visit after Dove soap washout.
89459622|NCT03655197|Experimental|Ocular Rosacea Subjects|Ocular rosacea subjects will receive mandatory Doxycycline intervention and will have samples collected at two visits, before starting intervention and at the completion of the intervention.
89459623|NCT03655197|Other|Cutaneous Rosacea Subjects|Doxycycline intervention is optional for cutaneous rosacea subjects. If they do not participate, samples will only be collected at one visit after Dove soap washout. If they do decide to participate, samples will also be collected after completion of the Doxycycline intervention.
89459624|NCT05317624|Experimental|Platelet rich plasma group|participants will receive Ultrasound guided subacromial injection of 3 ml platelet rich plasma+0.5 ml of PRP activator (10% calcium gluconate)+ 1ml 0.5%bupivacaine.
89459625|NCT05317624|Experimental|Methylprednisolone group|participants will receive Ultrasound guided subacromial injection of 1 ml methylprednisolone+ 1ml 0.5%bupivacaine + 2.5 ml normal saline.
89459626|NCT03482661|No Intervention|Control|The patients swallowed the capsule with water in the supine position. When the capsule reached the stomach, the capsule was lifted away from the posterior wall, rotated and advanced to the fundus and cardiac regions, and then to the gastric body, angulus, antrum and pylorus. After completing the stomach examination, the capsule moved automatically without magnetic control and entered the duodenum under physiological conditions. The position of the capsule was verified through real-time viewer.
89459627|NCT03482661|Experimental|Magnetic steering|After finishing the stomach examination as the control protocol, the capsule was lifted with the magnetic control, then rotating the capsule until the camera end oriented toward the pylorus . Next, the endoscopist could drag the capsule close to the pylorus with the guidance magnet robot, waiting for the open of pylorus. Once the pylorus opened, the capsule could enter the duodenum with gastric peristalsis.
89459628|NCT05283772|Experimental|Experimental|
89459629|NCT05283772|No Intervention|No intervention|
89459630|NCT03475095|Experimental|LDH patients|"ribs and bones Tuina therapy According to the diagnostic criteria ofvertebral dislocation,determine the position,degree and direction of the dislocation,assess the activity of the affected vertebrae.Treated with combining Tuina of muscle-loosing and bone-setting such as reinforcing ribs，kneading and plucking method,20 min every treatment,twice a week for a total time of 4 weeks."
89459631|NCT03475017|Active Comparator|Supplement A|Administration of 3 capsules with 500mg of curcumin and piperine per day, for 12 weeks
89459632|NCT03475017|Placebo Comparator|Supplement B|Administration of 3 capsules with 500mg of placebo (maize starch) per day, for 12 weeks
88941852|NCT01864317|Experimental|Ocular Hypertension|30 patients with ocular hypertension
88941853|NCT01864317|Other|Healthy subjects|30 healthy control subjects
88941854|NCT01864330|Experimental|Dry Eye Syndrome I|20 patients with moderate dry eye syndrome
88941855|NCT01864330|Active Comparator|Dry Eye Syndrome II|20 patients with moderate dry eye syndrome
88941856|NCT01864330|Active Comparator|Dry Eye Syndrome III|20 patients with moderate dry eye syndrome
88941857|NCT01864343|Experimental|Pre- and perinterventional hypothermia|Cooling will be initiated by the application of cooling pads in the out-of-hospital setting followed by an infusion of 1000-2000ml of cold saline. In the cath lab a endovascular cooling catheter will be placed into the inferior vena cava via a femoral vein to achieve a core temperature of <35°C prior to revascularization.
88941858|NCT01864356|Experimental|NT100 Dose 1|NT100 Dose 1
88941859|NCT01864356|Experimental|NT100 Dose 2|NT100 Dose 2
88941860|NCT01864356|Placebo Comparator|Placebo|Placebo
88941861|NCT01864369|Active Comparator|Control: eInfo + Usual Care|Usual Care + eInfo on general guidelines for heart healthy living
88941862|NCT01864369|Experimental|Behavioral: eCounseling + Usual Care|Behavioral:eCounseling + Usual Care: interactive web pages utilized to provide e-counseling messages and e-tools.
88941863|NCT01864382|Other|Standard Physiotherapy Exercises|Standard Physiotherapy Exercises 5 days a week during 5 weeks
88941864|NCT01864382|Experimental|Core stability|Core stability.5 days a week during 5 weeks
88941865|NCT01864395|Experimental|Control (CF)|Centrifugation Method (CF): currently used to separate whole blood into red blood cells (RBCs) and plasma components. The RBCs are washed with normal saline and re-infused into the patient, while the plasma portion is discarded.
88941866|NCT01864395|Experimental|Online MUF|Online MUF: hemofilter is used online while the heart-lung machine is connected to the patient.
89459633|NCT03480555|Active Comparator|Replenish Protein group|Subjects randomized to this group will receive 2 g of protein/kg/day (acceptable range as 1.8 - 2.2 g of protein/kg/day) for day 6-14.
89459634|NCT03480555|Other|Standard Protein group|Subjects randomized to this group will receive 0.8 - 1 g of protein/kg/day for day 6-14
89459635|NCT02674568|Experimental|Rovalpituzumab Tesirine|0.3 mg/kg rovalpituzumab tesirine administered intravenously on Day 1 of each 42-day cycle (every 6 weeks; Q6W) for 2 cycles. An additional 2 cycles of rovalpituzumab tesirine (retreatment) was permitted for eligible participants.
89459636|NCT05490784|Experimental|Lee Silverman Voice Treatment big with conventional treatment|Lee Silverman Voice Treatment big with conventional treatment
89459637|NCT05490784|Active Comparator|control group|Patients assigned to control group received conventional treatment program encompassing set of exercises such as complex motor sequences, stretching, dual tasking, mental imagery and core stability.
89459638|NCT03474939|Active Comparator|MIDAZOLAM|Patients receive midazolam 7,5mg night before and 60 minutes prior to surgery as part of preanesthetic medication
89459639|NCT03474939|Placebo Comparator|PLACEBO|Patients receive 1000mg Glucose tablets night before and 60 minutes prior to surgery during premedication
89459640|NCT03131271|Experimental|Experimental Group|In the experimental group, the researcher provided a cold application for 20 minutes by placing an ice bag to the site of the femoral catheter. Immediately after its removal, the responsible nurse removed the catheter. A neutral instruction set was used on each patient prior to application of the ice pack. Patients in the experimental group were told that they may or may not experience pain during the catheter removal. The patients were also told that the aim of the study was to measure the effect of ice bag application upon pain during catheter removal, and that ice pack application may or may not be effective in terms of their own pain.
89459641|NCT03131271|No Intervention|Control Group|The control group received the standard clinic procedure in that the catheter was removed by the assigned nurse without any cold application to the femoral region. Each control patient was informed that some patients may experience pain during catheter removal, and that they may or may not experience pain. Patients were also told that their pain levels would be measured during catheter removal.
88941867|NCT01864395|Experimental|Offline MUF|Offline MUF: hemofilter is used offline when the heart-lung machine is not connected to the patient.
88941868|NCT01864408|Other|Group 1|"Group 1: subjects will receive usual practice counseling regarding pelvic organ prolapse after new patient history and physical exam."
88941869|NCT01864408|Experimental|Group 2|"Group 2: subjects will receive usual practice counseling in addition to interactive patient/provider counseling using the pelvic organ prolapse web-based tool (iPad) after new patient history and physical exam."
88941870|NCT01864421||Deferred Clamping|Infants undergoing a deferring of umbilical cord clamping for 30 seconds or more
88941871|NCT01864421||Immeadiate Cord Clamping|Infants undergoing immediate umbilical cord clamping in the first 20 seconds of life.
88941872|NCT01864447|Experimental|VTE REHABILITATION|"The exercise prescription emphasizes gradual progression to longer duration (45-60 minutes per session), lower intensity (60-70% peak heart rate (PHR) exercise. Subjects have an exercise expenditure goal of >3000 kcal/wk, attained after 2 to 4 weeks of gradually lengthening exercise bouts. All exercise sessions will be performed onsite for the first two weeks, after which subjects will perform 2 additional sessions a week in the home environment. Exercise logs will be reviewed weekly.~The Dietary Behavioral Weight Loss Intervention(BWL) intervention consists primarily of 12 small group sessions led by a dietician emphasizing dietary records, itemization of food, and caloric content. Subjects will be given individualized daily caloric goals 500 kcal less than predicted maintenance calories based on their baseline body weight."
88941873|NCT01864447|No Intervention|CONTROL|The 12-week program will consist of monthly phone contacts to check-in to capture physical activity done outside of the intervention setting.
88941874|NCT01864473|Other|Kshar Sutra|
88941875|NCT01864486|Experimental|Intelligent Retinal Implant System|
88941876|NCT01864499|Experimental|Tumor Resection|
88941877|NCT01864499|Active Comparator|Biopsy Brain Tumor|
88941878|NCT01864512||ITP patients receiving eltrombopag therapy|
88941879|NCT01864551|Active Comparator|lamotrigine|maintenance treatment of the patients with bipolar disorder with olanzapine or lamotrigine
88941880|NCT01864551|Active Comparator|olanzapine|maintenance treatment of the patients with bipolar disorder with olanzapine or lamotrigine
88941881|NCT01864577|Experimental|With negative pleural suction|Patients are put on negative pleural suction at - 20 cm H2O
88941882|NCT01864577|Active Comparator|With water seal|Patients al left on water seal only
88941883|NCT01864590|Experimental|Open Abdomen - Vacuum Pack|Patients that Require open abdomen
88941884|NCT01864590|Active Comparator|Double Sylo Bag - Mesh Protocol|Open Abdomen
88941885|NCT01864616|Experimental|Group 3|Vitamin D3, 10,000 IU daily
88941886|NCT01864616|Experimental|Group 2|Vitamin D3 2,000 IU daily
88941887|NCT01864616|Experimental|Group 1|Vitamin D3 600 IU daily (Control group, RDA level)
89459642|NCT03163160|Experimental|Pelvic floor manual therapy group|Pelvic floor manual therapy is a clinical approach utilizing specifics hands-on mobilizing techniques to treat soft tissues. The technique require mobilization of soft-tissue by myofascial stretching maneuvers intended to improve bio-mechanical elasticity. The therapeutic protocol will be applied for 4 weeks.
89459643|NCT03163160|Experimental|Pelvic floor electrolysis group|Pelvic floor electrolysis technique consists in an ultrasound-guided application of a galvanic electrolytic current that causes a controlled local inflammatory process in the target tissue. This allows for phagocytosis and the subsequent regeneration of the affected tissue. The therapeutic protocol will be applied for 4 weeks.
89459644|NCT03474861|Experimental|Combination therapy|The subjects will be given combination therapy which consists of an anticancer medication (A01) and immune cells (IC01).
89459645|NCT05251480|Active Comparator|Standard of Care|The standard of care includes physical examination, wound debridement, total cast or offloading boot, non-adherent dressing (PolyMem®) for wound covering, weekly visit for ongoing assessment
89459646|NCT05251480|Experimental|DermGEN™|A decellularized dermal matrix created from donated human skin. This arm will receive the same care as the Standard of Care control arm-physical examination, wound debridement, total cast or offloading boot, non-adherent dressing (PolyMem®) for wound covering, weekly visit for ongoing assessment-with the addition of DermGEN™ onto the wound at the first visit.
89459647|NCT03163550|Experimental|Cohort 1|Healthy volunteers
89459648|NCT03163550|Experimental|Cohort 2|Healthy volunteers
89459649|NCT03163550|Experimental|Cohort 3|Healthy volunteers
89459650|NCT03163550|Experimental|Cohort 4|Healthy volunteers
89459651|NCT03163550|Experimental|Cohort 5|Healthy volunteers
89459652|NCT03131583|Experimental|Cohort 1|Colchicine 0.5 mg Oral Tablet Day-14~Day16 qd, Febuxostat 80 mg Oral Tablet Day1 and Day8 qd, SHR4640 10 mg Oral Tablet Day3~Day8 qd.
89459653|NCT05250622|Experimental|Japanese group|Participants who will receive Japanese-translated version of evidence summaries
89459654|NCT05250622|Active Comparator|English group|Participants who will receive English version of evidence summaries
89017015|NCT00269906|Placebo Comparator|Placebo|Participants will receive matching placebo as bolus IV injection followed by continuous infusion of matching placebo for at least 18 hours but no longer than 26 hours.
89459655|NCT03131349||column heading in tables|history examinations investigation:serum zinc and iron
89017016|NCT02960373|Active Comparator|White Bread (Control)|Participants will consume a test meal containing white bread (dose: 50g available carbohydrate) at three study visits.
89459656|NCT03131349||row heading in tables|history examinations investigation:serum zinc and iron
89459657|NCT04672928|Experimental|IBI318 in combination with paclitaxel|
89459658|NCT05249842||Respiratory function 3 months after hospital discharge in critically ill COVID-19 patients|All critically ill adult patients admitted to the ICU with confirmed diagnosis of COVID-19 were submitted at least 3 months after hospital discharge to spirometry (FVC, FEV1, FEV1 /;FVC and FEF 25-75%), the 6-minute walk test (6MWT) and evaluation of the physical component summary (PCS) of the SF-36 quality of life instrument.
89459659|NCT03162926|Experimental|Single-group|Up to six (6) VC-02-20 implants
89459660|NCT03162848|Experimental|SystemCHANGE intervention|The SystemCHANGE™ intervention utilizes the Socioecological Model and Plan-Do-Check Act model as its framework and focuses on changing the individual's environment to change behavior using small experiments with feedback.
89459661|NCT03162848|No Intervention|Attention Control|The attention control group will receive education at baseline, 1 month, and 2 months following America Heart Association brochures.
89459662|NCT03482427|Experimental|Intervention|After completion of the Healthy Hear Score assessment, participants will receive a lifestyle intervention based on the Healthy Heart Score results for 12-weeks by trained dietetic interns on-site. Participants will receive a check-in email or phone 6 weeks after the initial visit. A Registered Dietitian is also available to speak with patients. The intervention will consist on educational materials based on each component of the Healthy Heart Score and other lifestyle behaviors
89459663|NCT03482427|No Intervention|Control|Participants in the control group will follow their usual care protocol after taking the Healthy Heart Score assessment. Researchers will provide the Healthy Heart Score survey results, but will not discuss or interpret the results with them. Participants can discuss any concern they have with their usual physician if they choose. After the follow-up visit and upon completion of the study, all participants in the control group may also receive the educational handouts and will be granted access to the Healthy Heart Score application if they wish.
89459664|NCT05317390|No Intervention|Retrospective clinical validation of DystoniaNet|Retrospective studies will (1) clinically validate the diagnostic performance of DystoniaNet compared to a normal neurological state (normative test), and (2) develop and test DystoniaNet extensions in comparison with other neurological and non-neurological conditions (differential test).
89459665|NCT05317390|Experimental|Prospective clinical validation of DystoniaNet|Prospective randomized studies will validate DystoniaNet performance for accurate, objective, and fast diagnosis of dystonia in the actual clinical setting.
89459666|NCT04805385|Experimental|PS128|Subjects will consume the PS128 capsules every day, 2 capsules at a time, for 12 weeks.
89459667|NCT04805385|Placebo Comparator|Placebo|Subjects will consume the placebo capsules every day, 2 capsules at a time, for 12 weeks.
89459668|NCT04805385|No Intervention|Healthy Control|
89459669|NCT05676086|Experimental|indoor light intervention|Persons allocated to the indoor light intervention arm will be given a lamp to be placed at home
89459670|NCT05676086|Active Comparator|control group|Persons allocated to the control group will receive no indoor light supplementation and will undergo assessment procedures only
89459671|NCT03474783|Experimental|multidisciplinary intervention|
89459672|NCT05513248||patients who recovered from COVID-19|patients with previous COVID-19 infection who underwent anatomic lung resection (segmentectomy, lobectomy, bilobectomy or pneumonectomy)
89459673|NCT03474705|Experimental|Eccentric Training Group|Eccentric training of the upper trapezius muscles. The intervention will consist of ten sessions of 25-30 minutes (twice a week over 5 consecutive weeks) of eccentric exercises of the shoulder muscles, as neural activation increases after 4 weeks of eccentric training. The total duration of the intervention will be 2 hours and a half.
89459674|NCT03160820|Other|one dose of MMR|Subjects are vaccinated with MMR(Measles, mumps and rubella Combined Vaccine, Live) on 18 months old.
89459675|NCT03160820|Other|30 months after two doses of MMR|Subjects are vaccinated two doses of MMR(Measles, mumps and rubella Combined Vaccine, Live) on 18 month and 4 years old, sequentially.
89459676|NCT03160820|Other|42 months after two doses of MMR|Subjects are vaccinated two doses of MMR(Measles, mumps and rubella Combined Vaccine, Live) on 18 month and 5 years old, sequentially.
89459677|NCT03160820|Other|54 months after two doses of MMR|Subjects are vaccinated two doses of MMR(Measles, mumps and rubella Combined Vaccine, Live) on 18 month and 6 years old, sequentially.
88941888|NCT01864629|Other|Contraception after preterm birth|Intervention name: Focused contraception counseling This intervention will be provided to those randomized to the intervention group only. This counseling will follow a pre-written, structured script describing all contraceptive methods in rank order starting with most effective to least effective in preventing unplanned pregnancy.
89459678|NCT03114722|Active Comparator|heparin 10U/ml|Heparinised saline (10U/ml) lock in between each catheter use (with standard twice weekly normal saline flushing if catheter not being used)
89459679|NCT03114722|Experimental|citrate 4%|4% citrate lock in between each catheter use (with standard twice weekly normal saline flushing if catheter not being used)
89459680|NCT03474627|Active Comparator|Non-coated HA/TCP particles|Biphasic hydroxyapatite and beta-tricalcium phosphate bone graft
89459681|NCT03474627|Experimental|PLGA-coated HA/TCP particles|Biphasic hydroxyapatite and beta-tricalcium phosphate bone graft with PLGA coating
89459682|NCT03114410|Experimental|Re:MIX|In the experimental arm, the Re:MIX curriculum was implemented. The Re:MIX curriculum is a comprehensive teen pregnancy prevention consisting of ten hour-long sessions, delivered approximately once per week. The Re:MIX curriculum is taught by a professional health educator, partnered with a young parent educator who is a young parent (aged 18-25).
89459683|NCT03114410|No Intervention|Comparison|"In the comparison arm, teachers were given the option of implementing the Healthy Youth, Healthy You curriculum (focusing on nutrition, mental health, and fitness) or proceed with business as usual (no curriculum)."
88941889|NCT01864629|No Intervention|Control Group|Participants will receive the standard postpartum contraception counseling that is received by all patients who deliver at our institution.
88941890|NCT01864642|Experimental|osteopathic manipulative treatment|osteopathic manipulative treatment (OMT)
89201625|NCT04004650|No Intervention|Primary closure|Primary perineal closure after extralevator abdomino perineal resection
88941891|NCT01864655|Experimental|Saracatinib group 1|This group will receive AZD0530 (saracatinib) experimental oral drug , once daily, for a duration of 4 weeks. Dosage is 50mg per day.
89201626|NCT04004650|Experimental|Gluteal turnover flap|Gluteal flap reconstruction of the pelvic floor after extralevator abdomino perineal resection
88941892|NCT01864655|Experimental|Saracatinib group 2|Group 2 will receive saracatinib at a daily oral dose determined by the response to 50mg P.O. daily. Duration is 4 weeks.
89201627|NCT03730792|Experimental|SHIFT Onboard Intervention|A 12-month onboarding process and social challenge supported with goal setting, computer-based training, self-monitoring, and group motivational interviewing.
89201628|NCT03730792|No Intervention|Usual Practice Control|"Participants experience standard or Usual Practices in new employee onboarding processes at their workplace."
89201629|NCT04394182|Experimental|An experimental group receiving radiotherapy|an experimental group with a poor or no response to standard medical treatment and without invasive mechanical ventilation (IMV) will receive ultra low-dose lung radiotherapy (0.8 Gy single dose)
88941893|NCT01864655|Experimental|Saracatinib group 3|Group 3 will receive saracatinib at a dose determined by the response to 50mg P.O. daily, as well as dose given to group 2. Duration is 4 weeks.
88941894|NCT01864655|Placebo Comparator|Placebo group 1-3|Subjects receiving saracatinib in groups 1-3 will be compared to subjects receiving daily, oral, placebo drug.
88941895|NCT01864681|Experimental|Arm A|Gefitinib and metformin. Metformin starting at a dose of 500 mg twice a day, orally with meals. After one week, increase the dose of metformin to 1000 mg as the first dose of the day and 500 mg as the second dose. After another week, increase to 1000 mg of metformin two times a day. Metformin treatment will be initiated one week before beginning TKI therapy, if possible, but TKI therapy will not be delayed for metformin loading.
88941896|NCT01864681|Placebo Comparator|Arm B|Gefitinib and placebo. Placebo was given to patients in the same way as that of metformin in Arm A.
88941897|NCT01864694|Experimental|TLC-Diet|Participants receive diet intervention through automated telephone system: TLC-Diet
88941898|NCT01864694|Experimental|WEB-Diet|Participants receive diet intervention through web-based system: WEB-Diet
88941899|NCT01864694|Experimental|Control|Assessment-only control group
89201630|NCT05376124||original therapy|ETV 0.5mg/ day or TDF 300mg/ day or TAF 25mg/ day continued the original regimen (ETV 1.0mg/ day or TDF 300mg/ day or TAF 25mg/ day), Oral treatment lasted 48 weeks ②TDF 300mg/ day plus ETV 0.5mg/ day on initial treatment continued with the original regimen (TDF 300mg/ day plus ETV 0.5mg/ day) and oral therapy for 48 weeks ③TAF 25mg/ day plus ETV 0.5mg/ day as initial treatment continued the original regimen (TAF 25mg/ day plus ETV 0.5mg/ day) for 48 weeks of oral therapy
89201631|NCT05376124||rescue therapy|TDF 300mg/ day +ETV 1.0mg/ day or TAF 25mg/ day +ETV 1.0mg/ day, oral treatment for 48 weeks.
89201632|NCT04244890||Uninterrupted CPAP|Newborn infants in need of respiratory support directly after birth
89201633|NCT01563796||TCC positive|subjects with hematuria, dysuria or other irritative voiding symptoms, without evidence of other causative factors such as infections or stones that are found to have a bladder tumor confirmed by histopathology
89201634|NCT01563796||TCC negative|subjects with hematuria, dysuria or other irritative voiding symptoms, without evidence of other causative factors such as infections or stones that are found to NOT have a bladder tumor by histopathology or clinical observation.
89201635|NCT04223206|Experimental|Hemodialysis with sarcopenia|10 HD patients, affected by sarcopenia will a undergo 3-months supplementation with NATURLENS
89201636|NCT04223206|No Intervention|Controls|10 HD patients, affected by sarcopenia will be followed for 3 months without any supplementation
89201637|NCT03472768||ECMO-supported group|Thirty critically-ill children (age newborn to 18 years) who are intubated and supported by ECMO. Normal adult-level haptoglobin concentrations are achieved by 6-12 months of age. We will target enrollment of 15 subjects less than 12 months of age and 15 subjects over 12 months of age
89201638|NCT03472768||Age-matched group with respiratory failure|Sixty critically-ill children (age newborn to 18 years) who are intubated with acute respiratory failure due to any cause and not supported by ECMO. Two control subjects will be enrolled for every 1 experimental ECMO subject.
89201639|NCT04144348|Experimental|mRNA-1653, Adult participants|Participants will receive 1 of 2 doses of mRNA-1653, administered via intramuscular injection, on Day 1 and Day 57.
89201640|NCT04144348|Experimental|mRNA-1653 Pediatric participants|Participants will receive 1 of 2 possible doses of mRNA-1653, administered via intramuscular injection, on Day 1 and Day 57.
89201641|NCT04144348|Placebo Comparator|Placebo, Adult participants|Participants will receive mRNA-1653-matching placebo, administered via intramuscular injection, on Day 1 and Day 57.
89201642|NCT04144348|Placebo Comparator|Placebo, Pediatric participants|Participants will receive mRNA-1653-matching placebo, administered via intramuscular injection, on Day 1 and Day 57.
89201643|NCT03907072|Experimental|WVE-210201 (3 mg/kg)|Weekly IV administrations of WVE-210210 at 3 mg/kg
89501845|NCT02688933|Experimental|HOE901-U300|HOE901-U300 (Insulin glargine, 300 U/mL) once daily for 16 weeks on top of mealtime insulins analogs. Basal insulin doses were individually titrated (until the end of Week 14) to reach fasting self-measured plasma glucose (SMPG) levels of 80 to 100 mg/dL, while mitigating hypoglycemia.
89201644|NCT03907072|Experimental|WVE-210201 (4.5 mg/kg)|Weekly IV administrations of WVE-210210 at 4.5 mg/kg
89201645|NCT03907072|Placebo Comparator|Placebo|Weekly IV administrations of phosphate buffered saline solution visually identical in appearance to WVE-21021
89206149|NCT00824694|Active Comparator|Control Arms|Subjects will repeat the dose titration cycle under the guidance of a case manager until the target is reached, maximal recommended doses of medications are used, or a stop criterion is met. They will then resume glucose profiling to identify the next target. This process is repeated until all targets reach their optimal value. Control patients will monitor and be treated in the customary manner.
89459684|NCT05675852||Healthy participants|"Healthy participants aged from 1 to 75 years old. All experiments conducted in this study will make use of the electroencephalogram (EEG) recording technique. Healthy participants cannot participate if they suffer from dermatosis on the scalp. There is no other contraindication to the practice of an EEG, which simply consists of recording the electrical activity of the brain on a trace, after application of a conductive gel on the scalp where sensors connected to a recording device are placed.~We will collect the cerebral electrical response by the technique of steady state visual evoked potentials (SSVEP) which consists of presenting a visual stimulus periodically to interpret the EEG signal according to those variations."
89459685|NCT03474549|Experimental|Tigertriever revascularization device|Mechanical thrombectomy with Tigertriever
89459686|NCT05313490|Active Comparator|Beetroot Juice|The subject will ingest 140mL of a nitrate-rich beetroot juice each day for 7 consecutive days.
89459687|NCT05313490|Placebo Comparator|Placebo Beetroot Juice|The subject will ingest 140mL of a placebo (nitrate-depleted) beetroot juice each day for 7 consecutive days.
89459688|NCT03163082|Active Comparator|Cognitive Intervention|The cognitive intervention has partners come up with reasons why their partners do things they don't like, until they come up with benign attributions for those behaviors.
89459689|NCT03163082|Active Comparator|Behavioral Intervention|The behavioral intervention has partners develop an if-then plan for dealing with conflict and negativity, using strategies to downregulate their own negative emotions.
89459690|NCT03163082|Active Comparator|Interpretation Bias|"The Interpretation Bias intervention has partners look at morphed facial expressions and determine whether the face is happy or angry. Positive feedback is given for rating the faces as happy and negative feedback is given for rating the faces as angry."
89459691|NCT03163082|Active Comparator|Evaluative Conditioning|The Evaluative Conditioning intervention presents partners with pictures of ambiguous adult faces (conditioned stimuli) and pairs them with positive word descriptors (unconditioned stimuli; e.g., generous; loving).
89459692|NCT03163004|Experimental|Intervention group|Implementation of standing desks in the classroom
89459693|NCT03163004|No Intervention|Control group|
89459694|NCT03474315||CHF and CIED patients|600 CHF patients with ICD or CRT admitted to regulatory ambulatory visit.
89459695|NCT05246878|Experimental|EDP-235 SAD Cohorts|EDP-235 Dose 1, Dose 2, Dose 3, Dose 4 and Dose 5, orally, once daily in one single administration
89459696|NCT05246878|Experimental|EDP-235 MAD Cohorts|EDP-235 Dose 1, Dose 2 and Dose 3 orally, once daily for 7 days
89459697|NCT05246878|Placebo Comparator|EDP-235 SAD Placebo Cohorts|Matching placebo, orally, once daily in one single administration
89459698|NCT05246878|Placebo Comparator|EDP-235 MAD Placebo Cohorts|Matching placebo, orally, once daily for 7 days
89206150|NCT00830622|Experimental|1|Cell Phone Intervention: participant receives weekly SMS text message from the health care worker.
88941900|NCT01864707|Experimental|usual care + acupuncture|standardized acupuncture treatment in addition to usual care
88941901|NCT01864707|Experimental|usual care+mbsr|mindfulness based stress reduction in addition to usual care not recruiting anymore
88941902|NCT01864707|Active Comparator|usual care|usual care without additional treatment
88941903|NCT01864733|Experimental|intervention group|"1) The 'intervention' group: 3-month multimodal approach associating exercise rehabilitation, ONS, n-3 PUFAs and androgen substitution:~Physical rehabilitation including endurance and resistance exercises two to three times a week.~Oral nutritional supplements: Fortimel max® (Nutricia®) (300 ml, 720 kcal, 29 g de proteins), once per day.~n-3 polyunsaturated fatty acids : DHA phospholipids (GPL-DHA®), 240 mg/day.~Testosterone: Testopatch® 2.4 mg in men and 1.2 mg in women; 2 patches renewed every two days."
88941904|NCT01864733|Other|control group|2) The 'control' group: no multimodal approach but the treatment currently recommended: heart rehabilitation and dietary counseling during 3 months.
88941905|NCT01864759|Experimental|ICOVIR5|ICOVIR-5 oncolytic adenovirus, single administration, endovenous, dose escalation from 1E11 vp to 1E13 vp.
88941906|NCT01864785|Other|Fixation Alone|Use the Posterior approach to achieve the reduction and stabilization by pedicle screw and rod alone
88941907|NCT01864785|Other|Fixation Combined With Fusion|Posterior Fixation Combined With Articular Process Fusion in thoracolumbar Fracture.
88941908|NCT01864798|Experimental|Denosumab|
88941909|NCT01864811|Experimental|Baby-CIMT|The infants will be prevented from using the preferred hand while the other hand will be trained using amusing and easily handled toys.
88941910|NCT01864811|Experimental|baby-massage|The infants will receive baby massage
88941911|NCT01864824|Experimental|methyl donor|"Methyl donor is made up of:~2.5 mg of folic acid, 50 mg of vitamin B6, and 1 mg of vitamin B12 The design will include a 2 week placebo run-in followed by a baseline blank study (2-hrs exposure to medical air) to provide benchmarks for all assessed variables. Participants will then receive a 4-week placebo treatment before the first PM2.5 exposure study. A 4-week methyl-donor treatment (Dose: 2.5 mg of folic acid, 50 mg of vitamin B6, and 1 mg of vitamin B12 once a day) will precede the 2nd PM2.5 exposure."
88941912|NCT01864824|Placebo Comparator|placebo|placebo: The design will include a 2 week placebo run-in followed by a baseline blank study (2-hrs exposure to medical air) to provide benchmarks for all assessed variables. Participants will then receive a 4-week placebo treatment before the first PM2.5 exposure study. A 4-week methyl-donor treatment (Dose: 2.5 mg of folic acid, 50 mg of vitamin B6, and 1 mg of vitamin B12 once a day) will precede the 2nd PM2.5 exposure.
88941913|NCT01864837||Functional dyspepsia|They should meet the Rome III criteria for functional dyspepsia.
89459699|NCT03162770|Experimental|Intervention Group|This group will receive the Mindfulness meditation practice and after that patients will not receive any other intervention.
89017017|NCT02960373|Experimental|Dried Fruit - Glycemic Index|Participants will consume a test meal containing one variety of dried fruit (dose: 50g available carbohydrate) per visit for four visits. Varieties include raisins, sultanas, dates, and apricots.
89017018|NCT02960373|Experimental|Catalytic Fructose Dose Effect|Participants will consume a test meal containing white bread (dose: 50g available carbohydrate) and one variety of dried fruit (dose: 7g fructose) per visit for four visits. Varieties of dried fruit include: raisins, sultanas, dates, and apricots.
89459700|NCT03162770|No Intervention|No Control Group|Initially this control group will wait and after 12 weeks this group will receive the intervention
89459701|NCT05245084|Experimental|Sequence 1|"Period 1: D013, D326, D337- A single oral dose of 3 tablets under fasting condition~Period 2: CKD-386(2)- A single oral dose of 1 tablet under fasting condition~Period 3: D013, D326, D337- A single oral dose of 3tablet s under fasting condition~Period 4: CKD-386(2)- A single oral dose of 1 tablet under fasting condition"
89017019|NCT02960373|Experimental|High GI Displacement Effect|Participants will consume a test meal containing white bread (dose: 25g available carbohydrate) and one variety of dried fruit (dose: 25g available carbohydrate) per visit for four visits. Varieties of dried fruit include: raisins, sultanas, dates, and apricots.
89459702|NCT05245084|Experimental|Sequence 2|"Period 1: CKD-386(2)- A single oral dose of 1 tablet under fasting condition~Period 2: D013, D326, D337- A single oral dose of 3 tablets under fasting condition~Period 3: CKD-386(2)- A single oral dose of 1 tablet under fasting condition~Period 4: D013, D326, D337- A single oral dose of 3 tablets under fasting condition"
89017020|NCT00297336||001|
89017021|NCT02960984|Experimental|Neurorehabilitation|Participants in the experimental group will receive 1 hour treatment comprising 30' of aerobic training on an ergometer and 30' of task-oriented training focused on uppper limb rehabilitation.
89017022|NCT02960984|No Intervention|Baseline|No intervention is planned
89017023|NCT00297414||Patients with mild cognitive impairment|Patients with mild cognitive impairment who were treated with galantamine or placebo in previous 3 clinical studies.
89017024|NCT00297453|Experimental|Internet|Individual counseling + nicotine replacement. 6 sessions across a 3 month period.
89017025|NCT00297453|Experimental|Counseling|Individual counseling plus nicotine replacement treatment.
89017026|NCT00297453|Active Comparator|Self-Help|Self-help Manual plus nicotine replacment treatment.
89017027|NCT00270218|Experimental|1|Arm 1 participants will be given an injection of VRC-HIVADV014-00-VP vaccine on Days 0 and 168.
89017028|NCT00270218|Placebo Comparator|2|Arm 2 participants will be given an injection of final formulation buffer (FFB) on Days 0 and 168.
89459703|NCT03480321|Active Comparator|Cilostazol 100 mg|
89459704|NCT03480321|Experimental|PMR 150 mg|
89459705|NCT03480321|Experimental|PMR 200 mg|
89459706|NCT03482193||Adolescents|Adolescents in 2nd or 4th year in secondary school, from 9 different schools in Liège, Belgium.
89459707|NCT03160664|Experimental|magnetic seizure therapy|8-10 treatment sessions of MST, three times per week in the first two weeks, two times per in the following two weeks.
89459708|NCT03160664|Active Comparator|electroconvulsive therapy|8-10 treatment sessions of modified-ECT, three times per week in the first two weeks, two times per in the following two weeks.
89459709|NCT04928950|Experimental|Adults undergoing TEMLA|Adults undergoing TEMLA (Transcervical Extended Mediastinal Lymphadenectomy) take Oral Activated Charcoal (OAC) dissolved in apple juice a night before the surgery
89459710|NCT03160742||Non-invasive monitoring|In addition to standard monitoring, the Mespere VENUS 200CVP system will be used to record central venous pressures.
89017029|NCT00270218|Experimental|3|Arm 3 participants will be given an injection of VRC-HIVDNA009-00-VP vaccine on Days 0 and 28. Participants will also be given an injection of VRC-HIVADV014-00-VP on Day 168.
89459711|NCT03160586|Active Comparator|Stutter|Children who stuttering
89459712|NCT03160586|Active Comparator|Control|Children who non stuttering
89459713|NCT02523651|Experimental|DPSC injection|20 patients will receive DPSC injection（1000000 cells/ 0.5ml） at the local periodontal defects immediately after periodontal scaling and root planing.
89459714|NCT02523651|Placebo Comparator|Placebo control|20 patients will receive saline injection at the local periodontal defects immediately after periodontal scaling and root planing.
89459715|NCT03482037|Experimental|Rec 0/0438|Rec 0/0438 1 mg (first cohort), 2 mg (second cohort) to be administered by intravesical instillation once daily for four weeks
89459716|NCT03482037|Placebo Comparator|Placebo|Placebo, to be administered by intravesical instillation once daily for four weeks
89017030|NCT00270218|Placebo Comparator|4|Arm 4 participants will be given an injection of phosphate buffered saline (PBS) on Days 0 and 28 and an injection of FFB on Day 168.
89017031|NCT00270335|Active Comparator|A|General anesthesia titrated according to a cerebral state monitor
89017032|NCT00270335|Active Comparator|B|General anesthesia titrated according to usual clinical criteria
89017033|NCT00270374|Experimental|001|nesiritide
89017034|NCT00297804|Experimental|Arm 1|
89017035|NCT00297804|Active Comparator|Arm 2|
89017036|NCT00270647|Experimental|Vitamin E|Active or placebo vitamin E
89017037|NCT00270647|Experimental|Vitamin C|Active or placebo vitamin C
89017038|NCT00270647|Experimental|Multivitamin|Active or placebo multivitamin
89017039|NCT00270647|Experimental|Beta-carotene|Active or placebo beta-carotene
89017040|NCT00270764||Full cohort|Adult ART patients at 3 treatment facilities in South Africa
89017041|NCT00270803|Placebo Comparator|A|Low nicotine cigarettes without THC
89017042|NCT00270959|Experimental|1|Stepped collaborative care (combination of behavioral therapy and drug therapy)
89017043|NCT00270959|Active Comparator|2|Standard care provided to injured trauma survivors
89459717|NCT05313412|Experimental|Lens A, Then Lens B|Participants will wear Lens A for six hours and then cross over to wear Lens B for six hours.
89459718|NCT05313412|Experimental|Lens B, Then Lens A|Participants will wear Lens B for six hours and then cross over to wear Lens A for six hours.
89459719|NCT02986269|Experimental|Group SB|"Patient is scheduled for elective conisation or hysteroscopy under general anesthesia. The ventilation mode for this group is spontaneous breathing(SB) without pressure support ventilation (PSV) under laryngeal mask airway (LMA).~General anesthesia across LMA under SB without PSV"
89459720|NCT02986269|Active Comparator|Group PSV|General anesthesia across LMA under SB with PSV Patient is scheduled for elective conisation or hysteroscopy under general anesthesia. The ventilation mode for this group is SB with PSV under LMA.
89459721|NCT03474237||Non-functioning adrenal incidentaloma|patients who were diagnosed with non-functioning adrenal incidentaloma on computed tomography or magnetic resonance imaging
89459722|NCT03474237||Pheochromocytoma|patients who were diagnosed with pheochromocytoma biochemically or histologically
89459723|NCT03474237||Primary aldosteronism|patients who were diagnosed with primary aldosteronism by saline loading test
89459724|NCT03474237||Adrenal cushing syndrome|patients who were diagnosed with adrenal cushing syndrome by dexamethasone suppression test and 24 urine free cortisol test.
89459725|NCT03474237||Adrenocortical carcinoma|patients who were diagnosed with adrenocortical carcinoma by imaging study or histologic exam
89459726|NCT05277688|Experimental|experimental group|concurrent chemotherapy: cisplatin（DDP） weekly, 40mg/m2, begin with radiation Drug: cisplatin（DDP） weekly; pelvic radiotherapy: intensity modulated radiotherapy (IMRT) is given five fractions per week at 1.8-2 Gy/fraction/day with total dose summed up to 45-50Gy.
89459727|NCT05277688|Active Comparator|controlled group|pelvic radiotherapy alone: intensity modulated radiotherapy (IMRT) is given five fractions per week at 1.8-2 Gy/fraction/day with total dose summed up to 45-50Gy.
89459728|NCT02923401|Experimental|High-Intensity Interval Training (HIIT) Group|"Participants come to the Energy Balance Center to exercise 3 times a week for 12 weeks.~Participants receive written materials and instructions on how to perform their exercises.~Participants walk uphill on a treadmill for a total of 33 minutes 3 times a week for 12 weeks.~Participants complete questionnaires about their quality of life, exercise experience, and level of fatigue at baseline and at 12 weeks.~One (1) time each month, participant attends a motivational session."
89459729|NCT02923401|Experimental|Moderate-Intensity Continuous Training (MICT) Group|"Participants come to the Energy Balance Center to exercise 3 times a week for 12 weeks.~Participants receive written materials and instructions on how to perform their exercises.~Participants walk uphill on a treadmill or use a stationary bicycle continuously for 41 minutes 3 times a week for 12 weeks.~Participants complete questionnaires about their quality of life, exercise experience, and level of fatigue at baseline and at 12 weeks.~One (1) time each month, participant attends a motivational session."
89459730|NCT02923401|Active Comparator|Control Group|"Participants receive written materials and counseling by an exercise physiologist.~Participants called by a member of the study staff 1 time each week for 12 weeks and asked about any exercise they have done and their weight loss goals.~Participants complete questionnaires about their quality of life, exercise experience, and level of fatigue at baseline and at 12 weeks.~One (1) time each month, participant attends a motivational session."
89459731|NCT05277376|Active Comparator|BEMT Formulation SU-E-101413-85|PK evaluation of 6% BEMT after multiple applications of a topical sunscreen formulation.
89459732|NCT05277376|Active Comparator|BEMT Formulation SU-E-101413-87|PK evaluation of 6% BEMT after multiple applications of a topical sunscreen formulation.
89459733|NCT05277376|Active Comparator|BEMT Formulation SU-E-101413-89|PK evaluation of 6% BEMT after multiple applications of a topical sunscreen formulation.
89459734|NCT05259579|Experimental|Anti-reflux mucosal ablation|This technique creates an anti-reflux mechanism by performing mucosal ablation at the gastric cardia and inducing cicatrisation, and thereby rebuilds the flap valve at the gastric cardia
88941914|NCT01864863|Experimental|Test→Reference|HGP1206 125 mg 1 tablet → Traclear 62.5 mg 2 tablets
88941915|NCT01864863|Experimental|Reference→Test|Traclear 62.5 mg 2 tablets → HGP1206 125 mg 1 tablet
88941916|NCT01864876|Experimental|GLA-AF|5 mcg GLA-AF given as one subcutaneous injection.
88941917|NCT01864876|Experimental|GLA-SE|5 mcg GLA-SE given as one intramuscular injection.
88941918|NCT01864876|Experimental|EM060G (SE)|EM060G (SE) given as one intramuscular injection.
88941919|NCT01864889|Experimental|anti-CD19 CAR T cells|Patients receive anti-CD19-CAR retroviral vector-transduced autologous or donor-derived T cells on days 0,1, 2 in the absence of disease progression or unacceptable toxicity.
88941920|NCT01864902|Experimental|anti-CD33 CAR T cells|Patients receive anti-CD33-CAR retroviral vector-transduced autologous or donor-derived T cells on days 0,1, 2 in the absence of disease progression or unacceptable toxicity.
88941921|NCT01864915|Experimental|No Booster-low dose prucalopride booster|low dose prucalopride booster arm
88941922|NCT01864915|Experimental|Prucalopride Booster-high dose prucalopride booster|additional 2mg prucalopride at time of capsule ingestion
88941923|NCT01864915|Experimental|Picosalax Booster Arm|One sachet of Picosalax 2hrs after capsule ingestion and 1/2 sachet at 4 hrs after swallowing colon capsule.
88941924|NCT01864928||Stroke population|Adults with ischemic stroke.
88941925|NCT01864941|Active Comparator|Catheter Venography & Balloon Venoplasty|Patients will undergo catheter venography with balloon venoplasty procedure.
88941926|NCT01864941|Sham Comparator|Catheter Venography Only|Patients will undergo catheter venography only.
88941927|NCT01864954|Experimental|Enhanced Web+phone|Engaging and interactive website access plus phone calls from personal coach.
88941928|NCT01864954|Active Comparator|Basic Static Web|Static website access only, only introductory call.
88941929|NCT01864967||carbon dioxide infusion|Group I: receive carbon dioxide infusion
88941930|NCT01864967||control|did not receive carbon dioxide
89017044|NCT00271115|Other|Moms w/preterm infants|Mothers of preterm infants who are admitted to the newborn intensive care unit.
89017045|NCT00271193|No Intervention|1|Control group, receives physician advice for weight loss and materials
89017046|NCT00271193|Active Comparator|2|Active treatment group, receives physician advice, materials, and brief weight loss counseling
89017047|NCT02960256||Patients admitted to an internal medicine department due to an|
89017048|NCT00416234|Active Comparator|1|Laparoendoscopic Rendez vous (one stage management of cholelithiasis/choledocholithiasis)
89459735|NCT03357068|Active Comparator|Control|Autogenous bone block surgery without treatment of bone surfaces.
89017049|NCT00416234|Active Comparator|2|preoperative ERCP and CBD clearance followed by lap cholecystectomy (two stage management of cholelithiasis/choledocholithiasis)
89017050|NCT00418587|Experimental|1|800 IU oral daily dose level
89017051|NCT00418587|Experimental|2|2000 IU oral daily dose level
89017052|NCT00418587|Experimental|3|4000 IU oral daily dose level
89017053|NCT00416273|Experimental|Treatment group|Participants in the treatment group will receive Bortezomib at a dosage of 1.6 mg/m2.
89017054|NCT00416273|Experimental|Observation group|Participants in the observation group will not receive any consolidation therapy.
89017055|NCT00306462|Active Comparator|1|Intravenous magnesium sulfate or placebo
89017056|NCT00306462|Active Comparator|2|Oral nifedipine or placebo
89017057|NCT00306501|Other|Button Press|Training with button press
89017058|NCT00306501|Other|Vibtrotactile|Sensory Stimulation - Vibrotactile device with button press to initiate swallowing during retraining
89459736|NCT03357068|Experimental|Acid|Autogenous bone block surgery with citric acid treatment of bone block and recipient site
89459737|NCT03480165|Experimental|20 mg Parecoxib + 0.75% Ropivacaine|1 ml of 20 mg Parecoxib is given concurrently with 19 mls of 0.75% ropivacaine
89459738|NCT03480165|Active Comparator|0.75% Ropivacaine only|19 ml of Ropivacaine at a concentration of 0.75% is given concurrently with 1 ml of 0.9% saline
89459739|NCT03022799|Experimental|KM-819|Each cohort consists of 8 subjects; 6 subjects will receive planned dose of KM-819 and 2 subjects will receive placebo.
89201646|NCT04209322|Experimental|Pulsed Radiofrequency|Aseptic technique was adopted. Imaging guided (CT) catheter needle (active tip electrode) was inserted and a sensory stimulation test was carried out using an RF generator. The catheter needle was then advanced toward the DRG until the patient reported a tingling sensation and/or dysesthesia at less than 0.3V. PRF treatment was administered at 5 Hz and a 2 ms pulsed width for 10 minutes at 45V under the constraint that the electrode tip temperature not exceed 42°C. Finally, patients received 1mL lidocaine 20mg/mL mixed with 2mL dexamethasone 10mg/mL.
89459740|NCT03022799|Placebo Comparator|Placebo|Each cohort consists of 8 subjects; 6 subjects will receive planned dose of KM-819 and 2 subjects will receive placebo.
89459741|NCT02674334|Active Comparator|NIRS Monitored Not Treated|Anesthesiologist blinded to Near Infrared Spectroscopy (NIRS)
89459742|NCT02674334|Active Comparator|NIRS Monitored and Treated|Anesthesiologist treats based on Near Infrared Spectroscopy (NIRS)
89459743|NCT05276518||o Group (1): 30 cases who will undergo Two Layer Uterine Closure|o After the delivery the first group will undergo Two Layer Uterine Closure: Double-layer closure of the uterine incision will be performed using unlocked continuous Polyglactin thread sutures(1/0) for both layers, with a large portion of the myometrium and the endometrium included in the first layer. The second layer was a continuous running suture that imbricate the first layer, including serosal and myometrial tissue.
89017059|NCT00306501|Other|Cortical Stimulation|Training with Cortical stimulation - cortical stimulation during training with button press
89017060|NCT00306501|Other|Combined|Combined vibrotactile and cortical stimulation with button press training
89017061|NCT00306540|Active Comparator|1|Placebo Seroquel + existing therapy
89017062|NCT00306540|Experimental|2|Seroquel + existing therapy
89459744|NCT05276518||o Group (2): 30 cases who will undergo single layer uterine closure.|The second group will undergo continuous unlocked sutures in a single layer, Uterine closure will begin from one corner of the incision and then the uterine incision wound is closed using Polyglactin thread include endometrium, myometrium and serosa
89459745|NCT05676866|Experimental|Breast cancer patients with positive axillary nodes|Female with invasive breast cancer with axillary metastasis , who recieve neo adjuvant therapy with complete axillary response
89017063|NCT00271388|Experimental|Parameter Determination|Testing potential effects of GVS on the symptoms of neglect
89017064|NCT00306735|Experimental|Palonosetron|
89017065|NCT00306774|Experimental|1|Participants will receive vitamin D (cholecalciferol)
89017066|NCT00306774|Placebo Comparator|2|Participants will receive a matched placebo
89017067|NCT00271700|No Intervention|Usual Care|admission to medical team floor to usual care
89017068|NCT00271700|Experimental|Intervention|consists of usual care as well as an admission order set built into BWH's proprietary computer provider order entry (CPOE) system
89017069|NCT04718142|Experimental|vNEP with various shapes and sizes and overnight PSG|Administer vNEP therapy to study participants on the throat's anterior surface with a variable negative pressure ranging from -20 cmH2O up to -35 cmH2O. Assess participants for a reduction in Apnea-Hypopnea Index (AHI) for at least 120 minutes using polysomnography (PSG) and treatment tolerance compared to CPAP.
89017070|NCT00306930|Other|A|Acetabular cup replacement with total hip arthroplasty
89017071|NCT00307008|Experimental|Group A|
89017072|NCT00307203|Experimental|I|Experiment group received 300 mgs of bupropion, in addition to weekly CBT and nicotine replacement therapy
89017073|NCT00307203|Placebo Comparator|II|Placebo group received placebo, in addition to weekly CBT and nicotine replacement therapy
89017074|NCT00307320|No Intervention|1|
89017075|NCT00307320|Experimental|2|Relaxation techniques
89017076|NCT00307515|Experimental|1|Fibrin Sealant 2 (FS2)
89017077|NCT00307515|Active Comparator|2|Oxidized Regenerated Cellulose (Surgicel)
89017078|NCT00272285|Experimental|1|Intravenous (IV)
89017079|NCT00272285|Active Comparator|2|Intravenous (IV)
89017080|NCT00307593|Active Comparator|1|Rituximab
89459746|NCT03480087||Chemotherapy alone|Patient treated with anthracycline containing chemotherapy
89017081|NCT00307593|Active Comparator|2|Infliximab
89017082|NCT00272402|Other|1|Simulated case-based learning
89017083|NCT00272402|Other|2|EMR clinical decision support tool.
89017084|NCT00272402|No Intervention|3|Control group
89017085|NCT00307632|Experimental|Norelgestromine (NLGM)/Ethinyl Estradiol (EE)|
89017086|NCT00272480|Placebo Comparator|Placebo|Placebo in HAM/TSP 24
89017087|NCT00272480|Active Comparator|Zidvoudine plus lamivudine|Zidvoudine plus lamivudine in HAM/TSP 24
89017088|NCT00307671|Other|A|conventional treatment
89017089|NCT00307671|Experimental|B|reduction dose
89017090|NCT00272519|Experimental|Adolescent/caregiver dyads|Eight to ten adolescent/caregiver dyads
89017091|NCT00307710|Experimental|A: Trivalent Subvirion Vaccine|Group A: Trivalent subvirion vaccine - standard inactivated influenza vaccine by intramuscular injection.
89017092|NCT00307710|Experimental|B: Vaccine 15 μg|Group B: Trivalent rHA0 vaccine 15 μg per rHA0 (total 45 μg rHA0)
89017093|NCT00307710|Experimental|C: Vaccine 45 μg|Group C: Trivalent rHA0 vaccine 45 μg per rHA0 (total 135 μg rHA0)
89017094|NCT00307710|Experimental|D: Vaccine 135 μg|Group D: Trivalent rHA0 vaccine 135 μg per rHA0 (total 405 μg rHA0)
89017095|NCT00272597|Other|Risperidone LAI|"Subjects treated with any antipsychotic can be switched to Risperidone LAI.~If the subject is currently treated with an antipsychotic other than risperidone, the dosage will be tapered gradually and discontinued. Simultaneously, oral risperidone will be started at 2 mg/day and increased to no more than 6 mg/day. The subject will be treated with risperidone monotherapy for at least five days prior to entering the stabilization phase of the study.~On the other hand, if the patient has already been treated for more than 5 days with risperidone monotherapy then he/she may enter the stabilization phase of the study immediately."
89017096|NCT00307749|Placebo Comparator|1|
89017097|NCT00307749|Experimental|2|
89017098|NCT00307749|Experimental|3|
89017099|NCT00307749|Experimental|4|
89017100|NCT00307827|Experimental|Arm 1|Visilizumab low dose level
89017101|NCT00307827|Experimental|Arm 2|Visilizumab middle dose level
89017102|NCT00307827|Experimental|Arm 3|Visilizumab high dose level
89017103|NCT00282009|Active Comparator|Basic Internet|Basic Internet
89201647|NCT04209322|Active Comparator|Transforaminal Epidural Steroid Injection|Aseptic technique was adopted. Imaging guided (CT) catheter needle (active tip electrode) was inserted and a sensory stimulation test was carried out using an RF generator. The catheter needle was then advanced toward the DRG until the patient reported a tingling sensation and/or dysesthesia at less than 0.3V. After 10 minutes await (as per pRF), patients received 1mL lidocaine 20mg/mL mixed with 2mL dexamethasone 10mg/mL.
89201648|NCT04004572|Experimental|LEAP Regimen|Pegaspargase, 2500IU/m2, im, day 1 Sintilimab, 200mg, iv day1 Anlotinib, 8mg, oral, day 1-14 The LEAP regimen will be repeated every 3 weeks.
89201649|NCT04050436|Experimental|Cemiplimab in combination with RP1|Cemiplimab administered intravenously every 3 weeks in combination with RP1 administered as an intratumoral injection every 3 weeks
89201650|NCT04050436|Active Comparator|Cemiplimab|Cemiplimab administered intravenously as a single therapy every 3 weeks
89201651|NCT04045912|Experimental|HIVST + AGYW-Friendly Services|"Drug shops in Arm 1 will implement AGYW-friendly services, including a sexual and reproductive health (SRH) product display, a tablet with SRH videos, and a loyalty program (the Queen Club) through which AGYW can earn mystery prizes and discreetly request free SRH products. They will also provide HIV self-test (HIVST) kits to AGYW customers for free."
89201652|NCT04045912|Active Comparator|HIVST Only|Drug shops in Arm 2 will provide HIVST kits to AGYW customers for free.
89459747|NCT03480087||Chemotherapy plus radiotherapy|Patient treated with anthracycline containing chemotherapy followed by mediastinal radiotherapy
89459748|NCT05676788|Experimental|Intersegmental plane identification by HSI and ICG|"Hyperspectral Imaging Intersegmental plane identification:~Defined as distance between intersegmental plane identification with Hyperspectral Imaging compared to near-infrared indocyanine green fluorescence."
89017104|NCT00282009|Experimental|Enhanced Internet|Enhanced Internet
89017105|NCT00282009|Experimental|Enhanced Internet plus Phone|Enhanced Internet + proactive telephone counseling
89017106|NCT00307866|Experimental|Arm 1|
89017107|NCT00272831|Active Comparator|Cilostazol|Cilostazol 100 mg twice daily
89017108|NCT00272831|Placebo Comparator|Placebo|
89017109|NCT00417105||1|hemodialysis twice weekly 4 hours
89017110|NCT00417105||2|nocturnal dialysis twice weekly 8 hours
89017111|NCT00417105||3|nocturnal hemodialysis, 8 hours every other night
89017112|NCT00417105||4|nocturnal hemodialysis, 8 hours, six times per week
89017113|NCT00307905|Active Comparator|A|TRAUMEEL S
89017114|NCT00307905|Placebo Comparator|B|placebo remedy
89017115|NCT02960828|Experimental|"Intervention-Device:_Laser"|"Subthreshold focal photocoagulation~Intravitreal Anti-vascular endothelial growth factor (Anti-VEGF) injection"
89017116|NCT02960828|No Intervention|Control|Contralateral eye
89017117|NCT00282126|Experimental|1|Participants will receive 90 meq of potassium citrate.
89017118|NCT00282126|Experimental|2|Participants will receive 60 meq of potassium citrate.
89017119|NCT00282126|Placebo Comparator|3|Participants will receive placebo.
89017120|NCT00272909|Experimental|1|piclozotan IV infusion, low dose, for 72 hours.
89017121|NCT00272909|Experimental|2|piclozotan IV infusion, high dose, for 72 hours.
89017122|NCT00272909|Placebo Comparator|3|placebo (normal saline) IV infusion, for 72 hours.
89017123|NCT00282165|Placebo Comparator|placebo|four week double blind placebo treatment phase
89017124|NCT00282165|Active Comparator|naratriptan|four week double blind experimental treatment using daily naratriptan tablets
89017125|NCT00272948|Experimental|Prophylaxis Arm|
89017126|NCT00272948|Active Comparator|Control Arm|
89017127|NCT00308100|Experimental|1|
89017128|NCT00308100|Active Comparator|2|
89017129|NCT00282204|No Intervention|Control|Usual care control
89017130|NCT00282204|Experimental|Hypnosis + CD|Hypnosis plus audio cd on hypnosis
89017131|NCT00282204|Active Comparator|Audio CD on Hypnosis|Audio CD on hypnosis sessions weekly on three occasions after 34 weeks gestation
88941931|NCT01864980||Hb group:15 patients|scheduled for elective surgery associated with undetected, i.e., difficult to reliably monitor intraoperative blood loss.
89459749|NCT05311852|Experimental|PEA-LUT|patients were required to assume granulated PEA-LUT 700/70 mg, 2 time/day for 8 weeks
89459750|NCT05311852|Placebo Comparator|Placebo|patients were required to assume granulated placebo, 2 time/day for 8 weeks
89459751|NCT03026075|Experimental|Colonoscopy with MCS|Standard colonoscopy procedure with Motus Cleansing System
89459752|NCT01373918|Experimental|low dose intravenous fat emulsion|Subjects in this arm will receive approximately 1 g/kg/d IV of intravenous soybean oil (Intralipid).
89459753|NCT01373918|Active Comparator|standard dose intravenous fat emulsion|Subjects in this arm will receive approximately 3 g/kg/d IV of intravenous soybean oil (Intralipid).
89459754|NCT05310136|Experimental|Nurse-guided BBTi intervention group|Participants will experience 4-week treatment period (2 in person and 2 via telephone).
89459755|NCT05310136|No Intervention|Control group|Participants will received sleep hygiene at the enrollment of the study and be required to maintain their usual lifestyle and medical treatment for 4 weeks.
89459756|NCT03671915|Active Comparator|Usual System (Open-loop)|In open loop: sensor-augmented pump (SAP) therapy using standard insulin pump setting combined with the six-generation glucose sensor (Dexcom G6).
89459757|NCT03671915|Experimental|DIABELOOP System (Closed-loop)|"In the closed loop: Diabeloop software (an MPC-based glucose control algorithm) running on handset associated with the six-generation glucose sensor (Dexcom G6) and Kaleïdo insulin pump.~A remote monitoring system managed by specialized nurse on behalf diabetologist, is provided in closed-loop session."
89459758|NCT03671837|Experimental|Oyxgen|Nasal Insufflation with 15 L/min O2 and a nasopharyngeal airway
89459759|NCT03671837|Active Comparator|Air|Nasal Insufflation with 15 L/min air and a nasopharyngeal airway
89459760|NCT03302195|Active Comparator|Control group|"Heparin dose and cardiopulmonary bypass pump flow rate are calculated using total body weight.~An initial 400 IU/Kg Heparin dose will be administered, with an additional dose of 75 IU/kg if the activated clotting time remains below the 425 seconds target value. The cardiopulmonary bypass pump flow rate of 2.4 L/min/m2 of body surface area will be calculated."
89459761|NCT03302195|Experimental|Intervention group A|"Heparin dose is adjusted for lean body weight and cardiopulmonary bypass pump flow rate is calculated using total body weight.~An initial 400 IU/Kg Heparin dose will be administered, with an additional dose of 75 IU/kg if the activated clotting time remains below the 425 seconds target value. The cardiopulmonary bypass pump flow rate of 2.4 L/min/m2 of body surface area will be calculated."
89459762|NCT03302195|Experimental|Intervention group B|"Heparin dose is calculated using total body weight and cardiopulmonary bypass pump flow rate is adjusted for lean body weight.~An initial 400 IU/Kg Heparin dose will be administered, with an additional dose of 75 IU/kg if the activated clotting time remains below the 425 seconds target value. The cardiopulmonary bypass pump flow rate of 2.4 L/min/m2 of body surface area will be calculated."
88941932|NCT01864980||SpHb group: 15 patients|scheduled for elective surgery associated with undetected, i.e., difficult to reliably monitor intraoperative blood loss.
88941933|NCT01864993|Experimental|suspected NC gluten sensitive subjects|Patients referring gastrointestinal functional disorders will be selected and they will follow a gluten free diet
88941934|NCT01864993|Experimental|suspected NC gluten sensitive|Patients referring gastrointestinal functional disorders will be selected and they will follow a gluten free diet
88941935|NCT01865006||Ligasure LF1212|
88941936|NCT01865006||Ultracision|
88941937|NCT01865006||Conventional|
89459763|NCT03302195|Experimental|Intervention group C|"Heparin dose and cardiopulmonary bypass pump flow rate are adjusted for lean body weight.~An initial 400 IU/Kg Heparin dose will be administered, with an additional dose of 75 IU/kg if the activated clotting time remains below the 425 seconds target value. The cardiopulmonary bypass pump flow rate of 2.4 L/min/m2 of body surface area will be calculated."
89459764|NCT03113786|No Intervention|Standard of Care|Subjects randomized to standard of care will undergo a traditional lumbar discectomy procedure without any additional interventions
89459765|NCT03113786|Active Comparator|CLARIX™100|Subjects randomized to the CLARIX™100 arm will undergo a traditional lumbar discectomy, after which CLARIX™100 will be applied to the affected site. The tissue will be applied to the annulus at the defect site as a patch just prior to wound closure.
89459766|NCT03113786|Active Comparator|CLARIX CORD 1K|Subjects randomized to the CLARIX CORD 1K arm will undergo a traditional lumbar discectomy, after which CLARIX CORD 1K will be applied to the affected site. The tissue will be applied to the annulus at the defect site as a patch just prior to wound closure.
89459767|NCT03676595|Experimental|Group A|Group A received interactive video game-based exercise training for the first 6 weeks, with no exercise in the subsequent 6 weeks. The exercise program consisted of 30-minute sessions 3 times per week for 6 weeks. Outcomes were measured at weeks 0, 6, and 12.
88941938|NCT01865019||volume controlled|volume ontrolled ventilation
88941939|NCT01865019||pressure controlled|pressure controlled ventilation
88941940|NCT01865032||Skin Ulcers|Skin ulcers. No intervention. Subjects will be followed up by their respective primary providers.
88941941|NCT01865058||DLBCL|Patients with newly diagnosis of diffuse large B-cell lymphoma is offered enrollment in this protocol.
88941942|NCT01865071|Experimental|loop ileostomi|Compare early vs. late closer of the protecting ileostoma in patients requiring rectal resection for rectal cancer
88941943|NCT01865097|Experimental|Relaxation guided imagery|
88941944|NCT01865097|Active Comparator|Relaxing music|
88941945|NCT01865123|Experimental|Transcendental Meditation|TM is a simple, natural, effortless mental technique practiced with eyes closed sitting for 20 minutes twice a day. This allows the practitioner to experience lesser excited levels of the mind and correspondingly greater degrees of physical relaxation. TM is a traditional meditation technique that has its origin in the ancient Vedic tradition of India.
89017132|NCT00418626|Experimental|Nilotinib|
89017133|NCT00313950|Experimental|Group 1|
89017134|NCT00313950|Experimental|Group 2|
89017135|NCT00313950|Experimental|Group 3|
89017136|NCT00273104|Active Comparator|Bariatric surgery|Bariatric surgery (gastric bypass) offered to patients after informed consent and shared decision. The surgical procedure was performed at Vestfold Hospital Trust by experienced bariatric surgeons.
89201653|NCT01093976|Experimental|Dronabinol|Dronabinol (Marinol) - 2.5mg-15mg by mouth once a day for twelve-weeks
89201654|NCT00329719|Experimental|Group I (sorafenib tosylate, temsirolimus)|Patients receive sorafenib tosylate and temsirolimus as in Phase I.
89201655|NCT00329719|Experimental|Group II (sorafenib tosylate, temsirolimus, surgery)|Patients receive sorafenib tosylate PO BID on days 1-8 and temsirolimus IV over 30 minutes on day 1. Patients undergo surgery on day 8. After recovering from surgery, patients receive sorafenib tosylate and temsirolimus as in Phase I.
89201656|NCT00329719|Experimental|Group III (sorafenib tosylate, temsirolimus, anti-VEGF)|Patients who have received prior anti-VEGF therapy and are not undergoing surgery receive sorafenib tosylate and temsirolimus as in Phase I.
89201657|NCT04008628|Active Comparator|Nitrous oxide|Inhalation of a 50%/50% mixture of nitrous oxide and oxygen. Reassurance of the child during procedure
89201658|NCT04008628|No Intervention|Standard care|Infants will be reassured as currently performed in routine clinical practice
89201659|NCT02566148||HIV group|group living with HIV
89201660|NCT02566148||Hepatitis B group|group living with chronic hepatitis B
89201661|NCT02566148||Reference group|group who has neither HIV nor hepatitis B
89201662|NCT04004806|No Intervention|Pre-Intervention|Phase 1 (Observational phase): All residents and staff physicians rotating through the inpatient medicine services during the first three (3) months, who agreed to be a part of the study, will be provided with Hill Rom tracking devices to quantify the time spent at the patient's bedside by each member as part of the daily practice.
89201663|NCT04004806|Experimental|Intervention|Phase 2 (Intervention phase): The interventional phase will be six (6) months duration. During this period, the recorded time spent by the individual study participants at the patient's bedside will be compared to their respective peers, and percentile scores will be generated. Based on these percentile scores, the study participants will receive emails notifying them of the results. Participants whose scores fall in the lower 50th percentile will be encouraged to increase patient interaction times. Participants with scores in the top 50th percentile will receive congratulatory emails to encourage them to keep up the performance.
89206151|NCT00830622|No Intervention|2|SOC: Participant receives standard of care support but not weekly SMS text messages from the health care worker.
89206152|NCT01065883|Experimental|community health worker|community health workers will provide education in the home
88941946|NCT01865123|Active Comparator|Prolonged Exposure|Prolonged Exposure (PE) is a specialized type of Cognitive Behavorial Therapy employing a manualized, trauma-focused behavioral treatment for PTSD and is based on exposure principles and emotional processing theory.
88941947|NCT01865123|Placebo Comparator|Educational Control|Didactic based instructional classes will provide health education which will include the benefits of proper diet, exercise, and reducing smoking and alcohol. No stress management techniques will be taught.
88941948|NCT01865136|Other|Medical Post Abortion Care by Midwife|Women with incomplete abortion is diagnosed and treated with misoprostol by midwife
88941949|NCT01865136|No Intervention|Medical Post Abortion Care by physician|Women with incomplete abortion is diagnosed and treated with misoprostol by physician
88941950|NCT01865149||both optic nerve sheath diameter|
88941951|NCT01865175|Active Comparator|ionic iron|Subjects will take ionic iron daily for 7 days followed by 7 days of no medicine folloowed by 7 days of heme iron.
88941952|NCT01865175|Experimental|heme iron polypeptide|Subject will take heme iron daily for 7 days followed by 7 days of no medicine followed by 7 days of ionic iron.
89201664|NCT04004806|No Intervention|Post-Intervention|Phase 3: (Post Intervention observation phase): The final phase of the study will be again three (3) months. The intervention of feedback emails and text pages will be discontinued and the study participants will only be monitored to see if the past intervention made an impact on their daily clinical practice in terms of time spent with the patients.
89201665|NCT00743834|Other|A|Effectiveness of Luvox CR plus Web-based CBT for OCD
89201666|NCT00743912|Experimental|1|open-label rifaximin 550 mg TID
89201667|NCT02563886|Experimental|EAMT, then standard care|Electrically Assisted Movement Therapy precedes usual and customary care.
89201668|NCT02563886|Active Comparator|Standard care, then EAMT|Usual and customary care precedes Electrically Assisted Movement Therapy.
89201669|NCT05306080|Experimental|Tadekinig alfa|"Injection #1/Day 1: As clinically indicated in accordance with Figure 1.1-1.~Repeat Injection(s): Missed doses will not be made up.~Injection #2/Day 3: Approximately 48 hours (+/- 5 hours) after receipt of the 1st injection.~Injection #3/Day 5: Approximately 48 hours (+/- 5 hours) after receipt of the 2nd injection.~Continued Dosing (Optional): Approximately q48-72 hours; If the subject is responsive to initial therapy, but has ongoing symptoms of CRS/CRHLS.~Retreatment (Optional): May be considered"
88941953|NCT01865188|Experimental|LCZ696 200 mg|Patients randomized to this treatment arm will receive LCZ696 200 mg once daily for 8 weeks.
88941954|NCT01865188|Experimental|LCZ696 400 mg|Patients randomized to this treatment arm will receive LCZ696 400 mg once daily for 8 weeks.
88941955|NCT01865188|Active Comparator|Amlodipine 5 mg|Patients randomized to this treatment arm will receive amlodipine 5 mg once daily for 8 weeks.
89201670|NCT04060472|Experimental|albumin-bound paclitaxel + oxaliplatin|
89201671|NCT02563730|Experimental|Lung biopsy|assess the additional diagnostic value of cryobiopsy in patients with suspected Idiopathic Interstitial Pneumonia (IIP). Cryoprobe vs VATS
89206153|NCT01065883|Active Comparator|mailed information|information will be mailed to the home on the same schedule as the experimental intervention
89206154|NCT00830700|Experimental|CATMH intervention|Child telemental health service delivery intervention
89206155|NCT00830700|No Intervention|augmented TAU/PCP|Augmented treatment as usual with primary care physician
89206156|NCT00830778|Experimental|PG anastomosis|Pancreaticogastrostomy (PG) reconstruction/anastomosis after pancreaticoduodenectomy (PD)
88941956|NCT01865188|Active Comparator|Amlodipine 10 mg|Patients randomized to this treatment arm will receive amlodipine 10 mg once daily for 8 weeks.
88941957|NCT01865188|Experimental|LCZ696 200 mg and amlodipine 5 mg|Patients randomized to this treatment arm will receive LCZ696 200 mg and amlodipine 5 mg once daily for 8 weeks.
89459768|NCT03676595|Experimental|Group B|Group B had no exercise in the first 6 weeks and then underwent interactive video game-based exercise training in the subsequent 6 weeks. The exercise program consisted of 30-minute sessions 3 times per week for 6 weeks. Outcomes were measured at weeks 0, 6, and 12.
89459769|NCT02667626|Experimental|SCPR Intervention|"Young breast cancer participants will receive their SCPR and access to additional web-based educational reproductive health information, including resource lists of helpful websites, followed by regular reproductive health prompts and study adherence reminders for 24 weeks.~Healthcare providers of young breast cancer participants randomized to the intervention arm will receive their patient's SCPR and access to the same additional web-based educational reproductive health information as their patient, including resource lists of helpful websites."
89459770|NCT02667626|Active Comparator|Control|"Young breast cancer participants randomized to the waitlist control arm will receive access to the web-based resources and study adherence reminders. At completion of the 24 weeks of follow up, they will have access to their SCPR.~Healthcare providers of young breast cancer participants randomized to the waitlist control arm will receive access to the same web-based resources as their patient."
89459771|NCT03671681|Experimental|MT group|Education of patients, Pharmacological Prophylaxis prescribed based on patients' profile, and six group sessions of 45 minutes of mindfulness-based treatment.
89459772|NCT03671681|Other|MED group|Education of patients followed by Pharmacological Prophylaxis, prescribed based on patients' profile (i.e. clinical features, previous failures and contraindications)
89459773|NCT03479853||Cases : suffering from ocular or oculo-cutaneous rosacea|Classic ophthalmologic examination with visual acuity measurement and slit lamp examination of both eyes and eyelids. Then, meibographic and interferometric evaluation of his two inferior eyelids with the Lipiview device.
88941958|NCT01865188|Experimental|LCZ696 200 mg and amlodipine 10 mg|Patients randomized to this treatment arm will receive LCZ696 200 mg and amlodipine 5 mg once daily for 1 week followed by LCZ696 200 mg and amlodipine 10 mg once daily for 7 weeks.
88941959|NCT01865188|Experimental|LCZ696 400 mg and amlodipine 5 mg|Patients randomized to this treatment arm will receive LCZ696 200 mg and amlodipine 5 mg once daily for 1 week followed by LCZ696 400 mg and amlodipine 5 mg once daily for 7 weeks.
88941960|NCT01865188|Experimental|LCZ696 400 mg and amlodipine 10 mg|Patients randomized to this treatment arm will receive LCZ696 200 mg and amlodipine 5 mg once daily for 1 week followed by LCZ696 400 mg and amlodipine 10 mg once daily for 7 weeks.
88941961|NCT01865188|Placebo Comparator|Placebo|Patients randomized to this treatment arm will receive placebo once daily for 8 weeks.
88941962|NCT01865201|Experimental|Edaravone group|Edaravone was used at a dose of 30mg,intravenously, twice per day, for 14 days. All patients also received common fundamental management, which was as follows: ①Methylprednisolone, administered by intravenous infusion at a 500mg daily for 3 consecutive days and then gradually tailed off in 30 days with administration of oral prednisolone. ②Dehydration drugs.
88941963|NCT01865201|Experimental|Control group|All patients in this group received common fundamental management, which was as follows: ①Methylprednisolone, administered by intravenous infusion at a 500mg daily for 3 consecutive days and then gradually tailed off in 30 days with administration of oral prednisolone. ②Dehydration drugs.
88941964|NCT01865227|Active Comparator|Group Counseling|The major aim of the post-operative counseling groups is to engage patients in discussing and exchanging their thoughts on issues of concern related to their surgery and overall well-being. The selected patients will be informed about the purpose of these support groups and will be made aware that their attendance is entirely voluntary.
88941965|NCT01865227|No Intervention|Standard treatment|
88941966|NCT01865240|Experimental|Renal Denervation Group|participants randomised to undergo the renal denervation procedure
88941967|NCT01865240|No Intervention|Usual care|participants randomised to the usual care group will receive additional antihypertensive medication in an attempt to achieve blood pressure targets
88941968|NCT01865253|Experimental|Renal Denervation|Renal Denervation treatment
89206157|NCT00830778|Active Comparator|PJ anastomosis|Pancreaticojejunostomy (PJ) reconstruction/anastomosis after pancreaticoduodenectomy (PD)
89206158|NCT03981913||Healthy control (HC)|Participants without neurological or psychiatric disturbance (n= 30)
89459774|NCT03479853||Witnesses|"Without any present or past palpebral meibomian Gland Dysfunction~Classic ophthalmologic examination with visual acuity measurement and slit lamp examination of both eyes and eyelids. Then, meibographic and interferometric evaluation of his two inferior eyelids with the Lipiview device."
89459775|NCT03676517|Experimental|Preoperative short-course radiotherapy|1-week short-course radiation (5 Gy x 5) plus 6-week XELOX (capecitabine 1,000mg/m2 and oxaliplatin 130mg/m2 every 3 weeks) chemotherapy before total mesorectal excision (TME)
89459776|NCT05275114|Experimental|Hand Tasks + M1(1mA) & aIPS(1mA) tDCS|20 minutes of Hand Taks + applying 30 minutes of M1(1mA) & aIPS(1mA) tDCS and fNIRS
89459777|NCT05275114|Active Comparator|Hand Tasks + Sham tDCS|20 minutes of Hand Tasks + 30 minutes of sham tDCS and fNIRS
89459778|NCT03479775||Youth female athletes with poor muscle function|Youth female athletes (floorball, football and handball) with assessed poor muscle function at baseline.
89459779|NCT03479775||Youth female athletes with good muscle function|Youth female athletes (floorball, football and handball) with assessed good muscle function at baseline.
89459780|NCT03757455|Experimental|Enchanced recovery after surgery protocol|ERAS-protocol as described in low risk patients after pancreaticoduodenectomy or total pancreatectomy
89459781|NCT03757455|No Intervention|Standard protocol|Standard recovery protocol after pancreaticoduodenectomy or total pancreatectomy
89459782|NCT03114020|Experimental|Hyaluronic Acid inhalation solution|3mL of 0.03% Hyaluronic Acid inhalation solution BID for 28 days
89459783|NCT03114020|Placebo Comparator|Placebo Inhalation Solution|3mL matching placebo inhalation solution BID for 28 days
89459784|NCT03113864|Placebo Comparator|Placebo|Will be identical looking to treatment
89459785|NCT03113864|Experimental|Lutein|10 mg of FloraGLO Lutein
89459786|NCT03479619|Experimental|A/28/1|Lancing device A with personal lancet of size 28 G and minimum puncture depth.
89459787|NCT03479619|Experimental|A/28/5|Lancing device A with personal lancet of size 28 G and maximum puncture depth.
89459788|NCT03479619|Experimental|A/30/1|Lancing device A with personal lancet of size 30 G and minimum puncture depth.
89201672|NCT00329641|Experimental|Treatment (carboplatin, paclitaxel, sorafenib)|"Patients receive carboplatin IV and paclitaxel IV once on day 1 and oral sorafenib twice daily on days 2-19. Treatment repeats every 21 days for up to 6 courses.* After 6 courses, patients continue to receive oral sorafenib alone twice daily in the absence of disease progression or unacceptable toxicity.~[Note: *If sorafenib is discontinued prior to course 6, patients may continue to receive carboplatin and paclitaxel for up to 6 courses; if carboplatin and paclitaxel are discontinued prior to course 6, patients may continue to receive sorafenib alone twice daily on days 1-21 of each course in the absence of disease progression or unacceptable toxicity. ]"
89459789|NCT03479619|Experimental|A/30/5|Lancing device A with personal lancet of size 30 G and maximum puncture depth.
89459790|NCT03479619|Experimental|A/33/1|Lancing device A with personal lancet of size 33 G and minimum puncture depth.
89459791|NCT03479619|Experimental|A/33/5|Lancing device A with personal lancet of size 33 G and maximum puncture depth.
89459792|NCT03479619|Experimental|B/28/1|Lancing device B with personal lancet of size 28 G and minimum puncture depth.
89459793|NCT03479619|Experimental|B/28/5|Lancing device B with personal lancet of size 28 G and maximum puncture depth.
89459794|NCT03479619|Experimental|B/30/1|Lancing device B with personal lancet of size 30 G and minimum puncture depth.
89459795|NCT03479619|Experimental|B/30/5|Lancing device B with personal lancet of size 30 G and maximum puncture depth.
89017137|NCT00273104|Active Comparator|Intensive lifestyle intervention|Intensive lifestyle intervention (1-year endurance) at a rehabilitation centre. The intervention consisted of motivation for behaviour change including calorie restriction and increased physical activity.
88941969|NCT01865266|Experimental|NUTIG|"The normal dose of ulinastatin for injection group(NUTIG):~Ulinastatin(Techpool inc,Guangdong,China) was administered to the group as a bolus of 100,000 U diluted in 100 mL of normal saline every 8 hour.A course of treatment consisted of 7 days after the patients were diagnosed as VAP."
89017138|NCT04708691|Experimental|Aerobic exercise|aerobic exercise for 30 mins
89017139|NCT04708691|No Intervention|Control|sitting for 30 mins
89459796|NCT03479619|Experimental|B/33/1|Lancing device B with personal lancet of size 33 G and minimum puncture depth.
89459797|NCT03479619|Experimental|B/33/5|Lancing device B with personal lancet of size 33 G and maximum puncture depth.
89459798|NCT03479619|Experimental|C/28/1|Lancing device C with personal lancet of size 28 G and minimum puncture depth.
89017140|NCT02960178|Experimental|Perturbation-based training|Participants will practice standing and walking activities while secured in an overhead harness attached to an overhead track. While practicing these tasks, the trainer will apply pushes and pulls to the harness at unexpected times, causing a reactive step to be practiced.
89017141|NCT02960178|Active Comparator|Conventional walking training|Participants will practice standing and walking activities while secured in an overhead harness attached to an overhead track. No external perturbations will be applied.
89017142|NCT00314028|Active Comparator|1|Standard of care treatment
89017143|NCT00314028|Experimental|2|Educational program designed to motivate and provide information on the correct use of condoms
89017144|NCT00418782|Active Comparator|1|
89017145|NCT00418782|Experimental|2|
89017146|NCT00418782|Placebo Comparator|3|
89017147|NCT00314067|Experimental|1|
89017148|NCT00314067|Experimental|2|
89017149|NCT00314067|Active Comparator|3|
89017150|NCT00308256|Experimental|Nurse counseling|Phone calls performed by nurse 15 days after each monthly visit
89017151|NCT00308256|No Intervention|Control|Normal monthly follow-up without phone calls
89017152|NCT00273572|Active Comparator|Moderate lifestyle intervention|Moderate lifestyle intervention including two group sessions and one individual counselling session with a nutritionist, at recruitment. Individual sessions with a nutritionist after 6 and 12 months on follow-up.
89017153|NCT00273572|Experimental|Intensive lifestyle intervention|Intensive lifestyle intervention, including bi-monthly group sessions with a physical activity instructor; a monthly group session with a nutritionist, and a monthly individual session with a nutritionist.
89017154|NCT00273611|Experimental|Pharmacist education|Pharmacist education about vitamin D
89017155|NCT00273611|No Intervention|Usual care|Usual care
89017156|NCT00273689|Other|I|This is a crossover trial- Patients get randomly assign to albuterol or singulair and then cross overed to the alternate active medication.
89017157|NCT00273728|Active Comparator|HES, Septic shock, resuscitation|study group with HES 6%
89017158|NCT00308334|Experimental|Domperidone|Domperidone
89017159|NCT00308334|Placebo Comparator|placeob- Sugar pill|
89017160|NCT00273767|Experimental|1|epoetin beta
89017161|NCT00273767|Placebo Comparator|2|placebo of NaCl
89201673|NCT02566070|Active Comparator|Continuous Gastric Feeding (CGF)|CGF group will have total daily enteral nutrition requirement delivered at a constant rate via infusion over the entire 24 hour period.
89017162|NCT00273806|Experimental|1|Medical assistant identification and referral for behavioral risk factors.
89017163|NCT00273806|No Intervention|2|Usual care for behavioral risk factors.
89017164|NCT00273845|Experimental|1|One session of motivational interviewing
89017165|NCT00273845|Experimental|2|Five sessions of strengths-based case management
89017166|NCT00308412|Experimental|1|Two 10^5 PFU doses of rHPIV3cp45 vaccine given as nose drops to healthy infants and children aged 6 to 36 months of age. The two doses are given 4 to 10 weeks apart.
89017167|NCT00308412|Placebo Comparator|2|Two placebo vaccinations given as nose drops to healthy infants and children aged 6 to 36 months of age. The two doses are given 4 to 10 weeks apart.
89017168|NCT00419055||1 Control|Patients are discharged the day after PCI
89017169|NCT00419055||2 Study group|Patients will be discharged 4-6 hrs after PCI
89017170|NCT00416663|Experimental|single arm|open label,single arm,intervention is Angiogenic Cell Precusors(ACPs)
89017171|NCT00308763|Active Comparator|1|Nicotine patch plus placebo sustained-release bupropion
89017172|NCT00308763|Active Comparator|2|Placebo nicotine patch plus sustained-release bupropion
89017173|NCT00308763|Active Comparator|3|Nicotine patch plus sustained-release bupropion
89017174|NCT00314847|No Intervention|Control|IABP, inotropic drugs, antiplatelet agents according to site habits.
89017175|NCT00314847|Experimental|Experimental|ECLS +/- IABP, inotropic drugs, antiplatelet agents according to site habits.
89017176|NCT00277160|Experimental|Treatment Group 1 (Primary Prophylaxis)|Neulasta 6mg single administration per cycle of chemotherapy starting with cycle 1
89017177|NCT00277160|Active Comparator|Treatment Group 2 (Secondary Prophylaxis)|Per Investigator's discretion
89017178|NCT02960100|Experimental|Arm I (mHealth HPV vaccine intervention)|Participants receive targeted HPV vaccine narrative-style video via the mobile-friendly website. Participants also receive monthly HPV vaccination reminders via email or by text message.
89017179|NCT02960100|Active Comparator|Arm II (standard HPV information and HPV VIS)|Participants receive standard information with the HPV Vaccine Information Statement via the mobile-friendly website.
89017180|NCT00308919|Experimental|WST 09|Treatment with WST09 Vascular Photodynamic therapy
89017181|NCT00314925|Experimental|1|
89017182|NCT00277433||Atopic Dermatitis|
89017183|NCT00277433||Non-atopic control|
89017184|NCT00277472|Experimental|valsartan HCTZ|
89017185|NCT00277472|Active Comparator|HCTZ|
89201674|NCT02566070|Experimental|Bolus Gastric Feeding (BGF)|BGF group will have total daily enteral nutrition requirement delivered in interval, finite volumes over the course of the 24 hour period.
89459799|NCT03479619|Experimental|C/28/5|Lancing device C with personal lancet of size 28 G and maximum puncture depth.
89017186|NCT00277589|Experimental|1|
89017187|NCT00277589|Active Comparator|2|
89017188|NCT00277589|Active Comparator|3|
89017189|NCT00277589|Placebo Comparator|4|
89017190|NCT00277706|Experimental|FORTEO|
89017191|NCT00277706|Placebo Comparator|Placebo|
89017192|NCT00309075|Experimental|Arm 1|
89017193|NCT00419133|Experimental|1|Cholera Vaccine
89017194|NCT00419133|Placebo Comparator|2|Placebo
89017195|NCT00277784||1|Individuals with age related macular degeneration
89017196|NCT00309114|Experimental|Interventions for Experimental Arm|Bacterial Interference with Escherichia coli 83972. Each bladder inoculation contains the study organism, E. coli 83972, suspended as a clear solution in sterile physiological saline.
89017197|NCT00309114|Placebo Comparator|Interventions for Control Arm|Each bladder inoculation contains sterile physiological saline that does not contain the study organism.
89017198|NCT00277862|Active Comparator|1|"Pegylated IFN- alpha 2b~Ribavirin for 24 weeks (patients with RVR)"
89017199|NCT00277862|Active Comparator|2|"Pegylated IFN- alpha 2b~Ribavirin for 36 weeks (patients with complete EVR)"
89017200|NCT00277862|Active Comparator|3|"Pegylated IFN- alpha 2b~Ribavirin for 48 weeks (patients with partial EVR)"
89017201|NCT00277862|Active Comparator|4|"Pegylated IFN- alpha 2b~Ribavirin for 48 weeks (control)"
89017202|NCT00315159|No Intervention|No intervention|Patients with negative SLN will be followed on no intervention arm
89017203|NCT04719260|Experimental|Nutrition Thinking®|Nutrition Thinking® approach to promote weight loss and healthy diet pattern.
89459800|NCT03479619|Experimental|C/30/1|Lancing device C with personal lancet of size 30 G and minimum puncture depth.
89459801|NCT03479619|Experimental|C/30/5|Lancing device C with personal lancet of size 30 G and maximum puncture depth.
89459802|NCT03479619|Experimental|C/33/1|Lancing device C with personal lancet of size 33 G and minimum puncture depth.
89459803|NCT03479619|Experimental|C/33/5|Lancing device C with personal lancet of size 33 G and maximum puncture depth.
89459804|NCT03669731|Experimental|Group 1|Urinary urea 24 hours and food diary
89459805|NCT03669731|Experimental|Group 2|Urinary urea 24 hours and food diary
89017204|NCT04719260|Active Comparator|Standard Nutritional Approach|The traditional nutritional prescriptive approach.
89017205|NCT00315198|Active Comparator|Near activities|2 hours of daily patching combined with near visual activities while patching
89017206|NCT00315198|Active Comparator|Distance activities|2 hours of daily patching combined with distance visual activities while patching
89017207|NCT00315237|Experimental|1|
89017208|NCT00315237|No Intervention|2|best supportive care for 18 week duration
89017209|NCT00278135|Active Comparator|1|
89017210|NCT00278135|Placebo Comparator|2|
89017211|NCT00309348|Experimental|Weekly measurement of graft flow|The surveillance group was measured with the FloMon instrument weekly, and all procedures related to their access-grafts recorded
89017212|NCT00309348|No Intervention|Control|The control group was questioned weekly with regard to their graft status and whether there had been any graft-related procedures
89017213|NCT00416702|Experimental|1|QAB149
89017214|NCT00315354|Experimental|1|Low glycemic index diet
89017215|NCT00315354|Active Comparator|2|Low fat diet
89017216|NCT00315354|Active Comparator|3|Very low carbohydrate diet
89017217|NCT00278330|Experimental|Arm I|Patients will receive a 1-hour infusion of flavopiridol on 5 days in week 1 and vorinostat by mouth three times a day in weeks 1 and 2. Treatment may repeat every 3 weeks for as long as benefit is shown.
89017218|NCT00278369|Experimental|A|6 mcg/kg Denileukin Diftitox administered IV/daily on days 8-10 of standard interleukin 2 dose course
89017219|NCT00278369|Experimental|B|9 mcg/kg Denileukin Diftitox administered IV/daily on days -4 to -2 of standard interleukin 2 dose course
89017220|NCT00278369|Experimental|C|9 mcg/kg Denileukin Diftitox administered IV/daily on days 8-10 of standard interleukin 2 dose course
89017221|NCT00278408|Active Comparator|Interventional: 6 R-CHOP-21|Arm I (R-CHOP-21): Patients receive R-CHOP immunochemotherapy comprising rituximab IV, cyclophosphamide IV over 15 minutes, doxorubicin IV, and vincristine IV on day 1 and oral prednisone once daily on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
89017222|NCT00278408|Active Comparator|Interventional: 6 R-CHOP-21 + radiotherapy|Arm II (R-CHOP-21 and radiotherapy): Patients receive R-CHOP as in arm I. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Beginning 2-6 weeks after the last course of R-CHOP, patients who achieve a complete remission (CR) undergo radiotherapy 5 days a week for approximately 5½ weeks.
89206159|NCT03981913||Parkinson's disease (PD)|Participants with idiopathic Parkinson's disease but without other neurological or psychiatric disturbance (n= 30)
89459806|NCT03669731|Experimental|Group 3|Urinary urea 24 hours and food diary
89459807|NCT03623399|No Intervention|15 mmhg-15mmhg|Abdominal entrance pressure will be set to 15 mmhg , after laparoscopic visualization of abdomen ; maintenance pressure will be set to 15 mmhg.
89459808|NCT03623399|Other|15 mmhg-12 mmhg|"Abdominal entrance pressure will be set to 15 mmhg , after laparoscopic visualization of abdomen ; maintenance pressure will be set to 12 mmhg.~Low gas pressure laparoscopy"
89459809|NCT03623399|Other|12 mmhg-12 mmhg|"Abdominal entrance pressure will be set to 12 mmhg , after laparoscopic visualization of abdomen ; maintenance pressure will be set to 12 mmhg.~Low gas pressure laparoscopy"
89459810|NCT03473691|Experimental|Glembatumumab vedotin (GV)|
89459811|NCT03676361|Experimental|Desmopressin|All ten subjects will be evaluated pre and post nephrectomy at 6 months.
89459812|NCT05309278|Experimental|Physical and cognitive exercise group|Participants will be randomized to receive physical and cognitive training for a period of 12 weeks.
89459813|NCT05309278|Active Comparator|Physical exercise only group|Participants will be randomized to receive only physical training for a period of 12 weeks.
89459814|NCT04459845|Active Comparator|Parent Child Interaction Therapy|Parents and children will receive 12 weekly sessions of PCIT.
89459815|NCT04459845|Active Comparator|Child Parent Psychotherapy|Parents and children will receive 12 weekly sessions of CPP
89017223|NCT00278408|Active Comparator|Interventional: 6 R-CHOP-14|Arm III (R-CHOP-14): Patients receive R-CHOP as in arm I. Patients also receive filgrastim (G-CSF) subcutaneously once daily on days 4-13 or until blood counts recover. Treatment repeats every 14 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
89017224|NCT00278408|Active Comparator|Interventional: 6 R-CHOP-14 and radiotherapy|Arm IV (R-CHOP-14 and radiotherapy): Patients receive R-CHOP as in arm I. Patients also receive G-CSF an in arm III. Treatment repeats every 14 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Beginning 2-6 weeks after the last course of R-CHOP, patients who achieve CR undergo radiotherapy as in arm II.
89017225|NCT00278447|Active Comparator|1) CDM|Chronic Disease Management
89017226|NCT00278447|Active Comparator|2) Standard care|Standard care
89017227|NCT00315744|Experimental|Subjects receiving salmeterol/fluticasone|Eligible subjects will receive 60 individual doses of the salmeterol 50 microgram/ fluticasone 100 microgram combination. Subjects will also receive placebo.
89017228|NCT00315744|Active Comparator|Subjects receiving fluticasone|Eligible subjects will receive 60 individual fluticasone 100 microgram doses each.
89017229|NCT00278486|Experimental|stem cell transplantation|
89017230|NCT00278642|Experimental|stem cell transplantation|
89017231|NCT00278681|Experimental|I|Zinc and ORS
89017232|NCT02960139|Experimental|Test- Treatment with Sylys Surgical Sealant|Standard closure plus treatment with Sylys Surgical Sealant
89017233|NCT02960139|No Intervention|Control- Standard of Care|Control group is standard closure of anastomosis.
89017234|NCT00278837|Experimental|Mindfulness based meditation program|Meditation and Breast Cancer: Subjects will participate in an intervention consisting of group and individual instruction in a meditation-based practice of stress reduction and cognitive-affective-behavioral learning.
89017235|NCT00315900|Experimental|Depakote ER|Depakote ER
89017236|NCT00315900|Active Comparator|Seroquel|Seroquel
89017237|NCT00279110|Experimental|A|
89017238|NCT00279110|No Intervention|B|
89017239|NCT00309699|Placebo Comparator|003|Placebo Daily for 3 weeks
89459816|NCT03676205|Experimental|Platelet-Rich Plasma|"24-72 hours after having a muscular lesion, the doctor injects an intramuscular ecoguided infiltration of 6-7 ml of PRP .~After 4-5 days from the injury the patient starts physiotherapy adapted by stages, according to the muscular group affected.~After 7 days from the first infiltration, the patient will recived the second infiltration of 6-7 ml of PRP."
89459817|NCT03676205|Other|Traumel ®|"24-72 hours after having a muscular lesion, the doctor injects an intramuscular ecoguided infiltration of 4 ml of a homeopathic product (Traumeel ®) After 4-5 days from the date of injury, the patient starts physiotherapy adapted by stages, according to the muscular group affected.~After 7 days from the first infiltration, the patient will receive the second infiltration of 4 ml of a homeopathic product."
89459818|NCT03676127||Study Group|ultrasonographic dermal thickness measurements in patients with unilateral breast cancer related lymphedema
89459819|NCT02523417|Experimental|HepaSphere|breast cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
89459820|NCT02523417|Placebo Comparator|control|breast cancer patients received traditional therapy
89459821|NCT05237518|Other|36 adults|The test group should include both men and women subjects. Two equal sizes (18) sub-groups will be enrolled such that each sub-group will be monitored while lying on a different mattress type.
89017240|NCT00309699|Active Comparator|002|Quetiapine 400 to 800 mg daily, initially titrated and flexibly dosed, for 12 weeks
89017241|NCT00309699|Experimental|001|Paliperidone ER 3 to 12 mg daily, flexibly dosed, for 12 weeks
89017242|NCT00279149|Experimental|surgery|surgery
89017243|NCT00418860|Experimental|A|
89017244|NCT00316134||Pts scheduled to remove pleural fluid|
89017245|NCT00309855|Placebo Comparator|Double Placebo|(i.m. vehicle 0.5 mL weekly x three injections and oral placebo once daily x 21 days)
89017246|NCT00309855|Other|Testosterone IM and oral placebo|IM injections weekly x three injections and oral placebo once daily x 21 days
89017247|NCT00309855|Other|Testosterone and Oral Anastrozole|IM injections weekly x 3 injections and oral daily x 21 days
89017248|NCT00309855|Other|Testosterone and Dutasteride|IM injections weekly x 3 injections and oral once daily x 21 days
89017249|NCT00279422|Placebo Comparator|placebo|
89017250|NCT00279422|Experimental|visilizumab|
89017251|NCT00279461|Experimental|A,|Arm A: Vitamin D 2,000 units daily all in one capsule for 6 months
89017252|NCT00279461|Placebo Comparator|B|Arm B: matching placebo one capsule daily for 6 months
89017253|NCT00279617|Active Comparator|Levetricetam|open label treatment
89017254|NCT00309972|Active Comparator|Sequential arm (SEQ)|Four cycles of cisplatinum/vinorelbine given in a 21 day cycle followed by radical radiotherapy, 55 Gy in 20 once daily fractions in four weeks (2.75 Gy/day).
89017255|NCT00309972|Experimental|Experimental arm (CON)|Concurrent chemo-radiotherapy [55 Gy in 20 daily fractions in 4 weeks (2.75 Gy/day) with cisplatinum given concurrently with fractions 1-4 and 16-19, and vinorelbine prior to fractions 1, 6, 15 and 20] followed by two cycles of cisplatinum/vinorelbine.
89017256|NCT00279695||1|Subjects with glaucoma and age-matched normals
89017257|NCT00279695||2|normal volunteers, two age groups, one 18-25 years old, one 50 years and older.
89017258|NCT00279695||3|subjects with tumors of the iris and ciliary body
89017259|NCT00279695||4|subjects with age-related macular degeneration and age-matched normals
89017260|NCT00279734|Experimental|Group 1|
89017261|NCT00279734|Active Comparator|Group 2|
89017262|NCT00279734|Active Comparator|Group 3|
89017263|NCT00279734|Active Comparator|Group 4|
89017264|NCT00279773|Experimental|TKI258 - dose escalation|Dose-Escalation
89017265|NCT00279773|Experimental|TKI258 - dose expansion|Dose-Expansion
89017266|NCT00418899||GLIOGENE|International Multi-Center, Multidisciplinary Study Consortium
89017267|NCT00416741||1 Usual Care-Lifestyle counseling|Metabolic syndrome
89017268|NCT00416741||2 Intensive care-Lifestyle counseling|Metabolic Syndrome Implementation of guidelines
89017269|NCT00310167|Experimental|4 Gy|4 Gy in 2 fractions
89017270|NCT00310167|Active Comparator|24 Gy|24 Gy in 12 fractions
89017271|NCT00316563|Active Comparator|1|
89459822|NCT04458519|Experimental|Probiorinse|Nasal irrigations with Probiorinse (2.4 Billion CFU (Colony-Forming Units) of Lactococcus Lactis W136, (NPN: 80085895)) twice-daily for a period of fourteen days
89459823|NCT04458519|Active Comparator|Saline solution|Nasal irrigations with saline (NeilMed Sinus Rinse, (NPN: 80027142)) twice-daily for a period of fourteen days
89459824|NCT02523183||Subjects with medically refractory epilepsy|Pediatric epilepsy patients who are followed at Children's Hospital Colorado with medically refractory epilepsy, and whom the family has decided to treat with medical cannabis.
89459825|NCT05218486|Active Comparator|Isotretinoin group|Patients will be treated with Isotretinoin in a dose (from 20 to 40) for 3 months and serum YKL40 will be assessed before and after treatment
89459826|NCT05218486|No Intervention|Control group|Assessment of serum YKL40 in healthy individuals
89459827|NCT03251183||Main group|Blood sampling Comprehensive Cardiovascular magnetic resonance (CMR) Transthoracic echocardiography (TTE) (EchoErgo) Invasive pressure-volume (PV) Loops Left ventricular (LV) biopsy
89459828|NCT03251183||Reproducibility group|Stress-perfusion Cardiovascular magnetic resonance (CMR)
89459829|NCT03251183||Age/gender matched control group|Blood sampling Stress-perfusion Cardiovascular magnetic resonance (CMR) TTE (EchoErgo)
89459830|NCT03251183||Healthy volunteers|Blood sampling Stress-perfusion Cardiovascular magnetic resonance (CMR) TTE (EchoErgo)
89459831|NCT05216770|Other|Spatial and temporal CNS pathophysiology of laryngeal dystonia and voice tremor|Simultaneous fMRI with EEG and MEG imaging will be used to examine neural dynamics during phonation.
89459832|NCT05216770|Experimental|Sensorimotor modulations on CNS pathophysiology of laryngeal dystonia and voice tremor|"Topical laryngeal block will be used to modulate somatosensory feedback from the laryngeal mucosa during speech production and examine associated changes in brain activity.~The role of auditory feedback processing on task-induced speech sensorimotor activity will be examined using MEG imaging during perturbing pitch or formants of auditory feedback, unpredictably during speech production, and examining the behavioral and neural correlates of the resulting within-trial compensation responses."
89459833|NCT05216770|Other|Motor learning and CNS pathophysiology of laryngeal dystonia and voice tremor|"Implicit learning of the production of motor sequences will be examined during simultaneous fMRI/EEG and MEG imaging.~Sensorimotor adaptation of speech production during MEG imaging will be examined during perturbing pitch or formants of auditory feedback consistently during speech production and examining the behavioral and neural correlates of the resulting across-trial adaptation responses."
89459834|NCT03675971|Experimental|Medical Cannabis|Drug: Cannabidiol
89459835|NCT03675971|Placebo Comparator|Placebo|Placebo comparator
89459836|NCT05236270|No Intervention|Condition 1|Participants will not receive a text message notifying participants about COVID-19 vaccine availability, standard interpretation of serology SARS-CoV-2 antibody results with COVID-19 vaccination discussion, and an attention control educational message.
89459837|NCT05236270|Experimental|Condition 2|Participants will not receive a text message notifying participants about COVID-19 vaccine availability, standard interpretation of serology SARS-CoV-2 antibody results with COVID-19 vaccination discussion, and an educational message about COVID-19 vaccines.
89459838|NCT05236270|Experimental|Condition 3|Patients will not receive a text message notifying participants about COVID-19 vaccine availability, motivational interviewing about serology SARS-CoV-2 antibody results with COVID-19 vaccination discussion, and an attention control educational message.
89459839|NCT05236270|Experimental|Condition 4|Patients will not receive a text message notifying participants about COVID-19 vaccine availability, motivational interviewing about serology SARS-CoV-2 antibody results with vaccination discussion, and an educational message about COVID-19 vaccines.
89459840|NCT05236270|Experimental|Condition 5|Patients will receive a text message notifying participants about COVID-19 vaccine availability, motivational interviewing about serology SARS-CoV-2 antibody results with vaccination discussion, and an educational message about COVID-19 vaccines.
89017272|NCT00316563|Placebo Comparator|2|
89017273|NCT00416819|Experimental|methotrexate, leucovorin calcium, rituximab, and temozolomide|Determine the rate of toxicity, in terms of percentage of patients with grade 4 neurotoxicity, in patients with untreated primary CNS lymphoma treated with induction therapy comprising high-dose methotrexate, leucovorin calcium, rituximab, and temozolomide followed by consolidation therapy comprising cytarabine and etoposide phosphate.
89017274|NCT00310206|Experimental|ID injection-9 mcg|25 subjects to receive 9 mcg of inactivated influenza A/H5N1 vaccine intradermally on Days 0 and 28.
89017275|NCT00310206|Experimental|IM injection-15 mcg|25 subjects to receive 15 mcg of inactivated influenza A/H5N1 vaccine intramuscularly on Days 0 and 28.
89017276|NCT00310206|Experimental|IM injection-45 mcg|25 subjects to receive 45 mcg of inactivated influenza A/H5N1 vaccine intramuscularly on Days 0 and 28.
89017277|NCT00310206|Experimental|ID injection-3 mcg|25 subjects to receive 3 mcg of inactivated influenza A/H5N1 vaccine intradermally on Days 0 and 28.
89017278|NCT00280007|Experimental|1|bevacizumab infusion evey 2 weeks
89017279|NCT00280007|Placebo Comparator|2|placebo infusion
89017280|NCT00310323|Experimental|1|Children with OSAS identified via sleep study
89017281|NCT00280280|Experimental|1|This study will explore the safety and effectiveness of Botox versus baclofen in treatment subjects with upper-limb spasticity due to neurological damage or a stable neurological disorder. Subjects will be randomized to one of two treatment groups: intramuscular Botox plus oral placebo or intramuscular placebo plus oral baclofen.
89017282|NCT00316758|Experimental|1|
89017283|NCT00280319|Experimental|IPT arm|interpersonal psychotherapy for groups (IPT-G). this consists of psychotherapy provided to participants in a group format.
89017284|NCT00280319|Experimental|CP arm|Creative Play therapy consists of play activities provided to participants in groups.
89017285|NCT00280319|No Intervention|control|those who are wait-list controls
89017286|NCT00316797|Experimental|123-I INER|To assess 123-I INER
89017287|NCT00280475|Active Comparator|1|Device: Whole brain radiation therapy arm
89017288|NCT00280475|Experimental|2|Device: Salvage stereotactic radiosurgery arm
89459841|NCT05236270|Experimental|Condition 6|Patients will receive a text message notifying participants about COVID-19 vaccine availability, motivational interviewing about serology SARS-CoV-2 antibody results with vaccination discussion, and an attention control educational message.
89459842|NCT05236270|Experimental|Condition 7|Patients will receive a text message notifying participants about COVID-19 vaccine availability, standard interpretation of serology SARS-CoV-2 antibody results with COVID-19 vaccination discussion, and an attention control educational message.
89459843|NCT05236270|Experimental|Condition 8|Patients will receive a text message notifying participants about COVID-19 vaccine availability, standard interpretation of serology SARS-CoV-2 antibody results with COVID-19 vaccination discussion, and an educational message about COVID-19 vaccines.
89459844|NCT05236036|Experimental|Group 1 (TMZ, MMF)|Patients who have already undergone surgery or biopsy followed by chemoradiation receive TMZ PO QD on days 1-5 of each cycle and MMF PO BID. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
89459845|NCT05236036|Experimental|Group 2 (TMZ, MMF, radiation therapy)|Patients with unmethylated glioblastoma who have already undergone surgery or biopsy receive TMZ PO QD on days 1-5 of each cycle and MMF PO BID. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Starting at the same time as TMZ and MMF administration, patients also receive radiation therapy daily, 5 days per week, for 6 weeks.
89459846|NCT05236036|Experimental|Group 3 (TMZ, MMF, radiation therapy)|Patients who have already undergone surgery or biopsy receive TMZ PO QD on days 1-5 of each cycle and MMF PO BID. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Starting at the same time as TMZ and MMF administration, patients also receive radiation therapy daily, 5 days per week, for 6 weeks.
89459847|NCT05236036|Experimental|Group S (pre-surgical MMF, TMZ)|Patients planning to undergo surgery receive MMF PO BID and TMZ PO QD for 5 days prior to surgery in the absence of disease progression or unacceptable toxicity.
89459848|NCT02781779|Active Comparator|Silverlon®|Subjects randomized to this arm will receive Silverlon® dressing postoperative.
89459849|NCT02781779|Active Comparator|AQUACEL® AG|Subjects randomized to this arm will receive AQUACEL® AG dressing postoperative.
89459850|NCT05270200|Experimental|Azacitidine combined with Chidamide|Patients will recieve six courses of azacitidine 100mg through a needle under your skin on Days 1-5.Each course is 28 days long.At the same time patients will recieve oral chidamide 5mg per day for no more than 2 years.
89459851|NCT03025217|Experimental|TLC Program|The TLC Program consists of one in-person visit with a licensed dietician and biweekly phone coaching sessions. During the program, the dietician will 1) identify specific nutrition goals, 2) review and tailor the education materials to the patient's needs, and 3) set up regular telephone coaching sessions of up to two sessions per month for six months for each patient. Motivational interviewing and nutrition/health coaching will be provided.
89017289|NCT00316836||Group 1|Patients complete a 10-minute questionnaire about factors that might affect changes in breast density at baseline and another questionnaire at 1 year and 2 years post registration. Blood samples are collected at baseline (before initiation of treatment ) and at 1 year post registration for hormone and drug level analysis. Mammograms taken prior to registration (within 12 months prior to enrollment) and at approximately 1 and 2 years post-registration to this study are retrieved and digitized for determination of percent breast density and dense area.
89017290|NCT00280553|No Intervention|patient controlled analgesia (PCA) only|
89017291|NCT00280553|Other|PCA and pump with saline infusion for up to five days|
89459852|NCT03671135|Experimental|TCA Intrastromal Inlay|A monocular intrastromal corneal inlay will be implanted.
89017292|NCT00280553|Other|PCA and bupivicaine infusion for up to five days|
89017293|NCT00310557|Experimental|Arm 1|
89017294|NCT00280592|Placebo Comparator|Placebo|
89501846|NCT02688933|Active Comparator|Lantus|Lantus (Insulin glargine, 100 U/mL) once daily for 16 weeks on top of mealtime insulins analogs. Basal insulin doses were individually titrated (until the end of Week 14) to reach fasting SMPG levels of 80 to 100 mg/dL, while mitigating hypoglycemia.
89017295|NCT00280592|Experimental|Cranberry|Cranberry
89017296|NCT00316875|Experimental|Lapatinib Ditosylate and Doxil|
89459853|NCT03671057|Experimental|HospiAvontuur|Intervention group - Non-pharmacological (HospiAvontuur) preparation HospiAvontuur is a simple point and click adventure game on a I-pad. The game describes the pathway which a child and his parents will take before, during and just after a hospital admission for an elective otorhinolaryngeal procedure under general anaesthesia.
89459854|NCT03671057|Active Comparator|Midazolam|control group: The children of the control group will not play the game HospiAvontuur as an at home preparation for surgery. These children will be prepared for surgery according to the current practice at the Jessa hospital. Children receive only the basic information during the consultation with the surgeon. There is no specific at home preparation required. When admitted at the hospital, children receive a pharmacological preparation, 45 - 60 minutes prior to the induction of the anaesthesia. The medication is administered orally by a small syringe in the mouth and contains Dormicum 0.3mg/kg body weight and atropine 0.02mg/kg body weight supplemented with raspberry syrup.
89459855|NCT03669575|Experimental|omega 7 - placebo|Receiving the active first then switch to the placebo after three weeks
89459856|NCT03669575|Active Comparator|placebo - omega 7|Receiving the placebo first then switch to the active after three weeks
89459857|NCT05166850|Experimental|Preventive-Intervention-for-Cholera-for-7-Days (PICHA7) Mobile Health (mHealth) Program|Preventive-Intervention-for-Cholera-for-7-Days (PICHA7) mHealth program promoting handwashing with soap and water treatment for diarrhea patient households
89459858|NCT05166850|Active Comparator|Standard Arm|Standard recommendation in the Democratic Republic of the Congo for diarrhea patients upon discharge from health facilities
89459859|NCT03675659|Active Comparator|intra-articular injection|intra-articular injection with magnesium sulfate at weekly interval for four weeks
89459860|NCT03675659|Placebo Comparator|control|intra-articular injection with saline
89459861|NCT05234398||Naïve patients|"This study involve non-responder solid organ transplanted patients after an adapted vaccinal scheme (i.e. 3 doses or more of mRNA vaccines).~Patients included in Group 1 are naïve patients; there have never received anti-SARS Cov2 monoclonal antibodies.~They will have additional blood and saliva samplings during their study visits, which are included in their usual medical follow-up."
89459862|NCT05234398||Switched patients|"This study involve non-responder solid organ transplanted patients after an adapted vaccinal scheme (i.e. 3 doses or more of mRNA vaccines).~Patients included in Group 2 have previously received anti-SARS Cov2 monoclonal antibodies.~They will have additional blood and saliva samplings during their study visits, which are included in their usual medical follow-up."
89201675|NCT03366220|Experimental|initial resuscitation with plasma|Initial resuscitation with plasma will be 10 mL/kg (700 mL in a typical 70 kg adult). Traditional doses of plasma, when used to correct coagulopathy range from 10-15 mL/kg.23 The plasma will be administered at a rate of 2-3 mL/kg/hr (140-210 mL/hr in a typical 70 kg adult). A research physician will be at bedside to follow patient resuscitation. Plasma administration may be terminated before the entire dose is administered if patients show clinical improvement. After the initial dose of plasma has been given, subsequent resuscitation will follow usual care using balanced crystalloids.
89201676|NCT03366220|Active Comparator|initial resuscitation with balanced crystalloids|Usual care using balanced crystalloids (Iso-Lyte or Plasma-Lyte) only will follow Surviving Sepsis Campaign guidelines. Controls will receive 30 mL/kg (2100 mL in a typical 70 kg adult) of crystalloids within the first 3 hours. Subsequent resuscitation with balanced crystalloids will be titrated to the endpoints of resuscitation.
89201677|NCT00743990|Active Comparator|A|
89459863|NCT03670979|Experimental|bone swaging alone|xenograft alone
89459864|NCT03670979|Experimental|bone swaging plus EDTA|bone swaging with EDTA
89501847|NCT05497544|Experimental|Exercise recommendation group|
89201678|NCT00743990|Placebo Comparator|B|
89201679|NCT00743990|No Intervention|3|no intervention
89206160|NCT02548572|Experimental|Treatment group|Subjects in the treatment group will undergo bilateral transcorneal electrical stimulation using OkuStim device once a week for fifty-two weeks
89501848|NCT05497544|Experimental|Exercise recommendation plus guidebook group|
89501849|NCT05497544|No Intervention|Control|
89459865|NCT05234320|Experimental|stage I- Healty|The first 2 patients in this stage will receive the vehicle treatment and will not undergo the first 24 hour hospitalization. The 3rd and 4th patients will receive a lower dose of 12.5 mg of the DP once daily for 7 days, and the first 24 hours will be hospitalized for the first 24 hours. The 5th patient will receive the 25 mg from the DP once daily for 7 days and will be hospitalized for the first 24 hours. The next 2 patients will receive the 25 mg dose and will not undergo the first 24 hour hospitalization. The next 3 patients will receive the optimal dose of 50 mg and will not undergo the first 24 hour hospitalization
89459866|NCT05234320|Active Comparator|Stage II- Placebo + SOC|This arm will be include 20 This arm will be include 20 symptomatic non-hospitalized COVID-19 patients and will be conducted at patients' homes during their self-isolation, and they will be received Placebo + standard of care
89459867|NCT05234320|Active Comparator|Stage II- DP low dose (25 mg) + SOC|This arm will be include 20 symptomatic non-hospitalized COVID-19 patients and will be conducted at patients' homes during their self-isolation, and they will be received Drug product low does(25 mg) + standard of care
89459868|NCT05234320|Active Comparator|Stage II- DP planned dose (50 mg) + SOC|This arm will be include 20 This arm will be include 20 symptomatic non-hospitalized COVID-19 patients and will be conducted at patients' homes during their self-isolation, and they will be received Drug product planned does(50 mg) + standard of care
89459869|NCT03670901|Experimental|JHL1101|375 mg/m2 of JHL1101 is given intravenously on D1 of each cycle
89459870|NCT03670901|Active Comparator|MabThera|375 mg/m2 of Rituximab is given intravenously on D1 of each cycle
89459871|NCT03675425|Experimental|Group 1: non chest shielding|non chest shielding generic name: non dosage: non frequency and duration: in first 48 h eco with pad diameter will be measured in before and after phototherapy,
89459872|NCT03675425|Placebo Comparator|Group 2: chest shielding|chest shielding generic name: Phototrephy dosage: non frequency and duration: in first 48 h echo with pad diameter will be measured in before and after phototherapy,
89459873|NCT05166616|Experimental|Treatment (minnelide, osimertinib)|Patients receive minnelide PO QD on days 1-21 and osimertinib PO QD on days 1-28. Cycles repeat every 28 days for 6 months in the absence of disease progression or unacceptable toxicity.
89459874|NCT05213728|Experimental|Cohort 1|Single 1E11 dose administered via multiple sub-doses over a 4-hour period in adults (18-55 yrs).
89459875|NCT03023813|Experimental|Intervention|Individualized preventive care recommendations will be distributed to subjects.
89459876|NCT03023813|No Intervention|Control|Usual care
89459877|NCT03023813|Experimental|Development Phase|Non-randomized receipt of individualized preventive care recommendations
89459878|NCT05165836|Placebo Comparator|Erector Spinae Plane block without Dexmedetomidine group|Patients received Ultrasound-guided Erector Spinae Plane block at T2 using 19 ml of bupivacaine 0.25% + 1 mL saline
89459879|NCT05165836|Experimental|Erector Spinae Plane block with Dexmedetomidine group|Patients received Ultrasound-guided Erector Spinae Plane block at T2 using 19 ml of bupivacaine 0.25% + 1 mL dexmedetomidine 0.5 µg/kg
89459880|NCT05165758||Diabetic subjects without foot ulcer|27 diabetic subjects without foot ulcer will answer to the SF-36 score (mental health items) and to a french precarit index (EPICES:Evaluation de la précarité et des inégalités de santé dans les Centres d'examens de santé)
89459881|NCT05165758||Diabetic subjects with foot ulcer|54 diabetic subjects presenting foot ulcer will answer to the SF-36 score (mental health items) and to a french precarit index (EPICES:Evaluation de la précarité et des inégalités de santé dans les Centres d'examens de santé)
89459882|NCT05232448|No Intervention|Control Group|Data collection forms will be applied to the students in the control group first. They will then continue their normal education.
89459883|NCT05232448|Experimental|Intervention Group|Data collection forms will be applied to the students in the intervention group first. Afterwards, cognitive-behavioral therapy training will be implemented as four modules, lasting 1 month in total.
89459884|NCT01365130|Experimental|real drug|patients will receive Jevtana 25mg/m2, IV every 21 days until disease progression or unacceptable toxicity
89459885|NCT04238416|Experimental|IV BCAA + Lactulose|IV Branched Chain Amino Acids - 500mL once daily for 3 days plus Lactulose
89459886|NCT04238416|Active Comparator|Lactulose alone|Oral Lactulose alone
89459887|NCT04237558|Active Comparator|Vaginal hysterectomy|Removal of uterus through vagina in absence of prolapse
89459888|NCT04237558|Active Comparator|Laparoscopic hysterectomy|Key hole surgery through small incisions of the abdomen
88941970|NCT01865266|Experimental|HUTIG|"The high dose of ulinastatin for injection group(HUTIG):~Ulinastatin(Techpool inc,Guangdong,China) was administered to the group as a bolus of 200,000 U diluted in 100 mL of normal saline every 8 hour.A course of treatment consisted of 7 days after the patients were diagnosed as VAP."
88941971|NCT01865266|Placebo Comparator|CG|"The compare group(CG):~The group was given 100 mL of normal saline every 8 hour.A course of treatment consisted of 7 days after the patients were diagnosed as VAP."
88941972|NCT01865279|Experimental|Trial part 1|
88941973|NCT01865279|Active Comparator|Trial part 2|
88941974|NCT01865292|Experimental|Insulin degludec|
88941975|NCT01865292|Active Comparator|Insulin glargine|
88941976|NCT01865305|Experimental|Trial part 1|
88941977|NCT01865305|Experimental|Trial part 2|
88941978|NCT01865318|Experimental|Part 1 (Once-daily dosing regimen, high concentration)|
88941979|NCT01865318|Experimental|Part 2 (Twice-daily dosing regimen, high concentration)|
88941980|NCT01865318|Experimental|Part 3 (Once-daily dosing regimen, low concentration)|
88941981|NCT01865331|Experimental|Low dose, insulin degludec|
89459889|NCT05226754|Active Comparator|GROUP A|diacerein 50 mg (capsules) every 12 hours for 10 days
89459890|NCT05226754|Placebo Comparator|GROUP B|placebo capsules (lactose and magnesium stearate)
89459891|NCT01657162|Experimental|Alendronate|Participants received 70 milligrams (mg) of alendronate orally once per week beginning on Day 2 for up to 24 months after participating in Study BA058-05-003 during which participants received abaloparatide 80 micrograms (mcg) SC or abaloparatide-matching placebo daily for 18 months.
89459892|NCT04241692|Experimental|Application of Carnation Ambulatory Patch Monitoring System|The patient will wear a Standard Holter Monitor and the CAM Patch system simultaneously for 24 hours.
89459893|NCT04241692|Experimental|Application Conventional 24-Hour Holter Monitor Recorder|The patient will wear a Standard Holter Monitor and the CAM Patch system simultaneously for 24 hours.
88941982|NCT01865331|Experimental|Medium dose, insulin degludec|
88941983|NCT01865331|Experimental|High dose, insulin degludec|
88941984|NCT01865331|Experimental|IDegAsp 50|
88941985|NCT01865344||Heart surgery|Pain monitoring at different time periods
88941986|NCT01865357|Experimental|Patient|Clinically isolated neurological syndrome (CIS) compatible with a demyelinating inflammatory episode within the central nervous system, potentially beginning multiple sclerosis (MS) whatever the mode of presentation
88941987|NCT01865357|Experimental|Control|healthy subject
88941988|NCT01865370|Experimental|Kochujang Pills|
88941989|NCT01865370|Placebo Comparator|Placebo|
88941990|NCT01865383|Experimental|Microfinance and Health Leadership|Microfinance and Health Leadership: Participants will be eligible to receive small loans and business training as part of the microfinance component. Nominated leaders in camps will receive health leadership training on prevention of HIV risk behaviors and gender based violence perpetration, and then pass on knowledge to camp members.
88941991|NCT01865383|No Intervention|Control|Control: Participants will receive delayed HIV prevention training at the conclusion of the intervention involving participants in the other condition.
88941992|NCT01865409|Active Comparator|Kangoroo care|"While performing Kangaroo care the infant should be held skin-to-skin contact with her mother for 30-60 minutes. The baby, who is naked except for a diaper and a piece of cloth covering his or her back (either a receiving blanket or the parent's clothing), is placed in an upright position against a parent's bare chest. The values of heart rate variability will be measured during and also without Kangaroo Care in the same infants but different times."
88941993|NCT01865422|Experimental|chronic cough|
88941994|NCT01865435|Experimental|new borns|
88941995|NCT01865474|Experimental|Treatment I|DLBS1033 bioactive fraction tablet 490 mg thrice daily
89459894|NCT05209828||pfmmedical port implantation|Port implantation for continous vascular access.
89459895|NCT05207956|Experimental|Enhanced Electronic Platform|A basic electronic platform for data collection that contains additional features designed to increase motivation to collect data and ease of data collection.
89459896|NCT05207956|Active Comparator|Electronic Platform Not Enhanced|A basic electronic platform for data collection.
89459897|NCT05157646|Experimental|Exercise trackers|Fitbit physical activity trackers
89459898|NCT05206552||Parturients above the age of 18|Study participants will include women after labour whom gave birth to a healthy neonate at 37 weeks with the ability to comply with study requirments
89459899|NCT04889560|Experimental|Experimental group|Experimental group receives Home CoRe (Home CoRe Group)
89459900|NCT04889560|Other|Control group|Control group receives CoRe software (CoRe Group)
89459901|NCT02933606|Experimental|BNC210 600 mg b.i.d.|Suspension administered orally for 12 weeks.
89459902|NCT02933606|Experimental|BNC210 300 mg b.i.d.|Suspension administered orally for 12 weeks.
89459903|NCT02933606|Experimental|BNC210 150 mg b.i.d.|Suspension administered orally for 12 weeks.
89459904|NCT02933606|Placebo Comparator|Placebo b.i.d.|Suspension administered orally for 12 weeks.
89459905|NCT04883788||Pandemic group|Patients undergone hip and knee replacement during pandemic period (June-december 2020)
88941996|NCT01865474|Experimental|Treatment II|Placebo tablet of DLBS1033, thrice daily
88941997|NCT01865500|Active Comparator|Metil prednisolone & Budesonide 4mg|
88941998|NCT01865500|Active Comparator|Metil prednisolone & Budesonide 8 mg|
88941999|NCT01865500|Active Comparator|Budesonide 4 mg & Budesonide 8 mg|
88942000|NCT01865526|Active Comparator|Low protein diet|The patients of this group received a classical low protein diet (LPD),according to their desired body weight (DBW), obtained by multiplying the squared value of the height times a reference body mass index (BMI) value of 23. LPD were individually prepared and explained to the patients by a dedicated dietician and contained at least 30 kcal/kg/day (25 in overweight patients), with a dietary sodium intake restricted to 2.5 g/day.
88942001|NCT01865526|Experimental|Six point diet|These patients were assigned to receive the 6-points-diet, and were given by the Nephrologist the list of six items indicating how to modify their dietary habits; all the items were thoroughly explained and discussed with the patients
88942002|NCT01865565||Imatinib treat|"• Locally advanced unresectable GIST without metastasis at~EC junction requiring total gastrectomy,~Duodenum requiring Whipple operation;~Large GIST requiring multiviceral resection;~Rectum: requiring APR."
88942003|NCT01865578|Experimental|tDCS|Transcranial direct current stimulation
89459906|NCT04883788||Pre-pandemic group|Patients undergone hip and knee replacement during the pre-pandemic period (january-march 2020)
89459907|NCT05201482|Experimental|25 patients aged 8-16 years with moderate or severe visual impairment|25 patients aged 8-16 years with moderate or severe visual impairment will test the impact of a head-mounted augmented reality low vision aid (SightPlus) on vision and quality of life
88942004|NCT01865578|Sham Comparator|sham stimulation|sham stimulation
88942005|NCT01865591|Experimental|Renal denervation|Subjects are treated with unfocussed ultrasound-based renal denervation and are maintained on baseline anti-hypertensive medications.
88942006|NCT01865604|Experimental|Anodal tDCS|anaodal transcranial direct current stimulation
89459908|NCT01373294|Experimental|A: Combination Arm|"Bacille Calmette-Guerrin (BCG) and lenalidomide.~Participants were assigned to receive BCG or BCG and lenalidomide based on their cancer. This group received BCG + lenalidomide)"
89459909|NCT01373294|Active Comparator|B: Control Arm|"Bacille Calmette-Guerrin (BCG) only.~Participants were assigned to receive BCG or BCG and lenalidomide based on their cancer.~This group was not eligible to receive the combination of BCG + lenalidomide."
89459910|NCT05148598|Experimental|ADRC Arm|Subjects in the ADRC arm will receive standard care and active treatment (ADRCs)
89459911|NCT05148598|Placebo Comparator|Standard Care Arm|Subjects in the Standard Care arm will receive standard care and Placebo
89459912|NCT04367246||Affected Patients|Eligible subjects have a confirmed germline TP53 mutation or variant, OR have a family history of LFS and clinically managed as a LFS patient, OR meet LFS diagnostic criteria including Classic, Chompret, and LFL (Birch and Eeles) criteria. Medical information contribution is required for participation in the study. Subjects also have options to contribute a one-time DNA sample, a blood sample for plasma and a stool sample every six months, as well as access to their residual clinical tissues.
89459913|NCT04367246||Family Members|Biological relative of subjects with germline TP53 mutation or variant (LFS), including first degree (siblings, parents) and second degree (grandparents, aunts, uncles) relatives. Negative for germline TP53 mutation or variant. Medical information contribution is required for participation in the study. Subjects also have options to contribute a one-time DNA sample, a stool sample, as well as access to their residual clinical tissues.
89459914|NCT04367246||Household Members|Household member of subjects with germline TP53 mutation or variant (LFS), sharing a living space (apartment or free-standing home) for at least 6 months prior to study enrollment. Medical information contribution is required for participation in the study. Subjects also have options to contribute a one-time stool sample.
89459915|NCT05147428|Experimental|Patient-Provider|Both patients and providers will receive educational materials on inappropriate prescribing and deprescribing.
89459916|NCT05147428|Experimental|Provider Only|Only providers will receive educational materials on inappropriate prescribing and deprescribing.
89459917|NCT05147428|No Intervention|Usual Care|
89459918|NCT04422028|Experimental|Desogestrel Test Product|Participants received two tablets of the test formulation containing Desogestrel 0.075 mg. The tablets were taken with water and in a fasting condition.
89459919|NCT04422028|Active Comparator|Desogestrel Reference Product|Participants received two tablets of the marketed reference formulation containing Desogestrel 0.075 mg. The tablets were taken with water and in a fasting condition.
89459920|NCT04236856|Other|Robotic Endovascular Procedure|Subjects with a clinical indication for endovascular coil and/or stent assisted coiling embolization of cerebral aneurysms will be treated using the CorPath GRX System.
89459921|NCT01656304|Experimental|Treatment (monoclonal antibody, antiangiogenesis)|Patients receive bevacizumab IV over 30-90 minutes once every 14 days. Courses repeat every 14 days in the absence of disease progression and unacceptable toxicity.
89459922|NCT05143216||Chronic subdural haematoma post burr-hole drainage|Chronic subdural haematoma post burr-hole drainage
89459923|NCT05107648|Experimental|Gardner GOALS|Healthy lifestyle intervention by telehealth plus regular clinic visits
89459924|NCT05107648|No Intervention|Control|Regular clinic visits
89459925|NCT05107570|Other|Cold exposure applied to Western European individuals|Participants rested under thermoneutral conditions for 30 min, which was then followed by exposure to ~ 9°C air temperature for a maximum of 1 hour. Same duration as matched Siberian individuals.
89459926|NCT05107570|Other|Cold exposure applied to Siberian individuals|Participants rested under thermoneutral conditions for 30 min, which was then followed by exposure to ~ 9°C air temperature for a maximum of 1 hour. Same duration as matched European individuals.
88942007|NCT01865604|Active Comparator|Cathodal tDCS|cathodal transcranial direct current stimulation
88942008|NCT01865604|Sham Comparator|Sham tDCS|no stimulation
88942009|NCT01865630|Experimental|Etanercept|Patients with aneurysmal subarachnoid hemorrhage will be treated with etanercept, 25 mg subcutaneously starting within 36 hours of SAH, and then receive doses 3.5 days and 7 days later for a total of 3 doses.
88942010|NCT01865643|Other|Standard GlideScope intubation|This standard GlideScope (GS) technique involves a midline larygoscopy followed by insertion of a styleted endotracheal tube, once an adequate view of the vocal cords is achieved.
88942011|NCT01865643|Experimental|Alternative GlideScope intubation|"Alternative GlideScope (GS) intubation involves the insertion of the endotracheal tube under direct vision as a fish hook at the side of the mouth before the GS blade is introduced into the oropharynx."
88942012|NCT01865656|Other|4 intervention first referral units|"A Quasi-experimental intervention/control trial will be implemented to assess the impact of the following interventions on the outcome measures in a cluster of 4 intervention sites relative to a matched cluster of 4 control sites:~Refresher/simulation training to improve provider skills/knowledge Implementation of Emergency Obstetric Drills Revised Case sheets(for data collection and therefore part of both control and intervention sites), Mentoring and Supportive supervision, and Referral Strengthening"
88942013|NCT01865656|No Intervention|Control Arm|
88942014|NCT01865669|No Intervention|Control|A control sample from each patient (no oxytocin applied) will be measured concurrently with samples treated with varying concentrations of oxytocin.
88942015|NCT01865669|Experimental|Oxytocin|Samples from each patient will be bathed in a solution containing varying concentrations of oxytocin.
88942016|NCT01865695|Placebo Comparator|Placebo|Active treatment will be 2 capsules of Creon 25,000 units three times per day and the placebo will be 2 capsules three times per day; for 6 weeks treatment overall.
88942017|NCT01865695|Active Comparator|Creon|Active treatment will be 2 capsules of Creon 25,000 units three times per day and the placebo will be 2 capsules three times per day; for 6 weeks treatment overall.
89459927|NCT05197894|Experimental|VR experience|Participants will be given a list of VR applications to choose from. They will then be given instructions by a research assistant (approximately 10 minutes) on how to use the selected application they have chosen, as well as time for any questions they may have before starting their VR experience. They will then have an approximately 30-minute session of that VR experience. They may or may not be accompanied by a family member or significant other and will also have a research assistant available to aid them in any difficulties experienced during the VR experience.
89459928|NCT05103124|Experimental|Hydral|The participants will be asked to rinse their mouth five times a day with the experimental product. After one month, the administration will be stopped and the patients will be asked to fulfill the questionnaires mentioned in the methods section (XQ, QLQ-C30, QLQ HN35)
89459929|NCT05103124|Placebo Comparator|Placebo|The participants will be asked to rinse their mouth five times a day with the placebo comparator. After one month, the administration will be stopped and the patients will be asked to fulfill the questionnaires mentioned in the methods section (XQ, QLQ-C30, QLQ HN35)
89459930|NCT04421872|Experimental|General anesthesia Group|
89459931|NCT04421872|No Intervention|Healthy control group|
89459932|NCT05190016||Cases (Current/fresh)|Cases (current/fresh) are defined as those samples which has been tested positive by RT-PCR at IEDCR as a regular screening program and have not been stored in the freezer.
89459933|NCT05190016||Cases(stored)|Cases (stored) are defined as those samples which has been tested positive by RT-PCR at IEDCR as a regular screening program and have been stored in the -80°C freezer at IEDCR.
89459934|NCT05190016||Control (Current/fresh)|Control (Current/fresh) are defined as those samples which has been tested negative by RT-PCR at IEDCR as a regular screening program and have not been stored in the freezer.
89459935|NCT05190016||Control (stored)|Control (stored) are defined as those samples which has been tested negative by RT-PCR at IEDCR as a regular screening program and have been stored in the -80°C freezer at IEDCR
89459936|NCT05138770|Experimental|VC005 Tablets Dose escalation groups: 1、5、10、25、50、100mg|VC005 Tablets 1、5、10、25、50、100mg, qd
89459937|NCT05138770|Placebo Comparator|VC005 Tablets Placebo Dose escalation groups: 1、5、10、25、50、100mg|VC005 Tablets Placebo 1、5、10、25、50、100mg, qd
88942018|NCT01865721|Active Comparator|Continuous administration of Entonox|Patients randomized to this arm will be asked to inhale Entonox throughout the insertion phase of colonoscopy
89017297|NCT00280631|Experimental|1|Dose Escalation Study of TLK199 Tablets From 200 mg Per day To 6000 mg Per Day
89459938|NCT05138770|Experimental|VC005 Tablets food effects group|VC005 Tablets, qd
89459939|NCT03023423|Experimental|Treatment Arm A: Atezolizumab|Participants in Treatment Arm A will receive Atezolizumab 1,200 milligram (mg) intravenously (IV) on Day 1 of every 21-day cycle. Participants with confirmed disease progression based on RECIST 1.1 may cross over to Arm B and receive daratumumab and atezolizumab, provided crossover eligibility criteria are met.
89459940|NCT03023423|Experimental|Treatment Arm B: Atezolizumab and Daratumumab|Participants will receive daratumumab 16 milligram per kilogram [mg/kg] (Safety Run-in and Treatment Arm B) Intravenously (IV) weekly for 3 cycles (Day 1, 8 and 15), and Day 1 of every 21-day cycle thereafter. Atezolizumab will be administered at 1200 mg IV on Day 2 of Cycle 1 and on Day 1 of every 21-day cycle thereafter. Participants will continue to receive study treatment until confirmed disease progression, unacceptable toxicity, or any other treatment discontinuation criteria are met.
89459941|NCT05189782||Subjects of the GNC-038 clinical trial (1)|Patients enrolled in the GNC-038 Phase Ib/II clinical trial in Shanghai Ruijin Hospital.
89459942|NCT05189782||Non-malignant controls (2)|Patients who have tonsillectomy due to obstructive sleep apnea and hyponea syndrome.
89459943|NCT03670823||Healthy subjects|50 healthy subjects for a control group
89459944|NCT03670823||Patients with Major Depression|50 patients with major depression for a research group
89459945|NCT03675269|Experimental|Treatment|HBOT
89459946|NCT03675269|Active Comparator|Control|Standard wound care
89459947|NCT05136664|Experimental|Part A: Patiromer|Part A: 4-week, single-arm patiromer treatment phase (4 weeks)
89459948|NCT05136664|Placebo Comparator|Part B: Placebo|Part B: 8-week randomized, parallel group, placebo-controlled withdrawal phase
89459949|NCT05136664|Experimental|Part B: Patiromer|Part B: 8-week randomized, parallel group, placebo-controlled withdrawal phase
89459950|NCT03675191|Experimental|orlistat|Orlistat 120Mg Cap (120mg, three times a day, within 1hour after meal) combined with phentermine pill (37.5mg, once a day, within 1hour after meal)
89459951|NCT03675191|Placebo Comparator|placebo|placebo (120mg, three times a day, within 1hour after meal) combined with phentermine pill (37.5mg, once a day, within 1hour after meal)
89459952|NCT03675113|Experimental|upper extremity aerobic group|The upper extremity aerobic exercise training with an arm ergometer will be performed in the treatment group so that training intensity will be between 60% and 80% of the maximum heart rate, dyspnea perception will be 3-4 according to Modified Borg Scale and fatigue perception will be 5-6 according to Modified Borg Scale, training duration will be 3 day per a week through 6-weeks.
89459953|NCT03675113|Sham Comparator|control group|Deep breathing exercises combination with arm movements will be given as a home program in the control group. Training duration will be 3 day per a week through 6-weeks.
89459954|NCT05187988|Active Comparator|Supraclavicular approach group|probe placed firmly over the supraclavicular fossa, parallel to the clavicle to obtain a short-axis view of the divisions of the brachial plexus and the subclavian artery, lying on the first rib After skin infiltration with lidocaine 2% a 23-gauge 70mm block needle inserted in-plane with the ultrasound beam, in a lateral-to-medial direction, until the needle tip's positioned at the junction of the first rib and subclavian artery
89459955|NCT05187988|Active Comparator|Retroclavicular approach group|the probe will be placed below and perpendicular to the clavicle, in a paramedian sagittal plane, medial to the coracoid process, to obtain a short-axis view of the cords of the brachial plexus and the axillary vessels. The needle will be then inserted in the supraclavicular fossa, approximately 1 cm posteriorly to the clavicle, and advanced in plane and strictly parallel to the ultrasound transducer. After passing the initial blind zone of about 2 cm caused by the acoustic shadow of the clavicle, the needle tip is constantly seen, until it is positioned posterior to the axillary artery
89459956|NCT03198689|Experimental|Administration of Brentuximab vedotin|Maximum duration of treatment: 48 weeks Maximum dose allowed: 0.6 mg/kg Route of administration: intravenous use
89459957|NCT05135026|No Intervention|Control Group (CG)|Usual care
89459958|NCT05135026|Experimental|Intervention Group (IG)|In the intervention hospitals, we will perform USG additional 2 times during the 3rd visit of 24-26 weeks and 5th visit of 34 weeks (2 USG and even more USG if needed + additional 4 ANC + Health education; pictorial flip chart showing danger sign during pregnancy and potential risks for unnecessary caesarean delivery to increase awareness for safe delivery) for all the enolled pregnant mothers.
89459959|NCT03675035|Experimental|Endomina|Reduction trough sutures of the gastro-jejunal anastomosis
89459960|NCT05096416|No Intervention|Control arm|Patients in this arm will have standard of care where they will be annulated by the palpation method by the dialysis technician and nurse.
89459961|NCT05096416|Experimental|Intervention arm|Patients in this arm will have a three-dimensional (3D) printed vascular access model to assist the dialysis technician and nurse in cannulation.
89459962|NCT05187598|Experimental|Effective communication training in perinatal patient safety|Nursing department students will be given training on effective communication training in perinatal patient safety.
89459963|NCT05187598|No Intervention|Control group|There is no intervention for this group
89459964|NCT03670589||radiosurgery gammaknife group|Patient treated by radiosurgery gammaknife for a one side vestibular schwannoma
89459965|NCT03670589||microsurgery resection group|Patient treated by microsurgery resection for a one side vestibular schwannoma
89459966|NCT05134246||Carotid endarterectomy (CEA)|Patients who are treated with CEA.
89459967|NCT05134246||Carotid artery stenting (CAS)|Patients who are treated with CAS.
88942019|NCT01865721|Active Comparator|As required administration of Entonox|Patients randomised to this arm will be asked to use Entonox if and when they have pain
89459968|NCT03674879|No Intervention|Phone Call|Follow up contact is attempted via phone call.
89459969|NCT03674879|Experimental|Text Message|Follow up contact is attempted via text message.
89459970|NCT05185102|Experimental|Cognitive tasks|Electroencephalographic signals registration during different levels of difficulty of three tasks requiring very distinct cognitive functions: the updating of verbal memory, visuospatial span and mental motor inhibition.
89459971|NCT03185741|Experimental|UMS Strategy|"Patients of providers randomized to the UMS arm will receive study-related educational tools at their primary care visit to support the understanding, regimen consolidation, and use of prescriptions. These materials will be generated within the electronic health record.~Prescription instructions will be adapted to the UMS format to establish four standard time intervals (morning, noon, evening, bedtime) for prescribing and dispensing of medicine. UMS instructions also use simplified text and numeric characters instead of words to detail dose.~Single-page, plain language medication information sheets with important medication-related information following health literacy best practices."
89459972|NCT03185741|Experimental|UMS Strategy + SMS Text Messaging|In addition to the components from the UMS strategy arm, patients will receive daily text message reminders for 6 months.
89459973|NCT03185741|No Intervention|Usual Care|Patients of providers randomized to the usual care arm will receive their standard care
89459974|NCT05092204||Hospitalized patient in SSR geriatric service|
89459975|NCT04421716|Experimental|Ursolic Acid|Administration of Ursolic Acid twice a day for 2 weeks
89459976|NCT04421716|Experimental|Curcumin|Administration of Curcumin twice a day for 2 weeks
89459977|NCT04421716|Experimental|Ursolic Acid and Curcumin|Administration of Ursolic Acid and Curcumin. If subjects from Cohort 1 or 2 wish to continue in the study, they will undergo a washout period of at least 4 weeks before participating in Cohort 3
89459978|NCT03176225|Experimental|Test Arm|In Test Arm, the subjects will be implanted with test article - XenoSure patch. The interventions include: Open heart surgery to address the heart disease; Close the defects with XenoSure Patch
89459979|NCT03176225|Active Comparator|Control Arm|In Control Arm, the subjects will be implanted with comparator device - Polyester patch by Shanghai Chest Medical Technology Co. The interventions include: Open heart surgery to address the heart disease; Close the defects with Chest Polyester Patch
89459980|NCT05184868|Experimental|AT247|0.02 U/Kg/H Basal via continuous subcutaneous infusion with 2 bolus 0.15 U/Kg doses in a glucose clamp for one 3-day period
89459981|NCT05184868|Active Comparator|NovoLog®|0.02 U/Kg/H Basal via continuous subcutaneous infusion with 2 bolus 0.15 U/Kg doses in a glucose clamp for one 3-day period
89459982|NCT05184868|Active Comparator|Fiasp®|0.02 U/Kg/H Basal via continuous subcutaneous infusion with 2 bolus 0.15 U/Kg doses in a glucose clamp for one 3-day period
89459983|NCT03670511|Experimental|sit-to-stand|
89459984|NCT03670511|Active Comparator|six minute walking test|
89459985|NCT02672852|Experimental|Risankizumab|Participants randomized at Baseline to receive double-blind (DB) risankizumab 150 mg by subcutaneous injection at Weeks 0 and 4 (Part A1).
89459986|NCT02672852|Placebo Comparator|Placebo|Participants randomized at Baseline to receive double-blind (DB) placebo by subcutaneous injection at Weeks 0 and 4 (Part A1).
89459987|NCT03168659|Other|Treatment|Pulmonary vein isolation ablation with HeartLight Endoscopic Ablation System
89459988|NCT05129254|Experimental|Thulium laser (1927nm) and post-treatment topically administered platelet rich plasma (PRP)|All participating subjects will serve as their own baseline control and will receive treatment of their androgenetic alopecia with LaseMD, a 1927nm Fractionated Thulium laser and post-treatment topically applied autologous platelet rich plasma at monthly intervals for a total of 4 treatment. The total duration of laser application, venipuncture, PRP preparation, and topical administration will take approximately 30 minutes. Post-treatment surveillance: The subject will be observed in the clinic under direct supervision of the treating physician for any post-treatment side-effects for up to 15 minutes.
89459989|NCT05129254|Experimental|Platelet rich plasma injection|All participating subjects will serve as their own baseline control and will receive treatment of their androgenetic alopecia with autologous platelet rich plasma injection at monthly intervals for a total of 4 treatment. The total duration of venipuncture, PRP preparation, and injection will take approximately 15 minutes. Post-treatment surveillance: The subject will be observed in the clinic under direct supervision of the treating physician for any post-treatment side-effects for up to 15 minutes.
89459990|NCT05183620|Other|Nocturnal erection measurement|Overnight measurements of the temperature of the penile skin and outer thigh will be performed, while simultaneously the penile circumference and rigidity is determined by RigiScan measurements
88942020|NCT01865734|Experimental|Early Physical Therapy|Physical therapy after initial podiatry visit
88942021|NCT01865734|Active Comparator|Usual Podiatric Care|Usual care provided by podiatry
88942022|NCT01865760|Experimental|Gastric bypass surgery, hypoglycemia|Subjects with previous gastric bypass surgery (more then 1 year ago) and symptomatic hypoglycemia according to Whipples triade. These subjects will undergo an oral glucose tolerance test (OGGT), an isoglycemic intravenous glucose infusion (IIGI) and a 300 kcal liquid mixed meal. They will furthermore undergo two additional liquid mixed meal; one with concomitant treatment with synthetic Exendin 9-39 and another with treatment with Octreotide. All tests will be separated by at least one week.
88942023|NCT01865760|Active Comparator|Gastric bypass surgery, asymptomatic|Subjects with previous gastric bypass surgery (more then 1 year ago) without any signs of hypoglycemia. These subjects will undergo an oral glucose tolerance test (OGGT), an isoglycemic intravenous glucose infusion (IIGI) and a 300 kcal liquid mixed meal.
88942024|NCT01865760|Other|Controls|Healthy non-operated control subjects, matched on BMI, age and sex. These subjects will undergo an oral glucose tolerance test (OGGT), an isoglycemic intravenous glucose infusion (IIGI) and a 300 kcal liquid mixed meal.
88942025|NCT01865773|Experimental|HFR|We selected 8 inflamed chronic HD patients, which underwent a single 240 minutes HFR session
88942026|NCT01865786||FTC/TDF for PrEP|The study has one target prospective cohort defined as HIV-1 negative women who had been prescribed FTC/TDF for pre-exposure prophylaxis (PrEP); with two strata: a) those who continue to take FTC/TDF for PrEP during their pregnancy, and b) those who decide to stop FTC/TDF for PrEP during pregnancy.
88942027|NCT01865786||ARV population|The study has one comparison cohort defined as HIV-positive women who were on any antiretroviral (ARV) medication at the time the pregnancy was detected. This is a propensity score matched retrospective cohort selected from the prospective arm of the APR. This cohort is assembled retrospectively in order to appropriately match the subjects by calendar time and the correlates of exposure, with exposure being defined as being on FTC/TDF for PrEP vs being exposed to other ARVs.
88942028|NCT01865799||FTC/TDF for PrEP|This prospective case series is composed of every subject in a database containing de-identified patient-level data from all healthcare channels in the US, of individuals that are exposed to FTC/TDF or its components for any indication.
88942029|NCT01865825||Esophageal barium xray|"We will recruit 20 patients with GERD without dysphagia for an esophageal barium xray for esophageal diameter measurements.~The 20 Gastroesophageal Reflux Disease (GERD) patients will complete the Mayo Dysphagia Questionnaire 30-day and the Eosinophilic Esophagitis Actitivy Index (EEsAI) questionnaires"
88942030|NCT01865838|Active Comparator|Seprafilm (Sanofi, USA)|Patients in this arm received Seprafilm during surgery.
88942031|NCT01865838|No Intervention|Control|Patients in this arm does NOT receive Seprafilm during surgery.
88942032|NCT01865851|Active Comparator|Start with Classic Face Mask Group|The volunteers will be asked to breathe normally (Tidal Volume Breathing) through face mask for 5 minutes. After 5 minutes, the volunteers will be asked to breathe room air for 5 minutes and then breathe through a NuMask for 5 minutes. This will be followed by room air breathing for 5 minutes. At the end of the 5 minutes of room air breathing, the same volunteers will be asked to breathe through the face mask for 5 minutes.
88942033|NCT01865851|Active Comparator|Start with NuMask Group|The volunteers will be asked to breathe through the NuMask for 5 minutes, followed by room air breathing for 5 minutes, then 5 minutes of breathing through the face mask. This will be followed by room air breathing for 5 minutes and then 5 minutes of NuMask breathing.
88942034|NCT01865864||1|Compliant with CPAP
88942035|NCT01865864||2|noncompliant with CPAP
88942036|NCT01865877||PD Cohort|Subjects diagnosed with Parkinson's disease
88942037|NCT01865890||patient on hemodialysis taking plavix|patient on hemodialysis taking plavix
88942038|NCT01865903||Cohort 1|All with diagnose of NSCLC in Oslo during 6 months
89459991|NCT03674489|Active Comparator|Neurodynamic Slider Mobilization|
89459992|NCT03674489|Active Comparator|Neurodynamic Tensioner Mobilization|
89459993|NCT03674489|Sham Comparator|Sham Neurodynamic Mobilization|
89459994|NCT03114098|Experimental|CYP2D6 gene abnormalities|"A salivary sample (2 ml sample) which will allow the investigation of an anomaly of the metabolism of psychotropic drug.~Blood sampling will be performed to assess treatment tolerance (6 ml). A sample (4 ml) will be kept for possible future analyzes in relation to the objectives of this study for the recruiting center of Nice.~Electrocardiogram~Clinical exam~Clinical Global Impression Scale (CGI-S)~Children's Global Assessment Scale (CGAS)~Sheehan Disability Scale (SDS)~Wechsler Preschool and Primary Scale of Intelligence III (WPPSI-III )~Wechsler Intelligence Scale for Children - 4 (WISC-4)~Wechsler Adult Intelligence Scale 4 (WAIS 4)~Diagnostic and Statistical Manual of Mental Disorders (DSM)~Autism Diagnostic Interview (ADI)"
88942039|NCT01865903||Cohort 2|All NSCLC in Ulleval university hospital whom are in need of palliative chemotherapy
88942040|NCT01865916|Active Comparator|2 Liters Bi-Peglyte|Subjects will be asked to take split dose of 2 Liters PEG + 15mg bisacodyl for bowel preparation the day before colonoscopy.
88942041|NCT01865916|Experimental|2 Liters Moviprep|Subject will be asked to take split dose of 2 Liters PEG + ascorbic acid for bowel preparation the day before colonoscopy
88942042|NCT01865942|Active Comparator|open surgery|One arm receives open surgery. In our department open surgery is considered as the standard procedure since all spine surgeons are preforming this operation.
88942043|NCT01865942|Active Comparator|Minimal access surgery|We compare to well-known types of surgery for metastatic spinal cord compression. The other arm receive open surgery. In our department minimal access surgery is considered as a standard procedure but it is not preformed by all spine surgeons.
88942044|NCT01865955|No Intervention|Palpation|Palpation will be used to determine placement of the spinal needle.
88942045|NCT01865955|Experimental|Ultrasound|Ultrasound will be used prior to placement of the spinal needle.
88942046|NCT01865968|Experimental|Inactivated HAV vaccine|Healthy undergraduate students aged 16 to 25 years with anti-HAV negative received inactivated HAV vaccine containing 500u/vial with one-dose regimen.
89459995|NCT05089786|Experimental|Exablate Neuro System Treatment|MR-Guided Focused Ultrasound with Echo-Focusing will be used to ablate a target area selected by the physician.
89459996|NCT02671760|Experimental|Treatment|SM-1
89459997|NCT02671760|Active Comparator|Comparator|2-drug combination
88942047|NCT01865968|Active Comparator|Live attenuated HAV vaccine|Healthy undergraduate students aged 16 to 25 years with anti-HAV negative received live attenuated HAV vaccine containing 6.50 lgCCID50/vial with one-dose regimen.
88942048|NCT01865968|Experimental|Two-dose inactivated HAV vaccine|Healthy undergraduate students aged 16 to 25 years with anti-HAV negative received inactivated HAV vaccine containing 500u/vial with two-dose regimen.
88942049|NCT01865981||Hereditary VF|Patients with hereditary ventricular fibrillation, negative for known mutations
88942050|NCT01865981||Brugada|Patients suffering from Brugada syndrome
88942051|NCT01865994||Pediatric cardiac surgery|Children scheduled for elective cardiac surgery
88942052|NCT01866007|Experimental|Group 1|40 participants will receive a single subcutaneous (SC) injection of 100 mg guselkumab prepared from lyophilized formulation.
88942053|NCT01866007|Experimental|Group 2|40 participants will receive a single SC injection of 100 mg guselkumab, liquid formulation with UltraSafe Passive Delivery System (PFS-U).
88942054|NCT01866007|Experimental|Group 3|40 participants will receive a single SC injection of 100 mg guselkumab, liquid formulation with a prefilled syringe facilitated injection device (PFS FID).
88942055|NCT01866007|Experimental|Group 4|20 participants will receive a single intravenous (IV) infusion of 100 mg guselkumab prepared from liquid formulation.
88942056|NCT01866033|Experimental|PCI-32765|During Period 1, all patients will receive PCI-32765 560 mg administered by mouth (Treatment A). In Periods 2 and 3, patients will receive PCI-32765 560 mg administered by mouth without grapefruit juice (Treatment B) and PCI-32765 140 mg administered by mouth with grapefruit juice (Treatment C) according to a randomization schedule. An intravenous dose of 13C6 PCI-32765 will be administered 2 hours after each oral dose for reference purposes.
88942057|NCT01866046|Experimental|RESPECT-IPV|Rapid HIV testing and risk prevention intervention for victims of intimate partner violence
88942058|NCT01866059|Experimental|Calcium silicate cement|Biodentine
88942059|NCT01866059|Active Comparator|Glass Ionomer Cement|Fuji IX
88942060|NCT01866059|Active Comparator|Resin Modified Glass Ionomer Cement|Fuji II LC
88942061|NCT01866072||AVH|AVH: Patients with Acute Viral Hepatitis
88942062|NCT01866072||ACLF|ACLF: Patients with Acute on Chronic Liver Failure
88942063|NCT01866085|Active Comparator|AdVance|sling procedure
88942064|NCT01866085|Active Comparator|ARGUS|sling procedure
88942065|NCT01866124|Experimental|Cash transfer|"Mothers are the primary recipient of the CT. The proposed approach will be based on monthly seasonal CTs during 5 months, from May to September, for two years (2013 and 2014). A monthly 10 000 FCFA will be transferred to the selected households.~These CTs will be done via mobile phones, in collaboration with the mobile phone company Airtel."
88942066|NCT01866124|No Intervention|Comparison group|
88942067|NCT01866137||no treatment|no treatment
88942068|NCT01866176|Experimental|Knee osteoarthritis patients|Knee osteoarthritis patients with Kellgren & Lawrence grade I, II or III Stabilizing Knee Brace Valgus Knee Brace New Knee Brace
88942069|NCT01866189|Experimental|PET and MRI|Included patients will have F-MISO PET followed by brain MRI (MRI-1)(diffusion, FLAIR, perfusion, TOF) as soon as possible after stroke onset (less than 36 hours). A second brain MRI (MRI-2) will be performed on day 7.
88942070|NCT01866215|Experimental|Study1a|exercice performed 90 min before 13C fructose meal ingestion
88942071|NCT01866215|Experimental|study 1b|exercise performed 90 min after 13C fructose meal ingestion
88942072|NCT01866215|No Intervention|study 1c|no exercise
88942073|NCT01866215|Experimental|study 2a|meals containing fructose, cream and whey proteins over 24 hours after a glycogen/intramyocellular lipid depleting exercise
88942074|NCT01866215|Active Comparator|study 2b|meals containing glucose, cream and whey proteins over 24 hours after a glycogen/intramyocellular lipid depleting exercise
88942075|NCT01866228|No Intervention|No Consultation Recording|Participant does not receive consultation recording
88942076|NCT01866228|Experimental|Consultation Recording|Participant receives consultation recording
88942077|NCT01866241|Experimental|Arm A: sublingual misoprostol 600µg|Misoprostol is a uteretonic drug
88942078|NCT01866241|Placebo Comparator|Arm B: 10 IU Oxytocin|Oytocin is a standard of care treatment for PPH
89459998|NCT02671760|Placebo Comparator|Placebo|Placebo
89501850|NCT02688621|Active Comparator|Internet only|Participants will be required to attend a weekly Internet chat session with your group members and one of the behavioral weight control therapists. Participants will learn the principles of managing eating and exercise behaviors in weekly, hour-long chat sessions and by completing weekly lessons. Participants are asked to self-monitor foods and exercise through the use of a smartphone ap. Participants will wear a tracking device that monitors steps. All participants will be contacted via e-mail individually, by their group leader who will monitor their progress and offer advice and encouragement. Meetings are weekly for 24 weeks and monthly for 12 months.
88942079|NCT01866254|Experimental|Hydromorphone|100 mg, intrathecal administration
89501851|NCT02688621|Experimental|Internet + Incentives|Participants are given the same intervention as described for the internet only group, with the exception that they will have the opportunity to earn financial incentives. Financial incentives will be based on participants weight loss, and compliance with certain weight loss behaviors including meeting exercise goals, self-monitoring foods consumed, and daily weighing and reporting.
89501852|NCT00882505|Experimental|Vitamin D supplement|Receive vitamin D supplements.
88942080|NCT01866254|Active Comparator|Morphine|200 mg, intrathecal administration
88942081|NCT01866267|Other|Maraviroc|Patients infected with CCR5 tropic virus that have achieved an undetectable viral load on a non-Selzentry®-containing regimen [Protease Inhibitor (PI)/Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)/Integrase Inhibitor plus 2 Nucleoside Reverse Transcriptase Inhibitor (NRTI)] are switched to once-daily Selzentry® (600mg qd) plus the same 2 NRTIs previously administered.
88942082|NCT01866280|Experimental|Normal sleep Normal meals|Normal sleep/Normal meal times
88942083|NCT01866280|Experimental|Normal sleep Late meals|Normal sleep/Late meal times
88942084|NCT01866280|Experimental|Late sleep Late meals|Late sleep/Late meal times
88942085|NCT01866280|Experimental|Late sleep Normal meals|Late sleep/Normal meal times
88942086|NCT01866332|Active Comparator|Conventional Physical Therapy|Combination of manual therapy techniques, general exercises and specific exercises for spinal segmental stabilization. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week). The treatment will be tailored to the patient presentation (i.e. pragmatic treatment).
88942087|NCT01866332|Experimental|Conventional Physical Therapy plus Kinesiotaping|"Patients will receive conventional physical therapy plus an application of Kinesiotaping in their lumbar spine.~Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week)."
88942088|NCT01866345|Active Comparator|Conventional orthodontic treatment|conventional orthodontic treatment in the mandibular anterior region
88942089|NCT01866345|Experimental|Surgically facilitated Orthodontics|Surgically facilitated Orthodontic treatment in the mandibular anterior region
88942090|NCT01866358|Placebo Comparator|Umbilical vein infusion|using umbilical vein infusion for resucitation
88942091|NCT01866358|Experimental|Intraosseous infusion|using intraosseous infusion for resucitation
88942092|NCT01866384|Other|Normal Temperature|72 hours of Normal Temperature (36-37 degrees Celcius). Subjects in all arms will otherwise receive identical therapeutic interventions pre-defined by our local IPH management protocol.
88942093|NCT01866384|Experimental|Mild Induced Hypothermia|72 hours of mild induced hypothermia (32-34 degrees Celcius). Subjects in all arms will otherwise receive identical therapeutic interventions pre-defined by our local IPH management protocol.
88942094|NCT01866397|Experimental|Cidofovir pharmacokinetics|Patient received cidofovir due to clinical necessity (therapy resistant HCMV retinitis) while being on continuous hemofiltration. Pre- and postfilter plasma samples were taken at multiple timepoints during 24 hours.
88942095|NCT01866436|Experimental|Multimedia group|The multimedia group is the interventional arm of the study
88942096|NCT01866436|Experimental|Study Day Group|The study day group are the control arm of the study
88942097|NCT01866449|Experimental|Cabazitaxel|Cabazitaxel will be given at a dose of 25mg/m² as 1h infusion every 3 weeks
88942098|NCT01866462|Experimental|Metformin, NM504|metformin 500mg b.i.d. with NM504 b.i.d. for 1 week followed by metformin 500mg t.i.d. with NM504 b.i.d. for 1 week.
88942099|NCT01866462|Placebo Comparator|Metformin, Placebo|metformin 500mg b.i.d. with Placebo b.i.d. for 1 week followed by metformin 500mg t.i.d. with Placebo b.i.d. for 1 week.
88942100|NCT01866475|Active Comparator|Renal Disease|Those with mild to moderate renal disease and had an EZ-IO for 48 hours
88942101|NCT01866475|Active Comparator|Diabetes|Those with controlled diabetes and had an EZ-IO for 48 hours
88942102|NCT01866475|Active Comparator|Renal disease and diabetes|Those with both mild to moderate renal disease and controlled diabetes and had an EZ-IO for 48 hours
88942103|NCT01866475|Active Comparator|Healthy adults|Those who are healthy, defined as lacking co-morbidities that are a study exclusion, and had an EZ-IO for 48 hours
88942104|NCT01866488|Experimental|Cook Catheter, Oral Misoprostol|Cook Catheter is placed and a 50mcg misoprostol tablet is given orally. A repeat dose is administered in 3 hours.
88942105|NCT01866488|Placebo Comparator|Cook Catheter, Oral Placebo|Cook Catheter is placed and a placebo tablet is given orally. A repeat dose is administered in 3 hours.
88942106|NCT01866501|Experimental|Blended Technique|Using the blended technique device operators will establish proximal humerus intraosseous vascular access.
88942107|NCT01866514|Experimental|Anesthesia Arm|proximal humerus intraosseous vascular access will be established bilaterally in the proximal humerus using the anesthesia approach in which the arm is abducted from the body.
88942108|NCT01866527||all newborns born 1991-2006|all newborns born 1991-2006
88942109|NCT01866553|Experimental|Nilotinib, Pegylated interferon α2b|"Patients will be treated with nilotinib 300 mg BID during the first 3 months. Then the combination phase ensues with continued daily nilotinib 300 mg BID combined with PegIFN 25 ug/week for 3 months up to the Month 6 time point. If the patient has no more than grade 1 non-hematological toxicity or grade 2 hematological toxicity, the dose will be increased to 40 μg/w until Month 12. The follow-up phase with daily nilotinib 300 mg BID covers the next 12 months period (Month 12 to 24). until Month 12, which is followed by monotherapy phase of nilotinib 300 mg BID. Overall study duration for the individual patient is 24 months."
88942110|NCT01866566|Placebo Comparator|HBV-3|one dose HBV
89501853|NCT00882505|Placebo Comparator|Placebo|Receive placebo pills
88942111|NCT01866566|Placebo Comparator|HBV-6|one dose HBV
88942112|NCT01866566|Experimental|varicella-3|2 doses varicella vaccine either BCHT or Kengen and 3 month of the interval time
88942113|NCT01866566|Experimental|varicella-6|2 doses varicella vaccine either BCHT or Kengen and 6 month of the interval time
88942114|NCT01866579||ethambutol optic neuropathy|
88942115|NCT01866605|Placebo Comparator|1|Single un-warmed cotton blanket over body and limbs, and reassurance, during preoperative period in anaesthetic room
88942116|NCT01866605|Active Comparator|2|Single un-warmed cotton blanket over body and limbs, reassurance and intravenous midazolam 30 µg/kg i.v, during preoperative period in anaesthetic room
89459999|NCT03114176|Experimental|Divers group|Throughout each dive, subjects performed a 20-minute long mild exercise on an underwater bike. The depth of dive was set at 15 meters, where the subjects performed an activity guided by Borg CR-10 scale at intensity level 3 (25 rpm). The ascent rate was set at 10 m/min, with a decompression stop at 5 meters for 3 min, according to the US Navy Manual Diving Table. 48 h prior to the immersions, none of the participants consumed medications or dived or flew. In the first part of the experiment, all subjects performed a dive breathing Enriched Air Nitrox (EAN, 32% ppO2). Baseline clinical measurements were collected before and after this first dive in order to have a reference [CTRL] and to measure physiological modifications due to immersion [NTRX]. After twenty days of no diving activity, subjects were engaged in a KD for seven days. At the end of this period, subjects performed a single immersion breathing EAN. The measures were performed after this single dive [KETO-NTRX]
89460000|NCT03670433||Patients admitted in the Polyvalent Internal Medical Unit|"Patients over 65 years old admitted in the Polyvalent Internal Medical Unit (UMIP) of Rennes University Hospital between 09/04/2017 and 10/31/2017 or going back home or to a rehabilitation service during the same period.~Cost analysis of medication reconciliation."
89460001|NCT02667236|Active Comparator|A-101 Solution|A-101 Solution 40% administered once
89460002|NCT02667236|Placebo Comparator|Vehicle Solution|Vehicle Solution administered once
89460003|NCT01126749|Experimental|E7389 in combination with gemcitabine plus cisplatin|
88942117|NCT01866605|Active Comparator|3|Single un-warmed cotton blanket, reassurance and forced-air warming with a Bair Hugger, during preoperative period in anaesthetic room
88942118|NCT01866618||Natural IVF Cycle|All patients will undergo a natural IVF cycle using trigger shots of Leuprolide Acetate(Lupron) and human chorionic gonadotropin (hCG) to ensure the patient surges.
88942119|NCT01866631||No treatment|
88942120|NCT01866644|Experimental|N-acetylcysteine|At portal level, a cannula is inserted with the usual technique of infusion of 3000 ml of preservation fluid to free fall as containing or not scrambling inserted by the NAC scrub nurse then (400 mg of N-acetylcysteine at 10%, 4 ml ).
88942121|NCT01866644|Placebo Comparator|Saline|With usual technique
88942122|NCT01866670|Experimental|spiritual support|"-Spiritual Support: deep breathing + guided image + meditation~Each patient will participate individually in three sequential meetings (A1, A2 and A3).~In the experimental group, it will be developed the support spiritual intervention in all three meetings.~In all meetings, namely A1, A2 and A3 the physiological parameters will be recorded (PA, SpO2, HR) through the monitor BM5."
88942123|NCT01866670|Active Comparator|relaxation therapy|"Relaxation Therapy Each patient will participate individually in three sequential meetings (A1, A2 and A3).~In the control group, it will be performed just relaxing in all three meetings. In all meetings, namely A1, A2 and A3 the physiological parameters will be recorded (PA, SpO2, HR) through the monitor BM5."
88942124|NCT01866683|Experimental|Group 1|1 month respiratory training
88942125|NCT01866683|Experimental|Group 2|1 month waiting period
88942126|NCT01866696|Experimental|guided implant insertion and immediate loading|This work was designed as a prospective case series clinical study. Twenty patients have been consecutively rehabilitated with an immediately loaded oral implant supported fixed full prosthesis. A total of 120 oral implants (Nobel Replace Tapered Groovy; Nobel Biocare AB, Goteborg, Sweden) supporting 23 bridges (8 mandible, 15 maxilla) were placed , 22 of which in fresh post extraction sockets. 117 out of 120 oral implants were immediately loaded.
88942127|NCT01866722|Active Comparator|Usual Care|Participants will get a brief (<5 min) telephone counseling session about quitting. After that, printed materials with resources to help quitting will be mailed to the participants.
88942128|NCT01866722|Active Comparator|Reduction|Participants will have 3 telephone counseling sessions that focus on ways to reduce tobacco cigarette smoking. After the final session printed materials with resources to help quitting will be mailed to the participants.
88942129|NCT01866722|Active Comparator|5Rs|Participants will have 3 telephone counseling sessions that focus on the 5Rs for quitting tobacco cigarette smoking (Relevance, Risks, Rewards, Roadblocks, Repeat). After the final session printed materials with resources to help quitting will be mailed to the participants.
88942130|NCT01866735|No Intervention|Usual Care|
88942131|NCT01866735|Experimental|Standardized Rehabilitation Therapy|"Standardized Rehabilitation Therapy (SRT):~Participants randomized to the Standardized Rehabilitation Therapy arm will receive three types of interventions - Passive Range of Motion (PROM), Physical Therapy (PT) and Progressive Resistance Exercise (PRE). The SRT protocol will be administered by the BICU Mobility Team within 80 hours of ventilation and contains four levels of activity therapy. This Protocol will be delivered 7 days a week. Patients will be assessed daily and if appropriate will receive 3 separate sessions of activity each day."
88942132|NCT01866748|Experimental|Part A (single dose)|
88942133|NCT01866748|Experimental|Part B (multiple dose)|
88942134|NCT01866761||Periodontitis, Lifestyle-related disease|
88942135|NCT01866774|Experimental|Fecal calprotectin level|Fecal calprotectin level
88942136|NCT01866774|No Intervention|Symptom questionnaire|
88942137|NCT01866787||Study cohort|
88942138|NCT01866800|Active Comparator|Renal Guard|Renal Guard in addition to Saline and N-Acetylcysteine
88942139|NCT01866800|Placebo Comparator|Conventional Treatment|Saline and N-Acetylcysteine
88942140|NCT01866813|No Intervention|Waiting list control group|Waiting list control group who is offered cognitive training at the end of the data collection period.
88942141|NCT01866813|Experimental|Cognitive training intervention group|"Cognitive training intervention group: 6 weeks of intervention with the online cognitive training scientific brain training pro for 40-60 minutes a day/ 5 days a week. Reminders and motivational phone-calls throughout the intervention period. Phone and Internet-based technical support is available."
89017298|NCT00316953|Experimental|Stratum 1 (solid tumors)|Patients receive oral dasatinib twice daily on days 1-28. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
89017299|NCT00316953|Experimental|Stratum 2 (leukemia)|Patients receive dasatinib as in stratum 1. Cohorts of 3-12 patients receive escalating or de-escalating doses of dasatinib. The MTD is defined as the dose preceding that at which 7 of 12 patients experience DLT.
89017300|NCT00280670|Experimental|Cognitive Behavioral Therapy|
89017301|NCT00280670|No Intervention|Waitlist|
89460004|NCT01126749|Experimental|gemcitabine plus cisplatin|
89460005|NCT02521948|Experimental|MANTA Vascular Closure Device|The MANTA device, developed by Essential Medical, Inc., is a vascular closure device (VCD) intended for use in catheterization laboratories following percutaneous cardiac or peripheral procedures that use the retrograde common femoral artery access route for large bore (10-18F) interventional devices.
89460006|NCT03674333|Experimental|Group A|Folic acid 1mg daily will be given to the participants of Group A.
89460007|NCT03674333|Placebo Comparator|Group B|A Placebo (a sugar pill) will be given to the participants of the Group B.
89460008|NCT04216238||Cardiovascular surgical patients|Patients who received cardiovascular surgery and was released from the hospital due to meeting and exceeding a certain walking distance.
89460009|NCT03674255||1|Participants in group 1 will be recruited at their stress echocardiogram appointment. Anonymised versions of the stress echocardiograms will be obtained, in addition to venous blood samples obtained from the cannula inserted as part of the standard clinical procedure. These blood samples will be collected before and after the stress echocardiogram. These participants will be followed up by telephone call after one year to determine whether they had any additional cardiac tests or events outside of their hospital trust. Medical records relating to the participant will be reviewed annually for up to 10 years to identify if the patient has been admitted and obtain health outcome data.
89460010|NCT03674255||2|Participants in group 2 will be recruited at their stress echocardiogram appointment. Anonymised versions of the stress echocardiograms will be obtained. These participants will be followed up by telephone call after one year to determine whether they had any additional cardiac tests or events outside of their hospital trust. Medical records relating to the participant will be reviewed annually for up to 10 years to identify if the patient has been admitted and obtain health outcome data.
89460011|NCT03674255||3|Participants in group 3 will be recruited at their stress echocardiogram appointment. Anonymised versions of the stress echocardiograms will be obtained. These participants will be followed up by telephone call after one year to determine whether they had any additional cardiac tests or events outside of their hospital trust. Medical records relating to the participant will be reviewed annually for up to 10 years to identify if the patient has been admitted and obtain health outcome data.
89460012|NCT03674255||4|Participants in group 4 will be recruited at their stress echocardiogram appointment, regardless of the type of investigation. A simplified data set and an anonymised version of the stress echocardiography report will be collected as a part of this registry phase. Participants will be followed up over a 10-year period.
89460013|NCT03479463||Treatment with Dehydrated Human Amnion Chorion Allograft|
89460014|NCT03479463||Standard of Care|
89460015|NCT05126134||adolescents followed for gender dysphoria|The data collection by the examiner takes place during a single interview centered around the child's completion of a semi-structured questionnaire: the Kiddie Schedule for Affective Disorders and Schizophrenia. The child is interviewed alone and then with an accompanying parent.
89460016|NCT04059107|Experimental|Prosthetic Device|3D Printed Myoelectric Prosthetic Device
89460017|NCT03674099|Experimental|Imatinib|Imatinib will be administered orally one tablet (400mg) twice daily, 800mg per day for 14 consecutive days.
89460018|NCT03674099|Active Comparator|Methylprednisolone|Methylprednisolone will be administered once a day either in tablets; Medrol 1g per day or iv; Solumedrol 1000 mg per day, both for three consecutive days.
89460019|NCT05124340|Experimental|Vaccine|1 dose of BCG vial vaccine injected in right deltoid armintradermally
89460020|NCT05124340|Active Comparator|Active Comparator|1 dose of BCG ampoule vaccine injected in right deltoid arm intradermally
89460021|NCT03479385|Experimental|Integrative Medicine Intervention|Study participants randomized to the Integrative Medicine intervention will attend 14 sessions with an Integrative Medicine clinician over the course of 6 months potentially followed by a 6 month maintenance phase. The treatment modalities employed in the study will include nutrition and lifestyle recommendations.
89460022|NCT03479385|Experimental|Health Education Intervention|Study participants randomized to the Health Education intervention will attend 14 sessions with a Health Educator over the course of 6 months. The emphasis in the sessions will be to provide engaging educational information on common survivorship issues.
89017302|NCT00280709|Active Comparator|1|Covered metal stent
88942142|NCT01866878|Experimental|A group enjoying a corrective touch|"At first, the patient is asked to gradually define the different types of touch that is applied to the hyposensitive area (fixed or mobile touches) with different textures and then compare them with the healthy side. In a second step, the patient is asked to associate multiple items sensation shape and texture, shape and weight. In a third step is used everyday objects.~Desensitisation techniques find their interest mainly when symptoms or dysesthetic hyperesthésique. The objective is to increase the threshold of sensitivity to textures and particles eventually reduce dysaesthetic sensations.~The patient class in order of increasing tolerance 10 textures. Dysesthetic area is stimulated 5 to 10 minutes by the first texture to numb the area by saturation of the action potential. This helps promote functional work and recognition of objects. As soon as the texture causes more trouble we go to the next texture by applying the same job."
89460023|NCT04762628|Experimental|MAF capsules|MAF capsules 148 mg TID for 14 days + Standard of care
89460024|NCT04762628|Experimental|M capsules|M capsules 148 mg TID for 14 days + Standard of care
89460025|NCT04762628|Active Comparator|Comparison|Standard of care
89460026|NCT03670199|Experimental|Experimental group|nutritional and functional management coordinated by dieticians and physiotherapists, with adapted nutritional and physical advice and support, realized with the use of Nutrimus booklet in order to facilitate coordination and delivration of cares proposed to the patients
89460027|NCT03670199|Active Comparator|Control group|usual preoperative advice for patients who undergoing surgical procedure concerning nutritional cares and physical activity
89460028|NCT03481647|Active Comparator|Intervention|The intervention consists of professional oral care and swabbing of the mucosal membranes with a saline and bicarbonate solution, five daily rinses with a saline and bicarbonate solution, a diary to register oral care measures and rinses
89460029|NCT03481647|No Intervention|Control|Professional oral care once a week according to existing routine
89460030|NCT05084404|Experimental|4 mg/day of WY-8678 (guanabenz acetate)|
89460031|NCT05084404|Experimental|8 mg/day of WY-8678 (guanabenz acetate)|
89460032|NCT03473613|Active Comparator|Calcium infusion|10ml 10%calcium gluconate in 200ml normal saline solution given intravenously over thirty minutes, on ovum pick up day and continued for 4days
89460033|NCT03473613|Active Comparator|Oral Cabergoline|Receiving oral Cabergoline (cabergamon 0.5 milligram tablet ) from ovum pick up day and continued for 7days,once daily
89460034|NCT03673631||NFHC-O2 Group|NFHC-O2 therapy alone with gas flow at least 40L/min,
88942143|NCT01866878|Experimental|A group receiving TENS (TENS)|Well known in the management of neuropathic pain based on the gate control theory, the application of TENS in the rehabilitation of touch remains to be demonstrated. A recent study applied to the September highlighted the long-term interest of the transcutaneous electrical nerve stimulation (TENS) to improve sensitivity tact arguing possible action on brain plasticity.
88942144|NCT01866878|No Intervention|A control group|
88942145|NCT01866891|Experimental|single arm|
88942146|NCT01866904||Stable CAD patients aged 50 years or older|Stable CAD patients aged 50 years or older with documented history of presumed spontaneous MI with their most recent MI occurring 1 to 3 years prior to enrollment and have at least 1 additional risk factor
88942147|NCT01866969|Experimental|Supportive care (quality of life questionnaire)|Caregivers complete a self-administered questionnaire about factors associated with increased caregiver burden and decreased quality of life.
88942148|NCT01866982|Active Comparator|Umbilical Cord Milking|Milking the umbilical cord 4 times towards the infants at a speed of 20cm/2 seconds
88942149|NCT01866982|Active Comparator|Delayed Cord Clamping|Delayed clamping of the umbilical cord for 45-60 seconds
88942150|NCT01866995|Experimental|Raylis|"This arm (10 men with symptoms of prostatostasis) will get Raylis (1 kapsule contains: ginseng root powder 50 mg, false ginseng root powder 50 mg, codonopsis root powder 50 mg, astragalus membranaceus root powder 50 mg, epimedium alpinum herbal extract 100 mg) 2 kapsules a day per 3 months"
88942151|NCT01866995|Active Comparator|standard prostatostasis therapy|This arm (20 men with symptoms of prostatostasis) will get the standard (pathogenetic) therapy of prostatostasis
88942152|NCT01866995|Experimental|Raylis plus standard prostatostasis therapy|"This arm (20 men with symptoms of prostatostasis) will get Raylis (1 kapsule contains: ginseng root powder 50 mg, false ginseng root powder 50 mg, codonopsis root powder 50 mg, astragalus membranaceus root powder 50 mg, epimedium alpinum herbal extract 100 mg) 2 kapsules a day per 3 months together with standard prostatostasis therapy"
88942153|NCT01867034|Active Comparator|Bare Metal stent|Stent that has not been impregnated with an anti-restenotic drug
88942154|NCT01867034|Active Comparator|Drug Eluting Stent|Stent that has been impregnated with an anti-restenotic drug
88942155|NCT01867060|Other|Personal Heart Rhythm Monitor|Automated Cardiac Event Recorder in parallel with Personal Heart Rhythm Monitor.
88942156|NCT01867073||Advanced solid tumours|
89460035|NCT03673631||NIV/Standard-O2 Group|NIV sessions with at least 30% FiO2 and standard oxygen therapy
89460036|NCT03673631||NFHC-O2/NIV Group|combination of NIV sessions and NFHC-O2 therapy,
89460037|NCT03859011|Experimental|Acupuncture|After obtaining baseline data and questionnaires, patients will receive usual care (for example physical therapy, oral pain medication or ointments), plus acupuncture 2X/week over 2 weeks, then once per week over 8 weeks (12 total treatments over 10 weeks), then no acupuncture between 10 weeks and 6 months. After treatment is completed, final measurement instruments are applied at 6 months. Questionnaires will be readministered at 2.5 and 6 months.
89460038|NCT03859011|Placebo Comparator|"Usual care"|After obtaining baseline data and questionnaires, patients will receive usual care (for example physical therapy, oral pain medication or ointments) for 6 months. Questionnaires will be readministered at 2.5 and 6 months. After the control phase the participants will continue usual care (for example physical therapy, oral pain medication or ointments), plus acupuncture 2X/week over 2 weeks, then once per week over 8 weeks (12 total treatments over 10 weeks, 8.5 months), then no acupuncture between 8.5 months and 12 months.
89460039|NCT03670043|Active Comparator|Metformin ER|The subjects developing GI-related symptoms with metformin will be randomized to Metformin Extended Release (ER)
89201680|NCT00329407|Active Comparator|Topiramate Treatment|In this open label non-placebo controlled trial all subjects received topiramate, the active medication. Medication Dosing Schedule: Days 1-3 50 mg q PM Days 4-7 50 mg BID Days 8-11 50 mg q AM & 100 mg q PM Days 12-15 100mg BID Days 16-19 100 mg q AM & 150 mg q PM Days 20-23 150 mg BID Days 24-27 150 mg qAM & 200 mg q PM Days 28-70 200 mg BID Days 71-77 150 mg BID Days 78-84 100mg BID Days 85-87 50 mg BID Days 88-91 50 mg qPM
89201681|NCT04004728|Other|laser, leg veins, sclerotherapy|to compare laser and sclerotherapy on treating leg veins
89017303|NCT00280709|Active Comparator|2|Uncovered metal stent
89017304|NCT00310596|Experimental|Arm 1|
89017305|NCT00310596|Experimental|Arm 2|
89017306|NCT00310596|Experimental|Arm 3|
89017307|NCT00310596|Experimental|Arm 4|
89017308|NCT00310596|Active Comparator|Arm 5|
89017309|NCT00310596|Placebo Comparator|Arm 6|
89017310|NCT00316992|Experimental|Ramelteon 8 mg and Placebo|
89017311|NCT00317031|Active Comparator|1|Acamprosate
89017312|NCT00317031|Active Comparator|2|Naltrexone
89017313|NCT00317031|Placebo Comparator|3|Placebo
89017314|NCT00317070|Active Comparator|DMSO|Intravesical installation
89017315|NCT00317070|Experimental|Cocktail|
89017316|NCT00317148|Experimental|Placebo|
89460040|NCT03670043|Experimental|Psyllium|The subjects developing GI-related symptoms with metformin will be randomized to Psyllium
89017317|NCT00317148|Experimental|DHEA|
89017318|NCT00310713|Experimental|Group 1|
89017319|NCT00310713|Experimental|Group 2|
89017320|NCT00310713|Experimental|Group 3|
89201682|NCT01056757|Experimental|Ribavirin|
89201683|NCT00744068|Experimental|1|Structured Directive Telephone Support Calls
89460041|NCT05084092|Experimental|Intraoperative Radiotherapy (IORT)|Intraoperative Radiotherapy (IORT) administered during surgery
89460042|NCT02388464|Experimental|Low dose|
89017321|NCT00310713|Experimental|Group 4|
89017322|NCT00310713|Experimental|Group 5|
89017323|NCT00281255|Experimental|allopurinol|
89017324|NCT00281255|Placebo Comparator|placebo|
89017325|NCT00317187|Experimental|Hib-MenAC Lot 1 Group|Healthy male or female subjects aged 56 to 83 days of age at the time of the first study vaccine dose, with previous hepatitis B vaccine at birth, received Tritanrix-HepB combined vaccine mixed extemporaneously with Meningitec conjugate vaccine Lot 1 at 2, 4 and 6 months of age as an intramuscular injections in the anterolateral part of the left thigh.
89017326|NCT00317187|Experimental|Hib-MenAC Lot 2 Group|Healthy male or female subjects aged 56 to 83 days of age at the time of the first study vaccine dose, with previous hepatitis B vaccine at birth, received Tritanrix-HepB combined vaccine mixed extemporaneously with Meningitec conjugate vaccine Lot 2 at 2, 4 and 6 months of age as an intramuscular injections in the anterolateral part of the left thigh.
89460043|NCT02388464|Experimental|Intermediate dose|
89460044|NCT02388464|Experimental|High dose|
89017327|NCT00317187|Experimental|Hib-MenAC Lot 3 Group|Healthy male or female subjects aged 56 to 83 days of age at the time of the first study vaccine dose, with previous hepatitis B vaccine at birth, received Tritanrix-HepB combined vaccine mixed extemporaneously with Meningitec conjugate vaccine Lot 3 at 2, 4 and 6 months of age as an intramuscular injections in the anterolateral part of the left thigh.
89017328|NCT00317187|Active Comparator|Hiberix Group|Healthy male or female subjects aged 56 to 83 days of age at the time of the first study vaccine dose, with previous hepatitis B vaccine at birth, received Tritanrix-HepB vaccine mixed extemporaneously with conjugate vaccine Hiberix at 2, 4 and 6 months of age as intramuscular injection in the anterolateral part of the thigh.
89017329|NCT00310869|Experimental|E|
89017330|NCT00317304|Experimental|MBSR|
89017331|NCT00281489|Experimental|BIS Monitor guided algorithm|BIS guided algorithm (BIS target 40 to 60) during anesthesia. Alarms when BIS is outside this range.
89017332|NCT00281489|Active Comparator|Volatile anesthetic guided algorithm|Volatile anesthetic guided algorithm. Target anesthetic concentration 0.7 to 1.3 minimum alveolar concentration during anesthesia. Alarms when anesthetic concentration not in this range.
89017333|NCT02960061|Experimental|HIPEC|After receiving neoadjuvant chemotherapy and D2 radical resection, Hyperthermic intraperitoneal perfusion chemotherapy is conducted,4 catheters are placed in 4 position in the peritoneal cavity: ① under the left diaphragm ② hepatorenal recess ③ left pelvis ④ right pelvis.catheters, all four tubes are connected to the perfusion device.Perfusion prescription: cycle 1, Paclitaxel 75mg/ m2 diluted with 3000ml normal saline heated up to a fixed temperature of 43°C circulate continuously for 60min at a speed of 400-500ml/h; cycle 2 start within 24-48 hours after cycle 1, dosage of paclitaxel adjust to 100mg/ m2, the rest of the same. A total of two cycle is administered, routine adjuvant chemotherapy using SOX (oxaliplatin plus S-1 capsule)or XELOX regimens follows within 4-6 weeks.
89017334|NCT02960061|Sham Comparator|controlled group|After receiving neoadjuvant chemotherapy and D2 radical resection, patients receive peritoneal lavage with 3000ml distilled water.Adjuvant chemotherapy using SOX or XELOX regimens is administered as routine within 4-6 weeks.
89017335|NCT00317382|No Intervention|No Ultrasound|Standard LP without ultrasound use
89017336|NCT00317382|Experimental|Ultrasound Use|Ultrasound used to assess spine and best location for lumbar puncture.
89017337|NCT00416975|Other|Breast Cancer Risk Assessment Screening|Counseling Intervention and Eduation Intervention
89017338|NCT00317460|Active Comparator|1|Physician Management
89201684|NCT00744068|Experimental|2|Structured Non-Directive Telephone Continuing Care Support
89201685|NCT00744068|Experimental|3|Unstructured Directive Telephone Support
89460045|NCT02388464|Experimental|Placebo|
89460046|NCT03131427||Wilson's Disease|Patients who were diagnosed or possibly diagnosed with Wilson's disease. The diagnosis can be made or possibly made on the basis of Wilson's disease scoring system proposed by the Working Party at the 8th International Meeting on Wilson's disease, Leipzig 2001.
89460047|NCT03131427||Hereditary Hemochromatosis|Hereditary hemochromatosis can be clinically diagnosed if: ① transferrin saturation≥45% and/or elevated ferritin; ② iron overload in liver and/or spleen on magnetic resonance imaging (MRI) of liver or on liver histology; ③ exclude causes of secondary iron overload, such as alcoholic or other chronic liver disease, iron-overloading anemia, and parenteral iron overload.
89460048|NCT03131427||Hereditary Hyperbilirubinemias|Hereditary hyperbilirubinemias involve four syndromes: Gilbert, Crigler-Najjar, Dubin-Johnson and Rotor, among which the first two are characterized by unconjugated hyperbilirubinemia and the second two by conjugated hyperbilirubinemia. Diagnosis of hereditary hyperbilirubinemia should exclude other causes of hyperbilirubinemia, such as obstructive bile duct (slerosing cholangitis, calculi, parasites), intrahepatic cholestasis(drugs, hepatitis, immune-mediated, infectious), acute or chronic hepatocellular injury(sepsis, parenteral nutrition, severe blood loss/hypotension, trauma, conjestive heart failure), increased bilirubin production(hemolysis, hematological disease), decreased bilirubin uptake (drugs, portosystemic shunting ), reduced conjugation activity (neonatal, thyroid disease, chronic hepatitis/inflammation, wilson's disease).
89201686|NCT00744068|Experimental|4|Unstructured Non-Directive Telephone Support
89460049|NCT03131427||Inherited Cholestatic Liver Disease|Patients who were diagnosed or possibly diagnosed with Inherited cholestatic liver disease, including progressive familial intrahepatic cholestasis(PFIC) and benign recurrent intrahepatic cholestasis(BRIC).
89460050|NCT03131427||Other genetic/metabolic liver diseases|Patients who were diagnosed or possibly diagnosed with genetic/metabolic liver diseases except for Wilson's disease, hereditary hemochromatosis, hereditary hyperbilirubinemias or inherited cholestatic liver disease.
89201687|NCT00744068|No Intervention|5|
89201688|NCT01056835|No Intervention|control|
89201689|NCT03989323||Patients treated with immunotherapy|Patients receiving for the first time an immunotherapy treatment for their cancer (Checkpoints inhibitors, such as PD-1 or PD-L1 or CTLA4…). Patients will be enrolled before starting the immunotherapy treatment and will be followed up for 5 years or until the permanent discontinuation of the immunotherapy treatment to describe the arm.
89201690|NCT03986515|Experimental|treatment group|"apatinib 250mg orally once a day until disease progression of occurrence of intolerable adverse events.~SHR-1210 200mg every two weeks until disease progression of occurrence of intolerable adverse events.~(the first dose of SHR-1210 is set on the 3-5 days after apatinib"
89201691|NCT03989479|Active Comparator|Conventional Toothbrush|Brushing with conventional Kid's Soft Toothbrush, Colgate (5-9-year-old)
89201692|NCT03989479|Experimental|T-shaped Toothbrush|Brushing with T-shaped toothbrush (Denson™, Malaysia)
89201693|NCT01056991|Experimental|warming mattress|Patient warmed with electric mattress
89201694|NCT01056991|Active Comparator|warming blanket|Forced air warming blanket
89201695|NCT01054417||Appendicitis|Patients with suspected appendicitis who are to be operated upon by diagnostic laparoscopy
89201696|NCT00328783|Experimental|Active Breathing Coordinator|Patients breathe through the ABC device
88942157|NCT01867099||Post-successful ablation|Patients who had undergone PVI ablation for AF and were free of AF for at least one year
88942158|NCT01867112|Active Comparator|Individualized Program|Based on personal fitness an individualized physical activity program will be built and followed by each individual in the arm
89201697|NCT00567489|Active Comparator|Non glucose sparing|Dianeal only
89460051|NCT03114345|Other|Single arm|Measurement of interface pressure and Measurement of micro-vascularization related parameters
89460052|NCT05082376|Experimental|Test Arm|Single topical application: 80 +/- 2 milligrams (mg) (2.0 +/- 0.05 mg/centimeter^2) of ChapStick Lip Moisturizer Original will be applied to the assigned test site using a fingercot. The test product will be evenly spread over the test site using light pressure.
89460053|NCT05082376|No Intervention|Control Arm|No treatment will be applied to the assigned control site.
89460054|NCT04446429|Active Comparator|Usual Care|Usual care as determined by the PI
88942159|NCT01867112|Active Comparator|General Physical Activity Guidelines|The entire group of individuals in this arm will follow a physical activity program according to the General Physical Activity Guidelines
88942160|NCT01867125|Experimental|Lebrikizumab (125 mg)|Participants will receive SC injection of lebrikizumab (125 milligrams [mg]) every 4 weeks for 104 weeks.
89201698|NCT00567489|Experimental|glucose sparing|PEN solutions: Nutrineal, Extraneal, and Physioneal
89201699|NCT00669942|Experimental|Part 1 - AIN457A 0.3 mg/kg|AIN457A 0.3 mg/kg was administered intravenously as a single dose.
89201700|NCT00669942|Experimental|Part 1 - AIN457A 1.0 mg/kg|AIN457A 1.0 mg/kg was administered intravenously as a single dose.
89201701|NCT00669942|Experimental|Part 1 - AIN457A 3.0 mg/kg|AIN457A 3.0 mg/kg was administered intravenously as a single dose.
89201702|NCT00669942|Experimental|Part 1 - AIN457A 10 mg/kg|AIN457A 10.0 mg/kg was administered intravenously as a single dose.
89201703|NCT00669942|Placebo Comparator|Part 1 - Placebo|Placebo to AIN457A was administered intravenously as a single dose.
89201704|NCT00669942|Experimental|Parts 2 and 3 - AIN457A 1.0 mg/kg|AIN457A 1.0 mg/kg was administered intravenously as 2 doses 21 days apart, i.e. the first dose on day 1 and the second dose on day 22.
89201705|NCT00669942|Experimental|Parts 2 and 3 - AIN457A 3.0 mg/kg|AIN457A 3.0 mg/kg was administered intravenously as 2 doses 21 days apart, i.e. the first dose on day 1 and the second dose on day 22.
89201706|NCT00669942|Experimental|Parts 2 and 3 - AIN457A 10 mg/kg|AIN457A 10.0 mg/kg was administered intravenously as 2 doses 21 days apart, i.e. the first dose on day 1 and the second dose on day 22.
89201707|NCT00669942|Placebo Comparator|Parts 2 and 3 - Placebo|Placebo to AIN457A was administered intravenously as 2 doses 21 days apart, i.e. the first dose on day 1 and the second dose on day 22.
89201708|NCT00669942|Experimental|Part 1 - Healthy Volunteers - AIN457A 3 mg/kg|AIN457A 3.0 mg/kg was administered intravenously as a single dose.
89201709|NCT00669942|Experimental|Part 1 - Healthy Volunteers - AIN457A 10 mg/kg|AIN457A 10 mg/kg was administered intravenously as a single dose.
89201710|NCT00669942|Placebo Comparator|Part 1 - Healthy Volunteers - Placebo|Placebo to AIN457A was administered intravenously as a single dose.
89201711|NCT00929019|Experimental|dendritic cell vaccination|HLA-A2.1 positive patient will receive 3 biweekly intradermal/intravenous vaccination with autologous mRNA transfected mature dendritic cells, followed by a DTH skin test for monitoring purposes. One such cycle is repeated every 6 months if no signs of progression, up to a total of 3 cycles.
89460055|NCT04446429|Experimental|Proxalutamide + Usual Care|Proxalutamide + Usual care as determined by the PI
89460056|NCT05675384|Experimental|TENS Active Treatment|Transcutaneous Electrical Nerve Stimulation (TENS)-Assisted Weight Management (The Elira System)
89460057|NCT05675384|Sham Comparator|Sham Control Device|Sham TENS unit that provides no actual therapy
89460058|NCT04432467|Experimental|mesenchymal stem cells|Patients with impending caesarean section or with chronic inflammation in the mucosa of the uterus and fallopian tubes receiving standard treatment and mesenchymal stem cells
89460059|NCT04432467|Active Comparator|control|Patients with impending caesarean section or with chronic inflammation in the mucosa of the uterus and fallopian tubes receiving standard treatment
89460060|NCT05561660|Experimental|PFO closure|
88942161|NCT01867125|Experimental|Lebrikizumab (37.5 mg)|Participants will receive SC injection of lebrikizumab (37.5 mg) every 4 weeks for 104 weeks.
88942162|NCT01867125|Placebo Comparator|Placebo|Participants will receive SC injection of lebrikizumab matching placebo every 4 weeks for 52 weeks during placebo-controlled period and then SC injection of lebrikizumab at 125 or 37.5 mg for 52 weeks during active treatment extension period.
89460061|NCT05561660|Sham Comparator|Shame procedure|
89201712|NCT00929019|No Intervention|control arm|For comparison, HLA-A2.1 negative patients will be monitored for clinical response (secondary endpoint).
89460062|NCT03042819|Experimental|Selinexor plus Doxorubicin|"Selinexor will be given by mouth (orally) once a week:~Dose Level -1 = 40 mg Dose Level 1 (Starting Dose) = 60 mg Dose Level 2 = 80 mg~Doxorubicin will be given by vein (intravenously) at a dose of 75 mg/m2 once every 3 weeks."
89460063|NCT02388308||Patient volunteers|Patients who have received radiotherapy for prostate cancer which included a planning CT scan, or who are currently receiving radiotherapy including a CT scan.
89460064|NCT02388308||Gold fiducial marker group|Patients receiving radiotherapy for prostate cancer as part of a clinical trial or standard care which includes gold FM or EM insertion, or patients who have previously received RT for prostate cancer which included EM insertion.
89460065|NCT02388308||Electromagnetic marker group|Patients receiving radiotherapy for prostate cancer as part of a clinical trial or standard care which includes gold FM or EM insertion, or patients who have previously received RT for prostate cancer which included EM insertion.
89460066|NCT02388308||General patients|Patients who are receiving radiotherapy for prostate cancer and who are not receiving FMs. Attempts will be made to match Group 4 patients BMI and time receiving hormone therapy to patients in group 2 and 3 (see below, section 6.1 recruitment.
89460067|NCT02388542|Experimental|lifestyle counseling|we will have a trained peer mentor educating employees regarding lifestyle modification for control of cardiovascular disease risk factors and following them up for a duration of 3 months
89460068|NCT02832687|Active Comparator|normal saline|Patients will receive 100 milliliters of normal saline with the first dose given preoperatively in the holding area followed by re-dosing every four hours from that point up to a maximum of 4 doses in 24 hours. Blinded medication will be prepared by research pharmacist.
89460069|NCT02832687|Experimental|acetaminophen|Patients 50kg or more will receive either 1000mg IV acetaminophen with the first dose given preoperatively in the holding area followed by re-dosing every four hours from that point up to a maximum of 4 doses or 4000mg in 24 hours. Patients <50 kg will receive 12.5mg/kg to a maximum of 75 mg /per kg/per day as per the label dose with repeat dosing Q4 hours. Blinded medication will be prepared by research pharmacist in 100mL of normal saline
89460070|NCT04421794|Experimental|NMES group|For the NMES group one portable stimulator (Compex 2, Medicompex SA, Ecublens, Switzerland) will deliver NEMS (15 min; 75 EMS contractions completed during the training session; rise time = 0.25 s and descending time = 0.75 s). In order to maximize muscle tension without accompanying detrimental effects on fatigue onset, biphasic symmetric regular-wave pulsed currents (85 Hz) lasting 400 μs will be delivered. Each 4-s steady tetanic stimulation will be followed by pause lasting 8-s, during which subjects will be submaximally stimulated at 4 Hz on the medial arch muscles. According to the recommendations, the two electrodes are placed behind the head of the first metatarsal to stimulate the medial arch intrinsic muscles. The goal is to attain the highest tolerable level of muscle contraction without discomfort during the 15 minutes and to provide a full tetanic contraction of the intrinsic foot muscles during the contraction time.
89460071|NCT04421794|Placebo Comparator|Control group|For the control group the one portable stimulator (Compex 2, Medicompex SA, Ecublens, Switzerland) will be used to apply a stimulation of 15 minutes considered by TENS at the lowest intensity detectable by the participant in order to not influence the outcomes of interest. Our aim is to strengthen IFM which is not the role of TENS. The two electrodes will be placed on the dominant foot, at the same place than those for the NMES group.
89460072|NCT02388152|Experimental|Lu AF20513, low dose (Cohort 1)|10 Patients with mild Alzheimer's.
89460073|NCT02388152|Experimental|Lu AF20513, medium dose (Cohort 2)|10 Patients with mild Alzheimer's.
88942163|NCT01867138|Experimental|Cefazolin group|Initial empirical treatment with cefazolin and amikacin
88942164|NCT01867138|Active Comparator|Vancomycin|Initial empirical treatment with vancomycin and amikacin
89201713|NCT00907491||A|
89201714|NCT00929097|Experimental|Implementation aids|
89201715|NCT00929097|Active Comparator|Control|
89201716|NCT00769938|Active Comparator|Aspirin + clopidogrel + oral anticoagulation|
89460074|NCT02388152|Experimental|Lu AF20513, high dose (Cohort 3)|15 Patients with mild Alzheimer's.
89460075|NCT02388152|Experimental|Lu AF20513, double high dose (Cohort 4)|15 Patients with mild Alzheimer's.
89460076|NCT02388230||Patients 4 or more years post radiotherapy|IMPORT or FAST trial patients who received breast RT previously and are receiving four years (or more) follow-up assessment and have hardening of their breast as a result of breast radiotherapy.
89460077|NCT02388230||Patients 0 to 2 years post breast radiotherapy|Patients who are (1) undergoing, or undergone recently breast RT (general population) and have undergone a clinical assessment either during RT or at 3 month follow-up that found moderate or severe oedema, or (2) IMPORT patients who have received RT and are receiving one or two year follow-up, at which moderate or severe oedema is reported.
89460078|NCT04372017|Experimental|Cohort A: Healthcare worker (hydroxychloroquine)|
89460079|NCT04372017|Placebo Comparator|Cohort A: Healthcare worker (placebo)|
89460080|NCT04372017|Experimental|Cohort B: High-Risk participant (hydroxychloroqine)|
89460081|NCT04372017|Placebo Comparator|Cohort B: High-Risk participant (placebo)|
89460082|NCT03479229|Experimental|Geneveve Treatment|Active Treatment
89460083|NCT03479229|Placebo Comparator|Sham Treatment|Sham Treatment
89460084|NCT05233358|Experimental|HAIC combined with regorafenib and immune checkpoint inhibitors|Subjects received FOLFOX regimen HAIC treatment, within 2 weeks of regorafenib (28 days as a cycle, 80-160 mg qd regorafenib orally on days 1-21) and immune checkpoint inhibitors (continue treatment according to the original plan, 1 cycle every 3 weeks) treatment. HAIC treatment was repeated every 3 weeks for a maximum of six cycles.
89460085|NCT05233358|Active Comparator|TACE combined with regorafenib and immune checkpoint inhibitors|Choose traditional precise cTACE or dTACE treatment, and receive regorafenib within 2 weeks (28 days as a cycle, 80-160mg qd regorafenib orally on d1-21) and immune checkpoint inhibitors (continue treatment according to the original plan, every 3 weeks as a cycle) treatment. CT or MRI examination was repeated 4-6 weeks after the operation to evaluate whether there were active lesions. If there were still active lesions, one repeat TACE could be performed, and the number of TACE was less than 3 times.
89460086|NCT05120752|Experimental|FODMAP diet|
89460087|NCT05120440|Experimental|Breakfast Omission|This arm will consist of omission of breakfast and consumption of standardized food items solely at lunch preceding afternoon resistance exercise.
89460088|NCT05120440|Active Comparator|Breakfast Consumption|This arm will consist of consumption of standardized food items at breakfast and lunch preceding afternoon resistance exercise.
89460089|NCT03479151|Experimental|MR-HIFU of painful bone metastases|Magnetic Resonance guided High Intensity Focused Ultrasound (MRgHIFU) for Pain Palliation of Bone Metastases
89460090|NCT05675228||young adults|men and women aged 25 to 35
89460091|NCT02387918|Active Comparator|Dexamethasone|Patients will receive Intravenous dexamethasone 0.15 mg/kg immediately after induction of anesthesia.
89460092|NCT02387918|Active Comparator|Acupuncture|Acupuncture at point Neiguan (Pericardium-6) bilaterally and at point CV13 (Shang Wen) with acupuncture needles (0.25x25 mm) to a depth of approximately 7 mm will be performed on the children immediately after induction of anaesthesia and removed after 20 minutes
89460093|NCT04312971|Placebo Comparator|Placebo|Infusion of normal Saline 0.9%will be started following arterial cannulation before initiation of cardiopulmonary bypass and continued until aortic declamping time.
89201717|NCT00769938|Active Comparator|Oral anticoagulants + clopidogrel|
89201718|NCT02538393|Experimental|Treatment A-C-B-D|Subjects received a single oral dose of 400 mg sorafenib marketed tablets (2 * 200 mg) in fasting state (Treatment A) in the first intervention period; followed by a single oral dose of 200 mg sorafenib tablets for oral suspension (2 * 100 mg) in fasting state (Treatment C) in the second intervention period; followed by a single oral dose of 400 mg sorafenib tablets for oral suspension (4 * 100 mg) in fasting state (Treatment B) in the third intervention period; and then a single oral dose of 400 mg sorafenib tablets for oral suspension (4 * 100 mg) after a high-fat, high-calorie breakfast (fed state) (Treatment D) in the fourth intervention period. A washout period of at least 10 days was maintained between sorafenib administrations.
89460094|NCT04312971|Active Comparator|Norepinephrine|Infusion of norepinephrine (40 µg/ml) will be started following arterial cannulation before initiation of cardiopulmonary bypass and continued until aortic declamping time.
89460095|NCT01194596|Experimental|Spirometry and lifestyle counseling|Intervention group: will be given a brief but structured smoking cessation advice (according to the standards of the Tobacco Study Group of the Catalan Society of Family Medicine) together with a detailed and structured discussion of the spirometric results.
88942165|NCT01867151|Experimental|Gluten free diet|BMS patients following a GFD
88942166|NCT01867151|Sham Comparator|Normal Diet|Patients with BMS maintaing a normal diet
89460096|NCT01194596|No Intervention|Lifestyle counseling|No intervention group: will be given a brief but structured smoking cessation advice (according to the standards of the Tobacco Study Group of the Catalan Society of Family Medicine).
88942167|NCT01867177|Other|HIV testing|Identification of HIV infection among recently infected adults
89460097|NCT02737215|Active Comparator|CPAP group|patients will receive CPAP therapy for the first 7 days after extubation from CABG
89460098|NCT02737215|No Intervention|Control Group|Patients will receive usal care
89460099|NCT02697123||antepartum and postpartum|This prospective, observational cohort study was designed to assess the incidence of VTE in patients hospitalized for Cesarean Section, Vaginal delivery or any antepartum indication.
89460100|NCT03473457|Experimental|CART therapy in Acute myeloid leukemia|In order to assess the safety and validity of using CAR-T therapy refractory/relapsed acute myeloid leukemia（AML）patients with one kind of CD38-CART/CD33-CART/CD56-CART/CD123-CART/CD117-CART/CD133-CART/CD34-CART/Mucl-CART,subjects will receive 10^6-10^7/Kg transduced CAR T cells at one time.
89460101|NCT05231330|Experimental|silver nanoparticles|
89460102|NCT05231330|Active Comparator|silverdiamine fluoride|
89460103|NCT05231330|No Intervention|no medicament|
88942168|NCT01867177|Experimental|HIV care utilization|Improved access to HIV care and HIV care utilization, particularly among newly diagnosed adults
88942169|NCT01867177|Active Comparator|standard of care|Standard of HIV care; standard of linkage to HIV care
89201719|NCT02538393|Experimental|Treatment B-A-D-C|Subjects received a single oral dose of 400 mg sorafenib tablets for oral suspension (4 * 100 mg) in fasting state (Treatment B) in the first intervention period; followed by a single oral dose of 400 mg sorafenib marketed tablets (2 * 200 mg) in fasting state (Treatment A) in the second intervention period; followed by a single oral dose of 400 mg sorafenib tablets for oral suspension (4 * 100 mg) after a high-fat, high-calorie breakfast (fed state) (Treatment D) in the third intervention period; and then a single oral dose of 200 mg sorafenib tablets for oral suspension (2 * 100 mg) in fasting state (Treatment C) in the fourth intervention period. A washout period of at least 10 days was maintained between sorafenib administrations.
88942170|NCT01867190|Other|ASCT01|ASCT01 (Autologous Stem Cell Transplantation)
88942171|NCT01867203||Statin users|
88942172|NCT01867229||FEC- TC|Fluorouracil- Epiadriamycine- Cyclophosphamide Taxotère-Cyclophosphamide
88942173|NCT01867255|Other|venlafaxine ER|venlafaxine ER (extended-release) 75 mg once
88942174|NCT01867268|Experimental|Acetazolamide|administration of Acetazolamide for 10 days following the surgery
88942175|NCT01867268|No Intervention|Control|control group without any intervention
88942176|NCT01867268|Experimental|Prone positioning|Positioning the patient following surgery for 10 days
89460104|NCT03359421||Aeromedical transport|Patients transported to trauma center by helicopter
88942177|NCT01867268|Experimental|Acetazolamide and Prone positioning|applying both Acetazolamide and prone positioning
89460105|NCT03359421||Ground transport|Patients transported to trauma center by ground ambulance
88942178|NCT01867281|Active Comparator|Intervention: Aspirin|Participants will undergo aspirin desensitization over a 2-day period with increasing doses of aspirin (60, 125, 325 and 625 mg). Thereafter,they will be followed with 625 mg aspirin bid.
88942179|NCT01867281|Placebo Comparator|Control: placebo|Participants will receive placebo
88942180|NCT01867437|Active Comparator|RM-493|Double blind RM-493 will be administered at a dose of 1 mg/24 hrs via subcutaneous infusion for 3 days
88942181|NCT01867437|Placebo Comparator|Placebo|Double blind placebo will be administered via subcutaneous infusion for 3 days
88942182|NCT01867450||Biomarker Cross-section|Cross-sectional biomarker study in Chinese diesel workers
88942183|NCT01867463|Experimental|Group 1|Group 1: n=20, randomized to receive 16 g Pfs25-EPA/Alhydrogel (n=10) or the comparator (EuvaxB, n=10) on D0, D56
88942184|NCT01867463|Experimental|Group 2|Group 2: n=30, randomized to receive 47 g Pfs25-EPA/Alhydrogel (n=15) or the comparator (EuvaxB and Menactra , n=15) on D0, D56, D112, D480
88942185|NCT01867463|Experimental|Group 3|Group 3: n=70 randomized to receive 47 g Pfs25-EPA/Alhydrogel (n=35) or the comparator (EuvaxB and Menactra , n=35) on D0, D56, D112, D480
88942186|NCT01867476||Healthy Normals|
88942187|NCT01867489||Chemotherapy, Cancer|Adult cancer patients (with any type of cancer) being treated with chemotherapy
88942188|NCT01867502|Other|MET + Glibenclamide Group|"Usual Metformin stipulated: 500 or 850mg 3 times a day, if tolerated by patients.~The initial dose of glibenclamide group will be 5mg / day during the first week of study, later it will increase to 10 mg / day (2 x 5mg). When the adjustments will be done, the dose may reaching the maximum dose allowed, which is 20 mg / day."
88942189|NCT01867502|Other|MET + Vildagliptin Group|"Usual Metformin stipulated: 500 or 850mg 3 times a day, if tolerated by patients.~Vidagliptin group will receive 50mg of this drug twice a day during 12 weeks."
88942190|NCT01867528|Experimental|Laparoscopic adhesiolysis|
88942191|NCT01867528|Active Comparator|Open adhesiolysis|
88942192|NCT01867554||Intellectual disability|patients with intellectual disability or psycho-motor retardation and their parents and sibs (affected or not)
88942193|NCT01867567|Experimental|6 Hours|Removal of bandage after 6 hours
88942194|NCT01867567|Active Comparator|24 hours|removal of bandage after 24 hours
88942195|NCT01867593|Experimental|C-11 methionine PET|C-11 methionine PET pre and post radiation
88942196|NCT01867645|Active Comparator|IgM-enriched Intravenous Immunoglobulins|IgM-enriched IVIG (Pentaglobin, Biotest Pharma GmbH, Dreieich, Germany) at a dose of 0.25g/kg body weight/day as a continuous intravenous infusion at a rate of 2g/h over a period of 3 days
88942197|NCT01867645|Placebo Comparator|Human Albumin|Human albumin 1% (Biotest Pharma GmbH, Dreieich, Germany) as placebo at a dose of 0.25g/kg body weight/day as a continuous intravenous infusion at a rate of 2g/h over a period of 3 days
88942198|NCT01867684|No Intervention|Treatment as usual|Standard NHS care for the patient group (NHS care will vary as participants will be recruited from a variety of NHS clinics).
88942199|NCT01867684|Experimental|Psychotherapy|Brief psychotherapy intervention delivered over 8 weeks in addition to standard care.
89017339|NCT00317460|Experimental|2|Physician Management and counseling (drug counseling and medication adherence)
89017340|NCT00317499|Experimental|Etanercept|
88942200|NCT01867697|Active Comparator|Biweekly cetuximab with continuously FOLFIRI|Biweekly cetuximab 500 mg/m2 in combination with FOLFIRI (irinotecan 180 mg/m2 IV, leucovorin: 400 mg/m2 IV, 5FU bolus: 400 mg/m2 IV and 46 hours 5FU infusion of 2400 mg/m2 every 2 weeks)
88942201|NCT01867697|Experimental|Biweekly cetuximab with alternating FOLFIRI and mFOLFOX6|Biweekly cetuximab 500 mg/m2 in combination with FOLFIRI alternating with FOLFOX6 (Oxaliplatin: 85 mg/m2 IV, leucovorin: 400 mg/m2 IV, 5FU bolus: 400 mg/m2 IV and 46 hours 5FU infusion of 2400 mg/m2 every 2 weeks)
88942202|NCT01867723|Experimental|Internet communication application|Experiment 1 Effect of internet support program on cancer patients and their caregivers
88942203|NCT01867723|No Intervention|Control group|Control group get usual care
88942204|NCT01867736|Experimental|Passeo-18 Lux DRB|Passeo-18 Lux Drug Releasing Balloon catheter
88942205|NCT01867736|Active Comparator|Standard PTA (POBA)|Uncoated Passeo-18 PTA balloon catheter
88942206|NCT01867749|Experimental|Group Interpersonal Psychotherapy (IPT-G)|Participants in the IPT-G condition will receive 12 group therapy sessions over 2 weeks as well as 2 individual (pre-group and 1-month booster sessions). In addition, 3 of the 12 group sessions will invite women to include their partners or other support people to bolster the woman's social support system and to reduce conflicts over how to react to the loss. This study adapted IPT for treatment of depression after perinatal loss.
89017341|NCT00317499|Placebo Comparator|Placebo|
89017342|NCT00281606|Active Comparator|LPV/r (800/200 mg) 10 ml liquid|Once daily Lopinovir/ritonavir (800/200 mg) taken as a 10 ml liquid
89460106|NCT05305118|Experimental|Acute Inpatients With Spinal Cord Injury|Inpatient participants undergoing rehabilitation after acute traumatic SCI.
89460107|NCT05675072|Experimental|FB2001 group|FB2001 will be administered by nebulized inhalation, plus Standard Of Care(SOC)
89460108|NCT05675072|Placebo Comparator|Placebo group|Placebo will be administered by nebulized inhalation, plus Standard Of Care(SOC)
89460109|NCT03479073||Stroke group|Patients who experienced stroke or systemic embolic event following catheter ablation for AF.
89460110|NCT03479073||Control group|Patients who did not experienced stroke or systemic embolic event following catheter ablation for AF.
89460111|NCT05116618||Cohort 1|10 evaluable enrollments to Cohort 1 with EGFR-mutant NSCLC
89460112|NCT05116618||Cohort 2|10 evaluable enrollments to Cohort 2 with ALK-rearranged NSCLC
89460113|NCT05116618||Cohort 3|10 evaluable enrollments to Cohort 3 with ROS1-rearranged NSCLC
89460114|NCT03298269|Experimental|Mindfulness-Oriented Recovery Enhancement|
89460115|NCT03298269|Active Comparator|Supportive Counseling|
89460116|NCT03179475|Other|Oxycodone Naloxone Combination|Open-Label
89460117|NCT05115604|Experimental|Intrervention group|One and a half hour sessions (6 sessions) of cognitive behavioural therapy and psychoeducation. The sessions will consist of: sleep hygiene, cognitive therapy, bedtime restriction, stimulus control and relaxation.
89460118|NCT05115604|No Intervention|Control group|routine clinical follow-up
89460119|NCT05259267|Experimental|Online Group Therapy for PTG|It consists of eight sessions that occur during app. 90 minutes. A group therapist and a cotherapist will lead the therapy sessions. There will be one session per a week.
89460120|NCT05259267|Active Comparator|Online Support Group|It consists of eight sessions that occur during app. 90 minutes. A group therapist and a cotherapist will lead the therapy sessions without using any psychological methods. There will be one session per a week.
89460121|NCT05259267|No Intervention|Wait-list|We used a wait-list as a control group. After each participants in both online PTG group therapy and online support group completed the interventions, wait-list will be randomly assigned to one of these two interventions.
89460122|NCT02387528|Experimental|1- Mindfulness Intervention|"Mindfulness-Based Intervention: The intervention model tested was Breathworks for Stress.The mindfulness intervention used in the study had a total of eight encounters, lasting 120 minutes, that took place once a week. In order to accommodate employees' schedule. There was a recommendation of daily practice lasting an average of 15 minutes, as well as the suggestion to use the tools in everyday life.~In each session a theme was presented, with distinct practices and well-defined objectives"
89460123|NCT02387528|Placebo Comparator|2- Relaxation Intervention|Relaxation-Based Intervention was composed of four meetings, of two hours duration, held every two weeks. The activities involved mutual help conversations about work situations, psychoeducation on stress and various techniques of stress inoculation, such as: diaphragmatic breathing, progressive muscle relaxation, relaxing visualization and stretching. Each session had its own objective to promote the relaxation response effect.
89460124|NCT02387528|Other|3- Wait List Control Group|The wait list passive control group did not receive any intervention while the study was been enrolling.
89460125|NCT01656850|Experimental|Almond diet first, then NCEP Diet|In a 28-wk randomized, cross-over, controlled feeding trial with a 2 week washout between alternative diets, subjects were assigned to receive NCEP or almond diet for 12 weeks after a 2-weeks run-in period
89460126|NCT01656850|Experimental|NCEP diet first, then Almond diet|In a 28-wk randomized, cross-over, controlled feeding trial with a 2 week washout between alternative diets, subjects were assigned to receive NCEP or almond diet for 12 weeks after a 2-weeks run-in period
89460127|NCT03113630|Experimental|Acquisition on TouchScreen|Subjects practice the task and retention TouchScreen, transfer 1 on LeapMotion and transfer 2 on Kinect
88942207|NCT01867749|Active Comparator|Coping with Depression (CWD)|The Coping with Depression (CWD) course is a highly structured, manualized psycho-educational group treatment for MDD. The course content is cognitive-behavioral in nature and is designed to train skills that can be used in the alleviation of depression. The skill modules focus on relaxation, cognitive skills, and behavioral activation. CWD will consist of an individual pre-group interview, 12 group therapy sessions over 12 weeks and a 1-month individual booster session to provide an identical treatment dose as the experimental condition.
89460128|NCT03113630|Experimental|Acquisition on Kinect|Subjects practice the task and retention Kinect, transfer 1 on TouchScreen and transfer 2 on LeapMotion.
88942208|NCT01867775|Active Comparator|Mirtazapine|Mirtazapine, 15 mg once a day, at night for 14 days
88942209|NCT01867775|Placebo Comparator|Placebo|Placebo 15 mg, once a day at night for 14 days
88942210|NCT01867788||Parkinson's disease subjects|
89460129|NCT03113630|Experimental|Acquisition on LeapMotion|Subjects practice the task and retention LeapMotion, transfer 1 on TouchScreen and transfer 2 on Kinect.
89460130|NCT03113630|Active Comparator|Acquisition on TouchScreen Control Group|Subjects practice the task and retention TouchScreen, transfer 1 on LeapMotion and transfer 2 on Kinect
89460131|NCT03113630|Active Comparator|Acquisition on Kinect Control Group|Subjects practice the task and retention Kinect, transfer 1 on TouchScreen and transfer 2 on LeapMotion.
89460132|NCT03113630|Active Comparator|Acquisition on LeapMotion Control Group|Subjects practice the task and retention LeapMotion, transfer 1 on TouchScreen and transfer 2 on Kinect.
88942211|NCT01867788||Healthy Control subjects|
89460133|NCT03177525|Experimental|Social SUCCESS|
89460134|NCT03177525|Other|Wait List|
89460135|NCT03105986|Experimental|Treatment sequence AB|Participants will receive Treatment A (1000 milligram (mg) oral dose of JNJ-64041575 on Day 1) in Period 1, followed by Treatment B (1000 mg oral dose of JNJ-64041575 on Day 22 along with probenecid 500 mg on Day 21 to Day 28) in Period 2. A washout Period of 21 days will be maintained between each Period.
88942212|NCT01867814|Experimental|Pneumoperitoneum|Patients undergoing laparoscopic surgery
89501854|NCT00882505|No Intervention|Tanning bed user|Regular tanning bed users will be assessed for their vitamin D levels.
88942213|NCT01867827|Experimental|Neurofeedback and Physical Exercise|This group will undergo neurofeedback intervention in the fMRI scanner in weeks 1,5 and 12. They will also undergo physical exercise training on WiiFit device once a week after the first month till the end of the study at 12 weeks.
89460136|NCT03105986|Experimental|Treatment sequence BA|Participants will receive Treatment B (1000 mg oral dose of JNJ-64041575 on Day 1 along with probenecid 500 mg on Day -1 to Day 7) in Period 1, followed by Treatment A (1000 mg oral dose of JNJ-64041575 on Day 22) in Period 2. A washout Period of 21 days will be maintained between each Period.
89460137|NCT02391662|Experimental|Nab-paclitaxel plus Gemcitabine|Nab-paclitaxel 125 mg/m2 plus Gemcitabine 1000 days 1, 8 & 15 in a 28 days cycle
89460138|NCT05076604|Active Comparator|Cardioplegia|4:1 cardioplegia consists of 4 parts crystalloid intravenous fluid to one part human blood.
89460139|NCT05076604|Active Comparator|Microplegia|Nondiluted microplegia consists of all parts human blood.
89460140|NCT02391506|Experimental|Cartiva|Synthetic Cartilage Implant
89460141|NCT05177380|Experimental|Personalized rehabilitation program of facial involvement in systemic sclerosis|"3 sessions of 2 hours of facial rehabilitation in hospital over 2 weeks including:~Physiotherapy with facial and endo-oral massages, self-massages, active and passive exercises of the face and mouth, tongue exercises~Speech therapy with mobilization of the orofacial sphere applied to swallowing and speech difficulties~Individual workshop on the theme of dry mouth, dry mouth, swallowing disorders, and oral care~Individual therapeutic makeup workshop~A motivational interview~A patient notebook with a personalized protocol for self-rehabilitation of the face~A video tutorial for self-rehabilitation of the face Facial self-rehabilitation sessions at home"
89460142|NCT05177380|Other|Routine care|Delivery of a standard prescription for facial rehabilitation
89460143|NCT03116685|Experimental|Oxabact OC5 capsules|Oxabact OC5 - Oxalobacter formigenes HC-1
89460144|NCT03116685|Placebo Comparator|Placebo capsules|Placebo
89460145|NCT05177068|Experimental|Experimental|fruquintinib + sintilimab + SOX (S-1 + oxaliplatin)
89460146|NCT03058107|Experimental|Nutrition Therapy (NT) group|Nutrition Therapy is intensive dietary counseling based on practical measurements of energy expenditure, rather than calculating it using theoretic formulas or no method at all.
89460147|NCT03058107|Active Comparator|Control Therapy (CT) group|Control Therapy is standard dietary counseling bij state-wide recognized onco-dietitians. Energy expenditure is never measured in this standard protocol.
89460148|NCT02391272|Experimental|rhTPO|rhTPO will be given intravenously at a dose of 300U/kg every day. Dose will be tapered to 300U/kg every other day when platelet count rise over 50×10^9/L. Maintenance will be continued after delivery and the dose will be further reduced to 300U/kg per week.
89460149|NCT05258955|Active Comparator|Chlorhexidine|these are the group which received chlorhexidine based preparation for plaque reduction
88942214|NCT01867827|Active Comparator|Physical Exercise|This group will undergo Physical Exercise intervention on the WiiFit device 3 times a week in the first month and once a week after the first month till the end of the study at 12 weeks.
88942215|NCT01867840||arthritis|
88942216|NCT01867853||successful weaning|the SUCCESS of SBT or not need for reintubation or noninvasive ventilation within 48 h following extubation
88942217|NCT01867853||failed weaning|the failure of SBT or the need for reintubation or noninvasive ventilation within 48 h following extubation
88942218|NCT01867866|Experimental|TAS-102|
88942219|NCT01867866|Experimental|FTD (Trifluridine)|
88942220|NCT01867879|Experimental|TAS-102|
88942221|NCT01867879|Placebo Comparator|Placebo|
89460150|NCT05258955|Experimental|Natural honey|these group will received the honey base mouthwash and the its effect on plaque reduction will be observed in follow up visits
88942222|NCT01867892|Experimental|ICT of oxaliplatin,irinotecan,5-FU and leucovorinon and CCRT|Arm1:oxaliplatin,irinotecan,5-FU and leucovorinon D1,15 every 28days for 3 cycles,RT 5,040cGy in 28 fractions/5.5 wks and 5FU 450mg/m2 iv 30min weekly
88942223|NCT01867892|Active Comparator|ICT of gemcitabine,oxaliplatin,5-FU,leucovorin and CCRT|Arm 2:gemcitabine,oxaliplatin,5-FU,leucovorin on D1,15 every 28 days for 3 cycles,Evaluation of Tumor Response,CR/PR/SD or localized disease RT 5,040cGy in 28 fractions/ 5.5 wks Arm 2: Gem 400mg/m2 iv 40min weekly
88942224|NCT01867905||Severe sepsis and septic shock|Patients who present in severe sepsis or septic shock will have blood cultures taken before and after antibiotic administration. The antibiotic choice will be determined by the emergency physician and the patients will be treated as per routine hospital protocol. No therapeutic interventions will be administered.
88942225|NCT01867918|Experimental|Cheomotherapy and local treatment|Standard chemotherapy + local treatment
88942226|NCT01867918|Placebo Comparator|Cheomotherapy|Standard chemotherapy
88942227|NCT01867931||Erosive Esophagitis|
89460151|NCT05174260||hypotension developing group|Pregnant women who underwent elective C/S under spinal anesthesia with systolic arterial pressure below 90 mmHg or with hypotension symptoms such as dizziness, nausea and vomiting during the procedure.
89460152|NCT05174260||group without hypotension|Pregnant women who underwent elective cesarean section under spinal anesthesia whose systolic arterial pressure did not fall below 90 mmHg or did not have any symptoms of hypotension during the procedure.
89460153|NCT02391194|Experimental|AVB-620|Eligible subjects will receive a single dose of AVB-620 as an intravenous infusion before the surgical procedure.
89460154|NCT02391428|Experimental|Children who diagnosed with ADHD|The ADHD children will be asked to consume omega3 capsules for 6 months. Blood will be taken for omega3 analysis in day 0, after 3 and 6 months.
89460155|NCT02391428|Experimental|Control group of children without ADHD|"Blood test:~The control group of 30 children (age and gender match) without ADHD and related neuropsychiatric syndromes, who were hospitalized due to surgical or orthopedic problems. Only when blood will be taken for clinical purposes, the investigators will ask the children and their parents to allow the collection of an additional small blood tube."
89460156|NCT03034863|Experimental|SAFER|SAFER (Safe Actions for Families to Encourage Recovery): A novel, 5-session intervention to enhance currently mandated VA suicide safety planning by involving supporting partners to support its implementation. Incorporation of education about suicide risk factors and teaching communication skills of active listening and making a positive request will supply Veterans and supporting partners with the knowledge and tools needed to 1) identify potential warning signs, and 2) discuss Veteran ideation or partner concerns with assurance that such requests will be listened to with validation and support, creating an ally for the suicidal Veteran in his struggle. As discussed above, research has demonstrated compellingly that suicidal desire is motivated by two interpersonal factors; perceived burdensomeness and thwarted belongingness. SAFER aims to increase partner support for the Veteran to directly mitigate Veteran loneliness and sense of being a burden to others.
89460157|NCT03034863|Active Comparator|I-SPI|The comparison condition will be an assessment-only enhanced treatment-as-usual called the Individual Safety Planning Intervention (I-SPI), incorporating weekly scripted check-in phone calls to review mood symptoms and use of the safety plan, which will then be given as feedback to the Veteran's primary mental health provider.
89460158|NCT05173324|Experimental|3-doses HPV vaccination|Participants will receive three doses of HPV vaccine at 0, 2, and 6 months
89460159|NCT05173324|Experimental|1-dose HPV vaccination|Participants will receive HPV vaccine at entry, and placebo (HAV vaccine) at 2 and 6 months
89460160|NCT05173324|Placebo Comparator|Placebo|Participants will receive Hepatitis A (HAV) vaccine at 0, 2, and 6 months
89460161|NCT04223518|Active Comparator|Serum Bovine Immunoglobulin|Study product: Serum bovine immunoglobulin, also known by the trade name of Enteragam Dosage form: powdered packet Dosage: Each packet (10 g net weight) consists of 5 g of serum-derived bovine immunoglobulin/protein isolate (SBI) which is the active ingredient Frequency: one packet a day Duration: 60 days
89460162|NCT04223518|Placebo Comparator|Hydrolyzed Collagen|Placebo: hydrolyzed collagen Dosage form: powdered packet Dosage: 10 g of hydrolyzed collagen per packet Frequency: one packet a day Duration: 60 days
89460163|NCT03478995|Experimental|GX-I7|Determined dose of GX-I7 on Day1 of each cycle
88942228|NCT01867931||Non-erosive Reflux Disease|
88942229|NCT01867931||Heatlhy volunteers|
88942230|NCT01867944|Experimental|Perineal Self-Acupressure|Participants in this group (intervention group) will receive education in perineal self-acupressure in addition to education in conventional treatment options for constipation.
88942231|NCT01867944|Active Comparator|Educational Control|Participants in this group (the control group) will receive education in conventional treatment options for chronic constipation.
88942232|NCT01867957|Experimental|Low-dose GC1109|
89460164|NCT02387450|Active Comparator|Treated group|Sildenafil, oral, 100mg per day
89460165|NCT02387450|Placebo Comparator|Control group|placebo oral
88942233|NCT01867957|Placebo Comparator|Low-dose Placebo|
88942234|NCT01867957|Experimental|High-dose GC1109|
88942235|NCT01867957|Placebo Comparator|High-dose Placebo|
88942236|NCT01867970|Experimental|Tool + Self-management Support Program|"The system consists of three elements: a 3D accelerometer worn on the hip together with; an application (app) on a smartphone; a server and a website. The patient receives three types of feedback on the mobile phone concerning the amount of activity, the amount of activity in relation to an activity goal, and the response of a nurse based on the measured activity. Practice nurses will use a consultation approach to coach patients in their self-management regarding physical activity based on a five A's cycle counselling technique (assess-advise-agree-assist-arrange). Motivational interviewing, risk assessment, and goal setting are specific aspects of this approach.The patient comes to the practice four times: in the first week, after 2 weeks, after 8-12 weeks and after 16-24 weeks."
89460166|NCT04223440|Experimental|Postero-superior Rotator Cuff Tear|MRI, ultrasonographic explorations
89460167|NCT04223440|Other|Healthy Postero-superior Rotator Cuff|MRI, ultrasonographic explorations
89460168|NCT04458675|Experimental|Active|Activr capsule
89460169|NCT04458675|Placebo Comparator|Placebo|Placebo capsule
89460170|NCT04009395||Pregnant women|One-on-one in-depth interviewing
89460171|NCT04009395||Midwives|One-on-one in-depth interviewing or focus group discussions
89460172|NCT03473067|Experimental|Social Norms Marketing|This arm includes a social norms marketing campaign tailored to the school.
89460173|NCT03473067|Active Comparator|Capacity Building|This arm includes a series of teacher training, and parent engagement meetings, with the goal of building capacity to address violence in the school.
89017343|NCT00281606|Active Comparator|LPV/r (800/200 mg) 6 gel capsules|Once daily Lopinavir/ritonavir (800/200 mg) as 6 gel capsules
89460174|NCT00739401|Experimental|1|Test subjects requiring endovascular treatment of abdominal aortic or aorto-iliac aneurysms including a proximal cuff extension.
89460175|NCT02390882|Placebo Comparator|Placebo|Tamsulosin placebo (12 weeks)
89460176|NCT02390882|Experimental|Treatment 1|HGP0412 capsule (12 weeks)
89460177|NCT02390882|Experimental|Treatment2|HIP1402 capsule (12 weeks)
89460178|NCT02390570|Experimental|Implementation Arm|
89460179|NCT02387138|Experimental|SIRINOX|"S-1: Administered orally twice daily from day 1 for 7 consecutive days followed by a 7-day recovery period in a 14-day cycle.~The starting dose of S-1 will be two levels below the recommended dose defined in SIRI (20 mg/m² BID minimum) with a cohort dose escalation by 5 mg/m² increments (5 dose levels).~Irinotecan : fixed dose of 180 mg/m² IV over 90 minutes on d1 of every cycle Oxaliplatin : fixed dose of 85 mg/m² over 120 minutes on d1 of every cycle G-csf : d8 to d13 systematically"
89460180|NCT05258643|Other|Covid-19 patients|Whole blood and serum samples will be collected during acute disease (inclusion and 7 days after inclusion) and during patient follow-up at 2 months after infection
89460181|NCT05258643|Other|Controle|Whole blood and serum samples will be collected during the same period
89460182|NCT02386982|Experimental|HMS5552 dose 1|HMS5552 75mg.Oral administration,twice per day.
89460183|NCT02386982|Experimental|HMS5552 dose 2|HMS5552 75mg.Oral administration,once per day.
89460184|NCT03418857|Experimental|Experimental|Participants will consume one yogurt smoothie daily for the duration of the intervention that contains 3.16 × 109 colony forming units (CFU) bifidobacterium animalis subsp. lactis BB-12. Participants will be asked to refrain from consumption of other yogurt or probiotic-containing foods.
89460185|NCT03418857|Placebo Comparator|Control|Participants will consume one yogurt smoothie daily for the duration of the intervention that contains no BB-12. Participants will be asked to refrain from consumption of other yogurt or probiotic-containing foods.
89460186|NCT02387060|Experimental|H-Bupivacaine 11.5 mg + fentanyl 25 mcg.|Intrathecal administration of Hyperbaric Bupivacaine 1.5 ml 0.75% plus fentanyl 25 mcg.
89460187|NCT02387060|Active Comparator|H-Bupivacaine 11.5 mg.|Intrathecal administration of Hyperbaric Bupivacaine 1.5 ml 0.75%
89460188|NCT01365052|Experimental|Naproxen sodium 440 mg/DPH 50 mg (BAY98-7111)|
89460189|NCT01365052|Placebo Comparator|Placebo|
89460190|NCT05155215|Experimental|IM19 CAR-T cells|
89460191|NCT03471585|Placebo Comparator|Placebo oral capsule|Participants came in for the first session that involved encoding emotional pictures and lists of semantically related words (Deese-Roediger-McDermott or DRM task; a false memory task). Forty-eight hours later, participants received a placebo capsule (dextrose) and waited 2 hours Participants were monitored for the next 2 hours including physiological and subjective measures every 30 minutes. After 2 hours, participants' memory for the emotional stimuli and DRM stimuli was tested. Participants then encoded object stimuli overlaid onto scenes followed by a working memory test with simple color squares. After the memory tests and 3.5 hours post-capsule, if participants' physiological and subjective measures had returned to baseline, they were allowed to leave. Forty-eight hours later, memory for the object-scene stimuli was tested. Other than the capsule, this arm was identical to the THC arm.
88942237|NCT01867970|Experimental|Self- management Support Program|"Practice nurses will use a consultation approach to coach patients in their self-management regarding physical activity based on a five A's cycle counselling technique (assess-advise-agree-assist-arrange). Motivational interviewing, risk assessment, and goal setting are specific aspects of this approach.The patient comes to the practice four times: in the first week, after 2 weeks, after 8-12 weeks and after 16-24 weeks."
88942238|NCT01867970|No Intervention|Care as usual|Patients attend the practice regularly: at least once a year for a consultation with the GP. In addition, COPD patients have consultations (15-30 minutes) with the practice nurse once or twice a year. Most patients with diabetes type 2 see the GP ones per year and the practice nurse three times per year for a health check.Normally, physical activity is not high on the agenda during consultations with the practice nurse. Barriers for paying attention are the competition with other topics that should also be covered during consultations, co-morbidity and limitations of patients, and the assumption of most practice nurses that nowadays the patient decides on the topics of the consultation. All interviewees agreed that many patients do not perceive physical activity as an important issue.
88942239|NCT01867983|Active Comparator|Control|Behavioral: Smoking cessation
88942240|NCT01867983|Experimental|Simultaneous|Behavioral: Weight gain prevention and smoking cessation
88942241|NCT01867983|Experimental|Sequential|Behavioral: Weight gain prevention and smoking cessation
88942242|NCT01867996|Experimental|Retosiban and EFZ|All subjects will receive on Day 1, a 6 mg bolus of retosiban for 5 min, followed by a 6 mg/hr infusion for 12 hrs. On Day 2 a washout day will occur. On Days 3-17, subjects will receive EFZ 600 mg OD dose of in the evening. On Day 18, subjects will receive a 6 mg bolus of retosiban for 5 mins, followed by a 6 mg/hr infusion for 12 hrs plus a 600 mg dose of EFZ.
88942243|NCT01868048|Experimental|Sativex|"Contains delta -9 tetrahydrocannabinol (THC), 27 mg/mL:cannabidiol (CBD), 25 mg/mL, in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring.~Subjects received study medication delivered in 100 microlitre actuations by a pump action oromucosal spray. Maximum permitted dose is 10 actuations per day. Each actuation delivers THC 2.7 mg and CBD 2.5 mg."
88942244|NCT01868048|Placebo Comparator|Placebo|Oromucosal spray, containing no active drug but ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring and colorants. Maximum permitted dose is 10 actuations per day.
88942245|NCT01868061|Experimental|Lebrikizumab (125 mg)|Participants will receive SC injection of lebrikizumab (125 mg) every 4 weeks for 104 weeks.
88942246|NCT01868061|Experimental|Lebrikizumab (37.5 mg)|Participants will receive SC injection of lebrikizumab (37.5 mg) every 4 weeks for 104 weeks.
88942247|NCT01868061|Placebo Comparator|Placebo|Participants will receive SC injection of lebrikizumab matching placebo every 4 weeks for 52 weeks during placebo-controlled period and then SC injection of lebrikizumab at 125 or 37.5 mg for 52 weeks during active treatment extension period.
88942248|NCT01868087|Experimental|Impact Advanced Recovery®|3 briks daily (240 mL per brik) of Impact Advanced Recovery® to be take for 5 days before and after RC surgery
88942249|NCT01868087|Placebo Comparator|Boost Plus®|3 briks daily (240 mL per brik) of Boost Plus® to be take for 5 days before and after RC surgery
88942250|NCT01868100|No Intervention|self-completion questionnaire|
88942251|NCT01868113|Active Comparator|Inhaled fluticasone propionate|Inhaled corticosteroid
88942252|NCT01868113|Placebo Comparator|Inhaler propellant|Placebo
88942253|NCT01868126|Experimental|Group 1: DE-117 ophthalmic solution|One drop DE-117 Low Dose in each eye daily for 28 days
88942254|NCT01868126|Experimental|Group 2: DE-117 ophthalmic solution|One drop DE-117 Low Middle Dose in each eye daily for 28 days
88942255|NCT01868126|Experimental|Group 3: DE-117 ophthalmic solution|One drop DE-117 High Middle Dose in each eye daily for 28 days
88942256|NCT01868126|Experimental|Group 4: DE-117 ophthalmic solution|One drop DE-117 High Dose in each eye daily for 28 days
88942257|NCT01868126|Active Comparator|latanoprost ophthalmic solution|One drop latanoprost 0.005% in each eye daily for 28 days
88942258|NCT01868126|Placebo Comparator|placebo (vehicle of DE-117) ophthalmic solution|One drop DE-117 vehicle in each eye once daily for 28 days
88942259|NCT01868178||BIS Spectral Entropy Group|intraoperative monitoring with BIS and Spectral Entropy
88942260|NCT01868191|Placebo Comparator|Placebo for benfotiamine|Placebo for benfotiamine 600 mg/day for the first 3 months followed by 300 mg/day for 9 months
89501855|NCT04480359|Active Comparator|Bawei Shenqi group|participants should administrate both Bawei Shenqi Pill and Meloxicam tablets
89460192|NCT03471585|Experimental|THC|Participants came in for the first session that involved encoding emotional pictures and lists of semantically related words (Deese-Roediger-McDermott or DRM task; a false memory task). Forty-eight hours later, participants received a placebo capsule (dextrose) and waited 2 hours Participants were monitored for the next 2 hours including physiological and subjective measures every 30 minutes. After 2 hours, participants' memory for the emotional stimuli and DRM stimuli was tested. Participants then encoded object stimuli overlaid onto scenes followed by a working memory test with simple color squares. After the memory tests and 3.5 hours post-capsule, if participants' physiological and subjective measures had returned to baseline, they were allowed to leave. Forty-eight hours later, memory for the object-scene stimuli was tested. Other than the capsule, this arm was identical to the placebo arm.
89460193|NCT02386904|Experimental|Phosphate Enema|Phosphate Enema consisting on Monobasic Sodium Phosphate (USP) 19.2 gm /120 ml and Dibasic Sodium Phosphate (USP) 7.2 gm/120 ml Dosage Form: Enema Frequency: One time; 30 minutes before Sigmoidoscopy
89460194|NCT05171608|Experimental|Ultrasound-based protocol group (USP)|Preoperative intravenous (IV) fluid therapy is order according to the result of the preoperative ultrasound scans of the inferior vena cava and the lungs (2 hours and 30 minutes before surgery)
89460195|NCT05171608|No Intervention|Conventional fluid therapy|Preoperative IV fluid therapy (isotonic, balanced crystalloid infusion, if any) is determined by the discretion of the attending anesthesiologist.
89017344|NCT00311103|No Intervention|Care in the Control Group (CG)|Care in the Control Group (CG): was that provided by the General Practitioners, with basic diagnostic and therapeutic procedures without specified protocols.
89460196|NCT02523261|Experimental|ADAPT|
89460197|NCT02523261|Active Comparator|Stent Retriever|
89460198|NCT05072782|Other|Status quo arm|"If the patient received no prophylactic therapy after resection, no treatments will be started.~If the patient received a prophylactic therapy after resection, the same will be continued at the same dose."
89460199|NCT05072782|Experimental|Therapy escalation arm|Infliximab-CT-P13 will be started with two intravenous infusions of 5 mg per kg bodyweight at week 0 and week 2 and subcutaneous injections of 120 mg every 2 weeks from week 6 onwards.
89460200|NCT03379389|Experimental|Methenamine + Methylthioninium|Dosage: Methenamine (120mg) + Methylthioninium (20mg) Dosage form: coated tablets Frequency: 2 coated tablets twice daily Duration: 6 days
89460201|NCT03379389|Active Comparator|Methenamine+Methylthioninium+Acriflavine+Atropa belladona|Dosage: Methenamine (250mg) + Methylthioninium (20mg) + Acriflavine hydrochloride (15mg) + Atropa belladonna L. (15mg) Dosage form: coated tablets Frequency: 2 coated tablets twice daily Duration: 6 days
89460202|NCT03471429||Dog|Patient sees therapy dog for 15 minutes, which is standard of care at this hospital.
89460203|NCT03471429||No Dog|Patient receives standard of care
89460204|NCT01372748|Active Comparator|Standard CPR|American Heart Association (AHA)recommended cardiopulmonary resuscitation (CPR) of 30 compressions with brief pause for 2 ventilations
89460205|NCT01372748|Experimental|Continuous chest compressions|Continuous compression CPR
89460206|NCT05109520||investigational group|Participants of the FUTURE study who switched during the study to Gla-300
89460207|NCT05109520||control group|Participants of the FUTURE study who did not switch to Insulin Gla-300
89460208|NCT03478605|Experimental|Olanzapine|Olanzapine 5 mg/day p.o. d 0-4 + ondansetron 16 mg IV d 1 + dexamethasone 12 mg IV d 1, 8 mg b.i.d.; IM or P.O. d 2-4;
89460209|NCT03478605|Active Comparator|Aprepitant|Aprepitant 125 mg p.o d 1 + 80 mg p.o d 2,3 + ondansetron 16 mg IV d 1 + dexamethasone 12 mg IV d 1, 8 mg b.i.d. IM or P.O. d 2-4;
89460210|NCT03478527|Experimental|verum condition probiotics|The verum condition probiotics in the present study is a freely available product, Vivomixx® powder (dietary supplement). Each dose (4.4g) contains 450 billion bacteria, composed of eight bacterial strains: Lactobacilli (L. paracasei, L. plantarum, L. acidophilus, L.delbrueckii subsp. bulgaricus), Bifidobacteria (B. longum, B. infantis, B. breve), and Streptococcus thermophiles. 30 Participants will be randomly assigned to this condition. The intake period is 28 days, daily dose = 4.4g.
89460211|NCT03478527|Placebo Comparator|placebo condition|In the placebo condition participants will receive a placebo powder (comparable in taste and consistency to Vivomixx® = verum condition probiotics) that contains no probiotic bacteria. 30 Participants will be randomly assigned to that condition. The intake period is 28 days, daily dose = 4.4g.
89460212|NCT03673475||fluid responsiveness|Assessment of fluid responsiveness using pleth variebility index and jugular vein distensibility in patients undergoing major abdominal surgery
89460213|NCT02386748|Experimental|Chewing gum|Chewing sugarless gum
88942261|NCT01868191|Experimental|Benfotiamine|Treatment with benfotiamine 600 mg/day for 3 months followed by 300 mg/day for 9 months
88942262|NCT01868256|Experimental|Early discharge (< 72 h)|Patients randomized the early discharge group will be discharged from the hospital in < 72 hours
89460214|NCT02386748|Active Comparator|Oral fluids|Clear oral fluids
89460215|NCT02386748|Other|Intravenous fluids|No chewing gum No oral fluids Only intravenous fluids (Lactated Ringer's solution)
89460216|NCT05054062|Experimental|Healthy participants|
88942263|NCT01868256|Active Comparator|Conventional discharge|Patients randomized to the conventional discharge group will be discharged according to the local hospital protocol and/or treating physician criterion
88942264|NCT01868282|Experimental|Group 1|Hamstrings block
88942265|NCT01868282|Active Comparator|Group 2|Obturator block
88942266|NCT01868282|Sham Comparator|Group 3|Control group
88942267|NCT01868295|Experimental|Sleeping with denture|Sleeping with denture at night
88942268|NCT01868295|No Intervention|Sleeping without denture|Sleeping without denture at night
88942269|NCT01868308||Preterm Labor|"Symptomatic women with singleton pregnancy at high risk for preterm birth between 22 - 33 6/7 weeks gestational age. We define high risk for preterm birth as women who present to our triage unit with complaints of preterm labor, including but not limited to preterm contractions, abdominal cramping, back pain, vaginal pressure, and vaginal bleeding."
88942270|NCT01868321||Mechanical Ventilation|Patients under mechanical ventilation in the ICU
88942271|NCT01868347|Active Comparator|control|PEEP after pneumoperitoneum and trendelenburg
88942272|NCT01868347|Experimental|Treatment|preemptive PEEP before pneumoperitoneum and trendelenburg
89201720|NCT02538393|Experimental|Treatment C-D-A-B|Subjects received a single oral dose of 200 mg sorafenib tablets for oral suspension (2 * 100 mg) in fasting state (Treatment C) in the first intervention period; followed by a single oral dose of 400 mg sorafenib tablets for oral suspension (4 * 100 mg) after a high-fat, high-calorie breakfast (fed state) (Treatment D) in the second intervention period; followed by a single oral dose of 400 mg sorafenib marketed tablets (2 * 200 mg) in fasting state (Treatment A) in the third intervention period; and then a single oral dose of 400 mg sorafenib tablets for oral suspension (4 * 100 mg) in fasting state (Treatment B) in the fourth intervention period. A washout period of at least 10 days was maintained between sorafenib administrations.
89460217|NCT02736825|Active Comparator|Group A, Ulthera System with standard transducers|"Subjects randomized to Group A will receive an Ultherapy® treatment to the lower face and neck with a total minimum pulse count of 672 pulses (+5%) at the 4.5mm and 3.0mm depths using standard transducers. Energy levels for each transducer will be set to EL2:~Deep-See (DS) 4-4.5 at 0.9 Joules (J) with pitch of 1.5mm and 17 Thermal Coagulation Points (TCP)s per line~DS 7-3.0 at 0.30J with pitch of 1.1mm and 23 TCPs per line"
89460218|NCT02736825|Experimental|Group B, Ulthera System with prototype 2 simulines transducers|"Subjects randomized to Group B will receive a Ultherapy® treatment with a total minimum pulse count of 336 pulses (+5%) using the prototype 2 simulines transducers at the 4.5mm and 3.0mm depths. Energy levels for each transducer will be set to EL2:~Deep-See 4-4.5 Simulines (DS 4-4.5S) at 1.23J with pitch of 1.5mm and 17 TCPs per line~DS 4-3.0S at 0.88J with pitch of 1.3mm and 20 TCPs per line"
89460219|NCT04439708||Group 1|Patients with choroidal neovascularization in the context of age-related macular degeneration or central serous chorioretinopathy
89460220|NCT04439708||Group 2|Control group : patients without choroidal neovascularization
89460221|NCT02390804|Experimental|single-port laparoscopic hysterectomy|total laparoscopic hysterectomy via transumbilical single port
89460222|NCT02390804|Active Comparator|multi-port laparoscopic hysterectomy|total laparoscopic hysterectomy via multi-port (3 port)
89460223|NCT05071066|Experimental|Group-based ADHD+ Treatment|"This randomized controlled trial (RCT) will run in multi-sites including 5 non-governmental organizations (NGOs) in Hong Kong. Core treatment components are developed by an expert group comprised of psychiatrists and clinical psychologists including internet use/addiction intervention, cognitive training, etc.~The main intervention lasts for 3 months, and the booster intervention lasts for another 3 months."
89460224|NCT05071066|Other|wait-list control group|For participants in the waiting list control group, they will receive 1-3 hours psychoeducation during the 3 months wait period. Appropriate intervention will be offered after the treatment group.
89460225|NCT05672498|Active Comparator|TCM treatment|The patients are treated with traditional Chinese medicine. They take 150ml of liquid medicine every morning and evening for 7 days.
89460226|NCT05672498|Placebo Comparator|placebo treatment|The patients are treated with placebo. They take 150ml of liquid placebo every morning and evening for 7 days .
89460227|NCT03478449|Experimental|Fine sorting lymph node group|
89460228|NCT03478449|No Intervention|Regional sorting lymph node group|
89460229|NCT05258799|Experimental|lderly Patients With Acute Myeloid Leukemia|decitabine (15 mg/m2 daily, days 1-5); low-dose cytarabine (10 mg/m2 q12 h, days 3-9); rhTPO (15,000 U daily, days 2, 4, 6, 8, and 10-24 or until a platelet count > 50 × 109/L was observed); aclarubicin (14 mg/m2 daily, days 3-6); and G-CSF (300 μg daily, days 2-9).
89460230|NCT02670122||Patients with non resectable HCC|DEB-TACE with doxorubicin eluting 100 µ microspheres
89460231|NCT02390648|Experimental|Ginger|Ginger capsule (500 mg) taking twice a day by mouth during the first 5 days of chemotherapy cycle
89460232|NCT02390648|Placebo Comparator|Placebo|Placebo capsule taking twice a day by mouth during the first 5 days of chemotherapy cycle
89460233|NCT04233892|Experimental|CBD-bFGF|
89460234|NCT04233892|Experimental|Collagen/BMMNCs|
89460235|NCT04233892|Experimental|Estrogen|
89460236|NCT02386358|Active Comparator|Benznidazole|Benznidazole pills of 100 mg, dose 5 mg/Kg/day, twice a day during 60 days
89460237|NCT02386358|Placebo Comparator|Placebo|Placebo pills 100 mg, dose 5mg/Kg/day, twice a day, during 60 days
89460238|NCT05053204||unipolar depression group|In accordance with the diagnostic criteria of ICD-10 Unipolar depressive disorder, outpatients or inpatients in the Department of mood Disorders, Mental Health Center of Pudong New area.
89460239|NCT05053204||bipolar depression group|In accordance with the diagnostic criteria of ICD-10 Bipolar depression , outpatients or inpatients in the Department of mood Disorders, Mental Health Center of Pudong New area.
89460240|NCT05053204||healthy control group|Any mental disorder that does not meet the diagnosis of ICD-10, and the society recruits healthy controls who match the sex, age and education level of the patients in the case-group.
89460241|NCT02390726|Sham Comparator|Control|Sham FMT and Sham Microbial Maintenance plus standard therapy
89460242|NCT02390726|Experimental|Treatment|FMT and microbial maintenance plus standard therapy
89460243|NCT03283371|Experimental|Natalizumab 300 mg|Participants will undergo a prospective baseline period of 6 weeks (Weeks -6 to 0) followed by placebo controlled phase to receive natalizumab 300 mg intravenous (IV) infusion every 4 weeks from Week 0 to Week 24. Participants will continue to receive natalizumab 300 mg IV infusion every 4 weeks for up to an additional 24 weeks in open label phase.
89460244|NCT03283371|Placebo Comparator|Placebo|Participants will undergo a prospective baseline period of 6 weeks (Weeks -6 to 0) followed by placebo controlled phase to receive natalizumab matching placebo intravenous (IV) infusion every 4 weeks from Week 0 to Week 24. Participants will then receive natalizumab 300 mg IV infusion every 4 weeks for 24 weeks in open label phase.
89460245|NCT05069350|Experimental|bupivacaine 0.5%|
89460246|NCT05069350|Experimental|oxybuprocaine|
89460247|NCT03471351|Experimental|Tenalisib+Pembrolizumab|Participants receive Tenalisib in escalating doses Orally BID and pembrolizumab as a fixed dose intravenously (IV) in Escalation and Expansion.
89460248|NCT02386280|Experimental|Motivational Interviewing for Change of Parenting Styles|After measured parental style across the scale, the motivational interviewing will be applied in order to modify the parenting styles of risk for involvement with drug use and maintenance of protective factors. This approach will occur in 5 segments .
89460249|NCT02386280|Sham Comparator|Psicoeducation|General information about drugs and ways of prevention
89460250|NCT02386436|Experimental|Cohort 1- GSK2330811(0.1 mg/kg)|Subjects will be randomised to receive either 0.1 mg/kg GSK2330811 or placebo s.c single dose in a 3:1 ratio.
89460251|NCT02386436|Experimental|Cohort 2- GSK2330811(0.3 mg/kg)|Subjects will be randomised to receive either 0.3 mg/kg GSK2330811 or placebo s.c single dose in a 3:1 ratio.
89460252|NCT02386436|Experimental|Cohort 3- GSK2330811(1 mg/kg)|Subjects will be randomised to receive either 1 mg/kg GSK2330811 or placebo s.c single dose in a 3:1 ratio.
89460253|NCT02386436|Experimental|Cohort 4- GSK2330811(3 mg/kg)|Subjects will be randomised to receive either 3 mg/kg GSK2330811 or placebo s.c single dose in a 3:1 ratio.
89460254|NCT02386436|Experimental|Cohort 5- GSK2330811(6 mg/kg)|Subjects will be randomised to receive either 6 mg/kg GSK2330811 or placebo s.c single dose in a 3:1 ratio.
89460255|NCT05154435|Active Comparator|Grup HYT|The group (GRUP HYT) to be treated with targeted fluid therapy will be monitored with a Mostcaretm (Vygon, VytechHealth, Padova, Italy) pulse contour hemodynamic monitor after arterial cannulation. Cardiacindex (CI), stroke volume variance (SVV), pulse pressure variance (PPV), systemic vascular resistance (SVR), systemic vascular resistance index (SVRI), oxygen delivery (Do2), arterial elastance (Ea) measurements and mean arterial pressure Every 5 minutes to be followed, fluid therapy will be planned in accordance with our algorithm.
89460256|NCT05154435|No Intervention|Grup KON|Fluid deficit due to fasting time will be calculated in accordance with the 4-2-1 rule for patients in Group KON. half of the calculated fluid volume in the first hour; the remaining half will be given at the 2nd and 3rd Hours. (4ml/kg/hr for the first 10 kilograms, 2ml/kg/hr for the second 10 kg, 1ml/kg/hr for each subsequent kilogram). Maintenance fluid will be considered as a medium-sized surgical trauma and will be given at 4 ml/kg/hr. Hemorrhages will be replaced with 3 times the blood loss with balanced crystalloid or 1 times HES.
89460257|NCT02386592|Experimental|Intervention|Infection control package consisting of alcohol hand rub hand hygiene (HH), 2% chlorhexidine gluconate (CHG) body washes, infection control training, and text messages with basic Infection control reminders via SMS text
88942273|NCT01868360|Experimental|Group A subconjunctival aflibercept|"Patients will receive 2mg (0.05mL) subconjunctival aflibercept injection in addition to standard of care treatment (steroids and cyclosporine). Patients will receive one injection four weeks (+/- 1 week) prior to transplantation. They will receive a second injection at the conclusion of corneal transplantation.~Patients may receive as-needed repeat injections (minimum of 30 days in between treatments) for recurrence of corneal neovascularization (defined as >1.0 mm crossing onto the cornea, past the limbus, or extension of vessels beyond previously documented extent) during the follow-up period."
88942274|NCT01868360|Placebo Comparator|Group B: Standard of care only|Patients will receive standard of care (steroids and cyclosporine) treatment only.
88942275|NCT01868386|Experimental|Dose Level 1|Hypofractionated therapy, 26 treatments at 2.5 Gy
88942276|NCT01868386|Experimental|Dose Level 2|Hypofractionated therapy, 20 treatments at 2.83Gy
88942277|NCT01868386|Experimental|Dose Level 3|Hypofractionated therapy,15 treatments at 3.36 Gy
88942278|NCT01868386|Experimental|Dose Level 4|Hypofractionated therapy, 10 treatments at 4.26 Gy
88942279|NCT01868399||Suspected dengue fever subjects|No any intervention
88942280|NCT01868399||Community Healty Residents|No intervention
88942281|NCT01868412|Experimental|Resin & honey|Abilar 10% resin salve
88942282|NCT01868412|Active Comparator|Resin vs. honey|Activon Tube 25 g
88942283|NCT01868464|Experimental|BCG 16x10^6 CFU|30 subjects, one dose of Tice BCG intradermally, 16x10^6 cfu
88942284|NCT01868464|Experimental|BCG 2x10^6 CFU|30 subjects, one dose of Tice Bacillus Calmette-Guerin vaccine (BCG) intradermally, 2x10^6 colony forming units (cfu)
88942285|NCT01868464|Experimental|BCG 4x10^6 CFU|30 subjects, one dose of Tice BCG intradermally, 4x10^6 cfu
88942286|NCT01868464|Experimental|BCG 8x10^6 CFU|30 subjects, one dose of Tice BCG intradermally, 8x10^6 cfu
88942287|NCT01868490|Experimental|drug|single-group studies
88942288|NCT01868529|Experimental|Low dose|
88942289|NCT01868529|Experimental|Medium dose|
88942290|NCT01868529|Experimental|High dose|
89206161|NCT02548572|Placebo Comparator|Sham group|Subjects in the Sham group will wear the OkuSpex and OkuEl (applied to cornea upon the lower lid) and be attached to the OkuStim device in the same manner as the treatment group, but will receive no electrical stimulation for the 30 minutes that the TES fiber is applied to the cornea (even though the device has been turned on) once a week for fifty-two weeks
89206162|NCT00524368|Experimental|DRV/rtv 800/100 mg once daily|Two 400 mg darunavir (DRV) ie, TMC114 tablets + one 100 mg ritonavir (rtv) capsule once daily.
89501856|NCT04480359|Placebo Comparator|placebo group|participants should administrate both Bawei Shenqi Pill placebo and Meloxicam tablets
88942291|NCT01868555|Experimental|IDegAsp 30|
88942292|NCT01868555|Experimental|IDegAsp 45|
88942293|NCT01868555|Experimental|insulin degludec (B)|
88942294|NCT01868555|Experimental|insulin degludec (E)|
88942295|NCT01868568|Experimental|IDegAsp 30 + placebo|
88942296|NCT01868568|Experimental|Insulin aspart + insulin degludec - low concentration 1|
88942297|NCT01868568|Experimental|IDegAsp 40 + placebo|
88942298|NCT01868568|Experimental|Insulin aspart + insulin degludec - high concentration 1|
88942299|NCT01868568|Experimental|IDegAsp 45 + placebo|
88942300|NCT01868568|Experimental|Insulin aspart + insulin degludec|
88942301|NCT01868568|Experimental|IDegAsp 55 + placebo|
88942302|NCT01868568|Experimental|Insulin aspart + insulin degludec - high concentration|
88942303|NCT01868568|Active Comparator|BIAsp 30 + placebo|
88942304|NCT01868581|Experimental|insulin degludec|
88942305|NCT01868581|Experimental|IDegAsp|
88942306|NCT01868607||Adult lung function|
88942307|NCT01868620|Experimental|Iontophoretic CXL|The iontophoretic CXL involves a constant current source and two electrodes. The main electrode is a circular cup, with a surrounding annular suction ring to affix the device on the cornea during the procedure. The electrode itself is a stainless steel grid, placed into the cup at a minimal distance from the cornea. The reservoir is filled with riboflavin solution. The generator applies a constant current of 1mA for a preset period of 5 min. After the riboflavin administration by iontophoresis, the cornea is irradiated by a UVA light for 3mW/cm2 during 30 minutes.
89460258|NCT02390180||Sorting all tastes|This group will receive 15 samples to taste and sort into groups. The samples included: a blank solution, hexenoic acid, decenoic acid, oleic acid, linoleic acid, glucose, fructose, sodium chloride (2), citric acid, acetic acid, quinine, urea, monosodium glutamate, and inosine monophosphate.
89017345|NCT00311103|Experimental|Early Intervention Programa (IG)|Early Intervention Programa (IG): Patients assigned to the intervention group after the randomization were offered an immediate appointment. Patients, who voluntarily accepted, were attended by 2 rheumatologists. The rheumatologists acted as principal care providers in regular visits, home visits and phone contacts. The visits were structured following specific proceedings for the different diagnoses based on previously demonstrated approaches. Such protocols included education and promotion of independence, pharmacological and no pharmacological treatment, and timing of diagnostic tests in a stepwise manner. The program also incorporated administrative duties such as the prescription of medication for the patients. Patients were seen as often as necessary according to the medical rheumatologist decision (until the episode of disability was medically resolved).
89017346|NCT02960789|Experimental|Dehydrated Children|"Children between the ages of 2 to 18 years of age presenting to the Emergency Department at Children's Hospital Boston with complaints such as Dehydration, Gastroenteritis, Vomiting, and or Intolerance of POs be approached by study personnel for possible participation in the study.~Interventions:~Undertake and record a formalized clinical assessment of hydration status~Take a measurement of body weight on calibrated scales~RF wristband hydration status measurement~Measure capillary refill time with manual stopwatch~CRT device hydration status measurement"
89017347|NCT00282035|Experimental|APBI utilizing 3D-CRT radiation|Accelerated partial breast irradiation utilizing 3D-CRT
89017348|NCT00282035|Other|Whole breast irradiation|Whole breast irradiation
89017349|NCT00311298|Placebo Comparator|No micronutrients|Biscuit without additional micronutrients
89017350|NCT00311298|Experimental|Micronutrients|Biscuit with additional micronutrients
89017351|NCT00311298|Active Comparator|1 biscuit|1 biscuit with micronutrients
89017352|NCT00311298|Experimental|6 biscuits|1 biscuit with micronutrients, plus 5 biscuits without additional micronutrients
89017353|NCT00282425|Experimental|Allogeneic Hematopoietic stem cell transplantation|Allogeneic Hematopoietic stem cell transplantation will be performed on eligible patients
89017354|NCT00282503|Active Comparator|methylprednisolone equivalent.|2mg/kg daily will be administered initially and may be tapered according to a tapering schedule provided in the protocol.
89017355|NCT00282503|Experimental|Uvadex+ECP|"Those patients randomized to the ECP Treatment arm will receive ECP treatments by the following regimen:~Weeks 1 through Week 3 - 3 times within each week. (Treatments do not have to be performed on consecutive days but should be completed within the 7-day period),~Weeks 4 through 12 - 2 times each week. (It is preferable that patients receive ECP treatments on consecutive days"
89017356|NCT00311415|Experimental|Group 1: 2+4 Months (2-doses)|
89017357|NCT00311415|Experimental|Group 2: 2 Months (1-dose)|
89017358|NCT00311415|Experimental|Group 3: 6 Months (1-dose)|
89017359|NCT00311415|Active Comparator|Group 4: 12-16 Months (1 dose in the second year of life)|
89017360|NCT00317889|Experimental|Compaction|Compaction technique for femoral bone preparation prior to cementless femoral stem insertion.
89017361|NCT00317889|Active Comparator|Broaching|Broaching technique for femoral bone preparation prior to cementless femoral stem insertion.
89017362|NCT00282581|Placebo Comparator|placebo|
89017363|NCT00317967|Experimental|1|Atorvastatin
89017364|NCT00317967|Placebo Comparator|2|Placebo
89460259|NCT02390180||Sorting bitter tastes|This group will receive 12 samples to taste and sort into groups. The samples included: blank solutions (2), decenoic acid, oleic acid, linoleic acid, quinine (2), urea (2),caffeine, sucrose octaacetate, and propylthiouracil.
89460260|NCT05138679||Acute lower limb ischemia|Patients with acute lower limb ischemia (older than 18 years)
89460261|NCT02390258|Experimental|Part 1: Single Ascending Dose - Cohort 1|8 subjects (6 receiving 10mg XEN-D0103, 2 receiving placebo)
89460262|NCT02390258|Experimental|Part 1: Single Ascending Dose - Cohort 2|8 subjects (6 receiving 30mg XEN-D0103, 2 receiving placebo)
89460263|NCT02390258|Experimental|Part 1: Single Ascending Dose - Cohort 3|8 subjects (6 receiving 60mg XEN-D0103, 2 receiving placebo)
89017365|NCT00318006|Active Comparator|Spray|subjects were instructed in the technique of nasal lavage (irrigation group) or nasal saline spray (spray group) and were asked to do the assigned treatment twice daily for 8 weeks. They were provided with an 8-week supply of materials (Sinus Rinse irrigations from NeilMed Products Inc, and Deep Sea nasal saline spray distributed by Major Pharmaceuticals, Livonia, Michigan).
89017366|NCT00318006|Experimental|Irrigation|subjects were instructed in the technique of nasal lavage (irrigation group) or nasal saline spray (spray group) and were asked to do the assigned treatment twice daily for 8 weeks. They were provided with an 8-week supply of materials (Sinus Rinse irrigations from NeilMed Products Inc, and Deep Sea nasal saline spray distributed by Major Pharmaceuticals, Livonia, Michigan).
89017367|NCT00282776|Active Comparator|TAU|Participants will receive treatment as usual
89017368|NCT00282776|Experimental|DCM|Participants will receive care management for postpartum depression
89017369|NCT00282893|Experimental|pTBA|Prophylactic Transluminal Ballooning Angioplasty
89017370|NCT00282893|Active Comparator|Control|currently existing therapies for the treatment of vasospasm
89017371|NCT00318123|Experimental|A|Abacavir 600mg + lamivudine 300mg in on table QD + efavirenz 600mg QD
89017372|NCT00318123|Experimental|B|Abacavir 600mg + lamivudine 300mg in ine tablet QD * lopinavir/ritonavir 400/100 mg BID
89017373|NCT00283088|Active Comparator|Group 1|Groups 1 and 2: Parallel groups, randomized to hypothermia or no hypothermia. Both groups receive tPA as a part of standard of care.
89017374|NCT00283088|Active Comparator|Group 2|Groups 1 and 2: Parallel groups, randomized to hypothermia or no hypothermia. Both groups receive tPA as a part of standard of care.
89460264|NCT02390258|Experimental|Part 1: Single Ascending Dose - Cohort 4|8 subjects (6 receiving 120mg XEN-D0103, 2 receiving placebo)
89460265|NCT02390258|Experimental|Part 1: Single Ascending Dose - Cohort 5|8 subjects (6 receiving 200mg XEN-D0103, 2 receiving placebo)
89460266|NCT02390258|Experimental|Part 2: Fed-Fasted|17 subjects receiving 200mg XEN-D0103 with either a high fat meal or following an overnight fast.
89460267|NCT02390258|Experimental|Part 3: Multiple Ascending Dose - Cohort 1|10 subjects (8 receiving 30mg XEN-D0103 twice daily, 2 receiving placebo twice daily)
89460268|NCT02390258|Experimental|Part 3: Multiple Ascending Dose - Cohort 2|10 subjects (8 receiving 60mg XEN-D0103 twice daily, 2 receiving placebo twice daily)
89460269|NCT02390258|Experimental|Part 3: Multiple Ascending Dose - Cohort 3|10 subjects (8 receiving 150mg XEN-D0103 once daily, 2 receiving placebo once daily)
89460270|NCT03069417|Experimental|Intervention: INSPireD|"This 5-8 session group intervention, Integrating Nuanced Support for Perinatal adherence and Depression, aimed to decrease depressive symptoms and improve antiretroviral adherence among HIV-infected pregnant and postpartum women. Intervention content was based on two established cognitive-behavioral interventions: problem-solving therapy and Cognitive Behavioral Therapy for Adherence and Depression."
88942308|NCT01868620|Active Comparator|Standard CXL|In the standard CXL, the epithelium is mechanically removed. Then, a solution of riboflavin is instilled each minute for 30 minutes. Corneas are irradiated by a UVA light for 3mW/cm2 during 30 minutes.
89460271|NCT03069417|Other|Treatment-as-usual + abbreviated intervention|This group received treatment-as usual, plus the option of completing an abbreviated version of the intervention (one session of problem-solving related to adherence and mental health) at the conclusion of study.
89460272|NCT02390336|Experimental|Real mobilization-with-movement (MWM)|"In each volunteer of this group, the blind assessor will perform the pre-intervention measurements of intensity of pain, range of motion and physical function tests.~Next, the therapist will performed the real mobilization-with-movement. Then, all measurements, before described, will be repeated, by the assessor."
88942309|NCT01868659|Experimental|Diagnostic checklist|Diagnostic checklist used before patient discharged
88942310|NCT01868659|Placebo Comparator|Usual care|No diagnostic checklist used during patient encounter
89460273|NCT02390336|Sham Comparator|Sham mobilization-with-movement (MWM)|"In each volunteer of this group, the blind assessor will perform the pre-intervention measurements of intensity of pain, range of motion and physical function tests.~Next, the therapist will performed the sham mobilization-with-movement. Then, all measurements, before described, will be repeated, by the assessor."
89460274|NCT03059511|Active Comparator|intravenous|single iv application of nalbuphine 0.05mg/kg
89460275|NCT03059511|Active Comparator|intranasal|single intranasal application of nalbuphine 0.1mg/kg in infants.
88942311|NCT01868672|No Intervention|Control|Participant receives usual care.
88942312|NCT01868672|Experimental|Intervention|Educational print materials and coaching call: Intervention group participants receive three sets of mailed educational materials about making their home smoke-free and one coaching call.
88942313|NCT01868685|Placebo Comparator|Placebo|
88942314|NCT01868685|Experimental|BYM338|
88942315|NCT01868698|Experimental|Kinesiotherapy|Will be made active and resisted exercises of the lower limbs.
88942316|NCT01868698|Experimental|shortwave diathermy|Will be applied for 20 minutes on the lower limbs.
88942317|NCT01868698|Experimental|high-voltage electrical stimulation|The therapeutic current will be applied for 20 minutes on lower limbs.
89460276|NCT02390492|Experimental|Ipatasertib/[14C]-ipatasertib|
89460277|NCT03014037|Other|Unilateral Procurement of Bone Marrow|Participants currently scheduled to undergo a bone marrow aspirate concentration (BMAC) procedure will be randomized to unilateral procurement of bone marrow.
89460278|NCT03014037|Experimental|Bilateral Bone Marrow Procurement|Participants currently scheduled to undergo a bone marrow aspirate concentration (BMAC) procedure will be randomized to bilateral procurement of bone marrow.
89460279|NCT04439786|Placebo Comparator|control group|the control group will be given the same volume of saline as the experimental group
88942318|NCT01868737|Experimental|HIV exposed infants|Probiotic: L. rhamnosus GG (0.35 x 109 colony-forming units [CFU]) and B. infantis (0.35 x 109 CFU) daily
88942319|NCT01868737|Placebo Comparator|HIV- exposed infants|MCT oil
88942320|NCT01868737|Placebo Comparator|HIV-unexposed infants|MCT oil
88942321|NCT01868737|Experimental|HIV-unexposed|Probiotic: L. rhamnosus GG (0.35 x 109 colony-forming units [CFU]) and B. infantis (0.35 x 109 CFU) daily
88942322|NCT01868750|Active Comparator|Vitamin D (Calcitriol)|Calcitriol, 1.0ug twice daily for 7 days prior to surgery
89460280|NCT04439786|Experimental|lidocaine group|the experimental group will be given l-1.5mg lidocaine and then 2mg/kg/h
89460281|NCT03131115|Active Comparator|Lateral Crural Strut Graft|Lateral crura strut graft is a well described and universally used technique involves strengthening lateral crus of lower lateral cartilage of the nose with piece of cartilage.
89460282|NCT03131115|Active Comparator|Bone-Anchored suspension|Bone- Anchored suspension is a well described surgical technique which involves anchoring the nasal sidewall to the bony rim below the eye.
89460283|NCT02686203|Experimental|B-Cure Laser Pro and needles|"Treatment will consist of acupuncture applied by a combination of B-Cure Laser Pro, an approved handheld, portable device emitting low level laser, and needles using two to four acupoints (The Investigational Therapy).~The Investigational Therapy will be administered by a treating therapist designated by the Sponsor who is experienced in employing the treatment."
89460284|NCT02386124|Other|frailty evaluation|"all consecutive patients admitted to hospital for acute cardiac disease aged more than 69 years will be evaluated with Short Portable Mental Status Questionnaire (SPMSQ), handgrip and Short Physical Performance Battery (SPPB).~These three tests (SPMSQ, SPPB and handgrip) are the intervention of the study. They are the assays to establish the frailty status"
89460285|NCT02386202||Patients with hemorrhagic stroke|All patients with hemorrhagic stroke admitted to the neurosciences ICU are eligible for study enrollment.
89460286|NCT04930263|Experimental|Aerobic exercise|"Behavioral: walking exercise~The intervention was 24 weeks walking intervention program with moderate-intensity, 5 sessions a week for 30 minutes per section~individualized education~telephone and social media counselling~booklet guidance"
89460287|NCT04930263|Active Comparator|control group|Given routine care and life health manual for the participants.
89460288|NCT02665286|Placebo Comparator|Placebo|Naproxen 500mg tablets taken twice per day + placebo. Placebo dose will be either 1 capsule orally twice per day or 1 or 2 capsules orally, thrice per day Naproxen 500mg po BID x 10 days #20 + Placebo
89460289|NCT02665286|Active Comparator|Orphenadrine|Naproxen 500mg, orally twice per day + orphenadrine 100mg, orally twice per day for 10 days Naproxen 500mg po BID x 10 days #20 + Orphenadrine
89460290|NCT02665286|Active Comparator|Methocarbamol|Naproxen 500mg tablets, orally twice per day + methocarbamol 750mg, orally as 1 or 2 tabs, thrice per day Naproxen 500mg po BID x 10 days #20 + Methocarbamol
89460291|NCT03471273|Other|endoscopic management|
89460292|NCT03471273|Other|follow up|
89460293|NCT03471273|Other|surgery|
89460294|NCT05440136|Experimental|LY3462817 - SC|LY3462817 administered subcutaneously (SC)
89460295|NCT05440136|Experimental|LY3462817 - IV|LY3462817 administered intravenously (IV)
89460296|NCT05440136|Placebo Comparator|Placebo - SC|Placebo administered SC
88942323|NCT01868750|Placebo Comparator|Control|Placebo pill taken twice daily for 7 days prior to surgery
88942324|NCT01868763|No Intervention|control (C) group|The control group will remain in routine care for 12 weeks.
88942325|NCT01868763|Experimental|telemedical (TM) group|Participants in the telemedical (TM) group will get a weighing machine and a step counter, with automatic transfer into a personalized online portal, which can be monitored from both, the participant and the study centre.
88942326|NCT01868763|Experimental|telemedical coaching (TMC) group|Participants in the telemedical coaching (TMC) group will get a weighing machine and a step counter, with automatic transfer into a personalized online portal, which can be monitored from both, the participant and the study centre. Additionally, they will be called once per week for 12 weeks from the study centre aiming to discuss measured data and to fix target agreements.
88942327|NCT01868802|Experimental|Ketamine treated|
88942328|NCT01868802|Placebo Comparator|Control, placebo treated|
88942329|NCT01868828|Experimental|PAD Followed by ASCT|"Drug: Bortezomib(1.3mg/m2, iv, on day 1, 4, 8, 11)~Drug: Epidoxorubicin(15 mg/m2, iv, on days 1-4)~Drug: Dexamethasone(40mg, orally, on days 1-4)~After received induction therapy, patients will proceed to receive ASCT based on the willing of the patients and the decision of the investigators.~Not suitable for transplant patients will continue accept treatment for 8 cycles."
88942330|NCT01868828|Experimental|VCD Followed by ASCT|"Drug: Bortezomib (1.3mg/m2, iv, on day 1, 4, 8, 11)~Drug: Cyclophosphamide (200mg/m2, orally, on days 1-5)~Drug: Dexamethasone(40mg, orally, on days 1-4)~After received induction therapy, patients will proceed to receive ASCT based on the willing of the patients and the decision of the investigators.~Not suitable for transplant patients will continue accept treatment for 8 cycles."
88942331|NCT01868841|Active Comparator|Adreview LFOV SPECT Imaging followed by SFOV-HE Imaging|SPECT imaging of 10 millicurie of Adreview
88942332|NCT01868841|Active Comparator|AdreView SFOV-HE SPECT Imaging followed by LFOV Imaging|SPECT imaging of 10 millicurie of Adreview
88942333|NCT01868854||Radiographic Plane 1|the tip of peritoneal dialysis catheter is located at the bottom of the pelvis, below a line connecting the head of the femur
89460297|NCT05440136|Placebo Comparator|Placebo - IV|Placebo administered IV
89460298|NCT02390102|Active Comparator|Erythropoietin|Dose: darboepoetin 0.75µg/Kg + 200mg intravenous iron sucrose Administered at days 10 (±4) and 1 (±1) before the index procedure.
88942334|NCT01868854||Radiographic Plane 2|the tip of the peritoneal dialysis catheter is located above the plane 1 and below a line connecting the two iliac spines
89460299|NCT02390102|Placebo Comparator|Placebo|Dosage: Saline solution 0.9% Administered at days 10 (±4) and 1 (±1) before the index procedure.
89460300|NCT02389790|Experimental|MT-1303|
89460301|NCT02147795||Control cohort|Standard care before implementation (pre-implementation)
89460302|NCT02147795||PBM cohort|After implementation of PBM program (post-implementation)
89460303|NCT03664219|Active Comparator|isolation of IAN nerve with collagen membrane|
89460304|NCT03664219|Experimental|without isolation of the IAN with collagen|
89460305|NCT03663673|Other|Clinical pilot study|To compare skin barrier function, assessed by TEWL AUC, between non-lesional areas of the skin treated with EpiCeram®, Aveeno Daily Moisturising Sheer Hydration Lotion®, and no emollient use over a period of one week.
89501857|NCT05497466||Subjects who are male or female outpatients aged 18 years and scheduled for CCTA to rule out CAD|300 patients scheduled for coronary CTA examination to rule out CAD in PUMCH. Each subject will be selected and assigned in a specific tube-voltage arm by the scanner based on the patient's body habitus for individualized CTA scans, without any intervention
89501858|NCT03724825||obese men|Adult obese men (BMI ≥ 30 kg/m2)
89460306|NCT04057963|Experimental|Conventional plus Functional Inspiratory Muscle Training Group|Conventional program plus functional inspiratory muscle training will be carried out three sessions per week during the six weeks. The content of the program will be the same as for the conventional group. Additional functional inspiratory muscle training will be began with 50% of the maximal inspiratory pressure value in a specific device and it will be progressed 5% every week according to the tolerance.
89460307|NCT04057963|Active Comparator|Conventional Physiotherapy Program|Conventional program will be carried out three sessions per week during the six weeks. Cervical mobilization techniques (glidings-grade 2) of cyriax will be applied in the direction of lateral flexion and rotation. Stretching exercises, craniovertebral flexion exercise and scapulothoracic strengthening exercises will be performed.
89460308|NCT03663517||pregnant women|pregnant women in Hong Kong
89017375|NCT00283088|No Intervention|Group 3|Groups 3, 4, 5 and 6: Factorial groups, randomized to hypothermia plus tPA, hypothermia alone, tPA alone, or no treatment assignment (standard of care).
89460309|NCT04058041|Experimental|Neural mobilization|passive mobilization of the median nerve by the therapist following by an active movement of the fingers of the pathology hand
89460310|NCT04058041|Active Comparator|Surgery|the surgeon will release the median nerve in the tunnel carpal. After that the therapist will teach home exercises (no neural exercises) to the patients.
89460311|NCT04058041|Active Comparator|Surgery and Neural mobilization|the surgeon will release the median nerve in the tunnel carpal. After that the therapist will perform mobilizations of the median nerve just like the experimental group.
89460312|NCT04057885|Experimental|Device Arm|A prospective series of 10 patients will receive sensor-guided TKA using the this special Orthosensor™ VERASENSE™ Knee System assisted surgery for optimization of soft tissue balance
89460313|NCT04057885|Active Comparator|Standard of Care|10 patients will receive standard of care. Prior to cementing final implants, VERASENSE will be utilized with the standard of care group with the surgeon blinded to the data.
89460314|NCT04057729|Experimental|Arm 1 （IMP4297 100mg, Fasted-Fed）|Period 1: Fasted control → Period 2: Fed control
89460315|NCT04057729|Experimental|Arm 2（IMP4297 100mg, Fed- Fasted）|Period 1: Fed control → Period 2: Fasted control
89460316|NCT03664141|Placebo Comparator|Placebo group|1 drop of regular oil for food labeled as 3% cannabis oil once a day during 3 months
89460317|NCT03664141|Experimental|Cannabis oil group|1 drop of 3% cannabis oil once a day during 3 months
89460318|NCT03664531|Experimental|Gluten, ATIs, nocebo|Participants will start on 1 week of muesli bars with purified gluten followed by 14 days washout. They will then take 1 week of muesli bars with non-purified gluten (containing ATIs) followed by 14 days of washout. Finally, they will have 1 week of nocebo muesli bars (with nothing).
89460319|NCT03664531|Experimental|Gluten, nocebo, ATIs|Participants will start on 1 week of muesli bars with purified gluten followed by 14 days washout. They will then take 1 week of nocebo muesli bars (with nothing) followed by 14 days of washout. Finally, they will have 1 week of muesli bars with non-purified gluten (containing ATIs).
89460320|NCT03664531|Experimental|ATIs, gluten, nocebo|Participants will start on 1 week of muesli bars with non-purified gluten (containing ATIs) followed by 14 days washout. They will then take 1 week of muesli bars with purified gluten followed by 14 days of washout. Finally, they will have 1 week of nocebo muesli bars (with nothing).
89460321|NCT03664531|Experimental|ATIs, nocebo, gluten|Participants will start on 1 week of muesli bars with non-purified gluten (containing ATIs) followed by 14 days washout. They will then take 1 week of nocebo muesli bars (containing nothing) followed by 14 days of washout. Finally, they will have 1 week of muesli bars with purified gluten.
89460322|NCT03664531|Experimental|Nocebo, ATIs, gluten|Participants will start on 1 week of nocebo muesli bars (with nothing) followed by 14 days washout. They will then take 1 week of muesli bars containing non-purified gluten (containing ATIs) followed by 14 days of washout. Finally, they will have 1 week of muesli bars with purified gluten.
89460323|NCT03664531|Experimental|Nocebo, gluten, ATIs|Participants will start on 1 week of nocebo muesli bars (with nothing) followed by 14 days washout. They will then take 1 week of muesli bars with purified gluten followed by 14 days of washout. Finally, they will have 1 week of muesli bars with non-purified gluten (containing ATIs).
89460324|NCT02911519|Experimental|Brief Group Psychoeducation|It was designed after a review of the literature on the subject; content and procedures will be written in a manual. They will be five sessions of two hours once a week. Each session will be conducted by a clinical psychologist and a general practitioner trained in group management.
89460325|NCT02911519|Active Comparator|Treatment as Usual Only|The patients in both arms of the intervention will receive this type of attention. The TAU is the psychiatric care that patients with schizophrenia usually receive in the clinic. The frequency of consultations varies depending on severity of symptoms usually split between one and six months.
89460326|NCT03664063|Active Comparator|Azithromycin for Yaws|Patients will receive standard treatment for yaws alone
89460327|NCT03664063|Active Comparator|IDA for Lymphatic Filariasis|Patients will receive standard IDA (Ivermectin & Diethylcarbamazine & Albendazole) treatment for Lymphatic Filariasis alone
89460328|NCT03664063|Experimental|Combination Therapy of Azithromycin for Yaws and IDA for LF|Patients will receive combination therapy for both yaws and IDA for Lymphatic Filariasis at the same time.
89460329|NCT04057495|Placebo Comparator|no mango intake|No mango consumption on the study visit
89460330|NCT04057495|Experimental|white bread with same amount of calorie as mango|White bread consumption on the study visit
89017376|NCT00283088|Active Comparator|Group 4|Groups 3, 4, 5 and 6: Factorial groups, randomized to hypothermia plus tPA, hypothermia alone, tPA alone, or no treatment assignment (standard of care).
89017377|NCT00283088|Active Comparator|Group 5|Groups 3, 4, 5 and 6: Factorial groups, randomized to hypothermia plus tPA, hypothermia alone, tPA alone, or no treatment assignment (standard of care).
89017378|NCT00283088|Active Comparator|Group 6|Groups 3, 4, 5 and 6: Factorial groups, randomized to hypothermia plus tPA, hypothermia alone, tPA alone, or no treatment assignment (standard of care).
89206163|NCT00524368|Experimental|DRV/rtv 600/100 mg twice daily|One 600 mg TMC114 tablet + one 100 mg capsule of rtv twice daily.
89206164|NCT00777101|Experimental|Neratinib|
89206165|NCT00777101|Active Comparator|Lapatinib plus Capecitabine|
89460331|NCT04057495|Experimental|mango consumption|mango consumption on the study visit
89460332|NCT04054921|Experimental|Interventions|PTG-300
89460333|NCT02911285|Experimental|NAC/CBT|Participants will receive N-acetylcysteine (NAC) and Cognitive Behavioral Therapy (CBT) for 8 weeks.
89460334|NCT02911285|Placebo Comparator|Placebo/CBT|Participants will receive placebo pills and CBT for 8 weeks.
89460335|NCT02910739|Experimental|Part I: MK-8931 40 mg in Moderate HI Participants|Single oral dose of MK-8931 40 mg tablet in participants with moderate HI in fasted state (Part I)
89460336|NCT02910739|Active Comparator|Part I: MK-8931 40 mg in Healthy Participants|Single oral dose of MK-8931 40 mg tablet in healthy matched participants in fasted state (Part I)
89460337|NCT02910739|Experimental|Part II: MK-8931 40 mg in Mild HI Participants|Single oral dose of MK-8931 40 mg tablet in participants with mild HI in fasted state (Part II)
89460338|NCT02910739|Active Comparator|Part II: MK-8931 40 mg in Healthy Participants|Single oral dose of MK-8931 40 mg tablet in healthy matched participants in fasted state (Part II)
89460339|NCT03673397|Experimental|Aerobic exercise|Patients allocated to the intervention group will perform a single bout of supervised aerobic exercise. The starting time will be approximately 1630 hrs. The exercise mode will be a bicycle ergometer. After a warm-up period, during which the intensity is gradually increased, an intensity of 80% of the individual anaerobic threshold will be maintained for 30 minutes. The intensity level was chosen based on clinical experience that this corresponds to an approximate rate of perceived exertion of 13 (on a scale from 6-20) in this population.
89460340|NCT03673397|No Intervention|Control|Individuals allocated to the control group will be placed in a room with analogous conditions to the exercise group concerning light, temperature and absence of music at the same time as individuals performing the exercise intervention. The control group will be asked to remain seated and read magazines.
89460341|NCT04055935|Experimental|full thickness mucoperiosteal flap|A full thickness mucoperiosteal flap (FTMPF) was reflected on FTMPF side at the maxillary canine/premolar region by the same surgeon for all patients following the same procedures.
89460342|NCT04055935|Experimental|low level laser therapy|LLLT was done using a diode soft laser (Epic X, BioLase, USA). It is a semiconductor diode soft laser. Active medium is In-Ga-As with 940nm wave length
89460343|NCT04055935|No Intervention|Control for Full thickness mucoperiosteal flap|Control for Full thickness mucoperiosteal flap, in which canine retraction was done in a conventional method
89460344|NCT04055935|No Intervention|control for Low level laser therapy group|Control for Low level laser therapy , in which canine retraction was done in a conventional method
89460345|NCT04997902|Experimental|PIK3CA-dependent (Cohort 1)|Adult participants with R/M HNSCC whose tumors harbor PI3KCA (activating) mutations and/or amplifications
89460346|NCT04997902|Experimental|HRAS-dependent (Cohort 2)|Adult participants with R/M HNSCC whose tumors have increased HRAS dependency, defined as HRAS overexpression
89460347|NCT01061515|Experimental|Dose Level 1|"Intraperitoneal oxaliplatin 25 mg/m2 IP on day 1 of each cycle~Bevacizumab 5 mg/kg CIVI on day 1 of each cycle~Capecitabine PO BID on days 1-7 of each cycle.~Each cycle is 14 days long."
89460348|NCT01061515|Experimental|Dose Level 2|"Intraperitoneal oxaliplatin 50 mg/m2 IP on day 1 of each cycle~Bevacizumab 5 mg/kg CIVI on day 1 of each cycle~Capecitabine PO BID on days 1-7 of each cycle.~Each cycle is 14 days long."
89460349|NCT01061515|Experimental|Dose Level 3|"Intraperitoneal oxaliplatin 65 mg/m2 IP on day 1 of each cycle~Bevacizumab 5 mg/kg CIVI on day 1 of each cycle~Capecitabine PO BID on days 1-7 of each cycle.~Each cycle is 14 days long."
88942335|NCT01868854||Radiographic plane 3|The location of the catheter tip is on the line connecting iliac spines and below a line connecting the iliac crests
88942336|NCT01868854||Radiographic plane 4|The location of the catheter tip is on the line connecting the iliac crests
88942337|NCT01868867|Experimental|Intervention|Receives on line training and text messaging for treatment
88942338|NCT01868867|No Intervention|Treatment as Usual|Treatment as usual (TAU) for similar duration as intervention group. Intervention provided following TAU period.
89460350|NCT01061515|Experimental|Dose Level 4|"Intraperitoneal oxaliplatin 85 mg/m2 IP on day 1 of each cycle~Bevacizumab 5 mg/kg CIVI on day 1 of each cycle~Capecitabine PO BID on days 1-7 of each cycle.~Each cycle is 14 days long."
89460351|NCT01061515|Experimental|Dose Level 5|"Intraperitoneal oxaliplatin 100 mg/m2 IP on day 1 of each cycle~Bevacizumab 5 mg/kg CIVI on day 1 of each cycle~Capecitabine PO BID on days 1-7 of each cycle.~Each cycle is 14 days long."
89460352|NCT01069939|Experimental|Esomeprazole 20mg|Esomeprazole 20mg once daily oral
89460353|NCT01069939|Placebo Comparator|Placebo|Placebo once daily oral
89460354|NCT01069705|Experimental|Tobramycin Inhalation Powder (TIPnew)|Participants received four capsules of 28 mg TIPnew (112 mg), inhaled twice a day (b.i.d.) in the morning and the evening given in a cycle of 28 days on treatment followed by 28 days off treatment for three consecutive cycles.
89460355|NCT01069627|Experimental|1|
89460356|NCT04057261|Active Comparator|Liraglutide|Increasing dose of Liraglutide: 0.6 mg/d for the first week, 1.2 mg/d for the second week aiming for a maximum of 1.8 mg/d beginning with the third week (or highest tolerated dose).Subcutaneous injection once daily via pre-filled pen.
89460357|NCT04057261|Placebo Comparator|Placebo|Matching Placebo once daily, subcutaneous injection via pre-filled pen.
89460358|NCT03673319|Experimental|Positive expectative|"Participants in the positive expectation group will be told that DN procedure: is a very effective form of treatment used to treat neck-shoulder pain and it is expected to reduce your perception of pressure pain"
89501859|NCT03724825||normal men|normal weight men (18.5 ≤ BMI < 25 kg/m2 )
88942339|NCT01868906|Other|Arm-A: 18F-FMISO-PET without SCS|One 18F-FMISO-PET study for assessment of tumor hypoxia before radiotherapy and Temozolomide, without spinal cord stimulation.
88942340|NCT01868906|Other|Arm-B: 18F-FMISO-PET without/with SCS|"Two 18F-FMISO-PET studies for assessment of tumor hypoxia before radiotherapy and Temozolomide: one without and one with spinal cord stimulation"
88942341|NCT01868919|Experimental|Positive Parenting Program|Level 3 or 4 of Triple P
89017379|NCT00311610|Experimental|SN-38 liposome|"Patients receive SN-38 liposome IV over 90 minutes on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.~After completion of study treatment, patients are followed every 3 months for up to 3 years."
89017380|NCT00318201|Experimental|1|Altered efficacy for drug to drug interaction of diltiazam with erythromycin
89460359|NCT03673319|Experimental|Neutral expectatives|"Participants in the neutral expectation group will be told that DN procedure: is a form of treatment used to treat neck-shoulder pain that has unknown effects on your perception of pressure pain"
89017381|NCT00283166|Experimental|A|Tailored Coaching and Education
89017382|NCT00283166|Other|B|Active Control
89017383|NCT00318240|Experimental|1|High Intensity Focused
89017384|NCT04708652||preterm children|Our previous intervention study enrolled 178 VLBW (birth body weight less than 1,500 gm) preterm children who were born or admitted at the National Taiwan University Hospital, the Mackay Memorial Hospital and Taipei City Hospital, Branch for Women and Children in Taipei, Taiwan, during the time period of 2006 to 2008. No any intervention was conducted, just the observation.
89017385|NCT04708652||term children|Our previous intervention study enrolled 62 term children who were born or admitted at the National Taiwan University Hospital, the Mackay Memorial Hospital and Taipei City Hospital, Branch for Women and Children in Taipei, Taiwan, during the time period of 2006 to 2008. No any intervention was conducted, just the observation.
89017386|NCT00311688||1|Individuals will follow the schedule of the study they are participating in
89017387|NCT02960750|Experimental|Intervention group|Had access to the W@WS website program during 19 weeks.
89460360|NCT03622801||Intra-arterial administration|Patients with intra-arterial administration of Iopromide
89460361|NCT03622801||Intravenous administration|Patients with intravenous administration of Iopromide
89460362|NCT01064245|Experimental|Cough Variant Asthma|Those diagnosed with cough variant asthma.
89460363|NCT01064245|Experimental|Asthma|Those with diagnosed asthma.
89017388|NCT02960750|Active Comparator|Active comparison group|Maintained habitual behavior.
89460364|NCT03669965|Experimental|Part A Arm 1|KRT-232 120mg by mouth once daily for Days 1-7, off treatment for Days 8-21 (21-day cycles)
89460365|NCT03669965|Experimental|Part A Arm 2|KRT-232 240mg by mouth once daily for Days 1-7, off treatment for Days 8-21 (21-day cycles)
89460366|NCT03669965|Experimental|Part A Arm 3|KRT-232 120mg by mouth once daily for Days 1-7, off treatment for Days 8-28 (28-day cycles)
89460367|NCT03669965|Experimental|Part B KRT-232 Arm|Recommended KRT-232 dose and schedule from Part A
89460368|NCT03669965|Active Comparator|Part B Ruxolitinib Arm|Ruxolitinib per approved prescribing label
89460369|NCT03669965|Experimental|Part A Arm 4b|KRT-232 240mg by mouth once daily for Days 1-5, off treatment for Days 6-28 (28-day cycles)
89460370|NCT03669965|Experimental|Part A Arm 2b|KRT-232 240mg by mouth once daily for Days 1-7, off treatment for Days 8-28 (28-day cycles)
89460371|NCT03663049|No Intervention|Usual care|These patients will continue as statins as usual.
89460372|NCT03663049|Experimental|Discontinue statin|Patients randomized to this group will stop using the statins they are currently prescribed and will not use their statin medication for 12 weeks.
89017389|NCT00283322||Medical ICU patients|Patients admitted to a medical intensive care unit
89017390|NCT00283322||Surgical ICU patients|Patients admitted to a surgical-trauma intensive care unit
89017391|NCT00283322||Neuro ICU patients|Patients admitted to a neuro-trauma intensive care unit
89017392|NCT00311727|Experimental|Influenza A/H5N1|232 subjects receiving Influenza A/H5N1 vaccine.
89017393|NCT00311805|Active Comparator|1|
89017394|NCT00311805|Active Comparator|2|
89017395|NCT00311805|Placebo Comparator|3|
89017396|NCT00283010|Experimental|Experimental Treatment|Computerized Plasticity-Based Adaptive Cognitive Training
89017397|NCT00283010|Active Comparator|Active Control|Educational DVDs
89017398|NCT00318396|Experimental|Compaction|The bone is pressed very hard together before implantation of femoral component.
89017399|NCT00318396|Active Comparator|Conventional technique|The bone is broached before implantation of femoral component.
89017400|NCT00283517||001|
89017401|NCT00283556|Experimental|Cohort #1|"Cohort #1--Irinotecan 750 mg/m2 IV over 90 minutes every (Q) 3 weeks x 15 patients.~Additional increments of 50 mg/m2 for subsequent cohorts until MTD is reached."
89017402|NCT00283556|Experimental|Cohort #2|"Cohort #2--Irinotecan 500 mg/m2 IV over 90 minutes Q 2 weeks x 3 patients.~Additional increments of 50 mg/m2 for subsequent cohorts until MTD is reached."
89017403|NCT00283556|Experimental|Cohort #3|"Cohort #3--Irinotecan 600 mg/m2 IV over 90 minutes Q 2 weeks x 3 patients.~Additional increments of 50 mg/m2 for subsequent cohorts until MTD is reached."
89017404|NCT00311922|Active Comparator|Control|Active Control Arm receives Comprehensive Diabetes Education
89017405|NCT00311922|Experimental|Intervention Arm|Receives comprehensive education that is literacy/numeracy sensitive
89460373|NCT03663439|Experimental|modified shell technique|block of bone from the mandibular ramus divided into two shells ,grafting one shell in the anterior maxilla to increase width
89460374|NCT03663439|Active Comparator|onlay bone graft|grafting block of bone from the mandibular ramus in the atrophic anterior maxilla
89460375|NCT04056949|Other|IBI308 + Paclitaxel/Albumin-Bound Paclitaxel|IBI308 Combined with Albumin-Bound Paclitaxe
89460376|NCT03662503||nutrition not aggressive group|"Children will be grouped according to their calorie and protein during the first week of life. The tertile 1 will represent the group of children with the lowest nutritional intake (called the nutrition not aggressive )"
89460377|NCT03662503||aggressive nutrition group|"Children will be grouped according to their calorie and protein during the first week of life. the tertile 3 will define the group of children presenting the contributions highest nutritional levels (called the aggressive nutrition group)"
89460378|NCT04057417|Experimental|Urban Trail Expansion|Neighbourhoods within 400m to 800m of a neely built greenway, defined as a multi-use concrete/asphalt trail that was >4km in length)
89460379|NCT04057417|No Intervention|Control|Neighbourhoods that are located beyond 400 to 800m of a newly built greenway
89017406|NCT00318630|Experimental|Subjects receiving treatment 1|Eligible subjects will receive rosiglitazone immediate release tablet with a dose of 4 milligrams twice daily administered orally for 28 days followed by placebo oral tablet.
89460380|NCT04056793|Experimental|Parturients in situation of dystocia|Positioning of the parturients in an optimized birthing position
89460381|NCT03673241|No Intervention|Control Group|The Control Group will receive the standard support surface mattresses/bed surfaces and recovery chairs without the non-invasive perfusion enhancement system (The Guardian System)
89460382|NCT03673241|Experimental|Study Arm|The Study Arm will have the non-invasive perfusion enhancement system placed on their beds and recovery chairs. Patients will be utilizing the systems while lying in bed or sitting in the chair.
89460383|NCT03662425|Experimental|schizophrenia with oxytocin|Participants self-administered the oxytocin twice daily via intranasal route: before breakfast and before dinner. Each dose consists of six 0.1 ml insufflations (alternating between the left and right nostril) of oxytocin spray containing approximately 24 international units of oxytocin.
89460384|NCT03662425|Placebo Comparator|schizophrenia with Placebo|Participants self-administered the placebo twice daily via intranasal route: before breakfast and before dinner. Each dose consists of six 0.1 ml insufflations (alternating between the left and right nostril) of oxytocin spray containing approximately 24 international units of placebo.
89017407|NCT00318630|Experimental|Subjects receiving treatment 2|Eligible subjects will receive placebo oral tablet followed by rosiglitazone immediate release tablet with a dose of 4 milligrams twice daily for 28 days.
89460385|NCT03673163|Experimental|Lidocaine|Lidocaine treatment
89460386|NCT03673163|Placebo Comparator|Control|Placebo treatment
89460387|NCT03662269|Experimental|indomethacin treatment group|indomethacin (75mg, bid) + omeprazole (20mg, qd)
89460388|NCT03662269|Placebo Comparator|placebo treatment group|placebo (75mg, bid) + omeprazole (20mg, qd)
89460389|NCT04056325|Experimental|Phase 2a - Arm A|2 mg Moxidectin at day 0 administered orally
89460390|NCT04056325|Experimental|Phase 2a - Arm B|4 mg Moxidectin at day 0 administered orally
89460391|NCT04056325|Experimental|Phase 2a - Arm C|6 mg Moxidectin at day 0 administered orally
89460392|NCT04056325|Experimental|Phase 2a - Arm D|8 mg Moxidectin at day 0 administered orally
89460393|NCT04056325|Experimental|Phase 2a - Arm E|10 mg Moxidectin at day 0 administered orally
89460394|NCT04056325|Experimental|Phase 2a - Arm F|12 mg Moxidectin at day 0 administered orally
89460395|NCT04056325|Placebo Comparator|Phase 2a - Arm G|matching Placebo tablet(s) at day 0 administered orally
89460396|NCT04056325|Experimental|Phase 2b - Arm A|the recommended dose moxidectin (i.e. the most promising dosage identified in trial A; between 2-12 mg) at day 0 administered orally
89460397|NCT04056325|Active Comparator|Phase 2b - Arm B|200 µg/kg ivermectin at day 0 administered orally
89460398|NCT04056325|Placebo Comparator|Phase 2b - Arm P|matching Placebo tablet(s) at day 0 administered orally
89460399|NCT03673085|Experimental|Group 1-1|The dose of CN128 is 2.5 mg/kg bw.
89017408|NCT00283829|Other|I|Docetaxel followed by IL-2
88942342|NCT01868932|Experimental|hypertonic saline|inhalation of 4 ml nebulized study solution containing 3% hypertonic saline (HS, study group). Each dose of study solution will also contain a standard dose of bronchodilator (salbutamol, 0.15 mg/kg; 0.03 ml/kg of 0.5% salbutamol nebulizer solution) 1,2 added by the ED staff. Initial therapy will consist of 3 consecutive nebulizations given in rapid succession (back-to-back, approximately every 20 minutes).
89460400|NCT03673085|Placebo Comparator|Group 1-2|The dose of placebo is 2.5 mg/kg bw.
89460401|NCT03673085|Experimental|Group 2-1|The dose of CN128 is 5 mg/kg bw.
89460402|NCT03673085|Placebo Comparator|Group 2-2|The dose of placebo is 5 mg/kg bw.
89460403|NCT03673085|Experimental|Group 3-1|The dose of CN128 is 10 mg/kg bw.
89460404|NCT03673085|Placebo Comparator|Group 3-2|The dose of placebo is 10 mg/kg bw.
89460405|NCT03673085|Experimental|Group 4-1|The dose of CN128 is 15 mg/kg bw.
89201721|NCT02538393|Experimental|Treatment D-B-C-A|Subjects received a single oral dose of 400 mg sorafenib tablets for oral suspension (4 * 100 mg) after a high-fat, high-calorie breakfast (fed state) (Treatment D) in the first intervention period; followed by a single oral dose of 400 mg sorafenib tablets for oral suspension (4 * 100 mg) in fasting state (Treatment B) in the second intervention period; followed by a single oral dose of 200 mg sorafenib tablets for oral suspension (2 * 100 mg) in fasting state (Treatment C) in the third intervention period; and then a single oral dose of 400 mg sorafenib marketed tablets (2 * 200 mg) in fasting state (Treatment A) in the fourth intervention period. A washout period of at least 10 days was maintained between sorafenib administrations.
89460406|NCT03673085|Placebo Comparator|Group 4-2|The dose of placebo is 15 mg/kg bw.
89460407|NCT03673085|Experimental|Group 5-1|The dose of CN128 is 20 mg/kg bw.
89460408|NCT03673085|Placebo Comparator|Group 5-2|The dose of placebo is 20 mg/kg bw.
89460409|NCT03673085|Experimental|Group 6-1|The dose of CN128 is 30 mg/kg bw.
89460410|NCT03673085|Placebo Comparator|Group 6-2|The dose of placebo is 30 mg/kg bw.
89460411|NCT03673085|Experimental|Group 7-1|The dose of CN128 is 45 mg/kg bw.
88942343|NCT01868932|Active Comparator|saline|inhalation of 4 ml nebulized study solution containing saline 0.9% saline (NS, control group). Each dose of study solution will also contain a standard dose of bronchodilator (salbutamol, 0.15 mg/kg; 0.03 ml/kg of 0.5% salbutamol nebulizer solution) 1,2 added by the ED staff. Initial therapy will consist of 3 consecutive nebulizations given in rapid succession (back-to-back, approximately every 20 minutes).
88942344|NCT01868945|Experimental|5 µg/day Hy.D Calcifediol|
89460412|NCT03673085|Placebo Comparator|Group 7-2|The dose of placebo is 45 mg/kg bw.
89460413|NCT03673085|Experimental|Group 8-1|The dose of CN128 is 60 mg/kg bw.
89460414|NCT03673085|Placebo Comparator|Group 8-2|The dose of placebo is 60 mg/kg bw.
89460415|NCT03662191|Experimental|Treatment A|4 × 20 mg commercial tafamidis meglumine administered as soft gelatin capsules under fasted conditions
89460416|NCT03662191|Experimental|Treatment B|10 mgA tafamidis free acid administered as a wet-milled suspension under fasted conditions
88942345|NCT01868945|Experimental|10 µg/day Hy.D Calcifediol|
88942346|NCT01868945|Experimental|15 µg/day Hy.D Calcifediol|
89460417|NCT03662191|Experimental|Treatment C|a dose of tafamidis free acid projected to be an equivalent of 4 × 20 mg commercial tafamidis meglumine administered as a wet-milled suspension under fasted conditions
89460418|NCT03662191|Experimental|Treatment D|a dose of tafamidis free acid projected to be an equivalent of 5 × 20 mg commercial tafamidis meglumine administered as a wet-milled suspension under fasted conditions
89460419|NCT03662971|Experimental|0.0005% single-dose|Two subjects will be treated with Germinal peptide eye drops 0.0005% single dose.
89460420|NCT03662971|Experimental|0.001% single-dose|Ten subjects will be treated with Germinal peptide eye drops 0.001% single dose (eight treatment and two placebo).
89460421|NCT03662971|Experimental|0.002% single-dose|Ten subjects will be treated with Germinal peptide eye drops 0.002% single dose (eight treatment and two placebo).
89460422|NCT03662971|Experimental|0.004% single-dose|Ten subjects will be treated with Germinal peptide eye drops 0.004% single dose (eight treatment and two placebo).
89460423|NCT03662971|Experimental|0.008% single-dose|Ten subjects will be treated with Germinal peptide eye drops 0.008% single dose (eight treatment and two placebo).
89460424|NCT03662971|Experimental|0.002% multiple-dose|Ten subjects will be treated with Germinal peptide eye drops 0.002% multiple dose (eight treatment and two placebo).
89460425|NCT03662971|Experimental|0.004% multiple-dose|Ten subjects will be treated with Germinal peptide eye drops 0.004% multiple dose (eight treatment and two placebo).
89460426|NCT03662971|Experimental|0.008% multiple-dose|Ten subjects will be treated with Germinal peptide eye drops 0.008% multiple dose (eight treatment and two placebo).
89460427|NCT03669341|Experimental|Deep Inspiration Breath Hold (DIBH)|DIBH extended by prior hyperventilation while breathing 100% O2
89460428|NCT03669341|Active Comparator|High Frequency Percussive Ventilation (HFPV)|passive Ventilation by a jet ventilator
89460429|NCT03672851|Experimental|anti-CD123 CAR-T treatment|
89460430|NCT04057027|Experimental|Delayed Cord Clamping for 30 seconds|Infants whose umbilical cord clamping will be delayed for 30 secs.
89460431|NCT04057027|Experimental|Delayed Cord Clamping for 60 seconds|Infants whose umbilical cord clamping will be delayed for 60 secs.
89460432|NCT04057027|Experimental|Umbilical Cord Milking|Infants whose umbilical cord will be clamped after milking from the distance of 20 cm from mother's side to the baby for 3-4 times.
89460433|NCT03021551|Experimental|Rainbow sensor|
89460434|NCT03662893|Sham Comparator|Behavioural therapy with written guideline|Patients were instructed to apply only written guideline forms of behavioural therapy which were the same as those in the checklist over six-month period.
89460435|NCT03662893|Active Comparator|Behavioural therapy with checklist|Patients were instructed to apply behavioural therapy with a written checklist for patients to fully complete over six-month period.
89460436|NCT03662893|Active Comparator|antimuscarinic drug plus verbal behavioural therapy|Patients received medical treatment (once or twice per day) plus behavioural therapy without checklist over six-month period.
89460437|NCT03662893|Active Comparator|antimuscarinics plus checklist|Patients received medical treatment (once or twice per day) with a written checklist to fully complete over six-month period.
89460438|NCT04056637|No Intervention|Group 1: Standard of Care|Participants will be asked to complete follow-up in clinic 1-2 weeks following mifepristone administration for an ultrasound and consultation with a provider.
89460439|NCT04056637|Experimental|Group 2: Flexible Follow-Up|Participants will be offered three follow-up options, including: 1) follow-up in clinic 1-2 weeks following mifepristone administration for an ultrasound and consultation with a provider; 2) repeat serum beta-hCG testing; 3) repeat multi-level pregnancy test strategy
89460440|NCT03471195||CP|A total of 20 children with cerebral palsy and dental decay will undergothe following Collection of Saliva Total Salivary Cytokine Profile
89460441|NCT03471195||Control|A total of 20 verbal children without cerebral palsy matched for age and extent of dental decay will undergo the following Collection of Saliva Total Salivary Cytokine Profile
89460442|NCT04056559|Experimental|SIngle arm|The research is based on a population of men and women practicing a sport at risk of oral trauma.
89460443|NCT00645645||holoprosencephaly (HPE)|individuals with overt or subtle clinical findings consistent with the HPE spectrum are eligible to participate
89460444|NCT01585025|Experimental|Primary BAD|Defined as SeHCAT <10% without other causes such as Crohn's disease and/or ileal resection
89460445|NCT01585025|Experimental|Secondary BAD|With Crohn's disease or ileal resection
89460446|NCT01585025|Experimental|Idiopathic Diarrhoea Controls|Chronic diarrhoea with SeHCAT >15% and no Crohn's or ileal resection
89460447|NCT01068769|Experimental|Regorafenib|Regorafenib adminstered orally, 160 mg per day on days 1 through 21 of a 28 day cycle
89460448|NCT03663127|Experimental|Beauty Drink|"Subjects receive two bottles Beauty Drink per day for 8 weeks of a stage."
88942347|NCT01868945|Active Comparator|20 µg/day vitamin D3|
88942348|NCT01868958||CSM subjects|Subjects with clinical indications of cervical spondylotic myelopathy (CSM).
88942349|NCT01868958||Control group|Aged matched to the CSM group but with no signs of CSM
88942350|NCT01868971|Other|Colonoscopy procedure with the EndoRings|Colonoscopy procedure using an add-on device (EndoRings) that is attached to the distal tip of the endoscope
88942351|NCT01868984|Sham Comparator|Standard Therapy Alone|"Standard treatment of all stenotic lesions will be carried out in the usual fashion. Intravenous heparin will be administered in a standard dose of 70 units/kg. Lesions that respond poorly to angioplasty (>30% residual stenosis after angioplasty treatment with 2 inflations) will be stented. Stent selection will be based on clinical setting. Initial stent treatment will utilize an uncovered nitinol stent. Treatment of in-stent restenosis will include initial balloon angioplasty, and use of a covered stent (Viabahn, GORE, or Fluency, Bard).~For this control group, no paclitaxel is administered. The sham treatment is a period of 10 minutes that is allowed to elapse followed by the performance of a final completion angiogram to be labeled as PaciFIST Study Completion Angiogram. Any additional lesions identified with this study are then treated appropriately following standard technique."
89460449|NCT03663127|Placebo Comparator|Placebo|Subjects receive two bottles placebo per day for 8 weeks of a stage.
89460450|NCT00328653|Experimental|NOVA22007 0.05%|four times daily
89460451|NCT00328653|Experimental|NOVA22007 0.1%|four times daily
89460452|NCT00328653|Sham Comparator|Vehicle|administered four times daily
89460453|NCT03662581|Experimental|Mindfulness Group Program|A primary care mindfulness-based rolling admissions program where subjects must attend 4 of 8 consecutive group sessions, to be considered to have completed the program.
89460454|NCT05258253|Experimental|high intensity aerobics|"London bridges (8mins),Jumping lunges(8mins),Mountain climbers(8mins),Quadruped bent knee hip extension (8mins)"
89460455|NCT05258253|Active Comparator|pelvic clock exercises|Lie with your back on the floor in a neutral position with your legs bent and toes facing forward. Subject begin with gentle movements from 12 to 6 o'clock, as instructed to move from 3 o'clock to 9 o'clock. Then move in a clockwise manner from 12 to 3 to 6 to 9 and then back to 12 o' clock.
89460456|NCT03662113|Experimental|Experimental: Domperidone|5ml domperidone prior to VCE
89460457|NCT03662113|Other|Control: water|5ml warm water prior to VCE
89460458|NCT03478137|Experimental|CPAP intervention|Over the course of 4-7 months, participants will have to wear the CPAP every night, at least 4 hours per night.
89460459|NCT03478137|No Intervention|Control 1|Eligible participants who declined to participate in the study. Their main study visit data will be used to compare with the intervention group.
89460460|NCT03478137|No Intervention|Control 2|Eligible participants who were not approached, hence not given the opportunity to accept or decline. Their main study visit data will be used to compare with the intervention group.
89460461|NCT04924023|Experimental|Kaleidoscope Group|Children in this group were told what a kaleidoscope is and how to use it before their central venous catheter dressing. The children were then asked if they would like to look into the kaleidoscope. The children looked into the kaleidoscope and slowly turned it. The researcher asked the children about the colours and shapes seen inside the kaleidoscope. This distraction procedure began immediately before the central venous catheter dressing and continued until it was finished. The kaleidoscope was disinfected before each use. A kaleidoscope was provided for all children in this group by the same researcher. Parents accompanied their children during the catheter dressing.
89460462|NCT04924023|No Intervention|Control Group|No intervention was performed to reduce pain and anxiety for children in the control group. Parents accompanied their children during the procedure.
89460463|NCT03662035|Experimental|single-arm|Apatinib and S-1 Patients will be offered with Apatinib (500mg/d) and S-1 (60mg/d for BSA<1.25m2, 80mg/d for 1.25<BSA<1.5m2, and 100mg for BSA >1.5m2) until their disease have progressed.
89460464|NCT04861311|Experimental|Mindfulness/Acceptance-Based Smartphone App (MABSA) Intervention Group|The intervention is 6 weeks in duration. Participants will be asked to listen daily to at least one audio-guided mindfulness meditation embedded in the app. They will also be asked to watch a weekly video lesson on mindfulness and acceptance and will be asked to write a reflection about the video. They will also receive weekly emotional and technical support during the duration of the intervention.
89460465|NCT04861311|No Intervention|Wait-List Control Group|The control group is a wait-list control group. Participants in the control group will be offered to use the app after 10 weeks of being in the study. The control group participants once they opted to use the app after 10 weeks will only have access to the app for 6 weeks.
89460466|NCT03661957|Active Comparator|Non grafted maxillary sinus floor elevation with implant pacem|
89460467|NCT03661957|Experimental|using short dental implants for posterior atrophic maxilla|
89460468|NCT03661879|Experimental|NNC9204-1706|Participants will receive NNC9204-1706 for 10 weeks. There will be a 2-week follow-up period after the treatment period.
89460469|NCT03661879|Placebo Comparator|Placebo (NNC9204-1706)|Participants will receive placebo (NNC9204-1706) for 10 weeks. There will be a 2-week follow-up period after the treatment period.
89460470|NCT03478059|Experimental|Mild Traumatic Brain Injury|"60 minute, 3 times per week, 6 week long Cognitive and Motor Dual-task Intervention program. The intervention will consist of 6 stations that target known motor and cognitive impairments after mTBI.~Subjects with mTBI residuals will be gently progressed through exercise stations in an individually tailored fashion."
89460471|NCT03478059|Other|Healthy Control|"60 minute, 3 times per week, 6 week long Cognitive and Motor Dual-task Intervention program. The intervention will consist of 6 stations that target known motor and cognitive impairments after mTBI.~In addition to providing comparison data, the healthy control, athletic 18-34 year old subjects will be used to identify levels and intensity of progressions of dual-task training stations appropriate for highly trained athletes and military personnel recovering from concussion."
89460472|NCT05158881||Neonates delivered by normal vaginal delivery|
89460473|NCT05158881||Neonates delivered by elective cesarean section.|
89460474|NCT05158803||covid 19 in acute phase|
89460475|NCT05158803||covid 19 follow up|
89460476|NCT04802577||Primary Sjögren's syndrome|The patient's diagnosed with Primary Sjögren's according to 2016 ACR/EULAR classification criteria
89460477|NCT04802577||Healthy Controls|Healthy hospital workers without any chronic disease
89460478|NCT05798702|Active Comparator|intensive lifestyle modifications|VLCD 800-850 Kcal/day
89460479|NCT05798702|Active Comparator|Roux-en-y-gastric bypass|laparoscopic RYGB
88942352|NCT01868984|Active Comparator|Standard Therapy Plus Paclitaxel|"Standard treatment of all stenotic lesions will be carried out in the usual fashion. Intravenous heparin will be administered in a standard dose of 70 units/kg. Lesions that respond poorly to angioplasty (>30% residual stenosis after angioplasty treatment with 2 inflations) will be stented. Stent selection will be based on clinical setting. Initial stent treatment will utilize an uncovered nitinol stent. Treatment of in-stent restenosis will include initial balloon angioplasty, and use of a covered stent (Viabahn, GORE, or Fluency, Bard).~For this treatment group, Paclitaxel solution treatment of each lesion encountered from proximal to distal will be attempted until the 20 mg Paclitaxel dose limit is met."
88942353|NCT01869010||HIV Tenofovir|
88942354|NCT01869010||HIV No tenofovir|
89460480|NCT05798689|Active Comparator|PR|Fifty healthy volunteers were randomly allocated in the probiotic arm. To eliminate residual traces of gluten and similar proteins from the faecal material, both groups underwent a gluten-free diet (GFD) from day-1 to day-10. After 10 days, gluten administration started. The increasing administration plan was as follows: 50 mg/day for 4 days; 1 g/day for subsequent 4 days; 3 g/day for subsequent 4 days; and 10 g/day (in this case, reintroducing an equivalent amount of wheat-based bread - 4 slices) for subsequent 20 days. At this stage (10 + 4 + 4 + 4 + 10 days = total of 32 days), the administration of the probiotic preparation was interrupted, with a period of 10 days of wash-out.
89460481|NCT05798689|Placebo Comparator|PL|Twenty healthy volunteers were randomly allocated in the placebo.To eliminate residual traces of gluten and similar proteins from the faecal material, both groups underwent a gluten-free diet (GFD) from day-1 to day-10. After 10 days, gluten administration started. The increasing administration plan was as follows: 50 mg/day for 4 days; 1 g/day for subsequent 4 days; 3 g/day for subsequent 4 days; and 10 g/day (in this case, reintroducing an equivalent amount of wheat-based bread - 4 slices) for subsequent 20 days. At this stage (10 + 4 + 4 + 4 + 10 days = total of 32 days), the administration of placebo preparation was interrupted, with a period of 10 days of wash-out.
88942355|NCT01869010||Seronegative controls|
89460482|NCT05798676||mothers with pre-pregnancy normal weight and their infants|mothers with pre-pregnancy normal weight according to World Health Organization will provide blood and milk samples
89460483|NCT05798676||mothers with pre-pregnancy overweight or obesity and their infants|mothers with pre-pregnancy overweight or obesity according to World Health Organization will provide blood and milk samples
89460484|NCT05798598|Active Comparator|GIP - Face-to-face intervention group|Participants in the scientific writing face-to-face training course.
89460485|NCT05798598|Active Comparator|GIO: Online intervention group|Participants in the scientific writing online training course.
89460486|NCT05798598|No Intervention|GIC: Control intervention group|Participants in other face-to-face training courses not related to scientific writing.
89460487|NCT05798546|Experimental|Treament of Neo-T|"Part A dose escalation will use a 3+3 design and will enroll cohorts of 3-6 patients with MEL or NSCLC at escalating doses of 1.2×10^9 cells and 2.4×10^9 cells.~Part B will enroll 15 patients with MEL and 5 patients with NSCLC. The administration dose will be identified by the safty of Part A."
89460488|NCT05798494|Experimental|Intervention|Intervention group will receive dietary counseling by a trained dietitian from 3 months post-partum of the 1st child until birth of the 2nd child. The mother will receive advice to provide a moderate caloric restriction (-500 to 1000 kcal/d) and attend physical activity sessions to attain a 10 % weight loss according to pre-pregnancy weight. If the father is also overweight or obese, he will receive the same advice.
89460489|NCT05798494|No Intervention|Control|The control group will receive standard care and will not receive any dietary advice prior to pregnancy. During pregnancy control subjects will receive dietary advice according to standard care which means no counselling from a dietitian unless there are special needs (e.g., gestational diabetes), then they will receive counseling from a dietitian in accordance with standard care.
89460490|NCT05798455|Experimental|Intervention arm|Capsules containing sodium pentaborate pentahydrate 500, 1000 and 1500 mg
89460491|NCT05798442|Experimental|mHealth app-based intervention group|The app-based intervention group will be given access to a mHealth app that will be specifically designed to motivate the users to increase their physical activity and healthy diet intake while reducing smoking and alcohol intake. The app provides the patients with standardized dietary and exercise guidelines and sends them frequent advice and reminders to follow the guidelines. Changes in the CVD risk factors of the participants will be assessed based on blood biochemical and anthropometric measurements collected every 4 months over a period of 20 months. The app will be designed to include interactive functions which allow the patients to insert their daily caloric intake and exercise, biometric data, track the improvement in their CVD risk factors and CVD risk score.
89460492|NCT05798442|No Intervention|face-to-face consultation group|This group of patients will not have access to mHealth app and will receive the traditional face to face intervention.
89460493|NCT05798429|Experimental|experimental group|
89460494|NCT05798429|No Intervention|control group|
89460495|NCT05798364||Index patients|Adults MDR-E carriers.
89460496|NCT05798364||Household members|Adults or children living in the same household as the index case (i.e. sharing the same kitchen and/or bathroom and/or toilets) during the 3 months following inclusion
89460497|NCT05798312|Experimental|Intervention group|The intervention group will receive customizable support material.
89460498|NCT05798312|Sham Comparator|Standard group|The standard group will receive a non-customizable support material.
89460499|NCT05798299|Experimental|UP-C/C|UP-C/C intervention - 15 weekly sessions for children; 3 group sessions for parents; 1 family meeting before exposure sessions.
89460500|NCT05798299|Active Comparator|Coping Cat, Group Format|Coping Cat in group format intervention - 16 weekly sessions for children; 2 individual sessions for parents.
89460501|NCT05798208||hypertensive|Covid patients with exacerbated hypertension or new hypertension post covid
89460502|NCT05798208||non hypertensive|Covid patients with no change in blood pressure pre and post covid
88942356|NCT01869023|Other|6 h infusion Gemcitabine and Cisplatin|Gemcitabine 250 mg/m2 Cisplatin 30 mg/m2
88942357|NCT01869036|Active Comparator|caudal anesthesia|
88942358|NCT01869036|Active Comparator|caudal anesthesia supplemented with morphine|
88942359|NCT01869049||ITP patients accepted splenectomy|
88942360|NCT01869049||Trauma with spleen rupture underwent splenectomy|
88942361|NCT01869062|Other|SonR CRT Optimization 'On'|CRT-D device with the SonR optimization algorithm programmed being 'on'.
88942362|NCT01869062|Other|SonR CRT Optimization 'Off'|CRT-D device with the SonR optimization algorithm programmed being 'off' (Standard of Care).
88942363|NCT01869088|Active Comparator|TACE Only|TACE with chemothrapy drugs (E-ADM 50mg, Lobaplatin 50 mg, MMC 6mg)and followed with embolization with lipiodol or/and polyvinyl alcohol particles.
88942364|NCT01869088|Experimental|TACE Plus Adenovirus|After identifying the target artery of HCC, Recombinant Human Adenovirus Type 5 Injection（15.0*1011vp：0.5ml*3） will be first infused through the target artery of HCC patient and followed with chemothrapy drugs (E-ADM 50mg, Lobaplatin 50 mg, MMC 6mg) and lipiodol emulsion or/and polyvinyl alcohol particles(dependent on the tumor size) Procedure: TACE (Transcatheter arterial chemoembolization)
88942365|NCT01869127|No Intervention|Control|Standard care
88942366|NCT01869127|Experimental|Shoes|Shoes
88942367|NCT01869140|Sham Comparator|sham spinal manual therapy|activator set to zero
88942368|NCT01869140|Experimental|percussive spinal manual therapy|activator set to the maximum force
88942369|NCT01869140|Experimental|Firm thoracic spinal manual therapy|Firm thoracic manipulation
88942370|NCT01869153||Preterm infants|Preterm infants born at either <32 weeks gestation or < 1750g birth weight
88942371|NCT01869166|Experimental|anti-tumor response of CART-EGFR|
88942372|NCT01869179|Experimental|Community of Voices choir program|Participants will receive the 12 month choir program as soon as possible after study enrollment.
88942373|NCT01869179|Experimental|Wait-list control group|Waits six months, and at the end of the six months is offered the option of participating in the 12 month choir program.
88942374|NCT01869205|Experimental|Endobronchial valve:|Endobronchial valve (size 4.0 - 7.0 mm or 5.5 - 8.5 mm) insertion for target bronchi
88942375|NCT01869231|Experimental|major surgery|colic surgery
88942376|NCT01869231|Experimental|minor surgery|appendectomy; cholecystectomy
88942377|NCT01869231|Experimental|ileostomy and colostomy|ileostomy colostomy
88942378|NCT01869231|Experimental|other surgery|all of others abdominal surgical intervention
88942379|NCT01869244||hand resting splint|Patients with hand resting splint treatment
89460503|NCT05798195|Active Comparator|controlled group|conventional western medicine treatment including oxygen therapy, antibiotics, nebulization therapy, etc.
89460504|NCT05798195|Experimental|dexamethasone group|dexamethasone 1.5mg/day for one week and 0.75mg/day for another week basing on conventional western medicine.
89460505|NCT05798195|Experimental|Chinese medicine group|Strengthening spleen and tonifying lung decoction for 2 weeks basing on conventional western medicine.
89460506|NCT05798182||ICU patients|Adult patients admitted to the ICU.
89460507|NCT05798169|Experimental|Intervention Group|Group of participants receiving resistance training during hospitalisation
89460508|NCT05798169|Sham Comparator|Control Group|Group of participants receiving sham training during hospitalisation
89460509|NCT05798143|Experimental|Active arTMS treatment|rTMS is a non-invasive brain stimulation technique. It will be used a MagPro R30 with the Cool-B-70 figure-of-eight coil (MagVenture, Falun, Denmark).
89460510|NCT05798052|Other|Low-High stress group|Complete the first simulated clinical scenario in the low stress condition, then complete the second simulated scenario in the high stress condition.
89460511|NCT05798052|Other|High-Low stress groups|Complete the first simulated clinical scenario in the high stress condition, then complete the second simulated scenario in the low stress condition.
89460512|NCT05798000||Control|The control group without WHO and equipment checklist used
88942380|NCT01869257|Active Comparator|control|regular suture not coated with triclosan
88942381|NCT01869257|Experimental|triclosan|Experimental group will receive abdominal wound closure with suture matherial that is coated with triclosan
88942382|NCT01869283|Experimental|Kinesiotherapy group|The volunteer will be subjected to the following protocol: cervical traction, 3 sets of 1 minute, 30-second rest between sets; mobilization grade III postero-anterior on the spines processes of vertebrae C2 to C7, 10 oscillations for each vertebrae; myofascial release of the upper trapezius muscle, 3 sets of 1 minute for each side; static stretching of the upper trapezius muscle, 3 sets of 30 seconds, with an interval of 10 seconds between sets.
88942383|NCT01869283|Experimental|kinesiotherapy + static ultrasound group|Same protocol group kinesiotherapy + ultrasound on the trigger points of the upper trapezius muscle in a static way, with 1 MHz, continuous dose of 1.5 W/cm2, for 1.5 minutes.
88942384|NCT01869283|Experimental|kinesiotherapy + diadynamic currents group|Same protocol group kinesiotherapy + diadynamic currents, with negative electrode (7.0 x 7.0 cm) placed on the myofascial trigger point, while the positive electrode (7.0 x 7.0 cm) is placed between the shoulder blades. Will apply 4 minutes from the biphasic mode (DF) and 6-minute short period (CP), the first of which intesidade the sensory threshold and the second threshold motor, both bearable for the patient.
88942385|NCT01869283|No Intervention|Control group|The volunteers of this group will not be subjected to any form of treatment, was evaluated in three stages, as the other groups. It is noteworthy that, after the volunteer's participation, will be offered at the same physical therapy for myofascial pain.
88942386|NCT01869296|Active Comparator|higher flow rates endoscope pump|higher flow rates endoscope water pump : 10.4 ml/sec
88942387|NCT01869296|Experimental|lower flow rates endoscope water pump|lower flow rates endoscope water pump : 1.7 ml/sec
88942388|NCT01869309|No Intervention|Non-HPR group|The non-HPR group will have PD and genetic testing, with no change in medication.
88942389|NCT01869309|Active Comparator|HPR Group|This arm will be split into Group A and Group B which will receive Ticagrelor/Prasugrel in a crossover manner.
88942390|NCT01869322|Experimental|Sling and Swathe|In this arm, study subjects will receive sling and swathe immobilization for humeral shaft fracture.
88942391|NCT01869322|Active Comparator|Coaptation Splint|In this arm participants receive a coaptation splint for humeral shaft fracture.
88942392|NCT01869335|Active Comparator|radiography|Arm1: patients undergo mammographic localizations and radiography of the specimen after surgical resection.
88942393|NCT01869335|Active Comparator|MRI (magnetic resonance imaging)|Arm2: patients undergo MRI localization and ex vivo MRI after surgical resection.
88942394|NCT01869387|No Intervention|Standard treatment|Standard treatment consists in bronchodilator and parenteral corticosteroids and oxygen therapy.
88942395|NCT01869387|Experimental|Standard treatment plus non-invasive ventilation|This arm consists in bronchodilator and parenteral corticosteroids and oxygen therapy plus non-invasive ventilation.
88942396|NCT01869400||Yondelis-Pegylated liposomal Doxorubicin|30 mg/m² PLD i.v. followed by 1.1 mg/m² Yondelis® i.v. 3 h, q3weeks
88942397|NCT01869426|Active Comparator|VSL#3 drops|31 infants will receive 10 drops active product that should be taken daily (preferably in the morning before feeding) for 21 days.
88942398|NCT01869426|Placebo Comparator|VSL#3 drops placebo|31 infants will receive 10 drops of placebo product that should be taken daily (preferably in the morning before feeding) for 21 days.
88942399|NCT01869452|Other|therapeutic education class 1|patients in class 1 will have a follow up call with therapeutic education every 3 months. this is the light follow up.
88942400|NCT01869452|Other|therapeutic education class 2|patients in class 2 will have a follow up call with therapeutic education every month. this is the moderate follow up
88942401|NCT01869452|Other|therapeutic education class 3|patients in class 3 will have a follow up call with therapeutic education twice a month. this is the heavy follow up.
88956457|NCT05157360|Experimental|Treatment Arm|"Patients will be enrolled within 24 hours of diagnosis of sepsis related to a necrotizing soft-tissue infections (NSTI). HAT will be initiated within 4 hours of enrollment (thus treatment with HAT can occur no later than 28 hours from diagnosis).~Per Dr. Marik's original study, HAT consists of:~1.5 g vitamin C every 6 hours for 4 days or until ICU discharge~50 mg hydrocortisone every 6 hours for 7 days or until ICU discharge (followed by a taper over 3 days)~200 mg thiamine every 12 hours for 4 days or until ICU discharge In our study, due to the prolonged ICU course typical of most patients with NSTIs, it is not felt feasible to continue indefinitely until ICU discharge. Thus, treatment will be continued for 4 to 7 days plus a 3 day taper (respectively) as above, with no plan for a longer duration of treatment."
89460513|NCT05798000||Study|Other group, where WHO safety check-list and equipment check-list were implemented
89460514|NCT05797961|Experimental|HIV self-testing with online supervision|HIV self-testing with online supervision
89460515|NCT05797961|Other|Control|venue-based HIV testing
89460516|NCT05797948|Experimental|GZL sequential CD19/CD22 CAR-T|"Phase I (combined immunotherapy period):~2-4 cycle of combination chem-free therapy with Obinutuzumab, Zanubrutinib and Lenalidomide . Each cycle is 21 days.~Phase II (CAR-T therapy):~CAR-T therapy with AZA + FC (Azacitidine, Fludarabine and Cyclophosphamide) conditioning regimen. Targets of CAR-T cells are CD19/CD22."
89460517|NCT05797922|Experimental|DWP16001 to Group A|Group A: Fasting in Period 1 / Fed in Period 2
89460518|NCT05797922|Experimental|DWP16001 to Group B|Group B: Fed in Period 1 / Fasting in Period 2
89460519|NCT05797909||Target Population|The target population includes individuals diagnosed with PCOS by a healthcare provider, self-diagnosed with PCOS, or who are exhibiting PCOS Symptoms and willing to sign the consent.
89460520|NCT05797909||Control Population|The control population includes people born biologically female who have not been diagnosed with PCOS and who also do not have symptoms of PCOS.
89460521|NCT05797883|Experimental|FOLFOX/FOLFIRI|q2w, after 8 cycles of medication or patient intolerance or disease progression;
89460522|NCT05797844|Experimental|Experimental Group|Nurses included in experimental group were trained through a 4-hour presentation (passive implementation strategy) prepared in the presence of evidence-based guidelines and literature, in addition, they were given a brochure about cuff pressure measurement and a brochure about cuff pressure was hung in the intensive care units where there are handwashing sinks. In addition, 4 follow-up visits (active strategy) were carried out for ETT cuff pressure management using the one-on-one demonstration technique every 21 days.
89460523|NCT05797844|Active Comparator|Control Group|Nurses included in control group were trained through a 4-hour presentation (passive implementation strategy) prepared in the presence of evidence-based guidelines and literature, in addition, they were given a brochure about cuff pressure measurement and a brochure about cuff pressure was hung in the intensive care units where there are handwashing sinks.No follow-up visits were made to this group
88942402|NCT01869465|Active Comparator|Education arm|In the education arm, children will receive specific messages for schistosomiasis transmission and control 1 month prior to Mass Drug Administration. A synopsis of the messages will include the following:What schistosomiasis is and its public health significance among school age children, Schistosomiasis transmission methods, signs and symptoms and its complications, Control methods including the importance of taking preventive treatment annually, Side effects of preventive treatment, why some people suffer serious side-effects and others do not and what to do in order to mitigate the side effects.From each school, the head teacher and the school teacher in-charge of health and sanitation will be trained in the above ,basic principles of health education and in communication skills through a 2 days training workshop. The trained head teachers and heath teachers will in turn, deliver the messages to the children through face to face interactions during school assemblies, twice a week.
88942403|NCT01869465|Experimental|Snack arm|The snack will consist of a 300 ml Safi mango juice and a doughnut. Ingredients of the Safi mango juice include vitamin C, fruit flavors from concentrate, sugar, water, citric acid, color E 110 and preservative E 221. The doughnuts will be made of wheat flour, baking powder, sugar and cooking oil. A local manufacturer (House of Eden (U) Limited) will be contracted to make, pre-pack and distribute the snack to the research team at the schools during Mass Drug Administration (MDA). All children in the schools randomized to the snack arm will receive the snack shortly before swallowing the drug. The snack will be distributed by the class teachers who will also distribute record the treatment and snack in separate registers. The snack is estimated to cost about 1 US $ per child.
88942404|NCT01869491|Active Comparator|Sodium Alginate Double Action Tablets|Compound Sodium Alginate Double Action Chewable Tablets, 2 tablets four times daily
88942405|NCT01869491|Placebo Comparator|Matching placebo tablets|Matching placebo tablets, 2 tablets four times daily
88942406|NCT01869504|Experimental|Balloon-tipped intercostal drain|Subjects who have given written informed consent and who fulfill the inclusion and exclusion criteria will proceed to have the study drain inserted at the earliest opportunity as per standard hospital protocols using local anaesthetic, and conscious sedation where appropriate. All other aspects of their treatment will be identical to usual clinical care, including chest drain checks and fluid drainage strategies.
88942407|NCT01869517|Active Comparator|Intrastromal corneal continuous ring (Myoring)|
88942408|NCT01869517|Active Comparator|Intrastromal corneal ring segments (Keraring)|
88942409|NCT01869543|Experimental|Stand Alone Air Cleaner-True/Sham|The participant will have stand alone air cleaners placed in their home. They will have true filtration followed by sham filtration.
88942410|NCT01869543|Experimental|Stand Alone Air Cleaner-Sham/True|Participants will have stand alone air cleaners placed in their homes. They will begin with sham filtration.
88942411|NCT01869543|Experimental|HVAC modification-True/Sham|Participants will have their HVAC system modified to include high efficiency filtration. They will begin true filtration followed by sham filtration.
88942412|NCT01869543|Experimental|HVAC Modification-Sham/True|Participants will have their HVAC system modified to include high efficiency filtration. They will begin sham filtration.
88942413|NCT01869556|Active Comparator|Oxytocin only|Oxytocin 5IU IV bolus, followed by an infusion of oxytocin 20IU/L, running at at rate of 40mIU/min for 8 hours
88942414|NCT01869556|Active Comparator|Oxytocin + Ergot|Oxytocin 5IU IV bolus + Ergot 0.25mg IV, followed by an infusion of oxytocin 20IU/L, running at at rate of 40mIU/min for 8 hours
88942415|NCT01869556|Active Comparator|Oxytocin + Carboprost|Oxytocin 5IU IV bolus + Carboprost 0.25mg IM, followed by an infusion of oxytocin 20IU/L, running at at rate of 40mIU/min for 8 hours
89017409|NCT00419211|Experimental|Lifestyle counseling|Tailored exercise program
89017410|NCT00419211|No Intervention|No Intervention|Usual care group
89017411|NCT00283946|Experimental|1|
89017412|NCT00283946|Active Comparator|2|
89017413|NCT00312000|Active Comparator|1Capecitabine-irinotecan|1st line- 2nd line (3rd line oxaliplatin plus capecitabine)
89017414|NCT00312000|Experimental|2capecitabine plus irinotecan|1st line (2nd line oxaliplatin plus capecitabine)
89017415|NCT00419250|Experimental|dose-escalation to 5 mg lenalidomide (len)|escalate up to 5 mg once daily / 28-day cycle
89460524|NCT05797818|Experimental|Methylene Blue|"All subjects will have an initial baseline culture done of their nasal microbiome followed by an administration of 0.01% methylene blue solution. Next, subjects will undergo two minute of non-thermal red light exposure. A second round of solution administration and light exposure will be repeated resulting in 4 minutes of red light exposure.~Once the treatment has been completed, a new culture will be taken from the subjects nares followed by one at 4-, 8-, 24-, and 48-hours after treatment."
89460525|NCT05797818|Experimental|Chlorhexidine gluconate|"All subjects will have an initial baseline culture done of their nasal microbiome followed by an administration of 0.25% chlorhexidine solution. Next, subjects will undergo two minute of non-thermal red light exposure. A second round of solution administration and light exposure will be repeated resulting in 4 minutes of red light exposure.~Once the treatment has been completed, a new culture will be taken from the subjects nares followed by one at 4-, 8-, 24-, and 48-hours after treatment."
89460526|NCT05797818|Experimental|Methylene blue and Chlorhexidine gluconate|"All subjects will have an initial baseline culture done of their nasal microbiome followed by an administration of 0.01% methylene blue and 0.25% chlorhexidine gluconate solution. Next, subjects will undergo two minute of non-thermal red light exposure. A second round of solution administration and light exposure will be repeated resulting in 4 minutes of red light exposure.~Once the treatment has been completed, a new culture will be taken from the subjects nares followed by one at 4-, 8-, 24-, and 48-hours after treatment."
89460527|NCT05797818|Experimental|Light Only|"All subjects will have an initial baseline culture done of their nasal microbiome followed by 4 minutes of non-thermal red light exposure.~Once the treatment has been completed, a new culture will be taken from the subjects nares followed by one at 4-, 8-, 24-, and 48-hours after treatment."
89017416|NCT00419250|Experimental|dose-escalation to 10 mg lenalidomide (len)|escalate up to 10 mg once daily / 28-day cycle
89017417|NCT00419250|Experimental|dose-escalation to 15 mg lenalidomide (len)|escalate up to 15 mg once daily / 28-day cycle
89460528|NCT05797792|Experimental|Intraarterial alteplase|All the patients will be given a 15 minutes IA infusion of alteplase (Actylise®) at a drug concentration of 1.0 mg/ml. At 15 minutes of IA treatment onset, the infusion will be stopped and the angiographic score assessed. Study drug will be prepared according to the following steps: 1/ Dilute 2 vials of 10 mgs (rt-PA) in 20 cc of sterile water for injection (SWI), to attain a 20 ml solution at a concentration of 1mg/ml; 2. Calculate the volume of cc of infusion and therefore the total dose as per the formula: (Patient's weight in Kgs multiplied by 0.225). A patient of 89 Kgs or more will receive 20.0 cc of infusion for 15 min, totaling a dose of 20.0 mg of rt-PA.
89460529|NCT05797792|No Intervention|No intervention|Patients allocated to this arm will receive a similar care to patients allocated to IA alteplase except the thrombolytic
89460530|NCT05797779|Experimental|Skin biopsy|
89460531|NCT05797753|Experimental|Part-A, Period-1|Single dose of SAR443820 tablet on Day 1
89460532|NCT05797753|Experimental|Part-A, Period-2|Single dose of SAR443820 tablet on Day 6, and erythromycin ethyl succinate (EES) three-time a day (TID) from Day 1 to Day 9
89460533|NCT05797753|Experimental|Part-B, Period-1|Single dose of SAR443820 capsule on Day 1
89460534|NCT05797753|Experimental|Part-B, Period-2|Single dose of SAR443820 capsule on Day 6, and Itraconazole once daily (QD) from Day 1 to Day 11
89460535|NCT05797714|Experimental|TMF treatment group|TMF 25mg QD, from baseline to 48 weeks
89460536|NCT05797714|No Intervention|Blank control group|No antiviral therapy is given. If ALT>2 ULN (40 IU/L) for HBeAg-positive patients or > ULN for HBeAg-negative patients during the study period, blank control group can be switched to TMF treatment once a day, 25mg/ time orally until the end of the study.
89460537|NCT05797701|Experimental|Treatment A|Single dose of SAR443820 tablet in fasted condition
89460538|NCT05797701|Experimental|Treatment B|Single dose of SAR443820 capsule in fasted condition
89460539|NCT05797701|Experimental|Treatment C|Single dose of SAR443820 tablet in fasted condition
89460540|NCT05797701|Experimental|Treatment D|Single dose of SAR443820 tablet in fed condition
89017418|NCT00419250|Experimental|dose-escalation to 20 mg lenalidomide (len)|escalate up to 20 mg once daily / 28-day cycle
89017419|NCT00419250|Experimental|dose-escalation to 25 mg lenalidomide (len)|escalate up to 25 mg once daily / 28-day cycle
89017420|NCT00284102|Experimental|1|ALI/ARDS patients
89017421|NCT04718831|Other|Baseline|Did not take nutritious food
89017422|NCT04718831|Experimental|General dose|Taking 6g spirulina
89017423|NCT04718831|Experimental|Double dose|Taking 12g spirulina
89017424|NCT00284219|Active Comparator|Real high frequency rTMS|The patients will undergo a series of treatments of high frequency rTMS
89017425|NCT00284219|Sham Comparator|Sham high frequency rTMS|The patients will receive a series of sham treatments.
89017426|NCT00284258|Experimental|1|CPT-11 and TS-1
89017427|NCT00284258|Active Comparator|2|CPT-11, 5-FU and l-LV
89017428|NCT00284453||1|Forty(40)subjects that have received >2 appropriate ICD shock therapies
89017429|NCT00284453||2|Twenty(20)subjects that have received 1-2(low level)appropriate ICD therapies
89017430|NCT00284453||3|Ten(10)subjects that received inappropriate therapies from their ICD
89017431|NCT04718753|Experimental|Mindful Breathing Group|Mindful breathing intervention which has been used in mindfulness-based interventions
89017432|NCT04718753|No Intervention|Waitlist Control Group|Participants in the waitlist control group will receive the intervention after the immediate post-treatment assessment
89017433|NCT02959788||Chest pain patients|All patients who present to the ED with chest pain.
89017434|NCT00284492|Active Comparator|Lifestyle advice|
89017435|NCT00284492|Experimental|Lifestyle advice and acupuncture therapy|
89017436|NCT00284609|Experimental|1|
89017437|NCT00284609|Active Comparator|2|
89460541|NCT05797688|Experimental|Treatment|Patients will undergo a fat harvest procedure and the tissue will then be processed by The Celution System to isolate a 5 mL aliquot including stem cells. This will then be injected into the base and within in perimeter of the target wound.
89460542|NCT05797584|Other|EchocardiocolorDoppler|EchocardiocolorDoppler examination
89460543|NCT05797532|Active Comparator|breastfeeding|The mother was allowed to sit comfortably in the patient's room, the pulse oximeter probe was attached to the left foot of the newborn, and the newborn, who was placed on the mother's lap, was breastfeeding for 5 minutes before the heel lance, and breastfeeding was continued during the procedure.
89460544|NCT05797532|Active Comparator|skin to skin contact|The newborn's clothes were removed so that only the diaper and baby hat were left, and a pulse oximeter probe was attached to his left foot. The newborn was placed on the mother's bare chest between her two breasts, facing the mother's face, with her head up, in the prone position, covered with a baby blanket, and skin-to-skin contact was made between the mother and the newborn for at least 5 minutes before starting the heel lance procedure.
89460545|NCT05797532|Active Comparator|swaddling and holding|A pulse oximeter probe was attached to the newborn's left foot, and the legs were in flexion and abduction position, wrapped with a square cloth blanket and placed on his mother's lap. It was ensured that the newborn was held in the mother's lap with his head up and feet down for 5 minutes before heel lance.
89460546|NCT05797493||ES-SCLC|ES-SCLC receiving upfront chemo-immunotherapy
89460547|NCT05797428|Experimental|Logotherapy|3 months of logotherapy intervention by interviewing with the participant, once every two weeks, about 1-2 hours each time, a total of 6 times of logotherapy.
89460548|NCT05797428|No Intervention|Routine psychiatric outpatient treatment|Will not provide any logotherapy. Just routine psychiatric outpatient treatment.
89460549|NCT05797415||Sebaceous carcinoma|patients with sebaceous carcinoma both primary and relapsed after surgical and/or radiation-chemotherapy treatment at Fondazione Policlinico Universitario A. Gemelli IRCCS
89460550|NCT05797415||Merkel's carcinoma|patients with Merkel's carcinoma both primary and relapsed after surgical and/or radiation-chemotherapy treatment at Fondazione Policlinico Universitario A. Gemelli IRCCS
89460551|NCT05797415||Porocarcinoma|patients with Porocarcinoma both primary and relapsed after surgical and/or radiation-chemotherapy treatment at Fondazione Policlinico Universitario A. Gemelli IRCCS
89460552|NCT05797415||Conjunctival Melanoma|patients with Conjunctival Melanoma both primary and relapsed after surgical and/or radiation-chemotherapy treatment at Fondazione Policlinico Universitario A. Gemelli IRCCS
89460553|NCT05797415||Squamous cell Carcinoma|patients with squamous cell Carcinoma of the ocular surface and adnexa both primary and relapsed after surgical and/or radiation-chemotherapy treatment at Fondazione Policlinico Universitario A. Gemelli IRCCS
89460554|NCT05797402||young-aged patients|Patients aged 18 to 45 years old.
89460555|NCT05797402||middle-aged patients|Patients aged 46 to 64 years old.
89460556|NCT05797402||elderly patients|Patients aged 65 and older.
89460557|NCT05797363|Experimental|Experiment|Continuous midwifery support will be applied to the intervention group. The women included in the experimental group will be counseled on many issues such as nutrition, vaccinations, family planning, pregnancy follow-ups, normal birth and cesarean section surgery, coping with labor pain, puerperium process, baby care, starting from the pre-pregnancy period, during pregnancy, childbirth and postpartum periods.
89460558|NCT05797363|No Intervention|Control Group|No action will be taken against this group.
89460559|NCT05797350|Active Comparator|Paul Glaucoma Implant|"The Paul glaucoma implant (PGI) will be used as an active comparator group to compare its effectiveness and safety with the Ahmed glaucoma valve in the treatment of childhood glaucoma. The PGI works by diverting excess fluid from the eye to a plate placed under the conjunctiva, which allows the fluid to drain away from the eye and be absorbed. This helps to lower the pressure inside the eye, which is important for preventing vision loss and other complications associated with glaucoma.~The PGI has a smaller internal and external tube diameter than the Ahmed glaucoma valve, which reduces the contact area between the tube and the corneal endothelium. This theoretically reduces the rate of endothelial cell loss, which can be a complication of GDDs. Additionally, the extraocular portion of the PGI is smaller, which may reduce the long-term risk of tube erosion and exposure.~The smaller lumen may theoretically reduce the risk of postoperative hypotony as well."
89460560|NCT05797350|Active Comparator|Ahmed Glaucoma valve|"The Ahmed glaucoma valve (AGV) arm of the study is the active comparator group and is intended to be directly compared to the Paul glaucoma implant (PGI) in treating childhood glaucoma. The AGV is a type of glaucoma drainage device that is designed to lower intraocular pressure in patients with refractory glaucoma. It is made of a rigid plastic material and consists of a small drainage tube that is inserted into the eye and a valve mechanism that helps regulate the flow of aqueous humor from the eye to the external drainage tube.~The AGV is implanted during a surgical procedure, and its design allows it to be placed in a variety of locations in the eye. The valve mechanism helps to regulate the flow of aqueous humor, and the device is designed to be long-lasting with a low risk of complications. The AGV is a well-established treatment option for patients with refractory glaucoma and has been used for many years in clinical practice."
89460561|NCT05797298||cataract patients implanted with toric IOLs|Cataract patients who received the implantation of different toric IOLs with different haptic designs
89460562|NCT05797220||Botulinum toxin group|The procedures were performed at outpatient clinic without anesthesia. Lyophilized 100 IU BT Type-A (BOTOX, Alergan, CA, USA) was applied after diluted with 1 cc saline. A 26-G injector was used to inject 25 unit toxin in every 4 quadrants, to the alignment of clock 12, 3, 6, and 9 to internal anal sphincters.
89501860|NCT02232841||Mechanical ventilation|Hospitalized adult patients with lung injury receiving mechanical ventilation and who also have received or will receive a CT scan as part of their standard care
89017438|NCT00318942|Active Comparator|1|Crystalloids, any type of Crystalloids including isotonic or hypertonic saline, Ringer Lactates either modified or not
89017439|NCT00318942|Experimental|2|Colloids, including albumin, gelatines, starch any other synthetic colloids
89017440|NCT00312390|Other|Healthy Control Subjects|
89017441|NCT00312390|Other|Subjects with amblyopia|
89017442|NCT00312546|Experimental|2A|Discontinuation of VPA and enfuvirtide administered for 24 weeks. As of 05/20/08 this step was discontinued.
89017443|NCT00312546|Experimental|2B|Continuation of VPA for up to 96 weeks. As of 05/20/08 this step was discontinued.
89017444|NCT00312546|Experimental|3A|VPA may be added to enfuvirtide for 16 weeks. VPA and enfuvirtide will be continued for up to 96 weeks in responders, and the study will be discontinued in nonresponders.
89017445|NCT00312546|Experimental|3B|Enfuvirtide may be continued for up to 96 weeks. As of 05/20/08 this step was discontinued.
89017446|NCT00312585|Experimental|Acupuncture|
89017447|NCT00312585|Sham Comparator|Sham Acupuncture|
89460563|NCT05797220||Botulinum toxin plus topical diltiazem group|The procedures were performed at outpatient clinic without anesthesia. Lyophilized 100 IU BT Type-A (BOTOX, Alergan, CA, USA) was applied after diluted with 1 cc saline. A 26-G injector was used to inject 25 unit toxin in every 4 quadrants, to the alignment of clock 12, 3, 6, and 9 to internal anal sphincters. After BT injection, topical 2% diltiazem gel was prescribed, applied 2 times per day for 10 days (2 doses of 1 gr each per day)
89460564|NCT05797207|Experimental|Colonoscopy|Fecal samples will be obtained from patients who are enrolled for colonoscopy procedure for the suspicion of inflammatory bowel disease
89460565|NCT05797194||POD group|Patients were considered to surfer from postoperative delirium by a positive Confusion Assessment Method (CAM) questionnaire after surgery.
89460566|NCT05797194||No-POD group|Patients did not surfer from postoperative delirium by a positive CAM questionnaire after surgery.
89460567|NCT05797142|Experimental|: Virtual reality glasses|"Beginning 1-2 minute before the start of the procedure, the patients will be watched (30 minutes) with an android mobile phone inserted into the Cardboard Super Flex Binoculars Glasses, with a music background, licensed product Secret Garden, during the procedure (30 minutes)."
89460568|NCT05797142|No Intervention|Control group|Routine maintenance will be applied
89460569|NCT05797077|Experimental|Adjuvant chemotherapy combined with maintenance therapy|
89460570|NCT05797077|Sham Comparator|Single adjuvant chemotherapy|
89460571|NCT05797064||Training set|The training set is a dataset used to train the model, which includes randomly enrolled patients with colon and rectal cancer. The inputs include data such as gender, age, height, weight, BMI, tumor stage, tumor pathology type, and the output information is whether NOSES surgery was successful or not. During training, the model learns from this dataset to make predictions on whether new patients with colon and rectal cancer can undergo NOSES surgery successfully.
89460572|NCT05797064||test set|The test set is a dataset used to evaluate the performance of a trained machine learning model. It includes another randomly enrolled group of patients with colon and rectal cancer, as well as their clinical and pathological data and surgical outcomes. The outputs are not used during training, but are used to test the trained model to evaluate its predictive ability on unknown data. The purpose is to evaluate the model's generalization ability, that is, its performance on new and unknown data.
89460573|NCT05797038||TAC group in remission|The patients with idiopathic membranous nephropathy were divided into two groups, the remission group and the non-remission group after the application of tacrolimus. The renal pathological sections of the two groups were observed by microhyperspectral imaging system, and the differences in the spectra of the two groups were analyzed.
89460574|NCT05797038||TAC group without remission|The patients with idiopathic membranous nephropathy were divided into two groups, the remission group and the non-remission group after the application of tacrolimus. The renal pathological sections of the two groups were observed by microhyperspectral imaging system, and the differences in the spectra of the two groups were analyzed.
89460575|NCT05796986|Experimental|Wide neck saccular cerebral aneurysms patients|
89017448|NCT00312585|No Intervention|Usual care only|
89017449|NCT00285233|Experimental|1|
89460576|NCT05796960||Surgical operations for advanced thyroid cancer|All adult (18 years old and older) patients registered in EUROCRINE® database with stage IV thyroid cancer, M1, N1b, or T3b and above will be included
89017450|NCT00285389|Experimental|VAD Clorambucil Rituximab|
89460577|NCT05796934|Experimental|Moments that Matter|The intervention group will receive the Moments that Matter (MTM) program, which will involve monthly peer group sessions and monthly home visits that are delivered by ECD promoters over an 18-month program duration, training of faith leaders, and the formation of ECD committees at the community-level.
89460578|NCT05796934|No Intervention|Waitlist-Control|The control group will not immediately receive the MTM program but instead the standard of care services (e.g., those provided by community health volunteers which are primarily focused on maternal and child health and nutrition). After follow-up assessments are completed for the trial, then villages in the control group will receive the MTM program.
89460579|NCT05796908|Experimental|Aptis PRUJ Prothesis|Investigational Aptis PRUJ Prothesis treatment
89460580|NCT05796895|Experimental|Intervention Group|Children will be provided with the videogame through which we will teach them symptom management strategies.
89017451|NCT00312780|Experimental|Arm 1: XL784|
89017452|NCT00312780|Placebo Comparator|Arm 2: Placebo Gel capsules|
89017453|NCT00285428|Experimental|Dose level 1|120 mg/m2
89017454|NCT00285428|Experimental|Dose level 2|200 mg/m2
89017455|NCT00285428|Experimental|Dose Level 3|375 mg/m2
89017456|NCT00285428|Experimental|Dose level 1B|80 mg/m2
89017457|NCT00319371||1|women with vasospasm and difficulties of initiating sleep
89017458|NCT00319371||2|women without vasospasm and no difficulties of initiating sleep
89017459|NCT00312936|No Intervention|Wait List|
89017460|NCT00312936|Experimental|MBSR|8 week mindfulness based stress reduction
89017461|NCT00285545||Good blood flow|Group with normal blood flow to small intestine
89017462|NCT00285545||Poor blood flow|Group with partial ischemia to small intestine
89017463|NCT00319488|Active Comparator|1|Active ICS plus placebo LTRA plus albuterol inhalation treatments four times daily
89017464|NCT00319488|Active Comparator|2|Active LTRA plus placebo ICS plus albuterol inhalation treatment four times daily
89017465|NCT00319488|Placebo Comparator|3|Placebo ICS plus placebo LTRA plus albuterol inhalation treatments four times daily
89460581|NCT05796895|Active Comparator|Attention Control Group|An attention control group will be used in this study for comparison with the intervention group. Children of the attention control group will receive weekly WhatsApp messages on general health behaviours.
89460582|NCT05796830|Active Comparator|Intervention Group|Before the operation, the rules of the puzzle will be explained to the patients in the intervention group and how it will be applied will be shown. Then, Patient Diagnosis Form, Mini-Mental State Test and Quality of Life Scale will be administered.On the 1st, 2nd and 3rd days after the surgery, the rules of the puzzle will be reminded again and the puzzle will be applied to the patients once a day. After the puzzle application on the 1st, 2nd and 3rd days after the surgery, the Mini-Mental State Test will be applied to the patients. Postoperative Recovery Index and Quality of Life Scale will be applied on the 3rd postoperative day.
89460583|NCT05796830|No Intervention|Control Group|Patients in the control group will be followed according to routine clinical procedure. Since there are no procedures or interventions in clinical procedures, only patient monitoring will be performed. The patients in the control group will also be followed and evaluated with the same forms at the same time.
89460584|NCT05795985||abdominal pain|patients with abdominal pain
89460585|NCT05795972|Experimental|inulin supplementation|
89460586|NCT05795972|Active Comparator|standard therapy|
89460587|NCT05795933|Experimental|Study group|Children receive a single dose of intramuscular 200,000 IU vitamin D3
89460588|NCT05795933|No Intervention|Control group|Children receiving only the standard recommended dose of vitamin D3 as 400 IU/day orally
89460589|NCT05794269||Main Group|Each patient complete the Turkish version of the QoR-15 score (TQoR-15) at 3 times (before surgery, on Day 1, on Day 3).
89460590|NCT05791773||Group rTKA (robotic total knee arthroplasty)|the robot assisted total knee arthroplasty
89460591|NCT05791773||Group cTKA (conventional total knee arthroplasty)|the conventional jig-based total knee arthroplasty
89017466|NCT00319527||Observation|Living Kidney Donors with controls who have not donated a kidney or had certain criteria at the time of the donor's donation (i.e. no hypertension, no kidney disease, etc.).
89017467|NCT00285662|Active Comparator|1|1 day Sulfadoxine/Pyrimethamine + 3 days Amodiaquine
89017468|NCT00285662|Active Comparator|2|1 day of Sulfadoxine/Pyrimthamine and 3 days of Artesunate
89017469|NCT00285662|Placebo Comparator|3|children of this gorup will receive only placebo dugs
89460592|NCT05791188||1- Prediabetics|"Prediabetics who will be diagnosed by:~Glycated hemoglobin (HbA1C) test 5.7 - 6.4% % on two separate tests~Fasting blood sugar test 110-125 mg/dL (6.1 - 6.9 mmol/L) on two separate tests.~Glucose tolerance test 140 - 179 mg/dL (7.8 - 9.9 mmol/L)"
89460593|NCT05791188||2- Diabetic patients without complications|"Patients with Type 2 diabetes who will be diagnosed by:~Glycated hemoglobin (HbA1C) test ≥ 6.5% on two separate tests~Fasting blood sugar test ≥ 126 mg/dL (7 mmol/L) on two separate tests~Glucose tolerance test ≥ 200 mg/dL (11.1 mmol/L) Random blood sugar test ≥ 200 mg/dL (11.1 mmol/L)"
89017470|NCT00313053|Experimental|Human mAb 216|
89017471|NCT00285896|Active Comparator|Active|GLP-1
89017472|NCT00285896|Placebo Comparator|Placebo|Placebo
89017473|NCT00286130|Active Comparator|FOLFOX 6|"FOLFOX 6:~Oxaliplatin 100 mg/m² d1 concurrent with~Leucovorin 400 mg/m², followed by~Bolus 5FU 400 mg/m² , followed by~Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks:"
89017474|NCT00286130|Active Comparator|FOLFIRI|"FOLFIRI:~Irinotecan 180 mg/m² day 1 concurrent with~Leucovorin 400 mg/m² followed by~Bolus 5FU 400 mg/m², followed by~Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks"
89017475|NCT00286208|Active Comparator|Sublingual Misoprostol|400 mcg of sublingual misoprostol
89017476|NCT00286208|Active Comparator|Oral Misoprostol|Misoprostol administered orally
89017477|NCT00319878|Experimental|1|Participants will be treated with sirolimus and cyclosporine. In phase I, each dose cohort will initially enroll three patients. If no dose-limiting toxicity (DLT) is observed by Day 28 in any patient of a cohort, then 3 patients will be treated with the next highest sirolimus dose. If 1 out of 3 patients in any cohort experiences a DLT, then 3 more patients will be enrolled in that cohort. If no more patients have a DLT by Day 28, then sirolimus dose escalation will proceed. If one or more patients experience a DLT then that dose level will be considered to be the maximum tolerated sirolimus dose, and Phase II patients will be treated at the next lowest level. Cyclosporine will be given as a twice daily oral dose.
89017478|NCT00319917|Experimental|1|
89017479|NCT00319917|Placebo Comparator|2|
89017480|NCT00286481|Experimental|Lapaquistat Acetate 50 mg QD + Simvastatin|
89017481|NCT00286481|Experimental|Lapaquistat Acetate 100 mg QD + Simvastatin|
89017482|NCT00286481|Active Comparator|Simvastatin|
89017483|NCT02959710|Experimental|Group 1|AC-1204 mixed in water, AC-1202 mixed in water, AC-1202 mixed in Ensure®
89460594|NCT05791188||3- Diabetic patients with complications|Diabetic patients with complications (nephropathy, neuropathy, cardiovascular, retinopathy, metabolic disorders, diabetic ketoacidosis)
89460595|NCT05791188||4- Controls|apparently normal subjects who have matched age and sex with patients groups
89460596|NCT05788315|Experimental|Cultural Formulation Interview|The 16 semi-structured questions of the CFI cover the cultural definition of the problem, cultural perception of its cause, context and support, cultural aspects of coping, and past and present help-seeking behavior. The CFI informant version consists of 17 questions about the same themes. The CFI aims to bridge cultural differences by explicitly asking about the client's cultural background and its influence on the presented problems
89460597|NCT05788315|Active Comparator|Standard Care|Standard intake and care
89017484|NCT02959710|Experimental|Group 2|AC-1204 mixed in water, AC-1202 mixed in water, AC-1202 mixed in Ensure®
89017485|NCT02959710|Experimental|Group 3|AC-1204 mixed in water, AC-1202 mixed in water, AC-1202 mixed in Ensure®
89460598|NCT05787717|Experimental|Parental presence|Parents are present and active in the care of their child until general anesthesia has been established in the operating room
89460599|NCT05787717|No Intervention|Control|Parents leave their infant in the holding area of the operating rooms
89460600|NCT05756712|Active Comparator|Wonderlab Product plus Placebo|"Wonderlab product: White Kidney Bean Pressed Candy, 4g/tablet, per serving 750mg extracts of the white kidney bean.~Placebo: 4g/tablet, per serving 750mg Maltodextrin"
89460601|NCT05756712|Active Comparator|Placebo plus Wonderlab Product|Placebo: 4g/tablet, per serving 750mg Maltodextrin Wonderlab product: White Kidney Bean Pressed Candy, 4g/tablet, per serving 750mg extracts of the white kidney bean.
89460602|NCT05740865||patients who developed deep surgical site infection after thoracolumbar surgery|this group included patients who developed deep surgical site infection after open posterior instrumented thoracolumbar surgery
89460603|NCT05740865||patients who did not develop deep surgical site infection after thoracolumbar surgery|this group included patients who did not develop deep surgical site infection after open posterior instrumented thoracolumbar surgery
89460604|NCT05738837|Experimental|A-EAAA (Adolescent Enhanced Assess, Acknowledge, Act) immediately|Adolescent adaptation of EAAA sexual assault resistance education (4, 3-hr sessions) begun immediately after baseline randomization
89460605|NCT05738837|Active Comparator|Waitlist Control|Usual care 30-min session (brief presentation on consent/sexual assault; access to local resource pamphlets) immediately after baseline randomization; A-EAAA (4, 3-hr sessions) at 6-months post-randomization
89460606|NCT05714683||Participants with T2DM|All participants will be treated with Rybelsus for 26 weeks according to routine clinical practice at the discretion of the treating physician according to the label approved by Ministry of Food and Drug Safety (MFDS).
89460607|NCT05702918|Active Comparator|Group A - ESWT + exercise|"Participants in group A will complete a 12-week ankle dorsiflexion resistance training protocol according to Silbernagel. It is a series of heel rise exercises with a gradual progression of load according to defined criteria, which the patient practices every day.~In addition, participants will receive a low-energy focused ESWT. In total, it will be applied 4 times with an interval of 7 days from the BTL-6000 FSWT device with piezoelectric generator. The energy will be set to 0.14 mJ/mm2, frequency 6 Hz, total number of shocks 1800. The application will be semi-static at the location of the largest USG finding. 600 shocks are applied from all three sides (medial, lateral, dorsal). The set values will not change throughout the research. These parameters were selected in accordance to ISMST guidelines."
89460608|NCT05702918|Active Comparator|Group B - exercise|Participants in group B will complete a 12-week ankle dorsiflexion resistance training protocol according to Silbernagel. It is a series of heel rise exercises with a gradual progression of load according to defined criteria, which the patient practices every day.
89017486|NCT00286598|Experimental|Feet First|Phase 1: (enrollment to 3 months) 8 sessions with a physical therapist learning leg strengthening and balance exercises, and initiating a walking program Phase 2: Motivational enhancement calls from a nurse every 2 weeks.
89017487|NCT00286598|No Intervention|Control|Usual care
89017488|NCT00320073|Experimental|Arm A|Pemetrexed, Vinflunine, Folate, B12, Dexamethasone, Ondansetron, Midazolam
89017489|NCT00320073|Experimental|Arm B|Vinflunine, Erlotinib, Ondansetron, Midazolam
89017490|NCT00286832||Single group study|
89017491|NCT00417326|Placebo Comparator|P|
89017492|NCT00417326|Experimental|E|
89017493|NCT00417404|Active Comparator|vitamin A|
89460609|NCT05699070|Experimental|DWC202211|
89460610|NCT05699070|Experimental|DWC202212|
89460611|NCT05699070|Experimental|DWC202211 + DWC202212|
89460612|NCT05697653|Experimental|intervention group (skin-to-skin contact group)|skin-to-skin contact: It is the laying of the newborn in the prone position on the mother's bare chest area with only a diaper on.
89460613|NCT05697653|No Intervention|control group|The routine applications of the hospital were applied to the pregnant women in the control group.
89460614|NCT05692999|Experimental|Pulse Arm|
89460615|NCT05692999|Active Comparator|Control Arm|
89460616|NCT05692934|Experimental|HR20031 FDC 10/100/1000 mg in the fast state|
89460617|NCT05692934|Experimental|HR20031 FDC 10/100/1000 mg in the fed state|
89460618|NCT05692934|Experimental|HR20031 FDC 5/50/750 mg*2 in the fast state|
89460619|NCT05692934|Experimental|HR20031 FDC 5/50/750 mg*2 in the fed state|
89460620|NCT05661591|Experimental|Treatment group A|SHR2554+ Fluconazole Capsules
89460621|NCT05661058||Total number of participants|As this is not an intervention study, the investigators only have one group which the investigators will follow at two-time points to map the context of sedentary behaviour.
89460622|NCT05660018|Other|Active rTMS first and sham rTMS second|Participants in this arm will receive active rTMS in one visit first, then receive sham rTMS in another visit.
89017494|NCT00417404|Sham Comparator|sham injection|
89017495|NCT00313404|Experimental|Norovirus in groundwater|We dosed volunteers with safety tested infectious norovirus in groundwater (that met EPA standards for drinking water). The length of time norovirus remained in groundwater varied by volunteer.
89017496|NCT00417521|Experimental|Family therapy|
89017497|NCT02960906|Experimental|ccRCC molecular subgroup 1: 1A|"ccRCC molecular subgroup 1 -> randomisation: subjects with ccRCC1 treated with nivolumab 240mg IV every 2 weeks until disease progression, unacceptable toxicity or other reasons specified in the protocol.~Starting from the Cycle 7 possibility to switch from nivolumab 240 mg every 2 weeks to 480 mg every 4 weeks according to the Investigator's preference."
89017498|NCT02960906|Experimental|ccRCC molecular subgroup 1: 1B|"ccRCC molecular subgroup 1 -> randomisation: subjects with ccRCC1 treated with nivolumab 3 mg/kg IV combined with ipilimumab 1 mg/kg IV every 3 weeks for 4 doses then nivolumab 240mg IV every 2 weeks until disease progression, unacceptable toxicity or other reasons specified in the protocol.~Starting from the Cycle 7 possibility to switch from nivolumab 240 mg every 2 weeks to 480 mg every 4 weeks according to the Investigator's preference."
89017499|NCT02960906|Experimental|ccRCC molecular subgroup 4: 4A|"ccRCC molecular subgroup 4 -> randomisation: subjects with ccRCC1 treated with nivolumab 240mg IV every 2 weeks until disease progression, unacceptable toxicity or other reasons specified in the protocol.~Starting from the Cycle 7 possibility to switch from nivolumab 240 mg every 2 weeks to 480 mg every 4 weeks according to the Investigator's preference."
89460623|NCT05660018|Other|Sham rTMS first and active rTMS second|Participants in this arm will receive sham rTMS in one visit first, then receive active rTMS in another visit.
89460624|NCT05649254||study group|in which TENS application will be applied
89460625|NCT05649254||Control group|placebo treatment
89460626|NCT05647174|Active Comparator|MGPOCUS-assisted bronchoscope-guided intubation|
89460627|NCT05647174|Experimental|Bronchoscope-guided Intubation|
89460628|NCT05634148|Experimental|Dexmedetomidine group|Patients in this group will receive intravenous dexmedetomidine before extubation
89460629|NCT05634148|Placebo Comparator|Control group|Patients in this group will receive intravenous placebo (0.9 % saline) before extubation
89460630|NCT05625126|Experimental|Rumination Invervention - 3 week baseline|"Baseline measures will be collected weekly for 3 weeks.~All participants will then receive a one-session online Rumination Intervention for PTSD with a follow-up call to clarify/solidify learning."
89460631|NCT05625126|Experimental|Rumination Invervention - 5 week baseline|"Baseline measures will be collected weekly for 5 weeks.~All participants will then receive a one-session online Rumination Intervention for PTSD with a follow-up call to clarify/solidify learning."
89460632|NCT05624385|Experimental|MRgFUS treatment|
89460633|NCT05622253|Experimental|Combined Low-Dose Isotretenion and Long-Pulsed 1064 ND-YAG Laser in the Treatment of Acne Erythema|Selected patients will be treated with low-dose oral isotretinoin (10mg/day) over a period of sessions and six sessions of 1064 ND- YAG laser (Deka motous AY) using 150 J/cm2, 20-25 milliseconds pulse duration, and 5 mm spot size, at 2 weeks' interval.
89460634|NCT05622123|Experimental|Patients with type 1 diabetes who have completed the ENCAPSULATE-DM1 or FMT preserve-DM1 trial|PET/CT imaging after injection with 68Ga-NODAGA-exendin-4 to quantify beta cell mass
89460635|NCT05616806|Experimental|distress tolerance skills training|technology delivered distress tolerance skills training
89460636|NCT05614245|Experimental|Group G1, Subgroup G1-A|10 participants aged 18-40 years to receive one dose of VBI-2901e at 5 µg spike protein and 1 µg E6020 per dose at Day 1
89460637|NCT05614245|Experimental|Group G1, Subgroup G1-B|10 participants aged 18-40 years to receive two doses of VBI-901e at 5 µg spike protein and 1 µg E6020 per dose at Day 1 and Day 28
89460638|NCT05614245|Experimental|Group G2, Subgroup G2-A|10 participants aged 18-40 years to receive one dose of VBI-2901e at 5 µg spike protein and 3 µg E6020 per dose at Day 1
89460639|NCT05614245|Experimental|Group G2, Subgroup G2-B|10 participants aged 18-40 years to receive two doses of VBI-901e at 5 µg spike protein and 3 µg E6020 per dose at Day 1 and Day 28
89460640|NCT05614245|Experimental|Group G3, Subgroup G3-A|10 participants aged 18-40 years to receive one dose of VBI-2901e at 5 µg spike protein and 10 µg E6020 per dose at Day 1
89460641|NCT05614245|Experimental|Group G3, Subgroup G3-B|10 participants aged 18-40 years to receive two doses of VBI-901e at 5 µg spike protein and 10 µg E6020 per dose at Day 1 and Day 28
89460642|NCT05599321||Historical Controls Cohort|Lung cancer patients who have previously undergone a clinical bronchoscopy. This group represents the current state-of-the-art bronchoscopy practice.
89460643|NCT05599321||Consented Clinical Bronchoscopy Cohort|Lung cancer patients, scheduled for bronchoscopy, who are consented for bronchoscopy assisted by the Virtual Navigator.
89460644|NCT05577026|Experimental|Educational intervention with prescription feedback|Healthcare personnel will participate in a brief educational intervention with information regarding treatment guidelines, recommendations, and risks of prescribing opioids. The presentation will include benchmarking on clinic opioid prescription patterns compared to other primary health centers, followed by targeted feedback on prescription patterns over the subsequent 12 months. Standardized materials will be provided, including a patient-provider agreement, outline of a patient treatment plan, and recommendations of how shared routines at the center can be improved.
89460645|NCT05577026|Active Comparator|Written information on guidelines|The manager at each PHC center in the active control group will receive written information on treatment guidelines for pain management. These centers will not receive the intervention, consisting of the onsite educational visit and targeted prescription feedback.
89017500|NCT02960906|Experimental|ccRCC molecular subgroup 4: 4B|"ccRCC molecular subgroup 4 -> randomisation: subjects with ccRCC1 treated with nivolumab 3 mg/kg IV combined with ipilimumab 1 mg/kg IV every 3 weeks for 4 doses then nivolumab 240mg IV every 2 weeks until disease progression, unacceptable toxicity or other reasons specified in the protocol.~Starting from the Cycle 7 possibility to switch from nivolumab 240 mg every 2 weeks to 480 mg every 4 weeks according to the Investigator's preference."
89201722|NCT00770016|Experimental|1|the aim of the present study is to characterize the treatment related changes in insulin sensitivity, substrate metabolism and intrahepatic - intramyocellular lipids in 12 adult patients, recently diagnosed with hypothyroidism
89201723|NCT00924963|Experimental|Jet injection lidocaine|J-Tip jet injection of 1% buffered lidocaine
89460646|NCT05577026|No Intervention|Standard care|The passive control group will consist of PHC centers that met the eligibility criteria for the study but did not actively participate in the study. Care as usual will proceed at the centers. Prescription data will be gathered directly from regional registers and databases; thus there will be no need to communicate directly with the centers. This arm will be used only if the General Data Protection Regulation continues to allow access to regional registers and databases in primary health care.
89460647|NCT05574374|Experimental|Cohort 1|"Treatment A: DWC202202 1 tablet qd for 7days~Treatment B: DWC202202 1 tablet qd + DWP14012 1 tablet qd for 7days~Treatment C: DWC202202 1 tablet qd + DWC202203 1 tablet qd for 7days"
89460648|NCT05574374|Experimental|Cohort 2|"Treatment C: DWC202202 1 tablet qd + DWC202203 1 tablet qd for 7days~Treatment A: DWC202202 1 tablet qd for 7days~Treatment B: DWC202202 1 tablet qd + DWP14012 1 tablet qd for 7days"
89460649|NCT05574374|Experimental|Cohort 3|"Treatment B: DWC202202 1 tablet qd + DWP14012 1 tablet qd for 7days~Treatment C: DWC202202 1 tablet qd + DWC202203 1 tablet qd for 7days~Treatment A: DWC202202 1 tablet qd for 7days"
89201724|NCT00924963|Placebo Comparator|Jet injection saline|J-Tip jet injection of sterile saline
89201725|NCT00924963|Active Comparator|Lidocaine cream|Lidocaine 4%cream applied for 30 minutes prior to IV insertion or venipuncture
89460650|NCT05550779|Experimental|Mental Exercise A|Participants follow instructions on a 10-minute audio clip
89460651|NCT05550779|Active Comparator|Mental Exercise B|Participants follow instructions on a 10-minute audio clip
89017501|NCT02960906|Experimental|ccRCC molecular subgroup 2: 2C|ccRCC molecular subgroup 2 -> randomisation: TKI (sunitinib 50mg daily or Pazopanib 800mg daily) according to investigator's choice until disease progression, unacceptable toxicity or other reasons specified in the protocol.
89017502|NCT02960906|Experimental|ccRCC molecular subgroup 2: 2B|"ccRCC molecular subgroup 2 -> randomisation: subjects with ccRCC1 treated with nivolumab 3 mg/kg IV combined with ipilimumab 1 mg/kg IV every 3 weeks for 4 doses then nivolumab 240mg IV every 2 weeks until disease progression, unacceptable toxicity or other reasons specified in the protocol.~Starting from the Cycle 7 possibility to switch from nivolumab 240 mg every 2 weeks to 480 mg every 4 weeks according to the Investigator's preference."
89460652|NCT05539157|Experimental|Phase 1a:Dose escalation|"JCXH-211 will be delivered by intratumoral injection in 3 stages:~Single administration stage A single administration of JCXH-211 administered to cutaneous or subcutaneous lesions in escalating doses.~Multiple administration stage Up to 3 doses of JCXH-211 administered to a cutaneous or subcutaneous lesion in escalating doses. Assigned dose to be determined on the data from the single administration arm.~Visceral administration stage JCXH-211 administered to a visceral lesion in escalating doses. Assigned dose to be determined on the data from the single and multiple administration arms."
89017503|NCT02960906|Experimental|ccRCC molecular subgroup 3: 3B|"ccRCC molecular subgroup 3 -> randomisation: subjects with ccRCC1 treated with nivolumab 3 mg/kg IV combined with ipilimumab 1 mg/kg IV every 3 weeks for 4 doses then nivolumab 240mg IV every 2 weeks until disease progression, unacceptable toxicity or other reasons specified in the protocol.~Starting from the Cycle 7 possibility to switch from nivolumab 240 mg every 2 weeks to 480 mg every 4 weeks according to the Investigator's preference."
89017504|NCT02960906|Experimental|ccRCC molecular subgroup 3: 3C|ccRCC molecular subgroup 3 -> randomisation: TKI (sunitinib 50mg daily or Pazopanib 800mg daily) according to investigator's choice until disease progression, unacceptable toxicity or other reasons specified in the protocol.
89017505|NCT04717830|Experimental|Gamezumab 1/10 therapeutic dose|1/10 therapeutic dose (5 volunteers)
89017506|NCT04717830|Experimental|Gamezumab 1/2 therapeutic dose|1/2 therapeutic dose (5 volunteers)
89017507|NCT04717830|Experimental|Gamezumab full therapeutic dose|therapeutic dose (10 volunteers)
89460653|NCT05539157|Experimental|Phase 1b:Dose expansion|JCXH-211 will be delivered by intratumoral injection. The dose to be used will be determined after review of the data from Phase 1a.
89460654|NCT05535816|Experimental|Ultrasound|Before completing retrograde intrarenal surgery, a complete endoscopic examination will be performed along with ultrasound by the same endourologist to determine the size of the largest residual fragment.
89460655|NCT05535816|No Intervention|Fluoroscopy|Standard of care, control Before completing retrograde intrarenal surgery, a complete endoscopic examination will be performed along with fluoroscopy by the same endourologist to determine the size of the largest residual fragment.
89460656|NCT05528965|Experimental|Perpendicular Group|Perpendicular genicular radiofrequency application
89460657|NCT05528965|Active Comparator|Parallel Group|Parallel genicular radiofrequency application
89017508|NCT00287183|Active Comparator|PF-04494700 (TTP488)|
89017509|NCT00287183|Placebo Comparator|Placebo|
89017510|NCT00419406|Experimental|A: UVA1|
89017511|NCT00419406|Experimental|B: NB UVB|
89017512|NCT00287261|Experimental|zometa|3-weekly infusion of zometa (zoledronic acid) 4 mg
89017513|NCT00313599|Experimental|Lapatinib and Paclitaxel|Lapatinib will be self-administered orally on days 1 and 2 of weeks 1, 2, and 3 of a 4-week cycle. Lapatinib is the experimental therapy and is being administered using a dose escalation design guided by careful monitoring of toxicities. Abraxane will be administered IV weekly on day 3 of weeks 1, 2, and 3 of a 4-week cycle. Abraxane is being administered at the well tolerated and effective standard dose and schedule of 100mg/m2 weekly 3 out of 4 weeks as defined by previous phase I and II studies. Patients will continue on therapy as long as they are not experiencing toxicities and there is no evidence of disease progression.
89017514|NCT00287378|Experimental|1|
89017515|NCT00320580|Experimental|001|norelgestromin/ethinyl estradiol
89017516|NCT00320619|Experimental|1|Participants will receive either EACA.
89017517|NCT00320619|Placebo Comparator|2|Participants will receive placebo.
89017518|NCT00287495|Experimental|A|Patients with AIDS-KS receiving ritonavir will be given 200 mg BAY 43-9006 once daily with dose escalation up to 400 mg twice daily
89460658|NCT05524116|Active Comparator|Group TX (Telehealth Exercise)|Participants in this group will receive a supervised and group-based exercise program once a week for 8 weeks via telehealth.
89460659|NCT05524116|Experimental|Group TMX (Telehealth Exercise and Mindfulness)|Participants in this group will receive a supervised, group-based integrated mindfulness and exercise program once a week for 8 weeks via telehealth.
89460660|NCT05520463|Experimental|Ultrasound guided sacral lateral branch radiofrequency ablation|Patients in this group will receive sacral lateral branch radiofrequency ablation under ultrasound guidance.
89460661|NCT05520463|Active Comparator|Fluoroscopy guided sacral lateral branch radiofrequency ablation|Patients in this group will receive sacral lateral branch radiofrequency ablation under fluoroscopy guidance.
89460662|NCT05506787|Experimental|Esketamine Group|The patients in S-ketamine group received 0.25 mg/kg intravenous S-ketamine (Jiangsu Hengrui Pharmaceutical Co., Ltd., Jiangsu, China) drip under general anesthesia induction, followed by continuous infusion of S-ketamine with 0.12 mg/kg/h for more than 30 minutes through target-controlled infusion. Drug A: S-ketamine, diluted to 1mg/ml with normal saline, total 50ml).
89460663|NCT05506787|Placebo Comparator|Placebo Group|Patients in Placebo group received intravenous infusion of 0.9% saline during anesthesia induction and were maintained through the infusion pump of drug B (50 ml 0.9% saline) for more than 30 minutes.
89460664|NCT05503511|Experimental|Part A; Cohort 1|QD dosing of 10mg (1 day)
89460665|NCT05503511|Experimental|Part A; Cohort 2|QD dosing of 50mg (1 day)
89460666|NCT05503511|Experimental|Part A; Cohort 3|QD dosing of 160mg (1 day)
89460667|NCT05503511|Experimental|Part B; Cohort 1|Every 12-hour dosing of 20mg (7 days)
89460668|NCT05503511|Experimental|Part B; Cohort 2|Every 12-hour dosing of 40mg (7 days)
89460669|NCT05503511|Experimental|Part B; Cohort 3|Every 12-hour dosing of 80mg (7 days)
89460670|NCT05503355|Experimental|Treatment|BSR-236 + venetoclax
89460671|NCT05486052|Other|Evaluation of reliability, repeatability and validity of devices among healthy subjects|Evaluation of the reliability, repeatability and credibility of biofeedback-based devices such as Biometrics, Luna EMG, Vectis, Rotor and nIRS among healthy individuals
89460672|NCT05486052|Other|Biofeedback method and Health-resort based rehabilitation|Health-resort based treatments supplemented with biofeedback training
89460673|NCT05486052|Other|Health-resort based rehabilitation|Control group - health-resort based treatments, without biofeedback training.
89460674|NCT05484206|Experimental|Cohort 1: CPT-B (moderate HI) participants and matched healthy participants will be evaluated first|All participants in Cohort 1 will be receiving VIR-2218 monotherapy.
89460675|NCT05484206|Experimental|Cohort 2: CPT-C (severe HI) participants and matched healthy participants|This arm is optional based on Cohort 1. All participants in Cohort 2 will be receiving VIR-2218 monotherapy.
89460676|NCT05484206|Experimental|Cohort 3: CPT-A (mild HI) participants and matched healthy participants|This cohort is optional. All participants in Cohort 3 will be receiving VIR-2218 monotherapy.
89460677|NCT05484206|Experimental|Cohort 4: CPT-A (mild HI) participants and matched healthy participants|All participants in Cohort 4 will be receiving VIR-3434 monotherapy.
89460678|NCT05484206|Experimental|Cohort 5: CPT-B (moderate HI) participants and matched healthy participants|All participants in Cohort 5 will be receiving VIR-3434 monotherapy.
89460679|NCT05484206|Experimental|Cohort 6: CPT-C (severe HI) participants and matched healthy participants|This arm is optional based on Cohort 5. All participants in Cohort 6 will be receiving VIR-3434 monotherapy.
89460680|NCT05484206|Experimental|Cohort 7: CPT-A (mild HI) and matched healthy participants|All participants in Cohort 7 will be receiving VIR-3434 and VIR-2218 combination therapy.
89460681|NCT05484206|Experimental|Cohort 8: CPT-B (moderate HI) and matched healthy participants|All participants in Cohort 8 will be receiving VIR-3434 and VIR-2218 combination therapy.
89460682|NCT05484206|Experimental|Cohort 9: CPT-C (severe HI) and matched healthy participants|This arm is optional based on Cohort 8. All participants in Cohort 9 will be receiving VIR-3434 and VIR-2218 combination therapy.
89460683|NCT05473143|Experimental|Protocolized fluid removal|
88942416|NCT01869569|Active Comparator|Pregabalin|Arm I:At the 4-week dose-titration phase, will receive one capsule of pregabalin (75 mg) twice daily from Day 1 to Day 7, and two capsules of pregabalin (150 mg) twice daily from Day 8 to Day 14. From Day 15 to Day 28, patients will perform dosage adjustments based on the pain relief and tolerability. At maintenance phase, patients will take the optimized dosage of pregabalin.
89460684|NCT05473143|Active Comparator|Usual care|
88942417|NCT01869569|Placebo Comparator|Placebo|Arm II:At the 4-week dose-titration phase, will receive one capsule of placebo twice daily from Day 1 to Day 7, and two capsules of placebo twice daily from Day 8 to Day 14. From Day 15 to Day 28, patients will perform dosage adjustments based on the pain relief and tolerability. At maintenance phase, patients will take the optimized dosage of placebo.
88942418|NCT01869608|Experimental|postpartum screening|Oral glucose tolerance test 2 days post-partum
89460685|NCT05458193|Experimental|Daridorexant|50 mg once daily from Day 1 to Day 5
89460686|NCT05458193|Placebo Comparator|Placebo|Matching placebo once daily from Day 1 to Day 5
89460687|NCT05445024|Experimental|nalbuphine group|nalbuphine ED95, dexmedetomidine ED95 and ondansetron 16mg were added into normal saline to a total of 100ml
89460688|NCT05445024|Placebo Comparator|sufentanil group|sufentanil (1/1000* nalbuphine ED95), dexmedetomidine ED95 and ondansetron 16mg were added into normal saline to a total of 100ml
88942419|NCT01869621|Experimental|Metformin|6 days treatment with metformin
88942420|NCT01869660|Experimental|Shared Decision Making|The present SDM intervention is based on principles derived from previous randomized controlled trials of SDMs. SDM meetings comprise at least 4 weekly 20 minutes sessions. Meetings have at least three professionals: a case manager (psychiatrists or nurses), a primary doctor, and a nurse/social worker. The focus of the meeting is to empower patients to discuss their attitudes and preferences toward treatments.
88942421|NCT01869660|No Intervention|Usual Care|Patients with no special program about decision making.
88942422|NCT01869673|Active Comparator|Face Mask|Patients will be ventilated with a face mask first and with a oral mask thereafter
88942423|NCT01869673|Experimental|Oral Mask|Patients will be ventilated trough an oral mask first and trough a face mask thereafter
89017519|NCT00287495|Experimental|B|Patients with AIDS-KS not receiving ritonavir will be given 200 mg BAY 43-9006 once daily with dose escalation up to 400 mg twice daily
89017520|NCT00320658|Experimental|A|3 vaccinations with a dose of 40 mcg MSP1 42-C1/Alhydrogel given into the deltoid muscle of either arm. Each vaccination will be given 1 month apart. This arm will enroll concurrently with Arm B.
89017521|NCT00320658|Experimental|B|3 vaccinations with a dose of 40 mcg MSP1 42-C1/Alhydrogel and CPG7909 given into the deltoid muscle of either arm. Each vaccination will be given 1 month apart. This arm will enroll concurrently with Arm A.
89017522|NCT00320658|Experimental|C|3 vaccinations with a dose of 160 mcg MSP1 42-C1/Alhydrogel given into the deltoid muscle of either arm. Each vaccination will be given 1 month apart. This arm will enroll concurrently with Arm D after review of the results from Arms A and B.
89017523|NCT00320658|Experimental|D|3 vaccinations with a dose of 160 mcg MSP1 42-C1/Alhydrogel and CPG7909 given into the deltoid muscle of either arm. Each vaccination will be given 1 month apart. This arm will enroll concurrently with Arm C after review of the results from Arms A and B.
89017524|NCT00287534|Experimental|1|Anastrozole
89017525|NCT00287534|Active Comparator|2|Tamoxifen
89017526|NCT00313872|Experimental|FOLFIRI|
89017527|NCT00313872|Experimental|DP|"D1 Taxotere 75 mg/m2 + D5W 200 mL IV over 1 hr, D1 Cisplatin 75 mg/m2 + NS 150mL MIV over 1hr~D1 Irinotecan 150 mg/m2 + D5W 500mL MIV over 90 min D1 Leucovorin 100 mg/m2 + D5W 500mL MIV over 2hrs D1-2 5-FU 1500 mg/m2 + D5W 1000 ml CIV over 24 hrs (total 2doses) D1 atropine 0.3mg SQ before irinotecan"
89017528|NCT00287573|Experimental|Arm 1|
89017529|NCT00287573|Active Comparator|Arm 2|
89017530|NCT00320697|Other|Bupropion + Nicotine patch + Nicotine gum or lozenges|Open label phase All enrolled subjects received weekly CBT group sessions, bupropion 300 mg/daily (if medically eligible), nicotine patch 21 mg/day, and up to 20 mg/day of nicotine gum or lozenge for prn use. Subjects set a quit date between weeks 3 and 4; a ½ hour individual CBT session to help prepare them for the quit date. The open phase groups consisted of 8 weekly CBT meetings.
89017531|NCT00320697|Active Comparator|Bupropion + Nicotine Patch|Randomized phase: Subjects who achieved 2 weeks continuous abstinence at the end of the open intervention and who are medically eligible for bupropion were eligible for the double blind, relapse prevention trial.Subjects eligible for bupropion were randomized to receive either nicotine patch and bupropion or placebo patch and pill added to CBT for 44 weeks.
89017532|NCT00320697|Placebo Comparator|Placebo pill + placebo patch|Randomized phase: Subjects who achieved 2 weeks continuous abstinence at the end of the open intervention and who are medically eligible for bupropion were eligible for the double blind, relapse prevention trial. Subjects eligible for bupropion were randomized to receive either nicotine patch and bupropion or placebo patch and pill added to CBT for 44 weeks.
89017533|NCT00287612|Active Comparator|1|Arms:Lap. Fundo. with Mobilization of the Esophageal Junction
89017534|NCT00287612|Experimental|2|
89017535|NCT00287651|Active Comparator|2|Patients with diagnosed Diabetic Retinopathy are enrolled as treated with pulsatile intravenous insulin or as a control patient with weekly treatment sessions. Baseline and quarterly fundus photography is performed to measure and monitor progress.
89460689|NCT05440955|Experimental|active tDCS|tDCS (transcranial Direct Current Stimulation subjects) is a noninvasive brain stimulation technique that involves the passage of a small electric current through the scalp and skull to modulate brain activity [10]. The study intervention consists of ten 20-minutes sessions of active or sham tDCS. Sessions will be delivered twice daily and separated by at least 2 hours for 5 consecutive weekdays. The electric current will be generated by an electric stimulator (class IIa medical device).
89017536|NCT00287651|No Intervention|1|Patients diagnosed with Diabetic Retinopathy are enrolled as control patients that do not receive the pulsatile intravenous insulin therapy. Control patients come into the center receive baseline fundus photography and quarterly fundus photography to measure progress and outcomes of diabetic retinopathy and are compared to the patients who receive pulsatile intravenous insulin therapy.
89017537|NCT00287768|Experimental|1|Docetaxel + S-1
89017538|NCT00287768|Active Comparator|2|S-1
89017539|NCT00320775|Experimental|Part A|Part A: An open label study in which six successive cohorts of 3-6 patients each with neovascular AMD will receive a single intravitreal (ITV) injection of 0.05, 0.15, 0.5, 1.0, 2.0, or 4.0 mg of VEGF Trap into the study eye. The total volume of each injection will be 100 μL. Enrollment in new dose levels will not begin until all patients in the preceding dose level have completed Visit 5 (Day 15).
89017540|NCT00320775|Active Comparator|Part B|Part B: A controlled, prospective, randomized, double-masked study in which up to 30 subjects meeting eligibility criteria will be randomly assigned in a 1:1 ratio to receive a single ITV injection of2.0 mg/eye VEGF Trap (or the MTD if reached prior to 2.0 mg) followed by 1 sham injection six weeks later, or an initial dose of 0.3 mg pegaptanib sodium into the study eye, followed by a second dose six weeks later. Enrollment into Part B will begin 2 weeks after the last subject to receive the 2.0 mg/eye dose in Part A has been observed for 15 days and it has been determined that the safety profile of VEGF Trap at this dose level is adequate to support expansion of dosing at this dose level. The dose of pegaptanib sodium will be 0.3 mg, according to the package insert.
89017541|NCT00320775|Active Comparator|Part C|Part C: A controlled, prospective, randomized, double-masked study in which approximately 30 subjects meeting eligibility criteria will be randomly assigned in a 1:1 ratio to receive up to two ITV injections of either 0.15 or 4.0 mg/eye VEGF Trap. Initiation of Part C is contingent upon the 4.0 mg dose being adequately tolerated in Part A.
89017542|NCT00320814|Experimental|VEGF Trap-Eye|single IVT injection of 4.0 mg of VEGF Trap-Eye into the study eye on Day 1
89017543|NCT00287846|Experimental|Imatinib|400 to 800 mg/day for a maximal 12 months study duration.
89017544|NCT00287885|Experimental|Metronomic Docetaxel|Docetaxel will be administered by daily injection via pre-filled syringes into the patient's accessed subcutaneous port.
89017545|NCT00322530|Active Comparator|SLED|
89017546|NCT00322530|Active Comparator|CVVHD|
89017547|NCT00287963|Experimental|Vinorelbine + topotecan|
89017548|NCT00322569|Experimental|1|Corio™ Pimecrolimus-Eluting Cobalt Chromium Coronary Stent System
89017549|NCT00322569|Experimental|2|SymBio™ Pimecrolimus/Paclitaxel-Eluting Coronary Stent System
89017550|NCT00322569|Active Comparator|Control Arm|Costar ™ Paclitaxel-Eluting Coronary Stent System
89017551|NCT00288041|Experimental|Treatment (bortezomib, paclitaxel, carboplatin)|Patients will receive an infusion of bortezomib twice in week 1 and once in week 2. They will also receive a 3-hour infusion of paclitaxel and an infusion of carboplatin once in week 1. Treatment may repeat every 3 weeks for as long as benefit is shown.
89017552|NCT00322608|Experimental|Dose escalation|
89017553|NCT00288158|Experimental|Allopurinol|
89017554|NCT00288158|Experimental|Probenecid|
89017555|NCT00288158|Active Comparator|Placebo|
89017556|NCT04717752|Experimental|Double trigger unit|HCG: 6000IU (Ovidrel: 250ug) + GnRH-a (Troprilin) 0.2mg
89017557|NCT04717752|Sham Comparator|HCG trigger unit|HCG: 6000IU (Ovidrel: 250ug)
89017558|NCT00322686|Experimental|Oglemilast followed by placebo|
89017559|NCT00322686|Experimental|Placebo followed by Oglemilast|
89017560|NCT00321087|Experimental|1|T2000 dose escalation
89017561|NCT00321087|Experimental|2|Placebo followed by T2000 dose escalation
89017562|NCT00321087|Experimental|3|Placebo followed by T2000 dose escalation
89017563|NCT00288314||PTSD|
89017564|NCT00288314||CONTROLS|
89460690|NCT05440955|Sham Comparator|sham tDCS|The sham procedure is developed by the tDCS device manufacturer, which allows using the same tDCS device and the same procedure (i.e., 10 sessions delivered during five consecutive days) for both the active and sham procedures. In the sham condition, the electrodes will be placed in the same positions as in the active group; however, the stimulator will be only active for initial and final ramp up/ramp down periods, in order to mimic the sensation of active stimulation. In addition, brief pulses of 110 μA will be administered every 550 ms in order to control impedance and keep the manipulator blinded to the active or sham condition.
89017565|NCT00288353|Active Comparator|1|aripiprazole (Abilify)
89017566|NCT00288353|Active Comparator|2|ziprasidone (Geodon)
89017567|NCT00288431|Experimental|1|Different schedules and routes of administration of AP23573 will be examined. For each schedule, AP23573 + Doxorubicin will be co-administered on Day 1 of a 3-week cycle. AP23573 will be given orally and will range in dose from 10-30 mg per dose.
89017568|NCT04718363|Experimental|PNF stretching group|
89017569|NCT04718363|Experimental|Non-vibration foam rolling prior to PNF stretching group|
89017570|NCT04718363|Experimental|Vibration foam rolling prior to PNF stretching group|
89017571|NCT04718363|No Intervention|Control Group|
89017572|NCT00417560|Experimental|Influenza A/H5N1 Vaccine|Two 90ug Doses of Intramuscular Inactivated Influenza A/H5N1 Vaccine
89017573|NCT00417599|Experimental|Lifestyle intervention|Behavioral lifestyle intervention versus control group. The Behavioral intervention consists of behavioral lessons delivered over the internet.
89017574|NCT00417599|Experimental|control|The intervention for the waiting list control group was usual care.
89017575|NCT00417638|Experimental|patients with acute STEMI - treatment with Hypothermia +PCI|"Hypothermia using endovascular cooling with the Celsius Control System as an adjunct therapy.~Hypothermia before reperfusion by a combination of infusion of cold saline and endovascular catheter cooling as an adjunct therapy in patients with a STEMI scheduled to undergo primary percutaneous coronary intervention (PCI)."
89017576|NCT00417638|Active Comparator|Patients with an acute STEMI eligible for primary PCI|Standard of care treatment or the control group Patients with an acute STEMI eligible for primary PCI
89017577|NCT02960594|Experimental|Arm 1|2 mg INO-1400 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12
89017578|NCT02960594|Experimental|Arm 2|8 mg INO-1400 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12
89017579|NCT02960594|Experimental|Arm 3|2 mg INO-1400 + 0.5 mg INO-9012 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12
89017580|NCT02960594|Experimental|Arm 4|2 mg INO-1400 + 2 mg INO-9012 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12
89017581|NCT02960594|Experimental|Arm 5|8 mg INO-1400 + 0.5 mg INO-9012 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12
89017582|NCT02960594|Experimental|Arm 6|8 mg INO-1400 + 2 mg INO-9012 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12
89017583|NCT02960594|Experimental|Arm 7|2 mg INO-1401 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12
89017584|NCT02960594|Experimental|Arm 8|8 mg INO-1401 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12
89017585|NCT02960594|Experimental|Arm 9|8 mg INO-1401 + 0.5 mg INO-9012 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12
89017586|NCT02960594|Experimental|Arm 10|8 mg INO-1401 + 2 mg INO-9012 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12
89017587|NCT00321516|Experimental|1|
89017588|NCT06140277|Experimental|Chitosan|group will be treated using chitosan as a replacement of bone particles with collagen membrane after tooth extraction
89017589|NCT06140277|Active Comparator|Allograft|after extraction, the group will be treated using the gold standard protocol which is the (allograft) bone particles with collagen membrane.
89017590|NCT06140277|Placebo Comparator|placebo|the extraction will be done without placing any bone material inside
89017591|NCT06140238|Experimental|Experimental group|Groups of patients who have Parecoxib drug administration before start surgery
89017592|NCT06140238|Placebo Comparator|Control group|Group of patients who have normal saline (Placebo) administration before start surgery
89017593|NCT06140225|Experimental|"PACER Application"|It is an application that allows the recording of the sports activities performed. It includes alerts and reminders that allow the participant to plan his/her sports practice in advance, as well as a weekly record of the activities and kilometers run, and a comparative analysis with the previous week.
89017594|NCT06140225|Experimental|"MapMyWalk Application"|It is an application that promotes the practice of physical activity by recording the sports activities that the subject performs, as well as the dissemination of the same in social networks and participation in challenges available to users around the world. In addition, this application includes reminders of physical activity and personal achievements to encourage the practice of sports.
89017595|NCT06140225|Experimental|"Strava Application"|It is an application that promotes sports practice, nutritional habits and the necessary rest. Nutrition and sleep will be introduced as variables that favor a healthy lifestyle
89460691|NCT05440318||mRNA Vaccines Recipients|Participants will wear 2 devices during the specified monitoring period. They will wear both a small patch on their chest that captures continuous electrocardiogram (ECG), accelerometry, and temperature data, and a modified smartwatch measuring continuous photoplethysmography (PPG) and accelerometry data.
89460692|NCT05439252|Experimental|Exercise Snacking Group|For 28 days, this group will be asked to perform two 'exercise snacks' a day; once in the morning and once in the evening, and record exercise snacking compliance data in a log book
89460693|NCT05437146|Experimental|Puppet|pain and fear
89460694|NCT05437146|No Intervention|control|not pain and fear
89460695|NCT05429814|Experimental|Experimental|During the study, the patients' routine pharmacological treatments will continue and menthol will be applied only to reduce the effect of neuropathy. In the study, menthol 1% will be used topically, as it was used in studies after the literature review. Although it was stated in the studies that menthol had no side effects, it was decided to mix menthol with water-based cream according to the literature recommendation. Researchers will first determine how many grams of menthol will be sufficient by applying menthol to their hands and feet.After the gram of the prepared mixture is determined, it will be given to the patients. Patients in the intervention group will be taught how to regularly apply menthol cream (topical menthol) to their hands and feet, twice a day, every day. The effect on CIPN will be evaluated in patients with CIPN for 3 weeks immediately before and after 6 weeks of treatment with menthol administration.
89460696|NCT05429814|No Intervention|control group|control group will receive standard practice
89460697|NCT05420337|Active Comparator|Group Intramuscular|Transversus Abdominis Plane Block will administer with 20 ml of % 0.25 bupivacaine and 0.1 mg/kg morphine intramuscular
89460698|NCT05420337|Active Comparator|Group TAP|Transversus Abdominis Plane Block will administer with 20 ml of % 0.25 bupivacaine and 0.1 mg/kg morphine
89460699|NCT05418751|Experimental|Manual therapy group|Patients in this group (n=20) will receive a manual therapy protocol.
89460700|NCT05418751|Placebo Comparator|Placebo group|Patients in this group (n=20) will receive a placebo treatment.
89460701|NCT05390905|Experimental|HSK21542|HSK21542 injection
89460702|NCT05390905|Experimental|tramadol|Tramadol hydrochloride injection
89460703|NCT05390905|Placebo Comparator|placebo|placebo
89460704|NCT05379348||General study participants (patients)|
89460705|NCT05379348||Healthcare Practitioners|
89460706|NCT05379348||Pre-Program Chart Audits (100 patients what will be chart audited)|
89460707|NCT05367505|Experimental|iFuse-3D|Titanium fusion implant in combination with trans-iliac screws
89460708|NCT05367115||Familial Amyloidotic Polyneuropathy|The Familial Amyloidotic Polyneuropathy patients are validated in the catastrophic illness certification.
89460709|NCT05367115||Osteogenesis imperfecta|The Osteogenesis imperfecta patients are validated in the catastrophic illness certification.
89460710|NCT05367115||(Acute Hepatic) Porphyria|The (Acute Hepatic) Porphyria patients are validated in the catastrophic illness certification.
89460711|NCT05366621||Used osteoporosis medication|Patients who had used osteoporosis medication after osteoporotic fractures.
89460712|NCT05366621||Did not use osteoporosis medication|Patients who didn't use osteoporosis medication after osteoporotic fractures.
88942424|NCT01869712|Experimental|Cupping therapy (randomized)|Use retained cupping as the main cupping method, supplemented with flash cupping and/or moving cupping. First use empty cupping, which means the cups are removed after suction without delay, then practitioners should control the suction by gently moving the cup toward direction of DU and/or BL, repeat this moving for several times, finally cupping practitioners utilize the flaming heating power to achieve suction (minus pressure) inside the cups to make them apply on the desired part of the body. Cups should retain for 10 minutes daily, patients accept the treatment three times weekly for totally 15 times.
89017596|NCT06140225|Experimental|"POKEMON GO APPLICATION"|It is a mobile game that favors the increase of physical activity because it is necessary to walk to achieve the proposed objectives.
89460713|NCT05362227|Other|High-Volume|Patients in the group were instructed to take 4 L of solution on the day before the colonoscopy
89460714|NCT05362227|Other|Low-Volume|Patients in the group were instructed to take 2 L of solution on the day before the colonoscopy
89460715|NCT05359146|Experimental|Phase 0a, Group 1|"The first test injection will be with 161Tb-DOTA-LM3; the second one will be with 177Lu-DOTATOC. The ~ 3 therapy cycles will be performed with 177Lu-DOTATOC.~Test injection 1: 0.5 - 1 GBq ≤ 100 μg 161Tb-DOTA-LM3 with renal protection Test injection 2 (Cross over): 0.5 - 1 GBq ~ 200 μg 177Lu-DOTATOC with renal protection Not more than 6 weeks later patients will receive ~ 3 treatment cycles with 5.6 - 7.4 GBq 177Lu-DOTATOC in an interval of about 8 weeks (clinically established amount of activity). This is standard of care and not part of the study."
89460716|NCT05359146|Experimental|Phase 0a, Group 2|"The first test injection will be with 177Lu-DOTATOC; the second one will be with 161Tb-DOTA-LM3. The ~ 3 therapy cycles will be performed with 177Lu-DOTATOC.~Test injection 1: Group 2: 0.5 - 1 GBq ~ 200 μg 177Lu-DOTATOC with renal protection Test injection 2 (Cross over): 0.5 - 1 GBq ≤ 100 μg 161Tb-DOTA-LM3 with renal protection Not more than 6 weeks later patients will receive ~ 3 treatment cycles with 5.6 - 7.4 GBq 177Lu-DOTATOC in an interval of about 8 weeks (clinically established amount of activity). This is standard of care and not part of the study."
89460717|NCT05359146|Experimental|Phase 0b, Group 1|"Both test injections will be with 161Tb-DOTA-LM3 (with different peptide amounts). The ~ 2 therapy cycles will be performed with 161Tb-DOTA-LM3.~Test injection 1: ~ 2 GBq ≤ 100 μg 161Tb-DOTA-LM3 with renal protection Test injection 2: ~ 2 GBq ~ 300 μg 161Tb-DOTA-LM3 with renal protection Not more than 6 weeks later patients will receive ~ 2 cycles with ~ 3 GBq 161Tb-DOTA-LM3 in an interval of about 8 weeks if ~2 GBq is well tolerated"
89460718|NCT05359146|Experimental|Phase 0b, Group 2|"Start with the other peptide amount of 161Tb-DOTA-LM3. The ~ 2 therapy cycles will be performed with 161Tb-DOTA-LM3.~Test injection 1: ~ 2 GBq ~ 300 μg 161Tb-DOTA-LM3 with renal protection Test injection 2: ~ 2 GBq ≤ 100 μg 161Tb-DOTA-LM3 with renal protection Not more than 6 weeks later patients will receive ~ 2 cycles with ~ 3 GBq 161Tb-DOTA-LM3 in an interval of about 8 weeks if ~2 GBq is well tolerated"
89460719|NCT05340166|Active Comparator|Radiofrequency Neurolysis|Radiofrequency Neurolysis of genicular nerves
89460720|NCT05340166|Experimental|Chemical Neurolysis|Chemical Neurolysis of genicular nerves
89460721|NCT05325775|Experimental|ACER-801 50 mg BID|ACER-801 (osanetant) 50 mg BID (1 x 50 mg and 3 x placebo, twice daily)
89460722|NCT05325775|Experimental|ACER-801 100 mg BID|ACER-801 (osanetant) 100 mg BID (2 x 50 mg and 2 x placebo, twice daily)
89460723|NCT05325775|Experimental|ACER-801 200 mg BID|ACER-801 (osanetant) 200 mg BID (3 x 50 mg and 1 x placebo, twice daily)
89460724|NCT05325775|Placebo Comparator|Placebo|Placebo (4 x Placebo of ACER-801 twice daily)
89460725|NCT05324033||muscle invasive cancer bladder|
89460726|NCT05324033||non-muscle invasive cancer bladder|
89460727|NCT05319028|Experimental|Continuous Dosing Schedule|Mivavotinib 100 mg once daily (QD)
89460728|NCT05319028|Experimental|Induction Dosing Schedule|Mivavotinib 120 mg QD for 14 days, then 80 mg QD starting Day 15
89460729|NCT05308381|Experimental|Fasted exercise|Fasted prior to exercise
89460730|NCT05308381|Experimental|High protein breakfast exercise|High protein breakfast consumption prior to exercise
89460731|NCT05308381|Experimental|High carbohydrate breakfast exercise|High carbohydrate breakfast consumption prior to exercise
89460732|NCT05287997|Other|Baseline|Participants in this arm will be evaluated at 3 time periods. Initial pre-season visit, mid-season visit and end-of-season visit. Capillary blood sample collection will occur at each visit.
88942425|NCT01869712|Experimental|Cupping therapy (non-randomized)|Use retained cupping as the main cupping method, supplemented with flash cupping and/or moving cupping. First use empty cupping, which means the cups are removed after suction without delay, then practitioners should control the suction by gently moving the cup toward direction of DU and/or BL, repeat this moving for several times, finally cupping practitioners utilize the flaming heating power to achieve suction (minus pressure) inside the cups to make them apply on the desired part of the body. Cups should retain for 10 minutes daily, patients accept the treatment three times weekly for totally 15 times.
88942426|NCT01869712|Active Comparator|Acupuncture (non-randomized)|Sterilize the selected points with alcohol, and then select the specific size of needles to do the acupuncture. Do the manual stimulation for seconds after needles' insertion, including twist, pull up and deeper insert. Needles should be withdrawn after 30 minutes. Patients accept the treatment three times weekly for totally 15 times.
88942427|NCT01869712|Active Comparator|Acupuncture (randomized)|Sterilize the selected points with alcohol, and then select the specific size of needles to do the acupuncture. Do the manual stimulation for seconds after needles' insertion, including twist, pull up and deeper insert. Needles should be withdrawn after 30 minutes.
88942428|NCT01869738|Experimental|MGuard Prime|MGuard Prime stent
88942429|NCT01869738|Active Comparator|Control|(BMS/DES) Includes FDA approved bare metal or drug eluting stents, including ENDEAVOR, TAXUS Liberte, XIENCE Prime, PROMUS Element, ION, RESOLUTE, Driver, Vision, VeriFlex and Integrity.
88942430|NCT01869751||Prucalopride|Slow-transit constipation with treatment with prucalopride
88942431|NCT01869790|Experimental|Meal challenge|Different fat types
88942432|NCT01869816||Acute coronary syndrome (ACS)|Who were admitted to the coronary care units of the division of cardiology at Guro hospital in Korea University Medical Center. They have Acute myocardial infarction or unstable angina.
88942433|NCT01869816||Stable angina pectoris (SAP)|Who were admitted to the coronary care units of the division of cardiology at Guro hospital in Korea University Medical Center. They have Stable angina.
88942434|NCT01869816||Control|Who were recruited from the participants for a routine health check-up in the Health Promotion Center of Korea University Guro Hospital.
88942435|NCT01869842|Active Comparator|DM, angio group|
88942436|NCT01869842|Experimental|DM, OCT group|
88942437|NCT01869842|Active Comparator|non DM, angio group|
88942438|NCT01869842|Experimental|non DM, OCT group|
88942439|NCT01869855|Active Comparator|110 patients with cSDH assigned to subdural drainage|Randomization of 110 patients with cSDH to one treatment group (subdural or subperiosteal drainage) out of the 220 patients included in the study.
88942440|NCT01869855|Active Comparator|110 patients with cSDH assigned to subperiosteal drainage|Randomization of 110 patients with cSDH to one treatment group (subdural or subperiosteal drainage) out of the 220 patients included in the study.
88942441|NCT01869868||Depression, ECT|
88942442|NCT01869881|Active Comparator|Sarpogrelate|
89460733|NCT05287997|Experimental|Concussion|Participants in this arm will transition from the baseline arm to the concussion arm if they experience a concussion during the course of the sporting season. They will be evaluated with 72 hours of the injury and then at 2-, 4-, and 12-weeks post-injury. Capillary blood sample collection will occur at each visit.
89460734|NCT05284084|Placebo Comparator|Negative Control|Matched subjects by age, sex and BMI with no BA events, from a pool of 20,032 admission (01JAN2010 to 31DEC2019).
89460735|NCT05284084|Active Comparator|Positive Control|Matched subjects by age, sex and BMI with BA events, from a pool of 20,032 admission (01JAN2010 to 31DEC2019).
89460736|NCT05284084|Experimental|Experimental group|"Consecutive subjects admitted to the ICU (these subjects will be matched with historical controls with and without BA events) from 30MAR2021 to 30MAR2022 on three subgroups:~Head up from the bed 15 degrees + H2 blockers + mouth wash BID~Head up from the bed 30 degrees + H2 blockers + mouth wash BID~Head up from the bed 45 degrees + H2 blockers + mouth wash BID"
89460737|NCT05275673|Experimental|Group A - NFE2L2 Mutation, Dosing Cohort 1|sapanisertib 3 mg once daily (QD)
88942443|NCT01869881|Placebo Comparator|Placebo|
89460738|NCT05275673|Experimental|Group A - NFE2L2 Mutation, Dosing Cohort 2|sapanisertib 2 mg twice daily (BID)
89460739|NCT05275673|Experimental|Group B - NFE2L2 Wild-Type, Dosing Cohort 1|sapanisertib 3 mg QD
89460740|NCT05275673|Experimental|Group B - NFE2L2 Wild-Type, Dosing Cohort 2|sapanisertib 2 mg BID
89017597|NCT06140225|Experimental|"JEFIT APPLICATION"|It is an app whose goal is to be a support in training of strength-resistance training. Setting a specific goal, with a full databaseover of exercises to perform.
89460741|NCT05271760||S group|Single-shot Spinal group
89460742|NCT05271760||E group|Continuous Epidural
89460743|NCT05271760||C group|combined spinal-epidural
89460744|NCT05269875|Other|Advance care planning in heart failure patients|The patient and their closest relative will be offered a palliative care intervention by the Department of Cardiology.
89460745|NCT05263401|Experimental|Ketone salt|Na-D/L-3-hydroxybutyrate dissolved in tap water.
89460746|NCT05263401|Experimental|Ketone ester|(R)-3-Hydroxybutyl (R)-3-hydroxybutyrate
89460747|NCT05263401|Placebo Comparator|Placebo|Tap water
89460748|NCT05251571|Active Comparator|Conventional Exercise Group with Telerehabilitation|Exercises such as muscle strengthening exercises applied to antigravity muscles, agonist antagonist spastic muscles, stretching exercises for spastic muscles, weight transfer will be applied, and a telerehabilitation platform will be used in the home exercise program.
89460749|NCT05251571|Experimental|Balance Coordination Group with Telerehabilitation|Sit and stand exercise from chair, standing posture, weight transfer to right and left extremities, stepping over obstacles, standing on one leg with support from the table, standing on two legs with support from the table, hip abduction with support from the table, extension, flexion, supported tandem walking exercises such as stepping on the stairs, standing functional stretches will be applied. Whatsapp application-based Telerehabilitation platform will be used to deliver the home exercise program.
88942444|NCT01869894|Active Comparator|uncovered double bare metallic stent (S&G Biotech.)|uncovered double bare metallic stent
88942445|NCT01869894|Active Comparator|uncovered single bare metallic stent (S&G Biotech.)|uncovered single bare metallic stent
88942446|NCT01869894|Active Comparator|uncovered single bare metallic stent (Taewoong Medical.)|uncovered single bare metallic stent
88942447|NCT01869907|Placebo Comparator|Placebo|Placebo, once daily
88942448|NCT01869907|Active Comparator|Amitriptyline|Amitriptyline 25mg, once daily
88942449|NCT01869907|Active Comparator|Minocycline|Minocycline 100mg, once daily
88942450|NCT01869920|Experimental|intervention group|Intervention group receive a training education on breastfeeding. Education training is provided by an expert group from General Direction of Primary Care
88942451|NCT01869920|Other|Controll group|Usual care
88942452|NCT01869933|Experimental|1% OC-10X|Subjects selected to Cohort I will receive active 1% OC-10X in OD (Oculus Dexter - right eye) and placebo (vehicle) in OS (Oculus Sinister - left eye) in the Period 1 dosing. On Study Day 1 the subjects will have a drop instilled in each eye by personnel at study hours 0, 3, 6 and 9, and be evaluated frequently throughout the day. Subjects will be examined on Study Day 2 (24 hours after first dose). On Study Day 3 (48 hours after the first dose), these subjects will commence Period 2 dosing, with the active (OD) or placebo (OS). Dosing will continue q.i.d. for an additional 13 days.
88942453|NCT01869933|Experimental|2% OC-10X|Subjects selected to Cohort II will receive active 2% OC-10X in OD (Oculus Dexter - right eye) and placebo (vehicle) in OS (Oculus Sinister - left eye) in the Period 1 dosing. On Study Day 1 the subjects will have a drop instilled in each eye by personnel at study hours 0, 3, 6 and 9, and be evaluated frequently throughout the day. Subjects will be examined on Study Day 2 (24 hours after first dose). On Study Day 3 (48 hours after the first dose), these subjects will commence Period 2 dosing, with the active (OD) or placebo (OS). Dosing will continue q.i.d. for an additional 13 days.
89460750|NCT05248295|Experimental|Intervention|All participants will repeat sentences under four speech conditions, in a 2x2 design
89460751|NCT05238532|Experimental|Single Arm|CT303
89460752|NCT05223556||Shaoguan Diabetic cohort|Patients with diabetes ages 30-80 were enrolled in Shaoguan Diabetic Eye Screening Programme, who will receive diabetic retinopathy screening both in a remote diagnostic imaging site and in a tertiary hospital
89460753|NCT05215548|Experimental|Group I : Surgery group|The surgery group would receive take 12 weeks of EGFR TKI before randomization. After randomization, the surgery group would receive thoracic surgery with maximal regional control intent. Patients continue afatinib 1 to 2 weeks after surgery until disease progression or unacceptable toxicity. The residual local and metastatic sites of disease could undergo either surveillance or maintenance radio-treatment at the discretion of the treating physician.
89460754|NCT05215548|Active Comparator|Group II : Maintenance group|The control group would receive take 12 weeks of EGFR TKI before randomization. After randomization, the control group would receive afatinib until disease progression or unacceptable toxicity. The residual local and metastatic sites of disease could undergo either surveillance or maintenance radio-treatment at the discretion of the treating physician.
89460755|NCT05202145|Experimental|Part 1 - Cyclosporine|"Participants will receive ALXN2050 and cyclosporine in a fixed sequence over 3 periods.~Period 1: Participants will receive multiple doses of ALXN2050.~Period 2: Participants will receive multiple doses of cyclosporine.~Period 3: Participants will receive multiple doses of ALXN2050 co-administered with multiple doses of cyclosporine.~There will be a washout period between the last dose of ALXN2050 in Period 1 and the first dose of cyclosporine in Period 2 and between the last dose of cyclosporine in Period 2 and the first dosing in Period 3."
89460756|NCT05202145|Experimental|Part 2 - Tacrolimus|"Participants will receive tacrolimus and ALXN2050 in a fixed sequence over 2 periods.~Period 1: Participants will receive a single dose of tacrolimus.~Period 2: Participants will receive multiple doses of ALXN2050 alone and co-administered with a single dose of tacrolimus.~There will be a washout period between the dose of tacrolimus in Period 1 and the first dose of ALXN2050 in Period 2."
88942454|NCT01869946||Ropivacaine|Injection of local anaesthetic (ropivacaine) into the hip joint following hip arthroplasty. Total dose 180mls of 0.2% ropivacaine or 360mg at the time of surgery.
88942455|NCT01869972||Wide PHE group|Subjects prescribed diet alone to treat their PKU who have >1/3 of monitoring phenylalanine levels (with at least 3 levels measured) outside the target treatment range in the 6 months preceding enrolment. Target therapeutic range is 120 - 360 umol/L for age <12 years and 120 - 600 umol/L for age ≥ 12 years.
88942456|NCT01869972||Target PHE group|Subjects prescribed diet alone to treat their PKU who have ≤ 1/3 of monitoring phenylalanine levels (with at least 3 levels measured) outside the target treatment range in the 6 months preceding enrolment. Target therapeutic range is 120 - 360 umol/L for age <12 years and 120 - 600 umol/L for age ≥ 12 years.
88942457|NCT01869972||Kuvan(TM) group|Subjects on Kuvan(TM) (any dose for at least 3 months with no dosage change for most recent 1 month) ± diet therapy
88942458|NCT01869972||Control group|Subjects with non-PKU hyperphenylalaninemia (maximum phenylalanine level 120 - 599 umol/L on no therapy).
88942459|NCT01869985|Experimental|HCP1104|HCP1104
88942460|NCT01869985|Active Comparator|Mulex Tab. and Airtal Tab.|Eperisone Hydrochloride and Aceclofenac
88942461|NCT01869998||Low risk group (A)|(A)Vortex depth≥0.45
88942462|NCT01869998||High risk group 1 (B)|(B)Vortex depth<0.45 with anticoagulation
88942463|NCT01869998||High risk group 2 (C)|(C)Vortex depth <0.45 without anticoagulation
88942464|NCT01870011|Experimental|Desflurane balanced anesthesia group|
88942465|NCT01870011|Active Comparator|Propofol total intravenous anesthesia group|
88942466|NCT01870024|Active Comparator|1: Lorazepam + Placebo|[ L + P ] = lorazepam 0,1mg/kg by intravenous injection over a period of 2 to 3 minutes) + placebo 20 mg/kg by intravenous infusion over a period of 15 minutes
89201726|NCT00770094|Active Comparator|Group 1|WaveLight ALLEGRETTO WAVE™ wavefront guided excimer laser treatment in one eye of the subject and the AMO/VISX CustomVue™ wavefront guided Excimer Laser System performed on the contralateral eye
89201727|NCT00770094|Active Comparator|Group 2|WaveLight ALLEGRETTO WAVE™ wavefront guided excimer laser treatment in one eye of the subject and the Bausch and Lomb Zyoptix™ wavefront guided Excimer Laser System performed on the contralateral eye
89201728|NCT00770094|Active Comparator|Group 3|WaveLight ALLEGRETTO WAVE™ wavefront optimized excimer laser treatment in one eye of the subject and the Bausch and Lomb Planoscan™ Excimer Laser System performed on the contralateral eye
89201729|NCT00925041|Experimental|Kxl Vedera|
89460757|NCT05202145|Experimental|Part 3 - MMF|"Participants will receive MMF and ALXN2050 in a fixed sequence over 2 periods.~Period 1: Participants will receive a single dose of MMF.~Period 2: Participants will receive multiple doses of ALXN2050 alone and co-administered with a single dose of MMF.~There will be a washout period between the dose of MMF in Period 1 and the first dose of ALXN2050 in Period 2."
89460758|NCT05172102|Experimental|study group|"Will receive diaphragmatic breathing with pursed lips as (breathing exercise), They will instruct to perform 3 different conditions will be registered: (1) 6 min of quiet breathing (3 sets of 2 min each), defined as spontaneous breathing pattern; (2) 6 min of diaphragmatic breathing (3 sets of 2 min each); and (3) 6 min of diaphragmatic breathing plus pursed-lips breathing (3 sets of 2 min each).~For aerobic exercises: Will include the following exercises: walking, cycling, running and intermittent running. The exercises will perform for 18-60 minutes for 1-2 sets per week.~For resistance exercises: Will include the following 8 exercises: shoulder press, biceps curl, triceps curl, bench press, leg squats, leg press, leg curl and toe raise. The exercises will perform for 60 minutes for 2-3 sets per week."
89460759|NCT05172102|No Intervention|control group|not receiving any exercises
89460760|NCT05147831|Experimental|Remote Ischemic Preconditioning Protocol|
89460761|NCT05147831|No Intervention|Sham Preconditioning Protocol|
89460762|NCT05146284|Experimental|PXL770 500 mg QD|
89460763|NCT05146284|Experimental|PXL770 250 mg BID|
89460764|NCT05144815|Experimental|Exercise protocol + IPC group|Patients in this group (n=17) will undergo an endurance training protocol. Prior to this training (8-12 minutes before) they will undergo ischaemic preconditioning.
88942467|NCT01870024|Active Comparator|2: Clonazepam + Placebo|[ C + P ] = clonazepam 0,015 mg/kg by intravenous injection over a period of 2 to 3 minutes + placebo 20 mg/kg by intravenous infusion over a period of 2 15 minutes
88942468|NCT01870024|Active Comparator|3: Clonazepam + Fosphenytoin|[ C + F ] = clonazepam 0,015 mg/kg by intravenous injection over a period of 2 to 3 minutes + fosphenytoin 20 mg/kg Equivalent Phenytoin (EP) by intravenous infusion over a period of 15 minutes
88942469|NCT01870037|Placebo Comparator|Placebo (PBS-20% sucrose)|PBS-20% sucrose administered during two single-treatment dose levels (16000 micrograms [µg] and 24000 µg) by direct bladder wall intramuscular injections, 20 to 30 injections depending on active dose comparator.
88942470|NCT01870037|Experimental|hMaxi-K 16000 µg|Single treatment (16000 µg by 20 intramuscular injections). A total of 6 participants will receive hMaxi-K, and 3 will receive placebo.
88942471|NCT01870037|Experimental|hMaxi-K 24000 µg|Single treatment (24000 µg by 30 intramuscular injections). A total of 6 participants will receive hMaxi-K, and 3 will receive placebo.
88942472|NCT01870050|Active Comparator|dapsone gel - verum|dapsone gel - verum
88942473|NCT01870050|Placebo Comparator|dapsone gel - vehicle only|
88942474|NCT01870063||open heart surgery|
88942475|NCT01870089|Experimental|Study group|
88942476|NCT01870102|Active Comparator|Pelubiprofen IR (Pelubiprofen 30 mg)|
88942477|NCT01870102|Experimental|Pelubiprofen SR (Pelubiprofen 45 mg)|
88942478|NCT01870102|Other|Pelubiprofen SR (Pelubiprofen 45 mg) fasting condition|
88942479|NCT01870102|Other|Pelubiprofen SR (Pelubiprofen 45 mg) fed condition|
88942480|NCT01870115|Placebo Comparator|Fiber pill|2 plant fiber pills taken p.o. (by mouth) nightly for one year
89460765|NCT05144815|Sham Comparator|Exercise protocol + Sham IPC group|Patients in this group (n=17) will undergo the same training as the previous group and with the same frequency and duration, but the pressure cuff will be inflated by only 10 mmHg, so that it will act as a placebo.
89460766|NCT05142904|Experimental|Radiofrequency ablation|Patients allocated to the radiofrequency ablation (RFA) arm will undergo RFA under local anaesthesia with the moving-shot technique.
89460767|NCT05142904|Active Comparator|Radioactive iodine, study protocol|Patients allocated to this arm will undergo treatment with radioactive iodine (I-131) according to a standardized dose-calculation.
89460768|NCT05142904|Other|Radioactive iodine, cohort|This group contains patients who are not randomized and have given informed consent undergo treatment with radioactive iodine (I-131) according to local standard (e.g. fixed dose or dose-calculation based on iodine uptake and thyroid nodule mass).
89460769|NCT05136248|Experimental|intraarticular injection|intra-articular steroid injection with the ultrasound guidance technique,
89460770|NCT05136248|Active Comparator|peng block|Ultrasound guided drug injection between to iliopubic eminentia and psoas tendon
89460771|NCT05115864|Experimental|PFMT with device (intervention) group|The patients in PFMT with device (intervention) group followed the practice program three months. During three months, the intervention group is commanded to complete the PFMT program with the vaginal device and assess the grade of type I and II pelvic floor muscle fiber strength once three weeks.
88942481|NCT01870115|Active Comparator|strontium/melatonin/Vitamins K2 and D3|2 pills taken p.o. (by mouth) nightly for one year. Each pill contains strontium citrate (225 mg), melatonin (2.5 mg), Vitamin K2 (MK7) (30 mcg) and Vitamin D3 (1000 IU)
88942482|NCT01870128|Active Comparator|Methotrexate|Single agent Methotrexate 15 to 25 mg PO per week
88942483|NCT01870128|Active Comparator|Combination|Methotrexate 15 to 25 mg PO per week Hydroxychloroquine 200 mg Twice daily Sulfasalazine 2000 to 3000 mg per day
88942484|NCT01870128|Experimental|Combination Steroid|Methotrexate 15 to 25 mg PO per week Hydroxychloroquine 200 mg Twice daily Sulfasalazine 2000 to 3000 mg per day Methylprednisolone 1000 mg intravenous per day for 3 days
88942485|NCT01870141|Experimental|Psychological Intervention|Cognitive Behavioural Intervention
89201730|NCT00775788|Experimental|Implant Failure|
89201731|NCT00775788|Experimental|Post mastectomy breast reconstruction|
88942486|NCT01870141|No Intervention|Current standard of care|
88942487|NCT01870154|Experimental|Intervention group|The intervention consists of 16 hours of training, to be held at the subject's health center. The workshop involves mixed learning, comprising 4 sessions, each 2 hours long, in addition to personal work previous to and after each session of reading relevant bibliography and performing exercises, self-evaluation, and case studies (8 hours of individual work).
88942488|NCT01870154|Active Comparator|Control group|Usual care
88942489|NCT01870167|Placebo Comparator|placebo|Placebo
88942490|NCT01870167|Experimental|co-amoxiclav|co-amoxiclav is a combination antibiotic consisting of amoxicillin trihydrate, a β-lactam antibiotic, and potassium clavulanate, a β-lactamase inhibitor
88942491|NCT01870180|Experimental|EyeBag|Eye self-treated with heated eyebag in the morning and evening each day as per manufacturer's instructions (see http://www.eyebagcompany.com/how)
88942492|NCT01870180|Placebo Comparator|Placebo|Non-heated EyeBAG: As with eyebag arm but second eyebag applied on other eye at same time BUT not heated
88942493|NCT01870206|Experimental|Trivalent OPV Birmex|Newborns receive OPV vaccine produced in Vero cells by Birmex one dose of vaccine. A second dose four weeks after the first application.
88942494|NCT01870206|Active Comparator|Trivalent OPV Sanofi Pasteur|Newborns who receive OPV vaccine produced in Vero cells by Sanofi Pasteur one dose of vaccine. A second dose four weeks after the first application.
88942495|NCT01870219|Active Comparator|Group S|In group S, sevoflurane was initiated at %8 sevoflurane for anesthesia induction and maintained at 2% to %4 until the electrical stimulus was delivered, at which time it was turned off.
88942496|NCT01870219|Active Comparator|Group K|In group K, ketamine was given to 1mg/kg ıv bolus.
88942497|NCT01869582|Experimental|Doppler, Fetal heart rate|Eligible women in labour randomized to intermittent fetal heart rate assessments using a wind-up, hand-held Doppler
88942498|NCT01869582|Experimental|Fetoscope, Fetal heart rate|Eligible women in labour randomized to intermittent fetal heart rate assessments using a Pinard fetoscope, which is the current standard management
88942499|NCT01869582|Experimental|Upright Resuscitator, Resuscitation|Non-breathing newborn infants in need of positive pressure ventilation randomized to an Upright Resuscitator
88942500|NCT01869582|Experimental|Standard Resuscitator, Resuscitation|Non-breathing newborn infants in need of positive pressure ventilation randomized to a standard horizontal Resuscitator, which is the current standard management
88942501|NCT01870232|Experimental|US guided block|Greater palatine nerve or inferior alveolar nerve blocks will be performed under US guidance
88942502|NCT01870245|Experimental|ACHN-975|
88942503|NCT01870245|Placebo Comparator|Placebo|
88942504|NCT01870258|Placebo Comparator|those without MI in 2 weeks|patient without MI in 2 weeks
88942505|NCT01870258|Active Comparator|patient with MI|group with MI in 2 weeks
88942506|NCT01870271|Experimental|DCPT|Treatment with developmentally adapted D-CPT. 30 to 36 individual treatment sessions. Treatment sections comprise a commitment phase (5 sessions), emotion regulation phase (6 sessions), CPT (15 sessions) and a final phase targeting developmentally-related challenges (4 sessions).
88942507|NCT01870284|Experimental|Ixekizumab Dosing Regimen 1|Administered by 80 milligram (mg) subcutaneous (SC) injection
88942508|NCT01870284|Experimental|Ixekizumab Dosing Regimen 2|Administered by 80 mg SC Injection
88942509|NCT01870284|Placebo Comparator|Placebo|Placebo for ixekizumab and placebo for adalimumab administered by SC injection
88942510|NCT01870284|Active Comparator|Adalimumab|Administered by 40 mg SC injection
88942511|NCT01870310|No Intervention|Standard medical therapy|
88942512|NCT01870310|Experimental|Renal denervation + standard medical therapy|Patients in this arm will undergo catheterised renal denervation in addition to having optimization of medical therapy for heart failure.
88942513|NCT01870323|Experimental|SMART Behavioral Group|Intervention condition which has access to SMART Group Wall on Facebook and receives privately-delivered weekly behavioral modules. (SMART Facebook Group + video-based behavioral modules)
88942514|NCT01870323|Active Comparator|SMART Informational Group|Comparison condition (i.e., attentional control) has access to SMART Group Wall on Facebook, and receives privately-delivered weekly text-based messages with generic content. (SMART Facebook Group + NO video-based behavioral modules)
88942515|NCT01870336|Experimental|Lateral customized foot orthoses|Foot orthoses with arch support and lateral inclination set at 7° (alone)
88942516|NCT01870336|Experimental|Knee brace|OdrA Knee brace (alone)
88942517|NCT01870336|Experimental|Combination of the two treatments|Combination of Lateral customized foot orthoses and knee brace
88942518|NCT01870349||Titanium Implant Abutments|Gingival Crevicular Fluid Sampling
88942519|NCT01870349||Zirconium Implant Abutments|Gingival Crevicular Fluid Sampling
88942520|NCT01870362|Experimental|Probiotic (Inersan) Arm|Inersan Lozenges (2 Lozenges bid). Each probiotic lozenge contains not less than 1 billion CFU of L. brevis CD2
88942521|NCT01870362|Placebo Comparator|Placebo Arm|Placebo Lozenges (2 lozenges bid). Placebo lozenge contains only excipients (without probiotic).
88942522|NCT01870375||MPS IH, MPS IHS, MPS IS|MPS IH (Hurler syndrome) patients; MPS IHS (Hurler-Scheie syndrome) patients; and MPS IS (Scheie syndrome) patients
88942523|NCT01870375||MPS II|Hunter syndrome patients
88942524|NCT01870375||MPS IV|Morquio syndrome patients who will be considered for enrollment in the study on an individual basis
88942525|NCT01870375||MPS VI|Maroteaux-Lamy syndrome patients
88942526|NCT01870375||MPS VII|Sly syndrome patients who will be considered for enrollment in the study on an individual basis
88942527|NCT01870414|Other|cryotherapy by immersion|the dominant leg was immersed in cold water for 20 minutes [2, 17], temperature of 4º C [22, 24], water level at 20 cm.
88942528|NCT01870427|Experimental|Aflibercept (2.0 mg)|Intravitreal Aflibercept (2.0 mg)
88942529|NCT01868880|Experimental|ivabradine plus beta-blocker(bisoprolol)|Ivabradine will be administered at a dose of 5 mg twice daily in addition to a low dose of beta-blocker (bisoprolol 1,25 or 2,5 mg). After four weeks of treatment ivabradine will be eventually lowered up to 2,5 mg twice daily in the presence of side effects (phosphenes, diplopia, headache or dizziness).
88942530|NCT01868880|Active Comparator|beta-blocker (bisoprolol) titration|Beta blocker Bisoprolol will be titrated biweekly starting from the initial dose of 1,25-2,5 mg daily up to the max dose of 10 mg daily or to the maximum tolerated dose.
89017598|NCT06140225|Experimental|"FITBIT-FLEX APPLICATION"|It is a physical activity wereable. It acts as a witness to physical activity and transmits the data to the computer or smartphone.
89017599|NCT06140225|Experimental|"MEIZU BONG 2S APPLICATION"|It is a physical activity wereable. It acts as a witness to physical activity and transmits the data to the computer or smartphone.
89017600|NCT06140225|No Intervention|Control Group|They will not use any type of sports technology application. They will continue to perform their daily activities without intervention.
89017601|NCT06140212||Decline ICOPE group|The elderly individuals who have at least one impairment in ICOPE screening domains.
89017602|NCT06140212||Non-decline ICOPE group|The elderly individuals who do not have any impairment in ICOPE screening domains.
89017603|NCT06140199|Active Comparator|Pit-picking surgery|
89017604|NCT06140199|Experimental|Pit-picking surgery with Sinus Laser assisted Closure|
89017605|NCT06140160|Experimental|Patient with an indication for Doppler ultrasound of the supra-aortic trunks|
89017606|NCT06140095|Experimental|Full group|"Evolocumab 140 mg subcutaneously. Två months later, repetitive doses of atorvastatin 40 mg once daily.~After continued atorvastatin, evolocumab 140 mg is added subcutaneously."
89017607|NCT06140082||Gene mutation-type group|According to the characteristics of the patient's own disease, the clinician develops the corresponding medication regimen, and the patient uses one of the target drugs, cisplatin/carboplatin/nedaplatin/loplatin, or other regimen containing the target drug. Peripheral blood of patients was collected, genetic testing was performed, GSTP1 mutant (AG/GG) was classified into this group, and the time and degree of myelosuppression in this group were recorded.
89017608|NCT06140082||Gene wild-type group|According to the characteristics of the patient's own disease, the clinician develops the corresponding medication regimen, and the patient uses one of the target drugs, cisplatin/carboplatin/nedaplatin/loplatin, or other regimen containing the target drug. Peripheral blood of patients was collected for genetic testing, GSTP1 wild type (AA) was classified into this group, and the time and degree of myelosuppression in this group were recorded.
89017609|NCT06140069||Experimental: Patient treated at the Toulouse University Hospital for an abortion|Patient treated at the Toulouse University Hospital for an abortion between 14 and 16 weeks (dating by ultrasound) presenting with a single and evolving pregnancy.
89017610|NCT06140056|Active Comparator|Control|Duration: 3 hours
89017611|NCT06140056|Experimental|Intervention|Duration: 3 hours
89017612|NCT06139978||Pregnant women in male fetus|
89017613|NCT06139978||Pregnant women in female fetus|
89017614|NCT06139952|Experimental|High-dose Atorvastatin group|40 patients will receive 80 mg Atorvastatin before coronary angiography and will receive adequate hydration using (1ml/kg/hr)
89017615|NCT06139952|Experimental|N-acetyl cysteine group|40 patients will receive 200mg 3 times daily 2 days before coronary angiography and 2 days after and will receive adequate hydration using (1ml/kg/hr)
89017616|NCT06139952|Active Comparator|Control group|40 patients will receive adequate hydration using (1ml/kg/hr)
89017617|NCT06139939|Experimental|double layer technique|include 9 patients will receive lateral alveolar ridge augmentation with double bone graft layer technique for GBR (first layer autograft followed by xenograft second layer
89017618|NCT06139939|Other|control|include 9 patients will receive lateral alveolar ridge augmentation with stander protocol for GBR technique (mixture of autograft and xenograft
89017619|NCT06139926|Other|Dexmedetomidine administered intravenously|Dexmedetomidine was administered intravenously 15 min prior to patient induction (concentration 4 μg/ml; loading dose 1 μg/kg for 15 min; maintenance dose: 0.2 μg/(kg.h) until surgical specimen removal).
89017620|NCT06139926|Experimental|Dexmedetomidine administered intranasally|Intranasal administration of dexmedetomidine (original solution) was given at the bedside of the ward as per the pre-tested recommended dose. The patient's vital signs were maintained. On the day of surgery, 30 min before induction of anesthesia, intranasal dexmedetomidine (original solution) was administered in the operating room at the pre-tested recommended dose.
89017621|NCT06139913|Experimental|aerobic exercise|aerobic exercise using treadmill
89460772|NCT05115864|No Intervention|PFMT alone （control） group|The patients in PFMT alone (control) group are commanded to follow the same practice program three months without using the device.
89017624|NCT06139835|Active Comparator|Control|Individuals randomly assigned to the control arm where they brushed their teeth with a popular toothpaste (crest) in the morning and before bed. This routine was repeated daily for 4 weeks.
89017625|NCT06139835|Experimental|Tartarase brushing|In the morning, this group brushed with Tartarase for 30 seconds, spit, but did not rinse and repeated the process. In 30 minutes they brushed with Crest. They repeated this routine before bed. This routine was repeated daily for 4 weeks.
89017626|NCT06139835|Experimental|Tartarase tray|In the morning this group brushed with Tartarase for 30 seconds, filled a dental tray with Tartarase and applied it to the 6 lower front teeth and left it for 30 minutes, spit but did not rinse then brushed with Tartarase for another 30 seconds, spit, but did not rinse. In 30 minutes they brushed with Crest. Before bed they brushed with Crest alone. This routine was repeated daily for 4 weeks.
89017627|NCT06139822|Experimental|Experimental Group|"hamstring stretching, cold pack, stretching, strengthening of plantar fascia and calf muscles.~. Hamstring stretching will be used as an intervention protocol along with conventional physical therapy. Treatment protocol will be followed for thrice a week for 2 weeks. The session will be of approximately 20 minutes. Patient will be in supine lying, passively increase hip flexion while keeping the back straight, and the knee in the extended position from the start to the end of the stretching while the ankle will be in a neutral position~a 30-second rest period will be recommended between stretching repetitions. For each stretching repetition, the individual had to achieve a position of mild discomfort (not pain) which will sustain for 30 seconds."
89017628|NCT06139822|Active Comparator|Control Group|"Cold pack, stretching, strengthening of plantar fascia and calf muscles~Control group included Cold pack for 7 to 10 mins. Followed by stretching of plantar fascia through:~toe stretches to stretch the plantar fascia.~towel to stretch the bottom of foot (towel scrunches)~calf muscles stretching~After stretching exercises strengthening is performed by the following:~towel curls~heel raise Patients performed 2 sets, each repetition lasting 30 seconds, 2 times a day for each exercise."
89201732|NCT00775788|Experimental|Congenital malformations|
89460773|NCT05114564|Experimental|Lens A, Then Lens B|Participants will wear Lens A for one month and then cross over to wear Lens B for one month.
89460774|NCT05114564|Experimental|Lens B, Then Lens A|Participants will wear Lens B for one month and then cross over to wear Lens A for one month.
89460775|NCT05105113|Experimental|Zirconia dental implant|Patients treated with zirconia dental implant (Tav-dental) to replace missing tooth
89460776|NCT05081414|Experimental|Intervention Group|Beyond the active comparator, this group will receive the PEAC-IC, as described previously.
89460777|NCT05081414|No Intervention|Control Group|The Control Group will receive the usual care in the health care institution, which consists of guidance during hospital discharge and delivery of a discharge planning form and outpatient follow-up with medical and nursing consultations and exams when indicated.
89460778|NCT05062369|Experimental|Participants receiving active transcranial direct current stimulation (tDCS)|Participants in this group will receive 5 sessions of active transcranial direct current stimulation (tDCS) to dorsolateral prefrontal cortex (DLPFC) while in the Lodging Plus treatment program and then 5 remote sessions of active tDCS to DLPFC after discharge from the treatment program. All participants will engage in executive functioning tasks for cognitive training during tDCS intervention (active or sham) to prime the engagement of the nucleus accumbens prefrontal cortex circuit. All participants will complete 4 MRI sessions. Craving measures will be collected before the first and after the last day of tDCS sessions. Follow-up interviews will be conducted monthly during a 4-month follow-up period after intervention completion to query relapse status. The first two follow-up interviews, at approximately 1- and 2-months post-intervention, will also include collection of cognition data.
89460779|NCT05062369|Sham Comparator|Participants receiving active and sham active transcranial direct current stimulation (tDCS)|Participants in this group will receive 5 sessions of sham-tDCS sessions while in the Lodging Plus treatment program and then 5 remote sessions of active-tDCS to DLPFC after discharge from the treatment program. All participants will engage in executive functioning tasks for cognitive training during tDCS intervention (active or sham) to prime the engagement of the nucleus accumbens prefrontal cortex circuit. All participants will complete 4 MRI sessions. Craving measures will be collected before the first and after the last day of tDCS sessions. Follow-up interviews will be conducted monthly during a 4-month follow-up period after intervention completion to query relapse status. The first two follow-up interviews, at approximately 1- and 2-months post-intervention, will also include collection of cognition data.
89460780|NCT05057377||Post-TBI Participants|Over a 2-day period post-TBI adults age 18 years and older, will undergo overground assessments with a questionnaire regarding motivation during day 1, followed by robotic safety-environment assessments during day 2.
89460781|NCT05048758||Individuals with AUD + varying levels of ACE|Individuals with alcohol use disorder (AUD) and varying levels of adverse childhood experiences (ACE)
88942531|NCT01870440|Experimental|Ozurdex Injection|Ozurdex Intravitreal Injection (0.7 mg)
89460782|NCT05042648|No Intervention|Control group (Group A)|Group A will receive no intervention
89460783|NCT05042648|Experimental|Buprenorphine group (Group B)|Group B will receive buprenorphine patch of 10 mg (sustained release of 10 µg/h) applied either on chest or on outer side of arm 12 h before surgery. The transdermal buprenorphine patch should be applied to intact skin on the flat surfaces of the upper outer arm, upper chest, upper back, or the side of the chest.
89460784|NCT05038865||Malocclusion group|500 12-19 year olds with malocclusion, defined as IOTN-DHC grade 3, 4 or 5. The adolescents are consecutively recruited new patients at three orthodontic centers; Center for Orthodontics and Pediatric Dentistry, Norrköping, Public Dental Service Östergötland; Department of Orthodontics, Folktandvården Stockholms län AB, Folktandvården Eastmaninstitutet, Stockholm, Sweden and Department of Orthodontics, Malmö University, Malmö, Sweden. Patients are examined at the first visit at the orthodontic department, before any orthodontic treatment is begun.
89460785|NCT05038865||No malocclusion group|175 12-19 year olds without malocclusion, defined as IOTN-DHC grade 1 or 2. Patients are consectively recruited adolescents examined at their general dentistry clinic.
89460786|NCT05036395|Experimental|The neonates evaluated by the routine assessment protocol and AI-assisted cEEG Diagnostic tool|"This group will be monitored by cEEG with standard operating procedure. The cEEG recording will be evaluated by neonatologists with the routine assessment protocol and AI assisted cEEG diagnostic tool in real time during cEEG monitoring. Both real-time cEEG and amplitude-integrated EEG traces are displayed at the bedside for clinical review.~This group will follow the standard clinical protocols of the recruiting hospitals for ASM administration after the neonatologists' review."
88942532|NCT01870453||Isoflurane Anesthesia|Recruited subjects that were anesthetized with isoflurane for their surgery.
89460787|NCT05036395|Active Comparator|The neonates evaluated by the routine assessment protocol|"This group will be monitored by cEEG with standard operating procedure. The cEEG recording will be evaluated by neonatologists with the routine assessment protocol during cEEG monitoring. Both real-time cEEG and amplitude-integrated EEG traces are displayed at the bedside for clinical review.~This group will follow the standard clinical protocols of the recruiting hospitals for ASM administration after the neonatologists' review."
89460788|NCT05036317|Experimental|Empagliflozin|Standard dose of empagliflozin (Jardiance®; Boehringer Ingelheim GmbH), i. e. 10 mg. Empagliflozin is an orally available inhibitor of SGLT2 and approved for the treatment of type 2 diabetes mellitus and will be given per os once daily in the morning for 28 days.
89460789|NCT05036317|Placebo Comparator|Placebo|Placebo provided by Boehringer Ingelheim Switzerland. Per os once daily in the morning for 28 days.
88942533|NCT01870453||Sevoflurane Anesthesia|Recruited subjects that were anesthetized with sevoflurane for their surgery.
88942534|NCT01870453||Desflurane Anesthesia|Recruited subjects that were anesthetized with desflurane for their surgery.
88942535|NCT01870453||Propofol Anesthesia|Recruited subjects that were anesthetized with propofol for their surgery.
88942536|NCT01870466|Experimental|C -> C + S|cilostazol (C) in period 1, cilostazol + simvastatin (C+S) in period 2
89201733|NCT00775788|Experimental|Breast Ptosis|
88942537|NCT01870466|Experimental|C + S -> C|cilostazol + simvastatin (C+S) in period 1, cilostazol (C) in period 2
88942538|NCT01870466|Experimental|S -> S + C|simvastatin (S) in period 1, simvastatin + cilostazol (S+C) in period 2
88942539|NCT01870466|Experimental|C + S -> S|cilostazol + simvastatin (C+S) in period 1, simvastatin (S) in period 2
89017629|NCT06139809|Other|Intubation|Intubation will take place according to our local standard protocol for nasal intubation using non-invasive positive pressure ventilation (NIPPV) delivered through a nasopharyngeal tube. The intubation will be video-recorded to provide a clear view of the procedure and the pulse oximeter displaying the peripheral oxygen saturation (SpO2 [%]) and heart rate (HR [bpm]).
89460790|NCT05034874|Experimental|IXT-m200|Anti-methamphetamine monoclonal antibody, dose levels of 1.5 and 3 g
89460791|NCT05034874|Placebo Comparator|Placebo|Saline
89460792|NCT04990388|Experimental|UX053 Dose Level 1S ->OL-1R|Participants receive a single, peripheral intravenous (IV) infusion of UX053. After completion of the 90-day Follow up Period, participants can enter the open label repeat dose (OL-RD) cohort where they will receive UX053 every 4 weeks (Q4W) for 4 doses. Participants will also receive premedication, consisting of oral paracetamol/acetaminophen or ibuprofen, an H2 blocker, and an H1 blocker.
89460793|NCT04990388|Experimental|UX053 Dose Level 2S->OL-2R|Participants receive a single, peripheral intravenous (IV) infusion of UX053. After completion of the 90-day Follow up Period, participants can enter the open label repeat dose (OL-RD) cohort where they will receive UX053 every 4 weeks (Q4W) for 4 doses. Participants will also receive premedication, consisting of oral paracetamol/acetaminophen or ibuprofen, an H2 blocker, and an H1 blocker.
88942540|NCT01870466|Experimental|R -> C + R|rosuvastatin (R) in period 1, cilostazol + rosuvastatin (C+R) in period 2
88942541|NCT01870466|Experimental|C + R -> R|cilostazol + rosuvastatin (C+R) in period 1, rosuvastatin (R) in period 2
88942542|NCT01870479|Experimental|Live music|Patient preferred live music during chemotherapy session.
88942543|NCT01870479|Active Comparator|Taped music|Patient preferred taped music during chemotherapy
88942544|NCT01870479|No Intervention|Control|Usual care during chemotherapy
88942545|NCT01870492||Acute ischemic stroke or TIA|Patients presenting with acute ischemic stroke or transient ischemic attack and underwent treatment using Activase and/or endovascular therapy.
88942546|NCT01870518|Active Comparator|Parkinson's patients with MCI|Procedure: deep brain stimulation surgery
88942547|NCT01870518|Active Comparator|Parkinson's patients without MCI|Procedure: deep brain stimulation surgery
88942548|NCT01870544|Experimental|LGG Administration|Lactobacillus Rhamnosus GG (LGG) will be taken orally for 44 days. The daily dose is 2*10^10 organisms. The LGG is contained in capsules (1*10^10 organisms per capsule), and two capsules will be taken per day.
88942549|NCT01870544|Placebo Comparator|Placebo|Placebo to be taken orally for 44 days.
88942550|NCT01870557||Diabetes Mellitus type 1|n=100
88942551|NCT01870557||Diabetes Mellitus type 2|n=100
88942552|NCT01870570|Other|Reference Glucose|Glucose Standard (50g of Glucose)
88942553|NCT01870570|Experimental|Food Product A: Corn Flakes|Corn Flakes
88942554|NCT01870570|Experimental|Food Product B: Ginger Bread|Ginger Bread
88942555|NCT01870570|Experimental|Food Product C:Sandwiched Breakfast Biscuit|Sandwiched Breakfast Biscuit
88942556|NCT01870570|Experimental|Food Product D: Crackers Nature|Crackers Nature
88942557|NCT01870570|Experimental|Food Product E: Breakfast Biscuit|Breakfast Biscuit
88942558|NCT01870570|Experimental|Food Product F: White Bread|White Bread
88942559|NCT01870622|Active Comparator|ECO2|ECO2 will be used to confirm correct tube placement in newborn infants.
88942560|NCT01870622|Experimental|Flow waves|Flow waves will be used to confirm correct tube placement
88942561|NCT01870635|Experimental|Ondansetron|"4 mg oral disintegrating tablet of ondansetron~Participant weight 8-15 kg = half dose (2mg) Participant weight greater than 15 kg = full dose (4mg)"
88942562|NCT01870635|Placebo Comparator|Placebo (sugar pill)|
88942563|NCT01870648|Experimental|Ondansetron|"4 mg oral disintegrating tablet of ondansetron~Participant weight 8-15 kg = half dose (2mg) Participant weight greater than 15 kg = full dose (4mg)"
88942564|NCT01870648|Placebo Comparator|Placebo (sugar pill)|
88942565|NCT01870661|Experimental|Long axis ultrasound placement of IV|Long axis ultrasound placement of IV catheter
88942566|NCT01870661|Active Comparator|Short axis ultrasound placement of IV|Long axis ultrasound placement of IV catheter
89460794|NCT04990388|Experimental|UX053 Dose Level 3S->OL-3R|Participants receive a single, peripheral intravenous (IV) infusion of UX053. After completion of the 90-day Follow up Period, participants can enter the open label repeat dose (OL-RD) cohort where they will receive UX053 every 4 weeks (Q4W) for 4 doses. Participants will also receive premedication, consisting of oral paracetamol/acetaminophen or ibuprofen, an H2 blocker, and an H1 blocker.
89460795|NCT04990388|Experimental|UX053 or Placebo Dose Level DB-1R|Participants randomized to receive a single, peripheral IV infusion of UX053 or Placebo every 2 weeks (Q2W) for 5 doses. Participants will also receive premedication, consisting of oral paracetamol/acetaminophen or ibuprofen, an H2 blocker, and an H1 blocker.
89017630|NCT06139796|Experimental|Cohort A Twice daily|DRV/r twice daily (BID): 30 children with 1 or 2 DRV RAM* weighing 10 to <25 kg (10 per weight band: 10-13.9kg, 14-19.9kg, 20-24.9kg)
89017631|NCT06139796|Experimental|Cohort B Once daily|"DRV/r once daily (OD): 20 children with no DRV RAM* weighing 10 to <20 kg (10 per weight band: 10-13.9kg, 14-19.9kg)~*DRV RAMs: V11I, V32I, L33F, I47V, I50V, I54M, I54L, T74P, L76V, I84V and L89V"
89017632|NCT06139783|Experimental|Physycal Exercise|Patients included in the study will follow an online physical exercise program supervised by a physical exercise specialist in which they will perform up to 300 minutes of moderate-intensity aerobic exercise or up to 150 minutes of vigorous aerobic exercise and 2 strength sessions per week for 12 weeks (following WHO recommendations for cancer survivors).
89017633|NCT06139770|Active Comparator|Active follow-up|The patients will recieve 3 sessions of MCT
89017634|NCT06139770|Active Comparator|Passive follow-up|The group receives no sessions during follow-up
89017635|NCT06139744|Experimental|DAO supplement group|One tablet of the supplementary study product was taken orally before morning, lunch and dinner every day, and each tablet contained 4.2mg of dehydrated pea seedling powder.
89017636|NCT06139744|Placebo Comparator|Placebo group|Placebo was orally supplemented with one tablet each day before morning, lunch and dinner, and placebo did not contain dehydrated pea seedling powder 4.2mg.
89017637|NCT06139705|Experimental|Walking outdoors group (OUT group)|The OUT group will walk in natural environment.
89017638|NCT06139705|Experimental|Walking indoors group (IN group)|The IN group will walk indoors.
89017639|NCT06139679||Fenestrated|Patients with ASD who underwent surgical closure of ASD with fenestrated patch
89017640|NCT06139679||Non-fenestrated|Patients with ASD who underwent surgical closure of ASD with non-fenestrated patch
89017641|NCT06139666|Active Comparator|Control- Bupivacaine Alone|patients will receive a standard interscalene block with bupivacaine alone (25 cc of bupivacaine)
89017642|NCT06139666|Experimental|Study- Exparel|patients will receive an interscalene block with Exparel solution, which is an extended-release formulation of bupivacaine consisting of 10cc liposomal bupivacaine mixed with 15cc bupivacaine. This is approved and used at the study institution
89460796|NCT04990388|Experimental|UX053 Dose Level DB-2R|Participants randomized to receive a single, peripheral IV infusion of UX053 or Placebo every 2 weeks (Q2W) for 5 doses. Participants will also receive premedication, consisting of oral paracetamol/acetaminophen or ibuprofen, an H2 blocker, and an H1 blocker.
89460797|NCT04990388|Experimental|UX053 Dose Level DB-3R|Participants randomized to receive a single, peripheral IV infusion of UX053 or Placebo every 2 weeks (Q2W) for 5 doses. Participants will also receive premedication, consisting of oral paracetamol/acetaminophen or ibuprofen, an H2 blocker, and an H1 blocker.
89017643|NCT06139653|Active Comparator|Group 1 - IMT CB|"Moment 1: IMT and moment 2: CardioBreath. Participants will have PowerBreath device for IMT adjusted for 30% with weekly adjustment of maximal inspiratory pressure and will perform the exercise at home for five days/week. They will perform 5 sets of 10 repetitions twice a day for five weeks.~CardioBreathApp group will have the app settings of profile and spontaneous respiratory rate to determine the exercise rate of exercises, which will be performed at home for five days/week during 5 sets of one minute with 30' of rest between the sets twice a day. respiratory rate of exercise will be determined by 80% of spontaneous respiratory rate twice a day for five weeks. An once a week meeting will provide readjustment of respiratory rate to perform exercises. One week washout will be taken between the two interventions in order to cleanse motor memory of respiratory act."
89201734|NCT00775788|Experimental|Micromastia|
89201735|NCT00775788|Experimental|Asymmetric Breasts|
89201736|NCT00929175|Active Comparator|active CPAP|auto-PAP with therapeutic pressure
89201737|NCT00929175|Sham Comparator|sham-CPAP|auto-PAP with pressure less than 1cm H2O
89460798|NCT04964206||Neuraxial analgesia exposure|For mothers who accept neuraxial labor analgesia, epidural analgesia or combined spinal-epidural analgesia will be provided according to routine practice of each study center.
89460799|NCT04964206||No neuraxial analgesia exposure|For patients who do not accept neuraxial labor analgesia, analgesics will be prescribed by obstetricians according to routine practice.
89201738|NCT00929409|Active Comparator|Peroral iron - ferrous sulfate tablets|Peroral iron given as one tablet of ferrous sulfate 100 mg two times daily
89460800|NCT04958200|Experimental|mhealth-pc for alcohol and chronic pain|Smartphone-based intervention
89460801|NCT04958200|Active Comparator|Treatment As Usual|In person session that provides enhanced treatment as usual
89460802|NCT04909541||Patient with ureteral stent|Patients with ureteral stent that meet the inclusion, exclusion criteria complete the Canadian Endourology Group Stent Symptom Score (CEGSSS)
89460803|NCT04908241|Experimental|TRAIL|TRAIL is a 4-week progressive exercise and self-management intervention for lower extremity recovery delivered by a trained registered physical therapist, in a 2:1 participant-to-therapist ratio. Each participant grouping will receive two telerehabilitation sessions (60-90 minutes) each week for 4 weeks (total 8-12 hours).
89460804|NCT04908241|Active Comparator|EDUCATION|"The EDUCATION control arm is a 4-week education program focusing on stroke knowledge and risk factors. It will be delivered by health professionals who have experience working with individuals with stroke, knowledge of chronic disease self-management (e.g. physical or occupational therapists, nurses, kinesiologists), and who have completed study-specific training on the EDUCATION program~Participants will receive video conferencing sessions with the same schedule and 2:1 participant-to-coach ratio as TRAIL. Each participant grouping will receive two educational telerehabilitation sessions (60-90 minutes) each week for 4 weeks (total 8-12 hours)."
89460805|NCT04906135|Experimental|Usher Syndrome|Adult and pediatric cochlear implant users with Usher syndrome
89460806|NCT04906135|Active Comparator|Idiopathic Hearing Loss|Adult and pediatric cochlear implant users with idiopathic hearing loss
89460807|NCT04896866|Experimental|Antimicrobial stewardship|Antimicrobial stewardship prospective audit and feedback on physicians attending to patients admitted with community-acquired COVID-19 pneumonia to beds randomized to antimicrobial stewardship intervention.
89460808|NCT04896866|No Intervention|No antimicrobial stewardship|No antimicrobial stewardship prospective audit and feedback.
89460809|NCT04882592|Experimental|Therapeutic Arm|Spinal Cord Neuromodulation with SCiP during Activity Based NeuroRehab Therapy
89460810|NCT04882592|Sham Comparator|Sham Arm|Sham Stimulation during Activity Based NeuroRehab Therapy
89460811|NCT04837131|Experimental|Ixazomib in patients with scleroderma-interstitial lung disease (ILD)|Participants will be administered oral ixazomib for six cycles (each cycle is 28 days duration).
89460812|NCT04821570||Chemotherapy (IV and oral)|
89460813|NCT04821570||Immunotherapy|
89460814|NCT04821570||Chemotherapy + Immunotherapy|
89460815|NCT04821570||Cyclin- dependent kinase (CDK) 4/6 inhibitors|
89201739|NCT00929409|Active Comparator|Ferric carboxymaltose|Intravenous infusion of Ferric Carboxymaltose (Ferinject), the given dose is adapted according to the individual patient's requirement. No other form of iron supplementation is given.
89201740|NCT00772512|Experimental|A|
89201741|NCT00772512|Experimental|B|
89201742|NCT00772512|Placebo Comparator|C|
89201743|NCT00775866|Experimental|MRI guided prostate biopsy|
89201744|NCT00669864|Experimental|BIAsp 30-30|Individual adjusted dose of biphasic insulin aspart 30 administered before breakfast and dinner in combination with metformin 1000-2000mg, up to three times daily
89201745|NCT00770172|Experimental|Arm I|Patients receive filgrastim (G-CSF) subcutaneously (SC) once daily for 6 days beginning 1 week after the start of chemotherapy (days 7-12). If chemotherapy begins on day 8, patients receive G-CSF SC on days 9-14.
89460816|NCT04821570||Stem Cell Transplant recipients|
89460817|NCT04788433||ROCCO-A (A-symptomatic)|Patients with documented COVID-19 infection and NO symptoms
89460818|NCT04788433||ROCCO-P (Pauci-symptomatic)|Patients with documented COVID-19 infection and mild symptoms but NO oxygen support)
89460819|NCT04788433||ROCCO-L (mild)|Patients with documented COVID-19 infection and mild severity - requiring OXIGEN SUPPORT
89460820|NCT04788433||ROCCO-M (moderate)|Patients with documented COVID-19 infection and moderate severity - requiring OXIGEN SUPPORT by NON-INVASIVE modalities
89460821|NCT04788433||ROCCO-S(severe)|Patients with documented COVID-19 infection and severe disease requiring INVASIVE VENTILATION OR EXTRACORPOREAL MEMBRANE OXYGENATION
89460822|NCT04755101|Active Comparator|Righ-sided ARGP ablation|two-thirds of the patients will be randomized to procedural arm A: a diagnostic evaluation followed by cardio-neuromodulation (CardNM) and a pharmacological evaluation
89460823|NCT04755101|Sham Comparator|Placebo|one-third of the patients will be randomized to procedural arm B: a diagnostic evaluation followed by a pharmacological evaluation.
89460824|NCT04751916|Experimental|Proprietary Essential Amino Acid Protein Supplement|Essential amino acid protein supplement; 15 grams (one packet) dissolved in 8 ounces of water twice daily for 6 months.
89201746|NCT00770172|Experimental|Arm II|Patients receive G-CSF SC every 2 days on days 10-20 for up to 6 injections.
89201747|NCT02557620|Experimental|semaglutide OD + placebo semaglutide OW|
89201748|NCT02557620|Placebo Comparator|placebo semaglutide OW + placebo semaglutide OD|
89201749|NCT02557620|Experimental|semaglutide OW + placebo semaglutide OD|
89201750|NCT00776022|Experimental|1|Cetirizine Hydrochloride 10 mg tablet of Ohm Laboratories
89460825|NCT04751916|Active Comparator|Commercially-available whey protein supplement - Beneprotein®|Beneprotein® whey protein supplement; 15 grams (one packet) dissolved in 8 ounces of water twice daily for 6 months.
89460826|NCT04724460|Active Comparator|Long DOAC|Administration of Rivaroxaban for 18 months
89201751|NCT00776022|Active Comparator|2|Cetirizine Hydrochloride 10 mg tablet of Pfizer Labs
89460827|NCT04724460|Active Comparator|Short DOAC|Administration of Rivaroxaban for 6 months
89460828|NCT04723069|Experimental|Fuke Qianjin capsule|"Metronidazole tablets + Doxycycline Hyclate tablets simulant are consecutively taken for 14 days, while the Fuke Qianjin capsule is consecutively taken for 28 days.~Fuke Qianjin Capsules are taken as 2 capsules at a time, 3 times a day, orally after breakfast, lunch, and dinner, respectively; Metronidazole Tablets are taken as 2 tablets (0.2 g/tablet) at a time, twice a day, at the same time as breakfast and dinner, respectively; Doxycycline Hyclate Tablet simulants are taken as 1 tablet (0.1 g/tablet, Doxycycline Hyclate Tablet calculated as C22H24N2O8) at a time, twice a day, at the same time as breakfast and dinner, respectively."
89460829|NCT04723069|Active Comparator|Metronidazole tablets + Doxycycline hyclate tablets|"Metronidazole tablets + Doxycycline hyclate tablets are consecutively taken for 14 days, while Fuke Qianjin capsule simulation is consecutively taken for 28 days.~Fuke Qianjin Capsules simulants are taken as 2 capsules at a time, 3 times a day, orally after breakfast, lunch and dinner, respectively; Metronidazole Tablets are taken as 2 tablets (0.2 g/tablet) at a time, twice a day, at the same time as breakfast and dinner, respectively; Doxycycline Hyclate Tablet simulants are taken as 1 tablet (0.1 g/tablet, Doxycycline Hyclate Tablet calculated as C22H24N2O8) at a time, twice a day, at the same time as breakfast and dinner, respectively."
89460830|NCT04706416|Experimental|N-Acetyl Glucosamine|All patients in the treatment arm of the study were treated with N-Acetyl Glucosamine, a potential therapy for Coronavirus Disease-19 (COVID-19).
89460831|NCT04706416|Placebo Comparator|Control|All patients in the comparator arm were admitted to the same hospital with COVID-19 but did not receive N-Acetyl Glucosamine treatment. All these patients were identified retrospectively.
89460832|NCT04701749||with atrial closure|
89460833|NCT04701749||without atrial occlusion|
89460834|NCT04692922||Patients with disorders of consciousness|patients with a diagnosis of coma, vegetative state, or minimally conscious state minus (i.e. minimally conscious state without language function)
89460835|NCT04684563|Experimental|NHL Dose Level 1a (DL1a)|3x10^6 huCART19-IL18 cells administered as a single intravenous (IV) infusion or slow IV push
89201752|NCT00772746||exercise|Respiratory and cognitive exercises in panic disorder patients.
89201753|NCT00772824|No Intervention|1|10 patients (30 cycles) of chemotherapy will receive placebo
89201754|NCT00772824|Active Comparator|2|Intravenous glutamine
89201755|NCT00772824|Experimental|3|Oral Glutamine
89201756|NCT02557308||Remsima™|Patients who are taking Remsima™ for the treatment
89201757|NCT02557308||Other anti-TNF drugs|Patients who are taking other anti-TNF drugs such as infliximab (Remicade®), etanercept, adalimumab, etc.
89201758|NCT04047732|Experimental|Topical KB105|HSV1-TGM1 vector (KB105)
89460836|NCT04684563|Experimental|NHL Dose Level -1 (DL-1)|7x10^5 huCART19-IL18 cells administered as a single intravenous (IV) infusion or slow IV push; This dose level will only be explored if at least one DLT is observed at Dose Level 1a.
89460837|NCT04684563|Experimental|NHL Dose Level 1b (DL1b)|3x10^6 huCART19-IL18 cells following lymphodepleting chemotherapy administered as a single intravenous (IV) infusion or slow IV push
89460838|NCT04684563|Experimental|NHL Dose Level 2 (DL2)|7x10^6 huCART19-IL18 cells following lymphodepleting chemotherapy administered as a single intravenous (IV) infusion or slow IV push
88942567|NCT01870674|Experimental|YH12852|"<SAD cohort>~Experimental: YH12852 1mg/single dose, qd~Experimental: YH12852 3mg/single dose, qd~Experimental: YH12852 10mg/single dose, qd~<FSD cohort>~Experimental: YH12852 0.5mg/single dose, qd~Experimental: YH12852 1mg/single dose, qd~Experimental: YH12852 2mg/single dose, qd~Experimental: YH12852 3mg/single dose, qd~<MAD cohort>~Experimental: YH12852 0.5mg/repeat dose, qd~Experimental: YH12852 1mg/repeat dose, qd~Experimental: YH12852 2mg/repeat dose, qd~Experimental: YH12852 3mg/repeat dose, qd~Each dosing group(except MAD cohort 0.5mg which has single treatment arm taking YH12852 only) contains 12 subjects. 12 subjects are administered YH12852 or placebo/active comparators.(YH12852:placebo:active=8:2:2)"
89460839|NCT04684563|Experimental|NHL Dose Level 3 (DL3)|3x10^7 huCART19-IL18 cells following lymphodepleting chemotherapy administered as a single intravenous (IV) infusion or slow IV push
89460840|NCT04684563|Experimental|NHL Dose Level 4 (DL4)|7x10^7 huCART19-IL18 cells following lymphodepleting chemotherapy administered as a single intravenous (IV) infusion or slow IV push
89460841|NCT04684563|Experimental|NHL Dose Level 5 (DL5)|3x10^8 huCART19-IL18 cells following lymphodepleting chemotherapy administered as a single intravenous (IV) infusion or slow IV push
89460842|NCT04684563|Experimental|CLL Dose Level 1b (DL1b)|3x10^6 huCART19-IL18 cells administered as a single intravenous (IV) infusion or slow IV push; This dose level will only be explored if at least one DLT is observed at Dose Level 2.
89460843|NCT04684563|Experimental|CLL Dose Level 2 (DL2)|7x10^6 huCART19-IL18 cells following lymphodepleting chemotherapy administered as a single intravenous (IV) infusion or slow IV push
89460844|NCT04684563|Experimental|CLL Dose Level 3 (DL3)|3x10^7 huCART19-IL18 cells following lymphodepleting chemotherapy administered as a single intravenous (IV) infusion or slow IV push
89460845|NCT04684563|Experimental|CLL Dose Level 4 (DL4)|7x10^7 huCART19-IL18 cells following lymphodepleting chemotherapy administered as a single intravenous (IV) infusion or slow IV push
88942568|NCT01870674|Active Comparator|Prucalopride|<each cohort> Prucalopride succinate 1.321mg
88942569|NCT01870674|Placebo Comparator|Placebo|<each cohort> Matching Placebo
88942570|NCT01870687|Experimental|VAC BNO 1095 2x10 mg FCT|VAC BNO 1095 2x10 mg FCT 2 tablets of verum in the morning, oral, 3 months treatment
88942571|NCT01870687|Placebo Comparator|Placebo|2 tablets in the morning, oral, 3 months treatment
88942572|NCT01870700|Experimental|lactobacillus reuteri|Intervention: supplementation with the probiotic Lactobacillus reuteri (DSM 17938),Reuflor, was administered in the dose of 108 colony-forming units (CFU) in tablets of a commercially available preparation (Reuflor, Italchimici, Pomezia; BioGaia AB, Stockholm, Sweden), 30 minutes after feeding, twice per day for 4 weeks.
89460846|NCT04684563|Experimental|CLL Dose Level 5 (DL5)|3x10^8 huCART19-IL18 cells following lymphodepleting chemotherapy administered as a single intravenous (IV) infusion or slow IV push
89460847|NCT04684563|Experimental|ALL Dose Level 1b (DL1b)|3x10^6 huCART19-IL18 cells administered as a single intravenous (IV) infusion or slow IV push; This dose level will only be explored if at least one DLT is observed at Dose Level 2.
89460848|NCT04684563|Experimental|ALL Dose Level 2 (DL2)|7x10^6 huCART19-IL18 cells following lymphodepleting chemotherapy administered as a single intravenous (IV) infusion or slow IV push
89460849|NCT04684563|Experimental|ALL Dose Level 3 (DL3)|3x10^7 huCART19-IL18 cells following lymphodepleting chemotherapy administered as a single intravenous (IV) infusion or slow IV push
89460850|NCT04684563|Experimental|ALL Dose Level 4 (DL4)|7x10^7 huCART19-IL18 cells following lymphodepleting chemotherapy administered as a single intravenous (IV) infusion or slow IV push
89460851|NCT04684563|Experimental|ALL Dose Level 5 (DL5)|3x10^8 huCART19-IL18 cells following lymphodepleting chemotherapy administered as a single intravenous (IV) infusion or slow IV push
89460852|NCT04683926|Experimental|Desmetramadol 10 mg, fasted|While fasting a single oral dose of 10 mg desmetramadol under.
89460853|NCT04683926|Experimental|Desmetramadol 20 mg, fasted|While fasting a single oral dose of 20 mg desmetramadol.
89460854|NCT04683926|Experimental|Desmetramadol 30 mg , fasted|While fasting a single oral dose of 30 mg desmetramadol.
89460855|NCT04683926|Experimental|Desmetramadol 30 mg , fed|After feeding a single oral dose of 30 mg desmetramadol.
89460856|NCT04681170|Other|Age 5-10 years|Age 5-10 years Lomitapide dosing will commence with 2mg at week 1 for 8 Weeks,then increase to 5mg Week 8±3 days, 10 mg at Week 12±3 days to the maximum allowable dose of 20 mg by Week 16±3 days or the MTD by Week 20±3 days based upon acceptable safety and tolerability criteria in addition to LDL C values
89460857|NCT04681170|Other|Age11-15years|Lomitapide dosing will commence with 2mg at week 1 for 4 Weeks, then increase to 5mg Week 4±3 days, 10 mg at Week 8±3 days,20mgs at week, 12±3 days to the maximum allowable dose of 40 mg by Week 16±3 days or the MTD by Week 20±3 days based upon acceptable safety and tolerability criteria in addition to LDL C values
89460858|NCT04681170|Other|16 to ≤17 years|Lomitapide dosing will commence with 5mg at week 1 for 4 Weeks, then increase to 10mg Week 4±3 days,20 mg at Week 8±3 days,40mgs at week, 12±3 days to the maximum allowable dose of 60 mg by Week 16±3 days or the MTD by Week 20±3 days based upon acceptable safety and tolerability criteria in addition to LDL C values
89460859|NCT04670133|Experimental|Inulin|Supplementation with inulin for 4 weeks prior to and 10 weeks after sanative therapy. 10 g daily, divided into two equal doses.
89460860|NCT04670133|Placebo Comparator|Placebo|Supplementation with maltodextrin (as placebo) for 4 weeks prior to and 10 weeks after sanative therapy. 10 g daily, divided into two equal doses.
89460861|NCT04667793|Experimental|Thymic Epithelial Tumor|"For thymoma:~Neoadjuvant treatment stage: Toripalimab 240mg, q3w, i.v., 2-4 cycles; platinum-based chemotherapy (Carboplatin AUC 5, Amycin 50mg/m2, Cyclophosphamide 500mg/m2) q3w, i.v., 2-4 cycles, then receive chest CT evaluation.~Surgery stage: the patients will receive radical surgery after the neoadjuvant treatment.~Adjuvant treatment stage: the patients who did not receive 4 cycle therapy will receive 1-2 cycles therapy up to 4 cycles in total, the following therapy is according to the NCCN guidelines.~For thymic carcinoma:~Neoadjuvant treatment stage: Toripalimab 240mg, q3w, i.v., 2-4 cycles; platinum-based chemotherapy (Cisplatin 50mg/m2, Paclitaxel 200mg/m2) q3w, i.v., 2-4 cycles, then receive chest CT evaluation."
89460862|NCT04653818|Active Comparator|DAAs group|Those with complete HCC ablation who will start sofosbuvir / velpatasvir aiming to eradicate HCV.
89201759|NCT00772902|Experimental|Truvada + Kaletra|Truvada (emtricitabine 200 mg/tenofovir DF 300 mg) once daily for oral administration according to prescription information. As third agent, continuing Kaletra (lopinavir 200 mg/ritonavir 50 mg) for oral administration according to prescription.
89201760|NCT00772902|Active Comparator|Kivexa + Kaletra|Continuing Kivexa (abacavir sulfate 600 mg/lamivudine 300 mg) once daily for oral administration according to prescription. As third agent, continuing Kaletra (lopinavir 200 mg/ritonavir 50 mg) for oral administration according to prescription.
89460863|NCT04653818|Active Comparator|Postponed DAAs group|Those who will not start DAAs within the 12 months follow up from HCC ablation procedure. Patients of this group will receive DAAs provided that there is no HCC recurrence after the end of 1 year.
89460864|NCT04640857|Experimental|Test group: Silk'n Toothwave with vibration and electromagnetic field|Silk'n Toothwave with vibration and electromagnetic field use twice a day for 3 months.
89460865|NCT04640857|Sham Comparator|Control group: Silk'n Toothwave with-out an electromagnetic field ( only vibration)|Silk'n Toothwave without an electromagnetic field (only vibration ) use twice a day for 3 months.
89460866|NCT04640857|Active Comparator|Silk'n Toothwave with an electromagnetic field and without vibration|Silk'n Toothwave with an electromagnetic field and without vibration use twice a day for 3 months.
89460867|NCT04629807|Active Comparator|Demineralized Bone Matrix (DBM)|All enrolled subjects will undergo primary, contiguous 2-level ALIF without supplemental fixation. Study Implant (one-level) implanted with Demineralized Bone Matrix (DBM).
89460868|NCT04629807|Active Comparator|Cellular Bone Matrix (CBM)|All enrolled subjects will undergo primary, contiguous 2-level ALIF without supplemental fixation. Control Implant (one-level) implanted with Cellular Bone Matrix (CBM).
89460869|NCT04629794|Active Comparator|Demineralized Bone Matrix|Prospective cohort subjects undergoing deformity correction surgery that receive Demineralized Bone Matrix (DBM).
89460870|NCT04629794|Active Comparator|Bone Morphogenic Protein|Retrospective cohort subjects that underwent deformity correction surgery and received Bone Morphogenic Protein (BMP).
89460871|NCT04626076||Aga Khan University|Pakistan
89460872|NCT04626076||African Medical and Research Foundation- Uganda|Uganda
89460873|NCT04626076||African Medical and Research Foundation- Kenya|Kenya
89460874|NCT04626076||African Medical and Research Foundation- Zambia|Zambia
89460875|NCT04626076||African Medical and Research Foundation- Senegal|Senegal
89201761|NCT02557152||Patients that were treated with the GentleWave System|
89201762|NCT00779220|Placebo Comparator|1|
89201763|NCT00779220|Experimental|2|
89460876|NCT04626076||54Gene|Nigeria
89460877|NCT04626076||African Institute of Biomedical Science & Technology|Zimbabwe
89201764|NCT00779220|Experimental|3|
89460878|NCT04605302|Experimental|Single Arm Tandem Study|Patients are assigned to swallow a magnetically controlled capsule first then undergo standard gastroscopy
89460879|NCT04598841|Experimental|intervention group|Intravenous nutrition or oral high-calorie diet 7-10 days before surgery
89460880|NCT04598841|No Intervention|control group|normal diet before surgery
89460881|NCT04581304|Experimental|Bio-Oss Collagen|Transcrestal approach sinus augmentation using Geistlich Bio-Oss Collagen®.
89460882|NCT04581304|Active Comparator|Bio-Oss Granules|Transcrestal approach sinus augmentation using Geistlich Bio-Oss®.
89460883|NCT04578652|Active Comparator|MET|MET (850 mg po bid - standard of care) + Fiber placebo daily
89460884|NCT04578652|Active Comparator|FIBER|Fiber supplementation [35g fiber daily] + MET placebo po bid
89460885|NCT04578652|Experimental|FIBER + MET|Fiber supplementation [35g fiber daily] + MET 850 mg po bid
89460886|NCT04570631|Experimental|Safety Lead-in|Participants will receive escalating doses of eftozanermin alfa in combination with bortezomib and dexamethasone to determine recommended phase 2 dose (RP2D).
89460887|NCT04570631|Experimental|Dose Expansion|Participants will receive eftozanermin alfa at RP2D determined in Safety Lead-in part in combination with bortezomib and dexamethasone.
89460888|NCT04533542||Arm I (3 video or telephone conferences)|Participants attend up to 3 video or telephone conferences over 2 hours each with a minimum of 24 hours and maximum of 1 week between sessions. Participants take a fixed number of puffs on 3 randomly assigned conditions (combinations of carrier and nicotine concentrations).
89460889|NCT04533542||Arm II (2 video or telephone conferences)|Participants attend up to 2 video or telephone conferences over 2 hours each with a minimum of 24 hours and maximum of 1 week between sessions. Participants take a fixed number of puffs on a nicotine-free condition and 3 randomly assigned conditions (combinations of carrier concentration and nicotine form).
89460890|NCT04508998|Experimental|Patients with microvascular angina|Patients with clinical features of microvascular angina screened for the main PRIZE trial however not possessing the PHACTR1 GG minor allele single nucleotide polymorphism
89017644|NCT06139653|Active Comparator|Group 2 - CB IMT|"Moment 1: CardioBreath and moment 2: IMT. Participants will have PowerBreath device for IMT adjusted for 30% with weekly adjustment of maximal inspiratory pressure and will perform the exercise at home for five days/week. They will perform 5 sets of 10 repetitions twice a day for five weeks.~CardioBreathApp group will have the app settings of profile and spontaneous respiratory rate to determine the exercise rate of exercises, which will be performed at home for five days/week during 5 sets of one minute with 30' of rest between the sets twice a day. respiratory rate of exercise will be determined by 80% of spontaneous respiratory rate twice a day for five weeks. An once a week meeting will provide readjustment of respiratory rate to perform exercises. One week washout will be taken between the two interventions in order to cleanse motor memory of respiratory act."
89017645|NCT06139640|Active Comparator|The effects of rose oil on pain and anxiety level on pediatric dental patient|Rose oil aromatherapy
89460891|NCT04507061|Experimental|runcaciguat|Participant randomized to this arm will be up-titrated. A 30-day safety follow up will be performed after end of treatment or after early discontinuation from the study.
89460892|NCT04507061|Placebo Comparator|Placebo|Participant randomized to this arm will be sham-titrated. A 30-day safety follow up will be performed after end of treatment or after early discontinuation from the study.
89460893|NCT04476589||COVID-19 Disorders of Consciousness|Patients with COVID-19 and disorders of consciousness
89460894|NCT04430517|Experimental|Mild Cognitive Impairment and Alzheimer's Dementia|Participants will take 4 pills every day, each containing 250 mg NR (NIAGEN® by Chromadex; www.chromadex.com), via the oral route, for 12 weeks.
89460895|NCT04414943|Experimental|S-katamine group|For women in this group, study drug (s-ketamine 0.2 mg/kg in 20 ml normal saline) will be infused at a rate of 30 ml/h (infusion finished in 40 minutes) after giving birth. Women will be monitored for 60 minutes and then sent back to the ward.
89460896|NCT04414943|Placebo Comparator|Placebo group|For women in this group, study drug (20 ml normal saline) will be infused at a rate of 30 ml/h (infusion finished in 40 minutes) after giving birth. Women will be monitored for 60 minutes and then sent back to the ward.
89460897|NCT04405258|Active Comparator|PVI alone|Pulmonary vein isolation, superior vena cava isolation, and cavotricuspid isthmus ablation
89460898|NCT04405258|Active Comparator|PVI and PWI|Pulmonary vein isolation, superior vena cava isolation, cavotricuspid isthmus ablation, and left posterior wall isolation
89460899|NCT04396613|Active Comparator|Running Subcuticular Suture|
89460900|NCT04396613|Active Comparator|Interrupted Vertical Mattress Suture|
89460901|NCT04396613|Active Comparator|Staple Closure Techniques|
89201765|NCT00779220|Experimental|4:|
89460902|NCT04364295||Implanted with SeaSpine spinal or orthobiologics product|Standard of Care Registry- Patients must have been implanted with at least one SeaSpine product
89460903|NCT04354025|Experimental|Recipient: FLAG + CIML NK Cells + IL-2|-The recipient will begin a chemotherapy regimen of fludarabine, cytarabine and GCSF starting on Day -7. The haploidentical donor identified by HLA matching of the immediate family members will undergo non-mobilized large volume (20 L) leukapheresis on Day -1, and the NK cell product will be infused into the recipient on Day 0. CIML NK cells will be infused at maximum cell dose of 10 x 106/kg. Subcutaneous IL-2 will begin approximately 2-4 hours after infusion and will continue every other day through Day 12 for a total of 7 doses.
89460904|NCT04354025|Other|Donor:|-On Day -1 (one day before the planned NK cell infusion), peripheral blood mononuclear cells will be collected by a single standard apheresis over 4-5 hours (with a target volume of at least 20 L) from the identified haploidentical donor. The apheresis procedure will be done as per standard institutional procedures (which may include placement of a central line if necessary). If the goal minimum NK cell dose will not be met based on the initial assessment of the leukapheresis product, a second collection/procedure may be performed.
89460905|NCT04347720||Indomethacin Arm|Intravenous indomethacin at 0.1-0.3 mg/kg IV every 12-24h for a total of 3 doses as choice of initial pharmacotherapy.
89201766|NCT00779298||Healthy subjects|Healthy subjects, without symptoms or a prior history of gastrointestinal disease, abdominal surgery or diabetes mellitus
89460906|NCT04347720||Standard dose ibuprofen Arm|Standard dose ibuprofen [Oral/intravenous] at 10 mg/kg followed by 2 doses of 5mg/kg at 24 h intervals irrespective of postnatal age as choice of initial pharmacotherapy.
89460907|NCT04347720||Adjustable dose ibuprofen Arm|Adjustable dose ibuprofen [Oral/intravenous] as choice of initial pharmacotherapy. The dose of ibuprofen will be 10 mg/kg followed by 2 doses of 5 mg/kg at 24 h intervals if treated within the first 7 days after birth. Higher doses of ibuprofen up to 20 mg/kg followed by 2 doses of 10 mg/kg at 24 h intervals if treated after the postnatal age cut-off for lower dose as per the local center policy
89201767|NCT00776256|Active Comparator|1|effect of beta-glucan
89201768|NCT00776256|Active Comparator|2|effect of fructo-oligosaccharide
89460908|NCT04347720||Acetaminophen Arm|Acetaminophen [Oral/intravenous] at 15mg/kg every 6h for 3-7 days as choice of initial pharmacotherapy.
89460909|NCT04347720||Control group|Infants <29 weeks GA with echocardiography-confirmed PDA but never received any pharmacotherapy
89460910|NCT04347720||Reference group|Infants <29 weeks GA who were never diagnosed with PDA
89460911|NCT04343755|Experimental|Convalescent Plasma|Fresh or frozen plasma will be infused one time to patients
89201769|NCT00776256|Active Comparator|3|effect of beta-glucan and fructooligosaccharide
89201770|NCT00776256|Placebo Comparator|4|no beta-glucan nor fructooligosaccharide
89460912|NCT04325802|Experimental|Cohort 1: Placebo, then Intervention|Patients will start with placebo in week 1 and cross over to Naltrexone in week 3. There will be a wash-out phase during week 2 using only moisturizer regularly and if necessary as rescue medications topical corticosteroids and/or antihistamines. The same rescue medications can be used during the following weeks of the cross-over treatment. At visit 2 and 4 patients will be asked the area where they are experiencing most intense itch and we will take there suction blisters (preferably on the trunk). Suction blisters will be taken after week 1 (1 week on treatment arm 1) and after week 3 (1 week on treatment arm 2).
89460913|NCT04325802|Active Comparator|Cohort 2: Intevention, then Placebo|Patients will start with Naltrexone in week 1 and cross over to the palcebo treatment in week 3. There will be a wash-out phase during week 2 using only moisturizer regularly and if necessary as rescue medications topical corticosteroids and/or antihistamines. The same rescue medications can be used during the following weeks of the cross-over treatment. At visit 2 and 4 patients will be asked the area where they are experiencing most intense itch and we will take there suction blisters (preferably on the trunk). Suction blisters will be taken after week 1 (1 week on treatment arm 1) and after week 3 (1 week on treatment arm 2).
89460914|NCT04325802|No Intervention|Circadian Rhythm of Itch|Patients in this arm will receive no intervention, only data collection.
89460915|NCT04314583|Active Comparator|Attention Control Group|Adult patients attending cardiovascular rehabilitation.
89460916|NCT04314583|Experimental|Gratitude Journaling Group|Adult patients attending cardiovascular rehabilitation.
89460917|NCT04300777||Treated with Non-Cervical Pedicle Screw Systems|50 patients who have been implanted with SeaSpine Non-Cervical Pedicle Screw Systems
89460918|NCT04285346|Other|Open-label|ganaxolone suspension (50 mg/ml) TID for 12 weeks with 24 week extension
89460919|NCT04266873|Experimental|AffloVest HFCWO intervention|Use of the AffloVest for 30 mins, twice a day for 6 weeks
89460920|NCT04253899|Active Comparator|Standard pediatric group:|patients ≤17 yo with acute perforated appendicitis and interval appendectomy (n=25)
88942573|NCT01870700|Placebo Comparator|placebo|a supplementation with placebo was administered in tablets of a commercially available preparation 30 minutes after feeding, twice per day for 4 weeks
88942574|NCT01870713||type 2 diabetes patients with gastric bypass surgery.|Participants who have type 2 diabetes and with decreased glucose after gastric bypass surgery.
88942575|NCT01870713||Weight matched non-operated controls|Participants who are overweight to moderately obese, and have no personal of family history of Type 1, Type 2, or Gestational Diabetes.
89460921|NCT04253899|Experimental|Experimental pediatric group:|patients ≤17 yo with acute perforated appendicitis abscess and observation (n=25)
88942576|NCT01870752|Other|Transplantation of previously cryopreserved ovarian tissue|Surgical transplantation of previously collected cryopreserved ovarian cortical tissue.
88942577|NCT01870765|Active Comparator|non-invasive ventilation|Performance of bronchoscopy during non-invasive ventilation.
88942578|NCT01870765|Experimental|high-flow oxygen|Performance of bronchoscopy during high-flow oxygen therapy.
88942579|NCT01870791|Experimental|Omegaven|Omegaven in combination with EOX chemotherapy
88942580|NCT01870804|Active Comparator|Rosuvastatin|Rosuvastatin (40 mg on-admission followed by 20 mg/day) until discharge; then 20 mg/day (10 mg/day if creatinine clearance < 30 ml/min)
88942581|NCT01870804|Active Comparator|Atorvastatin|atorvastatin (80 mg on-admission followed by 40 mg/day before and after discharge)
88942582|NCT01870817|Active Comparator|Home jejunostomy feeding|Six weeks of post hospital discharge home enteral feeding
88942583|NCT01870817|No Intervention|Control|Standard care
88942584|NCT01870830|Other|A: low-intermediate-high altitude|Altitude exposure sequence A, 490-1650-2590m
88942585|NCT01870830|Other|B: low-high-intermediate altitude|Altitude exposure sequence B, 490-2590-1650m
89017646|NCT06139640|No Intervention|The effects of no treatment on pain and anxiety level on pediatric dental patient|
89460922|NCT04253899|Active Comparator|Standard adult group:|patients ≥18 yo with acute perforated appendicitis and interval appendectomy (n=25)
89460923|NCT04253899|Experimental|Experimental adult group:|Patients ≥18 yo with acute perforated appendicitis and observation (n=25)
88942586|NCT01870830|Other|C: intermediate-high-low altitude|Altitude exposure sequence C, 1650-2590-490m
88942587|NCT01870830|Other|D: high-intermediate-low altitude|Altitude exposure sequence D, 2590-1650-490m
88942588|NCT01870882|Active Comparator|Retraining|Using the PED, participants repeatedly complete a version of attentional bias task that orients their attention away from drug-related cues.
88942589|NCT01870882|Sham Comparator|Control|Using the PED, participants repeatedly complete versions of the attentional bias task in which their attention is oriented toward and away from drug-related cues on an equal number of trials.
88942590|NCT01870895|Experimental|YM060 group|
88942591|NCT01870895|Placebo Comparator|Placebo group|
88942592|NCT01870908||tacrolimus + biological agents|
88942593|NCT01870934||Telemedicine, Diabetes, foot ulcer|
89201771|NCT00779376|Experimental|1|Zidovudine 300mg tablets of Ranbaxy
89460924|NCT04234555||Provoked vestibulodynia (PVD)|Provoked vestibulodynia (PVD) is characterized by severe sharp and/or burning pain felt at the entrance to the vagina (i.e. the vulvar vestibule) when pressure is applied to this area or during attempts at vaginal insertional activities (i.e. provoked).
89460925|NCT04234555||Provoked vestibulodynia (PVD) + Vaginismus (VAG)|PVD is sometimes accompanied by intense, involuntary contraction of the PFMs3, termed vaginismus (VAG).
89460926|NCT04234555||Control|Participants matched by age (within 2 years), parity (parous vs nulliparous) and use of oral contraceptive medications (yes vs no) to women in the PVD group, with no signs and symptoms of PVD.
89460927|NCT04234542|Experimental|Low Level Laser Therapy Group|15 treatments will be provided over a 12 week period using a protocol developed in collaboration with BioFlexTM Laser. Each treatment will last approximately 45 minutes and will include the laser array first being applied to the skin overlying the sacral spine in a horizontal placement then in oblique placement bilaterally (red and infrared light) while a laser probe is applied over the base of the spine (red and infrared light). Next, the array will be applied to the surface of the perineum (red and infrared light) and the focal probe will be applied to painful sites on the perineum. Finally, the infrared light probe will be applied to the skin overlying branches of the pudendal nerve. All the stages will involve use of the same array and probe placement, but at each stage the dosage will be increased according to the BioFlex protocol. During teach treatment session, women will listen to an audio recording of a mindfulness-based meditation on CD through noise cancelling headphones.
89460928|NCT04234542|Sham Comparator|Sham Low Level Laser Therapy Group|15 treatments will be provided over a 12 week period using the same protocol developed in collaboration with BioFlexTM Laser, but at an intensity of 1% output for all sites and at all stages. Each treatment will last approximately 45 minutes. At each visit, the laser array will first be applied to the skin overlying the sacral spine in a horizontal then oblique placement bilaterally (red and infrared light) concurrently with a laser probe applied over the base of the spine (red and infrared light). Next, the array will be applied to the surface of the perineum (red and infrared light), followed by treatment at specific painful sites using the red light probe. Finally, the infrared light probe will be applied to the skin overlying branches of the pudendal nerve. Participants randomized to this group will listen to an audio recording of a mindfulness-based meditation on CD through noise cancelling headphones while receiving the sham laser treatment.
89460929|NCT04226144|Active Comparator|Breath Stacking Group|The lungs are inflated as fully as possible by stacking successive breaths without expiration until the patients' maximal inspiratory capacity (MIC). The participant will be instructed to sustain the air in the lung, closing the glottis. Once the lungs are maximally inflated, the compressed air volume is released under expiratory muscle force, thus generating a cough with lung and chest wall recoil. They will perform 5-8 cycles of breath stacking per session, stacking 3-5 breaths per cycle.
88942594|NCT01870947|Experimental|'Assisted-Rate' Exercise Intervention|Subjects in the assisted exercise group will cycle on the same stationary exercise bike; however, a motor will provide assistance to the patient in order to maintain a pedaling rate 35% greater than their voluntary rate. Subjects in the exercise groups will complete 45 minute to 1-hour sessions, three times per week for eight weeks.
88942595|NCT01870947|Experimental|'Voluntary-Rate' Exercise Intervention|Subjects in the voluntary group will exercise on a stationary recumbent exercise cycle and pedal at their preferred rate. Subjects in the exercise groups will complete 45 minute to 1-hour sessions, three times per week for eight weeks.
88942596|NCT01870986|Experimental|A|PF-06410293
88942597|NCT01870986|Active Comparator|B|Adalimumab-EU
88942598|NCT01870986|Active Comparator|C|Adalimumab-US
88942599|NCT01871012||non-diabetes mellitus group|Subjects undergoing Total Knee Replacement are not diagnosed with diabetes mellitus.
88942600|NCT01871012||diabetes mellitus group|subjects have been diagnosed diabetes mellitus mora than three years without serious nerve system complications.
88942601|NCT01871025|Experimental|Hospital and home exercise training|Usual care plus hospital exercise training (aerobic and strength) followed by exercise training at home until 30 days to discharge.
88942602|NCT01871025|Other|Usual care|Usual care in COPD
88942603|NCT01871038||Rotavirus Positive Cases|Children <6 years of age born on or after 8/10/2008 enrolled in active surveillance for AGE who tested positive for rotavirus.
88942604|NCT01871038||Rotavirus Negative Controls|Children <6 years of age born on or after 8/10/2008 enrolled in active surveillance for AGE who tested negative for rotavirus
88942605|NCT01871103|Other|Surgical flap|The dorsal homodigital island flap is a perforator type flap based on the DB, which uses the dorsal skin of the injured finger to provide soft tissue coverage for a volar defect.
88942606|NCT01871116|Experimental|POWER-remote|Participants will start a weight loss program called POWER-remote for Breast Cancer Survivors. This program involves two main components: an online portion accessed on a computer through the internet and a telephone portion to help monitor progress.
88942607|NCT01871116|Active Comparator|Self-directed|"Participants will receive a pamphlet entitled Aim for a Healthy Weight, to help guide weight loss goals without access to the web-based POWER-remote system and coach support."
89201772|NCT00779376|Active Comparator|2|Retrovir ®) 300 mg Zidovudine tablets of Glaxosmithkline
89460930|NCT04226144|Experimental|Breath stacking and EMT|This group will perform the breath stacking technique in addiction with EMT. It will change the one-way valve in this group to VUP (Lumiar, Sao Paulo, Brazil) one-way valve, which allows the patients blow out the air with a counter resistance during all expiratory phase. The initial expiratory pressure will be 8 cmH2O, and could be changed at each visit according to participants' tolerance (either report easy or difficult to exhale assessed by research coordinators. The participants are encouraged to blow out the most slowly that they can do it.
89460931|NCT04213144|Experimental|Magdent Cap MED|Soft and hard tissue healing with electomagnetic healing abutment.
89460932|NCT04213144|Sham Comparator|Sham MED|Soft and hard tissue healing with a regular healing abutment.
89460933|NCT04209192|Active Comparator|Control group (Amikacin)|"Patients in the control group will receive amikacin as prophylactic antibiotic. It will be administered intravenously 30 minutes before procedure. Patients with an estimated glomerular filtration rate (EGFR) greater or equal than 70 ml/min will receive 1 gram of Amikacin. Patients with an EGFR less than 70 ml/min will received a calculated dose following the next parameters.~Patients with EGFR between 69-40 ml/min should receive: the calculated GFR x 0.18 = mg/kg.~Patients with EGFR less than 40 ml/min should receive: the calculated GFR x 0.36 = mg/kg."
89460934|NCT04209192|Experimental|Intervention group (Fosfomycin)|Patients in the intervention group will receive Fosfomycin trometamol as prophylactic antibiotic. It will be administered orally in the night before procedure. Patients must be on fasting and will receive 3 grams.
89460935|NCT04178148|Experimental|BestDose|Therapeutic drug optimization of amikacin using the BestDose software algorithm
89460936|NCT04178148|No Intervention|Control|
89460937|NCT04163822||group with typical imaging changes|the BPD infants with typical chest imaging findings include fibrotic opacities and cysts on CXR or CT scans during the entire hospital stay.
89460938|NCT04163822||group without typical imaging changes|the infants meet the diagnosis criteria of BPD, but lack of typical chest imaging findings
89460939|NCT04148287|Experimental|APX001|APX001 IV or oral for up to 42 days
89460940|NCT04138914|Experimental|Focal Cryotherapy|Focal Cryotherapy using 2 freeze-thaw cycles
89460941|NCT04126681|Experimental|HQP1351 therapy cohort|HQP1351 40 mg, taken orally once every other day of a 28-day cycle
89460942|NCT04126681|Active Comparator|Best Available Therapy (BAT) cohort|Best available therapy (BAT) will be selected by the investigator for each participant.
89460943|NCT04118855|Experimental|Neoadjuvant arm|Patients will receive axitinib 5 mg bid combined with Toripalimab 3mg/KG q3w for up to 12 wk.
89460944|NCT04114604||Spinal Cord Injury|Adults who have sustained a spinal cord injury at the cervical or upper thoracic level (T6 or higher).
89460945|NCT04092790|Experimental|Virtual Gate Device (VGD)|The Virtual Gait Device (VGD) is a technology that uses fussy-logic technology to stimulate calf muscles in synchrony with the patient's heartbeat, enabling a virtual gait in patients who have limited mobility. The stocking-like device is especially useful in older patients who are acutely hospitalized and thus at risk for sarcopenia. While physical activity and physical resistance training are well-documented as preventive measures for sarcopenia, active physical exercise is an unrealistic option for most acutely hospitalized, mobility-limited, older patients. The VGD is a practical alternative that is simple to operate. One pilot study in the orthopedics department in Hadassah Medical Center in Jerusalem, Israel was performed on patients with fractured ankles with the goal of muscle wasting prevention. The VGD will be provided by the manufacturer for use in this pilot clinical study.
89501861|NCT02232919|Experimental|Deep Brain Stimulation|The design of this translation trial is a single-center, single cohort, open-label and non-masked study. The aim is to evaluate tolerability of chronic low-frequency electrical stimulation of the VMH, while achieving weight loss in morbidly obese subjects. The subjects must have a body-mass index [BMI] greater than 40, and no obesity co-morbidities, such as diabetes or cardiopulmonary abnormalities. Up to six subjects will be implanted in this protocol.
89501862|NCT02234401|Experimental|Non invasive ventilation (NIV)|Non invasive ventilation used for the first 7 days of study
89501863|NCT02234401|Active Comparator|Standard Care|High Flow Controlled Oxygen Therapy
88942608|NCT01871129|Placebo Comparator|Saline group|Difference from the normal protocol actualizes at the point when propofol infusion is cut off. From there on the patient in this group receives saline infusion up to the point where 15 minutes have passed after the extubation procedure.
88942609|NCT01871129|Active Comparator|Dexmedetomidine group|Difference from the normal protocol happens when normally the propofol infusion is cut off. From there on the patient in this group receives dexmedetomidine infusion up to the point where 15 minutes have passed after the extubation procedure.
88942610|NCT01871155|Experimental|Nutri-jelly along with radiotherapy|Continuous intake: orally take 1-3 boxes / day for at least 3 days/ week during radiotherapy
88942611|NCT01871155|No Intervention|Radiotherapy only|Receive either definitive (total of 30-35 fractions) or palliative ( total of 10 fractions) radiotherapy with no continuous intake of Nutri-Jelly
88942612|NCT01871168|Sham Comparator|Sham TAP block|Patients receive TAP catheters but saline infusion instead of local anesthetic
88942613|NCT01871168|Experimental|TAP block|Patients receive a continuous TAP block
89201773|NCT00779454|Other|KRAS wildtype|
89460946|NCT04074226|Experimental|Ultrasound-guided ESP block with liposomal bupivacaine|For the ESP block, the transducer will be placed parasagittally at the level of the tip of the scapula and the anesthesiologist will scan in a craniocaudal manner to identify the ipsilateral T10 transverse process and overlying erector spinae muscle. Following aseptic preparation of the injection site and the ultrasound probe, a 22-gauge, 10mm block needle will be introduced parallel to the ultrasound guided beam (in-plane technique) until its tip reaches the plane between the erector spinae muscle and transverse process. After negative aspiration, 20 ml of a mixture containing 10ml 0.25% bupivacaine and 10ml 1.3% liposomal bupivacaine will be injected in 5 ml increments to separate the fascial plane between the muscle and transverse process. The investigators will observe local anesthetic spread under real-time imaging. The block will then be performed in the same manner on the opposite site.
89460947|NCT04074226|Active Comparator|Ultrasound-guided QL block with liposomal bupivacaine|"For the QL block, the transducer will be placed transversely over the lumbar spine at the level of the iliac crest. Then, the anesthesiologist will scan laterally to identify the ipsilateral L3 transverse process, psoas muscle, and quadratus lumborum muscle to identify the Shamrock Sign (7). Following aseptic preparation of the injection site and the ultrasound probe, a 22-gauge, 10mm block needle will be introduced parallel to the ultrasound guided beam (in-plane technique) until its tip reaches the plane between the quadratus lumborum muscle and psoas muscle. After negative aspiration, 20 ml of a mixture containing 10ml 0.25% bupivacaine and 10ml 1.3% liposomal bupivacaine will be injected in 5 ml increments to separate the fascial plane between the two muscles. The investigators will observe local anesthetic spread under real-time imaging. The block will then be performed in the same manner on the opposite site."
89460948|NCT04021394||Non-metastatic, high-risk hormone sensitive prostate cancer|Phlebotomy collection of 2 tubes of blood then annual follow up for 5 years
89460949|NCT04021394||Low-volume metastatic hormone-sensitive prostate cancer|Phlebotomy collection of 2 tubes of blood then annual follow up for 5 years
89460950|NCT04021394||High-volume metastatic hormone-sensitive prostate cancer|Phlebotomy collection of 2 tubes of blood then annual follow up for 5 years
89460951|NCT04021394||Metastatic castrate-resistant prostate cancer|Phlebotomy collection of 2 tubes of blood then annual follow up for 5 years
89460952|NCT04012151||Pregnant cohort|Parturients of gestational age >= 32 weeks will have measurements of arm length, MAC, proximal arm circumference, distal arm circumference, finger circumference to generate the conicity index.
89460953|NCT04011150|Experimental|Variable volume Automated Mandatory Bolus (VVAMB)|The anaesthetic drug and pain medication are prepared in an epidural infusion pump with the VVAMB programme. The programme uses higher doses with lower frequency of medication (ropivacaine and fentanyl), and a patient control button for the patient to control the additional pain relief demands depending on the requirements during labour.
89460954|NCT04011150|Active Comparator|Automated mandatory bolus (AMB) of variable-frequency (VAMB)|The anaesthetic drug and pain medication are prepared in an epidural infusion pump with the VAMB programme. The programme uses lower doses with more frequency of medication (ropivacaine and fentanyl), and a patient control button for the patient to control the additional pain relief demands depending on the requirements during labour.
88942614|NCT01871181|Experimental|Ilioinguinal block|Patients in this group will receive an ultrasound-guided ilioinguinal nerve block.
88942615|NCT01871181|Active Comparator|Local infiltration|Patients in this group will receive the standard method of local infiltration of local anesthetic around the surgical site.
88942616|NCT01871194||Rivaroxaban|This is a non-interventional study
88942617|NCT01871194||Alternative anticoagulant therapy|This is a non-interventional study
88942618|NCT01871207||Diabetic patients|Diabetic patients who underwent vitrectomy for Proliferative Diabetic Retinopathy
88942619|NCT01871207||Non-diabetic patients|Non-diabetic patients who underwent vitrectomy for macular hole or pucker
88942620|NCT01871246||People with COPD & recent exacerbation|The group consists of people with COPD who have had an exacerbation in the last year.
88942621|NCT01871272||Meniscus Injury Patients|Patients having surgery for a meniscal tear.
88942622|NCT01871298|Other|Website access|While this pilot intervention is not a randomized trial, study participants who report internet use at least once a month will told of a Pilot Website Evaluation Component that they will be able to access for a 4-week study period. This website will contain a educational information tailored to the health needs of drug users. Web content will be similar to materials and public health messages released by the NYC Department of Health and therefore, harm is not likely to arise from viewing such content.
88942623|NCT01871298|No Intervention|No website access|Participants who report internet use less than once a month will not receive access to the Pilot Website Evaluation Component.
88942624|NCT01871324|Experimental|Lifestyle counseling|
88942625|NCT01871337|Experimental|Paula method|"the Paula method, a circular muscle exercise, invented in Israel by Paula Garbourg.The method is based on the principle that all sphincters in the body are synchronized, with the movement of one affecting the other.One can rehabilitate damaged muscles by contracting and relaxing specific circular muscles in other parts of the body."
88942626|NCT01871350|Experimental|Protein and Fish Oil|"Low Dose (FFM <49kg): 30.00g milk protein + 12.75g maltodextrin and 6g fish oil~High dose (FFM >49kg): 40.00g milk protein + 17.00g maltodextrin and 8g fish oil"
88942627|NCT01871350|Experimental|Protein|"Low Dose (FFM <49kg): 30.00g milk protein + 12.75g maltodextrin and 6g olive oil~High dose (FFM >49kg): 40.00g milk protein + 17.00g maltodextrin and 8g olive oil"
88942628|NCT01871350|Placebo Comparator|Placebo|"Low Dose (FFM <49kg): 12.75g maltodextrin and 6g olive oil~High dose (FFM >49kg): 17.00g maltodextrin and 8g olive oil"
88942629|NCT01871363|Experimental|preoperative chemoradiation|"radiotherapy: 50 Gy to the pelvis (25x 2 Gy on days 1-35, excluding weekends) .IMRT planing and technique with high energy photons will be used. All fields will be treated daily. Multileaf collimators will be used to shape individual radiation fields. Patients will be irradiated in a prone position with a full bladder and by using belly board to minimize exposure of the small bowel.~capecitabine 825 mg/m² p.o. twice daily on days 1-35 (including weekends),~bevacizumab: at dose 5 mg/kg on days -1, 15,31.~Radical surgery (TME): to be undertaken ideally 6-8 weeks following completion of chemoradiation."
89201774|NCT00779454|Other|KRAS mutation|Inclusion has been completed in the KRAS mutation arm.
89201775|NCT00772980|Experimental|1|Drug: Neramexa mesylate Double-blind treatment period of 17 weeks up to 75 mg Neramexane mesylate per day
89460955|NCT04001244||Endometriosis (EAP)|Surgical diagnosis of endometriosis (aim equal distribution of stage I/II and stage III/IV disease); at least one pelvic pain >3/10; pain not perceived by the patient as arising from the bladder; no urinary symptoms (e.g. urge, frequency)
89460956|NCT04001244||Bladder Pain Syndrome (BPS)|Bladder pain syndrome (as defined by ESSIC criteria: pelvic pain, pressure or discomfort for greater than 6 months, perceived to be related to the urinary bladder accompanied by at least one other urinary symptom like persistent urge to void or frequency); no history of endometriosis
89460957|NCT04001244||Endometriosis and Bladder Pain (EABP)|Surgical diagnosis of endometriosis; at least one pelvic pain >3/10; pain perceived by the patient as arising from the bladder AND from other area(s) of the pelvis; at least one urinary symptom (e.g. urge, frequency)
89460958|NCT04001244||Controls|No endometriosis; No pelvic pain (or dysmenorrhea; NRS <3/10)
89460959|NCT04001244||Pelvic Pain (PP)|At least one pelvic pain >3/10; no endometriosis; pain not perceived by the patient as arising from the bladder; no urinary symptoms (e.g. urge, frequency)
89460960|NCT03984695|No Intervention|Control|"15 minute discharge planning session with health educator~Health education booklet containing SHE-Women intervention content in print form(N~100)~access to health educator via text message"
89460961|NCT03984695|Experimental|Intervention|"Deliver text-Web intervention to (N ~100) women~Researchers will deliver the integrated, multimedia electronic women's health literacy intervention arm of SHEWomen in text-Web format for individuals recently released from jail. Two health educators will be responsible for delivering content to participants, with an estimated contact time of ~10 hours pushed to participants over approximately a 5-day period."
89460962|NCT03935321|Active Comparator|Patients with acute cervical spinal cord injury: NG-101|
89460963|NCT03935321|Placebo Comparator|Patients with acute cervical spinal cord injury: Placebo|
89460964|NCT03927378|Experimental|S-katamine group|For women in this group, study drug (s-ketamine 0.2 mg/kg in 20 ml normal saline) will be infused at a rate of 30 ml/h (infusion finished in 40 minutes) after giving birth. Women will be monitored for 60 minutes and then sent back to the ward.
89460965|NCT03927378|Placebo Comparator|Placebo group|For women in this group, study drug (20 ml normal saline) will be infused at a rate of 30 ml/h (infusion finished in 40 minutes) after giving birth. Women will be monitored for 60 minutes and then sent back to the ward.
89460966|NCT03923686|Experimental|LAMS plus DPS|Endoscopic ultrasound-guided (EUS) transmural drainage of walled-off pancreatic necrosis (WON) using lumen-apposing metal stent (LAMS) with coaxial double-pigtail plastic stent (DPS).
89460967|NCT03923686|Active Comparator|LAMS alone|Endoscopic ultrasound-guided (EUS) transmural drainage of walled-off pancreatic necrosis (WON) using lumen-apposing metal stent (LAMS) alone.
89460968|NCT03875391|Experimental|Oxytocin and trauma film paradigm|Intervention: Drug: Oxytocin nasal spray
89460969|NCT03875391|Placebo Comparator|Placebo and trauma film paradigm|Intervention: Drug: Placebos
89460970|NCT03869905|Experimental|Aquamin®|To be taken for 180 days
89460971|NCT03869905|Placebo Comparator|Placebo first then Aquamin®|Placebo: To be taken for the first 90 days. Aquamin®: To be taken for the last 90 days (after crossover)
89460972|NCT03857620|Active Comparator|Arm I (usual care)|Healthcare providers/institutions perform usual care.
89460973|NCT03857620|Experimental|Arm II (OPTI-Surg training and materials)|Healthcare providers/institutions receive OPTI-Surg training and informational materials.
89460974|NCT03857620|Experimental|Arm III (OPTI-Surg training and materials, coach)|Healthcare providers/institutions receive OPTI-Surg training and informational materials and meet with a coach.
89460975|NCT03836066|Experimental|Experimental: Atezolizumab plus Bevacizumab arm|1 group, Atezolizumab 1200mb + Bevacizumab 15 mg/kg (IV),every 21 days.
89460976|NCT03835741|Experimental|Automated Oxygen titration|In this arm, an automated adjustment of oxygen during patient hospitalisation by FreeO2 device
89460977|NCT03835741|Other|Manual Oxygen titration|In this arm, a manual adjustment of oxygen during patient hospitalisation by hospital staff
89460978|NCT03831256|Active Comparator|Standard of care (2nd tier NIPS)|For the standard-of-care arm (2nd tier NIPS) women will undergo Traditional integrated prenatal screening i.e. traditional biochemical (+/- NT) and those with a positive screen for T21 or T18 will be offered Second-tier Non-invasive prenatal screening (NIPS) (for T21, T18, T13) or Invasive prenatal testing for fetal aneuploidy. Ultrasound examination in first and second trimester will be done based on clinical care practice ordered by health care provider. Pregnant women with a positive NIPS test will be offered Invasive prenatal testing for fetal aneuploidy (fetal chromosome analysis).
89460979|NCT03831256|Experimental|First-tier NIPS|For the intervention arm (1st tier NIPS) women will receive First-tier Non-invasive prenatal screening (NIPS) i.e. provide a blood sample between 10-13+5 weeks gestation with NIPS results within 7 - 10 days of sample collection. Ultrasound examination in first and second trimester will be done based on clinical care practice ordered by health care provider. In case of a failed NIPS test (expected to be between 2% and 4% of samples), a new blood sample will be drawn for NIPS retest as well as for a traditional SIPS(serum integrated prenatal screening) or QUAD(quadruple marker prenatal screening) screen (depending on gestational age). Pregnant women with a positive NIPS test will be offered Invasive prenatal testing for fetal aneuploidy (fetal chromosome analysis).
89460980|NCT03826173|Experimental|Positive Psychology|On a weekly basis, participants will engage in group-based intervention sessions that focus on personal strengths and the value of positive emotions and cognitions. Participants will receive daily text-messages addressing the content introduced during group sessions.
89460981|NCT03826173|Active Comparator|Physical Activity Promotion|On a weekly basis, participants will engage in group-based intervention sessions that focus on the standard physical activity promotion components of the PPPA condition. Participants will receive daily text-messages addressing the content introduced during group sessions.
89460982|NCT03803995|Other|Mapping and Pacing the His Bundle|All patients will be in this arm. Mapping and Pacing the His Bundle will be performed.
89460983|NCT03778242|Active Comparator|Topical tranexamic acid|temporary uterine packing with gauze of the dimensions soaked with 2 gm tranexamic diluted in 60ml saline acid
89460984|NCT03778242|Placebo Comparator|normal saline|temporary uterine packing with gauze of the dimensions soaked with 2 gm placebo to tranexamic diluted in 60ml saline acid
89460985|NCT03772613|Active Comparator|Low ACT Target|ACT target range of 225 to 275 seconds is achieved prior to PCI if no planned glycoprotein IIb/IIIa inhibitor used
89460986|NCT03772613|Active Comparator|Medium ACT Target|ACT target range of 275 to 325 seconds is achieved prior to PCI if no planned glycoprotein IIb/IIIa inhibitor used
89460987|NCT03772613|Active Comparator|High ACT Target|ACT target range of 325 to 375 seconds is achieved prior to PCI if no planned glycoprotein IIb/IIIa inhibitor used
89460988|NCT03766022|Experimental|Heavy smoker patients|Marginal bone changes after 1 year after implant installation using Neo dental implant Alpha Bio Tec. Ltd.
89460989|NCT03766022|Active Comparator|non Smokers patients|Marginal bone changes after 1 year after implant installation using Neo dental implant Alpha Bio Tec. Ltd.
89460990|NCT03760029|Other|Study arm|All subjects in this study will be observed for 24-30 months.
89460991|NCT03739437|Experimental|Mobile Contingency Management|
89460992|NCT03739437|Active Comparator|Standard Care|
89460993|NCT03701555|Experimental|Part 1, Cohort 1A-1 to 1D-1 Healthy Participants|A single dose of PvP001 placebo, PvP001 100 mg, PvP001 300 mg, or PvP001 900 mg will be administered in ascending order to healthy participants in Cohorts 1A-1, 1B-1, 1C-1, and 1D-1.
89460994|NCT03701555|Experimental|Part 1, Cohort 1E-1 Healthy Participants|A single dose of the maximum feasible dose (MFD) of PvP002 will then be administered to healthy participants in Cohort 1E-1.
89460995|NCT03701555|Experimental|Part 1, Cohort 1A-2 - 1D-2 Celiac Disease (CeD)|A single dose of PvP001 placebo, PvP001 100 mg, PvP001 300 mg, or PvP001 900 mg will be administered in ascending order to participants with CeD in Cohorts 1A-2, 1B-2, 1C-2, and 1D-2.
89460996|NCT03701555|Experimental|Part 1, Cohort 1E-2 CeD|A single dose of the MFD of PvP002 will then be administered to participants with CeD in Cohort 1E-2.
89460997|NCT03701555|Experimental|Part 2, Cohort 2A - Cohort 2C Healthy Participants|Participants will be blinded to the PvP001 dose (placebo or MTD of PvP001) and will also receive MTD of PvP001 following 7 days of PPI treatment.
89460998|NCT03701555|Experimental|Part 2, Cohort 2D Healthy Participants|Participants will receive PvP001 placebo or MFD of PvP001.
89460999|NCT03701555|Experimental|Part 2, Cohort 2E Healthy Participants|Participants will receive PvP002 placebo or MFD of PvP002.
89461000|NCT03701555|Experimental|Part 2, Cohort 2F- Cohort 2H Healthy Participants|Participants will receive the PvP001 placebo and either 300 mg or 600 mg of PvP001.
89461001|NCT03701555|Experimental|Part 2, Cohort 2I and Cohort 2J Healthy Participants|Participants will receive the PvP001 placebo and 900 mg of PvP001.
88942630|NCT01871376|Active Comparator|Previously Treated|"Patients that have previously received treatment for polypoidal choroidal vasculopathy.~Intervention: Monthly 2.0mg intravitreal aflibercept injection, followed by Q8W dosing with 2.0mg intravitreal aflibercept injection or as often as monthly if needed for 1 year for previously treated arm."
89461002|NCT03701555|Experimental|Part 3, Cohorts 3A and 3B Healthy Participants|Participants will receive single dose of PvP003 placebo and 600 mg of PvP003 with pretreatment buffer solution before a standardized 1 gm gluten-containing study meal.
89461003|NCT03701555|Experimental|Part 3, Cohorts 3C and 3D Healthy Participants|Participants will receive single dose of PvP003 placebo and 600 mg of PvP003 without pretreatment buffer solution before a standardized 1 gm gluten-containing study meal.
89461004|NCT03701555|Experimental|Part 3, Cohorts 3E and 3F Healthy Participants|Participants will receive single dose of PvP003 placebo and 600 mg of PvP003 without pretreatment buffer solution after an approximately 50 milliliter (mL) portion of a standardized 1 gm gluten-containing study meal.
89461005|NCT03701555|Experimental|Part 3, Cohorts 3G and 3H Healthy Participants|Participants will receive single dose of PvP003 placebo and 600 mg of PvP003 without pretreatment buffer solution before a standardized gluten-free study meal followed approximately 30 minutes later by a standardized 1 gm gluten-containing study meal.
89461006|NCT03701555|Experimental|Part 4, Cohorts 4A and 4B Healthy Participants|Participants will receive multiple dose of PvP003 placebo and 600 mg of PvP003.
89461007|NCT03701555|Experimental|Part 3, Cohorts 3I and 3J Healthy Participants|Participants will receive single dose of PvP003 placebo and 150 mg of PvP003 without pretreatment buffer solution before a standardized 1 gm gluten-containing study meal.
88942631|NCT01871376|Active Comparator|Treatment-Naive|"Patients that have not received treatment for polypoidal choroidal vasculopathy.~Intervention: Monthly 2.0mg intravitreal aflibercept injection, followed by Q8W dosing with 2.0mg intravitreal aflibercept injection or as often as monthly if needed for 1 year for treatment-naive arm."
89461008|NCT03685422|Experimental|Virtual Reality|"Patients will be given a VR Gear Headset fitted with a smartphone, and will be offered to choose the calming scenario they wish to experience from a set of predefined scenarios before the surgery. They will be given time to experience VR for up to 25 mins. After the VR session, patients will be given questionnaires, satisfaction with VR, and pain scores.~After the surgery is completed, patient will be transferred to recovery room. Patients may resume VR session for up to 25 mins. After the use of VR, they will be asked on their satisfaction towards the VR experience, and also fill in questionnaires.~On the same day of surgery (0-24 hours post-op), patients will be asked to have another two more VR sessions (up to 25 mins per session), with questionnaire filled in after the sessions.~On the second day and third day of the surgery (48-72 hours post-op), questionnaires will be given.~All the headsets will be disinfected following the hospital's infection control guideline."
89461009|NCT03685422|No Intervention|Non Virtual Reality|"Before the surgery, only questionnaires and pain scores will be documented. After the surgery is completed, patient will be transferred to recovery room. Only questionnaires and pain scores will be documented.~On the second day and third day of the surgery (48-72 hours post-op), questionnaires will be given."
89461010|NCT03673748|Experimental|Mesenchymal stem cells (MSC)|Participants will receive a single Intravenous infusion of Mesenchymal Stem Cells (MSV) 2 million cells per kg wt suspended in 100 ml of physiological saline solution. All participants will receive the infusion at the Baseline (Day 0) visit. All participants will continue on their standard-of-care therapy during the trial. GMP-compliant MSV will be prepared by IBGM-University of Valladolid-Citospin.
89461011|NCT03673748|Placebo Comparator|Placebo|Participants will receive a placebo infusion (100 ml of physiological saline solution) that does not contain any mesenchymal stem cells.
89201776|NCT00772980|Placebo Comparator|2|Drug: Placebo Double-blind treatment period of 17 weeks placebo
89461012|NCT03659617|Experimental|Implant placement 3 mo. after tooth ext.|Alveolar ridge preservation using xenograft (BioOss Collagen) and Implant placement 3 mo. after tooth ext.
89461013|NCT03659617|Active Comparator|Implant placement 6 mo. after tooth ext.|Alveolar ridge preservation using xenograft (BioOss Collagen) and Implant placement 6 mo. after tooth ext.
89461014|NCT03659617|Active Comparator|Implant placement 9 mo. after tooth ext.|Alveolar ridge preservation using xenograft (BioOss Collagen) and Implant placement 9 mo. after tooth ext.
89461015|NCT03657667|Other|Ureteroscopy (URS) (standard treatment)|Endoscopic procedure used to remove kidney stones
89461016|NCT03640858|Experimental|Patients receiving hemodialysis|A group of hemodialysis patients will be receiving the Theranova dialyzer during their regularly scheduled sessions to remove larger middle molecules
89461017|NCT03604705|Experimental|APX001 Treatment|
89461018|NCT03571165|Experimental|Intervention|The intervention group received information on accessing My Tools 4 Care - In Care for 2 months.
89461019|NCT03569059|Experimental|Early Robotic/VR Therapy (EVR)|Subjects in this group will receive state-of-art inpatient usual care therapy plus 10 days of extra 1-hour/day of intensive therapy focusing on the hand using haptic robots integrated with complex gaming and virtual environments and initiated 5-30 days post stroke.
89461020|NCT03569059|Experimental|Delayed Robotic/VR Therapy (DVR)|Subjects in this group will receive state-of-art usual care therapy (inpatient and outpatient) plus 10 days of extra 1-hour/day of intensive therapy focusing on the hand using haptic robots integrated with complex gaming and virtual environments and initiated within 31-60 days post stroke.
89461021|NCT03569059|No Intervention|Usual Physical Therapy Care|Subjects in this group will receive state-of-art usual physical therapy/occupational therapy care.
89461022|NCT03569059|Experimental|Dose-Matched Usual Physical Therapy Care|Subjects in this group will receive state-of-art usual physical therapy/occupational therapy care plus an extra hour of state-of-art usual care.
89461023|NCT03552731||Subsequent|Patients who have been receiving chemotherapy more than once. A intervention survey will be administered.
89461024|NCT03552731||First Time|Patients who have been receiving chemotherapy first time. A intervention survey will be administered.
89461025|NCT03541733|Experimental|Tubing-group|mid-gut tubing prior to the MRE examination, administer contrast solution through the mid-gut tube
89461026|NCT03541733|No Intervention|Oral-group|administer contrast solution orally, mid-gut tubing after the MRE examination
89461027|NCT03541460||Older Cohort|Demographic, health and functional data will be collected from subjects 95 years and older by means of a structured interview. Blood will be collected for laboratory and genetic testing.
89461028|NCT03541460||Younger Controls|Demographic, health and functional data will be collected from the children of the older subjects and other aged-matched controls by means of a structured interview. Blood will be collected for laboratory and genetic testing.
89461029|NCT03406468|Experimental|Radiotherapy|Patients continue the same immune therapy they already received and get radiotherapy to one lesion. The lesion may or may not be symptomatic. The preferred radiotherapy dose is 24 Gy in 3 fractions (dosage on the 10 Gy isodose is allowed), but other fractionation schedules (e.g. 30 Gy/ 10 fractions, 20 Gy/ 5 fractions, 20-24 Gy / 1 fraction for SRS (stereotactic radiosurgery)) are allowed if these are standard for a certain location or palliative indication in the body.
89461030|NCT03403998|Experimental|Exercises|Neck flexors Training: Each patient will initially perform cranio-cervical flexion to sequentially reach 5 pressure targets in 2 mmHg increments from a baseline of 20 mmHg to the final level of 30 mmHg. For each target level, the contraction duration will be increased to 10 s, and the participant trained to perform 10 repetitions with brief rest periods between each contraction. Once one set of 10 repetitions of 10 s is achieved at one target level, the exercise will be progressed to train at the next target level up to the final target. Neck extensors training: Patients will perform cranio-cervical extension and upper cervical rotation in a prone on elbows position while maintaining the cervical spine in a neutral position, progressing to a 4-pt kneeling position.
89461031|NCT03403998|Placebo Comparator|Placebo|"The placebo group will receive placebo TENS (switched-off TENS apparatus with no perceptible stimulation). Four electrodes, 50 x 35 mm, will be placed on the neck muscles. The participant will be informed that this therapy is called a subthreshold current and they might not be able to feel any sensation underneath the electrodes during the treatment. The placebo treatment will be for 30 min twice a week for 8 weeks, as for the intervention group."
89461032|NCT03395145|Experimental|Bio-Oss Collagen and Mucograft Seal|Bone volume Changes after socket preservation using Geistlich Bio-Oss® Collagen and Geistlich Mucograft® Seal
89461033|NCT03395145|No Intervention|Natural healing|Evaluation of Bone volume Changes after tooth extraction (natural healing)
89461034|NCT03377179|Experimental|ABC294640 +/- HCQ treatment|Part 1: All participants will be receiving ABC294640, 500 mg twice a day (BID), continuously in 28 day cycles Part 2: All participants will be receiving ABC294640, 500 mg twice a day (BID) and HCQ at a determined level, continuously in 28 day cycles
89461035|NCT03261102|Active Comparator|Standard clinical care|"Adalimumab induction as per standard clinical care:~Week 0: 160 mg SC~Week 2: 80 mg SC~Followed by 40 mg SC every 2 weeks' maintenance therapy"
88942632|NCT01871389||cholecalciferol|
88942633|NCT01871389||usual treatment|
88942634|NCT01871454|Experimental|radiotherapy (SABR) plus pentoxifylline|standard of care radiotherapy (SABR) plus pentoxifylline and Vitamin E
88942635|NCT01871467|Experimental|Sargramostim administration|Subjects will receive sargramostim.
88942636|NCT01871480|Experimental|Group A|Gefitinib combination with CIK cell immunotherapy
88942637|NCT01871480|Active Comparator|Group B|Gefitinib alone
88942638|NCT01871493|Experimental|LY2605541-Part A|1.42 units per kilogram (U/kg) of LY2605541 given once daily (QD) for 1 day, subcutaneously (SQ) in 1 of 4 treatment periods.
88942639|NCT01871493|Active Comparator|Insulin Lispro-Part A|Single dose 0.36 U/kg of insulin lispro given QD for 1 day, SQ in 1 of 4 treatment periods.
89461036|NCT03261102|Active Comparator|Active optimization|"Same as Standard clinical care Arm, except:~If ADAL trough ≤15 μg/ml, dose escalation with 80 mg SC at week 6 followed by 40 mg SC every week~If ADAL trough >15 μg/ml, no dose escalation and continued standard of care dosing"
89461037|NCT03188601||Rambam|Approximately 40 patients in total.No intervention planned.
89461038|NCT03188601||Soroka|Approximately 10 patients in total.No intervention planned.
89461039|NCT03188601||Tel Aviv Souraski|Approximately 40 patients in total.No intervention planned.
89461040|NCT03188601||Jerusalem Hadassah|Approximately 50 patients in total. No intervention planned.
89461041|NCT03083548||Hand osteoarthritis|Men and women (40-70 years) with a diagnosis of hand OA based on clinical or ultrasound examination are included. Patients with systemic inflammatory joint diseases, psoriasis and hemochromatosis are excluded.
89461042|NCT03052283||Patients with CF|>2000 in Germany, France, Italy, Spain, Denmark, Belgium, Portugal, GB, Ireland, USA, Australia, Canada, Brazil, Argentina...
89461043|NCT03052283||Age-matched healthy controls|>100 in Germany >100 in each of the other participating countries
89461044|NCT03045965|Experimental|Salpingectomy|Concomitant salpingectomy at the time of hysterectomy for a benign reason
88942640|NCT01871493|Experimental|LY2605541/Lispro Mix 1-Part A|Single dose 0.54 U/kg of LY2605541 and 0.36 U/kg insulin lispro mixture given QD for 1 day, SQ in 1 of 4 treatment periods.
88942641|NCT01871493|Experimental|LY2605541/Lispro Mix 2-Part A|Single dose 1.42 U/kg of LY2605541 and 0.36 insulin lispro mixture given QD for 1 day, SQ in 1 of 4 treatment periods.
88942642|NCT01871493|Active Comparator|Insulin Lispro-Part B|0.18 U/kg insulin lispro given twice daily (BID) for 1 day, SQ in 1 of 4 treatment periods. Part B is contingent on data from Part A.
88942643|NCT01871493|Experimental|LY2605541/Lispro Mix-Part B|0.71 U/kg LY2605541 and 0.18 U/kg insulin lispro mixture given BID for 1 day, SQ in 1 of 4 treatment periods. Part B is contingent on data from Part A.
88942644|NCT01871493|Experimental|LY2605541 QD-Part B|0.54 U/kg of LY2605541 given QD for 1 day, SQ in 1 of 4 treatment periods. Part B is contingent on data from Part A.
88942645|NCT01871493|Experimental|LY2605541 BID-Part B|0.71 U/kg of LY2605541 given BID for 1 day SQ in 1 of 4 treatment periods. Part B is contingent on data from Part A.
88942646|NCT01871584|Experimental|Hydrocolonic cleansing|Subjects undergo colon cleansing by hydrotherapy with the study device
88942647|NCT01871584|Active Comparator|Standard preparation solution|Subjects undergo colon cleansing by standard preparation solution
88942648|NCT01871597|Experimental|Intervention Group|Intervention - Pulmonary Artery Energy Seal
88942649|NCT01871610|Experimental|Alzheimer disease after mild traumatic brain injury|Based on the TBI registry databank, to recruit patients 1, 5, 10, 15 years after mTBI for cognitive evaluatio
88942650|NCT01871610|Experimental|mild traumatic brain injury without Alzheimer disease|To recruit patients 1, 5, 10, 15 years after mTBI with or without cognitive impairment and age-gender-matched controls (a total of 3 groups) for amyloid- positron emission tomography (A-PET)
89201777|NCT00773058|Active Comparator|glucocorticoid+RAI|stress-dose glucocorticoid treatment, compared to placebo group and ACTH test hints RAI
89461045|NCT03045965|No Intervention|No salpingectomy|No salpingectomy at the time of hysterectomy for a benign reason
89461046|NCT02902952|Experimental|Physical Exercise Condition|An eight week physical exercise intervention
89461047|NCT02902952|Active Comparator|Control Condition|An eight week control condition consisting of sedentary activities
89461048|NCT02856412|Experimental|Veterans Group Exercise|Exercise 3 times weekly (for 12 weeks), with each total workout lasting approximately 60 minutes. Integrative Exercise incorporates elements of strength training, flexibility, cardiovascular training, and controlled breathing exercises.
88942651|NCT01871610|Experimental|Normal control|People aged 30 or older without mTBI or AD
88942652|NCT01871623|Experimental|Segmental Le Fort I Osteotomy|For some cases that bone filling over cleft site is not good enough for tooth movement, it is possible that we put them into this group which means by using Segmental Le Fort I Osteotomy to approximate two dental alveolar segments.
88942653|NCT01871623|Active Comparator|One-piece Le Fort I Osteotomy|For patients having ideal bone graft result over cleft site, traditional One-piece Le Fort I Osteotomy will be performed.
88942654|NCT01871636|Active Comparator|endoscopic mucosal resection|Endoscopic mucosal resection removes tissue in a piece meal technique or by snare limited to the mucosa.
88942655|NCT01871636|Active Comparator|Waterjet-assisted ESD|The waterjet-assisted endoscopic submucosal dissection (WESD) technology allows pressure controlled injection of fluids through the tip of a recently developed HybridKnife®. Submucosal injection, circumferential cutting and dissection of lesions.
89201778|NCT00773058|Placebo Comparator|placebo + RAI|no glucocorticoid But ATCH test hints RAI
89461049|NCT02856412|Active Comparator|Illness Management and Recovery|Attend 3 health education classes weekly (for 12 weeks), with each class lasting approximately 60 minutes. Illness Management and Recovery is an educational program focused on helping individuals more effectively manage their illnesses to pursue their personal recovery goals. The classes include the following topic areas which have been adapted for use in PTSD: recovery, practical facts about PTSD, stress-vulnerability, building social support, medications for PTSD, drug and alcohol use, reducing relapse, coping with stress, coping with persistent symptoms, getting needs met in the VA healthcare system, and living a healthy lifestyle.
89461050|NCT02848131|No Intervention|Group 1: Observational|Observational Only
89461051|NCT02848131|Active Comparator|Group 2: Dasatinib & Quercetin|The drugs dasatinib and quercetin will be used in this arm
89461052|NCT02792075||VH-IVUS|Patients with IVUS-derived virtual histology
89461053|NCT02792075||OCT|Patients with Optical coherence tomography
89461054|NCT02792075||NIRS|Patients with Near-infrared spectroscopy
89461055|NCT02792075||gray scale IVUS|Patients with gray-scale IVUS(Intravascular ultrasound)
89461056|NCT02712385|No Intervention|Control - usual care|Usual post-TIA/minor stroke care as per current healthcare system protocol will be given to patients in control group and details will be recorded.
89461057|NCT02712385|Active Comparator|Manual|Receiving usual post-TIA/minor stroke care plus 'The Healthy Brain Rehabilitation Manual'.
89461058|NCT02712385|Active Comparator|Manual + pedometer, 1|Receiving usual post-TIA/minor stroke care plus 'The Healthy Brain Rehabilitation Manual' and a pedometer with telephone follow-up from a General Practitioner.
89461059|NCT02712385|Active Comparator|Manual + pedometer, 2|Receiving usual post-TIA/minor stroke care plus 'The Healthy Brain Rehabilitation Manual' and a pedometer with telephone follow-up from a Stroke nurse.
89461060|NCT02619760|Active Comparator|1-month DAPT|1-month dual antiplatelet therapy (DAPT) composed of aspirin and P2Y12 receptor antagonists , followed by 59-month clopidogrel monotherapy
89461061|NCT02619760|Active Comparator|12-month DAPT|1-month dual antiplatelet therapy (DAPT) composed of aspirin and P2Y12 receptor antagonists with 11-month DAPT composed of aspirin and clopidogrel, followed by 48-month aspirin monotherapy
89461062|NCT02613988|Other|MR imaging and standard treatment|Patients with glioblastoma undergo 3-Tesla magnetic resonance imaging to measure tumor protein content (using CEST-MRI), cellularity (using DW-MRI), and perfusion (using DCE-MRI and DSC-MRI with IV administration of gadolinium-containing contrast agent) at pre-CCRT; 4 weeks after completion of the CCRT; and every 2 or 3 months during the adjuvant temozolomide therapy.
89461063|NCT02600936||Registry|A retrospective and prospectively maintained registry of patients who have undergone or will undergo vein stent placement for proximal venous outflow obstruction
89461064|NCT02590601|Active Comparator|Bromocriptine + Guideline-driven medical therapy|"In addition to heart failure treatment described above, patients will be administered bromocriptine 2.5 mg orally twice daily for 14 days, followed by 2.5 mg orally daily for 42 days.~Although not a study procedure, we recommend anticoagulation with prophylactic doses of subcutaneous low-molecular weight heparin during the whole duration of bromocriptine therapy."
89461065|NCT02590601|Other|Guideline-driven medical therapy|New onset PPCM will be managed according to the principles of guideline-driven medical therapy for new-onset heart failure as per the position statement for treatment of PPCM published by the European Society of Cardiology (ESC) and the Canadian Cardiovascular Society (CCS) update on heart failure and pregnancy . The choices and administration of GDMT will be left at the discretion of the treating physician
89461066|NCT02554773|Experimental|Fitusiran|Patients will be administered subcutaneous (SC) fitusiran once monthly or every 2 months according to the dose selection rules defined in protocol.
89461067|NCT02406274|Experimental|Contrast Enhanced Spectral Mammography|
89461068|NCT02393885|Experimental|AtriCure Bipolar System and AtriClip® PRO LAA Exclusion System|AtriCure Bipolar System and AtriClip® PRO LAA Exclusion System at day 1 of surgical procedure followed by endocardial catheter ablation procedure to occur at approximately 90 days after day 1 of surgical procedure.
89461069|NCT02178098|Experimental|ETC-1002|ETC-1002 180 mg/day
88942656|NCT01871649|Active Comparator|methotrexate|methotrexate is the active comparator, it will be compared to golimumab + methotrexate
88942657|NCT01871649|Experimental|golimumab and methotrexate|The combination of golimumab en methotrexate will be compared to methotrexate alone.
88942658|NCT01871662|Active Comparator|Group C: RIB + Peg-IFN|Ribavirin(800-1400 mg/day,divided BID PO) + Peg-IFN alfa2b (1.5 μg/kg/week SC)for 25 weeks if RVR has been achieved or 49 weeks if EVR has been achieved
88942659|NCT01871662|Experimental|Group B:Legalon® SIL + RIB + Peg-IFN|Silibinin (20 mg/Kg/day) for 6 days, followed by Silibinin + ribavirin (800-1400 mg/day, divided BID PO) + Peg-IFN alfa2b (1.5 μg/kg/week SC) for 15 days, followed by ribavirin (800-1400 mg/day, divided BID PO) + Peg-IFN alfa2b (1.5 μg/kg/week SC) + 2 days of Silibinin per week for 9 weeks, followed by ribavirin (800-1400 mg/day, divided BID PO) + Peg-IFN alfa2b (1.5 μg/kg/week SC) for 13 weeks if RVR has been achieved (for a total of 25 weeks of treatment) or 37 weeks if EVR has been achieved (for a total of 49 weeks of treatment)
88942660|NCT01871662|Experimental|Group A: Legalon® SIL + RIB|Silibinin (20 mg/Kg/day) for 6 days, followed by Silibinin + ribavirin (800-1400 mg/day, divided BID PO) for 15 days, followed by ribavirin (800-1400 mg/day, divided BID PO) + 2 days of Silibinin per week for 9 weeks, followed by ribavirin (800-1400 mg/day, divided BID PO) for 13 weeks if RVR has been achieved (for a total of 25 weeks of treatment) or 37 weeks if EVR has been achieved (for a total of 49 weeks of treatment)
88942661|NCT01871675|Experimental|Arm 1: IPI-145 plus Rituximab|"IPI-145 will be administered orally, twice daily, in 28-day (4-week) cycles, on a continuous basis at the maximum tolerated dose of 25 mg twice-daily (BID), as determined in the dose escalation phase. Twelve (12) cycles of IPI-145 will be administered. Patients who benefit from treatment may continue on study for additional cycles until toxicity or progressive disease.~Rituximab 375 mg/m2 will be administered intravenously (IV) beginning on Day 1 once weekly during a 28 day cycle; 2 cycles of rituximab will be administered."
89017647|NCT06139627|Experimental|Arm I (GA intervention)|Patients complete a geriatric assessment. Patients and physicians receive the geriatric assessment summary and assessment-based recommendations, which are provided prior to beginning chemotherapy and radiation, at the midpoint of chemotherapy and radiation treatment, and at the end of treatment. Patients also undergo blood and stool sample collection during screening and on study.
89461070|NCT02178098|Placebo Comparator|Placebo|Placebo control
89461071|NCT02087852||kidney cancer patients receiving care at MSKCC|Participation will consist of completing the Kidney Cancer Questionnaire Family History Questionnaire and complete the Epidemiologic Questionnaire (when applicable,), and providing a blood sample and saliva sample for germline DNA. In cases where tissue samples from surgically derived tumor specimens are obtained these will used to determine genetic alterations related to cancer predisposition or pathogenicity.
89461072|NCT02087852||relatives of patients with kidney cancer|Participation will consist of completing the Kidney Cancer Questionnaire Family History Questionnaire (when applicable,), and providing a saliva sample for germline DNA. In cases where tissue samples from surgically derived tumor specimens are obtained these will used to determine genetic alterations related to cancer predisposition or pathogenicity.
89461073|NCT02087852||healthy controls who are unrelated & do not have hx of cancer|Participation will consist of completing the Kidney Cancer Questionnaire Family History Questionnaire (when applicable,), and providing a saliva sample for germline DNA. In cases where tissue samples from surgically derived tumor specimens are obtained these will used to determine genetic alterations related to cancer predisposition or pathogenicity.
89017648|NCT06139627|Active Comparator|Arm II (usual care)|Patients complete a geriatric assessment, but information other than clinically significant cognitive impairment and depression is not provided to the oncology teams, per usual care. Patients also undergo blood and stool sample collection during screening and on study.
89017649|NCT06139562|Experimental|Time-Restricted Feeding (TRF)|Time-restricted feeding program from sunrise to sunset
89461074|NCT02087852||high risk|Participation will consist of completing the Epidemiologic Questionnaire, Family History Questionnaire (if + FH), provide saliva and blood sample , referral for screening evaluation
89461075|NCT01945307||Healthy adults|Healthy adults aged 18 to 70 years
89461076|NCT01800383||Control|No Axis I psychiatric disorder and no trauma exposure
89461077|NCT01800383||Trauma-Exposed Normal Control|History of trauma exposure and subthreshold PTSD symptoms.
89461078|NCT01800383||PTSD|Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) diagnosis of PTSD as determined by the Structured Clinical Interview for DSM-IV-Text Revised
89461079|NCT01770418|Experimental|Proton Radiotherapy with Chemotherapy|
89461080|NCT01766297|Experimental|Proton Radiotherapy|Proton Radiotherapy 4.0 Gy (RBE) x10 fractions to 40 Gy (RBE) Total Dose
89461081|NCT01758445|Experimental|Proton Radiotherapy|Proton Radiotherapy
89461082|NCT01693380|Experimental|Influenza vaccine|"Schoolchildren from 6 to 8 years received two intra-muscular doses of 0.5 ml of inactivated influenza vaccine, of the Southern Hemisphere, 2009.~Schoolchildren above 8 years received one intra-muscular dose of 0.5 ml of inactivated influenza vaccine, of the Southern Hemisphere, 2009."
89461083|NCT01693380|Sham Comparator|Control vaccine|"Schoolchildren received one intra-muscular dose of 0.5 ml of Meningococcal C conjugate vaccine.~Schoolchildren under nine years of age received also one intra-muscular dose of 0.5 ml of varicella vaccine one month after the Meningococcal C vaccine."
89461084|NCT01630434|Experimental|OCS Lung (Treatment Group)|The OCS Lung, which is a portable, integrated platform designed to maintain adult donor lungs in a normothermic state through continuous normothermic perfusion and ventilation, will be used to preserve and transport donor lungs.
89461085|NCT01630434|Active Comparator|Cold flush and storage (Control Group)|Donor lungs will be preserved using cold flush and storage (control group)
89461086|NCT01542879|Experimental|WB-DW-MR scan|simultaneous WB-DW-MR scan and 18-F FDG PET scan
89461087|NCT01492972|Active Comparator|Radiation Alone|Proton Radiation Total Dose=70 Gy(RBE) OR High Dose Radiation with IMRT Alone=81 Gy OR Intraoperative LDR Brachytherapy and IMRT=45 Gy
89461088|NCT01492972|Experimental|Radiation + Androgen Suppression|Androgen Suppression Therapy x 6 months + Radiation
89461089|NCT01383915||inpatients|Youth with a clinical diagnosis of a mood disorder or psychosis spectrum disorder
89461090|NCT01376752|Active Comparator|maximal cytoreductive surgery without HIPEC|The participant will have a regular cytoreductive surgery without the adjunction of HIPEC.
89461091|NCT01376752|Experimental|maximal cytoreductive surgery with HIPEC|The participant will have a regular cytoreductive surgery, then the adjunction of HIPEC: hyperthermic cisplatin will be used at 75mg/m²
89461092|NCT01341327||Left Main disease|Consecutive patients with unprotected LMCA diseases at participating centers will be evaluated for the entry into the study.
89461093|NCT01256398|Experimental|Treatment (chemotherapy, transplant)|See Detailed Description
89461094|NCT01230866|Other|Proton Radiation Hypofractionation|5 fractions (7.6 Gy(RBE) x 5)
89461095|NCT01230866|Active Comparator|Proton Radiation Standard Fractionation|44 fractions (1.8 Gy(RBE) x 44)
89461096|NCT01151423|Experimental|Caplacizumab|Caplacizumab 10 mg once daily
89461097|NCT01151423|Placebo Comparator|Placebo|Placebo once daily
89461098|NCT01040026|Experimental|NK cell infusions|10 NK cell infusions day 3-30; Treatment with in vitro expanded haploidentical NK cells
89461099|NCT01020383|Experimental|ALX-0081|
89461100|NCT01020383|Active Comparator|GPIIb/IIIa inhibitor|
89461101|NCT00889876|Experimental|Metformin|
89017650|NCT06139562|Active Comparator|Extended-Time Feeding (ETF)|Extended-time feeding program that allows them to eat at any time of the day
89201779|NCT00773058|Active Comparator|glucocorticoid|stress-dose glucocorticoid treatment, compared to placebo group and ACTH test does not hint RAI
89201780|NCT00773058|Placebo Comparator|placebo|no glucocorticoid But ATCH test does not hint RAI
89201781|NCT00776334|Experimental|1|fosinopril sodium 40 mg tablets of Ranbaxy
89461102|NCT00889876|Experimental|Exercise|
89461103|NCT00625417|Experimental|Optical spectroscopy on tumor margins|Optical spectroscopy is performed on breast tumor margins obtained from patients undergoing surgery
89461104|NCT00587067|Experimental|1|
89461105|NCT00579514|Active Comparator|1|"All incident second primary cancers of colon, breast, bladder, kidney, prostate, ovarian cancer lung cancer and lymphoid cancer diagnosed between 1999 and present will be included in the secondary design to compare second primary cancer cases and first primary controls."
89461106|NCT00579514|Placebo Comparator|2|Controls will be volunteer blood donors from the New York Blood Center as well as normal volunteers from other AMDeC sites.
89501864|NCT04227704|Placebo Comparator|Control|Shortly after cesarean delivery of their baby, participants will receive a subcutaneous injection and 40-minute intravenous infusion of 0.9% sodium chloride.
89461107|NCT00565617|Experimental|Synergy, Epidural cortical stimulation|Epidural cortical stimulation (medial prefrontal cortex) for treatment resistant depression. The primary aim of this pilot study was to assess the feasibility and safety of EpCS in patients with treatment-resistant depression. Ultimately, for EpCS to be found effective, a much larger double blind placebo controlled study would be needed.
89201782|NCT00776334|Active Comparator|2|Monopril® 40mg tablets
88942662|NCT01871675|Experimental|Arm 2: IPI-145 plus Rituximab/Bendamustine|"IPI-145 will be administered orally, twice daily, in 28 day cycles, on a continuous basis, until disease progression, unacceptable toxicity or patient refusal. The maximum tolerated dose of IPI-145 will be 25 mg twice-daily (BID) as determined in the dose escalation phase. Twelve (12) cycles of IPI-145 will be administered. Patients who benefit from treatment may continue on study for additional cycles until toxicity or progressive disease.~Rituximab 375 mg/m2 will be administered intravenously (IV) beginning on Day 1 once weekly of each 28 day cycle. A maximum of 6 cycles of rituximab will be given. Bendamustine 90 mg/m2 IV will be administered on Days 1 and 2, of each 28 day cycle. Rituximab should be administered prior to bendamustine."
88942663|NCT01871688|Other|pelvic floor exercise|pelvic floor rehabilitation program with neuromodulation
88942664|NCT01871701|Experimental|Quetiapine|Quetiapine 100 mg (Seroquel, Tablet)
88942665|NCT01871701|Experimental|Moxifloxacin|Moxifloxacin 400 mg (Avelox, Tablet)
88942666|NCT01871701|Experimental|Escitalopram|Escitalopram 20 mg (Lexapro, Tablet)
88942667|NCT01871701|Placebo Comparator|Placebo|Water intake
89461108|NCT00453154|Experimental|Arm I (Combination Chemotherapy + Sunitinib Maintenance)|"Participants will receive the following combination chemotherapy for 4-6 cycles (21 days):~Cisplatin 80 mg/m^2 by IV over 1 hour on day 1 every cycle OR Carboplatin AUC = 5* by IV Etoposide 100 mg/m^2 by IV over 1 hour on days 1, 2, and 3 every cycle~Maintenance: Following 4-6 cycles of combination chemotherapy, start sunitinib at 150 mg on day 1, then 37.5 daily until disease progression."
88942668|NCT01871714||XLHED affected Males|All males ages 4 and up affected by XLHED
88942669|NCT01871714||Females affected by XLHED|Adult females (ages 18-45) affected by XLHED
88942670|NCT01871714||Unaffected females|Unaffected adult female controls (ages 18-45)
88942671|NCT01871740|Experimental|Enalapril maleate and folic acid tablets|A fixed combination drug is given. The dose is fixed in enalapril 10 mg / folic acid 0.8 mg per day.
88942672|NCT01871740|Active Comparator|Enalapril maleate|Enalapril maleate 10 mg per day is given
88942673|NCT01871753|Experimental|Antibiotics|10 days of antibiotics, started and selected according to the antibiogram results. In case of reinfection or relapse, re-administration of antimicrobial agents will be performed according to the antibiogram results (for a maximum of 3 cycles of ten days of antibiotics during the 12 months of the follow-up).
88942674|NCT01871753|No Intervention|No treatment|no antibiotics delivered in case of asymptomatic bacteriuria, independently of the number of asymptomatic episodes.
88942675|NCT01871779|Experimental|Standard Treadmill Exercise|The first group would undergo standard treadmill exercise to the point of pain and repeat these cycles for a total period of 35-45 minutes twice weekly for 12 weeks
88942676|NCT01871779|Experimental|Intermittent Treadmill & Resistance Training|The second group would have a combination of intermittent treadmill and some resistance training with weights. They will undergo repeated cycles to a maximum of 35-45 minutes twice weekly for 12 weeks
88942677|NCT01871792|Experimental|Pitavastatin|Pitavastatin 4 mg/day for 7 days before coronary angiography/intervention
89201783|NCT00779610|Experimental|Active|Vibration with forearm flexion (active contraction)
89201784|NCT00779610|Sham Comparator|Passive|Vibration without forearm flexion (passive)
89461109|NCT00453154|Active Comparator|Arm II (Combination Chemotherapy + Placebo Maintenance)|"Participants will receive the following combination chemotherapy for 4-6 cycles (21 days):~Cisplatin 80 mg/m^2 by IV over 1 hour on day 1 every cycle OR Carboplatin AUC = 5* by IV Etoposide 100 mg/m2 by IV over 1 hour on days 1, 2, and 3 every cycle~Maintenance: Following 4-6 cycles of combination chemotherapy, start placebo at 150 mg on day 1, then 37.5 daily until disease progression."
89461110|NCT00309257|Experimental|ACE inhibitor, ATA II antagonists and Statins|
89461111|NCT00258960|Other|Caelyx,Cyclophosphamide,Trastuzumab|Caelyx (Liposomal Doxorubicin) 50 mg/m2 every 4 weeks for 6 cycles, Cyclophosphamide 600 mg/m2 every 4 weeks for 6 cycles, Trastuzumab weekly for 24 weeks, at dose of 2mg/kg (day 1 loading dose of 4mg/kg)
89461112|NCT00149305||Patients with gouthy diathesis|
89461113|NCT00149305||Healthy subjects|
89461114|NCT00121992|Active Comparator|Arm A: FAC|FAC (5-fluorouracil, doxorubicin, cyclophosphamide): 5-fluorouracil 500 mg/m2 iv on day 1, each 3 weeks, in combination with doxorubicin 50 mg/m2 iv and cyclophosphamide 500 mg/m2 iv
89201785|NCT00668148|Experimental|IMC-A12 (cixutumumab)|
88942678|NCT01871792|Placebo Comparator|Placebo|Placebo tablet for 7 days before coronary angiography/intervention
88942679|NCT01871818|Experimental|Combined program|"Combined program with physiotherapy, endurance training and resistance training.~120 patients will receive this combined program"
88942680|NCT01871818|Active Comparator|Physiotherapy|Active comparator: physiotherapy in private practice 120 patients will receive this usual rehabilitation
88942681|NCT01871844|Experimental|ITF2984 500 mcg/Placebo sc bid for 7 days|TF2984 500 mcg/Placebo sc bid for 7 days
88942682|NCT01871844|Experimental|ITF2984 1000 mcg/Placebo sc bid for 7 days|ITF2984 1000 mcg/Placebo sc bid for 7 days
88942683|NCT01871844|Experimental|ITF2984 2000 mcg/Placebo sc bid for 7 days|ITF2984 2000 mcg/Placebo sc bid for 7 days
88942684|NCT01871844|Active Comparator|octreotide 50 mcg tid|octreotide 50 mcg tid
88942685|NCT01871857|Active Comparator|Normal saline and epinephrine|0.9 % saline with 0.5 ml of 1:1000 epinephrine inhalation
89201786|NCT00667992|Active Comparator|Budesonide Hydrofluoroalkane (HFA) 100|Budesonide Hydrofluoroalkane (HFA) 100 mcg twice daily for 2 weeks
89201787|NCT00667992|Active Comparator|Budesonide HFA 400|Budesonide HFA 400 mcg twice daily for 2 weeks
89201788|NCT00667992|Active Comparator|Budesonide Chlorofluorocarbon (CFC) 100|Budesonide Chlorofluorocarbon(CFC) 100 mcg twice daily for 2 weeks
89201789|NCT00667992|Active Comparator|Budesonide CFC 400|Budesonide CFC 400 mcg twice daily for 2 weeks
89017651|NCT06139484|Active Comparator|SNT Group|Patients will be treated with neuronavigated transcranial magnetic stimulation. The treatment protocol is 90% motor threshold (RMT) stimulation intensity for 60 cycles of 10 triplet pulses each at a frequency of 50 Hz, in 2-second stimulation sequences (5 Hz) with 8-second intervals. Stimulation treatments were performed hourly. Ten treatments per day (18,000 pulses/day) for 5 consecutive days (90,000 pulses total).
89461115|NCT00121992|Experimental|Arm B: TAC|TAC (docetaxel, doxorubicin, cyclophosphamide): Docetaxel 75 mg/m2 iv on day 1, each 3 weeks, in combination with doxorubicin 50 mg/m2 iv and cyclophosphamide 500 mg/m2 iv
89461116|NCT00073060||NIH Platelepheresis Donors|75, Apheresis Study Group - donation procedures use same devices as leukapheresis donors, also requiring citrate infusion
89461117|NCT00073060||NIH Research Leukapheresis Donors|75, Apheresis Study Group - donation procedures use same devices as plateletpheresis donors, also requiring citrate infusion; citrate administered may be twice as great as during plateletpheresis.
89461118|NCT00073060||NIH Whole Blood Donors|150 age, gender, race-matched donors - CONTROL GROUP
89461119|NCT00070564|Active Comparator|Arm I|(closed 11/10/10) Patients receive doxorubicin IV and cyclophosphamide IV on day 1 and pegfilgrastim subcutaneously (SC) on day 2 or filgrastim (G-CSF) SC on days 3-10. Treatment repeats every 14 days for 6 courses. Beginning 2 weeks after completion of doxorubicin and cyclophosphamide, patients receive paclitaxel IV over 3 hours on day 1 and pegfilgrastim SC on day 2. Treatment repeats every 14 days for 6 courses.
89461120|NCT00070564|Experimental|Arm II|(closed 11/10/10) Patients receive doxorubicin IV on day 1, oral cyclophosphamide on days 1-7, and G-CSF SC on days 2-7. Treatment repeats every 7 days for 15 courses. Beginning 2 weeks after completion of cyclophosphamide, patients receive paclitaxel and pegfilgrastim as in arm I.
89461121|NCT00070564|Active Comparator|Arm III|(closed 11/10/10) Patients receive doxorubicin, cyclophosphamide, and pegfilgrastim or G-CSF as in arm I. Beginning 2 weeks after completion of doxorubicin and cyclophosphamide, patients receive paclitaxel IV over 1 hour on day 1. Treatment repeats every 7 days for 12 courses.
89461122|NCT00070564|Experimental|Arm IV|(closed 11/10/10) Patients receive doxorubicin, cyclophosphamide, and G-CSF as in arm II. Beginning 2 weeks after completion of cyclophosphamide, patients receive paclitaxel as in arm III.
89461123|NCT00070564|Experimental|Arm V|Patients receive doxorubicin IV and cyclophosphamide IV on day 1 and pegfilgrastim SC on day 2. Treatment repeats every 14 days for 4 courses. Patients receive doxorubicin IV and cyclophosphamide IV on day 1 and pegfilgrastim SC on day 2. Treatment repeats every 14 days for 6 courses. Beginning 2 weeks after completion of doxorubicin and cyclophosphamide, patients receive paclitaxel IV over 3 hours on day 1 and pegfilgrastim SC on day 2. Treatment repeats every 14 days for 6 courses.
89461124|NCT00070564|Experimental|Arm VI|Patients receive doxorubicin, cyclophosphamide, and pegfilgrastim as in arm V. Beginning 2 weeks after completion of doxorubicin and cyclophosphamide, patients receive paclitaxel IV over 1 hour on day 1. Treatment repeats every 7 days for 12 courses.
89461125|NCT04610775|Other|Small Cuff (0, +1, +2, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Small, Regular, Large, Small
89461126|NCT04610775|Other|Small Cuff (0, +2, +1, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Small, Large, Regular, Small
89461127|NCT04610775|Other|Small Cuff ( +1, 0, +2, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Regular, Small, Large, Small
89461128|NCT04610775|Other|Small Cuff ( +1, +2, 0, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Regular, Large, Small, Small
89461129|NCT04610775|Other|Small Cuff ( +2, 0, +1, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Large, Small, Regular, Small
89461130|NCT04610775|Other|Small Cuff ( +2, +1, 0, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Large, Regular, Small, Small
89461131|NCT04610775|Other|Regular Cuff (0, -1, +1, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Regular, Small, Large, Regular
89461132|NCT04610775|Other|Regular Cuff (0, +1, -1, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Regular, Large, Small, Regular
89461133|NCT04610775|Other|Regular Cuff (-1, 0, +1, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Small, Regular, Large, Regular
89461134|NCT04610775|Other|Regular Cuff (-1, +1, 0, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Small, Large, Regular, Regular
89017652|NCT06139484|Other|rTMS Group|Patients will be treated with the normal non-neuronavigated transcranial magnetic stimulation. The treatment protocol is 90%-100% RMT stimulation intensity; 10 Hz frequency for 4 seconds with 26 seconds of rest; 4,000 pulses per session; total duration 50 minutes, twice daily (8,000 pulses/day) for 5 days (40,000 pulses total).
89461135|NCT04610775|Other|Regular Cuff (+1, -1, 0, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Large, Small, Regular, Regular
89461136|NCT04610775|Other|Regular Cuff (+1, 0, -1, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Large, Regular, Small, Regular
89461137|NCT04610775|Other|Large Cuff (-1, 0, +1, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Regular, Large, Extra Large, Large
89461138|NCT04610775|Other|Large Cuff (-1, +1, 0, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Regular, Extra Large, Large, Large
89461139|NCT04610775|Other|Large Cuff (0, +1, -1, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Large, Extra Large, Regular, Large
89461140|NCT04610775|Other|Large Cuff (0, -1, +1, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Large, Regular, Extra Large, Large
89461141|NCT04610775|Other|Large Cuff (+1, 0, -1, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Extra Large, Large, Regular, Large
89461142|NCT04610775|Other|Large Cuff (+1, -1, 0, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Extra Large, Regular, Large, Large
88942686|NCT01871857|Experimental|Hypertonic saline and epinephrine|3 ml 7% saline with 0.5 ml of 1:1000 epinephrine inhalation
89461143|NCT04610775|Other|Extra Large Cuff (0, -2, -1, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Extra Large, Regular, Large, Extra Large
89461144|NCT04610775|Other|Extra Large Cuff (0, -1, -2, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Extra Large, Large, Regular, Extra Large
89461145|NCT04610775|Other|Extra Large Cuff (-1, 0, -2, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Large, Extra Large, Regular, Extra Large
89461146|NCT04610775|Other|Extra Large Cuff (-1, -2, 0, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Large, Regular, Extra Large, Extra Large
89461147|NCT04610775|Other|Extra Large Cuff (-2, -1, 0, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Regular, Large, Extra Large, Extra Large
89461148|NCT04610775|Other|Extra Large Cuff (-2, 0, -1 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Regular, Extra Large, Large, Extra Large
89461149|NCT05158725|Active Comparator|Standard Colonoscopy|Subjects will undergo colonoscopy using a standard colonoscope
89461150|NCT05158725|Active Comparator|Discovery aided colonoscopy|Subjects will undergo colonoscopy using a a standard colonoscope and the Discovery aided colonoscopy
89461151|NCT05158725|Experimental|Discovery and G-EYE aided colonoscopy|Subjects will undergo colonoscopy using the G-EYE Endoscope and the Discovery aided colonoscopy
89461152|NCT00702351|Experimental|Arm 1|150 µg Org 36286 (corifollitropin alfa)
89461153|NCT00702351|Experimental|Arm 2|100 µg Org 36286 (corifollitropin alfa)
89461154|NCT05158647|Placebo Comparator|control group|10-ml 0.5% isobaric bupivacaine and 1ml normal saline were prepared for IIIH blockade
89461155|NCT05158647|Active Comparator|MgSo4 group|10 ml 0.5% isobaric bupivacaine and 1ml of MgSo4 10% (100 mg) were used.
89461156|NCT03477981|Other|Study cohort|Participants will receive standard white bread for two weeks and then alginate bread for two weeks. All participants will receive the bread in the same order.
89461157|NCT03477825|Placebo Comparator|Placebo|"Group A: Placebo group (n = 10)~Supplement appearing similar to Herbal formulations~Each placebo tablet will contain microcrystalline cellulose, dicalcium phosphate, PVPK30, sodium starch glycolate, magnesium stearate, OpaDry orange coating.~Dose: subjects in this group will take 4 placebo tablets per day"
89461158|NCT03477825|Experimental|Rubia Cordifolia|"Group B: R. cordifolia group (n = 10)~2,000 mg R. cordifolia per day - supplied by Banyan Botanicals and following standard supplementation doses on commercially available supplement (https://www.banyanbotanicals.com/manjistha-tablets/)~Each tablet contains 500 mg of R. cordifolia per tablet."
89461159|NCT03477825|Experimental|Triphala|"Group C: Triphala group (n= 10)~Tablets of Triphala will be supplied from Banyan Botanicals (https://www.banyanbotanicals.com/triphala-tablets-11/)~Each tablet contains mix Emblica officinalis, Terminalia bellerica, and Terminalia chebula~Dose: subjects will take 4 tablets per day, with a total dose of 2,000 mg of total herb."
89461160|NCT04234659||Individuals Receiving Mechanical Circulatory Device Support|Individuals receiving mechanical circulatory support device (specifically the IMPELLA® device) for treatment of their index peripartum cardiomyopathy complicated by cardiogenic shock event.
88942687|NCT01871883|Experimental|Sensitive Skin|Subjects with sensitive skin, diagnosed by the lactic acid stinging test. Skin biopsy Oral mucosa specimen
88942688|NCT01871883|Active Comparator|Non-sensitive skin|Subjects without sensitive skin, determined by a negative lactic acid stinging test Skin biopsy Oral mucosa specimen
88942689|NCT01871896|Experimental|Weight Gain|Patients who previously underwent bariatric surgery who failed to lose the expected weight or regained weight.
89461161|NCT04234659||Individuals Without Mechanical Circulatory Device Support|Individuals not receiving mechanical circulatory support device (specifically the IMPELLA® device) for treatment of their index peripartum cardiomyopathy complicated by cardiogenic shock event.
89461162|NCT02523105|Other|Participants diagnosed with depression.|EEG monitoring and evaluation
89461163|NCT02523105|Other|Healthy participants.|EEG monitoring and evaluation
89537173|NCT02719691|Experimental|Dose Level 3: Alisertib 40 mg/MLNO128 2 mg|"This group will receive a Dose-Escalation: Combination of MLN0128 and Alisertib using a standard 3 + 3 design. The starting dose of Alisertib is 40 mg given PO twice daily (BID) Days 1-7 repeat every 21 days. The starting dose for MLN0128 is 1 mg given by mouth (PO) once daily with continuous dosing.~Alisertib: Participants will receive Alisertib in the dose-escalation and the dose-expansion part of the study."
89017653|NCT06139471|Experimental|study group (VR-enhanced Gagne's Instructional Model)|receive VR-enhanced Gagne's Instructional Model
89017654|NCT06139471|No Intervention|STUDY group|doesn't VR-enhanced Gagne's Instructional Model
89017655|NCT06139419|Experimental|Concurrent Tα-1 group|In this concurrent Tα-1 group, participants receive concurrent chemoradiotherapy followed by immunotherapy consolidation. During this treatment, thymosin alpha-1 was administered at 4.8mg each time.
89017656|NCT06139419|Other|Control group|In control group, participants receive concurrent chemoradiotherapy followed by immunotherapy consolidation.
89017657|NCT06139393|Experimental|Treatment group A: HR091506 tablets + placebo of febuxostat tablets|
89017658|NCT06139393|Active Comparator|Treatment group B: febuxostat tablets + placebo of HR091506 tablets|
89017659|NCT06139367|Experimental|TQB3454 tablets under fast condition|TQB3454 tablets 600mg, take one dose orally under fast condition.
89017660|NCT06139367|Experimental|TQB3454 tablets under fed condition|TQB3454 tablets 600mg, take one dose orally under fed condition.
89017661|NCT06139276|Experimental|Small Needle-Knife|The small needle-knife (SNF) group undergoes rehabilitation treatment, with additional small needle-knife treatment once a week after acupuncture needle insertion at the Tiaokou (ST38) and Chengshan (BL57) acupoints. This treatment regimen will span over a duration of 3 weeks.
89017662|NCT06139276|Active Comparator|Standard treatment|Rehabilitation treatment (based on the physician's assessment of the patient's clinical condition, using methods such as heat therapy, electrotherapy, manual therapy, or joint injections) at least once a week. This treatment regimen will span over a duration of 3 weeks.
89017663|NCT06139250||hypoxic-ischemic encephalopathy group|Photoacoustic/ultrasound imaging will be used for neonates with hypoxic ischemic encephalopathy
89017664|NCT06139250||control group|Photoacoustic/ultrasound imaging will be used for neonates without brain disease
89017665|NCT06139237|Experimental|High-protein supplement|The high-protein supplements contains 47.3% protein, 39.4% carbohydrates, 13.3% lipids. A dose containing 20.8 g protein and diluted to a volume of 200 mL will be administered (187 Kcal).
89017666|NCT06139237|Active Comparator|Balanced supplement|The high-protein supplements 22.2% protein, 67.85% carbohydrates, 9.95% lipids. A dose containing 20.8 g protein and diluted to a volume of 200 mL will be administered (399.3 Kcal)
89017667|NCT06139211|Experimental|Cohort 1: esophogeal squamous carcinoma|In Cohort 1, patients will be treated with JS015 in combination with paclitaxel or irinotecan
89017668|NCT06139211|Experimental|Cohort 2: gastric cancer|In Cohort 2, patients will be treated with JS015 in combination with paclitaxel
89017669|NCT06139211|Experimental|Cohort 3: gastric cancer|In Cohort 3, patients will be treated with JS015 in combination with toripalimab and XELOX
89017670|NCT06139211|Experimental|Cohort 4: colorectal cancer|In Cohort 4, patients will be treated with JS015 plus bevacizumab in combination with XELOX or FOLFIRI
89017671|NCT06139211|Experimental|Cohort 5: pancreatic cancer|In Cohort 5, patients will be treated with JS015 in combination with toripalimab, albumin-bound paclitaxel and gemcitabine
89017672|NCT06139198|Experimental|SMART-U intervention arm|"SMART-U will consist of 2 main components: a 12-week intensive group format stage and a 12-week remotely accessed telephone follow-up stage."
89017673|NCT06139198|No Intervention|Enhanced Treatment as usual|The participants will have usual care supplemented by written materials on epilepsy in their preferred language and tailored to the reading level of most patients at the clinic.
89017674|NCT06139172|Experimental|Functional Behavioral Training|
89017675|NCT06139172|Active Comparator|Positive Parenting Strategies-Treatment As Usual|
89017676|NCT06139159|Experimental|LHW as outreach agents/navigators|Conduct outreach activities with people in the community who are hard to reach and with limited access to health care, conduct screening for symptoms of mental illnesses, encourage and refer individuals at-risk, suspected of having, or affected by mental health issues for further triage.
89017677|NCT06139159|Experimental|LHW as navigators and auxiliary to care|"LHW continue conducting outreach and referral activities but in addition, LHW are more involved in their care. They arrange consultations, introduce the patient to the clinical team via a warm hand-off and assist in scheduling a follow -up visit, reviews the care plan with the patient and help reduce patient and system barriers impeding psychological well-being, support patients in achieving management goals; help patients address barriers through education, referral, and navigation to ancillary community services. They have frequent contact with the patient."
89017678|NCT06139159|Experimental|LHW stepped care and task shifting|LHW conduct activities of prior arms but in addition, they may provide specific components of mental health care (task-shifting), providing components of basic evidence-based treatments to patients with non-complex needs, and addressing other syndemic health and social conditions.
89017679|NCT06139120||Chronic subacromial pain|Patients with central sensitization associated with chronic pain syndrome
89017680|NCT06139120||Control|Healthy participants
89017681|NCT06139081|Experimental|Group A|Transnasal oxygen was administered by nasal catheter before gastroscopy, transoral oxygen was administered by nasal catheter after gastroscopy, and transnasal oxygen was administered by nasal catheter after withdrawal of gastroscope.
89017682|NCT06139081|No Intervention|Group B|Nasal catheter was used to give oxygen before, after and after withdrawal of gastroscope
89017683|NCT06139068|Experimental|intervention|Narrative group counseling consists of 8 sessions and will be applied to the intervention group by the researcher.
89017684|NCT06139068|Active Comparator|Control|For the control group, stress coping interviews will be held after the information meeting, apart from the students' routine practices.
89017685|NCT06139042||liver, biliary tract, and pancreatic cancers|participants with liver, biliary tract, and pancreatic cancers
89461164|NCT03637959|Experimental|Mechanical Vibrations with Ultrasound Shear Wave Imaging|Subjects that are scheduled to undergo a clinical indicated Magnetic Resonance Elastography (MRE) will also have mechanical vibrations ultrasound shear wave imaging to measure liver stiffness
89461165|NCT02738151|Experimental|Toujeo|Toujeo® (Insulin glargine, 300 U/mL) subcutaneous (SC) injection once daily up to Week 24 on top of non-insulin antidiabetic treatment.
89461166|NCT02738151|Active Comparator|Tresiba|Tresiba® (Insulin Degludec, 100 U/mL) SC injection once daily up to Week 24 on top of non-insulin antidiabetic treatment .
89461167|NCT04457661|Experimental|TCI711 probiotic|Taking one capsule (containing 10^10 of Bacillus coagulans TCI711) daily for one month
89461168|NCT05222139||Solid organ transplant recipients|Solid organ transplant recipients
89461169|NCT05222139||Patients with HIV infection|Patients with HIV infection
89461170|NCT05222139||Patients with oncological diseases|Patients with oncological diseases
89461171|NCT05222139||Patients with hematological diseases|Patients with hematological diseases
88942690|NCT01871909||Physical trauma|Patients with report of physical trauma within 24 hours of presentation to the hospital.
88942691|NCT01871922|Placebo Comparator|General anesthesia + placebo|Propofol/remifentanil anesthesia + saline
88942692|NCT01871922|Active Comparator|General anesthesia + atropine|Propofol/remifentanil anesthesia + atropine
88942693|NCT01871935|Active Comparator|Remifentanil|Anaesthesia with remifentanil/propofol
88942694|NCT01871935|Active Comparator|Sufentanil|Anaesthesia with sufentanil/propofol
88942695|NCT01871948|No Intervention|Patient survey at 2 points in time|Randomly assigned patients attending cancer clinics at Washington or Georgia sites during February 2013 to August 2013 will be presented with or mailed a survey about cancer communication approximately 2 weeks later and a follow-up survey approximately 3 months later.
88942696|NCT01871948|Experimental|"WeWant to Know campaign, patient survey at 2 time points"|Randomly assigned patients attending cancer clinics at Washington or Georgia sites during February 2013 to August 2013 will be presented with or mailed a survey about cancer communication approximately 2 weeks later and a follow-up survey approximately 3 months later. Additionally, this group will also receive a follow-up phone call approximately 4 weeks after baseline survey.
88942697|NCT01871961|Experimental|Methotrexate|
88942698|NCT01871974|Experimental|low-dose group FK949E|oral
88942699|NCT01871974|Experimental|high-dose group FK949E|oral
88942700|NCT01871987|Experimental|fasted group|receiving FK949E in fasted condition
88942701|NCT01871987|Experimental|low fat group|receiving FK949E after low fat meal
88942702|NCT01871987|Experimental|high fat group|receiving FK949E after high fat meal
88942703|NCT01872000|Experimental|Multifocal IOL|Phacoemulsification and IOL inserted following cataract surgery
88942704|NCT01872000|Active Comparator|Standard IOL|Phacoemulsification and IOL inserted following cataract surgery
88942705|NCT01872013|Experimental|low dose ASP7991|
88942706|NCT01872013|Experimental|middle dose ASP7991|
88942707|NCT01872013|Experimental|high dose ASP7991|
88942708|NCT01872013|Placebo Comparator|Placebo|
88942709|NCT01872026|Experimental|Part 1- single administration|The lowest, middle and the highest dose ASP7991 as a single oral administration on non-dialysis day in step 1 to 3 and the highest dose on day of dialysis in step 4.
88942710|NCT01872026|Experimental|Part 2- repeated administration|The lowest, middle and the highest dose ASP7991 as repeated oral administration in step 1 to 3.
88942711|NCT01872039|Active Comparator|Weight-based adjustment group|Dosage regimen according to the current Package Insert approved by SFDA
88942712|NCT01872039|Experimental|Non-weight-based adjustment group|Dosage regimen according to the Package Insert approved by FDA
88942713|NCT01872052|Experimental|Acutus Medical System|
88942714|NCT01872065|Experimental|ARC-520|Single dose, intravenous administration of ARC-520.
89461172|NCT05222139||Patients with autoimmune diseases|Patients with autoimmune diseases
89461173|NCT05222139||Patients with cystic fibrosis|Patients with cystic fibrosis
88942715|NCT01872065|Placebo Comparator|Normal Saline|Single dose, intravenous administration of Normal Saline
88942716|NCT01872091|Experimental|cryotherapy by immersion|Cryotherapy group immersion (GI) composed of 20 volunteers, which will be subjected to immersion cryotherapy upper limb dominant in cold water (6°C ± 2°C), at the level of the elbow joint.
88942717|NCT01872091|Experimental|Control group|(CG) consisted of 20 volunteers, which will be submitted to immersion of the dominant upper limb in water at room temperature indifferent to the level of the elbow joint;
88942718|NCT01872104|No Intervention|Chemotherapy alone|Group that be scheduled to undergo chemothrapy only using FOLFOX4 protocol.
88942719|NCT01872104|Experimental|PDT and Chemotherapy|Group that not only be scheduled to undergo chemothrapy using FOLFOX4 protocol,but also receive colonscopy-assisted PDT.
88942720|NCT01872117|Experimental|Applications of shortwave diathermy|
88942721|NCT01872117|Experimental|Applications of microwave diathermy|
88942722|NCT01872143|Experimental|transcranial Direct Current Stimulation|daily or twice-a-day administration of transcranial Direct Current Stimulation
88942723|NCT01871311|Experimental|Nilotinib + Cetuximab|All patients with receive Nilotinib BID for a 28-day cycle + Cetuximab 400 mg/m2 on day 1 dose then 250 mg/m2 weekly
88942724|NCT01872156|Experimental|Intervention GESTABAC|"Intervention based on the Clinician's Guide to helping Pregnant Women Quit Smoking on the rates of abstinence of the patients in whom it has been controlled in this period of time, at the end of the pregnancy and after the childbirth."
88942725|NCT01872156|Other|Control Group|The group control will act according to usual management.
89461174|NCT05222139||Patients with Parkinson Disease|Patients with Parkinson Disease
89461175|NCT05222139||Patients with rheumatological diseases|Patients with rheumatological diseases
89461176|NCT05222139||Pregnant women/ New-borns|Pregnant women/ New-borns
89461177|NCT05222139||Children|Children
89461178|NCT02120222|Experimental|Treatment (selinexor)|Patients receive selinexor PO BIW. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Blood will be collected for correlative studies to perform pK (pharmacokinetics) and pDn (pharmacodynamics) analysis pretreatment on day 1 and 8 hours after treatment, on day 1 of cycles 1 and 2.
89461179|NCT00969111|Experimental|Postop Non-High Risk|Proton to 66.6 CGE
89461180|NCT00969111|Experimental|Postop High Risk|IMRT to 45 Gy; prostate bed proton boost of 21.6 CGE
89461181|NCT00969111|Experimental|Salvage Non-High Risk|Proton to 70.2 CGE
89461182|NCT00969111|Experimental|Salvage High Risk|IMRT to 45 Gy; proton boost to prostate bed to 25.2 CGE
89461183|NCT05212389|Active Comparator|Femicept|3x28 days of treatment with Femicept. Each cycle consists of 21 days of active pill (Femicept) and 7 days of placebo pill.
89461184|NCT05212389|Placebo Comparator|Placebo|3x28 days of treatment with placebo
89461185|NCT03472755|Other|The posterolateral approach|The posterolateral approach was used for implantation among patients in lateral position. This approach goes through the gluteus maximus, the piriformis and superior gemeli muscles are detached and later reattached to bone
89461186|NCT03472755|Other|Direct anterior techniques.|. In the direct anterior technique, patients were fixed in a supine position, a small entry incision was made in the vessel free interval between the tensor fasciae latae and the sartorius muscles and the prosthesis socket were put in place. Via a second dorsal incision, after releasing the external rotators, the prosthesis stem and ball were implanted and the two parts of the prosthesis were attached.
89461187|NCT03471039|Active Comparator|Active|PACAP-27
89461188|NCT03471039|Placebo Comparator|Placebo|Saline
89461189|NCT05074719||Cohort A|Cohort A comprises individuals that enroll within two weeks of diagnosis of SARS-CoV-2 infection. These individuals will be asked to provide a baseline mid-turbinate nasal swab for SARS-CoV-2 testing and complete questionnaires at baseline and on Days 7 and 14. Through these questionnaires, index individuals will report on the clinical course of their illness and share information about their household environment, including potential exposures there-in and any COVID-19 transmission mitigation strategies implemented (whether intentional or as part of standard home routines). Enrolled Cohort A index individuals will also be invited to participate in the SARS-CoV-2 Antibody Sub-study and provide a dried blood spot specimen (at baseline) for antibody testing.
89461190|NCT05074719||Cohort B|Cohort B comprises individuals that enroll more than two weeks after diagnosis of SARS-CoV-2 infection. These individuals will be asked to provide a mid-turbinate nasal swab for SARS-CoV-2 testing and to complete a questionnaire reporting retrospectively on their COVID-19 illness and household environment. Through this questionnaire, index individuals will report on the clinical course of their illness and share information about their household environment, including potential exposures there-in and any COVID-19 transmission mitigation strategies implemented (whether intentional or as part of standard home routines). These individuals will also complete a questionnaire reporting on the persistence and/or delayed onset of symptoms and complications that they associate with their COVID-19 illness. Enrolled Cohort B index individuals will also be invited to participate in the SARS-CoV-2 Antibody Sub-study and provide a dried blood spot specimen (at baseline) for antibody testing.
89461191|NCT03472677|Experimental|Cohort 1|A comparison of two cooling methodologies in healthy volunteers after single intra-articular (IA) injection (15 mL) of 2% lidocaine (without epinephrine).
89461192|NCT03472677|Experimental|Cohort 2|Controlled cooling wrap versus ice pack cooling.
89461193|NCT03472677|Experimental|Cohort 3|Controlled cooling parameters will be determined after evaluation of data from prior cohorts.
89461194|NCT03472677|Experimental|Cohort 4|Controlled cooling with knee device versus no cooling (determined after evaluation of data from previous cohorts).
89461195|NCT04943601|Experimental|Action observation training group|The experimental group will receive a training program with Action observation by watching videos of complex tasks while imitating them. All the movements will be performed bilaterally so that regardless of the affected side the patient had the correct perspective to perform the exercise.
89461196|NCT04943601|Active Comparator|Conventional therapy group|The control group will receive conventional rehabilitation, with exercises of bimanual activities that will target their shoulder, elbow, wrist and finger joints similar to the experimental group but without Action observation
89461197|NCT02673567|Experimental|TEV-48125 - 1|Dose Regimen 1
88942726|NCT01872182|Experimental|Test arm|ALS-L1023 300mg in two tablets
88942727|NCT01872182|Placebo Comparator|Comparator arm|placebo in two tablets
88942728|NCT01872195|Experimental|* Before checklists|The comprehensive patient safety checklist system
88942729|NCT01872195|Experimental|* After checklists|Without the comprehensive patient safety checklist system
88942730|NCT01872221|Experimental|Surgery and radio-chemotherapy|Surgery (on the basis of all preoperative multimodal MRI) followed by standard radio-chemotherapy stupp protocol
88942731|NCT01872234|Experimental|Device Arm: Two Lead CRT-P|Intervention: Device: Two-lead CRT-P. Patients will be implanted with a two lead CRT-P system: right atrial lead, left ventricular lead and a dual chamber pacemaker. Patients in this group will also be under optimal pharmacologic therapy.
88942732|NCT01872234|No Intervention|Control: Optimal Pharmacologic Therapy|The control group will be managed on optimal pharmacologic therapy only. They will not be implanted with a device.
88942733|NCT01872286|Experimental|Pillcam SB2 first|patients were assigned to swallow PSB first, followed by the AKE
89461198|NCT02673567|Experimental|TEV-48125 - 2|Dose Regimen 2
89461199|NCT02673567|Experimental|TEV-48125 - 3|Dose Regimen 3
88942734|NCT01872286|Experimental|AKE-1 first|patients were assigned to swallow AKE first, followed by the PSB
88942735|NCT01872299||Control|Healthy control subjects
88942736|NCT01872299||Heart failure without co-morbidities|Patients with a clinical diagnosis of chronic heart failure without co-morbidities
88942737|NCT01872299||Heart failure with co-morbidities|Patients with a clinical diagnosis of chronic heart failure with co-morbidities
88942738|NCT01872299||Type 2 diabetes mellitus|Patients with type 2 diabetes mellitus and without heart failure
88942739|NCT01872351||pre and 12 months post ENT|"Compare the clinical status of CFS patients after at least 12 months of ENT to their status before ENT.~ENT consists of:~Daily conditioning exercise: 35-40 minutes~Nutraceutical supplements: acetyl-L-carnitine 500 mg bid, alpha-lipoic acid (Alpha Lipoic Sustain 300) 300 mg qd, CoQ10 (Ubiquinol QH-absorb) 100 mg qd, docosahexanoic acid (maxDHA) 300 mg qd, plus a multivitamin (Centrum Silver) ½ tab bid.~Diet: 25% protein, 35- 40% carbohydrate, 35-40% fat"
89461200|NCT02673567|Placebo Comparator|Placebo|Matching Placebo
89461201|NCT00702195||Experimental Group 1|all doses of Org 36286 (corifollitropin alfa) from trial 38805 (7.5 μg, 15 μg, 30 μg and 60 μg)
89461202|NCT00702195||Experimental Group 2|Placebo
89461203|NCT00702195||Experimental Group 3|all doses of Org 36286 (corifollitropin alfa) from trial 38807 (120 μg, 180 μg and 240 μg)
89461204|NCT00702195||Experimental Group 4|150 IU Puregon®
89461205|NCT01550237|Experimental|radiotherapy daily reduced|radiotherapy, with daily CT position verification and reduced safety margins
89461206|NCT01550237|Active Comparator|radiotherapy weekly standard|radiotherapy, with weekly orthogonal position verification and standard safety margins
89461207|NCT02915159|Experimental|Abatacept|Abatacept for subcutaneous injection 125mg/mL in 1 mL pre-filled syringe for 6 months followed by Open-Label Abatacept for subcutaneous injection 125mg/mL in 1 mL pre-filled syringe for 6 months
89461208|NCT02915159|Placebo Comparator|Placebo|Placebo for Abatacept for subcutaneous injection 125mg/mL in 1 mL pre-filled syringe for 6 months followed by Open-Label Abatacept for subcutaneous injection 125mg/mL in 1 mL pre-filled syringe for 6 months
89461209|NCT04058951|Placebo Comparator|High Animal Protein Diet (HAPD)|Consuming a diet high in protein primarily from animal origin.
89461210|NCT04058951|Experimental|High Plant Protein Diet (HPPD)|Consuming a diet high in protein exclusive from plant origin.
89461211|NCT03669263|Experimental|Fentanyl buccal soluble film (FBSF)|Single arm
88942740|NCT01872364||Dominican Republic patients at NPO Outpatient Surgery Center|
88942741|NCT01872377|Experimental|Radiotherapy Boost|All participants will receive the CyberKnife® Stereotactic Body Radiotherapy(SBRT)Boost treatment however, there are 5 dose levels that could be assigned according to Time-to-Event Continual Reassessment Method (TITE-CRM). Participants will be assigned to either receiving 6, 7, 8, 9 or 10 Gy X 3Fr.
88942742|NCT01872390|Experimental|CIP Participants|Participants will receive the usual procedures (standard of care) for management of HIV-infected TB patients, and in addition the Combination Intervention Package (CIP) with the programmatic, structural, and psychosocial components.
88942743|NCT01872390|Other|SOC Participants|Participants will receive the usual procedures (standard of care) for management of HIV-infected TB patients. TB and HIV services are fully integrated in a one-stop model, while at hospitals, ART is provided in the TB clinic for TB/HIV coinfected patients.
88942744|NCT01872403|Experimental|nanoparticle albumin-bound paclitaxel|Neoadjuvant chemotherapy of nanoparticle albumin-bound paclitaxel/carboplatin in stage Ⅱ B and IIIA squamous cell carcinoma of the lung
88942745|NCT01872416|Experimental|Refractory and relapsed SCLC|Liposomal Doxorubicin Combined With ifosfamide Second-line Treatment in Small Cell Lung Cancer
88942746|NCT01872429||Short-term group|Patients with postoperative 6-month laboratory data were included in the short-term group
88942747|NCT01872429||Long-term group|Patients with postoperative more than 6-month laboratory data were included in the long-term group
88942748|NCT01872442|Experimental|Dasatinib|Dasatinib,Bristol Myers Squibb
88942749|NCT01872442|Experimental|Peg-Interferon alpha2b|Peg-Interferon alpha2b (Peg-IFN α2b), Merck
88942750|NCT01872455|Active Comparator|Group CON|patients who refused to assume the n-3 rich diet and continued their usual diet
88942751|NCT01872455|Experimental|Group DIET|the patients assumed n-3 rich diet: Patients of the DIET group were requested to follow a diet specifically designed to increase the intake of n-3 PUFAs and to decrease the ratio n-6/n-3 by using natural foods.
88942752|NCT01872468|No Intervention|Control|There is not intervention in this group.
88942753|NCT01872468|Active Comparator|Structured intervention|Initial training session based on significant learning and follow up visits every four months at physicians and nurses´ offices over a two-year period
88942754|NCT01872481|Placebo Comparator|Sham stimulation|"rTMS with sham coil. Sessions will be administered 5 days a week (Monday to Friday) during two consecutive weeks."
88942755|NCT01872481|Experimental|Active stimulation|rTMS in series of 20 trains of 6 s in duration (54-s intertrain interval) at a stimulation rate of 10 Hz (1200 pulses) at an intensity of 90% rest motor threshold. Sessions will be administered 5 days a week (Monday to Friday) during two consecutive weeks.
88942756|NCT01872494|Experimental|Local|This group uses local analgesia infusion pump of 0.33% ropivacaine 250ml through the wound for postoperative analgesia.
88942757|NCT01872494|Active Comparator|intravenous|This group is treated with intravenous analgesia pump infusion of flurbiprofen axetil 150mg,palonosetron 0.5mg,pentazocine 240mg.
88942758|NCT01872507|Active Comparator|biofeedback training|usual treatment+12 treatment of biofeedback training
88942759|NCT01872507|No Intervention|control|usual treatment
88942760|NCT01872520||the Injection of DanShenDuoFenSuanYan|Patient who use the Injection of DanShenDuoFenSuanYan
88942761|NCT01872533|Experimental|Hypoxia Exposure|There was only one study arm: All participants slept in moderate hypoxia (see description below).
88942762|NCT01872546|Experimental|Adalimumab|
88942763|NCT01872559||3D sonographic analysis|The study is designed to evaluate a new imaging modality, 3D sonographic volumetric analysis, and compare it to the conventional 2-dimmensional analysis that is currently in place. Those patients who are scheduled to have an ultrasound as part of their infertility treatment will be offered the opportunity to have additional measurements done at the time of their ultrasound; these additional measurements will take less than 2 minutes and do no require any additional sonograms, tests, or interventions.
88942764|NCT01872572|Other|Cohort 1|Cohort 1: 6 subjects received Subcutaneous RB006 0.5 mg/kg and 2 subjects received SC placebo
88942765|NCT01872572|Other|Cohort 1-A|Cohort 1-A: 4 subjects received open-label Subcutaneous RB006 0.5 mg/kg
88942766|NCT01872572|Other|Cohort 2|Cohort 2: 6 subjects received Subcutaneous RB006 1.0 mg/kg and 2 subjects received SC placebo
88942767|NCT01872572|Other|Cohort 3|Cohort 3: 6 subjects received Subcutaneous RB006 3.0 mg/kg and 2 subjects received SC placebo
88942768|NCT01872572|Other|Cohort 4|"8 subjects received subcutaneous RB006 2.0 mg/kg as well as the following:~4 subjects received an IV bolus injection of 1 mg/kg RB007 at 72 hours post-RB006 administration~4 subjects received an IV bolus injection of 1 mg/kg RB007 at 24, 72, and 120 hours post-RB006 administration"
88942769|NCT01872585|Experimental|Mentalization based therapy|Women who are the primary caregivers of a child between the ages of 0-7 years and are involved with mental health services for themselves or a child.
89461212|NCT03658915||Osteoarthritis|"Thirty symptomatic knee with osteoarthritis will be recruited according to the following criteria:~INCLUSION CRITERIA:~Referred with a confirmed diagnosis of unilateral or bilateral OA of the knee based on the following criteria.~1.1. Morning stiffness < 30 minutes, 1.2. Crepitus on active knee movement. 1.3. Bony enlargement either palpable or visible in radiographs. 1.4. Bony tenderness.~Age 40-60 years old.~EXCLUSION CRITERIA:~Steroid injection within the past 2 months.~Presence of neurologic disorders.~Presence of of orthopedic diseases or trauma in the lower extremity or spine within the past year.~6. Severe pain with active movement 7. Poor memory or cognitive function"
89461213|NCT03658915||Control|Thirty asymptomatic knee will be recruited for this study. Control group participants will be age-matched to the osteoarthritis group, and should have no pain or other relevant clinical symptoms in lower quadrant.
89461214|NCT01208987|Experimental|Intervention (with Medication History)|these patient visits generated a medication history
89461215|NCT03477747|Experimental|Resistance Training Microcurrent|"Participants will combine a 10-week periodized and controlled resistance programme with 3 h of microcurrent after training.~Measurements pre and post-intervention will be body composition via DEXA, endurance performance (1 RM bench press and Squat) endurance (vo2max) and blood markers: haemoglobin; red blood cell; erythrocyte; haematocrit; mean corpuscular volume, transferrin; neutrophils; lymphocyte; monocytes, IL6, IL1, Myoglobin, salivary cortisol and testosterone. Elbow flexors, vastus medialis and vbastus lateralis muscle thickness"
89461216|NCT03477747|Sham Comparator|Resistance Training Shadow|"Participants will combine a 10-week periodized and controlled resistance programme with 3 h of sham comparator after training.~Measurements pre and post-intervention will be body composition via DEXA, endurance performance (1 RM bench press and Squat) endurance (vo2max) and blood markers: haemoglobin; red blood cell; erythrocyte; haematocrit; mean corpuscular volume, transferrin; neutrophils; lymphocyte; monocytes, IL6, IL1, Myoglobin, salivary cortisol and testosterone. Elbow flexors, vastus medialis and vbastus lateralis muscle thickness"
89537174|NCT02719691|Experimental|Dose Level 4: Alisertib 40 mg/MLN0128 3 mg|"This group will receive a Dose-Escalation: Combination of MLN0128 and Alisertib using a standard 3 + 3 design. The starting dose of Alisertib is 40 mg given PO twice daily (BID) Days 1-7 repeat every 21 days. The starting dose for MLN0128 is 3 mg given by mouth (PO) once daily with continuous dosing.~Alisertib: Participants will receive Alisertib in the dose-escalation and the dose-expansion part of the study."
88942770|NCT01872624|Active Comparator|Valves plus cells|Bronchoscopy Five patients will be selected to receive bone-marrow derived mesenchymal stromal cells delivered bronchoscopically right before insertion of one-way endobronchial valves.
88942771|NCT01872624|Placebo Comparator|Valves plus saline|Bronchoscopy Five patients will be selected for treatment with one-way endobronchial valves only, with saline injected prior to valve insertion.
88942772|NCT01872637|Experimental|Progressive Multi-Component Intervention|Patients in this exercise group will receive 10-18, 45-60 minute, physical therapy visits in their home. This group will consist of progressive resistance exercises for the upper and lower extremity with a portable training device, a motor control-based program of gait/balance training, Activities of Daily Living (ADL) training, and mobility training.
88942773|NCT01872637|Active Comparator|Usual Care Group|"The patients in this group will receive approximately five visits of usual home care but the total number of visits will be determined by the therapist as part of usual care. These visits will likely occur at 1-2 times per week for 3-4 weeks. This group will receive intervention as determined by the physical therapist's initial examination. Interventions may include patient education, home exercises, low intensity strengthening exercise, training in gait, balance and transfers; home safety and assistive device assessment."
88942774|NCT01872650|No Intervention|Control|No placement of an adhesion barrier
88942775|NCT01872650|Experimental|C-Qur|C-Qur film placement beneath the incision. Possibly placement of C-Qur film at other sites considered to be adhesiogenic (but not around the anastomosis)
88942776|NCT01872663|Experimental|Incentive spirometry (Voldyne®)|Individuals will be treated with incentive spirometry, Voldyne Model 5000® in the immediate and the first postoperative day, twice a day, in sessions of 6 sets of 15 repetitions each, with an interval of four hours between them.
88942777|NCT01872663|Experimental|Continuous positive airway pressure|Individuals will be treated with flow generator(Whisperflow, Caradyne, Ireland)and valve PEEP type spring-loaded which remain 10 cmH2O, in the immediate and the first postoperative day, twice a day, in sessions 30 minutes each, with an interval of four hours between them.
88942778|NCT01872663|Experimental|Expiratory Positive Airway Pressure|Subjects will be treated with oronasal mask affixed to the face, with the PEEP valve set at 10 cmH2O, in the immediate and the first postoperative day, twice a day, in sessions of 6 sets of 15 repetitions each, with an interval of four hours between them.
88942779|NCT01872663|Experimental|Intermittent positive pressure breathing|Subjects will be treated with application of Müller Resuscitator (Engesp®) through a nozzle, using a pressure endotracheal 20-30 cmH2O, refering to 2-3 kgf/cm², adjusted throttle valve oxygen, according to the patient's comfort and the micronebulizer coupled only saline as the diluent. The procedure will be performed in the immediate and the first postoperative day, twice a day, in sessions of 6 sets of 15 repetitions each, with an interval of four hours between them.
88942780|NCT01872663|Experimental|Bi-level positive airway pressure|Individuals will be treated with positive pressure in the BiPAP mode (Bi-level positive airway pressure) in the immediate and the first postoperative day, twice a day, in sessions 30 minutes each, with an interval of four hours between them.
88942781|NCT01872663|Experimental|Breath Stacking|Subjects will be treated with a siliconized mask connected to a unidirectional valve and adapted to the patient's face, allowing only the inspiration and the expiratory limb remains occluded, while the volunteer is instructed to perform successives inspiratory efforts, in the immediate and the first postoperative day, twice a day, in sessions of 6 sets of 15 repetitions each, with an interval of four hours between them.
88942782|NCT01872663|No Intervention|Control|Individuals will be treated with conventional physiotherapy according to the routine service of physiotherapy of the hospital.
88942783|NCT01872676|Experimental|Manipulation|The experimental group received upper thoracic manipulation of the T3 vertebra. The volunteer was instructed to lie in the supine position, interlace her fingers and position her hands in the posterior region of the base of the neck. The therapist than positioned a stabilizing hand in a pistol grip immediately caudal to the T3 vertebra, pushing the volunteer's arms downward to generate flexion of the upper thoracic spine.
89461217|NCT03477747|Experimental|Endurance Training Microcurrent|"Participants will combine a 10-week periodized and controlled endurance programme with 3 h of microcurrent after training.~Measurements pre and post-intervention will be body composition via DEXA, endurance performance (1 RM bench press and Squat) endurance (vo2max) and blood markers: haemoglobin; red blood cell; erythrocyte; haematocrit; mean corpuscular volume, transferrin; neutrophils; lymphocyte; monocytes, IL6, IL1, Myoglobin, salivary cortisol and testosterone. Elbow flexors, vastus medialis and vbastus lateralis muscle thickness"
89461218|NCT03477747|Sham Comparator|Endurance Training Shadow|"Participants will combine a 10-week periodized and controlled endurance programme with 3 h of microcurrent after training.~Measurements pre and post-intervention will be body composition via DEXA, endurance performance (1 RM bench press and Squat) endurance (vo2max) and blood markers: haemoglobin; red blood cell; erythrocyte; haematocrit; mean corpuscular volume, transferrin; neutrophils; lymphocyte; monocytes, IL6, IL1, Myoglobin, salivary cortisol and testosterone. Elbow flexors, vastus medialis and vbastus lateralis muscle thickness"
89461219|NCT04058483|Active Comparator|HIP First|Participants randomized to perform the in-person hypnotizability test first. This will be followed within 1 week with the by-phone rHIP test performed by a second, randomly-assigned investigator.
89461220|NCT04058483|Active Comparator|rHIP First|Participants randomized to perform the by-phone hypnotizability test first. This will be followed within 1 week with the in-peron HIP test performed by a second, randomly-assigned investigator.
89461221|NCT02924051|Experimental|Motivational Interview (MI)|Intervention group participants receive cooking skills and nutritional education via cookbooks, cooking classes, food preparation tools and prepared food dishes to take home to their families, along with monthly motivational interviewing conducted by a trained registered nurse
89461222|NCT02924051|Active Comparator|Cooking Skills/Nutritional Education|Participants in this arm receive cooking skills and nutritional education via cookbooks, cooking classes, food preparation tools and prepared food dishes to take home to their families.
89461223|NCT04058249|Experimental|Right DLPFC aiTBS stimulation|
89461224|NCT02923427|Active Comparator|Laryngeal mask Supreme|"Insertion of the Laryngeal mask Supreme and evaluation of its clinical performance"
89461225|NCT02923427|Experimental|i-gel|"Insertion of the i-gel and evaluation of its clinical performance"
89461226|NCT02669264|Experimental|Part 1: ADCT-402 dose escalation|"Weekly administration - Participants will receive an intravenous (IV) infusion of ADCT-402, on Days 1, 8, and 15 of each 3-week (21-day) cycle.~3-week administration - Participants will receive an IV infusion of ADCT-402, on Day 1 of each 3-week (21-day) cycle.~The dose escalation will be conducted according to a 3+3 design."
89461227|NCT02669264|Experimental|Part 2: ADCT-402 expansion|All participants will be assigned to the recommended dose and/or schedule of ADCT-402 identified in Part 1 by the Dose Escalation Steering Committee
89461228|NCT02521870|Experimental|Dose Escalation Phase 1b|Determine the maximum tolerated dose (MTD) of escalating doses of SD-101(1) administered in combination with pembrolizumab in patients with melanoma (anti-PD-1/L1 therapy naïve and experienced patients with progressive disease).
88942784|NCT01872676|Sham Comparator|Sham|The placebo group was placed precisely as the experimental group, with the exception of the positioning of the therapist's hand, which remained with the palm open and not in a pistol grip. Once positioned, the volunteers were instructed to breathe deeply. The maneuver was terminated after one cycle of deep breathing.
89017686|NCT06139042||liver, biliary tract, and pancreatic benign diseases|participants with liver, biliary tract, and pancreatic benign diseases
89017687|NCT06139042||non-liver, biliary tract, and pancreatic diseases|Participants with no known presence of malignancies or benign diseases
89017688|NCT06139016|Experimental|Treatment group|This single arm will include all participants of the study, who will all receive the intervention
89461229|NCT02521870|Experimental|Dose Expansion Phase 2 (Cohort 1)|Determine the safety and efficacy of SD-101(2) and pembrolizumab in anti-PD-1/L1 therapy naïve patients with recurrent or metastatic melanoma.
89461230|NCT02521870|Experimental|Dose Expansion Phase 2 (Cohort 2)|Determine the safety and efficacy of SD-101(2) and pembrolizumab in anti-PD-1/L1 therapy progressing patients with recurrent or metastatic melanoma.
89461231|NCT02521870|Experimental|Dose Expansion Phase 2 (Cohort 3)|Determine the safety and efficacy of SD-101(2) and pembrolizumab in anti-PD-1/L1 therapy naïve patients with recurrent head and neck squamous cell carcinoma.
89461232|NCT02521870|Experimental|Dose Expansion Phase 2 (Cohort 4)|Determine the safety and efficacy of SD-101(2) and pembrolizumab in anti-PD-1/L1 therapy progressing patients with recurrent head and neck squamous cell carcinoma.
89461233|NCT02521870|Experimental|Dose Expansion Phase 2 (Cohort 5)|Determine the safety and efficacy of SD-101(3) and pembrolizumab in anti-PD-1/L1 therapy naïve patients with recurrent or metastatic melanoma.
89461234|NCT02521870|Experimental|Dose Expansion Phase 2 (Cohort 6)|Determine the safety and efficacy of SD-101(3) and pembrolizumab in anti-PD-1/L1 therapy naïve patients with recurrent head and neck squamous cell carcinoma.
89461235|NCT02521870|Experimental|Dose Expansion Phase 2 (Cohort 7)|Determine the safety and efficacy of SD-101(3) and pembrolizumab in anti-PD-1/L1 therapy refractory or resistant patients with recurrent head and neck squamous cell carcinoma.
89461236|NCT02521870|Experimental|Dose Expansion Phase 2 (Cohort 8)|Determine the safety and efficacy of SD-101(3) and pembrolizumab in anti-PD-1/L1 therapy refractory or resistant patients with recurrent or metastatic melanoma.
89461237|NCT02923349|Experimental|INCAGN01949|
89461238|NCT02386046||Reference Group|Late preterm infants without any pathology. Intervention: Pulse oxymeter measurements at the hospital and weekly thereafter until 46 weeks postconceptional age.
89461239|NCT02386046||Study Group|Infants born 26-35 weeks requiring caffeine. Intervention: Pulse oxymeter measurements at the hospital before and after caffeine instituted, and weekly thereafter until 46 weeks postconceptional age.
89461240|NCT02386046||Control Group|Infants born 26-35 weeks not requiring caffeine. Intervention: Pulse oxymeter measurements at the hospital and weekly thereafter until 46 weeks postconceptional age.
89461241|NCT02385656|Experimental|Intervention group|Subjects who take modafinil for cancer-related fatigue for 4 weeks.
89461242|NCT02389868|Experimental|Lovastatin|
89461243|NCT03668249||All Participants|Participants diagnosed with CD from approximately 12 to 15 investigational sites will be observed retrospectively for previous 5 years.
89461244|NCT02521792|Experimental|Palovarotene|The protocol is open only to the subjects who completed Clementia Study PVO-1A-202. Eligible subjects will receive a weight-based equivalent dose of palovarotene 10 mg once daily for 14 days, followed by 5 mg once daily for 28 days. Should treatment be extended beyond 6 weeks, a weight-based equivalent dose of 5 mg will be administered in 2-week increments.
89461245|NCT03623087|Experimental|SIMPLE|cisplatin, gemcitabine, ifosfamide, etoposide (VP-16), L-asparaginase, dexamethasone
89461246|NCT02390024||Critically ill patients|Mechanical Ventilation
89461247|NCT05066932||Familial Hypercholesterolemia and hyperTriglyceridemia|Patients with Familial Hypercholesterolemia and hyperTriglyceridemia
89461248|NCT05066932||Familial Hypercholesterolemia without hyperTriglyceridemia|Patients with Familial Hypercholesterolemia and without hyperTriglyceridemia
89461249|NCT03668171|Experimental|MSC group|mesenchymal stem cell transplantation via peripheral vein: 0.1-1x10E6 MSCs/kg body weight administered via peripheral vein at week 0, 1, 2 weeks
89461250|NCT03668171|Placebo Comparator|control|placebo infusions (placebo infusion differs from the experimental infusion in only that placebo has no mesenchymal stem cells) will be administered via peripheral vein at week 0, 1, 2
89461251|NCT03669185|Placebo Comparator|Placebos|Placebos, 2 times daily 1 tablet, intake max. 133 days
89461252|NCT03669185|Active Comparator|Pentalong|Pentalong, 2 times daily 1 tablet, intake max. 133 days
89461253|NCT03668093|Experimental|ICCMS|Intervention
89461254|NCT03668093|Active Comparator|CAMBRA|Comparator
89461255|NCT03623165||Arm|Cordella™ Heart Failure System
89461256|NCT04058327||MHE group|Patients whose MHE test are positive
89461257|NCT04058327||no HE group|Patients whose MHE test are negative
89461258|NCT04058327||overt HE group|2/3/4 HE patients
89461259|NCT05065528|Placebo Comparator|Control|placebo pill twice daily for 3 days ondansetron 4mg twice daily for 3 days acetaminophen 500mg twice daily for 3 days
89461260|NCT05065528|Experimental|Intervention|Magnesium 500mg twice daily for 3 days ondansetron 4mg twice daily for 3 days acetaminophen 500mg twice daily for 3 days
89461261|NCT03113396|Experimental|baclofen|Patients will receive baclofen (10mg t.i.d) for 2 weeks, thereafter they will be crossed over to the alternative treatment, which is placebo (identically looking capsules). After 2 weeks of treatment, patients will undergo a High Resolution Impedance Manometry (HRiM) measurement, with meal. We will record for in total 2 hours. Patients are asked to fill out questionnaires concerning their overall wellbeing.
89461262|NCT03113396|Placebo Comparator|placebo|Patients will receive placebo for 2 weeks, thereafter they will be crossed over to the alternative treatment, which is baclofen (10mg t.i.d) (identically looking capsules). After 2 weeks of treatment, patients will undergo a High Resolution Impedance Manometry (HRiM) measurement, with meal. We will record for in total 2 hours. Patients are asked to fill out questionnaires concerning their overall wellbeing.
89461263|NCT03020615|Active Comparator|Stable Dosing|In the first 8 weeks (± 2 weeks) of this study, participants will receive standard treatment [a fixed dose of 20 (± 2.5) mg/kg/day of hydroxyurea]. After 8 weeks (± 2 weeks) of standard treatment, participants will be randomized (like flipping a coin) to one of two treatment groups. Group 1 (Stable Dosing) continues standard treatment.
89461264|NCT03020615|Experimental|Intensive Dosing|In the first 8 weeks (± 2 weeks) of this study, participants will receive standard treatment [a fixed dose of 20 (± 2.5) mg/kg/day of hydroxyurea]. After 8 weeks (± 2 weeks) of standard treatment, participants will be randomized (like flipping a coin) to one of two treatment groups. Group 2 (Intensive Dosing) will have their HU dose increased by 5 mg/kg/day every 8 weeks up to a maximum of 35 mg/kg/day.
89461265|NCT03020069|Experimental|Glucose Meter|Continuing Glucose Monitoring Device
89461266|NCT03020069|Active Comparator|No Glucose Meter|Average Blood glucose measure
89461267|NCT05064046|Experimental|LuCa + Health Disparity module|"Participants will be asked to complete the Health Disparities module that is an interactive CME/CE online course which offers 0.5 continuing education credit hours.~The will also be asked to complete the LuCa course."
89461268|NCT05064046|Active Comparator|LuCa only module|"LuCa is a free interactive CME/CE online course entitled, Lung Cancer and the Primary Care Provider. For the purpose of this study, participants will be asked to complete session 1 which offers 1.0 continuing education credit hours, including AMA PRA Category 1 credits, AANP, and AAFP Prescribed credits."
89461269|NCT05063500|Experimental|Experimental group|Experimental group: each oral bicyclol 50mg, three times daily for 4 weeks.
89461270|NCT05063500|Active Comparator|Control group|Control group: each oral polyene phosphatidylcholine 456mg, three times daily for 4 weeks.
89461271|NCT04058171||LSS group|Participants with a diagnosis of lumbar spinal stenosis
89461272|NCT04058171||PAD group|Participants with a diagnosis of peripheral artery disease
89461273|NCT04058171||LBP group|Participants with a diagnosis of non specific low back pain
89461274|NCT04995796|Experimental|Enrolled Participants|Study participation will involve 2 visits. The first visit will take approximately 90 minutes, but may be longer if participant desires longer interaction with the DSI/DA. The second visit will take approximately 5 minutes.
89461275|NCT04058093|Experimental|Functional Training Program|"Functional training program (FTP) will last for 6 months and will include:~Functional training sessions (each 45-minutes long, twice a week);~Group nutrition counseling (each 90-minutes long, in three different moments throughout the intervention: week 1, 12 and 20)."
89461276|NCT04058093|No Intervention|Waiting list control group|Participants will not participate in any specific intervention, but will receive the FTP after the experimental period (6 months).
89461277|NCT03669107|Experimental|Gum chewing|"Gum type was standardized with all subjects receiving sugar-free peppermint-flavored gum.~The patients in the chewing gum group, gum chewing began the morning of postoperative day 1. Patients chewed gum (one stick) 3 times daily in the morning, afternoon, and evening at 30 min. The administration of the therapy was implemented by ward nursing staff and recorded in the patients file. All gum-chewing patients completed their course of gum chewing until bowel function."
89461278|NCT03669107|No Intervention|Control group|no gum
89461279|NCT05063110|Experimental|Treatment arm|300 mg of ITACITINIB will be administrated per os every day for 30 days, dose with reduction to 200 mg per safety is allowed if AEs are observed or if co-administered a strong CYP3A inhibitor
88942785|NCT01872702|Experimental|malaria elimination using DP and low-dose primaquine|Two villages randomly allocated to intervention (chemo-elimination) at each of the 4 sites (population approximately 500 people in each village). In these villages the entire population will be invited to receive three, monthly rounds of treatment with dihydroartemisinin-piperaquine and primaqunine to kill malaria parasites. The micro-epidemiology of malaria will be studied and prevalence and patterns of transmission used for comparison. NB, in Cambodia there will be no intervention villages and all four villages will be used to study the micro-epidemiology of malaria transmission in the absence of malaria elimination.
88942786|NCT01872702|No Intervention|Control villages|"Two villages randomly allocated to control (no chemo-elimination) at each of the 4 sites (population approximately 500 people in each village). In these villages only the micro-epidemiology of malaria will be studied and prevalence and patterns of transmission used for comparison. NB, in Cambodia there will be no intervention villages and all four villages will be used to study the micro-epidemiology of malaria transmission in the absence of malaria elimination.~From June 2013 to June 2014 Cambodia site conducted surveys with no medical intervention (treatment arm). In July 2015 Cambodia implemented the TCE protocol with two intervention and two control villages. Primaquine is not used in the TCE treatment regimen in Cambodia. Both studies were approved under OxTREC reference no. 1017-13 and 1015-13."
88942787|NCT01872728|Placebo Comparator|Control|placebo for the realization of the facial block and morphine for intraoperative analgesia
88942788|NCT01872728|Active Comparator|Levobupivacaine|Levobupivacaine for the realization of the facial block and placebo for intraoperative analgesia
88942789|NCT01872741|Active Comparator|Ruptured intracranial aneurysms|Pterional craniotomy Minipterional craniotomy
88942790|NCT01872741|Active Comparator|Unruptured intracranial aneurysms|Pterional craniotomy Minipterional craniotomy
88942791|NCT01872754|Active Comparator|2: Propofol|Control arm: the use of TCI of hypnotic (Propofol) during realization bronchial fibroscopy.
88942792|NCT01872754|Experimental|1: Remifentanil|Interventional arm: the use of TCI of morphinomimetic (Remifentanil) during realization bronchial fibroscopy.
88942793|NCT01872767||Cirrhotics/ Acute on chronic liver failure admitted to ICU|
88942794|NCT01872780|Active Comparator|rosiglitazone|avandia
88942795|NCT01872780|Active Comparator|genetic polymorphism|avandia CYP2C8 genotype
88942796|NCT01872806|Experimental|Experimental: Mobile phone radiation|Dialing mobile phone placed against the ear/chest for a duration of 15 minutes, before and after 15 minutes sham phone will be placed against the ear/chest.
88942797|NCT01872832|Experimental|5 mg RDEA3170|RDEA3170 5 mg or placebo fasted and fed
88942798|NCT01872832|Experimental|10 mg RDEA3170|RDEA3170 10 mg or placebo fasted and fed
88942799|NCT01872832|Experimental|15 mg RDEA3170|RDEA3170 15 mg or placebo fasted and fed
88942800|NCT01872832|Experimental|2.5 mg RDEA3170|RDEA3170 2.5 mg or placebo fasted and fed
88942801|NCT01872845|Active Comparator|Rosuvastatin|All study subjects will be received percutaneous coronary intervention (PCI) with Biolimus-eluting stent as index procedure at the time of enrollment After index procedure, patients will be randomly assigned to receive pravastatin 40mg or rosuvastatin 20mg in a 1:1 ratio. a> Test group: Pravastatin 40mg PO daily for 1year from the day of BES implantation b> Control group: Rosuvastatin 20mg PO daily for 1year from the day of BES implantation
88942802|NCT01872845|Experimental|Pravastatin|All study subjects will be received percutaneous coronary intervention (PCI) with Biolimus-eluting stent as index procedure at the time of enrollment After index procedure, patients will be randomly assigned to receive pravastatin 40mg or rosuvastatin 20mg in a 1:1 ratio. a> Test group: Pravastatin 40mg PO daily for 1year from the day of BES implantation b> Control group: Rosuvastatin 20mg PO daily for 1year from the day of BES implantation
88942803|NCT01872858|Active Comparator|Aspirin|Aspirin, 100mg, Q.D, p.o, 2yr
88942804|NCT01872858|Experimental|Cilostazol|cilostazol, 100mg, B.I.D, p.o, 2yr
88942805|NCT01872871|Placebo Comparator|local anasthetic drops|topical anaesthetic drop with placebo
88942806|NCT01872871|Active Comparator|Paracetamol|Topical anaesthetic drop with Paracetamol
88942807|NCT01872884|Experimental|General anaesthesia|General anaesthesia with mechanical ventilation. Sevorane Remifentanil. Bloodpressure control, systolic pressure 140-180 mmHg.
88942808|NCT01872884|Placebo Comparator|Sedation|Sedation with spontaneous breathing. Remifentanil. Bloodpressure control, systolic pressure 140-180 mmHg
89461280|NCT03668483|Experimental|Pulmonary Rehabilitation|A 6-min walk test, peripheral and respiratory muscle strength measurements, and a dyspnea rating scale Mmrc will be applied to the lung transplantation candidates who are trained in 3-month hospital-based preoperative exercise training in the Pulmonary Rehabilitation unit. The tests will be carried out at the beginning and end of rehabilitation.
89461281|NCT05062954|Experimental|Polyphenol-rich cranberry extract supplement standardized in PACs|Supplementation with polyphenol-rich cranberry extract standardized in PACs (1 capsule / day)
89461282|NCT05062954|Placebo Comparator|Placebo supplement|Supplementation with placebo (1 capsule / day)
89501865|NCT04227704|Experimental|Ketamine SC|Shortly after cesarean delivery of their baby, participants will receive a subcutaneous injection of 0.5 mg/kg of ketamine and a 40-minute intravenous infusion of 0.9% sodium chloride.
88942809|NCT01872897|Active Comparator|Sodium Alginate Double Action Tablets|Four Compound Sodium Alginate Double Action Chewable Tablets administered as a single dose
89461283|NCT03021005|Experimental|Self Testing Kit|"This group will be provided a free Food and Drug Administration-approved HIV self-testing home kit (OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test). Participants in this group will also be provided 5 referral cards to give to their partners and peers in the drug, sex, and social networks for them to request a free HIV self-testing kit from the I Want The Kit website."
89461284|NCT03021005|No Intervention|No Self Testing Kit|"This group will not receive a free Food and Drug Administration-approved HIV self-testing home kit (OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test). Participants in this group will not receive referral cards for their partners or peers for them to request a free HIV self-testing kit from the I Want The Kit website."
89461285|NCT02389478|Experimental|colostrums|Oropharyngeal administration of colostrums, every 4 hours，continue for 7days
89461286|NCT02389478|Other|Normal saline|Oropharyngeal administration of Normal saline,every 4 hours，continue for 7days
89461287|NCT02389400|Experimental|Experimental arm|methotrexate,1g/m2,iv.d1 cytosine arabinoside,0.1g/m2,iv.,d1-5
89461288|NCT02914457|Experimental|Electrophysiological Study|Subjects will receive pacing from one right ventricular lead and one left ventricular catheter/lead with multiple LV pacing spots during electrophysiological study procedure.
88942810|NCT01872897|Placebo Comparator|Placebo tablets|Single dose of 4 Placebo tablets
88942811|NCT01872923|Experimental|Amphinex based PCI of bleomycin|The photosensitiser Amphinex is activated by Laser to enhance the effect of Bleomycin
88942812|NCT01872936|Other|Miravirsen every other week dosing|Miravirsen will be dosed as single subcutaneous injections. Subjects will receive 5 weekly doses at 7 mg/kg, then 6 every other week doses at 5 mg/kg in combination with telaprevir and ribavirin.
88942813|NCT01872936|Other|Miravirsen monthly dosing|Miravirsen will be dosed as single subcutaneous injections. Subjects will receive 5 weekly doses at 7 mg/kg, then 3 monthly doses at 7 mg/kg in combination with telaprevir and ribavirin.
88942814|NCT01872962|Experimental|Induction chemotherapy+IMRT and concurrent cisplatin|Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 3 cycles before radiotherapy, and then receive intensity modulated-radiotherapy (IMRT), concurrently with cisplatin 100 mg/m² every 3 weeks for 3 cycles.
88942815|NCT01872962|Active Comparator|IMRT and concurrent cisplatin|Patients receive intensity modulated-radiotherapy (IMRT), concurrently with cisplatin 100 mg/m² every 3 weeks for 3 cycles.
88942816|NCT01872988|Active Comparator|Tenofovir treatment|Start to administer Tenofovir treatment 300mg PO QD within 2 weeks after the 1st TACE. Maximum duration of tenofovir treatment: 3 years.
88942817|NCT01872988|Placebo Comparator|Placebo|Start to administer placebo 1 Tab PO QD within 2 weeks after the 1st TACE. Maximum duration of tenofovir treatment: 3 years.
88942818|NCT01873001|Experimental|Abiraterone acetate + pioglitazone HCl|Participants will receive 15 mg pioglitazone on Day 1 (Period 1). On Day 8 (Period 2), participants will receive 1000 mg abiraterone acetate followed by 15 mg of pioglitazone one hour later.
88942819|NCT01873014|Experimental|high Iodine intake|
88942820|NCT01873014|Active Comparator|low Iodine intake|
88942821|NCT01873027|Experimental|OFDI-guided PCI|"OFDI-guided PCI and assessment by OFDI at pre-PCI and post-PCI~Follow-up contact at the time of hospital discharge, 8 months and 12 months after PCI."
88942822|NCT01873027|Active Comparator|IVUS-guided PCI|"IVUS-guided PCI and assessment by IVUS at pre-PCI and post-PCI~Follow-up contact at the time of hospital discharge, 8 months and 12 months after PCI."
89461289|NCT05047744|Experimental|Prosthesis Cohort|Surgery dual mobility Prosthesis
88942823|NCT01873040|Experimental|Social media plus information pages|Participants will have access to the vaccine social media website with information pages and social media features including discussion forums, blogs, chat with an expert, and ask an expert.
88942824|NCT01873040|Experimental|Information Pages|Participants will have website access to vaccine information pages.
88942825|NCT01873040|No Intervention|Usual Care|Participants will not have access to the vaccine website. They will receive pediatric care as usual.
89461290|NCT02389322|Experimental|5μg/ml ESAT6-CFP10 after BCG immunization|A within group paired comparison of 5μg/ mL ESAT6-CFP10 and TB-PPD in 48 person of study population II. The 5μg/ mL ESAT6-CFP10 and TB-PPD agents are given concomitantly to each volunteer in the right and left forearms 12 weeks after BCG immunization, according to a randomisation scheme .
88942826|NCT01873053|Experimental|1st group : WIN-34B 900mg|Patients assigned to 1st group take WIN-34B 450mg BID for 12weeks
88942827|NCT01873053|Experimental|2nd group : WIN-34B 1800mg|Patients assigned to 2nd group take WIN-34B 900mg BID for 12weeks
88942828|NCT01873053|Placebo Comparator|3rd group : Placebo|Patients assigned to 3rd group take Placebo BID for 12weeks
88942829|NCT01873066|Experimental|Closed-loop insulin delivery|Glucose level is controlled by the automated closed-loop glucose control system. After initial training with the closed-loop system devices, subjects will use the closed-loop system day and night at home for a total duration of 7 days (phase 1) and 21 days (phase 2).
88942830|NCT01873066|Active Comparator|real-time CGM alone|Glucose level will be controlled by usual insulin pump therapy in conjunction with real time continuous glucose monitoring (CGM) during the day and night over 7 days (phase 1) and 21 days (phase 2).
88942831|NCT01873079|Active Comparator|Esomeprazole|esomeprazole 40mg bd for 10 days
88942832|NCT01873079|Sham Comparator|Standard care|No other study drug or placebo will be given
88942833|NCT01873092||Patients with COPD|Patients who meet criteria for chronic obstructive pulmonary disease
88942834|NCT01873105|Experimental|Health team educational intervention|Agency for Healthcare Research and Quality (AHRQ) TeamSTEPPS approach will be used to redesign health team communication processes regarding preparation for discharge. This redesign will be followed by education for all health team members.
88942835|NCT01873105|No Intervention|Control pre-intervention|Usual care control before implementation of the health team communication intervention
88942836|NCT05855785|Experimental|The exercise group|The exercise group underwent 8-week, 3 times a week, 60-minute group exercise sessions, which were comprised of moderate-to-high intensity exercise and simultaneous cognitive tasks. The exercise group also performed moderate-intensity home aerobic exercises for at least 60 minutes per week.
89461291|NCT02389322|Experimental|10μg/ml ESAT6-CFP10 after BCG immunization|A within group paired comparison of 10μg/ mL ESAT6-CFP10 and TB-PPD in 48 person of study population II. The 10μg/ mL ESAT6-CFP10 and TB-PPD agents are given concomitantly to each volunteer in the right and left forearms 12 weeks after BCG immunization, according to a randomisation scheme .
89461292|NCT02389322|Placebo Comparator|5μg/ml ESAT6-CFP10 after placebo immunization|A within group paired comparison of 5μg/ mL ESAT6-CFP10 and TB-PPD in 48 person of study population II. The 5μg/ mL ESAT6-CFP10 and TB-PPD agents are given concomitantly to each volunteer in the right and left forearms 12 weeks after placebo controlled immunization, according to a randomisation scheme .
89461293|NCT02389322|Placebo Comparator|10μg/ml ESAT6-CFP10 after placebo immunization|A within group paired comparison of 10μg/ mL ESAT6-CFP10 and TB-PPD in 48 person of study population II. The 10μg/ mL ESAT6-CFP10 and TB-PPD agents are given concomitantly to each volunteer in the right and left forearms 12 weeks after placebo controlled immunization, according to a randomisation scheme.
89461294|NCT04993768|Experimental|TPN-101, Dose A|
89461295|NCT04993768|Experimental|TPN-101, Dose B|
89461296|NCT04993768|Experimental|TPN-101, Dose C|
89461297|NCT04993768|Placebo Comparator|Placebo|
89461298|NCT02665052|Experimental|Home-Based BATRAC|Home-based BATRAC training will consist of 45 minutes of high intensity bilateral reaching and rest periods using the BATRAC followed by 15 minutes of video guided transition to task training (TTT). These videos will be linked from the VA MyHealtheVet site to study specific Youtube videos of the study therapist demonstrating the exercise. Asynchronous communication between the therapist and participant will be completed using the MyHealtheVet secure messaging system.
89461299|NCT02665052|Experimental|Lab-based BATRAC plus TTT|Lab-based BATRAC will consist of 60 minutes of training in the lab (45 minutes using BATRAC and 15 minutes of TTT). BATRAC training will include high intensity bilateral reaching and rest periods followed by 15 minutes of therapist guided transition to task training (TTT).
89461300|NCT02665052|Placebo Comparator|Delayed Entry Usual Care|Participants randomized to this group will initially serve as a control for the first 6 weeks of the study and not receive any study interventions except the protocol study evaluations in the same time intervals as those receiving active interventions. They will also receive weekly phone calls to record general activity level. After serving as a control, this group will be entered into their randomized active intervention group of either lab-based BATRAC + TTT training, or Lab-based Robot+ TTT.
89461301|NCT03019289|Experimental|pridopidine|Pridopidine (TV-7820) capsules
89461302|NCT02389166|Experimental|Optiflow group|
88942837|NCT05855785|Other|The control group|The control group performed 60-minute light intensity home exercise, 4 times a week for 8 weeks.
89461303|NCT02389166|Active Comparator|Control group|
89461304|NCT03669029|Experimental|Week 6 Responders|In patients with clinical response at week 6, serum golimumab levels and anti-golimumab antibody levels will be correlated with clinical response.
89461305|NCT03669029|Experimental|Week 6 Non Responders|In patients without clinical response at week 6, golimumab treatment will be optimized.
89461306|NCT05059444||Cohort 1: Muscle invasive carcinoma of the bladder, ureter, or renal pelvis (stage II-III)|
89461307|NCT05059444||Cohort 2: Non-small cell lung cancer (stage II-III)|
89461308|NCT05059444||Cohort 3: Invasive breast carcinoma with all of the following:|"Clinical stage T1-4/N0-3/M0 at presentation AND~Completed preoperative systemic chemotherapy-containing regimen AND~Underwent definitive surgical resection of the primary tumor AND~Has pathological evidence of residual invasive carcinoma in the breast and/or axillary lymph nodes AND~Hormone receptor and HER2 status are known"
89461309|NCT05059444||Cohort 4: Stage IIb-III cutaneous melanoma or limited (resectable) stage IV melanoma|
89461310|NCT05059444||Cohort 5: Esophageal or gastroesophageal junction carcinoma (stage II-III)|
89461311|NCT05059444||Cohort 6: Gastric adenocarcinoma (stage II-III)|
88942838|NCT05855772|Experimental|Extracorporeal shock waves therapy[ESWT] + posture corrective exercise programs[PCEP]|Before proceeding with the exercise, apply a radial-type Extracorporeal shock waves. This applies to the main muscles with TrP, the upper trapezius and Leavator scapulae muscle. It is conducted twice a week at 1000 impulse, 60 mJ/m (2), and 5 Hz frequencies. In addition, a posture correction exercise program will be conducted along with ESWT. Muscles such as weakened deep neck flexors, middle trapezius muscles, lower trapezius muscles, and serratus anterior muscles will undergo strengthening exercises, while muscles such as shortened and overactive upper trapezius muscle, Leavator scapulae muscle, and sternocleidomastoid muscle will apply relaxation stretching. This will be conducted privately at home by providing exercise leaflets, and will be conducted for a total of four weeks with a 30-minute program three times a week.
89017689|NCT06139003|Experimental|3d Printed implant overdenture|patients will receive maxillary CD and mandibular 2-implant retained overdenture over locator attachment constructed by digital technique.
89461312|NCT05059444||Cohort 7: Surgically resected pancreatic adenocarcinoma|
89461313|NCT05059444||Cohort 8: Invasive squamous cell carcinoma of the head and neck|Includes stage I-III oral cavity, oropharynx, hypopharynx, larynx, nasopharynx, nasal cavity, paranasal sinus, and salivary gland cancers.
89461314|NCT05059444||Cohort 9: High-risk epithelial ovarian or Fallopian tube carcinoma|Defined as stage IC-III or stage I that has high grade (grade 3-4) or clear cell histology).
89461315|NCT05059444||Cohort 10: High-risk endometrial carcinoma|Defined as having any of the following: serous or clear cell adenocarcinoma histology (any stage), grade 3 or 4 deeply invasive (T1b or greater) endometrioid carcinoma, stage III disease (any histology).
89461316|NCT05059444||Cohort 11: High-risk renal cell carcinoma|Defined as high grade (grade 3-4) stage II, stage III or limited (resectable) stage IV treated with curative intent.
89461317|NCT02385578|No Intervention|The control group|no intervention
89461318|NCT02385578|Experimental|The experimental group|an educational intervention
89501866|NCT04227704|Experimental|Ketamine IVI|Shortly after cesarean delivery of their baby, participants will receive a subcutaneous injection of 0.9% sodium chloride and a 40-minute intravenous infusion of 0.5 mg/kg ketamine.
89501867|NCT03608371|Experimental|BTRX-246040 Cohort 1|BTRX-246040 will be administered orally 40 mg (1capsule) in Cohort 1
89017690|NCT06139003|Experimental|Conventionally constructed implant overdenture|patients will receive maxillary CD and mandibular 2-implant retained overdenture over locator attachment constructed by conventional technique.
89017691|NCT06138964|Experimental|siSPARC microneedle patch|siSPARC microneedle patch
89017692|NCT06138964|Experimental|siSPARC + siLR4A microneedle patch|siSPARC + siLR4A microneedle patch
89017693|NCT06138938|No Intervention|Control Group|In the control group, abdominal irrigation as described in the study group was not performed.
89461319|NCT03668015|Experimental|Group A (Xylitol then sorbitol gum)|"Subjects were randomly allocated to a group and entered a 4-week washout period during which no gum was chewed, followed by a 3-week treatment period (treatment period 1) during which Group A used Xylitol gum.(2 gum pieces, 3 times daily after meals for 6 minutes).Then underwent another 4-week washout period before entering treatment period 2 during which Group A used Gum Sorbitol"
89461320|NCT03668015|Experimental|Group B (Sorbitol then xylitol gum)|"Subjects were randomly allocated to a group and entered a 4-week washout period during which no gum was chewed, followed by a 3-week treatment period (treatment period 1) during which Group B used sorbitol gum. Group B used Gum Sorbitol (2 gum pieces, 3 times daily after meals for 6 minutes).Then underwent another 4-week washout period before entering treatment period 2 during which Group B used Gum xylitol"
89461321|NCT03668405|Experimental|Lu AF20513 high dose|
89461322|NCT02385734|Experimental|Concentrated growth Factor Membrane|Autogenous platelet and leukocyte fibrin material was obtained from blood.
89461323|NCT02385734|Active Comparator|Coronally Advanced Flap|Periodontal plastic surgery procedure in the treatment of gingival recession
89461324|NCT03020927|Active Comparator|Therapist Delivered|Children in the therapist-delivered condition will receive two, 60-minute long sessions of Reciprocal Imitation Training each week for ten consecutive weeks. These sessions will be delivered by trained graduate, undergraduate, and post-graduate research staff. Parents will be permitted to observe sessions via live video, but will not be directly involved in intervention.
89461325|NCT03020927|Experimental|Parent + Therapist Delivered|Children in the parent + therapist-delivered condition will receive one, 60-minute long session of Reciprocal Imitation Training each week for ten consecutive weeks. These sessions will be delivered by trained graduate, undergraduate, and post-graduate research staff. During the same period of time, parents/guardians of children will receive one, 60-minute long parent education session per week with graduate and post-graduate research staff, aimed at teaching parents to implement Reciprocal Imitation Training at home with the child.
89461326|NCT02385500|Placebo Comparator|Placebo|Subjects will be started on placebo tablets, similar to fesoterodine 4 mg, and will have the option to escalate as well.
89461327|NCT02385500|Experimental|Fesoterodine|Drug intervention of fesoterodine 4 mg once a day in the morning after the two-week washout period. They will have the option to escalate to 8 mg (2 tablets of 4 mg each) after 4 weeks on fesoterodine. Patients will have the option to go back to one tablet (i.e., 4 mg) at any time in the study.
89461328|NCT02385422|Experimental|Carvedilol|Carvedilol，6.25mg-25mg/d,oral,6 months
89461329|NCT02385422|Active Comparator|Propranolol|Propranolol,30mg-160mg/d,oral,6 months
89461330|NCT02520388|Experimental|HLD200 (methylphenidate)|"Experimental: HLD200 (methylphenidate)~The investigational drug for this study is HLD200 MPH MR capsules comprised of the active pharmaceutical ingredient (MPH) in a dual-coated drug-layered core. Following a minimum 72-hour washout, subjects will be randomized (1:1) to double-blind HLD200 to be taken once daily during the evening for a period of 3-weeks prior to testing."
89461331|NCT02520388|Placebo Comparator|Placebo|Placebo capsules will be composed of microcrystalline cellulose beads in place of MPH containing beads found in the HLD200 capsules. Following a minimum 72-hour washout, subjects will be randomized (1:1) to double-blind placebo to be taken once daily during the evening for a period of 3-weeks prior to testing.
89017694|NCT06138938|Experimental|Study Group|All blood clots and other remnants were manually externalized with a sponge holder forceps from the pelvic areas following the uterine incision closure. Then, 1,000 mL of warm saline irrigation was poured into the vesicouterine cavity and aspirated as much as possible in the reverse Trendelenburg position using an aspirator, carefully avoiding any contact with the intestines.
89017695|NCT06138912||Age|20-29, 30-39, 40-49, 50-59, 60-69, and 70-79
89017696|NCT06138912||sex|each group included 10 subjects
89017697|NCT06138886|Experimental|Calisthenics exercise group|This group includes 30 burned patients who will perform calisthenics exercises program for 3 months (3 times/week) in addition to their traditional physical therapy program and medical treatment.
89017698|NCT06138886|Experimental|Pulsed electromagnetic therapy group|This group includes 30 burned patients who will receive pulsed electromagnetic therapy for 3 months (3 times/week) in addition to their traditional physical therapy program and medical treatment.
89017699|NCT06138886|Experimental|Calisthenics exercises and pulsed electromagnetic therapy group|This group includes 30 burned patients who will perform calisthenics exercises program and receive pulsed electromagnetic therapy for 3 months (3 times/week) in addition to their traditional physical therapy program and medical treatment.
89461332|NCT03667937|Experimental|CUTIMED|"After an initial culture to determine the bacterial load by smear, we will proceed to the cure of the ulcer by washing the area with physiological saline solution and to mechanical debridement, if necessary, to apply the CUTIMED dressing. It will be covered with a secondary gauze dressing and a double compression bandage with a normal crepe bandage.~If the wound exudate decreases, or the removal of the dressing is difficult, it will be changed to CUTIMED gel; in case of abundant exudate, the use of alginate without silver will be allowed for the treatment, because it is neutral with the bacterial load, placed on the CUTIMED dressing.~Primary and secondary end-points will be measured at baseline and at 4, 8 and 12 weeks, except quality of life (only baseline and at 12 weeks)."
89461333|NCT03667937|Active Comparator|AQUACEL silver|"After an initial culture to determine the bacterial load by smear, we will proceed to the cure of the ulcer by washing the area with physiological saline solution and to mechanical debridement, if necessary, to apply Aquacel-Ag. It will be covered with a secondary gauze dressing and a double compression bandage with a normal crepe bandage.~Primary and secondary end-points will be measured at baseline and at 4, 8 and 12 weeks, except quality of life (only baseline and at 12 weeks)."
89017700|NCT06138873|Experimental|AI-guided ablation|Use of AI guidance to conduct the ablation
89017701|NCT06138873|Active Comparator|non-AI guided ablation|Ablation without AI guidance, AI values masked to the operator.
89461334|NCT03666767||Oesophageal atresia (OA) +/- tracheo-oesophageal fistula (TOF)|
89461335|NCT03666767||Congenital diaphragmatic hernia (CDH)|
89461336|NCT03666767||Intestinal atresia (IA)|
89461337|NCT03666767||Gastroschisis|
89461338|NCT03666767||Exomphalos|
89461339|NCT03666767||Anorectal malformation (ARM)|
89461340|NCT03666767||Hirschsprung's disease|
89461341|NCT03666689||MHV reconstruction|Both ends of middle hepatic vein tributaries V8 and/or V5 of modified right lobe graft will be anastomosed to side of a single synthetic graft which will be anastomosed to recipient's middle/left hepatic vein orifice.
89461342|NCT03666689||Separate tributaries reconstruction|End of V8 middle hepatic vein tributary of modified right lobe graft; if present, will be anastomosed to end of a synthetic graft which will be anastomosed to recipient's middle/left hepatic vein orifice, and end of V5; if present; will be anastomosed to end of a synthetic graft which will be anastomosed to recipient's Inferior Vena Cava directly.
89461343|NCT05043922|Experimental|CYH33|40mg daily
89461344|NCT02668640||Participants with RA receiving adalimumab|40 mg adalimumab via subcutaneous (SC) injection every other week (eow) for 24 weeks
89461345|NCT05043766|Experimental|PF614|Part A will utilize a randomized, open-label, multiple-ascending dose design with up to 3 separate dose groups of 8 subjects. Within each dose group, subjects will be randomized to receive repeated BID doses, planned to be 12 hours apart over a 5 day period, for a total of 9 doses. Dose escalation to Dose Groups 2 and 3 will follow a review of pharmacokinetic, safety and tolerability data up to Day 10 of the preceding group. The doses or dosing regimen for Dose groups 2 and 3 may be modified based on a review of the data.
89461346|NCT05043766|Active Comparator|Part B Compare Bioavailability and Bioequivalence|"Part B will utilize an open-label, single-dose, randomized, 4-way crossover design. Following confirmation of eligibility, subjects will be randomized to receive each of the single oral doses of study drugs (one at each treatment period).~PF614 100 mg administered under fasted conditions; PF614 100 mg administered under fed conditions; OxyContin 40 mg administered under fasted conditions; OxyContin 40 mg administered under fed conditions"
89461347|NCT05043298|Experimental|IBI360|
89461348|NCT04991818|Experimental|Pregnant women or children 0-5 years of age|Pregnant women in third trimester or children 0-5 years of age
89461349|NCT02389010|Experimental|Allogeneic Cord Blood Platelet Gel-CBPG|For the medication of patients, one CBPG unit (mean volume 10 mL, range 5-15; mean platelet concentration 1 x 109/L, range 0.8 - 1.2 x 109/L. 10 mL in plasma) will be administered every 3-4 days. CBPG units, cryopreserved and stored in a plastic bag in a -80°C freezer, will be thawed at 37°C in a waterbath and activated with Calcium gluconate and immediately transported to sites of clinical use and applied to the skin ulcer without breaking the sterility chain.
89461350|NCT02389010|Active Comparator|Standard Local Medications-SLM|1 administration every 3-4 days for 4 weeks. Each clinical center will use their validated standard local medications. Details and specifications of the local standard medication procedures will be collected from each participating centre.
89461351|NCT05042830|Active Comparator|Active group|Birch allergic subjects receiving birch pollen extract challenge
89461352|NCT05042830|Placebo Comparator|Control group|Birch allergic subjects receiving saline
89461353|NCT02388854||Endometriosis|Sardinian Women with diagnosis of endometriosis
89461354|NCT02388854||Controls|Healthy blood Sardinian donors
89461355|NCT03462368|Active Comparator|Control|Root surface treatment by scaling and root planing
89461356|NCT03462368|Experimental|antimicrobial photodynamic therapy|Root surface treatment by antimicrobial photodynamic therapy
89461357|NCT03462368|Active Comparator|Photobiomodulation|Treatment of the whole surgical site with laser
89461358|NCT02663882|Experimental|smoking-related self control task|self control practice - smoking related task
89461359|NCT02663882|Active Comparator|Non-smoking-related self control task|self control practice - non-smoking related task
89461360|NCT02388620|Experimental|Normal Hepatic Function|Normal hepatic function; matched demography to hepatic impairment cohorts
89461361|NCT02388620|Experimental|Mild Hepatic Impairment|Child-Pugh Classification A (score 5-6)
89461362|NCT02388620|Experimental|Moderate Hepatic Impairment|Child-Pugh Classification B (score 7-9)
89461363|NCT02388620|Experimental|Severe Hepatic Impairment|Child-Pugh Classification C (score 10-15)
89461364|NCT02388698|Experimental|Cervical Swab, PET-CT and plasma HPV|Participants will have a cervical swab, and plasma HPV at baseline. In addition, a plasma HPV test drawn after completion of radiation. 3 months post chemoradiation, patients will have a PET-CT and plasma HPV completed. Plasma HPV will be drawn at progression/recurrence, if applicable.
89461365|NCT02383238|Active Comparator|Dapagliflozin|Dapagliflozin, 10 mg/day, oral administration, 6 weeks
89461366|NCT02383238|Placebo Comparator|Placebo|Placebo, oral administration, 6 weeks
89461367|NCT03011333|Experimental|Group 1: HTX-011|HTX-011 (bupivacaine/meloxicam), 60 mg/1.8 mg via nerve block.
89461368|NCT03011333|Experimental|Group 2: HTX-011|HTX-011(bupivacaine/meloxicam), 120 mg/3.6 mg via nerve block.
89461369|NCT03011333|Experimental|Group 3: HTX-011|HTX-011(bupivacaine/meloxicam), 240 mg/7.2 mg via nerve block.
89461370|NCT03011333|Experimental|Group 4: HTX-011|HTX-011 (bupivacaine/meloxicam), 400 mg/12 mg via nerve block.
89461371|NCT03011333|Experimental|Group 5: HTX-011|HTX-011 (bupivacaine/meloxicam), 400 mg/ 12 mg via instillation.
89461372|NCT03011333|Active Comparator|Group 6: Bupivacaine HCl|Bupivacaine HCl without epinephrine, 50 mg via nerve block.
89461373|NCT03011333|Placebo Comparator|Group 7: Saline Placebo|Saline placebo via nerve block.
89461374|NCT02383004|Experimental|Acupuncture|"Same premedication, induction and maintenance protocol as the No Acupuncture (Standard of Care) group.~The intervention will be placement of 4 acupuncture needles. The needles will be placed after inhalational anesthesia induction and removed prior to leaving the operating room. A total of 4 needles will be placed, one in each wrist at the HT7 point and one in each ear at the shen men point."
89501868|NCT03608371|Experimental|BTRX-246040 Cohort 2|BTRX-246040 will be administered orally 80 mg (2 capsules) in Cohort 2
89501869|NCT03608371|Experimental|BTRX-246040 Cohort 3|BTRX-246040 will be administered orally120 mg (3 capsules) in Cohort 3
89461375|NCT02383004|No Intervention|No Acupuncture (Standard of Care)|"If needed, the patient will receive a standard does of oral midazolam (0.5 mg /kg or less, up to 15mg) plus acetaminophen 12.5 mg/kg (V group). If the patient does not require premedication with midazolam, oral acetaminophen 12.5mg/kg will be given alone (NV group).~Induction of anesthesia by mask ventilation with sevoflurane in 50% nitrous oxide mixed with 50% oxygen. Sevoflurane will be incrementally titrated from 0% up to 8%. Nitrous oxide will be discontinued after induction. Anesthesia will be maintained with sevoflurane in an oxygen/air mixture. Sevoflurane concentration will be titrated to maintain the adequate depth of anesthesia. Prior to leaving the operating room, a dose of ketorolac 0.5mg/kg will be given intramuscularly."
89461376|NCT02383316|Experimental|Noonan Syndrome Children|"Children with Noonan Syndrome will be compared with age- and sex-matched healthy children. We hypothesize than Noonan Syndrome children have an increased insulin sensitivity compared to GHD children.~Study parameters will be collected including: clinical measurements (height, weight, body mass index, waist circumference, and blood pressure), glucose and insulin levels at baseline and after an oral glucose tolerance test (OGTT), body composition measured by dual-energy x-ray absorptiometry (DXA)."
89017702|NCT06138847||Group I|Group I consisted of children with epilepsy who were only taking one type of ASMs, either levetiracetam or carbamazepine
89461377|NCT03011099|Experimental|Robotic exoskeleton training|During the training, subjects will wear a lower extremity exoskeleton robotic walking device. Subjects will participate in individualized treatment sessions which may include: sit to stand, static and dynamic standing balance, weight shifting, walking, turning, and stand to sit. Each training session will last up to 90 minutes (60 minutes of training with 30 minutes for setup, don/doff of device) and training will be held 5 days per week for 3 weeks with a total of 15 sessions. During the training period, subjects will be required to maintain the same amount and level of regular daily physical activity and exercise.
89461378|NCT03011099|Active Comparator|Conventional Physical Therapy|During the training, subjects will receive conventional physical therapy that is designed to facilitate/promote gait. This will include individualized treatment sessions for each subject and may involve stretching, strengthening, balance training, standing, and gait training. Subjects will not be able to participate in any form of robotic assisted or body weight supported treadmill training. Each training session will last up to 60 minutes and training will be held 5 days per week for 3 weeks with a total of 15 sessions. Consistent with the RET group, subjects will be required to maintain the same amount and level of regular daily physical activity and exercise during study period.
89461379|NCT02382926|Experimental|contactless heart-, breathing rate, ECG|
89461380|NCT03667157|Active Comparator|moderate-to-severe Graves Orbitopathy|active, moderate-to-severe Graves Orbitopathy according to EUGOGO.
89461381|NCT03667157|Active Comparator|Dysthyroid Orbit Neuropathy|Dysthyroid Orbit Neuropathy according to EUGOGO
89017703|NCT06138847||Group II|Group II comprised forty-one age and sex-matched healthy children as a control group.
89461382|NCT02382770||Open Abdomen patients|All patients underwent to open abdomen procedure
89017704|NCT06138834|Experimental|Low-dose Y-6 sublingual tablet group|One Y-6 sublingual tablet (each tablet contains 25 mg Cilostazol and 6 mg Dexborneol), one placebo of Y-6 sublingual tablet (each tablet contains 0 mg Cilostazol and 0.06 mg Dexborneol to simulate the cool taste of Y-6 sublingual tablets when taken), and two halves Cilostazol mimicry tablets (each tablet contains 0 mg Cilostazol).
89017705|NCT06138834|Experimental|High-dose Y-6 sublingual tablet group|Two Y-6 sublingual tablets (each tablet contains 25 mg Cilostazol and 6 mg Dexborneol), and two halves Cilostazol mimicry tablets (each tablet contains 0 mg Cilostazol).
89201790|NCT02556294|Experimental|Self-acceptance behavioral intervention|The intervention will consist of individual and 4 group counseling sessions and 6 individual counseling sessions. The individual sessions are focused on specific individualized risk reduction plans, whereas the group sessions are focused on increasing self-acceptance and reducing HIV risk. Additionally, participants in this arm will receive HIV and STI counseling and testing.
89201791|NCT02556294|Other|Comparison/Control|The comparison group will receive HIV and STI counseling and testing.
89201792|NCT00776490|Experimental|1|Glimepiride 1 MG Tablets of ranbaxy
89461383|NCT03667859||Women undergoing Brachytherapy|Women with either uterine or cervical malignancy treated primarily by brachytherapy.
89461384|NCT03667859||Women undergoing Pelvic Radiation|Women with either uterine or cervical malignancy treated primarily by pelvic radiation.
89461385|NCT04570397|Experimental|Interventional arm|ravulizumab
89461386|NCT04570397|No Intervention|Control arm|patients in this arm will recieve standard care
89201793|NCT00776490|Active Comparator|2|AMARYL® 1 mg tablets
89201794|NCT00779844|Experimental|1|obese patients
89201795|NCT00779844|Active Comparator|2|lean patients
89461387|NCT02385188|Experimental|Imiquimod|Topical 5% imiquimod cream will be applicated to the vulvar skin lesion 3 times a week during 16 weeks.
89461388|NCT02385032|Experimental|AB|Ursodiol followed by URSO Forte
89461389|NCT02385032|Experimental|BA|URSO Forte followed by Ursodiol
89461390|NCT02384798|Experimental|ventilatory support|noninvasive ventilatory support to 5cmH2O used before the session of interval training and resistance exercises performed three times a week for 12 weeks
89461391|NCT02384798|Active Comparator|interval training|sessions of interval training and resistance exercises performed three times a week for 12 weeks
89461392|NCT02384954|Experimental|Phase I/II ALT-803 w/rituximab for rel/ref iNHL|
89017706|NCT06138834|Experimental|Low-dose Cilostazol group|Two tablets of placebo of Y-6 sublingual tablets (each tablet contains 0 mg Cilostazol and 0.06 mg Dexborneol to simulate the cool taste of Y-6 sublingual tablets when taken), one half Cilostazol tablet (each tablet contains 50 mg Cilostazol), and one half Cilostazol mimicry tablet(each tablet contains 0 mg Cilostazol).
89201796|NCT00773214|Experimental|exercise|
89461393|NCT02384876|Experimental|Ephedrine, dose : 0.6, 0.8, 1.0, 1.2 and 1.4 mg/kG|Dose escalation: 6 successive cohorts with a maximal increasing dose
89461394|NCT02384876|Active Comparator|Ephedrine, dose : 0.1 mg/kG, reference dose|Reference dose
88942839|NCT05855772|Active Comparator|posture corrective exercise programs[PCEP]|Only posture correction exercise programs are conducted. Muscles such as weakened deep neck flexors, middle trapezius muscles, lower trapezius muscles, and serratus anterior muscles will undergo strengthening exercises, while muscles such as shortened and overactive upper trapezius muscle, Leavator scapulae muscle, and sternocleidomastoid muscle will apply relaxation stretching. This will be conducted privately at home by providing exercise leaflets, and will be conducted for a total of four weeks with a 30-minute program three times a week.
88942840|NCT05855720||Intervention Group (IG)|Patients being treated in FIT model project
89461395|NCT02384642|Active Comparator|COMPASS|The COMPASS program will involve a structured intervention for girls between the ages of 10-14 that is intended to engage adolescent girls, those who are influential in their lives, service providers and other stakeholders, with the ultimate goal of co-creating environments in which girls are valued and safe. The program is centered on establishing or supporting community-supported safe spaces for girls where they can come and gather among themselves and participate in a structured life-skills curriculum.
89461396|NCT02384642|Experimental|COMPASS plus parenting|In the COMPASS plus parenting intervention arm, girls will receive the COMPASS intervention, and In addition to the safe spaces for girls, the COMPASS project will also implement structured activities for the parents and caregivers of participants. The study will examine the relative impact of the parenting initiative in addition to the program for adolescent girls. The study will seek to determine whether the structured intervention with girls' parents has an added impact on outcomes improve girls' safety and well-being.
89461397|NCT02384720||A|Gender: 10 Males, 10 Females
89461398|NCT02384720||B|Gender: 10 Males, 10 Females
89461399|NCT02384720||C|Gender: 10 Males, 10 Females
89461400|NCT03013985|Experimental|Basal bolus insulin with glargine U300 and glulisine insulin|Subjects treated with insulin prior to admission will receive 80% of the total daily dose (TDD) given as basal bolus insulin regimen with glargine U300 once daily plus rapid-acting glulisine insulin before meals. In insulin-naïve subjects treated with oral agents, the oral antidiabetic drugs will be discontinued and the bolus insulin dose described above will be given. Half of TDD will be given as glargine U300 and half as glulisine. To prevent hypoglycemia, if a subject is not able to eat, the dose of glulisine will be held.
89461401|NCT03013985|Active Comparator|Basal bolus insulin with glargine U100 and glulisine insulin|Subjects treated with insulin prior to admission will receive 80% of the total daily dose (TDD) given as basal bolus insulin regimen with glargine U100 once daily plus rapid-acting glulisine insulin before meals. In insulin-naïve subjects treated with oral agents, the oral antidiabetic drugs will be discontinued and the bolus insulin dose as described above will be given. Half of TDD will be given as glargine U100 and half as glulisine. To prevent hypoglycemia, if a subject is not able to eat, the dose of glulisine will be held.
89461402|NCT02377388|Active Comparator|treatment: DPP4 -i|"Use of DPP4-i :~sitagliptin 50 mg (if glomerular filtration rate-GFR <50 ml/min at randomization) or 100 mg (if GFR>50 ml/min at randomization),during 30 days,once-daily(OD)~OR~saxagliptin 2,5 mg (if glomerular filtration rate-GFR <50 ml/min at randomization) or 5 mg (if GFR>50 ml/min at randomization),during 30 days,once-daily(OD)"
89461403|NCT02377388|Placebo Comparator|control|placebo tablets identical to active comparator,administered according to GFR at randomization,during 30 days,OD
89461404|NCT03016403|Experimental|Stepped-Care Intervention|Intervention strategies are grounded in evidence-based Cognitive Behavioral Therapy (CBT), that includes stress management and relaxation treatment strategies and coping skills training. Treatment strategies have been adapted from the Transactional Model of Stress and Coping (TMSC), a theoretical model that predicts that individuals who are able to cope and adapt to the stress related to cancer treatment or caregiving will report less psychological distress than those unable to cope.
89501870|NCT03608371|Placebo Comparator|Placebo Cohorts 1-3|Placebo will be administered orally at the same number of capsules as active drug at each Cohort. Placebo capsules will consist of inactive ingredients and look identical to BTRX-246040.
89501871|NCT03720613||Naldemedine|Patients with chronic non-cancer pain who initiated naldemedine treatment for opioid-induced constipation.
88942841|NCT05855720||Control Group (CG)|Patients being treated in standard care (control hospitals)
88942842|NCT05855707|Experimental|maximum tolerated dose|"x10e6 WJ-MSC/kg/infusion for 3 weekly infusions 1.5x10e6 WJ-MSC/kg/infusion for 3 weekly infusions~x10e6 WJ-MSC/kg/infusion for 3 weekly infusions"
88942843|NCT05855655|Experimental|Mindfulness-Based Queer Resilience (MBQR)|MBQR is an online, Zoom-based mindfulness course that meets 2.5 hour per week for ten weeks, facilitated by queer mindfulness teachers, with weekly home practice and additional reflection and reading activities that can be completed by participants independently via study website portal. In addition to the 10 weekly sessions there is an all-day retreat (6hrs) that takes place around week 6. The participants also meet one-on-one with the instructor(s) at the beginning and middle of class for a 30-minute welcome call and check in.
88942844|NCT05855655|Active Comparator|Health Education|"The online Health Education course is a self-paced program that can be largely completed independently (no group meeting, no all-day) by control group participants. The ten weekly modules are estimated to take around 30 to 90 minutes each to complete and consist of readings, videos, infographics, and other related activities (e.g., reflections, quizzes).~Participants randomized to the control will be offered an optional MBQR-hybrid course after the 6-month follow-up assessment is complete. MBQR-hybrid is an online-based mindfulness course asynchronously facilitated by queer mindfulness teachers, with weekly home practice and additional reflection and reading activities that can be completed by participants independently via study website portal. Participants will also have the option of participating in weekly live 1-hour sessions. MBQR-hybrid is designed to be completed within a 3-months time frame (10 modules that can be paced to complete in a 10-14 weeks time frame)."
88942845|NCT05855642||Patients|All patients presented with degenerative or traumatic cervical spine matched the inclusion criteria will enrolled in our study from April 2023 to April 2024.
88942846|NCT05855629|Other|Topical Adapalene, Benzoyl Peroxide Gel|
88942847|NCT05855629|Other|Oral Lactobacillus Rhamnosus, D-chiro-inositol, Inulin Capsule|
88942848|NCT05855629|Other|Topical Adapalene,Benzoyl Peroxide Gel,Oral Lactobacillus Rhamnosus,D-chiro-inositol,Inulin Capsule|
88942849|NCT05855616|Experimental|"Group chlorhexidine dressing"|CHG Chlorhexidine Gluconate dressing
88942850|NCT05855616|Other|"Group solution"|2% aqueous-based chlorhexidine solution and covering with a semi-permeable self-adhesive polyurethane dressing.
89017707|NCT06138834|Experimental|High-dose Cilostazol group|Two tablets of placebo of Y-6 sublingual tablets (each tablet contains 0 mg Cilostazol and 0.06 mg Dexborneol to simulate the cool taste of Y-6 sublingual tablets when taken), and two halves Cilostazol tablet (each tablet contains 50 mg Cilostazol).
89017708|NCT06138834|Placebo Comparator|Placebo group|Two tablets of placebo of Y-6 sublingual tablets (each tablet contains 0 mg Cilostazol and 0.06 mg Dexborneol to simulate the cool taste of Y-6 sublingual tablets when taken), and two halves Cilostazol mimicry tablets (each tablet contains 0 mg Cilostazol).
89461405|NCT03016403|Active Comparator|Enhanced Usual Care|Denver Health, St. Mary's and St. Joseph's hospitals provide supportive mental health care for patients such as printed materials, support groups, crisis counseling, and specialized care (e.g., psychiatric medication). Because the amount of usual mental health care that each patient receives varies at each site, the investigators will standardize and monitor the usual care arm across the three sites with an enhanced usual care condition.
89461406|NCT02382536||Infusion set|Each subject will receive a total of 4 simultaneous subcutaneous infusions of insulin diluent, two using the investigational device (BD Scarlett Infusion Set) and two using the the comparator (Medtronic QuickSet Infusion Set).
89461407|NCT02382380|Experimental|Gadoterate|Patients who choose to receive Gadoterate will receive an MRI exam with standard pre-contrast and Gadoterate-enhanced acquisitions (0.2 mL/kg). The MRI protocol utilized in the study will be comprised of the standard Body protocols (routine abdomen, liver-pancreas, renal, prostate, angiography) as well as the standard Neurologic exam protocols (routine brain, orbital, brainstem, neck, angiography).
89461408|NCT02382380|Other|No Gadoterate|Patients who choose not to receive Gadoterate will receive an MRI exam with no Gadolinium contrast. MRI protocols utilized in the study will be comprised of the standard Body protocols (routine abdomen, liver-pancreas, renal, prostate, angiography) as well as the standard Neurologic exam protocols (routine brain, orbital, brainstem, neck, angiography).
89461409|NCT02382302|Experimental|Telemedicine system|Telemedicine system
89461410|NCT02382224|Experimental|Worry Exposure for GAD|WE is an optimized protocol that incorporates elements of CBT, without the addition of other miscellaneous methods of treatment. A therapist manual will be used and followed at all times to ensure standardized delivery of the program. Interventions that uniquely focus on addressing GAD symptoms will include confronting physical or imagined stimuli through in vivo exposure and WE respectively. Avoidance behaviors will be monitored and reduced systematically, an outcomes will be assessed at baseline, during the 12-week intervention, and at 6-month follow-up.
89461411|NCT02382224|Placebo Comparator|12-week Waitlist|Those who are randomized to the waitlist condition will wait for 12 weeks before beginning the worry exposure.
89461412|NCT02382458|Experimental|Lifestyle intervention|Participants will receive a year-long comprehensive, dietary, exercise, and stress management intervention. They will be asked to bring a partner of their choosing with them for support. The intervention will include a behavioral program to reduce inflammation.
89461413|NCT02382458|Active Comparator|Information intervention|Participants will receive a year-long intervention that will involve receiving weekly (for the first 3 months) and then monthly (for the following 9 months) newsletters on cancer prevention and control (via e-mail or mail) that will provide the participant with information about cancer prevention and control strategies.
89461414|NCT02377310||All patients|All patients will undergo coronary physiological study with measurement of resting Pd/Pa, iFR™, hyperaemic iFR and FFR.
89461415|NCT02377154|Other|Opthalmologically healthy individuals|Slit lamp, Autorefractor, IOLMaster 500, Pentacam HR, LenStar LS900, VERION Image Guided System
89461416|NCT02377232|Active Comparator|Usual Care Outreach for Colon Cancer Screening|Receives standard of care outreach concerning colon cancer screening.
89461417|NCT02377232|Active Comparator|Decision Aid for Colon Cancer Screening|Receives colon cancer screening decision aid intervention in addition to outreach.
89461418|NCT02382146|Experimental|dexamethasone and ondansetron|dexamethasone 8 mg with ondansetron 4mg administered in group DO
89461419|NCT02382146|Active Comparator|dexamethasone and dimenhydrinate|dexamethasone 8 mg with dimenhydrinate 1mg/kg administered in group DD
89461420|NCT02382068|Experimental|Supportive care (intratympanic dexamethasone)|Patients receive dexamethasone via intratympanic injection in one ear and placebo via intratympanic injection in the other ear. Cisplatin standard of care treatment.
89461421|NCT02376842|Active Comparator|Severe sepsis early warning best practice alert|Patients in this arm will actively generate the alert.
89461422|NCT02376842|Placebo Comparator|Standard care|This arm will be the current standard of care and will not generate the alert.
89461423|NCT02520310|Experimental|AVJ-514|The AVJ-514 system
89461424|NCT02381912||Hematuria - NMIBC|Primary hematuria due to NMIBC.
89461425|NCT02381912||Hematuria - other cause|Other non-malignant cause of hematuria.
89461426|NCT02381600|Experimental|Intervention group- vitamin D|Include patients aged 65 years and older that are found to have below-normal serum levels of vitamin D on routine laboratory testing. After providing informed consent (the study was submitted for approval by the Ethics Committee of the Clalit Health Services) eligible subjects will undergo cognitive and affective assessment
89461427|NCT03113084|Experimental|Group Sodium Heparin UQ First|The participants will receive the Sodium heparin UQ subcutaneous drug administration at first period and the Sodium heparin FK subcutaneous drug administration at second period
89461428|NCT03113084|Experimental|Group Sodium Heparin FK First|The participants will receive the Sodium heparin FK subcutaneous drug administration at first period and the Sodium heparin UQ subcutaneous drug administration at second period
89461429|NCT02384408|Placebo Comparator|Control|Control Group: Women without hormone replacement therapy. Transvaginal Ultrasound - Endometrial Thickness; Endometrial Biopsy. Endometrial Immunohistochemical Study
89501872|NCT03720613||Lubiprostone|Patients with chronic non-cancer pain who initiated lubiprostone treatment for opioid-induced constipation.
89501873|NCT03720613||Naloxegol|Patients with chronic non-cancer pain who initiated naloxegol treatment for opioid-induced constipation.
89017709|NCT06138821|Active Comparator|ESG + GLP-1RA treatment|Endoscopic sleeve gastroplasty suturing procedure with a prescription regimen of semaglutide (2.4 mg injection per week) for 12 months.
89017710|NCT06138821|Active Comparator|ESG Only|Endoscopic sleeve gastroplasty suturing procedure.
89017711|NCT06138821|Active Comparator|GLP-1RA Only|Semaglutide prescription (2.4mg injection per week) regimen for 12 months.
89461430|NCT02384408|Experimental|Hormone treatment|"Group Drospirenone: To whom a continuous combined treatment with drospirenone 2 mg and 17β-estradiol 1 mg (DRSP/E2) will be administered daily for 24 weeks.~Group Tibolone: To whom treatment with tibolone 1.25 mg (Tib) will be administered daily for 24 weeks.~Transvaginal Ultrasound - Endometrial Thickness; Endometrial Biopsy. Endometrial Immunohistochemical Study"
89461431|NCT02384330||Dysport® (abobotulinumtoxinA)|Botulinum Toxin Type A (BoNT-A) preparation, injected doses, number of points, volume per point, in accordance with local Summary of Product Characteristics and locally agreed therapeutic guidelines.
89461432|NCT02384330||Botox® (onabotulinumtoxinA)|Botulinum Toxin Type A (BoNT-A) preparation, injected doses, number of points, volume per point, in accordance with local Summary of Product Characteristics and locally agreed therapeutic guidelines.
89461433|NCT02384330||Xeomin® (incobotulinumtoxinA)|Botulinum Toxin Type A (BoNT-A) preparation, injected doses, number of points, volume per point, in accordance with local Summary of Product Characteristics and locally agreed therapeutic guidelines.
89461434|NCT04852640|Experimental|Active Rehabilitation Program (ARP)|Participants will be treated for symptomatic shoulder instability with the evidence-based, targeted treatment intervention. For eight weeks, there will be two treatment sessions per week lasting 30-45 minutes. Exercises in the ARP include: Low-load and high-duration rotator cuff strengthening exercises, progressive scapular muscle endurance training, plyometric strengthening exercises, and surface electromyographic (EMG) biofeedback. Each prescribed exercise in the ARP will be increased to match the participant's function at the discretion of the study clinician. Although the components of the ARP will be pre-determined, the parameters and volumes of the components will be determined and documented over the treatment phase.
89461435|NCT04852640|Experimental|Nonspecific Passive Intervention (NPI)|Participants will be treated for symptomatic shoulder instability with the non-specific, generalized treatment intervention. For eight weeks, there will be two treatment sessions per week lasting 30-45 minutes. The NPI consists of a general approach to treating shoulder pain with passive modalities for pain modulation. These interventions are commonly practiced but have little evidence to support their use in the treatment of symptomatic shoulder instability. Although the components of the NPI will be pre-determined, the parameters and volumes of the components will be determined and documented by a study clinician over the treatment phase.
89461436|NCT02377076|Experimental|DAIRY|Dietary calcium supplementation
89461437|NCT02377076|Placebo Comparator|CONTROL|Control
88942851|NCT05855590|Experimental|tranexamic acid|A total of 20 patients were included: 9 patients in the tranexamic acid group
88942852|NCT05855590|Placebo Comparator|placebo|A total of 20 patients were included: 11 patients in the control group using 0.9% isotonic saline solution.
88942853|NCT05855551|Experimental|Arm 1 - base cash + BCC|pregnant women in this arm will receive the standard package (800 BDT each month), and in addition intensive group-based BCC on nutrition with a focus on how to improve their dietary intake during pregnancy
88942854|NCT05855551|Experimental|Arm 2 - base cash + BCC + food|pregnant women in this arm will receive the standard package (i.e., arm 1) and in addition a monthly food basket. The monthly food basket will provide 10 kg micronutrient fortified rice, 3.5 kg of lentils, and 1000 ml of oil, valued at 1000 BDT.
88942855|NCT05855551|Experimental|Arm 3 - base cash + BCC + top-up cash|"pregnant women in this arm will receive the standard package (i.e., arm 1) and in addition a monthly top-up cash of 1000 BDT to be added to the base amount that is part of the standard program."
88942856|NCT05855538||Paroxysmal AF|200 patients
88942857|NCT05855538||Persistent AF|200 patients
88942858|NCT05855538||Permanent AF|200 patients
88942859|NCT05855512|No Intervention|Controlled group|No intervention was given, only the material was provided in the form of a booklet
88942860|NCT05855512|Experimental|Interventional Group|The nursing educational intervention sessions were conducted, and the material was provided in the form of a booklet
88942861|NCT05855499|Experimental|Plasma (CAPT)|Conventional wound treatment according to S3 guideline, 3 visits weekly for 4 weeks, additive plasma treatment during each visit.
89201797|NCT00776568|Active Comparator|2|
89461438|NCT02381834|Experimental|Bladder stimulation technique|This is a two-person technique. A health care aide or nurse (RN) begins by holding the infant under the axillae with its legs dangling. A second RN or physician then performs bladder stimulation by gentle finger tapping on the lower abdomen in the midline just above the pubic symphysis at a frequency of 100 taps/min. If this is unsuccessful after 30 seconds, lower back stimulation in the lumbar paravertebral zone is performed by light massage in a circular motion using both thumbs. This too is performed for 30 seconds maximum. These two manoeuvres are repeated in succession, for a maximum of 5 minutes total, until urination occurs. Unsuccessful attempts at midstream urine collection will be followed by further feeding/fluid administration and bladder catheterization.
88942862|NCT05855499|No Intervention|Standard wound treatment (SWT)|conventional wound treatment according to S3 guideline, 3 visits weekly for 4 weeks
88942863|NCT05855486|Experimental|Eyedrops treatment arm|
88942864|NCT05855473|Experimental|Semi-permanent needle|Five sessions of unilateral auricular acupuncture were applied alternately to the right and left ears, once a week, to the intensive care nurses in the semi-permanent needle group. Semi-permanent needles placed on the acupuncture points of the nurses' ears remained for one week with adhesive tapes. In the sessions in the following weeks, semi-permanent needles were replaced with new ones. Shen men (TF4), Sympathetic (AH6a), Lung, Liver (CO12) Kidney point (CO10) were applied to five specific points in the ear in accordance with the NADA protocol.
88942865|NCT05855473|Experimental|Seed|Five sessions of unilateral auricular acupuncture were applied alternately to the right and left ears, once a week, to the intensive care nurses in the seed group. Seeds placed on the acupuncture points of the nurses' ears remained for one week with adhesive tapes. In the sessions in the following weeks, seeds were replaced with new ones. The seed group was asked to apply pressure on the bands three times a day, 15 times each time. Shen men (TF4), Sympathetic (AH6a), Lung, Liver (CO12) Kidney point (CO10) were applied to five specific points in the ear in accordance with the NADA protocol.
88942866|NCT05855473|No Intervention|Control|This group received no intervention.
88942867|NCT05855460||Mycosis fungoides patients|Blood sample and skin biopsy for assessment of IL35 by ELISA
88942868|NCT05855460||Normal healthy controls|Blood sample and skin biopsy for assessment of IL35 levels by ELISA
89017712|NCT06138769|Experimental|Lenvatinib|Lenvatinib 12 mg (body weight 60 kg or greater) or 8 mg (body weight < 60 kg) once orally every day
89017713|NCT06138756||Pre-adolescence with migraine|Patients at the age of 9-11with migraines who used the Nerivio device at least once
89461439|NCT02381210||CLINICALLY CONFIRMED PREECLAMPSIA|Pregnant women with clinical diagnosis of preeclampsia (severe, mild or superimposed) will provide a urine sample to determine the presence or absence of proteinuria using the Congo Red Dot test.
89017714|NCT06138717|Active Comparator|only aerobic exercise|Aerobic exercises will be performed with a lower extremity ergometer for 30 minutes and 12 sessions.
89017715|NCT06138717|Active Comparator|combine aerobic exercise and yoga exercises|Aerobic exercises will be performed with a lower extremity ergometer for 30 minutes and 12 sessions.A yoga-based exercise programme consisting of exercises will be applied for 40 minutes and 12 session
89017716|NCT06138678|Experimental|Accelerated iTBS protocol|Magnetic pulses of 120% of visual motor threshold applied in triplets of 50 Hz bursts, repeated at 5 Hz; 2 seconds on and 8 seconds off; 1200 pulses per session; total duration of 6 min 40 s over the left DLPFC (F3), given in 2 sessions per day (50 min interval) on 15 week days.
89017717|NCT06138678|Active Comparator|Routine iTBS protocol|Magnetic pulses of 120% of visual motor threshold applied in triplets of 50 Hz bursts, repeated at 5 Hz; 2 seconds on and 8 seconds off; 600 pulses per session; total duration of 3 min 20 s over the left DLPFC (F3), given in 1 session per day on 30 week days.
89017718|NCT06138652|Experimental|App|Participants completed surveys at baseline and again after 8 weeks. Participants completed app-based games and consultation with a mentor over an 8 week period focused on alleviating anxiety.
89017719|NCT06138652|No Intervention|Control|Participants completed surveys at baseline and again after 8 weeks.
89461440|NCT02381210||CLINICALLY HEALTHY|Pregnant women admitted to the hospital for delivery of a healthy normal baby at term (induction of labor or an elective Caesarean Section) will provide a urine sample to determine the presence or absence of proteinuria using the Congo Red Dot test.
89461441|NCT02384252||obese patients|patients with BMI > 30
89461442|NCT02384252||no obese patients|norma weight patient (BMI<25) overweight patients ( 25< BMI >30)
89461443|NCT02384564|Experimental|Ambu King Vision Video Laryngoscope aBlade System|The trachea will be intubated using the Ambu King Vision Video Laryngoscope with the appropriate sized blade (size 1 or 2) based on manufacturer guidelines and clinical judgement.
89461444|NCT02384564|Active Comparator|Direct Laryngoscope|The trachea will be intubated via direct laryngoscopy using a traditional straight blade laryngoscope, with appropriately sized blade based on manufacturer guidelines and clinical judgement.
89461445|NCT05041972|Experimental|Cohort 1: HER2 Mutated Non-Small Cell Lung Cancer (NSCLC)|Intervention: Drug: ARX788
89461446|NCT05041972|Experimental|Cohort 2: HER2 Mutation Breast Cancer|Intervention: Drug: ARX788
89461447|NCT05041972|Experimental|Exploratory Cohort A: Other HER2-Mutated tumors|Intervention: Drug: ARX788
89461448|NCT05041972|Experimental|Cohort 3: HER2 Amplification Biliary Tract Cancer (BTC)|Intervention: Drug: ARX788
89461449|NCT05041972|Experimental|Cohort 4 HER2 Amplification Colorectal (CRC), Ovarian Endometrial, NSCLC, and other solid tumors|Intervention: Drug: ARX788
89461450|NCT05041972|Experimental|Cohort 5: HER2 Mutation or HER2 Amplification Solid Tumors|Intervention: Drug: ARX788
89461451|NCT02384486|Experimental|intervention group|"intervention group will receive the Training to Reduce Stress in Mothers of Children with (ASD)"
89461452|NCT02384486|Other|control group|control group will receive nothing but for ethical purposes will receive the same intervention after the end of the trial for the intervention group
89017722|NCT06138574|Active Comparator|Effects of Dexmetomidine|Patients in this group will be given dexmedetomidine infusion during the intraoperative period to provide controlled hypotension.
89017723|NCT06138574|Active Comparator|Effects of Remifentanil|Patients in this group will be given remifentanil infusion during the intraoperative period to provide controlled hypotension.
89017724|NCT06138561||Cisplatin-Ineligible Metastatic Bladder Cancer|"Participants receiving standard of care non-cisplatin based therapy (carboplatin-based chemotherapy, enfortumab vedotin plus pembrolizumab or immunotherapy) and will complete study procedures as outlined below:~Baseline visit with questionnaires.~Complete surveys every 3 weeks by telephone or by in-office visit for 8 months.~Optional follow-up phone calls every 6 months for up to 3 years."
89017725|NCT06138535|Other|Masticatory Muscle Disorder patients treated by digital stabilizing splint|digital stabilizing splint
89017726|NCT06138496|Experimental|Cadonilimab combined with Lenvatinib as neoadjuvant therapy|"Lenvatinib Treatment Lenvatinib (8mg [body weight < 60 kg] or 12 mg [body weight ≥ 60 kg]) orally once daily, with or without food.~Intravenous Infusion of Cadonilimab(Injection) Infuse Cadonilimab at a dose of 6mg/kg intravenously every two weeks, constituting one treatment cycle, a total of 6 cycles.~Radical nephrectomy; Utilization of other targeted therapies; Combination targeted therapy with immunotherapy. If not, continue medication for six cycles before surgery."
89017727|NCT06138470|Active Comparator|Saffron extract|
89017728|NCT06138470|Active Comparator|Scutellaria baicalensis extract|
89461453|NCT05041348||liver cirrhosis patients with muscle mass loss|The diagnosis of cirrhosis was made based on the combination of clinical and laboratory features or by liver histopathology. Skeletal muscle mass index (SMI), which was the ratio of lean tissue area to body height. Muscle mass loss was defined as an SMI less than 46.96 cm²/m² for males and less than 32.46 cm²/m² for females
89461454|NCT05041348||liver cirrhosis patients with normal muscle mass|Skeletal muscle mass index (SMI) was not decreased in this group.
89461455|NCT05041348||healthy group|People in healthy control group were excluded metabolic diseases (including diabetes, thyroid disorder, and so on) and other chronic diseases, according to their ultrasound and laboratory assessment.
89461456|NCT02384174|Experimental|Resistant starch (RS)|Resistant starch (RS3)
89461457|NCT02384174|Experimental|Dietary fibre|Dietary fibre (Arabinogalactan, gum guar, pectin)
89461458|NCT04439474|Experimental|Patients with vitamin D deficiency|This group receives 50,000 units of vitamin D3 daily for up to 8 days until the serum level of vitamin D reaches above 30 ng/ml.
89461459|NCT04439474|Active Comparator|Patients without vitamin D deficiency|Participants in this group receive only their usual treatments
89461460|NCT02662556|Experimental|sufentanil sublingual tablet 30 mcg|sufentanil sublingual tablet 30 mcg
89461461|NCT05055076||PODEYE TORIC|Adult patients who have undergone cataract surgery with mono- or bilateral implantation of POD EYE TORIC IOL (POD T 49P) and who meet all the inclusion and exclusion criteria will be invited to participate in the study.
89461462|NCT05039242|Active Comparator|Control Group A(Conventional Physical Therapy)|Balanced resistive hand exercise with use of physio hand ball squeezes
89461463|NCT05039242|Experimental|Experimental Interventional Group B (I-Band Application of Kinesiotaping)|Participants will receive exercise interventions as group A along with that the Kinesiotape, by using I application technique from proximal to distal on dorsum of hand and forearm.
89461464|NCT05039242|Experimental|Experimental Interventional Group C (fan shaped Application of Kinesiotaping)|Participants will receive exercise interventions as group A along with that the Kinesiotape will be applied, by using fan cut application technique on MCP joints involving extensor tendons of fingers on dorsal surface of both hands of subjects
89461465|NCT02381444||Standard of Care|Participants with advanced Parkinson's Disease
89461466|NCT02381444||Levodopa Carbidopa Intestinal Gel|Participants with advanced Parkinson's Disease
89461467|NCT05054686|Experimental|Combination of Stretching and Aerobic Exercises at Clinic|Combination of Stretching and Aerobic Exercises at Clinic and Strengthening and Aerobic Exercises at Home
89461468|NCT05054686|Active Comparator|Combination of Strengthening and Aerobic Exercises at Clinic|Combination of Strengthening and Aerobic Exercises at Clinic and Stretching and Aerobic Exercises at Home
89461469|NCT05054686|Active Comparator|Combination of Strengthening, Stretching and Aerobic Exercises at Clinic|Combination of Strengthening, Stretching and Aerobic Exercises at Clinic and Aerobic Exercises at Home
89461470|NCT04439864|Experimental|MyIDEA|Research Participants interacted with MyIDEA program both in the hospital and in the follow up cardiology appointment.
89461471|NCT04439864|No Intervention|Treatment as normal|The research participants were given the chance to play games on the tablet and received normal clinical education.
89461472|NCT04988620|Experimental|Whole Blood stored for 15-21 days|CPD Whole Blood leukoreduced with a platelet-sparing filter and stored cold for 15-21 days
89461473|NCT04988620|Active Comparator|Whole Blood stored for less than 7 days|CPD Whole Blood leukoreduced with a platelet-sparing filter and stored cold for less than 7 days. We aim at using as fresh as possible.
89461474|NCT04988620|Active Comparator|Whole Blood stored for 8-14 days|CPD Whole Blood leukoreduced with a platelet-sparing filter and stored cold for 8-14 days. This group may be added if deemed of interest after interim analysis.
89461475|NCT04988620|Active Comparator|Standard Blood Component|This group may be added for comparison if deemed of interest after interim analysis.
89461476|NCT02376608|Active Comparator|Pronova Pure 150:500 EE EU|2 × PronovaPure 150:500 EE EU
89461477|NCT02376608|Active Comparator|Pronovum PRF-037|2 × Pronovum PRF-037
89461478|NCT02376608|Active Comparator|Pronovum PRF-041|2 × Pronovum PRF-041
89461479|NCT02376608|Active Comparator|Eskimo-3|3 × Eskimo-3
88942869|NCT05855356|Experimental|LoCoDiRe-Dys|Respiratory physiotherapy, personalized aerobic and strength training in parallel with standard of care
88942870|NCT05855356|Active Comparator|Standard of Care|Standard of care including behavioural and medical advice
88942871|NCT05855291|Experimental|Integrated PET/MRI|The study patients receive 18F-FDG PET/MRI before and after neoadjuvant chemoradiotherapy.
88942872|NCT05855278|Experimental|Integrated PET/MRI|The study patients receive 18F-FDG PET/MRI before and during chemoradiotherapy.
88942873|NCT05855265|Experimental|study group (SG)|The patients in study group treated with photon therapy (3x/week) for 6 weeks with a total of 18 sessions and Routine methods of nursing were given during radiotherapy including health education, skin self-care, and skin protective agent .The severity of skin reactions was assessed by the criteria of the Radiation Therapy Oncology Group (RTOG) and dermoscopy for both groups were recorded.
89461480|NCT02381366|Experimental|PNEUMOSTEM®|Dose A: PNEUMOSTEM® 10 million cells per kg Dose B: PNEUMOSTEM® 20 million cells per kg
88942874|NCT05855265|Experimental|control group (CG)|Routine methods of nursing were given during radiotherapy including health education, skin self-care, and skin protective agent for control groups CG.The severity of skin reactions was assessed by the criteria of the Radiation Therapy Oncology Group (RTOG) and dermoscopy for both groups were recorded.
88942875|NCT05855213|Experimental|High Velocity Nasal Insufflation (HVNI)|"HVNI (Precision Flow; Vapotherm®, Inc, Exeter, NH) will be delivered using a small-bore nasal cannula initiated at a flow rate set to 35 L/min, temperature of 35-37°C and FiO2 at 1.0. Adjustments in flow (up to 40 L/min) and temperature will be titrated to optimize patient's comfort.~The target parameters after initiation will be as follows:~RR< 25 bpm~HR< 120 bpm~SpO2 92-94%"
89017729|NCT06138470|Active Comparator|Saffron and Scutellaria baicalensis extract|
89017730|NCT06138470|Placebo Comparator|Placebo (maltodextrin)|
89201798|NCT00776568|Experimental|1|
89461481|NCT02381054||Translation and cross-cultural adaptation phase|In this phase 96 Italian-speaking patients who are receiving cancer treatment or who have completed treatment for cancer within the past six months at one of the participating sites will first be asked to independently complete a series of PRO-CTCAE symptom items in a Patient Questionnaire. Following completion by the participant of the Patient Questionnaire containing PRO-CTCAE items, the interviewer will elicit participants' feedback regarding item comprehension, symptomatic adverse event terms, attribute terms, 7-day recall period, and response options, via a semi-scripted cognitive debriefing interview developed to assure consistency across interviews.
89461482|NCT02381054||Test-retest phase|In this phase a minimum of 59 Italian-speaking patients who are receiving cancer treatment will be asked to independently complete the Italian version PRO-CTCAE questionnaire on 2 consecutive business days.
89461483|NCT04732520|Experimental|Treatment|Patients participating in the treatment group will undergo pulsed electric field (PEF) treatment of a single NSCLC nodule measuring 1 to 4 cm by CT, using the Aliya System. The treatment may be performed endoluminally in conjunction with a diagnostic bronchoscopy, or percutaneously.
89461484|NCT04732520|No Intervention|Control|Patients declining to participate in the treatment arm may self-select to participate in an observational control arm.
89461485|NCT04845776|Experimental|Treatment Group|This group receives the vitamin/mineral supplement, ANRC Essentials Plus, for 3 months
89461486|NCT05036590|Active Comparator|Control group|"The design is a stepped-wedge cluster randomized controlled trial. The study will be conducted in 9 centers (clusters) and will be conducted in 6 successive phases of 4 months each.~During the first period, groups will be in the control period, then sequentially and according to a randomly defined order, at each time, one group will go into the intervention period after a transition period of 4 months allowing the intervention to be deployed (training of three health professionals for each center and then implementation of the BREF program).~Thus, each cluster will belong successively to the control group and the intervention group. During the control period, caregivers will be supported according to the usual practices of each center. During the intervention period, the BREF program will be offered to all eligible caregivers."
89461487|NCT05036590|Experimental|intervention group|Thus, each cluster will belong successively to the control group and the intervention group. During the intervention period, the BREF program will be offered to all eligible caregivers.
89461488|NCT02376452|Experimental|RALIRI|Raltitrexed combined with irinotecan
88942876|NCT05855213|Active Comparator|Non-invasive positive pressure ventilation (NIPPV)|"NIPPV will be initiated with an oronasal mask, with inspiratory and expiratory positive airway pressures (IPAP, EPAP) set at IPAP 10-20 cm H2O and EPAP 5-7 cm H2O to be titrated according to patient's response and comfort. FiO2 will be initiated at 1.0 for noninvasive positive-pressure ventilation.~The target parameters after initiation will be as follows:~RR< 25 bpm~HR< 120 bpm~SpO2 92-94%"
89461489|NCT02376452|Placebo Comparator|FOLFIRI|5-fluorouracil,folinate combined with irinotecan
89461490|NCT02383784|Experimental|Low-GI diet|Low glycemic index diet
89461491|NCT02383784|Experimental|High-GI diet|High glycemic index diet
89461492|NCT02383394||aborted women|women who got pregnant and have 2nd trimesteric abortion, follow up antenatal care by ultrasound and clinical monitoring
89461493|NCT02383394||continued women|women who got pregnant and completed her pregnancy follow up antenatal care by ultrasound and clinical monitoring
89461494|NCT02372084|Experimental|osilodrostat (LCI699)|Each participant will undergo a 28-day screening/baseline period (day -28 to day -1), followed by a 5 day treatment period (a single 30 mg dose of LCI699 ( Day 1) with 5 days of PK sample collection).
89461495|NCT02516098|Active Comparator|Hyoscine butylbromide SCT|
89461496|NCT02516098|Experimental|Hyoscine butylbromide|
88942877|NCT05855187|Experimental|T test|1 tablet contains 200 mg Modafinil administrated according to a randomization scheme with 240 ml of water.
88942878|NCT05855187|Active Comparator|R Reference|1 tablet contains 200 mg Modafinil administrated according to a randomization scheme with 240 ml of water.
88942879|NCT05855148||Lung Transplant Candidates|patients enlisted for lung transplant
88942880|NCT05855070|Experimental|Intralesional treatment with Hyaluronic acid|Patients will receive intralesional treatment with Hyaluronic acid (0.8% highly purified sodium salt Hyaluronic acid 6 mg/2 mL; Sinovial, IBSA, Lodi, Italy) weekly for 12 weeks.
88942881|NCT05855070|Experimental|Intralesional treatment with Verapamil|Patients will receive intralesional treatment with Verapamil (10 mg in 5 mL of normal saline water) weekly for 12 weeks.
88942882|NCT05855057||Flank suspended supine position percutaneous nephrolithotomy|This group included 41 patients in flank suspended supine position percutaneous nephrolithotomy.
88942883|NCT05855057||Supine percutaneous nephrolithotomy group|This group included 41 patients in supine percutaneous nephrolithotomy.
88942884|NCT05855057||Prone percutaneous nephrolithotomy group|This group included 41 patients in prone percutaneous nephrolithotomy.
89461497|NCT02372318|Experimental|Nalmefene Challenge|Participants will receive 18mg Nalmefene two hours prior to fMRI measurement. During fMRI scanning alcohol cues will be presented.
89461498|NCT02372318|Placebo Comparator|Placebo|Participants will receive Placebo two hours prior to fMRI measurement. During fMRI scanning alcohol cues will be presented.
89461499|NCT03105752|Experimental|Research participants|"Each participant of a clinical trial completed the Qualité de Compréhension des Formulaires d'information et de consentement questionnaire (QCFic) about its understanding of the information received. This questionnaire was retrieved immediately on the day of consent, with no possibility of referring to the content of information letter."
89461500|NCT03105674|Active Comparator|Standard Therapy|Patients will receive a combination of Marcaine and Lidocaine injection (standard local anesthetics) as a part of their peri-anal block prior to the surgery.
88942885|NCT05855018|Experimental|Atropine sulfate Concentration A|Subjects will be treated with atropine sulfate eye drop (at dosage Concentration A), administered once daily (QD).
88942886|NCT05855018|Experimental|Atropine sulfate Concentration B|Subjects will be treated with atropine sulfate eye drop (at dosage Concentration B), administered once daily (QD).
88942887|NCT05855018|Experimental|Atropine sulfate Concentration C|Subjects will be treated with atropine sulfate eye drop (at dosage Concentration C), administered once daily (QD).
88942888|NCT05854979||Diabetics taking a GLP-1 receptor agonist|
88942889|NCT05854979||Diabetics not taking a GLP-1 receptor agonist (control)|
88942890|NCT05854940||Eligible participants for early diagnosis of prostate cancer|According to the 2014 edition of China Prostate Cancer Diagnosis and Treatment Guidelines, patients need to undergo prostate biopsy
88942891|NCT05854901|Experimental|PCT-guided treatment|Patients randomized to this arm will only receive antibiotic treatment when the procalcitonin concentration is > 0.25ug/L.
88942892|NCT05854901|Active Comparator|Usual care|Patients randomized to this arm will receive antibiotic treatment based on the physician's decision.
89017731|NCT06138444|Experimental|Male received functional beverages|Male received single oral dose of functional beverages from submerged fermentation of Cordyceps militaris (FCM)
89017732|NCT06138444|Placebo Comparator|Male received placebo|Male received placebo
89017733|NCT06138444|Experimental|Female received functional beverages|Female received single oral dose of functional beverages from submerged fermentation of Cordyceps militaris (FCM)
89461501|NCT03105674|Experimental|Multi-drug local anaesthetics|"Patients will receive a combination [Multi-drug local anesthetics (Combination)] of following drugs as a part of their peri-anal block prior to the surgery (multi-drug local anesthetics)~Ropivacaine 0.5% - 30 ml~Ketorolac 30mg/ml - 1 ml~Kenalog 10 mg/ml - 5 ml~Lidocaine 1% with Epinephrine 1:100,000 - 20ml"
89017734|NCT06138444|Placebo Comparator|Female received placebo|Female received placebo
89017735|NCT06138431|Experimental|Virtual Cognitive Behavioral Therapy (CBT) group|The Cognitive Behavioral Therapy (CBT) groups will be 6 weekly one-hour parent groups run by a Cognitive Behavioral Therapy (CBT) therapist according to a Cognitive Behavioral Therapy (CBT) manual focusing on anxiety and depression related to having a child with food allergies.
89461502|NCT02380898|Experimental|Ketorolac|
89461503|NCT02380898|Placebo Comparator|Normal saline 0.9%|
89461504|NCT02380976|Experimental|Test 1|First phase: DW330SR+DW1030 7 days after Second phase: DW340
89461505|NCT02380976|Experimental|Test 2|First phase: DW340 7 days after Second phase: DW330SR+DW1030
89461506|NCT02381132|Active Comparator|MNK155|Hydrocodone Bitartrate/Acetaminophen Extended-Release Tablets
89461507|NCT02381132|Active Comparator|Norco 7.5mg/325mg|Norco 7.5mg/325mg
89461508|NCT05034484|Experimental|ALPN-303 Regimen A|
89461509|NCT05034484|Placebo Comparator|Placebo Regimen A|
89461510|NCT05034484|Experimental|ALPN-303 Regimen B|
89461511|NCT05034484|Placebo Comparator|Placebo Regimen B|
89461512|NCT02376296||hormone naïve|Subjects with hormone naïve metastatic prostate cancer that have high-volume disease and have been on androgen deprivation therapy for less than 120 days prior to starting docetaxel therapy.
89461513|NCT02376296||castrate resistant|Subjects with castrate resistant prostate cancer (CRPC) [defined as having evidence of prostate specific antigen (PSA) progression despite androgen deprivation therapy] that have had at least four weeks elapse between the withdrawal of anti-androgens (Bicalutamide, Flutamide or Nilutamide) and the initiation of docetaxel therapy.
89461514|NCT02380820|Experimental|AirsoftDuo first|"Patients randomized to this arm will be placed on the Airsoft Duo mattress, and the investigator will proceed with 2 series (for reproductibility) of measures for 30 minutes with the bed headboard at 0°. A pause, consisting of ten minutes of sitting and 1 minute of verticalization is then carried out. The bed is then positioned at 30°, and the 2 series of measures over 30 minutes are repeated. The next day, all of the above are repeated with the Softform Premium mattress (in static mode). The patient will then continue his/her stay with the Softform Premium mattress (in static mode) for 1 month.~Intervention: Airsoft Duo mattress Intervention: Softform Premier mattress (in static mode)"
89461515|NCT02380820|Experimental|Softform Premium first|"Patients randomized to this arm will be placed on the Softform Premium mattress (in static mode), and the investigator will proceed with 2 series (for reproductibility) of measures for 30 minutes with the bed headboard at 0°. A pause, consisting of ten minutes of sitting and 1 minute of verticalization is then carried out. The bed is then positioned at 30°, and the 2 series of measures over 30 minutes are repeated. The next day, all of the above are repeated with the Airsoft Duo mattress. The patient will then continue his/her stay with the Airsoft Duo mattress for 1 month.~Intervention: Softform Premier mattress (in static mode) Intervention: Airsoft Duo mattress"
89017736|NCT06138431|No Intervention|Waitlisted group|The comparator groups will be waitlisted groups of parents of children with food allergies.
89017737|NCT06138418|Experimental|Longitudinal cohort study|Longitudinal cohort study
89017738|NCT06138405|Experimental|Immediate Intervention Group|"Experiential, interactive, skills-oriented workshop for oral healthcare providers (i.e., dentists, hygienists, and assistants) involving simulated patients and immediate pre- and post-workshop testing. The workshop involves didactics on developmentally-appropriate child behavior in the dental setting, and over-practice of skills, to the point of habit, by providers."
89461516|NCT02371928|Active Comparator|Neuromuscular exercise program|"A 12-week physiotherapeutic, supervised exercise program with focus on neuromuscular shoulder control besides incorporation of kinetic chain exercises.~The exercise program contains the following focal points: Scapula and glenohumeral setting/control, dynamic shoulder stability, muscle co-contractions (weight-bearing upper extremity exercises) and proprioceptive training."
89461517|NCT02371928|Active Comparator|Standard home exercise program|"One physiotherapeutic-supervised instruction in 12 weeks of active exercises for the rotator cuff and scapular muscles.~Information about the shoulder injury and how to avoid pain provoking movements besides future implications is given. Also, participants receives one phone call after six weeks of training from a physiotherapist to ensure good compliance and answer any questions that the patient may have."
89461518|NCT02380664|No Intervention|Swimmers|Swimmers that continue their normal swimming activity
89461519|NCT02380664|Experimental|WBV swimmers|Swimmers that perform a whole-body vibration training
89461520|NCT02380664|Experimental|Plyometric swimmers|Swimmers that perform a plyometric training
89461521|NCT02380664|No Intervention|Sedentary controls|Controls that do not perform swimming or other physical activities
89017739|NCT06138405|Active Comparator|Delayed Intervention Group|The delayed intervention group will receive the same experiential, interactive, skills-oriented workshop, but two months after the immediate intervention group.
89017740|NCT06138392||Experimental group|
89201799|NCT00779922|Experimental|group 1 to 5|
89201800|NCT00776646|Experimental|1|hydrochlorothiazide 50 mg tablet
89201801|NCT00776646|Active Comparator|2|hydrochlorothiazide 50 mg tablet
89461522|NCT01364428|Experimental|IDeg 200 U/mL|
89461523|NCT01364428|Experimental|IDeg 100 U/mL|
89461524|NCT02376374|Experimental|10% OPV|In this arm, 10% of the households in this community will receive OPV.
89461525|NCT02376374|Experimental|30% OPV|In this arm, 30% of the households in this community will receive OPV.
89461526|NCT02376374|Experimental|70% OPV|In this arm, 70% of the households in this community will receive OPV.
89461527|NCT02376140||Women|Mothers of children 36-59 months old No intervention
89461528|NCT02376140||Children|Children 36-59 months old No intervention
89201802|NCT00780078||1|Patients intubated orotracheally for over 6 days
89461529|NCT05032534|Active Comparator|Newly developed cone for 6 weeks the currently used cone for 6 weeks|Starts off with treatment with the newly developed cone for transanal irrigation for 6 weeks and are then instructed to crossover to the contrary system, the currently used, for additional 6 weeks.
89461530|NCT05032534|Active Comparator|Currently used cone for 6 weeks the newly developed cone for 6 weeks|Starts off with treatment with the currently used cone for transanal irrigation for 6 weeks and are then instructed to crossover to the contrary system, the currently used, for additional 6 weeks.
89461531|NCT02371694|Experimental|Fat Test drink (50g)|This drink contains 50g sunflower oil and vehicle (almond milk, chocolate drink powder, sweetener)
89461532|NCT02371694|Experimental|Fat Test drink (38g)|This drink contains 38g sunflower oil and vehicle (almond milk, chocolate drink powder, sweetener)
89461533|NCT02371694|Experimental|Fat Test drink (25g)|This drink contains 25g sunflower oil and vehicle (almond milk, chocolate drink powder, sweetener)
89461534|NCT02371694|Experimental|Fat Test drink (13g)|This drink contains 13g sunflower oil and vehicle (almond milk, chocolate drink powder, sweetener)
89461535|NCT02371694|Placebo Comparator|Fat Test drink (3g)|This drink contains no sunflower oil and vehicle (almond milk, chocolate drink powder, sweetener)
89461536|NCT02371694|Active Comparator|Carbohydrate Test drink|This drink contains 20g of glucose from de-gassed lucozade energy.
89461537|NCT02371772|Other|Self-management anticoagulation treatment|Trained to monitor INR and dose warfarin
89461538|NCT02371772|No Intervention|Conventional anticoagulation treatment|Before enrolment
89461539|NCT02380586||Women in labor undergoing anesthesia care|Women in labor undergoing anesthesia care
89461540|NCT02375828|Experimental|Patients with neonatal diabetes|Patients with neonatal diabetes
89461541|NCT02380508|Experimental|Group 1|32 BCG-naïve subjects receiving BCG SSI or BCG Sii at standard dose (2-8x10^5 cfu) via Intradermal route.
89461542|NCT02380508|Experimental|Group 2|8-16 control volunteers receiving no vaccination.
89461543|NCT02380430||ambulatory surgery description|Medical questionnaire. Nausea and vomiting, pain, thromboprophylaxis description
89461544|NCT02371538|Experimental|Donor Breastmilk|Donated human milk is subjected to pasteurization prior to use. Milk consumption is to be overseen by a Registered Dietician. Oral or enteral milk feeding will begin at 180 ml/day and will be advanced as quickly as tolerated to a goal of 360 ml/day for 6 weeks. If symptoms and stool tests for norovirus do not improve after 6 weeks, milk administration may continue for an additional 6 weeks.
89461545|NCT02376218|Experimental|Hypertonic 50% dextrose pleurodesis|
89461546|NCT02376062|Experimental|Bundled Intervention|"On-site care coordinator and off-site psychiatric supervisors based in Nepal's capital, Kathmandu~Weekly case conferences~Surveys of clinicians and clinical supervisors in accordance with CME curriculum"
89461547|NCT02371226|Experimental|Cohort 1|1 mg/kg AGT-181 (fusion protein of anti-human insulin receptor monoclonal antibody and alpha-L-iduronidase; HIRMAb-IDUA) administered once weekly x 8 weeks
89461548|NCT02371226|Experimental|Cohort 2|3 mg/kg AGT-181 (HIRMAb-IDUA) administered once weekly x 8 weeks
89461549|NCT02371226|Experimental|Cohort 3|6-9 mg/kg AGT-181 (HIRMAb-IDUA) administered once weekly x 8 weeks
89461550|NCT02371304|Active Comparator|Total Mesorectal Excision|After local excision patients will receive additional TME surgery
89461551|NCT02371304|Experimental|Adjuvant chemoradiotherapy|After local excision. Patients will receive capecitabine 825 mg/m2 twice a day for 5 weeks only on weekdays. This will be combined with 1.8 Gy in 25 fractions with a limited dose only on the mesorectum
89201803|NCT00773448|Active Comparator|Limited Malignancy Screening|
89461552|NCT02380352|Experimental|Short-course|5 days amoxicillin 90 mg/kg/day divided TID followed by 5 days placebo TID
89461553|NCT02380352|Active Comparator|Standard|5 days amoxicillin 90 mg/kg/day divided TID followed by alternate formulation 5 days amoxicillin 90 mg/kg/day divided TID
89461554|NCT02380274||Patients with CRPC|Patients with CRPC
89461555|NCT02375750|Experimental|GBO and GBG|0.2 g-0,5 g GBO and 1 GBG once after decontamination of implant surface
89461556|NCT02375750|Active Comparator|Standard treatment|Decontamination of surface of implant
89461557|NCT02375594|Experimental|Exercise in park equipment|Participants in the intervention arm will attend a 3-month long program of 2 weekly one-hour exercise sessions in the exercise park equipment, guided by a physical therapist. The sessions will comprise a combination of aerobic, strength, balance and flexibility exercises. Up to 20 participants exercising simultaneously in the equipment under the guidance of an experienced LAPPSET physical therapist.
89461558|NCT02375594|No Intervention|Control|Participants in the control arm will receive usual advice on healthy habits. During the study, they will be offered to attend the talks on healthy living for elderly periodically organised by their primary care centre (CAP Vallcarca - Sant Gervasi). At the end of the study, they will be invited to an exercise session at the exercise park equipment, conducted by the study physical therapist.
89461559|NCT02380118|Experimental|Olanzapine|intramuscular olanzapine injection (zyprexa), 5 mg/dose, first dose and an optional second dose.
89461560|NCT02380118|Active Comparator|Haloperidol|intramuscular haloperidol injection, 5 mg/dose, first dose and an optional second dose.
89201804|NCT00773448|Experimental|Extensive Malignancy Screening|Limited screen as described above in combination with comprehensive computed tomography of the abdomen/pelvis
89201805|NCT00776724|Active Comparator|1|docetaxel-epirubicin for 4 cycles before surgery
89201806|NCT00776724|Experimental|2|Tailored regimens, base on immunohistochemical study of the tumor biopsy tissue, for 4 cycles before surgery.
89201807|NCT00773526|Experimental|1|
89201808|NCT00776802|Experimental|GCS-10|
89201809|NCT00780312|No Intervention|2|50 patients in this group get the existing hospital treatment: A 10 minute instruction in mouth opening exercises by a nurse before onset of radiotherapy treatment.
89461561|NCT02380118|Active Comparator|Midazolam|intramuscular midazolam injection, 5 mg/dose, first dose and an optional second dose.
89461562|NCT02375438||Cohort Group|Patients with a clinical presentation suggestive of mitochondrial cytopathy, in whom mitochondrial deletions above 20% have been found in muscle are considered eligible if they are older than 18 years and are willing and able to give written informed consent.
89461563|NCT02375438||Control Group|Twenty healthy individuals matched for age and gender will be included in the study and considered as controls.
89461564|NCT03113708|Sham Comparator|Heparinisation,actual body weight|In 'Heparinisation,actual body weight' group , heparin sodium; will be done according to actual body weight and ACT will be recorded prior to CPB. Before coming out CPB, protamine will be done according to heparin dose. And then ACT will be recorded.
88942893|NCT05854888|Experimental|PeMWaC (Perineal Massage and Warm Compresses)|In the second stage of labor, the midwife performed a soft perineal massage between 3 o'clock and 9 o'clock positions (U-shaped reciprocating motion) wearing sterile gloves and lubricated their hand with sterile lubricant. The massage lasted 10 minutes and the degree of downward pressure by the thumb was determined according to mothers' response. Perineal massage was established on the II Hodge Plan, between maternal contractions and regardless of maternal position. The women could adopted the birthing position they prefer. The application of warm compresses was performed by the midwife between the III and IV Hodge plans, during pushing and regardless of the mother's position. A metal jug filled with warm water (between 45° and 59°C) was used to soak the compresses, which were squeezed out before being gently placed on the perineum during contractions.
88942894|NCT05854888|Active Comparator|Control group (Hands-on)|"The midwife placed the index, middle, and little fingers of the non-dominant hand together on the child's occiput, with the palm facing the anterior region of the perineum, when the child's head was crowning. In this way, the expulsion was controlled, maintaining the flexion of the head. Simultaneously, the dominant hand was flattened and placed on the posterior region of the perineum, with the index finger and thumb, forming a U, exerting pressure on the posterior region of the perineum during the crowning process. During the birth of the shoulders and the rest of the body, the dominant hand was kept in place, protecting the posterior region of the perineum, while the non-dominant hand supported the infant's head, allowing external rotation and spontaneous birth of the shoulders. After both shoulders were removed, the midwife removed the dominant hand from the posterior perineum."
88942895|NCT05854875|Active Comparator|RYGBP|Laparoscopic Roux en Y Gastric Bypass
88942896|NCT05854875|Experimental|RYGBP + FR|Laparoscopic Roux en Y Gastric Bypass with fundus resection
88942897|NCT05854849|Experimental|GAP|
88942898|NCT05854849|Active Comparator|GPP|
88942899|NCT05854823|Experimental|de-escalation radiotherapy|Postoperative radiotherapy alone
88942900|NCT05854810|Active Comparator|PCOS Patient|
88942901|NCT05854810|Active Comparator|Male factor infertility|
88942902|NCT05854797|Active Comparator|Normal Walking Group|Adhering to FITT method, normal walking will be performed 5 days a week (frequency) to ensure optimal results. Speed (intensity) for normal will be 3.5 mph
88942903|NCT05854797|Experimental|Brisk Walking Group|Adhering to FITT method, brisk walking will be performed 5 days a week (frequency) to ensure optimal results. Speed (intensity) for normal will be 4.5 mph.
88942904|NCT05854771|Active Comparator|Single bout of yoga before eccentric exercise group|Yoga poses will be performed before the eccentric exercise of the four muscles group (elbow flexors and extensors, knee extensors and flexors) for a total time duration of 20-30 minutes. To induce delayed onset muscle soreness the participants will be asked to breathe and hold each yoga pose for 6-8 breaths. The participants will perform 6 sets of 10 repetitions of one repetition maximum eccentric drills of the elbow and knee with 3 minutes rest period between each set.
88942905|NCT05854771|Active Comparator|Single bout of yoga after eccentric exercise group|Yoga poses will be performed after the eccentric exercise of the four muscles group (elbow flexors and extensors, knee extensors and flexors) for a total time duration of 20-30 minutes. To induce delayed onset muscle soreness the participants will be asked to breathe and hold each yoga pose for 6-8 breaths. The participants will perform 6 sets of 10 repetitions of one repetition maximum eccentric drills of the elbow and knee with 3 minutes rest period between each set.
88942906|NCT05854758|Experimental|Core strengthening with conventional treatment|This group will perform planks, side planks and superman exercises along with knee to chest, pelvic rotation, back extension, and bridge exercises after baseline treatment of therapeutic hot pack and transcutaneous electrical nerve stimulation continuous mode for 10 minutes.
88942907|NCT05854758|Active Comparator|Conventional treatment|This group will perform knee to chest, pelvic rotation, bridge and back extension exercises after baseline treatment of therapeutic hot pack and transcutaneous electrical nerve stimulation. continuous mode for 10 minutes. Each exercise will be repeated 10 times, with 10 second holds, followed by a five-minute rest interval
88942908|NCT05854732|Experimental|Inclined Treadmill Training Group|"The Inclined Treadmill Training Group will be considered as an Experimental group with fixed speed of 5.0 mph and increased inclination of 1% after every one minute. The FITT program for the participants will be:~Warmup: 5 mints~Frequency: 5days/week for 4 weeks.~Intensity: fixed speed of 5.0 mph and increased inclination of 1% after every one minute.~Time: 30 minutes~Type: 1% Inclined treadmill~Cool down: 5 mints"
89201810|NCT00780312|Experimental|1|physiotherapy
89201811|NCT00776880||1|Patients assessed with ASA physical status scale
89201812|NCT00776880||2|Patients assessed with PPS scale
89461565|NCT03113708|Experimental|Heparinisation, lean body weight|In 'Heparinisation, lean body weight' group heparin sodium will be done according to lean body weight and ACT will be recorded prior to CPB. Before coming out CPB, protamine will be done according to heparin dose. And then ACT will be recorded.
89461566|NCT03113474|Experimental|Palatable-neutral|Participants are exposed to palatable food in the first test session, and to the neutral food in the second test session.
89461567|NCT03113474|Experimental|Neutral-palatable|Participants are exposed to neutral food in the first test session, and to the palatable food in the second test session.
89461568|NCT02371148|Experimental|Bortezomib-Rituximab-Bendamustine|Bortezomib-Rituximab-Bendamustine (BRB) combination in patients with relapsed/refractory lymphoplasmocytic/lymphoplasmocytoid lymphoma/Waldenstrom macroglobulinemia after one line of therapy.
89017741|NCT06138379|No Intervention|Control Group|"No Intervention: Control group The research will begin after obtaining the necessary legal and ethical permissions to collect data. At this stage of the research, participants who agree to participate in the research will be asked to fill out an informed consent form. All forms will be filled in to obtain pre-test data for the research.~These individuals who receive and continue to receive standard care will be informed about the research. Pre-test and post-test data from the control group will be obtained simultaneously with the study groups."
89017742|NCT06138379|Experimental|1. Experimental Group|"Experimental: Experimental group given video-supported training in line with the health belief model.~All forms (Patient Information Monitoring Form, Chronic Disease Adaptation Scale, Rational Drug Use Scale and Immunosuppressive Drug Form Scale) will be filled in to obtain pre-test data for the research. Individuals will be trained according to the training materials prepared for the Health Belief Model. They will be monitored one day each week. After 30 days, all forms will be filled out again to examine the sustainability of the training data."
89201813|NCT00780390|Placebo Comparator|CRPS patients without spinal cord stimulation|CRPS patients declining spinal cord stimulation therapy. Autonomic Function will be assessed at baseline and again within 2 years.
89461569|NCT02371070||Rivaroxaban|N=20
89461570|NCT02371070||Apixaban|N=20
89461571|NCT02371070||Dabigatran|N=20
89461572|NCT02375360||Children 8-12- control|Children aged 8-12 years with food allergy who are not undergoing oral immunoterapy
89461573|NCT02375360||Parents 0-12 - control|Parents to children aged 0-12 years with food allergy who are not undergoing oral immunoterapy
89461574|NCT02375360||Children 8-12 - OIT|Children aged 8-12 years with food allergy who are undergoing oral immunoterapy
89461575|NCT02375360||Teenagers 13-17 - OIT|Teenagers aged 13-17 years with food allergy who are undergoing oral immunoterapy
89461576|NCT02375360||Adults >18 - OIT|Adults> 18 years with food allergy who are undergoing oral immunoterapy
89461577|NCT02375360||Parents 0-12 - OIT|Parents to children aged 0-12 years with food allergy who are undergoing oral immunoterapy
89461578|NCT02375360||Parents 13-17 - OIT|Parents to teenagers aged 13-17 years with food allergy who are undergoing oral immunoterapy
89461579|NCT02375516|Experimental|Prevention Program|Youths in the intervention-arm will interact online with the initial intervention program between pretest and posttest measurement occasions and will interact with booster sessions subsequent to 1- and 2-year follow-up measurement occasions.
89461580|NCT02375516|No Intervention|Control group|Youths assigned to the control arm will receive no intervention.
89461581|NCT02380040||Term|Normal Term Newborn Intervention: PPG
89461582|NCT02380040||Preterm|Preterm babies admitted to the NICU not suffering from the conditions to be studied Intervention: PPG
89461583|NCT02380040||PDA|Patent Ductus Arteriosus Intervention: PPG
89461584|NCT02380040||PPHN|Persistent Pulmonary Hypertension Intervention: PPG
89461585|NCT03113318|Experimental|Lymph node dissection and pulmonary metastasectomy|Total mediastinal lymph node dissection and pulmonary metastasectomy from colorectal cancer
89461586|NCT03113318|Active Comparator|Pulmonary metastasectomy only|Only pulmonary metastasectomy from colorectal cancer
89461587|NCT02370992||Receiving I125 brachytherapy|I125 brachytherapy is a standard treatment and will be delivered using routine techniques involving a preimplant volume study followed by implantation of the I125 sources. This is undertaken as an inpatient or day case under general or spinal anaesthetic according to local practice
89461588|NCT02370680|Experimental|Durlaza™, 1 capsule|Aspirin run-in, followed with Durlaza™, one capsule QD (quaque die), for 14 ± 4 days and an in-patient visit
89461589|NCT02370680|Experimental|Durlaza™, 2 capsules|in a rollover with 10 subjects from the first arm, an aspirin run-in, followed by Durlaza™, two capsules QD, for 14 ± 4 days and an in-patient visit
89201814|NCT00780390|Experimental|CRPS patients: candidates for spinal cord stimulator|CRPS patients who are candidates for spinal cord stimulator implant. These patients will have Autonomic Function assessments before and after the Standard of Care spinal cord stimulation implant
89461590|NCT02370758|Active Comparator|Low CMV CMI|Patients that show low levels of cell-mediated immunity against CMV will have their antiviral therapy (oral Valganciclovir or Intravenous Ganciclovir) continued for an additional 2 months at half dose.
89461591|NCT02370758|No Intervention|High CMV CMI|Patients that show high levels of cell-mediated immunity against CMV will have their antiviral therapy (oral Valganciclovir or Intravenous Ganciclovir) stopped.
89461592|NCT03113240|Experimental|Glutamin|Intervention patients will be received enteral formula and glutamine 0.3 g/kg/day given via nasogastric tube as boluses q 4hrs.
89461593|NCT03113240|Placebo Comparator|maltodextrin|Control patients will be received enteral formula and maltodextrin mixed in with water and given via nasogastric tube as boluses q 4hrs.
89461594|NCT02370836|Experimental|Psycho-oncological education|One 60 minute psycho-oncological education session on late effects, fatigue and stress management.
89461595|NCT02370836|No Intervention|Usual Care|Usual care includes completion of a symptom checklist by the nurse practitioner
89461596|NCT02375282|Experimental|Ambulation Orderly Intervention|Patients that are in this group are those randomized to receive visits from the ambulation orderly (ambulation group). The patients in this group will receive the visits from the ambulation orderly in addition to the standard of care that occurs with the rest of the hospital and with the control group.
89461597|NCT02375282|No Intervention|Control Group|This is for the patients who are randomized to receive the standard care of Baystate Medical Center. The standard of care will be nurse-directed ambulation, as is currently done in all other nursing floors at Baystate Medical Center. Nurses will be instructed to walk with the patients as they did before the initiation of the ambulation orderly and as they do when the orderly is on vacation, at conferences, training, or away for illness. These patients will not receive visits from the ambulation orderly.
89461598|NCT03105596|Experimental|Chidamide plus DICE regimen|Chidamide combined with DICE (Dexamethasone, Ifosfamide, Cisplatin and Etoposide) regimen
89461599|NCT04669964||High-Risk For Dehydration|Patients with an Ileostomy output of >1L at discharge.
88942909|NCT05854732|Active Comparator|Uninclined Treadmill Training Group|"The uninclined Treadmill Training Group will be considered as active comparator with no inclination of the treadmill and speed of 5.0 mph. The FIIT program for the participants will be:~Warmup: 5 mints~Frequency: 5days/week for 4 weeks.~Intensity fixed speed of 5.0 mph and no inclination.~Time: 30 minutes~Type: uninclined treadmill~Cool down: 5 mints"
88942910|NCT05854706|Experimental|Active arm|Prolonged iTBS sessions are scheduled daily in a 5-day sequence for 10 sessions over two weeks
88942911|NCT05854706|Sham Comparator|Sham arm|Sham stimulation sessions are scheduled daily in a 5-day sequence for 10 sessions over two weeks
88942912|NCT05854693|Experimental|Active tDCS|The intervention consisted of 10 daily 20-min sessions of bilateral prefrontal tDCS (anodal-right/cathodal-left, 2mA; 1 × 1 Mini-CT)
88942913|NCT05854693|Sham Comparator|Sham tDCS|The sham group consisted of 10 daily 20-min sessions of sham stimulation
88942914|NCT05854680||Long term|Tai Chi has been practiced for at least five years, regular practice, at least three times a week, each practice for at least 30 minutes.
88942915|NCT05854680||Short term|Tai Chi practice time is less than three months, regular practice, at least three times a week, each practice for at least 30 minutes.
88942916|NCT05854589|Active Comparator|Active Group - Sodium Chloride Crystal Topical|Each patient of the Active group will have their Melanoma covered by 2 drops of water, followed by applying Sodium Chloride granules to saturate the melanoma surface then add 2 more drops of water, then cover the NaCl-granules-covered Melanoma with a bandage. The bandage will stay in place for 12 hours daily and the procedure will be repeated daily for a total of 7 consecutive days, in addition to their standard treatments they receive from their health care providers, if any.
88942917|NCT05854589|Placebo Comparator|Control Group - Plain Water topical application|Each patient of the Control group will have their Melanoma covered by 4 drops of water, then covered by a bandage. The bandage will stay in place for 12 hours daily and the procedure will be repeated daily for a total of 7 consecutive days, in addition to their standard treatments they receive from their health care providers, if any.
88942918|NCT05854511|Experimental|Daclatasvir Plus Sofosbuvir|"treatment-naïve children infected with chronic HCV will be stratified according to weight~Children weighing 14 <17 Kg~Children weighting 17<35 Kg"
88942919|NCT05854459|Experimental|HIIT and Nordic Curl exercise group|The participants will perform a weekly 50 minutes session for four weeks.
88942920|NCT05854459|Active Comparator|HIIT-only group|The participants will perform a weekly 40 minutes session for four weeks.
88942921|NCT05854446||Healthcare Experts|Experts with diverse backgrounds in healthcare and pain management.
89537175|NCT02719691|Experimental|Dose-Expansion of Alisertib and Dose-Expansion of MLN0128: Group 1|"This group will receive a Dose-Expansion of Alisertib and Dose-Expansion of MLN0128. In cycle 1, single agent Alisertib will be administered at the MTD on days 1-7 and MLN0128 will be administered on days 8-21. In cycle 2 and beyond, dosing with both agents will begin on day 1, with Alisertib administered days 1-7 and MLN0128 administered days 1-21.~Pancreatic Cancer Cohort:~This group will receive a Dose-Expansion of Alisertib and Dose-Expansion of MLN0128. On each cycle, Alisertib will be administered on days 1-7, while MLN0128 will be administered continuously on days 1-21."
89537176|NCT02719691|Experimental|Dose-Expansion of Alisertib and Dose-Expansion of MLN0128: Group 2|This group will receive a Dose-Expansion of Alisertib and Dose-Expansion of MLN0128. In cycle 1, MLN0128 will be administered at the MTD days 1-28 and Alisertib will be administered at the MTD on days 8-15. In cycle 2 and beyond, dosing with both agents will begin on day 1, with Alisertib administered days 1-7 and MLN0128 administered days 1-21.
88942924|NCT05854420|Experimental|Modified anterior Lamellar Recession|All patients in this arm underwent a combination of ALR, blepharoplasty, suprasternal fixation, and cauterization or internal bulb extirpation of posteriorly located lashes.
88942925|NCT05854394|Experimental|Prehabilitation group|Multimodal prehabilitation strategy includes physical exercise (moderate aerobic exercise combined with resistance exercise and respiratory training ), nutritional suggestion and optimization#whey protein supplement#, and psychological therapy, as well as conventional guidance (including drug treatment recommendations for chronic disease, quit smoking and abstinence).
88942926|NCT05854394|No Intervention|Control group|The patients will receive the conventional clinical guidance according to The First Affiliated Hospital of Xiamen University, including drug treatment recommendations for chronic disease, quit smoking and abstinence.
88942927|NCT05854355|Experimental|Intervention|This group received the multi-component school and home-based intervention (physical activity programme (aimed to increase children's physical activity and decrease sedentary behaviour)
88942928|NCT05854355|No Intervention|Control|"The primary school children in the control group did not receive the intervention.~The control arm continued with their usual practice and lesson delivery, no environmental changes were made to their classrooms."
88942929|NCT05854342|Experimental|bicarbonate-calcium water|participants of this group drink bicarbonate-calcium water
88942930|NCT05854342|No Intervention|low mineral water|participants of this group drink low mineral water
88942931|NCT05854290|Experimental|CRT plus CBT and Lifestyle modifications|
88942932|NCT05854290|Active Comparator|Usual care Psychoeducation|
88942933|NCT05854277|Other|Endoscopists|
88942934|NCT05854264|Active Comparator|microbiota and specialized nutrition|microbiota analysis in lower lavage (Bronco Alveolar Lavage: BAL) samples in patietns treated with specialized nutrition
88942935|NCT05854264|Sham Comparator|microbiota and standard nutrition|microbiota analysis in lower lavage (Bronco Alveolar Lavage: BAL) samples in patients treated with standard nutrition
88942936|NCT05854225|Other|single-arm|a prospective single-arm clinical study
88942937|NCT05854199|Experimental|Telehealth solution|Telehealth solution offered
88942938|NCT05854199|No Intervention|Usual care|Control
88942939|NCT05854186|Experimental|Telehealth solution|Telehealth solution offered.
88942940|NCT05854186|No Intervention|Control|Usual care.
89461600|NCT02379182|Active Comparator|Control group|Will not receive any treatment procedure. Patients allocated in the control group will be treated according to the standard clinical care of patients with dysphagia at our center, that includes: adaptation of fluids, diet and oral hygiene recommendations, and postural and swallowing maneuvers training if necessary.
89461601|NCT02379182|Experimental|Sensory Group|Patients allocated in the sensory group will be treated with transcutaneous electrical stimulation at sensory level. In addition, they will receive the standard clinical care described in the control group. The treatment procedure will consist of the application, at rest, of 80 Hz of transcutaneous electrical stimulus (biphasic, 700 µs) using VitalStim device (Chattanooga Group, Hixson, TN, USA), 2 sessions of 1 hour per day the first week, and 1 hour per day the next week. Sessions will be applied for two weeks. Treatment intensity will be set to 75% of motor threshold and electrode placement, thyro-hyoid (placement 3a described in the VitalStim Certification Program). The motor threshold will be determined by triplicate, as the intensity level at which the patient reports a grabbing or pulling sensation and confirmed by the clinician. Every 10 min, the patient will be asked if the initial sensation is maintained and, if necessary, treatment intensity will be re-adjusted.
89461602|NCT02379182|Experimental|Motor Group|Patients allocated in the motor group will be treated with transcutaneous electrical stimulation at motor level. In addition, they will receive the standard clinical care of patients with dysphagia described in the control group. The treatment procedure will consist of the application, at rest, of 80 Hz of transcutaneous electrical stimulus (biphasic, 700 µs) using VitalStim device (Chattanooga Group, Hixson, TN, USA), 2 sessions of 1 hour per day the first week, and 1 hour per day the next week. Sessions will be applied from Monday to Friday for two weeks. Treatment intensity will be set to the motor threshold and electrode placement, supra-hyoid. The motor threshold will be determined by triplicate, as the intensity level at which the patient reports a grabbing or pulling sensation and confirmed by the clinician. Every 10 min, the patient will be asked if the initial sensation is maintained and, if necessary, treatment intensity will be re-adjusted.
89461603|NCT02370524|Experimental|[18F]T807|At the [18F]T807 PET imaging visit, subjects will be given a bolus injection of no more than 10 mCi (370 MBq) of [18F]T807
89461604|NCT02370446||patient gets personalized medication log|Patients in the intervention group will receive a personalized medication log that includes all treatment medications (IV and oral), days of treatment and medication specific information such as timing or diet restrictions. The personalized medication log and patient education materials (fact cards) will be placed in a clear plastic envelope that the patient can carry with them throughout treatment.
89461605|NCT02370446||patient gets standard of care|Current MSKCC standards of professional nursing practice require the professional nurse to develop a plan of care that includes teaching the patient and support system the prescribed prescriptions / regimen and all doses, route, length of treatment, side effects and safety precautions.
89461606|NCT03105440|Experimental|Robotic rehabilitation|It Will be used a exoskeleton Armeo®Spring, to training to affected upper limb, the protocol of the treatment is constituted for 8 games. The equipment arm will be adjusted the volunteers height, in sitting position, allowing support against the action of gravity of the arm and forearm, supporting 45° of the shoulder flexion, which will be facilitation the member movement.
89461607|NCT03105440|Experimental|Virtual reality|"The software used in this study was developed by the members of the Laboratory of Sensory and Motor Engineering Rehabilitation Together with Federal University of Uberlândia. This virtual reality of projection software, which uses Kinact®, captures the patient's picture and transfers to the monitor. The exercises provided by game are similar to those performed in conventional therapy; however, in a more entertaining form.~Comprised 8 exercises to upper limbs and trunk. The patient should reach the red circle until it becomes green."
89461608|NCT03105440|Experimental|Vibration therapy|"The vibration mat used in this study was developed by the members of the Laboratory of Sensory and Motor Engineering Rehabilitation together with mark Vibra Ind. e Com. Prod. Electronics Ltda.~Will participate 20 woman, that stay in supine position, with the enveloped member of the vibration mat, elevated and supported. The volunteer will be submitted to 15 minutes of vibration with frequency of the 40 hertz, in both upper limbs."
89461609|NCT03105440|Experimental|Hand cycling|Will participate 20 woman, submitted hand cycling through of the adapted bicycle to upper members. The protocol will be comprised by track without obstacle, comprised by 10 turns. The cyclic movement velocity will be realized according to the physical fatigue of patients.
89461610|NCT03105440|Experimental|Control group|Will participate 20 healthy woman, that won't pass to the treatment physiotherapeutic, only will be collected the electromyography and dynamometer.
89461611|NCT03105440|Experimental|Canoeing|Will participate 20 woman, submitted canoeing activates, through rowing realized in therapeutic pool, with the aid and supervision of the therapeutic. It is important highlight that the exercises intensity will be to realized according to the physical fatigue of patients.
88942941|NCT05854173|Other|Pendulum Exercises|
88942942|NCT05854173|Experimental|Kaltenborn Mobilization|
88942943|NCT05854147|Experimental|Treadmill Training With Visual and Auditory Cues|
88942944|NCT05854147|Other|Treadmill Training Without Visual and Auditory Cues|
89461612|NCT02379026|Experimental|Exercise & Protein Drink/Diet|High-protein (1.2-1.5 g protein per kg bodyweight; a milk-based protein drink will provide 50 g protein/day) energy-restricted (500 kcal deficit) diet and a multimodal exercise program (balance, flexibility, aerobic, resistance) 3 times/week, each lasting 1 hour. 1 tablet of Vitamin D3 (25 micrograms) x three days/week. Total duration 16 weeks.
89461613|NCT02379026|Active Comparator|Exercise|A multimodal exercise program (balance, flexibility, aerobic, resistance) will take place 3 times/week, each one lasting 1 hour. Participants in this group will follow their habitual diet. 1 tablet of Vitamin D3 (25 micrograms) x three days/week. Total duration 16 weeks.
89461614|NCT02515942|Experimental|CLG561|CLG561 10 mg, one IVT injection every 28 days for a total of 12 injections
89461615|NCT02515942|Experimental|CLG561+LFG316|CLG561 5mg + LFG316 5 mg, one IVT injection every 28 days for a total of 12 injections
89461616|NCT02515942|Sham Comparator|Sham Injection|One sham injection every 28 days for total of 12 sham injections
89461617|NCT02374892|Experimental|Intervention|"Adolescents will attend a single one-on-one session with a nurse. Sessions will be youth-oriented, interactive, and engaging. They will make a health passport, go over their cardiac anatomy, watch videos among other things.~The adolescent will be given a study email address and encouraged to contact the nurse by email or text messaging with follow-up."
89461618|NCT02374892|No Intervention|Usual Care|Youth seen in the Cardiology clinic see a nurse only to measure weight, height, and blood pressure. They rely on their cardiologist for information about their heart condition. The approach and amount of time taken by each cardiologist with a youth varies.
89461619|NCT02991859|Experimental|Arm AB - FF followed by FP|Each treatment period (TP) comprises of 5 consecutive 7-day dosing phases with escalating doses of either FF or FP. In TP 1, subjects will receive evening (PM) dose of 1 puff of FF 25 microgram (mcg) (Total daily dose [TDD] = 25 mcg) in first phase followed by PM dose of 1 puff of FF 100 mcg (TDD = 100 mcg) in second phase; PM dose of 1 puff of FF 200 mcg (TDD = 200 mcg) in third phase; PM dose of 2 puff of FF 200 mcg (TDD = 400 mcg) in fourth phase and PM dose of 4 puff of FF 200 mcg (TDD = 800 mcg) in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of FP 50 mcg (TDD = 50 mcg) in first phase followed by morning (AM) and PM doses of 1 puff each of FP 100 mcg (TDD = 200 mcg) in second phase; AM and PM doses of 1 puff each of FP 250 mcg (TDD = 500 mcg) in third phase; AM and PM doses of 1 puff each of FP 500 mcg (TDD = 1000 mcg) in fourth phase and AM and PM doses of 2 puffs each of FP 500 mcg (TDD = 2000 mcg) in fifth phase. Washout period will be of 25-42 days.
89461620|NCT02991859|Experimental|Arm AC - FF followed by BUD|Each TP comprises of 5 consecutive 7-day dosing phases with escalating doses of either FF or BUD. In TP 1, subjects will receive PM dose of 1 puff of FF 25 mcg (TDD = 25 mcg) in first phase followed by PM dose of 1 puff of FF 100 mcg (TDD = 100 mcg) in second phase; PM dose of 1 puff of FF 200 mcg (TDD = 200 mcg) in third phase; PM dose of 2 puffs of FF 200 mcg (TDD = 400 mcg) in fourth phase and PM dose of 4 puffs of FF 200 mcg (TDD = 800 mcg) in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of BUD 100 mcg (TDD = 100 mcg) in first phase followed by AM and PM doses of 1 puff each of BUD 200 mcg (TDD = 400 mcg) in second phase; AM and PM doses of 1 puff each of BUD 400 mcg (TDD = 800 mcg) in third phase; AM and PM doses of 2 puffs each of BUD 400 mcg (TDD = 1600 mcg) in fourth phase and AM and PM doses of 4 puffs each of BUD 400 mcg (TDD = 3200 mcg) in fifth phase. Washout period will be of 25-42 days.
89461621|NCT02991859|Experimental|Arm AD - FF followed by ELLIPTA Placebo|Each TP comprises of 5 consecutive 7-day dosing phases with escalating doses of either FF or ELLIPTA Placebo. In TP 1, subjects will receive PM dose of 1 puff of FF 25 mcg (TDD = 25 mcg) in first phase followed by PM dose of 1 puff of FF 100 mcg (TDD = 100 mcg) in second phase; PM dose of 1 puff of FF 200 mcg (TDD = 200 mcg) in third phase; PM dose of 2 puffs of FF 200 mcg (TDD = 400 mcg) in fourth phase and PM dose of 4 puffs of FF 200 mcg (TDD = 800 mcg) in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of ELLIPTA Placebo in first, second and third phases followed by PM dose of 2 puffs of ELLIPTA Placebo in fourth phase and PM dose of 4 puffs of ELLIPTA Placebo in fifth phase. Washout period will be of 25-42 days.
89461622|NCT02991859|Experimental|Arm BA - FP followed by FF|Each TP comprises of 5 consecutive 7-day dosing phases with escalating doses of either FP or FF. In TP 1, subjects will receive PM dose of 1 puff of FP 50 mcg (TDD = 50 mcg) in first phase followed by AM and PM doses of 1 puff each of FP 100 mcg (TDD = 200 mcg) in second phase; AM and PM doses of 1 puff each of FP 250 mcg (TDD = 500 mcg) in third phase; AM and PM doses of 1 puff each of FP 500 mcg (TDD = 1000 mcg) in fourth phase and AM and PM doses of 2 puffs each of FP 500 mcg (TDD = 2000 mcg) in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of FF 25 mcg (TDD = 25 mcg) in first phase followed by PM dose of 1 puff of FF 100 mcg (TDD = 100 mcg) in second phase; PM dose of 1 puff of FF 200 mcg (TDD = 200 mcg) in third phase; PM dose of 2 puffs of FF 200 mcg (TDD = 400 mcg) in fourth phase and PM dose of 4 puffs of FF 200 mcg (TDD = 800 mcg) in fifth phase. Washout period will be of 25-42 days.
89461623|NCT02991859|Experimental|Arm BC - FP followed by BUD|Each TP comprises of 5 consecutive 7-day dosing phases with escalating doses of either FP or BUD. In TP 1, subjects will receive PM dose of 1 puff of FP 50 mcg (TDD = 50 mcg) in first phase followed by AM and PM doses of 1 puff each of FP 100 mcg (TDD = 200 mcg) in second phase; AM and PM doses of 1 puff each of FP 250 mcg (TDD = 500 mcg) in third phase; AM and PM doses of 1 puff each of FP 500 mcg (TDD = 1000 mcg) in fourth phase and AM and PM doses of 2 puffs each of FP 500 mcg (TDD = 2000 mcg) in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of BUD 100 mcg (TDD =100 mcg) in first phase followed by AM and PM doses of 1 puff each of BUD 200 mcg (TDD = 400 mcg) in second phase; AM and PM doses of 1 puff each of BUD 400 mcg (TDD = 800 mcg) in third phase; AM and PM doses of 2 puffs each of BUD 400 mcg (TDD =1600 mcg) in fourth phase and AM and PM doses of 4 puffs each of BUD 400 mcg (TDD = 3200 mcg) in fifth phase. Washout period will be of 25-42 days.
89501874|NCT02709512|Experimental|Drug: ADI-PEG 20 plus Pem Platinum|"Dose: 36 mg/m2 given weekly Route of Administration: Intramuscular (IM) Duration : Course of Study~In Combination With:~Pemetrexed Dose: 500 mg/m2 every 3 weeks Route of Administration: Intravenous Cisplatin Dose: 75 mg/m2 every 3 weeks Route of Administration: Intravenous Carboplatin Dose: AUC 5 mg/mL/min every 3 weeks Route of Administration: Intravenous~ADI-PEG 20 plus Pem Platinum: Investigational Drug in combination approved standard of care treatment for this indication"
89537177|NCT02719691|Experimental|Pancreatic Cohort|This group will receive a Dose-Expansion of Alisertib and Dose-Expansion of MLN0128. On each cycle, Alisertib will be administered on days 1-7, while MLN0128 will be administered continuously on days 1-21.
88942945|NCT05854134|Experimental|Closed Chain|
88942946|NCT05854134|Other|Aerobic Exercise|
88942947|NCT05854121|Other|Functional Electrical Stimulation|
88942948|NCT05854121|Experimental|Constrained Induced Movement Therapy|
88942949|NCT05854108|Other|Cervical Traction|
88942950|NCT05854108|Experimental|Snag Therapy|
88942951|NCT05854082|Other|Condition|Typical Reader or Individual with Dyslexia
88942952|NCT05854056|Active Comparator|Accelerated rehabilitation protocol|Elements of physical therapy Group 1 Accelerated rehabilitation Antioedema knee, calf, leg Day 1 Knee brace, ROM limitations No Weight-bearing limitations No, crutches are recommended for 4 weeks. Active exercises. Functional exercises. 1 week Active dynamic strengthening exercises. 5 weeks Closed chain exercises for muscle strengthening. 8 weeks Muscle endurance and neuromuscular control, progress strengthening exercises, jogging 12 weeks
88942953|NCT05854056|Active Comparator|Conservative rehabilitation protocol|"Elements of physical therapy Group 2 Conservative rehabilitation Antioedema knee, calf, leg Day 1 Knee brace, ROM limitations 6 weeks Weight-bearing limitations 4 weeks limb weight, followed by half body weight till week 6~Active exercises. Functional exercises. 8 weeks Active dynamic strengthening exercises. 8 weeks Closed chain exercises for muscle strengthening. 8 weeks Muscle endurance and neuromuscular control, progress strengthening exercises, jogging 12 weeks"
89201815|NCT00780468|Active Comparator|1|Existing diet plan
89201816|NCT00780468|Experimental|2|New diet plan
89201817|NCT00773760||dosing|
89201818|NCT00773994|Other|Normal velopharyngeal mechanism|All participants in this study are normal healthy adults, who have agreed to undergo to a videofluoroscopic Televex. These participants are acceptable control subjects because they are not diagnosed with VPI and/or submucous cleft palate (SMCP) and the velopharyageal mechanism functions the same in adults as it does in children. This procedure will take approximately 3 minutes to 5 minutes.
88942954|NCT05854043|Experimental|ERAS group|In this group, patients will be treated with modified ERAS protocol.
88942955|NCT05854043|Other|control group|In this group, patients will be treated with routine protocol.
88942956|NCT05854030||advanced lung squamous carcinoma|advanced pulmonary carcinoma with pathological diagnosis of squamous cell and are applied with first line treatment of anti-PD-L1 combined with chemotherapy
88942957|NCT05854030||normol volunteers|10 normol volunteers will be enrolled in the group
88942958|NCT05854004|Other|Therapeutic Ultrasound|
88942959|NCT05854004|Other|Myofascial Release Technique|
89201819|NCT00774072|Active Comparator|Tobramycin 80 mg|applied once daily via Pari Sinus nebulizer
89201820|NCT00774072|Placebo Comparator|isotonic saline|applied once daily via Pari Sinus nebulizer
88942960|NCT05853965|Experimental|Cohort 1|Belantamab Mafodotin 1.9 mg/kg Q6W Venetoclax 400mg QD
88942961|NCT05853965|Experimental|Cohort 2|Belantamab Mafodotin 1.9 mg/kg Q6W Venetoclax 800mg QD
88942962|NCT05853965|Experimental|Cohort 3|Belantamab Mafodotin 1.9 mg/kg Q6W Venetoclax 400mg QD Dexamethasone 40mg Q1W (20mg for subjects ≥ 75 years)
88942963|NCT05853965|Experimental|Cohort 4|Belantamab Mafodotin 1.9 mg/kg Q6W Venetoclax 800mg QD Dexamethasone 40mg Q1W (20mg for subjects ≥ 75 years)
89201821|NCT00774150|Experimental|1. Cognitive Behavioral Therapy|
89201822|NCT00774150|Active Comparator|2. Client Centered Therapy|
88942964|NCT05853952|Experimental|Non-invasive Neuromodulation|The non-invasive neuromodulation experimental group, are treated 20 sessions with the NXSignal non-invasive neuromodulation device (NESA)
88942965|NCT05853952|Placebo Comparator|Placebo Non-invasive Neuromodulation|The non-invasive neuromodulation placebo group, are treated 20 sessions with the NXSignal non-invasive neuromodulation device (NESA)
88942966|NCT05853939|Experimental|Visual Cortex, 1 Hz rTMS, Attended|
88942967|NCT05853939|Experimental|Visual Cortex, 1 Hz rTMS, Unattended|
88942968|NCT05853939|Experimental|Visual Cortex, 10 Hz rTMS, Attended|
88942969|NCT05853939|Experimental|Visual Cortex, 10 Hz rTMS, Unattended|
88942970|NCT05853939|Sham Comparator|Visual Cortex, Sham, Attended|
88942971|NCT05853939|Sham Comparator|Visual Cortex, Sham, Unattended|
88942972|NCT05853926|Experimental|Spinal Manipulation With Laser Therapy|
88942973|NCT05853926|Other|Dry Needling|
89201823|NCT02556996|Experimental|Killed ETEC/rCTB vaccine|Three doses administered orally at 2-week intervals
89201824|NCT02556996|Placebo Comparator|Placebo|Three doses administered orally at 2-week intervals
89201825|NCT00774228|Experimental|I-ZIP Ocular Bandage|I-Zip bandage application
89201826|NCT00774228|Active Comparator|Oasis 24 hour Soft Shield Collagen Corneal Shield|Oasis shield application
89201827|NCT00780624|Active Comparator|NIPPV|The NIPPV group receiving NIPPV treatment.
89201828|NCT00780624|Active Comparator|Control|The Control group receiving nCPAP treatment.
89201829|NCT04047498|Experimental|Within-subjects comparison of constant and alternating DBS|
89201830|NCT00780702|Experimental|Arm 1|
89201831|NCT00780702|Placebo Comparator|Arm 2|
89201832|NCT00780780|Active Comparator|1|Triamcinolone intravitreal injection + Nepafenac eye drops
89201833|NCT00780780|Other|2|Triamcinolone intravitreal injection
89201834|NCT00780858||Ganirelix|Patients with premature lutenization (progesterone >1,2 ng/ml) who did not get pregnant during the first IUI underwent a second IUI.
89461624|NCT02991859|Experimental|Arm BE - FP followed by DISKUS Placebo|Each TP comprises of 5 consecutive 7-day dosing phases with escalating doses of either FP or DISKUS Placebo. In TP 1, subjects will receive PM dose of 1 puff of FP 50 mcg (TDD = 50 mcg) in first phase followed by AM and PM doses of 1 puff each of FP 100 mcg (TDD = 200 mcg) in second phase; AM and PM doses of 1 puff each of FP 250 mcg (TDD = 500 mcg) in third phase; AM and PM doses of 1 puff each of FP 500 mcg (TDD = 1000 mcg) in fourth phase and AM and PM doses of 2 puffs each of FP 500 mcg (TDD = 2000 mcg) in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of DISKUS Placebo in first phase followed by AM and PM doses of 1 puff each DISKUS Placebo in second, third and fourth phase; AM and PM doses of 2 puffs each of DISKUS Placebo in fifth phase. Each TP will be followed by a washout period of 25-42 days.
88942974|NCT05853874|Experimental|Nutritional intervention|"Nutritional intervention consist in a macro- and micronutrients balanced nutritional protocol with a focus on sustainability and personalized according to the individual malnutrition severity. In particular, an adequate coverage of energy, protein and water requirements will be guaranteed according to Italian reference values (LARN) and European (ESPEN) guidelines.~In light of the scientific literature and the principal issues founding in malnourished older people, the proposed nutritional protocol will provide an adequate and sustainable consumption of animal and vegetable proteins and an appropriate water intake.~The nutritional intervention will be carried out by a qualified staff."
88942975|NCT05853874|Other|Control|The control group receive the standard of care provided for malnutrition treatment by hospitals
88942976|NCT05853809|Active Comparator|FeNO measurement|Anti inflammatory treatment guided by measurement of airway inflammation (FeNO).
88942977|NCT05853809|No Intervention|Usual care|
88942978|NCT05853796||Patients with acute ischemic stroke at young age (18-50 years)|Patients aged 18 to 50 years with first-ever ischemic stroke or transient ischemic attack.
88942979|NCT05853796||Healthy controls|Healthy controls (aged 18 to 50 years) without cardiovascular diseases in their medical history. Subjects age- and gender-matched to patients
88942980|NCT05853783||OPMDs that progressed to OSCC|No dysplasia, mild, moderate, severe dysplasia, CIS
88942981|NCT05853783||OPMDs that did not progress to OSCC|No dysplasia, mild, moderate, severe dysplasia, CIS
88942982|NCT05853770|Experimental|TGfU volleyball intervention|"According to the national curriculum, children in Serbia must attend three regular physical education (PE) classes per week.~Besides attending two regular PE classes, participants in the experimental group also followed a 16-week TGfU volleyball intervention that was implemented during the third PE class. The total number of sessions: 32 regular PE + 16 TGfU volleyball intervention ."
88942983|NCT05853770|Active Comparator|Control group|Control group (CG) participants followed the national physical education curriculum. The CG participants conducted three regular PE classes per week or 48 regular PE classes in total.
88942984|NCT05853718|Experimental|TAF antiviral therapy group|Eligible hepatitis B pregnant women are given TAF antiviral therapy (25mg, oral, 1/day) from week 28-32 of gestation until delivery
88942985|NCT05853692|Experimental|Test|The investigational product be administered for 63 days. Patient will use a spray based on zinc gluconate (three times a day)
88942986|NCT05853692|Active Comparator|Control|The investigational product be administered for 63 days. Patient will use a solution based on sodium chloride and bicarbonate (5 times a day)
88942987|NCT05853666|No Intervention|Control Group with Standard Care|Consenting families in the NICU during the baseline control period will receive standard care as it is already provided at each site. Data collection procedures will mirror intervention groups to ensure comparable control data.
89461625|NCT02991859|Experimental|Arm CA - BUD followed by FF|Each TP comprises of 5 consecutive 7-day dosing phases with escalating doses of either BUD or FF. In TP 1, subjects will receive PM dose of 1 puff of BUD 100 mcg (TDD =100 mcg) in first phase followed by AM and PM doses of 1 puff each of BUD 200 mcg (TDD =400 mcg) in second phase; AM and PM doses of 1 puff each of BUD 400 mcg (TDD = 800 mcg) in third phase; AM and PM doses of 2 puffs each of BUD 400 mcg (TDD =1600 mcg) in fourth phase and AM and PM doses of 4 puffs each of BUD 400 mcg (TDD = 3200 mcg) in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of FF 25 mcg (TDD = 25 mcg) in first phase followed by PM dose of 1 puff of FF 100 mcg (TDD = 100 mcg) in second phase; PM dose of 1 puff of FF 200 mcg (TDD = 200 mcg) in third phase; PM dose of 2 puffs of FF 200 mcg (TDD = 400 mcg) in fourth phase and PM dose of 4 puffs of FF 200 mcg (TDD = 800 mcg) in fifth phase. Washout period will be of 25-42 days.
88942988|NCT05853666|Experimental|Intervention Group Receiving CNH+|Eligible consenting families (following enrollment) will be provided a secure login code and instructions to access the CNH+ educational modules and to send and receive virtual calls and text messages. Parents will be asked to use CNH+ during their entire NICU stay. To ensure equity, interested families without a personal device to access CNH+ will be offered a study-provided iPad for the duration of their infant's stay. Parents will have access to CNH+ while on the unit and 6 months post-discharge.
88942989|NCT05853653|Experimental|Using dolls in breastfeeding education|In the breastfeeding training, the researchers will explain the pre-created training content. It will then be demonstrated practically using the baby. A training brochure will be given at the end of the training.
88942990|NCT05853653|No Intervention|Verbal expression is used in breastfeeding education|In the breastfeeding training, the researchers will verbally explain the pre-created training content. A training brochure will be given at the end of the training.
88942991|NCT05853627|Experimental|Mismatch reactivation condition|"The participant will recite their trauma narrative to the psychologist for 10-20 minutes. However, during each recitation, a mismatch condition, different for each session, will be added to the reactivation procedure by having the participant do the following (in order of sessions."
89201835|NCT00780858||Control|Patients without premature lutenization (progesterone >1,2 ng/ml) underwent a only one IUI.
89201836|NCT00776958||Ovarian or Breast Cancer Study Registry|
89201837|NCT00774384|Active Comparator|1|Immunisation with NZ MenB OMV vaccine (NZ98/254)
89461626|NCT02991859|Experimental|Arm CB - BUD followed by FP|Each TP comprises of 5 consecutive 7-day dosing phases with escalating doses of either BUD or FP. In TP 1, subjects will receive PM dose of 1 puff of BUD 100 mcg (TDD =100 mcg) in first phase followed by AM and PM doses of 1 puff each of BUD 200 mcg (TDD =400 mcg) in second phase; AM and PM doses of 1 puff each of BUD 400 mcg (TDD = 800 mcg) in third phase; AM and PM doses of 2 puffs each of BUD 400 mcg (TDD =1600 mcg) in fourth phase and AM and PM doses of 4 puffs each of BUD 400 mcg (TDD = 3200 mcg) in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of FP 50 mcg (TDD = 50 mcg) in first phase followed by AM and PM doses of 1 puff each of FP 100 mcg (TDD = 200 mcg) in second phase; AM and PM doses of 1 puff each of FP 250 mcg (TDD =500 mcg) in third phase; AM and PM doses of 1 puff each of FP 500 mcg (TDD = 1000 mcg) in fourth phase and AM and PM doses of 2 puffs each of FP 500 mcg (TDD = 2000 mcg) in fifth phase. Washout period will be of 25-42 days.
89461627|NCT02991859|Experimental|Arm CE - BUD followed by DISKUS Placebo|Each TP comprises of 5 consecutive 7-day dosing phases with escalating doses of either BUD or DISKUS Placebo. In TP 1, subjects will receive PM dose of 1 puff of BUD 100 mcg (TDD =100 mcg) in first phase followed by AM and PM doses of 1 puff each of BUD 200 mcg (TDD =400 mcg) in second phase; AM and PM doses of 1 puff each of BUD 400 mcg (TDD = 800 mcg) in third phase; AM and PM doses of 2 puffs each of BUD 400 mcg (TDD =1600 mcg) in fourth phase and AM and PM doses of 4 puffs each of BUD 400 mcg (TDD = 3200 mcg) in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of DISKUS Placebo in first phase followed by AM and PM doses of 1 puff each DISKUS Placebo in second, third and fourth phase; and AM and PM doses of 2 puffs each of DISKUS Placebo in fifth phase. Washout period will be of 25-42 days.
89461628|NCT02991859|Experimental|Arm DA - ELLIPTA Placebo followed by FF|Each TP comprises of 5 consecutive 7-day dosing phases with escalating doses of either ELLIPTA Placebo or FF. In TP 1, subjects will receive PM dose of 1 puff of ELLIPTA Placebo in first, second and third phase followed by PM dose of 2 puffs of ELLIPTA Placebo in fourth phase and PM dose of 4 puffs of ELLIPTA Placebo in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of FF 25 mcg (TDD = 25 mcg) in first phase followed by PM dose of 1 puff of FF 100 mcg (TDD = 100 mcg) in second phase; PM dose of 1 puff of FF 200 mcg (TDD = 200 mcg) in third phase; PM dose of 2 puffs of FF 200 mcg (TDD = 400 mcg) in fourth phase and PM dose of 4 puffs of FF 200 mcg (TDD = 800 mcg) in fifth phase. Washout period will be of 25-42 days.
89461629|NCT02991859|Experimental|Arm EB - DISKUS Placebo followed by FP|Each TP comprises of 5 consecutive 7-day dosing phases with escalating doses of either DISKUS Placebo or FP. TP 1, subjects will receive PM dose of 1 puff of DISKUS Placebo in first phase followed by AM and PM doses of 1 puff each of DISKUS Placebo in second, third and fourth phase; AM and PM doses of 2 puffs each of DISKUS Placebo in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of FP 50 mcg (TDD = 50 mcg) in first phase followed by AM and PM doses of 1 puff each of FP 100 mcg (TDD = 200 mcg) in second phase; AM and PM doses of 1 puff each of FP 250 mcg (TDD = 500 mcg) in third phase; AM and PM doses of 1 puff each of FP 500 mcg (TDD = 1000 mcg) in fourth phase and AM and PM doses of 2 puffs each of FP 500 mcg (TDD = 2000 mcg) in fifth phase. Washout period will be of 25-42 days.
89461630|NCT02991859|Experimental|Arm DC - ELLIPTA Placebo followed by BUD|Each TP comprises of 5 consecutive 7-day dosing phases with escalating doses of either ELLIPTA Placebo or BUD. In TP 1, subjects will receive PM dose of 1 puff of ELLIPTA Placebo in first, second and third phase followed by PM dose of 2 puffs of ELLIPTA Placebo in fourth phase and PM dose of 4 puffs of ELLIPTA Placebo in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of BUD 100 mcg (TDD =100 mcg) in first phase followed by AM and PM doses of 1 puff each of BUD 200 mcg (TDD =400 mcg) in second phase; AM and PM doses of 1 puff each of BUD 400 mcg (TDD = 800 mcg) in third phase; AM and PM doses of 2 puffs each of BUD 400 mcg (TDD =1600 mcg) in fourth phase and AM and PM doses of 4 puffs each of BUD 400 mcg (TDD = 3200 mcg) in fifth phase. Washout period will be of 25-42 days.
89461631|NCT04721366||Standard of Care (SoC)|Neonatal and pediatric participants who has been on ERT (VPRIV) will be followed up for 36 months from the time of treatment initiation as per SOC.
89461632|NCT02370290||Observational (QIM)|Patients' clinical and imaging data are collected from routine multiphase CECT imaging and used to establish and validate the classification/prediction rule for QIM.
88942992|NCT05853627|Active Comparator|Standard reactivation condition|The intervention will be the same for each of the six intervention sessions. The participant will recite to the psychologist the narrative they previously composed for 10-20 min. The psychologist will congratulate the participant for having succeeded in this task and advise them they are finished for the day.
88942993|NCT05853614|Experimental|Nurse-Led Quality of Life Intervention|"Participants and caregivers will complete study procedures as outlined:~Completion of surveys at four timepoints (baseline, one month, two months, and three months)~Three visits on-site with trained clinical research nursing staff.~Semi-structured exit interviews with participants and caregivers."
88942994|NCT05853588|Experimental|Experimental group|It was determined by lot by the volunteer nurses who accepted to participate in the study.
88942995|NCT05853588|No Intervention|Control group|It was determined by lot by the volunteer nurses who accepted to participate in the study.
88942996|NCT05852730|Experimental|DPI-386 Nasal Gel|DPI-386 Nasal Gel, 0.4 mg
88942997|NCT05852730|Experimental|Control|Another form of preventative or treatment medication for motion sickness (e.g., promethazine or meclizine)
88942998|NCT05851118||Non-Specific Low Back Pain patients|Participants must have pain located between the thoracolumbar hinge and the lower gluteal fold, with or without pain in either leg, present for more than 12 weeks, on a daily or almost daily basis (at least 4 days out of 7).
88942999|NCT05851118||Control group|Participant with no current or past chronic pain
89461633|NCT02370134|Experimental|Parkinson's glove|Parkinson's glove 14 days use with 4 times follow-up
89461634|NCT02370134|Placebo Comparator|sham glove|sham glove (with light and sound)14 days use with 4 times follow-up
89461635|NCT02374970|Experimental|Intervention group|Actual Lumbar stability exercises involving co-contraction of the transversus abdominis and Protocolized Physiotherapy (therapeutic exercises and thermotherapy during 12 sessions)
89461636|NCT02374970|Active Comparator|Control group|Protocolized Physiotherapy treatment: therapeutic exercises and thermotherapy during 12 sessions.
88943000|NCT05851066|Experimental|VSA003|single dose of VSA003 by subcutaneous (sc) injections: 50 mg, 100 mg, 200 mg
88943001|NCT05851066|Placebo Comparator|placebo|sterile normal saline (0.9% NaCl) calculated volume to match active treatment
88943002|NCT05850819|Experimental|Group A|Application of Gelatamp in the extraction socket
89461637|NCT02370212|Experimental|Creatine|"Creatine will be ingested after interval training and at supper time on training days and in the morning and afternoon on non-training days (0.05 g/kg body mass of creatine with 0.05 g/kg flavoured dextrose per dose).~Both experimental and placebo groups will perform the same high intensity interval training protocols (3x/week for 4 weeks)."
89461638|NCT02370212|Placebo Comparator|Placebo|"The placebo will be ingested after interval training and at supper time on training days and in the morning and afternoon on non-training days (0.1 g/kg flavoured dextrose per dose, isocaloric to the creatine).~Both experimental and placebo groups will perform the same high intensity interval training protocols (3x/week for 4 weeks)."
89461639|NCT02374736|Experimental|Human normal immunoglobulin G (IgG > 98 % purity)|"All subjects will be treated for 6 months. The treatment will start the day of inclusion (M0).~Privigen will be given as 2 g/kg for 2 days/month. The maximum daily dose authorized will be 80g.~The infusion rates are the recommended rates for Privigen in other indications and are in line with the market authorization for Privigen:~Infusions should start at a rate of 0.5 mg/kg/min (0.005 mL/kg/min; 0.3 mL/kg/h; 30 mg/kg/h). If well tolerated within 30 min, the rate can be increased in a first step to 1.0 mg/kg/min (0.01 mL/kg/min; 0.6 mL/kg/h; 60 mg/kg/h) for another 30 min.~If well tolerated, a stepwise increase to a maximum of 8 mg/kg/min (0.08 mL/kg/min; 4.8 mL/kg/h; 480 mg/kg/h) is allowed at the discretion of the investigator."
89461640|NCT02375048|Active Comparator|Hypofractionated WBI|Patients treated with hypofractionated Whole Breast Irradiation received Simultaneous Integrated Boost irradiation of the whole breast and surgical bed at two different dose levels using external intensity - modulated radiotherapy (VMAT RA).
89461641|NCT02375048|Experimental|Accelerated Partial Breast Irradiation|Patients treated with Accelerated Partial Breast Irradiation received the irradiation on surgical bed using external intensity - modulated radiotherapy (VMAT RA).
89461642|NCT02369978|Experimental|Nifurtimox (NFX)|60 days of active treatment with full-dose, or 120 days of active treatment with half-dose (allocation ratio 1:1). The 60-day group will receive active treatment in the first or second half of a 120-day treatment window, as per random allocation. The active treatment period will be followed/preceded by matching placebo (see placebo arm below)
89461643|NCT02369978|Active Comparator|Benznidazole (BZN)|60 days of active treatment with full-dose, or 120 days of active treatment with half-dose (allocation ratio 1:1). The 60-day group will receive active treatment in the first or second half of a 120-day treatment window, as per random allocation. The active treatment period will be followed/preceded by matching placebo (see placebo arm below)
89461644|NCT02369978|Placebo Comparator|Placebo|120 days of treatment with matching placebo
89461645|NCT04055545|Active Comparator|MICT|
89461646|NCT04055545|Active Comparator|HIIT|
89461647|NCT02379260|Other|Interview|Patients and urologists will be interview by a sociologist.
88943003|NCT05850819|Active Comparator|Group B|Extraction socket allowed to heal without application of Gelatamp
88943004|NCT05850429|Placebo Comparator|Control|0.6g/kg body mass maltodextrin in solution.
88943005|NCT05850429|Experimental|Low protein|0.6g/kg body mass maltodextrin PLUS 0.075g/kg body mass protein from Biodulse, in solution
88943006|NCT05850429|Experimental|Medium protein|0.6g/kg body mass maltodextrin PLUS 0.15g/kg body mass protein from Biodulse, in solution
88943007|NCT05850156||Adult sickle cell patients|In the context of routine care, 3 blood collection will be performed on adult sickle cell patients for the analysis of hemoglobin fractions. For each blood collection, an additional volume of blood will be taken for the research purposes.
89461648|NCT02379260|Other|Focus Groups|Focus groups contain 5-7 patients. Groups will be stratified according to socio-economic levels and according to treatment (radical prostatectomy with conservation or without preservation of the neuro vascular strips).
89461649|NCT02379104||Healthy Volunteers|Healthy volunteers fulfilling inclusion/exclusion criteria for reference interval sample group are tested with ROTEM sigma
89461650|NCT02379104||Patients with expected coagulopathy|Patients with expected bleeding and coagulation problems during elective surgery or at the ICU, or trauma patients are tested with ROTEM sigma and ROTEM delta comparatively
88943008|NCT05850156||pediatric sickle cell patients|In the context of routine care, 3 blood collection will be performed on pediatric sickle cell patients for the analysis of hemoglobin fractions. For each blood collection, an additional volume of blood will be taken for the research purposes.
88943009|NCT05850156||Adult sickle cell carriers (heterozygous patients)|In the context of neonatal screening for sickle cell disease, the parents will be called altogether with their children in order to check if they are sickle cell carriers or not. Only 1 blood collection will be performed for this group.
88943010|NCT05850156||Control patients|In the context of neonatal screening for sickle cell disease, the parents will be called altogether with their children in order to check if they are sickle cell carriers or not. Only 1 blood collection will be performed for this group.
88943011|NCT05846347|Experimental|GC012F injection (CD19-BCMA CAR-T cells)|Dose level： DL1：1±20%×10^5/kg, DL2：2±20%×10^5/kg DL3：3±20%×10^5/kg
89201838|NCT00774384|No Intervention|2|No vaccine
89201839|NCT00777114|Experimental|All patients|
89201840|NCT00669396|Experimental|1|IUD
89201841|NCT00669396|Active Comparator|2|Oral levonorgestrel
89201842|NCT00774462|Experimental|1|
89461651|NCT03661489|Experimental|Intravenous Remimazolam 50 mg|"For induction of general anesthesia, remimazolam is co-administered with remifentanil for analgesia and with a muscle relaxant as necessary.~For maintenance of general anesthesia remimazolam is titrated to effect. Administration of boluses of remimazolam is allowed. Remifentanil is continued and/or titrated. Boluses of muscle relaxants are given throughout the surgical procedure as needed."
89461652|NCT03661489|Active Comparator|Intravenous Propofol 2%|"For induction of general anesthesia, propofol is co-administered with remifentanil for analgesia and with a muscle relaxant as necessary.~For maintenance of general anesthesia propofol is titrated to effect. Administration of boluses of propofol is allowed. Remifentanil is continued and/or titrated. Boluses of muscle relaxants are given throughout the surgical procedure as needed."
89461653|NCT02378948|Experimental|Early oral feeding|Liquid oral feeding directly after esophagectomy.
89461654|NCT02378948|No Intervention|Delayed oral feeding|Liquid oral feeding 5 days after esophagectomy
89461655|NCT04056169|Active Comparator|Rosuvastatin|rosuvastatin 20 mg once a day for 6 months
89461656|NCT04056169|Experimental|ezetimibe/rosuvastatin|ezetimibe/rosuvastatin 10/5 mg once a day for 6 months
89461657|NCT04947670|Experimental|Treatment Group|Renal denervation and maintenance of heart failure medications
89461658|NCT04947670|Sham Comparator|Control Group|Sham intervention, maintenance of heart failure medications with option for cross-over renal denervation treatment after 12 months
89461659|NCT04439630|Sham Comparator|reference|Test product without the active components
89461660|NCT04439630|Experimental|Nopal fraction 1|Fraction one out of two possible
89461661|NCT04439630|Experimental|Nopal fraction 2|Fraction two out of two possible
89461662|NCT03660709|Experimental|Intervention|enhanced version of HIV testing and counseling
89461663|NCT03660709|Active Comparator|Control|standard-of-care HIV testing and counseling
89461664|NCT02374658|Experimental|Arts Intervention|This group will receive the weekly one-hour Living Through the Arts program in addition to their standard program of rehabilitation activities
89461665|NCT02374658|No Intervention|Control Group|This group of patients will only receive their standard program of rehabilitation activities
89461666|NCT02369822|Experimental|Vitamin C supplemented|patients with refractory idiopathic epilepsy will receive vitamin C supplement according to age for 1 month
89201843|NCT00777192||Symptoms in Colorectal Cancer|Colorectal Cancer Patients Receiving Oxaliplatin Chemotherapy
89461667|NCT02369822|No Intervention|None supplemented|followed up for 1 month
89461668|NCT03016325|Experimental|Part 1 Cohort 1 HNO Donor|
89461669|NCT03016325|Placebo Comparator|Placebo Part 1 Cohort 1|
89461670|NCT03016325|Experimental|Part 2 Cohort 2 HNO Donor- low dose|
89461671|NCT03016325|Experimental|Part 2 Cohort 2 HNO Donor- high dose|
89461672|NCT03016325|Placebo Comparator|Placebo Part 2 Cohort 2|
89461673|NCT04983004|Experimental|experimental group (tele-rehabilitation)|"Each patient will go on a treatment with 10 sections, and each section is 15 or 30 minutes depends on patient's ability.~The intervention is used by the communication software to interact with each other in real time. The treatment plan and treatment method are set according to the individual's movement needs, and the individual's movement instructions are clearly given during treatment."
89461674|NCT04983004|Active Comparator|control group (bedside rehabilitation)|Each patient will go on a treatment with 10 sections, and each section is 15 or 30 minutes depends on patient's ability. It is carried out by the bedside therapist. The treatment plan and treatment method are set according to the individual's movement needs, and the individual's movement instructions are clearly given during treatment.
89461675|NCT02988115|Experimental|bempedoic acid|bempedoic acid 180 mg tablet taken orally, daily. Patients remain on ongoing lipid-modifying therapy (not study provided)
89461676|NCT02988115|Placebo Comparator|placebo|Matching placebo tablet taken orally, daily. Patients remain on ongoing lipid-modifying therapy (not study provided)
89461677|NCT02374502|Experimental|Brief Intervention Group|Participants in this intervention group will receive a twelve week 'Brief Intervention' delivered by a physiotherapist. Participants will have an initial consultation with a physiotherapist, followed by a number of follow-up sessions. The number and timing of follow-up sessions will be at the participant's discretion (a minimum of 3 and a maximum of 11 over the duration of the study). The follow-up sessions can be face-to-face, over the telephone, or video conferencing depending on participant preference. Participants may additionally opt-in for a weekly email or text message reminder of physical activity goals.
89461678|NCT02374502|No Intervention|Control Group|Participants in this control group will be asked to continue with their current levels of physical activity.
89461679|NCT02378792|Experimental|Vagus Verve Stimulation is on|
89461680|NCT02378792|Sham Comparator|Placebo Vagus Verve Stimulation is off|
89461681|NCT04982770|Experimental|Intervention|The participants have to read ethical guidelines before they are asked to complete the questionnaire of the Oxford Utilitarianism Scale and exposed to medical triage dilemmas.
89461682|NCT04982770|No Intervention|No intervention|The participants do not have to read ethical guidelines before they are asked to complete the questionnaire of the Oxford Utilitarianism Scale and exposed to medical triage dilemmas.
89461683|NCT02378870|Experimental|A:Osteodex|3.0 mg/kg bodyweight solution for infusion
88943012|NCT05845684|Experimental|trial group|The physiotherapy group will receive a 10-minute massage in 30-minute sessions, 3 days a week for 1 month, oral and intraoral tactile stimulations, and non-nutritive sucking exercises to stimulate sucking. Positioning will be done for 15 minutes for mobilization purposes.
88943013|NCT05845684|Other|control group|In the control group, daily standard care practices will be performed.
89461684|NCT02378870|Placebo Comparator|B: Placebo|NaCl 0.9% solution for infusion
89461685|NCT03127111||Adjuvant chemotherapy|Samples from patients with stage III colorectal cancer who are going to receive fluorouracil-based adjuvant chemotherapy will be used for gene mutations analysis, gene methylation analysis, gene expression analysis, SNP analysis, and protein expression analysis.
88943014|NCT05845489|Experimental|Clopidogrel treatment group|Patients assigned to the clopidogrel treatment group will maintain clopidogrel 75mg once a day for at least 5 years.
89461686|NCT02369666|Experimental|LycoRed (code 40051) product|Dietary supplement, LycoRed (code 40051) product, experimental: Mixture of tomato-based carotenoids and phytochemicals in medium chain triglycerides (MCT). One capsule each day with the morning meal, for 4 weeks.
89461687|NCT02369666|Placebo Comparator|Placebo|Dietary supplement placebo: Only MCT oil. One capsule each day with the morning meal, for 4 weeks.
89461688|NCT02374268|Experimental|Exercise program alone|There will be 2 site sessions and 1 home session per week for 12 weeks. Each site exercise session will begin and end with a 5-10 minute warm-up and cool-down routine. The first part of the exercise program consists of 20-30 minute chair-based resistance exercises using Thera-Bands for muscle groups in both the upper and lower body. To target the development of muscle power in both the lower and upper extremities, participants will be instructed to perform each concentric movement 'as rapidly as possible,' and the eccentric movement in a slow and controlled manner. A 5-minute rest period will be given prior to the start of the second part of the exercise program that consists of aerobic exercises such as ball games using fitballs or Taichi. Participants will be asked to spend an hour/week on home exercise. Thera-Bands and a leaflet showing the exercise procedures will be given to them and their caregivers.
89537178|NCT04490135|Experimental|Carers group intervention|caregivers entered into the 8 week CARERS intervention (N=264) Group intervention, 8 x 2 hour sessions. Session 1-4 PST training, session 5-8 Simulation with standardized patients training Pre- post evaluations completed
88943015|NCT05845489|Active Comparator|No antiplatelet or anticoagulant group|Patients assigned to the no antiplatelet or anticoagulant group will not prescribe antithrombotics for at least 5 years. However, when there is a medical need for antithrombotic therapy during the follow-up, the prescription of antithrombotics is permitted with reporting to the research board.
88943016|NCT05833074|Experimental|Couples HIV testing and counseling retesting|Couples HIV testing and counseling is completed following Centers for Disease Control and Prevention (CDC) standard protocol. Participants also complete any adjunct CHTC components associated with their originally assigned condition in NCT05000866.
88943017|NCT05833074|Active Comparator|Individual HIV testing|Individual HIV testing and counseling.
88943018|NCT05830084|Experimental|Induction chemotherapy (VDC/IE) and local treatment /consolidation chemotherapy|"Standard ES treatment consists of: induction chemotherapy (VDC/IE) and local treatment (surgery/radiotherapy), followed by consolidation chemotherapy (VC/IE)/ Bu-Mel (according to physician and patient choice).~Regorafenib will be administered during induction chemotherapy (VDC/IE) and during consolidation chemotherapy with conventional chemotherapy (VC/IE) but not Bu-Mel therapy Conventional chemotherapy will be administered at the recommended dose (100%) and only regorafenib will be escalated/de-escalated.~Regorafenib will only be given concomitant to radiotherapy in case the primary tumor is located in the extremities. In case of primary tumors located in the pelvis, abdomen, thorax, spine, brain, head or neck, regorafenib will be stopped at least 1 week before start of radiotherapy."
88943019|NCT05826873|Other|Pediatric Hospitalists|Prescribing physicians and hospital employees will be recruited during regularly held staff meetings prior to the data collection period. The study team will briefly introduce the study aims and methods and let the hospitalists know that the study team will be emailing them separately to ask permission for Dr. Szymczak to shadow them. Only those who have agreed will participate in the ethnographic observations. For the interviews and surveys, the study team will recruit respondents via contact made during ethnographic observations. The study team will also utilize a snowball approach by asking respondents if they know of any other staff who might be interested in participating in an interview. Approximately 120 clinicians will participate in the interviews and surveys.
88943020|NCT05826873|No Intervention|Families of hospitalized children|Families of children who were hospitalized at one of the four participating sites will be approached for consent to participate in the study. Families who consent will complete 2 brief REDCap surveys and a wellness tracker after their child is discharged from the hospital.
88943021|NCT05818072|Experimental|One biopsy|Obtain one biopsy specimen at the proximal part of the the longest columnar-lined esophagus for patients with suspected Barrett's Esophagus
88943022|NCT05818072|Active Comparator|Three biopsy|Obtain three biopsy specimens at the proximal, middle and distal part of the longest columnar-lined esophagus for patients with suspected Barrett's Esophagus
88943023|NCT05818072|Sham Comparator|Seattle protocol|Obtain 4-quadrant biopsy specimens at intervals of every 1 to 2 cm throughout the the columnar-lined esophagus for patients with suspected Barrett's Esophagus
88943024|NCT05815602|Experimental|Ebastine verum and duspatalin placebo|
88943025|NCT05815602|Active Comparator|Duspatalin verum and ebastine placebo|
89537179|NCT04490135|No Intervention|Wating list control|Caregivers waiting for entry into active arm of CARERS intervention.During this time usual care allowed with no other intervention. Study measures administered at intake and immediately prior to starting the CARERS group. (N=83)
89537180|NCT04794699|Experimental|Part 1: Dose Escalation Monotherapy (Solid Tumors)|
88943026|NCT05810246|Experimental|Diagnostic imaging arm|68Ga-NY104 PET/CT Contrast-enhanced MRI of the brain and contrast-enhanced CT of abdomen and pelvis 68Ga-NODAGA-LM3 PET/CT (exploratory)
88943027|NCT05807568|Experimental|NCAEM EM-SART Pre-Screen|
88943028|NCT05806606|Experimental|Dyadic Empowerment-based Heart Failure program (De-HF)|The 16-week De-HF Program is delivered on a dyadic basis. The program consists of three core elements: i) joint dyadic interview in a home visit (1st-2nd week), ii) five ICT-enhanced empowerment-based modules (3rd-12th week; 2 sessions/ each module), and iii) post-module telephone follow-up (13th-16th week). The overall aim of the dyadic interview is to understand their usual pattern of collaboration, deficits, strengths and competing concerns in disease management. This is followed by the empowerment modules with the purpose to help the care dyads to get a consensus in disease interpretation (1st session: Perceptual and Cognitive Empowerment Session) and develop collaborative goal attainment process (2nd Session: Collaborative Gaol-Setting Process). This will be followed by two bi-weekly telephone calls to the care dyads using a speaker phone to monitor their level of goal attainment for the five modules, and to give further advice and counselling.
88943029|NCT05806606|Active Comparator|Dyadic education program|The 16-week HF education program comprises a home visit, five bi-weekly online training sessions, and the subsequent telephone follow-up for the care dyads. The nurse will first assess how they manage HF in terms of medication compliance, fluid and dietary control, symptom monitoring and responses in a home visit and clarify their major misconceptions in self-care. This will be followed by five bi-weekly online education sessions on the same topics as the empowerment modules in the De-HF program.
88943030|NCT05790369|Experimental|New ankle machine training group (NAMTG)|home-based ankle training program consisted of 6 exercises for their general physical fitness and use a device (new ankle machine) to provide progressive resisted exercise for the ankle strength
88943031|NCT05790369|Active Comparator|Elastic band training group (EBTG)|home-based ankle training program consisted of 6 exercises for their general physical fitness and use Thera band to provide progressive resisted exercise for the ankle strength
88943032|NCT05784727|Other|Earswitch Robustness|Participants will wear the Earswitch device and voluntarily contract their TT to complete a series of tasks shown on screen and/or explained audibly. We will also ask participants to complete questionnaires to understand participant opinions about the effectiveness, usability, and comfort of both their current device (if applicable) and the Earswitch.
88943033|NCT05784675|Experimental|MOBI-CPR|Participants use MOBI-CPR game at home environment.
88943034|NCT05784675|No Intervention|No MOBI-CPR|Participants do not use MOBI-CPR game at home environment.
88943035|NCT05778318||Control group|Patients without Lianhua Qingwen treatment.
88943036|NCT05778318||Observation Group|Patients with Lianhua Qingwen treatment.
88943037|NCT05777317|Experimental|10 kHz SCS plus CMM|Treatment with high frequency, 10 kHz spinal cord stimulation (SCS) in addition to conventional medical management (CMM)
88943038|NCT05777317|Active Comparator|CMM alone|Treatment with conventional medical management (CMM) alone
88943039|NCT05775484||A|"Cardiovascular measurements Non-invasive brachial blood pressure machine Echocardiography~Bio-specimen collection~Six-minute walk test~Musculoskeletal Analysis~Cardiopulmonary exercise test"
88943040|NCT05775484||B|"Cardiovascular measurements Non-invasive brachial blood pressure machine Echocardiography~Bio-specimen collection~Six-minute walk test~Musculoskeletal Analysis"
88943041|NCT05775484||C|"Cardiovascular measurements Non-invasive brachial blood pressure machine Echocardiography~Bio-specimen collection~Six-minute walk test~Musculoskeletal Analysis"
88943042|NCT05775484||D|"Cardiovascular measurements Non-invasive brachial blood pressure machine Echocardiography~Bio-specimen collection~Six-minute walk test (may require separate day visit to complete)~Musculoskeletal Analysis~Questionnaires"
88943043|NCT05771636|Experimental|Experimental G1 - imagery of planned activity|In this condition, the participant will have to think about 4 activities he will plan to do during the next 2 weeks. He will then complete a questionnaire about all the activities he identified and think about the major obstacle that could prevent him to do each activity, and a solution for each one. Then he will proceed to a mental imagery exercise where he imagines doing the activity as vividly as possible. He then will proceed to go home and repeat the imagery practice every day for the next two weeks, and do the planned activities. He will report in a booklet ratings of the mental imagery exercise and the activities he did.
88943044|NCT05771636|Experimental|Experimental G2 - imagery of best possible self|In this condition, the participant will first have to do a mental imagery exercise where he imagines his best possible self, having accomplished all his big life goals, as vividly as possible. He will then have to think about 4 activities he will plan to do during the next 2 weeks, in line with the imagery exercise. He will then complete a questionnaire about all the activities he identified. He then will proceed to go home and repeat the imagery practice every day for the next two weeks, and do the planned activities. He will report in a booklet ratings of the mental imagery exercise and the activities he did.
88943045|NCT05771636|Active Comparator|Control G3 - activity planification alone|In this condition, the participant will have to think about 4 activities he will plan to do during the next 2 weeks. He will then complete a questionnaire about all the activities he identified. There is no mental imagery exercise in this condition. He then will proceed to go home and receive the assignment to do the planned activities in the course of the next two weeks. He will report in a booklet ratings of the activities he did.
88943046|NCT05767554|Experimental|Brief modified behavioral activation|Participants randomized to the behavioral activation condition will meet with a graduate level clinician for one hour.
88943047|NCT05767554|No Intervention|Measurement-only control|Participants who are not randomized to the active condition will take part in a measurement-only control condition. They will participate in all portions of the study except for the in-person behavioral activation session. They will complete a baseline and fill out daily surveys.
89537181|NCT04794699|Experimental|Part 2: Monotherapy Dose Expansion (NSCLC, EG and Urothelial)|
89461689|NCT02374268|Experimental|Exercise program plus nutrition supplement|This group will receive both the exercise program as well as the nutrition supplement. The components of the exercise program will be same as those of the exercise program alone group. Participants will also be asked to consume two sachets of Ensure NutriVigor every day during the 12-week intervention period. Ensure NutriVigor (one sachet of 54.1 g powder) contains 231 calories, 8.61 g protein, 1.21 g hydroxyl-methyl-butyrate (HMB), 130 IU vitamin D, and 0.29 g omega 3 fatty acid per serving. Participants will be instructed on how to prepare the supplement.
89461690|NCT02374268|Other|Waitlist control group|This group will be asked to maintain their usual physical activities and dietary habits during the first 6 months of study period. After they complete the 24-week measurement, they will receive the same 12-week exercise program as of the exercise program alone group.
89461691|NCT03658681|Experimental|Test meal 1: Saturated fat 14.9 E%|Test meal with saturated fat 14.9 E%
89461692|NCT03658681|Experimental|Test meal 2: Polyunsaturated fat 13.6 E%|Test meal with polyunsaturated fat 13,6 E%
89461693|NCT02369588|Experimental|100% Portion Sizes|Food portion size Test meal consists of baseline (100%) portion size of all foods
89461694|NCT02369588|Experimental|133% Portion Sizes|Food portion size Test meal consists of portion sizes of all foods that are 133% the size of baseline portions
89461695|NCT02369588|Experimental|167% Portion Sizes|Food portion size Test meal consists of portion sizes of all foods that are 167% the size of baseline portions
89461696|NCT02369588|Experimental|200% Portion Sizes|Food portion size Test meal consists of portion sizes of all foods that are 200% the size of baseline portions
89461697|NCT02921425|Experimental|patient health record|The study intervention involved the provision to study participants of targeted instruction and practice on use of the Track Health function of the VA's patient health record known as My HealthyVet.
89461698|NCT05028712|Experimental|Visual Information Training|
88943048|NCT05758441|Experimental|Mentoring to be Active plus Family (MPBA+F)|"For the first phase, ten peer-mentoring sessions (1 day/week for 45 minutes each week) delivered virtually with a Project Leader, five peer mentors, and 8-10 mentees with 1:2 mentor/mentee ratios. Each session consists of a 10-15 minute content lesson followed by 20-30 minutes of guided practice, social support, feedback, and personal goal-setting for the following week in small peer mentor/mentee break-out rooms. Mentees track activities and efforts towards meeting personal goals. Parents return their child's weekly completed 'Tracker forms either electronically via the secure, password-protected project website or (if they prefer) by regular pre-paid mail service. The reinforcement component of MPBA+F is a guided, parent-directed 6-module (0nce a month for 6 months) program for parents/guardians to further support the child's home-based PA. Child participants assigned to MPBA will be provided the modules."
88943049|NCT05758441|Active Comparator|Tracking Health and Fitness|"Half of child participants will receive Tracking your Health and Fitness, a comparison program of 10 weekly, self-guided modules from Ohio State University (OSU) Extension mailed to their home.~Child participants assigned to the Tracking Health and Fitness program (comparison group) may voluntarily participate in a 6-month rewards-based self-regulation program to encourage sustainability of weekly PA."
89461699|NCT05028712|Experimental|Multimodal Training|
89461700|NCT03008915|Active Comparator|Aspirin first then placebo|Aspirin 81mg for 2 weeks followed by a washout period and then placebo for 2 weeks
88943050|NCT05755737|Active Comparator|Ondansetron|2 doses of Ondansetron 8mg PO (evening before and morning of study)
88943051|NCT05755737|Active Comparator|Placebo|2 doses of matching placebo 8 mg PO (evening before and morning of study)
88943052|NCT05746364|Experimental|RIDE intervention|Cognitive analytic therapy (CAT)-informed brief therapy for young people struggling with disordered eating
89461701|NCT03008915|Placebo Comparator|Placebo first then aspirin|Placebo for 2 weeks followed by a washout period and then aspirin 81mg for 2 weeks
89461702|NCT02374190||Hospital Admitted STEMI Patients|The analytical cohort for this study consisted of STEMI patients aged over 18 years admitted directly to '24/7' PPCI-capable hospitals for PPCI. STEMI patients were identified based on their discharge diagnoses and were selected as having received PPCI according to their initial reperfusion strategy. Hospitals performing only sporadic PPCI procedures, which we defined as less than 20 procedures per year, and only performing PPCIs during regular hours were not included in the analysis. Interhospital transfers were not included in the analysis, and we limited our analysis to PPCIs conducted within 6 hours on hospital arrival on the assumption that patients with a DTB time beyond this did not receive PCI as a primary reperfusion strategy. The analysis was conducted for the time period for which data were available-1 January 2007 to 31 December 2012. We conducted a complete-case analysis.
89461703|NCT03658603|Experimental|Study group|Thoracodorsal artery perforator flap
89461704|NCT03658603|Active Comparator|control group|Conventional free flaps
89461705|NCT04439162|Experimental|group A|antegrade cardioplegia
89461706|NCT03667625|Experimental|Aquatic group|Aquatic multidimensional mobility exercises were given in the treatment pool at Balcova Thermal Centre, Izmir, Turkey. Group of 6-7 patients was instructed by a specialized physiotherapist twice in a week for eight weeks. The water temperature was 33-340C and the depth was between 110-140 cm, patients were asked to keep T11 level submersion during vertical exercises. Exercise span was kept 30-40 min in first 4 weeks then increased to 45-50 min with additional exercises.
89537182|NCT04794699|Experimental|Part 3: Combination Dose Escalation with docetaxel or paclitaxel (NSCLC, EG and Urothelial)|
89537183|NCT04794699|Experimental|Part 4: Combination Dose Expansion with docetaxel or paclitaxel (NSCLC, EG and Urothelial)|
88943053|NCT05741957|Experimental|Once-a-week Exercise|Once-a-week vigorous-intensity exercise for 4 months.
88943054|NCT05741957|Experimental|Thrice-a-week Exercise|Thrice-a-week vigorous-intensity exercise for 4 months.
88943055|NCT05741957|Other|Usual Care Control|Bi-weekly health education for 4 months.
88943056|NCT05736952|Experimental|Oral Topotecan Combined With Anlotinib|
89461707|NCT03667625|Experimental|Land group|Multidimensional mobility exercises were given at exercise unit of Dokuz Eylul University School of Physical Therapy, Izmir, Turkey. Group of 6-7 patients were instructed by a specialized physiotherapist twice in a week for eight weeks. The room temperature was 23-240C. Exercise span was kept 30-40 min in first 4 weeks then increased to 45-50 min with additional exercises.
89461708|NCT03667625|Active Comparator|Control group|A conventional home exercise programme was given by a specialized physiotherapist to control group. Patients were checked and encouraged to continue their programs by weekly phone calls for eight weeks.
89461709|NCT03658525|Experimental|MR LINAC RADIOTHERAPY|RADIOTHERAPY DELIVERED ON MR LINAC
89461710|NCT03622489|Experimental|Tab ibuprofen + IV acetaminophen|"All women will receive immediately after surgery, in the recovery room:~IV morphin 5 mg, repeat doses every 10 minutes for VNS>3~IV Tramal 100 mg, once~After Admitted to Maternity ward:~- Scheduled doses: 08:00 hr, Tab. Ibuprofen 400 mg, and IV Acetaminophen 1 gr 14:00 hr, IV Acetaminophen 1 gr 19:00 hr, Tab. Ibuprofen 400 mg 00:00 hr, IV Acetaminophen 1 gr~-Additional analgesia if needed according to VNS scale: PO drops Dipyrone 1 gr, for VNS>4, up to 4 times a day, at least 6 hours between doses.~Tab Tramadex 100 mg, for VNS>6, or if pain persists for 1 hour after receiving Dipyrone, up to 3 times a day, at least 4 hours between doses."
89461711|NCT03622489|Experimental|Tab Ibuprofen + Tab acetaminophen|"All women will receive immediately after surgery, in the recovery room:~IV morphin 5 mg, repeat doses every 10 minutes for VNS>3~IV Tramal 100 mg, once~After Admitted to Maternity ward:~- Scheduled doses: 08:00 hr, Tab. Ibuprofen 400 mg, and PO Acetaminophen 1 gr 14:00 hr, PO Acetaminophen 1 gr 19:00 hr, Tab. Ibuprofen 400 mg 00:00 hr, PO Acetaminophen 1 gr~- Additional analgesia if needed according to VNS scale: PO drops Dipyrone 1 gr, for VNS>4, up to 4 times a day, at least 6 hours between doses.~Tab Tramadex 100 mg, for VNS>6, or if pain persists for 1 hour after receiving Dipyrone, up to 3 times a day, at least 4 hours between doses."
89461712|NCT03622489|Experimental|"On demand analgesia"|"All women will receive immediately after surgery, in the recovery room:~IV morphin 5 mg, repeat doses every 10 minutes for VNS>3~IV Tramal 100 mg, once~After Admitted to Mternity ward:~Will not receive scheduled pain medication, but offered some only upon patients' request according to VNS score:~Tab. Acetaminophen 1 gr, for VNS 1-3, up to 4 times a day, at east 6 hours between doses.~PO drops Dipyrone 1 gr, for VNS 4-7, or if pain persists for 1 hour after receiving Acetaminophen, up to 4 times a day, at least 6 hours between doses.~Tab Ibuprofen 400 mg, for VNS 8-10, or if pain persists for 1 hour after receiving Dipyrone, up to 3 times a day, at least 8 hours between doses."
89461713|NCT03667001|Experimental|Lidocaine Hydrochloride|"1.5 mg/kg lean body mass lidocaine (lidocaine 1%) bolus I.V. as general anesthesia steady state concentration is accomplished~1.5 mg/kg lean body mass/h lidocaine I.V. with beginning of surgical procedures~after completion of surgery: transfer to PACU, pain evaluation for 48 hours~duration of intervention: lidocaine infusion up to four hours from completion of surgery, or till transfer to surgical ward"
89461714|NCT03667001|Placebo Comparator|Saline Solution|"0.15 ml/kg lean body mass saline 0.9% bolus I.V. as general anesthesia steady state concentration is accomplished~0.15 ml/kg lean body mass/h saline 0.9% I.V. with beginning of surgical procedure~after completion of surgery: transfer to PACU, pain evaluation for 48 hours~duration of intervention: saline infusion up to four hours from completion of surgery, or till transfer to surgical ward"
89461715|NCT04439084||Chronic Liver Disease Group|COVID-19 patients with Chronic Liver Disease.
89461716|NCT04439084||Control Group|COVID-19 patients without Chronic Liver Disease.
89461717|NCT04055779||Induced hypotension and arterial occlusion pressure|The patients will receive induced hypotensive anesthesia and the tourniquet pressure will be based on the the tourniquet pressure will be determined based on the AOP which will be determined by the estimation formula (AOP=[SBP+10]/KTP) . The calculation is based on using initial SBP and tissue padding coefficient values , according to limb circumferences of the patient.After calculation of AOP, tourniquet pressures will be determined by adding a safety margin of 20 mmHg to AOP values(tourniquet pressure=AOP+20 mmHg).
89501875|NCT02709512|Placebo Comparator|Drug: Placebo plus Pem Platinum|"Dose: 36 mg/m2 given weekly Route of Administration: Intramuscular (IM) Duration : Course of Study~In Combination With:~Pemetrexed Dose: 500 mg/m2 every 3 weeks Route of Administration: Intravenous Cisplatin Dose: 75 mg/m2 every 3 weeks Carboplatin Dose: AUC 5 mg/mL/min every 3 weeks Route of Administration: Intravenous~Placebo plus Pem Platinum: Placebo in combination approved standard of care treatment for this indication"
89461718|NCT04055779||induced hypotension and limb occlusion pressure|the patients will receive induced hypotensive anesthesia and the tourniquet pressure will be based on the LOP.using the ultrasound Doppler technique and the tourniquet will be inflated until the arterial pulsations disappear at the side of the operation. This pressure will be recorded as LOP .the tourniquet cuff will be inflated to the pressure according to theguidelines of the Association of Perioperative Registered Nurses(AORN) which recommends that a safety margin of 40 mmHg should be added for AOP below 130 mmHg, 60 mmHg for AOP between 131 mmHg and 190 mmHg, and 80 mmHg for AOP above 190 mmHg for adult patients
89461719|NCT02379650|Experimental|Hydroxychloroquine (HCQ)|Subjects in the experimental arm will take 400 mg hydroxychloroquine pills every day, starting before they get pregnant and continuing until 36 weeks of pregnancy or until the pregnancy is over.
89461720|NCT02379650|Placebo Comparator|Placebo|Subjects in the experimental arm will take placebo pills every day, starting before they get pregnant and continuing until 36 weeks of pregnancy or until the pregnancy is over.
89461721|NCT02374034|Experimental|Treatment|Experimental group (n=20) completed a corrective exercise routine, as per the Egoscue Method, at least five days per week for two weeks.
89461722|NCT02374034|No Intervention|Control|The control group maintained their current lifestyle for the two-week duration of the study.
89461723|NCT03666923|Experimental|THR-687 dose level 1|Subjects in this arm will receive a single intravitreal injection of THR-687 dose level 1
89461724|NCT03666923|Experimental|THR-687 dose level 2|Subjects in this arm will receive a single intravitreal injection of THR-687 dose level 2
89461725|NCT03666923|Experimental|THR-687 dose level 3|Subjects in this arm will receive a single intravitreal injection of THR-687 dose level 3
89461726|NCT02369432|Experimental|Group of healthy volunteers and group of patients|"Healthy volunteers: Microparticles will be applied to the skin of the forearm and then a skin biopsy of this area will be performed~Patients suffering from atopic dermatitis: Microparticles will be applied to the skin of the forearm both to an area affected by dermatitis and to an area deprived from the disease. A skin biopsy of these two areas will be performed"
89461727|NCT03658369|Active Comparator|Lanconone®|Lanconone®: 2 Capsules once a day after breakfast
89461728|NCT03658369|Placebo Comparator|Methyl Crystalline Cellulose|2 Capsules once a day after breakfast
89461729|NCT03667469|Experimental|Stapleless one anastomosis gastric bypass|Laparoscopic stapleless-separated one anastomosis (mini-) gastric bypass procedures
89461730|NCT03667469|Active Comparator|Staple use mini-gastric bypass|Laparoscopic stapler-separated one anastomosis (mini-) gastric bypass procedures
89461731|NCT03667469|Active Comparator|Hypocaloric diet therapy|Hypocaloric diet therapy with energy restriction (-500 kcal/d)
88943057|NCT05732506||Patients|Elderly patients diagnosed with nonvalvular atrial fibrillation who meet the frailty criteria and who had been receiving anticoagulant treatment with Edoxaban for no more than 6 months prior to inclusion in the study.
88943058|NCT05719779|Active Comparator|MAD-active|MAD = mandibular advancement appliance, in 60-70% forward position from maximum possible jaw advancement for a given participant
88943059|NCT05719779|Sham Comparator|Neutral MAD- control|Mandibular advancement appliance in neurtral-control position, 10-20% of advancement - a non functional position to open upper airway
88943060|NCT05719155|Experimental|Sequence 1|Period 1: Reference drug(D759+D745+D150) Period 2: Test drug(CKD-379)
88943061|NCT05719155|Experimental|Sequence 2|Period 1: Test drug(CKD-379) Period 2: Reference drug(D759+D745+D150)
88943062|NCT05694442|Experimental|Lipmatte K|Participants will used Lipmatte K everyday for 4 weeks
89461732|NCT03622645|Experimental|Range of motion in hand|Assessment of Wrist flexion/extension, radial/ulnar deviation, supination/pronation, 1.-5. DIP, PIP and MCP flexion/extension ROM measurements of the fingers with universal goniometer and Leap motion sensor
89461733|NCT03666299|Experimental|Lidocaine|Lidocaine treatment
89461734|NCT03666299|Placebo Comparator|Control|Placebo treatment
89461735|NCT04420780|Experimental|Xyl Group|Children will receive sugar-free gums containing 100% Xylitol as sweetener
89461736|NCT04420780|Active Comparator|Pol Group|Children will receive sugar-free gums containing a polyols mixture plus a low amount of Xylitol (22%).
89461737|NCT03660397|Experimental|Intervention|Selective endovascular chemical ablation of adrenal gland after adrenal angiography.
89461738|NCT03660397|Active Comparator|Control|No intervention, but treated with standard antihypertensive drugs
89461739|NCT03591380|Experimental|Experimental: Belimumab|Belimumab 10mg/kg will be administered IV at the following intervals: at the time of transplant (Day 0), then post-transplant at 2, 4, 8, 12, 16, and 20 weeks.
89461740|NCT03704740|Experimental|NBP607-QIV|One or two doses of 0.5mL of NBP607-QIV by intramuscular injection
88943063|NCT05694429|Experimental|Product K cleanser and moisturizer|Participants will used product K cleanser and moisturizer twice daily for 8 weeks
88943064|NCT05686967|Experimental|Aerobic Exercise plus MitoQ|"Moderate intensity aerobic exercise, 50 minutes of treadmill exercise, 65-75% of maximal heart rate, 3 d/week for 10 weeks plus experimental MitoQ, 20mg/d.~Each MitoQ capsule contains 20 mg of mitoquinol mesylate. Dosage: 20 mg orally per day for 10 weeks."
88943065|NCT05686967|Placebo Comparator|Aerobic Exercise plus Placebo|"Moderate intensity aerobic exercise, 50 minutes of treadmill exercise, 65-75% of maximal heart rate, 3 d/week for 10 weeks plus matching placebo capsule/d for 10 weeks.~Matched placebo capsules."
88943066|NCT05686967|Experimental|No Exercise plus MitoQ|No exercise plus experimental MitoQ, 20mg/d. Each MitoQ capsule contains 20 mg of mitoquinol mesylate. Dosage: 20 mg orally per day for 10 weeks.
89461741|NCT03704740|Active Comparator|Agrippal|One or two doses of 0.25mL of Agrippal by intramuscular injection
89461742|NCT04057469|Experimental|Tulobuterol patch|
89461743|NCT04057469|Placebo Comparator|Placebo|
89461744|NCT03660319|Experimental|Environmental Music Therapy|Music Therapy Intervention (EMT)
89461745|NCT03660319|No Intervention|Control|Control - No Environmental Music Therapy. Does not experience Environmental Music Therapy during wait time in radiation oncology waiting room.
89461746|NCT03666221|Experimental|Nimotuzumab plus IMRT|Patients with recurrent nasopharyngeal carcinoma were given an initial dose of nimotuzumab (200 mg) 7days before receiving concurrent intensity modulated radiation therapy(IMRT) , folowing weekly nimotuzumab (200 mg/week) for totally 8 weeks concurrent with IMRT.
89461747|NCT02378324|Active Comparator|Intervention and control|Intervention arm: screening without fee.
89461748|NCT02378324|No Intervention|Control group|Control arm: screening with the regular fee, 100SEK.
89461749|NCT03623009|Experimental|Intervention|An article meant to trigger certain psychosocial behaviors is administered to the intervention arm prior to laparoscopic skills assessment.
89461750|NCT03623009|Sham Comparator|Control|The control arm will receive a neutral article prior to completing the assessment.
89461751|NCT03658291|Experimental|Sanjin tablets group|Sanjin tablets+ levofloxacin simulants
89461752|NCT03658291|Placebo Comparator|Levofloxacin group|Sanjin tablets simulants +levofloxacin
89461753|NCT03658291|Active Comparator|Sanjin tablets+ Levofloxacin group|Sanjin tablets+ levofloxacin
89461754|NCT02378168||cohort of RCT (StV 5-2007; NCT00924222)|Patient group with either sevoflurane or propofol sedation of the RCT (StV 5-2007; NCT00924222)
89461755|NCT04054973|Experimental|L-arginine and Kuvan|Open-label single arm study, all participants will be in this group
89461756|NCT02373956|Experimental|MELECTIS G|"In addition to usual care as described for the other arm, patients randomized to this arm will have MELECTIS G added to their wound dressing according to the manufacturer's instructions.~Intervention: Usual care Intervention: MELECTIS G"
89461757|NCT02373956|Active Comparator|Usual care|"Patients randomized to this are will receive usual care according the current procedures at the Nîmes University Hospital (ICMD010 concerning pressure sore care and SCMD002 concerning referenced anti-pressure sore dressings).~Intervention: Usual care"
89461758|NCT02369198|Experimental|Single arm, open label TargomiRs|"TargomiRs are IV injected.~Phase 1 Planned dose levels~Dose level 1: 5 billion once a week Dose level 2: 5 billion twice a week Dose level 3: 5 billion once a week with cardiac monitoring Dose level 4: 2.5 billion twice a week with cardiac monitoring Dose level 5: as for dose level #3 with a dexamethasone challenge~All patients begin on a micro dose of one billion and increase their dose over 2 weeks and reach their phase 1 dose level on week 3.~Schedule of assessments includes laboratory and physical assessments in the 24 hours after each treatment as well as periodic assessments such as PET and CT scans for tumour assessment.~100% of the data will be source data verified. Analysis will be simple phase 1 analysis based on a 3+3 model."
89461759|NCT03658213|Experimental|ZOLADEX 10.8 mg depot group|• ZOLADEX 10.8 mg depot group: subcutaneous depot injection once every 12 weeks
89461760|NCT03658213|Active Comparator|ZOLADEX 3.6 mg depot group|• ZOLADEX 3.6 mg depot group: subcutaneous depot injection once every 4 weeks
89461761|NCT02373878|Active Comparator|Telecoaching plus plate|Telecoaching plus portion control plate
89461762|NCT02373878|Active Comparator|Usual Care|Usual Care
89461763|NCT02369276||post SND within 3 months|20 Head and Neck Cancer(HNC) complicated with ipsilateral shoulder disability post SND within 3 months, evaluate the soft tissue of shoulder girdle with musculoskeletal ultrasonography and elastography, compare the finding in each group and the range of motion of their shoulder, the severity of wing scapula, visual pain analog scale and the score of The Disability of Arm, Shoulder and Hand
89461764|NCT02369276||post SND within >3- 6months|20 Head and Neck Cancer(HNC) complicated with ipsilateral shoulder disability post SND within >3- 6months, evaluate the soft tissue of shoulder girdle with musculoskeletal ultrasonography and elastography, compare the finding in each group and the range of motion of their shoulder, the severity of wing scapula, visual pain analog scale and the score of The Disability of Arm, Shoulder and Hand
89461765|NCT02369276||post SND within 6 months -1 year|20 Head and Neck Cancer(HNC) complicated with ipsilateral shoulder disability post SND within 6 months -1 year, evaluate the soft tissue of shoulder girdle with musculoskeletal ultrasonography and elastography, compare the finding in each group and the range of motion of their shoulder, the severity of wing scapula, visual pain analog scale and the score of The Disability of Arm, Shoulder and Hand
89461766|NCT02369276||post SND within more than 1 year|20 Head and Neck Cancer(HNC) complicated with ipsilateral shoulder disability post SND within more than 1 year, evaluate the soft tissue of shoulder girdle with musculoskeletal ultrasonography and elastography, compare the finding in each group and the range of motion of their shoulder, the severity of wing scapula, visual pain analog scale and the score of The Disability of Arm, Shoulder and Hand
89461767|NCT02369276||without shoulder disability|20 Head and Neck Cancer(HNC) post SND without shoulder complication at the control group, evaluate the soft tissue of shoulder girdle with musculoskeletal ultrasonography and elastography, compare the finding in each group and the range of motion of their shoulder, the severity of wing scapula, visual pain analog scale and the score of The Disability of Arm, Shoulder and Hand
89461768|NCT02920957|Active Comparator|comfilcon A|Participants are randomized to wear the comfilcon A lens for one month during the cross over study.
89461769|NCT02920957|Active Comparator|senofilcon C|Participants are randomized to wear the senofilcon C lens for one month during the cross over study.
88943067|NCT05685043|Experimental|best medical treatment and mechanical thrombectomy based on perfusion CT criteria|In the experimental treatment group, mechanical thrombectomy is only performed when prespecified perfusion CT criteria are fulfilled. If not, the patient will only receive best medical treatment (intravenous fibrinolysis if applicable).
88943068|NCT05685043|No Intervention|best medical treatment and mechanical thrombectomy|All patients in the active control arm will receive the combination of best medical treatment (intravenous fibrinolysis if applicable) and mechanical thrombectomy, regardless of the results from the perfusion CT scan. This is the current standard of care for stroke patients arriving in hospital within 6 hours after onset.
89461770|NCT02369120|Active Comparator|Normal care by GP|"Control group: Will follow conventional treatment provided by the family physician in primary care. This treatment is based on the clinical guidelines of the Institut Català de la Salut (http://www.gencat.cat/ics/professionals/guies/docs/guia_lumbalgies.pdf)."
89501876|NCT03664921|Experimental|Omnitram|Oral Omnitram (10 mg tablets) dosed three times daily. During the first two weeks each dose will be titrated between 1 tablet (10 mg) and 4 tablets (40 mg) to provide pain relief. The doses administered at the end of two weeks will be maintained during the final two weeks of treatment.
89461771|NCT02369120|Experimental|Educational intervention using a website|This group of subjects will be given access to our web-site in where they will find information related to CLBP. This information will be provided in different formats: explanatory video by the author, animated video about the neurophysiology of pain, written format using metaphors, and FAQs. All this information will be based on the information provided by the subjects on QUAL. The aim of this educational intervention is to change patient´s misbeliefs about CLBP with the last outcome of reducing pain intensity, improving function, and reducing disability.
89461772|NCT03006887|Experimental|lenvatinib 20 mg plus pembrolizumab 200 mg|Participants with selected tumors will receive oral lenvatinib at a starting dose of 20 milligrams (mg) once daily in combination with intravenous pembrolizumab 200 mg every 3 weeks (Q3W) on a 21-day treatment cycle until disease progression, development of unacceptable toxicity, withdrawal of consent, or sponsor termination of the study.
89461773|NCT03657823||Fetal growth cohort|Longitudinal measurements of fetal growth, fetal circulation and maternal circulation
89461774|NCT03657823||Hypertensive cohort|Retrospective cohort of women with heart disease that underwent oregnancy and childbirth
89461775|NCT02377856|Active Comparator|intervention|40 patients will receive pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks combination treatment, followed by 24 weeks of follow-up. 'pegylated interferon alpha 2a, ribavirin'
89461776|NCT02377856|No Intervention|observation|40 patients without treatment will be followed for the clinical course for 1.5 year
89461777|NCT03658135|Experimental|BIIB092|The investigational drug, BIIB092, will be given intravenously, every 4 weeks for 20 weeks
89461778|NCT03658135|Placebo Comparator|Placebo|Inactive ingredient
89461779|NCT02373800||The study population|"The study population is composed of pregnant women with a medical indication for the induction of pre-term (37-42 weeks of gestation) labor and who are consulting in the participating center.~Intervention: Cervical ultrasound with elastography"
89461780|NCT03665987||properative assessment clinic group|The treatment group will be seen in the preoperative clinic before hospitalization.
89461781|NCT03665987||Control group|The control group will get anesthetic consultation after hospitalization without clinic service.
89461782|NCT02377778|Experimental|Propofol|In this arm patients will be receiving propofol for anaesthesia at doses 3-5mg depending on the time needed to complete oocyte retrieval
89461783|NCT02377778|Active Comparator|Thiopental|In this arm patients will receive thiopental for anaesthesia at doses 7mg and a repeat dose of 2-3mg depending on the time needed to completed oocyte retrieval
89461784|NCT02514772|Experimental|GP2013 - proposed biosimilar rituximab|10 mg/mL in 500 mg (50 mL) single-use vials. For i.v. administration, two 500 mg vials (1000 mg of active molecule) of concentrate are diluted in 0.9% NaCl solution and infused i.v. The treatment course consists of 2 i.v. infusions 2 weeks apart (at Day 1 and Day 14).
89461785|NCT02514772|Active Comparator|Originator rituximab - Rituxan ® or MabThera ®|10 mg/mL in 500 mg (50 mL) single-use vials. For i.v. administration two 500 mg vials (1000 mg of active molecule) of concentrate are diluted in 0.9% NaCl solution and infused i.v. The treatment course consists of 2 i.v. infusions 2 weeks apart (at Day 1 and Day 14).
89461786|NCT03658057|Active Comparator|ROC|Neuromuscular blockade is performed in the ROC group by administering rocuronium 0.4~0.8mg/kg before the insertion of laryngeal airway.
89461787|NCT03658057|No Intervention|Control|Neuromuscular blockade is not performed.
89461788|NCT02378012|Active Comparator|GROUP A (participants provide own computer or tablet device)|A member of the research personnel helps the participants install Netflix, Spotify, and Skype applications on their computers if they wish to do so. Participants will be given subscriptions to each application and usernames for access on days -5 to 10.
89461789|NCT02378012|Experimental|GROUP B (Apple BuckiPad)|Participants receive an iPad for days -5 to 10. Participants also receive the BuckiPad manual for instructions on how to use the iPad and Netflix, Skype, and Spotify applications. Participants are also directed to the official Apple's iPad user's manual on their device and have questions answered by research personnel on day -5.
89461790|NCT02378012|No Intervention|GROUP C (no intervention)|Participants do not receive an iPad for days -5 to 10.
88943070|NCT05671354|Experimental|The auto-wrapping commode chair|The experimental group will use the auto-wrapping commode chair for 7 days.
88943071|NCT05664854|Experimental|sVNS and EIT of cervical vagus nerve|Selective vagus nerve stimulation (sVNS) with a spatially selective vagal nerve cuff with physiological readouts such as electrocardiogram (ECG), heart rate, end-tidal carbon dioxide (EtCO2), respiratory rate, laryngeal electromyogram (EMG), etc., and electrical impedance tomography (EIT) recordings of the nerve.
88943072|NCT05658328|Experimental|Intervention Group|Caregivers (MCI or healthy) randomized into this group walk 3x/week for 16 weeks with their care-partner (person living with early-stage dementia - PLWD) and their caregiver support person (MCI or healthy). Caregivers (and optionally for PLWD), wears an actigraphy watch, uses an under-the-mattress sleep sensor, and on a weekly basis completes weight and a health update survey. Mid- and end-study focus groups evaluate program effectiveness and needed adaptations.
89461791|NCT03664817|Experimental|social capital intervention|This group will receive intervention developed from Phase 1 study and based on photovoice project
89461792|NCT03664817|Active Comparator|group-based health promotion intervention|"The intervention will be a modified version of Health for Life or H4L, which was used as a control arm intervention in a recently completed protocol of the Adolescent Trials Network which was co-chaired by Dr. Harper (University of Michigan)"
89461793|NCT03657979|Experimental|Ropivacaine|Conventional PCA morphine +TAP-block ropivacaine 0.2%
89461794|NCT03657979|Placebo Comparator|TAP-block with placebo|Conventional PCA morphine treatment with TAP-block with placebo
89461795|NCT02373488|Other|control|lifestyle advice
89461796|NCT02373488|Active Comparator|intervention-1|connective tissue manipulation
89461797|NCT02373488|Active Comparator|intervention-2|abdominal massage
89461798|NCT03660007||Fresh embryo transfer|This exposure is an IVF pregnancy with fresh embryo transfer performed directly after ovarian stimulation
89461799|NCT03660007||Frozen embryo transfer|This exposure is an IVF pregnancy with frozen embryo transfer, which was thawed and transferred in a later, non-stimulated cycle
89461800|NCT03660007||Natural pregnancy|Spontaneous pregnancy without IVF
89461801|NCT03659851||Levosimendan before LVAD implantation|Levosimendan use 24 hrs. before LVAD implantation
89017743|NCT06138379|Experimental|2. Experimental Group|"Experimental: The experimental group was given video-supported training in line with Classical Education.~All forms (Patient Information Monitoring Form, Chronic Disease Adaptation Scale, Rational Drug Use Scale and Immunosuppressive Drug Form Scale) will be filled in to obtain pre-test data for the research. Individuals will be trained according to the training materials prepared for the Health Belief Model. They will be monitored one day each week. After 30 days, all forms will be filled out again to examine the sustainability of the training data."
89461802|NCT03659851||Dobutamine/milrinone before LVAD implantation|Dobutamine/milrinone use 24 hrs. before LVAD implantation
89461803|NCT05026060||Patients with arterial disease|Minor patients with acute or chronic arterial disease: diagnosis of Moyamoya, diagnosis of sickle cell disease, acute or chronic arterial infarction.
89461804|NCT03659383|Experimental|Optimal hypoglycemic treatment|The patients will receive optimal hypoglycemic treatments, including adjustment of insulin dose and oral antidiabetic agents
89461805|NCT04978792|Experimental|Self-compassion Intervention|The intervention will include 14 self-compassion exercises completed over a 3-week period. The intervention will include methods of psychoeducation, meditation, and self-compassion exercises similar to Beshai et al.'s (2020) self-compassion-based intervention. The psychoeducation will focus on self-compassion, the meditations will be kindness and loving meditations and self-compassion breaks. The self-compassion exercises will be based on the writing exercises available on Neff's self-compassion website.
89461806|NCT04978792|Active Comparator|Control Group|The active control will also include 14 exercises completed over a 3-week period. The 14 exercises will comprise of a psychoeducation video, writing exercises, video/audio-guided relaxation, and journal entries. The same psychoeducation video used in the intervention will be shown to participants, however, the other exercises will be altered to focus on factual information and not focused on self-compassion. The exercises will be matched to the self-compassion exercise so that similar exercises are completed in parallel time with the intervention.
89461807|NCT02368730||desmopressin|Treatment according to standard clinical practice.
89461808|NCT03622931|Experimental|the experimental arm|standard chemotherapy at 3/4-weekly intervals (cf. inclusion criteria) + romiplostim 750 μg sc once per week for up to 4 cycles
89461809|NCT03622931|Placebo Comparator|the placebo arm|standard chemotherapy at 3/4-weekly intervals (cf. inclusion criteria) + placebo once per week for up to 4 cycles
89461810|NCT03659305|Experimental|RPH-001|Humanized recombinant monoclonal anti-VEGF antibody. 5 mg/kg single intravenous infusion (for no less than 90 minutes)
89461811|NCT03659305|Active Comparator|Avastin|Humanized recombinant monoclonal anti-VEGF antibody. 5 mg/kg single intravenous infusion (for no less than 90 minutes)
89461812|NCT02368808|Experimental|Abangane Support Group|Bereavement support group for adolescents
89461813|NCT02368808|No Intervention|Wait List|Wait-listed adolescents will be able to participate in Abangane at the close of the study.
89461814|NCT04978246||Study Group|The study group consists of 50 individuals aged 18-50 years who have received a positive COVID-19 RT-PCR test in the past 60 days.
89017744|NCT06138340||Dex group|Participants will be sedated and maintained by dexmedetomidine.
89461815|NCT04978246||Control Group|The control group consists of 50 healthy individuals aged 18-50 years who have not had COVID-19.
89461816|NCT02369042|Experimental|Cohort I|Patients admitted with the primary diagnosis of HF and are currently being assessed with clinically indicated hemodynamic monitoring.The Kyma device will be worn by the patient and data collected from the device will be compared to the data collected through hemodynamic monitoring. The device will be worn for 60 days post hospital discharge.
89017745|NCT06138340||Propofol group|Participants will be sedated and maintained by propofol.
89017746|NCT06138327|Experimental|BMN 255 Investigational drug arm|Oral administration of BMN 255 at a dose of 100mg per day for 7 days in Treatment Period 1 or 2
89017747|NCT06138327|Placebo Comparator|Placebo Comparative drug arm|Oral administration of Placebo at a dose of 100mg per day for 7 days in Treatment Period 1 or 2
89017748|NCT06138314|Active Comparator|Control group|The control group will perform a physical exercise program twice a week for a period of 8 weeks.
89017749|NCT06138314|Experimental|Experimental group|The experimental group will perform the same physical exercise program performed by participants in the control group, in addition to neural mobilization techniques twice a week for a period of 8 weeks.
89017750|NCT06138301|Experimental|Experimental group|Patients with SI treated with CBT+CR
89017751|NCT06138301|Active Comparator|Control group|Patients with SI treated with CBT
89017752|NCT06138262|Experimental|health promotion education about preconception nutrition|
89017753|NCT06138223|No Intervention|Usual Care|Patients randomized to the control group will receive standard medical care, including nutritional care as provided by the center in usual care. Additionally, they receive an activity tracker (like the intervention group) but without specific instructions. We will advise control patients to avoid inactivity and be as physically active as current abilities and conditions allow, with the aim to progress towards being physically active for 150 min/week in line with the current physical activity guidelines.
89017754|NCT06138223|Experimental|Combined exercise and nutritional intervention.|Intervention: exercise and nutrition program group
89017755|NCT06138210|Experimental|Exosomes group|Patients in this arm will be given exosomes derived from human induced pluripotent stem cell for injection once a day for 7 days.
89017756|NCT06138210|Placebo Comparator|Exosomes placebo group|Patients in this arm will be given a placebo of exosomes derived from human induced pluripotent stem cell for injection once a day for 7 days.
89017757|NCT06138171||Fibromyalgia - FM|"Cohort of women diagnosed with FM recruited consecutively in the clinical department following the criteria:~age range 18-65 years~education > 5 years~diagnosis of FM according to Wolfe, 2016~Exclusion criteria~severe psychiatric disorders and/or cognitive impairment~difficulties in comprehension/expression in Italian~history of other chronic pain disorder(s)~history of other neurological disorders besides migraine"
89017758|NCT06138171||Chronic migraine - CM|"Cohort of women diagnosed with CM recruited consecutively in the clinical department following the criteria:~age range 18-65 years~education > 5 years~diagnosis of CM according to Olesen, 2017~Exclusion criteria~severe psychiatric disorders and/or cognitive impairment~difficulties in comprehension/expression in Italian~history of other chronic pain disorder(s)~history of other neurological disorders besides migraine"
89017759|NCT06138171||Vulvodynia - VU|"Cohort of women diagnosed with VU recruited consecutively in the clinical department following the criteria:~age range 18-65 years~education > 5 years~diagnosis of VU according to Bornstein et al., 2016~Exclusion criteria~severe psychiatric disorders and/or cognitive impairment~difficulties in comprehension/expression in Italian~history of other chronic pain disorder(s)~history of other neurological disorders besides migraine"
89461817|NCT02369042|Experimental|Cohort II|Patients admitted with the primary diagnosis of HF and are being assessed with or without hemodynamic monitoring. The Kyma device will be worn by the patient and data collected from the device will be compared to the data collected while the patient is hospitalized. The device will be worn for 60 days post hospital discharge.
89461818|NCT05024890|Experimental|WASH in Schools programme|Schools in the intervention group will receive the Splash WASH in Schools programme (Project WISE) during the study period (2021/2022 academic year), including sanitation, water storage and filtration, drinking water and handwashing stations, and hygiene and menstrual health education.
89461819|NCT05024890|No Intervention|Control|Schools in the control group will receive no intervention during the study period (2021/2022 academic year), but will be on a waitlist to receive the Project WISE intervention after the end of the study period (2022/2023 academic year or later).
89461820|NCT02368964|Experimental|High dose hCG|The hCG group- will be triggered for final follicular maturation with high dose hCG (500 mcg)-38 hours prior to oocyte aspiration
89461821|NCT02368964|Experimental|Double trigger|Double trigger Group- will receive GnRH agonist (Decapeptyl 0.2mg) 40 hours prior to oocyte aspiration and hCG (250mcg) 34 hours prior to the oocyte aspiration
89461822|NCT05024812|Experimental|Experimental|fruquintinib + toripalimab + SOX
89461823|NCT02786251|Other|BAT+|Individuals with significant amounts of BAT (>20 ml)
89461824|NCT02786251|Other|BAT-|Individuals with no/minimal amounts of BAT (<20 ml)
89461825|NCT02373722|Experimental|Group I (video, text message)|Patients watch an educational video about Mohs surgery before their surgery, a video about wound care after the surgery and receive text messages about wound care on days 1-5 after the surgery. Patients also receive instructions to reduce movement and use a Fitbit activity tracker. Beginning 48 hours after surgery, patients are instructed to apply petroleum jelly BID to the wound area.
89461826|NCT02373722|Experimental|Group II (educational video)|Patients watch an educational video about Mohs surgery before their surgery, an educational video about wound care after the surgery and receive instructions to reduce movement and use a Fitbit activity tracker. Beginning 48 hours after surgery, patients apply petroleum jelly BID to the wound area
89461827|NCT02373722|Experimental|Group III (text message)|Patients receive text messages about wound care on days 1-5 after the surgery and receive instructions to reduce movement and use a Fitbit activity tracker. Beginning 48 hours after surgery, patients are also instructed to apply petroleum jelly BID to the wound are.
89461828|NCT02373722|Experimental|Group IV (control)|Patients receive no video or text messages. Patients receive instructions to reduce movement and use a Fitbit activity tracker. Beginning 48 hours after surgery, patients are also instructed to apply petroleum jelly BID to the wound area.
89461829|NCT05024578|Sham Comparator|Sham|In the sham condition, participants will wear the EEG headband monitor (DREEM2, Dreem, Paris, France) for 1 week, but the sound stimulation feature will be deactivated.
89461830|NCT05024578|Experimental|Auditory Stimulation|In the active experimental condition, participants will complete 1 week of slow oscillation (SO) stimulation with the EEG headband monitor (DREEM2, Dreem, Paris, France) in the form of auditory stimuli (100ms pink noise pulses, i.e., below the waking threshold as established in prior work) sent on the ascending phase of the SO during N3 sleep.
89461831|NCT03659149|Experimental|Group 1|Period 1: Test drug 1(CKD-333 formulation I) Period 2: Test drug 2(CKD-333 formulation II) Period 3: Reference drug(CKD-330 + D086)
89461832|NCT03659149|Experimental|Group 2|Period 1: Test drug 1(CKD-333 formulation I) Period 2: Reference drug(CKD-330 + D086) Period 3: Test drug 2(CKD-333 formulation II)
89461833|NCT03659149|Experimental|Group 3|Period 1: Test drug 2(CKD-333 formulation II) Period 2: Reference drug(CKD-330 + D086) Period 3: Test drug 1(CKD-333 formulation I)
89461834|NCT03659149|Experimental|Group 4|Period 1: Test drug 2(CKD-333 formulation II) Period 2: Test drug 1(CKD-333 formulation I) Period 3: Reference drug(CKD-330 + D086)
89461835|NCT03659149|Experimental|Group 5|Period 1: Reference drug(CKD-330 + D086) Period 2: Test drug 1(CKD-333 formulation I) Period 3: Test drug 2(CKD-333 formulation II)
89461836|NCT03659149|Experimental|Group 6|Period 1: Reference drug(CKD-330 + D086) Period 2: Test durg 2(CKD-333 formulation II) Period 3: Test drug 1(CKD-333 formulation I)
89461837|NCT04202770|Experimental|Treatment|Patients deemed potentially appropriate candidates for exosome and focused ultrasound therapy for either treatment refractory depression (trMDD), anxiety, or neurodegenerative dementia will be treated with exosomes derived from healthy, full-term Cesarean section amniotic fluid. Up to one hour of transcranial focused ultrasound will be administered immediately prior to exosome treatment in an attempt to facilitate enhanced deployment to the subgenual cingulate for trMDD, the amygdala for anxiety, or the hippocampus for dementia. Target location will be determined by the physician upon enrollment depending on the patient's specific syndrome. Patients will be given 15cc of unconcentrated solution allogenic exosomes (equivalent to 21 million stem cells, Kimera Corporation) intravenously in 200 ccs of normal saline dripped over thirty minutes to one hour.
89461838|NCT03000179|Experimental|Avelumab Monotherapy|Participants receive avelumab by IV infusion following pretreatment with H1 blockers and acetaminophen once every 2 weeks.
89461839|NCT03622567|Other|Push Notifications|Push notification number (0, 1, 3, 5) will be counter balanced within-subjects.
89461840|NCT03659071|Experimental|DONORS|donors from the siblings of survivors of acute childhood leukemia who have received hematopoietic stem cell transplantation questionnaire VSP-A will be performed
89461841|NCT03659071|Other|NON DONORS|non-donor siblings. questionnaire VSP-A will be performed
89461842|NCT02373644|Experimental|HVLA Thrust Manipulation and DN|
88943073|NCT05658328|Active Comparator|Waitlist Control|Caregivers (MCI or healthy) randomized into this group first complete baseline measures for 16 weeks, consisting of wearing an actigraphy watch, using an under-the-mattress sleep sensor, and, on a weekly basis, completing weight and a health update survey. These baseline measures are optional for PLWD. After 16 weeks of baseline data collection, the primary caregiver continues these measures while walking 3x/week for 16 weeks with their triad. The PLWD optionally completes measures and optionally wears the watch and sleep sensor. Mid- and end-study focus groups during the walking phase evaluate program effectiveness and needed adaptations.
89461843|NCT02373644|Active Comparator|Conventional Physical Therapy|
89461844|NCT03664973|Experimental|continuous|continuous local anesthetic infusion (ropivacaine 0.2%)on the serratus plane for at least 72h adds to a Single-shot serratus plane block with ropivacaine 0.37% solution 20 ml.
89461845|NCT03664973|Active Comparator|single-shot|Single-shot serratus plane block with ropivacaine 0.37% solution 20 ml
89461846|NCT03658993|Active Comparator|Rifaxamine 550 mg|Study drug Oral Rifaximin 550 mg TID for 4 weeks .
89461847|NCT03658993|Placebo Comparator|Placebo|Placebo TID for 4 weeks
89461848|NCT05023564||Early onset dementia|Dementia patients with onset age lower than 65y/o
89461849|NCT05023564||Late onset dementia|Dementia patients with onset age between 65y/o and 85y/o
89461850|NCT05023564||Oldest old dementia|Dementia patients with onset age older than 85y/o
89461851|NCT05023564||Cognitive normal control|Normal Aging with normal cognitive function
89461852|NCT02373566|Experimental|Dermal substitute with STSG|Novomaix dermal substitute in combination with STSG
89461853|NCT02373566|No Intervention|STSG alone|STSG alone
89461854|NCT03664661|Experimental|experimental group|BCMA nanobody CAR-T cells
89461855|NCT03657901|Experimental|Breathing|Guided slow breathing for 30 minutes before sleep onset
89461856|NCT03657901|Active Comparator|Music listening|Guided music listening for 30 minutes before sleep onset
89461857|NCT02373410|Experimental|Umbilicus|The height of the operating table which set at the needle insertion point, is the level of umbilicus of the anesthesiologist in a standing posture.
88943074|NCT05651633|Experimental|Lidocaine ear drops with usual care|usual care: oral analgesic with/without antibiotics
88943075|NCT05651633|No Intervention|usual care|usual care: oral analgesic with/without antibiotics
88943076|NCT05648448|Experimental|Oseltamivir (TAMIFLU®)|
88943077|NCT05648448|Experimental|Favipiravir|
88943078|NCT05648448|Experimental|Zanamivir (RELENZA®)|
88943079|NCT05648448|Experimental|Baloxavir (XOFLUZA®)|
88943080|NCT05648448|Experimental|Molnupiravir|
88943081|NCT05648448|Experimental|Peramivir (RAPIVAB®)|
88943082|NCT05648448|Experimental|Laninamivir (INAVIR®)|
88943083|NCT05648448|No Intervention|Negative control group|No treatment (except antipyretics- paracetamol)
88943084|NCT05647616|Experimental|Strengthening exercises|The participants in this group will be given instructions to follow a resistance exercises to strengthen the peroneus longs muscle.
88943085|NCT05647616|No Intervention|Control|Participants in this group will be given no treatment.
88943086|NCT05645055||Patients with stricturing Crohn's diseases|Patients with stricturing Crohn's diseases
88943087|NCT05641064|Placebo Comparator|Saline|Continuous infusion of saline starting after invasive monitoring placement and before initiation of cardiopulmonary bypass (CPB) until the end of surgery
88943088|NCT05641064|Experimental|Dexmedetomidine 0.5|Continuous infusion of dexmedetomidine in dose 0.5 mcg/kg/min starting after invasive monitoring placement and before initiation of cardiopulmonary bypass (CPB) until the end of surgery
89461858|NCT02373410|Active Comparator|Lowest rib margin|The height of the operating table which set at the needle insertion point, is the level of lowest rib margin of the anesthesiologist in a standing posture.
89461859|NCT02373410|Active Comparator|Xiphoid|The height of the operating table which set at the needle insertion point, is the level of xiphoid of the anesthesiologist in a standing posture.
89461860|NCT02373410|Active Comparator|Nipple|The height of the operating table which set at the needle insertion point, is the level of nipple of the anesthesiologist in a standing posture.
89461861|NCT04975672|Experimental|Group 1, with myofunctional therapy and SN1 functional orthopedic appliances|The participant will receive a session of myofunctional therapy every month, for 9 months. In this group, a series of procedures and techniques are carried out to create and mechanize muscular and orofacial patterns at rest and in function, eliminate habits, correct muscular imbalance, improve the aesthetics of the patient and normalize the functions of the stomatognathic system.
89461862|NCT04975672|Experimental|Group 2, without myofunctional therapy and SN1 functional orthopedic appliances.|Once the investigation is finished, the patient will decide whether or not to perform myofunctional therapy one every month, for 9 months.
89461863|NCT02920177|Experimental|platelet-rich plasma|platelet-rich plasma injection into the head-neck junction of the hip joint
89461864|NCT02920177|Active Comparator|Kenalog 10 mg/mL Injectable Suspension|corticosteroid injection into the head-neck junction of the hip joint
89461865|NCT03006341||Dabigatran etexilate|NVAF patients initiating dabigatran etexilate
89461866|NCT03006341||Warfarin|NVAF patients initiating warfarin
89461867|NCT05022784||Idiopathic Pulmonary Fibrosis Patients|Medicare beneficiaries with IPF who newly initiated treatment with nintedanib
89461868|NCT02368574|No Intervention|Class III hysterectomy Arm|Class III hysterectomy (radical hysterectomy): This procedure may be performed through laparotomy or laparoscope. Perivesical space and perirectal space should be opened, and the ureteral tunnel is completely separated and pushed down to the junction of ureter and urinary bladder. The uterine arteries are ligated at the level of internal iliac artery, and all the supporting ligaments and connective tissues around the uterus should be separated and abscised. The uterosacral ligament is removed near the sacrum, the cardinal ligament is removed near the pelvic wall, and the vagina is removed after the excision of peivaginal connective tissues, about 3-4cm from the cervical lesion. The pelvic lymph nodes are usually dissected at the same time.
89501877|NCT03664921|Placebo Comparator|Placebo|Oral placebo (tablets) dosed three times daily. During the first two weeks each dose will be titrated between 1 tablet and 4 tablets to provide pain relief. The doses administered at the end of two weeks will be maintained during the final two weeks of treatment.
89461869|NCT02368574|Experimental|Class II hysterectomy Arm|Class II hysterectomy (modified radical hysterectomy): This procedure may be performed through laparotomy or laparoscope. The scope of surgery is more extensive than Class I epifascial panhysterectomy, demanding the excision of more parametrium but reservation of the blood supply for distal ureter and urinary bladder. The ureter is separated from the ureteral tunnel, the vesicouterine ligament should be intact, and 1/2 uterosacral ligament and 1cm vagina are excised. The pelvic lymph nodes are usually dissected at the same time.
88943089|NCT05641064|Experimental|Dexmedetomidine 1|Continuous infusion of dexmedetomidine in dose 1 mcg/kg/min starting after invasive monitoring placement and before initiation of cardiopulmonary bypass (CPB) until the end of surgery
89461870|NCT02368418||PCP and SRS|participants had received two interventions (PCP and SRS)
89461871|NCT02368418||PCP only|participants had received PCP intervention only
89461872|NCT02368418||SRS only|participants had received SRS intervention only
89461873|NCT02368418||control group|participants had received usual care (neither PCP nor SRS)
89461874|NCT02744365||Prediction Group|The women recruited in the biobank through the Prediction Study (NCT02189148) are low-risk pregnant women between 11 and 13 6/7 weeks of gestation (N=7600 maximum).
89461875|NCT02744365||PEARL Group|"The women recruited in the biobank through the PEARL Study (NCT02379832) are :~low-risk pregnant women between 11 and 13 6/7 weeks of gestation (controls, N=45)~pregnant women with diagnosis of preeclampsia between 20 and 41 6/7 weeks of gestation (cases, N=45)"
89461876|NCT02744365||GAP Group|The women recruited in the biobank through the GAP Trial (NCT02280031) are women pregnant with twins between 11 3/7 and 13 6/7 weeks of gestation(N=50 maximum) randomized for placebo or aspirin.
89461877|NCT02744365||PREDICTION 2 Group|The women recruited in the biobank through the Prediction-2 Study (NCT03067298) are nulliparous pregnant women between 14 and 15 6/7 weeks of gestation (N=1000 maximum).
89461878|NCT02744365||HAUPE Study|Women that are at risk of pre-eclampsia and great obstetrical syndroms (elevated maternal age, invitro fertilization, chronic disease) (N=60) and a control group not at risk (N=60)
89461879|NCT03455465||No intervention|Patients in this arm will not be approached by community health workers during their visit to the Emergency Department.
89461880|NCT03455465||Community Health Worker Program|Participants in this group will be approached by a community health worker during their visit to the Emergency Department with the goal of enrolling them in a comprehensive post-discharge program.
89461881|NCT02368496|Experimental|Children and young adults on long-term parenteral nutrition|long-term parenteral nutrition : 2 years
89461882|NCT03935594|Experimental|PRP injection right half|"The scar to be treated will first be wiped with an alcohol swab, then measured and marked out with a marking pen such that the entirety of the scar will fit into a symmetric ellipse that is drawn, and the ellipse is filled entirely with the scar tissue. A ruler will be used to measure the scar in its greatest horizontal span, and the midway point will be marked with a vertical line. A coin flip will determine if the PRP injection (the experimental half) will be on the right half of the scar (as opposed to the left half). The half of the scar that will not receive PRP will be the control half.~After finishing the VSS and POSAS, the area inside the control half of the ellipse will then be subdivided with a marking pen into 1cm x 1cm square boxes, with the plan of injecting 1mL normal saline into each 1 square cm box at 0 months, 1 month, 4 months, and 6 months.~Punch biopsies from each scar will be will be obtained at both six months and one year from enrollment."
89461883|NCT03935594|Experimental|PRP injection left half|"The scar to be treated will first be wiped with an alcohol swab, then measured and marked out with a marking pen such that the entirety of the scar will fit into a symmetric ellipse that is drawn, and the ellipse is filled entirely with the scar tissue. A ruler will be used to measure the scar in its greatest horizontal span, and the midway point will be marked with a vertical line. A coin flip will determine if the PRP injection (the experimental half) will be on the right half of the scar (as opposed to the left half). The half of the scar that will not receive PRP will be the control half.~After finishing the VSS and POSAS, the area inside the experimental half of the ellipse will then be subdivided with a marking pen into 1cm x 1cm square boxes, with the plan of injecting 1mL PRP into each 1 square cm box at 0 months, 1 month, 4 months, and 6 months.~Punch biopsies from each scar will be will be obtained at both six months and one year from enrollment."
89461884|NCT03665753|Experimental|Ketorolac 10mg|Subjects will be administered 10 mg of Ketorolac.
89461885|NCT03665753|Experimental|Ketorolac 20mg|Subjects will be administered 20 mg of Ketorolac
89461886|NCT03665753|Experimental|Ketorolac 30mg|As a part of standard care, subjects will be administered 30 mg of Ketorolac.
89461887|NCT03566108|Experimental|VISTA|VISTA incision with CAF and ADM
88943090|NCT05634967||Disease-matched cohort (Comparison Group 1)|comparison group consisting of women diagnosed with MS who have not used Kesimpta during pregnancy (unexposed disease-matched comparison group).
88943091|NCT05634967||Healthy cohort (only applicable in the Kesimpta-OTIS sub-study) (Comparison Group 2)|healthy women who are not diagnosed with MS or any other autoimmune disease, have not had exposure to a known human teratogen, and have not taken Kesimpta in pregnancy (healthy comparison group). Since the DMSKW register is an MS population specific register that does not collect data on non-MS population, this cohort is only applicable in the Kesimpta-OTIS sub-study.
89461888|NCT03566108|Active Comparator|Sulcular Tunnell access|Sulcular tunnel surgery with CAF and ADM
89461889|NCT02512042|Experimental|Brinzolamide 1% Ophthalmic suspension|Brinzolamide Pharmaceutical dosage form: Ophthalmic suspension Strength: 1% Manufactured by: Indoco Remedies, Ltd for Watson Pharma Pvt. Ltd
89461890|NCT02512042|Active Comparator|Azopt® 1% Ophthalmic suspension|Azopt® (Contains Brinzolamide) Pharmaceutical dosage form: Ophthalmic suspension Strength: 1% Manufactured by: Alcon Laboratories, Inc
89461891|NCT02911025||Patients Treated With Clobazam|Single group, patients treated with clobazam by their treating physician (no interventions from PI), followed longitudinally for 1 week after reaching effective clobazam dose.
89461892|NCT02377544|Placebo Comparator|Placebo|Saccharum lactis
88943092|NCT05634967||Kesimpta-exposed cohort|women and infants who are exposed to Kesimpta during pregnancy to treat MS.
88943093|NCT05627570|Experimental|Diet A then Diet B, followed by a 6-month behavioural support programme|8-weeks of Diet A then 8-weeks of Diet B, then 6 months of goal-based behavioural support for consuming a healthy, balanced diet, increasing physical activity and reducing sedentary behaviour.
88943094|NCT05627570|Experimental|Diet B then Diet A, followed by a 6-month behavioural support programme|8-weeks of Diet B then 8-weeks of Diet A, then 6 months of goal-based behavioural support for consuming a healthy, balanced diet, increasing physical activity and reducing sedentary behaviour.
89461893|NCT02377544|Experimental|Probiotic|Bifidobacterium animalis lactis
89461894|NCT03665519|Experimental|Dietary supplement and ursodeoxycholic acid therapy.|Participants will take a supplement (sublimated mare milk) of 1 sachet (20 mg) dissolved in 200 ml of warm water (36-37 °C) twice/day accompanied with standard therapy of ursodeoxycholic acid therapy (dosage of 15/kg/day) for 3 months.
89461895|NCT03665519|Other|Ursodeoxycholic acid therapy only.|Patients would be given the standard treatment of ursodeoxycholic acid only for 3 months.
89461896|NCT02919475|Experimental|JTE-051 Dose 1|One dose of study drug by mouth daily for 12 weeks
89461897|NCT02919475|Experimental|JTE-051 Dose 2|One dose of study drug by mouth daily for 12 weeks
89461898|NCT02919475|Experimental|JTE-051 Dose 3|One dose of study drug by mouth daily for 12 weeks
89461899|NCT02919475|Experimental|JTE-051 Dose 4|One dose of study drug by mouth daily for 12 weeks
89461900|NCT02919475|Experimental|Placebo|One dose of study drug by mouth daily for 12 weeks
89461901|NCT02373332||Healthy subjects|Healthy subjects for oxylipin effect Platelets from healthy donors will be assessed for regulation of platelet reactivity by fatty acids and 12-lipoxygenase oxylipins.
89461902|NCT02373332||Type 2 diabetes mellitus (T2DM) patients|T2DM patients for oxylipin effect Platelets from healthy donors will be assessed for regulation of platelet reactivity by fatty acids and 12-lipoxygenase oxylipins.
89461903|NCT03664505|Active Comparator|Garment based on manual measurement|Garment based on manual measurement is used on burn scar
89461904|NCT03664505|Experimental|Garment based on scan measurement|Garment based on scan measurement is used on burn scar
89461905|NCT03543605|Experimental|PROA Experimental|"It consists of the intervention measures described in the general antimicrobial stewardship program (PROA Control) plus clinical advice.~The clinical assessments have been adapted for this project to the unique characteristics of infectious diseases in nursing homes.~These are individual training activities whose main objective is to modify prescribing behaviors when they are inadequate and reinforce them when they are correct.~They are carried out between the medical adviser, an expert in infectious diseases, and the doctor of the nursing home, through the structured review of a case attended by the doctor in the last 24 hours. The recommendations are not compulsory, and do not seek to change the decisions made in that patient, but the future ones in the case that is necessary.~The counseling will be done by video-conference, with an approximate duration of 10 minutes. Each of the doctors will receive two monthly assessments during the intervention period."
89461906|NCT03543605|Other|PROA Control|"The intervention of the general antimicrobial stewardship program (PROA) contains the following set of measures:~Creation of the local team of the PROA: one of the Family Physicians responsible for the patients and the pharmacist of the reference hospital of the center.~Presentation of the project by the local team in its own center.~Choice of the Aljarafe guide as a reference document for the diagnosis and treatment of infectious diseases. It is an accredited guide and widely disseminated among primary care and hospital doctors.~Permanent information of the project (poster with its synthesis, a pocket triptych with the guide for the clinical management of the main clinical syndromes of infections in the residents of the nursing homes).~Feedback of the results that will serve each center to know the evolution of its results, and to stimulate the comparison with the other centers."
89461907|NCT02368262||CP- incontinent|Children with CP and daytime incontinence. Evaluation consisted of a questionnaire and micturition and drinking diaries, uroflowmetry, pelvic floor EMG and bladderscan.
89461908|NCT02368262||CP- continent|Children with CP without daytime incontinence. Evaluation consisted of a questionnaire and micturition and drinking diaries, uroflowmetry, pelvic floor EMG and bladderscan.
89461909|NCT02368262||NoDev - incontinent|Children with normal development with daytime incontinence. Evaluation consisted of a questionnaire and micturition and drinking diaries, uroflowmetry, pelvic floor EMG and bladderscan.
89461910|NCT02368262||NoDev - continent|Children with normal development without daytime incontinence. Evaluation consisted of a questionnaire and micturition and drinking diaries, uroflowmetry, pelvic floor EMG and bladderscan.
89537184|NCT05456243|Experimental|Low Dose Group|Adult kidney transplant recipients with subclinical rejection (biopsy-proven antibody-mediated and/or cellular rejection, including borderline rejection) will be administered one low dose of allogeneic A-MSC.
88943095|NCT05618093|Experimental|Patients diagnosed with PAH or CTEPH|Patients with a confirmed diagnosis or suspected diagnosis of pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH) prior to initiation or change in therapy.
88943096|NCT05612685|Experimental|Intervention|This arm will receive a healthcare provider referral to a tax filing app
88943097|NCT05606510|Experimental|Intervention|A 12-week, group-based mindful exercise program which will be conducted 5 times per week, 30 minutes per session.
88943098|NCT05606510|Other|Control|Routine medicine, nursing care, and hospital-recommended exercise.
89017760|NCT06138171||Control group (no chronic pain condition)|"Cohort of women recruited consecutively from the general population with the following criteria:~age range 18-65 years~education > 5 years~no previous diagnosis of chronic pain conditions~Exclusion criteria~severe psychiatric disorders and/or cognitive impairment~difficulties in comprehension/expression in Italian~history of other chronic pain disorder(s)~history of other neurological disorders"
89201844|NCT00669318|Experimental|Treatment (Pentostatin, Alemtuzumab, Rituximab)|"Course 1: Patients receive:~2 mg/m^2 pentostatin IV on days 8 and 22;~3 mg alemtuzumab subcutaneously (SC) on day 3;~10 mg alemtuzumab SC on day 4;~30 mg alemtuzumab SC on days 5, 8, 10, 12, 15, 17, 19, 22, 24, 26, 29, 31, and 33;~20 mg/m^2 rituximab IV on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26, 29, 31, and 33;~6 mg Sargramostim (GM-CSF) SC on days 10-14. Patients then proceed to course 2.~Courses 2 and 3: Patients receive:~2 mg/m^2 pentostatin IV on days 1 and 15;~30 mg alemtuzumab SC on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26;~20 mg/m^2 rituximab IV on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26;~6 mg GM-CSF SC on days 3-7. After completion of course 2, patients with a complete response proceed to observation. Patients with a partial response or stable disease receive another course of therapy (course 3)."
89201845|NCT00781092|Experimental|1|Systane Ultra
89201846|NCT00781092|Active Comparator|2|Bausch and Lomb Sensitive Eyes
88943099|NCT05603923|Active Comparator|Group 1: Lumen Coached Group|Participants in this group will attend an Intervention Orientation session to receive the Coach Lumen tutorial, a study iPad, and a Lumen Intervention Workbook. They will complete 8 PST sessions with Coach Lumen using their study assigned iPad at home over 12 weeks. The first 4 sessions occur weekly and then the last 4 occur every other week. Participants will receive automated reminders on the day before and on the day of their scheduled session, and have the opportunity to reschedule sessions through the iPad. Participants will work with Coach Lumen to learn problem-solving skills to address current life challenges, plan activities, and complete home activities. Participants will also complete surveys before and after each PST session: a mood assessment survey before and a user experience survey after. At the end of study, Participants may be invited to provide their perspective regarding their Lumen use experience.
89461911|NCT01066897|Experimental|Pramipexole|Patients will receive 0.125 mg of pramipexole three times a day for the first week, 0.25 mg three times a day for the second week, and 0.5 mg three times a day for the third week. The dose will then be adjusted as needed by the treating physician (Dr. DeBattista), with a target range of 1.0 mg to 1.5 mg per day. Dose escalations will continue until 1) achievement of the primary endpoint (> 50% reduction from baseline on the HDRS scores; 2) intolerable side effects; or 3) completion of the 8-week study. Participants will be seen weekly the first four weeks and biweekly thereafter. Side effects, depression, and anhedonia will assessed at each visit.
89461912|NCT01066897|No Intervention|Healthy Controls|Non depressed, non-intervention comparison group
89461913|NCT02373254|Active Comparator|Ibuprofen 400 mg|Ibuprofen 400 mg po q 8 hours as needed (PRN) for pain. Subjects will receive Norco, 5/525 mg po q 6 hours PRN if pain relief with Ibuprofen is not sufficient.
89461914|NCT02373254|Active Comparator|Ibuprofen 800 mg|Ibuprofen 800 mg po q 8 hours PRN pain. Subjects will receive Norco, 5/525 mg po q 6 hours PRN if pain relief with Ibuprofen is not sufficient.
89461915|NCT02373254|Active Comparator|Norco|Norco (acetaminophen/hydrocodone) 10/325 mg po q 6 hours PRN pain. If pain is not relieved, physician should be contacted.
89461916|NCT04376372||TD_lefthanders|Typical developing lefthanded children and adolescents Assessment : sensibility, strength,writing,manual dexterity,degree of lefthandedness, body representation, movement analysis, motor control, quality of life, participation
89461917|NCT04376372||F_lefthanders|Forced left handed NBPP children Assessment : sensibility, strength,writing,manual dexterity,degree of lefthandedness, body representation, movement analysis, motor control, quality of life, participation
89461918|NCT03657355|Experimental|50 mg ACT-541468|ACT-541468 will be administered as tablets for oral use.
89461919|NCT03657355|Experimental|100 mg ACT-541468|ACT-541468 will be administered as tablets for oral use.
89461920|NCT03657355|Experimental|150 mg ACT-541468|ACT-541468 will be administered as tablets for oral use.
89461921|NCT03657355|Active Comparator|150 mg suvorexant|Suvorexant will be administered as tablets for oral use.
89461922|NCT03657355|Active Comparator|30 mg zolpidem|Zolpidem will be administered as tablets for oral use.
89461923|NCT03657355|Placebo Comparator|Placebo|Placebo will be administered as tablets for oral use.
89461924|NCT03818516|Experimental|Oral Glucose Tolerance Test (OGTT)|Medically stable participants with schizophrenia and a range of insulin resistance will have an oral glucose tolerance test.
89461925|NCT02985541|Experimental|Levonorgestrel IUS (Mirena, BAY86-5028)|Mirena during extended use (Years 6 to 8).
89461926|NCT01946672|Experimental|isotopic intraoperative detection|Lower-limb drainage isotopic intraoperative detection
89461927|NCT02368028||Caries Free|Participants who do not have caries (cavities) will have oral samples collected.
89461928|NCT02368028||Caries Active|Participants who do have caries (cavities) will have oral samples collected.
88943100|NCT05603923|Active Comparator|Group 2: Human Coached Group|Participants in this group will receive a study iPad and Human-Coached Intervention Workbook and will complete the first of 8 PST sessions in person with a trained health coach. Participants' first PST session will be in person for approximately 1 hour. Participants will complete the remaining sessions remotely via Zoom (or by phone, if necessary) using their study iPad. The first 4 sessions occur weekly and then the last 4 occur every other week. Participants will receive automated reminder notifications on the day before and on the day of their scheduled session, and have the opportunity to reschedule sessions with their coach. Participants will also complete a mood assessment survey at the beginning of each PST session. Participants will work with their health coach to learn problem-solving skills to address current life challenges, plan activities, and complete home activities.
89017761|NCT06138158|Experimental|Exercise and Education Group|They will perform an exercise program oriented according to the back school, as well as educational guidelines related to pain.
89017762|NCT06137105||Group 1|Group I : Romiplostim and Eltrombopag
89461929|NCT04385095|Active Comparator|SNG001|inhalation using the I-neb device.
89461930|NCT04385095|Placebo Comparator|Placebo|inhalation using the I-neb device.
89461931|NCT02368106||Radiation Therapy|Participants receiving one of the 11 listed therapy modalities.
89461932|NCT03113006|Active Comparator|Standard Panretinal Photocoagulation|Localized to all four retinal quadrants.
89461933|NCT03113006|Experimental|Individ. Panretinal Photocoagulation|Localized to only the affected quadrants.
89461934|NCT02367950|Experimental|Single Arm Study|All participants receive active treatment (exercise) tailored to their level of health ad fitness
89461935|NCT03657589||patients with 1 missing tooth|Patients with 1 missing anterior or premolar tooth and planned for implant surgery were recruited. Gingiva and alveolar bone were ultrasound scanned and compared to CT scans and direct measures during implant surgery.
89461936|NCT02365532|Placebo Comparator|Placebo to match GS-6615|Placebo to match GS-6615 + dofetilide or placebo to match dofetilide twice daily
89461937|NCT02365532|Experimental|GS-6615|GS-6615 or placebo to match GS-6615 + dofetilide or placebo to match dofetilide twice daily
89461938|NCT03113162|Experimental|Autologous Hematopoietic Stem Cell with BEAM Regimen|Autologous HSCT following Reduced-Intensity BEAM Regimen
89461939|NCT02461225|Active Comparator|Erchonia® FX-635™|The Erchonia® FX-635™ is made up of 3 independent 17 milliWatts (mW), 635 nanometers (nm) red laser diodes mounted in scanner devices with flexible arms positioned equidistant from each other.
89461940|NCT02461225|Placebo Comparator|Placebo Laser|The Placebo Laser has the same appearance as the Erchonia® FX-635™ but does not emit any therapeutic light.
89461941|NCT02368340||Adults with pulmonary fibrosis|This group includes adults with HPS who have known pulmonary fibrosis. Subjects in this group will provide blood and urine specimens.
89461942|NCT02368340||Adults at-risk|"This group includes adults with HPS with subtypes at-risk for pulmonary fibrosis, but who do not have known pulmonary fibrosis.~Subjects in this group will undergo chest CT and pulmonary function testing, and provide blood and urine specimens."
88943101|NCT05603923|Placebo Comparator|Group 3: Optional (Delayed) Lumen Coached Group|Participants assigned to this group can choose to attend a Lumen Orientation session to receive training and a study iPad to complete 8 PST sessions with Coach Lumen after their follow-up assessment at 18 weeks. They will receive 8 Sunday mood assessment surveys to complete (4 every Sunday and then 4 every other Sunday).
88943102|NCT05594706||Newly diagnosed patients with T1DM|The investigators will do prospective measures in 10 to 15 children aged 2 to 18 years, at the time of diagnosis, four months after diagnosis and one year after diagnosis.
89461943|NCT02368340||HPS adults not at-risk|"This group includes adults with HPS subtypes considered not at-risk for pulmonary fibrosis.~Subjects in this group will provide blood and urine specimens."
89461944|NCT02368340||Children with HPS at-risk|This group includes children with HPS subtypes at-risk for pulmonary fibrosis. Subjects in this group will undergo pulmonary function testing, and provide blood and urine specimens.
89461945|NCT02910037|Experimental|patients enrolled for mNGS testing|Patients with meningitis and/or encephalitis will be enrolled in this study in order to analyze the clinical utility of mNGS for pathogen detection. There is no control group for this study (Investigators will identify historical controls by retrospective chart review and clinical reimbursement documents).
89461946|NCT02372864|No Intervention|Care as usual|"All participants in the intervention and control group receive the care as usual. The care as usual consists of a clinic appointment with the research nurse. In this appointment the RRSO-induced menopausal complaints will be discussed in more detail. Depending on the complaints at hand, information, reassurance and life style advice will be offered. A leaflet with relevant information will be provided for. Furthermore, the usual medical care may include prescription of (non-)hormonal medicationsTwelve weeks after the clinic appointment, the research nurse will contact all participants per telephone to ask whether there are issues that remain to be addressed.~Participants are allowed to continue the use of all their current medication."
89461947|NCT02372864|Experimental|Mindfullness based stress reduction|
89461948|NCT04059848|Experimental|tDCS combined with NMES|In addition to conventional rehabilitation, all subjects received an additional tDCS combined with NMES protocol with a total of 15 sessions for 3 weeks (5 times per week, 30 minutes daily).
89461949|NCT04059848|Active Comparator|tDCS combined with sham NMES|In addition to conventional rehabilitation, all subjects received an additional tDCS combined with sham NMES protocol with a total of 15 sessions for 3 weeks (5 times per week, 30 minutes daily).
89461950|NCT04059848|Sham Comparator|sham tDCS combined with sham NMES|In addition to conventional rehabilitation, all subjects received an additional sham tDCS combined with sham NMES protocol with a total of 15 sessions for 3 weeks (5 times per week, 30 minutes daily).
89461951|NCT02356705|Placebo Comparator|Saline Placebo|Control patients will receive intranasal saline
89461952|NCT02356705|Active Comparator|Nasal Midazolam Only|Patients will receive 0.2 mg/kg of intranasal midazolam
89461953|NCT02356705|Active Comparator|Midazolam Plus Xylocaine|Patients will receive 0.2 mg/kg intranasal midazolam plus xylocaine 4% in a dose based on 50% of the volume of the midazolam.
89461954|NCT02373176|Experimental|[14C] PRC-4016 (Icosabutate)|Investigational medicinal product (IMP), [14C] PRC-4016 (Icosabutate) solution (600 mg in 2 mL, 200.0 μCi [7.4 MBq]). The radiochemical purity of [14C]PRC-4016 will be at least 97%.
88943103|NCT05594706||Patients with T1DM of different duration|As the functional beta-cell mass gradually declines as disease duration increases, the investigators will do measurements in a cohort of children aged ≤ 18 years, with increasing diabetes duration. The investigators plan to analyze groups of 5 patients with a disease duration of 3 (36 - 47 months), 5 (60 - 71 months) and 10 years (120 - 131 months), respectively.
88943104|NCT05592639|Active Comparator|Videoendoscopic Inguinal Lymphadenectomy|Removal of inguinal nodes using Videoendoscopic Inguinal Lymphadenectomy
88943105|NCT05592639|Other|Open Inguinal Lymphadenectomy|Removal of inguinal nodes using Open radical inguinal lymphadenectomy
88943106|NCT05589077|Experimental|Knowledge Assessment and Educational Intervention|All participants will be asked to complete the pre-intervention survey assessing knowledge and confidence of female athlete nutritional concerns. Then participants will engage in an educational intervention on these same topics. Following the intervention, participants will repeat the same survey.
88943107|NCT05581160|Experimental|12-months prospective multicenter longitudinal cohort with the biological samples collection.|This is a single-arm interventional study. After acceptance of the study (signature of the informed consent form), patients are included in the single-arm interventional study for a period of 12 months with follow-up visits every 3 months and intermediate visits in the case of the symptoms presence or sexual contacts with partners having STIs (corresponding to standard care for the PrEP users).
88943108|NCT05578755|Experimental|Smartphone-based intervention|
88943109|NCT05578755|Experimental|Virtual reality intervention|
88943110|NCT05578755|Active Comparator|Goal-setting control condition|
89461955|NCT02511184|Experimental|Dose finding and dose expansion phases|Find and expand the maximum tolerated dose of crizotinib in combination with pembrolizumab 200 mg iv infusion every 3 weeks.
89461956|NCT02367638|Experimental|MG1111|
89461957|NCT02367638|Active Comparator|VARIVAX|
89461958|NCT02367560|Active Comparator|NDSSI|Participants in this arm of the trial will be referred for Needle decompression with subacromial steroid (Depo medrol) injection (NDSSI) as their treatment for calcific tendinitis
89017763|NCT06137105||Group 2|Group II : recived corticosteroid.
89461959|NCT02367560|Active Comparator|SWT|Participants in this arm of the trial will be referred for Shockwave therapy (SWT) using an Ultrasound device, delivered by a physiotherapist, as their treatment for calcific tendinitis
89461960|NCT02372942|Experimental|Lattoferrin|Use of Lattoferin for prevention of preterm delivery
89461961|NCT02372942|Experimental|Progesterone|Use of Progesterone for prevention of preterm delivery
89461962|NCT04975048|Experimental|Group A|Group A was consisted of 16 rs2236513/rs2297508/rs4925119 C/G/G carriers and 16 AA/CC/AA homozygotes. And it was first assigned egg yolk intervention during intervention period 1, and then macronutrient equivalent control during intervention period 2
89461963|NCT04975048|Other|Group B|Group B was also consisted of 16 rs2236513/rs2297508/rs4925119 C/G/G carriers and 16 AA/CC/AA homozygotes. It was first assigned macronutrient equivalent control during intervention period 1, and then egg yolk during intervention period 2
89461964|NCT02365220|Active Comparator|No expectancy (control)|No expectancy instruction with regard to the efficacy of the daily smartphone-based training
89461965|NCT02365220|Experimental|Prospective expectancy|"Prospective expectancy instruction (Training will have an effect on...) with regard to the efficacy of the daily smartphone-based training"
89461966|NCT02365220|Experimental|Retrospective expectancy|"Retrospective expectancy instruction (Training already had an effect on...) with regard to the efficacy of the daily smartphone-based training"
89461967|NCT02365220|Experimental|Prospective and retrospective expectancy|"Prospective (Training will have an effect on...) and retrospective (Training already had an effect on...) expectancy instruction with regard to the efficacy of the daily smartphone-based training"
89461968|NCT02365142|Active Comparator|Platelet Rich Plasma (PRGF)|Platelet Rich plasma (PRGF) 3 intraarticular onjections sepataded by 7 days.
89461969|NCT02365142|Active Comparator|BMMSC with Platelet Rich Plasma (PRGF)|Single intraarticular injection of 100 million Bone marrow mesenchimal stem cells and three intraarticular injections of plateler Rich Plasma (PRGF) separatede by 7 days.
89461970|NCT02364986|Experimental|Rebif/Avonex|Rebif® 44µg (day 1, 3, 5 and 8) s.c. Avonex 30µg (day 1 and 8) i.m.
89461971|NCT02373020||group 1|colonoscopic biopsies from patients with colorectal cancer patients
89201847|NCT02555904||Heart failure syndrome & pulmonary congestion|Patients who are admitted for inpatient management with acute heart failure syndrome with pulmonary congestion who require intravenous diuretics are potential candidates for the study and shall be screened for suitability based on the inclusion and exclusion criteria.
89461972|NCT02373020||(Group 2|colonoscopic biopsies from healthy controls
89461973|NCT02372786|Other|Acne Keloidalis Nuchae|2,5% lidocaine / 2,5% prilocaine cream and 7% lidocaine / 7% tetracaine cream will be applied for 60 minutes. After removal of the creams patients will recieve laser hair removal treatment using a neodymium-doped yttrium aluminium garnet (Nd:Yag) laser.
89461974|NCT02372786|Other|Tattoo|2,5% lidocaine / 2,5% prilocaine cream and 7% lidocaine / 7% tetracaine cream will be applied for 60 minutes. After removal of the creams patients will recieve laser tattoo removal treatment using a Q-switched nd Yag laser.
89461975|NCT02364908|Other|Patients with Systemic Lupus|
89461976|NCT02372552|Experimental|CROMA|Microwave coagulation of small blood vessels
89461977|NCT02372708||Experimental|diluted dinitrophenyl(DNP) Vaseline (which equaled to 2% DNP 0.1ml) was started to be directly spread on the surfaces of primary or metastatic tumors of malignant melanoma patients since the first day of every circle of chemotherapy, simultaneously laser irradiation was carried out for 10 min, the power density of laser irradiation was 1W/cm2. The tumors were wrapped and blocked for two days to induce contact dermatitis. If lymph nodes had been cleared, sensibilization of 2×2cm was performed at occipital region. It was repeated once a week.
89461978|NCT02372708||Control|only diluted DNP Vaseline was spread and the operation were the same with the treatment group
89461979|NCT02364674|Experimental|HRCT scans|HRCT scan will be taken
89461980|NCT02367404|No Intervention|Control|Keigel's exercise
89201848|NCT00774540|Experimental|1|Ketorolac
89201849|NCT00774540|Placebo Comparator|2|saline
88943111|NCT05573620|Experimental|ACT+In vivo exposure|5 individual weekly sessions which included ACT methods + in vivo exposure
88943112|NCT05573620|Experimental|ACT+Virtual reality|5 individual weekly sessions which included ACT methods + virtual reality
89461981|NCT02367404|Active Comparator|Duloxetine|Duloxetine 60mg for 3 months
89461982|NCT02367404|Active Comparator|Duloxetine + PMFT|Duloxetine 60mg for 3 months PMFT weekly for 3 months
89461983|NCT02367404|Active Comparator|Pelvic Floor Muscle Training|PMFT weekly for 3 months
89461984|NCT02367248|Active Comparator|Deferoxamine|Deferoxamine mesylate supplied in vials containing 500 mg of sterile, lyophilized, powdered deferoxamine mesylate. The drug will be reconstituted for injection, by dissolving in 20 ml of sterile water.
89461985|NCT02367248|Active Comparator|Xingnaojing injection|Xingnaojing injection supplied in vials containing 20 ml liquid xingnaojing.
89461986|NCT02367248|Placebo Comparator|Normal Saline|0.9% sodium chloride
89461987|NCT02984995|Experimental|Initial dose 30 mg/day quizartinib|Participants who received an initial dose of 30 mg/day of quizartinib and, if no QT prolongation, the dose escalated to 60 mg/day at Day 15.
89461988|NCT02984995|Experimental|Initial dose 20 mg/day quizartinib|Participants who received a CYP3A4 strong inhibitor received an initial dose of 20 mg/day of quizartinib and, if no QT prolongation, the dose escalated to 30 mg/day at Day 15.
89461989|NCT02367326||Patients with Inflammatory Bowel Disease|patients with Crohn's Disease or Ulcerative Colitis meeting clinical, endoscopic and histological criteria and on thiopurines at stable doses for at least 3 months, monotherapy or combined with corticotherapy
89461990|NCT03656965|Experimental|Antiviral Drug with Chemoradiotherapy|Antiviral therapy Acyclovir 800 mg per day during the whole course of treatment.
89461991|NCT03656965|Other|Chemoradiotherapy|Patients will receive concurrent chemoradiotherapy which consisted of Cisplatin 40 mg/m2 weekly or 100mg/m2 every 3 weeks with IMRT 70Gy/35 fractions.
89461992|NCT02364830|Active Comparator|Anise-oil EC|Intervention Group: Anise-oil EC Capsule,One Cap(187mg)/day for 4 weeks. Patients will be Followed at Baseline, 4 and 6 Weeks after Starting Intervention.
88943113|NCT05573620|No Intervention|Waiting list|Participants assigned to Waiting List arm waited for 5 weeks before receiving treatment (i.e., after completing the measures they continued in the study and then were randomly assigned to ACT+in vivo exposure or ACT+virtual reality arms).
89461993|NCT02364830|Placebo Comparator|Placebo|Placebo Group: One Placebo Capsule/Day for 4 Weeks. Patients Will be Followed at Baseline, 4 and 6 Weeks after Starting Intervention.
89461994|NCT02364830|Active Comparator|Colpermin®|Colpermin® Group: One Colpermin® Capsule/Day for 4 Weeks. Patients Will be Followed at Baseline, 4 and 6 Weeks after Starting Intervention.
89461995|NCT03622333|Experimental|Familial Carcinoid Tumors|All patients with proven Familial Carcinoid Tumors
88943114|NCT05572372|Experimental|ACT group|Psychological intervention will consist in an 8-session individual on line-delivered ACT-based treatment.
89461996|NCT02364518|Experimental|Snoreplasty|Treatment of Snoring and/or mild obstructive sleep apnea with snoreplasty.
89461997|NCT03270956|Experimental|Renal Autologous Cell Therapy (REACT)|Renal Autologous Cell Therapy (REACT) Treatment - Patients will receive their first treatment of 2 injections of REACT as soon as REACT product is made available.
89461998|NCT02384239|Experimental|Palbociclib 100mg and, fulvestrant or tamoxifen|Palbociclib dose 100mg, and either fulvestrant (500 mg IM on days 1 and 15 in the first 28 days, then every 28 days thereafter) or tamoxifen (20 mg PO daily by physician choice)
89461999|NCT02384239|Experimental|Palbociclib 125mg and, fulvestrant or tamoxifen|Palbociclib dose 125mg and either fulvestrant (500 mg IM on days 1 and 15 in the first 28 days, then every 28 days thereafter) or tamoxifen (20 mg PO daily by physician choice)
89462000|NCT02372474|Experimental|Stem Cell therapy in POF|POF cases were evaluated hormonally, HP and IH using ESS. Autologous MSC were prepared and laparoscopically transplanted.
89462001|NCT02364752|Experimental|Healthy|Part 1: Blood is obtained from healthy participants on 3 consecutive days, and participants undergo Cardiac Magnetic Resonance Imaging (CMR) and two-dimensional speckle tracking echocardiography (2DSTE) on one of those 3 days.
89462002|NCT02364752|Experimental|Mild/moderate heart failure (HF)|Part 1: Blood is obtained from participants with mild/moderate HF on 3 consecutive days, and participants undergo CMR and 2DSTE on one of those 3 days. Part 2: Within 5 days of completing Part 1 participants have a 24 hour loop diuretic withdrawal, and 15 hour 0.9% normal saline infusion; followed by a blood draw, CMR and 2DSTE.
89462003|NCT02364752|Experimental|Severe HF|Part 1: Blood is obtained from participants with severe HF on 3 consecutive days, and participants undergo CMR and 2DSTE on one of those 3 days. Part 2: Within 5 days of completing Part 1 participants have a 24 hour loop diuretic withdrawal, and 15 hour 0.9% normal saline infusion; followed by a blood draw, CMR and 2DSTE.
89462004|NCT03657199||Bypass graft failure|Patients with at least one detected graft failure after routine cardiac computed tomography before discharge
89462005|NCT03657199||No bypass graft failure|Patients without occluded bypass grafts after routine cardiac computed tomography before discharge
89017764|NCT06136754|Active Comparator|Group I|A fluoride varnish containing 5.0% NaF w/w A fluoride free toothpaste A commercially available adult soft bristle toothbrush
89017765|NCT06136754|Experimental|Group II|A fluoride free varnish A fluoride free toothpaste A commercially available adult soft bristle toothbrush
89017766|NCT06136572|Experimental|Rathus Assertiveness scale|All participants
89017767|NCT06136247||Healthy controls|Healthy controls, people not living with opioid use disorder or on medication assisted therapy for such.
89201850|NCT00777270|Experimental|1 continuous|continuous suture technique with continuous non-locking suture in the vagina, perineum and subcutaneous tissue.
89201851|NCT00777270|Experimental|2 interrupted|interrupted technique with continuous locking suture of the vagina, interrupted sutures in the perineum muscle and interrupted transcutaneous suture
89462006|NCT02372240|Experimental|VLX1570 and dexamethasone|"VLX1570 IV (0.05, 0.15, 0.3, 0.6, 1.2, 2.0 mg/kg) on days 1, 2, 8, 9, 15 and 16 of a 28-day cycle~Dexamethasone 20 mg PO/IV"
89462007|NCT02364596|Experimental|1|SA4Ag vaccine
89462008|NCT02364440|Experimental|Ultherapy™ System|Ultherapy™ System
89462009|NCT02364206|Experimental|LY2228820 + TMZ + Radiotherapy|"addition of LY2228820 to standard radiotherapy and concomitant treatment by temozolomide (TMZ).~LY2228820 will be administered orally for two 28 day cycles, from one week before the beginning of radiotherapy, and during standard chemoradiotherapy. Three dose levels of LY2228820 will be tested.~After a 4 week break after concomitant treatment, patient were then received up to 6 cycles of adjuvant TMZ according to the standard 5-day schedule every 28 days ."
89462010|NCT02366858|Active Comparator|19 gauge|Evaluate the ability to perform molecular marker or immunohistochemistry studies on tissue procured with a 19 gauge needle.
89462011|NCT02366858|Active Comparator|22 gauge|Evaluate the ability to perform molecular marker or immunohistochemistry studies on tissue procured with a 22 gauge needle.
89462012|NCT02372162||Group A - TACE|"Patients with transarterial chemoembolization (TACE) will get an Image Fingerprint and Molecular Fingerprint for tumor characterization in vivo."
89462013|NCT02372162||Group B - Sorafenib|"Patients with Sorafenib treatment will get an Image Fingerprint and Molecular Fingerprint for tumor characterization in vivo."
89462014|NCT02366546|Experimental|Low dose TBI-1301 with pre-treatment 1|TBI-1301(5*10^8) single-dose administration with pre-treatment of cyclophosphamide alone.
89462015|NCT02366546|Experimental|High dose TBI-1301 with pre-treatment 1|TBI-1301(5*10^9) single-dose administration with pre-treatment of cyclophosphamide alone.
89462016|NCT02366546|Experimental|High dose TBI-1301 with pre-treatment 2|TBI-1301(5*10^9) single-dose administration with pre-treatment of cyclophosphamide and fludarabine.
89462017|NCT02366546|Experimental|TBI-1301 with pre-treatment 1 or 2|Arm1, 2 or 3, which is considered as optimal.
89462018|NCT02984683|Experimental|SAR566658 90 mg/m^2|Participants received SAR566658 90 milligram per square meter (mg/m^2) as intravenous infusion on Day 1 and Day 8 of each 21-day treatment cycle (maximum number of cycles received was 3).
89462019|NCT02984683|Experimental|SAR566658 120 mg/m^2|Participants received SAR566658 120 mg/m^2 as intravenous infusion on Day 1 and Day 8 of each 21-day treatment cycle (maximum number of cycles received was 3).
89462020|NCT02364284||Urinary Tract Infection (cUTI)|Patients ≥18 years with diagnosis of urinary tract infection.
89462021|NCT02364284||Intra Abdominal Infection(cIAI)|Patients ≥ 18 years with diagnosis of Intra Abdominal Infection
89462022|NCT02364284||Nosocomial Pneumonia (NP)|Patients ≥ 18 years with diagnosis of Hospital acquired pneumonia
89462023|NCT02524327|Experimental|Toolbox: Automated group|"Toolbox: Automated administration of intravenous anesthetic (propofol 1%) and analgesic (remifentanil, Ultiva(r)) guided by the Bispectral index through a controller with a previously described algorithm.~Objective of depth anesthesia: 40-60"
89462024|NCT02524327|Active Comparator|Manual group|"Manual administration of intravenous anesthetic (propofol 1%) and analgesic (remifentanil, Ultiva(r)) guided by the Bispectral index as usually performed in the operative theater.~Objective of depth anesthesia: 40-60"
89462025|NCT02364362|Experimental|Famitinib + docetaxel|Low, medium and high dose of famitinib and 60 mg/m^2 docetaxel every 3 weeks
89462026|NCT02149147||Physical Activity Variety|participants will complete the Self-Efficacy questionnaire, the Physical Activity Enjoyment Scale, the Behavioral Regulation in Exercise-2 questionnaire, and an Outcome Expectations questionnaire. Participants will be instructed to wear the SenseWear® armband which will measure physical activity-related energy expenditure for the course of the study. The armband will be worn every day for at least 10 hours per day. In addition, participants will be asked to complete a physical activity diary to record their physical activity as well as additional information about the environment in which the physical activity was conducted. Participants will be instructed to engage in their normal physical activity regimen, wear the armband, and complete the physical activity diary for 3 weeks.
88943115|NCT05569018|Experimental|Blended group transversal protocol (BLGr-TP)|Treatment protocol based on the transdiagnostic perspective administered in blended (face-to-face + online) and group format. It consists of the following components: Psychoeducation about emotional disorders and emotion regulation; Motivation for change; Psychoeducation about emotions; Awareness of emotional experiences; Promotion of cognitive flexibility; Psychoeducation and awareness of avoidance strategies that maintain emotional problems; Interoceptive exposure: exposure to physical sensations; Situational and emotional exposure; Learning to move on; Learning to enjoy; Learning to live; Living and learning; Relapse prevention.
89462027|NCT02364128|No Intervention|Control|Potential bariatric surgery patients who receive both the baseline questionnaire and follow-up questionnaire.
89462028|NCT02364128|Other|Decision Aid|Potential bariatric surgery patients who receive both the baseline questionnaire decision aid/conjoint analysis and follow-up questionnaire.
89462029|NCT04574180|Active Comparator|Group 1|Zirconia crown anterior (NuSmile, Houston, Texas, USA).
89462030|NCT04574180|Active Comparator|Group 2|Zirconia crown posterior (NuSmile, Houston, Texas, USA).
89462031|NCT04574180|Active Comparator|Group 3|Stainless steel crown (3M-ESPE, St. Paul, Minnesota, USA)
89462032|NCT04574180|Active Comparator|Group 4|Strip Crown (3M-ESPE, St. Paul, Minnesota, USA)
89462033|NCT02909101|Experimental|Active Cognitive Training (ACT)|Participants will complete computerized games designed to enhance working memory. Participants will complete 48 training sessions over 8 weeks.
89462034|NCT02909101|Sham Comparator|Control Training (CON)|Participants will complete 48 training sessions over 8 weeks. The control games are not designed to enhance memory.
89462035|NCT03656575|Active Comparator|intra-articular alpha-2-macroglobulin|intra-articular injection of 1 mL of the 40 mg/ml strength (1 vial)
89462036|NCT03656575|Active Comparator|intra-articular Platelet-rich Plasma (PRP) injection|Standard of care PRP treatment
89462037|NCT03656575|Active Comparator|Intra-articular corticosteroid|Standard of Care steroid treatment
89462038|NCT03004469|Experimental|P-3074 + Finasteride Placebo|Participants received topical application of P-3074 contained finasteride 0.25% in morning onto dry scalp only (up to 4 puffs) and followed by placebo of finasteride 1 milligram (mg) tablet orally once daily for 24 weeks.
88943116|NCT05569018|Active Comparator|Face-to-face group transversal protocol (FFGr-TP)|Treatment protocol based on the transdiagnostic perspective administered in traditional (face-to-face) group format. It consists of the following components: Psychoeducation about emotional disorders and emotion regulation; Motivation for change; Psychoeducation about emotions; Awareness of emotional experiences; Promotion of cognitive flexibility; Psychoeducation and awareness of avoidance strategies that maintain emotional problems; Interoceptive exposure: exposure to physical sensations; Situational and emotional exposure; Learning to move on; Learning to enjoy; Learning to live; Living and learning; Relapse prevention.
88943117|NCT05563558|Experimental|Study Arm|6 cycles of Pembrolizumab+Cabazitaxel+Carboplatin + 15 cycles of Pembrolizumab
89462039|NCT03004469|Placebo Comparator|P-3074 Vehicle + Finasteride Placebo|Participants received topical application of P-3074 vehicle in morning onto dry scalp only (up to 4 puffs) and followed by placebo of finasteride 1 mg tablet orally once daily for 24 weeks.
89462040|NCT03004469|Active Comparator|Oral Finasteride + P-3074 Vehicle|Participants received finasteride 1 mg tablet orally once daily followed by topical application of P-3074 vehicle in morning onto dry scalp only (up to 4 puffs) for the 24 weeks.
89462041|NCT02358902|Experimental|Group A|tDCS (tDCS - DC stimulator, Neurocom, Germany) / AE Group in which will receive active intervention of aerobic exercise training and active tDCS intervention
89462042|NCT02358902|Experimental|Group B|AE group which will receive active intervention of aerobic exercise and placebo tDCS (tDCS - DC stimulator, Neurocom, Germany)
89462043|NCT02358902|Experimental|Group C|tDCS group which will receive placebo AE and active intervention for tDCS (tDCS - DC stimulator, Neurocom, Germany)
89462044|NCT02366702||Individuals with Bilateral Transfemoral Amputation|
89462045|NCT02366780|Experimental|Manual expression followed by electric pump|Mothers will be assigned to first express breast milk manually followed by electric pump
89462046|NCT02366780|Experimental|Electric pump followed by manual expression|Mothers will be assigned to first express breast milk by electric pump followed by manual expression
89462047|NCT02364050||Elderly patients with DLBCL|Elderly patients (Age ≥ 65 years) with large B-cell lymphoma classified FIT or UNFIT or FRAIL by Multidimensional Geriatric Assessment (MGA)
89462048|NCT02910713|Experimental|Intranasal Application|Intranasal Tear Neurostimulator applied intranasally device (active), intranasal application for approximately 3 minutes on Day 0 when the participant experienced an ODS ≥ 3 at 2 or more consecutive time points in at least one eye during the CAE exposure.
89462049|NCT02910713|Sham Comparator|Extranasal Application|Intranasal Tear Neurostimulator device applied extranasally (control) for approximately 3 minutes on Day 0 when the participant experienced an ODS ≥ 3 at 2 or more consecutive time points in at least one eye during the CAE exposure.
89462050|NCT04478786||Focus Groups 1-4|An anticipated 3-8 participants who meet the inclusion criteria of being aged 18 or over, a employee of the local ambulance service, are employed as an operational ambulance crew member, irrespective of title and to have had experienced an out of hospital resuscitation where MCCD was used, irrespective of the type of device or their level of involvement, and who also volunteer and agree to take part in the online focus group.
89462051|NCT02358824|Experimental|CKD-828(Fixed Dose Combination)|FDC tablet consisting of Telmisartan 80mg/S-Amlodipine 5mg
89462052|NCT02358824|Active Comparator|Combination Therapy|Coadministration of Telmisartan 80mg and S-amlodipine 5mg
88943118|NCT05557890|Experimental|System Constellation VR-Seminar (exp. group)|By externalising significant elements, systemic constellations render the inner image someone has of a personally important social system in a visible and tangible way to get more clarity about psycho-social conflicts to make goal-oriented changes. In this study, the method System Constellation will be applied in a Virtual Reality (VR) setting during two to three day seminars.
88943119|NCT05557890|Experimental|System Constellation VR-Seminar (control group)|By externalising significant elements, systemic constellations render the inner image someone has of a personally important social system in a visible and tangible way to get more clarity about psycho-social conflicts to make goal-oriented changes. In this study, the method System Constellation will be applied in a Virtual Reality (VR) setting during two to three day seminars. Study participants randomized to this group receive the intervention (system constellations VR-seminar) 4 months after the experimental group.
88943120|NCT05557097||Group ultrasound + vaginal examination|Patients submitted to instrumental delivery by clinicians who routinely perform intrapartum sonography as an adjunct to clinical examination prior to vacuum delivery
88943121|NCT05557097||Group vaginal examination|Patients submitted to instrumental delivery by clinicians not performing intrapartum sonography prior to vacuum delivery
88943122|NCT05545735|Experimental|4 Days of Antibiotics Group|Participants will receive 4 days of antibiotic therapy administered as per the standard of care for the treatment of early ventilator associated pneumonia (VAP).
88943123|NCT05545735|Active Comparator|7 Days of Antibiotics Group|Participants will receive 7 days of antibiotic therapy administered as per the standard of care for the treatment of early ventilator associated pneumonia (VAP).
89017768|NCT06136247||Patients living with Opioid Use Disorder|Individuals with opioid use disorder who have been on a stable dose of medication assisted therapy for at least a week.
89017769|NCT06135948|Experimental|Intervention Group|Hypothyroidism patients who received an increased dose of L-thyroxine, 25 mcg, n = 50
89462053|NCT02998541|Experimental|SHP640|Participants will receive one drop of SHP640 (0.1 percent [%] dexamethasone and 0.6% PVP-I) ophthalmic suspension in each eye 4 times daily (QID) for 7 days.
89462054|NCT02998541|Active Comparator|PVP-I 0.6%|Participants will receive one drop of 0.6% PVP-I ophthalmic solution in each eye QID for 7 days.
89462055|NCT02998541|Placebo Comparator|Placebo|Participants will receive one drop of placebo ophthalmic solution in each eye QID for 7 days.
89462056|NCT02359136|Placebo Comparator|LIA placebo|local infiltration anesthesia using saline i addition to multimodal analgesic regimen
89462057|NCT02359136|Experimental|LIA Ropivacaine|local infiltration anesthesia using Ropivacaine and Epinephrine i addition to multimodal analgesic regimen
89462058|NCT02363894||Subjects enrolled in DEFINITIVE AR|
89462059|NCT02363582|No Intervention|Breast fed|healthy term infants on exclusively breast feeding , enrollment age: 30-50days old
89462060|NCT02363582|Experimental|Formula fed|healthy term infants on exclusively formula fed , enrollment age: 30-50days old
89462061|NCT02366078|Experimental|Stress management|Participants will receive SMART traiing
89462062|NCT02366156|Placebo Comparator|Placebo|Inactive capsules
89462063|NCT02366156|Active Comparator|Low Dose Grape Blend|Low dose grape blend providing 375 mg whole grape extract + 375 mg grape seed extract/d (750 mg total botanical extracts/d).
89462064|NCT02366156|Active Comparator|High Dose Grape Blend|High dose grape blend providing 500 mg whole grape extract + 500 mg grape seed extract/d (1000 mg total botanical extracts/d)
89462065|NCT02366234||Fracture of Distal Tubercle of Scaphoid|"Questionnaires~Quick DASH after trauma (< 2 weeks)~11-point ordinal measure of overall pain intensity 6 months after trauma~11-point ordinal measure of satisfaction with treatment 6 months after trauma"
89462066|NCT02366390|Experimental|Psychoeducative intervention|A psychoeducative dialogue and one telephone booster session
89462067|NCT02366390|No Intervention|Usual care|Usual care according to current guidelines.
89462068|NCT02358980||Study group|Participants will receive FLC removal HD undertaken using an extended dialysis schedule on KIDNEY therapy system. Treatments (4 hours each) were carried out for 8 consecutive days and then every other day.
89462069|NCT02998151|Experimental|All Study Participants|Participants received, in random order, a single dose of placebo, acamprosate, lovastatin, minocycline, or baclofen, with a two-week washout period between doses. Midway through the study (n=16) it was determined that acamprosate was undetectable in serum and this intervention was replaced by baclofen. Remaining participants (n=13) received baclofen and 5 participants were re-enrolled to receive baclofen or a second round of placebo, so investigators and participants would remain blinded to drug status during the baclofen visit. The second round of placebo was not analyzed.
89462070|NCT02358590|Experimental|HAPA menu-based mini-video|This group will watch mini-videos, which are multi-target menu-based interventions designed to deliver information about vitamin D adherence and its effect on osteoporosis
89462071|NCT02358590|Active Comparator|Standard care|This group will be advised by the treating physician to take vitamin D
89462072|NCT03664349||Older Adult Participants and Informal/Formal Caregiver Pairs|A sub-cohort of approximately 10 participant-caregiver pairs will utilize SE9000 and communication strategies over a 4-6-week period between LVR visits.
89462073|NCT03664349||Older Adult Participants|The pilot cohort of approximately 100 adults over age 60, with vision impairment, will complete the Hearing Handicap Inventory for the Elderly (HHIE), an assessment of perceived impact of hearing impairment, and an objective hearing evaluation.
89462074|NCT03664349||Formal/Informal Caregivers|Identified persons who assist willing and eligible older adult pilot participants with two or more ADLs/IADLs.
89462075|NCT02994290|Experimental|receive inpatient HPV vaccine|We will select a purposive sample of postpartum women into two groups: those who receive inpatient HPV vaccine and those who decline the inpatient dose to interview until we reach thematic saturation which we anticipate to occur with about 8-10 individuals per group. Patients will be selected to include diverse representation in age, race, ethnicity, and parity.
89462076|NCT02994290|Experimental|decline the inpatient dose|We will select a purposive sample of postpartum women into two groups: those who receive inpatient HPV vaccine and those who decline the inpatient dose to interview until we reach thematic saturation which we anticipate to occur with about 8-10 individuals per group. Patients will be selected to include diverse representation in age, race, ethnicity, and parity.
89201852|NCT00774618|Experimental|Resection|Those subjects undergoing resection with or without plate fixation
89201853|NCT00774618|No Intervention|Nonoperative|These patients were not considered candidates for surgical intervention by the investigators, declined surgical intervention, or did not receive insurance approval for surgery
89201854|NCT00777426||Thai HAD individuals (25 cases)|
89462077|NCT04058015||adult patients with thoracoabdominal injuries|adult patients with moderate to severe thoracoabdominal injuries
89462078|NCT04057781|No Intervention|Control|
89537185|NCT05456243|Experimental|High Dose Group|Adult kidney transplant recipients with subclinical rejection (biopsy-proven antibody-mediated and/or cellular rejection, including borderline rejection) will be administered one high dose of allogeneic A-MSC.
89201855|NCT00777426||Thai Non-HAD individuals (25 cases)|
89201856|NCT00777426||Thai Non-infected individuals (10 cases)|
89201857|NCT00669240||1. Non-interventional|Patients prescribed varenicline in a non interventional manner.
89201858|NCT00669162|Experimental|RT, Docetaxel, Hormonal Therapy|Radiation Therapy (RT) to 66 Gy in 33 treatment fractions at 2.0 Gy/fx Concurrent Docetaxel (with RT) at 20 mg/m2 weekly x 7 Casodex (50 mg po daily)x 6 months Zoladex (10.8 mg sc q 3 mos x 2) or Lupron (22.5 mg im q 3 mos x 2)
89201859|NCT00774696|Experimental|1|Clarithromycin 500 mg Tablets
89201860|NCT00774696|Active Comparator|2|BIAXIN® 500 mg tablets
89201861|NCT00774774|Placebo Comparator|2|No intervention
89201862|NCT00774774|Experimental|1|Mask
89462079|NCT04057781|Active Comparator|Dry Needling (DN)|"Subjects will receive dry needling treatment every 2 weeks for 6 weeks (weeks 0, 2, 4, 6).~Outcomes will be measured at baseline (week 0), 4 weeks after initiation of study (week 4), 6 weeks after initiation of study (week 6), and 6 weeks after last treatment (week 12)."
89462080|NCT04057781|Active Comparator|Dry Needling with Intramuscular ES (DNES)|"Subjects will receive dry needling treatment with electrical stimulation every 2 weeks for 6 weeks (week 0, 2, 4, 6)~Outcomes will be measured at baseline (week 0), 4 weeks after initiation of study (week 4), 6 weeks after initiation of study (week 6), and 6 weeks after last treatment (week 12)."
89462081|NCT03388775||Patients with deep venous thrombosis|"Five-year prospective records of deep venous thrombosis have been collected by the RHEUNI group of five public schools in the State of São Paulo.~Demographic data of patients will be evaluated along with the main risk factors, clinical picture, diagnostic methods, use of different drugs to treat the disease and its complications."
89462082|NCT03664271|Experimental|in-clinic video intervention|Intervention: Caregivers will watch an educational video in clinic, and also be given information about how to access the video from home (ideal condition). The intervention video will contain educational information about eczema, as well as routine skincare and common treatments.
89462083|NCT03664271|Active Comparator|at home video intervention|Intervention: Caregivers will be given information about how to watch the video at home, but will not watch it in clinic (real-world condition).The intervention video will contain educational information about eczema, as well as routine skincare and common treatments.
89462084|NCT03664271|No Intervention|usual care|Control: Caregivers will not watch the educational video, but will be given access to it at the conclusion of the study.
89462085|NCT03663491|Experimental|Unsedated Nasal Gastroscopy|Transnasal Endoscopy. No sedation used. Use of local anesthesia.
89462086|NCT03663491|Active Comparator|Oral Gastroscopy, unsedated|Transoral Endoscopy. No sedation used. Use of local anesthesia.
89462087|NCT03663491|Active Comparator|Oral Gastroscopy, sedated|Transoral Endoscopy. Intravenous sedation used.
89462088|NCT04057625|Other|lung ultrasound|using lung ultrasound in diagnosis and follow up of vap measuring the largest area of consolidation according to intercostal space and the direction of the probe
89462089|NCT01066819||Cohort|Participants chronically infected with the hepatitis C virus including genotypes 1 to 6.
89462090|NCT04056299|Active Comparator|AR201 powder|Subjects were randomized to active arm of AIME01 and administered AR201 in escalating doses for approximately 6 months, followed by a maintenance dose for approximately 12 weeks
89462091|NCT04056299|Placebo Comparator|Placebo powder|Subjects were randomized to placebo arm of AIME01 and administered placebo for approximately 6 months, followed by maintenance placebo for approximately 12 weeks.
89462092|NCT04057547|Experimental|Experimental group|Mesalazine sustained-release granules, orally, 0.5g/time, 4-6 times/d Modified Gegen Qinlian Decoction, Oral, 7.2g per bag, 2 times / day, 30 minutes before breakfast and dinner
89462093|NCT04057547|Active Comparator|Control group|Mesalazine sustained-release granules, orally, 0.5g/time, 4-6 times/d Bifico(Bifidobacterium triple viable capsule), orally，2 capsules/time, 2 days/time.
88943124|NCT05544305|Experimental|Digitised Home Based Care pathway|The investigators have co-designed an innovative digital care pathway, Home Based Care (HBC), that delivers self-management support and clinical expertise to the patient's home, supported by digitally-enabled remote monitoring with a wrist-worn sensor, the Parkinson's Kinetograph, and digitally-delivered questionnaires, to replace the current pen-and-paper processes.
88943125|NCT05531994|Other|TR|Administration order: montelukast sodium oral thin films with water, montelukast sodium chewable tablets with water.
89201863|NCT02556060|Experimental|lamotrigine|lamotrigine extended release up to 200 mg/day,
88943126|NCT05531994|Other|RT|Administration order: montelukast sodium chewable tablets with water, montelukast sodium oral thin films with water.
89201864|NCT02556060|Placebo Comparator|Placebo|Identical Placebo
89201865|NCT00354770|Active Comparator|N-Acetyl Cysteine|N-Acetyl Cysteine
89462094|NCT01069523|Placebo Comparator|Placebo|Patients will be started on 1 mg of guanfacine extended release matching placebo tablets at week 1. A physician blind to drug status will titrate the study medication in week 2-3 to a maximum of 4 mg (4 tablets).
89462095|NCT01069523|Experimental|Guanfacine Extended Release|Patients will be started on 1 mg of guanfacine extended release at week 1. A physician blind to drug status will titrate the study medication in week 2-3 to a maximum of 4 mg (4 tablets).
89462096|NCT01069289|Experimental|1|Symbicort Turbuhaler 160/4.5 microgram, 2 inhalations twice daily
89462097|NCT01069289|Active Comparator|2|Oxis Turbuhaler 4.5 microgram, 2 inhalations twice daily
89462098|NCT04057313|Active Comparator|Group 1|Group 1 will receive 80 cc of coffee in the dialysis session
89462099|NCT04057313|Placebo Comparator|Group 2|Group 2 will receive 80 cc of decaffeinated coffee in the dialysis session
89462100|NCT03663413||BIS|Monitored with BIS (bispectral index) monitor in addition to other conventional monitors of blood pressure, ECG, oxygen saturation and anesthetic agent concentration.
89462101|NCT03663413||Narcotrend|Monitored with Narcotrend monitor in addition to other conventional monitors of blood pressure, ECG, oxygen saturation and anesthetic agent concentration.
89462102|NCT03303989|Experimental|pegloticase + MMF|Participants randomized to this arm will receive pegloticase + mycophenolate mofetil.
89462103|NCT03303989|Placebo Comparator|pegloticase + placebo|Participants randomized to this arm will receive pegloticase + placebo
89462104|NCT02510794|Experimental|Port Delivery System with Ranibizumab 10mg/mL|Participants had the Implant (prefilled with approximately 20 μL of 10-mg/mL ,approximately 0.2 mg dose, of ranibizumab) surgically inserted in the study eye at the Day 1 visit following their randomization visit. Starting at the Month 1 visit, participants were evaluated monthly for the need for Implant refill with the 10-mg/mL formulation of ranibizumab according to their randomization as per protocol-specified refill criteria.
89462105|NCT02510794|Experimental|Port Delivery System with Ranibizumab 40mg/mL|Participants had the Implant (prefilled with approximately 20 μL of 40-mg/mL, approximately 0.8 mg dose, of ranibizumab) surgically inserted in the study eye at the Day 1 visit following their randomization visit. Starting at the Month 1 visit, participants were evaluated monthly for the need for Implant refill with the 40-mg/mL formulation of ranibizumab according to their randomization as per protocol-specified refill criteria.
89462106|NCT02510794|Experimental|Port Delivery System with Ranibizumab 100mg/mL|Participants had the Implant (prefilled with approximately 20 μL of 100-mg/mL, approximately 2 mg dose, of ranibizumab) surgically inserted in the study eye at the Day 1 visit following their randomization visit. Starting at the Month 1 visit, participants were evaluated monthly for the need for Implant refill with the 100-mg/mL formulation of ranibizumab according to their randomization as per protocol-specified refill criteria.
89462107|NCT02510794|Active Comparator|Intravitreal Injection with Ranibizumab 0.5mg|Participants received ranibizumab 0.5 mg monthly ITV injections of 10 mg/mL formulation at Day 1 and every month thereafter.
89462108|NCT04056923|Experimental|3D-printed template-guided(3D-G)|Intraoperative 3D-G methylene blue dye marking in the operating room
89462109|NCT04056923|Active Comparator|CT-guided(CT-G)|Preoperative localization is performed by CT-G indocyanine green marking in the radiology department
89462110|NCT03664115|Experimental|Itraconazole Arm|"Patients will receive intravenous doses of cisplatin 80 mg/m2 on day 1 plus gemcitabine 1000 mg/m2 on days 1 and 8 every 3 weeks for a maximum of 6 cycles + itraconazole 200 mg oral tablet daily, on a 21-day cycle.~Alternatively, Carboplatin may be used instead of Cisplatin, Carbplatin AUC 5 DAY 1 only Dose = AUC x (GFR + 25) IV in 250 mL Normal Saline over 30 minutes"
89462111|NCT03664115|Active Comparator|Control Arm|"Patients will receive intravenous doses of cisplatin 80 mg/m2 on day 1 plus gemcitabine 1000 mg/m2 on days 1 and 8 every 3 weeks for a maximum of 6 cycles.~Alternatively, Carboplatin may be used instead of Cisplatin, Carbplatin AUC 5 DAY 1 only Dose = AUC x (GFR + 25) IV in 250 mL Normal Saline over 30 minutes"
89462112|NCT03370757|Active Comparator|3-hour bundled care|Infants in this group will have their diaper changed every 3 hours during 3-hour bundled care.
89462113|NCT03370757|Active Comparator|6-hour bundled care|Infants in this group will have their diaper changed every 6 hours.
89462114|NCT03622853|Experimental|intraarticular steroid injection|intraarticular steroid hydrodilatation (shincort 40mg )
89462115|NCT02363426|Other|Medical Device: INVOcell Culture Device|5 day oocyte incubation using INVOcell Culture Device within the vaginal cavity.
89462116|NCT02363426|Active Comparator|Medical Device: IVF Incubator|5 day oocyte incubation using traditional IVF incubation.
89462117|NCT02363504||Healthy older controls|7 Tesla MRI with memory task and non-invasive neurostimulation
89462118|NCT02363504||Prodromal Alzheimer's disease patients|7 Tesla MRI with memory task and non-invasive neurostimulation
89462119|NCT04052243|Other|All patients|Exercise is added to resting right heart catheterization
89462120|NCT02363348|Placebo Comparator|Placebo (A)|"were administered 5 capsules per day each capsule contained 600 mg of magnesia calcinada. Duration: from week 20th of pregnancy until the end of the same.~dose was administered as follows: two capsules in the morning at breakfast and three capsules at night in dinner."
89462121|NCT02363348|Experimental|L arginine (B)|were administered 5 capsules per day each capsule contained 600 mg of L arginine. Duration: from week 20th of pregnancy until the end of the same dose was administered as follows: two capsules in the morning at breakfast and three capsules at night in dinner.
89462122|NCT04056845|Experimental|Knee brace group|Patients in this group will receive a valgus knee brace (Medex K39-OA Corrector), to be worn for at least four hours a day, during the study period, on top of the presrciption of physiotherapy and oral analgesic (diclofenac and panadol).
89462123|NCT04056845|Active Comparator|Control Group|Patients in this group will receive physiotherapy and oral analgesic (diclofenac and panadol).
89201866|NCT00354770|Placebo Comparator|2|Placebo
89201867|NCT00741494|No Intervention|1|HBA score over 65% control
89462124|NCT02363192|Experimental|Pharmacist Intervention Group|
89462125|NCT02363192|No Intervention|Usual Care Group|
89462126|NCT03663959||Vaginal Sacrospinous Fixation group|Women who had vaginal sacrospinous fixation procedure with Dr.Aksakal's Desta suture carrier in our clinic between January 2014 and June 2018.
89462127|NCT03663959||Laparoscopic Pectopexy Group|Women who had Laparoscopic Pectopexy procedure in our clinic between January 2014 and June 2018
89462128|NCT02510014|Experimental|Roll-over Subjects|Subjects who completed RB-US-13-0001 received SUBOXONE sublingual film during the Run-In period, followed by an initial open-label injection of 300 mg RBP-6000. Participants continued with monthly injections of either 300 mg or 100 mg (based on judgement of the Investigator) for a total of 6 months in the Treatment period.
89462129|NCT02510014|Experimental|De Novo Subjects|Subjects who did not participate in RB-US-13-0001 received SUBOXONE sublingual film during the Run-In period, followed by an initial open-label injection of 300 mg RBP-6000. Participants continued with monthly injections of either 300 mg or 100 mg (based on judgement of the Investigator) for a total of 12 months in the Treatment period.
89017770|NCT06135948|No Intervention|Control Group|Hypothyroidism patients who received standard/regular dose of L-thyroxine, n = 46
89017771|NCT06135831|Experimental|Calciovitmag (CDCaMg)|Daily supplementation of diet with vitamin C (1000 mg), vitamin D3 (500 mg), calcium (Ca) (500 mg ) and magnesium (Mg) (300 mg)
89462130|NCT02358512|Experimental|Intermittent enteral feeding|The intermittent feeding regimen will consist of six bolus feeds (one bolus every four hours).
89462131|NCT02358512|Active Comparator|Continuous enteral feeding|The continuous feeding regimen consists of the total volume of feed administered over 24 hours.
89462132|NCT03257579|Experimental|90 Day Supply|Intervention: At Hamilton Health Sciences a policy change implementing a standardized discharge prescription form of a 90-day supply with 3 repeats for all cardiac medications available on all wards where MI patients are managed.
89462133|NCT03257579|Experimental|Education Alone|At St. Joseph's Hospital and Niagara Health System education regarding the benefits of lengthening prescriptions to a 90 day supply with 3 repeats for all cardiac medications will be implemented.
89462134|NCT03257579|No Intervention|Control|Remaining Ontario cardiac sites will receive usual care and act as concurrent control group.
89462135|NCT02358746|Experimental|combined endo/epicardial approach|combining endocardial scar homogenization with epicardial scar homogenization in the first VT ablation approach
89462136|NCT02358746|Active Comparator|stepwise approach|endocardial scar homogenization only at the first VT ablation procedure
89462137|NCT03663803|Experimental|Intervention|Participants in the intervention group received the offer of four 2h group sessions during five weeks, and two further sessions after one and six months. The attendance rates of the sessions were 95%, 88%, 87%, 73%, 67% and 51%, respectively. The course was delivered by health care staff in the Holstebro Health Care Centre, including a dietitian and an occupational therapist, both with health pedagogic competences. It was delivered to seven intervention groups, which varied in size from 5 to 15 participants.
89462138|NCT03663803|No Intervention|Control|Usual practice
89462139|NCT03662945|Experimental|Intervention group|Mobile Geriatric Team intervention including physicians and nurses with the aim of developing person-centered, safe, sustainable and coordinated care plans. These care plans are developed in collaboration with the patient, his/her relatives and staff from the municipality. Among the main ambitions of this concept are improved communication flows between patients, their relatives and healthcare providers in combination with the delivery of medical as well as care measures. Other ambitions are to avoid unnecessary traditional healthcare utilization in the form of inpatient care and EMR visits, for example.
89462140|NCT03662945|No Intervention|Control group|Standard care including primary care units, home care and home help.
89462141|NCT02509312|Experimental|Experimental|Patients in this arm will be given ketorolac at cord clamp with standard dose of 30 mg, then 3 additional 30 mg doses every 6 hours
89462142|NCT02509312|Placebo Comparator|Control|Patients in this arm will be given a placebo medication at cord clamp, and then 3 additional doses of placebo every 6 hours.
89462143|NCT03662477|Experimental|EGFR+NK+|The EGFR mutation positive patients were with the principles of randomized and NK cells treatment.
89462144|NCT03662477|No Intervention|EGFR+NK-|The EGFR mutation positive patients were with the principles of randomized and without NK cells treatment .
89462145|NCT03662477|Experimental|EGFR-NK+|The EGFR mutation negative patients were with the principles of randomized and NK cells treatment .
89462146|NCT03662477|No Intervention|EGFR-NK-|The EGFR mutation negative patients were with the principles of randomized and without NK cells treatment.
89462147|NCT02362880|Active Comparator|mutation carrier|
89462148|NCT02362880|Sham Comparator|mutation non-carrier|
89462149|NCT04057079|Experimental|Anugel|"In this arm, after the surgery a hydrogel impregnated sponge will be placed in the rectum.~The patient is evaluated after the operation and the following day when the sponge is removed.~A hydrogel impregnated foam pad is applied on the surface of the wound the following 5 days.~The patient is evaluated on post op, on day 1 (usually before discharge) and day 5~The pain of the patients are evaluated according to the VAS scale and the use of analgesics and opioids is monitored."
89462150|NCT04057079|Active Comparator|Sponge|"Currently used treatment method i.e. insertion of gelatine sponge in to the rectum post operation.~The patient is evaluated on post op, on day 1 (usually before discharge) and day 5~The pain of the patients are evaluated according to the VAS scale and the use of analgesics and opioids is monitored."
89462151|NCT03662399|Experimental|Insole A|Investigational product - Insole A
89462152|NCT03662399|Experimental|Insole B|Investigational product - Insole B
89462153|NCT03662399|Experimental|Insole C|Investigational product - Insole C
89017772|NCT06135831|Placebo Comparator|Control|Daily supplementation of diet with vitamin D3 (500 mg), Ca (500 mg) and Mg (300 mg)
89462154|NCT03662399|Experimental|Insole D|Investigational product - Insole D
89462155|NCT03662399|Experimental|Insole E|Investigational product - Insole E
89462156|NCT03662399|Experimental|Insole F|Investigational product - Insole F
89462157|NCT03662399|Experimental|Insole G|Non-Investigational product - Standard shoe
89462158|NCT02362958|Experimental|Lapatinib and Capecitabine or Vinorelbine|Lapatinib 1250mg qd and Capecitabine 1000mg/m2 bid or Vinorelbine 25mg/m2 iv (d1,d8)
89462159|NCT04973800|Experimental|Experimental arm: Simvastatin|Simvastatin 20mg ON PO for 28-30 days
89462160|NCT04973800|Placebo Comparator|Control arm: Placebo|Sucrose placebo ON PO for 28-30 days
89462161|NCT02363036||Active labor|Women in active labor normal pregnancy at term.
89462162|NCT02363036||Planned Cesarian Section|Women, normal pregnancy at term who came for elective Cesarean Section without signs of labor (pain/contractions, etc).
89017773|NCT06135831|Experimental|Phosphorovitmag (PDCaMg)|Daily supplementation of diet with bisphosphonates (150 mg), vitamin D3 (500 mg), Ca (500 mg ) and Mg (300 mg)
89017774|NCT06135831|Experimental|Functional Olive paste|Daily supplementation of diet with 364 mg polyphenols via 50 g of an innovative functional food (Kalamata olive paste with mountain tea rich in polyphenols, (total phenolics 7,28±3.11 gallic acid/g) along with vitamin D3 (500 mg), Ca (500 mg) and Mg (300 mg)
89462163|NCT03662867|Experimental|Family-based mindfulness intervention|Family-based mindfulness intervention is a parallel-group intervention containing one parent program and one child program. The parent mindfulness program lasts for 6 weeks, one session per week, and each session lasts for 1.5 hours. The child mindfulness program lasts for 8 weeks, one session per week, and each session lasts for 1 hour. In the fourth and sixth sessions of the parent program, 30-minute joint practice of parents and children is incorporated. All sessions are implemented by qualified instructors.
89462164|NCT03662867|Other|Wait-list control|Intervention group participants were assessed at baseline (T1) and after the intervention (T2). Control group participants were assessed at the same time with the intervention group, and would receive the same program after posttest of intervention groups.
89462165|NCT03662321||sexual behavior on the internet|this group of teenagers use internet for sexuality
89462166|NCT03662321||not sexual behavior on the internet|this group of teenagers doesn't use internet for sexuality
89462167|NCT03662243||Acquired brain injury participants|People with acquired alexia and/or agraphia secondary to brain injury who participate in the reading/writing intervention.
89462168|NCT03662555|Experimental|NMES and BFR (80%)|Group 1, participants will undergo NMES and BFR (80% pressure) applied to the quadriceps for 25 min.
89462169|NCT03662555|Experimental|NMES and BFR (40%)|Group 2, participants will undergo NMES and BFR (40% pressure) applied to the quadriceps for 25 min.
89462170|NCT03662555|Active Comparator|NMES alone|Group 3, participants will undergo NMES applied to the quadriceps for 25 min.
89462171|NCT03662165|Experimental|Intervention|"The primary intervention consisted of a text message informing participants that HIV self-test kits were available at all North Star Alliance clinics in Kenya. The message was sent three times, one week apart, first in Kiswahili, then in English and then again in Kiswahili, and read: You can now self-test at home or in the clinic for HIV using a new test kit available from all North Star Alliance clinics in Kenya. Your health, our priority."
89462172|NCT03662165|Experimental|Enhanced Standard of Care|"Those randomized to the enhanced Standard of Care (SOC) arm received the SOC message reminding clients about HIV testing sent three times, one week apart first in Kiswahili, then in English and then again in Kiswahili. The message read: North Star Alliance East Africa would wish to kindly remind you to visit any of our roadside wellness centres for HIV testing. Your health, our priority."
89462173|NCT03662165|Active Comparator|Traditional Standard of Care|"Those randomized to the traditional SOC arm received the SOC message one time sent simultaneously in both Kiswahili and English. The message read: North Star Alliance East Africa would wish to kindly remind you to visit any of our roadside wellness centres for HIV testing. Your health, our priority."
89462174|NCT02509156|Experimental|Allo-MSCs|Target dose of 100 million allo-MSCs
89462175|NCT02509156|Placebo Comparator|Placebo|Buminate solution
89462176|NCT03662087|Experimental|HMA+DLI|For AL patients who achieved CR at pre-transplantation undergoing allo-HSCT, DLI was not given and immunosuppressant were withdrawn if patients were MRD persistently negative. MRD status were monitored every 30 days. If patients were MRD negative by Day+30 post-transplantation, MRD status would be continued to be monitored by Day+60. If patients were MRD positive by Day+30 post-transplantation, immunosuppressant were withdrawn. If MRD were persistently positive until Day+60 or MRD changed from negative by Day+30 to positive by Day +60 post-transplantation, HMA and DLI were given. DLI was given 48 hours after administration of HMA. DLI was given monthly until GVHD occurred or MRD became negative or a total of four times. If MRD changed from positive by Day+30 to negative by Day+60 post-transplantation, MRD status would be continued to be monitored by Day+90 post-transplantation. If patients were MRD positive by Day+90 post-transplantation, HMA and DLI were given as shown above.
89201868|NCT00741494|No Intervention|2|HBA score over 65%, non-participant (to even out the participation between patients with low HBA scores and those with high HBA scores)
89201869|NCT00741494|Active Comparator|3|HBA score over 65%. PICSI dish is used to select the sperm for ICSI.
89201870|NCT00741494|Experimental|4|HBA score less than 65%. PICSI dish used to select sperm for ICSI.
89201871|NCT00741494|No Intervention|5|HBA Score less than 65%. Control
89462177|NCT03662087|Experimental|DLI|For AL patients who achieved CR at pre-transplantation undergoing allo-HSCT, DLI was not given and immunosuppressant were withdrawn if patients were MRD persistently negative. MRD status were monitored every 30 days. If patients were MRD negative by Day+30 post-transplantation, MRD status would be continued to be monitored by Day+60 post-transplantation. If patients were MRD positive by Day+30 post-transplantation, immunosuppressant were withdrawn. If MRD were persistently positive until Day+60 or MRD changed from negative by Day+30 to positive by Day+60 post-transplantation, DLI was given. DLI was given monthly until GVHD occurred or MRD became negative or a total of four times. If MRD changed from positive by Day+30 to negative by Day+60 post-transplantation, MRD status would be continued to be monitored by Day+90 post-transplantation. If patients were MRD positive by Day+90 post-transplantation, DLI was given as shown above.
89201872|NCT00744146|Experimental|1|"Six volunteers total.~Randomized such that four volunteers will receive Protexia as a single 50 mg dose and two volunteers will receive saline placebo of the same volume on Study Day 1.~Volunteers to be followed for approximately 71 days total."
89462178|NCT03661619|Experimental|Control Group|Envelope technique + sub-epithelial connective tissue graft harvested from the palatal for root coverage procedure
89462179|NCT03661619|Experimental|Test Group|Envelope technique + sub-epithelial connective tissue graft harvested from the tuberosity for root coverage procedure
89462180|NCT03661931|Experimental|DQPN Validation|We are planning to recruit 150 individuals who are patients in the Boston Heart Lifestyle Program and are already having fatty acids measured as part of clinical care, and ask them to complete the DQPN, FFQ, and a User Experience Questionnaire for each dietary assessment method.
89462181|NCT01654666|Experimental|RIPC group|"Treatment:Patients in this group received standard medical therapy and remote ischemic preconditioning (RIPC) treatment.~Device:RIPC consisted of five 5-min cycles of bilateral arm ischemia/reperfusion, which is induced by an automated cuff-inflator placed on bilateral arm and inflated to 200 mmHg for 5-min followed by deflating the cuff for 5-min,each patient in the RIPC group do it twice a day for at least two weeks before carotid artery stenting.~Procedure: Carotid Artery Stenting"
89462182|NCT01654666|Active Comparator|Control group|Treatment:Patients in this group received standard medical therapy alone. Procedure: Carotid Artery Stenting
89462183|NCT01654666|Sham Comparator|Sham RIPC group|"Treatment:Patients in this group received standard medical therapy and sham remote ischemic preconditioning treatment.~Device:Sham RIPC consisted of five 5-min cycles of bilateral arm ischemia/reperfusion, which is induced by an automated cuff-inflator placed on bilateral arm and inflated to 60 mmHg for 5-min followed by deflating the cuff for 5-min, each patient in RIPC group do it twice a day for at least two weeks before carotid artery stenting.~Procedure: Carotid Artery Stenting"
89462184|NCT04973332|Experimental|Thrombectomy-SINOMED SR|Patients diagnosed with acute ischemic stroke within 24 hours from the onset of the stroke to the completion of femoral artery puncture, regardless of whether intravenous thrombolysis has been performed. Intracranial thrombectomy stents can be used to remove the thrombus in the large vessels of the brain in patients with ischemic stroke To restore blood flow.
89462185|NCT04973332|Active Comparator|Thrombectomy-Solitaire FR|Intracranial thrombectomy was performed with a control product（name:Solitaire FR）
89462186|NCT04971928|Experimental|Participants with Moderate (CP-B) hepatic impairment|
89462187|NCT04971928|Experimental|Participants with Mild (CP-A) hepatic impairment|
89462188|NCT04971928|Experimental|Healthy participants|
89462189|NCT02519842|Experimental|Fosaprepitant Regimen Cycle 1|Participants received a single dose of fosaprepitant 150 mg (or age-based adjustment) administered intravenously (IV) on Day 1 prior to chemotherapy plus ondansetron IV on Day 1 prior to chemotherapy and at investigator's discretion on day(s) of chemotherapy and up to 24 hours after chemotherapy. Participants may have also received dexamethasone IV at investigator's discretion on day(s) of chemotherapy and up to 24 hours after chemotherapy.
88943127|NCT05530148|Experimental|Martial Arts Group|Participants will be trained in the martial arts exercises using both in-person group sessions and asynchronous remote learning via video content distributed to them each week. Participants will be asked to attend as many of the 24 in-person sessions as they can. Heartrate will be monitored periodically to make sure the intensity of exercise is consistent with mild to moderate cardiovascular exercise as in the active comparator.
88943128|NCT05530148|Active Comparator|Flexing, Toning and Balance|Flexibility, Toning and Balance or FTB will be used to refer to our resistive exercise comparison. As in the experimental group, participants will be asked to attend as many of the 24 in-person intervention sessions as they can, whilst also practicing the exercises remotely via video content distributed to them. The remote portion of this intervention will be asynchronous. Heart-rate will be monitored periodically to make sure the intensity of exercise is consistent with mild to moderate cardiovascular exercise as in the martial arts experimental group.
88943129|NCT05528198|Other|ABC|Administration order: montelukast sodium oral thin films without water, montelukast sodium oral thin films with water, montelukast sodium chewable tablets with water.
88943130|NCT05528198|Other|BCA|Administration order: montelukast sodium oral thin films with water, montelukast sodium chewable tablets with water, montelukast sodium oral thin films without water.
88943131|NCT05528198|Other|CAB|Administration order: montelukast sodium chewable tablets with water, montelukast sodium oral thin films without water, montelukast sodium oral thin films with water.
89017775|NCT06135428|Experimental|Experimental|"Training content was prepared in three stages according to the resilience model in midwives. The training will be in the form of 45-minute presentations and sharings, and individual studies will be carried out in the form of homework according to people's methods of coping with stress. These homework assignments may occasionally include more or less individual meetings depending on the person's coping situation. However, at least 3 meetings will be held. Training and interviews will be conducted by researchers. For this, at least one of the researchers will receive training including personal awareness and motivational interviews."
89201873|NCT00744146|Experimental|2|"Six volunteers total.~Randomized such that four volunteers will receive Protexia as a single 100 mg dose and two volunteers will receive saline placebo of the same volume on Study Day 1.~Volunteers to be followed for approximately 71 days total."
89201874|NCT00744146|Experimental|3|"Eight volunteers total.~Randomized such that six volunteers will receive Protexia as a single 250 mg dose and two volunteers will receive saline placebo of the same volume on Study Days 1 and 72.~Volunteers to be followed for approximately 142 days total."
89201875|NCT00744146|Experimental|4|"Six volunteers total.~Randomized such that four volunteers will receive Protexia as a single 500 mg dose and two volunteers will receive saline placebo of the same volume on Study Day 1.~Volunteers to be followed for approximately 71 days total."
89462190|NCT02519842|Placebo Comparator|Control Regimen Cycle 1|Participants received a single dose of matched placebo for fosaprepitant IV on Day 1 prior to chemotherapy plus ondansetron IV on Day 1 prior to chemotherapy and at investigator's discretion on day(s) of chemotherapy and up to 24 hours after chemotherapy. Participants may have also received dexamethasone IV at investigator's discretion on day(s) of chemotherapy and up to 24 hours after chemotherapy.
89462191|NCT02519842|Experimental|Fosaprepitant Regimen Cycles 2-6|Participants received a single dose of fosaprepitant 150 mg (or age-based adjustment) IV on Day 1 prior to chemotherapy plus a 5-hydroxytryptamine 3 (5-HT3) antagonist on Day 1 prior to chemotherapy and per product label or standard of care. Participants may also have received dexamethasone IV at investigator's discretion on day(s) of chemotherapy and up to 24 hours after chemotherapy.
89462192|NCT02509078|Active Comparator|Early Neuromuscular Blockade (NMB)|Patients will receive cisatracurium besylate for the first 48 hours of the trial.
89462193|NCT02509078|No Intervention|Control: No Routine Early NMB|Use of non-study NMB will be discouraged.
89462194|NCT02993783|Experimental|Vedolizumab 300 mg|Vedolizumab 300 mg, intravenous (IV) infusion, once on Days 1, 15, 43, 71 and 99.
89462195|NCT02993783|Experimental|Vedolizumab 600 mg|Vedolizumab 600 mg, IV infusion, once on Days 1, 15, 43, 71 and 99.
89462196|NCT03661853|Active Comparator|Control|This microintervention is intended to control for the effect of nonspecific therapy factors such as therapeutic alliance, time spent with a therapist, talking about alcohol, and/or effects related to assessment reactivity, and consists of 60 minutes of psycho-education on alcohol and drugs. The therapist will talk about historical and scientific information on different types of alcohol and drugs and will not overlap with CBT treatment. The participants will not be encouraged to personalize this information, make any behavioral changes, or do homework. The control does not have any active interventions that would specifically target or affect our outcome variables.
89462197|NCT03661853|Experimental|Functional Analysis|"Functional Analysis (FA) is a core intervention in Cognitive Behavioral Therapy (CBT) for AUD, and helps to break the chain of events (external and internal) that lead from cue (trigger) to alcohol use to consequences of use. The FA microintervention teaches the patient to think and behave in new, more controlled ways in response to triggers, to identify maladaptive, impulsive behavior chains and to replace them with more deliberate ones."
89462198|NCT03661853|Experimental|Cognitive Restructuring|"Cognitive Restructuring of Thoughts About Alcohol (CR) is a core technique in CBT to help patients identify automatic (habituated) thoughts that happen quickly and are often not noticed, and change automatic thoughts occurring in response to alcohol triggers."
89462199|NCT03661853|Experimental|Dealing with Cravings|Dealing with Cravings (DC) is designed to directly target the reward and arousal systems, helping the patient accept the nature of cravings as time limited and deflated by continued abstinence so that craving is no longer associated with urgency. DC also teaches skills to reduce cravings by conjuring images such as a spider floating in a glass of wine, or of older versions of oneself sitting alone and dejected in a bar. Distraction techniques and breathing skills to reduce physiological arousal occurring in response to alcohol cues are also taught.
89462200|NCT03661775|Experimental|controlled group|controlled group : administration of magnesium sulfate is 4 grams for loading dose in 15 minutes, followed by 2 grams for maintenance dose per hour
89462201|NCT03661775|Experimental|Experimental group|group : administration of magnesium sulfate is 4 grams for loading dose in 15 minutes, followed by 2.5 grams for maintenance dose per hour
89462202|NCT04055597|Experimental|Robot and tDCS on-line|Combined transcranial direct current stimulation(tDCS) on-line and upper extremity rehabilitation robot
89462203|NCT04055597|Sham Comparator|Robot and sham tDCS|Combined sham tDCS and upper extremity rehabilitation robot
89462204|NCT04055363|Experimental|Formula-fed infants|Infants fed exclusively with experimental formula
89462205|NCT04055363|Experimental|Mixed-fed infants|Infants receiving breastmilk and experimental formula
89462206|NCT04055363|No Intervention|Breast-fed infants|Reference group of exclusively breastfed
89462207|NCT03205475|Active Comparator|A. Above Fidelity Phase 1 and Above Fidelity Phase 2|Alternating coaching and streamed or video feedback each week through phase 1, moves to video feedback only for phase 2.
89462208|NCT03205475|Active Comparator|B. Below Fidelity Phase 1 and Above Fidelity Phase 2|Receive weekly coaching in phase 1, move to video feedback only in phase 2
89462209|NCT03205475|Active Comparator|C. Above Fidelity Phase 1, Below in Phase 2- Add Refresher|Alternating coaching and streamed or video feedback each week through phase 1. In phase 2, the interventionist is still working toward 90% fidelity and is randomly assigned (50/50) to one of two different types of support from the Senior Trainer. The interventionist will receive a one week intensive in person refresher and then continue with weekly coaching and video feedback from the Senior Trainer (Enhanced Feedback plus intensive refresher course) for the final 12 weeks.
89462210|NCT03205475|Active Comparator|D. Above Fidelity Phase 1, Below in Phase 2- Add Peer|Alternating coaching and streamed or video feedback each week through phase 1. In phase 2, the interventionist is still working toward 90% fidelity and is randomly assigned (50/50) to one of two different types of support from the Senior Trainer. The interventionist will receive weekly coaching and video feedback from the Senior Trainer plus a weekly session paired with a local interventionist at fidelity (Enhanced Feedback plus peer support).
89462211|NCT03205475|Active Comparator|E. Below Fidelity Phase 1, Below in Phase 2- Add Refresher|Receive weekly coaching in phase 1. In phase 2, the interventionist is still working toward 90% fidelity and is randomly assigned (50/50) to one of two different types of support from the Senior Trainer. The interventionist will receive a one week intensive in person refresher and then continue with weekly coaching and video feedback from the Senior Trainer (Enhanced Feedback plus intensive refresher course) for the final 12 weeks.
89462212|NCT03205475|Active Comparator|F. Below Fidelity Phase 1, Below in Phase 2- Add Peer|Receive weekly coaching in phase 1. In phase 2, the interventionist is still working toward 90% fidelity and is randomly assigned (50/50) to one of two different types of support from the Senior Trainer. The interventionist will receive weekly coaching and video feedback from the Senior Trainer plus a weekly session paired with a local interventionist at fidelity (Enhanced Feedback plus peer support).
88956458|NCT05157360|Placebo Comparator|Control Arm|The control arm will receive the same standard ICU care for NSTI but will not receive HAT. They will receive a placebo consisting of normal saline, indistinguishable to the treatment team (blinded) but known to the pharmacy team (unblinded to treatment and placebo groups). This is so that if the treatment team elects to give stress dose steroids, they can be administered without breaking protocol (i.e. if the patient is getting HAT, it includes steroids, so if the treating team wanted to start hydrocortisone - because they didn't know if the patient was on HAT or placebo and felt steroids were indicated - the pharmacist could ensure the patient was on steroids one way or another without unblinding the providers).
89462213|NCT03660761|Experimental|apatinib 500mg|
89462214|NCT02993471|Experimental|Drug Cocktail|Drug cocktail (caffeine, warfarin [plus vitamin K], omeprazole, dextromethorphan, and midazolam) administered orally once in Period 1 (day 1).
89201876|NCT00744146|Experimental|5|"Six volunteers total.~Randomized such that four volunteers will receive Protexia as a single 750 mg dose and two volunteers will receive saline placebo of the same volume on Study Day 1.~Volunteers to be followed for approximately 71 days total."
89462215|NCT02993471|Experimental|Drug Cocktail + Ixekizumab|Drug cocktail (caffeine, warfarin [plus vitamin K], omeprazole, dextromethorphan, and midazolam) administered orally twice in Period 2 (day 8 and day 85). Ixekizumab administered subcutaneously (SC) on multiple occasions in Period 2.
89462216|NCT02988713|Experimental|Spinal cord stimulation|Spinal cord stimulation (SCS) in patients undergoing a Boston Scientific (BSC) spinal cord stimulation (SCS) temporary trial
89462217|NCT01068743|Other|Arm A (saxagliptin 2.5 mg + metformin 850 mg; Fasting)|A single oral dose of 2.5-mg Onglyza tablet and 850-mg Glucophage (marketed by Merck Serono) tablet administered together in the fasted condition.
89462218|NCT01068743|Other|Arm B (saxagliptin 2.5 mg + metformin 850 mg FDC; Fasting)|A single oral dose of 2.5-mg saxagliptin/850-mg metformin fixed dose combination (FDC) administered in the fasted condition.
89462219|NCT01068743|Other|Arm C (saxagliptin 2.5 mg + metformin 850 mg; Fed)|A single oral dose of 2.5-mg Onglyza tablet and 850-mg Glucophage (marketed by Merck Serono) tablet administered together in the fed condition.
89462220|NCT01068743|Other|Arm D (saxagliptin 2.5 mg + metformin 850 mg FDC; Fed)|A single oral dose of 2.5-mg saxagliptin/850-mg metformin FDC administered in the fed condition.
89462221|NCT02992691|Experimental|Test Product 1|Participants will be instructed to dose a toothbrush with full ribbon of dentifrice. Participants will brush their teeth once for one timed minute.
89462222|NCT02992691|Experimental|Test Product 2|Participants will be instructed to dose a toothbrush with full ribbon of dentifrice. Participants will brush their teeth once for one timed minute.
89462223|NCT02992691|Experimental|Test Product 3|Participants will be instructed to dose a toothbrush with full ribbon of dentifrice. Participants will brush their teeth once for one timed minute.
88943132|NCT05518474|Experimental|Self-proning|"Participants assigned to the intervention arm will receive a SMS link to a PDF containing instructions on proning/repositioning and information about its physiological benefits. They'll also receive a PDF with standard recommendations for treating COVID-19 at home. Participants will be encouraged to lie flat on their belly, on their side, or sit upright and rotate between these positions when lying down during the day and night. Participants will be sent a daily SMS proning reminder and asked to complete a secure REDCap survey regarding their proning activity. They'll be advised to prone and reposition for seven days minimum whenever they are lying down. Participants who have failed to reach their functional baseline after this time period will be advised to continue doing so. Follow up assessment by telephone will be conducted in 7 day increments from baseline up to 28 days."
88943133|NCT05518474|No Intervention|Standard care|Participants assigned to the comparator arm will receive a SMS link to a PDF with standard recommendations for treating COVID-19 at home. This includes antipyretics and analgesics for fever, myalgias, and headaches; hydration; and rest with advancement of activity as soon as tolerated. Follow up assessment by telephone will be conducted in 7 day increments from baseline up to 28 days.
88943134|NCT05510596|Other|Patients with CAR-T Cell treatment|Single arm All patient will undergo an MRI with contrast injection, a blood withdrawal and a neurological consultation with neuropsychological tests
88943135|NCT05510206|Active Comparator|Super elastic NiTi Group|0.014-inch super elastic nickel-titanium archwire (ortho Technology™ , west Columbia, USA) will be placed in mandibular arch at the day of bonding. Eight weeks later it will be replaced by the 0.018-inch archwire for another eight weeks.
88943136|NCT05510206|Experimental|Smartarch Group|0.016-inch Smartarch archwir (Ormco™, USA) will be placed in mandibular arch at the day of bonding. Re-ligated every four weeks for 16 weeks.
88943137|NCT05498519|Experimental|Dose-escalation and Dose-expansion|SY-4798 will be given orally in ascending doses (escalation cohort) until the DLT or RP2D is reached. In dose-expansion phase, preliminary anti-tumor activity will be assessed in FGF19+ advanced tumor.
88943138|NCT05493605|Other|Cases|The intervention consists in setting up a morphological and rhythmological cardiological follow-up patients with confirmed Wilson disease. It will require the wearing of a long Holter duration (21 days) and for some patients the installation of an implantable cardiac monitor.The long-time ECG holter is used to record heart rhythm for 21 days and detect possible arrhythmias (accelerations of the heart) or conduction disorders (slowdowns of the heart).
88943139|NCT05471011||civilian|
88943140|NCT05471011||Veteran|
88943141|NCT05460663|Experimental|VTC/In-person SMART training|The two-hour VTC or in-person will be provided SMART synchronously to a maximum of 10 individuals. A study team member will contact participants in the VTC group to provide available dates and times of scheduled classes, and these participants will be scheduled for a class they would like to attend. Participants in the VTC group will be provided a web-link prior to the session, and each session will have a unique password to access the training. Participants in the on-line training group will be provided a code to access the training website. If local conditions permit in-person group meetings (i.e. Health Protection Condition [HPCON] Alpha or Bravo), in-person group SMART training in a classroom will be offered as an alternative to VTC sessions.
88943142|NCT05460663|Experimental|CBT SMART training|SMART will be provided via completion of a self-paced, on-line version completed over a period of four to eight weeks.
89017776|NCT06135428|No Intervention|Control|No intervention
89201877|NCT00744224|Placebo Comparator|1|
89201878|NCT00744224|Active Comparator|2|
89462224|NCT02992691|Active Comparator|Positive Control|Participants will be instructed to dose a toothbrush with full ribbon of dentifrice. Participants will brush their teeth once for one timed minute.
89462225|NCT02992691|Other|Negative Control|Participants will be instructed to dose a toothbrush with full ribbon of dentifrice. Participants will brush their teeth once for one timed minute.
89462226|NCT03622541|Experimental|sorafenib|
89462227|NCT04055831||GD1 subjects with no bone complications|1. GD1 subjects with no bone complications (n=10)
89462228|NCT04055831||GD1 patients with mild bone complication|2. GD1 subjects with mild bone complications
89462229|NCT04055831||GD1 with severe bone complications|3. GD1 subjects with severe bone complications
89462230|NCT04055831||No bone disease|Controls with no known bone disease (n=10)
89462231|NCT03658733|Experimental|Esomeprazole-containing therapy|"All the participants will go through a gastroscopy. Biopsy specimens will be taken for histologic assessment and rapid urease test. Two additional biopsy samples will be obtained from the antrum and body for bacterial culture and antimicrobial susceptibility test. Liver and kidney function will be monitored by blood test before and after the treatment. Then, patients will receive a 14-day modified sequential therapy containing esomeprazole for the Helicobacter pylori eradication irrespective of antimicrobial susceptibility test results. The regimen contains esomeprazole, amoxicillin, tetracycline and furazolidone for the first 7 days, followed by esomeprazole,amoxicillin, tetracycline and colloidal bismuth pectin for the second 7 days.~Drugs: 1. esomeprazole 40mg bid for 14 days, 2. amoxicillin 1000mg bid for 14 days, 3. tetracycline 500mg qid for 14 days, 4. furazolidone 100mg tid for the first 7 days, 5. colloidal bismuth pectin 200mg bid for the second 7 days."
88943143|NCT05458375|No Intervention|Control Group|Participants will receive standard pessary care. Participation requires follow up visit 6 months from initial baseline visit. At this visit, participants are asked about vaginal bleeding, degree of bother due to vaginal discharge, and degree of pessary discomfort and a physical exam is performed.
88943144|NCT05458375|Experimental|Estrogen Group|Participants will receive standard pessary care, and those participants randomized to the experimental group will then be given a prescription for vaginal estradiol and instructed to apply it in the vagina nightly for two weeks and then twice weekly thereafter. Participation requires follow up visit 6 months from initial baseline visit. At this visit, participants are asked about vaginal bleeding, degree of bother due to vaginal discharge, and degree of pessary discomfort and a physical exam is performed.
89201879|NCT00744224|Active Comparator|3|
89201880|NCT00744302|Experimental|PCD|Physiological calcium (1.25 mmol/L) dialysate therapy All subjects in the study phase will continue to take calcium carbonate and/or active vitamin D agents.
89462232|NCT03658733|Active Comparator|Rabeprazole-containing therapy|"All the participants will go through a gastroscopy. Biopsy specimens will be taken for histologic assessment and rapid urease test. Two additional biopsy samples will be obtained from the antrum and body for bacterial culture and antimicrobial susceptibility test. Liver and kidney function will be monitored by blood test before and after the treatment. Then, patients will receive a 14-day modified sequential therapy containing rabeprazole for the Helicobacter pylori eradication irrespective of antimicrobial susceptibility test results. The regimen contains rabeprazole, amoxicillin, tetracycline and furazolidone for the first 7 days, followed by rabeprazole, amoxicillin, tetracycline and colloidal bismuth pectin for the second 7 days.~Drugs: 1. rabeprazole 20mg bid for 14 days, 2. amoxicillin 1000mg bid for 14 days, 3. tetracycline 500mg qid for 14 days, 4. furazolidone 100mg tid for the first 7 days, 5. colloidal bismuth pectin 200mg bid for the second 7 days."
89462233|NCT02921087|Other|Test followed by control|Subjects will be randomized in a 1:1 ratio based on a randomization schedule according to sequentially assigned subject numbers to the test daily disposable soft contact lenses at the first visit. Subjects will crossover to the control daily disposable soft contact lenses at the second visit.
89462234|NCT02921087|Other|Control followed by test|Subjects will be randomized in a 1:1 ratio based on a randomization schedule according to sequentially assigned subject numbers to the control daily disposable soft contact lenses at the first visit. Subjects will crossover to the test daily disposable soft contact lenses at the second visit.
89462235|NCT03660605|Experimental|Rhythmic Auditory Stimulation|Participants will walk on treadmill to metronome set at 85% of typical cadence, followed by overground walking with metronome set at 115% of typical cadence.
89462236|NCT04056143||Dabigatran|Subjects who are receiving long-term Dabigatran for certain clinical conditions, and without any contraindication are enrolled for this cohort group.
89462237|NCT04056143||Rivaroxaban|Subjects who are receiving long-term Rivaroxaban for certain clinical conditions, and without any contraindication are enrolled for this cohort group.
89462238|NCT04056143||Apixaban|Subjects who are receiving long-term Apixaban for certain clinical conditions, and without any contraindication are enrolled for this cohort group.
89201881|NCT00744302|Active Comparator|NCD|Normal calcium (1.5 mmol/L) dialysate therapy All subjects in the study phase will continue to take calcium carbonate and/or active vitamin D agents.
89462239|NCT04056143||Edoxaban|Subjects who are receiving long-term Edoxaban for certain clinical conditions, and without any contraindication are enrolled for this cohort group.
89462240|NCT03658655|Experimental|Stem Cells From Human Exfoliated Teeth|According to the weight of 0.1IU /kg with Stem Cells From Human Exfoliated Teeth, three injections will be given respectively at the time of enrollment, one week and four weeks after enrollment.
89462241|NCT03661463|Experimental|Aspirin|Aspirin (Acetylsalicylic Acid [ASA]) tablets, 300mg once a day, for 90 days.
89462242|NCT03661463|No Intervention|No Treatment|No medical treatment
89462243|NCT03660527||6-17 year old|
89462244|NCT03660527||18-44 year old|
89462245|NCT03660527||45-59 year old|
89462246|NCT03660527||above 60 year old|
89462247|NCT03622463|Experimental|Antroquinonol 100 mg PO QD|Antroquinonol (Hocena) 50mg/capsule. 2 capsules antroquinonol,once a day.
89201882|NCT00666588|Experimental|Bortezomib 1.3mg/m2-assess efficacy-low anthracycline exposure|Bortezomib 1.3mg/m2 to assess efficacy in low prior anthracycline exposure. Patients receive idarubicin IV (12 mg/m2/day) over 15 minutes on days 1-3, low-dose cytarabine IV (100 mg/m2/day) continuously over days 1-7, and bortezomib IV (1.3 mg/m2) on days 1, 4, and 8. All patients receive intrathecal cytarabine (30 mg - age 1-1.99 years, 50 mg - age 2-2.99 years, 70 mg - age ≥ 3 years) prior to courses 1 and 2. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity (closed as of 08/01/10). Dosage modification based on age < 3 years old.
89462248|NCT03622463|Experimental|Antroquinonol 50 mg PO QD|Antroquinonol (Hocena) 50mg/capsule. 1 capsules antroquinonol and 1 capsule placebo, once a day.
89462249|NCT03622463|Placebo Comparator|Placebo|Placebo capsule, 2 capsules placebo, once a day
89462250|NCT03658499|Experimental|Experimental|"Those assigned to the experimental condition will be provided with treatment as usual (the two day skills group) and exposure to the video intervention adjuncts.~two day skills group plus treatment adjuncts"
89462251|NCT03658499|Other|control|"Those in the control condition will be provided with treatment as usual (the two day skills group) without access to the video intervention adjuncts.~two day skills group control group"
89462252|NCT03661229|Experimental|CVInsight Monitoring|Single group arm: All participants receive the same intervention/treatment CVInsight non-contact device and CVInsight contact device application.
89462253|NCT03658421|Experimental|H group|H group stands for High concentration group. A single bolous of 20 ml ropivacaine 0.2% in ultrasound-guided femoral nerve block (FNB) before the TKA surgery, followed by continuous femoral nerve block (CFNB) using ropivacaine 0.2% (5 ml/h) for postoperative analgesia which started right after surgery. After surgery, all patients received multimodal analgesia of 200mg celecoxib every 12 hours. All subjects received anothother intravenous patient-controlled analgesia pump (IV-PCA pump), which included 50 mg morphine in 50 ml saline: bolus 2 mg; lock out time, 15 minutes.
89462254|NCT03658421|Experimental|L group|L group stands for low concentration group. A single bolous of 20 ml ropivacaine 0.1% in ultrasound-guided femoral nerve block (FNB) before the TKA surgery, followed by continuous femoral nerve block (CFNB) using ropivacaine 0.1% (5 ml/h) for postoperative analgesia which started right after surgery. All subjects received anothother intravenous patient-controlled analgesia pump (IV-PCA pump), which included 50 mg morphine in 50 ml saline: bolus 2 mg; lock out time, 15 minutes.
89462255|NCT03658421|Experimental|LD group|LD group stands for low concentration group with dexmedetomidine. A single bolous of 20 ml ropivacaine 0.1% plus 2 μg/kg dexmedetomidine in ultrasound-guided femoral nerve block (FNB) before the TKA surgery, followed by continuous femoral nerve block (CFNB) using ropivacaine 0.1% (5 ml/h) for postoperative analgesia which started right after surgery. All subjects received anothother intravenous patient-controlled analgesia pump (IV-PCA pump), which included 50 mg morphine in 50 ml saline: bolus 2 mg; lock out time, 15 minutes.
89462256|NCT03660293|No Intervention|diabetic- no cardioprotectives|25 child with type 1 diabetes mellitus will not receive any cardio protective drug
89462257|NCT03660293|Experimental|diabetic-Atorvastatin|25 child with type 1 diabetes mellitus will receive Statin (2 mg/kg/day)
89462258|NCT03660293|Experimental|diabetic-Captopril|25 child with type 1 diabetes mellitus will receive Captopril (0.2 mg/kg/day)
89462259|NCT03660293|Experimental|diabetic-L-Carnitine|25 child with type 1 diabetes mellitus will receive L-carnitine (50 mg/kg/day)
89462260|NCT03660293|No Intervention|Controls|50 healthy children, of matched age and sex, with no symptoms of cardiac diseases
89462261|NCT03660137|Experimental|MOLLI Localization|All patients will be implanted with a MOLLI magnetic seed in addition to the standard-of-care RSL seed. Both systems will be use to localize the respective seeds during the lumpectomy surgery.
89462262|NCT02907619|Experimental|PF-06252616|Either 5mg/kg, 20mg/kg or 40mg/kg will be assigned to a subject based on their maximum tolerated dose from B5161002
89462263|NCT02986373|Experimental|Risankizumab|Participants received open-label risankizumab 150 mg by subcutaneous injection at Weeks 0, 12, 24, and 36.
89462264|NCT03659903||younger patients (age < 80)|age < 80 patients， All the variables' definitions are encoded in the SEER database. To identify the PDAC cases, site codes (C25 pancreas, C25.0-C25.9) and histology codes (8140 adenocarcinoma, 8500 infiltrating duct carcinoma) based on the International Classification of Diseases for Oncology, Third Edition (ICD-O-3) were used.11 Only cases that underwent PD and microscopically confirmed were included.
89462265|NCT03659903||older patients (age≥ 80 )|age ≥ 80 years-old patients，All the variables' definitions are encoded in the SEER database. To identify the PDAC cases, site codes (C25 pancreas, C25.0-C25.9) and histology codes (8140 adenocarcinoma, 8500 infiltrating duct carcinoma) based on the International Classification of Diseases for Oncology, Third Edition (ICD-O-3) were used.11 Only cases that underwent PD and microscopically confirmed were included.
89462266|NCT02986139|Experimental|Sequence AB|Participants received a single 50 mg subcutaneous (SC) dose of the commercial formulation etanercept in a prefilled SureClick autoinjector on day 1 (Treatment A) followed by a single 50 mg SC dose of the new formulation of etanercept in a prefilled SureClick autoinjector on day 8 (Treatment B).
89462267|NCT02986139|Experimental|Sequence BA|Participants received a single 50 mg SC dose of the new formulation of etanercept in a prefilled SureClick autoinjector on day 1 (Treatment B) followed by a single 50 mg SC dose of the commercial formulation etanercept in a prefilled SureClick autoinjector on day 8 (Treatment A).
89462268|NCT02989805|Active Comparator|Professional Care Manager|Each participating site will have a nurse or social worker to provide care management. Training activities will include modules for each of the key domains covered in the intervention: shared decision making, action planning; motivational interviewing; and mental health as a cornerstone of recovery, working effectively within the mental health system; and self-care and stress management.
89462269|NCT02989805|Experimental|Peer Specialist Care Manager|Each participating site will have a peer specialist to provide care management. Peer specialists will have a minimum of a high school education, a history of a mental illness, be self-described as 'in recovery,' and have reliable transportation to the study site. All certified peer specialists will receive training in a curriculum that supports identifying and pursuing goals for recovery; developing and documenting recovery-focused treatment plans; and supporting linkages with community-based services. Peers learn to help other individuals with mental health conditions to facilitate mental health dialogues; explore mental health choices and options; identify and work with a clinician; and obtain access to community health supports.
89462270|NCT03622255|Other|MINST|Minimally invasive non-surgical technique (MINST): Root instrumentation under local anesthesia using specific hand instruments (micro- curettes) and delicate piezon ultrasonic instruments in the area of intraosseous defect.
89462271|NCT03622255|Active Comparator|MINST with EMD|Minimally invasive non-surgical technique (MINST) with application of Enamel Matrix Derivative (EMD): Root instrumentation under local anesthesia using micro- curettes and delicate piezon ultrasonic instruments in the area of intraosseous defect. Experimental intervention by application of EDTA gel for 2 minutes on the root surface of the involved tooth, followed by rinsing with saline, drying and application of Enamel Matrix Derivative gel, to fill the defect.
89462272|NCT03661151||Antireflux surgery following PPI|A single cohort with the GERD patients who had acid suppressive medication with proton pump inhibitor (PPI) followed by laparoscopic antireflux surgery
89462273|NCT02236351|Placebo Comparator|Control|Patients assigned to the Control Arm will be taught to apply their patches using the standard technique -- applying the patch evenly and flatly around the orbit.
89462274|NCT02236351|Experimental|Pinched Patch|Patients assigned to the Pinched Patch Arm will be taught to apply their patches after pinching the middle of the superior and inferior edges of the patch so that the patch is convex and the center is raised above the eye.
89201883|NCT00666588|Experimental|Bortezomib 1.0mg/m2-assess feasibility high anthracycline exp|Bortezomib 1.0 mg/m2 to assess feasibility in high prior anthracycline exposure. Patients receive etoposide IV (150 mg/m2/dose) over 1 hour on days 1-5, high-dose cytarabine IV (1000 mg/m2/dose) over 1 hour twice daily on days 1-5, and bortezomib IV (1.0 mg/m2) on days 1, 4, and 8. All patients receive intrathecal cytarabine (30 mg - age 1-1.99 years, 50 mg - age 2-2.99 years, 70 mg - age ≥ 3 years) prior to courses 1 and 2. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
89462275|NCT03659825|Placebo Comparator|Placebo + Normoxia|Taste, volume and appearance matched drink given before cognitive testing in normoxia
89462276|NCT03659825|Placebo Comparator|Placebo + Hypoxia|Taste, volume and appearance matched drink given before cognitive testing in hypoxia
89462277|NCT03659825|Experimental|Ketone Ester + Normoxia|Ketone ester drink given before cognitive testing in normoxia
89462278|NCT03659825|Experimental|Ketone Ester + Hypoxia|Ketone ester drink given before cognitive testing in hypoxia
89462279|NCT03659747|Experimental|Probiotic|"6 g sachet containing probiotic powder (1.8 x 10^12 colony forming units (CFU) Probiotic) in sachet~One sachet of the investigational product will be consumed with 521 ml of Weihenstephan fat-free milk once in the beginning of a 6-hour challenge at a study visit."
88943145|NCT05446064|Experimental|Enhanced Treatment|Participants will receive the stigma-reduction intervention as well as typical services including care co-ordination and linkage to public health nurses in local communities.
88943146|NCT05446064|No Intervention|Treatment-as-Usual|Participants will receive typical services including care co-ordination and linkage to public health nurses in local communities.
88943147|NCT05444725|Other|Stage of decision making|"Same questionnaire for all three arms except validated question Stage of decision making followed by question about participation in screening or not when invited at age 50.~This is not an intervention but a survey study with three different versions of the questionnaire."
89462280|NCT03659747|Active Comparator|Lactrase|"6 g sachet containing 4500 FCC units of lactase (Lactrase, Oy Verman Ab, Kerava, Finland) and maltodextrin as a carrier~One sachet of the investigational product will be consumed with 521 ml of Weihenstephan fat-free milk once in the beginning of a 6-hour challenge at a study visit."
89462281|NCT03659747|Placebo Comparator|Placebo|"6 g sachet containing placebo powder (maltodextrin) in sachet~One sachet of the investigational product will be consumed with 521 ml of Weihenstephan fat-free milk once in the beginning of a 6-hour challenge at a study visit."
89462282|NCT03658265|Active Comparator|7 days SIE plus 4 weeks PRE|Participants in this group will start shoulder isotonic exercise 7 days after surgery and begin progressive resistance exercise 4 weeks after surgery.
89462283|NCT03658265|Experimental|7 days SIE plus 3 weeks PRE|Participants in this group will start shoulder isotonic exercise 7 days after surgery and begin progressive resistance exercise 3 weeks after surgery.
89462284|NCT03658265|Experimental|3 days SIE plus 4 weeks PRE|Participants in this group will start shoulder isotonic exercise 3 days after surgery and begin progressive resistance exercise 4 weeks after surgery.
89462285|NCT03658265|Experimental|3 days SIE plus 3 weeks PRE|Participants in this group will start shoulder isotonic exercise 3 days after surgery and begin progressive resistance exercise 3 weeks after surgery.
88943148|NCT05444725|Other|Choice framing|"Same questionnaire for all three arms except text and question presenting breast cancer screening as a choice (between screening and alternative of no screening) followed by question about participation in screening or not when invited at age 50.~This is not an intervention but a survey study with three different versions of the questionnaire."
89017777|NCT06135311|Experimental|Pulse Width 260us|electrodes placed per treatment arm, performed at bedtime, session time 30 min, frequency setting of 10Hz, pulse width setting 260us, intensity setting to patient's tolerance, duration 30 days
89017778|NCT06135311|Experimental|Pulse Width 50us|electrodes placed per treatment arm, performed at bedtime, session time 30 min, frequency setting of 10Hz, pulse width setting 50us, intensity setting to patient's tolerance, duration 30 days
89017779|NCT06134609|Experimental|Assigned to intercourse|The study group is subjected to perform intercourse without using a condom at the evening/night after the embryo transfer
89017780|NCT06134609|No Intervention|Assigned to abstain|The control group is assigned to abstain from coitus the next 48 hours after the embryo transfer.
89017781|NCT06133582|Experimental|Internet-Based Psychodynamic Psychotherapy|Participants received the internet-based intervention for 10 weeks, supported by messages from their Therapeutic Support Worker.
89017782|NCT06133582|No Intervention|Waitlist Control|Participants will receive no intervention for 10 weeks
89017783|NCT06133400|Experimental|Subjects representative of the adult population (18-69 y) of French Polynesia|Population sample composed of people aged 18 to 69. These people must have been living in French Polynesia for more than two years at the time of the 2017 census
89462286|NCT03658187|Placebo Comparator|Placebo|2 tablets orally with water and 2 ml of liquid spray to be kept for 30 sec sublingually, before swallowing. To be taken half an hour before dinner prior to the day of site visit.
89462287|NCT03658187|Experimental|IP|2 tablets orally with water and 2 ml of liquid spray to be kept for 30 sec sublingually, before swallowing. To be taken half an hour before dinner prior to the day of site visit.
89017784|NCT06133244||VEDOSS|defined as RP, presence of SSc specific autoantibodies (ACA, ATA, ARA), puffy fingers and abnormal nailfold capillaroscopy (giant capillaries or capillary loss with or without haemorrhages), but not fulfilling the EULAR-ACR 2013 classification criteria for SSc
89462288|NCT03659591|Active Comparator|Cognitive Behaviour Therapy|10 week, manual-based group CBT treatment for depression and anxiety, followed by optional booster sessions
89462289|NCT03659591|Active Comparator|Adaptive Psychological Training|5 week, manual-based group APT treatment for depression and anxiety, followed by optional booster sessions
89462290|NCT03656419|Experimental|aPDT group|For photodynamic therapy will be used an equipment developed for this project with emission of red LED (660nm) and tip of 2.84 cm² .One session of the Chimiolux® photosensitizing aPDT will be performed, at a concentration of 0.005%, to be applied enough to cover the middle third and back of the tongue for 2 minutes for incubation. Four points will be irradiated with a distance of 1cm between the points, considering the scattering halo and the effectiveness of aPDT. The LED apparatus will be previously calibrated with wavelength 660 nm, with energy of 72 J, power of 800 mW for 90 seconds per point, creep of 282mW / cm².
89462291|NCT03656419|Active Comparator|Tongue Scraper|Tongue scraper 10 times in the tongue, from the back to the front.
89462292|NCT03656419|Experimental|aPDT and tongue scraper|Tongue scraper 10 times in the tongue, from the back to the front. For aPDT will be used an equipment developed for this project with emission of red LED (660nm) and tip of 2.84 cm² . One session of the Chimiolux® photosensitizing aPDT will be performed, at a concentration of 0.005%, to be applied enough to cover the middle third and back of the tongue for 2 minutes for incubation. Four points will be irradiated with a distance of 1cm between the points. Based on previous studies carried out with the aPDT for the treatment of halitosis the apparatus will be previously calibrated with wavelength 660 nm, with energy of 72 J, power of 800 mW for 90 seconds per point, creep of 282mW / cm².
89462293|NCT04295395||group1|preterm infant with closed ductus arteriosus, <32 weeks birth weight < 1500g, and > 72 hours of age
89462294|NCT04295395||group2|preterm infant with PDA < 32 weeks, birth weight < 1500g, and > 72 hours of age
89462295|NCT04295395||group3|preterm infant with hemodynamically significant PDA < 32 weeks, birth weight < 1500g, and > 72 hours of age
89462296|NCT02906917|Experimental|IDegAsp|
89462297|NCT02906917|Active Comparator|IGlar + IAsp|
89017785|NCT06133244||SSc with disease duration of < 4 years without hand contractures|
89017786|NCT06133244||SSc with hand contractures|
89017787|NCT06133166|Experimental|EG017 ointment 3%|60 subjects，Apply once a night on the skin side of both eyelids at bedtime, approximately 100 mg/eye per dose, for 8 weeks
89017788|NCT06133166|Experimental|EG017 ointment 5%|60 subjects，Apply once a night on the skin side of both eyelids at bedtime, approximately 100 mg/eye per dose, for 8 weeks
89017789|NCT06133166|Experimental|EG017 ointment 9%|60 subjects，Apply once a night on the skin side of both eyelids at bedtime, approximately 100 mg/eye per dose, for 8 weeks
89017790|NCT06133166|Placebo Comparator|Placebo A|40 subjects，Apply once a night on the skin side of both eyelids at bedtime, approximately 100 mg/eye per dose, for 8 weeks
89462298|NCT03656341|Experimental|2 Feet 4 Life|Intervention group will receive one hour intervention weekly for four consecutive weeks. Outcomes will be measured at baseline (before the intervention), immediately after the intervention (1 month), three months post-intervention, and six months post-intervention
89462299|NCT03656341|No Intervention|True control group|Will complete the same four assessment visits as the intervention group.
89462300|NCT03656341|No Intervention|Bias control group|Will complete outcome assessments at baseline and the final assessment.
89462301|NCT03656263||High risk cardiac surgery patients|"Defined as either:~Multiple surgical procedures planned and/or,~EuroSCORE ≥ 5% and/or,~Known pulmonary hypertension (mPAP>25 mmHg or sPAP > 40 mmHg)"
89017791|NCT06133166|Placebo Comparator|Placebo B|20 subjects，Apply once a night on the skin side of both eyelids at bedtime, approximately 100 mg/eye per dose, for 8 weeks
89017792|NCT06129916||PWID who opt for LADB|People with opioid dependence who opt to initiate LADB across a range of LMIC settings over a 48-week period
89017793|NCT06129916||PWID who opt for standard of care|People with opioid dependence who refuse to initiate LADB and opt for standard of care
89017794|NCT06129682|No Intervention|Standard of care|
89017795|NCT06129682|Experimental|Self rehabilitation at home|
89206166|NCT00830856|Experimental|1|Early initiation of antiretroviral therapy. Patients in this treatment group were started on Fluconazole 800mg by mouth every day for Cryptococcal Meningitis, and within 72hrs of diagnosis were started on First line antiretroviral therapy per Zimbabwe treatment guidelines which is Stavudine, Lamivudine and Nevirapine.
89462302|NCT03655795|Experimental|Bronchial basal cells|Autologous transplantation of bronchial basal cells
89462303|NCT02982187|Experimental|Sub-study 1 : ELLIPTA followed by DISKUS+ HANDIHALER +PQ1|In this sequence, subjects will be randomized to use ELLIPTA inhaler in period 1 and then DISKUS + HANDIHALER in period 2. At the end of Visit 1, subjects will complete version 1 of the PQ (PQ1)
89462304|NCT02982187|Experimental|Sub-study 1 : DISKUS + HANDIHALER followed by ELLIPTA+PQ2|In this sequence, subjects will be randomized to use DISKUS + HANDIHALER in period 1 and then ELLIPTA in period 2. At the end of Visit 1, subjects will complete version 2 of the PQ (PQ2)
89462305|NCT02982187|Experimental|Sub-study 1 : ELLIPTA followed by DISKUS+ HANDIHALER +PQ2|In this sequence, subjects will be randomized to use ELLIPTA inhaler in period 1 and then DISKUS + HANDIHALER in period 2. At the end of Visit 1, subjects will complete PQ2
89462306|NCT02982187|Experimental|Sub-study 1 : DISKUS + HANDIHALER followed by ELLIPTA+PQ1|In this sequence, subjects will be randomized to use DISKUS + HANDIHALER in period 1 and then ELLIPTA in period 2. At the end of Visit 1, subjects will complete PQ1
89462307|NCT02982187|Experimental|Substudy 2: ELLIPTA followed by TURBUHALER + HANDIHALER +PQ3|In this sequence, subjects will be randomized to use ELLIPTA inhaler in period 1 and then TURBUHALER + HANDIHALER in period 2. At the end of Visit 1, subjects will complete version 3 of the PQ (PQ3)
89462308|NCT02982187|Experimental|Substudy 2: TURBUHALER + HANDIHALER followed by ELLIPTA+PQ4|In this sequence, subjects will be randomized to use TURBUHALER + HANDIHALER inhaler in period 1 and then ELLIPTA in period 2. At the end of Visit 1, subjects will complete version 4 of the PQ (PQ4)
89462309|NCT02982187|Experimental|Substudy 2: ELLIPTA followed by TURBUHALER + HANDIHALER +PQ4|In this sequence, subjects will be randomized to use ELLIPTA inhaler in period 1 and then TURBUHALER + HANDIHALER in period 2. At the end of Visit 1, subjects will complete PQ4
89017796|NCT06127836|Experimental|patients undergoing preoperative lymphoscintigraphy|Patients will undergo radiocolloid lymphoscintigraphy before their surgery; the surgeon will be blinded to the results of this procedure. The surgeon will subsequently inject ICG in accordance with the SLN protocol in the operating room and will identify and remove the SLN by use of near-infrared imaging guidance only.
89017797|NCT06127667|Experimental|Experimental group|Healthy participants in 3 age groups
89462310|NCT02982187|Experimental|Substudy 2: TURBUHALER + HANDIHALER followed by ELLIPTA+PQ3|In this sequence, subjects will be randomized to use TURBUHALER + HANDIHALER inhaler in period 1 and then ELLIPTA in period 2. At the end of Visit 1, subjects will complete PQ3
89462311|NCT03655483|Experimental|GLS-010|GLS-010
89462312|NCT02981953|Other|Cardioband Tricuspid procedure|Tricuspid valve repair with Cardioband implanted via transcatheter procedure under transesophageal echocardiography (TEE) and fluoroscopy guidance
89462313|NCT03656653|Experimental|Future-based recovery-oriented imagery|Mental Imagery for Craving Reduction: mental imagery aimed at describing a future without cocaine use
89462314|NCT03656653|Experimental|Future-based cocaine-aversive imagery|Mental Imagery for Craving Reduction: mental imagery aimed at describing a future where cocaine is causing significant distress
89462315|NCT03656653|Experimental|Past recovery-oriented imagery|Mental Imagery for Craving Reduction: mental imagery aimed at describing a past event without cocaine use
89462316|NCT03656653|Experimental|Past cocaine-aversive imagery|Mental Imagery for Craving Reduction: mental imagery aimed at describing a past event where cocaine use has caused significant distress
89462317|NCT03655873|Experimental|HEC30654AcOH capsule|"single ascending-dose study: Including 7 dose groups(5-、10、15-、30-、60-、90-、120mg)，Day1 ante meridiem(AM) 8:00 (±1h) with 240ml warm water to taking the experiment drug，On an empty stomach .~multiple ascending-dose study: Including 3 dose groups(15-、30-、60mg),Day1-Day7 AM 8:00 (±1h), 18:00 Post Meridiem(PM) (±1h), with 240ml warm water to take the experiment drug On an empty stomach;Day8 AM 8:00 (±1h)with 240ml warm water to taking the experiment drug，On an empty stomach."
89462318|NCT03655873|Placebo Comparator|placebo capsule|"single ascending-dose study: Including 6 dose groups(10、15-、30-、60-、90-、120mg)，Day1 morning 8:00 (±1h) with 240ml warm water to taking the placebo capsule，On an empty stomach .~multiple ascending-dose study: Including 3 dose groups(15-、30-、60mg),Day1-Day7 AM 8:00 (±1h), 18:00 PM (±1h), with 240ml warm water to take the placebo capsule on an empty stomach;Day8 AM 8:00 (±1h)with 240ml warm water to taking the placebo capsule，on an empty stomach."
89462319|NCT03655327||stroke patients|stroke patients with upper limb paresis
89462320|NCT03655327||healthy control group|healthy participants with no motor disability of the upper limb
89462321|NCT03655249|Experimental|Asl + CPT|Aerosotherapy + Autogenic drainage
89462322|NCT03655249|Active Comparator|Asl|Aerosoltherapy alone
89462323|NCT03655171||H&Y 0|"Age-matched non-disease population, or prodromal Parkinson's patients with no noticeable motor symptoms.~This group of patients will perform the video-recorded UPDRS-III test at the time of enrollment and evaluate the motor function using video-based quantitative methods."
89462324|NCT03655171||H&Y 1|"Hoehn and Yahr disability stage was 1: Unilateral involvement only usually with minimal or no functional disability.~This group of patients will perform the video-recorded UPDRS-III test at the time of enrollment and evaluate the motor function using video-based quantitative methods."
89462325|NCT03655171||H&Y 2|"Hoehn and Yahr disability stage was 2: Bilateral or midline involvement without impairment of balance.~This group of patients will perform the video-recorded UPDRS-III test at the time of enrollment and evaluate the motor function using video-based quantitative methods."
89462326|NCT03655171||H&Y 3|"Hoehn and Yahr disability stage was 3: Bilateral disease: mild to moderate disability with impaired postural reflexes; physically independent.~This group of patients will perform the video-recorded UPDRS-III test at the time of enrollment and evaluate the motor function using video-based quantitative methods."
89462327|NCT03655171||H&Y 4|"Hoehn and Yahr disability stage was 4: Severely disabling disease; still able to walk or stand unassisted.~This group of patients will perform the video-recorded UPDRS-III test at the time of enrollment and evaluate the motor function using video-based quantitative methods."
89462328|NCT03655093||Patients with multiple sclerosis|Patients with MS according to the diagnostic criteria of 2010 Validation of AMSQ questionnaire
89462329|NCT02021071||XperGuide|Image-guided needle procedures with XperGuide performed prior to this study within institution (retrospective data).
89462330|NCT02021071||XperGuide with virtual path planning|Image-guided needle procedures with XperGuide with virtual path planning
89462331|NCT03654937|Active Comparator|2h|The participants were asked to report for their vaccination immediately after an intensive bout of training (not later than two hours after). The influenza vaccine was administered via intra-muscular injection into the deltoid muscle of the non-dominant arm in a standardized manner.
89462332|NCT03654937|Active Comparator|26h|The athletes of the second group were vaccinated after an entire day (between 24 and 26 hours) after their last training session.The vaccine was administered via intra-muscular injection into the deltoid muscle of the non-dominant arm in a standardized manner.
89462333|NCT01066585|Experimental|0.5% Ivermectin Cream|
89462334|NCT01066585|Placebo Comparator|Vehicle control|
89462335|NCT03654781|Active Comparator|Triple therapy|Conventional triple antibiotic treatment would be applied to all patients (consisted of a 10-day course of Lansoprazole (a proton pump inhibitor) combined with amoxicillin ( 2 × 1 g daily) and clarithromycin (2 × 500 mg daily).
89462336|NCT03654781|Experimental|Combined treatment|"Periodontal treatment would be administered in addition to triple therapy consisted of a 10-day course of a Lansoprazole (proton pump inhibitor )combined with amoxicillin (2 × 1 g daily) and clarithromycin (2 × 500 mg daily).~Periodontal treatment consisted of supra and sub gingival scaling and root planing, oral hygiene instruction"
89462337|NCT03654703|Experimental|Cyclophophamide|Cyclophosphamide 50mg/kg/day on day+3，+4 after HSCT. Intervention: drugs:Cyclophosphamide.
89462338|NCT03654703|Experimental|Placebo|5% GLS（Placebo) 50ml/day on day+3，+4 after HSCT. Intervention: drugs: Placebo other name: placebo (for Cyclophosphamide) 5%Glugose in water 50ml or normal saline
89462339|NCT02980783|Experimental|Juvéderm® VOLIFT®™ with Lidocaine|Juvéderm® VOLIFT®™ (hyaluronic acid) with Lidocaine was injected into the dynamic radial cheek line skin depressions on Day 1; volume of injection was determined by the investigator. If applicable, a touch-up of Juvéderm® VOLIFT®™ with Lidocaine was injected on Day 14.
89462340|NCT02980705|Experimental|SUNPG1622 I|SUNPG1622 I dose
89462341|NCT02980705|Placebo Comparator|Placebo|Placebo dose
89462342|NCT03654625|Experimental|Standard Written Exposure|Four writing sessions at the laboratory
89462343|NCT03654625|Experimental|Enhanced Written Exposure|Four writing sessions at the laboratory
89462344|NCT03654625|Placebo Comparator|Control Condition|Four writing sessions at the laboratory
89462345|NCT02989649||Alogliptin or Alogliptin Fixed Dose Combinations (FDCs)|Participants with type 2 diabetes mellitus (T2DM) who received alogliptin or alogliptin FDCs, orally, prescribed by the physician as part of participants' T2DM treatment program (independent of participation in this study) were observed for approximately 6 months, or up to loss to follow-up or death, whichever occurred first.
89462346|NCT03659435|Experimental|RID-TDS 9.5 mg/24 h|3 consecutive applications of 1 patch (1st patch for 4 days, 2nd patch for 3 days, 3rd patch for 4 days) covering an 11-day period
89462347|NCT03659435|Active Comparator|Exelon® 9.5 mg/24 h|11 consecutive applications of 1 patch (each patch will be applied for 1 day) covering an 11-day period
89462348|NCT02905435|Experimental|Biodegradable Temporizing Matrix|Biodegradable Temporizing Matrix (BTM)
89462349|NCT03659357||A-first CTE examination|
89462350|NCT03659357||B-first MRE examination|
89462351|NCT02978833|Experimental|PRP|
89462352|NCT02978833|Active Comparator|Whole Blood|
89462353|NCT01067339|Experimental|Darapladib|Subjects randomized to this arm will receive a darapladib tablet, 160 mg, by mouth, once per day for 6 months.
89462354|NCT01067339|Placebo Comparator|Placebo|Subjects randomized to this arm will receive a placebo tablet matching the study drug, once per day for 6 months.
89462355|NCT02198911|Active Comparator|Order 1|Gum chewing order for sessions, 1-3 respectively: NO GUM, MCC, C
89462356|NCT02198911|Active Comparator|Order 2|Gum chewing order for ice-cream sessions, 1-3 respectively: MCC, C, NO GUM
89462357|NCT02198911|Active Comparator|Order 3|Gum chewing order for ice-cream sessions, 1-3 respectively: C, NO GUM, MCC
89462358|NCT03654391|Active Comparator|InnoSlim|Subjects ingested 2 capsules InnoSlim® (Experimental group) in the morning and 3 capsules in the evening (5 capsules/d) for 12 weeks of a stage.
89462359|NCT03654391|Placebo Comparator|Placebo|Subjects ingested 2 capsules placebo (Control group) in the morning and 3 capsules in the evening (5 capsules/d) for 12 weeks of a stage.
89462360|NCT04484675|Active Comparator|Group IH(inhaled milrinone)|After induction of anesthesia and stable hemodynamics inhaled milrinone( 1 mg/ml) is initiated and intravenous placebo ( normal saline )infusion are administered
89462361|NCT04484675|Active Comparator|Group Iv(Intravenous milrinone)|After induction of anesthesia and stable hemodynamics inhaled placebo( normal saline) is initiated and intravenous ( 1 mg/ml) (0.5 μg/kg/min)infusion are administered
89462362|NCT03658109|Active Comparator|Lidocaine Bolus Infusion|"Patients will also undergo a loading dose of lidocaine, followed by continuous lidocaine infusion in the lidocaine group.~Patients will undergo an injection of intrathecal opioid medication (morphine) preoperatively.~Patients will undergo a simulated QL block."
89462363|NCT03658109|Active Comparator|QL Block & Saline Bolus Infusion|"Patients will undergo a posterior QL block.~Patients will undergo an injection of intrathecal opioid medication (morphine) preoperatively.~Patients will receive a saline bolus infusion."
89462364|NCT03658109|No Intervention|Intrathecal Morphine Alone|"Patients will undergo an injection of intrathecal opioid medication (morphine) preoperatively.~Patients will undergo a simulated QL block.~Patients will receive a saline bolus infusion."
89462365|NCT03654313|Experimental|Part A MEDI6570 Cohort 1|Part A MEDI6570 Cohort 1 dose level
89462366|NCT03654313|Experimental|Part A MEDI6570 Cohort 2|Part A MEDI6570 Cohort 2 dose level
89462367|NCT03654313|Experimental|Part A MEDI6570 Cohort 3|Part A MEDI6570 Cohort 3 dose level
89462368|NCT03654313|Experimental|Part A MEDI6570 Cohort 4|Part A MEDI6570 Cohort 4 dose level
89462369|NCT03654313|Placebo Comparator|Part A Placebo|Part A Placebo
89462370|NCT03654313|Experimental|Part B MEDI6570 Cohort 1|Part B MEDI6570 Cohort 1 dose level
89462371|NCT03654313|Experimental|Part B MEDI6570 Cohort 2|Part B MEDI6570 Cohort 2 dose level
89462372|NCT03654313|Experimental|Part B MEDI6570 Cohort 3|Part B MEDI6570 Cohort 3 dose level
89462373|NCT03654313|Placebo Comparator|Part B Placebo|Part B Placebo
89462374|NCT03654313|Experimental|Part A MEDI6570 Cohort 5|Part A MEDI6570 Cohort 5 Dose level
89462375|NCT03654313|Experimental|Part A MEDI6570 Cohort 6|Part A MEDI6570 Cohort 6 dose level
89462376|NCT03660995|Experimental|SLI children|
89462377|NCT03660995|Active Comparator|Control children|
89462378|NCT03654235|Experimental|PNE and PE program|Pain neuroscience education (Health education) and Physical exercise program.
88943149|NCT05444725|Other|Opportunity framing|"Same questionnaire for all three arms except text and question presenting breast cancer screening as an opportunity (no presentation of alternative) followed by question about participation in screening or not when invited at age 50.~This is not an intervention but a survey study with three different versions of the questionnaire."
88943150|NCT05420584|Experimental|experimental arm|
88943151|NCT05416580|Experimental|UDCA + metformin|"UDCA in addition to Metformin Treatment~All subjects will be treated with UDCA 1500 mg/day, and Metformin, up to 2000 mg/day, by oral administration, respectively, for 8 weeks."
88943152|NCT05416580|Placebo Comparator|Placebo + metformin|"Placebo of UDCA in addition to Metformin Treatment~All subjects will be treated with a Placebo of UDCA, and Metformin, up to 2000 mg/day, by oral administration, respectively, for 8 weeks."
88943153|NCT05414071|Experimental|NMS Assist|NMS Assist provides a system of linking PwP, CPs, and healthcare providers (HCPs) to monitor and empower self-management of non-motor symptoms through the use of a mobile app and web portal.
88943154|NCT05412511|Experimental|Training|Participants in this arm will perform seven medicine ball training exercises (acute bout per exercise) at two different conditions [Throwing a ball (TB) and no Throwing a ball (NTB)].
88943155|NCT05412511|No Intervention|Control|Participants in this arm will receive no intervention.
88943156|NCT05401578|Active Comparator|Study Intervention: Canakinumab|"Standard dose of canakinumab (Ilaris®; Novartis Switzerland), i. e. 150 mg subcutaneously.~Canakinumab (Ilaris®, Novartis) is a recombinant, human monoclonal IgG1/kappa antibody inhibiting IL-1β by neutralizing its biological activity through binding to the IL-1 receptor."
88943157|NCT05401578|Placebo Comparator|Control Intervention: Placebo (0.9% NaCl)|Placebo: 1 ml of 0.9 % NaCl
88943158|NCT05391542|Experimental|Coaxial tubular superelastic nickel-titanium Group (TuNT)|0.016-inch coaxial tubular superelastic nickel-titanium archwire (TuNT) (Speed tubular supercable, Speed System™ Orthodontics, Ontario, Canada) will be placed in mandibular arch at the day of bonding. Eight weeks later it will be replaced by the 0.018-inch archwire for another eight weeks
88943159|NCT05391542|Experimental|Copper-nickel-titanium Group (CuNT)|0.014-inch Copper-nickel-titanium archwire (CuNT) (Damon Optimal-Force Copper Ni-Ti®, Ormco, Glendora, Calif) will be placed in mandibular arch at the day of bonding. Eight weeks later it will be replaced by the 0.018-inch archwire for another eight weeks.
88943160|NCT05391334||Usual Care|Contact mat (CareMat®) for bed-exit detection in combination with Qumea fall detection.
88943161|NCT05391334||Intervention|Contactless motion sensor (Qumea®) for bed-exit detection in combination with Qumea fall detection.
89462379|NCT03654235|Active Comparator|Usual care in Primary Care Physiotherapy|Usual care in Primary Care Physiotherapy Units
89462380|NCT03658031|Experimental|Dapagliflozin|Dapagliflozin 10mg per/day in prediabetes cases with MI before breakfast
89462381|NCT03658031|No Intervention|Placebo|Antiplatelet, ACEI and Betablockers
89462382|NCT03660917|Experimental|Riluzole|Riluzole 50 mg twice daily for 12 months in the treated group. In pre-pubertal subjects the dosage will be adjusted on a mg/m2 basis according to the recommended human daily dose (RHDD; 100 mg).
89462383|NCT03660917|Placebo Comparator|Placebo + riluzole|Placebo twice daily for 6 months and riluzole 50 mg twice daily for the following 6 months in the comparison group
89462384|NCT02573259|Experimental|Arm 1 PF-06801591|0.5 mg/kg IV every 21 days (Part 1)
89462385|NCT02573259|Experimental|Arm 2 PF-06801591|1.0 mg/kg IV every 21 days (Part 1)
89462386|NCT02573259|Experimental|Arm 3 PF-06801591|3.0 mg/kg IV every 21 days (Part 1)
89462387|NCT02573259|Experimental|Arm 4 PF-06801591|10 mg/kg IV every 21 days (Part 1)
89462388|NCT02573259|Experimental|Arm 5 PF-06801591|300 mg SC every 28 days (Part 1 and 2)
89462389|NCT02977507|Experimental|Lytera 2.0|Lytera 2.0 applied to the affected areas (dark patches) on one side of the face twice a day, in the morning and evening, every day for 12 weeks. SkinMedica Facial Cleanser, SkinMedica Rejuvenative Moisturizer, and SkinMedica Essential Defense Mineral Shield Broad Spectrum SPF 35 Sunscreen were also applied to the face as directed.
89462390|NCT02977507|Active Comparator|4% Hydroquinone Topical Cream|4% hydroquinone topical prescription cream applied to the affected areas (dark patches) on the other side of the face twice a day, in the morning and evening, every day for 12 weeks. SkinMedica Facial Cleanser, SkinMedica Rejuvenative Moisturizer, and SkinMedica Essential Defense Mineral Shield Broad Spectrum SPF 35 Sunscreen were also applied to the face as directed.
89462391|NCT03657953|Active Comparator|anterior (MI-A) surgical approach|The minimally invasive anterior surgical approach was carried out using a modified Smith-Petersen access as described by Bender et al. (Bender et al. 2009) with the patient in supine position.
89462392|NCT03657953|Active Comparator|anterolateral (MI-AL) surgical approach|For the minimally invasive anterolateral surgical approach, a modified Watson-Jones approach according to Röttinger (Rottinger et al. 2006) was applied with the patient in supine position.
89462393|NCT03657953|Active Comparator|direct lateral (DLA) surgical approach|The direct lateral surgical approach was performed according to the technique described by Hardinge et al. (Hardinge et al. 1982) with the patient positioned supine
88956459|NCT05154760|Active Comparator|one on one video conference|Pelvic floor muscle training, diaphragmatic breathing exercise, core strengthening exercise will continue for 8 weeks. Participants will be asked to practice the exercises at least 4 days in a week, and the program will be continued in the form of one on one interviews with video conference method once a week.
89462394|NCT03622177||HIV+|
89462395|NCT03622177||HIV- STI+|
89462396|NCT03622177||HIV- STI-|
89462397|NCT04471415|Experimental|Part 1a & Part 1b|"Single-agent dose escalation of DRP-104 to define the MTD (up to approximately 50 patients) starting at Dose Level 1 of 3.3 mg/m2 via intravenous injection~Single-agent dose escalation of DRP-104 to define the MTD (up to approximately 50 patients) starting at Dose Level 1 at 10 mg via subcutaneous injection"
89462398|NCT04471415|Experimental|Part 2|"Cohort 1: Phase 1 single-agent safety expansion of DRP-104 administered subQ (the RP2R) in patients with advanced solid tumors (excluding primary CNS tumors and HCC). DRP-104 will be administered twice weekly subQ in this safety expansion at the twice weekly subQ MTD/MAD/RP2D of DRP-104 determined in Part 1-Cohort 1b. A minimum of 14 and up to 20 patients will be enrolled.~Cohort 2: Phase 2a expansion at the MTD/MAD/RP2D/RP2R and schedule of administration (subQ twice or thrice weekly) of DRP-104 in patients with locally advanced or metastatic NSCLC whose tumors contain a known mutation in kelchlike ECH-associated protein 1 (KEAP1), nuclear factor erythroid 2-related factor 2 (NFE2L2) and/or serine/threonine kinase 11 (STK11), (N=55). If the thrice weekly schedule is selected as the RP2S, a safety review will be conducted after 8 patients have enrolled and are followed for at least one cycle of treatment before additional patients are enrolled into Part 2-Cohort 2."
89462399|NCT04471415|Experimental|Part 3|Phase 1 combination dose escalation of DRP-104 and atezolizumab in patients with advanced solid tumors (excluding primary CNS tumors and HCC) previously treated with an agent targeting checkpoint pathway inhibition (such as anti-PD-1, anti-PD-L1, and/or anti-CTLA-4 antibody), starting one dose level below the MTD/MAD/RP2D (MTD-1) of the recommended phase 2 route and schedule of administration of singleagent DRP-104 and in combination with 1200 mg atezolizumab administered via intravenous infusion on day 1 and repeated every 3 weeks (up to approximately 12 patients);
89462400|NCT04471415|Experimental|Part 4|Phase 1 combination safety expansion at the MTD/MAD/RP2D, route, and schedule of administration of DRP-104 with atezolizumab in a similar patient population as the dose-escalation (N=14 patients).
89462401|NCT02976103|Other|Standard Care|-Standard Care pain medicine/management will be given
89462402|NCT02976103|Experimental|JACKI® RECOVERY JACKET + Standard Care|"Patient will be encouraged to use the Jacki Recovery Jacket at home~Patient will be taught how to tuck the drainage tubes in the jacket pocket~Patient will be taught how to un-tuck the drainage tubes from jacket pocket~Standard care pain medicine/management will be given"
89462403|NCT03659279|Experimental|Let's Get Organized|Group intervention with 10 weekly sessions, each lasting 1.5 hours.
89462404|NCT03654001|Experimental|Albumin + Balanced|"Human Albumin In parallel with fluid administration for volume resuscitation, patients will receive 400 ml of 20% albumin solution both at randomization (D0) and at day 1 (D1). Subsequently, from day 2 (D2) until day 90 (D90) or ICU discharge (whichever comes first), 20% albumin will be administered on a daily basis, to maintain serum albumin concentration equal to or greater than 30 g/L, based upon serum albumin determination.~Balanced crystalloid solutions~According to the preference and the standard use of the participating center:~Ringer Lactate~Ringer Acetate~Crystalsol"
88943162|NCT05387161||Observational group|"A nutritional assessment will be held with the detection of anthropometric parameters. Each participant will be asked to fill in the SF36, the VAS scales, the KESS questionnaire, the SFFI questionnaire, the Questionnaire PUF and O'Leary/Santn, the BDI and the TAS for an assessment of the psychological component.~In addition, patients will be asked to fill in a FFQ of food consumption and a 7 days food diary. Finally, routine blood chemistry tests will also be performed, to which will be added those for measuring the inflammatory state and stool examination for the evaluation of fecal Calprotectin for the measurement of intestinal inflammatory markers.~The nutritional intervention will consist in providing general nutritional indications specific for endometriosis and an indicative daily diet plan, which must be followed for 6 months.~At the end of the 6 months, all anthropometric assessments, blood chemistry and stool tests will be repeated, together with the questionnaires."
88943163|NCT05385406|Experimental|Triage by genotyping|The study intervention will consist in applying HPV genotyping as a triage method of HPV-positive women for cervical cancer screening. After primary screening with the Xpert HPV test, positive women will be sorted according to two groups of genotypes: group 1 (HPV types 16,18,45, 31, 33, 35, 52 and/or 58 obtained from channels 1, 2 and 3) and group 2 (HPV types 51, 59, 39,56, 66 and/or 68 obtained from channels 4 and 5). Women of group 1 will immediately treated, while those of group 2 will not receive immediate treatment and will be followed-up at 12 months. An exception will be made for participants with lesions suspicious of invasive cancer upon examination, which will be referred for further investigations regardless of the HPV type.
88943164|NCT05385406|Active Comparator|Triage by visual inspection after application of acetic acid (VIA)|The control arm will consist in triage of HPV-positive women by VIA, as currently recommended by the WHO. Women with a positive VIA will be treated immediately, while VIA-negative women will not be treated and will be followed-up at 12 months.
88943165|NCT05377463|Experimental|Condition 1: Components 1, 2, 3 and 4|"Participants will be assigned to receive all of the four intervention programs:~Peer-Support for Medication-Assisted Treatment~Behavioral Activation Therapy~Patient Navigation for HIV Care~Life Steps Program for Medication Adherence"
88943166|NCT05377463|Experimental|Condition 2: Components 1, 2, 3|"Peer-Support for Medication-Assisted Treatment~Behavioral Activation Therapy~Patient Navigation for HIV Care"
88943167|NCT05377463|Experimental|Condition 3: Components 1, 2 and 4|"Peer-Support for Medication-Assisted Treatment~Behavioral Activation Therapy~4) Life Steps Program for Medication Adherence"
88943168|NCT05377463|Experimental|Condition 4: Components 1 and 2|"Peer-Support for Medication-Assisted Treatment~Behavioral Activation Therapy"
88943169|NCT05377463|Experimental|Condition 5: Component 1, 3, and 4|"1) Peer-Support for Medication-Assisted Treatment~3) Patient Navigation for HIV Care~4) Life Steps Program for Medication Adherence"
88943170|NCT05377463|Experimental|Condition 6: Component 1 and 3|"1) Peer-Support for Medication-Assisted Treatment~3) Patient Navigation for HIV Care"
88943171|NCT05377463|Experimental|Condition 7: Component 1 and 4|"1) Peer-Support for Medication-Assisted Treatment~4) Life Steps Program for Medication Adherence"
88943172|NCT05377463|Experimental|Condition 8: Component 1|1) Peer-Support for Medication-Assisted Treatment
88943173|NCT05377463|Experimental|Condition 9: Components 2, 3, and 4|"2) Behavioral Activation Therapy~3) Patient Navigation for HIV Care~4) Life Steps Program for Medication Adherence"
89462405|NCT03654001|Experimental|Albumin + Saline|"Human Albumin In parallel with fluid administration for volume resuscitation, patients will receive 400 ml of 20% albumin solution both at randomization (D0) and at day 1 (D1). Subsequently, from day 2 (D2) until day 90 (D90) or ICU discharge (whichever comes first), 20% albumin will be administered on a daily basis, to maintain serum albumin concentration equal to or greater than 30 g/L, based upon serum albumin determination.~Normal Saline Na+ 154 mEq/L, Cl- 154 mEq/L (0.9% NaCl)."
88943174|NCT05377463|Experimental|Condition 10: Components 2 and 3|"2) Behavioral Activation Therapy~3) Patient Navigation for HIV Care"
88943175|NCT05377463|Experimental|Condition 11: Component 2 and 4|"2) Behavioral Activation Therapy~4) Life Steps Program for Medication Adherence"
88943176|NCT05377463|Experimental|Condition 12: Component 2|2) Behavioral Activation Therapy
88943177|NCT05377463|Experimental|Condition 13: Component 3 and 4|"3) Patient Navigation for HIV Care~4) Life Steps Program for Medication Adherence"
88943178|NCT05377463|Experimental|Condition 14: Component 3|3) Patient Navigation for HIV Care
88943179|NCT05377463|Experimental|Condition 15: Component 4|4) Life Steps Program for Medication Adherence
88943180|NCT05377463|Experimental|Condition 16: No Components|Participants not assigned to any of the 4 components. They are placed on a wait list and will receive components after the primary data collection period.
88943181|NCT05365815|Experimental|MGMC Intervention Group|"In the MGMC (intervention) group, pregnant women will participate in group prenatal care and have ~2-hour visits with the same two co-facilitators, a Black midwife and a Black care coordinator, along with 8-12 other Black women at a similar stage of pregnancy, for all prenatal and one postnatal care visits.~The care coordinator will proactively engage with women throughout pregnancy and up to 12 months postpartum. The care coordinator helps women make appointments, sends reminders, and follows-up to ensure care was received, understood, and was appropriate. In the 3rd trimester, women in MGMC will be introduced to a community-based postpartum doula. The doula will make home visits once before birth and within the first 2 weeks postpartum; they will have approximately 50 contact hours available for 12 months postpartum for primarily in-person support, but they will be available by phone and text."
88943182|NCT05365815|No Intervention|Usual Care|In the usual care (comparator) group, pregnant women attend individually scheduled visits with a midwife or obstetrician for a physical assessment and counseling. Although this can vary by provider, continuity of care is rare and racial concordance is not a consideration. Referrals for medical or social services are given to the patient to complete in both prenatal and postnatal care.
88943183|NCT05365607|Experimental|NightWare|In individuals randomized to the active condition, when the stress index is reached during sleep, NightWare will intervene with varying degrees of vibratory stimulation to the watch over a variable length of time to arouse the person out of the nightmare without awaking.
88943184|NCT05365607|Sham Comparator|Sham NightWare|In individuals randomized to the sham condition, the NightWare intervention will not be enabled.
88943185|NCT05361980||Longitudinal Observational Group|Pediatric patients indicated for the device-specific indication, per physician discretion and as indicated in the device IFU.
88943186|NCT05360849|Experimental|Practice Facilitation|Practice Facilitation is an established evidence-based intervention to improve primary health care processes and outcomes, including the delivery of preventive services, through the creation of an ongoing, trusting relationship between an external Practice Facilitator (PF) and a clinical practice. In Practice Facilitation, a trained PF uses organization development, project management, quality improvement, and practice improvement approaches to build the internal capacity of a clinic to support it in reaching its goals for healthcare delivery, A PF's work includes relationship-building, helping to identify a clinic change champion, and facilitating change through logistical support, technical assistance, and external partnership building.
88943187|NCT05357547|Experimental|Buspirone|
88943188|NCT05357547|Placebo Comparator|Control|
89462406|NCT03654001|Experimental|Balanced|Balanced crystalloid solutions (Ringer Lactate, Ringer Acetate, Crystalsol)
88943189|NCT05344833|Experimental|Isatuximab and Lenalidomide Maintenance|"All participants will receive:~Isatuximab 10mg/kg IV Days 1,8, 15, 22 Cycle 1 (all cycles 28 days). Isatuximab 10mg/kg Days 1, 15 Cylces 2 and 3. Isatuximab 10mg/kg Day 1, Cylces 4-39. Lenalidomide 10mg PO Days 1-21 Cylces 1-3 (all cycles 28 days) Lenalidomide 15mg PO Days 1-21 Cycle 4 and can continue until disease progression."
88943190|NCT05342090|Active Comparator|Standardized Counselling Tool|If randomized to the treatment group, patients will be counselled using the structured counselling tool, and given a bulleted list of the counseling instrument to take home with them.
88943191|NCT05342090|No Intervention|Control|Routine postoperative counselling and care will be administered with no specific standardized counselling for return to sexual activity after surgery.
88943192|NCT05339100|Experimental|Anifrolumab administered using AI|Randomized participants will receive a single SC dose of anifrolumab via AI.
88943193|NCT05339100|Active Comparator|Anifrolumab administered using APFS|Randomized participants will receive a single SC dose of anifrolumab via APFS.
88943194|NCT05337514|Experimental|EngAGE|Older adult subjects will receive an Alexa Echo Show that runs an exercise app called EngAGE.
88943195|NCT05337514|Active Comparator|Physical Exercise Handouts|Older adults subjects will receive a paper booklet containing exercise instructions.
88943196|NCT05329714||Patients with Pulmonary Hypertension|Patients with a diagnosis of pulmonary hypertension typically diagnosed via right heart catheterization.
88943197|NCT05329714||Control Group|Participating PH centers can optionally provide data about patients with exclusion of pulmonary hypertension
88943198|NCT05327153|Experimental|intervention group|Breast cancer patients from the IPPT Breast Clinic who meet the inclusion criteria will be contacted and informed about the study and procedure. Informed consent will be obtained once the respondent agrees to participate. In the case of group psychological intervention, 8 breast cancer patients form one group, and group psychological intervention is given once a week for four weeks as part of the treatment process. The batteries of assessment were carried out at 3-time points; pre-intervention, post-intervention, and 3 months after the intervention.
88943199|NCT05327153|Other|waitlist group|After the intervention of the intervention group, the waitlist group was interfered again. The batteries of assessment was same as the intervention group.
88943200|NCT05323838||Control Healthy Women|Aged-matched control group of healthy women.
88943201|NCT05323838||Only Fibromyalgia|Patients diagnosed only with fibromyalgia.
89462407|NCT03654001|No Intervention|Saline|Normal Saline Na+ 154 mEq/L, Cl- 154 mEq/L (0.9% NaCl).
89462408|NCT03659201|Experimental|Neosil complete|"The patient will take the tablets, as follow:~3 tablets of Neosil, Oral, per day - during the initial 12 weeks; and~2 tablets of Neosil Oral, per day - during the last 12 weeks."
89462409|NCT03659201|Experimental|Pantogar|"The patient wil take the tablets, as follow:~3 tablets of Placebo, Oral, per day - during the initial 12 weeks; and~3 tablets of Pantogar, Oral, per day - during the last 12 weeks."
89462410|NCT03659201|Experimental|Neosil|"The patient will take the tablets, as follow:~2 tablets of Neosil Oral, per day - during the 12 weeks."
89462411|NCT03653923|Experimental|Waiting-List|
89462412|NCT03653923|Experimental|Treatment|
89462413|NCT03653923|No Intervention|Healthy Controls|Not randomized healthy control group for comparison to normal functioning
89462414|NCT03653845|Experimental|Intevention|Patients in this group will be treated with endovascular chemical ablation of adrenal glandp by endovascular injection of dehydrated alcohol. Sequenced antihypertensvie drugs with titrated dosage(amlodipine 5-10 mg/d ; terazosin 2-6mg/d) will be prescribed if home blood pressure (HBP) exceeds ≥160/100 mmHg.
89462415|NCT03653845|Active Comparator|Control|Patients in this group will be treated only with sequenced antihypertensvie drugs with titrated dosage(amlodipine 5mg/d→plus spironolactone 20 mg/d→plus spironolactone 40 mg/d→plus spironolactone 60 mg/d→→plus amlodipine 10 mg/ d →plus terazosin 2-6mg / d) if home blood pressure (HBP) exceeds ≥160/100 mmHg.
89462416|NCT04630977|Experimental|Multi-Ingredient Pre-workout Supplement|"This group of participants will intake a multi-ingredient supplement around ~15 minutes before every workout.~The nutritional information of the supplement is: ~90 Kcal. for 25g of powder: carbohydrates -isomaltulose, fructose, maltodextrin- 15 g, essential amino-acids -Beta-alanine: 2.5g, L-arginine AKG: 2.5g, L-Leucine: 800mg, Taurine: 500mg, L-citrulline: 500mg- 6.8 g, Creatine monohydrate: 2.0g, Guarana Extract: 800mg, total caffeine: 160mg, and Magnesium: 112.5mg.~They will also follow a previously designed progressive resistance training (3 times a week, around 1 hour a day, consisting of different exercises).~Also, they will receive a specific guideline with simple tips to improve their nutritional patterns.~The training sessions and the nutritional guideline will be the same for the three groups."
89462417|NCT04630977|Active Comparator|Isocaloric Placebo|"This group of participants will intake an isocaloric (only carbohydrates: Maltodextrin) supplement comparator, around ~15 minutes before every workout.~The nutritional information of the supplement is: ~90 Kcal. for 23g of powder.~They will also follow a previously designed progressive resistance training (3 times a week, around 1 hour a day, consisting of different exercises).~Also, they will receive a specific guideline with simple tips to improve their nutritional patterns.~The training sessions and the nutritional guideline will be the same for the three groups."
89462418|NCT04630977|Sham Comparator|Control|"These participants will drink a non-caloric admixture with the same taste, texture and flavour.~They will also follow a previously designed progressive resistance training (3 times a week, around 1 hour a day, consisting of different exercises).~Also, they will receive a specific guideline with simple tips to improve their nutritional patterns.~The training sessions and the nutritional guideline will be the same for the three groups."
89462419|NCT03470961|Experimental|Anti-Tlymphocyte Globulins|intravenous，2mg/kg/d，for 5 days
89462420|NCT03470961|Active Comparator|Anti-thymocyte Globulins|intravenous，1.5mg/kg/d，for 4 days
89462421|NCT03470883||endoscopic resection of a colorectal lesion|Patient having undergone endoscopic resection of a colorectal lesion stage 4 or 5 of the modified Vienna classification during the last 5 years at the institute.
89462422|NCT05017857|Experimental|Simultaneous rTMS and PST|
89462423|NCT05017857|Experimental|Sequential rTMS and PST|
88943202|NCT05323838||Fibromyalgia and Chronic Fatigue Syndrome|Patients diagnosed with fibromyalgia and chronic fatigue syndrome.
88943203|NCT05302999|Experimental|Low dose|600mg treatment group will receive 2 capsules of gabapentin by mouth 3 times per day for 90 days.
88943204|NCT05302999|Experimental|Medium dose|1800 mg treatment groups will receive 2 capsules of gabapentin by mouth 3 times per day for 90 days.
89462424|NCT03130881|Experimental|PLB1003|ALK-positive (ALK+) advanced NSCLC
89462425|NCT01066039|Experimental|Bisoprolol|
89462426|NCT02919995|Experimental|Higher Dose RPL554|Single dose of inhaled 6 mg RPL554
89462427|NCT02919995|Experimental|Lower dose RPL554|Single dose of inhaled 1.5 mg RPL554
89462428|NCT02919995|Placebo Comparator|Placebo|Inhaled placebo dose
89462429|NCT04972695||Glaucoma|People with diagnosis of Primary Open Angle Glaucoma (POAG)
88943205|NCT05302999|Placebo Comparator|Control|The control group will receive 2 placebo capsules of inert cellulose by mouth 3 times per day for 90 days.
88943206|NCT05298865|Placebo Comparator|Neutral recall message|Control group will receive a set of messages guiding them to recall neutral life senarios/objects. The messages will contain eight brief paragraphs of neutral text and icon-based pictures to guide participants to recall their life senarios. The text message will include yesterday's meals, yesterday's wearing, home environment and nearby locations. This control condition equated attention and time on task but expect not to induce any emotions in participants.
89462430|NCT04972695||Ocular Hypertension / glaucoma suspect|People with diagnosis of Ocular Hypertension or POAG suspicion
89462431|NCT03653767|No Intervention|Control Group|The control group will use conventional school furniture.
89462432|NCT03653767|Experimental|Adjustable Furniture Group|The experimental group will use adjustable ergonomic school furniture.
89462433|NCT03653689|Active Comparator|FODMAPs|Dietary supplement: FODMAPs 50 grams three servings per day for seven days.
89462434|NCT03653689|Active Comparator|Gluten|Dietary supplement: Gluten 17.3 grams three servings per day for seven days.
89462435|NCT03653689|Placebo Comparator|Placebo|Dietary supplement: Placebo rice porrige three servings per day for seven days.
89462436|NCT04396379|Experimental|Device Implantation|To epicardially reshape the mitral valve annulus and left ventricle without the need for cardiopulmonary bypass (CPB) and open-heart access (atriotomy) using an epicardial implant.
89462437|NCT04457427|No Intervention|Tracheostomy, no DPS|5 patients undergoing tracheostomy for failure to wean will receive no additional intervention.
89462438|NCT04457427|Experimental|Trachesotomy with immediate DPS stimulation and monitoring|5 patients undergoing tracheostomy for failure to wean will have DPS implanted concurrently and receive immediate stimulation and monitoring.
89017798|NCT06127108|Experimental|Experimental: Nasal sampling/Testing (professional use)|Operator or delegated study staff will collect one anterior nasal swab sample from both nostrils. The collected anterior nasal swab will the tested with the Panbio™ COVID-19/Flu A&B Panel by the operator at the study site in a near patient testing setting (e.g. GP center or hospital clinic). After the anterior nasal swab is collected, the operator or delegated study staff will collect one anterior nasal swab from both nostrils of the subject for RT-PCR testing. VTM samples will be shipped daily to the central lab for testing with the RT-PCR protocols for Flu A, Flu B and SARS-CoV-2.
89017799|NCT06124313|Experimental|Intervention Group|Participants will take one capsule of the test product every day, with water.
89017800|NCT06119867|Experimental|Japanese pathological investigation method group|The surgeon will be involved into the Japanese pathological investigation method. The surgeon will perform the intraoperative markings and the postoperative lymph node harvest, after which the specimen will be assessed by the pathologist.
89017801|NCT06119867|Active Comparator|European pathological investigation method group|After receiving the resected specimen, the entire process will be independently managed by the pathologist.
89017802|NCT06114680|Other|Session 1 - test group|130 subjects with self-reported hearing difficulties according to the HHIE-s questionnaire (score of >4)
89017803|NCT06114680|Other|Session 1 - control goup|60 subjects with no self-reported hearing difficulties according to HHIE-s questionnaire (score of ≤4)
89017804|NCT06114680|Other|Session 2|60 subjects who participated in session 1 - test group
89017805|NCT06114433|Active Comparator|Traditional model group|Received a regular learning
89017806|NCT06114433|Experimental|3D-printed presention group|Received a regular learning plus 3D printing model
89017807|NCT06103617|Experimental|Penicillamine group|Participants in this group are treated with Penicillamine (250mg each time, 4 times per day) during reradiation.
89017808|NCT06099977|Experimental|I (Binaural)|Binaural sound using headphone will be applied.
89017809|NCT06099977|Placebo Comparator|II (Placebo)|Only headphone without sound will be applied.
89017810|NCT06094426|Experimental|GT316 treatment group|
89017811|NCT06091059||Subjects|All adult patients with capacity and requiring an ultrasound guided Botox injection in the Radiology Department will be invited to take part in the study.
89017812|NCT06088784|Experimental|Part 1a (Single Ascending Doses (SAD)): ATH-399A|Participants will receive single oral dose of ATH-399A capsule in up to 5 ascending dose levels (5mg, 10mg, 20mg, 40mg, 80mg).
89017813|NCT06088784|Placebo Comparator|Part 1a (SAD): Placebo|Participants will receive single oral dose of placebo-matched to ATH-399A capsule.
89017814|NCT06088784|Experimental|Part 1b (High calorie): ATH-399A|Participants will receive single oral dose of ATH-399A capsule after high-calorie, high-fat breakfast and then will cross over to receive single oral dose of ATH-399A capsule after fasting.
89017815|NCT06088784|Experimental|Part 1b (Fasting): ATH-399A|Participants will receive single oral dose of ATH-399A capsule after fasting and then will cross over to receive single oral dose of ATH-399A capsule after high-calorie, high-fat breakfast.
89017816|NCT06088784|Experimental|Part 2 (Multiple Ascending doses (MAD)): ATH-399A|Participants will receive once daily (QD) dose of ATH-399A capsules from Day 1 to Day 12 in fasted state.
89017817|NCT06088784|Placebo Comparator|Part 2 (MAD): Placebo|Participants will receive QD dose of placebo-matched to ATH-399A capsules from Day 1 to Day 12 in fasted state.
89017818|NCT06088784|Experimental|Additional Cohort (Ages 56-80 years old): ATH-399A|Participants will receive QD dose of ATH-399A capsules from Day 1 to Day 12 in fasted state following MAD dosing.
89017819|NCT06088784|Placebo Comparator|Additional Cohort: (Ages 56-80 years old) Placebo|Participants will receive QD dose of placebo-matched to ATH-399A capsules from Day 1 to Day 12 in fasted state following MAD dosing.
89017820|NCT06085859|Experimental|Mask oxygen supply group|The anaesthesia provider supplied oxygen via a nasal cannula at an oxygen flow rate of 8 Litres/minute supplied from an oxygen flowmeter
89462439|NCT04457427|Active Comparator|Trachesotomy with DPS monitoring, stimulation on day 5|5 patients undergoing tracheostomy for failure to wean will have DPS implanted concurrently and receive immediate monitoring followed by stimulation on day 5 post-procedure.
89462440|NCT04457583|Experimental|Intervention|Procedure: Inspiratory muscle training with powerbreathe with a linear pressure resistance using an inspiratory load of 40% of maximal inspiratory pressure (adjusted weekly), seven days a week, 30 exercises daily for 12 weeks.
89017821|NCT06085859|Experimental|Nasal oxygen supply group|The study team applied the mask with a head strap to ensure a proper seal,simultaneously ensuring the same oxygen flow rate as the control group
89017822|NCT06083480|Experimental|GlyNAC (combination of glycine and n-acetylcysteine)|GlyNAC 200 mg/kg/day (100mg glycine and 100mg N-acetyl-cysteine) will be administered orally in two divided doses each day for four weeks prior to TKA and six weeks postoperatively. The preparation will be a commercially available product of 1:1 ratio of glycine and N-acetyl-cysteine.
89017823|NCT06083480|Placebo Comparator|Placebo (alanine)|Placebo (alanine) 200 mg/kg/day will be administered orally in two divided doses each day for four weeks prior to TKA and six weeks postoperatively.
89017824|NCT06080581||Mitochondrial myopathy|Individuals with pathogenic mtDNA mutations
89017825|NCT06080581||Control|Individuals without mtDNA mutations
89017826|NCT06080568||Mitochondrial myopathy|Individuals with pathogenic mtDNA mutations
89017827|NCT06080568||Control|Individuals without mtDNA mutations
89017828|NCT06064578|Experimental|Project SOLVE|Project SOLVE is a ~30-minute self-guided digital intervention designed to teach children and adolescents how to set goals and solve problems systematically. Specifically, Project SOLVE is based on problem solving, a core component of cognitive behavioral therapy, a gold standard treatment for internalizing disorders. Project SOLVE uses vignettes, interactive activities, and engaging graphics to teach youth a systematic strategy for solving problems. Project SOLVE was previously found to be effective in reducing mental health symptoms among American children (https://link.springer.com/article/10.1007/s12310-023-09598-7).
89017829|NCT06064578|Other|Delayed Receipt of Project SOLVE Control Condition|No intervention for first three months; will receive SOLVE after 3-months and become a second-wave intervention condition.
89017830|NCT06060626|Active Comparator|Propofol|Patients in whom only propofol will be administered during sedation. Intermittent boluses of propofol titrated to moderate level of sedation.
89017831|NCT06060626|Active Comparator|Fentanyl|"Patients in whom combination of propofol and fentanyl will be administered during sedation.~Fentanyl 1 ug/kg bolus 3 minutes before induction + Propofol intermittent boluses titrated to moderate level of sedation."
89017832|NCT06060613|Experimental|Participants with advanced solid tumors|Participants will receive conditioning therapy prior to administration of OBX-115 regimen.
89017833|NCT06059014|Experimental|177Lu-PSMA-1|Radiopharmaceutical - injectable solution
89462441|NCT04457583|No Intervention|Control|Procedure: Training with the same equipment but without load-generating resistance.
89462442|NCT03109821||THA patients|
89462443|NCT05156697|Placebo Comparator|Placebo + Exercise|Placebo pills + 60 min of aerobic exercise
89462444|NCT05156697|Experimental|Dihydrocapsiate + Exercise|12 mg of dihydrocapsiate pills + 60 min of aerobic exercise
89462445|NCT04217967|Active Comparator|Lenalidomide group|lenalidomide 25mg qod d1~21 days, rest 7 days
89462446|NCT04217967|Active Comparator|Ixazomib group|ixazomib 4mg orally, once a week, 3 times a month
89462447|NCT04217967|Experimental|Combination group|ixazomib 4mg orally, once a week, 3 times a month lenalidomide 25mg qod d1~21 days, rest 7 days use in combination
89462448|NCT02919761|Experimental|Part 1: All Enrolled Participants|All participants receive Acthar Gel 1 mL twice weekly for 12 weeks
89462449|NCT02919761|Experimental|Part 2: Acthar Gel|Participants receive Acthar Gel 1 mL twice weekly for an additional 12 weeks
89462450|NCT02919761|Placebo Comparator|Part 2: Placebo|Participants receive Placebo 1 mL twice weekly for an additional 12 weeks
89462451|NCT04211181|Experimental|The multifaceted QI interventions|Hospitals randomized into experimental group will implement follow interventions including：the distribution of the guideline and pathway, a computer alert(computer-based clinical decision support system and computerized reminders),audit and feedback.
89462452|NCT04211181|Active Comparator|Routine VTE prophylaxis in local clinical practice|Patients in the routine VTE prophylaxis(control) group will receive routine VTE prophylaxis according to current guidelines and clinical practices.
89462453|NCT02910167||Men with spasmodic syndromes|Men with any type of gastrointestinal, hepato-biliary, urinary or genital spasmodic syndromes
89462454|NCT02910167||Women with spasmodic syndromes|Women with any type of gastrointestinal, hepato-biliary, urinary or genital spasmodic syndromes
89462455|NCT04458285|Experimental|Sacubitril/valsartan|Patients in experimental group will receive sacubitril/valsartan with the recommended starting dose: 50mg twice daily (if previous angiotensin converting enzyme inhibitor(ACEI), ensure 36-hour washout period), after 2-4 weeks, the dose will be doubled to the target maintenance dose of 100mg twice daily(if tolerated) for 12 weeks.
89462456|NCT04458285|Active Comparator|Valsartan|Patients in active comparator group will receive Valsartan with an dose of 80 mg once daily.
89017834|NCT06058767|Active Comparator|Two-stage PTA+OAE hearing screening (TS-PO)|"Children initially undergo a PTA screening test, recommended by the American Academy of Audiology and supported by published evidence. This screening assesses their hearing ability through conditioned-play responses to 25 dB HL pure tones at 1000, 2000, and 4000 Hz, yielding results of PASS, REFER, or UNABLE to test. Those UNABLE to be tested will receive a second OAE screening. Children who REFER either the PTA or OAE test, or are UNABLE to be tested by both, are referred to their pediatrician for further evaluation and management.~All children will undergo both PTA and OAE screening and the group allocation will be determined post hoc."
89017835|NCT06058767|Active Comparator|Single-Stage OAE hearing screening (SS-O)|"Children undergo only screening with OAEs, detecting distortion-product OAEs in response to tone pairs centered at 2000, 3000, 4000, and 5000 Hz. If they PASSED the OAE, they would be assigned a PASS for the SS-O Hearing Screen outcome; if they REFERRED or were UNABLE to test, they would be assigned a REFER.~All children will undergo both PTA and OAE screening and the group allocation will be determined post hoc."
89462457|NCT05156541|Experimental|Interferon|After a cryodestruction session, therapy with Ingaron 100,000 IU once a day every other day. The course of treatment consisted of 5 injections.
89462458|NCT05156541|No Intervention|Control|Cryodestruction session only.
89462459|NCT03469869|Experimental|balanced and sustainable diet|The intervention group will receive menu recommendation of restriction calorie balanced and sustainable diet for 8 weeks. the control group will receive menu recommendation of balanced diet for 8 weeks. these menus are given in the apps
89017836|NCT06053853|Experimental|Investigational Product|"Diphtheria Antitoxin (DAT)~Administered intravenously.~Dosage:~Mild diphtheria (nose, skin): 20,000 unit~Moderate diphtheria (tonsil - limited): 40,000 - 60,000 unit~Severe diphtheria (more than 1 tonsil, or to the pharyngeal wall, or more than 5 days of illness, or with bull neck): 80,000 - 120,000 unit"
89017837|NCT06051305|Experimental|Sensory Training|Daily protocol - gamified sensory training
89462460|NCT03469869|Active Comparator|balanced diet|the intervention group receive get menu recommendation of restriction calorie balanced and sustainable diet for 8 weeks. the other group will receive menu recommendation of balanced diet for 8 weeks. these menus are given in the apps
89462461|NCT01067105|Experimental|ciclesonide|ciclesonide HFA 160 μg once daily
89462462|NCT03470727|Experimental|Citrate arm|Citrate dialysate Phase 1 : Reduce heparin to 50% Phase 2: Reduce heparin to 25% Phase 3: Heparin free
89462463|NCT03657719|Experimental|GC3114|Pre-filled syringe inj., 0.5ml, Once, IM
89462464|NCT03657719|Active Comparator|Active Comparator: GCFLU Quadrivalent|Pre-filled syringe inj., 0.5ml, Once, IM
89462465|NCT03924765|Experimental|Individuals post-stroke using a powered hip exoskeleton|This study will be conducted on a sample population of stroke subjects (single arm). Each subject will test with each condition of the exoskeleton (repeated measures).
89462466|NCT02910089|Other|Shared Decision Making/Brief Negotiated Interviewing|This prospective study will include 700 beneficiaries of Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ).
89462467|NCT02910089|No Intervention|Control Arm|Seven hundred patients will also be identified by Horizon Analytics as a control group for analyses purposes only; these patients will not be contacted.
88943207|NCT05298865|Experimental|Positive imagination stimulation|Positive-affect-priming group (PA) will receive a set of messages guiding participants to imagine positive future life senarios. Prior receiving the PA messages, a brief instruction will also be provided to guide participants to imagine concrete and personal images while browsing the following messages. The PA messages will contain eight pictures representing the life senarios and accompanying with short text to guide participants' imagination. Each senario will contain two pictures, one is used to familiarized participants with the context that they are going to imagine (i.e. imagine one of your best friends); the second one provides richer information to stimulate participants' concrete imagination (i.e. imagine you share a good news with your friend). These intervention messsages aim to intentionally manipulate participants' feelings arousal and mental representation for positive future life.
89462468|NCT03472209||Group A|ETCO2=26-35 mmHg
89462469|NCT03472209||Group B|ETCO2=36-45 mmHg
89462470|NCT02985515|No Intervention|Budesonide Nasal Irrigation|"30-day run-in course of budesonide nasal irrigation.~1-month supply of budesonide capsules, an 8-oz sinus rinse bottle, and a 1-month supply of commercially prepared isotonic salt packets.~Participants were instructed to dissolve 2 budesonide capsules (0.5mg per capsule) into the sinus rinse bottle along with the saline mixture and then irrigate both nasal cavities once daily."
89462471|NCT02985515|Experimental|Budesonide Nasal Irrigation + Smell Training|Budesonide nasal irrigation + smell training for 12 weeks
89462472|NCT02985515|No Intervention|Controls|Baseline olfaction testing and rs-fMRI
89462473|NCT03797313||Patient's expectations met at Hospital discharge|ARF survivors whose expectations for recovery at hospital discharge are fully met 6 months later.
89462474|NCT03797313||Patient's with unmet expectations at Hospital Discharge|ARF survivors whose expectations for recovery at hospital discharge are not fully met 6 months later.
89462475|NCT03470649|Experimental|Treatment|Patients in this group would receive Iron Isomaltoside 1000 (Monofer®) after main procedure of total knee arthroplasty. The dose of iron isomaltoside would be determined based on the patient's body weight.
89462476|NCT03470649|No Intervention|Control|Patients in this group would receive 100ml of normal saline after main procedure of total knee arthroplasty.
89462477|NCT03657563|Experimental|Intervention group|Nurses with burnout are recruited in the intervention group and participate in positive psychological intervention.
89462478|NCT03657563|No Intervention|Control group|Nurses with burnout are recruited in the control group and none interventions are conducted to them.
89462479|NCT03657329|Experimental|Suspicion of sleep-disordered breathing|Dreem
89462480|NCT02696759|Other|Blood & Fecal Collection|Subjects receiving neoadjuvant chemotherapy for advanced breast cancer will be asked to complete questionnaires, provide two blood samples, and provide 2 fecal samples while receiving standard of care neoadjuvant chemotherapy
89462481|NCT03706911|Experimental|VM-1500A-LAI 150mg|VM-1500A-LAI 150mg IM single dose
89462482|NCT03706911|Experimental|VM-1500A-LAI 300mg|VM-1500A-LAI 300mg IM single dose
89462483|NCT03706911|Experimental|VM-1500A-LAI 600mg|VM-1500A-LAI 600mg IM single dose
89462484|NCT03706911|Experimental|VM-1500A-LAI 1200mg|VM-1500A-LAI 1200mg IM single dose
89462485|NCT03706911|Experimental|VM-1500A-LAI 600 mg Multiple|VM-1500A-LAI Multiple dose (2 injections every 4 weeks)
89462486|NCT02910011|Experimental|Topical Administration of Study Drug|2.5 grams of Nanodox 1% (doxycycline monohydrate hydrogel) will be applied topically to an indicated lesion daily for 28 days
89462487|NCT03472131|Experimental|Septic spondylodiscitis|A unilateral posterolateral approach and debridement with titanium cage insertion supplemented by screw fixation for severe sick patients suffering from septic spondylodiscitis
89462488|NCT03657485|Experimental|interventional|In the interventional group we supplemented the probiotic containing Bifidobacterium breve PB04 i Lactobacillus rhamnosus KL53A (FFbaby, IBSS Biomed SA, Poland) orally during the first hour of life and after 12 hours in mother's milk or formula (the total amount of the probiotic was 2 x 10 6 CFU bacteria).
89462489|NCT03657485|No Intervention|control|No intervention. Feeding with mother milk
89462490|NCT03657485|No Intervention|comperative|Comparing stool composition of vaginally born newborns
89462491|NCT03472053|Experimental|BIO-11006 plus standard of care|Aerosolized BIO-11006 (125mg BID) plus standard of care (Pemetrexed plus Carboplatin) is administered for three months.
89462492|NCT03472053|Experimental|Standard of Care|Pemetrexed (500 mg/meter square) and Carboplatin (AUC6, Calvert's Formula) is administered every three weeks for three months.
88943208|NCT05298150|Experimental|Dynamic cycling|The cycling parameters will change according to motor performance of the participants. Motor performance will be measured by assessing the change in tremor and movement speed.
88943209|NCT05298150|Active Comparator|Forced cycling|The cycling parameters will not change regardless of the motor performance. Motor performance will be measured by assessing the change in tremor and movement speed.
88943210|NCT05297500||Adult healthy subjects|Adult healthy subjects capable of undergoing controlled hypoxemia to the levels outlined in the desaturation profile in an at rest state
88943211|NCT05295797|Experimental|Dance Program|Participants will take 2 in person dance classes led by peer dance instructors per week for 12 weeks
88943212|NCT05295797|No Intervention|Control|Participants in the waitlist control will be assigned to a waiting list and will be invited to participate in dance classes after the intervention arm 12-week dance program has ended
88943213|NCT05291520|Experimental|Part 1: VH3810109 + rHuPH20|Healthy participants will receive a single SC dose of VH3810109 injection with rHuPH20.
88943214|NCT05291520|Experimental|Part 2: VH3810109|Healthy participants will receive a single IV dose of VH3810109 injection.
88943215|NCT05285306|Experimental|PEACE Program|3 sessions of tailored coping skills related to pelvic examinations
88943216|NCT05271006|Experimental|Exercise group|"Weeks 1 - 12:~For the duration of the study, participant will be completing any of the physical activities customizable within the Down Dog apps. He/she will be asked to complete a minimum of four 20-minute workouts per week.~Every two weeks, participant will receive a survey to complete.~Week 24:~At week 24 (12 weeks after their initial 12-week participation in the study), participant will receive a check-in email with the final survey to complete.~Investigators will also record the use of the apps at week 24."
88943217|NCT05271006|No Intervention|Waitlist control group|"Weeks 1 - 12:~For the 12 weeks of the study, participant will be asked to continue their typical, pre-study daily and weekly routine, maintaining the physical activity he/she was completing before the start of the study.~Every two weeks, the participant will receive a survey to complete.~Week 24:~• At the end of the first 12 weeks that he/she have access to the suite of apps (i.e., 24 weeks following their randomization to the waitlist control group), participant will receive a check-in email with the final survey to complete."
89462493|NCT03657017|Other|PET/MR|Patients are examined with PET/MR.
88943218|NCT05265806|Experimental|Intranasal oxytocin|Participants will be randomly assigned to the administration of oxytocin intranasal spray (24 IU).
88943219|NCT05265806|Experimental|Oral oxytocin|Participants will be randomly assigned to the administration of oxytocin lingual spray (24 IU).
88943220|NCT05265806|Placebo Comparator|Placebo|Participants will be randomly assigned to the administration of placebo.
89462494|NCT02908841|Other|Control|30 patients randomized to the control group and will receive standard of care. Control patients will be managed with direct compression with gauze pads or laparotomy pads for four minutes. If hemostasis is not achieved by compression after four minutes, the source and rate of bleeding will be reevaluated and management will be determined by the surgeon. If the surgeon uses SurgicelSnow to achieve hemostasis at some point after 4 minutes, the patient will be included in the control group, but the data will be and flagged for the analysis. If failure of hemostasis at 4 minutes with an estimated loss of ≥25 cc/min, patient will be managed as per judgment of surgeon. Persistent bleeding at the 10 minute observation point will be treated as per the surgeon's judgment.
88943221|NCT05256238|Experimental|usual supportive care + comprehensive supervised exercise program (CSEP)|
88943222|NCT05256238|No Intervention|usual supportive care|
89501878|NCT03530293|Experimental|Pre-randomization Valbenazine|Participants received valbenazine once daily for up to 12 weeks, depending on if and when randomization occured. The starting dose was 20 mg for participants <50 kg at baseline and 40 mg for participants ≥50 kg at baseline, and could be escalated in increments of 20 mg every 2 weeks to a maximum of 60 mg for participants <50 kg and 80 mg for participants ≥50 kg to achieve an optimal dose of valbenazine for each participant.
89462495|NCT02908841|Other|Treatment|"30 patients randomized to the treatment group will receive Surgicel Snow. For patients with qualifying bleeding (rated on initial evaluation as at least mild) who have been randomized to receive Surgicel Snow, a single thin layer of dry Surgicel Snow will be applied over the area of bleeding and positioned firmly in direct contact to the areas of bleeding with blunt surgical instruments. Surgicel Snow will be left in the cavity to be absorbed. Dry gauze will not be placed over the material. No adjuncts will be added to the enhance hemostasis, but patients with small arteriolar bleeding will have pressure maintained on the bleeding site for 60 seconds. Hemostatic failure at 4 minutes will be reassessed for rate of blood loss and if the rate of loss is estimated at less than 25 cc per minute, additional observations will be made at 7 and 10 minutes."
89462496|NCT04706559|Experimental|Group A (Interventional group)|Along with below mentioned conventional treatment, the participants in group A (i.e. Interventional group) will receive conventional treatment of AD for a short duration along with probiotics for 8 weeks. One probiotic sachet twice a day will be prescribed. A sachet of 2 grams containing 1.25 billion cells per gram of 4 strains (Lactobacillus rhamnosus, Lactobacillus acidophilus, Bifidobacterium longum, and Saccharomyces boulardii) will be used. The child will receive a total of 5 billion cells of probiotics per day.
89462497|NCT04706559|Active Comparator|Group B (Conventional group)|All patients (i.e. in both arms) with atopic dermatitis will be prescribed emollients and cleanser as a part of routine skin care. Topical corticosteroid (i.e. Fluticasone 0.05% cream) and topical calcineurin inhibitor (tacrolimus 0.1% ointment) for sensitive areas like periorbital regions, flexures and face, will be given once daily. All patients will be given an oral antihistamine (syrup/ tablet cetirizine 0.3mg/kg) at night. It is referred to as conventional treatment.
89462498|NCT04457037|Experimental|MSC|Patients with trophic ulcers received standard treatment and MSC
89462499|NCT04456803|Experimental|Ferric citrate tablet|Ferric citrate arm will receive ferric citrate tablets three times a day with each meal.
89462500|NCT04456803|Active Comparator|Sevelamer carbonate tablet|Sevelamer carbonate arm will receive sevelamer carbonate tablets three times a day with each meal.
89462501|NCT02909153|Experimental|single dose of Triferic in the peritoneal dialysis solution|The patient will receive a single dose of Triferic in the peritoneal dialysis solution (IP) during a long (12 hour) peritoneal dialysis dwell. Each Cohort will receive a different ascending IP dose ( 5 mg/L, 12.5 mg/L, 20 mg/L). Blood samples will be drawn periodically over a 12 hour period for analysis.
89462502|NCT02909153|Experimental|single IV dose of Triferic 6.6 mg over a 4 hour period|The patient will receive a single 6.6 mg intravenous (IV) dose of Triferic in the over a 4 hour period. All Cohorts will receive the same IV dose. Blood samples will be drawn periodically over a 12 hour period for analysis.
89462503|NCT02522949|Active Comparator|ColdZyme|ColdZyme® mouth spray. Treatment (6 doses per day) will be applied for 11 days from the day of inoculation.
89462504|NCT02522949|Placebo Comparator|Placebo|Sugar based mouth spray manufactured to mimic ColdZyme® mouth spray. Treatment (6 doses per day) will be applied for 11 days from the day of inoculation.
89462505|NCT02908529|Placebo Comparator|Placebo|Placebo 2 hours before bedtime
89462506|NCT02908529|Active Comparator|Combination product of Atomoxetine and Oxybutynin|Combination product of Atomoxetine 80 mg and Oxybutynin 5 mg 2 hours before sleep
89462507|NCT04456725|Active Comparator|Control|Usual care group
89462508|NCT04456725|Experimental|Intervention|Intensive management utilizing longitudinal patient tracking, proactive outreach, multidisciplinary action planning and careful outcomes monitoring.
89462509|NCT04989543|Other|healthy population|"Interventions: vaginal swabs:~Nugent scores,~cytobacteriological examination (in particular to determine the Clue Cells)~evaluation of the vaginal microbiota.~On receipt of the Nugent score results, the doctor will confirm whether or not the patient is included in one of the two arms under study:~healthy population~pathological population with bacterial vaginosis"
89462510|NCT04989543|Other|pathological population|"Interventions: vaginal swabs:~Nugent scores,~cytobacteriological examination (in particular to determine the Clue Cells)~evaluation of the vaginal microbiota.~On receipt of the Nugent score results, the doctor will confirm whether or not the patient is included in one of the two arms under study:~healthy population~pathological population with bacterial vaginosis"
89462511|NCT02443181|Experimental|Activa PC+S|Patients will be implanted with standard DBS electrodes for treatment of essential tremor, at the Vim nucleus of the thalamus, and an additional subdural electrode array overlying hand motor cortex.. The patient will receive standard of care programming for thalamic stimulation for essential tremor. During research study visits, implementation and evaluation of closed-loop DBS using the PC+S system will be performed.
89462512|NCT03656861||Athletes|122 were athletes (41 females and 81 males). Of the 41 female athletes, 32 were endurance athletes, and 9 strength athletes. From 81 male athletes, 56 were endurance athletes, and 25 were strength athletes.
89462513|NCT03656861||Non-athletes|29 were non-athletes (14 females and 15 males)
89462514|NCT03130803|No Intervention|Baseline|9 hour sleep opportunity at habitual sleep/wake times for 14 days at home and 1 day in lab repeated for visit 1 and visit 2
89462515|NCT03130803|Experimental|Insufficient Sleep|2 days with 5 hour sleep opportunities immediately following baseline on both visit 1 and visit 2.
89462516|NCT02984267|Experimental|Ultrasound Group|The interventional group that will have their spine evaluated by ultrasound prior to epidural placement
89462517|NCT02984267|Other|Palpation Group|The control group that will have their epidural placed in the usual fashion based on palpation
88943223|NCT05255081|Experimental|Treatment Arm|Application of AdSpray™ over all organs under the laparotomy incision at the end of operation
88943224|NCT05255081|Placebo Comparator|Control Arm|Spray with saline would be applied to organs under incision
88943225|NCT05243017|Experimental|Cohort 1 (Low Dose of AMT-130)|Low dose AMT-130 (6 × 10^12 gc/subject)
88943226|NCT05243017|Experimental|Cohort 2 (High Dose of AMT-130)|High dose AMT-130 (6 × 10^13 gc/subject)
88943227|NCT05242419|Experimental|Treatment group|Huperzine A Injection
88943228|NCT05242419|Placebo Comparator|Control group|0.9% Sodium Chloride Injection
88943229|NCT05241301|Other|One to one interviews with family carers of older people from Turkish and Moroccan origin|one to one interviews
89462518|NCT03130725|Experimental|Amalgam sealant|Amalgam sealant placed on incipient enamel caries and deep enamel fissures.
89462519|NCT03130725|Active Comparator|Resin based sealant|Resin based sealant placed on incipient enamel caries and deep enamel fissures.
89462520|NCT03469557|Experimental|Esophageal Squamous Cell Carcinoma (ESCC)|
89462521|NCT03469557|Experimental|Gastric (GC) and Gastroesophageal Junction (GEJ) Carcinoma|
89462522|NCT04466553||NICO BrainPath™ Patients|"50 patients will be enrolled in Group A NICO BrainPath™ system.~The NICO BrainPath™ System has been proposed to reduce high morbidity and mortality associated with ICH through minimally invasive clot evacuation. Previous, single-center trials concluded evacuation of ICH using the BrainPath™ system as being safe and effective. Additionally, previous studies concluded that lesser ICH removal was correlated with mortality benefit and that the NICO BrainPath™ system approach was shown to be safe and effective with a high rate of clot evacuation and functional independence. This system warrants further research because of the need to optimize clinical outcome in these patients and to better define the role of hematoma evacuation in the care of these patients."
89462523|NCT04466553||Standard of Care|50 patients will be matched retrospectively of similar diagnosis, undergoing standard of care (e.g. no surgical intervention). These patients will be matched to the surgical patients based on age, gender, and location of hemorrhage.
89462524|NCT03109587|Active Comparator|Vivomixx (Visbiome)|2 packets of probiotics by mouth/day for 12 weeks
89462525|NCT03109587|Placebo Comparator|Placebo|identical in appearance, but without probiotics.
89462526|NCT03470415||Group A|Patients with type 2 diabetes milletus with normoalbuminuria.
89462527|NCT03470415||Group B|Patients with type 2 diabetes milletus with microalbuminuria.
89462528|NCT03470415||Group C|Patients with type 2 diabetes milletus with macroalbuminuria.
89462529|NCT02675751|Experimental|wavefront-guided PRK with iDesign|wavefront-guided PRK for treatment of myopic refractive errors based upon measurements obtained with the iDesign System using the STAR S4 IR laser
89462530|NCT03109665||Glaucoma within NICOLA|NICOLA study Participants Eligible for GwNICOLA by meeting inclusion criteria
89462531|NCT02643381|Experimental|Etomidate|Patients randomized to this group will receive etomidate immediately prior to emergency endotracheal intubation.
88943230|NCT05232227|Active Comparator|Standard regimen Primaquine single dose over 14 days|The standard regimen consists of administering Chloquine Phosphate 10 mg/kg on days 1 and 2, and 5 mg/kg on day 3 plus Primaquine Phosphate 3.5 mg/kg divided over 14 days (0.25mg/kg/day)
88943231|NCT05232227|Experimental|Treatment regimen Primaquine double dose over 14 days|The treatment regimen consists of administering Chloquine Phosphate 10 mg/kg on days 1 and 2, and 5 mg/kg on day 3 plus Primaquine Phosphate 7 mg/kg divided over 14 days
89462532|NCT02643381|Experimental|Ketamine|Patients randomized to this group will receive ketamine immediately prior to emergency endotracheal intubation.
89462533|NCT02611713||Arm A: Participants with Advanced Parkinson's Disease|Participants who along with their physicians have elected for treatment with Duodopa/Duopa and are prescribed according to the local product label and reimbursement guidelines for their participating countries.
89462534|NCT02611713||Arm B: Participants with Advanced Parkinson's Disease|Participants who along with their physicians have elected for treatment with Duodopa/Duopa and are prescribed according to the local product label and reimbursement guidelines for their participating countries. Participants will be evaluated with a wearable device
89462535|NCT03469479|Experimental|Resection plus HAIC with FOLFOX|Patients receive 4 times of neoadjuvant hepatic arterial infusion chemotherapy with FOLFOX and hepatic resection
89462536|NCT03469479|Active Comparator|Resection|Patients receive hepatic resection without neoadjuvant hepatic arterial infusion chemotherapy
89462537|NCT02974855|Experimental|PF-06741086 (Cohort 1)|
89462538|NCT02974855|Experimental|PF-06741086 (Cohort 2)|
89462539|NCT02974855|Experimental|PF-06741086 (Cohort 3)|
89462540|NCT02974855|Experimental|PF-06741086 (Cohort 4)|
89462541|NCT04473651|Experimental|Part A: Single dose of Lu AG06479 or Placebo|
88943232|NCT05225363|Experimental|Treatment (TAG72-CAR T cells)|Patients receive fludarabine IV and cyclophosphamide IV on days -5 to -3. Patients receive TAG72-CAR T cells IP on day 0.
88943233|NCT05221229||Study Cohort|A total of 30 patients will be included in the study group after screening of inclusion and exclusion criteria. Patients will have upstream risk factors assessed at the clinic consultation and offered risk factor optimization advice. In addition, they will received daily Liraglutide injections for 13 weeks before and 52 weeks after ablation.
88943234|NCT05215587|No Intervention|Medical Therapy|Patients will be treated with standard medical therapy, i.e., antihypertensives, pulse-rate regulators, and pain medication.
89462542|NCT04473651|Experimental|Part B: Repeated dose of Lu AG06479 and Food interaction|"Sequence B1: Fed - Fasting - Fasting~Sequence B2: Fasting- Fed - Fasting~Sequence B3: Fasting- Fasting - Fed"
89462543|NCT04328961|Placebo Comparator|Ascorbic Acid|Ascorbic acid 500 mg orally daily for 3 days, then 250 mg orally daily for 11 days
89462544|NCT04328961|Experimental|Hydroxychloroquine|Hydrochloroquine 400 mg orally daily for 3 days, then 200 mg orally daily for an additional 11 days
89462545|NCT04228575|Experimental|Extended Contact|Clients in the Extended Contact condition will be asked at the 6 week mark if they like they can extend their treatment and receive up to 12 weeks of support. They will be informed that this may be helpful if they feel they have fallen behind in reviewing of the materials, if they would like to receive support while they work on supplementary resources or if they would like extended support while they work on core lessons. If they would like additional support, participants will answer questions presented on the website about their desire for this additional support what they would like to focus on during this time. Those clients who indicate that they would like this extended support will automatically have their therapists check-in with them for up to 12 weeks. Those that do not request the additional support will end treatment as planned at the end of 8 weeks.
89462546|NCT04228575|Experimental|8 Week ICBT no Booster|In the standard condition, clients will receive 8 weeks of therapist support. They will not be given the option to extend their treatment and support to 12 weeks. The booster course will not be offered in this condition.
89462547|NCT04228575|Experimental|Extended Contact with Booster|"Clients in the Extended Contact condition will receive an email at the 6 week mark letting them know that they if they like they can extend their treatment and receive up to 12 weeks of support. At week 6, clients will answer questions on the website about whether they would like this additional support or not and what they would like to focus on during this time. Clients who indicate they would like this extended support will automatically have their therapists check-in with them for up to 12 weeks.~They will also be told that at 16 weeks they will have access to a booster session (online materials that go over core skills such as thought challenging, deep breathing, behavioural activation, and graded exposure). At 16 weeks, they will be sent an email reminder to log in for the booster course. The therapist will send a supportive email to the client offering to assist with any challenges the client reports in the check-in questionnaire by email or phone call over the next 2 weeks."
89501879|NCT03530293|Placebo Comparator|Randomized Placebo|Participants received placebo (matching valbenazine) once daily from randomization (Week 8, 10, or 12) through Week 36. Randomization into this arm occurred after treatment with valbenazine once daily through randomization.
88943235|NCT05215587|Active Comparator|Stent Therapy|Patients will be treated with both standard medical therapy, in addition to placement of a thoracic endovascular aortic repair stent graft.
88943236|NCT05211063|Experimental|Saffron extract (Crocus sativus)|Daily intake of one tablet for 42 days.
88943237|NCT05211063|Placebo Comparator|Placebo|Daily intake of one tablet for 42 days. This tablet is organoleptically indistinguishable from the experimental tablet.
88943238|NCT05210231|Experimental|Active anodal tDCS|The direct electric current will be applied through a pair of sponges humidified with saline solution (150 mMols of NaCl diluted in water Milli-Q) on the electrodes (35 cm2). The electrodes (anode and cathode) will be connected to a continuous electric stimulator (Model: Microestim Foco Research, Brand: NKL, Souza Cruz, Brusque - SC, Brazil), with one energy battery (9 V) and will be mounted in accordance with the International 10-20 EEG System. For anodal polarity stimulation over the left TC, the anodal electrode will be placed over the scalp on the T3 area located at 40% of the distance on the left from the Cz point. The cathode electrode will be placed over the contralateral supraorbital area (Fp2). Thereafter, a constant electric current of 2 mA will be applied for 20 min.
88943239|NCT05210231|Sham Comparator|Sham anodal tDCS|The direct electric current will apply through a pair of sponges humidified with saline solution (150 mMols of NaCl diluted in water Milli-Q) on the electrodes (35 cm2). The electrodes (anode and cathode) will be connected to a continuous electric stimulator (Model: Microestim Foco Research, Brand: NKL, Souza Cruz, Brusque - SC, Brazil), with one energy battery (9 V) and will be mounted in accordance with the International 10-20 EEG System. For the sham condition, the electrodes will be placed at the same positions as for the anodal tDCS. However, the stimulator will turn off after 30 s of stimulation. As a result, subjects will report the same sensory feelings from the beginning of the real tDCS conditions, specifically itching and tingling feelings on the scalp for the first few seconds of tDCS, but not thereafter, whether or not the stimulation will continue or stop.
88943240|NCT05203120|Experimental|Proton Arm|All patients in the study will receive proton therapy with 67.5 Gray/15 fractions(fx) /5fx per week .
88943241|NCT05195840|Experimental|Personalized Treatment for Eating Disorders|Participants will complete 3 sessions of education about the treatment while completing 2 weeks of mobile application questions. After completion of treatment education and mobile application questions, participants will complete 17 sessions of personalized treatment for eating disorders.
88943242|NCT05195840|Active Comparator|Cognitive Behavioral Therapy for Eating Disorders|Participants will complete 3 sessions of education about the treatment while completing 2 weeks of mobile application questions. After completion of treatment education and mobile application questions, participants will complete 17 sessions of Cognitive Behavioral Therapy for Eating Disorders.
88943243|NCT05194800|Experimental|Unilateral upper extremity amputees|Unilateral upper extremity amputees suffering from chronic phantom limb pain > 1 yr will be recruited from a hospital based outpatient Physical Medicine and Rehabilitation Amputee Clinic at UAB.
88943244|NCT05189106|Experimental|Baricitinib|Baricitinib 2mg administered by mouth once daily for the first 8 weeks, followed by baricitinib 4mg administered by mouth once daily for 16 weeks.
88943245|NCT05184842|Experimental|Decitabine/Venetoclax (Single Arm)|Administration: Decitabine is reconstituted with 5 ml sterile water to facilitate subcutaneous administration. Decitaboine is given by subcutaneous injection. Venetoclax is taken as a tablet prepared by patients pharmacy. Venetoclax is given at a dose of 400 mg po once per week concurrently with the Decitabine dose (+/- 1 day allowed ).
88943246|NCT05169333||Group 1|Participants attending cardiology department, hypertension or outpatient clinics.
89462548|NCT04228575|Experimental|8 week ICBT with Booster|Clients in the booster condition will be told that at 16 weeks they will have access to a booster session (online materials that go over core skills such as thought challenging, deep breathing, behavioural activation, and graded exposure). At 16 weeks, they will be sent an email reminder to log in for the booster course. The therapist will send a supportive email to the client offering to assist with any challenges the client reports in the check-in questionnaire by email or phone call over the next 2 weeks.
89462549|NCT03653533|Other|MiniMed™ 640G alone|MiniMed™ 640G (insulin pump) is used without Captor CGM Enlite® (captor) at phase 1 and phase 4 of the study. ADDQoL, BIPQ and HADS questionnaire are performed.
89462550|NCT03653533|Other|MiniMed™ 640G + Captor CGM Enlite®|insulin pump coupled with captor without SmartGuard® function tat phase 2 of the study. ADDQoL, BIPQ and HADS questionnaire are performed.
89462551|NCT03653533|Other|MiniMed™ 640G + Captor + SmartGuard®|insulin pump + captor + SmartGuard® function are used at phase 3 of the study. ADDQoL, BIPQ and HADS questionnaire are performed.
89462552|NCT04172025||Patients with colonization or infections with a pathogen|All patients with either colonisations or infections with either a bacterial or a viral pathogen, where whole genome sequencing data and available minimal epidemiological, demographic and clinical data
89462553|NCT03653377||Patients with self-administered questionnaire|
89462554|NCT00455403|Experimental|Chloroquine Subjects|Participants will receive 80 mg of chloroquine on a daily basis.
89462555|NCT00455403|Placebo Comparator|Placebo Subjects|Participants will receive a placebo comparator tablet on a daily basis.
89462556|NCT04061031|Experimental|Parent-Child Interaction Therapy|
89462557|NCT04061031|Active Comparator|Child-Centered Therapy with Parent Education|
89462558|NCT04397367|Experimental|Ruxolitinib10 mg twice a day combined with Corticosteroids|Newly diagnosed acute GVHD patients started therapy with methylprednisolone of 1 mg/kg/day after diagnosis. Ruxolitinib was administered at a median of 2 days after the use of methylprednisolone. Participants began oral administration of ruxolitinib at 10 mg twice a day. Ruxolitinib was subsequently tapered due to the resolution of acute GVHD after three months of therapy. A dose-tapering schedule that would discontinue ruxolitinib in three months was recommended.
89462559|NCT04397367|Experimental|Ruxolitinib5 mg twice a day combined with Corticosteroids|Newly diagnosed acute GVHD patients started therapy with methylprednisolone of 1 mg/kg/day after diagnosis. Ruxolitinib was administered at a median of 2 days after the use of methylprednisolone. Participants began oral administration of ruxolitinib at 5 mg twice a day. Ruxolitinib was subsequently tapered due to the resolution of acute GVHD after three months of therapy. A dose-tapering schedule that would discontinue ruxolitinib in three months was recommended.
89462560|NCT04397367|Experimental|Ruxolitinib5 mg once a day combined with Corticosteroids|Newly diagnosed acute GVHD patients started therapy with methylprednisolone of 1 mg/kg/day after diagnosis. Ruxolitinib was administered at a median of 2 days after the use of methylprednisolone. Participants began oral administration of ruxolitinib at 5mg once a day. Ruxolitinib was subsequently tapered due to the resolution of acute GVHD after three months of therapy. A dose-tapering schedule that would discontinue ruxolitinib in three months was recommended.
89462561|NCT04397367|Experimental|Ruxolitinib 2.5 mg twice a day combined with Corticosteroids|Newly diagnosed acute GVHD patients started therapy with methylprednisolone of 1 mg/kg/day after diagnosis. Ruxolitinib was administered at a median of 2 days after the use of methylprednisolone. Participants began oral administration of ruxolitinib at 2.5 mg once a day. Ruxolitinib was subsequently tapered due to the resolution of acute GVHD after three months of therapy. A dose-tapering schedule that would discontinue ruxolitinib in three months was recommended.
89462562|NCT05160909||Beach Chair|Patient positioned in beach chair position during arthroscopic shoulder stabilization
89201884|NCT00666588|Experimental|Bortezomib 1.3 mg/m2-assess feasibility high anthracycline exp|Bortezomib 1.3 mg/m2 to assess feasibility in high prior anthracycline exposure. Patients receive etoposide IV (150 mg/m2/dose) over 1 hour on days 1-5, high-dose cytarabine IV (1000 mg/m2/dose) over 1 hour twice daily on days 1-5, and bortezomib IV (1.3 mg/m2) on days 1, 4, and 8. All patients receive intrathecal cytarabine (30 mg - age 1-1.99 years, 50 mg - age 2-2.99 years, 70 mg - age ≥ 3 years) prior to courses 1 and 2. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity (dose-finding phase closed as of 10/10).
89462563|NCT05160909||Lateral decubitus|Patient positioned in lateral decubitus position during arthroscopic shoulder stabilization
89462564|NCT05160831|Experimental|Human umbilical cord mesenchymal stem cells|Human umbilical cord mesenchymal stem cells injection is applied for knee OA patients.
89462565|NCT03471897||RCC|Patients with pathologically confirmed diagnosis of RCC
89462566|NCT03471897||Controls|Subjects self-reported as healthy
89462567|NCT04394169|Experimental|Intervention arm|The intervention is a program that includes early patient care, therapeutic education, and psychological intervention. It will be performed through three medical visits and a psychological intervention that requires seven face-to-face sessions.
89462568|NCT04394169|No Intervention|Standard care arm|Standard medical practice: patient follow-up is carried out by their referring physicians (primary care physicians or specialists) who are outside the study.
89462569|NCT03470337|Experimental|Phlogenzym|Treatment with German licensed drug Phlogenzym (6 tablets/day)
89462570|NCT03470337|Placebo Comparator|Placebo|Placebo equates Phlogenzym but without active ingredients
89462571|NCT04162275|Experimental|pre-trial, fasting administration|2 cases were given 150mg Finamine tablets（pre-trial，fasting administration）
89462572|NCT04162275|Experimental|pre-trial,after high fat meal|2 cases were given 150mg Finamine tablets (pre- trial，after high fat meal)
88943247|NCT05169333||Group 2|Participants who are recruited prospectively, during their clinically indicated CT scan, and they are followed-up prospectively for clinical endpoints; A follow-up CCTA at least 6 months later will be offered to a subgroup of these patients, to assess disease progression.
88943248|NCT05169333||Group 3|Individuals where at least 6 months have elapsed from previous CCTA will undergo repeat CCTA scan and enter prospective follow up for clinical endpoints.
89462573|NCT04162275|Placebo Comparator|formal trial-150mg|4 cases were given 150mg Finamine tablets 2 cases were given placebo
88943249|NCT05169333||Group 4|Cohort of consecutive patients who have undergone clinical CTAs or unenhanced CT chest, abdomen and pelvis in the past, linking the index CT scan with prospective outcomes collection already accumulated.
88943250|NCT05149976||Normal group|"A person judged normal among VFSS (video fluoroscopic swallowing study) examiners~Normal subjects without symptoms of dysphagia"
88943251|NCT05149976||Residue Group|- As a result of VFSS (video fluoroscopic swallowing study), the subjects who have residues left around the pharynx or airway
88943252|NCT05149976||Aspiration Group|- VFSS (video fluoroscopic swallowing study) test result, the subjects who have aspiration in the airway
88943253|NCT05140018||Kidney Transplant Recipients with an immunological high risk for ABMR|"Kidney transplant recipients ≥18 years old~About to receive a post mortal or living donor renal transplant~Immunological high risk for rejection~Luminex positive DSAs ; or~Retransplantation with repeated mismatch ; or~Husband to wife donation (after fathering children); or~Offspring to mother donation"
88943254|NCT05140018||Living Kidney Donors|Participants who are about to donate their kidney to a Recipient with a high immunological risk (as described above)
88943255|NCT05135650|Experimental|Prevention (Sotrovimab)|Patients receive sotrovimab IV over 30 minutes within 1-7 days prior to the start of pre-transplant conditioning. Patients also undergo blood and nasal swab sample collection throughout the trial.
88943256|NCT05121688|Experimental|Tele-physiotherapy group|"Allocated participants to intervention group will receive 18 Tele-physiotherapy sessions (three sessions per week, with 30 min. of duration) during six weeks. In this sessions, participants will carry out a tele-face-to-face multimodal physical therapy program based on health education, respiratory exercises, physical training exercises, aerobic exercises and functional mobility.~This group will receive conventional medical care too."
88943257|NCT05121688|Active Comparator|Control group|"No Physical therapy intervention. Allocated participants to control group will receive one consultation session by the physiotherapist, but will not received any physical Therapy treatment. At this session, patients will be educated about how to perform their daily activities, breathing exercises, walking. Conventional medical care will be provided.~In the control group, the same measurements will be made at the same times as the subjects in the intervention group. Once the study is finished, the researcher agrees to carry out the intervention to the patients in the control group."
88943258|NCT05111990||Maternal pre-gestational BMI 18.5<25|
88943259|NCT05111990||Maternal pre-gestational BMI 25<30|
88943260|NCT05111990||Maternal pre-gestational BMI >30|
88943261|NCT05111834|Experimental|Supervised resistance training plus nutritional endorsement|"The study participants receive a progressive moderate-to-high-intensity resistance training program (a 60 minutes twice a week for a period of 24- weeks) plus nutritional endorsement. The training will take place at the NCT Heidelberg, in regional qualified facility centers or online under supervision and guidance of experienced exercise therapists.~The progressive resistance program for participants who train at facility centers comprises of 6 machine-based exercises, each performed 2 sets,12 repetitions of 60%-80% of 1 RM. For participants who train online, the training load will be defined during the introductory training session with the aim of choosing a load which to perform two times 12 repetitions. The program targets major upper and lower body muscle groups (with emphasis on the lower extremities). In addition, patients receive nutritional advice/diet modification, depending on their individual requirements and/or changes in general condition."
88943262|NCT05111834|Active Comparator|Nutritional endorsement only|Patients receive nutritional advice/diet modification, depending on their individual requirements and/or changes in general condition.
88943263|NCT05096936|Experimental|Pilates PBMT|This group will receive training in the Pilates method associated with the effective application of photobiomodulation.
88943264|NCT05096936|Experimental|Pilates|This group will receive training in the Pilates method associated with the not effective (placebo) application of photobiomodulation.
88943265|NCT05096936|Placebo Comparator|PBMT|This group will receive effective application of photobiomodulation and will not perform the pilates method training
88943266|NCT05092100|Experimental|Behavioral|This arm will use behavioral procedures to test memory for different visual stimulus conditions.
89462574|NCT04162275|Placebo Comparator|formal trial-300mg|6 cases were given 300mg Finamine tablets 2 cases were given placebo
89462575|NCT04162275|Placebo Comparator|formal trial-600mg|6 cases were given 600mg Finamine tablets 2 cases were given placebo
88943267|NCT05092100|Experimental|fMRI pattern similarity|This arm will use fMRI and behavioral methods to test memory for different visual stimulus conditions.
88943268|NCT05092100|Experimental|eye tracking|This arm will use eye tracking and behavioral methods to test memory for different visual stimulus conditions.
88943269|NCT05082844|Experimental|Evaluation of clinical and radiographic findings after surgical treatment for cuff rotator lesion|Evaluation of the clinical-radiological results from the case series of patients surgically treated for cuff rotator lesions from 2009 to 2020 at the Shoulder-Elbow Department . At 12 months the result is considered stabilized, so we will proceed to collect all case histories that have passed this follow-up period.
89462576|NCT04162275|Placebo Comparator|formal trial-1200mg|6 cases were given 1200mg Finamine tablets 2 cases were given placebo
89462577|NCT03470259|Experimental|EMI-137 0.09mg/kg administration|"Three patients will be once administered with EMI-137 0.09 mg/kg. Thereafter the patient will be observed for an hour. Two hours after injection surgery will be performed and only ex-vivo imaging and spectroscopy will be performed of thyroid glands and lymph nodes with a multispectral Near Infrared Fluorescence (NIRF) camera system and spectroscopy system.~After interim analysis will be decided if this dosage group has an adequate tumor-to-background ratio and dose extension will be performed."
89462578|NCT03470259|Experimental|EMI-137 0.13mg/kg administration|"Three patients will be once administered with EMI-137 0.13 mg/kg. Thereafter the patient will be observed for an hour. Two hours after injection surgery will be performed and only ex-vivo imaging and spectroscopy will be performed of thyroid glands and lymph nodes with a multispectral Near Infrared Fluorescence (NIRF) camera system and spectroscopy system.~After interim analysis will be decided if this dosage group has an adequate tumor-to-background ratio and dose extension will be performed."
89462579|NCT03470259|Experimental|EMI-137 0.18mg/kg administration|"Three patients will be once administered with EMI-137 0.18 mg/kg. Thereafter the patient will be observed for an hour. Two hours after injection surgery will be performed and only ex-vivo imaging and spectroscopy will be performed of thyroid glands and lymph nodes with a multispectral Near Infrared Fluorescence (NIRF) camera system and spectroscopy system.~After interim analysis will be decided if this dosage group has an adequate tumor-to-background ratio and dose extension will be performed."
88943270|NCT05073822|Other|standard of care Immunosuppression (SOC-IS) therapy|"serum tacrolimus level : target tacrolimus levels 8-12ng/ml in the first 3 months target tacrolimus levels 6-8ng/ml in months 4-12 target tacrolimus level 4-8ng/ml after the 1st year~Mycophenolate mofetil dose :~2g/day for 1 month 1.5mg/day between months 2-12~1g/day after the 1st year"
88943271|NCT05073822|Other|minimised immunosuppression (Min-IS) therapy|"serum tacrolimus level : target tacrolimus levels 6-8ng/ml for first 3 months target tacrolimus levels 4-8ng/ml in months 4-12.~Mycophenolate mofetil dose:~1.5g/day in the first month~1g/day until 1 year post-transplantation"
88943272|NCT05047952|Experimental|Vortioxetine|"Participants aged 18-64 years: start at 10 mg vortioxetine once daily for the first 2 weeks, then dosed up to 20 mg vortioxetine once daily for weeks 2-8.~Participants aged 65+ years: start at 5 mg vortioxetine once daily for the first 2 weeks, then dosed up to 10 mg vortioxetine once daily for weeks 2-8."
88943273|NCT05047952|Placebo Comparator|Placebo|Placebo capsule taken once daily for weeks 0-8.
88943274|NCT05028660||Cohort 1|At least 76 patients with MIBC and elected for NAC
88943275|NCT05009680|Experimental|Part 1 GB1211, Single Dose (Child Pugh B)|GB1211 is a galectin-3 inhibitor an orally available small molecule anti-fibrotic. It is administered orally twice a day.
88943276|NCT05009680|Experimental|Part 1 GB1211 Healthy Matched Participants, Single Dose|GB1211 is a galectin-3 inhibitor an orally available small molecule anti-fibrotic. It is administered orally twice a day.
88943277|NCT05009680|Experimental|Part 2 GB1211 Multiple Dose, Twice a day (Child Pugh B)|GB1211 is a galectin-3 inhibitor an orally available small molecule anti-fibrotic. It is administered orally twice a day.
88943278|NCT05009680|Placebo Comparator|Part 2 Placebo, Twice a day (Child Pugh B)|Placebo is administered twice daily
88943279|NCT05009680|Experimental|Part 1 GB1211, Single Dose (Child Pugh C)|Part 1 GB1211 Healthy Matched Participants, Single Dose
88943280|NCT05009680|Experimental|Part 3 GB1211 Healthy Matched Participants, Single Dose|Part 1 GB1211 Healthy Matched Participants, Single Dose
88943281|NCT05001828|Experimental|Previously Treated AML|Previously treated AML based on the revised 2017 European LeukemiaNet (ELN) criteria with age at least 18 years, and having ≥10% blasts in bone marrow or peripheral blood
88943282|NCT05001828|Experimental|Untreated AML With High Risk Features|Untreated AML per ELN criteria with high risk features, or age ≥ 65 years and ineligible for intensive chemotherapy because of older than 75 years, cardiac disease or prior anthracycline use or high probability of treatment-related mortality
88943283|NCT05000866|No Intervention|CHTC as usual|Participants complete the standard Couples HIV Testing and Counseling session (CHTC).
88943284|NCT05000866|Active Comparator|CHTC and communications skills training video|Participants complete the standard Couples HIV Testing and Counseling session and also watch a communication skills training video together.
88943285|NCT05000866|Active Comparator|CHTC and substance use module|Participants complete the standard Couples HIV Testing and Counseling session and also complete a substance use module together.
88943286|NCT05000866|Active Comparator|CHTC, communications skills training and substance use module|Participants complete the standard Couples HIV Testing and Counseling session and watch a communication skills training video and complete a substance use module together.
88943287|NCT04998734||Chronic pain|Patients with chronic non-cancer pain referred to secondary and tertiary care
88943288|NCT04997577|Experimental|Auditory training paradigm|Participants perform speech-in-noise perception tasks with real-world scenarios.
88943289|NCT04997577|Experimental|Auditory-cognitive training paradigm|Participants perform speech-in-noise perception tasks with real-world scenarios. A short-term memory component is added to the training paradigm to make the task more engaging and challenging.
88943290|NCT04991792|Experimental|Standard Infant Formula with synbiotics (CS-born)|CS born infants, randomized to receive infant formula with synbiotics
88943291|NCT04991792|Experimental|Standard Infant Formula with prebiotics (CS-born)|CS born infants, randomized to receive infant formula with prebiotics
88943292|NCT04991792|Active Comparator|Control Group 1: Standard Infant Formula (CS-born)|CS born infants, randomized to receive standard infant formula without synbiotics
88943293|NCT04991792|Active Comparator|Control Group 2 : Standard Infant Formula (VD-born)|VD born infants, receiving standard infant formula without synbiotics (self-selected for formula-feeding = non-randomized)
88943294|NCT04991792|No Intervention|Reference Group 1: Breastfed (CS-born)|CS-born infants, receiving exclusive breast-feeding with mother's own breast milk (non-randomized)
88943295|NCT04991792|No Intervention|Reference Group 2: Breastfed (VD-born)|VD-born infants, receiving exclusive breast-feeding with mother's own breast milk (non-randomized)
88943296|NCT04989881|Experimental|Da Vinci Simulator|Participants will undergo a single session of training using the da Vinci Simulator
88943297|NCT04989881|Active Comparator|Laparascopic training box|Participants will undergo a single session of training using a laparoscopic training box
88956460|NCT05154760|Active Comparator|group videoconference|Pelvic floor muscle training, diaphragmatic breathing exercise, core strengthening exercise will continue for 8 weeks. Participants will be asked to practice the exercises at least 4 days in a week, and the program will be continued in the form of group interviews with video conference method once a week.
88956461|NCT05141006|Experimental|BOTOX|Participants will receive BOTOX on Day 1 and will be followed for at least 12 weeks in treatment period 1. An optional dose of BOTOX in Treatment 2 can be requested between Weeks 12 and 24.
89462580|NCT03470259|Experimental|EMI-137 0.045mg/kg administration|"If we have a excellent tumor to background ratio ((tumor fluorescence)/(surrounding tissue fluorescence)) in the 0.09 mg/kg group, we will de-escalate back to a 0.045 mg/kg group to evaluate TBR and reduce possible tracer toxicity in a thyroid cancer population with 90% 20 year survival.~Three patients will be once administered with EMI-137 0.045 mg/kg. Thereafter the patient will be observed for an hour. Two hours after injection surgery will be performed and only ex-vivo imaging and spectroscopy will be performed of thyroid glands and lymph nodes with a multispectral Near Infrared Fluorescence (NIRF) camera system and spectroscopy system.~After interim analysis will be decided if this dosage group has an adequate tumor-to-background ratio and dose extension will be performed."
89462581|NCT02979613|Experimental|TAF 25 mg|Double-blind (DB) phase: TAF 25 mg + TDF placebo for up to 53 weeks. Open-label extension (OLE) phase: TAF 25 mg for up to 52 weeks.
89462582|NCT02979613|Active Comparator|TDF 300 mg|DB phase: TDF 300 mg + TAF placebo for up to 50 weeks. OLE phase: TAF 25 mg for up to 52 weeks.
89462583|NCT03811665|Experimental|Stereotactic body radiation therapy (SBRT)|
89462584|NCT03811665|Active Comparator|Radiofrequency Ablation (RFA)|
89462585|NCT03469401||intervention|Adult patient (over 18 yr-old) admitted to the ICU for acute peritonitis with a peritoneal fl:uid sample obtained via surgery or radiological drainage
89462586|NCT04458129|Experimental|Polyethylene glycol treatment|Study participants will take a 3-month laxative treatment with polyethylene glycol for 3 months.
89462587|NCT03576261|Experimental|Preoperative echo + fluids|20 individuals investigated by preoperative transthoracic echocardiography. Preoperative colloid fluid bolus (Gelofusine, Fresenius Kabi AB, Sweden) 6 ml/kg lean body weight, is infused intravenously immediately before anesthesia induction.
89462588|NCT03576261|Active Comparator|Preoperative echo, control|20 individuals investigated by preoperative transthoracic echocardiography. No intravenous fluids are infused before anesthesia induction.
88943298|NCT04985422|Experimental|Experimental group: Smartphone-based daily ecological momentary intervention (EMI)|"The experimental group receives 4 weeks of smartphone-based daily EMI. Participants are prompted 6 times a day (with an interval of at least 30 minutes between each digital prompt), on a daily basis over the 4-week period. Within 15 minutes of the digital prompt, participants are to first complete a brief (1-2 minutes) momentary survey (ecological momentary assessment [EMA]), and subsequently select 1 out of 5 personalised intervention actions of interest to complete in the moment (time to complete spans from 1 minute to 5 minutes).~The interventions are brief simple behavioural actions (mostly 1-2 minutes, up to 5 minutes) which could be done in the moment. Simple action tasks include guided breathing, mindful walking, and mindful sound hearing (etc.).~Participants could also use the platform at any other times to redo intervention actions when preferred. Individualised reports for the EMI completed are provided."
88956462|NCT05141006|Placebo Comparator|Placebo|Participants will receive placebo on Day 1 and will be followed for at least 12 weeks in treatment period 1. An optional dose of BOTOX in Treatment 2 can be requested between Weeks 12 and 24.
88956463|NCT05140902|Experimental|Glioblastoma patients|glioblastoma patients with newly or enlarged enhancing lesion within 3 months after completing 6 weeks of adjuvant chemoradiation therapy
89462589|NCT03469323|Experimental|Nonintubated VATS succinylcholine|Nonintubated VATS using mini-dose succinylcholine in the beginning of open pneumothorax
89462590|NCT03469323|Placebo Comparator|Nonintubated VATS placebo|Nonintubated VATS not using succinylcholine in the beginning of open pneumothorax
89462591|NCT05160285|Experimental|Neoadjuvant nivolumab treatment arm|Nivolumab 360mg intravenous adminstration every 3 weeks
89501880|NCT03530293|Experimental|Randomized Valbenazine|Participants received their optimized dose of valbenazine once daily from randomization (Week 8, 10, or 12) through Week 36. Randomization into this arm occurred after treatment with valbenazine once daily through randomization.
89501881|NCT03516487|Experimental|SAD HV: SYNB1618 (1 x 10^10 CFU)|HV subjects receive a single oral dose of SYNB1618 (1 x 10^10 colony-forming units [CFU]) in a chilled buffered solution on Day 1 in the SAD study (Part 1).
89462592|NCT03652831|Active Comparator|Soft Tissues mobilization with Neural mobilization|"Soft Tissue Mobilization with Neural mobilization group will be assessed by spurling test and than will involved in treatment protocol i.e Cervical Traction, Hot packs, Post Isometric Relaxation Techniques and Neural mobilization Techniques which involve Median, Radial and Ulnar Nerve Mobilization.~Frequency for neural mobilization is 3 sets of 10 repetitions for each and duration of 15minute. Participant will be scheduled to attend 12 treatment session (3 sessions every week for 4 weeks, 50mints each session)"
89201885|NCT00666588|Experimental|Bortezomib 1.3 mg/m2-assess efficacy high anthracycline exp|Bortezomib 1.3 mg/m2 to assess efficacy in high prior anthracycline exposure. Patients receive etoposide IV (150 mg/m2/dose) over 1 hour on days 1-5, high-dose cytarabine IV (1000 mg/m2/dose) over 1 hour twice daily on days 1-5, and bortezomib IV (1.3 mg/m2) on days 1, 4, and 8. All patients receive intrathecal cytarabine (30 mg - age 1-1.99 years, 50 mg - age 2-2.99 years, 70 mg - age ≥ 3 years) prior to courses 1 and 2. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity
89201886|NCT00689390|Other|Participants from Boceprevir Studies|Participants who previously participated in treatment studies in which boceprevir was administered were subsequently enrolled in Part 1 of the current follow-up study P05063 (NCT00689390). Participants may have received boceprevir or control peginterferon plus ribavirin (PR) in the previous treatment study. No treatment was administered in the current follow-up study.
89462593|NCT03652831|Active Comparator|Soft Tissues mobilization without Neural mobilization|"Soft Tissue Mobilization with Neural mobilization group will be assessed by spurling test and than will involved in treatment protocol i.e Cervical Traction, Hot packs, Post Isometric Relaxation Techniques.~Participant will be scheduled to attend 12 treatment session (3 sessions every week for 4 weeks, 35mints each session)"
89462594|NCT03622099||The study group|As a routine work in adult critical care unit at Menoufia University hospital for patients with circulatory failure, A 100 ml bolus of Normal Saline Flush, 0.9% Injectable Solution was given to the patient over 1 minute through a central venous catheter or jugular cannula. For prediction of responders, echocardiographic parameters measured followed by infusion of the remaining 400 ml of Normal Saline Flush, 0.9% Injectable Solution at a constant rate over 10 minutes then echocardiographic parameters measured again to detect the patient response.
89462595|NCT03470181||Participants with Diagnosed CVS|This cohort will consist of 15 current patients previously diagnosed with Cyclic Vomiting Syndrome.
89462596|NCT03470181||Healthy Volunteers|This cohort will consist of 15 healthy volunteers, with no history of Cyclic Vomiting.
89462597|NCT03622021|Experimental|AK111 30mg|Single dose of 30mg AK111 or placebo is administered subcutaneously to healthy subjects
89462598|NCT03622021|Experimental|AK111 75mg|Single dose of 75mg AK111 or placebo is administered subcutaneously to healthy subjects
89462599|NCT03622021|Experimental|AK111 150mg|Single dose of 150mg AK111 or placebo is administered subcutaneously to healthy subjects
89462600|NCT03622021|Experimental|AK111 300mg|Single dose of 300mg AK111 or placebo is administered subcutaneously to healthy subjects
89462601|NCT03622021|Experimental|AK111 450mg|Single dose of 450mg AK111 or placebo is administered subcutaneously to healthy subjects
89462602|NCT03622021|Experimental|AK111 600mg|Single dose of 600mg AK111 or placebo is administered subcutaneously to healthy subjects
89462603|NCT03653299|Experimental|Group A - Placebo, 10J, 30J and 50J|"The phototherapy will be divided in programs 1, 2, 3 and 4. One of these programs will consist in placebo and the others in active phototherapy 10J, 30J and 50J.~The subjects allocated in group Phototherapy A will receive the programs in the following order 1, 2, 3 and 4, before the tests."
89462604|NCT03653299|Experimental|Group B - Placebo, 10J, 30J and 50J|"The phototherapy will be divided in programs 1, 2, 3 and 4. One of these programs will consist in placebo and the others in active phototherapy 10J, 30J and 50J.~The subjects allocated in group Phototherapy B will receive the programs in the following order 2, 3, 4 and 1, before the tests."
89462605|NCT03653299|Experimental|Group C - Placebo, 10J, 30J and 50J|"The phototherapy will be divided in programs 1, 2, 3 and 4. One of these programs will consist in placebo and the others in active phototherapy 10J, 30J and 50J.~The subjects allocated in group Phototherapy C will receive the programs in the following order 3, 4, 1 and 2, before the tests."
89462606|NCT03653299|Experimental|Group D - Placebo, 10J, 30J and 50J|"The phototherapy will be divided in programs 1, 2, 3 and 4. One of these programs will consist in placebo and the others in active phototherapy 10J, 30J and 50J.~The subjects allocated in group Phototherapy D will receive the programs in the following order 4, 1, 2 and 3, before the tests."
89462607|NCT03469245||abdominal aortic aneurysms treated by fenestrated endovascular|Patients have an abdominal aortic aneurysms treated by fenestrated endovascular anacondaTM of society Vascutek will be included. Predisurge society will perform numerical simulation.
89462608|NCT03813459||Subsyndromal delirium positive|Presence of Subsyndromal delirium in Intensive Care patients
89462609|NCT03813459||Delirium positive|Presence of Delirium in Intensive Care patients
89462610|NCT03813459||No delirium|Non subsyndromal delirium or delirium in Intensive Care patients
89462611|NCT03471819||Patients withf Atopic Dermatitis|Diagnosis is based upon American Academy of Dermatology recommendations for Diagnostic Criteria 2014.
89462612|NCT03471819||healthy volunteers|Normal individuals not complaining of any dermatological diseases
88956464|NCT05139316|Experimental|DTX401, Then Placebo|Participants receive single peripheral intravenous (IV) infusion of DTX401 in solution. At week 48 participants receive single peripheral IV infusion of Placebo.
88956465|NCT05139316|Placebo Comparator|Placebo, Then DTX401|Participants receive single peripheral IV infusion of Placebo. At week 48 eligible participants receive single peripheral IV infusion of DTX401 solution.
88956466|NCT05139316|Experimental|DTX401 (Japan Only)|Participants receive single peripheral intravenous (IV)infusion of DTX401 in solution.
89201887|NCT00689390|Other|Participants from Narlaprevir Studies|Participants who previously participated in treatment studies in which narlaprevir was administered were subsequently enrolled in Part 2 of the current follow-up study P05063 (NCT00689390). Participants may have received narlaprevir or control PR in the previous treatment study. No treatment was administered in the current follow-up study.
88943299|NCT04985422|Other|Control group: Smartphone-based weekly-delivered information|"The control group receives 4 weeks of smartphone-based weekly-delivered information. The smartphone system (SMS + Qualtrics) as well as the contents of the interventions are identical to those provided to the EMI group. Rather than interventions delivered in the moment on a daily basis over the 4-week period, participants in the control group are provided with a new set of information on a weekly basis over the 4-week period (4 sets in total, 1 new set each week). Participants in the control group are also required to complete a brief 5-minute assessment within 3 days.~The information includes brief simple behavioural actions (mostly 1-2 minutes, up to 5 minutes) which could be done anytime. Simple action tasks include guided breathing, mindful walking, and mindful sound hearing (etc.).~Participants could complete any intervention of interest in the information provided at any time throughout the 4-week period."
89537186|NCT05671211|Active Comparator|Control Group|Participants in control group will receive an exercise program consisted of upper and lower extremity strengthening and balance exercises.The exercises will be started as 8-10 repetitions and one set and the number of sets will be increased according to the progression of the patient. Exercises will be applied for 6 weeks, 5 days a week, for a total of 30 sessions, each session for 1 hour.
88943300|NCT04970953||Patients with intermediate risk for HFpEF at rest|Patients with a HFA-PEFF score of 2-4 points and no obvious extracardiac explanation for exercise-induced dyspnea. Right heart catheterization with be performed at rest and during stress testing.
88943301|NCT04965454|Experimental|Tested with Biomarkers|For this single arm study, all enrolled subjects will undergo diagnostic testing with FCH PET/CT and genomic liquid biopsy before treatment involving an immune checkpoint inhibitor agent. A fluorine-18 fluorodeoxyglucose (FDG) PET/CT may also be performed before treatment and after 8 weeks if the pre-treatment FCH PET/CT shows low or heterogeneous tumor uptake.
88943302|NCT04959773||COVID+ with exercise intolerance|"Patients of both sexes who have contracted SARS-COV-2 infection (swab positive and positive serological test (IgG)) and who suffer from muscle weakness after more than two months from infection.~The presence of cardiovascular or internal pathologies or in any case of serious disease will be considered an exclusion criterion.~general conditions."
88943303|NCT04959773||COVID+ without exercise intolerance|"Patients of both sexes who have contracted SARS-COV-2 infection (swab positive and positive serological test (IgG)) and who recovered and came to their normal life.~The presence of cardiovascular or internal pathologies or in any case of serious disease will be considered an exclusion criterion."
88943304|NCT04959773||Control healthy subjects (CTRL)|Subjects of both sexes who do not have contracted SARS-COV-2 infection (swab negative and negative serological test (IgG)). The presence of cardiovascular or internal pathologies or in any case of serious disease will be considered an exclusion criterion.
88943305|NCT04941924|Experimental|Intervention|Biliary stenting plus radio-frequency ablation of the bile duct
88943306|NCT04941924|Active Comparator|Control|Biliary stenting alone
88943307|NCT04939454|Experimental|sarcopenic COPD patient|
88943308|NCT04939454|Other|non-sarcopenic COPD patient|
88943309|NCT04937998|Experimental|Autologous PRP injection|This group of patients will be treated with single intra-articular injection of Autologous PRP.
88943310|NCT04937998|Active Comparator|HA injection|This group of patients will be treated with single intra-articular injection of Hyaluronic Acid (HA)
88943311|NCT04937309|Experimental|intervention|standard anti emetic treatment use of non invasive vagal stimulation twice a day from the day before chemotherapy till 4 days after, with a transcutaneous auricular device. This stimulation is to be done for the three first cycles of chemotherapy.
88943312|NCT04937309|Sham Comparator|control|"standard anti emetic treatment use of non invasive vagal stimulation twice a day from the day before chemotherapy till 4 days after, with a transcutaneous auricular sham device. This stimulation is to be done for the three first cycles of chemotherapy."
88943313|NCT04933552||Siponimod-Exposed|Pregnant women with MS exposed to siponimod during pregnancy
88943314|NCT04933552||Disease-Matched Comparison|Pregnant women with MS not exposed to siponimod during pregnancy
88943315|NCT04933552||Healthy Comparison|Pregnant women who are neither diagnosed with MS nor with any other autoimmune disease, and not exposed to siponimod or any known teratogenic agent during pregnancy
88943316|NCT04924985|Experimental|Physiological Feedback CPR|
88943317|NCT04924985|Active Comparator|Non-Physiological (Audiovisual) Feedback CPR|
88943318|NCT04917484|Active Comparator|Standard|Patients in this arm receive our standard treatment. Four treatment with standard dose of 7.4 GBq Lu-177-DOTATOC
88943319|NCT04917484|Experimental|Dosimetry|Patients in this treatment arm receive individualized calcuted treatment depending on kidney function and kidney dose. The treatment activity can differ from one treatment to the next.
88943320|NCT04916613|Experimental|ADT + darolutamide|ADT + darolutamide 600 mg po bid
88943321|NCT04916613|Placebo Comparator|ADT + placebo|ADT + placebo po bid
88943322|NCT04916314|Experimental|Low Carbohydrate Diet|". The intervention, provided by Second Nature, involves diet, activity and behaviour change components. It comprises a three-month remote behavioural change programme with mentoring from a registered dietitian or nutritionist (health coach), peer group support, structured education articles and activity tracking technology. These elements are accessed via a smartphone or web-based application. Each participant will also receive a hard copy of an instructional handbook and a recipe book."
88943323|NCT04916314|No Intervention|Standard NHS type 2 diabetes care|Participants randomised to the control group will receive no additional intervention, and will continue to receive their usual NHS diabetes care from their general practice.
88943324|NCT04883320||participants with no asthma|Have no evidence of any long term lung condition or any other disabling condition and they must not have had a chest infection in the preceding 4 weeks.
88943325|NCT04883320||participants with mild/moderate asthma|
88943326|NCT04883320||participants with severe asthma|
88943327|NCT04878679|Experimental|"Strength training + WB-EMS"|Strength training combined with WB-EMS : 2 times/week for 20 minutes
89201888|NCT00781248|Experimental|1|starting with active NG Shield
88943328|NCT04878679|Experimental|Cardiovascular training + WB-EMS|Cardiovascular training, using rowing machine, combined with WB-EMS : 2 times/week for 20 minutes
89462613|NCT03653221|Experimental|standardized patients with VRNET|The medical students examine the standardized patients who have neurological deficits which presented by VRNET.
89462614|NCT03653221|Placebo Comparator|standardized patients|The medical students examine the standardized patients who have neurological deficits which presented by words or pictures.
88943329|NCT04878679|Active Comparator|Control group|No physical activity
88943330|NCT04878445||Cohort A: 10 participants with no COPD|"Control patients Have no physician diagnosis of COPD Have no other significant chronic lung disease (asthma, fibrotic diseases) or ongoing lung infection other than the suspected cancer for which they have been referred for surgery.~Lifelong never-smokers or ex-smokers (< 10 pack years). (1 pack year= 20 cigarettes/day for 1 year)."
88943331|NCT04878445||Cohort B: 10 participants with COPD - chronic bronchitis|Have a physician diagnosis of COPD with primarily a chronic bronchitis presentation (determined via CT, spirometry, histopathology, GOLD COPD classification).
88943332|NCT04878445||Cohort C: 10 participants with COPD emphysema|Have a physician diagnosis of COPD with primarily a emphysema presentation (determined via CT, spirometry, histopathology, GOLD COPD classification) .
88943333|NCT04875130||confirmed pulmonary embolism|"Patients with intermediate high and high risk of an acute pulmonary embolism with clinical symptoms.~On image based procedures confirmed pulmonary embolism (TTE, contrast CT-angiography).~Age under 18.~Written agreement to the examination."
88943334|NCT04865848|Experimental|Mandibular infiltration dental anesthesia with Articaine|"Step-by-step:~Reflect tissue to expose injection site.~Orient bevel of the needle to be parallel to the bone and insert needle into mucobuccal fold~Proceed to the depth that approximates the apices of the buccal roots of the primary molars.~Aspirate.~Deposit bolus of local anesthetic slowly at a rate of 1 ml/min.~Remove needle.~A subsequent lingual infiltration is delivered.~The armamentarium includes: 4% articaine HCl with 1:100,000 epinephrine (Septocaine ®, Septodont, Lancaster, Penn. USA) in 1.7 ml cartridges and 30-gauge short needle manufactured by Henry Schein® (Melville, N.Y., USA). All injections are given using a self-aspirating syringe (A-Titan, Orchard Park, N.Y., USA)."
88943335|NCT04865848|Active Comparator|Inferior Alveolar Nerve Block with Lidocaine|"Step-by-step:~Dry injection site with gauze.~The barrel of the syringe should be directed on a plane between the two primary molars on the opposite side of the arch. It is advisable to inject a small amount of the solution as soon as the tissue is penetrated and to continue to inject minute quantities as the needle is directed toward the mandibular foramen.~Insert to the depth that is adjacent to bone.~Aspirate.~Slowly inject bolus of anesthetic at a rate of 1 ml/min.~Remove needle.~The armamentarium includes 2% lidocaine HCl with 1:100,000 epinephrine (Henry Schein ® Lidocaine, Novocol, Cambridge, Ontario, Canada) in 1.7 ml cartridges, as well as 27-gauge long needles manufactured by Henry Schein® (Melville, N.Y., USA). All injections are given using a self-aspirating syringe (A-Titan, Orchard Park, N.Y., USA)."
88943336|NCT04864808|Experimental|Behavioral Parenting Training|
88943337|NCT04859322|Experimental|Healthy Participants|20 healthy participants included in the arm for 3 experimental days each. On each experimental day infusions of stable isotope glucose (0,6 micromol/kg/min), glucagon (1 hour low; 0,6 ng/kg/min, 2 hours high; 4,0 ng/kg/min), somatostatin (450 micrograms/hour) and insulin (0,1 mU/kg/min) will be administered. Between the first two experimental days the participants will follow a sedentary lifestyle combined with a high-calorie diet intervention
88943338|NCT04846647||Unexplained hypophosphatemia|Collection of additional blood volume (approximately 10 mL) during blood tests provided as part of the usual medical care.
89201889|NCT00781248|Experimental|2|Starting with inactive NG Shield
89462615|NCT04055077|Active Comparator|ASA I/LFNO|Low-flow nasal oxygenation (LFNO) O2 flow 5L/min, FiO2 40%
89462616|NCT04055077|Active Comparator|ASA II/LFNO|Low-flow nasal oxygenation (LFNO) O2 flow 5L/min, FiO2 40%
89462617|NCT04055077|Active Comparator|ASA III/LFNO|Low-flow nasal oxygenation (LFNO) O2 flow 5L/min, FiO2 40%
89462618|NCT04055077|Experimental|ASA I/HFNO|High Flow nasal oxygenation (HFNO) O2 flow 40L/min, FiO2 40%
89462619|NCT04055077|Experimental|ASA II/HFNO|High Flow nasal oxygenation (HFNO) O2 flow 40L/min, FiO2 40%
89462620|NCT04055077|Experimental|ASA III/HFNO|High Flow nasal oxygenation (HFNO) O2 flow 40L/min, FiO2 40%
89501882|NCT03516487|Experimental|SAD HV: SYNB1618 (5 x 10^10 CFU)|HV subjects receive a single oral dose of SYNB1618 (5 x 10^10 CFU) in a chilled buffered solution on Day 1 in the SAD study (Part 1).
89462621|NCT03618693|Experimental|spinal analgesia SSS|"Patients will receive a spinal analgesia (group SSS) with a single shot of bupivacaine 0.5% combined with fentanyl intrathecally during induction of anaesthesia. The technique used is referred to daily practice.~All patients included in the study will receive the same postoperative multimodal analgesia starting at the end of surgery with the following regimen: 30 mg ketorolac 3* per day for 48 hours intravenously and 1 gr 4* per day metamizol intravenously or per oral, depending of the return of bowel function as baseline analgesia during length of hospitalization.~Additional rescue analgesia will be provided and consisted in boluses of 25 mcg fentanyl intravenously (first 24 hours) and thereafter 5-10 mg oxycodone tablets (per oral administration).~Postoperative rehabilitation according to the investigators enhanced recovery program including early mobilization and drinking (clear drinks)."
89462622|NCT03618693|Experimental|TAP block|"Patients will receive a TAP block with a single shot of ropivacaine 0.375% combined with clonidine bilaterally. The technique used is referred to daily practice. The blocks will be performed under ultrasound guidance.~All patients included in the study will receive the same postoperative multimodal analgesia starting at the end of surgery with the following regimen: 30 mg ketorolac 3* per day for 48 hours intravenously and 1 gr 4* per day metamizol intravenously or per oral, depending of the return of bowel function as baseline analgesia during length of hospitalization.~Additional rescue analgesia will be provided and consisted in boluses of 25 mcg fentanyl intravenously (first 24 hours) and thereafter 5-10 mg oxycodone tablets (per oral administration).~Postoperative rehabilitation according to the investigators enhanced recovery program including early mobilization and drinking (clear drinks)."
89462623|NCT03618693|Active Comparator|Standard|"Standard care for prostatectomy in the investigators institution consists in the concomitant systemic administration of lidocaine to standard general anaesthesia. Lidocaine will administered initially during induction with a bolus of 1.5 mg per kgBW, followed by an infusion of 1.5 mg per kgBW per hour for 24 hours.~All patients included in the study will receive the same postoperative multimodal analgesia starting at the end of surgery with the following regimen: 30 mg ketorolac 3* per day for 48 hours and 1 gr 4* per day metamizol intravenously or per oral, depending of the return of bowel function as baseline analgesia during length of hospitalization.~Additional rescue analgesia will be provided and consisted in boluses of 25 mcg fentanyl intravenously (first 24 hours) and thereafter 5-10 mg oxycodone tablets.~Postoperative rehabilitation according to the investigators enhanced recovery program including early mobilization and drinking (clear drinks)."
89462624|NCT05159505||"the before group"|40 teenagers after scoliosis surgery before interdisciplinary program implementation
89462625|NCT05159505||"the after group 1"|40 teenagers after scoliosis surgery after ERAS program implementation
89462626|NCT05159505||"the after group 2"|40 teenagers after scoliosis surgery after ERAS and educational program implementation
88943339|NCT04846374||PowerPort Subjects|This study will involve a chart review of patients at UNC who were referred for change from a vortex port to a powerflow port.
89462627|NCT01064167|Experimental|Tranexamic Acid group|
89462628|NCT01064167|Placebo Comparator|Control group|
89462629|NCT04205305|Active Comparator|Conventional blood pressure control group|systolic blood pressure <180 mmHg
89462630|NCT04205305|Experimental|Intensive blood pressure control group|systolic blood pressure <140 mmHg
89462631|NCT03470103||Treatment naïve wAMD|The decision regarding treatment is made at the discretion of the attending physician, according to his/her medical practice
88943340|NCT04839666||Propofol|
88943341|NCT04838262|Experimental|Assessment of Daily Stress Processes|Subjects will report cumulative exposure, perceived severity, and emotional responsiveness to commonly occurring everyday psychosocial stressors utilizing an ecological momentary assessment approach for 8 consecutive days.
88943342|NCT04831957|Other|Patient underwent TAVI procedure|- Elderly patients who will undergo a TAVI procedure coming to the geriatric day hospital
88943343|NCT04827420|Experimental|MiQuit Care|Intervention arm: Advise to quit + automatic linkage to quitline + patient navigation
88943344|NCT04827420|Active Comparator|Enhanced Standard of Care|Active Comparator: Advise to quit + written self-help materials
88943345|NCT04825106|Active Comparator|Expected|Anaphylactic shock occurs after the injection of a drug known to cause allergic reactions
89462632|NCT03470103||Treatment naïve DME|The decision regarding treatment is made at the discretion of the attending physician, according to his/her medical practice
88943346|NCT04825106|Active Comparator|Unexpected, no distractor|Anaphylactic shock occurs unexpectedly, but their is no medical distractor
88943347|NCT04825106|Active Comparator|Unexpected, with distractor|Anaphylactic shock occurs unexpectedly. Scenario is set up such, that a tension pneumothorax may be a likely explanation
88943348|NCT04824846|Experimental|Ambulance drivers with received Integrated back pain module (IBPM)|Behavioral: Integrated back pain module (IBPM)
88943349|NCT04824846|Other|Ambulance drivers with received Health Educational Pamphlet.|Other: Health Educational Pamphlet.
88943350|NCT04805216||Immunocompromised patients (study group)|People who are likely to have a suppressed immunity due to their haematological disorder or its treatment
88943351|NCT04805216||Immunocompetent volunteers (control group)|People without suppressed immunity
89462633|NCT03470103||Previously treated wAMD|The decision regarding treatment is made at the discretion of the attending physician, according to his/her medical practice
89462634|NCT03470103||Previously treated DME|The decision regarding treatment is made at the discretion of the attending physician, according to his/her medical practice
89462635|NCT02974543|Other|Sham 1st (Auditory only) then Active (Bimodal)|"To mitigate potential placebo effects, subjects receive both a sham treatment and an active treatment. The subjects will be blinded to which treatment they are receiving. Both treatments are delivered using a take-home device programmed in the lab.~During active treatment, the device will deliver electric somatosensory and auditory stimulation."
89462636|NCT02974543|Other|Active (Bimodal) then Sham (Auditory only)|"During active treatment, the device will deliver electric somatosensory and auditory stimulation.~To mitigate potential placebo effects, subjects receive both a sham treatment and an active treatment. The subjects will be blinded to which treatment they are receiving. Both treatments are delivered using a take-home device programmed in the lab."
89462637|NCT03471741||MARA-2: IMRT with concomitant boost|A forward planned IMRT technique was used and the prescribed dose to the whole breast was 50 Gy plus a concomitant boost of 10 Gy to the tumor bed
89462638|NCT03471741||CG: 3D-RT with sequential boost|The whole breast received 50.4 Gy in 28 fractions delivered with 3D-RT, followed by a sequential boost on the tumor bed of 10 Gy in 4 fractions delivered with electrons
89462639|NCT02523027|Experimental|Experimental Group 1:|Oral nutritional supplement (List No S691/Z0) and dietary counseling
89462640|NCT02523027|Experimental|Experimental Group 2|Oral nutritional supplement (List No- P968/Z0) and dietary counseling.
89462641|NCT02523027|No Intervention|Control Group|Dietary Counselling only.
89462642|NCT05391009|Experimental|PNF GROUP|PNF exercise twice daily five days per week for 8 weeks. D1 and D2 flexion and extension pattern for upper limb. In D1 Flexion-adduction -external rotation d1, extension -abduction-internal rotation and in D2 flexion-abduction-external rotation, extension-adduction-internal rotation
89462643|NCT05391009|Experimental|TRT GROUP|The duration of a TRT session Will be 60 min. Each session started with warm-up exercises for 10 min followed by 50 min of TRT. Each task will be repeated approximately 10 to 20 times, for 1 to 5 sets, or alternatively for 2 to 5 min. A 2 min rest period after every 15 min of practice will be allowed. Before commencing the exercise session, tasks will be demonstrated to each patient using the non-affected UE.
89462644|NCT05159271|Experimental|Azeol spray nasal group|Azéol Spray Nasal is a nasal spray. The constituents responsible for achieving the intended action are: Bifidobacterium breve LA 708, extract of cypres Cupressus sempervirens L., extract of Leguminosae Glycyrrhiza glabra L., glycerin and mannitol.
89462645|NCT05159271|Placebo Comparator|Placebo group|The control product is a placebo with the same characteristics of appearance and packaging as Azéol Spray Nasal without the active ingredients
89462646|NCT03469947|Experimental|Prehospital Tranexamic Acid|1 gram of Tranexamic Acid will be given during medical transport
89462647|NCT03469947|No Intervention|Matched Controls|Retrospective matched controls
89462648|NCT05157087||Commercial Population|Individuals with at least one omalizumab prescription in the Marketscan commercial claims during the identification period (07/07/2016 - 12/31/2018)
89462649|NCT05157087||Medicaid Population|Individuals with at least one omalizumab prescription in the Truven Medicaid claims during the identification period (07/07/2016 - 12/31/2018)
89462650|NCT02974153|Experimental|ALD403 (Eptinezumab) Dose Level 1|ALD403 (Eptinezumab) Dose Level 1 (IV)
89462651|NCT02974153|Experimental|ALD403 (Eptinezumab) Dose Level 2|ALD403 (Eptinezumab) Dose Level 2 (IV)
89462652|NCT02974153|Placebo Comparator|Placebo|Placebo (IV)
89462653|NCT05124639|Experimental|Group self-management support|Group self-management support program for anxiety disorders developped by Relief (https://myrelief.ca/).
89462654|NCT05124639|No Intervention|Treatment-as-usual|Treatment-as-usual and a delayed intervention (if desired by participants) after the 12-month follow up
89462655|NCT04053829|Experimental|HOLOBalance|The experimental arm will use the HOLOBalance tele-rehabilitation system to provide the intervention. Participants will be required to use the HOLOBalance system on a daily basis for the duration of the 8 week study. Although participants will have daily interaction with the HOLOBalance system, they will be free to choose when to complete their exercises.
89501883|NCT03516487|Experimental|SAD HV: SYNB1618 (1 x 10^11 CFU)|HV subjects receive a single oral dose of SYNB1618 (1 x 10^11 CFU) in a chilled buffered solution on Day 1 in the SAD study (Part 1).
89462656|NCT04053829|Active Comparator|OTAGO Home Exercise Programme|The comparator for this study is the OTAGO home exercise programme. The OTAGO is a systematic, progressive strength and balance training programme and is supported by a comprehensive workbook that provides written and pictorial instructions for each exercise. The OTAGO is well-established and is widely used in clinical practice in the UK for the management of older adults who fall or have increased risk for falling. It has been shown to be well tolerated in older adults in community settings with good adherence rates, and reduces falls rate in older adults by 35%, with greatest effects observed in frailer older women
89462657|NCT04054063|Experimental|HSK3486+etomidate|Cohort 1: HSK3486 0.324 mg/kg + etomidate 0.15 mg/kg Cohort 2: HSK3486 0.216 mg/kg + etomidate 0.2 mg/kg Cohort 3: HSK3486 0.432 mg/kg + etomidate 0.1 mg/kg There were an additional 2 cohorts (Cohorts 4 and 5) planned for dose escalation once the optimal ratio of the drug combination was identified from the first 3 cohorts. However, these 2 cohorts were not done as the results of Cohorts 1 to 3 suggested that dose increases would cause higher occurrence of drug-related adverse events (AEs).
89462658|NCT03652519|Experimental|High-intensity Interval Training (HIIT)|Participants of the HIIT group will exercise three times per week over a period of three weeks (inpatient rehabilitation) on a cycle ergometer. Exercise intensity will be regulated and heart rate controlled based on the achieved maximum heart rate (HRmax) assessed during the initial Cardiopulmonary Exercise Testing. Each exercise session will last 30 minutes and will be started and finalized with three minutes at low intensity (50% HRmax, warm-up / cool-down). During each exercise session, participants of the HIIT group will perform 5x one-and-a-half Minute high-intensive exercise bouts at 95-100% of their HRmax followed by active breaks of unloaded pedalling over 2 minutes with the aim to achieve 60% HRmax.
89462659|NCT03652519|Active Comparator|Moderate Continous Training (ST)|Participants of the ST group will exercise three times per week over a period of three weeks (inpatient rehabilitation) on a cycle ergometer. Exercise intensity will be regulated and heart rate controlled based on the achieved maximum heart rate (HRmax) assessed during the initial Cardiopulmonary Exercise Testing. Each exercise session will last 30 minutes and will be started and finalized with three minutes at low intensity (50% HRmax, warm-up / cool-down). During each exercise session, participants of the ST group will exercise 30 minutes continuously at 65% of HRmax. This moderate continous training program represents the standard care at the local rehabilitation clinic.
88943352|NCT04804007|Experimental|Maintenance Oral Etoposide|Maintenance daily oral Etoposide.
88943353|NCT04804007|No Intervention|Observation|If randomized to Observation, subjects will jump to follow-up.
88943354|NCT04801381|Active Comparator|Aquablation therapy|Aquablation therapy: Computer-assisted transurethral ablation of prostate tissue using a high-pressure water jet. Subsequent removal of residual ablated tissue at the bladder neck and haemostasis by transurethral electroresection (TUR).
88943355|NCT04801381|Active Comparator|Transurethral laser enucleation|Transurethral laser enucleation of the prostate using thulium laser (ThuLEP) or holmium laser (HoLEP).
88943356|NCT04799665||All Participants|
88943357|NCT04782180|Experimental|Rapid PrEP group|Participants will receive PrEP i.e. Descovy for 12 months at the syringe services program.
88943358|NCT04763499|Experimental|Freeze dried strawberry powder|"39g of freeze dried strawberry powder, which represents three daily servings of strawberries.~The powder will be mixed in one cup of water."
88943359|NCT04763499|Placebo Comparator|control powder|39 g of a powder that matches the sugar and caloric content of the experimental powder. The powder will be mixed in one cup of water.
88943360|NCT04762017|Experimental|OCS-05|Once daily IV infusions of OCS-05 (n=18) for 5 consecutive days
88943361|NCT04762017|Placebo Comparator|Placebo|Once daily IV infusions of Placebo (n=18) for 5 consecutive days
88943362|NCT04757584|Active Comparator|Beta Blocker ABAB Sequence|"This arm will follow an ABAB sequence. A representing ON beta blockers and B representing OFF beta blockers. Subjects in this arm will continue their home dose during the initial A period, they will then crossover into Period 2, where dose reduction will begin until they are off of beta blockers. During Period 3, they will restart beta-blockers, gradually uptitrating until reaching their home dose and finally during period 4, we will again conduct a dose reduction until off of beta blockers."
88943363|NCT04757584|Active Comparator|Beta Blocker BABA Sequence|"This arm will follow a BABA sequence. A representing ON beta blockers and B representing OFF of beta blockers. Subjects in this arm will have their previously prescribed beta blocker dose reduced until they are completely off of beta blockers during Period 1. They will then crossover into Period 2, where uptitration will begin until they are back on their previously prescribed dose of beta blockers. During Period 3, we will again conduct a dose reduction, until the subject is off of beta blockers and finally during Period 4, we will uptitrate them back to their home dose of beta blockers."
88943364|NCT04756791|Active Comparator|Local infiltration anesthesia|Patients will receive local infiltration anesthesia with ropivacaine placed by surgeon.
88943365|NCT04756791|Experimental|Serratus anterior plane block|Patients receive a SAPB with ropivacaine placed by anesthesiologist.
88943366|NCT04752475|Experimental|Lasix (furosemide)|Furosemide 20 mg, oral, once daily for 5 days
88943367|NCT04752475|Placebo Comparator|Placebo|Identical-appearing placebo, oral, once daily for 5 days
88943368|NCT04748289|Experimental|NICU patients|All patients admitted to the Neurointensive Care Unit (NICU)
88943369|NCT04746586||Cases|20 patients with adolescent idiopathic scoliosis in a ratio of 5:1 between females and males will be enrolled.
88943370|NCT04746586||Controls|10 healthy controls, of which 5 females and 5 males will be enrolled.
88943371|NCT04740801|Other|PVI procedure|Subjects will undergo ablation treatment of the pulmonary veins with the Rhythmia HDx mapping system with DirectSense technology. Subjects indicated for ablation treatment of de-novo PAF will be selected based on the inclusion/exclusion criteria and if deemed to be eligible for participation, will be asked to sign the Informed Consent Form. For all enrolled subjects who undergo the ablation procedure, the subjects will be treated with the commercial Rhythmia HDx System with commercially available Software Version 4.0.1 or greater (commercially approved version) with DIRECTSENSE™ and Force Computation Software Module; the IntellaMap Orion mapping catheter and the IntellaNav StablePoint ablation catheter.
89462660|NCT05107245||COVID-19 patients|Hospitalised COVID-19 patients
89462661|NCT05107245||Controls|Exposed medical staff
89462662|NCT03652441|Experimental|Maintenance|Brentuximab Vedotin will be administered i.v. at 1.8mg/kg at 3-weekly intervals for up to 16 infusions
89462663|NCT02508532|Experimental|Part 1 Avapritinib (formerly BLU-285) 30 mg QD|"Part 1: Patients received a starting dose of 30 mg QD for 28 days and they were assessed for dose limiting toxicities (DLT). If no DTLs were observed the dose escalation continued.~Patients received avapritinib in continuous 28 day cycles until discontinuation."
89462664|NCT02508532|Experimental|Part 1 Avapritinib (formerly BLU-285) 60 mg QD|"Part 1: Patients received a starting dose of 60 mg QD for 28 days and they were assessed for dose limiting toxicities (DLT). If no DTLs were observed the dose escalation continued.~Patients received avapritinib in continuous 28 day cycles until discontinuation."
89462665|NCT02508532|Experimental|Part 1 Avapritinib (formerly BLU-285) 90 mg QD|"Part 1: Patients received a starting dose of 90 mg QD for 28 days and they were assessed for dose limiting toxicities (DLT). If no DTLs were observed the dose escalation continued.~Patients received avapritinib in continuous 28 day cycles until discontinuation."
89462666|NCT02508532|Experimental|Part 1 Avapritinib (formerly BLU-285) 135 mg QD|"Part 1: Patients received a starting dose of 135 mg QD for 28 days and they were assessed for dose limiting toxicities (DLT). If no DTLs were observed the dose escalation continued.~Patients received avapritinib in continuous 28 day cycles until discontinuation."
89462667|NCT02508532|Experimental|Part 1 Avapritinib (formerly BLU-285) 200 mg QD|"Part 1: Patients received a starting dose of 200 mg QD for 28 days and they were assessed for dose limiting toxicities (DLT). If no DTLs were observed the dose escalation continued.~Patients received avapritinib in continuous 28 day cycles until discontinuation. ."
89462668|NCT02508532|Experimental|Part 1 Avapritinib (formerly BLU-285) 300 mg QD|"Part 1: Patients received a starting dose of 300 mg QD for 28 days and they were assessed for dose limiting toxicities (DLT). If no DTLs were observed the dose escalation continued.~Patients received avapritinib in continuous 28 day cycles until discontinuation. Patients that received at least one dose of avapritinib were included in the Part 2 analysis."
89462669|NCT02508532|Experimental|Part 1 Avapritinib (formerly BLU-285) 400 mg QD|"Part 1: Patients received a starting dose of 400 mg QD for 28 days and they were assessed for dose limiting toxicities (DLT). If no DTLs were observed the dose escalation continued.~Patients received avapritinib in continuous 28 day cycles until discontinuation.~Patients that received at least one dose of avapritinib were included in the Part 2 analysis."
88943372|NCT04720885||Patients with a placental remnant in medical history|
88943373|NCT04719078|Other|All patients|There are no study arms. All patients obtain all imaging modalities.
88943374|NCT04717362|Experimental|Standard Reboot with Natesto|Standard Reboot Protocol + Natesto
88943375|NCT04706273||GORE® VIABAHN® Endoprosthesis|Participants with symptomatic peripheral arterial disease in superficial femoral artery lesions.
88943376|NCT04701177||Subjective cognitive decline (SCD)|subjective perception of cognitive decline in the absence of cognitive impairment in formal neuropsychological assessment.
88943377|NCT04701177||Mild cognitive impairment (MCI)|Single or multidomain cognitive deficits with preservation of activities of daily living.
88943378|NCT04701177||Prodromal Parkinson's Disease|Parkinson's disease (PD) has a prodromal phase during which nonmotor clinical features as well as physiological abnormalities may be present.
88943379|NCT04700917|Experimental|Intervention Group|This group will receive the iCBT for IBD online intervention once enrolled.
88943380|NCT04700917|No Intervention|Treatment as Usual|This group will be offered the iCBT for IBD intervention 24 weeks after enrollment.
88943381|NCT04700826|Experimental|Direct Oral anticoagulants (DOAC)|Commence DOAC even with low or intermediate risk of stroke or thromboembolism, which could include currently licensed drugs apixaban, dabigatran, edoxaban or rivaroxaban; choice of drug and dose according to local practice guidelines
88943382|NCT04700826|No Intervention|No anticoagulant therapy (usual care)|Continuation of usual anticoagulant prescribing practice in patients with AF; e.g. according to National Institute for Health and Care Excellence (NICE), patients with AF should commence oral anticoagulation with a CHA2DS2-VASc score of 2 or above.
88943383|NCT04700189|Experimental|Treatment with Streamline following cataract surgery|Treatment with Streamline System following phacoemulsification
88943384|NCT04693949|Active Comparator|APA|Air-borne particle abrasion of zirconia RBFDPs prior to bonding
88943385|NCT04693949|Experimental|NAC|Pretreatment of zirconia RBFDP with nanostructured alumina coating after milling of RBFDP's framework
88943386|NCT04689256|Experimental|MR-010 walking therapy|Subjects will use the MR-010 three times a week for 30 minutes per session for 90 days. Subjects will undergo a 10-meter walk test bi-weekly and at 45 and 90 days.
88943387|NCT04689256|No Intervention|Standard of Care|Subjects will undergo a 10-meter walk test bi-weekly for 90 days and at 45 and 90 days
88943388|NCT04688528|Experimental|Arm A: Unilateral RT|If SPECT/CT shows ipsilateral drainage and the tumor does not cross the midline, the subject will automatically be assigned to Arm A, and will receive ipsilateral Radiotherapy with reduced prophylactic dose outside of the macroscopically involved nodes. The contralateral side of the neck will be spared according to the absence of sentinel lymph node drainage.
88943389|NCT04688528|Experimental|Arm B: Whole level|"If SPECT/CT shows contralateral drainage, the subject will be randomized between 'Whole level' and 'SLN alone'.~Arm B 'Whole Level': on the contralateral side of the neck, the whole level(s) containing the draining sentinel lymph node(s) will be irradiated at the reduced prophylactic dose. The ipsilateral side of the neck will be irradiated conform to arm A."
88943390|NCT04688528|Experimental|Arm C: SLN alone|"If SPECT/CT shows contralateral drainage, the subject will be randomized between 'Whole level' and 'SLN alone'.~Arm C 'SLN alone': on the contralateral side of the neck, only the sentinel node(s) will be irradiated at the reduced prophylactic dose. The ipsilateral side of the neck will be irradiated conform to arm A."
88943391|NCT04687917|Active Comparator|Training, Feedback, Consultation, and Facilitation|A multilevel implementation strategy
89462670|NCT02508532|Experimental|Part 1 Avapritinib (formerly BLU-285) 600 mg QD|"Part 1: Patients received a starting dose of 600 mg QD for 28 days and they were assessed for dose limiting toxicities (DLT). If no DTLs were observed the dose escalation continued.~Patients received avapritinib in continuous 28 day cycles until discontinuation."
89017838|NCT06047509|Experimental|Arm I Treatment|After inserting the laser, a thermal-optical probe will be inserted via a multichannel needle guide or tranperineal grid in the prostate using transrectal ultrasound guidance. The sensor probe will be placed at a pre-determined depth and location based on the treatment zone. Targets will be identified prior to laser treatment using multi-parametric MRI and delineated by the radiologist for visualization by the treatment operator. The lesion will be visible both on a 3D reconstruction and during real-time ultrasound imaging. Applications of laser energy up to 15 watts of power will be used to treat the target region. Confirmation of appropriate laser position will be made with real-time ultrasound prior to application of laser energy and repeatedly during activation of the laser. Energy delivery will be planned specific to each patient's tumor geometry, with the assistance of the Avenda Health Unfold-AI Software.
89017839|NCT06044649|Experimental|Cognitive Behavioral Therapy|8-session, individual, Cognitive Behavioral Therapy delivered remotely by skilled CBT therapists
89462671|NCT02508532|Experimental|Part 1 and Part 2 Avapritinib (formerly BLU-285) 300 mg or 400 mg QD|"Part 1 and Part 2: Patients enrolled in Part 1 and Part 2 at a starting dose of 300 or 400 mg QD were included in the Part1/Part 2 safety and efficacy analysis.~Patients received avapritinib in continuous 28 day cycles until discontinuation."
89462672|NCT04455165||RVAo MITAVA|Patient operated since 2009 for aortic valve replacement through right anterior minithoracotomy approch in Dijon Burgundy University Hospital
89462673|NCT04455321|Active Comparator|Vicryl|Single layer locked uterine closure with vicryl suture material
89462674|NCT04455321|Experimental|rapide vicryl|Single layer locked uterine closure with rapide vicryl suture material
89462675|NCT02918071|Experimental|Arm Benralizumab|Benralizumab administered subcutaneously every 4 weeks
89462676|NCT05113173||Type I Achalasia|Severe loss of ganglion cells,loss of ICCs.
89462677|NCT05113173||Type II Achalasia|Loss of ICCs, mild loss of ganglion cells.
89462678|NCT05113173||Type III Achalasia|Preserved ICCs, less loss of ganglion.
89462679|NCT05162703|Experimental|Intervention group|Participants will be equipped with a spirometer and and the AsthmaTuner mobile phone app to perform an exercise tests in their natural training environment. Feasibility will be evaluated using questionnaires.
89462680|NCT05162625|Active Comparator|Topical Moxifloxacin|Pre-surgical prophylaxis with the use of topical 0.5% moxifloxacin eye drops every 3 hours until the surgery.
89462681|NCT05162625|Active Comparator|Intravenous Cephazolin and Ciprofloxacin|Pre-surgical prophylaxis with cefazolin 1 gram every 6 hours and ciprofloxacin 400 milligrams intravenously every 12 hours, until the surgery.
89462682|NCT02507752||Rituximab|Participants who are receiving 1000 milligrams (mg) intravenous (IV) infusion of rituximab on Day 1 and Day 15 as part of standard of care of the treating site will be included in this observational study.
89462683|NCT04652895||Moderate-to-severe traumatic brain injury inpatients|Moderate-to-severe traumatic brain injury inpatients
89462684|NCT05111379||LEAD (Fontaine IIa)|Patients with mild intermittent claudication.
89462685|NCT05111379||Control|Healthy controls.
89462686|NCT05314959|Experimental|Physician Awareness|The physician will have access to the pre-visit Control Preference Scale survey results for women assigned to this group
89462687|NCT05314959|Active Comparator|Usual Care|The physician will not have access to the pre-visit Control Preference Scale survey results for women assigned to this group
89462688|NCT04971460||Mother and Baby Unit|Fathers and partners of women admitted to a Mother and Baby Unit
89462689|NCT04971460||Peri-natal Community Mental Health Services|Fathers and partners of women accessing community perinatal mental health services
88943392|NCT04687917|Experimental|Training, Feedback, Consultation, Facilitation, and P4P|An enhanced version of the multilevel implementation strategy
88943393|NCT04647032|Experimental|Theta Stimulation Group|This group will receive 6 Hz (theta) stimulation
88943394|NCT04647032|Active Comparator|Delta Stimulation Group|This group will receive 1 Hz (delta) stimulation
88943395|NCT04646486|Experimental|Intervention - Video debriefing|Baseline period (year 1): Standard practice. Intervention period (year 2-3): All teams will be assigned to video debriefing.
88943396|NCT04611191|Experimental|Team Sports|Elderly men and women performing team sports in local sports clubs
88943397|NCT04611191|Experimental|Control|Elderly men and women continue their normal lifestyle
88943398|NCT04608214|Experimental|Alisporivir|Administration of alisporivir and standard of care (SOC)
88943399|NCT04608214|Active Comparator|Standard of care (SOC)|Locally accepted regimen protocols for patient care
88943400|NCT04601727||Rectal cancer patients|
88943401|NCT04571762|Experimental|Single arm|Patients with low-risk, intermediate-risk and low-volume metastatic prostate cancer eligible for stereotactic body radiotherapy will be recruited.
88943402|NCT04553289|Experimental|exercising into pain|The participants will train during 12 with progressive loaded exercises, three times per week. There are 9 sessions of supervised physiotherapy treatment, lasting 30 minutes, while the rest of the sessions is conducted as home exercises. There are 4 strengthening exercises, including 2 in closed kinetic chain exercises and 2 executed with the elastic band or with dumbbell/weight. One exercise will be performed with pain ranging between 4 and 7 on a NPRS (Numeric Pain Rating Scale) and the rest of the exercises will be performed with no/slight pain, ranging between 0 and 2 on NPRS. At week 9, patients will continue to exercise with pain between 0 and 2 in all exercises. 10/15 minutes of manual therapy (posterior capsular release) will be applied during the physiotherapy session.
88943403|NCT04553289|Active Comparator|exercising with no/slight pain|The participants will train during 12 weeks with progressive loaded exercises, three times per week. There are 9 sessions of supervised physiotherapy treatment, lasting 30 minutes, while the rest of the sessions is conducted as home exercises. There are 4 strengthening exercises, including 2 in closed kinetic chain exercises and 2 executed with the elastic band or with dumbbell/weight. All the exercises will be performed with no/slight pain, ranging between 0 and 2 on NPRS. 10/15 minutes of manual therapy (posterior capsular release) will be applied during the physiotherapy session.
89462690|NCT04971460||Control group|Fathers and partners of women who are not accessing mental health services in the perinatal period
89462691|NCT02506816||Olaparib|Drug exposure has a limited duration 28 (+/- 5) days.
89462692|NCT02506036|Active Comparator|Control then Social Cognitive Training|Patients assigned to this arm will first receive a control therapy on a laptop followed by the Brain HQ social-cognitive training.
89462693|NCT02506036|Experimental|Social Cognitive Training then Control|Patients assigned to this arm will first receive the Brain HQ social-cognitive training and then undergo a control therapy.
89462694|NCT05017168|Experimental|CT-P63|Single Ascending Dose
89462695|NCT05017168|Placebo Comparator|Placebo|Single Ascending Dose
89462696|NCT05009901|Experimental|Alpha Lipoic Acid|alpha lipoic acid PO 600 mg daily for 8 weeks
89462697|NCT05009901|Placebo Comparator|Placebo|placebo PO daily for 8 weeks
89462698|NCT05015374|Placebo Comparator|placebo|Compared the difference of changes in psychometrics between Astaxanthin users and placebo group.
89017840|NCT06044649|Experimental|Acceptance and Commitment Therapy|8-session, individual, Acceptance and Commitment Therapy delivered remotely by skilled ACT therapists
89017841|NCT06044649|Experimental|Emotional Awareness and Expression Therapy|8-session, individual, Emotional Awareness and Expression Therapy delivered remotely by skilled EAET
89017842|NCT06044649|Other|Treatment As Usual|In this control condition, participants will engage in their usual care for neck/back pain with no additional experimental intervention
89017843|NCT06040567||Patients with polyneuropathy|Adults (> 18 years) diagnosed with polyneuropathy
89462699|NCT05015374|Active Comparator|Astaxanthin|Compared the difference in adverse effects between Astaxanthin users and placebo group.
89462700|NCT04988529|Experimental|Smartphone-based supported serious game intervention|Group that receives the smartphone-based serious game intervention and receives technical support
89462701|NCT04988529|No Intervention|Waiting list control|Group that does not receive any treatment
89462702|NCT04970680|Active Comparator|blind glossopharyngeal nerve block|patients will have the glossopharyngeal nerve block with the blind technique
89462703|NCT04970680|Active Comparator|ultrasonic glossopharyngeal nerve block|patients will have the glossopharyngeal nerve block using the ultrasonic technique
89462704|NCT03109509|Active Comparator|Fitbit-only Group|Participants randomized to the FB group were provided a Fitbit Zip activity monitor and were instructed on how to wear the monitor, how to pair the activity monitor to their smartphone, and asked to provide our team consent to access their Fitbit data through Fitbit's Application Programming Interface (API)
89462705|NCT03109509|Experimental|Fitbit + Pokémon Go Group|Participants randomized to the FB+P group received the same Fitbit Zip activity monitor and text message reminders as the FB group. This group was also shown how to download the Pokémon Go application to their smartphone and were provided brief instructions on how to play the game. Participants were instructed to simply explore the game and play it at their leisure. Participants were not provided any specific goals related to game play or physical activity in general.
89462706|NCT04421326||Patients with acute ischemic stroke|Patients undergoing Mechanical Thrombectomy for large vessel occclusion with acute ischemic stroke
89017844|NCT06040567||Healthy controls|Healthy adults (>18 years)
89017845|NCT06033664|Experimental|Grocery Prescription Program|Participants will receive the Fresh Funds through Instacart
89017846|NCT06020144|Experimental|sequence A|TLL018 tablets, 2piece,BID
89462707|NCT05162235|Experimental|AR-localization|
89017847|NCT06020144|Active Comparator|sequence B|Tofacitinib tablets, 1piece,BID
89017848|NCT06006858||Moderna COVID-19 Vaccine|Clinically healthy adults aged ≥ 18 years who received Primary Moderna COVID-19 Vaccine
89017849|NCT06006416|Experimental|Fenugreek Fibre|Fenugreek Fibre - 2 x 10g powder per day with/in food
89017850|NCT06002490|Experimental|P1101|Conventional treatment based on phlebotomies, low-dose aspirin (acetylsalicylic acid, 75-150 mg/day) plus the subcutaneous administration of pegylated proline-interferon alpha-2b (P1101, ropeginterferon alfa-2b) once every 2 weeks.
89017851|NCT05992376|Active Comparator|Intervention|
89017852|NCT05992376|No Intervention|Control/No Intervention|
89017853|NCT05976165|Experimental|Breath Test Evaluation for SIBO|Subjects with symptoms of gastroesophageal reflux disease (GERD) treated with a short course of proton pump inhibitors (PPI) clinically will undergo breath testing evaluating for small intestinal bacterial overgrowth (SIBO).
89017854|NCT05975788|Experimental|Staphylococcus and Neisseria group|Experimental group will receive Staphylococcus and Neisseria Tablets (0.3mg/tablet) and standard care. Administration Staphylococcus and Neisseria is 4 tablets each time and 3 times a day, and treatment period ranges from 3 to 6 months.
89462708|NCT01063855|Experimental|Dapoxetine + PDE5I|Dapoxetine 30 mg to 60 mg tablets 1 to 3 hours before sexual activity prn (as needed) not to be taken more than once every 24 hours for 12 weeks + a PDE5I (phosphodiesterase-5 inhibitor) prescribed prior to study entry for the treatment of erectile dysfunction.
89017855|NCT05975788|No Intervention|Standard care group|Standard care based on clinical experience without interventions.
89017856|NCT05975476|Experimental|Physical Activity|Individuals in this group will wheel on a paved trail within the park for 30 minutes 2 times per week for 5 weeks.
89017857|NCT05975476|Experimental|Sensory Engagement|Individuals in this group will sit comfortably in a peaceful area of the park and enjoy the sights and sounds of nature for 30 minutes 2 times per week for 5 weeks.
89017858|NCT05971888|Active Comparator|Intervention|
89017859|NCT05971888|No Intervention|Control|In Amhara, an equal number of districts outside the program coverage area with characteristics similar to the intervention districts will serve as the control.
89017860|NCT05969795|Other|Study Group|Intermittent ultrasound scans to monitor follicular growth and serial measurements of serum LH, E2 and P4 levels throughout the cycle to determine ovulation. Embryo transfer (ET) will be scheduled on the fifth day after ovulation. Blood for P4 measurement will be drawn upon admission to the clinic for the ET procedure. P4 will be measured on day 5 or day 6 after the ET procedure and together with the hCG 10 days after ET procedure.
89201890|NCT00567879|Experimental|Panobinostat with trastuzumab|Panobinostat intravenously (i.v.) or orally was given in combination with trastuzumab.
89017861|NCT05969795|Other|Control Group|Intermittent ultrasound scans to monitor follicular growth and serial measurements of serum LH, E2 and P4 levels throughout the cycle to determine ovulation. Embryo transfer (ET) will be scheduled on the fifth day after ovulation. Administer on FET day 200 mg of P4 and increase to 300 mg/day from the day after the ET onwards until the pregnancy test. Blood for P4 measurement will be drawn before starting LPS in form of vaginal progesterone. P4 will be measured on day 5 or day 6 after the ET procedure and together with the hCG 10 days after ET procedure. In case of an implantation, vaginal P4 will be continued until 7 weeks of pregnancy.
89017862|NCT05966220|Other|Total hip arthroplasty (THA) and Revision THA|Patients will be monitored for up to 15 years postoperatively.
89017863|NCT05966220|Other|Traumatology: femoral neck Total hip arthroplasty or hemiarthroplasty|Patients will be monitored for up to 10 years postoperatively.
89462709|NCT01063855|Placebo Comparator|Placebo + PDE5I|Placebo tablets identical in appearance to dapoxetine taken 1 to 3 hours before sexual activity prn (as needed) not to be taken more than once every 24 hours for 12 weeks + a PDE5I (phosphodiesterase-5 inhibitor) prescribed prior to study entry for the treatment of erectile dysfunction.
89462710|NCT05162001|Experimental|Disulfiram|A group of adults with a body mass index bigger than 22, treated with disulfiram
89462711|NCT03469167|Experimental|CEGP003|
89462712|NCT03469167|Active Comparator|Injection Tx|
89017864|NCT05965817|Experimental|Patients with colorectal livermetastases receiving SGM-101 and ICG|In total 10 patients will be included who are scheduled for resection of colorectal liver metastases and receive SGM-101 and ICG
89017865|NCT05957081|Experimental|Phase 1 a: Part A: PMC-309 Monotherapy Dose Escalation|"Phase 1a will enroll participants with advanced or metastatic solid tumors to assess safety, tolerability, PK and clinical efficacy in response to treatment with PMC-309 as a monotherapy~Dosage form and Route of administration: The duration of a treatment cycle is 3 weeks/21 days. Participants will be administered a weekly dose of PMC-309 per cycle as follows:~Cycle Week 1/Day 1~Cycle Week 2/Day 8 ± 2 days~Cycle Week 3/Day 15 ± 2 days PMC-309 will be administered intravenously over 1 hour (± 0.5 hours), after which participants will be observed for a period of 1.5 hours post administration."
89201891|NCT00777504|Active Comparator|A|When PD is being determined the patient will continue with the oral angiogenesis inhibitors for 2 more weeks. After 2 weeks, an Avastinscan will be made and/or a dynamic contrast enhanced MRI (DCE-MRI). After evaluating these scans patients in group A now stop the orale angiogenesis inhibitor.
89462713|NCT01063153|Experimental|Concerta|Open-Label Concerta (Osmotic Release Methylphenidate)
89462714|NCT01063153|No Intervention|Control group|Healthy subjects without ADHD will be assessed using EEG.
89462715|NCT05161299||Control (normal practice)|Patients that underwent surgery (across all specialities), performed by a surgeon in an operating theatre, AND had a positive SARS-CoV-2 PCR swab or rapid antigen test (if PCR swab is not available) within 7 days before or 30 days after surgery. Patients can be included regardless of whether a specific variant is suspected or unknown
89462716|NCT01062841|Active Comparator|Intervention: Targeted Infection Control|Nursing homes allocated to the Intervention Arm will implement a series of new infection control programs.
89462717|NCT01062841|No Intervention|Control|Nursing homes allocated to the control group will continue with their standard infection control procedures. No changes will be made to their practices.
89462718|NCT05161221|Active Comparator|Pre-operative femoral nerve catheter|participants undergoing ACL reconstruction surgery will receive a femoral prior to their surgery
88943404|NCT04552717|Experimental|Intervention|"Participants will complete a web based pre-assessment and then given access to the app My Grief for three months followed by a web based post-assessment and an interview via telephone regarding their experiences of using the app, and follow-up questionnaires."
88943405|NCT04552717|No Intervention|Waitlist controll|Participants will get access to the app after three months.
88943406|NCT04549207|Active Comparator|Standard BMA frequency|Continue standard BMA frequency (every 4 or 12 weeks) as administered previously. If a change in BMA frequency (every 4 weeks to every 12 weeks OR every 12 weeks to every 4 weeks) was prescribed by the physician, this would still be considered on protocol treatment.
88943407|NCT04549207|Active Comparator|De-escalate BMA to once every 24 weeks|Bone modifying agent once every 24 weeks.
88943408|NCT04537195|Experimental|Intervention Group|ADSMP-C
88943409|NCT04537195|No Intervention|Control Group|Wait-list control group
88943410|NCT04535492|Other|Colorectal Cancer Screening Recommended|The USPSTF recommends screening for colorectal cancer starting at age 50 years and continuing until age 75 years.
88943411|NCT04535492|Other|Lung Cancer Screening Recommended|The USPSTF recommends annual screening for lung cancer with low-dose computed tomography (LDCT) in adults ages 50 to 80 years who have a 20 pack-year smoking history and currently smoke or have quit within the past 15 years.
88943412|NCT04535492|Other|Breast Cancer Screening Recommended|The USPSTF recommends biennial screening mammography for women aged 50 to 74 years.
88943413|NCT04526444|Experimental|Ftiness tracker|Participants in the group A will be provided the fitness tracker Mi Smart Band 5 with the computational algorithm PAI.
88943414|NCT04526444|Experimental|Home training platform and fitness tracker|Participants in group B will be provided with both the fitness tracker Mi Smart Band 5 with the computational algorithm PAI and access to Les Mills On Demand to perform training classes from home.
88943415|NCT04526444|Experimental|Peer support, home training platform and fitness tracker and|Participants in group C will be offered the fitness tracker Mi Smart Band 5 with the computational algorithm PAI, Les Mills On Demand and additional peer support via social media.
88943416|NCT04506437|Experimental|Family-based mental health navigation|Family-based navigator intervention combined with mHealth practices to improve mental health treatment initiation and engagement
88943417|NCT04506437|Active Comparator|Standard of care, then family-based mental health navigation|During wait-list period receive standard of care engagement practices and services-as-usual, and after the wait-list period the participants receive the family-based navigator intervention combined with mHealth practices
88943418|NCT04505345|Experimental|Virtual reality cognitive training|Virtual reality cognitive training consists of a behavioral intervention of 10 sessions of training using virtual reality exercises depicting daily life activities from the Systemic Lisbon Battery aiming cognitive impairments.
88943419|NCT04505345|Other|Treatment-as-usual|Treatment-as-usual for alcohol use disorder (AUD) in our partner institution, a therapeutic community for rehabilitation of AUD, is conducted according to the Minnesota Model requiring alcohol abstinence.
88943420|NCT04494711|Experimental|Physical functional literacy|5 week physical literacy program for adults with multiple chronic conditions
88943421|NCT04439734|Experimental|Whole-Body Electromyostimulation|WB-EMS once per week for for 16 week (85 Hz, 350 µs, bipolar, duty cycle 4s-4s)
88943422|NCT04439734|No Intervention|Non WB-EMS control|No WB intervention, but maintained physical activity and habitual exercise habits
88943423|NCT04438083|Experimental|CTX130|Administered by IV infusion following lymphodepleting chemotherapy.
88943424|NCT04418453||Integration of telemedicine in primary care settings for MOUD|Primary care providers may refer OUD patients to receive telemedicine for MOUD
88943425|NCT04345211|Active Comparator|Group1 (G1): walking group|"All walks will be done immediately after the MT and TB intervention, as this has been shown to improve the synergistic effect of combining the two interventions. The walking sessions will be organized twice a week. The walking sessions will begin with a 10-minute warm-up. After warming up, you will take a continuous walk for 10-20 min, at a target intensity of 13 (somewhat difficult) on the Borg scale. Using the Borg scale, which ranges from 6 to 20, participants will be asked to walk at an intensity of 13 (perception of somewhat difficult activity). Each session will be completed with a 10 minute cool down period. The objectives of Walinking will be individualized according to the level of physical condition of each participant. The walking group will include a weekly walking goal of 75 minutes."
88943426|NCT04345211|Active Comparator|Group 2 (G2): walking plus manual therapy|"Walking as previously described plus a self-administered manual chest therapy:~- Neurolymphatic points pressure: Participants will be placed in a neutral position and their arms next to their bodies. They are asked to take a conscious breath. The physical therapist will apply firm, direct rotary pressure through the thumb or fingertip for 1 minute from the T1 transverse processes to the T12 transverse processes. Suboccipital decompression / mobilization, slippage of the cervical vertebral joints (anterior / posterior), myofascial release of sternocleidomastoid and trapezius, slippage of the sternoclavicular joint (anterior / posterior direction), myofascial release of intercostal muscles and paravertebral muscles (anterior rib mobilization, posterior, lateral), mobilization of the scapulothoracic joint, diaphragmatic release."
88943427|NCT04345211|Active Comparator|Group 3 (G3): walking plus thorax exercises with Theraband.|Walking as previously described plus a self-administered exercises with elastic-band. The exercises will include chest and arms exercises in sitting position.
89462719|NCT05161221|Active Comparator|Pre-operative adductor canal block with liposomal bupivacaine|participants undergoing ACL reconstruction surgery will receive a nerve block using liposomal Bupivacaine (Exparel)
89462720|NCT02505334|Experimental|Liraglutide 1.8 mg|The total trial duration for the 1.8 mg/day treatment arm will be approximately 67 weeks, consisting of 2 weeks screening period, a 12 weeks run-in period, a 26-week main treatment period, a safety extension period of 26 weeks and a follow-up visit.
89462721|NCT02505334|Active Comparator|Liraglutide 0.9 mg|The total trial duration for the 0.9 mg/day treatment arm will be approximately 41 weeks, consisting of 2 weeks screening period, a 12 weeks run-in period, a 26-week treatment period, and a follow-up visit.
88943428|NCT04345211|No Intervention|Group 4 (G4): control group|Control group will do usual life and assessments as the rest of the groups.
88943429|NCT04340531|Experimental|Arm I (early arm)|Providers undergo training over 60 minutes to explain the Break Free program and basics of quitting smoking during months 13-24. Female smokers interested in quitting in the next 6 months will be referred to an in-person counseling session at the clinic. Participants then receive 4 phone counseling over 15-20 minutes with a trained tobacco treatment specialist.
88943430|NCT04340531|Active Comparator|Arm II (delayed arm)|Female smokers receive usual care during months 13-24. Providers undergo training over 60 minutes to explain the Break Free program and basics of quitting smoking during months 25-36. Female smokers interested in quitting in the next 6 months will be referred to an in-person counseling session at the clinic. Participants then receive 4 phone counseling over 15-20 minutes with a trained tobacco treatment specialist.
88943431|NCT04335214|Other|Interview|One to one interview with older people from moroccon origin in Belgium
88943432|NCT04328038||USA|Cohort from the USA
88943433|NCT04328038||Germany|Cohort from Germany
88943434|NCT04325815||CADDIE|The endoscopist will be assisted with CADDIE system to detect polyps. The endoscopist will perform optical diagnosis of polyps with the assistance of the CADDIE's polyp characterisation function.
88943435|NCT04325815||Standard Procedure|In addition to routine colonoscopy the endoscopist will perform optical diagnosis of detected polyps without the assistance of the CADDIE.
88943436|NCT04319328||Cefazolin|n = 20
88943437|NCT04319328||Ceftazidime|n = 20
88943438|NCT04319328||Ciprofloxacin|n = 20
88943439|NCT04317326|Experimental|Life style modification|"Lifestyle modifications group (Control) will consist of a 1,000-calorie/day diet and to maintain proper sleep hygiene and habits (avoid supine decubitus position, maintain regular sleep habits and exercise, not take sedatives, stimulants, alcohol, tobacco or heavy meals within four hours before bedtime). Oxygen therapy can be prescribed by the treating team using standard criteria (awake PaO2 <55 mmHg or room air oxygen saturation below 88% (Masa JF et al. J Clin Sleep Med. 2016 ;12:1379-88)"
88943440|NCT04317326|Active Comparator|Life style modificacion and automatic NIV(AVAPS-AE)|Automatic NIV: In addition to lifestyle modification and oxygen (if required), the ventilator will be adjusted to a range of predetermined parameters with the intelligent ventilation mode (pressure of intelligent support with guaranteed volume with automatic backup frequency) with the following adjustment: maximum pressure: 35 cmH2O; respiratory rate: automatic; maximum pressure support: 20 cm H2O; minimum pressure support: 4 cmH2O; maximum EPAP pressure: 15 cmH2O; minimum EPAP pressure: 4 cmH2O; and tidal volume (Vt) based on 8-10 ml/kg of predicted body weight. These parameters may be modified according to patient tolerance or non-compensated leak.
88943441|NCT04317326|Experimental|Life style modification and titrated NIV(S/T mode)|In-laboratory polysomnographic NIV titration will be performed according to published guidelines (Berry R et al JCSM 2010). In addition to lifestyle modification and oxygen (if required), home NIV therapy with fixed pressures will be started. The ventilator mode will be a bilevel PAP with backup respiratory rate (BIPAP S/T mode). The ventilator adjustment will be firstly performed in awake situation and then during sleep by means of a PSG.
88943442|NCT04317326|Active Comparator|Life style modification and titrated CPAP|In-laboratory polysomnographic CPAP titration will be performed according to published guidelines (SEPAR guideline or AASM guideline). In addition to lifestyle modification and oxygen (if required), home CPAP therapy at a fixed pressure will be initiated.
88943443|NCT04255160|Experimental|Estradiol|Transdermal estradiol (0.1mg/day patch)
89462722|NCT03469089|Placebo Comparator|Placebo/placebo|Placebo for ketamine (0.9% NaCl) + Placebo for modafinil (microcrystalline cellulose capsule)
89462723|NCT03469089|Experimental|Ketamine 0.58/placebo|Ketamine (0.23 mg/kg + 0.58 mg/kg/h) + Placebo for modafinil
89462724|NCT03469089|Experimental|Ketamine 0.58/modafinil|Ketamine (0.23 mg/kg + 0.58 mg/kg/h) + Modafinil (200 mg)
89462725|NCT03469089|Experimental|Ketamine 0.31/placebo|Ketamine (0.12 mg/kg + 0.31 mg/kg/h) + Placebo for modafinil
88943444|NCT04255160|Placebo Comparator|Placebo|Placebo
88943445|NCT04254562|Experimental|Experimental Group: HYPE Services|The experimental arm will receive the HYPE intervention for 12 months.
89462726|NCT05161143|Experimental|Experimental: Donafenib plus TACE|"Donafenib: 4-8 weeks after radical surgery,patients will take donafenib, 200mg Bid,at least 6 months.~TACE:4-8 weeks after radical surgery,Patients will receive TACE once."
89462727|NCT01062061||VARIVAX|Attenuated live varicella vaccine was administered in usual practice. Recommended dosing is a single 0.5 mL subcutaneous injection in children 12 months to 12 years of age.
89462728|NCT03652207|Placebo Comparator|Sucrose|Test products i.e. low-fat yogurt drink, fruits drink and sweetener sachet for cereals containing sucrose
89462729|NCT03652207|Experimental|Palatinose(TM)|Test products i.e. low-fat yogurt drink, fruits drink and sweetener sachet for cereals containing isomaltulose (Palatinose™)
89462730|NCT04969510|Experimental|PRAX-114 (10 mg)|10 mg PRAX-114 once daily
89462731|NCT04969510|Experimental|PRAX-114 (20 mg)|20 mg PRAX-114 once daily
89462732|NCT04969510|Experimental|PRAX-114 (40 mg)|40 mg PRAX-114 once daily
89462733|NCT04969510|Experimental|PRAX-114 (60 mg)|60 mg PRAX-114 once daily
89462734|NCT04969510|Placebo Comparator|Placebo|Placebo once daily
88943446|NCT04254562|Active Comparator|Control Group: Enhanced Academic Services as Usual|"The control arm will receive a special personalized packet of resources available on campus and off-campus within a 10-mile radius, as enhanced academic services as usual."
88943447|NCT04243512|Experimental|Time-restricted eating|Participants will be asked to follow a TRE meal pattern for 14 consecutive days. Participants will be encouraged to consume food and beverages only within a 10-h time window for the 14-day intervention, with the exception of water, which will be encouraged at any time.
89462735|NCT02504320|Experimental|Treatment Sequence ABDC|Febuxostat XR 80 mg capsule Formulation 1 (F1), orally, once on Day 1 of Period 1 (A), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule Formulation 2 (F2), orally, once on Day 1 of Period 2 (B), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule Formulation 4 (F4), orally, once on Day 1 of Period 3 (D), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule Formulation 3 (F3), orally, once on Day 1 of Period 4 (C).
89462736|NCT02504320|Experimental|Treatment Sequence DACB|Febuxostat XR 80 mg capsule F4, orally, once on Day 1 of Period 1 (D), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F1 orally, once on Day 1 of Period 2 (A), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F3, orally, once on Day 1 of Period 3 (C), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F2, orally, once on Day 1 of Period 4 (B).
88943448|NCT04225156|Experimental|efgartigimod|patients receiving efgartigimod
88943449|NCT04184687|Experimental|Nanofractures treatment of the cartilaginous lesions|Patients undergoing to anterior cruciate ligament reconstruction with concomitant treatment of the cartilaginous lesions with nanofractures technique.
88943450|NCT04184687|Active Comparator|no treatment of the cartilaginous lesions|Patients undergoing to anterior cruciate ligament reconstruction. Cartilaginous lesions won't be treated
88943451|NCT04179123|Experimental|Healthy|Conventional and customised PAP interfaces
88943452|NCT04179123|Experimental|Patients|Conventional and customised PAP interfaces
88943453|NCT04138433|Experimental|Real tDCS|fMRI task plus anodal tDCS
88943454|NCT04138433|Sham Comparator|Sham tDCS|fMRI task plus sham tDCS
88943455|NCT04135586|Experimental|Exercise|The patients in this arm will follow an exercise program for 24 weeks (i.e., during neo-adjuvant treatment), with two sessions per week including both aerobic and resistance training. Exercise intensity will range between 65% and 100% of the maximum score in the scale of Rated Perceived Exertion (RPE).
88943456|NCT04135586|Other|Control|The patients follow their usual habits as well as a Yoga program. They will also receive educational sessions on the benefits of regular physical activity (brisk walking).
88943457|NCT04132128|Experimental|study|6 meetings with a dietician diabetes educator assimilating simple CC tool
88943458|NCT04132128|Other|control|meeting with dietician as needed with regular education of CC
88943459|NCT04131491|Other|Patients with Mild Cognitive Impairment (MCI) due to AD|Neuropsychological investigation, lumbar puncture, long term-EEG monitoring and/or MEG-EEG, magnetic resonance imaging (MRI), blood sample with deep genetic profiling and Apolipoprotein E (APOE) determination.
88943460|NCT04131491|Other|Healthy volunteers|Neuropsychological investigation, lumbar puncture, long term-EEG monitoring and/or MEG-EEG, MRI, blood sample with deep genetic profiling and APOE determination.
89462737|NCT02504320|Experimental|Treatment Sequence CDBA|Febuxostat XR 80 mg capsule F3, orally, once on Day 1 of Period 1 (C), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F4 orally, once on Day 1 of Period 2 (D), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F2, orally, once on Day 1 of Period 3 (B), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F1, orally, once on Day 1 of Period 4 (A).
89462738|NCT02504320|Experimental|Treatment Sequence BCAD|Febuxostat XR 80 mg capsule F2, orally, once on Day 1 of Period 1 (B), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F3 orally, once on Day 1 of Period 2 (C), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F1, orally, once on Day 1 of Period 3 (A), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F4, orally, once on Day 1 of Period 4 (D).
89462739|NCT05014516||Single arm|Those participants who have experienced a documented case (documented by positive COVID19 test and/or clinical history) mild or severe COVID19 infection including those with symptoms and those who were hospitalized with COVID19 infection, all of whom are within 3 months post recovery
89462740|NCT01061671|Active Comparator|simvastatin|40 mgms of simvastatin daily
89462741|NCT01061671|Placebo Comparator|placebo|Matched placebo pill daily
89201892|NCT00777504|Active Comparator|B|When PD is being determined the patient will continue with the oral angiogenesis inhibitors for 2 more weeks. After 2 weeks, an Avastinscan will be made and/or a dynamic contrast enhanced MRI (DCE-MRI). After evaluating these scans patients in group B continue with angiogenesis inhibitors for 2 more weeks. After these 2 weeks(so 4 weeks after inclusion) another Avastinscan will be made and/or a dynamic contrast enhanced MRI (DCE-MRI) and a FDG-PET-scan.
89201893|NCT00781482|Experimental|1|This is a crossover study. Each study drug will be administered (one at a time and in random order) to each subject on separate occasions over the course of the study.
89462742|NCT04969120|Active Comparator|(group 1) receiving intravenous metoclorpramide|this group receive 10mg intravenous metoclopramide
89462743|NCT04969120|Placebo Comparator|(group 2) receiving placebo|this group receive 10mg intravenous placebo(0.9 sodium chloride)
89462744|NCT03652363|Placebo Comparator|Placebo|Placebo administered via convection enhanced delivery
89462745|NCT03652363|Experimental|glial derived neurotrophic factor|Recombinant-methionyl human glial cell line-derived neurotrophic factor (r-metHuGDNF), administered via convection enhanced delivery
89462746|NCT00709995|Experimental|Part 1 Arm A: Enzastaurin + Sunitinib|"(Cohort 1): On cycle 1, day 1 a loading dose 125 milligram (mg) of Enzastaurin was administered by mouth orally, (BID) twice a day, followed by Enzastaurin 125 mg administered, twice a day, Days 2 through 42 of a 6-week cycle.~(Cohort 2): Cycle 1, Day 1 loading dose 375 mg of Enzastaurin administered po three times a day (TID), followed by 250 mg, po, BID continuously until disease progression, unacceptable toxicity, death, or discontinuation from the study for any other reason.~Sunitinib 50 mg was administered orally, once daily, Days 1-28, then rest (no drug given) days 29-42.~Phase 2 (Part 2): Randomized Double-Blind: Dosing was determined by Part 1. Part 2 was not activated per recommendation of safety review committee.~Enzastaurin: Cycle 1, Day 1 loading dose 375 mg administered orally, (TID) three times a day, followed by Part 1 dose twice a day on Days 2-42 of 6 week cycle.~Sunitinib: 50 mg administered orally, once daily, on Days 1-28, then rest Days 29-42."
89462747|NCT00709995|Placebo Comparator|Part 2 Arm B: Sunitinib + Placebo|"Part 2 was not activated per recommendation of safety review committee.~Sunitinib: 50 mg administered orally, once daily, Day 1-28, then rest Days 29-42.~Placebo: Cycle 1 Day 1 loading dose 3 tablets on Day 1, then 2 tablets daily, days 2-42."
88943461|NCT04103346|Active Comparator|air filtration with hepa filter|air purifier used is the Holmes HAP8650B-NU-1 with the hepa filter inserted.
88943462|NCT04103346|Sham Comparator|air filtration with hepa filter removed|sham comparator uses the Holmes HAP8650B-NU-1 air purifier to be operated with the filter removed.
88943463|NCT04101669|Experimental|EndoBarrier|Patients in ARM 1, will receive an upper endoscopy and will be treated with the EndoBarrier Liner
88943464|NCT04101669|Sham Comparator|Sham|Patients in Arm 2 will receive an upper endoscopy, but will not be treated with the EndoBarrier Liner.
88943465|NCT04099485|No Intervention|Current State|Clinicians of patients randomized to this arm will have access to the Atrial Fibrillation Decision-Support Tool (AFDST) embedded in our EHR (as they do now), but will not receive BPAs alerting them to patients who might benefit significantly from a change in anticoagulation treatment.
88943466|NCT04099485|Experimental|AFDST with BPA|Clinicians of patients randomized to this arm will receive BPAs when they are in the medical record of an AF patient who might gain significantly from a change in anticoagulation treatment. In addition, clinicians will have the ability to refer patients to a pharmacist-staffed AF Thromboprophylaxis Shared Decision-Making Service based in our Anticoagulation Clinic.
88943467|NCT04099173|Experimental|Brief Mindfulness Based Intervention|Some participants, as a result of random selection, will be asked to participate in four, 45-minute sessions that will occur on four separate days while on the Inpatient Psychiatric Unit (IPU). These four sessions are in addition to the standard IPU treatment and are experimental. These four sessions will include mindfulness meditation practice and education, creating a Crisis Response Plan, and a brief introduction into self-compassion. As stated above, practicing mindfulness means focusing attention on what is occurring in the present moment in a non-judgmental way. The focus may be on what one is seeing or hearing or physical sensations, such as touch, as well as thoughts and emotions. Meditation is just sitting quietly and practicing mindful awareness.
88943468|NCT04099173|No Intervention|Treatment as Usual|Participants will be asked to fill out several short paper and pencil tests to assess your response to the treatment (10 to 15 minutes) pre-intervention and immediately post-intervention while on the Inpatient Psychiatric Unit (IPU), as well as a follow-up phone call or mail one month after discharge from the IPU. All participants will receive the IPU's normal standard of care treatment (for study purposes this called treatment as usual).
88943469|NCT04092387|Experimental|RC 1 only|Research cigarettes #1
88943470|NCT04092387|Experimental|RC 2 only|Research Cigarettes #2
88943471|NCT04092387|Experimental|RC 2 + EC 1|Research Cigarettes #2 plus E-cigarettes #1
88943472|NCT04092387|Experimental|RC 2 + EC 2|Research Cigarettes #2 plus E-cigarettes #2
88943473|NCT04082416|Experimental|RC18 160mg|Patients received the test group RC18 160mg weekly administered subcutaneously for 52 times.
88943474|NCT04082416|Placebo Comparator|Placebo|Patients received the test group Placebo weekly administered subcutaneously for 52 times.
89462748|NCT03652129|Experimental|Laser Group|Disinfection using biostimulating LASER
89462749|NCT03652129|Experimental|Nano irrigant Group|Disinfection using Nano irrigant
88943475|NCT04070781|Experimental|Itacitinib + Tocilizumab|"A dose de-escalation design will be used to identify the MTD of both itacitinib and tocilizumab when given in combination. The following two levels will be tested with at least 6 patients per dose:~Dose level 1: Itacitinib 200 mg daily + tocilizumab 8mg/kg on cycle 1, day 1 (can repeat cycle 2 day 1 if Partial Response (PR) - Starting dose level~Dose level -1: Itacitinib 200 mg daily + tocilizumab 4mg/kg on cycle 1, day 1 (can repeat cycle 2 day 1 if Partial Response (PR) - Dose De-escalation level~Itacitinib will be given daily in 28-day long cycles, tocilizumab will be given every 4 weeks in 28-day cycles."
88943476|NCT04070781|Experimental|Dose Expansion|Once the MTD is determined, an additional 10 patients as an expansion cohort to further define the safety profile of the combination and estimate its response rate.
88943477|NCT04066166||Subjects|Healthy
88943478|NCT04064164|Experimental|Treatment|The treatment NHs will received immediate feedback from the Speeko App after each recording sessions
88943479|NCT04064164|No Intervention|Control|The Control NHs will not receive app feedback until all recording sessions are complete.
88943480|NCT04063709|Experimental|Symptomatic with 50-69% stenosis|Patients 18 years of age or older who have been selected by their treating physician to be in need of carotid revascularization by CEA, with 50-69% stenotic carotid plaque with associated neurological symptoms. Acoustic Radiation Force Impulse (ARFI) ultrasound imaging will be performed on the carotid plaque.
88943481|NCT04063709|Experimental|Symptomatic with 70-99% stenosis|Patients 18 years of age or older who have been selected by their treating physician to be in need of carotid revascularization by CEA, with 70-99% stenotic carotid plaque with associated neurological symptoms. ARFI ultrasound imaging will be performed on the carotid plaque.
89201894|NCT00925275|Experimental|Dosimetric|
89201895|NCT00907725|Other|1|serum BhCG follow-up
89201896|NCT00907725|Other|2|ultrasonographic follow-up
89462750|NCT03652129|Active Comparator|Conventional irrigation protocol group|disinfection using normal irrigation protocols
89462751|NCT02503540|Other|Aflibercept|Monthly aflibercept for 6 months and then every other month for 6 months.
89462752|NCT03621865|Experimental|subject sequence 1|subject allocation sequence 1. Intervention: The subject will receive the five products (TG, STE, NOV, PHYT or TEP) in a certain order.
89462753|NCT03621865|Experimental|subject sequence 2|subject allocation sequence 2. IIntervention: The subject will receive the five products (TG, STE, NOV, PHYT or TEP) in a certain order.
89462754|NCT03621865|Experimental|subject sequence 3|subject allocation sequence 3. Intervention: The subject will receive the five products (TG, STE, NOV, PHYT or TEP) in a certain order.
89462755|NCT03621865|Experimental|subject sequence 4|subject allocation sequence 4. Intervention: The subject will receive the five products (TG, STE, NOV, PHYT or TEP) in a certain order.
88943482|NCT04063709|Experimental|Asymptomatic with 70-99% stenosis|Patients 18 years of age or older who have been selected by their treating physician to be in need of carotid revascularization by CEA, with 70-99% stenotic carotid plaque without associated neurological symptoms. ARFI ultrasound imaging will be performed on the carotid plaque.
88943483|NCT04063709|Experimental|Asymptomatic with 50-69% stenosis|Patients 18 years of age or older who have been diagnosed with 50-69% carotid artery stenosis without clinical indication for CEA.
88943484|NCT04041050|Experimental|Part 1: Navitoclax Monotherapy|Participants will receive various doses of navitoclax once daily (QD).
88943485|NCT04041050|Experimental|Part 2: Navitoclax + Ruxolitinib Combination Therapy|Participants will receive various doses of navitoclax once daily (QD) in combination with ruxolitinib twice daily (BID).
88943486|NCT04041050|Experimental|Part 3: Navitoclax Monotherapy|Participants will receive navitoclax once daily (QD).
88943487|NCT04041050|Experimental|Part 4: Navitoclax + Celecoxib|Participants will receive navitoclax once daily (QD) starting on Day 3. Participants will also receive celecoxib single dose on Day 1 and Day 7.
88943488|NCT04041050|Experimental|Part 5: Navitoclax + Ruxolitinib Combination Therapy|Participants will receive ruxolitinib BID and navitoclax QD for drug-drug interaction (DDI) assessment, followed by continued administration of navitoclax in combination with ruxolitinib.
88943489|NCT04035369|Active Comparator|Endophthalmitis Post Intravitreal Injections - TAI|Patients 18 years and older with presumed infectious endophthalmitis after non-steroid intravitreal injections randomized to TAI
88943490|NCT04035369|Active Comparator|Endophthalmitis Post Intravitreal Injections - PPV|Patients 18 years and older with presumed infectious endophthalmitis after non-steroid intravitreal injections randomized to PPV
88943491|NCT04018313|Experimental|CT-P39 (Part 1)|150 mg/mL, Solution for injection in PFS
88943492|NCT04018313|Active Comparator|EU-approved Xolair (Part 1)|150 mg/mL, Solution for injection in PFS
88943493|NCT04018313|Experimental|CT-P39 (Part 2)|150 mg/mL, Solution for injection in PFS
88943494|NCT04018313|Active Comparator|EU-approved Xolair (Part 2)|150 mg/mL, Solution for injection in PFS
88943495|NCT04018313|Active Comparator|US-licensed Xolair (Part 2)|150 mg/mL, Solution for injection in PFS
88943496|NCT04011332|Experimental|Intervention Group|
88943497|NCT04011332|No Intervention|Control Group|
89462756|NCT03621865|Experimental|subject sequence 5|subject allocation sequence 5. Intervention: The subject will receive the five products (TG, STE, NOV, PHYT or TEP) in a certain order.
88943498|NCT04006405||Cohort 1|140 patients with a minimum follow-up of 12 months
88943499|NCT04006405||Cohort 2|up to 140 patients with a minimum follow-up of 12 months
88943500|NCT04005976||Patients with causal mutations in the known H-TAD genes|
88943501|NCT03974412|Experimental|All eligible participants|All eligible participants are randomly assigned to one of two interventions- early Head-Up Tilt Table procedure or early Implantable Loop Recorder. The assignment is random and at a 1:1 ratio between the two strategies.
88943502|NCT03973203|Experimental|Niacin in controls|The arm includes healthy controls supplemented with niacin.
88943503|NCT03973203|Experimental|Niacin in mitochondrial myopathy patients|The arm includes mitochondrial myopathy patients supplemented with niacin.
88943504|NCT03930823|Other|Interview|One to one interviews with older people from Turkish origin in Belgium
88943505|NCT03916926|Experimental|"A simple medical strategy consisting of SDF"|The treatment will be bi-annual application (at baseline and 26 weeks) of topical 38% silver diamine fluoride (Advantage Arrest, Elevate Oral Care LLC., West Palm Beach, FL) following manufacturer's instructions and guidelines published by UCSF (2016).
88943506|NCT03916926|Active Comparator|"A typical dental strategy consisting of ART + FV"|Atraumatic Restorative Treatment (ART) will be a modification of the approach used by Lo and colleagues (2006), and the cavity restored at baseline with resin reinforced glass-ionomer cement (GIC) (GC Corporation, Japan). Participants in this arm will also receive biannual topical fluoride varnish application (FluoriMax, Elevate) according to manufacturer's instructions.
88943507|NCT03906370||MS patients/cases|Patients admitted for diagnostic investigations to the MS clinic were offered participation if aged >18 years and no previous use of immunosuppressing or modifying drugs within 6 months. The diagnosis healthy/diseased was made by 2017 Mc Donald criteria.
89462757|NCT03621865|Experimental|subject sequence 6|subject allocation sequence 6. Intervention: The subject will receive the five products (TG, STE, NOV, PHYT or TEP) in a certain order.
89462758|NCT03621865|Experimental|subject sequence 7|subject allocation sequence 7. Intervention: The subject will receive the five products (TG, STE, NOV, PHYT or TEP) in a certain order.
89462759|NCT03621865|Experimental|subject sequence 8|subject allocation sequence 8. Intervention: The subject will receive the five products (TG, STE, NOV, PHYT or TEP) in a certain order.
89462760|NCT03621865|Experimental|subject sequence 9|subject allocation sequence 9. Intervention: The subject will receive the five products (TG, STE, NOV, PHYT or TEP) in a certain order.
89462761|NCT03621865|Experimental|subject sequence 10|subject allocation sequence 10. Intervention: The subject will receive the five products (TG, STE, NOV, PHYT or TEP) in a certain order.
89462762|NCT04222101|Other|cardiomyopathy|only one arm, all participants undergo oral glucose tolerance testing and results are used to evaluate association with degree of cardiac dysfunction
89462763|NCT04054297|Experimental|High GI/SFA diet|Subjects will adhere to a two-week high GI and high SFA diet. Crossover design, randomly assigned to start with either high GI/SFA or low GI/SFA. 4 week washout between the two diets.
89462764|NCT04054297|Experimental|Low GI/SFA diet|Subjects will adhere to a two-week low GI and low SFA diet. Crossover design, randomly assigned to start with either high GI/SFA or low GI/SFA. 4 week washout between the two diets.
89462765|NCT03652597|Active Comparator|Left|Subjects are ascribed to left hemispheric stimulation
89462766|NCT03652597|Active Comparator|Right|Subjects are ascribed to right hemispheric stimulation
89462767|NCT02502526|Experimental|CVS with 45° Balanced Tip|Centurion® Vision System, 45° Balanced Tip used with INTREPID® Ultra Infusion Sleeve in one time routine surgical procedure followed by 3 months (+/- 14 days) of post-operative follow-up
89462768|NCT02502526|Active Comparator|CVS with 45° MFK Tip|Centurion® Vision System, 45° MFK Tip used with INTREPID® Ultra Infusion Sleeve in one time routine surgical procedure followed by 3 months (+/- 14 days) of post-operative follow-up
89462769|NCT02502526|Active Comparator|IVS with 45° MFK Tip|lnfiniti® Vision System, 45° MFK Tip used with Ultra Infusion Sleeve in one time routine surgical procedure followed by 3 months (+/- 14 days) of post-operative follow-up
89462770|NCT05390697|Experimental|Intervention group|The educational videos included five modules distributed over five weeks.
89462771|NCT05390697|No Intervention|Control group|Participants in the control group were given exposure to the digital version of the MCH handbook, 2020 edition, consisting of animated pictures and simple instructions.
89462772|NCT02972515|Experimental|See Me Smoke-Free|"Participants received access to the See Me Smoke-Free mobile application (app) delivered via smart phone, and were asked to use the app most days for 30 days post-enrollment. The app contained five guided imagery audio files (Introduction to Guided Imagery, Be Smoke Free, Eat Well, Get Active, and Feel Fantastic), a tracking calendar, awards, resources, reminders, and tips and techniques."
88943508|NCT03906370||Healthy subjects/controls|Patients admitted for diagnostic investigations to the MS clinic were offered participation if aged >18 years and no previous use of immunosuppressing or modifying drugs within 6 months. The diagnosis healthy/diseased was made by 2017 Mc Donald criteria.
88943509|NCT03899857|Experimental|Pembrolizumab|Temozolomide-based radiochemotherapy (TMZ/RT=>TMZ) represents the standard of care for patients with newly diagnosed glioblastoma. In this study, pembrolizumab will be administered (200 mg every 3 weeks) in addition to TMZ/RT=>TMZ.
88943510|NCT03871491|Experimental|Intervention|The study intervention is a single 2 g dose of directly observed oral azithromycin.
88943511|NCT03871491|Placebo Comparator|Placebo|By random allocation, participants will receive four oral placebo pills containing a non-antimicrobial agent directly after randomization.
88943512|NCT03853902|Experimental|Mindfulness Program Online|Online 4-week mindfulness program that is intended to reduce stress and improve the quality of life of patients with metastatic prostate cancer
88943513|NCT03853902|Active Comparator|Mindfulness Program Face-to-Face|In-person 4-week mindfulness program that is intended to reduce stress and improve the quality of life of patients with metastatic prostate cancer
88943514|NCT03847324|Active Comparator|Usual Care|Group-based preoperative biomedical education, postoperative hospital and home rehabilitation.
88943515|NCT03847324|Experimental|PNE|Usual care + Preoperative Pain Neuroscience Education
88943516|NCT03847324|Experimental|Multimodal Physiotherapy|Usual care + Preoperative Multimodal physiotherapy
88943517|NCT03846947|Experimental|All participants|All participants will receive the investigational MR Fingerprinting sequence.
88943518|NCT03839914|Active Comparator|Intervention - Vancomycin|Intervention: 1g vancomycin powder locally applied to the deep wound and subcutaneous layer prior to closure.
88943519|NCT03839914|No Intervention|Control - No vancomycin application|No intervention, control group All other wound closure procedure and wound care and monitoring are the same
89462773|NCT05012332|Other|Erector Spinae Plane Block|All volunteers will be given the choice of procedural pain relief in the form of rapifen 0,5-1 mg. All volunteers included will receive an unilateral ESPB at the T7 level with 30 ml of 2,5 mg/ml ropivacaine and a total of 0,3 mmol gadolinium. The intervention will be performed by the PhD candidate connected to the study. The ESPB will be performed under ultrasound guidance, where the needle target is the transverse process of the Th7 vertebra, under the musculus (m.) erector spinae. All volunteers will be tested for cold and pinprick sensation 30 minutes after block completion, and the results plotted on a dermatome map before they undergo an MRI.
89462774|NCT04455087||before intervention|1000 patients befor sensitization
89462775|NCT04967482|Experimental|DEB-TACE|DEB-TACE will be performed for the patients who choose DEB-TACE as the primary treatment.
89462776|NCT04967482|Active Comparator|cTACE|cTACE will be performed for the patients who choose cTACE as the primary treatment.
89462777|NCT04053985|Experimental|TAI+lenvatinib group|TAI combine lenvatinib
89462778|NCT04053985|Active Comparator|lenvatinib group|lenvatinib only
89462779|NCT04455243|Experimental|Intervention group|
88943520|NCT03838263|Experimental|Experimental arm|Experimental arm with nivolumab 2 infusions (2 weeks apart) before Standard of care chemoradiation for 7 weeks with high-dose cisplatin (100 mg/m²) at week 1, 4 and 7
88943521|NCT03838263|Active Comparator|Control arm|Control arm: Standard of care chemoradiation for 7 weeks with high-dose cisplatin (100 mg/m²) at week 1, 4 and 7
89206167|NCT00830856|Experimental|2|Delayed initiation of antiretroviral therapy. Patients in this treatment group were started on Fluconazole 800mg by mouth every day for Cryptococcal Meningitis, and after completion of high dose fluconazole for 10 weeks, the patients in this group were started on First line antiretroviral therapy per Zimbabwe treatment guidelines which is Stavudine, Lamivudine and Nevirapine.
89462780|NCT04455243|Placebo Comparator|Control group|
89462781|NCT04854993|Experimental|Increased dose of sugammadex|A dose of 6 mg/kg of sugammadex will be given intravenously for deep neuromuscular block reversal at the end of surgery
89462782|NCT04854993|Active Comparator|Standard dose of sugammadex|A dose of 6 mg/kg of sugammadex will be given intravenously for deep neuromuscular block reversal at the end of surgery
89462783|NCT02972359|Experimental|Neridronic acid|Neridronic acid 100 mg administered on Day 1, Day 4, Day 7, and Day 10, resulting in a total dose of neridronic acid 400 mg.
89462784|NCT04455009|Experimental|100mg Caffeine Formula|10kcal drink containing a total of 100 mg of caffeine from a proprietary blend of caffeine, guarana, ginger, and green tea extract containing epigallocatechin gallate
89462785|NCT04455009|Experimental|140mg Caffeine Formula|10kcal drink containing a total of 140 mg of caffeine from a proprietary blend of caffeine, guarana, ginger, and green tea extract containing epigallocatechin gallate
89462786|NCT04455009|Placebo Comparator|Placebo Formula|non-caloric/non-caffeinated drink
89462787|NCT04454775||group I|50 cases who received raloxifene and calcium therapy
88943522|NCT03808051|Experimental|Physiological-based cord clamping|Stabilisation of the infant is performed while the cord is intact and the cord will be clamped after the infant is cardiopulmonary stable. Stable is defined as the establishment of heart rate greater than 100 bpm and oxygen saturation above 85% while using supplemental oxygen lower than 40%. The maximum cord clamping time is 10 minutes and prior to cord clamping a trial of weaning from PPV to CPAP is performed. With the exception that the infant is stabilised close to the mother and the cord is clamped later, the infant will receive standard resuscitation interventions.
88943523|NCT03808051|Active Comparator|Time-based cord clamping|Infants are clamped first and then moved to the standard resuscitation table for further treatment and intervention needed for cardiopulmonary stabilisation. Clamping is time based and performed immediately or delayed at 30-60 seconds, depending on the clinical condition of the infant. Uterotonic drugs are administered immediately after cord clamping.
88943524|NCT03801642|Experimental|Dapagliflozin|10 mg dapagliflozin oral tablet taken once daily for 12 weeks
88943525|NCT03801642|Placebo Comparator|Matching placebo|Placebo oral tablet taken once daily for 12 weeks
88943526|NCT03790657|Experimental|tDCS Dosage A|"mild electrical stimulation (Dosage level A) delivered to the frontal region of the brain during practice of a complex walking task"
88943527|NCT03790657|Experimental|tDCS Dosage B|"mild electrical stimulation (Dosage level B) delivered to the frontal region of the brain during practice of a complex walking task"
88943528|NCT03713645|Experimental|Tacrolimus extended-release 0.13mg/kg/day|Tacrolimus extended-release is initiated within post-operative day 3 of kidney transplant
88943529|NCT03705507|Experimental|Selumetinib + Dexamethasone - Group A (18 years and above)|Patients will receive the adult cohort specified dose of selumetinib by mouth, as a single dose on cycle 1 day 1, then twice daily continuously from cycle 1 day 4 onwards. Combined with pulsed doses of dexamethasone at 6mg/m2/day on days 2-4 and 8-11 then at 4mg/m2/day on days 15-18 and 22-25 divided into two doses (as per local practice) by mouth during cycle 1, then on days 1-4 at 4mg/m2/day at the start of cycle 2, then on days 1-5 at 6mg/m2/day during subsequent cycles.
88943530|NCT03705507|Experimental|Selumetinib + Dexamethasone - Group P (under 18 years)|Patients will receive the paediatric cohort specified dose of selumetinib by mouth, as a single dose on cycle 1 day 1, then twice daily continuously from cycle 1 day 4 onwards. Combined with pulsed doses of dexamethasone at 6mg/m2/day on days 2-4 and 8-11 then at 4mg/m2/day on days 15-18 and 22-25 divided into two doses (as per local practice) by mouth during cycle 1, then on days 1-4 at 4mg/m2/day at the start of cycle 2, then on days 1-5 at 6mg/m2/day during subsequent cycles.
88943531|NCT03686410|Experimental|1. Therapeutic Educational Intervention|"The subjects assigned to this group will follow a web-based therapeutic educational intervention on pain and poor sleep quality.~All the subjects assigned to this intervention will have free access to the website from any device with internet access and will be able to consult it as many times as they wish during the intervention. The intervention will last for four weeks."
88943532|NCT03686410|Active Comparator|2. Convetional Tretament|"The subjects assigned to this condition will continue with their usual treatment is based on the recommendations of the clinical practice guideline for the treatment of fibromyalgia Guide of Fibromyalgia developed by the Department of Health of the Generalitat de Catalunya and the Servei Català de Salut."
88943533|NCT03675308|Placebo Comparator|Placebo|Participants randomized to receive double-blind placebo at Week 0, Week 4, and Week 16 in Period 1. At Week 24 participants will receive 150 mg risankizumab followed by open-label 150 mg risankizumab at Week 28, and every 12 weeks thereafter in Period 2 until the final dosing time point at Week 316.
88943534|NCT03675308|Experimental|Risankizumab|Participants randomized to receive 150 mg risankizumab administered by subcutaneous injection at Week 0, Week 4, and Week 16 in Period 1. At Week 24 participants will receive blinded placebo followed by open-label 150 mg risankizumab at Week 28, and every 12 weeks thereafter in Period 2 until the final dosing time point at Week 316.
88943535|NCT03667807|Experimental|rTMS condition 1|
88943536|NCT03667807|Experimental|rTMS condition 2|
88943537|NCT03667807|Experimental|rTMS condition 3|
88943538|NCT03664687|Active Comparator|Zoledronate one dose (4 mg)|One 4 mg dose of Zoledronate
88943539|NCT03664687|Active Comparator|Zoledronate 4 mg every 6 months x 3 years|One 4 mg dose of Zoledronate given every 6 months for 3 years
88943540|NCT03663504|Active Comparator|No Preparation|No preparation before surgery
88943541|NCT03663504|Active Comparator|Oral Antibiotics|Oral antibiotics (neomycin and flagyl), to be taken the day before the surgery
88943542|NCT03654066|Active Comparator|Botulinum toxin|A one time dose of Botulinum toxin (Botox) is injected into the muscle of the LES leading to blockage of acetylcholine release from nerve endings resulting in increased relaxation.
88943543|NCT03654066|Active Comparator|Botulinum toxin and dilation|A one time dose of Botulinum toxin (Botox) is injected into the muscle of the LES leading to blockage of acetylcholine release from nerve endings resulting in increased relaxation. Subjects will also undergo distal esophageal dilation using a 20mm through the scope balloon positioned across the LES.
88943544|NCT03653650|Experimental|PRP plus BCL|Bandage contact lens (BCL) plus 1 autologous platelet-rich plasma (PRP) eye drop every 1 to 3 hours.
88943545|NCT03653650|Active Comparator|BCL plus PFL|Bandage contact lens (BCL) plus 1 preservative-free lubricant (PFL) eye drop every 1 to 3 hours.
89462788|NCT04454775||group II|30 cases who received only calcium therapy
89462789|NCT04911777|Experimental|Pentarlandir™ UPPTA - High Dose|High dose of Pentarlandir™ UPPTA, q8h (over 3 hours postprandially)
89462790|NCT04911777|Experimental|Pentarlandir™ UPPTA - Low Dose|Low dose of Pentarlandir™ UPPTA and placebo, q8h (over 3 hours postprandially)
89462791|NCT04911777|Placebo Comparator|Placebo|Pacebo, q8h (over 3 hours postprandially)
89462792|NCT05390619|Experimental|50% dose of PDT|Patients received 50% dose of verteporfin PDT therapy.
88943546|NCT03653650|Active Comparator|Eye patch plus ocular lubricant ointment|Eye patch plus ocular lubricant ointment every 24 hours.
89206168|NCT01068067|Experimental|pharmacogenetics plus SchE guided dosing|
89462793|NCT05390619|Experimental|70% dose of PDT|Patients received 70% dose of verteporfin PDT therapy.
89462794|NCT04857411|Experimental|Participant 'Buddies'|Participants will have an 8-week program initiation phase followed by a maintenance phase through 6-months, supported by Ambassadors.
89462795|NCT01486537||theeth undergoing pulpotomy|
89462796|NCT01486537||teeth undergoing pulpectomy|
89462797|NCT03770559|Active Comparator|Open-RAMPS|Patients with pancreatic cancer treated by traditional open surgery
89462798|NCT03770559|Experimental|MI-RAMPS|Patients with pancreatic cancer treated by laparoscopic surgery
89462799|NCT01790035|Experimental|LGG|LGG (containing 10^10 viable bacteria) taken by mouth twice daily beginning at baseline (but starting at least 3 days prior to the start of radiation) and continue during RT and for the 2 weeks following RT.
89462800|NCT01790035|Experimental|Placebo|Placebo taken by mouth twice daily beginning at baseline (but starting at least 3 days prior to the start of radiation) and continue during RT and for the 2 weeks following RT.
89462801|NCT01790035|No Intervention|No intervention|Patients who prefer not to receive LGG will not be randomized and will receive standard of care RT. These patients will serve as a non-intervention comparator cohort to the first 20 patients and will have specimens collected but will not receive the placebo.
89462802|NCT03651817|Active Comparator|6ml/kg volume|Patients ventilation will provided with a tidal volume of 6ml/kg
89462803|NCT03651817|Active Comparator|8ml/kg volume|Patients ventilation will provided with a tidal volume of 8ml/kg
88943547|NCT03590691|Active Comparator|Comparison group|Vietnam National Hypertension Program: a training program for health care workers and a health educational program for general public.
88943548|NCT03590691|Experimental|Intervention group|"Vietnam National Hypertension Program including training program for health care workers and an health educational program for general public.~PLUS~Three selected enhancements integrated into routine clinical care:~expanded community health worker services;~home blood pressure self-monitoring; and~a storytelling intervention."
88943549|NCT03568552|Experimental|Patient Decision Aid|Participating clinics (and their patients) will be randomly selected to implement the intervention, at which time their patients will receive Patient Decision Aid for Medication Assisted Treatment for opioid use disorder.
89206169|NCT01068067|Active Comparator|standard dosing|
89206170|NCT00827190|Experimental|1|ILS-920
89462804|NCT01381159|Experimental|Motivational Communication|Up to 3 x 30 minute brief MC sessions within 4-6 week period
89462805|NCT01381159|Placebo Comparator|Control|Usual care
89462806|NCT03651739||TKR Patients|Any patient undergoing total knee arthroplasty and will use the Knee Connect during their knee classes at the Holland Centre
89462807|NCT04723251|Experimental|Taking Photographs|Participants will be asked to take photos with their cell phone.
89462808|NCT03604185|Experimental|Choir Singing Group|Choir participants will take part in weekly two-hour group choral sessions over the course of fourteen weeks, during which time they will receive pitch training and vocal direction. In addition to the weekly group choir sessions, participants will be offered optional individual online musical and vocal training exercises (up to one hour weekly).
89462809|NCT03604185|Active Comparator|Music Appreciation Group|Participants assigned to the music appreciation class will take part in a fourteen week course which will emphasize analytic listening to musical excerpts, which will match the choir class in terms of duration, homework demands, and instructor - both classes will be taught by the same person.
89462810|NCT03604185|No Intervention|Do-Nothing Control Group|The do-nothing control group will not receive any active training.
88943550|NCT03568552|No Intervention|Prior to intervention|All participating clinics will start with a baseline period without the intervention. The clinics and their patients will remain in the no intervention condition until randomly selected to crossover to receive the intervention.
88943551|NCT03553810|Experimental|Treatment Arm|Entresto (valsartan/sacubitril) 100mg once a day
88943552|NCT03553810|Active Comparator|Controlled Arm|Valsartan 40mg once a day
88943553|NCT03543865|Experimental|New Hope (NH)|"The investigators will employ a SMART design to evaluate the effectiveness of New Hope (NH), Elders' Resilience intervention (ER), Case Management (CM) and the combination of these approaches on reducing suicidal thoughts and promoting resilience among AI youth ages 10-24 who are confirmed by surveillance case managers to have recently experienced suicide ideation, attempt or a binge substance use and ideation.~Youth who assent will complete the baseline (CM visit 1 and will be referred to mental health care). During the same visit, youth will be randomized 1:1 to either New Hope (NH) plus Case Management (CM), or CM alone, using a blocked randomized design, stratifying participants by age and event type."
88943554|NCT03543865|Experimental|Elders' Resiliency (ER)|"The investigators will employ a SMART design to evaluate the effectiveness of New Hope (NH), Elders' Resilience intervention (ER), Case Management (CM) and the combination of these approaches on reducing suicidal thoughts and promoting resilience among AI youth ages 10-24 who are confirmed by surveillance case managers to have recently experienced suicide ideation, attempt or a binge substance use and ideation.~All youth will complete another study assessment after 30 days. The 30-day time frame will allow ample time to complete the NH intervention with participants and assess any changes in youth's mental health status for all study arms. Following another 30-day period, all participants will be re-assessed and re-randomized, using the same blocking and 1:1 ratio to either the Elders' Resilience (ER) intervention plus CM, or CM alone. To track long term outcomes, all youth will complete a final assessment 3 month later (6 months post-enrollment)."
88943555|NCT03543865|Other|Control Condition|"The control condition will only receive Case Management (CM) (n=76).~The investigators will employ a SMART design to evaluate the effectiveness of New Hope (NH), Elders' Resilience intervention (ER), Case Management (CM) and the combination of these approaches on reducing suicidal thoughts and promoting resilience among AI youth ages 10-24 who are confirmed by surveillance case managers to have recently experienced suicide ideation, attempt or a binge substance use and ideation. Youth who assent will complete the baseline (CM visit 1 and will be referred to mental health care). During the same visit, youth will be randomized 1:1 to either New Hope (NH) plus Case Management (CM), or CM alone, using a blocked randomized design, stratifying participants by age and event type."
88943556|NCT03543865|Experimental|New Hope (NH), Elders' Resiliency (ER), Case Management (CM)|The investigators will employ a SMART design to evaluate the effectiveness of New Hope (NH), Elders' Resilience intervention (ER), Case Management (CM) and the combination of these approaches on reducing suicidal thoughts and promoting resilience among AI youth ages 10-24 who are confirmed by surveillance case managers to have recently experienced suicide ideation, attempt or a binge substance use and ideation. Youth who assent will complete the baseline (CM visit 1 and will be referred to mental health care). During the same visit, youth will be randomized 1:1 to either New Hope (NH) plus Case Management (CM), or CM alone, using a blocked randomized design, stratifying participants by age and event type. All youth will complete another study assessment after 30 days.After another 30-days, all participants will be re-assessed/re-randomized, using the same blocking and 1:1 ratio to either the ER intervention plus CM, or CM alone.
88943557|NCT03516513|Active Comparator|Problem Solving Therapy as Usual|"Clinicians in this arm of care will have access to the Case Management Tracking System which is already in use.~Intervention: unguided PST"
88943558|NCT03516513|Experimental|Assisted Problem Solving Therapy|"This arm will be designed and finalized in Phase 1 and 2 of the project. We anticipate that the intervention will leverage clinical notes required to be completed by clinicians and will provide information to clinicians to help patients improve over time, as well as help clinicians implement PST to high quality.~Intervention: guided PST"
88943559|NCT03483766|No Intervention|Baseline before robotic functional rehabilitation|Baseline spinal cord MRI scan
88943560|NCT03483766|Experimental|post rehabilitation|Those patients will receive 3 months muscle strength enhancement as pre-rehabilitation. Then, we will design robotic hand rehabilitation programme for each individuals. All participants will receive robotic rehabilitation for 1 year. After then, a follow-up spinal cord MRI scan and clinical assessment will evaluate the results of this project.
88943561|NCT03467165|Experimental|Hand ExAblate|MRgFUS treatment of pain caused by trapeziometacarpal OA (and/or scaphotrapezial OA)
88943562|NCT03467165|Experimental|Hip ExAblate|MRgFUS treatment of pain caused by hip OA
89462811|NCT00843817|Experimental|DRUG|PULMOZYME
89462812|NCT04655547|No Intervention|Control|The participants will follow the usual offered course on the outpatient clinic of Hammel Neurocenter. They wil anticipate in data collection three times in line with the intervention group.
89462813|NCT04655547|Experimental|Intervention|The participants will receive dietary guidance from an dietician, with focus on energy intake and food texture. This guidance will include two sessions on site and three phone meetings. The last on site meeting, will be concluding.
88943563|NCT03453372|Experimental|Active|MRgFUS treatment of pain caused by knee osteoarthritis
89462814|NCT03651661|Active Comparator|nasal insulin|160 U of human insulin as nasal spray
89462815|NCT03651661|Placebo Comparator|nasal placebo|placebo as nasal spray
89462816|NCT01682317|Experimental|Three Meal|Participants in this condition will be instructed to limit their number of eating frequency to three meals per day.
88943564|NCT03453372|Placebo Comparator|Placebo|Procedures in the placebo group will be identical to procedures in the active group, except no sonications (ultrasound emission) will be used.
88943565|NCT03407560|Experimental|SintLife|Use of SintLife putty as bone substitute for spinal fusion in lumbar spine surgery for degenerative diseases.
88943566|NCT03405129|Active Comparator|Factoid Group|The Factoid group will receive a smartphone app that delivers 2 factual messages per day
88943567|NCT03405129|Experimental|Phoenix Group|The Phoenix group will receive a smartphone app that includes multiple components that vary based upon the participant's smoking cessation stage
88943568|NCT03405129|Experimental|Phoenix + NRT Group|"The Phoenix + (Nicotine Replacement Therapy) NRT group will receive a smartphone app that is identical to the Phoenix group, with one additional feature. Participants will be able to click an Order Nicotine Patches and Gum button to order NRT."
88943569|NCT03404596|Experimental|Smoking Cessation Therapy|Participants will receive 6 weeks of the nicotine patch therapy and brief counseling sessions. Participants will also receive mindfulness strategies for 10 days during both the pre- and post-quit periods via smartphone to aid in their cessation attempt. AutoSense will be worn to detect stress and lapse throughout the 10 day period.
88943570|NCT03400605||Program Clients|Parkdale Parents' Primary Prevention Project (5P's) clients
88943571|NCT03355456|Active Comparator|Pulmonary vein isolation (PVI) alone|Radiofrequency ablation procedure to isolate pulmonary veins without other intervention performed..
88943572|NCT03355456|Active Comparator|PVI+Total LT Atrial low voltage ablation|"PVI radiofrequency ablation along with ablation of areas of low voltage identified."
88943573|NCT03340220|Experimental|Drug: XEN1101 XPF-008 Formulation Oral|XEN1101 XPF-008 Formulation Part 1 - Single ascending dose: Single oral dose for each cohort Part 2 - Multiple ascending dose: 7 days of single oral dose daily for each cohort
88943574|NCT03340220|Placebo Comparator|Placebo - Microcrystalline cellulose oral|"Part 1- Single Ascending Dose: Single oral dose for each cohort~Part 2 - Multiple Ascending Dose: 7 days of single oral dose daily for each cohort"
88943575|NCT03340220|Experimental|Drug: XEN1101 XPF-008 Formulation Oral Drug: XEN1101 XPF-010 Formulation Oral|"XEN1101 XPF-008 and XPF-010 Formulation Cross Over~Part 3 will explore dose proportionality of XPF-010 and confirm dosing for subsequent cohorts, and the food effect and relative bioavailability of XPF-010 compared to XPF-008"
88943576|NCT03340220|Experimental|Drug: XEN1101 XPF-010 Formulation Oral|"XEN1101 XPF-010 Formulation Oral~Part 4 will explore multiple dose PK"
88943577|NCT03340220|Experimental|Drug: XEN1101 XPF-010 Formulation Oral Drug: Itraconazole 400mg Oral|"XEN1101 XPF-010 Formulation + Itraconazole~Part 5 will explore the drug-drug interaction of XPF-010, when given with itraconazole (400mg, single dose, oral solution, fasted)"
88943578|NCT03324529|Experimental|Participants in the NYU takotsubo registry|"10 patients with a confirmed history of takotsubo syndrome~10 age- and sex-matched healthy controls with no significant history of cardiac or neurological illness"
88943579|NCT03304223|Experimental|[18F]FB-IL2 PET scan|Renal transplant recipients with a clinical suspicion for renal transplant rejection.
88943580|NCT03293056|Experimental|High-intensity Interval Hydrogynmastics|High-intensity Interval training Hydrogynmastics, 2x/week, for 3 months.
88943581|NCT03293056|Active Comparator|Hydrogynmastics Continuous Moderate|Hydrogynmastics Continuous Moderate training (HCM), 2x/week, for 3 months.
89462817|NCT01682317|Experimental|Grazing|Participants in the increased eating frequency condition will be instructed to eat > 100 kcals every 2-3 hours.
89462818|NCT03574389|Experimental|13-valent Pneumococcal Conjugate Vaccine (13vPnC)|"Participants in cohort 1 will receive each dose of 13vPnC in months 2, 4 and 6, and then a booster dose during months 12-15.~Participants in cohort 2 will receive first dose dose 13vPnC at the age of months 7(included) to months 12 (less than months 12), and the second dose will be given at least 28 days after first dose, and the third dose will be months 12 to 15 (and at least 56 days after the second dose).~Participants in cohort 3 will receive the first dose of 13vPnC during 1 (included) to 2 years (less than 2 years of age) of age, and the second dose will be given at least 56 days after first dose.~Participants in cohort 4 will receive only one dose at the age of 2 (included) to 6 (less than 6 years of age) years of age."
88943582|NCT03274960|Experimental|Griess, Culture and antibiotic|Griess reagents, sulfanilamide and NED added in urine sample for 20 minutes, urine culture using blood agar for 24 hours and treatment with antibiotic every trimester for up to 7 days.
89462819|NCT03574389|Active Comparator|Haemophilus influenzae type b (Hib)|"No participants in cohort 1 will receive Hib vaccine.~Participants in cohort 2 will receive the first dose of Hib vaccine at the age of months 7 (included) to 12 (less than 12 months), and the second dose will be given at least 28 days after the first dose, the third dose will following local practice or national recommendation at the discretion of the investigator.~Participants in cohorts 3 and 4 will receive the only one dose Hib vaccine at the age of 1 (included) to 6 (less than 6 years) years of age."
89462820|NCT04455945||Open|Patients with open surgery for rectal cancer planned in our department.
89462821|NCT04455945||Laparoscopic|Patients with laparoscopic surgery for rectal cancer planned in our department.
89462822|NCT01060111|Experimental|Topiramate Standard|Topiramate 25 mg will be administered once daily and the dose will be increased by 25 mg per day at an interval of 1-week up to a dose of 50 mg to 100 mg up to Week 6. A maintenance dose of 50 mg to 100 mg will be administered twice daily up to Week 10 as per Physician's discretion.
89462823|NCT01060111|Experimental|Topiramate Slow|Topiramate 25 mg will be administered once daily and the dose will be increased by 25 mg per day at an interval of 2-weeks up to a dose of 50 mg to 100 mg up to Week 6. A maintenance dose of 50 mg to 100 mg will be administered twice daily up to Week 10 as per Physician's discretion.
89462824|NCT01060111|Experimental|Topiramate Slow and Propranolol Booster|Topiramate 25 mg will be administered once daily and the dose will be increased by 25 mg per day at an interval of 2-weeks up to a dose of 50 mg to 100 mg up to Week 6. A maintenance dose of 50 mg to 100 mg will be administered twice daily up to Week 10 as per Physician's discretion. Propranolol 80 mg will be administered once daily, 40 mg in the morning and 40 mg in the evening up to Week 6.
89462825|NCT04586907|Experimental|LY3537021 (Part A/Healthy)|LY3537021 administered subcutaneously (SC) to healthy participants.
89462826|NCT04586907|Experimental|LY3537021 (Part A/Type 2 Diabetes)|LY3537021 administered SC to participants with type 2 diabetes mellitus (T2DM).
89017866|NCT05957081|Experimental|Phase 1a: Part B: PMC-309 Dose Escalation in Combination with Pembrolizumab|"Part B will establish the MTD/preliminary RP2D of PMC-309 when administered in combination with 200 mg pembrolizumab. Part B will be conducted after completion of Part A (PMC-309 monotherapy dose escalation) and before the commencement of Phase 1b.~Dosage form and Route of administration: The duration of a treatment cycle is 3 weeks/21 days. Participants will be administered a weekly dose of PMC-309 plus one dose of pembrolizumab at 200 mg per cycle as follows:~Cycle Week 1/Day 1: pembrolizumab (administered first), followed by administration of PMC-309.~Cycle Week 2/Day 8 ± 2 days: PMC-309 only~Cycle Week 3/Day 15 ± 2 days: PMC-309 only. Both PMC-309 and pembrolizumab will be administered intravenously."
89462827|NCT04586907|Placebo Comparator|Placebo (Part A)|Placebo administered SC.
89462828|NCT04586907|Experimental|LY3537021 (Part B/Healthy)|LY3537021 administered SC to healthy participants.
89462829|NCT04586907|Experimental|LY3537021 (Part B/Type 2 Diabetes)|LY3537021 administered SC to participants with T2DM.
89462830|NCT04586907|Placebo Comparator|Placebo (Part B)|Placebo administered SC.
89462831|NCT03651583|Other|Pilot Trial|Behavioral Intervention Kiko exercises-combines breathing and movement all study subjects no placebo or control group
89462832|NCT02969863|Active Comparator|Usual Care Arm - Monitored|"Subjects will manage their own diabetes and will wear a blinded Dexcom G4 CGM to record their glucose data during the week. They will be monitored for CGM connectivity and hypoglycemia.~Monitored for hypoglycemia"
89017867|NCT05957081|Experimental|Phase 1b: Dose Expansion|"Phase 1b will enroll participants after completion of DLT assessments for Phase 1a.~Phase 1b will enroll participants with advanced or metastatic tumor types into 1 of 2 cohorts to assess response of monotherapy of PMC-309 and response of PMC-309 in combination with pembrolizumab.~Cohort A: PMC-309 monotherapy therapy~- PMC-309 dosing will be at the preliminary RP2D, as identified in Phase 1a: Part A~Cohort B: PMC-309 plus pembrolizumab combination therapy - PMC-309 dosing will be as identified in Phase 1a: Part B in combination with 200 mg pembrolizumab Participants will be randomly assigned to Cohort A or Cohort B until 20 participants are enrolled in each cohort."
89462833|NCT02969863|Active Comparator|Usual Care Arm - Unmonitored|"Subjects will manage their own diabetes and will wear a blinded Dexcom G4 CGM to record their glucose data during the week. They will be monitored only for CGM connectivity, not hypoglycemia.~Not monitored for hypoglycemia"
89462834|NCT02969863|Experimental|Bihormonal Bionic Pancreas - Monitored|"Subjects will wear the bihormonal bionic pancreas, consisting of a Dexcom G4 CGM, an insulin and glucagon pump and an iPhone running the study algorithm. They will be monitored for CGM connectivity and hypoglycemia.~Monitored for hypoglycemia"
89462835|NCT02969863|Experimental|Bihormonal Bionic Pancreas - Unmonitored|"Subjects will wear the bihormonal bionic pancreas, consisting of a Dexcom G4 CGM, an insulin and glucagon pump and an iPhone running the study algorithm. They will be monitored only for CGM connectivity, not hypoglycemia.~Not monitored for hypoglycemia"
89462836|NCT02969863|Experimental|Insulin Only Bionic Pancreas - Monitored|"Subjects will wear the insulin only bionic pancreas, consisting of a Dexcom G4 CGM, an insulin pump, and an iPhone running the study algorithm. They will be monitored for CGM connectivity and hypoglycemia.~Monitored for hypoglycemia"
89462837|NCT02969863|Experimental|Insulin Only Bionic Pancreas - Unmonitored|"Subjects will wear the insulin only bionic pancreas, consisting of a Dexcom G4 CGM, an insulin pump, and an iPhone running the study algorithm. They will be monitored only for CGM connectivity, not hypoglycemia.~Not monitored for hypoglycemia"
89462838|NCT03651427|Experimental|Transgender Women|"Transgender women who already completed GAS or that agreed to start gonadotropin release hormone analogue to suppress endogenous sex hormones.~If the participants were using CSHT in the moment of the study assignment, they were asked to stop hormones for 30 days to evaluate the impact of hypogonadism in the brain.~After this first assessment, they received prescriptions for Estradiol (equine conjugated oestrogen, or estradiol valerate, or topic 17-beta estradiol formulations) for 60 days, and the impact of CSHT was evaluated again to compare to washout condition."
89462839|NCT05285293|Active Comparator|Group 1 Control|PRF in intra-bony defects
89462840|NCT05285293|Experimental|Group 2 Experimental|PRF and Retinol in intra-bony defects
89462841|NCT03650335||group I|with a total of 20 mL 0.25% bupivacaine injection to be administered
89462842|NCT03650335||group II|with a total of 30 mL 0.25% bupivacaine injection to be administered
89017868|NCT05953753|Active Comparator|Intervention|
89017869|NCT05953753|No Intervention|Control/No intervention|
89462843|NCT02969707|Experimental|Active rTMS|The active group will receive repetitive Transcranial Magnetic Stimulation
89462844|NCT02969707|Sham Comparator|Sham rTMS|The sham repetitive Transcranial Magnetic Stimulation group will have the stimulation blocked.
89462845|NCT03651193||AOSD|Patients fulfill Japan's Yamaguch AOSD classification
89462846|NCT03651193||Control|Use 1:1 group matching, should meet the following condition -s : same gender as matching case; same age as matching case or the difference ranges within 1 year; no Immune related diseases (e.g. Psor -iasis, Systemic Lupus Erythematos -us, Dermatomyositis, Scleroderma, Rheumatoid Arthritis, Type 1 Diabet -es, Behcet's disease, Sjogren's Syndrome, Hyperthyroidism, etc.); no family history of immune related diseases.
89462847|NCT03650257|Experimental|gp96 group|"Patients receive standard treatment with radiation and temozolomide after surgery.~Then 6 times of autologous gp96 vaccination are administered via subcutaneous injection in 25μg doses at the 2nd week after the end of postoperative radiotherapy.~( gp96 is administered once a week for the first 4 weeks, the 5th injection is administered 2 weeks after the 4th injection, and the 6th injection is administered 3 weeks after the 5th injection. )~The first adjunctive temozolomide startes on the day of the fifth gp96 injection.~(150-200 mg/m2/day for 5 days, then stop for 23 days, one cycle is 28 days for a total of 6 cycles)"
89462848|NCT03650257|Active Comparator|control group|Patients receive standard treatment with radiation and temozolomide after surgery. Then only adjuvant treatment with temozolomide is administered.
89462849|NCT03649399|Experimental|Patients with pancreatic stent|abdominal ultrasound and x-ray for stent detection.
89462850|NCT03651115||Neonates with gentamicin|
89462851|NCT03651115||Neonates with vancomycin|
89462852|NCT03650179||Patients enrolled in the cohort|Patients over 18 years old, consulting for functional digestive disease, without neurologic or urologic disease, and performing an urodynamic examination in neuro-urology and functional explorations department.
89462853|NCT03621709||CoreValve™ Evolut R™ 34mm|All consecutive real-world patients with aortic stenosis selected for TAVI as part of routine clinical care, using a CoreValve™ Evolut R™ 34mm during the inclusion period will be entered the registry.
89462854|NCT03649243||Propolis group|The patients receive propolis (3% in Propylene Glycol) in all the wound surface in each healing until cicatrisation or at least 8 weeks. (n=20)
89462855|NCT03649243||control group|the patients received the same care in the healing of their wounds, but no new component or propolis 3% was administered (n=8)
89462856|NCT03649165|Experimental|Treatment Sequence 1|Participants will receive Treatment A (selumetinib 25 mg granule, fasted state) in Part 1, Period 1, Treatment B (selumetinib 50 mg capsule, fasted state) in Part 1, Period 2, Treatment C (selumetinib 25 mg granule, fed state) in Part 2, Period 3, and Treatment D (selumetinib 50 mg capsule, fed state) in Part 2, Period 4. Participants will also receive a single 500 mg dose of acetaminophen at the same time as selumetinib administration where it will act as a marker for gastric emptying.
89462857|NCT03649165|Experimental|Treatment Sequence 2|Participants will receive Treatment B (selumetinib 50 mg capsule, fasted state) in Part 1, Period 1, Treatment A (selumetinib 25 mg granule, fasted state) in Part 1, Period 2, Treatment C (selumetinib 25 mg granule, fed state) in Part 2, Period 3 and Treatment D (selumetinib 50 mg capsule, fed state) in Part 2, Period 4. Participants will also receive a single 500 mg dose of acetaminophen at the same time as selumetinib administration where it will act as a marker for gastric emptying.
89462858|NCT03649165|Experimental|Treatment Sequence 3|Participants will receive Treatment A (selumetinib 25 mg granule, fasted state) in Part 1, Period 1, Treatment B (selumetinib 50 mg capsule, fasted state) in Part 1, Period 2, Treatment D (selumetinib 50 mg capsule, fed state) in Part 2, Period 3 and Treatment C (selumetinib 25 mg granule, fed state) in Part 2, Period 4. Participants will also receive a single 500 mg dose of acetaminophen at the same time as selumetinib administration where it will act as a marker for gastric emptying.
89462859|NCT03649165|Experimental|Treatment Sequence 4|Participants will receive Treatment B (selumetinib 50 mg capsule, fasted state) in Part 1, Period 1, Treatment A (selumetinib 25 mg granule, fasted state) in Part 1, Period 2, Treatment D (selumetinib 50 mg capsule, fed state) in Part 2, Period 3 and Treatment C (selumetinib 25 mg granule, fed state) in Part 2, Period 4. Participants will also receive a single 500 mg dose of acetaminophen at the same time as selumetinib administration where it will act as a marker for gastric emptying.
89462860|NCT03651037|Experimental|Thrivors+BH|For Thrivors+BH, a module will be developed for users to input pain and energy levels, enabling real-time customization of exercise regimens. Modules of clinically validated bone health exercises with instructional videos will be developed. Additionally, users will be able upload and send videos of themselves exercising for feedback and assessment. This version will contain bone health educational content, mindfulness and nutrition resources.
89462861|NCT03651037|Experimental|Thrivors Basic|A Thrivors Basic version that lacks customization and video content will be developed. This version will contain bone health educational content, mindfulness and nutrition resources.
89017870|NCT05953064|Experimental|DHA-NAT|Oral administration with a test meal of 55 kJ/kg bodyweight, with 60% of calories from fat.
89462862|NCT03649009|Placebo Comparator|Normal Saline|"Normal Saline 50 mls infused over 1 hour 3 times per day for total 3 days for placebo group after recruitment and randomization done.~If patients develop rashes or redness after normal saline administration, IV hydrocortisone (corticosteroid) 200mg stat dose will be given."
89462863|NCT03649009|Active Comparator|IV Thiamine|"IV Thiamine 200mg diluted in 50mls normal saline infused over 1 hour 3 times per day for total 3 days for Thiamine group after recruitment and randomization done.~If patients develop nausea after thiamine administration, IV metoclopramide (antiemetic)10mg stat dose will be given. If patients develop redness and rashes after Normal Saline infusion, IV hydrocortisone (corticosteroid) 200mg stat dose will be given."
89017871|NCT05953064|Placebo Comparator|Placebo|Oral administration with a test meal of 55 kJ/kg bodyweight, with 60% of calories from fat.
89462864|NCT03650023|Experimental|Chitosan Oligosaccharide (GO2KA1)|Chitosan Oligosaccharide (GO2KA1) capsule was provided to the study participants. The Chitosan Oligosaccharide (GO2KA1) capsule was consumed within 15 min, and then 2-h oral sucrose tolerance test was conducted. The Chitosan Oligosaccharide (GO2KA1) one capsule had Chitosan Oligosaccharide 250mg.
89462865|NCT03650023|Placebo Comparator|White egg|White egg capsule was provided to the study participants. The White egg capsule was consumed within 15 min, and then 2-h oral sucrose tolerance test was conducted. The Chitosan Oligosaccharide (GO2KA1) one capsule had White egg 250mg.
89462866|NCT04054999|Experimental|Cyanokit|Single dose intraoperatively of Hydroxocobalamin (Cyanokit): 5g IV infusion over 15 minutes
89462867|NCT04054999|Active Comparator|Methylene Blue|Single dose intraoperatively of Methylene blue (PROVAYBLUETM), 2 mg/kg IV bolus administered over 15 minutes
88943583|NCT03274960|No Intervention|No Griess, culture, treatment|No Griess reagents added in urine sample, no culture test with blood agar and no treatment with antibiotic for every positive results every trimester
88943584|NCT03274882|Experimental|S95005|Film-coated tablet containing 15 mg of trifluridine and 7.065 mg of tipiracil hydrochloride, or 20 mg of trifluridine and 9.42 mg of tipiracil hydrochloride (with a molar ratio of 1:0.5) was administered at 35 mg/m²/dose orally twice a day, within 1 hour after completion of morning and evening meals, for 5 days on/2 days off, over 2 weeks, followed by a 14-day rest period. This treatment cycle was repeated every 4 weeks until treatment withdrawal criteria are met.
88943585|NCT03263247|Experimental|Visual Imaging Training|"Participants will receive visual imaging training to facilitate learning of written information.~Intervention: Visual Imaging Training in individual sessions"
88943586|NCT03263247|Active Comparator|Psychoeducation|"Participants will receive information about memory functioning and aging.~Intervention: behavioral: Psychoeducation in individual sessions"
88943587|NCT03263247|Experimental|Alphabet Search|"Participants will receive alphabet search training.~Intervention: Alphabet Search in individual sessions"
88943588|NCT03246841|Other|Analysis of the gene panel|The laboratory will carry out the TUMOSPEC gene panel analysis at the same time as the BRCA1 and BRCA2 analysis and will return a negative (no mutation) or positive (presence of a mutation allowing enrolment of family members) result.
89462868|NCT03649945|Active Comparator|Test Group 1|Docetaxel plus Nedaplatin combined with Endostar
89462869|NCT03649945|Active Comparator|Test Group 2|Docetaxel plus Nedaplatin
89462870|NCT03649945|No Intervention|Control Group|No medicine intervention
89462871|NCT03650959|Experimental|Faculty-led|
89462872|NCT03650959|Experimental|Peer tutor-led|
89462873|NCT03650959|Experimental|Computer augmented self-directed learning|
88943589|NCT03241693|Other|control group|Physiotherapy students
88943590|NCT03241693|Experimental|experimental group|Physiotherapy students
88943591|NCT03171064|Experimental|Experimental intervention arm (EX)|The supervised progressive endurance and resistance exercise program will be undertaken twice weekly in small groups and will be guided by an exercise physiotherapist over 12 weeks. All sessions will start with a warm-up passing over to the endurance training part and finish with a cool-down and will take approximately 60 minutes. The moderate-to-high-intensity endurance training will be performed at the beginning of each training session on a cycle ergometer for 20 min at 75 to 80 % of peak heart rate obtained from the baseline cardiorespiratory exercise test. This training intensity is within the range of intensities recommended by the American College of Sports Medicine (ACSM) exercise guidelines for cancer survivors. The moderate-to-high-intensity progressive resistance training regime (12 repetition maxima - 3 sets for each exercise) will include 6 exercises that target major upper and lower body muscle groups.
88943592|NCT03171064|No Intervention|Wait list - control group (UC)|Wait list control group will receive usual care. After primary endpoint assessment, UC patients will be offered to participate in the exercise interventions program.
88943593|NCT03171012|Experimental|Lower limbs CRT+ PNF|Lower Limbs Cardiorespiratory training associated with Proprioceptive Neuromuscular Facilitation
88943594|NCT03171012|Active Comparator|Lower limbs CRT + respiration|Lower limbs Cardiorespiratory training associated with respiration
89462874|NCT03649789||No Salivary Gland Hypofunction|These individuals have an unstimulated salivary flow rate of greater than 0.1 mL saliva/min.
88943595|NCT03171012|Experimental|Upper limbs CRT + PNF|Upper limbs Cardiorespiratory training associated with Proprioceptive Neuromuscular Facilitation
88943596|NCT03171012|Active Comparator|Upper limbs CRT + respiration|Upper limbs Cardiorespiratory training associated with respiration
88943597|NCT03161860|Experimental|Personalised citizen assistance|The experimental group will receive the Personalised citizen assistance for social participation (APIC), i.e. weekly 3-hour personalised stimulation sessions by a trained volunteer over 12 months. Sessions will encourage empowerment, gradual mobilisation of personal and environmental resources, and community integration.
89462875|NCT03649789||Salivary Gland Hypofunction|These individuals have an unstimulated salivary flow rate of less than 0.1 mL saliva/min.
89462876|NCT03650881|Experimental|Neutrogena ® Light Therapy Acne Mask (MASK)|Over-the-counter powered light-based device for the treatment of acne
89462877|NCT03650881|Active Comparator|Topical benzoyl peroxide 2.5% gel and OTC adapalene|Over-the-counter medication for the treatment of acne + 0.1% Adepalene Gel
89462878|NCT03648307||Trauma splenectomized|Patients who had gone through trauma splenectomy. BMI, lipid profile, blood pressure and glucose tolerance of patients were assessed. Hb A1C and lipid profile were assessed through blood sampling.
89462879|NCT03648307||Bowel resection|Patients who had gone through bowel resection due to obstruction. BMI, lipid profile, blood pressure and glucose tolerance of patients were assessed. Hb A1C and lipid profile were assessed through blood sampling.
89462880|NCT02904265|Active Comparator|Diazepam|Diazepam 0.5 mg/kg (up to maximum 20 mg) by mouth nightly. Duration of therapy is 4 weeks.
89462881|NCT02904265|Experimental|Acetazolamide|Acetazolamide 8-10 mg/kg (up to a maximum dose of 375 mg) by mouth (PO)divided twice daily X 1 week, then increased to 11-16 mg/kg (up to a maximum dose of 750 mg) by mouth divided twice daily thereafter. Duration of therapy is 4-8 weeks.
89462882|NCT03648229|Experimental|SLT|The study eye will undergo 360-degree selective laser trabeculoplasty (SLT), followed, if needed, by repeat 360-degree SLT.
88943598|NCT03161860|No Intervention|Control group|The control group will receive the publicly-funded universal healthcare services available to all Quebecers.
89462883|NCT03648229|Active Comparator|MED|The study eye will receive latanoprost ophthalmic solution 0.005% once daily, followed, if needed, by adjunctive timolol ophthalmic solution 0.5% twice daily. Medications will be provided at no cost to the subject.
89462884|NCT03648229|Active Comparator|RX|The study eye will receive latanoprost ophthalmic solution 0.005% once daily, followed, if needed, by adjunctive timolol ophthalmic solution 0.5% twice daily. Medications will be provided by prescription to be obtained at the subject's expense. This represents usual care for glaucoma in Africa and other regions of the world.
89462885|NCT03461211|Experimental|Teprotumumab|Eight infusions of teprotumumab every 3 weeks (q3W) for a total of 21 weeks: teprotumumab 10 mg/kg administered on Day 1 and teprotumumab 20 mg/kg administered q3W for the remaining 7 infusions.
89462886|NCT03648697|Experimental|EBV-TCR-T cells(YT-E001)|"EBV-TCR-T (YT-E001) cells are prepared via lentiviral infection. 6-10 days prior to infusion of TCR-T cells (YT-E001), subjects receive fludarabine at dose 30mg/m2/day for 4 days and cyclophosphamide treatment at dose 30mg/kg/day for 2 days and take a rest for one day before infusion.~A single dose of EBV-TCR(YT-E001) transduced T cells (about 2×108) will be intravenously (i.v.) administered."
89462887|NCT03648619|Other|Oncologic patients|Oncologic patients with a previous PET/CT for whole-body staging
89462888|NCT02967679|Experimental|MD1003|MD1003 100mg capsules, 1 capsule tid for 48 weeks
88943599|NCT03147859|Experimental|Group A-150mg dose of vedolizumab per infusion followed by ATI - Low Dose|* Please note that the previous low dose arm was 75mg of vedolizumab per infusion, but no participant was ever given this dose. The study will have a 20-week treatment phase and a 28-week follow-up phase over one year. Intravenous infusion of 150 mg of vedolizumab per infusion per visit schedule will be administered to 4 participants. The visit schedule will be the same for each group - Infusion at weeks 0, 2, 5, 8 and every 4 weeks thereafter up to 40 weeks for at least 7 doses as tolerated. ATI will begin between weeks 6 and 7, and infusions continued at weeks 8, 12, 16 and 20.
88943600|NCT03147859|Experimental|Group B-300mg dose of vedolizumab per infusion followed by ATI - Mid Dose|The study will have a 20-week treatment phase and a 28-week follow-up phase over one year. Intravenous infusion of 300 mg of vedolizumab per infusion per visit schedule will be administered to 4 participants. The visit schedule will be the same for each group - Infusion at weeks 0, 2, 5, 8 and every 4 weeks thereafter up to 40 weeks for at least 7 (and up to 12) doses as tolerated. ATI will begin between week 10, and infusions continued at weeks 12, 16 and 20. Infusions may also be given at weeks 24, 28, 32, 36 and 40 depending on tolerance and pVL response.
88943601|NCT03147859|Experimental|Group C-600mg dose of vedolizumab per infusion followed by ATI - High Dose|The study will have a 20-week treatment phase and a 28-week follow-up phase over one year. Intravenous infusion of 600 mg of vedolizumab per infusion per visit schedule will be administered to 4 participants. The visit schedule will be the same for each group - Infusion at weeks 0, 2, 5, 8 and every 4 weeks thereafter up to 40 weeks for at least 7 (and up to 12) doses as tolerated. ATI will begin between week 10, and infusions continued at weeks 12, 16 and 20. Infusions may also be given at weeks 24, 28, 32, 36 and 40 depending on tolerance and pVL response.
88943602|NCT03103789||GERD patients|Patients who are undergoing standard of care EGD with or without BRAVO pH capsule placement and have been diagnosed with GERD will have mucosal impedance measured by single catheter and balloon assembly.
88943603|NCT03103789||control|Patients who are undergoing standard of care EGD with or without BRAVO pH capsule placement will have mucosal impedance measured by single catheter and balloon assembly.
89462889|NCT04447053|Experimental|Belimumab + SOC|Patients will be administered Belimumab, 10mg/kg, intravenously (IV) (together with SOC) in 1 hour on days 0, 14, and 28, and then every 28 days (4 weeks) until week 48.
89462890|NCT04447053|No Intervention|SOC only|Patients will receive SOC based on the discretion of attending physicians in accordance with the clinical disease manifestations of SLE and NUH practice of the treatment of SLE.
89462891|NCT03650647|Active Comparator|Indirect Pulp Capping|"Nonselective removal to hard dentine (formerly complete excavation or complete caries removal) : removal of soft dentin, only hard dentine is left on the cavity, so that demineralized dentine free of bacteria is completely removed.~Intervention: Total soft and leathery caries removal. Carious dentin removal"
89501884|NCT03516487|Experimental|SAD HV SB: SYNB1618 (1 x 10^11 CFU)|HV subjects receive a single oral dose of SYNB1618 (1 x 10^11 CFU) in a chilled buffered solution on Day 1 in the SAD study (Part 1). On Day 1, subjects in this cohort receive a solid breakfast (SB) that contains approximately the same amount of calories and protein as the meal supplement shake given to subjects in the other SAD cohorts.
89017872|NCT05935436|Active Comparator|CSWT Group|CSWT is performed three times a week (days 1, 3, and 5) in a session with a 3-month interval between sessions or 1-month intensive treatment.
89017873|NCT05935436|Sham Comparator|Control Group|Patients in the control group receive sham CSWT, the energy of cardiac shock wave therapy was the lowest, and the water bladder was in contact with the skin but not close to the skin.
89017874|NCT05935384||Cohort 1: Unresectable Stage III/IV NSCLC|Blood samples collected will be banked
89017875|NCT05935384||Cohort 2: Stage IV Colorectal|Blood samples collected will be banked
89017876|NCT05935384||Cohort 3: Unresectable Stage III/IV Breast - HR+ HER2-|Blood samples collected will be banked
89017877|NCT05935384||Cohort 4: Unresectable Stage III/IV Breast - HR- HER2+|Blood samples collected will be banked
89017878|NCT05935384||Cohort 5: Unresectable Stage III/IV Breast - Triple Positive|Blood samples collected will be banked
89017879|NCT05935384||Cohort 6: Unresectable Stage III/IV Breast - Triple Negative|Blood samples collected will be banked
89017880|NCT05931302|Experimental|68Ga-FAPI-46 PET scan + 18-FDG PET scan|
89017883|NCT05916651|Experimental|Intervention (LOS training) + care as usual (intervention group)|Intervention group: mindfulness (LOS) training + CAU
89017884|NCT05916651|Active Comparator|Care-as-usual (CAU)-only (control group)|Control group: CAU-only
89017885|NCT05915975|Experimental|Behavioral Care Coordinated with Medical Care|Participants in this group will work with a study team member for four months to improve your skills to manage diabetes, to strengthen the child-caregiver relationship, and/or to address emotional challenges that your child might be experiencing.
89017886|NCT05915975|Active Comparator|Behavioral Care Not Coordinated with Medical Care|Participants will receive the standard of care treatment for four months plus a list of clinics that accept their insurance.
89017887|NCT05907057|Experimental|Open-Label Ivosidenib in combination with Azacitidine|All participants will receive both Ivosidenib and Azacitidine for a maximum of 28 cycles. Each cycle will be 4 weeks or 28 days long. Ivosidenib will be taken continuously throughout each cycle and Azacitidine will be taken only for 7 days at the beginning of each cycle.
89017888|NCT05903391|Experimental|3D-Printed Finger Splints|Participants who wear the experimental customizable 3D-printed finger splints
89017889|NCT05903391|Active Comparator|Conventional Finger Splints|Participants who wear the control, conventionally made finger splints
89017890|NCT05895565|Experimental|Experimental|Including 3 dose groups (15 mg/kg, 30 mg/kg and 40 mg/kg), with 10 subjects (8 of whom receiving the investigational product) enrolled into each group. Intravenous infusion for 30 min (±5 min), once every 4 weeks, for 3 doses.
89017891|NCT05895565|Placebo Comparator|Placebo Comparator|Including 3 dose groups (15 mg/kg, 30 mg/kg and 40 mg/kg), with 10 subjects (2 of whom receiving placebo) enrolled into each group. Intravenous infusion for 30 min (±5 min), once every 4 weeks, for 3 doses.
89017892|NCT05886712|Experimental|SAIA-Naloxone|SAIA-Naloxone is an intervention that facilitates an organizational SSP level analysis of naloxone delivery by assigning a trained SAIA-Naloxone coach to apply tools and techniques and engage staff to define barriers, identify solutions, and evaluate their success in cycles until achieving desired change regarding naloxone distribution. Coaches will meet with SSPs twice per month for the first 3 months and once per month for the remaining 9 months during the 12-month intervention period.
89017893|NCT05886712|Other|Implementation as Usual|SSPs randomized to the IAU arm will not receive support to improve naloxone distribution. SSPs in California have already adopted naloxone distribution. The investigators are therefore testing the ability of SAIA-Naloxone to optimize naloxone distribution within SSPs. Accordingly, IAU is characterized by the absence of SAIA-Naloxone with the goal of comparing whether SAIA-Naloxone improves SSPs' Naloxone distribution.
89462892|NCT03650647|Experimental|Stepwise excavation|"Stepwise removal is carious tissue removal in 2 stages, i.e., visits. Soft carious tissue is left over the pulp in the first step, while peripheral dentine is prepared to hard dentine to allow a complete and durable seal of the lesion. A provisional restoration is placed, which should be sufficiently durable to last up to 6 months to allow changes in the dentine and pulp to take place. After this period, a second excavation is done and, if there is hard dentin formed, the tooth is restored.~Intervention: Part of the soft caries is removed. Final restoration is placed on the second visit. Carious dentin removal"
89017894|NCT05884866|Active Comparator|Dapagliflozin|1 tablet Dapagliflozin 10 mg + 1 capsule Balcinrenone 50mg matching Placebo + 1 capsule Balcinrenone 100 mg matching Placebo
89017895|NCT05884866|Experimental|Balcinrenone|1 capsule Balcinrenone 50mg + 1 capsule Balcinrenone 100 mg + 1 tablet Dapagliflozin matching Placebo
89462893|NCT03650647|Experimental|Selective caries removal|"Selective caries removal: only part the soft dentine is removed, so soft carious tissue is left over the pulp, while peripheral enamel and dentine are prepared to hard dentine, to allow a tight seal and placement of a durable restoration.~Intervention: Part of the soft caries is removed. Final restoration is place over the soft dentin. Carious dentin removal"
89462894|NCT03104205|Experimental|Evaluate home-based MOWI|Conduct and assess the feasibility, acceptability, and potential effectiveness of home-based MOWI in improving physical function.
89462895|NCT03647605|Experimental|VR Mind|Two VR Mind sessions using experimental virtual reality scenarios. During these two sessions, participants will be exposed to virtual reality environment, for 2 x 10 min each session.
89462896|NCT02966509|Experimental|A: Intervention Arm|All participants randomized to Arm A will receive the EPAC intervention as well as usual oncologic care.
89462897|NCT02966509|No Intervention|B: Control Group Arm|All participants randomized to Arm B will receive usual oncologic care.
89462898|NCT04361799|Experimental|Closed-loop insulin therapy|
89462899|NCT04361799|Active Comparator|Standard insulin therapy|
88943604|NCT03063463||Pneumatic Dilation|Subject with achalasia undergoing routine care EGD (Esophagogastroduodenoscopy) with pneumatic dilation
88943605|NCT03063463||Surgical Myotomy|Subject with achalasia undergoing routine care EGD with surgical myotomy
88943606|NCT03055208|Experimental|Radiosurgery|"Following intraoperative confirmation of glioblastoma (frozen section):~Early (24-72h post surgery) stereotactic ablation (gamma knife radiosurgery) of residual tumor (defined in early postoperative T1-weighted MRI scanning with and without contrast), followed by standard-of-care therapy (chemo-radiotherapy with 60 Gy external beam radiation therapy (EBRT) and 75 mg/m2/d temozolomide, followed by adjuvant chemotherapy with 150-200 mg/m2/d/cycle temozolomide in a 5/28 days schedule)."
88943607|NCT02948725|Experimental|cross-education + standard rehabilitation|The cross-education group will engage in strength training of the non-paretic hand in addition to standard rehabilitation. Cross-education will be progressive in nature, beginning with 2 sets of 8 repetitions and increasing up to a maximum of 6 sets of 8 repetitions of maximal voluntary effort isometric handgrip contractions as tolerated. Grip training will be performed using standard grip trainers (Digi-Flex Grip trainers) to train both finger flexors and full hand and wrist isometric contractions. In addition, patients will perform controlled dynamic wrist flexion and extension training of the non-paretic hand using exercise tubing with the same prescription. Patients will be asked to complete exercises 3 times per week for 26 weeks, and to record adherence in a training log. An average of one session per week will be considered 'trained'.
88943608|NCT02948725|No Intervention|standard rehabilitation|Standardized rehabilitation involves several strategies tailored to the patient and remains somewhat based on clinician preference. These therapies may involve functional electrical stimulation, neuro-facilitation, strengthening, range of motion (ROM), mirror therapy, and force-use therapy (e.g., CIMT). Patients engage in therapy 5 days per week as inpatients, and 2 days per week as outpatients with additional home exercises. Specific therapies for each patient will be tracked using a therapy log.
88943609|NCT02914613|Experimental|SF0166 low dose BID|SF0166 low dose instilled in study eye BID for 28 days of treatment.
88943610|NCT02914613|Experimental|SF0166 high dose BID|SF0166 high dose instilled in study eye BID for 28 days of treatment.
88943611|NCT02908984|Experimental|Specific neck rehabilitation|The intervention includes specific neck rehabilitation as described by Jull and Falla over a period of 4 weeks and recommendations for further training.
88943612|NCT02908984|Active Comparator|Standard primary health care|This represents individualized therapy administered by the primary physician.
88943613|NCT02793726||Symptomatic|Patients with pain and or other sign of prothesis failure
88943614|NCT02793726||Asymptomatic|Patients with regular clinical and radiographic evolution of the implant. No pain
88943615|NCT02781857||100 patients with lung cancer|"Group A: 70 patients with any type of lung cancer eligible for lung cancer surgery~Group B: 30 patients with any type of lung cancer not eligible to surgery (small-cell carcinoma, squamous cell carcinoma, adenocarcinoma, large-cell carcinoma)."
88943616|NCT02781857||60 controls|60 controls (group C) matched for age, gender, smoking history.
88943617|NCT02753335|Experimental|GMI and Desensitization|Left/right judgement, imagine movements of the affected area, mirror treatment and tactile stimulation of the affected limb with different materials.
88943618|NCT02753335|Experimental|Desensitization|Tactile stimulation of the affected limb with different materials.
88943619|NCT02723474|Other|MRI at baseline and over time|Patients with chronic lung disease will undergo pulmonary function tests, hyperpolarized Helium and or Xenon MRI at each visit.
88943620|NCT02713945|Experimental|Simvastatin|Simvastatin administrated orally at 10 mg once a day in the morning during the first month Simvastatin administrated orally at 20 mg once a day in the morning during the second month During months 3 to 12, the dose will be fixed at 20 mg per day for children aged 12 years and younger and 40 mg for adolescent older than 12 years.
88943621|NCT02713945|Placebo Comparator|Control|Placebo administrated orally once daily in the morning
89017896|NCT05884866|Experimental|Dapagliflozin + Balcinrenone|1 tablet Dapagliflozin 10mg + 1 capsule Balcinrenone 50mg + 1 capsule Balcinrenone 100 mg
89017897|NCT05884866|Placebo Comparator|Placebo|1 tablet Dapagliflozin matching Placebo + 1 capsule Balcinrenone 50mg matching Placebo + 1 capsule Balcinrenone 100 mg matching Placebo
89017898|NCT05880940|Experimental|Boost - Moveable wheelchair Arm rest|Movable wheelchair arm rest device group: participants in this group will be provided with a wheelchair equipped with movable wheelchair arm rest device and will be trained by training therapists on how to use the device. Therapists will determine if the participant is capable of using the device in either a stationary mode or overground mode. Afterwards, participants will be allowed to utilize the device within the inpatient facility on their own. The investigators encourage at least 30 minutes per day of device use, although this is not required or limited to 30 minutes. Therapists may adjust the difficulty of the device utilize to provide additional challenge as they deem suitable for the participant. Once participants are discharged from the unit, they will be allowed to keep the movable wheelchair arm rest devices until their 3-month post stroke follow up visit, the last visit of the study.
89017899|NCT05880940|Active Comparator|Electronic Arm Exercises|Electronic exercise program designed by training therapists. These exercises will be assigned to the participants electronically using a commercial home exercise program platform commonly used by hospital systems (i.e.: Medbridge). They will be encouraged to exercise for 30 min/day in addition to the regular rehabilitation therapy at Acute Rehab Unit (ARU), although this is not required or limited to 30 minutes. Therapists may adjust the difficulty of exercise program to provide additional challenge as they deem suitable for the participant. Once participants are discharged from the unit, they will be allowed to keep the electronic exercise program until their 3-month post stroke follow up visit, the last visit of the study.
89017900|NCT05875441|Experimental|Moxidectin 8mg|Moxidectin 8 mg (over encapsulated) will be administered as a single dose on Day 0. Each subject will receive the same number of capsules made up of moxidectin 2 mg over encapsulated tablets and placebo capsules to maintain the blind.
89017901|NCT05875441|Experimental|Moxidectin 16mg|Moxidectin 16 mg (over encapsulated) will be administered as a single dose on Day 0. Each subject will receive the same number of capsules made up of moxidectin 2 mg over encapsulated tablets and placebo capsules to maintain the blind.
89017902|NCT05875441|Experimental|Moxidectin 32mg|Moxidectin 32 mg (over encapsulated) will be administered as a single dose on Day 0.
89462900|NCT03647995|Active Comparator|Probiotic-receiving group|The probiotic-receiving group will receive once daily probiotics containing 25Bn CFU of which: 5Bn CFU Lactobacillus rhamnosus GG, 5Bn CFU Sacchromyces boulardii, 5Bn CFU Bifidobacterium breve, 4.5Bn CFU Bifidobacterium lactis, 2.5 Bn CFU Lactobacillus acidophilus, 2.5Bn CFU Lactobacillus plantarum and 500Mn CFU Lactobacillus reuteri.
89462901|NCT03647995|Placebo Comparator|Placebo|The placebo group will receive once daily, identical capsules containing 0 Bn CFU.
89462902|NCT03752541|Experimental|BCMA-UCART|Each subject will accept one of the following dosages of BCMA-UCART cells intravenously (IV) on day 0: 0.5-1*10~6/KgBW, 1-2*10~6/KgBW,2-3*10~6/KgBW.
89462903|NCT02966353|Experimental|All Subjects|10 mg BID (2 tablets of 5mg) was self-administered as starting dose for all patients. This dose was maintained for the first 12 weeks and titrated up thereafter unless they had met criteria for dose hold or dose reduction. Dose was to have been increased or decreased per standardized dosing paradigm and not to have exceeded 25 mg bid.
89462904|NCT04260789|Other|Treatment|Treatment with Seraph Filter
89462905|NCT04260789|No Intervention|Control|
89462906|NCT03647839|Experimental|Arm 1|Nivolumab and BNC105
89462907|NCT03647839|Experimental|Arm 2|Nivolumab and BBI-608
89462908|NCT05389917||Consecutive adult patients undergoing pancreaticoduodenectomy|All the consecutive patients who undergo pancreaticoduodenectomy will be recruited into the study after obtaining informed consent
89462909|NCT03647683|Experimental|Self-Compassion|After pretreatment heat pain assessment, participants are introduced to the concept of self-compassion. Participants practice the new strategy with heat pain stimuli three times. Next, the posttreatment pain assessment is conducted. For a one week period, participants receive daily self-compassion audio-interventions. Afterwards, the follow-up pain assessment is conducted.
89017903|NCT05875441|Placebo Comparator|Placebo|16 Placebo capsules will be administered as a single dose on Day 0.
89017904|NCT05866237|Experimental|Intervention group|Individuals allocated to this group will be receiving care from their GP as well as the patient engagement tool (intervention). This will include messages being sent to patients in regards to vaccine information and uptake at different time points (three times).
89017905|NCT05866237|No Intervention|Control Group|The individuals in this group will receive standard care from their GP and nothing additional to this.
89462910|NCT03647683|Experimental|Acceptance|After pretreatment heat pain assessment, participants are introduced to the concept of acceptance. Participants practice the new strategy with heat pain stimuli three times. Next, the posttreatment pain assessment is conducted. For a one week period, participants receive daily acceptance audio-interventions. Afterwards, the follow-up pain assessment is conducted.
89462911|NCT03647683|Experimental|Distraction|After pretreatment heat pain assessment, participants are introduced to the concept of distraction. Participants practice the new strategy with heat pain stimuli three times. Next, the posttreatment pain assessment is conducted. For a one week period, participants receive daily distraction audio-interventions. Afterwards, the follow-up pain assessment is conducted.
89017906|NCT05863312|Active Comparator|Pars plana vitrectomy + sulfur hexafluoride gas tamponade|
89462912|NCT04454541|Active Comparator|Greater occipital nerve block with ultrasound|A-Greater occipital nerve block The ultrasound-guided GONB was performed to more accurately locate the nerve. The patient was asked to lie prone on the table. To locate the nerve, we searched for the occipital artery in the medial one-third of the superior nuchal line between the occipital tubercle and mastoid process. The scalp was cleaned with iodine. After that, the skin was sterilized, and the probe was sheathed in a sterile plastic package GONB was performed by applying the injection to the medial of the artery. A 22-gauge needle was advanced beneath the lateral border of the probe using real-time ultrasound guidance and an in-plane technique. In all patients the occipital nerve was seen medial to the artery. The injected side was determined by the patients' clinical symptoms and according to the painful side reported in their headache diaries. The patients were required to lie down for 30 minutes after the injection to avoid dizziness.
89462913|NCT04454541|Experimental|Multifidus cervicis plane block with ultrasound guided|Patients placed in a lateral position with their affected side upwards. Several gel cushions were placed under their head, neck, and arm to put the neck in a stable and slightly anterior flexion position spinal level was determined by identifying the transverse process of the seventh and sixth cervical vertebrae (C7 and C6). The seventh cervical transverse process (C7) differs from the levels above by having a rudimentary anterior tubercle and a prominent posterior tubercle. After aseptic preparation of the injection area, lidocaine 1% was used to anesthetize the skin. Under continuous ultrasound guidance, the needle (22-G, 0.7 mm × 60 mm, Plexufx, B-BRAUN, Tokyo, Japan) was introduced in-plane through the skin and advanced into the fascial plane between the multifidus cervicis and semispinalis cervicis muscles for the MCP block.
89462914|NCT04454619|Active Comparator|Hand antisepsis with propanolol-1 60%|Effectiveness of pre-surgical hand washing in reducing bacterial load using propanolol-1 60% as control
89462915|NCT04454619|Experimental|Hand antisepsis with Clorhexidina and solution|chlorhexidine gluconate with the addition of an alcoholic solution of chlorhexidine digluconate and potassium sorbate.
89462916|NCT04454853||Lung cancer with positive methylated DNA|Blood DNA methylation abnormalities are found in lung cancer.
88943622|NCT02685605|Experimental|Experimental Arm (A)|Standard surgery plus intraoperative radiotherapy (20-30 Gy) followed by radiochemotherapy (EBRT: 60 Gy, 75 mg/m2/d temozolomide) and adjuvant chemotherapy with 150-200 mg/m2/d temozolomide per cycle (5/28 days).
88943623|NCT02685605|Active Comparator|Control Arm (B)|Standard surgery followed by radiochemotherapy (EBRT: 60 Gy, 75 mg/m2/d temozolomide) and adjuvant chemotherapy with 150-200 mg/m2/d temozolomide per cycle (5/28 days).
88943624|NCT02664935|Experimental|Arm A: AZD4547|AZD4547 - FGFR Inhibitor Route & Formulation: Oral, Tablets Strengths: 20 & 80mg Trial Dose & Schedule: 80 mg BD, Continuous dosing, 21 day cycle.
88943625|NCT02664935|Experimental|Arm B: Vistusertib (AZD2014)|Vistusertib (AZD2014) - MTORC1/2 Inhibitor Route & Formulation: Oral, Tablets Strengths: 25mg Trial Dose & Schedule: 125 mg BD, Intermittent dosing (2 continuous days in 7), 28 day cycle.
88943626|NCT02664935|Experimental|Arm C: Palbociclib|Palbociclib - CDK4/6 Inhibitor Route & Formulation: Oral, Capsules Strengths: 75, 100 & 125mg Trial Dose & Schedule: 125 mg OD, Intermittent dosing (21 days on, 7 days off), 28 day cycle.
88943627|NCT02664935|Experimental|Arm D: Crizotinib|Crizotinib - ALK Inhibitor Route & Formulation: Oral, Capsules Strengths: 200 & 250mg Trial Dose & Schedule: 250 mg BD, Continuous dosing, 21 day cycle.
88943628|NCT02664935|Experimental|Arm E: Selumetinib & Docetaxel|"AZD6244 (Selumetinib) - MEK Inhibitor Route & Formulation: Oral, Capsules Strengths: 25mg Trial Dose & Schedule: 75 mg BD, Continuous dosing, 21 day cycle.~Docetaxel - Chemotherapy Route & Formulation: IV infusion over 30-60 minutes, concentrate for solution for infusion.~Trial Dose & Schedule: 75 mg/m2, 3-weekly, 21 day cycle."
88943629|NCT02664935|Experimental|Arm F: AZD5363|AZD5363 - AKT Inhibitor Route & Formulation: Oral, Tablets Strengths: 80 & 200mg Trial Dose & Schedule: 480 mg BD, Intermittent dosing (4 days on, 3 days off), 28 day cycles.
88943630|NCT02664935|Experimental|Arm G: Osimertinib (AZD9291)|Osimertinib (AZD9291) - EGFRM+ and T790M+ Inhibitor Route & Formulation: Oral, Tablets Strengths: 80mg Trial Dose & Schedule: 80 mg OD, Continuous dosing, 21 day cycles.
88943631|NCT02664935|Experimental|Arm NA: Durvalumab (MEDI4736)|Durvalumab (MEDI4736) - Anti-PDL1 Route & Formulation: IV Infusion, Lyophilized powder for solution for infusion Strengths: Vial containing 200mg Trial Dose & Schedule: 10 mg/kg IV, 2-weekly.
89462917|NCT04454853||Lung cancer with negative methylated DNA|Blood DNA methylation abnormalities are not found in lung cancer.
89462918|NCT04454853||Suspected lung cancer with positive methylated DNA|Blood DNA methylation abnormalities are found in suspected lung cancer.
89462919|NCT04454853||Suspected lung cancer with negative methylated DNA|Blood DNA methylation abnormalities are not found in suspected lung cancer.
89462920|NCT03647449|Experimental|Juice fast|"In the juice fasting arm, participants will be given vegetable/fruit pressed juices and be instructed to engage in a three-day juice fast diet totaling 800-900 kcal-per-day. The specific juices will be assigned for each day in order to maintain the calorie level."
89462921|NCT03647449|Experimental|Caloric restriction via Plant-based meals|"In the caloric restriction diet arm, participants will be on a whole-food plant-based diet totaling 800-900 kcal-per-day (matching the daily calories of juice fasting)."
89462922|NCT03647449|Experimental|Juice plus ad hoc|"In the juice plus ad hoc arm, participants will be given the same juice for three days but continue with their usual diet in addition to the juice. For this arm, there is no restriction of caloric intake or restriction to liquid only."
89462923|NCT04454307|Experimental|Tramadol|tramadol 100 mg twice daily for 10 days
89462924|NCT04454307|Active Comparator|standard care|standard care plus (placebo twice daily for 10 days).
89462925|NCT03647371|Other|Macintosh laryngoscope|direct laryngoscope - laryngoscope with Macintosh blade
89462926|NCT03647371|Other|McGrath videolaryngoscope|McGrath Videolaryngoscope
89462927|NCT03647293|Active Comparator|Control Group|Neonates who underwent a peripherally inserted central catheter
89462928|NCT03647293|Active Comparator|Intervention Group|Neonates who underwent an Ultrasound Guided Central Catheter Insertion
89462929|NCT05388123|Experimental|Low dose Vemurafenib and Rituximab|Eligible patients will receive vemurafenib at a dose of 240 mg orally twice daily (b.i.d.) continuously for 8 weeks. Rituximab 375 mg/m2 will be administered every 2 weeks for a total of 16 weeks. The entire duration of treatment will be 16 weeks.
88943632|NCT02664935|Experimental|Arm H: Sitravatinib|Sitravatinib - VEGFR Inhibitor Route & Formulation: Oral, Capsules Strengths: 10 & 40mg Trial Dose & Schedule: 120 mg OD, Continuous dosing, 21 day cycles.
88943633|NCT02664935|Experimental|Arm J: AZ6738 & Durvalumab|"AZD6738 - ATR Inhibitor Route & Formulation: Oral, Tablets Strengths: 20mg, 80mg, 100mg Trial Dose & Schedule: 240 mg twice daily (BD) on days 15-28 of 28 day cycle.~Durvalumab (MEDI4736) - Anti-PDL1 Route & Formulation: IV Infusion, Lyophilized powder for solution for infusion Strengths: Vial containing 500mg Trial Dose & Schedule: 1500mg on day 1 of each 28 day cycle"
88943634|NCT02658474|Experimental|ACT-group|Group based Acceptance and Commitment Therapy. The patients will attend to three sessions which last for three days. Between the sessions the patients will train at home on ACT related topics. The whole intervention will last for three months.
88943635|NCT02658474|No Intervention|Primary care|Treatment in a primary care setting.
89462930|NCT03647059||LSCM examination|
88943636|NCT02610179|Active Comparator|Standard Glucola GCT|A prospective cohort of 617 women who will undergo screening for gestational diabetes with the standard glucola GCT between 24 and 28 weeks gestational age.
88943637|NCT02610179|Experimental|Twizzlers challenge|At a later date, the same prospective cohort of 617 women Participants will receive their Twizzlers challenge between 24 and 28 weeks gestational age.
89462931|NCT04455711|Placebo Comparator|Remifentanil group|Emerge with continuous infusion of remifentanil 1.5 ng/ml
89462932|NCT04455711|Experimental|Lidocaine group|Emerge with continuous infusion of remifentanil 1.5 ng/ml with IV bolus of lidocaine 1.5 mg/kg
89462933|NCT04052503|Experimental|Fully Supported Group|Meetings with knowledge broker 6 times over 10 months to design and implement knowledge translation intervention. Intervention consisted of audit and feedback, goal setting, education, reminders, documentation changes, and KB support.
89462934|NCT04052503|Active Comparator|Partially Supported Group|Meetings with knowledge broker 4 times over 10 months to design and partially implement knowledge translation intervention. Group meets 2 additional times without knowledge broker to self implement intervention. Intervention consisted of audit and feedback, goal setting and documentation changes. Group self implemented education and reminders.
89462935|NCT04052347|Experimental|Shared decision-making with a patient decision-aid|
88943638|NCT02586207|Experimental|Single Arm|Pembrolizumab + Cisplatin + Radiation
88943639|NCT02579408||LDLT donor|Donors of living donor-related liver transplantation
89462936|NCT04052347|Active Comparator|routine shared decision-making|control group
89462937|NCT03717987|Active Comparator|Botulinum toxin A injection|"Botulinum toxin type A will be injected in all patients at both sides into the Yonsei point, (3Units) the point that would target 3 muscles responsible for upper lip elevation during smiling, including the LLSAN, in a single injection. This landmark was identified as the center of a triangle formed by the convergence of the LLSAN, the LLS, and the Zminor muscles and is located 1 cm lateral to the ala horizontally and 3 cm above the lip line vertically in both men and women."
89462938|NCT03717987|Active Comparator|Zinc supplementationj prior to Botulinum toxin A injection|"Patients in the intervention group will take zinc supplement tablets to increase zinc levels for 4 days before botulinum toxin injections. While patients in the control group will take placebo tablets 4 days prior to the injections. All tablets will be placed in envelopes for blinding the operator, and numbered by a supervisor to allocate patients again in their groups for statistical results. Botulinum toxin type A will be injected in all patients at both sides into the Yonsei point, (3Units) the point that would target 3 muscles responsible for upper lip elevation during smiling, including the LLSAN, in a single injection. This landmark was identified as the center of a triangle formed by the convergence of the LLSAN, the LLS, and the Zminor muscles and is located 1 cm lateral to the ala horizontally and 3 cm above the lip line vertically in both men and women."
89462939|NCT03646903|Experimental|Cognitive Bias Modification for Help-Seeking Stigma (CBM-HS)|"CBM-HS is a 15-minute web-based intervention designed to alter maladaptive cognitions related to mental health help-seeking. In this task, individuals are presented with a series of statements regarding beliefs about using mental health services (e.g., Seeking help for my problems means I am weak). Individuals then select True or False in response to each statement. Incorrect responses (i.e., demonstrating help-seeking stigma) are followed by corrective feedback. Conversely, correct responses (i.e., promoting help-seeking) are positively reinforced (e.g., That's right! You are correct!). Participants in this condition will complete three separate 15-minute CBM-HS sessions."
89462940|NCT03646903|Placebo Comparator|Placebo Cognitive Bias Modification|Participants randomized to this condition will complete a similar CBM task with neutral stimuli. The duration of the CBM-Placebo task will be comparable to the duration of the CBM-HS task (i.e., three 15-minute sessions).
89462941|NCT03646903|Active Comparator|Self-Directed Psychoeducation|Participants randomized to this condition will review psychoeducation on mental health literacy, mental illness stigma, and treatment options. Readings will be compiled from resources available in the public domain. The duration of self-directed psychoeducation will be comparable to the duration of study tasks for individuals in the CBM-HS study condition (i.e., three 15-minute sessions).
89462942|NCT04101903|Experimental|Diagnostic Aid|The experimental group will use the trial diagnostic aid for all 6-week infant hip checks
88943640|NCT02573324|Experimental|Depatuxizumab Mafodotin, Radiation and Temozolomide (TMZ)|Depatuxizumab mafodotin is given on Day 1 of Week 1, 3 and 5 along with the standard therapy of TMZ and radiation during the chemoradiation phase. Depatuxizumab mafodotin is given on Day 1 and 15 of each cycle along with TMZ (Days 1-5 of each cycle) per standard of care during the adjuvant phase.
88943641|NCT02573324|Placebo Comparator|Placebo, Radiation and TMZ|Placebo is given on Day 1 of Week 1, 3 and 5 along with the standard therapy of TMZ and radiation during the chemoradiation phase. Placebo is given on Day 1 and 15 of each cycle along with TMZ (Days 1-5 of each cycle) per standard of care during the adjuvant phase.
88943642|NCT02573324|Experimental|Open-Label Sub-Study: Depatuxizumab Mafodotin, Radiation and TMZ|Depatuxizumab mafodotin is given to participants with hepatic impairment on Day 1 of Week 1, 3 and 5 along with the standard therapy of TMZ and radiation during the chemoradiation phase. Depatuxizumab mafodotin is given on Day 1 and 15 of each cycle along with TMZ (Days 1-5 of each cycle) per standard of care during the adjuvant phase.
88943643|NCT02572557|Experimental|Spray cryotherapy using liquid nitrogen|Device: TruFreeze Spray CryoTherapy Drug: Liquid nitrogen
88943644|NCT02553642|Experimental|melanoma and bladder cancer patients|All eligible patients with melanoma will receive ipilimumab at a dose of 3 mg/kg combined with nivolumab at a dose of 1 mg/kg. The ipilimumab and nivolumab will be dosed every 3 weeks for 4 doses. Thereafter, patients may be eligible to continue to receive nivolumab monotherapy at a dose of 240 mg administered every 2 weeks OR nivolumab at dose of 480mg every 4 weeks for up to 2 years All eligible patients with bladder cancer will receive nivolumab at a dose of 240 mg administered every 2 weeks for up to 2 years, if the patient is clinically benefitting, the PI and treating investigator may elect to continue treatment beyond 2 years. All eligible patients with bladder cancer will receive nivolumab at a dose of 240 mg administered every 2 weeks for up to 2 years, if the patient is clinically benefitting, the PI and treating investigator may elect to continue treatment beyond 2 years.
88943645|NCT02523092|Experimental|Acthar gel|After a 4-week period of baseline monitoring, Acthar gel will be administered by intramuscular or subcutaneous injection. Initial dosing will be 40 U every 72 hours (or twice per week) for 4 weeks. Dosage will then be increased to 80 U with similar frequency for 8 weeks and up to 16 weeks.
88943646|NCT02482350|Experimental|Reading Training|A 3-months study design. There will be three distinct phases: base-line testing, reading training, and follow-up testing. T1-T7 indicate the 7 time-points at which we assess the following: reading speeds (word-per-minute), visual field test, visual search test, and Activities of Daily Living rating scale (T1: Day 1, Initial assessments; T2: Day 30, Pre-training assessments; T3: Day 60, During Reading Training (RT) after 5-hours; T4: During RT after 10-hours; T5: During RT after 15-hours; T6: During RT after 20-hour; T7: Day 90, Post-training assessments). Arabic reading patients with left-sided HA will receive app-delivered reading training in a single subject control based design for 1 month.
88943647|NCT02450773|Experimental|Furosemide/Potassium chloride|40 mg furosemide; 20 meq potassium chloride
88943648|NCT02450773|Placebo Comparator|Placebo|Placebo #1, Placebo #2
88943649|NCT02445248|Experimental|Tisagenlecleucel|Adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who will receive tisagenlecleucel.
88943650|NCT02420548|Active Comparator|Services as Usual|Participants continue with any services they may be receiving outside of the study.
88943651|NCT02420548|Experimental|Parent Ed. and Youth Skills Coaching|The experimental intervention will have two components: (1) a caregiver parenting group, including all caregiver types (biological, foster, kinship), that meets weekly for 90-minutes for four months, focused on increasing parenting skills, and (2) a Life Coach component where trained and supported skills coaches meet individually with youth weekly for 60 minutes over the same four-month period to build the girls' social skills and peer/partner relationships skills.
88943652|NCT02397226|Active Comparator|Radiofrequency ablation|Treatment with radiofrequency ablation using radiofrequency ablation catheter. This intervention implies tumescent anesthesia.
88943653|NCT02397226|Active Comparator|High ligation/stripping|Treatment with high ligation/stripping using a vein stripping catheter. This intervention implies general anesthesia.
88943654|NCT02308878|No Intervention|Treatment-as-usual|This group consists of treatment-as-usual for opioid dependence syndrome.
89462943|NCT04101903|No Intervention|Standard of Care|The control group will assess infants according to standard practice, during the 6-week hip check.
88943655|NCT02308878|Experimental|Mobile health cognitive stimulation|Cognitive stimulation using mobile technology with m-Health applications.
88943656|NCT02296684|Experimental|Cohort 1: Neoadjuvant MK-3475 and Adjuvant MK-3475|"MK-3475 will be given intravenously once approximately 2-3 weeks prior to standard of care surgery.~Adjuvant therapy will be dictated by surgical pathology and occurs after standard of care surgery and will consist of:~risk-based intensity modulated radiation therapy consisting of 60 Gy in 2 Gy once-daily fraction size (total of 30 fractions)once-daily fraction size (total of 30 fractions)~optional image-guided radiation therapy~risk-based cisplatin administered intravenously on Days 1, 22, and 43 of treatment course~MK-3475 will be given intravenously once every 3 weeks for a maximum of 6 doses if participant is considered high-risk based surgical pathology from standard of care surgery. These doses of MK-3475 will be given after surgery and after all acute toxicities of post-operative standard of care chemotherapy and radiation have resolved to grade 1 or less."
88943657|NCT02296684|Experimental|Cohort 2: Neoadjuvant MK-3475|-MK-3475 will be given once intravenously and then given again 21 days after dose 1 (14-24 days before standard of care surgery)
88943658|NCT02279199||Control|Normative data from standardized assessment
88943659|NCT02279199||Hemophilia|Persons aged 4-21 with any severity of hemophilia A or B
88943660|NCT02165787||patients|
88943661|NCT02165787||healthy control subjects|
88943662|NCT02107261|Active Comparator|Placebo Then Botulinum Toxin|Placebo dose first does then boosters at week 2 and week 4 then 4 weeks washout, then Incobotulinumtoxin A first dose, with boosters at 2 week and week 4.
88943663|NCT02107261|Active Comparator|Incobotulinumtoxin A Then Placebo|Incobotulinumtoxin A dose first does then boosters at week 2 and week 4 then 4 weeks washout, then Placebo first dose, with boosters at 2 week and week 4.
88943664|NCT02098265|Experimental|Experimental Group - Immediate BCI Therapy|EEG - BCI training (closed loop)
88943665|NCT02098265|Experimental|Experimental Group - Delayed BCI Therapy|Scanned and tested 4 times over a 10-week period before EEG-BCI training
88943666|NCT02098265|Experimental|Experimental Group - RecoveriX|Recruited from participants who have completed the study intervention
88943667|NCT02098265|Active Comparator|Control Group 1|48 stroke patients, 48 participants with risk factors for stroke, 48 healthy controls receiving 4-6 training sessions on the EEG-BCI, pre- and post- behavioral testing, and MRI
88943668|NCT02098265|Active Comparator|Control Group 2|24 Stroke Patients with UE impairment receiving standard FES only therapy
88943669|NCT02083835||post-surgical patients|post-surgical patients > 18 years
88943670|NCT02083835||pediatric patients post-op day 1|pediatric patients <18 years on post-op day 1 (sub-project QUIPSI - PAIN OUTinfant)
88943671|NCT02014597|Experimental|Normal - No glaucoma|HOCD
88943672|NCT02014597|Experimental|Glaucoma|HOCD
88943673|NCT01942954|Experimental|Mobile health cognitive stimulation|Experimental group
89462944|NCT03647215||All Participants|Participants with CML and Ph+ALL who are being treated with their first or subsequent TKI therapy. CML patients must meet the ELN criteria for warning and failure ) or have high SOKAL score (>0.8) or presence of additional chromosomal abnormalities (ACAs) and have detectable BCR-ABL levels. Ph+ALL patients need detectable BCR-ABL levels only.
89462945|NCT04456335||Caries-free|Caries-free children
88943674|NCT01942954|No Intervention|Treatment-as-usual|This group consists of treatment-as-usual for alcohol abstinence according to the Minnesota Model.
88943675|NCT01900574|Experimental|Golimumab|
88943676|NCT01607359||dabigatran group|All patients receiving dabigatran as periprocedural anticoagulation during the study time period
88943677|NCT01607359||warfarin group|A randomly selected group of patients treated with warfarin during the study time period matching the number of dabigatran treated patients in the same time period.
88943678|NCT01582204|Experimental|124IcG250|This is a pilot study of 124I-cG250-PET/CT in 25 evaluable patients with advanced and/or metastatic clear cell renal cell carcinoma (ccRCC) who are scheduled to begin treatment with sunitinib or pazopanib. 124I-cG250-PET/CT will be assessed for its ability to predict response in comparison to standard CT scan of the chest, abdomen, and pelvis.
88943679|NCT01558999|Experimental|High concentration SI-614|
88943680|NCT01558999|Experimental|Low concentration SI-614|
88943681|NCT01558999|Placebo Comparator|Vehicle|
88943682|NCT01491568|Experimental|Investigational|
88943683|NCT01342367|Experimental|Oral Androgen Therapy|Subjects will receive two oral hormonal drugs (bicalutamide with dutasteride or bicalutamide with finasteride)
88943684|NCT01220908|Experimental|permanent Coil(s) implant, QOL measure|Coil implantation as treatment. Treatment is permanent implant.
88943685|NCT01185171|Experimental|ZD1839 500mg by mouth (po) daily|Single arm, two-stage, phase II trial of induction therapy with carboplatin and paclitaxel, followed by ZD1839, 5-FU, hydroxyurea, and hyperfractionated radiotherapy, followed by adjuvant ZD1839 alone.
88943686|NCT01106261|Experimental|Pulmonary metastasectomy|Pulmonary metastasectomy
88943687|NCT01106261|Active Comparator|Active monitoring|Active monitoring
88943688|NCT01026571||Bicuspid aortic valve|Collection of patients who are known to have bicuspid aortic valve disease, diagnosed by prior cardiac imaging
88943689|NCT01026571||Relative|Collection of patients who are a relative to a patient known to have bicuspid aortic valve disease, diagnosed by prior cardiac imaging
88943690|NCT00987532|Experimental|parent intervention plus gym lessons|Parent-focused participatory preschool intervention in addition to twice weekly gym lessons over 6 months. The participatory intervention includes parents, teachers and children.
88943691|NCT00987532|Active Comparator|gym lessons only|Twice weekly one-hour gym lessons delivered by a specially trained external physical education teacher over 6 months
89017907|NCT05863312|Experimental|Pars plana vitrectomy with scleral buckle + sulfur hexafluoride gas tamponade|
89462946|NCT04456335||Early childhood caries|Children with early childhood caries
89462947|NCT04456257|Experimental|Fractional Picosecond 1,064 nm laser|The subjects with abdominal striae alba were treated with a fractional picosecond 1,064 nm laser
88943692|NCT00896493|Experimental|Total lymphoid irradiation & anti-thymocyte immunoglobulin|TLI is administered from a 6 MeV linear accelerator in 80c- 120c Gy fractions. Anti-thymocyte-Globulin (ATG) is administered intravenously for a total dose of 7.5 mg/kg.
88943693|NCT00790010|Experimental|Bevacizumab Plus Ipilimumab Cohort 1|5 subjects for this cohort
88943694|NCT00790010|Experimental|Bevacizumab Plus Ipilimumab Cohort 2|17 subects for this cohort
88943695|NCT00790010|Experimental|Bevacizumab Plus Ipilimumab Cohort 3|12 subjects
88943696|NCT00790010|Experimental|Bevacizumab Plus Ipilimumab Cohort 4|12 subjects
88943697|NCT00697411||Experimental|Individuals with Aicardi syndrome and their first-degree relatives
88943698|NCT00695552|Experimental|1|Aerobic exercise on stationary bikes. Three sessions/week for 3 three months. First month the workload is equivalent to 65% of HRmax, the second month the workload is equivalent to 70% of HRmax, and the third month the workload is equivalent to 75% of HRmax
88943699|NCT00695552|Placebo Comparator|2|Participants meets 3 times/week for 3 months. They will engage in low impact activities such as stretching exercises.
88943700|NCT00598026|Experimental|1|Tele- follow-up: remote transmission to the implantation centre every 3 months
88943701|NCT00598026|Active Comparator|2|Conventional follow-up: visits at the implantation centre every 3 months
88943702|NCT00585065||Pediatric and adolescent patients receiving CRT with BVP for treating chronic heart failure|"Pediatric and adolescent patients who are receiving cardiac resynchronization therapy with biventricular pacing as a method of treating chronic heart failure. Children of both genders, who are followed in the Division of Pediatric Cardiology at Primary Children's Medical Center, who meet all inclusion and no exclusion criteria are eligible for participation in this clinical study.~No intervention is administered as part of this study. Prospective longitudinal case series study to describe and evaluate clinical and hemodynamic effects of CRT and to identify echocardiographic predictors of positive response to CRT in Group described."
88943703|NCT00444093|Experimental|Opii normata treatment|Treamtment with opii normata in case of diarrhea
88943704|NCT00444093|Experimental|Loperamid Treatment|Treatment with Loperamid in case of diarrhea
88943705|NCT00316290|Experimental|1|Participants will receive integrated parent training.
88943706|NCT00316290|Active Comparator|2|Parents will receive behavioral parent training.
88943707|NCT00003042|Experimental|1 cycle of neoadjuvant chemotherapy|Patients receive chemotherapy, surgical removal of the cancer followed by additional chemotherapy, followed by two treatment cycles of very high-dose chemotherapy, return of bone marrow derived cells, followed by radiation therapy and if indicated five years of tamoxifen treatment.
88943708|NCT00003042|Experimental|More than 1 cycle of neoadjuvant chemotherapy|Patients receive chemotherapy, followed by two treatment cycles of very high-dose chemotherapy, return of bone marrow derived cells, followed by radiation therapy and if indicated five years of tamoxifen treatment.
88943709|NCT01873118|No Intervention|Usual Care Control hospital unit|This study involves implementation of interventions across entire hospital units. This arm is a usual care control unit paired to the intervention unit.
88943710|NCT01873118|Experimental|implementation unit|"3 implementation protocols implemented sequentially:~RN-RHDS: implementation of discharge readiness assessment by the discharging nurse~RN-RHDS+PT-RHDS: implementation of discharge readiness assessment by the discharging nurse which is informed by patient self-assessment of discharge readiness~RN-RHDS+PT-RHDS+NIAF: implementation of discharge readiness assessment by the discharging nurse which is informed by patient self-assessment of discharge readiness followed by documentation of nurse actions initiated in response to the assessment. Nurse are instructed that action must be taken if any assessment item scores less than 7 ( on a 10 point scale)."
89462948|NCT05387967|Experimental|Treatment group|All the recruited patients were prescribed Sacubitril/Valsartan at a starting dose of 50 (24/26) mg BID which was up-titrated, over the period of initial 6 weeks, to the maximum tolerated dose up to 200 (97/103) mg BID and further followed for a total of 12 weeks.
88943711|NCT01873144|Active Comparator|HSS (3%) + epinephrine|Nebulized solution containing 0.5 mL/kg (maximum 3 mL) of epinephrine 1/1000 plus 2 mL of HSS(3%) every 4h for three times and afterwards at physician in charge criteria.
88943712|NCT01873144|Experimental|HHHFNC+epinephrine+Normal Saline(0.9%)|Flow depending on weight (Tidal volume x respiratory rate x 9) and nebulized solution containing 0.5 mL/kg (maximum 3 mL) of epinephrine 1/1000 plus 2 mL of Normal Saline (NS) (0.9%) every 4h and afterwards at physician in charge criteria.
88943713|NCT01873157|Placebo Comparator|Placebo (NaCl solution)|"Patients will receive two cycles of Placebo (NaCl solution) at an interval of three months.~Each cycle will consist of intravenously administered (within 3-5 seconds) Placebo twice weekly on days 1, 4, 8 and 11."
88943714|NCT01873157|Active Comparator|Bortezomib (Velcade®)|"Patients will receive two cycles of Bortezomib (Velcade®) at an interval of three months.~Each cycle will consist of intravenously administered (within 3-5 seconds) Bortezomib 1.3 mg/m2 twice weekly on days 1, 4, 8 and 11."
88943715|NCT01873183|Experimental|The IGDT group|"30 morbidly obese subjects scheduled for bariatric surgery by laparoscopic Roux-en-Y gastric bypass (RYGB) will be consecutively enrolled for the study.~The individualized goal-directed therapy (IGDT) with focus on level of venous return will be implemented in two steps in the intervention group. First, preoperative optimizing of venous return will be performed 45 minutes before surgery in a preoperative room with TTE. Second, after induction of anaesthesia perioperative fluid therapy will be implemented by utilizing the FloTrac-device."
88943716|NCT01873183|No Intervention|The control group|20 morbidly obese subjects scheduled for bariatric surgery by laparoscopic Roux-en-Y gastric bypass (RYGB) will consecutively be enrolled for the study. Conventional monitoring will be conducted perioperatively.
89462949|NCT00389649|Active Comparator|HR=60|Pacemaker set at 60
89462950|NCT00389649|Active Comparator|HR=75|Pacemaker set at 75
89462951|NCT00389649|Active Comparator|HR=90|Pacemaker set at 90
89462952|NCT05389137|Other|Trial group 1 (No previous influenza vaccination)|Subjects with no previous influenza vaccination
88943717|NCT01873196|Experimental|Receive extra oil|This arm will receive enough oil to prepare the CSB they receive in the newly recommended proportion of 100g CSB: 30g oil. They will receive education and instructions on the new method of preparation.
89462953|NCT05389137|Other|Trial group 2 (previous vaccinated with one dose of influenza vaccine)|Subjects previously vaccinated with one dose of influenza vaccine
89462954|NCT05389137|Other|Trial group 2 (previous vaccinated with two doses of influenza vaccine)|Subjects previously vaccinated with two dose of influenza vaccine
89462955|NCT03856359|Experimental|Rifaximin|rifaximin 550 milligrams (mg) orally twice daily for 3 months
88943718|NCT01873196|No Intervention|Control-No extra oil received|This group will continue to receive only 1L of oil with their CSB has they already have been. They also will not receive any new education.
88943719|NCT01873196|Experimental|Receives behavior changed messages on CSB package|Group receiving CSB repackaged into 2kg packages with messages on package on how to prepare. Only in Phase II.
88943720|NCT01873196|No Intervention|Control-No repackaged CSB|
89462956|NCT03663855|Experimental|Cystinuria Patients|
88943721|NCT01873222|Experimental|OFDI-guided PCI & IVUS|"Assessment by IVUS at post-PCI~Assessment by OFDI at a 8-month follow-up"
88943722|NCT01873222|Active Comparator|IVUS-guided PCI & OFDI|"Assessment by OFDI at post-PCI~Assessment by OFDI at a 8-month follow-up"
88943723|NCT01873248|Experimental|Diagnostics with PET|68Ga-DOTATATE PET scans will be performed on subjects
88943724|NCT01873274|Active Comparator|basic yogurt enriched with MK-7|one study group will receive daily two basic dairy products enriched with MK-7 (50 μg)
89462957|NCT02965573|Active Comparator|ARGX-113|During the Treatment period, eligible patients will be randomized at a 1:1 ratio to receive ARGX-113
89462958|NCT02965573|Placebo Comparator|Placebo|During the Treatment period, eligible patients will be randomized at a 1:1 ratio to receive placebo
89462959|NCT04052659|Experimental|Treatment (sintilimab,chidamide and azacitidine)|"Sintilimab: 200 mg IV, Q3W, d1~Chidamid: 30 mg PO, BIW, d1, d4~Azacidine: 100 mg SC, Q3W, d1-7"
89462960|NCT02898727|Other|Local Therapy|"The local therapy offered will be determined by the participant's doctor in consultation with the site multidisciplinary team and will be dependent on the size and location of the brain metastases.~Neurosurgery: The surgery may be performed up to 6 weeks before participant being registered on the trial or up to 4 weeks after registration.~Sometimes stereotactic radiosurgery is required to be delivered to the cavity left after the metastasis has been removed (Cavity Boost).~Stereotactic Radiosurgery: Treatment is to commence within 4 weeks of study registration. The size, number and location of the brain metastasis will determine the dose and fractionation schedule of radiotherapy."
89462961|NCT02964325|Experimental|Mirasol platelets (MIR PLTs)|Leukoreduced, Trima Accel® apheresis platelets stored in 100% plasma, pathogen reduced with the Mirasol® Pathogen Reduction Technology (PRT) System
89462962|NCT02964325|Active Comparator|Reference platelets (REF PLTs)|Leukoreduced, apheresis platelets stored in 100% plasma
89462963|NCT03645889|Experimental|Paediatric Lung Tonic (PLTG)|Traditional Chinese Medicine (TCM) in granules dosage form to be dissolved for consumption.
89462964|NCT03645889|Placebo Comparator|PLTG Placebo|Starch granules with 10% TCM to mimic the colour, taste and smell of active TCM.
89462965|NCT02964247|Experimental|liraglutide + SGLT2i ± metformin|
88943725|NCT01873274|Active Comparator|MK-7 containing capsule|one study group will receive daily a softgel capsule consisting of 50 μg MK-7
88943726|NCT01873274|Active Comparator|nutrient enriched yogurt with MK-7|one study group will receive daily two nutrient-enriched dairy products containing extra nutrients and omega-3 FA (fish-oil)
88943727|NCT01873300|Experimental|treatment group|Patients undergoing POEM procedure
88943728|NCT01873313||Ropivacaine|Injection of local anaesthetic (ropivacaine) into the knee joint following knee arthroplasty. Total dose 200mls of 0.2% ropivacaine or 400mg at the time of surgery plus up to 5 top-up boluses (40mls of 0.2% ropivacaine or 80mg) postoperatively.
88943729|NCT01873339|Experimental|Darapladib|The subjects will receive a single oral dose of midazolam 5 mg on Day 1. The subjects will receive darapladib 160 mg once daily on Days 3-14. The subjects will also receive a single dose of midazolam 5 mg on Day3 and 14.
88943730|NCT01873352|Active Comparator|CA+RD|Catheter ablation of atrial fibrillation plus renal sympathetic denervation
88943731|NCT01873352|Active Comparator|CA (control)|Catheter ablation of atrial fibrillation (control group)
88943732|NCT01873365||Prospective Group|Japanese adults, aged greater than or equal to sixty years, diagnosed with HZ.
88943733|NCT01873378|Experimental|GnRH agonist pretreatment|triptorelin 3.75 mg, im, monthly, three times
89462966|NCT02964247|Placebo Comparator|liraglutide placebo + SGLT2i ± metformin|
89462967|NCT03645733|No Intervention|Control Group|The control group will be at the standard dialysate temperature of 36.5 °C (which is the standard of care in the sites), 3 times a week for 12 months
89462968|NCT03645733|Experimental|Lower Temperature Group|These patients will receive haemodialysis with a dialysate temperature of 35 degree centigrade. The intervention group will start off using a dialysate temperature that is 36 °C. Thereafter the dialysate temperature will be reduced every two week by 0.5 °C until 35 °C or the lowest tolerated temperature reached. Patients who would fail to tolerate the temperature of 35 °C, the lowest tolerated temperature will be carried over to the end of the study.
89462969|NCT03645733|No Intervention|Caregivers|Patients, who consent for the study, will be asked to identify the most suitable carer to participate in the study who could be approach in person, over the phone or by post as deemed suitable by the research team and convenient by the carer. Patient's permission to contact their identified carer will be recorded. Carers of consenting patients will be approached in the same manner as above after obtaining patients consent to contact their carers. Patients will still be able to take part in the study even if their carer declines consent.
89501885|NCT03516487|Experimental|SAD HV: SYNB1618 (2 x 10^11 CFU)|HV subjects receive a single oral dose of SYNB1618 (2 x 10^11 CFU) in a chilled buffered solution on Day 1 in the SAD study (Part 1).
89501886|NCT03516487|Experimental|SAD HV: SYNB1618 (5 x 10^11 CFU)|HV subjects receive a single oral dose of SYNB1618 (5 x 10^11 CFU) in a chilled buffered solution on Day 1 in the SAD study (Part 1).
88943734|NCT01873378|No Intervention|No pharmacological treatment|
88943735|NCT01873391|Active Comparator|Normal saline|Normal saline is a distension media of uterine cavity in diagnostic hysteroscopy.
88943736|NCT01873391|Active Comparator|Carbon dioxide|Carbon dioxide is a distension media of uterine cavity in diagnostic hysteroscopy.
88943737|NCT01873430|Active Comparator|Melatonin: Melatonin cream 2,5%|One square on the back of each volunteers will be randomized to have the above mentioned dose of melatonin cream applied
88943738|NCT01873430|Active Comparator|Melatonin: Melatonin cream 0,5%|One square on the back of each volunteers will be randomized to have the above mentioned dose of melatonin cream applied.
88943739|NCT01873430|Active Comparator|Melatonin: Melatonin cream 12,5%|One square on the back of each volunteers will be randomized to have the above mentioned dose of melatonin cream applied.
88943740|NCT01873430|Placebo Comparator|placebo cream|One square on the back of each volunteers will be randomized to have placebo cream (vehicle) applied.
88943741|NCT01873430|No Intervention|No treatment|One square on the back of each volunteers will be randomized to receive no treatment.
88943742|NCT01873443|Experimental|Rituximab, MTX, folic acid|
88943743|NCT01873469||Radiochemotherapy|glioblastoma patients with indication to radiochemotherapy
88943744|NCT01873482|Experimental|Movement with rhythm|Subjects will move for 1 hour in time to the Congolese rhythm called Zebola.
88943745|NCT01873508|Experimental|Fast release MR capsule|
88943746|NCT01873508|Experimental|Slow release MR capsule|
88943747|NCT01873508|Experimental|Target release MR capsule|
88943748|NCT01873521|Active Comparator|NIV PS|The patients in this arms will received non invasive ventilation in PS mode.
89462970|NCT05284279||Health professionals practicing with children|"To participate, health professionals will have to speak French fluently, practice with children as a dentist (general or pediatric), a general practitioner, or a paediatrician and work in hospital or ambulatory facility. As paediatricians and general practitioners meet the child regularly during the first 6 years of life for medical follow-up, they are key stakeholders in the early detection of caries, referrals to dentist and counselling.~The participants will be recruited using a semi-random sampling method. The sample will be constituted with a maximum variation in age, gender, years in practice, occupation and types of practice (solo, group or interdisciplinary team)."
89462971|NCT03645655||hepatoblastoma|The diagnosis of hepatoblastoma is based on enhanced CT scanning and/or histopathology.
89462972|NCT03645655||hepatic hemangioendothelioma|The diagnosis of hepatic hemangioendothelioma is based on enhanced CT scanning and/or histopathology.
89462973|NCT03645655||Healthy control|The healthy control group consist of people undergoing routine medical examination.
89462974|NCT04051801|Experimental|Dose Escalation of VU319 - Dose 1|
89462975|NCT04051801|Placebo Comparator|Dose Escalation of Placebo - Dose 1|
89462976|NCT04051801|Experimental|Dose Escalation of VU319 - Dose 2|
89462977|NCT04051801|Placebo Comparator|Dose Escalation of Placebo - Dose 2|
89462978|NCT04051801|Experimental|Dose Escalation of VU319 - Dose 3|
88943749|NCT01873521|Active Comparator|NIV NAVA|The patients in this arm will received non invasive ventilation in NAVA mode.
88943750|NCT01873547|Active Comparator|rehabilitation|Patients in the group accept rehabilitation for three weeks in hospital and other eleven months in their home under the guidance of physical therapist.
88943751|NCT01873547|Experimental|cell therapy|Patients in the group accept cell therapy including four times stem cells transplant via intrathecal injection.
88943752|NCT01873547|No Intervention|control|Patients receive no professional treatment in hospital or rehabilitation centre.
88943753|NCT01873573|Active Comparator|EGD with Dilation|Standard of Care: Esophagogastroduodenoscopy (EGD) with dilation alone. If participants are assigned to Arm A and are not showing any clinical improvements as determined by their physician after the first three endoscopic dilation sessions, then they will be crossed over into Arm B.
88943754|NCT01873573|Active Comparator|EGD with Dilation, plus Triamcinolone|Standard of Care: EGD with dilation and Triamcinolone injection.
88943755|NCT01873599|Experimental|Intervention|Participants in the intervention condition will be asked to write for 15 minutes on three days each week to one of the seven positive affect writing prompts on www.stressvax.com. Subjects who do not complete a journal entry within 7 days will receive an email reminder, in case they have lost their password or have some technical problem accessing the site.
88943756|NCT01873599|No Intervention|Control|As there is no clinical standard of care treatment for psychological distress, patients randomized into this condition will receive their usual care. At the end of three months, subjects in this condition will be given access to the positive affect journaling intervention.
89462979|NCT04051801|Placebo Comparator|Dose Escalation of Placebo - Dose 3|
89462980|NCT03846115|Experimental|Peer-Led Seeking Safety app|This app is designed for Peer-Led Seeking Safety and includes enhanced app features.
89462981|NCT03846115|Active Comparator|Control app|This is a basic app that controls for time and attention. The basic app serves as the intervention in this trial.
89462982|NCT05283967||Adults and children, U.S.|We will conduct a prospective, observational study of the pharmacokinetics of first-line anti-TB drugs (isoniazid, rifampin, and pyrazinamide) among TB patients (i.e. patients with active TB disease).
89462983|NCT05283967||Tanzanian children|We will conduct a prospective, observational study of the pharmacokinetics of first-line anti-TB drugs (isoniazid, rifampin, and pyrazinamide) among TB patients (i.e. patients with active TB disease).
89462984|NCT03654729|Experimental|PledOx (2 µmol/kg)|Calmangafodipir (2 µmol/kg) on day 1 every two weeks to patients as an intravenous infusion, combined with mFOLFOX6 chemotherapy.
89462985|NCT03654729|Experimental|PledOx (5 µmol/kg)|Calmangafodipir (5 µmol/kg) on day 1 every two weeks to patients as an intravenous infusion, combined with mFOLFOX6 chemotherapy.
89462986|NCT03654729|Placebo Comparator|Placebo|Placebo will be given to patients as an intravenous infusion, on top of mFOLFOX6 chemotherapy.
89462987|NCT03646747|Experimental|MRI scan|"10 healthy participants will be asked to undergo two baseline OE-MRI scans with either nasal cannula or facial mask to breathe air and oxygen throughout.~Following this initial pilot, OE-MRI will be tested in 30 patients with solid head and neck tumours."
89462988|NCT04052269|Experimental|eyes with glaucoma|patients with glaucoma will have imaging of retina post administration of Sildenafil or Tadalafil.
89462989|NCT04052269|Other|Healthy (unaffected) eyes|patients with healthy eyes who are already taking Sildenafil or Tadalafil have their imaging of retina post administration of Sildenafil or Tadalafil.
89462990|NCT03827317|Other|HER2 positive metastatic breast cancer|8 HER2 positive patients (determined using the most recent biopsy) will be recruited. Dynamic [18F]GE-226 PET imaging over 90 minutes, radial artery sampling will be performed to establish the pharmacokinetic profile of [18F]GE-226 and hence determine the optimal imaging time point for [18F]GE-226 PET scans. Tumour uptake in individual metastases (and the target lesion) will be reported. Uptake will be compared between HER2 positive and negative tumours.
89462991|NCT03827317|Other|HER2 negative metastatic breast cancer|8 HER2 negative patients (determined using the most recent biopsy) will be recruited. Dynamic [18F]GE-226 PET imaging over 90 minutes, radial artery sampling will be performed to establish the pharmacokinetic profile of [18F]GE-226 and hence determine the optimal imaging time point for [18F]GE-226 PET scans. Tumour uptake in individual metastases (and the target lesion) will be reported. Uptake will be compared between HER2 positive and negative tumours.
88943757|NCT01873612|Experimental|Sedation with dexmedetomidine|Sedation with dexmedetomidine
88943758|NCT01873612|Experimental|Sedation with propofol|Sedation with propofol
88943759|NCT01873625|Placebo Comparator|placebo|Normal salin injection in patients with rheumatoid arthritis for resurfacing of articular cartilage of knee due to osteoarthritis.
88943760|NCT01873625|Active Comparator|mesencymal stem cell|Mesenchymal stem cell transplantation in patients with rheumatoid arthritis for resurfacing of articular cartilage of knee due to osteoarthritis.
88943761|NCT01873638|Other|Minilaparotomy|Minilaparotomy cholecystectomy as a day surgery
88943762|NCT01873638|Other|Laparoscopy|Laparoscopic cholecystectomy as a day surgery
88943763|NCT01873651|Experimental|Delta III|Implantation of a Delta III Prosthesis
88943764|NCT01873664|Experimental|Jaw tapping|All subjects performed the jaw-tapping for 4 weeks at home.
88943765|NCT01873690|Placebo Comparator|Placebo|Placebo
88943766|NCT01873690|Active Comparator|Ciprofloxacin|Ciprofloxacin
88943767|NCT01873716|Experimental|Injection of Indocyanine Green|Injection of Indocyanine Green prior to carotid endarterectomy surgery. Collection of specimen during surgery with subsequent carotid tissue analysis.
88943768|NCT01873716|No Intervention|No injection|No injection prior to carotid endarterectomy surgery. Collection of specimen during surgery with subsequent carotid tissue analysis.
88943769|NCT01873768|Active Comparator|Tranexamic acid (TXA)|1g in 50ml of saline given over 30 minutes just prior to raising the tourniquet and making the initial incision. A second 1g in 50ml of saline will be infused over 30 minutes beginning at the time of wound closure.
88943770|NCT01873768|Active Comparator|ε-Aminocaproic Acid (EACA)|7g in 50ml of saline given over 30 minutes just prior to raising the tourniquet and making the initial incision. A second 7g of EACA in 50ml saline will be infused over 30 minutes beginning at the time of wound closure.
88943771|NCT01873781||30 healthy male and female subjects|30 healthy male and female subjects aged 18-35
88943772|NCT01873794|Active Comparator|Bright white light|using systematic light exposure (SLE), consisting of a daily 30-minute exposure to as much as 10,000 lux of light from a commercially available light box
88943773|NCT01873794|Active Comparator|Dim red light|using systematic light exposure (SLE), consisting of a daily 30-minute exposure to as much as 10,000 lux of light from a commercially available light box
88943774|NCT01873807|Experimental|IDA-Etoposide Intensified Conditioning|
88943775|NCT01873807|Active Comparator|Non-IDA Conditioning|
88943776|NCT01873820|Experimental|Calcium ascorbate -> ascorbic acid|
88943777|NCT01873820|Experimental|Ascorbic acid -> calcium ascorbate|
88943778|NCT01873872|Active Comparator|Theralac probiotic|
88943779|NCT01873872|Active Comparator|Culturelle probiotic|
88943780|NCT01873872|Placebo Comparator|Placebo|
88943781|NCT01873885|Experimental|Cohort 1: Single IV Infusion Vasomera (PB1046) or Placebo|Cohort 1 - Single 30 minute infusion Vasomera (PB1046) at 0.01 mg/kg diluted in 0.9% Sodium Chloride or Placebo (0.9% Sodium Chloride)
88943782|NCT01873885|Experimental|Cohort 2: Single IV Infusion Vasomera (PB1046) or Placebo|Cohort 2 - Single 30 minute infusion Vasomera (PB1046) at 0.005mg/kg in 0.9% Sodium Chloride or Placebo (0.9% Sodium Chloride)
88943783|NCT01873885|Experimental|Cohort 3: Single IV Infusion Vasomera (PB1046) or Placebo|Cohort 3 - Single 30 minute infusion Vasomera (PB1046) at 0.02mg/kg 0.9% Sodium Chloride or Placebo (0.9% Sodium Chloride)
88943784|NCT01873898|Experimental|Single Arm|This is a single arm, prospective study to collect data on the safety and effectiveness of the Rex Medical Closer™ Vascular Closure System. Only subjects who are scheduled to undergo an interventional diagnostic procedure that requires closure of the femoral access site are eligible for study participation.
88943785|NCT01873937|Experimental|Red LED|Irradiation parameters: 630 nm, 60 sec and 18 J/cm² per point.
88943786|NCT01873937|Experimental|infrared LED|Irradiation parameters: 850 nm, 60 sec and 18J/cm² per point
88943787|NCT01873937|Active Comparator|LASER|Irradiation parameters: 780 nm, 60 sec and 105 J/cm²
88943788|NCT01873963||Pediatric cardiomyopathy|Diagnosis of primary or idiopathic dilated, hypertrophic or restrictive cardiomyopathy. Diagnosis must have been made before the age of 18 and must be confirmed by established echocardiographic criteria or cardiac MRI (cMRI) at the time of diagnosis.
88943789|NCT01873976||Incident DCM|A case of dilated cardiomyopathy that presents to the study site for the first time.
88943790|NCT01873976||Incident/Recent HCM|A new or existing diagnosis of idiopathic or familial hypertrophic cardiomyopathy, diagnosed within the past 2 months and with a cMRI within 2 months of diagnosis.
88943791|NCT01873976||Prevalent HCM or DCM|Any child with a diagnosis of dilated cardiomyopathy or idiopathic or familial hypertrophic cardiomyopathy who has survived transplant-free at least 24 months from the date of cardiomyopathy diagnosis.
88943792|NCT01874002||Combo stent|Consecutive patients in whom a treatment with a Combo stent in the setting of routine clinical care is attempted are entered into the registry.
88943793|NCT01874015|Active Comparator|mesenchymal cell and fibroblast transplantaion|The patients with crohn's disease who underwent mesenchymal cell and fibroblast injection.
88943794|NCT01874015|Active Comparator|mesenchymal cell transplantaion|The patients with Crohn's disease who underwent mesenchymal cell transplantation.
88943795|NCT01874028|Experimental|Trientine dihydrochloride|
88943796|NCT01874041|Experimental|Massage group|The massage group was submitted to three weekly 30-minute sessions of massage of the muscles of mastication over four consecutive weeks.
88943797|NCT01874041|Experimental|The occlusal splint group|The occlusal splint group was submitted to treatment with an occlusal splint for four weeks.
88943798|NCT01874041|No Intervention|Control group|The control group was not submitted to any form of intervention and was evaluated on two occasions, with a four-week interval between evaluations.
88943799|NCT01874080|Experimental|Arm A: Saxagliptin/Metformin XR FDC (Mt. Vernon/Humacao)|Saxagliptin 5 mg /Metformin 1000 mg (Mt. Vernon/Humacao) tablet by mouth once daily on Day 1 of Periods 1 and 2
88943800|NCT01874080|Experimental|Arm B: Saxagliptin/Metformin XR FDC (Mt. Vernon)|Saxagliptin 5 mg/Metformin 1000 mg (Mt. Vernon) tablet by mouth once daily on Day 1 of Periods 1 and 2
88943801|NCT01874080|Experimental|Arm C: Saxagliptin/Metformin XR FDC (Mt. Vernon/Humacao)|Saxagliptin 5 mg/Metformin 500 mg (Mt. Vernon/Humacao) tablet by mouth once daily on Day1 of Periods 1 and 2
88943802|NCT01874080|Experimental|Arm D: Saxagliptin/Metformin XR FDC (Mt. Vernon)|Saxagliptin 5 mg/Metformin 500 mg (Mt. Vernon) tablet by mouth once daily Day 1 of Periods 1 and 2
88943803|NCT01874093|Experimental|Active Stimulation|INS implantation, 5 Days of Ischemic Stroke System (ISS) Stimulation + Standard of Care
88943804|NCT01874093|Sham Comparator|Sham Stimulation|Sham implantation, 5 Days of Sham Stimulation + Standard of Care
88943805|NCT01874106|Experimental|Diet therapy|The patients in this arm were educated to follow a especial type of diet (anti-inflammatory diet)in addition to nutrition counseling for 10 weeks.
88943806|NCT01874106|Other|Control Group|The patients in this arm received nutrition counseling and education in general based on their needs as a control group for 10 weeks.
89462992|NCT03130647|Experimental|Focused ultrasound|Repeated measures sham control
89462993|NCT03646591||Neoadjuvant chemotherapy|"FLOT Chemotherapy regimen~A cycle consist of Day 1: 5-fluorouracil (5-FU) 2600mg/M2 intravenous Via peripherally inserted central catheter (PICC) for 24 hour Day 1: Leucovorin 200mg/M2 intravenous Day 1: Oxaliplatin 85mg/ M2 intravenous Day 1: Docetaxel 50mg/M2 intravenous Repeated every 15th day"
89462994|NCT03645265|Experimental|Gestures|Use of hand gestures to improve speech rhythm and speech production
89462995|NCT03645265|Experimental|Auditory|Use of auditory cues to improve speech rhythm and speech production
89462996|NCT01377987|Experimental|Acetazolamide|
89462997|NCT01377987|Placebo Comparator|Sugar pill|
89462998|NCT03645187|Active Comparator|FOLFERI|FOLFERI regien
89462999|NCT03645187|Active Comparator|FOLFERI and celecoxib|FOLFERI and celecoxib
89463000|NCT03645109|Experimental|Vitamin D|Will receive capsules with 5,000 IU of vitamin D3, one capsule orally once a day for eight weeks
89463001|NCT03645109|Placebo Comparator|Placebo|Will receive capsules with placebo (talcum food grade) one capsule orally once a day for eight weeks
89463002|NCT05380167|Experimental|BRJ Nitrate|This arm consumed daily for 12 weeks a 70 mL bottle of beetroot juice containing 380 mg of nitrate.
89463003|NCT05380167|Placebo Comparator|BRJ Placebo|This arm consumed daily for 12 weeks a 70 mL bottle of beetroot juice containing 0 mg of nitrate.
89463004|NCT03573375|Experimental|Cancer Patients in Supportive Care Clinic (SCC)|
89463005|NCT05165745|Other|Cisgender Women and Trans Individuals (CWTI)|Cisgender women and trans individuals (CWTI) who are taking PrEP, have considered and decided not to take PrEP, or who have discontinued PrEP.
89463006|NCT05165667|Experimental|team meeting|the team meeting will help to measure the effectiveness of rehabilitation team meeting on disability among stroke patinets in Functional Independent Measure (FIM) score
89463007|NCT05165667|Active Comparator|patient|they will be the subject
89463008|NCT03351387||SPY Intra-operative Angiography|The SPY Fluorescent Imaging System
89463009|NCT05165589|Experimental|Part 1: Initial data collection for device feasibility|3 subjects for 4 days included to collect initial data for algoritm development for device feasibility
88943807|NCT01874158||TV postive women|All women who are TV positive by wet prep or in-pouch and meet the inclusion exclusion requirements.
88943808|NCT01874171|Active Comparator|Cisplatin|Three doses of cisplatin 100mg/m2 given at days 1, 22 and 43 from start of radiotherapy.
88943809|NCT01874171|Experimental|Cetuximab|Initial dose of 400mg/m2 one week before start of radiotherapy followed by seven weekly doses of 250 mg/m2 during radiotherapy.
88943810|NCT01874184|Experimental|Arm I (DEEM intervention)|Participants take part in weekly 2-hour group counseling sessions for 6 months with taper beginning at 3 months. Group sessions include education, group process, and experiential learning on the benefits of physical activity, balanced nutrition, and mindfulness techniques. Participants set goals for changing their dietary habits with the help of a mental health counselor and are also encouraged to exercise 3-4 times per week, including experiential group activities such as brisk walking, yoga, Zumba, and group fitness.
88943811|NCT01874184|No Intervention|Arm II (usual care)|Participants receive their usual care and are provided with study materials on healthy diet and exercise at the end of the study.
88943812|NCT01874197|Other|B -TEVAR|Implantation of the B-TEVAR device
88943813|NCT01874210||Hemodialysis|Hemodialysis patients
88943814|NCT01874210||Control|"Household contacts on the same diet~Healthy unrelated controls"
88943815|NCT01874236|Active Comparator|1st sequence|Blinded 3 blocks (2 bupivacaine, 1 sham block)
88943816|NCT01874236|Active Comparator|2nd sequence|Blinded 3 blocks (2 bupivacaine, 1 sham block)
88943817|NCT01874236|Active Comparator|3rd sequence|Blinded 3 blocks (2 bupivacaine, 1 sham block)
88943818|NCT01874249|Experimental|Electronic detailed information|Standard of care for patients with diagnosis of fatty liver by ultrasound, plus electronic detailed information about non alcoholic fatty liver disease.
88943819|NCT01874249|Experimental|NAFLD Score|Standard of care for patients with diagnosis of fatty liver by ultrasound, plus electronic detailed information about non alcoholic fatty liver disease, plus diagnosis of advanced fibrosis by NAFLD score.
88943820|NCT01874249|Experimental|NAFLD Score plus Transient elastography|Standard of care for patients with diagnosis of fatty liver by ultrasound, plus electronic detailed information about non alcoholic fatty liver disease, plus diagnosis of advanced fibrosis by NAFLD score and transient elastography.
89463010|NCT05165589|Experimental|Part 2: Device feasibility|10 subjects for 7 days included to evaluate device feasibility
89463011|NCT04455555|Experimental|rotigotine treatment group|rotigotine sustained release microspheres therapy by injection
89463012|NCT04455555|Placebo Comparator|placebo comparator|placebo comparator/null microspheres
89463013|NCT02898259|Experimental|Lenalidomide + Ixazomib + Rituximab|Ixazomib will be orally administered with a starting dose of 2.0mg. Lenalidomide will be administered orally with a starting dose of 20mg. Rituximab will be administered intravenously at the standard dose of 375mg/m2. The study will use a standard 3 + 3 design for determination of MTD during cycle 1. There will be three dose levels for escalation, followed by two expansion cohorts of 12 patients each at the MTD, one cohort with follicular lymphoma and one cohort with non-follicular low-grade lymphoma (SLL, marginal zone, lymphoplasmacytic). Patients will be treated for 12 cycles of 4 week duration.
89463014|NCT03646435|Experimental|Wearable device (Fitbit Charge 2)|The Fitbit Charge 2 is the wearable of interest for this pilot study. All 50 study participants will be requested to wear the electronic device for the duration of their stay in the hospital (maximum of 6 days). The Fitbit will passively collect health information of patients which will be tracked on mobile devices by the study investigators.
89463015|NCT03645343|Active Comparator|Activator|Patients will be treated using the Activator appliance for one and a half year
89463016|NCT03645343|Experimental|Twin Block|Patients will be treated using the Twin Block appliance for 18 months on average
89463017|NCT03645343|No Intervention|Control|Patients will be monitored until the last assessment times in the other groups. This group will serve as a control group
89463018|NCT05283733|Experimental|group A|the group who was subjected to the reverse conversion technique
89017908|NCT05863312|Experimental|Pars plana vitrectomy + perfluoropropane gas tamponade|
89463019|NCT05283733|No Intervention|group B|the control group who was completed by open technique
89463020|NCT03704545|No Intervention|Control group|
89463021|NCT03704545|Experimental|Experimental group from the hospital|
89463022|NCT03704545|Experimental|Experimental group from the city|
89463023|NCT03644797||Patients|Patients presenting intellectual disability and previously diagnosed as carriers of a 16p13.11 copy number variant using Cytogenetic Micro Array.
89463024|NCT03646201|Experimental|FFF|FFF teaches authoritative parenting skills for reducing children's exposure to and intakes of SoFAS, including changes to the family food environment, mothers' own eating behaviors, and food parenting practices.
89463025|NCT03646201|No Intervention|Control Group|Data are collected at baseline and post intervention session.
89463026|NCT02963935|Experimental|Liraglutide|
89463027|NCT02963935|Placebo Comparator|Placebo|
89463028|NCT03644329|Other|Control group, CT|In the CT, the postmenopausal breast cancer survivers does not perform exercise.
89463029|NCT03644329|Experimental|Lower-load resistance training (LL)|In the LL, the postmenopausal breast cancer survivers will be submitted to 12 weeks of resistance training with low loads ( i.e. three sets with 30% of one-repetition maximum).
89463030|NCT03644329|Experimental|Higher-load resistance training (HL)|In the HL, the postmenopausal breast cancer survivers will be submitted to 12 weeks of resistance training with high loads (i.e. three sets with 80% of one maximum repetition).
89463031|NCT03644329|Experimental|Higher-volume resistance training (HV)|In the HV, the postmenopause breast cancer survivers will be submitted to 12 weeks of resistance training with high volume ( i.e. six sets with 80% one maximum repetition).
89463032|NCT03644719|Experimental|Cognitive behavior skills training|The first session is intended to establish rapport, build therapeutic cohesion through ice-breaking activities, and educate participants about the drug regulations stated in the Statute for Drug Hazard Prevention and Control. The following four sessions are devoted to interactively practicing refusal skills, communication skills, decision-making skills, and positive conflict resolution skills. The final session is to review what has been learned and reminds participants about the association of drug use with HIV/HCV.
89463033|NCT03644719|No Intervention|Education as usual|The EAU group received six hours of informational lectures about ketamine, its effects on the brain, relevant regulations and laws, and the risks and modes of transmission of infectious diseases, including HIV and hepatitis C.
89463034|NCT03644641|Experimental|Desflurane Group|Induction and anesthesia will be held by using desflurane
89463035|NCT03644641|Experimental|Propofol Group|Induction and anesthesia will be held by using target-control anesthesia with propofol
89463036|NCT05283421|Active Comparator|Active estrogen|Will receive pretreatment with vaginal application of estrogen 30 microgram (three tablets) once a day for 14 days.
89463037|NCT05283421|Placebo Comparator|Placebo|Will receive pretreatment with vaginal application with no estrogen (three tablets) once a day for 14 days.
89463038|NCT03643783||Bariatric Obese Patients|Obese patients, including men and women, White (Caucasians), Africa American, and Hispanic or Latino racial categories, and ages 18-70 years, who are enrolled and planning to undertake bariatric surgery in the Outpatient Bariatric Surgery Clinic at Tulane University, HSC (Christopher G. Ducoin, MD, MPH; Chair of Bariatric Surgery Clinic and Surgeon, and Shauna Levy, MD, Bariatric Surgeon Specialist).
89017909|NCT05863312|Experimental|Pars plana vitrectomy with scleral buckle + perfluoropropane gas tamponade|
89463039|NCT03643783||Lean Control Patients|Plasma samples from lean control patients that have already been collected and are available as part of the Tulane Obesity-Endocannabinoids Study (Tina Thethi, M.D, Collaborator).
89463040|NCT03643627|Placebo Comparator|Placebo|
89463041|NCT03643627|Experimental|1 mg/kg|
89463042|NCT03643627|Experimental|3 mg/kg|
89463043|NCT03643627|Experimental|10 mg/kg|
89463044|NCT03643627|Experimental|30 mg/kg|
89463045|NCT03641521|Experimental|Intervention|The intervention consisted of an enhanced Cooking Matters® for Families program that included behavioral strategies derived from behavioral economics, to be implemented by parents at home for increasing vegetable intake of low-income 9-12 year old children
89463046|NCT03641521|No Intervention|Control|The control arm consisted of the enhanced Cooking Matters® for Families program alone--without lessons about the behavioral strategies for the parents
89463047|NCT03641443|Experimental|Non-invasive measurement of intracranial pressure|Patient with mass effective brain tumor that undergo non-invasive intracranial pressure measurement
89463048|NCT03641365|Experimental|Test group|Test group: Surgical template without metallic sleeves. In this case the surgical template has all been designed and fabricated in acrylic material by mean of stereolitographic technology.
88943821|NCT01874249|Experimental|Transient elastography|Standard of care for patients with diagnosis of fatty liver by ultrasound, plus electronic detailed information about non alcoholic fatty liver disease, plus diagnosis of advanced fibrosis by transient elastography.
88943822|NCT01874249|No Intervention|Standard of care|Standard of care for patients with diagnosis of fatty liver by ultrasound.
88943823|NCT01874301|Experimental|High quantity probiotic food product|
88943824|NCT01874301|Experimental|Low quantity probiotic food product|
88943825|NCT01874301|Placebo Comparator|Placebo|
88943826|NCT01874314|Experimental|SQ109 450 mg|Single daily dose of oral 450mg SQ109 for 7 days.
88943827|NCT01874314|Active Comparator|Moxifloxacin|Single daily dose of oral 400mg moxifloxacin for 7 days followed by 7 days washout period.
88943828|NCT01874314|Placebo Comparator|SQ109 Placebo|Single daily dose of oral SQ109 placebo for 7 days followed by 7 days washout period.
88943829|NCT01874314|Experimental|SQ109 300 mg|Single daily dose of oral 300mg SQ109 for 7 days followed by 7 days washout period.
88943830|NCT01874327|Active Comparator|Baby JASPER|This classroom will spend the majority of the time focusing on social-communication goals
88943831|NCT01874327|Active Comparator|Standard Baby Classroom|This classroom will focus more heavily on developing motor and cognitive skills
88943832|NCT01874366|Experimental|P11187|"Part I: Step wise dose escalation in subsequent cohorts and will be based upon the review of safety and tolerability results of the preceding cohort~Part II: Step wise dose escalation in the multiple dosing for 14 consecutive days after review of the safety and tolerability of the preceding cohorts~Part III: Study drug will be administered under the fasted or fed conditions in two different periods separated by a wash-out interval of 7-10 days"
88943833|NCT01874366|Placebo Comparator|Placebo|Placebo capsules will be matching in appearance with the active drug capsules of P11187.
88943834|NCT01874379|Experimental|Guided Imagery|The therapist will instruct the patient on the Guided Imagery protocol and will provide the patient with headphones and an MP-3 player to use for the guided imagery intervention. The patient will listen to the Guided Imagery for 18min 30 sec.
88943835|NCT01874379|Active Comparator|Standard of Care|This group will serve as the control arm
88943836|NCT01874379|Experimental|'M'-Technique®|The 'M'-Technique will be administered to the patient's hands and feet for a total of 18-20 minutes, to be equally divided between extremities used according to limitations as outlined. Any hand or foot that is accessed by an IV will be avoided.
88943837|NCT01874418|Other|Biomarker study|Oligomeric beta-amyloid 42 in serum, as well as, monomeric beta-amyloid 42, total tau and phosphorylated tau in CSF
88943838|NCT01874444|Experimental|Active rTMS1|Combined low frequency frontal and temporal repetitive transcranial magnetic stimulation of left primary auditory cortex and left dorsolateral prefrontal cortex .
88943839|NCT01874444|Experimental|Active rTMS2|Temporal low frequency rTMS of left primary auditory cortex.
88943840|NCT01874444|Experimental|Active rTMS3|Frontal low frequency rTMS of left dorsolateral prefrontal cortex .
88943841|NCT01874444|Sham Comparator|Sham rTMS4|sham treatment Sham rTMS, applied with the same combination of parameters as active rTMS, except for the number of stimulations per session.
88943842|NCT01874470|Placebo Comparator|standard medication|Standard Medication: Continued usage of 3 or more antihypertensive medications of different classes, including a diuretic
88943843|NCT01874470|Experimental|renal denervation|Allegro Renal Denervation System (AngioCare)
88943844|NCT01874483|Experimental|BI 187004 dose 1|multiple dose given over 14 days
88943845|NCT01874483|Experimental|BI 187004 dose 2|multiple dose given over 14 days
88943846|NCT01874483|Experimental|BI 187004 dose 3|multiple dose given over 14 days
88943847|NCT01874483|Experimental|BI 187004 dose 4|multiple dose given over 14 days
88943848|NCT01874483|Experimental|BI 187004 dose 5|multiple dose given over 14 days
88943849|NCT01874483|Experimental|BI 187004 dose 6|multiple dose given over 14 days
88943850|NCT01874483|Placebo Comparator|Placebo|placebo
88943851|NCT01874483|Experimental|BI 187004 dose 7|multiple dose given over 14 days
88943852|NCT01874496|Experimental|GDS, meal|GDS, meal
88943853|NCT01874496|Experimental|GDS, no meal|GDS, no meal
88943854|NCT01874496|Active Comparator|control, no meal|control, no meal
88943855|NCT01874496|Active Comparator|control, meal|control, meal
88943856|NCT01874509|Active Comparator|Check Your Drinking screener|"Internet based program of lower intensity as compared to the Alcohol Help Centre. It was designed to assesses drinking patterns, increase self-awareness of individual triggers, and set and achieve goals regarding abstinence."
88943857|NCT01874509|Experimental|Alcohol Help Centre|"Internet based program of higher intensity as compared to the Check Your Drinking intervention. It was designed to assesses drinking patterns, increase self-awareness of individual triggers, and set and achieve goals regarding abstinence."
88943858|NCT01874522|Experimental|TAS-102 tablets|
88943859|NCT01874522|Experimental|TAS-102 oral solution|
88943860|NCT01874548||Normal cervix|Control group (n=30) comprising surgical candidates with normal cervical tissue will be collected for comparison.
88943861|NCT01874548||Cervical cancer|"1st year: 30 surgical candidates with cervical cancer tissue collected during operation.~2nd year: Enroll another 30 surgical candidates and complete the data regarding clinical MRS/DWI and tissue high resolution MRS. Together with the 30 cancer subjects in part one there will be in total 60 cancer subjects for analysis.~3rd year: enroll 60 patients primarily treated with CCRT and collect the data using clinical MR and tissue high resolution MRS."
88943862|NCT01874561|Experimental|Group 1|"Group 1: investigational product (custirsen) will receive:~320 mg of custirsen + 5 mg of dexamethasone on day 1~480 mg of custirsen + 5 mg of dexamethasone on day 3~640 mg of custirsen + 3 mg of dexamethasone on day 5~640 mg of custirsen on day 7 under fasting conditions"
88943863|NCT01874561|Placebo Comparator|Group 2|"Group 2: placebo (normal saline) will receive:~placebo + 5 mg of dexamethasone on day 1~placebo + 5 mg of dexamethasone on day 3~placebo + 3 mg of dexamethasone on day 5~placebo on day 7 under fasting conditions"
88943864|NCT01874561|Active Comparator|Group 3|"Group 3: positive control (moxifloxacin) will receive:~placebo + 5 mg of dexamethasone on day 1~placebo + 5 mg of dexamethasone on day 3~placebo + 3 mg of dexamethasone on day 5~400 mg of moxifloxacin + placebo (immediately after moxifloxacin administration) on day 7 under fasting conditions"
89463049|NCT03641365|Active Comparator|Control group|Control group: Surgical template with metallic sleeves. Surgical template has designed and fabricated in acrylic material by mean of stereolitographic technology and metallic sleeves have been bonded after its production.
89463050|NCT02963701|Experimental|Ibuprofen+Pseudoephedrine-HCl|Fixed dose combination
89463051|NCT02963701|Active Comparator|Ibuprofen+Pseudoephedrine-HCl (RhinAdvil®)|Fixed Dose Combination
89463052|NCT01345591|Experimental|Fat Grafting|Twenty (20) subjects who have had severe facial trauma, 18 years of age and older enrolled to clinical trial will receive Fat grafting intervention procedure
89463053|NCT03644251|Experimental|AMUC Dosage 1|25mg amniotic and umbilical cord matrix
89463054|NCT03644251|Experimental|AMUC Dosage 2|50mg amniotic and umbilical cord matrix
89463055|NCT03644251|Experimental|AMUC Dosage 3|100mg amniotic and umbilical cord matrix
89463056|NCT03621319|Active Comparator|Hybrid argon plasma ablation (HAPC)|Eligible participants will be randomized to receive ablation of dysplasia with Hybrid argon plasma coagulation (HAPC) after EMR of visible lesions (if present) has been performed as per standard of care.
89463057|NCT03621319|Active Comparator|Radiofrequency ablation (RFA)|Eligible participants will be randomized to receive treatment of dysplasia with RFA after EMR of visible lesions (if present) has been performed as per standard of care.
89463058|NCT02961751|Other|Ciprofloxacin|One dose of directly-observed ciprofloxacin 500 mg administered orally. N=381
89463059|NCT02963311|Experimental|ALN-PCSSC|300 milligrams (mg) administered subcutaneous (SC) on Day 1. Participants with a mean serum proprotein convertase subtilisin/kexin type 9 (PCSK9) levels not suppressed by >70% at Day 60 or Day 90, as compared to baseline, will receive a second dose at Day 90 or Day 104, respectively, based on PCSK9 levels from the previous visit. Participants also received standard of care as background therapy.
89463060|NCT02263209|Experimental|Bioguard Group|Randomised study to either Bioguard or control stock
89463061|NCT02263209|Active Comparator|Control Group|Randomised study to either Bioguard or control stock
89463062|NCT03641053|Experimental|Honey|0.05 cc of honey (Madu Nusantara®) per 1 cm of laceration, given every predetermined wound care schedule
89463063|NCT03641053|Active Comparator|Povidone-iodine|0.05 cc of povidone-iodine per 1 cm of laceration, given every predetermined wound care schedule
88943865|NCT01874574|Experimental|Single shot Hylan G-F 20 (Synvisc)|Intra-articular injection of the Single shot 6 mL of Hylan G-F 20 (Synvisc)
89463064|NCT03641053|Active Comparator|Paraffin gauze|1 layer of paraffin gauze, given every predetermined wound care schedule
89463065|NCT05261113||Intervention cohort|Patients that were operated due to liver neoplasms with use of CE-IOUS
89463066|NCT05261113||Control cohort|Patients that were operated due to liver neoplasms without use of CE-IOUS
89463067|NCT05348343|Other|Autocontrolled Arm|The subject will be treated with both the experimental treatment and the active comparator.
89463068|NCT03643393|Other|incarceration rectal prolapse|
89463069|NCT04805619|Experimental|Arm 1|Patients with long or very long lesions (≥ 30 mm) in native coronary arteries.
88943866|NCT01874574|Active Comparator|Corticosteroid (Triamcinolone acetonide)|Intra-articular injection of 1 mL of 40 mg Triamcinolone acetonide plus 5 mL of 1% xylocaine with adrenaline injected at the knee by single shot
89463070|NCT03640975||case : eosinophilic esophagitis|Children with symptoms suggestive of EoE and requiring an upper gastrointestinal endoscopy with biopsies of the esophageal mucosa
89463071|NCT03640975||control|Children in whom an endoscopy performed to explore symptoms of EoE revealed another condition (peptic oesophagitis, achalasia), or children in whom an endoscopy with biopsies has been performed to explore chronic abdominal or epigastric pain or suspected chronic inflammatory bowel disease
89463072|NCT03160365|Other|ACQUISITION OF IMAGES|4 MRIs were performed at Day 0, day 1, day 15 and day 30 and a preoperative CT scan without injection of a contrast agent.
89463073|NCT05165277|Experimental|Acidic phosphate buffer solution|pH5.2 phosphate buffer solution
89463074|NCT05165277|Placebo Comparator|Neutral phosphate buffer solution|pH7.4 phosphate buffer solution
89463075|NCT03468777|Experimental|Part 1: Treatment Sequence (ABC)|Participants will receive Treatment A as a single oral dose of 1000 milligram (mg) lumicitabine (4*250 mg tablets) under fasted condition on Day 1 of period 1 then Treatment B as a single oral dose of 30 mg lansoprazole under fasted condition on Days 1 to 4 and on Day 5 (administered 2 hours before a single oral dose of 1,000 mg lumicitabine) in period 2 followed by Treatment C (optional Part 2) as a single dose of 150 mg ranitidine administered after 2 hours of single dose of 1000 mg lumicitabine (4*250 mg tablets) under fasted condition on Day 1 of period 3. A washout period of at least 21 days will be maintained between each treatment period.
89463076|NCT03468777|Experimental|Part 1: Treatment Sequence (BAC)|Participants will receive Treatment B on Days 1 to 5 of period 1 then Treatment A on Day 1 of period 2 followed by Treatment C (optional Part 2) on Day 1 of period 3. A washout period of at least 21 days will be maintained between each treatment period.
89463077|NCT03468777|Experimental|Optional Part 3: Treatment Sequence (DEF)|Participants will receive Treatment D as a single oral dose of 1000 mg lumicitabine (4*250 mg tablets) after standardized breakfast on Day 1 of period 1 then Treatment E as a single oral dose of 30 mg lansoprazole under fasted condition on Days 1 to 4 and on Day 5 (administered 2 hours before a single oral dose of 1,000 mg lumicitabine) in period 2 followed by Treatment F as a single oral dose of 150 mg ranitidine administered after 2 hours after a single oral dose of 1000 mg lumicitabine (4*250 mg tablets) after standardized breakfast on Day 1 of period 3. A washout period of at least 21 days will be maintained between each treatment period.
89463078|NCT03468777|Experimental|Optional Part 3: Treatment Sequence (EFD)|Participants will receive Treatment E on Days 1 to 5 of period 1 then Treatment F on Day 1 of period 2 followed by Treatment D on Day 1 of period 3. A washout period of at least 21 days will be maintained between each treatment period.
89463079|NCT03468777|Experimental|Optional Part 3: Treatment Sequence (FDE)|Participants will receive Treatment F on Days 1 of period 1 then Treatment D on Day 1 of period 2 followed by Treatment E on Days 1 to 5 of period 3. A washout period of at least 21 days will be maintained between each treatment period.
89463080|NCT03468777|Experimental|Optional Part 3: Treatment Sequence (FED)|Participants will receive Treatment F on Day 1 of period 1 then Treatment E on Days 1 to 5 of period 2 followed by Treatment D on Days 1 of period 3. A washout period of at least 21 days will be maintained between each treatment period.
89463081|NCT03468777|Experimental|Optional Part 3: Treatment Sequence (EDF)|Participants will receive Treatment E on Days 1 to 5 of period 1 then Treatment D on Day 1 of period 2 followed by Treatment F on Day 1 of period 3. A washout period of at least 21 days will be maintained between each treatment period.
89463082|NCT03468777|Experimental|Optional Part 3: Treatment Sequence (DFE)|Participants will receive Treatment D on Day 1 period 1 then Treatment F on Day 1 of period 2 followed by Treatment E on Days 1 to 5 of period 3. A washout period of at least 21 days will be maintained between each treatment period.
89463083|NCT00431457|Active Comparator|Implantation intracranial electrode with immediate stimulation|
89463084|NCT00431457|Placebo Comparator|Implantation intracranial electrode without stimulation|
89463085|NCT00431457|Active Comparator|Resective surgery: amygddohyppocampertomy|
89463086|NCT03640377|Active Comparator|Praziquantel 40 mg/kg dose only baseline treatment|150 children will receive 40 mg/kg Praziquantel at baseline as single treatment and placebo six months following baseline
88943867|NCT01874587|No Intervention|standard radiotherapy|single pre-treatment planning before radiotherapy
88943868|NCT01874587|Experimental|adaptative radiotherapy|adaptive Radiotherapy based on a weekly replanning
88943869|NCT01874600||Epilepsy Patients|This study will compare accuracy of seizure detection by the study device to simultaneously collected data of seizure detection by video EEG.
88943870|NCT01874613|Experimental|Skull bone reconstruction|Patients with skull bone defect
89463087|NCT03640377|Active Comparator|Praziquantel 80 mg/kg dose only baseline treatment|150 children will receive 80 mg/kg Praziquantel at baseline as single treatment and placebo six months following baseline
89463088|NCT03640377|Active Comparator|Praziquantel 40 mg/kg dose at baseline and 6 months|150 children will receive 40 mg/kg Praziquantel at baseline and again six months later.
89463089|NCT03640377|Active Comparator|Praziquantel 80 mg/kg dose at baseline and 6 months|150 children will receive 80 mg/kg Praziquantel at baseline and again six months later.
88943871|NCT01874613|Experimental|Orbital floor defect|Patients with orbital floor defect
89017910|NCT05857774||Cases|Adult patients ≥18 years of age undergoing invasive mechanical ventilation in the ICU for any reason within 36 hours of intubation
89463090|NCT05283655|Experimental|Intervention group|10 weekly sessions of gut-directed hypnotherapy (behavioral intervention).
89463091|NCT03643315|Experimental|Exercise and Meal (EX)|The EX protocol will involve a 30 minute acute bout of high intensity intermittent exercise on a stationary exercise bike followed by an ad-libitum test meal.
89463092|NCT03643315|Experimental|No-Exercise and Meal (NEX)|The NEX protocol will involve a 30 minute period of rest (to match the exercise period in EX) where participants will be provided a video/movie. Following this, participants will be provided ad-libitum access to a test meal (as per EX energy intake assessment protocol)
89463093|NCT03643237|Experimental|Video game-based intervention|The participants in the experimental group will receive a cognitive-behavioral intervention for active aging via an interactive online multimedia video game with a complementary App. The intervention will consist of 8 modules each approximately 45 minutes long that will be administered at a rate of 1 per week with between-session homework.
89463094|NCT03643237|Active Comparator|Control group|Individuals assigned to this group will receive online therapeutically inactive information about active aging.
89463095|NCT05044923|Experimental|Targeted Epidural Spinal Stimulation|Participants will undergo surgery to implant devices that will be used for Targeted Epidural Spinal Stimulation (TESS).
89463096|NCT05246449|No Intervention|Standard of care group|with patients starting their regular CPAP/APAP treatment without stratification, with medical follow-up, and with standard home CPAP/APAP service provided by home healthcare,
89463097|NCT05246449|Experimental|VitalCare group|with patients starting their CPAP/APAP treatment and with a personalized follow-up by the homecare provider.
88943872|NCT01874639|Experimental|hepatectomy ( conventional hemostasis )|"After validation of the inclusion and exclusion criteria, the patients include in this clinical trial will be randomized between the two arms of the study:~- Control group: hepatectomy with conventional hemostasis using standard bipolar coagulation"
88943873|NCT01874639|Other|hepatectomy with Aquamantys|"After validation of the inclusion and exclusion criteria, the patients include in this clinical trial will be randomized between the two arms of the study:~- Test group: hepatectomy with Aquamantys®"
89463098|NCT05165043||PC group|"The patients who conducted position change due to massive EGVB resulting in poor visualization in the stomach were included. The patients were characterized in terms of age, sex, causes of liver cirrhosis, adverse events (AEs) during position change, additional findings after body position change, treatment regimens and follow-up information.~During position changing procedure, endoscopist withdrew the gastroscope from the stomach and patients changed from the left lateral position to the right lateral position with the help of the nurses. Then endoscopist reinserted the gastroscope into the stomach and tried to detect the addition varices after position change.~Bleeding varices were treated by injection of N-butyl-Cyanoacrylate glue (glub B or Beltran, Compex) or/and Lauromacrogol (Shanxi, Tianyu)."
89463099|NCT03643081|Experimental|"use of camera Fluobeam"|
89463100|NCT03643081|No Intervention|"Without use of the camera Fluobeam"|
89463101|NCT03130569|No Intervention|Control Group|Will simply complete surveys at baseline and at the three-month follow-up.
89501887|NCT03516487|Placebo Comparator|SAD HV: Placebo|HV subjects receive a single oral dose of placebo in a chilled buffered solution on Day 1 in the SAD study (Part 1).
88943874|NCT01874652|Experimental|Light Weight Breast Implants|Assessment of Safety and Efficacy of Light Weight Breast Implant
88943875|NCT01874678|Experimental|TS-1/Cisplatin|single arm
89463102|NCT03130569|Experimental|Web-based Module Group|Participants will complete surveys at baseline. Participants in this arm will be provided with information to access and complete a web-based educational module (AKA the intervention), at the end of which will be given the opportunity to request and complete genetic testing for skin cancer. Participants who elect to complete the genetic testing will receive their genetic testing results along with a two-week follow-up call. All participants will also complete the survey at the three month follow-up.
88943876|NCT01874704|Other|biomarkers of stress|Comparison of biomarkers of stress in emergency physicians working a 24-hour shift or a 14-hour night shift
89463103|NCT03642925|Experimental|Meal replacement diet|Obese subjects (BMI>27; n=50, male 23, female 27) were requested to replace (intervention) two meals/day (breakfast and lunch or dinner) by balanced nutritional meal replacement diet (equal to 240 kcal) for 8 weeks
89463104|NCT03640897|Experimental|Liniderm|"Oleocalcareous liniment Liniderm:~The product will be applied on the diaper area by parents/ caregivers at each diaper change."
88943877|NCT01874717|Experimental|oral midazolam|oral administration of midazolam : the dose administered is twice the individual dose determined in session 1.
88943878|NCT01874717|Other|intravenous midazolam|intravenous administration of midazolam at the individual dose determined in session 1
88943879|NCT01874730|Other|Standard of Care (SOC)|Intraoperative fluid management includes Volulyte® (6% hydroxyethyl starch {HES} 130/0.4 in balanced solution) as the only colloid solution to be used, the daily dosage of Volulyte® is restricted to 50 ml/kg. Intraoperative anesthesia and postoperative analgesia will follow the established practice of the individual institution.
88943880|NCT01874730|Active Comparator|Enhanced Recovery Strategy (ERS) group|GDFT regimen using Volulyte® (6% HES 130/0.4 in balanced solution) during surgery. The daily dosage of Volulyte® is restricted to 50 ml/kg. Combined epidural-general anesthesia (CEGA) will be used intraoperatively and patient-controlled epidural analgesia (PCEA) will be used postoperatively in a multimodal analgesic regimen.
88943881|NCT01874743|Experimental|Rosuvastatine 20 mg|Rosuvastatin 20 mg/day, once a day during 3 months
88943882|NCT01874769||Blood collection and skin biopsies|
88943883|NCT01874782|Experimental|Transcranial electrical stimulation|Subject will be determined as autonomically complete or incomplete injury with measuring of the sympathetic skin responses (SSR+), an established protocol for measuring integrity of sympathetic spinal pathways, versus complete autonomic injury (SSR-).
88943884|NCT01874795|Experimental|Ganglionar Electrical Stimulation|TENS intervention consisted of continuous flow, symmetrical and rectangular TENS biphasic pulses. The frequency ofstimulation was 80 Hz and the pulse duration was 150 μs, with the intensity in adjusted to the point of muscle contraction.
88943885|NCT01874795|Sham Comparator|Placebo|The frequency of stimulation was 80 Hz and the pulse duration was 150 μs, equipment did not provide stimulation current.
88943886|NCT01874808||Healthy|Healthy
88943887|NCT01874808||ALS with postural instability|ALS with postural instability
88943888|NCT01874808||ALS without postural instability|ALS without postural instability
88943889|NCT01874821|Experimental|Dynasplint|Along with standard manual physical therapy, patients will have a stretching device (Dynasplint) used in rehabilitation to regain ROM in stiff joints. Patients will use this device 20-30 minutes 2 times per day at home.
88943890|NCT01874821|Other|Control|Patient's in the Physical Therapy Group will have the standard manual treatments during their usual physical therapy visits with no additional intervention
89463105|NCT03640897|Active Comparator|Wipes|Free-fragrance baby wipes The product will be used on the diaper area by parents/ caregivers at each diaper change.
88943891|NCT01874834|Placebo Comparator|Filtered air exposure|2 hr exposure to clean, filtered air with intermittent exercise
88943892|NCT01874834|Experimental|Ozone|2 hr exposure to 300 ppb ozone with intermittent exercise
88943893|NCT01874834|Experimental|Diesel Exhaust, No ozone|2 hr exposure to whole diesel exhaust (300 ug/m3; gases + particles) with intermittent exercise; no ozone
88943894|NCT01874834|Experimental|Ozone + Diesel Exhaust|2 hr exposure to a combination of 300 ppb ozone an 300 ug/m3 whole diesel exhaust with intermittent exercise
88943895|NCT01874847|Experimental|Melatonin 10mg|Melatonin 10mg capsule(high dose arm), oral, once at night, given for 28 days
88943896|NCT01874847|Placebo Comparator|Sugar Pill|Sugar Pill, one capsule, once at night, 28 days
88943897|NCT01874847|Experimental|Melatonin 3mg|Melatonin 3mg capsule (low dose arm), once, at night, 28 days
88943898|NCT01874873|Experimental|Anlotinib|
88943899|NCT01874886||Cannabis users|⋄Heavy Marijuana Users : 60-80 years old; Marijuana use initiated in adolescence with marijuana use of no more than 1-2 x/month after 30 years of age; Used marijuana more than 20 times/month for at least 1 year during this period. Cigarette smoking (tobacco) and alcohol will be allowed in both groups, which will be matched on number of smokers and nicotine dependence, measured according to the Fagerstrőm Test for Nicotine Dependence. Light alcohol use will also be allowed in and matched across both groups (< 14 drinks/week for men; < 7 drinks/week for women; may not meet DSM-IV criteria for alcohol dependence).
88943900|NCT01874886||Clean or Non-Users|⋄No marijuana use, may smoke cigarettes, fewer than 7 drinks/week (women) or 14 drinks/week (men). 60-80 years old.
88943901|NCT01874899||Manual, then Automatic Stimulation|The RestoreSensor neurostimulator will be programed for manual stimulation adjustments and the patients will crossover to automatic stimulation group after 1.5 months
88943902|NCT01874899||Automatic, then Manual Stimulation|The RestoreSensor neurostimulator will be programed for automatic stimulation adjustments and the patients will crossover to manual stimulation group after 1.5 months.
89017911|NCT05857774||Control condition A|Non-invasively ventilated patients in the ICU within 36 hours of initiating non-invasive ventilation
89017912|NCT05857774||Control condition B|Non-ventilated patients admitted to the ICU receiving no respiratory support or oxygen therapy alone, including high flow nasal cannula
89463106|NCT03640897|Active Comparator|Water|Water and cotton pads The product will be used on the diaper area by parents/ caregivers at each diaper change.
89463107|NCT03642847|Active Comparator|Prevnar 13|13 valent Pneumococcal Conjugate
89463108|NCT03642847|Experimental|multivalent pneumococcal conjugate formulation 1|multivalent pneumococcal conjugate formulation 1
89463109|NCT03642847|Experimental|multivalent pneumococcal conjugate formulation 2|multivalent pneumococcal conjugate formulation 2
89463110|NCT03621163|Experimental|bleaching agent|intervention : bleaching agent ( Boost 40%)
89463111|NCT03621163|Active Comparator|laminate veneers|laminate veneers ( monolithic lithium - silicate)
89463112|NCT04871763|Experimental|Geldis® gel|Patients will brush their essix retainers with a toothbrush and with Geldis® gel.
89463113|NCT04871763|Active Comparator|Tablets|Patients will leave their essix retainers in a glass with water and Polident tablets.
89463114|NCT04871763|Active Comparator|Water|Patients will brush essix retainers with a toothbrush under running water.
89463115|NCT04760535|Experimental|Arm A: Invisalign® First clear aligners|"The Invisalign® First aligners are fabricated in a multilayer aromatic thermoplastic polyurethane/co-polyester 0.75mm (.030)-thick with a fine 3D manufacturing process."
89463116|NCT04760535|Active Comparator|Arm B: tooth-borne Hyrax-type maxillary expander|The Hyrax-type maxillary expander is a tooth-borne expansion appliance that is fixed to the upper second deciduous molars (or to the first permanent molars) using bands and includes a midline 12-mm self-locking screw (Forestadent, Pforzheim, Germany; 0.9 mm, complete turn). The expansion screw is connected to the conventional molar bands or printed clasps, modeled surrounding the molars, via a framework of 0.9mm stainless-steel wire. The framework is soldered to the bands and extending on the palatal side to the deciduous canines. The expander will be fabricated by qualified laboratory technician.
89463117|NCT03632187|Experimental|Experimental group|Subcutaneous abatacept every weeks during 3 months (W0 to W11). Then, at W12, if PMR-AS>10, they will receive GCs according to the PMR-AS (PMR-AS≤10: no GCs, PMR-AS between 10-20: 10mg/day, PMR-AS between 21-30: GCs at 15mg/d and if PMR-AS> 30: 20mg/d). Dosage of GCs will be decreased between W16 and W24 (1mg every week) in each arm according to PMR-AS (PMR-AS < 10: decrease, PMR-AS > 17 increase to previous dosage, 10 ≤ PMR-AS ≤ 17: stable dose). If PMR-AS ≤10, the patients wont receive any treatment until a flare.
89463118|NCT03632187|Placebo Comparator|Control group|Subcutaneous placebo every week during 3 months (W0 to W11). Then, at week 12, if PMR-AS>10, they will receive GCs according to the PMR-AS (PMR-AS≤10: no GCs, PMR-AS between 10-20: 10mg/day, PMR-AS between 21-30: GCs at 15mg/d and if PMR-AS> 30: 20mg/d). Dosage of GCs will be decreased between W16 and W24 (1mg every week) in each arm according to PMR-AS (PMR-AS < 10: decrease, PMR-AS > 17 increase to previous dosage, 10 ≤ PMR-AS ≤ 17: stable dose). If PMR-AS ≤10, the patients won't receive any treatment until a flare.
89463119|NCT05110209||Aflibercept|Patients/patient eyes who were treated only with aflibercept in 2019
89463120|NCT05110209||Ranibizumab|Patients/patient eyes who were treated only with ranibizumab in 2019
89463121|NCT05110209||Bevacizumab|Patients/patient eyes who were treated only with bevacizumab in 2019
89463122|NCT05110209||≥2 Different Anti- VEFGFs|Patients/patient eyes who were treated with ≥2 different anti-VEGFs in 2019
89463123|NCT04454151|Experimental|Azithromycin|1x250
89463124|NCT02038725||TIA in last 2 weeks|
89463125|NCT05697315|Sham Comparator|Control group|No block was performed, tramadol was administered with patient-controlled analgesia (PCA) and all patients were followed in the ward.
89463126|NCT05697315|Active Comparator|Erector spinae plane block|Erector spinae plane block was performed, tramadol was administered with patient-controlled analgesia (PCA) and all patients were followed in the ward.
89463127|NCT00965757|Experimental|1|
89017913|NCT05857566|Experimental|RDX-002|50 mg oral tablet; 200 mg BID for 7 days
89017914|NCT05857566|Other|Olanzapine|10 mg oral tablet; 10 mg QD for 14 days
89017915|NCT05857358|Experimental|Adult patients suffering from xerostomia and autoimmune disease|"Xerostomia treatment consist of 3 steps (including 2 surgical steps) in the Hospital de la Conception of Marseille, in the same ward :~The plastic/maxillofacial surgeon : collects the adipose tissue, and transfers it to the cell therapy unit;~The cell therapy unit processes and controls the experimental product (adipose-derived stromal vascular fraction; AD-SVF) from the harvested adipose tissue. The AD-SVF batch is nominatively transported to the surgeon;~The maxillofacial surgeon injects the AD-SVF without delay under local anesthesia."
89463128|NCT00965757|Placebo Comparator|2|
89463129|NCT03468699|Experimental|Autologous BMMC transplantation|Stem cell transplantations include 2 administrations of autologous bone marrow mononuclear cells via the hepatic artery at baseline and 6 months afterward
89463130|NCT03130413|Experimental|Ambu Aura Gain|Ambu Aura Gain supraglottic airway size 2 or 2.5 will be inserted once patients are paralyzed
89463131|NCT03130413|Active Comparator|Air-Q|Air-Q supraglottic airway size 1.5 and 2.0will be inserted once the patients are paralyzed
89463132|NCT05697237|Experimental|Advanced or metastatic cholangiocarcinoma|In this study, carrilizumab combined with sovantinib in the second-line treatment of patients with advanced or metastatic cholangiocarcinoma with single arm, open, Exploratory clinical trials.The specific treatment regimen was carrilizumab 200mg Q3W d1; Sofantinib: 300mg,Take orally, once a day, continuously. Treatment continues or until disease progression occurs or the patient becomes intolerant to treatment regimens.The efficacy was evaluated every 2 cycles.
89463133|NCT05164497|Experimental|Deliberate practice training|The experimental condition consists of deliberate practice training of non-specific psychotherapy skills using role-play and Theravue, an online skill-building system with therapy videos.
89463134|NCT05164497|Active Comparator|Theoretical teaching|The control condition will consist of theoretical teaching of non-specific psychotherapy skills.
89463135|NCT05272683|Experimental|GLPG3667 + itraconazole|
89463136|NCT05649423|Experimental|Postural drainage with percussion|Chest percussion is performed with cupped hands in an alternating rhythmic manner The force applied must be equal 8 weeks, 3 sessions per week , each session took about 30 minutes
89537187|NCT05671211|Experimental|Task-Oriented Training Group|Participants in the task-oriented training group will receive the same treatment given to the control group, with an additional 30 minutes of task-oriented training.Task-Oriented Training Program will include several everyday tasks (Getting up from the chair, walking 10 steps taking a book from the table and walking backwards to sit on the chair,Walking forward and sideways over obstacles...etc.).The exercises will be started as 12-15 repetitions and 1 set at the beginning, and the number of sets will be increased according to the progression of the patient. A total of 30 sessions will be applied, 5 days a week for 6 weeks, with a total of 1.5 hours of exercises.
89537188|NCT05635539|Experimental|patients with COVID|27 patients with COVID in comorbidity with NCDs as T2D, hypertension, and NASH
89537189|NCT05635539|Experimental|patients with Influenza|35 patients with Influenza in comorbidity with NCDs as T2D, hypertension, and NASH
89537190|NCT04779177|Experimental|Lumateperone 42 mg once daily for 5 days|
89537191|NCT04779177|Experimental|Lumateperone 28 mg once daily for 5 days|
89537192|NCT04745013|Experimental|PRIORITY|Patients randomized to the hybrid exercise intervention (PRIORITY) will receive a personalized exercise prescription generated by the EXPERT tool which will then be person-tailored by the physiotherapist during one-on-one physical activity consultation. Over a period of one year, patients will participate in 18 supervised center-based exercise sessions in adjunct to a remotely monitored and guided home-based exercise intervention.
89537193|NCT04745013|Placebo Comparator|Usual care|The usual care group will receive from the physiotherapist a personalized written exercise prescription that includes an individually tailored recommendation on frequency, intensity, type, time and volume of exercise. This exercise prescription will be generated by means of the EXPERT tool. No counselling or guidance on objective measures of physical activity by means of wearables or platform will be provided.
89537194|NCT05635461|Active Comparator|Suspension (fasted)|150 milligrams (mg) of CVN424 administered in a single dose of suspension formulation.
88943903|NCT01874964|Experimental|Methadone Maintenance|Participants assigned to Arm 1 will be maintained on ther pre-incarceration methadone dosage during short term incarceration (6 months or less) and will be actively transferred back to their community methadone clinic upon release from incarceration. Additionally, the study will pay for the cost of methadone maintenance treatment for 10 weeks after re-enrollment post release.
88943904|NCT01874964|Active Comparator|Methadone Detoxification|Individuals assigned to Arm 2 will undergo methadone detoxification as is standard procedure at the Rhode Island Department of Corrections. They will receive active assistance with returning to their home methadone clinic upon release from incarceration and 10 weeks financial assistance to pay for treatment.
88943905|NCT01874977|Experimental|Pedometer only|This group will receive the educational booklet and discussion, plus a pedometer and a diary to record their daily step counts from the pedometer. Participants will be shown how to wear the pedometer, and instructed to wear it from the time they get out of bed in the morning until they go to bed at night, except while showering or bathing. (If any subjects begin a swimming- or cycling-based activity program, we will ask them to remove the pedometer at that time but track the time they are in the water. Step counts will be adjusted to account for this time by adding 150 steps for every minute engaged in swimming and/or cycling.)
88943906|NCT01874977|Experimental|Pedometer + step count goals|Pedometer + step goals. This group will receive the educational booklet and discussion, and the pedometer and step diary, plus will be given individualized daily step targets.
88943907|NCT01874977|Other|Education materials|"Educational materials. This group will receive the educational booklet (Be Active Your Way: A guide for Adults; http://www.health.gov/paguidelines/adultguide/default.aspx).and a discussion of simple ways to increase physical activity in daily life based on the booklet, following the baseline assessment. They will receive follow-up contact at the same time points as the intervention groups, although the Week 0 and Week 1 contacts will be by phone instead of in-person and the content of contacts will be different."
88943908|NCT01874990|Experimental|women with a history of severe preeclampsia|women with a history of severe preeclampsia(< 34 weeks gestation) between 5 and 10 years ago
88943909|NCT01874990|Experimental|control|women with no history of pregnancy-related hypertensive complications
88943910|NCT01875003|Experimental|Lebrikizumab High|Participants with uncontrolled asthma on ICS therapy (total daily dose of 500-2000 micrograms [mcg] of fluticasone propionate dry powder inhaler [DPI] or equivalent) and a second controller medication, will receive SC injection of lebrikizumab (high dose) Q4W for 52 weeks during placebo-controlled period and up to 76 weeks or 104 weeks for participants who will be willing to take part in optional active-treatment extension period.
88943911|NCT01875003|Experimental|Lebrikizumab Low|Participants with uncontrolled asthma on ICS therapy (total daily dose of 500-2000 mcg of fluticasone propionate DPI or equivalent) and a second controller medication, will receive SC injection of lebrikizumab (low dose) Q4W for 52 weeks during placebo-controlled period and up to 76 weeks or 104 weeks for participants who will be willing to take part in optional active-treatment extension period.
88943912|NCT01875003|Placebo Comparator|Placebo|Participants with uncontrolled asthma on ICS therapy (total daily dose of 500-2000 mcg of fluticasone propionate DPI or equivalent) and a second controller medication, will receive SC injection of lebrikizumab matching placebo Q4W for 52 weeks during placebo-controlled period and then SC injection of lebrikizumab at high or low dose will be administered from Weeks 52 to 76 or 104 to participants who are willing to take part in optional active-treatment extension period.
89537195|NCT05635461|Active Comparator|Tablet (fed)|150 milligrams (mg) tablet of CVN424 administered in a single dose after ingestion of a standardized high-fat, high-calorie meal according to FDA Guidance for Industry (Food-effect bioavailability and fed bioequivalence studies, Jun 2022).
89537196|NCT05635461|Active Comparator|Tablet (fasted)|150 milligrams (mg) tablet of CVN424 administered in a single dose.
88943913|NCT01875029|Sham Comparator|sham-tDCS + Back School|"This group will receive sham-tDCS for 5 days before back school beginning. The anode will be placed on the primary motor cortex (M1) of the dominant hemisphere and the cathode on the contralateral supraorbital area. The direct current is transmitted through a pair of sponge electrodes, with a surface of 35 cm2 (7x5), soaked in saline solution and, it is generated by a constant current stimulator, with rechargeable batteries. This continuous stimulation lasted 30 seconds, with an intensity of 1 milliampere.~The back school session, a behavioural intervention,will be given 10 times for 4 weeks."
88943914|NCT01875029|Experimental|real-tDCS + Back School|"This group will receive continuous stimulation lasting 20 minutes daily, for 5 days before back school beginning. The back school session, a behavioural intervention,will be given 10 times for 4 weeks.~Transcranial direct current stimulation (tDCS) will be administered as follows. The anode will be placed on the primary motor cortex (M1) of the dominant hemisphere and the cathode on the contralateral supraorbital area. The direct current is transmitted through a pair of sponge electrodes, with a surface of 35 cm2 (7x5), soaked in saline solution and, it is generated by a constant current stimulator, with rechargeable batteries. This continuous stimulation lasted 20 minutes, with an intensity of 1 milliampere."
88943915|NCT01875042|Experimental|TENS|Transcutaneous Electrical Nerve Stimulation
88943916|NCT01875042|Sham Comparator|Sham TENS|Sham Transcutaneous Electrical Nerve Stimulation
88943917|NCT01875055|Experimental|NIRS derived cerebral oximetry|NIRS derived cerebral oximetry device used but data not visable to ICU caregivers
88943918|NCT01875055|Active Comparator|NIRS and Algorithm|NIRS derived cerebral oximetry device used and the caregiver in the ICU will see the data in order to guide the use of the interventional algorithm to treat the cerebral desaturation
88943919|NCT01875068|Experimental|NPs & PAs referral discussions with a supervising physician|required consultations between NPs and PAs and their supervising physicians
88943920|NCT01875068|Other|NPs and PAs - no consultations with supervising physisians|NPs and PAs who are not required to discuss patient referrals
88943921|NCT01875081|No Intervention|Control group|Best Supportive care
88943922|NCT01875081|Experimental|1-time injection group: Livercellgram|Within 1 month after extracting bone marrow, directly inject 5X107 autologous bone marrow-derived mesenchymal stem cells within liver through the hepatic artery.
88943923|NCT01875081|Experimental|2-time injection group: Livercellgram|Within 1 month after extracting bone marrow, directly inject 5X107 autologous bone marrow-derived mesenchymal stem cells within liver through the hepatic artery. Within 1 month after cell injection, re-inject autologous bone marrow-derived mesenchymal stem cells.
88943924|NCT01875094|Experimental|Self-Management / MTM via Health IT|Stroke survivors are trained to measure and enter BP into an online health management tool
88943925|NCT01875094|No Intervention|Usual Care|
89463137|NCT05649423|Active Comparator|Postural drainage|Postural drainage without Percussion Each position should be held for a minimum of five minutes Use pillows, foam wedges for comfort make position on patient back, side and stomach 8 weeks, 3 sessions of alternating positions per , each session took about 30 minutes
89463138|NCT05164185|Active Comparator|Ischemia reperfusion +remote ischemic conditioning|Active administration of short cykcles of ischemia.
88943926|NCT01875107|Experimental|insulin pre-treatment|insulin pre-treatment of pregnant diabetic patients who receive betamethasone
88943927|NCT01875120||Female patients with increased risk to experience PONV.|
88943928|NCT01875133|Other|A: low-intermediate-high altitude|Altitude exposure sequence A, 490-1630-2590m
89463139|NCT05164185|Sham Comparator|Ischemia reperfusion +sham|Placebo experiment without remote ischemic conditioning.
89463140|NCT03789357||Single Arm|All patients admitted to the Acute Stroke Unit
88943929|NCT01875133|Other|B: low-high-intermediate altitude|Altitude exposure sequence B, 490-2590-1630 m
88943930|NCT01875133|Other|C: intermediate-high-low altitude|Altitude exposure sequence C, 1630-2590-490 m
88943931|NCT01875133|Other|D: high-intermediate-low altitude|Altitude exposure sequence D, 2590-1630-490 m
88943932|NCT01875146|Active Comparator|4x4 min HIT|Conventional 4x4 min high-intensity interval training
88943933|NCT01875146|Experimental|4x4 min HIT + WBV (18 Hz)|4x4 min high-intensity interval training in combination with whole-body vibration at 18 Hz during the active rest
88943934|NCT01875146|Experimental|4x4 min HIT + WBV (30 Hz)|4x4 min high-intensity interval training in combination with whole-body vibration at 30 Hz during the active rest
88943935|NCT01875146|Active Comparator|whole-body vibration at 30 Hz|4x3 min whole-body vibration at 30 Hz
88943936|NCT01875172|Experimental|Bupropion SR|Study medication (150 mg bupropion SR) daily for 14 days. Women still smoking at 2-weeks & 4-weeks were encouraged to increase their medication to two times per day (150 mg bid). Women received smoking cessation counseling at baseline, 2, 4, 6, and 8 weeks.
88943937|NCT01875172|Placebo Comparator|Placebo|Study medication (placebo) daily for 14 days. Women still smoking at 2-weeks & 4-weeks were encouraged to increase their medication to two times per day. Women received smoking cessation counseling at baseline, 2, 4, 6, and 8 weeks.
88943938|NCT01875185|Experimental|Aspirin|The patients are given aspirin 81 mg orally for 7 days.
88943939|NCT01875198|Experimental|RAMPS|Radical Antegrade Modular Pancreatectomy with Splenectomy
89463141|NCT05164029||ART couples|Couples in reproductive age undergoing ART treatment
89463142|NCT05164029||natural pregnancy couples|Couples who get pregnant naturally
89463143|NCT04455399|Other|Intravitreal injection guide|Single use, combination ocular surface caliper to determine point of intravitreal injection and set-depth injection guide to limit injection needle entry into the eye
89463144|NCT04455399|Other|Dual blade eyelid speculum|Dual blade eyelid speculum to open eyelids followed by Castroviejo surgical caliper to measure injection point 3.5 mm from limbus
89463145|NCT05219721|Experimental|CAR-GPRC5D cells|"The tolerability and safety of CAR-GPRC5D cells will be assessed according to the 3+3 dose-escalation design. There will be three dose levels, 0.5×10^6, 1.0×10^6, and 2.0×10^6, CAR+T cells/kg. For each level, 3-6 subjects will be enrolled."
89463146|NCT03934671|Experimental|Antioxidant dressing (active product)|
89463147|NCT03934671|Active Comparator|Usual care dressing (standard clinical practice)|
89463148|NCT03891381|Experimental|Tetragraph|Patients will be randomized to receive quantitative monitoring in the operating room. Neuromuscular management will be guided by information provided by the monitor
89463149|NCT03891381|Active Comparator|Qualitative monitoring|The screen of the Tetragraph will be covered so that information is not provided to the clinician. The monitor will therefore function as a standard peripheral nerve monitor (clinicians will only observe the response to nerve stimulation)
89463150|NCT03791853||Light-CT|All specimens are detected using Light-CT
89463151|NCT03338361|Experimental|AAT active - VPT sham|Approach avoidance training active intervention and visual probe training sham intervention
89463152|NCT03338361|Experimental|VPT active - AAT sham|Visual probe training active condition and approach avoidance training sham condition
89463153|NCT03338361|Experimental|AAT active - VPT active|Approach avoidance training active condition and visual probe training active condition
89463154|NCT03338361|Sham Comparator|AAT sham - VPT sham|Approach avoidance training sham condition and visual probe training sham condition
89463155|NCT03587883|Experimental|Cocoa Flavanol intervention|Capsules containing Mars Cocoa Extract manufactured by the Cocoapro® process, providing 300 mg of cocoa flavanols per capsule: 900 mg of cocoa flavanols consumed daily for 2 weeks; 2 intervention periods: Cocoa flavanols I and cocoa flavanols II.
89463156|NCT03587883|Placebo Comparator|Control intervention|Cocoa-based, flavanol-free, control-matched capsules consumed for 2 weeks; 2 intervention periods: control I and control II.
89463157|NCT03160443|Other|Participants|"All participants performed the same evaluation: clinical and neuropsychological assessment.~All of them are patients with an eating disorder."
88943940|NCT01875198|Active Comparator|RAMP|Radical Antegrade Modular Pancreatectomy without splenectomy
88943941|NCT01875224|Experimental|Belatacept and CellCept|Belatacept administered based on patient's weight once a month after initial period, Cellcept taken twice daily.
88943942|NCT01875224|Active Comparator|Tacrolimus and CellCept|Tacrolimus and CellCept taken twice daily based on patient response.
88943943|NCT01875263|Experimental|Experimental|Cloxacillin 2g / 4 hours iv, 5 days followed levofloxacin 500 mg po / 24, 9 days.
88943944|NCT01875263|Active Comparator|Control|Cloxacillin 2g / 4 hrs iv 14 days
88943945|NCT01875276||Persistent Patients|Defined as those with ≥1 treatment for allergic rhinitis in the six months preceding the IPD (defined as the first script of the hay fever season - May to August)
88943946|NCT01875276||Seasonal Rhinitis|No treatment for allergic rhinitis in the six months preceding the IPD
88943947|NCT01875289|Experimental|Ropivacain|Local anaesthesia
88943948|NCT01875289|Placebo Comparator|NaCl 0.9%|Saline
88943949|NCT01875328|Experimental|Telemedicine|Telemedicine group
88943950|NCT01875328|Active Comparator|Clinic|Clinic group
88943951|NCT01875341|Active Comparator|Active treatment with NCPAP|This group will receive treatment with NCPAP, Nasal Continuous Positive Airway Pressure for 6 weeks. Nasal Continuous Positive Airway Pressures will be increased until apneas & hypopneas are prevented during all sleep stages.
88943952|NCT01875341|Sham Comparator|Sub- active treatment with NCPAP|This group will receive treatment with Nasal Continuous Positive Airway Pressure at sub-therapeutic levels for 6 weeks. Patients will be taught how to use NCPAP in the sleep lab. Pressures will be left unchanged at the lowest possible value for the NCPAP device. After completion of treatment patients will be provided usual NCPAP therapy.
89463158|NCT05216679|Experimental|Main study|This is the only arm of the study. It is a 6 week period where the participants will either be using night splints or the TESS device to treat their plantar fasciitis symptoms.
89463159|NCT05159895|Experimental|[14C]-DZD9008|A Single dose of [14C]-DZD9008
89463160|NCT03130179|Experimental|Nicorette Strongmint lozenge 4mg|A single dose of one nicotine 4 mg lozenge will be administrated orally to slowly dissolve in the mouth for nicotine absorption via the buccal mucosa.
89463161|NCT03130179|Active Comparator|Niquitin Minimint lozenge 4mg|A single dose of one nicotine 4mg lozenge will be administrated orally to slowly dissolve in the mouth for nicotine absorption via the buccal mucosa.
89463162|NCT05400135|Experimental|Qungasvik Intervention Group|Qungasvik implements intervention modules creating episodes of Yup'ik cultural engagement. In traditional Yup'ik practices prior to formal western schooling, the education and training of young people included introduction to cultural protocols, knowledge, and values while learning skills through participation in daily activities of family and community life such as subsistence, tool-building, and ceremony (Rasmus, Charles, & Mohatt, 2014). The intervention manual provides outlines for 18 modules described as teachings, and conducted at the individual, family, or community level through one or more 1-3 hour sessions. Each module promotes 2-4 of a total of 13 protective factors.
89463163|NCT05399901|Experimental|EMG BFB|An educational program will be implemented, and active exercises of the PFM will be performed using verbal instructions together with electromyographic biofeedback (BFB).
89463164|NCT05399901|Experimental|M-mode US|An educational program will be implemented, and active exercises of the PFM will be performed using verbal instructions together with transabdominal M-mode ultrasound biofeedback (US).
89463165|NCT03467295||Surgically treated group|Surgical removal of intracerebral CMs by craniotomy with or without following stereotactic radiosurgery.
89463166|NCT03467295||Conservatively treated group|Observation with the best medicine administration and supportive treatment are performed.
89017916|NCT05853731|Experimental|Green light therapy group|Subjects in the intensive care unit (ICU) setting after cardiac surgery will have green light therapy via green light emitting diode (GLED) for the duration of the ICU stay or up to 1 week.
89463167|NCT05399745||Children with biliary atresia|
89463168|NCT05399745||Children with Tetralogy of Fallot|
89463169|NCT05399745||Healthy control children|
89463170|NCT05439837|Active Comparator|Infraclavicular and subomohoid block|
89463171|NCT05439837|Active Comparator|Paracoracoid subscapularis plane block|
88943953|NCT01875354|Placebo Comparator|Placebo and Low Fat Eating Plan|"Placebo Supplement A Powder Mix Days 1 - 15, (1 packet mixed in water or favorite beverage once a day) Placebo Supplement B Days 1 - 90, (1 capsule taken three times a day with a meal) Placebo Supplement C Days 1 - 90, (2 capsules taken with morning and evening meal)~The placebo group will be instructed to consume every day, a low fat standard of care eating plan delivering approximately 1200-1500 Kcals."
89463172|NCT03467139|Experimental|Study Group|Hotpack was applied for 15 min and TENS was applied for 15 min and ultrasonics for 5 min. Then scapular mobilization and passive stretching exercises were applied in 10 sets of 3 sets (flexion, abduction, internal and external rotation) to increase joint range of motion by physiotherapist. Then, abdominal breathing exercise training was given 3 times a week as 30 sets of 3 sets a week and the patients were treated for 8 weeks
89463173|NCT03467139|No Intervention|Control Group|Hotpack was applied for 15 min and TENS was applied for 15 min and ultrasonics for 5 min. Then scapular mobilization and passive stretching exercises were applied for 8 weeks in 10 sets of 3 sets (flexion, abduction, internal and external rotation) to increase joint range of motion.
89463174|NCT04726761||Frequent/Non-frequent|Patients randomized to this order will first have an ABPM conducted with the frequent measuring intervals (3 times an hour during day and 2 times an hour at night) and then a few days later have another ABPM conducted with the non-frequent measuring interval (1 time an hour during all 24 hours)
88943954|NCT01875354|Experimental|Dietary Supplements and TR90 Eating Plan|"Supplement A Powder Mix Days 1 - 15, (1 packet mixed in water or favorite beverage once a day) Supplement B Days 1 - 90, (1 capsule taken three times a day with a meal) Supplement C Days 1 - 90, (2 capsules taken with morning and evening meal)~Experimental group will be instructed to consume every day, dietary supplements and a moderate protein eating plan delivering approximately 1200-1500 Kcals."
88943955|NCT01875380|Experimental|Regorafenib|Regorafenib will be administered orally at the initial dosage of 160 mg per day for 3 weeks,followed by one week of rest, according to the 3/1 regimen.
88943956|NCT01875393|Experimental|TOOKAD® Soluble|TOOKAD® Soluble, lyophilized formulation,given at a dose of 4 mg/kg.
88943957|NCT01875406|Experimental|diagnostic exercises|The three diagnostic exercises will be administered in random order to minimize effects of order and period on the results. Enrollment logs and study randomization will be administered electronically via a respective REDCap data modules. The enrollment, randomization and diagnostic tests will be administered by research coordinator or PI. The patients will be independently evaluated and scheduled for SIJ injection by Cleveland Clinic pain clinic staff and fellow pain physicians.
88943958|NCT01875419|Experimental|Patients tDCS|A group of 30 patients will receive active tDCS stimulation once a week for 8 weeks, immediately prior to CBT.
88943959|NCT01875419|Sham Comparator|Patients - Sham|Another group of 30 patients will receive sham stimulation once a week during 8 weeks, immediately prior to CBT.
88943960|NCT01875484||High miR-126 group|
88943961|NCT01875484||Moderate miR-126 group|
88943962|NCT01875484||Low miR-126 group|
88943963|NCT01875497|Experimental|Dietary Supplement|Before the exercise, the individuals intake only one capsule with 205 mg of the grape fruit extract in capsule with 205 mg.
88943964|NCT01875523|Experimental|Group 1 Treatment with serelaxin|Patients with severe renal impairment will receive a single 4 hour i.v. infusion of serelaxin
88943965|NCT01875523|Experimental|Group 2 Treatment with serelaxin|Patients with end stage renal disease will receive a single 4 hour i.v. infusion of serelaxin and dialysis will be done on the day of treatment
88943966|NCT01875523|Experimental|Group 3 Treatment with serelaxin|Patients with end stage renal disease will receive a single 4 hour i.v. infusion of serelaxin and treatment and PK will be done in dialysis-free interval
88943967|NCT01875523|Experimental|Group 4 Treatment with serelaxin|Healthy volunteers will receive a single 4 hour i.v. infusion of serelaxin and dialysis will be done on the day of treatment
88943968|NCT01875536|Experimental|rTMS|The experimental group received rTMS to the primary motor cortex of the unaffected side in 10 sessions, 3 days per week, and conventional physical therapy
88943969|NCT01875536|Sham Comparator|control|The control group received sham stimulation (same area as the experimental group) in 10 sessions, 3 days per week, and conventional physical therapy
88943970|NCT01875549|Active Comparator|Unilateral stent insertion group|the use of unilateral stent insertion in malignant hilar obstruction for using endoscopic retrograde cholangiopancreatography(ERCP)
89463175|NCT04726761||Non-frequent/frequent|Patients randomized to this order will first have an ABPM conducted with the non-frequent measuring interval (1 time an hour during all 24 hours) and then a few days later have another ABPM conducted with the frequent measuring intervals (3 times an hour during day and 2 times an hour at night)
89463176|NCT05439525|Experimental|Group A|the patient will receive Shoulder complex mobilization with movement three time a week for two weeks
89463177|NCT05439525|Active Comparator|Group B|will receive Conventional therapy three times a week for two weeks.
88943971|NCT01875549|Active Comparator|Bilateral stent insertion group|the use of bilateral stent insertion in malignant hilar obstruction for using endoscopic retrograde cholangiopancreatography(ERCP)
88943972|NCT01875562|Experimental|Qishe Pill|
88943973|NCT01875575|Active Comparator|Glucose 10g|10g Glucose in 200ml tap water given orally (plus 50 mg 13C-sodium acetate)via nasogastric tube
88943974|NCT01875575|Active Comparator|Glucose 25g|25g Glucose in 200ml tap water given orally (plus 50 mg 13C-sodium acetate)via nasogastric tube
88943975|NCT01875575|Placebo Comparator|Placebo|intragastric tap water
88943976|NCT01875627|Placebo Comparator|Carbohydrate Noodles|0g Konjac Noodles
89463178|NCT05398965|Experimental|Intervention Group|The group will receive standard COVID medication + Eucalyptus oil on external use for 14 days
89463179|NCT05398965|Active Comparator|Comparator Group|The group will receive standard COVID medication only
89463180|NCT03467061|Active Comparator|Nitrate-rich beetroot juice|2 x 70mL concentrated juice per day for 14 days
89463181|NCT03467061|Placebo Comparator|Nitrate-depleted beetroot juice|2 x 70mL concentrated juice per day for 14 days
89463182|NCT03467061|Other|Antibacterial mouthwash|2 x 10mL antibacterial mouthwash per day for 14 days
89463183|NCT05398887|Active Comparator|Low dose Chest CT scan|"Underwent low dose chest CT with 30% lower radiation dose~Interventions:~Radiation: Low radiation dose CT Other: Image quality analysis"
89463184|NCT05398887|Experimental|Ultra low dose CT scan with Artificial Intelligence|"Interventions:~Radiation: Low radiation dose CT Image quality Other: Deep-learning based contrast boosting algorithms"
88943977|NCT01875627|Experimental|Carbohydrate and Konjac Noodles|Half Carbohydrate and Half Non-Caloric Konjac Noodles - 122.5g Konjac
88943978|NCT01875627|Experimental|Konjac Noodles|Non-Caloric Konjac Noodles (viscous gel meal) - 240g Konjac
88943979|NCT01875640||Usual Care|After obtaining consent, we will audio-record standard clinical consultations with specialists represented on the DSD team. These appointments will not utilize the Decision Support Tool. A qualitative analysis of these recordings will assess quality assurance and provide guidance for the development of the Decision Support Tool.
88943980|NCT01875640||Use of Decision Support Tool|After obtaining consent, we will audio-record standard clinical consultations with specialists represented on the DSD team. These appointments will utilize the Decision Support Tool (DST). A qualitative analysis of these recordings will assess the practicality of use and possible benefits of the DST's implementation.
88943981|NCT01875653|Active Comparator|Autologous PBMCs in GM-CSF (MC)|"DOSE/ROUTE/REGIMEN:~Treatment Duration: Doses of MC will be administered subcutaneously weekly for 3 consecutive weeks, then monthly for the next 5 months.~Dosage: Each dose of MC contains approximately 10 million cells. Each dose is suspended in 500 mcg GM-CSF prior to administration.~Mode of Administration: Subcutaneous (SC) injections."
88943982|NCT01875653|Experimental|Autologous Dendritic Cell-Tumor Cell Immunotherapy (DC-TC)|"DOSE/ROUTE/REGIMEN:~Treatment Duration: Doses of DC-TC will be administered subcutaneously weekly for 3 consecutive weeks, then monthly for the next 5 months.~Dosage: Each dose of DC-TC contains approximately 10-20 million cells. Each dose is suspended in 500 mcg GM-CSF prior to administration.~Mode of Administration: Subcutaneous (SC) injections."
89463185|NCT03466983|Experimental|Iron Isomaltoside|Iron Isomaltoside (Monofer) administered IV
89463186|NCT03466983|Active Comparator|Ferric Carboxymaltose|Ferric Carboxymaltose (Injectafer) administered IV
88943983|NCT01875666|Active Comparator|Trastuzumab|single dose intravenous infusion administration of trastuzumab (8 mg/kg)
88943984|NCT01875666|Active Comparator|pertuzumab|single dose infusion of pertuzumab (840 mg)
88943985|NCT01875666|Active Comparator|trastuzumab plus pertuzumab|single dose infusion of combination trastuzumab (8 mg/kg) plus pertuzumab (840 mg)
88943986|NCT01875666|Active Comparator|trastuzumab plus lapatinib|combination of single dose infusion of trastuzumab (8 mg/kg) plus oral lapatinib (1000 mg daily for 7 days)
88943987|NCT01875679|Active Comparator|Conventional residency training|This group will continue their regular surgical training without any specific intervention.
88943988|NCT01875679|Experimental|Comprehensive Surgical Coaching (SCS)|The participants will receive an analysis of the technical performance as observed on baseline recordings of the index procedure. Training needs will be identified and a personalized coaching concept will be designed. Coaching sessions will include video debriefing of the participant's performance (sample recordings will be submitted by the participant during the sessions) and video assisted behavioral modeling using examples of good and poor technical performance. Coaching will also target increasing awareness of weaknesses and potential pitfalls in surgical technical task execution (error recognition).
89463187|NCT03466905|Active Comparator|Intervention|Assessment of Ambulance Medical Service
89463188|NCT03466905|No Intervention|Control|Local treatment guidelines
89463189|NCT05439213|Experimental|Group 1|adrenaline 0,33 mg per litter
89463190|NCT05439213|Experimental|Group 2|adrenaline 1 mg per litter
89463191|NCT05398575|Experimental|Standard treatment with tailored music playlist|Music playlist tailored for a group of 5-8 individuals.
89463192|NCT05398575|Active Comparator|Standard treatment with radio music|Listening to local radio channel with music
88943989|NCT01875705|Experimental|Stage I-Dose Escalation|
88943990|NCT01875705|Experimental|Stage II-Cohort-Expansion|
88943991|NCT01875718|Active Comparator|UC1010 low dose|
88943992|NCT01875718|Active Comparator|UC1010 high dose|
88943993|NCT01875718|Placebo Comparator|Vehicle|
88943994|NCT01875744|Experimental|Polyethylene glycol small dose|Polyethylene glycol 4000: 0.3 g/kg/day for 6 weeks
88943995|NCT01875744|Active Comparator|Polyethylene glycol high dose|Polyethylene glycol 4000: 0.7g/kg for 6 weeks
89463193|NCT05398575|No Intervention|Standard treatment without music|Standard physiotherapy with no audio intervention
88943996|NCT01875757|Experimental|Vitamin D3 1000 IU/day|Infants will be supplemented with vitamin D and/or placebo to receive a total amount of vitamin D3 of 1.000 IU/day during the first year of life, taking into account the vitamin D received with artificial milk
88943997|NCT01875757|Active Comparator|Vitamin D3 400 IU/day|Infants will be supplemented with vitamin D and/or placebo to receive a total amount of vitamin D3 of 400 IU/day during the first year of life, taking into account the vitamin D received with artificial milk
88943998|NCT01875770||Treated with Ranibizumab in previous trial|Treated with Ranibizumab in previous trial
88943999|NCT01875796|Experimental|Cannabis & Anxiety Reduction Treatment|Cognitive-behavioral treatment program that integrates strategies to manage both cannabis use and anxiety with techniques to address motivation to change cannabis use.
88944000|NCT01875796|Active Comparator|Motivation/cognitive-behavioral therapy|Motivational Enhancement Therapy (MET) and cognitive-behavioral therapy (CBT) that includes techniques to address motivation to change cannabis use with strategies to manage use.
89463194|NCT03466749|Experimental|Intervention group|Paclitaxel Eluting Balloon Catheter treatment
89463195|NCT05398419|Experimental|Music group|The participants will listen to music at bedtime and overnight for 7 consecutive nights. The music selected in our study will be pleasant instrumental slow tempo music in a major mode. It will also be low contrast (without periods of silence).
89463196|NCT05398419|Active Comparator|Non-musical sounds group|The participants will listen to non-musical sounds at bedtime and overnight for 7 consecutive nights. The non-musical sounds will be low-contrast nature sounds such as waves or rain. The investigators plan to use non-musical sounds that align with the frequency range of the musical stimuli.
89463197|NCT05398419|No Intervention|Standard of care (Control)|The participants will have no change to their usual sleep routine on the Geriatric Assessment Unit.
88944001|NCT01875809||Renal denervation (RDN)|Change of catecholamine spill-over during RDN
88944002|NCT01875809||Electrophysiology (EP) Ablation|Change of catecholamine spill-over during EP ablation
88944003|NCT01875822|Experimental|Supercurcumin|The study protocol stipulates that subjects diagnosed as DSM IV-TR (Diagnostic Statistical Manual IV-Transitional Revised) would be receiving either 1 gm Super-Curcumin@ capsule once daily or 4 gm Super-Curcumin@ once daily for a total of 16 weeks. Super-Curcumin@ in capsule form is a patented formulation of curcumin certified by Sabinsa Corp.NJ USA and produced by America's Finest Inc. 1 gm-capsule Super-Curcumin@ consist of 1 gm Curcumin C-3 complex and 5 mg of Bioperine.
88944004|NCT01875835|Active Comparator|DES|Everolimus-Eluting Stent implanted in patients with ST-segment elevation myocardial infarction (STEMI)
88944005|NCT01875835|Active Comparator|BMS|Bare-Metal Stent implanted in patients with ST-segment elevation myocardial infarction (STEMI)
88944006|NCT01875887||treat bilateral maxillofacial deformties|treatment of bilateral maxillofacial post-traumatic deformities
88944007|NCT01875900|Active Comparator|Video-assisted learning and self-directed training|The Neonatal Resuscitation Program (NRP) digital video disc (DVD) will be provided for video study and a low-fidelity newborn manikin for self-directed resuscitation training (90 minutes training time, six students per group).
88944008|NCT01875900|Experimental|Simulation-based neonatal resuscitation training|Students will learn initial assessment of newborns and basic resuscitation skills and actively apply these skills during simulated clinical scenarios both with a low- and high-fidelity manikin (90 minutes training time, six students per group).
88944009|NCT01875913|Experimental|Standard Message|Participants will receive email messages that encourage them to complete their VHR.
88944010|NCT01875913|Experimental|Curiosity Message|"Participants receive email messages containing curiosity-inducing questions. The messages tell the participants that they will receive the answer to the question after they complete their VHR."
88944011|NCT01875926|Experimental|ALX-0171 Oral Inhalation - Single Dose (SD)|
88944012|NCT01875926|Experimental|ALX-0171 Oral Inhalation - Multiple Dose (MD)|
88944013|NCT01875926|Experimental|ALX-0171 Intravenous (IV)|
88944014|NCT01875939|Other|Oral WCK 2349 fed/fasting|This is a single center, randomized, open label, 2X2 oral IV cross over, food-effect and absolute bioavailability study. The study will be conducted in three parts i.e., Period 1 and Period 2 (foodeffect study) and Period 3 (absolute bioavailability study).
88944015|NCT01875939|Other|IV WCK771|This is a single center, randomized, open label, 2X2 oral IV cross over, food-effect and absolute bioavailability study. The study will be conducted in three parts i.e., Period 1 and Period 2 (foodeffect study) and Period 3 (absolute bioavailability study).
88944016|NCT01875952|Other|one arm|All patients with response to positive purified protein derivative (PPD) test are treated
88944017|NCT01876004|Experimental|Methotrexate|Administered a single intramuscular dose of 50 mg/m2 of Methotrexate.
88944018|NCT01876004|Placebo Comparator|Placebo|Prescribed Placebo intramuscularly.
88944019|NCT01876017|Other|BMMNC|Intravenous transfer of Autologous Bone Marrow derived Mono Nuclear Stem Cell (BMMNCs)
88944020|NCT01876030|Experimental|FES|All subjects will receive a 15-30 minutes a day treatment for 5 days a week. When the subjects achieves the ability to walk with supervision, but with no physical assistance, safely and consistently during the physiotherapy sessions, then either the FES will be provided to the subject to allow ongoing gait practice with the nursing staff in the ward environment. After discharge, the assistive device will be provided for home usage till the end of the research.
88944021|NCT01876030|No Intervention|Conventional|Treated with regular gait re-education with or without AFO fitting. All subjects will receive a 15-30 minutes a day treatment for 5 days a week. When the subjects achieves the ability to walk with supervision, but with no physical assistance, safely and consistently during the physiotherapy sessions, then either the AFO will be provided to the subject to allow ongoing gait practice with the nursing staff in the ward environment. After discharge, the assistive device will be provided for home usage till the end of the research.
89017917|NCT05853731|Placebo Comparator|Placebo Group|Subjects in the intensive care unit (ICU) setting after cardiac surgery will have filtered white light emitting diodes (WLED) as a placebo for the duration of the ICU stay or up to 1 week.
88944022|NCT01876056|Experimental|Brief CaCBTp|The experimental group will receive brief for of Culturally adapted CBT for psychossis
88944023|NCT01876056|No Intervention|Treatment As Usual|Treatment as usual means seeing a mental health professional and taking the prescribed anti psychotics and being cared by family members
88944024|NCT01876069|Active Comparator|22 gauge ProCore needle aspiration|EUS-guided pancreatic mass aspiration with 22 gauge ProCore needle
88944025|NCT01876069|Active Comparator|22 gauge Fine needle aspiration|EUS-guided pancreatic mass aspiration with 22 gauge Fine needle
89537197|NCT02466347|Experimental|Synflutide HFA MDI, 250/25 mcg/dose|Synflutide HFA MDI(Fluticasone propionate/ Salmeterol, 250/25mcg), Single dose, 4 puffs
89537198|NCT02466347|Active Comparator|SeretideTM EvohalerTM, 250/25 mcg/dose|SeretideTM EvohalerTM (Fluticasone propionate/ Salmeterol, 250/25mcg), Single dose, 4 puffs
89537199|NCT05729763||Patients with localized renal tumor|Patients with localized renal tumor scheduled for minimally invasive partial nephrectomy in which 2D- and 3D-PADUA nephrometric score assessment was performed preoperatively
89537200|NCT03066375|Experimental|Echocardiography-Doppler|Ultrasonographic recordings, systemic arterial pressure, heart rate, and respiratory rate are recorded immediately before and after volume expansion (VE), performed as a 30-minute infusion of 500 mL of 4% gelatin. Inferior Vena Cava diameters are measured during spontaneous and standardized respiratory cycles. Stroke volume is measured during spontaneous respiratory cycles.
89537201|NCT02466269||the preauricular approach|A classic preauricular incision was used to treat diacapitular condylar fractures
89537202|NCT05635149||Fruquintinib and anti-PD-1 plus radiotherapy|"Fruquintinib is administrated as 4mg orally, once daily for 2 weeks on/1 week off.~anti-PD-1 antibody is administrated as 200mg once every 3 weeks. Patients with isolated or localized metastasis will receive radiotherapy."
89537203|NCT05635149||Fruquintinib and anti-PD-1 alone|"Fruquintinib is administrated as 4mg orally, once daily for 2 weeks on/1 week off.~anti-PD-1 antibody is administrated as 200mg once every 3 weeks."
89537204|NCT03067857|Experimental|Stem Cells|Intravenous and Intrathecal thecal transplantation via interventional radiology of purified autologous bone-marrow derived specific stem cell populations.
89537205|NCT02466191|Experimental|memantine first|Patients will be randomly assigned to start on either memantine or gabapentin. For tolerance reasons, each treatment begins with a progressive increasing dose and stops with a progressive decreasing dose. The duration of the period of last dose (8 to 11 days) will be chosen according to the investigator's availability to organize post-tests.
89537206|NCT02466191|Experimental|gabapentin first|Patients will be randomly assigned to start on either memantine or gabapentin. For tolerance reasons, each treatment begins with a progressive increasing dose and stops with a progressive decreasing dose. The duration of the period of last dose (8 to 11 days) will be chosen according to the investigator's availability to organize post-tests.
89537207|NCT05729685|Experimental|Interval training|The interval group trained using the interval trainining method.
89537208|NCT05729685|Experimental|Continuous training|The continuous group trained using the continuous training method.
89537209|NCT02466113|Experimental|An experimental group|A 6 microRNA stratified tool is applied in this group.Investigators defined high risk patient and low risk patient according to the microRNA stratified tool.The high risk group should receive adjuvant chemotherapy while the low risk group observation.
89537210|NCT02466113|Other|A control group|A classic stratified tool is applied in this group. Investigators defined high risk and low risk patient according to classical pathological features.The high risk group should receive adjuvant chemotherapy while the low risk group observation.
89537211|NCT05573321|Experimental|BFR-RE|In the BFR-RE intervention, the exercise will be done as a set of 30 repetitions with a loading of 30% of 1 RM and an additional 3 sets x 15 repetitions, with 30 seconds rest between sets.
88944026|NCT01876095|Experimental|Multidisciplinary medication review|"The multidisciplinary medication review consists of 5 steps:~Step #1: Assessing patients' experiences and preferences regarding medicine use en assessing their medical history, allergies and lab results Step #2: Drug reviewing to assess contra-indicated medication and duplicate medication using consensus criteria e.g. START STOPP Beers criteria Step #3: Reflecting on results of drug reviewing Step #4: Setting up a pharmacotherapeutical action plan Step #5: Execution of pharmacotherapeutical action plan"
88944027|NCT01876095|No Intervention|usual care|Includes medication safety monitoring and ad hoc medication reviews on clinical indication that differ in quality and frequency, but no standardized multidisciplinary multistep medication reviews in the way as described for the intervention arm
88944028|NCT01876108|Experimental|H.pylori eradication|H.pylori eradication by quadruple antibiotic therapy for two weeks plus obtaining ideal body weight by calorie restriction diet and programmed physical activity.
88944029|NCT01876108|No Intervention|Lifestyle modification|Obtaining ideal body weight by calorie restriction diet and programmed physical activity
88944030|NCT01876121||Celecox group|
89537212|NCT05573321|Active Comparator|HL-RE|In the HL-RE intervention, the exercise will be performed with a loading of 80% of 1 RM, with 4 sets x 7 repetitions, with 60 seconds of rest between sets.
88944031|NCT01876134||Elective cardiac surgery|
88944032|NCT01876147||Order of vision tests 1|Undergo testing with BRVT first, FrACT second.
88944033|NCT01876147||Order of vision tests 2|Undergo testing with FrACT first, BRVT second.
88944034|NCT01876160|Experimental|threshold of sensory perception|Eighty healthy volunteers were evaluated; 40 women and 40 men divided into two equal groups of young and elderly subjects. Half of the individuals in each group were stimulated with 5 and 50Hz frequency, with pulse duration of 20, 100, 400, 1000 and 3000µs applied on the flexor muscle bellies of the wrist and fingers. The threshold of sensory perception was identified as the first sensation of increased current intensity and the threshold of motor response as the minimum muscle contraction detected.
88944035|NCT01876160|Experimental|threshold of motor response|Eighty healthy volunteers were evaluated; 40 women and 40 men divided into two equal groups of young and elderly subjects. Half of the individuals in each group were stimulated with 5 and 50Hz frequency, with pulse duration of 20, 100, 400, 1000 and 3000µs applied on the flexor muscle bellies of the wrist and fingers. The threshold of motor response as the minimum muscle contraction detected.
89017918|NCT05848375|Experimental|Loco regional anesthesia alone|Arthroscopic rotator cuff repair performed under LRA alone
89463198|NCT03466671|Other|Low dose once per day and placebo|"Four weeks administrations of TTA-121 3U once per day in morning and placebo once per day in evening.~After four weeks washout, four weeks administrations of placebo twice per day in morning and evening."
89463199|NCT03466671|Other|Low dose twice per day and placebo|Four weeks administrations of TTA-121 3U twice per day in morning and evening. After four weeks washout, four weeks administrations of placebo twice per day in morning and evening.
89463200|NCT03466671|Other|High dose once per day and placebo|"Four weeks administrations of TTA-121 10U once per day in morning and placebo once per day in evening.~After four weeks washout, four weeks administrations of placebo twice per day in morning and evening."
89463201|NCT03466671|Other|High dose twice per day and placebo|Four weeks administrations of TTA-121 10U twice per day in morning and evening. After four weeks washout, four weeks administrations of placebo twice per day in morning and evening.
89463202|NCT03466671|Other|Placebo and low dose once per day|Four weeks administrations of placebo twice per day in morning and evening. After four weeks washout, four weeks administrations of TTA-121 3U once per day in morning and placebo once per day in evening.
89463203|NCT03466671|Other|Placebo and low dose twice per day|Four weeks administrations of placebo twice per day in morning and evening. After four weeks washout, four weeks administrations of TTA-121 3U twice per day in morning and evening.
89463204|NCT03466671|Other|Placebo and high dose once per day|Four weeks administrations of placebo twice per day in morning and evening. After four weeks washout, four weeks administrations of TTA-121 10U once per day in morning and placebo once per day in evening.
89463205|NCT03466671|Other|Placebo and high dose twice per day|Four weeks administrations of placebo twice per day in morning and evening. After four weeks washout, four weeks administrations of TTA-121 10U twice per day in morning and evening.
89463206|NCT05438901|Experimental|before and after application|Before the hirudotherapy application, it was planned to study the oxidant and antioxidant parameters in the venous blood of the patient. In addition, it was planned to study the oxidant and antioxidant parameters in the patient's venous blood after 2 sessions of Hirudotherapy, 1 month apart.
89463207|NCT03466593|Experimental|Prospective cohort-prehabilitation|A prehabilitation program including advice about diet, increased physical activity and cessation of smoking and drinking alcohol.
89463208|NCT03466593|Active Comparator|Retrospective cohort|Routine care before the prehabilitation program was introduced
89463209|NCT03466593|Experimental|Extra early mobilization|Mobilization the day of surgery
89463210|NCT03466593|Active Comparator|Traditional mobilization|Routine care with mobilization the day after surgery
89463211|NCT05438823|Experimental|İntervention group|The sample of the study will be the parents of children who have had hematopoietic stem cell transplantation at Akdeniz University Hospital and whose discharge is planned (n=20).
89463212|NCT05438823|No Intervention|Control group|The control group will be the parents of children who underwent hematopoietic stem cell transplantation at Akdeniz University Hospital and are planned to be discharged (n=20). Participants in this group will receive routine care, and at the end of the study, training program will be applied.
89463213|NCT03466515|Experimental|intervention|Patients enrolled in the study will be treated for their anal fistula by surgical closure of the internal opening, debridement of the fistula and injection of patients own stem cells enriched fatty tissue around the fistula.
89463214|NCT04520841|Active Comparator|Standard dry dressing in total hip or knee arthroplasty|Standard dressing in total hip or knee arthroplasty surgery revision: a dry sterile dressing is applied on the surgical wound at the end of surgery
89463215|NCT04520841|Experimental|Prevena in total hip or knee arthroplasty|"Prevena incision management system in total hip or knee arthroplastsy surgery revision:~The Prevena incision management system is applied on the surgical wound at the end of surgery"
88944036|NCT01876173|Experimental|Patient Decision Aid for an ICD (primary prevention, non-CRT)|The intervention group will receive the PtDA, which provides a lay summary that outlines the facts, risks, benefits (including probabilities), specific to the option of an implantable defibrillator or the option of medical management to prepare them for consultation with the physician. Values are assessed to reveal which features of each option are important to patients.
88944037|NCT01876173|No Intervention|Usual care|The control group will not receive the patient decision aid prior to consultation with the physician.
88944038|NCT01876186|Experimental|Solifenacin for 12 weeks group|Solifenacin (5 mg qd) for 12 weeks
88944039|NCT01876186|Active Comparator|Solifenacin for 24 weeks group|Solifenacin (5 mg qd) for 24 weeks
88944040|NCT01876199|Experimental|Intense follow up|2-week follow up appointment with addition of a reminder mobile phone call or short text message (SMS) if possible, plus a home visit by a community counselor if the participant fails to present on the appointed date.
88944041|NCT01876199|No Intervention|standard follow-up|2-week follow-up appointment with no reminders
89463216|NCT04520841|Active Comparator|Standard dry dressing in lower limb amputation|Standard dressing in lower limb amputation: a dry sterile dressing is applied on the surgical wound at the end of surgery
89463217|NCT04520841|Experimental|Prevena in lower limb amputation|"Prevena incision management system in lower limb amputation:~The Prevena incision management system is applied on the surgical wound at the end of surgery"
89463218|NCT04501731||Young PFT survivors|
89463219|NCT04501731||Age-matching controls|
89463220|NCT03466437|Experimental|Glass-fiber post + composite resin restoration|
89463221|NCT03466437|Experimental|Glass-fiber post + metalceramic crown|
88944042|NCT01876225|No Intervention|No coughing|Cervical punch biopsy without forced coughing intervention
88944043|NCT01876225|Experimental|coughing|Forced coughing during cervical punch biopsy
88944044|NCT01876238|Experimental|T-PAT Intervention|Prognosis discussion intervention with study team.
88944045|NCT01876238|Active Comparator|Control: Standard Care|Usual care appointment
89463222|NCT03466437|Active Comparator|Cast-metal post + metalceramic crown|
89463223|NCT05438745||Experimental Group|Ambulance Service Staff participating in pet therapy sessions.
89463224|NCT03466359|Experimental|DEF-EI|these adolescents will follow a dietary restriction of 10% of their daily energy intake.
89463225|NCT03466359|Experimental|DEF-EX|these adolescents will increase their physical activity-induced energy expenditure by 10% per day.
89463226|NCT05438433|Sham Comparator|Group A|50 patients with isolated rheumatic mitral valve disease (group A)
88944046|NCT01876264|Experimental|Extended resection|Patients undergoing an extended resection are subjected to a traditional ileocolic resection with a 2cm macroscopically normal proximal margin. A further 8cm of ileum is then resected from the proximal margin prior to formation of the ileocolic anastomosis
88944047|NCT01876264|Active Comparator|Conventional resection|Patients undergoing a traditional ileocolic resection for Crohn's disease with a 2cm proximal macroscopically disease-free margin
88944048|NCT01876277||Adolescent males with cancer|Males aged 13-21 who have been treated at the Royal Marsden Hospital for cancer.
88944049|NCT01876290|Experimental|Dexamethasone and Ondansetron|Each patient will receive Dexamethasone and Ondansetron
88944050|NCT01876290|Placebo Comparator|Placebo|Each patient will receive placebo instead of Dexamethasone and Ondansetron
88944051|NCT01876303||Ancillary-Correlative (genetic epidemiology of Ewing sarcoma)|Genomic DNA is extracted from participants' saliva samples and analyzed for expression of EWS-FLI1 and other ES-target genes.
88944052|NCT01876316|Active Comparator|Moxifloxacin|single oral administration of 400mg of moxifloxacin
88944053|NCT01876316|Placebo Comparator|Placebo|single oral administration of 400mg of placebo
88944054|NCT01876342|Experimental|Open repair|Open minimal repair (OMR) of Sportsman's hernia using 2-0 continuous sutures
88944055|NCT01876342|Active Comparator|Endoscopic TEP repair|Totally Endoscopic extraperitoneal repair (TEP)using lightweight mesh
88944056|NCT01876394|Experimental|Coconut oil|
88944057|NCT01876394|Experimental|Canola oil|
88944058|NCT01876394|Experimental|Grapeseed oil|
88944059|NCT01876394|Experimental|Chia oil|
88944060|NCT01876394|Placebo Comparator|Butter|
89463227|NCT05438433|Other|Group B|50 patients with mitral disease and myocardial ischemia (group B)
89463228|NCT06326970||99mTc-FAPI imaging in heart diseases|Participant involves patients with myocarditis, hypertension, arrhythmia, myocardial infarction, dilated cardiomyopathy, and cardiac tumors.
88944061|NCT01876407|Experimental|Low energy laser|Administration of a low energy laser for oral mucositis.
88944062|NCT01876407|Placebo Comparator|Placebo|
88944063|NCT01876433|Active Comparator|Beta-3-agonist|Mirabegron 25 mg x 2 titrated up to maximal tolerated dosis or a maximum of 150 mg x 2.
88944064|NCT01876433|Placebo Comparator|Placebo|Placebo 25 mg x 2 titrated up to maximal tolerated dosis or a maximum of 150 mg x 2.
88944065|NCT01876459|Other|"Alzheimer's Disease arm"|Patient with Alzheimer's disease
88944066|NCT01876459|Other|"Lewy Body Disease arm"|Patient with Lewy Body Disease
88944067|NCT01876472||Children aged 3 - 10 years|Assessment of music perception skills with cochlear implant recipients aged 3 - 10 years
88944068|NCT01876472||Teenagers aged 11 - 15 years|Assessment of music perception skills with cochlear implant recipients aged 11 - 15 years
88944069|NCT01876472||Adults aged 16 - 70 years|Assessment of music perception skills with cochlear implant recipients aged 16 - 70 years
88944070|NCT01876498||Patient with M. Dupuytren|Xiaflex Surgery
88944071|NCT01876537|Active Comparator|Usual surgery|
89463229|NCT06326944|Active Comparator|Group A|Patients will receive fascia transversalis block
89463230|NCT06326944|Active Comparator|Group B|Patients will receive Transversus abdominus plane block
89463231|NCT06326931|Experimental|Thermal pulsation group|Group treated in both eyes with a single Systane iLux thermal pulsation treatment
89463232|NCT06326931|Active Comparator|Warm compress group|Group treated in both eyes with 10 minute application of Bruder warm compress mask, twice daily for 8 weeks
89463233|NCT06326918||Functional dyspepsia|"Patients who are 18 years old or more and exhibit at least one of the following four symptoms for the last 3 months, with symptom onset occurring at least 6 months prior to diagnosis.~1.1 Postprandial distress syndrome (symptoms occurring at least 3 days per week), including:~Postprandial fullness and/or~Early satiation~1.2 Epigastric pain syndrome (symptoms occurring at least 1 day per week), including:~Epigastric pain and/or~Epigastric burning~Participants undergo esophago-gastro duodenoscopy (EGD) to confirm the absence of any structural abnormalities."
88944072|NCT01876537|Active Comparator|Hardware wound healing|
88944073|NCT01876550|Experimental|Mupirocin Calcium Cream, 2%|Mupirocin Calcium Cream, 2% (Taro Pharmaceuticals Inc.)
89463234|NCT06326918||Control|"Patients with no or minimal upper GI symptoms (not match the criteria of FD) and current EGD appear normal or insignificant gastritis~Age- and sex-matched to the functional dyspepsia (FD) patient group."
89463235|NCT06326905|Experimental|Open Label Pilot|The Open Label Pilot will include testing the CAPABLE Transplant intervention with 3 individuals on the waitlist.
89463236|NCT06326905|Experimental|Randomized Control Pilot- Intervention Arm|After the open label pilot, 15 participants will be randomized to the CAPABLE Transplant intervention. They will be assessed at baseline, after the 4 month intervention, and after the waitlist control arm.
89463237|NCT06326905|Active Comparator|Randomized Control Pilot- Waitlist Control Arm|The waitlist control group, 15 participants, will receive the intervention after they have served as controls to the immediate treatment group, ensuring all participants have access to the intervention.
89463238|NCT06326840|Experimental|metformin intervention|All participants were administered 1500 mg/day of metformin for eight weeks.
89463239|NCT06326827||In'Oss™ (MBCP® Putty)|Participants will be recruited from a population who are undergoing orthopaedic bone trauma surgery at the investigational site. All admitted patients will be screened and assessed to determine whether patients may be eligible to take part based on the inclusion and exclusion criteria. Patient participation in this study will include a screening visit within 48 hours of admission to hospital prior the surgery.
89463240|NCT06326814|Experimental|SAR443809 and placebo dose 1 Arm|6 participants receiving SAR443809 and 2 receiving placebo, intravenous administration dose 1
89463241|NCT06326814|Experimental|SAR443809 and placebo dose 2 Arm|6 participants receiving SAR443809 and 2 receiving placebo, intravenous administration dose 2
89463242|NCT06326814|Experimental|SAR443809 and placebo dose 3 Arm|6 participants receiving SAR443809 and 2 receiving placebo, intravenous administration dose 3
89463243|NCT06326814|Experimental|SAR443809 and placebo dose 4 Arm|6 participants receiving SAR443809 and 2 receiving placebo, intravenous administration dose 4
89463244|NCT06326814|Experimental|SAR443809 and placebo dose 5 Arm|6 participants receiving SAR443809 and 2 receiving placebo, subcutaneous administration dose 5
89463245|NCT06326814|Experimental|SAR443809 and placebo dose 6 Arm|Optional: 6 participants receiving SAR443809 and 2 receiving placebo, intravenous administration dose 6
89463246|NCT06326814|Experimental|SAR443809 and placebo dose 7 Arm|Optional: 6 participants receiving SAR443809 and 2 receiving placebo, intravenous administration dose 7
88944074|NCT01876550|Active Comparator|Bactroban® Cream|Bactroban® Cream (mupirocin calcium cream, 2%) (GlaxoSmithKline)
88944075|NCT01876550|Placebo Comparator|Cream vehicle of test product|Cream vehicle of test product (Taro Pharmaceuticals Inc.)
88944076|NCT01876563|Active Comparator|diabetes, vitamin D|patients with type 2 diabetes who receive 4000 IU/day vitamin D
88944077|NCT01876563|Placebo Comparator|placebo, diabetes|patients with type 2 diabetes who receive one tab placebo
88944078|NCT01876576|Active Comparator|clear liquids|Clear liquids the day of bowel preparation up to 2.5 hrs before colonoscopy
88944079|NCT01876576|Active Comparator|low residue diet|Low residue breakfast and lunch up to 1pm; clear liquids thereafter up to 2.5 hrs before colonoscopy
88944080|NCT01876589|Active Comparator|Bioresorbable vascular scaffold|Paritcipants will receive a bioresorbable vascular scaffols (BVS)
88944081|NCT01876589|Active Comparator|Xience Prime|Participant will receive a Xience Prime stent
89463247|NCT06326801|Active Comparator|Treatment A|"Resistive Diaphragmatic breathing exercise~Pursed lips breathing exercise~Conventional stroke physiotherapy"
89463248|NCT06326801|Active Comparator|Treatment B|"Diaphragmatic breathing exercise~Pursed lips breathing exercise~Conventional stroke physiotherapy"
88944082|NCT01876602|Experimental|Exercise prescription|"Participants are given an exercise prescription in the form of a target heart rate range for exercising. The range is determined based on their personal preferences so that it is an intensity that feels good."
89463249|NCT06326801|Active Comparator|Control group|a) Conventional stroke physiotherapy
89463250|NCT06326788|Experimental|Short Duration Moderate Intensity Soleus Push-ups (Group A)|Moderate physical activity involving weighted soleus push-ups performed till patient MHR is achieved.
89463251|NCT06326788|Experimental|Sustained Soleus Push-ups (Group B)|sustained soleus push-ups will be performed for up to 270 min.
89463252|NCT06326762||Myocardial Dysfunction|
89463253|NCT06326762||No Myocardial Dysfunction|
88944083|NCT01876602|Active Comparator|traditional exercise|participants are given an exercise prescription based on percent of vo2 peak
88944084|NCT01876615|Experimental|YH4808 or Diclofenac or YH4808+Diclofenac(arm 1)|"6 arm, 3 Sequence design~YH4808 or Diclofenac or YH4808+Diclofenac~3 week wash out period is between each period."
88944085|NCT01876615|Experimental|YH4808 or Diclofenac or YH4808+Diclofenac (arm 2)|"6 arm, 3 Sequence design~YH4808 or Diclofenac or YH4808+Diclofenac~3 week wash out period is between each period."
89501888|NCT03516487|Experimental|SAD PKU: SYNB1618 (7 x 10^10 CFU)|Subjects with PKU receive a single oral dose of SYNB1618 (7 x 10^10 CFU) in a chilled buffered solution on Day 1 in the SAD study (Part 1).
89501889|NCT03516487|Placebo Comparator|SAD PKU: Placebo|HV subjects receive a single oral dose of placebo in a chilled buffered solution on Day 1 in the SAD study (Part 1).
89501890|NCT03516487|Experimental|MAD HV: SYNB1618 (1 x 10^10 CFU)|HV subjects receive oral SYNB1618 (1 x 10^10 CFU) in a chilled buffered solution 3 times per day (TID) for 7 days in the MAD study (Part 2).
89501891|NCT03516487|Experimental|MAD HV: SYNB1618 (5 x 10^10 CFU)|HV subjects receive oral SYNB1618 (5 x 10^10 CFU) in a chilled buffered solution TID for 7 days in the MAD study (Part 2).
89463254|NCT06326749|Experimental|Modified Graded Motor Imagery and Conventional Treatment Group:|The modified DMI program consists of 4 stages: lateralization, open motor imagery including action observation training, mirror therapy and upper extremity functional exercise. The program will be implemented for 8 weeks, 3 days a week, under the supervision of a physiotherapist. Lateralization training will be applied in the first 2 weeks. Motor imagery training will be implemented in the 3rd and 4th weeks. For the second stage, the application will be combined with action observation training. As the 3rd stage, mirror therapy will be performed in the 5th and 6th weeks. The participant will be asked to perform some exercises while watching the reflection of the intact extremity in the mirror. In the final stage, they will be asked to physically perform upper extremity functional exercises. The total treatment time will be 40-50 minutes, with patients receiving 20-30 minutes of modified grade motor imagery and 20 minutes of conventional treatment.
89501892|NCT03516487|Experimental|MAD HV: SYNB1618 (7 x 10^10 CFU)|HV subjects receive oral SYNB1618 (7 x 10^10 CFU) in a chilled buffered solution TID for 7 days in the MAD study (Part 2).
88944086|NCT01876615|Experimental|YH4808 or Diclofenac or YH4808+Diclofenac (arm 3)|"6 arm, 3 Sequence design~YH4808 or Diclofenac or YH4808+Diclofenac~3 week wash out period is between each period."
88944087|NCT01876615|Experimental|YH4808 or Diclofenac or YH4808+Diclofenac (arm 4)|"6 arm, 3 Sequence design~YH4808 or Diclofenac or YH4808+Diclofenac~3 week wash out period is between each period."
88944088|NCT01876615|Experimental|YH4808 or Diclofenac or YH4808+Diclofenac (arm5)|"6 arm, 3 Sequence design~YH4808 or Diclofenac or YH4808+Diclofenac~3 week wash out period is between each period."
88944089|NCT01876615|Experimental|YH4808 or Diclofenac or YH4808+Diclofenac (arm6)|"6 arm, 3 Sequence design~YH4808 or Diclofenac or YH4808+Diclofenac~3 week wash out period is between each period."
88944090|NCT01876641|Experimental|Study Treatment|In Cohorts 1-4, a subcutaneous dose of decitabine will be administered three times/week over a 2 week period. Cohorts 5 and 6 will receive decitabine two times a week for 8 weeks and Cohorts 7 and 8 will receive decitabine three times a week for 8 weeks. Patients will start treatment with decitabine initially at the cohort in which they enter the study. Patients will remain in the cohort in which they were initially enrolled for the entire treatment course. Vemurafenib + Cobimetinib will be given continuously for subjects in Cohorts 5, 6, 7 and 8. Vemurafenib will be given on a 28-day cycle at the standard dose of 960 mg p.o. BID. Cobimetinib will be given on a 21-day cycle with a 7-day rest between cycles. Decitabine will be given for 2 cycles only. Each cycle will be 28 days long. Vemurafenib + Cobimetinib will be continued indefinitely until disease progression.
88944091|NCT01876654|Experimental|TruMatch® patient specific cutting guide|In patients randomized to experimental arm, TKR components will be implanted using TruMatch® patient specific cutting guides.
88944092|NCT01876654|No Intervention|Conventional cutting guide|In patients randomized to control arm, TKR components will be implanted using Attune® instrumentation (femoral intra-medullary guide, tibial extra-medullary guide), without TruMatch® patient specific cutting guides.
88944093|NCT01876667|Active Comparator|Intervention (CPCRS) Group|CPCRS will ensure patients have regular laboratory monitoring and blood pressure measures, appropriate lipid-lowering and antihypertensive medications, and receive follow-up in a timely manner.
88944094|NCT01876667|Placebo Comparator|Usual Care|Usual Care: Patients randomized to Usual Care will continue to receive interventions/procedures they normally receive according to standard/usual care practices
88944095|NCT01876680|Experimental|Group 1: Stretching and aerobic exercise|Group 1 undertook a stretching programme for neck/shoulder muscles three times weekly and performed aerobic exercise för 30 minutes three times weekly.
88944096|NCT01876680|Experimental|Group 2: Strength training|Group 2 undertook a stretching programme for neck/shoulder muscles three times weekly, performed aerobic exercise three times weekly and performed weight training using dumbbells for the neck/shoulder area and exercises to strengthen core and leg muscles for 45 minutes three times weekly.
88944097|NCT01876693|No Intervention|control|nutrition counselling with nasogastric tube insertion in the cases of weight loss more than 10% or severe mucositis developed during chemoradiotherapy
88944098|NCT01876693|Experimental|prophylactic percutaneous gastrostomy|prophylactic percutaneous gastrostomy with nutrition counselling
88944099|NCT01876745||NovoSeven® (activated recombinant factor VII)|
88944100|NCT01876758|Experimental|Cognitive Intervention: Memory Training|Memory training before and after ECT
88944101|NCT01876758|Active Comparator|Comparable general mental stimulation|Puzzle games before and after ECT
88944102|NCT01876758|No Intervention|Treatment as Usual|No memory training or puzzle games, just the study evaluations
88944103|NCT01876797|Other|ticagrelor-prasugrel|in period 1, 180 mg of ticagrelor will be administrated at a single oral dose. in period 2, 60 mg of prasugrel will be administrated at a single oral dose.
88944104|NCT01876836|Experimental|i-gel|i-gel placed after induction
88944105|NCT01876836|Active Comparator|C-LMA|C-LMA placed after induction
88944106|NCT01876849|Experimental|Group A|Exenatide injection 5mcg or 10 mcg, twice daily
88944107|NCT01876862|Experimental|STOP ART|"Antiretroviral treatment interruption in 3 successive groups of 5 patients.~Zero-risk strategy If after 8 weeks of treatment interruption, at least 1 patient from group 1 does not present any of the failure criteria, patients from group 2 will be included and their treatment interrupted. If after 8 weeks of treatment interruption, at least 2 patients from groups 1 and 2 do not present any failure criteria, patients from group 3 will be included and their treatment interrupted."
88944108|NCT01876875|Experimental|Intervention group|The patients of this group were randomized to receive an energy-restricted diet (20 kcal/kg/ideal body weight/day) enriched of n-3 PUFAs (average 2.6 g/d).
88944109|NCT01876875|Active Comparator|Control group|The participants of this group are randomized to receive drug therapy alone, continuing their usual diet
88944110|NCT01876914||DME patients|Patients suspected to have a problem with at least one eye called diabetic macular edema or DME
89463255|NCT06326749|Experimental|Graded Motor Imagery and Conventional Treatment Group:|The DMI program consists of 3 stages: lateralization, open motor imagery and mirror therapy. The program will be implemented for 8 weeks, 3 days a week, under the supervision of a physiotherapist. First, lateralization training will be applied. In the second stage, motor imagery training will be applied. This phase will be carried out in a quiet environment by asking the participants to fully focus on the visualization of the movements. Two methods will be used for the imagined movements. In particular, visuals of the shoulder and hand used in the lateralization phase will be used to visualize movements related to the normal movement of the upper extremity. Participants will also be asked to imagine different activities in daily life. In the final stage, mirror therapy will be applied. The participant will be asked to perform some exercises while watching the reflection of the intact extremity in the mirror.
88944111|NCT01876927|Experimental|Arm A|"DOX 4 cycles - Surgery - Follow-up~DOX:~Docetaxel 35 mg/m2 day 1 and 8 by one hour infusion; Oxaliplatin 80 mg/m2 day 1 by two hours infusion; Capecitabine 750 mg/m2 x 2 daily for 2 weeks, per OS.~Treatment should be administered for 4 cycles before surgery. Each cycle will be repeated every 3 weeks."
88944112|NCT01876927|Experimental|Arm B|"DOX 2 cycles - Surgery - DOX 2 cycles - Follow-up~DOX:~Docetaxel 35 mg/m2 day 1 and 8 by one hour infusion; Oxaliplatin 80 mg/m2 day 1 by two hours infusion; Capecitabine 750 mg/m2 x 2 daily for 2 weeks, per OS.~Treatment should be administered for 2 cycles before surgery and for further 2 cycles after surgery, unless progression of disease or unacceptable toxicity occurs, or patient refusal. In these cases patients will go off treatment.~Each cycle will be repeated every 3 weeks."
88944113|NCT01876940|Active Comparator|Fiberoptic Intubation performed by an expert|Tracheal intubation will be performed by an expert anesthesia attending with and without use of the air-Q
88944114|NCT01876940|Experimental|Fiberoptic Intubation performed by a novice|Tracheal intubation will be performed by an anesthesia trainee with and without use of the air-Q
88944115|NCT01876966|Experimental|ETR, artemether/lumefantrine|treatment with artemether/lumefantrine 80/480 mg during 3 days (treatment A) and treatment during 22 days with etravirine for 22 days and artemether/lumefantrine 80/480 mg from day 8 to day 11 (treatment B) with a washout of at least 4 weeks between the 2 treatment periods
88944116|NCT01876966|Experimental|DRV/rtv, artemether/lumefantrine|treatment with artemether/lumefantrine 80/480 mg during 3 days (treatment A) and treatment during 22 days with darunavir/ritonavir and artemether/lumefantrine 80/480 mg from day 8 to day 11 (treatment B) with a washout of at least 4 weeks between the 2 treatment periods
88944117|NCT01877005|Experimental|Ruxolitinib|"Induction period: Ruxolitinib will be given twice daily during 6 cycles of 28 days.~Maintenance period: patients who achieve at least a stable disease (according Cheson 2007) at the end of cycle 6 and for whose a clinical benefit is observed according to the Investigator's opinion will be eligible for maintenance treatment by ruxolitinib twice daily every day of 28-day cycles."
88944118|NCT01877018|Experimental|electronic reminder|Electronic reminder introduced into primary care medical health record.
88944119|NCT01877018|No Intervention|Usual care|Usual care control group
88944120|NCT01877031|Active Comparator|Ultrasound|Ultrasound only guidance of central line insertion - current standard of care.
88944121|NCT01877031|Experimental|Virtual Reality|Use of ultrasound plus virtual reality guidance to insert central line
88944122|NCT01877044|Placebo Comparator|Placebo|Maltodextrin
88944123|NCT01877044|Experimental|NAXUS 7.5 grams|Arabinoxylan
88944124|NCT01877044|Experimental|NAXUS 15.0 grams|Arabinoxylan
89017919|NCT05848375|Active Comparator|Loco regional anesthesia associated to general anesthesia|Arthroscopic rotator cuff repair performed under LRA and GA
88944125|NCT01877057|Experimental|Saturn|For the different prototypes of pea protein extract used in this study pea protein NUTRALYS F85M or F85G, Acacia Gum 381A or 396I and water will be used.
88944126|NCT01877096|Experimental|Motivational Interviewing|Participants will undergo a brief (20-30 minutes) motivational interviewing session after their primary care appointment
88944127|NCT01877096|Active Comparator|Attention Control|Participants will undergo a brief (20-30 minutes) attention control session after their primary care appointment
88944128|NCT01877109||Lymphoma|Lymphoma patients
88944129|NCT01877122|Experimental|Proflex® Mesh|Device: Partially absorbable lightweight mesh Intervention: Mesh implantation
88944130|NCT01877122|Active Comparator|Marlex® Mesh|Device: Non-absorbable Heavyweight mesh Intervention: Mesh implantation
88944131|NCT01877135||Anal AIN3|patients > 18 years, with anal AIN3, without history of anal carcinoma
88944132|NCT01877174||MICHI(TM) NPS+f|Patients routinely treated with the CE marked MICHI(TM) NPS+f System
88944133|NCT01877200||Subjects with diabetes (type 2)|
88944134|NCT01877213|Experimental|Coaching with coordinate care|After discharge from hospital, patients randomized in the coaching group will be coached by a coordinator nurse.
88944135|NCT01877213|No Intervention|Usual care|After discharge from hospital, patients randomized in the no intervention group will be managed as usually.
89463256|NCT06326749|Experimental|Conventional Treatment Group:|Within the scope of the conventional treatment Bobath Method, facilitating movement and functional activities in the upper and lower extremities, activating trunk muscles, facilitating basic functional activities such as turning in bed, coming to sit and standing, improving weight bearing while sitting and standing, postural control, balance and walking. A targeted exercise program will be created. In line with this goal, upper and lower extremity exercises; don't turn around, don't come to sit, don't stand up; Exercises to activate core muscles; such as bridging, functional reaching; weight bearing and balance training; It is planned to implement walking training. Treatment time will be 40-50 minutes.
89463257|NCT06326736|Experimental|Pancreatic Cancer|Resectable primary pancreatic tumor
89463258|NCT06326723|Experimental|25mg group|Dose:25mg daridorexant or placebo Treatment Assignment :Day 1 SD, Day 4 - Day 8 MD (qdy) Number of subjects:16 (12 daridorexant + 4 placebo)
88944136|NCT01877226|Experimental|Tapentadol|Tapentadol tamper resistant prolonged-release formulation (TRF) will be administered as 250 milligram oral tablet once (in the morning, 30 minutes after breakfast) on Day 1 and 6, and twice daily (in the morning, 30 minutes after breakfast and in the evening) on Day 4 and 5.
89463259|NCT06326723|Experimental|50mg group|Dose:50mg daridorexant or placebo Treatment Assignment :Day 1 SD, Day 4 - Day 8 MD (qdy) Number of subjects:16 (12 daridorexant + 4 placebo)
88944137|NCT01877252||Endovascular treatment|Angioplasty +/- stent
88944138|NCT01877252||Open treatment|Bypass (vein or prosthetic)
88944139|NCT01877252||Patchplasty/Hybrid treatment|Femoral artery patchplasty +/- profundoplasty +/- endovascular treatment
88944140|NCT01877252||Conservative treatment|no vascular intervention
88944141|NCT01877291||Nonsmokers|Young healthy nonsmokers
88944142|NCT01877291||Smokers<2.5 pack years|"Young healthy or asymptomatic smokers (aged < 35 y.o.) with smoking history <2.5 pack years"
88944143|NCT01877291||Smokers≥ 2.5 pack-years|"Young healthy or asymptomatic smokers (aged < 35 y.o.) with smoking history ≥ 2.5 pack-years"
88944144|NCT01877304|Experimental|AKITA with program central deposition|Nebulization for central deposition
88944145|NCT01877304|Active Comparator|AKITA with program for peripheral deposition|Nebulization for peripheral deposition
88944146|NCT01877317|Experimental|SelfFit adjusted hearing device|Hearing impaired people with mild to moderate sensorineural hearing loss (PTA124<50 dB) in the test ear compare the performance of their hearing aids adjusted through SelfFit mobile medical App (I-Pad) with the performance of their hearing aids adjusted through conventional audiogram-based fitting.
88944147|NCT01877330|Active Comparator|Injection in interscalene groove|Patients undergoing shoulder arthroscopy will have an interscalene nerve block by injection of ropivacaine in the interscalene groove anterior and posterior to the brachial plexus nerves.
88944148|NCT01877330|Active Comparator|Injection between nerve roots|Patients undergoing shoulder arthroscopy will have an interscalene nerve block by injection of ropivacaine in the interscalene groove inbetween the C5 and C6 nerve roots.
88944149|NCT01877356|Experimental|bilateral spinal anesthesia|bilateral spinal anesthesia prilocaine plain 20% 50 mg ambulatory surgery
88944150|NCT01877356|Experimental|unilateral spinal anesthesia|unilateral spinal anesthesia prilocaine hyperbaar 2% 30 mg ambulatory surgery
88944151|NCT01877382|Experimental|Part 1, Milademetan Alone|Participants receive milademetan alone with different dose schedules.
88944152|NCT01877382|Experimental|Part 2, Milademetan Alone|Participants with advanced melanoma and diffuse large B cell lymphoma (DLBCL) receive milademetan alone with different dose schedules.
89017920|NCT05839691||Mothers|Mothers enrolled in Home Visiting Programs that have or will be participating in past or future projects.
89463260|NCT06326710|Experimental|mHealth Group|This arm of participants will be receiving 4 sessions of face-to-face or online delivered mHealth intervention.
89463261|NCT06326710|Active Comparator|Control Group|This arm of participants will be receiving 4 sessions of face-to-face or online exercise delivered health talks.
89463262|NCT06326697|Experimental|Test Product: Azacitidine 300 mg Film coated tablets|Single oral dose of Azacitidine 300 mg Film coated tablets
89463263|NCT06326697|Active Comparator|Reference Product: Onureg® 300 mg Film Coated Tablets|Single oral dose of Onureg® 300 mg Film Coated Tablets
88944153|NCT01877434||Reversed TESS|Patient undergone reversed shoulder arthroplasty
88944154|NCT01877447|Experimental|cathodal F4|"Transcranial Direct Current Stimulation~Cathodal tDCS over F4 (right dorsolateral prefrontal cortex) Anodal tDCS over the left deltoid (extra-cephalic) n=15"
88944155|NCT01877447|Experimental|Anodal F3|"Transcranial Direct Current Stimulation'~Anodal tDCS over F3 (right dorsolateral prefrontal cortex) Cathodal tDCS over the right deltoid (extra-cephalic) n=15"
88944156|NCT01877460|Experimental|Sodium alginate-free chocolate milk|Sodium alginate-free chocolate milk (1% fat) (Beatrice Ltd., Toronto, Ontario)
88944157|NCT01877460|Experimental|1.25% sodium alginate chocolate milk|Chocolate milk (Beatrice Ltd., Toronto, Ontario) with 1.25% sodium alginate
88944158|NCT01877460|Experimental|2.5% sodium alginate chocolate milk|Chocolate milk (Beatrice Ltd., Toronto, Ontario) with 2.5% sodium alginate
88944159|NCT01877460|Experimental|2.5% sodium alginate milk-free water-based solution|Water solution with 2.5% sodium alginate
88944160|NCT01877473|Active Comparator|Reverse remodeling|Pretreatment with dofetilide or sotalol and restoration of sinus rhythm followed by PVI only ablation
88944161|NCT01877473|Active Comparator|Standard ablation|PVI ablation with additional CFAE and/or linear LA ablation
88944162|NCT01877486||Cryoballoon ablation|After pre-treatment with dofetilide and conversion of persistent AF to sinus rhythm, performance of PVI using cryoballoon
88944163|NCT01877499||optimization of HDF key parameters|The cohort is composed of patients with end-stage renal disease receiving dialysis for at least 6 weeks, either as standard hemodialysis (low- or high-flux) or hemodiafiltration (HDF).
88944164|NCT01877512|Active Comparator|Low dose Growth Hormone|Halve of the group of men and group of women will receive a decrease of their regular dose of Growth Hormone treatment, with the IGF-I target level of -2 - -1 SD score (low dose=LD).
88944165|NCT01877512|Active Comparator|High dose Growth Hormone|Halve of the group of men and group of women will receive an increase of their regular dose of Growth Hormone treatment, with the IGF-I target level of 1 - 2 SD score (high dose=HD).
88944166|NCT01877525||All patients in one cohort|Consecutive adult patients undergoing colonoscopy for colorectal cancer screening or routine surveillance indications were prospectively enrolled between October 2011 and October 2012.
88944167|NCT01877577|Active Comparator|2000 I/U Vitamin D3|2000 I/U Vitamin D3 Daily
88944168|NCT01877577|Active Comparator|4000 I/U Vitamin D3|4000 I/U Vitamin D3 Daily
88944169|NCT01877590|Placebo Comparator|placebo group|An identical placebo daily
88944170|NCT01877590|Experimental|alpha-lipoic acid group|alpha-lipoic acid 600 mg daily for one year.
88944171|NCT01877603||type 2 diabetes|We select 200 newly diagnosed type 2 diabetic patients. Plasma irisin levels will be measured, and endothelial function will be determined.
88944172|NCT01877616|Other|diagnostic test|all persons with a definitive diagnosis of a major sleep disorder (insomnia, hypersomnia, sleep-disordered breathing) will be followed annually for at least five years
88944173|NCT01877629|Experimental|ACT-129968 tablet/capsules|Subjects attend two treatment periods. In the first treatment period subjects receive a single, oral dose of ACT-129968 500 mg administered as a tablet (1 tablet, 500 mg) in the fasted state. In the second treatment period subjects receive a single, oral dose of ACT-129968 500 mg administered as capsules (2 capsules, 250 mg each) in the fasted state. There is a 7-9 day washout period between the first treatment period and the second treatment period.
88944174|NCT01877629|Experimental|ACT-129968 capsules/tablet|Subjects attend two treatment periods. In the first treatment period subjects receive a single, oral dose of ACT-129968 500 mg administered as capsules (2 capsules, 250 mg each) in the fasted state. In the second treatment period subjects receive a single, oral dose of ACT-129968 500 mg administered as a tablet (1 tablet, 500 mg each) in the fasted state. There is a 7-9 day washout period between the first treatment period and the second treatment period.
88944175|NCT01877681|Experimental|Assisted Care|Assisted care (Tele=assistance) provided by an expert nurse through a informatic online application
88944176|NCT01877681|Active Comparator|Active comparator|Usual care as stated by the Clinical Practice Guidelines for Pressure Ulcers treatment
88944177|NCT01877694|Experimental|Auriclosene Solution 0.3%|Dosed QID for 4 Days
88944178|NCT01877694|Placebo Comparator|Auriclosene Vehicle|Dosed QID for 4 days
88944179|NCT01877707|Other|Cystic Fibrosis patients|Patients with a diagnosis of cystic fibrosis, who are able to produce daily sputum samples. With a history of at least two pulmonary infective exacerbations within the past 12 months.
88944180|NCT01877733|Experimental|Maximal strenght training|Training maximal strength training 3 times a week/1 physiotherapy session for 8 weeks
88944181|NCT01877733|No Intervention|Standard rehabilitation|2-3 physiotherapy sessions a week for 8 weeks/telephone contact by project leader once a week/writing training diary
88944182|NCT01877746|Experimental|R1 - combined immunosuppressive therapy|application of the combined immunosuppressive therapy in the first dosing regimen
88944183|NCT01877746|Experimental|R2 - combined immunosuppressive therapy|application of the combined immunosuppressive therapy in the second dosing regimen
88944184|NCT01877746|Other|S - standard therapy|only standard medical therapy of chronic heart failure without application of the combined immunosuppressive therapy
88944185|NCT01877759|Other|Mesenchymal stem cell|hUMAN MESENCHYMAL STEM CELLS
88944186|NCT01877785|Experimental|MHAA4549A Arm|
88944187|NCT01877785|Placebo Comparator|Placebo Arm|
88944188|NCT01877798|Experimental|△PCO2/Ca-vO2|△PCO2/Ca-vO2 directed group
88944189|NCT01877798|Experimental|ScvO2|ScvO2 directed group
88944190|NCT01877811|Experimental|RXDX-105|
88944191|NCT01877824|Experimental|Fast-track training|A skills-lap course (1 day) followed by opportunity to perform 20 planned surgical procedures of each type (open groin hernia repair and laparoscopic cholecystectomy) under supervision and within 4-8 weeks. Videorecording at start, mid and end and at follow-up before ending first year of training.
88944192|NCT01877824|No Intervention|Control|Follows the existing training program without intervention. Video recording of the trainee performing a open groin hernia repair and a laparoscopic cholecystectomy procedure at start end end of first training year.
88944193|NCT01877850||case|patients with BPAW-M more than 15 or between 10 and 15, but with Tobin <100 will be weaned with the weaning protocol by nurses
88944194|NCT01877850||control|patients with any BWAP-M will be weaned by clinical judgment of physicians
88944195|NCT01877863|Experimental|intradialytic exercise|baseline data prior to starting exercise program will be obtained and then compared to the data after 12 weeks of an intradialtyic biking program
88944196|NCT01877876||Patient undergoing spine surgery|
88944197|NCT01877889|Experimental|Part 1: Cana|Each volunteer will receive 300 mg of canagliflozin once daily for 4 days.
88944198|NCT01877889|Experimental|Part 2: Sequence 1 (Dapa/Cana)|Each volunteer will receive 10 mg of dapagliflozin once daily for 4 days (treatment period 1) followed by 300 mg of canagliflozin once daily for 4 days (treatment period 2). Each treatment period will be separated by a 12- to 14-day washout period (with no medication).
88944199|NCT01877889|Experimental|Part 2: Sequence 2 (Cana/Dapa)|Each volunteer will receive 300 mg of canagliflozin once daily for 4 days (treatment period 1) followed by 10 mg of dapagliflozin once daily for 4 days (treatment period 2). Each treatment period will be separated by a 12- to 14-day washout period.
88944200|NCT01877902||Pemetrexed 500 mg/m 2|
88944201|NCT01877928|Experimental|Boussignac CPAP device|Patients previously diagnosed with obstructive sleep apnea and who are undergoing abdominal or peripheral surgery will have the Boussignac CPAP mask applied for 1 hour starting immediately post-extubation
88944202|NCT01877928|Active Comparator|standard CPAP|Patients previously diagnosed with obstructive sleep apnea who are undergoing peripheral or abdominal surgical procedures will receive the standard-of-care for obstructive sleep apnea. This typically involves CPAP application only at night
88944203|NCT01877954||IPDI Qvar|ICS initiation as Extra-fine hydrofluoroalkane beclometasone dipropionate
88944204|NCT01877954||IPDI FP|ICS initiation as fluticasone propionate
88944205|NCT01877967|Experimental|Intervention|This group will intake the recommended daily amount of the food supplement VSL#3 (two sachets of the supplement in powder form) every day for twelve weeks. The two sachets will either be taken together or one in the morning and one in the evening.
88944206|NCT01877967|Placebo Comparator|Placebo|This group will intake two sachets (2x4.4g) of a placebo each day for 12 weeks. The placebo is in the same powdered form as the food supplement taken by the intervention group. The two sachets will either be taken together or one in the morning and one in the evening.
88944207|NCT01878058|Other|MRI Scan|Patients will receive an extra MRI scan in addition to their routine scan.
88944208|NCT01878071||Single group cross sectional|
88944209|NCT01878110|Experimental|COMB|
88944210|NCT01878123|Experimental|AMP-110|Escalating doses of AMP-110
89463264|NCT06326671|Experimental|Test Product Tiotropium Bromide Inhalation Powder (Strength: 18 mcg)|The subjects randomly received single oral inhalation dose of Tiotropium bromide inhaling powder generic product.
89463265|NCT06326671|Active Comparator|Reference Product (Spiriva®Handihaler®, Strength: 18 mcg)|The subjects randomly received single oral inhalation dose of the reference listed drug (RLD) Spiriva®Handihaler®.
88944211|NCT01878123|Placebo Comparator|Placebo|
88944212|NCT01878136|Active Comparator|Intraventricular tPA|"Tissue Plasminogen Activator (tPA)~Dose: 1 mg Q8 hr x 12 doses, or until blood is cleared from the ventricles and cisterns Adminstration: Intraventricular; via previously placed external ventricular drain"
88944213|NCT01878136|Placebo Comparator|Placebo|"Placebo~Dose 1 mL sterile saline"
88944214|NCT01878188|Experimental|BC-819/PEI and BCG alternating|4 or 6 weekly treatments of BC-819/PEI alternating with 6 treatments of BCG
88944215|NCT01878188|Experimental|BC-819/PEI and BCG Vaccine sequential|4 weekly treatments of BC-819/PEI followed by 6 weekly treatments of BCG
88944216|NCT01878188|Experimental|twice-weekly treatments of BC-819 and BCG|6 twice-weekly treatments of BC-819/PEI and BCG
88944217|NCT01878201|Experimental|Fimasartan 30 mg|Take one capsule filled with a Fimasartan 30 mg in the every morning
88944218|NCT01878201|Active Comparator|Valsartan 80 mg|Take one capsule filled with a Valsartan 80 mg in the every morning
88944219|NCT01878227|Experimental|Coenzyme A 400mg|Coenzyme A 400mg per day
88944220|NCT01878227|Active Comparator|Fenofibrate 200mg|Fenofibrate 200mg per day
88944221|NCT01878240|Active Comparator|EVAR|Endovascular repair of an Abdominal Aortic Aneurysm
88944222|NCT01878240|Experimental|Coil embolization during EVAR|coil embolization during Endovascular repair
88944223|NCT01878266|Experimental|Hypofractionated Arm (1)|A total dose of 39 Gy in daily fractions of 3 Gy, 5 Fractions per week , by conformal radiotherapy sparing of the supratentorial brain. The planning target volume included the tumor as defined by the T2-weighted MRI images with a margin of 1.5-2.0 cm. Margins were adjusted for bony structures and tentorium. With exception of steroids, no neoadjuvant, concomitant, or adjuvant systemic treatment was allowed
88944224|NCT01878266|Experimental|Hypofractionated Arm (2)|The same planning and treatment procedures will be performed. The total dose will be 4500 cGy in 15 fractions in 3 weeks; giving 300 cGy per fraction.
88944225|NCT01878266|Other|Conventional Arm (3)|The same planning and treatment procedures will be performed with 54.0 Gy in 30 fractions giving 1.8 Gy per fraction.
88944226|NCT01878279||HIV negative|
88944227|NCT01878279||HIV positive|HIV positive children in care
88944228|NCT01878305||MARS|Study patients are treated with albumin dialysis (Molecular Adsorbents recirculating system), based on the clinical judgement by the treating physician. Of the 20 patients, two did not need MARS and the rest received MARS treatment with varying treatment cycles.
88944229|NCT01878318|Experimental|RoActemra/Actemra|
88944230|NCT01878331||Roxolid|Patient do not receive an intervention in the extension study. Rather they are followed on the implant treatment from the core study which included a split-mouth design where all patients received both a Roxolid and SLActive implant.
88944231|NCT01878331||SLActive|Patient do not receive an intervention in the extension study. Rather they are followed on the implant treatment from the core study which included a split-mouth design where all patients received both a Roxolid and SLActive implant.
88944232|NCT01878357|Experimental|DHP monthly|Three mass screening and selective treatment using dihydroartemisinin-piperaquine and primaquine i.e. on month 1 (MST1), month 2 (MST2), and month 3 (MST3) with an interval of 6 weeks between each MST
88944233|NCT01878357|Experimental|DHP bi-monthly|Two mass screenings and selective treatment using dihydroartemisinin-piperaquine and primaquine i.e. on month 1 (MST1) and month 3 (MST3) with an interval of 3 months.
89463266|NCT06326658|Experimental|Bufei Yishen Prescription|Bufei Yishen formula consists of Radix Panax Ginseng 6g, Radix Astragali 15g, Cornu Cervi Pantotrichum 12g, Fructus Lycii 12g, Fructus Schisandrae Chinensis 9g, Fructus Epimedium Brevicornum 9g, Fructus Pelargonium Chinense 9g, Radix Paeoniae Lactiflorae 9g, Rhizoma Dillonis 9g, Fructus Ziziphiroxylon 9g, Fructus Schisandrae Chinense 15g, Pericarpium Citriodora 9g
89463267|NCT06326658|Placebo Comparator|Bufei Yishen Prescription placebo|Bufei Yishen Prescription placebo is prepared by adding 5% of the drug on the basis of dextrin and bitter agent, and its appearance, weight, color and smell are consistent with Chinese medicine granules.
89463268|NCT06326645|Experimental|Crofelemer Group|
88944234|NCT01878357|No Intervention|Arm 3|Without MST
88944235|NCT01878370|Experimental|High risk|Feedback reports focusing on the identification and management of patients who appear to have poorly managed diseases and who may require recall into clinic.
88944236|NCT01878370|Experimental|Best Practice|Feedback reports focusing on the achievement of optimal care targets for patients with chronic disease.
88944237|NCT01878396||Mutated Anti-B-RAF|Fourth stage Melanoma patients with both measurable and not measurable lesions undergoing treatment with selective B-RAF inhibitors.
88944238|NCT01878409||Parkinson Disease|Patients with Parkinson Disease
88944239|NCT01878409||Healthy Subjects|Healthy Subjects
89017921|NCT05839691||Home Visitors|Home Visitors/Educators employed by Home Visiting Programs that have or will be participating in past or future projects.
89017922|NCT05839691||Supervisors|Supervising staff of Home Visiting Programs that have or will be participating in past or future projects.
89017923|NCT05834036|Experimental|Healthy Controls|
89017924|NCT05828355|No Intervention|Clinic-based Rehabilitation|Individualised clinic-based face-to-face sessions with a physiotherapist in public or private rehabilitation facility
89017925|NCT05828355|Experimental|Knee Care@Home|Individualised synchronous internet-based remote sessions at home via conferencing software under the supervision of a certified exercise and health coach as a complement to conventional clinic-based rehabilitation sessions.
88944240|NCT01878422|Experimental|Arm A: FOLFIRI or FOLFOX + Bevacizumab|"BEVACIZUMAB: Day 1,1st cycle 5 mg/kg IV infusion of 90 min Day 1, 2nd cycle if well tolerated, 5 mg/kg IV infusion of 60 min Day 1, 3rd cycle and subsequent cycles if well tolerated, 5 mg/kg IV infusion of 30 min after 5-FU bolus~FOLFIRI Day 1: Irinotecan 180 mg/m2 IV infusion 30-90 min~Day 1,2:~L-Folinic acid 100 mg/m2 IV infusion of 2 hours 5-Fluorouracil 400 mg/m2 as a bolus 5-Fluorouracil 600 mg/m2 continuous IV infusion of 22 hours~- FOLFOX Day 1: Oxaliplatin 85 mg/m2 IV infusion of 2hours~Day 1,2:~L-Folinic acid 100 mg/m2 IV infusion of 2 hours 5-Fluorouracil 400 mg/m2 as a bolus 5-Fluorouracil 600 mg/m2 continuous IV infusion of 22 hours"
88944241|NCT01878422|Experimental|Arm B: FOLFIRI or FOLFOX|If FOLFIRI: FOLFIRI as specified in arm A without Bevacizumab If FOLFOX: FOLFOX as specified in arm A without Bevacizumab
89463269|NCT06326632|Experimental|CL-AE group|The CL-AE group received a 12-week constant-load aerobic training besides the respiratory retraining program.
89463270|NCT06326632|Experimental|G-AE group|The G-AE group received a 12-week intensity- and duration-graded aerobic training in addition to the respiratory re-training.
89463271|NCT06326632|Active Comparator|Control group|The control group received the respiratory re-training only for 12 consecutive weeks.
88944242|NCT01878422|Experimental|Arm C: FOLFIRI or FOLFOX|Arm C: FOLFIRI or FOLFOX: for patients from arm A: FOLFIRI or FOLFOX (the CT schedule not received in 1st line trial, as defined in arm B)
88944243|NCT01878422|Experimental|Arm D: FOLFIRI or FOLFOX plus CETUXIMAB|Arm D: FOLFIRI or FOLFOX plus CETUXIMAB: for patients from arm B: FOLFIRI or FOLFOX (the CT schedule not received in 1st line trial, as described in arm B) plus CETUXIMAB
88944244|NCT01878422|Experimental|Arm E: FOLFIRI or FOLFOX plus BEVACIZUMAB|for patients from arm B: FOLFIRI or FOLFOX (the CT schedule not received in the 1st line trial, as defined in arm B) plus BEVACIZUMAB
88944245|NCT01878422|Experimental|Arm F: FOLFIRI or FOLFOX plus BEVACIZUMAB and CETUXIMAB;|for patients from arm B: FOLFIRI or FOLFOX (the CT schedule not received in the first-line trial, as defined in arm B) plus BEVACIZUMAB and CETUXIMAB; cycle to be repeated every 2 weeks, whilst cetuximab will be administered weekly.
88944246|NCT01878448|Experimental|Anlotinib|
88944247|NCT01878474|Experimental|Single ascending dose in Caucasian men|
88944248|NCT01878474|Experimental|Age-effect in Caucasian men|
88944249|NCT01878474|Experimental|Gender-effect in Caucasian women|
88944250|NCT01878474|Experimental|Single ascending dose in Japanese men|
88944251|NCT01878474|Placebo Comparator|Placebo: Single ascending dose in Caucasian men|
88944252|NCT01878474|Placebo Comparator|Placebo: Age-effect in Caucasian men|
88944253|NCT01878474|Placebo Comparator|Placeo: Gender-effect in Caucasian women|
88944254|NCT01878474|Placebo Comparator|Placebo: Single ascending dose in Japanese men|
88944255|NCT01878487|Other|Only one arm|All patients will receive the same treatment, i.e. there is no randomization. There is therefore only one arm, all patients will by treated as per standard practice with thrombus aspiration and stenting as required, the lumen size of the vessel will be assessed with intravascular ultrasound at baseline, after thrombus aspiration and after stenting.
88944256|NCT01878513|Experimental|Low-dose-titration condition|Poor and intermediate CYP2D6 metabolizers will be randomized to either low-dose-titration condition or treatment-as-usual condition. In the low-dose-titration condition, patients will be treated with risperidone 0.5mg bid for 5 days, then 1mg bid for 5 days, which may be increased to 1.5mg bid for another 5 days.
88944257|NCT01878513|Experimental|Treatment-as-usual condition|Poor and intermediate CYP2D6 metabolizers will be randomized to either low-dose-titration condition or treatment-as-usual condition. In the treatment-as-usual condition, patients will be treated with risperidone 1mg bid for 5 days, then 2mg bid for 5 days, which may be increased to 3mg bid for another 5 days.
89463272|NCT06326619||SYST|Systemic treatment only. Systemic treatment was defined as the application of chemotherapy, antibody, or immunotherapy (alone or in combination) starting within 12 months after diagnosis (definition for both groups)
89463273|NCT06326619||PTR+SYST|primary tumor resection and systemic treatment At least one of the following surgical procedures were performed: German procedure codes OPS 5-455.*, 5-456.*, 5-484.*, 5-485.*
89463274|NCT06326606|Active Comparator|MLS101|MLS101 capsule(s) administered orally as a once a day dose
89463275|NCT06326606|Placebo Comparator|Placebo|Active treatment matching capsules will be administered orally as a once a day dose
88944258|NCT01878513|Experimental|Open-label treatment-as-usual condition|Extensive and ultrarapid CYP2D6 metabolizers will be treated open-label in the treatment-as-usual condition. Patients will be treated with risperidone 1mg bid for 5 days, then 2mg bid for 5 days, which may be increased to 3mg bid for another 5 days.
88944259|NCT01878539|Experimental|Health Center training|The intervention will consist of a patient training programme involving the provision of information and practical training concerning their condition and its treatment, as well as how to use a portable blood coagulation monitoring device and adjust their anticoagulant dose.
88944260|NCT01878552||ARDS|Mechanically ventilated patients with Acute Respiratory Distress Syndrome
88944261|NCT01878565|Experimental|Drug treatment|Drug: Given four times in week 0, 4, 12 and 24. At each time of treatment, the patients will be hospitalized and treated with 800 unit of HBIG intramuscularly at day 0, 1, 2, 3 and 4, then were treated with 75 μg of GM-CSF subcutaneously at day 2, 3, 4, 5 and 6, and finally were injected 20μg of HBV vaccine subcutaneously at day 6.
88944262|NCT01878565|Other|GM-CSF control|GM-CSF was given four times as control in week 0, 4, 12 and 24. At each time of treatment, the patients will be hospitalized and treated with GM-CSF intramuscularly or subcutaneously at day 2, 3, 4, 5, 6.
88944263|NCT01878578|Experimental|Eslicarbazepine acetate|ESL 600 mg tablets
88944264|NCT01878578|Active Comparator|phenytoin|Hidantina® 100 mg tablets
88944265|NCT01878578|Placebo Comparator|Placebo|Placebo tablets
88944266|NCT01878591||Women in active second stage of labour|Ultrasound examinations
88944267|NCT01878630|Experimental|Remote Patient Management|intervention group
88944268|NCT01878630|Active Comparator|Usual Care|control group
88944269|NCT01878643|Placebo Comparator|Drug: Placebo|normal saline 2 mL nebulized Q 8 hours placebo for gentamicin or vancomycin
88944270|NCT01878643|Experimental|Drug: vancomycin or gentamicin|vancomycin 120 mg every 8 hours or gentamicin 80 mg every 8 hours
88944271|NCT01878695|Experimental|IV and oral n-acetylcysteine|"50-150mg/kg of n-acetylcysteine intravenously once a week for at least two weeks.~600mg n-acetylcysteine orally twice daily except on day of infusion"
88944272|NCT01878708|Experimental|PEG-L-asparaginase/Dexamethasone|Patients will receive Oncaspar® (PEG-asparaginase) at a dose of 2,000 IU/m2 administered intramuscularly on day 3 of each 3 week cycle, with dexamethasone 40mg given orally on days 1-4.
88944273|NCT01878721||Staphylococcus aureus bacteremia|PET/CT in patients with Staphylococcus aureus bacteremia
89463276|NCT06326593|Experimental|Group (A): Wii aerobic training|This group included 38 children with inhalation injury post thermal burn; they will receive Wii aerobic training and conservative chest care.
89017926|NCT05826912|Active Comparator|Intervention 1: Atorvastatin calcium (ATOR)|By Mouth (PO) Twice a day (BID) 80 mg/day, with no loading dose, for 28 days
89463277|NCT06326593|Sham Comparator|Group (B): control group|This group included 38 children with inhalation post thermal burn; they will receive conservative chest care.
89463278|NCT06326567|No Intervention|Baseline Phase|Each site will complete an 18-month Baseline Phase, in which patients and sites are observed during a period of usual care, prior to introducing the C4 Program intervention. In this phase, a sample of newly diagnosed patients will be recruited and enrolled in the Baseline Group, and data will be collected on them via patient surveys and EHR data abstraction over a period of four months for most outcomes, except for overall survival, which will be assessed at 12 months after diagnosis
89463279|NCT06326567|Experimental|Implementation|new sample of newly diagnosed patients (excluding anyone from the Baseline Phase) will be recruited and enrolled in the Implementation Group, and the same data will be collected on them that was collected in the Baseline Group, at the same time points
89463280|NCT06326554|Experimental|STEP2|Moderate-to-severe symptoms on the ESAS-r+ symptom assessment tool will trigger an email to the study team and the study triage nurse. The study triage nurse will review the scores via Epic and call the patient within 2 business days to offer immediate advice by phone. During the phone call, the APN will offer to schedule a formal in-person or virtual palliative care clinic (PCC) visit. Participants agreeing to the PCC referral subsequently receive at least monthly in-person and/or virtual PCC follow-up visits until study end, based on patient needs and care provider preference.
89463281|NCT06326541|Experimental|music therapy|music therapy
89463282|NCT06326528||SGLT2 group|First group will receive SGLT2 (Dapaglifozin or Empagliflozin) inhibitors one month before surgery and three months after surgery.
89463283|NCT06326515|Experimental|Experimental: Treatment Group|"Experimental: Treatment Group~Experimental Group:~Participants in the experimental group would receive 8-10 session of psychoeducational based Program.~Waitlist control Group:~Participants in the Control group would not receive psychoeducational Intervention"
89463284|NCT06326515|No Intervention|No Intervention: Control Group|"No Intervention: Control Group~Control Group:~Participants in the control group did not receive the said psychoeducational intervention"
88944274|NCT01878721||Salmonella spp. bacteremia|PET/CT in patients with Salmonella spp. bacteremia
88944275|NCT01878721||Endocarditis|PET/CT in patients with infective endocarditis
88944276|NCT01878721||Pacemaker infection|PET/CT in patients with pacemaker infection
88944277|NCT01878721||Vasculitis|PET/CT in patients with vasculitis
88944278|NCT01878734|No Intervention|Control|This arm will act as a control and will not receive Micronutrient Powders
88944279|NCT01878734|Experimental|Micronutrient Powders|This is the treatment arm, which will be receiving Micronutrient Powders (MNP)
88944280|NCT01878747|Experimental|P-TIPS group|Provider Tailored Intervention for Perioperative Stress (P-TIPS) aims at reducing preoperative anxiety in children via modifying adults' behavior.P-TIPS program is developed from the proximal-distal theory that suggested that in acute procedural settings specific adult behaviors directly affect children's distress and coping behaviors.
88944281|NCT01878747|No Intervention|Control Group|Subjects in this group will not be trained with the P-TIPS method. They will receive a 2-hour seminar on the management of preoperative anxiety and postoperative pain and otherwise will provide standard care to patients.
88944282|NCT01878773|Other|High Quality Volume CT Scan; MRI Scan|Patients will have the High Quality volume CT scan immediately after their CT scan followed by MRI Scan.
88944283|NCT01878838|Active Comparator|Catalys Treated Eyes|Patient's aged 22 and older with visually significant cataracts undergoing Femtosecond Laser Assisted Cataract Surgery w/ Catalys Laser
88944284|NCT01878838|Active Comparator|LenSx Treated Eyes|Patient's aged 22 and older with visually significant cataracts undergoing Femtosecond Laser Assisted Cataract Surgery w/ LenSx Laser.
88944285|NCT01878851||pulpotomy|
88944286|NCT01878864|Experimental|Bupivacaine lozenge|Single dose administration of a 25 mg bupivacaine lozenge before the scaling and root planning was performed.
88944287|NCT01878864|Active Comparator|Lidocaine-adrenalin injection|Xyloplyin Dental Adrenalin (20 mg/ml lidocaine, 12.5 microgram/ml adrenaline). Frequency and duration of injections was decided by the dentist preforming the scaling and root planning.
89017927|NCT05826912|Active Comparator|Intervention 2: Minocycline hydrochloride (MINO)|By Mouth (PO) Twice a day (BID) 200 mg loading dose on Day 1, then 100 mg twice daily for 6 days, then placebo twice daily for 21 days
88944288|NCT01878903||i-pad VAS|All patients will be in one arm and they will be asked for post-operative pain using verbal NRS and visual VAS with i-pad
88944289|NCT01878929|Active Comparator|Allergen(Tree, Grass, Weeds) -Held|"Allergen(Tree, Grass, Weeds)-Held~Weekly administration of Greer manufactured allergen extract at same dose and concentration patient was on prior to allergen season for the duration of patients allergen season."
88944290|NCT01878929|Active Comparator|Allergen(Tree, Grass, Weeds) -Build-up|"Allergen(Tree, Grass, Weeds) -Build-up~Weekly administration of Greer manufactured allergen extract at escalating dose and concentration patient for the duration of patients allergen season."
88944291|NCT01878942|Other|Placebo, LSD|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but two treatment conditions in the same subject.
88944292|NCT01878955||->6 4-9 mm follicles in bilateral ovaries|Between the ages of 18-35 patients diagnosed with PCOS according to the Roterdam criteria
88944293|NCT01878968|Experimental|Script and Video|Patients in the Script and CPR/Mechanical ventilation video arm will receive information on CPR and mechanical ventilation via a script and a video.
88944294|NCT01878968|Experimental|Script only|Patients in the Script only arm will receive information on CPR and mechanical ventilation via a script only.
88944295|NCT01878994|Placebo Comparator|Counselling Group|Each family will receive a single monthly meeting, a total of 8 with 10 minutes duration each one. The sessions will take place in the consultation of the paediatrician and it will be delivered by the child's nurse or/and paediatrician. The sessions' contents are about promotion of healthy eating and physical activity habits.
89017928|NCT05826912|Active Comparator|Intervention 3: Candesartan cilexetil (CAND)|By Mouth (PO) Twice a day (BID) 8 mg once on Day 1, then 16 mg daily for 27 days
89017929|NCT05826912|Placebo Comparator|Matching Placebo|By Mouth (PO) Twice a day (BID) 2 capsules 2x/day
89463285|NCT06326476|Experimental|siplizumab|All participants will receive a 40 mg subcutaneous dose of siplizumab from week 0 to week 4 then at weeks 6 and 8.
89463286|NCT06326463|Experimental|CD70- CAR T cell Therapy|Patients will receive autologous (their own) cells.
89501893|NCT03516487|Experimental|MAD HV: SYNB1618 (1 x 10^11 CFU)|HV subjects receive oral SYNB1618 (1 x 10^11 CFU) in a chilled buffered solution TID for 7 days in the MAD study (Part 2).
88944296|NCT01878994|Experimental|Nereu Group|The Nereu treatment program is an intensive family-based behavioural multi-component lifestyle intervention. Consist in an intensive treatment of 8 months duration (from October to May, that is, an academic year). The intervention is a multidisciplinary intervention consisting in 4 structured components: (a) physical activity training for children, (b) family theoretical and practical sessions for parents, (c) behaviour strategies, that involves both parental and child participation (d) weekend extra activities.
88944297|NCT01879007|Experimental|group 1|received one intravenous administration and one oral medication with interval of 1 week,
88944298|NCT01879007|Experimental|group 2|received one oral administration and one intravenous medication with interval of 1 week
88944299|NCT01879020|Experimental|TA-8995 1 mg|
88944300|NCT01879020|Experimental|TA-8995 2.5 mg|
88944301|NCT01879020|Experimental|TA-8995 5 mg|
88944302|NCT01879020|Experimental|TA-8995 10 mg|
88944303|NCT01879020|Experimental|TA-8995 25 mg|
88944304|NCT01879020|Placebo Comparator|Placebo (TA-8995 1mg)|
88944305|NCT01879020|Placebo Comparator|Placebo (TA-8995 2.5mg)|
88944306|NCT01879020|Placebo Comparator|Placebo (TA-8995 5mg)|
88944307|NCT01879020|Placebo Comparator|Placebo (TA-8995 10mg)|
89463287|NCT06326450|Experimental|Experimental: Augmented Reality Enhanced Simulation (Treatment group)|Participants will experience augmented simulations with a holographic mixed-reality setting based on different workplace scenarios such as medical crisis via Augmented Reality (AR) headset.
89463288|NCT06326450|No Intervention|Traditional In Situ Simulation (Control group)|Participants will experience in-person simulations of different workplace scenarios such as medical error and workplace harassment
89463289|NCT06326437|Experimental|6-week dyadic intervention|A 6-week psychosocial dyadic programme will comprise 1 weekly 60-90min face-to-face session, followed by 5 weekly internet-based sessions.
88944308|NCT01879020|Placebo Comparator|Placebo (TA-8995 25mg)|
88944309|NCT01879033|Active Comparator|Obese adolescents|Those with BMI more than or equal to 95th percentile. This group was further divided into two subgroups on the basis of Oral Glucose Tolerance Test (OGTT) into normal and impaired glucose tolerance groups. Reactive hyperemia peripheral artery tonometry (Rh-PAT)score and blood levels for glucose, insulin, lipids and adipocytokines will be measured in the study.
88944310|NCT01879033|Placebo Comparator|Lean adolescents|BMI between 5th-85th percentile.Reactive hyperemia peripheral artery tonometry (Rh-PAT)score and blood levels of glucose, insulin, lipids and adipocytokines will be measured in the study.
88944311|NCT01879046|Experimental|Surgical intervention|Blood, bone marrow and Hoffa's fat pad samplings during surgical intervention
88944312|NCT01879111|Experimental|state-of-art depression screening + patient-targeted feedback|Using a randomised-controlled study design half of the patients will receive a patient-targeted written screening feedback. This feedback contains information about depression in general, depression-severity adapted treatment guidelines and contact-information for treatment.
88944313|NCT01879111|No Intervention|state-of-art depression screening|
88944314|NCT01879124||Kidney transplant recipients|All de novo renal allograft recipients transplanted at the University Hospitals Leuven between March 2004 and October 2007
88944315|NCT01879137||healthy adults|
88944316|NCT01879137||Patients with a polyuria-polydipsia syndrome|
89206171|NCT04442334||The LITMUS Study Cohort|Prospectively recruited NAFLD patients, recruited according to The European NAFLD Registry study protocol.
89463290|NCT06326437|No Intervention|Usual care|The control group to receive the usual care provided by the clinical team in the hospital.
89463291|NCT06326424||Observational DELIRIUM cohort|We will follow up to 60 adults 65+ years old with dementia or suspected dementia who are likely to be in the emergency department, observation unit, or hospital for 48 hours. We will follow them for up to 48 hours while they wear an FDA approved biosensor watch and perform delirium checks.
89463292|NCT06326359|Active Comparator|autologous stromal vascular fraction derived from denovo|autologous stromal vascular fraction derived from denovo in male androgenic alopecia
89463293|NCT06326359|Active Comparator|autologous stromal vascular fraction after platelet rich plasma enhanced donner site|autologous stromal vascular fraction after platelet rich plasma enhanced donner site in male androgenic alopecia
89463294|NCT06326307|Experimental|Group 1|Children who received puppet behavior guidance during their first visit and tell-show-do guidance in their second visit, 2 weeks later. (P-TSD)
89463295|NCT06326307|Experimental|Group 2|Children who received the tell-show-do behavior guidance during their first visit and puppet behavioral guidance in their second visit, 2 weeks later.(TSD-P)
89463296|NCT06326294|Other|Thermo ablation treatment|"Participants allocated in this group will be treated with thermo ablation. Before TA, perform biopsies of any acetowhite lesions by colposcopy and/or positive by AVE and an endocervical curettage (ECC); In women who do not have any lesions noted by colposcopy or AVE, one random cervical biopsy at the squamocolumnar junction and an endocervical curettage (ECC) will be obtained.~TA is performed during the same exam (immediately following biopsies/ECC)TA will be done according to the manufacturer's instructions and specifications."
89463297|NCT06326294|Other|LEEP treatment|Participants allocated in this group will be treated with LEEP. LEEP will be done according to standard procedure. No biopsies are taken, only LEEP is performed, unless clinically indicated.
89463298|NCT06326281|Active Comparator|External oblique intercostal plane block group|A linear ultrasound probe will be placed in the sagittal plane between the mid-clavicular and anterior axillary lines at the 6th rib level, with the orientation marker of the linear ultrasonography probe cranially.The ultrasonography probe will then be rotated with the cranial end directed slightly medially and the caudal end laterally to obtain a paramedian sagittal oblique view with a short-axis view of the ribs, approximately 1 to 2 cm medial to the anterior axillary line. It will be injected between the external oblique and intercostal muscles using the hydrodissection method of the tissue plane between the ribs, and then the peripheral block needle will be directed caudally towards the eighth rib.A total of 20 mL of 0.25% bupivacaine will be injected, a negative aspiration will be made with the 'in-plane' method parallel to the ultrasonography probe, and the local anesthetic distribution will be monitored with ultrasonography during the injection.
89463299|NCT06326281|Active Comparator|Oblique subcostal TAP block group|The linear ultrasonography probe was placed from the end of the xiphoid process of the sternum, parallel to the right costal border and oblique to the sagittal plane, and then the rectus abdominis muscle, posterior rectus sheath and transversus abdominis muscle located deep in the posterior rectus sheath. After the current image is obtained, the area between the rectus sheath and the fascia of the transversus abdominis muscle is taken as the target and the peripheric block needle is entered from the side of the xiphoid process parallel to the ultrasonography probe, advanced towards the inferolateral with the 'in-plane' method and negative aspiration is performed to total 20 mL 0.25% bupivacaine will be injected and local anesthetic distribution will be monitored with ultrasonography during the injection. The procedure will be performed unilaterally, observing that the transversus abdominis muscle is pushed posteriorly during the injection.
89463300|NCT06326281|Active Comparator|Local anesthetic infiltration group|4 trocars will be used by the surgical team during the operation, and these trocars will be placed 10 mm infraumbilical, 10 mm in the middle epigastrium, 5 cm below the xiphoid, 5 mm in the midclavicular line and in the right subcostal region, and 5 mm in the anterior axillary line. Before trocar placement, 0.25% bupivacaine will be applied to the skin, fascia, muscle and preperitoneal area in accordance with the infiltration rules. A total of 20 mL of 0.25% bupivacaine will be used, 6 mL for 10 mm trocar sites and 4 mL for 5 mm trocar sites.
89463301|NCT06326281|Sham Comparator|Control Group|Standard multimodal analgesia will be applied and will be taken as a control group.
89501894|NCT03516487|Placebo Comparator|MAD HV: Placebo|HV subjects receive oral placebo in a chilled buffered solution TID for 7 days in the MAD study (Part 2).
88944317|NCT01879150|Experimental|CYCLAPLEX bone anchors|"Following a 28-day screening period, eligible subjects requiring surgical correction for HV deformity (1st IMA >12degree, =<20 degree) will be enrolled to undergo HV deformity correction procedure with CYCLAPLEX under local or spinal anesthesia.~The device is implanted via small holes drilled in 1st and 2nd metatarsals. Complementary normal medical procedures such as bunionectomy, soft tissue release and HV angle correction will be performed as required.~Subjects will be followed-up for 50 weeks post-procedure."
88944318|NCT01879163|Experimental|Group A|The first six volunteers will receive an intradermal injection of 1x10^7 pfu MVA85A-IMX313 (non-randomised).
89463302|NCT06326268|Other|Photobiomodulation|• Patients: In induction of acute myeloblastic leukemia OR Allografts in first remission with myeloablative conditioning OR Autografts in the context of aggressive lymphoma;
89463303|NCT06326255|Experimental|Laughter Yoga Group|The intervention is a laughter yoga program consisting of 12 sessions, two 1-hour sessions per month.
89463304|NCT06326255|No Intervention|wait-list-control group|Participants will receive the same intervention after the 3-Months Follow-up (T2).
89463305|NCT06326242||Solid Tumor|Phase 1 patient with solid tumor
89463306|NCT06326229||Musculoskeletal patients|Patients suffering from musculoskeletal problems referred by a family physician for management in primary care physiotherapy services.
89463307|NCT06326216||Observational (Cohort I)|Prostate cancer patients undergo blood and urine sample collection on study. Patients' medical records are also reviewed.
88944319|NCT01879163|Active Comparator|Group B|12 subjects receiving intradermal injection of 5x10^7 pfu MVA85A-IMX313 (following completion of group A, subjects will be randomised to either group B or group C).
88944320|NCT01879163|Active Comparator|Group C|12 subjects receiving intradermal injection of 5x10^7 pfu MVA85A (following completion of group A, subjects will be randomised to either group B or group C).
89463308|NCT06326216||Observational (Cohort II)|Female urology clinic patients and female volunteers undergo blood and urine sample collection on study.
89463309|NCT06326203|Experimental|EMBRYONIC STEM CELLS|Cellular Therapy Treatment: The treatment will consist of **20 participants (n=20) who will receive treatment with expanded mesenchymal stem cells (MSCs). The patient will undergo a surgical debridement procedure for the ulcer to be in its optimal condition (Visit 1). Subsequently, the patient will receive MSC application via perilesional injections and a biocovering produced by the study team, also containing the same cells (single session - the MSC-containing dressing will remain in contact with the ulcer for 7 days). After removal of the biological dressing, the ulcer will receive local care with a topical hydrogel dressing, dry gauze, and a crepe bandage, with a minimum of one change per day.
89463310|NCT06326203|Active Comparator|CONVENTIONAL DRESSING (Control Group)|The control group will consist of 20 participants (n=20) who will receive local care for the ulcer. The patient will undergo a surgical debridement procedure for the ulcer to be in its optimal condition (Visit 1). Subsequently, the patient will receive the application of a conventional dressing with Hydrogel, dry gauze, and a crepe bandage. The patient will be instructed to change the dressing at least once a day.
89463311|NCT06326190|Active Comparator|Control group: local standard of care (LOC)|"According to local standard practice, treatment in the control arm is left to the investigator's discretion.~Hydroxyurea~Bevacizumab~Sunitinib~Octreotide (Sandostatin LAR)~Everolimus~No treatment (observation with regular follow-up and best supportive care)"
89463312|NCT06326190|Experimental|Experimental group: 177Lu-DOTATATE|Patients will receive 177Lu-DOTATATE with a total dose of 7.4 GBq/cycle every six weeks for four cycles as an IV infusion
89463313|NCT06326164|Active Comparator|Group A|Control group.
89463314|NCT06326164|Active Comparator|Group B|Experimental group.
89501895|NCT03516487|Experimental|MAD PKU: SYNB1618 (7 x 10^10 CFU)|Subjects with PKU receive oral SYNB1618 (7 x 10^10 CFU) in a chilled buffered solution TID for 7 days in the MAD study (Part 2).
88944321|NCT01879189|Experimental|Decision Aid|Those in the decision aid arm of the study will be given access to the breast cancer screening decision aid.
88944322|NCT01879189|No Intervention|Standard of Care|Those in the standard of care arm will not be given access to the decision aid.
88944323|NCT01879202|Active Comparator|Methylphenidate modified release|The active agents is racemic methylphenidate hydrochloride, modified release, a mild central nervous system stimulant (pharmacotherapeutic group: psychostimulants). Study medication will be taken once daily. Initially patients will be provided with 20mg and 30mg capsules of study medication. They are instructed to take 20mg within the first week and within the second week 30mg capsules. Visit 2 is scheduled two weeks after baseline and at Visit 2 patients will be provided with 40mg capsules and instructed to take them for the rest of the study.
89501896|NCT03516487|Placebo Comparator|MAD PKU: Placebo|Subjects with PKU receive oral placebo in a chilled buffered solution TID for 7 days in the MAD study (Part 2).
89501897|NCT00510055|Experimental|A|scars receive subdermal manipulation ONLY
89501898|NCT00510055|Experimental|B|scars receive subdermal manipulation AND injection of a filler
89463315|NCT06326151|Active Comparator|Health Education Programme|"Why: Upon discharge from the hospital, at the end of the baseline assessment, caregivers will receive instructions and recommendations for maintaining an active and healthy lifestyle. This will be done by encouraging self-care and good practices in caring for their dependent family member, as part of a health education programme. The benefits of an active lifestyle and general guidelines are emphasized.~What (materials): Instructions and recommendations for a health education programme.~What (procedures): Participants will receive instructions and recommendations on how to maintain an active and healthy lifestyle, promoting self-care and good practices in caring for their dependent family member.~How: The caregiver will receive the material individually at the time of referral, before being discharged from the hospital.~When and for how long: The intervention consists of a single session and details of the time and duration will be provided to participants."
89463316|NCT06326151|Experimental|Interdisciplinary Psychoeducational Programme|"Why: The programme is based on an interdisciplinary psychoeducational intervention from the fields of occupational therapy and psychology.~What (materials): projector, computer, screen, presentation of content, stationery, chairs, tables and self-recording of home tasks.~What (procedures): Patients assigned to the experimental group will follow an interdisciplinary psychoeducational programme structured and supervised at the University of Salamanca, consisting of a health education programme combined with an interdisciplinary psychoeducational programme from the perspective of psychology and occupational therapy.~Who will carry out the interventions: modules: (I) understanding the syndrome or disease and managing difficult everyday caring situations or behaviours, (II) emotions and misconceptions about caring, and (III) self-care (Table 1).~When and for how long: Each participant will receive 4 sessions per month for 3 months, for a total of 12 sessions."
89463317|NCT06326138|Experimental|Group 1 - Roux en Y gastric bypass and Sleeve Gastrectomy|Edoxaban pharmacodynamic and pharmacokinetic will be evaluated before and 48 ± 5 hours after bariatric surgery (sleeve gastrectomy and Roux-en-Y gastric bypass).
89463318|NCT06326138|Experimental|Group 2 - Roux en Y gastric bypass|Edoxaban pharmacodynamic and pharmacokinetic will be evaluated at 12 ± 3 months following Roux-en-Y gastric bypass surgery.
89463319|NCT06326112|Experimental|Active deresuscitation|"Fluid minimization: clinical and research teams will review all intravenous orders and attempt to reduce fluids to 10-15 ml/hr.~Active deresuscitation:~Administer bolus furosemide 0.5 mg/kg bid or tid~Target daily negative fluid balance as follows:~Calculated positive balance:~< 3 liters -600 - -800 ml/24 hours 3-6 liters 0.8 - 1.2 liters/24 hours 6- 10 liters 1.2 - 2.0 liters/24 hours >10 liters >2.0 liters/24 hours~If bolus furosemide fails to achieve these goals, results in hypotension or tachycardia, or at the discretion of the attending intensivist, start furosemide infusion titrated on an hourly basis to achieve above goals~If single agent ineffective, consider addition of metolazone"
89463320|NCT06326112|No Intervention|Usual care|Care at the discretion of the attending team.
89463321|NCT06326099|Experimental|Brief Online Binge Eating and Drinking Intervention|The intervention is a 30 minute mobile phone program designed to address binge eating and drinking. The program addresses underlying loss of control, impulsivity, and emotion regulation common to both binge drinking and binge eating through videos, interactive activities, and psychoeducation.
89463322|NCT06326099|No Intervention|Resources Only|Campus-specific resources for how to access the university's counseling office (i.e., student mental health services), information about the Eating Disorders program at the university, and information on accessing the university's alcohol and drug awareness offices.
89463323|NCT06326086||CMT for patients receiving chemotherapy,|
89463324|NCT06326086||TKI/IO for patients receiving targeted and immunotherapy|
89463325|NCT06326073|Experimental|Group I: SP|smokers with periodontitis
89463326|NCT06326073|Experimental|Group II: P|non-smokers with periodontitis
89463327|NCT06326073|No Intervention|Group III: SH|smokers with periodontal healthy individuals
89463328|NCT06326073|No Intervention|Group IV: H|non-smokers with periodontal healthy individuals
89463329|NCT06326060|Experimental|Dosing scheme a: NNC0519-0130|Participants will receive NNC0519-0130 at 1 dose level subcutaneously (s.c.) once-weekly up to 36 weeks.
89463330|NCT06326060|Placebo Comparator|Dosing scheme a: Placebo|Participants will receive NNC0519-0130 matched placebo s.c. once-weekly up to 36 weeks.
89463331|NCT06326060|Experimental|Dosing scheme b: NNC0519-0130|Participants will receive NNC0519-0130 at 2 dose levels s.c. once-weekly up to 36 weeks.
89463332|NCT06326060|Placebo Comparator|Dosing scheme b: Placebo|Participants will receive NNC0519-0130 matched placebo s.c. once-weekly up to 36 weeks.
89463333|NCT06326060|Experimental|Dosing scheme c: NNC0519-0130|Participants will receive NNC0519-0130 at 3 dose levels s.c. once-weekly up to 36 weeks.
89463334|NCT06326060|Placebo Comparator|Dosing scheme c: Placebo|Participants will receive NNC0519-0130 matched placebo s.c. once-weekly up to 36 weeks.
89463335|NCT06326060|Experimental|Dosing scheme d: NNC0519-0130|Participants will receive NNC0519-0130 at 4 dose levels s.c. once-weekly up to 36 weeks.
89463336|NCT06326060|Placebo Comparator|Dosing scheme d: Placebo|Participants will receive NNC0519-0130 matched placebo s.c. once-weekly up to 36 weeks.
89463337|NCT06326060|Experimental|Dosing scheme e: NNC0519-0130|Participants will receive NNC0519-0130 at 5 dose levels s.c. once-weekly up to 36 weeks.
89463338|NCT06326060|Placebo Comparator|Dosing scheme e: Placebo|Participants will receive NNC0519-0130 matched placebo s.c. once-weekly up to 36 weeks.
89463339|NCT06326060|Experimental|Dosing scheme f: NNC0519-0130|Participants will receive NNC0519-0130 at 6 dose levels s.c. once-weekly up to 36 weeks.
89463340|NCT06326060|Placebo Comparator|Dosing scheme f: Placebo|Participants will receive NNC0519-0130 matched placebo s.c. once-weekly up to 36 weeks.
89463341|NCT06326060|Active Comparator|Dosing scheme g: Tirzepatide|Participants will receive tirzepatide at 6 dose levels s.c. once weekly up to 36 weeks.
89463342|NCT06326047|Experimental|Dosing scheme A (NNC0519-0130)|Participants will receive NNC0519-0130 at 3 dose levels once weekly (QW) as subcutaneous (s.c.) injection in dose escalating manner.
89463343|NCT06326047|Placebo Comparator|Dosing scheme A (Placebo)|Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods.
89463344|NCT06326047|Experimental|Dosing scheme B (NNC0519-0130)|Participants will receive NNC0519-0130 at 3 dose levels once weekly (QW) as s.c. injection in dose escalating manner.
89463345|NCT06326047|Placebo Comparator|Dosing scheme B (Placebo)|Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods.
89463346|NCT06326047|Experimental|Dosing scheme C (NNC0519-0130)|Participants will receive NNC0519-0130 at 5 dose levels once weekly as s.c. injection in dose escalating manner.
89463347|NCT06326047|Placebo Comparator|Dosing scheme C (Placebo)|Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods.
89463348|NCT06326047|Experimental|Dosing scheme D (NNC0519-0130)|Participants will receive NNC0519-0130 at 5 dose levels once weekly as s.c. injection in dose escalating manner.
89463349|NCT06326047|Placebo Comparator|Dosing scheme D (Placebo)|Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods.
89463350|NCT06326047|Experimental|Dosing scheme E (NNC0519-0130)|Participants will receive NNC0519-0130 at 7 dose levels once weekly as s.c. injection in dose escalating manner.
89463351|NCT06326047|Placebo Comparator|Dosing scheme E (Placebo)|Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods.
89463352|NCT06326047|Active Comparator|Dosing scheme F (tirzepatide)|Participants will receive tirzepatide at 6 dose levels once weekly as s.c. injection in dose escalating manner.
89463353|NCT06326034|Experimental|Dapagliflozin group|The study's outcomes measured the changes pre- and post-treatment with Dapagliflozin (week 0 to weeks 16). The following parameters being measured: HbA1c, fasting plasma glucose (FPG), postprandial plasma glucose (PPG; glucose level measured 2 hours after standardized breakfast), body weight (BW), height (Ht), waist circumference (WC), body mass index (BMI), index of central obesity (ICO), and patients' QoL.
89463354|NCT06326021|Experimental|Autologous FL-33 CAR T|Peripheral blood mononuclear cells for the production of FL-33 CAR T cells are collected from patients.
89463355|NCT06326021|Experimental|Prior-HSCT donor-derived FL-33 CAR T|Peripheral blood mononuclear cells for the production of FL-33 CAR T cells are collected from prior-HSCT donors.
88944324|NCT01879202|Placebo Comparator|Maltodextrin|Study medication has to be taken once daily. Initially patients will be provided with 20mg and 30mg capsules of study medication. They are instructed to take 20mg within the first week and within the second week 30mg capsules. Visit 2 is scheduled two weeks after baseline and at Visit 2 patients will be provided with 40mg capsules and instructed to take them for the rest of the study.
89463356|NCT06325995|Active Comparator|A (COPORT)|COPORT over 7 weeks.
89463357|NCT06325995|Experimental|B（HYPORT）|HYPORT over 5 weeks.
89463358|NCT06325982|Experimental|Triethanolamine cream group|Triethanolamine cream retention enema was given once every night before going to bed during radiotherapy until the end of radiotherapy. Triethanolamine cream retention enema was given once before going to bed the day after radiotherapy for 3 months
88944325|NCT01879215|Active Comparator|Suprapatellar Approach|Suprapatellar Approach to Intramedullary Nailing. Surgeons will be allowed to use any size intramedullary tibial nail through an suprapatellar incision and splitting the quadriceps tendon.
88944326|NCT01879215|Active Comparator|Infrapatellar Approach|Infrapatellar Approach Intramedullary Nailing. Surgeons will be allowed to use any size intramedullary tibial nail through an infrapatellar incision using either a medial parapatellar approach or a transpatellar approach. The knee will then be scanned using T1Rho MRI at 2 weeks postoperatively and 6 months postoperatively.
88944327|NCT01879254||DBS for OCD|
88944328|NCT01879267|Other|Exercise Training: HD subjects|Endurance exercise for 6 months (30 min per week) starting one week after a 6-months natural course observation
88944329|NCT01879267|Other|Exercise Training: healthy subjects|6 months of exercise training (2 times 30 min per week)
88944330|NCT01878162|Experimental|Exercise|Exercise will occur 3 times weekly for 6 months in 20-minute exercise sessions. Sessions will take place independently. Follow-up and progression of the home program will be completed in person or by video teleconferencing at regular intervals throughout the intervention phase.
89463359|NCT06325969||Women with PCOS|Women aged 18 to 45 who meet the 2003 Rotterdam criteria for PCOS.
89463360|NCT06325969||Women without PCOS|Non-PCOS women aged 18 to 45.
89463361|NCT06325956|Experimental|Metformin therapy|Metformin intervention, 1000mg daily for the first week, 1500mg daily starting in the second week until six months of treatment.
89463362|NCT06325917|Experimental|whatsApp ongoing support|70 patients will receive the usual care by DSN in the diabetes clinic through monthly visits supported by ongoing follow-up via what's App for a 3month.
89463363|NCT06325917|Placebo Comparator|usual care|monthly follow-up at the diabetes education clinic patients receiving individual care and education by diabetes nurse specialist
89463364|NCT06325891||Gastric cancer group|"Adult patients (≥18 years of age) and undergoing esophagogastroduodenoscopy~Patients with pathological diagnosis of high-grade dysplasia or gastric cancer"
89463365|NCT06325891||Control group|"Adult patients (≥18 years of age) and undergoing esophagogastroduodenoscopy~Patients with no or minimal upper GI symptoms and current EGD appear normal or minimal gastritis"
89463366|NCT06325839|Experimental|HypnoBirthing training and oxytocin massage group|Pregnant women who received HypnoBirthing training and oxytocin massage constituted the experimental group.
89463367|NCT06325839|No Intervention|The group without HypnoBirthing training and oxytocin massage|Pregnant women who did not receive HypnoBirthing training and oxytocin massage constituted the control group.
89463368|NCT06325813|Active Comparator|Active repetitive TMS|
89463369|NCT06325813|Sham Comparator|Sham repetitive TMS|
89463370|NCT06325800||Controls|Patients with arterial biomechanics values lower than or equal to the 50th percentile of the distribution, and absence of vascular target organ damage and cardiovascular disease.
89501899|NCT03659929|Experimental|Arm 1: 20 mg/day|Amphetamine Sulfate
88944331|NCT01879098|Placebo Comparator|Placebo|Placebo will be taken once daily for 6 weeks by every subject at some point in the study (crossover design).
88944332|NCT01879098|Experimental|Probiotic: Bacillus subtilis|Bacillus subtilis will be taken as a capsule once daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
88944333|NCT01879098|Experimental|Probiotic: Lactobacillus plantarum|Lactobacillus plantarum will be taken as a capsule once daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
88944334|NCT01879098|Experimental|Probiotic: Bifidobacterium animalis|Bifidobacterium animalis will be taken as a capsule once daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
88944335|NCT01879280|Experimental|osteoplastic craniotomy|Half of the study population will be randomized to traditional pterional craniotomy as the method of exposure. The other half will be randomized to osteoplastic craniotomy as the method of exposure. All other aspects of medical care will remain the same.
88944336|NCT01879280|Active Comparator|traditional pterional craniotomy|traditional pterional craniotomy
88944337|NCT01879293|Experimental|Metformin group|In this group, metformin 0.5 three times daily for one year.
88944338|NCT01879293|Placebo Comparator|Placebo group|In this group, placebo will be given twice daily for one year.
88944339|NCT01879358|Active Comparator|ORSIRO stent|ORSIRO stent group
88944340|NCT01879358|Active Comparator|NOBORI stent|NOBORI stent group
88944341|NCT01879384|Experimental|Microdialysis with CMA 70 catheter|CMA 70 catheter directly positioned in bone tissue
88944342|NCT01879397||CEA Group|Subjects with atherosclerotic stenosis of the carotid artery and are scheduled for a clinically indicated Carotid Endarterectomy (CEA) procedure to remove the atherosclerotic plaque. Prior to CEA procedure, a research ultrasound exam will be performed. The plaque tissue removed during the CEA will be collected and processed into histological slides.
88944343|NCT01879397||Normal Group|Subjects who are not scheduled for a Carotid Endarterectomy (CEA) procedure and have had no prior carotid artery interventions. Subjects will have a Research Ultrasound Exam performed.
88944344|NCT01879423|Experimental|Lamotrigine (Lamictal) D/C 5mg*5, Crossover|Single dose of lamotrigine dispersible/chewable (D/C)5mg*5 tablets at Day1 and Single dose of Lamotrigine Compressed 25mg*1 tablet at Day15
88944345|NCT01879423|Experimental|Lamotrigine (Lamictal) Compressed 25mg, Crossover|Single dose of lamotrigine compressed 25mg*1 tablet at Day1 and Single dose of lamotrigine dispersible/chewable 5mg*5 tablets at Day15
88944346|NCT01879436||Pregnant women|"Women during first trimester of pregnancy (age: 18-45)~Group contain 50 healthy pregnant women, age 18-45. Sera will be taken from: 1. the same branula that will be introduced into the pregnant women as a routine during pregnancy termination procedure.2. from the vein of volunteered pregnant women which do not terminate pregnancy. First trimester placenta will be collected after pregnancy termination.~The measure of outcome is composite and includes several changes:~Changes in:~cell death (% from tested cells)~cell cycle (% cells in G1, G2 and S phases)~cell migration (% closure in Scratch test)~cell invasion (% cells passing through membrane in Transwell assay)~RNA repertoire (Fold change)~miRNA repertoire (Fold change) Investigators will not treat the women with any drug."
88944347|NCT01879436||Non pregnant women|Group contain 50 healthy women, age 18-45. Sera will be taken from the vein of the volunteered women. Investigators will not treat the women with any drug.
88944348|NCT01879462|Experimental|Cohort A|Subjects in this cohort will receive 3 treatments (either active drug or placebo for each dose level) in 3 treatment periods (one per period). Subjects will receive GSK2878175 5 mg, GSK2878175 50 mg, and GSK2878175 200 mg in treatment period 1, 2, and 3 respectively in fasted state (with 1:3 ratio of placebo to active treatment at each treatment period).
88944349|NCT01879462|Experimental|Cohort B|Subjects in this cohort will receive 3 treatments (either active drug or placebo for each dose level) in 3 treatment periods (one per period). Subjects will receive GSK2878175 15 mg in fasted state, GSK2878175 100 mg in fasted state, and GSK2878175 100 mg in fed state in treatment period 1, 2, and 3 respectively (with 1:3 ratio of placebo to active treatment at each treatment period).
88944350|NCT01879462|Experimental|Cohort C|Subjects in this cohort will receive GSK2878175 15 mg single dose or placebo for 7 days in fasted state (with 1:4 ratio of placebo to active treatment).
88944351|NCT01879462|Experimental|Cohort D|Subjects in this cohort will receive placebo and GSK2878175 50 mg single dose or placebo for 7 days in fasted state, (with 1:4 ratio of placebo to active treatment).
88944352|NCT01879462|Experimental|Cohort E|Subjects in this cohort will receive placebo and GSK2878175 100 mg single dose or placebo for 7 days in fasted state, (with 1:4 ratio of placebo to active treatment).
89463371|NCT06325800||Cases|Patients with arterial biomechanics values higher than the 50th percentile of the distribution and/or presence of vascular target organ damage or cardiovascular disease.
88944353|NCT01879462|Experimental|Cohort F|Subjects in this cohort will receive placebo and GSK2878175 200 mg single dose or placebo for 7 days in fasted state, (with 1:4 ratio of placebo to active treatment).
88944354|NCT01879475|Experimental|032-11|032-11 topical haemostat.
88944355|NCT01879475|Active Comparator|Floseal (R)|Floseal(R) topical haemostat
88944356|NCT01879488|Active Comparator|Nebulization during pressure support ventilation|Patients ventilated in pressure support mode during nebulization
88944357|NCT01879488|Active Comparator|Nebulization during volume assist control mode|Patients ventilated in volume assist control mode during nebulization
88944358|NCT01879501|Experimental|Low Vision Self-Management Program|Intervention: The program will work with participants to choose a specific and achievable goal they wish to achieve, involve participants in the learning process, provide information, explore experiences with low vision, and solutions to develop problem solving skills to enhance self efficacy. Participants will learn new techniques to cope with their activities of daily living. In addition to this, local guest experts in the field will be sourced and invited to provide training in aspects of low vision care.
89017930|NCT05812534|Experimental|experimental group|Subjects who met the study population conditions were treated with Cadonilimab 10mg/kg + bevacizumab 7.5 mg/kg + carboplatin (AUC 5) + pemetrexed 500mg/m2. Every 3 weeks is a cycle, with a total of 4-6 cycles (the number of chemotherapy cycles is determined by the researchers). Cadonilimab 10mg/kg, bevacizumab 7.5 mg/kg and pemetrexed 500mg/m2 were then maintained until disease progression, intolerable toxicity or other causes specified in the regimen occurred. When the subject first has imaging disease progression, if the researcher judges that it is clinically beneficial and tolerant to the test drug, he will be allowed to continue treatment.
89017931|NCT05799144|Experimental|Treatment (pBI-11, TA-HPV, pembrolizumab)|Patients receive pBI-11 vaccine IM, TA-HPV vaccine IM, and pembrolizumab IV on study. Patients undergo CT or MRI and blood sample collection during screening and on study. Patients may undergo tumor biopsy during screening and on study.
88944359|NCT01879501|No Intervention|Usual Care|Usual care delivered at the Singapore National Eye Centre
88944360|NCT01879514|Experimental|Combination Group|Chinese Herb Prescription Granule, 6g, Bid, po. 48weeks plus prednisone, 0.5mg-1mg/kg·d, po. 48weeks
88944361|NCT01879514|Placebo Comparator|Placebo|Placebo of Chinese Herb Prescription Granule, 6g, Bid, po. 48weeks plus prednisone, 0.5mg-1mg/kg•d, po. 48weeks
88944362|NCT01879527|Active Comparator|Amiloride hydrochlorothiazide|5,68 mg Amiloridhydrochloride 2H20 (analogue 4,32 mg Amilorid) und 50 mg Hydrochlorothiazid. Trade name of the agent: Amilostad HCT 5/50mg tablets Manufacturer: Stada initial dose: 1 x 5/50mg once daily target dose: 2 x 5/50mg once daily Patients will be provided with capsules (size 00) containing one tablet of study medication and instructed to take these capsules once daily in the morning together with breakfast. Visit 2 will be scheduled one week after baseline and at visit 2 patients will be provided with capsules containing two tablets of study medication
88944363|NCT01879527|Placebo Comparator|Sugar pill|Patients will be provided with capsules (size 00) containing sugar and instructed to take these capsules once daily in the morning together with breakfast.
88944364|NCT01879592||Asthma + sickle cell disease|African American children affected with both sickle cell disease and asthma
88944365|NCT01879592||Sickle cell disease|African American children affected with sickle cell disease but who do not have asthma
88944366|NCT01879592||Asthma|African American children affected with asthma but without sickle cell disease
88944367|NCT01879592||Healthy control|African American children who are healthy with no chronic disease
88944368|NCT01879605|Experimental|Enema|Docusate natrium and sorbitol, 240 ml enema, the evening before surgery
88944369|NCT01879605|Active Comparator|Suppository|Bisacodyl, suppository 10 mg, the evening before surgery.
88944370|NCT01879605|No Intervention|Control grup|No intervention
88944371|NCT01879631||mild to moderate keratoconus cases|keratoconus with a central corneal thickness (CCT) over 400µm, poor corrected visual acuity (≤0.4 at Snellen visual acuity charts), contact lens intolerance, no apical scarring, no ocular or systemic problem other than keratoconus
88944372|NCT01879644|Active Comparator|Neurofeedback with Psychoeducation (NF + PE)|Neurofeedback plus Parental Psychoeducation
88944373|NCT01879644|Active Comparator|Self-Management with Psychoeducation (SM + PE)|Self-management + parental psychoeducation
88944374|NCT01879644|Active Comparator|NF+PE and additional Social Support (SU)|Neurofeedback + parental psychoeducation enhanced with social support
88944375|NCT01879644|Active Comparator|SM+PE and additional Social Support (SU)|Self-management + parental psychoeducation enhanced with social support
88944376|NCT01879670||Synergy|Patients in the Synergy group will have severe advanced heart failure (see inclusion criteria) and will have been selected by their clinical team for implantation of a CircuLite Synergy left ventricular assist device.
88944377|NCT01879670||Control|Patients in the Synergy group will have severe advanced heart failure (see inclusion criteria) and will have been selected by their clinical team to continue current optimal medical and device therapy.
88944378|NCT01879696|Experimental|Treatment|Treatment are subjects will have catheter vacuum active for the removal of fluid from the muscle compartment.
88944379|NCT01879696|No Intervention|Control|Treatment are subjects will have catheter vacuum in-active for the removal of fluid from the muscle compartment.
88944380|NCT01879709|Experimental|Yoga Training Group|Yoga Training: Participants will be imparted yoga training for twenty-one days, for one hour a day. This will include postures or Asanas (exercises) and Pranayam (Breathing protocols).
88944381|NCT01879709|Placebo Comparator|Treatment as Usual Group|Participants who will continue in the department with clinical treatment as usual. No supplementation will be provided
88944382|NCT01879709|Active Comparator|Physical Exercise Group|Physical Exercise: This group will take part in a general physical exercise program incorporating simple physical exercises for one hour daily, including Saturdays. The schedule will include fifteen minutes of brisk walking followed by light exercises.
88944383|NCT01879748|Experimental|Rasagiline|Rasagiline mesylate oral tablets (AZILECT®) are provided at dose strengths of 0.5 and 1 mg (based on rasagiline base). Rasagiline oral tablets will be dispensed for 10 consecutive days of treatment. The oral dose will be administered each day with 240 mL water at room temperature after an overnight fast of at least 10 hours.
88944384|NCT01879748|Placebo Comparator|Placebo|Placebo tablets match in size and appearance to rasagiline tablets for each dose strength. Placebo tablets will be dispensed for 10 consecutive days of treatment. The oral dose will be administered each day with 240 mL water at room temperature after an overnight fast of at least 10 hours.
88944385|NCT01879787|Experimental|physiotherapy + anodal tDCS + mCIMT|Before a anodal tDCS with duration of 13 minutes and intensity of 1mA applied at the injured motor cortex, the patient will be submitted to a 30 minutes physiotherapy protocol. Lastly the individual will realized a 45 minutes mCIMT protocol. The experimental sessions will be repeated three times per week, will be realized 10 sessions. At home the patient will spend 6 hours per day with the restraint for the paretic upper limb.
88944386|NCT01879787|Experimental|Physiotherapy + cathodal tDCS + mCIMT|Before a cathodal tDCS with duration of 9 minutes and intensity of 1mA applied at the healthy motor cortex, the patient will be submitted to a 30 minutes physiotherapy protocol. Lastly the individual will realized a 45 minutes mCIMT protocol. The experimental sessions will be repeated three times per week, will be realized 10 sessions. At home the patient will spend 6 hours per day with the restraint for the paretic upper limb.
88944387|NCT01879787|Experimental|Physiotherapy+bi-hemispheric tDCS+mCIMT|Before a bi-hemispheric tDCS with duration of 13 minutes and intensity of 1mA applied at the healthy (cathode) and injured (anode) motor cortex, the patient will be submitted to a 30 minutes physiotherapy protocol. Lastly the individual will realized a 45 minutes mCIMT protocol. The experimental sessions will be repeated three times per week, will be realized 10 sessions. At home the patient will spend 6 hours per day with the restraint for the paretic upper limb.
88944388|NCT01879787|Sham Comparator|Physiotherapy+sham tDCS+mCIMT|Before a sham tDCS with duration of 30 seconds and intensity of 1mA applied at the injured motor cortex, the patient will be submitted to a 30 minutes physiotherapy protocol. Lastly the individual will realized a 45 minutes mCIMT protocol. The experimental sessions will be repeated three times per week, will be realized 10 sessions. At home the patient will spend 6 hours per day with the restraint for the paretic upper limb.
88944389|NCT01879787|Experimental|Physiotherapy+tDCS+mental practice|Before a tDCS protocol applied during de mental practice training , the patient will be submitted to a 30 minutes physiotherapy protocol. The experimental sessions will be repeated three times per week, will be realized 10 sessions.
88944390|NCT01879787|Sham Comparator|Physiotherapy+sham tDCS+mental practice|Before a sham tDCS protocol applied during the mental practice training, the patient will be submitted to a 30 minutes physiotherapy protocol. The experimental sessions will be repeated three times per week, will be realized 10 sessions.
88944391|NCT01879787|No Intervention|Physiotherapy|The patient will be submitted to a 30 minutes physiotherapy protocol. The experimental sessions will be repeated three times per week, will be realized 10 sessions.
88944392|NCT01879813|Active Comparator|Phospholipid drink|Participants will consume a phospholipid drink daily for 6 weeks
89463372|NCT06325774|Experimental|Hypofractionated Radiotherapy|Hypofractionated Radiotherapy over 3 weeks.
88944393|NCT01879813|Placebo Comparator|Placebo milk drink|Participants will consume a placebo drink (no added phospholipids) daily for 6 weeks
89463373|NCT06325761|Experimental|Fasted dosing followed by fed dosing|A single oral dose in the fasted state at Period 1 followed by fed dosing at Period 2
89463374|NCT06325761|Experimental|Fed dosing followed by fasted dosing|A single oral dose in the fed state at Period 1 followed by fasted dosing at Period 2
89463375|NCT06325748|Experimental|SENTI-202 CAR NK cell therapy|"Part 1 Dose Finding: Sequential cohorts will receive doses of SENTI-202 using a modified 3+3 study design to determine the recommended phase 2 dose (RP2D). The starting dose will be 1 billion cells. Other doses may be explored depending on study data.~Part 2 Cohort Expansion: After determination of the RP2D, additional subjects will be enrolled in disease-specific expansion cohorts at that dose to further explore safety, biodynamics, and anti-cancer activity of SENTI-202"
89463376|NCT06325735||full term pregnancy|"Total Participants: The study included full-term pregnant women.~Exclusion Criteria: Participants were carefully selected, excluding those with specific conditions that could confound the study results. These conditions included gestational and pregestational diabetes, chronic hypertension, gestational hypertension, pre-eclampsia/eclampsia, intrauterine fetal growth restriction, preterm delivery, multiple pregnancies, and prenatally detected fetal abnormalities."
89463377|NCT06325683|Experimental|Arm I (nivolumab, relatlimab)|Patients receive nivolumab IV over 30 minutes followed by relatlimab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo MRI at baseline and every 8 weeks until progression and then at least 8 weeks after objective response. Additionally patients undergo surgery or biopsy and blood sample collection throughout study.
88944394|NCT01879839|No Intervention|Control Group|Patients who don't follow a special diet.
88944395|NCT01879839|Other|Diet Group|Patients who subsist on a special diet.
88944396|NCT01879865|Other|Non-stimulation|No auditory stimulation during dexmedetomidine infusion and recovery.
88944397|NCT01879865|Other|Stimulation|Auditory stimulation during dexmedetomidine infusion and recovery.
88944398|NCT01879878|Experimental|Verum, broccoli sprout grain|Active sulforaphane distributed in capsules each containing broccoli sprout grain
88944399|NCT01879878|Placebo Comparator|Placebo|Inactive substances (methylcellulose) with identical capsule and portion distribution
88944400|NCT01879891|Other|Non-Biopsy|"The Non-Biopsy group will complete a VO2 maximum test, are provided food 2 days prior to assessments, exercise in the metabolic chamber, have a Resting Energy Expenditure test, complete a DEXA and have blood drawn. This group will stay overnight in the metabolic chamber and have the clamp procedure. Exercise training is exactly the same for both groups.~Those who select the Non-Biopsy group, in lieu of the biopsy test, will complete an Activities of Daily Living (ADL) test that involves sub-maximal VO2 assessment. The participants will also be asked to where an accelerometer home for 4 consecutive days after the ADL test."
88944401|NCT01879891|Other|Biopsy|The Biopsy group will also complete a VO2 maximum test, are provided food 2 days prior to assessments, exercise in the metabolic chamber, have a Resting Energy Expenditure test, complete a DEXA and have blood drawn. As with the Non-Biopsy group, this group will stay overnight in the metabolic chamber and have the clamp procedure. Exercise training is exactly the same for both groups. One week following the overnight metabolic chamber visit, participants in this group will undergo a muscle biopsy. This group will not complete the Activities of Daily Living (ADL) test nor will they be asked to wear an accelerometer.
88944402|NCT01879904|Experimental|Endoscopic submucosal dissection (ESD)|Endoscopic submucosal dissection (ESD)
88944403|NCT01879917|Active Comparator|Liraglutide|1.8 mg
88944404|NCT01879917|Placebo Comparator|Saline|
89463378|NCT06325683|Active Comparator|Arm II (lomustine)|Patients receive lomustine PO on day 1 of each cycle. Cycles repeat every 42 days in the absence of disease progression or unacceptable toxicity. Patients also undergo MRI every 9 weeks until progression and then at least 6 weeks after objective response. Additionally patients undergo surgery or biopsy and blood sample collection throughout study.
89463379|NCT06325670|Experimental|BED treatment|The BED group therapy program consists of 11 sessions, followed by a 3-month follow-up session. Each 3-hour session accommodates eight patients and two psychologists. Treatment follows a manualized cognitive behavioral therapy approach, with patients receiving a complimentary manual at the start. Sessions are conducted both in-person and online using a blended care model, with about one-third delivered virtually.
89463380|NCT06325670|Other|Waitlist|The waitlist control group consists of participants who are placed on a waiting list to receive treatment. While participants in the treatment group immediately receive BED treatment (Arm 1), those in the waitlist control group do not receive active treatment initially. They remain on the waiting list for 6 months until the treatment group completes their intervention. At that point, participants in the waitlist control group also receive the same BED treatment, serving as a comparison group to evaluate the intervention's effectiveness.
89463381|NCT06325657|Experimental|RSVpreF vaccine|RSV vaccine (RSVpreF)
89463382|NCT06325657|Placebo Comparator|Placebo|Placebo
89501900|NCT03659929|Experimental|Arm 2: 40 mg/day|Amphetamine Sulfate
88944405|NCT01879930|Active Comparator|doxycycline|Zadorin-100® (doxycycline), licence number Swissmedic: 43051 Legal holder: Mepha Pharma AG, Aesch/BL
88944406|NCT01879930|Placebo Comparator|placebo|Placebo Galepharm Composition: lactose monohydrate, ceolus PH 102, croscarmellose sodium, magnesiumstearat, manufacturer: Pharmacy Hotz, 8700 Küsnacht, Switzerland
88944407|NCT01879943|Experimental|PillCam COLON 2 and Standard Colonoscopy|"Patients will have videocapsule colonoscopy after bowel preparation, followed by standard colonoscopy the next day.~Interventions:~Device: PillCam COLON 2 on D0~Procedure: Standard colonoscopy on D1"
88944408|NCT01879956|Active Comparator|OGI Method|- experimental group: use the OGI method to improve the executive functioning of patients with refractory schizophrenia.
88944409|NCT01879956|Placebo Comparator|craft activities|- control group: use of craft activities, attend the same-number of sessions, but without the intervention of therapists.
88944410|NCT01879969|Experimental|asymmetric patients, classic procedure|random selected
89463383|NCT06325644|Experimental|Ketogenic Diet|The KD will follow general principles the investigators have described with the aim to achieve blood ketones >0.5 mM, which will require most participants to consume <50 g/day carbohydrate and ~1.5 g/kg reference weight protein. Fat will comprise the remaining calories with an emphasis on monounsaturated and saturated sources from whole foods.
88944411|NCT01879969|Experimental|asymmetric patients, computer assisted|random selected
88944412|NCT01879982||Wellness Wearable System & Smartphone|
88944413|NCT01880008||Treatment|All patients included in this study were treated with temozolomide and radiotherapy after subtotal resection of a WHO grade III or IV glioma.
88944414|NCT01880034||Regional Anesthesia Section Heads|This group will consist of Regional Anesthesia Section Heads at anesthesia residency training programs.
88944415|NCT01880112|Experimental|4 gram dose|Pre-operative prophylactic dose of 4 grams of cefazolin
88944416|NCT01880112|Active Comparator|2 gram dose|Pre-operative prophylactic dose of 2 grams of cefazolin
88944417|NCT01880125|Other|Group A|Period 1: Tramadol HCI/Acetaminophen 37.5/325mg PO once with water 240ml at fasted state Period 2: Tramadol HCI/Acetaminophen 75/650mg PO once once with water 240ml at fasted state
88944418|NCT01880125|Other|Group B|Period 1: Tramadol HCI/Acetaminophen 75/650mg PO once once with water 240ml at fasted state Period 2: Tramadol HCI/Acetaminophen 37.5/325mg PO once with water 240ml at fasted state
88944419|NCT01880138|Experimental|watching animated cartoon|
88944420|NCT01880138|Placebo Comparator|not watching animated cartoon|
88944421|NCT01880151|Experimental|Prodromal AD|Presence of memory impairment Absence of impairment in activities of daily life EEG
88944422|NCT01880151|Experimental|Mild AD dementia|Presence of memory impairment Presence of impairment in activities of daily life EEG
88944423|NCT01880151|Experimental|Healthy control group|Absence of memory impairment Absence of impairment in activities of daily life Absence of known neurological conditions EEG
88944424|NCT01880164||Nonoperative|Adult spinal deformity (degenerative or idiopathic) with an ODI of 30 or greater
88944425|NCT01880177||Current smokers|Current smokers (>10 pk yrs.)
88944426|NCT01880177||Ex-smokers|Ex-smokers with a history of >10 pk yrs
88944427|NCT01880177||Never-smokers|Never-smokers, defined as ≤100 cigarettes/pipes/cigars over life
88944428|NCT01880190|Active Comparator|Ringer's Lactate|Crystalloid solution
88944429|NCT01880190|Active Comparator|HES 130/0.4 and Ringer's Lactate|Colloid solution
88944430|NCT01880203|Experimental|aspiration for Molecular Cytogenetic Analysis.|
88944431|NCT01880216|Active Comparator|Enoxaparin sodium|subcutaneous for 7±2 days and starting on Day 2 additionally the oral anticoagulant warfarin
88944432|NCT01880216|Experimental|Bemiprin sodium|Bemiparin sodium (LMWH) s.c. for 7±2 days and starting on Day 2 additionally the oral anticoagulant warfarin
88944433|NCT01880229||non-frail|Categorized as non-frail based on Fried's five phenotypic criteria (Fried L.P., et al. Frailty in Older Adults: Evidence for a Phenotype. Journal of Gerontology: 2001, Vol. 56A, No. 3, M146-M156)
88944434|NCT01880229||pre-frail|Categorized as pre-frail based on Fried's five phenotypic criteria (Fried L.P., et al. Frailty in Older Adults: Evidence for a Phenotype. Journal of Gerontology: 2001, Vol. 56A, No. 3, M146-M156)
88944435|NCT01880229||frial|Categorized as frail based on Fried's five phenotypic criteria (Fried L.P., et al. Frailty in Older Adults: Evidence for a Phenotype. Journal of Gerontology: 2001, Vol. 56A, No. 3, M146-M156)
89463384|NCT06325631|Experimental|Fluoroscopy|
89463385|NCT06325631|Experimental|Ultrasound|
89463386|NCT06325631|Experimental|Anatomic|
88944436|NCT01880242||Orsiro DES|"Subjects requiring coronary revascularization with Drug Eluting Stents (DES). subgroups: Subjects presenting with~Diabetes (all types)~Small vessels (≤2.75 mm)~Chronic total occlusion (CTO)~Acute Myocardial Infarction (incl. STEMI and NSTEMI)"
88944437|NCT01880255|Active Comparator|Active rTMS|"Active treatment will be delivered at an intensity that is 90% of the resting motor threshold (RMT). Stimulation will be delivered at 20 Hz with 25 stimulation trains of 30 stimuli each (i.e., 750 stimuli) and an intertrain interval of 30 sec. Treatment will be applied in sequential order bilaterally to the left and right dorsolateral prefrontal cortex (DLPFC). The order of bilateral stimulation (i.e. right then left or left then right) will be held constant for all 20 treatments.~Intervention: Device: Repetitive Transcranial Magnetic Stimulation"
88944438|NCT01880255|Sham Comparator|Sham rTMS|"Sham stimulation will be delivered using the same stimulation parameters and at the site of active treatment, but with only the side-edge resting on the scalp. The coil will be angled 45 degrees away from the skull in a single-wing tilt position. This method produces sound and some somatic sensation (e.g., contraction of scalp muscles) similar to those of active stimulation, but with minimal direct brain effects.~Intervention: Device: Repetitive Transcranial Magnetic Stimulation"
88944439|NCT01880268|Experimental|BCI-then-Standard Rehab Group (Group A)|Participants will take 8 weeks of BCI rehabilitation first (3 rehabilitation sessions each week, a total of 24 sessions); participants receive 100 minutes of standard rehabilitation and 20 minutes BCI rehabilitation training using BCI-controlled neurorehabilitation device during each session. After finishing 8 weeks of BCI rehabilitation, participants will take 3 standard rehabilitation therapy sessions (for 2 hours) each week for 8 weeks (a total of 24 sessions)
89017932|NCT05792137|Experimental|High saturated fat challenge meal followed by high mono-unsaturated fat challenge meal|High saturated fat mixed macronutrient challenge meal with palm oil followed by high mono-unsaturated fat mixed macronutrient challenge meal with olive oil two weeks later
89017933|NCT05792137|Experimental|High mono-unsaturated fat challenge meal followed by high saturated fat challenge meal|High mono-unsaturated fat mixed macronutrient challenge meal with olive oil followed by high saturated fat mixed macronutrient challenge meal with palm oil two weeks later
89463387|NCT06325618||Turner Syndrome|Women with karyotype verified Turner Syndrome n=100
89463388|NCT06325618||Female controls|Healthy, age-matched controls n=50
89206172|NCT04442334||The LITMUS Metacohort|Collated data and biological samples on patients with histologically characterised NAFLD prospectively recruited at contributing academic centres across Europe.
89501901|NCT03659929|Placebo Comparator|Arm 3: Placebo|Placebo, no active drug
89501902|NCT03505957|Experimental|SafeBreak Vascular Intervention|Every study participant will have SafeBreak Vasculars installed in each of their IV lines.
89463389|NCT06325605|Experimental|Observation group|"Patients in the observation group were treated with oral Bifidobacterium (0.07g/capsule, approval number: Guo Yao Zhun Zi S10950032, Shanghai Sine Pharmaceutical Co., Ltd.) 3 capsules, 3 times a day, for 8 consecutive weeks, and high-frequency rTMS. In the rTMS treatment, the transcranial magnetic stimulation device with an 8-shaped coil with a diameter of 70mm was placed on the dorsolateral area of the left prefrontal lobe of the patient. The motor threshold was set to 90%. A 10-Hz pulse sequence was applied for 4 secs followed by a 20 secs interval. 10 pulses per train were used, and the total stimulation time was 30mins per day, 4 times a week, for 8 consecutive weeks."
89501903|NCT03500263|Active Comparator|Cohorts 1 and 2: PTI-808 Active Co-admin with PTI-801 Active|Subjects will be randomized to receive either PTI-808 co-administered with PTI-801 or placebos once-a-day for a total of 14 days. A follow up visit will occur on Day 21.
88944440|NCT01880268|Experimental|Standard-then-BCI Rehab Group (Group B)|Participants will take 8 weeks of standard rehabilitation therapy first (3 sessions per week, 2 hours for each session, a total of 24 sessions). After that, participants will take 8 weeks of BCI rehabilitation (3 rehabilitation sessions each week, a total of 24 sessions); participants receive 100 minutes of standard rehabilitation and 20 minutes BCI rehabilitation training using BCI-controlled neurorehabilitation device during each session.
88944441|NCT01880281|Active Comparator|Meat diet without any vegetables or fruits|"The volunteers will follow a diet of 3 days with at least 400g of meat per day. The 3rd day, the volunteers will do a collect of 24-hour urine.~The investigational's day, they will receive 50meq of ammonium chlorid over a period of one hour in order to avoid the effect of nausea."
88944442|NCT01880281|Active Comparator|Vegetarian diet without any sources of protein|"The volunteers will follow a diet of 3 days with at least 600g of fruits and vegetables per day without any proteins (animal or vegetal like soybean). The 3rd day, the volunteers will do a collect of 24-hour urine.~The investigational's day, they will receive 1g of bicarbonate."
88944443|NCT01880294||Asian participants with chronic constipation|Asian participants diagnosed with chronic constipation using Asian Neurogastro-enterology and Motility Association (ANMA) diagnostic questionnaire.
88944444|NCT01880307|Experimental|Top-down|Infliximab and azathioprine; patients will receive 5 infliximab infusions of 5 mg/kg (IFX induction at week 0, 2 and 6, followed by 2 maintenance infusions every 8 weeks). IFX will be discontinued after 5 IFX infusions. Patients will also receive oral azathioprine 2-3 mg/kg, once daily as maintenance treatment.
88944445|NCT01880307|Active Comparator|Step-up|Prednisolon and azathioprine; Patients will receive induction treatment with oral prednisolone 1 mg/kg (maximum 40 mg) once daily for 4 weeks, then tapering of prednisolone in 6 weeks until stop, and receive oral azathioprine 2-3 mg/kg, once daily as maintenance treatment.
88944446|NCT01880333|Experimental|Children on Modified Atkin Diet|
88944447|NCT01880346|Active Comparator|100,000 IU D-50 powder|Vitamin D oil vs powder. 100,000 IU powder form of vitamin D, assessment of D3 absorption. One Dose of vitamin D powder format administered. Absorption rate monitored over 72 hour period
88944448|NCT01880346|Active Comparator|100,000 IU Maximum D3 in oil|Vitamin D oil vs powder. One Dose of 100,000 IU vitamin D oil format administered. Absorption rate monitored over 72 hour period
88944449|NCT01880372|Experimental|Alpha Lipoic Acid Assignment Group|Alpha lipoic acid assignment group will follow routine care and receive 600 mg oral administration of lipoic acid daily.
88944450|NCT01880372|No Intervention|Alpha Lipoic Acid Control Group|The control group will follow routine care alone.
88944451|NCT01880385|Experimental|bevacizumab, inflammatory breast cancer|Neoadjuvant therapy associating bevacizumab, cyclophosphamide, fluorouracil and epirubicin hydrochloride q3w, 4 cycles Adjuvant therapy by docetaxel q3w, 4 cycles +/- trastuzumab q3w, 18 cycles if tumors overexpress HER2
89501904|NCT03500263|Placebo Comparator|Cohorts 1 and 2: PTI-808 Placebo Co-admin with PTI-801 Placebo|Subjects will be randomized to receive either PTI-808 co-administered with PTI-801 or placebos once-a-day for a total of 14 days. A follow up visit will occur on Day 21.
88944452|NCT01880398||Kshar Sutra|The Kshar Sutra was a standard medicated thread smeared with Kshar of Apamarga (Achyranthus aspera), Shnuhi (Eforbia Nerrifolia) which has quality of cutting and Haridra(Curcuma Longa) which is used as a antiseptic. The ph value of the thread thus prepared was determined and its sterilization effected by ultraviolet radiation. The alkalinity of Kshar Sutra was 9.2ph.
88944453|NCT01880411|Experimental|PEK Fusion Protein Vaccine|PEK Fusion Protein Vaccine Injection 0.1mg, 0.3mg and 1.2mg One injection at one week intervals
88944454|NCT01880450|Experimental|Project Prepared|
88944455|NCT01880450|Active Comparator|TEEN-Teen Education & Employment Network|
88944456|NCT01880463|Active Comparator|Vitamin D + fish oil placebo|"Vitamin D3 (cholecalciferol), 2000 IU per day~Fish oil placebo"
88944457|NCT01880463|Active Comparator|Vitamin D placebo + fish oil|"Vitamin D placebo~Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg. of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])"
88944458|NCT01880463|Placebo Comparator|Vitamin D placebo + fish oil placebo|"Vitamin D placebo~fish oil placebo"
89463390|NCT06325605|Active Comparator|Control group|Patients in the control group were treated with oral escitalopram oxalate (manufacturer: Sichuan Kelun Pharmaceutical Co., Ltd.; approval No.: Guo Yao Zhun Zi H20080788). The initial dose was 5mg/d, for 7 consecutive days. The dose was increased to 10 mg/d according to the tolerance of the patients for another 7 consecutive days, and then to 20 mg/d according to the patient's condition and tolerance for 8 weeks.
89463391|NCT06325592||group 1|patients underwent laparoscopic hysterectomy within 3 days after LEEP
89463392|NCT06325592||group 2|patients underwent abdominal hysterectomy within 3 days after LEEP
89463393|NCT06325592||group 3|patients underwent laparoscopic hysterectomy 4 weeks after LEEP
89463394|NCT06325592||group 4|underwent abdominal hysterectomy 4 weeks after LEEP
89463395|NCT06325592||control group|Patients who underwent laparoscopic hysterectomy (LH) due to benign gynecological diseases were included in the control group.
88944459|NCT01880463|Active Comparator|Vitamin D + fish oil|"Vitamin D (cholecalciferol), 2000 IU per day~Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg. of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])"
88944460|NCT01880476|Experimental|Home visits and group program|
88944461|NCT01880489|Experimental|MI + CBST Intervention|Seven sessions of Motivational Interviewing and Cognitive Behavioral Skills Training
88944462|NCT01880489|No Intervention|Wait List Control Condition|
88944463|NCT01880502|Experimental|Belviq 10mg|
88944464|NCT01880502|Experimental|Belviq 20mg|
88944465|NCT01880502|Placebo Comparator|Placebo|
88944466|NCT01880580||Normal Group|In Group I, up to 100 women, at least 40 years of age, who have had a routine standard mammogram read as BI-RADS® 0, 1, 2, or 3 will also undergo 3D breast imaging using a cone beam CT scanner specifically designed to image the breast. Of these 100, we hope to enroll at least 30 subjects with mammograms read as BI-RADS® 0 and at least 30 read as BI-RADS® 3. The BI-RADS® 0 category refers to patients for whom additional imaging is required after a screening mammogram provided incomplete diagnostic information.
89463396|NCT06325566|Experimental|Rexlemestrocel-L + HA|Participants will receive rexlemestrocel-L 2.0 mL injection of approximately 6 million rexlemestrocel-L cells in freeze media mixed in a 1:1 by-volume ratio with hyaluronic acid (HA) solution on Day 0.
89463397|NCT06325566|Sham Comparator|Control Group|Participants will receive saline solution as a sham procedure to simulate the active treatment injection on Day 0.
89463398|NCT06325553||1|"Case group (PFB transfusion) Inclusion criteria~Newly diagnosed acute leukemia (either acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) patients underwent intensive chemotherapy~Age greater than 18 years~Participants receiving an induction chemotherapy and at least one cycle of consolidation chemotherapy~Exclusion criteria~1. Participants with positive platelet antibody detected by SPRCA method at presentation~Withdrawal or termination criteria~Loss to follow up or death before completion of first consolidation chemotherapy~Participants receiving granulocyte infusion during time of study~Participants receiving SDP transfusion during time of study"
89463399|NCT06325553||2|"Historical control group 1 (non-leukocyte depleted blood product) Inclusion criteria~Newly diagnosed acute leukemia (either AML or ALL) patients underwent intensive chemotherapy during 2018-2022~Age greater than 18 years~Participants receiving an induction chemotherapy and at least one cycle of consolidation chemotherapy~Participants receiving only non-leukocyte depleted blood products (LPB and LPPC)~Exclusion criteria~Loss to follow up or death before completion of first consolidation chemotherapy~Participants receiving granulocyte infusion during time of study"
89463400|NCT06325553||3|"Historical control group 2 (leukocyte depleted blood product) Inclusion criteria~Newly diagnosed acute leukemia (either AML or ALL) patients underwent intensive chemotherapy during 2018-2022~Age greater than 18 years~Participants receiving an induction chemotherapy and at least one cycle of consolidation chemotherapy~Participants receiving leukocyte depleted blood products (PFB and SDP)~Exclusion criteria~Loss to follow up or death before completion of first consolidation chemotherapy during 2018-2022~Participants receiving granulocyte infusion during time of study~Participants receiving non-leukocyte depleted blood products greater than 20% of all transfused blood products during induction and first consolidation chemotherapy"
89463401|NCT06325540|Experimental|theracal pt|Teeth treated with indirect pulp capping with theracal pt
89463402|NCT06325540|Experimental|therabase|Teeth treated with indirect pulp capping with therabase
89463403|NCT06325540|Active Comparator|biodentine|Teeth treated with indirect pulp capping with biodentine
88944467|NCT01880580||Diagnostic Group|The goals of Group II will be to compare the CBCT study with standard imaging for the diagnosis of breast disease in palpable or non-palpable breast lesions (having a BI-RADS® score of 4 or 5). Forty (40) women, who have had abnormalities detected by physical exam or an imaging modality and are also scheduled for breast biopsy of the index lesion, will also undergo a CBCT of the breast(s), prior to biopsy.
88944468|NCT01880606||patients with PSC-IBD|Only patients, colonoscopy with endomicroscopy
88944469|NCT01880619|Placebo Comparator|Group A|Patients in this group will receive placebo
88944470|NCT01880619|Active Comparator|Group B|Patients in this group will receive Tamsulosin
88944471|NCT01880619|Active Comparator|Group C|Patients in this group will receive Solifenacin
88944472|NCT01880632|Experimental|XELOX|Clinically diagnosed stage T2-3/N+M0,orT4aN+M0 according to CT/MRI scan, and resectable
89463404|NCT06325501|Active Comparator|misoprostol|receiving a preoperative rectal dose of 800 ug of misoprostol half an hour before surgery
89463405|NCT06325501|Active Comparator|oxytocin|After the induction of general anaesthesia (GA), an infusion of 40 IU oxytocin in 500 ml normal saline was started at the rate of 250 ml/hour
89463406|NCT06325488||Patients with Fabry Disease and impaired kidney function|"Participants included in this group~18 years of age or above~Fabry Disease as verified by genetic analysis prior to inclusion~Impaired kidney function according to the KDIGO classification (UACR ≥ 30 mg/g and eGFR < 60 ml/min/1.73m2 [≥ CKD G3a/A2])"
89463407|NCT06325488||Patients with Fabry Disease and normal kidney function|"Participants included in this group~18 years of age or above~Fabry Disease as verified by genetic analysis prior to inclusion~Normal kidney function according to the KDIGO classification (UACR < 30 mg/g and eGFR ≥ 60 will be included [≤ CKD G2/A1])"
89463408|NCT06325488||Healthy controls|"Participants included in this group~18 years of age or above~Normal kidney function according to the KDIGO classification (UACR < 30 mg/g and eGFR ≥ 60 will be included [≤ CKD G2/A1])~Furthermore, healthy controls are excluded~Suspected of Fabry Disease or verified by genetic analysis~Related to a patient with Fabry Disease~Have cancer with an expected influence on life expectancy~Known apoplexia cerebri, heart failure or established kidney disease~Recently initiated or have had recent changes in antihypertensive medication (within 3 months)"
89463409|NCT06325475|Active Comparator|Group A|"Pregnant women in Group A will receive neuraxial labor analgesia (dural puncture epidural or combined spino epidural analgesia).~If postpartum analgesic needs arise, patients in Group A will receive 0.0625% bupivacaine via epidural route."
89463410|NCT06325475|Active Comparator|Group B|Pregnant women in Group A will not receive neuraxial labor analgesia. If postpartum analgesic needs arise, patients in Group B will receive iboprufen and acetaminophen if needed.
89463411|NCT06325462||Group S|27 patients will receive inhalational general anesthesia using sevoflurane.
89463412|NCT06325462||Group P|27 patients will receive intravenous anesthesia using propofol infusion.
89463413|NCT06325449|Experimental|STREAM Weight-loss Program|All patients who participate in the study will be recruited to the Intervention Arm and will undergo the STREAM program, a 24-week weight loss program which includes meal replacement, dietician teaching and regular appointments with their bariatric medicine specialist.
89463414|NCT06325397||High Intraocular Pressure (IOP)|Eyes in this arm will maintain an Intraocular Pressure (IOP) of 65 millimeters of mercury (mmHg) throughout the cataract surgery.
89463415|NCT06325397||Low Intraocular Pressure (IOP)|Eyes in this arm will maintain an Intraocular Pressure (IOP) of 24 millimeters of mercury (mmHg) throughout the cataract surgery.
89463416|NCT06325384|Active Comparator|Cuff Arm|Blood Pressure Cuff
89463417|NCT06325384|Experimental|LifeLight Arm|Contactless Vital Signs Monitor using RPPG
89463418|NCT06325358||Subjects with Multiple sclerosis|"Age ≥ 18 years~Diagnosis of MS according to 2017 McDonald criteria~Relapsing-remitting (RR) MS~Residence in the provinces of Pavia or Milan (Italy)~Informed consent form signed"
89463419|NCT06325345|Other|Standard Medical Therapy|Standard Medical Treatment will be administered by board certified gastroenterologists through the EDS Clinic gastroenterology clinical care pathway. Therapies will be individualized to the participants' current symptoms and severity of symptoms as per current clinical guidelines for management of IBS. Potential therapies that may be administered include dietary changes, supplemental fibre, and pharmacotherapy (including neuromodulators) as appropriate.
89463420|NCT06325345|Experimental|Standard Medical Therapy plus Gut-Directed Hypnotherapy|In addition to Standard Medical Therapy, participants randomized to this arm will attend 8 sessions of gut-directed hypnotherapy by a trained behavioral therapist. The treatment protocol developed for the proposed study was adapted from the empirically-supported Manchester Protocol for gut-directed hypnotherapy. At each visit, a voluntary, pleasant, and dream-like state of deep relaxation will be induced and suggestions made for greater relaxation, abdominal comfort, and normalization of gut function. The first session will be 90 minutes in duration and the remaining sessions will be 60 minutes. At the first session, participants will be provided with 30 minutes of education on the nature of the gut-brain axis and hypnotherapy before they undergo hypnotherapy.
89463421|NCT06325332||Cohort 1: Nirsevimab-Exposed Cohort|Full-term (born ≥ 37 weeks gestational age) infants born on or after 01 April 2023, without a high-risk condition, who receive nirsevimab before or during their first RSV season per recommendations, ie, before or during the 2023-2024 RSV season.
89463422|NCT06325332||Cohort 2: Comparator Cohort|Full-term (born ≥ 37 weeks gestational age) infants born on or after 01 April 2023, without a high-risk condition, who do not receive nirsevimab before or during the 2023-2024 RSV season.
89463423|NCT06325332||Cohort 3: Historical Control Cohort|Full-term (born ≥ 37 weeks gestational age) infants without a high-risk condition from previous RSV seasons 2016-2017, 2017-2018, 2018-2019, 2019-2020, and 2022-2023. The 2020-2021 and 2021-2022 seasons are excluded due to low circulation of RSV during the COVID-19 pandemic. Historical seasons' data are intended for descriptive purpose only, to contextualize the impact of the treatment during the 2023-2024 season.
89463424|NCT06325332||Cohort 4: Infant Cohort with High-Risk Conditions|Infants born < 37 weeks gestational age and those diagnosed with a high-risk condition between birth and the end of the observation period (regardless of gestational age at birth), will be considered infants with high-risk conditions. Infants with high-risk conditions will be excluded from Cohort 1, Cohort 2, and Cohort 3. Descriptive statistics will be separately assessed for this high-risk cohort.
89501905|NCT03500263|Active Comparator|Cohort 3 PTI-808 Active + PTI-801 Active + PTI-428 Active|Subjects will be randomized to receive either PTI-808 co-administered with PTI-801 and PTI-428 or placebos once-a-day for a total of 14 days. A follow up visit will occur on Day 21.
89463425|NCT06325319|Experimental|M-MAMA Champions group|Those study participants randomized to the intervention arm will receive the intervention being tested in this study. The intervention will be community engagement through the M-MAMA Champions on obstetric danger signs, birth preparedness, and complication readiness, whereby sensitization to pregnant women will be done. The sensitization package will be delivered by M-MAMA Champions and will encompass obstetric danger signs, birth preparedness, and complication readiness that will be adapted from the Ministry of Health, Tanzania. The package is being used to empower Community Health Workers (CHWs). The intervention is expected to be delivered in two (2) wards (4 Clusters) to be selected in Bahi Council, Dodoma for a period of one month from March to April 2024 and raise awareness by at least 20% in the intervention arm within a study period.
89463426|NCT06325319|No Intervention|Routine service group|The study participants who will be randomized to the control arm won't receive the intervention, instead, they will continue receiving the routine services. The routine services for pregnant women specifically on knowledge-related empowerment include the package delivered by the healthcare workers at the reproductive and child health clinics. The package is delivered during every Ante Natal Care (ANC) visit to the pregnant woman. The package contains basic information that is also tailored to the specific needs of pregnant women and is delivered with much emphasis to those who are prone to experience pregnancy-related complications for instance, those with Bad Obstetric History (BOH), cardiovascular diseases, or diabetics. The control groups are expected to be derived from two (2) wards (4 Clusters) to be selected in Bahi Council, Dodoma
89463427|NCT06325306|No Intervention|Control Group|Participants in this arm receive no specific intervention. They are on a waiting list for the 'Citoyen en mouvement pour ma santé' program, allowing for natural observation of their health progression without targeted physical literacy interventions. This group serves as a baseline to compare the effects of the adapted physical activity (APA) programs with and without physical literacy components.
89463428|NCT06325306|Experimental|Traditional APA Group|This group engages in a standard adapted physical activity program, focusing on improving physical fitness and mobility. The intervention is designed for chronic disease management, emphasizing regular physical exercises without an explicit incorporation of physical literacy principles. The same APA educator supervises all sessions to maintain consistency in the delivery of physical activity interventions.
89201897|NCT00603915|Experimental|GC Plus Erlotinib|Eligible patients are treated with cisplatin/carboplatin and gemcitabine (GC) for 6 cycles of therapy followed by maintenance erlotinib. Those patients achieving SD or PR with chemotherapy will be started on maintenance erlotinib until disease progression. Those patients achieving CR with chemotherapy will be started on erlotinib for 6 cycles of treatment and those achieving CR on erlotinib will be treated with a maximum of 6 further cycles of erlotinib. Those patients with disease progression while on chemotherapy will be offered erlotinib 2 weeks following the last dose of chemotherapy until further disease progression.
89463429|NCT06325306|Experimental|APA+PL Group|Participants in this arm participate in an adapted physical activity program enriched with physical literacy elements. The intervention aims to enhance physical activity engagement through increased motivation, confidence, knowledge, and understanding. This arm explores the added benefits of integrating physical literacy into traditional APA programs for chronic disease patients.
89463430|NCT06325293|Active Comparator|IMP arm|"Azithromycin Pfizer® powder for oral suspension:~1 daily dose for 5 days, 10mg/kg/day on day 1 and 5mg/kg/day on days 2-5"
89463431|NCT06325293|Placebo Comparator|Placebo arm|5 days of placebo
89463432|NCT06325280||Congenital heart disease|Participants aged 10-18 years who have congenital heart disease.
89463433|NCT06325280||Heart transplant recipient|Participants aged 10-18 years who have recieved a heart transplant.
89463434|NCT06325228||Young Athletes|300 young athletes (boys and girls, 9 - 16 years-old) from clubs, teams, associations, sports classes of various disciplines in the Pomeranian Voivodeship
89501906|NCT03500263|Placebo Comparator|Cohort 3 PTI-808 placebo + PTI-801 Placebo + PTI-428 Placebo|Subjects will be randomized to receive either PTI-808 co-administered with PTI-801 and PTI-428 or placebos once-a-day for a total of 14 days. A follow up visit will occur on Day 21.
89201898|NCT00929487|Experimental|Contact lens solution #1|
89463435|NCT06325215|Experimental|Hydrocolloid tape group|In this group, after the columella and nasal area of preterm infants were cleaned and dried with sterile water, hydrocolloid dressings were applied to the areas in contact with the nasal cannula. NasalNem nasal ointment was applied twice a day to the nasal passages in contact with the cannula. If the hydrocolloid dressings melted or peeled off, they were removed, the area was cleaned, and then reapplied. In the data collection process, assessments of the included preterm infants were conducted by two nurses. The upper lip, nasal passages, nasal septum, and columella region of the preterm infants were evaluated.
89463436|NCT06325215|No Intervention|Control group|In this group, premature infants underwent the routine procedure of the NICU. As per the clinic's routine procedure, after cleaning and drying the columella and nasal area with sterile water, NasalNem nasal ointment was applied twice a day to the nasal passages in contact with the cannula. In the data collection process, assessments of the included preterm infants were conducted by two nurses. The upper lip, nasal passages, nasal septum, and columella region of the preterm infants were evaluated.
89463437|NCT06325189|No Intervention|Medication alone|Participants in this arm will not receive any specific intervention. They will only receive standard care medications after angioplasty. No additional treatments or therapies will be administered.
89463438|NCT06325189|Experimental|Aerobic Interval Training and medication|In this arm, participants will receive the intervention. The intervention consists of aerobic interval training in addition to medication.
89463439|NCT06325176|Experimental|Cryotherapy group|During the 1st visit, the patients will be assessed for pain and episiotomy wound. The cryotherapy group will include 12 postnatal women. This group will use a bag of ice packs applied to the perineal region. The ice pack will be sealed in a plastic bag and wrapped with one layer of thin cotton tissue so that the skin of the participant will not be in direct contact with ice, which could cause discomfort. During the intervention, the women will be asked to remove their underpants and hygienic pads and remain in the dorsal recumbent position during cryotherapy that lasts 20 minutes. This procedure will be done twice a day for seven consecutive days
89463440|NCT06325176|Active Comparator|Infrared light therapy|The infrared group will include 12 postnatal women they will be encouraged to place an infrared lamp at a distance of 45 cm from the perineum and the heat produced with 230 volts for twenty minutes. But the mother is checked after the first five minutes to make sure that she is not being burned. The researcher will demonstrate for each woman how to use an infrared lamp, and it will be followed by re-demonstrations and discussions. These procedures will be carried out in the morning and evening for seven consecutive days. The researcher gives the infrared lamp device to each woman and then restores it after completion of the study
89463441|NCT06325163|Experimental|A single arm consisting of 3 stages|"This study will include 3 stages:~CBCT examination stage: In this stage, CBCT scanning will be done and examined by by 2 blinded endodontists and the number of canals identified will be recorded~Clinical Stage: This is a clinical stage where patients will be randomly distributed upon 6 Practitioners using randomization software (Microsoft Office Excel). Practitioners will then proceed with the pretreatment procedures under dental operating microscope~Artificial intelligence stage: The carrying out of this stage will be solely undertaken by the principal investigator. The CBCT images will be uploaded to convolutional neural network software (CNN) that uses a deep learning algorithm and CBCT segmentation. The software will then record the number of canals it found"
89463442|NCT06325150|Experimental|Light glasses type 1|Experimental light emitting glasses.
89463443|NCT06325150|Placebo Comparator|Light glasses type 2|Placebo light emitting glasses
89463444|NCT06325150|No Intervention|No glasses control|No glasses control group
89463445|NCT06325137||Patients with steroid-resistant nephrotic syndrome|Identification of a possible molecular signatures at t0 by whole transcriptome analysis from PBMCs
89463446|NCT06325137||Patients with steroid sensitive nephrotic syndrome|Identification of a possible molecular signatures at t0 by whole transcriptome analysis from PBMCs
89463447|NCT06325124|Active Comparator|Muscle Energy Technique of Calf and hamstrings|Muscle Energy Technique of Calf and hamstrings (soft tissue technique)
89463448|NCT06325124|Other|Conventional PT|Cervical isometric exercises Hot pack
89463449|NCT06325111||Patients with T1D and optimal glycaemic control|Optimal glycaemic control will be defined as HbA1c values <7%
89463450|NCT06325111||Patients with T1D and poor glycaemic control|Poor glycemic control will be defined as HbA1c value ≥7%
89463451|NCT06325098|Experimental|Patients with SSNS|Patients with SSNS and patients undergoing renal transplantation for NS with post-transplant disease recurrence will be enrolled for serum sampling for the study of immunological and/or permeabilizing factors (including anti-nephrin antibodies).
89463452|NCT06325098|Experimental|Patients with SRNS undergoing genetic testing by WES|Patients with SRNS undergoing genetic testing by WES and variant prioritization will undergo serum sampling for the study of immunologic and/or permeabilizing factors (including the anti-nephrin antibodies), and urine sampling for u-RPC cultures.
89463453|NCT06325085|Experimental|Compensatory and restorative rehabilitation techniques|compensatory and restorative rehabilitation techniques in stroke patients
89463454|NCT06325085|Active Comparator|Traditional cognitive Rehabilitation training|Naming words Counting numbers backwards Spell the word backwards
89463455|NCT06325072|Experimental|Pathogenic variants|Variants fitting bioinformatic prioritization criteria for pathogenicity according to ACMG guidelines and the clinical phenotype, and variants already reported in the literature will be defined as pathogenic variants
89463456|NCT06325072|Experimental|Potentially Pathogenic Variants|Variants fitting bioinformatic prioritization criteria but apparently do not correlate with the clinical phenotype and have not been previously reported in the literature will be defined as potentially pathogenic variants
89463457|NCT06325072|Experimental|Variants of Unknown Significance (VUS)|Variants fitting the phenotype but not fitting bioinformatic prioritization criteria will be defined as variants of uncertain clinical significance (VUS)
89463458|NCT06325059|Experimental|Patients with kidney diseases undergoing renal biopsy|Patients with kidney diseases undergoing renal biopsy for diagnostic purposes
89201899|NCT00929487|Experimental|Contact lens solution #2|
89201900|NCT00929487|Experimental|Contact lens solution #3|
89201901|NCT00929487|Experimental|Contact lens solution #4|
89463459|NCT06325046|Experimental|Arm I (near margin-less ART)|Patients undergo near margin-less ART for 2 treatments at least 3 days apart in the absence of disease progression or unacceptable toxicity. Patients also undergo CBCT and may undergo CT and/or MRI on study.
89463460|NCT06325046|Active Comparator|Arm II (standard SABR)|Patients undergo standard SABR for 5 treatments at least 2 days apart in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and/or MRI on study.
89463461|NCT06325033||Patients age ≥ 18 - <65 and BMI <30|Adult patients for procedural sedation in the University Medical Center Groningen (UMCG) between 01-01-2024 and 01-01-2025.
89463462|NCT06325033||Patients age ≥ 18 - <65 and BMI ≥ 30|Adult patients for procedural sedation in the UMCG between 01-01-2024 and 01-01-2025.
89463463|NCT06325033||Patients age ≥ 65 and over|Adult patients for procedural sedation in the UMCG between 01-01-2024 and 01-01-2025.
89463464|NCT06325020||Patients with possible angina|"Participants will complete a digital health questionnaire, at home, that asks about their risk factors for coronary artery disease, past medical history and their symptoms.~Patients will then have a standard 12 lead ECG and perform their own personal ECG. They will then have high sensitivity cardiac troponin measured.~The results of all of the above will allow patients to be started as low, intermediate or high risk for future cardiovascular events."
89463465|NCT06325007|Active Comparator|group 1 - study group|Candidates will drink a mixture of 60 ml of castor oil and 140 ml of orange juice. 30 minutes later, A 22-French Foley catheter will be inserted above internal cervical os and will be filled with 60 mL of normal saline.
89463466|NCT06325007|Active Comparator|group 2- control|A foley catheter will be inserted into cervical canal as described above according to the department protocol without ingestion of castor oil.
89463467|NCT06324994|Experimental|cohort 1|Patients with relapsed refractory lymphoblastic mantle cell lymphoma who have not previously received treatment with PI3K inhibitors and BCL-2 inhibitors
89463468|NCT06324981|Active Comparator|Generic text messages|The information content for these messages will be derived from trusted sources of medical information and contain links to websites such as American Heart Association. An example of such a message would be: Remember to take your blood pressure today! You can find more information from the American Heart Association by clicking here. Patients will be able to return texts with questions which will be addressed by the study team, including a clinical pharmacist if needed.
89463469|NCT06324981|Active Comparator|Interactive AI chatbot text messaging|This AI system will utilize NLP and ML to facilitate bi-directional system-patient dialogue with messages that incorporate content utilizing tailoring, behavioral nudges and persuasive messaging as described above. An example message would be: Make a promise to yourself to check your blood pressure today! Your goal is to have the top number at 120 or lower and the bottom number at 80 or lower. Each message will end with a question for the participant that will encourage engagement with the AI conversational chatbot that allows greater opportunity to use theoretical content to engage patient autonomy, competence and relatedness, the mechanisms through which we will impact behaviors.
89463470|NCT06324981|Active Comparator|Interactive AI chatbot text messaging + proactive pharmacist management|The AI chatbot will be the same as arm 2 (Interactive AI chatbot text messaging alone). In this arm, however, pharmacists will review patient's baseline LE8 risk factors and proactively contact patients via telephone and/or the EHR patient portal to address any risk factor that is in poor/intermediate health categories. The investigators are proposing proactive pharmacist involvement as a population-based approach to address patients with uncontrolled CV risk factors.
89463471|NCT06324968|Experimental|Sjögren's disease|SSp patients followed by the Internal Medicine Department of Nice University Hospital will be offered participation in this study as part of their usual follow-up.
89463472|NCT06324968|No Intervention|Control|Control subjects will be recruited from the nursing staff of Nice University Hospital on a voluntary basis.
88944473|NCT01880645|Other|Ultrasound + Breast Surgery + Lymph Node Removal|Patient receives an ultrasound of lymph nodes at diagnosis and on the day of surgery. Marker clip(s) placed using a needle in the abnormal lymph node(s). If patient received chemotherapy before surgery, fine needle aspiration (FNA) performed of any abnormal lymph nodes either right before or during standard breast and underarm surgery. To perform FNA, area is numbed with anesthetic and a needle is inserted into the affected area so that cells can be collected. Standard breast and underarm surgery (underarm lymph node removal and either a partial mastectomy or total mastectomy with or without reconstruction) performed.
88944474|NCT01880658|Experimental|Capecitabine|Patients undergo R0-R1 resection and receive adjuvant chemotherapy FOLFOX or Capox for no less than 4 months. Radiotherapy may be applied for patients with rectal cancer if clinicians suspect that is necessary. Then patients receive oral capecitabine for 12 months maintenance.
89463473|NCT06324955|Active Comparator|Common/Standard Language Group|
88944475|NCT01880671|Experimental|Migraine Medical Device|
88944476|NCT01880671|Placebo Comparator|Inactive Migraine Medical Device|
88944477|NCT01880684||Passive Leg Rising|
88944478|NCT01880749|Experimental|RAD001|RAD001 taken by mouth 10mg daily for 10 days before surgery
88944479|NCT01880775|Experimental|prilocaine heavy 2%& fentanyl|prilocaine heavy 2% 30 mg and fentanyl 20 micgr ampoule intrathecal
88944480|NCT01880775|Active Comparator|bupivacaine heavy 0.5% & fentanyl|bupivacaine heavy 0.5% 7.5 mg and fentanyl 20 micg ampoule intrathecal
88944481|NCT01880788||CNV secondary to CSC|
88944482|NCT01880788||CSC without CNV|
88944483|NCT01880788||CNV secondary to advanced AMD|
88944484|NCT01880814|Experimental|Cognitive Behavioral Therapy (CBT)|Type of talk therapy that focuses on individual behavioral and cognitive skills.
89463474|NCT06324955|Experimental|Positive Language Group|
88944485|NCT01880814|Experimental|Caregiver-Child Treatment|Type of talk therapy that involves the child and the caregiver and focuses on behavioral and cognitive skills.
88944486|NCT01879241|Experimental|Rasagiline|"Rasagiline~1 mg/day; 18 months"
88944487|NCT01879241|Placebo Comparator|Placebo|once daily, 18 months
88944488|NCT01880827|Active Comparator|Royx-en-Y surgery|Mixed meal test (MMS) with flow studies before and 2 months after the operation
88944489|NCT01880827|Active Comparator|Control|Healthy volunteer group, GIP, GLP-1 and MMS studies
89463475|NCT06324942|Experimental|Surgeon-administered Transversus Abdominis Plane Block (TAP block)|After uterine closure, the anterior abdominal wall on the contralateral side to the surgeon is elevated and retracted laterally by an assistant. The bowel and uterus is retracted using the surgeon's non-dominant hand, with or without a sponge. Under direct visualization, a blunted spinal needle is inserted lateral to the rectus muscle to avoid injury to inferior epigastric blood vessels. The needle is then gently advanced through the transversus abdominis fascia into the TAP plane, identified at loss of resistance, or 'a pop'. After aspiration to confirm no accidental placement of the needle intravascularly, local anaesthetic is infiltrated into the transverse abdominis plane through the parietal peritoneum by the surgeon at a prespecified dose of 0.25% bupivicaine 0.25 mL/kg (approximately 20cc). This is repeated on the contralateral side, after which closure of the fascia, subcutaneous tissue, and skin were performed.
89463476|NCT06324942|No Intervention|No TAP block|A sham procedure will not be performed but the patient will be unaware of whether or not an injection was done.
89463477|NCT06324877|Other|Single arm (full group)|Single arm, open-label. Dose will be via oral capsule supplementation Nicotinamide Riboside at 25mg/kg/day divided into 3 doses (max 300mgs 3 times per day). Dosing will occur via 3 equal doses 3 times a day for 12 months.
88944490|NCT01880827|Experimental|Sleeve gastrectomy|Mixed meal test (MMS) with flow studies before and 2 months after the operation
88944491|NCT01880853|Experimental|group 1|screening with mammography alone
88944492|NCT01880853|Experimental|group 2|screening with ultrasonography alone
88944493|NCT01880853|Experimental|group 3|screening with both mammography and ultrasound
88944494|NCT01880866|Experimental|(-)-Epicatechin|A single dose of 100mg or 200mg (-)-Epicatechin to be administered orally
88944495|NCT01880879|Experimental|helios stent|the group with helios stent implanted
88944496|NCT01880905|Experimental|female undergoing gynecological surgery|
88944497|NCT01880918||ColonRing|The ColonRing device is intended to be used for the creation of intestinal anastomoses in colorectal surgery in both open and laparoscopic surgeries. This indication is within the currently cleared indication of the ColonRing device, which has been cleared by the US FDA and carries the CE Mark for use throughout the alimentary trct for the creation of circular end-to-end, side-to-end or side-to-side anastomosis.
88944498|NCT01880931|Experimental|Normotensive patients|To find out the effect site concentration of remifentanil for preventing QTc prolongation < 15 sec during intubation : Dixon's up-and-down method
88944499|NCT01880931|Experimental|Hypertensive patients|To find out the effect site concentration of remifentanil for preventing QTc prolongation < 15 sec during intubation : Dixon's up-and-down method
88944500|NCT01880944||ER-spine trauma|patients with spinal trauma, who initially visits in emergency room
88944501|NCT01880944||OUT-spine trauma|patients with spinal trauma, who initially visits in outpatient clinic
88944502|NCT01880970|Active Comparator|Starter infant formula with pro and prebiotics|starter infant formula from enrollment till 6 months of age, followed by a commercially available Nestlé follow-up formula from 6 to 12 months of age
88944503|NCT01880970|Placebo Comparator|starter infant formula without pro and prebiotics|starter infant formula from enrollment till 6 months of age, followed by a commercially available Nestlé follow-up formula from 6 to 12 months of age
88944504|NCT01880970|No Intervention|Breastfeeding group|exclusively breastfeeding during the first 3 months of age, followed by a commercially available Nestlé starter infant formula from 4 to 6 months of age (if applicable) and the follow-up infant formula from 6 to 12 months of age
88944505|NCT01880996|Experimental|Tai-chi/Qi-gong|30 gynecological cancer patients scheduled for the first or second line of chemotherapy treatment will be recruited for this study to receive Tai-chi/qigong treatment initiated at the beginning of chemotherapy therapy, once a week (45 min each), for 10 weeks.
88944506|NCT01880996|No Intervention|Usual Care|30 gynecological cancer patients scheduled for primary or secondary chemotherapy treatment, will be evaluated by the same measures as the intervention group.
88944507|NCT01881022|Experimental|Psychosexual Intervention|The intervention will consist of 6 weekly sessions of couples psychosexual counseling delivered via videoconferencing.
88944508|NCT01881035|Experimental|Renal nerve denervation|Renal nerve denervation
89463478|NCT06324864|Active Comparator|START NOW Adapted|"The intervention group will receive a culturally adapted version of the yet well-validated START NOW training. The skills taught within START NOW aim to change dysfunctional negative attitudes and behaviour, improve emotion regulation capacities and enhance the ability to achieve individual goals by addressing key aspects of mental health and resilience. The training includes 10 group sessions including exercises and discussion.~The sessions will be held by a trained facilitator (staff member of institution, social worker, or else) with the same cultural background in the respective language (depending on group constellation) and supervised by a certified START NOW trainer from the START NOW team."
89463479|NCT06324864|No Intervention|Treatment as Usual|The control group will receive treatment as usual.
88944509|NCT01881074||Triclosan containing toothpaste|Patients with type II diabetes will receive triclosan containing toothpaste and will be asked to brush their teeth using only this toothpaste for the duration of the study (12 months). Patients will be asked to return for an oral exam, dental cleaning and sample collection for up to 12 months following their baseline appointment.
88944510|NCT01881074||Non-triclosan containing toothpaste|Patients with type II diabetes will receive non-triclosan containing toothpaste and will be asked to brush their teeth using only this toothpaste for the duration of the study (12 months). Patients will be asked to return for an oral exam, dental cleaning and sample collection for up to 12 months following their baseline appointment.
88944511|NCT01880710|Active Comparator|Total hysterectomy|removal of the entire uterus including the cervix. open abdominal surgery. No specific procedures were asked of the surgeon. They were free to do the procedure the way they were used to doing it.
88944512|NCT01880710|Experimental|Subtotal Hysterectomy|removal of the uterine body only leaving the cervix in situ. The surgeon was free to do the procedure as he was used to. The only direction was that the cervical canal should be electrocoagulated.
88944513|NCT01881100|Experimental|resin infiltration|The test group (41 children) had caries lesions treated with the infiltration technique using Icon (DMG, Hamburg, Germany) and fluoride varnish (Duraphat, Colgate Palmolive, Hamburg, Germany)at baseline evaluation. Fluoride varnish was applied every control visit every three months during 1 year.
88944514|NCT01881100|Active Comparator|fluoride varnish|The control group (40 children) had all tooth surfaces including WSL treated with fluoride varnish (Duraphat Colgate Palmolive, Hamburg, Germany)only at baseline evaluation and every control visit every three months during 1 year.
88944515|NCT01881139|Experimental|experimental 1|men with exercise training for 3 months
88944516|NCT01881152|Experimental|Intervention|Educational campaign
88944517|NCT01881152|Other|Control|Usual care
88944518|NCT01881165|Experimental|Cranberry|Each capsule contains 500 mg of cranberry powder at a concentration ratio of 36:1 (36 grams of cranberries equals 1 gram of concentrate).
88944519|NCT01881165|Placebo Comparator|Placebo|A capsule containing control formulation
88944520|NCT01881178|Active Comparator|Apricot|Supplement: Apricot Juice
88944521|NCT01881178|Experimental|Nopalea|Supplement: Nopalea
88944522|NCT01881191||Aubagio MRI|Patients with relapsing-remitting multiple sclerosis who take Aubagio will have an MRI, eye test, blood drawn, and complete a questionnaire.
88944523|NCT01881191||Healthy controls|Subjects who are otherwise healthy, without neurological disorders will have an MRI, eye test, blood drawn, and complete a questionnaire.
88944524|NCT01881204|Experimental|Hesperidin and Calcilock|Subjects will consume 4 cookies containing Hesperidin and Calcilock.
88944525|NCT01881204|Experimental|Hesperidin|Subjects will consume 4 cookies containing Hesperidin, 552mg, daily
89463480|NCT06324838|Experimental|Extended mesenteric resection|Arm receiving ileocecal resection with extended mesenteric resection.
88944526|NCT01881204|Placebo Comparator|Control|Subjects will consume 4 cookies daily without Hesperidin or Calcilock.
88944527|NCT01881217|Experimental|BAY1179470 (Dose escalation)|BAY1179470 will be administered as a 1-hour intravenous infusion every 21 days.
88944528|NCT01881217|Experimental|BAY1179470 (additional)|Additional cohort: BAY1179470 will be administered as a 1-hour intravenous infusion every 21 days.
88944529|NCT01881217|Experimental|BAY1179470 (expansion)|Expansion cohort: BAY1179470 will be administered as a 1-hour intravenous infusion every 21 days.
88944530|NCT01881243||Adult patients resuscitated from cardiac arrest|
88944531|NCT01881269||No treatment|No treatment, prospective observational
88944532|NCT01881282|Experimental|Carraghenates Cream|
88944533|NCT01881282|Active Comparator|Mayinglong Musk Hemorrhoid Ointment|
88944534|NCT01881295|Placebo Comparator|Placebo control|Subjects will consume tablets containing no potassium in addition to a basal diet containing 2336 mg potassium
88944535|NCT01881295|Experimental|Low dose potassium gluconate|Subjects will consume 720 mg potassium in the form of potassium gluconate tablets daily in addition to a basal diet containing 2336 mg potassium
88944536|NCT01881295|Experimental|Medium dose potassium gluconate|Subjects will consume 1440 mg potassium in the form of potassium gluconate tablets daily in addition to a basal diet containing 2336 mg potassium
88944537|NCT01881295|Experimental|High dose potassium gluconate|Subjects will consume 2160 mg potassium in the form of potassium gluconate tablets daily in addition to a basal diet containing 2336 mg potassium
88944538|NCT01881295|Experimental|Low dose potato|Subjects will consume 720 mg potassium in the form of potato daily in addition to a basal diet containing 2336 mg potassium
88944539|NCT01881295|Experimental|Medium dose potato|Subjects will consume 1440 mg potassium in the form of potato daily in addition to a basal diet containing 2336 mg potassium
88944540|NCT01881295|Experimental|High dose potato|Subjects will consume 2160 mg potassium in the form of potato daily in addition to a basal diet containing 2336 mg potassium
88944541|NCT01881295|Experimental|High dose French fries|Subjects will consume 2160 mg potassium in the form of french fries daily in addition to a basal diet containing 2336 mg potassium
88944542|NCT01881295|Experimental|Basal diet control|Subjects will consume a basal diet containing 2336 mg potassium daily
88944543|NCT01881321|Experimental|Group 1: Counseling Intervention|Contraceptive counseling session based on the principles of motivational interviewing
89463481|NCT06324838|Active Comparator|Controls (Standard mesenteric resection)|Arm receiving standard ileocecal resection.
89463482|NCT06324825|Experimental|Fuzhegn Nizeng Formula|
89017934|NCT05789446|Experimental|BaSICS Intervention|"Intervention = Building a String Identity and Coping Skills (BaSICS). Children randomized to participate in 16 twice weekly BaSICS intervention sessions. Children learn coping skills, identity development, and collective action as ways to buffer against chronic stress.~These children also complete pre- and post-intervention assessments, as well as 6-month and 12-month follow-up assessments."
89017935|NCT05789446|No Intervention|Control|These children complete assessments only--timed to coincide with the intervention groups' assessments: pre- and post-intervention assessments, as well as 6-month and 12-month follow-up assessments. No intervention.
89017936|NCT05787366|Other|Usual care|usual care and follow-up by a nurse: control group receiving conventional management, i.e. referral to a specialist(s) according to symptoms, as well as nursing follow-up.
89017937|NCT05787366|Experimental|Intervention group|usual care and Personalized Multifactorial Intervention: group benefiting from the Personalized Multifactorial Intervention coordinated by a nurse
89017938|NCT05781542|Experimental|Group 1|a total of approximately 9 participants will receive 3 administrations of sD-NP-GT8 DNA at a dose of 0.4 mg, coformulated with IL-12 DNA at a dose of 0.1 mg at days 1, 29, and 85. Study products will be administered intradermally via EP of the skin on each upper arm
89463483|NCT06324825|Active Comparator|Moluodan patient medicine|
89463484|NCT06324812|Experimental|611|subcutaneous injection, 611 450/600mg (loading dose) + 300mg once every 2 weeks/4 weeks
89463485|NCT06324799|Experimental|Position group every 2 hours|Newborns in the study group will change position (supine, prone, lateral) every 2 hours.
89463486|NCT06324799|No Intervention|Control group|Newborns in the control group will change position (supine, prone, lateral) every 6 hours.
89017939|NCT05781542|Experimental|Group 2|a total of approximately 18 participants will receive 3 administrations of sD-NP-GT8 DNA at a dose of 1.6 mg, coformulated with IL-12 DNA at a dose of 0.4 mg at days 1, 29, and 85. Study products will be administered intradermally via EP of the skin on each upper arm
89017940|NCT05781542|Experimental|Group 3|a total of approximately 18 participants will receive 3 administrations of sD-NP-GT8 DNA at a dose of 1.6 mg, coformulated with IL-12 DNA at a dose of 0.4 mg at days 1, 29, and 85. These doses will be administered intradermally via EP of the skin on each upper arm. All participants in Group 3 will also receive 2 administrations of Trimer 4571 at a dose of 100 mcg adjuvanted with 5 mcg of 3M-052-AF + 500 mcg Alum via IM injections into the deltoid muscle at days 85 and 169
89017941|NCT05781217|Active Comparator|short-term ADT (6 months)|"ARM 1:~LHRH analogues for 6 months + bicalutamide 50 for 30 days"
89017942|NCT05781217|Active Comparator|long-term ADT (24 months)|LHRH analogues for 24 months + bicalutamide 50 for 30 days
89017943|NCT05773378|Experimental|Pessary Intervention|"Participants randomized to this group will receive an Uresta Incontinence Pessary to use each time they run over a 12-week period. They will be instructed to use the pessary only while running and remove it and wash it with soap and water when the training is over.~Uresta is a reusable and removable device made of hypoallergenic medical-grade resin that is inserted into the vagina to provide mechanical support. It comes with a starter kit with 3 different sizes which work for over 80% of women. Participants will be instructed on how to test the 3 sizes to find out which one is right for them."
89017944|NCT05773378|Experimental|Tampon Intervention|Participants randomized to this group will receive 60 regular Tampax tampons and will be instructed to use them each time they run over a 12-week period. The tampon should be used only while running and removed and discarded when the training is over.
89017945|NCT05773378|No Intervention|Control Group|Participants randomized to this group won't receive any intervention and will be asked to continue their running training as usual for 12-weeks. They will also be instructed to not begin any treatment for urinary incontinence until their reassessment. After 12-weeks, they will be reassessed and will be offered the opportunity to receive a pessary if they desire so.
89463487|NCT06324786|Experimental|IBMT|An evidence-based preventive intervention - integrative body-mind training (IBMT) has shown positive effects in reducing stress and improving self-control and brain plasticity. It has bodifulness and mindfulness components.
89463488|NCT06324786|Experimental|NF|An evidence-based intervention - NF can not only provide real-time feedback for practice but also target the self-control networks, suggesting the possibility of augmenting IBMT effects via NF.
89463489|NCT06324786|Experimental|IBMT + NF|The combined IBMT and NF also show positive effects in reducing substance use.
89463490|NCT06324786|Sham Comparator|Sham NF|Sham NF has the same settings as the active NF but does not have correct parameters of stimulation.
89463491|NCT06324747|Other|Control group|Control group will have a full thickness flap, followed by an immediate implant placement using a surgical guide. Then a guided bone regeneration will be achieved by bone graft (autogenous bone chips and xenograft particles and a membrane barrier 1 mm thickness will be applied. The membrane shield then will be stabilized to the apical bone using 2 membrane tacks, customized healing abutment will be connected , then, the elevated flap will be sutured to its original position.
89501907|NCT03500263|Active Comparator|Cohort 4 PTI-808 Active + PTI-801 Active + PTI-428 Active|Subjects will be randomized to receive either PTI-808 co-administered with PTI-801 and PTI-428 or placebos once-a-day for 7 days immediately followed by PTI-808 co-administered with PTI-801 or placebos once-a-day for 7 days. A follow-up visit will occur on Day 21.
89463492|NCT06324747|Active Comparator|Test group|Elaskary Vestibular socket therapy instruments will be used for the intervention, A 1 cm long vestibular access incision at the allocated hopeless tooth will be made at the base of the hopeless tooth to the adjacent teeth. The vestibular pouch will then be dissected in an incisal direction exposing the total socket area and allowing direct access to the socket environment. An immediate implant will be installed using a surgical guide. A membrane shield 1 mm thick will be, trimmed, and tucked through the vestibular access incision starting at 1 mm beyond the socket orifice and reaching to the apical area of the socket. The gap and/ or the defect between the implant body and the shield will then be filled with the same grafting components so the control group. Finally, the vestibular incision will be secured with sutures. The socket will be sealed with a customized healing abutment.
88944544|NCT01881321|No Intervention|Group 2: Usual Care|The standard clinic-based contraceptive counseling with no additional or theory-based contraceptive counseling session
89463493|NCT06324721|Experimental|Breast cancer patients|Women and men diagnosed with breast cancer scheduled for surgery
89463494|NCT06324708|Experimental|Hip arthroplasty group|This single group is composed by patients undergoing hip arthroplasty
89463495|NCT06324695|Experimental|HautKompass intervention|Participants in the intervention group will attend the self-guided 8-session online psychosocial intervention HautKompass.
89463496|NCT06324695|No Intervention|Waiting list|Participants in the control group will not attend any psychosocial intervention during the course of the RCT (waiting list). They will be offered the opportunity to attend the HautKompass program after the follow-up phase.
89463497|NCT06324682||Conventional right ventricular (RV) pacing|"The device (pace maker or implantable cardiac defibrillator) is implanted in the subcutaneous subclavian area (right or left) and it is connected to transvenous lead/leads (active or passive) implanted in the right cardiac chambers (atrium and ventricle or ventricle only), which detect intrinsic electrical activity and stimulate when needed. The ventricle pacing might be obtained with an apical or septal stimulation.~Vascular access might be from the cephalic, axillary or subclavian veins. Once positioned, lead's pacing threshold, sensing and impedance are measured. If the investigators find good and stable electrical parameters, the catheter(s) is(are) fixed and left in place."
89463498|NCT06324682||Conduction System Pacing|"The approach for the insertion of the device and of the transvenous leads is similar to the previous ones.~The ventricle activation might be obtained with the his bundle stimulation or with the left bundle branch area pacing downstream of the conduction block. Vascular access might be from the cephalic, axillary or subclavian veins.~Both selective and non-selective stimulation of the His bundle and the stimulation of the left bundle branch and left septum are considered successful. In both cases, attempts are made to locate the atrio-ventricular junction by fluoroscopic methods or with three-dimensional electroanatomical mapping system. The Hisian potential is sought and the catheter is positioned. In the LBBAP the investigators place the lead 1.5 cm below the His region and, with the pacemaking method, the investigators identify an area that electrocardiographically shows a W signal in V1 lead with D2 more positive than D3 - after checking the electrical parameters."
89463499|NCT06324682||Cardiac resynchronization therapy (CRT) either -pacing (CRTP) or -defibrillation (CRTD)|"The approach for the insertion of the device and of the transvenous leads is similar to the previous ones.~The right ventricle pacing (with a pacing lead or a defibrillation coil) might be obtained with an apical or septal stimulation, while the left ventricular pacing is achieved by placing a catheter (active or passive) in the posterolateral area through a venous branch of the coronary sinus.~Cardiac resynchronisation therapy (CRT) delivers biventricular or left ventricular only pacing.~Vascular access might be from the cephalic, axillary or subclavian veins. Once positioned, lead's pacing threshold, sensing and impedance are measured. If the investigators find good and stable electrical parameters, the catheter(s) is(are) fixed and left in place - paying attention to the phrenic nerve capture threshold."
89463500|NCT06324682||Epicardial pacing|"The device is usually placed in the subcutaneous abdominal area and the lead(s) is(are) secured in the epicardial surface. It is often used in congenital heart defects or post-cardiac surgery scenarios.~Surgeons may access the epicardium during open-heart surgery or with minimally invasive techniques."
89463501|NCT06324682||Leadless pacing|"The leadless device is placed via a percutaneous approach through a large-calibre (femoral) vein inside the right ventricle. It is suitable for patients needing a single chamber pacing such as patients with permanent atrial fibrillation with slow ventricular response, in some cases of paroxysmal atrioventricular block, or patients with a history of CIED infections.~The only one currently available has a cardiac muscle fixation system consisting of 4 self-expanding barbs.~Once positioned, pacing threshold, sensing and impedance are measured. If the investigators find good and stable electrical parameters, the catheter is left in place."
89463502|NCT06324669|Experimental|Ketone supplementation|100 mL flavoured drink containing 0.3 g/kg ketone monoester ((R)-3-hydroxybutyl (R)-3-hydroxybutyrate; ΔG®, University of Oxford; https://www.deltagketones.com)
88944545|NCT01881347|Experimental|Active First|Active resveratrol first, placebo second
88944546|NCT01881347|Experimental|Placebo first|Placebo first, active resveratrol second
88944547|NCT01881360|Experimental|Gluten-free diet|
88944548|NCT01881360|Active Comparator|Hypocaloric diet|
88944549|NCT01881386||Lymphoma|Lymphoma patients before and after receiving standard CHOP therapy
88944550|NCT01881386||Metastatic Colorectal|Patients with metastatic colorectal cancer
88944551|NCT01881386||Phase 1|Patients enrolled in Phase 1 clinical trials of new agents, whose mechanism of action is expected to lead to changes in lactate concentration
88944552|NCT01881386||Brain|Patients with primary brain tumours and patients with cerebral lymphoma
88944553|NCT01881399|Experimental|Fluorescence/Virtual cholangiography/IOC|"Prior to cholecystectomy, patients will undergo:~Fluorescence cholangiography (visualization following up to a maximum of 0.5 mg/kg ICG - usually 10 ml of 0,5 mg/ml solution)~Virtual cholangiography (enhanced-reality) superimposed on fluorescence images~Conventional IOC (intraoperative cholangiography)"
89463503|NCT06324669|Placebo Comparator|Placebo|Placebo with stevia and bitter agent to flavour match
89463504|NCT06324656|Active Comparator|Crystallized phenol|Crystallized phenol group: The patients will undergo to crystallized phenol application.
89463505|NCT06324656|Experimental|Crystallized phenol + platelet rich plasma|Crystallized phenol + platelet rich plasma group. Alongside the crystallized phenol application + patients also will receive platelet rich plasma injections in the same session.
89463506|NCT06324643|Experimental|Use Designed occupational therapy program in childern with erb's palsy|1st group treated by strengthening exercises , stretching ,and occupational therapy
89463507|NCT06324643|Experimental|Use designed occupational therapy program and sensory motor integration training|2nd group treated by strengthening exercises , stretching ,and occupational therapy and sensory motor integration training (use different textures and different temperature)
89463508|NCT06324630|Active Comparator|Produce Prescription Mobile Market|Usual care control is a produce prescription model prescribed by a clinician, providing funds to purchase 21 servings of fruit and vegetables per person at designated mobile market provider(s).
89463509|NCT06324630|Experimental|Produce Prescription Delivery|Intervention arm 1 is a healthy food delivery model, wherein the participant receives a customizable produce box providing 21 servings of fruits and vegetables per person.
89463510|NCT06324630|Experimental|Healthy Meal Kit Delivery|Intervention arm 2 is a healthy meal kit delivery model providing all ingredients to make 3+ meals with 21 servings of fruits and vegetables, with 6-9 meal options to choose from each week.
89463511|NCT06324604|Placebo Comparator|Cohort A1S - Healthy Volunteers|Cohort A1S (n = 6): MTX-101, Dose level 1 IV or Placebo IV, Single dose
89463512|NCT06324604|Placebo Comparator|Cohort A2S - Healthy Volunteers|Cohort A2S (n = 6): MTX-101, Dose Level 2 IV or Placebo IV, Single dose
89463513|NCT06324604|Placebo Comparator|Cohort A3S - Healthy Vounteers|Cohort A3S (n = 6): MTX-101, Dose Level 3 IV or Placebo IV, single dose
89463514|NCT06324604|Placebo Comparator|Cohort A4S - Healthy Volunteers|Cohort A4S (n =6): MTX-101, Dose Level 4 IV or Placebo IV, single dose
89463515|NCT06324604|Placebo Comparator|Cohort A5Sa - Healthy Volunteers|Optional Cohort A5Sa (n = 6): MTX-101, Dose level 6 IV or Placebo IV, Single Dose
89463516|NCT06324604|Placebo Comparator|Cohort A6M - Healthy Volunteers|Cohort A5M (n=8): MTX-101,Dose Level 4 IV or Placebo IV, dosed on Days 1 and 22 for a total of 2 doses
89463517|NCT06324604|Placebo Comparator|Cohort A7M - Healthy Volunteers|Cohort A6M (n = 6): MTX-101, Dose Level 5 IV or Placebo IV, dosed on Days 1 and 22 for a total of 2 doses
89463518|NCT06324604|Placebo Comparator|Cohort A7Ma - Healthy Volunteers|Optional Cohort A6Ma (n = 6): Dose Level 6 IV or Placebo IV, dosed on Days 1 and 22 for a total of 2 doses
89463519|NCT06324604|Placebo Comparator|Cohort B8 - Celiac Disease or Type 1 Diabetes Patients|"Dose Group 1 (n = 6): MTX-101 Dose Level 4 IV Day 1, placebo IV Day 22~Dose Group 2 (n = 6): Placebo IV Day 1, MTX-101 Dose Level 3 IV Day 22"
89463520|NCT06324604|Placebo Comparator|Cohort B9 -Celiac Disease or Type 1 Diabetes Patients|Dose Group 1 (n = 6): MTX-101 Dose Level 5 IV Day 1, placebo IV Day 22 Dose Group 2 (n = 6): Placebo IV Day 1, MTX-101 Dose Level 5 IV (or the maximum tolerated dose in Part A MAD) Day 22
89463521|NCT06324604|Placebo Comparator|Cohort A5Sa -Healthy Volunteers|Optional Cohort A5Sa (n = 6): MTX-101, up to Dose Level 6 IV or Placebo IV, Single Dose
89463522|NCT06324591|Other|patient with Chron's Disease|Only patient with Crohn's Disease
89463523|NCT06324578||subjects with AT|
89201902|NCT00929487|Active Comparator|Saline/blister pack solution|
89463524|NCT06324565||Ovarian Torsion|All female patients under the age of 18 with suspicious signs and symptoms of ovarian torsion
89463525|NCT06324539||Celiac Disease subjects|
89463526|NCT06324539||Controls subjects|
89463527|NCT06324513|Experimental|Med-CDED|The Mediterranean Crohn's Disease Exclusion Diet (Med-CDED) is the exclusion diet (CDED) adapted to the Mediterranean diet pattern. The Med-CDED consists of 2 phases in dietary therapy and a maintenance phase: the first phase lasting 8 weeks, the second phase lasting 16 weeks, and the maintenance phase, which for the purposes of the study will last 28 weeks.
89017946|NCT05768269||Cellular Therapy|Participants who have previously received an induced pluripotent stem cell (iPSC)-derived, ex vivo genome edited cellular therapy product in an eligible Century-sponsored index trial will be enrolled in this study for up to 180 months following the last treatment with a cellular therapy product in an eligible index trial.
89463528|NCT06324513|Active Comparator|CDED|The original Crohn's disease exclusion diet, used as a comparator, is widely employed among first-line treatments in clinical practice for inducing remission in pediatric patients with Crohn's disease
89463529|NCT06324487|Active Comparator|SEP Group|The treatment will be individualized by calculating the appropriate resistance loads for the exercise program. All participants will undergo progressive exercises in sessions conducted by a physiotherapist.
89463530|NCT06324487|Experimental|BFRT Group|People in the BFRT categories will perform the exercise program at approximately 20-30% resistance of 1-RM, and an upper arm reinforcement occlusion cuff will be used during strengthening exercises with dumbbells for the rotator cuff and scapula girdles
89463531|NCT06324474|Experimental|scaling and root planning with Hyaluronic acid application|patients will receive Hyaluronic acid topical gel after scaling and root planning at first week and receive the gel after one week
89463532|NCT06324474|Experimental|scaling and root planning only|patients will receive scaling and root planning only
89463533|NCT06324461|Experimental|Semaglutide group|Subject randomized into this group will receive single subcutaneous dose of Semaglutide 0.25mg 1 to 4 days prior to surgery, on top of routine peri-operative care
89463534|NCT06324461|No Intervention|Control group|Subject randomized into this group will receive routine peri-operative care
89463535|NCT06324435|Experimental|Apremilast|Apremilast (60mg/day). Administered orally twice daily at 8:00 AM and 8:00 PM while titrating to the full dose. Titration schedule: Day 1 10mg AM; Day 2 10mg AM, 10mg PM; Day 3 10mg AM, 20mg PM; Day 4 20mg AM, 20mg PM; Day 5 20mg AM, 30mg PM; Day 6 30mg AM, 30mg PM. Once at steady state, administration is orally twice daily at 8:00 AM (30mg) and 8:00 PM (30mg).
89463536|NCT06324422|Experimental|Aerobic exercise group|Participants must be clinically fatigued when enrolled and furthermore meet additional inclusion criteria.
89463537|NCT06324422|Experimental|Waitlist control group/resistance exercise group|Participants must be clinically fatigued when enrolled and furthermore meet additional inclusion criteria.
89463538|NCT06324396|Experimental|Assessment Arm|Assessment group will receive a single dose of oral sildenafil and oral pravastatin.
89463539|NCT06324383|Other|Intervention|Participants will be paired with an English language learner and engage in 8 weeks, 1 hour videoconferencing sessions.
89463540|NCT06324370|Experimental|Healthy Filipino male participants (18 to 45 yrs old)|"Healthy Filipino male participants 18 to 45 years old with optimum weight as related to height and body frame.~1.2ml/kg/dose of virgin coconut oil (VCO) will be administered orally with 240 ml of water and standardized food for a single dose, and 0.6ml/kg/dose of virgin coconut oil (VCO) with 240 ml of water and standardized food twice a day for 7 days for multiple doses."
89463541|NCT06324097||colorectal lesion|
89463542|NCT06324071|Experimental|Control group|Group supplemented with a daily dose of placebo
89463543|NCT06324071|Experimental|Experimental group|Group supplemented with 125 mg/day of TetraSOD®
89463544|NCT06323954|Experimental|tVNS stimulation|Brief electrical current will be applied to the vagus nerve area (the tragus or cymba concha, depending on the shape and size of the ear) immediately after successful trials during finger control training.
89463545|NCT06323954|Sham Comparator|Sham stimulation|Brief electrical current will be applied to the non-vagus nerve area (the earlobe) immediately after successful trials during finger control training.
89463546|NCT06323941|Experimental|Motor Imagery plus Isometric Exercise|This group will perform a therapeutic exercise programme (isometric exercises training) to which motor imagery training will be added.
89463547|NCT06323941|Active Comparator|Isometric Exercise|This group will perform a therapeutic exercise programme (isometric exercises training) to which sham motor imagery training will be added.
89463548|NCT06323538||vegans|vegan diet: no products of animal origin
89463549|NCT06323538||vegetarians|vegetarian diet: no meat and fish, but dairy products and eggs
89463550|NCT06323538||pescetarians|pescetarian diet: no meat, but fish
89463551|NCT06323538||mixed diet|mixed diet: plant-based foods and animal-based foods
89463552|NCT06323070|Active Comparator|Low-fat cookies|Subjects consume 100 kcal of low-fat cookies daily for 4 weeks.
89463553|NCT06323070|Experimental|Watermelon|Subjects consume 100 kcal of watermelon daily for 4 weeks.
89463554|NCT06323057|Experimental|Single-pulse Peak Phase TMS|Participants will receive a single active TMS pulse during the peak phase target of each task trial and delivered at 110% of participants' resting motor threshold over the predefined frontal target . For the second TMS session, participants will receive single pulse Sham TMS during the peak phase target of each task trial and delivered at 110% of participants' resting motor threshold over the predefined frontal target. Total number of TMS pulse for each session is 520 pulses
89463555|NCT06323057|Experimental|Single-pulse Trough Phase TMS|Participants will receive a single active TMS pulse during the trough phase target of each task trial and delivered at 110% of participants' resting motor threshold over the predefined frontal target . For the second TMS session, participants will receive single pulse Sham TMS during the peak phase target of each task trial and delivered at 110% of participants' resting motor threshold over the predefined frontal target. Total number of TMS pulse for each session is 520 pulses
89463556|NCT06322992||Cancer Patients Undergoing Treatment|The investigators will recruit 60 diverse cancer patients from the statewide M Health Fairview system to participate in month-long feasibility tests. The enrolled participants will be asked to: 1) Install the prototype app from the Google Play or Apple App Store on their smartphone (the investigators will provide a smartphone with the app pre-installed to participants who do not own one); 2) Carry the smartphone for 30 consecutive days while outside the home; 3) Keep smartphone location and motion services active; 4) Confirm and correct (if needed) smartphone-detected activities and trips; 5) Use the app interface to provide additional information on treatment-related activities and trips along with well-being ratings; and 6) Review a logistic toxicity summary report that will be available within the app towards the end of the field test.
89463557|NCT06322953|Active Comparator|Start/Restart DOAC at 1 week|Participants will be restarted/started on DOAC 1 week post traumatic intracranial hemorrhage (tICrH).
89017947|NCT05767736||Vumerity Cohort|Participants who have been prescribed Vumerity as a newly initiating treatment and not previously treated with Tecfidera are selected and the available data is collected retrospectively.
89017948|NCT05767736||Tecfidera Cohort|Participants who have been prescribed Tecfidera as a newly initiating treatment and not previously treated with Vumerity are selected and the available data is collected retrospectively.
89017949|NCT05767736||Vumerity/Tecfidera Switch Cohort|Participants who have been treated with Tecfidera and then switched to Vumerity as per routine medical care are selected and the available data is collected retrospectively.
89017950|NCT05767736||Selected Disease Modifying Therapies (DMTs) Treated Cohort|Participants who have been prescribed with other selected DMTs (teriflunomide, beta-interferons, or glatiramer acetate) and are not previously treated with Vumerity or Tecfidera are selected and the available data is collected retrospectively.
89017951|NCT05764928|Experimental|Phase I: 1.5 mg/kg BLEX404|Oral administration BID
89017952|NCT05764928|Experimental|Phase I: 3.0 mg/kg BLEX404|Oral administration BID
89017953|NCT05764928|Experimental|Phase I: 6.0 mg/kg BLEX404|Oral administration BID
89463558|NCT06322953|Active Comparator|Start/Restart DOAC at 4 weeks|Participants will be restarted/started on DOAC 4 weeks post traumatic intracranial hemorrhage (tICrH).
89463559|NCT06322576|Experimental|SPECT CT Dosimetry|Absorbed dose in tumor and normal organs will by measured using SPECT/CT dosimetry in Cohort 1.
89463560|NCT06322303|Placebo Comparator|Placebo (CBD 0%)|Participants are required to vaporize a placebo at 0% CBD concentration
89463561|NCT06322303|Experimental|CBD 15%|Participants are required to vaporize CBD at a concentration of 15%.
89463562|NCT06322303|Experimental|CBD 30%|Participants are required to vaporize CBD at a concentration of 30%.
89463563|NCT06322251|Other|Use of questionnaire|Intervention I: Over a period of two months, healthcare professionals will ask standardized questions about exposure to violence using a questionnaire that measures exposure to physical, psychological, and sexual violence over the past 12 months. These questions will be verbally asked to all patients visiting the care units, regardless of the reason for their visit.
89463564|NCT06322251|Other|Use of virtual patient|"Intervention II: Healthcare professionals will undergo training to ask questions about violence in close relationships and practice how to utilize the answers, determine necessary care and interventions, and refer patients further. This training will utilize a virtual patient scenario where users interact with a realistic simulated patient through recorded video sequences. The training with the virtual patient will be conducted individually. On the digital platform, users will have access to the patient's medical background and other relevant information. Users can choose questions from a question bank, and based on their choices, they will receive feedback from both the patient and experts on their questions and treatment in the final part of the platform."
89017954|NCT05764928|Experimental|Phase II: RDL of BLEX 404|Oral administration BID
89017955|NCT05757687|Experimental|Omega procedure|
89017956|NCT05745467|Experimental|Povidone Iodine|5% povidone iodine will be swabbed in patients' nares (experimental group), one in each nostril, twice before incision.
89017957|NCT05745467|No Intervention|Usual Care|Half of the patients will not receive 5% povidone iodine and will proceed with usual care.
89463565|NCT06322251|Other|Combined use of questionnaire and virtual patient|Intervention III: This intervention combines Intervention I and II methods. Participants will investigate the identification of intimate partner violence over a two-month period after training with the virtual patient and in parallel with administering the violence questionnaire.
89017958|NCT05741788|Experimental|Experimental group|Prospective cohort of patients clinically scheduled to undergo spinal cord stimulation for the treatment of chronic back pain or radiculopathy.
89463566|NCT06321991|Placebo Comparator|Dupuytren Disease patients receiving Vasiline (Placebo)|40 patients with Dupuytren Disease (primary DD nodules: stage 0, no contracture in the involved hand) will be randomized into the group where they will receive Vasiline
89463567|NCT06321991|Active Comparator|Dupuytren Disease patients receiving Remederm® (Vitamine E creme)|40 patients with Dupuytren Disease (primary DD nodules: stage 0, no contracture in the involved hand) will be randomized into the group where they will receive Remederm® (Vitamine E creme)
89017959|NCT05738499|Experimental|CSSTEP Group|"On the basis of routine post-stroke care, the CSSTEP programme was added for a total of three weeks. Each week includes one session course and three after-session strengths-based practicing activities. The names of the three sessions are: 1. Individualised education on character strengths and guidance on daily life skills in stroke; 2. Practicing activities onthree good things of character strengths and physical rehabilitation training for stroke; 3. New ways to use signature strengths and secondary stroke prevention."
89017960|NCT05738499|Placebo Comparator|Control Group|On the basis of routine post-stroke care, the regular structured treatment and education programme will be comducted for a total of three weeks. Each week includes one session course of structured treatment and education programme.
89017961|NCT05718843|Experimental|Group 1: Participants with severe renal impairment|
89017962|NCT05718843|Experimental|Group 2: Participants with normal renal function individually matched to participants of Group 1|
89017963|NCT05718843|Experimental|Group 3: Participants with moderate renal impairment|
89017964|NCT05718843|Experimental|Group 4: Participants with normal renal function matching Group 3|
89017965|NCT05718843|Experimental|Group 5: Participants with mild renal impairment|
89017966|NCT05718843|Experimental|Group 6: Participants with normal renal function matching Group 5|
89017967|NCT05716048|Experimental|KF-mSMT Plus Aerobic Exercise Training|Participants will undergo 12 weeks of supervised aerobic cycling exercise training. During the last 8 weeks of cycling exercise, participants will also undergo treatment with the Kessler Foundation modified Story Memory Technique as an approach for cognitive rehabilitation.
88944554|NCT01881438||Participants exposed to oral fluoroquinolones|Oral fluoroquinolones in this study are ciprofloxacin, levofloxacin, gatifloxacin, gemifloxacin, moxifloxacin, norfloxacin, and ofloxacin.
89463568|NCT06321458|Experimental|Intensive weight loss intervention|The intensive weight loss intervention (IWL) includes total dietary replacements, behavioural support, and weight loss medication. The intervention consists of three phases: induction, weight loss continuation, maintenance, and it will lasts two years in total.
89463569|NCT06321458|Active Comparator|Usual care|Denmark: usual care offered by the GP or local municipality. The UK: tier 3 weight management services.
89463570|NCT06321445||Experts|ASA scores provided by anesthesiologists
89463571|NCT06321445||ChatGpt|ASA scores provided by ChatGpt
89463572|NCT06321432|Experimental|Intensive weight loss intervention|The intensive weight loss intervention (IWL) includes total dietary replacements, behavioural support, and weight loss medication. The intervention consists of three phases: induction, weight loss continuation, maintenance, and it will lasts two years in total.
89463573|NCT06321432|Active Comparator|Usual care|Denmark: usual care offered by the GP or local municipality. The UK: usual care in primary care, Tier 2 weight management services.
89463574|NCT06321172|Experimental|FES cycling group|Six months of FES-cycling trainings twice a week were performed for each pilot. Each session includes at most 30 minutes of stimulation.
89463575|NCT06320925||Study Subjects|Patients who have undergone a surgical procedure (per product indications for use) using the Stryker implants who meet all of the following criteria will be screened and enrolled by participating Investigators.
89463576|NCT06320652|No Intervention|Standard care|All willing patients who are offered cardiac rehabilitation will comprise the control group. Patients in the control group will have access to standard care at the cardiac outpatient clinic program comprising standard center-based cardiac rehabilitation. The cardiac outpatient clinic registers activities and monitors patient participation in cardiac rehabilitation. Data on patient demographic, diagnoses, educational backgrounds, civil status, and patient-reported outcomes will be collected from self-reported questionnaires at baseline, and 3 months after.
89463577|NCT06320652|Experimental|Cardiac Telerehabilitation|"Patients in the intervention group will, in addition to standard care, be offered an individually tailored family-focused cardiac telerehabilitation (video consultations and home monitoring) developed through a co-creative process.~The cardiac outpatient clinic registers activities and monitors patient participation in cardiac rehabilitation. Data on patient demographic, diagnoses, educational backgrounds, civil status, and patient-reported outcomes will be collected from self-reported questionnaires at baseline, and 3 months after the intervention."
89463578|NCT06320262|Active Comparator|Intervention group|They will receive wet cupping therapy (WCT) every month for 3 consecutive months in addition to a home-based graded exercise program.
88944555|NCT01881464||endothelial dysfunction assessment|This study is a one arm study . In this arm we will assess endothelial function (with Endopath device) in patients with Crohn's disease, before and after treatment of anti TNF α and other medication, and evaluate the possible role of tumor necrosis factor (TNF)-α in the pathophysiology of this abnormality.
88944556|NCT01881477|Experimental|kinetics modalities|passive movements active movements assisted movements resisted movements
88944557|NCT01881490|Active Comparator|Group 1|120 Children with Crohn's disease undergoing MRE & colonoscopy will be enrolled and followed for 18 months. MRE exam will be repeated at 18 months.
88944558|NCT01881490|Active Comparator|Group 2|120 children with Crohn's disease undergoing colonoscopy will be recruited and will have an MRE/pelvic MRI performed. The two or three contending versions of each index (PICMI and pMEDIC) developed based on Group 1, will be then subjected to head-to-head evaluation of Group 2.
89463579|NCT06320262|No Intervention|Control group|they will receive a home-based graded exercise program, which is comprised of both aerobic and stretching exercises. The patients will be instructed to do the protocols with a gradual increase in both intensity and frequency.
89463580|NCT06320184||Intervention cohort|LDCT screening volunteers enrolled in the BioMILD trial (clinicaltrial.gov NCT02247453) with solid and sub-solid baseline LDCT lung nodules, including baseline-identified cancer patients.
88944559|NCT01881503|Other|All subjects|all qualifying subjects will receive HBOC-201 (Hemopure) to treat their life-threatening anemia
88944560|NCT01881516|Active Comparator|Acupuncture|Participants will receive 30-min sessions of true acupuncture per week after randomization for 6 weeks
88944561|NCT01881516|Sham Comparator|sham acupuncture|Participants will receive 30-min sessions of sham acupuncture per week after randomization for 6 weeks.
88944562|NCT01881529||Limited Scleroderma|
88944563|NCT01881529||Diffuse Scleroderma|
88944564|NCT01881555|Other|FRACTIONAL FLOW RESERVE|"Patients will have FFR measured in each diseased vessel identified by the coronary angiographic evaluation. Intra-coronary adenosine (at least 100 micrograms performed 2 times) OR intravenous adenosine (at a dose of 140µg/kg/min during at least 4 minutes) will be administered prior to FFR assessment.~Revascularization strategy will be based upon FFR findings and revascularization either by coronary stenting or CABG will only be performed on target lesions with FFR≤0.8."
89463581|NCT06320184||Validation cohort|LDCT screening volunteers enrolled in the SMILE trial (clinicaltrial.gov NCT03654105) and in the RISP trial (clinicaltrial.gov NCT05766046).
89463582|NCT06319794|Experimental|Bimiralisib - 2 weeks treatment|Topical bimiralisib for 2 weeks
89463583|NCT06319794|Experimental|Bimiralisib - 4 weeks treatment|Topical bimiralisib for 4 weeks
89463584|NCT06318884|Experimental|SCTB35|SCTB35 injection is subcutaneously given every week for the first 4 cycles, and thereafter every 3 weeks. Cycles will be repeated every 3 weeks until disease progression, study discontinuation, or death, whichever occurs first.
89463585|NCT06317987|Experimental|Care Navigation (pilot)|Mental health care coordinators are able to offer and refer patients to a care navigator in addition to offering substance use resources and treatment options as usual.
89463586|NCT06317987|No Intervention|Services as Usual (pilot)|Mental health care coordinators will continue offering substance use resources and treatment options to patients as usual
89463587|NCT06317753|Experimental|Experimental condition 1|Participants allocated to the Experimental condition 1 will be following a aerobic exercise training program.
89463588|NCT06317753|Experimental|Experimental condition 2|Participants allocated to the Experimental condition 2 will be following an agility-cognitive exercise training program.
89463589|NCT06317753|Active Comparator|Control condition|Participants allocated to the Control condition will be following a stretching/relaxation training program.
89463590|NCT06317493||Hearing threshold without aids|Case group with hearing impairment (HI) (hearing threshold >35 dB) without aids
89463591|NCT06317493||Hearing threshold with cochlear implant|Case group with hearing threshold corrected with cochlear implant (CI)
89463592|NCT06317493||Hearing threshold with aids|Case group with hearing threshold corrected with hearing aids
89463593|NCT06317493||Control group|Control group of normally hearing age-matched children
88944565|NCT01881555|Other|ANGIOGRAPHY|Patients undergo an angiography. Based on angiographic evaluation, the physicians define the revascularization strategy.
88944566|NCT01881568|Experimental|Experimental|"Topical administration of 3g of Tranexamic Acid in 100mL of normal saline (0.9% sodium chloride) as follow:~50mL by irrigation before wound closure~50mL by intraarticular administration (Drenofast) after wound closure.~Intravenous administration of Normal saline (0.9% sodium chloride) as follow:~100mL before tourniquet realised~100mL 3 hours after surgery"
88944567|NCT01881568|Active Comparator|Comparator|"Topical administration of Normal saline (0.9% sodium chloride) as follow:~50mL by irrigation before wound closure~50mL by intraarticular administration (Drenofast) after wound closure~Intravenous administration of two dosis of Tranexamic Acid as follow:~15mg/kg of Tranexamic Acid in 100mL of normal saline (0.9% sodium chloride), before tourniquet realised~15mg/kg of Tranexamic Acid in 100mL of normal saline (0.9% sodium chloride), 3 hours after surgery"
88944568|NCT01881581|Experimental|Lower dose DNA or Placebo|2.0 mL lower dose D-GPEi (0.5mg) or Saline solution at weeks 0
88944569|NCT01881581|Experimental|Medium dose DNA or Placebo|2.0 mL medium dose D-GPEi (2mg) or Saline solution at weeks 0
88944570|NCT01881581|Experimental|High dose DNA or Placebo|2.0 mL high dose D-GPEi (4mg) or Saline solution at weeks 0
88944571|NCT01881581|Experimental|Lower dose MVA or Placebo|100μL lower dose M-GPE (3×10^7pfu) or Saline solution at weeks 0
88944572|NCT01881581|Experimental|Medium dose MVA or Placebo|100μL medium dose M-GPE (1×10^8pfu) or Saline solution at weeks 0
88944573|NCT01881581|Experimental|High dose MVA or Placebo|300μL high dose M-GPE (3×10^8pfu) or Saline solution at weeks 0
88944574|NCT01881581|Experimental|Low dose DNA+MVA or Placebo control|The dose below the maximum tolerated dose of D-GPEi or 2.0 mL Saline solution at week 0,1; The dose below the maximum tolerated dose of M-GPE or 100/300μL Saline solution at week 2,3
88944575|NCT01881581|Experimental|High dose DNA+MVA or Placebo control|The maximum tolerated dose of D-GPEi or 2.0 mL Saline solution at week 0,1;The maximum tolerated dose of M-GPE or 100/300μL Saline solution at week 2,3
88944576|NCT01881594|Active Comparator|No stimulation|unstimulated patients prior to surgery,ileostomy closure surgery without prior stimulation of efferent limb.
88944577|NCT01881594|Experimental|Stimulation|stimulation of the efferent limb of the ileostomy prior to ileostomy closure.
88944578|NCT01881607|No Intervention|Control|Schoolchildren aged 12-13 years in the first year of Compulsory Secondary Education (Enseñanza Secundaria Obligatoria in the Spanish educational system) in the city of Terrassa. The CONTROL arm is formed by schoolchildren in schools that willnot receive the intervention and will continue with ongoing (usual) health education sessions.
89017968|NCT05716048|Active Comparator|KF-mSMT Plus Stretching Exercise Training|Participants will undergo 12 weeks of supervised stretching and toning exercise training. During the last 8 weeks of stretching exercise, participants will also undergo treatment with the Kessler Foundation modified Story Memory Technique as an approach for cognitive rehabilitation.
89201903|NCT00603837|Experimental|Blanket|This arm includes those Extremely low gestational age newborns (ELGANs) who are to be placed on a sodium acetate warming blanket after delivery.
89463594|NCT06316453||Non pre-existing ASCVD|ASCVD risk in adults will be assessed alongside demographics and clinical history. The study will calculate 10-year, 30-year, and lifetime ASCVD risks, incorporating genetic assessment for Apo B. Personalized management recommendations based on ASCVD risk will be provided, and a six-month follow-up will track ASCVD events.
89463595|NCT06312709|Experimental|teleABLE|Participants meet with a study therapist 2x/week for 6 weeks (12 sessions) to complete behavioral activation focused on adding personally meaningful non-sedentary activities during times when they typically spend sitting. All sessions are delivered remotely using Zoom videoconferencing.
89463596|NCT06312709|Active Comparator|Health Education|Participants meet with a study therapist 1x/week for 6 weeks (6 sessions) to review fact sheets focused on healthy lifestyles after stroke. All sessions are delivered remotely using Zoom videoconferencing.
89463597|NCT06311071||patient group|patient suspected to have coronary artery disease in noninvasive tests
89463598|NCT06310148|Experimental|Participating in Chronic Disease Co-Care Pilot Scheme|Participants will receive comprehensive health management plans and necessary medication treatment from family doctors, based on their clinical condition. Nurse clinic will provide disease prevention education, health assessment, and counselling services, whereas allied health professionals (including optometrists, podiatrists, dietitians, and physiotherapists) will provide individualized intervention services for participants.
89463599|NCT06310148|No Intervention|Not participating in Chronic Disease Co-Care Pilot Scheme|Eligible non-CDCC participants will only be referred to the laboratories of a designated service provider by the research team for physical examination, blood tests, and urine test as a screening for DM and HT. No health management plans and necessary medication treatment would be provided to them in this study.
89463600|NCT06308666|Experimental|Refit|Refit and dispense participant with delefilcon A contact lenses and evaluate lens performance
89463601|NCT06307431|Experimental|V940 + Pembrolizumab|Participants will receive V940 1 mg via intramuscular (IM) injection every 3 weeks (Q3W) for up to 9 doses plus Pembrolizumab 400 mg via an intravenous (IV) infusion every 6 weeks (Q6W) for 9 cycles (up to ~54 weeks). Each cycle is 6 weeks.
89463602|NCT06307431|Active Comparator|Placebo + Pembrolizumab|Participants will receive placebo as an IM injection Q3W for up to 9 doses plus Pembrolizumab 400 mg via an IV infusion Q6W for 9 cycles (up to ~54 weeks). Each cycle is 6 weeks.
89463603|NCT06304740|Experimental|IMG-007 Cohort 1 (Healthy Participant)|Cohort 1 will receive a single subcutaneous dose of IMG-007 Dose 1 or matching placebo.
89463604|NCT06304740|Experimental|IMG-007 Cohort 2 (Healthy Participant)|Cohort 2 will receive a single subcutaneous dose of IMG-007 Dose 2 or matching placebo.
89463605|NCT06304740|Experimental|IMG-007 Cohort 3 (Healthy Participant)|Cohort 3 will receive a single subcutaneous dose of IMG-007 Dose 3 or matching placebo.
89463606|NCT06303986||Observational Group|These are the neonates enrolled in the study to collect data and aid in establishing continuous monitoring advantages.
89463607|NCT06302088|No Intervention|Waitlist Control Arm|Control Arm engages in baseline, 6-and-12-month surveys, as well as baseline interviews and 24-month interviews. They engage in standard operating procedures and do not take part in the intervention
89463608|NCT06302088|Experimental|SAINTS program Intervention Arm|Intervention arm engages in baseline, 6-and-12-month surveys, as well as baseline interviews and 24-month interviews. They engage in safety training programs and quality improvement cycles during the duration of the intervention.
89463609|NCT06300723|Experimental|BRL-101|Autologous CD34+ hHSPCs modified with CRISPR-Cas9 at the BCL11A gene. Subjects will receive a single infusion of BRL-101.
89463610|NCT06298630||BRL-101|All patients who have received BRL-101
88944579|NCT01881607|Experimental|Intervention|"The intervention at the classroom consisted of six sessions with the pupils of one hour each that were conducted by the teacher/tutor. We provided the teachers with a training session and a teachers' guide, and we gave each pupil a workbook with the activities. At the school level, the intervention consisted of four types of posters with specific messages directed to students, teachers, and parents, and the fourth poster type advertised the new smoking laws. we gave teachers and school managers the guide Towards a Smoke-Free School to facilitate the prevention and control of smoking (active and passive) in the school environment. Family level activities: Parents were required to complete the My risk thermometer activity at home with their children. Parents received a brochure with information on the risks of SHS exposure and recommendations to prevent SHS exposure, and a refrigerator magnet with the logo of the program."
88944580|NCT01881633|Experimental|ISU302|15 U/kg I.V. injection
88944581|NCT01881633|Experimental|ISU302 30 U/kg|Drug ISU302 I.V. injection
88944582|NCT01881633|Experimental|ISU302 60 U/kg|Drug ISU302 I.V. injection
88944583|NCT01881633|Placebo Comparator|Placebo|ISU302 Placebo I.V. injection
88944584|NCT01881646|Experimental|Positron emission tomography (PET)|Positron emission tomography (PET) using [11C]PBR28
88944585|NCT01881672||Coma patients in ICU under mechanical ventilation|
88944586|NCT01881711|Experimental|SCMP plus Imaging|SCMP plus Imaging will be compared to clinical outcomes within 7 days of ED/NC visit - either shunt obstruction confirmed during shunt revision surgery or shunt patency confirmed by no surgery or patency confirmed in surgery.
88944587|NCT01881711|Active Comparator|Imaging Alone|Imaging alone will be compared to clinical outcomes within 7 days of ED/NC visit - either shunt obstruction confirmed during shunt revision surgery or shunt patency confirmed by no surgery or patency confirmed in surgery.
88944588|NCT01881711|Experimental|SCMP Rule Out for Low Risk Cases|"SCMP results in patients judged by the physician to be Unlikely to require shunt surgery will be compared to clinical outcomes within 7 days of ED/NC visit - either shunt obstruction confirmed during shunt revision surgery or shunt patency confirmed by no surgery or patency confirmed in surgery - to determine Negative Predictive Value in ruling out shunt malfunction"
88944589|NCT01881711|Active Comparator|Imaging Rule for Low Risk Cases|"Imaging results in patients judged by the physician to be Unlikely to require shunt surgery will be compared to clinical outcomes within 7 days of ED/NC visit - either shunt obstruction confirmed during shunt revision surgery or shunt patency confirmed by no surgery or patency confirmed in surgery - to determine Negative Predictive Value in ruling out shunt malfunction"
88944590|NCT01881711|Experimental|SCMP plus Imaging in Uncertain Cases|"SCMP plus imaging results in patients who are admitted for observation results in patients judged by the physician to be Unlikely to require shunt surgery will be compared to clinical outcomes within 7 days of ED/NC visit - either shunt obstruction confirmed during shunt revision surgery or shunt patency confirmed by no surgery or patency confirmed in surgery - to determine Positive and Negative Predictive Value"
89463611|NCT06298604|Active Comparator|Standard EUS-guided FNB|Patients scheduled for EUS-guided liver or pancreas biopsy will undergo the procedure using a standard 19-gauge needle
89463612|NCT06298604|Experimental|Motorized EUS-guided FNB|Patients scheduled for EUS-guided liver or pancreas biopsy will undergo the procedure using a motorized 20-gauge needle.
89463613|NCT06295835|Other|Method comparison for K and iCa Tests using capillary whole blood specimens.|Compare the performance of the K and iCa Tests using the IUO i-STAT CG8+ Cartridge on the i-STAT 1 Analyzer to the performance of the K and iCa Tests on the comparator device using capillary whole blood specimens collected from two separate fingersticks.
89463614|NCT06293274|Experimental|Discharge education|"Participants assigned to the discharge education group will receive discharge education about postpartum blues and postpartum depression. A Personal Information Form will be used. Discharge training and data collection are expected to take approximately 15-20 minutes. 5-7 days postpartum after the mothers are discharged. The 32-item Motherhood Sadness Scale will be administered by the researcher by telephone during the following days. In the 6th week of the postpartum period, the mothers will be contacted by the researcher by telephone and the 10-item Edinburgh Postpartum Depression Scale will be administered."
88944591|NCT01881711|Active Comparator|Imaging alone in Uncertain Cases|"Imaging results in patients who are admitted for observation results in patients judged by the physician to be Unlikely to require shunt surgery will be compared to clinical outcomes within 7 days of ED/NC visit - either shunt obstruction confirmed during shunt revision surgery or shunt patency confirmed by no surgery or patency confirmed in surgery - to determine Positive and Negative Predictive Value"
88944592|NCT01881724|No Intervention|Usual Care|
88944593|NCT01881724|Experimental|sleep education program|
89017969|NCT05712707|Experimental|BXCL501 (180 micrograms)|The current study is a randomized, double-blind, double-dummy inpatient study comparing BXCL501 (180 and 240 ug BID), lofexidine (as a positive control), and placebo.
89201904|NCT00603837|Experimental|Wrap|This arm includes those ELGANs randomized to be wrapped in polyethylene after delivery.
89463615|NCT06293274|No Intervention|Routine discharge training|"Participants assigned to the routine discharge training group will receive routine discharge training. A personal information form will be used. Discharge training and data collection are expected to take approximately 15-20 minutes. 5-7 days postpartum after mothers are discharged. The 32-item Motherhood Sadness Scale will be administered by the researcher by telephone during the following days. In the 6th week of the postpartum period, the mothers will be contacted by the researcher by telephone and the 10-item Edinburgh Postpartum Depression Scale will be administered."
89463616|NCT06291909|Placebo Comparator|Condensed Program Group|Identification of optimal time use with comparison to current time use. No research staff supported goal setting, provision of lifestyle information resources through website (no other website functionality available).
89463617|NCT06291909|Experimental|Extended Program Group|Identification of optimal time use with comparison to current time use, complete access to the Small Steps digital interface, frequent one-on-one support from research staff, supported goal setting and behaviour change choices.
89463618|NCT06291493|Other|Precision assessment of Potassium (K) test in capillary blood sample|Prospectively collected capillary specimens from two separate fingerstick blood draws.
89463619|NCT06290388|Experimental|Phase 1|Participants will receive escalating doses of 23ME-01473
89463620|NCT06286917|Active Comparator|NIV initiation in outpatient clinic in patients with ALS|Starting the NIV at the outpatient clinic
89463621|NCT06286917|Active Comparator|NIV initiation in pulmonary ward in patients with ALS|Starting the NIV in the pulmonary ward
89463622|NCT06283615|Experimental|Vitamin D|Experimental group: In addition to conventional treatment, additional intramuscular injection of vitamin D2 was given once every two weeks, each dose of 600,000 units, and the treatment lasted for 12 weeks.
89463623|NCT06283615|No Intervention|Control|Control group: routine treatment only, no additional vitamin D intervention therapy.
89463624|NCT06283147|Experimental|RAMP Knee OA|"Patients allocated to the intervention group will continue their usual care at the GOPCs, plus enrolment into the RAMP-Knee OA program."
89463625|NCT06283147|No Intervention|Usual Care group|"Patients allocated to the usual care arm will continue receiving their usual care at the GOPCs without any additional intervention. Usual care typically refers to the established and commonly provided treatments, interventions, and practices that patients would receive in routine clinical practice for their particular condition or disease. For GOPCs in Hong Kong, the follow-up period for all chronic diseases is typically every 4 months. Each consultation at GOPC has an average duration of 3-5 minutes, during which physicians will address all chronic diseases, including knee OA. Physicians may provide brief healthcare advice, prescribe chronic medications and analgesics if necessary, and refer patients to physiotherapy if indicated. The management approach for knee OA and other chronic diseases will be solely at the discretion of the attending physicians."
89463626|NCT06277752|Experimental|IBI128|IBI128 po. QD(Quaque Die)
89463627|NCT06277232|Other|All participants|"Through the Diet4painrelief platform, the dietician will follow up the progress of each participant in different timepoints during pain rehabilitation process: 4 weeks before the Interdisciplinary Pain Rehabilitation Program (IPRP), 1-2 meetings with patients as well as other professionals integrated in IPRP, and 4 weeks after IPRP rehabilitation (via chat function).~The IPRP is conducted in groups of six to nine participants and is based on cognitive behavioral treatment principles and included physiotherapy, ergonomics, training in coping strategies, occupational therapy, and education in pain management. An IPRP delivers a group-treatment format by an interdisciplinary team (i.e., physician in rehabilitation, a physiotherapist, an occupational therapist, and a psychologist). The IPRP lasts for 12 weeks."
89463628|NCT06277141|Experimental|Standard message|standard message reminder to screen for breast cancer.
89463629|NCT06277141|Experimental|Radiology Booking Site Link|Message with an online link to a radiology practice booking site.
89463630|NCT06277141|Experimental|Radiology practice telephone numbers|Message with a list and telephone numbers of radiology practices.
89017970|NCT05712707|Experimental|BXCL501 (240 micrograms)|The current study is a randomized, double-blind, double-dummy inpatient study comparing BXCL501 (180 and 240 ug BID), lofexidine (as a positive control), and placebo.
89463631|NCT06277141|No Intervention|Control - no message|Participants will not receive any messaging regarding mammography.
89463632|NCT06277141|Experimental|Radiology booking site link and telephone numbers.|Message with a direct online link to a radiology practice booking site and telephone numbers of radiology practices.
89463633|NCT06276998|Experimental|LNK01001 12 mg|Period 1: Participants receive LNK01001 12 mg twice daily for 24 weeks. Period 2: Participants will continue on LNK01001 12 mg twice daily from Week 24 to Week 76.
89463634|NCT06276998|Placebo Comparator|Placebo / LNK01001 12 mg|Period 1: Participants receive a placebo twice daily for 24 weeks. Period 2: Participants will switch to receive LNK01001 12 mg twice daily from Week 24 to Week 76.
89463635|NCT06276946|Active Comparator|Mean Parotid|Standard radiotherapy planning aims to restrict the mean parotid radiation dose to less than or equal to 14 Gy.
89463636|NCT06276946|Experimental|Parotid Duct|Magnetic resonance images will be used to localize the parotid ducts and limit the radiation dose to these structures to less than or equal to 14 Gy.
89017971|NCT05712707|Active Comparator|Lofexidine (Positive Control)|The current study is a randomized, double-blind, double-dummy inpatient study comparing BXCL501 (180 and 240 ug BID), lofexidine (as a positive control), and placebo.
89463637|NCT06275841|Experimental|vepdegestrant with or without esomeprazole|vepdegestrant administered as a single dose in Period 1 and Period 2. Esomeprazole administered once a day for 5 days in Period 2
89463638|NCT06273605|Other|Egg Ladder|An egg ladder is a form of home-based dietary advancement therapy that aims to facilitate the development of natural tolerance through the gradual introduction of egg containing foods with increasing quantity and allergenicity through different cooking processes. This intervention involves 5 steps over a 12 month period 1.baked egg, 2.well-cooked egg as an ingredient, 3. well cooked whole egg, 4. lightly cooked whole egg and 5.then raw egg.
89463639|NCT06270667|Experimental|Aerobic Exercise|Aerobic Exercise twice weekly for 5 months.
89463640|NCT06270667|Experimental|Combined Aerobic and Resistance Exercise|Combined Aerobic and Resistance Exercise twice weekly for 5 months.
89463641|NCT06270667|No Intervention|Standard Care|Standard Care, i.e no exercise intervention.
89463642|NCT06270667|Active Comparator|Reference Aerobic Exercise|Aerobic Exercise twice weekly for 5 months.
89463643|NCT06267586|Experimental|PeptiSleep 250 mg/day|Low dose Given as 1 capsule 1 hour before bed
89463644|NCT06267586|Experimental|PeptiSleep 500 mg/day|Middle dose Given as 2 capsules 1 hour before bed
89463645|NCT06267586|Experimental|PeptiSleep 1000 mg/day|High dose Given as 4 capsules 1 hour before bed
89463646|NCT06267586|Placebo Comparator|Microcrystalline Cellulose 500mg/day|Placebo Given as 2 capsules 1 hour before bed
89463647|NCT06262919||Tafinlar/Mekinist|Patients with BRAF V600E mutation positive unresectable advanced or recurrent solid tumors treated with dabrafenib and trametinib as per Japanese Package Insert.
89463648|NCT06262607|Experimental|CLE-400 (Detomidine topical gel)|Topical CLE-400 gel 0.28% once daily
88944594|NCT01881802||morphine or heroin dependence patients|
88944595|NCT01881802||normal control group|
88944596|NCT01881815||No treatment|No cohort as this study is not using a treatment or intervention only swabs are being collected.
88944597|NCT01881841|No Intervention|Treatment As Usual|Those randomized to Treatment as Usual (TAU) will not complete cMET but will receive standard treatment from the doctor.
88944598|NCT01881841|Experimental|cMET|Those randomized to cMET will complete a 2-session computerized Motivational Enhancement Therapy (cMET) intervention.
88944599|NCT01881854||craniopharyngioma|Patients treated for craniopharyngioma, most of them on pituitary substitution therapy
88944600|NCT01881854||Healthy controls|matched for gender, age and BMI to the patients
88944601|NCT01881880|Other|Tomosynthesis|Bilateral mammography with 4 views Tomosynthesis
88944602|NCT01881893|No Intervention|Usual Care|Patients in this arm of the study will continue to receive their regular level of care.
88944603|NCT01881893|Experimental|ACHD-CARE Program|"Group based psychosocial intervention.~Educational: congenital heart disease information~Behavioral: cognitive behavioral therapy~Behavioral: social interactions and communication skills"
89463649|NCT06262607|Placebo Comparator|Vehicle|Topical vehicle gel once daily
88944604|NCT01881906|Other|Control - usual care|"The patients randomized to the control group received no training but are offered the chance to participate in the supervised training after they have completed their antineoplastic treatment, at least after twelve weeks. Patients in early 2nd line treatment (switch maintenance) will be offered training after 12 weeks, although they have not completed chemotherapy."
88944605|NCT01881906|Other|Exercise + usual care|The supervised exercise training is carried out in groups of 12-16 patients and each session has a duration of 1.5 hours. The training comprised warm up exercises, strength and fitness training as well as stretching. Warm up exercises consisted of 10 minutes of light, stationery cycling, adjusted to 60-90% of the patient's maximum HR. The practical aim of strength training was to complete 3 series of 5-8 sets, with 70-90% of 1RM. Cardiovascular training was carried out as interval training on stationery bikes. Intensity was equivalent to 85-95% of each patient's maximum HR and lasted approximately 10-15 minutes. After the training session, 5-10 minutes were dedicated to stretching the large muscle groups in order to increase agility. Following each training session, progressive relaxation of 15-20 minutes was performed.
88944606|NCT01881919|Experimental|Treatment|Daily intake of Quercetin supplement 500mg tablet for 28 days with meal (breakfast preferred.)
88944607|NCT01881919|Placebo Comparator|Placebo|Daily intake of Placebo (lactose) tablet for 28 days with meal (breakfast preferred)
88944608|NCT01881945|Experimental|Physiological measurments|
88944609|NCT01881958|Experimental|DiaPep277®|
89463650|NCT06259552|Experimental|Part 1: Dose escalation and expansion study of SPX-303|"Dose Escalation Phase: SPX-303 will be administered intravenously (IV) every 3 weeks (Q3W). Participants enroll with measurable disease who have progressed on or after prior therapy and who are not eligible or decline treatment options.~Dose Expansion phase: SPX-303 will be administered at the dose level chosen during the escalation phase in the dose expansion cohort."
89463651|NCT06259552|Experimental|Part 2: Dose expansion study of SPX-303 in specific indications|SPX-303 will be administered in specific solid tumor patients to evaluate the preliminary antitumor activity and define the RP2D.
89463652|NCT06256003|Active Comparator|UC-A|UC-0A is a digital mobile app intervention that uses cognitive control skills for task performance. The intervention is used once a day, 5 days a week, for 7 weeks.
89463653|NCT06256003|Active Comparator|UC-N|UC-0N is a digital mobile app intervention that uses cog control skills for problem solving. The intervention is used once a day, 5 days a week, for 7 weeks.
89463654|NCT06250023||Standart of care|"Standard of care (comparator)~Uncomplicated PVO: 2 weeks IV ABs followed by oral ABs for 4 weeks.~Complicated PVO: 2-4 weeks IV ABs followed by oral ABs for 8 weeks."
89017972|NCT05712707|Placebo Comparator|Placebo|The current study is a randomized, double-blind, double-dummy inpatient study comparing BXCL501 (180 and 240 ug BID), lofexidine (as a positive control), and placebo.
89463655|NCT06250023||Early shift|"Early shift to oral ABs (intervention)~Uncomplicated PVO: 1 week IV ABs followed by 5 weeks of oral ABs.~Complicated PVO: 1 week IV ABs followed by 11 weeks of oral ABs."
89463656|NCT06248268||Suicide attempters|Patients with at least one previous suicide attempt
89463657|NCT06248268||Suicide ideators|Patients with suicidal thoughts, but no previous suicide attempt
89463658|NCT06248268||Clinical control group|Patients without suicidal behavior and thoughts
89463659|NCT06248268||Healthy controls|Healthy persons without suicidal behavior and thoughts
89463660|NCT06243887|Other|Conventional group|patients of minimally invasive esophagectomy with standard of care approaches
89463661|NCT06243887|Other|ERAS group|patients of minimally invasive esophagectomy with enhanced recovery after surgery protocol
89463662|NCT06240637|Active Comparator|Telemonitoring group|Follow-up model adding telemonitoring with remote review of HMV data on a daily basis during the first 2 weeks and subsequently weekly up to 6 months. Telephone contact with the patient in case of any eventuality and timely adjustments to therapy. Patients will attend in-person follow-up visits at 2, 4, and 6 months after initiating HMV. Clinical and gasometric control, nocturnal pulse oximetry, questionnaires, and download of ventilator data. Timely adjustments to therapy.
89463663|NCT06240637|No Intervention|Control group|Exclusive in-person follow-up model with control visits at 2 weeks, 1, 2, 4, and 6 months after initiating HMV. Clinical and gasometric control, nocturnal pulse oximetry, questionnaires, and download of ventilator data. Timely adjustments to therapy
89463664|NCT06229145|Experimental|Pegloticase + Methotrexate Q4W|16 mg pegloticase will be administered intravenously every 4 weeks for 24 weeks during double blind treatment and 24 weeks during open label.
89463665|NCT06229145|Experimental|Pegloticase + Methotrexate Q2W|8 mg pegloticase will be administered intravenously every 2 weeks for 24 weeks during double blind treatment and 16 mg pegloticase every 4 weeks for 24 weeks during open label.
89463666|NCT06224673|Experimental|Cohort 1: HR+/HER2-low|Participants with hormone receptor positive (HR+), human epidermal growth factor receptor 2 (HER2)-low will receive ARX788 intravenously over 90 minutes on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Participants also undergo CT, PET/CT, and collection of blood samples throughout the study.
89463667|NCT06224673|Experimental|Cohort 2: TNBC|Participants with confirmed triple negative breast cancer (TNBC), human epidermal growth factor receptor 2 (HER2)-low will receive ARX788 intravenously over 90 minutes on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Participants also undergo CT, PET/CT, and collection of blood samples throughout the study.
89463668|NCT06214897|Experimental|C-RUSF (Ready-to-use Supplemental Food with added choline)|A daily dose of 500 Kcal of RUSF containing 500mg choline will be provided
89463669|NCT06214897|Active Comparator|S-RUSF (Standard Ready-to-use Supplemental Food without added choline)|A daily dose of 500 Kcal of RUSF without choline
89463670|NCT06214156|Experimental|T3011|
89463671|NCT06213571|Experimental|Supportive Care (home-based exercise program)|Participants participate in a home-based exercise program with an exercise prescription that will include resistance band and body weight exercises targeting the 5 major large muscle groups along with 3 booklets about exercise and exercise training and attend weekly exercise coaching sessions to report on exercise adherence and to progress exercise over 10 weeks on study.
89463672|NCT06212154|Experimental|ThisCART19A|ThisCART19A comprises of allogeneic T-cells, which are genetically engineered to express chimeric antigen receptor (CAR) and targets cells expressing CD19.
89463673|NCT06209359|Active Comparator|Ammonium chloride|"Participants will be randomized to ammonium chloride vs placebo. On Day 0 and 1, the participant will take ammonium chloride or placebo 75 mmol twice daily.~On Day 2, the participant will take ammonium chloride 150 mmol or placebo once"
89463674|NCT06209359|Placebo Comparator|Placebo|"Participants will be randomized to ammonium chloride vs placebo. On Day 0 and 1, the participant will take ammonium chloride or placebo 75 mmol twice daily.~On Day 2, the participant will take ammonium chloride 150 mmol or placebo once"
89017973|NCT05707078|Other|Surgery|Based on PET/CT scan patients will undergo neck dissection.
89017974|NCT05692154|Experimental|Arm A (active-active)|Two days of pre-treatment with Fexofenadine, then Fexofenadine180 mg during the test pollen challenge.
89017975|NCT05692154|Experimental|Arm B (placebo-active)|Two days of pre-treatment with Placebo, then Fexofenadine180 during the test pollen challenge.
89017976|NCT05680844||normal cholesterol level group|Serum total cholesterol level of < 5.17 mmol/L
89463675|NCT06201416|Experimental|SBT777101 Dose 1|Low dose SBT777101
89463676|NCT06201416|Experimental|SBT777101 Dose 2|Mid dose SBT777101
89463677|NCT06201416|Experimental|SBT777101 Dose 3|High dose SBT777101
89463678|NCT06194877|Experimental|Part 1: Dose Finding Part|Participants with advanced or metastatic CRC and with known mutation status and tumor harboring an oncogenic mutation of BRAF, KRAS, or NRAS and with documented disease progression by RECIST during or after at least 1 line of prior therapy will be enrolled into 4 planned sequentially run cohorts. Participants will receive escalating doses of BGB-3245 in combination with panitumumab to establish the MTD and RP2D by assessing the safety, tolerability, preliminary antitumor activity, and pharmacokinetics (PK) for the combination of BGB-3245 with panitumumab.
89463679|NCT06194877|Experimental|Part 2: Dose Expansion Part, Group 1|Participants with advanced or metastatic CRC that harbors KRAS or NRAS mutations who have been treated and had documented disease progression by RECIST criteria during or after at least 1 line of prior therapy. Participants will receive the RP2D of BGB-3245 in combination with panitumumab to further evaluate the safety, PK, and assess the preliminary antitumor activity of the RP2D of the BGB-3245 and panitumumab combination.
89501908|NCT03500263|Placebo Comparator|Cohort 4 PTI-808 Placebo + PTI-801 Placebo + PTI-428 Placebo|Subjects will be randomized to receive either PTI-808 co-administered with PTI-801 and PTI-428 or placebos once-a-day for 7 days immediately followed by PTI-808 co-administered with PTI-801 or placebos once-a-day for 7 days. A follow-up visit will occur on Day 21.
89463680|NCT06194877|Experimental|Part 2: Dose Expansion Part, Group 2|Participants with advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) that harbors KRAS mutations who have been treated and had documented disease progression by RECIST criteria during or after at least 1 line of prior therapy. Participants will receive the RP2D of BGB-3245 in combination with panitumumab to further evaluate the safety, PK, and assess the preliminary antitumor activity of the RP2D of the BGB-3245 and panitumumab combination.
89463681|NCT06184737|Experimental|iSIPsmarter|iSIPsmarter is a technology-based behavioral and health literacy intervention. It is comprised of six Internet-delivered Cores, an integrated short message service (SMS) strategy to engage users in tracking SSB behaviors, and the incorporation of a cellular enabled scale for in-home weight tracking. Participants will be prompted (via email or text) to self-monitor their sugar-sweetened beverage intake. iSIPsmarter is a highly interactive, structured, and self-guided program that uses strategies previously proven to promote behavior change. iSIPsmarter also incorporates a stepped care approach to re-engage users who struggle to complete components.
89463682|NCT06184737|Active Comparator|Patient Education (PE)|The PE website will include scientifically accurate information that is typical of nutrition education websites and will include information about SSB recommendations, types of SSB and portion size, SSB-related health risks, energy balance information, identifying personal motivators and barriers to reducing SSB intake, interpreting SSB nutrition labels, and recognizing media influences and misclaims in SSB advertisements, as well as printable forms to track SSB and weight. Unlike iSIPsmarter, the content will not be tailored and will be presented all at once.
89463683|NCT06182995|Active Comparator|Usual Care|routine clinic visits
89463684|NCT06182995|Experimental|Anticipating Decline and Providing Therapy (ADAPT) care|The program includes a routine validated cognitive screen for high-risk older adults at 6 weeks and 6 months post-ICU discharge
89463685|NCT06181227|Experimental|Low dose AVD-104|Three intravitreal injections at 1.0 milligram per eye each 28 days apart will be administered to the study eye. Participants will be followed for 84 days total.
89463686|NCT06181227|Experimental|High dose AVD-104|Two intravitreal injections at 2.0 milligrams per eye 56 days apart will be administered to the study eye. Participants will be followed for 84 days total.
89463687|NCT06181214|Placebo Comparator|Placebo|Maltodextrin + Flavoring
89463688|NCT06181214|Experimental|AG1 - Nutritional Supplement|A foundational nutritional supplement consisting of vitamins, minerals, probiotics, prebiotics, and whole food ingredients
89463689|NCT06180525||Retrospective part|Patients for whom follow-up data up to at least 1 year after surgery is available at the start of the study.
88944610|NCT01881971|Placebo Comparator|Placebo|manufactured sugar pill to mimic rouvastatin once a day for 24 weeks
88944611|NCT01881971|Experimental|Rouvastatin calcium|Rouvastatin calcium once a day by mouth for 24 weeks.
88944612|NCT01881997|Placebo Comparator|Normal Saline|IM normal saline
88944613|NCT01881997|Experimental|Fentanyl|IM Fentanyl
88944614|NCT01882010|Sham Comparator|Controls|Caregivers, spouse, friends, relatives of PD patients, have blood draws, MEG.
88944615|NCT01882010|Placebo Comparator|PD Patients placebo|PD patients that receive placebo, have blood draw, physical exam and UPDRS part III assessment, MEG, Motion analysis.
88944616|NCT01882010|Experimental|PD Patients sargramostim|PD patients that receive Leukine, have blood draw, physical exam and UPDRS part III assessment, MEG, Motion analysis.
88944617|NCT01882049|Experimental|Treatment|Use of Realize gastric band (Ethicon) in adolescents for weight reduction
88944618|NCT01882075|Active Comparator|Open loop|fluid replacement (hydroxyethyl starch 130/0.4) is decided by the physicians according to continuous cardiac output measured by LidCO rapid device
88944619|NCT01882075|Experimental|Closed-loop|Fluid replacement is automated. An algorithm has been developed ; the input value is continuous cardiac output measured by LidCO rapid device; the computer steers iv infusion of hydroxyethyl starch 130/0.4.
88944620|NCT01882101|Experimental|Posterior tibial nerve stimulation|
88944621|NCT01882101|Experimental|Biofeedback|
88944622|NCT01882127|Active Comparator|High dose-DEX|40 patients are enrolled to take dexamethasone orally at a dose of 40 mg daily for 4 days
88944623|NCT01882127|Experimental|ATRA & High dose-DEX|40 patients are enrolled to take Dexamethasone orally at 40mg a day for 4 days and all-trans retinoic acid at 10mg tablet every 8 hours a day for 12 consecutive weeks.
88944624|NCT01882140|Experimental|Study Group|Patients in the Study Group will receive daily treatment for 60 minutes. The treatment is initiated within 24 hours following surgery to achieve graft. Use of Electrical Stimulation by Capacitive Field was the only addition to the current standard of care of the Emergency Unit of HC-FMRP/USP. These Electrical Stimulation by Capacitive Field devices do not produce heat or cause any sensation in tissue. The equipment will produce an electrical stimulation of low intensity pulsed output (1.5 MHz, 1:4 duty cycles, 30mW). The electrodes consist of two metal plates (20x20cm) separated by an insulating material.
89017977|NCT05680844||hypercholesterolemia group|Serum total cholesterol level of >= 5.17 mmol/L
89017978|NCT05670418||Long COVID-19|Patients post-COVID-19 with Long COVID-19 Syndrome
89017979|NCT05670418||COVID-19|Patients post-COVID-19 without Long COVID-19 Syndrome
89017980|NCT05660655|Active Comparator|Baricitinib 2mg and methotrexate 10mg|Baricitinib 2mg once daily plus methotrexate 10mg per week
89017981|NCT05660655|Experimental|Baricitinib 4mg and methotrexate 10mg|Baricitinib 4mg once daily plus methotrexate 10mg per week
89017982|NCT05657301|Experimental|KH631 Dose 1|KH631 One-Time Intraocular Injection Dose Level 1
89017983|NCT05657301|Experimental|KH631 Dose 2|KH631 One-Time Intraocular Injection Dose Level 2
89017984|NCT05657301|Experimental|KH631 Dose 3|KH631 One-Time Intraocular Injection Dose Level 3
89017985|NCT05657301|Experimental|KH631 Dose 4|KH631 One-Time Intraocular Injection Dose Level 4
89017986|NCT05657301|Experimental|KH631 Dose 5|KH631 One-Time Intraocular Injection Dose Level 5
89017987|NCT05645900|Experimental|experimental vaccine 1|Subjects received 2 doses of 0.5 mL of quadrivalent influenza virus subunit vaccine, 28 days apart
89017988|NCT05645900|Experimental|experimental vaccine 2|Subjects received 2 doses of 0.25 mL of quadrivalent influenza virus subunit vaccine, 28 days apart
89017989|NCT05645900|Active Comparator|control vaccine|Subjects received 2 doses of 0.25 mL of Quadrivalent split influenza virus vaccine, 28 days apart
89017990|NCT05638217||Patients of 4 to 12 years old eligible to received dental cavity treatment|"Patients of 4 to 12 years old that are eligible to received dental cavity treatment. The goal of this observational study is to identify the efficacy of silver diamine fluoride 38% followed by sodium fluoride varnish 5%, using CaviGuard® as delivery method, in a population with untreated dental caries age range 4 to 12 years old."
89017991|NCT05634863|Experimental|KIDNEY TRANSPLANT PATIENTS WITH THE IMPLANTABLE CONTINUOUS VASCULAR MONITORING DEVICE|The intervention that is intended to be investigated is the implantable vascular monitoring device manufactured by COOK Medical Company. Its principle intended use is continuous monitoring of the graft perfusion (i.e. transplanted kidney) for the first 72 hours postoperatively. The kidney transplant patients in the intervention group will receive implantable continuous vascular monitoring device surveillance for the first 72 hours in addition to the standard care clinical observation as part of their postoperative care. The intervention will be removed after 72 hours postoperatively.
89017992|NCT05634863|No Intervention|KIDNEY TRANSPLANT PATIENTS WITH STANDARD CARE CLINICAL OBSERVATION|The kidney transplant patients in this group will receive the standard care clinical observation as part of their postoperative care. Their graft will be monitored postoperatively by the standard care clinical observation as per the NHS protocol.
89017993|NCT05627661|Experimental|Autoimmune Epilepsy with Biosensors|Subjects with suspected autoimmune epilepsy will wear biosensors on wrist or upper arm during the at home monitoring period.
89017994|NCT05627661|Active Comparator|Healthy Controls with Biosensors|Neurologically normal adult healthy controls will wear biosensors on wrist or upper arm during the at home monitoring period.
89017995|NCT05625945||Symptomatic statin users|Statin users with self-reported muscle symptoms
89017996|NCT05625945||Asymptomatic statin users|Statin users without muscle symptoms
89201905|NCT04015089|Experimental|Partially hydrolyzed formula (pHF)|Infants fed exclusively with a infant formula based on partially hydrolyzed serum cow's milk proteins.
89017997|NCT05624658|Active Comparator|PCSK9 inhibitors in combination Atorvastatin at a dose of 80 mg /Rosuvastatin 40 mg/ day|Patients who showed high compliance and did not reach the target LDL-C values 1 month after the development of ACS on the 2nd visit will be randomized into two groups of 60 patients each. Group 1 - taking PCSK9 inhibitors (Alirocumab 150 mg by subcutaneous injection once every 2 weeks or Evolocumab 140 mg by subcutaneous injection once every 2 weeks - open-label prescription of drugs) while taking Atorvastatin at a dose of 80 mg./ Rosuvastatin 40 mg / day.
89017998|NCT05624658|Active Comparator|Ezetimibe at a dose of 10 mg in combination with Atorvastatin 80 mg / Rosuvastatin 40 mg/ day.|Group 2 - receiving Ezetimibe at a dose of 10 mg in combination with Atorvastatin 80 mg / Rosuvastatin 40 mg/day.
89017999|NCT05619731|Experimental|Experimental arm with oncology tele-consultation and pharmaceutical tele-expertise|patients will benefit from geriatric oncology tele-consultation and pharmaceutical tele-expertise
89018000|NCT05619731|No Intervention|Conventional care|patients will benefit from conventional care
89018001|NCT05609448|Experimental|MRI-guided radioembolization|Study patients will receive radioembolization with holmium microspheres in an MRI guided setting.
89018002|NCT05606770|Other|Structured exercise|Participants assigned to Structured Exercise will be provided with twice weekly strengthening exercise classes, delivered through the digital platform. The exercise classes will follow a circuit class style, in order to target a moderate-vigorous exercise intensity, in keeping with recent guidelines on secondary stroke prevention. Classes will include a full body warm up followed by a circuit of eight strengthening exercises completed for between one and three sets of 12 repetitions. Participants will be encouraged to exercise to fatigue on the 12th repetition of each set. This will be repeated for increasing sets and adding resistance through the use of resistance bands. During each session, participants will be reminded to reach their targeted weekly step count goals. The structured exercise component is informed by international clinical guidelines (Kleindorfer et al 2021 and Billinger et al 2021).
89018003|NCT05606770|Other|Lifestyle Physical Activity|The Lifestyle PA component was developed using the Behaviour Change Wheel (BCW) Guide to Designing Interventions and is underpinned by the COM-B model of behavior change (Michie et al., 2014). This posits that people need capability(C), opportunity(O), and motivation(M) to perform a behavior(B). The aim of the Lifestyle PA component is to increase the capability, opportunity, and motivation of participants to reach their daily step count goals. To achieve this the 3 stages of the BCW intervention design process were followed. The first stage, understanding the behaviour, is done through a review of the literature and primary qualitative research(Cardy et al., 2022). This stage identifies the change objectives of the intervention. Stage 2 requires the selection of intervention functions and the policies that would support them. The final stage is defining the content of the intervention using behaviour change techniques (BCTs) and selecting their mode of delivery.
89018004|NCT05597098|Experimental|Female|The participant will initially attend either in person or virtually for a screening visit for eligibility. Cantharidin will be applied on the second visit to the forearm, back or abdomen (depending on patient preference) via 1cm2 cantharidin soaked filter paper. The particpant will then attend for two further cantharidin applications (24 hr and 48 hr after the first application). 72 hours after initial cantharidin application the blister fluid will be collected.
89018005|NCT05597098|Experimental|Male|The participant will initially attend either in person or virtually for a screening visit for eligibility. Cantharidin will be applied on the second visit to the forearm, back or abdomen (depending on patient preference) via 1cm2 cantharidin soaked filter paper. The particpant will then attend for two further cantharidin applications (24 hr and 48 hr after the first application). 72 hours after initial cantharidin application the blister fluid will be collected.
89018006|NCT05595746|Experimental|equicrestally placement with higher vertical mucosa|Implants with a vertical mucosal height greater than 2 mm (A) and placed equicrestally (I) are in group A-I.
89018007|NCT05595746|Experimental|subcrestally placement with higher vertical mucosa|Implants with a vertical mucosal height greater than 2 mm (A) and placed subcrestally (II) are in group A-II.
89018008|NCT05595746|Experimental|equicrestally placement with less vertical mucosa|Implants with a vertical mucosal height of 2 mm or less (B) and placed equicrestally (I) are in group B-I.
89018009|NCT05595746|Experimental|subcrestally placement with less vertical mucosa|Implants with a vertical mucosal height of 2 mm or less (B) and placed subcrestally (II) are in group B-II.
89018010|NCT05595018||End user|A Delphi study will be conducted with two rounds to reach consensus
89018011|NCT05595018||Demand side management|A Delphi study will be conducted with two rounds to reach consensus
89018012|NCT05595018||Supply side|A Delphi study will be conducted with two rounds to reach consensus
89018013|NCT05595018||Funder|A Delphi study will be conducted with two rounds to reach consensus
89018014|NCT05595018||Academia|A Delphi study will be conducted with two rounds to reach consensus
89018015|NCT05592353|Active Comparator|Brace|
89018016|NCT05592353|No Intervention|No Brace|
89018017|NCT05585151|Experimental|Evolocumab treatment group|Evolocumab treatment, 1ml：140mg, every 2 weeks, for 26 weeks
89018018|NCT05585151|Active Comparator|Intensive statin treatment group|Atorvastatin 40mg/day or rosuvastatin 20mg/day, for 26 weeks
89201906|NCT04015089|Active Comparator|Standard formula (SF)|Infants fed exclusively with a standard formula based on intact cow's milk proteins
89201907|NCT00929565||Lung cancer|Comparison between individuals with and without pulmonary malignancy
89201908|NCT00925665||Glidescope|Patients intubated with the Glidescope technique
89201909|NCT00925665||Macintosh|Patients intubated via the conventional direct laryngoscopy with a Macintosh laryngoscope
89201910|NCT00925743|Experimental|1|"5, 15, 20 or 25 mg/m2~one injection of cabazitaxel on day 1 of each cycle (3 weeks)"
89501909|NCT02232529|Experimental|Part 1: MIN-101|"MIN-101~modified release formulation (MR),single oral dose between 16 and 64 mg"
89463690|NCT06180525||Prospective part|Both for patients not yet undergoing treatment intervention, at the start of the study, according to the inclusion criteria, both regarding those in follow-up for whom data are not available according to the time of observation required (1 year), will begin once all necessary authorizations have been obtained administrative requests
89463691|NCT06177912|Experimental|V116|Participants will receive a single 0.5 mL intramuscular (IM) injection of V116 on Day 1
89463692|NCT06177912|Active Comparator|PPSV23|Participants will receive a single 0.5 mL IM dose of PPSV23 on Day 1.
89463693|NCT06172621|Active Comparator|SCAP alone|Two weeks (6 sessions) of SCAP intervention alone.
89463694|NCT06172621|Experimental|SCAP plus task-oriented exercise|Two weeks (6 sessions) of SCAP intervention plus upper extremity task-oriented exercise.
89463695|NCT06170619||All subjects|
89463696|NCT06165783|Experimental|evaluate the effect of using therapeutic exercises and ultrasound|evaluate the effect of using therapeutic exercises and ultrasound for the rehabilitation of partially injured hamstring muscles.
89463697|NCT06165783|Experimental|analyse its effectiveness on the speedy healing|analyse its effectiveness on the speedy healing, which will be defined through some physical variables (hamstring muscle strength, the electrical activity of hamstring muscles) and pain perception.
89463698|NCT06161116|Experimental|Base Study: Dose 1|Participants receive subcutaneous (SC) MK-6194 dose regimen 1.
89463699|NCT06161116|Experimental|Base Study: Dose 2|Participants receive SC MK-6194 dose regimen 2.
89463700|NCT06161116|Placebo Comparator|Base Study: Placebo|Participants receive an SC placebo regimen.
89463701|NCT06161116|Experimental|Extension: Dose 1|"Participants receive SC MK-6194 dose regimen 1. Participants from the arms Base Study: Dose 1 or Base Study: Placebo may be enrolled in this arm after completing participation in their original arm."
89463702|NCT06161116|Experimental|Extension: Dose 2|"Participants receive SC MK-6194 regimen 2. Participants from the arms Base Study: Dose 2 or Base Study: Placebo may be enrolled in this arm after completing participation in their original arm."
89463703|NCT06157086||ofatumumab|MS adult patients who initiated ofatumumab as per neurologist practice and regardless of the study protocol
89463704|NCT06153966|Experimental|ION717 + Placebo, Regimen 1|Participants will receive multiple doses of study drug (ION717 and placebo) during the 24-week treatment period. The order of doses is blinded.
89463705|NCT06153966|Experimental|ION717 + Placebo, Regimen 2|Participants will receive multiple doses of study drug (ION717 and placebo) during the 24-week treatment period. The order of doses is blinded.
88944625|NCT01882140|Placebo Comparator|Control Group (Sham devices)|Patients in the control group (Sham group) will receive the same treatment but the device remains off. Use of Electrical Stimulation by Capacitive Field was the only addition to the current standard of care of the Emergency Unit of HC-FMRP/USP.
88944626|NCT01882166|Experimental|fostimon|subcutaneous 150 IE Fostimon®. When leading follicles are > 17 mm ovulation will be induced by Ovitrelle® 500μg sc(hCG-injection). Ovum pick up (OPU) will be performed 32-36 hours later.
88944627|NCT01882166|Experimental|puregon|subcutaneous 150 IE Puregon®. When leading follicles are > 17 mm ovulation will be induced by Ovitrelle® 500μg sc(hCG-injection). Ovum pick up (OPU) will be performed 32-36 hours later.
89463706|NCT06148831|Experimental|Infant Carrier|In the intervention group, in the prenatal period (~37 weeks gestation) will watch a short training video on how to use the carrier, including a demonstration of safe and ergonomic use. The home visitor will support the client in practicing using the carrier and will provide materials to support continued learning.
89463707|NCT06148831|No Intervention|Infant Carrier Waitlist|Participants assigned to the waitlist control will receive home visitation care as usual. At 6-months postpartum they will watch a short training video on how to use the carrier, including a demonstration of safe and ergonomic use. The home visitor will support the client in practicing using the carrier and will provide materials to support continued learning.
89463708|NCT06148675||Participants with emergent large vessel occlusion undegoing intracranial mechanical thromebctomy|Participants with emergent large vessel occlusion undergoing intracranial mechanical thrombectomy where the reperfusion catheter was delivered over a macrowire to perform thrombectomy.
89463709|NCT06146374|Experimental|Group 2|600mg (6x 100mg capsules) of SLV213 (N=8) or placebo (N=4) administered orally every 12 hours for 7 days to healthy male and female participants 18-65 years of age.
89463710|NCT06146374|Experimental|Group 3|800mg (8x 100mg capsules) of SLV213 (N=8) or placebo (N=4) administered orally every 12 hours for 7 days to healthy male and female participants 18-65 years of age.
89463711|NCT06146374|Experimental|Group1|400mg (4x 100mg capsules) of SLV213 (N=8) or placebo (N=4) administered orally every 12 hours for 7 days to healthy male and female participants 18-65 years of age.
89463712|NCT06144710|Experimental|SG301 SC|"Part A: Dose escalation of SG301 SC will be done in healthy volunteers at 1 mg/kg dose group and 2 mg/kg dose group.~Part B: Dose escalation of SG301 SC will be done in Systemic lupus erythematosus subjects in 4 dose groups, namely 2 mg/kg, 4 mg/kg, 8 mg/kg, and 12 mg/kg dose groups. 8 subjects will be randomized to SG301 SC injection in an 8:2 ratio at each dose group."
89463713|NCT06144710|Placebo Comparator|Placebo|Part B: Dose escalation of SG301 SC will be done in Systemic lupus erythematosus subjects in 4 dose groups, namely 2 mg/kg, 4 mg/kg, 8 mg/kg, and 12 mg/kg dose groups. 2 subjects will be randomized to SG301 SC injection in an 8:2 ratio at each dose group.
89463714|NCT06141473|Experimental|Frexalimab|Participants will receive Frexalimab infusion and placebo tablet.
89463715|NCT06141473|Active Comparator|Teriflunomide|Participants will receive teriflunomide tablet and placebo infusion.
89501910|NCT02232529|Experimental|Part 2: MIN-101 low dose|"MIN-101~single daily oral dose, low dose MR formulation, from Day 1 to Day 7"
89501911|NCT02232529|Placebo Comparator|Part 2: placebo|"placebo MIN-101~daily oral dose from Day 1 to Day 7"
88944628|NCT01882179|Placebo Comparator|Placebo|Intravenous saline bolus prior to PPCI followed by oral placebo for 3 months
88944629|NCT01882179|Active Comparator|Mineralocorticoid receptor antagonist|"1st dose (day 0) given i.v. (potassium-canrenoate), before primary PCI day 1 - 12 weeks: spironolactone 25mg daily, which is uptitrated to 50mg daily after 2 weeks, if possible~In case the LVEF <40% on baseline MRI and the patient shows signs of heart failure or is diabetic, the patient will receive open label eplerenone instead of the study drug, according to current guidelines."
89463716|NCT06137274|Experimental|Adaptive Radiotherapy treatment|Patients will undergo adaptive radiotherapy boost for head/neck squamous cell carcinomas. A base conventional IMRT plan of 46-50Gy in 2 Gy to gross disease in the primary/nodes and 41.4-45 Gy in 1.8 Gy to the elective nodes per fraction will be utilized. The MR simulation will be utilized for boost treatment planning. Patients will receive their 6th fraction of the week on the adaptive platform treating the gross disease until completion of the base plan to 20 Gy in 2Gy daily fractions (10 fractions). Each ART treatment will be recontoured/replanned by the treating head/neck radiation oncologist as deemed clinically or dosimetrically necessary.
89463717|NCT06133478|Experimental|NUV001 active|Single oral administration (treatment period 1 - SAD) and after a washout of at least 5 days, repeated once daily (q.d.) administrations for 14 days (treatment period 2 - MAD)
89463718|NCT06133478|Placebo Comparator|NUV001 Placebo|Single oral administration (treatment period 1 - SAD) and after a washout of at least 5 days, repeated once daily (q.d.) administrations for 14 days (treatment period 2 - MAD)
88944630|NCT01882192|Experimental|Family physical activity planning|The intervention condition will receive the same guidelines as the comparison condition but will also be provided with family physical activity planning material.
89463719|NCT06132022|Experimental|Intervention group|The intervention group will be asked to practice the mandala twice a week, for 30 minutes, for a month. At the end of one month, the scales will be applied again.
89463720|NCT06132022|Placebo Comparator|Control group|Caregivers in the control group will not take any action, and at the end of one month, after the scales have been applied, they will be offered mandala applications.
89463721|NCT06131866|Experimental|intervention group 1 in which psychoeducation based on acceptance and commitment therapy was applied|"After explaining the purpose of the study to the individuals, after obtaining their consent, Personal Information Form, Coping Attitudes Evaluation Scale COPE-R and '' The pre-test will be applied by applying the Meaning and Purpose of Life Scale, then the 8-week Acceptance and Commitment Therapy Based Psychoeducation programme will be applied and the post-test data will be collected. In the 12th week, follow-up test will be applied and evaluation will be made."
89463722|NCT06131866|No Intervention|Control group 1|"After explaining the purpose of the study to the individuals participating in the study, after obtaining their consent, Personal Information Form, Coping Attitudes Evaluation Scale COPE-R and '' Meaning and Purpose of Life Scale'' will be applied and pre-tests will be applied. Then, the post-test will be applied 8 weeks later without any intervention. One month after the post-test, i.e. at the 12th week, a follow-up test will be applied and an evaluation is planned."
89463723|NCT06131866|Experimental|Intervention group 2 in which psychoeducation based on acceptance and commitment therapy was applied|"After explaining the purpose of the study to the individuals, after obtaining their consent, Personal Information Form, Coping Attitudes Evaluation Scale COPE-R and '' The pre-test will be applied by applying the Meaning and Purpose of Life Scale, then the 8-week Acceptance and Commitment Therapy Based Psychoeducation programme will be applied and the post-test data will be collected. In the 12th week, follow-up test will be applied and evaluation will be made."
89463724|NCT06131866|No Intervention|Control group 2|"After explaining the purpose of the study to the individuals participating in the study, after obtaining their consent, Personal Information Form, Coping Attitudes Evaluation Scale COPE-R and '' Meaning and Purpose of Life Scale'' will be applied and pre-tests will be applied. Then, the post-test will be applied 8 weeks later without any intervention. One month after the post-test, i.e. at the 12th week, a follow-up test will be applied and an evaluation is planned."
89463725|NCT06131866|Experimental|Intervention group 3 in which psychoeducation based on acceptance and commitment therapy was applied|"After explaining the purpose of the study to the individuals, after obtaining their consent, Personal Information Form, Coping Attitudes Evaluation Scale COPE-R and '' The pre-test will be applied by applying the Meaning and Purpose of Life Scale, then the 8-week Acceptance and Commitment Therapy Based Psychoeducation programme will be applied and the post-test data will be collected. In the 12th week, follow-up test will be applied and evaluation will be made."
89463726|NCT06131866|No Intervention|Control group 3|"After explaining the purpose of the study to the individuals participating in the study, after obtaining their consent, Personal Information Form, Coping Attitudes Evaluation Scale COPE-R and '' Meaning and Purpose of Life Scale'' will be applied and pre-tests will be applied. Then, the post-test will be applied 8 weeks later without any intervention. One month after the post-test, i.e. at the 12th week, a follow-up test will be applied and an evaluation is planned."
89463727|NCT06131866|Experimental|Intervention group 4 in which psychoeducation based on acceptance and commitment therapy was applied|"After explaining the purpose of the study to the individuals, after obtaining their consent, Personal Information Form, Coping Attitudes Evaluation Scale COPE-R and '' The pre-test will be applied by applying the Meaning and Purpose of Life Scale, then the 8-week Acceptance and Commitment Therapy Based Psychoeducation programme will be applied and the post-test data will be collected. In the 12th week, follow-up test will be applied and evaluation will be made."
89501912|NCT02232529|Experimental|Part 2: MIN-101 high dose|"MIN-101~single daily oral dose, low dose MR formulation, from Day 1 to Day 7"
89501913|NCT03448081|Active Comparator|SNA-120 + Calcipotriene|
89501914|NCT03448081|Placebo Comparator|Placebo + Calcipotriene|
89501915|NCT04792879|Experimental|Peripheral veins Doppler ultrasound|
89018019|NCT05585125|Active Comparator|Beta-Blocker AB Sequence|This arm will follow an AB sequence: ON beta-blockers (A) and OFF beta-blockers (B). Subjects start with their home dose in Period 1 (A), then switch to Period 2 (B), where the study team slowly reduces their dose until they are off their beta-blocker (or the lowest dose they can tolerate). Subjects are then asked if they have enough information to clarify their preference about continuing or discontinuing their beta-blocker. Subjects can choose to engage in 2-6 periods based on whether they need more information to make a preference. These extra phases follow the same ON-OFF pattern (ABABAB), meaning if the subject chooses to continue into Period 3 (A), the study team will restart the subject's beta-blocker, and slowly up-titrate until they reach their home dose. This continues until the subject has enough information to clarify their preference about continuing or discontinuing their beta-blocker, with a limit of 6 periods.
89201911|NCT00925821|Experimental|Allogeneic stem cell transplant|Second scheduled transplantation performed from an HLA-matched MRD or MUD after conditioning with treosulfan and fludarabine
89201912|NCT00925821|Active Comparator|High-dose melphalan chemotherapy|Second high-dose melphalan therapy followed by transplantation of peripheral blood stem cells
89463728|NCT06131866|No Intervention|Control group 4|"After explaining the purpose of the study to the individuals participating in the study, after obtaining their consent, Personal Information Form, Coping Attitudes Evaluation Scale COPE-R and '' Meaning and Purpose of Life Scale'' will be applied and pre-tests will be applied. Then, the post-test will be applied 8 weeks later without any intervention. One month after the post-test, i.e. at the 12th week, a follow-up test will be applied and an evaluation is planned."
89463729|NCT06129552||Healthy controls|
88944631|NCT01882192|No Intervention|Control|The standard (comparison group) package will consist of Canada's family guide to physical activity guidelines recommending 60 minutes of activity a day in bouts as short as five to ten minutes for children and a breakdown of ways for the family to achieve this physical activity (structured, unstructured, endurance, strength, activities, less than 60 minutes of sustained sedentary activity, reduce screen viewing by 30 min per day) commensurate with this guide. This will include the new insert by CSEP. The guide also contains arguments and information about the benefits of physical activity.
88944632|NCT01882205|Active Comparator|OLYMPUS CHROMO|Group A: HDTV Olympus colonoscopes and Chromo-endoscopy, methylene blue 0.1%
88944633|NCT01882205|Experimental|OLYMPUS NBI|Group B: Virtual chromoendoscopy: HDTV Olympus colonoscopes and Narrow band Imaging (NBI)
88944634|NCT01882205|Active Comparator|FUJINON CHROMO|Group C: CCD Fujinon colonoscopes and Chromo-endoscopy, methylene blue 0.1%
88944635|NCT01882205|Experimental|FUJINON FICE|Group D: Virtual chromoendoscopy: CCD Fujinon colonoscopes and Fujinon Intelligent Color Enhancement n° 4
88944636|NCT01882205|Active Comparator|PENTAX CHROMO|Group E: HD-Pentax colonoscopes and Chromo-endoscopy, methylene blue 0.1%
89463730|NCT06129552||CRSwNP patients|
89463731|NCT06129552||AR patients|
88944637|NCT01882205|Experimental|PENTX i-scan|Group F: Virtual chromoendoscopy: HD Pentax colonoscopes and I-scan 2 settings
88944638|NCT01882218|Active Comparator|Standard treatment|Standard liver surgery and post-operative treatment
88944639|NCT01882218|Experimental|Galactose|Standard liver surgery with direct peritoneal resuscitation with galactose after surgery.
89201913|NCT00925977|Active Comparator|insulin Glargine + insulin Apidra|insulin Glargine + insulin Apidra
89501916|NCT02232607|Experimental|Lacidipine, low dose|
88944640|NCT01882231|Other|DCE-MRI, DW-MRI, MT-MRI, and CEST-MRI|Patients will have dynamic contrast-enhanced (DCE), diffusion-weighted (DW), magnetization transfer (MT), and chemical exchange saturation transfer (CEST) magnetic resonance imaging (MRI) performed before and after 1 cycle of chemotherapy.
88944641|NCT01882244|Experimental|Neural Pathfinder Training|Neural Pathfinder training (PATH) will involve 6-8 weeks of training sessions with a trainer (1-2 hour sessions, average of 1 session per week), up to 3 hours of telephone contact with the trainer (about 15 minutes per week), and approximately 20 hours of home practice). Some subjects will only receive the PATH intervention.
88944642|NCT01882244|Active Comparator|Brain Health Education|Brain Health Education (EDU) will involve 6-8 weeks of training sessions with a trainer (1-2 hour sessions, average of 1 session per week), up to 3 hours of telephone contact with the trainer (about 15 minutes per week), and approximately 20 hours of home practice). Some subjects will only receive the EDU intervention. Some subjects will receive both the PATH and EDU interventions.
88944643|NCT01882270||Mild Pericoronitis|Those with mild signs/symptoms of pericoronitis affecting at least one lower 3rd molar with adjacent 2nd molar will be monitored for 12 months following study entry or 3 months for those electing to have 3rd molar extraction.
88944644|NCT01882283|Experimental|Tea Treatment Group|5 cups brewed tea beverage per day for 28 days, brewed from 700 mg of black tea solids per cup
88944645|NCT01882283|Placebo Comparator|Placebo Group|5 cups tea-like placebo per day for 28 days. Placebo was exactly matched to tea except for flavonoid composition. Placebo was flavonoid-free.
88944646|NCT01882296|Experimental|AGSPT_10|tablet, 10mg, QD, 7days
88944647|NCT01882296|Experimental|AGSPT_20|tablet, 20mg, QD, 7days
88944648|NCT01882296|Experimental|AGSPT_40|tablet, 20mg x 2, QD, 7days
88944649|NCT01882296|Active Comparator|Pantoprazole_20|tablet, 20mg, QD, 7days
88944650|NCT01882296|Active Comparator|Pantoprazole_40|tablet, 40mg, QD, 7days
88944651|NCT01882322|Experimental|Advagraf conversion group|Oral
88944652|NCT01882322|Active Comparator|Prograf maintenance group|Oral
88944653|NCT01882335|Experimental|Behavioral|Peer support for mothers to encourage them to exclusively breastfeed their babies for 6 months
88944654|NCT01882335|No Intervention|Control|No peer support for exclusive breastfeeding
88944655|NCT01882348|No Intervention|Usual Care Control|"Control groups will receive equal number of contacts for training in preparation for enrollment and data collection for the study.~Clinicians will be given the option to receive a standard American Academy of Pediatrics tobacco control pamphlet to distribute.~Control groups have the option to receive access to the CEASE online module intervention at the conclusion of the research study which allows practitioners in this group to receive 26 continuing education credit hours."
88944656|NCT01882348|Experimental|Intervention|The Intervention Group will receive the CEASE Intervention
88944657|NCT01882361|Active Comparator|injectable naltrexone|One dose of injectable extended release naltrexone (Vivitrol), 380mg dosage, given every four weeks in a 48-week trial.
88944658|NCT01882361|Placebo Comparator|placebo injection for naltrexone|placebo comparator injection starting at week 24 in a 48-week trial.
88944659|NCT01882374|Experimental|TXA127, blood draws, physical exams|Single-arm safety/efficacy trial of TXA127 (Angiotensin 1-7) in subjects undergoing double cord blood transplantation for the treatment of hematologic malignancies. Treatment dose is 300 mcg/kg/day TXA127.
88944660|NCT01882387|Experimental|TXA127, blood draws, physical exams|Single-arm safety/efficacy trial of TXA127 (Angiotensin 1-7) in subjects undergoing allogeneic peripheral blood stem cell transplantation for the treatment of a variety of hematologic malignancies for whom there is no available therapy with substantive anti-disease effect. Treatment dose is 300 mcg/kg/day TXA127.
88944661|NCT01882400|Experimental|Bisphosphonate treatment|Add a weekly bisphosphonate to adequate doses of calcium and vitamin D supplements
88944662|NCT01882426|Active Comparator|Enhanced treatment algorithm|Treatment algorithm featuring the early use of combination therapy, treatment intensification guided by objective assessments of inflammation and the use of remission as a therapeutic goal
88944663|NCT01882426|Placebo Comparator|Usual Care|These subjects will be managed according to local treatment guidelines for the treatment of UC.
88944664|NCT01882452|Experimental|Memory Specificity Training|Five weekly one-hour sessions of memory specificity training administered in groups of 5-8 participants.
88944665|NCT01882452|Active Comparator|Education and Support|Five weekly one-hour sessions of an education-and-discussion supportive intervention, administered in groups of 5-8 participants.
88944666|NCT01882478||failure to respond to RF ablation|patients undergoing endoscopic RF ablation therapy with persistent BE with HGD or IMCA despite 2 or more serial RF ablation treatment sessions
88944667|NCT01882491|Placebo Comparator|Placebo|
88944668|NCT01882491|Experimental|gevokizumab|
88944669|NCT01882504|Experimental|gevokizumab|Solution for subcutaneous injection
88944670|NCT01882517|Active Comparator|Yogurt that contains plant stanol esters|Dietary Supplement: Yogurt that contains plant stanol esters
88944671|NCT01882517|Placebo Comparator|Placebo yogurt|Dietary Supplement: Placebo yogurt
88944672|NCT01882530|Placebo Comparator|Control group C: Placebo|All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
88944673|NCT01882530|Experimental|Group P: Paracetamol|All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
88944674|NCT01882530|Experimental|Group N: Nefopam|All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
88944675|NCT01882530|Experimental|Group K: Ketoprofen|All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
88944676|NCT01882530|Experimental|Group PN: paracetamol and nefopam|All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
89201914|NCT00925977|Active Comparator|Insulin NPH + Insulin Apidra|12 weeks treatment with Insulin NPH + Insulin Apidra
89201915|NCT00926055|No Intervention|Control|
89463732|NCT06125197|Experimental|TILT-123 and Pembrolizumab|"Patients will receive multiple administrations of TILT-123 and Pembrolizumab.~Escalation to the next dose of TILT-123 will occur when the safety data has been evaluated for patients in the preceding dose level."
89463733|NCT06122129|Experimental|Flexible ureteroscope with ureteral access sheath|Stones will be treated by flexible ureteroscope with ureteral access sheath
89463734|NCT06122129|Active Comparator|Flexible ureteroscope without ureteral access sheath|Stones will be treated by flexible ureteroscope without ureteral access sheath
89463735|NCT06117683|Active Comparator|Bag mask ventilation with Adult Sotair device|The anesthesia provider will manually bag ventilate with the Adult Sotair® device for 3 minutes.
89463736|NCT06117683|No Intervention|Mechanical Ventilation|The anesthesia provider will remove the bag valve mask and Adult Sotair® device and connect the patient to the mechanical ventilator. The recording of pressure and flow will last for 3 minutes.
89463737|NCT06117059|Experimental|3 fractions of prostate Stereotactic Body Radiotherapy (SBRT)|3 fractions of SBRT with image guidance using the RayPilot HypoCath system given on 3 consecutive days
89463738|NCT06113328|Experimental|Base Study: Dose 1|Participants receive subcutaneous (SC) MK-6194 dose regimen 1.
89463739|NCT06113328|Experimental|Base Study: Dose 2|Participants receive SC MK-6194 dose regimen 2.
89463740|NCT06113328|Placebo Comparator|Base Study: Placebo|Participants receive an SC placebo regimen.
89463741|NCT06113328|Experimental|Extension: Dose 1|"Participants receive SC MK-6194 dose regimen 1. Participants from the arms Base Study: Dose 1 or Base Study: Placebo may be enrolled in this arm after completing participation in their original arm."
89463742|NCT06113328|Experimental|Extension: Dose 2|"Participants receive SC MK-6194 regimen 2. Participants from the arms Base Study: Dose 2 or Base Study: Placebo may be enrolled in this arm after completing participation in their original arm."
89463743|NCT06111196|Experimental|BAT3306 injection|100mg/4ml,intravenous injection
89463744|NCT06111196|Active Comparator|KEYTRUDA® (EU-sourced)|100mg/4ml,intravenous injection
89501917|NCT02232607|Experimental|Lacidipine, medium dose|
88944677|NCT01882530|Experimental|Group PK: paracetamol and ketoprofen|All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
88944678|NCT01882530|Experimental|Group NK: nefopam and ketoprofen|All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
88944679|NCT01882530|Experimental|Group PNK: paracetamol, nefopam and ketoprofen|All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
88944680|NCT01882556|Experimental|Botulinum Toxin - Type A (onabotulinumtoxinA)|Botulinum Toxin - Type A. One set of injections of up to 200 Units of Botox (Allergan). Injected to Biceps, Brachialis, Flexor Dig Superficialis, Flexor Dig Profundus, Flexor Carpi Radialis and Flexor Carpi Ulnaris.
88944681|NCT01882556|Placebo Comparator|0.9% NaCl Saline Injection|Saline - Injected to Biceps, Brachialis, Flexor Dig Superficialis, Flexor Dig Profundus, Flexor Carpi Radialis and Flexor Carpi Ulnaris.
88944682|NCT01882569||Back surgery|
88944683|NCT01882595|Experimental|Nebulization through the tracheostomy|Each subjects received two nebulization sessions. The first session was performed prior the tracheostomy removal (through the tracheostomy) and the second one when the when the tracheostome was totally scared (through the mouth)
88944684|NCT01882595|Active Comparator|Nebulization through the mouth|Each subjects received two nebulization sessions. The first session was performed prior the tracheostomy removal (through the tracheostomy) and the second one when the when the tracheostome was totally scared (through the mouth)
88944685|NCT01882608|No Intervention|Treatment-as-usual|Treatment-as-usual, with no active intervention or follow-up. TAU patients will have readmission events monitored over the six-month interval by the study RA via periodic chart reviews and updates from their clinicians
88944686|NCT01882608|Experimental|Mental Health Telemetry (MHT)|Patients in the MHT group will be encouraged to provide daily symptom self-reports using MHT. MHT patients will also have readmission events monitored over the six-month interval by the study RA via periodic chart reviews and updates from their clinicians
88944687|NCT01882621|Active Comparator|Monosialoganglioside(GM1)|Monosialoganglioside(GM1)80mg + N.S 250ml,qd,D0-D3
88944688|NCT01882621|Placebo Comparator|normal saline|placebo 80mg + N.S 250ml,qd,D0-D3
88944689|NCT01882634|Experimental|Ultrasound arm|
88944690|NCT01882673|Experimental|Brief Computer Motivational Interviewing for Smoking Cessation|Brief computer motivational interviewing intervention to motivate tobacco quitline use
88944691|NCT01882673|Active Comparator|Nutrition Control|Computer delivered nutrition education
88944692|NCT01882686|Experimental|Classification Based Cognitive Functional Therapy|
88944693|NCT01882712|Experimental|CD07805/47 Gel 0.5%|active arm
88944694|NCT01882712|Placebo Comparator|CD07805/47 Gel Placebo|Comparator arm
88944695|NCT01882777|No Intervention|Existing water management and cooking practices|Households in the control arm continue following their existing drinking water management and cooking practices
88944696|NCT01882777|Active Comparator|Provision of water filters and improved cookstoves|Households in intervention arm are provided with drinking water filters and improved cook stoves
88944697|NCT01882842|Experimental|Endometrial biopsy arm|Participants randomised to this arm arm will undergo an endometrial biopsy procedure using Pipelle endometrial sampler (Pipelle de Cornier, Laboratoire CCD, Paris, France) or Wallace/ Wallach endometrial sampler as an alternative device on cycle day LH+7 to LH+9 of the cycle directly preceding commencement of down-regulation prior to IVF or ICSI treatment. A transvaginal ultrasound scan will be performed prior to the biopsy.
88944698|NCT01882842|No Intervention|Control group|Participants randomised to control group will undergo a transvaginal ultrasound scan on day LH+7 to LH+9 of the cycle directly preceding commencement of IVF/ICSI treatment.
88944699|NCT01882881|Active Comparator|Healthy American Control Diet|
88944700|NCT01882881|Experimental|Dark Chocolate/Cocoa Diet|
88944701|NCT01882881|Experimental|Almond Diet|
88944702|NCT01882881|Experimental|Dark Chocolate/Cocoa + Almond Diet|
89463745|NCT06109467|Experimental|Treatment with Neratinib with Trastuzumab, Pembrolizumb and mFOLFOX|All patients will be treated with combination of neratinib with trastuzumab, pembrolizumab and mFOLFOX. All patients will receive standard dose 5FU/oxaliplatin/trastuzumab every 2 weeks. Pembrolizumab 400 mg intravenously will be administered once every 6 weeks. Neratinib will be dosed 240 mg orally daily
89463746|NCT06107868|Experimental|Part A - Dose Escalation|"RP6306, 40 mg orally, twice a day, continuously or on Days 1 to 3, for 1 or 2 weeks, every 21-day cycle.~Carboplatin, AUC 5 intravenously, on Day 1 of every 21-day cycle.~Paclitaxel, 175 mg/m2 intravenously, on Day 1 of every 21-day cycle."
89463747|NCT06107868|Experimental|Part B - Dose Expansion|"RP6306, 40 mg orally at the best schedule determined in Part A.~Carboplatin, AUC 5 intravenously, on Day 1 of every 21-day cycle.~Paclitaxel, 175 mg/m2 intravenously, on Day 1 every 21-day cycle."
89463748|NCT06104592|Experimental|Radiation Therapy and CAR T-Cell Infusion|Following T-cell apheresis for CD19 CAR T-cell therapy, eligible enrolled study participants patients will undergo Comprehensive Ablative Bridging Irradiation (CABI) to all pretreatments lesions that are able to be feasibly and safely treated by the treating radiation oncologist. Upon completion of bridging radiotherapy, patients will undergo lymphodepleting chemotherapy period (Days -5, -4, -3) followed by axi-cel infusion (Day 0).
89463749|NCT06102213|Experimental|Cohort A: HMO 9.0 g and B. infantis|HMO will be administered at 9.0 g orally twice a day (BID), and B. infantis will be administered orally twice a day (BID) (total of 43 days of dosing).
89463750|NCT06102213|Experimental|Cohort B: HMO 4.5 g and B. infantis|HMO will be administered at 4.5 g orally BID, and B. infantis will be administered orally BID (total of 43 days of dosing).
89463751|NCT06102213|No Intervention|Cohort C|Participants in this cohort will not receive any study drug
89463752|NCT06101342|Experimental|Randomized Phase: Lenacapavir (LEN) Group|Participants will receive subcutaneous (SC) LEN 927 mg on Day 1 and Week 26 and oral LEN 600 mg on Days 1 and 2.
89463753|NCT06101342|Experimental|Randomized Phase: Emtricitabine/ Tenofovir Disoproxil Fumarate (F/TDF) Group|Participants will receive daily F/TDF (200/300 mg) fixed dose combination (FDC) tablets for up to 52 weeks.
89463754|NCT06101342|Experimental|Pharmacokinetic (PK) Tail Phase: F/TDF|After the completion of the Randomized Phase, participants in LEN group will be transitioned to receive F/TDF FDC tablets and participants in F/TDF group will continue to receive F/TDF FDC tablets in the PK Tail Phase. All participants will receive F/TDF FDC tablets, once daily for up to 78 weeks beginning 26 weeks after the last LEN injection.
89463755|NCT06101030||Signal On|Patient Signals ON
89463756|NCT06101030||Signal Off|Patient Signals Off
89463757|NCT06099483|Active Comparator|action observation and motor imegary|The motor imagery and action observation group was asked to watch a previously recorded breathing exercise video and imagine it as if they were doing it themselves.
89463758|NCT06099483|Active Comparator|Active Breathing Exercise Group|Respiratory control, diaphragmatic breathing and thoracic expansion exercises were actively performed for 10 repetitions each.
89463759|NCT06099483|Active Comparator|Control group|Participants will remain in a sitting position throughout the entire experimental group application. Participants were prevented from making physical movements and were asked to keep their minds closed by closing their eyes and not thinking about anything.
89463760|NCT06098482|Experimental|Delivery of speech perception materials using the experimental method (Mobile Research App)|
89463761|NCT06098482|Active Comparator|Standard of Care validated delivery of speech perception materials|
89463762|NCT06098482|Experimental|Delivery of speech perception materials using the experimental method (MRA) in home environment|
89463763|NCT06096337|Experimental|Pulsed Field Ablation (PFA)|Pulsed Field Ablation (PFA) is used as the initial treatment for subjects with persistent atrial fibrillation (AF)
89463764|NCT06096337|Active Comparator|Anti-Arrhythmic Drug (AAD)|Anti-Arrhythmic Drug (AAD) is used as the initial treatment for subjects with persistent atrial fibrillation (AF)
88944703|NCT01882894|Experimental|Custom PFO orthosis|This is a custom made orthosis
88944704|NCT01882894|Placebo Comparator|Faux foot orthosis|Foam insert without arch support
88944705|NCT01882920|Experimental|Goal directed therapy intravenous restricitve fluid protocol|
88944706|NCT01882920|Active Comparator|Control arm|
88944707|NCT01882946|Experimental|DCVax-Direct|DCVax-Direct: autologous, activated dendritic cells for intratumoral injection
88944708|NCT01882959||Placebo|
88944709|NCT01882959||Intervention|Radiofrequncy Denervation
88944710|NCT01882972|Experimental|Exercise|Exercise 12 week home-based resistance exercise training intervention. Participants will be coached to engage in resistance training 3 days per week and aerobic exercise for 30 minutes at least 5 days per week for 12 weeks.
88944711|NCT01882972|Placebo Comparator|control|Participants in the attention control arm will not be asked to cease activity they already participate in but will be instructed not to begin a new exercise program for 12 weeks. Participants will receive a meditation CD to use daily to account for the time intervention arm participants are engaged in exercise.
88944712|NCT01882998|Experimental|Women-Extended Repeat Testing and Enhanced Counseling|Pregnant/breastfeeding women enrolled individually and randomized to the intervention arm will receive extended repeat HIV testing and enhanced counseling at the time of labor and delivery and throughout the lactation period at 3, 6, 12, 18 and 24 months postpartum or until cessation of breastfeeding, whichever occurs first.
88944713|NCT01882998|Experimental|Couples-Extended Repeat Testing and Enhanced Counseling|Pregnant/breastfeeding women enrolled in couples with their male partners and randomized to the intervention arm will receive extended repeat HIV testing and enhanced counseling at the time of labor and delivery and throughout the lactation period at 3, 6, 12, 18 and 24 months postpartum or until cessation of breastfeeding, whichever occurs first.
88944714|NCT01883011|Experimental|Piracetam|"IV infusion 12 g piracetam in 60 ml~IV Ampoules 3 g piracetam in 15 ml~Oral solution 33 % piracetam (bottle of 125 ml)~Oral tablets 1200 mg piracetam (blisters of 10 tablets)"
88944715|NCT01883011|Placebo Comparator|Placebo|"IV infusion 12 g placebo in 60 ml~IV Ampoules 3 g placebo in 15 ml~Oral solution 33% placebo (bottle of 125 ml)~Oral tablets 1200 mg placebo (blisters of 10 tablets)~All IV forms were identical in presentation, size and color to allow a double blind design.~All oral forms were identical in shape, size, color and taste to allow a double blind design."
88944716|NCT01883037||Laboratory blood glucose|Blood glucose value from Lab
89463765|NCT06091761|Experimental|AA + TEA|Auricular acupuncture (AA) every week in eight weeks (eight sessions). Combined with Thread embedding acupuncture (TEA) every two weeks in eight weeks (four sessions).
89463766|NCT06091761|Sham Comparator|AA + Sham-TEA|Auricular acupuncture (AA) every week in eight weeks (eight sessions). Combined with Sham Thread embedding acupuncture (Sham-TEA) every two weeks in eight weeks (four sessions).
89463767|NCT06088901|Experimental|Arm 1: First Occurrence|All patients who meet criteria and consent to involvement will be treated per institutional protocols with a tube thoracostomy. Chest tube size will be determined by the physician of record. Once the chest tube is placed, it will be placed to suction for a minimum of two minutes to allow for lung re-expansion while 2 ml/kg of whole blood (max 100 ml) is obtained via venipuncture (preferably a previously established intravenous catheter). This blood will then be injected via the chest tube which will then be clamped for 180 minutes, before being returned to suction. During this period of clamping, the patient will be rotated from side to side intermittently to help the blood move around the extrapleural space.
89463768|NCT06088901|Experimental|Arm 2: Recurrence|All patients who meet criteria and provide informed consent will be treated per institutional protocols with a thoracoscopic blebectomy and mechanical pleurodesis or pleurectomy. At the conclusion of the procedure, 2 ml/kg of whole blood (max 100 ml) obtained via venipuncture will be injected into the pleural space. The chest tube will be left clamped for 180 minutes post-procedure and then placed back to suction. During this period of clamping, the patient will be rotated from side to side intermittently to help the blood move around the extrapleural space.
89463769|NCT06079879|Experimental|Bomedemstat|Participants will begin treatment at a dose of 50 mg of bomedemstat daily. Dosage will be adjusted either up or down within specified time parameters for each participant to the dose that provides sufficient exposure to safely inhibit thrombopoiesis to decrease platelet counts to the target range. All participants will be treated daily for up to 52 weeks, and are eligible for an extended treatment phase up to 152 weeks.
89501918|NCT02232607|Experimental|Lacidipine, high dose|
89463770|NCT06079879|Active Comparator|Best Available Therapy|Each participant will receive either anagrelide, busulfan, interferon alfa/pegylated interferon alfa, or ruxolitinib as determined by investigator. All participants will be treated per respective approved product labels for up to 52 weeks. Participants receiving BAT for 52 weeks who stop responding to BAT are eligible to switch to bomedemstat and receive this for up to 152 weeks at the investigators discretion.
89463771|NCT06072963|Experimental|Group 1|Will receive intranasal insulin therapy as well as Oral Semaglutide.
89463772|NCT06072963|Sham Comparator|Group 2|Will receive active intranasal insulin therapy and placebo Oral Semaglutide.
89463773|NCT06072963|Sham Comparator|Group 3|Will receive intranasal insulin placebo and active Oral Semaglutide .
89463774|NCT06072963|Placebo Comparator|Group 4|Will receive intranasal insulin placebo and Oral Semaglutide placebo.
89463775|NCT06071325||AID Group|We anticipate enrolling between 30 and 50 participants who will be recruited to participate in the Automated Insulin Delivery (AID) system study.
89463776|NCT06071325||MDI + CGM Group|We anticipate that between 10 and 30 participants will be enrolled in the study and will be utilizing Multiple Daily Injections (MDI) therapy in conjunction with Continuous Glucose Monitoring (CGM). MDI therapy will be defined as administering three or more injections per day.
89463777|NCT06065501|Experimental|PACE intervention|The intervention group (PACE intervention) utilizes mobile social network support, employing a LINE group to implement a personalized plan based on the TTM model for establishing a care program.
89463778|NCT06065501|Active Comparator|Control group|The control group receives usual care, which involves standard CKD education and consultation.
89463779|NCT06063603|Experimental|Group I (Pain management)|See detailed description.
89463780|NCT06063603|Active Comparator|Group II (Interview)|ASCENT study interventionists complete an interview on study.
89463781|NCT06063603|Active Comparator|Group III (Focus group)|Medical oncology providers participate in a focus group on study.
89463782|NCT06057012|Experimental|BRII-296 600 mg|Participants will receive BRII-296 600 milligram (mg) by intramuscular injection admixed with Depo Medrol (80 milligram per milliliter [mg/mL]) on Day 1.
89463783|NCT06055985|Experimental|UCB0022-Dose A|Study participants randomized to this arm will receive UCB0022 Dose A orally administered as tablet during the Treatment Period.
89463784|NCT06055985|Experimental|UCB0022-Dose B|Study participants randomized to this arm will receive UCB0022 Dose B orally administered as tablet during the Treatment Period.
89463785|NCT06055985|Placebo Comparator|Placebo|Study participants randomized to this arm will receive matching placebo orally administered as tablet during the Treatment Period.
89463786|NCT06055894|Experimental|Omega-3|For 2 weeks, patients will receive omega 3 fatty acid supplements 1640 mg (2 capsules) twice daily Qwell™ Omega 3 by The Veggie Doctor™. Each 820 mg omega 3 supplement capsule contains 700 mg Docosohexaenoic acid, 100 mg Docosapentaenoic acid, and 20 mg Eicosapentaenoic acid. No dietary changes will be made but data on dietary intake will be collected.
89463787|NCT06055894|Experimental|Curcumin|For 2 weeks, patients in the curcumin arm will receive Curcumin C3 complex 1000 mg with 5 mg BioPerine twice daily from Sabinsa pharmaceuticals. No dietary changes will be made but data on dietary intake will be collected.
88944717|NCT01883037||HemoCue Glucose 201 RT|Blood glucose value from HemoCue Glucose 201 RT
89463788|NCT06055894|Experimental|Probiotic|For 2 weeks, patients in the probiotic arm will receive Ultra-50 probiotics with 50 billion CFU per capsule (one capsule) twice daily from Vita Miracle pharmaceuticals. No dietary changes will be made but data on dietary intake will be collected.
89463789|NCT06055894|Experimental|Whole food, plant-based diet (WFPBD)|For 2 weeks, on the WFPBD arm, patients will receive 14 items weekly, prepared and shipped by U.S. based company, Daily Harvest once a week. The meals will have range from 2 breakfast, 11 lunch/dinners, 1 snack (provided Week 1), and whole grains items (provided Week 2). The meals will contain legumes, fruits, vegetables, whole grains, and plant-based fats that have undergone minimal processing. Detailed recommendations for additional meals outside those given by Daily Harvet meeting the standard of a WFPBD will also be given to supplement their individual daily calorie needs through the guidance of the research dietitian. Patients will receive a varied menu created by Daily Harvest and the study team on a weekly basis.
89201916|NCT00926055|Active Comparator|Ezetimibe|
89463790|NCT06055179|Experimental|XCHT group|Patients will be administered with XCHT (9 g, qd, po) for 5 days each cycle of FOLFIRI/mXELIRI chemotherapy for 3 cycles. The XCHT administration begins 3 days before chemotherapy in each cycle, that is the chemotherapy begins on the 4th day of XCHT administration. Plasma will be collected for pharmacokinetic testing (using raloxifene 60mg po as probe), on the day before chemotherapy, that is on the 3rd day of XCHT administration in each cycle.
89463791|NCT06055179|Placebo Comparator|Placebo group|Patients will be administered with placebo (9 g, qd, po) for 5 days each cycle of FOLFIRI/mXELIRI chemotherapy for 3 cycles. The placebo administration begins 3 days before chemotherapy in each cycle, that is the chemotherapy begins on the 4th day of placebo administration. Plasma will be collected for pharmacokinetic testing (using raloxifene 60mg po as probe), on the day before chemotherapy, that is on the 3rd day of placebo administration in each cycle.
89463792|NCT06052059|Experimental|Study 1: High Dose Induction, High Dose Maintenance|Participants receive high dose intravenous (IV) tulisokibart, followed by a high dose subcutaneous (SC) tulisokibart regimen.
89201917|NCT00926055|Experimental|Ezetimibe/Simvastatin|
88944718|NCT01883050|Other|Self Monitoring of Software Application|log into self monitoring software application from a home computer. Log on 3-4 times weekly for 12 weeks for important reminders, care tips and educational materials.
88944719|NCT01883050|No Intervention|No Intervention|No Intervention
88944720|NCT01883063|Experimental|WRx™ Intramedullary Nail|Patients in this arm of the study will be treated with a minimally invasive WRx™ Intramedullary Nail for their wrist fracture.
88944721|NCT01883063|Active Comparator|Non surgical treatment (Cast)|Patients in this arm of the study will be treated with a cast for their wrist fracture.
88944722|NCT01883076|Experimental|autologous cell-based delivery|autologous cell-based delivery a target dose of 3 million cells / kg of body weight will be delivered into the right heart muscle at the time of surgery. Cells are derived from autologous (self) umbilical cord blood.
88944723|NCT01883089|Other|Other|Participants will be recruited to complete a 90 day daily monitoring study during which time will be invited to participate in a 4 week brief alcohol intervention during days 31-60 (i.e., second month).
88944724|NCT01883102|Experimental|Capsaicin 0.1%|Capsaicin cream 0.1% will be applied to site A or B on the subject's abdomen daily for 7 days.
88944725|NCT01883102|Placebo Comparator|Placebo/cream without 0.1% capsaicin|The placebo cream will be applied to site A or B on the subject's abdomen daily for 7 days.
88944726|NCT01883115||Telescopic group|All eligible patients referred with inguinal/femoral hernias will be enrolled into the study from February 2013
88944727|NCT01883128|Experimental|Whole body MRI|Comparing the detection rate of metastases of whole body MRI compared to current standard of care tests - Choline PET and Bone scan.
88944728|NCT01883128|Experimental|MRI Targeted Biopsies|Transperineal MRI-targeted biopsies and whole-gland transperineal prostate mapping biopsies
88944729|NCT01883128|Experimental|Focal Salvage Therapy|Focal salvage HIFU and cryotherapy of recurrent prostate cancer tumors only
88944730|NCT01883154||IUGR pregnancies|Pregnancies complicated with IUGR. Fetal growth beneath the 10th percentile
88944731|NCT01883154||pregnancies with Gestational Diabetes|Normal glucose levels before 20 weeks, and positive Oral glucose tolerance test
88944732|NCT01883154||Pre Gestational Diabetes|A diagnosis of Diabetes before pregnancy or elevated glucose levels before 20 weeks.
88944733|NCT01883154||IVF pregnancies|
88944734|NCT01883167|Experimental|Febuxostat|"Days 1-7: febuxostat 40 mg qd. Days 8-14: RDEA3170 10 mg or placebo qd in combination with febuxostat 40 mg qd.~Days 15-21: RDEA3170 10 mg or placebo qd."
88944735|NCT01883167|Experimental|RDEA3170|"Days 1-7: RDEA3170 10 mg or placebo qd. Days 8-14: RDEA3170 10 mg or placebo qd in combination with febuxostat 40 mg qd.~Days 15-21: febuxostat 40 mg qd."
88944736|NCT01883180|Experimental|ATG 7.5mg/kg|ATG 7.5mg/kg group refers to treatment with ATG in the total dose of 7.5mg/kg.
88944737|NCT01883180|Experimental|ATG 10mg/kg|ATG 10mg/kg group refers to treatment with ATG in the total dose of 10mg/kg.
88944738|NCT01883193|Experimental|Arm 1: Preconception|Arm 1 will commence the comprehensive maternal nutrition intervention at 3-7 months postpartum. Delivery of the intervention will be monitored biweekly by collection of empty and unused sachets of the lipid-based supplement (LNS), maternal report, and casual observation of household behavior. Arm 1 participants will be weighed monthly and Body Mass Index (BMI) calculated. If BMI <20 an additional energy supplement will be provided. Menstrual history will be obtained at each visit and a urine pregnancy test will be performed if menses is delayed.
88944739|NCT01883193|Experimental|Arm 2: Pregnancy|Participants in Arm 2 will commence the same comprehensive maternal nutrition intervention at 12 weeks gestation.
88944740|NCT01883193|No Intervention|Arm 3: Control|Participants in Arm 3 will receive biweekly visits to monitor pregnancy status. No health advice will be given other than information about prenatal care, location of delivery, and breastfeeding education in the third trimester.
88944741|NCT01883219|Experimental|TKI therapy|Treatment with TKI will be initiated if the level of BCR-ABL transcript in the bone marrow is detectable and transcript levels increased for two consecutive tests. TKIs will be given for patients without BCR/ABL mutations and sensitive TKIs will be given for those with mutations.
88944742|NCT01883232|Active Comparator|2% lidocaine with 1:100,000 epinephrine|2% lidocaine with 1:100,000 epinephrine
88944743|NCT01883232|Experimental|Onset Mixing Pen by Onpharma|Sodium Bicarbonate 8.4% mixed with the onset mixing pen
88944744|NCT01883245|Active Comparator|sham tDCS|This group will receive sham-tDCS for 5 days. The anode will be placed on the primary motor cortex (M1) of the dominant hemisphere and the cathode on the contralateral supraorbital area. The direct current is transmitted through a pair of sponge electrodes, with a surface of 35 cm2 (7x5), soaked in saline solution and, it is generated by a constant current stimulator, with rechargeable batteries. This continuous stimulation lasted 30 seconds, with an intensity of 1 milliampere.
88944745|NCT01883245|Experimental|real tDCS|"This group will receive continuous stimulation lasting 20 minutes daily, for 5 days.~Transcranial direct current stimulation (tDCS) will be administered as follows. The anode will be placed on the primary motor cortex (M1) of the dominant hemisphere and the cathode on the contralateral supraorbital area. The direct current is transmitted through a pair of sponge electrodes, with a surface of 35 cm2 (7x5), soaked in saline solution and, it is generated by a constant current stimulator, with rechargeable batteries. This continuous stimulation lasted 20 minutes, with an intensity of 1 milliampere."
88944746|NCT01883258|Experimental|High intensity aerobic interval training|Type 2 diabetes subjects will complete 8 weeks of high intensity aerobic interval exercise training.
88944747|NCT01883258|Experimental|Continuous moderate intensity exercise|Type 2 diabetes subjects will complete 8 weeks of continuous moderate intensity exercise training.
88944748|NCT01883258|No Intervention|Non-exercise control group|Type 2 diabetes subjects assigned to the non-exercise control group will maintain their normal lifestyle for 8 weeks.
89463793|NCT06052059|Experimental|Study 1: High Dose Induction, Low Dose Maintenance|Participants receive high dose IV tulisokibart, followed by a low dose SC tulisokibart regimen.
89463794|NCT06052059|Experimental|Study 1: Low Dose Induction, Low Dose Maintenance|Participants receive low dose IV tulisokibart, followed by a low dose SC tulisokibart regimen.
89463795|NCT06052059|Placebo Comparator|Study 1: Placebo|Participants receive IV placebo, followed by an SC placebo regimen.
89463796|NCT06052059|Experimental|Study 1: High Dose Extension|Participants receive a high dose SC tulisokibart regimen. Participants may be enrolled in this arm after completing participation in their original arm, if they meet protocol-specific prerequisites.
89463797|NCT06052059|Experimental|Study 1: Low Dose Extension|Participants receive a low dose SC tulisokibart and placebo regimen. Participants may be enrolled in this arm after completing participation in their original arm, if they meet protocol-specific prerequisites.
89463798|NCT06052059|Experimental|Study 2: High Dose Induction|Participants receive high dose IV tulisokibart.
89463799|NCT06052059|Experimental|Study 2: Low Dose Induction|Participants receive low dose IV tulisokibart.
89463800|NCT06052059|Placebo Comparator|Study 2: Placebo|Participants receive IV placebo. Participants who meet protocol-specified conditions may later enter either the Study 2: High Dose Extension arm or Study 2: Low Dose Extension arm.
89463801|NCT06052059|Experimental|Study 2: High Dose Extension|Participants receive a high dose SC tulisokibart regimen. Participants may be enrolled in this arm only after completing participation in their original arm, if they meet protocol-specific prerequisites.
89463802|NCT06052059|Experimental|Study 2: Low Dose Extension|Participants receive a low dose SC tulisokibart regimen. Participants may be enrolled in this arm only after completing participation in their original arm, if they meet protocol-specific prerequisites.
88944749|NCT01883258|No Intervention|Healthy control group|Healthy subjects will be assigned to the healthy control group and will undergo baseline measures only.
88944750|NCT01883271|Experimental|High intensity aerobic interval training|Older adults will complete 8 weeks of high intensity aerobic interval exercise training.
88944751|NCT01883271|Experimental|Continuous moderate intensity exercise|Older adults will complete 8 weeks of continuous moderate intensity exercise training.
88944752|NCT01883271|No Intervention|Non-exercise control group|Older adults assigned to the non-exercise control group will maintain their normal lifestyle for 8 weeks.
88944753|NCT01883271|No Intervention|Young Healthy controls|Young healthy subjects will be assigned to the healthy control group and will undergo baseline measures only.
88944754|NCT01883284|Experimental|Cystic Fibrosis patients (CF)|Tests in vitro after sampling nasal cells of CF patients or controls are the intervention done on these subjects
88944755|NCT01883284|Other|Control subjects (non CF)|Tests in vitro after sampling nasal cells of CF patients or controls are the intervention done on these subjects
88944756|NCT01883310|Active Comparator|sham tDCS + TOCT|The sham transcranial direct current stimulation group will consist of anodal transcranial direct current stimulation applied for a total duration of 30 s over the right cerebellar position.
88944757|NCT01883310|Experimental|real tDCS + TOCT|the real transcranial direct current stimulation group will consist of anodal transcranial direct current stimulation applied for a total duration of 15 minutes over the right cerebellar position.
88944758|NCT01883323|Experimental|Cyclophosphamide and Fludarabine followed by TILs and IL-2|Cyclophosphamide, i.v., 60mg/kg per day for 2 days and Fludarabine, i.v., 25mg/m2 per day for 5 days; then Tumor-Infiltrating Lymphocytes, i.v., 1x10^10 - 1.6x10^11 cells and Low-Dose Interleukin, i.v., 125,000 IU/kg subcut per day, for 2 weeks (2 days rest between each week)
88944759|NCT01883349||ESRD patients|ESRD patients awaiting renal transplantation
88944760|NCT01883349||Control Arm|Subjects without kidney disease
88944761|NCT01883375|Experimental|Dignity Talk dyad completers|Those dyads where both patient and family member co-participant complete the protocol using the Dignity Talk Communication Topics
88944762|NCT01883375|Experimental|Dignity Talk non-completers|Those dyads where patient and family member co-participant either do not complete the protocol or do not use the Dignity Talk Communication Topics (November 2016 - the investigators have not as yet enrolled any participants who have not completed the study without using the Dignity Talk Topics. However some participants have withdrawn from the study without completing.
88944763|NCT01883401|Experimental|High dose strawberry|50g freeze-dried strawberries/day
88944764|NCT01883401|Experimental|Low-dose strawberry|25g freeze-dried strawberries/day
88944765|NCT01883401|Other|Fiber/calorie control (high dose)|Dietary fiber (8g)
88944766|NCT01883401|Other|Fiber/calorie control (low dose)|Dietary fiber (4g)
88944767|NCT01883414|Active Comparator|Group A|Subjects randomized to Group A will receive Ultherapy™ treatment on the superior or lateral half of the scar.
88944768|NCT01883414|Active Comparator|Group B|Subjects randomized to Group B will receive Ultherapy™ treatment on the inferior or medial half of the scar.
88944769|NCT01883466|Experimental|Diesel exhaust exposure|1 hour exposure to dilute diesel exhaust (approximate particle matter concentration 300 mcg/m3) during intermittent exercise
88944770|NCT01883466|Experimental|Biodiesel exhaust exposure|1 hour exposure to dilute biodiesel exhaust (generated at same running conditions as diesel exhaust) during intermittent exercise
88944771|NCT01883479|Experimental|Exercise|Telephone-based intervention designed to increase exercise among postpartum women.
88944772|NCT01883479|Experimental|Wellness/Support|Telephone-based intervention designed to provide support to postpartum women.
88944773|NCT01883479|No Intervention|Usual care|Participants receive usual care and will receive their choice of the interventions at 9 months.
88944774|NCT01883518|Experimental|Autologous dendritic cell vaccine|Autologous dendritic cell vaccine loaded with allogeneic tumor lysate expression of cancer testis antigens
89463803|NCT06048120|Experimental|i.v. infusion cohorts|Each participant will receive a single dose of study intervention, either BAY2701250 or placebo. Study intervention will be administered by means of short time i.v. infusion. Up to 7 dose steps are planned to be investigated for i.v. administration.
89463804|NCT06048120|Experimental|s.c. injection cohorts|Each participant will receive a single dose of study intervention, either BAY2701250 or placebo. Study intervention will be administered by means of s.c. injection. Up to 3 dose steps are planned to be investigated for s.c. administration.
89463805|NCT06042309|Experimental|NON-SLS, Allergic participants|Participants allergic to thiurams or carbamates assigned to the NON-SLS group.
89463806|NCT06042309|Experimental|NON-SLS, Control participants|Participants not allergic to thiurams or carbamates assigned to the NON-SLS group.
89463807|NCT06042309|Experimental|SLS, Allergic participants|Participants allergic to thiurams or carbamates assigned to the SLS group.
89463808|NCT06042309|Experimental|SLS, Control participants|Participants not allergic to thiurams or carbamates assigned to the SLS group.
89463809|NCT06041581|Experimental|SHADES Intervention|The SHADES intervention is a 6-month, modernized, collaborative care intervention in which a multidisciplinary team delivers established insomnia treatments consistent with patient preference. It uses a stepped, flexible, treat-to-target approach that harnesses technology to maximize access to and convenience of effective treatments and to minimize personnel, training, and space requirements. Our Intervention Team consists of an insomnia clinical specialist, a clinical behavioral sleep medicine and CBT-I delivery expert, a sleep research/medicine expert, and the patients' primary care providers. Treatments to be delivered are CBT-I in different modalities - internet, phone, and face-to-face - all of which are empirically supported.
89463810|NCT06041581|Active Comparator|Active Control|Active Control (AC) consists of sleep education and hygiene (study staff), symptom monitoring (study staff), and usual primary care for insomnia (clinical staff).
89463811|NCT06041256|Experimental|AURN001 High|Neltependocel High and Rho-associated protein kinase
88944775|NCT01883531|Placebo Comparator|Inhaled Placebo|Eight-week treatment period with inhaled placebo b.d.
89463812|NCT06041256|Experimental|AURN001 Medium|Neltependocel Medium and Rho-associated protein kinase
89463813|NCT06041256|Experimental|AURN001 Low|Neltependocel Low and Rho-associated protein kinase
89463814|NCT06041256|Experimental|Neltependocel - High|Neltependocel - High
89463815|NCT06041256|Experimental|ROCK|Rho-associated protein kinase (ROCK)
89463816|NCT06039384|Experimental|Part 1: Dose Finding|INCB099280 administered in combination with adagrasib in participants with previously treated KRAS glutamine to cysteine mutation at codon 12 (KRASG12C) mutant advanced solid tumors, will be evaluated to identify dose(s) for further evaluation in the dose expansion phase of the study.
89463817|NCT06039384|Experimental|Part 2: Dose Expansion|Up to 80 participants will be enrolled in 1 of 2 disease-specific cohorts: Cohort A: previously treated KRASG12C mutated non-small cell lung cancer (NSCLC) Cohort B: previously treated KRASG12C-mutated colorectal cancer (CRC). Up to 3 doses may be selected from Part 1: Dose Finding for the Part 2: Dose Expansion.
89463818|NCT06035120|Experimental|AeriSeal|All enrolled subjects meeting final eligibility will undergo the AeriSeal procedure to block collateral ventilation by closing the lobar fissure gaps or collateral air channels.
89463819|NCT06032754||First group : SSC with PSVD|medical file analysis of patients affected by SSC and PSVD
89463820|NCT06032754||Second group : PVSD without SSC|medical file analysis of patients affected by PSVD only
89463821|NCT06032754||Third group : SSC without PVSD|medical file analysis of patients affected by SSC only
89463822|NCT06032299|Active Comparator|Single Distal Femur Implant Group|Subjects will receive one of two types of implants for the distal femur fracture. The single implant will be either a plate and screws or a rod. The type of single implant used will be determined by the surgeon based on the characteristics of the fracture.
88944776|NCT01883531|Active Comparator|Inhaled Mannitol|Eight-week treatment period Inhaled Mannitol 400 mg b.d.
88944777|NCT01883544|Experimental|ALXN1007|Infusion of ALXN1007
89463823|NCT06032299|Experimental|Dual Distal Femur Implant Group|Subjects will receive two implants for fixation of the distal femur fracture. The dual implant will be either 2 plates with screws or a plate with screws and a rod. The type of dual implant used will be determined by the surgeon based on the characteristics of the fracture.
89463824|NCT06031623|No Intervention|Control|Patients allocated to this arm receives conventional resuscitative measures according to the 2020 AHA CPR Guidelines.
89463825|NCT06031623|Experimental|REBOA|After enrollment and randomization, patients allocated to this arm receives REBOA in addition to conventional ACLS according to the 2020 AHA CPR guidelines. The common femoral artery is accessed with ultrasound guidance. A sheath catheter is inserted, followed by a REBOA catheter. The REBOA is ballooned with 20cc of normal saline or until resistance is felt.
89463826|NCT06029127|Experimental|Stage 1: BGB-A445 + Docetaxel|BGB-A445 + Docetaxel
89463827|NCT06029127|Experimental|Stage 1: BGB-A445 + BGB-15025|BGB-A445 + BGB-15025
89463828|NCT06029127|Experimental|Stage 2: BGB-A445 + selected investigational agent(s) from Stage 1|BGB-A445 + selected investigational agent(s) from Stage 1 (either Docetaxel or BGB-15025)
89463829|NCT06029127|Other|Docetaxel + Ramucirumab|Reference to Stage 2: Ramucirumab + Docetaxel
89463830|NCT06026332||ADSTILADRIN|
88944778|NCT01883544|Placebo Comparator|placebo|Infusion placebo
88944779|NCT01883570|Experimental|trained visual search strategy|An expert's visual search strategy for reading the chest x-ray was recorded using a gaze tracking device. This strategy was reproduced using a dynamic cursor and will be made available to participants in the experimental group using an interactive website.
88944780|NCT01883570|Active Comparator|not trained in visual search strategy|Participants will learn to read chest x-rays by having access to a library of chest x-rays identical to the one used by the experimental arm, but without the search strategy.
88944781|NCT01883583|Experimental|Pilot group|Contrast-enhanced Ultrasound And Sonoelastography of transplanted kidney will be performed for acquisition of a number of parameters and time-intensity curves, before ultrasound guided biopsy of transplanted kidney.
88944782|NCT01883596|Experimental|0.12% Chlorhexidine|Bexident® (0.12% chlorhexidine) solution, applied topically, every 8 hrs.
88944783|NCT01883596|Placebo Comparator|Placebo|7.4% alcohol, glycerine, normal saline solution, applied topically, every 8 hrs.
88944784|NCT01883609|Active Comparator|Group 1|Group 1 receive combination vaccination strategy: RTS,S/AS01B at weeks 0, ChAd63 ME-TRAP at week 2, RTS,S/AS01B at weeks 4 and 8, then MVA ME-TRAP at week 10 followed by sporozoite challenge (mosquito bite) at week 12.
88944785|NCT01883609|Active Comparator|Group 2|Group 2 receive three vaccinations (RTS,S/AS01B) at weeks 0, 4 and 8 followed by sporozoite challenge (mosquito bite) at week 12.
88944786|NCT01883609|No Intervention|Group 3|Groups 3 is an infectivity-control group for the sporozoite challenge procedures: these volunteers will not be vaccinated. Group 3 will undergo sporozoite challenge at the same time as Group 1 and 2 volunteers (week 12).
89463831|NCT06025903||Primary Progressive multiple sclerosis|patients affected by primary progressive multiple sclerosis
89463832|NCT06025903||Relapsing Remitting multiple sclerosis|patients affected by primary progressive multiple sclerosis
89463833|NCT06024642|Experimental|V117957|
89463834|NCT06024642|Placebo Comparator|Placebo|
89463835|NCT06024083|No Intervention|Assessment only|Daily assessment of emotion regulation and self-efficacy variables.
89463836|NCT06024083|Experimental|Acceptance-oriented skills followed by change-oriented skills|Administration of acceptance-oriented skills videos first followed by change-oriented skills videos.
89463837|NCT06024083|Experimental|Change-oriented skills followed by acceptance-oriented skills|Administration of change-oriented skills videos first followed by acceptance-oriented skills videos.
89463838|NCT06015529|No Intervention|Control group - current practices|The investigating physicians of the participating centers in the control group will be free to provide care as they see fit. However, a reminder of national and European guidelines for PE management will be given to them and they will have the recommendation to apply a validated strategy. To make it easier, the different scores will be included in the clinical help-decision support software called SPEED. Investigators will be asked to enter data about the included patients directly into SPEED, which will act as the study's electronic case report form (eCRF). A paper version of the CRF will also be available.
89463839|NCT06015529|Active Comparator|Intervention group - 4PEPS strategy|Physicians of the participating centers in the intervention group will have the recommendation to apply the 4PEPS strategy. To make it easier to apply, the 4PEPS score will be included in SPEED. Investigators will be asked to enter the information relating to patients included in the study directly into SPEED before performing any testing. Entering these data will enable the 4PEPS score to be calculated automatically and specific recommendations to be provided. A paper version of the CRF will also be available
89463840|NCT06014541||MECP2 Duplication Syndrome Disease Participants|Participants with a diagnosis of MDS with genetic confirmation of MECP2 duplication (or triplication) will undergo CSF and blood collection, electrophysiological and clinical assessments, up to Week 104 as a part of prospective study. Each participant's medical and family history data will be collected retrospectively from available medical notes and charts, from birth up to the end of the study (up to 110 weeks). Participants will have an option to participate in an optional sub-study that will capture pre-defined list of activities at home video.
89463841|NCT06013475||Apalutamide|
89463842|NCT06013475||Darolutamide|
89463843|NCT06013475||Enzalutamide|
89463844|NCT06004440||Subjects with biopsy, with or without localization, of pulmonary lesion using Ion Endoluminal System|Subjects in which a pulmonary lesion biopsy, with or without localization, was attempted or performed with the Ion Endoluminal System.
89463845|NCT06003803|Experimental|digital learning in motivational interviewing|Receive digital learning in motivational interviewing for three months, once a week, 40 minutes each time
89463846|NCT06003803|No Intervention|conventional education|Receive conventional education for three months.
89463847|NCT06002204||Diagnosed with Mood Disorder|Individuals with a lifetime or a current diagnosis of a mood disorder (based upon a semi-structured diagnostic interview)
89201918|NCT04015635||Study group|"80 with hypertension, defined on office BP readings and confirmed with ambulatory blood pressure monitoring.~Clinical and laboratory assessment. NO intervention."
89201919|NCT04015635||Control|"80 WITHOUT hypertension, defined on office BP readings and confirmed with ambulatory blood pressure monitoring.~Clinical and laboratory assessment. NO intervention."
89463848|NCT06002204||At-risk for Developing Mood Disorder|Individuals at risk for developing mood disorders (has history of anxiety disorder, substance use disorder, trauma, or mood disorder that does not meet criteria for MDD or Bipolar Disorder or a first-degree relative with a history of mood disorders)
89463849|NCT06002204||Healthy Control|Healthy individuals who do not have a psychiatric diagnosis (including no history of mood disorders and no first-degree relative with a history of mood disorders)
89463850|NCT06002061|Experimental|Muscle Activation|Participants in this arm will receive intervention via application of brief air pressure maneuvers.
89463851|NCT06001775|Experimental|Patient Priorities Care Eligible Persons Living With Dementia and Mild Cognitive Impairment|Patients (and their care partners when available) will receive a packet of information about Patient Priorities Care, and when feasible, a trained facilitator(s) will initiate a Patient Priorities Care conversation with the patient or patient care partner dyad. This conversation will be documented in the Electronic Health Record.
89463852|NCT05997017|Experimental|Endometrioid Endometrial Cancer|Patients with advanced or recurrent endometrioid endometrial carcinoma
89201920|NCT00926133||STEMI patients|Patients with acute STEMI treated by PCI without previously known type 2 diabetes.
89463853|NCT05987592|Experimental|Brain Education and WELLness with Migraine Group A|8 weekly virtual sessions plus online platform
89463854|NCT05987592|Experimental|Brain Education and WELLness with Migraine Group B|8 weekly virtual sessions plus online platform
89463855|NCT05971875|Active Comparator|vNOTES vs Vaginal Hysterectomy|Group A: If VH is concidered safe and feasable; the patient is randomized between VH and vNOTES
89463856|NCT05971875|Active Comparator|vNOTES vs Laparoscopic Hysterectomy|If VH is not concidered safe and feasable; The patient is randomized between LH and vNOTES
89501919|NCT02232607|Active Comparator|Placebo|
89201921|NCT00667602|Experimental|MenACWY-CRM197 (2 doses) + Concomitant Vaccines|Infants received two doses of MenACWY-CRM197 at 6 to 8 and 12 months of age and concomitant dose of PCV7 (Pneumococcal 7-valent Conjugate Vaccine) and DTPa-IPV-HepB-Hib (Diphtheria-Tetanus-acellular Pertussis, Hepatitis B, Inactivated Poliovirus and Haemophilus influenzae type b) at 12 months.
89206173|NCT04442334||EFPIA Clinical Trial Cohort|Collated data and biological samples on patients with histologically characterised NAFLD that have participated in phase 2 and phase 3 trials of IMPs for NAFLD.
89463857|NCT05963204|Active Comparator|Biostimulator and Facial Moisturizer A|"Biostimulator is sterile dry powder poly L-lactic acid with sodium carboxymethylcellulose, non-pyrogenic mannitol. Mode of administration: injection. Dosage: at investigator's discretion for optimal outcome. Frequency and duration: injection at baseline and at week 6.~Facial Moisturizer A is a cream with active TriHex technology. Mode of administration: topical application. Frequency and duration: twice daily on half of the face for the entire study."
89463858|NCT05963204|Active Comparator|Biostimulator and Facial Moisturizer B|"Biostimulator is sterile dry powder poly L-lactic acid with sodium carboxymethylcellulose, non-pyrogenic mannitol. Mode of administration: injection. Dosage: at investigator's discretion for optimal outcome. Frequency and duration: injection at baseline and at week 6.~Facial Moisturizer B is a neutral, oil-free moisturizing lotion. Mode of administration: topical application. Frequency and duration: twice daily on half of the face for the entire study."
89463859|NCT05962541|Experimental|PPD-TURBT (no Re-TURBT)|Primary PDD-TURBT, not followed by Re-TURBT
89463860|NCT05962541|No Intervention|WL TURBT plus Re-TURBT (Standard of Care)|Standard of care consisting in primary WL TURBT followed by WL Re-TURBT within 2 - 6 weeks from initial WL TURBT
89463861|NCT05956795||BWH stage T2a tumors in patients who are on chronic immunosuppression|Patient's whose cutaneous squamous cell carcinoma is BWH stage T2a and also have a history of organ transplant, hematologic malignancy, autoimmune disease. After these participants are diagnosed, the participants are entered into the study without any further imaging or sentinel lymph node biopsy. The participants will have ultrasound surveillance every 6 months and regular visits every 3 months throughout the duration of the study (2 years).
89463862|NCT05956795||BWH stage T2b|Participants whose cutaneous squamous cell carcinoma is BWH stage T2b. Participants will initially undergo CT imaging of the nodal basin immediately after diagnosis. If the CT is positive, the participants will be excluded from the study. If the CT is unremarkable, patients will undergo sentinel lymph node biopsy (SLNB), which has a higher sensitivity to detect occult micro-metastases. If the SLNB is negative, the participants are entered into the study. The participants will have ultrasound surveillance every 6 months and regular visits every 3 months throughout the duration of the study (2 years).
89501920|NCT04638049|Active Comparator|Prostate (Bed) only RadioTherapy (PBRT)|Primary, adjuvant or salvage RT of the prostate (bed) without RT of the pelvic nodal regions in the small pelvis, according to local hospital guidelines and protocols.
89463863|NCT05956795||BWH stage T3|Participants whose cutaneous squamous cell carcinoma is BWH stage T3. Participants will initially undergo CT imaging of the nodal basin immediately after diagnosis. If the CT is positive, The participants will be excluded from the study. If the CT is unremarkable, patients will undergo sentinel lymph node biopsy (SLNB), which has a higher sensitivity to detect occult micro-metastases. If the SLNB is negative, the participants are entered into the study The participants will have ultrasound surveillance every 6 months and regular visits every 3 months throughout the duration of the study (2 years).
89463864|NCT05952297|Experimental|Sleep Wellness Device|The wearable sleep wellness device that contains specially designed coils that generate micro electromagnetic stimulation located in the neckband and is worn around the neck like headphones for at least 3 hours per day.
89463865|NCT05952297|Sham Comparator|Inactive Sleep Wellness Device|This sleep wellness device is running an inactive program in the application (no electromagnetic stimulation).
89463866|NCT05950269|Experimental|Walking aid (WA) group|Participants will receive the walking aid and training in the use of the device.
89463867|NCT05950269|Experimental|Walking aid with telemonitoring (WAT) group|Participants will receive the walking aid and training in the use of the device associated with telemonitoring.
89463868|NCT05950269|Other|Control group|Participants will receive verbal guidance and printed material.
89463869|NCT05945342|Active Comparator|Simple Medication|Escitalopram alone treatment
89463870|NCT05945342|Active Comparator|Simple Psychotherapy|Simple interpersonal psychotherapy group
89463871|NCT05945342|Experimental|Medication combined with psychotherapy|Medication combined with interpersonal psychotherapy
89463872|NCT05945342|Experimental|Medication combined with physical therapy group|Medication combined with robotic navigational repetitive transcranial magnetic stimulation
89463873|NCT05945342|Sham Comparator|Medication combined with sham physical therapy group|Medication combined with sham robotic navigational repetitive transcranial magnetic stimulation
89463874|NCT05938283|Active Comparator|Transvenous Implantable Defibrillator|Routine TV ICD implant
89463875|NCT05938283|Active Comparator|Subcutaneous Implantable Defibrillator|SICD ICD implant as per study protocol
89463876|NCT05937763||Primary Care Paramedic (PCP) Block|A PCP will be staffed in the emergency department offload zone 3 days a week (Monday, Wednesday, and Friday) on a 10am - 10pm shift, in addition to the standard staffing model.
89463877|NCT05937763||Registered Nurse (RN) Block|An experienced emergency department RN with triage training will be staffed in the emergency department offload zone 3 days a week (Monday, Wednesday, and Friday) in a 10am - 10pm shift, in addition to the standard staffing model
89463878|NCT05937763||Current Workflow Block|The currently hospitals staffing models of the emergency department offload zone.
89463879|NCT05935033|Experimental|Severe Hepatic Impairment|Participants will receive a single oral dose of 10 milligrams (mg) emraclidine.
89463880|NCT05935033|Experimental|Moderate Hepatic Impairment|Participants will receive a single oral dose of 10 mg emraclidine.
89463881|NCT05935033|Experimental|Mild Hepatic Impairment|Participants will receive a single oral dose of 10 mg emraclidine.
89463882|NCT05935033|Experimental|Normal Hepatic Function|Participants will receive a single oral dose of 10 mg emraclidine.
89463883|NCT05932069|Experimental|SPIN|Exercise 3 times a week on a stationary ergometer @ 50-80% of maximal heart rate reserve for 20 minutes to 45 minutes per session
89201922|NCT00667602|Experimental|MenACWY-CRM197 (1 dose) + Concomitant Vaccines|Infants received one dose of MenACWY-CRM197 at 12 months of age and concomitant dose of PCV7 (Pneumococcal 7-valent Conjugate Vaccine) and DTPa-IPV-HepB-Hib (Diphtheria-Tetanus-acellular Pertussis, Hepatitis B, Inactivated Poliovirus and Haemophilus influenzae type b) at 12 months of age.
89463884|NCT05932069|Active Comparator|Non-aerobic, stretching/balance intervention Control|For this arm of the intervention, randomized participants followed the same guidelines as the SPIN group but did not partake in aerobic exercise. To equalize contact/monitoring of the groups this group met for the same total duration time as the SPIN group; however, instead of aerobic exercise, progressive whole body stretching and toning exercises
89463885|NCT05927480|Experimental|Audio Distraction|Those included in this study and randomized into the treatment arm will be given an mp3 device and headphones to listen to genre of music of their choosing in addition to be treated to the routine care with the skeletal traction pin.
89463886|NCT05927480|No Intervention|Control|Those randomized into this arm will receive the current routine care which is treatment with a skeletal traction pin and no audio distraction.
89463887|NCT05922423|Experimental|MBSR|Week 1: Introduce mindfulness theory knowledge to participants and guide them to engage in mindfulness breathing training; Week 2: Sitting meditation, explaining the essence of meditation and practicing with music; Week 3: Explain the connotation of walking meditation, inform the participants of precautions, and guide them to practice; Week 4: Explain the connotation and requirements of body scanning, guide participants in practice; Week 5: Introduce the connotation of hatha yoga and guide participants to practice; Week 6: Explain the meaning of mindfulness sounds and thoughts, guide participants to practice; Week 7: Explain the characteristics of non selective perception, combined with music practice; Week 8: Emphasize mindfulness to promote health, encourage participants to practice internalization, and develop into their own patterns.
89463888|NCT05922423|Placebo Comparator|health education|For cancer patients who have entered the comfort group, automatic tweets and health knowledge related to science popularization will be provided knowledge
89463889|NCT05920356|Experimental|Sotorasib combined with carboplatin and pemetrexed|Sotorasib administered in combination with carboplatin and pemetrexed.
89463890|NCT05920356|Active Comparator|Pembrolizumab combined with carboplatin and pemetrexed|Pembrolizumab administered in combination with carboplatin and pemetrexed.
89463891|NCT05914259||Diagnosed cohort - CKD Stage 1|Based on diagnosis codes (International Classification of Diseases (ICD) codes) indicating Stage 1.
89463892|NCT05914259||Diagnosed cohort - CKD Stage 2|Based on diagnosis codes (International Classification of Diseases (ICD) codes) indicating Stage 2.
89463893|NCT05914259||Diagnosed cohort - CKD Stage 3|Based on diagnosis codes (International Classification of Diseases (ICD) codes) indicating Stage 3.
89463894|NCT05914259||Diagnosed cohort - CKD Stage 4|Based on diagnosis codes (International Classification of Diseases (ICD) codes) indicating Stage 4.
89463895|NCT05914259||Diagnosed cohort - CKD Stage 5|Based on diagnosis codes (International Classification of Diseases (ICD) codes) indicating Stage 5.
89463896|NCT05914259||Diagnosed cohort - CKD Stage Unspecified|Based on diagnosis codes (International Classification of Diseases (ICD) codes) indicating Stage Unspecified.
89463897|NCT05914259||Lab based cohort - CKD Stage 1|Two abnormal lab measures of estimated Glomerular Filtration Rate (eGFR), or Urine Albumin-Creatinine Ratio (uACR)/ Urine Protein Creatinine Ratio (uPCR) using Logical Observation Identifiers Names and Codes (LOINC) codes based on Kidney Disease Improving Global Outcomes (KDIGO) guidelines indicating Stage 1.
89463898|NCT05914259||Lab based cohort - CKD Stage 2|Two abnormal lab measures of estimated Glomerular Filtration Rate (eGFR), or Urine Albumin-Creatinine Ratio (uACR)/ Urine Protein Creatinine Ratio (uPCR) using LOINC codes based on Kidney Disease Improving Global Outcomes (KDIGO) guidelines indicating Stage 2.
89463899|NCT05914259||Lab based cohort - CKD Stage 3 overall|Two abnormal lab measures of estimated Glomerular Filtration Rate (eGFR), or Urine Albumin-Creatinine Ratio (uACR)/ Urine Protein Creatinine Ratio (uPCR) using LOINC codes based on Kidney Disease Improving Global Outcomes (KDIGO) guidelines indicating Stage 3 overall.
89463900|NCT05914259||Lab based cohort - CKD Stage 3a|Two abnormal lab measures of estimated Glomerular Filtration Rate (eGFR), or Urine Albumin-Creatinine Ratio (uACR)/ Urine Protein Creatinine Ratio (uPCR) using LOINC codes based on Kidney Disease Improving Global Outcomes (KDIGO) guidelines indicating Stage 3a.
89463901|NCT05914259||Lab based cohort - CKD Stage 3b|Two abnormal lab measures of estimated Glomerular Filtration Rate (eGFR), or Urine Albumin-Creatinine Ratio (uACR)/ Urine Protein Creatinine Ratio (uPCR) using LOINC codes based on Kidney Disease Improving Global Outcomes (KDIGO) guidelines indicating Stage 3b.
89463902|NCT05914259||Lab based cohort - CKD Stage 4|Two abnormal lab measures of estimated Glomerular Filtration Rate (eGFR), or Urine Albumin-Creatinine Ratio (uACR)/ Urine Protein Creatinine Ratio (uPCR) using LOINC codes based on Kidney Disease Improving Global Outcomes (KDIGO) guidelines indicating Stage 4.
89463903|NCT05914259||Lab based cohort - CKD Stage 5|Two abnormal lab measures of estimated Glomerular Filtration Rate (eGFR), or Urine Albumin-Creatinine Ratio (uACR)/ Urine Protein Creatinine Ratio (uPCR) using LOINC codes based on Kidney Disease Improving Global Outcomes (KDIGO) guidelines indicating Stage 5.
89463904|NCT05914259||Lab based cohort - CKD Stage unspecified|Two abnormal lab measures of estimated Glomerular Filtration Rate (eGFR), or Urine Albumin-Creatinine Ratio (uACR)/ Urine Protein Creatinine Ratio (uPCR) using LOINC codes based on Kidney Disease Improving Global Outcomes (KDIGO) guidelines indicating Stage unspecified.
89463905|NCT05909397|Experimental|Arm A (Investigational Arm)|"Participants will receive:~ARV-471, orally, once daily, continuously, in a 28-day cycle, plus~Palbociclib, orally, once daily for 21 consecutive days followed by 7 days off treatment in a 28 day cycle"
89463906|NCT05909397|Active Comparator|Arm B (Comparator Arm):|"Participants will receive:~Letrozole, orally, once daily, continuously, in a 28-day cycle, plus~Palbociclib, orally, once daily for 21 consecutive days followed by 7 days off treatment, in a 28-day cycle."
89463907|NCT05908227|Experimental|NHF high|Nasal high flow therapy 8L/min
89463908|NCT05908227|Experimental|NHF low|Nasal high flow therapy 6L/min
89463909|NCT05908227|Active Comparator|NCPAP|Nasal continuous positive airway pressure 6 cm H20
89463910|NCT05907746|Experimental|Arm A|JSP191, Fludarabine, Total Body Irradiation
89463911|NCT05907746|Experimental|Arm B|JSP191, Fludarabine, Cyclophosphamide, Total Body Irradiation
89463912|NCT05907122|Experimental|ABP 206|Subjects will receive Dose A of ABP 206 via intravenous (IV) infusion.
89463913|NCT05907122|Active Comparator|FDA-licensed Nivolumab|Subjects will receive Dose A of FDA-licensed Nivolumab via IV infusion.
89463914|NCT05907122|Active Comparator|EU-authorized Nivolumab|Subjects will receive Dose A of EU-authorized Nivolumab via IV infusion.
89463915|NCT05905783|Placebo Comparator|Group 1: Placebo subcutaneous once weekly|Participants will receive placebo every week to week 15, then izokibep to week 51.
89463916|NCT05905783|Experimental|Group 2: Izokibep subcutaneous once weekly|Participants will receive izokibep every week to week 51
89463917|NCT05904132|Placebo Comparator|Healthy Controls|
89463918|NCT05904132|Experimental|MCI Subjects|
89463919|NCT05897827|Experimental|PLANTS|Schools will receive the online-delivered PLANTS intervention, which includes 3 asynchronous training modules and 3 synchronous group events.
89463920|NCT05897827|Active Comparator|EMAILS|Comparison schools will receive emails with publicly available resources for supporting LGBTQ+ students as a control intervention.
89463921|NCT05896566|Experimental|Arm A: Giredestrant|Giredestrant
89463922|NCT05896566|Experimental|Arm B: Giredestrant plus triptorelin|Giredestrant plus triptorelin
89463923|NCT05896566|Active Comparator|Arm C: Anastrozole plus triptorelin|Anastrozole plus triptorelin
89463924|NCT05888844|Experimental|Part 1: INCB099280 Dose 1|Participants will receive INCB099280 dose 1 twice daily (BID) for up to 2 years.
89463925|NCT05888844|Experimental|Part 1: INCB099280 Dose 2|Participants will receive INCB099280 dose 2 twice daily (BID) for up to 2 years.
89463926|NCT05888844|Experimental|Part 1: INCB099280 Dose 3|Participants will receive INCB099280 dose 3 twice daily (BID) for up to 2 years.
89463927|NCT05888844|Experimental|Part 2: INCB099280 Dose selected from Part 1|Participants will receive INCB099280 dose selected from Part 1 twice daily (BID) for up to 2 years.
89463928|NCT05888636||MGUS|
89463929|NCT05888636||MM smouldering|
89463930|NCT05888636||Syntomatic MM|
89463931|NCT05888493|Experimental|Tisagenlecleucel|Participants randomized to the tisagenlecleucel treatment strategy will receive a single infusion of 0.6 to 6 x 10^8 CAR-positive viable T-cells
89463932|NCT05888493|Active Comparator|R2 or R-CHOP|Participants randomized to Standard of Care treatment will receive either R2 or R-CHOP based on investigator choice of therapies, and this has to be determined prior to randomization.
89463933|NCT05886621|Experimental|Smiling instead of Smoking - HIV|"Participants will be onboarded to the smartphone app Smiling instead of Smoking - HIV (SiS-H), and will be asked to use it for 8 weeks while they quit smoking."
89463934|NCT05886621|Active Comparator|QuitGuide|"Participants will be onboarded to the smartphone app QuitGuide (QG), and will be asked to use it for 8 weeks while they quit smoking."
89463935|NCT05884879||Tinnitus group|"Adults, i.e. 18-69 year old;~Pure tone average <35 dB HL (0.5, 1, 2, 4 kHz);~Proficient and native speaker of Dutch language;~Severe unilateral or bilateral tinnitus disorder (TQ > 46)."
89463936|NCT05884879||Control group|"Adults, i.e. 18-69 year old;~Pure tone average <35 dB HL (0.5, 1, 2, 4 kHz);~Proficient and native speaker of Dutch language;~No tinnitus."
89463937|NCT05883449|Experimental|Safety run-in in Hodgkin Lymphoma|"4 safety run-in cohorts:~Cohort 1: 200 mg AFM13 + AB-101 (2 × 10e9 cells on Day 1, Day 8, Day 15)~Cohort 2: 300 mg AFM13 + AB-101 (2 × 10e9 cells on Day 1, Day 8, Day 15)~Cohort 3: 200 mg AFM13 + AB-101 (4 × 10e9 cells on Day 1; 2 × 10e9 cells on Day 8, Day 15)~Cohort 4: 300 mg AFM13 + AB-101 (4 × 10e9 cells on Day 1; 2 × 10e9 cells on Day 8, Day 15)"
89463938|NCT05883449|Experimental|Dose Level A in Hodgkin Lymphoma|Randomized Simon 2-stage design in Hodgkin Lymphoma Dose Level A (selected from cohort 1-4 of Safety run-in)
89463939|NCT05883449|Experimental|Dose Level B in Hodgkin Lymphoma|Randomized Simon 2-stage design in Hodgkin Lymphoma Dose Level B (selected from cohort 1-4 of Safety run-in)
89463940|NCT05883449|Experimental|Exploratory: AFM13 + AB-101 on CD30-positive PTCL|AFM13 + AB-101 on select CD30-positive PTCL subtypes (Dose Level A or B)
89463941|NCT05878704|Experimental|Treatment|GBT021601
89463942|NCT05877976|Experimental|Registered Nurses|Participants will receive an intervention of museum educator-led workshops that introduce nurses to arts appreciation skills to improve their practice and overall wellbeing.
89463943|NCT05873413|Active Comparator|Motivate-the-Bystander|A Zoom-based motivational interviewing prevention program that enhances knowledge, motivation, and skills for increased bystander behaviors.
89463944|NCT05873413|Experimental|Motivate-the-Bystander+Alcohol|A Zoom-based motivational interviewing prevention program that enhances knowledge, motivation, and skills for reduced alcohol use and increased bystander behaviors.
89463945|NCT05873413|Placebo Comparator|Attention-only control|A Zoom-based stress reduction program in which progressive muscle relaxation and other techniques are introduced and practiced.
89463946|NCT05872347|Experimental|SPH4336 Tablets|SPH4336 Tablets; Letrozole tablets; Fulvestrant; Exemestane
89463947|NCT05862064|Experimental|Arm-A|"SHR1210 (carrelizumab): 200 mg in combination with chemotherapy (described below) intravenously (IV), Q2W, and famitinib (10 mg) orally once daily (QD). This was followed by maintenance therapy with SHR1210 (carrelizumab) (200 mg, IV every 2 weeks [Q2W]) and famitinib (10 mg) orally once daily (QD) to complete treatment with a total duration of 1 year from the first dose.~Chemotherapy: Intensive intravenous dose of epirubicin (80-90 mg/m2) + IV cyclophosphamide (600 mg/m2) repeated administration of Q2W for a total of 4 doses, followed by (IV) paclitaxel (80 mg/m2) once weekly (QW) for 12 weeks."
89463948|NCT05862064|Sham Comparator|Arm-B|Chemotherapy: Intensive intravenous dose of epirubicin (80-90 mg/m2) + IV cyclophosphamide (600 mg/m2) repeated administration of Q2W for a total of 4 doses, followed by (IV) paclitaxel (80 mg/m2) once weekly (QW) for 12 weeks.
89463949|NCT05861271|Experimental|Arm-1|"Pyrotinib: 400mg QD Po for half a year, and Capecitabine: 500mg Tid Po for half a year Use of endocrine drugs in endocrine receptor (HR)-positive patients after chemotherapy. For premenopausal patients: tamoxifen (10 mg po, bid, for 5 years) or toremifene (60 mg po, qd, for 5 years); for postmenopausal patients: letrozole (2.5 mg, po, qd for 5 years) or anastrozole (1 mg, po, qd for 5 years) or exemestane (25 mg, po, qd for 5 years).~After chemotherapy, radiation therapy will be started if necessary."
89463950|NCT05861271|No Intervention|Arm-2|"No adjuvant chemotherapy or targeted therapy. Use of endocrine drugs in endocrine receptor (HR)-positive patients after chemotherapy. For premenopausal patients: tamoxifen (10 mg po, bid, for 5 years) or toremifene (60 mg po, qd, for 5 years); for postmenopausal patients: letrozole (2.5 mg, po, qd for 5 years) or anastrozole (1 mg, po, qd for 5 years) or exemestane (25 mg, po, qd for 5 years).~After chemotherapy, radiation therapy will be started if necessary."
89463951|NCT05860465|Experimental|SPH4336 Tablets|SPH4336 Tablets; Letrozole tablets; Fulvestrant injection
89463952|NCT05860465|Placebo Comparator|SPH4336 Tablets Placebo|SPH4336 Tablets Placebo; Letrozole tablets; Fulvestrant injection
89463953|NCT05856487|Experimental|NVP-2203|NVP-2203 Plus other Placebo for up to 8 weeks, oral dose
89463954|NCT05856487|Active Comparator|NVP-2203-R1|NVP-2203-R1 Plus other Placebo for up to 8 weeks, oral dose
89463955|NCT05856487|Active Comparator|NVP-2203-R2|NVP-2203-R2 Plus other Placebo for up to 8 weeks, oral dose
89463956|NCT05856487|Active Comparator|NVP-2203-R3|NVP-2203-R3 Plus other Placebo for up to 8 weeks, oral dose
89463957|NCT05853211||Clear aligner|Patient with class II malocclusion, treated with class II elastics on aligners
89463958|NCT05853211||Fixed appliance|Patient with class II malocclusion, treated with class II elastics on fixed appliance
89463959|NCT05852860|No Intervention|Usual Care|Clinicians and patients will receive no further interventions beyond usual practice.
89463960|NCT05852860|Experimental|Clinician Nudge|Clinicians will receive a nudge via a Best Practice Alert within the electronic medical record.
89463961|NCT05852860|Experimental|Patient Nudge|Patients will receive a message sent through the patient portal or via text.
89463962|NCT05852860|Experimental|Combined Nudge: Clinician and Patient Nudge|Both the clinician nudge and the patient nudge will be used.
89018020|NCT05585125|Active Comparator|Beta-Blocker BA Sequence|This arm will follow a BA sequence: OFF beta-blockers (B) and ON beta-blockers (A). Subjects start Period 1 (B) with the study team slowly reducing the subject's beta-blocker home dose until they are off (or the lowest dose they can safely tolerate), then switch to Period 2 (A), where they restart their beta-blocker and slowly up-titrate until they reach their home dose. Subjects are then asked if they have enough information to clarify their preference about continuing or discontinuing their beta-blocker. Subjects can choose to engage in 2-6 periods based on whether they need more information. The extra phases follow the same OFF-ON pattern (BABABA), meaning if they choose to continue into Period 3 (B), the subject will slowly reduce their beta-blocker dose until they are off (or the lowest dose they can safely tolerate). This continues until the subject has enough information to clarify their preference about continuing or discontinuing their beta-blocker, with a max of 6 periods.
89018021|NCT05574192|Other|Social Engagement Intervention|The social engagement intervention includes in-person visits by peer-workers to undertake accompanied social activities with enrolled participants. Each visit will last one hour, occur two times per month over a 12 month period. Activity categories will be self-selected by participants based on physical abilities and interests. Categories include: a) arts based activity; b) physical activity.
89018022|NCT05566821|Experimental|STRENGTH Outreach Intervention|Participants enrolled in STRENGTH intervention elements
89018023|NCT05563584|No Intervention|Usual Care|Patients will continue Usual Care, which will include aspirin, a statin and routine lifestyle advice
89463963|NCT05849350|Experimental|Protein|Participants will receive a whey protein supplement.
89463964|NCT05849350|Placebo Comparator|Maltodextrin|Participants will receive an isocaloric maltodextrin supplement.
89463965|NCT05849298|Experimental|Arm A|Participants will receive 7.4 GBq (+/- 10%) of AAA617 (Lutetium [177Lu] vipivotide tetraxetan) once every 6 weeks for 6 cycles. ADT must be ongoing; Best supportive care is allowed.
89463966|NCT05849298|Experimental|Arm B|Participants will receive 7.4 GBq (+/- 10%) of AAA617 (Lutetium [177Lu] vipivotide tetraxetan) once every 6 weeks for 6 cycles. In addition of SOC (ADT plus choice of ARPI as per physician's decision), Best supportive care is allowed.
89463967|NCT05848544|Other|Symptomatic knee osteoarthritis|obese patients with symptomatic knee osteoarthritis eligible to a very low calories ketogenic diet
89463968|NCT05848544|Other|obese patients with fibromyalgia|obese patients with with fibromyalgia eligible to a very low calories ketogenic diet
89463969|NCT05847881|Experimental|Reflective process group|
89018024|NCT05563584|Experimental|Super Rehab plus Usual Care|12-month Super Rehab programme plus Usual Care
89018025|NCT05561855|Experimental|lifestyle intervention|"Weight monitoring: Participants are required to record the weighting data in the WeChat official account at least once a week to lose 5% or more of their initial body weight in 3 months.~Goals record: At baseline, the participants need to complete a behavioral goals questionnaire. All these behaviors are then ranked for each participant based on an algorithm that determines the participants'self-reported necessity, self-efficacy, and estimated caloric deficit from performing that behavior. The top six goals are assigned to each participant with two for every 4-week cycle.~Exercise: The form is the combination of aerobic exercise (3d/w) and resistance exercise(2d/w). Each participant will be equipped with a Huami watch as a means of monitoring.~Health education: Participants are provided with T2DM-related knowledge. They can also contact the endocrinologist online and offline."
89018026|NCT05561855|No Intervention|usual-care control|Participants assigned to the control group will receive routine medical care and diabetes education, and be treated with hypoglycemic drugs under the guidance of endocrinologists according to the patient's condition and clinical treatment standards throughout their participation in the trial. After finishing the study, they will be offered healthy management as the participants in the multi-component lifestyle intervention group.
89463970|NCT05837013|Experimental|General anesthesia (GA) and TEP Group|General anesthesia: No premedication will be applied. In the waiting room, 10 mL/kg of Ringer's lactate solution will be infused IV in 30 minutes. In Group I, 2-2.5 mg/kg propofol and 1 μg/kg fentanyl IV will be given for induction; 0.6 mg/kg rocuronium will then be used to provide the muscle relaxation needed for intubation. After intubation, the tidal volume will be set to 6-8 mL/kg and the respiratory frequency PetCO2 32-36 mmHg in volume-controlled ventilation (VCV) mode. Anesthesia will continue to be provided with sevoflurane (1.5%-2%), oxygen-air mixture (FiO 2 = 0.4) and repeated doses of rocuronium (0.015 mg/kg). At the end of the surgery, neostigmine (2-2.5 mg) and atropine (1 mg) will be given IV to antagonize the residual neuromuscular block.
89463971|NCT05837013|Active Comparator|Spinal anesthesia (with nerve block) (SA) and TEP Group|Spinal Anesthesia and Nerve Block: No premedication will be applied. Spinal anesthesia will be administered to the patients in this group in the sitting position with a 27G Quincke needle (15 mg hyperbaric 0.5% bupivacaine) to be entered through the L2-L3 or L3-L4 interval. If hypotension develops, it will be corrected with a crystalloid infusion and ephedrine. These patients will be administered intravenous sedation with increasing doses of midazolam to provide adequate sedation. According to Hadzic, II and IH nerve block will be performed by applying 10 mL of 0.75% ropivacaine 2 cm above and 2 cm medial to the anterior superior iliac spine.
89463972|NCT05837013|Experimental|General anesthesia (GA) and open surgical procedure (Lichtenstein)|General anesthesia: No premedication will be applied. In the waiting room, 10 mL/kg of Ringer's lactate solution will be infused IV in 30 minutes. In Group I, 2-2.5 mg/kg propofol and 1 μg/kg fentanyl IV will be given for induction; 0.6 mg/kg rocuronium will then be used to provide the muscle relaxation needed for intubation. After intubation, the tidal volume will be set to 6-8 mL/kg and the respiratory frequency PetCO2 32-36 mmHg in volume-controlled ventilation (VCV) mode. Anesthesia will continue to be provided with sevoflurane (1.5%-2%), oxygen-air mixture (FiO 2 = 0.4) and repeated doses of rocuronium (0.015 mg/kg). At the end of the surgery, neostigmine (2-2.5 mg) and atropine (1 mg) will be given IV to antagonize the residual neuromuscular block.
89463973|NCT05837013|Active Comparator|Spinal anesthesia (with nerve block) (SA) open surgical procedure (Lichtenstein)|Spinal Anesthesia and Nerve Block: No premedication will be applied. Spinal anesthesia will be administered to the patients in this group in the sitting position with a 27G Quincke needle (15 mg hyperbaric 0.5% bupivacaine) to be entered through the L2-L3 or L3-L4 interval. If hypotension develops, it will be corrected with a crystalloid infusion and ephedrine. These patients will be administered intravenous sedation with increasing doses of midazolam to provide adequate sedation. According to Hadzic, II and IH nerve block will be performed by applying 10 mL of 0.75% ropivacaine 2 cm above and 2 cm medial to the anterior superior iliac spine.
89463974|NCT05828823|Experimental|Clinically-matched Incremental Hemodialysis ( CMIHD)|Randomized group to have hemodialysis prescription tailored based on residual kidney function and clinical manifestations starting at twice weekly.
89463975|NCT05828823|Active Comparator|Conventional Hemodialysis (CHD)|Randomized group to conventional three times a week hemodialysis.
89463976|NCT05824923|Experimental|Pulmonary Artery Denervation (PADN)|Patients in the PADN group will receive pulmonary artery denervation procedure.
89463977|NCT05824923|Active Comparator|Guideline-directed medical therapy (GDMT) for heart failure|Patients in the control group will take their baseline anti-heart failure medications at the original doses according to 2023 ESC Guidelines for heart failure, without any changes except when medically required. The anti-heart failure drugs treatment is consistent in both arms.
89463978|NCT05823272|Experimental|oral nutritional supplement|In the oral nutritional supplement group, in addition to diet, and patients will also consume enteral nutrition powder (500 ml/d, 500kcal/d) lasted for 6 months after discharge.
89463979|NCT05823272|No Intervention|control|In the control group, patients will receive nutrition counseling in addition to diet.
89463980|NCT05819073|Experimental|PROP non-taster subjects|This arm will comprise of PROP non-taster subjects. Subjects will use a cranberry-derived oral rinse twice a day for 11 days following a 3-day plain water-rinse period.
89018027|NCT05557708|Experimental|212-Lead Pentixather|"Single intravenous infusion of Pentixather radiolabeled with Lead-212. Administered activity to participant is calculated from bone marrow and renal radiation constraints.~Treatment is administered in 2 cycles with 6 weeks between the cycles."
89018028|NCT05556629||NATPARA: Participants|Participants who have been approved for NATPARA and a part of the special use program (SUP) prior to survey implementation will participate in the survey via telephone or internet.
89018029|NCT05556629||NATPARA: Healthcare Provider (Prescribing Physician)|Healthcare provider (HCPs)/Prescribing physician who can provide a 10-digit National Provider Identifier (NPI) number and who are certified in the NATPARA risk evaluation and mitigation strategy (REMS) by successfully completing the NATPARA REMS program training module for prescribing physicians, including the knowledge assessment, and submitting a NATPARA REMS Program Prescriber Enrollment Form will participate in the survey via telephone or internet.
89018030|NCT05546164||Hemiparetic group|This group will contains 60 children with hemiparesis
89018031|NCT05546164||Normal group|This group will contains 60 children with normal children
89463981|NCT05819073|Experimental|PROP super-taster subjects|This arm will comprise of PROP super-taster subjects. Subjects will use a cranberry-derived oral rinse twice a day for 11 days following a 3-day plain water-rinse period.
89463982|NCT05807490|Experimental|PF-07328948 and Placebo (Cohort 1)|Dose level 1: Multiple dose administration of PF-07328948 and placebo over 14 days in healthy participants; 8 participants will receive PF-07328948 and 2 will receive placebo
89463983|NCT05807490|Experimental|PF-07328948 and Placebo (Cohort 2)|Dose level 2: Multiple dose administration of PF-07328948 and placebo over 14 days in healthy participants; 8 participants will receive PF-07328948 and 2 will receive placebo
89463984|NCT05807490|Experimental|PF-07328948 and Placebo (Cohort 3)|Dose level 3: Multiple dose administration of PF-07328948 and placebo over 14 days in healthy participants; 8 participants will receive PF-07328948 and 2 will receive placebo
89463985|NCT05807490|Experimental|PF-07328948 and Placebo (Cohort 4)|Dose level 4: Multiple dose administration of PF-07328948 and placebo over 14 days in healthy participants; 8 participants will receive PF-07328948 and 2 will receive placebo
89463986|NCT05807490|Experimental|PF-07328948 and Placebo (Cohort 5)|Dose level 5: Multiple dose administration of PF-07328948 and placebo over 14 days in healthy participants; 8 participants will receive PF-07328948 and 2 will receive placebo
89463987|NCT05807490|Experimental|PF-07328948 and Placebo (Cohort 10)|Optional cohort - Multiple dose administration of PF-07328948 and placebo over 14 days in healthy Japanese participants; 5 participants will receive PF-07328948 and 1 will receive placebo
89463988|NCT05807490|Experimental|PF-07328948 and Placebo (Cohort 7)|Dose level 7: Multiple dose administration of PF-07328948 and placebo over 14 days in healthy participants; 8 participants will receive PF-07328948 and 2 will receive placebo
89463989|NCT05807490|Experimental|PF-07328948 and Placebo (Cohort 8)|Optional cohort - Dose level TBD. Multiple dose administration of PF-07328948 and placebo over 14 days in healthy participants; 8 participants will receive PF-07328948 and 2 will receive placebo
89463990|NCT05807490|Experimental|PF-07328948 oral tablet and oral suspension (Cohort 11)|Assessment of relative bioavailability PF-07328948 oral tablet compared to PF-07328948 oral suspension under fed and fasted condition; 12 participants will be enrolled, and 6 participants randomized to 1 of 2 sequences
89463991|NCT05807490|Experimental|PF-07328948 and Placebo (Cohort 6)|Dose level 6: Multiple dose administration of PF-07328948 and placebo over 14 days in healthy participants; 8 participants will receive PF-07328948 and 2 will receive placebo
89463992|NCT05807490|Experimental|PF-07328948 and Placebo (Cohort 9)|Optional cohort - Dose level TBD. Multiple dose administration of PF-07328948 and placebo over 14 days in healthy participants; 8 participants will receive PF-07328948 and 2 will receive placebo
89463993|NCT05800964|Experimental|Part A: Dose Exploration|Participants will receive escalating doses of AMG 305.
89463994|NCT05800964|Experimental|Part B: Dose Expansion|Participants with non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic cancer, and other solid tumors will receive the RP2D identified in Part A.
89463995|NCT05795153|Experimental|LOU064 (remibrutinib)|Open label single arm trial.
89463996|NCT05790473||Case|Fetuses with brain anomalies
89463997|NCT05790473||Controls|Normal with normal brain
89463998|NCT05789082|Experimental|Cohort A - Combination Dose Finding + Dose Expansion|"Participants enrolled in this cohort will receive divarasib (different dose levels will be evaluated) once a day (QD) combined with pembrolizumab 200 mg intravenous (IV) infusion every 3 weeks (Q3W).~During the expansion stage, some participants are planned to be randomized to one divarasib combination dose level; other participants are planned to be randomized to another divarasib combination dose level. Divarasib will be given in combination with pembrolizumab."
89463999|NCT05789082|Experimental|Cohort B - Combination Dose Finding + Dose Expansion|Participants enrolled in this cohort will receive divarasib (different dose levels will be evaluated) QD combined with pembrolizumab 200 mg IV Q3W plus investigator's choice of platinum-based chemotherapy (carboplatin or cisplatin) and pemetrexed.
89464000|NCT05786040|Experimental|Treatment (tafasitamab, rituximab)|Patients receive tafasitamab IV and rituximab IV or SC on study. Patients who have CR or PR after 4 cycles may receive additional tafasitamab and rituximab on study. Patients also undergo PET or CT, biopsy, and collection of blood samples throughout the trial.
89464001|NCT05782413|Experimental|Group A|The child will receive a design exercise program. The therapy was based on the principles of NDTBobath neurodevelopmental therapy.
89464002|NCT05782413|Experimental|Group B|The child will receive a design exercise program for 45 min then mechanical vestibular exercise for 15 mins.
89018032|NCT05545202|Other|A: Pentaisomaltose 16 %|Pentaisomaltose 40 % sterile solution; 40 mL will be transferred to a total volume of 100 mL, so the final concentration is 16 %.
89018033|NCT05545202|Active Comparator|B: DMSO 10 %|"Comparator:~DMSO 99.9 % sterile solution; 10 mL will be transferred to a total volume of 100 mL, so the final concentration is 10 %."
89201923|NCT00667602|Active Comparator|MenC (1 dose) + Concomitant Vaccines|Infants received one dose of MenC vaccine at 12 months of age and concomitant dose of PCV7 (Pneumococcal 7-valent Conjugate Vaccine) and DTPa-IPV-HepB-Hib (Diphtheria-Tetanus-acellular Pertussis, Hepatitis B, Inactivated Poliovirus and Haemophilus influenzae type b) at 12 months of age.
89464003|NCT05782140||Mayo Clinic Rochester Surgical Patients|Mayo Clinic Watch Device
89018034|NCT05541497|Experimental|Varenicline + Self-Change Pamphlet|"Days 1-3: 0.5mg study pill once per day~Days 4-7: 0.5mg study pill twice per day~Weeks 2-8: 1mg study pill twice per day in combination with a minimal, self-guided behavior change booklet. This booklet includes general tips for e-cigarettes cessation and information about the free web-based e-cigarette cessation program sponsored by The Truth Initiative and Mayo called This is Quitting. This study will have an 8-week treatment period and a 4-week follow-up."
89018035|NCT05541497|Placebo Comparator|Placebo + Self-Change Pamphlet|"Days 1-3: 0.5mg placebo pill once per day~Days 4-7: 0.5mg placebo pill twice per day~Weeks 2-8: 1mg placebo pill twice per day in combination with a minimal, self-guided behavior change booklet. This booklet includes general tips for e-cigarettes cessation and information about the free web-based e-cigarette cessation program sponsored by The Truth Initiative and Mayo called This is Quitting. This study will have an 8-week treatment period and a 4-week follow-up."
89018036|NCT05541458|Experimental|Educational sessions plus a nutrition box and recipes|Monthly nutrition education sessions will be attended by the subjects and then each subject will receive a free nutrition box that includes recipes that pertain to the food contents in the prepackaged box
89464004|NCT05781321|Experimental|Arm A (short course RT)|Patients undergo short course RT for 5-10 fractions over 1-2 weeks on study. Patients also receive temozolomide PO on days 1-5 every 28 days during radiation therapy. Starting one month post-radiation, patients continue temozolomide on days 1-5 every 28 days for up to 5 adjuvant cycles in the absence of disease progression or unacceptable toxicity. Patients undergo PET/CT with 18-F-DOPA administered IV prior to RT on study, and undergo MRI throughout the trial. Patients may optionally undergo blood sample collection during screening and on the trial.
89464005|NCT05781321|Active Comparator|Arm B (standard course RT)|Patients undergo standard course RT for 15-30 fractions over 3-6 weeks on study. Patients also receive temozolomide PO QD concurrently with radiation therapy and for up to 6 adjuvant cycles in the absence of disease progression or unacceptable toxicity. Patients undergo PET/CT with 18-F-DOPA administered IV prior to RT on study, and undergo MRI throughout the trial. Patients may optionally undergo blood sample collection during screening and on the trial.
89464006|NCT05769608|Placebo Comparator|Placebo|Placebo once daily for 12 weeks
89464007|NCT05769608|Experimental|Dose 1|lorundrostat Dose 1 once daily for 12 weeks
89464008|NCT05769608|Experimental|Dose 2|lorundrostat Dose 1 once daily for 4 weeks then lorundrostat Dose 2 once daily for 8 weeks
89464009|NCT05768165|Experimental|Intervention group|Cardiorespiratory and strength exercise training 2-3 sessions per week
89464010|NCT05768165|No Intervention|Care as usual|Care as usual and information of health enhancing physical activity according to general recommendations
89464011|NCT05768100|Experimental|1,3-Butanediol|
89464012|NCT05768100|Placebo Comparator|Placebo|
89464013|NCT05765669|Experimental|Operative|Percutaneous transiliac-transsacral screw fixation
89464014|NCT05765669|Experimental|Non-operative|Pain management and physical therapy advanced with weight bearing as tolerated.
89464015|NCT05764096||COVID-19 patients|38 patients admitted to the intensive care unit due to COVID-19 contagion
89464016|NCT05764096||Healthy control participants|An age- and education-matched group of 38 healthy individuals who did not report a previous COVID-19 contagion
89464017|NCT05750459|Experimental|Arm 1|Participants will receive the standard of care with IV artesunate for treatment of severe malaria. Each 60-mg vial of artesunic acid will be dissolved in 1 mL of 5% sodium bicarbonate to form sodium artesunate and then mixed with 5 mL of 5% dextrose. This will be injected as a bolus into an indwelling IV cannula. Children weighing <20 kg will receive IV artesunate at a dose of 3.0 mg/kg/dose compared to older children weighing >/= 20kg who will receive 2.4 mg/kg/dose, at times 0, 12, 24. If unable to take oral medication, IV artesunate will continue at 48 and 72 hours. Children who recover and are able to transition to oral antimalarial therapy after a minimum of 24 hours, will initiate a 3-day course of oral artemisinin-combination therapy per national guidelines. N = 100
89464018|NCT05743426||Single Arm|Subjects who are with gastrointestinal malignancies or sarcoma receive radiotherapy.
89464019|NCT05740982|Active Comparator|4|0.5 mL of 1 x 10^8 (50% Tissue Culture Infectious Dose (TCID50) JYNNEOS (Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN)) administered subcutaneously on adults ages 18-50 years on Days 1 and 29. N=135
89018037|NCT05527847|Active Comparator|Healthy Living with Diabetes (HLWD)|Participants will have a 6-week self-management program, followed by the option to work with a Community Health Worker for the remaining 4 months.
89464020|NCT05740982|Experimental|5|0.5 mL of 1 x 10^8 (50% Tissue Culture Infectious Dose (TCID50) JYNNEOS (Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN)) administered subcutaneously on adolescents ages 12-17 years on Days 1 and 29. N=315
89464021|NCT05739370|Experimental|Ger-iPST|Prospective participants will be contacted by telephone to confirm eligibility, explain the study protocol, and obtain informed consent. An in-person or videoconference assessment will be used to administer baseline PHQ-9 to confirm enrolment criteria and will be asked questionnaire to gather demographic information. Participants will then be provided with an email link to access the Online Psycho Therapy Tool (OPTT). PHQ-9 will be collected again at the mid-point (4 weeks) and after completing the program through OPTT. Caregivers will be invited to assist the participant if required in completing Ger-iPST modules, and weekly telephone support calls by a research assistant will be provided to assist with any difficulty navigating technical aspects of the Ger-iPST platform.
89464022|NCT05736393|Experimental|Exosuit Augmented Physical Therapy|participants will attend an in person screening, initial visit (1), 10 (2-11) sessions of physical therapy and a discharge visit (12). Participants will undergo a comprehensive biomechanical analysis on visits 1, 3, 6, 9 and 12, completing an extensive battery of surveys at visits 1, discharge, and 1-month post-discharge. Treatment will incorporate evidence-based physical therapy care based on clinical presentation to include manual therapy, therapeutic exercise, and functional therapeutic activities. A portion of each session will include exosuit use.
89464023|NCT05732428|Experimental|ARV-471|
89464024|NCT05731050|Experimental|NM8074|All subjects will receive a dose of 15 mg/kg NM8074 every two weeks with a total of 6 doses, from Day 1 to Day 84 during the treatment period.
89018038|NCT05527847|Experimental|Peers EXCEL|Participants will have an 8-week self-management program, and will participate in phone calls with a peer for the remaining 4 months.
89018039|NCT05525520|Experimental|EP547 100 mg|
89018040|NCT05525520|Placebo Comparator|Placebo|
88944787|NCT01883609|No Intervention|Group 4|Group 4 is an infectivity-control group for the sporozoite challenge procedures: these volunteers will not be vaccinated. Group 4 volunteers will be used as infectivity controls if any volunteers from groups 1 and 2 are rechallenged 5 - 7 months after the initial CHMI. CHMI may be administered in two separate cohorts if necessary due to limitations on volunteer availability.
89464025|NCT05722834|Experimental|SOAR intervention|The SOAR intervention will be a remote intervention that will follow a self-regulation process in which the participant first selects a specific problem to address and researches how asthma is preventing resolution of the problem, and finally identifies and develops a plan to achieve the objective.
89464026|NCT05720117|Experimental|PYX-201 Dose Escalation|Participants will receive escalating doses of PYX-201 to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and antitumor activity of PYX-201. Intra-participant dose escalation may be considered for participants who have adequately tolerated therapy.
89464027|NCT05718323|Experimental|Treatment Arm|
89464028|NCT05713669|Experimental|Residents meet ICU patients during follow-up visit (encounter)|Residents will be paired according to the patient that were cared.
89464029|NCT05713669|Other|Residents in the non-encounter group|Residents will not meet with patients that were in the ICU.
89464030|NCT05708222||Self Reported Assessment|This group of patients will self report their answers to the MINI assessment.
89464031|NCT05708222||Clinician Interview Assessment|This group of patients will complete the MINI assessment via an interactive interview conducted by a qualified clinician.
89464032|NCT05705466|Experimental|Navtemadlin in combination with pembrolizumab|"Navtemadlin will be administered orally, once daily (QD), on days 1-7 in a 21-day cycle.~Pembrolizumab will be administered intravenously on Day 1 of a 21-day cycle."
89464033|NCT05705466|Placebo Comparator|Navtemadlin placebo in combination with pembrolizumab|"Navtemadlin placebo will be administered orally, once daily (QD), on days 1-7 in a 21-day cycle.~Pembrolizumab will be administered intravenously on Day 1 of a 21-day cycle."
89464034|NCT05704244|Experimental|FE 999326|
89464035|NCT05701163|Experimental|Healthy Volunteers|Healthy males with no significant comorbidities, aged 20-45 years who are able to produce a semen sample by masturbation.
89464036|NCT05693129|Experimental|Leniolisib|Leniolisib film-coated granules in 10, 15 and 20 mg strengths administered orally BID by body weight for 12 weeks for Part I and for 1 year for Part II.
89464037|NCT05689905||Common HLA antigens with the lung donor|Children who have common HLA antigens with the lung donor of their mother
89464038|NCT05689905||No common HLA antigens with the lung donor|Children without common HLA antigens with the lung donor of their mother.
89464039|NCT05683496|Experimental|Cohort 1|Single SC injection of dose 1 of lonigutamab or placebo at Day 1 and Day 21
89464040|NCT05683496|Experimental|Cohort 2|multiple doses of dose 2 of lonigutamab administered SC injection weekly
89464041|NCT05683496|Experimental|Cohort 3|multiple doses of lonigutamab dose 3 administered SC injection every 4 weeks.
89464042|NCT05681780|Experimental|TIL+ Nivolumab|Nivolumab infusion every 3 weeks prior to lymphodepletion chemotherapy with cyclophosphamide/fludarabine, TIL infusion and interleukin-2. Then nivolumab infusion every 4 weeks up to 12 months.
89464043|NCT05681351|Experimental|Olezarsen|Participants who completed either ISIS 678354-CS5 (NCT05079919) or ISIS 678354-CS6 (NCT05552326) study would be enrolled to receive olezarsen, subcutaneous (SC) injection, once every 4 weeks from Week 1 through Week 49.
89464044|NCT05679570|Experimental|Satralizumab （Genetical Recombination）|
89464045|NCT05679024|Active Comparator|Apixaban 2.5 mg twice daily and standard of care|Apixaban 2.5 mg twice daily (low dose) and all other standard of care
89464046|NCT05679024|No Intervention|Standard of care and no anticoagulation|All other Standard of care and no anticoagulation
89464047|NCT05674799|Experimental|Healthy Lifestyle|"Women in the Healthy Lifestyle group will be invited to attend the online NDPP-NextGen class which will cover how to eat healthy, be active, and lose weight before getting pregnant. The classes will be led by a trained Lifestyle Coach. Each class lasts about 1 hour. Classes initially meet about once a week (for the first 6 months), then twice a month (for the next 3 months), and then once a month (for the last 3 months). Classes will meet virtually through video-conference. Lifestyle coaches will also call participants in between classes to discuss how participants are doing, answer questions, and provide reminders for upcoming classes. Prior to the first class, women will also participate in a pre-session designed to increase NDPP engagement via discussion of diabetes risks and treatment options (i.e., clarify relevance) and motivational interviewing to resolve barriers."
89464048|NCT05674799|No Intervention|Healthy Women|Women in the Healthy Women group get a packet of information standardly given in OB clinics about how to be healthy before, during and after pregnancy.
88944788|NCT01883622||Type 1 diabetes|Pregnant women affected by type 1 diabetes mellitus
88944789|NCT01883622||GDM|Pregnant women affected by gestational diabetes mellitus
88944790|NCT01883622||Healthy|Healthy pregnant women
88944791|NCT01883648|Experimental|Coconut Oil Beverage|The treatment will consist of a 1.25 oz serving size taken orally, two times daily by subjects. This treatment arm will last 3 months.
88944792|NCT01883648|Placebo Comparator|Placebo Beverage|The treatment will consist of a 1.25 oz serving size taken orally, two times daily by subjects.This will similar in look and taste but not have the same ingredients of the actual coconut oil beverage. This treatment arm will last 3 months.
88944793|NCT01883661|Other|BMMNC|Administration of of Bone Marrow derived Mono Nuclear Stem Cell (MNCs)
88944794|NCT01883674|Experimental|Milk proteins|This group will do a resistance training + milk proteins (milk beverage)
88944795|NCT01883674|Experimental|Essential amino acids (add to soya bvg)|This group will do a resistance training + essential amino acids (added to soya beverage)
89464049|NCT05671861|Experimental|Part I (medical device usage, questionnaire)|Each participant will complete a single 45-minute visit in which consists of questionnaires about features that are important to them in trismus treatment, test a prototype of a trismus therapy device, and complete an online feedback questionnaire about their experience using the device.
89501921|NCT04638049|Active Comparator|Whole Pelvis RadioTherapy (WPRT)|Primary, adjuvant or salvage RT of the pelvic nodal regions in the small pelvis with possible additional RT of the prostate (bed), according to local hospital guidelines and protocols.
89018041|NCT05501275|Experimental|With Psychoeducation|interventional group will receive psychoeducation.
89018042|NCT05501275|No Intervention|Basic Therapy Only|this group will receive only basic therapy
89464050|NCT05671861|Experimental|Part II (medical device usage, mobile app usage)|Participants will be asked to use the device at least three times per week and up to daily for a period of 15-20 minutes over 6 weeks. Participants will be evaluated at baseline, at the 3-week (halfway) visit, and at the end of the 6-week treatment period under supervision of a speech language pathologist on study. Participants will then utilize a mobile app to help track treatment progress.
89464051|NCT05670106|Experimental|[177Lu]Lu-PSMA-617 plus best supportive/best standard of care (BS/BSOC)|Patients will receive the investigational product 7.4 GBq (+/- 10%) 177Lu-PSMA-617 intravenously every 6 weeks (+/- 1 week) for a maximum of 6 cycles. Best supportive/best standard of care (BS/BSOC) may be used
89464052|NCT05668013|Experimental|TEV-48574 Dose Regimen A for Ulcerative Colitis (UC)|Administered by subcutaneous infusion for participants with UC
89464053|NCT05668013|Experimental|TEV-48574 Dose Regimen A for Crohn's Disease (CD)|Administered by subcutaneous infusion for participants with CD
89464054|NCT05668013|Experimental|TEV-48574 Dose Regimen B for Ulcerative Colitis (UC)|Administered by subcutaneous infusion for participants with UC
89464055|NCT05668013|Experimental|TEV-48574 Dose Regimen B for Crohn's Disease (CD)|Administered by subcutaneous infusion for participants with CD
89464056|NCT05667194|Experimental|KH617 dose 1|Three times (on days 1, 2, and 3) weekly for the first three consecutive weeks in a 28-day cycle
89464057|NCT05667194|Experimental|KH617 dose 2|Three times (on days 1, 2, and 3) weekly for the first three consecutive weeks in a 28-day cycle
89464058|NCT05667194|Experimental|KH617 dose 3|Three times (on days 1, 2, and 3) weekly for the first three consecutive weeks in a 28-day cycle
89464059|NCT05667194|Experimental|KH617 dose 4|Three times (on days 1, 2, and 3) weekly for the first three consecutive weeks in a 28-day cycle
89464060|NCT05667194|Experimental|KH617 dose 5|Three times (on days 1, 2, and 3) weekly for the first three consecutive weeks in a 28-day cycle
89464061|NCT05658068|Experimental|SAFE Spaces training and coaching|Staff in facilities assigned to this arm are offered the SAFE Spaces training and coaching model.
89464062|NCT05658068|No Intervention|Training as Usual|Staff in facilities assigned to this arm receive training as usual.
89464063|NCT05651620||Calorie Restriction (CR)|Individuals in the CR group were prescribed a 25% reduction from their baseline energy intake during the two-year CALERIE trial.
89464064|NCT05651620||Ad Libitum (AL)|Individuals in the AL group were asked to continue their usual dietary intake during the two-year CALERIE trial.
89464065|NCT05645692|Active Comparator|Arm A|Participants will receive intravenous (IV) atezolizumab every 3 weeks (Q3W).
89464066|NCT05645692|Experimental|Arm B|Participants will receive IV tobemstomig Q3W.
89464067|NCT05645692|Experimental|Arm C|Participants will receive IV tobemstomig + IV tiragolumab Q3W.
89464068|NCT05644093|Experimental|Psychedelic Experienced IM then IV crossover|Participants will be dosed with IM SPL026 then IV SPL026 2-3 weeks later.
89464069|NCT05644093|Experimental|Psychedelic Naive IM dosing only|Participants will be dosed with IM SPL026 one time.
89464070|NCT05640336|Active Comparator|Single DAIR Surgery Arm|Subjects will undergo a single Debridement Antibiotics and Implant Retention (DAIR) surgical procedure, along with IV antibiotics and followed by oral suppressive antibiotics. This method is currently used and considered to be standard of care.
89464071|NCT05640336|Active Comparator|Double DAIR Surgery Arm|Subjects will undergo planned double Debridement Antibiotics and Implant Retention (DAIR) surgical procedure, along with IV antibiotics and followed by oral suppressive antibiotics. This method is currently used and considered to be standard of care.
89464072|NCT05636020|Experimental|Treatment (ICARE)|ICARE treatment consisting of 12 sessions that train affect recognition and empathic behaviors.
89464073|NCT05633303|Experimental|Patients with underlying LVZs (≥30% of LVZs in the LA body)|"Study 1- Developing a methodology and technique for sequential CV assessment. Twenty patients.~Study 2- Assess the mechanistic importance of RDCV slowing sites in AF. Twenty patients.~Study 3- Assess the impact autonomic modulation has on CV dynamics and RDCV slowing sites. Twenty patients.~Study 4- GP site ablation and substrate modification guided by RDCV slowing sites whereby substrate ablation is limited to substrate with these electrical properties and the impact on freedom from AF/AT during 12 months follow-up. Forty patients.~. Study 5- RDCV slowing sites and GP site identification on cardiac MRI. Twenty patients."
89018043|NCT05500105|Experimental|Simple cognitive task intervention|"Session 1: A memory cue followed by playing the computer game Tetris (e.g. on own smartphone) with mental rotation instructions.~Options to engage in self-administered/guided booster sessions per intrusive memory."
89018044|NCT05489523|Experimental|Treatment Arm|Tafamidis 61 mg
89018045|NCT05483283|Other|Arm 1|Empowerment and Navigation
89018046|NCT05483283|Other|Arm 2|Standard of Care (SOC)
89464074|NCT05633303|Experimental|Patients without underlying LVZs (<30% of LVZs in the LA body)|"Study 1- Mechanistic importance of GP site ablation. Twenty patients.~Study 2- GP site ablation in addition to PV isolation and the impact on freedom from AF/AT during 12 months follow-up. Forty patients.~Study 3- RDCV slowing sites and GP site identification on cardiac MRI. Twenty patients."
89464075|NCT05631223|Experimental|Interventional Telemedicine Arm|Single Arm Intervention
89464076|NCT05626855|Experimental|Treatment Period|Patients who are ≥2 years of age with Type 2 and Type 3 SMA will receive apitegromab 20 mg/kg every 4 weeks by intravenous (IV) infusion during the 104-week Treatment Period
89018047|NCT05459688|Experimental|Experimental 2 mg CIN-107 tablets QD|Treatment with 2 mg CIN-107 tablets, by mouth, once per day. Starting at Visit 1 and concluding at EOT (Visit 7).
89018048|NCT05453656|Other|exercise|live and on demand exercise sessions on the Kidney BEAM-KIDS platform
89464077|NCT05625347|Experimental|Arm 1: I-ASA 100mg, then C-ASA 162mg tablet|"Treatment A: Single dose of 100 mg ASA powder for oral inhalation (I-ASA) via DPI.~Treatment B: Single dose of 162 mg chewable non-enteric-coated Aspirin (C-ASA) tablets."
89464078|NCT05625347|Experimental|Arm 2: C-ASA 162mg tablet, then I-ASA 100mg|"Treatment A: Single dose of 162 mg chewable non-enteric-coated Aspirin (C-ASA)tablets.~Treatment B: Single dose of 100 mg ASA powder for oral inhalation (I-ASA) via DPI."
89201924|NCT04034199|Experimental|Denosumab group|Patients randomized into the denosumab group will receive denosumab 60mg subcutaneously every 6 months, for a total duration of 1 year. DEXA scan would be repeated at 1 year.
89464079|NCT05625334|Experimental|Arm 1: I-ASA 100mg, then C-ASA 162mg tablet|"Treatment A: Single dose of 100 mg ASA powder for oral inhalation (I-ASA) via DPI.~Treatment B: Single dose of 162 mg chewable non-enteric-coated Aspirin (C-ASA)."
89464080|NCT05625334|Experimental|Arm 2: C-ASA 162mg tablet, then I-ASA 100mg|"Treatment B: Single dose of 162 mg chewable non-enteric-coated Aspirin (C-ASA).~Treatment A: Single dose of 100 mg ASA powder for oral inhalation (I-ASA) via DPI."
89464081|NCT05622851|Active Comparator|Restylane Contour|"Form: transparent gel of Hyaluronic Acid with the addition of lidocaine hydrochloride.~Mode of administration: injection Dosage: at investigator's discretion for optimal outcome. Frequency and duration: injection at baseline and optional touch-up at week 4."
89464082|NCT05622851|Active Comparator|Juvederm Voluma|"Form: sterile, biodegradable, non-pyrogenic, viscoelastic, clear, colorless, homogenous gel implant of Hyaluronic Acid crosslinked with BDDE, formulated with lidocaine.~Mode of administration: injection Dosage: at investigator's discretion for optimal outcome. Frequency and duration: injection at baseline and optional touch-up at week 4."
89464083|NCT05620043|Active Comparator|Poly L-Lactic Acid (PLLA)|Lyophilized PLLA with sodium carboxymethylcellulose, non-pyrogenic mannitol. Treatment needs to be reconstituted prior to injection, following product instruction.
89464084|NCT05620043|Active Comparator|Calcium Hydroxylapatite (CaHA)|Opaque, sterile, non-pyrogenic, semi-solid, cohesive implant whose component is synthetic CaHA suspended in a gel carrier of glycerin, sodium carboxymethylcellulose, 0.3% lidocaine hydrochloride, and sterile water. Treatment injection follows product instruction.
89464085|NCT05616676|Experimental|Brief digital imagery-competing task|Access to a brief digital imagery-competing task for 24 weeks (first 4 weeks with optional researcher support).
89464086|NCT05616676|Experimental|Brief digital music-listening task|Access to a brief digital music-listening task for 24 weeks (first 4 weeks with optional researcher support).
89464087|NCT05616676|Experimental|Treatment As Usual|Access to routine care that participants would otherwise receive if having intrusive memories of traumatic events for 24 weeks.
89464088|NCT05607550|Experimental|furmonertinib 240 mg|
89464089|NCT05607550|Experimental|furmonertinib 160 mg|
89464090|NCT05607550|Active Comparator|platinum-based chemotherapy|carboplatin or cisplatin based on investigator's choice + pemetrexed intravenously
89464091|NCT05595499|Experimental|Arm A (fisetin)|Patients receive fisetin PO on the trial. Patients also undergo collection of blood throughout the trial.
89464092|NCT05595499|Placebo Comparator|Arm B (placebo)|Patients receive placebo PO on the trial. Patients also undergo collection of blood throughout the trial.
89464093|NCT05593575|Experimental|SPH3127-1|1 tablet of SPH3127 (50 mg) ，3 tablets of SPH3127 (50mg)matching placebo， 1 capsule of valsartan matching placebo, orally, once daily for 12 consecutive weeks
89464094|NCT05593575|Experimental|SPH3127-2|2 tablet of SPH3127 (50 mg) ，2 tablets of SPH3127 (50mg)matching placebo， 1 capsule of valsartan matching placebo, orally, once daily for 12 consecutive weeks
89201925|NCT04034199|Active Comparator|Zoledronic acid|Patients randomized into the denosumab group will receive one dose of zoledronic acid at 5mg intravenously. DEXA scan would be repeated at 1 year.
89464095|NCT05593575|Experimental|SPH3127-3|4 tablet of SPH3127 (50 mg) ，1 capsule of valsartan matching placebo, orally, once daily for 12 consecutive weeks
89464096|NCT05593575|Experimental|SPH3127-4|4 tablets of SPH3127 (50mg)matching placebo， 1 capsule of valsartan , orally, once daily for 12 consecutive weeks
89464097|NCT05591859|Other|Restoration Anatomic Acetabular Shell|
89464098|NCT05587296|Experimental|Elinzanetant (BAY3427080)|Participants will receive 120 mg elinzanetant orally once daily.
89464099|NCT05587296|Placebo Comparator|Placebo|Participants will receive matching placebo orally once daily.
89464100|NCT05585684||Oncology Patients|All participants in the study.
89464101|NCT05575765||Patients with rectal cancer|
89201926|NCT02538237|Experimental|ibuprofen mouthwash|Subgingival Irrigation of ibuprofen 2% mouthwash (made from the Faculty of Pharmaceutical Sciences, Islamic Azad University, Tehran) with an insulin syringe 0.5 ml were rinsed
89201927|NCT02538237|Sham Comparator|placebo mouthwash|Subgingival Irrigation of placebo 2% mouthwash (made from the Faculty of Pharmaceutical Sciences, Islamic Azad University, Tehran) with an insulin syringe 0.5 ml were rinsed
89201928|NCT00691028|Experimental|TA-650 3 mg/kg|
89201929|NCT00691028|Experimental|TA-650 6 mg/kg|
89464102|NCT05573165|Experimental|3h Group|the patient's parents are instructed to stop feeding 3 hours for scheduled anesthesia. (3 hours of preoperative fasting for breast milk)
89464103|NCT05573165|Active Comparator|4h Group|the patient's parents are instructed to stop feeding 4 hours for scheduled anesthesia (4 hours of preoperative fasting for breast milk)
89464104|NCT05570552|Experimental|mHealth arm|mHealth arm will receive mobile phone based behavior change communication intervention to exclusively use clean fuel LPG for domestic cooking.
89464105|NCT05570552|No Intervention|Control arm|Control arm will receive no mHealth based intervention.
89464106|NCT05568680|Experimental|SynKIR-110|Single dose gravity drip IV administration
89464107|NCT05568199||Group 1|"Patients will make one visit to the M Health Clinical Research Unit (CRU) after overnight withdrawal of PD medications (still on-DBS) and undergo motor and cognitive assessments in the following three conditions:~clinically-optimized stimulation~model-based stimulation directed towards motor subregions of STN and GPi~model-based stimulation directed towards associative/limbic subregions of STN/GPi~Randomized to start with condition1 assessment"
89464108|NCT05568199||Group 2|"Patients will make one visit to the M Health Clinical Research Unit (CRU) after overnight withdrawal of PD medications (still on-DBS) and undergo motor and cognitive assessments in the following three conditions:~clinically-optimized stimulation~model-based stimulation directed towards motor subregions of STN and GPi~model-based stimulation directed towards associative/limbic subregions of STN/GPi~Randomized to start with condition 2 assessment"
89018049|NCT05452590|Experimental|Ultrasound-guided wire-in-needle technique|The guidewire will be connected to the needle. The IJV will be punctured in a long-axis in-plane approach. When the needle tip enters the IJV, the guidewire will be advanced through the needle into the IJV under continuous ultrasound visualization. The needle will then be removed. The correct guidewire position in the IJV will be confirmed in the long-axis and short-axis view. Afterwards, the second guidewire will be placed in the same IJV approximately 1-2 centimeters distal to the fist guidewire using the same technique. The correct guidewire position in the IJV will be confirmed in the long-axis and short-axis view again.
89018050|NCT05452590|No Intervention|Traditional technique|A syringe will be connected to the needle. The IJV will be punctured in a long-axis in-plane or short-axis out-of-plane approach (as preferred by the anesthesiologist). When the needle tip enters the IJV, blood is aspirated using the syringe. The operator will then discontinue US-guidance, disconnect the syringe and advance the guidewire through the needle into the IJV. The needle will then be removed. The correct guidewire position in the IJV will be confirmed in the long-axis and short-axis view. Afterwards, the second guidewire will be placed in the same IJV approximately 1-2 centimeters distal to the fist guidewire using the same technique. The correct guidewire position in the IJV will be confirmed in the long-axis and short-axis view again.
89018051|NCT05452005|Experimental|Experimental [18F]-αvβ6-BP|Patients receive [18F]-αvβ6-BP BP IV and then undergo a PET/CT scan over 30 minutes 60 minutes post-injection.
89018052|NCT05445050|Other|clinical application of mULM to support breast cancer diagnosis and therapy|"The study arm includes three parts A, B and C. In part A, the scan protocol, including the injection of the clinically approved contrast agent SonoVue® and the data acquisition time range, is optimized based on the mULM measurements of participants with primary breast cancer.~The following part B consists of 2D-mULM measurements applied to triple-negative breast cancer patients throughout their neoadjuvant chemotherapy cycles with the aim to evaluate to which degree 2D-mULM allows for an assessment of the tumor response during therapy.~In the last part C, participants with neoplasms of uncertain dignity will be investigated by 2D- and 3D-mULM measurements and the accuracy of differentiation between the lesions assessed."
89018053|NCT05439590|Experimental|High dose CSO|Participants will be randomly assigned to a smoothie containing 60 g of CSO per day for four weeks.They will be asked to consume smoothies any time of the day.
89018054|NCT05439590|Experimental|Low dose CSO|Participants will be randomly assigned to a smoothie containing 30 g of CSO per day for four weeks.They will be asked to consume smoothies any time of the day.
89464109|NCT05568199||Group 3|"Patients will make one visit to the M Health Clinical Research Unit (CRU) after overnight withdrawal of PD medications (still on-DBS) and undergo motor and cognitive assessments in the following three conditions:~clinically-optimized stimulation~model-based stimulation directed towards motor subregions of STN and GPi~model-based stimulation directed towards associative/limbic subregions of STN/GPi~Randomized to start with condition 3 assessment"
89018055|NCT05439590|Active Comparator|High dose OO|Participants will be randomly assigned to a smoothie containing 60 g of OO per day for four weeks.They will be asked to consume smoothies any time of the day.
89018056|NCT05439590|Active Comparator|Low dose OO|Participants will be randomly assigned to a smoothie containing 30 g of OO per day for four weeks.They will be asked to consume smoothies any time of the day.
89018057|NCT05435885|Experimental|Tele-rehabilitation group|The Tele-rehabilitation group performs 12 training sessions during four weeks. (3 sessions/week)
89018058|NCT05435885|Other|Control group|The control group receives usual care with only one educational session.
89018059|NCT05435547|Experimental|Steroids|Will be given pre-operative corticosteroid regimen
89018060|NCT05435547|Placebo Comparator|placebo|Will be given Placebo
89018061|NCT05432986||Hydrocephalus Patients|Hydrocephalus patients with an existing ventriculoperitoneal shunt and symptoms of a shunt malfunction.
89464110|NCT05565937|Experimental|BL-3100-NBR03|BL-3100-NBR03 multi-purpose solution
89464111|NCT05565937|Active Comparator|renu® Advanced Formula|renu® Advanced Formula multi-purpose solution
89464112|NCT05562674|Experimental|Veteran Voices & Visions (VVV)|This is the experimental condition, testing the manual the investigators have developed.
89464113|NCT05562674|Active Comparator|Healthy Lifestyles|This is the control condition, matched for location, format, degree of interaction, and duration.
89018062|NCT05415319|Other|Emotion regulation observation in middle childhood/pre-adolescence|All participants will engage in brief laboratory tasks that are designed to elicit a brief experience of emotion/uncertainty.
89464114|NCT05560256|Experimental|Youth Engage with Diary|24 youth will use the Diary for one month
89464115|NCT05548127|Experimental|ARV-471 in combination with Abemaciclib|ARV-471 administered orally once daily (QD) and Abemaciclib orally twice daily (BID) on 28-day cycle
89464116|NCT05544968|Experimental|CD30biAb-AATC|Patients will undergo weekly administration of dose escalating CD30 biAb-AATC infusions with twice weekly subcutaneous GM-CSF in 4-week cycles for a maximum of two total cycles.
89018063|NCT05414747|Experimental|Participants randomized to ABV-1701 Ocular Endotamponade|Participants randomized to the interventional device ABV-1701 Ocular Endotamponade undergoing the vitrectomy surgery for uncomplicated retinal detachment
89464117|NCT05539729|Experimental|Vancomycin|125mg antibiotic taken 4 times daily by mouth
89464118|NCT05539729|Placebo Comparator|Placebo|Matching placebo taken 4 times daily by mouth
89464119|NCT05537766|Experimental|Substudy A (Relapsed/Refractory Waldenstrom Macroglobulinemia): Brexucabtagene Autoleucel|"Participants will receive fludarabine 30 mg/m^2/day and cyclophosphamide 500 mg/m^2/day lymphodepletion chemotherapy for 3 days followed by a single infusion of brexucabtagene autoleucel at target dose of 2 × 10^6 anti-CD19 chimeric antigen receptor (CAR) T cells/kg.~This arm is no longer recruiting."
89464120|NCT05537766|Experimental|Substudy B (Relapsed/Refractory Richter Transformation): Brexucabtagene Autoleucel|Participants will receive fludarabine 30 mg/m^2/day and cyclophosphamide 500 mg/m^2/day lymphodepletion chemotherapy for 3 days followed by a single infusion of brexucabtagene autoleucel at target dose of 2×10^6 anti-CD19 CAR T cells/kg.
88944796|NCT01883674|Placebo Comparator|No protein (control)|This group will do a resistance training + ingestion of the control beverage (no protein, rice beverage)
88944797|NCT01883687|Experimental|Septoplasty|patients will receive septoplasty together with Le Fort I osteotomy
88944798|NCT01883687|No Intervention|No septoplasty|patient will only receive Le Fort I osteotomy
88944799|NCT01883700|Experimental|Low-GI, High-GL Meal|Boiled Pasta
88944800|NCT01883700|Experimental|Low-GI, High GL Meal|Boiled Chickpeas with Oil
88944801|NCT01883700|Experimental|High-GI, High-GL Meal|Instant Mashed Potatoes
88944802|NCT01883700|Experimental|High-GI, Low-GL Meal|Instant Mashed Potatoes with Egg Whites
88944803|NCT01883713||Heart surgery during CPB|All patients undergoing heart surgery using cardiopulmonary bypass who have a pre-operative Hb value greater than 90 g/L, no evidence of hypoxemia (SaO2 > 90%) and no history of congenital methemoglobinemia. Exclusion criteria will include severe hypoxemia, acute or chronic renal failure requiring dialysis, emergency surgery or the lack of a PA catheter. Non invasive brain oximetry will be used to assess the brain oxygen tension during surgical procedure.
88944804|NCT01883726|Experimental|Grayson NAM|Intervention: Grayson nasoalveolar molding This technique uses an acrylic plate to mold the alveolar segments and uses an extension to mold the alar cartilage of the nasal component. The construction is made by gradual modification of the acrylic plate with periodic acrylic add on and grinding. When the alveolar gap is reduced to 5 mm, nasal component are added to gradually mold the nasal cartilage and other nasal structures.
88944805|NCT01883726|Experimental|Figueroa NAM|Intervention: Figueroa's nasoalveolar molding Figueroa technique uses labial tapes and acrylic relief to the palatal plate to approximate alveolar gap [3]. The nasal component is added in the beginning of the treatment to mold the nasal cartilage.
88944806|NCT01883739|Experimental|Parental Presence at Handover Rounds|"Subjects will receive an educational document prior to transfer rounds introducing the concept of Patient and Family Centered Care and the role of a parent in transfer rounds. These parents will have the option of meeting with a parental peer support person for a coaching or training session prior to their participation in transfer rounds. During the transfer rounds parents will be actively included in discussion of their child's medical management plan upon discharge to the wards."
88944807|NCT01883752|No Intervention|Control|Baseline crystalloid infusion of 5 mL/kg/hr of body weight.
88944808|NCT01883752|Experimental|Goal-directed Therapy group|Goal-direct therapy
88944809|NCT01883765|Experimental|Neurofeedback active|Active neurofeedback training, theta/beta-protocol
88944810|NCT01883765|Sham Comparator|Neurofeedback sham|Neurofeedback training is simulated to subjects in this condition
89464121|NCT05537766|Experimental|Substudy C (Relapsed/Refractory Burkitt Lymphoma): Brexucabtagene Autoleucel|Participants will receive fludarabine 30 mg/m^2/day and cyclophosphamide 500 mg/m^2/day lymphodepletion chemotherapy for 3 days followed by a single infusion of brexucabtagene autoleucel at a target dose of 2x10^6 anti-CD19 CAR T cells/kg.
89464122|NCT05537766|Experimental|Substudy D (Relapsed/Refractory hairy cell leukemia): Brexucabtagene Autoleucel|"Participants will receive fludarabine 30 mg/m^2/day and cyclophosphamide 500 mg/m^2/day lymphodepletion chemotherapy for 3 days followed by a single infusion of brexucabtagene autoleucel at a target dose of 2 × 10^6 anti-CD19 CAR T cells/kg.~This arm is no longer recruiting."
89464123|NCT05533346|Experimental|Experimental - with WISE|The experimental group will provide walking health education leaflets and exercise measurement wristbands for exercise monitoring, and will be given the intervention of the WISE program: three times a week, each time walking for at least 30 minutes, with a pace between 100-130 steps/ minutes, and then increase the number or time weekly according to personal ability.
88944811|NCT01883765|Active Comparator|Metacognitive Training|Metacognitive training, cognitive behavioral therapy
89464124|NCT05533346|Active Comparator|Control - without WISE|The procedure of the control group will be the same as that of the experimental group, providing walking and health education leaflets and exercise measurement wristbands for exercise monitoring, but no intervention in the WISE program.
88944812|NCT01883778||Emergency Department Patients|
89201930|NCT00691028|Experimental|TA-650 10 mg/kg|
89464125|NCT05531526|Active Comparator|Group A - Active Comparator|Active, AR1001 30 mg QD will be administered daily for 52 weeks during the Treatment Phase of the study. In the Extension Phase, all eligible participants who choose to participate will receive AR1001 30 mg QD for 104 weeks.
89464126|NCT05531526|Placebo Comparator|Group B - Placebo Comparator|Placebo QD will be administered daily for 52 weeks during the Treatment Phase of the study. In the Extension Phase, all eligible participants who choose to participate will receive AR1001 30 mg QD for 104 weeks.
89464127|NCT05524545|Experimental|Evorpacept (ALX148) + Enfortumab Vedotin|"Phase 1a Dose Escalation: Evorpacept (ALX148) infusions will be administered every two weeks.~Enfortumab vedotin will be administered at 1.25 mg/kg IV on Days 1, 8, and 15 of each 28-day cycle."
89464128|NCT05518877|Active Comparator|Ketamine 15 Minutes|Participants receive 0.25mg/kg Ketamine dose intravenous for pain over 15 minutes.
89464129|NCT05518877|Experimental|Ketamine 30 Minutes|Participants receive 0.25mg/kg Ketamine dose intravenous for pain over 30 minutes.
88944813|NCT01883778||Emergency Medicine Physicians|
88944814|NCT01883791|Experimental|SBIRT|The SBIRT condition will include the WHO's Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST) and its accompanying brief intervention that uses motivational interviewing techniques to provide feedback, emphasize personal responsibility, give advice, provide a menu of options, convey empathy, and promote self-efficacy.
88944815|NCT01883791|Other|Health Education|The control group will receive a Health Education (HE) session, informational brochures and a contact information for addiction treatment sites that we will develop with Ventura County. The session will be administered in an individual format for 30-minutes and will address general health, wellness and lifestyle topics.
88944816|NCT01883830|Experimental|gaming therapy (Xbox)|Subjects belonging to the first group will receive a gaming therapy protocol using the Xbox console. They will receive 24 sessions of treatment within 8 weeks (3 sessions per week). Patients will be required to concentrate in games whose major purposes are increasing balance, selective attention and attention shifting. During sessions the patient will be carefully controlled by a researcher who will prevent the risk of falling and impulsiveness reactions.
89464130|NCT05518539||The Clareon™ PanOptix™ Trifocal (toric and non-toric models)|Bilateral implantation with the Clareon PanOptix Trifocal (toric and non-toric models)
89464131|NCT05516797|Experimental|Continuous Glucose Monitoring (CGM)|Participants in this arm will use the FreeStyle Libre 2 CGM sensor.
89464132|NCT05516797|No Intervention|Blood Glucose Monitoring (BGM)|Participants in this arm will use the Precision Xtra fingerstick blood glucose meter throughout the study.
89464133|NCT05510661|Experimental|Intervention Group|Manual thrombus aspiration (use of export catheter) followed by primary PCI
89464134|NCT05510661|Active Comparator|Control group|Predilatation with balloon catheter (≤2.00 mm diameter) followed by primary PCI
89464135|NCT05510297|Other|In-home feasibility test|In this single-arm trial, participants will use an active seating system for a 3- to 7-day period. The system provides a seating platform and treadles to pedal while in a seated or semi-reclined position. The system will also include a digital user interface to track performance.
89464136|NCT05505578|Experimental|GamerFit Condition|Includes use of a Fitbit and exergaming devices, the GamerFit app, and weekly telehealth coaching sessions.
89464137|NCT05505578|Active Comparator|Comparator Condition|Youth assigned to the comparator condition (n=30-35) will receive a Fitbit device (same as the intervention condition) and the Fitbit account activated on their device (e.g. phone/tablet/computer). They will receive instructions on using the PA and sleep tracking features, as well as a booklet of healthy habit tips. They will receive reminders to charge, sync and review their Fitbit data for the duration of the intervention.
89464138|NCT05500417|Experimental|Group 1A|Each subject will receive a 1 mL intramuscular (IM) injection containing 1 microgram of Campylobacter jejuni Conjugate Vaccine 2 (CJCV2) on Days 1, 29, and 57. 3 sentinel subject will be dosed first; if no safety signals are noted within 7 days after sentinel dosing, the remaining 7 subjects will be dosed. N=10
89464139|NCT05500417|Experimental|Group 1B|Each subject will receive a 1 mL intramuscular (IM) injection containing 1 microgram of Campylobacter jejuni Conjugate Vaccine 2 (CJCV2) and a full dose of Army Liposome Formulation containing QS-21 (ALFQ) on Days 1, 29, and 57. 3 sentinel subject will be dosed first; if no safety signals are noted within 7 days after sentinel dosing, the remaining 7 subjects will be dosed. N=10
89464140|NCT05500417|Experimental|Group 2A|Each subject will receive a 1 mL intramuscular (IM) injection containing 3 micrograms of Campylobacter jejuni Conjugate Vaccine 2 (CJCV2) on Days 1, 29, and 57. 3 sentinel subject will be dosed first; if no safety signals are noted within 7 days after sentinel dosing, the remaining 7 subjects will be dosed. N=10
89464141|NCT05500417|Experimental|Group 2B|Each subject will receive a 1 mL intramuscular (IM) injection containing 3 micrograms of Campylobacter jejuni Conjugate Vaccine 2 (CJCV2) and a full dose of Army Liposome Formulation containing QS-21 (ALFQ) on Days 1, 29, and 57. 3 sentinel subject will be dosed first; if no safety signals are noted within 7 days after sentinel dosing, the remaining 7 subjects will be dosed. N=10
88944817|NCT01883830|Active Comparator|Dynamic balance platform training|Control group will receive the same amount of therapy (24 sessions) using a dynamic balance platform (Biodex).
88944818|NCT01883843|Experimental|real tDCS + TOCT|"Every day will be given continuous stimulation duration of 15 minutes with intensity of 0.5 mA (for a current density of 60μA/cm2), generated by a constant current stimulator rechargeable batteries for 10 consecutive days after any rehabilitation treatment in the gym. Two sponge electrodes are placed, soaked in saline solution, fixed by an elastic band, the anode consists of an electrode oblong 8cm2 positioned at M1 area on the lower limb affection (following the medial sagittal axis, with the center of the electrode positioned at one centimeter laterally to the vertex) while the cathode (48cm2) is placed in the contralateral supraorbitale area as reference electrode.~The current reaches 0.5mA and decreases with a ramp of 10 seconds."
88944819|NCT01883843|Active Comparator|sham tDCS + TOCT|Every day will be given a continuous low-intensity stimulation of 0.5mA (for a current density of 60μA/cm2) only for 10 seconds at the beginning and at the end of the stimulation for 10 consecutive days after any rehabilitative treatment. The mounting of electrodes for sham stimulation is the same used for the experimental group.
88944820|NCT01883869|Experimental|ticagrelor|180 mg orally once and then 90 mg orally daily for 7 days or until hospital discharge if sooner
88944821|NCT01883869|Placebo Comparator|placebo|One loading dose and then daily for 7 days or until hospital discharge if sooner
88944822|NCT01883882|Experimental|taper support|Weekly visits with pharmacological and psychological support for opioid taper at 10% of original dose per week
88944823|NCT01883882|No Intervention|Usual care|Usual care for chronic pain. All care allowed except buprenorphine.
88944824|NCT01883921||Immunoglobulin Therapy|
88944825|NCT01883934|Experimental|Enhanced clinic-based support/counseling|Scheduling a consult with a licensed social worker to discuss embryo disposition options. Additional enhanced support services and educational services provided by embryologists, nurses and physicians in the Frozen Embryo Donation Service will be offered.
88944826|NCT01883934|Active Comparator|Patients receiving standard of care|Patients who receive standard of care regarding embryo disposition options
89201931|NCT05280327|Experimental|experimental group|virtual reality application
89201932|NCT05280327|No Intervention|control group|standard care group
89201933|NCT00741572||1|
89464142|NCT05500417|Experimental|Group 3A|Each subject will receive a 1 mL intramuscular (IM) injection containing 10 micrograms of Campylobacter jejuni Conjugate Vaccine 2 (CJCV2) on Days 1, 29, and 57. 3 sentinel subject will be dosed first; if no safety signals are noted within 7 days after sentinel dosing, the remaining 7 subjects will be dosed. N=10
89464143|NCT05500417|Experimental|Group 3B|Each subject will receive a 1 mL intramuscular (IM) injection containing 10 micrograms of Campylobacter jejuni Conjugate Vaccine 2 (CJCV2) and a full dose of Army Liposome Formulation containing QS-21 (ALFQ) on Days 1, 29, and 57. 3 sentinel subject will be dosed first; if no safety signals are noted within 7 days after sentinel dosing, the remaining 7 subjects will be dosed. N=10
89464144|NCT05499000|Experimental|Experimental group|"Emotional freedom technique will be applied online with the researcher in 2 sessions, 3 days apart.~KBF, SUE, PMSS pre-tests will be applied before the intervention, SUE will be applied before and after each session, At the end of the second session, post-test data will be obtained with SUE, PMSS."
89464145|NCT05499000|No Intervention|Control group|KBF, SUE and PMSS pre-tests will be applied to the participants, SUE, PMSS and post-test data will be obtained simultaneously with the experimental group.
89464146|NCT05490732|Experimental|Therapeutic drug monitoring of methadone|6 samplings per subject: 3 venipunctures and 3 microsamplings
89464147|NCT05481827|Experimental|GT005|GT005 is a gene therapy for GA and is a recombinant adeno-associated viral serotype 2 (AAV2) vector encoding for human complement factor I. GT005 was administered to all participants in an antecedent study prior to enrollment in ORACLE and GT005 is not administered in the ORACLE study
89464148|NCT05477862|Experimental|Alzheimer Disease (AD)|
89464149|NCT05477862|Experimental|Cognitively Healthy (CH)|
89464150|NCT05471206|Experimental|Milk intolerant volunteers|
89464151|NCT05471206|Active Comparator|Milk tolerant volunteers|
89464152|NCT05468619|Experimental|Cohort 1|A cohort of neonates who are at risk of acquiring neonatal herpes simplex virus disease will receive 10 mg/kg of valacyclovir will be administered orally two times daily for 5 days. N=8
89464153|NCT05468619|Experimental|Cohort 2|If the safety profile and the drug exposure concentrations in Cohort 1 are acceptable, eight new subjects will be enrolled in Cohort 2. If the mean of observed acyclovir exposures of subjects in Cohort 1 are below 24,000 ngxhr/mL, AND if no Grade 3 or Grade 4 AEs or SAEs are detected in any of the study subjects, then the 8 subjects enrolled in Cohort 2 will receive oral valacyclovir at a dose of 20 mg/kg administered two times daily for 5 days. Alternatively, if the mean of observed acyclovir exposures of subjects in Cohort 1 are above 48,000 ngxhr/mL AND if no Grade 3 or Grade 4 AEs or SAEs are detected in any of the study subjects, then the 8 subjects enrolled in Cohort 2 will receive oral valacyclovir at a dose that has been linearly adjusted downward to target 36,000 ngxh/mL area-under-the-concentration-time curve from 0 to 12 hours (AUC12).
89464154|NCT05457283|Experimental|Finerenone Open-Label safety Extension|Participants will receive finerenone treatment.
89464155|NCT05453578|Active Comparator|Stage 1/2a Arm 2|4x10^7 plaque forming units (PFU) of WRAIR-PAM-CF1 administered intravenously with approximately 25 mL of 0.9 percent Sodium Chloride saline solution for 30 mins as a single dosage. Stage 1: N=2 (sentinel subjects); Stage 2a: N=8
89464156|NCT05453578|Active Comparator|Stage 1/2a Arm 3|4x10^8 plaque forming units (PFU) of WRAIR-PAM-CF1 administered intravenously with approximately 25 mL of 0.9 percent Sodium Chloride saline solution for 30 mins as a single dosage. Stage 1: N=2 (sentinel subjects); Stage 2a: N=8
89464157|NCT05453578|Active Comparator|Stage 1/2a Arm 4|4x10^9 plaque forming units (PFU) of WRAIR-PAM-CF1 administered intravenously with approximately 25 mL of 0.9 percent Sodium Chloride saline solution for 30 mins as a single dosage. Stage 1: N=2 (sentinel subjects); Stage 2a: N=8
89464158|NCT05453578|Placebo Comparator|Stage 2a Arm 1|25 mL of 0.9 percent Sodium Chloride saline solution administered intravenously for 30 mins as a single dosage. N=8
89464159|NCT05453578|Placebo Comparator|Stage 2b Arm 1|25 mL of 0.9 percent Sodium Chloride saline solution administered intravenously for 30 mins as a single dosage. N=17
89018064|NCT05414747|Active Comparator|Participants randomized to SF6 Gas Ocular Endotamponade|Participants randomized to the control device SF6 Gas Ocular Endotamponade undergoing the vitrectomy surgery for uncomplicated retinal detachment
89201934|NCT00741572||2|
89464160|NCT05453578|Active Comparator|Stage 2b Arm 2|WRAIR-PAM-CF1 concentration determined after post stage 2a analysis, administered intravenously with 25 mL of 0.9 percent Sodium Chloride saline solution for 30 mins as a single dosage. N=17
89464161|NCT05451004|Experimental|Lympathic Mapping with SPECT-CT guided Radiotherapy|
89464162|NCT05451004|Active Comparator|Bilateral Neck Radiotherapy|
89464163|NCT05438407|Experimental|Leniolisib|Leniolisib - Film Coated Tablets Leniolisib tablets in 10 and 30 mg strengths administered orally BID by body weight for 12 weeks for Part I and for 1 year for Part II.
89464164|NCT05421364|Experimental|Endometrial cell composition|The cell composition and their quantities will be compared before and after intrauterine administration of PBMC in the endometrial biopsies.
89464165|NCT05420636|Experimental|Iadademstat plus Paclitaxel|Iadademstat oralon a 5 day ON and 2-day OFF schedule every week plus Paclitaxel administered intravenously weekly on day 1, 8 and 15 on day 1 of a 21 day treatment cycle.
89464166|NCT05417113|Active Comparator|Bupivacaine only|bupivacaine 0.25% in ESP blocks
89018065|NCT05413239|Experimental|Intervention Group|The Intervention Group will receive the monthly intervention sessions during the first year of the study.
89018066|NCT05413239|No Intervention|Control Group|The Control Group will receive the monthly intervention sessions during the second year of the study (after assessment of primary outcomes at 1 year).
89018067|NCT05394259|Experimental|Piflufolastat F18|Piflufolastat F18 will first be given by vein over about 5 seconds.
89018068|NCT05388838|Active Comparator|Negative control|uveitis patients with a diagnosis other than ocular diagnosis other than ocular lymphoma and without cerebral lymphoma (15 patients),
89018069|NCT05388838|Active Comparator|Primary ocular Lymphoma without brain involvementand never treated|patients with primary ocular lymphoma without brain involvement and never treated (5 patients),
89018070|NCT05388838|Active Comparator|Primary ocular Lymphoma without brain involvement and treated|patients with primary ocular lymphoma without brain involvement, treated and considered in remission (5 patients),
89018071|NCT05388838|Active Comparator|Primary ocular Lymphoma without brain involvement in relapse|patients with primary ocular lymphoma without brain involvement, considered in relapse (5 patients),
89018072|NCT05388838|Active Comparator|Positive control|patients with cerebral lymphoma with or without ocular involvement and without uveitis (15 patients).
89018073|NCT05388838|Active Comparator|Patients without brain involvement and without uveitis|Patients presenting for cataract follow-up (pre- or post-operative), glaucoma, retinal detachment or epiretinal membrane, with no brain damage or uveitis (15 patients).
89018074|NCT05388084|Active Comparator|Male peer led intervention|Male partners of women randomized to the intervention arm will receive a phone call from the male peer to encourage them to test for HIV at the clinic. Male peer fathers will offer to meet men at the clinic and guide them through the process of HIV testing. Men who are not willing/able to attend the clinic for HIV testing will be offered testing in a private and confidential location in the community; the peer male counselor meet men and offer to assist them through the process of using and interpreting an oral HIVST. Men who are not interested in testing with the peer father will be offered the HIVST kit to take home. Peer fathers will obtain men's consent to participate in the study.
89018075|NCT05388084|Active Comparator|Standard of care and delayed intervention|Standard of care standard of care invitation letter to provide to their partner for fast-track HIV testing and male peer father phone calls after a 3 month delay.
89201935|NCT00929721|Other|Subjects with Community-Acquired Pneumonia|Subjects with Community-Acquired Pneumonia
89201936|NCT04533230|Experimental|Educational intervention with prescription feedback|The manager and physicians at each intervention center will participate in a brief educational intervention about benzodiazepines and benzodiazepine-like hypnotics and receive 12 months of targeted feedback on prescription of these drugs. The education will cover national and regional treatment guidelines for anxiety, depression, and insomnia, which include guidelines on prescription of benzodiazepines and benzodiazepine-like hypnotics.
89464167|NCT05417113|Experimental|Liposomal Bupivacaine and Bupivacaine|liposomal bupivacaine in addition to 0.25% bupivacaine in ESP blocks
89464168|NCT05406544||FD qualitative study on quality of life.|FD patients (FD monostotic, FD polyostotic, with or without craniofacial damages) will be invited to attend a focus group on the following themes: symptoms, self-image, psychological and emotional well-being, difficulties in daily life and adaptative strategies. The focus-groups will be conducted in a semi-directive manner by a moderator and will be recorded; after a verbatim transcription of the focus group recordings, the data will be analyzed manually and with the help of a semantic analysis software. It will allow common notions about quality of life in FD to emerge. A demographic questionnaire will also be completed by the participants.
89464169|NCT05406544||FD quantitative sudy on quality of life and olfaction.|Participants will receive two questionnaires to complete: the SF36 questionnaire (quality of life) and the SELF-MOQ questionnaire (olfaction impairment evaluation). Other data required for the study will be extracted from the medical record: age, weight, height, affected bone sites, Radiological/ biological activity data, sensorial deficit, medication. A demographic questionnaire will also be completed.
89464170|NCT05406544||FD qualitative and quantitative study on quality of life and olfaction.|Patients will be invited to attend a focus group on quality of life (qualitative study) as described for group 1 and to complete questionnaires on quality of life and olfaction (quantitative study) as described for group 2
89464171|NCT05398796|Experimental|Group 1|25 mcg IM
89464172|NCT05398796|Experimental|Group 2|50 mcg IM
89464173|NCT05398796|Experimental|Group 3|100 mcg IM
89464174|NCT05398796|Experimental|Group 4|
89464175|NCT05398445|Experimental|Arm A|Rocatinlimab Dose 1 every 4 weeks (Q4W) + loading dose at Week 2
89464176|NCT05398445|Experimental|Arm B|Rocatinlimab Dose 2 Q4W + loading dose at Week 2
89464177|NCT05398445|Placebo Comparator|Arm C|Placebo Q4W+ loading dose at Week 2
89464178|NCT05387317|Experimental|Pfizer-BioNTech Standard dose after CoronaVac priming|"Pfizer-BioNTech (BNT162b2, or Comirnaty®) Dose: 30ug in 0.3ml~The 50 participants in this arm received second CoronaVac priming dose at least 6 months prior to randomisation."
89464179|NCT05387317|Experimental|Pfizer-BioNTech Fractional dose after CoronaVac priming|"Pfizer-BioNTech (BNT162b2, or Comirnaty®) Dose: 15ug in 0.15ml~The 50 participants in this arm received second CoronaVac priming dose at least 6 months prior to randomisation."
89464180|NCT05387317|Experimental|AstraZeneca Standard dose after CoronaVac priming|"AstraZeneca (ChAdOx1-S, Vaxzevria®). Dose: 0.5ml~The 50 participants in this arm received second CoronaVac priming dose at least 6 months prior to randomisation."
89464181|NCT05387317|Experimental|AstraZeneca Fractional dose after CoronaVac priming|"AstraZeneca (ChAdOx1-S, Vaxzevria®). Dose: 0.25ml~The 50 participants in this arm received second CoronaVac priming dose at least 6 months prior to randomisation."
89464182|NCT05387317|Experimental|Moderna Standard Dose after CoronaVac priming|"Moderna (mRNA-1273 or Spikevax®) Dose: 50ug in 0.25ml~The 100 participants in this arm received second CoronaVac priming dose at least 6 months prior to randomisation."
89464183|NCT05387317|Experimental|Moderna Fractional Dose after CoronaVac priming|"Moderna (mRNA-1273 or Spikevax®) Dose: 20ug in 0.1ml~The 100 participants in this arm received second CoronaVac priming dose at least 6 months prior to randomisation."
89464184|NCT05387317|Experimental|Pfizer-BioNTech Standard dose after AstraZeneca priming|"Pfizer-BioNTech (BNT162b2, or Comirnaty®) Dose: 30ug in 0.3ml~The 50 participants in this arm received second AstraZeneca priming dose at least 6 months prior to randomisation."
89464185|NCT05387317|Experimental|Pfizer-BioNTech Fractional dose after AstraZeneca priming|"Pfizer-BioNTech (BNT162b2, or Comirnaty®) Dose: 15ug in 0.15ml~The 50 participants in this arm received second AstraZeneca priming dose at least 6 months prior to randomisation."
88944827|NCT01883947|Experimental|Touch massage|Intervention group will receive touch massage on hands and feet and the intervention will start one week after the onset of stroke and last for 30 minutes each time, five days a week for two weeks
88944828|NCT01883947|Sham Comparator|non-TENS|The sham treatment will start one week after the onset of stroke and last for 30 minutes each time, five days a week for two weeks
89464186|NCT05387317|Experimental|AstraZeneca Standard dose after AstraZeneca priming|"AstraZeneca (ChAdOx1-S, Vaxzevria®). Dose: 0.5ml~The 50 participants in this arm received second AstraZeneca priming dose at least 6 months prior to randomisation."
89464187|NCT05387317|Experimental|AstraZeneca Fractional dose after AstraZeneca priming|"AstraZeneca (ChAdOx1-S, Vaxzevria®). Dose: 0.25ml~The 50 participants in this arm received second AstraZeneca priming dose at least 6 months prior to randomisation."
89464188|NCT05387317|Experimental|Moderna Standard Dose after AstraZeneca priming|"Moderna (mRNA-1273 or Spikevax®) Dose: 50ug in 0.25ml~The 100 participants in this arm received second AstraZeneca priming dose at least 6 months prior to randomisation."
89464189|NCT05387317|Experimental|Moderna Fractional Dose afterAstraZeneca priming|"Moderna (mRNA-1273 or Spikevax®) Dose: 20ug in 0.1~The 100 participants in this arm received second AstraZeneca priming dose at least 6 months prior to randomisation."
89464190|NCT05386368|Other|Right receives ReCell (A)|Right perioral area of face receives ReCell/ Left receives saline
89464191|NCT05386368|Other|Left receives ReCell (B)|Left perioral area of face receives ReCell/ Right receives saline
89464192|NCT05383638|Other|Health promotion|Health education and popularization of science
89464193|NCT05377034|Experimental|Study Arm|SIRT-Y90 + 1200mg atezolizumab + 15mg/kg bevacizumab
89464194|NCT05377034|Experimental|Control Arm|SIRT-Y90 + placebos (IV)
89464195|NCT05375552|Active Comparator|Active transcranial direct current stimulation|Active transcranial direct current stimulation
89464196|NCT05375552|Placebo Comparator|Placebo transcranial direct current stimulation|Placebo transcranial direct current stimulation
89464197|NCT05366725||Adult patients with locally advanced or metastatic urothelial cancer|
88944829|NCT01883960||healthy adults|Inclusion criteria for healthy adults were as follows: 40-70 y/o; good cognition and cooperation; and healthy adults.
88944830|NCT01883960||stroke subjects|Inclusion criteria for subjects with brain damage by stroke were as follows: a diagnosis of first-time-onset stroke and aged 40-70 years old.
89464198|NCT05364424|Experimental|R/R DLBCL|Participants will receive up to 3 21-day cycles of glofitamab, rituximab, ifosfamide, carboplatin, and etoposide (glofit-R-ICE).
89464199|NCT05364073|Experimental|Stage 1 Dose Escalation and Backfill|Experimental: Previously treated patients with advanced or metastatic NSCLC with activating EGFR or HER2 mutations
88944831|NCT01883960||CP subjects|Inclusion criteria for subjects with brain damage by CP were as follows: a diagnosis of CP and aged 16-18 years old.
88944832|NCT01883960||healthy children|Inclusion criteria for healthy children were as follows: ages of 6-18 y/o ; good cognition and cooperation; and healthy children.
88944833|NCT01883973||MER guidance|Will undergo DBS implantation in the awake state using a frame based stereotactic technique and intraoperative microelectrode recording to guide final lead placement.
88944834|NCT01883973||MRI Guidance|Will undergo DBS implantation under general anesthesia using anatomical targeting in an operating room equipped with an intraoperative MRI to guide electrode placement
89464200|NCT05364073|Experimental|Stage 2 Expansion Cohort 1|Previously Treated NSCLC Patients with EGFR Exon 20 Insertion Mutations
89464201|NCT05364073|Experimental|Stage 2 Expansion Cohort 2|Previously treated NSCLC Patients with HER2 Exon 20 Insertion Mutations
89464202|NCT05364073|Experimental|Stage 2 Expansion Cohort 3|Previously treated NSCLC Patients with EGFR Activating Mutations, who are not eligible for Cohorts 1 and 4
89464203|NCT05364073|Experimental|Stage 2 Expansion Cohort 4|Untreated or Previously treated EGFR TKI Naïve NSCLC Patients with EGFR Uncommon Mutations, excluding EGFR exon 20 insertion mutations
89464204|NCT05361551|Experimental|Liver ablation|The ablation procedure will be performed in 1 day
89464205|NCT05359237||Observational (SOC vincristine, biospecimen collection)|Patients receive vincristine IV per SOC. Patients undergo collection of blood samples at baseline (before first vincristine dose), and 2, 6-8, and 18-24 hours after a dose of vincristine. Patients may also undergo collection of blood samples with a second SOC vincristine dose at the same time points.
89464206|NCT05357755|Experimental|Group 1: JNJ-77242113 Dose 1|Participants will receive JNJ-77242113 Dose 1 as delayed release tablets orally once daily from Week 0 through Week 16.
89464207|NCT05357755|Experimental|Group 2: JNJ-77242113 Dose 2|Participants will receive JNJ-77242113 Dose 2 as delayed release tablets orally once daily from Week 0 through Week 16.
89464208|NCT05357755|Placebo Comparator|Group 3: Placebo|Participants will receive oral dose of matching placebo once daily from Week 0 through Week 16.
89464209|NCT05354232|Experimental|2mA transcranial direct current stimulation|
89464210|NCT05354232|Experimental|1mA transcranial direct current stimulation|
89464211|NCT05354232|Sham Comparator|Sham transcranial direct current stimulation|
88944835|NCT01884012|Experimental|Supplemental oxygen|Supplemental oxygen 3 liters/minute given via a nasal cannula for 16 hours a day
89501922|NCT02310464|Experimental|Dose escalation|Each subject will be given a total of 10 doses of OBI-833/OBI-821 subcutaneously at weeks 1,2,3,4,6,8,12,16,20,and 24 (Visits 1,2,3,4,5,6,7,8,9 and 10, respectively). Post treatment, subjects will be continually evaluated for safety and immune response every 4 weeks until the end of study, which is 12 weeks after the last dose, i.e., week 36. Subsequently, subjects will be followed for survival every 8 weeks up to 12 months after the end of study.
88944836|NCT01884012|Sham Comparator|Sham room air|Room air given at a flow rate of 3 liters per minute for 16 hours a day
88944837|NCT01884090|Experimental|Youth Empowerment Solutions (YES)|Participants receiving the The 16-week, 30-session YES curriculum YES as a part of the 21st Century after-school program at middle schools that have high economic and academic needs. 21st Century is a U.S. Department of Education program which provides academic enrichment opportunities during non-school hours and during the summer for children who attend low-performing schools in areas with high poverty (U.S. Department of Education, 2009).
89464212|NCT05353491|Experimental|Technology assisted Thinking Healthy Program delivered by peers|"A technology adapted version of the Thinking Healthy Program (THP) delivered by peers using multimedia android based app. The bespoke android app leverages human-centered design and makes use of 2-d videos demonstrating narrative scripts delivered by culturally appropriate animated avatars representing depressed mothers, families, peers and mental health experts.~It is designed as a low intensity psychosocial multicomponent intervention based on cognitive behavioral approaches. The THP improves depression through psychoeducation, behavior activation, thought challenging, improving problem solving skills and by activating social support networks.~The intervention program comprises of 8 sessions delivered by trained peers."
88944838|NCT01884090|Active Comparator|Standard After School Programming|Youth in the comparison arm of the study will participate in standard after-school programming administered by Flint Community Schools and Genesee Intermediate School District. The standard program is the 21st Century after-school program at middle schools that have high economic and academic needs. 21st Century is a U.S. Department of Education program which provides academic enrichment opportunities during non-school hours and during the summer for children who attend low-performing schools in areas with high poverty (U.S. Department of Education, 2009)
89464213|NCT05353491|Active Comparator|Standard Thinking Healthy Program delivered by community health workers|"The Thinking Healthy Programme (THP) is a CBT-based manualised paper version of the intervention targeting women with perinatal depression in low socioeconomic settings.~The CBT techniques include guided discovery using illustrated brief vignettes, behavioural activation, and problem solving. Non-specific techniques include empathic listening and promoting social support from key family members for the mother in negotiating challenges during the perinatal period. This intervention programme is paper based utilizing reference manual, health calendar and job aid as tools for delivering content.~The intervention employs these techniques to improve outcomes in three areas: maternal well-being, mother-infant interaction and relationship with significant others. The intervention consists of 8 core sessions starting in the second or third trimester of pregnancy and continuing to 3 months postnatal."
89464214|NCT05349214|Experimental|Arm A|ianalumab exposure level 1
89464215|NCT05349214|Experimental|Arm B|ianalumab exposure level 2
89464216|NCT05349214|Placebo Comparator|Arm C|placebo
89464217|NCT05338216|Experimental|Traditional Ecological Momentary Assessment (Traditional EMA)|People with aphasia (PWA) in the traditional EMA arm will receive four prompts per day to complete a set of nine picture naming trials per prompt for a total of n = 36 prompts/day for three weeks.
89464218|NCT05338216|Experimental|Micro-Interaction Ecological Momentary Assessment (µEMA)|People with aphasia (PWA) in the µEMA condition will complete a single naming trial at a time, 36 times per day for three weeks.
89464219|NCT05318976|Experimental|1.0 mg/kg XPro1595|1.0 mg/kg of XPro1595 will be administered via subcutaneous injection once a week for 23 weeks.
89464220|NCT05318976|Placebo Comparator|1.0 mg/kg Placebo|1.0 mg/kg of Placebo will be administered via subcutaneous injection once a week for 23 weeks.
89464221|NCT05312970|Active Comparator|Varithena®|Varithena® (polidocanol injectable foam) 1%
89464222|NCT05312970|Active Comparator|FDA-approved ETA systems|FDA-approved ETA systems, including Radiofrequency ablation (RFA) systems or Endovenous laser ablation (EVLA) systems.
89464223|NCT05304767|Experimental|Drug: KarXT|
89464224|NCT05303597|Other|diagnostic superior cluneal nerve block|Patients with low back pain will be evaluated by two physicians. The clinical history and physical examination of all patients with low back pain will be taken by the first physician. Patients with a trigger point in the posterior iliac crest will be evaluated by a second physician and diagnostic nerve block will be performed ultrasound-guided with the preliminary diagnosis of superior cluneal nerve entrapment. General Electric LogiqP5 model ultrasound device will be used and lidocaine will be applied between the posterior iliac crest and thoracolumbar fascia, which is viewed under the guidance of ultrasonography, for diagnosis and treatment. Patients who have had a diagnostic injection will be re-evaluated 1 hour later. Patients whose pain is reduced by more than 70% will be diagnosed with superior cluneal nerve entrapment.
89464225|NCT05301842|Experimental|Arm A|Tremelimumab, Durvalumab and Lenvatinib in combination with Transarterial Chemoembolization (TACE)
88944839|NCT01884103||EMS Providers|Field Triage Decision-making for older adult patients with potential TBI.
88944840|NCT01884116|Active Comparator|NSAID patch group|administer the NSAID patch
88944841|NCT01884116|Experimental|NSAID patch + transcutaneous electric nerve stimulation group|
88944842|NCT01884116|Experimental|NSAID patch + heating pad group|
88944843|NCT01884116|Experimental|NSAID patch + topical capsaicin group|
88944844|NCT01884142|No Intervention|Heart Failure Untrained Group|Control Group
88944845|NCT01884142|Experimental|Heart Failure Exercise-trained Group|Aerobic Exercise Training
89464226|NCT05301842|Experimental|Arm B|Tremelimumab and Durvalumab in combination with Transarterial Chemoemobolization (TACE)
89464227|NCT05301842|Active Comparator|Arm C|Transarterial Chemoembolization (TACE)
89464228|NCT05297734|Active Comparator|Technology-based supportive cancer care|Patients receive educational materials to assist with advance care planning and symptom management through a technology-based supportive cancer care weekly during months 1-4 and every other week during months 5-12.
89464229|NCT05297734|Experimental|Redesigned team-based supportive cancer care|Patients are paired with a health educator who will discuss the same educational materials from ARM A either in person or by telephone discussions weekly during months 1-4 and every other week during months 5-12.
89464230|NCT05295732|Experimental|TMB-001 0.05%|TMB-001 0.05% ointment: Induction phase QD for 3 weeks, followed by BID for 9 weeks. Maintenance therapy for additional 12 weeks randomized QD vs BID
89464231|NCT05295732|Placebo Comparator|Vehicle|Matching vehicle ointment with no action isotretinoin: Induction phase QD for 3 weeks, followed by BID for 9 weeks. Cross over to 12 weeks TMB-001 0.05% BID.
89464232|NCT05295732|Experimental|Maximal use|Optional Parallel Arm to evaluate the systemic exposure and safety of TMB-001 0.05% under conditions of maximal use.
89464233|NCT05293106|Active Comparator|Pathogen-reduced (PR) platelet transfusions|FDA approved and already used in this patient population
89464234|NCT05293106|Active Comparator|Large volume delayed sampling - LVDS|FDA approved and already used in this patient population
89464235|NCT05292183|Experimental|Stimulation|This part will include 24 randomly chosen images from each of four categories (total of 96 images varying in valence and arousal) and will be presented block-randomized amygdala stimulation.
89464236|NCT05292183|No Intervention|No stimulation|This part will include 24 randomly chosen images from each of four categories (total of 96 images varying in valence and arousal) and will be presented without amygdala stimulation.
89464237|NCT05283538|Experimental|Coronary Artery Calcification Evaluation|
89464238|NCT05282823||Treatment Subjects|Subjects will be clinically indicated for pulmonary vein isolation ablation procedure (in compliance with instructions for use (IFU)/Tenpubunsyo as legally approved conditions) for the treatment of paroxysmal AF.
89464239|NCT05271643|Experimental|CF-CBT-A intervention|Participants will meet with a therapist, a mental health provider on their cystic fibrosis care team who has received training in CF-CBT-A, for a baseline interview and introduction plus 9 weekly sessions of CF-CBT-A.
89464240|NCT05268302|Experimental|Low Dose Dengue 4 Live Virus Human Challenge (DENV-4-LVHC)|0.95 x 10^2 Plaque Forming Units
89464241|NCT05268302|Experimental|Medium Dose Dengue 4 Live Virus Human Challenge (DENV-4-LVHC)|0.95 x 10^3 Plaque Forming Units
89464242|NCT05268302|Experimental|High Dose Dengue 4 Live Virus Human Challenge (DENV-4-LVHC)|0.95 x 10^4 Plaque Forming Units
88944846|NCT01884155|Experimental|Allogeneic umbilical cord blood therapy|Allogeneic umbilical cord blood therapy
88944847|NCT01884168||gene expression profile|T-Cell Receptor/B-Cell Receptor gene expression in cavity effusion is detected by micro-array to explore the mechanism that DC-CIK immunotherapy controls the malignant cavity effusion.
88944848|NCT01884181||Huntington Disease Group|Established diagnosis by a neurological examination and genetic assessment of CAG expansion in the Htt gene.
88944849|NCT01884181||Healthy Controls|"The healthy control subjects without a clinically significant neuropsychiatric disorders.~Able to understand and provide signed informed consent.~Age range and gender matched with Patients with Huntington Disease Group."
88944850|NCT01884194||Retinoblastoma patients|patients with diagnosed retinoblastoma
88944851|NCT01884194||non-retinoblastoma patients|aged matched control cohort without the diagnosis of ocular or brain tumor
88944852|NCT01884207||orbital tumors|
88944853|NCT01884220||Patients with Disease|Patients with Wolman disease (WD), Cholesteryl Ester Storage Disease (CESD), or Lysosomal acid lipase (LAL) deficiency.
88944854|NCT01884233|Experimental|Text Messaging CBT (TXT-CBT)|This condition will receive CBT based text messaging (TXT-CBT). Those assigned to TXT-CBT will also be given a treatment manual (developed in Phase I) containing descriptions of core therapeutic content/topics for each week. HIV-infected participants will have an initial meeting with a CBT clinician to review the Life-Steps concepts. The 3 most applicable medication adherence skills will be identified for emphasis in tailored messages. A research coordinator will meet with the participants weekly at data collection visits throughout the intervention phase to answer any technical questions and ensure that the intervention program is working properly.
88944855|NCT01884233|Active Comparator|Standard Care|Those assigned to the Standard Care condition will receive the standard monthly medical management physician visit typically associated with HIV care. In addition, a pamphlet with information about HIV, the importance of ART adherence, and relapse prevention will be provided to participants in this condition.
89464243|NCT05257213|Active Comparator|Heparin solution|Administration of 3 ml heparin solution into the uterine cavity via a syringe immediately post operative hysteroscopy.
89464244|NCT05257213|Active Comparator|Anti-adhesion barrier gel|Intrauterine application of 2 ml biodegradable anti-adhesion barrier gel immediately post operative hysteroscopy.
89464245|NCT05254613|Experimental|Cohort 1|Participants will receive a single SC dose of ALXN1830 or placebo (750 mg).
89464246|NCT05254613|Experimental|Cohort 2|Participants will receive a single SC dose of ALXN1830 or placebo (1500 mg).
89464247|NCT05254613|Experimental|Cohort 3|Participants will receive a single SC dose of ALXN1830 or placebo (2250 mg).
89464248|NCT05254613|Experimental|Cohort 4|Participants will receive multiple SC doses of ALXN1830 or placebo (300 mg twice weekly; 8 doses total).
88944856|NCT01884246|Experimental|Self-care CVD risk reduction|A patient-centered, culturally appropriate lifestyle approach to promoting self-care in high risk patients.
89464249|NCT05254613|Experimental|Cohort 5|Participants will receive multiple SC doses of ALXN1830 or placebo (750 mg once weekly; 12 doses total).
89464250|NCT05254613|Experimental|Cohort 6|Participants will receive multiple SC doses of ALXN1830 or placebo (1500 mg once weekly; 4 doses total).
89464251|NCT05254613|Experimental|Cohort 7|Participants will receive multiple SC doses of ALXN1830 or placebo (2250 mg once weekly; 4 doses total).
89464252|NCT05240898|Experimental|RO7623066 Monotherapy (Dose Escalation)|RO7623066 will be administered orally once daily (QD) continuously as monotherapy. Once the maximum tolerated dose (MTD) for RO7623066 monotherapy has been reached this concludes the Dose Escalation phase.
89464253|NCT05240898|Experimental|RO7623066 + Olaparib (Dose Escalation and Expansion)|RO7623066 will be tested in combination with olaparib. Escalating dose levels will be tested until the maximum tolerated dose (MTD), or lower, of RO7623066 is reached or MTD, or lower, of the combination is reached (whichever occurs first). Combination arms can enroll concurrently. Olaparib will be dosed per standard of care (SoC).
89464254|NCT05240898|Experimental|RO7623066 + Carboplatin (Dose Escalation and Expansion)|RO7623066 will be tested in combination with carboplatin. Escalating dose levels will be tested until the maximum tolerated dose (MTD), or lower, of RO7623066 is reached or MTD, or lower, of the combination is reached (whichever occurs first). Combination arms can enroll concurrently. Carboplatin will be dosed per standard of care (SoC).
89464255|NCT05239728|Experimental|Belzutifan + Pembrolizumab|Participants receive belzutifan 120 mg orally once daily (QD) for up to approximately 54 weeks PLUS pembrolizumab 400 mg via intravenous (IV) infusion once every 6 weeks (Q6W) for up to 9 administrations (up to approximately 54 weeks).
89464256|NCT05239728|Experimental|Placebo + Pembrolizumab|Participants receive placebo orally QD for up to approximately 54 weeks PLUS pembrolizumab 400 mg via IV infusion once Q6W for up to 9 administrations (up to approximately 54 weeks).
89464257|NCT05233098||Clinical Cohort|Patients enrolled in the study will have 3 imaging scans taken after Tc-99m MAA injection. The final scan will occur between 18 and 24 hours after Tc-99m MAA injection.
89464258|NCT05223920|Experimental|Bomedemstat|Participants will receive bomedemstat daily for 169 days with additional treatment continuing in participants deriving clinical benefit.
89464259|NCT05222620|Other|Arm A (single fraction SRS)|Patients undergo single fraction SRS.
89464260|NCT05222620|Other|Arm B (fractionated SRS)|Patients undergo fractionated SRS.
89464261|NCT05191277|Experimental|Open discontinuation (OD)|Participants will discontinue their antidepressant medication and will be fully informed about treatment (i.e., high expectation).
89464262|NCT05191277|Experimental|Hidden discontinuation (HD)|Participants will discontinue their antidepressant medication, but will be informed about a 50% chance of discontinuing versus remaining on their antidepressant medication (i.e., moderate expectation).
89464263|NCT05191277|Experimental|Open continuation (OC)|Participants will remain on their initial antidepressant medication and will be fully informed about treatment (i.e., high expectation).
89464264|NCT05191277|Experimental|Hidden continuation (HC)|Participants will remain on their initial antidepressant medication, but will be informed about a 50% chance of discontinuing versus remaining on their antidepressant medication (i.e., moderate expectation).
89464265|NCT05190705|Experimental|Loncastuximab Tesirine + Dexamethasone|"Participants will be given~Loncastuximab Tesirine on Day 1 of every 28 day study cycle and continue for up to 6 cycles.~Participants will also receive pre-medications to reduce the chance of having a sensitivity reaction to the study treatment. Participants who tolerate the study treatment without a reaction may have pre-medications changed per determination of their doctor.~Dexamethasone will be given prior to study treatment on Day -1 or up to 2 hours prior to loncastuximab tesirine and the day after treatment"
89464266|NCT05180032|Experimental|Romosozumab group|Romosozumab (evenity) administered monthly from baseline to month 11 followed by denosumab (prolia) at month 12 and 18
89464267|NCT05180032|Placebo Comparator|Control group|Placebo administered monthly from baseline to month 11 followed by denosumab (prolia) at month 12 and 18
89464268|NCT05174611|Experimental|Treatment group|Subject in treatment group will receive one capsule of 2000IU Vitamin D3 supplement per day with the duration of 16 weeks.
89464269|NCT05174611|Placebo Comparator|Placebo group|Subject in placebo group will receive one capsule of placebo per day which looks exactly same as the Vitamin D3 capsule with the duration of 16 weeks.
89464270|NCT05174585|Experimental|Arm A, JAB-BX102 monotherapy, Phase 1, Dose Escalation|Dose escalation of JAB-BX102 will be administered as monotherapy to determine the MTD and RP2D.
89464271|NCT05174585|Experimental|Arm B, JAB-BX102 combination with pembrolizumab, Phase 2a, Dose Expansion|JAB-BX102 will be administered in combination with pembrolizumab in specific solid tumor patients to evaluate the preliminary antitumor activity.
89464272|NCT05164744||Diagnosed with COVID-19|Participants in the study cohort will have been diagnosed with COVID-19 by a PCR (polymerase chain reaction) positive test
89464273|NCT05152784|Experimental|Octaray catheter|VT ablation guided by activation mapping using the Octaray catheter and integrated cardiac MRI data.
89464274|NCT05152784|Active Comparator|Standard of care|Identified retrospectively from registry data: propensity matched-controls undergoing VT ablation guided by substrate-modification alone.
89464275|NCT05145868|Experimental|Intervention|
89464276|NCT05145868|Sham Comparator|Attention Control|
89464277|NCT05145413|Experimental|Drug: KarXT|
89464278|NCT05145413|Placebo Comparator|Placebo|
89464279|NCT05142683|Active Comparator|Treatment as Usual|Study involvement for all sites will begin in the TAU condition, which is the typical treatment at the participating community mental health agency. A range of treatments observed in our previous survey of sites will be on offer in these agencies, depending on the preferences and context of the local agency. In typical TAU in community mental health agencies, depressive symptoms and function are not systematically monitored via standardized rating scales. TAU may or may not include referral to psychotherapy and/or parent support. There are no prompts to prescribe specific medications, and/or internal and external referrals to treatment and other services, guided by local service standards.
89501923|NCT02310464|Experimental|Cohort expansion phase|Each subject will be given OBI-833/OBI-821 at Weeks 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, and every 8 weeks thereafter (Visits 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, and every 8 weeks thereafter) until disease progression. For the subjects discontinued treatment because of disease progression, subjects will be continually evaluated for safety and immune response every 8 weeks until the end of the study, which is 24 weeks after the last dose.
88944857|NCT01884246|Active Comparator|Referral to primary care provider|The study team provides a primary care provider for the patient, makes the referral and sends appropriate CVD risk reduction guidelines to the provider.
88944858|NCT01884272|Experimental|Lesinurad 400 mg and naproxen 250 mg|Lesinurad once daily (qd) Day 1, naproxen twice daily (bid) Day 2-6, lesinurad qd with naproxen bid Day 7-14.
88944859|NCT01884272|Active Comparator|Lesinurad 400 mg and indomethacin 25 mg|Lesinurad qd Day 1, indomethacin bid Day 2-6, lesinurad qd with indomethacin bid Day 7-14.
88944860|NCT01884285|Experimental|Part A: AZD8186 monotherapy|Patients will receive a single dose on Day 1 followed by ongoing multiple dosing. The initial schedule will use intermittent dosing of AZD8186.
88944861|NCT01884285|Experimental|Part C2: AZD8186/abiraterone|Patients will receive a week of abiraterone acetate with prednisone followed by combination dosing with AZD8186.
88944862|NCT01884285|Experimental|Part D1: AZD8186 and AZD2014|Combination dosing with AZD8186 and AZD2014 both given on an intermittent schedule at escalating dose levels of each IMP for combination dose finding
88944863|NCT01884285|Experimental|Part B: AZD8186 monotherapy|Part B - multiple dosing of intermittent dose schedule
88944864|NCT01884285|Experimental|Part D2: AZD8186/ AZD2014|Expanded cohort of patients will be treated at a tolerated combination dose level established in Part D1
88944865|NCT01884285|Experimental|Part C1: AZD8186 & abiraterone|Patients will receive a week of abiraterone acetate with prednisone followed by combination dosing with AZD8186 at escalating doses of AZD8186 for the purpose of dose finding
88944866|NCT01884298|Experimental|patients with isolated systolic hypertension|patients combined with isolated systolic hypertension undergoing abdominal surgery
88944867|NCT01884324|No Intervention|Late delivery|"This will be a randomized clinical investigation. The subjects will be allocated into early and late delivery groups using concealed allocation envelopes, which will be created prior to the start of the study using a random allocation sequence. The trial will be conducted in an intent-to-treat fashion."
88944868|NCT01884324|Experimental|Early delivery|The early group will undergo induction of labor at 34 weeks with cesarean delivery reserved for obstetrical indications.
88944869|NCT01884363|Experimental|Walnuts|This group will receive one ounce of walnuts per day
88944870|NCT01884363|No Intervention|Usual diet (no walnuts)|Control group (does not receive walnuts in the diet)
88944871|NCT01884376|Experimental|Neuromaix implantation|Implantation of Neuromaix during an diagnostic nerve biopsy
88944872|NCT01884389|Experimental|Patient Navigation|"Patients are admitted to the navigation program, provided through a local community partner agency. Each of these subjects will be assigned an advanced practice nurse (APN) and licensed social worker (LSW) as co-case managers, with their relative contributions depending on the nature of the subject's needs. Level of need (1, 2 or 3) will be confirmed for each patient, and the level will inform the amount of in-person and phone call contacts made to provide on-going support and monitoring of patients. Additionally, this group will meet with the research team for data collection at enrollment and at four 9-month intervals for a total of 5 time points."
88944873|NCT01884389|No Intervention|Usual Care|"The control group will receive usual care - medical care and support provided by their primary care provider. They will not receive any of the navigation program services. To provide control for the effects of attention, we will contact these subjects at baseline and every other month thereafter by phone. During these contacts, we will ask a scripted social query (e.g. How are things going for you?). A subject who raises any health issues or need for specific information will be referred to the primary care provider. Additionally, this group will meet with the research team for data collection at enrollment and at four 9-month intervals for a total of 5 time points."
88944874|NCT01884402||Pegasys, injection subcutaneous|HCV patients monoinfected or coinfected genotype 1/4 treated with Peginterferon alfa-2a and Ribavirin
88944875|NCT01884415|Experimental|Second HBV vaccination cycle|Second cycle of HBV vaccination (0, 1 and 2 months)will be administered. Three intramuscular doses of 40 µg.
88944876|NCT01884415|Active Comparator|Single dose of HBV vaccine|Single dose (40µg) of HBV vaccine will be administered at 6 months after 1 cycle of HBV vaccination
88944877|NCT01884428|Experimental|Panobinostat + IGEV|Panobinostat + IGEV regimen (Ifosfamide, Gemcitabine, Vinorelbine, Prednisolone)
88944878|NCT01884441|Experimental|BeGEV|Bendamustine, Gemcitabine and Vinorelbine (BeGEV)
88944879|NCT01884454||Total sleep deprivation|Healthy volunteers will be submitted to total sleep deprivation (TSD) for 48 hours.
88944880|NCT01884454||moderate to severe OSA|Patients diagnosed with moderate to severe obstructive sleep apnea syndrome (OSA) with normal or overweight body mass index (BMI), will be recruited.
88944881|NCT01884454||REM sleep deprivation|Healthy volunteers will be submitted to selective REM sleep deprivation (REMSD) for 48 hours.
88944882|NCT01884454||Control|The control group will be subjects with an apnea hypopnea index <5/h.
88944883|NCT01884467|Experimental|Gentamicin|Intervention: Gentamicin; Dosage form: 120mg reconstituted in 250cc of normal saline; Dosage: 30mL; Frequency: nightly instillation into bladder (to remain overnight until draining it out in morning); Duration: 1 year
88944884|NCT01884467|Placebo Comparator|Placebo|Drug: Normal saline; Dosage form: N/A; Dosage: 30 mL; Frequency: nightly bladder instillation; Duration: 1 year
88944885|NCT01884480||500 Stable renal transplant recipients|cohort of 500 stable RTRS. A subset of this group who required dose adjustment after conversion will be compared to a matched cohort not requiring dose adjustment. Genotyping for Cyp3A5 will be done for both cohorts
89501924|NCT03365947|Active Comparator|ARO-HBV Injection|
89501925|NCT03365947|Placebo Comparator|Placebo|
89501926|NCT02232685|Experimental|Choline PET/CT|18F-Choline PET/CT
89464280|NCT05142683|Experimental|CARIBOU-2|"After the CARIBOU-1 pilot study, the Principal Investigator revised the ICP to render it more applicable to community settings as well as offer a second-line psychotherapy (Brief Psychosocial Intervention) for youth who do not engage with, or respond to, cognitive-behavioural therapy. The revised version is called the CARIBOU-2 intervention. The current iteration of the pathway involves a series of steps: (1) structured assessment, including safety assessment; (2) education on depression, sleep, exercise, and diet; (3) psychotherapy (with 1st line Cognitive Behavioural Therapy, 2nd line Brief Psychosocial Intervention); (4) a caregiver structured support group; (5) medication options (1st line fluoxetine, 2nd line sertraline); (6) team reviews every four weeks, (meeting with the youth and involved clinicians to review measures and discuss treatment changes); and, (7) discharge and follow-up planning."
89464281|NCT05142228|Active Comparator|Erenumab-aooe|"Erenumab-aooe 140 mg/ml. Subcutaneous injection. Administered once every 4 weeks/28 days at visit 1, visit 2 and visit 3 for a total of 3 cycles.~Other Name: Aimovig®"
88944886|NCT01884480||500 renal transplant recipients|500 Stable renal transplant recipients converted from prograf to advagraf
88944887|NCT01884493|Experimental|real iTBS|The paradigm will use a theta burst stimulation pattern (TBS) in which 3 pulses of stimulation will be given at 50Hz, repeated every 200 ms. In the iTBS, a 2-second train of TBS is repeated every 10 seconds for a total of 190 seconds (600 pulses). Subjects will be 8 courses of iTBS stimulation in 10 business days.
88944888|NCT01884493|Sham Comparator|sham iTBS|Subjects will be 8 courses of sham iTBS stimulation in 10 business days.
88944889|NCT01884506|Experimental|labeled iron meal|Test meal (bread with honey) with a labeled iron solution
88944890|NCT01884506|Experimental|labeled iron and ascorbic acid meal|Test meal (bread with honey) with a labeled iron solution and ascorbic acid
88944891|NCT01884532||2 year post-op|Patients that underwent an ASR-XL Metal-on-Metal (MoM) total hip replacement (THR)and at the time of enrollment, based on their date of surgery, were 2 years post-operative. Alternatively, these are patients who have had their ASR-XL Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
88944892|NCT01884532||3 year post-op|Patients that underwent an ASR-XL Metal-on-Metal (MoM) total hip replacement (THR)and at the time of enrollment, based on their date of surgery, were 3 years post-operative. Alternatively, these are patients who have had their ASR-XL Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
89464282|NCT05142228|Placebo Comparator|Placebo|"Placebo. Subcutaneous injection.Administered once every 4 weeks/28 days at visit 1, visit 2 andvisit 3 for a total of 3 cycles.~Other name: Placebo"
89201937|NCT04533230|Active Comparator|Information on guidelines|The manager and physicians at each center in the active control group will receive written information on national and regional treatment guidelines for anxiety, depression, and insomnia, which include guidelines on prescription of benzodiazepines and benzodiazepine-like hypnotics. These centers will not receive the onsite educational intervention or 12 months of targeted prescription feedback.
89201938|NCT04533230|No Intervention|No active intervention: standard care|The manager and physicians at each primary health care center in the passive control group will receive no active intervention. The passive control group will consist of primary health care centers that are not actively participating in the study. Data will be gathered from regional registers and databases. Thus, there will be no need to contact or communicate directly with the centers. This arm will be used only if the General Data Protection Regulation continues to allow access to regional registers and databases in primary health care.
89201939|NCT00908193|Experimental|1|robot-assisted coelioscopy
89464283|NCT05140525|Active Comparator|participants with inoperable CTEPH|subject with inoperable Chronic thromboembolic Pulmonary Hypertension
89464284|NCT05140525|Active Comparator|post PTE residual CTEPH|Subject with post pulmonary endarterectomy (PTE) residual Chronic Thromboembolic Pulmonary Hypertension
89464285|NCT05135676|Active Comparator|Standard Target Group|Standard therapy with glucose target 140-180 mg/dL (ADA guidelines) and masked CGM
89464286|NCT05135676|Experimental|Intensive Target Group|Intensive therapy with glucose target 90-130 mg/dL with real-time CGM
88944893|NCT01884532||4 year post-op|Patients that underwent an ASR-XL Metal-on-Metal (MoM) total hip replacement (THR)and at the time of enrollment, based on their date of surgery, were 4 years post-operative. Alternatively, these are patients who have had their ASR-XL Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
89464287|NCT05122936||XOWI Group|Obesity Cohort undergoing XRXPY-based Obesity Wellness Intervention
88944894|NCT01884532||5 year post-op|Patients that underwent an ASR-XL Metal-on-Metal (MoM) total hip replacement (THR)and at the time of enrollment, based on their date of surgery, were 5 years post-operative. Alternatively, these are patients who have had their ASR-XL Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
88944895|NCT01884532||6 year post-op|Patients that underwent an ASR-XL Metal-on-Metal (MoM) total hip replacement (THR)and at the time of enrollment, based on their date of surgery, were 6 years post-operative. Alternatively, these are patients who have had their ASR-XL Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
88944896|NCT01884558|Experimental|isavuconazole and metformin|Metformin single dose on days 1 and 8. Isavuconazole three times a day (TID) on Days 4 and 5 followed by isavuconazole once daily (QD) on Days 6-9.
88944897|NCT01884584|Experimental|Indocyanine green (ICG)|ICG will be administered by intravenous infusion over a 20 second period in a 2-8 hour time window before the time of completion of the surgical procedure.
88944898|NCT01884636|Experimental|isavuconazole and methotrexate|Methotrexate single dose on days 1 and 8. Isavuconazole three times a day (TID) on days 4 and 5 followed by isavuconazole once daily (QD) on days 6 - 9
88944899|NCT01884649||Group of Hashimoto thyroiditis patients|
88944900|NCT01884649||Healty control group|
88944901|NCT01884662|Experimental|Virtual walking|A 3D video of legs walking from a first person perspective have been developed in consultation with persons with SCI and virtual reality experts. Participants are provided with a 3D monitor and Blue Ray player for daily viewing of the tape for two weeks.
88944902|NCT01884662|Active Comparator|Wheeling tape|A 3D video was produced of legs in a wheelchair covering the identical conditions of the walking experimental video.
88944903|NCT01884701|Experimental|Intervention|Intervention
88944904|NCT01884714|Experimental|High fat/high calorie meal|All subjects are provided a high calorie (~1300kcal) and high fat (~60g fat) breakfast meal.
88944905|NCT01884727|Active Comparator|ASEA water|Subjects to consume 4-ounces of ASEA water at 9:00 am before breakfast and 4-ounces of ASEA water at 10:15 pm prior to bedtime. 24-h resting energy expenditure and RQ to be measured.
88944906|NCT01884727|Placebo Comparator|Salt water|Subjects to consume 4-ounces of salt water at 9:00 am before breakfast and 4-ounces of salt water at 10:15 pm prior to bedtime. 24-h resting energy expenditure and RQ to be measured.
88944907|NCT01884766||Epilepsy|All kind of epilepsy, including febrile seizures
88944908|NCT01884766||Control|children without seizures at presentation in the emergency but fever due to banal infections
88944909|NCT01884792|Placebo Comparator|Sitting Oral Glucose Tolerance Test|An OGTT is performed while the subject sits at their desk for the entire 2-hour period. 5 blood sugar measurements are taken and a 75g dextrose beverage is consumed following the first, baseline blood sugar reading. The blood sugar is then measured every 30 minutes up to 120 min.
88944910|NCT01884792|Experimental|Standing Oral Glucose Tolerance Test|The participant stands at their desk for the duration of the 2-hour blood sugar test. The same procedure is performed as in the sitting condition.
88944911|NCT01884792|Placebo Comparator|Sitting Continuous Glucose Monitor|A continuous blood glucose monitor is worn for 5 days while at work. In the sitting condition the participant only sits at their desk for the duration of the week. Blood sugar is monitored 4 times per day to calibrate the CGM and an accelerometer is worn to track physical activity.
88944912|NCT01884792|Experimental|Standing Continuous Glucose Monitor|Participants are instructed to stand intermittently for at least half of their work day during this 5 day period. Blood sugar is monitored and physical activity is tracked with an accelerometer.
88944913|NCT01884805|Other|Monocular Adaptive Optics Visual Simulator (AOVIS-I)|
88944914|NCT01884818|Experimental|Manipulation|Subjects will receive 6 manipulation treatments within 3 weeks period. The manipulated segments are determined individually in baseline assessment.
89501927|NCT01949246||CRT patients|Patients undergoing CRT device implantation
89501928|NCT01949246||Healthy patients|Healthy controls
88944915|NCT01884818|Sham Comparator|TNS for thoracic spine|6 TNS treatments at home for 20min in limited power of devices in three weeks period.
88944916|NCT01884831|Experimental|cell therapy|study of the efficacy of skin equivalent comprising living cells and skin biodegradable substrate for the treatment of skin lesions
88944917|NCT01884857|Active Comparator|'TOPROL-XL®' ER Tablets 50 mg|'TOPROL-XL®' ER Tablets 50 mg of Astrazeneca LP, USA
88944918|NCT01884857|Experimental|Metoprolol Succinate ER Tablets 50 mg|Metoprolol Succinate ER Tablets 50 mg of Ipca Laboratories Limited, India
88944919|NCT01884870|Other|Surgical Treatment|Silent Ureteral Stone - Surgical Treatment
88944920|NCT01884883|Other|Internal unicompartmental knee brace|
88944921|NCT01884896|Active Comparator|'TOPROL-XL®' ER Tablets 200 mg|'TOPROL-XL®' ER Tablets 200 mg of Astrazeneca LP, USA
88944922|NCT01884896|Experimental|Metoprolol Succinate ER Tablet 200 mg|Metoprolol Succinate ER Tablet 200 mg of Ipca Laboratories Limited, India
88944923|NCT01884909|Active Comparator|'TOPROL-XL®' ER Tablets 200 mg|'TOPROL-XL®' ER Tablets 200 mg of Astrazeneca LP, USA
88944924|NCT01884909|Experimental|Metoprolol Succinate ER Tablet 200 mg|Metoprolol Succinate ER Tablet 200 mg of Ipca Laboratories Limited, India
88944925|NCT01884935|Experimental|Natalizumab|300 mg intravenously (IV) every 4 weeks
88944926|NCT01884948|Active Comparator|Omegaven™|Omegaven™ (approval number:54750 Swissmedic)- 100ml intravenously. The first dose (Omegaven™ or placebo) is administered in the evening before surgery, the second dose at the beginning of anesthesia. The maximum infusion rate must be adjusted to bodyweight (0.5 ml Omegaven™/kg/hour).
88944927|NCT01884948|Placebo Comparator|NaCl 0.9%|100ml of saline is used as a placebo comparator and administered as described above.
89501929|NCT02232763|Experimental|Losartan|12 weeks of losartan or placebo with crossover to the other
88944928|NCT01884961|Experimental|arm A|"Boost of radiotherapy + high dose IL-2 treatment: Three daily doses boost radiotherapy at 6-12 Gy to at least 1, and up to a maximum of 5, metastatic fields, will be administrated on days -4 -3 -2 or -3 -2 -1 before the first and the third cycle of IL-2 (Interleukin 2). The first day of administration of IL-2 of each cycle is the day +1.~Treatment with IL-2 (dose 18 MIU/m2/day in 500cc by continuous IV (intravenous) infusion for 72 hours) will start on day +1 and will be administered every 3 weeks up to 4 cycles, than every 3-4 weeks for a further 2 cycles.~Patients will be evaluated every 8 weeks with computed tomography to determine the response, and every 3 months after completion of treatment until death."
88944929|NCT01884974||myeloproliferative disease|Patients with Myeloproliferative Diseases as specified under inclusion and exclusion criteria
88944930|NCT01884987||group one will receive non-GM1 conservative therapy|"Group one will receive conservative therapy such as hyperbaric therapy or corticosteroids therapy or wait and see policy"
88944931|NCT01885013|Experimental|Metformin + Myocet + Cyclophosphamide|"arm A : Metformin 1000 mg, 2 times daily per os*. Myocet 60 mg/m2, intravenous infusion, on day 1, every 21 days Cyclophosphamide 600 mg/m2, intravenous infusion, at day 1 every 21 days.~* During cycle 1, patients will assume only metformin from day 1 to day 13 and will begin chemotherapy from day 14. From day 1 to day 3, patients will assume Metformin 1000 mg once a day. Starting from day 4 patients will assume Metformin 1000 mg 2 times a day."
88944932|NCT01885013|Active Comparator|Myocet + Cyclophosphamide|arm B : Myocet 60 mg/m2, intravenous infusion, on day 1, every 21 days Cyclophosphamide 600 mg/m2, intravenous infusion, on day 1, every 21 days
88944933|NCT01885026|Experimental|eScreen|Web based self-monitoring of problematic alcohol and drug use, and Internet-based treatment for depression or anxiety
88944934|NCT01885026|Experimental|Control|Assessment only of alcohol and drug use and Internet-based treatment for depression or anxiety
88944935|NCT01885052|Placebo Comparator|1|Receives weekly assessment messages ONLY
88944936|NCT01885052|Active Comparator|2|Receives two week countdown messaging to quit date, and weekly assessment messages post quit date
88944937|NCT01885052|Active Comparator|3|Receives two week countdown messages to quit date, receives mulitiple messages per day post quit date with tips, encouragement and supportive messaging
88944938|NCT01885065|Experimental|Gel-based artificial saliva|Continuous oral intake of edible gel-based artificial saliva (30-50 ml/day) for four weeks
88944939|NCT01885091|Experimental|Kinerase|
88944940|NCT01885143||Artifact Correction|A minimum of 6 subjects will be recruited for the purpose of evaluating artifact correction
88944941|NCT01885143||Lossy Compression|A minimum of 6 subjects will be recruited for the purpose of evaluating lossy compression
88944942|NCT01885169||Cohort A|Participants with CF; Flumist®-naïve
88944943|NCT01885169||Cohort B|Siblings of Cohort A without CF; Flumist®-naïve
88944944|NCT01885169||Cohort C|Participants with CF; Flumist®-experienced
88944945|NCT01885221|Experimental|Multimedia Support Intervention|(a) access to a website providing the content of our supporter guidebook, supplemented with interactive components, video elements, and a supporters' forum, and (b) a mailed copy of our supporter guidebook
88944946|NCT01885221|No Intervention|Delayed Treatment Control|Access to the Multimedia Intervention after participant completes the final follow-up assessment
88944947|NCT01885234|Experimental|Aerobic exercise|Pregnant women with Gestational Diabetes and pregnant women with chronic hypertension will perform 50 minutes of aerobic exercise in a bicycle, 3 times a week
88944948|NCT01885234|Placebo Comparator|Stretch exercise|Pregnant women with Gestational Diabetes and pregnant women with chronic hypertension will perform 50 minutes of stretch exercise, once a week
88944949|NCT01885273|Experimental|Pressurized irrigation method|Cleansing wound with pressurized irrigation technique using a pressurized irrigation device.
88944950|NCT01885273|Active Comparator|Swabbing wound cleansing method|All patients in control group had wounds cleansed with swabbing technique using forceps and cotton wool (in sterile dressing pack), and received the 'standardized usual care'. Frequency of dressing change depended on the amount of exudates.
88944951|NCT01885312|Active Comparator|Tailored not adaptive based Intervention|Tailored Text Messaging - not adaptive in the moment and once a day intervention to reduce problem drinking
88944952|NCT01885312|Other|Ecological Momentary Assessment|Mobile Assessment only
88944953|NCT01885312|Experimental|Tailored Adaptive Text Messaging|Tailored Adaptive Text Messaging intervention to reduce problem drinking
88944954|NCT01885312|Active Comparator|Consequence based text messaging|Consequence based Text Messaging intervention to reduce problem drinking
88944955|NCT01885325|Experimental|Physical Activity Preschool Intervention|Preschools randomized to the multi-component physical activity preschool intervention received four major components: Move IN (physical education and other indoor activity programming), Move OUT (recess and structured outdoor activity), Move to Learn (Physical Activity in classroom, academic lessons), and enhancing the social environment to promote Physical Activity.
89201940|NCT00908193|Active Comparator|2|conventional coelioscopy
89464288|NCT05113966|Experimental|Trilaciclib + Sacituzumab Govitecan-hziy|During the Treatment Phase patients will receive trilaciclib + sacituzumab govitecan-hziy on days 1 & 8 of a 21 day cycle. Trilaciclib is administered first, followed by sacituzumab govitecan-hziy. Administer diluted trilaciclib solution as a 30-minute IV infusion to be completed within 4 hours prior to the start of sacituzumab govitecan-hziy.
88944956|NCT01885325|No Intervention|Control|The preschools in the control group did not receive the intervention
88944957|NCT01885338|Experimental|N-acetylcysteine (NAC)|Capsules containing N-acetylcysteine 600mg, with inactive ingredients of cellulose, L-leucine, and silica used as filler. Dosage is 2 capsules by mouth twice daily for 8 weeks.
88944958|NCT01885338|Placebo Comparator|Inactive placebo capsule|A placebo capsule is used that is identical to the active treatment but lacks NAC. The inactive ingredients in the placebo capsule are cellulose, L-leucine, and silica. Dose is 2 capsules by mouth twice daily for 8 weeks.
88944959|NCT01885351|Experimental|Phase II: MyCRCS+Prefs|"Patients who are identified by the IPHR as study participants will see an attractive link. In the Prefs arm, via question prompt lists, patients will first identify their CRCS preference using previously developed elicitation strategies.~Tailoring will be used to increase salience of information, motivation, communication, and action plans. We envision the Prefs+ arm in its entirety will be 5-7 minutes, but will depend on Phase I formative work. If the patient remains non-adherent, they will receive an e-mail reminder generated by the IPHR (specific text and frequency determined in Phase I). The Prefs content is identical to the preference portion of the Prefs+Barriers arm, which will allow us to assess the incremental benefit of addressing preferences only and the incremental benefit of addressing preferences and barriers."
88944960|NCT01885351|Experimental|Phase II: MyCRCS+Prefs+Barriers|"Patients who are identified by the IPHR as study participants will see an attractive link. In the Prefs+Barriers arm, via question prompt lists, patients will first identify their CRCS preference using previously developed elicitation strategies, and subsequently based on their test preference determine their top 3 test-specific barriers/concerns in real time.~Tailoring will be used to increase salience of information, motivation, communication, and action plans. We envision the Prefs+Barriers arm in its entirety will be 15-25 minutes, but will depend on Phase I formative work. If the patient remains non-adherent, they will receive an e-mail reminder generated by the IPHR (specific text and frequency determined in Phase I). The Prefs content is identical to the preference portion of the Prefs+Barriers arm, which will allow us to assess the incremental benefit of addressing preferences only and the incremental benefit of addressing preferences and barriers"
88944961|NCT01885351|No Intervention|Phase II: Usual Care|The IPHR will be programmed so that where the IPHR-CRCS would normally present patients, who based on their demographics and health conditions, with content advising them to seek CRCS and links to third-party sites, they would instead be randomized to receive the usual care (IPHR-CRCS).
88944962|NCT01885364|Placebo Comparator|Placebo & propofol|Pretreatment with normal saline before injection of propofol
88944963|NCT01885364|Experimental|esmolol 0.05 mg/kg & propofol|Pretreatment with esmolol 0.05 mg/kg before injection of propofol
88944964|NCT01885364|Experimental|esmolol 1 mg/kg & propofol|Pretreatment with esmolol 1 mg/kg before injection of propofol
88944965|NCT01885364|Active Comparator|remifentanil 0.35 ug/kg & propofol|Pretreatment with remifentanil 0.35 ug/kg before injection of propofol
88944966|NCT01885390|Experimental|Experimental: Group A|ROX Coupler + continuing standard antihypertensive medications
88944967|NCT01885403|Experimental|Respiratory Parameters Measurements|
88944968|NCT01885416|Active Comparator|high fat meal without dairy products|high fat meal without dairy products
89464289|NCT05105542|Experimental|11C-EMO - A Novel PET Radiotracer for Muscarinic M1 Receptor|Participants will undergo a single PET scan with [11C]EMO ≤ 20 mCi
89464290|NCT05082402|Experimental|All Participants|50 participants identified in the Northwestern Medicine Division of Vascular Surgery.
88944969|NCT01885416|Experimental|high fat meal with additional milk|high fat meal with additional milk
88944970|NCT01885416|Experimental|dairy product meal|dairy product meal
88944971|NCT01885429|Experimental|Positive Control|Group 1 (Positive(+) Control) will receive: 25g of whey protein. Positive Control
88944972|NCT01885429|Experimental|Negative Control|Group 2 (Negative(-) Control) will receive: 6.25g whey. Negative Control
88944973|NCT01885429|Experimental|Low Protein + Low Leucine Spike|Group 3 (Low Protein + Low Leucine Spike) will receive: 6.25g whey + low added leucine. Low Protein Low Leucine Spike
88944974|NCT01885429|Experimental|Low Protein + High Leucine Spike|Group 4 (Low Protein + High Leucine Spike) will receive: 6.25g whey + high added leucine. Low Protein High Leucine Spike
88944975|NCT01885429|Experimental|Low Protein + High Leucine + BCAA Spike|Group 5 (Low Protein + High Leucine + BCAA Spike) will receive: 6.25g whey + added branched-chain amino acids. Low Protein + High Leucine + BCAA Spike
88944976|NCT01885442|Experimental|In-bed leg cycle ergometry|
88944977|NCT01885455|Active Comparator|Usual Care Arm|Participants who are assigned to the usual care arm may receive the following services: complete staging work-up (CT/PET scan and possible mediastinoscopy), surgical consultation with a general or cardiothoracic surgeon, cardiac clearance and/or pulmonary function testing (if deemed necessary by the evaluating surgeon), surgical resection (wedge resection, lobectomy, pneumonectomy, or radiosurgery, as indicated by the size and location of the tumor), and adjuvant therapy (radiotherapy and/or chemotherapy, as determined by the intraoperative findings and pathology results).
88944978|NCT01885455|Experimental|Intervention Arm|"The PN will provide each patient with a copy of the NCI's What You Need to Know About Lung Cancer booklet and encourage them to re-contact his/her primary care physician (or the physician who diagnosed their probable/proven NSCLC) to discuss treatment options.~The PNs will provide patients with their contact information and brief patients on their role. The PNs will navigate study participants for up to 4 months (16 weeks, 112 days) after NSCLC diagnosis, until the patient is deemed ineligible for LDTCI (i.e., lung resection or SBRT) by their physician(s), until receipt of LDTCI, or death (whichever comes first).~During the EPDPN intervention period, PNs will contact each intervention group participant by telephone (or in-person) on weekly basis (at minimum)."
88944979|NCT01885481|Active Comparator|ESI-1|epidural steroid injection using dexamethasone
89501930|NCT02232763|Experimental|Placebo|12 weeks of losartan or placebo with crossover to the other
89501931|NCT03335371|Experimental|TTP399 400 mg|
89501932|NCT03335371|Placebo Comparator|Placebo|
89464291|NCT05077722|Experimental|AI Parent Child Interaction Therapy|Subjects enrolled in Parent Child Interaction Therapy (PCIT) will wear a Garmin smartwatch that will provided targeted messages during tantrums picked up by the Garmin devices that will instruct them on how to deescalate their child.
89464292|NCT05077722|Sham Comparator|Sham Biometric - Parent Child Interaction Therapy|Subjects enrolled in Parent Child Interaction Therapy will wear Garmin smartwatch and will receive only random messages throughout the day with various relaxation strategies such as reminders to practice deep breathing with their child.
89464293|NCT05071716|Experimental|Rifaximin SSD-40mg IR|
89464294|NCT05071716|Placebo Comparator|Placebo|
89464295|NCT05069558|Experimental|Investigational PFO Closure Device|PFO closure with the study Occlutech Flex II PFO device.
89464296|NCT05069558|Active Comparator|Standard of Care PFO Closure Device|PFO closure with either of the standard of care PFO occlusion devices; Amplatzer PFO Occluder or the Gore Cardioform PFO Occluder.
89464297|NCT05058274||Single arm|All participants
89464298|NCT05052801|Experimental|Bemarituzumab with mFOLFOX6|
89464299|NCT05052801|Active Comparator|Placebo with mFOLFOX6|
89464300|NCT05050916|Experimental|1/High Dose Vitamin D|Deficient women will be assigned to the Endocrine Society recommendation for deficiency, 50,000 IU/week.
88944980|NCT01885481|Experimental|ESI-2|epidural steroid injection using betamethasone
88944981|NCT01885494||15µg AFFITOPE® PD01A|Patients With Parkinson's Disease vaccinated with 4 injections of 15µg AFFITOPE® PD01A adsorbed to adjuvant during AFF008
88944982|NCT01885494||75µg AFFITOPE® PD01A|Patients With Parkinson's Disease vaccinated with 4 injections of 75µg AFFITOPE® PD01A adsorbed to adjuvant during AFF008
88944983|NCT01885494||Control group|Untreated control group
88944984|NCT01885507||Control phase (before)|Process of care and outcomes before the educational program
88944985|NCT01885507||Training phase (after)|"Process of care and outcomes after the educational program which recommends:~the use of tidal volume < 7 ml/kg and of a positive expiratory pressure = 6 to 8 cmH20 (centimeter of water)~extubation as soon as ventilatory weaning is associated with a glasgow coma scale equal or above 10 and cough"
88944986|NCT01885520|Experimental|fasting condition|eperisone SR administrated under fasting condition
88944987|NCT01885520|Active Comparator|Fed condition|eperisone SR administrated under fed condition
88944988|NCT01885533||Post-radioiodine medication|Anti-thyroid drugs
88944989|NCT01885533||Post-radioiodine medications|anti-thyroid drugs and thyroxine
88944990|NCT01885533||Post-radiodione medication|watchful monitoring
88944991|NCT01885546|Other|Enhanced meter feature usability|Home diabetes monitoring by patient using provided blood glucose monitoring system.
88944992|NCT01885572|Other|TiLOOP Bra|Treatment with TiLOOP Bra
88944993|NCT01885585||Patients with risk of VTE|Patients undergoing elective total hip replacement arthroplasty or elective total knee replacement arthroplasty and signed on the data release
88944994|NCT01885598||Nonvalvular Atrial Fibrillation patients with risk of Stroke|Patients undergoing elective total hip replacement arthroplasty or elective total knee replacement arthroplasty and signed on the data release
88944995|NCT01885611|Active Comparator|Multi-Drug Therapy (Novartis Ⓡ)|"Multi-Drug Therapy PB pack consists of 600 milligrams (mg) of rifampicin (NovartisⓇ) single dose once a month and 100mg of dapsone (NovartisⓇ) daily for six months (PB patients)~Multi-Drug Therapy MB pack consists of 600mg of rifampicin (NovartisⓇ), 300mg of clofazimine (NovartisⓇ) as a single dose monthly and 50mg of clofazimine (NovartisⓇ) and 100mg of dapsone (NovartisⓇ) daily for six months (MB patients)"
88944996|NCT01885611|Experimental|Virgin Coconut Oil (VCO) with MDT|"VCO 10 milliliters (mL) three times a day in addition to MDT of 600mg of rifampicin (NovartisⓇ) single dose once a month and 100mg of dapsone (NovartisⓇ) daily for a period of six months (PB patients)~VCO 10mL three times a day in addition to MDT of 600mg of rifampicin (NovartisⓇ), 300mg of clofazimine (NovartisⓇ) as a single dose monthly and 50mg of clofazimine (NovartisⓇ) and 100mg of dapsone (NovartisⓇ) daily or a period of six months (MB patients)"
88944997|NCT01885624|Experimental|TAB08|Single TAB08 i.v. infusion
88944998|NCT01885650|Experimental|Normal airway clearance|The patients usual airway clearance technique
88944999|NCT01885650|Experimental|Non-Invasive Ventilation|The addition of positive pressure via a non-invasive ventilator to the participants usual airway clearance technique
89201941|NCT00781560||1|patients being diagnosed as dyslipidemia but not receiving Crestor®
88945000|NCT01885663|Experimental|Umbilical cord blood therapy|Umbilical cord blood therapy
88945001|NCT01885676|Experimental|PRGF-Endoret|
88945002|NCT01885676|Placebo Comparator|Saline Solution|
88945003|NCT01885715|Placebo Comparator|Rocuronium-placebo|"At anesthetic induction, rocuronium 0.6 mg/kg will be injected for muscle relaxation.~During surgical procedure, we will monitor train of four (TOF) using nerve stimulator. When TOF ratio recover to 0.5, normal saline 5 ml will be injected. And we will measure time to take from TOF ratio 0.5 to 1.0"
88945004|NCT01885715|Active Comparator|Rocuronium-neostigmine 10 ㎍|"At anesthetic induction, rocuronium 0.6 mg/kg will be injected for muscle relaxation.~During surgical procedure, we will monitor train of four(TOF)using nerve stimulator. When TOF ratio recover to 0.5, neostigmine 10 ㎍/kg will be injected. And we will measure time to take from TOF ratio 0.5 to 1.0."
89201942|NCT00781560||2|hypercholesterolemia or mixed dyslipidemia and have been initiated treatment with Crestor®
89201943|NCT00926445||Preterm (BW < 1500 grams)|
89201944|NCT00926445||Critically ill term newborn|ventilation > 48 hours
89201945|NCT00926445||Healthy term newborn|
89201946|NCT00781716|Active Comparator|Cypher Stent|Cypher Sirolimus-Eluting Coronary Stent System
89201947|NCT00781716|Active Comparator|Endeavor Stent|Endeavor Zotarolimus-Eluting Coronary Stent System
89464301|NCT05050916|Placebo Comparator|2/Placebo|Sufficient women who will receive placebo instead of Vitamin D supplementation.
89464302|NCT05042206|Experimental|Cellgram-CKD|"Subjects receive a safety evaluation at 1 month, 3 months, 6 months, 9 months and 12 months after intravenous infusion of Cellgram-CKD 10mL at intervals of 2 weeks (14 days) 3 times.~In the case of Cellgram-CKD, a milky white cell suspension solution is filled in a colorless and transparent plastic syringe, and the syringe tip is fixed with an obturator."
89464303|NCT05028621|Experimental|Genomic analysis|When a participant's disorder was diagnosed, blood or tissue specimen was collected. A part of the tissue or blood will be sent to an outside company, Tempus, to be tested for specific genetic changes and the results will be sent back to participants' physician.
89464304|NCT05020249|Experimental|Bimekizumab arm|Study participants randomized to this arm will receive bimekizumab (BKZ; UCB4940) at pre-specified time points during the Treatment Period.
89464305|NCT05020249|Placebo Comparator|Placebo arm|Study participants randomized to this arm will receive placebo (PBO) at pre-specified time points during the Treatment Period.
88945005|NCT01885715|Active Comparator|Rocuronium-neostigmine 20 ㎍|"At anesthetic induction, rocuronium 0.6 mg/kg will be injected for muscle relaxation.~During surgical procedure, we will monitor train of four(TOF)using nerve stimulator. When TOF ratio recover to 0.5, neostigmine 20 ㎍/kg will be injected. And we will measure time to take from TOF ratio 0.5 to 1.0"
88945006|NCT01885715|Active Comparator|Rocuronium-neostigmine 40 ㎍|"At anesthetic induction, rocuronium 0.6 mg/kg will be injected for muscle relaxation.~During surgical procedure, we will monitor train of four(TOF)using nerve stimulator. When TOF ratio recover to 0.5, neostigmine 40 ㎍/kg will be injected. And we will measure time to take from TOF ratio 0.5 to 1.0"
88945007|NCT01885715|Placebo Comparator|Cisatracurium-placebo|"At anesthetic induction, cisatracurium 0.15 mg/kg will be injected for muscle relaxation.~During surgical procedure, we will monitor train of four(TOF)using nerve stimulator. When TOF ratio recover to 0.5, normal saline 5 ml will be injected. And we will measure time to take from TOF ratio 0.5 to 1.0"
88945008|NCT01885715|Active Comparator|Cisatracurium-neostigmine 10 ㎍|"At anesthetic induction, cisatracurium 0.15 mg/kg will be injected for muscle relaxation.~During surgical procedure, we will monitor train of four(TOF)using nerve stimulator. When TOF ratio recover to 0.5, neostigmine 10 ㎍/kg will be injected. And we will measure time to take from TOF ratio 0.5 to 1.0"
88945009|NCT01885715|Active Comparator|Cisatracurium-neostigmine 20 ㎍|"At anesthetic induction, cisatracurium 0.15 mg/kg will be injected for muscle relaxation.~During surgical procedure, we will monitor train of four(TOF)using nerve stimulator. When TOF ratio recover to 0.5, neostigmine 20 ㎍/kg will be injected. And we will measure time to take from TOF ratio 0.5 to 1.0"
88945010|NCT01885715|Active Comparator|Cisatracurium-neostigmine 40 ㎍|"At anesthetic induction, cisatracurium 0.15 mg/kg will be injected for muscle relaxation.~During surgical procedure, we will monitor train of four(TOF)using nerve stimulator. When TOF ratio recover to 0.5, neostigmine 40 ㎍/kg will be injected. And we will measure time to take from TOF ratio 0.5 to 1.0"
88945011|NCT01885728|Active Comparator|Arginine rich nutritional supplement|237 ml of an arginine rich nutritional supplement 4 times a day for the five days preceding surgery.
88945012|NCT01885728|No Intervention|No nutritional supplement|No specific nutritional requirements have to be met in this group.
88945013|NCT01885741|Experimental|IPBS|
88945014|NCT01885754||Lung cancer patient with cachexia|Muscle lumbar area < 55cm2/m2 for men and < 39 cm2/m2 for women
88945015|NCT01885754||Lung cancer patients without cachexia|Muscle lumbar area over 55cm2/m2 for men and 39 cm2/m2 for women
88945016|NCT01885780|Experimental|Astigmatic keratotomy|
88945017|NCT01885793||Cuffed endotracheal tube|Surgical patients who require endotracheal intubation with a cuffed endotracheal tube (ETT).
88945018|NCT01885806|Experimental|Repetitive TMS|"Patients will receive 10 consecutive sessions of repetitive transcranial magnetic stimulation with the following protocol:~Frequency: 10 Hz Intensity: 90% motor limiar Session duration: 16 minutes (20 sequencies of 6 seconds of stimulation followed by intervals of 30 seconds); Localization: Left pre-frontal dorsolateral cortex;"
88945019|NCT01885806|Sham Comparator|Sham TMS|Patients will receive 10 consecutive sessions of sham transcranial magnetic stimulation following the same protocol as the intervention arm, but with no magnetic stimulation of the brain.
88945020|NCT01885819|Experimental|Treatment|Autologous stromal vascular fraction cells
88945021|NCT01885832|Experimental|Treatment|In the treatment arm, autologous stromal vascular fraction (SVF) will be injected into joints of 20 patients with grade 2, 3, or 4 radiographic OA severity.
88945022|NCT01885845|Experimental|BRASSS-V drape|Immediately after delivery and cord clamping, blood measurement will begin. The calibrated delivery drape should be placed under the buttocks of the woman and tied around the woman's waist with the funnel portion hanging down between her legs. Blood loss will be measured for at least one hour or, if bleeding continues after one hour, until active bleeding has stopped.
89464306|NCT05007106|Experimental|Pembrolizumab/Vibostolimab Co-Formulation|Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous (IV) infusion every 3 weeks (Q3W) up to 35 cycles.
89464307|NCT05007106|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg via IV infusion Q3W up to 35 cycles.
89464308|NCT05007106|Experimental|Pembrolizumab/Vibostolimab Co-Formulation + Lenvatinib (Endometrial Cancer Cohort)|Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous IV infusion Q3W up to 35 cycles, plus lenvatinib 20 mg once daily (qd) until meeting discontinuation criteria.
89501933|NCT04294784|Experimental|Nab-P/PD-1|Patients in this arm receive albumin-bound paclitaxel and SHR-1210 (PD-1 inhibitor) thepary.
88945023|NCT01885845|Experimental|Indirect weight method|"Just after delivery and cord clamping, a sheet with plastic backing will be placed under the buttocks of the woman. A basin will be placed directly under her on a small shelf on the delivery table. Blood loss will be measured for at least one hour or, if bleeding continues after one hour, until active bleeding has stopped.~After bleeding has stopped, all gauze pieces and mops will be counted and then placed in the collection basin. The basin will be placed on the scale and weighed. The weight of the blood will be assessed by subtracting the weight of the basin, gauzes and mops from the total weight of the soaked materials assuming that one gram is equivalent to 1 ml."
88945024|NCT01885858|Other|Sequence 1|Clinics receive first the indigenous and then the mestizo profile.
88945025|NCT01885858|Other|Sequence 2|Clinics receive first the mestizo and then the indigenous profile.
88945026|NCT01885884|Experimental|Supportive Care Intervention|Monthly (minimum) patient & caregiver visits with a Supportive Care physician, embedded within their standard oncological care (through collaboration with oncology providers).
88945027|NCT01885884|No Intervention|Usual Care|Participants will receive standard oncology care from their oncology providers.
89464309|NCT05007106|Experimental|Pembrolizumab/Vibostolimab Co-Formulation + Lenvatinib (Hepatocellular Cancer Cohort)|Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous IV infusion Q3W up to 35 cycles, plus lenvatinib 12 mg (body weight [BW] ≥60 kg) or lenvatinib 8 mg (BW <60 kg) qd until meeting discontinuation criteria.
89464310|NCT05007106|Experimental|Pembrolizumab/Vibostolimab + 5-Fluorouracil + Cisplatin|Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion Q3W, plus 5-fluorouracil (5-FU), plus Cisplatin as background therapy.
89464311|NCT05007106|Experimental|Pembrolizumab/Vibostolimab Co-Formulation + Paclitaxel|Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion Q3W up to 35 cycles, plus paclitaxel as background therapy until meeting discontinuation criteria.
89464312|NCT05007106|Experimental|Pembrolizumab/Vibostolimab Co-Formulation + Gemcitabine/Cisplatin|Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion Q3W up to 35 cycles, plus gemcitabine (until disease progression or unacceptable toxicity) and cisplatin (up to 8 cycles) as background therapy.
89464313|NCT05007106|Experimental|Pembrolizumab/Vibostolimab Co-Formulation+ Carboplatin/Paclitaxel/Bevacizumab|Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion Q3W up to 35 cycles, plus carboplatin, paclitaxel, and bevacizumab as background therapy.
89464314|NCT05007106|Experimental|Pembrolizumab/Vibostolimab Co-Formulation + Capecitabine/Oxaliplatin|Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion Q3W up to 35 cycles, plus capecitabine and oxaliplatin as background therapy.
89464315|NCT05000502|Experimental|Home-based aerobic exercise training|home-based aerobic exercise condition will receive a fitness bracelet (with heart rate measurement capability) and weekly exercise counseling from an exercise trainer (i.e., exercise physiologist) by videoconference. The weekly counseling will be guided by the fitness bracelet data (both participant and exercise trainer will share the same log in information). The aerobic exercise progression will gradually increase duration and intensity of aerobic exercise with the goal of improving cardiorespiratory fitness.
89464316|NCT05000502|Active Comparator|Home-based standard attention flexibility/toning control|Home-based standard attention flexibility/toning control will receive light resistance bands, stretching/toning log book, and weekly videoconference counseling from an exercise trainer.
89464317|NCT04998851|Experimental|Women with CIS or MS|Lactating women with CIS or MS (in line with the locally approved indications) who decided together with their treating physician to continue on, or start treatment with, OCREVUS (ocrelizumab) post-partum. Women resuming treatment with ocrelizumab post-partum will be included only if the last exposure to ocrelizumab occurred more than 3 months before the last menstrual period to exclude any interference between fetal exposure and exposure via lactation.
89464318|NCT04991402||Pregnant women living with HIV initiating Dolutegravir (DTG) in pregnancy (iDTG)|Pregnant women living with HIV initiating DTG-based ART in pregnancy at the 1st visit
89464319|NCT04991402||Pregnant women living with HIV already on DTG-based ART prior to pregnancy (cDTG)|Pregnant women living with HIV already on DTG-based ART prior to enrollment and continuing DTG use through pregnancy
89464320|NCT04991402||HIV uninfected pregnant women|Pregnant women not living with HIV
89464321|NCT04989218|Experimental|Novel combination of chemotherapy and immunotherapy|"This study has one arm. All enrolled patients will receive a combination of a platinum based chemotherapy regimen (gemcitabine and cisplatin) and a combination of two immune check point inhibitors, anti- CTLA4 (Tremelimumab) and anti PDL-1 (durvalumab).~Gemcitabine will be administered (gemzar) intravenously, 1000mg/m2 on Day 1 and Day 8 of a 21 day cycle for up to 4 cycles. Cisplatin (Platinol) will be administered intravenously, 25mg//m2 on Day 1 and Day 8 of a 21 day cycle for up to 4 cycles.~Tremelimumab will be administered intravenously, 300mg flat dose, on Day 1 of cycle 1 only. Durvalumab will be administered intravenously 1500mg on Day 1 of a 21 day cycle for 4 cycles."
89464322|NCT04989127||group 1|platelet-rich fibrin placed into the socket of the extracted tooth.+ Augmentin 1 gr tablet prescribed 3 times a day
89464323|NCT04989127||group 2|platelet-rich fibrin + 0.5 ml amoklavin I.V. 1.2 gr placed into the socket of the extracted tooth.
89464324|NCT04989127||group 3|platelet-rich fibrin placed into the socket of extracted tooth + Clin 150 mg capsule prescribed 4 times a day
89464325|NCT04989127||group 4|platelet-rich fibrin + 0.5 ml Clin 600 mg/4 ml IM/IV, 0.5 ml placed into the socket of the extracted tooth.
89464326|NCT04989127||control group|platelet-rich fibrin placed into the socket of extracted tooth and no antibiotic is prescribed.
89464327|NCT04981795||1|Group 1: Racial and ethnic minority patients (at least 50 patients)
89464328|NCT04981795||2|Group 2: Non Hispanic White (NHM) patients (at least 50 patients)
89501934|NCT04294784|Active Comparator|Nab-P|Patients in this arm receive albumin-bound paclitaxel single-agent chemotherapy.
88945028|NCT01885923|Active Comparator|20% antisychotic dose increase in prodromes|Antipsychotic dose increase upon prodromes occurence detected by Device- ITAREPS system. All antipsychotics currently registered in Czech Republic will be allowed in this study. All patients will remain on antipsychotic treatment adjusted prior enrollment, so that dose adjustment will be based on their ordinary medication. Participants will be instructed to complete the 10-item EWS Questionnaire upon SMS request sent automatically weekly to their mobile phones. EWSQ detects proportional worsening of the symptoms compared to the last week's score of the questionnaire. Individual EWSQ scores will be sent by participants back to the ITAREPS system as a SMS. If the total score exceeds the given score threshold, an immediate ALERT would be declared and announced to the investigator as an e-mail message and a therapeutic intervention is requested. After detecting the early warning signs by ITAREPS, an immediate 20% increase in the dose of antipsychotic will be required.
88945029|NCT01885923|No Intervention|Treatment as usual|In the control group (treatment-as-usual) participants will not be enrolled in the ITAREPS system.
88945030|NCT01885962|No Intervention|Treatment as Usual (TAU)|Participants in this group engage in typical rehabilitation and perform usual skin care routine.
88945031|NCT01885962|Experimental|TAU + iSHIFTup|Participants in this group engage in typical rehabilitation and use iSHIFTup, Internet Skin Health Intervention for Targeted Ulcer Prevention. Participants are instructed to perform program recommendations to engage in preventive skin care behaviors.
89018076|NCT05380973|Experimental|fiber reinforced resin composite|"Short fiber resin composite (SFRC) (Ever X Posterior, GC, Japan) The material will be applied according to manufacturer instructions. A thin layer of flowable resin composite will be applied prior placing the short fiber reinforced composite, then SFRC (Ever X Posterior, GC, Tokyo, Japan) will be injected in bulk, and light cured for 20 seconds, nanohybrid resin composite will be placed to the rest of the cavity incrementally.~Polyethylene ribbon fiber (Ribbond Inc., Seattle, WA, USA) The material will be applied according to manufacturer instructions. After application of a thin layer of the flowable resin composite to the cavity, a layer of Polyethylene ribbon fiber on the unpolymerized flowable composite will be condensed with a plugger and polymerized for 20 seconds then, nanohybrid resin composite will be placed to the rest of the cavity incrementally."
89018077|NCT05380973|Active Comparator|Nanohybrid resin composite|A thin layer of flowable composite will be applied then nanohybrid resin composite will be applied to the rest of the cavity using the conventional incremental technique according to manufacturer instructions.
89018078|NCT05380739|Active Comparator|In-Person, MCI|Participants diagnosed with MCI will undergo 10 sessions of WM training in person.
89464329|NCT04976634|Experimental|Arm 1: Pembrolizumab + Belzutifan + Lenvatinib|Participants will receive pembrolizumab 400 mg PLUS belzutifan 120 mg PLUS lenvatinib 20 mg (For HCC: 8 mg [body weight <60kg] or 12 mg [body weight ≥ 60 kg]). Pembrolizumab will be administered via intravenous (IV) infusion once every 6 weeks (Q6W) for a maximum of 18 doses (approximately 2 years). Belzutifan and lenvatinib will be administered orally once daily (QD) until progressive disease or discontinuation.
89464330|NCT04976634|Experimental|Arm 2: Pembrolizumab + Lenvatinib|Participants with IO resistant ESCC will receive pembrolizumab 400 mg PLUS lenvatinib 20 mg. Pembrolizumab will be administered via intravenous (IV) infusion once every 6 weeks (Q6W) for a maximum of 18 doses (approximately 2 years). Lenvatinib will be administered orally once daily (QD) until progressive disease or discontinuation.
89464331|NCT04976192|Experimental|TEV-45779-300 mg Main Treatment period|TEV-45779 (Omalizumab) injection 150 mg/mL pre-filled syringe administered twice (total dosage 300 mg) at week 0, 4, 8
89464332|NCT04976192|Active Comparator|Xolair-300 mg Main Treatment Period|XOLAIR (omalizumab) injection 150 mg/mL pre-filled syringe administered twice (total dosage 300 mg) at week 0, 4, 8
89464333|NCT04976192|Experimental|TEV-45779-150 mg Main Treatment period|TEV-45779 (Omalizumab) injection 150 mg/mL pre-filled syringe administered with one placebo injection at week 0, 4, 8
89464334|NCT04976192|Active Comparator|Xolair-150 mg Main Treatment Period|XOLAIR (omalizumab) injection 150 mg/mL pre-filled syringe administered with one placebo injection at week 0, 4, 8
89464335|NCT04976192|Experimental|TEV-45779-300 mg Main / TEV45779-300 mg Transition Period|TEV-45779 (Omalizumab) injection 150 mg/mL pre-filled syringe administered twice (total dosage 300 mg) at week 12,16,20 in patients that were randomized to TEV-45779-300 mg in the Main Treatment period.
89464336|NCT04976192|Experimental|Xolair-300 mg Main / TEV45779-300 mg Transition Period|TEV-45779 (Omalizumab) injection 150 mg/mL pre-filled syringe administered twice (total dosage 300 mg) at week 12,16,20 in patients that were randomized to Xolair-300 mg in the main treatment period.
89464337|NCT04976192|Active Comparator|Xolair-300 mg Main / Xolair-300 mg Transition Period|XOLAIR (omalizumab) injection 150 mg/mL pre-filled syringe administered twice (total dosage 300 mg) at week 12,16,20 in patients that were randomized to Xolair-300 mg in the main treatment period.
89464338|NCT04976192|Experimental|TEV-45779-150 mg Main / TEV-45779-150 mg Transition Period|TEV-45779 (Omalizumab) injection 150 mg/mL pre-filled syringe administered with one placebo injection at week 12,16,20 in patients that were randomized to TEV-45779-150 mg in the main treatment period.
89464339|NCT04976192|Experimental|Xolair-150 mg Main / TEV-45779-150 mg Transition Period|TEV-45779 (Omalizumab) injection 150 mg/mL pre-filled syringe administered with one placebo injection at week 12,16,20 in patients that were randomized to XOLAIR-150 mg in the main treatment period.
89464340|NCT04976192|Active Comparator|Xolair-150 mg Main / Xolair-150 mg Transition Period|XOLAIR (omalizumab) injection 150 mg/mL pre-filled syringe administered with one placebo injection at week 12,16,20 in patients that were randomized to XOLAIR -150 mg in the main treatment period.
89464341|NCT04974554|Experimental|FIT Families|1. FIT Families is a 6 month comprehensive multicomponent family-based behavioral intervention delivered by Community Health Workers (CHWs). FIT Families integrates home-based service delivery, Motivational Interviewing (MI; intrinsic motivation), Cognitive Behavior Skills Treatment (CBST; skills acquisition), supervised physical activity (PA), and Contingency Management (CM; extrinsic motivation). Sessions occur twice weekly for the first three months, and weekly for the second three months.
89464342|NCT04974554|Active Comparator|Home-Based Family Support|2. Home-based Family Support (HBFS). Adolescents and their primary caregiver randomly assigned to HBFS will receive 6 months of weekly, home-based, client-centered, non-directive supportive family counseling.
89464343|NCT04971161|Experimental|allo-APZ2-CVU (dose group 1: 1 x 10e6 cells/cm²)|Application of IMP on patients wound
89464344|NCT04971161|Placebo Comparator|Placebo|Application of IMP on patients wound
89464345|NCT04971161|Experimental|allo-APZ2-CVU (dose group 2: 3 x 10e6 cells/cm²)|Application of IMP on patients wound
89464346|NCT04971161|Experimental|allo-APZ2-CVU (dose group 3: 6 x 10e6 cells/cm²)|Application of IMP on patients wound
89464347|NCT04961164|Experimental|Resistant Potato Starch|15g RPS mixed with water will be consumed twice per day during intervention
89501935|NCT02262559|Experimental|BIBR 277 tablet|
89464348|NCT04961164|Placebo Comparator|Corn Starch|15 g corn starch mixed with water will be consumed twice per day during intervention
89464349|NCT04960709|Experimental|Durvalumab + Tremelimumab + Enfortumab vedotin|Participants will receive 3 preoperative 21-day cycles of Durvalumab + Tremelimumab + Enfortumab Vedotin, followed by radical cystectomy, followed by 1 cycle of postoperative Tremelimumab and 9 cycles of Durvalumab. Each postoperative cycle is 28 days.
89464350|NCT04960709|Experimental|Durvalumab + Enfortumab vedotin|Participants will receive 3 preoperative 21-day cycles of Durvalumab + Enfortumab Vedotin, followed by radical cystectomy, followed by 9 cycles of Durvalumab. Each postoperative cycle is 28 days.
89464351|NCT04960709|Active Comparator|Cystectomy with or without approved Adjuvant Therapy.|Participants may receive SoC (nivolumab approved as adjuvant treatment for MIBC based on high risk criteria) per approved label in the country OR Participants receive standard of care surgery (radical cystectomy) alone.
89464352|NCT04957719|Experimental|Selatogrel|Study treatment administration may occur at any time between the randomization visit and the final study visit when the participant experiences symptoms suggestive of an acute myocardial infarction. Study treatment administration triggers protocol pre-defined assessments or visits.
89464353|NCT04957719|Placebo Comparator|Placebo|Study treatment administration may occur at any time between the randomization visit and the final study visit when the participant experiences symptoms suggestive of an acute myocardial infarction. Study treatment administration triggers protocol pre-defined assessments or visits.
89464354|NCT04945772|Experimental|MCO-010- High Dose|Participants receive 1.2E11gc/eye of MCO-010
89464355|NCT04945772|Experimental|MCO-010- Low Dose|Participants receive 0.9E11gc/eye of MCO-010
88945032|NCT01885988|Active Comparator|Nebivolol|Nebivolol 5, 10 or 20 mg tablet, oral, daily for 3 months. Nebivolol dosage will be titrated per blood pressure results.
88945033|NCT01885988|Placebo Comparator|Sugar pill|Sugar pill 5, 10 or 20 mg tablet, orally, daily. Sugar pill dosage will be titrated per blood pressure results.
88945034|NCT01886001|Experimental|Povidone-Iodine (Betadine)|Umbilical stump care. Povidone-Iodine, USP, Swabstick Singles, applied once a day to cord stump while umbilical line(s) are in place
88945035|NCT01886001|Experimental|Chlorhexidine|Umbilical stump care. ChloraPrep® Chlorhexidine Gluconate 2% w/v; 70% Isopropyl Alcohol v/v Swabstick Single, applied once a day to cord stump while umbilical line(s) are in place
88945036|NCT01886001|Experimental|Pluronic|Umbilical stump care. Pluronic gel - (F68, Polymyxin, Nystatin, Nitrofurantoin )applied once a day to cord stump while umbilical line(s) are in place
88945037|NCT01886001|Sham Comparator|Control (no application)|Control arm, no product is applied, which is standard of care.
88945038|NCT01886014|Experimental|oxytocin|application of intranasal oxytocin 40IE
88945039|NCT01886014|Placebo Comparator|placebo|"application of intranasal saline~Both sprays (saline/oxytocin) are delivered in identical containers manufactured by the University pharmacy to assure blinding."
88945040|NCT01886027|Experimental|Emotional Awareness and Expression|Emotional awareness and expression training (EAET) is an emotional processing intervention.
88945041|NCT01886027|Active Comparator|Relaxation|Relaxation training will teach patients different relaxation training skills.
88945042|NCT01886027|No Intervention|Wait-list control|Standard medical care until the 3-month follow-up is completed
88945043|NCT01886040||cases with endometrial cancer|
88945044|NCT01886053|Active Comparator|Ertapenem|
88945045|NCT01886053|Experimental|Faropenem（low-dose group)|
88945046|NCT01886053|Experimental|Faropenem（high dose group）|
88945047|NCT01886079|Experimental|Dexmedetomidine group|
88945048|NCT01886079|Placebo Comparator|Saline group|
88945049|NCT01886092|Active Comparator|Active rTMS1|Combined low frequency frontal and temporal repetitive transcranial magnetic stimulation of left primary auditory cortex and left dorsolateral prefrontal cortex
88945050|NCT01886092|Active Comparator|Active rTMS2|Temporal low frequency repetitive transcranial magnetic stimulation of left primary auditory cortex
88945051|NCT01886092|Active Comparator|Active rTMS3|Frontal low frequency repetitive transcranial magnetic stimulation of left dorsolateral prefrontal cortex
88945052|NCT01886092|Sham Comparator|Sham Condition|Combined low frequency frontal and temporal repetitive transcranial magnetic stimulation of left primary auditory cortex and left dorsolateral prefrontal cortex
88945053|NCT01886118|Experimental|Autologous Endometrial Co-Culture|The embryos will be transferred to Endocell co-culture media for Autologous Endometrial Co-Culture between day 2 and day 5.
88945054|NCT01886118|Active Comparator|Conventional media culture|Patients in this arm will have their embryos cultured in conventional media
88945055|NCT01886131|Experimental|Synchronised video-polysomnography|
88945056|NCT01886144||Knee OA|People with knee OA of one knee
88945057|NCT01886157|Active Comparator|Corticosteroid injection|Standard corticosteroid injection.
88945058|NCT01886157|Experimental|Corticosteroid Injection and Trigger Splint|Corticosteroid Injection + Trigger Splint + Education + Home Exercises
89464356|NCT04945772|Sham Comparator|Sham Injection|Participants receive sham injection
89464357|NCT04939064||ART Infertile|Women that are part of a couple diagnosed with unexplained infertility that conceived on the first embryo transfer (ET) attempt
89464358|NCT04939064||Early Implantation Failure (EIF)|Infertility defined by a failure to conceive after: a) three or more failed transfers of high-quality blastocyst(s) (grade 3BB or higher); or b) two or more transfers of euploid blastocyst
89464359|NCT04939064||Early Pregnancy Failure (EPF)|defined by two or more biochemical pregnancies after transfer of a high-quality or euploid blastocyst with a positive hCG 12 days after ET but without subsequent clinical signs of pregnancy
89464360|NCT04939064||Normal Fertile|Women with proven parity based on spontaneous conception without fertility treatment or prior diagnosis of infertility, normal uncomplicated pregnancy, birth of at least one healthy baby
89464361|NCT04939064||Recurrent Pregnancy Loss (RPL)|defined as the loss of two or more pregnancies after transfer of a high-quality or euploid blastocyst with a positive HCG 12 days after ET and subsequent clinical signs of pregnancy
89501936|NCT02262559|Active Comparator|BIBR 277 capsule|
89464362|NCT04914845|Active Comparator|De-escalation Cohort; 20mg|For the purposes of dose escalation decisions, a standard 3+3 dose escalation design will be used.The initial cohort, Cohort 1, will consist of 3 enrolled patients who will be treated at 30 mg. If the MTD is exceeded at cohort 1, de-escalation to cohort 0 (20 mg) will occur. If the MTD is not exceeded in cohort 1, dose escalation will continue based on a standard 3+3 design at the dose levels.
89464363|NCT04914845|Active Comparator|Cohort 1; 30 mg|The initial cohort, Cohort 1, will consist of 3 enrolled patients who will be treated at 30 mg.
89464364|NCT04914845|Active Comparator|Cohort 2; 40mg|Dose escalation to 40 mg after initial cohort (Cohort 1) after a minimum of 1 cycle of treatment, defined as receiving ≥75% of KPT-9274 doses during Cycle 1 (e.g., ≥9 of 12 doses in the 3 doses/week schedule), or have a DLT within the first cycle of treatment to be evaluable for dose escalation decisions.
89464365|NCT04914845|Active Comparator|Cohort 3; 60mg|Dose escalation to 60 mg after initial cohort (Cohort 1) after a minimum of 1 cycle of treatment, defined as receiving ≥75% of KPT-9274 doses during Cycle 1 (e.g., ≥9 of 12 doses in the 3 doses/week schedule), or have a DLT within the first cycle of treatment to be evaluable for dose escalation decisions.
89464366|NCT04914845|Active Comparator|Cohort 4; 80mg|Dose escalation to 80 mg after initial cohort (Cohort 1) after a minimum of 1 cycle of treatment, defined as receiving ≥75% of KPT-9274 doses during Cycle 1 (e.g., ≥9 of 12 doses in the 3 doses/week schedule), or have a DLT within the first cycle of treatment to be evaluable for dose escalation decisions.
89464367|NCT04914845|Active Comparator|Cohort 5; 100mg|Dose escalation to 100 mg after initial cohort (Cohort 1) after a minimum of 1 cycle of treatment, defined as receiving ≥75% of KPT-9274 doses during Cycle 1 (e.g., ≥9 of 12 doses in the 3 doses/week schedule), or have a DLT within the first cycle of treatment to be evaluable for dose escalation decisions.
89464368|NCT04901208|Active Comparator|Users of Juul|Individuals who use Juul devices to vape nicotine
89464369|NCT04901208|No Intervention|Controls|Healthy non-smokers
89464370|NCT04896008|Placebo Comparator|Placebo plus background PAH therapy|Placebo administered subcutaneously (SC) every 21 days plus background PAH therapy
89464371|NCT04896008|Experimental|Sotatercept plus background PAH therapy|Sotatercept at a starting dose of 0.3 mg/kg, with a target dose of 0.7 mg/kg, SC every 21 days plus background PAH therapy
89464372|NCT04887831|Active Comparator|Platinum-based chemotherapy followed by avelumab maintenance therapy|Gemcitabine (1000 mg/m2) + Cisplatin (70 mg/m2) or Carboplatin (AUC 4.5) followed by Avelumab (800 mg)
89464373|NCT04887831|Experimental|Trilaciclib plus platinum-based chemotherapy followed by avelumab maintenance therapy|Trilaciclib (240 mg/m2) + Gemcitabine (1000 mg/m2) + Cisplatin (70 mg/m2) or Carboplatin (AUC 4.5) followed by Trilaciclib (240 mg/m2) + Avelumab (800 mg)
89464374|NCT04880239|Active Comparator|Sacralcolpopexy with posterior colpoperineorrhaphy|
89464375|NCT04880239|No Intervention|Sacralcolpopexy without posterior colpoperineorrhaphy|
89464376|NCT04879160||1/ Cohort 1A|Clinician raters familiar with NF1
89464377|NCT04879160||2/ Cohort 1B|Clinician raters without specific NF1 familiarity
89464378|NCT04879160||3/ Cohort 2A|Non-clinician raters familiar with NF1
89464379|NCT04879160||4/ Cohort 2B|Non-clinician raters without specific NF1 familiarity
89464380|NCT04879160||5/ Cohort 3|Subjects with NF1
88945059|NCT01886170|No Intervention|Hemoglobin A1C|The arms apply to the second phase of the study. This is the control arm. Participants will receive information regarding their diabetes control using the hemoglobin A1C value (standard medical information)
89464381|NCT04877522|Experimental|Asciminib single agent group|Participants with CML or ALL, from Novartis sponsored asciminib studies, including but not limited to ABL001A2301, ABL001A2302, ABL001X2101, ABL001A2202, ABL001AUS04 and ABL001AUS08 studies, that were receiving asciminib
89464382|NCT04877522|Other|Bosutinib single agent group|Participants with CML-CP, from Novartis sponsored asciminib study ABL001A2301, that were receiving bosutinib
88945060|NCT01886170|Experimental|Experimental Format #1|In phase II of the study, participants in this arm will receive information about their current diabetes control conveyed using experimental format #1. The experimental formats will be determined based on the results from Phase I of the study.
89464383|NCT04877522|Experimental|Bosutinib-asciminib switch group|Participants with CML-CP, from Novartis sponsored asciminib study ABL001A2301 that were receiving bosutinib treatment and switched to asciminib when entering this study or during the course of this study
89464384|NCT04877522|Experimental|Asciminib in combination with imatinib group|Participants with CML from Novartis sponsored asciminib studies ABL001E2201 or CABL001X2101 that were receiving asciminib combined with imatinib
89464385|NCT04877522|Experimental|Asciminib in combination with nilotinib group|Participants with CML or ALL from Novartis sponsored asciminib studies ABL001E2201or CABL001X2101 that were receiving asciminib combined with nilotinib
88945061|NCT01886170|Experimental|Experimental Format #2|In phase II of the study, participants in this arm will receive information about their current diabetes control conveyed using experimental format #2. The experimental formats will be determined based on the results from Phase I of the study.
88945062|NCT01886183|Experimental|Virtual Reality Training|The virtual reality training will be done by experimental group with ten games of Nintendo Wii Fit.
89464386|NCT04877522|Other|Imatinib single agent group|Participants with CML-CP, from Novartis sponsored asciminib study ABL001E2201 that were receiving imatinib
88945063|NCT01886183|Active Comparator|Control group: Physical Therapy|The Control Group will be trained by conventional Physical Therapy exercises.
88945064|NCT01886196|Experimental|Non-steroidal anti-inflammatory drug|ibuprofen after exercise training sessions (400 mg, 3 times per week for 9 months)
88945065|NCT01886196|Placebo Comparator|placebo|placebo after exercise training sessions(3 times per week for 9 months)
89464387|NCT04877522|Other|Nilotinib single agent group|Participants with CML-CP, from Novartis sponsored asciminib study ABL001E2201 that were receiving nilotinib
89464388|NCT04877522|Experimental|Asciminib in combination with dasatinib group|Participants with CML from Novartis sponsored study ABL001X2101 that were receiving asciminib with dasatinib
89501937|NCT04293458|Experimental|EsoCheck vs. EGD with or without biopsies|All subjects will undergo both the EsoCheck (non-invasive esophageal cell sample collection) followed by EGD (with or without biopsies)
89464389|NCT04876131|Experimental|Arm 1, 1 dose|"Single dose IV to cover Gram negative bacteria followed by 2 days of oral antibiotics~Single dose IV to cover Enterococcus spp~IV antibiotics are as per local institutional guidelines and microbiology eg: IV gentamicin with or without IV benzylpenicillin. Gentamicin is used when Gram Negative coverage is appropriate, benzylpenicillin is also used when Enterococcus coverage is appropriate, depending on local microbiology data. Once the IV component is complete the patient will be given an oral antibiotic (cefalexin) on day 2 and 3 of the study."
89464390|NCT04876131|Active Comparator|Arm 2, 3 doses|"3 doses IV to cover Gram negative bacteria~3 days IV antibiotics to cover Enterococcus spp~IV antibiotics are as per local institutional guidelines and microbiology eg: IV gentamicin with or without IV benzylpenicillin. Gentamicin is used when Gram Negative coverage is appropriate, benzylpenicillin is also used when Enterococcus coverage is appropriate, depending on local microbiology data."
89464391|NCT04875286||Observational (medical record review, questionnaires))|Patients' medical records are reviewed and then complete questionnaires over 27 minutes.
89464392|NCT04870333|Active Comparator|Niclosamide|"INN: Niclosamide Ethanolamine Chemical name (IUPAC): 5-chloro-N-(2-chloro-4-nitrophenyl)-2-hydroxybenzamide.2 aminoethanol CAS registry number: 1420-04-8 Lab code: UNI911~The IMPs niclosamide Nasal Spray 1% and matching Nasal Spray Placebo will be provided in 20 mL amber glass vials with nasal spray pumps, containing 8.5 mL of the respective solution, delivering 140 μL per spray shot. It is an isotonic and euhydric aqueous solution with red colour."
89464393|NCT04870333|Placebo Comparator|Placebo niclosamide|Placebo to match niclosamide will be supplied, stored, labelled, dispensed and dosed as for the active formulation. The placebo product is formulated to have the same appearance as the active solution.
89464394|NCT04870333|Active Comparator|Ciclesonide|"Chemical name (IUPAC): 2-[(1S,2S,4R,8S,9S,11S,12S,13R)-6-cyclohexyl-11-hydroxy-9,13-dimethyl-16-oxo-5,7-dioxapentacycloicosa-14, 17-dien-8-yl]- 2-oxoethyl 2-methylpropanoate CAS registry number: 141845-82-1~It is a pressurised solution, intended for inhalation use and commercialised under the brand Alvesco. The recommended dose of ciclesonide is 160μg once daily, which leads to asthma control in the majority of patients. However, this may be increased if necessary to 320μg twice daily, in severe asthma."
89464395|NCT04870333|Placebo Comparator|Placebo ciclesonide|Matched placebo contains the same solvent and propellant as the active product but no drug substance.
89464396|NCT04870333|Experimental|Sotrovimab|Sotrovimab, VIR-7831, GSK4182136 Sterile solution for intravenous infusion, 62.5 mg/mL, intravenous infusion Colourless or yellow to brown, liquid solution 20 mM histidine, 7% sucrose (w/v), 0.04% PS80 (w/v), 5 mM L-methionine at pH 6.0
89464397|NCT04870333|Placebo Comparator|Placebo sotrovimab|This will be in the form of 0.9% sodium chloride 100mL for infusion and will be sourced from commercially available stock by the site. It may be procured and stored as per sites usual procedures and only requires handling as an IMP upon dispensing and labelling.
89464398|NCT04868643|Other|In-Center arm|Subjects undergo In-Center treatment in Phase 2 as defined.
89464399|NCT04868643|Other|In-Home arm|"Subjects undergo In-Home treatments in Phase 4 as defined.~Subjects in Phase 2 and Phase 4 will be the same."
88945066|NCT01886196|Experimental|resistance exercise|3 sets of 8-12 repetitions of resistance exercises focused on distal radius to be performed 3 times/week for 9 months
88945067|NCT01886196|Sham Comparator|flexibility training|flexibility training to be performed 3 days/week for 1 hour for 9 months
88945068|NCT01886209|Experimental|Cohort 1|Prednisone 10 mg tablet on Day 1 and 7; VX-509 200 mg tablets on Days 2 thru 7
88945069|NCT01886209|Experimental|Cohort 2|Methylprednisolone 8 mg tablet on Day 1 and 7; VX-509 200 mg tablets on Days 2 thru 7
88945070|NCT01886222|Experimental|Long-term mild hypothermia|Focused intervention
88945071|NCT01886222|Other|Normothermia|Standard management
88945072|NCT01886248|Experimental|Antithrombin-III Human 500IU|"Freeze-dried Concentrated Human Antithrombin Ⅲ 500 IU~Units required (IU)/kg = 50 + [(desired-baseline AT-III level) x weight (kg) / 1.4]"
88945073|NCT01886274|Experimental|tDCS|The experimental group received tDCS to the occipital cortex in 12 sessions, 3 days per week.
88945074|NCT01886274|Sham Comparator|control|The control group received sham stimulation to the occipital cortex in 12 sessions, 3 days per week.
88945075|NCT01886274|No Intervention|healthy subjects|This group was submitted to one evaluation session of cortical excitability.
88945076|NCT01886326|Experimental|Consumption of 42 g of salted peanuts|Consumption of 42 grams of peanuts daily
88945077|NCT01886326|Experimental|Consumption of 42 g of unsalted peanuts|Consumption of 42 grams of peanuts daily
88945078|NCT01886326|Experimental|Consumption of 42 g of spicy peanuts|Consumption of 42 grams of peanuts daily
88945079|NCT01886326|Experimental|Consumption of 42 g of honey peanuts|Consumption of 42 grams of peanuts daily
88945080|NCT01886326|Experimental|Consumption of 42 g of 3 diff. varieties|Consumption of 42 grams of peanuts daily
88945081|NCT01886326|Experimental|Consumption of 42 g of var. of types|Consumption of 42 grams of peanuts daily
88945082|NCT01886339||Healthy population|
88945083|NCT01886352|Active Comparator|Infiltration of portal sites with 0,5% levobupivacaine.|The first group of patients will receive the standard treatment (paracetamol, diclofenac and an opioid if necessary) with infiltration of the portal sites with the local anesthetic ( 0.5% levobupivacaine).
88945084|NCT01886352|Experimental|Additional injection of 0.5% levobupivacaine via a trocar|The second group of patients will receive the standard of care, with infiltration of the portal sites with the local anesthetic ( 0.5% levobupivacaine) and additional injection of the local anesthetic ( 0.5% levobupivacaine, non -diluted) in the peritoneal cavity via a trocar both at the beginning and the end of the surgery.
88945085|NCT01886352|Experimental|Additional intraperitoneal atomization of levobupivacaine.|The third group of patients will receive the standard of care, with infiltration of the portal sites with the local anesthetic ( 0.5% levobupivacaine) and additional intraperitoneal atomization of the local anesthetic.
88945086|NCT01886365|Active Comparator|Group A|With start of the cardiopulmonary bypass, computerized algorithmic application of insulin was performed with a dedicated computerized syringe pump system (Space GlucoseControl System, B. Braun, Germany). The targeted corridor for blood glucose was determined with 80 - 150 mg/dl. During surgery, blood glucose was measured every 30 min, and on the ICU every 2 hours. TGC management was continued until ICU discharge.
89464400|NCT04865341|Experimental|IMB|Individuals randomized to this arm will receive a behavioral intervention based on the Information-Motivation-Behavior (IMB) model designed to increase HIV self-testing, among other protective behaviors.
89464401|NCT04865341|No Intervention|No Intervention|Individuals randomized to this arm will receive no intervention.
89464402|NCT04859946|Experimental|Supportive care (itacitinib)|"CONDITIONING: Patients receive busulfan IV over 3 hours on days -20, -13, and -6 to -3, thiotepa IV on day -7, and fludarabine IV over 1 hour on days -6 to -3.~STEM CELL TRANSPLANT: Patients undergo stem cell transplant on day 0.~GVHD PROPHYLAXIS: Patients receive cyclophosphamide IV over 3 hours on days 3 and 4. Patients also receive itacitinib PO QD on days 5-60 in the absence of disease progression or unacceptable toxicity. Beginning day 5 after stem cell transplant, patients also receive tacrolimus IV over 24 hours until able to tolerate oral tacrolimus, whereby patients then receive tacrolimus PO BID."
89464403|NCT04846244||Participants Receiving Upadacitinib|Participants receiving Upadacitinib for axial spondyloarthritis (axSpA).
89464404|NCT04829110|Experimental|A. ETOH|5 Males and 5 Females will receive deuterated water and drink 2.15 ounces of alcohol in the form of vodka and have de novo Lipogenesis measured at 11 time points during and after.
89464405|NCT04829110|Experimental|ETOH + Sucrose|5 Females will receive deuterated water and drink 1.72 ounces of alcohol in the form of vodka + 7 grams of sucrose and have de novo Lipogenesis measured at 11 time points during and after.
89464406|NCT04829110|Experimental|C. Sucrose|5 Females will receive deuterated water and drink a solution containing water and 35 grams of sucrose, and have de novo Lipogenesis measured at 11 time points during and after.
89464407|NCT04815356|Experimental|Experimental therapy: Dose Escalation|Escalating doses of autologous anti-CD22-CAR T-cells in subjects to determine the MTD
89464408|NCT04815356|Experimental|Experimental therapy: Dose Expansion|Autologous anti-CD22-CAR T-cells at the MTD
89464409|NCT04810702||patients with von Willebrand disease|
89464410|NCT04810702||case control|
88945087|NCT01886365|Active Comparator|Group B|Corresponding computerized algorithmic application of insulin management was used as for group A. However, only the interval of blood glucose measurement during surgery was adjusted to 15 minutes.
88945088|NCT01886365|Other|Group C|With start of the cardiopulmonary bypass conventional therapy with a fixed insulin dosing scheme was initiated. If blood glucose was > 150 mg/dl, manual insulin therapy was started following a fixed insulin dosing scheme. Measurements of blood glucose were performed during surgery every 30 minutes, and on the ICU every 2 hours until discharge (Routine Care).
88945089|NCT01886430|Experimental|Functional Electrical Stimulation|Functional Electrical Stimulation for 10 days
88945090|NCT01886430|Placebo Comparator|Control Electrical Stimulation|Control Electrical Stimulation for 10 days
88945091|NCT01886456|Experimental|PLT|patients treated with patterned laser trabeculoplasty
88945092|NCT01886456|Active Comparator|SLT|patients treated with selective laser trabeculoplasty
88945093|NCT01886469|Experimental|Adolescents (12-17yrs)|
88945094|NCT01886469|Experimental|Children (6-11 yrs)|
88945095|NCT01886482|Active Comparator|nutrition intervention|high protein diet
88945096|NCT01886482|No Intervention|no intervention|control diet
88945097|NCT01886495|Active Comparator|nutrition intervention|high protein diet
88945098|NCT01886495|No Intervention|control diet|
88945099|NCT01886508|Experimental|NSRH|patients in Arm NSRH undergo nerve-spring radical hysterectomy (NSRH)
88945100|NCT01886508|Active Comparator|RH|patients in Arm RH undergo radical hysterectomy (RH)
89464411|NCT04808999|Experimental|Pembrolizumab|Neoadjuvant Phase: 200 mg IV infusion, every 3 weeks (Day 1 of each 3-week cycle, 2 cycles) Adjuvant Phase: Day 1 of each 3-week cycle, 15 cycles
89464412|NCT04806386|Experimental|Psyllium fiber supplement treatment|All patients will receive psyllium fiber in the form of edible bars, 7g, twice a day to total 14g per day.
89464413|NCT04798274|Experimental|Active cTBS|This intervention involves active repetitive magnetic stimulation. The coil emits a magnetic field
88945101|NCT01886521|Experimental|Lumbar drain group|Lumbar drain
88945102|NCT01886521|Active Comparator|Ventricular drain|Ventricular drain
88945103|NCT01886534|Experimental|Enhanced Caregiver Support with Caregiver|"Standardized Heart Failure Discharge Summary to Primary Care Physicians©~Standardized education sessions~Heart Failure Diuretic Decision Support Tool for Patient Self Management©~Digital talking scale"
88945104|NCT01886534|Other|Usual Care with Caregiver|Usual care
88945105|NCT01886534|Experimental|Enhanced Support without Caregiver|"Standardized Heart Failure Discharge Summary to Primary Care Physicians©~Standardized education sessions~Heart Failure Diuretic Decision Support Tool for Patient Self Management©~Digital talking scale"
88945106|NCT01886534|Other|Usual Care without Caregiver|Usual Care
88945107|NCT01886547||New patient presented with prostate disease|prostate disease identified
88945108|NCT01886560|Placebo Comparator|Placebo|Adding eatable flour into the pills
88945109|NCT01886560|Experimental|Doxycycline treatment|Doxycycline treatment 50mg bid x 14 days then 50mg qd x 10 weeks
88945110|NCT01886573|Experimental|Treatment (azacitidine, entinostat)|Patients receive azacitidine SC on days 1-6 and 8-10 and entinostat PO on days 3 and 10. Patients undergo surgery between days 11-20 (this period can be extended 10 more days if adverse events from therapy impose a surgical risk).
88945111|NCT01886586|Active Comparator|Problem Solving Therapy|8-12 sessions of Problem Solving Therapy (both members of dyad)
88945112|NCT01886586|Active Comparator|Problem Solving Therapy + Exercise|6-12 sessions of Problem Solving Therapy + Exercise (both members of dyad)
88945113|NCT01886586|Active Comparator|Enhanced Usual Care|Staff will will document and monitor all mental health treatment (e.g., medications that participant may be taking) and psychotherapy (e.g. counseling or social services).
88945114|NCT01886599|Experimental|Arm A: Subjects with normal renal function|Asunaprevir 100 mg tablet by mouth twice daily for 7 days
88945115|NCT01886599|Experimental|Arm B: Subjects with end stage renal disease|Asunaprevir 100 mg tablet by mouth twice daily for 7 days
88945116|NCT01886599|Experimental|Arm C: Subjects with mild renal impairment|Asunaprevir 100 mg tablet by mouth twice daily for 7 days
88945117|NCT01886599|Experimental|Arm D: Subjects with moderate renal impairment|Asunaprevir 100 mg tablet by mouth twice daily for 7 days
89464414|NCT04798274|Sham Comparator|Sham cTBS|This intervention involves sham (placebo) repetitive transcranial magnetic stimulation. The coil is blinded, but does not emit any magnetic field
89464415|NCT04797962|Experimental|Intervention|dedicated case management
89464416|NCT04797962|No Intervention|Usual care|usual care
89464417|NCT04797299||Single Arm Cohort|Evaluating the risk of Local Recurrence (LR) in a group of women postulated to be at low risk of LR following Breast Conserving Surgery alone defined by a combination of clinicopathological factors and Oncotype DX DCIS score.
89464418|NCT04786652|Experimental|Assessment of fluid responsiveness|
89464419|NCT04786561||HUNT4 70+|All inhabitants of Nord-Trøndelag 70 years or older were invited to participate in HUNT 4 70+. HUNT4 refers to the fourth wave of the HUNT-study (HelseUndersøkelse i Nord-Trøndelag or health survey in northern part of Trøndelag community in Middle of Norway) and 70+ refers to the part of the survey directed to participants aged seventy years and older.
89464420|NCT04786561||HUNT4 70+ Trondheim|All inhabitants of one district in Trondheim 70 years or older were invited to participate in HUNT 4 70+
89464421|NCT04778410|Experimental|Safety Run-in Cohort 1 (1L Unfit AML Mag+Ven+Aza)|Participants with newly diagnosed untreated AML who are ineligible for intensive induction chemotherapy will receive magrolimab, venetoclax and azacitidine.
89464422|NCT04778410|Experimental|Safety Run-in Cohort 2 (R/R AML Mag+MEC)|Participants with relapsed or refractory (r/r) AML will receive magrolimab and MEC.
89464423|NCT04778410|Experimental|Safety Run-in Cohort 3 (Post-Chemo Maintenance Mag+CC-486)|Participants with newly diagnosed AML who are in complete remission (CR) or complete remission with incomplete hematologic recovery (CRi) with minimal residual disease (MRD) positivity following intensive chemotherapy will receive magrolimab and CC-486.
89464424|NCT04778410|Experimental|Phase 2 Cohort 1 (1L Unfit AML Mag+Ven+Aza)|Participants with newly diagnosed untreated AML who are ineligible for intensive induction chemotherapy will receive magrolimab at the recommended Phase 2 dose (RP2D) determined in the Safety run-in cohort 1, venetoclax and azacitidine.
89464425|NCT04778410|Experimental|Phase 2 Cohort 2 (R/R AML Mag+MEC)|Participants with relapsed or refractory (r/r) AML will receive magrolimab at the RP2D determined in the Safety run-in cohort 2 and MEC.
89464426|NCT04778410|Experimental|Phase 2 Cohort 3 (Post-Chemo Maintenance Mag+CC-486)|Participants with newly diagnosed AML who are in complete remission (CR) or complete remission with incomplete hematologic recovery (CRi) with minimal residual disease (MRD) positivity following intensive chemotherapy will receive magrolimab at the RP2D determined in the Safety run-in cohort 3 and CC-486.
89464427|NCT04774718|Experimental|ALK-Fusion Positive|Part 1 is a dose-confirmation phase to confirm the recommended phase 2 dose (RP2D). In Parts 2 and 3, participants will receive alectinib at the RP2D on Days 1-28 of each 28-day cycle
89464428|NCT04771806||Observational (MRI)|Patients undergo MRI with and without contrast immediately before radiotherapy (for radiation planning) and at mid treatment (week 3). Patients also undergo MRI without contrast on weeks 1, 2, 4, 5, and 6 of radiotherapy. Patients may also undergo neurocognitive function testing over 70 minutes before treatment, at the end of each week of treatment, and at 3 and 6 months after completion of treatment.
88945118|NCT01886599|Experimental|Arm E: Subjects with severe renal impairment|Asunaprevir 100 mg tablet by mouth twice daily for 7 days
88945119|NCT01886612|Experimental|DVT Prophylaxis|"Neuromuscular electrical stimulation is to be applied using a custom-built, two-channel stimulator (Duo-STIM (stimulator), Bioelectronics Research Cluster, National University of Ireland, Galway) with a frequency of 36 Hz, a balanced biphasic waveform with a pulse width of 350μs, a ramp up time of 500ms, a contraction time of 1s and a ramp down time of 500ms. Stimulation is to be applied every 20 seconds over a period of 5 minutes.~Intermittent pneumatic compression is to be applied using the Novamedix A-V Impulse System Model 6000 (Novamedix distribution Limited, England), programmed to deliver compression every 20 seconds at a pressure of 130 mmHg for a 1 second duration over a period of 5 minutes."
89464429|NCT04755153|Experimental|Practice Facilitation|Practice Facilitation to support implementation of the Kaiser Blood Pressure Control Bundle
89464430|NCT04755153|Active Comparator|Non-Practice Facilitation|implementation of the Kaiser Blood Pressure Control Bundle without Practice Facilitation
89464431|NCT04752384|Experimental|Drug Treatment|The main objective of this study is to provide preliminary evidence that FDA approved dose of transdermal buprenorphine in conjunction with oral tramadol can provide adequate analgesia of radiation-induced mucositis pain during treatment and follow up period in head and neck cancer patients.
89464432|NCT04746963|Experimental|Low Dose|AXT107 0.1 mg/eye
89464433|NCT04746963|Experimental|Mid Dose|AXT107 0.25 mg/eye
89464434|NCT04746963|Experimental|High Dose|AXT107 0.5 mg/eye
89464435|NCT04740047||Pulmonary Nodule|Pulmonary nodule is suitable for elective bronchoscopy with a moderate to high risk of lung cancer based on clinical, demographic and radiologic information or with suspected metastatic disease.
89464436|NCT04739059|Experimental|CSL312|Fully human immunoglobulin G subclass 4/lambda recombinant inhibitor monoclonal antibody administered subcutaneously
89464437|NCT04738968|Experimental|Cochlear implant for single-sided deafness|Children with single-sided deafness, cochlear implant in the deaf ear
89464438|NCT04738968|No Intervention|Control single-sided deafness|Children with single-sided deafness, no intervention
88945120|NCT01886625|Experimental|Sympathicotomy|unilateral single-port VATS sympathicotomy
88945121|NCT01886638|Experimental|Abacavir|Abacavir 600mg (as two 300mg tablets) once daily for 15 days
88945122|NCT01886664|Active Comparator|Sevoflurane|Performing liver transplantation under general anesthesia using sevoflurane
88945123|NCT01886664|Experimental|Desflurane|Performing liver transplantation under general anesthesia using desflurane
88945124|NCT01886677|Experimental|Immediate diet and exercise intervention|A healthful diet plus exercise intervention to promote a weight loss of up to 2 pounds/week
89018079|NCT05380739|Active Comparator|Online, MCI|Participants diagnosed with MCI will undergo 10 sessions of WM training online.
89464439|NCT04738968|No Intervention|Control normal hearing|Children with normal hearing, no intervention
89464440|NCT04738487|Experimental|Pembrolizumab/Vibostolimab|Participants will receive pembrolizumab/vibostolimab as a coformulation (MK-7684A).
89464441|NCT04738487|Active Comparator|Pembrolizumab|Participants will receive pembrolizumab (MK-3475) alone.
89464442|NCT04734106|Experimental|Desert Harvest Super-Concentrated, Freeze-Dried Aloe Vera Capsules|Participants will self-administer Desert Harvest super-concentrated, freeze-dried aloe vera capsules orally over a sixteen week period. The dosing regimen includes administering 3 capsules twice daily for the first month, 3 capsules three times daily for the second month, and 4 capsules three times daily for the third month. During the fourth month, participants will administer 10 capsules per day the first week (4 in the morning, 2 in the afternoon, and 4 in the evening), 8 capsules per day the second week (4 in the morning, 4 in the evening), 6 capsules per day the third week (3 in the morning, 3 in the evening), and 4 capsules per day the fourth week (2 in the morning, 2 in the evening). A participant must stay on a minimum of 6 capsules per day for the first three months in order to remain in the study.
89464443|NCT04734106|Placebo Comparator|Placebo|Participants will self-administer placebo capsules orally, matching the dosing regimen of the experimental treatment, over a sixteen week period. Placebo capsules will be identical in appearance and packaging to the experimental capsules.
89464444|NCT04726410|Experimental|Cold-stored Platelet (CSP)|early infusion of up to 2 units of urgent release cold stored platelets (CSP)
88945125|NCT01886677|Other|Delayed diet and exercise intervention|This arm will receive the same diet and exercise intervention as the experimental arm once recovery from prostatectomy is achieved.
88945126|NCT01886703|Experimental|Walking Intervention|Pedometer Walking Program
88945127|NCT01886729|Active Comparator|tDCS simultaneously with hyperbaric oxygen therapy|
88945128|NCT01886729|Active Comparator|tDCS 3 weeks after start tinnitus|
88945129|NCT01886742|Active Comparator|Control group|Standard dose group (2 g intravenous (IV) cefazolin dose for patients <120 kg, and 3 g IV cefazolin for patients >120 kg)
88945130|NCT01886742|Experimental|Treatment group|Weight-based dose group (30 mg/kg cefazolin IV)
89464445|NCT04726410|Active Comparator|Standard care|standard care therapy
89464446|NCT04715451|No Intervention|Conventional Swaddle|The management of the non-intervention group is with a cotton swaddle that is standard of care. It represents a conventional standard management method using a swaddle made of cotton.
89464447|NCT04715451|Experimental|Novel Swaddle|The Novel Swaddle is made of fabric consisting of 85% nylon and 15% polyurethane. This fabric provides heat retention, is hygroscopic and stretches in both longitudinal and transverse directions, thus more accurately replicating the intrauterine environment. The novel material is sewed into a bag shape.
88945131|NCT01886755|Experimental|ORS with probiotic and zinc|ORS with probiotic and zinc Oral rehydration solution with freeze-dried Lactobacillus reuteri DSM 17938 and zinc sulphate
88945132|NCT01886755|Placebo Comparator|Placebo Comparator|Standard oral rehydration solution
88945133|NCT01886768|Experimental|Double pledget nasal anesthesia|All patients in the double pledget nasal anesthesia group receive endoscopic-guided gauze nasal pledgetting to both the inferior nasal meatus and middle nasal meatus. Each patient will receive an anterior rhinoscopy to select the most patent meatus by a validated meatus scoring scale. The endoscope is preloaded with a 1.8 mm biopsy forceps to pick up a right-angled gauze strip. A preloaded biopsy forceps is protruded slowly into the middle meatus first under endoscope monitoring. The second gauze pledgetting procedure is performed two minutes after the first gauze pledgetting which serves to induce turbinate size reduction to both the INT and MNT. A gauze strip is at least brought onto the posterior end of the inferior or middle turbinate.
88945134|NCT01886768|Active Comparator|Single pledget nasal anesthesia|All patients in the single pledget nasal anesthesia group receive endoscopic-guided gauze nasal pledgetting to either the inferior nasal meatus or middle nasal meatus determined by anterior rhinoscopy. Each patient will receive an anterior rhinoscopy to select the most patent meatus by a validated meatus scoring scale. The endoscope is preloaded with a 1.8 mm biopsy forceps to pick up a right-angled gauze strip. A gauze strip is at least brought onto the posterior end of the inferior or middle turbinate.
88945135|NCT01886820|Experimental|[18F]NAV4694|Intravenous [18F]NAV4694 radioactive dose 8.1 mCi(300 MBq) given once
88945136|NCT01886898|Placebo Comparator|Standard starter infant formula|starter infant formula from enrollment till 16 weeks of age
88945137|NCT01886898|Experimental|starter infant formula with prebiotics|starter infant formula from enrollment till 16 weeks of age
89464448|NCT04715074|Experimental|Develop and Pilot #iBeatCRC|"Intervention development will be informed by (1) integrating Aims 1 and 2 findings, (2) Community Action Board [CAB] input, and (3) the Behaviour Change Wheel,48 a step-by-step intervention development approach that identifies and addresses barriers using theory and evidence-based methods.~The intervention pilot may be based on a multicomponent media campaign, as endorsed by the Community Preventive Services Taskforce for promoting CRC screening among individuals ≥ age 50. #iBeatCRC may entail both outdoor mass media and online social media. #iBeatCRC will target Utah and Wisconsin hotspots and non-hotspots for comparison, with pre-post-assessment among 17 individuals in each group for both sites."
89464449|NCT04710628|Experimental|PEMBROLIZUMAB + LENVATINIB|"Pembrolizumab 200 mg will be administered to patients as 30-minute IV infusion every 3 weeks (a window of -5 minutes and +10 minutes is permitted).~Lenvatinib 20 mg (2 capsules of 10 mg) will be administered daily at the same time, with or without food. At the day 1 of each cycle, lenvatinib will be administered within 4 hours after finishing pembrolizumab (lenvatinib after pembrolizumab). Lenvatinib cannot be chewed"
89464450|NCT04707625|Other|Aflibercept|All subjects will receive aflibercept every 4 weeks. Once vascular endothelial growth factor levels become normal and macular edema improves treatment windows will be extended up to every 12 weeks.
89464451|NCT04702880|Experimental|Arm A: Carboplatin + Etoposide + Nivolumab + BMS-986012|
89464452|NCT04702880|Experimental|Arm B: Carboplatin + Etoposide + Nivolumab|
89464453|NCT04698382||Non-COVID-19-related sepsis|"Non-COVID-19 sepsis patients will be identified with sepsis or septic shock without a COVID-19 diagnosis code or a positive COVID-19 laboratory test.~Sepsis patients will be defined as patients with concurrent infection and organ dysfunction. Presumed concurrent infection will be defined as a blood culture order and ≥ 3 days of antibiotics administration, including at least 24h of intravenous antibiotics, or death while on antibiotics within 3 days of admission. Organ dysfunction will be defined by ICD-10-modified acute organ failure score. Sensitivity analyses will use ICD-10 explicit sepsis codes to define non-COVID-19 sepsis instead.~COVID-19 will be identified based on receiving a diagnosis code for COVID-19 (U07.1) or legacy coding (prior to the implementation of a specific COVID-19 code) present-on-admission and/or a positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) polymerase chain reaction (PCR) test on admission"
89464454|NCT04698382||Non-COVID-19, Non-Sepsis Control Population|"This will be defined as patients identified with emergency conditions of interest without a diagnosis code of sepsis, COVID19 or a positive COVID-19 laboratory test.~These include~Acute Gastrointestinal Bleeding (GIB): Patients with at least one GIB ICD-10 code and one relevant CPT intervention codes.~Myocardial Infarction (MI): Patients with at least one MI ICD-10 code and one relevant CPT intervention codes"
89464455|NCT04697758|Experimental|Low Dose|AXT107 0.1 mg/eye
88945138|NCT01886898|Experimental|starter infant formula with pro and prebiotics|starter infant formula from enrollment till 16 weeks of age
88945139|NCT01886898|Other|breastfeeding group|exclusively breastfeeding during the first 16 weeks of age
88945140|NCT01886911|Active Comparator|Control for Attention Intervention|Attentional Control Game is an active control group. We expect subjects in this group to play a control game for 2 weeks (plus or minus 7 days).
88945141|NCT01886911|Experimental|Prosocial Training Intervention Game|The prosocial intervention group, which we expect will be play the experimental prosocial training game for 2 weeks (plus or minus 7 days).
88945142|NCT01886911|Experimental|Attention Training Intervention Game|The attention intervention group, which we expect will be play the experimental attention training game for 2 weeks (plus or minus 7 days).
88945143|NCT01886911|Active Comparator|Control for Prosocial Intervention|This is an active control group. We expect subjects in this group to play a control game for 2 weeks (plus or minus 7 days).
88945144|NCT01886924|Experimental|Brief Computer MI for Smoking Cessation|Brief computer MI intervention to motivate tobacco quitline use
88945145|NCT01886924|Active Comparator|Nutrition Control|Computer delivered nutrition education
89464456|NCT04697758|Experimental|Mid Dose|AXT107 0.25 mg/eye
89464457|NCT04697758|Experimental|High Dose|AXT107 0.5 mg/eye
89464458|NCT04691375|Experimental|Part A: PY314 Single agent dose level 1|PY314 single agent dose level will depend on any safety signal observed in this cohorts only. Following the determination of the safety and tolerability of at least two PY314 dose levels by the safety review committee.
89464459|NCT04691375|Experimental|Part A: PY314 Single agent dose level 2|PY314 single agent dose level 2 dose escalation of PY314 as a single agent will continue in the absence of unacceptable dose limiting toxicity to the maximum administered dose as defined in the predefined dose escalation schema.
89464460|NCT04691375|Experimental|Part A: PY314 Single agent dose level 3|PY314 single agent dose level 3 to identify the maximum tolerated dose and/or to determine the recommended dose for expansion of PY314
89464461|NCT04691375|Experimental|Part A: PY314 Single agent dose level 4|PY314 single agent dose level 4 to characterize the pharmacokinetic profile of PY314 as a single agent.
89464462|NCT04691375|Experimental|Part A: Combination dose level 1|Combination dose level 1 to characterize the safety and tolerability of PY314 as a single agent and in combination with pembrolizumab in subjects with advanced refractory solid tumors including refractory to check point inhibitor.
89464463|NCT04691375|Experimental|Part A: Combination dose level 2|PY314 combination dose level 2 to identify the maximum tolerated dose and/or to determine the recommended dose for expansion of PY314 administered alone and in combination with pembrolizumab.
89464464|NCT04691375|Experimental|Part A: Combination dose level 3|PY314 combination dose level 3 to characterize the pharmacokinetic profile of PY314 as a single agent and in combination with pembrolizumab.
89464465|NCT04691375|Experimental|Part A: Combination dose level 4|PY314 combination dose level 4 to describe, in subjects selected by pre-specified tumor histology, anti-tumor activity of PY314 administered alone and in combination with pembrolizumab.
88945146|NCT01886976|Experimental|anti-CD138 CAR T cells|Patients receive anti-CD138-CAR retroviral vector-transduced autologous or donor-derived T cells on days 0,1, 2 in the absence of disease progression or unacceptable toxicity.
88945147|NCT01886989|Experimental|Cocoa|Cocoa polyphenols (960mg)
88945148|NCT01886989|Placebo Comparator|Placebo|Placebo powder (109mg polyphenols) in water
88945149|NCT01887015|Experimental|Standard oxygen therapy|Our hypothesis is that, compared with standard oxygen therapy, early application of nasal high flow oxygen therapy can reduce the need for postoperative NPPV for postoperative hypoxemia (defined as PaO2/FiO2 ratio <300).
88945150|NCT01887015|Other|nasal high flow oxygen therapy|Our hypothesis is that, compared with standard oxygen therapy, early application of nasal high flow oxygen therapy can reduce the need for postoperative NPPV for postoperative hypoxemia (defined as PaO2/FiO2 ratio <300).
88945151|NCT01887054|Active Comparator|Training Group|"There are 2 study visits. Subjects in this group will complete the following:~Visit 1~Gait evaluation~Neuropsychological testing~Questionnaires and assessments~Taught how to complete a visual problem-solving task (Tower of Hanoi)~Given a diary to record training at home.~In-home~•For 6 weeks at home, complete the in-home visual problem-solving tasks as instructed at Visit 1~Visit 2~Gait evaluation~Neuropsychological testing~Questionnaires and assessments"
88945152|NCT01887054|Placebo Comparator|Non Training Group|"There are 2 study visits. Subjects in this group will complete the following:~Visit 1~Gait evaluation~Neuropsychological testing~Questionnaires and assessments~Visit 2~Gait evaluation~Neuropsychological testing~Questionnaires and assessments"
88945153|NCT01887080|Experimental|Exercise|Experimental group 1 performed cardiovascular rehabilitation home-based program
88945154|NCT01887080|Experimental|Exercise afther Microcurrent|Experimental group 2 performed cardiovascular rehabilitation home-based program just after microcurrent.
88945155|NCT01887080|Other|Cardiovascular Risk Factors|Education about risk factors
88945156|NCT01887093|Experimental|Morning walking|Participants were requested to walk in the morning at the speed of 2.5 miles/h for 30 min/day or more on at least 5 days/week for a period of 12 weeks. We demanded everyone to record the situation of walking including duration, distance and time daily in a log book. Each participant was telephoned at least once a week to ensure the adherence to the exercise program. Patients were called back every month to hand in the log book and to understand the information about medication use. Furthermore, at the beginning and end of the 12-week program, both the walking groups were supervised by researchers to walk for continuous three days and the duration and distance of walking were recorded.
88945157|NCT01887093|Experimental|Evening walking|Participants were requested to walk in the evening at the speed of 2.5 miles/h for 30 min/day or more on at least 5 days/week for a period of 12 weeks. We demanded everyone to record the situation of walking including duration, distance and time daily in a log book. Each participant was telephoned at least once a week to ensure the adherence to the exercise program. Patients were called back every month to hand in the log book and to understand the information about medication use. Furthermore, at the beginning and end of the 12-week program, both the walking groups were supervised by researchers to walk for continuous three days and the duration and distance of walking were recorded.
88945158|NCT01887093|No Intervention|No walking|The control group was requested to maintain their usual level of physical activity.
88945159|NCT01887106|Experimental|GLPG1205 single dose|Single oral dose of GLPG1205 suspension - ascending doses
88945160|NCT01887106|Placebo Comparator|Placebo single dose|Single oral dose of placebo suspension
89464466|NCT04691375|Experimental|Part B: Single agent dose expansion dose level 1|PY314 single agent dose expansion dose level 1 to define further the safety and tolerability of PY314 alone.
89464467|NCT04691375|Experimental|Part B: Combination dose expansion cohort 1|PY314 in combination with pembrolizumab dose expansion cohort 1 to define the safety and tolerability of PY314 alone and in combination with pembrolizumab over multiple treatment cycles in subjects with pre-defined tumor histologies and confirmed TREM2 expression.
89464468|NCT04691375|Experimental|Part B: Combination dose expansion cohort 2|PY314 in combination with pembrolizumab dose expansion cohort 2 to further characterize the PK profile of PY314 as a single agent and in combination with pembrolizumab.
89464469|NCT04691375|Experimental|Part B: Combination dose expansion cohort 3|PY314 in combination with pembrolizumab dose expansion cohort 3 to characterize the anti-tumor activity of PY314 alone and in combination with pembrolizumab in subjects with selected prespecified tumor histologies and known TREM2 expression.
89464470|NCT04691375|Experimental|Part B: Combination dose expansion cohort 4|PY314 in combination with pembrolizumab dose expansion cohort 4 to evaluate the incidence of ADA formation and TREM2 expression.
89464471|NCT04691375|Experimental|Part B: Combination dose expansion cohort 5|PY314 in combination with pembrolizumab dose expansion cohort 5 to further explore and characterize the anti-tumor activity of PY314 alone and in combination with pembrolizumab in subjects with selected prespecified tumor histologies and known TREM2 expression.
89201948|NCT05461586||MR #1/MR #2|Subjects who participated in PCOL-102-AHSF who were bilaterally implanted with TECNIS IOL lenses will be randomized into the (MR #1/MR #2) sequence and receive two different maximum refractive techniques one at a time consecutively.
89201949|NCT05461586||MR#2/MR#1|Subjects who participated in PCOL-102-AHSF who were bilaterally implanted with TECNIS IOL lenses will be randomized into the (MR#2/MR#1) sequence and receive two different maximum refractive techniques one at a time consecutively.
89464472|NCT04682431|Experimental|Part A: PY159 Single agent dose level 1|PY159 dose level 1 IV administration, Q3 weekly until consent withdrawal, intolerable toxicity or investigator decision.
89464473|NCT04682431|Experimental|Part A: PY159 Single agent dose level 2|PY159 dose level 2
89464474|NCT04682431|Experimental|Part A: PY159 single agent dose level 3|PY159 dose level 3
89464475|NCT04682431|Experimental|Part A: PY159 single agent dose level 4|PY159 dose level 4
89464476|NCT04682431|Experimental|Part A: PY159 single agent dose level 5|PY159 dose level 5
89464477|NCT04682431|Experimental|Part A: PY159 single agent dose level 6|PY159 dose level 6
89464478|NCT04682431|Experimental|Part A: PY159 single agent dose level 7|PY159 dose level 7
89464479|NCT04682431|Experimental|Part A: PY159/Pembrolizumab Combination dose level 1|PY159 dose level 1 in combination with pembrolizumab
89464480|NCT04682431|Experimental|Part A: PY159/Pembrolizumab Combination dose level 2|PY159 dose level 2 in combination with pembrolizumab
89201950|NCT00690794|Experimental|Travoprost|One drop self-administered in the study eye(s) once daily for 90 days
89464481|NCT04682431|Experimental|Part A: PY159/Pembrolizumab Combination dose level 3|PY159 dose level 3 in combination with pembrolizumab
89464482|NCT04682431|Experimental|Part A: PY159/Pembrolizumab Combination dose level 4|PY159 dose level 4 in combination with pembrolizumab
89464483|NCT04682431|Experimental|PY159 Part B: Single agent dose expansion cohort(s)|PY159 Single agent dose expansion cohort(s)
89464484|NCT04682431|Experimental|PY159 Part B: PY159/Pembrolizumab Combination dose expansion cohort 1|PY159 in combination with pembrolizumab dose expansion cohort 1 to further explore and characterize the anti-tumor activity of PY159 alone and in combination with pembrolizumab in subjects with selected prespecified tumor histologies and known TREM1 expression.
89464485|NCT04682431|Experimental|PY159 Part B: PY159/Pembrolizumab Combination dose expansion cohort 2|PY159 in combination with pembrolizumab dose expansion cohort 2 to further explore and characterize the anti-tumor activity of PY159 alone and in combination with pembrolizumab in subjects with selected prespecified tumor histologies and known TREM1 expression.
89464486|NCT04682431|Experimental|PY159 Part B: PY159/Pembrolizumab Combination dose expansion cohort 3|PY159 in combination with pembrolizumab dose expansion cohort 3 to further explore and characterize the anti-tumor activity of PY159 alone and in combination with pembrolizumab in subjects with selected prespecified tumor histologies and known TREM1 expression.
89464487|NCT04682431|Experimental|PY159 Part B: PY159/Pembrolizumab Combination dose expansion cohort 4|PY159 in combination with pembrolizumab dose expansion cohort 4 to further explore and characterize the anti-tumor activity of PY159 alone and in combination with pembrolizumab in subjects with selected prespecified tumor histologies and known TREM1 expression.
89464488|NCT04682431|Experimental|PY159 Part B: PY159/Pembrolizumab Combination dose expansion cohort 5|PY159 in combination with pembrolizumab dose expansion cohort 5 to further explore and characterize the anti-tumor activity of PY159 alone and in combination with pembrolizumab in subjects with selected prespecified tumor histologies and known TREM1 expression.
89464489|NCT04682431|Experimental|PY159 Part B: PY159/Pembrolizumab Combination dose expansion cohort 6|PY159 in combination with pembrolizumab dose expansion cohort 6 to further explore and characterize the anti-tumor activity of PY159 alone and in combination with pembrolizumab in subjects with selected prespecified tumor histologies and known TREM1 expression.
89464490|NCT04682197|Active Comparator|Cereset Research|For this single arm, open label, exploratory trial this will be the intervention arm using 4 CR sessions.
89464491|NCT04682197|Other|Continued Current Care|Participants will continue their current care.
89464492|NCT04675333|Experimental|evorpacept (ALX148) + pembrolizumab + Chemotherapy|evorpacept (ALX148) 45 mg/kg IV, pembrolizumab 200 mg IV, and chemotherapy given every 3 weeks.
89464493|NCT04675333|Active Comparator|pembrolizumab + Chemotherapy|pembrolizumab 200 mg IV and chemotherapy given every 3 weeks.
89464494|NCT04675294|Experimental|evorpacept (ALX148) + pembrolizumab|evorpacept (ALX148) 45 mg/kg IV and pembrolizumab 200 mg IV given every 3 weeks.
89464495|NCT04675294|Active Comparator|pembrolizumab|pembrolizumab 200 mg IV given every 3 weeks.
89464496|NCT04674410||Empiric Antibiotic|All patients with COVID19 diagnosed on admission who received empiric antibiotics within 48 hours of admission without another site of infection identified or suspected septic shock.
89464497|NCT04674410||Control group|All patients admitted with COVID19 who did not receive empiric antibiotics in the first 48 hours of admission
88945161|NCT01887106|Experimental|GLPG1205 multiple doses|Multiple oral doses of GLPG1205 suspension - ascending doses
89464498|NCT04668768|Experimental|Glucarpidase|Prophylactic glucarpidase treatment
89464499|NCT04660539|Experimental|Satralizumab Treatment|Participants will receive satralizumab subcutaneously (SC) every 4 weeks (Q4W)
88945162|NCT01887106|Placebo Comparator|Placebo multiple doses|Multiple oral doses of placebo suspension
89201951|NCT00690794|Active Comparator|Latanoprost|One drop self-administered in the study eye(s) once daily for 90 days
89201952|NCT00741650|Experimental|1|Information and peer advisor
89201953|NCT00741650|Experimental|2|Information, peer advisor and referral to further treatment
89201954|NCT00741650|No Intervention|3|Treatment as usual
89201955|NCT00666276||linezolid (Zyvox)|Patients taking Linezolid.
89464500|NCT04659863|Experimental|Inclisiran|Year 1 - inclisiran sodium 300 mg subcutaneous injection (given at Days 1, 90, and 270) Day 360 only - placebo subcutaneous injection Year 2 - inclisiran sodium 300 mg subcutaneous injection (given at Days 450 and 630)
89464501|NCT04659863|Placebo Comparator|Placebo|Year 1 - placebo subcutaneous injection (given at Days 1, 90 and 270) Year 2 - inclisiran sodium 300 mg subcutaneous injection (given at Days 360, 450, and 630)
89464502|NCT04628481|Experimental|Ladarixin|400 mg b.i.d. for 13 cycles of 14 days on/14 days off
89464503|NCT04628481|Placebo Comparator|Placebo|matching placebo b.i.d. for 13 cycles of 14 days on/14 days off
89464504|NCT04624204|Experimental|Group A - Pembrolizumab 200 mg|Participants will receive 4 cycles of standard-of-care chemotherapy (etoposide/platinum) plus pembrolizumab 200 mg every 3 weeks (Q3W) concurrently with standard thoracic radiotherapy, followed by 9 cycles of pembrolizumab 400 mg every 6 weeks (Q6W) plus olaparib matching placebo twice daily (BID) for 12 months or until specific discontinuation criteria are met.
89464505|NCT04624204|Experimental|Group B - Pembrolizumab 200 mg plus Olaparib 300 mg BID|Participants will receive 4 cycles of standard-of-care chemotherapy (etoposide/platinum) plus pembrolizumab 200 mg Q3W concurrently with standard thoracic radiotherapy, followed by 9 cycles of pembrolizumab 400 mg Q6W plus olaparib 300 mg BID for 12 months or until specific discontinuation criteria are met.
89464506|NCT04624204|Placebo Comparator|Group C (Pembrolizumab and Olaparib Matching Placebos)|Participants will receive 4 cycles of standard-of-care chemotherapy (etoposide/platinum) plus pembrolizumab placebo (saline) Q3W concurrently with standard thoracic radiotherapy, followed by 9 cycles of pembrolizumab placebo (saline) Q6W plus olaparib matching placebo for 12 months or until specific discontinuation criteria are met.
89464507|NCT04615130|Experimental|Intervention|Patients will undergo 6 weeks of outpatient rehabilitation.
89464508|NCT04615130|No Intervention|Control|Patients will receive no intervention throughout the 6 weeks period.
89464509|NCT04600258|Experimental|Chocolate Group|Administration of 40g dark chocolate per day, for 2 months
89464510|NCT04600258|No Intervention|Control Group|No intervention and analysis will be performed before and after 2 months
89464511|NCT04598828|Experimental|Treatment 1|Participants will receive Experimental treatment 1 stimulation for a duration of 12 weeks, twice daily for 19 minutes
89464512|NCT04598828|Experimental|Treatment 2|Participants will receive Experimental treatment 2 stimulation for a duration of 12 weeks, twice daily for 19 minutes
89464513|NCT04594525|Experimental|Perinatal women receiving Low intensity psychosocial interventions|One Arm (Intervention): Will receive baseline assessment (personal characteristics) and standard psychological distress screening tools Plus WHO-low intensity psychological interventions through Telemental health.
89464514|NCT04594525|No Intervention|Participants-Perinatal women (pregnant women and post-partum) not receiving intervention|One Arm (Control): baseline assessment (personal characteristics) and standard psychological distress screening tools without the WHO-low psychological intervention through Telemental health.
89464515|NCT04593459|Experimental|Probiotic|"Probiotic product consisting of these 7 bacterial strains:~Lactobacillus salivarius W57~Lactobacillus casei W56~Lactobacillus rhamnosus W71~Lactococcus lactis W58~Enterococcus faecium W54~Lactobacillus plantarum W62~Lactobacillus acidophilus W22~Additional ingredients: Corn starch, maltodextrin, fructo-oligosaccharides, galacto-oligosaccharides, polydextrose, plant proteins, potassium chloride, magnesium sulfate, bacterial strains, manganese sulfate, lactose, 2000 IU vitamin D~Participants ingest one sachet of powder (5 grams) in 200 ml of water per day for 6 months"
89464516|NCT04593459|Placebo Comparator|Placebo|"Similar to probiotic product in optics and smell, less ingredients and no bacterial strains or vitamin D~Ingredients: Corn starch, maltodextrin, potassium chloride, magnesium sulphate, manganese sulphate"
89464517|NCT04593459|Active Comparator|Metformin|"Metformin is an established drug for treating PCOS-related symptoms. The investigators are comparing the probiotic not only to a placebo group, but also to the benchmark treatment.~Participants in the metformin arm will start treatment with 500 mg daily for the first week, then increasing the dose to 2x500 mg daily for the duration of the intervention."
89501938|NCT05491460|Active Comparator|Apixaban|"Volunteers receive one oral dose of 5mg Apxiaban followed by sequential blood and urine sampling over 72 hours During the study liquid-chromatography mass-spectrometry analysis is performed in plasma and urine and DOAC Dipstick in urine.~Biological and clinical safety parameters are measured."
88945163|NCT01887119|Active Comparator|Eplerenone|Eplerenone 50 mg 1dd during four weeks
88945164|NCT01887119|Placebo Comparator|Placebo|Eplerenone-matched placebo
88945165|NCT01887145|Active Comparator|Open surgery|Open surgery is Open carpal tunnel release
88945166|NCT01887145|Experimental|Endoscopic surgery|Endoscopic surgery is 2-portal endoscopic carpal tunnel release
88945167|NCT01887158|Active Comparator|bisacodyl plus 2-Liter Polyethylene glycol|Patients randomized to the low-volume arm, will be invited to consume 2 sachets of Lovol-esse (Polyethylene glycol) in one liter of water at 8:00 PM the evening before the colonoscopy and 2 sachets in one liter of water 4 hours before their scheduled colonoscopy appointment; furthermore, the patients will be instructed to take three 5-mg tablets of bisacodyl the day before the procedure, at 5:00 PM.
88945168|NCT01887158|Active Comparator|4-Liter Polyethylene glycol|Patients assigned to the high-volume arm will be invited to consume 2 envelopes of Selg-esse 1000 (polyethylene glycol) in 2 litres of water and drink the resulting solution in about 2-3 hours starting at 6:00 PM the evening before the colonoscopy; the day of the procedure, starting 5 hours before the procedure, the patients will be invited to complete the preparation with 2 others envelopes of Selg-esse 1000 (polyethylene glycol) dissolved in 2 litres of water.
88945169|NCT01887184|Placebo Comparator|Normal Saline|Normal saline was given intranasally
89464518|NCT04581382|Experimental|Treatment (radiation therapy, plasma exchange, immunotherapy)|Patients undergo radiation therapy daily on days 1-5 (weekdays). Patients then undergo therapeutic plasma exchange over 1-2 hours on days 4-6 or 5-7. Beginning on day 7, patients receive pembrolizumab IV or nivolumab IV. Treatment with pembrolizumab continues every 3 weeks or treatment with nivolumab continues every 2 weeks in the absence of disease progression or unacceptable toxicity.
89464519|NCT04579991|Active Comparator|Active Group|Apply small amount of topical visnadin, ethyl ximeninate, coleus barbatus and millet in emulgel on mucosal surface of vulva included clitoris every day before bedtime for 8-week period.
89464520|NCT04579991|Placebo Comparator|Placebo Group|Apply small amount of topical emulgel-only on mucosal surface of vulva included clitoris every day before bedtime for 8-week period.
89464521|NCT04559464|Other|AeriSeal and Zephyr Valve Treatment|"Stage 1 will address the closure of the lobar fissure gaps (or collateral air channels) to block collateral ventilation (CV) with the AeriSeal System (conversion of the CV+ target lobe to CV-).~Stage 2 will include successfully converted subjects in Stage 1. Converted CV- target lobes will follow standard of care and receive the Zephyr Endobronchial valves per the Zephyr Instructions for Use (IFU) to perform bronchoscopic lung volume reduction (BLVR)."
89464522|NCT04558099|Experimental|MBSR|MBSR according to international standards (2.5 hours group session once a week in 8 weeks; a silence retreat day; and 45-60 minutes homework six days a week). Content in accordance with MBSR curriculum.
89464523|NCT04558099|No Intervention|Wait-list control|Usual practice
89464524|NCT04556929|Experimental|Intraoperative imaging of 5-ALA during tumour resection|Participants will undergo 5-ALA guided tumour resection via craniotomy with the aim of achieving maximal safe tumour resection without significant neurological deficit. On completion of tumour resection, digital images will be taken of the resection cavity under blue light using (i) an in-built camera in the operative microscope and (ii) an ultra-high sensitivity camera attached to the side arm of the operative microscope. Biopsies approximately 5x5x5mm in size will then be taken from the anterior, posterior, lateral and inferior areas of the resection cavity which were imaged. These biopsies will be analysed by histopathology to determine the presence of glioma cells.
89464525|NCT04548609|Experimental|Inhibitory Control/ Fear Extinction|This arm will investigate the effect of tDCS on tasks assessing Inhibitory Control/ Fear Extinction. This group will undergo three sessions of tDCS: two active sessions and one sham session. The order of the sessions is randomized.
89464526|NCT04548609|Experimental|Inhibitory Control/ Goal-Orientated vs Habit-Based Behavior|This arm will investigate the effect of tDCS on tasks assessing Inhibitory Control/ Goal-Orientated versus Habit-Based Behavior. This group will undergo three sessions of tDCS: two active sessions and one sham session. The order of the sessions is randomized.
89464527|NCT04542720||Observational: Decompression|Eligible patients may have a preference for the surgical procedure they wish to have. In these instances, they may choose to undergo a decompression alone or a decompression with extension of fusion. These patients are eligible for the study and will be enrolled under observational arms. This arm refers to the decompression alone observational study arm.
89464528|NCT04542720||Observational: Extension Fusion|Eligible patients may have a preference for the surgical procedure they wish to have. In these instances, they may choose to undergo a decompression alone or a decompression with extension of fusion. These patients are eligible for the study and will be enrolled under observational arms. This arm refers to the decompression with extension of fusion observational study arm.
89464529|NCT04540302|Experimental|AVF Peripheral study treatment group|Subjects randomised to treatment with the WRAPSODY Endovascular Stent Graft
89464530|NCT04540302|Other|AVF Peripheral control group|Subjects randomised to treatment with standard percutaneous transluminal angioplasty (PTA)
89464531|NCT04540302|Experimental|AVG Anastomosis|All subjects in this single arm cohort will receive treatment with the WRAPSODY Endovascular Stent Graft
89464532|NCT04538625|Placebo Comparator|Placebo|Subjects randomized to the placebo arm, will receive oral doses of matching placebo tablets twice daily with or without food.
89464533|NCT04538625|Experimental|Crofelemer|Subjects randomized to the crofelemer arm, will receive oral doses of crofelemer 125mg delayed-release tablets twice daily with or without food.
89464534|NCT04532814|Other|Lean|Control
88945170|NCT01887184|Active Comparator|Dexmedetomidine|1.5mcg dexmedetomidine was given intranasally before procedure
88945171|NCT01887197|Experimental|Repeatability|Subjects perform two sequential absorptive clearance scans (within 30 days) to determine the repeatability of the technique. Subjects also perform a third scan two years later so that longitudinal change can be measured.
88945172|NCT01887197|Experimental|Response|Subjects perform three different absorptive clearance scans. One is a baseline measurement while the other two measure absorptive clearance after an intervention (inhaled hypertonic saline, mannitol inhalation powder).
88945173|NCT01887223|Experimental|Transconjunctival needling revision|Eyes with primary glaucoma surgery failure with encapsulated bleb submitted to surgical revision
88945174|NCT01887223|Active Comparator|Medical treatment|Eyes with primary glaucoma surgery failure with encapsulated blebs were treated with medical treatment (hypotensive eye drops)
88945175|NCT01887236|Active Comparator|Step Physical Activity|A physical activity program that is based on the Step Apparatus Training Program
88945176|NCT01887236|Active Comparator|Stability Ball|A physical activity program that is based on the Stability Ball
88945177|NCT01887249|Experimental|15 day sequential eradication therapy|the 15-day sequential therapy regimen, which consisted of esomeprazole (40 mg) plus amoxicillin (1000 mg) twice a day for 5 days, then esomeprazole (40 mg) with clarithromycin (500 mg) and metronidazole (500 mg) twice a day for 10 days.
88945178|NCT01887249|Active Comparator|10-day sequential eradication therapy|the 10-day sequential therapy regimen, which consisted of esomeprazole (40 mg) plus amoxicillin (1000 mg) twice a day for 5 days, then esomeprazole (40 mg) with clarithromycin (500 mg) and metronidazole (500 mg) twice a day for another five days
89464535|NCT04532814|Experimental|Obese|
89464536|NCT04521621|Experimental|Part 1, Cohort A: Triple-Negative Breast Cancer|This arm will enroll participants with triple-negative breast cancer (TNBC) solid tumors. Participants receive gebasaxturev intratumorally for 8 cycles, and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 is 28 days, and cycles 2-35 are 21 days.
89464537|NCT04521621|Experimental|Part 1, Cohort B: Head and Neck Squamous Cell Carcinoma|This arm will enroll participants with head and neck squamous cell carcinoma (HNSCC) solid tumors. Participants receive gebasaxturev intratumorally for 8 cycles, and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 is 28 days, and cycles 2-35 are 21 days.
89464538|NCT04521621|Experimental|Part 1, Cohort C: Cutaneous Squamous Cell Carcinoma|This arm will enroll participants with cutaneous squamous cell carcinoma (cSCC) solid tumors. Participants receive gebasaxturev intratumorally for 8 cycles, and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 is 28 days, and cycles 2-35 are 21 days.
89464539|NCT04521621|Experimental|Part 2 Dose Level 1, Solid Tumors + Liver Metastases|This arm will enroll participants with solid tumors with liver metastases. Participants receive dose level 1 of gebasaxturev intratumorally for 8 cycles, and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 is 28 days, and cycles 2-35 are 21 days.
89464540|NCT04521621|Experimental|Part 2 Dose Level 2, Solid Tumors + Liver Metastases|This arm will enroll participants with solid tumors with liver metastases. Participants receive dose level 2 of gebasaxturev intratumorally for 8 cycles, and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 is 28 days, and cycles 2-35 are 21 days.
89464541|NCT04521621|Experimental|Part 2 Dose Level 3, Solid Tumors + Liver Metastases|This arm will enroll participants with solid tumors with liver metastases. Participants receive dose level 3 of gebasaxturev intratumorally for 8 cycles, and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 is 28 days, and cycles 2-35 are 21 days.
89464542|NCT04521621|Experimental|Part 2, Cohort D: Hepatocellular Carcinoma (HCC)|This arm will enroll participants with hepatocellular carcinoma (HCC) solid tumors. Participants receive the gebasaxturev recommended phase 2 dose (RP2D) intratumorally for 8 cycles, and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 is 28 days, and cycles 2-35 are 21 days.
89464543|NCT04521621|Experimental|Part 2, Cohort E: Gastric Carcinoma|This arm will enroll participants with gastric carcinoma solid tumors. Participants receive the gebasaxturev recommended phase 2 dose (RP2D) intratumorally for 8 cycles, and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 is 28 days, and cycles 2-35 are 21 days.
89464544|NCT04521231|Experimental|Dose Escalation Phase: Blinatumomab Subcutaneous Formulation 1 (SC1)|Cohorts of at least 3 participants each will be treated with escalating doses of bilinatumomab to determine the maximum tolerated dose (MTD). The MTD will be defined as the dose for which the estimate of the toxicity rate from an isotonic regression (Yan et al, 2017) is closest to the target toxicity rate. Safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy will be assessed.
88945179|NCT01887249|No Intervention|7-day PPI triple eradication therapy|7-day PPI triple therapy regimen, which consisted of esomeprazole (40mg) plus amoxicillin (1000mg) and clarithromycin (500mg) twice daily for 7 days.
88945180|NCT01887262|Experimental|Intervention|Incident peritoneal dialysis (PD) patients who are randomly allocated to BCM-guided fluid management will receive BCM measurement every two months over 1-year period. The BCM results will be notified to the physicians and the participating subjects. Based on the BCM results along with the clinical information such as blood pressure, edema and weight, the physicians will prescribe PD fluid and diuretics, targeting within 1L of overhydration status. They will prescribe dietary education to the patient, if necessary.
88945181|NCT01887262|Active Comparator|Control|BCM will be measured at the beginning and end of the study, respectively. However, the BCM results will be blinded to the physicians and the control group. The physician will prescribe drugs, PD fluids, and dietary education to the patients based on the clinical information alone - such as blood pressure, edema and body weight.
89018080|NCT05380739|Active Comparator|Online, Healthy|Cognitively intact older adults will undergo 10 sessions of WM training online.
89018081|NCT05379127|Other|Standard follow-up|standard care during follow-up
89018082|NCT05379127|Experimental|Patient-empowered follow-up|
89018083|NCT05376137|Active Comparator|Default comfort settings|Comfort settings will be set to default (out of the box setttings)
89018084|NCT05376137|Experimental|Personalized Therapy Comfort Settings|Comfort settings will be personalized to each user
89018085|NCT05367141|Active Comparator|CDSS|patient management with aid of CDSS
89018086|NCT05367141|No Intervention|standart care|patient management with standard care according to guidelines
89018087|NCT05343572|Experimental|Endometrial Disorders|"Three groups of patients, with 10 subjects per group:~Asherman's syndrome, as classified by the American Society of Reproductive Medicine (ASRM) by extent of uterine cavity involvement and adhesion type. Specifically, refractory Asherman's syndrome: patients who have had at least one operative hysteroscopy which was unsuccessful.~Atrophic endometrium, as defined by maximal endometrial lining thickness ≤6mm documented in at least 2 cycles on either:~Day of luteinizing hormone (LH) surge in natural cycle~Day of human chorionic gonadotropin (hCG) trigger in the setting of fresh IVF cycle~Day 14 of estradiol in the setting of frozen embryo transfer things (FET) cycles~Recurrent implantation failure, defined as failure to achieve a clinical pregnancy after transfer of at least four good-quality embryos in a minimum of three fresh or frozen transfer cycles in a woman under 40 years"
89018088|NCT05342675|Experimental|Rapid Rollover|Participants will have their body re-positioned upon being transferred to the stretcher from the CT scanner table such that the biopsy site is down. Participants will be maintained in the same position for the post-biopsy CT scanner as well as in the post-procedure recovery area for a minimum of 2 hours.
89018089|NCT05342675|No Intervention|Control|CT-guided lung biopsy will be performed per standard protocols
89018090|NCT05329337|Experimental|10 patients with high insulin levels (13.3 ± 9.2 microU/mL) and markers of metabolic syndrome|These are individuals who were isolated from the previous MetACTIV study due to their specific immune profile (Profile 2) defined by 43 immune activation markers and characterized by a high percentage of differentiated T cells and activated T cells.
89018091|NCT05329337|Active Comparator|20 patients with other immune profiles|
89464545|NCT04521231|Experimental|Dose Expansion Phase: Blinatumomab SC1|Up to 4 cohorts of participants with R/R B-ALL will be enrolled to the preliminary recommended phase 2 dose (RP2D) and schedule determined from dose escalation phase. Each cohort will aim to further assess safety, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy.
89464546|NCT04521231|Experimental|Ph-IIC: Clinical PK Evaluation of SC Blinatumomab Formulations|1 cohort of participants will be enrolled into the Ph-IIC arm. The clinical PK evaluation cohort (Ph-IIC) will be conducted to compare the PK of SC1 and SC2 formulations at the RP2D determined from the dose expansion phase, in participants with R/R B-ALL.
89464547|NCT04508296|Experimental|GEDVI-oriented de-escalation|Patients received de-escalation fluid management using either diuretics or ultrafiltration during continuous RRT. In the case of GEDVI > 650 mL/m2 the primary goal of de-escalation is to obtain a cumulative fluid balance after 48 hrs from the study baseline of 0 to -3000 mL. In the case of GEDVI < 650 mL/m2 he target fluid balance is in the range of 0 to +3000 mL
89464548|NCT04508296|Experimental|EVLWI-oriented de-escalation|Patients received de-escalation fluid management using either diuretics or ultrafiltration during continuous RRT. In the case of EVLWI > 10 mL/kg the primary goal of de-escalation is to obtain a cumulative fluid balance after 48 hrs from the study baseline of 0 to -3000 mL. In the case of EVLWI < 10 mL/kg, the target fluid balance is in the range of 0 to +3000 mL
89464549|NCT04505254|Experimental|Treatment (acalabrutinib, obinutuzumab)|Patients receive acalabrutinib PO BID every 12 hours starting on day 1 of cycle 1, and obinutuzumab IV over 4-6 hours on days 1 and 2 of cycle 3, and day 1 of cycles 4-8. Patients who do not achieve a complete response or remission after cycle 8 may receive single-agent acalabrutinib therapy PO BID for an additional 6 cycles at the discretion of their treating physician. Patients who are in partial response or who have stable disease receive an additional 6 cycles of acalabrutinib PO BID and obinutuzumab IV. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
89464550|NCT04501328|Experimental|CIC+VA-CRAFT|Coaching Into Care plus VA-CRAFT consists of four 45-min. telephone coaching calls over 8-12 weeks, delivered by a coach following a manual, while participants are completing the VA-CRAFT for PTSD web-based course.
89464551|NCT04501328|Active Comparator|CIC|Coaching Into Care is an existing national VA program that provides telephone consultation and coaching to family members of Veterans with mental health needs who want to help connect them with mental health care by providing referrals, educational information, and a unique coaching service to help callers talk to their Veterans about their decision to seek care.
89464552|NCT04496739|Active Comparator|Group I (educational materials)|Patients receive standard educational materials about breast cancer risk and chemoprevention in RealRisks via the patient portal or website.
89018092|NCT05325879|Active Comparator|Asymptomatic Individuals|Individuals aged between 18-50 who volunteered to participate in the study, will form the control group.
89018093|NCT05325879|Experimental|Individuals with neck pain|Individuals with neck pain aged between 18-50 who volunteered to participate in the study, will form the study group.
89018094|NCT05315726|Experimental|Phase 1|
89018095|NCT05315726|Experimental|Phase 2: Intervention group|
89018096|NCT05315726|Active Comparator|Phase 2: control group|
89018097|NCT05314283|Experimental|DV3395 C1|
89018098|NCT05313620|Experimental|Ulcerative colitis patients treated with tofacitinib|Tofacitinib 5 mg/day oral per clinical practice
89201956|NCT03880682||Study Group|Kidney transplant recipients with chronic HCV infection who were treated using direct acting antivirals.
89201957|NCT00567255|Experimental|NB32|Naltrexone SR 32 mg/bupropion SR 360 mg/day with ancillary therapy
89501939|NCT05491460|Active Comparator|Dabigatran|"Volunteers receive one oral dose of 150mg Dabigatran followed by sequential blood and urine sampling over 72 hours During the study liquid-chromatography mass-spectrometry analysis is performed in plasma and urine and DOAC Dipstick in urine.~Biological and clinical safety parameters are measured."
89464553|NCT04496739|Experimental|Group II (educational materials, decision support, interview)|Patients receive standard educational materials about breast cancer risk and chemoprevention in RealRisks via the patient portal or website. Patients receive patient-centered decision support within the patient portal via an action plan summarizing their breast cancer risk profile, their risks and benefits of SERMs and AIs, and personal preferences for chemoprevention. Health care providers receive decision support and action plans based on their patients' interactions with RealRisks via the BNAV provider-centered support tool within the EHR. A sample of patients participate in an audio-recorded interview via telephone or video conference over 45-60 minutes at 12 months after registration. A sample of health care providers participate in 3 audio-recorded interviews via telephone or video conference over 45-60 minutes each at baseline, within 12-36 months after study activation, and within 12 months after study closure to accrual.
89464554|NCT04484220|Experimental|Ellipsys Vascular Access System|The Ellipsys System is indicated for the creation of a proximal radial artery to perforating vein anastomosis via a retrograde venous access approach in patients who have chronic kidney disease requiring dialysis.
89464555|NCT04482244|Experimental|Cannabidiol|"After screening procedures confirm participation in the research study, participants will be randomized one of two groups:~Participants in the experimental arm will complete questionnaires and then receive a single dose of CBD prior to diagnostic CT scan or positron emission tomography (PET) .~Cannabidiol: Oral, per protocol dosage, single dose~Additional questionnaires 2 hours post scan and follow up via phone call 1 week regarding experience"
89464556|NCT04482244|Placebo Comparator|Placebo|"After the screening procedures confirm participation in the research study, participants will be randomized one of two groups:~Participants in the placebo arm will complete questionnaire and then receive a single dose of placebo prior to diagnostic CT scan or positron emission tomography (PET) .~Placebo: Oral, per protocol dosage, single dose~Additional questionnaires 2 hours post scan and follow up via phone call 1 week regarding experience"
89464557|NCT04474821|Experimental|Prevention (HPV educational program)|Patients receive educational materials on HPV and are asked of their willingness to proceed with the first HPV vaccination. Patients who express interest in receiving the HPV vaccination, then receive the first dose of the HPV vaccine and the next 2 doses approximately 2 months and 6 months following the initial vaccine.
89464558|NCT04470947||Next generation functional drug screening|
89464559|NCT04470947||Comprehensive genomic profiling|
89464560|NCT04470947||Physician's choice|
89464561|NCT04468087|Experimental|Atazanavir|600 mg (2 capsules) twice daily on the first day and 300 mg (1 capsule) twice daily for the subsequent 9 days.
89464562|NCT04468087|Experimental|Daclatasvir 60 mg|initial dose of 120mg (2 capsules), followed by 60mg (1 capsule) once daily for 9 days.
89464563|NCT04468087|Experimental|Sofusbuvir + Daclatasvir 60 mg|400 mg twice daily (2 capsules) on the first day and 400 mg (1 capsules) once daily for the subsequent 9 days (sofosbuvir) + initial dose of 120mg (2 capsules), followed by 60mg (1 capsule) once a day for 9 days (daclastavir)
88945182|NCT01887275|Experimental|medical ozone therapy with humares|
88945183|NCT01887275|Active Comparator|conventional interferon-α|
88945184|NCT01887314|Experimental|Standardized Ginger extract soft gel capsules|Patients receive 2 soft gel capsules of Ginger extract, twice a day
88945185|NCT01887314|Placebo Comparator|Placebo soft gel capsules|Patients receive 2 soft gel capsules of Placebo, twice a day
88945186|NCT01887340|Experimental|Cohort 1|"PET-TDM~carboplatine: Dose (mg) = AUC x (GFR + 25)~GFR : glomérulaire filtration (ml/min)~AUC : area under curve (mg/ml x min)"
88945187|NCT01887340|Experimental|Cohort 2|"PET-TDM~ETOPOSIDE (100 mg/m2 D1 to D5) and CISPLATINE (20 mg/m2 de D1 to D5)~carboplatine: Dose (mg) = AUC x (GFR + 25)~GFR : glomérulaire filtration (ml/min)~AUC : area under curve (mg/ml x min)"
88945188|NCT01887379|Experimental|GRDF furosemide fasting conditions|Subjects will be tested under fasting conditions after administration of GRDF Furosemide.
88945189|NCT01887379|Experimental|GRDF furosemide fed conditions|Subjects will be tested under fed conditions after administration of GRDF Furosemide.
88945190|NCT01887392|Experimental|Wave A|LTC Homes randomized into Wave A will receive the intervention first. The intervention includes Knowledge Translation Education Sessions.
88945191|NCT01887392|Experimental|Wave B|LTC Homes randomized into Wave B will receive the intervention after Wave A. The intervention includes Knowledge Translation Education Sessions.
88945192|NCT01887405|Active Comparator|Adrenaline: Session 1 Jext, 2 Epipen|Subjects will be randomised 1:1 to use Jext in session 1 and EpiPen in session 2.
89464564|NCT04468087|Placebo Comparator|Placebo Atazanavir|2 capsules twice daily on the first day and 1 capsule twice daily for the subsequent 9 days.
89464565|NCT04468087|Placebo Comparator|Placebo Daclatasvir|2 capsules twice daily on the first day and 1 capsule twice daily for the subsequent 9 days.
89464566|NCT04468087|Placebo Comparator|Placebo Sofusbuvir + Daclatasvir|2 capsules twice daily on the first day and 1 capsule twice daily for the subsequent 9 days.
89464567|NCT04463771|Experimental|Group A - retifanlimab|Select participants naïve to checkpoint inhibitors will be administered retifanlimab intravenously
88945193|NCT01887405|Active Comparator|Adrenaline: Session 1 Epipen, 2 Jext|Subjects will be randomised 1:1 to use EpiPen in session 1 and Jext in session 2.
88945194|NCT01887431|Experimental|Telecare|Each patient will transmit glucometer and pump data electronically via a web site to diabetes team and will receive feedback by telephone. Frequency of data transfer will be directly related to patients' metabolic control.
88945195|NCT01887431|Active Comparator|Conventional therapy|3-month routine clinic visits
88945196|NCT01887444|Experimental|Lactobacillus reteuri|Dietary Supplement: Lactobacillus reuteri DSM17938 probiotic 2 x 10(8) CFU/day 21 days
88945197|NCT01887444|Placebo Comparator|Placebo|Other: Placebo
88945198|NCT01887457|Experimental|Voriconazole|Standard adult Voriconazole (VFEND) Loading (1 hr infusion): 6mg/kg at 1 hour and 12 hours on day 1. Followed by standard maintenance dose 4mg/kg at 1 hour and 12 hours on day 2 (1 hour infusion). Day 3 follows the same schedule, expect the dose is adjusted, this dose is used on Day 4 and a further dose adjustment is made that is administered as above on Day 5.
88945199|NCT01887483|Active Comparator|Vetal Laban active|Vetal Laban with L. acidophilus
88945200|NCT01887483|Placebo Comparator|Placebo|Vetal Laban -like product without L. acidophilus
88945201|NCT01887496||Chickenpox complications|Cases were identified by International Classification of Disease of the Tenth Revision (ICD-10) diagnostic codes for chickenpox infection or chickenpox-associated complications, if available.
88945202|NCT01887535|Experimental|Cohort 1: JNJ-54861911 3 mg|Participants will be administered single doses of JNJ-54861911 on Days 1 to 14. Initially the doses will be once per day, but the frequency of daily dosing (eg, once-daily, twice-daily, three times daily) may change prior to or during study conduct depending on the pharmacokinetic data from the ongoing single-ascending dose study (54861911ALZ1001) or ongoing cohorts in this current study. Actual dose levels as well as the magnitude of dose escalation will depend on the results of the ongoing single-ascending dose study, the observed safety and tolerability profile as well as the observed exposures.
88945203|NCT01887535|Experimental|Cohort 2: JNJ-54861911 10 mg|
88945204|NCT01887535|Experimental|Cohort 3: JNJ-54861911 30 mg|
88945205|NCT01887535|Experimental|Cohort 4: JNJ-54861911 80 mg|
89464568|NCT04463771|Experimental|Group B - retifanlimab|Select participants naïve to checkpoint inhibitors will be administered retifanlimab intravenously
88945206|NCT01887535|Experimental|Cohort 5: JNJ-54861911 25 mg|
88945207|NCT01887535|Placebo Comparator|Cohorts 1-4: Placebo|Participants in Cohorts 1-4 will receive matching placebo.
88945208|NCT01887548|Experimental|Active CD|Patients whose CDAI score >150 points would be enrolled in this group.
88945209|NCT01887548|Active Comparator|Quiescent CD|Patients whose CDAI score ≤150 points would be enrolled in this group.
88945210|NCT01887561|No Intervention|treatment|
88945211|NCT01887574|Experimental|Open|
88945212|NCT01887613||Regnite group|Patients who receive Regnite
88945213|NCT01887626|Experimental|A|Ticagrelor 90 mg as a whole tablet
88945214|NCT01887626|Experimental|B|Ticagrelor 90 mg tablet crushed and suspended in water
88945215|NCT01887626|Experimental|C|Dispersed ticagrelor 90 mg tablet suspended in water and administered through a nasogastric tube into the the stomach
89464569|NCT04463771|Experimental|Group C - retifanlimab + epacadostat|Select participants who are allowed on prior checkpoint inhibitors will be administered retifanlimab intravenously in combination with oral epacadostat (IDO1 inhibitor)
88945216|NCT01887639||Unipolar major depression|Outpatients Individuals between 18 and 75 years old with a current episode of non-psychotic unipolar major depression that are treated with an antidepressant drug according to physician´s current and usual practice.
88945217|NCT01887665|Experimental|Incentives|Prize-based financial incentives, informed by contingency management principles, are offered to patients who attend treatment visits.
88945218|NCT01887691|Experimental|eszopiclone|We will evaluate the impact of pharmacologic enhancement of effective sleep with nightly eszopiclone (taken before bedtime for 1 week, home environment) on glycemic profiles (continuous glucose monitoring, 72 hrs) in prediabetics and diabetics compared to pretreatment baseline. The dose of eszopiclone will be the lowest tolerated dose (1-3 mg) via dose escalation and side effect profile assessment.
89201958|NCT00567255|Placebo Comparator|Placebo|Placebo with ancillary therapy
89464570|NCT04463771|Experimental|Group D - retifanlimab + pemigatinib|Select participants who are allowed on prior checkpoint inhibitors will be administered retifanlimab intravenously in combination with oral pemigatininb (FGFR 1,2,3 inhibitor)
89464571|NCT04463771|Experimental|Group E - retifanlimab + epacadostat|Select participants naïve to checkpoint inhibitors will be administered retifanlimab intravenously in combination with oral epacadostat
89464572|NCT04463771|Experimental|Group F - retifanlimab + INCAGN02385 and INCAGN02390|Select participants who are allowed on prior checkpoint inhibitors will be administered retifanlimab in combination with INCAGN02385 and INCAGN02390 intravenously
89464573|NCT04458857|Experimental|Fremanezumab|"Participants weighing ≥ threshold will receive Dose A subcutaneously monthly, for 3 months.~Participants weighing < threshold will receive Dose B subcutaneously monthly, for 3 months."
89464574|NCT04458857|Placebo Comparator|Placebo|Matching placebo
89464575|NCT04452084|Active Comparator|Control|
89464576|NCT04452084|Experimental|Experimental Procedure|
89464577|NCT04428905|Experimental|Arm I (personalized care plan, telehealth sessions)|Patients receive a personalized care plan/resource manual. Patients also participate in 5 telehealth sessions with a nurse over 60 minutes each for 4 months (months 1-4) about self-management skills building, then 3 maintenance telehealth sessions with a nurse over 60 minutes each for 3 months (months 5-7) for additional self-management skills building support. A copy of patient's care plan is also sent to their PCP.
89464578|NCT04428905|Active Comparator|Arm II (ASCO care plan, telehealth sessions)|Patients receive an ASCO care plan. Patients also participate in 5 telehealth sessions with a nurse over 60 minutes each for 4 months (months 1-4) to answer questions on a handbook about life after cancer treatment, then 3 monthly telehealth sessions with a nurse over 60 minutes each for 3 months (months 5-7) to answer questions about the handbook. A copy of the ASCO care plan is also sent to their PCP.
89464579|NCT04428151|Experimental|Lenvatinib + Pembrolizumab|Participants will be treated with the combination of lenvatinib (once daily 20 mg oral dose) plus pembrolizumab (200 mg 30-minute intravenous (IV) infusion on Day 1 of each 21-day cycle for 35 cycles), until centrally verified disease progression, or until a protocol-specified discontinuation criterion is met. Participants may receive up to an additional 17 cycles of pembrolizumab as Second Course treatment, with or without lenvatinib.
89464580|NCT04428151|Active Comparator|SOC Chemotherapy|Participants will be treated with investigator's choice of standard of care (SOC) chemotherapy (docetaxel, paclitaxel, cetuximab, or capecitabine) until centrally verified disease progression, or until a protocol-specified discontinuation criterion is met.
89464581|NCT04428151|Active Comparator|Lenvatinib Monotherapy|Participants will be treated with lenvatinib monotherapy (once daily 24 mg oral dose) until centrally verified disease progression, or until a protocol-specified discontinuation criterion is met.
89464582|NCT04410796|Experimental|Osimertinib alone|All patients will receive osimertinib 80mg orally daily. Subjects randomized to Arm A may be dispensed osimertinib for 2 cycles from Cycle 4 onward. Patients will be required to complete a pill diary beginning at Cycle 4.
89464583|NCT04410796|Experimental|Osimertinib plus Carboplatin and Pemetrexed|All patients will receive osimertinib 80mg orally daily. Patients receive Carboplatin (AUC 5 IV q 3 weeks) and Pemetrexed (500mg/m2 IV q 3 weeks) for a total of 4 cycles followed by pemetrexed maintenance from cycle 8 onwards. Patients will be required to complete a pill diary beginning at Cycle 4.
89464584|NCT04387656||Observational Cohort (data collection, biospecimen collection)|Patients undergo collection of medical information about COVID-19 symptoms, treatments/cancer treatments and outcomes, and results from laboratory tests and imaging scans performed as part of routine care for up to 2 years. Patients also undergo collection of blood samples at the same times they receive routine bloodwork up to 8 times for adults and up to 5 times for children. Patients who are hospitalized for COVID-19 undergo collection of blood samples at up to 6 additional times for adults and up to 3 additional times for children. Adult patients also complete quality of life questionnaire.
89464585|NCT04383275|Experimental|IRIS-A|
88945219|NCT01887704|Experimental|Rotablator|"Rotablator plus conventional angioplasty and/or stenting was performed in 120 patients in the R group.~Rotablator using 140, -160, 000 rpm, small rota burr (burr-to-artery ratio, 0.6:1), avoid drop of >5000 rpm for 5s.~Conventional intervention will be performed in the rotablator group. All subjects were given 100 mg/day aspirin and clopidogrel (300 mg loading dose and 75 mg/day maintenance dosage) at least 24 h before the procedure. A cutting balloon, buddy wire balloon, buddy wire, or DES (including sirolimus-eluting stent, paclitaxel-eluting stent, everolimus-eluting stent,zotarolimus-eluting stent) was implemented at the discretion of the operator in both groups."
88945220|NCT01887704|Active Comparator|Conventional|"Conventional angioplasty and/or stenting was performed in 120 patients in the C group.~Conventional intervention without rotablator was performed in the C group. All subjects were given 100 mg/day aspirin and clopidogrel (300 mg loading dose and 75 mg/day maintenance dosage) at least 24 h before the procedure. A cutting balloon, buddy wire balloon, buddy wire, or DES (including sirolimus-eluting stent, paclitaxel-eluting stent, everolimus-eluting stent,zotarolimus-eluting stent) was implemented at the discretion of the operator in both groups."
89201959|NCT00744458|Active Comparator|1|
89464586|NCT04383275|Experimental|IRIS-B|
89464587|NCT04382482||Tachidino|This group is being treated through the web platform Tachidino for remote rehabilitation of reading and spelling disorders
88945221|NCT01887730|Active Comparator|arm 2|Hand washing with soap and water according to instructions. The effect of intervention is assessed by following occurrence of infections.
88945222|NCT01887730|Placebo Comparator|arm 0|No specific advice on hand hygiene. The effect of intervention is assessed by following occurrence of infections.
88945223|NCT01887730|Active Comparator|Arm 3|Hand cleaning with alcohol-containing hand rub
88945224|NCT01887743|Experimental|Pantoprazole|This will be a single dose study where participants will receive 1.2mg/kg or no more than 100mg total one time dose as a liquid containing Carbon 13 labeled Pantoprazole with a final concentration of 4.0mg/mL.
88945225|NCT01887756|Experimental|Single arm study|The clients will receive tele-rehabilitation treatment via the Gertner Tele-Motion Rehabilitation system with remote online monitoring by the therapist. Treatment feedback is given in the form of Knowledge of results (game scores) and Knowledge of performance (feedback of compensatory movements made while using the upper extremity) to enhance motor learning. The software generates a report which includes the duration and type of exercises performed by the subject.
88945226|NCT01887769||Lung cancer patient at diagnosis|
88945227|NCT01887782|Experimental|HFL rTMS|High Frequency Left repetitive transcranial magnetic stimulation five days per week for 4 weeks
88945228|NCT01887782|Active Comparator|iTBS|intermittent Theta Burst Stimulation (iTBS) five days per week for 4 weeks
88945229|NCT01887795|Experimental|1. WBRT alone|Selected 224 patients with multiple brain metastases from NSCLC, they will be randomized to WBRT or Erotinib concurrent WBRT. It was enough to compare the efficacy of Erotinib concurrent WBRT vs. WBRT
89464588|NCT04381650|Experimental|Dose Escalation: TAK-981 + Pembrolizumab (Fixed Dose)|Escalating doses of TAK-981 with starting dose of 40 mg, intravenous (IV) infusion, on Days 1, 4, 8 and 11 or Days 1 and 8 or Days 1, 8 and 15 in each 21-day Treatment Cycle and pembrolizumab 200 mg, IV infusion, as a fixed dose every 3 weeks on Day 1 of 21-day Treatment Cycle until RP2D is determined (for a maximum of 24 months).
88945230|NCT01887795|Experimental|2. Erlotinib concurrent WBRT|Selected 224 patients with multiple brain metastases from NSCLC, they will be randomized to WBRT or Erotinib concurrent WBRT. It was enough to compare the efficacy of Erotinib concurrent WBRT vs. WBRT
88945231|NCT01887821|Active Comparator|Chloroquine|25mg base/kg for 3 days
88945232|NCT01887821|Active Comparator|Dihydroartemisinin/Piperaquine|Dihydroartemisinin 40 mg + piperaquine phosphate 320 mg per tablet; once daily for three days, doses depend on weight
89018099|NCT05313620|Active Comparator|Ulcerative colitis patients treated with an anti-TNFα drug|Infliximab (Infusion 5mg/kg milligram(s)/Kilogram-Intravenous use) per clinical practice, or adalimumab (Subcutaneus 40 mg milligram(s)-subcutaneus) per clinical practice, or golimumab (subcutaneus 50 mg milligram(s)-subcutaneus) per clinical practice
89501940|NCT05491460|Active Comparator|Edoxaban|"Volunteers receive one oral dose of 60mg Edoxaban followed by sequential blood and urine sampling over 72 hours During the study liquid-chromatography mass-spectrometry analysis is performed in plasma and urine and DOAC Dipstick in urine.~Biological and clinical safety parameters are measured."
89018100|NCT05313620|No Intervention|healthy controls|
89018101|NCT05306574|Experimental|Telitacicept 160 mg|Telitacicept 160 mg + SOC
89464589|NCT04381650|Experimental|Dose Expansion Phase: Cohort A: Non-squamous NSCLC|TAK-981 as IV infusion in participants with non-squamous non-small cell lung cancer (NSCLC) on Days 1, 4, 8 and 11 or Days 1 and 8 or Days 1, 8 and 15 in each 21-day Treatment Cycle up to disease progression or 24-months and pembrolizumab 200 mg IV infusion as a fixed dose every 3 weeks on Day 1 of 21-day Treatment Cycle for a maximum of 24 months.
89464590|NCT04381650|Experimental|Dose Expansion Phase: Cohort B: Cervical Cancer|TAK-981 as IV infusion in participants with cervical cancer on Days 1, 4, 8 and 11 or Days 1 and 8 or Days 1, 8 and 15 in each 21-day Treatment Cycle up to disease progression or 24-months and pembrolizumab 200 mg IV infusion as a fixed dose every 3 weeks on Day 1 of 21-day Treatment Cycle for a maximum of 24 months.
89464591|NCT04381650|Experimental|Dose Expansion Phase: Cohort C: MSS-CRC|TAK-981 as IV infusion in participants with microsatellite stable colorectal cancer (MSS-CRC) on Days 1, 4, 8 and 11 or Days 1 and 8 or Days 1, 8 and 15 in each 21-day Treatment Cycle up to disease progression or 24-months and pembrolizumab 200 mg IV infusion as a fixed dose every 3 weeks on Day 1 of 21-day Treatment Cycle for a maximum of 24 months.
89464592|NCT04381650|Experimental|Dose Expansion Phase: Cohort D: Cutaneous Melanoma|TAK-981 as IV infusion in participants with cutaneous melanoma on Days 1, 4, 8 and 11 or Days 1 and 8 or Days 1, 8 and 15 in each 21-day Treatment Cycle up to disease progression or 24-months and pembrolizumab 200 mg IV infusion as a fixed dose every 3 weeks on Day 1 of 21-day Treatment Cycle for a maximum of 24 months.
89464593|NCT04381650|Experimental|Dose Expansion Phase: Cohort E: Squamous NSCLC|TAK-981 as IV infusion in participants with squamous non-small cell lung cancer (NSCLC) on Days 1, 4, 8 and 11 or Days 1 and 8 or Days 1, 8 and 15 in each 21-day Treatment Cycle up to disease progression or 24-months and pembrolizumab 200 mg IV infusion as a fixed dose every 3 weeks on Day 1 of 21-day Treatment Cycle for a maximum of 24 months.
89464594|NCT04381650|Experimental|Dose Expansion Phase: Cohort F: CPI Refractory Squamous or Nonsquamous NSCLC|TAK-981 as IV infusion in participants with checkpoint inhibitors (CPI) refractory squamous or nonsquamous NSCLC on Days 1, 4, 8 and 11 or Days 1 and 8 or Days 1, 8 and 15 in each 21-day Treatment Cycle up to disease progression or 24-months and pembrolizumab 200 mg IV infusion as a fixed dose every 3 weeks on Day 1 of 21-day Treatment Cycle for a maximum of 24 months.
89464595|NCT04380753|Experimental|Treatment Arm|Subjects will be enrolled and will receive AMG 510 PO QD.
89464596|NCT04379596|Experimental|Arm 1A|T-DXd and 5-fluorouracil (5-FU)
89464597|NCT04379596|Experimental|Arm 1B|T-DXd and capecitabine
89464598|NCT04379596|Experimental|Arm 1C|T-DXd and durvalumab
89464599|NCT04379596|Experimental|Arm 1D(b)|T-DXd, capecitabine, and oxaliplatin
89464600|NCT04379596|Experimental|Arm 1E(a)|T-DXd, 5-FU, and durvalumab
88945233|NCT01887834|Placebo Comparator|Kyodophilus matching placebo capsules|"Kyodophilus Matching Placebo Capsules~Subjects will be provided with two bottles containing 30 capsules each of matching placebo upon randomization. Subjects will be instructed to take one capsule with breakfast daily for the full 12 weeks duration of the trial. While one bottle contains enough capsules for the time frame between each visit, two bottles have been provided to permit a surplus in the event scheduling conflicts arise. The third bottle, providing the remainder or study capsules, will be provided at visit 2."
88956467|NCT05137119|No Intervention|Methicillin-resistant staphylococcus aureus (MRSA) - Standard Therapy Arm (backbone therapy)|"Vancomycin or Daptomycin - Standard Therapy Arm~Either intravenous vancomycin dosed as per Australian Therapeutic Guidelines: This includes a loading dose of 25 mg/kg (up to 3000mg) if considered appropriate by the treating clinician, initial maintenance dosing at 15-20 mg/kg q12h, with subsequent adjustment to maintain area under the concentration-time curve (AUC) of 400 to 600 mg.hr/L OR trough levels at 10-20 mg/L, and the initial level taken 48-72 hours after the initiation of the first dose. Daptomycin 8-10mg/kg per day intravenously. The choice of vancomycin or daptomycin will be at the clinician's discretion. Dosing will be based on renal function."
89201960|NCT00744458|Active Comparator|2|
89464601|NCT04379596|Experimental|Arm 1E(b)|T-DXd, capecitabine, and durvalumab
89464602|NCT04379596|Active Comparator|Arm 2A|Trastuzumab, 5-FU or capecitabine, and cisplatin or oxaliplatin
89464603|NCT04379596|Experimental|Arm 2B|T-DXd monotherapy
89464604|NCT04379596|Experimental|Arm 2C|T-DXd, 5-FU or capecitabine
89464605|NCT04379596|Experimental|Arm 2D|T-DXd, pembrolizumab and 5-FU or capecitabine
89464606|NCT04379596|Experimental|Arm 2E|T-DXd and pembrolizumab
89464607|NCT04379596|Experimental|Arm 2F|T-DXd, pembrolizumab and 5-FU or capecitabine
89464608|NCT04379596|Experimental|Arm 3A|T-DXd, Volrustomig and 5-FU or capecitabine
89464609|NCT04379596|Experimental|Arm 3B|T-DXd, Volrustomig and 5-FU or capecitabine
89464610|NCT04379596|Experimental|Arm 4A|T-DXd, Rilvegostomig and 5-FU or capecitabine
89464611|NCT04379596|Experimental|Arm 4B|T-DXd, Rilvegostomig and 5-FU or capecitabine
88945234|NCT01887834|Active Comparator|Kyodophilus multi strain probiotic capsules|"Kyodophilus multi-strain probiotic capsules~The Kyo-Dophilus study product is a gelatin capsule containing three proprietary probiotic bacterial strains. The total quantity of bacteria per capsule is 1.5 billion colony forming units (1.5 x 109 cfu) and is composed of the following strains:~Lactobacillus gasseri KS-13 1.2~Bifidobacterium bifidum G9-1 0.15~Bifidobacterium longum MM-2 0.15~Subjects will be provided with two bottles containing 30 capsules each of matching placebo upon randomization. Subjects will be instructed to take one capsule with breakfast daily for the full 12 weeks duration of the trial. While one bottle contains enough capsules for the time frame between each visit, two bottles have been provided to permit a surplus in the event scheduling conflicts arise. The third bottle, providing the remainder or study capsules, will be provided at visit 2."
88945235|NCT01887847|Experimental|sublingual nicotine tablet|investigational 2 mg sublingual nicotine tablet
88945236|NCT01887847|Active Comparator|COMMIT nicotine lozenge|COMMIT 2 mg nicotine lozenge
88945237|NCT01887873|Other|Hyaluronan Thiomer i.o. implantable device|active treatment
88945238|NCT01887899|Experimental|transcranial direct current stimulation|
88945239|NCT01887899|Placebo Comparator|sham stimulation|
88945240|NCT01887925||breast cancer|breast cancer patients receiving chemotherapy
88945241|NCT01887951|Active Comparator|Tramadol|Tramadol HCL. Dosage form: Injection Strength: 50mg/ampoule Frequency: 1 time
88945242|NCT01887951|Experimental|Penthrox|Dosage form: Inhalation; Strength: 3ml/bottle; Frequency: Up to 6ml per day. Total weekly dose should not exceed 15ml.
88945243|NCT01887964|Other|Community-1|Received control flour first and then Resistant starch type 4 (RS4) flour
88945244|NCT01887964|Other|Community-2|Received RS4 flour first and then control flour
88945245|NCT01887977|Experimental|Computational modeling|
88945246|NCT01888016|Experimental|fascial manipulation|
88945247|NCT01888016|Active Comparator|standard treatment|
88945248|NCT01888029|Experimental|transcranial direct current stimulation|
88945249|NCT01888029|Placebo Comparator|sham stimulation|
88945250|NCT01888042|Experimental|Everolimus|Everolimus will be administered per os every day at the same hour immediately after a meal with a glass of water 10 mg (1 tablet of 10 mg)
88945251|NCT01888055|Experimental|transcranial direct current stimulation|
88945252|NCT01888055|Placebo Comparator|sham stimulation|
88945253|NCT01887652|Active Comparator|conventional ovarian stimulation|women whose protocol of ovarian stimulation was based on age, ovarian size and previous treatment
89464612|NCT04372953|Active Comparator|Static PEEP Group|Delivery of PEEP at 5-6 cmH2O via a T-piece resuscitator using an initial fraction of inspired oxygen (FiO2) of 0.30 via local standard interface (facemask, nasopharyngeal tube or nasal prong). FiO2 and other aspects of respiratory care are then titrated using a standardised resuscitation algorithm.
89464613|NCT04372953|Experimental|Dynamic PEEP Group|"Dynamic delivery of PEEP at 8 cmH2O via a T-piece resuscitator using an initial fraction of inspired oxygen (FiO2) of 0.30 via local standard interface (facemask, nasopharyngeal tube or nasal prong). PEEP levels increased step-wise to 10 and/or 12 cmH2O if FiO2/respiratory care needs to be escalated as per a standardised resuscitation algorithm.~If an infant shows evidence of respiratory improvement during resuscitative care, PEEP will be reduced in a stepwise method by 2 cmH2O each reduction, but to no lower than 8 cmH2O."
89464614|NCT04362865||COVID-19 infection|Patients with confirmed or suspected COVID-19 infections
89464615|NCT04362865||No COVID-19 infection|Patients without confirmed or suspected COVID-19 infections (i.e., normal donors)
89464616|NCT04353804|Experimental|Computerized Cognitive Rehabilitation|Computerized Cognitive Rehabilitation
89464617|NCT04353804|Active Comparator|Active Control computer games|Active Control computer games
89464618|NCT04353492|Experimental|Ofatumumab|Ofatumumab 20 mg subcutaneous injections every 4 weeks, following loading of 3 doses in the first 14 days
89464619|NCT04350138|Experimental|Group 1|Bexsero vaccine will be administered as an intramuscular injection in 1 mL single-dose prefilled syringe in two doses with a two-month apart (at enrollment/Visit 1 and Visit 3). N=1100.
89464620|NCT04350138|Placebo Comparator|Group 2|Placebo will be administered as an intramuscular injection in single-dose prefilled syringe in two doses with a two-month apart (at enrollment/Visit 1 and Visit 3). N=1100.
89464621|NCT04346108|Experimental|Epoch 1: IGIV 200-600 mg/kg|Participants received 200 to 600 mg/kg of Immunoglobulin Intravenous (IGIV) infusion for every 3 or 4 weeks for up to 13 weeks.
88945254|NCT01887652|Active Comparator|individualized ovarian stimulation|women whose protocol of ovarian stimulation was based on anti-mullerian hormone
88945255|NCT01888068||No treatment|
88945256|NCT01888081|Experimental|A-dmDT390-bisFv(UCHT1) with Ionizing Radiation|A-dmDT390-bisFv(UCHT1) Fusion Protein in Combination With Ionizing Radiation
88945257|NCT01888094|Experimental|ultrasound guided for cannulation and examination|Prospective, randomized controlled clinical unicentric study, in ICU, Cannulation of the subclavian venous and examination guided with ultrasound
88945258|NCT01888094|Other|landmark method and examination with chest radiography|Prospective, randomized controlled clinical unicentric study, in ICU, Cannulation of the subclavian venous and examination guided with ultrasound
88945259|NCT01888107|Experimental|Risperidone Long-acting Injectable (LAI)|Risperidone LAI will be administered in dosages of 25, 37.5, and 50 mg.
88945260|NCT01888120||Severe Chronic Pain|
89018102|NCT05306574|Experimental|Telitacicept 240 mg|Telitacicept 240 mg + SOC
89018103|NCT05306574|Placebo Comparator|Placebo|Placebo + SOC
88945261|NCT01888133|Experimental|Group Walk First|Participants attend a weekly walking group session from weeks 1-6 and are not required to attend from weeks 7-12.
88945262|NCT01888133|Experimental|Individual Walk First|Participants are not required to attend a weekly group walking sessions from weeks 1-6 and attend a weekly walking group session from weeks 7-12.
89464622|NCT04346108|Experimental|Epoch 2: IGSC (20%) 50-200 mg/kg|Participants who entered to Epoch 2 from Epoch 1 received 50-200 mg/kg of Immune Globulin Subcutaneous (Human) 20% infusion once a week up to approximately 24 weeks after Epoch 1.
88945263|NCT01888146|Experimental|Interdisciplinary pain program|Interdisciplinary pain program, which includes behavioral health, nurse case management, physical therapy, and pharmacy embedded in primary care.
88945264|NCT01888146|No Intervention|Treatment as usual|Patients in this arm will receive care as usual and utilize services as they currently exist in the health plan system.
88945265|NCT01887028|Experimental|12mmHg intraperitoneal pressure (cool, dry CO2 gas )(n=20)|
88945266|NCT01887028|Other|12mmHg intraperitoneal pressure (warmed, humidified CO2 gas)|
88945267|NCT01887028|Other|8mmHg intraperitoneal pressure with cool, dry CO2 gas (n=20)|
88945268|NCT01887028|Other|8mmHg intraperitoneal pressure (warmed, humidified CO2 gas)|
88945269|NCT01888159|Active Comparator|Tubal Sterilization with bipolar|Salpingectomy vs Tubal Sterilisation
88945270|NCT01888159|Active Comparator|Bilateral Salpingectomy|Salpingectomy vs Tubal Sterilisation
88945271|NCT01888172|Experimental|Weight Watchers Online|
88945272|NCT01888172|Experimental|Weight Watchers Online + ActiveLink|
88945273|NCT01888172|Active Comparator|Internet Delivered Eating and Activity Program|
88945274|NCT01888185||Parkinson's Disease (PD)|Patients with a clinical diagnosis of PD (in various stages)
88945275|NCT01888185||Progressive supranuclear palsy (PSP)|Patients with a clinical diagnosis of PSP (in various stages)
88945276|NCT01888185||Multiple system atrophy (MSA)|Patients with a clinical diagnosis of MSA (in various stages)
88945277|NCT01888185||Controls|Age and gender-matched adults free from neurological disease
88945278|NCT01888211|Experimental|Omega 3 fatty acid supplementation|Omacor 2 grams daily
88945279|NCT01888211|Placebo Comparator|Olive Oil|Olive Oil capsule 2 grams daily
88945280|NCT01888224|Experimental|Isotretinoin capsules, 40 mg|Isotretinoin Capsules, 40 mg of Dr.Reddy's Laboratories Ltd
88945281|NCT01888224|Active Comparator|AMNESTEEM|AMNESTEEM 40 mg of Mylan Pharmaceuticals Inc
88945282|NCT01888237|Active Comparator|Sequential therapy (ST)|10 day Sequential therapy: lansoprazole 30 mg b.d. plus amoxicillin 1000 mg b.d. for 5 days then lansoprazole 30 mg b.d., metronidazole 400 mg b.d. and clarithromycin 500 mg b.d. for the remaining 5 days
89464623|NCT04346108|Experimental|Epoch 3: IGSC (20%) 100-400 mg/kg|Participants who entered to Epoch 3 from Epoch 1 received 100-400 mg/kg of Immune Globulin Subcutaneous (Human) 20% infusion biweekly up to approximately 12 weeks after Epoch 2.
89464624|NCT04333433||MicroShunt treatment group|Subjects previously randomized to this arm in pivotal study conducted under IDE G130028 were implanted with the device
89464625|NCT04333433||Trabeculectomy control arm|Subjects previously randomized to this arm in pivotal study conducted under IDE G130028 underwent trabeculectomy procedure
89464626|NCT04324112|Experimental|Arm 1/Experimental therapy|Treatment with encorafenib and binimetinib
89464627|NCT04322383|Experimental|Arm 1/Experimental therapy|Treatment with binimetinib
89464628|NCT04312126||Arm 1|46 healthy young (18-35) volunteers
88945283|NCT01888237|Experimental|High dose PPI triple therapy(TT)|10 day high dose PPI triple therapy: lansoprazole 60 mg b.d. plus clarithromycin 500 mg b.d. and amoxycillin 1000 mg b.d. for 10 days
88945284|NCT01888250|Experimental|Lamotrigine Extended Release Tablets|Lamotrigine Extended Release Tablets, 25 mg, 50 mg, 100 mg, 200 mg and 300 mgof Dr. Reddy's Laboratories Limited
89464629|NCT04312126||Arm 2|46 healthy older (50-80) volunteers
89464630|NCT04312126||Arm 3|46 chronic (>6 months post-stroke) stroke patients
88945285|NCT01888250|Active Comparator|LAMICTAL XR|(containing Lamotrigine)Extended Release tablets 200mg of GlaxoSmithKline Research Triangle Park, NC
88945286|NCT01888263|Experimental|Lamotrigine Extended Release Tablets|Lamotrigine Extended Release Tablets, 25 mg, 50 mg, 100 mg, 200 mg and 300 mgof Dr. Reddy's Laboratories Limited
88945287|NCT01888263|Active Comparator|LAMICTAL XR|(containing Lamotrigine)Extended Release tablets 200mg of GlaxoSmithKline Research Triangle Park, NC
88945288|NCT01888276|Other|healthy volunteers|evaluation of word generation and of motivation
88945289|NCT01888276|Other|compulsive gamblers|evaluation of word generation and of motivation
88945290|NCT01888289|Experimental|Isotretinoin capsules, 40 mg|Isotretinoin Capsules, 40 mg of Dr.Reddy's Laboratories Ltd
88945291|NCT01888289|Active Comparator|ACCUTANE|ACCUTANE 40 mg of Roche Laboratories Inc
88945292|NCT01888302|Experimental|Treatment (cisplatin, gemcitabine hydrochloride, sirolimus)|Patients receive cisplatin IV over 1 hour and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, and sirolimus PO daily or three times weekly. Treatment repeats every 3 weeks for up to 8 courses in the absence of disease progression or unacceptable toxicity.
88945293|NCT01888315|Experimental|Catheter-based renal denervation|"One procedure will be performed using one of the CE-marked devices for renal denervation:~Device: Renal denervation with Symplicity Flex Medtronic/Ardian Device: Renal denervation with EnligHTN St. Jude Medical Device: Renal denervation with Paradise Recor Device: Renal denervation with V2 Vessix"
88945294|NCT01888315|No Intervention|Medical therapy|Best medical therapy using guideline recommended drugs in each disease state.
88945295|NCT01888328|Experimental|Isotretinoin capsules, 40 mg|Isotretinoin Capsules, 40 mg of Dr.Reddy's Laboratories Ltd
88945296|NCT01888328|Active Comparator|ACCUTANE|ACCUTANE 40 mg of Roche Laboratories Inc
88945297|NCT01888341|Experimental|Isotretinoin capsules, 20 mg|Isotretinoin Capsules, 20 mg of Dr.Reddy's Laboratories Ltd
88945298|NCT01888341|Active Comparator|ACCUTANE|ACCUTANE 20 mg of Roche Laboratories Inc
88945299|NCT01888354|Experimental|Acthar Gel 80 IU x 14 days|Acthar Gel 80 IU SQ x 14 days
88945300|NCT01888354|Experimental|Acthar Gel 80 IU x 5 days|Acthar Gel 80 IU SQ x 5 days
88945301|NCT01888380|Experimental|Foetuses|"still birth and termination of pregnancies~intervention: minimally invasive, virtual autopsy"
89464631|NCT04311723|Active Comparator|Group I (conventional mechanical ventilation)|Patients receive anesthesia using a standard short breathing tube called LMA and then undergo standard of care bronchoscopy.
89464632|NCT04311723|Experimental|Group II (VESPA)|Patients receive anesthesia using a longer breathing tube called an endotracheal tube and then undergo standard of care bronchoscopy.
88945302|NCT01888380|Experimental|Newborns|"who died of natural- and non-natural cause~intervention: minimally invasive, virtual autopsy"
88945303|NCT01888380|Experimental|Children and adolescents|"who died of natural- and non-natural cause~intervention: minimally invasive, virtual autopsy"
88945304|NCT01888393|Experimental|Group A|Approximately 12 subjects (male and female) with moderate hepatic impairment
88945305|NCT01888393|Experimental|Group B|Approximately 12 healthy subjects (male and female)
88945306|NCT01888406|Experimental|Guided Self-Help|Participants receive self-help materials, including a book (Overcoming Binge Eating by C. Fairburn, handouts, and online resources. In addition, participants receive 8 individual sessions with a peer coach who supports participants in working the self-help program.
88945307|NCT01888406|Other|Pure Self-Help|Participants receive self-help materials, including a book (Overcoming Binge Eating by C. Fairburn, handouts, and online resources.
89464633|NCT04302025|Experimental|ALK Cohort|Participants will receive up to 8 weeks of alectinib neoadjuvant treatment before undergoing surgical resection per standard of care. All participants that undergo surgical resection and whose tumors have pathological response or lack radiographic progression will be eligible for the Adjuvant Treatment Phase with alectinib. Adjuvant therapy will consist of 4 cycles of chemotherapy followed by up to 2 years of alectinib.
88945308|NCT01888419|No Intervention|No active treatment|Clinical follow-up, no active intervention.
88945309|NCT01888419|Experimental|Lipotransplantation|Lipotransplantation in general anaesthesia to the mastectomy site.
88945310|NCT01888445|Experimental|ASP1517 Low dose group|Participants received an oral dose of ASP1517 three times a week.
89464634|NCT04302025|Experimental|ROS 1 Cohort|Participants will receive up to 8 weeks of entrectinib neoadjuvant treatment before undergoing surgical resection per standard of care. All participants that undergo surgical resection and whose tumors have pathological response or lack radiographic progression will be eligible for the Adjuvant Treatment Phase with entrectinib. Adjuvant therapy will consist of 4 cycles of chemotherapy followed by up to 2 years of entrectinib.
89464635|NCT04302025|Experimental|NTRK Cohort|Participants will receive up to 8 weeks of entrectinib neoadjuvant treatment before undergoing surgical resection per standard of care. All participants that undergo surgical resection and whose tumors have pathological response or lack radiographic progression will be eligible for the Adjuvant Treatment Phase with entrectinib. Adjuvant therapy will consist of 4 cycles of chemotherapy followed by up to 2 years of entrectinib.
89464636|NCT04302025|Experimental|BRAF Cohort|"Participants will receive up to 8 weeks of vemurafenib plus cobimetinib neoadjuvant treatment before undergoing surgical resection per standard of care. All participants that undergo surgical resection and whose tumors have pathological response or lack radiographic progression will be eligible for the Adjuvant Treatment Phase with vemurafenib plus cobimetinib. Adjuvant therapy will consist of 4 cycles of chemotherapy followed by up to 2 years of of vemurafenib plus cobimetinib.~Enrollment closed."
89464637|NCT04302025|Experimental|RET Cohort|"Participants will receive up to 8 weeks of pralsetinib neoadjuvant treatment before undergoing surgical resection per standard of care. All participants that undergo surgical resection and whose tumors have pathological response or lack radiographic progression will be eligible for the Adjuvant Treatment Phase with pralsetinib. Adjuvant therapy will consist of 4 cycles of chemotherapy followed by up to 2 years of pralsetinib.~Enrollment closed."
89464638|NCT04302025|Experimental|PD-L1 Cohort|Participants with positive PD-L1 in ≥1% tumor cells will receive 4 cycles of atezolizumab neoadjuvant treatment. During neoadjuvant Cycle 1 of atezolizumab, patients will also receive low-dose SBRT (8Gy X 3). Adjuvant treatment consists of SOC treatment as determined by the investigator, per NCCN guidelines
89201961|NCT00744458|Active Comparator|3|
89464639|NCT04302025|Experimental|KRAS G12C Cohort|Participants will receive up to 8 weeks of divarasib as neoadjuvant treatment before undergoing surgical resection per standard of care. PD-L1 negative patients whose tumors have pathological response or lack radiographic progression will be have the option of continuing divarasib for up to 2 years as adjuvant therapy
89464640|NCT04296604|Experimental|Traumatic Brain Injury|This group consists of individuals diagnosed with traumatic brain injury. This group will undergo three sessions of tDCS: two active sessions and one sham session. The order of the sessions is randomized.
89464641|NCT04296604|Experimental|Major Depressive Disorder|This group consists of individuals diagnosed with major depressive disorder. This group will undergo three sessions of tDCS: two active sessions and one sham session. The order of the sessions is randomized.
89464642|NCT04296604|Experimental|Bipolar Disorder|This group consists of individuals diagnosed with bipolar disorder. This group will undergo three sessions of tDCS: two active sessions and one sham session. The order of the sessions is randomized.
89464643|NCT04296604|Experimental|Schizophrenia|This group consists of individuals diagnosed with schizophrenia. This group will undergo three sessions of tDCS: two active sessions and one sham session. The order of the sessions is randomized.
89464644|NCT04296604|Experimental|Attention Deficit Hyperactivity Disorder|This group consists of individuals diagnosed with attention deficit hyperactivity disorder. This group will undergo three sessions of tDCS: two active sessions and one sham session. The order of the sessions is randomized.
89464645|NCT04296604|Experimental|Borderline Personality Disorder|This group consists of individuals diagnosed with borderline personality disorder. This group will undergo three sessions of tDCS: two active sessions and one sham session. The order of the sessions is randomized.
89464646|NCT04296604|Experimental|Substance Use Disorder|This group consists of individuals diagnosed with substance use disorder. This group will undergo three sessions of tDCS: two active sessions and one sham session. The order of the sessions is randomized.
89464647|NCT04296604|Active Comparator|Healthy Controls|This group consists of individuals diagnosed with healthy controls. This group will undergo three sessions of tDCS: two active sessions and one sham session. The order of the sessions is randomized.
89464648|NCT04294667|Experimental|Dapirolizumab pegol|Subjects will receive dapriolizumab pegol througout the Treatment Period.
89464649|NCT04294667|Placebo Comparator|Placebo|Subjects will receive placebo througout the Treatment Period.
89464650|NCT04289389||HUNT4 70+|All inhabitants in Nord-Trøndelag 70 years of age and older were invited.
88945311|NCT01888445|Experimental|ASP1517 Middle dose group|Participants received an oral dose of ASP1517 three times a week.
88945312|NCT01888445|Experimental|ASP1517 High dose group|Participants received an oral dose of ASP1517 three times a week.
89464651|NCT04289389||HUNT4 Trondheim 70+|All inhabitants of one district in Trondheim 70 years of age and older were invited.
89464652|NCT04287530|Experimental|Tachidino + PUFA supplementation|Group 1 will be treated with the usual rehabilitation protocol adopted at IRCCS E. Medea (remote intervention delivered through the Tachidino platform). The program will be delivered during four weeks, starting two months after the pre-testing session. Additionally, the children will receive daily supplementation with 6 daily PUFA (Omega-3 and Omega-6) chewable capsules from the beginning (immediately after the pre-testing session) to the end (immediately before the post-testing session) of the observation period, for a total of three months.
88945313|NCT01888445|Active Comparator|Darbepoetin group|Participants received Darbepoetin alfa intravenously once a week.
88945314|NCT01888458|Experimental|Micafungine|
88945315|NCT01888471|Other|Cases Group|"Cases Group will be defined as:~Maternal subjects identified with invasive GBS disease from the enrolled maternal-newborn dyad Study cohort: Cases will be classified as follows:~EOD (Early onset disease): isolation of GBS from the blood or cerebrospinal fluid (CSF) within 0-6 days of birth.~LOD (Late onset disease): isolation of GBS from the blood or cerebrospinal fluid (CSF) within 7-90 days of birth."
88945316|NCT01888471|Other|Controls Group|Controls will be defined as newborns to mothers, enrolled into the study and identified as colonized by a serotype which is homologous to that of cases, but who do not develop invasive GBS disease.
88945317|NCT01888510|Experimental|Diagnostic (imaging studies)|Patients undergo conventional free breathing CT, 4D CT, ABC CT, ABC CBCT, and free breathing CBCT before undergoing radiation therapy.
88945318|NCT01888523|Experimental|Everyday experiences writing|Involves logging in to an online survey and writing in the survey about your everyday experiences. This requires 20-30 minutes of writing a day for 4 consecutive days. You will also provide saliva samples.
88945319|NCT01888523|Experimental|Expressive writing|Involves logging in to an online survey and writing in the survey about your thoughts and feelings about your cancer. This requires 20-30 minutes of writing a day for 4 consecutive days. You will also provide saliva samples.
88945320|NCT01888536|Experimental|Limaprost & Placebo|Limaprost 5㎍ tablet and a capsule of Pegabalin-Placebo thrice a day for 8 weeks.
89464653|NCT04287530|Active Comparator|Tachidino + Placebo|Group 2 will be treated with the usual rehabilitation protocol adopted at IRCCS E. Medea (remote intervention delivered through the Tachidino platform), delivered during four weeks, starting two months after the pre-testing session, exactly as Group 1. Additionally, the children will receive daily supplementation with 6 daily Placebo (triglycerides) chewable capsules from the beginning (immediately after the pre-testing session) to the end (immediately before the post-testing session) of the observation period, for a total of three months.
88945321|NCT01888536|Active Comparator|Pregabalin & Placebo|Pregabalin 75mg capsule and a tablet of Limaprost-Placebo thrice a day for 8 weeks.
89464654|NCT04287530|Experimental|PUFA supplementation|Groups 3 will receive only daily supplementation with 6 daily PUFA (Omega-3 and Omega-6) chewable capsules from the beginning (immediately after the pre-testing session) to the end (immediately before the post-testing session) of the observation period, for a total of three months.
89464655|NCT04287530|Placebo Comparator|Placebo|Groups 4 will receive only daily supplementation with 6 daily Placebo (triglycerides) chewable capsules from the beginning (immediately after the pre-testing session) to the end (immediately before the post-testing session) of the observation period, for a total of three months.
89464656|NCT04287530|No Intervention|Control group|Typically Developing participants, as a comparison group for experimental tasks and for PUFA levels in the blood
89464657|NCT04286178|Experimental|Treatment|patients in this arm will be treated with creatine and coenzyme Q10 supplements
89464658|NCT04286178|Placebo Comparator|Placebo|patients in this arm will be given placebo supplements that look and taste identical to the active supplements
89464659|NCT04270149|Experimental|ESR1 peptide vaccine|200 mcg ESR1 peptides plus 1ml Montanide and 100 mcg GM-CSF administered subcutaneously weeks 0, 1, 2, 4, 5, 6 for a total of 6 injections.
89464660|NCT04269928||Adrenal Artery Ablation|Patients in the intervention group will be treated with ablation of adrenal gland by endovascular injection of dehydrated alcohol
89464661|NCT04269928||Adrenalectomy|Patients in this group will be treated with unilateral laparoscopic adrenalectomy
89464662|NCT04256967||Sport sciences|Bachelor and master students who study sport science or physical activity and health science
89464663|NCT04256967||Controls|Bachelor and master students who study other fields not related to sport or physical activity and health sciences.
89464664|NCT04254289|Active Comparator|Usual Care|Usual care administered at the Pulmonary Arterial Hypertension (PAH) clinic at the University of Michigan.
89464665|NCT04254289|Experimental|Home-based exercise program|Home-based individualized exercise program based on heart rate reserve (HRR).
89464666|NCT04246164|Active Comparator|HD-tDCS combined with CT|HD-tDCS combined with CT, administered to participants with amnestic MCI (aMCI) in blocks of 5 daily treatments for a total of 15 sessions. There will be one treatment block/month for a total of 3 months
88945322|NCT01888536|Active Comparator|Limaprost+Pregabalin|Limaprost 5㎍ tablet and Pregabalin 75mg capsule thrice a day for 8 weeks.
88945323|NCT01888549|Experimental|arm1-High dose PPI|
89464667|NCT04246164|Sham Comparator|sham HD-tDCS combined with CT|sham HD-tDCS combined with CT, administered to participants with amnestic MCI (aMCI) in blocks of 5 daily treatments for a total of 15 sessions. There will be one treatment block/month for a total of 3 months
89464668|NCT04242199|Experimental|Cohort 1|Participants with select solid tumors who are immunotherapy treatment-naive
89464669|NCT04242199|Experimental|Cohort 2|Participants with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR) tumors who are immunotherapy treatment-naïve.
89464670|NCT04242199|Experimental|Cohort 3|Participants with progression of any solid tumor treated with an approved anti-PD-1 monoclonal antibody therapy
89464671|NCT04239989|Experimental|Treatment (itacitinib)|Patents receive itacitinib PO QD for up to 1 year in the absence of disease progression or unacceptable toxicity.
89464672|NCT04221542|Experimental|Part 1: AMG 509 Intravenous (IV) Monotherapy|"Part 1 will evaluate AMG 509 in participants with metastatic castration-resistant prostate cancer (mCRPC) who have been previously treated with novel hormonal therapy (NHT) and 1 to 2 prior taxanes.~The dose exploration phase of the study will estimate the MTD of AMG 509 using a Bayesian logistic regression model (BLRM; Neuenschwander et al, 2008).~RP2D may be identified based on emerging safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) data, as well as patient experience prior to reaching an MTD. Alternative dosing schedule(s) (including a third step dose) may be explored based on emerging efficacy, safety, PK data and patient experience.~During the dose expansion phase, individual cohorts of participants from China will be enrolled with a safety lead-in at 1 dose level below the MTD or RP2D followed by evaluation at the MTD or RP2D to confirm the safety, tolerability, MTD and/or RP2D of AMG 509 in Chinese participants."
89501941|NCT05491460|Active Comparator|Rivaroxaban|"Volunteers receive one oral dose of 20mg Rivaroxaban followed by sequential blood and urine sampling over 72 hours During the study liquid-chromatography mass-spectrometry analysis is performed in plasma and urine and DOAC Dipstick in urine.~Biological and clinical safety parameters are measured."
88945324|NCT01888549|Active Comparator|arm2-standard dose PPI|
88945325|NCT01888549|Placebo Comparator|arm3-placebo|Esomeprazole placebo
88945326|NCT01888562|Experimental|Ponatinib|Ponatinib 45mg po daily for 4 weeks (4 weeks equal 1 cycle).
88945327|NCT01888575||Aspirin discontinuers; Aspirin non-discontinuers|Patients on low dose ASA for secondary prevention that discontinue aspirin and those not discontinuing aspirin
88945328|NCT01888575||Drug|PPI continuous use; No PPI use
88945329|NCT01888588||Cases|Patients with symptomatic peptic ulcer (UPU)
88945330|NCT01888588||Control group|Control group without symptomatic peptic ulcer (UPU).
88945331|NCT01888614||Sickle Cell Patients|Patients with Sickle Cell, over 18 years of age
88945332|NCT01888627|Experimental|Integrated care|The IC model was implemented into a network of the Psychosis Center of the University hospital (UKE), private psychiatrists of the UKE catchment area and other outpatient facilities. Integrated Care involves ACT treatment within this network. Patients have access to all evidence-based interventions according to need.
88945333|NCT01888666||rapid palatal expansion (RPE) using the Haas appliance|
88945334|NCT01888666||slow palatal expansion (SPE)|
88945335|NCT01888679|Experimental|head movement|head movement in extension, flexion, right and left rotation
88945336|NCT01888705||Control group|Group of nonsmokers individuals without respiratory disease.
89464673|NCT04221542|Experimental|Part 2: AMG 509 Subcutaneous (SC) Monotherapy|"Part 2 will explore the safety, tolerability, and PK of AMG 509 SC dosing in participants with mCRPC who have been previously treated with NHT and 1 to 2 prior taxanes.~Recommended phase 2 dose for SC monotherapy may be identified based on emerging safety, efficacy, PK, and PD data, as well as patient experience prior to reaching an MTD."
89464674|NCT04221542|Experimental|Part 3: AMG 509 IV Monotherapy in Earlier Lines of Treatment|Part 3 will explore AMG 509 in participants with mCRPC who have received 1 prior NHT (may have been given for HSPC) and no prior taxanes (may have been given for HSPC). This dose expansion will be conducted to confirm safety, PK, and PD of AMG 509 at the MTD or RP2D determined in Part 1 dose exploration, and to obtain further safety and efficacy data and correlative biomarker analysis.
89464675|NCT04221542|Experimental|Part 4: AMG 509 IV Combination Therapy|"Part 4 will explore the safety, tolerability, and PK of AMG 509 for participants with mCRPC who have received no or 1/2 prior NHT (for hormone sensitive or castration-resistant disease) at dose regimens previously determined to be safe and tolerable in Part 1, in combination with abiraterone (Part 4A), or enzalutamide (Part 4B) and no or 1 prior taxane for hormone sensitive disease in Parts 4A and 4B. Part 4 consists of a dose exploration phase and a dose expansion phase.~This dose exploration study will estimate the MTD and/or RP2D of AMG 509 in combination with abiraterone or enzalutamide using a modified toxicity probability interval design. The dose-expansion phase will confirm safety, PK, and PD at the MTD or RP2D and to obtain further safety and efficacy data and correlative biomarker analysis."
89464676|NCT04221542|Experimental|Part 5: AMG 509 IV Monotherapy in Outpatient Setting|"Part 5 will evaluate the safety and tolerability of AMG 509 IV dosing in participants with mCRPC who have been previously treated with NHT and 1 to 2 prior taxanes, when administered in outpatient infusion centers.~The Part 5 dosing regimen and schedule was selected based on emerging data and DLRT recommendations and will utilize the doses explored in Part 1 dose-expansion phase"
89464677|NCT04216524|Experimental|Treatment (SL-401, venetoclax, chemotherapy)|See detailed description.
89464678|NCT04210700|Active Comparator|Fascia iliaca compartment block|Participants will receive fascia iliaca compartment block before spinal anesthesia and operation
89464679|NCT04210700|Experimental|Pericapsular nerve group block group|Participants will receive pericapsular nerve group block before spinal anesthesia and operation
89464680|NCT04204850|Experimental|Cabozantinib|Cabozantinib, at a dose of 60 mg orally (by mouth), once a day (at bedtime), continuously.
89464681|NCT04192591|Experimental|Superion™ IDS device|Superion™ Indirect Decompression System (IDS)
89464682|NCT04179175|Active Comparator|secukinumab 1 HiSCR Responder|HiSCR responder at Week 52 in core trial, secukinumab 300mg every 2 weeks
89464683|NCT04179175|Active Comparator|secukinumab 2 HiSCR Responder|HiSCR responder at Week 52 in core trial, secukinumab 300mg every 4 weeks
89464684|NCT04179175|Placebo Comparator|placebo 1 HiSCR Responder|HiSCR responder at Week 52 in core trial, placebo to secukinumab 300mg every 2 weeks
89464685|NCT04179175|Placebo Comparator|placebo 2 HiSCR Responder|HiSCR responder at Week 52 in core trial, placebo to secukinumab 300 mg every 4 weeks
89464686|NCT04179175|Other|HiSCR non-responders|non-responder at Week 52 in core trial treatment; secukinumab 300mg every 2 weeks
89464687|NCT04175041|Other|ADHD|Patients with ADHD.
88945337|NCT01888705||NE|Smokers wiht normal spirometry.
88945338|NCT01888705||LV|Patients with COPD level I, mild.
88945339|NCT01888705||MOD|Patients with COPD level II, moderate.
88945340|NCT01888705||GV|Patients with COPD level III, severe.
88945341|NCT01888705||MGV|Patients with COPD level IV, very severe.
88945342|NCT01888718|Experimental|Fexofenadine Hydrochloride Orally Disintegrating|Fexofenadine Hydrochloride Orally Disintegrating Tablets 30 mg of Dr.Reddy's Laboratories Ltd
88945343|NCT01888718|Active Comparator|ALLEGRA|ALLEGRA orally disintegrating tablets 30 mg of Sanofi Aventis
88945344|NCT01888731|Experimental|Lamotrigine Extended Release Tablets|Lamotrigine Extended Release Tablets, 25 mg, 50 mg, 100 mg, 200 mg and 300 mgof Dr. Reddy's Laboratories Limited
88945345|NCT01888731|Active Comparator|LAMICTAL XR|(containing Lamotrigine)Extended Release tablets 50 mg of GlaxoSmithKline Research Triangle Park, NC
88945346|NCT01888744|Active Comparator|Group 1 (GnRH agonist group)|The long GnRH agonist protocol starts on day 21 of the preceding cycle with the administration of GnRH agonist, Decapeptyl® 0,1 mg subcutaneously daily or buserelin acetate, Suprefact® 600 μg daily intranasal. The administration of highly purified human menopausal gonadotropin (hp-HMG), Menopur® 225 IU subcutaneously is started after three weeks of desensitization. The desensitization is checked by ultrasound (absence of cysts) and hormonal measurement (Estradiol levels < 80 pg/ml, FSH ≤ 10 IU/l and progesterone < 1,5ng/ml)
88945347|NCT01888744|Active Comparator|Group 2 (GnRH antagonist group)|Ovarian stimulation is started at day 2 of the menstrual cycle with 225 IU of HMG (Menopur ®) subcutaneously. At day 6 of the stimulation GnRH antagonist (Orgalutran®) 0,25 mg subcutaneously is added. Basal hormonal status will be confirmed in the antagonist group before starting.
88945348|NCT01888757|Experimental|Lamotrigine Extended Release Tablets|Lamotrigine Extended Release Tablets, 25 mg, 50 mg, 100 mg, 200 mg and 300 mgof Dr. Reddy's Laboratories Limited
88945349|NCT01888757|Active Comparator|LAMICTAL XR|(containing Lamotrigine)Extended Release tablets 50 mg of GlaxoSmithKline Research Triangle Park, NC
88945350|NCT01888770||Normotensive Term|Infants born at term (>37 weeks) to Normotensive pregnancies
88945351|NCT01888770||Term Preeclampsia|Infants born at term (>37 weeks gestation) and exposed to a preeclamptic pregnancy
88945352|NCT01888770||Preterm Normotensive|Infants born to Normotensive pregnancies at <37 weeks gestation
88945353|NCT01888770||Preterm Hypertensive|Infants born to hypertensive pregnancies at <37 weeks completed gestation
88945354|NCT01888770||Term Pregnancy-induced Hypertension|Infants born at term (>37 weeks gestation) and exposed to pregnancy-induced hypertension
88945355|NCT01888783|Experimental|CRPS Type I|Patients diagnosed with complex regional pain syndrome type I of the upper limb
89201962|NCT00781794|Experimental|1|Dose 1
89201963|NCT00781794|Experimental|2|Dose 2
89201964|NCT00781794|Placebo Comparator|3|
89018104|NCT05302518|Experimental|Cognitive behavioral therapy with exposure in virtual reality|This arm of the study will receive cognitive behavioral therapy with exposure in virtual reality. The intervention is individual and manualized and delivered by a psychologist. The intervention consists of 10 weekly session with a duration of 60 minutes. Exposure is conducted from session 4 to 9. Homework is assigned and it includes exposure in vivo. The amount of exposure is controlled for.
89018105|NCT05302518|Active Comparator|Cognitive behavioral therapy with exposure in vivo|This arm of the study will receive cognitive behavioral therapy with exposure in vivo. The intervention is individual and manualized and delivered by a psychologist. The intervention consists of 10 weekly session with a duration of 60 minutes. Exposure is conducted from session 4 to 9. Homework is assigned and it includes exposure in vivo. The amount of exposure is controlled for.
89018106|NCT05293288|Experimental|EEG-guided general anesthesia|EEG-guided general anesthesia group (i.e., intervention group): For pEEG monitoring we will use the SEDLine monitor (Masimo, Irvine, CA) which provides the patient state index (PSi; a processed EEG parameter with values from 1 to 100), density spectral array (DSA; a display that represents the frequencies and amplitudes of brain waves through time), spectral edge frequency (SEF), and the raw EEG signal.
89018107|NCT05293288|No Intervention|Routine care|Routine care group (i.e., control group): Adjustment of depth of general anesthesia will be at the discretion of the treating anesthesiologist.
89018108|NCT05285917|Active Comparator|Weight Based Starting Dose|25 mg/kg starting dose Hydroxyurea
89464688|NCT04175041|Other|Healthy Control|Volunteers without Neuropsychiatric Disorders.
89464689|NCT04175028|Other|ADHD|Patients with ADHD.
89464690|NCT04175028|Other|Healthy Control|Volunteers without Neuropsychiatric Disorders.
89464691|NCT04171960||Acute Blood Biomarker Branch|Blood draw within 12 hours or 12-24 hours following injury for i-STAT Testing and in-person outcome assessments.
89464692|NCT04171960||Acute Blood Biomarker Plus Follow-up Branch|Blood draw and 3T Magnetic Resonance Imaging (MRI) at 2 weeks and 6 months following injury, in-person and phone outcome assessments.
89464693|NCT04170153|Experimental|Part A1: Monotherapy Dose Escalation|Participants will initially receive Tuvusertib (M1774) once daily under fasting conditions. Additional schedules may be evaluated if needed.
89464694|NCT04170153|Experimental|Part A2 - Preliminary Food Effect Assessment|Participants in the food effect assessment will receive Tuvusertib (M1774) at the dose and schedule determined as recommended dose for expansion (RDE) in Part A1. A single dose of Tuvusertib (M1774) will be administered on Day -7 under a fed (low-fat meal) or fasted condition, followed by a 1-week washout period. After completion of the scheduled food effect assessments, participants will follow the same schedule as participants in Part A1.
89464695|NCT04170153|Experimental|Part A3 - Monotherapy Expansion|Part A3 is an expansion of Part A1 where Tuvusertib (M1774) will be administered as a single agent at the RDE established in Part A1. Participants with defined loss-of-function mutation in ARID1A, ATRX and/or DAXX, and ATM will be enrolled.
89464696|NCT04170153|Experimental|Part B1: Combination Therapy Dose Finding|"B1a: Participants with baseline body weight less than (<) 77 kilogram (kg) or platelets <150,000 cubic per millimeter (mm^3) will receive Niraparib once daily combined with different doses of Tuvusertib (M1774).~B1b: Participants with baseline body weight greater than or equal to (>=) 77 kg and or platelets >= 150,000 mm^3 will receive Niraparib once daily combined with different doses of Tuvusertib (M1774) and schedule determined as recommended dose for expansion (RDE) in Part B1a."
89464697|NCT04170153|Experimental|Part A4: Japan Dose Confirmation Monotherapy|Starting at global RDE from Part A1, in Japan. Participants will initially receive Tuvusertib (M1774) once daily under fasting conditions. Additional schedules may be evaluated if needed.
89464698|NCT04170153|Experimental|Part A5: China Dose Confirmation Monotherapy|Starting at global RDE from Part A1, in China. Participants will initially receive Tuvusertib (M1774) once daily under fasting conditions. Additional schedules may be evaluated if needed.
89464699|NCT04161898|Experimental|Arm 1: Upadacitinib|Participants will be administered updadacitinib once daily (QD) along with prednisolone.
89464700|NCT04161898|Experimental|Arm 2: Placebo for Upadacitinib|Participants will be administered placebo once daily (QD) along with prednisolone.
89018109|NCT05285917|Experimental|PK-guided starting dose|Individualized, PK-guided starting dose Hydroxyurea
89464701|NCT04153565|Experimental|Pembrolizumab + Cisplatin + Pemetrexed|Pembrolizumab 200 mg IV every 3 weeks (Q3W) in combination with Cisplatin 75 mg/m^2 IV, and Pemetrexed 500 mg/m^2 IV for 4-6 cycles followed by monotherapy of Pembrolizumab up to 35 cycles from the first dose of the study in treatment phase (approximately 2 years).
89464702|NCT04142177|Active Comparator|Internet-based pain self-management program|Internet-based treatment (Step 1 Treatment)
89464703|NCT04142177|Active Comparator|Enhanced Physical Therapy|Intervention that combines the internet-based pain self-management program with tailored exercise and physical activity guided by a physical therapist (Step 1 treatment)
89464704|NCT04142177|Placebo Comparator|Continued Care and Active Monitoring (CCAM)|CCAM will not be standardized keeping in line with the pragmatic nature of this trial. CCAM may be variable across sites and for individual participants reflecting de facto clinical practice for cLBP. Clinical practice may involve pharmacological and non-pharmacological treatments for cLBP. Current analgesics (including opioids, acetaminophen, NSAIDs, topical analgesics (capsaicin), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, skeletal muscle relaxants, and alpha-2-delta ligands (gabapentin-like drugs)) and non-pharmacological treatments may be continued by participants. CCAM participants will be encouraged to discuss pain problems with their treating physician, but not begin new treatments if possible. Patients will specifically be discouraged from starting CBT, chiropractic, or yoga. Other than this, there will be no attempt by study personnel to influence pain management (Step 1 Treatment)
89464705|NCT04142177|Active Comparator|Cognitive Behavioral Therapy (CBT)|Participants randomized to CBT in Step 2 will receive treatment with a trained therapist using the VA's CBT-chronic pain (CBT-CP) protocol involving one planning session and 9 treatment sessions (10 total) over 3 months (Step 2 Treatment).
89501942|NCT03311269|Active Comparator|ClariVein RES 1% Injection|Sodium Tetradecyl Sulfate 1% Injection single administration
89501943|NCT03311269|Active Comparator|ClariVein RES 3% Injection|Sodium Tetradecyl Sulfate 3% Injection single administration
89501944|NCT04286906||One group (cohort)|Asthmatic patients
89501945|NCT02762929|Experimental|HTX-011A: 200 mg|HTX-011A (bupivacaine/meloxicam), 200 mg/6 mg via injection.
89464706|NCT04142177|Active Comparator|Spinal Manipulation Therapy (SMT)|After examination by a qualified Doctor of Chiropractic (DC), a SMT intervention consisting of up to 10 sessions over 3 months will be designed focusing on spinal manipulation and/or mobilization of the lower thoracic, lumbar and/or sacroiliac joints. Adjunctive use of myofascial and/or stretching techniques are allowed as they are commonly used along with SMT, and can be considered a standard accompaniment to SMT (Step 2 Treatment).
89464707|NCT04142177|Active Comparator|Yoga|The Yoga for Veterans with cLBP program consists of up to 10 weekly, 60-minute instructor-led sessions along with 15-20 minutes of yoga practiced at home each non-session day. The initial session is 75 minutes (15 minutes longer than the other sessions). The yoga program can be considered classical hatha yoga with influences from Iyengar and Viniyoga yoga. These styles emphasize modifications and adaptations including the use of props such as straps and blocks to minimize the risk of injury and make the poses accessible to people with health problems and limitations (Iyengar, 1979). The instructor leads participants through a series of 23 yoga poses (32 total variations) at a slow-moderate pace (Step 2 Treatment).
89464708|NCT04140500|Experimental|Part A: Single-Agent Dose Escalation|Participants will receive RO7247669 every 2 weeks (Q2W) or every 3 weeks (Q3W) up to the maximum tolerated dose (MTD) until disease progression, unacceptable drug toxicity, or withdrawal of consent, for up to 24 months.
89464709|NCT04140500|Experimental|Part B: Tumor Specific Expansion Cohorts|Participants with selected solid tumor indications will receive RO7247669 at a dose derived from Part A until disease progression, unacceptable drug toxicity, or withdrawal of consent, for up to 24 months.
89464710|NCT04130958|Experimental|MDE and Active iTBS-TMS|This group will consist of patients diagnosed with MDE that are receiving active iTBS-TMS.
89464711|NCT04130958|Experimental|BPD and Active iTBS-TMS|This group will consist of patients diagnosed with BPD that are receiving active iTBS-TMS.
89464712|NCT04130958|Sham Comparator|MDE and Sham iTBS-TMS|This group will consist of patients diagnosed with MDE that are receiving sham iTBS-TMS.
89464713|NCT04130958|Sham Comparator|BPD and Sham iTBS-TMS|This group will consist of patients diagnosed with BPD that are receiving sham iTBS-TMS.
89464714|NCT04119024|Experimental|Treatment (chemotherapy, IL13Ralpha2, Il-2)|Patients receive cyclophosphamide IV over 1 hour on days -5 to -4 and fludarabine phosphate IV over 15-30 minutes on days -4 to -1. Patients then receive IL13Ralpha2 CAR T cell IV on day 0. Patients may also receive recombinant interleukin-2 SC BID on days 1-7.
89464715|NCT04113616|Experimental|Part A - Arm 1|"KRT-232+LDAC:~KRT-232 will be administered orally, once daily (QD), on Days 1-7 in combination with LDAC administered at 20 mg/m2/day subcutaneously on Days 1-10 in a 28-day cycle."
89464716|NCT04113616|Experimental|Part A - Arm 2|"KRT-232(7-Day)+Decitabine:~KRT-232 will be administered orally, once daily (QD), on Days 1-7 in combination with Decitabine administered at 20 mg/m2/day intravenously on Days 1-5 in a 28-day cycle."
89464717|NCT04113616|Experimental|Part A - Arm 3|"KRT-232(14-Day)+Decitabine:~KRT-232 will be administered orally, once daily (QD), on Days 1-7 and Days 15-21 (7 days on/7 days off/7 days on/7 days off) in combination with Decitabine administered at 20 mg/m2/day intravenously on Days 1-5 in a 28-day cycle."
88945356|NCT01888783|Active Comparator|Median Nerve Neuropathy|Patients diagnosed with a neuropathy of the median nerve of the upper limb.
88945357|NCT01888783|Active Comparator|Healthy Controls|Healthy adult persons.
88945358|NCT01888796|Active Comparator|Linagliptin|Linagliptin 5 mg (tablets) once daily for 6 month
88945359|NCT01888796|Placebo Comparator|Placebo|Placebo (tablets) once daily for 6 month
88945360|NCT01888809|Experimental|Comprehensive preventive services|Combined comprehensive services:Parents as Teachers Home visitation, Child-Parent Psychotherapy, and/or Interpersonal Psychotherapy with outreach support
88945361|NCT01888809|Active Comparator|Screening and referral|Annual screening and referral for services as needed
88945362|NCT01888822|Placebo Comparator|Placebo|Intravenous infusion of 0.9% Sodium Chloride 250 ml during induction of anesthesia and before laparoscopic cholecystectomy.
88945363|NCT01888822|Active Comparator|Ampicillin-sulbactam|Intravenous infusion of 3gr ampicillin-sulbactam in 0.9% Sodium Chloride 250 ml during induction of anesthesia and before laparoscopic cholecystectomy.
88945364|NCT01888822|Active Comparator|Ciprofloxacin|Intravenous infusion of 400 mg ciprofloxacin in 0.9% Sodium Chloride 250 ml during induction of anesthesia and before laparoscopic cholecystectomy.
88945365|NCT01888835|Active Comparator|Mirtazapine|mirtazapine 30 mg orally per day
88945366|NCT01888835|Placebo Comparator|Placebo|placebo (30 mg) orally per day
89464718|NCT04113616|Experimental|Part B - Arm 1|KRT-232 administered at 360 mg orally, once daily (QD) on Days 1-7 with 21 days off on a 28-day treatment cycle
89464719|NCT04113616|Experimental|Part B - Arm 2|KRT-232 administered at 360 mg orally, once daily (QD) on Days 1-7 with 21 days off on a 28-day treatment cycle in Cycle 1, followed by 240 mg orally, once daily (QD) on Days 1-7 with 21 days off on a 28-day cycle, in the subsequent cycles.
89464720|NCT04113616|Experimental|Part B - Arm 3|KRT-232 administered at 180 mg orally, once daily (QD) on Days 1-7 with 14 days off on a 21-day treatment cycle.
89464721|NCT04097431|Experimental|Precursors as Response Chain or Class|The precursor behavior occurs as a part of a sequence, or for the same maintaining variable, leading up to the severe problem behavior.
89501946|NCT02762929|Experimental|HTX-011B: 30 mg|HTX 011B (bupivacaine/meloxicam), 30 mg/0.9 mg via injection.
89501947|NCT02762929|Experimental|HTX-011B : 60 mg|HTX-011B (bupivacaine/meloxicam) 60 mg/1.8 mg via injection or instillation.
89501948|NCT02762929|Experimental|HTX-011B: 120 mg|HTX- 011B (bupivacaine/meloxicam), 120 mg/3.6 mg via injection or instillation.
89501949|NCT02762929|Experimental|HTX-011B: 200 mg|HTX- 011B (bupivacaine/meloxicam), 200 mg/6 mg via injection.
89501950|NCT02762929|Active Comparator|Bupivacaine HCI|Bupivacaine HCI, 50 mg via injection.
88945367|NCT01888848|Experimental|blueberry|Participants randomized into this arm of the study consume freeze-dried blueberry.
88945368|NCT01888848|Placebo Comparator|placebo|Participants randomized into this arm of the study consume a blueberry placebo.
88945369|NCT01888861|Experimental|alpha-lipoic acid|the patients in this arm were received 900mg alpha-lipoic acid for 10 days through nasogastric(NG) tube.
88945370|NCT01888861|Placebo Comparator|placebo|the patients in this arm were received 900mg placebo through NG tube.
89464722|NCT04092829|No Intervention|FROZEN EMBRYO TRANSFER IN NATURAL CYCLE|After confirming ovarian rest (follicles < 10 mm) with menstruation by means of vaginal ultrasound, an ultrasound control of the natural cycle will be carried out, inducing ovulation when an ovulatory follicle of size ≥ 17mm and an endometrium ≥ 7mm are found. Serum estradiol and progesterone values will be determined that day. This induction will be carried out with an ampoule of 250 μg of rHCG (Ovitrelle®). After the injection of Ovitrelle®, the administration of micronized vaginal progesterone (Progeffik® or Utrogestan®) 200 mg/ 12 hours and 7 days after the injection, thawing and transfer of a frozen euploid blastocyst will begin 48 hours later.
89464723|NCT04092829|Active Comparator|FROZEN EMBRYO TRANSFER IN SUBSTITUTED CYCLE|After confirming ovarian rest (follicles < 10 mm) with menstruation by vaginal ultrasound, hormone replacement therapy with oestrogens (6 mg/day of oral oestradiol valerate - Progynova® or Progyluton®- or 150 ug/48 h of oestradiol in patches - Evopad®) will be started on day 2-3 of the cycle. On day 10-15 of treatment an ultrasound scan will be performed to assess endometrial growth and ovarian rest. After confirming an endometrial thickness ≥ 7mm by vaginal ultrasound, ovaries with follicles smaller than 10 mm, blood estradiol >100 pg/ml and serum progesterone < 1 ng/ml, luteal phase support will begin with the administration of 400 mg of micronized vaginal progesterone every 12 hours, a total of 10 shots, prior to embryo transfer of a thawed euploid blastocyst. same day. If the level of serum progesterone on the day of transfer is less than 9.2 ng/ml, a daily injection of subcutaneous progesterone (Prolutex®) will be added on the same day.
89464724|NCT04088968|Experimental|Prehabilitation|Intervention: Patients allocated to the intervention group receive weekly counselling sessions in 6 weeks as an integrated prehabilitation program tailored to meet the individual patient's need for risk reduction at surgery. It is introduced via the surgical 'Engage in the process of change'. The smoking and alcohol cessation intervention follows the Gold Standard Programme and patients in the intervention group are introduced to a standardized exercise training programme taking individualized needs into account. Nutritional support is also individualized.
89464725|NCT04088968|No Intervention|Treatment as usual|Treatment as ususal covers shorter interventions, e.g. advice, brief counselling, and handing out the national folders on smoking and alcohol and surgery. Patients are ensured that they are free to access support to lifestyle changes in the community.
89018110|NCT05278975|Experimental|Phase 1 - Dose Escalation|RSO-021 administered in increasing doses as a solution for pleural infusion through an indwelling IP catheter, administered as a single dose on Day 1 of each week of a 21-day treatment cycle.
89464726|NCT04075136|Active Comparator|Arm A: Lucentis|A standard of care treatment of 0.05ml/0.5mg Lucentis given every 4 weeks for 48 weeks.
89464727|NCT04075136|Experimental|Arm B: Lucentis & PDT Laser|A one time treatment of 0.05ml/0.5mg Lucentis in combination with PDT laser administered at half-fluence.
89464728|NCT04075136|Experimental|Arm C: Lucentis, PDT Laser and Triescense|A one time treatment of 0.05ml/0.5mg Lucentis in combination with PDT laser administered at half-fluence and an intravitreal injection of 0.5ml-2mg Triescence at the time of PDT treatment.
89464729|NCT04071548|Experimental|HIIT Exercise|All individuals recruited in exercise portion will be on an active exercise intervention
89464730|NCT04059952||Unipolar Depression|Patients diagnosed with Major Depressive Disorder.
89464731|NCT04059952||Bipolar Depression|Patients diagnosed with Bipolar I or II.
89464732|NCT04059952||Healthy Control|Patients without psychiatric diagnoses.
89464733|NCT04051216|Experimental|Supportive Care|Caregivers receive the Roadmap information system loaded on an Apple iPad® for use during the inpatient hospitalization of CART therapy. The Roadmap information system consists of 5 modules personalized to the CART patient: laboratory studies, medications, clinical trial enrollment, healthcare providers, and criteria for discharge. Patients wear an activity monitoring device on days 0-100. Patients wear the device as long as they can each day to monitor physical activity level, sleep/wake patterns, skin temperature, heart rate and respiratory rate.
89018111|NCT05278975|Experimental|Ph2 - Dose Expansion - MPE from non-mesothelioma solid tumors|RSO-021 administered at the MTD/RP2D as a solution for pleural infusion through an indwelling IP catheter, administered as a single dose on Day 1 of each week of a 21-day treatment cycle in patients with MPE from non-mesothelioma solid tumors.
89018112|NCT05278975|Experimental|Ph2 - Dose Expansion - MPE from mesothelioma|RSO-021 administered at the MTD/RP2D as a solution for pleural infusion through an indwelling IP catheter, administered as a single dose on Day 1 of each week of a 21-day treatment cycle in patients with MPE from mesothelioma.
89464734|NCT04042701|Experimental|Part 1 (Dose Escalation)|HER2-positive breast cancer, HER2-low expressing breast cancer, HER2-expressing NSCLC, and HER2-mutant NSCLC participants who received escalating doses of DS8201a (initial dose 3.2 mg/kg Q3W) and pembrolizumab 200 mg.
89018113|NCT05278975|Experimental|P2 - Dose Expansion - mesothelioma -First line treatment prior to Ipi/Nivo|RSO-021 administered at the MTD/RP2D as a solution for pleural infusion through an indwelling IP catheter, administered as a single dose on Day 1 of each week of a 21-day treatment cycle in patients with mesothelioma. This local treatment with RSO-021 is prior to systemic treatment of Ipi/Nivo.
89018114|NCT05278975|Experimental|Ph2 - Dose Expansion - MPE from non-mesothelioma solid tumors combination with Paclitaxel|RSO-021 administered at the MTD/RP2D as a solution for pleural infusion through an indwelling IP catheter, administered as a single dose on Day 1 of each week of a 21-day treatment cycle in patients with MPE from non-mesothelioma solid tumors. In combination with Paclitaxel. Paclitaxel will be administered as a systemic therapy per SoC and the approved labeling based on the tumor type being treated. Paclitaxel is commercially available in the UK
89018115|NCT05278494|Experimental|Dextromethorphan|
89018116|NCT05278494|Placebo Comparator|Placebo|
89018117|NCT05275244||Osteoarthritis Group|The patients diagnosed with single or preferential symptomatic osteoarthritis of the shoulder or hip treated with KD Intra-Articular® gel 2.2% - 44 mg in 2 ml - (Pronolis® HD one 2.2%), and ankle or base of the thumb treated with KD Intra-Articular® gel 1.6% - 16 mg in 1 ml - (Pronolis® HD mini 1.6%). Each patient will be administrated three injections, one per week.
89018118|NCT05273385|Experimental|Nanodropper|Participants will receive the Nanodropper with instructions and attend clinic visits at baseline, 1, and 3 months. Participants will administer their eye drops using the Nanodropper.
89018119|NCT05273385|No Intervention|Standard of Care Dropper|Participants will receive standard of care eye dropper with instructions and attend clinic visits at baseline, 1, and 3 months. Participants will administer their eye drops using the standard of care eye dropper.
88945371|NCT01888978|Experimental|Modified FOLFOX-6|Oxaliplatin 85 mg/m2 day 1 and 5-fluorouracil 400 mg/m2 day 1 and Leucovorin 400 mg/m2 day 1 and 5-fluorouracil 2400 mg/m2 over 46 hours on day 1-3 of every 14 day cycle All drugs will be administered until disease progression or unacceptable toxicity are observed
88945372|NCT01888978|Experimental|Ox-Tax|Docetaxel 65 mg/m2 and Oxaliplatin 100 mg/m2 on day 1 every 3 weeks All drugs will be administered until disease progression or unacceptable toxicity are observed
88945373|NCT01888978|Experimental|FOLFIRI|Irinotecan 180 mg/m2 on day 1 and 5-FU 400 mg/m2 on day 1 and Leucovorin 400 mg/m2 day 1 and 5-FU 2400 mg/m2 over 46 hours, days 1-3 as a continuous infusion All drugs will be administered until disease progression or unacceptable toxicity are observed
88945374|NCT01888978|Experimental|Tax-Iri|2 weeks on, 1 week off of Docetaxel 35 mg/m2/week and Irinotecan 50 mg/m2/week Both administered on day 1 of each week of treatment All drugs will be administered until disease progression or unacceptable toxicity are observed
88945375|NCT01888978|Experimental|Gem-Ox|Gemcitabine: 1000 mg/m2 over 100 minutes on Day 1 Oxaliplatin: 100 mg/m2 over 120 minutes on Day 2 of every 14 day cycle All drugs will be administered until disease progression or unacceptable toxicity are observed
88945376|NCT01888978|Experimental|Gem-5FU|Gemcitabine: 1000 mg/m2 over 30 minutes 5-FU 2000/m6 as a 24 hour infusion on days 1, 8, and 15 of every 28 day cycle All drugs will be administered until disease progression or unacceptable toxicity are observed
88945377|NCT01888978|Experimental|Gem-Tax|Gemcitabine 1000 mg/m2 over 30 minutes and Docetaxel 35 mg/m2 over 60 minutes on days 1, 8, and 15 of every 28 day cycle
88945378|NCT01888991|No Intervention|water with resting condition|
88945379|NCT01888991|Experimental|glucose with resting condition|
88945380|NCT01888991|Experimental|water with exercise condition|
88945381|NCT01888991|Experimental|glucose with exercise condition|
88945382|NCT01889004|Experimental|Dexmedetomidine|Intravenous dexmedetomidine using target controlled infusion
88945383|NCT01889004|Experimental|Propofol|Intravenous propofol using target controlled infusion
88945384|NCT01889030||Target population|This observational, cross-sectional, national multicenter designed study will describe the frequency of use of different evaluation methods (risk scores or subjective assessment) employed to determine the cardiovascular risk of patients in a primary care setting, at both General Practitioners (GPs) or Cardiologists offices.
88945385|NCT01889056|Experimental|Erythropoietin (Epoetin beta)|Short infusion of 60.000 IU Epoetin beta in 0.9% sodium chloride solution (250 ml)
88945386|NCT01889056|Placebo Comparator|0.9% sodium chloride solution|Short infusion of 0.9% sodium chloride solution (250 ml)
88945387|NCT01889082|Active Comparator|Face to Face Behavioral Weight Loss|12-week treatment program consisting of weekly, in-person group meetings and brief, bi-weekly individual check-ins
88945388|NCT01889082|Active Comparator|Web Based Behavioral Weight Loss|12-week treatment program consisting of an initial in-person group session (weight loss 101 and intro to website), followed by weekly web-based program and e-coaching
88945389|NCT01889082|Active Comparator|Web Based Behavioral Weight Loss Plus Optional Group Sessions|12-week treatment program consisting of an initial in-person group session (weight loss 101 and intro to website), followed by weekly web-based program and e-coaching. Participants in this arm will also have the option to attend several experiential group sessions that will help those interested to apply the material and skills they are being taught (e.g., cooking demonstration, circuit training). *New material / content is not provided in these optional sessions, rather they are meant to serve as a place to practice applying the core content from the lessons.
88945390|NCT01889095|Experimental|BIAsp 30|patients receiving variable doses of Insulin BIAsp 30.start with 0.2 to 0.6unit per kg
88945391|NCT01889095|Active Comparator|NPH/Reg|patients receiving Variable doses Of Insulin NPH Start with 0.2 to 0.6 unit per kg
88945392|NCT01889121||Methadone maintenance program|Mothers on methadone treatment at time of delivery who delivered at Good Samaritan Hospital but were not enrolled in psychosocial intervention offered through the HOPE (Helping Opiate-addicted Pregnant women Evolve) program.
88945393|NCT01889121||Psychosocial intervention|Pregnant women who were in methadone maintenance program PLUS structured psychosocial intervention at the time of delivery (HOPE Program).
88945394|NCT01889134|Experimental|Alendronate|Sedron (alendronate) 70 mg taken orally once a week for 12 months
88945395|NCT01889134|Active Comparator|Parathyroidectomy|Selective parathyroidectomy
88945396|NCT01889134|No Intervention|Control group|No intervention
88945397|NCT01889147|Active Comparator|14C-hRESCAP|Peak plasma concentration response of a dose hRESCAP will be examined and compared with the saline condition
88945398|NCT01889147|Placebo Comparator|saline|Peak plasma concentration response of different dosages of hRESCAP will be examined and controlled with the saline condition
88945399|NCT01889147|Active Comparator|Microdose|Peak plasma concentration of a very low dose of hRESCAP as a first test in humans (first starting dose, before the other arms).
88945400|NCT01889160|Experimental|Part A Active|AZD4721 Solution
88945401|NCT01889160|Placebo Comparator|Part A Placebo|Placebo for AZD4721
88945402|NCT01889160|Experimental|Part B solution|AZD4721 Solution
88945403|NCT01889160|Active Comparator|Part B Suspension|AZD4721 Suspension
88945404|NCT01889173|Experimental|TNX-102 SL Tablets at 2.8 mg|1 x TNX-102 SL Tablets (with potassium phosphate) at 2.8 mg
88945405|NCT01889173|Experimental|TNX-102-B SL Tablets at 2.8 mg|1 x TNX-102-B SL Tablets (with sodium phosphate) at 2.8 mg
88945406|NCT01889173|Experimental|TNX-102-C SL Tablets at 2.8 mg|1 x TNX-102-C SL Tablets (with trisodium citrate) at 2.8 mg
89018120|NCT05252585|Experimental|Everolimus|Participants with confirmed diagnosis of TSC-AML and who fulfil the local (Taiwan) reimbursement criteria of everolimus for TSC-AML treatment
89464735|NCT04042701|Experimental|HER2-positive breast cancer (Part 2 Dose Expansion)|HER2-positive breast cancer participants with prior ado-trastuzumab emtansine (T-DM1) with disease progression and who received DS8201a at the RDE in combination with pembrolizumab 200 mg.
89464736|NCT04042701|Experimental|HER2-low breast cancer (Part 2 Dose Expansion)|HER2 low breast cancer participants with prior failed standard treatments who received DS8201a at the RDE in combination with pembrolizumab 200 mg.
89464737|NCT04042701|Experimental|HER2-expressing NSCLC (Part 2 Dose Expansion)|HER2-expressing NSCLC participants who had not received any prior treatment with anti-PD-1, anti-PD-L1, or HER2 agents and received DS8201a at the RDE in combination with pembrolizumab 200 mg.
89464738|NCT04042701|Experimental|HER2-mutant NSCLC (Part 2 Dose Expansion)|HER2-mutant NSCLC participants who had not received any prior treatment with anti-PD-1, anti-PD-L1, or HER2 agents and received DS8201a at the RDE in combination with pembrolizumab 200 mg.
89464739|NCT04036331|Active Comparator|Adolescent Participants|Brenner FIT pediatric weight management program enrollment. an interdisciplinary, family-based pediatric weight management clinic based upon the Familial Approach to Treatment of Childhood Obesity. Patients are referred by a physician for obesity or overweight with a weight-related comorbidity. Treatment teams are comprised of a pediatrician, counselor, dietitian, and physical activity specialist, with others (e.g., social workers, physical therapists) as needed. The entire family is encouraged to attend all aspects of the treatment program, although only one attending caregiver is required.
89464740|NCT04036331|Experimental|Caregivers of Adolescent Participants|Weight loss program for adults/caregivers of those enrolled in Brenner FIT. Participants in the By Design condition (adult caregivers) will be prescribed the Essentials lifestyle intervention which includes tailored dietary and physical activity goals designed to achieve 1-2 lbs./week of weight loss, provided by a multidisciplinary team of medical providers, dietitians, behaviorists, and exercise specialists. A daily calorie restriction of 500 kcal/day is prescribed based on estimates of total energy expenditure (TEE) obtained from a measured resting metabolic rate (RMR) prior to enrollment.
89464741|NCT04036331|Experimental|Co-enrollment|This condition is for dyads that are co-enrolled in This component adds four additional strategies: dyad group sessions, one-on-one parent/child communication sessions, joint goal setting/tracking, and home environment assessment. This innovative approach will seek to employ components of motivation and communication theories to increase self-monitoring, positive communication, problem solving, and social support to increase healthy physical activity and eating behaviors to increase the effectiveness of the weight loss programs beyond gains observed in matched controls.
89018121|NCT05240001|Experimental|Thulium Fibre Laser (TFL)|Patients randomized to this arm will undergo treatment using the TFL.
89018122|NCT05240001|Experimental|MOSES Holmium Laser|Patients randomized to this arm will undergo treatment using the MOSES Holmium laser.
89018123|NCT05222529|Experimental|Glycopyrronium 25μg|Glycopyrronium 25μg for two weeks
89018124|NCT05222529|Experimental|Glycopyrronium 12.5μg|Glycopyrronium 12.5μg for two weeks
89018125|NCT05222529|Placebo Comparator|Placebo|Placebo for two weeks
89018126|NCT05194397|Experimental|Nicotinamide Riboside (NR)|"Investigators will use Good Manufacturing Process (GMP)-grade 300 mg capsules of the dietary supplement nicotinamide riboside (ChromaDex, Irvine CA). Investigators dose based on body weight, and monitor for adverse effects (AEs).~For individuals with weight > 72 kg: 900 mg po qd x 16 wks.~For individuals with weight > 48 kg and ≤ 72 kg: 600 mg po qd x 16 wks.~For individuals with weight 24 ≤ 48 kg: 300 mg po qd x 16 wks."
89018127|NCT05194397|Placebo Comparator|Placebo|"Matched placebo will contain the same excipients without the active supplement and is generally recognized as safe. The placebo will be covered in an identical capsule (NR will be covered in the same capsule). Doses of placebo will match the body weight schema for dosing of NR. Investigators dose based on body weight, and monitor for adverse effects (AEs).~For individuals with weight > 72 kg: 900 mg po qd x 16 wks.~For individuals with weight > 48 kg and ≤ 72 kg: 600 mg po qd x 16 wks.~For individuals with weight 24 ≤ 48 kg: 300 mg po qd x 16 wks."
89018128|NCT05194397|Experimental|Exercise Intervention and NR|"The exercise program consists of at-home training sessions including: aerobic and strengthening components designed to progress persons gradually to 150-300 minutes of the equivalent of moderate aerobic activity, and twice weekly strength training exercises.~Participants in this arm will receive both the Exercise Intervention and the NR."
89018129|NCT05194397|Experimental|Exercise Intervention and Placebo|"The exercise program consists of at-home training sessions including: aerobic and strengthening components designed to progress persons gradually to 150-300 minutes of the equivalent of moderate aerobic activity, and twice weekly strength training exercises.~Participants in this arm will receive both the Exercise Intervention and the Placebo"
89018130|NCT05169710|Experimental|SEP-4199 CR 200 mg|SEP-4199 CR 200 mg/day
89018131|NCT05169710|Experimental|SEP-4199 CR 400 mg|SEP-4199 CR 400 mg/day
89018132|NCT05169710|Placebo Comparator|Placebo|Placebo
89018133|NCT05151757|Experimental|To test the effectiveness of a training course to improve graders ability to detect glaucoma|"Study design: This is an uncontrolled interventional experimental before and after study in which a minimum of 42 non-physician graders shall be trained to screen for glaucoma using optic nerve photos obtained for diabetic retinopathy (DR) screening in Vietnam.~The standard image training set will consist of about 50 normal optic nerve images of people without glaucoma and about 50 images of people with glaucoma, obtained from the on-going ORBIS CAFÉ DR screening programme (in which the graders are working), population-based eye studies in the UK (NICOLA) and the standard Glaucomatous Optic Neuropathy Evaluation (GONE) set of images. (https://gone-project.com/newgone/). The test set contains 60 normal and glaucomatous optic disc images."
89464742|NCT04032418|Active Comparator|Arm I (200mg pembrolizumab 3 weeks)|Patients receive 200mg pembrolizumab IV over 30 minutes every 3 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity.
89464743|NCT04032418|Experimental|Arm II (200mg pembrolizumab 12 weeks)|Patients receive 200mg pembrolizumab IV over 30 minutes every 12 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity.
89464744|NCT04028492|Experimental|Tradipitant|Oral Capsule
89464745|NCT04028492|Placebo Comparator|Placebo|Oral Capsule
89464746|NCT04028492|Experimental|Open Label Tradipitant|Oral Capsule
89464747|NCT04002947|Experimental|1|Acalabrutinib 100 mg orally twice a day for 14 days; Following window: patients with > or = to 25% tumor reduction, treat with DA-EPOCH-R or R-CHOP + acalabrutinib 100mg orally twice a day for the first 10 days, for 6 cycles; whereas, patients with <25% tumor reduction, treat with DA-EPOCH-R or R-CHOP alone for 6 cycles
89464748|NCT04002583|Experimental|Early-onset Alzheimer's disease (EOAD) subjects|Subjects with mild cognitive impairment due to EOAD will undergo a 48 hour computer assisted ambulatory electroencephalogram
88945407|NCT01889173|Active Comparator|Cyclobenzaprine tablets|1 x 5 mg cyclobenzaprine oral tablet
88945408|NCT01889212|Experimental|NSCLC, erlotinib treatment, 11C-erlotinib PET/CT|
88945409|NCT01889225||Multiple Risk Factor Intervention Trial - Usual Group|
88945410|NCT01889225||Multiple Risk Factor Intervention Trial - Referred Group|
88945411|NCT01889225||Framingham Heart study|
88945412|NCT01889225||Framingham Offspring cohort|
88945413|NCT01889225||Atherosclerosis Risk In Communities|
88945414|NCT01889225||Charleston Heart study|
88945415|NCT01889225||Cardiovascular Health study|
88945416|NCT01889225||Rancho Bernardo study|
88945417|NCT01889225||Nurses' Health I study|
88945418|NCT01889225||Panel Study Income Dynamics|
88945419|NCT01889225||MRFIT Referred Care|
88945420|NCT01889225||HDFP Referral Care|
88945421|NCT01889225||Alameda County Health and Ways of Living Study|
88945422|NCT01889225||Nurses' Health II study|
88945423|NCT01889225||Tecumseh County Health study|
88945424|NCT01889225||EPESE-East Boston|Established Populations for Epidemiologic Studies of the Elderly-East Boston
88945425|NCT01889225||EPESE-Duke|Established Populations for Epidemiologic Studies of the Elderly-Duke
88945426|NCT01889225||EPESE-Iowa|Established Populations for Epidemiologic Studies of the Elderly-Iowa
88945427|NCT01889225||EPESE-New Haven|Established Populations for Epidemiologic Studies of the Elderly-New Haven
88945428|NCT01889264||Critically Ill Pediatric Patients|Critically ill septic pediatric patients, Age 1 month-3 years, Age 4-12 years and Age 13-19 years, males and females
88945429|NCT01889277|Experimental|MT-3995-Low|MT-3995-Low Dose
88945430|NCT01889277|Experimental|MT-3995-High|MT-3995-High Dose
88945431|NCT01889277|Placebo Comparator|Placebo|Placebo
88945432|NCT01889290|Experimental|Methylnaltrexone|Pharmacokinetics of methylnaltrexone administered once daily
88945433|NCT01889316|Other|AN24 in addition to new device (Novii)|"FDA-cleared device (The AN24 device) used in conjunction with the new device (Novii).~Both devices will be placed on the patient's abdomen. Hence the patient acts as their own control."
88945434|NCT01889342|Experimental|Metacognitive therapy|The treatment is based on the generic manual by Wells (2009).
88945435|NCT01889342|Active Comparator|Cognitive behavorial therapy|CBT includes the diagnose specific manuals for panic disorder (Clark, 1986), Social Phobia (Clark & Wells, 1995) and PTSD (Foa, 2007).
88945436|NCT01889368|Active Comparator|Grape Seed Extract|This is a 30 day arm. At the baseline study visit, subjects will consume one 300 mg capsule of MegaNatural Gold followed by 3 high fat meals: breakfast, lunch, and dinner. Blood will be drawn at specified intervals throughout the day. Flow mediated dialysis will be performed before breakfast and again 1.5 hours later, after capsule consumption and breakfast. A minimum 14 day washout period will be between arms if this is the first arm in the randomized cross-over.
88945437|NCT01889368|Placebo Comparator|Placebo|This is a 30 day arm. At the baseline study visit, subjects will consume one placebo (maltodextrin) capsule followed by 3 high fat meals: breakfast, lunch, and dinner. Blood will be drawn at specified intervals throughout the day. Flow mediated dialysis will be performed before breakfast and again 1.5 hours later, after capsule consumption and breakfast. A minimum 14 day washout period will be between arms if this is the first arm in the randomized cross-over.
88945438|NCT01889394|Active Comparator|limberg flap|primary wound closure using a limberg flap
88945439|NCT01889394|Active Comparator|secondary wound healing|secondary wound healing
88945440|NCT01889407||IA regimen|IA regimen: Patients receive idarubicin (8mg/m2.d) iv drip on days 1-3 and cytarabine (100-200mg/ m2.d) iv drip on days 1-7.
88945441|NCT01889407||DA regimen|Patients receive daunomycin (45mg/ m2.d) iv drip on days 1-3 and cytarabine (100-200mg/ m2.d) iv drip on days 1-7.
88945442|NCT01889433|Experimental|Algeron|Algeron at a dose of 1.5 µg/kg of body weight subcutaneously, once a week, and Rebetol, orally, at a daily dose of 800 mg (for body weight <65 kg), 1,000 mg (for body weight 65 - 85 kg), 1,200 mg (for body weight 86 - 105 kg) or 1,400 mg (for body weight > 105 kg).
88945443|NCT01889433|Active Comparator|Pegasys|Pegasys in a dose of 180 µg subcutaneously, once a week, in combination with Rebetol, orally, at a daily dose of 800 mg for patients with genotype 2 or 3, and for genotypes 1 or 4 at a daily dose of 1000 mg (for body weight <75 kg) or 1200 mg (for body weight ≥75 kg)
88945444|NCT01889446|Placebo Comparator|Calcium propionate|Addition of calcium propionate (PA arm) in a capsule (1000 mg) consumed together with a mixed meal of 500 kCal in the morning following an overnight fast. Blood is taken at baseline and every 30 minutes for 4 hours. This arm is compared to a placebo capsule (following identical protocol). Following a washout period of a week, the arms will be crossed over and the PA arm participants will repeat the same protocol in the 'placebo arm'.
88945445|NCT01889446|Placebo Comparator|Placebo|Addition of placebo (PA arm) in a capsule consumed together with a mixed meal of 500 kCal in the morning following an overnight fast. Blood is taken at baseline and every 30 minutes for 4 hours. This arm is compared to the PA arm (PA, 1000 mg in a capsule). Following a washout period of a week, the arms will be crossed over and the PA arm participants will repeat the same protocol in the 'placebo arm', and vice versa.
89464749|NCT03996850||Health service research (MIBI SPECT/CT, questionnaire)|Patients receive technetium Tc-99m sestamibi IV then undergo SPECT/CT.
88945446|NCT01889459||PCI for CTO|
88945447|NCT01889472|Active Comparator|oro-nasal mask|Oro-nasal mask during 1 month of auto CPAP
88945448|NCT01889472|Experimental|Nasal mask and oral appliance|Nasal mask and oral appliance during 1 month of auto CPAP
88945449|NCT01889498|No Intervention|control group with no acetazolamide|Treatment as usual without acetazolamide treatment
88945450|NCT01889498|Active Comparator|Acetazolamide|Treatment arm
88945451|NCT01889511|Experimental|Intervention group - texts|The intervention group will receive text messages for 21 days that are tailored to their oral agent regimen.
88945452|NCT01889511|No Intervention|Control group|The control group will receive usual care, which consists of standard care and materials provided by the oncology office or pharmacy. In general, this includes instructions and information on the oral agent regimen (i.e., amount and timing), common side effects, how to manage symptoms, general ways to remember to take your pill (e.g., calendar or pill box), medication safety (i.e., storage), and how to contact a clinician for problems that arise.
88945453|NCT01889524|Active Comparator|NIV plus jet|Noninvasive ventilation-NIV plus jet nebulizer
88945454|NCT01889524|Experimental|NIV plus Mesh|Noninvasive ventilation- NIV plus Mesh nebulizer
88945455|NCT01889537|Experimental|VR during burn care with Ketamine|Comparing Virtual Reality during burn care with Ketamine
88945456|NCT01889537|Experimental|VR durin burn care without Ketamine|Comparing virtual reality during burn care without Ketamine.
88945457|NCT01889550|Active Comparator|Access to the website www.graviditetsportalen.dk|The website www.graviditetsportalen.dk contains information about the screeningtest for Downs syndrome. The website uses both text, video and animated graphics.
88945458|NCT01889550|Placebo Comparator|Access to the website www.ouh.dk|Access to the usual information from the hospital website
88945459|NCT01889576|Experimental|Supplementation of Magnesium oxide.|Supplementation of magnesium oxide (450 mg up to 3 times daily maximum), aiming at a serum magnesium concentration of >= 1,9 mg/dL).
88945460|NCT01889576|No Intervention|No supplementation or minimal dose.|No supplementation (or a minimal dose to keep serum magnesium concentration ≥ 1.2mg/dL depending on the treating physician).
88945461|NCT01889589||NYC adults|
89464750|NCT03991832|Experimental|Cohort A: IDH mutated glioma|Olaparib, by mouth (orally), twice a day, every day. Durvalumab, by vein (intravenously), on Day 1 of every 28 day cycle.
89464751|NCT03991832|Experimental|Cohort B: IDH mutated cholangiocarcinoma|Olaparib, by mouth (orally), twice a day, every day. Durvalumab, by vein (intravenously), on Day 1 of every 28 day cycle.
89464752|NCT03990662||TMD|Patients (aged ≥18 years) with a diagnosis of Temporomandibular Disorders
89464753|NCT03979794|Experimental|Be-WEL Intervention|Behavioral Intervention for Wellness and Engaged Living (Be-WEL) is a 4-session (2 preoperative, 2 postoperative) telephone intervention focused on improving emotional and physical health through relaxation, behavioral activation, increased physical activity, and adherence to medication and wound care.
89464754|NCT03979794|No Intervention|Standard Care|Standard Care consists of the standard care patients typically receive from their medical team.
89464755|NCT03970954|Experimental|1|Low-dose IL-2
89464756|NCT03970447|Active Comparator|Control Arm|"Newly Diagnosed GBM: Radiation therapy (XRT) 60 Gy for 6 weeks. Temozolomide 75 mg/m2 orally daily during radiation therapy. Rest Period 2-6 weeks from the last day of radiation, and the start of the first cycle of Maintenance Therapy 2-6 weeks after the last day of radiotherapy. The start of all subsequent maintenance therapy cycles (2-12) every 4 weeks + 7 days after the first daily dose of temozolomide of the preceding cycle. Total number of cycles should comply with institutional or country standards. During maintenance therapy, the first cycle of temozolomide will be at 150 mg/m2 for Days 1-5 of a 28-day cycle. Second and subsequent cycles of maintenance therapy will be at 200 mg/m2 for Days 1-5 of a 28-day cycle.~Recurrent GBM: Lomustine started at 110 mg/m2/day on Day 1 of a 42-day cycle as per local standards. Treatment will continue for up to 6 total cycles."
89464757|NCT03970447|Experimental|Regorafenib Treatment Arm|"Newly Diagnosed MGMT Unmethylated GBM: XRT 60 Gy for 6 weeks. Temozolomide 75 mg/m2 orally daily during radiation therapy. Rest Period 4 weeks from the last day of radiation. Maintenance period: Regorafenib (Dosage Form: Tablet for oral administration; Strength: 40 mg) 160 mg orally (PO) every day (QD) for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off).~Recurrent GBM: Regorafenib (Dosage Form: Tablet for oral administration; Strength: 40 mg) 160 mg orally (PO) every day (QD) for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off)."
88945462|NCT01889615||Suspected ovarian cancer|dual time PET/CT
88945463|NCT01889628|Other|Chinese ethnicity|Three nutritional formulae (Isocal, Protinex and Diasip) and liquid glucose
88945464|NCT01889628|Other|Malay ethnicity|Three liquid nutritional formulae (Isocal, Diasip and Protinex) and liquid glucose
88945465|NCT01889628|Other|Indian Ethnicity|Three liquid nutritional formulae (Isocal, Diasip and Protinex) and liquid glucose
88945466|NCT01889641||Patients with lupus|Patients with lupus (four levels of activity disease)
88945467|NCT01889641||healthy volunteers|Subjects controls
88945468|NCT01889654||patient|
88945469|NCT01889654||healthy volunteers|
88945470|NCT01889680|Active Comparator|Arm 1: 5-FU + LV|Patients receive mFOLFOX6 plus ziv-aflibercept every 14 days for 6 cycles (induction regimen), followed by 5-FU/LV every 14 days until disease progression (continuation regimen)
88945471|NCT01889680|Experimental|Arm 2: 5-FU + LV + ziv-aflibercept|Patients receive mFOLFOX6 plus ziv-aflibercept every 14 days for 6 cycles (induction regimen), followed by 5-FU/LV plus ziv-aflibercept every 14 days until disease progression (continuation regimen)
88945472|NCT01889693||acute coronary syndrome|patients with acute myocardial infarction and unstable angina
88945473|NCT01889693||chronic stable angina|patients with chronic stable angina
88945474|NCT01889693||control|control subjects without coronary artery disease
88945475|NCT01889719|Experimental|Vaccination with MVA-CMDR Group 1|Six to 27 subjects who previously received vaccination with DEC-205, will receive vaccination with MVA-CMDR
88945476|NCT01889719|Active Comparator|Vaccination with MVA-CMDR Group 2|Six to 27 subjects who previously did not receive vaccination with DEC-205, will receive vaccination with MVA-CMDR
88945477|NCT01889732||ROTEM|
88945478|NCT01889758|Active Comparator|Sequence 1|Tacrolimus Hi for 1 week with full PK on Day 7, then tacrolimus Lo for 1 week with full PK on Day 14, then Prograf for 1 week with full PK on Day 21, then tacrolimus Hi with full PK on Day 28, then Prograf for 1 week with full PK on Day 35, and then tacrolimus Lo for 1 week with full PK on Day 42
88945479|NCT01889758|Active Comparator|Sequence 2|Tacrolimus Lo for 1 week with full PK on Day 7, then Prograf for 1 week with full PK on Day 14, then tacrolimus Hi for 1 week with full PK on Day 21, then tacrolimus Lo with full PK on Day 28, then tacrolimus Hi for 1 week with full PK on Day 35, and then Prograf for 1 week with full PK on Day 42
88945480|NCT01889758|Active Comparator|Sequence 3|Prograf for 1 week with full PK on Day 7, then tacrolimus Hi for 1 week with full PK on Day 14, then tacrolimus Lo for 1 week with full PK on Day 21, then Prograf with full PK on Day 28, then tacrolimus Lo for 1 week with full PK on Day 35, and then tacrolimus Hi for 1 week with full PK on Day 42
88945481|NCT01889771|Experimental|Nicotine Patch (4 weeks)|participants receive one 4-weeks supply of nicotine patches
88945482|NCT01889771|Experimental|Nicotine Patch (8 weeks)|participants receive up to 8 weeks of nicotine patches in up to two 4-week supplies
88945483|NCT01889784|Other|Individuals with diabetes mellitus (phototherapy 150J)|The intervention of this study is phototherapy through light emitting diode (LED) and dose of 150J each muscle. The Effective-LED or Placebo-LED will be applied in femoral quadriceps and triceps surae muscles bilaterally before constant-load exercise tests in bike. Each individual will perform two tests with Effective-LED and two tests with Placebo-LED randomly allocated. Evaluations will be completed in 4 days in total, respecting 14 days of rest to ensure the long washout phototherapy.
88945484|NCT01889784|Other|Health individuals - 150J (phototherapy 150J)|The intervention of this study is phototherapy through light emitting diode (LED) and dose of 150J each muscle. The Effective-LED or Placebo-LED will be applied in femoral quadriceps and triceps surae muscle bilaterally before constant-load exercise tests in bike. Each individual will perform two tests with Effective-LED and two tests with Placebo-LED randomly allocated. Evaluations will be completed in 4 days in total, respecting 14 days of rest to ensure the long washout phototherapy.
88945485|NCT01889784|Other|Individuals with diabetes mellitus (phototherapy 300J)|The intervention of this study is phototherapy through light emitting diode (LED) with 300J. The Effective-LED or Placebo-LED will be applied in femoral quadriceps and triceps surale muscles bilaterally before constant-load exercise tests in bike. Each individual will perform two tests with Effective-LED and two tests with Placebo-LED randomly allocated. Evaluations will be completed in 4 days in total, respecting 14 days of rest to ensure the long washout phototherapy.
89464758|NCT03970447|Experimental|Paxalisib Treatment Arm|"Newly Diagnosed MGMT Unmethylated GBM: XRT 60 Gy for 6 weeks. Temozolomide 75 mg/m2 orally daily during radiation therapy. Rest Period 4 weeks from the last day of radiation. Maintenance period: Paxalisib (Dosage Form: Tablet for oral administration; Strength: 15 mg per tablet) 45 mg orally (PO) every day for 28 days for the first cycle. If tolerated, increase dose to 60 mg orally (PO) every day for 28 days for all subsequent cycles.~Recurrent GBM: Paxalisib (Dosage Form: Tablet for oral administration; Strength: 15 mg per tablet) 45 mg orally (PO) every day for 21 days for the first cycle. If tolerated, increase dose to 60 mg orally (PO) every day for 21 days for all subsequent cycles."
89464759|NCT03970447|Experimental|VAL-083 Treatment Arm|"Newly Diagnosed MGMT Methylated and Unmethylated GBM: XRT 60 Gy for 6 weeks. Temozolomide 75 mg/m2 orally daily during radiation therapy. Rest Period 4 weeks from the last day of radiation. Maintenance period: VAL-083 (Dosage Form: Infusion for intravenous administration; Strength: 30 mg/m2) on Day 1, 2 and 3 of 21-day cycle.~Recurrent GBM: VAL-083 (Dosage Form: Infusion for intravenous administration; Strength: 30 mg/m2) on Day 1, 2 and 3 of 21-day cycle."
89464760|NCT03970447|Experimental|VT1021 Treatment Arm - Dose Finding Phase|"Newly diagnosed MGMT Methylated and Unmethylated GBM: Rolling 6 design. Treatment as outlined in section Experimental: VT1021 Treatment Arm with the first 6 patients receiving VT1021 at 12 mg/kg twice weekly in combination with temozolomide and radiation therapy. If there are two dose limiting toxicities reported, the dose will be de-escalated to 9 mg/kg two times a week. 6 patients will then be receiving 9 mg/kg two times a week and observed for DLTs for 4 weeks.~Recurrent GBM: Dose Finding Phase is not applicable for patients with Recurrent GBM in the VT1021 treatment arm."
89464761|NCT03970447|Experimental|VT1021 Treatment Arm - Enhanced Safety Management (ESM)|"Experimental: VT1021 Treatment Arm - Enhanced Safety Management (ESM) Newly diagnosed MGMT Methylated and Unmethylated GBM: Supplemental safety assessments including bi-weekly collection of adverse events, dose modification profile, hematology, serum chemistry and coagulation panels. PK and PD assessments are done for patients as a part of ESM. ESM will continue until the Data Safety Monitoring Board (DSMB) suspends collection of additional data.~Recurrent GBM: ESM is not applicable for patients with Recurrent GBM in the VT1021 treatment arm."
89464762|NCT03970447|Experimental|VT1021 Treatment Arm|"Newly diagnosed MGMT Methylated and Unmethylated GBM: XRT 60 Gy for 6 weeks. Temozolomide 75 mg/m2 orally daily and VT1021 (Dosage Form: Infusion for intravenous administration; Strength: 10 mg/mL; Dose: As confirmed through the dose finding phase) twice weekly during radiation therapy. Rest period: 2-6 weeks from last day of radiation. VT1021 dosing will continue during the rest period. Maintenance period: The first cycle of temozolomide will be at 150 mg/m2 for days 1-5 of a 28-day cycle. Second and subsequent cycles of maintenance therapy will be at 200 mg/m2 for days 1-5 of a 28-day cycle. Temozolomide will be administered for up to 6 cycles in the maintenance phase in combination with VT1021. After 6 cycles, VT1021 only.~Recurrent GBM: VT1021 (Dosage Form: Infusion for intravenous administration; Strength: 10 mg/mL; Dose: 12mg/kg) twice weekly."
89501951|NCT02762929|Active Comparator|Saline Placebo|Saline placebo via injection.
89501952|NCT02762929|Experimental|HTX-002, 60 mg|HTX- 002, 60 mg via injection.
89018134|NCT05130190|Other|RF Treatment|At the time of the subject's trans-abdominal or laparoscopic hysterectomy, the ProVu System will be used to apply RF treatment to one or two adenomas, focal areas of adenomyosis, or diffuse adenomyosis.
89018135|NCT05117229|Experimental|MetaWear Sensor on radiograph|subjects being considered for surgical orthopedic surgery will have a MetaWear sensor added to their standard of care lateral sit to stand radiograph
89018136|NCT05114096|Experimental|Single-Dose Celestone|"Having already received the first dose of Celestone as part of eligibility criteria, participants randomized to the experimental Single-Dose arm will receive a similar appearing placebo injection."
89018137|NCT05114096|Active Comparator|Double-Dose Celestone|"Having already received the first dose of Celestone as part of eligibility criteria, participants randomized to the Double-Dose arm will receive the standard 2nd dose of Celestone injected intramuscularly (i.e. they will receive the standard double-dose regimen)."
89018138|NCT05111509|Experimental|[203Pb]VMT-α-NET SPECT/CT|injection of [203Pb]VMT-α-NET with serialized imaging and dosimetry measurements
89018139|NCT05100979|Experimental|Art of Medicine Series|Participants receiving the Art of Medicine Series will be sent text messages throughout the 4 week study intervention period. Each text message contains a link to a short, animated video teaching an evidence-based communication technique.
89018140|NCT05092295||TBI Patients|TBI participants 13 to 45 years of age, recruited from patients at a clinical research facility who present with head trauma. Clinical evaluation for the patient can be positive (target condition present) or negative (target condition absent) for mTBI. Enrollment is to occur within 2 weeks of the incident injury.
89018141|NCT05092295||Controls|Participants should not be part of the Intended Use Population. Subjects that present to the hospital, clinic or emergency department, either as a patient or non-patient, with no history of head trauma.
89018142|NCT05085951|Experimental|Prophylactic pyloric balloon dilatation|OGD and dilatation
89018143|NCT05085951|Placebo Comparator|No endoscopic intervention|OGD but no dilatation
89018144|NCT05068700|Active Comparator|Integrated Pulmonary Index disabled|Nurses randomized to the experimental arm will be asked to disable the Integrated Pulmonary Index feature of the Medtronic Capnostream 35p monitor when monitoring sedated patients with capnography.
89018145|NCT05068700|Experimental|Integrated Pulmonary Index enabled|Nurses randomized to the experimental arm will be asked to enable the Integrated Pulmonary Index feature of the Medtronic Capnostream 35p monitor when monitoring sedated patients with capnography.
89018146|NCT05047965|Experimental|Diagnostic (standard MRI, Dixon MRI)|Patients undergo MRI with additional Dixon based sequences with fat and water over a total of 49 minutes.
89018147|NCT05043792|Active Comparator|Dose 1 (Low dose)|TT-00920, orally, three times daily (t.i.d.) from Day 1 to Day 13 and once on Day 14.
89018148|NCT05043792|Active Comparator|Dose 2 (High dose)|TT-00920, orally, three times daily (t.i.d.) from Day 1 to Day 13 and once on Day 14.
89018149|NCT05043792|Placebo Comparator|Placebo|TT-00920 Placebo, orally, three times daily (t.i.d.) from Day 1 to Day 13 and once on Day 14.
89018150|NCT05036291|Experimental|NB004|"Part1: Dose escalation phase of study drug NB004 monotherapy:~Part 2: Dose Escalation Phase for the NB004 in combination with Sotorasib:~Part 3: COMBO Dose Expansion Phase for the NB004 in combination with Sotorasib:"
89018151|NCT05034601|Experimental|ESPB group|0.25% ropivacaine 0.5 ml/kg is injected at the fascial plane deep to the erector spinae muscle
89018152|NCT05034601|Active Comparator|TPVB group|0.25% ropivacaine 0.5 ml/kg is injected into the thoracic paravertebral space (T5) using TPVB approach.
89018153|NCT05017623|Experimental|Intervention/treatment|All subject will receive YH003 intravenously as single agent every three weeks (Q3W) for up to 1 years, until intolerable toxicity, confirmed disease progression, withdrawal of consent, or Investigator decision, whichever comes first.
89018154|NCT05000814||cDLT|patients using conventional double lumen tube for thoracic surgery
89018155|NCT05000814||VDLT|patients using Vivasight DLT for thoracic surgery
89018156|NCT04981860|Experimental|Treatment naïve participants First Group L|Treatment naïve participants randomized to receive Betadine on the left eye and Avenova on the right Eye
89018157|NCT04981860|Experimental|Treatment naïve participants Second Group R|Treatment naïve participants randomized to receive Avenova on the left eye and Betadine on the right Eye
89018158|NCT04981860|Experimental|Participants undergoing intravitreal injection First Group L|Participants undergoing intravitreal injection will receive betadine in the eye that is receiving injections and Avenova in the other eye. Group L are patients that are having intravitreal injections and will receive betadine in the left eye and Avenova in the right eye.
89018159|NCT04981860|Experimental|Participants undergoing intravitreal injection Second Group R|Participants undergoing intravitreal injection will receive betadine in the eye that is receiving injections and Avenova in the other eye. Group R are patients that are having intravitreal injections and will receive betadine in the right eye and Avenova in the left eye.
89018160|NCT04979910|Active Comparator|Ixekizumab|Ixekizumab 160 mg (two 80 mg injections) at Week 0, followed by 80 mg at Weeks 2 and 4 via subcutaneous route.
89018161|NCT04979910|Placebo Comparator|Placebo|Matching saline placebo at Week 0 (two injections), followed by one injection at Weeks 2 and 4 via subcutaneous route.
89018162|NCT04976465|Experimental|combined with aPL(+)|the antiphospholipid antibodies appear in blood at least once
89018163|NCT04976465|Experimental|combined with aPL(-)|the antiphospholipid antibodies never appear in blood
89018164|NCT04975776|Experimental|Sleep restriction therapy|Four group sessions delivered at the participants' primary health care centers once a week for 3 weeks and again after a 4-week pause. The first session will last for 2 hours and the other sessions for 1 hour.
89018165|NCT04975776|Active Comparator|Sleep hygiene|Participants in the active comparator group will receive a brochure with sleep hygiene advice from the primary health care center at baseline.
89018166|NCT04969380|Experimental|face and/or neck and/or submental zones|the full face and/or neck and/or submental zones including 1. -The forehead and temples (left and right including the peri orbital zone) to lift the eyebrows 2. The cheeks (left and right including perioral zone and nasolabial folds) 3. Submental and sides of the neck
89018167|NCT04964297|Other|Cohort 1: Predetermined points measurement|"Cohort 1: Predetermined points measurement: 10 subjects with measurement of bowel gas at 8 predetermined time points during right laparoscopic colectomy as follow:~Initiation of surgery/laparoscopy start Insufflation~Abdominal exploration~Completion of colon mobilization~Colon transection~At Colotomy~At Enterotomy~Anastomosis completion~End of surgery- after re-insufflation before closure"
89018168|NCT04964297|Other|Cohort 2: Continuous monitoring|Cohort 2: Continuous monitoring: 10 subjects with continuous monitoring of bowel gases through the surgery. The level of H2 and CH4 gases will be noted at the 8 predetermined time points during the continuous monitoring as well.
89018169|NCT04931147|Experimental|Part A SAD - Cohort 1|This is the first treatment arm in Part A (Single Ascending Dose) of the study. 4 participants will be randomised to receive 2 mg of RXC007 on one occasion on Day 1. The remaining 2 participants will receive matching placebo.
89018170|NCT04931147|Experimental|Part A SAD - Cohort 2|This is the second treatment arm in Part A (Single Ascending Dose) of the study. 4 participants will be randomised to receive a selected dose of RXC007 (following Cohort 1 Dose Escalation Data Review) on one occasion on Day 1. The remaining 2 participants will receive matching placebo.
89018171|NCT04931147|Experimental|Part A SAD - Cohort 3|This is the third treatment arm in Part A (Single Ascending Dose) of the study. 4 participants will be randomised to receive a selected dose of RXC007 (following Dose Escalation Data Review of previous cohorts data) on one occasion on Day 1. The remaining 2 participants will receive matching placebo.
89018172|NCT04931147|Experimental|Part A SAD - Cohort 4|This is the fourth treatment arm in Part A (Single Ascending Dose) of the study. 4 participants will be randomised to receive a selected dose of RXC007 (following Dose Escalation Data Review of previous cohorts data) on one occasion on Day 1. The remaining 2 participants will receive matching placebo.
89018173|NCT04931147|Experimental|Part A SAD - Cohort 5|This is the fifth treatment arm in Part A (Single Ascending Dose) of the study. 4 participants will be randomised to receive a selected dose of RXC007 (following Dose Escalation Data Review of previous cohorts data) on one occasion on Day 1. The remaining 2 participants will receive matching placebo.
89018174|NCT04931147|Experimental|Part A SAD - Cohort 6|This is the sixth treatment arm in Part A (Single Ascending Dose) of the study. 4 participants will be randomised to receive a selected dose of RXC007 (following Dose Escalation Data Review of previous cohorts data) on one occasion on Day 1. The remaining 2 participants will receive matching placebo.
89018175|NCT04931147|Experimental|Part A SAD - Optional Cohort 7|This is an optional seventh treatment arm in Part A (Single Ascending Dose) of the study. If deemed as necessary following Dose Escalation Data Review of previous cohorts data, up to 8 participants may be enrolled into this optional cohort. If enrolled, up to 6 participants will be randomised to receive a selected dose of RXC007 (following Dose Escalation Data Review of previous cohorts data) on one occasion on Day 1. The remaining 2 participants will receive matching placebo.
89018176|NCT04931147|Experimental|Part A SAD - Optional Cohort 8|This is an optional eighth treatment arm in Part A (Single Ascending Dose) of the study. If deemed as necessary following Dose Escalation Data Review of previous cohorts data, up to 8 participants may be enrolled into this optional cohort. If enrolled, up to 6 participants will be randomised to receive a selected dose of RXC007 (following Dose Escalation Data Review of previous cohorts data) on one occasion on Day 1. The remaining 2 participants will receive matching placebo.
89018177|NCT04931147|Experimental|Part B MAD - Cohort 1|This is the first treatment arm in Part B (Multiple Ascending Dose) of the study. 4 participants will be randomised to receive a selected dose of RXC007 (following Dose Escalation Data Review of SAD cohort data) once daily for 14 days. The remaining 2 participants will receive matching placebo.
89018178|NCT04931147|Experimental|Part B MAD - Cohort 2|This is the second treatment arm in Part B (Multiple Ascending Dose) of the study. 4 participants will be randomised to receive a selected dose of RXC007 (following Dose Escalation Data Review of SAD and previous MAD cohort data) once daily for 14 days. The remaining 2 participants will receive matching placebo.
89018179|NCT04931147|Experimental|Part B MAD - Optional Cohort 3|This is an optional third treatment arm in Part B (Multiple Ascending Dose) of the study. If deemed as necessary following Dose Escalation Data Review of previous cohorts data, up to 8 participants may be enrolled into this optional cohort. If enrolled, up to 6 participants will be randomised to receive a selected dose of RXC007 (following Dose Escalation Data Review of previous cohorts data) once daily for 14 days. The remaining 2 participants will receive matching placebo.
89018180|NCT04931147|Experimental|Part B MAD - Optional Cohort 4|This is an optional fourth treatment arm in Part B (Multiple Ascending Dose) of the study. If deemed as necessary following Dose Escalation Data Review of previous cohorts data, up to 8 participants may be enrolled into this optional cohort. If enrolled, up to 6 participants will be randomised to receive a selected dose of RXC007 (following Dose Escalation Data Review of previous cohorts data) once daily for 14 days. The remaining 2 participants will receive matching placebo.
89018181|NCT04931147|Experimental|Part A SAD - Optional Cohort 9|This is an optional ninth treatment arm in Part A (Single Ascending Dose) of the study. If deemed as necessary following Dose Escalation Data Review of previous cohorts data, up to 8 participants may be enrolled into this optional cohort. If enrolled, up to 6 participants will be randomised to receive a selected dose of RXC007 (following Dose Escalation Data Review of previous cohorts data) on one occasion on Day 1. The remaining 2 participants will receive matching placebo.
89018182|NCT04931147|Experimental|Part A SAD - Optional Cohort 10|This is an optional tenth treatment arm in Part A (Single Ascending Dose) of the study. If deemed as necessary following Dose Escalation Data Review of previous cohorts data, up to 8 participants may be enrolled into this optional cohort. If enrolled, up to 6 participants will be randomised to receive a selected dose of RXC007 (following Dose Escalation Data Review of previous cohorts data) on one occasion on Day 1. The remaining 2 participants will receive matching placebo.
89501953|NCT02762929|Experimental|HTX-002, 120 mg|HTX-002, 120 mg via injection.
89501954|NCT02762929|Experimental|HTX-002, 200 mg|HTX-002, 200 mg via injection.
89501955|NCT02762929|Experimental|HTX-009|HTX-009, 3.6 mg via injection.
88945486|NCT01889784|Other|Health individuals (phototherapy 300J)|The intervention of this study is phototherapy through light emitting diode (LED). The Effective-LED or Placebo-LED will be applied in femoral quadriceps and triceps surae muscle bilaterally before constant-load exercise tests in bike. Each individual will perform two tests with Effective-LED and two tests with Placebo-LED randomly allocated. Evaluations will be completed in 4 days in total, respecting 14 days of rest to ensure the long washout phototherapy.
88945487|NCT01889823|Experimental|Hypoxia|Subjects will be breathing an individualized mix of nitrogen and room air titrated to an oxygen saturation of 80-85%.
88945488|NCT01889823|Experimental|Hyperoxia|Subjects will be breathing 100% of oxygen
88945489|NCT01889836|Experimental|MenCC-Bio|The experimental group will receive one dose of meningococcal C vaccine adsorbed produced by Bio-Manguinhos.
88945490|NCT01889836|Active Comparator|MENJUGATE®|The control group will receive one dose of meningococcal C vaccine adsorbed - MENJUGATE®.
88945491|NCT01889849|Experimental|BIP48|Will be recruited for the study 32 volunteers, all of whom will receive two products in two stages separated by at least 4 weeks. Volunteers will be randomized into 2 groups of 16 and at the time of the intervention, the volunteer will receive product application labeled with its corresponding number. The second step in the product administered will necessarily be one that contains the number and it was not administered in the first step.
88945492|NCT01889849|Active Comparator|Pegasys|Will be recruited for the study 32 volunteers, all of whom will receive two products in two stages separated by at least 4 weeks. Volunteers will be randomized into 2 groups of 16 and at the time of the intervention, the volunteer will receive product application labeled with its corresponding number. The second step in the product administered will necessarily be one that contains the number and it was not administered in the first step.
88945493|NCT01889875|No Intervention|Control group|
88945494|NCT01889875|Active Comparator|Subcutaneous Immunotherapy (SCIT)|"Treatment using ALK AluTard 225 Phleum pratense"
88945495|NCT01889875|Active Comparator|Sublingual Allergen Immunotherapy Tablets (AIT)|"Treatment using ALK Grazax 75,000 SQ-T Phleum pratense"
88945496|NCT01889888|Experimental|ADRC injection|
88945497|NCT01889914|Experimental|continuous infusion of insulin by pump|"in this arm called continuous infusion of insulin with a pump the patient receive continuous rapid insulin (APIDRA ®)with an external pump.~An hepatic IRM and a botnia test will be practice before and six months after the beginning of this treatment(continuous insulin)"
88945498|NCT01889914|Experimental|discontinuous insulin multiple injections|"An arm called  intensification of the multiple daily injections : the patient will receive an additional injection of basal insulin LEVEMIR® : five injections per day (2 injections of Levemir® and 3 injections of Apidra®) instead of four previously (1 injection of Levemir® and 3 injections of Apidra®).~An hepatic IRM and a botnia test will be practice before and six months after the beginning of the treatment"
88945499|NCT01889927|No Intervention|Group 1: Control|Control Group (Arm 1): Children randomised to the control group will receive 24-months of current model of specialist CF care.
88945500|NCT01889927|Active Comparator|Group 2: Exercise Intervention|Intervention group (Arm 2): Children randomised to the intervention group will receive 24-months of current model of specialist CF care PLUS a weekly structured, individually prescribed and personally supervised exercise intervention at a local fitness facility or at school.
88945501|NCT01889940|No Intervention|Pre-intervention group.|"The initial assessment includes pre-intervention measures (baseline) for the patient, his/her relative (or main caregiver) and the rehabilitation staff.~Patients are assessed during the first week (or ≥ 10 days of SCI Unit admission) and at discharge (an expected average of 8 weeks). At the time of each patient's discharge, their family or main caregiver is also surveyed.~Lastly, rehabilitation team members are also assessed across the pre-intervention phase."
88945502|NCT01889940|Other|Post-intervention group.|Once intervention and coaching period for professionals has ended, post-intervention sample (patients, family and professionals) is assessed with the same time criteria than the pre-intervention sample.
88945503|NCT01889953|Other|EUS-guided biliary drainage|Patients in this arm will receive EUS-guided biliary drainage.
88945504|NCT01889966|Experimental|Sildenafil|oral Sildenafil 20 mg three times a day for 90 days
88945505|NCT01889979|Experimental|Tramadol|100 mg of tramadol SC (single dose) = 2 mL
88945506|NCT01889979|Placebo Comparator|Placebo|2 mL of a sterile solution SC
88945507|NCT01890018|Active Comparator|Control|"This arm will use GlowCaps to have their adherence tracked with no additional modifications:~Arm 1. Control group no modifications~Electronic Pill Bottle tracking"
88945508|NCT01890018|Experimental|Feedback group|"This arm will use GlowCaps to have their adherence tracked with the following modifications:~Arm 2. Feedback group participants will receive an adherence message after 48 hours of not using the GlowCaps~Electronic Pill Bottle tracking; Adherence Messaging"
89464763|NCT03970447|Experimental|Troriluzole Treatment Arm - Dose Finding Phase|"Newly diagnosed MGMT Methylated and Unmethylated GBM: Rolling 6 design. The first 6 patients will receive troriluzole at 100 mg BID for the first two weeks followed by 200 mg BID for the next two weeks in combination with temozolomide and radiation therapy. If there are two dose limiting toxicities (DLTs) reported, the dose will be de-escalated to 100 mg in the morning and followed by 200 mg in the evening. 6 patients will receive this dose and observed for 4 weeks. If there are two DLTs reported, then this dose will be de-escalated to 100 mg BID. 6 patients will then be receiving this dose and observed for DLTs for 4 weeks.~Recurrent GBM: Rolling 6 design. The first 6 patients receiving troriluzole 100 mg twice a day (BID) for the first two weeks followed by 200 mg BID for the next two weeks in combination with lomustine. The dose de-escalation is similar to that of newly diagnosed patients during the rolling 6 design."
89201965|NCT00746174|Active Comparator|Rosiglitazone|Subjects in this arm will be randomly assigned to treatment with Rosiglitazone 4mg daily. After 4 weeks, we will assess changes in glucose levels and liver enzymes. The dose will then be increased to Rosiglitazone 8mg daily (if indicated). The patients will be reevaluated every 4 weeks, and at the end of 16 weeks, the participants will all be admitted to the research center at UTSW to measure changes in the following: 1) insulin sensitivity; 2) lipid content of heart, liver, & skeletal muscle; and 3) lipid oxidation using respiratory gas exchange. The patients will then switch to the alternative therapy for 16 additional weeks before the studies are repeated.
89464764|NCT03970447|Experimental|Troriluzole Treatment Arm - Enhanced Safety Management (ESM)|Newly diagnosed MGMT Methylated and Unmethylated GBM and Recurrent GBM: Supplemental safety assessments including bi-weekly collection of adverse events, dose modification profile, hematology, serum chemistry and coagulation panels. ESM will continue until the Data Safety Monitoring Board (DSMB) suspends collection of additional data.
89464765|NCT03970447|Experimental|Troriluzole Treatment Arm|"Newly diagnosed MGMT Methylated and Unmethylated GBM: XRT 60 Gy for 6 weeks. Temozolomide 75 mg/m2 orally daily and troriluzole (Dosage Form: Capsule for oral administration; Strength: 100 mg; Dose: As confirmed by dose finding phase) BID. Rest period: 2-6 weeks from last day of radiation. Troriluzole dosing will continue during the rest period. Maintenance period: The first cycle of temozolomide will be at 150 mg/m2 for days 1-5 of a 28-day cycle. Second and subsequent cycles of maintenance therapy will be at 200 mg/m2 for days 1-5 of a 28-day cycle. Temozolomide will be administered for up to 6 cycles in the maintenance phase in combination with troriluzole. After 6 cycles, troriluzole only.~Recurrent GBM: Lomustine 100 mg/m2 orally on day 1 of a 42-day cycle in combination with troriluzole (Dosage Form: Capsule for oral administration; Strength: 100 mg; Dose: As confirmed by dose finding phase) BID. After 6 cycles, troriluzole only."
89464766|NCT03970447|Experimental|ADI-PEG 20 Treatment Arm - Dose Finding Phase|"Newly diagnosed MGMT Methylated and Unmethylated GBM: Dose Finding Phase is not applicable for newly diagnosed patients on the ADI-PEG 20 treatment arm.~Recurrent GBM: Rolling 6 design. The first 6 patients will receive ADI-PEG 20 at 36 mg/m2 once a week in combination with lomustine 100 mg/m2 orally on day 1 of a 42-day cycle. 6 patients will receive this dose and be observed for 4 weeks. If there are two dose limiting toxicities (DLTs) reported, the dose will be de-escalated to 18 mg/m2 once a week. 6 patients will receive this dose and be observed for 4 weeks."
89464767|NCT03970447|Experimental|ADI-PEG 20 Treatment Arm - Enhanced Safety Management (ESM)|"Newly diagnosed MGMT Methylated and Unmethylated GBM: ESM is not applicable for newly diagnosed patients on the ADI-PEG 20 treatment arm.~Recurrent GBM: Supplemental safety assessments including bi-weekly collection of adverse events, dose modification profile, hematology, serum chemistry and coagulation panels. ESM will continue until the Data Safety Monitoring Board (DSMB) suspends collection of additional data."
89464768|NCT03970447|Experimental|ADI-PEG 20 Treatment Arm|"Newly diagnosed MGMT Methylated and Unmethylated GBM: XRT 60 Gy over 6 weeks. Temozolomide (75 mg/m2 orally daily and ADI-PEG 20 (Dosage Form: Solution for intramuscular injection; Strength: 11.5 ± 1.0 mg/ml; Dose: 36 mg/m2) once a week. Rest period: 2-6 weeks from last day of radiation. ADI-PEG 20 dosing will continue during rest period. Maintenance period: The first cycle of temozolomide will be at 150 mg/m2 for days 1-5 of a 28-day cycle. Subsequent cycles will be at 200 mg/m2 for days 1-5 of a 28-day cycle. Temozolomide will be administered for up to 6 cycles in the maintenance phase in combination with ADI-PEG 20. After 6 cycles, ADI-PEG 20 only for up to 104 weeks of total treatment.~Recurrent GBM: Lomustine 100 mg/m2 orally on day 1 of a 42-day cycle in combination with ADI-PEG 20 (Dosage Form: Solution for IM injection; Strength: 11.5 ± 1.0 mg/ml; Dose: As confirmed by dose finding phase, once a week. After 6 cycles, ADI-PEG 20 only for up to 104 weeks of total treatment."
89464769|NCT03963375|Other|Group 1: LP at Baseline and Week 5|Group 1: LP at Baseline and end of Week 5. Week 5 is the optimal time point for assessing cladribine concentrations in CSF
89464770|NCT03963375|Other|Group 2: LP at Baseline and Week 10|"Group 2: LP at Baseline and end of Week 10. Week 10 is the expected nadir time for lymphocyte and monocyte levels in CSF"
89201966|NCT00746174|Placebo Comparator|Placebo|Subjects in this arm will be randomly assigned to treatment with placebo. After 4 weeks, we will assess changes in glucose levels and liver enzymes. The patients will be reevaluated every 4 weeks, and at the end of 16 weeks, the participants will all be admitted to the research center at UTSW to measure changes in the following: 1) insulin sensitivity; 2) lipid content of heart, liver, & skeletal muscle; and 3) lipid oxidation using respiratory gas exchange. The patients will then switch to the alternative therapy for 16 additional weeks before the studies are repeated.
89201967|NCT00784446|No Intervention|XELOX, Bevacizumab, Imatinib|
89201968|NCT00744536|Experimental|Lenalidomide and Melphalan|Lenalidomide + Melphalan both given metronomically
89201969|NCT03880526||Semi-Structured Interview|Participants will choose to participant in an individual in-depth interview to be conducted by investigators to gain information about the participant's background, cancer status and treatment.
89201970|NCT03880526||Focus Groups|Participants may choose to participate in one of three focus groups of no more than 10 participants in each group to to gain information about the participant's background, cancer status and treatment.
89201971|NCT05028972|Experimental|Intervention: Personal Amplifier|Consenting participants will be randomly assigned to the intervention group while receiving care in the emergency department
89201972|NCT05028972|Other|Control: No Personal Amplifier|Consenting participants will be randomly assigned to the control group while receiving care in the emergency department
89201973|NCT00744614||1|Medical Intensive care unit patients with asthma, COPD, ILD or coronary disease who are at risk of intubation
89464771|NCT03963375|Other|Group 3: LP at Baseline and End of Year 1|Group 3: LP at Baseline and end of Year 1. To assess if cladribine effects on CSF markers are maintained at the end of the first treatment cycle
89464772|NCT03963375|Other|Group 4: LP at Baseline and End of Year 2|Group 4: LP at Baseline and end of Year 2. To assess if cladribine effects on CSF markers are maintained at the end of the last treatment cycle
89201974|NCT00929799|Experimental|Growth Hormone|Therapy with recombinant human GH (Genotropin® 1 mg = 3 IU, Pfizer Inc., NY, USA) daily by subcutaneous injection using a Genotropin pen at maximal GH dose of 0.003 mg/kg/day in patients with severe GHD
89201975|NCT00777738|Experimental|bortezomib|bortezomib
89201976|NCT00926523||Healthy Controls|Subjects are made up of healthy adults
89201977|NCT00926523||Affected|Subjects have Pulmonary Hypertension
89201978|NCT02563652||Major abdominal surgery|Patients undergoing major abdominal surgery (laparotomy). Surgical procedures considered for inclusion include, but are not restricted to, procedures such as gastrectomy, pancreatic surgery, liver resection, open prostatectomy, colonic surgery, radical cystectomy with ileal conduit, open nephrectomy and vascular abdominal aortic surgery.
89201979|NCT00781872|Experimental|Treatment with autologous mesenchymal stem cells (MSC) intrathecally and intravenously|Intrathecal and intravenous treatment with autologous mesenchymal stem cells (MSC) intrathecally and intravenously in patients with active multiple sclerosis, failures to respond to other treatments
89464773|NCT03937765|Experimental|PRP|Intervention group will receive PRP instead of the standard of care for skin grafts. PRP Group-will remove surgical dressing post operative day 5. Donor site will be cleaned with soap and water daily and dressed with gauze daily until drainage stops.
89464774|NCT03937765|No Intervention|Control|Control group receiving the standard of care for skin grafts. Control Group-will remove gauze dressing post operative day 2 but leave adeptic. Donor site will be cleaned daily with soap and water. Gauze applied daily as needed for drainage and will be stopped when drainage stops. The adeptic, which forms a biologic dressing, will be removed by the patient over time as it lifts from the wound.
89464775|NCT03937713|Experimental|BBTI plus eszopiclone|participants randomized to the combination therapy will receive eszopiclone 2 mg orally at bedtime or placebo starting with the BBTI sessions for a period of 2 weeks in combination with 4 sessions of BBTI over 4 weeks.
89464776|NCT03937713|Active Comparator|BBTI|participants randomized to BBTI will receive 4 sessions of BBTI over 4 weeks.
89464777|NCT03936777|Experimental|ZX008 (Fenfluramine Hydrochloride)|ZX008 is supplied as an open-label oral solution.Doses will include up to 0.8 mg/kg/day divided into 2 daily doses, up to a maximum of 30 mg/day (subjects taking concomitant STP will receive up to 0.5 mg/kg/day, up to a maximum of 20 mg/day) in a concentration of 2.5 mg/mL.
88945509|NCT01890018|Experimental|Adherence partner group|"This arm will use GlowCaps to have their adherence tracked with the following modifications:~Arm 3. Adherence partner group participants will designate a family member or friend who will serve as an adherence partner, encouraging adherence of the patient~Electronic Pill Bottle tracking; Social Influence"
88945510|NCT01890018|Experimental|Adherence partner along with feedback|"This arm will use GlowCaps to have their adherence tracked with the following modifications:~Arm 4. Adherence partner along with feedback group participants will designate a family member or friend who will serve as an adherence partner, encouraging adherence of the patient, both the patient and partner will receive a message after 48 hours of not using the GlowCaps~Electronic Pill Bottle tracking; Adherence Messaging; Social Influence"
88945511|NCT01890278|Active Comparator|Whole Brain IMRT|Whole brain radiation therapy delivered via IMRT (37.5 Gy to brain tumor, 30 Gy to the uninvolved brain in 15 fractions), mean dose of less than 18 Gy to scalp.
88945512|NCT01890278|Active Comparator|Conventional whole brain RT|Conventional whole brain radiation therapy (37.5 Gy to the brain tumors and uninvolved brain in 15 fractions).
88945513|NCT01890317|Experimental|Mild hypothermia|Induction of mild hypothermia for 24 hr with invasive cooling in addition to primary percutaneous coronary intervention and optimal medical therapy
88945514|NCT01890317|No Intervention|Control|Percutaneous coronary intervention and optimal medical therapy according to current guidelines
88945515|NCT01890330|Experimental|Canola Oil 25 g/d|Participants randomized to this arm will be provided with food items including entrées, side dishes, salad dressing, baked goods, and desserts prepared with traditional canola oil to incorporate into their usual eating pattern. They will consume one or two food items per day containing a total of 25 g/d of Canola oil.
88945516|NCT01890330|Active Comparator|Non-Canola Oil Mixture 25 g/d|Participants randomized to this arm will be provided with food items including entrées, side dishes, salad dressing, baked goods, and desserts prepared with an oil mixture representing the typical Western diet to incorporate into their usual eating pattern. They will consume one or two food items per day containing a total of 25 g/d of the non-canola oil mixture.
88945517|NCT01890538|Active Comparator|Piracetam|2 g intravenous piracetam
88945518|NCT01890538|Active Comparator|Dimenhydrinate|Dimenhydrinate 100 mg intravenous
88945519|NCT01890681|Active Comparator|Back to Sleep|"The Back to Sleep arm will encourage safe sleep practices to reduce the risk of Sudden Infant Death Syndrome (SIDS) in child care and at home. This include:~center and family self-assessment,~center intervention materials delivered several times over the 6-month period, and;~parent handouts~After the intervention period, comparator centers will receive an abbreviated version of the Baby NAP SACC intervention."
88945520|NCT01890681|Experimental|Baby NAP SACC|"The intervention will include four complementary and mutually reinforcing components:~center and family self-assessment;~targeted technical assistance by Baby NAP SACC consultant for providers and parents;~training workshops for child care providers; and~parent outreach and support."
88945521|NCT01891123|Placebo Comparator|body surface area|patients receive fixed dose of PTX or DOC based on body surface area every cycle, PTX 175mg/m2, DOC 75mg/m2. Patients should finish up to 6 cycles chemotherapy
88945522|NCT01891123|Active Comparator|Detection Kit|PTX 175mg/m2, DOC 75mg/m2 at first cycle. the dose of PTX or DOC will adjust based on the pharmacokinetic results of previous cycle. A optimal target of PTX(TC>0.05) and DOC(AUC) have been set from published PK model with an established limited sampling strategy
89464778|NCT03933163|Other|Resveratrol followed by placebo|1g micronised resveratrol twice daily for 24 weeks, a wash-out period of 4 weeks, followed by twice daily placebo for 24 weeks.
89464779|NCT03933163|Other|Placebo followed by Resveratrol|Twice daily placebo for 24 weeks, a wash-out period of 4 weeks, followed by 1g micronised resveratrol twice daily for 24 weeks
88945523|NCT01891188||Cardiac Cath|All pediatric patients requiring cardiac catheterization who consent
88945524|NCT01891279|Experimental|elemental formula, Elecare®|Babies will receive elemental formula, Elecare®, if breast milk is not available.
89464780|NCT03924479|Experimental|Breathing muscle training|The breathing muscle training will consist of 7 sessions per week (1 per day) for 8 weeks. Each training session will consist of breathing ~15 times each minute for 30 minutes at 40% of maximal breathing muscle strength, while using the breathing muscle trainer. During the inhalation, participants will be instructed to inhale as fast as they can, while exhalations will be performed at the participants discretion.
89464781|NCT03924479|Sham Comparator|Sham breathing muscle training|The breathing muscle training will consist of 7 sessions per week (1 per day) for 8 weeks. Each training session will consist of breathing ~15 times each minute for 30 minutes at 2%% of maximal breathing muscle strength, while using the breathing muscle trainer. During the inhalation, participants will be instructed to inhale as fast as they can, while exhalations will be performed at the participants discretion.
89464782|NCT03915951|Experimental|Treatment Period|"Study treatment with encorafenib and binimetinib will be self-administered orally without regard to food.~Patients will receive the following per 28-day (± 3 days) cycle:~Encorafenib: 450 mg (6 × 75 mg capsule) once daily (QD)~Binimetinib: 45 mg (3 × 15 mg tablet) twice daily (BID)"
89464783|NCT03913065||Included patients|Cardiac arrest patients from sites participating in the TTM-2 CT-substudy still unconscious 48 hours after cardiac arrest are routinely examined with head computed tomography as soon as possible after inclusion.
89464784|NCT03912428|Other|Single arm|all groups get the same studies
89464785|NCT03910478|Experimental|Self-collected Dried Blood Spot (DBS) monitoring|N=100 Subject collected DBS CMV monitoring with mobile technology support
89464786|NCT03910478|Active Comparator|Standard Monitoring Control|N=50 Standard care with office based testing
89464787|NCT03910452|Experimental|1|This is a single arm open-label pilot study.
89464788|NCT03909880|No Intervention|Control|Without Kinesio tape on the forearm
89464789|NCT03909880|Placebo Comparator|Kinesio taping with neutral tension|Kinesio tape with neutral tension on the forearm
89464790|NCT03909880|Experimental|Kinesio taping with additional 20% tension|Kinesio tape with 20% additional tension on the forearm
89464791|NCT03887780||Treatment|Rivaroxaban treatment-naïve patients, at least 18 years of age and presenting with NVAF will be considered eligible for participation in this study only after the decision to treat with rivaroxaban has been made by the treating physician.
89464792|NCT03887741|Experimental|Plasmapheresis|3 patients will have monthly plasmapheresis for 6 months and followed for a total of 12 months
89464793|NCT03887741|Experimental|Plasma infusion|3 patients will have biweekly plasma infusion for 6 months and followed for 12 months
89464794|NCT03887741|No Intervention|Control group|3 patients will be followed for 12 months
89464795|NCT03885089||Infliximab [infliximab biosimilar 3]|Patients with Psoriasis Vulgaris, Psoriasis Arthropathica, Pustular Psoriasis, or Erythrodermic Psoriasis treated by Infliximab BS
89464796|NCT03883646|Experimental|Mindfulness|Mindfulness
88945525|NCT01891279|Experimental|part hydrolyzed formula, Pregestimil®|Babies will receive partially hydrolyzed formula, Pregestimil®, if breast milk is not available.
88945526|NCT01891292|No Intervention|Control|
89464797|NCT03883646|Experimental|Relapse Prevention|
89464798|NCT03883646|No Intervention|Waitlist Control|
89464799|NCT03883646|No Intervention|Treatment as Usual|
89464800|NCT03866603||Parkinson´s disease individuals|"The participant has been clinically diagnosed with Parkinson's disease within the last 5 years (≤ 5 years)~The participant is between 30 and 80 years old"
89464801|NCT03865472|Experimental|Arm I (rTMS)|Patients undergo rTMS QD or BID over 16 minutes for 8, 12, or 16 days.
89464802|NCT03865472|Sham Comparator|Arm II (sham rTMS)|Patients undergo sham rTMS QD or BID over 16 minutes for 8, 12, or 16 days.
89464803|NCT03859765|Experimental|HCT Symptoms and Steps|HCT Symptoms and Steps participants will complete in-person (3) and video-conferencing (4) coping skills training and activity coaching sessions teaching cognitive behavioral coping skills to manage pain, fatigue, and distress and increase activity. Participants will be given a wireless activity tracker and a smartphone for accessing the study mobile app.
89464804|NCT03859765|No Intervention|HCT Education|HCT Education participants will receive 1 brief in clinic session prior to discharge home providing education related to symptom management and physical activity, and a wireless activity tracker. HCT Education participants will also receive 6 brief phone calls upon return home.
89464805|NCT03842384|Experimental|iENDURE|iENDURE involves two delivery modes: computer and text message. The intervention initially targets motivational processes in combination with introductory strategies for managing physical and emotional distress through a single, brief, computer-delivered session followed by eight weeks of theoretically-informed text messages intended to enhance motivation and promote distress tolerance (DT).
89464806|NCT03842384|No Intervention|Treatment-as-Usual|Participants in the TAU comparison control group will engage in buprenorphine treatment as determined by their clinical team. This could include medication evaluations, individual or group counseling, case management or peer recovery. TAU was selected as the comparison condition as it represents a robust and evidence-based approach to the treatment of OUD.
89464807|NCT03841617|Active Comparator|124I PET/CT scan after rhTSH|124I PET/CT scan after preparation with human recombinant TSH
89464808|NCT03841617|Active Comparator|124I PET/CT scan after thyroid hormone withdrawal|124I PET/CT scan after preparation with thyroid hormone withdrawal
89464809|NCT03836040|Experimental|Dose level 1|Participants will be randomized to one of two doses determined by their body weight at Day 1. Participants who enrolled under the original protocol or protocol amendment 1 will be identified as group 1. Those enrolled under protocol amendment 2 will be identified as group 2.
89464810|NCT03836040|Experimental|Dose level 2|Participants will be randomized to one of two doses determined by their body weight at Day 1. Participants who enrolled under the original protocol or protocol amendment 1 will be identified as group 1. Those enrolled under protocol amendment 2 will be identified as group 2.
89464811|NCT03836040|Placebo Comparator|Placebo|Participants will be randomized to a placebo comparator.
89464812|NCT03834961|Experimental|Treatment (larotrectinib)|Patients receive larotrectinib PO or by NG or G-tube BID on days 1-28. Treatment repeats every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity, or complete surgical resection of tumor.
89464813|NCT03832998|Experimental|Dose Level 1|Participants will be randomized to one of two doses determined by their body weight at Day 1. Participants who enrolled under the original protocol or protocol amendment 1 will be identified as group 1. Those enrolled under protocol amendment 2 will be identified as group 2.
89464814|NCT03832998|Experimental|Dose Level 2|Participants will be randomized to one of two doses determined by their body-weight at Day 1. Participants who enrolled under the original protocol or protocol amendment 1 will be identified as group 1. Those enrolled under protocol amendment 2 will be identified as group 2.
88945527|NCT01891292|Active Comparator|Enalapril|
88945528|NCT01891292|Active Comparator|N-Acetylcysteine|
89201980|NCT00741728||general population|Observational study of 10000 adult men and women from the general population who benefited from a free extensive health check up in Paris, France
89201981|NCT00784680|Active Comparator|1|Arimidex 1mg + Nolvadex placebo
89464815|NCT03832998|Placebo Comparator|Placebo|
89464816|NCT03832855|Experimental|Treatment|4 mg pING-hHER3FL ID or IM
89464817|NCT03818412|Experimental|Soft Tissue Sarcoma|"A sample of archival tumor tissue will be collected.~Blood samples (about 20-30 mL or 1-2 tablespoons each sample) will be taken:~Prior to planned radiation treatment~2-4 weeks after cancer surgery~Every 12 weeks after surgery for up to 2 years"
89464818|NCT03818178|Experimental|Intralipid|
89464819|NCT03818178|Experimental|Palm Oil|
89464820|NCT03818178|Placebo Comparator|Saline|
89464821|NCT03805919||Cohort 1|Participants with germline pathogenic or likely pathogenic variants in prostate cancer-related risk genes
89464822|NCT03796962|Experimental|25 mg XEN1101|Capsule filled with 25 mg XEN1101
89464823|NCT03796962|Experimental|20 mg XEN1101|Capsule filled with 20 mg XEN1101
88945529|NCT01891448|Experimental|WebCONSORT tool|This WebCONSORT tool allows authors to combine different extensions relevant to their trial and generate a list of items and a flowchart specific to their trial design and the type of intervention tested.
89464824|NCT03796962|Experimental|10 mg XEN1101|Capsule filled with 10 mg XEN1101
89464825|NCT03796962|Placebo Comparator|Placebo|Placebo capsule
89464826|NCT03795298|Experimental|WATCHMAN FLX|WATCHMAN FLX implant including modified post-implant drug regimen.
89464827|NCT03795298|Active Comparator|Market-approved OAC|Used per IFU for atrial fibrillation stroke prevention for the duration of the trial.
88945530|NCT01891448|Other|Modified WebCONSORT tool|This tool will include the flowchart part of the WEBCONSORT tool but not the main checklist or elements relating to CONSORT extensions.
88945531|NCT01891487|Active Comparator|Track A|Those on active study medication
88945532|NCT01891487|Placebo Comparator|Track B|Those on placebo.
88945533|NCT01891552||Tacetux|DEBIRI+ CETUXIMAB ADMINISTRATION
88945534|NCT01891552||DEBIRI|only DEBIRI treatment
88945535|NCT01892033|Experimental|Aerobic Exercise|The aerobic exercise intervention is a 12-week program consisting of four 30- to 40-minute exercise sessions of brisk walking per week.
89464828|NCT03781141|Experimental|Absorbable suture|Wound closure with absorbable suture.
89464829|NCT03781141|Active Comparator|Non-absorbable suture|Wound closure with non-absorbable suture.
89464830|NCT03771508||PillCam SB3 procedure|Subjects with normal/abnormal PillCam SB3 procedure
89464831|NCT03755791|Experimental|Experimental arm|Subjects with advanced HCC will receive cabozantinib 40 mg oral, qd + atezolizumab 1200 mg infusion, q3w
89464832|NCT03755791|Active Comparator|Control arm|Subjects with advanced HCC will receive sorafenib 400 mg bid (twice a day)
89464833|NCT03755791|Other|Single-Agent Cabozantinib arm|Subjects with advanced HCC will receive cabozantinib 60 mg qd
89464834|NCT03755154|Experimental|S65487 - initial scheme|
89464835|NCT03755154|Experimental|S65487 - alternative scheme|
89464836|NCT03753412||ICUAW ECMO group|The physical and psychological effects of ICUAW on patients receiving extracorporeal membrane oxygenation for severe cardiorespiratory failure will be observed. Physical function and HRQoL will be analysed and correlated with RFcsa. Additionally, biological markers will be used to understand molecular and genomic profiles.
89464837|NCT03748433|Experimental|Continuous Glucose Monitoring (CGM)|The RT CGM group will receive a Dexcom G6 transmitter and sensors, as well as a structured education refresher focusing on hypoglycaemia avoidance, recognition, and management.
89464838|NCT03748433|No Intervention|Self Monitoring Blood Glucose (SMBG)|The SMBG group will additionally undergo blinded CGM at weeks 1 and 2, weeks 4 to 6 and weeks 9 to 12 using the Dexcom G6 system. Participants in this group will be shown how to insert the Dexcom G6 at the first clinic visit and sensors provided so they can do this at home.
89464839|NCT03748433|Experimental|Continuous Subcutaneous Insulin Infusion (CSII)|All participants will be re-consented with the choice to continue using RT-CGM for a further 16 weeks or be re-randomised to either receive the Tandem t:slim X2 insulin pump or RT-CGM. Participants randomised to the Tandem t:slim X2 group will be proficiently trained to safely use the Tandem t:slim X2 insulin pump. All participants (Tandem t:slim X2 and RT-CGM) will be provided with Dexcom G6 real time CGM transmitters and sensors for the 16-week second extension phase.
89464840|NCT03737994|Experimental|ALK L1198F mutation (alone or combination with ALK inhibitor)|Patients with ALK L1198F mutation (alone or in combination with another ALK mutation) receive crizotinib PO QD. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
88945536|NCT01892280|Experimental|Teenwork Group|Teen/family will receive the Teenwork intervention at each quarterly study visit.
88945537|NCT01892280|Experimental|Teenwork/Text Message Group|Teen/family will receive the Teenwork intervention at each quarterly study visit. Teen will receive text message reminders to check blood glucose levels at self-selected times.
88945538|NCT01892280|Experimental|Text Message Group|Teen will receive text message reminders to check blood glucose levels at self-selected times.
88945539|NCT01892280|No Intervention|Usual Care Group|Teen/family will receive routine clinical care for the first year of the study (the time period for assessment of primary outcomes). After year 1, teen/family will receive the Teenwork intervention at each remaining study visit and teen will receive text message reminders to check blood glucose levels at self-selected times.
88945540|NCT01892319||All patients|
88945541|NCT01892579|Experimental|Tailored Activity Program|"The Tailored Activity Program unfolds over 3 phases: Phase I (sessions 1-2) involves assessment of Person with Dementia (PwD)capacity and interests, caregiver (CG) interactions and the physical environment and CG education. Phase II (sessions 3-6) involves identifying and implementing 3 Activity Prescriptions tailored to PwD's cognitive and interest profile using an algorithmic guide. The prescription summarizes PwD capabilities in lay language, identifies the activity and a specific activity goal, and provides specific instructions for introducing the activity. CGs are trained to integrate activities in daily care. Also provided are simple deep breathing stress reduction techniques to address CG upset. Phase III (sessions 7-8) involves instructing CGs in simplifying activities for future cognitive declines and applying simplification principles to other care challenges."
89018183|NCT04931147|Experimental|Part B MAD - Optional Cohort 5|This is an optional fifth treatment arm in Part B (Multiple Ascending Dose) of the study. If deemed as necessary following Dose Escalation Data Review of previous cohorts data, up to 8 participants may be enrolled into this optional cohort. If enrolled, up to 6 participants will be randomised to receive a selected dose of RXC007 (following Dose Escalation Data Review of previous cohorts data) once daily for 14 days. The remaining 2 participants will receive matching placebo.
89201982|NCT00784680|Active Comparator|2|Arimidex placebo + Nolvadex 20mg
89201983|NCT00784680|Active Comparator|3|Arimidex 1mg + Nolvadex 20mg
89464841|NCT03737994|Experimental|C1156Y|Patients with Cy1156Y mutation receive either lorlatinib PO QD, alectinib PO BID, or brigatinib PO QD. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89464842|NCT03737994|Experimental|Compound mutation|Patients with a compound mutation receive lorlatinib PO QD. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89464843|NCT03737994|Experimental|F1174|Patients with F1174 receive either lorlatinib PO QD, alectinib PO BID, or brigatinib PO QD. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89201984|NCT00908271|Other|Dapagliflozin|PO and IV
89464844|NCT03737994|Experimental|G1202 (including G1202del and G1202R)|Patients with G1202 (including G1202del and G1202R) receive either lorlatinib PO QD or brigatinib PO QD. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89464845|NCT03737994|Experimental|I1171|Patients with I1171 mutation receive either lorlatinib PO QD, ceritinib PO QD, or brigatinib PO QD. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89464846|NCT03737994|Experimental|L1196 (including L1196M)|Patients with L1196 (including L1196M) mutation receive either lorlatinib PO QD, ceritinib PO QD, alectinib PO BID, brigatinib PO QD, or ensartinib PO QD. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89464847|NCT03737994|Experimental|MET amplification|Patients with MET amplification receive crizotinib PO QD. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89464848|NCT03737994|Experimental|No ALK-resistance mutations|Patients with no ALK-resistant mutations receive either lorlatinib PO QD, ceritinib PO QD, alectinib PO BID, brigatinib PO QD, ensartinib PO QD, or pemetrexed IV over 10 minutes on day 1 with or without either cisplatin IV or carboplatin IV on day 1. ALK inhibitor cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Pemetrexed-based treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Maintenance treatment of pemetrexed may continue until disease progression or unacceptable toxicity.
89018184|NCT04931147|Experimental|Part B MAD - Optional Cohort 6|This is an optional sixth treatment arm in Part B (Multiple Ascending Dose) of the study. If deemed as necessary following Dose Escalation Data Review of previous cohorts data, up to 8 participants may be enrolled into this optional cohort. If enrolled, up to 6 participants will be randomised to receive a selected dose of RXC007 (following Dose Escalation Data Review of previous cohorts data) once daily for 14 days. The remaining 2 participants will receive matching placebo.
89018185|NCT04931147|Experimental|Part C DDI - Cohort 1 Rosuvastatin|This is the first treatment arm in Part C (Drug-Drug Interaction) of the study. All participants within the cohort (12 participants) will to receive a selected dose of RXC007 (following Dose Escalation Data Review from Part A and Part B) and 10 mg rosuvastatin as follows: single dose of rosuvastatin (10 milligrams) on Day 1 followed by three single doses of RXC007 on Day 6, Day 7 & Day 8 before taking a single dose of both RXC007 and rosuvastatin together on Day 9.
89018186|NCT04931147|Experimental|Part C DDI - Cohort 2 Metformin|This is the second treatment arm in Part C (Drug-Drug Interaction) of the study. All participants within the cohort (12 participants) will to receive a selected dose of RXC007 (following Dose Escalation Data Review from Part A and Part B) and 500 mg metformin as follows: single dose of metformin (500 milligrams) on Day 1 followed by three single doses of RXC007 on Day 4, Day 5 & Day 6 before taking a single dose of both RXC007 and metformin together on Day 7.
89464849|NCT03737994|Experimental|V1180|Patients with V1180 mutation receive either lorlatinib PO QD, ceritinib PO QD, or brigatinib PO QD. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89464850|NCT03737695||Observational (biospecimen, clinical info collection)|Patients' archival and newly collected tissue and blood samples are collected periodically for genetic testing. Patients also undergo collection of clinical information within 30 days of biopsy procedure and every 4 months.
89464851|NCT03737370|Experimental|Dose escalation|"There are four dose cohorts (1, 1a, 2, 2a) in this arm and two dose levels of docetaxel (40mg/m^2 [level 1] and 50mg/m^2 [level 2]). Dosing of Radium 223 remains the same in all cohorts (55 KBq/kg given every 28 days for 6 cycles).~Maximum tolerated dose (MTD) of docetaxel will be assessed. MTD is defined as the highest dose-level, among those tested, associated with a rate of less than a 33% dose limiting toxicity (DLT)."
89464852|NCT03737370|Experimental|Dose expansion|If the maximum tolerated dose (MTD) of docetaxel is found in arm 1, this dose level will be expanded to include an additional 25 subjects to confirm the safety and explore the preliminary anti-cancer effect. If the MTD is not identified, the study will be stopped and the expansion cohort will not be accrued.
89464853|NCT03735667|Experimental|ACURATE Valve - Main Randomized|"Patients assigned to this group will be implanted with ACURATE neo2™ transfemoral TAVR System.~*A subset of subjects will also be enrolled in the 4D CT Imaging Substudy."
89464854|NCT03735667|Experimental|ACURATE Valve - Single-arm Roll-in|Patients assigned to this group will be implanted with ACURATE neo2™ transfemoral TAVR System.
89464855|NCT03735667|Active Comparator|Commercial Valve - Main Randomized|"Medtronic CoreValve TAVR System OR, Edwards SAPIEN 3 TAVR System~Patients assigned to this group will be implanted with commercially available balloon-expandable SAPIEN 3™ Transcatheter Heart Valve or future iteration (SAPIEN 3; Edwards Lifesciences LLC, Irvine, CA, USA) or a commercially available self-expanding CoreValve® Transcatheter Aortic Valve Replacement System, CoreValve® Evolut™ R Recapturable TAVR System, EVOLUT™ PRO System, or future iteration (CoreValve; Medtronic, Inc., Dublin, Ireland) TAVR device.~*A minimum of 200 subjects will also be enrolled in the 4D CT Imaging Substudy."
89464856|NCT03735667|Experimental|ACURATE Valve - Single-arm Prime XL|"Patients assigned to this group will be implanted with ACURATE Prime™ transfemoral TAVR System XL.~*50 subjects will be enrolled in the Prime™ XL Nested Registry"
89464857|NCT03735667|Experimental|ACURATE Valve - Extended Durability Randomized|Patients assigned to this group will be implanted with ACURATE neo2™ transfemoral TAVR System (S, M, L) or ACURATE Prime™ transfemoral TAVR System XL. Only low risk patients are enrolled in this group.
89464858|NCT03735667|Active Comparator|Commercial Valve - Extended Durability Randomized|"Medtronic CoreValve TAVR System OR, Edwards SAPIEN 3 TAVR System~Patients assigned to this group will be implanted with commercially available balloon-expandable SAPIEN 3™ Transcatheter Heart Valve or future iteration (SAPIEN 3; Edwards Lifesciences LLC, Irvine, CA, USA) or a commercially available self-expanding CoreValve® Transcatheter Aortic Valve Replacement System, CoreValve® Evolut™ R Recapturable TAVR System, EVOLUT™ PRO System, or future iteration (CoreValve; Medtronic, Inc., Dublin, Ireland) TAVR device. Only low risk patients are enrolled in this group."
89464859|NCT03735667|Experimental|ACURATE Valve - Continued Access Study|Patients assigned to this group will be implanted with ACURATE neo2™ transfemoral TAVR System (S, M, L) or ACURATE Prime™ transfemoral TAVR System XL.
89464860|NCT03734653|Experimental|Square Wave Testosterone Therapy + SOC|All patients will receive transdermal testosterone. All patients will also receive standard of care enzalutamide. Patients will alternate between the two therapies.
89464861|NCT03722407|Experimental|Ruxolitinib|All patients will be given their first dose of oral Ruxolitinib, 20 mg at first scheduled visit. After that dose and on all other days patients will self-administer oral Ruxolitinib at a dose of 40 mg daily divided into two equal doses approximately 12 hours apart. Patients will be treated for a total of 16 weeks. After treatment, patients will be followed monthly.
89018187|NCT04928534||Athletes with rmTBI history|50 active or retired athletes from the Weightlifting, Wrestling, Judo, Boxing and Taekwondo Sports Management Center of Tianjin Sports Bureau
89018188|NCT04928534||Patients with rmTBI history|50 patients with multiple (≥2 times) exposure to brain trauma attending Tianjin Medical Insurance designated hospitals such as Tianjin Medical University General Hospital
89464862|NCT03719599||Children|Children 6 -12 months of age presenting for routine clinic visits
89464863|NCT03719599||Pregnant Women|Pregnant Women 18 years and older presenting for routine clinic visits
89464864|NCT03718559|Experimental|Edoxaban alone|
89464865|NCT03718559|Active Comparator|Combination of edoxaban plus single antiplatelet|
89464866|NCT03712618|Active Comparator|Group A|Group A: Long Transfusion followed by Short Transfusion in the first block
89018189|NCT04928534||Healthy volunteer|20 healthy volunteers
89018190|NCT04928209|No Intervention|Usual Care (High-Income)|This group will receive comprehensive assessments every 9 months for the 18-month period of enrollment, for a total of 3 assessments. They will not be randomized to receive supplemental teletherapy (intervention) and usual care.
89018191|NCT04928209|No Intervention|Usual Care (Low-Income)|"This group includes the low-income families who satisfy the criteria to receive supplemental speech-language teletherapy but are not randomized to receive the intervention after allocation. Like the Usual Care (High-Income) arm, they will only receive comprehensive assessments every 9 months for the 18-month period of enrollment, for a total of 3 assessments and usual care."
89018192|NCT04928209|Experimental|Usual Care + Teletherapy (Low-Income)|This group includes the low-income families who satisfy the criteria to receive supplemental speech-language teletherapy and are randomized to receive the intervention. They will receive both 3x comprehensive assessments every 9 months AND access to supplemental speech-language teletherapy for the 18-month study period.
89018193|NCT04910776|Experimental|Avalglucosidase alfa|Administered intravenously every 2 weeks
89464867|NCT03712618|Active Comparator|Group B|Group B: Short Transfusion followed by Long Transfusion in the first block
89464868|NCT03706365|Experimental|A1. Abiraterone plus Prednisone and Abemaciclib|Abiraterone plus prednisone administered orally and abemaciclib administered orally.
89464869|NCT03706365|Experimental|A2. Abiraterone plus Prednisone and Abemaciclib|Abiraterone plus prednisone administered orally and abemaciclib administered orally.
89464870|NCT03706365|Active Comparator|B1. Abiraterone plus Prednisone and Placebo|Abiraterone plus prednisone administered orally and placebo administered orally.
89464871|NCT03706365|Active Comparator|B2. Abiraterone plus Prednisone and Placebo|Abiraterone plus prednisone administered orally and placebo administered orally.
89464872|NCT03706365|Experimental|A. Abiraterone plus Prednisone and Abemaciclib|Abiraterone plus prednisone administered orally and abemaciclib administered orally.
89464873|NCT03706365|Active Comparator|B. Abiraterone plus Prednisone and Placebo|Abiraterone plus prednisone administered orally and placebo administered orally.
89464874|NCT03701282|Experimental|Arm A (ibrutinib, obinutuzumab, venetoclax)|Patients receive ibrutinib PO daily on days 1-28 and obinutuzumab IV over 4 hours on days 1, 2, 8, and 15 of cycle 1 and on day 1 of cycles 2-6. Patients also receive venetoclax PO QD on days 1-28 of cycles 3-14. Treatment repeats every 28 days for up to 19 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo biopsy and CT scans before and after treatment and collection of blood throughout the study.
89464875|NCT03701282|Active Comparator|Arm B (ibrutinib, obinutuzumab)|Patients receive ibrutinib PO and obinutuzumab as in arm A. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo biopsy and CT scans before and after treatment and collection of blood throughout the study.
89464876|NCT03692611|Experimental|Skills to Manage Pain (STOMP)|The intervention group will receive treatment as usual plus the STOMP behavioral intervention. The STOMP behavioral intervention consists of 12 intervention sessions (6 group and 6 individual sessions). The sessions will be completed over a period of 12-16 weeks from enrollment. The first intervention session will be a group session for all participants followed by individual and then alternating group and individual sessions for the rest of the intervention. The intervention group will utilize a study manual on pain management in which they will use with each session.
89464877|NCT03692611|Active Comparator|comparison group|The comparison group will receive treatment as usual.The comparison group will also be provided with the intervention manual, however, no additional treatment will be provided to participants allocated to the control group. The group will not receive the PSM intervention.
89464878|NCT03690388|Experimental|Cabozantinib|cabozantinib (60 mg) once daily orally (qd)
89464879|NCT03690388|Placebo Comparator|Placebo|placebo once daily orally (qd)
88945542|NCT01892579|Active Comparator|Home Safety and Education Program|This arm receives 6 in-home and 2 brief telephone education sessions. Each contact is structured to provide helpful education. Sessions include information on home safety, fall risk assessment, talking to your doctor, advanced planning, identifying resources, and caring for the caregiver (CG). Each session is prescriptive and designed to maximize attention; yet, sessions will not involve any component of the intervention group. To engage the person with dementia (PwD), the interventionist will socially engage the person briefly in select sessions. Time spent with CG and PwD in the control group is comparable to that for intervention dyads.
88945543|NCT01892800||Study population - lung resection|Patients with suspected lung cancer undergoing lung resection by anatomic lobectomy
89464880|NCT03660826|Experimental|Arm I (cediranib maleate)|Patients receive cediranib maleate PO QD. Cycles repeat every 28 days in the absence of disease progression or unaccepted toxicity. Additionally, patients undergo blood sample collection, bone marrow aspiration and biopsy, CT, Echo or MUGA on study.
89464881|NCT03660826|Experimental|Arm II (olaparib)|Patients receive olaparib PO BID. Cycles repeat every 28 days in the absence of disease progression or unaccepted toxicity. Additionally, patients undergo blood sample collection, bone marrow aspiration and biopsy, CT, Echo or MUGA on study.
89464882|NCT03660826|Experimental|Arm III (cediranib maleate, olaparib)|Patients receive olaparib PO BID and cediranib maleate PO QD. Cycles repeat every 28 days in the absence of disease progression or unaccepted toxicity. Additionally, patients undergo blood sample collection, bone marrow aspiration and biopsy, CT, Echo or MUGA on study.
89464883|NCT03660826|Experimental|Arm IV (olaparib, capivasertib)|Patients receive olaparib PO BID on days 1-28 and capivasertib PO BID on days 1-4 each week. Cycles repeat every 28 days in the absence of disease progression or unaccepted toxicity. Additionally, patients undergo blood sample collection, bone marrow aspiration and biopsy, CT, Echo or MUGA on study.
89464884|NCT03660826|Experimental|Arm V (olaparib, durvalumab)|Patients receive olaparib PO BID on days 1-28 and durvalumab IV on day 1. Cycles repeat every 28 days in the absence of disease progression or unaccepted toxicity. Additionally, patients undergo blood sample collection, bone marrow aspiration and biopsy, CT, Echo or MUGA on study.
89464885|NCT03660826|Experimental|Arm VI (cediranib maleate, durvalumab)|Patients receive cediranib maleate PO BID on days 1-28 and durvalumab IV on day 1. Cycles repeat every 28 days in the absence of disease progression or unaccepted toxicity. Additionally, patients undergo blood sample collection, bone marrow aspiration and biopsy, CT, Echo or MUGA on study.
89464886|NCT03644706|Active Comparator|ADV7103|Patients continue to receive ADV7103 twice a day at their open label dose over 6 days
89464887|NCT03644706|Placebo Comparator|Placebo Comparator|Patients receive matched placebo twice a day until they reach a bicarbonate level of 18mEq/L
89464888|NCT03641313|Experimental|Treatment (irinotecan and M6620)|Patients receive irinotecan IV over 90 minutes and berzosertib IV over 60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo endoscopic or CT assisted biopsy and MRI on study.
89464889|NCT03632941|Active Comparator|VRP-HER2 Vaccine|VRP-HER2 Vaccine 4 x 10EE8 IU given as a single injection every 2 weeks for 3 injections total (Cycle 1: Day 1 and Day 15 Cycle 2: Day 8)
89464890|NCT03632941|Active Comparator|Pembrolizumab|5 administrations of Pembrolizumab 200 mg every 3 weeks for 5 total IV infusions (Day 1 of each 3 week cycle x 5 cycles)
89464891|NCT03632941|Experimental|VRP-HER2 Vaccine + Pembrolizumab|VRP-HER2 Vaccine 4 x 10EE8 IU given as a single injection every 2 weeks for 3 injections total (Cycle 1: Day 1 and Day 15 Cycle 2: Day 8)+ 5 administrations of Pembrolizumab 200 mg every 3 weeks for 5 total IV infusions (Day 1 of each 3 week cycle x 5 cycles)
89464892|NCT03625570|Experimental|PT³|Power Training combined with interval treadmill training
89464893|NCT03625570|Active Comparator|Traditional training|Strength training combined with traditional treadmill training
89464894|NCT03608579|Experimental|Single Injection|Single administration of Autologous Adipose Derived Mesenchymal Stromal Cells into the hip by single ultrasound guided injection
89464895|NCT03608579|Experimental|Two Injections|Two-dose administration (2 x ultrasound guided injections) of Autologous Adipose Derived Mesenchymal Stromal Cells into the hip with one month interval between doses
89464896|NCT03590054|Experimental|Dose Escalation: (abexinostat, pembrolizumab)|Participants receive abexinostat PO BID on days -7 to -4 of the lead-in period, and days 1-4, 8-11 of each treatment cycle and pembrolizumab over 30 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89464897|NCT03590054|Experimental|Cohort A: Dose Expansion (abexinostat, pembrolizumab)|Participants with primary resistance to prior anti-PD-1/PD-L1 will receive abexinostat PO BID on days -7 to -4 of the lead-in period, and days 1-4, 8-11 of each treatment cycle and pembrolizumab over 30 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89464898|NCT03590054|Experimental|Cohort B: Dose Expansion (abexinostat, pembrolizumab)|Participants with acquired resistance, defined as treatment duration on prior CPI for greater than 6 months with evidence of clinical benefit (tumor regression or disease stabilization) with subsequent disease progression will receive abexinostat PO BID on days -7 to -4 of the lead-in period, and days 1-4, 8-11 of each treatment cycle and pembrolizumab over 30 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
88945544|NCT01893008|Experimental|Usual care + Inspiratory Muscle Training (IMT)|
88945545|NCT01893008|No Intervention|Usual care (no IMT)|
88945546|NCT01893112|Experimental|Unity Workshop|The intervention is a workshop facilitated by a peer advocate (an African American woman who is also HIV positive) and a social worker. It has exercises, videos and group discussions intended to equip participants with coping skills to overcome HIV related stigma and the negative outcomes related to stigma. The workshop will last about 8 hours total across 2 two days (4 hours per day). The researcher in the current study has done a lot of work in adapting this intervention for African American women. The workshop has been piloted in Seattle and had promising results. Based on results in the pilot study, a 2 hour booster session has been added 6 months after the initial workshop
89464899|NCT03578367|Experimental|Asciminib 60mg QD + Imatinib 400mg QD|Asciminib 60 mg taken once daily in combination with Imatinib 400 mg taken once daily
89464900|NCT03578367|Experimental|Asciminib 40mg QD + Imatinib 400mg QD|Asciminib 40 mg taken once daily in combination with Imatinib 400 mg taken once daily
89464901|NCT03578367|Active Comparator|Imatinib 400mg QD|Imatinib 400 mg taken once daily
89464902|NCT03578367|Active Comparator|Nilotinib 300mg BID|Nilotinib 300 mg taken twice daily
89464903|NCT03578367|Experimental|Asciminib 80mg QD|Asciminib 80 mg taken once daily
89464904|NCT03575364||Primary Analytic|Patients with unilateral acute or subacute DVT of less than 6 weeks' duration.
89464905|NCT03575364||Registry|Patients with proximal lower extremity DVT.
89464906|NCT03573349|Other|Ketamine|Open-label, non-randomized
89464907|NCT03571828|Experimental|Part 1: Dose Exploration|Dose exploration cohorts to estimate the MTD, safety, tolerability, and PK of different doses of AMG 562 in subjects with relapsed/refractory DLBCL, MCL or FL using a Bayesian logistic regression model (BLRM; Neuenschwander et al, 2008).
89464908|NCT03571828|Experimental|Part 2: Dose Expansion|dose expansion part to gain further clinical experience, safety and efficacy data for AMG 562 in subjects with relapsed / refractory DLBCL. The dose to be evaluated will be at or below the MTD estimated in the dose exploration cohorts.
89464909|NCT03570892|Experimental|Tisagenlecleucel treatment strategy|Patients will receive investigator's choice of optional platinum-based immunochemotherapy followed by lymphodepleting chemotherapy and a single dose of tisagenlecleucel
89464910|NCT03570892|Active Comparator|Standard of care treatment strategy|Patients will receive investigator's choice of platinum-based immunochemotherapy followed in responding patients by high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)
89464911|NCT03562728|Active Comparator|ECMO- Bridge to Transplant|Interventions: MRP+MNES(neuromuscular electric stimulation).Patients in the treatment arm will receive additional physical therapy(arm and leg exercises, using light weight machines, hand weights, or rubber bands, exercise machines such as portable arm or seated bikes) as well as therapy with an electric stimulator device. This device uses weak electric impulses to involuntarily exercise the muscles(one-two sessions a day).Four muscle groups(quadriceps and dorsiflexors bilaterally) will be stimulated using surface electrodes .In addition, patients in the experimental group will receive nutrition supplementation with essential amino acids 3 times a day in their feeding to prevent muscle breakdown and promote positive nitrogen balance.
89464912|NCT03562728|Other|ECMO- Bridge to Transplant Control Group|"Interventions: standard of care~Patients are not going to receive any additional intervention."
89464913|NCT03562728|Active Comparator|Transplant|Interventions: MRP+MNES(neuromuscular electric stimulation).Patients in the treatment arm will receive additional physical therapy(arm and leg exercises, using light weight machines, hand weights, or rubber bands, exercise machines such as portable arm or seated bikes) as well as therapy with an electric stimulator device. This device uses weak electric impulses to involuntarily exercise the muscles(one-two sessions a day).Four muscle groups(quadriceps and dorsiflexors bilaterally) will be stimulated using surface electrodes .In addition, patients in the experimental group will receive nutrition supplementation with essential amino acids 3 times a day in their feeding to prevent muscle breakdown and promote positive nitrogen balance.
89018194|NCT04893265|Active Comparator|Text Messaging Only|Participants will receive a weekly SMS Text or instant message on a topic related to COVID-19 testing over 12 weeks. In addition, participants will receive as-needed messages on updates of COVID-19 testing related information. The messages will be responsive to the rapid evolving developments and changes related to COVID-19 testing guidelines. Some of the messages will include a link to allow participants to get to the entire message/information on the study website.
89464914|NCT03562728|Other|Transplant Control Group|"Interventions: standard of care.~Patients are not going to receive any additional intervention."
89464915|NCT03524430|Experimental|Single Interventional Study Arm|There will be 2 biopsy collection time points with 2 core needle biopsy specimens taken at each biopsy collection time point for RDA analysis during neoadjuvant chemotherapy.
89464916|NCT03521830|Active Comparator|Previous Systemic Therapy Patients|Cohort A: Nivolumab 480mg IV q4weeks for up to 48 weeks (six 8-week cycles)
89464917|NCT03521830|Experimental|Progression after anti-PD-1 therapy (Cohort A) and Cohort C|Cohort B: Nivolumab 240mg IV + ipilimumab 1mg/kg IV q3 weeks x 4 doses, then nivolumab 480mg IV q4 weeks x 7 doses for up to 48 total weeks of therapy.
89464918|NCT03521830|Experimental|Progression after anti-PD-1 therapy (Cohort A)|Cohort C: Nivolumab 480 mg IV q4 weeks plus relatlimab 480 mg IV q4 weeks for up to 48 weeks.
89464919|NCT03508570|Experimental|Group I (nivolumab)|Patients receive nivolumab i.p. over 90 minutes on days 1, 15, and 29. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
89464920|NCT03508570|Experimental|Group II (nivolumab and ipilimumab)|Patients receive nivolumab as in group I and ipilimumab i.p. on day 1. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
89464921|NCT03485365|Experimental|Part A: Cohort 1: GSK3858279|Eligible participants will receive GSK3858279 via IV route.
89464922|NCT03485365|Experimental|Part A: Cohort 2: GSK3858279|Eligible participants will receive GSK3858279 via IV route.
89464923|NCT03485365|Experimental|Part A: Cohort 3: GSK3858279|Eligible participants will receive GSK3858279 via IV route.
89464924|NCT03485365|Experimental|Part A: Cohort 4: GSK3858279|Eligible participants will receive GSK3858279 via IV route.
89464925|NCT03485365|Experimental|Part A: Cohort 5: GSK3858279|Eligible participants will receive GSK3858279 via IV route.
89464926|NCT03485365|Experimental|Part A: Cohort 6: GSK3858279|Eligible participants will receive GSK3858279 via SC route.
89464927|NCT03485365|Placebo Comparator|Part A: Placebo|Eligible participants will receive placebo matching to GSK3858279 via SC or IV route.
89464928|NCT03485365|Experimental|Part B: GSK3858279|Eligible participants will receive GSK3858279 via SC route.
89464929|NCT03485365|Placebo Comparator|Part B: Placebo|Eligible participants will receive placebo matching to GSK3858279 via SC route.
89464930|NCT03478839||CRF completion|Individuals with a diagnosis of GACI or ARHR2 with sufficient chart data to be included in the study will be eligible for enrollment, as well as all their siblings and parents.
89464931|NCT03478826||ILD|250 patients (male and females >18 years of age) with the diagnosis of fibrotic DILD (IPF (n=100), fibrotic NSIP (n=50), chronic hypersensitivity pneumonia (n=20), sarcoidosis(n=50), progressive rheumatoid lung disease (n=10) and scleroderma lung disease (n=20), 10 patients with other fibrosing disease (fibrosing mediastinitis), and 50 patients with lymphangioleiomyomatosis.
89464932|NCT03478826||Healthy|100 healthy participants as a control group.
89464933|NCT03478826||Pneumonia|25 patients with pneumonia as a control group.
89464934|NCT03463239|Experimental|Autologous tissue engineered corpora|All subjects enrolled will undergo a corpora cavernosum biopsy. Endothelial and smooth muscle cells will be isolated and expanded, then seeded onto a scaffold that will later be implanted into the subject.
89464935|NCT03436654|Experimental|ADT + Apalutamide|
89464936|NCT03436654|Experimental|ADT + Apalutamide + Abiraterone Acetate + Prednisone|This arm is no longer being assigned to subjects.
89464937|NCT03436654|Experimental|Apalutamide, SBRT, Radiation|
89464938|NCT03423199|Experimental|Palbociclib + Tamoxifen ± Goserelin|Palbociclib 125 mg/day, orally once daily on Day 1 to Day 21 followed by 7 days off treatment for each 28 day cycle, plus tamoxifen 20 mg orally once daily (continuously)
88945547|NCT01893112|Other|Breast Cancer Screening|The time and attention control group workshop will be facilitated by a research coordinator. The control group program is based on another program that is designed explore issues related to breast cancer screening among African American women. The program has the same format as the Unity Workshop, with video and group discussion. Although breast cancer may be associated with stigma, we anticipated that breast cancer stigmas would not be related to HIV-associated stigma, which is our primary outcome of interest. The control groups will be held during the same week as the Unity Workshops, and control group participants will complete assessments on the same schedule as the Unity Workshop participants.
88945548|NCT01893229|Experimental|Valproate|Name: Valproate; dosage form: tablet, 250mg; dosage and frequency: 800mg-- 1200mg/d; duration: 6 weeks.
88945549|NCT01893229|Experimental|Oxcarbazepine|Name: Oxcarbazepine, dosage form: 300mg, tablet; dosage and frequency: 600-1200mg/d; duration: 6 weeks
88945550|NCT01893229|Experimental|Quetiapine|name: Quetiapine, dosage form: 200mg,tablet; dosage and frequency: 600mg-- 800mg/d; duration: 6 weeks
89464939|NCT03423199|Active Comparator|Placebo + Tamoxifen ± Goserelin|Placebo orally once daily on Day 1 to Day 21 followed by 7 days off treatment for each 28 day cycle, plus tamoxifen 20 mg orally once daily (continuously)
89464940|NCT03417999|Experimental|Cohort 1|"Cohort 1A:~Dexmedetomidine 2 μg/kg~Under general oral endotracheal anesthesia~7 subjects age >2 yo and ≤ 6 yo~7 subjects age ≥1 mo and ≤2 yo~Cohort 1B:~Dexmedetomidine 2 μg/kg~Under sedation with a natural airway~7 subjects age >2 yo and ≤ 6 yo~7 subjects age ≥1 mo and ≤2 yo"
89464941|NCT03417999|Experimental|Cohort 2|"Dexmedetomidine 4 μg/kg~Under general oral endotracheal anesthesia~7 subjects age >2 yo and ≤ 6 yo"
89464942|NCT03372317||Non-demented elders|Participants aged 55-90 that are cognitively normal or have mild cognitive impairment will receive 18F-MK-6240 to identify the presence of tau protein in the brain.
89464943|NCT03370276|Experimental|Phase I - Affiliate Sites Only|"Nivolumab and dose escalation of Cetuximab.~Dose Level 1:~Lead-in Day -14 before Cycle 1 only: Cetuximab 500 mg/m^2; Nivolumab - none. Cycle 1 Day 1 and all subsequent doses every 2 weeks (Q2W): Cetuximab 500 mg/m^2; Nivolumab 240 mg.~Dose Level -1:~Lead-in Day -14 before Cycle 1 only: Cetuximab 500 mg/m^2; Nivolumab - none. Cycle 1 Day 1 and all subsequent doses every 2 weeks (Q2W): Cetuximab 250 mg/m^2; Nivolumab 240 mg."
89464944|NCT03370276|Experimental|Phase I - Moffitt Site Only|"Nivolumab and dose escalation of Cetuximab.~Dose Level 1:~Lead-in Day -14 before Cycle 1 only: Cetuximab 500 mg/m^2; Nivolumab - none. Cycle 1 Day 1 and all subsequent doses every 2 weeks (Q2W): Cetuximab 500 mg/m^2; Nivolumab 240 mg.~Dose Level -1:~Lead-in Day -14 before Cycle 1 only: Cetuximab 500 mg/m^2; Nivolumab - none. Cycle 1 Day 1 and all subsequent doses every 2 weeks (Q2W): Cetuximab 250 mg/m^2; Nivolumab 240 mg."
89464945|NCT03370276|Experimental|Phase II - Affiliate Sites Only|Nivolumab and Cetuximab at recommended Phase II dose (RP2D).
89464946|NCT03370276|Experimental|Phase II - Moffitt Site Only|Nivolumab and Cetuximab at recommended Phase II dose (RP2D).
89464947|NCT03295734|Active Comparator|Perindopril|4 mg qd titrated to 8 mg qd perindopril + aerobic exercise
89464948|NCT03295734|Active Comparator|Losartan|50 mg qd titrated to 100 mg qd losartan + aerobic exercise
89464949|NCT03295734|Active Comparator|HCTZ|12.5 mg qd titrated to 25 mg qd HCTZ + aerobic exercise
89464950|NCT03295227|Experimental|Treatment (pembrolizumab)|Participants receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
89464951|NCT03284385|Experimental|Treatment (adavosertib)|Patients receive adavosertib PO QD on days 1-5 and 8-12. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89464952|NCT03258554|Active Comparator|Arm I (cetuximab, radiation therapy)|Patients receive cetuximab IV weekly over 60-120 minutes. Treatment repeats every week for up to 8 cycles in the absence of disease progression or unacceptable toxicity. Beginning 5-7 days after first cetuximab dose, patients undergo IMRT 5 fractions per week for up to 7 weeks.
89464953|NCT03258554|Experimental|Arm II (durvalumab, radiation therapy)|Patients receive durvalumab IV over 60 minutes every 4 weeks. Treatment repeats every 4 weeks for up to 7 cycles in the absence of disease progression or unacceptable toxicity. Beginning week 2, patients undergo IMRT 5 fractions per week for up to 7 weeks.
89464954|NCT03233711|Experimental|Arm A (nivolumab)|Patients receive nivolumab while on study. Patients undergo sigmoidoscopy, colonoscopy or anoscopy, proctoscopy or digital rectal exam, x-ray, CT scan, MRI, biopsy and blood sample collection throughout the study.
89464955|NCT03233711|Other|Arm B (clinical observation)|Patients undergo observation while on study. Patients undergo sigmoidoscopy, colonoscopy or anoscopy, proctoscopy or digital rectal exam, x-ray, CT scan, MRI, biopsy and blood sample collection throughout the study.
89464956|NCT03215095|Experimental|Radioiodine (RAI) in Combination with Durvalumab (Medi4736)|Enrolled patients will be treated with durvalumab 1500 mg IV every 4 weeks. In Cycle 1/Week 3, Thyrogen 0.9 mg IM will be administered on two consecutive calendar days followed by 100 mCi (+/- 10 mCi) of RAI the next calendar day. Durvalumab will be continued every 4 weeks.
89464957|NCT03206047|Experimental|Cohort I (atezolizumab)|Patients receive atezolizumab IV over 30-60 minutes on days 1 and 15. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
89464958|NCT03206047|Experimental|Cohort II (guadecitabine, atezolizumab)|Patients receive guadecitabine SC on days 1-5. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients also receive atezolizumab IV over 30-60 minutes on days 8 and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
89464959|NCT03206047|Experimental|Cohort III (guadecitabine, atezolizumab, CDX-1401 vaccine)|Patients receive guadecitabine and atezolizumab as in Cohort II. Patients also receive CDX-1401 vaccine IV on day 15 and poly ICLC SC on days 15-16. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
89464960|NCT03199885|Experimental|Arm I (pertuzumab, trastuzumab, taxane therapy, atezolizumab)|Patients receive pertuzumab IV over 30-60 minutes on days 1 and 22, trastuzumab IV over 30-90 minutes on days 1 and 22, and paclitaxel IV over 60 minutes on days 1, 8, 15, 22, 29, and 36 or docetaxel IV over 60 minutes on days 1 and 22. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. Patients also receive atezolizumab IV over 30-60 minutes on day 22 of cycle 1 and days 1 and 22 of subsequent cycles. Cycles repeat every 6 weeks for 2 years in the absence of disease progression or unacceptable toxicity. Patients may undergo a biopsy at baseline. Patients undergo a CT or MRI at baseline, prior to weeks 10, 19, 28 and then at 9, 12, 15, 18, 21, and 24 months from study entry, every 3 months through year 3, every 6 months for years 4 and 5, and then every 6 months for years 6 through 10 from study entry. Patients undergo a bone scan at baseline, every 6 months from study entry, every 6 months through year 3, and every 12 months for years 4 and 5.
89464961|NCT03199885|Active Comparator|Arm II (pertuzumab, trastuzumab, taxane therapy, placebo)|Patients receive pertuzumab, trastuzumab, and paclitaxel or docetaxel as in Arm I. Patients also receive placebo IV 30-60 minutes on day 1 of cycle 22 and days 1 and 22 of subsequent cycles. Cycles repeat every 6 weeks for 2 years in the absence of disease progression or unacceptable toxicity. Patients may undergo a biopsy at baseline. Patients undergo a CT or MRI at baseline, prior to weeks 10, 19, 28 and then at 9, 12, 15, 18, 21, and 24 months from study entry, every 3 months through year 3, every 6 months for years 4 and 5, and then every 6 months for years 6 through 10 from study entry. Patients undergo a bone scan at baseline every 6 months from study entry, every 6 months through year 3, and every 12 months for years 4 and 5.
89464962|NCT03194893|Experimental|Alectinib|Participants will receive alectinib at the same dose and schedule and according to the same administration guidelines as they received at the time of discontinuation from the parent trial.
89464963|NCT03194893|Experimental|Crizotinib|Participants will receive crizotinib at the same dose and schedule and according to the same administration guidelines as they received at the time of discontinuation from the parent trial.
89464964|NCT03155620|Experimental|Subprotcol M (HRAS gene alterations)|Patients receive tipifarnib PO or via nasogastric or gastric tube BID on days 1-7 and 15-21. Treatment repeats every 28 days for up to 26 cycles (2 years) in the absence of disease progression or unacceptable toxicity.
89464965|NCT03155620|Experimental|Subprotocol A (NTRK1, NTRK2, or NTRK3 gene fusion)|Patients with a NTRK1, NTRK2, or NTRK3 gene fusion receive larotrectinib sulfate PO or via nasogastric- or gastric-tube BID on days 1-28. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.
89464966|NCT03155620|Experimental|Subprotocol B (FGFR1, FGFR2, FGFR3, or FGFR4 gene mutation)|Patients with a FGFR1, FGFR2, FGFR3, or FGFR4 gene mutation receive erdafitinib PO QD on days 1-28 of each cycle. Treatment repeats every 28 days for up to 26 cycles (2 years) in the absence of disease progression or unacceptable toxicity. Patients undergo an x-ray, CT scan, MRI, radionuclide imaging, and/or bone scan, as well as a bone marrow aspiration and/or biopsy during screening and on study. Patients also undergo blood sample collection on study.
89464967|NCT03155620|Experimental|Subprotocol C (EZH2, SMARCB1, or SMARCA4 gene mutation)|Patients with an EZH2, SMARCB1, or SMARCA4 gene mutation receive tazemetostat PO BID on days 1-28. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.
89464968|NCT03155620|Experimental|Subprotocol D (TSC1, TSC2, or PI3K/mTOR gene mutation)|Patients with a TSC1, TSC2, or PI3K/mTOR gene mutations receive PI3K/mTOR inhibitor LY3023414 PO BID on days 1-28. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.
88945551|NCT01893229|Experimental|Olanzapine|Name: Olanzapine, dosage form: 5mg tablet; dosage and frequency: 10mg--20mg/d; duration: 6 weeks
89201985|NCT02556840|Active Comparator|Insulin therapy from the beginning of pregnancy|"Insulin therapy (Glargine/Lantus®, Détémir/Levemir® , Insulatard® , Umuline NPH® , Lispro/Humalog® , Asparte/Novorapid® or Actrapid ®) administered from the beginning of pregnancy according to maternal blood glucose (if fasting blood glucose > 0.95g/l or post-prandial blood glucose > 1.20g/l) as recommended by the national guidelines for gestational diabetes mellitus.~Insulin administered to patients either by subcutaneous injections or by pump."
89464969|NCT03155620|Experimental|Subprotocol E (activating MAPK pathway gene mutation)|Patients with an activating MAPK pathway gene mutation receive selumetinib sulfate PO BID on days 1-28. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.
89464970|NCT03155620|Experimental|Subprotocol F (ALK or ROS1 gene alteration)|Patients with an ALK or ROS1 gene alteration receive ensartinib PO BID on days 1-28. Cycles repeat every 28 days for 2 years (up to 26 cycles) in the absence of disease progression or unacceptable toxicity. Patients undergo an x-ray, CT scan, MRI, PET scan, radionuclide imaging, and/or bone scan, as well as a bone marrow aspiration and/or biopsy during screening and on study. Patients also undergo blood sample collection on study.
89464971|NCT03155620|Experimental|Subprotocol G (BRAF V600 gene mutation)|Patients with a BRAF V600 gene mutation receive vemurafenib PO BID on days 1-28. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.
89464972|NCT03155620|Experimental|Subprotocol H (ATM, BRCA1, BRCA2, RAD51C, RAD51D mutations)|Patients deleterious ATM, BRCA1, BRCA2, RAD51C, or RAD51D gene mutations receive olaparib PO BID on days 1-28. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.
89464973|NCT03155620|Experimental|Subprotocol I (Rb positive, alterations in cell cycle genes)|Patients with Rb positive advanced solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with activating alterations in cell cycle genes receive palbociclib PO QD on days 1-21. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
89464974|NCT03155620|Experimental|Subprotocol J (MAPK pathway mutations)|Patients with MAPK pathway mutations receive ulixertinib PO BID. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
89464975|NCT03155620|Experimental|Subprotocol N (activating RET mutations)|Patients with activating RET gene alterations receive selpercatinib PO BID on days 1-28. Treatment repeats every 28 days for up to 26 cycles (2 years) in the absence of disease progression or unacceptable toxicity. Patients may also undergo PET, CT, MRI, PET/CT, PET/MRI, and/or CT/MRI, scintigraphy, and x-ray imaging throughout the trial.
89464976|NCT03152773|Experimental|1|Open label
89464977|NCT03137433|Experimental|Meal-Replacements|Participants will be asked to strictly follow the individually-prescribed eating regimen, which will include shakes (breakfast and lunch) and pre-packaged frozen entrée meals for dinner, two servings of fruit, and three servings of vegetables per day. Daily caloric allotment will be tailored for each individual (number of shakes and frozen meals) by calculating the average daily caloric deficit necessary to achieve negative energy balance (using the metabolic rate/energy expenditure data).
89464978|NCT03137433|Experimental|Meal-Replacements Plus|Participants will be asked to strictly follow the individually-prescribed eating regimen, which will include shakes (breakfast and lunch) and pre-packaged frozen entrée meals for dinner, two servings of fruit, and three servings of vegetables per day. Daily caloric allotment will be tailored for each individual (number of shakes and frozen meals) by calculating the average daily caloric deficit necessary to achieve negative energy balance (using the metabolic rate/energy expenditure data). This group will be provided additional information to go along with meal-replacements.
89464979|NCT03127059|Experimental|Breathing Exercises|"Individual instruction from a nurse at baseline aimed at knowledge on pharmacological treatment and optimized inhalation techniques. The participants will be encouraged to use online video instruction.~Three physiotherapist-sessions of Breathing Exercises (BrEX) with duration of 60 minutes (the initial) and 30 minutes (other sessions) at week 1, 4, and 9. The participant is expected to do 10 minutes of home exercise twice daily. The entire intervention combines elements of the Papworth method, and the Buteyko technique."
89464980|NCT03127059|Other|Usual care|"Individual instruction from a nurse at baseline aimed at knowledge on pharmacological treatment and optimized inhalation techniques. The participants will be encouraged to use online video instruction.~Besides the individual instruction described above, patients will receive only short information given initially at recruitment. They are allowed to receive instruction in positive expiratory pressure-treatment and physiotherapy targeting other problems than dysfunctional breathing (DB)."
89464981|NCT03092817|Active Comparator|Dexamethasone|standard anti-tuberculosis drugs plus dexamethasone for 6-8 weeks
89464982|NCT03092817|Placebo Comparator|Identical placebo|standard anti-tuberculosis drugs plus placebo for 6-8 weeks
89464983|NCT03075696|Experimental|Part I: Dose Escalation|Participants (single participant cohorts) will receive obinutuzumab (Gpt) 1000 milligrams (mg) single dose IV infusion on Day -7 (pre-treatment) followed by glofitamab IV infusion on Day 1 and Day 8 of Cycle 1. From Cycle 2 onwards, ascending doses of glofitamab will be administered on Day 1 of every 2 week cycle up to Cycle 12 (24 weeks) or until unacceptable toxicity or disease progression. Glofitamab dosing will be initiated at 5 micrograms (mcg) (flat dose) followed by doses of 15 mcg, 45 mcg, 135 mcg, 405 mcg and 810 mcg.
89464984|NCT03075696|Experimental|Part II: Dose Escalation|"In each treatment regimen, participants will receive obinituzumab (Gpt) 1000 milligrams (mg) IV infusion on Day -7 (pre-treatment); or 2000 mg either administered on Day -7, or split into two 1000 mg doses on Days -1 and -7. The first glofitamab IV infusion will be given on Day 1 of Cycle 1 and a total of 12 cycles will be administered.~Monotherapy, glofitamab as a single agent: ascending doses of glofitamab administered on Day 1 of every 2 or 3 week cycle until either the MTD/OBD is defined.~Combination Therapy: From Cycle 2 onwards, a fixed dose of 1000 mg obinutuzumab will be administered via IV infusion in combination with ascending doses of glofitamab on Day 1 of every 3 week cycle until either the MTD/OBD is defined.~Step-up dosing: Q3W, participants will receive an initial low dose of glofitamab on C1D1, followed by a higher dose on C1D8; the total dose in C1 will not exceed the previously determined MTD. Higher doses may be explored from C2 or later cycles."
89501956|NCT01209182|Experimental|Device image reading|Tissue images generated by the device are read by surgeons to determine if the tissue area under test has abnormal component or not. When Images generated by the device are read by surgeons as abnormal an additional margin of tissue is removed. The new margin is also imaged by the device to ensure complete tumor excision.
89464985|NCT03075696|Experimental|Part III: Dose Expansion|"Part III will start once MTD/OBD is defined. Participants will receive Gpt 1000 mg single dose IV infusion on Day -7 (pre-treatment), followed by glofitamab at a fixed dose regimen or step-up dose regimen on a Q2W or Q3W dosing schedule as determined in Part II. A total of 12 cycles will be administered.~Combination Therapy: From Cycle 2 onwards, a fixed dose of 1000 mg obinutuzumab will be administered via IV infusion in combination with glofitamab at the dosing regimen determined in Part II."
89464986|NCT03043599|Experimental|Combination Therapy|Consolidative Ipilimumab and Nivolumab with Thoracic Radiotherapy after Platinum Based Chemotherapy. Radiotherapy, followed by a 14 to 21 day break between radiotherapy and the beginning of study drug treatment.
89464987|NCT03017131|Experimental|Treatment (decitabine, genetically modified T cells)|COURSE 1: Patients receive decitabine IV daily over 1 hour on days -8 to -6, cyclophosphamide IV over 2 hours on days -4 and -3, and genetically engineered NY-ESO-1-specific T lymphocytes IV and IP on day 0. Patients also receive aldesleukin SC BID on days 1-14..
89464988|NCT03014726|Experimental|DCB Treatment|Stricture patients treated by DCB
89464989|NCT03013218|Experimental|Evorpacept (ALX148)|The Part 1 Dose Escalation: Evorpacept (ALX148) infusions will be administered weekly or every two weeks.
89464990|NCT03013218|Experimental|Evorpacept (ALX148) + Pembrolizumab|The Part 2 Dose Escalation/Expansion: Evorpacept (ALX148) infusions will be administered weekly or every two weeks in combination with pembrolizumab infusions.
88945552|NCT01893229|Experimental|Ziprasidone|Name: Ziprasidone, dosage form: 10mg tablet; dosage and frequency: 80mg-160mmg/d; duration: 6 weeks
88945553|NCT01893229|Experimental|Lithium|name: lithium; dosage form: 250mg Tablet; dosage and frequency: 750mg-2000mg/d;serum Li level: 0.6mmol-1.2mmol/L; duration: 6 weeks
89464991|NCT03013218|Experimental|Evorpacept (ALX148) + Trastuzumab|The Part 2 Dose Escalation/Expansion: Evorpacept (ALX148) infusions will be administered weekly or every two weeks in combination with trastuzumab infusions.
88945554|NCT01893645||Pregnant women|Pregnant women admitted to the British Columbia Women's Hospital for vaginal or cesarean delivery will get their Hb values spot-checked using the Pronto-7 device.
88945555|NCT01893749|Experimental|CATCH-IT|"200 randomized teens 13-18 year old (inclusive) will be enrolled into the online program that contains 14 modules focused various therapeutic techniques, a booster session of 6 modules at the end of the online program and three 15 minute visits with their primary care doctor to discuss the benefits and disadvantages of the program.~Parents will also be invited to participant in a partnering online program involving 4 modules online and 1 optional module. They will be asked to then participate in three 15 minute interviews with a member of the study team to discuss the benefits and disadvantages of the program."
89464992|NCT03013218|Experimental|Evorpacept (ALX148) + Rituximab|The Part 2 Dose Escalation/Expansion: Evorpacept (ALX148) infusions will be administered weekly or every two weeks in combination with rituximab infusions.
89464993|NCT03013218|Experimental|Evorpacept (ALX148) + Pembrolizumab + 5FU + Platinum|The Part 2 Dose Escalation: Evorpacept (ALX148) infusions will be administered weekly or every two weeks in combination with pembrolizumab + 5FU + platinum infusions.
89464994|NCT03013218|Experimental|Evorpacept (ALX148) + Trastuzumab + Ramucirumab + Paclitaxel|The Part 2 Dose Escalation: Evorpacept (ALX148) infusions will be administered weekly or every two weeks in combination with trastuzumab + ramucirumab + paclitaxel infusions.
89464995|NCT03010982|Experimental|Tazemetostat and [14C] Tazemetostat|"Tazemetostat 800 mg BID orally as tablets continuously starting on Day 1, with the exception of the morning dose on Day 16;~A single IV dose of approximately 12 µg tazemetostat that contains approximately 500 nCi of [14C] tazemetostat on Day 15;~A single oral dose of 800 mg tazemetostat as a solution containing approximately 400 µCi (14.8 MBq) of [14C] tazemetostat on Day 16."
89464996|NCT03008278|Experimental|Treatment (olaparib, ramucirumab)|Patients receive olaparib PO BID on days 1-14 of each cycle and ramucirumab IV over 60 minutes on day 1 of each cycle. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.
89464997|NCT03007147|Experimental|Arm A (imatinib mesylate, EsPhALL chemotherapy)|See Detailed Description
89464998|NCT03007147|Experimental|Arm B (imatinib mesylate, COG/BFM chemotherapy)|See Detailed Description.
88945556|NCT01893749|No Intervention|Health Education|"200 randomized teens, ages 13-18 year old (inclusive) receiving an online program with 14 modules that focus on general health education, depression, diet, exercise, hygiene and safety.~Parents will also be invited to participate in an online program with 4 modules that also focus on general health education."
88945557|NCT01893775|Experimental|1|Hu-Mik-Beta-1 every 3 weeks
88945558|NCT01894269|Experimental|Anti-viral treatment|Oral antiviral drugs will be commenced after TACE. That is: Lamivudine 100mg once daily; or Entecavir 0.5mg once daily.
88945559|NCT01894269|No Intervention|Control|No anti-viral therapy after TACE.
89464999|NCT03007147|Experimental|Arm C (imatinib mesylate, EsPhALL chemotherapy, HSCT)|See Detailed Description
89501957|NCT02262637||Hypertensive patients - Cardiologists|
89501958|NCT02262637||Hypertensive patients - Nephrologists|
89465000|NCT02971501|Experimental|Arm I (osimertinib, bevacizumab)|Patients receive osimertinib PO QD on days 1-21 and bevacizumab IV over 30-90 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan, MRI, tumor biopsy and blood sample collection throughout the study.
88945560|NCT01894347||Colistin inhalative|"Adult ICU patients with~invasive ventilation with assumed or assured bacteria with an elevated resistance pattern found in a tracheal or bronchial secretion with or without clinical signs of infection~indicated colistin co-therapy or eradication-attempt with inhalative colistin (β-Lactam) therapy according to the standard operation procedure (SOP) of the hospital~Patients included into the study group receive additional TDM, Monitoring of Neuro-and Nephropathology"
89465001|NCT02971501|Experimental|Arm II (osimertinib)|Patients receive osimertinib PO QD on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan, MRI, tumor biopsy and blood sample collection throughout the study.
89465002|NCT02960087|Active Comparator|Arm 1 LDR|Low Dose Rate (LDR) brachytherapy with I-125 to a total dose of 144 Gy
89465003|NCT02960087|Active Comparator|Arm 3 HDR|High Dose Rate brachytherapy: 27 Gy in 2 fractions
89465004|NCT02911077||AUD population|The participants/group were treatment-seeking AUD individuals admitted to the NIH CC 1SE Addictions Unit.
89465005|NCT02909686|Experimental|Boswellia Serrata|400-800mg in capsule form by mouth every day
89465006|NCT02909686|Experimental|Curcumin|1000-2000mg in capsule form by mouth every day
89465007|NCT02909686|Experimental|Epimedium|1000-2000mg in capsule form by mouth every day
88945561|NCT01894789|Experimental|stable CAD management|Experimental: Ticagrelor (BrilintaTM) 90 mg tablet by mouth twice a day
88945562|NCT01894789|Active Comparator|CAD comparison group|Active comparator: clopidogrel 75 mg plus placebo tablet by mouth twice a day.
88945563|NCT01894815|Experimental|Active tDCS / placebo pill|transcranial direct current stimulation, using the parameters specified in Interventions.
88945564|NCT01894815|Active Comparator|Sham tDCS / escitalopram|Escitalopram oxalate (Reconter), 10mg/day (first 3 weeks) and 20mg/day (week 3 to week 10).
88945565|NCT01894815|Placebo Comparator|Sham tDCS / placebo pill|"For sham tDCS, the device is automatically turned off after 30 second of stimulation and remains turned off during the 30-min session.~For placebo pill, the pill has the same size, taste and color than escitalopram, and placebo and escitalopram will be provided in identical bottles, differing only according to a random-generated number placed in the label."
88945566|NCT01894893||Breastfeeding mothers|
88945567|NCT01895049|Active Comparator|Mycophenolate sodium|Induction therapy with Thymoglobulin, prednisone, mycophenolate sodium, and late introduction of tacrolimus
88945568|NCT01895049|Experimental|Everolimus|Induction therapy with Thymoglobulin, prednisone, everolimus, and late introduction of tacrolimus.
88945569|NCT01895751|No Intervention|Conservative therapy|"Conservative therapy group involves optimal medical therapy according to local hospital protocols with selective invasive management as clinically appropriate. Patients assigned to the conservative group may be referred for invasive management if the patient meets one of the following pre-specified criteria:~Recurrent or refractory (class III or IV) angina with documented ischaemic ECG changes while on optimal medical therapy.~New ST segment elevation in two contiguous leads without Q waves or T wave inversion greater than 3 mm or development of hemodynamic instability Deterioration in heart failure status (defined as Killip class 3 or 4)."
88945570|NCT01895751|Active Comparator|Invasive management|Invasive management is timed as appropriate according to local NHS protocols. Usually, invasive management is expected to be performed in line with contemporary guidelines.
88945571|NCT01896024|Active Comparator|General Psychiatric Management (GPM; Gunderson & Links, 2008)|psychodynamic-psychiatric treatment for borderline personality disorder
88945572|NCT01896024|Experimental|GPM plus Motive-Oriented Therapeutic Relationship|use of Plan Analysis and Motive-oriented therapeutic relationship, as add-on variable to GPM
88945573|NCT01896570||Group A: cardioversion at AT|after achievement of AT, pts were cardioverted
88945574|NCT01896570||Group B: ablation to SR|After AT has been achieved, all subsequent AT were ablated with the endpoint of procedural SR termination
88945575|NCT01896622|Experimental|A|Ritonavir
88945576|NCT01896622|Experimental|B|Cobicistat
88945577|NCT01896947||MRI and MRA group|All patients will receive 3T MRI and MR arthrogram
89465008|NCT02909686|Experimental|Fisetin|200-800mg in capsule form by mouth every day
89465009|NCT02909686|Experimental|Luteolin|200-400mg in capsule form by mouth every day
88945578|NCT01897051|Experimental|Combination therapy|Rifaximin(normix®)+nonselective beta-blocker(Propranolol)
88945579|NCT01897051|Placebo Comparator|Monotherapy|nonselective beta-blocker(Propranolol) + Placebo(of Rifaximin)
88945580|NCT01897090|Experimental|Elimination Diet|"thirty (30) patients will be on the Crohn's Disease Diet (primarily an anti-inflammatory diet that is an elimination diet - gluten-free, casein-free based with limited carbohydrate)"
89465010|NCT02909686|Experimental|Nettle|435-1305mg in capsule form by mouth every day
89465011|NCT02909686|Experimental|Pycnogenol|200-400mg in capsule form by mouth every day
89465012|NCT02909686|Experimental|Reishi Mushroom|1600-3200mg in capsule form by mouth every day
89465013|NCT02909686|Experimental|Resveratrol|200-600mg in capsule form by mouth every day
89465014|NCT02909686|Placebo Comparator|Placebo|in capsule form by mouth every day
89501959|NCT02262637||Hypertensive patients - Diabetologists|
89501960|NCT03301051|Experimental|Quadrivalent VLP Vaccine|Participants received one intramuscular (IM) injection of 0.5 mL of 30 μg/strain of the Quadrivalent VLP Influenza Vaccine on Day 0.
89501961|NCT03301051|Placebo Comparator|Placebo|Participants received one IM injection of 0.5 mL of placebo on Day 0.
89501962|NCT00467233|Experimental|1|Laser Treatment
89501963|NCT00467233|Experimental|2|Acid peel
89501964|NCT01662986|Active Comparator|18 mcg tiotropium bromide|Patient to receive one tiotropium bromide inhalation powder capsule daily (in the morning) via HandiHaler
89465015|NCT02908672|Experimental|Atezolizumab + Cobimetinib + Vemurafenib + Vemurafenib Placebo|Run-In Period (Cycle 1=28 days): Participants will receive vemurafenib 960 mg (four, 240 mg tablets) PO BID along with cobimetinib 60 mg (three, 20 mg tablets) PO QD on Days 1 to 21 followed by vemurafenib 720 mg (three, 240 mg tablets) PO BID on Days 22 to 28 and vemurafenib placebo (1 tablet) PO BID on Days 22 to 28. Triple Combination Period (Cycle 1 onwards): Participants will receive atezolizumab 840 mg IV infusion on Day 1 and 15, cobimetinib 60 mg (three, 20 mg tablets) PO QD on Days 1 to 21, vemurafenib 720 mg (three, 240 mg tablets) PO BID on Days 1 to 28, and vemurafenib placebo (1 tablet) PO BID on Days 1 to 28 of each 28-day cycle. Study treatment will continue until investigator-determined disease progression, death, unacceptable toxicity, withdrawal of consent, or pregnancy, whichever occurs first.
89465016|NCT02908672|Experimental|Atezolizumab Placebo + Cobimetinib + Vemurafenib|Run-In Period (Cycle1=28 days): Participants will receive vemurafenib 960 milligrams (mg) (four, 240 mg tablets) orally (PO) twice a day (BID) along with cobimetinib 60 mg (three, 20 mg tablets) PO once a day (QD) on Days 1 to 21 followed by vemurafenib 960 mg (four, 240 mg tablets) PO BID on Days 22 to 28. Triple Combination Period (Cycle 1 onwards): Participants will receive ATZ placebo by intravenous (IV) infusion on Day 1 and 15, cobimetinib 60 mg (three, 20 mg tablets) PO QD on Days 1 to 21, and vemurafenib 960 mg (four, 240 mg tablets) PO BID on Days 1 to 28 of each 28-day cycle. Study treatment will continue until investigator-determined disease progression, death, unacceptable toxicity, withdrawal of consent, or pregnancy, whichever occurs first.
89465017|NCT02901262||qEEG patients|All the patients with continuous EEG (>24 hours) in the two study units
89465018|NCT02899442|No Intervention|individual prevention|"The individual preventive advice will be delivered to the control group by occupational physicians during routine medical examinations (defined by law, each 6 months), in occupational medical centres. The type and time spent to explain this advice will be collected in case report form.~To ensure each night workers included in the control group received the same advice, a booklet was provided outlining the content under 5 main headings:~Information about health risks for night workers~Dietetic intake~Leisure physical activities~Sleep and alertness~Lifestyle behaviors (Tobacco, alcohol and psychoactive drugs consumption)~That's a current practice in France for Occupational physicians."
89465019|NCT02899442|Experimental|individual and collective prevention|In addition to this individual prevention, the night workers from the experimental group will benefit from implementation of preventive actions in the workplace (collective prevention in workplace ). These collective preventive measures will be dispensed by the occupational health team (occupational physicians and technician of occupational risks prevention).
89465020|NCT02882282|Active Comparator|Arm A (observation)|Patients undergo observation.
89465021|NCT02882282|Experimental|Arm B (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
89465022|NCT02859727|Experimental|CDZ173|140mg/day
89465023|NCT02858531||patients < 24 months or 60 years with bronchiolitis or ARF|ARF = Acute Renal Failure
89465024|NCT02851043|Experimental|pneuRIP(breathing with resistance)|Testing the subjects breathing with resistance
89465025|NCT02851043|No Intervention|Respitrace system (Carefusion) (breathing without resistance)|Testing subjects breathing without resistance
89465026|NCT02844465|Experimental|Treatment|Visualase MRI-guided laser ablation procedure
89465027|NCT02816788|Experimental|Equine Assisted Therapy (EAT)|Equine Assisted Therapy (EAT) treatment group
89465028|NCT02806388||tumor tissue for molecular profiling|
89465029|NCT02790346|Experimental|arthrodesis talonavicular|arthrodesis talonavicular in addition to tendon gestures
89465030|NCT02790346|Active Comparator|tendon gestures|tendon gestures only
88945581|NCT01897090|Active Comparator|Dietary Guidelines for Americans|The DASH eating plan is based on 1,600, 2,000, 2,600 and 3,100 calories.
89465031|NCT02784210|Experimental|Methylprednisolone|3 day course of intravenous methylprednisolone 1000 mg/day
89465032|NCT02784210|Experimental|prednisone|3-day course of oral prednisone 1250 mg/day
89465033|NCT02758717|Experimental|Treatment (brentuximab vedotin, nivolumab)|Patients receive brentuximab vedotin IV over 30 minutes and nivolumab IV over 60 minutes on day 1. Treatment repeats every 21 days for 7 cycles and 6-8 weeks in cycle 8 in the absence of disease progression or unacceptable toxicity.
89501965|NCT01662986|Placebo Comparator|placebo|Patient to receive one placebo inhalation powder capsule daily (in the morning) via HandiHaler
89501966|NCT05497232|Experimental|the homolateral simultaneous pancreas and kidney transplantation|SPK using the surgical technique was performed in our department from September 2016 to January 2023 in the Department of Transplantation of the Second Affiliated Hospital of Guangzhou Medical University.
88945582|NCT01897142|Experimental|PF-05230907 and Placebo Cohort 1|
88945583|NCT01897142|Experimental|PF-05230907 and Placebo Cohort 2|
88945584|NCT01897142|Experimental|PF-05230907 and Placebo Cohort 3|
89465034|NCT02746081|Experimental|BAY1436032|"Dose escalation: Patients with any type of IDH1-R132X-mutant solid tumor may be eligible for enrollment. A minimum of 3 patients per cohort will be treated. If dose limiting toxicities (DLTs) occur, Bayesian dose-DLT modeling will be performed to help guide dosing decisions and to identify the maximum tolerated dose (MTD). If the MTD is not reached, a recommended phase II dose (RP2D) will be chosen based on available safety, tolerability, PK, PD and clinical efficacy data.~Dose expansion: The dose and schedule that was determined to be most appropriate in the dose escalation part of the study, which may be the MTD and / or the RP2D, will be used. Cohorts will consist of patients with the following IDH-R132X-mutant tumor types: (1) anaplastic glioma; (2) glioblastoma; (3) intrahepatic cholangiocarcinoma; (4) tumor types other than those in Cohorts 1-3."
89465035|NCT02735239|Experimental|Cohort A1: Metastatic/locally advanced OC, Durva + Chemotherapy (Chemo)|Durvalumab (750 mg IV every two weeks [Q2W]) was to be given for up to 11 doses. Oxaliplatin (130 mg/m^2 IV)/capecitabine (1250 mg/m^2/day given orally) chemotherapy was started on the day of the third dose of durvalumab and continued for 6 doses.
89465036|NCT02735239|Experimental|Cohort A2: Metastatic/locally advanced OC, Durva, Treme + Chemo|Durvalumab (750 mg IV Q2W) was to be given for up to 11 doses. One dose of tremelimumab (37.5 mg IV) was given on the same day as the first dose of durvalumab. Oxaliplatin (130 mg/m^2 IV)/capecitabine (1250 mg/m^2/day given orally) chemotherapy was started on the day of the third dose of durvalumab and continued for 6 doses.
89465037|NCT02735239|Experimental|Cohort B: Metastatic/locally advanced OC, Durva, Treme + Chemo|Durvalumab (750 mg IV Q2W) was to be given for up to 11 doses. One dose of tremelimumab (75 mg IV) was given on the same day as the first dose of durvalumab. Oxaliplatin (130 mg/m^2 IV)/capecitabine (1250 mg/m^2/day given orally) chemotherapy was started on the day of the third dose of durvalumab and continued for 6 doses.
89465038|NCT02735239|Experimental|Cohort C: Operable OC; Durva + Chemo|Durvalumab (750 mg IV Q2W) was to be given for up to 5 doses. Two cycles of neoadjuvant oxaliplatin (130 mg/m^2 IV)/capecitabine (1250 mg/m^2/day given orally) chemotherapy were to be administered before surgery. Subjects were to undergo surgery 6 to 8 weeks after completing chemotherapy or according to institutional policies for surgery; and would be eligible to resume durvalumab dosing (to a maximum of 12 infusions) once recovered from surgery, provided that this was within 3 months of surgery.
89465039|NCT02735239|Experimental|Cohort C-FLOT: Operable OC, Durva + FLOT Chemotherapy|Durvalumab (750 mg IV Q2W) was to be given for up to 6 doses. Two cycles of neoadjuvant 5-fluorouracil (5-FU) (2600 mg/m^2 24-hr IV), leucovorin (200 mg/m^2 IV), oxaliplatin (85 mg/m^2 IV), and docetaxel (50 mg/m^2 IV) chemotherapy (FLOT) were to be administered before surgery starting on the day of the third dose of durvalumab. Subjects were to undergo surgery 6 to 8 weeks after completing chemotherapy or according to institutional policies for surgery; and would be eligible to resume durvalumab dosing (to a maximum of 12 infusions), FLOT or durvalumab plus FLOT at the discretion of the Investigator once recovered from surgery, provided that this was within 3 months of surgery.
89465040|NCT02735239|Experimental|Cohort D/D2: Operable OC, Durva + Neoadjuvant Chemo(radio)therapy|"Durvalumab (750 mg IV Q2W) was to be given for 2 doses. This was followed by five weekly doses of neoadjuvant paclitaxel (50 mg/m^2 IV) / carboplatin (AUC 2) IV chemotherapy + radiotherapy (41.4 Gy radiotherapy given over 23 fractions) before surgery. Subjects could receive an additional dose of durvalumab after completion of chemoradiation.~In Cohort D2, subjects continued durvalumab for 3 additional doses while receiving chemoradiation. Subjects were to undergo surgery 6 to 8 weeks after completing chemo(radio)therapy or according to institutional policies for surgery; and would be eligible to resume durvalumab dosing (to a maximum of 12 infusions) once recovered from surgery, provided that this was within 3 months of surgery."
89465041|NCT02708303||Foregut Surgery|Foregut surgery includes conditions of the esophagus, stomach and proximal small intestine. More specifically foregut surgery includes surgery for gastroesophageal reflux disease, hiatal hernias, and paraesophageal hernias.
89465042|NCT02701829|Experimental|Health Fairs (HF)|Drivers will undergo U&C Health Fair follow-up either Regular or Urgent Follow-up: Timeline is determined by health status, with regular follow-up continuing for at least two weeks and urgent follow-up continuing for at least a month
89465043|NCT02701829|Experimental|HF + text messaging + home BP monitoring|Drivers will receive: U&C HF follow-up, Mobile text messaging intervention w/ interactive 2- way messaging to encourage BP management for nine months A home BP monitoring equipment with instructions to self-monitor BP for nine months
89465044|NCT02701829|Experimental|HF +Tech + social network support (SNS).|"Drivers will receive:~U&C HF follow-up, Mobile text messaging intervention w/ interactive 2- way messaging to encourage BP management for nine months and home BP monitoring equipment with instructions to self-monitor BP for nine months A social network support intervention in which selected family/peers encourage drivers to maintain healthy behaviors for nine months"
89465045|NCT02603341|Active Comparator|Photon|Photon therapy: once a day, 5 days a week, for 5 to 7 weeks
89465046|NCT02603341|Active Comparator|Proton|Proton therapy: once a day, 5 days a week, for 5 to 7 weeks
89465047|NCT02595944|Experimental|Arm I (nivolumab)|Patients receive nivolumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 4 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and/or PET/CT throughout the trial and blood sample collection during screening and follow-up. Patients may undergo an ECHO as clinically indicated on study.
89465048|NCT02595944|Active Comparator|Arm II (observation)|Patients are followed serially with CT and/or PET/CT imaging for up to 1 year and then during follow-up. Patients also undergo blood sample collection during screening and follow-up. Patients may undergo an ECHO as clinically indicated on study.
89465049|NCT02583646||normal weight|Girls age 8-14 below 85% in respect to weight for their age group
89465050|NCT02583646||overweight|Girls age 8-14 at or above 85% in respect to weight for their age group
89465051|NCT02579655|Active Comparator|Copayment Elimination and Personalized Education|In this arm, participants would have copayment elimination (no cost for preventative medications for hypertension, diabetes, and cardiovascular disease) and free enrollment in a new personalized education program to help participants manage their chronic conditions
88945585|NCT01897142|Experimental|PF-05230907 and Placebo Cohort 4|
88945586|NCT01897142|Experimental|PF-05230907 and Placebo Cohort 5|
88945587|NCT01897142|Experimental|PF-05230907 and Placebo Cohort 6|
88945588|NCT01897220||University Hospital Patients|Consecutive patients with cardiovascular disease(s) undergoing non-cardiac surgery
88945589|NCT01897298|Experimental|Urban training Intervention|Patients will be advised to walk in the defined urban trails.
88945590|NCT01897298|No Intervention|Usual care|Patients will continue their usual care
88945591|NCT01897649|Experimental|NUTRIOSE|group of volunteers fed with NUTRIOSE
88945592|NCT01897649|Active Comparator|GLUCIDEX|gruop of volunteers fed with GLUCIDEX
88945593|NCT01897662|Experimental|NUTRIOSE|Group of volunteers fed with NUTRIOSE
88945594|NCT01897662|Active Comparator|GLUCIDEX|Group of volunteers fed with GLUCIDEX
89465052|NCT02579655|Active Comparator|Copayment Elimination Only|In this arm, participant's would be randomized to Copayment Elimination (no cost for preventative medications for hypertension, diabetes, and cardiovascular disease) and receive some basic educational information about their chronic disease
89465053|NCT02579655|Active Comparator|Personalized Education Only|In this arm, participants would be randomized to free enrollment in a new personalized education program to help patients manage their chronic conditions
89465054|NCT02579655|No Intervention|No intervention|In this arm, participants will have access to some basic online educational information about their chronic disease. There is no intervention in this arm. The comparative group.
89465055|NCT02520544|Active Comparator|Accolade stem|All patients in a participating centre matching all of the inclusion criteria and none of the exclusion criteria and who receive the Accolade or Accolade II stem and Trident/Tritanium cup with X3 liner.
89465056|NCT02520544|Active Comparator|Accolade II stem|All patients in a participating centre matching all of the inclusion criteria and none of the exclusion criteria and who receive the Accolade or Accolade II stem and Trident/Tritanium cup with X3 liner.
89465057|NCT02511028|Experimental|ferumoxytol|A 510 mg dose (17 mL) of ferumoxytol diluted in 50 mL of 0.9% normal saline will be intravenously infused over 17 minutes
88945595|NCT01897753||Small For Gestational Age (SGA) Children|SGA children under growth hormone treatment for more than 36 months.
88945596|NCT01897870|Experimental|HomeCoMe-program group|the arm receiving the pharmacist home visit
88945597|NCT01898065|Experimental|PET imaging, 18 F-miso|Single Arm study
88945598|NCT01898221|Active Comparator|Standard Catheter Ablation Patient Group|Patients will have a standard procedure ablation
88945599|NCT01898221|Active Comparator|Vein of Marshall and Standar procedure|The doctor will inject Ethanol through a balloon catheter into the VOM
88945600|NCT01898338|Experimental|Fosfomycin and Daptomycin|fosfomycin 2gr/6h + 10mg/kg/24h iv during 14 or 28 days
88945601|NCT01898338|Active Comparator|Daptomycin|daptomycin 10mg/kg/cada 24h iv during 14 or 28 days
88945602|NCT01898572||Newly diagnosed T2DM|Newly diagnosed T2DM with no CVD. Standard care.
88945603|NCT01898572||Control individuals|Control individuals matched by age, gender, dyslipidemia, hypertension and smoking habit. Standard care.
88945604|NCT01898897|Active Comparator|robot general anesthesia|"General anesthesia for robot assisted laparoscopic urogenital surgery includes premedication with alprazolam (0.5 mg per os), induction with sufentanil, propofol (1-2 mg/kg), neuromuscular blocking agents (rocuronium 0.5 mg/kg) to facilitate tracheal intubation. Anesthesia is maintained with volatile agents (sevoflurane, desflurane) and reinjection of rocuronium and sufentanil as needed.~Robotic assisted laparoscopic interventions are realised with Da Vinci surgical robot, known to assure a minimally invasive approach with good results in urologic surgery. The system consists of an ergonomic surgeon console, a patient cart with four interactive robotic arms, a 3D high resolution visualization interface and specific EndoWrist articulated tools."
88945605|NCT01898897|Experimental|robot combined anesthesia|Combined anesthesia is defined as association of epidural analgesia to general anesthesia. Epidural catheter is inserted at low thoracic level in the operation theatre before the induction of anesthesia. Correct position is verified with 15 mg bupivacaine plain 0.5%. Infusion is started after the incision at a rate of 6-8 ml/ hour.Epidural continuous infusion of local anesthetic is maintained 12 hours postoperative in the postoperative anesthesia care unit.
89465058|NCT02481154|Experimental|AG881|AG-881 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Patients may continue treatment with AG-881 until disease progression, development of other unacceptable toxicity or Investigator discretion
89465059|NCT02468024|Active Comparator|Arm 1 lung surgery|Sublobar Resection (SR)
88945606|NCT01898936|Experimental|Pretreatment CO2 laser|"The treatment will be a field treatment performed with a 30 W Lutronic carbondioxide laser; covering one of the symmetrical treatment areas allocated to fractional carbondioxide laser.~The laser settings will be as follows:~The fluence will initially be 10mJ/cm2 delivered with a 120 micron tip (producing 120 micron ablative columns) with 5% density. The fluence will be increased until the patient experiences pain (pain indicating penetration to dermis), and then reduced to maximum fluence without pain. Allocation to laser therapy is blinded for the future evaluato"
89465060|NCT02468024|Experimental|Arm 2 radiation therapy|Stereotactic Ablative Radiotherapy (SAbR)
89465061|NCT02455791|Experimental|Ultrasound-Guided Biopsy of Tumor Site|Ultrasound-guided biopsy of the tumor site performed before scheduled surgery.
89465062|NCT02455687|Active Comparator|Hi-Mg + Bud|Group one will receive a high,then standard dose of intravenous magnesium sulfate with blinded nebulized budesonide.
89465063|NCT02455687|Placebo Comparator|Hi-Mg + P|Group two will receive a high,then standard dose of intravenous magnesium sulfate with blinded nebulized normal saline.
89465064|NCT02455687|Active Comparator|Std-Mg + Bud|Group three will receive a single standard dose of intravenous magnesium sulfate plus one dose of intravenous normal saline with blinded nebulized budesonide.
89465065|NCT02455687|Placebo Comparator|St-Mg + P|Group four will receive a single dose of intravenous magnesium sulfate plus one dose of intravenous normal saline with blinded nebulized normal saline
89465066|NCT02421939|Experimental|Gilteritinib|Participants received 120 mg dose (3 tablets of 40 mg) orally once a day in continuous 28-day cycles, at least 2 hours after or 1 hour before food. Gilteritinib treatment continued until participants met one of the treatment discontinuation criteria.
89465067|NCT02421939|Active Comparator|Salvage Chemotherapy|Participants received chemotherapy in 28-day cycles. Participants on Low-Dose Cytarabine (LoDAC) received 20 mg of cytarabine twice daily by subcutaneous (SC) or intravenous (IV) injection for 10 days. Participants on azacitidine received 75 mg/m^2 daily by SC or IV injection for 7 days. Participants on LoDAC or azacitidine treatment continued until they met discontinuation criteria. Participants on MEC chemotherapy received mitoxantrone 8 mg/m^2 daily by IV for 5 days, etoposide 100 mg/m^2 daily by IV for 5 days and cytarabine 1000 mg/m^2 daily by IV for 5 days (days 1-5). Participants on FLAG-IDA chemotherapy received G-CSF 300 μg/m^2 daily by SC/IV for 5 days (days 1-5), fludarabine 30 mg/m^2 daily by IV for 5 days (days 2-6), cytarabine 2000 mg/m^2 daily by IV for 5 days (days 2-6) and idarubicin 10 mg/m^2 daily by IV for 3 days (days 2-4). Participants receiving MEC or FLAG-IDA received 1 cycle of therapy and were assessed for response on or after day 15.
89465068|NCT02421393|Experimental|Exercise|Supervised exercise training on top of standard care (exercise, EXE, group; n=100)
89465069|NCT02421393|No Intervention|Control|Standard care including advises to maintain a physically active lifestyle, according to current guidelines, by performing any type of commuting, occupational, home and and leisure-time physical activity (PA) (control, CON, group; n=100).
89465070|NCT02352324|Experimental|Fluid responsiveness tests|After the end of surgery in ICU the positive end-expiratory pressure (PEEP) test of 15 cm H2O for 300 seconds will be performed. Following PEEP test, the two-step fluid load test of 6 ml/kg balanced crystalloid solution will be performed sharing in two portions: Initial mini FLT (mFLT) of 1.5 ml/kg within 1 min (approximately 100 mL) followed by the registration of continuous CI and traditional fluid responsiveness parameters and the rest of standard FLT (4.5 mL/kg) within 5 minutes (approximately 350 mL) followed by transpulmonary thermodilution, registration of continuous cardiac index (CI) and classic fluid responsiveness parameters.
89465071|NCT02343042|Experimental|1: Selinexor, Low-dose Dexamethasone and Pomalidomide (SPd)|"Each cycle is of 28 days~Cohort 1.1: Selinexor (SEL) 60/80/100 mg orally (PO) once weekly (QW); Dexamethasone (DEX) 40 mg PO once weekly; Pomalidomide (POM) 2/3/4 mg PO Days 1-21.~Cohort 1.2: SEL 40/60/80 mg PO twice weekly (BIW); DEX 20 mg PO twice weekly; POM 3/4 mg PO Days 1-21.~Cohort 1.3: Selinexor, Dexamethasone and Pomalidomide will be dosed at RP2D-1.~Cohort 1.4: SEL 40 mg PO QW; DEX 40 mg PO QW; POM 4mg PO once daily (QD) Days 1-21."
89465072|NCT02343042|Experimental|2: Selinexor, Low-dose Dexamethasone and Bortezomib (SVd)|"Each cycle is of 35 days~Cohort 2.1: SEL 60/80/100 mg PO once weekly; DEX 40 mg PO once weekly; Bortezomib (BOR) 1.3 milligram per meter square (mg/m^2) subcutaneous (SC) once weekly.~Cohort 2.2: SEL 40/60/80 mg PO twice weekly; DEX 20 mg PO twice weekly; BOR 1.3 mg/m^2 subcutaneous (SC) once weekly.~Cohort 2.3: Selinexor, Dexamethasone and Bortezomib will be dosed at RP2D-2."
89465073|NCT02343042|Experimental|3: Selinexor, Low-dose DEX, and Lenalidomide (SRd) in RRMM|"Each cycle is of 28 days~Cohort 3.1: SEL 40/60/80/100 mg PO once weekly; DEX 40 mg PO once weekly; Lenalidomide (LEN) 15/25 mg PO Days 1-21.~Cohort 3.2: SEL 40/60/80 mg PO twice weekly; DEX 20 mg PO twice weekly; LEN 15/25 mg PO Days 1-21.~Cohort 3.3: Selinexor, Dexamethasone and Lenalidomide will be dosed at RP2D-3."
89501967|NCT01337167|Experimental|V419|V419 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Daptacel™ 0.5 mL IM at 15 months of age; PedvaxHIB™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.
88945607|NCT01898936|Sham Comparator|Only photodynamic therapy|This group will not get pretreatment with CO2 laser
88945608|NCT01899001|Experimental|CBT and Nutrition Counseling|8 weeks of Cognitive Behavioral Therapy (CBT) and 16 weeks of Nutrition Counseling
88945609|NCT01899001|Other|Nutrition Counseling|16 weeks of Nutrition Counseling alone
88945610|NCT01899105|Experimental|Part A|A single dose of 2 fixed-dose combination tablets of 200mg lumacaftor/125mg ivacaftor (total of 400mg lumacaftor/250mg ivacaftor) in the fed state and fasted state with a 14 day washout period in between each dosing occasion
88945611|NCT01899105|Experimental|Part B|A single dose of 3 fixed-dose combination tablets of 200mg lumacaftor/83mg ivacaftor (total of 600mg lumacaftor and 250mg ivacaftor) in the fed with a 14 day washout period in between dosing occasions
88945612|NCT01899456|No Intervention|Medical therapy|Best medical therapy using guideline recommended drugs in each disease state.
89465074|NCT02343042|Experimental|4:Selinexor, Low-dose dexamethasone, Pomalidomide, Velcade (SPVd)|"PK Run-in Period: Selinexor and Clarithromycin:~For the first 9 patients enrolled into this dose escalation arm~14 day run-in period after which patients will proceed to Dose-Escalation Phase C1D1~Selinexor 40 mg will be dosed on Days 1 and 8. Clarithromycin 500 mg will be dosed twice daily on Days 2-8.~PK samples will be collected on Days 1 and 8 at 1, 1.5, 2, 3, 4, 5, 6, 8, and 24 hours post dose.~Dose-escalation Phase:~All patients enrolled into this Arm~Each cycle is of 28 days.~Cohort 4.1:~SEL 40/60 mg PO once weekly; DEX 40 mg PO once weekly; POM 4 mg PO Days 1-21; BOR 1.3 mg/m^2 subcutaneous (SC) once weekly.~Cohort 4.3: Selinexor, Dexamethasone, Pomalidomide, Velcade (Bortezomib) will be dosed at RP2D-4."
89465075|NCT02343042|Experimental|5: Selinexor, Low-dose dexamethasone, and Daratumumab (SDd)|"Each cycle is of 28 days~Cohort 5.1:~SEL 80/100 mg PO once weekly; DEX 40 mg once weekly (IV or PO); DARA: 16 mg/kg IV infusion Cycle 1-2: Once weekly, Cycle 3-6: Every other week, Cycle 6 and greater: Once a month.~Cohort 5.2:~SEL: 60 mg PO twice weekly; DEX: 40 mg weekly (IV or PO); DARA: 16 milligram per kilogram (mg/kg) IV infusion Cycle 1-2: Once. weekly, Cycle 3-6: Every other week, Cycle 6 and greater: Once a month.~Cohort 5.3: Selinexor, Dexamethasone and Daratumumab will be dosed at RP2D-5."
89465076|NCT02343042|Experimental|6: Selinexor, Low-dose dexamethasone, and Carfilzomib (SKd)|"PK Run-in Period: Selinexor and Clarithromycin:~For the first 9 patients enrolled into this dose escalation arm~14 day run-in period after which patient will proceed to Dose-Escalation Phase C1D1~Selinexor 40 mg will be dosed on Days 1 and 8. Clarithromycin 500 mg will be dosed twice daily on Days 2-8.~PK samples will be collected on Days 1 and 8 at 1, 1.5, 2, 3, 4, 5, 6, 8, and 24 hours post dose.~Dose-Escalation Phase:~All patients enrolled into this Arm~Each cycle is of 28 days~Cohort 6.1:~SEL 40/60/80/100 mg PO once weekly on days 1, 8, 15, and 22; DEX 40 mg IV or PO once weekly; Carfilzomib (CAR) 56 or 70 mg/m^2 IV infusion once weekly on days 1, 8, and 15.~Cohort 6.2:~SEL 60/80/100 mg PO once weekly on days 1, 8, and 15; DEX 40 mg IV or PO once weekly; CAR 56 or 70 mg/m^2 IV infusion once weekly on days 1, 8, and 15.~Cohort 6.3: Selinexor, Dexamethasone and Carfilzomib will be dosed at RP2D-6."
89465077|NCT02343042|Experimental|7: Selinexor, Low-dose DEX and Lenalidomide (SRd) in NDMM|"Each cycle is of 28 days~Cohort 7.1:~SEL 40/60/80 mg PO once weekly; DEX 40 mg PO once weekly; LEN 25 mg PO Days 1-21.~Cohort 7.3: Selinexor, Dexamethasone and Lenalidomide will be dosed at RP2D-7."
89465078|NCT02343042|Experimental|8: Selinexor, Low-dose dexamethasone, and Ixazomib (SNd)|"PK Run-in Period: Selinexor & Clarithromycin:~For the first 9 patients enrolled into this dose escalation arm~14 day run-in period after which patient will proceed to Dose-Escalation Phase C1D1~Selinexor 40 mg will be dosed on Days 1 and 8. Clarithromycin 500 mg will be dosed twice daily on Days 2-8.~PK samples will be collected on Days 1 and 8 at 1, 1.5, 2, 3, 4, 5, 6, 8, and 24 hours post dose.~Dose-Escalation Phase:~All patients enrolled into this Arm~Each cycle is of 28 days~Cohort 8.1:~SEL 40/60/80/100 mg PO once weekly; DEX 20 mg PO twice weekly; IXA 3/4 mg PO once weekly.~Cohort 8.3: Selinexor, Dexamethasone and Ixazomib will be dosed at RP2D-8."
89465079|NCT02343042|Experimental|9: Selinexor, Low-dose DEX, Pomalidomide and Elotuzumab (SPEd)|"PK Run-in Period: Selinexor and Clarithromycin:~For the first 9 patients enrolled into this dose escalation arm~14 day run-in period after which patient will proceed to Dose-Escalation Phase C1D1~Selinexor 40 mg will be dosed on Days 1 and 8. Clarithromycin 500 mg will be dosed twice daily on Days 2-8.~PK samples will be collected on Days 1 and 8 at 1, 1.5, 2, 3, 4, 5, 6, 8, and 24 hours post dose.~Dose-Escalation Phase:~All patients enrolled into this Arm~Each cycle is of 28 days~Cohort 9.1:~SEL 20/40/60 mg PO once weekly; DEX 28/20 mg PO twice weekly; POM 4 mg PO QD Days 1-21; Elotuzumab (ELO) 10/20 mg/kg IV will be given once weekly on Days 1,8, 15 and 22 of Cycles 1-2. Starting on Cycle 3 and continuing for future cycles, elotuzumab will be dosed at 20 mg/kg on Day 1 of each cycle only.~Cohort 9.3: Selinexor, Dexamethasone, Pomalidomide and Elotuzumab will be dosed at RP2D-9."
89501968|NCT01337167|Active Comparator|Control|Pentacel™ 0.5 mL IM at 2, 4, and 6 months of age; Recombivax HB vaccine 0.5 mL IM at 2 and 6 months of age; Daptacel™ 0.5 mL IM at 15 months of age; ActHIB™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.
89206174|NCT00297427|Experimental|Acupuncture|Subjects will 12 acupuncture treatments over 6 weeks; treatment sessions occur twice a week. A total of 12 acupuncture needles will be inserted bilaterally at two leg points and four back points. Needles are manually inserted through a standard guide tube contained within a fitted sheath and the basal ring secured to the skin by double-sided tape. The needles remain in place for 25 minutes and are manually stimulated twice during each treatment.
88945613|NCT01899456|Experimental|Catheter-based renal denervation|Renal denervation will be performed in the native renal arteries of patients after renal transplantation. Access side is the contralateral femoral artery.
89465080|NCT02343042|Experimental|10. Selinexor, Dexamethasone, and Belantamab Mafodotin (SBd)|"Each cycle is of 21 days~Cohort 10.1:~SEL 40/60/80 mg PO once weekly on Days 1, 8, and 15; DEX 40 mg PO QW on Days 1, 8, and 15; Belantamab Mafodotin (BEL) 2.5 mg/kg IV infusion every 3 weeks (Q3W) Day 1 of each cycle.~Cohort 10.3:~Selinexor, Dexamethasone, and Belantamab Mafodotin will be dosed at RP2D-10."
89465081|NCT02343042|Experimental|11. Selinexor, Dexamethasone, Pomalidomide, and Daratumumab (SDPd)|"Each Cycle is of 28 days~Cohort 11.1 SEL 40/60 mg PO once weekly on Days 1, 8, and 15; DEX total 40 mg weekly (IV or PO) single or divided doses on Days 1, 8, 15, and 22; POM 4 mg PO QW Days 1-21; DARA 16 mg/kg IV or SC QW on Days 1, 8, 15 and 22 of Cycles 1-2 and on Days 1 and 15 of Cycles 3-6, Day 1 of every Cycle greater than (>6).~Cohort 11.3 Selinexor, Dexamethasone, Pomalidomide, and Daratumumab will be dosed at RP2D-11."
89465082|NCT02343042|Experimental|12. Selinexor + dexamethasone + mezigdomide (SMd)|The dose of selinexor will be formally escalated from 40 mg QW to 60 mg QW in combination with mezigdomide 0.6 mg daily. Mezigdomide dosing may be de-escalated as per 3+3 criteria to 0.3 mg or escalated to 1.0 mg. The dose level that passes DLT evaluation will be considered the MTD for the cohort.
89465083|NCT02339012||Frail|frail individuals ages 50-64 years; 65-79 years; 80+ years
89465084|NCT02339012||Healthy|healthy individuals ages 20-34 years; 35-39 years; 50-64 years; 65-79 years; 80+ years
89465085|NCT02339012||Non-Healthy/Non-Frail|non-healthy/non-frail individuals ages 20-34 years; 35-39 years; 50-64 years; 65-79 years; 80+ years
89465086|NCT02337686|Experimental|Treatment (pembrolizumab, surgery)|Patients receive pembrolizumab IV over 30 minutes on day -21 and day -1, and then undergo surgery on day 0. After 2-3 weeks or recovery from surgery, patients continue to receive pembrolizumab IV over 30 minutes every 3 weeks. Courses repeat every 42 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
89465087|NCT02327884||Group 1|Healthy Volunteers matched with Sjogren's Syndrome patients
89465088|NCT02327884||Group 2|Family Members, affected and unaffected
89465089|NCT02327884||Group 3|any other cause salivary gland dysfunction
89465090|NCT02306161|Experimental|Regimen A (VDC/IE)|See Design Details.
89465091|NCT02306161|Experimental|Regimen B (VDC/IE + ganitumab)|"INDUCTION THERAPY: Patients receive Induction therapy as in Regimen A and receive ganitumab IV over 30-60 minutes or 60-120 minutes on day 1 of weeks 1, 3, 5, 7, 9, and 11.~LOCAL CONTROL THERAPY: Between weeks 13-18, patients undergo surgery and/or radiation therapy.~CONSOLIDATION THERAPY: Patients receive Consolidation therapy as in Regimen A and receive ganitumab IV over 30-60 minutes or 60-120 minutes on day 1 of weeks 7, 9, 11, 13, and 15.~METASTATIC SITE IRRADIATION: Patients with lung metastases undergo whole lung radiation and patients with bone metastases undergo definitive SBRT or EBRT.~MAINTENANCE: Patients receive ganitumab IV over 30-60 minutes or 60-120 minutes every 3 weeks for 8 cycles."
89465092|NCT02278094|Experimental|Experimental group|Subjects will be in random cluster assign to walking exercise (WE), Threshold Inspiratory Muscle Trainer (TIMT) and Tongue Muscle Trainer (TMT) treatment groups.
88945614|NCT01899469|Experimental|Electromagnetic therapy (EM)|The group had performed 20 sessions of EM therapy for 20 minutes and after had a 25 minutes from Back School intervention.
89465093|NCT02278094|Active Comparator|Control group|Up to 95% of OSAS cases are treated with continuous positive airway pressure (CPAP), CPAP treatment group will be the control group.
89465094|NCT02141438||Radium-223 dichloride (Xofigo, BAY88-8223)|Single-arm cohort observational study with CRPC patients with bone metastasis treated with Radium-223.
89465095|NCT02135874|Experimental|Treatment (combination chemotherapy)|See Detailed Description.
89465096|NCT02121132||No treatment|
89465097|NCT02112916|Active Comparator|Arm A (combination chemotherapy)|Patients receive combination chemotherapy without bortezomib. See Detailed Description.
89465098|NCT02112916|Experimental|Arm B (combination chemotherapy, bortezomib)|Patients receive combination chemotherapy with bortezomib (4 doses at 1.3 mg/m^2 during Induction and 4 doses at 1.3 mg/m^2 during Delayed Intensification). See Detailed Description.
89465099|NCT02101853|Active Comparator|Arm A (HR and IR control)|Patients receive Block 2 over 4 weeks, Block 3 over 4 weeks, and then undergo allogeneic HSCT. Closed effective September 18, 2019.
88945615|NCT01899469|Experimental|Transcutaneous Electrical Neurological Stimulation (TENS)|The group had performed 20 sessions of TENS therapy for 20 minutes and after had a 25 minutes from Back School intervention.
89465100|NCT02101853|Experimental|Arm B (HR and IR blinatumomab)|Patients receive Blinatumomab Block 1 over 5 weeks, Blinatumomab Block 2 over 5 weeks, and then undergo allogeneic HSCT.
89465101|NCT02101853|Active Comparator|Arm C (LR control)|Patients receive Block 2 over 4 weeks, Block 3 over 4 weeks, Continuation 1 over 8 weeks, Continuation 2 over 8 weeks, and then Maintenance.
89465102|NCT02101853|Experimental|Arm D (LR blinatumomab)|Patients receive Block 2 over 4 weeks, Blinatumomab Cycle 1 over 5 weeks, Continuation 1 over 8 weeks, Blinatumomab Cycle 2 over 5 weeks, Continuation 2 over 8 weeks, Blinatumomab Cycle 3 over 5 weeks, and then Maintenance.
89465103|NCT02099864|Experimental|Treatment (Enzalutamide)|Patients receive enzalutamide PO QD in the absence of disease progression or unacceptable toxicity. Patients undergo a tumor biopsy of a metastatic site at study entry (prior to initiation of enzalutamide) and after the time of progression. Per the investigator, patients may continue treatment beyond progression.
89465104|NCT02062463|No Intervention|Stage 1: Empty Spiromax Followed by Empty Turbohaler|Participants will be trained on the proper use of empty Spiromax followed by empty Turbohaler devices.
89465105|NCT02062463|No Intervention|Stage 1: Empty Turbohaler Followed by Empty Spiromax|Participants will be trained on the proper use of empty Turbohaler followed by empty Spiromax devices.
89465106|NCT02062463|Experimental|Stage 2: BF Spiromax|Participants who have currently received 800 to 1000 micrograms (μg) beclomethasone-equivalent inhaled corticosteroid (ICS) per day will receive budesonide/formoterol twice daily using the BF Spiromax 160/4.5 device. Therefore, the daily, ex-mouthpiece doses of budesonide and formoterol using BF Spiromax will be 640 μg and 18 μg, respectively. Participants who have currently received 1600 to 2000 μg beclomethasone-equivalent ICS per day will receive budesonide/formoterol twice daily using the BF Spiromax 320/9 μg device. Therefore, the daily, ex-mouthpiece doses of budesonide and formoterol using BF Spiromax will be 1280 μg and 36 μg, respectively.
89501969|NCT05496764|Active Comparator|Group A|26 patients we planned to inject them local steroid( 4 mg of dexamethasone acetate combined with 1% lidocaine into the carpal tunnels) directly into the carpal tunnel in (group A)
89465107|NCT02062463|Active Comparator|Stage 2: Symbicort Turbohaler|Participants who have currently received 800 to 1000 μg beclomethasone-equivalent ICS per day will receive budesonide/formoterol twice daily using the Symbicort Turbohaler 200/6 μg device. Therefore, the daily, ex-mouthpiece doses of budesonide and formoterol using Symbicort Turbohaler will be 800 μg and 24 μg respectively. Participants who have currently received 1600 to 2000 μg beclomethasone-equivalent ICS per day will receive budesonide/formoterol twice daily using the Symbicort Turbohaler 400/12 μg device. Therefore, the daily, ex-mouthpiece doses of budesonide and formoterol using Symbicort Turbohaler will be 1600 μg and 48 μg respectively.
89465108|NCT01950520|Experimental|Cohort 2|Interventions, in random order, will be administered during one of the six one-day stays
89465109|NCT01950520|Experimental|Cohort 3|Interventions, in random order, will be administered during one of the four overnight inpatient stays
89465110|NCT01950520|Experimental|Low Temperature 1st|Low temperature before 27c (Cohort 1 only)
89465111|NCT01950520|Experimental|Low Temperature 2nd|Low temperature after 27c (Cohort 1 only)
88945616|NCT01899469|Experimental|Back School (BS)|The group had performed 20 sessions of Back School therapy for 25 minutes.
88945617|NCT01899547|Experimental|Arm I|Patients undergo laparoscopic-assisted rectal resection.
88945618|NCT01899547|Active Comparator|Arm II|Patients undergo conventional open rectal resection.
88945619|NCT01899599|Experimental|PankoMab-GEX|1700mg, i.v., q3w
88945620|NCT01899599|Placebo Comparator|Placebo|matching placebo
88945621|NCT01899612||Symptomatic postmenopausal women|Postmenopausal women with vulvovaginal symptoms
88945622|NCT01899612||Asymptomatic postmenopausal women|Postmenopausal women without vulvovaginal symptoms
88945623|NCT01899664|Other|Primary Study Population|Study participants (primary study population) will include patients with spinal cord injury at the mid cervical level who are undergoing evaluation for possible surgical treatment with nerve transfers and or tendon transfer/tenodesis to improve their upper extremity function. All enrolled participants will receive the same standard of care surgical procedures.
89465112|NCT01924533|Experimental|Olaparib+ paclitaxel|olaparib + paclitaxel
88945624|NCT01899716|Experimental|Exercise|Aerobic Exercise, 3 times peer week, A dose of 16.5 kcal/kg weight peer week.
88945625|NCT01899716|No Intervention|Control|
89465113|NCT01924533|Placebo Comparator|Placebo+paclitaxel|placebo+ paclitaxel
89465114|NCT01919099||Post-transplant|Patients receiving allogenic stem cell transplants at the NIH CC
89465115|NCT01883297|Experimental|Re-Stimulated Tumor-Infiltrating Lymphocytes and interleukin-2|Cyclophosphamide will be given prior to Re-Stimulated Tumor-Infiltrating Lymphocytes, and interleukin-2.
88945626|NCT01900015|Active Comparator|Raltegravir|Patients on current EFV plus two nucleoside analogs will be randomly assigned to switch EFV to RAL (400mg BID), maintaining nucleoside analogs unchanged, or to continue the current regimen.
88945627|NCT01900015|Active Comparator|Efavirenz|Patients on current EFV plus two nucleoside analogs will be randomly assigned to switch EFV to RAL (400mg BID), maintaining nucleoside analogs unchanged, or to continue the current regimen.
88945628|NCT01900028|Experimental|Olaparib alone, olaparib+itraconozole|Sequential treatments of olaparib alone followed by olaparib+itraconazole, with a washout period in between.
88945629|NCT01900041|Experimental|Pantovigar + Minoxidil 2%|Minoxidil 2% is given as background therapy in both arms
88945630|NCT01900041|Other|Minoxidil 2% only|Minoxidil 2% is given as background therapy in both arms
88945631|NCT01900080|Experimental|Same-Day ART Group|"Same-Day HIV testing and ART initiation:~All participants in the same-day ART group will receive rapid HIV antibody testing, CD4 cell testing, clinically relevant testing for OIs, WHO staging, counseling and social support, and ART initiation on the day of presentation for HIV testing."
88945632|NCT01900080|Active Comparator|Standard ART Group|"Standard ART Initiation:~The standard group will receive the same services as the same-day ART group (including same-day HIV and CD4 cell testing) except that instead of same-day ART, they will receive the standard GHESKIO protocol of 3 sequential visits for ART readiness counseling and testing for OIs prior to ART initiation."
89018195|NCT04893265|Experimental|INFORMED|"Participants will receive a weekly SMS Text or instant message on a topic related to COVID-19 testing as described in the Text Messaging Only. In addition, participants will receive a Lay Health Worker (LHW) Educational Outreach Program, which includes 2 group sessions via video calls like Zoom or another video conferencing platform and 2 follow-up contacts via telephone, text or other media assignment."
89465116|NCT01842386|Experimental|Rituximab|Adults (=18 years of age) with anticytokine autoantibodyassociated diseases who are refractory to conventional treatment and who test negative for the human immunodeficiency virus (HIV)
89465117|NCT01799538|Experimental|1|Nebullizer
89465118|NCT01799538|Active Comparator|2|Inhaler
89465119|NCT01754610||Families participating in SFCR|Families who have experienced multiple traumas and high stress related to poverty
89465120|NCT01730092||Healthy Volunteers|Enroll up to 120 healthy volunteers, in order to obtain approximately 55 evaluable healthy volunteers matched to pulmonary arterial hypertension subjects for age and gender
89465121|NCT01730092||Pulmonary Arterial Hypertension Subjects|150 subjects with pulmonary arterial hypertension; male or female, age grater than or equal to 18 99 years
89465122|NCT01719692|Experimental|Rituximab A group|375mg/m2 for once
89465123|NCT01719692|Active Comparator|Rituximab B group|100mg/week for four weeks
89465124|NCT01702805|Active Comparator|Low Threshold Transfusion|Transfusions will be administered using a lower threshold hemoglobin value. The low threshold values reflect more common practice, so this is considered the 'usual treatment' group
89465125|NCT01702805|Active Comparator|High Threshold Transfusion|Transfusions will be administered using a higher threshold hemoglobin value.
89465126|NCT01668082|Experimental|surgical resection of a brain tumor|"The patient will undergo surgical removal of the tumor after infusion of 13C-glucose using standard neurosurgical technique, including frameless stereotaxy for surgical navigation, and microsurgical technique.~--------------------------------------------------------------------------------"
89465127|NCT01652287|Active Comparator|BB-12 supplemented yogurt|Probiotic, Bifidobacterium animalis subsp. lactis (B. lactis) strain BB-12 (BB-12), supplemented strawberry yogurt, 4 ounces taken orally for 10 days
89465128|NCT01652287|Placebo Comparator|Strawberry flavored yogurt|Placebo, strawberry yogurt, 4 ounces taken orally for 10 days
89465129|NCT01617408||1|Neurologically normal subjects aged 18 to 50 years old
89465130|NCT01543659|Experimental|89Zr-DFO-huJ591|Registered patients will undergo a baseline FDG PET scan up to 14 days before administration of a single dose of the 89Zr-DFO-huJ591 tracer, this scan is considered for research purposes. The exception to the 14-day timeframe is that patients who have already had an FDG PET scan up to 4 weeks prior to registration are not required to repeat the FDG PET scan on study.
89465131|NCT01432847||Affected|Participants affected by ocular diseases/conditions.
89465132|NCT01432847||Healthy Volunteers|Age, gender, and ethnicity-matched to participants with ocular conditions or the unaffected relatives of participants with ocular conditions
89465133|NCT01419561|No Intervention|1|Evaluation for Alternative Causes of KICS Symptoms (inactive)
89465134|NCT01419561|No Intervention|2|Natural history/Observation arm (inactive)
89465135|NCT01419561|Experimental|3|High dose zidovudine + valganciclovir (inactive)
89465136|NCT01419561|Experimental|4|Rituximab with or without liposomal doxorubicin (inactive)
89206175|NCT00297427|Sham Comparator|Sham acupuncture|Subjects will receive 12 sham acupuncture treatments (delivered twice a week) over 6 weeks. The sham needle is blunted needle whose shaft telescopes into the handle when tapped. While the needle appears to have been inserted, it does not actually penetrate the skin. It is held in place by the same standard guide tube used in the true acupuncture group. The acupuncture points and duration of treatment are the same as for the true acupuncture group.
89465137|NCT01419561|Other|5|Standard and alternative rational therapies (inactive)
88945633|NCT01900080|Experimental|Sub-Study - Same-Day ART, CD4>500|Sub-Study - Same-Day CD4 Count and ART Initiation for Patients with CD4 Count >500 cells/mm3: Participants will receive counseling and start ART on the day of study enrollment. They will have follow-up visits with the physician on Days 3, 10, 17, and 24, and with the social worker on Days 3, 10, and 17. They will have also have physician visits at weeks 8 and 12. Participants who are clinically stable, asymptomatic, and adherent at week 12 will then qualify for expedited care at future visits, which includes dispensing of ART directly by nurses in the clinic every four weeks, to reduce waiting time for patients. Participants who are symptomatic or non-adherent will be referred to a physician for evaluation.
88945634|NCT01900080|Active Comparator|Sub-Study - Pre-ART Care, CD4>500|Participants will receive standard GHESKIO pre-ART care, which includes a monthly visit with a physician for 3 months, and then every other month physician visits.
88945635|NCT01900093|Experimental|Acthar Gel|80 units of subcutaneous Acthar Gel therapy daily
88945636|NCT01900106|Experimental|abacavir/lamivudine + raltegravir|abacavir/lamivudine + raltegravir
88945637|NCT01900106|Active Comparator|ABC/3TC + DRV/r|abacavir/lamivudine + darunavir/ritonavir
89465138|NCT01419561|Other|6|Natural history
88945638|NCT01900158|Experimental|Phase I|Experimental PCI treatment in dose escalation cohorts consist of Amphinex injection (at different doses) plus a single standard dose of Gemcitabine (1000 mg/m2) plus intraluminal light at the tumour area (at different doses). In addition up to 8 cycles of standard chemotherapy doses of Gemcitabine (1000 mg/m2) and Cisplatin (25 mg/m2) was provided. In the Extended part of the study (last cohort) an additional PCI treatment was introduced at Cycle 5 in the treatment Schedule.
89465139|NCT01399385|Experimental|Group 1|Group 1 will consist of subjects with a 10-year total CHD risk <10% (low)They will undergo a series of multiple small discovery studies in order to look at the multiple different MR methods of visualizing the coronary arteries
89465140|NCT01399385|Experimental|Group 2|Group 2 will consist of subjects with a 10-year total CHD risk 10-20% (intermediate)They will undergo a series of multiple small discovery studies in order to look at the multiple different MR methods of visualizing the coronary arteries
89465141|NCT01399385|Experimental|Group 3|Group 3 will consist of subjects with a 10-year total CHD risk >20% (high)They will undergo a series of multiple small discovery studies in order to look at the multiple different MR methods of visualizing the coronary arteries
89465142|NCT01399385|Experimental|Group 4|Group 4 no known risk factors (control subjects)They will undergo a series of multiple small discovery studies in order to look at the multiple different MR methods of visualizing the coronary arteries
89465143|NCT01324206||Healthy Volunteers|Healthy Volunteers, 18 or older years
89465144|NCT01319565|Experimental|1/ACT|Non-myeloablative lymphodepleting preparative regimen of cyclophosphamide and fludarabine + young TIL + highdose aldesleukin
89465145|NCT01319565|Experimental|2/ACT + TBI|Non-myeloablative lymphodepleting preparative regimen of cyclophosphamide and fludarabine + young TIL + highdose aldesleukin + TBI
89465146|NCT01306084||1|NIH campus employees who have recently recovered from COVID-19
89465147|NCT01306084||2|Clinical Center health care workers and ancillary staff who have close patient contact and possible exposures to SARS-CoV-2
89465148|NCT01306084||3|Healthy and immunocompromised subjects who have or are suspected to have a viral infection
89465149|NCT01306084||4|Healthy and immunocompromised subjects exposed to someone who has a viral infection or is suspected of having a viral infection
89465150|NCT01306084||5|Healthy subjects who grew up in dengue endemic areas.
89465151|NCT01306084||6|Healthy subjects with a history of viral hepatitis
89465152|NCT01174108|Experimental|1|Target doses: CD34+ cells 8 x 106/kg; CD3+ cells 2 x 107/kg
89465153|NCT01174108|No Intervention|2|Donor
89465154|NCT01164241||1|Eczema
89465155|NCT01164241||2|unaffected relatives
89465156|NCT01164241||3|healthy volunteers
89465157|NCT01164241||4|other allergic phenotypes
88945639|NCT01900171|Experimental|10 mg of QGC001|Each dose of QGC001 was administered orally with 100 mL of sterile water for irrigation at 08:00 in the morning of Day 1.
88945640|NCT01900171|Experimental|50 mg of QGC001|Each dose of QGC001 was administered orally with 100 mL of sterile water for irrigation at 08:00 in the morning of Day 1.
88945641|NCT01900171|Experimental|125 mg of QGC001|Each dose of QGC001 was administered orally with 100 mL of sterile water for irrigation at 08:00 in the morning of Day 1.
89465158|NCT01148381||controls|healthy non-smoking, participants with no substance use disorders
89465159|NCT01148381||psychiatric disorders|individuals with other psychiatric disorders
89465160|NCT01148381||smokers|healthy individuals with nicotine use disorder
89465161|NCT01148381||substance use disorders|healthy individuals with other substance use disorders
89465162|NCT01148381||treatment seeking individuals|treatment seeking individuals with substance use disorders
89465163|NCT01130545||Volunteers|Volunteers (maybe Volunteers, NIH employee and current NIH protocol participants)
88945642|NCT01900171|Experimental|250 mg of QGC001|Each dose of QGC001 was administered orally with 100 mL of sterile water for irrigation at 08:00 in the morning of Day 1.
88945643|NCT01900171|Experimental|500 mg of QGC001|Each dose of QGC001 was administered orally with 100 mL of sterile water for irrigation at 08:00 in the morning of Day 1.
88945644|NCT01900171|Experimental|750 mg of QGC001|Each dose of QGC001 was administered orally with 100 mL of sterile water for irrigation at 08:00 in the morning of Day 1.
88945645|NCT01900171|Experimental|1,000 mg of QGC001|Each dose of QGC001 was administered orally with 100 mL of sterile water for irrigation at 08:00 in the morning of Day 1.
88945646|NCT01900171|Experimental|1,250 mg of QGC001|Each dose of QGC001 was administered orally with 100 mL of sterile water for irrigation at 08:00 in the morning of Day 1.
89465164|NCT01087346|Active Comparator|Control|Information about child health
89465165|NCT01087346|Experimental|Family Environment Information|Information about family environment factors in children's obesity risk
89465166|NCT01087346|Experimental|Gene times Family Environment Information|Information about interactions between genetic and family environment factors in children's obesity risk
89465167|NCT01087346|Experimental|Genetic Information|Information about genetic factors in child obesity risk
89465168|NCT01087333||1|Patients with hematologic malignancies or solid tumors.
89465169|NCT01087333||2|Normal Donors who are defined as individuals without a diagnosis of or history of any cancer.
89465170|NCT01036971||1|potential research subjects
89465171|NCT01036685||379-bench-control|healthy control who will only do behavioral tasks
89465172|NCT01036685||379-bench-other-psych-diagnosis|someone with a DSM-V disorder, stable and in treatment (i.e., no medication changes in the previous four weeks and a clearly identified treating psychiatrist) who will only do behavioral tasks
89465173|NCT01036685||379-bench-smoker|daily smoker of tobacco cigarettes for at least one year (excluding quit attempts) who will only do behavioral tasks
89465174|NCT01036685||379-bench-user|someone with a DSM-V substance use disorder on a substance other than nicotine who will only do behavioral tasks
88945647|NCT01900171|Placebo Comparator|Placebo|The placebo was administered orally with 100 mL of sterile water for irrigation at 08:00 in the morning of Day 1.
88945648|NCT01900184|Experimental|500 mg bid of QGC001|Each dose of QGC001 will be administered in solution with 200 mL of purified water.
88945649|NCT01900184|Experimental|750 mg bid of QGC001|Each dose of QGC001 will be administered in solution with 200 mL of purified water.
88945650|NCT01900184|Experimental|1,000 mg bid of QGC001|Each dose of QGC001 will be administered in solution with 200 mL of purified water.
88945651|NCT01900184|Placebo Comparator|Placebo|The placebo will be administered in solution with 200 mL of purified water.
88945652|NCT01900197||Iron deficiency anemia|Patients with iron deficiency anemia treated on the doctor's discretion with 10% Iron Isomaltoside 1000 (Monofer®) as standard treatment according to current practice
89465175|NCT01036685||379-control|healthy control who can do MRI
89465176|NCT01036685||379-other-psych -diagnosis|someone with a DSM-V disorder, stable and in treatment (i.e., no medication changes in the previous four weeks and a clearly identified treating psychiatrist) who can do MRI
89465177|NCT01036685||379-smoker|daily smoker of tobacco cigarettes for at least one year (excluding quit attempts) who can do MRI
89465178|NCT01036685||379-user|someone with a DSM-V substance use disorder on a substance other than nicotine who can do MRI
89465179|NCT01031160||U.S. high school students|U.S. high school students who were in 10th grade in the 2009-2010 school year.
89465180|NCT01019343|Placebo Comparator|Healthy Volunteers|Healthy Volunteers
89465181|NCT01019343|Active Comparator|Movement Disorder|Subjects diagnosed with movement disorder
89465182|NCT00977977|Experimental|Combination of Rituximab plus cyclosporine|2 infusions (each 1000 mg) separated by 2 weeks; repeated after 6 months. Daily therapy for 6 months (3-5 mg/kg), then tapered and discontinued.
89465183|NCT00943514||1|chronic or recurring respiratory infections including pulmonary nontuberculous mycobacterial disease
89465184|NCT00943514||2|Relatives
89465185|NCT00924196||Biologic parents of children and adults with NFI|Biologic parents of children and adults with NFI will be evaluated at one time point, using a Neuropsychological Test Battery and QOL Assessment. Closed to enrollment
89465186|NCT00924196||Children and adults with NFI|Children and adults with NFI whose tumor and non tumor related manifestations will be longitudinally evaluated. Closed to enrollment
89465187|NCT00924196||Unaffected siblings of children and adults with NFI|Unaffected siblings of children and adults with NFI will be evaluated at one time point using a Neuropsychological Test Battery and QOL Assessment. Closed to enrollment
89465188|NCT00923221||1/Patient samples|blood samples from patients with diagnosed prostate cancer
89465189|NCT00923065||Consults|Individuals being seen as a consult.
89465190|NCT00923065||Donors|Donors of cellular products.
89465191|NCT00923065||Genetic Follow-Up|Individuals with a known/suspected germline genomic research incidental pathogenic or likely pathogenic variant, and/or who require CLIA confirmation.
89465192|NCT00923065||Patients|Individuals being enrolled for the treatment or follow-up of their disease.
89465193|NCT00923026||A/Gene Therapy|Patients who have received gene therapy
89465194|NCT00923026||B/Non-Gene Therapy|Patients who have not received gene therapy
89465195|NCT00923013|Experimental|1|Cladribine with immediate Rituximab
89201986|NCT02556840|Experimental|Insulin therapy initiated according to fetal growth|"Insulin therapy (Glargine/Lantus®, Détémir/Levemir® , Insulatard® , Umuline NPH® , Lispro/Humalog® , Asparte/Novorapid® or Actrapid ®) initiated according to fetal growth evaluated by ultrasonography measurements. MODY2 women will not be treated with insulin until delivery, except when the fetal abdominal circumference exceeds ≥ the 75 percentile on one US or maternal fasting capillary blood glucose is ≥ 1,20 g/L or maternal post-prandial capillary blood glucose is ≥ 2,00 g/L.~Insulin administered to patients either by subcutaneous injections or by pump."
89465196|NCT00923013|Active Comparator|2|Cladribine with Rituximab delayed by at least 6 months after Cladribine if and when minimal residual disease is detected
89465197|NCT00923013|Experimental|3|Non-randomized group receving Cladribine with immediate Rituximab (before rather than after the 1st of the 5 daily doses of cladribine on day 1)
89465198|NCT00804154|Experimental|Single Arm|advanced cancer patients with pain
89201987|NCT00741806|Experimental|GHB04L1|Single dose, dose escalation
89465199|NCT00624494|Active Comparator|Conventional monitoring|hemodynamic monitoring - conventional monitoring
89465200|NCT00624494|Active Comparator|Advanced monitoring|hemodynamic monitoring - advanced monitoring
89465201|NCT00382070|Experimental|Group 2 Letrozole|Patients receive oral letrozole once daily for up to 5 years.
89465202|NCT00382070|Placebo Comparator|Group 1 Placebo|Patients receive oral placebo once daily for up to 5 years.
89201988|NCT00741806|Placebo Comparator|SPGN buffer|
89201989|NCT00929877|Experimental|Ketoprofen lysinate 12.5 mg|
89465203|NCT00350103|Experimental|Lacosamide Standard Titration (ST)|Subjects had their dose titrated from 100 mg/day to 400 mg/day at weekly intervals of 100 mg. Subjects in this treatment group reach their target dose of 400 mg/day 3 weeks after Visit 2. All subjects completing the Titration Phase enter a 12-week Maintenance Phase.
89018196|NCT04889664|Experimental|Ketamine and Written Exposure Therapy|Intravenous Ketamine 0.5 mg/kg and Written Exposure Therapy
89465204|NCT00350103|Experimental|Lacosamide Fast Titration (FT)|Subjects receive 200 mg/day LCM for the first 3 days, 300 mg/day for the next 4 days, and reach their target dose of 400 mg/day after 1 week. They undergo sham titration for the remaining 3 weeks of the Titration Phase. All subjects completing the Titration Phase enter a 12-week Maintenance Phase.
89465205|NCT00350103|Placebo Comparator|Placebo|Subjects underwent sham titration for the entire Titration Phase. All subjects completing the Titration Phase enter a 12-week Maintenance Phase
89465206|NCT00344331||Patients with a diagnosis of Niemann-Pick type C (NPC) of either sex and any age|Participants may range from neurologically asymptomatic to severe and may have liver disease or unrelated comorbidities, but must be stable enough to safely travel and tolerate medical evaluations.
89465207|NCT00342654||1|Participants from two large, nutritional intervention trials that were conducted in Linxian, China between 1985-1991.
89201990|NCT00929877|Experimental|Ketoprofen lysinate 6.25 mg|
89201991|NCT00929877|Placebo Comparator|Matching placebo|
89201992|NCT00741884|Experimental|Arm 1|
89201993|NCT00741884|Experimental|Arm 2|
89465208|NCT00340405||Tin Miners in China at risk of lung cancer|Tin Miners in China at risk of lung cancer
89465209|NCT00339937||Cases|Adults in Italy with Kaposi's sarcoma
89465210|NCT00339937||Controls|Adults in Italy without Kaposi's sarcoma
89465211|NCT00339495||Non-Screening|Participants received their usual care
89465212|NCT00339495||Screening|Participants received trial-provided screening examinations for prostate, lung, colorectal, and ovarian cancer
89465213|NCT00314119||1|Men and women between 20 and 50 years of age diagnosed with NF1 and their biological parents are eligible for this study.
89465214|NCT00308724|Experimental|1|Cognitive Behavior Therapy
89465215|NCT00308724|Active Comparator|2|Usual Care
89465216|NCT00109174|Other|One arm|Subjects receive the same test
89465217|NCT00068159||1|Untreated-NYHA Class I HH subjects without conventional therapy for HH
89465218|NCT00068159||2|Treated- NYHA Class I HH subjects with conventional phlebotomy and/or iron chelation therapy
89465219|NCT00068159||3|Age-gender matched healthy HH control volunteers
89465220|NCT00065676|Experimental|1 gram quercetin|1 gram quercetin with 6 hour OGTT
89465221|NCT00065676|Experimental|2 grams quercetin|2 gram quercetin with 6 hour OGTT
89465222|NCT00065676|Experimental|placebo|placebo with 6 hour OGTT
89465223|NCT00059423||1|Individuals of African descent with benign ethnic neutropenia (BEN) at baseline
89465224|NCT00059423||2|Individuals of African descent without benign ethnic neutropenia (BEN) at baseline
89201994|NCT00741884|Experimental|Arm 3|
89201995|NCT00741884|Active Comparator|Arm 4|
89201996|NCT00741884|Placebo Comparator|Arm 5|
89018197|NCT04871295|No Intervention|Wait List|
89465225|NCT00039689||HIV chronic infection|For example, an individual infected with HIV-1 for an indeterminate amount of time.
89465226|NCT00039689||HIV early infection|For example, a negative HIV antibody immunoassay within 6 months of a positive HIV antibody assay and confirmatory test (as defined by current CDC criteria).
89465227|NCT00028080||Lyme Disease|Participants who have been diagnosed with or are strongly suspected to have Lyme disease.
89465228|NCT00026754||Cohort 1|Patients
89465229|NCT00026754||Cohort 2|Healthy Volunteers
89465230|NCT00004850||HBV positive|HBV positive subjects
88945653|NCT01900210|Experimental|WaySafe|WaySafe -- Participants in this arm received a curriculum titled WaySafe that focused on identifying, planning for, and avoiding HIV risk behaviors after release from prison. WaySafe included 6 hour-long, group-based, highly interactive sessions normally held weekly with homework assignments given between sessions.
88945654|NCT01900210|No Intervention|Treatment as usual|Participants in this arm completed pre- and post-surveys and attended normal substance abuse programming.
88945655|NCT01900223||Shoulder prosthesis bearer|
88945656|NCT01900236|No Intervention|Control|Control arm participants will receive standard clinical care (i.e. receive usual clinic treatment)
88945657|NCT01900236|Experimental|Motivation Behavioral Technique|Behavioral: 4 sessions of tailored, interactive agenda based on behavioral motivational interviewing (MI) techniques. Each iENGAGE intervention session includes: interventionist-delivered educational content for managing HIV medical care appointment-keeping and information sessions for learning to manage HIV medications. The goal of this intervention is for the participant to establish early behaviors that help him/her to arrive at scheduled medical appointments and learn to take medications as prescribed during the initial year of HIV care in order in order to achieve viral suppression and improve overall health.
88945658|NCT01895179|Experimental|Time-Restricted Feeding (early in the day eating)|Participants will consume all meals early in the day and within a 6-hour window.
88945659|NCT01895179|Placebo Comparator|Grazing|Participants will eat meals spread out over the course of the day.
88945660|NCT01900262|Experimental|Strengthening|Novice recreational runners from the Calgary area.
88945661|NCT01900262|Experimental|Balance Training|Novice recreational runners from the Calgary area.
88945662|NCT01900262|Experimental|Stretching|Novice recreational runners from the Calgary area.
88945663|NCT01900275||Septic shock or major trauma|Patients admitted within 24 hours to ICU for septic shock or major trauma (ISS > 15). Septic shock is defined by sepsis with hypotension requiring >4 hours of vasopressor support over previous 24 hours.
88945664|NCT01900288|Experimental|HPN Group Clinic Appointments (Group 1)|"A mobile device (iPad mini) is loaned to Group 1 subjects providing a connection to HPN Internet information for the 6 to 12 months of the study. Two scheduled times during the study period, visual connections to geographically distant professionals and peers over the iPad mini (HPN Group Clinic Appointment) will be held for approximately 1 ½ to 2 hours each time (called Healthy Living Connections).~On the iPad mini screen during the HPN Group Clinic Appointments, subjects will be able to see professionals and peers all at the same time and they will be able to see them in their home. This group will also receive electronic prompts about healthy activities."
88945665|NCT01900288|Placebo Comparator|Mobile Device Access (Group 2)|"A mobile device (iPad mini) is loaned to Group 2 subjects providing a connection to Internet information for the 6 to12 months of the study. At the end of the study period, Group 2 subjects will have 1 scheduled time during the study to connect to professionals and peers over the iPad mini for approximately 1 ½ to 2 hours (called Healthy Living Connections) before the study concludes.~On the iPad mini screen during the placebo control group clinics, subjects will be able to see professionals and peers all at the same time and they will be able to see them in their home. This group will also receive one electronic prompt about healthy activities as a comparison control to the intervention group."
88945666|NCT01900301|Experimental|Scopolamine .4mg|Participants will be randomized to either .4mg/.01 mL Scopolamine, .5mg/.01 mL Scopolamine or .6mg/.01 mL Scopolamine, administered via nasal drops, prior to each session of exposure therapy
88945667|NCT01900301|Placebo Comparator|Intranasal placebo|Participants will be randomized to a placebo, administered via nasal drops, prior to each session of exposure therapy
88945668|NCT01900301|Experimental|Scopolamine .5mg|Participants will be randomized to either .4mg/.01 mL Scopolamine, .5mg/.01 mL Scopolamine or .6mg/.01 mL Scopolamine, administered via nasal drops, prior to each session of exposure therapy
89018198|NCT04871295|Experimental|Noom Healthy Weight|
89201997|NCT00777816|Active Comparator|1|
89201998|NCT00777816|Placebo Comparator|2|
89201999|NCT00931437|Experimental|vitamin K-rich dairy product|one single intake of a dairy product containing several K-vitamins: phylloquinone, menaquinone-7,8,9-and 10.
89202000|NCT00741962|Experimental|1|
89202001|NCT00741962|Placebo Comparator|2|
89202002|NCT00782028|No Intervention|Standard Care|No intervention consists of routine well child care
89202003|NCT00782028|Other|Centering parenting/Group well child care|
89465231|NCT00004850||HCV positive partners|HCV positive partner subjects
89465232|NCT00004850||HCV postive|HCV positive subjects
89465233|NCT00004568||Inherited Neurological Patients|Includes individuals and families with a known or unknown inherited neurological condition.
89465234|NCT00001888||1|Asthmatics
89465235|NCT00001888||2|Research Volunteers
89465236|NCT00001727||1|Subjects with Polyostotic Fibrous Dysplasia and McCune-Albright Syndrome.
89465237|NCT00001711||Healthy Volunteers and Patients|Healthy volunteers and patients age 18 and older.
89465238|NCT00001486||Normal Controls|Male and female adult healthy volunteers
89465239|NCT00001486||Parents|Parents of Probands and siblings for the purposes of DNA collection
89465240|NCT00001486||Probands|Adult Subjects with Schizophrenia Spectrum Disorders
89465241|NCT00001486||Siblings|Adult siblings of Probands
89465242|NCT00001350||1|ALPS patients and relatives of all ages
89465243|NCT00001247||1|Individuals with schizophrenia-spectrum illness from the community.
89465244|NCT00001244||General Population|MD referred or self-referred
89465245|NCT00001186||Cohort 1|Children 7-17 years of age who are currently being treated for cancer or are up to 5 years post therapy.
89465246|NCT00001186||Cohort 2|Young adults with cancer (YACers) 18-25 years of age acting as counselors at Camp Fantastic and are enrolled in another NIH protocol.
89465247|NCT00001184||1|Patients between the ages of 0 and 75 years of age with Crohn s disease or ulcerative colitis or symptoms of inflammatory bowel disease may be eligible for this study.
89465248|NCT00001154||Patients|Subjects with new and undefined dyslipidemia
89465249|NCT03466281|Active Comparator|IBS School|Patient education provided in a group setting
89465250|NCT03466281|Active Comparator|Internet patient education|Patient education provided via the internet
89465251|NCT03465969|Other|Liver or kidney transplant participants of Advagraf|Transplant participants will provide 1 whole blood venepuncture sample and 1 whole blood finger prick MITRA sample at pre-dose of participant's usual oral dose of commercial Advagraf and at approximately 1 and 3 hours post-dose.
89465252|NCT05397873|Experimental|Group A|The patients will undergo baseline assessment and receive the intervention, being assessed after the intervention.
88945669|NCT01900301|Experimental|Scopolamine .6mg|Participants will be randomized to either .4mg/.01 mL Scopolamine, .5mg/.01 mL Scopolamine or .6mg/.01 mL Scopolamine, administered via nasal drops, prior to each session of exposure therapy
88945670|NCT01900327|Experimental|neoadj. Treatment|Neoadjuvant CRT with weekly Gemcitabine neoadjuvant 300mg/m2 for 6 weeks combined with external beam radiation (EBRT) delivering a total dose of 50.4 Gy over 28 days in 1.8 Gy fractions will be followed by classical or pylorus-preserving partial pancreato-duodenectomy (PD) and adjuvant chemotherapy (CTx), preferentially using Gemcitabine adjuvant (1000 mg/m2 6 cycles at day 1, 8, 15 of each 28-day cycle).
88945671|NCT01900327|Active Comparator|Upfront Surgery|Upfront PD followed by adjuvant CTx, preferentially with Gemcitabine adjuvant (1000 mg/m2 6 cycles at day 1, 8, 15 of each 28-day cycle).
88945672|NCT01900340|Placebo Comparator|iv saline, intraduodenal saline|intravenous infusion of saline plus intraduodenal administration of saline
88945673|NCT01900340|Active Comparator|IV exendin(9-39) plus intraduodenal (ID) saline|intravenous infusion of exendin(9-39) plus intraduodenal administration of saline
88945674|NCT01900340|Placebo Comparator|IV saline, intraduodenal nutrient|intravenous infusion of saline plus intraduodenal administration of nutrient
88945675|NCT01900340|Active Comparator|Exendin(9-39) plus ID nutrient|Exendin(9-39) as intravenous infusion plus intraduodenal nutrient administration
88945676|NCT01900353|Active Comparator|horizontal brushing method|brushing methods
88945677|NCT01900353|Active Comparator|Vertical brushing method|brushing methods
88945678|NCT01900366||Obese subjects for fat biopsy|10 patients recruited during fat biopsies for sample collection
88945679|NCT01900366||Lean controls for fat biopsy|5 Lean controls will be recruited
88945680|NCT01900379|Experimental|OSA/CPAP|OSA patients intervention : CPAP treatment
88945681|NCT01900379|Sham Comparator|OSA/sham CPAP|OSA patients intervention : Sham CPAP treatment
88945682|NCT01900379|No Intervention|control group|Patients without any apnea syndrome
88945683|NCT01900405||Dexmedetomidine|All children undergoing
89202004|NCT04014621|Active Comparator|Treated|Treated arm patients will be implanted and treated with one session of SPG stimulation for 6 hours and 5 additional consecutive sessions (4 hours each) of SPG stimulation, the first starting within 18-24 hours from stroke onset and the others 18-26 hours from previous treatment initiation.
89465253|NCT05397873|No Intervention|Group B|The patients will perform the same tests for assessment as in group A, however, no intervention will be done. They may enrol in the study as group B after completing group B participation.
89465254|NCT05397795|Experimental|Group(A)|subjects will be triggered by 10000 IU of hCG (Choriomon5000 IU; IBSA) given intramuscularly.
88945684|NCT01900418|Active Comparator|Walking|Walk with Ease
88945685|NCT01900418|No Intervention|Wait list control|Wait list control receiving the active intervention 6 weeks later.
88945686|NCT01900457|Active Comparator|Volunteer healthy|healthy volunteers
88945687|NCT01900457|Experimental|patients|vestibular defective patients
88945688|NCT01900470|Experimental|CHW Goal Support|IMPaCT CHWs will perform the following functions, depending on the needs of the participants: 1) Deconstructing Distal Goals into Proximal Goals: IMPaCT CHWs will help patients to deconstruct collaborative distal clinical goals into patient driven proximal goals and develop strategies for achieving each proximal goal.2) Creating Roadmaps: Roadmaps are individualized strategies for achieving each proximal goal identified by patients. 3) IMPaCT CHWs conduct weekly follow-up with patients through either telephone or home visit in order to support the achievement of proximal goals. As part of these followup encounters, CHWs ask patients to measure their chronic disease control during their weekly followup calls/visits. 4) Group: CHWs and their Project Manager run a group session for patients in the IMPaCT arm. This group meets weekly and is a forum for patients to discuss common issues around chronic disease management and form a social support network.
88945689|NCT01900470|No Intervention|Usual Primary Care|Patients will be encouraged to make follow-up appointments as needed with their primary care clinic for support towards their health goals. During these appointments, clinicians will help patients determine progress made on existing proximal goals, adjust goals based on self-efficacy, and help patients to create new proximal goals as needed. They will also work with PCPs to adjust medications when appropriate, provide health behavior education and make referrals to community-based services based on patient need.
88945690|NCT01900483||pre bariatric surgery|
88945691|NCT01900483||post bariatric surgery|
89465255|NCT05397795|Experimental|Group(B)|subjects will be triggered by 10000 IU of hCG (Choriomon5000 IU; IBSA) intramuscular injection in addition to the GnRH agonist triptorelin 0.2 mg (Decapeptyl 0.1 mg; Ferring) subcutaneously.
89465256|NCT02940639||Cohort 1|Participants with advanced/metastatic renal cell cancer (RCC) starting nivolumab monotherapy after prior therapy
89465257|NCT02940639||Cohort 2|Participants with advanced/metastatic RCC starting 1st line therapy with nivolumab and ipilimumab combination therapy, in intermediate/poor risk participants
89465258|NCT03130101|Other|80% basal insulin reduction|
88945692|NCT01900496|Experimental|Brentuximab vedotin & Rituximab|"Brentuximab vedotin:~Will be administered at 1.8 mg/kg IV over 30 minutes is given for up to 10 doses (cycles), with a cycle length of 21 days. Brentuximab vedotin is first given on day 1 of cycles 1, 2, 3, and 4 as a single agent (weeks 0, 3, 6, and 9, respectively). Four cycles are chosen because of the 12-week median time to CR in the pivotal phase 2 trial of brentuximab vedotin after autologous BMT for HL.~Brentuximab vedotin will be administered with Rituximab at 375 mg/m2 IV is given for up to 8 induction doses: day 1 of week 6, 7, 8, and 9; day 1 of week 12, 15, 18 and 21. This is followed by rituximab maintenance (375 mg/m2 IV once every 3 months x 2 doses) to complete a ~ 1 year total course of therapy."
88945693|NCT01900509|Experimental|Treatment|"All participants who meet eligibility for this study will follow the same treatment regimen.~INTERVENTIONS: bendamustine, clofarabine, etoposide (or etoposide phosphate), dexamethasone."
88945694|NCT01900522|Experimental|Multiple Rising Dose (MRD) Phase: Ascending ITI-214 Doses|ITI-214 Doses (A, B, C, D, matching placebo), solution, orally, once daily for 14 days.
89465259|NCT03130101|Other|50% basal insulin reduction|
89465260|NCT03130101|Other|100% basal insulin reduction|
89465261|NCT01067521|Experimental|GA 40 mg / GA 40 mg|Also referred to as the 'Early Start' treatment arm, participants were administered glatiramer acetate (GA) 40 mg/mL by subcutaneous injection three times a week for 12 months during the Double-Blind Period, and then continued that treatment as open-label therapy until the drug was commercially available or development stopped.
89465262|NCT01067521|Placebo Comparator|Placebo / GA 40 mg|Also referred to as the 'Delayed Start' treatment arm, participants were administered placebo subcutaneous injections three times a week for 12 months during the Double-Blind Period, and then switched to GA 40 mg/mL subcutaneous injections three times a week as open-label therapy until the drug was commercially available or development stopped.
89465263|NCT05434455|Experimental|RIPC|RIPC was induced with 3 cycles of 5 minutes of ischaemia and 5 minutes of reperfusion on the upper arm. By using blood pressure cuff inflation, patients in the RIPC group were exposed to a pressure 50 mmHg higher than the systolic radial artery pressure baseline.
89465264|NCT05434455|No Intervention|Con|The control group had a deflated cuff placed on the upper arm for the same time.
89465265|NCT05397483|Experimental|LETiT|"The LETiT intervention will cover (a) Legal education with numerous aspects relating to human rights, access to legal support and tackling traumatic experiences.~(b) The Trauma-informed Therapy component will involve addressing trauma, dispelling negative thoughts and building more positive thinking.~It is worth adding that the LETiT intervention has undergone standardisation of procedure by adopting a coherent manual (e.g., the Legal Education plus Trauma-informed Therapy manual) specifically designed for the proposed intervention. For example, the legal education contents are collated from extant laws, including the 1999 Constitution of the Federal Republic of Nigeria."
89465266|NCT05397483|Active Comparator|Intervention As Usual (IAU)|"The Intervention As Usual (IAU) component of the proposed project is designed through a systematic collation of numerous government and non-governmental organisations' support information (e.g., news information and basic re-orientation of community members affected by terrorism). Thus, the IAU group will receive the government intervention involving media messages from the National Orientation Agency devoid of legal education or trauma-informed therapy.~The training materials are organised to address key aspects of care such as (a) acknowledgement of the severity of lived experiences (b) reflection of current help received from the government and humanitarian services (c) essential aspects of self-care and caring for the vulnerable family and community members (d) inspiration for the future etc."
89465267|NCT02735577|Experimental|Disulfiram|Patients in this arm will receive disulfiram 250 mg daily for a total of 40 days.
89465268|NCT03642535|Experimental|ALA for all face group|Scales and crusts were gently removed by curettage, and the lesions to be treated were scraped carefully to avoid bleeding. Immediately afterwards, a 1-mm thick layer of 10% ALA was applied to the all face. The area was covered with an occlusive dressing for 3 h, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's lamp. Treatment area (all face)was then separately illuminated with red light-emitting diode lamps with peak emission at 630 nm and total light dose of 100 J/cm2. The treatment is once a week for total 3 times. The patients then follow up in clinic 3 years after their treatment to have the number of actinic keratoses counted.
89018199|NCT04867668|Experimental|Digital intervention|Participants will be randomized to receive variable levels of exposure (including no exposure control) of digital anti-vaping and anti-smoking messages. We will evaluate the effects of experimental condition and exposure on outcomes (tobacco product use).
89018200|NCT04867668|No Intervention|Control|No exposure control condition
89018201|NCT04850274|Experimental|Remote Therapy Intervention|Youth will receive the maximal dose of six S-RTI therapy sessions delivered by a remote therapist with no alteration in intensity
89018202|NCT04850274|Experimental|Artificial Intelligence Remote Therapy Intervention|Youth will first receive a remote therapy session in the Emergency Department (ED). The RL system will then make decisions about the intensity of each subsequent therapy session (the initial decision is seven days post ED visit and bi-weekly [i.e., every other two weeks] thereafter) for the next 11 weeks. Potential treatment decisions include a 30-minute remote therapy session delivered via phone or video chat (mirroring the S-RTI), a less intensive tailored Motivational Interviewing (MI)-adherent electronic remote therapy (delivered by an electronic robot), or an assessment only without intervention.
89202005|NCT04014621|Sham Comparator|Control|Control arm patients will be implanted and receive 6 hours of sham stimulation and 5 additional consecutive sessions (4 hours each) of sham stimulation, the first starting within 18-24 hours from stroke onset and the others 18-26 hours from previous treatment initiation.
89202006|NCT00742040|Experimental|1|
89018203|NCT04850274|No Intervention|Enhanced Usual Care|The youth's retaliatory risk will be assessed and a pamphlet with referrals for violence, substance use, and mental health services will be provided.
89018204|NCT04847531||Stage 3 chronic kidney disease patients|Patients with two consecutive eGFR measurements indicating stage 3 CKD (≥30 and <60 mL/min/1.73m2) during the observation period
89202007|NCT00742040|Active Comparator|2|
89018205|NCT04836195|Experimental|PCLX-001 intervention|"The Dose-Escalation phase will follow a standard 3+3 cohort design. Three patients will be treated at each dose level. If 0/3 patients experience DLT, 3 patients will be treated at the next dose level. Escalation will terminate as soon as two or more patients experience any DLT attributable to study drugs, at a given dose level.~Oral PCLX-001 will be provided as continuous daily dosing on a 28-day cycle."
89018206|NCT04827992|Experimental|Medical Marijuana + Prescription Opioid Taper Support (POTS) behavioral treatment|This group can begin using medical marijuana immediately and will participate in the POTS treatment groups.
89018207|NCT04827992|Active Comparator|Prescription Opioid Taper Support (POTS) treatment alone|This group must abstain from marijuana use and will participate in the POTS behavioral treatment alone.
89018208|NCT04804020|Active Comparator|NC (Natural cycle)|Performing the first ultrasound scan will be performed on the second to the fourth day of the menstrual cycle to identify any problem related to the patients' uterus or adnexa. The second ultrasound will be performed on the sixth day of the cycle. Daily ultrasound and serum estradiol and LH level evaluation will be performed when the mean diameter of the dominant follicle of ≥14 mm. LH surge initiation is defined as a concentration of 180% above the latest serum value available in that patient with a continued rise thereafter to a level of 20 IU/l or more detected by the ECLIA method (Roche Cobas® E 801, Roche Diagnostics, Germany). Embryo transfer will be scheduled by the time of the initiation of LH and embryo stages.
89018209|NCT04804020|Active Comparator|mMC (modified Natural cycle)|Performing the first ultrasound scan on the second to the fourth day of the menstrual cycle to identify any problem related to patients' uterus or adnexa. A second ultrasound scan will be performed on the sixth day of the cycle; if there is at least one follicle with a diameter of ≥12 mm, an ultrasound scan will be performed daily. When the dominant follicle's mean diameter is ≥16 mm, human chorionic gonadotropin (Ovitrelle® 250 μg; Merck, Kenilworth, NJ, USA) will be injected to trigger ovulation. Embryo transfer will be scheduled by the time of the hCG injection and embryo stages.
89018210|NCT04804020|Active Comparator|AC (Artificial cycle)|Preparing the endometrium by using oral estradiol valerate (Valiera®; Laboratories Recalcine) 8 mg/day, ranging from the second or fourth menstruation day. The endometrial thickness will be monitored from day six onwards, and vaginal progesterone (Utrogestan®; Besins) 800 mg/day will be initiated when endometrial thickness reaches ≥7 mm. Estradiol exposure must be lasting for ≥9 days before progesterone administration. Embryo transfer will be scheduled by the time of the initiation of progesterone and embryo stages.
89018211|NCT04781166|Experimental|Intervention|Participants will be immediately assigned to the intervention.
89018212|NCT04781166|Other|Waitlist control|Participants will complete measures before and after a waitlist equivalent to the duration of the intervention, to assess whether change is observed with time and repeated assessment. After the waitlist control, participants will be provided the opportunity to take part in the intervention. In this RDICT design, the pre- post- treatment data will be included in analyses.
89202008|NCT00777894|Experimental|Radiation: 3-dimensional conformal radiation therapy|
89202009|NCT00926757|Experimental|Entecavir prophylaxis|Participants will initiate entecavir 0.5 mg/day orally on day 1 of the first course of chemotherapy, and will be continued until 3 months after completion of the chemotherapy.
89465269|NCT03642535|Active Comparator|ALA for AK lesion group|Scales and crusts were gently removed by curettage, and the lesions to be treated were scraped carefully to avoid bleeding. Then a 1-mm thick layer of 10% ALA was applied to the lesion and 5 mm of surrounding healthy tissue. Vehicle control cream was applied to the non-lesion area. All area was covered with an occlusive dressing for 3 h, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's lamp. Treatment area (all face)was then separately illuminated with red light-emitting diode lamps with peak emission at 630 nm and total light dose of 100 J/cm2. The treatment is once a week for total 3 times. The patients then follow up in clinic 3 years after their treatment to have the number of actinic keratoses counted.
89465270|NCT04453605||Patients with neo-diagnosed type 2 diabetes|Patients referring for the first time to the outpatient diabetes clinic in the department of Internal Medicine between January 2008 and December 2015 and matching the inclusion criteria.
89465271|NCT02522559|Experimental|Spice Intervention|Spice intervention: Student-approved vegetable recipes will be served in the school cafeteria.
89465272|NCT05171257||repeat group|patients receiving empiric therapy with the same IV antibiotics from prior
89465273|NCT05171257||change group|patients receiving differing IV antibiotics from prior
89465274|NCT03640741||Laparoscopy|The group consists of patients who undergoes laparoscopy procedure during which changes in cerebral oxygenation are estimated.
89465275|NCT05397327|No Intervention|Conventional planning group|Conventional preoperative planning using x-rays and 2D and 3D CT scan
89465276|NCT05397327|Experimental|3D virtual planning group|Preoperative planning using x-rays, 2D and 3D CT scans and 3D virtual planning software
89465277|NCT03640819|Experimental|Tattooing of biopsied node|The biopsied node will be tattooed at the time of needle biopsy (fine needle aspiration or core biopsy) or separate visit under ultrasound guidance.
89465278|NCT05397249|Experimental|Mindfulness only training|Face to face twice weekly 10 minutes training of Mindfulness only training.
89018213|NCT04758650|Experimental|Cancer, lymphoma, carotid plaque, patients suspected for HLH, sarcoidosis|"Cohort 1: Patients diagnosed with pathology malignancies of the head and neck~Cohort 2: Patients diagnosed with any malignancy with a solid component~Cohort 3: Patients diagnosed with carotid plaque, planned for SOC carotid endarterectomy~Cohort 4: Patients with a biopsy-proven Hodgkin or non-Hodgkin lymphoma~Cohort 5: Patients suspected for HLH, planned for (SOC) bone marrow in case it is not done before~Cohort 6 : Patients with endomyocardial biopsy proven or suspected cardiac sarcoïdosis~Cohort 7 : Patients with biopsy-proven sarcoïdosis"
89018214|NCT04754672|Experimental|Continuous aerobic and resistance exercise (AE+RE)|"Two 60 min moderate-to-high intensity exercise sessions per week supervised by a physiotherapist.~Continuous aerobic exercise: 15-20 min continuous aerobic exercise (e.g. walking) of moderate intensity (Borg 13-14 'somewhat hard').~Resistance exercise (25 min): 6 exercises targeting large muscle groups vertical row, squat, bench press, pull over, abdominal crunch, and lunge. 2 sets of 10 repetitions at 70-80% of 1 RM. To ensure adequate training load over time, tests are repeated every 3/4 weeks aligned with the chemotherapy cycle.~One additional (third) session from home at moderate intensity for at least 30 min.~A brochure with exercise guidelines is provided."
89465279|NCT05397249|Experimental|Mindfulness with spirituality|Face to face twice weekly 10 minutes training of Mindfulness only training plus the Spirituality components.
89465280|NCT05397249|Experimental|Low dose Mindfulness only|Face to face once weekly 10 minutes training of Mindfulness only training.
89465281|NCT05397249|Experimental|Low dose Mindfulness with Spirituality|Face to face once weekly 10 minutes training of Mindfulness only training plus the Spirituality components.
89465282|NCT05397249|No Intervention|No treatment|No intervention is being delivered, however, participants are led to believe that they are receiving some degree of a mindfulness training embedded in their regular course curriculum.
89465283|NCT01068613|Experimental|QAX028 high dose|
89465284|NCT01068613|Experimental|QAX028 low dose|
89465285|NCT01068613|Active Comparator|Tiotropium|
89465286|NCT01068613|Placebo Comparator|Placebo|
89465287|NCT05222425|Experimental|Treatment group|Patients in the Treatment arm receive Xagrotin extract 2 grams three times a day in combination to the standard of care for sars-cov-2.
89465288|NCT05222425|No Intervention|Control group|Patients in the Control arm received the standard of care for sars-cov-2.
89465289|NCT05222425|Placebo Comparator|Placebo group|Patients in the Treatment arm receive green tea 2 grams three times a day in combination to the standard of care for sars-cov-2.
89465290|NCT05396937|Experimental|T+A+RAD|
89465291|NCT01345123|Experimental|Decision Aid with Health Coaching|
89465292|NCT01345123|Experimental|Decision Aid only|
89465293|NCT01345123|No Intervention|No condition specific support|
89465294|NCT03642223|Active Comparator|normal-weight|
89465295|NCT03642223|Experimental|peripheral adiposity|
89465296|NCT03642223|Experimental|central adiposity|
89202010|NCT00926757|Active Comparator|Therapeutic arm|In patients with HBV reactivation and ALT flare > 100 U/L, entecavir 0.5mg daily will be prescribed for the cases till hepatitis remission
89465297|NCT03640663||Midwife led continuity model of care|Women who received antenatal care from midwives from the hospital reaching out to the rural villages
89465298|NCT03640663||Regular care group|Women who received care from doctors, nurses or midwives employed at primary Health care centres in rural villages
89465299|NCT03642145|Experimental|Arm A: Deflazacort 0.9 mg/kg|Participants will receive approximately 0.9 mg/kg deflazacort once daily orally for 52 weeks in Period 1 and for 52 weeks in Period 2. The target dose could be varied +/- 20 percent (%) depending upon the available tablet strengths and change in participant's weight.
89465300|NCT03642145|Experimental|Arm B: Deflazacort 0.45 mg/kg|Participants will receive approximately 0.45 mg/kg deflazacort once daily orally for 52 weeks in Period 1. Participants will either continue to receive 0.45 mg/kg deflazacort or escalated dose of deflazacort (0.9 mg/kg) once daily orally in Period 2 at the investigator's discretion and in consultation with the caregiver. The target dose could be varied +/- 20% depending upon the available tablet strengths and change in participant's weight.
89465301|NCT03642145|No Intervention|Natural History Control Group|Control participants matching to the study population as closely as possible, will be used as a comparator to characterize the safety and tolerability of deflazacort.
89465302|NCT05396625|Experimental|Family Strengthening, Mental Health, Economic Empowerment|Group will receive: 1) Usual Care, 2) Family Strengthening, 3) Mental Health Screening & Referral, and 4) Economic Empowerment Interventions
89465303|NCT05396625|Experimental|Family Strengthening, Mental Health|Group will receive: 1) Usual Care, 2) Family Strengthening, and 3) Mental Health Screening & Referral Interventions
89465304|NCT05396625|Experimental|Family Strengthening, Economic Empowerment|Group will receive: 1) Usual Care, 2) Family Strengthening, and 3) Economic Empowerment Interventions
89465305|NCT05396625|Experimental|Family Strengthening Only|Group will receive: 1) Usual Care and 2) Family Strengthening Interventions
89465306|NCT05396625|Experimental|Mental Health, Economic Empowerment|Group will receive: 1) Usual Care, 2) Mental Health Screening & Referral, and 3) Economic Empowerment Interventions
89465307|NCT05396625|Experimental|Mental Health Only|Group will receive: 1) Usual Care and 2) Mental Health Screening & Referral Interventions
89465308|NCT05396625|Experimental|Economic Empowerment Only|Group will receive: 1) Usual Care and 2) Economic Empowerment Interventions
89465309|NCT05396625|Experimental|Usual Care Only|Group will receive: Usual Care Intervention only
89501970|NCT05496764|Active Comparator|Group B|26 patients we planned to inject them local glucose 5% ( 10 ml glucose) directly into the carpal tunnel in (group A)
89465310|NCT03640585|Experimental|Music therapy|Children listened to Classical music disc for 45 minutes.Children treated by neurodevelopmental therapy while listening to this music.A total of 15 treatments were administered for 5 weeks, 3 sessions per week for all patients.
89465311|NCT03640585|Placebo Comparator|Control|Only the neurodevelopmental therapy was applied in the control group without music. A total of 15 treatments were administered for 5 weeks, 3 sessions per week for all patients. The sessions were 45 minutes.
89465312|NCT01064791|Experimental|Arm 1|sotrastaurin (100mg bid) + tacrolimus + standard of care medications
89465313|NCT01064791|Experimental|Arm 2|sotrastaurin (200mg bid) + tacrolimus + standard of care medications
89465314|NCT01064791|Experimental|Arm 3|sotrastaurin (300mg bid) + tacrolimus + standard of care medications
89465315|NCT01064791|Active Comparator|Arm 4|mycophenolic acid (720mg bid) + tacrolimus + standard of care medications
89465316|NCT03465501||Low Dose Rate|Patients treated with brachytherapy at low dose rate of the anal canal with aim of boost
89465317|NCT03465501||High Dose Rate|Patients treated by brachytherapy with a high dose rate of the anal canal aiming for boost
89465318|NCT03641989|Active Comparator|Plaque disclosing toothpaste|Based on a randomization schema, a 30 day supply of the plaque disclosing toothpaste will be distributed to the participant. Participants will be instructed to brush two times a day for 30 days with the plaque disclosing toothpaste; avoiding the use of mouth rinses and floss. They will also be instructed to avoid any dental prophylaxis (e.g., cleaning, scaling or root planing to mechanically remove plaque and calculus) while on the trial and 30 days before they are enrolled.
89465319|NCT03641989|Placebo Comparator|Non-plaque disclosing toothpaste|Based on a randomization schema, a 30 day supply of the over-the-counter, non-plaque disclosing toothpaste will be distributed to the participant. Participants will be instructed to brush two times a day for 30 days with the plaque disclosing toothpaste; avoiding the use of mouth rinses and floss. They will also be instructed to avoid any dental prophylaxis (e.g., cleaning, scaling or root planing to mechanically remove plaque and calculus) while on the trial and 30 days before they are enrolled.
89465320|NCT03465423||patients with nonfunctioning pituitary tumor|patients with nonfunctioning pituitary tumor undergoing transsphenoidal pituitary surgery under total intravenous anesthesia
89465321|NCT03465423||patients with pituitary somatotroph tumor|patients with pituitary somatotroph tumor undergoing transsphenoidal pituitary surgery under total intravenous anesthesia
89465322|NCT05161351|Experimental|Baclofen|Participants will receive a single dose of either 10mg, 30mg, 60mg or 90mg of Baclofen administered as oral tablets.
89465323|NCT05161351|Placebo Comparator|Vitamin D3|Participants will receive a single dose of either 20μg, 60μg or 120μg of Vitamin D3 administered as oral tablets.
89465324|NCT02588001|Experimental|Enzalutamide Group|
89465325|NCT03465345|Experimental|Metformin + OPC dose escalation|
89202011|NCT00746408||Main 1|Insurants of the health insurance company BARMER using the prototype to receive expert system guided tailored internet information about the type of headache they suffer from.
89465326|NCT03465267|Experimental|Armeo power|Armeo power robot for upper extremity
89465327|NCT03465267|Experimental|Armeo spring|Armeo spring robot for upper extremity
89465328|NCT04230135|Active Comparator|Generic (surface adaptation)|The generic version of Hap-pas-Hapi includes only surface adaptations (i.e., adaptation of text and illustrations that are inacceptable or non-meaningful for the target group)
89501971|NCT05491070|Experimental|Dual Proglide|Use Two Progilde for closure of femoral artery with large sheath in transfemoral TAVI
89501972|NCT05491070|Experimental|Progilde + AngioSeal|Use Progilde + AngioSeal for closure of femoral artery with large sheath in transfemoral TAVI
89501973|NCT05496608|Placebo Comparator|Open Flap Debridement|Subjects with infrabony defects had full thickness flap reflection and debridement of periodontal lesion
89018215|NCT04754672|Experimental|Continuous aerobic and aerobic interval exercise (AE+AI)|"Continuous aerobic exercise: 15-20 min continuous aerobic exercise (e.g. walking) of moderate intensity (Borg 13-14 'somewhat hard').~Aerobic interval (25 min): cycling with high intensity intervals alternated with recovery intervals. Intensity of the interval: between 85% and 95% of estimated maximum heart rate, adjusted to Borg 16-18 'hard - very hard'. In between the intervals, light intensity cycling will be performed for active recovery at 30% of Wmax estimated from Steep ramp test and adjusted to Borg < 12.~One additional (third) session from home at moderate intensity for at least 30 min.~A brochure with exercise guidelines is provided."
89018216|NCT04754672|No Intervention|Usual care control group|Patients in the usual care group receive care as usual. In addition, a brochure with exercise guidelines for cancer survivors is provided
89018218|NCT04740671|Experimental|HLX04-O|Biologic recombinant anti-VEGF humanized monoclonal antibody
89018219|NCT04740671|Active Comparator|Ranibizumab|Biologic anti-VEGF recombinant humanized monoclonal antibody fragment
89018220|NCT04734262|Experimental|Cohort A|Subjects will receive 70mg sitravatinib in combination with 200mg tislelizumab until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
89018221|NCT04734262|Experimental|Cohort B|Subjects will receive 100mg sitravatinib in combination with 200mg tislelizumab until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
89018222|NCT04734262|Experimental|Cohort C|Subjects will receive sitravatinib in combination with 200mg tislelizumab and 100 mg/m2 nab-paclitaxel until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
89018223|NCT04733443|Experimental|Biolimus|BA9 Drug-eluting Coronary Artery Balloon Catheter Length: 10 / 15 / 20 / 25 / 30 / 35 / 40 /45mm Diameter: 2.0/2.25/2.5/2.75/3.0/3.5/4.0 mm
89018224|NCT04733443|Active Comparator|SeQuent® Please Neo|paclitaxel released coronary balloon catheters Length: 10 / 15 / 20 / 25 / 30 / 35 / 40 mm Diameter: 2.0/2.25/2.5/2.75/3.0/3.5/4.0 mm
89018225|NCT04702308|Experimental|Intervention Group|The intervention will contain two components: 1) a non-interruptive best practice advisory (BPA) in the Epic Storyboard and 2) a default suggested calculator tab in the MDCalc Connect app. Six clinical decision rules will be included: Canadian CT Head Rule, Canadian C-spine Rule, HEART Score, PERC Rule, Wells' PE Criteria and Wells' DVT Criteria. Predefined criteria based on chief complaint, patient age and vital signs will be used to determine when a decision rule may be relevant in a patient encounter. When a patient meets all of the predefined criteria, the intervention will be triggered.
89465329|NCT04230135|Experimental|Adapted (deep structure adaptation)|For the experimental intervention, Hap-pas-Hapi was adapted to Albanian immigrants' cultural concepts of distress (CCD). An ethnopsychological study was conducted for this purpose, since evidence on CCD in South Eastern Europe is scarce. Based on this study, three deep-structure adaptations were done: i) the symptom narrative provided by the narrator in the app was re-written to reflect Albanian immigrants' CCD; ii) a new explanatory model builder was implemented to address the target group's fatalistic beliefs; and iii) a goal-setting task was programmed to address the target group's socio-centric notion of the self.
89465330|NCT02735421|Experimental|Part 1: ABPO Forte Gel|
89465331|NCT02735421|Placebo Comparator|Part 1: ABPO Forte Vehicle Gel|
89465332|NCT02735421|Experimental|Part 2: ABPO Forte Gel|
89465333|NCT02735421|Placebo Comparator|Part 2: ABPO Forte Vehicle Gel|
89465334|NCT04469205|Experimental|Intervention Group|intervention group that will receive return-to-work coaching sessions. The intervention consists of 3 individual coaching sessions with a certified professional coach. This personalized accompaniment will complete the standard accompaniment offered to all patients.
89465335|NCT04469205|No Intervention|Control Group|"control group who will receive the current care which consists of a psychosocial care.~This care consists in offering the patient regular information meetings organized with social workers of the Health Insurance, to consult a psychologist and to access patients' homes at the frequency of their choice and according to their need."
89465336|NCT02983799|Experimental|gBRCAm;|germline BRCA mutant
89465337|NCT02983799|Experimental|sBRCAm and germline BRCA wild type;|somatic BRCA mutant, germline BRCA wild type
89465338|NCT02983799|Experimental|myChoice® HRD positive and BRCAwt;|genomic instability positive and no BRCA mutation
89465339|NCT02983799|Experimental|myChoice® HRD negative and BRCAwt|genomic instability negative and no BRCA mutation
89465340|NCT03622307|Experimental|S-ICD therapy combined with VT Ablation|To evaluate the feasibility and safety of a management approach that incorporates VT-ablation and S-ICD implantation in secondary prevention patients
89465341|NCT04320017||COVID-19 patients|Patients diagnosed with COVID-19 by PCR done on nasal sample.
89465342|NCT03465033|No Intervention|Usual Care|Patients will receive basic indications of rehabilitation consisting of daily mobilization of the jaw (perform several movements a day opening movements, laterotrusion and mouth protrusion).
89465343|NCT03465033|Experimental|Early Physiotherapy|
89018226|NCT04702308|No Intervention|Control Group|The control group will be usual care. Specifically, providers in the control group will not receive the clinical decision rule alert or the default suggested calculator tab in the MDCalc Connect app. The control group providers will have access to the MDCalc Connect app in its standard form and functionality.
89465344|NCT03954249|Experimental|Erector Spinae nerve block group|Receive multimodal analgesia and in addition erector spinae plane block
89465345|NCT03954249|Active Comparator|Multimodal Analgesia group|Receive standard multimodal analgesia
89465346|NCT05386641||Experimental Group|Breast cancer survivors with shoulder joint motion restriction
89018227|NCT04701398|Experimental|Multimodal intervention|supervised physical training (1-hour sessions, 24 sessions, 8 weeks) + nutritional supplementation + psychological advice
89018228|NCT04701398|No Intervention|Standard Care|Healthy living recommendations
89202012|NCT00746408||Main 2|Insurants of the health insurance company BARMER using search engines and portals to gather internet information about the type of headache they suffer from.
89202013|NCT00746408||Online 1|Internet users using the prototype to receive expert system guided tailored internet information about the type of headache they suffer from.
89465347|NCT05386641||Control group|Breast cancer survivors without shoulder joint motion restriction
89465348|NCT03464877|Experimental|Intervention group|Standardized six-week duration multi-station full-body supervised exercise program. The frequency was 2-3 sessions per week. The duration of each session was 60 minutes.
89465349|NCT05385705|Experimental|Experimental: NKs|Subjects will be treated with cyclophosphamide single dose between days -5 and -3 before the NK-cell infusion. On Day 1 single loading doses of trastuzumab (8mg/kg iv) and pertuzumab (840 mg iv) will be administered followed by maintenance doses of 6mg/kg and 420mg respectively, every three weeks. After that, NK infusion will be done on day 2 and that will be followed by administration of IL-2 on day 2, 4 and 6 as a subcutaneous dose of 5x105 UI/m2.
89465350|NCT05329701|Experimental|Individualized treatment duration|"Antibiotic treatment will be discontinued when both of the following two criteria are fulfilled:~The infant has had 24 hours without clinical symptoms of infection, after systematic clinical evaluation by a neonatologist. Clinical symptoms specified in Table 1.~CRP is < 30 mg/l. If CRP is > 30 at the time when the infant has been symptom-free for 24 hours, CRP will be assessed once every 24 -48 hours and antibiotics will be stopped when CRP < 30."
89465351|NCT05329701|No Intervention|Standard treatment duration|Standard treatment duration is seven days.
88945695|NCT01900522|Experimental|Neuroimaging Phase: ITI-214 Doses|ITI-214 (E,F, G, H, matching Placebo) Oral solution, once daily for 7 days in 3 periods with placebo and two of the ITI-214 Doses (E, F, G and H) in a cross-over fashion with minimum 7 days washout between periods
89202014|NCT00746408||Online 2|Internet users using search engines and portals to gather internet information about the type of headache they suffer from.
89465352|NCT04390503|Experimental|Convalescent Plasma (anti-SARS-CoV-2 plasma)|Participants randomized to the experimental arm will receive 2 units (approximately 200 to 250 mL per unit, total 400-500mL) of convalescent plasma that was collected from a volunteer who recovered from COVID-19 disease.
89465353|NCT04390503|Active Comparator|Control (albumin 5%)|Participants randomized to the control arm will receive 2 units of 250 mL (500mL total) of albumin (human) 5% infusion. The albumin will be prepared in bags that are identical to the bags used for plasma. The similar appearance of albumin and plasma will facilitate maintaining the blinded status of subjects and most of the study staff.
89465354|NCT05381337|Experimental|the sideburns mini incision group|Forty patients (the sideburns mini incision group) were treated with sideburns mini incision.
89465355|NCT05381337|Other|the coronal scalp incision group|Forty patients (the coronal scalp incision group) were treated with coronal scalp incision.
89465356|NCT03654261|Experimental|1-Day CBT Workshop - Immediate|Women assigned to the immediate workshop group will participate in the first of two workshops (9 weeks apart).
89465357|NCT03654261|Experimental|1-Day CBT Workshop - Waitlist|Women assigned to the waitlist will participate in the second of two workshops (12 weeks apart).
89465358|NCT02186847|Active Comparator|Chemoradiation|60 Gy Radiation therapy with concurrent paclitaxel and carboplatin followed by consolidation paclitaxel and carboplatin
89465359|NCT02186847|Experimental|Metformin + Chemoradiation|Metformin plus 60 Gy Radiation therapy with concurrent paclitaxel and carboplatin followed by consolidation paclitaxel and carboplatin
89465360|NCT01066871|Experimental|Sprifermin (AS902330) 10 mcg|
89465361|NCT01066871|Experimental|Sprifermin (AS902330) 30 mcg|
89465362|NCT01066871|Experimental|Sprifermin (AS902330) 100 mcg|
89465363|NCT01066871|Placebo Comparator|Placebo|
89465364|NCT02982863||All Patients|
89465365|NCT05288205|Experimental|Dose escalation|
89465366|NCT05288205|Experimental|Dose expansion|
89465367|NCT05274789|Placebo Comparator|Placebo group|Use 250 ml of saline as placebo group.
89465368|NCT05274789|Experimental|Experimental group|Use dexmedetomidine as experimental group
89465369|NCT03622229|Active Comparator|EUS-FNB with side-fenestrated needle|"Before randomization, the endosonographer chooses the needle gauge to perform biopsy preferring the 25 gauge caliber for difficult lesions. The needle advances inside the lesion and the operator will perform some needle movements back and forth into the lesion while slowly withdrawn the stylet (slow-pull technique). If possible the direction of the needle inside the lesion will be changed during the movements (fanning technique) to sample different areas of the lesion. Three needle passes will be performed and the material acquired at each pass will be placed directly in formalin in a single vial.~Diagnostic Test: Histologic evaluation"
89465370|NCT03622229|Active Comparator|EUS-FNB with fork-tip needle|"Intervention: like above.~Diagnostic Test: Histologic evaluation."
88945696|NCT01900548|Experimental|Whey protein (HPHL)|Whey protein supplementation and resistance training for four month.
88945697|NCT01900548|Experimental|Soy protein (HPLL)|Soy protein supplementation and resistance training for four month.
88945698|NCT01900548|Placebo Comparator|Placebo (P)|Maltodextrin supplementation and resistance training for four month.
89465371|NCT02353247|Other|Norethindrone acetate (aygestin)|Norethindrone acetate (aygestin) will be used to manage bothersome bleeding. Patients will be prescribed aygestin 5 mg by mouth twice daily for one month, followed by aygestin 5 mg by mouth once daily for two months. Medication will then be discontinued. Patients will be evaluated in the office three months after medication initiation, and then again six months after medication initiation. If the patient is unable to take norethindrone acetate (aygestin) due to medical contraindications or cost, they will receive medroxyprogesterone acetate (provera) 10 mg once daily as alternate oral progesterone. Figure 1 below highlights the study
89501974|NCT05496608|Active Comparator|L-PRF|Subjects with infrabony defects had full thickness flap reflection and debridement of periodontal lesion followed by application of the L-PRF within the bony defect
89465372|NCT03389217|Experimental|Real-tDCS + rehabilitation programme|The real transcranial Direct Current Stimulation group will consist of anodal transcranial direct current stimulation applied for a total duration of 30 minutes over the the left dorsolateral prefrontal cortex and rehabilitation programme for prevention and management of pain.
89465373|NCT03389217|Active Comparator|Sham-tDCS + rehabilitation programme|The sham transcranial Direct Current Stimulation group will consist of anodal transcranial direct current stimulation applied for a total duration of 30 s over left dorsolateral prefrontal cortex and rehabilitation programme for prevention and management of pain.
89465374|NCT03656471||Clear aligner group|Patients receiving clear aligner treatments for their malocclusions
89465375|NCT03656471||Fixed appliance group|Patients receiving fixed appliance treatments for their malocclusions
89465376|NCT05357703|Experimental|Standard treatment + Active B-Cure laser|Subjects from Standard treatment + Active B-Cure laser will receive standard care and in addition will self-treat at home with the B-Cure device.
89465377|NCT03368937|Experimental|Tandem t:slim X2 with Control-IQ Technology|Subjects will use the Tandem t:slim X2 with Control-IQ Technology during a 36-48 hour hotel admission.
89465378|NCT05354661||Hypotension Prediction Index (HPI) group|Hemodinamic monitoring with HPI working with ClearSight
89465379|NCT05354661||Control group|Hemodinamic monitoring with classic ClearSight
89465380|NCT03464721||Surgery Outpatients|
89465381|NCT04343651|Placebo Comparator|Placebo|The placebo comparator consists of the formulation buffer for leronlimab, i.e., the placebo is the same as the active arm without leronimab. The placebo is presented in the same container closure at the same fill volume as the active (nominal 1mL fill volume). The formulation buffer contains histidine, glycine, sodium chloride, sorbitol, polysorbate 20 and sterile water for injections.
89465382|NCT04343651|Experimental|700mg Leronlimab|Each vial of active contains 175mg of leronlimab at a concentration of 175mg/ml (nominal 1mL fill volume) in formulation buffer containing histidine, glycine, sodium chloride, sorbitol, polysorbate 20 and sterile water for injections.
89465383|NCT05261061||Old patients hospitalized in acute geriatric unit|
89465384|NCT05261061||Old patients hospitalized for other medical diagnosis in acute geriatric unit|
89465385|NCT03464643|Other|Single embryo culture|Embryo is cultured individually in 25 ul media
89465386|NCT03464643|Other|Group embryo culture|2-3 Embryos are group cultured in 50 ul media
89202015|NCT00782106|Experimental|1|Tolerability of subcutaneous infusions
89202016|NCT00782106|Experimental|2|Tolerability of subcutaneous infusions and pharmacokinetics
89465387|NCT03464565||Patients with acute ischemic stroke secondary to LVO|
89465388|NCT05333367|Other|Patients undergoing extracorporeal photochemotherapy|
89465389|NCT03464487|Active Comparator|Daily LGIT|The children with drug resistant epilepsy in this arm will receive Low Glycemic Index Therapy diet everyday along with the antiepileptic drugs.
89465390|NCT03464487|Active Comparator|Intermittent LGIT|The children with drug resistant epilepsy in this arm will receive Low Glycemic Index Therapy Diet on five days of each week along with antiepileptic drugs. Rest of the two days, they will receive a liberal diet.
89465391|NCT03464331|Experimental|EXP group|Participants in EXP group (EXP) will be asked to practise Zero-time exercises (ZTE) at least 20-30 minutes per day, and on most and preferably all days of the week.
89465392|NCT03464331|Placebo Comparator|CON group|Participants in CON group (CON) will be asked to practise relaxation exercises (RE) and deep-breathing exercises (DBE) at least 30 mins every day.
89465393|NCT05324241|Experimental|Microencapsulated fat stomach|Participants will consume a drink containing 400kcal of microencapsulated fat that will be released in the stomach.
89465394|NCT05324241|Experimental|Microencapsulated fat intestine|Participants will consume a drink containing 400kcal of microencapsulated fat that will be released in the intestine.
89465395|NCT05309889||high exposure level|Patients have a high level of exposure factors
89465396|NCT05309889||low exposure level|Patients have a low level of exposure factors
89465397|NCT04327089|Experimental|Part 1- Cohort 1|Single oral dose of 400 mg Setanaxib administered as 1x400 mg tablet in fasting conditions.
89465398|NCT04327089|Experimental|Part 1- Cohort 2|Single oral dose of 800 mg Setanaxib administered as 2x400 mg tablet in fasting conditions.
89465399|NCT04327089|Experimental|Part 1- Cohort 3|Single oral dose of 1200 mg Setanaxib administered as 3x400 mg tablet in fasting conditions.
89465400|NCT04327089|Experimental|Part 1- Cohort 4|Single oral dose of 1600 mg Setanaxib administered as 4x400 mg tablet in fasting conditions.
89465401|NCT04327089|Experimental|Part 2- Cohort 5|Repeated 10-Day dosing of 1200mg/day of Setanaxib administered as 2x400mg tablet in the morning and as 1x400mg tablet in the evening in fedding conditions.
89465402|NCT04327089|Experimental|Part 2- Cohort 6|Repeated 10-Day dosing of 1600mg/day of Setanaxib administered as 2x400mg tablet in the morning and as 2x400mg tablet in the evening in fedding conditions.
89465403|NCT04327089|Experimental|Cohort 7|Repeated 10-Day dosing of 1600mg/day of Setanaxib administered as 2x400mg tablet in the morning and as 2x400mg tablet in the evening in fedding conditions. Additionnaly, this cohort includes the evaluation of potential Drug-Drug interactions with CYPs and transporters.
89465404|NCT05302869||Students|
89465405|NCT05302869||Physiotherapist|
89465406|NCT05301699||training cohort|The training cohort was used for data analysis.
89465407|NCT05301699||validation cohort|The validation cohort was used for validating the nomogram
89465408|NCT05150223|Active Comparator|Traditional strength training group|traditional strength training (running, jumping forward over a barrier with one leg and two legs, heel-rise, push up and ball throw with load, bench press, and flexion-abduction-external rotation pattern with theraband)
89465409|NCT05150223|Experimental|Power Training group|progressive functional strength training protocol (running, jumping forward over a barrier with one leg and two legs, heel-rise, push up and ball throw with load, bench press, and flexion-abduction-external rotation pattern with theraband)
89465410|NCT05150223|No Intervention|Control group|no intervention Typically developing children
89465411|NCT05253105|Experimental|TAB006 60mg and Torpalimab 240mg repeat dose every 21 days up to 2 years|
89465412|NCT05253105|Experimental|TAB006 240mg and Torpalimab 240mg repeat dose every 21 days up to 2 years|
89465413|NCT05253105|Experimental|TAB006 600mg and Torpalimab 240mg repeat dose every 21 days up to 2 years|
89465414|NCT05253105|Experimental|TAB006 1800mg and Torpalimab 240mg repeat dose every 21 days up to 2 years|
89465415|NCT05253105|Experimental|Dose Expansion / TAB006 RP2D and Torpalimab 240mg repeat dose every 21 days up to 2 years|
89465416|NCT05253105|Experimental|Indication Specific / TAB006 RP2D and Torpalimab 240mg repeat dose every 21 days up to 2 years|
89465417|NCT03463707|Experimental|Treatment with BP101|
89465418|NCT03463707|Placebo Comparator|Treatment with placebo|
89465419|NCT05226897|Experimental|Test|Take YYC405-T and Metformin≥1000mg, Dapagliflozin 10mg
89465420|NCT05226897|Placebo Comparator|Placebo control|Take YYC405-T Placebo and Metformin≥1000mg, Dapagliflozin 10mg
89465421|NCT04453761|Experimental|Drugs Group|Thiamine IV
89465422|NCT04453761|Placebo Comparator|Placebo|NaCl IV
89465423|NCT03463629|Experimental|Specialized multidisciplinary diabetes team (SMDT) approach|"The implementation of the pilot study will consist of a specialized multidisciplinary diabetes team care (SMDT) that includes endocrinologists, a nurse practitioner, dieticians, pharmacists and a licensed professional counselors (LPCs) to collaborate and coordinate care. Subjects in the pilot study will follow a multidisciplinary team approach process with the following team members: pharmacist, LPC, and dietician.~There will be 3 individualized visits: 1 visit with the counselor (LPC), 1 visit with the Pharmacist, and 1 visit with the Dietician.~In addition, a follow up phone call post visit, that can range from 5 to 30 minutes, will be scheduled from each of the team members during the study. Also, throughout the pilot study participant's blood glucose readings will be monitored weekly via a transmittable wireless patient transmission monitor."
89465424|NCT03463629|Active Comparator|Traditional model of care|Receive the traditional model of care, but will not receive diabetes education by pharmacists or counseling services. Data for this arm will be collected through retrospective chart review.
89465425|NCT03463551|Experimental|ABL-101 IV as per dosing cohort + Supplementary O2 for 24h|"Patients will receive either ABL-101 or placebo (equivalent volume of 0.9% Sodium Chloride) within ascending dose groups of 6 patients each (4 to ABL-101, 2 to placebo).The starting cohort will be Cohort 1: 0.5mL/kg.~In the event that the start dose of Cohort 1 is considered intolerable in the opinion of the iDMC based on incidence of patients experiencing dose-limiting toxicities (DLTs), the iDMC will have the option of recommending a lower dose cohort (Cohort -1) of 0.25ml/kg (to a maximum of 25ml) be undertaken.~Cohort 1: 0.5 mL/kg to a maximum of 50ml; Cohort 2: 1.5mL/kg to a maximum of 150ml; Cohort 3: 3.0mL/kg to a maximum of 300ml.~All patients will receive Oxygen 60% by face mask (8l/min) for approximately 24h after ABL-101 or placebo administration."
89018229|NCT04701112|Experimental|His-bundle pacing first|"AV sequential His-bundle pacing (or VVI pacing if in atrial fibrillation) via temporary right atrial and His-bundle electrodes.~Then AV sequential Biventricular pacing via the patient's already implanted CRT device.~Measurements of stroke volume, cardiac output, pressure in the right ventricle and pulmonary capillary wedge pressure, during rest and exercise. Simultaneous 12 lead ECG registration."
89018230|NCT04701112|Active Comparator|Biventricular pacing first|"AV sequential biventricular pacing (or VVI pacing if in atrial fibrillation) via the patient's already implanted CRT device. Then AV sequential or VVI His-bundle pacing via temporary right atrial and His-bundle electrodes.~Measurements of stroke volume, cardiac output, pressure in the right ventricle and pulmonary capillary wedge pressure, during rest and exercise. Simultaneous 12 lead ECG registration."
89018231|NCT04698291||Controls|This research aims to recruit only adult volunteers that have taken part of the Gene & Health program. We will focus on two groups: individuals presenting the polymorphisms of interest and individuals without the genetic variants in the genes of interest, which will be used as matched controls. Eligible individuals will consent to donate blood samples for this study, in addition to consent access to their medical and health records.
89018232|NCT04698291||Cases|This research aims to recruit only adult volunteers that have taken part of the Gene & Health program. We will focus on two groups: individuals presenting the polymorphisms of interest and individuals without the genetic variants in the genes of interest, which will be used as matched controls. Eligible individuals will consent to donate blood samples for this study, in addition to consent access to their medical and health records.
89018233|NCT04684212|Experimental|Device Arm|The LAmbre PlusTM Left Atrial Appendage Closure System (LAmbre device)
89018234|NCT04684212|Active Comparator|Control Arm|Market approved oral anticoagulation (OAC)
89018235|NCT04684212|Other|Roll-in Arm|225 roll-in subjects
89018236|NCT04679012|Experimental|Polatuzumab vedotin plus R-EPCH|Polatuzumab vedotin will be given in conjunction with 6 cycles of R-EPCH (rituximab, etoposide, prednisone, cyclophosphamide, hydroxydaunorubicin). The dosing schedule and regimen for R-EPCH will follow established protocols. Polatuzumab vedotin will be administered on Day 1 of each 21-day cycle.
89465426|NCT03463551|Placebo Comparator|IV 0.9% NaCl as per dosing cohort + supplementary O2 for 24h|"Cohort 1: Volume matched to the calculation used for ABL-101 using patient weight; Cohort 2: Volume matched to the calculation used for ABL-101 using patient weight; Cohort 3: Volume matched to the calculation used for ABL-101 using patient weight.~All patients will receive Oxygen 60% by face mask (8l/min) for approximately 24h after ABL-101 or placebo administration."
89465427|NCT03463395|No Intervention|Standard of Care|Group A will receive standard of care
89465428|NCT03463395|Experimental|Reza band use|Group B will receive standard care plus the Reza band (worn as recommended by the manufacturer)
89465429|NCT03463317|Experimental|LAA closure group|Left atrial appendage closure by use of CE-mark approved LAA closure devices followed by post procedure treatment (antiplatelet therapy e.g. acetylsalicylic acid, clopidogrel)
89465430|NCT03463317|Active Comparator|Best medical care group|No left atrial appendage closure. Treatment with best medical care (NOACs (dabigatran, rivaroxaban, apixaban, edoxaban) or VKA (phenprocoumon, warfarin)
89465431|NCT03462147|Sham Comparator|SHAM|No stimulation will be given
89465432|NCT03462147|Experimental|High Density Stimulation|New way of spinal cord stimulation
89202017|NCT00929955|Active Comparator|Ondansetron|
89202018|NCT00929955|Active Comparator|Simvastatin|
89465433|NCT03462147|Active Comparator|Conventional stimulation|the most used stimulation of the spinal cord
89465434|NCT02906579|Experimental|IW-1973|Placebo taken once daily Day 1-Day 3; 10 mg IW-1973 take once daily Day 4-Day 6; 20 mg IW-1973 taken once daily Day 7-Day 9; 30 mg IW-1973 taken once daily Day 10-Day 12; 40 mg IW-1973 taken once daily Day 13-Day 15; 50 mg IW-1973 taken once daily Day 16-Day 18
89465435|NCT03461913|Active Comparator|normal pregnancy|women at full term healthy pregnancy who underwent elective Cesarean section
89465436|NCT03461913|Active Comparator|pregnancy hypertension|women at full term pregnancy associated with hypertension who underwent elective Cesarean section
89465437|NCT04975347|Experimental|kisspeptin, GnRH, naloxone|Arm Description: IV administration of kisspeptin 112-121; six boluses in two up to 13-hour periods. IV administration of GnRH; two boluses in two up to 13-hour periods. IV administration of naloxone; one bolus and an infusion over an up to 13-hour period.
89465438|NCT03463083|Active Comparator|Bupivacaine dexmedetomidine group|Group 1 (bupivacaine + dexmedetomidine (BD) group); will Receive an epidural study solution of 18 ml of 0.25% of bupivacaine hydrochloride plus 1 ml of dexmedetomidine (1 mcg/kg) plus 1 ml normal saline keeping the total volume of 20 ml in a syringe pump .
89465439|NCT03463083|Active Comparator|Bupivacaine fentanyl group|Group 2 (bupivacaine + fentanyl (BF) group) ; will Receive an epidural study solution of 18 ml of 0.25% bupivacaine plus 2 ml fentanyl (1 mcg/kg) keeping the total volume of 20 ml in a syringe pump .
89465440|NCT04971837|Experimental|Two Visits Including A Test Meal|Separated by a minimum of 4 days.
89465441|NCT04971837|Experimental|Five Visits Not Involving A Test Meal|Separated by a minimum of 14 days.
89465442|NCT04963569||Albumin|Participants enrolled in the ABC Sepsis trial who have been randomised to 5% Human Albumin Solution as the sole resuscitative fluid in the first 6 hours.
89465443|NCT04963569||Balanced Crystalloid|Participants enrolled in the ABC Sepsis trial who have been randomised to Balanced Crystalloid as the sole resuscitative fluid in the first 6 hours.
89465444|NCT01328535|Experimental|Treatment (individualized chemotherapy)|Patients with an established biorhythm receive TMZ PO on recommended day for 5 days. Treatment repeats every 21-42 days until disease progression or unacceptable toxicity. Patients without an established biorhythm receive TMZ PO on days 1-5. Courses repeat every 28 days until disease progression or unacceptable toxicity.
89465445|NCT03129633|Experimental|Promotores Network|Promotores will engage participants using the materials A Page of My Life and the Success Plan. Promotores will ask participants to rank their satisfaction with each of the domains included in the A Page of My Life and ask them what domain they want to change. Using non-directive questions, promotores will guide the participant to draft a plan for success. The promotor/a will follow up with participants within a week of enrollment and at least monthly via phone/text during six months. During the intervention period, promotores will meet with participants (child and parent together, if applicable) at least three times in-person during which they will deliver the short (15-minutes) educational components of the intervention.
89465446|NCT03129633|No Intervention|Wait-list Control|The community liaison will deliver a short (15-minute) educational session on the benefits of a healthy lifestyle and preventive use of health care, and give participants a pamphlet with relevant local health care and social service resources.
89465447|NCT03461679|Experimental|Intervention|Adductor canal block Femoral triangle block
89465448|NCT03461679|Active Comparator|Standard|Femoral triangle block
89465449|NCT03461601|Active Comparator|HCG uterine flushing group|Uterine flushing was done one day before Intrauterine insemination (IUI) with HCG (500 IU) in 10 ml of saline followed by Intrauterine insemination (IUI).
89465450|NCT03461601|Placebo Comparator|IUI alone group|Intrauterine insemination alone plus vaginal flushing with 10 ml normal saline
89465451|NCT03463005|Experimental|Royal jelly|The study subjects included healthy women who had husbands with male-factor infertility problems.
89465452|NCT03463005|Active Comparator|IUI group|The study subjects included in IUI group were healthy women who had husbands with male-factor infertility problems.
89465453|NCT04949061|Experimental|Intervention Arm: Culturally Adapted Cognitive Behavioral Intervention (CA-CBI)|The experimental group will receive an 8-session CA-CBI in an online group format.
89465454|NCT04949061|Other|Control Arm: Enhanced Treatment as Usual (ETA-U)|The control group will receive the information about freely available psychological support options. Also, they will receive brief psychoeducation about the mental health problems and psychological distress via online leaflets. After all the measurements are completed, the control group will be able to receive the CA-CBI.
89465455|NCT02905331|Experimental|Group 1 (Guselkumab: Placebo)|Participants will receive 100 milligram (mg) guselkumab administered as a 100 milligram per milliliter (mg/mL) solution in a single-use prefilled syringe (PFS) assembled in a SelfDose device at Weeks 0, 4, 12, 20, and 28; liquid placebo for guselkumab 100 mg at Week 16 to maintain the study blind.
89465456|NCT02905331|Experimental|Group 2 (Placebo: Guselkumab)|Partcipants will receive placebo at Weeks 0, 4, and 12 followed by guselkumab 100 mg at Weeks 16, 20, and 28.
89465457|NCT02522169|Active Comparator|Conventional treatment|"The patients of the control group undergo Infliximab-maintenance according to the approved dosing scheme, initially with 5 mg/kg body weight Infliximab. Before each administration laboratory parameters will be controlled (Albumin, CrP, Calprotectin) and disease activity scores will be obtained (PCDAI / PUCAI). Infliximab trough levels will be assessed but not have any implication. In the presence of clinical signs of a disease exacerbation and after exclusion of other causes an adjustment of the dosage will follow for the next Infliximab-infusion:~A) interval shortening, or B) Dose increase to 10 mg / kg body weight. With a clinical stable course of the disease without signs of deterioration, the dosage and the eight-week interval will be maintained."
89465458|NCT02522169|Experimental|Intervention Group|Aiming to maintain the therapeutic window of Infliximab a de- or increase of the dose or infusion interval will be carried out for the following administration, provided the patient shows no signs of a clinical worsening. With good trough levels and clinically stable conditions the therapy will be continued without modification until next check-up. In the case of an eminent disease exacerbation Infliximab trough levels and the search for anti - Infliximab antibodies should guide further treatment decisions. With trough levels below the target range antibody testing should be performed.
89465459|NCT04307537|Experimental|pcRUG|Peri-catheter retrograde urethrography
89465460|NCT04307537|Active Comparator|VCUG|Voiding cysto-urethrography
89465461|NCT03656393|Experimental|Gefitinib therapy group|Patients are treated with Gefitinib (250 mg, orally, every day) for 56 days and then have an operation. If there is progress after intervention, Patients are further treated with pemetrexe (500 mg/m2, intravenously drip, once a week) plus cisplatin (75 mg/m2, iv. once a week) for 4 weeks.
89465462|NCT03656393|Active Comparator|Vinorelbine combination therapy group|Patients are treated with vinorelbine (60 mg/m2, orally, Once every three weeks) plus carboplatin (AUC5, intravenously drip, once a week) for 6 weeks and then have an operation. If there is progress after intervention, Patients are further treated with pemetrexe (500 mg/m2, intravenously drip, once a week) plus cisplatin (75 mg/m2, iv. once a week) for 4 weeks.
89202019|NCT00929955|Placebo Comparator|Placebo|
89465463|NCT03656237|Experimental|Usual training + Audits + LDHF training|"Usual training of health workers, in classroom, following standard curriculum~+ Mortality and Morbidity Audits in facility every two weeks followed by LDHF training focused on gaps in knowledge or practice identified during the audits"
89465464|NCT03656237|Experimental|Audits + LDHF training|Mortality and Morbidity Audits in facility every two weeks followed by LDHF training focused on gaps in knowledge or practice identified during the audits
89465465|NCT03656237|Active Comparator|Usual Training|Control Arm exposed to usual training of health workers, in classroom, following standard curriculum
89465466|NCT03656003|Experimental|Procore needle|EchoTip ProCore needle (Cook Medical Inc., Bloomington, Ind., USA)
89465467|NCT03656003|Active Comparator|Conventional needle|Conventional 22-gauge EBUS-TBNA needle (Vizishot, Olympus, Japan)
89465468|NCT02979197|Experimental|Amlodipine+Celecoxib|OE 10 mg amlodipine besylate tablet + OE 200 mg celecoxib capsule qd for 14 days
89465469|NCT02979197|Active Comparator|Amlodipine+Placebo|OE 10 mg amlodipine besylate tablet + matched placebo for OE celecoxib capsule qd for 14 days
89465470|NCT02979197|Sham Comparator|Placebo+Placebo|Matched placebo for OE amlodipine besylate tablet + matched placebo for OE celecoxib capsule qd for 14 days
89465471|NCT02982239|Other|Sleep Intervention|N=20 Participants received fitness tracker, information session, a link to complete a daily sleep diary, intermittent text messages that included adherence reminders, encouraging statements, and tips for improving sleep. Daily monitoring with sleep diaries, daily monitoring of sleep tracker sync activity and regret lottery for 10 weeks
89465472|NCT02982239|Other|Sleep Intervention plus Tech|N=20 Participants received fitness tracker, LED light, Blue-blocking glasses along with information session, a link to complete a daily sleep diary, intermittent text messages that included adherence reminders, encouraging statements, and tips for improving sleep. Daily monitoring with sleep diaries, daily monitoring of sleep tracker sync activity and regret lottery for 10 weeks.
89465473|NCT03655925||Patients with Chronic Heart Failure (CHF)|Entire cohort/ Patients with recent diagnosis of chronic heart failure as defined by the guidelines of the European Society of Cardiology (ESC) and with cardiac ejection fraction <40
89465474|NCT03655535|Experimental|BTI320|4 g BTI320 administered 10 min before breakfast, lunch, and dinner
89465475|NCT03655535|Placebo Comparator|Placebo|Placebo administered 10 min before breakfast, lunch, and dinner
89465476|NCT03654365|Active Comparator|Control|Pts in the control arm receive usual care. Usual care includes a EHR based reminder of single HCV testing for patients who are in the birth cohort. (routine alerting)
89465477|NCT03654365|Experimental|Intervention|Pts in the intervention arm receive bulk messaging and bulk ordering of the HCV ab test.
89465478|NCT03654287||Treatment with CPFA|The critically ill children who treated by CRRT and CRRT mode is decide as CPFA.
89465479|NCT03654287||Treatment with TPE+CVVHDF|The critically ill children who treated by CRRT and CRRT mode is decide as TPE+CVVHDF.
89465480|NCT03654287||Treatment with CVVHDF|The critically ill children who treated by CRRT and CRRT mode is decide as CVVHDF.
89465481|NCT03654287||Treatment without CRRT/ECMO|The critically ill children who are not treated by CRRT or ECMO.
89465482|NCT03654287||Treatment with ECMO|The critically ill children who are treated by ECMO whether treated by CRRT
89465483|NCT03655847|Experimental|Dexmedetomidine|Drug: Dexmedetomidine dexmedetomidine, 0.1ug/kg up or down Other Name: precedex
89465484|NCT03655457|Experimental|group 1 Poractant alfa|Poractant alfa generic name: curosurf 120 and 240 mg flk dosage: 200 mg/ kg intratracheal application frequency and duration: in the first two hours
89465485|NCT03655457|Active Comparator|group 2 beractant|beractant generic name: survanta 8 cc flk dosage: 4 cc/ kg intratracheal application frequency and duration: in the first two hours
89465486|NCT03653975||Nodding syndrome|"I) probable Case of Nodding Syndrom (according to the WHO epidemiologic surveillance case definition) *reported head nodding ** in a previously healthy person with at least 2 major and 1 minor criteria~Major criteria~Age 3 to 18 y at onset of head nodding~Nodding frequency 5 to 20 times per min~Minor criteria~Other neurologic abnormalities~Clustering in space or time with similar cases~Triggering by eating or cold weather~Delayed sexual or physical development~Psychiatric manifestations~As agreed upon at the first International Conference on Nodding Syndrome, Kampala, Uganda, July 2012 (16). ** Repetitive involuntary drops of the head toward the chest on >2 occasions."
89501975|NCT05496608|Active Comparator|L-PRF + CM|Subjects with infrabony defects had full thickness flap reflection and debridement of periodontal lesion followed by application of the L-PRF within the bony defect and coverage with collagen xenogeneic membrane
89018237|NCT04671901|Experimental|Pediatric Participants|Male and female patients aged 1-21 years with a primary solid tumor undergoing treatment with the pre-defined chemotherapy regimens of EFT, MAP or D9803.
89018238|NCT04662281|Placebo Comparator|Placebo|Following a 2-week Single-blind Run-in period, participants will receive a single loading dose of matching-placebo to LX9211 tablet, orally, on Day 1 and maintenance doses, orally, once daily from Day 2 to Week 6.
89018239|NCT04662281|Experimental|LX9211|Following a 2-week Single-blind Run-in period, participants will receive a single loading dose of 200 milligrams (mg) tablet, orally, on Day 1 and maintenance doses of 20 mg, orally, once daily from Day 2 to Week 6.
89018240|NCT04659993||Telemental Group|The virtual group will be conducted within a secure platform such as Microsoft WebEx. Assessments (pre-, post-, mid-way) will be distributed through REDCap, a secure virtual platform, as will session handouts and forms.
89465487|NCT03653975||epilepsy and onchocerciasis|"II) People with epilepsy (PWE) and onchocerciasis (n= 50)~confirmed or suspected generalized and idiopathic epilepsy~confirmed active infection with O. volvulus (microscopy, PCR and serology)~Patients with cardiovascular or renal comorbidities, a history of birth or traumatic brain injuries, psychiatric comorbidities, insecure comprehension of the information given, lacking or withdrawn consent will be excluded."
89465488|NCT03653975||epilepsy, no onchocerciasis|"III) People with epilepsy (PWE) without onchocerciasis (n= 50)~confirmed or suspected generalized and idiopathic epilepsy~excluded active or past infection with O. volvulus (microscopy, PCR and serology)~Patients with cardiovascular or renal comorbidities, a history of birth or traumatic brain injuries, psychiatric comorbidities, insecure comprehension of the information given, lacking or withdrawn consent will be excluded."
89465489|NCT03653975||no epilepsy but onchocerciasis|"IV) Controls with onchocerciasis, otherwise healthy (n= 50)~no evidence for epilepsy or other neurological diseases~confirmed active infection with O. volvulus (microscopy, PCR and serology)~Patients with cardiovascular or renal comorbidities, a history of birth or traumatic brain injuries, psychiatric comorbidities, insecure comprehension of the information given, lacking or withdrawn consent will be excluded."
89465490|NCT03653975||no epilepsy, no onchocerciasis|"V) Healthy Controls without onchocerciasis (n= 50)~no evidence for epilepsy or other neurological diseases~excluded active or past infection with O. volvulus (microscopy, PCR and serology)~Patients with cardiovascular or renal comorbidities, a history of birth or traumatic brain injuries, psychiatric comorbidities, insecure comprehension of the information given, lacking or withdrawn consent will be excluded."
89465491|NCT03653975||controls for Wechsler Nonverbal (WNV)|"Healthy Controls for cognitive assessment only, (n= 750)~no evidence for epilepsy or other neurological diseases no detailled examination on O. volvulus performed~Patients with cardiovascular or renal comorbidities, a history of birth or traumatic brain injuries, psychiatric comorbidities, insecure comprehension of the information given, lacking or withdrawn consent will be excluded."
89465492|NCT03655379|Experimental|Nasal Doppler|Pregnant patients who present with preterm labor will be evaluated with ultrasonography and fetal nasal Doppler will be used to detect specific fetal breathing patterns
89465493|NCT01066793||Cohort|Participants chronically infected with the hepatitis C virus including genotypes 1 to 6
89465494|NCT03985293|Placebo Comparator|Placebo|
89465495|NCT03985293|Experimental|PF-06882961 2.5 milligrams (mg)|
89465496|NCT03985293|Experimental|PF-06882961 10 mg|
89018241|NCT04629716||Intervention|The intervention group will be comprised of adults 50 and older who report severe or chronic pain, are newly registered for the Medical Marijuana Registry in the State of Florida, have no prior history of medical marijuana use, can communicate in English, and are willing and able to complete study procedures. The control group will be age, sex, and race matched. The primary study outcome is simulated driving performance (i.e. errors in response time, attention, and executive functioning tasks that predict on-road performance). Secondary outcomes include adverse effects.
89018242|NCT04629716||Control|The control group will be comprised of adults 50 and older who report severe or chronic pain, have no prior history of medical marijuana use, can communicate in English, and are willing and able to complete study procedures. The control group will be age, sex, and race matched. The primary study outcome is simulated driving performance (i.e. errors in response time, attention, and executive functioning tasks that predict on-road performance). Secondary outcomes include adverse effects.
89202020|NCT00742118|Experimental|2|patient with chronic inflammatory intestinal disease
89465497|NCT03985293|Experimental|PF-06882961 40 mg|Participants will be titrated up to 2 weeks to reach desired dose level
89465498|NCT03985293|Experimental|PF-06882961 80 mg|Participants will be titrated up to 4 weeks to reach desired dose level
89465499|NCT03985293|Experimental|PF-06882961 120 mg|Participants will be titrated up to 6 weeks to reach desired dose level
89465500|NCT03655145|Experimental|Haploidentical donor stem cell transplantation|The stem cell source will be bone marrow for haploidentical transplantation.The bone marrow collection is carried out according to the practice of each centre with a minimal target dose of 3x108 TNC/kg.
89465501|NCT03655145|Active Comparator|HLA 10/10 MUD stem cell transplantation|The stem cell source will be peripheral blood stem cell for HLA-matched unrelated transplantation.Peripheral blood stem cell (PBSC) for HLA-matched unrelated SCT will be mobilized by G-CSF (Neupogen®) administered to the donor from Day-4 to Day-1 subcutaneously (10µg/kg/day) with the minimal target dose of 4.106 CD34+ cells/kg.
89465502|NCT03654911||aMCI subjects|EEG recording, ApoE testing
89465503|NCT03654755|Experimental|ASN002 40 mg|ASN002 40 mg
89465504|NCT03654755|Experimental|ASN002 60 mg|ASN002 60 mg
89465505|NCT03654755|Experimental|ASN002 80 mg|ASN002 80 mg
89465506|NCT03654677|Experimental|inactivated hepatitis A vaccine|Inactivated hepatitis A virus antigen 500U(Name of viral strain: TZ84)
89465507|NCT03654677|Active Comparator|Havrix Inj|1440 ELISA/mL_Adult Inj.(Name of Viral strain: HM175 Inj)
89465508|NCT03468621|Other|Intradermal wound closure|Intradermal wound closure of the groin wound
89465509|NCT03468621|Other|Transdermal wound closure|Wound closure of the groin wound with metal staples
89018243|NCT04612790|Experimental|Benralizumab|"Benralizumab subcutaneously (SC) loading dose followed by repeat dosing of SC benralizumab plus Oral Corticosteroids per SoC tapering.~Open-Label (OLE): after completion of the double-blind treatment period, all participants will have the option of entering an OLE period, starting at week 36 benralizumab SC until study closure."
89018244|NCT04612790|Experimental|Placebo|Placebo plus Oral Corticosteroids per SoC tapering. Open-Label (OLE): after completion of the double-blind treatment period, all participants will have the option of entering an OLE period, starting at week 36 benralizumab SC until study closure.
89018245|NCT04602377|Experimental|Pembrolizumab|Single arm study
89018246|NCT04587869|Experimental|Intervention|The intervention is an 8-session cognitive behavior therapy (CBT) group intervention that addresses coping with discrimination and medical mistrust among Black sexual minority men (SMM).
89465510|NCT03653897|Experimental|ID-Capsules- Active|Subjects will ingest ID-Capsules containing the ingestible sensor which emits a signal from within the subject's stomach. This signal is detected by the wearable Reader, and the ingestion event is recorded.
89465511|NCT03462849|Other|Patients with EFL at PEP 5|Patients with EFL at PEP 5 at the time of inclusion either in supine or semi-recumbent position
89465512|NCT03462849|Other|Patients with no EFL at PEP 5|Patients with no EFL at PEP 5 at the time of inclusion in both supine and semi-recumbent positions
89465513|NCT02980601|Experimental|Integra and a Split Thickness Skin Graft (STSG)|A sheet of Integra directly on the wound bed with subsequent removal of the overlying silicone sheet and immediate application of a 0.008mm STSG.
89465514|NCT02980601|Active Comparator|Split Thickness Skin Graft (STSG)|reconstruction as dictated by the protocol. They will either receive 1) a 0
89465515|NCT03462771|Experimental|Group exercise fish oil|Using the Randomizer Research program, 15 elderly women will participate in a resistance exercise protocol and receive omega-3 fatty acid supplements to be ingested 2g in the main meals, totaling 4g daily.
89465516|NCT03462771|Placebo Comparator|Group exercise placebo|Using the Randomizer Research program, 15 elderly women will participate in a resistance exercise protocol and receive sunflower oil to be ingested 2g in the main meals, totaling 4g daily.
89465517|NCT04453371|Experimental|Study group|Thrombolysis
89465518|NCT04453371|Placebo Comparator|Control group|Ringer's solution infusion
89465519|NCT03461133||Reference|All patients admitted to the participating surgical wards from 2015-01-01 to 2015-12-31
89465520|NCT03461133||Intervention|All patients admitted to the participating surgical wards from 2016-07-01 to 2017-06-30
89018247|NCT04587869|No Intervention|No-treatment control|Participants who are assigned to the control group will not receive the intervention.
89018248|NCT04581902|Experimental|Morning rTMS treatment|Eligible participants will be assigned to the afternoon treatment group. Prior to the onset of rTMS treatment, EEG scans and magnetic resonance imaging (MRI) sessions including diffusion weighted imaging will be recorded as baseline measures. These measures will also be repeated at treatment midpoint and within one month of rTMS discontinuation in order to track structural and functional changes that occur over the course of treatment. Participants will complete an initial screening followed by 30-40 daily sessions of repetitive transcranial magnetic stimulation (rTMS) to the dorsolateral prefrontal cortex (DLPFC), completed with their TMS provider.
89018249|NCT04581902|Experimental|Afternoon rTMS treatment|Eligible participants will be assigned to the afternoon treatment group. Prior to the onset of rTMS treatment, EEG scans and magnetic resonance imaging (MRI) sessions including diffusion weighted imaging will be recorded as baseline measures. These measures will also be repeated at treatment midpoint and within one month of rTMS discontinuation in order to track structural and functional changes that occur over the course of treatment. Participants will complete an initial screening followed by 30-40 daily sessions of repetitive transcranial magnetic stimulation (rTMS) to the dorsolateral prefrontal cortex (DLPFC), completed with their TMS provider.
89018250|NCT04579380|Experimental|Tucatinib + Trastuzumab (+ Fulvestrant)|Tucatinib + trastuzumab (+ fulvestrant in hormone-receptor positive HER2-mutant breast cancer only)
89018251|NCT04574024|Experimental|Cohort A: Treatment with NBT-NM108�|Patients will receive NBT-NM108 at 60 g/day for 8 weeks.
89465521|NCT03654521|Active Comparator|Diabetes group|Women with gestational or pre-gestational diabetes mellitus.
89465522|NCT03654521|Active Comparator|Control group|Women without gestational or pre-gestational diabetes mellitus.
89465523|NCT03462693||Group 1|Dry needling plus standard physiotherapy treatment
89465524|NCT03462693||Group 2|Standard physiotherapy treatment
89465525|NCT03462537|Experimental|Experimental group 1|This group performed aerobic exercise just after low level laser therapy in the abdominal region with eight electrodes distributed in line.
89465526|NCT03462537|Experimental|Experimental group 2|This group performed aerobic exercise just after low level laser therapy in the abdominal region with eight electrodes distributed in line, but low level laser therapy device was switched off.
89465527|NCT03462537|Placebo Comparator|Placebo group|Low level laser therapy without power. This group performed the low level laser therapy protocol, but low level laser therapy device was switched off.
89465528|NCT03461055|Experimental|Lavender|Lavandula angustifolia aromatherapy. 1 drop on a cotton ball placed in a porous pouch. Given to patients at the time of their intrauterine insemination.
89465529|NCT03461055|Placebo Comparator|Water|1 drop of water on a cotton ball placed in a porous pouch. Given to patients at the time of their intrauterine insemination.
89465530|NCT03462381|Experimental|Protein|Three endurance training sessions weekly with protein supplementation post-exercise and before sleep.
89465531|NCT03462381|Placebo Comparator|Carbohydrate|Three endurance training sessions weekly with carbohydrate supplementation post-exercise and before sleep.
89465532|NCT04928157|Experimental|CPAP|Use of CPAP, a device used with a nose or face mask which delivers airflow/pressure into the airway, holding the airway open and keeping it from collapsing. Device will be used for 8 weeks.
89465533|NCT04928157|No Intervention|Control|No CPAP use, otherwise usual care
88945699|NCT01900587|Experimental|Tapentadol Extended release (ER) TRF then tapentadol ER PR2|Single dose of tapentadol ER 50 milligram (mg), tamper-resistant formulation (TRF) tablet will be administered under fasted condition in first treatment period; after that in second treatment period, single-dose of tapentadol ER 50 mg, prolonged released (PR2) tablet will be administered under fasted condition. A washout period of 7 to 14 days will be maintained between each treatment period.
89465534|NCT03462303|Placebo Comparator|tDCS sham + balanced drink|
89465535|NCT03462303|Experimental|tDCS sham + tyrosine depleted drink|
89465536|NCT03462303|Experimental|tDCS anodal + balanced drink|
89465537|NCT03462303|Experimental|tDCS anodal +tyrosine depleted drink|
89465538|NCT02980523|Experimental|PRO-157 BID (2 times per day)|"60 eyes of 30 research subjects will be evaluated with the following therapeutic regimen:~instill one drop in each eye of PRO-157 (pazufloxacin), every 12 hours per day (BID), for 7 days~instill one drop in each eye of Lagricel Ofteno® (Sodium hyaluronate 0.4%)every 6 hours per day, for 7 days. (Can be applied 15 minutes after PRO 157)"
89465539|NCT02980523|Experimental|PRO-157 TID (3 times per day)|"60 eyes of 30 research subjects will be evaluated with the following therapeutic regimen:~instill one drop in each eye of PRO-157 (pazufloxacin), every 8 hours per day (TID), for 7 days~15 minutes after, instill one drop in each eye of Lagricel Ofteno® (Sodium hyaluronate 0.4%) every 6 hours per day, for 7 days. (Can be applied 15 minutes after PRO 157)"
89465540|NCT02980523|Experimental|PRO-157 QID (4 times per day)|"60 eyes of 30 research subjects will be evaluated with the following therapeutic regimen:~instill one drop in each eye of PRO-157 (pazufloxacin), every 6 hours per day (QID), for 7 days~15 minutes after, instill one drop in each eye of Lagricel Ofteno® (Sodium hyaluronate 0.4%) every 6 hours per day, for 7 days. (Can be applied 15 minutes after PRO 157)"
89465541|NCT02980523|Active Comparator|Moxifloxacin (Vigamox®)|"60 eyes of 30 research subjects will be evaluated with the following therapeutic regimen:~instill one drop in each eye of Moxifloxacin, every 8 hours per day, for 7 days.~15 minutes after, instill one drop in each eye of Lagricel Ofteno® (Sodium hyaluronate 0.4%) every 6 hours per day for 7 days. (Can be applied 15 minutes after moxifloxacin)"
89465542|NCT02980523|Active Comparator|Gatifloxacin (Zymar®)|"60 eyes of 30 research subjects will be evaluated with the following therapeutic regimen:~instill one drop in each eye of Gatifloxacin, every 8 hours per day, for 7 days.~15 minutes after, instill one drop in each eye of Lagricel Ofteno® (Sodium hyaluronate 0.4%) every 6 hours per day for 7 days.one drop 4 times a day for 7 days in each eye.(Can be applied 15 minutes after gatifloxacin)"
88945700|NCT01900587|Experimental|Tapentadol ER PR2 then tapentadol ER TRF|Single dose of tapentadol ER 50 milligram (mg), PR2 tablet will be administered under fasted condition in first treatment period; after that in second treatment period, single-dose of tapentadol ER 50 mg, TRF tablet will be administered under fasted condition. A washout period of 7 to 14 days will be maintained between each treatment period.
88945701|NCT01900600|Placebo Comparator|Placebo|Placebo
88945702|NCT01900600|Active Comparator|Canakinumab 50 mg quarterly|Canakinumab 50 mg quarterly
89202021|NCT00742118|Other|3|patient having no symptoms
88945703|NCT01900600|Active Comparator|Canakinumab 150 mg quarterly|Canakinumab 150 mg quarterly
88945704|NCT01900600|Active Comparator|Canakinumab 300 mg quarterly|Canakinumab 300 mg quarterly
88945705|NCT01900613|Experimental|Intervention|Niños Sanos Familia Sana consists of CBPR developed nutrition education and economic vouchers for fruit and vegetable purchase in Firebaugh supermarket
88945706|NCT01900613|Active Comparator|Comparison|Comparison community of San Joaquin
88945707|NCT01900639|Active Comparator|aspirin on awakening|intake of 80 acetylsalicylic acid on awakening for 2 weeks
89202022|NCT00742118|Experimental|1|patient with irritable bowel syndrome
89202023|NCT03873012||OCT-guided group|OCT-guided PCI with EES or BES
89202024|NCT03873012||Angiography-guidance group|Angio-guided PCI with EES or BES
89202025|NCT00742196||1|No parapapillary atrophy
89465543|NCT03468465|Experimental|Medical device: Transcutaneous electrical neurostimulation|Medical device 4 weeks with daily sessions of 30 minutes
89465544|NCT03468465|Active Comparator|Solifenacin|10 mg tablet daily during 75 days maximum
89465545|NCT03460821||Employees|Male and female employees (≥ 18 years of age) of the Department of Anesthesiology and Operative Intensive Care Medicine (CCM, CVK), Charité Universitätsmedizin Berlin experienced in the field of neurocognitive testing: residents, specialist physician for anesthesiology, senior physicians, medical students engaged in research projects
89465546|NCT04939233|Experimental|Exoskeleton Glove|Perform a feasibility trial of the robotic orthosis device by providing it to a small cohort of adult patients suffering from paralysis due to a brachial plexus injury.
89465547|NCT03460743|Experimental|Study group|single or two doses of quadrivalent recombinant 180 ugm hemagglutinin influenza vaccine
89465548|NCT03460743|Active Comparator|Control group|single or two doses of quadrivalent inactivated influenza vaccine.
89465549|NCT02980133|Placebo Comparator|Placebo MDPI|Participants received matching placebo via multidose dry powder inhaler (MDPI) for 12 weeks.
89465550|NCT02980133|Experimental|Fp MDPI 25 mcg BID|Participants received 1 inhalation of 25 mcg fluticasone propionate (Fp) via MDPI twice daily (BID) (total daily dose: 50 mcg) for 12 weeks.
89465551|NCT02980133|Experimental|Fp MDPI 50 mcg BID|Participants received 1 inhalation of 50 mcg fluticasone propionate via MDPI BID (total daily dose: 100 mcg) for 12 weeks.
88945708|NCT01900639|Experimental|aspirin at bedtime|intake of 80mg acetylsalicylic acis at bedtime
88945709|NCT01900678|Experimental|VytronUS Ablation System|Treatment with the VytronUS Ablation System.
88945710|NCT01900717|Active Comparator|chimiotherapy alone|"LV5FU2 simplified,~5-fluorouracil/leucovorin with oxaliplatin 4 (FOLFOX) simplified,~fluorouracil, leucovorin, and irinotecan(FOLFIRI) modified."
88945711|NCT01900717|Experimental|chemiotherapy + bevacizumab 5 mg/kg/ 2 weeks|"LV5FU2 simplified,~FOLFOX 4 simplified,~FOLFIRI modified.~Bevacizumab 5 mg/kg/ 2 weeks"
89202026|NCT00742196||2|Parapapillary atrophy
89202027|NCT00784914|Active Comparator|Cohort 1|Patients do not receive temsirolimus.
89202028|NCT00784914|Experimental|Cohort 2|48 hours after surgery, patients receive one 200 mg dose of temsirolimus IV.
89202029|NCT04060238||Normal colour vision|Normal trichromopsia
89202030|NCT04060238||Inherited red blindness|Protanopia
89465552|NCT02980133|Experimental|FS MDPI 50/12.5 mcg BID|Participants received 1 inhalation of 50/12.5 mcg fluticasone propionate/salmeterol (FS) via MDPI BID (total daily dose: 100/25 mcg) for 12 weeks.
89465553|NCT03460665|Experimental|Microparticles|arteriography and an injection of inert microparticles of 75 µm in neovessels
89465554|NCT03460665|Placebo Comparator|Placebo|knee arteriography and injection of saline solution in neovessels
89465555|NCT03654443|Experimental|Group Painful stimulus|The CPOT tool is administered in a crossover manner in Group one prior to a painful stimulus (IT0), during the painful stimulus (IT1) and soon afterwards (IT2)
89465556|NCT03654443|Experimental|Group Non-painful stimulus|The CPOT tool is administered in a crossover manner in Group one prior to a non-painful stimulus (IIT0), during the painful stimulus (IIT1) and soon afterwards (IIT2)
89465557|NCT04867161||Patients with COVID-19 pneumonia without superinfection|Patients with confirmed COVID-19 pneumonia not fulfilling criteria for diagnosis HAP/VAP (International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia )
89465558|NCT04867161||Patients with COVID-19 pneumonia with superinfection|Patients with confirmed COVID-19 pneumonia fulfilling criteria for diagnosis HAP/VAP (International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia )
89465559|NCT03653819|Other|HIIT + compression|2 sessions of High Intensity Interval Training (HIIT) on a stationary bike. First exercise session with compression garments/second without.
89465560|NCT03653819|Other|HIIT - compression|2 sessions of High Intensity Interval Training (HIIT) on a stationary bike. First exercise session without compression garments/second with
89465561|NCT03653663|Placebo Comparator|Placebo|8 weeks treatment with placebo (or until muscle symptoms appear for at least 1 week or are unbearable)
89465562|NCT03653663|Active Comparator|20 mg simvastatin|8 weeks treatment with 20 mg simvastatin daily (or until muscle symptoms appear for at least 1 week or are unbearable)
89465563|NCT02521857|Experimental|ALKS 5461|Sublingual tablet
89465564|NCT03468387|Active Comparator|Primary realignment|
89465565|NCT03468387|Active Comparator|Suprapubic cystostomy|
89465566|NCT03460509|Placebo Comparator|Sugammadex 0 mg/kg|Placebo NaCl 0,9%
89465567|NCT03460509|Active Comparator|Sugammadex 0,25 mg/kg|Sugammadex 0.25 mg/kg IBW
89465568|NCT03460509|Active Comparator|Sugammadex 0,5 mg/kg|Sugammadex 0.50 mg/kg IBW
89465569|NCT03460509|Active Comparator|Sugammadex 1mg/kg|Sugammadex 1.0 mg/kg IBW
89465570|NCT03460509|Active Comparator|Sugammadex 2mg/kg|Sugammadex 2 mg/kg IBW
88945712|NCT01900743|Experimental|Arm A|Regorafenib (160 mg/d) once daily for 3 weeks on / 1 week off plus Best Supportive Care (BSC) until progression (according to RECIST 1.1), intolerance or consent withdrawal.
88945713|NCT01900743|Placebo Comparator|Arm B|Placebo plus BSC until progression (according to RECIST 1.1) or unacceptable toxicity. Patients who have received placebo may be offered open-label regorafenib (cross-over option) after objective tumor progression
89465571|NCT03879915||Prospective Dental Implant placement|Patients prospectively included and treated following current recommendations
89465572|NCT03879915||Retrospective Dental Implant placement|Patients retrospectively included, that did not benefit from current recommendations
89465573|NCT03460431|Experimental|fractional CO2 laser 10,600nm|fractional CO2 laser 10,600nm one session every month for 4 months
89465574|NCT03460431|Experimental|Nd YAG laser 1064nm|Nd YAG laser 1064nm
89465575|NCT03460431|Experimental|combined two laser types|combined fractional CO2 laser 10,600nm and Nd YAG laser 1064nm lasers treatment to keloid
88945714|NCT01900756|Active Comparator|Behavioral|"Pre-appointment phone text~In-clinic educational video~Patient report card~Post-clinic phone text~Outpatient stroke registry"
88945715|NCT01900756|No Intervention|Standard care|Routine and customary management.
88945716|NCT01900769|Experimental|Blood Volume Dilution|
88945717|NCT01900782|Experimental|Dosing Regimen 1|Subcutaneous injection
88945718|NCT01900782|Active Comparator|Active Comparator|Subcutaneous injection
88945719|NCT01900782|Placebo Comparator|Placebo|Subcutaneous injection
88945720|NCT01900782|Experimental|Dosing Regimen 2|Subcutaneous injection
88945721|NCT01900795|Experimental|V117957|
88945722|NCT01900795|Active Comparator|Ibuprofen|
88945723|NCT01900795|Placebo Comparator|Placebo|
88945724|NCT01900808||Patients with chronic liver disease|
88945725|NCT01900821||Women|All women having mammograms
88945726|NCT01900834||All participants|
88945727|NCT01900860|Active Comparator|vitamin D 10,000 IU|Subjects in this arm receive 10,000 IU Vitamin D p.o. (as 5 drops of a blinded vitamin D solution) per day. Duration: 3 years
88945728|NCT01900860|Active Comparator|Vitamin D 4000 IU|Subjects in this arm receive 4,000 IU Vitamin D p.o. (as 5 drops of a blinded vitamin D solution) per day. Duration: 3 years
88945729|NCT01900860|Active Comparator|Vitamin D 400 IU|Subjects in this arm receive 400 IU Vitamin D p.o. (as 5 drops of a blinded vitamin D solution) per day. Duration: 3 years
88945730|NCT01900873|Experimental|Inspiratory Muscle Strength Training|High intensity inspiratory muscle training
88945731|NCT01900873|Sham Comparator|Inspiratory Muscle Endurance Training|Sham inspiratory muscle training at low intensity
88945732|NCT01900886||Pegasys, injection subcutaneous|Hepatitis C Virus (HCV) patients monoinfected or coinfected, all genotypes, treatment naive to Peginterferon alfa-2a and Ribavirin (RBV)
88945733|NCT01900912|Experimental|CLTS communities|Assigned to a community led total sanitation (CLTS) intervention, carried out by the government with support from Unicef (n=60 communities). The CLTS intervention includes a triggering session facilitated by the government to encourage community members to build their own latrines and stop open defecation. Regular monitoring is conducted by government program staff until the community is declared open defecation free.
88945734|NCT01900912|No Intervention|Rural communities|No intervention will be delivered (n=61 communities)
88945735|NCT01900925|Active Comparator|Low back treatment only (pragmatic)|"advise to stay active,~discourage bed rest,~appropriate medication use,~reassurance.~Short term use of manipulation/medication,~supervised exercise,~cognitive behavioral therapy,~multidisciplinary treatment,~termination of use of modalities."
89465576|NCT04452903|Experimental|Reassurance intervention|The physiotherapist in the intervention group (n=15) will participate in a 3-hour communication skill workshop, followed by a month-long period to assimilate and implement the new set of skills, with supervision available by phone from the trainers.
89465577|NCT04452903|No Intervention|Control|The physiotherapist in the control group (n=15) receives no training.
89465578|NCT02979431|Experimental|ALX-0171 3.0 mg/kg|Inhalation of ALX-0171 3.0 mg/kg once daily for 3 consecutive days
89465579|NCT02979431|Experimental|ALX-0171 6.0 mg/kg|Inhalation of ALX-0171 6.0 mg/kg once daily for 3 consecutive days
89465580|NCT02979431|Experimental|ALX-0171 Dose 9.0mg/kg|Inhalation of ALX-0171 9.0 mg/kg once daily for 3 consecutive days
89465581|NCT02979431|Placebo Comparator|Placebo|Inhalation of Placebo once daily for 3 consecutive days
89465582|NCT03460275|Other|single group|Osimertinib Mesylate Tablets 80 mg, one time a day until disease progression
89465583|NCT03653585||Lesion negative hemisphere in Healthy Controls (HC)|Data grouped as an un-lesioned primary sensorimotor cortical hemisphere in age and sex matched healthy voluntary participants
89465584|NCT03653585||Lesion negative hemisphere in patients (PT-N)|Data grouped as an un-lesioned primary sensorimotor cortical hemisphere in MS patients
89465585|NCT03653585||Lesion positive hemisphere in patients (PT-P)|"Lesion positive hemisphere in patients:~Data grouped as a lesioned primary sensorimotor cortical hemisphere in MS patients"
89465586|NCT03468231|Active Comparator|Sorafenib plus HAIC of FOLFOX|Sorafenib combined with Hepatic arterial infusion chemotherapy with Oxaliplatin, Fluorouracil and Leucovorin
89465587|NCT03468231|Experimental|Sorafenbi plus HAIC of OXA|Sorafenib combined with Hepatic arterial infusion chemotherapy with Oxaliplatin
89465588|NCT03652883|Experimental|ItFits-toolkit|A generic 'Integrated Theory-based Framework for Implementation Tailoring Strategies' toolkit (the ItFits-toolkit) functions as an online self-help toolkit by which users are guided through the process of tailoring site-specific implementation strategies. The ItFits-toolkit includes four modules that implementers need to work through: 1) identifying and prioritising implementation goals and determinants of practices, 2) matching up implementation determinants to strategies, 3) designing a plan for carrying out strategies in a local context, and 4) applying strategies, and reviewing progress. In each of these four modules, evidence-informed materials such as iCBT relevant determinants of practices and implementation strategies, are included as well as methods for engaging with stakeholders.
89465589|NCT03652883|Active Comparator|Implementation as Usual|Implementation-as-Usual (IAU) refers to any existing approaches and efforts to embed and integrate iCBT within an organisation. All implementation sites included in IMA are engaged in and conducting IAU. IAU activities can be, but are not necessarily planned or guided by scientific evidence and often emerge from practice experiences and other sources of information. No standardisation in IAU across the sites is applied except for the implementation objective. That is, all implementation sites pursue the goal of increasing the number of patients treated by the iCBT service.
89465590|NCT03468153|Experimental|CAR-T cell therapy|Patient-derived dual specificity CD19 and CD22 CAR-T
89465591|NCT03653195|Other|Pre-injury|Each participant will act as their own control. Pre-injury samples were collected.
89465592|NCT03653195|Active Comparator|Post-injury|Post-injury samples were collected at the same time and within 72 hours of injury.
89465593|NCT03460041|Placebo Comparator|Control|
89465594|NCT03460041|Active Comparator|Magnesium|
89018252|NCT04574024|Placebo Comparator|Cohort B: Non-treatment|Patients will not receive NBT-NM108.
89465595|NCT03460041|Active Comparator|Dexmetedomedine|
89465596|NCT03459885|Experimental|PAS|The intervention is given to peripheral nerve - motor cortex pairs selected by the investigator.
89465597|NCT03622151|Experimental|Intervention group|Primer la Llar Program (housing first model): to live in permanent and individual housing and receiving weekly visits from a multidisciplinary team.
89465598|NCT03622151|No Intervention|Control group|"Treatment as usual:~attention from the resources of the homeless network in Barcelona."
89465599|NCT02522013|Experimental|Aminophylline group|IV injection of aminophylline
89465600|NCT02522013|Placebo Comparator|isotonic saline group|IV injection of isotonic saline group
89465601|NCT03459573|Active Comparator|T2D: One Drop with Fitbit Ionic|
89465602|NCT03459573|Active Comparator|T2D: One Drop without Fitbit Ionic|
89465603|NCT03459573|No Intervention|T2D: Waitlist Control|
89465604|NCT03459573|Active Comparator|T1D: One Drop with Fitbit Ionic|
89465605|NCT03459573|Active Comparator|T1D: One Drop without Fitbit Ionic|
89465606|NCT03459573|Active Comparator|PD: One Drop with Fitbit Charge 2|
89465607|NCT03459573|Active Comparator|PD: One Drop without Fitbit Charge 2|
89465608|NCT02978417|Active Comparator|Vivitrol|All drug court clients in the pilot RCT will receive standard psychosocial treatment for opioid dependence from FHR as part of their drug court program participation. Participants randomized to Vivitrol® will receive standard treatment along with monthly Vivitrol® injections administered by study staff at outpatient visits. Vivitrol® is naltrexone for extended-release injectable suspension. It is an injectable suspension containing 380 mg of naltrexone in a microsphere formulation and 4 mL diluent. The recommended dose of Vivitrol® is 380 mg delivered intramuscularly every 4 weeks or once a month. The injection should be administered by a healthcare provider as an intramuscular (IM) gluteal injection, alternating buttocks for each subsequent injection (see Links section of PRS for more information about Vivitrol).
89465609|NCT02978417|Active Comparator|Oral naltrexone|Subjects randomized to oral naltrexone in addition to standard psychosocial treatment for opioid dependence from FHR as part of their drug court program participation. Oral naltrexone is the daily tablet formulation naltrexone that carries the same risks and benefits as the long-acting injectable formulation (Vivitrol®), except it does not have any of the risks related to injection (discomfort, potential for infection). Oral naltrexone is administered and provided by FHR to interested and eligible clients as part of the range of their usual care services.
89465610|NCT03459183|Experimental|Infrasound - verum|In this condition, participants are exposed with non-audible infrasound from the Infrasound (85dB; 6Hz) source, for 8 constant hours during their night sleep. The source is placed close to the participant's bed (approximately 1-2 meters).
89018253|NCT04573205|Experimental|> 50 years|"Healthy individuals > 50 years of age divided into age groups 50-59 years, 60-69 years and >70 years, approximately 20 participants in each group.~Vaccinated with 4 doses FSME immune Adult intramuscular injection according to the recommended primary vaccine Schedule in Sweden for individuals > 50 years of age, at time 0, 1, 2 and 7 months."
89465611|NCT03459183|Placebo Comparator|Infrasound - placebo|In this condition, participants are not exposed to any sound. The infrasound dummy source is placed close to the participant's bed, exactly like in the Infrasound - verum condition (1-2 meters). The Infrasound dummy source looks exactly like the active infrasound source but produces no sound at all. Participants are told that this source emits sound for 8 constant hours during their night sleep.
89465612|NCT03459183|Experimental|Ultrasound - verum|In this condition, participants are exposed to non-audible ultrasound, emitted by the Ultrasound (10dB below hearing threshold; 22.4 kHz) source for 8 constant hours during their night sleep. The source is placed close to the participant's bed (1-2 meters), at the level of the participant's head (for instance on a nightstand).
89465613|NCT03459183|Placebo Comparator|Ultrasound - placebo|In this condition, participants are not exposed to any sound. The Ultrasound dummy source is placed close to the participant's bed, exactly like in the Infrasound - verum condition (1-2 meters). The Ultrasound dummy source looks exactly like the active ultrasound source, but produces no sound at all. Participants are told that this source emits sound for 8 constant hours during their night sleep.
89465614|NCT03458637|Experimental|LITE Program with usual care.|LITE Program with usual care. LITE program involves four x 180 min weekly sessions, followed by three x 90 min monthly sessions, for adolescents and parents. The key aspects covered in the LITE program are in keeping with Health Promotion Board guidelines for the management of overweight and obesity and include healthy food choices and eating patterns, increasing physical activity and reducing sedentary behavior. The parenting aspects aim to support and increase parental capacity to implement and maintain the lifestyle changes.
89465615|NCT03458637|Active Comparator|Usual Care|Usual care consisting of Weight management clinic consultation at baseline randomization, 3 and 6 months post randomization in a tertiary setting in KK Hospital. Duration of treatment is 6 months. Qualified pediatrician, trained in screening for causes and medical complications of obesity in children, runs the weight management clinic and review the participant at each visit. Optional physical activity, dietary consultation at each weight management clinic visit.
89465616|NCT03458559|Active Comparator|Radium-223-chloride|Radium-223-chloride 50kBg/kg, every 4 weeks intravenously, for a total of 6 administrations.
89465617|NCT03458559|Experimental|Rhenium-188-HEDP|Rhenium-188-HEDP 40MBq/kg, every 8 weeks intravenously, for a total of 3 administrations.
89465618|NCT02522091|Other|young healthy volunteers (18-44 years old)|young healthy volunteers (18-44 years old)
89465619|NCT02522091|Other|healthy volunteers (45-69 years old)|healthy volunteers (45-69 years old)
89465620|NCT02522091|Other|Mild Cognitive Impairment Patients|Mild Cognitive Impairment Patients
89465621|NCT02522091|Other|Alzheimer's Disease patient|Alzheimer's Disease patient
89465622|NCT02522091|Other|old healthy volunteers (70+ years old)|old healthy volunteers (70+ years old)
89465623|NCT04644549||Subjects with CLN6 Batten disease|
89465624|NCT04644549||Subjects with juvenile CLN3 Batten disease|
89465625|NCT03458169|Experimental|LEAP usability|"Therapist LEAP session feedback~Participant LEAP session feedback~LEAP risk control validation"
89465626|NCT03457623|Experimental|Innovative supported|In addition to usual care, patients benefit from connected tools (overpoise, sphygmomanometer...), physical activity, a strong accompaniment with a referent person
89465627|NCT03457623|No Intervention|conventional supported|Patients benefit from usual care
89465628|NCT03457467|Experimental|SBRT+apatinib group|Apatinib mesylate tablets: 500mg / day, 28 days / cycle, follow-up to the progress of the disease, toxicity intolerable or patients require withdrawal; SBRT: according to the different treatment sites given the corresponding dose: 1200cGy × 4 times or 800cGy × 7 times, or according to the specific situation dose adjustment.
89465629|NCT03130335|Experimental|Bone Marrow Aspirate (BMA) Injection|
89465630|NCT03456297|Experimental|Experimental cluster|The Web-based clinical pedagogy program (WCP) will be provided to the participants in the experimental cluster.
89465631|NCT03456297|No Intervention|Control cluster|The participants in the control cluster will receive the current face-to-face preceptorship course.
89465632|NCT05191875|Experimental|group 1 of stage I|14-day therapy：Saccharomyces boulardii. 500mg b.i.d
89465633|NCT05191875|No Intervention|group 2 of stage I|Observe for one month before treatment
89465634|NCT05191875|Other|stage 2|14-day therapy：Ilaprazole. 5mg b.i.d Doxycycline. 0.1g b.i.d Furazolidone. 0.1g b.i.d Colloidal Bismuth Tartrate . 220mg b.i.d
89465635|NCT03454971|Experimental|MinOS arm|Patients are followed according to MinOS protocol:
89465636|NCT04475679|Experimental|Adhese Universal DC|
89018254|NCT04573205|Active Comparator|< 40 years|Healthy individuals < 40 years of age. Vaccinated with 3 doses FSME immune Adult intramuscular injection according to the standard recommended primary vaccine at time 0, 1, and 7 months.
89018255|NCT04573140|Experimental|Phase I adult (Stratum 1)|A maximum of 28 adult patients will be enrolled in dose-escalation study using the BOIN design with an initial embedded accelerated titration design (ATD).
89465637|NCT04475679|Active Comparator|Adhese Universal|
89465638|NCT04435041||Remote assessment tools|Qualitative methods: semi-structured interviews for approx 40 front line clinical practitioners
89465639|NCT04435041||RECAP early warning score|Development of disease specific early warning score, building on earlier work through literature review and NEWS2 score
89465640|NCT04435041||Implementation/Scale up case studies|Study of implementation and scale up of remote-by-default at four different UK sites
89465641|NCT04435041||Infrastructure strengthening|Theory and data driven change effort involving policymakers, regulators, professional bodies, industry, patients and citizens with a view to overcoming interacting issues impacting success of digital projects.
89465642|NCT03467607|Active Comparator|3ml/kg|15 patients ventilated with 3ml/kg ideal body weight while on one lung ventilation
89465643|NCT03467607|Active Comparator|4ml/kg|15 patients ventilated with 4ml/kg ideal body weight while on one lung ventilation
89465644|NCT03467607|Active Comparator|control|15 patients ventilated using the anaesthetists usual ventilation strategy
89465645|NCT04370145|Experimental|moderate cholangitis|Meropenem injection, iv. drip,20mg/Kg，Q12h; Tinidazole injection, iv. drip,20mg/Kg,Qd.
89465646|NCT04370145|Experimental|severe cholangitis|Meropenem injection, iv. drip,20mg/Kg，Q8h; Teicoplanin injection, iv. drip,10mg/Kg,Qd; Tinidazole injection, iv. drip,20mg/Kg,Qd.
89465647|NCT04370145|Active Comparator|control group|Sulperazon, iv.,drip,100mg/Kg,Bid; Tinidazole injection, iv. drip,20mg/Kg,Qd
89465648|NCT03453723|Experimental|magic glove hypnosis|Magic glove hypnosis technique use before propofol infusion
89465649|NCT03453723|Active Comparator|lidocaine|extemporaneous mixture with lidocaine for propofol infusion
89465650|NCT03634683|Experimental|LioCyx|"This is a single-arm study.~Patients will receive escalating doses of LioCyx on Day 1, Day 8, Day 15 and Day 22 of the first 28-day treatment cycle, followed by every 2-week dosing on Day 1, Day 15, Day 29 and Day 43 of repeated cycle. A 21-day treatment break will be given between each cycle."
89465651|NCT03452787||Boston Puerto Rican Health Study (NCT01231958)|40 with CC and 40 with TT genotypes at APOA2 rs5082. Participants of each genotype will be further divided into two subgroups based on SFA intake: low, <22 grams/day, high, ≥22 grams/day.
89465652|NCT03452787||GOLDN (NCT00083369)|107 participants with CC genotype and 272 with TT genotype for APOA2 rs5082.
89465653|NCT03452787||Framingham Heart Study (NCT00005121)|73 with CC and 170 with TT genotypes at APOA2 rs5082. Participants of each genotype will be further divided into two subgroups based on SFA intake: low, <22 grams/day, high, ≥22 grams/day.
89465654|NCT04774965|Experimental|Slumber Curve Group|Patients receiving Slumber Curve sleep aid for management of pain and sleep quality following rotator cuff repair.
89465655|NCT04774965|No Intervention|Normal Sleep Routine Group|Patients not receiving sleep aid.
89465656|NCT03452709|No Intervention|Control group: no intervention|Only the normal practise
89465657|NCT03452709|Experimental|therapeutic exercise|In this group the intervention is the prescription of physical activity. The duration of the groups is planned to be from 12 weeks with 3 programmed sessions per week.
89465658|NCT03452709|Experimental|ABPM|In this group the arterial pressure is evaluated with ABPM.
88945736|NCT01900925|Experimental|LBP treatment and Hip treatment|Group two will receive the same pragmatically applied, guideline-oriented treatment that is recommended from group 1. In addition, group 2 will receive prescriptive hip exercises that include 1) Clam Abduction exercises in sidelying, 2) Hip extension in quadruped, 3) a unilateral bridge, and the manual therapy treatment techniques of; 1) anterior to posterior mobilization of the hip with distraction, 2) long axis distraction of the hip and 3) posterior-anterior mobilization of the hip in prone.26 (See Appendix A for photos of the techniques and descriptions)
89465659|NCT03452709|Experimental|therapeutic exercise + ABPM|
89465660|NCT03577119|Experimental|Full-fat yogurt|Participants will receive a 21-day controlled diet that includes three daily servings of whole (3.25% fat) yogurt (38% of energy from fat, 44% of energy from carbohydrates, and 18% of energy from protein).
89465661|NCT03577119|Experimental|Non-fat yogurt (Control)|Participants will receive a 21-day controlled diet that includes three daily servings of fat-free yogurt (28% of energy from fat, 54% of energy from carbohydrates, and 18% of energy from protein).
89465662|NCT03452553|Experimental|Open Label Treatment|Chemoembolization using LC Bead LUMI™ (Radiopaque (RO) Bead) loaded with doxorubicin
89465663|NCT03452475|Active Comparator|Arterolane-piperaquine|Arterolane-piperaquine for 3 days
89465664|NCT03452475|Active Comparator|Arterolane-piperaquine+mefloquine|Arterolane-piperaquine + mefloquine for 3 days
89465665|NCT03452475|Active Comparator|Artemether-lumefantrine|Artemether-lumefantrine for 3 days
89465666|NCT03451305|Experimental|Pillow group|Before surgery, with the patient lying in the supine position, a soft pillow was placed under the segment of the collapsed vertebrae, which resulted in a hyperextension position. 12 hours duration suggested from 11:00 pm 1 night before the surgery till next day.
88945737|NCT01900938|Active Comparator|Intermittent bolus injection of propofol|A loading dose of 2 mg of midazolam and 0.4 mg/kg of propofol is initially injected and then repeated intermittent bolus injection of 20 mg of propofol is followed according to patients' sedation level.
88945738|NCT01900938|Active Comparator|Continuous infusion of propofol|Propofol is continuously administered intravenously via infusion pump starting with 20 mg/kg/hr and then titrated to about 5 mg/kg/hr according to patients' sedation level.
88945739|NCT01900951|Experimental|Temozolomide|"Patients in the study will receive the following for the duration of the study:First-line chemotherapy according to the NCCN guidelines. The study will consist of 21-day cycles, to a maximum of 6 cycles of therapy for the first-line chemotherapy. After first-line treatment, temozolomide will be given alone as maintenance therapy in all patients who have achieved study entry hematologic criteria and who do not have progressive disease or severe toxicity. During temozolomide maintenance therapy, patients will receive temozolomide at 150mg/m2/d for 5 days of a 28-day cycle orally daily. Temozolomide maintenance therapy will continue until progressive disease or irreversible toxicity occurs.~Re-staging will be performed every 2 cycles (every 8 weeks) during the study"
88945740|NCT01900964|Active Comparator|PTFE membrane|A non-resorbable PTFE (polytetrafluoroethylene) membrane will be used as a positive control treatment.
88945741|NCT01900964|Experimental|Collagen membrane|A resorbable collagen membrane will be used in the test group.
88945742|NCT01900990|Experimental|Noninvasive ventilation weaning|Patients in this group were weaned by noninvasive ventilation
88945743|NCT01900990|No Intervention|Conventional weaning|Patients in this group were weaned by conventional stratiges.
88945744|NCT01901003|Placebo Comparator|placebo group|placebo
88945745|NCT01901003|Active Comparator|no premedication group|no premedication
88945746|NCT01901003|Experimental|Lorazepam group|lorazepam
88945747|NCT01901016|Experimental|Jacobson progressive muscular relaxation|Jacobson progressive muscular relaxation
88945748|NCT01901016|Experimental|Schultz's autogenic training|Schultz's autogenic training
88945749|NCT01901016|No Intervention|control|The CG continued to receive their standard care. After data collection at the six-month follow-up, the CG participants were invited to attend one of two relaxation interventions.
89465667|NCT03451305|No Intervention|No pillow group|No intervention was given in this group before surgery.
89465668|NCT03451227|Experimental|Dexmedetomidine Group|The study drug dexmedetomidine (PrecedexTM) is supplied as dexmedetomidine HCL 200mcg/vial (100mcg/ml). This will be added to 98 ml 0.9% NaCl to achieve a concentration of 2mcg/ml and infused at 0.2-1mcg/kg/hour from the start of the case. The infusion rate will be commenced at 1mcg/kg/hour in those less than or equal to 65 years of age, and at 0.7mcg/kg/hr in those greater than 65 years of age, and then titrated based on the intraoperative sedation scores (to achieve a Sedation and Agitation scale (SAS) score of less than or equal to 4) and cardiovascular parameters (within 30% of baseline).
89465669|NCT03451227|Active Comparator|Remifentanil Group|Remifentanil HCL will be infused at 0.01-0.2 mcg/kg/min titrated to sedation level (SAS less than or equal to 4) and cardiovascular parameters (within 30% of baseline)
89465670|NCT03449355||vaginal group|
89465671|NCT03449355||cesarean section group|
89465672|NCT03449277|Active Comparator|take oral nifedipine tablets|Women who take the oral tablets of nifedipine till discharge of hospital
89465673|NCT03449277|Active Comparator|take oral labetalol tablets|Women who take the oral tablets of labetalol till discharge of hospital
89465674|NCT03508323|Experimental|Teneligliptin|
89465675|NCT03508323|Placebo Comparator|Placebo|
89465676|NCT02529813|Experimental|Arm I (CD19 positive chimeric antigen receptor T-cells)|"LYMPHODEPLETING CHEMOTHERAPY: Patients may receive standard chemotherapy comprised of fludarabine phosphate IV over 1 hour and cyclophosphamide IV over 3 hours on days -5 to -3 or cyclophosphamide IV every 12 hours on days -5 to -3 at the discretion of the treating physician.~Within 30 days post completion of lymphodepletion, patients receive CD19 positive chimeric antigen receptor T-cells IV over 15-30 minutes on day 0, or split into two portions on days 0 and 1."
89465677|NCT03129711|Experimental|glazed Celtra Duo|zirconia reinforced lithium silicate glass ceramic is infiltrated with 10% zirconia by weight, producing zirconia reinforced lithium silicate ceramic
89465678|NCT03129711|Active Comparator|Glazed IPS Empress CAD|glazed Leucite based glass ceramics ,Its a glass ceramic which is etchable and proved to have good esthetics if used for laminate veneers
89465679|NCT03440463|Placebo Comparator|Intervention-only Control|Participants navigate through e-checkup to go, the well-established alcohol intervention. Their email 2 weeks later contains only a reminder to participate in follow-up surveys.
89465680|NCT03440463|Experimental|Intervention plus Norms-only booster|Participants navigate through e-checkup to go, the well-established alcohol intervention. Their email 2 weeks later contains a reminder to participate in follow-up surveys, plus personalized feedback based on participant reported perceived alcohol norms, actual alcohol norms, and their own use.
89465681|NCT03440463|Experimental|Intervention plus Norms-plus-Strategies booster|Participants navigate through e-checkup to go, the well-established alcohol intervention. Their email 2 weeks later contains a reminder to participate in follow-up surveys, plus personalized feedback based on participant reported perceived alcohol norms, actual alcohol norms, and their own use. It also includes reported harm reduction strategies, and other strategies they might consider.
89465682|NCT05322057||patients with Crohn's disease and complex perianal fistula|14 patients with Crohn's disease refractory to standard treatment for complex perianal fistula got enrolled in this study.
89465683|NCT03433599|Active Comparator|rAIH + training by research staff|Participants will receive repeated exposure to acute Intermittent Hypoxia (rAIH) and training by research staff.
89465684|NCT03433599|Sham Comparator|sham rAIH + training|Participants will sham receive repeated exposure to acute Intermittent Hypoxia (rAIH) and training by the research staff.
89465685|NCT05321823|No Intervention|Control|Two districts in Ife East Local County with an estimated screening population of 4,500 will be randomly selected to serve as the control community. The control arm will not receive iBE screening and clinical breast examinations by the community health nurses and nor get navigated to have ultrasound, mammography, biopsy and referral for treatment to the tertiary hospital if indicated within their community. All women for screening and diagnostic workup in the control community will be directed to the tertiary hospital to receive breast care.
89465686|NCT05321823|Experimental|Intervention|Three districts in Ife North Local County with an estimated screening population (women 40-70 years) of 5,800 will be randomly selected to serve as the intervention community. Women in the intervention community will receive iBreast and clinical breast examinations by the community health nurses and get navigated to have ultrasound, mammography, biopsy and referral for treatment to the tertiary hospital if indicated within their community.
89465687|NCT03449121|Experimental|Slow breathing|Slow breathing techniques with exhale greater than inhale
89465688|NCT05321667||SMuRF-less|Patients presenting no standard modifiable risk factor of cardiovascular disease (diabetes mellitus, hyperlipidemia, hypertension, and cigarette smoking).
89465689|NCT05321667||SMuRFs|Patients presenting at least one standard modifiable risk factor of cardiovascular disease (diabetes mellitus, hyperlipidemia, hypertension, and cigarette smoking).
88945750|NCT01901029||men of floating population|males who live in Dongguan more than 6 months and without residence cards
88945751|NCT01901029||men of non-floating population|males who live in Dongguan more than 6 months and with residence cards
88945752|NCT01901042|Experimental|Symbiotic|Patients in this group received sachets with a symbiotic product in powder form containing 4.3 g of dietary fiber and Lactobacillus reuteri in a concentration greater than 1.0 x 108 colony forming units (CFU), with five grams per sachet (Fibermais Flora Nestlé Brazil).
88945753|NCT01901042|Placebo Comparator|Maltodextrin|patients in this group received sachets five grams of maltodextrin per sachet with identical casing and identical aspect to the product of the other arm group, and were instructed to proceed in the same way as those of the symbiotic group
88945754|NCT01901068||MonoMax|Elective primary laparotomy
88945755|NCT01901081|Experimental|Prosthetic Training with IMES prosthesis|
88945756|NCT01901107||Kiklin group|
88945757|NCT01901120||Betanis|the usual adult dosage of mirabegron once daily after a meal
88945758|NCT01901133|Experimental|A: Mild hepatic impairment subjects + control|
88945759|NCT01901133|Experimental|B: Moderate hepatic impairment subjects + control|
88945760|NCT01901159|Experimental|RO4995819 capsule|
88945761|NCT01901159|Experimental|RO4995819 tablet|
88945762|NCT01901172|Experimental|Extension|
88945763|NCT01901172|Experimental|Part 1: Drug-drug interaction|
89018256|NCT04572295|Experimental|Part 1 Dose Escalation: E7090 + Fulvestrant or Exemestane|Participants will receive E7090 tablets, orally, once daily along with fulvestrant 500 milligram (mg), intramuscular injection on Days 1 and 15 of Cycle 1 and each Day 1 of cycle 2 or later, or along with exemestane 25 mg tablet, orally, once daily in 28 days cycle. Each cycle length equals to (=) 28 days.
89465690|NCT05321589|Other|technique 1: conventional splinted open tray impression|"a conventional open tray impression technique splinted with ligature wire and duralay resin was done with polyvinyl siloxane impression .~analogues were screwed to the impression copings and casts were poured."
89465691|NCT05321589|Other|technique 2: digital intraoral impression technique|"scan bodies were screwed to implants intraorally and digital scanner was used to record digital impression, scanning protocol started from occlusal ,buccal to palatal surfaces.~The resulting scans were then exported in the standard tessellation format (.STL)"
89465692|NCT05321511|Active Comparator|a-GnRH|Administration of triptorelin acetate 0.2 mg for final oocyte maturation.
89465693|NCT05321511|Active Comparator|hCG|Administration of coriogonadotropine alfa 250 mcg for final oocyte maturation.
89465694|NCT05321511|Experimental|a-GnRH + hCG|Administration of triptorelin acetate 0.2 mg and coriogonadotropine alfa 250 mcg for final oocyte maturation.
89465695|NCT02733627|Experimental|BI 1467335 10 mg (low dose)|
89465696|NCT02733627|Experimental|BI 1467335 15 mg (medium dose)|
89465697|NCT02733627|Experimental|BI 1467335 20 mg (high dose)|
89465698|NCT02733627|Placebo Comparator|Placebo|
89465699|NCT02417103|Active Comparator|GLP-1 (Liraglutide)|Daily subcutaneous injection of Lirglutide over 9 weeks prior to bariatric surgery with a dosing of 0,6-1,8 mg
89465700|NCT02417103|Placebo Comparator|Placebo Comparator|Daily subcutaneous injection of PL1/PR1 Placebo over 9 weeks prior to bariatric surgery with a dosing of 0,6-1,8 mg
89465701|NCT02097225|Experimental|Treatment (dabrafenib, trametinib, onalespib)|Patients receive dabrafenib PO BID and trametinib PO QD on days 1-28, and onalespib IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89465702|NCT02958865|Experimental|PF-06651600 Drug Dose Level 1|Delivered orally for 8 weeks
89465703|NCT02958865|Experimental|PF-06651600 Drug Dose Level 2|Delivered orally for 8 weeks
89018257|NCT04572295|Experimental|Part 2 Monotherapy: E7090|Participants will receive E7090 tablets, orally, once daily in 28 days cycle. Each cycle length =28 days.
89465704|NCT02958865|Experimental|PF-06651600 Drug Dose Level 3|Delivered orally for 8 weeks.
89465705|NCT02958865|Placebo Comparator|PF-06651600 Placebo|Delivered orally for 8 weeks.
89465706|NCT02958865|Experimental|PF-06700841 Drug Dose Level 1|Delivered orally for 8 weeks
89465707|NCT02958865|Experimental|PF-06700841 Drug Dose Level 2|Delivered orally for 8 weeks.
89465708|NCT02958865|Experimental|PF-06700841 Drug Dose Level 3|Delivered orally for 8 weeks.
89465709|NCT02958865|Placebo Comparator|PF-06700841 Placebo|Delivered orally for 8 weeks.
89465710|NCT02958865|Experimental|PF-06651600 Drug Dose Level 4|Delivered orally for 24 weeks.
89465711|NCT02958865|Experimental|PF-06700841 Drug Dose Level 4|Delivered orally for 24 weeks.
89465712|NCT01990209|Experimental|Orteronel|The planned dose of orteronel is 300mg orally (PO) twice daily (BID), for a total daily dose of 600mg.
89465713|NCT05321277|Active Comparator|Walnut diet|Participants will consume 56 g of walnuts each day at home for 3 weeks.
89465714|NCT05321277|Active Comparator|No-nut diet|Participants will follow a no-nut diet for 3 weeks.
89465715|NCT03141099|Active Comparator|Low normal MAP and low normal PaO2|MAP 63 mmHg and PaO2 9-10 kPa during targeted temperature management (36 hours) after OHCA.
89465716|NCT03141099|Active Comparator|High normal MAP and low normal PaO2|MAP 77 mmHg and PaO2 9-10 kPa during targeted temperature management (36 hours) after OHCA.
89465717|NCT03141099|Active Comparator|Low normal MAP and high normal PaO2|MAP 63 mmHg and PaO2 13-14 kPa during targeted temperature management (36 hours) after OHCA.
89465718|NCT03141099|Active Comparator|High normal MAP and high normal PaO2|MAP 77 mmHg and PaO2 13-14 kPa during targeted temperature management (36 hours) after OHCA.
89465719|NCT03448887|Experimental|Study group|Extended HD with MCO dialyzer
89465720|NCT03448887|Active Comparator|Control group|Online hemodiafiltration
89465721|NCT02958553|Other|emPOWER Ankle (powered prosthesis)|The subject's own passive prosthesis will be used as a baseline and crossed over after the emPOWER has been worn 3-4 months. Then the passive foot will be crossed back to the emPOWER for a final series of tests.
89465722|NCT02501902|Experimental|Palbociclib + Nab-Paclitaxel|Palbociclib oral dosing on Days 1 to 21 of each 28-day cycle. Nab-paclitaxel IV dosing on Days -2, 6, and 13 of Cycle 1, and on Days 1, 8, and 15 of subsequent cycles.
89465723|NCT03641599||heart failure with preserved ejection fraction|
89465724|NCT03641599||heart failure with mid range ejection fraction|
89465725|NCT03641599||heart failure with reduced ejection fraction|
89465726|NCT03076047||end tidal CO2 (ETCO2) monitoring|We will continuously record capnography data from the patients while they are in the post-anesthesia care unit (PACU). Study personnel will visit each patient while the patient is in the PACU to promote compliance with continuous CO2 monitoring.
89465727|NCT05320575|Experimental|zanubrutinib|
89465728|NCT03740217|Other|Treatment A|Single oral dose of 400 mg GKT137831 administered as 4 x 100 mg capsules in fasting conditions.
89465729|NCT03740217|Other|Treatment B:|Single oral dose of 400 mg GKT137831 administered as 1 x 400 mg tablets in fasting conditions.
89465730|NCT03740217|Other|Treatment C|Single oral dose of 400 mg GKT137831 administered as 1 x 400 mg tablets in fed conditions.
89465731|NCT05320341||TIVA group|During the anesthesia maintenance of the TIVA group, 3 μg.kg-1 fentanyl, 0.01-0.05 mg.kg-1 midazolam, and 0.2 mg.kg-1 rocuronium bromide were applied throughout the operation to keep BIS between 40 and 60, approximately once every 45 minutes.
89465732|NCT05320341||SEVO group|During the anesthesia maintenance of the SEVO group, 2-3% sevoflurane (1-2 MAC), 3 μg.kg-1 fentanyl and 0.2 mg.kg-1 rocuronium bromide were applied throughout the operation to keep BIS between 40-60.
89465733|NCT03448731|Experimental|Doxycycline|Doxycycline 50 mg p.o. daily during 6 weeks
89465734|NCT01955109|Experimental|Viaskin Peanut 250 mcg|
89465735|NCT04452669|Experimental|Study Treatment|Up to 10 days of inhaled epoprostenol delivered by a breath actuated dedicated delivery system for patients with COVID-19 who are mechanically ventilated.
89465736|NCT04452669|Placebo Comparator|Placebo Control|Up to 10 days of inhaled 0.9% sodium chloride solution delivered by a breath actuated dedicated delivery system for patients with COVID-19 who are mechanically ventilated.
89465737|NCT03467997|No Intervention|Filtered Air|Subjects sit in a room for two hours breathing in filtered air which resembles levels of air pollution found in the ambient environment
89465738|NCT03467997|Active Comparator|Diesel Exhaust|Subjects sit in a room for two hours breathing in diesel exhaust at 200 micrograms of meter cubed.
89465739|NCT03467997|Active Comparator|TSST/Stress only|Subjects undergo a mental stress test, known as the Trier Social Stress Test (TSST), which involves a public speaking and math task.
89465740|NCT03467997|Active Comparator|Diesel Exhaust and stress|Subjects sit in a room for two hours breathing in diesel exhaust at 200 micrograms of meter cubed and are subject to a mental stress test (TSST) which involves a public speaking and math task.
89465741|NCT04452279|Experimental|Ocular Surface Disease post-stenting|Eyes will undergo phacoemulsification cataract surgery combined with iStent or iStent inject implantation according to standard clinical practice. From baseline through 3 months postoperatively, participants will complete subjective and objective assessments of ocular surface disease.
89465742|NCT05304897|Active Comparator|Control group|
89465743|NCT05304897|Experimental|PRP group|
89465744|NCT03811041|Experimental|PC articulated with MDA|Depressed parent encountered in PC for confirmation of depression with Hopkins Symptom Checklist-25 (HSCL25) scale. If confirmed, the adolescent will also be encountered by the GP for a screening test of depression (Adolescent Depression Rating Scale - ADRS). If negative, the patient will go out of the study. If positive, 2 others tests will be performed to study the intensity of the depression (Child depressionInventory - CDI) and the quality of life (Pediatric Quality of Life InventoryTM).Finally, the patient will be oriented to the MDA of Brest and will meet again the GP at 6 and 12 month to answers the same tests.
89465745|NCT03811041|Active Comparator|Routine cares|Depressed parent encountered in PC for confirmation of depression with Hopkins Symptom Checklist-25 (HSCL25) scale. If confirmed, the adolescent will also be encountered by the GP for a screening test of depression (Adolescent Depression Rating Scale - ADRS). If negative, the patient will go out of the study. If positive, 2 others tests will be performed to study the intensity of the depression (Child depressionInventory - CDI) and the quality of life (Pediatric Quality of Life InventoryTM). Finally, the patient will be oriented to the routine cares and will meet again the GP at 6 and 12 month to answers the same tests.
88945764|NCT01901172|Experimental|Part 2: Relative bioavailability|
88945765|NCT01901172|Experimental|Part 3: Food effect|
88945766|NCT01901198|Experimental|Human Serum Albumin/interferon alpha2a|Human Serum Albumin/interferon alpha2a 300-1200 mcg single dose S.C.
88945767|NCT01901198|Active Comparator|Pegasys|Peginterferon 180 mcg single dose S.C.
88945768|NCT01901237|Other|Hatha Yoga Program|Single-arm pilot study of a 7-week home/hospice-based Hatha yoga program for adolescent and young adults with non-curative cancer.
88945769|NCT01901263||patient with alzheimer's disease|"Cohort of patients with psychological symptoms of dementia hospitalised in Cognitive and Behaviorial Units (CBUs)~Evaluation of these units through the observation of the behavioral and psychological symptoms of dementia evolution : NPI score, caregivers quality of life, caregivers burden, collection of psychotropic drugs, the rehospitalisation rate"
88945770|NCT01901276|Experimental|Omeprazole 40 mg bid x 4-8 weeks|See study description for further details.
88945771|NCT01901315|Experimental|Online consultation|Monthly video consultations with psychiatrist
88945772|NCT01901315|Experimental|Face-to-face consultation|Monthly face-to-face consultations with psychiatrist
88945773|NCT01901354|Active Comparator|Low-tidal-volume ventilation|Subjects will be ventilated with a goal tidal volume of 6 cc/kg predicted body weight (PBW), a goal plateau pressure of <30 cm H2O, and a goal respiratory rate of 6-35 bpm to achieve a goal arterial pH of 7.30 to 7.45. Positive end-expiratory pressure is set as per the ARDSNet Positive end-expiratory pressure table
88945774|NCT01901354|Active Comparator|Airway pressure release ventilation (APRV)|"Airway Pressure Release Ventilation (APRV) is a time cycled, inverse-ratio, pressure controlled strategy that allows spontaneous breathing throughout the respiratory cycle.~Initial settings: Pressure high will be set initially to equal the plateau pressure on baseline ARDSNet settings. Time low will be set to 0.5-0.8 seconds to achieve an end expiratory flow 25-50% of peak expiratory flow, and Time high will be set to obtain a set respiratory rate 60%-70% that of baseline settings. Time high will be adjusted to achieve similar continuous exhaled carbon dioxide levels as baseline ARDSNet settings. Low pressure will be set at <5 cm H20."
88945775|NCT01901367|Experimental|Arm I (intervention)|Patients receive standard of care individualized diet and exercise plan and monthly booster follow-up sessions from the nutritionist and exercise physiologist and weekly phone counseling with a trained health coach to address barriers to improve plan adherence.
88945776|NCT01901367|No Intervention|Arm II (control)|Patients receive standard of care individualized diet and exercise plan
88945777|NCT01901380||extensively hydrolysed casein formula + LGG|children receiving extensively hydrolysed casein formula plus Lactobacillus GG
88945778|NCT01901380||other formulas|children receiving formulas without supplementation of Lactobacillus GG
88945779|NCT01901406||ERM|idiopathic epiretinal membrane patients
88945780|NCT01901432|Experimental|Givinostat|"In Part A patients will treated in dose levels at the following daily doses of Givinostat:~50 mg b.i.d.,~100 mg b.i.d.;~150 mg b.i.d.,~200 mg b.i.d.;~150 mg t.i.d.;~200 mg t.i.d.. Intermediate dose levels and, consequently, additionally dose levels may be used to establish the Maximum Tolerated Dose.~In Part B patients will be treated at the Maximum Tolerated Dose established in Part A.~The product will be supplied as hard gelatine capsules for oral administration at the strength of 50 mg, 75 mg and/or 100 mg each."
88945781|NCT01901445|Experimental|Educational action group|
88945782|NCT01901445|No Intervention|Control group|
88945783|NCT01901458|Experimental|IDL-Set|Peripheral blood progenitor cell apheresis in G-CSF mobilized allogeneic donors using the Spectra Optia® IDL-Set in combination with the Spectra Optia® cell separator and the WBC-D program
89465746|NCT03811041|Experimental|Parental depression|Parental depression will be studied. Depressed adolescent encountered in MDA of Marseille for confirmation of depression with 3 tests : ADRS, CDI and PedsQL. If positive, the parent will come to the MDA for a screening test of depression (HSCL25). Parents and adolescent are seen only once.
89465747|NCT03719001|Experimental|Phenylephrine|Phenylephrine (100 ug/ml) infusion will be used to increase blood pressure by 20 mmHg
89465748|NCT03719001|Experimental|Dexmedetomidine|Dexmedetomidine infusion will be used to increase blood pressure by 20 mmHg
89465749|NCT03719001|Experimental|Clevidipine|Clevidipine infusion will be used to increase blood pressure by 20 mmHg
89465750|NCT03719001|Experimental|Calcium Chloride|Calcium Chloride will be administered to increase blood pressure and to increase blood calcium concentration
89465751|NCT03719001|Experimental|tetanic stimulus|A 5 second 70 mA tetanic stimulus will be used to increase peripheral vascular tone
89465752|NCT03719001|Experimental|Increased venous pressure|A 5 minute inflation of a noninvasive blood pressure cuff to 30 mmHg to increase venous pressure in the arm.
89465753|NCT02500732|Placebo Comparator|Placebo|Placebo capsule to be given the night before the study tilt, and the morning of the study tilt test.
89465754|NCT02500732|Active Comparator|Atomoxetine|Atomoxetine 40mg PO to be given the night before the study tilt, and the morning of the study tilt test.
89465755|NCT03448497||Advanced Melanoma patients who intiated first-line therapy|patients who initiated any first-line therapy for advanced melanoma and had not previously received treatment for their advanced disease
89465756|NCT02518048|Active Comparator|LEO 90100 Aerosol foam|Calcipotriol (as monohydrate) 50 mcg/g and betamethasone (as dipropionate) 0.5 mg/g (LEO 90100 Aerosol foam)
89465757|NCT02518048|Active Comparator|Betesil® 2.25 mg|Betamethasone (as valerate). Each 7.5 cm x 10 cm medicated plaster contains: 2.250 mg of betamethasone valerate (corresponding to 1.845 mg of betamethasone).(Betesil® )
89465758|NCT03129399|Experimental|King Vision video laryngoscope|
89465759|NCT03129399|Active Comparator|McGrath MAC video laryngoscope|
89465760|NCT03792711|Experimental|HMB group|2 servings (440 mL)/day Ensure® Plus Advance for use as a supplement with or between meals
89465761|NCT03792711|No Intervention|Control group|Standard of care includes mainly dietary consultation for healthy aging by dietitians to reach sufficient dietary protein intake.
89465762|NCT03448809|Experimental|MMM (Mind My Mind training)|Mind My Mind training
89465763|NCT03448809|Active Comparator|TAU (Treatment as Usual)|Treatment as Usual
89465764|NCT05009914|Experimental|cardiac denervation group|In this group, patients undergoing CABG will receive the procedure of our new way of cardiac denervation, excision of Marshall ligament and Waterstone fat pad.
89465765|NCT05009914|No Intervention|controlled group|In this group ,patients undergoing CABG will not receive the procedure of cardiac denervation.
89465766|NCT03788577|Experimental|Oligonol intake group|This experimental arm will be applied for Oligonol 200mg/tab 1 tab per day. The program will last for 12 weeks.
89465767|NCT03788577|Placebo Comparator|Placebo group|This Placebo arm will be given capsules made of starch 1 tab per day. The program will last for 12 weeks.
89465768|NCT03448575|Sham Comparator|Control - Medication Alert Only|The control arm medication alert is a simple text pop-up in the EMR that will inform the prescriber of Choosing Wisely® recommendations developed the American Psychiatric Association regarding antipsychotic medication use in children and adolescents.
89465769|NCT03448575|Experimental|Intervention - Alert + CAP Review AND Enhanced BH Access|"The intervention alert prompts the prescriber to keep/remove the antipsychotic order, and/or order any study services: behavioral health navigation, expedited psychotherapy access, virtual consult with a child and adolescent psychiatrist (CAP). Passive case review by the study CAP will occur for all intervention arm cases. A virtual consult will be scheduled if the prescriber ordered it or the CAP needs to discuss the case. The CAP will provide the prescriber with a written summary of his/her review.~Following review by the CAP, a navigator reaches out to the eligible intervention arm patient/family to offer extra support. The navigator's role is to (a) provide extra support to facilitate access and engagement in appropriate psychosocial therapies; (b) coordinate short-duration bridging therapy sessions for teens/families not engaged in psychotherapy, when appropriate; and (c) keep the prescriber informed of any clinically relevant updates."
89465770|NCT03448263|Experimental|Group BF|The root canals were cleaned and shaped using a #40 instrument for thin or curved canals and a #55 file for widespread canals.
89465771|NCT03448263|Experimental|Group WON|WaveOne files was used to prepare narrow, straight and curved canals, and a file (40.08) was used for large and wide canals.
89465772|NCT03448263|Experimental|Reciproc instruments|Reciproc instrument was used in thin and curved RC, and R40 files (40.06) were used in wide canals.
89465773|NCT02499952|Experimental|Experimental Arm|Pembrolizumab
89465774|NCT02499406|Other|Skills group|Dialectical behavior therapy skills group
89465775|NCT05113485|Active Comparator|Diabetes Prevention Program-based lifestyle change intervention (DPP)|The Diabetes Prevention Program-based lifestyle change intervention (DPP) is designed to help overweight breast cancer survivors to reduce their risk of breast cancer recurrence by reducing their excess body fat.
89465776|NCT05113485|Experimental|Highly Microbiota-Accessible Foods (HMAFs) intervention|The Highly Microbiota-Accessible Foods (HMAFs) lifestyle change intervention is designed to help overweight breast cancer survivors reduce their risk of breast cancer recurrence by reducing their elevated low-grade inflammation.
89465777|NCT03333135|Experimental|HK100 Pulsed Electromagnetic Field|20 athletes (ideally a mix of elite and amateur level athletes and veteran (40-65y) and young (20-39y). Athletes will be recruited at the 2018 and 2019 Hong Kong 100 races. In addition, these athletes will use the pulsed electromagnetic field (PEMF) for the two weeks prior to the race.
89465778|NCT03333135|Sham Comparator|HK100 Pulsed Electromagnetic Field Sham|20 athletes (ideally a mix of elite and amateur level athletes and veteran (40-65y) and young (20-39y). Athletes will be recruited at the 2018 and 2019 Hong Kong 100 races. In addition, these athletes will use a PEMF device that doesn't produce electromagnetic fields (sham) for the two weeks prior to the race.
89465779|NCT03333135|Experimental|UTMB Pulsed Electromagnetic Field|20 athletes (ideally a mix of elite and amateur level athletes and veteran (40-65y) and young (20-39y). Athletes will be recruited at the 2018 and 2019 Ultra Trail du Mont Blanc (UTMB) races. In addition, these athletes will use the pulsed electromagnetic field (PEMF) for the two weeks prior to the race.
89465780|NCT03333135|Sham Comparator|UTMB Pulsed Electromagnetic Field Sham|20 athletes (ideally a mix of elite and amateur level athletes and veteran (40-65y) and young (20-39y). Athletes will be recruited at the 2018 and 2019 Ultra Trail du Mont Blanc (UTMB) races. In addition, these athletes will use a PEMF device that doesn't produce electromagnetic fields (sham) for the two weeks prior to the race.
89465781|NCT03443817|No Intervention|Control group|There is no conventional rehabilitation follow up program, but all patients are encouraged to continue training
89465782|NCT03443817|Experimental|Intervention group|The intervention group will obtain telerehabilitation
89465783|NCT02498392|Placebo Comparator|Responders-Placebo|Participants who responded in the placebo lead-in period will be administered with Matching Placebo orally.
89465784|NCT02498392|Experimental|Responders-JNJ-42165279|Participants who responded in the placebo lead-in period will be administered with JNJ-42165279 orally at a dose of 25 milligrams (mg) tablets once daily for 6 weeks.
89465785|NCT02498392|Placebo Comparator|Non Responders-Placebo|Participants who did not respond in the placebo lead-in period will be administered with Matching Placebo orally.
89465786|NCT02498392|Experimental|Non Responders-JNJ-42165279|Participants who did not respond in the placebo lead-in period will be administered with JNJ-42165279 orally at a dose of 25 mg tablets once daily for 6 weeks.
89465787|NCT03205605|Other|baseline patch|patch
89465788|NCT03205605|Other|baseline gel|gel
89465789|NCT03205605|Other|patch with heat|patch
89465790|NCT03205605|Other|gel with occlusion|gel
89465791|NCT03443661|Experimental|FOLFOXIRI|oxaliplatin 85 mg/m2 irinotecan 150 mg/m2, 5FU 2,400 mg/m2 by 46 h infusion repeated at 2week intervals
89465792|NCT05008588|Experimental|Conditioned medium combined with Umbilical cord mesenchymal stem cells treatment|Intranasal of 3 cc of conditioned medium each, for 3 days in a row and Intra-parenchymal transplantation of 20x10^6 UC-MSCs
89465793|NCT05008588|Experimental|Umbilical cord mesenchymal stem cells treatment|Intra-parenchymal transplantation of 20x10^6 UC-MSCs
89465794|NCT05008588|Active Comparator|Standard treatment (control)|Neurologic and Neutrophic Drugs
88945784|NCT01901458|Active Comparator|MNC-Set|Peripheral blood progenitor cell apheresis in G-CSF mobilized allogeneic donors using the Spectra Optia® Collection Set in combination with the Spectra Optia® cell separator and the MNC program
89465795|NCT03448029||Endovascular Patients|Patients undergoing endovascular interventions for symptomatic PAD
89465796|NCT03048045||Supportive Periodontal Treatment (SPT)|"at least 18 years old.~periodontal treatment (antiinfective therapy with subgingival debridement under local anesthesia and if required periodontal surgery) at the Dept. of Periodontology starting after April 2005 durchgeführt.~complete periodontal charting (PPD and PAL-V at 6 sites per tooth, furcation involvement [Hamp et al. 1975] at all furcation sites of multi-rooted teeth) prior to treatment (baseline, T0) and after completion of active periodontal treatment (APT) (reevaluation 1 or 2/start of supportive periodontal therapy, T1)~radiographs of all teeth (periapical radiographs or panoramic radiograph) from baseline~written informed consent"
89465797|NCT05006638|Placebo Comparator|control group|will receive the traditional supportive treatment according to (PCC-ASUH) protocol
89465798|NCT05006638|Active Comparator|case group|will receive the traditional supportive treatment plus administration of ILE (20%) 1.5 ml/kg as a bolus over 2-3 minutes. Followed immediately by an infusion of 20 % lipid emulsion at a rate of 0.25 mL/kg/min. After 3 minutes of this infusion rate, response to the bolus and initial infusion should be assessed. If there has been a significant response, the infusion rate can be adjusted to 0.025 mL/kg/min with monitoring of blood pressure, heart rate, and other available hemodynamic parameters during the infusion with a maximum dose of 10 mL/kg
88945785|NCT01901471|Experimental|CsA Group|
89465799|NCT04451889|Experimental|Confocal laser endomicroscopy diagnostic study|"Cohort 1: COVID-19 patients. Cohort 2: patients with lung diseases unrelated to COVID-19.~All the patients will be examined using confocal laser endomicroscopy during bronchoscopy with a special Alveoflex miniprobe during the hospitalisation period. Records will be done and analysed prospectively with the included software for the endomicroscopic system.~Using Alveoflex is a minimally invasive intervention."
89465800|NCT03443349|Other|Use of the medical Device: Vibwife One|"The medical device will be used according to its market authorization.~Because it will be used for the first time in pregnant women, the following three step application procedure has been determined:~First five pregnant women use the device for 10 minutes. Each of them in a position and module proposed by the midwife with the agreement of the woman.~Next 10 pregnant women use the device for 20 minutes. Again, position and module according to the decision of the midwife with the agreement of the woman.~All the remaining pregnant women (35) use the device for 30 minutes. Position and module according to the decision of the midwife with the agreement of the woman.~During the intervention period, position and module might be changed once if required."
89465801|NCT02498236|Experimental|Oxytocin 6-84 IU|Subjects will be randomly assigned to one of eight doses of intranasal oxytocin.
89465802|NCT02498236|Placebo Comparator|Placebo|Subjects will be administered intranasal placebo using the same spray volume as experimental condition
89465803|NCT01443819|Other|Lumbar Transforaminal Epidural Corticosteroid Injection|
89465804|NCT01443819|Other|Physical Therapy|
89465805|NCT01443819|Other|Cohort observational|
89465806|NCT04961086|Experimental|energy drink arm|an open label branded energy drink which contains any one or more of the following ingredients: caffeine, ginseng, taurine
89465807|NCT04961086|Active Comparator|tea 5gm sugar arm|the usual easily available black tea with sugar 5 grams, and milk
89465808|NCT01283997|Placebo Comparator|Placebo Group|1 dose on first day of induction therapy, then every 12 hours for 10 weeks.
89465809|NCT01283997|Experimental|Minocycline Group|200 mg orally for 1 dose, then 100 mg orally every 12 hours for 10 weeks.
89465810|NCT02496676|Active Comparator|Magnesium, then placebo|In phase 1, participants received oral magnesium L-threonate for 12 weeks then crossover to placebo for 12 weeks, followed by a 2-week washout period. In phase 2, all participants received 3 days of intravenous MgSO4 in 3 daily doses totaling 30 mg/kg/day followed by oral magnesium L-threonate for 24 weeks.
89465811|NCT02496676|Placebo Comparator|Placebo, then magnesium|In phase 1, participants received oral placebo for 12 weeks then crossover to oral magnesium L-threonate for 12 weeks, followed by a 2-week washout period. In phase 2, all participants received 3 days of intravenous MgSO4 in 3 daily doses totaling 30 mg/kg/day followed by oral magnesium L-threonate for 24 weeks.
89465812|NCT02517268|Active Comparator|Standard 7-Day Pathway|Patients follow the standard 7-day pathway following pancreaticoduodenectomy
89465813|NCT02517268|Experimental|Accelerated 5-Day Pathway|Patients follow the Whipple accelerated 5-day pathway following pancreaticoduodenectomy. The accelerated pathway includes more rapidly leaving the ICU setting, early mobilization and enhanced physical therapy, multimodal pain control, dietary modifications, and increased and standardized phone contact by a nurse practitioner during the first week following hospital discharge.
89465814|NCT04957342|Active Comparator|Sutures|Patients assigned to Sutures group will not have the allograft placed on the donor site. One current clinical standard of practice is to place sutures on donor site. Patients assigned to Sutures group will have sutures placed on donor site.
89465815|NCT04957342|Experimental|Allograft and Sutures|Patients assigned to Allograft and Sutures will have allograft placed and secured with sutures on the donor site.
89465816|NCT05001490|Experimental|Experimental group|
89465817|NCT05001490|No Intervention|Control group|
89465818|NCT01160211|Experimental|Lapatinib plus trastuzumab plus aromatase inhibitor|Experimental
89465819|NCT01160211|Active Comparator|trastuzmab plus aromatase inhibitor|Active Comparator
89465820|NCT01160211|Active Comparator|lapatinib plus aromatase inhibitor|Active Comparator
89465821|NCT03443271|Experimental|Group T (TAP Block with Bupivicaine)|Ultrasound guided TAP block will be performed in this group. Bupivicaine 0.25 % 20 ml will be administered in the block on either side.
89465822|NCT03443271|Placebo Comparator|Group C (TAP Block with Placebo drug)|Ultrasound guided TAP block will be performed in this group. 0.9 % Saline 20 ml will be administered in the block on either side.
89465823|NCT01064687|Experimental|1.5 mg LY2189265|"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks~Metformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks~Pioglitazone: at least 30 mg/day, oral, for 52 weeks"
89465824|NCT01064687|Experimental|0.75 mg LY2189265|"LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks~Metformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks~Pioglitazone: at least 30 mg/day, oral, for 52 weeks"
89465825|NCT01064687|Active Comparator|Exenatide|"Exenatide: 5 micrograms (mcg), subcutaneous (SC), twice daily for 4 weeks, followed by 10 mcg, SC, twice daily for 48 weeks~Metformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks~Pioglitazone: at least 30 mg/day, oral, for 52 weeks"
89465826|NCT01064687|Placebo Comparator|Placebo|"Placebo: subcutaneous (SC), once weekly for 26 weeks~LY2189265 (Dulaglutide): After 26 weeks, participants were randomized to receive either 0.75 milligrams (mg) or 1.5 mg, SC, once weekly for an additional 26 weeks (from week 26 through week 52).~Metformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks~Pioglitazone: at least 30 mg/day, oral, for 52 weeks"
89465827|NCT05029167|Active Comparator|Restrictive PaO2 and low normal MAP|Patients receiving PaO2 9-10 kPa (68-75 mmHg) and MAP 63 mmHg during targeted temperature management (36 hours) after OHCA.
88945786|NCT01901471|Placebo Comparator|Placebo group|
89465828|NCT05029167|Active Comparator|Restrictive PaO2 and high normal MAP|Patients receiving PaO2 9-10 kPa (68-75 mmHg) and MAP 77 mmHg during targeted temperature management (36 hours) after OHCA.
89465829|NCT05029167|Active Comparator|Liberal PaO2 and low normal MAP|Patients receiving PaO2 13-14 kPa (98-105 mmHg) and MAP 63 mmHg during targeted temperature management (36 hours) after OHCA.
89465830|NCT05029167|Active Comparator|Liberal PaO2 and high normal MAP|Patients receiving PaO2 13-14 kPa (98-105 mmHg) and MAP 77 mmHg during targeted temperature management (36 hours) after OHCA.
89465831|NCT04983693|Experimental|Dementia-friendly Worship Service|Caregiver and persons living with dementia dyads attending six dementia-friendly worship services in person or online.
89465832|NCT03447873|Active Comparator|Triple therapy|To Continue with triple therapy with Elvitegravir/cobicistat + tenofovir alafenamide + emtricitabine or Dolutegravir + abacavir + lamivudine once daily.
89465833|NCT03447873|Experimental|Switch to dual therapy A|Switch to dual therapy with Darunavir/cobicistat (800150 mg) + lamivudine (300 mg) once daily once daily.
89465834|NCT03447873|Experimental|Switch to dual therapy B|Switch to dual therapy with Dolutegravir (50 mg) + lamivudine (300 mg) once daily
89465835|NCT03447795|Experimental|autogenous tooth grafted sites|
89465836|NCT03447795|Active Comparator|autogenous demineralised dentin grafted sites|
89465837|NCT02493946|Experimental|BTX-A-HAC NG|Clostridium Botulinum Toxin Type A (BTX A HAC NG), total treatment volume 0.25mL will be divided into 5 injections (0.05mL per injections) injected in 5 pre-defined sites across the glabellar region. A total of 50 Units of BTX-A-HAC NG will be injected/ cycle.
89465838|NCT02493946|Placebo Comparator|Placebo|The total placebo volume 0.25mL will be divided into 5 injections (0.05mL per injections) injected in 5 pre-defined sites across the glabellar region. Administered in Cycle 1 of the double blind phase only.
89465839|NCT03447717|Experimental|ActiGait|Patients who get the ActiGait implant
89465840|NCT02310633|Active Comparator|Memory Strategy Training|This arm involves intervention that teaches participants to use active encoding strategies to learn and remember new information.
89465841|NCT02310633|Active Comparator|Errorless Learning|This arm involves intervention that enhances consolidation of correct target information by preventing false recall of incorrect information during the acquisition phase.
89465842|NCT02310633|Active Comparator|Retrieval Practice|This arm involves intervention that enhances retrieval of correct target information by actively practicing retrieval in the presence of a cue.
89465843|NCT04451967||Transfer after thrombolysis|
89465844|NCT04451967||Transfer after DAPT|
89465845|NCT04451967||Direct transfer|
89465846|NCT02267421|Experimental|Home based aerobic exercise|Home based aerobic exercise on cycle ergometer. Three times per week, 30-60 minutes per session.
89465847|NCT02267421|No Intervention|Usual Care group|These patients will continue with their normal activities of daily living and will not be provided with equipment or coaching for home based exercise during the study period .
89465848|NCT01064531||MIS Femoral Neck Stem|Subject will be randomized to either MIS or Synergy implant.
89465849|NCT01064531||Synergy Hip System|Subject will be randomized to either Synergy or MIS implant.
89465850|NCT04451811|Experimental|OPL-002 SDD 20 mg|20 mg SDD formulation of OPL-002
89465851|NCT04451811|Experimental|OPL-002 5 mg Tablet|5 mg tablet formulation of OPL-002
89465852|NCT04451811|Experimental|OPL-002 20 mg Tablet|20 mg tablet formulation of OPL-002
89465853|NCT03621995||Obstructive azoospermia|Malondialdehyde and Catalase level measurement before and after cryopreservation
89465854|NCT03621995||Non obstructive azoospermia|Malondialdehyde and Catalase level measurement before and after cryopreservation
89465855|NCT03621995||Negative group|Malondialdehyde and Catalase level measurement without cryopreservation
89465856|NCT02220855|Experimental|BKM120|BKM120, 100mg capsule for oral use, taken once daily for two or more months for a maximum of one year. Each cycle is 28 days.
89465857|NCT04054583||Residents|Residents living on a special care unit in a long-term care facility. All 60 residents residing in the unit pre- and post-renovation will be eligible, and all will have intermediate or advanced dementia.
89465858|NCT04054583||Family Members|Family members are defined as the key person who supports the resident on a regular basis. This could include a spouse, adult child, adult grandchild, niece or nephew, close friend, former neighbour, or other significant person to the resident.
89465859|NCT04054583||Staff|Staff are the people who work on the special care unit. They may work only briefly or work on the design of the renovations. Types include: managers, nurses, health care aides, recreation facilitators, social worker, occupational therapist, physiotherapist, rehabilitation assistant, speech language pathologist, physicians, designers, and cleaning staff.
89465860|NCT03443037||Amantadine group|Patients admitted to the critical care with diagnosis of coma state who have received amantadin 200 mg / day for fourteen days according to İCU protocols decided by primary physician
89465861|NCT03443037||Control group|Patients admitted to the critical care with diagnosis of coma state who haven't received amantadin
89465862|NCT03442959||patient with primary resection of the Small Intestinal TNE|
89465863|NCT03442959||patient without primary resection of the Small Intestinal TNE|
89465864|NCT04915599|Experimental|Intervention group|Patients are assigned to using the Cooral® MCD after radiotherapy for 60 min. along with general oral care (GOC). The MCD will be placed into the subjects' mouth and remain intraorally for 60 minutes. After each fraction, i.e. session of RT, the subjects insert the MCD inside their mouth and can start the Cooral ® thermostat system themselves when they feel comfortable. The stopwatch will be started by the patient as soon as thermostat is running. The patient is asked to write down the starting and the stopping time of the 60-minute procedure. Thereafter the subject will receive a questionnaire to record the tolerance for the device. Patients will be also informed about standard of care (SOC) that should be regularly performed.
89465865|NCT03442881||benign adnexal mass|pathological examination of the specimen after excision reveals benign criteria
89465866|NCT03442881||Malignant adnexal mass|pathological examination of the specimen after excision reveals malignant criteria
89465867|NCT03442803|Experimental|Propofol TCI|Delivery of Propofol via a Target-controlled infusion pump for procedural sedation.
89465868|NCT03442647|Active Comparator|Living donors|sinistrin clearance dynamic measurement
89465869|NCT03442647|Active Comparator|ADPKD patients|sinistrin clearance dynamic measurement
89465870|NCT03442647|Active Comparator|Patients with primary renal tumor|sinistrin clearance dynamic measurement
89465871|NCT03442491||Hayman's Haemostatic Suture|Women that had major Post-partum Haemorrhage, defined as postpartum blood loss in excess of 2000 ml, resistant to pharmacologic treatment and that underwent Hayman's Haemostatic Suture.
89465872|NCT03447561|Experimental|Anticipatory + consummatory food reward|PET-MR scan session with a combination of anticipatory (viewing high-calorie food images) and consummatory food reward (drinking sips of chocolate milkshake). This scan session will consist of four blocks with a duration of 45 minutes each and 15 minute breaks in between. The first three blocks represent the 'control condition' (viewing neutral images and drinking sips of water) and the fourth block the 'food reward condition' (viewing high-calorie food images and drinking sips of chocolate milkshake).
89465873|NCT03447561|Experimental|Consummatory food reward|PET-MR scan session with purely consummatory food reward (drinking sips of chocolate milkshake). This scan session will consist of four blocks with a duration of 45 minutes each and 15 minute breaks in between. The first three blocks represent the 'control condition' (drinking sips of water) and the fourth block the 'food reward condition' (drinking sips of chocolate milkshake).
89465874|NCT03447483|Other|Cohort of patients starting a treatment by ICI|
89465875|NCT02918279|Experimental|Liraglutide|
89465876|NCT02918279|Placebo Comparator|Placebo|
89465877|NCT03447327|Other|operated group|patients undergoing surgery for chronic subdural hematoma by single burr hole under local anaesthesia
89465878|NCT04268745|Experimental|Virtual Reality|Progressive immersive training with the virtual reality app Scenes: start from most salient to the patient, eventually do all Duration: start at 60 seconds, increase over time up to 3 minutes per scene Complexity: start minimal, gradually increase up to most complex Tasks: standing with diverse base of support (BOS), head turns (progress with speed, planes); stepping, turning 8 weeks, 1 visit per week, 30 minutes long In home: Gait and balance exercises, No exercises with eyes closed, 8 weeks, 6 times per week, twice per day, 10 minutes long
89018258|NCT04572295|Experimental|Part 3 Dose Expansion: E7090 + Fulvestrant|"Participants will receive E7090 tablets, orally, once daily along with fulvestrant 500 mg, intramuscular injection on Days 1 and 15 of Cycle 1 and each Day 1 of cycle 2 or later. Each cycle length =28 days.~The dose of E7090 for Part 3 in combination with fulvestrant will be determined based on the safety, tolerability, pharmacokinetic (PK), and biomarker data obtained from Part 1."
89465879|NCT04268745|Active Comparator|Traditional Vestibular Rehabilitation|"Progressive gait, gaze stability and balance exercises Gait: walking with head turns, progress with range, speed and planes of head movement; change of walking BOS: wide, normal, tandem Gaze: focus on a target while moving head side to side / up down. Progress with speed, duration, busier background, standing to walking.~Balance: standing balance tasks, progress with BOS (wide to narrow to tandem), support surface, eyes closed, duration, head turns.~8 weeks, 1 visit per week, 30 minutes long In home: Gait, gaze stability and balance exercises, including exercises with eyes closed, 8 weeks, 6 times per week, twice per day, 10 minutes long"
89465880|NCT03447171||Refractive Error|
89465881|NCT02956837|Experimental|GSK3003891A vaccine formulation 1 Group|Subjects in this group received a single 30 micrograms (µg) dose injection of the investigational GSK3003891A vaccine at Day 0.
89465882|NCT02956837|Experimental|GSK3003891A vaccine formulation 2 Group|Subjects in this group received a single 60µg dose injection of the investigational GSK3003891A vaccine at Day 0.
89465883|NCT02956837|Experimental|GSK3003891A vaccine formulation 3 Group|Subjects in this group received a single 120µg dose injection of the investigational GSK3003891A vaccine at Day 0.
89465884|NCT02956837|Placebo Comparator|Control Group|Subjects in this group received a single placebo injection at Day 0.
89465885|NCT02521935|Active Comparator|Complete traditional dentures|Complete maxillary/mandible dentures made in the traditional manner.
89465886|NCT02521935|Active Comparator|Complete CADCAM dentures|Complete maxillary/mandible dentures made with CADCAM (computer-aided design/computer-aided manufacturing) technology
89465887|NCT03447093||Control group|30 healthy volunteers were included in the healthy control group
89465888|NCT03447093||Drug treatment group|30 GD patients who received treatment with Methimazole Pill or propylthiouracil pill
89465889|NCT03447093||Incipient group|30 untreated GD patients
89465890|NCT03447093||Hashimoto's thyroiditis group|30 HT patients
89465891|NCT04054037||HBV-ACLF Group|Patients with HBV related acute on chronic liver failure
89465892|NCT03442257|Experimental|SMS group|Participants in the intervention group will receive four semi-personalized messages per week in addition to their usual care according to the National Board of Health and Welfare guidelines for hypertension treatment.
89465893|NCT03442257|No Intervention|Control|The control group will receive usual care according to the National Board of Health and Welfare guidelines for hypertension treatment.
89465894|NCT01063595|Experimental|Octaplas LG|Participants received 1200 mL of Octaplas LG intravenously once.
89465895|NCT01063595|Active Comparator|Octaplas SD|Participants received 1200 mL of Octaplas SD intravenously once.
89465896|NCT03640351|Active Comparator|Preservative free diquafosol group|The subjects use preservative free diquafosol ophthalmic solution after cataract surgery
89465897|NCT03640351|Active Comparator|Preservative containing diquafosol group|The subjects use preservative containing diquafosol ophthalmic solution after cataract surgery
89465898|NCT03640351|Active Comparator|Preservative free sodium hyaluronate group|The subjects use preservative free sodium hyaluronate ophthalmic solution after cataract surgery
89465899|NCT03640273|Experimental|Prapchompoothaweep|Group 1 will be received Prapchompoothaweep remedy 1,000 mg for 3 times before meals (for 6 weeks).
89465900|NCT03640273|Experimental|Loratadine|Group 2 will be received Loratadine 10 mg per day before meals (for 6 weeks)
89465901|NCT03449823||TTTS Cases|Cases of monochorionic / diamniotic twin pregnancies diagnosed with twin-twin transfusion syndrome.
89018259|NCT04571970|Experimental|Single Arm|6.5 × 10^10 GC/g brain mass of RGX-121
89465902|NCT03449823||MCDA Controls|Controls of monochorionic / diamniotic twin pregnancies without a diagnosis of twin-twin transfusion syndrome.
89465903|NCT03442023|Experimental|Chlorhexidine 2%|Subjects in this arm will receive standard care plus mouth rinse every 12 hours via spray with 2% chlorhexidine concentration, one week intervention, Drug: Chlorhexidine gluconate at 2%
89465904|NCT03442023|Active Comparator|Chlorhexidine 0.12%|Subjects in this arm will receive standard care plus mouth rinse every 12 hours via spray with 0.12% chlorhexidine concentration, one week intervention, Drug: Chlorhexidine gluconate at 0.12%
89465905|NCT03441945|No Intervention|control|"The patients swallowed the capsule with water in the lying position.After finishing the stomach examination, the operation of the capsule is adjusted to small bowel mode without magnetic control. Capsule entered the duodenum under physiological peristalsis. The position of the capsule was established using a real-time viewer. If the capsule failed to enter the duodenum after one hour, domperidone (10 mg) was orally administered."
89465906|NCT03441945|Experimental|magnetic steering|"After finishing the stomach examination as the control protocol, the capsule was lifted with the magnetic control, then rotating the capsule until the camera end oriented toward the pylorus . Next, the endoscopist could drag the capsule close to the pylorus with the guidance magnet robot, waiting for the open of pylorus. Once the pylorus opened, the capsule could enter the duodenum with gastric peristalsis. After reaching the duodenal bulb, capsule was held to the maximum position of Z, then the capsule would scan the duodenal bulb automatically with the mode 360° automatic scanning."
89465907|NCT01063283|Active Comparator|Group A|Carboplatin and Pemetrexed with Bevacizumab 7.5 mg/kg once, followed three weeks later by Carboplatin and Pemetrexed with Bevacizumab 7.5 mg/kg and bevacizumab every 3 weeks for two doses
89465908|NCT01063283|Active Comparator|Group B|Carboplatin and Pemetrexed with Bevacizumab 7.5 mg/kg once, followed three weeks later by Carboplatin+Pemetrexed+Bevacizumab 15 mg/kg and bevacizumab every 3 weeks for two doses
89465909|NCT03441867|Experimental|(CBT-Sz) - PNES|Participants with history of a head injury and confirmed Psychogenic Non-Epileptic Seizures will complete 2 brain fMRI scans along with 12 weeks of one hour CBT-Sz sessions by a trained therapist.
89465910|NCT03441867|Experimental|(CBT-Sz) - PTE|Participants with history of a head injury and confirmed Post-Traumatic Epilepsy (PTE) will complete 2 brain fMRI scans along with 12 weeks of one hour CBT-Sz sessions by a trained therapist.
89465911|NCT03441867|Active Comparator|TBI Control|Participants with TBI will complete 2 brain fMRI scans.
89465912|NCT03441867|Active Comparator|Healthy Volunteer|Healthy control volunteers will complete 2 brain fMRI scans.
89465913|NCT02521779|Experimental|Test Meal Saturated Fat|Saturated-fat Treatment Meal
89465914|NCT02521779|Experimental|Test Meal N-6 Fat|N-6 fat Treatment Meal.
89465915|NCT02521779|Experimental|Test Meal N-3 Fat|N-3 fat Treatment Meal.
89465916|NCT02521779|Experimental|Test Meal Low-fat|Low-fat Treatment Meal.
89465917|NCT03438279||First-Line Ipilimumab|patients who received ipilimumab as their first-line treatment
89465918|NCT01062971|Active Comparator|A|IOP Dorzolamide-Timolol-Brimonidine group
89465919|NCT01062971|Active Comparator|B|IOP dorzolamide-timolol group
89465920|NCT03446937|Experimental|Dexamethasone sodium phosphate injection|Intervention: Drug: Dexamethasone sodium phosphate injection Two doses Intramuscular Dexamethasone sodium phosphate 12mg given12 hours apart. (produced by Taizhou Overseas International Ltd. 126-128 Qingnian Road Jiaojiang, Taizhou, Zhejiang, China)
89465921|NCT03446937|Experimental|Betamethasone sodium phosphate injection|Intervention: Drug: Betamethasone sodium phosphate injection Two doses of intramuscular betamethasone sodium phosphate 12mg given 12 hours apart. (obtained from Twinbrook pkwy, Rockville, MD Singapore. CAT No 1068004, Lot: R004e0)
89465922|NCT03446937|Placebo Comparator|Water for injection|Intervention. Drug: Water for injection. Two doses of intramuscular water for injection given 12 hours apart.
89465923|NCT03652493|Experimental|CARBOPLATIN|CARBOPLATIN in Intraveinous Dose AUC 5 according to Calvert every 3 weeks, for a duration of 6 to 9 cycles
89465924|NCT02521701|Experimental|NFL101|"Level 1: 100 µg~50 µg per injection (in each arm), two injections at day 1 and two injections at day 29~The 140 µg must be diluted in 2.8 mL of dilution solution in order to obtain a 50 µg.mL-1 concentration.~Level 2: 200 µg~100 µg per injection (in each arm), two injections at day 1 and two injections at day 29~The 140 µg must be diluted in 1.4 mL of dilution solution in order to obtain a 100 µg.mL-1 concentration. Therefore, for this level only, two vials are needed to inject 2 x 1.0 mL."
88945787|NCT01901484|Active Comparator|Drug: Praziquantel|Praziquantel 40mg/Kg - single dose
89465925|NCT03446859|Experimental|TENS|It consists of 25 subjects with primary dysmenorrhea which were put on TENS for 30 minutes, three for 3 days. The subject were placed in supine lying in a comfortable position as possible. The abdomen to the inguinal region were decently exposed and cleaned, after inspection of the area for cuts, skin infections or any abnormalities. A pair of electrodes ( inactive electrodes) will be placed a little below the umbilicus ( Right and Left) and the other pair(active electrode) along the inguinal region at the level of pubic symphysis ( Right and Left) according to (Akinbo et al 2000). A quadripolar method will be used for electrode placement.
88945788|NCT01901484|Active Comparator|Praziquantel|double dose
88945789|NCT01901497|Experimental|Solo nebulizer|Amikacin (500 mg/4 mL) administered with an Aerogen AeroNeb Solo nebulizer associated with a bilevel ventilator
88945790|NCT01901497|Experimental|Pro nebulizer|Amikacin (500 mg/4 mL) administered with an Aerogen AeroNeb Pro nebulizer associated with a bilevel ventilator
88945791|NCT01901497|Experimental|NIVO nebulizer|Amikacin (500 mg/4 mL) administered with an Aerogen AeroNeb NIVO nebulizer associated with a bilevel ventilator
89465926|NCT03446859|No Intervention|Control|These are 25 subjects which were not in any intervention. These were subjects that were not placed on TENS and were not used to drug taken for the amelioration of the dysmenorrhea. They were educated on the purpose of research and their inform consent was obtained. Their pain intensity was measured firs, third and 5th days
89465927|NCT04054349|Experimental|Low FODMAP Diet Group|The parent/caregiver was given detailed nutrition education by the investigator concerning the low FODMAP diet and was asked to implement for 2 weeks.
89465928|NCT04054349|No Intervention|Control Group (Habitual Diet)|The parent/caregiver was asked to continue their child's usual dietary intake for 2 weeks.
88945792|NCT01901510|Active Comparator|chromoendoscopy|The intervention arm will have Indigo carmine added to the colonic preperation to perform chromoendoscopy
88945793|NCT01901510|Other|Control|The control arm will have minimal Indigo carmine added to the colonic prep in a concentration which will not be enough to perform chromoendoscopy
88945794|NCT01901523|Experimental|Provision of information|Reporting of discrepancy to journal
88945795|NCT01901536|Experimental|Intervention Group|Couples randomly assigned to the Intervention Group received the Family Foundations Coparenting Program.
88945796|NCT01901536|No Intervention|Control Group|Couples in the Control group did not receive the Family Foundations Coparenting Program.
88945797|NCT01901549|Active Comparator|PCI+Renal denervation|
88945798|NCT01901549|Active Comparator|PCI alone|
88945799|NCT01901601|Experimental|LALAK|laser-assisted lamellar anterior keratoplasty. Optical Coherence Tomography, femtosecond laser, topical anesthesia, and Retrobulbar Block or General Anesthesia will be used.
88945800|NCT01901601|Active Comparator|IEK|Intralase-enabled keratoplasty. Femtosecond laser and Retrobulbar Block or General Anesthesia will be used.
88945801|NCT01901627||Adalimumab|Chinese adult patients with a diagnosis of AS who meet the requirements per the local label for treatment with adalimumab.
89465929|NCT03446703|Experimental|SCIT Social cognition interactive|Psychosocial intervention based on the Spanish translation of the original SCIT (Social Cognition and Interaction Training) instruction manual (Combs & Penn; Lahera & Benito, in press).
89465930|NCT03446703|Active Comparator|TAR Training in affect recognition|Training in Affect Recognition it is a 12-session training on facial affect recognition over a period of 6 weeks.
89465931|NCT03652727|Experimental|ECG-EM Guidance|PICC insertion using electrocardiographic and electromagnetic guidance [Site~Rite® 8 Ultrasound System with integrated SHERLOCK 3CG™ Diamond Tip Confirmation System (TCS)]
89465932|NCT03652727|Active Comparator|FX Guidance|PICC insertion using fluoroscopic guidance
89465933|NCT01348165|Experimental|BI 137882 Dose 1|Powder for oral solution
89465934|NCT01348165|Experimental|BI 137882 Dose 2|Powder for oral solution
89018260|NCT04569747|Experimental|PERTUZUMAB + TRASTUZUMAB + ADJUVANT ENDOCRINE THERAPY|"Study treatment will be administered in 21-day (3- week, +/- 3 days) cycles for one year (18 cycles).~Trastuzumab + Pertuzumab SC fixed dose combination~Hormonal therapy- oral, daily per cycle (may add LHRH agonist per investigator discretion)"
89465935|NCT01348165|Experimental|BI 137882 Dose 3|Powder for oral solution
89018261|NCT04569123|Active Comparator|Vibration|The device will deliver imperceptible vibration for the treatment group.
89465936|NCT01348165|Experimental|BI 137882 Dose 4|Powder for oral solution
89465937|NCT01348165|Experimental|BI 137882 Dose 5|Powder for oral solution
89465938|NCT01348165|Experimental|BI 137882 Dose 6|Powder for oral solution
89465939|NCT01348165|Experimental|BI 137882 Dose 7|Powder for oral solution
89465940|NCT01348165|Experimental|BI 137882 Dose 8|Powder for oral solution
89465941|NCT01348165|Experimental|BI 137882 Dose 9|Powder for oral solution
89465942|NCT01348165|Placebo Comparator|Placebo|Powder for oral solution
89501976|NCT04424732|Other|Stereotactic Body Radiotherapy for Breast Bony oligometastases|Newly diagnosed bone only oligometastatic breast cancers with 1-3 bone metastases will be enrolled in this protocol. Patients will receive SBRT to all metastatic sites.
89501977|NCT05496530|Active Comparator|Diabetic macular edema|Cases with diabetic macular edema with central macular thickness more than 300 microns measured by optical coherence tomography.
88945802|NCT01901640|Experimental|DA-8159|Udenafil(The study had one arm.)
88945803|NCT01901666|Experimental|Growth hormone deficient group|0.3mg/kg/week GH in seven divided doses will be given subcutaneously for one year.
88945804|NCT01901692|Experimental|TACE+External beam RT|Transarterial chemoembolization plus external beam radiation therapy
88945805|NCT01901692|Active Comparator|Sorafenib|Sorafenib 800 mg/day orally
88945806|NCT01901705|Active Comparator|Indigo|The Indigo naturalis ointment will be provided and patients are instructed to use it twice daily for 8 weeks or achieve completely skin clearing whichever comes first.
88945807|NCT01901705|Placebo Comparator|Placebo|The Placebo will be provided and patients are instructed to use it twice daily for 8 weeks or achieve completely skin clearing whichever comes first.
88945808|NCT01901718||Subsys|Cancer patients experiencing breakthrough pain.
88945809|NCT01901731|Experimental|Embolisation of pelvic veins & treatment of leg varicose veins|Transjugular coil embolisation of pelvic veins followed by endovenous treatment of leg varicose veins
88945810|NCT01901731|Active Comparator|Endovenous treatment of leg varicose veins alone|Endovenous treatment of legs varicose veins only
88945811|NCT01901744|Experimental|Patients undergoing cataract surgery|
88945812|NCT01901757|Experimental|HCP1201, Fasted followed by fed|HCP1201 dosing in the fasted state followed by fed dosing
88945813|NCT01901757|Experimental|HCP1201, Fed followed by fasted|HCP1201 dosing in the fed state followed by fasted dosing
88945814|NCT01901783|Active Comparator|With primary closure|The ridge augmentation graft will be covered with a barrier membrane and the soft tissue will be primarily closed.
88945815|NCT01901783|Experimental|Without primary closure|The ridge augmentation graft will be covered with a barrier membrane and the soft tissue will not be primarily closed.
88945816|NCT01901796|Experimental|Screening and CBT|Screening and Cognitive Behavioral Therapy. The intervention group will be screened and if they need criteria they will complete the 6, 30-minute online, interactive CBT modules over 6 weeks.
88945817|NCT01901796|No Intervention|Usual care|Usual prenatal care
88945818|NCT01901822|Active Comparator|Sutured separately|The soft tissue and the allograft will each be sutured separately using a continuous sling suture.
88945819|NCT01901822|Experimental|Sutured together|The soft tissue and the allograft will be sutured together using a continuous sling suture.
88945820|NCT01901835|Experimental|Arm I (humorous followed by non-humorous movies)|Participants are provided headphones and a tablet and choose among a selection of humorous movies. Upon the third course of chemotherapy, participants are provided a selection of non-humorous movies.
88945821|NCT01901835|Experimental|Arm II (non-humorous followed by humorous movies)|Participants are provided headphones and a tablet and choose among a selection of non-humorous movies. Upon the third course of chemotherapy, participants are provided a selection of humorous movies.
88945822|NCT01901887|Experimental|Study Juice|"3,300 mg of Omega-3 HUFAs per day for 6 months~Other names: none"
88945823|NCT01901887|Placebo Comparator|Placebo Juice|"3,300 mg of macadamia nut oil per day for 6 months~Other names: none"
88945824|NCT01901913|Experimental|MD-bolus calculator for pre meal bolus|closed loop session with MD-bolus calculator for pre-meal bolus.
88945825|NCT01901913|Active Comparator|No MD-bolus calculator for pre-meal bolus|closed loop session without MD-bolus calculator for pre-meal bolus
88945826|NCT01901926|Active Comparator|Periodontal Treatment|"Periodontal Treatment in the form of Full mouth scaling and root planning will be given at one time only i.e. at baseline after full mouth dental checkup.~Checkup will be repeated at 3, 6 & 9 month interval along with HbA1C levels"
88945827|NCT01901926|No Intervention|Non treatment group|this group will only receive detailed dental check ups at the specified time 0, 3, 6 and 9 months respectively and there will be no scaling done. HbA1C levels will be estimated at the above specified times
88945828|NCT01901939|Experimental|exercise|daily bedside tailored low intensity pedaling exercise
88945829|NCT01901952|Active Comparator|Standard of care|
88945830|NCT01901952|Experimental|Intensive education and support|
88945831|NCT01901978|Experimental|Weight Loss|Caloric restrictive diet
89018262|NCT04569123|Sham Comparator|No Vibration|The device will deliver no vibration for the control group.
89018263|NCT04568616|Experimental|Treatment|Letrozole 2.5mg tablet administered once daily for 4 to ~12 weeks (window of + 4 weeks for surgical scheduling flexibility) final dose taken the day of surgery.
89018264|NCT04567238|Experimental|Reduced Use Condition|Participants in the reduced use condition will be provided mobile contingency management, in which they are paid to provide marijuana saliva readings that suggest they have been abstinent from marijuana use.
89018265|NCT04567238|No Intervention|Control Condition|Participants in the control condition will be asked to provide marijuana saliva readings, but they are not paid for abstinent readings. Instead, their payments are yoked to the average amount of payment made by two participants in the reduced use condition.
89018266|NCT04543409|Experimental|Benralizumab|Benralizumab active solution will be administered SC to patients by healthcare professionals in this clinical study using an accessorized prefilled syringe (APFS)
89018267|NCT04543409|Placebo Comparator|Placebo|Placebo solution will be administered SC to patients by healthcare professionals in this clinical study using an accessorized prefilled syringe (APFS)
89018268|NCT04518813|Experimental|RSP-24|Subjects will perform calibrations on the IMD (Prototype 0.5) for 41 days over a 60 day period.
89018269|NCT04497727||Patients undergoing routine colonoscopy|Patients with and without hypertension who routinely undergo colonoscopy
89018270|NCT04495088|Experimental|A (experimental arm)|The experimental arm A starts with 6 cycles of mFOLFOX or 4 cycles of XELOX. Surgery is scheduled four or six weeks after day 1 of the last mFOLFOX or XELOX cycle, respectively. No postoperative chemotherapy is planned
89018271|NCT04495088|Active Comparator|B (control arm)|In the standard arm B, patients undergo surgical resection of the primary tumor followed by stage- (risk-)adapted adjuvant chemotherapy 4-8 weeks after surgery according to recommendations of the S3 guidelines in analogy to colon cancer. Details of the recommended protocols are provided in the protocol.
89018272|NCT04486989|Experimental|Cardiovascular Conditioning Protocol|Participants will complete a sub maximal cardiovascular training program twice per week for a period of 4 weeks.
89018273|NCT04486989|Active Comparator|Voice Production Exercises|Participants will complete voice production exercises twice per week for a period of 4 weeks.
89018274|NCT04474184|Experimental|Aim 1 (focus group)|Participants attend a focus group over 2 hours about endometrial cancer including knowledge of abnormal uterine bleeding, post-menopausal bleeding, risk factors, sources of medical information, barriers to seeking gynecologic care, and acceptance of tampon self-collection for endometrial cancer detection.
89018275|NCT04474184|Experimental|Aim 2 (vaginal kit)|Participants receive a tampon kit for collection of vaginal samples.
89465943|NCT02493868|Experimental|Intranasal Esketamine plus oral antidepressant|Open-Label Induction Phase: Direct-entry participants will self-administer esketamine intranasally twice per week for 4 weeks as a flexible dose regimen in the Open-label Induction Phase. Participants will initiate a new oral antidepressant on Day 1 of this phase. Optimization Phase: Direct-entry and transferred-entry participants will self-administer intranasal esketamine (same dose) at weekly treatment sessions for the first 4 weeks of this phase, then individualized to either once weekly or once every other week based on depressive symptoms. Participants continue same oral antidepressant treatment from induction phase. Maintenance Phase: Direct-entry and transferred-entry participants assigned to esketamine will self-administer intranasal esketamine (same dose) once weekly or once every other week based on depressive symptoms. Participants continue same oral antidepressant treatment from induction phase.
89465944|NCT02493868|Experimental|Placebo Plus Oral Antidepressant|Optimization Phase: Transferred-entry participants will self-administer intranasal placebo at weekly treatment sessions for the first 4 weeks of this phase, then individualized to either once weekly or once every other week based on depressive symptoms. Participants continue same oral antidepressant treatment from induction phase. Maintenance Phase: Direct-entry and transferred-entry participants assigned to intranasal placebo will self-administer intranasal placebo once weekly or once every other week based on depressive symptoms. Participants continue same oral antidepressant treatment from induction phase.
89465945|NCT03619057||> 18 years|
89465946|NCT03619057||10 to 18 years|
89465947|NCT04884867|Experimental|Supportive life skills coaching|CBT-based supportive like skills delivered by phone by lay coaches
89465948|NCT04451655|Experimental|Interventional|
89018276|NCT04448366|Experimental|Cognitive behavioral therapy group|Patients in this group will undergo a total of 7 sessions of CBT in 5 months in addition to usual care.
89018277|NCT04448366|No Intervention|Usual care|Patients in this group will undergo usual care only.
89202031|NCT00784992|No Intervention|1|Endonasal DCR with silicone tubes (this is the control group since it is the standard procedure / gold standard, although the evidence base for the use of tubes is lacking, hence the need for this trial)
89202032|NCT00784992|Active Comparator|2|Endonasal DCR without silicone tubes (this is the 'intervention' arm)
89465949|NCT03441711||Group 1|elevated sFlt-1/PlGF ratio
89465950|NCT03441711||Group 2|normal sFlt-1/PlGF ratio
89465951|NCT03438201|Active Comparator|High-protein diet|High Protein Diet (2,0 - 2,5g/Kg body weight/day) Physical Activity protocol
89465952|NCT03438201|Active Comparator|Normoproteic diet|Standard Protein Diet (1,0 - 1,2g/Kg body weight/day) Physical Activity protocol
89465953|NCT03446625|Experimental|Resveratrol|Resveratrol will be administered orally at the dose of 2 g/day for 9 days, starting on the day of ovulation triggering.
89465954|NCT03446625|Placebo Comparator|Control|Placebo treatment will be administered for 9 days, starting on the day of ovulation triggering.
89465955|NCT04957186|Active Comparator|Patient Focus Group|Group consisting of 10 patients who have undergone breast cancer surgery (tumorectomy, mastectomy, lymph node dissection).
89465956|NCT04957186|Active Comparator|Caregiver Focus Group|Group consisting of 10 caregivers composed of 3 surgeons, 3 algologists, 3 oncologists and one study coordinator.
89465957|NCT04603521||Hypertrophic cardiomyopathy (HCM)|Survival after Myectomy Operation
89018278|NCT04438317|Active Comparator|Seldinger Technique|Small bore chest tubes inserted by Seldinger technique. A needle is inserted into the intercostal space, and the aspiration of a fluid allows the confirmation the correct position, possibly after ultrasound tracking. A metal guidewire is inserted through the needle, which is then removed. A dilator is then inserted on the metal guidewire to dilate the skin and the subcutaneous tissues. The chest tube is finally inserted on the guide, which is finally removed, and the chest tube is connected to the aspiration system after fixation to the chest wall.
89018279|NCT04438317|Active Comparator|Surgical-like Technique|Large bore chest tube inserted by surgical-like technique. Progressive chest wall dissection is conducted with appropriate instruments (scissors, scalpel, clamps…) by a non-surgeon physician. Large bore drain with rigid introductor is blindly inserted in the pleural cavity, secured to the chest wall with suture fixation and further connection to the aspiration system.
89018280|NCT04434937|Experimental|parsaclisib|parsaclisib will be taken orally QD with water without regard to food except on mornings of PK clinic visits
89018281|NCT04421560|Experimental|Pembrolizumab + Ibrutinib + Rituximab|"Phase 1b~Dose escalation will occur using a standard 3+3 dose-escalation approach, beginning at dose level I (560 mg daily) and potentially escalating to dose level 2 (840mg) with rules for escalation and de-escalation.~Ibrutinib: orally 2x daily~Pembrolizumab: 200 mg intravenously every 3 weeks~Rituximab/biosimilar: 375mg/m^2 intravenously once per week for 4 weeks (4 total doses).~Phase 2~Participants will receive Pembrolizumab, Rituximab and Ibrutinib at the pre-determined dosage level established in Phase 1b.~Ibrutinib: orally maximum tolerated dose from phase 1 daily (560 mg or 840mg)~Pembrolizumab: 200 mg intravenously every 3 weeks~Rituximab/biosimilar: 375 mg/m^2 intravenously once per week for 4 weeks (4 total doses)."
89018282|NCT04405167|Experimental|A1: Tasquinimod single agent dose escalation|There are up to 5 planned dose levels, with 3 de-escalation dose levels available in case dose level 1 is determined to exceed the MTD. This arm will enroll 15-30 subjects if all dose levels are explored.
89018283|NCT04405167|Experimental|A2: Tasquinimod single agent expansion|Additional subjects will enroll in arm A2 at the MTD and optimal schedule, so that 12 subjects total who are evaluable for response will have received the MTD/optimal schedule of single agent tasquinimod. Enrollment in arm A2 will not begin until enrollment in arm A1 has been completed and a single agent MTD/optimal schedule has been established.
89018284|NCT04405167|Experimental|B1: Tasquinimod+IRd dose escalation|Dose levels will be defined according to the same tasquinimod doses as in the single agent (Arm A1) dose escalation. Enrollment in arm B1 will not begin until enrollment in arm A1 has been completed and an MTD/optimal schedule has been established for single agent tasquinimod. Initial subjects in arm B1 will be enrolled at the lower of dose level 1 or one dose level below the single agent MTD . If this initial dose level is determined to exceed the combination MTD, further subjects will be enrolled at one dose level lower. Enrollment is not planned in arm B1 at doses higher than the single agent MTD. There are 9-12 planned subjects if all dose levels are explored.
89018285|NCT04405167|Experimental|B2: Tasquinimod+IRd expansion|Additional subjects will enroll in arm B2 at the MTD and optimal schedule, so that 12 subjects total who are both evaluable for response and previously refractory to their most recent Imid/PI combination will have received the MTD/optimal schedule of tasquinimod in combination with ixazomib, lenalidomide, and dexamethasone. To facilitate rapid enrollment and gain more experience with the combination therapy, up to 12 additional subjects with triple-class refractory myeloma (who are not previously refractory to their most recent Imid/PI combination) may be enrolled in cohort B2. Enrollment in arm B2 will not begin until enrollment in arm B1 has been completed and a combination MTD/optimal schedule has been established.
89018286|NCT04395365|Experimental|Co-trimoxazole|Co-trimoxazole, 960mg capsule oral tablet, to be taken daily for 18 months
89018287|NCT04395365|Placebo Comparator|Placebo|Placebo, 960mg capsule oral tablet, to be taken daily for 18 months
89018288|NCT04391114|Active Comparator|Traditional HoLEP|Holmium laser enucleation of the prostate (HoLEP), first reported by Fraundorfer et al in 1998, is a more recent step in the evolution of holmium laser prostatectomy. HoLEP is a safe and effective procedure which has demonstrated comparable results to Transurethral Resection of the Prostate (TURP) and open prostatectomy for patients with symptomatic enlarged prostate, with low morbidity and short hospital stay [4]. The improvement in outcome parameters is durable, and the late complications and reoperation rates reported are very low [5]. HoLEP is equally suitable for small, medium and larger prostate glands, with clinical outcomes that are independent of prostate size, unlike TURP. HOLEP offers patients the alterative of being treated endoscopically with minimal blood loss, short catheterization time, and decreased hospital stay [6].
89018289|NCT04391114|Active Comparator|Top-Down HoLEP|"The Top-Down HoLEP technique is a novel technique which offers potential benefits to the Traditional HoLEP procedure, including decreased complexity, a reduced learning curve, with anticipated improved continence [8]. A variation of this method is also being explored in Japan (termed the en-bloc technique with anteroposterior dissection HoLEP) [9]. The main difference between the Top-Down and Traditional approach is that the direction of lateral dissection begins from upwards to downwards. This could help in avoiding the overtraction of the mucosal strip overlying the posterior urethral sphincter, which theoretically leads to a decrease in the incidence of postoperative stress incontinence. Moreover, using the Top-Down approach should lead to a decrease in the incidence of lost enucleation planes, which results in decreasing the intraoperative time and decreasing the number of cases required to master the HoLEP technique."
89018290|NCT04389853|Active Comparator|Flexible ureteroscopy (fURS)|Retrograde intrarenal surgery (RIRS) has gained much popularity especially when the role of SWL, in management of LPS, has been significantly diminished in the few last years5. RIRS is dependent mainly on flexible ureteroscopy (fURS). fURS increases the quality and performance of upper urinary tract exploration, allowing for the treatment of the majority of stones at all sites. Moreover, it is associated with no risk of renal parenchymal injuries and a very low risk of bleeding.
89202033|NCT00745004|Experimental|1|Ondansetron 4mg OD, dose titrated up to a maximum of 8mg tds or down to a minimum of 4mg alternate days.
89202034|NCT00745004|Placebo Comparator|2|Placebo 1 capsule OD, dose titrated up to a maximum of 2 capsules tds or down to a minimum of 1 capsule alternate days.
89202035|NCT00745160||1|Never-smokers with lung cancer
89202036|NCT04060550||Normal controls|No history of skin disease and atopy
89202037|NCT04060550||ADEH-|Atopic dermatitis without a history of eczema herpeticum
89202038|NCT04060550||ADEH+|Atopic dermatitis with a history of eczema herpeticum
89202039|NCT00921674|Experimental|Ivermectin|ivermectin
88945832|NCT01901991|Experimental|Radioactive seed localization (RSL)|"Patients are randomised for preoperative lesion localization with either radioactive seed localization (RSL) or wire-guided localization (WGL).~In this arm 205 patients will have RSL performed. The radioactive seed is introduced through a gauge needle using standard ultrasound guidance. Once guided to the nonpalpable breast lesion, the seed is deployed into the breast tissue by advancing a stilette in the needle. The exact location is confirmed by mammography. The nonpalpable lesion is located during the operation with a handheld gamma probe, identical to the one used for the sentinel node procedure. The surgical specimen is orientated and examined at the Department of Radiology and Pathology in accordance with the existing guidelines of WGL."
88945833|NCT01901991|Active Comparator|Wire-guided localization (WGL)|"Patients are randomised for preoperative lesion localization with either radioactive seed localization (RSL) or wire-guided localization (WGL).~In this arm 205 patients will have WGL performed. Guided by ultrasound or mammography a flexible wire is introduced into the breast by the radiologist just before the operation. The tip of the wire must mark the nonpalpable lesion, and correct localization is verified by mammography. The surgeon uses the wire and mammography as a guide during the operation. The surgical specimen is orientated and examined at the Department of Radiology and Pathology in accordance with the existing guidelines of WGL."
88945834|NCT01902017|Experimental|Operative, Ketotifen|Ketotifen 5mg orally twice per day for 6 weeks.
88945835|NCT01902017|Experimental|Non-operative, Ketotifen|Ketotifen 5mg orally twice per day for 6 weeks.
88945836|NCT01902017|Placebo Comparator|Operative, Placebo|Placebo oral medication twice daily for 6 weeks.
88945837|NCT01902017|Placebo Comparator|Non-operative, Placebo|Placebo oral medication twice daily for 6 weeks.
88945838|NCT01902030||Proven/Probable IA Patients|Case Population
89465958|NCT03441399|Experimental|Escalating Incentives|Participants assigned to the escalating financial incentives will receive an increasing financial incentive for taking their antidepressant medication for the initial 6 weeks of treatment.
89465959|NCT03441399|Experimental|De-escalating Incentives|Participants assigned to the de-escalating financial incentives will receive a decreasing financial incentive for taking their antidepressant medication for the initial 6 weeks of treatment.
89465960|NCT03441399|No Intervention|Control|Participants in this condition will receive usual care.
89465961|NCT02516410|Experimental|VX-661/IVA|VX-661 100 milligram (mg) plus IVA 150 mg fixed dose combination (FDC) tablet administered orally in the morning and IVA 150 mg film-coated tablet administered orally in the evening up to Week 12.
89465962|NCT02516410|Placebo Comparator|Placebo|Placebo matched to VX-661 plus IVA FDC tablet administered orally in the morning and placebo matched to IVA film-coated tablet administered orally in the evening up to Week 12.
89465963|NCT03438123|Experimental|CZT SPECT|CZT SPECT imaging with/without the addition of CT on the Spectrum Dynamics camera
89465964|NCT02493712|Experimental|High dose|High dose, twice a day for 6 weeks.
89465965|NCT02493712|Placebo Comparator|Placebo: C|Placebo, twice a day
89018291|NCT04389853|Active Comparator|Mini-percutaneous nephrolithotomy (mini-PCNL)|PCNL has regained popularity thanks to the possibility of using reduced calibers and modern technology, which has reduced the complications without compromising the stone clearance, and more efficient intracorporeal lithotripter modalities. However, PCNL is still a challenging surgical technique and can be associated with significant complications that may compromise its efficacy. In the present time, we have available calibers ranging from 4.8 to 30 French. Many reports advocate that morbidity after PCNL may be reduced by recent modifications, such as mini-PCNL (miniperc). One meta-analysis of mini-PCNL and conventional PCNL demonstrated that mini-PCNL had a greater safety profile with similar stone free rates (SFRs)4
89018292|NCT04386941|Active Comparator|Greenlight XPS Vaporization|Greenlight 532nm laser photoselective vaporization of the prostate (PVP) is an appealing treatment modality with hemoglobin as tissue target chromophore and relatively short learning curve. The introduction of the Xcelerated Performance System (XPS) 180W in 2010 with the MoXy fibers represents the highest-powered system currently in use for this type of laser. It encourages the adoption of the enucleation principle, making it a real contender to HoLEP in treating large adenomas. Despite the fact that large prostates often require more energy and longer operative time, the XPS system has reduced the operative time and number of fibres required in these situations.
89018293|NCT04386941|Active Comparator|Xpeeda Fibre Laser Vaporesection|Holmium Xpeeda side firing fibre was introduced and it stands apart from other available technologies as a combination of power and efficiency, which minimizes vaporization time. This technology seems to revolutionize utilization of the Holmium power and delivering more energy directly to the tissue, due to its capability of being in contact with the tissue. Moreover, hemostasis would be improved by the pulse reshaping technology with a wider pulse width, activated by a dedicated footswitch. Therefore, the Lumenis Pulse™ 100W will make prostate vaporesection procedures more precise, faster and efficient, with excellent hemostasis. Consequently, bleeding is minimal, tissue is easier to remove and patients can have their catheter removed faster.
89018294|NCT04381338|Experimental|Rehabilitation in COVID-19 patients in ICU|"Every person admitted to ICU for ARDS with a confirmed diagnosis of COVID-19 Motor program~Intubated patient GCS >8: passive mobilization; postural positioning GCS< 8: passive and active-assist mobilization; postural positioning~Extubated patient~If strength < 3 MRC: passive and/or active-assist; functional retraining~If strength ≥3 MRC: active-assist and active; strength training; functional retraining Pulmonary Rehabilitation~Intubated patient GCS >8: postural positioning GCS< 8: postural positioning, cautious inspiratory muscle training~Extubated patient~If strength < 3 MRC: postural positioning, positive pressure expiration exercise,inspiratory muscle training~If strength ≥3 MRC: postural positioning, positive pressure expiration exercise, inspiratory muscle training The intensity of exercise will prescribed based on the results of the PFIT. and modified Borg Scale.~Frequency of sessions: 3×15 min/day"
89018295|NCT04381338|No Intervention|COVID-19 in ICU without Rehabilitation|Standard of care without rehabilitation in ICU
89018296|NCT04338763|Experimental|Arm A: RP72 monotherapy|
89018297|NCT04338763|Experimental|Arm B: RP72 in combination with Gemcitabine|
89018298|NCT04328532|Experimental|Pregnancy with risk factors for PPA|
89018299|NCT04318886|No Intervention|Usual Care|
89018300|NCT04318886|Experimental|Project ENABLE Cornerstone|
89018301|NCT04306120|Active Comparator|noxious cold group|The group received noxious cold (3 - 4°C) stimuli on the affected leg for 30 minutes.
89018302|NCT04306120|Active Comparator|noxious heat group|The group received noxious heat (46 - 47°C) stimuli on the affected leg for 30 minutes.
89018303|NCT04306120|Active Comparator|alternative thermal stimulation group|The group received alternative noxious heat (46 - 47°C) and noxious cold (3 - 4°C) stimuli on the affected leg for 30 minutes.
89018304|NCT04301401|Experimental|Patients being evaluated for changes in microbiota|Patients being evaluated for changes in vaginal microbiota following transvaginal surgery.
89202040|NCT00667446|Experimental|Leuprolide Acetate 3M Depot 11.25 mg|Twelve intramuscular injections of leuprolide acetate for depot suspension 11.25 mg administered 3 months (3M) apart.
89202041|NCT00667446|Experimental|Leuprolide Acetate 3M Depot 30 mg|Twelve intramuscular injections of leuprolide acetate for depot suspension 30 mg administered 3 months apart.
89465966|NCT02493712|Experimental|Low dose|Low dose, twice a day for 6 weeks
89465967|NCT04851483|Experimental|Group 1_BAY2328065 _male participants|Approximately 6 participants will be randomly assigned to one of the 2 study intervention sequences (Group 1 or Group 2).
89465968|NCT04851483|Experimental|Group 2_BAY2328065 _male participants|Approximately 6 participants will be randomly assigned to one of the 2 study intervention sequences (Group 1 or Group 2).
89465969|NCT04851483|Experimental|Group 3_BAY2328065 _male participants|Approximately 8 participants will be assigned to the study intervention with one fixed sequence.
89465970|NCT04851483|Experimental|Group 4_BAY2328065 _female participants|Approximately 9 participants will be randomly assigned to receive BAY2328065.
89465971|NCT04851483|Placebo Comparator|Group 4_Placebo _female participants|Approximately 3 participants will be randomly assigned to receive placebo.
89465972|NCT04850859||group of scapulae bones|Human adult dry scapulae bones 40 of unknown sex and age will be collected.
89202042|NCT00742352||Breast cancer patients|
89465973|NCT04850859||group of hip bones|Human adult dry hip bones 40 of unknown gender and age will be collected
89465974|NCT03437967|Other|ABAB|"Treatment, either LASER (arm A) or LOW LEVEL LASER (arm B) will be provided 3 (not less than 2) days a week for three weeks at which time crossover into the alternate arm occurs (BABA to ABAB or ABAB to BABA).~ABAB initial period is active treatment - LASER.~Active Treatment:~LASER light is delivered to the skin and deeper tissues affected by pain using either a wand or glass roller ball. Ten to 25 Watts of LASER energy is delivered to the painful regions for 8 to 16 minutes depending on the size of the area treated and other factors such as skin pigmentation."
89465975|NCT03437967|Other|BABA|"Treatment, either LASER (arm A) or LOW LEVEL LASER (arm B) will be provided 3 (not less than 2) days a week for three weeks at which time crossover into the alternate arm occurs (BABA to ABAB or ABAB to BABA).~BABA initial period is sham treatment - LOW LEVEL LASER.~LOW LEVEL LASER treatment:~Low level LASER is provided in a similar fashion using LASER power levels (1 Watt) that produce warmth only at superficial skin levels."
89465976|NCT03441243||Case group:Cesarean section urgently|- 43 patients had an emergency caesarean section between 01/01/2015 and 31/12/2016.
89465977|NCT03441243||Case group:Hemorrhage of deliverance|- 85 patients had haemorrhage of the delivery with need for a transfusion between 01/01/2015 and 31/12/2017.
89465978|NCT03441243||Control group: delivery physiological low path|- A control group will consist of 128 patients who had a physiological low birth delivery over the same period.
89465979|NCT03441087|Other|Transvaginal ultrasound|Transvaginal ultrasound was applied 216 women with abnormal uterine bleeding.The transvaginal ultrasound diagnoses were compared with the received endometrial samples.
89465980|NCT03441087|Other|Hysteroscopy|Hysteroscopy was also performed under general anesthesia.Hysteroscopy was performed by a single operator (NNY).The operator and two supervising endoscopists were blinded to the ultrasound results.After the hysteroscopy, endometrial sampling was also done. The diagnoses were compared with the received endometrial samples.
89465981|NCT03446547|No Intervention|Arm A|SBRT and follow-up
89465982|NCT03446547|Experimental|Arm B|SBRT followed by Durvalumab
89465983|NCT02516332|Experimental|Supervised Aerobic Exercise|Patients will exercise three times per week, under medical supervision, at a level of 70-85% of their VO2peak as determined at the time of their baseline exercise stress test. Patients' exercise will consist of 10 minutes of gradual warm-up exercises followed by 35 minutes of continuous walking, biking, or jogging, and 5 minutes of cool down exercises for a total a 50 minutes per session. Patients will be instructed to monitor their radial pulses and will be checked at least three times per session to ensure that they are within their prescribed exercise training ranges.
89465984|NCT02516332|Experimental|Lexapro|Treatment in the medication will be supervised by a study psychiatrist. Drug dispensing will be done by licensed pharmacists at the Duke Investigational Pharmacy Service. The investigators will use the SSRI escitalopram (Lexapro), which has received FDA approval for the treatment of anxiety, in 5 mg capsules. Medication will be dispensed as capsules of escitalopram in individually coded bottles. Medication adherence will be assessed using pill count at each study visit. Patients will visit face-to-face with a study psychiatrist at week 0 (baseline), week 1, week 2, week 4, week 8, and week 12 with phone encounters at weeks 3 and 6. The psychiatrist will make all medication adjustments based primarily upon Spielberger Anxiety Scores. Depending on symptoms, daily escitalopram doses will be titrated to 10 mg after week 2 and to 15 mg or placebo equivalent at week 3 if patients show no change or only minimal improvement.
89465985|NCT02516332|Placebo Comparator|Placebo|Treatment in the medication and placebo pill arms will be supervised by a study psychiatrist. Drug dispensing will be done by licensed pharmacists at the Duke Investigational Pharmacy Service, who have extensive experience in clinical trials. Medication will be taken once daily in the morning but can be switched to once daily in the evening if deemed necessary. Placebo medication administration will follow the same protocol as outlined for Lexapro.
89465986|NCT03437811||Active Treatment|Active arm, Electro Flo Percussor, Model 5000 airway clearance system for daily basis as needed (pro re nata).
89465987|NCT03446469|Experimental|Individuals with Chronic Ankle instability|Individuals with history of ankle sprains will be screened using the inclusion criteria before being included in the study
89465988|NCT04954846|Experimental|OMNi-BiOTiC SR-9|Treatment is taken twice a day for 3 months
89465989|NCT04954846|Placebo Comparator|Control|Placebo is taken twice a day for 3 months
89465990|NCT03129477|Experimental|Telemonitoring in NonInvasiveVentilation|"Tele-monitoring in noninvasive ventilation with Lumis 150 and others Resmed equipments with AirView monitoring system, in COPD patients.~• Education and adaptation of the patient to NIV."
89465991|NCT03129477|No Intervention|2- conventional monitoring group|"Conventional monitoring group~• Education and adaptation of the patient to NIV."
89465992|NCT02483572|Experimental|Functional Communication Training|Participants assigned to this condition will receive treatment immediately after assignment. The investigators will implement functional communication training (FCT) to teach the participant an appropriate request response, known as a functional communication response or FCR. FCT training will continue until the participant emits independent FCRs in at least 90% of the 30-s intervals and until destructive behavior decreases by 90% (relative to pre-treatment baseline) for two consecutive sessions.
89501978|NCT05496530|Active Comparator|Vogt-koyanagi harada|Cases with vogt-koyanagi harada and complicated with exudative retinal detachment confirmed by optical coherence tomography.
89202043|NCT00742352||Lung cancer patients|
89202044|NCT00742430||Resistant|patients who are resistant to standard antithrombotic drugs
89202045|NCT00742430||Nonresistant|patients who are not resistant to standard dual antithrombotic drugs
89202046|NCT00688844||PKU subjects - baseline|Male and female subjects with PKU at baseline starting KuvanTM therapy.
89202047|NCT02555670||BIA and CT|Patients who had a CT-scan made for diagnostic reasons.
89202048|NCT00777972|Experimental|1|Fosinopril sodium and hydrochlorothiazide 20-12.5 mg tablets by Ranbaxy Laboratories Limited
89465993|NCT02483572|No Intervention|Waitlist-Control Condition|Participants assigned to the waitlist-control condition will not immediately receive services. These participants will be paired with an FCT-condition participant such that the no-treatment duration for these participants is yoked to the amount of time their respective FCT-condition participants receive services (e.g., most treatment last approximately 4 months, or 16 weeks); if Participant A finishes treatment in 16 weeks, Participant B will not receive treatment for at least 16 weeks for comparative measures). After the wait period, these participants will then receive the same services as those assigned to the immediate treatment (FCT Condition).
89465994|NCT03437655|Active Comparator|Zinc oxide and eugenol|Temporary direct restoration with zinc oxide and eugenol.
89465995|NCT03437655|Active Comparator|Mineral trioxide aggregate|Temporary direct restoration with Mineral trioxide aggregate.
89465996|NCT04813497|Other|Participants who refuse the SARS-CoV-2 vaccine|Participant who does not wish to be vaccinated against the SARS-CoV-2 virus and who wishes to perform the serological test during the vaccination campaign and the second 12-14 weeks after the first serological test.
89465997|NCT04813497|Other|Participants who received the first dose of SARS-CoV-2 vaccine before the first serological test|Participant who has received his first dose of vaccine and who performs his serological test when he receives the second dose of vaccine against the SARS-CoV-2 virus to determine his immunity. The second serological test will be done 12 to 14 weeks after the second dose of the SARS-CoV-2 vaccine to determine its immunity.
89465998|NCT04813497|Other|Participants who start with the serological test before SARS-CoV-2 vaccine|Participant who performed the serological test before the first dose of vaccine and 12 to 14 weeks after the second dose of vaccine against the SARS-CoV-2 virus to determine his immunity.
89465999|NCT04813497|Other|Participants who received the third dose of SARS-CoV-2 vaccine|Participant who performs his serological test when he receives the third dose of vaccine against the SARS-CoV-2 virus to determine his immunity.
89466000|NCT04813497|Other|Participant who received the third dose of SARS-CoV-2 vaccine and|Participant who performs a serological test between 12 and 14 weeks after the third dose of SARS-CoV-2 vaccine to determine immunity. And who has agreed to undergo serological testing prior to the third dose of the vaccine.
89466001|NCT03446391||Kinematic alignment with GMK Sphere®|Patients enrolled prospectively with surgeries planned to get kinematic alignment
89466002|NCT03446391||Mechanical alignment with GMK Sphere®|Historical group who had mechanical alignment, match-paired with the prospective group
89466003|NCT03437499|Active Comparator|Positive Pressure Ventilation|Positive Pressure Ventilation ( peak pressure set at 25 cmH20 and PEEP set at 5 cmH2O, with 40 inflations per minute)
89466004|NCT03437499|Experimental|Sustained Inflation|Prolonged inflation ( 25 cmH20 for 15 seconds) followed by PEEP set at 5 cmH2O
89466005|NCT03446313|Experimental|MVN Group|Participants assigned to the MVN Group will be using the Movn Rehab mobile app after they are discharged from cardiac rehab.
89466006|NCT03446313|No Intervention|Usual Care|Participants assigned to the Usual Care group will receive standard instructions and educational handouts after they are discharged from cardiac rehab.
89466007|NCT01062425|Experimental|Cediranib, TMZ, and RT|Cediranib (3 days) followed by radiation therapy (RT) + daily temozolomide (TMZ) + cediranib followed by cediranib monotherapy (4 weeks) followed by TMZ + cediranib for 12 cycle maximum.
89466008|NCT01062425|Active Comparator|Placebo, TMZ, and RT|Placebo (3 days) followed by radiation therapy (RT) + daily temozolomide (TMZ) + placebo followed by placebo monotherapy (4 weeks) followed by TMZ + placebo for 12 cycle maximum.
89466009|NCT03446235|Experimental|Connected Health|This group will get 2 interviews about physical exercise (exercise instruction with motivational interview) and 6 communications with individualized instruction and counseling of their physical exercise (investigators can access activity data and exercise log) including the usage of the monitoring device.
89466010|NCT03446235|Active Comparator|Self-Monitoring|This group will do physical exercise following the initial instruction and self-monitor them. Investigators can access activity data and exercise log but will not discuss with the subjects about the data.
89466011|NCT03440541|Experimental|treated|Patients who received patches of REGE pro on psoriasis lesion weekly for 8 weeks
89466012|NCT03437187|Other|Cholecystectomy without nerve blocks|Cholecystectomy, enteral and parenteral analgesics
89466013|NCT03437187|Placebo Comparator|Cholecystectomy with placebo nerve block|Cholecystectomy, NaCl as a placebo Quadratus lumborum block
89466014|NCT03437187|Active Comparator|Cholecystectomy with naropin nerve block|Cholecystectomy, Quadratus lumborum block with naropin
89466015|NCT05127525|Experimental|Test Drug|IRX-101 drops instilled prior to intravitreal injection
89466016|NCT05127525|Active Comparator|Control|Povidone-Iodine/Betadine drops instilled prior to intravitreal injection
89501979|NCT05496530|Active Comparator|Retinal vein occlusion|Cases with retinal vein occlusion and complicated with macular edema confirmed by optical coherence tomography.
88945839|NCT01902030||possible/No IA Patients|Control population
88945840|NCT01902056|Active Comparator|one layer allograft|One layer allograft as a positive control
88945841|NCT01902056|Experimental|Two layer allograft|Two layer allograft as the test group.
88945842|NCT01902069|Experimental|Phosholean dietary supplement|Subjects in the PhosphoLean group will receive two capsules of PhosphoLEAN orally daily (total of 55 mg of NOPE and 100 mg of EGCG), one capsule consumed 60 minutes prior to lunch and one capsule 60 minutes prior to dinner.
88945843|NCT01902069|Placebo Comparator|Placebo (rice flour) group|The control (placebo) group will receive a placebo (identical in appearance, but containing 100 mg of rice flour per capsule), one capsule consumed 60 minutes prior to lunch and one capsule 60 minutes prior to dinner.
88945844|NCT01902082|Experimental|Mesenchymal stem cell arm|Patients received one dose of 1x 10^6 allogeneic adipose-derived mesenchymal stem cells/kg body weight intravenously within 48 hours of enrollment.
88945845|NCT01902082|Placebo Comparator|Placebo|Patients received one dose of normal saline.
88945846|NCT01902095|Experimental|Tooth powder (test) arm|Experimental arm: tooth powder
88945847|NCT01902095|Active Comparator|Tooth Paste (control)|Tooth Paste
88945848|NCT01902108|Experimental|Clonidine|Clonidine 150μg added to bupivacaine in a local infiltration before wound incision
88945849|NCT01902108|Active Comparator|Bupivacaine|Bupivacaine 0.25 % alone in the wound infiltration
88945850|NCT01902121|Experimental|TI 30 units (10 unit + 20 unit|Technosphere® Insulin 30 units given as 2 cartridges: one 10 unit cartridge + one 20 unit cartridge
88945851|NCT01902121|Experimental|TI 30 units (30 unit cartridge|Technosphere® Insulin 30 units given as one 30 unit cartridge
88945852|NCT01902147||Elective major abdominal, thoracic, and arthroplasty surgery|All consenting patients scheduled for elective major abdominal, thoracic, and arthroplasty surgery will be followed for 8 weeks after surgery to measure the quality of recovering using the PQRS.
88945853|NCT01902160|Experimental|Treatment (temsirolimus, brentuximab vedotin)|Patients receive temsirolimus IV over 30-60 minutes on days 1 and 8 or days 1, 8, and 15 and brentuximab vedotin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 16 courses in the absence of disease progression or unacceptable toxicity.
88945854|NCT01902186|Experimental|raltegravir|raltegravir and atazanavir and ritonavir
88945855|NCT01902186|Active Comparator|tenofovir/emtricitabine|tenofovir/emtricitabine and atazanavir and ritonavir
88945856|NCT01901861|Active Comparator|Sitagliptin|Sitagliptin 100mg is given before meal ingestion
88945857|NCT01901861|Placebo Comparator|Placebo|Placebo is given before meal ingestion
88945858|NCT01902199|Active Comparator|TRAA|participants will be given the active TRAA intervention where landscape images are linked with a push motion, and portrait images linked with a pull motion. Pictures will exclusively be related to smoking.
88945859|NCT01902199|Placebo Comparator|Control|participants will be given a mix of landscape and portrait pictures, equally divided into push or pull. the images will be a mix of smoking related pictures and non smoking pictures.
88945860|NCT01902212|Experimental|Oral Nutritional Supplement|2 servings a day
88945861|NCT01902225|Experimental|Istodax, Doxil|"Istodax; Intravenous; 8-14 mg/m2; Days 1, 8, and 15; over 4 hours~Doxil; Intravenous; 20 mg/m2; Day 1; over 1 hour"
88945862|NCT01902238|Experimental|EUS-guided ethanol-lipiodol mixture ablation|By using 3D-volumetric analysis, the optimal volume of ethanol is calculated by computer estimation of areas on each axial image, using EUS software permitting volume calculation. After calculating optimal ethanol volume by 3D volumetric analysis, we advance the needle into the tumor and inject estimated volume of ethanol/lipiodol (1:1 mixture), typically 1 to 1.5 ml.
88945863|NCT01902251|Experimental|Enzalutamide tablet|Multiple once daily oral doses of enzalutamide formulated as a tablet for approximately 8 weeks
88945864|NCT01902251|Active Comparator|Enzalutamide capsule|Multiple once daily oral doses of enzalutamide formulated as liquid-filled soft gelatin capsule for approximately 8 weeks
88945865|NCT01902264|Experimental|EE20/DRSP/L-5-MTHF|
88945866|NCT01902277||Adult critically ill patients|All adult patients treated within study time frame on Intensive Care Units across Norfolk, Suffolk, and Cambridgshire, UK
88945867|NCT01902329|Experimental|SGN-CD33A + HMA|SGN-CD33A with hypomethylating agent
88945868|NCT01902329|Experimental|SGN-CD33A Monotherapy|SGN-CD33A
88945869|NCT01902342|Experimental|CES1 gene variant group|Oseltamivir 75 mg 1 cap
88945870|NCT01902342|Experimental|CES1 gene wild type group|Oseltamivir 75 mg 1 cap
88945871|NCT01902355|Experimental|modified Seldinger technique|Use needle that is covered with guiding sheath. After desired vessel puncture, guiding sheath is instantly slid over the needle into the vessel. The needle is withdrawn, guidewire is advanced through the guiding sheath, central catheter is placed into the vessel.
88945872|NCT01902355|Active Comparator|Seldinger technique|The desired vessel is punctured with a sharp hollow needle, syringe is detached and guidewire is advanced through the lumen of the needle, and then the needle is withdrawn. Central catheter is then passed over the guidewire into the vessel.
88945873|NCT01902368|Other|screen detected, early diagnosis cohort|Subjects will be informed they have celiac disease and will be started on the gluten free diet.
88945874|NCT01902368|No Intervention|screen detected, delayed diagnosis cohort|Subjects will not be told they have celiac disease and will not start the gluten free diet.
88945875|NCT01902394|Experimental|Whole grain rich diet|Participants in the whole grain (WG) group will receive a diet providing 100% of energy requirements in a diet rich in whole grains.
89537213|NCT03067623|Experimental|PRP-infusion|PRP will be obtained from a fresh whole blood collected from a peripheral vein; the blood sample will be centrifuged at 1500g (RCF) for 10 minutes and the repeated reversal of the tube will allow obtaining the PRP at the concentration required. Then 0,5-1ml of PRP will be infused into the uterine cavity through a Tomcat catheter. The endometrial thickening will be evaluated by ultrasonography 24-48h after the instillation and, if the endometrial lining reaches 7mm the Embryo-transfer will be arranged.
88945876|NCT01902394|Placebo Comparator|Refined grain rich diet|Participants in the refined grain (RG) group will receive a diet providing 100% of energy requirements in a diet rich in refined grains.
88945877|NCT01902394|No Intervention|Negative control|Subjects randomized to the negative control group will consume their own usual diet (i.e. not receive foods and beverages from the study).
88945878|NCT01902420||patients with acromegaly|patients with acromegaly caused by a growth hormone secreting pituitary adenoma
88945879|NCT01902420||healthy control|healthy volunteers without a personal or family history of pituitary adenoma
88945880|NCT01902433|Experimental|Astym|A form of soft tissue mobilization using instruments
88945881|NCT01902433|Active Comparator|Eccentric Exercise|Eccentric exercise is a form of exercise where the benefit comes from applying a controlled lengthening stress to the muscle and tendon.
88945882|NCT01902446||Chlorhexidine gluconate|Intubated subjects transported by one air service will be treated with 5 mL chlorhexidine gluconate 0.12% applied for at least 30 seconds during helicopter transport.
88945883|NCT01902446||Normal saline (placebo)|Intubated subjects assigned transported by another air service will not have any additional treatment (in addition to usual care) during helicopter transport.
88945884|NCT01902472||FTC/TDF for PrEP|HIV-1 negative adults (any sex/gender, including transgender) who seroconvert while taking FTC/TDF for PrEP
88945885|NCT01902485|Active Comparator|Quickstart|Immediate start
88945886|NCT01902485|Active Comparator|Afterstart|Delayed start
88945887|NCT01902498|Experimental|Aspirin 162mg twice daily|Patients will receive 162mg twice daily during the postoperative period, until day 7 postop or the end of hospitalization.
88945888|NCT01902498|Active Comparator|Aspirin 325mg daily|Patients will receive 325mg daily during the postoperative period, until day 7 postop or the end of hospitalization.
88945889|NCT01902498|Active Comparator|Aspirin 81mg daily|Patients will receive 81mg daily during the postoperative period, until day 7 postop or the end of hospitalization.
88945890|NCT01902511|Experimental|G-CSF + Erythropoietin|
88945891|NCT01902511|Active Comparator|G-CSF|
89537214|NCT05729529|Active Comparator|Lipoic acid gel|Patients were treated with a topic gel of lipoic acid
89537215|NCT05729529|Placebo Comparator|Placebo|Patients treated with a placebo gel control
89466017|NCT01060553|Experimental|Arm 1|The treatment program consisted of 24 semi-individualized acupuncture treatments over 12 weeks. It combines front and back treatments to avoid point fatigue (tolerance due to frequent use). The front treat-ment uses 11 needles, bilateral at acupuncture points LR3, PC6, HT7, ST36, SP6, and one at Yintang; the back treatment uses 14 needles, bilateral at points GB20, and BL14, 15, 18, 20, 21, and 23. There are 15 other points from which the flexibly prescribed points could be chosen
89466018|NCT01060553|No Intervention|wait list control|subjects were put on a wait list control. due to small numbers completing in both groups, the data from the wait list who completed acupuncture are combined with the experimental treatment group for analysis.
89466019|NCT05077995|Experimental|Healthy adult group|Sixty healthy adults, aged 18-65 years, will be included following written informed consent.
89466020|NCT05100927||An MR pulse sequence developing on the MRIdian system|This a pilot study to assess and optimize an MR pulse sequence that we are developing on the MRIdian system. It is a single-center trial recruiting only normal volunteers. Volunteers may be grouped by anatomic region of assessment.
89466021|NCT03436953|Experimental|CX-8998 T-type calcium channel blocker|
89466022|NCT03436953|Placebo Comparator|Comparator|
88945892|NCT01902524|Experimental|Fentanyl-TTS|Study drug administered in a form of one patch, either 21.0 cm2 or 10.5 cm2.
88945893|NCT01902537||Participants With Constipation|Participants with constipation receiving prucalopride will be observed for for the health related quality of life (QoL).
89466023|NCT02491684|Placebo Comparator|Placebo (matching)|Placebo, once daily inhalation for 14 days
89466024|NCT02491684|Experimental|Interferon beta-1a|Interferon beta-1a, 24 μg (metered dose) once daily inhalation for 14 days
89466025|NCT04755465|Experimental|Resistance Exercise Group|The lower extremity resistance exercise (REx) program was designed by reviewing the exercise principles recommended by the ACSM and the literature on physical activity and hematological cancer patients. The patients were treated for 40-60mins, 6 weeks. The exercise program includes active movements of the upper and lower extremities, stretching exercises, and resistance exercises for the lower extremities. REx to be applied with resistance bands of different resistance or with the patient's body weight. Clinical force generation of therapy bands follows a progression. Our proposed training protocol includes 4-6 different exercises for each extremity. Intensity, sets, and reps were adjusted to a target score of 12 to 14 using the Borg scale. Patients performed 1 set of 10 repetitions of each REx based on their fatigue level. Intensity (~ RPE 15-16) and resistance were gradually increased. When the patient complained of extreme fatigue, the resistance was reduced to the previous level.
89466026|NCT04755465|Experimental|NMES Training Group|In addition to resistance exercises, NMES will be applied to the quadriceps muscles in both legs of the patients in this group. The application will be made with a portable device using disposable electrodes. One of the electrodes will be placed proximally, that is, at the midpoint of the quadriceps muscle, while the second electrode will be placed on the distal part. In order to ensure that the patients get used to the device, low-intensity current with a frequency range of 5 Hz, 10-30 minutes. Afterward, the treatment program will continue with a high-frequency current with a frequency range of 50 Hz, 15 minutes. Participants were instructed to voluntarily contract the quadriceps muscles during periods of HF-NMES stimulation to increase the strengthening effect and improve NMES tolerance.
89466027|NCT03128697|Experimental|Satiating diet-Low satiety phenotype|Low satiety phenotype subjects who were submitted to the experimental diet (satiating diet) for a 16-week period.
89466028|NCT03128697|Experimental|Satiating diet-High satiety phenotype|High satiety phenotype subjects who were submitted to the experimental diet (satiating diet) for a 16-week period.
89466029|NCT03128697|Active Comparator|Control diet-Low satiety phenotype|Low satiety phenotype subjects who were submitted to the control diet (based on the Canadian Food Guide) for a 16-week period.
89466030|NCT03128697|Active Comparator|Control diet-High satiety phenotype|High satiety phenotype subjects who were submitted to the control diet (based on the Canadian Food Guide) for a 16-week period.
89466031|NCT01061723|Placebo Comparator|Placebo|Placebo (for sarilumab) weekly (qw) for 12 weeks.
89466032|NCT01061723|Experimental|Sarilumab 100 mg q2w|Sarilumab 100 mg Subcutaneous (SC) injection alternating with placebo every other week (q2w) for 12 weeks.
89466033|NCT01061723|Experimental|Sarilumab 150 mg q2w|Sarilumab 150 mg SC injection alternating with placebo q2w for 12 weeks.
89466034|NCT01061723|Experimental|Sarilumab 100 mg qw|Sarilumab 100 mg SC injection qw for 12 weeks.
89466035|NCT01061723|Experimental|Sarilumab 200 mg q2w|Sarilumab 200 mg SC injection alternating with placebo q2w for 12 weeks.
89466036|NCT01061723|Experimental|Sarilumab 150 mg qw|Sarilumab 150 mg SC injection qw for 12 weeks.
89466037|NCT03445767|No Intervention|Standard Care|All patients will receive perioperative care per the standards of TOH. Standard care relevant to our study consists of a history by a nurse or physician; a best possible medication history performed by a pharmacy technician; and standardized perioperative-specific medication recommendations (e.g., anticoagulant, diabetes agent, and ACE-inhibitor management) based on medical directives. Medication recommendations beyond these medical directives do not occur as standard care in our clinics. Participants will be informed that their medical care will proceed as usual and that they are being recruited for a study to evaluate medication recommendations before surgery
89466038|NCT03445767|Experimental|Intervention|In addition to standard care, the intervention will include a structured preoperative polypharmacy management strategy that consists of: a) input of best possible medication history and comorbidities into our polypharmacy management tool (MedSafer); b) communication of the prioritized deprescribing plan (if indicated) to the patient's active treating physicians (automatically via fax), to the perioperative team (surgeon, anesthesiologist), and to the electronic medical record. During the pre-operative visit, the patient will receive a generalized information flyer about deprescribing. As in the usual care phase, patients will continue to receive usual recommendations from the perioperative team based on medical directives relevant to the perioperative period.
89466039|NCT03445611|Experimental|Group 1|These patients will receive a corticosteroid solution with lidocaine containing parabens.
89466040|NCT03445611|Active Comparator|Group 2|These patients will receive corticosteroid solution with paraben free lidocaine.
89466041|NCT03440307|Placebo Comparator|Email Only|Participants received weekly email about health and fitness education. No face-to-face intervention, and not provided any other information about bisphenol exposure.
89202049|NCT00777972|Active Comparator|2|Monopril ®.-HCT 20-12.5 mg tablets by Bristol-Meyers Squibb following a single oral dose (1 x 20-12.5 mg tablet
89466042|NCT03440307|Experimental|Face-to-Face Meetings|Participants met with a counselor once per week for 3-weeks to reduce bisphenol exposure. Intervention included same weekly email about health and fitness education as Email only group, and a weekly face-to-face meetings to reduce bisphenol exposures from food, cosmetics, and packaged products. Women provided with bisphenol-free cosmetics, hygiene, and glass food/water containers.
89466043|NCT03440151|Experimental|contralateral submental flap for tongue cancer defect|
89466044|NCT03440151|Active Comparator|primary closure for tongue cancer defect|
89466045|NCT04054739|Experimental|Robot-assisted gait training|experimental group that applied the end-effector robot-assisted gait training
89466046|NCT04054739|Active Comparator|Treadmill gait training|control group that applied the treadmill gait training
89466047|NCT03440073|Experimental|Mulligan Concept Intervention|Mulligan Concept Intervention, including Mobilizations with Movement intervention is administered. Up to 30 minutes total treatment time.
89466048|NCT03440073|Sham Comparator|Sham Mulligan Concept Treatment|Assessment procedures of the Mulligan Concept are followed, but no manual pressure is applied to the participant during treatment to provide a sham Mulligan Concept Treatment.
89466049|NCT01061567||Male and female patients with Parkinson's disease|
89466050|NCT04360629|Experimental|high dose TXA|TXA will be given as a 20mg/kg bolus followed by infusion of 5mg/ kg/hr per our anesthesia protocol
89202050|NCT00745238|Experimental|Myotonic Dystrophy 1|
89466051|NCT04360629|Experimental|low dose TXA|TXA will be given as a 10mg/kg bolus followed by infusion of 1mg/ kg/hr per our anesthesia protocol
89466052|NCT04360629|Placebo Comparator|normal saline|saline will be given as a 4ml/kg bolus followed by infusion of 1ml/ kg/hr per our anesthesia protocolprotocol4ml/kg
89466053|NCT04741035|Experimental|Modified sternal precautions|Interventional group (Modified sternal precautions)
89466054|NCT04741035|Active Comparator|Conventional sternal precautions|Control group (Conventional sternal precautions)
89202051|NCT00785070||1|Perioperative
89202052|NCT00782262|Other|Group 1 (n=20)|BP < 140/90, no diabetes mellitus and fasting glucose < 5.5
89466055|NCT03445455||De novo AHRF|"Acute hypoxemic non hypercapnic respiratory failure with a PaO2/FiO2 ratio < 200.~The following oxygenation devices are used and assessed during routine care:~High concentration mask, High flow nasal canula, NIV using buco-nasal mask or Helmet.~Electro impedence tomography signal will be recorded throughout this assessement for tidal volume measurement"
89466056|NCT03445377|Active Comparator|Real-time continuous glucose monitoring|Subjects will be reviewed and a blood sample will be taken for the measurement of HbA1c. Training on the use of DEXCOM G5 or similar will be provided by the research team. Competency on the use of the system will be evaluated. Participants will be advised to use real-time CGM continuously for the next 8 weeks. At the end of the first intervention, a blood sample for the measurement of HbA1c will be taken. Validated questionnaires evaluating diabetes-related distress, management and user acceptance will be completed.
89466057|NCT03445377|Placebo Comparator|Self-monitoring of blood glucose|Subjects will be reviewed and a blood sample will be taken for the measurement of HbA1c. During the Control Period, masked CGM will be applied for one week, during Week 1, 4 and 8. At the end of this, a blood sample for the measurement of HbA1c will be taken. Validated questionnaires evaluating diabetes-related distress, management and user acceptance will be completed.
89466058|NCT03436719|Experimental|Oral with Intravenous|Oral metronidazole and erythromycine administration on the day before surgery with intravenous cefoperazone before surgery (30-90 min) and additional doses every third hour during surgery
89466059|NCT03436719|Active Comparator|Intravenous|Intravenous dose cefoperazone before surgery (30-90 min) and additional doses every third hour during surgery
89466060|NCT04182659|Active Comparator|Active rTMS at the LMC|Subjects will receive the repetitive Transcranial Magnetic Stimulation (rTMS) study procedure at the left motor cortex (LMC)
89466061|NCT04182659|Sham Comparator|Sham rTMS at the LMC|Sham rTMS will appear the same as the active, with the same parameters, but will not receive the actual magnetic stimulation to the LMC.
89466062|NCT04452123|Experimental|Argon plasma|Patients with endometrioma treated with laparoscopic argon plasma energy.
89466063|NCT04452123|Experimental|Stripping and suture/coagulation|Patients with endometrioma treated with laparoscopic excision with suture or gentle coagulation of the rest of ovary.
89466064|NCT03439995|Experimental|Open Lung Protective Ventilation|Volume cycled assist control ventilation with tidal volume 8 cc/kg predicted body weight, PEEP 10 cm water (H2O), recruitment maneuvers every 8 hours and after any ventilator disconnect
89202053|NCT00782262|Other|Group 2 (n=20)|BP > 140/100, no diabetes mellitus and fasting glucose < 5.5
89466065|NCT03439995|Active Comparator|Conventional Ventilation|Volume cycled assist control ventilation with tidal volume 10 cc/kg predicted body weight, PEEP 5 cm H2O, recruitment maneuvers after any ventilator disconnect
89466066|NCT04452201|Experimental|Guided Participation (GP)|A GP intervention is participatory formal and informal education to support learning of a practice beyond what could occur as efficiently and effectively without guidance. GP uses strategies for teaching-learning that make best use of the family's situation and opportunities, tailored to the parents' needs. The overall goal of the GP intervention is to support parent couples in effectively communicating for parenting work, including care-giving and maintaining the couple's relationship
89466067|NCT04452201|No Intervention|Usual Care (UC)|The UC group will receive standard of care
89466068|NCT01061333|Experimental|Placebo|Placebo
89466069|NCT01061333|Experimental|Montelukast|Montelukast
89466070|NCT01061333|Experimental|Nedocromil|Nedocromil
89466071|NCT01061333|Experimental|Mometasone|Mometasone
89466072|NCT03445299|Experimental|Music|Daily music listening for 30 minutes at bedtime
89466073|NCT02489968|Experimental|empagliflozin 10 mg + linagliptin 5 mg|patient to receive a tablet containing low dose empagliflozin and linagliptin once daily
89466074|NCT02489968|Experimental|empagliflozin 10 mg|patient to receive a tablet containing low dose empagliflozin once daily
89466075|NCT02489968|Experimental|empagliflozin 25 mg + linagliptin 5 mg|patient to receive a tablet containing high dose empagliflozin and linagliptin once daily
89202054|NCT00782262|Other|Group 3 (n=20)|BP <140/100, no diabetes mellitus, fasting glucose 5.5 - 6.9
89202055|NCT00745472||1|
89466076|NCT02489968|Experimental|empagliflozin 25 mg|patients to receive a tablet containing high dose empagliflozin once daily
89466077|NCT03439761|Experimental|PT-112 Injection|PT-112 Injection alone
88945894|NCT01902550|Experimental|Metoprolol plus placebo then Metoprolol plus JNJ-54452840|Metoprolol tartrate immediate-release (metoprolol IR) will be administered as single oral dose of 100 milligram (mg) tablet or capsule. After two hours, placebo (normal saline) will be administered intravenously over 1 minute on Day 1.
88945895|NCT01902550|Experimental|Metoprolol plus JNJ-54452840 then Metoprolol plus placebo|Metoprolol IR will be administered as single oral dose of 100 mg tablet or capsule. After two hours, JNJ-54452840 (12 milliliter [ml] solution containing 240 mg JNJ-54452840) will be administered intravenously over 1 minute.
89466078|NCT04941586|Experimental|Education in pain, Manual Therapy and Exercises|The therapies will be performed by one a physical therapist with experience in rehabilitation, twice a week, lasting 60 minutes, for one month. Each therapy will last 20 minutes.
89466079|NCT04941586|Active Comparator|Manual Therapy and Exercises|The terapies will be performed by one a physical therapist with experience in rehabilitation, twice a week, lasting 40 minutes, for one month. Each therapy will last 20 minutes.
89466080|NCT03436407||PrEP Group|Subject offered to start PrEP treatment in routine clinical practice
89466081|NCT03436407||Control Group|"Enrolled patients will be regarded as their own control when it comes to their sexual health and quality of life reported for period prior to inclusion in the study.~Subjects diagnosed with HIV within last 12 months in general clinical practice and referred to the outpatient clinic at the Dept. of Infectious Diseases, OUS. (details in protocol 3.3.2)~Frequency of STI reported to the National Institute of Public Health (MSIS) will be compared with the frequency of STIs in the study cohort."
89466082|NCT04451421|Experimental|Standing Angle|Assist the electric hospital bed to conduct different Angle standing training, starting from 20 degrees, every five minutes to rise 5 degrees, the maximum rise to 80 degrees
89466083|NCT03436329|Experimental|Vein ligation first|During this procedure, patients undergo lobectomy with the pulmonary vein ligated first.
89466084|NCT03436329|Active Comparator|Artery ligation first|During this procedure, patients undergo lobectomy with the pulmonary artery ligated first.
89466085|NCT04451577||EMPLOYEES WITHOUT COVID-19 INFECTION|"Humanitas group employees (including ICH, Humanitas University and Gavazzeni), and two validation cohorts.~Negativity to COVOD-19 will be tested by peripheral blood samples every month for 6 months (or until seroconversion). If they are positive for anti- covid 19 antibodies, a test for positivity of the virus will be carried out. T"
89466086|NCT04451577||EMPLOYEES WITH COVID-19 INFECTION|"Humanitas group employees (including ICH, Humanitas University and Gavazzeni), and two validation cohorts.~employees that are Sars-Cov-2 positive both symptomatic and asymptomatic, there will be at least 2 peripheral blood samples (5 and 3 ml) at every control visit until ascertained negativity. They will also undergo a pharyngeal swab for viral titers and microbiota analysis at enrollment and at negativity. In addition, a sample of saliva/sputum will be collected for most of the employees at positivity and at every control visit.~For employees hospitalized but not requiring intensive care the following samples will be collected:~an aliquot of samples from the respiratory tract (e.g., bronchial aspirate, bronchoalveolar lavage) residual from the normal clinical practice~saliva/sputum~pharyngeal swab not used for diagnosis both at admission and at the first check up~blood sample in EDTA for plasma and peripheral blood mononuclear cell (PBMC)"
89466087|NCT04451343||Patients|Patients with a diagnosis of colorectal cancer before 65 years.
89466088|NCT04451343||Family|The spouse and /or children and /or parents of a patient 's diagnosis of colorectal cancer before 65 years.
89466089|NCT03444987||patients group|"include 35 pre-menopausal women (age ˂ 50 years) enrolled to undergo hysterectomy for symptomatic UF at the women health hospitals, Assiut University.~The protein expression of the followings markers will be estimated in tumor tissue samples:~Fibroblast activation protein (FAP) will be measured by quantitative real time polymerase chain reaction qRTPCR (mRNA level) and ELISA (protein level).~Autophagy markers level (LC3 and p62) will be measured by qRTPCR (mRNA level) and by immunohistochemical analysis.~Phosphorylated protein kinase B (pAKT ) by ELISA (protein level). analysis.~Markers of oxidative stress (Malondialdehyde as lipid peroxide) by a colorimetric method.~Reduced glutathione, an antioxidant marker by a colorimetric method~."
89466090|NCT03444987||Control group|"include 35 normal myometrial tissue samples obtained 1 cm away from the fibroid capsule from the same patients.~The protein expression followings markers will be estimated in normal myometrial tissue samples~Fibroblast activation protein (FAP) will be measured by quantitative real time polymerase chain reaction qRTPCR (mRNA level) and ELISA (protein level).~Autophagy markers level (LC3 and p62) will be measured by qRTPCR (mRNA level) and by immunohistochemical analysis.~Phosphorylated protein kinase B (pAKT) by ELISA (protein level).~Markers of oxidative stress (Malondialdehyde as lipid peroxide) by a colorimetric method.~Reduced glutathione, an antioxidant marker by a colorimetric method~."
89466091|NCT03436251|Experimental|Local Hyperthermia at 44℃ for HPV+/CIN-1|Local hyperthermia at 44℃ for 30 mins on cervical region, at days of 1,2,3 and 17, 18. HPV+ and normal cytology or HPV+/CIN-1
89466092|NCT03436251|Sham Comparator|local hyperthermia at 37℃ for 30 mins|HPV+/CIN-1
88945896|NCT01902589||Patients with Helicobacter pilorii in biopsy|Patients with Helicobacter pylori in biopsy, cultures will be obtained and subsequently sensitivity to antibiotics studied.
89466093|NCT03436251|Active Comparator|coniztion of the cervix treatment|coniztion of cervix for HPV+/CIN2, including LEEP or cold knife coniztion
89466094|NCT03436251|Experimental|Local Hyperthermia at 44℃ for CIN2/HPV+|Local hyperthermia at 44℃ for 30 mins at days of 1,2,3 and 17, 18. HPV+ and CIN2.
89466095|NCT03129165|Experimental|Screening and prevention of CVD|
88945897|NCT01902615||Cohort|
88945898|NCT01902641|Active Comparator|Succinylcholine|Patient received succinylcholine as a muscle relaxant(0.5 mg /kg)for induction of anaesthesia for rigid bronchoscopy.
88945899|NCT01902641|Active Comparator|Rocuronium/Sugammadex|Patient received rocuronium (0.25 mg/ kg) as muscle relaxant for induction of anaesthesia for rigid bronchoscopy, at the end of procedure rocuronium was reversed with sugammadex (0.5mg/kg.)
88945900|NCT01902641|Active Comparator|Rocuronium|Patients received rocuronium (0.25 mg /kg)as muscle relaxant for induction of anaesthesia for rigid bronchoscopy.
89202056|NCT00745472||2|
89466096|NCT03436173|Experimental|Fluoxetine|Fluoxetine 10 mg/2.5 ml
89466097|NCT03436173|Placebo Comparator|Placebo|Peppermint syrup measured to equivalent volume
89466098|NCT03436095||research group|bundle measures to help patient to weaning ventilator
89466099|NCT03436095||historical control group|retrospect the patients who were difficult to wean from ventilator and collect some materials to compare.
89466100|NCT03436095||External control group|contrast other same level hospitals measures to patients who are difficult to wean ventilator.
89466101|NCT03444831|Experimental|Buspirone plus Omeprazole|
89466102|NCT03444831|Placebo Comparator|Placebo plus Omeprazole|
89466103|NCT03439215|Experimental|Lorlatinb Arm|Eligible patients will be treated with Lorlatinib at the dose of 100 mg QD p.o.
89466104|NCT02483416||group 1|Group without 'remote additional personalised nurse-led follow-up: patients will receive the healthcare given routinely by their medical team
89466105|NCT02483416||group 2|Group with 'remote additional personalised nurse-led follow-up: patients will receive telephone calls from a nurse in addition to the healthcare given routinely by their medical team
89466106|NCT03128463||significantly effective group|visual improvement ≥15 letters in Early Treatment Diabetic Retinopathy Study (EDTRS) table after intravitreal injection of conbercept
89466107|NCT03128463||effective group|visual improvement ≥5 letters and <15 letters in EDTRS table after intravitreal injection of conbercept
88945901|NCT01902654||Knee osteoarthritis|Patients over 50 years who presented to an outpatient rheumatology for 1 year and who had knee osteoarthritis.
88945902|NCT01902654||Hand osteoarthritis|Patients over 50 years who presented to an outpatient rheumatology for 1 year and who had hand osteoarthritis.
88945903|NCT01902654||Soft tissue disease|All patients over 50 years who presented during the same period of time of other cohorts, to an outpatient rheumatology and who had soft tissue disease with no other rheumatic condition.
88945904|NCT01902667||Curative intent surgery alone|Patients with retroperitoneal sarcoma randomised into surgery alone arm.
88945905|NCT01902667||Pre-operative radiotherapy plus surgery|Patients with retroperitoneal sarcoma randomised to Arm 2: pre-operative radiotherapy plus surgery.
88945906|NCT01902680|Experimental|Focal brachytherapy|Focal brachytherapy with permanent I125 localized implant.
89466108|NCT03128463||invalid group|visual improvement <5 letters and visual reduction<5 letters in EDTRS table after intravitreal injection of Combercept
89466109|NCT03128463||deterioration group|visual reduction≥5 letters in EDTRS table after intravitreal injection of conbercept
89466110|NCT04953364|Experimental|SMART|The experimental group will receive access to SMART online platform (6 weeks). SMART includes mental and physical wellness, residual/prosthetic limb managements, use of a prosthesis and weekly peer-support calls or video call over Zoom, hosted by University of British Columbia, depends on participant's preference, promoting motivation and establishing goal setting and action planning. SMART will also allow asynchronous contact with trainers through a secure website.
89466111|NCT04953364|Active Comparator|Control|The control group will receive a care booklet and weekly contacts for 6 weeks.
89466112|NCT03438903||Normal group|Healthy subjects without any ocular problems Repeat exams of OCT device (SD and SS-OCT)
89466113|NCT03438903||Retinal diseases group|Patients with various macular diseases Repeat exams of OCT device (SD and SS-OCT)
89466114|NCT01061177|Experimental|Nilotinib|This was a single-arm study; therefore all participants received nilotinib (AMN107) 300 mg bid given as two 150 mg capsules twice daily.
89466115|NCT02481934|Experimental|NKAE cells infusion + chemotherapy|Expanded and activated autologous NK cells (NKAEs) + chemotherapy (lenalidomide OR bortezomib).
89466116|NCT03436017||ADHD|Patient with ADHD diagnosis criterion. The aim is the identification of Biomarkers of ADHD by a Metabolomic Approach
88945907|NCT01902719|Experimental|Community Health Worker (CHW) Intervention|Participants randomized to this arm will receive the Community Health Worker Intervention that will include training in the use of home blood pressure machine, education on diet and exercise, and one-on-one support to assist with overcoming barriers to hypertension control (e.g., accessing healthcare, social and community services).
89466117|NCT03436017||non ADHD|"Patient with symptom of hyperactivity and/or attention deficiency but without ADHD diagnosis criterion.~The aim is the identification of Biomarkers of ADHD by a Metabolomic Approach."
89466118|NCT03444519|Experimental|Mannitol A|in this group, Mannitol (1.0g/kg) is given just after the induction of general anesthesia
89466119|NCT03444519|Active Comparator|Mannitol B|in this group, Mannitol (1.0g/kg) is given at the time of skin incision
89466120|NCT04309383||ShuntCheck|Participants will be administered the ShuntCheck diagnostic test.
88945908|NCT01902719|Experimental|CHW Intervention and Communication Skills Training|Participants randomized to this arm will receive the Community Health Worker Intervention and a communication skills training to partner with their physician providers in a way that encourages their greater involvement and shared decision-making with their physicians about hypertension care.
88945909|NCT01902719|Experimental|CHW and Problem Solving Skills Training|Participants randomized to this arm will receive the Community Health Worker Intervention and the Problem Solving Skills Training Intervention, a 9-week peer based self-management intervention to help patients improve their hypertension self-management by learning and employing skills to overcome their self-identified barriers to self-management.
88945910|NCT01902732|Other|Implantation of valves (IBV)|Following catheter-based measurement of collaertal ventilation, each patient is treated by a complete occlusion of the targeted lobe by intrabronchial valves.
88945911|NCT01902745|Active Comparator|Fatigue Reduction Diet|"The FRD maintains a participant on a diet with their typical caloric intake and replaces some of their calories with the following foods on a daily basis; whole grains, vegetables (one leafy green, one tomato, and on yellow/orange), fruit (one high in vitamin C), fatty fish and nuts and/or seeds.~A social cognitive theory intervention method will take place that motivates the participant to change their behavior and lifestyle for overall well being."
88945912|NCT01902745|Active Comparator|General Health Curriculum|"Counseling sessions on oral health, healthy eyesight, over-the-counter drug disposal, skin and hair health, cell phone and health, hearing loss, colorectal cancer screening, and preventing colds and flu.~A social cognitive theory intervention method will take place that motivates the participant to change their behavior and lifestyle for overall well being."
88945913|NCT01902771|Experimental|DC Vaccine + Lysate|"Leukapheresis: Baseline, post-surgery;~Dendritic Cell Vaccine (DC Vaccine): Post-Leukapheresis, administered intradermally once weekly via intradermal injection, for 4 weeks for a total of four vaccinations;~Tumor Lysate (Lysate): Post-DC Vaccine therapy. Administered intradermally during weeks 8, 12, 16, and 28;~Imiquimod: Self-applied topically by subject before and after scheduled DC Vaccine or Lysate administrations."
88945914|NCT01902784|Experimental|Storytelling Interview|"Participants assigned to receive the intervention will participate in an interview with a trained interventionist who will facilitate the telling of their 'story' - the personal experience they went through as a surrogate decision-maker for a loved one in the intensive care unit (ICU), who subsequently died after decisions were made to limit life-sustaining treatments (LST).~These participants will be evaluated with questionnaires at baseline, 3 months, and 6 months after the death of their loved one (ICU patient)."
88945915|NCT01902784|No Intervention|Monitoring of well-being|Participants assigned to the Monitoring of well-being group will receive follow up phone calls from study staff and be evaluated with questionnaires at baseline, 3 months, and 6 months after the death of their loved one (ICU patient).
88945916|NCT01902797|Experimental|Household|In each camp, the camp residences are divided into different sections (as clusters for sampling) by camp registration. In the first stage, sections are selected using Population-proportion-to size (PPS) method. In the second stage, households are randomly selected from the household list in each section provided by NGO and local committee. When a household is not responding, a nearest household on the north will be used as replacement. All family members and overnight guests aged above 5 years in the selected household will be invited for venous blood sample (2 ml); for children aged 1-5 years old, the blood sample (100 microL) will be obtained by finger prick; children younger than 1 year old are excluded. The head of household will be invited for a short questionnaire.
88945917|NCT01902810|Active Comparator|Propranolol|Propranolol by mouth given daily throughout hospitalization
88945918|NCT01902810|Placebo Comparator|Sugar Pill|Placebo by mouth given daily throughout hospitalization
88945919|NCT01902823|No Intervention|No Nurse Navigator Services|
88945920|NCT01902823|Experimental|Services from a Nurse Navigator|
88945921|NCT01902836|Experimental|Conventional Treatment plus DLE|"Conventional treatment plus DLE~Conventional treatment: oral Cetirizine 0.25mg/kg, every day, for 4 weeks; chlorpheniramine 0.35 mg/Kg, daily divided in 3 doses, for 4 weeks; and topical Methylprednisolone 0.1% over affected skin area, every 12h for 10 days, then every 24h for 10 days, then every 48h for 10 days and suspend;~Dialyzed Leukocyte Extracts as Adjuvant Treatment: oral DLE (Transferon) (2mg/5mL), then every day for 5 days, and then every 72hrs to complete one month."
88945922|NCT01902836|Placebo Comparator|Conventional treatment plus placebo|"Conventional treatment plus placebo:~oral Cetirizine 0.25mg/kg, every day, for 4 weeks; chlorpheniramine 0.35 mg/Kg, daily divided in 3 doses, for 4 weeks; and topical Methylprednisolone 0.1% over affected skin area, every 12h for 10 days, then every 24h for 10 days, then every 48h for 10 days and suspend; plus oral placebo, every day for 5 days, then every 72hrs to complete one month."
88945923|NCT01902849||Group 1 - TIVA-TCI|"include 35 patients with colorectal cancer undergoing surgery~anaesthesia is induced and maintained with total intravenous target-controlled infusion ( TIVA-TCI) of propofol and remifentanil.~for propofol initial target plasma concentration (Cp) is set to 4 micrograms/ml (modified Marsh model)( Base Primea™, Fresenius, France) and then adjusted in steps 0.2 micrograms/ml to maintain the BIS values between 40-55 during surgery.~for Remifentanil initial Cp is set at induction at 4 ng/ml and then the Cp is maintained between 3-8 ng/mL(increments of 0.5 ng/ml in case of inadequate anesthesia).~intervention:blood sampling for IL measurement"
88945924|NCT01902849||Group II- ISOFLURANE|"include 35 patients with colorectal cancer undergoing surgery~anesthesia is induced with propofol bolus 1,5-2 mg/kg and remifentanil TCI mode (Minto model) (Base Primea™, Fresenius, France) with an initial Cp 4 ng/ml~maintenance of anesthesia is achieved with isoflurane 1-1.5 MAC in order to maintain the BIS value between the values of 40-55 and remifentanil TCI with Cp between 3-8 ng/mL (increments of 0.5 ng/ml in case of inadequate anesthesia)~intervention:blood sampling for IL measurement"
88945925|NCT01902862|Experimental|Bortezomib plus rituximab|Bortezomib will be administered as intravenous infusion as 1.6 milligram per meter square (mg per m^2) on Days 1, 8, 15 and 22 of cycle 1 and Days 36, 43, 50, 57 of cycle 2 and (if applicable) on Days 71, 78, 85, and 92 of Cycle 3. Rituximab will be administered as intravenous infusion as 375 mg per m^2 on Days 36, 43, 50, 57 of cycle 2 and (if applicable) on Days 71, 78, 85, and 92 of Cycle 3.
88945926|NCT01902875||TP regimen + CIK group|This group are treated with Preconditioning Chemotherapy （Paclitaxel + Cisplatin） Combined with Cytokine Induced Killer Cell Immunotherapy （CIK cell therapy）.
88945927|NCT01902875||TP regimen group|This group are treated with Chemotherapy （Paclitaxel + Cisplatin） only.
88945928|NCT01902914|Experimental|Hearing Aids, Model P02|A body-worn, local made, digital hearing aids Hearing Aids evaluation
88945929|NCT01902914|Active Comparator|Other hearing aids|Other Hearing Aids, Hearing Aids Evaluation
88945930|NCT01902927|Experimental|COPD patients|COPD patients will perform a constant workrate treadmill exercise test until exhaustion with positve/neutral/negative visual distraction images during the exercise test assigned in a randomized order
88945931|NCT01902940||Natural History|Assessment of natural history in IBM and CCFDN
88945932|NCT01902979|Experimental|Lifestyle intervention|In Weeks 1 and 6, people in the intervention group will meet with a Registered Dietitian and an Exercise Physiologist for personalized sessions. They will receive a pedometer and instructions on how to log in to the e-health site (https://sspanli.mtroyal.ca). They will wear the pedometer daily and log in to the website each week for a nutrition education session, a weekly step goal, and tips.
88945933|NCT01902979|No Intervention|Usual Care|
89202057|NCT00778050|Experimental|1|amoxicillin tablets for oral suspension 600 mg by Ranbaxy Laboratories Limited
89202058|NCT00778050|Active Comparator|2|Amoxil ® for oral suspension 400 mg/ 5 mL by SmithKline Beecham Pharmaceuticals (600mg dose)
89466121|NCT03129009|Active Comparator|Total intravenous anesthesia group|Total intravenous anesthesia induced with sufentanil,etomidate,cisatracurium and midazolam and maintained with propofol,cisatracurium and remifentanil target controlled infusion
89466122|NCT03129009|Experimental|Balanced anesthesia group|Balanced anesthesia induced with sufentanil,etomidate,cisatracurium and midazolam and maintained with cisatracurium and remifentanil target controlled infusion and sevoflurane inhalation
89466123|NCT03129087|Experimental|Vocal activity|The vocal activity arm will require the participant to remain in the clinic and read aloud continuously for a period of one hour after a botulinum toxin injection
89466124|NCT03129087|Experimental|Vocal rest|The vocal rest arm will require the participant to remain in the clinic and remain on complete vocal rest for a period of one hour after a botulinum toxin injection
89466125|NCT03438591|Experimental|Cerclage-CRT (medtronic 4196 lead)|trans-coronary sinus intraseptal pacing (cerclage pacing) which technology to position the pacemaker lead into the septum for 'parahisian pacing'
89466126|NCT02973425|Active Comparator|NRT and mHealth assessment tool without feedback|"For the comparison group, implementation will be balanced in all variables except the Take a Break Intervention. The investigators will balance the two groups further by having the comparison (NRT-Sampling group) complete mHealth assessments (without feedback or goal-setting) as an attention control.~Participants randomized to the comparison group will only have access to a mHealth assessment tool similar to the Challenge Quizzes but without feedback."
89466127|NCT02973425|Experimental|Take a Break as an augmentation to NRT in Motivation|"The Intervention: Take a Break as an augmentation to NRT-sampling in Motivation Phase. Take a Break is an intervention in which smokers are encouraged to engage in smoking abstinence. The main element, the Break, is a two-week challenge where smokers report days they are smoke-free. The Break is preceded by a 1-week training challenge where Challenge Quizzes (ecological momentary assessments) collect information to guide the smokers during the Break. At baseline, all smokers will be provided NRT lozenges for sampling. At weeks 1 and 3 of the Marathon, our Tobacco Treatment Specialist will call all smokers, assess their experiences and collect data.Participants in the intervention will receive the full tool suite."
89466128|NCT03435861|Experimental|VX-745|In the present study, VX-745 will be given at the dosage of 40 mg twice a day (1 tab. of 40 mg, twice), orally for 12 weeks
89466129|NCT03435861|Placebo Comparator|placebo|In the present study, placebo will be given twice a day (1 tab. , twice), orally for 12 weeks
89466130|NCT02489500|Active Comparator|melphalan|Neupogen 16mcg/kg x 4 days Stem cell collection Drug: high dose melphalan 140 or 200 mg/m2 stem cell infusion
89466131|NCT02489500|Experimental|melphalan + Bortezomib|Neupogen 16mcg/kg x 4 days Stem Cell collection drug: high-dose melphalan 140 or 200 mg/m2 drug: Bortezomib 1.0 mg/m2/dose x 4 doses stem cell infusion
89466132|NCT03438513||Problem Solving Therapy|This program is intended for caregivers to acquire techniques to manage stressful situations encountered in everyday life.
89466133|NCT03438513||Speaking group|The group will be led by a psychologist.
89466134|NCT03438513||Standard medical care|Occupational Therapy Assessment Psychological assessment
89466135|NCT03652649|Experimental|3:1 Ketogenic Complete Meal Replacement|Evaluating glycemic control and weight loss in obese participants with type 2 diabetes treated for 6 months with 3:1 [fat]:[protein+carbohydrate] ratio, 1600 kcal/day complete meal replacement ketogenic diet
89466136|NCT03438435|Experimental|QRH-882260 Heptapeptide|Five mL of reconstituted (with sterile 0.9% NaCl) QRH-882260 Cy-5-labeled heptapeptide
89466137|NCT04053959|Experimental|AI Group|Artificial intelligence assisted insulin titration system group
89466138|NCT04053959|Active Comparator|Control Group|Physicians decided insulin titration group
89466139|NCT03433443|Active Comparator|Control group|Usual physical rehabilitation group
89466140|NCT03433443|Experimental|Intervention group|Case manager assisted rehabilitation
89466141|NCT03652571|Experimental|Nortriptyline|"Nortriptyline in an escalating dose regimen:~Week 1-2: 10mg daily Week 3-4: 25mg daily Week 5-12: 50mg daily"
89466142|NCT03652571|Placebo Comparator|Placebo|Placebo
89466143|NCT03433365||1|Potential study subjects will sign an informed consent prior undergoing any study related procedure. Patients enrolled in this study will receive Lenalidomide-based regimen as maintenance therapy according to their previous decided therapeutic schedule. All consecutive patients treated with Lenalidomide-based regimen as maintenance therapy and with inclusion criteria will be asked to participate to this study.
89466144|NCT03652103|No Intervention|GCont|Only dressing will be applied to patients without actually nerve catheter performed
89466145|NCT03652103|Experimental|GBlock|"Ultrasound Guided Erector Spinae Plane Block Catheter will be applied: 20ml Bupivacaine 0.25% Injectable Solution* will be administered initially.~20 ml Bupivacaine %0.25 Injectable Solution** will be administered 30 minutes before ambulation at postoperative day(POD) 0 and before removal of nephrostomy at POD 2~*10ml %0,5 Bupivacaine will be diluted with 10ml Saline solution."
89466146|NCT03433209|Active Comparator|Ligasure device|This group of women undergoing hysterectomy were randomized to the Ligasure energy device
89466147|NCT03433209|Active Comparator|Articulating Enseal|This group of women undergoing hysterectomy were randomized to the articulating Enseal energy device
89466148|NCT03652337|Experimental|BlephEx|The subjects who are enrolled in this arm will undergo electronic lid margin debridement using the BlephEx instrument.
89466149|NCT03652337|Experimental|Manual debridement|The subjects who are enrolled in this arm will undergo manual lid margin debridement using a stainless steel ophthalmic golf spud.
89466150|NCT03652025|Experimental|Study group|perimenopausal women
89466151|NCT03444363|Experimental|Study group|SRP plus diode laser (810 nm wavelength, 1 W power)
89466152|NCT03444363|Active Comparator|Control group|SRP plus placebo
89466153|NCT01725425|Experimental|Control|Participants will receive equal amounts of foods.
89466154|NCT01725425|Experimental|Increase Portion Size|Participants will receive increased portion sizes.
89466155|NCT01725425|Experimental|Decrease Portion Sizes|Participants will receive decreased portion sizes.
89466156|NCT01725425|Experimental|Mixed Portion Sizes|Participants will receive mixed portion sizes.
89466157|NCT03444285|Active Comparator|Warm Up|
89466158|NCT03444285|Active Comparator|Hot Pack|
89466159|NCT03651947|Experimental|QL1206|QL1206 injection (120mg) by subcutaneous injection once on the first day.
89466160|NCT03651947|Active Comparator|Xgeva®|Xgeva® injection (120mg) by subcutaneous injection once on the first day.
89466161|NCT02732847|Other|Post-Dated Prescription|a delayed prescription dated 2 days after clinical office visit
89466162|NCT02732847|Other|Usual|usual date
89466163|NCT04003701|Active Comparator|Usual care group (control group)|Within the usual care, no one of the attendees in the room will have specific interaction with the child during this procedure, with the exception of normal/necessary interaction by the nurse and/or parent. Only minimal distraction is allowed. The child will sit down on the treatment table with the legs stretched out in front of him and the puncture-side arm in a 90-90 position next to the head or stretched out and lying down along the body, with the nurse at the puncture side and the parent at the other side standing next to him. The researcher is also present in the room, within the child's field of vision. At the end of the procedure, the nurse tells the child that he/she did very well.
89466164|NCT04003701|Experimental|Robot-assisted puncture procedure (experimental group)|During the experimental intervention, the child, a nurse, one of the parents/guardians, a researcher and the humanoid robot NAO (H25 Academic Edition, Aldebaran Robotics, Paris, France) will be present in the same room. The child will sit down in the same position as with the usual care. Next to the patient a humanoid robot of three-foot tall will sit on eye level on a slanted reading table, at the non-puncture side. The nurse will carry out the puncture procedure as performed as usual. The robot is programmed to distract the child during the entire procedure (before, during and after the puncture) by playing a game with the child based on his/her interests. The child can therefore choose between a number of games in different themes. In the end the robot tells the child that he/she did very well. During the whole intervention, the robot will be re-activated for each phase only when the child and the nurse are ready.
89466165|NCT05006703|Experimental|Intervention group|Access to digital intervention
89466166|NCT05006703|No Intervention|Control group|Usual care group
89466167|NCT03651869|Experimental|Condition 1|
89466168|NCT03651869|Experimental|Condition 2|
89466169|NCT03651869|Experimental|Condition 3|
89466170|NCT03651869|Experimental|Condition 4|
89466171|NCT04966221||Adult healthy volunteers|Adult healthy volunteers, age matched to patient volunteers. Will undergo a combination of functional and structural lung MRI scans.
89466172|NCT04966221||Adults with Chronic Obstructive Pulmonary Disease|Will undergo a combination of functional and structural lung MRI scans. Some participants in this cohort will have lung volume reduction (LVR) as part of their normal clinical care. These participants will be given the option to attend two study visits - one before and one after LVR.
89466173|NCT04966221||Adults with alpha-1-antitrypsin deficiency|Will undergo a combination of functional and structural lung MRI scans.
89466174|NCT03651791|Experimental|USPIO labeled MSC injection|USPIO labeled MSC injection
89466175|NCT04053647||Hypoparathyroid patients|Patients with persistent hypoparathyroidism after total thyroidectomy, defined as serum PTH inferior to 15 pg/mL 6 months after surgery and the need of vitamin-calcic supplementation.
89466176|NCT04053647||Control patients, without hypoparathyroidism|
89466177|NCT04958655|Other|Tetris, Positive Image|Participants randomised to order of intervention: this arm has; Tetris (Active Comparator) then Positive Future Image (Intervention).
89466178|NCT04958655|Other|Positive Image, Tetris|Participants randomised to order of intervention: this arm has; Positive Future Image (Intervention) then Tetris (Active Comparator).
89466179|NCT03435549|No Intervention|Arm 1: Control Arm (Usual care)|If Patient is randomized to Arm 1, no contact will occur, patient will receive standard and routine clinical care
89466180|NCT03435549|Experimental|Arm 2a: Remote monitoring|If Patient is randomized to Arm 2a they will remote monitoring for 6 weeks post-surgery
89466181|NCT03435549|Experimental|Arm 2b: Remote monitoring plus goal setting and social support|If Patient is randomized to Arm 2b, they will receive a remote monitoring plus social support and nudge messaging for 6 weeks post-surgery
89466182|NCT03651713|Experimental|GLU+EX|Subjects will consume a 75g glucose beverage three times daily for seven days while participating in five structured aerobic exercise sessions throughout the experimental protocol.
89466183|NCT03651713|Active Comparator|GLU|Subjects will consume a 75g glucose beverage three times daily for seven days without participating in structured aerobic exercise.
89466184|NCT03651557|Experimental|Neu2000KWL high dose|
89466185|NCT03651557|Experimental|Neu2000KWL low dose|
89466186|NCT03651557|Placebo Comparator|saline|
89466187|NCT05056467|Experimental|IOL|Preeclampsia High-risk Women schedule labor induction at 39 weeks of gestation
89466188|NCT05056467|No Intervention|Expectant Management|Preeclampsia High-risk Women under expectant management
89466189|NCT03435471|Experimental|G1 - Clinician-Directed Therapy|"Clinician-Directed Weekly Swallowing Therapy: Once weekly face-to-face meetings with a study speech pathologist for a total of six sessions, to participate in active swallowing exercises and review the home swallowing exercise program. Each session will last 30 minutes +/- ten minutes. Other assessments include:~Clinician-Directed Prophylactic Swallowing Exercises~Prophylactic Swallowing Home Exercise Program~Penetration/Aspiration Scale (PAS)~Functional Oral Intake Scale (FOIS)~Eating Assessment Tool-10 (EAT-10)~University of Washington Quality of Life (UW-QOL)~Performance Status Scale for Head and Neck Cancer Patients (PSS-HN)~DIGEST Safety Grade"
89466190|NCT03435471|Active Comparator|G2 - Patient-Directed Home Therapy|"Patient-Directed Home Swallowing Therapy: One face-to-face meeting with a study speech pathologist prior to initiation of treatment. During that session, they will be encouraged to practice the given exercises independently on a specific daily schedule regime throughout their treatment. Other assessments include:~Prophylactic Swallowing Home Exercise Program~Penetration/Aspiration Scale (PAS)~Functional Oral Intake Scale (FOIS)~Eating Assessment Tool-10 (EAT-10)~University of Washington Quality of Life (UW-QOL)~Performance Status Scale for Head and Neck Cancer Patients (PSS-HN)~DIGEST Safety Grade"
89466191|NCT02489344|Experimental|GZ/SAR402671|Participants received GZ/SAR402671 15 milligrams (mg) once daily orally for 30 months in this extension study (LTS14116).
89466192|NCT03433053|Placebo Comparator|Control|Participants will be exposed to a generic HIV testing message.
89466193|NCT03433053|Experimental|Experiment|Participants will be exposed to a targeted HIV testing message, developed specifically for African American women.
89202059|NCT00746486|Experimental|A|One budesonide 3 mg capsule TD or one budesonide 3 mg capsule BD and 12-16 mg ursodeoxycholic acid/kg BW/d
89537216|NCT02466815|Experimental|Treatment A, then Treatment B and then Treatment C|Participants will receive treatment A (JNJ-42756493 10 milligram [mg] tablet, current clinical formulation [G-018] which uses milled active pharmaceutical ingredient [API]) in period 1, treatment B (JNJ-42756493 10 mg tablet, Prototype Formulation I [G-025] which uses coarser API) in period 2 and then treatment C (JNJ-42756493 10 mg tablet, Prototype Formulation II [G-025] which uses coarser API) in period 3.
89537217|NCT02466815|Experimental|Treatment B, then Treatment C and then Treatment A|Participants will receive treatment B in period 1, treatment C in period 2 and then treatment A in period 3.
88945934|NCT01902992|Experimental|Depiquick® Birch|At the screening visit (Visit 1), patients will be instructed how to complete the eDiary. Eligible patients will return for visit 2 as soon as they experience significant allergic symptoms. Significant allergic symptoms are defined by a symptom score ≥ 2. If the patients' eligibility has been confirmed according to inclusion/exclusion criteria checklist, randomization to one of the 2 treatment arms will be conducted. Patients will receive two consecutive subcutaneous injections of study medication (0,2 and 0,3 ml) with a time lag of ≥ 30 minutes. Patients return to the study site in weekly intervals for visit 3, visit 4, visit 5, visit 6, and visit 7 to receive study medication injections (0,5 ml each). If treatment is completed before the end of the tree pollen season, patients will be followed-up by telephone calls every 4 weeks until the end of the tree pollen season. The study completion visit will take place 4 weeks after the end of the tree pollen season.
88945935|NCT01902992|Placebo Comparator|Placebo|At the screening visit (Visit 1), patients will be instructed how to complete the eDiary. Eligible patients will return for visit 2 as soon as they experience significant allergic symptoms. Significant allergic symptoms are defined by a symptom score ≥ 2. If the patients' eligibility has been confirmed according to inclusion/exclusion criteria checklist, randomization to one of the 2 treatment arms will be conducted. Patients will receive two consecutive subcutaneous injections of study medication (0,2 and 0,3 ml) with a time lag of ≥ 30 minutes. Patients return to the study site in weekly intervals for visit 3, visit 4, visit 5, visit 6, and visit 7 to receive study medication injections (0,5 ml each). If treatment is completed before the end of the tree pollen season, patients will be followed-up by telephone calls every 4 weeks until the end of the tree pollen season. The study completion visit will take place 4 weeks after the end of the tree pollen season.
88945936|NCT01903018|Experimental|P276-00|
88945937|NCT01903044|Experimental|BM-MNC injection|Injection of autologous bone marrow-derived mononuclear cells
88945938|NCT01903057|Experimental|Combination treatment|"Combination treatment with azithromycin, ivermectin and albendazole on day 1, followed by placebo on day 8~Placebo has same appearance and dosing as azithromycin."
88945939|NCT01903057|Placebo Comparator|Control (Standard of Care)|"Standard treatment with placebo, ivermectin and albendazole on day 1, followed by azithromycin on day 8~Placebo has same appearance and dosing as azithromycin."
88945940|NCT01903070|Experimental|Linagliptin in TD2 subjects|Linagliptin in TD2 subjects with normal renal function
88945941|NCT01903070|Experimental|Linagliptin in TD2 subjects with impaired renal function|Linagliptin in TD2 subjects with impaired renal function
88945942|NCT01903083|Experimental|Immunochemoradiotherapy|Immunotherapy with oral tadalafil daily; three doses of chemotherapy with IV Gemcitabine in 21-day cycles for up to 4 cycles; three fractions of external beam radiation to the pancreas and and regional lymph nodes; pancreaticoduodenectomy (surgical resection) for eligible patients.
88945943|NCT01903096|Experimental|Cognitive Behavioral Treatment (CBT)|Cognitive Behavioral Treatment. Seven 90-minute sessions of group treatment along 24 weeks.
88945944|NCT01903096|Active Comparator|Treatment-As-Usual (TAU)|Primary Care Treatment As Usual
88945945|NCT01903109|Active Comparator|Cevimeline first, the Evoxac|Single dose 30 mg cevimeline capsule, then single dose 30 mg Evoxac capsule (after washout period)
88945946|NCT01903109|Active Comparator|First Evoxac, then cevimeline|Single dose 30 mg Evoxac capsule, then single dose 30 mg cevimeline capsule (after washout period)
88945947|NCT01903122|Active Comparator|Cevimeline|Single Dose 30 mg Capsule
88945948|NCT01903122|Active Comparator|Evoxac|Single dose 30 mg capsule
88945949|NCT01903135|Other|[HCO3-] >= 27 mmol/L (Group 1)|All obese patients with plasmatic[HCO3-] >= 27 mmol/L will be addressed to a pneumologist. The pneumology investigations will establish(or not) the diagnosis of OHS
88945950|NCT01903135|Other|[HCO3-]< 27mmol/L+pneumologist (Group 2)|Among obese patients with serum [HCO3-]< 27 mmol/L, 300 randomized patients will be addressed to a pneumologist. The pneumology investigations will refute(or not)the diagnosis of OHS.
88945951|NCT01903135|Other|[HCO3-]< 27 mmol/L (Group 3)|Obese patients with a [HCO3-]<27 mmol/L randomized to group 3 will receive usual medical follow-up (end of study)
88945952|NCT01903161|Experimental|delayed remote ischemic preconditioning|applying pneumatic cuff on upper extremity (5 minutes cycles of limb ischemia and reperfusion with pneumatic cuff up to 200 mmHg repeated by four times)
88945953|NCT01903161|Placebo Comparator|control|All the procedures were the same in the control group, except for the fact that the three-way stopcock between the pneumatic cuff and the cuff inflator was opened and therefore the cuff pressure did not increase.
88945954|NCT01903174|Experimental|AeroForm Tissue Expansion|AeroForm Breast Tissue Expander placed after mastectomy
88945955|NCT01903200|Experimental|FK949E Fed Group|FK949E is administered after breakfast
88945956|NCT01903200|Experimental|FK949E Fasted Group|FK949E is administered in the morning under fasting conditions
88945957|NCT01903213||Kiklin group|Oral
89537218|NCT02466815|Experimental|Treatment C, then Treatment A and then Treatment B|Participants will receive treatment C in period 1, treatment A in period 2 and then treatment B in period 3.
89537219|NCT02466815|Experimental|Treatment A, then Treatment C and then Treatment B|Participants will receive treatment A in period 1, treatment C in period 2 and then treatment B in period 3.
89537220|NCT02466815|Experimental|Treatment B, then Treatment A and then Treatment C|Participants will receive treatment B in period 1, treatment A in period 2 and then treatment C in period 3.
88945958|NCT01903226|Experimental|High intensity training|Patients in this group will perform high aerobic intensity training, in 30 minutes, twice a week, in a 12 week period.
88945959|NCT01903226|Experimental|Moderate intensity training|Patients in this group will perform moderate aerobic intensity training, in 45 minutes, three times a week, in a 12 week period.
88945960|NCT01903226|No Intervention|controll|Patients in this group will perform no (additional) training.
88945961|NCT01903239|Other|Low-Risk BCC Excisional Margins|This is a study investigating the efficiency of 1-2 mm margins for the excision of low-risk basal cell carcinoma.
88945962|NCT01903278|Experimental|PEG-IFN-SA /RBV T1(Genotype2,3)|PEG-IFN-SA/RBV, 1.5μg/kg/week im and RBV 1000mg-1200mg/d po bid（BW<75kg,1000mg/d; BW≥75kg, 1200mg/d）,24 weeks
88945963|NCT01903278|Active Comparator|Pegasys /RBV C1(Genotype 2,3)|Pegasys 180μg/week and RBV 1000mg-1200mg/d bid depending on body weight(BW),（BW<75kg，1000mg/d；BW≥75kg，1200mg/d）for 24 weeks
88945964|NCT01903278|Experimental|PEG-IFN-SA /RBV T2(Non-genotype 2,3)|PEG-IFN-SA 1.5μg/kg/week and RBV 1000mg-1200mg/d bid depending on body weight(BW),（BW<75kg，1000mg/d；BW≥75kg，1200mg/d）for 48 weeks
88945965|NCT01903278|Active Comparator|Pegasys /RBV C2(Non-genotype 2,3)|Pegasys 180μg/week and RBV 1000mg-1200mg/d bid depending on body weight(BW),（BW<75kg，1000mg/d；BW≥75kg，1200mg/d）for 48 weeks
88945966|NCT01903291||dimethyl fumarate|To be taken according to the United States Prescribing Information (USPI)
89531371|NCT00706901|Experimental|Arm 2 IHMD|Participants randomized to In-Home-Messaging Devices (IHMD) received a 27-day Care Coordination Home Telehealth (CCHT) program targeting their acute recovery from alcohol and other substance use disorder. Participants received their IHMD device through the Charleston VAMC CCHT program, including device accessories and a phone number to reach their CCHT provider. They were provided with specific instructions on how to set up their IHMD in their residence after discharge. The research associate followed-up with the patient one day after receiving the device to ensure that the device was successfully set up and to provide assistance as necessary. Participants received standard VA CCHT services.
88945967|NCT01903304|Experimental|olive oil|intervention with olive oil for 3 months
89466194|NCT04451031|Experimental|LiFT Program|LiFT is a two-module curriculum workshop for youth and their parenting adults. Topics for youth include communication skills, condom use, and skill building to access sexual healthcare resources. For parenting adults, topics include building a climate of trust and open communication with youth about sexual health. Trained and certified facilitators deliver each 2.5 hour module over one or two sessions. Youth and parents participated in simultaneous but separate programming in community locations such as schools or health care settings. They received participant guides that encourage communication between them. They could opt-in to receive 12 weekly texts that offered additional resources. Parenting adults received a phone call from the facilitator a month after the workshop to reinforce the skills learned during the program.
89466195|NCT04451031|No Intervention|Comparison Group|The comparison group received business as usual. The youth and parents enrolled in the study could receive the existing services available within the broader community, which may have included sexual education delivered in the local school system. Study staff collected data throughout the study to track access to other TPP programming offered at the study sites.
89466196|NCT03432975|Experimental|Povidone Iodine 10%|The side of the mouth receiving the subgingival irrigations of povidone iodine.
89466197|NCT03432975|Placebo Comparator|Sterile saline solution|The other side of the mouth will be irrigated with a sterile saline solution.
89466198|NCT04906629|Experimental|INO-4201|One intradermal injection of INO-4201 followed by electroporation
89466199|NCT04906629|Placebo Comparator|Placebo|One intradermal injection of normal saline followed by electroporation
89466200|NCT03444207|Experimental|Group A|Endurance training
89466201|NCT03444207|Experimental|Group B|Endurance-strength training
89466202|NCT03444129|Active Comparator|Control|This group will participate in a health education workshop with weekly sessions (control group)
89466203|NCT03444129|Experimental|Game|This group will participate in the health education workshop plus the interactive health game (intervention group).
89466204|NCT03444051||20-gauge Procore®|"Between March and December 2017, 68 EUS-FNB were consecutively performed in our unit for a pancreatic or peripancreatic mass. The choice of the needle depended upon the availability at the time of admission:~34 punctures were performed with a 20-gauge Procore® during the period study"
89466205|NCT03444051||22-gauge Acquire®|"Between March and December 2017, 68 EUS-FNB were consecutively performed in our unit for a pancreatic or peripancreatic mass. The choice of the needle depended upon the availability at the time of admission:~34 punctures were performed with a 22-gauge Acquire® during the period study"
89466206|NCT02488330|Experimental|Control and/or Onartuzumab treatment|Participants will receive treatment with either the control treatment (erlotinib, bevacizumab) and/or onartuzumab-based study treatment (as during their P-trial) until progression of disease, unacceptable treatment related toxicity, withdrawal of consent, or death (whichever occurs first). All participants will continue on the same dose and schedule of control treatment as specified in their respective P-trial. The dose of onartuzumab will be calculated based on the participant's weight at the screening visit for the E-trial.
89537221|NCT02466815|Experimental|Treatment C, then Treatment B and then Treatment A|Participants will receive treatment C in period 1, treatment B in period 2 and then treatment A in period 3.
88945968|NCT01903304|Placebo Comparator|Placebo|Intervention with placebo for 3 months
88945969|NCT01903317||Topical Therapy|Subjects who use topical therapy as the standard treatment of care for their psoriasis.
88945970|NCT01903317||Phototherapy and Systemic Therapy|Subjects who use phototherapy and systemic therapy as the standard treatment of care for their psoriasis.
88945971|NCT01903317||Biologic Therapy|Subjects who use biologic therapy as the standard treatment of care for their psoriasis.
88945972|NCT01903343||Healthy Volunteers|Single group of healthy male medical students at Ninewells Hospital & Medical School, Dundee.
88945973|NCT01903369||Elective orthopaedic surgery patients|All patients presenting for elective orthopaedic surgery >16 years of age.
88945974|NCT01903382||Adult patients|All patients undergoing general anesthesia between January 2006 and December 2013
88945975|NCT01903395|Experimental|Nurse-led counselling|First-degree relatives of patients undergoing active treatment for colorectal cancer are offered a nurse-led counselling by telephone regarding emotional and cognitive barriers to screening utilization.
88945976|NCT01903395|No Intervention|Usual Care|Usual print media, offered standardly by the recruiting centres.
88945977|NCT01903447|Active Comparator|SSRI|sertraline: 100-200mg, citalopram 20-40mg, escitalopram 10-20mg, paroxetine 20-60mg; fluoxetine 20-80mg
88945978|NCT01903447|Active Comparator|CBT|12 weeks of individual cognitive behavioral therapy
88945979|NCT01903499|Active Comparator|Bean patty|Bean Patty
88945980|NCT01903499|Active Comparator|Beef patty|Beef patty
88945981|NCT01903512||arthrocentesis in TMJ internal derangement|30 patients with TMJ internal derangement and pain with history of failed conservative management.
88945982|NCT01903538|Experimental|Cathodal transcranial direct current stimulation|
88945983|NCT01903538|Sham Comparator|Sham transcranial direct current stimulation|
88945984|NCT01903551|Experimental|Loco-regional catheter|A suprafascial catheter will be positioned at the end of cardiac intervention during the thoracotomy closure. The catheter will be connected to a elastomeric pump, which delivers the analgesic drug (ropivacaine).
88945985|NCT01903551|No Intervention|Intravenous analgesia|At the end of the cardiac intervention each patient will receive intravenous analgesia with morphine at 0.8 mg/h.
88945986|NCT01903577|Experimental|Novice Laparoscopic and Robotic Surgeons|"Students and surgical trainees with less than 100 laparoscopic and less than 50 robotic cases.~Will participate in Robotic Task Performance and Laparoscopic Task Performance"
89466207|NCT04451499|Experimental|Intervention group -smartphone app|"All the participants will receive the standard care of 3-6 preparation to bariatric surgery meetings with a dietitian.~All the participants will get access to our study's smartphone app site."
89466208|NCT04451499|No Intervention|Control group|All the participants will receive the standard care of 3-6 preparation to bariatric surgery meetings with a dietitian.
89466209|NCT03435159|Experimental|Manual Chiropractic Spinal Manipulation|Demographic informations, pain, previous trauma, diseases, current medicine, past surgical operations, pregnancy, smoking use and cervical artery dissection history in family are questioned. Cervical flexion, extension, right and left rotations, right and left lateral flexions are measured by physiotherapist, in sitting position and with goniometer.Upper extremity muscle strength was measured with manual muscle testing in sitting position by physical therapist. The muscles innervated by C4, C5, C6, C7, C8 and T1 cervical nerves were examined bilaterally. Cervical foraminal compression test was used to eliminate cervical root compression.Vertebrobasilar artery was assessed by premanipulative vertebrobasilar insufficiency test.Neck Disability Index was used to evaluate the functional neck status of the participants. After all assessments, participants who were eligible for this study were undertaken Doppler Ultrasonography before and after manual manipulative intervention.
89466210|NCT03435159|Experimental|Instrumental Chiropractic Spinal Manipulation|The same assessments were applied to determine the eligibility of participants for this study. After all assessments, participants who were eligible for this study were undertaken Doppler Ultrasonography before and after instrumental manipulative intervention.
89466211|NCT02521545|Experimental|BIIB061|Single oral dose of 30 mg BIIB061 of the new formulation
89466212|NCT02521623|Experimental|Surgimend|Patients randomized to this arm will receive SurgiMend® Acellular Dermal Matrix in their direct to implant primary breast reconstruction.
89466213|NCT02521623|Active Comparator|Strattice|Patients randomized to this arm will receive Strattice™ Acellular Dermal Matrix in their direct to implant primary breast reconstruction.
89466214|NCT02521467|Active Comparator|PRF|Platelets Rich Fibrin
89466215|NCT02521467|Placebo Comparator|palatal stent|Palatal stent
89466216|NCT03432663|Experimental|24h infusion|Intravenous amiodarone infusions at doses of 5 mg/Kg for over 30 min, followed by 20 mg/Kg until 24 h was reached Intravenous amiodarone (1)
89466217|NCT03432663|Experimental|72h infusion|Intravenous amiodarone infusions at doses of 5 mg/Kg for over 30 min, followed by 20 mg/Kg every 24 h for up to 72 h or until sinus rhythm was reached Intravenous amiodarone (2)
89466218|NCT03443895|Active Comparator|Experimental: AEF0117|Subjects in cohorts 1 through 3 receive active treatments. Subjects in Cohorts 1 through 3 will receive a single dose of 0.6, 2 and 6mg respectively of AEF0117 on Day 1 to Day 7.
89466219|NCT03443895|Placebo Comparator|Placebo|Subjects in Cohorts1 through 3 will be randomly assigned in an 6:2 allocation to receive active or placebo treatments.
89466220|NCT03434847|No Intervention|Control|Standard preoperative assessment
89466221|NCT03434847|Active Comparator|Education|Pre-operative education regarding post-operative pain expectations
89466222|NCT03432585||Family Support Grant applicants|Participants include applicants for the Family Support Grants that will be provided for the American Society for Nutrition annual meeting who are willing to complete the applicant survey.
89466223|NCT03432507||disc herniation|patients suffering from disc herniation
89466224|NCT03432507||spinal stenosis|patients suffering from spinal stenosis
89466225|NCT03428841||Patients with dural puncture at epidural|Patients who sustained an accidental dural puncture during the epidural procedure.
89466226|NCT03428841||Patients with no dural puncture|Patients with no dural puncture during epidural procedure, to serve as a control group.
89466227|NCT03428763|Experimental|Homebased disease monitoring (eHealth)|Participants allocated to the intervention group will be trained in self-monitoring of their RA
89466228|NCT03428763|Active Comparator|Standard clinical disease monitoring|Those allocated to the control arm of the study will continue usual clinical care (i.e. they will not self-monitor or have access to the eHealth solution). No other medication changes will be mandated and participating investigators will be asked to manage all other care according usual clinical practice. Individuals in the control group will not be given the option to self-monitor.
89466229|NCT03432351||Children: 0-36mo|EEG sensor will be placed on the subject's forehead to observe and record EEG activity. No other applicable intervention.
89466230|NCT04450875|Experimental|Experimental group (with diet)|It consisted in the administration of nutritional therapy with foods high in methionine according to the National Nutrient Database For Standard Reference (USDA) and adapted to the consumption and usual cost in the Mexican diet.
89466231|NCT04450875|No Intervention|Control|The control group continued with their usual diet for the same period of 3 months as the experimental group.
89466232|NCT04450641|Experimental|Treatment|Treatment group used GuessWhat during the 4 week intervention period.
89466233|NCT04450641|Other|Control|Participants in control group received standard treatment as usual.
89466234|NCT03432273|Experimental|Nicotine 2 mg mint lozenges|
89466235|NCT03432273|Active Comparator|NiQuitin 2 mg mint lozenges|
89537222|NCT03067779|Other|Survey and mHealth Tool|"A survey has been designed that evaluates CRIC participants' computer and mobile phone usage, and perceived e-health literacy.~There is also a mobile health-based (mHealth) patient safety educational curriculum that evaluates CRIC participants' knowledge of patient safety hazards in CKD. The mHealth patient safety curriculum tool is also known as eCRIC."
89537223|NCT05555069|Active Comparator|Menthol Flavor Electronic Cigarette|400 adult cigarette smokers will receive 12 weeks of menthol-flavored electronic cigarettes.
88945987|NCT01903577|Experimental|Expert Laparoscopists, Novice Roboticists|"Surgeons with more than 100 laparoscopic cases, less than 50 robotic cases.~Will participate in Robotic Task Performance and Laparoscopic Task Performance"
88945988|NCT01903577|Experimental|Expert robotic and laparoscopic surgeons|"Surgeons with greater than 100 laparoscopic and greater than 50 robotic cases.~Will participate in Robotic Task Performance and Laparoscopic Task Performance"
88945989|NCT01903590|Active Comparator|Transvaginal Tape Surgery|Randomized 50 patients undergoing TVT
88945990|NCT01903590|Experimental|Transobturator tape surgery|Randomized 50 patients undergoing TOT
88945991|NCT01903603||Healthy Children|Inclusion criteria for healthy children were as follows: ages of 4-20 y/o ; good cognition and cooperation; and healthy children.
88945992|NCT01903603||CP subjects|Inclusion criteria for subjects with brain damage by CP were as follows: a diagnosis of CP and aged 4-20 years old.
88945993|NCT01903629|Experimental|magnetic-controlled capsule endoscocpy (MCE)|patients were assigned to swallow MCE first, followed by the gastroscopy
88945994|NCT01903642|Other|Patients with inflammatory syndrome|
88945995|NCT01903655|Other|patients with a first episode of major depressive disorder|a group of patients with a first episode of major depressive disorder according to DSM-IV-TR including depressive episodes with melancholic features
88945996|NCT01903655|Other|patients with recurrent depressive disorder|a group of patients with recurrent depressive disorder according to DSM-IV-TR including depressive episodes with melancholic features (at least three episodes of depression)
88945997|NCT01903655|Other|control group|patient with no depressive disorder during the study period and no psychiatric history
88945998|NCT01903681|Active Comparator|Circadin 10 mg|Second arm higher dose
88945999|NCT01903681|Active Comparator|Circadin 2 mg|First arm lower dose
88946000|NCT01903694|Active Comparator|sorafenib|800 mg of sorafenib twice daily orally.
88946001|NCT01903694|Experimental|sorafenib-pravastatin|800 mg of sorafenib twice daily oral doses associated with 40 mg of pravastatin in a taken per os. Pravastatin will be taken during dinner.
88946002|NCT01903707|Experimental|Cognitive Remediation Therapy|Participants will undertake approximately 30 minutes of computerized CRT training for 8 weeks, 5 days per week. They will meet a therapist once per week to discuss any difficulties, help motivation.
88946003|NCT01903707|Placebo Comparator|Placebo Comparator|Participants will meet therapist once per week but will not undertake the Computerized Cognitive remediation training.
88946004|NCT01903746||Patients in septic shock|
88946005|NCT01903759|Other|Patients with spontaneous rupture of the fetal membranes|
88946006|NCT01903772|Experimental|Inspiratory Muscle Training|Procedure: Inspiratory Muscle Training Three times daily inspiratory muscle training (2x30 breaths) at an intensity of >50% Pi,max
88946007|NCT01903772|Sham Comparator|Sham Inspiratory Muscle Training|Twice daily inspiratory muscle training (3x30 breaths) at an intensity of 5 centimeters of water (H2O)
88946008|NCT01903785|Experimental|Salbutamol|400ug of salbutamol (one single inhalation) will be inhaled 60min prior to the begin of a time trial. Mean power output during the following 10km time trial will be described to 1600ug salbutamol and placebo.
89537224|NCT05555069|Active Comparator|Tobacco Flavor Electronic Cigarette|400 adult cigarette smokers will receive 12 weeks of tobacco-flavored electronic cigarettes.
88946009|NCT01903785|Placebo Comparator|Placebo|400ug of placebo (one single inhalation) will be inhaled 60min prior to the begin of a time trial. Mean power output during the following 10km time trial will be described to 400ug and 1600ug salbutamol.
88946010|NCT01903824|Experimental|CEP-26401 5 μg, 25 μg, 125 μg, placebo|Participants are dosed four times during this cross-over study. This group takes three active interventions (CEP-26401 in each of the dose options: 5, 25 and 125 μg, and one dose that only contains the placebos.)
88946011|NCT01903824|Experimental|CEP-26401 5 μg, 25 μg, placebo, donepezil|Participants are dosed four times during this cross-over study. This group takes three active interventions (CEP-26401 at 5 and 25 μg, and donepezil at 10mg and one dose that only contains the placebos.)
88946012|NCT01903824|Experimental|CEP-26401 5 μg, 125 μg, placebo, modafinil|Participants are dosed four times during this cross-over study. This group takes three active interventions (CEP-26401 at 5 and 125 μg, and modafinil at 200mg) and one dose that only contains the placebos.)
88946013|NCT01903850|Experimental|spray cryotherapy|spray cryotherapy: 4 -5 second sprays at Baseline (possible additional tx. to be determined at follow up)
88946014|NCT01903889|Active Comparator|Clinic based intervention|basic intervention is introduced, whereby HIV/AIDS providers are trained on contraception for HIV-positive women. They are charged with counseling C&T clients on FP; offering condoms, pills and injectables; and referring clients for other FP methods
88946015|NCT01903889|Experimental|clinic and community based intervention|The basic intervention is introduced along with an intervention for constructive male engagement in HIV and FP services. This includes training of C&T providers on gender-based influences on health behaviors; provision of couples' HIV testing and FP counseling services; and community-based education for men to promote gender equitable norms and male participation in health services.
88946016|NCT01903902|Experimental|Drug-eluting balloon|Balloon angioplasty using paclitaxel-eluting SeQuent Please drug-eluting balloon in native small coronary artery (vessel diameter > 2.25 mm and ≤ 2.75 mm)
88946017|NCT01903915||Patients|Schizophrenia group
88946018|NCT01903915||Control|Healthy control group
88946019|NCT01903928|Experimental|ASP0113 group|Participants receive 1 mL of ASP0113 intramuscularly 5 times, on days -14 to -3, 14 to 40, 60 ± 5, 90 ± 10, and 180 ± 10, counting from the transplantation (stem cell transfusion) day (day 0)
88946020|NCT01903941|Experimental|Training|Aerobic
88946021|NCT01903941|Placebo Comparator|Control|Not exercise
88946022|NCT01903967||"Control Group"|Patients cured with no evidence of disease up to 5 years will be the controls.
88946023|NCT01903967||"Case Group"|Patients, in recurrence or progression before 5 years will be the cases
88946024|NCT01903980||EFN Cases|Cases of patients with epipericardial fat necrosis CT findings
89466236|NCT02481310|Experimental|Treatment (combination chemotherapy, rituximab, ixazomib)|"INDUCTION:~Patients receive ixazomib citrate PO on day 1 and day 8 or 15; etoposide IV, vincristine sulfate IV, and doxorubicin hydrochloride IV continuously over 96 hours on days 1-4; prednisone PO BID on days 1-5; rituximab IV should be started at 50 mg/hr, and increased in 50-mg/hr increments every 30 minutes to a maximum rate of 400 mg/hr on day 1; and cyclophosphamide IV over 90 minutes on day 5.~CNS PROPHYLAXIS:~Patients with a negative LP receive methotrexate IT once per course. Patients with a positive LP receive methotrexate IT or intraventricularly OR cytarabine IT or intraventricularly OR methotrexate IT or intraventricularly, cytarabine IT or intraventricularly, and therapeutic hydrocortisone IT or intraventricularly.~MAINTENANCE:~Patients not treated with consolidative SCT, receive ixazomib citrate PO BID on days 1, 8, and 15. Treatment repeats every 28 days for up to one year in the absence of disease progression or unacceptable toxicity."
89466237|NCT04450485|Active Comparator|Medial para-patellar approach|Fast track protocol applied total knee arthroplasty patients operated by using medial para-patellar approach
89466238|NCT04450485|Active Comparator|Mini mid-vastus approach|Fast track protocol applied total knee arthroplasty patients operated by using mini mid-vastus approach
89466239|NCT03432195|Experimental|Donepezil TDS Back|Corplex Donepezil TDS 10 mg/day applied to the Back for 1 week (7 days)
89466240|NCT03432195|Experimental|Donepezil TDS Buttock|Corplex Donepezil TDS 10 mg/day applied to the Buttock for 1 week (7 days)
89466241|NCT03432195|Experimental|Donepezil TDS Leg|Corplex Donepezil TDS 10 mg/day applied to the Leg for 1 week (7 days)
89466242|NCT04450251||Pregnant women, at least 24 weeks gestation|
89466243|NCT03432117|Experimental|Fixed respiratory rehabilitation program(A)|respiratory rehabilitation program for 12 weeks
89466244|NCT03432117|Experimental|Mixed respiratory rehabilitation program(B)|Fixed respiratory rehabilitation for 6 weeks, and then responsive respiratory rehabilitation for 6 weeks
89466245|NCT03432117|No Intervention|Control(C)|Ordinary rehabilitation service of the site for 12 weeks
89466246|NCT03432039|Placebo Comparator|Psychoeducation arm|This arm will provide information about admission procedures, story telling and a follow-up phone call
89466247|NCT03432039|Experimental|Behavioral intervention|This arm will provide information about what invasive procedures maybe given to the child, the emotional and behavioral reactions of the child while on the ward, games and stories that the child can engage with the mother and a follow-up phone call
89466248|NCT03431961|Placebo Comparator|Placebo|0.9% normal saline administered twice daily for 14 days
89466249|NCT03431961|Experimental|Intranasal Corticosteroid|Triamcinolone acetonide aqueous nasal spray at a dose of 220 mcg administered twice daily (for a total daily dose of 440 mcg) for 14 days
89466250|NCT02480764|Experimental|Azilsartan medoxomil 40 mg|Run-in Period: azilsartan medoxomil 40 mg placebo-matching tablets, azilsartan medoxomil 80 mg placebo-matching tablets, and valsartan two 80 mg placebo-matching capsules, orally, once daily, for 2 weeks prior to the start of the treatment period. Treatment Period: azilsartan medoxomil 40 mg tablets, orally, once daily, azilsartan medoxomil 80 mg placebo-matching tablets, orally, once daily, and valsartan two 80 mg placebo-matching capsules, orally, once daily, for up to 8 weeks.
89466251|NCT02480764|Experimental|Azilsartan medoxomil 80 mg|Run-in Period: azilsartan medoxomil 40 mg placebo-matching tablets, azilsartan medoxomil 80 mg placebo-matching tablets, and valsartan two 80 mg placebo-matching capsules, orally, once daily, for 2 weeks prior to the start of the treatment period. Treatment Period: azilsartan medoxomil 80 mg tablets, orally, once daily, azilsartan medoxomil 40 mg placebo-matching tablets, orally, once daily, and valsartan two 80 mg placebo-matching capsules, orally, once daily, for up to 8 weeks.
89466252|NCT02480764|Active Comparator|Valsartan 160 mg|Run-in Period: azilsartan medoxomil 40 mg placebo-matching tablets, azilsartan medoxomil 80 mg placebo-matching tablets, and valsartan two 80 mg placebo-matching capsules, orally, once daily, for 2 weeks prior to the start of the treatment period. Treatment Period: valsartan two 80 mg capsules, orally, once daily, azilsartan medoxomil 40 mg placebo-matching tablets, orally, once daily, and azilsartan medoxomil 80 mg placebo-matching tablets, orally, once daily, for up to 8 weeks.
89466253|NCT03434691|Experimental|DEX group|continuous infusion of Dexmedetomidine at 0.4 μg/kg per hour and remifentanyl A microdialysis probe was placed into the femoral quadriceps. An initial set of measurements will be obtained during the sedation with Midazolam and remifentanyl (before randomization). This set of measurements will be considered as baseline. Then samples were collected every 6 hours for 3 days. The changes in the energy-related metabolites lactate, the lactate/pyruvate ratio, glucose and glycerol were analyzed. Concomitantly with dialysate sampling, the effects on global haemodynamics, were assessed. Lactate and L/P clearances were also calculated.
89466254|NCT03434691|Active Comparator|MDZ group|continuous infusion of a Midazolam at 0,1 mg/kg/h and remifentanyl A microdialysis probe was placed into the femoral quadriceps. An initial set of measurements will be obtained during the sedation with Midazolam and remifentanyl (before randomization). This set of measurements will be considered as baseline. Then samples were collected every 6 hours for 3 days. The changes in the energy-related metabolites lactate, the lactate/pyruvate ratio, glucose and glycerol were analyzed. Concomitantly with dialysate sampling, the effects on global haemodynamics, were assessed. Lactate and L/P clearances were also calculated.
89466255|NCT03434613|Active Comparator|Rosuvastatin monotherapy|Rosuvastatin 5mg 1T daily for 6 months
89466256|NCT03434613|Experimental|Rosuvastatin + ezetimibe combination therapy|Rosuvastatin 5mg / Ezetimibe 10mg combination 1T daily for 6 months
88946025|NCT01904006|Experimental|New Culture Condition|Intervention group embryos cultured grouped under low oxygen tension in benchtop incubators.
88946026|NCT01904006|Active Comparator|Standard Culture Condition|Control group embryos cultured individually under atmospheric oxygen tension in large-box incubators.
88946027|NCT01904084|Active Comparator|Volar locked plating|One group with distal radius fracture is operated with Locking plate
88946028|NCT01904084|Active Comparator|Hoffman external fixator|One group with distal radius fracture is operated with Hoffman external fixator
88946029|NCT01904097|Sham Comparator|Pregabalin, Sham tDCS|Patients will receive pregabalin 150 mg oral (PO) twice per day (BID), and sham transcranial direct current stimulation (sham tDCS) five times per week during 2 weeks, and then twice per week until week 8th. The sham tDCS consists of the same montage of the active tDCS, but the device is turned off 30 seconds after initiating stimulation (without letting the patient notice it). Rest of the montage is kept identical as the active one during the 30 minutes that the session lasts.
89018305|NCT04279067|Experimental|BCI-FES dorsiflexion therapy with physiotherapy|"Subjects will undergo placement of an EEG cap using standard technique connected to our custom BCI system. Subjects will provide 5 min of training EEG data as they engage in alternating epochs of idling and attempted foot dorsiflexion (of the paretic side). In the online phase, the subjects will perform 20-25 BCI-FES runs. A total of 12 sessions will be performed at a rate of 3x/week (over 4 weeks). Each BCI-FES therapy session will be followed by 1 hour of conventional physiotherapy.~Conventional Physical Therapy: This will consist of a standardized regimen of activities typical of conventional post-stroke gait therapy, including passive/active range of motion exercises (to reduce/prevent excessive plantarflexor contractures), lower-extremity muscle strengthening, and a progression from treadmill to overground walking exercises."
89466257|NCT03434535|Experimental|Intervention|The participants will complete a digital health-related quality of life survey on a programmed tablet at baseline and each month for the following 3-6 months. They will also receive an activity sensor and weight scale. Health state data from this group will be generated over a 3-6 month period and remotely monitored. These data will be used to provide personalized feedback regarding the participant's progress towards established goals.
89018306|NCT04279067|Experimental|Dose-and intensity-matched physiotherapy|"Conventional Physical Therapy: This will consist of a standardized regimen of activities typical of conventional post-stroke gait therapy, including passive/active range of motion exercises (to reduce/prevent excessive plantarflexor contractures), lower-extremity muscle strengthening, and a progression from treadmill to overground walking exercises. A total of 12 sessions will be performed at 3x/week.~In the dose-matched control group (Group 2), it will be 2 hours/session."
89466258|NCT03434535|No Intervention|Control|The participants will complete a digital health-related quality of life survey on a programmed tablet at baseline and each month for the following 3-6 months.
89466259|NCT04953052|Experimental|Intravenous Imatinib Mesylate|Intravenous Imatinib Mesylate solution- 200mg as an 8mg/ml solution, administered twice daily (400mg total daily dose). Each dose administered in a 25ml solution over a two-hour infusion period.
89466260|NCT04953052|Placebo Comparator|Intravenous Placebo|Intravenous Placebo matched solution- administered 25ml solution, twice daily over a two-hour infusion period
89466261|NCT03428685|Active Comparator|Intervention group|
89466262|NCT03428685|Placebo Comparator|Placebo group|
89466263|NCT05665647|Experimental|Cohort 1: SIM0417/ritonavir and itraconazole|Interaction between SIM0417/ritonavir and itraconazole
89466264|NCT05665647|Experimental|Cohort 2: SIM0417/ritonavir and rifampicin|Interaction between SIM0417/ritonavir and rifampicin
89466265|NCT05665647|Experimental|Cohort 3: SIM0417/ritonavir and midazolam|Interaction between SIM0417/ritonavir and midazolam
89466266|NCT04941196|Experimental|Test Group|Oral administration of Anplag® 90mg (Ticagrelor) whole Tablet, manufactured by PharmEvo Private Laboratories (Pak) Ltd., after at least 10 hours fast together with 240 mL of ambient temperature water at their scheduled dosing time-point.
89466267|NCT04941196|Active Comparator|Reference Group|Oral administration of Brilinta® 90mg (Ticagrelor) Whole Tablet, manufactured by AstraZeneca Pharmaceuticals., after at least 10 hours fast together with 240 mL of ambient temperature water at their scheduled dosing time-point.
89466268|NCT03434223||Single Cohort|
89466269|NCT02487472||HZ cohort|All patients ≥ 50 years old with a HZ diagnosis (as the primary diagnoses and no earlier case of HZ) during approximately 6 months inclusion period will be included in the HZ cohort, until total study target is achieved.
89466270|NCT03431805|Experimental|Tranexamic acid|intravenous administration of 10-mL of tranexamic acid (EXACYL® 1 g/10 ml I.V., solution injectable)
89466271|NCT03431805|Placebo Comparator|Chloride solution|sodium intravenous administration of 10-mL of chloride solution (0.9% -10mL).
89466272|NCT02451670|Experimental|Prioritized Clinical Decision Support|Patients receiving care in clinics randomized to the intervention arm of the study and their primary care providers were presented with patient-specific written advice as to prioritized treatment and lifestyle changes that could reduce their cardiovascular risk, prompted by an electronic health record-based alert during their primary care visit.
88946030|NCT01904097|Experimental|Pregabalin, tDCS|Patients will receive pregabalin 150 mg oral(PO) twice per day (BID), and transcranial direct current stimulation (tDCS) five times per week during 2 weeks, and then twice per week until week 8th. The tDCS consists of application of low intensity direct current (2 mA), with the anode placed in the dominant motor cortex (M1) and the cathode in the ipsilateral supraorbital region during 30 minutes each session, using sponge electrodes soaked with normal saline solution.
89466273|NCT02451670|No Intervention|Usual Care|Patients receiving care in clinics randomized to the usual care arm of the study and their providers were not presented with the prioritized clinical decision support.
88946031|NCT01904110|Experimental|Risenex M|Patients who were treated with Resenex M (Risendronate/Cholecalciferol combination in one tablet) once a month for 12months
88946032|NCT01904110|Active Comparator|Risenex Plus|Patients who were treated with Risenex plus (Risendronate/Cholecalciferol combination in one tablet) once a week for 12months
89466274|NCT03928119|Experimental|Intervention group|community public education, non-PCI center and emergency transfer system improvement, and inhospital green-channal optimization for PCI center.
89466275|NCT03928119|No Intervention|Control group|Usual care of AMI public and medical health service
89466276|NCT03428607|Experimental|AZD6738+Olaparib|AZD6738 160mg QD per os administered for 7 days and olaparib 300mg BID per os administered daily. One cycle is considered of 28 days.
89466277|NCT02521233|Experimental|Test 1: Candesartan + Chlorthalidone|The patients will take 1 tablet (Candesartan cilexetil 8 mg + Chlorthalidone 12,5 mg) a day, in the morning.
89466278|NCT02521233|Experimental|Test 2: Candesartan + Chlorthalidone|The patients will take 1 tablet (Candesartan cilexetil 8 mg + Chlorthalidone 25 mg) a day, in the morning.
89466279|NCT02521233|Active Comparator|Comparator: losartan+hydrochlorothiazide (Hyzaar®)|he patients will take 1 tablet (Losartan 50 mg + Hydrochlorothiazide 12,5 mg) a day, in the morning.
89466280|NCT04942522|Experimental|ASD children A|Participants received probiotics PS128 [6×10^10 CFU(colony forming unit)/capsule} one capsule orally twice daily for 8 weeks. After a washout period (4 weeks), they then received placebo(450mg/capsule) one capsule orally twice daily for 8 weeks. Stool, urine and blood specimen will be collected at baseline, week 8, week 12 and week 20.
89466281|NCT04942522|Experimental|ASD children B|Participants received placebo(450mg/capsule) one capsule orally twice daily for 8 weeks. After a washout period (4 weeks), they then received probiotics PS128(6×10^10 CFU/capsule) one capsule orally twice daily for 8 weeks. Stool, urine and blood specimen will be collected at baseline, week 8, week 12 and week 20.
88946033|NCT01904175||Reduced Intensity Allogeneic Transplant|Subjects undergoing a reduced intensity allogeneic stem cell transplant
89466282|NCT00434837|Experimental|Low-tension|Patients recruited to study the initial graft tension during ACL reconstruction surgery who were randomized to the Low-tension group will receive the low-tension treatment with initial graft tension set so that the anterior-posterior (A-P) displacement of the reconstructed knee is equal to that of the uninjured knee.
89466283|NCT00434837|Experimental|High-tension|Patients recruited to study the initial graft tension during ACL reconstruction surgery who were randomized to the High-tension group will receive the high-tension treatment with the initial graft tension set to reduce A-P displacement by 2 millimeters relative to that of the uninjured knee.
89466284|NCT00434837|No Intervention|Uninjured Control Group|Uninjured age, sex, and race matched control group
88946034|NCT01904214|Experimental|severe renal impairmnt|
88946035|NCT01904214|Experimental|moderate renal impairment|
88946036|NCT01904214|Experimental|mild renal impairment|
88946037|NCT01904214|Experimental|healthy subjects|
88946038|NCT01904227|Experimental|Inpatient Adaptation of DBT|"Patients are in treatment 5 days a week, during 12 weeks. Staff is only present in daytime. During the weekends the patients stay at home.~The therapy consists of DBT skills training (Linehan, 1996), individual psychotherapy (Linehan, 2002), crisis consultation if needed, and weekly meetings of the consultation team for all trainers and therapists for one hour. Staff also receives supervision twice-weekly.~Patients also receive daily mindfulness classes, 2 hours of drama therapy, psycho educational classes about sexuality, substance abuse and medication, and the possibility to get help in applying principles of validation and behavioral analysis skills."
88946039|NCT01904227|Active Comparator|Outpatient DBT|Control condition: Standard outpatient DBT
88946040|NCT01904253|Experimental|TAS-102|
88946041|NCT01904253|Active Comparator|Investigator Choice of Amrubicin or Topotecan|Investigator Choice of Amrubicin (Japan only) or Topotecan (Europe and Japan)
88946042|NCT01904266|Sham Comparator|GA + sham block|Patients will receive general anesthetic plus a sham paravertebral block
88946043|NCT01904266|Experimental|GA + paravertebral block|Patients will receive general anesthetic plus a paravertebral block
88946044|NCT01904279|Experimental|TCZ SC 162 mg Q3W|Participants with body weight less than (<) 30 kilograms (kg) will be administered 162 milligrams (mg) of TCZ as a SC injection every 3 weeks (Q3W) for 52 weeks.
88946045|NCT01904279|Experimental|TCZ SC 162 mg Q2W|Participants with body weight greater than or equal to (>/=) 30 kg will be administered 162 mg of TCZ as a SC injection every 2 weeks (Q2W) for 52 weeks.
88946046|NCT01904292|Experimental|Tocilizumab|Participants will receive SC dose of tocilizumab based on body weight; participants with <30 kg will receive 162 milligrams (mg) of tocilizumab Q2W and those participants =>30 kg will receive 162 mg of tocilizumab QW, for 52 weeks.
88946047|NCT01904305||Patients receiving bronchoscopy|Patients suspected of having pneumonia received bronchoscopy to examine the lungs and to capture alveolar lavage culture
88946048|NCT01904318|Experimental|IDP-73152 mesylate 40 mg|
88946049|NCT01904318|Experimental|IDP-73152 mesylate 80 mg|
88946050|NCT01904318|Experimental|IDP-73152 mesylate 160 mg|
88946051|NCT01904318|Experimental|IDP-73152 mesylate 320 mg|
88946052|NCT01904318|Experimental|IDP-73152 mesylate 640 mg|
88946053|NCT01904318|Experimental|IDP-73152 mesylate 1280 mg|
88946054|NCT01904318|Placebo Comparator|Placebo|
88946055|NCT01904331||Breast cancer patients|Women who were curatively treated with chemo- and/or radiotherapy for breast cancer
88946056|NCT01904331||Controls|Women matched on age and general practitioner with the breast cancer patients
88946057|NCT01904344|Other|Sensor testing and validation|
88946058|NCT01904357|Active Comparator|Cefazolin 1 GM Injection|Subjects weighing ≥25 kg and < 50 kg will receive the 1g dose.
88946059|NCT01904357|Active Comparator|Cefazolin 2 GM Injection|Subjects weighing ≥50 kg to ≤85 kg will receive the 2g dose.
88946060|NCT01904396|Experimental|CarnitineDeficient|Patients identified with primary and secondary carnitine deficiency in the cardiomyopathy population will be prescribed with carnitine supplements to assess cardiac muscle function and status.
88946061|NCT01904422|Experimental|conventional periodontal treatment|Treatment group by quadrant in five weeks. Patients in this group will receive periodontal treatment including plaque control instructions, supragingival and subgingival debridement and root planing. This treatment is done in 5 sessions with a periodicity of 1 session per week. In the first session patients will receive hygiene instruction and supragingival debridement performed with and ultrasonic device. In the following session, there will be done the scaling and root planing to one quadrant per session, using site specific hand curettes. In case of being partially edentulous patients will be implemented at least 3 teeth per quadrant in each session.
88946062|NCT01904422|Experimental|Intensive periodontal treatment|Intensive treatment group in 24 hours: Patients in this group will receive periodontal treatment including: plaque control instructions, supragingival and subgingival debridement and scaling and root planing. This treatment is carried out in 2 sessions within 24 hours. In the first session hygiene instruction and supragingival and scaling and root planing of the teeth in right side at the upper jaw and mandible will be performed. The implementation of each upper and lower hemiarcade will be made until the periodontist treating check manually the removal of all subgingival calculus deposit and feel the smoothness of the root surface. In the second session, there will be an identical procedure in the arch left.
88946063|NCT01904461|Experimental|Vacuum device surgery|At first the surgeon proceed to the dissection of children tonsils and at last he uses the innovative vacuum device to obtain wounds hemostasis
88946064|NCT01904461|Active Comparator|Conventional surgery|At first the surgeon proceed to the dissection of children tonsils and at last he uses a bipolar forceps to obtain wounds hemostasis
88946065|NCT01904474|Experimental|Next.Step|"Experimental group participants, in addition to the standard treatment program are invited to get restricted access to the e-therapeutic platform (Next.Step), which includes a diverse set of resources, such as: educational resources (videos, brochures, menus, weekly tips, access to other links), self-monitoring (food, weight and physical activity records), social support (chats, discussion forums and personalized messages), interactive training modules (self-assessment quizzes, making their own diets) and motivational tools (personal goals planning, treatment progression registry, positive reinforcement).~Intervention length will be 36 weeks (24 weeks of direct intervention with a follow-up of 12 weeks), being based on case management methodology."
88946066|NCT01904474|Active Comparator|Standard protocol|The control group will follow the POC/HSM standard treatment protocol, which includes a baseline evaluation session with a paediatrician for initial screening, followed by appointments with the nutritionist and exercise physiologist. The second set of appointments will take place one month after for adjustments. After this, the adolescent will have appointments at 3, 6, 9 and 12 months. These adolescents will join a waiting list and nine months (36 weeks) after having started the standard treatment, they will receive the personal codes for accessing Next.Step.
88946067|NCT01904487|Experimental|PET scans|Both alcoholics and healthy controls will undergo two [11C]flumazenil PET scans: one at baseline and one post administration of 0.2 mg/kg Tiagabine.
88946068|NCT01904500|Other|Cefazolin 2 grams|
88946069|NCT01904500|Active Comparator|Cefazolin 3 grams|
88946070|NCT01904513|Experimental|Probiotic|Daily consumption of yogurt supplemented with L. rhamnosus GR-1 at ~10^10 CFU/day
88946071|NCT01904513|Other|Milk|Daily consumption of pasteurized whole milk
88946072|NCT01904539|Experimental|Healthy Volunteer|Healthy volunteers receiving a single dose of obeticholic acid 10 mg.
88946073|NCT01904539|Experimental|Mild Hepatic Impairment|Subjects with mild hepatic impairment defined as Child-Pugh class A receiving a single dose of obeticholic acid 10mg.
88946074|NCT01904539|Experimental|Moderate Hepatic Impairment|Subjects with moderate hepatic impairment defined as Child-Pugh class B receiving obeticholic acid 10mg.
88946075|NCT01904539|Experimental|Severe Hepatic Impairment|Subjects with severe hepatic impairment defined as Child-Pugh class C receiving obeticholic acid 10 mg.
88946076|NCT01904552|Experimental|apical periodontitis (AP)|clinical pulp necrosis periapical index scores of 3, 4 or 5
88946077|NCT01904552|Experimental|normal periapex (NP)|clinical pulp vitality periapical index score of 1
88946078|NCT01904565|Experimental|Thermoradiotherapy|Patients subjected to the planned therapeutic intervention of local hyperthermia and proton beam therapy
88946079|NCT01904578|Experimental|true acupressure|Massage the effective pressure points as a self-care method at home [ Four acupoints were chosen for subjects in the acupressure group. They were Shenmen on the wrist crease, Sanyinjiao point (SP6) on both feet, Fengchi on the hairline of the back neck (occipital area)and Yintang, at the top of the nose on the centre line between the ends of the eyebrows] for 10 minutes. It was done 1 to 2 hours before sleeping, each night (except Fridays) by circular massage with a 1 Cm circle diameter.
88946080|NCT01904578|Sham Comparator|sham acupressure|Massage the sham pressure points as a self-care method at home for 10 minutes. It was done 1 to 2 hours before sleeping, each night (except Fridays) by circular massage with a 1 Cm circle diameter.
88946081|NCT01904578|No Intervention|control|The control group only received the weekly control of blood pressure and speech communication .
88946082|NCT01904591|Experimental|Selenium and Vitamin E|single arm, all subjects receive both vitamins for 1 year from time zero.
88946083|NCT01904617|Experimental|D5NS at 125 mL/hr|5% dextrose in normal saline at 125 mL/hr
88946084|NCT01904617|Experimental|D2.5NS at 250mL/hr|2.5% dextrose in normal saline at 250 mL/hr
88946085|NCT01904617|Experimental|NS at 250mL/hr|Normal saline at 250mL/hr
88946086|NCT01904630||CRC high risk|Participants belong to a family with increased risk for CRC, will be analyzed with gene sequencing
88946087|NCT01904643|Experimental|Treatment (lenalidomide, combination chemotherapy)|"LENALIDOMIDE PRIMING: Patients receive lenalidomide PO for 5 or 7 days.~RE-INDUCTION CHEMOTHERAPY: Patients receive etoposide IV over 1 hour, cytarabine IV over 3 hours, and mitoxantrone hydrochloride IV over 15-30 minutes on days 1-5. Patients failing to achieve blast count < 5% at 21 days may receive a second course of induction therapy. Patients achieving complete remission proceed to lenalidomide priming.~LENALIDOMIDE PRIMING: Within 4-6 weeks, patients receive lenalidomide PO for 5 or 7 days and then proceed to consolidation therapy.~CONSOLIDATION CHEMOTHERAPY: Patients receive etoposide IV over 1 hour, cytarabine IV over 3 hours, and mitoxantrone hydrochloride IV over 15-30 minutes on days 1-4. Treatment repeats every 28-35 days for up to 2 courses in the absence of disease progression or unacceptable toxicity."
88946088|NCT01904669||Women who are trying to conceive|Women ages 18-44 without a history of fertility problems who are in a stable relationship with a male partner who have regular access to the Internet and have been trying to conceive <3 months.
88946089|NCT01904682|Experimental|Oral rigosertib|Patients will take 560 mg oral rigosertib (two 280 mg capsules) in the morning and 280 mg (one 280 mg capsule) in the afternoon, in fasting conditions, for 21 consecutive days of 21-day cycle (continuous regimen).
88946090|NCT01904695|Experimental|Antihypertensive drugs & Herbs|Thiazide diuretics and ACE inhibitor and β-blocker & Herbs for 8 weeks
88946091|NCT01904695|Active Comparator|Antihypertensive drugs|Thiazide diuretics and ACE inhibitor and β-blocker for 8 weeks
88946092|NCT01904708|No Intervention|Sedentary Visit|Subjects will do quiet, sedentary activities for 8 hours. Hourly blood draws and breath sampling will be collected. Bolus C13-Lysine will be given at hour 4.
88946093|NCT01904708|Active Comparator|Exercise Visit|Subjects will do quiet, sedentary activities until hour 5. Blood and breath samples will be collected. At hour 4, subject will consume a bolus of C13-Lysine and immediately walk on a treadmill at a moderate intensity (exercise at 75% of max heart rate) for 45 minutes.
88946094|NCT01904734|Active Comparator|No previous male hormone treatment|Clomiphene
88946095|NCT01904734|Active Comparator|Previously treated with testosterone|Clomiphene
88946096|NCT01904747|Experimental|Palbociclib given to healthy volunteers|
88946097|NCT01904786|Experimental|Melatonin|Melatonin 40 mg every 8 hours for a total of six doses given over 48 hours orally (per nasogastric tube).
88946098|NCT01904786|Placebo Comparator|Placebo|Placebo consists of the solvent solution without melatonin. Solvent solution consists of 5 mL of saline/alcohol mixture in a ratio of 90:1
88946099|NCT01904799|Other|Cognitive Assessment|
88946100|NCT01904812|Other|Lupus erythematosus|
88946101|NCT01904838||Patients in Pittsburgh, Pennsylvania|persons receiving treatment at integrative and conventional medicine clinics in Pittsburgh, Pennsylvania
88946102|NCT01904838||Internet sample|internet sample of persons reporting that they receive, or have received in the past year, integrative medicine or conventional medical treatments.
88946103|NCT01904877||HIV testing|Enhancing HIV testing: By partnering with the local CDC and the gay community, we will use SMS-I intervention by cell phones, web advertisement, community outreach, and peer referral strategies to recruit MSM in Beijing City for receiving HIV testing.
88946104|NCT01904877||Phase II: 367 HIV positive MSM|"Linking to care:~Providing enhanced HIV care."
88946105|NCT01904890|Experimental|CRC Prevention and Screening Education|Intervention Lay Health Workers (LHWs) will be taught to teach their participants about CRC screening through 2 outreach sessions and 2 telephone calls aimed at increasing their CRC screening receipt.
88946106|NCT01904890|Active Comparator|Nutrition Education|LHWs and participants in the comparison group will receive a bilingual CRC brochure as well as 2 lectures on healthy nutrition for cardiovascular health delivered by a health educator and an optional post- intervention LHW outreach session on CRC screening.
89202060|NCT00746486|Active Comparator|B|One placebo capsule TD or One placebo capsule BD and 12-16 mg ursodeoxycholic acid/kg BW/d
89202061|NCT00785148|Experimental|1|Dermacyd PH_DETINLYN Sweet Flower (Lactic Acid)
89537225|NCT03067701|Experimental|Carbon Monoxide Inhalation|In healthy young adults 18-39 years of age, The Investigator will determine if intermittent inhalation a 0.1% CO, from a 1-liter bag once every minute for 30-40 minutes, at a level that approaches the CO boost with hookah smoking, augments endothelial function, thus implicating CO as the major endothelial vasodilator substance in hookah smoke.
89537226|NCT05548439|Experimental|Group G1|33 participants aged 18-64 years to receive two doses of VBI-2901a at 5 µg per dose at Day 1 and Day 56.
89537227|NCT05548439|Experimental|Group G2|33 participants aged 18-64 years to receive two doses of VBI-2901a at 10 µg per dose at Day 1 and Day 56.
89537228|NCT05548439|Experimental|Group G3|33 participants aged 18-64 years to receive one dose of VBI-2901a at 10 µg per dose at Day 1.
89537229|NCT03069573||Eosinophilic Esophagitis - EoE|Diagnosis of pediatric EoE under current guidelines.
89537230|NCT03069573||Gastroesophageal reflux disease - GERD|Diagnosis of pediatric GERD under current guidelines.
89537231|NCT03069573||Control|Exclusion diagnosis of EoE or GERD, with non specific gastrointestinal general complaints.
89537232|NCT03069339|Experimental|Carvedilol+EVL|
89537233|NCT03069339|Experimental|Carvedilol|
89537234|NCT03069339|Active Comparator|EVL|
89537235|NCT03069105||Family caregivers|The sample for this study will consist of caregivers of patients with cancer. Eligible subjects who agrees to participate in the research study and sign the consent form will participate by completing paper and pencil or electronic questionnaires.
89537236|NCT05542589|Experimental|Phenytoin phonophoresis group|The topical phenytoin will be applied on the head of ultrasound and is usually given for 5-10 minute sessions, three times per week and six weeks as a total treatment duration.
89537237|NCT05542589|Sham Comparator|sham phenytoin phonophoresis group|The topical phenytoin will be applied on the head of ultrasound (sham ultrasound) and is usually given for 5-10 minute sessions, three times per week and six weeks as total treatment duration.
89537238|NCT03069027|Placebo Comparator|Group I(control)|patients allocated for external nasal nerve block with saline adrenaline 1/200,000 (placebo)
89537239|NCT03069027|Active Comparator|Group II(block)|'External nasal nerve block by Xylocaine, adrenaline'
89537240|NCT05635071|Experimental|Nintedanib 100mg|Traditional hormone replacement (HRT) cycle medication (Tegretol 2mg bid for 20 days, followed by Darvon 10mg bid for the last 10 days) + Nintedanib 100mg bid *15 days orally.
89537241|NCT05635071|Experimental|Nintedanib 150mg|Traditional hormone replacement (HRT) cycle medication (Tegretol 2mg bid for 20 days, followed by Darvon 10mg bid for the last 10 days) + Nintedanib 150mg bid *15 days orally.
89537242|NCT04489979||Analgetics only|Children with epididymitis / orchitis treated by analgetics only.
89537243|NCT04489979||Analgetics and antibiotics|Children with epididymitis / orchitis treated by analgetics and antibiotics.
89537244|NCT05634993||MS Group|
89537245|NCT04568967|Experimental|intervention arm|"The intervention arm for this trial consists of HIV patients with TB testing performed regardless of presence of TB symptoms. Testing will be done on expectorated sputum, stool and concentrated urine with Ultra, and urine with AlereLAM.~To fulfil exploratory objectives, we will also collect and store 2x tongue swabs for molecular TB diagnostic assay (Xpert Ultra and/or LumiraDx) testing, blood for testing with CRP, and urine samples which will be stored for retrospective FujiLAM testing and analysis."
89537246|NCT04568967|No Intervention|control arm|"The control arm for this trial will consist of patients managed according to the current WHO recommended TB testing practices for HIV positive inpatients (as of Q1 2020).~TB testing will be done as follows:~Sputum Ultra performed whenever the patient has cough, fever, weight loss over night sweats and/or Ultra performed on any tissue (including lymph nodes) from patients with clinical suspicion of extrapulmonary TB.~and/or: Urine Alere TB-LAM performed if patients have signs and symptoms of TB (pulmonary and/or extrapulmonary), or with advanced HIV disease, or who are seriously ill, or else irrespective of signs and symptoms of TB, but combined with a CD4 cell count of less than 200 cells/mm ."
89202062|NCT00778128|Experimental|1|"Step 1: Dose escalation - oral CP-4126~Step 2: Oral CP-4126 on day 1 and 15 in a 4 week schedule. One dose (only) gemcitabine IV on day 8."
89202063|NCT00778128|Experimental|2|"Step 1: Dose escalation - oral CP-4126~Step 2: Oral CP-4126 on day 8 and 15 in a 4 week schedule. One dose (only) gemcitabine IV on day 1."
89202064|NCT00778284|Experimental|1|Amoxicillin 400mg + clovalunic acid 57.5mg chewable tablets of Ranbaxy
89202065|NCT00778284|Active Comparator|2|Augumentin chewable tablets of Glaxosmithkline
89202066|NCT02563418|Experimental|Patient with Huntington's disease|
89202067|NCT00749060|Other|1|conventional treatment
89202068|NCT00749060|Other|2|kyphoplasty by balloons
89202069|NCT00749060|Other|3|vertebroplasty
89202070|NCT00785304||Traumatic Brain Injury|Active Duty military blast-related TBI patients
89202071|NCT00785304||Other Injury Control|Active duty military patients with other injuries but no TBI
89202072|NCT00749138|Experimental|tamoxifen|open label giving of tamoxifen
89202073|NCT05001906|No Intervention|Control group|The control group (CG) will consist of pregnant women with standard prenatal care, who attending theoretical classes on childbirth (CG, n = 35). The control group will not exercise. The sedentary participants will continue their regular daily activities and life habits.
89202074|NCT05001906|Experimental|Exercise group|The exercise group (EG) will consist of pregnant women who will attend theoretical classes and prenatal exercises in the program of psychophysical preparation for childbirth (EG, n = 35). The experimental group will exercise for 45 minutes, three times a week.
89202075|NCT02563340|Experimental|MSCs group|cAMR patients in this group receive additional intravenous allogeneic BM-MSCs (1*10^6/kg) every two weeks for four consecutive doses, besides current desensitization therapy including at least one of the following treatments: plasmapheresis (PP), intravenous immunoglobulin (IVIG), rituximab or Bortezomib.
88946107|NCT01904916|Other|Histological biopsy procedure|This is a diagnostic multicenter study combining histological biopsy of tumor material with DNA sequencing using Ion Torrent®, Next Generation Sequencing (NGS) platform. The study aims improve stratification of cancer patients by obtaining fresh tumor biopsies for next-generation sequencing for participation in clinical trials.
89202076|NCT02563340|Active Comparator|Control group|cAMR patients in this group receive current desensitization therapy including at least one of the following treatments: plasmapheresis (PP), intravenous immunoglobulin (IVIG), rituximab or Bortezomib.
89466285|NCT03434145||patients with chronic kidney diseases|patients with end stage retinal disease undergoing hemodialysis underwent various ophthalmologic exams before and after hemodialysis.
88946109|NCT01904981|Experimental|Atenolol|Atenolol group
88946110|NCT01904981|Experimental|Valsartan|Valsartan group
88946111|NCT01904994|No Intervention|Standard of Care|Participants will be managed per standard of care following prevailing Swaziland Ministry of Health guidelines.
88946112|NCT01904994|Experimental|Combined Intervention Strategy|Point-of-care (POC) CD4+ (cluster of differentiation 4) Count Accelerated ART initiation for ART eligible participants Basic care and prevention package Cellular Appointment Reminders and Follow-Up Financial Incentives
88946113|NCT01905007|Active Comparator|Defibrillation testing|Defibrillation testing at initial ICD implantation
89202077|NCT00782652|Active Comparator|1|inhaled nitric oxide at 40 or 80ppm
89202078|NCT00782652|Placebo Comparator|2|inhaled nitrogen at either 40 or 80ppm
89202079|NCT00746642|Experimental|A|"Glucose measurements using Mellitor device."
89202080|NCT00746642|Active Comparator|B|"Glucose measurements conducted by using gold standard, Yellow Springs glucose analyzer"
89202081|NCT00778362||Splenectomy|all patients received splenectomy (patient list will be applied from Dept. of Pathology) at National Taiwan University Hospital in the last 20 years.
89202082|NCT02562092|No Intervention|Focus Group|Participants will complete a questionnaire and will be involved in a group discussion regarding good sites within the community to perform HIV testing.
89202083|NCT02562092|Other|Venue Testing Group- Negative Test|Participants will perform a rapid HIV test and will be asked to answer questions about their sexual life and living situation. No followup is needed for a negative HIV test.
89202084|NCT02562092|Other|Venue Testing Group- Positive Test|Participants will perform a rapid HIV test and will be asked to answer questions about their sexual life and living situation. Participants with a positive HIV test will receive care from a psychologist and case manager for one year.
89202085|NCT00782730||Bladder Scan Group|Patients who agree to enroll in the trial and allow their known bladder volumes and residual bladder volumes to be measured by actual volumes retrograde instilled, and also by bladder scanner ultrasound.
89202086|NCT00782808||1 HIV DNA will be stratified by high|
89202087|NCT00782808||2 HIV DNA will be stratified by low|
89202088|NCT00745706|Other|A|Implantable Loop Recorder (ILR) implant
89202089|NCT00785382|Placebo Comparator|1|
89202090|NCT00785382|Experimental|2|
89202091|NCT00745784||1|Young spouses/domestic partners (20-49 years old) of cancer patients who have died from cancer.
89202092|NCT00745862||1|female patients undergoing surgical treatment of cutaneous melanoma within two years of diagnosis and treatment
89202093|NCT00667368|No Intervention|Control|Bi-monthly testing for BV without treatment.
89466286|NCT02486692|Experimental|Phase II- Experimental Group|Participants were provided with instructions and a web link for accessing the AboutFace website after the baseline assessment.
89018307|NCT04271046|Experimental|Experimental Group- STAR-C-VTF|"This study will use a parallel, two-arm randomized trial design. Participants will be 100 Person-with-Dementia-Caregiver dyads in which the person with dementia lives at home and recently filled a new prescription for antipsychotic medication. The experimental intervention will combine three elements:~self-directed learning in which the caregiver will receive training materials delivered electronically through a web-based learning portal;~one orientation phone visit with a coach;~ongoing support from the coach via telephone and secure messaging in the web-portal.~Participants will complete self-report assessments at baseline, 8-weeks post-enrollment, and 6 months post-enrollment. Automated medication and primary care utilization data will be collected throughout the 6 month study period."
89018308|NCT04271046|Active Comparator|Control|"One orientation phone visit with a coach. Participants in the control condition will receive mailed material from the Alzheimer's Association, web links and template secure messages.~Participants will complete self-report assessments at baseline, 8-weeks post-enrollment, and 6 months post-enrollment. Automated medication and primary care utilization data will be collected throughout the 6 month study period."
89018309|NCT04270045||Single|Non-invasive forced airway oscillometry. Normative data will be established form term neonates without pulmonary disease
89018310|NCT04268771|Experimental|Arm A: DRL_RI|Subjects who have already received at least 1 full course comprising two 1000 mg infusions of either US-rituximab or EU-rituximab and are candidates for re-treatment with Rituximab, will be enrolled. DRL_RI will be administrated in combination with MTX as two 1000 mg infusions on Day 1 and Day 15
89018311|NCT04268771|Active Comparator|Arm B: US-Rituximab or EU-Rituximab|"Subjects who have already received at least 1 full course comprising two 1000 mg infusions of either US-rituximab or EU-rituximab and are candidates for re-treatment with rituximab, will be enrolled.~Patients enrolled in Arm -B will continue to receive US-rituximab or EU-rituximab. The rituximab reference product used (US-licensed rituximab [Rituxan] or EU-approved rituximab [MabThera]) should be the same in the prior and the randomized treatment course, respectively."
89018312|NCT04260243|Sham Comparator|Sham Myofascial + Respiratory rehabilitation|Respiratory rehabilitation programme + sham Myofascial Release
89018313|NCT04260243|Experimental|Experimental-Myofascial + Respiratory rehabilitation|Respiratory rehabilitation programme + Myofascial Release
89018314|NCT04253145|Experimental|PM01183 w/ Atezolizumab|Patients will receive atezolizumab at a fixed dose of 1200 mg intravenously (i.v.) as a 60-minute infusion (the second and subsequent infusions may be administered over 30 minutes) followed by PM01183 at a starting dose of 2.5 mg/m2 i.v. as a 1-hour infusion on Day 1 every three weeks (q3wk). Following analysis of cohorts, dose levels can be escalated from 2.5mg to 3.2, to a maximum dose of 3.5 mg of PM01183
89018315|NCT04251741|Active Comparator|Usual care group|Based on a secondary randomization schedule patients are treated with etanercept or a non-TNFi (abatacept, rituximab, tocilizumab, or sarilumab)
89018316|NCT04251741|Experimental|'Drug concentration guided' group|Patients with a concentration <1.0 mg/L switch to etanercept and patients with a concentration ≥ 1.0 start a non-TNFi (abatacept, rituximab, tocilizumab, or sarilumab)
89018317|NCT04246606||ER+/HER2- infiltrating early breast cancer|Patients with ER+/HER2- infiltrating early breast cancer for which EndoPredict molecular signature was performed.
89018318|NCT04244188||Patients treated for aortic arch aneurysms|Patients treated for aortic arch aneurysms by double branched endovascular repair (Bolton Medical) will be included.
89018319|NCT04239339|Placebo Comparator|Control Group|The placebo control group will be administered the exact same procedure as the intervention group, the only difference being that this group will be administered a placebo pill.
89018320|NCT04239339|Experimental|Intervention Group|The intervention group will be administered 20mg of Escitalopram daily for approximately 3 weeks.
89018321|NCT04238715|Experimental|E7090 140 mg|Participants will receive E7090 140 mg (milligram), tablets orally once daily (QD), in 28-days treatment cycle until disease progression, development of unacceptable toxicity, participant requests to discontinue, withdrawal of consent or study termination.
89018322|NCT04225832|Experimental|CBT Coping Intervention|The intervention is an 8-session cognitive behavior therapy (CBT) group intervention that aims to improve HIV outcomes by increasing adaptive, effective coping responses to stigma from intersectional identities related to ethnicity, immigration status, sexual minority identity, HIV status, and PrEP among Latinx sexual minority men (SMM). The intervention sessions will address topics such as: understanding and coping with intersectional stigma, multiple identities (e.g., race/ethnicity, sexual orientation), medical mistrust, social support, and structural stigma. Intervention groups will be led by a trained facilitator (with expertise in group therapy with Latinx SMM) and a trained peer co-facilitator matched in identities with participants (Latinx SMM).
89018323|NCT04225832|No Intervention|Control|Participants who are randomized to the control condition will be referred to the standard of care program at Bienestar, which includes an ongoing weekly open wellness-oriented support group available to all clients.
89018324|NCT04222920|Experimental|Low serum drug concentration|Adalimumab dose reduction aiming a drug level of 2 mg/L
89018325|NCT04222920|Active Comparator|High serum drug concentration|Adalimumab dose reduction aiming a drug level of 5 mg/L
89018326|NCT04208230||Subjects diagnosed with type 2 diabetes mellitus|Subjects with type 2 diabetes defined as those with (1) history and diagnosis of T2D and pharmacologic treatment for a minimum of 3 years OR (2) history and diagnosis of T2D with documented HgbA1C of 6.5 or higher for a minimum of 3 years if they are not under pharmacologic treatment (i.e., diet-controlled)
89018327|NCT04208230||Control|Non-diabetic control group. These subjects must not have pre-diabetes.
89018328|NCT04198506|Experimental|Tailored tacrolimus dosing|Tacrolimus doses will be adapted according to tacrolimus blood level (conventional therapeutic drug monitoring - TDM) and additionally depending on TTV viral load.
89018329|NCT04198506|Active Comparator|Conventional tacrolimus dosing|Tacrolimus doses will be adapted according to tacrolimus blood level (conventional therapeutic drug monitoring - TDM).
89018330|NCT04196972|Experimental|Arm A (ECHO telementoring)|Participants attend ECHO telementoring sessions over 1 hour weekly for 13 weeks.
89018331|NCT04196972|Experimental|Arm B (wait-list, ECHO telementoring)|Participants are placed on a wait-list for 13 weeks and then attend ECHO telementoring sessions over 1 hour weekly for 13 weeks.
89202094|NCT00667368|Experimental|Intervention|Metronidazole 500mg twice daily for 7 days for Bacterial Vaginosis (BV) detection
89202095|NCT00785460|Experimental|Benfotiamine and Smoking|
89018332|NCT04194827|Experimental|Concentration guided dose reducion|Dose reduction of adalimumab will be based on adalimumab through concentration after 16 weeks of treatment with adalimumab.
89018333|NCT04194827|Active Comparator|Disease activity quided dose reduction|Dose reduction of adalimumab will be based on disease activity after 28 weeks of treatment with adalimumab
89018334|NCT04177914|Active Comparator|ETV+CPC|Subjects randomized to this arm will undergo an ETV+CPC procedure for treatment of Hydrocephalus
89018335|NCT04177914|Active Comparator|Ventriculoperitoneal Shunt|Subjects randomized to this arm will undergo a Ventriculoperitoneal Shunt procedure for treatment of Hydrocephalus
89018336|NCT04177849|Active Comparator|Anterior Cervical Decompression and Fusion (ACDF)|Patients entered into this arm are treated via an anterior approach with disk excision, root canal decompression and fusion of the affected segment with a cage and plate.
89018337|NCT04177849|Experimental|Posterior Foraminotomy (PF)|Patients entered into this arm are treated via a posterior approach through intermuscular planes. The root canal is decompressed by burring the medial third of the facet joint. No fusion is performed.
89018338|NCT04173442||Cohort 1: Dupilumab-Exposed Cohort|Pregnant women with approved indications exposed to dupilumab during pregnancy
89018339|NCT04173442||Cohort 2: Disease-Matched Comparison Cohort|Pregnant women with approved indications not exposed to dupilumab during pregnancy
89018340|NCT04173442||Cohort 3: Healthy Comparison Cohort|Pregnant women who are not diagnosed with any dupilumab-approved indications, and not exposed to dupilumab during pregnancy
89018343|NCT04149288|Active Comparator|High-polyphenol olive oil|Participants will consume 40 mL of high-polyphenol olive oil each day at home for 2 weeks.
89018344|NCT04149288|Active Comparator|Low-polyphenol olive oil|Participants will consume 40 mL of low-polyphenol olive oil each day at home for 2 weeks.
89018345|NCT04144972|Active Comparator|Active DBS|Chronic brain recordings and stimulation with bilateral implantations in pain-related brain regions. All participants will participate in active DBS, blinded to the participant.
89018346|NCT04144972|Sham Comparator|Inactive DBS|Non-active chronic brain stimulation in pain-related brain regions. brain recordings will remain active during this period. All participants will participate in inactive DBS, blinded to the participant.
89018347|NCT04126135|Active Comparator|Usual Care Group|Subjects are asked to completely stop smoking on their quit day and use a daily Nicotine Replacement Therapy (NRT) patch for 25 days.
89018348|NCT04126135|Experimental|Treatment Group|Subjects will start a 25-day course of Cytisine tablets started during the four days before the quit date and are asked to reduce smoking during this time.
89466287|NCT02486692|No Intervention|Phase II- Usual Care Group|Participants were provided with instructions and a web link for accessing some online PTSD education materials after the baseline assessment.
89466288|NCT03434067||Primary hyperthyroidism|Patients diagnosed with primary hyperparathyroidism are prepared for parathyroid surgery. PTH test paper is used addtional at the time point according to Miami principle
89466289|NCT03434067||Secondary hyperthyroidism|Patients diagnosed with Secondary hyperthyroidism are prepared for parathyroid surgery. PTH test paper is used addtional at the time point according to Miami principle
89466290|NCT03434067||Unilateral thyroidectomy|Patients diagnosed with unilateral thyroid benign tumor were prepared for unilateral thyroidectomy. PTH test paper is used addtional at postoperation
89466291|NCT03434067||thyroidectomy and bilateral CCD|Patients diagnosed with bilateral thyroid carcinoma were prepared to undergo total thyroidectomy and bilateral central clearing.PTH test paper is used addtional at postoperation
89466292|NCT03428529|Experimental|Capecitabine|Neoadjuvant capecitabine plus RT
89466293|NCT03428529|Active Comparator|5-Flourouracil|Neoadjuvant 5-Fluorouracil plus RT
89018356|NCT04086823|Active Comparator|RZL-012|"A single-treatment injection, multiple subcutaneous injections of RZL-012 administered into 48 sites in the submental fat (0.05/0.1mL per site):~Up to 120mg administered at 48 sites in a volume of 0.05 ml at each injection site (total injected volume 2.4mL)~Up to 240 mg administered at 48 sites in a volume of 1 ml at each injection site (total volume injected 4.8mL)"
89018357|NCT04086823|Placebo Comparator|Vehicle|"Subject receive a single-treatment injection. Multiple injections of the Placebo are administered at 48 sites (0.05/0.1mL per site) into the submental fat.~Up to a total of 2.4 mL will be injected for placebo subjects enrolled during cohort 1.~Up to a total of 4.8 mL will be injected for placebo subjects enrolled during cohort 2."
89018358|NCT04085744|No Intervention|control group|In this group any drug will be applied on the cuff of the intubation tube
89018359|NCT04085744|Active Comparator|lidocaine group|10% lidocaine spray will be applied on the cuff of the intubation tube topically and patient will be intubated.
89018360|NCT04085744|Active Comparator|steroid group|mometasone furoate spray will be applied on the cuff of the intubation tube topically and patient will be intubated.
89018361|NCT04060693|Experimental|Protocol 1|The subjects enrolled in this protocol will dedicate 30 days of home-based measurement, scheduled within a 40 days' time frame. For reference measurements, subjects will be equipped with a BG-meter (Contour Next One, Ascenia). Optical measurements are collected with the IMD. Each day of measurements consists of four sessions each comprising two capillary blood glucose measurement with a BG-meter and two IMD measurements. IMD measurements will be performed within 3 minutes after the BG measurement using the thenar of the right hand of the subject.
89466294|NCT03433989|Experimental|Diagnosis and follow up arm|
89466295|NCT00427193|Experimental|Caloric Restriction (CR)|25% caloric restriction
89466296|NCT00427193|Active Comparator|Control, Ad libitum (AL)|Ad libitum energy intake
89466297|NCT03428451|Active Comparator|Group A (Hypertonic saline )|patients will receive NaCl 3% HS at a dose of 4 ml/kg/hr.
89466298|NCT03428451|Active Comparator|Group B (Hypertonic saline)|patients will receive NaCl 3% HS at a dose of 2 ml/kg/hr.
89466299|NCT03428451|Active Comparator|Group C (Normal saline)|patients will receive NaCl 0.9% NS at a dose of 6 ml/kg/hr.
89466300|NCT03128541||Ultrasound Spine in sitting position|Participants will be assigned to a sitting decubitus position to identify the Tuffier's Line
89466301|NCT03128541||Ultrasound Spine in lateral position|Participants will be assigned to a lateral decubitus position to identify the Tuffier's Line
89466302|NCT04450017||Clinical Features of Severe Patients With COVID-19|Critical ill patients with COVID-19 admitted to the ICU. The demographic, clinical data, laboratory data, and Instrumental data will be analysed.
89018362|NCT04053582|Active Comparator|Augmented Mindfulness Training (AMT)|Participants will receive real-time neurofeedback from the PCC during mindfulness practice in the MRI
89202096|NCT00785460|Placebo Comparator|Smoking alone|
88946114|NCT01905007|No Intervention|No defibrillation testing|No defibrillation testing at initial ICD implantation
88946115|NCT01905020|Active Comparator|Conventional insulin pump therapry|Subjects will use conventional pump therapy to regulate their glucose levels.
88946116|NCT01905020|Active Comparator|Single-hormone closed-loop system|Variable subcutaneous insulin infusion rate will be used to regulate glucose levels. Insulin Aspart (Novorapid) will be infused using a subcutaneous infusion pump. The glucose level as measured by the real time sensor will be entered manually into the computer every 10 minutes. The pump's infusion rate will then be changed manually based on the computer-generated recommendations of infusion rates.
88946117|NCT01905020|Active Comparator|Dual-hormone closed-loop system|Insulin Aspart (Novorapid) and glucagon (Paladin) will be infused using two separate subcutaneous infusion pumps. The glucose levels as measured by the real time sensor will be entered manually into the computer every 10 minutes. The pumps' infusion rate will then be changed manually based on the computer generated-recommendation delivery levels.
88946118|NCT01905059|Active Comparator|monoPI - boosted lopinavir or boosted darunavir|"boosted lopinavir (LPV/rtv 200/50 mg 2 tbs BID) or boosted darunavir (DRV 400 mg 2 tbs plus RTV 100 mg QD)~This arm has been stopped on advise of DSMB (approved by Scientific Committee), patients are switched to standard second line triple therapy and followed until the end of the study at week 96."
88946119|NCT01905059|Active Comparator|bi therapy - (boosted lopinavir or darunavir) + lamivudine|boosted lopinavir (LPV/rtv 200/50 mg 2 tbs BID) with lamivudine 300 mg QD or boosted darunavir (DRV 400 mg 2 tbs plus RTV 100 mg QD)with lamivudine 300 mg QD
88946120|NCT01905072|Experimental|Education Home Visits|The intervention group will receive the full intervention delivered by community health workers (CHWs) through home visits. CHWs will deliver the intervention in the subjects' homes. Home visits will be arranged at subjects' convenience and occur on a planned schedule. The intervention content will be based on the Institute of Medicine recommendations.
88946121|NCT01905072|No Intervention|Control Group|The control group will receive only measurement visits, with no intervention or interaction during the home visits. They will receive only support from their WIC clinic.
88946122|NCT01905098|Experimental|Observation-First Arm|"A group that first attends 4 observation visits without sauna, and then attends sauna sessions 5 times a week for 3.5 hours per visit for 3 weeks.~Participants in this Arm will undergo both listed interventions: Observation and Sauna Protocols."
88946123|NCT01905098|Active Comparator|Sauna-First Arm|"A group that first attends sauna sessions 5 times a week for 3.5 hours per visit for 3 weeks and then attends 4 observation visits without sauna.~Participants in this Arm will undergo both listed interventions: Observation and Sauna Protocols."
88946124|NCT01905111|Experimental|BI 853520|BI 853520 once daily in a dose escalation schedule
88946125|NCT01905124|Experimental|Drug: CF101|CF101 1 mg q12 hours
88946126|NCT01905124|Placebo Comparator|Placebo tablets of CF101|Placebo tablets q12 hours
88946127|NCT01905137|Active Comparator|Botulinum Toxin Type A|Patients in the treatment group will receive 200 Units of Botulinum toxin diluted in 20 mL of saline injected globally into their pelvic floor muscles followed by 8 treatments of pelvic floor physical therapy.
88946128|NCT01905137|Placebo Comparator|Saline|Patients in the placebo group will receive 20 mL of saline injected globally into their pelvic floor muscles followed by 8 treatments of pelvic floor physical therapy.
88946129|NCT01905150|Experimental|G-FLIP+VitaminC, then G-FLIP-DM+VitaminC|G-FLIP in combination with Vitamin C, then G-FLIP-DM in combination with Vitamin C
88946130|NCT01905150|Active Comparator|G-FLIP, then G-FLIP-DM|G-FLIP alone, then G-GLIP-DM alone
88946131|NCT01905163|Experimental|laparoscopic management|Tumor Debulking Surgery by laparoscopy
88946132|NCT01905176|Experimental|Predischarge educational intervention|In person education on heart failure topics before discharge
88946133|NCT01905176|Experimental|Telephone educational intervention|Telephone support and education post-discharge
88946134|NCT01905176|Experimental|Combination|Pre-discharge in person education and post-discharge telephone education and support
88946135|NCT01905176|No Intervention|Usual care (control group)|Patients receive the routine care provided by the hospital which does not involve protocol driven discharge-planning
88946136|NCT01905189|Experimental|Hemodynamic study, cardiac pacing|We propose to study the hemodynamic response to a temporary atrio-dual right ventricular stimulation in pulmonary arterial hypertension subjects.Patients will be is own comparator.
88946137|NCT01905202|Experimental|Secretrol|Secretrol Capsules 80/80 once daily for 6 months
88946138|NCT01905215|Experimental|Group A|Subjects in this group will receive a single dose of formulation 1 of RSV vaccine
88946139|NCT01905215|Experimental|Group B|Subjects in this group will receive a single dose of formulation 2 of RSV vaccine
88946140|NCT01905215|Experimental|Group C|Subjects in this group will receive a single dose of formulation 3 of RSV vaccine
88946141|NCT01905215|Experimental|Group D|Subjects in this group will receive a single dose of formulation 4 of RSV vaccine
88946142|NCT01905215|Experimental|Group E|Subjects in this group will receive a single dose of formulation 5 of RSV vaccine
88946143|NCT01905215|Experimental|Group F|Subjects in this group will receive a single dose of formulation 6 of RSV vaccine
88946144|NCT01905215|Placebo Comparator|Group Placebo 1|Subjects in this group will receive a single dose of placebo
89202097|NCT00778518|Active Comparator|1|low dose
89202098|NCT00778518|Active Comparator|2|Medium dose
89202099|NCT00778518|Active Comparator|3|High Dose
89466303|NCT03431649|Experimental|Beraprost Sodium|"Beraprost 1mcg/kg/day, divided in 3 doses orally patient was followed up for 12 weeks, then echocardiography evaluation was performed in patient completed the study.~22 patients"
89466304|NCT03431649|Active Comparator|Sildenafil citrate|"Sildenafil 0.4 mg/kg/time, 4 times daily per oral patient was followed up for 12 weeks, then echocardiography evaluation was performed in patient completed the study.~20 patients"
89466305|NCT03431571|Other|Single arm|ReLEx SMILE treatment can be done binocular or monocular, no masking and randomization used, no control group
89466306|NCT03431415|Active Comparator|Surgery|Patients that will undergo surgery (anatomical segmentectomy, lobectomy or bilobectomy) as primary lung cancer treatment
89466307|NCT03431415|Active Comparator|SBRT (Stereotactic Body Radiation Therapy)|Patients that will undergo SBRT as primary lung cancer treatment
89466308|NCT03428295|Experimental|Experimental: Single Cohort in CRC|This study is a single-arm, single-center, observational clinical trial being conducted in a Clinical Research Center (CRC) setting.
89466309|NCT04450095|Active Comparator|Treated group|Tab. Volibris 10mg given once a day for 5 days, starting 48 hours before surgery (in addition for the standard treatment for partial nephrectomy)
89466310|NCT04450095|No Intervention|Control group|Treated with the standard treatment for partial nephrectomy
89466311|NCT03101475|Experimental|immunotherapy + local tumor ablation|Patients with unresectable colorectal liver metastases which show at least stable disease or partial remission after 4-6 months will receive treatment with durvalumab and tremelimumab plus local tumor ablation (Radiofrequency ablation RFA or Sterotactic body radiation therapy SBRT) of selected liver lesions, followed by maintenance treatment with durvalumab.
89466312|NCT03431181|Experimental|MAP target 60-65 mmHg|Treating teams will adjust vasopressors to a target MAP range of 60 to 65 mmHg, avoiding vasopressor-induced MAP above this range.
88946145|NCT01905215|Placebo Comparator|Group Placebo 2|Subjects in this group will receive a single dose of placebo
89466313|NCT03431181|Active Comparator|Usual Care|Patients in the control arm will receive usual care (as per local practices).
89466314|NCT01060007|Experimental|Neoadjuvant radiation followed by FOLFOX|"Radiation - 20 Gy in 5 fractions to regional nodes. 25 Gy in the same 5 fractions to macroscopic disease. This is given over 1 week.~FOLFOX Chemotherapy - after two weeks rest - oxaliplatin 85 mg/m2 and leucovorin 400 mg/m2 IV/2 hours followed sequentially by 5FU 400 mg/m2 IV push and 5FU 2400 mg/m2 over 46 hour CIVI. Repeat ever other week for a total of 4 courses (this equals 6 weeks).~If 5-FU is unavailable -- oral capecitabine can be given as 1000 mg/m2 BID on days 1-7 every 14 days."
89466315|NCT03431103|Other|After home exercise program|"Patients will be instructed to use the Wii Fit for 20 minutes at least twice a week for 12 weeks using specific Wii Fit exercises while on the Wii pressure sensor floor mat. The Wii Fit exercises will be as follows: 1. Basic Run (warm-up exercise by walking in place); 2.Bird's Eye, Bull's-Eye (mostly arms, requires arm flipping); 3.Free Step (lower extremity exercise); 4.Hula Hoop (gyration exercise)"
88946146|NCT01905228|Experimental|CBL0137|"Dose Level 9: 150 mg/m2, IV~Dose Level 10: 180 mg/m2, IV~Dose Level 11: 240 mg/m2, IV~Dose Level 12: 320 mg/m2, IV~Dose Level 13: 400 mg/m2, IV~Dose Level 14: 540 mg/m2, IV~Dose Level 15: 700 mg/m2, IV~Dose Level 16: 920 mg/m2, IV~Dose Level 17: 1200 mg/m2, IV~Dose Level 18: 1600 mg/m2, IV~Dose Level 19: 2100 mg/m2, IV~Dose Level 20: 2700 mg/m2, IV"
88946147|NCT01905280|Experimental|Acellular dermal matrix|A ridge preservation graft will be performed and then covered using acellular dermal matrix as a membrane.
88946148|NCT01905280|Active Comparator|Non-resorbable membrane|A ridge preservation graft will be performed and then covered using a non-resorbable PTFE membrane.
88946149|NCT01905293|Experimental|100% portion size|100% portion size condition
88946150|NCT01905293|Experimental|150% portion size|150% portion size condition
88946151|NCT01905293|Experimental|200% portion size|200% portion size condition
88946152|NCT01905306|Experimental|computer guided implant planning|radiographic and clinical evaluation of full-arch dental implant rehabilitation
88946153|NCT01905306|Experimental|free hand implants placement|radiographic and clinical evaluation of full-arch dental implant rehabilitation
88946154|NCT01905319||Subsequent new juvenile arthritis cases|During years 1998-2000, all new subsequent cases of juvenile idiopathic arthritis diagnosed in Estonia were included in the study group.
88946155|NCT01905332|Experimental|Literacy promoting home based program|Those 4 year old children who fall below the cutoff score on the literacy screening will be randomized to either receive standard of care (literacy toolkit) or will be given a referral to a home -based literacy promoting program through the Columbus Metropolitan Library.
89466316|NCT03431025|No Intervention|Control|Participants in the Control Arm will wear sensors to monitor their upper limb movement but will not receive feedback from these sensors to encourage usage of the impaired limb during activities of daily living.
89466317|NCT03431025|Experimental|Intervention|Participants in the Experimental Arm will wear sensors to monitor their upper limb movement and will receive feedback from these sensors to encourage usage of the impaired limb during activities of daily living.
89466318|NCT04187937|Experimental|Experimental|Stereotactic image-guided non-anatomical resection
89466319|NCT02971163|Experimental|SynDA|The research coordinator will print the appropriate version of the SynDA based on the patient's individualized risk score and the corresponding estimated probability of a serious medical event within 30 days.
89466320|NCT02971163|No Intervention|Control|Patients in the control arm will receive usual emergency care pertaining to syncope.
89466321|NCT04175925|Experimental|Part A: BMS-986322|
89466322|NCT04175925|Experimental|Part B: BMS-986322 Placebo|
89466323|NCT04175925|Experimental|Part C: BMS-986322 with famotidine|
89466324|NCT04140435||TTNB group|Patients with PCLs suitable for biopsy.
89466325|NCT02971007|Experimental|CAMB 200 mg|200 mg CAMB (MAT2203) Oral Amphotericin B
89466326|NCT02971007|Experimental|CAMB 400 mg|400 mg CAMB (MAT2203) Oral Amphotericin B
89466327|NCT02971007|Active Comparator|Fluconazole 150 mg|Fluconazole Diflucan
89466328|NCT03881553|Experimental|Premature Infants (NICU)|Premature infants receiving care in the Neonatal Intensive Care Unit (NICU) will participate in up to 2 sessions with NEATCAP intervention and up to 2 sessions with SVS mattress intervention.
88946156|NCT01905332|Active Comparator|Literacy Toolkit|Children who fall below the cut off score on the GRTR-R will be randomized to either receive a literacy toolkit (current standard of care) or a referral to a home based literacy promoting program. The toolkit will contain age-appropriate books and games.
88946157|NCT01905345|Experimental|Endurance and Resistance Training|Endurance and resistance exercise
88946158|NCT01905345|Experimental|Resistance Training|resistance exercise (12wk)
88946159|NCT01905345|Experimental|Resistance and resistance Training|resistance exercise (24 wk)
88946160|NCT01905371|Experimental|Dextroamphetamine + Physical therapy (PT)|"Treatment with d-amphetamine + physical therapy administered under two regimens administered sequentially:~10 mg of d-amphetamine combined with 1 hr PT session beginning 1 hr after drug administration every 4 days, for a total of 6 or 10 sessions"
88946161|NCT01905371|Placebo Comparator|Placebo + Physical Therapy (PT)|"Treatment with placebo + physical therapy administered under two regimens administered sequentially:~Regimen 1: 10 mg of placebo combined with 1 hr PT session beginning 1 hr after placebo administration every 4 days, for a total of 6 or 10 sessions"
88946162|NCT01905410|Experimental|single treatment - VVZ-149 Injection|"single ascending dose escalation~0.25, 0.5, 1, 2, 4, 6, and 8 mg/kg Cohorts~4 hours IV infusion"
88946163|NCT01905410|Placebo Comparator|single treatment - placebo|"The matching volume of placebo (water for injection) to each experimental cohort~4 hours IV infusion"
88946164|NCT01905410|Experimental|multiple treatment - VVZ-149 Injection|"Based on the results of SAD trials, low and high dosage are determined for MAD trials.~high and low dosage~4 hours IV infusion x 2 times/day x 3 days"
88946165|NCT01905410|Placebo Comparator|multiple treatment - placebo|"The matching volume of placebo (water for injection) to each experimental cohort~4 hours IV infusion x 2 times/day x 3 days"
88946166|NCT01905449|Experimental|Ultrasound plus prosodic cues|One sound in error is treated with ultrasound visual feedback while also cueing prosodic variation (7 one-hour sessions). Another sound in error is treated with the ultrasound visual feedback with no prosodic variation (7 one-hour sessions). Prosodic variations are cues to coordinate production of the target sound with intonation patterns such as questions (rising intonations), commands (loud/emphatic), or statements (neutral)
88946167|NCT01905449|Experimental|Ultrasound vs Traditional treatment|One sound in errors is treated with ultrasound visual feedback for approximately half of each session and traditional treatment for half of the session (7 one-hour sessions). Another sound in error is treated with no ultrasound visual feedback, using traditional treatment for the entire session (7 one-hour sessions). These traditional cues include verbal instructions on how to move the tongue to achieve a particular speech sound.
88946168|NCT01905462||Exposed cohort|Women with the first day of LMP between 30 days before and 45 days after any Cervarix dose and between 30 days before and 90 days after any Cervarix dose.
88946169|NCT01905462||Non-exposed cohort|Women with the first day of LMP between 120 days and 18 months after their last Cervarix dose (and no further Cervarix dose before the outcome).
88946170|NCT01905475|Experimental|POL6326|POL6326 intravenous infusion
88946171|NCT01905475|Placebo Comparator|Placebo|Placebo intravenous infusion
88946172|NCT01905488||Group N|patients who didn't show internal jugula vein valve incompetency (IJVVI)
88946173|NCT01905488||Group PT|patients who showed IJVVI after pneumoperitoneum or Trendelenburg position
88946174|NCT01905488||Group S|patients who showed IJVVI in supine position
88946175|NCT01905501|Active Comparator|Total intravenous anesthesia|Total intravenous anaesthesia
88946176|NCT01905501|Experimental|Balanced anesthesia|
88946177|NCT01905514|No Intervention|control|using Medication event monitoring system
88946178|NCT01905514|Active Comparator|internet mobile application|using both mobile internet application and medication event monitoring system
88946179|NCT01905527||Standard Services of Group A (Group A1)|
88946180|NCT01905527||Customized Services of Group A (Group A2)|
88946181|NCT01905527||Group B|
88946182|NCT01905579|Experimental|patients with uveitis|Paracentesis of the anterior chamber in Paients with uveitis undergoing cataract surgery
88946183|NCT01905579|Experimental|patients without uveitis|Paracentesis of the anterior chamber in patients without uveitis undergoing routine cataract surgery
88946184|NCT01905605|Experimental|phosphatidylcholine supplementation|Phosphatidylcholine supplementation to be administered BID for 8 weeks
88946185|NCT01905605|Placebo Comparator|placebo supplementation|Placebo to be administered BID for 8 weeks
88946186|NCT01904240||Parkinson's disease patients|Patients with Parkinson's disease
88946187|NCT01904240||Subjects without Parkinson's disease|Control subjects without Parkinson's disease
88946188|NCT01905566|Active Comparator|Clopidogrel|clopidogrel: 75mg once a day
88946189|NCT01905566|Experimental|Ticagrelor|ticagrelor: 90mg twice a day
88946190|NCT01905618|Experimental|Multi Modal Education (MME)|Medical students in the medical schools randomized to the MME will receive four interventions during the course of their medical education. The four interventions/components are: 1) web-based curriculum on tobacco dependence treatment; 2)tobacco counseling role play; 3) preceptor training and teaching medical students, preceptor modeling the 5As, student observation, and student feedback; and 4)booster session.
88946191|NCT01905618|No Intervention|Traditional Education (TE)|Medical schools randomized to the Traditional Education (TE) will represent usual care and includes the current content and mode for tobacco teaching in the medical school.
88946192|NCT01905644|Experimental|With ultrasound|"Patients in this group will have perineal ultrasound for the detection of anal sphincter ruptures.~Intervention: Perineal ultrasound"
88946193|NCT01905644|No Intervention|Without ultrasound|Patients in this group will not have perineal ultrasound for the detection of anal sphincter ruptures.
88946194|NCT01905670|Experimental|Implant|Implant of the WiCS-LV system
88946195|NCT01905696|Experimental|N-Acetylcysteine (NAC)|After initial measurements of SNO-Hb level, forearm blood flow in response to exercise and hypoxia, subjects will take oral NAC 600 mg twice daily. Measurements will then be repeated.
88946196|NCT01905709|Experimental|All patients|150-500 ml of human fecal matter
88946197|NCT01905722|Other|3 Tesla|3 Tesla scanning with intravenous infusion of tracers
88946198|NCT01905722|Experimental|7 Tesla|7 Tesla scanning with intravenous infusion of tracers
89018363|NCT04053582|Active Comparator|Sham|Participants will receive an artificial neurofeedback signal during mindfulness practice in the MRI
89466329|NCT03881553|Experimental|Opioid-Exposed Newborns (NICU)|Opioid-exposed newborns receiving care in the Neonatal Intensive Care Unit (NICU) will participate in up to 2 sessions with NEATCAP intervention and up to 2 sessions with SVS mattress intervention.
89466330|NCT03881553|Experimental|Hospitalized Infants (PICU)|Infants receiving treatment in the Pediatric Intensive Care or Inpatient Unit will participate in up to 2 sessions with NEATCAP intervention and up to 2 sessions with SVS mattress intervention.
89466331|NCT04069611|Experimental|Test Group|Subjects in the test group will receive scaling and root planing, plus the take two probiotic lozenges per day for 3 months (one in the morning and one in the afternoon after brushing their teeth), starting after the last session of SRP. Lozenges will contain L. reuteri (2 x 108 colony forming units/tablet of strains ATCC 55730 and ATCC PTA 5289; Sunstar GUM Periobalance).
89466332|NCT04069611|Placebo Comparator|Control Group|Subjects assigned to the placebo group will receive scaling and root planing, and will take lozenges exactly like the test ones but without bacteria.
89466333|NCT02970929|Experimental|SEP-363856|SEP-363856 capsule (25 mg, 50 mg, or 75 mg) once daily
89466334|NCT03817593||Transcendental Meditation (TM)|"Each participant will have an individual instruction for 1 hour, followed by a course of 3 weekly group meetings (1-1.5 hours) The students shall meditate in a group for 10 minutes, twice a day, during 3 months, under the supervision of school teachers who will be instructed in TM technique.~To ensure the quality of practice, a group follow-up will be performed 10 days after a completion of the course, and then each participant will receive personal meetings with TM instructor on a weekly basis during the first month, and twice a month for the second and third months.~After additional 3 months participants in this group will be examined again, to assess sustainability of the effect"
89466335|NCT03817593||controls|Control group - Treatment as usual (TAU)
89018364|NCT04030143|Experimental|Aripiprazole 2M LAI 960 mg: Schizophrenia or Bipolar I Disorder|Participants with schizophrenia or bipolar I disorder received aripiprazole 2 month (2M) long-acting injection (LAI) 960 milligrams (mg) for a total of 4 injections administered every 56 days (± 2 days) over the course of 32 weeks.
89018365|NCT04030143|Experimental|Aripiprazole IM Depot 400 mg: Schizophrenia or Bipolar I Disorder|Participants with schizophrenia or bipolar I disorder received aripiprazole IM 400 mg, for a total of 8 injections administered every 28 days (± 2 days) over the course of 32 weeks.
89466336|NCT00148733|Experimental|Zinc|Zinc sulphate 10 or 20 mg (elemental zinc) per day. Intervention and placebo given perorally mixed with approximately 5 mL of breastmilk or clean water
89466337|NCT00148733|Placebo Comparator|Placebo|Placebo
89466338|NCT03430713|Experimental|Dental colour measurement|Comparison of dental colour measurement between two shade guides VITA Classical and VITA Toothguide 3D-Master and two spectrophotometers VITA Easyshade and Spectroshade Micro
89466339|NCT04053413|No Intervention|Usual care|Women in this group will undergo usual care and the complete the survey questions on knowledge and involvement in the decision for trial of labor after cesarean (TOLAC) or repeat cesarean.
89466340|NCT04053413|Active Comparator|Decision Aid|Women in this group will receive a decision aid prior to undergoing counseling by their physician. Following completion of the decision aid and physician counseling, they will complete a series of survey questions to assess their perceptions of their knowledge and involvement in the decision for trial of labor after cesarean (TOLAC) or repeat cesarean delivery.
89466341|NCT03428139|Active Comparator|Group I|Each patient in this group was treated with pulsed radiofrequency on the affected dorsal root ganglion at 42°C for 120 seconds
89466342|NCT03428139|Active Comparator|Group II|Each patient in this group was treated with pulsed radiofrequency as in group I plus oral alpha lipoic acid (ALA) 600 mg.
89466343|NCT03651089|Active Comparator|SP16 0.0125|0.0125 mg/kg of SP16 will be administered by subcutaneous injection once
89466344|NCT03651089|Active Comparator|SP16 0.050|0.050 mg/kg of SP16 will be administered by subcutaneous injection once
89466345|NCT03651089|Active Comparator|SP16 0.20|0.20 mg/kg of SP16 will be administered by subcutaneous injection once
89466346|NCT03651089|Placebo Comparator|placebo|Placebo (sterile saline) will be administered by subcutaneous injection once
89466347|NCT04449939|Experimental|Group 1|Single dose of KY1005 by i.v. infusion
89466348|NCT04449939|Experimental|Group 2|Single lower dose KY1005 by s.c. injection
89466349|NCT04449939|Experimental|Group 3|Single higher dose KY1005 by s.c. injections
89466350|NCT03651635||Medical ICU Patients|All patients admitted to the medical intensive care unit of the University hospital of Zurich during the recruitment period
89466351|NCT03428061||Intervention group|The intervention under study will be the integrated care for cardiovascular risk management (CVRM), based on the Dutch CVRM guideline. Patients with a history of cardiovascular disease (CVD), a high cardiovascular risk (CVR) (>10%) or use of antihypertensives or lipid lowering drugs are included in the program. Patients will be invited for an intake consultation, including a blood test, an interview, physical examination and estimation of the 10-years cardiovascular risk. If indicated, treatment with medication will be started and general lifestyle advises will be given. Patients can be referred to smoking cessation therapy, dietician and exercise programs or a physiotherapist. Patients will be controlled on a regular base to evaluate and adjust their personal goals.
89466352|NCT03428061||Control group|Usual care will be based on the Dutch CVRM guideline, describing how to calculate the CVR and advices to lower this risk by lifestyle intervention and/or medication. However systematic identification of patients eligible for CVRM, actively inviting patients for a visit, regular follow-up and standardized collaboration with other disciplines in the health care chain are not necessarily part of usual care.
89466353|NCT03127917|Experimental|CitrullinePlacebo|Subjects allocated to the CitrullinePlacebo study arm received L-citrulline first, followed by placebo.
89018366|NCT04025814|Experimental|dHealth tool and BPT Group|Parents and School Mental Health Providers (SMHPs) will participate in a 2-month trial during which they will use a digital Health (dHealth) tool in daily life contexts while receiving BPT, aimed to improve parent adherence sustained use of evidence-based parenting strategies. They will also participate in focus groups and discussions to facilitate the build, design, and use of the dHealth.
89018367|NCT04025814|Experimental|BPT Group|Parents and School Mental Health Providers (SMHPs) will participate in a 2-month trial during which they will be receiving BPT without the use of a digital Health (dHealth) tool.
89466354|NCT03127917|Experimental|PlaceboCitrulline|Subjects allocated to the PlaceboCitrulline study arm received placebo first, followed by L-citrulline.
89466355|NCT03427983|Other|US-guided regular injection|US in-plane injection with corticosteroid and 1cc of lidocaine. Total of 2cc.
89466356|NCT03427983|Other|US-guided hydrodissection|US in-plane injection with corticosteroid and 1cc of lidocaine, and 3cc of saline. Total of 5cc.
89466357|NCT03427905|Active Comparator|GROUP I|lipoaspiration and transplantation of ADSVCs (for adipose-derived stromal vascular cells/primary fresh cells without culture) Interventions: - Procedure: Lipoaspiration; - Procedure: Transplantation
89466358|NCT03427905|Active Comparator|GROUP II|lipoaspiration and transplantation of ADSCs (for adipose-derived mesynchymal stem cells/after culture) Interventions: - Procedure: Lipoaspiration; - Procedure: Transplantation
89466359|NCT03650543|Experimental|amoxicillin clarithromycin omeprazole 1|"This group received triple standard therapy with standard doses of omeprazole. 20 mg omeprazole before breakfast and before dinner. 500 mg clarithromycin after breakfast and after dinner and 1 g amoxicillin after breakfast and after dinner for 10 days."
89466360|NCT03650543|Experimental|amoxicillin clarithromycin omeprazole 2|"This group received triple standard therapy, using 500 mg clarithromycin after breakfast and after dinner and 1 g amoxicillin after breakfast and after dinner for 10 days in addition with omeprazole but omeprazole doses were prescribed according to CYP2C19 genotype as a follows: a) Patients with CYP2C19 *1/*1 genotype (Early and ultrarapid Metabolizer): 40mg omeprazole before breakfast and before dinner. b) Patients with CYP2C19 *1/*2 or *1/*3 genotype (Intermediate Metabolizer): 20mg omeprazole before breakfast, 20mg before lunch and 20mg before dinner. c) Patients with CYP2C19 *2/*2 (Poor Metabolizer): 20mg omeprazole before breakfast and 20 mg before dinner."
89466361|NCT03427671|Experimental|Occlusin 500 microspheres|Uterine fibroid embolization
89466362|NCT03427593|Experimental|Patients|Patients with the phenotype (PID and Neutropenia and lymphoproliferation)
89466363|NCT03427593|Other|relatives (parents)|
89466364|NCT03427593|Sham Comparator|Controls|
89466365|NCT03785769|Active Comparator|HVGIC restoration with pre-etching|Pre-etching of the surface with polyacrylic acid for 10 s, followed by HVGIC restoration.
89466366|NCT03785769|Experimental|HVGIC restoration with non pre-etching|HVGIC restoration without the pre-etching of the surface.
89466367|NCT02970305|Experimental|Pimavanserin|Drug- pimavanserin 34 mg, 20 mg, or 10 mg taken as two tablets + background antipsychotic, once daily by mouth
89466368|NCT02970305|Placebo Comparator|Placebo|Placebo, taken as two tablets + background antipsychotic, once daily by mouth
89466369|NCT03743571|Active Comparator|anodal tDCS during exposure|anodal transcranial direct current stimulation (2mA) will be applied over EEG coordinate FpZ to target mPFC activation during exposure therapy
89466370|NCT03743571|Sham Comparator|sham tDCS during exposure|sham transcranial direct current stimulation will be applied over EEG coordinate FpZ during exposure therapy at a level that provides the physical sensations of tDCS but which is non-therapeutic
89466371|NCT03430557|Experimental|Periapical surgery with PRP|MTA Retrograde filling will be performed after apicectomy for involved teeth and PRP will be filled in the lesion before closure of flap
89466372|NCT03430557|Active Comparator|Periapical surgery without PRP|MTA Retrograde filling will be performed after apicectomy for involved teeth and flap will be closed without placement of PRP
89466373|NCT03698409|No Intervention|Botox in preservative-free saline|OnabotulinumtoxinA (Botox) 200u will be reconstituted using 4 ml of preservative-free saline, as recommended by the manufacturer. 155-195 u of Onabotulinumtoxin A (Botox) will be injected in subjects with chronic migraine, consistent with FDA-approval indications, following the standard injection protocol (31 sites)
89018368|NCT04005547|Experimental|Program+survey|
89018369|NCT04005547|No Intervention|Survey-only|
89018370|NCT04003428|Experimental|Per-caesarean HIFU shots|Adjuvant treatment with High Intensity Focused Ultrasound (HIFU) performed the day of the scheduled childbirth, after confirmation of placenta accreta, and after fetal extraction by caesarian section.
89466374|NCT03698409|Active Comparator|Botox in preserved saline|OnabotulinumtoxinA (Botox) 200u will be reconstituted using 4 ml of preservative saline (i.e. bacteriostatic saline). 155-195 u of Onabotulinumtoxin A (Botox) will be injected in subjects with chronic migraine, consistent with FDA-approval indications, following the standard injection protocol (31 sites).
89018371|NCT03993873|Experimental|Phase 1 elzovantinib|"The dose-escalation part of the study will determine the safety, tolerability, MTD, and RP2D of elzovantinib.~The dose-expansion part of the study will determine the safety, tolerability, PK, and preliminary efficacy in specific cohorts.~Dose expansion cohorts: Cohort I (NSCLC, METΔex14, treatment Naive) Enrollment Closed; Cohort II (NSCLC with METΔex14, MET therapy pre-treated) Enrollment closed; Cohort III (MET amplified NSCLC, GCN≥10); Cohort IV (MET amplified GI cancer GC/GEJ, CRC/HCC, GCN≥10); Cohort V (NSCLC or GI MET amplified, GCN≥5 and < 10); Cohort VI (Solid tumors with MET fusions, or oncogenic MET mutations or MET amplified other than GI/NSCLC"
89466375|NCT03650465|Experimental|CT/BTP|Cognitive-behavioral therapy (CBT) in the form of Borkovec's treatment package (CT/BTP for GAD) was derived from Borkovec and Costello's (1993) therapeutic approach, relying on principles of CT for anxiety (A. T. Beck & Emery, 1985) and including applied relaxation. The CT/BTP protocol included several directions as primary goals in therapy: providing a cognitive conceptualization of the problem, identifying and restructuring automatic thoughts, intermediate and core beliefs through cognitive and behavioral techniques (i.e., behavioral experiments), enhancing adaptive behavior (i.e., activity scheduling, dealing with avoidance behavior, social skills training), and using applied relaxation as a coping strategy.
89202100|NCT05264844|Experimental|masking tape group|Masking tape will be used
89466376|NCT03650465|Experimental|REBT|Cognitive-behavioral therapy (CBT) in the form of REBT was based on the approach of Dryden & DiGiuseppe (1990), having as a central tenet changing dysfunctional emotions (e.g., anxiety) into functional ones (e.g., healthy anxiety/concern) by changing irrational beliefs into rational beliefs using cognitive, emotive, and behavioral techniques. The structure of an REBT session parallels the CT/BTP session structure including the same elements, but often with a different content. In its elegant/specific form, used here, REBT is focused on changing the core irrational beliefs (i.e., evaluative beliefs/appraisals) seen as the fundamental etiopathogenetic mechanism of GAD.
89466377|NCT03650465|Experimental|ACT/ABBT|Cognitive-behavioral therapy (CBT) in the form of the ACT/ABBT protocol was derived from the principles and techniques proposed by Eifert and Forsyth (2005) and Roemer and Orsillo (2005). From this perspective, GAD is maintained by dysfunctional reactions to internal experiences (i.e., emotions, thoughts, bodily sensations), experiential avoidance, and behavioral restriction, so the treatment aims to address all of these problems. In this sense, ACT/ABBT includes three major treatment goals: (1) education about the nature of anxiety, worry and the role of experiential avoidance; (2) practicing mindfulness and acceptance skills when dealing with disturbing internal experiences; and (3) identifying values and following valued action paths when facing obstacles.
89466378|NCT04449783||study patients|Patients undergoing elective cancer surgery, who will receive pre-operative screening including reporting symptoms and nose and throat swabbing 48 hours prior to surgery
89466379|NCT03429933|Experimental|Single Ascending Dose|BMS-986278 or placebo
89466380|NCT03429933|Experimental|Multiple Ascending Dose|BMS-986278 or placebo
89466381|NCT03650621|Experimental|Intervention - Magnetic acupuncture|"Infants randomized to the intervention arm will have 5 magnetic stickers placed on both ears approximately 1 hour before the eye-exam and will stay in place for approximately 1 hour after the eye-exam.~Total duration of study 2.5-3 hours"
88946199|NCT01905735|Placebo Comparator|placebo|1/2 ml of dispensing alcohol administered orally at every 7 day for 5 month .
88946200|NCT01905735|Active Comparator|Rhustoxicodendron 30|1/2ml Rhustoxicodendron 30 is administered orally every 7 day for 5 month.
88946201|NCT01905748|Experimental|Patients during Migraine attacks|Patients with Migraine before, during and after Migraine attacks. Acute phase reaction profile, and activation of the coagulation system will be investigated together with thrombophilia profile.
88946202|NCT01905748|Experimental|Control group|Patients with acute neurologic events like convulsions not related to fever or central nervous system (CNS) infections will be studied including acute phase reaction laboratory tests, thrombophilia and activation of the coagulation system
88946203|NCT01905774||Deferasirox|The patients will be treated by the primary physician according to clinical status. The Deferasirox dose range is between 20 to 40 mg/kg/day once daily dose. The treatment is a continuous treatment and not a single course.
88946204|NCT01905787||Group 2 - Dana group|50 patients will be included in the study.
88946205|NCT01905787||Group 3 - Schneider group|50 patients will be included in the study
88946206|NCT01905787||Group 4 - Detroit group|100 patients will be included in the study, Homozygous SCA patients and Sickle Cell β Thalassemia Patients (β0 and β+) will be included).
88946207|NCT01905787||Group 1 - Emek group|100 patients will be included in the study, including Homozygous SCA patients and Sickle Cell β Thalassemia Patients (β0 and β+ patients will be included).
88946208|NCT01905800|Active Comparator|Barbecue treatment without acceleration|Treatment of horizontal BPPV with adapted maneuvers using a biaxial rotational chair and infrared videoscopy goggle. The patient is positioned in supine position and rotated 30 degrees stepwise towards the unaffected ear, thus applying an overall 360 degrees rotation. The patient remains in each position for 30 seconds
88946209|NCT01905800|Experimental|Barbecue treatment with acceleartion|Treatment of horizontal BPPV with adapted maneuvers using a biaxial rotational chair and infrared videoscopy goggle. The patient starts in supine position and will be rotated about a horizontal axis from head to feet. The patient will be rotated 360 degrees with a succession of eight fast rounds in the axial plane towards the unaffected side.
88946210|NCT01905800|Placebo Comparator|Placebo treatment|Positional examination of horizontal BPPV with adapted maneuvers using a biaxial rotational chair and infrared videoscopy goggle. The patient is positioned in supine position and rotated 30 degrees stepwise towards the unaffected ear, thus applying a rotation towards the other side.
88956468|NCT05137119|Experimental|Methicillin-resistant staphylococcus aureus (MRSA) - Standard + B-Lactam Arm (backbone therapy)|"Vancomycin or Daptomycin (Standard Therapy) + Beta-Lactam (β-lactam) Arm~In addition to standard treatment an intravenous β-lactam will be added for the first 7 calendar days following randomisation (day 1 being the day of randomisation - hence patients will receive 6-7 days of β-lactam). This β-lactam will be intravenous cefazolin 2g every 8 hours. For patients with renal impairment the intravenous cefazolin administration doses will be adjusted."
89466382|NCT03650621|Placebo Comparator|Control - Placebo control|"In this arm the infants will have 5 stickers (magnets removed) placed on their ear approximately 1 hour before the eye-exam and will stay in place for approximately 1 hour after the eye-exam.~Total duration of study 2.5-3 hours"
89466383|NCT05285657|No Intervention|Control Arm|Febrile children will be managed according to the IMCI (integrative management of childhood illnesses) and the guideline of diagnostic and treatment (GDT), which are part of the routine system existing in Burkina Faso. Treatment will be done according to the national guideline.
88946211|NCT01905878|Experimental|single dose DLBS1033|Before taking the drug, blood samples will be collected from subject to assess PAP complex level, serum creatinine, SGOT, SGPT, PT and aPTT. After that, subjects will instructed to take three tablets enteric coated of DLBS1033 in front of investigator. After take the medicine blood sample will be collected on 30 minute, 60 minute, 90 minute, 2 hour, 3 hour, 4 hour, 6 hour, 8 hour, 10 hour, 12 hour, and 24 hour to evaluate serial PAP complex. Subjects will undergo a clinical assessment including vital signs and the presence of adverse events at the time of blood sampling. On this trial, subjects are only permitted to eat food from investigator.
88946212|NCT01905878|Experimental|steady state of DLBS1033|On day 1 blood samples will be collected to assess PAP complex level, serum creatinine, SGOT, SGPT, PT and aPTT. After that, subjects will instructed to take one tablet of DLBS1033 in front of investigator. Study drug packages (that consist of 8 tablets) will dispense to the subjects at day-1 and instructed to take the drug 3 times daily 30 minutes before meals. Subjects also will instructed to record any adverse events and concomitant medication prescribed in diary card. Subjects have to take the drug on 3 days (day 1, 2, and 3). On day 4, blood sample will be collected on 0 minutes, 30 minute, 60 minute, 90 minute, 2 hour, 3 hour, 4 hour, 6 hour, 8 hour, 10 hour, 12 hour, and 24 hour to evaluate serial PAP complex. Subjects will undergo a clinical assessment including vital signs and the presence of adverse events at the time of blood sampling. On this trial, subjects are only permitted to eat food from investigator.
88946213|NCT01905891|Other|Subjects at risk of skin cancer|Subjects at risk of skin cancer (sun-damaged skin) a superficial shave biopsy will be performed.
89466384|NCT05285657|Active Comparator|RDTs decisional Arm|The clinical examination based on IMIC will be supported by two-step malaria RDT and bacterial infections RDTs. Prescription will be left to the discretion of the healthcare workers.
89466385|NCT05285657|Active Comparator|e-algorithm Arm|Artificial intelligence integrating multiple layers of clinical information such as clinical examination, signs/symptoms and medical history, and laboratory information such as outcomes of biomarkers (CRP and WBC) and pathogen specific POCT (malaria and bacterial infections) and oximetry will be developed. The e-algorithm will serve to guide the diagnostic and management of febrile infections in children from 2 to 59 months.
89466386|NCT03649763|Active Comparator|Lidocaine distal forearm|Lidocaine 1% - Ultrasound-guided specific blocks of the DISTAL median and ulnar nerves with perineural injections of Lidocaine1%. Volume injected is 6 mL/nerve; 12 mL total.
89466387|NCT03649763|Active Comparator|Bupivacaine distal forearm|Bupivacaine 0.5%-Ultrasound-guided specific blocks of the DISTAL median and ulnar nerves with perineural injections of Bupivacaine0.5%. Volume injected is 6 mL/nerve; 12 mL total.
89466388|NCT03649763|Active Comparator|Lidocaine distal and proximal forearm|Lidocaine 1%- Ultrasound-guided specific blocks of the DISTAL and PROXIMAL median and ulnar nerves with perineural injections of Lidocaine 1%. Volume injected is 3 mL/nerve; 12 mL total
89466389|NCT03649763|Active Comparator|Bupivacaine distal and proximal forearm|Bupivacaine 0.5%- Ultrasound-guided specific blocks of the DISTAL and PROXIMAL median and ulnar nerves with perineural injections of Bupivacaine 0.5 %. Volume injected is 3 mL/nerve; 12 mL total.
89466390|NCT03650309|Experimental|Deep Brain Stimulation|All patients will receive deep brain stimulation (DBS) targeting two brain areas involved in the pathophysiology of obesity. No other changes to pre-existing treatment will be made. This is the only arm in this experiment.
89466391|NCT03648593|Experimental|behavioral|work recovery intervention
89466392|NCT03648593|Experimental|waiting list control|work recovery intervention after 6 months
89537247|NCT02720081|Experimental|MK-1029 150 mg + Montelukast 10 mg|Participants receive single-blind MK-1029 Matching-image Placebo + open-label Montelukast 10 mg for a 2 to 4 week run-in period while discontinuing or tapering off asthma controller medications. Participants receive double-blind MK-1029 150 mg + Montelukast 10 mg for 6 weeks in the treatment period. Participants can use rescue medication during both periods as needed.
89537248|NCT02720081|Placebo Comparator|MK-1029 Placebo + Montelukast 10 mg|Participants receive single-blind MK-1029 Matching-image Placebo + open-label Montelukast 10 mg for a 2 to 4 week run-in period while discontinuing or tapering off asthma controller medications. Participants receive double-blind MK-1029 Matching-image Placebo + Montelukast 10 mg for 6 weeks in the treatment period. Participants can use rescue medication during both periods as needed.
89537249|NCT04552197|Experimental|Part 1: Treatment A (JNJ-64251330)|Participants will receive JNJ-64251330 (dose 1), once daily for 5 days under fasting conditions.
89537250|NCT04552197|Experimental|Part 1: Treatment B (JNJ-64251330)|Participants will receive JNJ-64251330 (dose 1), twice daily for 5 days under fasting conditions.
89537251|NCT04552197|Experimental|Part 1: Treatment C (JNJ-64251330)|Participants will receive JNJ-64251330 (dose 2), twice daily for 5 days under fasting conditions.
89537252|NCT04552197|Active Comparator|Part 1: Treatment D (JNJ-64251330)|Participants will receive tofacitinib tablet twice daily for 5 days under fasting conditions.
89537253|NCT04552197|Experimental|Part 2: Treatment EF (JNJ-64251330)|Participants will receive a single dose of JNJ-64251330 (dose 2), on Day 1 once under fasting conditions (Treatment E) in Period 1 followed by a single dose of JNJ-64251330 (dose 2), on Day 1 once with high fat breakfast (Treatment F) in Period 2. There will be a minimum of 5 days washout between dosing in the two treatment periods.
88946214|NCT01905891|Other|Subjects with healthy skin|Subjects without sun-damaged skin a superficial shave biopsy will be performed.
88946215|NCT01905904|Active Comparator|sevorane|Sevorane 4% concentration during anesthesia induction
88946216|NCT01905904|Active Comparator|sevorane %7|Sevorane 7% concentration during anesthesia induction
88946217|NCT01905917|No Intervention|Control|Usual care
88946218|NCT01905917|Experimental|Tele-Rehabilitation|A tele-rehabilitation intervention involving weekly video-conferencing with a therapist, training exercise videos and use of wearable sensors to capture patient participation in exercises.
89466393|NCT03649607|Other|Accelerated Resolution Therapy|Participants will complete a clinical intake assessment before meeting with the therapist and initiating the ART® protocol. Participants will receive the ART intervention over a 21-day period, where imaginal exposure and imagery re-scripting will be used replace previous traumatic experiences. The ART intervention will be assessed through pre- and post-test measures at 60-days post enrolment.
89466394|NCT04449627||Naturalistic cohort|Patients who were hospitalised between March and June from Covid19, who did not require treatment in intensive care, who at 8 weeks post discharge have symptoms of anxiety or depression. All patients are offered access to an audio based self help programme based on applied relaxation and mindfulness based cognitive therapy.
89466395|NCT03649529|Experimental|GPA-TriMAR-T|Patients' autologous T cells will be isolated and transduced by GPA-TriMAR lentivirus to generate the GPA-TriMAR-T cells, and these cells will then be infused back into the patient for intervention.
89466396|NCT03427515|Experimental|Lactobacillus|Lactobacillus rhamnosus GG (ATCC 53103) - encapsulated
89466397|NCT03427515|Placebo Comparator|Placebo|Placebo - encapsulated mixture of maltodextrins
89466398|NCT03427515|Experimental|Saccharomyces|Saccharomyces boulardii (CNCM I-1079) - encapsulated
89466399|NCT03427437|Active Comparator|Conventional Group|Caudal block was performed by conventional method with %0,25 bupivacaine plus 1/200.000 adrenalin
89466400|NCT03427437|Active Comparator|Ultrasound Group|Caudal block was performed by ultrasound method with %0,25 bupivacaine plus 1/200.000 adrenalin
89466401|NCT03649373||ED Patients|We retrospectively reviewed patient charts of all patients admitted for shoulder dislocation at the ED at Copenhagen University Hospital Hvidovre between January 1st 2014 and December 31st 2014. A total of 151 patients' charts were reviewed.
89466402|NCT03648515||Malocclusion patients|"Patients with different types of malocclusion will be included. Plaster models will be fabricated after pouring the impressions with hard gypsum.~Then, digital images of the dental arches of each patient will be taken using a dedicated camera with very high resolution. Finally, digital images of models that were poured with gypsum will be taken also with the same camera and in the same conditions."
89466403|NCT03427359|Experimental|experimental arm|Induction chemotherapy: capecitabine tablet 1000mg/m2 po bid from day1 to 14,cisplatin injection 80mg/m2 iv day1,every 3 weeks for a total of 3 cycles. Then followed by concurrent chemoradiotherapy with cisplatin injection 100mg/m2 iv every 3 weeks for a total of 2 cycles.
89466404|NCT05053659|Experimental|Loncastuximab tesirine & venetoclax|"Participants will receive a baseline disease assessment via PET/CT in FDG avid lymphomas; CT scan (chest, abdomen, pelvis; inclusion of neck in selected cases). Bome marrow biopsy in selected cases.~Premedication includes:~Allopurinol (to reduce uric acid) 300mg orally daily starting day -1 and continuing at least until day 7 of each cycle.~Dexamethasone (steroid pre-medication) 4mg orally twice daily on day -1, day 1 and day 2 of each cycle.~Adequate oral hydration starting on day -1 or -2, defined as 1 - 2 liters of oral intake of liquids in 24 hours~Study treatment to be given every 21 days.~Loncastuximab tesirine (50 - 150 μg/kg) intravenously (IV) on day 1 of each 21-day cycle~Venetoclax (400 - 800 mg) orally, every day on days 1 - 5 of each 21-day cycle. Dose ramp-up on cycle 1 (over days 1 - 5 for target dose 400mg, 1 - 6 for target dose 600mg and 1 - 7 for target dose 800mg"
89466405|NCT03649295|Experimental|Functional Electrical Stimulation|"- Functional electrical stimulation device obeying the following steps: Muscle heating - 2 min, 10 Hz, 250 μm; Potentiation of muscle fibers type I - 8 min, 30 Hz, 250 μm; Potentiation of muscle fibers type II - 8 min, 80 Hz, 300 μm; Toning - 8 min, 30 Hz, 300 μm; Muscle Relaxation - 4 min, 5 Hz, 200 μm One channel of electrodes will be placed in the submental region and the other in the thyroid. Treatment should be started at minimum levels of intensity, increasing carefully until appropriate effects are achieved in the procedure. Conventional therapy should be performed in conjunction with functional electrostimulation~-Conventional speech therapy with laryngeal elevation exercises, stimulation of oral reflexes, tongue movements, lips and cheeks, gustatory therapy"
89466406|NCT03649295|Placebo Comparator|Placebo|"Sham.The electrodes are placed at 0 Hz~-Conventional speech therapy with laryngeal elevation exercises, stimulation of oral reflexes, tongue movements, lips and cheeks, gustatory therapy"
88946219|NCT01905930|Experimental|PCM Cervical Disc|Patients enrolled in the IDE clinical study and treated with the PCM Cervical Disc to treat degenerated cervical discs and neurological symptoms at one level from C3 to T1
89466407|NCT03423615|Experimental|CHHIP Arm|"All enrolled students in schools in the CHHIP Arm were eligible to receive the CHHIP intervention. The CHHIP intervention was delivered by lay fieldworkers (SHAs). Intervention activities included:~Health Education: activity-based curriculum with lessons delivered once per week. Units include hygiene, nutrition, safety, disease prevention& management, and social, emotional, and behavior development.~Basic Primary Health Services: school-based treatment including deworming and iron supplementation; screening and referral programs including growth monitoring, well-child exam, vision screening, epilepsy screening, and oral health; psychosocial and counseling support for students with atypical behaviors.~Health School Environment: improvements to physical infrastructure including latrines and water systems; modeling of positive behavior reinforcement, inclusive learning environment, and avoidance of corporal punishment."
89466408|NCT03423615|No Intervention|Comparison Arm|All enrolled students in schools in the Comparison Arm received school health activities as were routinely available in their school, through their curriculum, or through special events.
89466409|NCT03648203|Experimental|TEAMS|Routine asthma care, as provided in the University of Rochester Medical Center Medicine Clinic, will be augmented by three intervention components over a six-month pilot period : (1) Patient subject smartphone asthma monitoring; (2) Nursing telemedicine follow up (virtual home visits); (3) EMR custom programming to guide nursing assessment and management.
89466410|NCT03128073|Experimental|Single group|The intervention is with the Carry Life system ultrafiltration (CLS UF) device, which administers a Glucose-salt solution intermittently to a volume of the intraperitoneal fluid in the device.
89466411|NCT03650153|Active Comparator|Trans-rectal MRI targeted Biopsy|Trans-rectal to perform the prostate MRI targeted biopsy The puncture points are at the rectal
89466412|NCT03650153|Active Comparator|Trans-perineal MRI targeted Biopsy|Trans-perineal to perform the prostate MRI targeted biopsy The puncture points are at the perineal
89466413|NCT03423537|Experimental|Group 1 [HCG (+) group]|"Group 1 will indicate the application of the protocol by adding hCG with the initiation of standard GnRH agonist protocol for IVF / ICSI with rFSH"
89466414|NCT03423537|Placebo Comparator|Group 2 [placebo]|"Group 2 will indicate the application of the standard GnRH agonist protocol without the addition of hCG, but placebo, instead"
89466415|NCT03650075|Placebo Comparator|Single Ascending Dose (SAD)|
89466416|NCT03650075|Placebo Comparator|Multiple Ascending Dose (MAD)|
89466417|NCT03650075|Experimental|Food Effect Part|
89466418|NCT03649139|Active Comparator|artemisia annua (sweet sagewort) allergen extract drops|Drug: sublingual immunotherapy drops
89466419|NCT03649139|Placebo Comparator|Placebo drops|Drug: sublingual placebo drops
89466420|NCT03423381|Experimental|Cereal product 1|Cereal based müsli no. 1, made from typical Swedish cereals. All experimental products have different types and amounts of dietary fibre (df). The test portion is consumed as a single evening meal prior to determinations of test variables in the morning.
89466421|NCT03423381|Experimental|Cereal product 2|Cereal based muesli no. 2 made from typical Swedish cereals. All experimental products have different types and amounts of df. The test portion is consumed as a single evening meal prior to determinations of test variables in the morning.
89466422|NCT03423381|Experimental|Cereal product 3|Cereal based muesli no.3 made from typical Swedish cereals. All experimental products have different types and amounts of df.The test portion is consumed as a single evening meal prior to determinations of test variables in the morning.
89466423|NCT03423381|Experimental|Cereal product 4|Cereal based muesli no. 4 made from typical Swedish cereals. All experimental products have different types and amounts of df. The test portion is consumed as a single evening meal prior to determinations of test variables in the morning.
89466424|NCT03423381|Experimental|Cereal product 5|Cereal based muesli no. 5 made from typical Swedish cereals. All experimental products have different types and amounts of df. The test portion is consumed as a single evening meal prior to determinations of test variables in the morning.
89466425|NCT03423381|Placebo Comparator|Control product|A cereal based product with low concentrations of df. The control portion is consumed as a single evening meal prior to determinations of test variables in the morning.
89466426|NCT03648125|Other|Rowing training session|"Power tests, balance and tonicity tests are performed eyes opened and eyes closed :~with artificial occlusal disturbance and~without artificial occlusal disturbance"
89466427|NCT03429855|Experimental|study group|Bobath based trunk exercises
89466428|NCT03429855|Other|control group|conventional physiotherapy approaches
89466429|NCT03648047|Experimental|Experimental group|Patients in this group will receive a mixed home-based rehabilitation program consisting of face-to-face sessions with a Physical Therapist (with decreasing periodicity depending on program stage) as well as sessions performed with a digital kinematic biofeedback system.
89466430|NCT03648047|Active Comparator|Conventional rehabilitation|Patients in this group will receive a home-based rehabilitation program consisting of face-to-face sessions with a Physical Therapist 3 times per week, for 1 hour. Patients will also be instructed to perform additional unsupervised sessions in at least two other days of the week. Compliance to these additional sessions is not mandatory, but patients will be asked to fill in a diary regarding these extra-sessions.
89466431|NCT03429777|Experimental|Hearing Loss Group|The investigators will characterize hearing-in-noise thresholds (also referred to as a speech-reception threshold) as measured by the HearMe app in patients with hearing loss.
89018372|NCT03973489|Experimental|Wild Type (WT) MUD Group|Wild Type (WT) Group: individuals who are WT for the TAAR1 gene
89466432|NCT03429777|Active Comparator|Control Group|The investigators will characterize hearing-in-noise thresholds (also referred to as a speech-reception threshold) as measured by the HearMe app in control subjects without any prior or current hearing loss.
89018373|NCT03973489|Experimental|Common Variant (CV) MUD Group|Common Variant (CV) Group: individuals who are hetero-or homozygous for the V288V SNP on the TAAR1 gene
89018374|NCT03973489|Experimental|Wild Type (WT) Healthy Control Group|Wild Type (WT) Group: individuals who are WT for the TAAR1 gene
89466433|NCT03649997|Experimental|Part 1 (Single Ascending Dose [SAD]): Cohort 1|Participants will receive single oral dose of JNJ-61393215 145 milligram (mg) suspension or matching placebo on day 1, under fasted conditions.
89466434|NCT03649997|Experimental|Part 1 SAD: Cohort 2|Participants will receive single oral dose of JNJ-61393215 225 mg suspension or matching placebo on day 1 under fasted conditions. Dose in this cohort will be determined based on safety and PK data of cohort 1.
89466435|NCT03649997|Experimental|Part 2 Cohort 3: Treatment Sequence CDEF|Participants will receive single oral dose of JNJ-61393215 30 mg suspension under fasted condition (Treatment C) in Period 1, then participants will receive single oral dose of JNJ-61393215 30 mg capsule under fasted condition (Treatment D) in Period 2, single oral dose of JNJ-61393215 30 mg capsule with high fat/high-calorie breakfast (Treatment E) in Period 3 followed by single oral dose of JNJ-61393215 30 mg capsule with standardized breakfast (Treatment F) in Period 4, on day 1 of each treatment period. There will be a washout period of at least 7 days between study drug intake in subsequent treatment periods.
89466436|NCT03649997|Experimental|Part 2 Cohort 3: Treatment Sequence DFCE|Participants will receive Treatment D in Period 1, then Treatment F in Period 2, then Treatment C in Period 3 followed by Treatment E in Period 4 on Day 1.
89466437|NCT03649997|Experimental|Part 2 Cohort 3: Treatment Sequence ECFD|Participants will receive Treatment E in Period 1, then Treatment C in Period 2, then Treatment F in Period 3 followed by Treatment D in Period 4 on Day 1.
89466438|NCT03649997|Experimental|Part 2 Cohort 3: Treatment Sequence FEDC|Participants will receive Treatment F in Period 1, then Treatment E in Period 2, then Treatment D in Period 3 followed by Treatment C in Period 4 on Day 1.
89466439|NCT03649997|Experimental|Part 2 Cohort 4: Treatment Sequence GHIJ|Participants will receive single oral dose of JNJ-61393215 suspension under fasted condition (Treatment G) in Period 1, then participants will receive single oral dose of JNJ-61393215 capsule under fasted condition (Treatment H) in Period 2, single oral dose of JNJ-61393215 capsule with high fat/high-calorie breakfast (Treatment I) in Period 3 followed by single oral dose of JNJ-61393215 capsule with standardized breakfast (Treatment J) in Period 4, on day 1 of each treatment period. There will be a washout period of at least 7 days between study drug intake in subsequent treatment periods. Dose in this cohort will be based on the results obtained in Part 1.
89466440|NCT03649997|Experimental|Part 2 Cohort 4: Treatment Sequence HJGI|Participants will receive Treatment H in Period 1, then Treatment J in Period 2, then Treatment D in Period G followed by Treatment I in Period 4 on Day 1.
89466441|NCT03649997|Experimental|Part 2 Cohort 4: Treatment Sequence IGJH|Participants will receive Treatment I in Period 1, then Treatment G in Period 2, then Treatment J in Period 3 followed by Treatment H in Period 4 on Day 1.
89466442|NCT03649997|Experimental|Part 2 Cohort 4: Treatment Sequence JIHG|Participants will receive Treatment J in Period 1, then Treatment I in Period 2, then Treatment H in Period 3 followed by Treatment G in Period 4 on Day 1.
89466443|NCT03649997|Experimental|Part 3 Cohort 5: Multiple Ascending Dose|Participants will receive oral JNJ-61393215 145 mg suspension or matching placebo once daily for 7 days under fasted conditions.
89466444|NCT03649997|Experimental|Part 3 Cohort 6: Multiple Ascending Dose|Participants will receive oral JNJ-61393215 225 mg suspension or matching placebo once daily for 7 days under fasted conditions. Dose may be lowered or increased based on the evaluation of safety and PK of Cohort 5. This dose may be the same as the dose chosen for Cohort 2 (Part 1), or it could be different.
89466445|NCT03429699|Experimental|Intervention group|
89466446|NCT03429699|Other|Control group|
89466447|NCT03423225|Experimental|ADVAGRAF®|One arm: Treatment conversion will take placefrom twice daily tacrolimus to once daily tacrolimus (ADVAGRAF) 3 months after transplant in new liver transplant recipients.
89537254|NCT04552197|Experimental|Part 2: Treatment FE (JNJ-64251330)|Participants will receive a single dose of JNJ-64251330 (dose 2), on Day 1 once with high fat breakfast (Treatment F) in Period 1 followed by a single dose of JNJ-64251330 (dose 2), on Day 1 once under fasting conditions (Treatment E) in Period 2. There will be a minimum of 5 days washout between dosing in the two treatment periods.
89537255|NCT03067545|Experimental|step rate increase|increase in running stride rate by 10%
89018375|NCT03973489|Experimental|Common Variant (CV) Healthy Control Group|Common Variant (CV) Group: individuals who are hetero-or homozygous for the V288V SNP on the TAAR1 gene
89018376|NCT03961919|Experimental|FLAT-Auto|Treosulfan in a combination regimen with ARA-C and fludarabine as conditioning therapy prior to autologous PBSCT
89018377|NCT03958643||1|In a population of adult patients with SCD we will comprehensively evaluate renal function.
89537256|NCT05244473|Experimental|Brentuximab vedotin + ART|Brentuximab vedotin given on Day 1 and Day 15. ART will be given throughout the study.
89537257|NCT05244473|Placebo Comparator|Placebo + ART|Placebo given on Day 1 and Day 15. ART will be given throughout the study.
89537258|NCT03067389||History of invasive breast cancer|Subjects with a diagnosis of invasive breast cancer within the past 12 months will provide a blood or saliva sample for genetic diagnostic testing and provide information about their personal medical and cancer history and family cancer history.
89537259|NCT03067389||No history of invasive breast cancer|Subjects with no history of breast cancer will provide a blood or saliva sample for genetic diagnostic testing and provide information about their personal medical and cancer history and family cancer history.
89537260|NCT05501795||WaveLight® FS200 femtosecond laser|Flap creation with the WaveLight® FS200 femtosecond laser
89537261|NCT05634681|Experimental|Intervention arm|
89537262|NCT05634681|Active Comparator|Control arm|
89537263|NCT05728983|Experimental|Treatment group|Participants randomly assigned to the treatment group arm experience both a well-rested and sleep-restricted week during the study
89537264|NCT05728983|Placebo Comparator|Control group|Participants randomly assigned to the treatment group arm experience two well-rested weeks during the study (and they still have an ad lib sleep week in between the two well-rested weeks)
89537265|NCT05634603|Active Comparator|Intervention|Lactose-free milk formula (Frisolac LF ®)
89537266|NCT05634603|Placebo Comparator|Placebo|Regular infant milk formula
89537267|NCT03067233|Experimental|Polysomnography|Three polysomnographic recordings will be made on 3 consecutive nights with Electroencephalogry.
89466448|NCT02521077|Experimental|Odd Cycle Intravenous Ascorbic Acid|Women randomized to this study arm will receive intravenous ascorbic acid (50g in 500 ml sterile water) prior to their odd-numbered chemotherapy cycles. During the even-numbered chemotherapy cycles, these subjects will receive intravenous normal saline (0.9%).
89018378|NCT03955068|Other|Strict Classic Ketogenic Diet Arm|The classic ketogenic diet is individually calculated for each patient based on age, weight, and nutritional needs. The diet is typically administered from a 2:1 to 4:1 ratio; this means 2 to 4 parts of fat to 1 part of both protein (calculated based on RDA and whatever remaining portion of carbohydrates. The basis of calculations is first on the amount of required protein needed to meet RDA to insure adequate growth. Fine tuning of ketogenic diet therapy is based on serum beta-hydroxybutyrate levels (target levels of 3.5-6.5 mmol/L), tolerance of the diet, and response to treatment.
89018379|NCT03950635|Experimental|Group I (fiber-rich diet)|Patients consume a whole-foods, fiber-rich diet for 6 weeks.
89018380|NCT03950635|Experimental|Group II (ketogenic diet)|Patients consume a high fat, low carbohydrate (ketogenic) diet for 6 weeks.
89018381|NCT03947385|Experimental|Dose Escalation Monotherapy|IDE196 dosed orally, twice daily (BID) for each 28-day cycle
89018382|NCT03947385|Experimental|Dose Expansion Monotherapy|RP2D in MUM and non-MUM tumors harboring GNAQ/11 mutations or PRKC fusions (cutaneous melanoma, CRC, other solid tumors)
89018383|NCT03947385|Experimental|Dose Escalation Binimetinib Combination|IDE196 dosed orally, twice daily (BID) for each 28-day cycle and Binimetinib dosed orally, twice daily (BID) for each 28-day cycle
89018384|NCT03947385|Experimental|Dose Expansion Binimetinib Combination|RP2D in MUM and non-MUM tumors harboring GNAQ/11 mutations (cutaneous melanoma, CRC, other solid tumors)
89018385|NCT03947385|Experimental|Dose Escalation Crizotinib Combination|IDE196 dosed orally, twice daily (BID) for each 28-day cycle and Crizotinib dosed orally, twice daily (BID) for each 28-day cycle
89018386|NCT03947385|Experimental|Dose Expansion Crizotinib Combination|RP2D in MUM and non-MUM tumors harboring GNAQ/11 mutations (cutaneous melanoma, CRC, other solid tumors)
89018387|NCT03947385|Experimental|Dose Optimization Crizotinib Combination|IDE196 dosed orally, twice daily (BID) for each 28-day cycle and Crizotinib dosed orally, twice daily (BID) for each 28-day cycle
89018388|NCT03947385|Experimental|Crizotinib Monotherapy with Crossover to Combination|Crizotinib dosed orally, twice daily (BID) for each 28-day cycle until disease progression then IDE196 added and dosed orally, twice daily (BID) for each 28-day cycle
89018389|NCT03947385|Experimental|Tablet PK Substudy|IDE196 dosed orally, once on Cycle 1 Day 1; thereafter, twice daily (BID) for each 28-day cycle
89018390|NCT03942328|Experimental|Phase II(pheresis, EBRT, dendritic cells, Prevnar, atezo, bev)|Patients with unresectable HCC undergo apheresis for dendric cell manufacturing and standard of care high-dose EBRT for 5 or 15 fractions over 1-3 weeks (cycle 1). Patients then receive autologous dendritic cells IT on day 1 of cycles 2-8 and pneumococcal 13-valent conjugate vaccine IM on day 1 of cycles 2-4 only. Patients also receive standard of care atezolizumab IV and bevacizumab IV starting on day 2 of cycles 2-8. Treatment repeats every 21 days for up to 7 cycles in the absence of disease progression or unacceptable toxicity.
89018391|NCT03942328|Experimental|Pilot study (pheresis, EBRT, dendritic cells, Prevnar)|Patients with unresectable intrahepatic CCA undergo apheresis for dendric cell manufacturing and standard of care high-dose EBRT for 5 or 15 fractions over 1-3 weeks (cycle 1). Patients then receive autologous dendritic cells IT on day 1 of cycles 2-8 and pneumococcal 13-valent conjugate vaccine IM on day 1 of cycles 2-4 only. Treatment repeats every 28 days for up to 7 cycles in the absence of disease progression or unacceptable toxicity.
89018392|NCT03934931|Experimental|Facilitated Directly Observed Therapy (DOT)|Facilitated DOT arm participants will attend the Mulago Immune Suppression Syndrome (ISS) clinic on a weekly basis to ingest 3HP medication under direct observation. DOT will be defined as a designated clinic staff member observing ingestion of each dose of 3HP. Additionally, participants randomized to facilitated DOT will receive: 1) DOT cards with instructions to present directly to the pharmacy for a pharmacy-only visit, without the need to wait in the general queue; 2) Automated short message service (SMS) or phone call reminders at no cost to participants the day before each appointment, 3) A fixed level of reimbursement (~$5/visit) for each weekly visit, conditional on either directly observed therapy or evidence of an adverse event that would preclude further treatment.
89018393|NCT03934931|Experimental|Facilitated Self-Administered Therapy (SAT)|Facilitated SAT participants will take their 1st dose of medication under direct observation and be given a 4-week 3HP supply to take weekly via self-administration. Participants will return to the Mulago ISS clinic after completing their 5th dose to review adherence data with the clinic pharmacy technician and receive 5 additional 3HP doses (doses 7-11). At the scheduled refill visit (dose 6) and end-of-treatment visit (dose 12) participants will ingest 3HP via direct observation. Participants will also receive: 1) Free automated SMS reminders or phone call reminders before each scheduled dose; 2) Weekly check-ins inquiring about side effects via two-way SMS with a follow-up phone call depending on participant response, 3) Fixed level of reimbursement (~$5/visit) for the refill/end-of-treatment visit, conditional on either directly observed therapy or evidence of an adverse event that would preclude further treatment.
89018394|NCT03934931|Experimental|Patient Choice between facilitated DOT and facilitated SAT|Participants randomized to the Patient Choice between facilitated DOT and facilitated SAT arm will be offered a choice between arms 1 and 2. A research nurse will review each section of the decision aid with participants, discuss values and preferences, and, after addressing any questions, ask participants to select facilitated DOT or facilitated SAT. Participants will have the option to switch between DOT and SAT at any time. The reason for switching and time spent under each strategy will be recorded.
89018395|NCT03929718|Active Comparator|Standard Therapy|subjects undergoing CTI ablation
89018396|NCT03929718|Experimental|Interventional Therapy|subjects treated with an aldosterone antagonist after CTI ablation
89018397|NCT03927144|Experimental|AMG334 70 mg/140 mg|"Participants were randomized to receive 70 mg or 140 mg of AMG334 as a subcutaneous injection once per month for 52 weeks in the Core Phase.~Participants were permitted to switch to an approved oral prophylactic based on treatment failure status and at the investigator's and participant's discretion.~Participants who completed visits through Week 52 of the Core Phase were eligible to participate in the 52-week Extension Phase of the study."
89202101|NCT05264844|No Intervention|standard catheter dressing group|Medical plaster to be used (It is routine practice in the clinic.)
89202102|NCT00567567|Active Comparator|Consolidation Arm A: single myeloablative consolidation|Patients receive melphalan IV over 15-30 minutes on days -7 to -5, etoposide IV over 24 hours and carboplatin IV over 24 hours on days -7 to -4, and G-CSF SC or IV beginning on day 0 and continuing until blood counts recover. Patients undergo autologous PBSCT on day 0.
88946220|NCT01905930|Active Comparator|Ant. Cervical Discectomy & Fusion(ACDF)|Patients enrolled in the IDE clinical study and treated with an anterior cervical discectomy and fusion (ACDF) using a cervical plate and bone graft in patients with degenerated cervical discs and neurological symptoms at one level from C3 to T1
88946221|NCT01905969||Biomarker positive|NF-kB(+)/JNK(-) in curatively removed specimens
88946222|NCT01905969||Biomarker negative|NF-kB(-)/JNK(+) in curatively removed specimens
88946223|NCT01905982|Experimental|Conventional breathing therapy|first: conventional breathing therapy, second: reflectory breathing therapy
89466449|NCT02521077|Experimental|Even Cycle Intravenous Ascorbic Acid|Women randomized to this study arm will receive intravenous ascorbic acid (50g in 500 ml sterile water) prior to their even-numbered chemotherapy cycles. During the odd-numbered chemotherapy cycles, these subjects will receive intravenous normal saline (0.9%).
89466450|NCT03422991|Other|Congestive Heart Failure patients Cohort|Cluster of patients with congestive heart failure NYHA ≥2, with at least one cardiac decompensation, NT-proBNP (N-terminal pro-brain natriuretic peptide) > 500 ng/l. Will be followed during 18 months.
89466451|NCT02732691|Experimental|Transcatheter Aortic Valve Replacement (TAVR)|Transcatheter aortic valve replacement (TAVR) will be performed using the JenaValve pericardial valve and delivery system.
89466452|NCT03427203|Experimental|Arm 1|"The subjects test the products in the following order~SenSura Mio (comparator) Coloplast Ostomy device 1 Coloplast Ostomy device 2 Coloplast Ostomy device 3"
89466453|NCT03427203|Experimental|Arm 2|"The subjects test the products in the following order~SenSura Mio (comparator) Coloplast Ostomy device 1 Coloplast Ostomy device 3 Coloplast Ostomy device2"
89466454|NCT03422913|Experimental|CLCVP Group|Controlled low central venous pressure(CLCVP) will be performed combined with intraoperative combined hilar intermittent (Pringle method)
89466455|NCT03422913|No Intervention|Control Group|Only intraoperative combined hilar intermittent (Pringle method) will be performed
89466456|NCT03422835|Active Comparator|R-TME|Robotic total mesentery excision surgery for rectal cancer.
88946224|NCT01905982|Experimental|Reflectory breathing therapy|first: Reflectory breathing therapy second:Conventional breathing therapy
88946225|NCT01905995||Patients with advanced Parkinson's disease|no intervention - observational study
88946226|NCT01906021|Experimental|1|Intra-patient comparison of temperature map obtained during CT/CBCT with standard ablation temperature measurements
88946227|NCT01906034|Experimental|Exercise with supervision|The expert panel selected balance and strength / power exercises which can be performed with one's own bodyweight or with the help of small, low-cost exercise equipment (i.e., small weights, resistance bands, unstable surfaces). In this study, intensity during training will be regulated using the Borg Rating of Perceived Exertion scale (i.e., 6-20 points, maximal exertion at 20 points). According to the individual fitness level, exercises should be performed with a perceived exertion between 12 and 16 points (somewhat hard - hard) during balance and strength / power training. Exercise intensity will be progressed individually using the Borg Rating of Perceived Exertion scale and varying the balance and strength / power exercises in order to sufficiently stimulate the neuromuscular system. Strength / power exercises will be progressed from single to multiple joint, isometric to dynamic muscle contraction, short to long lever arm and slow to fast exercises.
88956469|NCT05137119|No Intervention|Methicillin-susceptible staphylococcus aureus (MSSA) - Standard Therapy Arm (backbone therapy)|"Flucloxacillin or cloxacillin - Standard Therapy Arm~Either intravenous flucloxacillin/cloxacillin 2g every 4 or 6 hours. The minimum protocol duration of allocated study treatment is 14 days for those not allocated to early oral switch, and 5 days for those allocated to early oral switch. For patients with renal impairment or critical illness the intravenous flucloxacillin administration dose will be adjusted."
89202103|NCT00567567|Experimental|Consolidation Arm B: tandem myeloablative consolidation|Patients receive thiotepa IV over 2 hours on days -7 to -5, cyclophosphamide IV over 1 hour on days -5 to -2, and G-CSF SC or IV beginning on day 0 and continuing until blood counts recover. Following clinical recovery from initial myeloablative therapy, patients also receive melphalan, etoposide, and carboplatin as in Arm A. Patients undergo autologous PBSCT on day 0.
89202104|NCT00666198||SILDENAFIL|Patients taking SILDENAFIL.
89466457|NCT03422835|Experimental|R-TaTME|Robotic transanal total mesentery excision surgery for rectal cancer.
89466458|NCT03429621|Experimental|Simethicone|Each woman in the intervention group will be given Simethicone (Air-X®; 80 mg) 2 tablets chewing with water 50 ml at 2-8 hours before surgery.
89466459|NCT03429621|No Intervention|No simethicone|The women will not be given Simethicone.
89466460|NCT03426969|Experimental|Treatment (combination chemotherapy, TBI, HCT)|Patients receive melphalan IV over 30 minutes on days -5, fludarabine phosphate IV over 1 hour on days -5 to -2. Patients undergo TBI on day -1 and HCT on day 0. Patients then receive cyclophosphamide IV over 1-2 hours on days 3 and 4. Beginning on day 5, patients receive tacrolimus IV continuously for approximately 2 weeks, then PO for 6 months followed by a taper, mycophenolate mofetil PO TID until day 100, and filgrastim SC daily from day 7 until continued until ANC > 1,500/mm^3 for 3 consecutive days. Treatment continues in the absence of disease progression or unexpected toxicity.
89466461|NCT03422757|Experimental|adaptive DBS|adaptive Deep Brain Stimulation, by AlphaDBSvext.
89466462|NCT03422757|Active Comparator|conventional DBS|conventional Deep Brain Stimulation, by AlphaDBSvext.
89466463|NCT03426813|Other|Early mobilization|Historical control group for early mobilization
89466464|NCT03429465|Experimental|EVO|All children receive 4 weeks of EVO 5 days/week for 20 minutes per day in a stepped wedge design.
88946228|NCT01906034|Experimental|Home-based without supervision|The expert panel selected balance and strength / power exercises which can be performed with one's own bodyweight or with the help of small, low-cost exercise equipment (i.e., small weights, resistance bands, unstable surfaces). In this study, intensity during training will be regulated using the Borg Rating of Perceived Exertion scale (i.e., 6-20 points, maximal exertion at 20 points). According to the individual fitness level, exercises should be performed with a perceived exertion between 12 and 16 points (somewhat hard - hard) during balance and strength / power training. Exercise intensity will be progressed individually using the Borg Rating of Perceived Exertion scale and varying the balance and strength / power exercises in order to sufficiently stimulate the neuromuscular system. Strength / power exercises will be progressed from single to multiple joint, isometric to dynamic muscle contraction, short to long lever arm and slow to fast exercises.
88946229|NCT01906034|No Intervention|control group|The control group is a traditional waiting group and will receive a supervised training program after the completion of this study
88946230|NCT01906060|Experimental|Air-Q Intubation Laryngeal Mask|Patients will be intubated using the Air-Q Intubation Laryngeal Mask and subsequently intubated with a commercially available endotracheal tube via the Intubation Laryngeal Mask.
88946231|NCT01906073|Experimental|intranasal fentanyl spray|Fentanyl for nasal administration (NF), is supplied as sprays containing a phosphate buffered solution of fentanyl citrate. NF is available in three strengths: 0.5 mg/ml, 1 mg/ml and 2 mg/ml in multiple-dose sprays. The corresponding doses are 50, 100 and 200 µg/puff. NF is applied as one puff in one nostril. One puff defines and equals one dose. Applying a puff to each nostril the upper dose can be increased to 400 µg. The doses used in this study are 50, 100, 200 ad 400µg. Fentanyl may be administered for up to 6 pain episodes/ 24 hours. For each pain episode, a dose of NF is self-administrated in one nostril. If pain relief is not achieved, another dose of NF could be administered in the opposite nostril after 15 minutes.
88946232|NCT01906073|Active Comparator|slow release morphine|The active substance is released gradually during its transit through the gastrointestinal tract. Slow release (SR) morphine is available in 5, 10, 30, 60, 100 and 200 mg. SR morphine is administered twice a day, usually every twelfth hour.
88946233|NCT01906086|Experimental|legume consumption|legume consumption, 4 servings per week, for 6 weeks
88946234|NCT01906086|Active Comparator|healthy dietary recommendations|no nutritional intervention
88946235|NCT01906099|Experimental|legume enriched diet|legume consumption, 4 servings per week, for 6 weeks
88946236|NCT01906099|Active Comparator|healthy dietary recommendations|no nutritional intervention
88946237|NCT01906112|No Intervention|Controlled|No surgery for primary breast tumor.
88946238|NCT01906112|Experimental|Study|Surgery for primary breast tumor.
88946239|NCT01906125|Experimental|Palbociclib given to Healthy Volunteers|
88946240|NCT01906138|Other|SENSIMED Triggerfish®|All eligible patients will be assigned to 24-hour intraocular pressure recording using Triggerfish
88946241|NCT01906151|Other|SENSIMED Triggerfish®|SENSIMED Triggerfish® (TF) is a CE-marked portable device that monitors the 24-hour intraocular pressure (IOP) pattern by a wireless contact lens sensor (CLS) placed on the eye that sends its signals wirelessly via a periorbital patched adhesive antenna to a recorder. Upon completion, the recording can be transmitted to a computer for read-out and visualization
88946242|NCT01906164|Experimental|ALS-008176|
88946243|NCT01906164|Placebo Comparator|Placebo|
88946244|NCT01906190|Experimental|vaccinated group|Vaccinated group means that subjects whose antibodies less than 1:40 6 months later after primary vaccination will receive a booster dose of seasonal influenza vaccine.
88946245|NCT01906203|Experimental|ultramarathon|
88946246|NCT01906216|Active Comparator|Sorafenib|All subjects will take two tablets of sorafenib (200 mg tablets) twice daily (each morning and evening). Sorafenib may be taken either with a low/moderate fat meal or without food. Subjects are to continue sorafenib according to the study protocol if the adverse events could be safely controlled.
89466465|NCT03422601||3 months treatment|FOLFOX or CAPOX
88946247|NCT01906216|Experimental|Sorafenib combined with TACE|Sorafenib will be supplied as 200 mg tablets. All subjects will take two tablets of sorafenib (200 mg tablets) twice daily (each morning and evening). In addition, the subjects in this arm will receive the treatment of conventional transarterial chemoembolization. In all cases, TACE consists of an injection containing a mixture of chemotherapeutic agents(doxorubicin) and lipiodol followed by embolization with polyvinyl alcohol (PVA) or beads.
88946248|NCT01906229||Acute respiratory distress syndrome (ARDS)|
88946249|NCT01906229||Systemic inflammatory response syndrome (SIRS)|
88946250|NCT01906229||ARDS+SIRS|
88946251|NCT01906242|Placebo Comparator|Water|Patients' dentures are treated with water (placebo) once a week for 10 min.
88946252|NCT01906242|Active Comparator|sodium hypochlorite|Patients' dentures are treated with a solution of sodium hypochlorite 0.5% once per week for 10 min
88946253|NCT01906242|Active Comparator|0.5% chlorhexidine|Patients' dentures are treated with 0.5% chlorhexidine once a week for 10 min.
88946254|NCT01906242|Active Comparator|0.12% sodium bicarbonate|Patients' dentures are treated with sodium bicarbonate 0.12% once a week for 10 min.
88946255|NCT01906255||FTC/TDF for PrEP|HIV-1 negative adults (any sex/gender, including transgender, pregnancy) who are participating in observational or clinical studies on FTC/TDF for PrEP
88946256|NCT01906268|Experimental|TAU + ABMT active|"Treatment as usual (TAU): selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor~Attention Bias Modification Treatment (ABMT) - active"
89466466|NCT03422601||6 months treatment|FOLFOX or CAPOX
89466467|NCT02022033|Experimental|FOLFOXA|"Abraxane: 150mg/m2 IV over 30 minutes, day 1 (administered first) every 14 days.~Oxaliplatin: 85mg/m2, IV over 2 hours, day 1 every 14 days Leucovorin: 400mg/m2, IV over 2 hours, day 1 every 14 days 5-FU infusion:1200mg/m2/day, as a continuous IV infusion over 2 days, day 1 and day 2 (for a total dose of 2400mg/m2 over 46 hours.)"
89466468|NCT03422445|Experimental|Apatinib plus Temozolomide|this trial is designed single arm. all the subjects enrolled will receive the experimental intervention,apatinib+temozolomide.
89466469|NCT03429387|Experimental|FDG-PET/CT arm|Participants with persistent febrile neutropenia after 72 hours of onset who are randomized to this arm will have an FDG-PET/CT performed to look for source of fever.
89466470|NCT03429387|Active Comparator|Conventional CT arm|Participants with persistent febrile neutropenia after 72 hours of onset who are randomized to this arm will have a conventional CT (HRCT chest and sinuses +/- other regions as per clinician's discretion) performed to look for source of fever.
89466471|NCT03429309|Other|Anesthesia-induction with propofol|
89466472|NCT03429231||Active Group|Women who are taking coenzyme Q and who will continue taking it for 3 months
89466473|NCT03429231||Control Group|Women who are not taking coenzyme Q and who will not take it in the next 3 months
89466474|NCT03426735|Experimental|Dry heat|Dry heat application with a termal bag
89466475|NCT03426735|Active Comparator|Dry cold|Dry cold application with a termal bag
89466476|NCT01852851|Active Comparator|Intervention Group|The intervention group will participate in the on-line eLearning program, an ergonomic assessment by an Occupational Therapist and job retention vocational counselling by a Vocational Rehabilitation Counsellor
89466477|NCT01852851|No Intervention|Control Group|"The control group will receive usual care and receive printed educational materials about work and arthritis."
89466478|NCT03429075|Experimental|Psilocybin|Patients receive Psilocybin
89202105|NCT00778596|Experimental|Prednisolone priming|Prednisolone priming 4 weeks, then treated with telbivudine.
89202106|NCT00778596|Placebo Comparator|Placebo priming|Placebo priming for 4 weeks, then followed a telbivudine treatment for 2 years.
89466479|NCT03429075|Active Comparator|Escitalopram|Patients receive Escitalopram
89466480|NCT03422367|Experimental|Treatment Group|The Treatment Group begins the JASPER intervention immediately upon enrollment in the study.
89466481|NCT03422367|Active Comparator|Delayed Treatment Group|The Delayed treatment group receives the same JASPER intervention as the Treatment Group, but after 6 months of receiving services in the community as usual.
89466482|NCT03422367|No Intervention|Control|Participants who are unable to complete JASPER due to age or time/distance commitment can enroll for single-time point participation
89466483|NCT03428919|Active Comparator|Intracytoplasmic Sperm Injection (ICSI)|"All patients will be treated with a GnRH antagonist protocol. hCG (Ovitrelle 250 mg) will be used in the presence of at least three leading follicles of 17 mm. In women with ≥15 follicles ≥12 mm, 0,2 mg Triptorelin (Diphereline) will be used when there is at least two leading follicles of 17 mm. Oocyte retrieval will be performed 36 hours after triggering.~Insemination will be performed by using ICSI, 3 - 4 hours after oocyte retrieval. OCCs will be stripped by using hyaluronidase. Only matured oocytes will be inseminated.~Fertilization check will be performed at period of 16-18 hours after insemination. Embryo transfer will be performed on day 3 under ultrasound guidance. A maximum of 2 embryos will be transferred into the uterus. The remaining grade 1 and 2 embryos will be frozen."
89466484|NCT03428919|Active Comparator|In Vitro Fertilization (IVF)|"All patients will be treated with a GnRH antagonist protocol. hCG (Ovitrelle 250 mg) will be used in the presence of at least three leading follicles of 17 mm. In women with ≥15 follicles ≥12 mm, 0,2 mg Triptorelin (Diphereline) will be used when there is at least two leading follicles of 17 mm. Oocyte retrieval will be performed 36 hours after triggering.~Insemination will be performed by conventional IVF. Two hours after retrieval, collected OCCs will be inseminated for another 2 hours (100,000 motile sperm/ml). Inseminated OCCs will be cultured overnight in culture medium.~Fertilization check will be performed at period of 16-18 hours after insemination. Embryo transfer will be performed on day 3. A maximum of 2 embryos will be transferred. The remaining grade 1-2 embryos will be frozen."
89466485|NCT03422289|Experimental|Myo-inositol + folic acid|2 g myo-inositol and 0.2 mg folic acid orally twice a day for three months, in order to induce ovulation.
89466486|NCT03422289|Experimental|Myo-inositol + folic a. + α-lactalbumin|2 g myo-inositol and 0.2 mg folic acid plus 50 mg α-lactalbumin, twice a day for three months in order to test if α-lactalbumin addition allows to induce ovulation
89466487|NCT03422211||Sports orthopaedic surgery|Patients that recently underwent orthopaedic sports surgery performed by two separate surgeons
89466488|NCT02521389|Experimental|Part 1|3 sequential groups (Groups A, B and C), comprising 3, 6 and 6 subjects, respectively, with 2 optional additional groups (Groups D and E), each comprising 6 subjects, to assess alternative dose levels or formulations (described below), if required.
89466489|NCT02521389|Experimental|Part 2|Single dose, 2-way crossover design to assess a selected formulation of PWT-143 in the fed and fasted states in 8 subjects.
89466490|NCT03422133||Pre-Implementation Phase|"Participants in this group (before the eHealth app is implemented in the PAU) will be English or French speaking patients, aged 18 and older, scheduled for major non-cardiac elective surgery.~Patients will be recruited using standardized procedures, and process and outcome measures will be recorded using the same tools and methods in both study phases to decrease the risk of measurement and selection bias."
89466491|NCT03422133||Post-Implementation Phase|Participants in this group (after the eHealth app is implemented in the PAU) will be English or French speaking patients, aged 18 and older, scheduled for major non-cardiac elective surgery.
89466492|NCT03505671|Experimental|Group 1 (acupuncture)|Participants undergo 8 45-minute acupuncture treatments over 10 weeks.
89466493|NCT03505671|Active Comparator|Group 2 (usual care)|Participants receive usual care.
89466494|NCT04449159|Placebo Comparator|Placebo|
89202107|NCT00785694|Experimental|B|One instillation of mitomycin C after transurethral resection in white and blue fluorescence light with Hexvix.
89202108|NCT00785694|No Intervention|A|Multiple instillations of mitomycin C after transurethral resection in white light alone.
89202109|NCT00778674|Experimental|1|Benazepril HCl/ Hydrochlorothiazide 20 mg/ 25 mg Tablets
89202110|NCT00778674|Active Comparator|2|Lotensin® HCT tablets
89202111|NCT00778752|Experimental|A|"Lenalidomide-treatment starts between 100 and 180 days after allogeneic stem cell transplantation. Three dose-levels will be investigated.~Dose-level -1: 2.5 mg/d if 2.5mg capsules are available, day 1-21, otherwise 5 mg every other day, day 1-21~Dose-level 0: 5 mg/d, day 1-21~Dose-level 1: 10 mg/d, day 1-21~Dose-level 2: 15 mg/d, day 1-21"
89466495|NCT04449159|Experimental|Vinh Wellness Collagen|
88946257|NCT01906268|Sham Comparator|TAU + AMBT placebo|"Treatment as usual (TAU): selective serotonin reuptake inhibitor or serotonin norepinephrine reuptake inhibitor~Attention Bias Modification Treatment (ABMT) - placebo (sham)"
88946258|NCT01906281||Inflammatory knee osteoarthritis|One group of patients with inflammatory condition in physical evaluation. We will make a blood analyse and arthrocentesis when synovial fluid were found in ultrasound examination. Ultrasound of affected knee and carotid artery will be performed.
88946259|NCT01906281||Non-inflammatory knee osteoarthritis|Patients with no inflammatory condition in physical examination. We will make a blood analyse and arthrocentesis when synovial fluid were found in ultrasound examination. Ultrasound of affected knee and carotid artery will be performed.
88946260|NCT01906294||Type 2 Diabetes Mellitus|Patients with antidiabetic treatment for Type 2 Diabetes Mellitus
88946261|NCT01906307|Experimental|LJPC-501|LJPC-501, continuous infusion
88946262|NCT01906320|Experimental|Training group|
88946263|NCT01906320|No Intervention|Control Group|
88946264|NCT01906333|Experimental|Exercise & Glucose|2 hour exercise while getting glucose-supplementation
88946265|NCT01906333|Experimental|Exercise & Fasted|2 hour exercise while staying fasted
88946266|NCT01906359|Experimental|Dietary fat - PO|Native palm olein (IV56)
88946267|NCT01906359|Experimental|Dietary fat - IPO|Chemically interesterified palm olein (IV56)
88946268|NCT01906359|Experimental|Dietary fat - HOS|High oleic sunflower oil
88946269|NCT01906398|Other|Experimental: ketogenic diet|Treatment will consist of KD will consist of 3:1 [fat]: [protein + carbohydrate] weight ratio, with 1600 kcal restriction for patients with body mass index (BMI) of ≥ 21. The diet will be initiated with a 24 hour fast to induce ketosis. The diet will be supplemented with vitamins, calcium and phosphorus supplements to meet the requirements of US Dietary Reference Intakes (DRI) standard. If seizure frequency does not improve after 3 months of KD treatment, [fat]: [protein + carbohydrate] weight ratio will be increased to 4:1
88946270|NCT01906411||subjecst with different BMI|
88946271|NCT01906424|Other|Control Grp#1: Training w/ and w/o Stim|Control- Group #1: 4 weeks training without any transcutaneous electrical stimulation followed by 2 weeks of training plus transcutaneous electrical spinal cord stimulation applied to one or two locations of the cervical (neck) region of the spinal cord.
88946272|NCT01906424|Active Comparator|Grp#2: Training+Single Site Stimulation|Group #2: Four weeks of training plus transcutaneous electrical spinal cord stimulation applied to one location along the cervical (neck) region of the spinal cord; followed by 2 weeks of training without stimulation
88946273|NCT01906424|Active Comparator|Grp #3: Training + Two Site Stimualtion|Group #3: Four weeks of training plus transcutaneous electrical spinal cord stimulation applied to two locations along the cervical (neck) region of the spinal cord; followed by 2 weeks of training without stimulation
88946274|NCT01906437||Cardiac Magnetic Resonance|Cardiac Magnetic Resonance scan at visits 1 and 2
88946275|NCT01906450|Experimental|Scaling and root planing plus Azithromycin|Single session of scaling and root planning. Azithromycin tablets 500mg, 1 tablet every 24 hours for 5 days
88946276|NCT01906450|Placebo Comparator|Scaling and root planing plus placebo|Single session of scaling and root planning placebo tablets 500mg, 1 tablet every 24 hours for 3 days
88946277|NCT01906450|No Intervention|baselline screening only|Dental prophylaxis is offered
88946278|NCT01906502|Experimental|Device|Portable device that monitors the 24-hour IOP pattern by a wireless contact lens sensor (CLS) placed on the eye that sends its signals via an antenna around the orbital cavity to a recorder. Upon completion, the recording can be transmitted to a computer for read-out and visualization.
88946279|NCT01906528|Experimental|Males vs females|Constant-rate IV infusions of Mivacurium, range 1.0 - 3 micro/kg/min, duration 150 - 180 min
88946280|NCT01906541|Experimental|ex-vivo gene-therapy|transplantation of genetically modified autologous CD34+ cells
88946281|NCT01906554|Experimental|Egg Dose|
88946282|NCT01906567||severe preeclamptic women|"Severe preeclampsia is defined as the presence of 1 of the following symptoms or signs in the presence of preeclampsia:~• SBP of 160 mm Hg or higher or DBP of 110 mm Hg or higher on 2 occasions at least 6 hours apart~• Proteinuria of more than 5 g in a 24-hour collection or more than 3+ on 2 random urine samples collected at least 4 hours apart~• Pulmonary edema or cyanosis~• Oliguria (< 400 mL in 24 h)~• Persistent headaches~• Epigastric pain and/or impaired liver function~• Thrombocytopenia~• Oligohydramnios, decreased fetal growth, or placental abruption"
88946283|NCT01906567||mild preeclamptic women|Mild preeclampsia is defined as the presence of hypertension (BP ≥140/90 mm Hg) on 2 occasions, at least 6 hours apart, but without evidence of end-organ damage in the patient.
88946284|NCT01906567||Healthy Pregnant Women|healthy pregnant women at term who not developed any complication of pregnancy
88946285|NCT01906580|Experimental|Peg-IFNα-2a monotherapy|Participants will receive 180ug peg-IFNα-2a therapy for 72 weeks, and then followed to 96 weeks.
88946286|NCT01906580|Experimental|Sequential therapy|Participants will receive entecavir monotherapy for 12 weeks, and 180ug peg-IFNα-2a therapy is added for the following 12 weeks. After that, entecavir will be stopped and 180ug peg-IFNα-2a monotherapy for the following 48 weeks. All participants will followed to 96 weeks.
88946287|NCT01906580|Experimental|Combination therapy|Participants will receive 180ug peg-IFNα-2a combined with entecavir therapy for 72 weeks, and then followed to 96 weeks.
88946288|NCT01906593||Tiantan biologial's vaccine|Tiantan Biological's vaccine group is the population injected with this vaccine.
89202112|NCT00926835|Experimental|Paroxetine|Paroxetine monotherapy
89466496|NCT03422055|Experimental|99mTc-Fucoidan SPECT|
88946289|NCT01906593||other group|Other vaccine group is the population injected with other manufacturers' vaccine except Tiantan Biological CO, Ltd.
88946290|NCT01906606|Experimental|Parenting Program|12 session community-based parenting program
88946291|NCT01906606|No Intervention|Control Group|received visual aids on nutrition
88946292|NCT01906619||Febrile illness WITH febrile seizure|The cohort comprises children aged between 3 months and 5 years who had a febrile seizure during the actual febrile disease.
89466497|NCT04449315|Experimental|Peppermint and Lavender Essential Oil|Young Living Essential oil of Peppermint and Lavender will be used to patients who meet the inclusion criteria.
89466498|NCT04449237|Other|volunteer|40 volunteer will not accept any treatment
88946293|NCT01906619||Febrile illness WITHOUT febrile seizure|The cohort comprises children aged between 3 months and 5 years with a febrile illness who had never a febrile seizure.
89202113|NCT00926835|Active Comparator|Escitalopram|Escitalopram monotherapy
88946294|NCT01906632|Other|gene expression profile|
89466499|NCT04449237|Placebo Comparator|patients with unmodified music group|40 participants in this group will listen to music without any modification
89466500|NCT04449237|Experimental|patients with modified tinnitus relieving music|40 participants in this group will listen to the music modified according to the matched dominant tinnitus pitch
89466501|NCT04449471|Experimental|Naproxen Tablet|Subjects will received a single 220-mg dose of naproxen sodium (Aleve) by mouth.
89466502|NCT03426189||HIV infected individuals on long term ART|"Leukapheresis~Lymph node biopsy"
89466503|NCT03127371|Experimental|Nitrous Oxide|Patients undergoing incision and drainage of abscess will undergo an initial medical assessment including the history, physical examination, and vital signs. The patients will then receive Nitrous Oxide gas via a gas mixer device while undergoing standard incision and drainage of cutaneous abscess using lidocaine local anesthesia administered subcutaneously. The device will mix and deliver nitrous oxide and oxygen in a 1:1 ratio, at a fixed concentration of 50%/50%. The on demand valve requires patient inspiration to trigger dosing.
89466504|NCT03127371|Experimental|Oxygen|Patients undergoing incision and drainage of abscess will undergo an initial medical assessment including the history, physical examination, and vital signs. The patients will then receive 100% oxygen gas via the Nitrous Oxide gas mixer device while undergoing standard incision and drainage of cutaneous abscess using lidocaine local anesthesia administered subcutaneously. The device will deliver only oxygen at a fixed concentration of 100%. The on demand valve requires patient inspiration to trigger dosing.
89466505|NCT03421899||Genetic Parkinson's group|Those participants with Parkinson's disease and a genetic mutation known to cause or increase risk of Parkinson's disease (e.g. Parkin, PINK1, GBA or LRRK2)
89466506|NCT03421899||Idiopathic Parkinson's group|Those participants with Parkinson's disease but without a known genetic mutation known to cause or increase risk of Parkinson's disease
89466507|NCT03421899||Healthy control group|Those participants unaffected by Parkinson's disease
89466508|NCT02796027|Experimental|Experimental: BRIDGE|NSPs assigned to this arm would receive an integrated HIV service model
89466509|NCT02796027|No Intervention|Pre-implementation|NSPs assigned to this arm would receive standard care (treatment as usual) and would not be exposed to the integrated HIV service model.
88946295|NCT01906645|No Intervention|Usual Care|Usual care consists of 1) a routine nurse intake 2) medication reconciliation performed by treating physicians. Given resource constraints (routine medication reconciliation did not include corroborating medication histories with outpatient pharmacies, routine use of pill cards or pill boxes, or review of Medicaid formularies) Uninsured patients were financially responsible for most medications at discharge. 3) Discharge patient education was performed by inpatient nurses and treating physicians at the time of discharge. 4) Patients without a usual source of primary care were often given a list of the fourteen area safety-net clinics, which have limited capacity for uncompensated care.
88946296|NCT01906645|Experimental|C-TraIn|Care Transitions Innovation (C-TraIn) was delivered in addition to usual care, and includes (1) transitional nurse coaching and education, including post-discharge phone calls and home visits for highest risk patients; (2) pharmacy care that includes patient education, medication reconciliation, guidance to inpatient providers to encourage low-cost medications, and provision of 30 days of medications after discharge for those without prescription drug coverage; (3) post-hospital primary care linkages; (4) and explicit efforts at system integration through monthly quality improvement meetings.
89466510|NCT04448925|Experimental|Recovery duration 15 seconds|Resting for 15 sec
89466511|NCT04448925|Experimental|Recovery duration 30 seconds|Resting for 30 sec
88946297|NCT01906671|Experimental|Puri-Nethol|Tablet formulation of 6-mercaptopurine
89466512|NCT04448925|Experimental|Recovery duration 45 seconds|Resting for 45 sec
88946298|NCT01906671|Experimental|Xaluprine|Oral liquid formulation of 6-mercaptopurine
89202114|NCT00926835|Active Comparator|Venlafaxine|Venlafaxine monotherapy
89202115|NCT00926835|Active Comparator|Paroxetine+Bupropion|
89466513|NCT04448691|Other|CCTA|Suspected coronary disease patients enrolled in EVINCI trial with CCTA where recalled for follow up CCTA and blood sampling
89202116|NCT00926835|Active Comparator|Paroxetine+Lamotrigine|
89202117|NCT00926835|Active Comparator|Paroxetine+Lithium|
89202118|NCT00926835|Active Comparator|escitalopram+mirtazapine|
89202119|NCT00926835|Active Comparator|Escitalopram+Aripiprazole|
89466514|NCT03421821|Experimental|Subfascial Injection Group|30 ml of 0.33% ropivacaine was injected to subfascial.
89466515|NCT03421821|Active Comparator|Extrafascial Injection Group|30 ml of 0.33% ropivacaine was injected to extrafascial.
89466516|NCT02520999|Active Comparator|5days|5 days after blood sampling, various external pressure test will be done. Blood wil be stored in refrigerator(Celsius 4 degree) until study day. External pressure 0, 100, 150, 200, 250, 300mmHg will be applied to each blood sample.
89466517|NCT02520999|Active Comparator|35days|35 days after blood sampling, various external pressure test will be done. Blood wil be stored in refrigerator(Celsius 4 degree) until study day. External pressure 0, 100, 150, 200, 250, 300mmHg will be applied to each blood sample.
88946299|NCT01906684|Experimental|Acthar Gel|Acthar Gel is supplied as 5 mL multi-dose vial (63004-8710-1) containing 80 USP Units per mL. H.P. Acthar Gel (repository corticotropin injection). Acthar Gel will be administered as a subcutaneous daily dose of 80 units for up to 2 weeks.
88946300|NCT01906697|Active Comparator|group B|middle turbinate resection
88946301|NCT01906697|Active Comparator|group C|middle turbinate medialization
89466518|NCT03421743|Experimental|Inhaled molgramostim/antimycobacterials|Inhaled molgramostim administered in subjects who remain sputum culture positive while currently on a multidrug Nontuberculous Mycobacterial (NTM) guideline based antimycobacterial regimen, which has been ongoing for at least 6 months prior to the Baseline Visit
89202120|NCT00926835|Active Comparator|Paroxetine + Venlafaxine|
89466519|NCT03421743|Experimental|Inhaled molgramostim|Inhaled molgramostim administered in subjects who remain sputum culture positive but have stopped a multidrug Nontuberculous Mycobacterial (NTM) guideline based antimycobacterial regimen at least 28 days prior to Screening due to lack of response or intolerance, or who never started such treatment
89466520|NCT03421665||Titan 3-D Wedge System|Subjects who receive one or more Titan 3D wedge(s).
89466521|NCT03416907|Active Comparator|Original|Participants will review the full-length, original consent form for the clinical trial.
89466522|NCT03416907|Experimental|Shortened|Participants will review a shortened consent form for the clinical trial, which includes only material indicated as important by 2/3 of participants from a previous study.
89466523|NCT03416907|Experimental|Reordered|Participants will review a reordered, shortened consent form. This form is based on the shortened consent form, but the sections are reordered based on a previous study, such that sentences previously rated as more likely to impact a participant's decision is more likely to be presented first (except for an initial introductory section).
89466524|NCT03416907|Experimental|Highlighted|Participants will review a shortened consent form with a highlights box, where the highlights box includes the 10 sentences rates as most likely to impact a participant's decision from a previous study.
89466525|NCT03416907|Experimental|Interactive|Participants will review an interactive, shortened consent form, where hyperlinks to different sections of the consent form are provided. The landing page includes the introductory section.
89466526|NCT03421587||Individuals exposed to an intentional/non-intentional trauma|
89466527|NCT03421587||Healthy controls without trauma-exposure|
89466528|NCT02747433|Active Comparator|ALPS + Robot-Assisted Therapy (RT)|Armeo and Amadeo robot-assisted intensive upper extremity therapy 1 hr sessions 3x week for 6 weeks plus ALPS training
89466529|NCT02747433|Active Comparator|ALPS + Robot + Task-Oriented Training (RT-TOT)|Armeo and Amadeo robot-assisted intensive upper extremity therapy 30 mins, 3x week for 6 weeks plus ALPS training. Task oriented training will be provided for remaining 30 min of each treatment session
89202121|NCT00930033|Active Comparator|A|Nephrectomy + sunitinib
89466530|NCT01103349|Experimental|BI 671800|Patients receive BI 671800 capsules twice daily
89466531|NCT01103349|Active Comparator|Montelukast|Patients receive Montelukast encapsulated tablets once daily
89466532|NCT01103349|Placebo Comparator|Placebo|Patients receive placebo capsules and/or encapsulated placebo tablets
89466533|NCT03416751|Experimental|Fecal Microbial transplantation|Patients will get one-dose of 90ml of FMT enema on day 1 that has been received from OpenBiome using a rational donor
89466534|NCT03416751|Placebo Comparator|Placebo|Patients will get one-dose of 90ml of saline enema on day 1
89466535|NCT03416673|Active Comparator|CTG+CAF|The surgical procedure will include a connective tissue graft harvested from the palate and used under a coronally advanced flap
88946302|NCT01906697|Active Comparator|group A|middle turbinate Radio Frequency (RF) turbinoplasty
89202122|NCT00930033|Experimental|B|Sunitinib alone
89202123|NCT00931593|Experimental|volunteers|"This is a descriptive study to compare two techniques (manometry with perfused dentsleeve probe vs high resolution manometry for the identification of tLESr). Each subject is his own control.~The date of perfused manometry is randomized to avoid bias due to examinations' order."
89202124|NCT00664560|Experimental|ARM 1 PN 400 (VIMOVO)|PN400: 500 mg naproxen/20 mg esomeprazole
89466536|NCT03416673|Experimental|peCTG+CAF|A papillary extended connective tissue graft reshaped after harvested from the palate will be used under a coronally advanced flap
89466537|NCT02022423|Active Comparator|Telephone Counseling|Weekly telephone calls to assess compliance to exercise prescription and discuss various topics related to adoption and adherence to walking programs
89466538|NCT02022423|Experimental|Internet-based walking program|Weekly automated goals are delivered via email to subject; goals are based on previous week's step count accumulation.
89466539|NCT02022423|Experimental|Telephone counseling and Internet-based walking program|Weekly telephone calls to assess compliance to exercise prescription and discuss various topics related to adoption and adherence to walking programs plus weekly automated goals are delivered via email to subject; goals are based on previous week's step count accumulation.
89466540|NCT02022423|No Intervention|Usual Care|Subjects will continue with their health care as usual
89466541|NCT03416595|Active Comparator|N1115 Probiotic Supplement|A probiotic supplement containing Lactobacillus paracasei N1115 [Junlebao Lp. N1115] Participators, who met inclusion criteria, will receive following product during 8 weeks: N1115 Probiotic Supplement in the form of powder packaged in sachet (one sachet containing 10^9 CFU Lp. N1115).
89466542|NCT03416595|Placebo Comparator|Placebo control|Dietary Supplement: Placebo Participators, who met inclusion criteria, will receive an identical N1115 Probiotic Supplement looking and tasting placebo.
89466543|NCT03421275|Experimental|Esketamine|intravenous anaesthetic and analgetic
89466544|NCT03421275|Active Comparator|Fentanyl Citrate|intravenous opioid analgetic
89466545|NCT03421275|Placebo Comparator|Saline Nasal|"intravenous Natriumklorid b. Braun 9 mg/ml"
89466546|NCT03416517|Experimental|Anlotinib and Irinotecan(phase 1b)|Anlotinib 12 or 8 mg/d PO on days 1-14 q3w. Irinotecan 20 or 15mg/m^2/d over 60 minutes on days 1-5 and 8-12 q3w. Vincristine 1.4mg/m^2/d IV on days 1,8 q3w. Treatment repeats every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity.
89466547|NCT03416517|Experimental|Anlotinib and Irinotecan(phase 2)|Anlotinib 12 or 8 mg/d PO on days 1-14 q3w. Irinotecan 20 or 15 mg/m^2/d IV over 60 minutes on days 1-5 and 8-12 q3w. The final dose of anlotinib and irinotecan depends on the result from previous phase Ib study. Vincristine 1.4mg/m^2/d IV on days 1,8 q3w. Treatment repeats every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity.
89466548|NCT03416439|Experimental|intervention arm|lifestyle intervention program carried out by trained professionals
89466549|NCT03416439|No Intervention|control arm|standard, unstructured information given by the family physicians
89466550|NCT03426111|Placebo Comparator|Placebo|Diagnostic upper endoscopy plus lifestyle modification.
89466551|NCT03426111|Active Comparator|Treatment|Endoscopic gastric tubulization with OverStitch® system (Apollo Endosurgery, Austin, TX, USA) plus lifestyle modification.
89466552|NCT03421119|Experimental|CinnaGen-liraglutide|CinnaGen-liraglutide (Liraglutide 6 MG/ML Pen Injector by CinnaGen Company) will be administered 1.8 mg/day subcutaneously. Doses of CinnaGen-liraglutide will be up-titrated from 0.6 mg/day in the first week to 1.2 mg/day in the second, third and fourth weeks, up to 1.8 mg/day from the start of the fifth week to the end of 26th week. Patients in this group will continue to receive metformin along with a Sulfonylurea/non-sulfonylurea insulin secretagogues with maximum tolerable dose.
89466553|NCT03421119|Active Comparator|Victoza®|Victoza® (Liraglutide 6 MG/ML Pen Injector by Novo Nordisk Company) will be administered 1.8 mg/day subcutaneously. Doses of Victoza® will be up-titrated from 0.6 mg/day in the first week to 1.2 mg/day in the second, third and fourth weeks, up to 1.8 mg/day from the start of the fifth week to the end of 26th week. Patients in this group will continue to receive metformin along with a Sulfonylurea/non-sulfonylurea insulin secretagogues with maximum tolerable dose.
89466554|NCT03426033|Experimental|Single dose of warfarin|Single dose of warfarin administered to obtain pharmacokinetic information.
89466555|NCT03426033|Experimental|Warfarin in combination with ISIS 681257|ISIS 681257 administered and pharmacokinetic assessments are taken. Then ISIS 681257 is administered with warfarin and additional pharmacokinetic information is obtained.
89466556|NCT03416205|Experimental|EST|EST is an operation using the Erbao electric knife and Three-cavity incision knife to make a large incision to the duodenal nipples，and the incision scope is the nipple mouth uplift length of 4/5. It has been used since 1974. The technique is intuitive and intact. However, EST cut too small to achieve the purpose of treatment and will affect the next step, and if the incision is too large it may be easier to occur gastrointestinal perforation and bleeding.The EST will also damage the anatomy of the Oddi sphincter structure,which causes bacterial reflux to the bile duct, the recurrence of CBD.Some surgeons prefer it because it's postoperative pancreatitis rate is lower and it may be easier to find the lesion position if bleeding or perforation occurs.
89466557|NCT03416205|Experimental|EPBD|EPBD is an operation using the Columnar expansion balloon to expand duodenal to achieve the purpose of using the basket and other instruments to take stone out. Balloon expansion may retain part of the sphincter not destroyed, and basically retain the normal physiological function of the nipple sphincter.Thus it may reduce the risk of recurrence of stones and bacterial reflux. However,the postoperative pancreatitis rate is high(4.8% -19.5% ), and nipple sphincter tear is uncontrollable in EPBD.If the digestive tract perforation or bleeding occur after EPBD,it is hard to accurately find the lesion position.Some surgeons prefer it for it's lower bleeding and perforation rate.
89466558|NCT03416205|Experimental|sEST+EPBD|sEST+EPBD is an operation combining EST and EPBD. Investigators use the Erbao electric knife and Three-cavity incision knife to make a small incision to the duodenal nipples, and the incision length is less than 5mm while the incision scope is less than the nipple mouth uplift length of 1/2. Then, Investigators match the appropriate Columnar expansion balloon according to the diameter of the common bile duct and gradually expand the duodenal nipples.This method allows the nipple sphincter to be cut in a small range, then the balloon can guide the direction of the nipple sphincter tearing after the expansion , so that the digestive tract bleeding, perforation may be smaller and more controllable. Besides,it may reduce postoperative pancreatitis rate and the recurrence rate of stones.
89466559|NCT03420885|Experimental|Ba Duan Jin Group|Ba Duan Jin plus health education. Participants take part in 16-week program. The health education is conducted as the Health Education Group. Besides, the participants attended two 90-minute sessions of group-based Ba Duan Jin training per week and practiced at least three 30-minute Ba Duan Jin sessions at home per day.
89466560|NCT03420885|Active Comparator|Health Education Group|Health education. Participants take part in 16-week program. The health education includes work, rest, diet and other basic programs according to the different conditions of participants.
89466561|NCT04567173|Experimental|Anti-SARS-CoV-2 convalescent plasma|About 500 mL of type-specific anti-SARS-CoV-2 convalescent plasma collected by whole blood donation or standard pheresis from a volunteer who recovered from COVID-19 transfused intravenously as 2 aliquots of 250 mL
89466562|NCT04567173|No Intervention|Standard of care|Patients in the control group are those will only receive local standard of care as deemed appropriate by the primary attending physicians and guided by institutional pathways
89466563|NCT04522089|Experimental|AdimrSC-2f Group 1|low dose mcg
89466564|NCT04522089|Experimental|AdimrSC-2f Group 2|low dose mcg+AL
89466565|NCT04522089|Experimental|AdimrSC-2f Group 3|medium dose mcg
89466566|NCT04522089|Experimental|AdimrSC-2f Group 4|high dose mcg
89466567|NCT03425955|Experimental|GROUP 1|Normotypic or overweight subjects with rounded, oval or squared face (aged 35-50 years)
89466568|NCT03425955|Experimental|GROUP 2|"Thin subjects with oval or triangular face and sagging skin (aged 45-60 years)"
89466569|NCT03420729|Experimental|magnetic assisted capsule endoscopy|All participants will undergo magnetic assisted capsule endoscopy at the sloan medical centre
89466570|NCT03420729|Active Comparator|gastroscopy|All participants will undergo gastroscopy as standard of care at sheffield teaching hospitals
89466571|NCT03415971|Active Comparator|ASTRA TECH implants|implant restoration(replace of a missing tooth) - 35 patients
89466572|NCT03415971|Active Comparator|CROWN|to fixed denture restorations in own teeth - 32 patients
89466573|NCT03415971|Placebo Comparator|non-edontulos|control group will consist 38 non-edotulos patients
89466574|NCT02959177|Experimental|120 milligrams (mg) Galcanezumab|120 mg galcanezumab (LY2951742) administered subcutaneously (SC) once a month for 6 months.
89466575|NCT02959177|Experimental|240 mg Galcanezumab|120 mg galcanezumab (LY2951742) administered SC once a month for 6 months.
89466576|NCT02959177|Placebo Comparator|Placebo|Placebo administered SC once a month for 6 months.
89202125|NCT00664560|Active Comparator|Arm 2 (celebrex)|Celecoxib 200 mg
89466577|NCT03420495|Experimental|OCD Group|Meet Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria for principal OCD. These participants will complete clinician interviews, self-report questionnaires, and receive the Decision-Making Tasks Intervention.
89466578|NCT03420495|Experimental|Non-psychiatric Control Group|No current DSM-5 diagnosis. These participants will also complete clinician interviews, self-report questionnaires, and receive the Decision-Making Tasks Intervention.
89466579|NCT03415815||T1-T3 esophageal cancer|Pathologically diagnosed patients with T1-T3 esophageal cancer who received surgeries
89018398|NCT03927144|Active Comparator|Oral Prophylactic|"Participants were randomized to receive a standard of care (SOC) locally approved oral prophylactic migraine medication once per day for 52 weeks in the Core Phase, as prescribed per local country labels.~Participants were permitted to switch to a different approved oral prophylactic based on treatment failure status and at the investigator's and participant's discretion.~Participants who completed visits through Week 52 of the Core Phase were eligible to participate in the 52-week Extension Phase of the study."
89018399|NCT03919708||Enriched Population|Children between the ages of 2-8 who present to an eye clinic. Eligible and recruited children will be scanned with a PVS device and an RBI device, and then be provided with a full, gold standard eye exam by a pediatric ophthalmologist. All scans and exam should be performed within a single visit. Scans should take no longer than 20 seconds each, and ophthalmic exam should take approximately 30 minutes.
89466580|NCT02432547|Active Comparator|Aflibercept Monotherapy|Intravitreal aflibercept injections according to a treat and extend regimen.
89466581|NCT02432547|Experimental|Targeted laser therapy with Aflibercept|Targeted laser photocoagulation therapy to areas of peripheral retinal ischaemia and intravitreal aflibercept injections using a treat and extend regimen.
89466582|NCT03640195|Experimental|Experimental group|Transcutaneous nerve electrical stimulation and Auricular acupressure.
89466583|NCT03640195|No Intervention|Control group|without intervention
89466584|NCT03420417|Experimental|Assessement of respiratory mechanics|Measurement of respiratory mechanics characteristics
89466585|NCT03618433|Experimental|Study group|"Standart exercise protocol and KİNECT® video based physiotherapy~The treatment protocol of the study group will consist of soft tissue massage, passive mobilization, stretching, self-stretching exercises.In total, a 25-minute Kincet® video game program will be applied in addition to the 15-minute basic and standart exercise program."
89466586|NCT03618433|Active Comparator|Control group|"Standart exercise protocol and Upper extremity rehabilitation~The control group included soft tissue massage, stretching, self-stretching, passive mobilization, coordination, posture exercises, progressive active and assisted shoulder exercises, proprioception and strengthening exercises in the exercise therapy protocol"
89466587|NCT03415659|Experimental|HWH340 monotherapy|HWH340 tablet, oral administration
89466588|NCT02031757|Experimental|perturbation training|Standard physiotherapy augmented with perturbation training (BaMPer system).
89466589|NCT02031757|Active Comparator|balance exercise|standard physiotherapy augmented with balance exercises.
89466590|NCT02345733|Experimental|Ulcerative Colitis Diet|Patients will receive a structured novel diet termed the UCD for 6 weeks, and those in remission at week 6 will receive the step down diet for another 6 weeks.
89466591|NCT02345733|Experimental|Antibiotic Treatment|This antibiotic treatment will be given as an open label for patients who refuse diet therapy or for patients who show no improvement by week 3 , deteriorate by week 6, or patients who are not in full remission by week 6 will receive a 14 day course of antibiotics as previously described by Kato and colleagues.
89466592|NCT03618901|Experimental|Rock Steady Boxing|Non-contact boxing program.
89466593|NCT03618901|Active Comparator|PD SAFEx|Sensory attention focused exercise.
89466594|NCT03420261|Active Comparator|Crystalloid group|individualized goal-directed fluid optimization (cardiac preload) by 250 ml boluses of 0.9% saline (up to a maximum of 30 ml/kg)
89018400|NCT03919708||Unenriched Population|Children between the ages of 2-8 who present to a general pediatric clinic, with no history of eye disorders or amblyopia. Eligible and recruited children will be scanned with a PVS device and an RBI device, and then be provided with a full, gold standard eye exam by a pediatric ophthalmologist. All scans will be performed at a single visit, but the exam may require a follow up visit, depending on the availability of a pediatric ophthalmologist at the clinic at the time of study enrollment. Scans should take no longer than 20 seconds each, and ophthalmic exam should take approximately 30 minutes.
89202126|NCT00664560|Placebo Comparator|Arm 3 (placebo)|sugar pill
89466595|NCT03420261|Experimental|Colloid group|individualized goal-directed fluid optimization (cardiac preload) by 250 ml boluses of HES 130/0.4 (up to a maximum of 30 ml/kg, VOLUVEN ®, Fresenius Kabi)
89466596|NCT02331147|Sham Comparator|Standard of Care|Surgical debridement of DFU, The wound will be debrided and cleaned. Patient ulcers will be assessed and measured weekly in cm length by width. Application of collagen alginate and gauze dressing application to be changed daily by patient. Patient will practice off loading
89466597|NCT02331147|Active Comparator|Human Dermis|"Application of Human Allogenic Dermis with Dressing Application, to be changed weekly. Patient would will be measured in cm length by width weekly Patient will practice Offloading.~If the ulcer has not closed completely, an additional piece of Human Dermis will be applied weekly at weeks 2-11 in a similar fashion"
89466598|NCT03415503|Placebo Comparator|placebo|The placebo capsules only contained pullulan and maltodextrin.During the trial period, the participants were instructed to consume 2 Medox® placebo capsules twice daily (30 min after breakfast or supper).
89466599|NCT03415503|Experimental|40mg/d anthocyanins|Medox® Anthocyanin capsules is consisted of 17 different natural purified anthocyanins.from bilberry (Vaccinium myrtillus) and black currant (Ribesnigrum). To achieve the double-blind,every group are instructed to consume the same amount of capsule. During the trial period, the participants will be instructed to consume one Medox® anthocyanin capsules and one Medox® placebo capsules 30 min after breakfast and consume two Medox® placebo capsules 30 min after supper.The anthocyanin capsules (40 mg anthocyanins per capsule) will provid a total daily intake of 40 mg anthocyanins.
89466600|NCT03415503|Experimental|80mg/d anthocyanins|Medox® Anthocyanin capsules is consisted of 17 different natural purified anthocyanins.from bilberry (Vaccinium myrtillus) and black currant (Ribesnigrum).To achieve the double-blind,every group are instructed to consume the same amount of capsule. During the trial period, the participants will be instructed to consume one Medox® anthocyanin capsules and one Medox® placebo capsules 30 min after breakfast and consume two Medox® placebo capsules 30 min after supper.The anthocyanin capsules (80 mg anthocyanins per capsule) will provid a total daily intake of 80 mg anthocyanins.
89466601|NCT03415503|Experimental|320mg/d anthocyanins|Medox® Anthocyanin capsules is consisted of 17 different natural purified anthocyanins.from bilberry (Vaccinium myrtillus) and black currant (Ribesnigrum).To achieve the double-blind,every group are instructed to consume the same amount of capsule. During the trial period, the participants will be instructed to consume two Medox® anthocyanin capsules 30 min after breakfast and after supper.The anthocyanin capsules (80 mg anthocyanins per capsule,4 per day) will provid a total daily intake of 320 mg anthocyanins.
89466602|NCT03127683|Experimental|AuraGain group|"An AuraGain will be placed in all patients, and mechanical ventilation will be performed using a volume-controlled mode with a tidal volume of 10 ml/kg.~The expiratory tidal volume, peak inspiratory pressure, oropharyngeal leak pressure, and ventilation score will be assessed first for the neutral head position and then for the extended, flexed, and rotated head positions in a random order."
89466603|NCT03415347|Active Comparator|Abscess de-roofing and curettage|Abscess de-roofing and curettage. The patient will be placed in the lateral position with the buttocks spread apart using tape. The cleft of the buttocks will be shaved prior to cleaning and preparation of the skin. A spindle-shaped (elliptical) excision will be performed to the lateral aspect of the abscess formation with a scalpel staying away from the midline. Once the pus has been drained through this lateral incision the wound cavity will then be curetted and washed out with hydrogen peroxide. The wound size will be measured by the operating surgeon who will record the maximal length and width of the wound. Once haemostasis (cessation of any bleeding) is achieved the wound will be packed with Kaltostat ribbon and the wound dressed with blue gauze and mefix tape. The wound is therefore left open.
89466604|NCT03415347|Active Comparator|Abscess wide local excision|Wide local excision. Patients will be placed in the prone position with the buttocks spread apart using tape. The cleft of the buttocks will be shaved prior to cleaning and preparation of the skin. Diluted methylene blue will be injected in all visible pits and a wide spindle-shaped (elliptical) midline excision of the skin and the underlying subcutaneous tissue down to the coccygeal (pre-sacral) fascia including all sinuses will be performed with electrocautery. The specimen will be sent for histology as per routine surgical practice. The wound will be washed with hydrogen peroxide. The wound size will be measured by the operating surgeon who will record the maximal length and width of the wound. Once haemostasis (cessation of any bleeding) is achieved the wound will be packed with Kaltostat ribbon and the wound dressed with blue gauze and mefix tape. The wound is therefore left open.
89466605|NCT03415269|Experimental|20 mg ambroxol|20 mg ambroxol lozenge delivered once on one day
89466606|NCT03618589|Placebo Comparator|opioid only|Patients in the opioid group received the only opioid (5mg of oxycodone three times a day) for 8 weeks.
89466607|NCT03618589|Experimental|pregabalin add-on|Patients in the pregabalin add-on group received 75mg of pregabalin twice a day for the first week (150 mg/day) and 150mg of pregabalin twice a day (300 mg/day) for the second week and 300mg of pregabalin twice a day (600mg/day) for subsequent 6 weeks.
89466608|NCT05384899||COVID-19 Patients|The focus will be on patients with AKI in the setting of COVID-19 disease.
89466609|NCT03425877|Experimental|Parkinson's disease Group|"The study envisages the recruitment of 45 subjects (see Sample Size on page 11), to be divided into 15 subjects per group. The groups will be formed by subjects diagnosed with Parkinson's and Stroke disease, for 50% men and 50% for women. The control subjects, on the other hand, will be neurologically healthy volunteers of equal age and scholarship and gender.~All the groups will attend the same procedure and interventions: MS Band 2 , Rest, Emotion Assessment, Single Task, Dual Task ."
89466610|NCT03425877|Experimental|Stroke Group|"The study envisages the recruitment of 45 subjects (see Sample Size on page 11), to be divided into 15 subjects per group. The groups will be formed by subjects diagnosed with Parkinson's and Stroke disease, for 50% men and 50% for women. The control subjects, on the other hand, will be neurologically healthy volunteers of equal age and scholarship and gender.~All the groups will attend the same procedure and interventions: MS Band 2 , Rest, Emotion Assessment, Single Task, Dual Task ."
89466611|NCT03425877|Experimental|Healthy Subjects Group|"The study envisages the recruitment of 45 subjects (see Sample Size on page 11), to be divided into 15 subjects per group. The groups will be formed by subjects diagnosed with Parkinson's and Stroke disease, for 50% men and 50% for women. The control subjects, on the other hand, will be neurologically healthy volunteers of equal age and scholarship and gender.~All the groups will attend the same procedure and interventions: MS Band 2 , Rest, Emotion Assessment, Single Task, Dual Task ."
89466612|NCT03127449|Experimental|Alflutinib|patients take Alflutinib orally once per day at different dose
89466613|NCT03420105|Other|Group A|Patients perform neuropsychological, psycho-pathological and quality of life assessments, and sleep tests
89466614|NCT03420105|Other|Group B|Patients perform neuropsychological, psycho-pathological and quality of life assessments, and sleep tests
89466615|NCT03420105|Other|Healthy volunteers|Healthy volunteers perform neuropsychological, psycho-pathological and quality of life assessments, and sleep tests
89466616|NCT03425721||All Participants|
89466617|NCT02521155|Experimental|Intervention group|Safeguard Your Smile an oral health literacy intervention.
89466618|NCT02521155|No Intervention|Control group|No intervention, only a conventional pamphlet will be given.
89466619|NCT03415191|Experimental|Ketamine Group|Five minutes before thoracotomy incision, Ketamine Group received a bolus dose of ketamine 1 mg/kg intravenously
89466620|NCT03415191|Placebo Comparator|Placebo Group|Five minutes before thoracotomy incision, Placebo Group received a bolus dose of normal saline 1 mg/kg intravenously
89202127|NCT00566709|Experimental|RBCT based on rSO2 value|Intervention: In the rSO2 - strategy group, patients will be transfused to attain a post-transfusion rSO2 values higher than 60%.
89466621|NCT03414957||Malay PCOS women|Malay women underwent clinical assessment, followed by pelvic ultrasound scan, biochemical and hormonal blood tests. Using the Rotterdam criteria for the diagnosis of PCOS, Malay women who fulfilled these criteria were inducted into this group. These women were then identified whether they had Metabolic Syndrome or not based on the WHO criteria
89466622|NCT03414957||Malay women without PCOS|Malay women underwent clinical assessment, followed by pelvic ultrasound scan, biochemical and hormonal blood tests. Using the Rotterdam criteria for the diagnosis of PCOS, Malay women who did not fulfill these criteria were inducted into this group. These women were then identified whether they had Metabolic Syndrome or not based on the WHO criteria.
89466623|NCT03414879|Active Comparator|Ketamine group|Nebulization with ketamine
89466624|NCT03414879|Active Comparator|Lidocaine group|Nebulization with with lidocaine
89466625|NCT03419793|Experimental|physical therapy intervention and segmental muscle vibration|physiotherapy intervention and segmental muscle vibration device
89466626|NCT03419793|Sham Comparator|physical therapy intervention|physical therapy intervention alone
89466627|NCT03414801|Active Comparator|Cohort 1|Cat Allergic Subjects
89466628|NCT03414801|Active Comparator|Cohort 2|Non-Allergic Subjects will
89466629|NCT03425487|Experimental|MBSR+TAU|Mindfulness based Intervention (MBSR) + Usual specialized treatment in mental health. MBSR consists of 8 weekly groupal sessions of 150 minutes/session (10-16 people). Written material and sound recordings will be offered as support elements. The estimated duration of the program is two months.
89466630|NCT03425487|Experimental|ABCT+TAU|Compassion based Intervention (ABCT) + Usual specialized treatment in mental health. ABCT consists of 8 weekly groupal sessions of 120 minutes/session (10-16 people). Written material and sound recordings will be offered as support elements. The estimated duration of the program is two months.
88946303|NCT01906710|Placebo Comparator|usual care|During admission patients receive standard, non - ward based, pharmaceutical care from a pharmacy team in taking responsibility for the appropriate, safe and cost-effective use of medication from a central hospital pharmacy. The pharmaceutical care consist of daily screening of generated alerts by the Computerized physician order entry (CPOE) system and consultation by phone. Dependent on the local situation the current medication reconciliation process is being performed by nursing and/or medical staff either protocolised or not.
88946304|NCT01906710|Active Comparator|integrated medicines management|"integrated medicines management consists of~patient centred medication reconciliation~intermediate medication review~discharge counseling~transfer of information to primary care"
88946305|NCT01906749|Placebo Comparator|Placebo|Placebo
88946306|NCT01906749|Active Comparator|Colchicine|Colchicine 0.5mg once daily for 24 months
89466631|NCT03425487|Active Comparator|TAU|Usual specialized treatment in mental health (psychological or/and psychiatric)
89466632|NCT03419715|Experimental|Bimatoprost Topical Solution|0.03% bimatoprost topical solution applied daily to the nail bed of fingers on one hand for 12 weeks
89466633|NCT03419715|Placebo Comparator|Control|Saline placebo topically applied daily to the nail be of fingers on one hand for 12 weeks
89466634|NCT03618355|Experimental|Cohort 1: 0.5 mg weekly|"Oral administration with consecutive enrollment of overlapping dose-escalation cohorts, total treatment period 3 months. Patients will conclude treatment with previously scheduled standard of care prostate biopsy.~eRapa (encapsulated rapamycin) is dosed at 0.5 mg every week."
89466635|NCT03618355|Experimental|Cohort 2: 1 mg weekly|"Oral administration with consecutive enrollment of overlapping dose-escalation cohorts, total treatment period 3 months. Patients will conclude treatment with previously scheduled standard of care prostate biopsy.~eRapa (encapsulated rapamycin) is dosed at 1 mg every week."
89466636|NCT03618355|Experimental|Cohort 3: 0.5 mg daily|"Oral administration with consecutive enrollment of overlapping dose-escalation cohorts, total treatment period 3 months. Patients will conclude treatment with previously scheduled standard of care prostate biopsy.~eRapa (encapsulated rapamycin) is dosed at 0.5 mg daily."
89466637|NCT03618355|Experimental|Cohort 4: 1 mg daily|"Oral administration with consecutive enrollment of overlapping dose-escalation cohorts, total treatment period 3 months. Patients will conclude treatment with previously scheduled standard of care prostate biopsy.~eRapa (encapsulated rapamycin) is dosed at 1 mg daily."
89466638|NCT04706403|Experimental|Message 1|"Participants were randomized to receive version #1 of 5 different versions of a message from a physician regarding the COVID-19 vaccination. All messages included a statement that the vaccine is very safe and very effective. In Message 1, this statement was followed by a participatory-style recommendation (What do you think?)"
89466639|NCT04706403|Experimental|Message 2|"Participants were randomized to receive version #2 of 5 different versions of a message from a physician regarding vaccination. All messages included a statement that the vaccine is very safe and very effective. In Message 2, this statement was followed by a comparison of the COVID-19 vaccine to the flu shot and an explicit recommendation (I recommend that you get it)."
88946307|NCT01906762|Experimental|Acetaminophen|Specified dosage for Acetaminophen was 15 mg/kg. so based on the patient's weight(averagely 70 kg), about 1gr Acetaminophen (one complete Apotel Ampule) was used.
88946308|NCT01906762|Experimental|Morphine|Specified dosage for Morphine was 0.1 mg/kg. so based on the patient's weight(averagely 70 kg), about 7 mg Morphine was used.
88946309|NCT01906775||Patients with PIT|Identification of patients with pacemaker-induced ventricular tachycardias
88946310|NCT01906788|Active Comparator|Group 1|Active comparator: Artemether Lumefantrine 6 dose regime orally
88946311|NCT01906788|Experimental|Group 2|Experimental: Artemether Lumefantrine 6 dose regime Plus single dose Primaquine (0.75/kg) on day 0
88946312|NCT01906788|Experimental|Group 3|Experimental: Artemether Lumefantrine 6 dose regimen plus single dose of Primaquine (0.75/kg) on day 2
88946313|NCT01906801|Experimental|Glucosamine sulfate & Diacerein|Glucosamine sulfate (sachet) 1500 mg and Diacerein 50 mg tablet by mouth once daily for 24 weeks
89466640|NCT04706403|Experimental|Message 3|"Participants were randomized to receive version #3 of 5 different versions of a message from a physician regarding vaccination. All messages included a statement that the vaccine is very safe and very effective. In Message 3, this statement was followed by a statement that millions of people have already received the COVID-19 vaccine and an explicit recommendation (I recommend that you get it)."
89466641|NCT04706403|Experimental|Message 4|"Participants were randomized to receive version #4 of 5 different versions of a message from a physician regarding vaccination. All messages included a statement that the vaccine is very safe and very effective. In Message 4, this statement was followed by an acknowledgment of concerns and reassurance that the physician personally reviewed the safety data and an explicit recommendation (I recommend that you get it)."
89466642|NCT04706403|Experimental|Message 5|"Participants were randomized to receive version #5 of 5 different versions of a message from a physician regarding vaccination. All messages included a statement that the vaccine is very safe and very effective. In Message 5, this statement was followed by an emphasis on protecting others an explicit recommendation (I recommend that you get it)."
89466643|NCT03454165|Experimental|Single Arm|Evaluate the MTD of BNC105P in combination with ibrutinib in patients with relapsed/refractory CLL. Treatment will be administered on an outpatient basis but will also be permitted inpatient. BNC105P will be administered as a single agent prior to initiation of ibrutinib. Beginning with cycle 2, ibrutinib will be administered concomitantly with BNC105P at a starting dose of 420 mg PO daily. Each cycle will last for 21 days. Provided no toxicities occur, each patient will be treated for 6 cycles.
89466644|NCT03425409|Other|Continuous Flow|Oxygen delivery at 4 liters per minute is the standard method
89466645|NCT03425409|Other|Pneumatic Pulsed Flow|Oxygen delivery using test method
89466646|NCT03618277|Other|Intra individual|Before and after being treated by a product (outside the study)
89466647|NCT03414645|Experimental|CAM-101 10%|FD hPL 10 vol/vol %
89466648|NCT03414645|Experimental|CAM-101 30%|FD hPL 30 vol/vol %
89466649|NCT03414645|Placebo Comparator|Vehicle Control|PlasmaLyte-A, vehicle control, a preservative-free ophthalmic drop
89466650|NCT03618511|Experimental|Financial Incentive Group|
89466651|NCT03618511|Experimental|Reminders Group|
89466652|NCT03618511|Experimental|Financial Incentive and Reminders Group|
89466653|NCT03618511|No Intervention|Control Group|
89466654|NCT03618511|Experimental|Information Group|
89466655|NCT03618511|Experimental|Stigma-relieving Group|
89466656|NCT03618511|Experimental|Information and Stigma-relieving Group|
89466657|NCT02236585|Active Comparator|Patient-controlled epidural analgesia|Patient-controlled epidural analgesia
89466658|NCT02236585|Placebo Comparator|Continuous epidural analgesia|Continuous epidural analgesia
89466659|NCT04649307|Other|MI-CBT|The treatment will be based on the AF treatment developed by the research group and further be developed and adapted during the course the study, based on the clinical presentation of the MI patients and their response to the CBT interventions detailed below. The MI-specific CBT will consist of 8 weekly face-to face digital video sessions with home assignments that can be reviewed and reported in the research groups secure platform. CBT for MI primarily targets two processes of disability; cardiac anxiety, and depressive inactivity
88946314|NCT01906801|Active Comparator|Glucosamine sulfate & Placebo|Glucosamine sulfate 1500 mg and Placebo (for Diacerein) 50 mg by mouth once daily for 24 weeks
89466660|NCT04448457|Experimental|SSTS group|Patients received sufentanil nanotab patient controlled analgesia (PCA) system (Zalviso) 15 mcg with 20 min of lockout interval during 48 hours postoperatively
89466661|NCT04448457|Active Comparator|Oxycodone group|Patients received oxycodone extended-release tablet (OxyContin) 10 mg every 12 hours systematically plus Oxycodone 5 mg every 6 hours if numeric rating scale is above 3 during the 48 hours postoperatively
89466662|NCT03425175|No Intervention|Control group|Standard care with recording of video but no audio-recording
89466663|NCT03425175|Experimental|Intervention group|Standard care with the addition of simultaneous audio-recording during the operation.
89466664|NCT02236663|Experimental|App Based Safety Decision Aid|Personalized App-Based Safety Decision Aid
89466665|NCT02236663|Active Comparator|Control App|Usual Care Safety Plan
89466666|NCT05384743|Experimental|Rituximab Monotherapy|
89466667|NCT03414333|Experimental|Roux-en- Y gastric bypass (RYGB)|Roux-en- Y gastric bypass (RYGB) is the most popular bariatric procedure and it has been associated with improvements in glycemic control and cognitive function. It works by decreasing the amount of food you can eat at one sitting and by changing the hormones released at the bottom of the stomach and duodenum.we propose that RYGB is a model of chronic elevation of GLP-1 providing an opportunity to explore relationship between changes in the circulating hormone and brain glucose metabolism, cognitive function and neuroplasticity.
89466668|NCT03414333|Active Comparator|GLP-1|GLP-1 is an intestinal hormone secreted in response to nutrients.
89466669|NCT03618043|Experimental|SH-1028|Oral Once-Daily Administration of SH-1028
89466670|NCT02031835|Other|BWSTT (3 days a week for maximum of 20 minutes session)|BWSTT (20 minutes of treadmill training (velocity (≥0.1km/h) and body weight support (≤40% of patients weight) according to patients capability and comfort
88946315|NCT01906827||pregnant with ICP|pregnant with ICP
88946316|NCT01906840|Experimental|drug: turmeric capsule|Intervention is turmeric (one capsule with each meal containing 500 mg turmeric, of which 22.1 mg was the active ingredient curcumin; three capsules daily) for 8 weeks
88946317|NCT01906840|Placebo Comparator|Drug: placebo,capsule|Intervention is daily starch capsules 500 mg for 8 weeks
88946318|NCT01906879|Active Comparator|Triple therapy (A)|lansoprazole, 30mg, twice daily, for 14 days, po clarithromycin, 500mg, twice daily, for 14 days, po amoxicillin, 1gm, twice daily, for 14 days, po
88946319|NCT01906879|Experimental|non-bismuth quadruple therapy|Group (B): non-bismuth quadruple therapy for 10 days: lansoprazole 30mg bid + amoxicillin 1gm bid + clarithromycin 500mg bid + metronidazole 500mg bid
88946320|NCT01906879|Experimental|bismuth quadruple therapy for 10 days|Group (C): bismuth quadruple therapy for 10 days D1-D10: lansoprazole 30mg bid + colloidal bismuth subcitrate 300mg tid + metronidazole 500mg tid + tetracycline 500mg tid
89466671|NCT03618121|Experimental|Biofeedback plus gaming (Nevermind)|1) Group A is a biofeedback plus gaming group. Participants in this group play a horror videogame called Nevermind, while also wearing a chest strap heart rate monitor. The object of the videogame is to assist a patient by entering his/her mind and helping him/her work through some trauma memories. The way the game works is that the more anxious players are, the faster their heart beats, and the faster the heart beats, the harder and scarier the game gets. Thus, in order for one to do well in the game, he or she has to learn how to control the heartbeat and stress through relaxation. A therapist will help people in this group to learn relaxation techniques to help calm their body and finish the game.
89466672|NCT03618121|Active Comparator|Gaming only|2) Group B is a gaming only group. Like Group A, participants in this group play a Nevermind, but this time they do not wear a heart rate monitor. A therapist will still be present to help people in this group to learn relaxation techniques to help calm themselves during game play, but in this case the game does not change based on heart rate.
89466673|NCT03618121|Active Comparator|Biofeedback only (The Pip)|3) Group C is a biofeedback only group. In Group C, participants use a device called The Pip that measures Galvanic Skin Response. The Pip interacts with a few basic apps used in this study to teach relaxation. In one app, players control flying dragons. The more relaxed players are (as measured by GSR), the higher and faster their dragon flies. In another app, players control the changing of seasons. The more relaxed players are, the faster they can make seasons change from winter to spring. In another app, players can watch a simple graph of their stress over a period of time. Participants can learn to decrease stress by learning to make the line on the graph go down. In Group C, a therapist will also be present with participants to help them learn techniques to reduce stress.
89466674|NCT03618121|Active Comparator|Relaxation training only|4) Group D is a relaxation training only group. In Group D, participants receive relaxation training from a trained therapist. Participants in this group learn and practice with their therapist different techniques to help them relax and reduce stress.
89466675|NCT03617029|Experimental|Microcoil|Needle localization for deep-seated lung nodules with microcoil placement
89466676|NCT03617029|Active Comparator|Contrast|Needle localization for deep-seated lung nodules with contrast injection
89466677|NCT03616873||Adults aged 60 or older|
89466678|NCT03616795|Experimental|LY3154207 and [14C]-LY3154207|A single dose of LY3154207 and [14C]-LY3154207administered orally.
89466679|NCT03616639|Experimental|Oxycodone|Continuous subcutaneous infusion (CSCI) of oxycodone.
89466680|NCT03616639|Active Comparator|Morphine|Continuous subcutaneous infusion (CSCI) of morphine.
89466681|NCT03616561||Apremilast|The cohort will be recruited in Hospital General de Granollers and Hospital Moises Broggi
89466682|NCT03617965||Mild thrombocytopenia|Patients with a platelet count of 100 × 10e9 to 149 × 10e9/L.
89466683|NCT03617965||Moderate thrombocytopenia|Patients with a platelet count of 50 × 10e9 to 99 × 10e9/L
89466684|NCT03617965||Severe thrombocytopenia|Patients with a platelet count<50 × 10e9/L
89466685|NCT03617965||Control group|Patients with normal platelet count (i.e.150 × 10e9 to 399 × 10e9/L)
89466686|NCT03617887|Experimental|Experimental group|Plank exercise, Lateral plank exercise, Bird dog exercise, Pelvic drop exercise, and Stabilization of the middle gluteus in the knee valgus:
89466687|NCT03617887|Experimental|Control group|Plank exercise, Lateral plank exercise and Bird dog exercise
89466688|NCT03617809||Prewarming|Active Prewarming will be performed using a forced-air blanket (WarmTouch lower body blanket, Covidien Ltd, Mansfield, USA) over the whole body and connected to a forced-air warmer (WarmTouch Model 5900, Covidien Ltd, Mansfield, USA). Patients will be warmed using a surgical blanket during the intraoperative period. Esophageal thermometer will be used to measure the temperature throughout the intraoperative period.
89466689|NCT03617809||Control|Non-active prewarming. Patients will be warmed using a surgical blanket during the intraoperative period. Esophageal thermometer will be used to measure the temperature throughout the intraoperative period.
89466690|NCT03615313|Experimental|PD-1 antibody expressing mesoCAR-T cells|Patients will receive two cycles of PD-1 antibody expressing mesoCAR-T cells treatment. Every cycle, peripheral blood mononuclear cells (PBMC) are collected on day -18, CAR-T cells are cultured in a GMP standard workshop. Patients are given a three-day regimen of chemotherapy consisting of fludarabine and cyclophosphamide aimed to deplete the lymphocytes before cells infusion. Then the patients will receive an i.v.gtt infusion of PD-1 antibody expressing mesoCAR-T cells from day 1 to day 3 (±3days).
88946321|NCT01906892|Experimental|1a|6 weeks of group drumming workshops
88946322|NCT01906892|Experimental|1b|6 weeks of group drumming workshops
88946323|NCT01906892|Experimental|2a|2 weeks of active group drumming followed by 2 weeks of control activity involving a literary-based activity
88946324|NCT01906892|Active Comparator|2b|2 weeks of the literary-based comparative activity followed by 2 weeks of watching live group drumming
88946325|NCT01906892|Active Comparator|2c|2 weeks of listening to live group drumming followed by 2 weeks of listening to recordings of group drumming
88946326|NCT01906892|Active Comparator|2d|2 weeks of listening to recorded group drumming followed by 2 weeks of participation in group drumming
89206176|NCT00830934|Active Comparator|Individual care|The first treatment group (individual care group) will involve 3 sessions held weekly. Each session will last approximately 45 minutes.
89466691|NCT03617653|Other|Group A - Intervention|Baseline procedure, Bio specimen collection , Six minute walk, Musculoskeletal Analysis, Exercise intervention from Visit 2 to Visit 13, End of 3 month assessment.
89466692|NCT03617653|Other|Group B- Control|Baseline procedure, Bio specimen collection , Six minute walk, Musculoskeletal Analysis & End of 3 month assessment.
89466693|NCT03617575|Placebo Comparator|apo-Lactoferrin|unsaturated (= no iron) form of Lactoferrin Lactoferrin is a bovine milk protein Test Meal A1
89466694|NCT03617575|Placebo Comparator|holo-Lactoferrin|saturated (= contains a certain amount of iron) form of Lactoferrin Lactoferrin is a bovine milk protein Test Meal B1
89466695|NCT03617575|Placebo Comparator|FeSO4|Ferrous sulfate = FeSO4 acting as the reference Test Meal C1
89466696|NCT03617575|Placebo Comparator|1. FeSO4|Ferrous sulfate = FeSO4 Test Meal A2
89466697|NCT03617575|Placebo Comparator|FeSO4 after 1 day break|Ferrous sulfate = FeSO4 Test Meal B2
89466698|NCT03617575|Placebo Comparator|FeSO4 after 2 day break|Ferrous sulfate = FeSO4 Test Meal C2
89466699|NCT02983617|Experimental|Tirabrutinib + Entospletinib|Participants will receive tirabrutinib 80 mg (4 x 20 mg tablets/2 x 40 mg tablets/1 x 80 mg tablet) + entospletinib 400 mg (2 x 200 mg tablets) for up to 104 weeks.
89466700|NCT02983617|Experimental|Tirabrutinib + Entospletinib + Obinutuzumab|Participants will receive tirabrutinib 80 mg (4 x 20 mg tablets/ 2 x 40 mg tablets/ 1 x 80 mg tablet) + entospletinib 400 mg (2 x 200 mg tablets) for up to 104 weeks + obinutuzumab 100 mg on Day 1, 900 mg on Day 1 or 2, and 1000 mg subsequently for up to 8 doses on Day 1 of Weeks 2, 3, 5, 9, 13, 17 and 21.
89466701|NCT03401203|Experimental|rotational atherectomy followed by balloon angioplasty|
89466702|NCT03401203|Active Comparator|balloon angioplasty|
89466703|NCT03616405|Experimental|14-day modified sequential therapy|"All the participants will go through a gastroscopy. Biopsy specimens will be taken for histologic assessment and rapid urease test. Two additional biopsy samples will be obtained from the antrum and body for bacterial culture and antimicrobial susceptibility test. Liver and kidney function will be monitored by blood test before and after the treatment.~Then, patients will receive a 14-day modified sequential therapy for the Helicobacter pylori eradication irrespective of antimicrobial susceptibility test results. The regimen contains rabeprazole, amoxicillin, tetracycline and furazolidone for the first 7 days, followed by rabeprazole，amoxicillin, tetracycline and colloidal bismuth pectin for the second 7 days.~Drugs: 1. rabeprazole 10mg bid for 14 days, 2. amoxicillin 1000mg bid for 14 days, 3. tetracycline 500mg qid for 14 days, 4. furazolidone 100mg tid for the firs 7 days, 5. colloidal bismuth pectin 200mg bid for the second 7 days."
89466704|NCT03419559|Experimental|LN-145 in combination with durvalumab|After nonmyeloablative (NMA) lymphodepletion, patients are infused with their autologous TIL (LN-145) followed by IL-2 administration.
89466705|NCT03616327|Other|MATRx in-lab or MATRx plus test|Participants will undergo the MATRx in-lab or MATRx plus home test to determine adequacy for mandibular repositioning oral appliance therapy. The tests only differ in their setting (i.e., in the sleep lab or at home). All participants will receive the same treatment protocol preceding and following the MATRx/MATRx plus test.
89466706|NCT03419247|Experimental|Tumor tissue and blood sample collection|
89466707|NCT03615157|Experimental|Home-based exercise rehabilitation|Patients will be submitted to a 12-weeks training program, with walking at 60-70% of heart rate reserve monitored by a heart rate monitor (30 minutes/session for 5 days/week) and peripheral muscle training including upper and lower limbs (50% of the 1-maximum repetition test)
88946327|NCT01906892|Experimental|3a|10 weeks of participatory group drumming workshops
89466708|NCT03615157|Active Comparator|Supervised exercise rehabilitation|Patients will be submitted to a 12-weeks training program, with sessions (3 days/week) supervised by a physiotherapist, including cycling at 60-70% of heart rate reserve and peripheral muscle training of upper and lower limbs (50% of the 1-maximum repetition test)
89466709|NCT03414177|Active Comparator|Telemedicine Group|Telemedicine participants will have asthma subspecialty follow-up visits conducted via real-time audio and video conferencing in conjunction with electronic examination peripherals and remote pulmonary function testing (PFT). Participants will receive a survey link to complete an electronic survey to assess Asthma Control Test (ACT) score, healthcare utilization, and satisfaction.
89466710|NCT03414177|Active Comparator|In-Person Group|In-Person participants will have asthma subspecialty follow-up visits at a subspecialty clinic. They will receive pulmonary function testing (PFT). Participants will receive a survey link to complete an electronic survey to assess Asthma Control Test (ACT) score, healthcare utilization, and satisfaction.
89466711|NCT02873689|Experimental|Dexlansoprazole 30 mg|Dexlansoprazole 30 mg, delayed-release capsule, orally, once daily for up to 4 weeks.
89466712|NCT02873689|Experimental|Placebo|Dexlansoprazole placebo-matching capsules, orally, once daily for up to 4 weeks.
89466713|NCT03414099|Experimental|Ketum|Each participant will consume a sequence of active ketum or placebo drinks. Pain tolerance will be measured using the cold pressor task after consuming each drink.
89466714|NCT03414099|Placebo Comparator|Placebo|Each participant will consume a sequence of active ketum or placebo drinks. Pain tolerance will be measured using the cold pressor task after consuming each drink.
89466715|NCT02901431|Placebo Comparator|Placebo|Participants received a matching placebo orally. Approximate treatment duration was up to 24 weeks.
89466716|NCT02901431|Experimental|Balovaptan (RO5285119) 10 mg/d equivalent|Participants received age-adjusted total daily oral dose approximately equivalent to the adult dose of 10 milligrams per day (mg/d) of balovaptan (RO5285119). Approximate treatment duration was up to 24 weeks (up to 52 additional weeks for those enrolled in the OLE).
88946328|NCT01906892|Active Comparator|3b|10 weeks of engagement with other non-musical social activities
88946329|NCT01906918|Experimental|IRPC, Remote preconditioning|This group will be submitted to ischemic preconditioning
88946330|NCT01906918|Placebo Comparator|Control|This patients will be submitted to the standard surgery protocol in the institution. The patients will not be submitted to 5 minutes of upper limb compression by cuff followed by 5 minutes of reperfusion.
88946331|NCT01906931|Experimental|Portable Oxygen Concentrator first|
88946332|NCT01906931|Active Comparator|Portable oxygen cylinder first|
88946333|NCT01906944|Active Comparator|Trigger point injection|Trigger point injection under ultrasound guidance into the fascial layer above the external oblique or rectus muscle, whichever corresponds to patient's identifiable trigger point. The injectate will include 5 ml of bupivacaine 0.25% mixed with triamcinolone 20 mg.
88946334|NCT01906944|Active Comparator|Transversus abdominis plane block|Injection into transversus abdominis plane layer under ultrasound guidance on the affected side along the mid-axillary line. The injectate will include 10 ml of bupivacaine 0.25% mixed with triamcinolone 20 mg.
89466717|NCT02901431|Experimental|Balovaptan (RO5285119) 4 mg/d equivalent|Participants received age-adjusted total daily oral dose approximately equivalent to the adult dose of 4 mg/d of balovaptan (RO5285119). Approximate treatment duration was up to 24 weeks. This arm is open only to those participants enrolled prior to Version 6 of the study protocol.
89466718|NCT02873377|Experimental|Enhanced Care|"Interventions: Nicorette Gum/Nicoderm CQ, Behavioral Smoking Cessation Counseling & Smoking Quitline Referral. Participants in the Enhanced Care intervention arm will receive a single face-to-face behavioral counseling session delivered at the construction site lunch truck, two brief follow-up phone counseling calls, fax referral to the Florida tobacco quitline (QL), and provision of up to 8 weeks of free Nicotine Replacement Therapy (up to 6 weeks provided by the study and 2 weeks provided by the QL). Participants in will receive two follow-up phone assessments at 3-, and 6-months of enrollment."
89466719|NCT02873377|Active Comparator|Standard Care|"Interventions: Nicorette Gum/Nicoderm CQ, Smoking Quitline Referral. The Standard Care group (NRT) will receive fax referral to the Florida QL and provision of up to 8 weeks of free Nicotine Replacement Therapy (up to 6 weeks provided by the study and 2 weeks provided by the QL). Participants will receive two follow-up phone assessments at 3-, and 6-months of enrollment."
89466720|NCT03649919||1 spinal muscular atrophy, SMA|Progressive muscular atrophy (SMA) is a group of autosomal recessive neuromuscular diseases characterized by degeneration of the anterior horn cells of the spinal cord, which is characterized by progressive generalized muscle weakness and muscle atrophy. The incidence of SMA is about 1/11000, and the occurrence of SMA is caused by mutation of the SMN1 gene. SMA can be classified into type I-III according to age of onset, maximum muscle activity, and survival.
89466721|NCT03649919||2 DMD|Progressive muscular dystrophy (DMD) is a group of hereditary skeletal muscle degeneration diseases. It is clinically characterized by slow and progressive development of muscle atrophy and muscle weakness. The inheritance can be divided into sexual chain recessiveness. Genetic type. For children with high suspected DMD/BMD, the current DMD diagnosis is preferred by MLPA method for detection of DNA in peripheral blood; MLPA diagnostic kit can only detect about 65% of large gene deletions or repeat types, thus detecting undetected gene mutations.
89466722|NCT03649919||3 X-linked adrenoleukodystrophy X-ALD|X-linked adrenoleukodystrophy X-ALD is an X-linked episode of a group of diseases characterized by progressive central nervous system demyelination and adrenal insufficiency. About 1/20000 male children. Most cases of X-ALD are treated for neurological symptoms for the first time, most of them start from 3-10 years old. Early manifestations include slow mental function, decreased academic performance, lack of interest or hyperactivity, difficulty in speech, difficulty in articulation, etc. Visual impairment and progressive hemiplegia are more common symptoms.
89466723|NCT03649919||4 tuberous sclerosis complex，TSC|Tuberous sclerosis complex (TSC) is an autosomal dominant genetic disease involving multiple systems. About 1 in every 6,000-10,000 people in TSC suffer from tuberous sclerosis, and children in the neurology department are diagnosed with developmental delay or seizures, and about 2/3 have no positive family history. Nearly 2 million people worldwide suffer from TSC, and there are about 200,000 in China.
89466724|NCT02966795|Experimental|Glecaprevir/Pibrentasvir for 8 Weeks|Non-cirrhotic participants with hepatitis C virus genotype 5 or 6 received oral glecaprevir/pibrentasir (300 mg/120 mg) once daily with food for 8 weeks, according to label.
89466725|NCT02966795|Experimental|Glecaprevir/Pibrentasvir for 12 Weeks|Participants with hepatitis C virus genotype 5 or 6 and compensated cirrhosis received oral glecaprevir/pibrentasir (300 mg/120 mg) once daily with food for 12 weeks, according to label.
89466726|NCT04052789|Active Comparator|Zirconia single posterior crowns veneered with ceramics|'In the first visit, a Face-to-Face adherence session will be held in which the patient should be informed about the study steps and how to maintain oral hygiene measures. Further sessions will occur at the follow-up visits
89466727|NCT04052789|Experimental|BioHpp PEEK single posterior crowns veneered with compos|In the first visit, a Face-to-Face adherence session will be held in which the patient should be informed about the study steps and how to maintain oral hygiene measures. Further sessions will occur at the follow-up visits
89466728|NCT03648749|Experimental|Speech-to-noise feedback|A target speech-to-noise level is specified and feedback about achievement of the target level is provided
89466729|NCT04053257|No Intervention|Before intervention|HH opportunities, compliant moments and HAIs recorded before the intervention
89466730|NCT04053257|Active Comparator|After intervention|HH opportunities, compliant moments and HAIs recorded after the intervention
89466731|NCT04053179|Experimental|Connected patch validation|
89466732|NCT03647813|Active Comparator|Photobiomodulation group|Patients were submitted to three sessions of PBM (baseline, 7 and 14 days). PBMT was administered by a single professional using a continuous wave AsGaAl diode laser (Photon Lase III - DMC, São Paulo, Brazil) with a wavelength of 808 nm (infrared). Irradiation was performed in punctual contact mode (ʎ = 808 nm, 100 mW, 142 J/cm2 and 4 J per point). A total of 20 points were applied in each session/day being three extraoral points in the parotid region (right and left n=6), three points in buccal mucosa (right and left, n=6), two extraoral (right and left, n=4) and two intraoral (right and left, n=4) points in the submandibular and sublingual regions.
89466733|NCT03647813|Placebo Comparator|Placebo group|Patients were submitted to same protocol as the photobiomodulation group, but the laser was turned off.
89466734|NCT03647735|Experimental|Group PCS|Patients in Group PCS (patient-controlled sedation) received intravenous (IV) propofol via a patient controlled analgesia (PCA) infusion pump. The machine was set to deliver a demand bolus dose of 0.25 mg/kg with 1-minute lockout interval, without basal infusion.The patient was instructed to press on a hand-held device as often as required, to achieve their desired level of comfort or sedation.
88946335|NCT01906983||Doppler ultrasound.|Doppler ultrasound will be performed to All patients 18 and up, admitted to Rambam Medical Center with diagnosis of blunt splenic trauma and agree to participate the study.
89466735|NCT03647735|Active Comparator|Group TCIS|Patients in Group TCIS (target-controlled infusion sedation) received IV propofol via a target-controlled infusion (TCI) pump, targeted at an initial effect site concentration (Cet) of 0.6 μg/ml, using the Schnider pharmacokinetic model. Upon attainment of 0.6 μg/ml Cet, the patient's sedation level was assessed. The Cet was increased or reduced accordingly by 0.2 μg/ml to attain an OAA/S score of 3.
89466736|NCT03647579|Active Comparator|midazolam plus ketamine|
89466737|NCT03647579|Active Comparator|dexmedetomidine plus ketamine|
89466738|NCT02873221|Active Comparator|Usual Care|Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of migraine attacks for up to 1 year.
89466739|NCT02873221|Experimental|Ubrogepant 50 mg|Ubrogepant 50 mg tablet orally plus placebo-matching ubrogepant tablet for the treatment of a qualifying migraine attack for up to 8 treatments every 4 weeks for up to 1 year. Participants may choose to take a second dose orally after the initial dose if migraine continues or returns.
89466740|NCT02873221|Experimental|Ubrogepant 100 mg|Ubrogepant 100 mg (two 50 mg tablets) orally for the treatment of a qualifying migraine attack for up to 8 treatments every 4 weeks for up to 1 year. Participants may choose to take a second dose orally after the initial dose if migraine continues or returns.
89466741|NCT04046861|Active Comparator|Vitamin C|2g vitamin C (ascorbic acid) iv before cardiopulmonary bypass, 2 g vitamin C iv before removing the aortic clamp, 1g vitamin C iv 8 h after aortic clamp removal and every 8 h thereafter(2 times)
89466742|NCT04046861|Placebo Comparator|Placebo (saline)|placebo (saline) iv before cardiopulmonary bypass, placebo before removing the aortic clamp, placebo iv 8 h after aortic clamp removal and every 8 h (2 times)
89466743|NCT02236741||users of anti-parkinsonian drugs|
89466744|NCT03616249|Experimental|Sleep quality|To compare if elderly sartcopics present sleep losses at higher levels than non-sarcopenic elderly
89466745|NCT03616249|Experimental|sleep-wake cycle.|To compare if elderly sarcopenics present sleep-wake cycle. disorders at higher levels than non-sarcopenic elderly
89466746|NCT03616249|Active Comparator|Exercise And Sleep quality|Comparing resistance training in the sarcopenician elderly showed improvements in sleep patterns.
89466747|NCT03616249|Active Comparator|Exercise And sleep-wake cycle.|Comparing resistance training in the elderly with sarcopenia presents better sleep-wake cycle.
89466748|NCT02966015|Experimental|Testing the new Coloplast Test catheter|The subjects used the new Coloplast Test catheter for 1 week
89466749|NCT03616093|Experimental|Test Beet shot|Active supplement containing 6.2 mmol nitrate
89466750|NCT03616093|Placebo Comparator|Placebo beverage|Placebo supplement containing negligible nitrate
88946336|NCT01906996||proximal row carpectomy|patients were treated with a proximal row carpectomy
88946337|NCT01906996||four corner fusion|patients were treated with a four corner fusion
89466751|NCT03616015|Experimental|Patient|"For all patients included in the study, the following interventions will be performed :~several blood samples (quantity collected requiring classification of this study as interventional according to French law)~several fecal samples~anxiety tests~stress tests"
89466752|NCT03648671||PD with PAIN|12 patients will undergo add-on drugs therapy with safinamide metansolfonato.
89466753|NCT03648671||PD without PAIN|12 patients will undergo add-on drugs therapy with safinamide metansolfonato.
89466754|NCT03648671||PD with PAIN rasagilina|12 patients will undergo add-on drugs therapy with rasagilina mesilato.
89466755|NCT03648671||PD without PAIN rasagilina|12 patients will undergo add-on drugs therapy with rasagilina mesilato.
89466756|NCT03617341||Brain MRI|Regular brain MRI can detect early brain metastases in metastatic Breast cancer with high risk subgroups, such as HER2-positive and triple negative.
89466757|NCT02968433|Experimental|Infusions of Young Plasma|"All participants will undergo neuropsychological, neuropsychiatric, and kinematic assessments prior to receiving infusions of young plasma as the treatment.~Participants will receive 1 unit of young plasma, twice a week over a four week duration.~After the four weeks of plasma infusions, participants will undergo neuropsychological, neuropsychiatric and kinematic reassessments. No deception will be used."
89466758|NCT03615859||Healthy volunteers|Healthy volunteers whose data represents a negative control
89466759|NCT03615859||Prednisolone replacement group|Participants with adrenal insufficiency who are treated with replacement doses of prednisolone
88946338|NCT01907022|Experimental|Left dorsolateral prefrontal cortex (DLPFC) Butterfly Coil|High frequency rTMS ( Alpine Biomed Mag Pro Option): 2000 stimuli of 20 Hz over the left DLPFC (each session), Butterfly-water-cooled-Coil, 110% motor threshold; followed by: low frequency rTMS ( Alpine Biomed Mag Pro Option) applied over left temporoparietal cortex, Butterfly-water-cooled-Coil (2000 Stimuli of 1 Hz each session), 110% motor threshold. Relaxation therapy during the 1Hz stimulation with external audio tape instructions.
88946339|NCT01907035|Experimental|Cognitive-behavioral intervention|Cognitive-behavioral intervention: Evaluate the effectiveness of a cognitive-behavioral intervention by psychologists in collaboration with practitioner plus routine therapy in the field of primary care in anxiety-depressive patients mild to moderate, with respect to standardized usual care by physicians, improve quality of life of these people, producing at least ten-point increase in the level of overall quality of life (SF-36)
88946340|NCT01907035|Active Comparator|Usual care|Family practice attention without the psychologist support
88946341|NCT01907048||Group 1|Survey to measure physician awareness and understanding of the key messages in the prescriber guide.
88946342|NCT01907048||Group 2|Survey to measure patient awareness and understanding of the key messages in the patient card.
88946343|NCT01907061|Active Comparator|600 mg N-acetylcysteine or placebo IV|600 mg N-acetylcysteine or placebo IV perfused over 15 minutes during the transplant procedure, prior to reperfusion,
89466760|NCT03615859||Hydrocortisone replacement group|Participants with adrenal insufficiency who are treated with replacement doses of hydrocortisone
89466761|NCT03615859||New adrenal insufficiency group|Participants who have recently been given a new diagnosis of adrenal insufficiency
89466762|NCT03615859||High dose steroids groups|Participants who are treated with high dose steroids for management of any medical condition to serve as a positive control
89466763|NCT03647423|Experimental|NANT Chordoma Vaccine|A combination of agents will be administered to subjects in this study: Aldoxorubicin Hydrochloride HCI, ALT-803, ETBX-051, ETBX-061, GI-6301, haNK, avelumab, cetuximab, cyclophosphamide, SBRT.
89466764|NCT03647423|Active Comparator|Controlled Arm - Radiation|SBRT
89466765|NCT03615781|Experimental|Two week's arm - surgery|The investigators perform a surgical drainage and removal of the infected orthopedic implant.
89466766|NCT03615781|Active Comparator|Four week's arm - surgery|The investigators surgically remove the infected implant.
89202128|NCT00566709|Active Comparator|RBCT based on hemoglobin level value|Intervention: In the hemoglobin - strategy group, patients will be transfused to reach post-transfusion hemoglobin levels between 8.5 g/dL and 10 g/dL.
89466767|NCT03615781|Experimental|Two week's arm - drugs|The investigators perform a surgical drainage and removal of the infected orthopedic implant. They start an empirical antibiotic treatment based on patient's history and co-morbidities, such as vancomycin or amoxicillin/clavulanic acid. The adapt later on the targeted antibiotic therapy according to the causative pathogens and their antibiotic susceptibility testing.
89466768|NCT03615781|Active Comparator|Four week's arm - drugs|The investigators surgically remove the infected implant and all soft tissue infection. Instead of a total of 2 week's of antibiotic therapy, they administer a total of 4 weeks of systemic antibiotic therapy targeted to the pathogen(s).
88946344|NCT01907061|Active Comparator|600 mg N-acetylcysteine or placebo NG|600 mg NAC or placebo administered via NG tube starting at 12 hrs + 30 min post O.R. infusion,
88946345|NCT01907061|Active Comparator|N-acetylcysteine or placebo q 12 hour|600 mg NAC or placebo administered via NG tube every 12 hrs + 30 min for 3 additional doses (at 24, 36 and 48 hrs post O.R. infusion). The total administration will be 3000 mg over a 48 hr period.
89466769|NCT04030403||Microbial Keratitis participants|151 participants presenting with clinically suspected microbial keratitis will be recruited from St Paul's Eye Unit, Royal Liverpool University Hospital.
89466770|NCT04030403||Healthy control participants|20 participants with no history of microbial keratitis who use no eye drop medication will be recruited.
89466771|NCT04030403||Contact-lens wearers|20 participants with no history of microbial keratitis who are contact-lens wearers will be recruited.
89466772|NCT04030403||Glaucoma eye drop users|20 participants who have no history of microbial keratitis but are on eye drop treatment for glaucoma. This group has been included to assess for changes in the corneal microbiome that could be secondary to drop treatment.
89466773|NCT04030403||Keratoconus participants|30 participants with keratoconus who are undergoing cross-linking will be recruited. These participants as part of the routine cross-linking procedure will have their corneal epithelium removed. This removed epithelium from an otherwise healthy corneal surface will allow for a direct comparison between the corneal microbiome characterised from the corneal impression membrane and that characterised directly from the epithelium.
89466774|NCT03646097|Active Comparator|Blinded-group|Lesion assessment, selection of PCI landing zone as well as stent selection will be performed by investigators only based on angiographic lesion evaluation (standard care)
89466775|NCT03646097|Active Comparator|OCT-group|Patients underwent OCT-imaging before PCI. Lesion assessment, selection of PCI landing zone as well as stent selection will be performed by investigators based on OCT findings
89466776|NCT03646097|Experimental|ACR-group|Patients underwent ACR-imaging before PCI. Lesion assessment, selection of PCI landing zone as well as stent selection will be performed by investigators based on ACR-findings
89466777|NCT02872285|Experimental|LYC-30937-EC 25 mg PO once daily (QD)|LYC-30937-EC 25 mg by mouth once daily for 12 weeks
89466778|NCT02872285|Placebo Comparator|Matching Placebo PO QD|Placebo enteric coated (EC) by mouth once daily for 12 weeks
89466779|NCT03647345|Experimental|Experimental 1: Anodal Dual-mode stimulation|"10Hz of rTMS was applied over the left DLPFC for 10 minutes with simultaneous application of anodal tDCS on the right DLPFC.~Each participant's 2-back verbal/nonverbal working memory task and variety cognitive function test are assessed and their resting-state fMRI data at three times: prior to stimulation (pre-stimulation), immediately after stimulation (post-stimulation) and 2 months after stimulation (f/u) are acquired."
89466780|NCT03647345|Experimental|Experimental 2: Cathodal Dual-mode stimulation|"10Hz of rTMS was applied over the left DLPFC for 10 minutes with simultaneous application of cathodal tDCS on the right DLPFC.~Each participant's 2-back verbal/nonverbal working memory task and variety cognitive function test are assessed and their resting-state fMRI data at three times: prior to stimulation (pre-stimulation), immediately after stimulation (post-stimulation) and 2 months after stimulation (f/u) are acquired."
89466781|NCT03647345|Active Comparator|Active Comparator: Single sham stimulation|"10Hz of rTMS was applied over the left DLPFC for 10 minutes with simultaneous application of tDCS with sham mode (no stimulation) on the right DLPFC.~Each participant's 2-back verbal/nonverbal working memory task and variety cognitive function test are assessed and their resting-state fMRI data at three times: prior to stimulation (pre-stimulation), immediately after stimulation (post-stimulation) and 2 months after stimulation (f/u) are acquired."
89466782|NCT04052711|Experimental|FMX-101|
89466783|NCT03619265|Experimental|Prickly pear juice|Prickly pear juice, 3 oz daily for 8 weeks.
89466784|NCT03619265|Placebo Comparator|Pear-flavored juice|Pear-flavored juice, 3 oz daily for 8 weeks.
89466785|NCT03646955|Active Comparator|Partial breast irradiation|External beam irradiation 40 Gy / 15 fractions, 5 fractions per week, 3 weeks
89466786|NCT03646955|No Intervention|No partial breast irradiation|No radiation therapy
89466787|NCT02871739|Experimental|DA viewing with SPI Feedback|Group 1 receives three decision aids and feedback on their standardized patient (SPI) interaction rating their shared decision making skills and highlighting opportunities for improvement.
89466788|NCT02871739|Experimental|DA viewing with no SPI Feedback|Group 2 receives three decision aids. This group does not receive any feedback from the SPI.
89466789|NCT02871739|Experimental|Webinar with SPI Feedback|Group 3 receives an online, interactive webinar that focuses on SDM skills in clinical encounters and feedback on their standardized patient (SPI) interaction rating their shared decision making skills and highlighting opportunities for improvement.
88946346|NCT01907126|Experimental|Women's Prison CoOp (WPC)|Will receive 5 group psychoeducation sessions plus individual pre-release and post-release goal planning sessions. Psychoeducation sessions will cover HIV risk and violence prevention, interpersonal violence-specific sexual safety skills, empowerment through knowledge and treatment, and skills for increasing affect regulation and social support.
88946347|NCT01907126|Placebo Comparator|Nutrition program (NP)|Participants in this condition will receive dose-matched nutrition education.
88946348|NCT01907139|Experimental|Distributed constraint-induced therapy (dCIT)|The dCIT group will focus on restriction on movement of the unaffected hand by placement of the hand in a mitt for 6 hours/day and intensive training of the affected UL in functional tasks for 1.5 hours/weekday over the 4 weeks.
89466790|NCT02871739|Experimental|Webinar with no SPI Feedback|Group 4 receives an online, interactive webinar that focuses on SDM skills in clinical encounters. This group does not receive any feedback from the SPI.
89466791|NCT03646019||Normal coronary arteries|
89466792|NCT03646019||Non significant coronary artery disease|
88956470|NCT05137119|Experimental|Methicillin-susceptible staphylococcus aureus (MSSA) - Interventional Arm (backbone therapy)|"Cefazolin - Interventional Arm~Intravenous cefazolin 2g every 6 or 8 hours. The minimum protocol duration of allocated study treatment is 14 days for those not allocated to early oral switch, and 5 days for those allocated to early oral switch. For patients with renal impairment or critical illness the intravenous cefazolin administration dose will be adjusted."
88956471|NCT05137119|No Intervention|Penicillin-susceptible staphylococcus aureus (PSSA) - Standard Therapy Arm (backbone therapy)|"Flucloxacillin or cloxacillin - Standard Therapy Arm~Either intravenous flucloxacillin/cloxacillin 2g every 4 or 6 hours. The minimum protocol duration of allocated study treatment is 14 days for those not allocated to early oral switch, and 5 days for those allocated to early oral switch. For patients with renal impairment or critical illness the intravenous flucloxacillin administration dose will be adjusted."
89202129|NCT00785850|Experimental|1|Dermacyd PH_DETINBACK (Lactic Acid) Sweet Flower
89466793|NCT03646019||Significant coronary artery disease|
89466794|NCT02032069||NHBD|Non Heart Beating Donors
89466795|NCT02032069||BDD|Brain death donors
89466796|NCT03621683|Experimental|ovarian bio-stimulation|"Intervention:~ovarian bio-stimulation: blood rich plasma platelets"
88946349|NCT01907139|Experimental|Robot-assisted therapy (RT)|The ArmeoSpring (Hocoma AG, Switzerland) will be adopted in this study. It is a 5 degree-of-freedom skeleton mechanism that automates arm movement in a gravity-supported and computer-enhanced environment. The design of the arm support component of the ArmeoSpring is based on Wilmington Robotic Exoskeleton, an antigravity arm support. The ArmeoSpring g provides weight support for the arm across a large 3D workspace, enabling naturalistic movement across approximately 66% of the normal workspace in the vertical plane and 72% in the horizontal plane. Its main structure consists of an arm exoskeleton with elastic bands that relieve the weight of the limb and provide a sense of arm flotation at all positions in the available workspace. A custom grip sensor consisting of a water-filled cylindrical bladder detects grip pressure and finger movement and allows incorporation of grasp and release practice into arm training.
88946350|NCT01907139|Active Comparator|Dose-matched control therapy (DMCT)|The DMCT group mediated by the therapists will be designed to control for the duration of therapy in amount of therapy hours. This group will received a structured protocol using conventional occupational therapy techniques such as neuro-developmental techniques with emphasis on functional tasks and muscle strengthening.
88946351|NCT01907139|Experimental|RT + dCIT|In this combination therapy group, the participants will received 2 weeks of RT using the ArmeoSpring and followed by 2 weeks of distributed CIT. The treatment principles of RT and distributed CIT are the same with those described in the monotherapy of RT or dCIT, respectively. This combined intervention group may integrate proximal (shoulder and elbow) to distal (wrist and hand) training of the UL and help transfer from motor ability gained to functional performance improvement. That is, it appears to associate with the advantages/effects of each RT and dCIT intervention.
88946352|NCT01907152|Experimental|Protein enriched yoghurt drink and bread|Yoghurt drink enriched with Whey Protein Concentrate Whole wheat bread enriched with cereal protein and soy
88946353|NCT01907152|No Intervention|Regular yoghurt drink and bread|Commercially available yoghurt drink and whole wheat bread
88946354|NCT01907165|Experimental|Maintenance Temozolomide + Disulfram|"Beginning 4-6 weeks after completion of radiation therapy, patients receive maintenance temozolomide 150-200 mg/m2 PO QD on Days 1-5 every 28 days for 6 months. Disulfiram (dose level 0 = 500 mg PO QD or dose level 1 1000 mg PO QD) on days 1-28. Treatment repeats every 28 days for 6 courses* in the absence of disease progression or unacceptable toxicity.~NOTE: *Patients may receive additional maintenance temozolomide at the discretion of the treating medical oncologist."
88946355|NCT01907165|Experimental|Maintenance Temozolomide + Disulfiarm + Copper Gluconate|"Beginning 4-6 weeks after completion of radiation therapy, patients receive maintenance temozolomide 150-200 mg/m2 PO QD on Days 1-5 every 28 days for 6 months, disulfiram 500 mg PO QD (dose of disulfiram determined to be the MTD) on Days 1-28, and copper gluconate 6 mg PO QD on Days 1-28. Treatment repeats every 28 days for 6 courses* in the absence of disease progression or unacceptable toxicity.~NOTE: *Patients may receive additional maintenance temozolomide at the discretion of the treating medical oncologist."
88946356|NCT01907178||Postoperative pain management|The postoperative pain level will be assessed during hospitalization and at home, in patients undergoing total knee replacement
88946357|NCT01907204|Active Comparator|Oral|Oral drug (methylprednisolone) administration
88946358|NCT01907204|Experimental|Metered dose inhaler|
88946359|NCT01907204|Experimental|Nebulized|
88946360|NCT01907230|Experimental|Entecavir, Prophylactic group|Participants will initiate entecavir 0.5 mg/day orally one week before biologic treatment. Entecavir treatment will be continued normally for 12 months (6 months after stopping biologic therapy or till restart another course of biologic treatment if the clinicians' judgment is minimal risk of reactivation after the first course of biologic agent treatment).
88946361|NCT01907230|No Intervention|Control group (pre-emptive treatment)|Patients will start entecavir therapy, 0.5 mg/day orally, when reactivation of HBV (defined as detectable HBV viral loads for 2 consecutive visits with at least one month apart), and continued entecavir treatment until undetectable HBV viral loads for 1 year (consistent with current APASL recommendation).
88946362|NCT01907243|Active Comparator|spreader flap|Usage of spreader flap of upper lateral cartilage
88946363|NCT01907243|No Intervention|Control group|performing of rhinoplasty without spreader flap
88946364|NCT01907256|Active Comparator|group A|stair step incisions
88946365|NCT01907256|Active Comparator|Group B|inverted V incision
88946366|NCT01907282|Experimental|Family Focused Treatment|Family-Focused Treatment (FFT) consists of 18 sessions of psychoeducation, communication enhancement training, and problem-solving skills training in six months
88946367|NCT01907282|Active Comparator|Enhanced Care|Enhanced care is a 3-session family psychoeducational therapy focused on prevention of psychotic symptoms
88946368|NCT01907308|Experimental|Combination of AMG 386 with Docetaxel|All treated patients will receive AMG 386 30mg/kg IV weekly plus docetaxel 75mg/m2 IV every 3 weeks.
88946369|NCT01907347||ICU patients|
88946370|NCT01907373|Active Comparator|olmesartan medoxomil, PK of olmesartan|drug: olmesartan medoxomil; dosage form: oral tablet; dosage: 20mg/time; frequency: once a day; duration: 4 days
88946371|NCT01907373|Experimental|olmesartan medoxomil+probenecid, PK of olmesartan|drug1: olmesartan medoxomil; dosage form: oral tablet; dosage: 20mg/time; frequency: once a day; duration: 4 days; drug2: probenecid; dosage form: oral tablet; dosage: 500mg/time; frequency: 2 times/day; duration: 1 day
88946372|NCT01907386|Other|QSE-LSME and SSWI ultrasound|"QSE-LSME and SSWI ultrasound examinations combined with a clinically required CT-scan. We will screen 3 groups of 15 patients each, with at least one-year follow-up after EVAR, matched for sex, age and aneurysm diameter at baseline (before EVAR).~Group 1. Patients without endoleak and a maximal diameter reduction at one year of at least 10% and a volume reduction of 20%.~Group 2. Patients with a stable sac volume and diameter (less than 10% volume and 5% diameter variation within a year).~Group 3. Patients with type I, type II or type V endoleak (endotension) with more than 10% diameter progression and 20% volume progression."
88946373|NCT01907399|Other|obese patients|(BMI> 30 kg/m2) androids (waist circumference> 102 cm in men and> 88 cm in woman)
88946374|NCT01907399|Other|obese patients with type 2 diabetes|(BMI> 30 kg/m2) androids (waist circumference> 102 cm in men and> 88 cm in woman)with diabetes
88946375|NCT01907399|Other|healthy volunteers|free of disease inflammatory or infectious and will have a BMI <25 Kg/m2et fasting glucose <1g / L
88946376|NCT01907438||non-carriers|Tissues from premenopausal women undergoing esthetic breast surgery with no family history of breast or ovarian cancers will be obtained.epithelial breast cells will be isolated, treated with estrogen for 48 h and then will be irradiated.
88946377|NCT01907438||BRCA1 mutation carriers|Tissues from risk-reducing mastectomy in healthy premenopausal women with BRCA1 mutations undergoing.epithelial breast cells will be isolated, treated with estrogen for 48 h and then will be irradiated.
88946378|NCT01907438||BRCA2 mutation carriers|Tissues from risk-reducing mastectomy in healthy premenopausal women with BRCA2 mutations undergoing.epithelial breast cells will be isolated, treated with estrogen for 48 h and then will be irradiated.
88946379|NCT01907451||The control group|"will receive support traditional10 hours per week: techniques called neuro-facilitators"
88946380|NCT01907451||test group|enjoy the same support as control group at 7 hours week, coupled with a personalized retraining effort ergometer for 3 hours per week: after a 5 minute warm to 50% of Heart Rate Maximum (HRmax) of the initial test effort (TE), continuous work of 20 minutes at an intensity corresponding to 70% HRmax, followed by a recovery period of 5 min between active 40 and 50% of maximum heart rate (5 times per week).
88946381|NCT01907464|Experimental|Patients with anorexia nervosa|This arm is the experimental arm composed of patients
88946382|NCT01907464|Active Comparator|controls subjects|This arm is composed of healthy volunteers
89466797|NCT03621683|Active Comparator|Antioxidant therapy|"Intervention:~antioxidants: Q10, DHEA, Vitamin E, Vitamin C, omega 3"
89466798|NCT05284331|Other|follow-up visit at 6 months and 1 year after inclusion.|addition of a follow-up visit at 6 months and 1 year after inclusion. No treatment will be given specifically for this study. Other visits are part of the normal and usual rhythm of follow-up and evaluation of treatment in these patients
88946383|NCT01907477|Other|neutropenic patients|
88946384|NCT01907503|Other|Patients with Primary hip osteoarthritis|Patients with Primary hip osteoarthritis
88946385|NCT01907503|Other|Healthy volunteer|Healthy volunteer
88946386|NCT01907529|Experimental|Chemo plus Endostar|Docetaxel, epirubicin and cyclophosphamide plus endostar
88946387|NCT01907529|Active Comparator|Chemo only|docetaxel, epirubicin and cyclophosphamide
89466799|NCT03614845|Active Comparator|VCV-Lung Ultrasonography|patients undergoing laparoscopic surgery will be performed pre and postoperatively lung ultrasonography. after induction of anesthesia patients will be supported by mechanical ventilation on volume controlled ventilation mode.
88946388|NCT01907542|Active Comparator|Monocryl suture skin closure|Monocryl skin suture
88946389|NCT01907542|Active Comparator|Stapled skin closure|stapled skin closure
89466800|NCT03614845|Active Comparator|PCV-VG- Lung Ultrasonography|patients undergoing laparoscopic surgery will be performed pre and postoperatively lung ultrasonography.after induction of anesthesia patients will be supported by mechanical ventilation on pressure controlled volume guaranteed mode
89466801|NCT03621605|Experimental|VIB9600|"Single dose of VIB9600 administered by IV infusion or SC injection.~Multiple dose VIB9600 administered by IV infusion every 2 weeks for 4 weeks."
88946390|NCT01907555||- Patients presenting Cohen syndrome and two VPS13B mutations|
88946391|NCT01907555||Patients presenting Cohen syndrome without a VPS13B mutation|
88946392|NCT01907555||Patients presenting neutropenia|
88946393|NCT01907568||Patients with schizophrenia|With and without hallucinations
88946394|NCT01907568||Patients with borderline personality disorder|With and without hallucinations
88946395|NCT01907568||Patients with hearing impairment|With and without hallucinations
88946396|NCT01907568||Patients with visual loss|With and without hallucinations
88946397|NCT01907568||Patients with Parkinson's Disease|With and without hallucinations
88946398|NCT01907568||Patients with Alzheimer's Disease|With and without hallucinations
89466802|NCT03621605|Placebo Comparator|Placebo|Placebo comparator administered by slow IV infusion or SC injection.
89466803|NCT03614065|Placebo Comparator|arm a|This group is a placebo control group, and we will use radiation therapy plus Placebos as the control group for the study
89466804|NCT03614065|Experimental|arm b|This group belongs to the experimental group. We will use radiotherapy combined with endostar for treatment, so as to judge the efficacy of the medicine
89466805|NCT03621527|Active Comparator|Standard group|"For each vertebra treated: 10 ml of lidocaine hydrochloride 1% are applied to the skin and the lower structures including the periosteum.~An additional, anesthesia combined with intravenous analgesia by remifentanil is provided and adapted to the patients needs during the whole procedure"
89466806|NCT03621527|Experimental|Epidural group|"Fluoroscopy-guided epidural anesthesiaI is the identification of the epidural space using fluoroscopy and the injection of a small quantity of contrast medium or air.~According to patient's height, 10-15 ml of lidocaine hydrochloride 1% are injected by the radiologist into the epidural space.~An additional, anesthesia combined with intravenous analgesia by remifentanil is provided and adapted to the patients needs during the whole procedure"
89466807|NCT02032147||NGF group|This group will be treated with NGF 18u daily for 60 days.
89466808|NCT02032147||control group|"this group will receive conservative therapy such as hyperbaric therapy or corticosteroids therapy or wait and see policy"
89466809|NCT03647189|Experimental|Treatment Arm|Subjects will be treated with hybrid fractional laser
89466810|NCT03647189|Placebo Comparator|Control Arm|
89466811|NCT03645317|Other|Single arm|Blood samples (FBC, lipids, cholesterol, troponin, CRP, BNP) Cardiac imaging (cardiac CT, cardiac ultrasound, 12-lead ECG)
89466812|NCT03615625|No Intervention|Control session|Control session without any exercise. The participants remained in seated rest throughout 40 min
89466813|NCT03615625|Experimental|Power Training Session|The power training session lasted 40 min, in which the participants performed a resistance exercise session using high velocity contractions during the exercises characterizing a power training session
89466814|NCT03646799|Experimental|Group 1|Period 1: 1 tablet of reference drug(D484) Period 2: 1 tablet of test drug(CKD-387)
89466815|NCT03646799|Experimental|Group 2|Period 1: 1 tablet of test drug(CKD-387) Period 2: 1 tablet of reference drug(D484)
89466816|NCT03646721|Experimental|[Part1] DA-1241 : 6 subjects in each cohort(Cohort 1-3)|Subjects will participate in 1 of 3 cohorts consisting of 8 subjects per cohort. Within cohorts, subjects will be randomized to a ratio of 6:2 (DA-1241 to matching placebo).
89466817|NCT03646721|Placebo Comparator|[Part1] Placebo : 2 subjects in each cohort(Cohort 1-3)|Subjects will participate in 1 of 3 cohorts consisting of 8 subjects per cohort. Within cohorts, subjects will be randomized to a ratio of 6:2 (DA-1241 to matching placebo).
89466818|NCT03646721|Experimental|[Part2] DA-1241 : 15 subjects in each cohort(Cohort 4-6)|Subjects will participate in 1 of 3 cohorts consisting of 25 subjects per cohort. Within cohorts, subjects will be randomized to a ratio of 3:1:1 (DA-1241 to matching placebo and active comparator).
89466819|NCT03646721|Placebo Comparator|[Part2] Placebo : 5 subjects in each cohort(Cohort 4-6)|Subjects will participate in 1 of 3 cohorts consisting of 25 subjects per cohort. Within cohorts, subjects will be randomized to a ratio of 3:1:1 (DA-1241 to matching placebo and active comparator).
89466820|NCT03646721|Active Comparator|[Part2] Sitagliptin : 5 subjects in each cohort(Cohort 4-6)|Subjects will participate in 1 of 3 cohorts consisting of 25 subjects per cohort. Within cohorts, subjects will be randomized to a ratio of 3:1:1 (DA-1241 to matching placebo and active comparator).
89466821|NCT04052399|Active Comparator|Anodal tDCS|Anodal tDCS of the lateral hypothalamus-cognitive or medial hypothalamus-cognitive network (2 conditions)
89466822|NCT04052399|Active Comparator|Cathodal tDCS|Cathodal tDCS of the lateral hypothalamus-cognitive or medial hypothalamus-cognitive network (2 conditions)
89466823|NCT04052399|Placebo Comparator|Sham stimulation|Single blind sham stimulation (ramp-up ramp-down stimulation will be applied for 30 seconds in order to simulate the active condition without any further continuous administration of current)
89466824|NCT03646643|Active Comparator|PVI, non-PV triggers|Interventions: Atrial fibrillation ablation, including conventional pulmonary vein isolation (PVI) and non-PV triggers ablation.
89466825|NCT03646643|Active Comparator|PVI, non-PV triggers & CS-LA connection|Interventions: Atrial fibrillation ablation, including conventional pulmonary vein isolation (PVI) and non-PV triggers ablation in addition to coronary sinus-left atrium connection elimination. Distal coronary sinus pacing will be utilized to localize the earliest connection (aside from septal) from the coronary sinus to the left atrial musculature. Once localized, focal radiofrequency lesions will be applied at the discretion of the investigator until distal coronary sinus to left atrial connections are eliminated.
89466826|NCT03613753|Experimental|Arm A|Chemotherapy:irinotecan plus lobaplatin
89466827|NCT03613753|Active Comparator|Arm B|Chemotherapy:irinotecan
89466828|NCT03946007||Patients with melanoma or NSCLC|Patients (age ≥18 years) with melanoma or NSCLC ≥2 years since treatment with at least one cycle of immune checkpoint inhibitor (CTLA-4 inhibitor, PD-(L)1 inhibitor, or both) within the Department of Medical Oncology or Pulmonary Oncology of the UMCG.
89466829|NCT04051853|Experimental|Sorafenib with midazolam clearance test|"Before start of treatment patients receive a single oral dose of midazolam to phenotype CYP3A4 activity. Blood samples will be taken at several time points to measure sorafenib and midazolam concentrations.~Patients will receive sorafenib at a starting dose of 200 mg twice daily. In the absence of toxicity dosage will be escalated with weekly intervals up to 400 mg BID (max dose)."
89466830|NCT04051853|Experimental|Sorafenib with CYP cocktail test|"In this subgroup of 15 patients (in the Academic Medical Center Amsterdam), the midazolam test will be replaced by an oral cocktail of subclinical doses of caffeine, midazolam, omeprazole, warfarin and metoprolol and will be repeated after 4 weeks of treatment to assess the influence of sorafenib on cytochrome P450 (CYP) 1A2, 3A4, 2C19, 2C9 and 2D6 activity, respectively.~Patients will receive sorafenib at a starting dose of 200 mg twice daily. In the absence of toxicity dosage will be escalated with weekly intervals up to 400 mg BID (max dose)."
89466831|NCT03646409||Patients with esophageal cancer receiving chemotherapy|Patients > 18 years with esophageal cancer receiving neoadjuvant chemotherapy
89466832|NCT03646331|Experimental|Tablet A in Session 1 and Tablet B in Session 2|Tablet A = reference product Tablet B = test product
89466833|NCT03646331|Experimental|Tablet B in Session 1 and Tablet A in Session 2|Tablet A = reference product Tablet B = test product
89466834|NCT03869177|Other|Intervention arm|Clusters (psychiatric outpatient clinics) in the intervention arm receives a comprehensive implementation support program during the trial period.
89466835|NCT03869177|No Intervention|Control arm|Clusters (psychiatric outpatient clinics) in the control arm receives no implementation support during the trial period.
89466836|NCT03645629|Active Comparator|Food skin tests at 0 month|the skin test results of food extract at time 0 months after preparation
89466837|NCT03645629|Active Comparator|Food skin tests at 3 month|the skin test results of food extract at time 3 months after preparation
89466838|NCT03645629|Active Comparator|Food skin tests at 6 month|the skin test results of food extract at time 6 months after preparation
89466839|NCT03843593||Melanoma patients|This is a pilot prospective study to identify the factors patients consider in deciding whether or not to undergo adjuvant therapy. Patients are eligible regardless of whether they decide to accept adjuvant therapy. If the researcher plans to treat the participant with pembrolizumab instead of nivolumab, it should be known that although the video discusses nivolumab, the risks and benefits are the same.
89466840|NCT03646253||Patients with proximal humerus fracture|
89466841|NCT03645473|Experimental|Monarch device settings assessment group|"Patients with cystic fibrosis who have experience with the Monarch Airway Clearance System will be enrolled in the study.~The duration of subject participation is approximately 4 - 6 hours during 1 study visit. Each subject will receive therapy with The Monarch® System at multiple frequency and intensity combinations as defined in the Study procedures."
89466842|NCT03838991|Experimental|Monostotic fibrous dysplasia|Patients with monostotic Fibrous dysplasia.
89466843|NCT03838991|Experimental|Polyostotic fibrous dysplasia|Patients with polyostotic Fibrous dysplasia.
89466844|NCT03838991|Active Comparator|Controls|Control patients having a scheduled surgery for osteoarthritis.
89466845|NCT03816995|Active Comparator|Alexis O Wound Protector|Participants will undergo standard surgical procedure using the Alexis O wound protector.
89466846|NCT03816995|Experimental|CleanCision Wound Protector|Participants will undergo standard surgical procedure using the CleanCision Wound Retraction and Protection System
89466847|NCT03614767||Successes|Patients with >50% improvement during test procedure of sacral neuromodulation.
89466848|NCT03614767||Failures|Patients with <50% improvement during test procedure of sacral neuromodulation.
89466849|NCT03643835|Experimental|Thermal rehab machine|Participants, following exercise-induced hyperthermia, will be cooled using a Thermal Rehab Machine (Polar Breeze, Statim Technologies, LLC, Clearwater Florida), which is a micro-environmental air chiller. The device will be placed over the subjects head and through trans pulmonary cooling, will cool the body.
89466850|NCT03643835|Active Comparator|Forearm Ice Towels|Participants, following exercise-induced hyperthermia, will be cooled using forearm ice towels. Cotton-blend towels will be doused in ice-water and then wrapped around participant's forearms (elbow to wrist). The towels will be rotated (re-wetted) every 2 minutes)
89466851|NCT03643835|No Intervention|Passive Cooling|Participants, following exercise-induced hyperthermia, will undergo a period of passive rest to allow the body to cool via natural mechanisms of evaporation of sweat from the skin's surface and convection
88946399|NCT01907568||Patients with dementia with Lewy Bodies|With and without hallucinations
89466852|NCT03645161|Active Comparator|Local rat and mouse skin test|All patients receive local skin prick test for mouse and rat. The result were recorded and compared to the imported one.
89466853|NCT03645161|Active Comparator|Imported rat and mouse skin test|All patients receive imported skin prick test for mouse and rat. The result were recorded and compared to the local one.
89466854|NCT03645083|Experimental|Telephone call|Participants receive a telephone call reminder three days after their initial visit
89466855|NCT03645083|Experimental|Text message|Participants receive a text message reminder three days after their initial visit
89466856|NCT03645083|No Intervention|Control|Participants do not receive any intervention after their initial visit
89466857|NCT03645005|Experimental|My Guide (psychoeducation & self-management program)|
89466858|NCT03645005|Active Comparator|My Health (health education program)|
89466859|NCT03644459|Experimental|LYN00101|Intravenous Infusion at the rate of 8 mg/kg of the patient's weight every 14 days.
89466860|NCT03643757|Active Comparator|Thoracic Epidural Analgesia|Population to whom thoracic epidural analgesia with bupivacaine as a component of multimodal analgesia was administered.
89466861|NCT03643757|Active Comparator|Intravenous analgesia|Population to whom combined intravenous analgesia was administered.
89466862|NCT03718793|Experimental|All subjects with asthma|In addition to normal diagnostic work out we will measure small airway inflammation based on peripheral exhaled nitric oxide and assess small airway dysfunction using impulse oscillometry. In addition, inflammatory markers in peripheral blood and genotype will be assessed.
89466863|NCT02896361|Experimental|Stimulation order 1|"Stimulations delivered in following order:~Standard burst~Burst Microdosing 1~Burst Microdosing 2"
89466864|NCT02896361|Experimental|Stimulation order 2|"Stimulations delivered in following order:~Burst Microdosing 1~Burst Microdosing 2~Standard burst"
89466865|NCT02896361|Experimental|Stimulation order 3|"Stimulations delivered in following order:~Burst Microdosing 2~Standard burst~Burst Microdosing 1"
89466866|NCT03643679|Experimental|Kwit smartphone app|This arm will receive the Kwit smartphone app.
89466867|NCT03621371|Experimental|Metacognitive therapy|
89466868|NCT03621371|Experimental|Intolerance of uncertainty therapy|
89466869|NCT03703895|Active Comparator|Active Comparator|Active Comparator, Topical AFX5931, a medication combining a small, potent anti-inflammatory molecule. Subjects will complete up to 4 study visits where Topical AFX5931 will be applied twice daily for 28 days.
89466870|NCT03703895|Placebo Comparator|Placebo Comparator|Placebo Comparator, Topical Placebo. Subjects will complete up to 4 study visits where Topical Placebo will be applied twice daily for 28 days.
89466871|NCT03643601||Non-Dialysis (ND) Patients|For the ND patients, data are captured on each clinic visit during the course of the year (2-4 times per year), the last available record for 2015 will be used.
89466872|NCT03643601||Dialysis (DD) Patients|For the DD patients, data are input from a randomly selected visit to the hospital in September to October 2015; the evaluation will be based on this record.
89466873|NCT03643523||ALbumin level|Detection of serum albumin levels in postoperatory of colorectal surgery
89466874|NCT02962739|Active Comparator|33%/67% dosing|The 33% and 67% dosing regimens will use skipped doses spaced by days (i.e. 67% is two daily doses followed by skipping a day, repeated for 12 weeks; 33% dosing is a daily dose followed by two skipped days, repeated for 12 weeks).
89466875|NCT02962739|Active Comparator|33%/100% dosing|The 33% dosing regimens will use skipped doses spaced by days (i.e. 33% dosing is a daily dose followed by two skipped days, repeated for 12 weeks). 100% will dose daily for 12 weeks, no skipped doses.
89466876|NCT02962739|Active Comparator|67%/33% dosing|The 33% and 67% dosing regimens will use skipped doses spaced by days (i.e. 67% is two daily doses followed by skipping a day, repeated for 12 weeks; 33% dosing is a daily dose followed by two skipped days, repeated for 12 weeks).
89466877|NCT02962739|Active Comparator|67%/100% dosing|67% dosing regimens will use skipped doses spaced by days (i.e. 67% is two daily doses followed by skipping a day, repeated for 12 weeks. 100% will dose daily for 12 weeks, no skipped doses.
89466878|NCT02962739|Active Comparator|100%/33% dosing|The 33% dosing regimens will use skipped doses spaced by days (i.e. 33% dosing is a daily dose followed by two skipped days, repeated for 12 weeks). 100% will dose daily for 12 weeks, no skipped doses.
89466879|NCT02962739|Active Comparator|100%/67% dosing|67% dosing regimens will use skipped doses spaced by days (i.e. 67% is two daily doses followed by skipping a day, repeated for 12 weeks. 100% will dose daily for 12 weeks, no skipped doses.
89466880|NCT03644693|Experimental|Investigational|Subjects assigned to this arm will receive the Nutritional Formulation containing exogenous ketones.
89466881|NCT03644693|Placebo Comparator|Placebo|Subjects assigned to this arm will receive the Placebo Formulation.
89466882|NCT03643445|Experimental|Motivational Interviewing (MI) Treatment|Motivational interviewing is a psychotherapeutic stance aimed at helping patients in resolving ambivalence toward change and increasing their intrinsic motivation to engage in healthy behaviour choices. Patients assigned to these MI-trained therapists will be in the motivation-oriented condition. All individual meetings patients have with their therapist while they are in the program will entail sessions that are guided by MI principles. That is, revisiting patients' motivation to recover and overcoming obstacles to ambivalence or low motivation.
89466883|NCT03643445|Active Comparator|Psychoeducation-Oriented Treatment|"The psychoeducation-oriented treatment condition is intended to teach patients about the causes of eating disorders, the expected course of recovery, obstacles to recovery, and the importance of behavioural changes required for recovery from an eating disorder. Two staff members in the eating disorders program will deliver the psychoeducation-infused interventions, which are intended to be equivalent to treatment-as-usual in many eating disorder programs, but in a structured and standardized way, and with the use of the self-help manual. Psychoeducation is a very common intervention, often used as part of cognitive-behavioural treatment for eating disorders. The idea is that information about eating disorders and their health risks facilitates recovery and allows patients to buy in to treatment."
89466884|NCT03643289||Cohort A|Patients with stage 4 melanoma due to commence immunotherapy. Patients should be naïve to immunotherapy.
89466885|NCT03643289||Cohort B|Patients with stage 3 melanoma who are naïve to immunotherapy
89466886|NCT03644537|Other|heavy force 100gm|heavy intrusive force is to be applied on a first premolar on one side
89466887|NCT03644537|Other|medium force 25 gm|medium intrusive force is to be applied on a first premolar on one side
88946400|NCT01907568||Patients with Posttraumatic Stress Disorder|With and without hallucinations
89466888|NCT03644537|Other|light force 10 gm|light intrusive force is to be applied on a first premolar on one side
89466889|NCT03641495|Experimental|Pain education plus exercise therapy (PE + ET)|"Pain education according to the book Explain Pain written by Lorimer Moseley and David Butler~Exercise therapy based primarily in aerobic exercise according clinical guidelines last recommendations."
89466890|NCT03641495|Active Comparator|Exercise therapy (ET)|Exercise therapy based primarily in aerobic exercise according clinical guidelines last recommendations.
89466891|NCT03643055||MTC 18F-fluorocholine PET/CT|Patients with medullary thyroid cancer imaged using 18F-fluorocholine PET/CT.
89466892|NCT03641417|Experimental|GLWL-01|Oral administration of GLWL-01 300mg BD for 10 days
89466893|NCT03641417|Placebo Comparator|Placebo|Identical oral capsules with no active ingredient, administered BD for 10 days
89466894|NCT01344629|Experimental|Telmisartan80mg/Amlodipin5mg FDC|single-dose, four-period replicated crossover design
89466895|NCT01344629|Experimental|Telmisartan80mgtab + Amlodipin5mg tab|single-dose, four-period replicated crossover design
89466896|NCT01092117|Other|Ovation™ Abdominal Stent Graft System|Implant of Ovation™ Abdominal Stent Graft System
89466897|NCT03642977||Allogeneic HSCT recipients|"Adult patients receiving allogeneic hematopoietic stem cell transplant (HSCT) at University Hospitals of Geneva and who are enrolled in the Cohort of infectious disease in hematopoietic stem cell transplant patients."
88946401|NCT01907568||Patients with delirium|With and without hallucinations
88946402|NCT01907568||Healthy participants|With and without hallucinations
88946403|NCT01907568||Patients with mood disorder|With and without hallucinations
88946404|NCT01907581|Other|Patients admitted to an ICU|
89466898|NCT03642899||Patients with anterior ischaemic optic neuropathy|estimation of best visual acuity, fondus, measurement of retinal nervous layer thickness, ganglionar cells layer thickness, and a macular and papillar OCT angiography during a consultation
89466899|NCT03642899||control group. Normal eyes|estimation of best visual acuity, fondus, measurement of retinal nervous layer thickness, ganglionar cells layer thickness, and a macular and papillar OCT angiography during a consultation
89466900|NCT03641261|Experimental|Therapeutic Patient Education program|All included patients will follow a Therapeutic Patient Education program dedicated to the hereditary ichthyosis and using a web application, WebIchtyose
89466901|NCT03413943|Experimental|explicit gaze training|This is an arm of the second phase of the study utilizing gaze training in two different teaching techniques (explicit vs implicit).
89466902|NCT03413943|Experimental|implicit gaze training|This is an arm of the second phase of the study utilizing gaze training in two different teaching techniques (explicit vs implicit).
89466903|NCT03413943|Sham Comparator|sham gaze training|This is an arm of the second phase of the study utilizing gaze training in two different teaching techniques (explicit vs implicit).
89466904|NCT03621293|Active Comparator|Liberal Oxygenation (LO) group|"A modulation of inspired fraction of oxygen will be performed with an objective of PaO2 between 90 to 105 mmHg that will be checked on arterial blood gases (ABG). Between these measurements, SpO2 will be kept more or equal to 96 percent. Alarms will be set at 95 percent for SpO2.~Intervention: Drug: Modulation of Inspired Fraction of Oxygen (FiO2)"
89466905|NCT03621293|Experimental|Conservative Oxygenation (CO) group|"A modulation of inspired fraction of oxygen will be performed with an objective of PaO2 between 55 to 70 mmHg that will be checked on arterial blood gases. Between these measurements, SpO2 will be kept between 88 and 92 percent. Alarms will be set between 87 and 93 percent for SpO2.~Intervention: Drug: Modulation of Inspired Fraction of Oxygen (FiO2)"
89466906|NCT04835727|Experimental|Semi-vegetarian diet|All patients in this study will be advised by an experienced nutritionist to intake high fiber diets with a low intake of red meat and processed food.
89466907|NCT03642743|Experimental|Two and six week follow up|Patients will be assigned to routine two and six week postoperative follow up appointments
89466908|NCT03642743|Experimental|Six week follow up only|Patients will be assigned to a single six week postoperative follow up appointment
89466909|NCT03419169|Experimental|Light load BFR resistance training|This arm of the clinical trial will involve eight weeks of twice weekly light load resistance training with BFR. Patients in this arm will complete four sets (30, 15, 15 and 15 repetitions, respectively) of unilateral leg press exercise at 30% of predicted one repetition maximum. BFR will be applied at 80% of total limb arterial occlusive pressure. Both legs will be trained, with the affected limb trained first and the unaffected limb matched for volume at a relative percentage of one repetition maximum. Both legs will be trained with BFR.
89466910|NCT03419169|Active Comparator|Heavy load resistance training|This arm of the clinical trial will involve eight weeks of twice weekly heavy load resistance training. Patients in this arm will complete three sets of ten repetitions of unilateral leg press exercise at 70% of predicted one repetition maximum. Both legs will be trained, with the affected limb trained first and the unaffected limb matched for volume at a relative percentage of one repetition maximum.
89466911|NCT03419091|Active Comparator|Reusable Ureteroscope|Standard ureteroscope.
89466912|NCT03419091|Experimental|single-use flexible digital ureteroscope (LithoVue)|Disposable ureteroscope being tested.
89466913|NCT03413865|Experimental|OTN virtual clinic|Pharmacist and nurse led OTN based remote teleconference based clinic (OTN) The OTN clinic will be conducted by providing the patient with a link via email which will allow the patient to access OTN teleconferencing and meet virtually with a pharmacist and nurse during a previously scheduled appointment. Virtual clinic appointments will be 30 minutes long and will consist of a patient assessment and open ended questions about the patient health status using a modified version of the validated MOATT (MASCC Oral Agent Teaching Tool) created by the Multidisciplinary Association of Supportive Care in Cancer.
89466914|NCT03413865|No Intervention|In person Visits|Patients are followed in person at the cancer clinic based on standard of care guidelines
89466915|NCT03419013|Experimental|Test of new adhesive strip|A new adhesive strip has been developed and will be tested in this investigation
89466916|NCT05229419||acute pediatric poisoning cases|All cases of acute pediatric poisoning of both sexes, in age group less than or equals to 18 years old will presenting to Assiut University Hospital with acute poisoning whose their adverse effects occurring following administration of single dose of a substance or multiple doses exposure within 24 hours.
89466917|NCT03641105||lung adenocarcinoma|patients with lung adenocarcinoma
89466918|NCT03413709|Active Comparator|Treatment Group (n=350)|The sample for the treatment group for the impact evaluation will only include fathers who are receiving the full 240 hour Family Formation Program (and not the abbreviated 80 hour program). The treatment group will receive FSC's Family Formation Program, which is a six week, 240 hour program implementing a set of curricula focusing on responsible parenting, healthy relationships,and economic stability and mobility. In addition, participants will receive case management and a variety of employment, legal and support services for up to one year following the completion of the curriculum.
88946405|NCT01907594|Active Comparator|D-cycloserine|The investigators will randomize participants to either DCS 250 mg or placebo, administered daily for four days.
88946406|NCT01907594|Placebo Comparator|Gelatin Capsule|The investigators will randomize participants to either DCS 250 mg or placebo, administered daily for four days.
88946407|NCT01907620|Other|Normal pregnancy|women pregnant
89018401|NCT03918642|Experimental|Emotional Awareness and Expression Therapy|Seeks to reduce physical (e.g., pain) and emotional (e.g., depression, anxiety) symptoms by helping individuals become aware of their emotions, express them, and resolve emotional conflicts. It will use techniques such as writing about stress, role playing how to handle difficult relationships, recognizing and expressing anger and other feelings, and being more open with others.
89018402|NCT03918642|Active Comparator|Cognitive Behavior Therapy|Seeks to help individuals function better and improve symptoms by teaching various cognitive and behavioral skills to manage symptoms. It will use techniques such as relaxation training, engaging in pleasant activities, pacing yourself, and changing unhelpful ways of thinking.
89018403|NCT03904251|Experimental|Treatment (CPX-351, gemtuzumab ozogamicin)|"INDUCTION: Patients receive liposome-encapsulated daunorubicin 44mg/m2 - cytarabine 100mg/m2 IV over 90 minutes on days 1, 3, and 5, and gemtuzumab ozogamicin 3 mg/m2 (max 4.5 mg) IV over 120 minutes on day 7, or days 4 and 7, or days 1, 4, and 7 in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Patients who achieve CR/CRi receive consolidation therapy at the discretion of the treating physician and/or proceed to allogeneic HSCT."
89466919|NCT03413709|No Intervention|Comparison Group (n=350)|The sample comparison group will receive only the abbreviated 80 hour program. Which consist of economic stability and mobility only. These participants will receive employment case management and legal services for up to one year following the completion of the curriculum.
89466920|NCT03413631|Experimental|Prenatal mentalization intervention|The intervention group participants were offered three mentalization-focused 4D interactive ultrasounds at 24, 30 and 34 gestational weeks and a mentalization-focused week-by-week pregnancy diary combined with three prenatal sessions and option for one session after delivery in addition to obstetric care as usual (see Prenatal obstetric treatment as usual).
89466921|NCT03413631|Active Comparator|Prenatal obstetric treatment as usual|The control group received obstetric care as usual in a tertiary setting. The comprehensive treatment as usual was conducted at the hospital antenatal outpatient clinic, including regular obstetric ultrasounds. The multidisciplinary treatment team, consisting of an obstetrician, a midwife, a social worker and a psychiatric nurse, assess and support health and psychosocial situation of the pregnant woman. The pregnant woman was referred to addiction and psychiatric treatment when needed.
89466922|NCT04448769|Other|Anti-SARS-CoV-2 IgT seropositivity|Analysis of the serology result: The ELISA method allows semi-quantitative detection of total IgT antibodies. A positive sample will be defined by a ratio ≥ 1.0.
89466923|NCT03642353|Experimental|G1: Triclosan/health children|Children from health parents will use the triclosan toothpaste for 45 days.
89466924|NCT03642353|Placebo Comparator|G2: Placebo/health children|Children from health parents will use the placebo toothpaste for 45 days.
89466925|NCT03642353|Experimental|G3: Triclosan/GAP children|Children from GAP parents will use the triclosan toothpaste for 45 days.
89466926|NCT03642353|Placebo Comparator|G4: Placebo/GAP children|Children from GAP parents will use the placebo toothpaste for 45 days.
89018404|NCT03901339|Experimental|Sacituzumab Govitecan-hziy|Participants will receive sacituzumab govitecan-hziy 10 mg/kg via intravenous (IV) injection administered on Day 1 and Day 8 of a 21-day cycle.
89018405|NCT03901339|Active Comparator|Treatment of Physician's Choice (TPC)|"Participants will receive TPC determined prior to randomization from one of the following single-agent treatment:~Dosing per National Comprehensive Cancer Network (NCCN) guidelines (with dose modifications for if toxic)~Eribulin: 1.4 mg/m^2 for North American sites, 1.23 mg/m^2 for European sites) via IV on Days 1 and 8 of a 21-day cycle~Capecitabine: 1000-1250 mg/m^2 orally twice daily for 2 weeks followed by a 1-week rest period given as a 21-day cycle~Gemcitabine: 800-1200 mg/m^2 via IV on Days 1, 8, and 15 of each 28-day cycle or per institution~Vinorelbine: 25 mg/m^2 via IV on Day 1 weekly cycle per institution"
89018406|NCT03900923|Experimental|98% pure CBD|98% pure CBD. The CBD will be 100mg/mL oral solution provided by Greenwich Biosciences, Inc.
89466927|NCT03413553|Active Comparator|control group|patient will receive immediate implant alone.
89466928|NCT03413553|Other|intervention group|"immediate implant combined with connective tissue graft and platelet rich fibrin .~."
89466929|NCT03642275|Experimental|iCardia4HF|Participants will be using a heart failure mobile app, wearable activity tracking device, Bluetooth-enabled blood pressure monitor and weight scale for self-monitoring, and receive tailored text-messages about self-care.
89466930|NCT03642275|No Intervention|Control Group|Participants assigned to the usual care group will receive standard medical care, which includes nurse-led patient education about HF self-care before discharge, and follow-up visits at the UI Health, outpatient Heart Failure program.
89466931|NCT03424863|Experimental|Aortic stent graft patients|Patients who have received an aortic stent graft who will perform one session of moderate intensity muscle strengthening during which blood pressure will be measured.
89466932|NCT03424863|Experimental|Healthy volunteers|Healthy volunteers in general good health with no history of heart disease who will perform one session of moderate intensity muscle strengthening during which blood pressure will be measured.
89466933|NCT05284175|Experimental|Orelabrutinib, orally, 50 mg QD|Orelabrutinib, orally, 50 mg QD
89466934|NCT03642197|Experimental|Support Figure Attended (SFA)|Using simple randomization patients (female or male) not in romantic relationships will be randomized into support figure attended (SFA) and SFA-TU groups. Patients in all arms will receive routine care, which includes four pre-surgery classes and routine clinical visits. Support figures in the SFA arm will be requested to attend the four pre-surgery classes with the patient and the three clinical visits. The intervention is support figure attendance. Assessments will be completed by patients and support figures at the first pre-surgery class (T1) and routine clinical visits: the pre-surgery appointment (T2), two-weeks post-surgery appointment (T3), and at the two-months post-surgery appointment (T4).
89466935|NCT03642197|No Intervention|SFA - Treatment as Usual (SFA-TAU)|Using simple randomization patients (female or male) not in romantic relationships will be randomized into support figure attended (SFA) and SFA-TU groups. Patients in all arms will receive routine care, which includes four pre-surgery classes and routine clinical visits. Support figures in the SFA-TU arm will not be requested to attend the four pre-surgery classes with the patient and the three clinical visits- patients will attend alone. Assessments will be completed by patients and support figures at the first pre-surgery class (T1) and routine clinical visits: the pre-surgery appointment (T2), two-weeks post-surgery appointment (T3), and at the two-months post-surgery appointment (T4).
88946408|NCT01907620|Other|pregnancy complicated by pre-eclampsia|women with pregnancy complicated by pre-eclampsia
89466936|NCT03642197|Experimental|Partner Attended (PA)|Using simple randomization female patients in cohabiting romantic relationships for at least 6 months will be randomized into partner attended (PA) and PA-TU groups. Patients in all arms will receive routine care, which includes four pre-surgery classes and routine clinical visits. Partners in the PA arm will be requested to attend the four pre-surgery classes with the patient and the three clinical visits. The intervention is partner attendance. Assessments will be completed by patients and partners at the first pre-surgery class (T1) and routine clinical visits: the pre-surgery appointment (T2), two-weeks post-surgery appointment (T3), and at the two-months post-surgery appointment (T4).
88946409|NCT01907633||Domperidone/ a proton pump inhibitor/metoclopramide users|Study patients had at least one prescription for domperidone, a proton pump inhibitor, or metoclopramide. Proton pump inhibitors observed in this study are: omeprazole, lansoprazole, esomeprazole, rabeprazole, and pantoprazole.
88946410|NCT01907646|Experimental|Bladder training group|The patients of this group were submitted to passive vesical gymnastic during the second and third postoperative days, throughout the closure of the catheter for 3 h and open it for 15 min all day long.
88946411|NCT01907646|Experimental|No bladder training group|The patients of this group were not submitted to passive vesical gymnastic during the second and third postoperative days
88946412|NCT01907659|No Intervention|Standard of care|Standard of care for respiratory infections
88946413|NCT01907659|Experimental|Release of test results|Health care providers will receive viral PCR and PCT test results along with an algorithm recommending antibiotic treatment based on PCT level.
88946414|NCT01907672|Experimental|Rapid Diagnostic Test|Rapid Diagnostic Test for malaria to direct antimalarial dispensing decisions in Chemical Shops
88946415|NCT01907672|No Intervention|No RDT|Chemical sellers dispense antimalarials as per their own decisions without the benefit of test results
88946416|NCT01907685|Experimental|AVE8062 / Docetaxel|AVE8062 30-minute IV, 11.5 to 42 mg/m2, followed by Docetaxel, 1-hour IV, 75 and 100 mg/m2 in 3-week cycles until disease progression or unacceptable toxicity or study discontinuation criteria
88946417|NCT01907698||Vaginal coitus group|Pregnant women assigned to have vaginal coitus at least twice a week
88946418|NCT01907698||Control group|Pregnant women assigned to have no vaginal intercourse
88946419|NCT01907711|Sham Comparator|Sham Acupuncture.|That through the center of the guide tube is inserted blunt rod, producing the sensation of a prick in each of the eight points that are not acupuncture points. No intervention is a completely inert as it involves some type of peripheral stimulus, but the technique is closer to a placebo and offers interesting option from a methodologic al point of view showing and ability to mimic real acupuncture The points are not used acupuncture points but are fictional points. The patient should remáis lying prone during the 20 minutes of the session, so the placebo technique remains hidden. Every five minutes the acupuncturist will repeat the action in the corresponding eigh points.
88946420|NCT01907711|Active Comparator|True acupuncture|The AV is an energy balance treatment with the aim of restoring health and well-being of the patient. Since each patient may have moré than three diagnoses of Traditional Chinese Medicine, will undertake a Major effort of synthesis of acupuncture points for treatment in a session, use the AV 8 - 12 needles, are held in place for 20 minutes with bidirectional rotation of the sleeve needle for one minute every five minutes (a total of four rotations for session). And in the AS 8 tube rod guides with blunt tip for 20 minutes. The same time be devoted to the patients in each treatment group similar, the time requested for the period of pre and post-treatment will be identical in all cases.
88946421|NCT01907724|Experimental|IDX719 + RTV|Participants take IDX719 150 mg once daily (QD) + ritonavir 30 mg QD on Days 1-7, and then take IDX719 150 mg QD + simeprevir 75 mg QD + TMC647055 450 mg QD + RTV 30 mg QD on Days 8-14.
88946422|NCT01907724|Experimental|Simeprevir/TMC647055 + RTV|Participants take simeprevir 75 mg QD + TMC647055 450 mg QD + RTV 30 mg QD on Days 1-7, and then take IDX719 150 mg QD + simeprevir 75 mg QD + TMC647055 450 mg QD + RTV 30 mg QD on Days 8-14.
89466937|NCT03642197|No Intervention|PA - Treatment as Usual (PA-TAU)|Using simple randomization female patients in cohabiting romantic relationships for at least 6 months will be randomized into partner attended (PA) and PA-TU groups. Patients in all arms will receive routine care, which includes four pre-surgery classes and routine clinical visits. Partners in the PA-TU arm will not be requested to attend the four pre-surgery classes with the patient and the three clinical visits- patients will attend alone. Assessments will be completed by patients and partners at the first pre-surgery class (T1) and routine clinical visits: the pre-surgery appointment (T2), two-weeks post-surgery appointment (T3), and at the two-months post-surgery appointment (T4).
89466938|NCT03424707|Experimental|combination|
89466939|NCT03424707|Active Comparator|single|
89466940|NCT03424707|Placebo Comparator|placebo|
89466941|NCT05174351|Experimental|HFpEF patients|HFpEF patient who are currently taking beta blockers
89466942|NCT03418935|Experimental|Remaxol 400 ml|Group I: treatment with Remaxol 400 ml IV + Ringer solution 400 ml IV for 7 days. Drug: Remaxol (succinate + methionine + inosine + nicotinamide)
89466943|NCT03418935|Experimental|Remaxol 800 ml|Group II: treatment with Remaxol 800 ml IV for 7 days. Drug: Remaxol (succinate + methionine + inosine + nicotinamide)
89466944|NCT03418935|Placebo Comparator|Control|Group III: Ringer's solution 800 ml IV for 7 days. Drug: Ringer's solution
89466945|NCT03641963|Experimental|Stroke patients with ICP measurement|All patients with the possibility to evolve a malignant MCA infarct according to the initial assessment, will be included in our study, to measure ICP non-invasive. The ICP will be measured non-invasive with the Vittamed 205 Non-invasive intracranial pressure (ICP) meter.
89466946|NCT03641885|Experimental|mother and adolescents|an intervention group in which mothers and adolescents receive the intervention and questionnaires via Telegram social media
89466947|NCT03641885|Experimental|adolescents|an intervention group in which adolescents receive the intervention and questionnaires via Telegram social media
89466948|NCT03641885|Active Comparator|active control|mothers and adolescents are in active control group and only receive the questionnaires
89466949|NCT00530049||questionnaires|"The purpose of this study is to develop a PRO instrument that measures quality of life as relates to facial appearance after head and neck cancer reconstruction surgery and after dermatologic surgery for patients with cutaneous skin cancers. . To develop this measure, we will adhere to the following sequential steps recommended by quality of life experts. Thus, the study will have three parts:~Questionnaire content generation and development of preliminary instrument~Field-testing the preliminary questionnaire with item reduction and development of final questionnaire~Psychometric evaluation of final questionnaire"
89466950|NCT03413319|Experimental|ABBV-8E12|ABBV-8E12 administered by intravenous (IV) infusion.
89466951|NCT03644303|Experimental|SBRT + ADT|Enzalutamide OR Abiraterone at licensed doses in combination with stereotactic radiotherapy: 30 Gray in 5 fractions
89466952|NCT03418623|Experimental|GET73|GET73 is administered at the dose of 300 mg t.i.d. per day, with a minimum gap of 4 hours between administrations and a maximum gap of 9 hours. Each subject ingests a total of 5 capsules of GET73: 3 capsules of GET73 on the first day of the related phase, according to randomization, and 2 capsules on the second day of each phase.
89466953|NCT03418623|Placebo Comparator|Placebo|Placebo is administered t.i.d. per day, with a minimum gap of 4 hours between administrations and a maximum gap of 9 hours. Each subject ingests a total of 5 capsules of Placebo: 3 capsules of Placebo on the first day of the related phase, according to randomization, and 2 capsules on the second day.
89466954|NCT05188937|Experimental|validity and reliability of Dual-task Questionnaire|"This study was conducted as test-retest design and the psychometric properties of Dual-task Questionnaire were examined in patients with MS."
89466955|NCT02365922||Patients with FTLD or family members|Participants with FTLD syndrome diagnoses and/or strong family histories of FTLD.
89466956|NCT03424629|Experimental|Low-Dose UC-MSCs|Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) 1 x 10^6 cells/kg in normal saline injection
89466957|NCT03424629|Experimental|High-Dose UC-MSCs|Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) 3 x 10^6 cells/kg in normal saline injection
89466958|NCT03424629|Active Comparator|Methotrexate|5-25mg Methotrexate orally
89466959|NCT03641807|Experimental|Acupuncture|
89466960|NCT03641807|Sham Comparator|Sham acupuncture|
89466961|NCT04618029|Experimental|Treatment Group|"Home Assessment and Modification A two-component individualized home hazards management program will be provided for each participant in the intervention group according to the results of the HOME FAST. Basic home safety strategies and basic modifications are developed and will be prescribed for this study according to the HOME FAST assessment (weeks et al. 2010)~Education Education on optimization of functional performance in the home will be provided via pamphlets on fall prevention, including energy conservation techniques (Chumbler et al., 2010), ergonomics (Edwards et al., 2019) and task simplification techniques (Wesson et al., 2013) will be provided. These techniques will also be provided for participants' caregivers."
89466962|NCT04618029|No Intervention|Controlled Group|1. Standard Care The standard care defined for this study is any care that are provided from the respective hospital. This will include common therapies and interventions for stroke rehabilitation in general.
88946423|NCT01907750|Active Comparator|Transanastomotic tube|use of transanastomotic tube.
88946424|NCT01907750|Active Comparator|Transcystic tube|use of transcystic tube to drain bile duct
88946425|NCT01907763|Experimental|SOTB07 200mg|One tablet of SOTB07 200mg and One tablet of SOTB 400mg Placebo are administered twice a day.
88946426|NCT01907763|Experimental|SOTB07 400mg|One tablet of SOTB07 400mg and One tablet of SOTB 200mg Placebo are administered twice a day.
88946427|NCT01907763|Placebo Comparator|Placebo|One tablet of SOTB 200mg Placebo and One tablet of SOTB 400mg Placebo are administered twice a day.
88946428|NCT01907776|Experimental|ME1100|ME1100 inhalation solution (arbekacin for oral inhalation at 150 mg/mL), 0.6, 2.0, 3.0, 4.0, 6.0, or 9.0mL, Single Dose
88946429|NCT01907776|Placebo Comparator|Placebo|ME1100 placebo inhalation solution
88946430|NCT01907802|Experimental|Treatment (dabrafenib)|Patients receive dabrafenib PO BID on days 1-28 (QD on day 1 of course 1). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89018407|NCT03896750|Active Comparator|Part A Group 1A|6 healthy participants with normal estimated Glomerular Filtration Rate (eGFR > / = 90 mL/min) matched to Group 2 by race, gender, age (+/- 10 years, but between 18 to 70 years of age) and weight at dosing (+/- 20% of weight) will receive a single oral dose of 200 mg pretomanid
89018408|NCT03896750|Experimental|Part A Group 2|6 participants with Severe renal impairment; Stage 4, Modification of Diet in Renal Disease (MDRD) (eGFR 15-29 mL/min) and End Stage Renal Disease (ESRD) not on dialysis: Stage 5, Modification of Diet in Renal Disease (MDRD) with estimated Glomerular Filtration Rate (eGFR < 15 mL/min) matched to Group 1A will receive a single oral dose of 200 mg pretomanid
89018409|NCT03896750|Active Comparator|Part B Group 1B|6 healthy participants with normal eGFR of > / = 90 mL/min matched to Group 3 by race, gender, age (+/- 10 years, but between 18 to 70 years of age) and weight at dosing (+/- 20% of weight ) will receive a single oral dose of 200 mg pretomanid after the PK and safety of subjects enrolled in Part A have been reviewed
89018410|NCT03896750|Active Comparator|Part B Group 1C|6 healthy participants with normal eGFR > / = 90 mL/min matched to Group 4 by race, gender, age (+/- 10 years, but between 18 to 70 years of age) and weight at dosing (+/- 20% of weight) will receive a single oral dose of 200 mg pretomanid after the PK and safety of subjects enrolled in Part A have been reviewed
89018411|NCT03896750|Experimental|Part B Group 3|6 participants with mild renal impairment: Stage 2, MDRD (eGFR 60-89 mL/min) matched to Group 1B will receive a single oral dose of 200 mg pretomanid after the PK and safety of subjects enrolled in Part A have been reviewed
89018412|NCT03896750|Experimental|Part B Group 4|6 participants with moderate renal impairment: Stage 3, MDRD (eGFR = 30-59 mL/min) matched to Group 1C will receive a single oral dose of 200 mg pretomanid after the PK and safety of subjects enrolled in Part A have been reviewed
89018413|NCT03895879|Experimental|Intervention|Tocilizumab administered every 2 weeks
89018414|NCT03895879|Active Comparator|Control|Tocilizumab administered every week
89018415|NCT03895879|Active Comparator|Standard dose (screening < 15 mg/L)|Tocilizumab administered every week
89466963|NCT05283707|Experimental|Intervention Group|"Continuation of standard post-cesarean section care in the clinic.~Implementation of Paula Method Exercises Training Plan 6-8 hours after cesarean section (Paula Method Exercises Practice Card PEUK, Paula Method Exercises Video, Paula Method Exercises Flipcard)~Paula Method Exercises; by the researcher, after cesarean section 0.day 6-8 hours, 1st day morning, 2nd day morning.~Paula Method Exercises; It was applied by the researcher to the patient on the 0th day 6-8 hours, the 1st day in the morning, and the 2nd day in the morning after the cesarean section.~6-8 hours on day 0, morning on day 1, morning on day 2 after cesarean section Evaluation and recording of bowel sounds before and after Paula Method Exercises, application of McGill Pain Scale Short Form,~Evaluation of first flatulence after cesarean section and first defecation"
89018416|NCT03885713|Active Comparator|Patients with treatment|Infliximab (Infusion 5mg/kg milligram(s)/Kilogram-Intravenous use) per clinical practice, or adalimumab (Subcutaneus 40 mg milligram(s)) per clinical practice, or golimumab (subcutaneus 50 mg milligram(s)) per clinical practice, or vedolizumab (infusion 300 mg milligram(s)) per clinical practice or ustekinumab (subcutaneous 90 mg milligram(s)) per clinical practice or tofacitinib (oral 5mg bid oral) per clinical practice
89018417|NCT03885713|No Intervention|healthy control|Patients without treatment
89466964|NCT05283707|No Intervention|Control Group|"Continuation of standard post-cesarean section care in the clinic.~6-8 hours on day 0, morning on day 1, morning on day 2 after cesarean section Evaluation and recording of bowel sounds, application of McGill Pain Scale Short Form,~Evaluation of first flatulence after cesarean section and first degassing"
89466965|NCT02358122|Active Comparator|Refined wheat|Refined wheat grain, a variety of cereal foods providing no wholegrain
89466966|NCT02358122|Experimental|Wholegrain wheat|Wholegrain wheat grain, a variety of cereal foods providing >100g wheat wholegrain/day
89466967|NCT02358122|Experimental|Wholegrain rye|Wholegrain rye grain, a variety of cereal foods providing >100g rye wholegrain/day
89466968|NCT03424551|Experimental|Vibrator|Local or Whole body vibration was applied at six different frequencies to Healthy control and spastic spinal cord injury. For local vibration, vibration frequencies were 50, 85, 140, 185, 235 and 265 Hz . For whole body vibration, vibration frequencies were 35, 37, 39, 41, 43 and 45 Hz
89018418|NCT03869892|Experimental|S95005 + Bevacizumab|
88946431|NCT01907841|Experimental|Ischemic Preconditioning|IPC (4 x 5 minute cycles @ 220 mmHg) with 5 min reperfusion between trials.
88946432|NCT01907841|Placebo Comparator|Ischemic Preconditioning Placebo|Placebo (4 x 5 minute cycles @ 20mmHg) with 5 minutes between each cycle
88946433|NCT01907867|Experimental|Cohort 1|"Day 1: Finafloxacin 800 mg will be administered as an oral dose once in the morning (first dose). Subjects will have plasma PK samples drawn at specified times around the first dose. Bronchoscopic microsampling will be performed to obtain bronchial ELF samples in triplicate at 3 hours after the oral dose.~Day 2: Finafloxacin 800 mg will be administered as an oral dose once in the morning (second dose).~Day 3: Finafloxacin 800 mg will be administered as an oral dose once in the morning (third dose). Subjects will have plasma PK samples drawn at specified times around the third dose. Bronchoscopic microsampling will be performed to obtain bronchial ELF samples in triplicate at 6 hours after the oral dose, followed immediately by BAL to obtain alveolar ELF samples."
89018419|NCT03869892|Active Comparator|Capecitabine + Bevacizumab|
89018420|NCT03859973|Experimental|BI 425809 10 mg + Computerized Cognitive Training|
89018421|NCT03859973|Placebo Comparator|Placebo + Computerized Cognitive Training|
89018422|NCT03814876|Experimental|SCI intervention|Spinal cord injury intervention group
89018423|NCT03814876|Active Comparator|SCI control|Spinal cord injury control
89018424|NCT03814876|Experimental|TBI intervention|Traumatic brain injury intervention group
89018425|NCT03814876|Active Comparator|TBI control|Traumatic brain injury control group
89018426|NCT03812666||Severe stroke|Patients with severe (defined as NIHSS score of > 10) acute stroke, either ischemic or hemorrhagic. (n= 150)
89466969|NCT03641729|Other|Intervention|Patients were eligible if they were aged 18 years or older, referred for HSCT and admitted to the Bone Marrow Transplant Unit (BMTU). Patients were screened in the BMTU admission and recruited to the study after avaliation in the first-day internation.
89466970|NCT02366000|Experimental|Brief Parental Training Intervention|Participants will have to attend two 3-hour Brief Parental Training Intervention Programme, with three weeks apart. There will also be two telephone follow-up sessions to reinforce learnt strategies and skills for home practice between workshops.
89466971|NCT02366000|Other|Wait-list Group|Participants will receive the same Brief Parental Training Intervention Programme as the intervention group. However, they will wait until the questionnaires have been completed by the intervention group for the second time (i.e. immediately after intervention) before they receive their programme.
89466972|NCT03641573|Experimental|[14C] ASN002|[14C] ASN002
89466973|NCT04448379|Experimental|Dose Escalation Cohort|"Two dose levels of JMT101 combined with afatinib or osimertinib will be tested according to the 3 + 3 dose-escalation design.~The dose-limiting toxicity (DLT) will be assessed from the first administration to the end of the first cycle (28 days)."
89466974|NCT04448379|Experimental|Dose Expansion Cohort|Once the effective dose has been determined, an expansion cohort will be opened to evaluate the efficacy and safety of the selected dose.
89466975|NCT03621215|Experimental|Tart cherry juice|30 mL tart cherry concentrate (CherryActive, UK) diluted with 220 mL of water once per day (250 mL total volume per day). According to available manufacturers data, this is equivalent to consuming 90-100 fresh cherries per day.
89466976|NCT03621215|Placebo Comparator|Fruit-flavoured placebo drink|"Matched for sensory characteristics and energy (with the addition of glucose).~once per day (250 mL total volume per day)"
89466977|NCT03640871|Experimental|URGO AWC_019 dressing (AWC=Advanced Wound Care)|URGO AWC_019 dressing (AWC=Advanced Wound Care)
89466978|NCT04448223|Experimental|CKD-351|CKD-351
88946434|NCT01907867|Experimental|Cohort 2|"Day 1: Finafloxacin 800 mg will be administered as an oral dose once in the morning (first dose). Subjects will have plasma PK samples drawn at specified times around the first dose. Bronchoscopic microsampling will be performed to obtain bronchial ELF samples in triplicate at 8 hours after the oral dose.~Day 2: Finafloxacin 800 mg will be administered as an oral dose once in the morning (second dose).~Day 3: Finafloxacin 800 mg will be administered as an oral dose once in the morning (third dose). Subjects will have plasma PK samples drawn at specified times around the third dose.~Bronchoscopic microsampling will be performed to obtain bronchial ELF samples in triplicate at 12 hours after the oral dose, followed immediately by BAL to obtain alveolar ELF samples."
88946435|NCT01907867|Experimental|Cohort 3|"Day 1: Finafloxacin 800 mg will be administered as an oral dose once in the morning (first dose). Subjects will have plasma PK samples drawn at specified times around the first dose. Bronchoscopic microsampling will be performed to obtain bronchial ELF samples in triplicate at 12 hours after the oral dose.~Day 2: Finafloxacin 800 mg will be administered as an oral dose once in the morning (second dose).~Day 3: Finafloxacin 800 mg will be administered as an oral dose once in the morning (third dose). Subjects will have plasma PK samples drawn at specified times around the third dose.~Bronchoscopic microsampling will be performed to obtain bronchial ELF samples in triplicate at 24 hours after the oral dose, followed immediately by BAL to obtain alveolar ELF samples."
88946436|NCT01907880|Active Comparator|Pamidronate and placebo|Patients will receive two infusions simultaneously, at each study visit, one of Pamidronate and another of the placebo. After completing 3 cycles of study treatment, patients will resume their monthly intravenous pamidronate infusions as per current standard of care.
88946437|NCT01907880|Active Comparator|Zoledronic acid and placebo|Patients will receive two infusions simultaneously, at each study visit, one of Zoledronic acid and another of the placebo. After completing 3 cycles of study treatment, patients will resume their monthly intravenous pamidronate infusions as per current standard of care.
89466979|NCT04448223|Active Comparator|Latanoprost+Dorzolamide|Latanoprost(50ul/ml) Dorzolmamide(20mg/ml)
89466980|NCT03644225|Other|Healthy Control|Healthy controls, who signed an informed consent, age ≥18 years old will be age and sex matched to the SSc patients
89466981|NCT03644225|Other|Systemic sclerosis patients|"SSc patients who signed an Informed consent~Age ≥18 years old~Diagnosis of systemic sclerosis according to the ACR/EULAR 2013 criteria~Skin thickening diagnosed by clinical expert"
89466982|NCT03644147|Experimental|Treatment|Patients in this group will receive 1 gram of acetaminophen intravenously after the end of surgery.
89466983|NCT03644147|No Intervention|Control|Patients in this group will receive 100 ml of normal saline intravenously after the end of surgery.
89466984|NCT01543256|Active Comparator|Metal stents|The WallFlex Biliary Fully Covered Stent System is being evaluated for treatment of benign biliary strictures secondary to chronic pancreatitis.
89466985|NCT01543256|Active Comparator|Plastic Stents|Plastic stents per Investigator preference are being evaluated for treatment of benign biliary strictures secondary to chronic pancreatitis.
89466986|NCT02743923|Active Comparator|carboplatin-paclitaxel- bevacizumab|carboplatin AUC 6, paclitaxel 200 mg/m2, bevacizumab 15 mg/kg all administered intravenously on day 1 every 3 weeks for 4-6 cycles, followed by bevacizumab maintenance every 3 weeks until progression
89466987|NCT02743923|Active Comparator|cisplatin-pemetrexed|pemetrexed 500 mg/m2 administered intravenously on day 1 and cisplatin 75 mg/m2 administered intravenously on day 1 every 3 weeks for 4-6 cycles, followed by maintenance pemetrexed every 3 weeks until progression.
89466988|NCT01065779||FOSAMAX PLUS or FOSAMAX PLUS D|Patients with Osteoporosis treated with FOSAMAX PLUS (70 mg/2800 IU) or FOSAMAX PLUS D (70 mg/5600 IU).
89466989|NCT03424395|Other|Personalized dietary and wellness program|An integrated personalized nutrition program which includes a combination of dietary and wellness advice/counseling on wellness and meals, or dietary and wellness advice/counseling alone, each for 10 weeks.
89466990|NCT02357966|Experimental|514G3|Phase I of the study will include a single dose of 514G3 at three different dose levels. Phase II utilizes a single dose of 514G3 at the highest dose level. Standard antibiotic therapies will be used in both phases.
89466991|NCT02357966|Placebo Comparator|Placebo|Both Phase I and II will include a single dose of placebo in addition to standard antibiotic therapies.
89466992|NCT03570359|Active Comparator|Interferon beta 1a|"Part 1- Interferon beta 1a once a day for 3 days via inhalation~Part 2 - Interferon beta 1a once a day for 14 days via inhalation"
89466993|NCT03570359|Placebo Comparator|Placebo|"Part 1- placebo once a day for 3 days via inhalation~Part 2 - placebo once a day for 14 days via inhalation"
89466994|NCT03424317|Active Comparator|Sodium intake reduction and exercise|education of sodium intake reduction and regular exercise
89466995|NCT03424317|Placebo Comparator|Exercise|education of regular exercise only
89466996|NCT01345838||Dysplasia|Patients with developmental dysplasia of the hip undergoing PAO
89466997|NCT03418467||tachycardiomyopathy|Sustained heart rate of over 100 bpm, exclusion of other causes of congestive heart failure including significant valvular disease and coronary artery stenosis over 50%, and partial or complete recovery of left ventricular function after restoration of sinus rhythm or rate control and characteristic histological findings.
88946438|NCT01907893|Experimental|Trauma Collaborative Care Plus Treatment as Usual|Three components: (1) Services provided through the Trauma Survivors Network (TSN) Program; (2) Provider training to reinforce referral to and use of TSN programs; and (3) Enhancement of collaborative care through the use of a TSN Coordinator (TSN-C).
89466998|NCT03418467||dilated cardiomyopathy|Patients with dilated cardiomyopathy according to the 2016 ESC (European Heart Association) Guidelines for the diagnosis and treatment of acute and chronic heart failure.
89466999|NCT02358200|Experimental|Treatment|BMN-673: Oral, every day, Days 1-21; Carboplatin: intravenous, every week, 750 μg/day; Paclitaxel: intravenous, every week, 0.75 x Maximum Tolerated Dose μg/day
89467000|NCT03418311|No Intervention|Control-Group|Control-group-women receive management as usual; i.e. expectant management with interventions only in terms of a tertiary prevention of PTB according to guidelines for premature rupture of membranes, premature labour or other pregnancy complications.
89467001|NCT03418311|Experimental|Cervical Pessary-Group|placement of the cervical pessary (non-invasive) at enrollment; removal of the cervical pessary (non-invasive) in a regular preventive examination at WoG 37.
89467002|NCT03112616||Left-brain damaged chronic patients|
88946439|NCT01907893|No Intervention|Treatment as Usual|Study patients treated at Control Sites will have access to all services typically available to patients treated at these centers.
89467003|NCT03112616||Right-brain damaged chronic patients|
88946440|NCT01907919||conventional group,RM-GIC|1. Group A: Five teeth were treated with traditional rotating instruments, the cavities were prepared with diamond drills by turbine, multiple-blade drills by headpiece for removing the decayed dentine and, after cleaning and control of bleeding with cotton pellets with saline solution,RM-GIC (3M ESPE, USA) light-hardening paste was placed gently on the exposed part of the pulp and cavity floor next final restoration with composite z350 flow able and p60 (3M ESPE, USA).
88946441|NCT01907919||Diode 808 nm laser-assisted group|"2. Group B : Five teeth cavities were prepared as the same with group one with traditional rotating instruments, hemostatic and cavities sterilization were achieved by a diode 808 nm (Picasso- AMD, USA) laser using following parameters:~Hemostatic: 1.5 W, CW, fiber diameter 400µm, in contact, 2s per 1mm, vertical and horizontal scanning movement on exposure site.~Cavity sterilization: 1W, CW, fiber diameter 400µm, in contact, 2mm per s, circular movement.~After hemostatic and cavity sterilization, RM-GIC (3M ESPE, USA) light-hardening paste was placed on the exposed part of the pulp and cavity floor next final restoration with composite z350 flow able and p60 (3M ESPE, USA)."
88946442|NCT01907932|Experimental|normal and various degrees splenomegaly|"VScan Ultrasound (GE Healthcare, USA) all subjects will be measured by 5 different medical residents~Each resident will complete questionaire:~Adequacy of image quality~What is best view obtained~Greatest Longitudinal Measure~Diagnosis~Diagnostic Certainty~Time to Complete exam"
88946443|NCT01907945|Experimental|Intervention|Participant households in this arm are eligible for participation in the social network-based water treatment education program (referred to as the Microclinic Water Program). Participant households who do not enroll in the Microclinic Water Program receive household-based education identical to that of the 'comparison' arm.
89467004|NCT03413085|Other|Group A|"Intervention name: multifocal soft contact lens/single vision soft contact lens~Left eye: multifocal soft contact lens Right eye: single vision soft contact lens"
89467005|NCT03413085|Other|Group B|"Intervention name: multifocal soft contact lens/single vision soft contact lens~Left eye: single vision soft contact lens Right eye: multifocal soft contact lens"
89467006|NCT03112772|Experimental|Group I|Participants who are receiving socket preservation using allograft (Puros® Allograft, Zimmer dental, Zimmer, USA) covered by membrane (size: 15x20mm) made of type I collagen fibers purified from bovine tendon (BioMend® Membrane, Zimmer dental, Zimmer, USA).
89467007|NCT03112772|Experimental|Group II|Participants who are receiving socket preservation cancellous particulate bovine bone xenograft (CopiOs® Cancellous Particulate, Zimmer dental, Zimmer, USA) covered by membrane (size: 15x20mm) made of type I collagen fibers purified from bovine tendon (BioMend® Membrane, 15x20mm, Zimmer dental, Zimmer, USA).
89467008|NCT03112772|No Intervention|Group III|No grafting materials will be inserted, so it serves as a negative control group.
89467009|NCT01065935|Active Comparator|ALN-RSV01|
89467010|NCT01065935|Placebo Comparator|Normal saline|
89467011|NCT02357888|Experimental|Sequence 1|Treatment group sequence: Test Product on Day 1 and Placebo on Day 2
89467012|NCT02357888|Experimental|Sequence 2|Treatment group sequence: Placebo on Day 1 and Test Product on Day 2
89467013|NCT03418233|Active Comparator|Active Group|"Patients randomized to the active treatment group: Transcoronary or trans-bypass graft administration of CardioCell consist 30 000 000 cells (suspended in 20 ml of 0.9% NaCl and 5% albumin) will be performed using a dedicated cell delivery catheter.~The cell delivery catheter is a typical coronary balloon catheter that is CE marked (1.2x10 mm balloon, RX system) modified to include cell delivery perforations in the balloon section of the catheter. The cell delivery catheter has been demonstrated not to affect cell viability or other cell properties."
89467014|NCT03418233|Placebo Comparator|Control Group|Patients randomized to the placebo group will receive Placebos consist 0.9% NaCl and 5% albumin injections (in the same volumes as CardioCell) via the coronary arter(ies)/bypass grafts. The CardioCell and placebo are distributed encoded, in an indistinguishable form.
89467015|NCT03112538|Active Comparator|Insulin pump|Medtronic Minimed Paradigm Veo Insulin Pump utilising rapid acting insulin Glulisine or Aspart
89467016|NCT03112538|Active Comparator|Multiple daily injections of insulin|Multiple daily injections consisting of a single basal insulin injection(Glargine) and 3 bolus insulin injections (rapid acting insulin Glulisine or Aspart) before each meal
89467017|NCT03644069|Experimental|Nexvax2|
89467018|NCT03644069|Placebo Comparator|Placebo|
89467019|NCT03418155|Experimental|Treatment of TongBi Capsule|
89467020|NCT03418155|Placebo Comparator|Treatment of TongBi Placebo|
89467021|NCT05283551|Experimental|Single arm|
89467022|NCT02357732|Experimental|Nivolumab and Dabrafenib Combination (doublets)|Level -1, Nivolumab 1mg/kg IV every 2 weeks (q2 weeks); Dabrafenib 100mg by mouth (PO) twice a day(BID) every day (QD); Level 1, Nivolumab 1mg/kg IV q2 weeks; Dabrafenib 150mg PO BID QD; Level 2, Nivolumab 3mg/kg IV q2 weeks; Dabrafenib 150mg PO BID QD;
89467023|NCT02357732|Experimental|Nivolumab and Trametinib Combination (doublets)|Level -1, Nivolumab 1mg/kg IV q2 weeks; Trametinib 1mg PO QD; Level 1, Nivolumab 1mg/kg IV q2 weeks; Trametinib 2mg PO QD; Level 2, Nivolumab 3mg/kg IV q2 weeks; Trametinib 2mg PO QD;
89467024|NCT02357732|Experimental|Nivolumab, Dabrafenib and Trametinib Combination (triplet)|Level -1, Nivolumab 1mg/kg IV q2 weeks; Dabrafenib 150mg PO BID; Trametinib 1mg PO QD; Level 1, Nivolumab 1mg/kg IV q2 weeks; Dabrafenib 150mg PO BID; Trametinib 2mg PO QD; Level 2, Nivolumab 3mg/kg IV q2 weeks; Dabrafenib 150mg PO BID; Trametinib 2mg PO QD;
89467025|NCT03424083||1 cohort|adult patients of both sexes (>18 and <80 years) with no previous diagnosis or follow up by a pulmonologist, send by a general practitioner to the lung function lab
89467026|NCT03412851||A Direct Aspiration First Pass Technique|
89467027|NCT03412851||Stentriever Thrombectomy|
89467028|NCT02353052||Treatment observation group|According to the morphological criteria, the NIH scheme, and the WHO standard, GIST patients are divided into two groups, benign group and malignant group. In fully informed of their illness, patients are free to choose the sequence treatments according to their own gene mutation status and economic conditions. Patients who choose postoperative Imatinib treatment are labeled treatment group.
89467029|NCT02353052||Control observation group|According to the morphological criteria, the NIH scheme, and the WHO standard, GIST patients are divided into two groups, benign group and malignant group. In fully informed of their illness, patients are free to choose the sequence treatments according to their own gene mutation status and economic conditions. Patients who choose no Imatinib treatment are labeled observation group.
89467030|NCT03412695|Experimental|Arm A|Use of the MyFood tool among patients and nurses (intervention group)
89467031|NCT03412695|No Intervention|Arm B|No intervention. Regular hospital routines
89467032|NCT02357498|Active Comparator|microscopic|Microscopic transsphenoidal surgery, including endoscopic-assisted approach (350 subjects)
89467033|NCT02357498|Active Comparator|endoscopic|Fully endoscopic transsphenoidal surgery (350 subjects)
89467034|NCT02362568|No Intervention|Cervical ultrasound exploration|A cervical ultrasound exploration will be performed in all patients admitted for a planned surgery performed under general anesthesia during the stay in the postoperative room.
88946444|NCT01907945|Active Comparator|Comparison|Participant households in this arm receive household drinking water treatment education at the household level.
88946445|NCT01907971||Ebstein anomaly|Patients with Ebstein anomaly
88946446|NCT01907984|Experimental|Diclofenac and Midazolam|Diclofenac 100 mg tablet and Midazolam 7.5 mg tablet were administered by mouth as premedication 30 minutes before surgical interventions.
89467035|NCT04479254|Experimental|Indirect Calorimetry- Directed Nutrition|Enteral Nutrition (EN) will be the preferred route of nutrition, and will be initiated within the first 24-48 hours of ICU admission. Caloric requirements will be measured by indirect calorimetry IC as soon as possible after recruitment and will be repeated in every 24 hrs. The amount of delivery is gradually increased to avoid the possibility of gastrointestinal intolerance. If EN fails to reach caloric goals or not feasible supplementary Parenteral nutrition(PN) will be initiated after 5-7days
88946447|NCT01907984|Active Comparator|Midazolam|Midazolam 7.5 g tablet was administered as premedication by mouth 30 minutes before surgical interventions.
88946448|NCT01907997|Experimental|Group L|Intravenous lidocaine infusion group
88946449|NCT01907997|Placebo Comparator|Group C|Intravenous normal saline infusion - control group
88946450|NCT01908010|Experimental|Group 1, low dose|ABT-354
88946451|NCT01908010|Experimental|Group 2, high dose|ABT-354
88946452|NCT01908023|Experimental|exercise|
88946453|NCT01908049|Experimental|Probiotic|A probiotic (Saccharomyces boulardii) 2 caps/ 8h for 12 weeks.
88946454|NCT01908049|Placebo Comparator|Placebo|No active substance is given.
88946455|NCT01908075||BDP/FOR|Patients receiving ICS/LABA therapy as FP/SAL (Seretide®) who, at an index prescription date (IPD): Change their therapy to BDP/FOR (Fostair®) at same or lower BDP-equivalent ICS dose
88946456|NCT01908075||FP/SAL|Patients receiving ICS/LABA therapy as FP/SAL (Seretide®) who, at an index prescription date (IPD) : Remain on FP/SAL at the same BDP-equivalent ICS dose
88946457|NCT01908088|Experimental|fibroblast transplant|Transplantation of autologous cultured fibroblast on amniotic membrane in patients with Epidermolysis Bullosa with mitten hand deformity
88946458|NCT01908114|No Intervention|Group A|Routine Polio Program activities will be carried out with out any active intervention
88946459|NCT01908114|Experimental|Group B|"Expanded intervention with following components~Community support groups for both male and female at village/community level~Enhanced communication package and involvement of local social networks for group counseling on promotion of nutrition, hygiene and Expanded Program of Immunization (EPI) vaccinations~Involvement of Private sector (General Physicians,health care providers etc.) through advocacy and inclusion in Supplementary Immunization activities (SIAs)~Delivery of interventions & commodities through low cost health camps during National Immunization days (NIDs) and SIAs (will also assist in mop-up campaigns)"
88946460|NCT01908114|Experimental|Group C|All Interventions of Group A and B Plus combined bOPV/IPV strategy in the SIAs during the project
88946461|NCT01908153||Overweight/Obese|Children with BMI percentile of 85 or above.
88946462|NCT01908153||Healthy Weight|Children with BMI percentile between 15 and 85.
88946463|NCT01908166|Experimental|Diagnostic (ultrasound elastography)|Patients undergo ultrasound elastography.
88946464|NCT01908192|Experimental|NaBen®|NaBen® is a white oral tablet (500 mg), which will be taken twice daily at a total dose of 1000 mg/day during this study.
88946465|NCT01908192|Placebo Comparator|Placebo|The control treatment is placebo.
88946466|NCT01908218||ULBT group|344 adult patients undergoing general anesthesia with orotracheal intubation
88946467|NCT01908231||Pulmonary Embolism|Consecutive adult patients (minimum age eighteen) who presented to the ED of the hospitals participating in the study with clinical suspicion of PE will be considered for the study. We excluded patients with life expectancies of less than 3 months, and patients with first symptoms 15 days or more before inclusion.
88946468|NCT01908244|No Intervention|Control|No pentatonic music
88946469|NCT01908244|Experimental|Music|
88946470|NCT01908257|Experimental|Sequence 1 fasted|"Day 1: Lesinurad 400 mg once daily (qd)~Day 5: Ranitidine 150 mg twice daily (bid)~Day 6: Lesinurad 400 mg (qd) + ranitidine 150 mg (bid). Ranitidine dosed at -2 hours predose and 12 hours postdose of lesinurad.~Day 7: Ranitidine 150 mg (bid)"
88946471|NCT01908257|Experimental|Sequence 2 fasted|"Day 1: Ranitidine 150 mg (bid)~Day 2: Lesinurad 400 mg (qd) + ranitidine 150 mg (bid). Ranitidine dosed at -2 hours predose and 12 hours postdose of lesinurad~Day 3: Ranitidine 150 mg (bid)~Day 7: Lesinurad 400 mg (qd)"
88946472|NCT01908270|Experimental|Yoga|Yoga intervention 12 weeks, weekly 90-minute intervention Yoga postures, breathing, relaxation, and meditation
88946473|NCT01908270|Other|Usual care|Patients continue usual care by their practitioner
88946474|NCT01908283|Experimental|Patient non immunosuppressed|Group 1 : patient without immunosuppressive treatment
88946475|NCT01908283|Experimental|Patient immunosuppressed|Group 2 : patient with immunosuppressive treatment
88946476|NCT01908296|Experimental|FK949E group|receiving FK949E with and without fluvoxamine
88946477|NCT01908309|Active Comparator|Iodixanol|Patients randomized to coronary angiography/angioplasty with Iodixanol 320
89467036|NCT04479254|Active Comparator|Standard weight-based equation- Directed Nutrition|Enteral Nutrition (EN) will be initiated within the first 24-48 hours of ICU. Admission. Enteral nutrient delivery is gradually increased to avoid the possibility of gastrointestinal intolerance so that a few days are required to achieve the caloric target. PN will be started after 5-7 days if EN is not feasible. Energy and protein goals will be calculated by the standard weight-based equation of 25 kcal/kg BW body weight and 1.2-2.5 g/kg body weight, respectively.
89467037|NCT03423927|Experimental|Intervention group : hypnosis + self-care|Groupal intervention combining self-care techniques and self-hypnosis exercises
89467038|NCT03423927|No Intervention|Control group : no intervention|Control group receiving usual care but not the intervention
89467039|NCT03127293||Hyperemesis Gravidarum group|Blood samples (10 mL) were drawn at the time of DEXA scans in postpartum period
89467040|NCT03127293||control group|Blood samples (10 mL) were drawn at the time of DEXA scans in postpartum period
89467041|NCT02363114||Stroke Prevention Clinic Patients|All consecutive patients presenting to six high volume Regional Stroke Prevention Clinics.
89467042|NCT03412461|Experimental|Thought Spot Application|Participants randomly assigned to the experimental arm will have access to the Thought Spot application. The Thought Spot application is a mobile app and website. This digital platform was designed and produced in partnership with transition aged youth in post-secondary education. The platform maps out wellness and mental health services across the Greater Toronto Area. This group will continue to have access to usual care.
89467043|NCT03412461|Active Comparator|Resource pamphlet|Participants randomly assigned to the active comparator will receive a pamphlet that outlines mental health services and wellness services across the Greater Toronto Area. This group will continue to have access to usual care.
89467044|NCT03153722|Experimental|Pediatric discharge process intervention|All patients hospitalized on the pediatric ward under the pediatric hospitalist service will participate in pediatric discharge process interventions.
89467045|NCT03418077|Experimental|energy drink|Participants will serve as their own controls and have repeated measures obtained to determine if there is a difference between the placebo-control and energy drink arms
89467046|NCT03418077|Placebo Comparator|Placebo-control|Participants will serve as their own controls and have repeated measures obtained to determine if there is a difference between the placebo-control and energy drink arms
89467047|NCT03112304|Experimental|MATCH-ADTC Wave 1|Wave 1 clinicians received MATCH training at the beginning of the project and used MATCH to treat participating children from their clinic for two years, with weekly case consultation from MATCH experts who were part of the study team, and then received consultation from their own clinic supervisors who had been trained as MATCH Associate Consultants (ACs), supported by the TRAC system.
89467048|NCT03112304|Experimental|MATCH-ADTC Wave 2|Wave 2 clinicians provided treatment as usual (e.g., usual care) with the children they treated during the initial two years of the project. Afterwards, they trained in MATCH and used it to treat children in their clinics with weekly case consultation from our study team of MATCH experts, supported by the TRAC system.
89467049|NCT05171361||Pancreaticojejunostomy|With Dunking Technique after Pancreaticodudenectomy
89467050|NCT05171361||Pancreaticogastrostomy|With Dunking Technique after Pancreaticodudenectomy
89467051|NCT03160196|Experimental|Experimental practices|The decision support tool is a Web-based software program accessed via a GP computer desktop icon. Clicking the icon opens a single page of tick boxes asking for relevant aspects of the presenting illness. Most fields for relevant medical history and patient demographics are automatically populated from data in the electronic health record. Depending on diagnosis and risk estimation, the tool recommends a guideline-based management strategy. Override options exist but require a justification from the GP. The tool also provides relevant prescriptions, radiology access, and referral forms, and a variety of patient information leaflets. GPs in practices randomized to the intervention group will have to initiate the tool but will not have to follow the tool's advice.
89467052|NCT03160196|Active Comparator|Control practices|Control practices will be aware of the tool but will be unable to access it and managed patients by usual care, which could include care aligned with the Guidelines. Prior to randomization, GPs from all participating practices (control and intervention) will attend a 1-hour face-to-face didactic education session on diabetes mellitus 2 management and the Colombia diabetes mellitus 2 Guidelines. The intervention pertains to the cluster level.
89467053|NCT03112148|Experimental|Treatment A|Single oral 10 mg dose of tofacitinib MR-FAST administered in the fed state.
89467054|NCT03112148|Experimental|Treatment B:|Single oral 10 mg dose of tofacitinib MR-SLOW administered in the fed state.
89467055|NCT03112148|Experimental|Treatment C|Single oral 10 mg dose of tofacitinib MR-FAST administered in the fasted state.
89467056|NCT03112148|Experimental|Treatment D|Single oral 10 mg dose of tofacitinib MR-SLOW administered in the fasted state.
89467057|NCT03112148|Experimental|Treatment E|Single oral 10 mg dose of tofacitinib MR-MODERATE administered in the fasted state
89467058|NCT03112148|Experimental|Treatment F|Single oral 10 mg dose of tofacitinib IR Solution (10 mL of the 1 mg/mL solution) administered in the fasted state
89467059|NCT03423849|Experimental|The original program (NG/NP)|Vinorelbine injection 25mg/m2 on day 1 and day 8, Gemcitabine injection 1250mg/m2 on day1 and day 8,every 3 weeks for 3 cycles（for the patients who used the NG salvage therapy） or Vinorelbine injection 25mg/m2 on day 1 and day 8,Cisplatin injection 25mg/m2 on day1,every 3 weeks for 3 cycles（for the patients who used the NP salvage therapy ）
89467060|NCT03423849|Experimental|One of the original program (N)|Vinorelbine injection,25mg/m2 on day 1 and day 8,every 3 weeks for 6 cycles. or, Vinorelbine oral 60mg/m2 on day 1,every week for 6 cycles.
89467061|NCT03423849|Experimental|Capecitabine monotherapy|Capecitabine oral 1250mg/m2,bid,for 6 cycles
89467062|NCT02362490|Experimental|peginterferon alpha 2a|in this group, patients who were on treatment of Nucleoside (Acid) Analogues and had achieved HBsAg level ≤250 IU/ml will switch to treatment of peginterferon alpha 2a for 72 week.
89467063|NCT02362490|No Intervention|control group|in this group, patients who were on treatment of Nucleoside(Acid) Analogues and had achieved HBsAg level ≤250 IU/ml will be continue to treatment of Nucleoside(Acid) Analogues for 72 week.
89467064|NCT03417843|Experimental|EUSRA RF electrode|new ablation catheter RFA (RADIOFREQUENCY under EUS), developed by TAEWOONG company for the treatment of pancreatic premalignant and early malignant cystic lesion.
89467065|NCT03159962|Active Comparator|Treated Group 1|Patient treated with bonded RME (Rapid Maxillary Expander) with a 13-mm screw. The acrylic splints of the bonded expander extended from the first deciduous molars through the first permanent molars.
89467066|NCT03159962|Active Comparator|Treated Group 2|Patients treated with banded RME (Rapid Maxillary Expander) in the form of a butterfly palatal expander with a 13-mm screw cemented through bands on the second deciduous upper molars.
89467067|NCT03159962|No Intervention|Untreated Control Group|Matched untreated Class II control group prospectively evaluated after one year
89467068|NCT03423771|Experimental|NPF-08 Low dose （1-day treatment）|
89467069|NCT03423771|Experimental|NPF-08 Medium dose （2-day split dose）|
89467070|NCT03423771|Experimental|NPF-08 High dose （2-day split dose）|
89467071|NCT03423771|Experimental|NPF-08 Medium dose （1-day treatment）|
89467072|NCT03423771|Experimental|NPF-08 High dose （1-day treatment）|
89467073|NCT03423771|Experimental|NPF-08 Low～High dose （1-day treatment）|
89467074|NCT03423771|Experimental|NPF-08 Medium～High dose （2-day split dose）|
89467075|NCT04324814|Experimental|Dose level 1|Subjects will receive a single dose of SHR-1701 at Dose level 1 on Day 1 of each cycle
89467076|NCT04324814|Experimental|Dose level 2|Subjects will receive a single dose of SHR-1701 at Dose level 2 on Day 1 of each cycle
89467077|NCT04324814|Experimental|Dose level 3|Subjects will receive a single dose of SHR-1701 at Dose level 3 on Day 1 of each cycle
89467078|NCT04324814|Experimental|Dose level 4|Subjects will receive a single dose of SHR-1701 at Dose level 2 1 on Day 1 and Day 15 of each cycle
89467079|NCT04324814|Experimental|Dose level 5|Subjects will receive a single dose of SHR-1701 at Dose level 3 on Day 1 and Day 15 of each cycle
89018427|NCT03812666||Moderately stroke|Patients with moderately severe (defined as NIHSS score of > 5 but < 11) acute stroke, either ischemic or hemorrhagic. (n= 25)
89467080|NCT04324814|Experimental|Dose expansion 1|Subjects will receive a single dose of SHR-1701 on a selected dose level Day 1 of each cycle
89467081|NCT04324814|Experimental|Dose expansion 2|Subjects will receive a single dose of SHR-1701 on a selected dose level on Day 1 of each cycle
89467082|NCT03417765|Experimental|Cohort A: 5 mg (FE 203799/Placebo)|Drug: FE 203799 Drug: BEAM Procedure: myeloablative chemotherapy Procedure: autologous stem cell transplantation
89467083|NCT03417765|Experimental|Cohort B: 10 mg (FE 203799/Placebo)|Drug: FE 203799 Drug: BEAM Procedure: myeloablative chemotherapy Procedure: autologous stem cell transplantation
89467084|NCT03417765|Experimental|Cohort C: 25 mg (FE 203799/Placebo)|Drug: FE 203799 Drug: BEAM Procedure: myeloablative chemotherapy Procedure: autologous stem cell transplantation
89467085|NCT03126903|Experimental|Single-Arm|KeraKlear Non-Penetrating Keratoprosthesis
89467086|NCT02362256|Experimental|Intervention|"Opioid antagonist induction. Day 4. Duration 12-16 hours.~Naltrexone gradual increase from 50 µg p/o to a total dose of 12,5 mg according to a predefined protocol:~st hour 50 µg~nd hour 50 µg~rd hour 100 µg~th hour 100 µg~th hour 200 µg~th hour 400 µg~th hour 800 µg~th hour 1600 µg~th hour 3200 µg~th hour 6000 µg~Correction of symptoms for opioid abstinence:~Clonidine 150 µg p/o every 4 hours (Day 3 and Day 4) Lorazepam 5 mg p/o every 4 hours (Day 3 and Day 4), Lorazepam 2,5 mg po every 4 hours (Day 5, Day 6)"
89467087|NCT02362256|Active Comparator|Control|"Opioid antagonist induction. Day 4. Duration 12-16 hours. Naltrexone single dose 12,5 mg p/o~Correction of symptoms for opioid abstinence:~Clonidine 150 µg p/o every 4 hours (Day 3 and Day 4) Lorazepam 5 mg p/o every 4 hours (Day 3 and Day 4), Lorazepam 2,5 mg po every 4 hours (Day 5, Day 6)"
89467088|NCT03417609||Sarcopenia|Elderly patients with sarcopenia
89018428|NCT03812666||Mild stroke|Patients with mild (defined as NIHSS score of <6) acute stroke, either ischemic or hemorrhagic. (n= 25)
89467089|NCT03417609||Control|Elderly patients without sarcopenia
89467090|NCT00592592|Experimental|Proton Beam Radiation|Proton Beam Radiation
89467091|NCT03126981|Experimental|Whole, natural almonds|1.5 oz of whole, natural almonds
89467092|NCT03126981|Placebo Comparator|Low-fat, high refined starches/sugars|Low-fat foods,high in refined starches and added sugars
89467093|NCT02362100|Placebo Comparator|nonoperative management|"Treatment will consist of sling immobilization for a period of 6 weeks. Details and treatment timeline as follows:~0 - 3 weeks: immobilization with a shoulder sling, range of motion of elbow, hand and wrist~3 - 6 weeks: same as 0-3 weeks, with addition of pendulum exercises every two hours~After 6 weeks: Active mobilization and removal of sling. Light activity permitted and physiotherapy for range of motion permitted as tolerated.~After 6 months: no further restriction will be placed. Full home and work activity permitted."
89467094|NCT02362100|Active Comparator|locking plate surgical fixation|"Standardized operative management protocol as follows:~Pre-operative medical clearance established via anesthesia consults if required for medically complex patients.~Provision of pre-operative intravenous (IV) antibiotic prophylaxis:~Administration of general anesthetic.~Patient positioning and preparation:~Patient is carefully placed in the beach-chair position,~Deltopectoral approach Fracture reduction and fixation with confirmation with intraoperative fluoroscopy images."
89467095|NCT03412305|Active Comparator|Amoxicillin oral tablets|2 g amoxicillin tablets orally 1 hour before implant placement
89467096|NCT03412305|Placebo Comparator|Placebo|Placebo tablets orally 1 hour before implant placement
89467097|NCT02352740|Experimental|Healthy subjects with 'hypertriglyceridemic waist'|"Subjects with overweight, elevated waist circumference and elevated fasting triglyceridemia.~Intervention : A form arginine and B form arginine"
89467098|NCT02352740|Experimental|Healthy subjects|"Control subjects, i.e. without overweight, elevated waist circumference and elevated fasting triglyceridemia.~Intervention : A form arginine and B form arginine"
88946478|NCT01908309|Active Comparator|Iobitridol|Patients randomized to coronary angiography/angioplasty with Iobitridol 350
88946479|NCT01908322||Group 1|
88946480|NCT01908335|Experimental|A (PEG-IFN-SA /RBV low dose)|PEG-IFN-SA 0.75μg/kg/week and RBV 1000mg-1200mg/d bid depending on body weight(BW),（BW<75kg，1000mg/d；BW≥75kg，1200mg/d）
88946481|NCT01908335|Experimental|B (PEG-IFN-SA /RBV middle dose)|PEG-IFN-SA 1.5μg/kg/week and RBV 1000mg-1200mg/d bid depending on body weight(BW),（BW<75kg，1000mg/d；BW≥75kg，1200mg/d）
88946482|NCT01908335|Experimental|C (PEG-IFN-SA /RBV high dose)|PEG-IFN-SA 2.0μg/kg/week and RBV 1000mg-1200mg/d bid depending on body weight(BW),（BW<75kg，1000mg/d；BW≥75kg，1200mg/d）
88946483|NCT01908335|Active Comparator|D (Pegasys /RBV)|Pegasys 180μg/week and RBV 1000mg-1200mg/d bid depending on body weight(BW),（BW<75kg，1000mg/d；BW≥75kg，1200mg/d）
89467099|NCT02109081|Experimental|Dexamethasone|Patients will be administered dexamethasone 10 mg at induction of anesthesia
89467100|NCT02109081|Placebo Comparator|Placebo-2.5 cc of saline|Patients will be administed placebo at induction of anesthesia
89467101|NCT02352584|Experimental|GC3110A(Quadrivalent)|0.5ml, intramuscular, a single dosing
89467102|NCT02352584|Active Comparator|GC Flu (Trivalent)|0.5ml,intramuscular,a single dosing
88946484|NCT01908348|Experimental|Erythritol|Orange-flavored beverage containing 6, 12, or 18 grams of erythritol
88946485|NCT01908361|Experimental|Unilateral Hybrid (InMotion3 plus CIT) Intervention|Participants will receive 3 weeks of robot-assisted therapy (RT) using the InMotion3 Wrist Robot, followed by 3 weeks of CIT training.
89467103|NCT02352584|Active Comparator|GC3110A(Trivalent)|0.5ml,intramuscular,a single dosing
89467104|NCT03423693||Asthma with SAO+|Asthmatic patients with RV/TLC > or = 40
89467105|NCT03423693||Asthma with SAO-|Asthmatic patients with RV/TLC < 40
89467106|NCT03423693||ACO|Asthmatic patients with smoking > or = 10 pack years who have persistent airway obstruction (post-BD FEV1/FVC < 0.7) or COPD patients who have bronchodilator (BD) reversibility (absolute increase in FEV1 > or = 200 ml and FEV1% > or =12% after BD)
89467107|NCT03423693||COPD|Patients with history of smoking > or = 10 pack year with post-BD FEV1/FVC < 0.7 and negative BD reversibility (absolute increase in FEV1 < 200 ml and FEV1% <12% after BD)
89467108|NCT02352662||Study Group|Three blood samples will be collected intra-operatively from each subject enrolled
88946486|NCT01908361|Experimental|Bilateral Hybrid (BMT plus BAT) Intervention|Participants in this bilateral treatment group will receive 3 weeks of RT using the Bi-Manu-Track (BMT) robot (Reha-Stim Co., Berlin, Germany), followed by 3 weeks of therapist-based BAT.
88946487|NCT01908361|Active Comparator|Conventional Rehabilitation (CR)|The CR intervention will be designed to match the duration and intensity of the hybrid interventions.
88946488|NCT01908374|Active Comparator|DHA-rich fish oil|DHA-rich fish oil versus Phospholipid-rich fish oil Fish oil in triglyceride form (12 capsules/d providing 575 mg/d EPA; 1843 mg/d DHA; 259 mg/d n-3 DPA)
88946489|NCT01908374|Experimental|Phospholipid-rich fish oil|DHA-rich fish oil versus Phospholipid-rich fish oil Fish roe high in EPA/DHA phospholipids [(12 capsules/d providing 628 mg/d EPA; 1810 mg/d DHA; 137 mg/d n-3 docosapentaenoic acid (DPA)]
88946490|NCT01908387|Experimental|Oral azacitidine|
88946491|NCT01908400|Other|BMMNCs|Intravenous transfer of (BMMNCs)
88946492|NCT01908413|Experimental|CUDC-427|
88946493|NCT01908439|Experimental|Whole-body vibration|A new method for muscle reflex latency measurement
88946494|NCT01908452|Experimental|vitamin B6 (pyridoxine)|The 150 participating subjects will be randomized into 2 groups: 75 patients will receive vitamin B6 (1200 mg/day) and 75 patients will receive placebo, each for 12 weeks in a double-blind mode
88946495|NCT01908452|Placebo Comparator|placebo|The 150 participating subjects will be randomized into 2 groups: 75 patients will receive vitamin B6 (1200 mg/day) and 75 patients will receive placebo, each for 12 weeks in a double-blind mode
88946496|NCT01908478|Experimental|Combination: veliparib, gemcitabine, and IMRT|
88946497|NCT01908491|Active Comparator|IV PCA|hydromorphone with ketorolac
88946498|NCT01908491|Experimental|Continuous wound infusion|ON-Q Painbuster with ropivacaine
88946499|NCT01908504|Other|PET-CT|
89467109|NCT03417453|Active Comparator|Eye Drop Dispenser TYPE Opticare|subject will assess TYPE 1 dispenser
89467110|NCT03417453|Active Comparator|Eye Drop Dispenser Autodrop|subject will assess Autodrop dispenser
89467111|NCT02352428|Experimental|Skin Cancer Screening Training|Recruited family physicians and dermatologists in Calgary, Canada, take part in a 5.5-hour face-to-face skin cancer screening training program. Screening for skin cancer will be conducted by trained physicians according to instructions they received in the training program.
89467112|NCT02352428|No Intervention|No Skin Cancer Screening Training|Recruited family physicians and dermatologists in Edmonton, Canada, WILL BE TRAINED AFTER THE SCREENING PHASE, i.e. during the screening phase non-trained physicians will carry out skin cancer screenings according to standard medical practice.
89467113|NCT02352272|Experimental|Sleep extension|Subject spend 10 hours Time in bed per day during 6 nights. This period is follow by a total sleep deprivation intervention (i.e. 39 hours awaking) in laboratory.
89467114|NCT02352272|Sham Comparator|Habitual sleep|Subject respect their habitual Time in bed during 6 nights. This period is follow by a total sleep deprivation intervention (i.e. 39 hours awaking) in laboratory.
89467115|NCT04448067|Experimental|LOW Lentil Intake|Consumption of meals containing 60 g of lentils 5 out of 7 days per week for 8 weeks.
89467116|NCT04448067|Experimental|HIGH Lentil Intake|Consumption of meals containing 120 g of lentils 5 out of 7 days per week for 8 weeks
89467117|NCT04448067|Sham Comparator|CONTROL|Consumption of meals matched in total energy and protein to the lentil meals but containing 0 g of lentils 5 out 7 days per week for 8 weeks
89467118|NCT03417375|Experimental|Osteocel Plus|Experimental product will be placed in one sinus while the control product will be placed in the contralateral sinus. (Randomized)
89467119|NCT03417375|Active Comparator|alloOss|The control product will be placed in one sinus while the control product will be placed in the contralateral sinus. (Randomized)
89467120|NCT02362178|Experimental|Thromboelastography (TEG)|Patients in the TEG group received fresh frozen plasma at the dose of 10 ml/kg of ideal body weight, only if INR was higher than 1.8 and r time longer than 40 minutes. They received platelets at the amount of 1 apheresis Unit, only if platelets count was lower than 50000/μl and MA was shorter than 30 millimeter.
89467121|NCT02362178|Active Comparator|Standard of Care (SOC)|In the SOC group patients received fresh frozen plasma at the dose of 10 ml/kg of ideal body weight, when INR was higher than 1.8. They received platelets at the amount of 1 apheresis Unit, when platelets count was lower than 50000/μl.
89467122|NCT04894305|Experimental|Group 1 (Test Group): Ad26.COV2.S (0.3 mL)|Participants will receive single dose Ad26.COV2.S 0.3 milliliter (mL) intramuscular (IM) injection on Day 1 in test group.
89467123|NCT04894305|Active Comparator|Group 2 (Reference Group): Ad26.COV2.S (0.5 mL)|Participants will receive single dose Ad26.COV2.S 0.5 mL IM injection on Day 1 in reference group.
89467124|NCT03112850|Active Comparator|Group A|Participants who will be fitted with hearing aids for the first 3 months of 6 months auditory training program
89467125|NCT03112850|Active Comparator|Group B|Participants who will be fitted with hearing aids for the second 3 months of 6 months auditory training program
89467126|NCT02356952|Experimental|Mediterranean Diet|Randomized prescription with indication about type of foods that can be consumed frequently (green foods), sometimes (yellow foods) and never (red foods).
89467127|NCT02356952|Experimental|Low Glycemic Index Diet|Randomized prescription with indication about type of foods that can be consumed frequently (green foods), sometimes (yellow foods) and never (red foods).
89467128|NCT02356952|Experimental|Low Glycemic Index Mediterranean Diet|Randomized prescription with indication about type of foods that can be consumed frequently (green foods), sometimes (yellow foods) and never (red foods).
89467129|NCT04854447|Experimental|Study Group|Part-time myopia correction with single-vision spectacles
89467130|NCT04854447|Active Comparator|Control Group|Full-time myopia correction with single-vision spectacles
89467131|NCT04447599|Experimental|Photographs|Photographs
89467132|NCT02352194||Assessment|"One part of this study is to quantify physical capacity of patients with Multiple sclerosis.~Thirty patients will be enrolled in this study and performed assessments."
89467133|NCT02352194||Rehabilitation|A second part of this study is to quantify the benefit of a usual rehabilitation program in the day hospital. Thirty patients will be enrolled in this study and receive rehabilitation. They will be assessed before and after the rehabilitation program (physiotherapy and physical activity)
89467134|NCT04802811|Experimental|Treatment group A|
89467135|NCT04802811|Experimental|Treatment group B|
89467136|NCT04802811|Experimental|Treatment group C|
89467137|NCT04802811|Experimental|Treatment group D|
89467138|NCT04802811|Experimental|Treatment group E|
89467139|NCT02352350||Cardiac Arrest Patients|All adult patients with non traumatic cardiac arrest in Alachua County Florida will have blood lactate levels taken and neurological outcomes performed based on the Cerebral Performance Categories (CPC) Scale
89467140|NCT04795557|Experimental|ADAPT232|"50 patients take ADAPT-232® oral solution in the daily dose of 60 ml ( 30 ml two times daily) for 14 days.~One mL of oral solution contains:~Schisandra chin. fructus native extract 10,0 mg DERnative 2,0-5,0:1 Eleutherococcus sent. radix native extract 2,6 mg DERnative 17-30:1 Rhodiola rosea radix native extract. 3,0 mg DERnative 2,0-5,0:1 Inactive excipients,"
89467141|NCT04795557|Placebo Comparator|Placebo|50 patients take Placebo oral solution in the daily dose of 60 ml ( 30 ml two times daily) for 14 days.
89467142|NCT02357030|Experimental|Methyl-P plus GWI Nutrient Formula|Methylphenidate hydrochloride plus a GWI Nutrient Formula (K-PAX Synergy), both taken twice daily.
89467143|NCT02039102||Non-users of hormonal contraceptives|
89467144|NCT02039102||Users of hormonal contraceptives|
89467145|NCT03397875|Active Comparator|Zinc oxide based sealer|After root canal treatment obturation with gutta percha will be done using zinc oxide based sealer.
89467146|NCT03397875|Experimental|Epoxy resin based sealer|After root canal treatment obturation with gutta percha will be done using epoxy resin based sealer.
89467147|NCT03397875|Experimental|Bioactive silicone based sealer|After root canal treatment obturation with gutta percha will be done using bioactive silicone based sealer.
89467148|NCT02362022|Placebo Comparator|Group Saline|Group Saline (Group S) received i.v saline 0.9 % in 10 ml volume (n=30)
89467149|NCT02362022|Active Comparator|Group Morphine 1|Group Morphine 1 (Group M1) received i.v morphine 0.1 mg kg-1, in 10 ml volume (n=30)
89467150|NCT02362022|Active Comparator|Group Morphine 2|Group Morphine 2 (Group M2) received i.v morphine 0.2 mg kg-1, in 10 ml volume (n=30)
89467151|NCT05170347||Post-Haematopoietic Stem Cell Transplantation (Post-HSCT) patients|"Patient aged 18 or above~Underwent allogeneic HSCT in Queen Mary Hospital(QMH) in the two-year recruitment period"
89467152|NCT05170347||Family Control Subjects|The research team will invite an accompanying family member to be the family control. Microbiome and tear samples will be collected for comparison. The sample collection schedule is the same as the corresponding post-HSCT case.
88946500|NCT01908517|Experimental|HPV Vaccine Electronic Reminders|Parents in the intervention group will receive 1 electronic message per month in addition to the baseline and final assessments which equates to 8 contacts over a 7 month period. Specifically, intervention group participants will receive 4 education messages, 2 reminder/education messages, as well as 1 baseline and 1 final assessment survey.
88946501|NCT01908556|Experimental|Letrozol|All patients are treated with letrozole 2.5 mg for 5 years for the adjuvant treatment of postmenopausal patients with a hormone receptor positive primary breast cancer. Patients are treated according to the authorities' approval of the drug. Of all patients a germline DNA sample will be obtained before the treatment starts and serum samples will be taken at months 0, 6 and 12. Furthermore the paraffin embedded tissue block will be sent to a central pathology laboratory for central assessment of tumor biomarkers.
88946502|NCT01908569|Active Comparator|NO MACS + Time-lapse technology|The sperm capacitation will be performed through a density gradient. This sperm will be used in the IVF/ICSI treatment of the patient and the embryos obtained will be cultured using time-lapse technology (Embryoscope).
88946503|NCT01908569|Experimental|MACS + time-lapse technology|The sperm capacitation will be performed through a density gradient. After that, it will be subjected to the MACS technique in order to select the non-apoptotic spermatozoids. This sperm will be used in the IVF/ICSI treatment of the patient and the embryos obtained will be cultured using time-lapse technology (Embryoscope).
88946504|NCT01908621|Active Comparator|G-CSF (filgrastim)|Patients will receive G-CSF(filgrastim) at 10 μg/kg per day (divided into two doses every 12 hours) subcutaneously for up to 7 days. On day 5, circulating CD34+ level will be determined. Leukapheresis will be started when the CD34+ blood level will reach at least 10/µl. If the level will be not achieved, G-CSF administration will be continued until CD34+ level will decrease compared to the preceding day. Leukaphereses will be performed using Spectra-Optia Apheresis System (TherumoBCT Inc, Lakewood, CO, USA) according to the manufacturers protocols for mononuclear cell harvesting, processing 2 total blood volumes. In case of failing to harvest targeted number of stem cells (5 × 10^6 CD34+ cells/kg), next leukapheresis can be performed on following two days (maximum 3 leukaphereses) if circulating CD34+ cell level will remain as described above.
88946505|NCT01908621|Active Comparator|Cytosine arabinoside + G-CSF (filgrastim)|Cytosine arabinoside will be administered as a 2-hour i.v. infusion at a dose of 0.4 g/m2 twice daily on days 1 and 2 (total dose 1.6 g/m2). G-CSF (filgrastim) 5-10 ug/kg will be started on day 5 and continued until last leukapheresis. The number of circulating CD34+ cells will be first evaluated after neutrophil recovery from nadir. Leukapheresis will be started when the CD34+ blood level will reach at least 10/µl. If the level will be not achieved, G-CSF administration will be continued until CD34+ level will decrease. Leukaphereses will be performed using Spectra-Optia Apheresis System (TherumoBCT Inc, Lakewood, CO, USA) according to the manufacturers protocols for mononuclear cell harvesting, processing 2 total blood volumes. In case of failing to harvest targeted number of stem cells (5 × 10^6 CD34+ cells/kg), next leukapheresis can be performed on following two days (maximum 3 leukaphereses) if circulating CD34+ cell level will remain as described above.
88946506|NCT01908647|Experimental|Exp RT fMRI/Exp Cognitive Training|Both experimental conditions.
88946507|NCT01908647|Experimental|Exp RT fMRI/Ctrl Cognitive training|Experimental real-time fMRI and control cognitive training.
88946508|NCT01908647|Experimental|Ctrl RT fMRI/Exp Cognitive Training|Control RT fMRI (real-time functional MRI) and experimental cognitive training.
88946509|NCT01908647|Sham Comparator|Ctr RT fMRI/Ctr Cognitive Training|Control real-time fMRI and control cognitive training.
89467153|NCT02361866|Experimental|GC1107|0.5ml, intramuscular, a single dosing
89467154|NCT02361866|Active Comparator|Tetanus and Diphtheria(Td vaccine)|0.5ml, intramuscular, a single dosing
89467155|NCT03412149|Active Comparator|Mini Gastric Bypass|Mini Gastric Bypass: The gastric pouch will be performed starting below the incisura angularis (transverse resection 4 cm) on the lesser curvature (18).Then the stomach will be transected against a 36 Fr bougie up to the gastro-esophageal junction Then 1/3 of the small bowel will be excluded (approximately 200cms) and 3.5-4 cm gastro-jejunostomy will be performed by linear stapler.
89467156|NCT03412149|Active Comparator|Roux en Y Gastric Bypass|Roux en Y Gastric Bypass: The steps of the standard double loop RYGB technique will be followed (17). The gastric pouch will be created 7 cm from the gastro-esophageal junction to obtain a volume of 30-40 ml, and the length of the alimentary limb will be 150 cm and 3.5-4 cm gastro-jejunostomy will be performed by linear stapler. The length of the biliopancreatic limb will be from 65 to 75 cm beyond the ligament of Treitz. The lengths of both limbs should carefully measured with a graduated instrument. The mesenteric defects will be closed.
89467157|NCT03153644||Patients|Women with chronic medical conditions
89467158|NCT03153644||Primary Care Providers and Medical Staff|"Primary care providers can include doctors and advanced practice professionals, including midwives, nurse practitioners, and physician assistants.~Medical staff can include social workers, nurses, medical assistants, and administrative staff"
89467159|NCT03153644||Primary Practice|Primary care practices (family medicine, internal medicine, medicine-pediatric, or any combination of these) that at a practice-level already provide contraceptive counseling and services to reproductive-age women
89467160|NCT03412071|No Intervention|Control group|25 HIV-uninfected, uncircumcised men will be immediately circumcised following enrollment. This group will serve as the comparison to the four intervention groups.
89467161|NCT03412071|Active Comparator|Oral tinidazole group|25 HIV-uninfected, uncircumcised men will be randomized to receive oral tinidazole 2g once a day for two days.
89467162|NCT03412071|Active Comparator|Topical metronidazole (0.75%) group|25 HIV-uninfected, uncircumcised men will be randomized to apply topical 0.75% metronidazole cream to the foreskin twice a day for one week, and then twice a week for three weeks.
89467163|NCT03412071|Active Comparator|Topical clindamycin (2%) group|25 HIV-uninfected, uncircumcised men will be randomized to apply topical 2% clindamycin cream to the foreskin twice a day for one week, and then twice a week for three weeks.
89467164|NCT03412071|Active Comparator|Topical hydrogen peroxide (1%) group|25 HIV-uninfected, uncircumcised men will be randomized to apply 1% hydrogen peroxide cream to the foreskin twice a day for one week, and then twice a week for three weeks.
89467165|NCT02356874|Experimental|Exercise group|Exercise
89467166|NCT02356874|No Intervention|Control group|Participants in the control group will be asked to continue their usual physical activity habits
89467167|NCT02352038|Experimental|LLLT group|LLLT group: orthodontic treatment and low-level laser therapy
89467168|NCT02352038|Placebo Comparator|control group|Control group: orthodontic treatment and no laser treatment.
89467169|NCT03397797||Group with muscle relaxant|Rocuronium is used during the operation to maintain moderate relaxation.
89467170|NCT03397797||Group without muscle relaxant|Rocuronium is not used during the operation for the eletrophysiological monitoring.
89467171|NCT03153332||MDCT group|The MDCT images of seven hepatic tumors were loaded on software to uniform study conditions, allowing both axial and coronal scans visualization.
89467172|NCT03153332||3D visualization system group|The 3D virtual reconstructions of seven hepatic tumors were loaded on the visualization software which enables the rotation of the virtual model.
89467173|NCT03153332||3D printing group|3D-printed models of seven hepatic tumors were created based on MDCT images, participants were allowed to freely handle them.
89467174|NCT05170191||Sleep deprivation|Participant data will be acquired before and after 24 hours of sleep deprivation.
89467175|NCT02361710||vitamin D deficient patients|Serum 25- (hydroxide) OH Vitamin D levels <20ng/L undergoing Frozen embryo transfer (Vitamin D levels are measured on the day of embryo transfer)
89467176|NCT02361710||vitamin D sufficient patients|Serum 25- (hydroxide) OH Vitamin D levels >20ng/L undergoing Frozen embryo transfer (Vitamin D levels are measured on the day of embryo transfer)
89467177|NCT02361632|Experimental|Group 1|"Dietary Supplement. Participants drink coffee with or without milk in following order:~Black coffee~Coffee with 20% milk added~Coffee with 50% milk added"
89467178|NCT02361632|Experimental|Group 2|"Dietary supplement. Participants drink coffee with or without milk in following order:~Coffee with 20% milk added~Black coffee~Coffee with 50% milk added"
89467179|NCT02361632|Experimental|Group 3|"Dietary supplement. Participants drink coffee with or without milk in following order:~Black coffee~Coffee with 50% milk added~Coffee with 20% milk added"
89467180|NCT02357108|Active Comparator|Group 1: Video/Doctor Sequence 1|Participants watch two videos with varying video/doctor sequence and complete 3 surveys (one before the first video and one survey after each video)
89467181|NCT02357108|Active Comparator|Group 2: Video/Doctor Sequence 2|Participants watch two videos with varying video/doctor sequence and complete 3 surveys (one before the first video and one survey after each video)
89467182|NCT02357108|Active Comparator|Group 3: Video/Doctor Sequence 3|Participants watch two videos with varying video/doctor sequence and complete 3 surveys (one before the first video and one survey after each video)
89467183|NCT02357108|Active Comparator|Group 4: Video/Doctor Sequence 4|Participants watch two videos with varying video/doctor sequence and complete 3 surveys (one before the first video and one survey after each video)
88946510|NCT01908660||Antiretroviral drugs|Pre-treated or treatment-naive HIV-infected patients with chronic hepatitis B and/or chronic hepatitis C who change an existing antiretroviral regimen or who start a new regimen.
89467184|NCT03397641|Active Comparator|Active|x mg HBI-3000 as x mL of a 50 mg/mL solution for intravenous infusion. Doses of HBI-3000 (Cohorts A to G) may range from 20 mg to a level at which it is expected that the drug exposure will not exceed an AUC(0-t) of 20 µg.h/mL and Cmax of 20 µg/mL (based on the NOAEL) in both 14-day repeat-dose toxicology species rat and minipig) and the expected therapeutic dose.
88946511|NCT01908673|Active Comparator|HRV biofeedback|heart rate variability biofeedback
89467185|NCT03397641|Placebo Comparator|Placebo|Matching placebo for x mg HBI-3000 as x mL of a 50 mg/mL solution for intravenous infusion.
89467186|NCT04479098|Experimental|Exercise training|Postmenopausal breast cancer survivors undergoing tamoxifen treatment, who will do the evaluations before the beginning and after 12 weeks of exercise training and subsequently 12 weeks of detraining.
89467187|NCT05169879|Experimental|Early acoronal flaring|In group A, ProGlider PG (size 16, .02 taper) instrument with a length of 25 mm will be used to the working length, then early coronal flaring will be performed using Gates Glidden drill #3 in a brushing motion away from dangerous zone
89467188|NCT05169879|Active Comparator|Non coronal flaring|In group B no coronal flaring will be performed following minimally invasive approach.
88946512|NCT01908673|Active Comparator|ASTM|Automatic Self Transcedental Meditation
88946513|NCT01908686|Active Comparator|Pivotal Response Training|Pivotal Response Training with children ages 4-35 years of age with an Autism Spectrum Disorder diagnosis
89467189|NCT02356796|Experimental|Multidisciplinary group treatment|"Multidisciplinary group intervention at the University Hospital of North Norway. The group intervention is led by physiotherapists, with contributions from a gynecologist, nutritionist and a peer patient. The treatment consists of active exercises and theory lessons. The focus is to enhance the participants body awareness and to recognize the integration of mental and physical processes. The aim is to create change in patterns that influence the participants health negatively.~The treatment lasts one year. The first meeting has a duration of 10 days, then follow-up after 3, 6 and 12 months."
89467190|NCT02356796|Active Comparator|Standard physiotherapy treatment|Standard treatment in primary or secondary health care physiotherapy. Patients are referred to a physiotherapist with appropriate training/competence, as close to their home as possible.
89467191|NCT05170581|Experimental|PD-1 inhibitor combined with chemotherapy|Sintilimab will be administered one day before platinum-containing chemotherapy.
89467192|NCT02039024|Experimental|18F- DTBZ for Parkinson's Disease|"This study will compare the amyloid deposition of brain by florbetapir F-18 PET imaging and monoaminergic function by18F- DTBZ PET in 10 NC group, 30 PD group, 30 PDD group, 20 AD group. We will also analyze monoaminergic function by18F- DTBZ PET in 30 PDI group.~Each evaluable subject involved in this study must fulfill all the inclusion and exclusion criteria according the subject grouping, healthy subjects, PD, PDD, and AD patients will have 4 visits in this study. PDI patients will have 3 visits in this study. Safety measurement will be evaluated by medical history, vital signs, physical examinations, laboratory examinations and collecting of adverse events."
89467193|NCT02356718|Experimental|Experimental|Computerized cognitive training activities
89467194|NCT02356718|Active Comparator|Control|Non-adaptive computerized cognitive training activities
89467195|NCT03397563|Experimental|CPAP treatment|Continuous Positive Airway Pressure (CPAP)
89467196|NCT03397563|Sham Comparator|Sham-CPAP treatment|sham Continuous Positive Airway Pressure (sham-CPAP)
89467197|NCT02351882|Active Comparator|Nabilone|Participants randomized into the nabilone arm will be prescribed nabilone for 6 weeks. After one-week placebo washout, they will be taking placebo for an additional 6 weeks.
89467198|NCT02351882|Placebo Comparator|Placebo|Participants randomized into the placebo arm will be receiving placebo for 6 weeks. After one-week placebo washout, they will be prescribed nabilone for an additional 6 weeks.
89467199|NCT04710693|Other|CAD polyp-detection system|In this arm, a CAD polyp detection system will be used during the colonoscopy.
89467200|NCT04710693|No Intervention|Standard (no CAD polyp-detection system)|In this arm, a CAD polyp detection system will not be used during the colonoscopy.
89467201|NCT02356640|Active Comparator|EUS-guided celiac ganglion neurolysis|Endoscopic ultrasound guided celiac ganglion neurolysis would be performed
89467202|NCT02356640|Active Comparator|Percutaneous celiac plexus neurolysis|Percutaneous celiac plexus neurolysis would be performed
89467203|NCT05169801|Experimental|Treatment group A|
89467204|NCT05169801|Active Comparator|Treatment group B|
89467205|NCT03397485|Experimental|Growing Milk|"Experimental Fortified milk has energy from fatty acids, protein and carbohydrates. This milk has probiotics and essential micronutrients such as Zn, Fe, vitamins ( A, D, E, K, C and B complex), selenium and Copper among others.~Intervention Milk powder was prepared and reconstituted every weekday at each day-care center according to WHO and Day Care guidelines. Bottles were used to facilitate measuring in milliliters and were weighted before and after preparing milk in a diet measuring scale. Mothers were given the amount of milk necessary to prepare 480 ml per day during the weekend."
89467206|NCT03397485|Active Comparator|Fortified Milk|Fortified milk has no energy from fatty acids nor micronutrients such as vitamin B12, Selenium and Copper. This milk was prepared and reconstituted every weekday at each day-care center according to WHO and Day Care guidelines. Bottles were used to facilitate measuring in milliliters and were weighted before and after preparing milk in a diet measuring scale. Mothers were given the amount of milk necessary to prepare 480 ml per day during the weekend.
89467207|NCT02356406|Experimental|Celiac Plexus Radiosurgery|"The study has a prospective, single arm design. It will be composed from an initial run-in safety assessment that will include 6 patients and then continue as a phase II trial.~All eligible patients will receive the same protocol of celiac plexus radiosurgery"
89467208|NCT05169645||CSUA patients|CSUA patients
88946514|NCT01908686|No Intervention|Waitlist Control|Children in WL will be offered treatment following WL condition.
89467209|NCT03153176|Experimental|intervention|Training program for Physical Education teacher. Individual level: moderate to vigorous physical activity. Organizational level: school health policy for healthy lifestyle
89467210|NCT03153176|No Intervention|no intervention|Physical Education and school curriculum as usual
88946515|NCT01908764|Experimental|AL-60371/Posology 1|AL-60371 otic suspension, single dose of 200 µL following surgical insertion of tympanostomy tubes
88946516|NCT01908764|Experimental|AL-60371/Posology 2|AL-60371 otic suspension, single dose of 4 drops following surgical insertion of tympanostomy tubes
88946517|NCT01908790||Heart Failure Patients|Acute and chronic heart failure patients already receiving right heart catheterization (RHC) as part of their usual care
88946518|NCT01908855|Experimental|ENCERT|ENCERT contains 1) psychoeducation (session1), 2) relaxation techniques for coping with stress (sessions 2-4), 3) non-judgmental awareness of body perceptions, (sessions 5-7), 4) modifying illness behavior and accepting unpleasant body perceptions (sessions 8-13), 5) attention defocusing on positive perceptions plus emotional self-support (sessions 14- 15), 6) analyzing interpretation processes to understand situational cues (sessions 16-17), and 7) change of behavior and interpretations (sessions 18-20). The innovative elements of ENCERT are: improving the awareness for the association of somatic symptoms with emotions, learning non-judgmental awareness and acceptance of unpleasant body perceptions, achieving high-frequent skill exercising with the emotion regulation audio training.
89018429|NCT03784677|Experimental|Treatment (TRPV6 calcium channel inhibitor SOR-C13)|Patients receive TRPV6 calcium channel inhibitor SOR-C13 IV over 2 hours on days 1, 2, 8, 9, 15, 16, 22, and 23. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89467211|NCT03411681|Active Comparator|Normal Weight|
89467212|NCT03411681|Experimental|Obese|
89467213|NCT03152396|Other|Patients with inflammatory arthritis|All patients enrolled have a form of inflammatory arthritis and at least one uncontrolled CV risk factor (i.e. blood pressure, LDL-cholesterol, HbA1C, or current tobacco use). Pharmacist will assess each participants CV risk score using the validated RxEACH CV risk calculator. Over the 6 month intervention period, pharmacists will assist patients to modify a contributing risk factor thru treatment recommendations, prescription adaptation, and prescribing where necessary to meet treatment targets.
89467214|NCT04447443|Experimental|Prebiotic Fiber|
89467215|NCT04447443|Placebo Comparator|Maltodextrin|
89467216|NCT03411603||INCA2 2006-07|"French National Dietary Intake Survey, conducted in 2006-2007 by the French Agency for Food, Environmental and Occupational Health Safety.~Adults aged 18y and over, n=1918 included in the analyses."
89467217|NCT03411603||NHANES 2011-12|Wave 2011-12 of the National Health and Nutrition Examination Survey, the US national dietary intake Survey, conducted by the Centers for Disease Control and Prevention (CDC) Adults aged 18y and over, n=5073 included in the analyses.
89467218|NCT02361164||Mother/child pair|Mother/child pair.
89467219|NCT02361242|Experimental|PXT00864 Dose 1|1 orange capsule containing 0.4 mg of acamprosate and 1 white capsule containing 6 mg of baclofen are taken orally b.i.d during 24 weeks.
89467220|NCT02361242|Experimental|PXT00864 Dose 2|1 orange capsule containing 1 mg of acamprosate and 1 white capsule containing 15 mg of baclofen are taken orally b.i.d during 24 weeks.
89467221|NCT02361242|Experimental|PXT00864 Dose 3|1 orange capsule containing 20 mg of acamprosate and 1 white capsule containing 12 mg of baclofen are taken orally b.i.d during 24 weeks.
89467222|NCT02520687|Experimental|Dietary nitrate, beetroot juice|Once daily 70mL dose of beetroot juice, containing 400mg inorganic nitrate, for 7 consecutive days.
89467223|NCT02520687|Placebo Comparator|Nitrate-depleted beetroot juice|Once daily 70mL dose of beetroot juice, depleted of nitrate, for 7 consecutive days.
89467224|NCT02356250||PORTAL HYPERTENSION|PAIEBT WITH PORTAL HYPERTENSION
89467225|NCT02356328||NovaTears®|
89467226|NCT04695873|Experimental|Treatment Group|Foam Cushion, applied daily on Days 1, 2 and 3 of the investigation.
89467227|NCT04695873|No Intervention|No Treatment Group|No treatment
89467228|NCT02356172||Healthy Controls|Healthy males or females who are greater than or equal to 18 years old.
89467229|NCT02356172||Patients|Males or females with a diagnosis of IGD (Isolated GnRH Deficiency) who are greater than or equal to 18 years old.
89467230|NCT02361086|Experimental|Regimen 1: 7dayPM+DT|VT-464: given orally once daily in 28 day cycles. Dosing in the evening before bed 7-days a week with a 2-week dose titration.
88946519|NCT01908855|Active Comparator|CBT|"This arm is based on traditional cognitive-behavioral therapy that can be considered the current treatment of choice, being the only intervention with an evidence grade 1a (Kroenke, 2007). As such, it presents the reference of efficacy and safety for new regimen. The strictly manualized program includes the following components focusing on the special needs of chronic somatoform patients: psychoeducation providing a framework for psychotherapy, attention defocusing, reduction of over-interpretation of symptoms, increase of physical activity, stress reduction."
88946520|NCT01908868|Experimental|EBUS-TBNA|EBUS-TBNA (with endobronchial and transbronchial lung biopsy)
88946521|NCT01908868|Active Comparator|Conventional TBNA|Conventional TBNA (with endobronchial and transbronchial lung biopsy)
88946522|NCT01908881|Active Comparator|Control (usual care)|"This arm receives usual care (control group) consisting in: home visits, evaluation by social worker and planning interventions according to multidisciplinary team usually done en Family Primary Health Care Centers"
88946523|NCT01908881|Experimental|Intervention (group workshop+usual care)|Group intervention (group workshop) described elsewhere
88946524|NCT01908894|Experimental|BIOD-123|SC administration of 0.20 U/kg
88946525|NCT01908894|Experimental|BIOD-125|SC administration of 0.20 U/kg
88946526|NCT01908894|Active Comparator|Humalog|SC administration of 0.20 U/kg
88946527|NCT01908920|Other|OMT|Each osteopathic session is based on structural evaluation and treatment using indirect techniques.
89018430|NCT03782610||Primary Study Cohort|450 Infants
89467231|NCT02361086|Experimental|Regimen 2: 7dayPM-DT|VT-464: given orally once daily in 28 day cycles. Dosing in the evening before bed 7-days a week without dose titration.
89467232|NCT02361086|Experimental|Regimen 3: 7dayAM+DT|VT-464: given orally once daily in 28 day cycles. Dosing in the morning 7-days a week with a 2-week dose titration.
89467233|NCT02361086|Experimental|Regimen 4: 7dayAM-DT|VT-464: given orally once daily in 28 day cycles.Dosing in the morning 7-days a week without dose titration.
89467234|NCT02361086|Experimental|Regimen 5: 5dayPM-DT|VT-464: given orally once daily in 28 day cycles.Dosing in the evening before bed 5-days a week without dose titration.
89467235|NCT02361086|Experimental|Regimen 6: 5dayAM-DT|VT-464: given orally once daily in 28 day cycles.Dosing in the morning 5-days a week without dose titration.
89467236|NCT03411525|Experimental|Commitment invitation at time 1|In the stepped wedge cluster randomized design, the first clinic will remain in the control period (no intervention) for 1 month, followed by a 1 month transition period (where data will not be collected), before crossing over to the intervention period for 8 months.
88946528|NCT01908920|Other|SHAM|"Sham therapy was administered with subjects lying supine on the treatment table while the operator used light manual contact to treat the subject. A pre-determined protocol has been used. The practitioner's attention was distracted by subtracting calculation in silence."
88946529|NCT01908920|Other|CONTROL|No intervention
88946530|NCT01908933|Experimental|AeriSeal Emphysematous Lung Sealant Syst|This is a prospective, open label, single-arm, multicenter, investigational study. Patients will receive either unilateral or bilateral AeriSeal System therapy as appropriate utilizing 20 mL/subsegment dosing at 2 to 4 subsegments.
88946531|NCT01908946|Experimental|SMS Reminders|SMS reminders
88946532|NCT01908946|No Intervention|Standard verbal counseling|One time standard verbal counseling at the time of initial visit and timing for EPI vaccines at 6, 10 and 14 weeks
88946533|NCT01908959|Experimental|Madres para la Salud|Participants attended Madres para la Salud sessions in a group, led by a promotora at the Maricopa Medical Center and other community based sites. Sessions consisted of a 30 minute education and social support session where women learned to walk at least 150 minutes a week at a 20 minute-mile pace, and up to 30 minutes of moderate intensity walking with the group. Participants received an Omron pedometer and learned to monitor walking intensity. Participants set and reviewed weekly walking goals at the group sessions and recorded aerobic steps per day. After the 12 week sessions, participants met with the promotora once a week for 40 weeks, in-group, to walk at a moderate intensity for 30 minutes, to download and review pedometer data. Data was collected at baseline, 3, 6, 9 and 12 months.
88946534|NCT01908959|No Intervention|Attention-control|"Participants in the attention receive monthly brief telephone calls by research technicians and collection of study data on-site at the Maricopa Medical Center and other community based sites at baseline, 6, and 12 months (T1, T3, T5). The staff did not give advice or support specific to walking, which enabled a valid evaluation of the intervention effect. The content given to the attention-control group did not include the active ingredients of the Madres para la Salud intervention. The attention-control group received monthly mailings of health-related information regarding common postpartum or newborn concerns, such as breastfeeding, infant sleep, sibling rivalry, emotional support related to new parenthood, and early childhood development topics."
88946535|NCT01908998|Active Comparator|Sandal|
88946536|NCT01909024|Experimental|embolisation of pelvic veins & treatment of leg varicose veins|transjugular coil embolisation of pelvic veins followed by endovenous treatment of leg recurrent varicose veins
88946537|NCT01909024|Active Comparator|endovenous treatment of leg recurrent varicose veins alone|endovenous treatment of leg recurrent varicose veins alone
88946538|NCT01909037|Experimental|Flexofytol (bio-optimized curcumin)|
88946539|NCT01909050||refractory celiac disease|
88946540|NCT01909050||well-controlled celiac disease|
88946541|NCT01909050||uncontrolled celiac disease|either newly diagnosed with celiac disease or not on a gluten-free diet
88946542|NCT01909050||gluten-sensitivity|
88946543|NCT01909050||disorders other than celiac disease.|
88946544|NCT01909063|Experimental|Arm A|200 IU vitamin D and 700 mg of calcium per day in 2 glasses of juice per day for 2 weeks
88946545|NCT01909063|Experimental|Arm B|"200 IU vitamin D, 12 IU vitamin E, 2000 IU vitamin A as beta carotene, and 700 mg of calcium per day in 2 glasses of juice~Vitamin D, Vitamin E, and Vitamin A"
88946546|NCT01909063|Placebo Comparator|Arm C|"Control, 700 mg of calcium per day in 2 glasses of juice~Control, 700 mg Calcium"
88946547|NCT01909076|Active Comparator|Control PCPs and their patients|PCPs randomized to the control condition will receive electronic decision support tools. Patients of control PCPs will receive education materials that will be developed and made available to both control and intervention patients.
88946548|NCT01909076|Experimental|Intervention PCPs and patients|The Intervention Condition has three main components: access to nurse care management, access to the patient registry, and academic detailing for intervention PCPs. Intervention PCPs will also receive the control intervention of electronic decision support tools, and patients of intervention PCPs will receive the same patient education materials as patients of control PCPs.
88946549|NCT01909115|Active Comparator|1000 IU of Vitamin D Daily|Participants randomized to take a 1000 IU capsule of Vitamin D every day for 6 months.
88946550|NCT01909115|Experimental|4000 IU of Vitamin D Daily|Participants randomized to take a 4000 IU capsule of Vitamin D capsule every day for 6 months.
88946551|NCT01909128|Experimental|fermented milk|
88946552|NCT01909128|Experimental|fermented rice|
88946553|NCT01909128|Placebo Comparator|placebo|
88946554|NCT01909193|Experimental|Attention Bias Modification (ABM)|Attention training via 8 weekly repeated trials of a dot-probe task intended to direct attention away from threat stimuli.
88946555|NCT01909193|Experimental|Cognitive Behavior Therapy|CBT will consist of 16-20 weekly individual treatment sessions aimed to reduce symptoms via cognitive and behavioral interventions
88946556|NCT01909219|Active Comparator|Group A: standard regimen|Patients in the group A (standard regimen) will be instructed to take the two sachets of sodium picosulphate/magnesium citrate diluted in a glass of water 2-4 hours apart, starting at 5 pm the day before colonoscopy.
89467237|NCT03411525|Experimental|Commitment invitation at time 2|In the stepped wedge cluster randomized design, the second clinic will remain in the control period (no intervention) for 2 months, followed by a 1 month transition period (where data will not be collected), before crossing over to the intervention period for 7 months.
88946557|NCT01909219|Active Comparator|Group B|Patients in the group B (split regimen) will be instructed to take the first sachet of sodium picosulphate/magnesium citrate at 7 pm the day before colonoscopy and the second one at 6 am in the morning on the day of colonoscopy.
88946558|NCT01909258||The study population.|"Healthy volunteers 20 to 40 years of age.~Intervention: Goniometric measure of pelvic extension reserve. Intervention: Photographic measure of pelvic extension reserve. Intervention: EOS measure of pelvic extension reserve."
88946559|NCT01909271|Experimental|Intervention Group|Participants will receive education through a novel program called Stroke Education Film Viewing.
88946560|NCT01909271|Other|Usual Care Group|Participants will receive education through Stroke Education Pamphlet Exposure.
89467238|NCT03411525|Experimental|Commitment invitation at time 3|In the stepped wedge cluster randomized design, the third clinic will remain in the control period (no intervention) for 3 months, followed by a 1 month transition period (where data will not be collected), before crossing over to the intervention period for 6 months.
89467239|NCT03411525|Experimental|Commitment invitation at time 4|In the stepped wedge cluster randomized design, the fourth clinic will remain in the control period (no intervention) for 4 months, followed by a 1 month transition period (where data will not be collected), before crossing over to the intervention period for 5 months.
89467240|NCT03411525|Experimental|Commitment invitation at time 5|In the stepped wedge cluster randomized design, the fifth clinic will remain in the control period (no intervention) for 5 months, followed by a 1 month transition period (where data will not be collected), before crossing over to the intervention period for 4 months.
89467241|NCT03411525|Experimental|Commitment invitation at time 6|In the stepped wedge cluster randomized design, the sixth clinic will remain in the control period (no intervention) for 6 months, followed by a 1 month transition period (where data will not be collected), before crossing over to the intervention period for 3 months.
89467242|NCT03411525|Experimental|Commitment invitation at time 7|In the stepped wedge cluster randomized design, the seventh clinic will remain in the control period (no intervention) for 7 months, followed by a 1 month transition period (where data will not be collected), before crossing over to the intervention period for 2 months.
89467243|NCT03411525|Experimental|Commitment invitation at time 8|In the stepped wedge cluster randomized design, the eighth clinic will remain in the control period (no intervention) for 8 months, followed by a 1 month transition period (where data will not be collected), before crossing over to the intervention period for 1 month.
89467244|NCT01345253|Experimental|Belimumab|10mg/kg
88946561|NCT01909284|Experimental|Acupuncture & Epidural nerve block|acupuncture plus epidural block
89467245|NCT01345253|Placebo Comparator|Placebo|placebo
89467246|NCT02038712|Experimental|Binge eating disorder (BED)|Blood samples, subjective appetite ratings and fMRI scan will be collected in subjects who meet the current criteria for binge eating disorder (BED) in the fed condition and fasted condition.
89467247|NCT02038712|Experimental|Control|Blood samples, subjective appetite ratings and fMRI scan will be collected in subjects who do not meet the current criteria for BED (Controls) in the fed condition and fasted condition.
89467248|NCT03411447|Active Comparator|Parenteral nutrition|Patients will receive parenteral nutrition during the first week of mechanical ventilation. After Day 3, the parenteral route may be switched to the enteral route if shock resolve (vasoactive drug stopped since 24 hours and serum lactate level < 2 mmol/l). After Day 7, all patients will be fed via the enteral route.
89467249|NCT03411447|Active Comparator|Enteral nutrition|Patients will receive nutrition only via the enteral route during the firs week of invasive mechanical ventilation.
89467250|NCT03640715|Other|group A|Group A: no vulnerability according to expert with no indication of any PASS marker care
88946562|NCT01909284|Active Comparator|Epidural nerve block|epidural block alone
88946563|NCT01909297|Active Comparator|ProSeal LMA|Supraglottic airway device
88946564|NCT01909297|Active Comparator|suprema LMA|Supraglottic airway device
89467251|NCT03640715|Other|group B|Group B: probable vulnerability according to the expert with indication of at least one PASS marker care
89467252|NCT03640715|Other|group c|Group C: high vulnerability according to the expert with indication of at least two care markers PASS
89467253|NCT02351726|Experimental|Mitroflow DL|Treatment with Mitroflow Pericardial Aortic Heart Valve with Phospholipid Reduction Therapy (Model DL)
89467254|NCT01065077|Experimental|Arm 1|
89467255|NCT01065077|Experimental|Arm 2|
88946565|NCT01909297|Active Comparator|I-gel LMA|Supraglottic airway device
88946566|NCT01909310|Active Comparator|with head support|patients are ventilated with their heads positioned on a support
88946567|NCT01909310|Sham Comparator|without head support|patients are ventilated without head support
88946568|NCT01909323|Placebo Comparator|sugary dessert cream|
88946569|NCT01909323|Experimental|maltitol alone|
88946570|NCT01909323|Experimental|maltitol 85% / FOS 15%|
88946571|NCT01909323|Experimental|maltitol 68% / FOS 32%|
88946572|NCT01909323|Experimental|maltitol 50% / FOS 50%|
88946573|NCT01909323|Experimental|FOS alone|
88946574|NCT01909349|No Intervention|Control Group|Control Group will gain access to the intervention after the intervention group has finished the program (>8 weeks after signing up)
88946575|NCT01909349|Experimental|Intervention Group I|Self-regulation support Behavior sequence: Physical activity, then fruit & vegetable intake
88946576|NCT01909362||Early recurrence (≤ 12 months)|Biospecimens from 25 patients who have had early recurrence (≤ 12 months) of their metastatic colorectal cancer
88946577|NCT01909362||Late recurrence (> 12 months)|Biospecimens from 25 patients who have had late recurrence (> 12 months) of their metastatic colorectal cancer
88946578|NCT01909388|Experimental|MRI-TRUS fusion guided real time HDR|Patients treated with dose escalation to Dominant Intraprostatic Lesions
88946579|NCT01909440|Experimental|Arm I (RT + PS)|Patients undergo total body high-intensity RT thrice weekly and perform static stretching exercises after each session. Exercises progress from low intensity and high volume to higher intensity and lower volume over the course of the 12-week program. Patients also receive whey protein supplementation orally twice a day for 12 weeks.
88946580|NCT01909440|Experimental|Arm II (total body RT)|Patients undergo total body RT and stretching as in Arm I.
88946581|NCT01909440|Experimental|Arm III (protein supplementation)|Patients receive whey protein supplementation as in Arm I. Patients also undergo a home flexibility program 3 times per week, consisting of the same static stretching exercises performed after RT. After 12 weeks, patients may undergo the RT program as in Arm I.
89467256|NCT01065077|Experimental|Arm 3|
89467257|NCT01065077|Placebo Comparator|Arm 4|
89467258|NCT03397329|Active Comparator|Sequence A|
89467259|NCT03397329|Active Comparator|Sequence B|
89467260|NCT03150134|Experimental|early reduction|Usually in the absence of GvHD, immunosuppressive drugs(Cyclosporine) were gradually reduced by 6 weeks and discontinued in three months after transplant in the advanced patients while immunosuppressive agents were gradually reduced by 2 months and discontinued in four months after transplant in the advanced patients in haploidentical SCT even if complete donor chimerism (CDC) achieved. If donor chimerism had not achieved CDC with no significant acute GVHD at four weeks after HSCT, immunosuppressive agents were gradually reduced. If GvHD was present during the time of immunosuppressive agents reduction, CsA was added again and tapering was done over longer periods.
89467261|NCT03150134|Placebo Comparator|routine reduction|Arm/Group Descriptions.Immunosuppressive drugs(cyclosporine) were routine reduced by 3 months and discontinued in the 5 months without GvHD in the CR group. We used the result of chimerism as the reference.
89467262|NCT02351648|Experimental|Intervention'|"Intervention extend from transfer of care to the study team from the initial admission medical team through 90 days after discharge~Intervention in hospital includes the following. Comprehensive discharge planning based on the 6 principles. Discharge planning initially within 24 hours of recruitment Daily ward review of patients Weekly multi-disciplinary meeting Consolidation of medication and follow-up appointment before discharge Assessment of needs before discharge Comprehensive discharge summary and medication record at discharge~Intervention after discharge:~Work done mainly by integrated care nurse Review of patients within 48 hours after discharge via home visit or phone call Subsequent home visit as needed based on patient's needs At least weekly contact with pt or caregiver via telephone Telephone availability working weekday 8 AM to 5 PM Multi-disciplinary meeting for problematic cases Use chronic disease pathway for suitable patients"
89467263|NCT02351648|Active Comparator|Control'|Patients receive usual standard of care from the internal medicine team
89467264|NCT03411057||Mindfulness Based Stress Reduction (MBSR)|Inflammatory Arthritis (Rheumatoid Arthritis, Psoriatic Arthritis) and scleroderma participants in this group will attend an 8 week MBSR course. The MBSR course meets once per week for 2.5 hours with a 4-hour retreat on week 8.
89467265|NCT03411057||Control|Rheumatoid Arthritis, Psoriatic Arthritis, and scleroderma participants in this group will watch an educational stress reduction video (10 minutes).
89467266|NCT02356094||Cases|Patients with primary open angle glaucoma, randomly selected from the Glaucoma Outpatient Clinic to be submitted to Pentacam examination
89467267|NCT02356094||Controls|Control group of age and central corneal thickness matched healthy subjects, randomly selected from the General Ophthalmology Outpatient Clinic to be submitted to Pentacam examination
89467268|NCT03640637||Suspected IBD|A prospective study of 50 pediatric patients suspected of IBD. Participants will undergo routine diagnostic procedures for evaluation of pediatric IBD including blood samples, faecal samples, endoscopies (colonoscopy and gastroscopy with biopsy/histology) and MRI of the abdomen. In addition, a PET scan will be performed in this protocol and combined with MRI. For accuracy measures, PET/MRI scan will be compared to the combined findings of endoscopy, histology and severity of inflammation by clinical scoring systems (weighted Pediatric Crohn's Disease Activity Index (wPCDAI) for CD and Pediatric Ulcerative Colitis activity Index (PUCAI) for CU), faecal calprotectin and biochemistry.
88946582|NCT01909440|Active Comparator|Arm IV (attention control)|Patients undergo the home flexibility program as in Arm III. After 12 weeks, patients may undergo total body RT as in Arm I.
88946583|NCT01909505||Normal Males|Males with normal levels of serum testosterone
88946584|NCT01909505||Hypogonadal males|Males known to have low levels of serum testosterone
88946585|NCT01909518||pCLE examination|pCLE is used to distinguish the suspected lesions detected by I-SCAN in esophagus
88946586|NCT01909544|Experimental|Oxygen|
88946587|NCT01909544|Sham Comparator|Room air|
88946588|NCT01909557|Active Comparator|Acetyl-L-carnitine|Acetyl-L-carnitine 2 gr tablets
88946589|NCT01909557|Placebo Comparator|placebo|
88946590|NCT01909583|Active Comparator|STAGES PRE-GROUP|"INTERVENTION: this group will receive our STAGES booklet PRE-operatively"
88946591|NCT01909583|Placebo Comparator|STAGES POST-GROUP|INTERVENTION: This arm will only receive the STAGES-booklet POST-operatively
88946592|NCT01909596|Experimental|Knee osteoarthritis patients|Without orthoses 6° lateral wedge insoles 10° lateral wedge insoles Neutral customized foot orthoses 6° lateral customized foot orthoses 7° lateral customized foot orthoses 8° lateral customized foot orthoses 9° lateral customized foot orthoses 10° lateral customized foot orthoses Orthotist integrated lateral customized foot orthoses Orthotist lateral customized foot orthoses
88946593|NCT01909609|Sham Comparator|Parent Survival Guide|This arm of the study will focus on the document that is normally given to all parents of newborn infants. It contains information on newborn care such as feeding, cleaning of the baby's penis, etc.
88946594|NCT01909609|Experimental|AAP Documents + Parent Survival Guide.|This arm of the study will focus on documents created based off of the American Academy of Pediatrics 2012 policy statement. They contain information on the potential risks and benefits of neonatal circumcision. The Parent Survival Guide contains information on newborn care such as feeding, cleaning of the baby's penis, etc.
88946595|NCT01909622|Experimental|Vitamin D-fortified milk|Skim milk fortified with 600 IU vitamin D3 / 250 mL
88946596|NCT01909622|Active Comparator|Vitamin D-unfortified milk|Unfortified skim milk
88946597|NCT01909635|Experimental|Food Feelings|If you are randomized to this group, you will be asked to think about your feelings of hunger, fullness, and the sensory qualities of the food (such as texture, smell, flavor) as you eat your meal.
89467269|NCT03640637||Treatment response group|A pilot study of 10-15 patients previously diagnosed with CD who will undergo PET/MRI scan as an investigational procedure before initiation of biological treatment with an anti-TNF-alpha antibody (infliximab, adalimumab) because of disease relapse or steroid dependent disease. Patients will be scheduled for a PET/MRI again after one month. This study will evaluate if PET/MRI can diagnose a flare in CD and if PET/MRI is a reliable imaging tool to monitor intestinal inflammation. In this study the patient will act as his/her own control.
89467270|NCT03411369|Experimental|Creatine, D-Ribose, B1 Vitamin, and B6 vitamin|Water-soluble powder in sachets of 4 grams. Each sachet contains 1 gram of Creatine, 2.5 grams of D-Ribose, 0.33 mg of B1 vitamin and 0.42 mg of B6 vitamin.
89467271|NCT03411369|Placebo Comparator|Placebo|Water-soluble powder in sachets of 4 grams containing inert product consisting of starch powder.
89467272|NCT03160352|Experimental|Exergame|The Senso is a training system (dividat, Schindellegi, Switzerland) for improving physical and cognitive function was used as exergame. With foot pushes participants triggered on a pressure-sensitive plate. The Senso game was projected with a beamer at white wall. To promote head movement during training the direction of the beamer was vertical tilted (± 15°) and horizontal turned (90°) with a remote controlled power panner.
89467273|NCT04653207|Other|Control 1|Glucose 50g
89467274|NCT04653207|Other|Control 2|Glucose 50g
89467275|NCT04653207|Other|Control 3|Glucose 50g
89467276|NCT04653207|Experimental|Sucrose/Isomaltulose 100:0|A drink with 50g sucrose/isomaltulose 100:0
89467277|NCT04653207|Experimental|Sucrose/Isomaltulose 0:100|A drink with 50g sucrose/isomaltulose 0:100
89467278|NCT04653207|Experimental|Sucrose/Isomaltulose 50:50|A drink with 50g sucrose/isomaltulose 50:50
89467279|NCT04653207|Experimental|Sucrose/Isomaltulose 60:40|A drink with 50g sucrose/isomaltulose 60:40
89467280|NCT04653207|Experimental|Sucrose/Isomaltulose 70:30|A drink with 50g sucrose/isomaltulose 70:30
89467281|NCT04653207|Experimental|Sucrose/Isomaltulose 80:20|A drink with 50g sucrose/isomaltulose 80:20
89467282|NCT03411291||Diet: MRI/MR Spectroscopy/MR Perfusion|Healthy candidates for statin therapy to lower cholesterol pre-electing to lower cholesterol by diet for three months. Candidates in this arm have pre-elected to lower cholesterol by diet as described under the care of their treating physicians. Candidates will have 1 (one) brain MRI / MR spectroscopy/MR resonance perfusion scan at baseline and 1 (one) brain MRI / MR spectroscopy/MR resonance perfusion scan at 3 (three) months.
89467283|NCT03411291||Statin: MRI/MR Spectroscopy/MR Perfusion|Healthy candidates for statin therapy pre-electing to lower their cholesterol using atorvastatin (Lipitor) 20 mg per day as prescribed by their treating physician per standard of care. There are no research-related interventions for this group. Candidates will have 1 (one) brain MRI / MR spectroscopy/MR resonance perfusion scan at baseline and 1 brain MRI / MR spectroscopy/MR resonance perfusion scan at 3 months.
89467284|NCT02351804|Experimental|Ropivacaine + dexamethasone|20 ml ropivacaine 0.5% + 0.5 ml dexamethasone 4 mg7ml
89467285|NCT02351804|Placebo Comparator|Ropivacaine + placebo|20 ml ropivacaine 0.5% + 0.5 ml isotonic saline ad
89467286|NCT03411213|Experimental|Vascular function|Diffuse optical tomography detection of differences in vascular function between healthy volunteers and patients with proven heart disease or diabetes.
89467287|NCT03411213|Experimental|Coronary artery disease|Diffuse optical tomography prediction of presence or severity of coronary artery disease on angiography.
89467288|NCT03149900||Secukinumab|"Patients will be recruited in the Comprehensive Center for Inflammation Medicine. The study population will consist of 40 subjects (both male and female), aged 18 years and older, in whom treatment with Secukinumab is clinically indicated and according to the licensed product specifications. The study drug will be prescribed by a doctor who is independent of this study. Visit 1 will be carried out prior to the first injection of Secukinumab.~All patients will receive a number and the data will be recorded in a pseudo-anonymised form. No blinding is necessary for investigators or patients (open study), as all patients receive the same treatment (marketed product)."
89467289|NCT03410979|Experimental|GLPG2737 single dose|Single doses of GLPG2737 oral suspension at up to 5 dose levels in ascending order
89467290|NCT03410979|Placebo Comparator|Placebo single dose|Single doses of Placebo oral suspension
89467291|NCT03410979|Experimental|GLP2737 multiple dose|Multiple doses of GLPG2737 oral suspension at up to 3 dose levels in ascending order
89467292|NCT03410979|Placebo Comparator|GLPG2737 multiple dose|Multiple doses of Placebo oral suspension
89467293|NCT02356016|Active Comparator|Whole body Electromyostimulation (WB-EMS)|18 min of WB-EMS/week (one session/week)
89467294|NCT02356016|Active Comparator|WB-EMS and Nutritional Supplements|18 min of WB-EMS/week (one session/week) and supplements with high protein (Leucin) contents
89018431|NCT03782610||Validation Cohort|225 Infants. Will allow subsequent validation of models derived from the Primary Study Cohort.
89467295|NCT02356016|Sham Comparator|Control|Monthly dietary counseling for 6 months
88946598|NCT01909635|Experimental|Other Feelings|If you are randomized to this group, you will be asked to think about how hot or cold you feel, and how tired you are feeling as you eat your meal.
88946599|NCT01909648|Other|HbA2 Leuven|Presence of HbA2 Leuven mutation, demonstrated by molecular diagnosis on blood sample.
89467296|NCT03640403|Experimental|DP|Dihydroartemisinin-piperaquine (DP), antimalarial drug to be given every 4 months 3 rounds for the first year. A second non-interventional year will assess possible rebound effects.
89467297|NCT03640403|Active Comparator|ASAQ|Artesunate-amodiaquine (ASAQ), antimalarial drugs to be given every 4 months 3 rounds for the first year. A second non-interventional year will assess possible rebound effects.
89467298|NCT03640403|No Intervention|Control|No intervention drugs will be given, but normal routine standard of care will be provided.
89467299|NCT03126357|Experimental|Product usage order ABECD|Subjects will use each of the 5 products (ABECD) sequentially for 1 and 1/2 days during an 11 day confinement, followed by a 4 hour Test Session.
89467300|NCT03126357|Experimental|Product usage order BCADE|Subjects will use each of the 5 products (BCADE) sequentially for 1 and 1/2 days during an 11 day confinement, followed by a 4 hour Test Session.
89467301|NCT03126357|Experimental|Product usage order CDBEA|Subjects will use each of the 5 products (CDBEA) sequentially for 1 and 1/2 days during an 11 day confinement, followed by a 4 hour Test Session.
89467302|NCT03126357|Experimental|Product usage order DECAB|Subjects will use each of the 5 products (DECAB) sequentially for 1 and 1/2 days during an 11 day confinement, followed by a 4 hour Test Session.
88946600|NCT01909661|Experimental|Damira/Celia peptide hydrolyzed casein|Extensively Hydrolyzed (EH)casein infant formula
88946601|NCT01909661|Experimental|Picot riz/Celia rice/Sanutri arroz|Picot riz/Celia rice/Sanutri arroz Extensively Hydrolyzed (EH) rice protein infant formula
88946602|NCT01909700|Experimental|Single Incision Mesh|intervention: single incision mesh implantation
88946603|NCT01909726||Interactive media|ScreenPlay
88946604|NCT01909726||Passive media|Silent nature video
88946605|NCT01909726||No media|Standard care
88946606|NCT01909739|Experimental|Statin group|
88946607|NCT01909739|Placebo Comparator|Placebo group|
88946608|NCT01909752|Experimental|DRibble Vaccine Alone|Cyclophosphamide (300 mg/m2) will be administered as a single dose three days prior to beginning vaccine therapy. DRibble vaccine will be administered at Weeks 1, 4, 7, 10, 13, 16, 19, 25, 31, 37, and 43. Immunization with HPV vaccine intramuscular injection at the time of the first and third vaccinations.
88946609|NCT01909752|Experimental|DRibble vaccine with imiquimod|Cyclophosphamide (300 mg/m2) will be administered as a single dose three days prior to beginning vaccine therapy. DRibble vaccine will be administered at Weeks 1, 4, 7, 10, 13, 16, 19, 25, 31, 37, and 43. Imiquimod cream (5%, 250 mg containing 12.5 mg imiquimod - one packet/day) will be self applied once per day starting with the second vaccine (week 4) and for four days following each vaccine cycle. Immunization with HPV vaccine intramuscular injection at the time of the first and third vaccinations.
89467303|NCT03126357|Experimental|Product usage order EADBC|Subjects will use each of the 5 products (EADBC) sequentially for 1 and 1/2 days during an 11 day confinement, followed by a 4 hour Test Session.
89467304|NCT03126357|Experimental|Product usage order DCEBA|Subjects will use each of the 5 products (DCEBA) sequentially for 1 and 1/2 days during an 11 day confinement, followed by a 4 hour Test Session.
88946610|NCT01909752|Experimental|DRibble vaccine with GM-CSF|Cyclophosphamide (300 mg/m2) will be administered as a single dose three days prior to beginning vaccine therapy. DRibble vaccine will be administered at Weeks 1, 4, 7, 10, 13, 16, 19, 25, 31, 37, and 43. GM-CSF will be administered at 50 mcg/day starting with the second vaccine (week 4) and continuing with each subsequent vaccine. Immunization with HPV vaccine intramuscular injection at the time of the first and third vaccinations.
88946611|NCT01909765|Active Comparator|Dorsal slite|Skin and mucosa insicion made together
89467305|NCT03126357|Experimental|Product usage order EDACB|Subjects will use each of the 5 products (EDACB) sequentially for 1 and 1/2 days during an 11 day confinement, followed by a 4 hour Test Session.
89467306|NCT03126357|Experimental|Product usage order AEBDC|Subjects will use each of the 5 products (AEBDC) sequentially for 1 and 1/2 days during an 11 day confinement, followed by a 4 hour Test Session.
89467307|NCT03126357|Experimental|Product usage order BACED|Subjects will use each of the 5 products (BACED) sequentially for 1 and 1/2 days during an 11 day confinement, followed by a 4 hour Test Session.
89467308|NCT03126357|Experimental|Product usage order CBDAE|Subjects will use each of the 5 products (CBDAE) sequentially for 1 and 1/2 days during an 11 day confinement, followed by a 4 hour Test Session.
89467309|NCT02477800|Experimental|Low Dose|Monthly intravenous (IV) infusion
88946612|NCT01909765|Experimental|Double incision|Skin and mucosa incision made separately
88946613|NCT01909817||Routine coronary angiogram patients|
88946614|NCT01909830|Experimental|Arm A : Gemcitabine + Pemetrexed|"Arm A : Gemcitabine: 1000 mg/m2 by intravenous infusion over an exact period of 30' (preferably by a pump to guarantee a constant speed of infusion) on day 3 of each cycle repeated every 14 days.~Pemetrexed: 150 mg/m2 by intravenous continuous infusion over an exact period of 8h on day 1 of each cycle repeated every 14 days."
88946615|NCT01909843|Experimental|ALX-0171 Oral inhalation|
88946616|NCT01909856|Experimental|Arm1|1st cycle Palonosetron, 2nd cycle Granisetron
88946617|NCT01909856|Experimental|Arm2|1st cycle Granisetron, 2nd cycle Palonosetron
88946618|NCT01909869|Experimental|EXCEL-Ⅱ|A new Cobalt ChRomium Alloys Sirolimus Eluting BioDegradable Polymer Stent In the Treatment of Patients with de novo Coronary Artery Lesions.
88946619|NCT01909882|Other|Family member's massage therapy|Family member's massage therapy
88946620|NCT01909908|Experimental|ECM in Saline|
88946621|NCT01909908|Active Comparator|Blood Products|
88946622|NCT01909908|Experimental|ECM in Blood Products|
88946623|NCT01909947||Intubated extreme preterm infants|Infants with a birth weight ≤ 1250 grams and requiring endotracheal tube and mechanical ventilation
88946624|NCT01909960|Experimental|Surgery|Patients who will undergo flow imaging and neurosurgery (shunting). (25% of the studied population)
88946625|NCT01909960|Experimental|Clinical follow-up|Patients who will undergo flow imaging but not surgery (75% of the studied population)
88946626|NCT01909986|Experimental|E1|[14C]-ONO-4053
88946627|NCT01909999|Experimental|Immediate loading implants|The clinical and immunological comparisons compared implants that received Immediate loading prosthesis, i.e., full arch Branemark protocol prosthesis installed within 3 days after surgery, with unloaded implants.
88946628|NCT01909999|Active Comparator|Unloaded Implants|The variables, immunological and clinical, obtained in immediate loading groups were compared to unloaded implants, i.e., no prosthetic rehabilitation during osseointegration.
88946629|NCT01910038|Experimental|Prednisone+Tocilizumab|Prednisone (0.7 mg/Kg/d and then progressively tapered to reach 0.1 mg/Kg/d at W24) + tocilizumab 8mg/Kg/4 weeks for a total of 4 infusions (S0, S4, S8, S12).
88946630|NCT01910077|Experimental|Tacrobell capsule 1mg|Tacrolimus 1mg / 1 capsule
88946631|NCT01910077|Active Comparator|Prograf capsule 1mg|Tacrolimus 1mg / 1 capsule
89467310|NCT02477800|Experimental|High Dose|Monthly intravenous (IV) infusion
89467311|NCT02361398|Experimental|EIT group|the Individualized PEEP titration by EIT was administered to the patients in the EIT group.
89467312|NCT02361398|No Intervention|control group|If patients are assigned to the control group, the Individualized PEEP Setting was by PEEP-FiO2 table based on ARDS-net protocol.
89467313|NCT02355938|Experimental|Fidaxomicin Arm|Oral Fidaxomicin 200 mg every 12 hours (Placebo for 2 doses) for 10 days
89467314|NCT02355938|Active Comparator|Vancomycin Arm|Oral Vancomycin 125 mg every 6 hours for 10 days
89467315|NCT03397173|Experimental|Azacitidine + Ascorbic acid|Azacitidine will be administered intravenously or subcutaneously at a fixed dose of 75mg/m2/day for 7 consecutive days, (allowing for weekends, and holidays) of each 28-day cycle. Ascorbic acid will be administered orally daily at 1 g/day three days prior to start azacitidine and then continues daily for a total of 28 days of each 28 day cycle.
89467316|NCT02360930||Tanner Stage </=2|Patients will be stratified by phase of treatment, and they will be classified into Tanner stage ≤ 2 or ≥ 4, based on physical examination. We plan to have 15 patients in Tanner staging ≤ 2 and 15 patients in Tanner staging ≥ 4.
89467317|NCT02360930||Tanner Stage >/= 4|Patients will be stratified by phase of treatment, and they will be classified into Tanner stage ≤ 2 or ≥ 4, based on physical examination. We plan to have 15 patients in Tanner staging ≤ 2 and 15 patients in Tanner staging ≥ 4.
89467318|NCT02957747|Experimental|Safety and Health Experiences Program|Participants in the SHE arm of the study will receive a web-based intervention utilizing motivational interviewing and education.
89467319|NCT02957747|No Intervention|Control|Participants randomized to this arm will receive referrals to VA and community resources
89467320|NCT02360852|Experimental|A4250|A4250 once daily
89467321|NCT03126279||Preoperative Chronic Knee OA Patients|Patients will be recruited from orthopaedic preoperative clinics from those awaiting total knee replacement surgery.
89467322|NCT03126279||Healthy Volunteers|Healthy volunteers will be recruited that are aged match to our OA patient cohort so meaningful comparisons regarding brain activity and pain sensitisation characteristics can be assessed.
89467323|NCT02361008|Experimental|TPDC group|Patients who matched inclusion criteria and randomly divided into TPDC group underwent the TEE-guided perventricular device closure without CBP. But of them,who underwent TPDC failure during the procedure would be dropped out of the trial.
89467324|NCT02361008|Experimental|SR group|Patients who matched inclusion criteria and randomly assigned into SR group underwent the surgery repair with CBP.
89467325|NCT03397095|Experimental|CSWT+BMMSCs|Patients in CSWT+BMMSCs group will receive a 3-month cardiac shock wave therapy and then a total of 1 million/kg BMMSCs will be infused using the stop-flow technique through an over-the-wire balloon catheter positioned in a coronary artery or bypass graft supplying the targeting viable myocardium.
88946632|NCT01910090|Experimental|FLURBIPROFEN 100 mg FAMOTIDINE 20 mg MULTI-LAYER TABLET|FLURBIPROFEN, FAMOTIDINE 100/20 mg MULTI-LAYER TABLET one tablet, once
88946633|NCT01910090|Active Comparator|ANTADYS® and PEPCID®|ANTADYS® 100 mg, PEPCID® 20 mg two tablets, taken once
88946634|NCT01910142|Active Comparator|calcium supplement with vitamin K|Milk product supplying about 420 mg Ca and 7.5 μg vitamin D3 and 100 μg vitamin K. Additional 200 mg calcium in the form of carbonate
88946635|NCT01910142|Placebo Comparator|calcium supplement without vitamin K|Milk product supplying about 420 mg Ca and 7.5 μg vitamin D3. no vitamin K. Additional 200 mg calcium in the form of carbonate
88946636|NCT01910155|Experimental|Test|Ciprofloxacin/Dexamethasone
88946637|NCT01910155|Active Comparator|Reference|Ciprodex (R)
88946638|NCT01910155|Placebo Comparator|Placebo|Placebo
88946639|NCT01910168||Cohort|
88946640|NCT01910194|Other|Lyxumia|4 weeks Luxumia plus another 4 weeks combination
88946641|NCT01910194|Other|Lantus|4 weeks Lantus plus another 4 weeks combination
88946642|NCT01910220|Placebo Comparator|Group 1|placebo
88946643|NCT01910220|Experimental|Group 2|REGN1033 (SAR391786)
88946644|NCT01910220|Placebo Comparator|Group 3|placebo + exercise regimen
88946645|NCT01910220|Experimental|Group 4|REGN1033 (SAR391786) + exercise regimen
88946646|NCT01910233||adult patients with acute dyspnea in ED|
88946647|NCT01910246|Experimental|Metformin, Insulin Resistance, Cardiac Function,|Metformin Hydrochloride Tablets will be administered with a start dose of 500mg twice daily with meals.
88946648|NCT01910259|Experimental|Amiloride|Amiloride 5 mg twice per day (5 mg once per day for first 4 weeks) for 96 weeks
88946649|NCT01910259|Experimental|Riluzole|Riluzole 50 mg twice per day (50 mg once per day for first 4 weeks) for 96 weeks
89467326|NCT03397095|Sham Comparator|CSWT+Sham operation|Placebo group will receive a 3-month CSWT and a sham procedure.
89467327|NCT03640247|Other|Narcotic group regimen|"Tylenol tablet 1000 mg by mouth every 8 hours alternating with~Ibuprofen tablet 800 mg by mouth every 8 hours~Oxycodone 5 mg by mouth every 6 hours as needed for pain, #10 tablet or if needed based on patient allergies, hydrocodone 5 mg/tramadol 50 mg."
88946650|NCT01910259|Experimental|Fluoxetine|Fluoxetine 20 mg twice per day (20 mg once per day for first 4 weeks) for 96 weeks
88946651|NCT01910259|Placebo Comparator|Placebo|Matched placebo 1 capsule twice per day (1 capsule a day for first 4 weeks) for 96 weeks
88946652|NCT01910285|Experimental|Remifentanyl- sufentanil placebo|3 mg/kg of propofol combined with 3 µg/kg of remifentanil
88946653|NCT01910285|Active Comparator|Sufentanil - remifentanyl placebo|3 mg/kg of propofol combined with 0.3 mg/kg of sufentanil
88946654|NCT01910324|Experimental|Multidimensional Family Therapy Cross-Systems|In Stage 1 (in detention) Multidimensional Family Therapy Cross-Systems (MDFT-CS) consists of two major components: standard initial/engagement work with parents in the home and with adolescents in detention, plus a state-of-the-art HIV education prevention module. In Stage 2, MDFT-CS includes the standard MDFT components: 1) interventions with the adolescent, 2) interventions with the parent, 3) interventions to improve the parent-adolescent relationship, 4) interventions with other family members, and 5) interventions with external systems.
88946655|NCT01910324|Other|Enhanced Services as Usual|In Stage 1 (in detention) ESAU includes two major components: standard drug treatment services delivered by detention staff, and state-of-the-art HIV education prevention intervention. In Stage 2, community drug treatment providers deliver high quality drug treatment on an outpatient basis.
88946656|NCT01910337||Screening|this first day, the patient will be evaluated with polar and blood pressure monitor. These data will be the basal one.
88946657|NCT01910337||Intervation|One week later the screening, the patient underwent to the surgery to remove his lower third molar. In this day, will be analyzed 4 points: basal, after the anesthesia, after the avulsion and 20 minutes after the surgery.
88946658|NCT01910337||Post operative|One week later the surgery, the patients will be evaluated again.
88946659|NCT01910350|Experimental|Cancer prevention intervention|Cancer prevention intervention: Experimental group receives intensive 2 hour education in each breast and cervical cancer risks and prevention intervention, and face to face reading of post intervention surveys by an community health worker.
88946660|NCT01910350|Active Comparator|Control group receives standard care|The control group receives reading materials and brochures on breast and cervical cancer such as one would receive in a doctors office and post condition surveys. All materials are read by the participant without the interaction or assistance of the community health worker.
88946661|NCT01910363|Experimental|A2NTX|single intramuscular injection of 300 units of A2NTX, a purified low molecular weight (150 kDalton) botulinum toxin preparation of type A2
88946662|NCT01910363|Active Comparator|BOTOX|single intramuscular injection of 300 units of BOTOX®, a commercially available botulinum toxin preparation of type A1
88946663|NCT01910376||Control cohort|Nursing home residents without cancer
88946664|NCT01910376||Cancer patient cohort|Patients in nursing homes with suspected or diagnosed active invasive cancer where a diagnostic or treatment decision has to be taken
88946665|NCT01910376||Biomarker cohort|Subgroup of individuals in the control cohort willing to provide a blood sample
89018432|NCT03761394|Experimental|Intervention Group|Testing devices plus Cardea Solo device by Cardiac Insight for 14-day period.
89467328|NCT03640247|Active Comparator|Non-narcotic group regimen|"Tylenol tablet 1000 mg by mouth every 8 hours alternating with~Ibuprofen tablet 800 mg by mouth every 8 hours"
89467329|NCT02360696||Peds/Adol Pts w/ FD - CMH GI APT clinic|"Phase 1. Standard-of-Care Endoscopy to establish baseline data and immunohistochemistry studies. Additional biopsies taken for DNA and microarray analysis. If participant biopsies meet criteria (> or = 20/hpf) and no nodularity or tumors, s/he will be eligible to move to second phase.~Phase 2. Standard of care treatment of 3 mg/kg ranitidine bid and 20 mg. montelukast each AM for three weeks. Based on response to global assessment score, participants will be placed in non-responder or responder group. Participants from the responder group will move to final phase of the study.~Phase 3: Research endoscopy to measure response to montelukast therapy. Biopsies taken for cell density counts and immunohistochemistry studies. Additional biopsies taken for DNA and microarray analysis."
89467330|NCT03396939|Experimental|Orthosis|The intervention will be performed individually and will run for 12 weeks both at the community rehabilitation unit (3 times a week for 3 weeks) and at home (9 weeks). The group will receive an orthotic device for use during the study-specific exercises.
89467331|NCT03396939|No Intervention|Control|The group will receive the same amount of a study-specific training program without the orthotic device.
89467332|NCT03640169|Experimental|Management of TCM preventive medicine|The Health management model include: (1) Body constitution measurement (2) Health promotion literacy education lectures (3) Duo-in qigong practice.
89467333|NCT03394131|Experimental|Hyalase|injection and hydro-dissection of median nerve using hyaluronidase followed by 10 cc normal saline ultrasonic guided
89467334|NCT03394131|Placebo Comparator|Placebo|injection and hydro-dissection of median nerve hydro-dissection using 10 cc saline injection ultrasonic guided
89467335|NCT03394131|Active Comparator|Insilin|injection and hydro-dissection of median nerve hydro-dissection using 10 IU insuline followed by 10 cc normal saline ultrasonic guided
89467336|NCT02360618|Experimental|Metformin and Simvastatin Treatment|Patients in this group will receive 850 mg of Metformin and 20 mg of Simvastatin daily from the time they are enrolled in the study until the day before their surgery (approximately 12 weeks), in the absence of any safety or tolerability concerns.
89467337|NCT03640091|Experimental|Pre-extractive inter-radicular implant bed preparation|
89467338|NCT02360462|Experimental|Active tDCS|Active tDCS will be applied in the head of the patients in 20 minute sessions, twice. First session will be applied in the night before and the second session, in the morning before the surgical procedure. The stimulation will be administered with a pair of surface electrodes, sponge coated, soaked in saline. A battery-powered constant current stimulator will be used for this purpose (tDCS device). The stimulation is performed by placing the anodal electrode in the primary motor cortex (M1) and the cathodal one in the contralateral supraorbital area, and it will use a 2 mA current
89467339|NCT02360462|Sham Comparator|Sham tDCS|The sham tDCS consists in the same montage of the active tDCS, but the device is turned off 30 seconds after starting stimulation (without letting the patient notice it). The rest of the montage is kept identical to the active one during the 20 minutes session.
89467340|NCT01344161|Placebo Comparator|Lactose|
89467341|NCT01344161|Experimental|Vitamin D|
89467342|NCT03410745|Experimental|Exercise group|
89467343|NCT03410745|No Intervention|Control group|
89467344|NCT02451358|Experimental|Quadrivalent Influenza Vaccine Group 1: 6 to 35 Months|Participants aged 6 to 35 months received 2 doses of 0.25 mL QIV (2016-2017 NH formulation) intramuscularly, 1 injection each at Day 0 and 28.
89467345|NCT02451358|Experimental|Quadrivalent Influenza Vaccine Group 2: 3 to 8 Years|Participants aged 3 to 8 years received 2 doses of 0.5 mL QIV (2016 SH formulation) intramuscularly, 1 injection each at Day 0 and 28.
89467346|NCT02451358|Experimental|Quadrivalent Influenza Vaccine Group 3: 9 to 17 Years|Participants aged 9 to 17 years received 1 dose of 0.5 mL QIV (2015-2016 NH formulation) intramuscularly, at Day 0.
89467347|NCT02451358|Experimental|Quadrivalent Influenza Vaccine Group 4: >=18 Years|Participants aged >=18 years received 1 dose of 0.5 mL QIV (2015 SH formulation) intramuscularly, at Day 0.
89467348|NCT04754373|Experimental|GFA-918|Participants will be instructed to take one GFA-918 capsule twice per day with their morning and evening meals for 12 weeks.
89467349|NCT04754373|Placebo Comparator|Placebo|Participants will be instructed to take one Placebo capsule twice per day with their morning and evening meals for 12 weeks.
89467350|NCT02360384|Placebo Comparator|Sham diet|The placebo intervention will be healthy eating advice in patients with irritable bowel syndrome of the alternating subtype for 28 days.
89467351|NCT02360384|Active Comparator|Lincalotide|All patients with constipation predominant IBS will receive linaclotide 280mcg po od for 28 days.
89467352|NCT02360384|Experimental|FODMAP diet|The FODMAP diet will be introduced in patients with irritable bowel syndrome of the alternating subtype for 28 days.
89467353|NCT03396861|Experimental|Subconjunctival aflibercept|Subconjunctival aflibercept 2 milligrams (mg) /0.05 milliliters (mL) administered at baseline visit and possibly again at Month 1 visit depending on initial response.
89467354|NCT03410589||Single arm|
89467355|NCT04924972||Intracutaneous Suture|
89467356|NCT04924972||running Suture|
89467357|NCT02520843|Experimental|Crohn's disease treated by SVF|Patients with Crohn's disease and fistula-in-ano refractory to conventional medical and surgical treatment, treated by Stromal Vascular Fraction ( SVF) reinjection
89467358|NCT02749721|Other|Other - vortioxetine|Open-label vortioxetine
89467359|NCT02351336||threatened preterm labour|"Women who are diagnosed as having threatened preterm labour based on the American college of obstetricians and gynaecologists guidelines (ACOG,2003) :~Presence of uterine contractions ( at least 4 in 20 minutes or 8 in 60 minutes )~Cervical dilataion >1cm, &/or~Cervical effacement ≥ 80%"
89018433|NCT03761394|Active Comparator|Control Group|Only Cardea Solo device by Cardiac Insight for 14-day period.
89467360|NCT03396627||muller muscle|muller muscle and conjunctiva excised during muller muscle conjunctival resection
89467361|NCT02351102|Active Comparator|Valacyclovir|Participants will receive Valacyclovir at a dose of 8g/d starting at time of proof of primary maternal CMV infection and until amniocentesis (minimum 21 weeks gestation)
89467362|NCT02351102|Placebo Comparator|Placebo|Participants will receive placebo pills (same daily amount as the intervention group) starting at time of proof of primary maternal CMV infection and until amniocentesis (minimum 21 weeks gestation)
89467363|NCT03393897||Hemodynamic instability with hypotension|
89467364|NCT02350868|Experimental|Arm 1|Subjects will be treated with oral doses of MPT0E028 in consecutive, 28-day cycles, and will be evaluated regularly for safety. Subjects who tolerate the drug and who do not experience progressive disease may continue to receive MPT0E028 at the discretion of the principal Investigator for up to 6 cycles.
89467365|NCT03126201||Study Group|Patients with biopsy-proven primary focal segmental glomerulosclerosis.
89467366|NCT02351024|Experimental|OXP005|
89467367|NCT02351024|Active Comparator|Naproxen|
89467368|NCT04631367|Experimental|Kukaa Salama: mHealth intervention|This is a pre-test/post-test trial, therefore all participants will receive the Kukaa Salama mHealth intervention and will be offered a COVID-19 prevention parcel.
89467369|NCT02355704|Active Comparator|Atorvastatin|22 patients received oral atorvastatin 40 mg 1 time for day for 4 weeks
89467370|NCT02355704|Placebo Comparator|Placebo|22 patients received oral placebo 40 mg 1 time for day for 4 weeks
89467371|NCT03396549|Experimental|real tDCS|20 min of 2 mA tDCS over the right and left dorsolateral prefrontal cortex
89467372|NCT03396549|Sham Comparator|new sham tDCS|20 min 2 mA tDCS over the left and right sensorimotor cortex
89467373|NCT02355548||Outpatient Treatment|All patients eligible for the study will have their PE treated in the outpatient setting.
89467374|NCT03396393|Experimental|Dihydroartemisinin 40mg|Randomized 30 patients will be received Dihydroartemisinin tablets 40mg in oral continuously from Week 0 to Week 24 in addition to SOC.
89467375|NCT03396393|Experimental|Dihydroartemisinin 80mg|Randomized 30 patients will be received Dihydroartemisinin tablets 80mg in oral continuously from Week 0 to Week 24 in addition to SOC.
89467376|NCT03396393|Experimental|Dihydroartemisinin 120mg|Randomized 30 patients will be received Dihydroartemisinin tablets 120mg in oral continuously from Week 0 to Week 24 in addition to SOC.
89467377|NCT03396393|Placebo Comparator|placebo|Randomized 30 patients will be received placebo tablets in oral continuously from Week 0 to Week 24 in addition to SOC.
89467378|NCT02355470|Experimental|Intervention|Participants will receive the GIFTSS intervention provided by college health center staff and clinicians
89467379|NCT02355470|Active Comparator|Control|Participants will receive a brief alcohol use reduction intervention based on NIAAA guidelines provided by college health center staff and clinicians
88946666|NCT01910415|Experimental|Part A|"Will consist of up to 4 cohorts with subjects receiving lumacaftor or placebo for 7 days.~Cohort 1: 600 mg lumacaftor once a day Cohort 2: 1000 mg lumacaftor once a day Cohort 3: 1200 mg lumacaftor once a day"
88946667|NCT01910415|Experimental|Part B|"Will consist of 3 cohorts. All cohorts will be dosed in parallel. Cohort A will receive 600 mg Lumacaftor once a day plus 250 mg Ivacaftor twice a day for 7 days. From day 8-14 subjects will receive a supratherapeutic dose of Lumacaftor (TBD) plus 450 mg Ivacaftor twice a day.~Cohort B will receive lumacaftor and ivacaftor matching placebo for 14 days Cohort C will receive a single dose of 400 mg moxifloxacin on day 14"
88946668|NCT01910428|Experimental|L-asparaginase encapsulated in RBC|L-asparaginase encapsulated in RBC dose titration: 50, 100, 150 or 200 IU/kg
88946669|NCT01910454|Experimental|Cognitive-Oriented Strategy Augmented Rehabilitation (COSTAR)|
88946670|NCT01910454|Active Comparator|Task Specific Training (TST)|
88946671|NCT01910467|Experimental|NIRS visible and predefined interventions|NIRS measurements are visible and the patients will be treated according to predefined clinical interventions: If cTOI/pTOI ratio increases >5% within a six-hours-period echocardiography will be performed and based on results of echocardiography and blood pressure a volume bolus or, if ventilated, modification of ventilation or treatment of patent ductus arteriosus will be considered.
88946672|NCT01910467|Other|NIRS not visible and treatment as usual|NIRS measurements are not visible and the patients will be treated according to routine ('treatment as usual')
88946673|NCT01910480|Experimental|NBI-98854 followed by NBI-98854 with ketoconazole|50 mg NBI-98854 on Study Days 1 and 6 and 200 mg ketoconazole twice daily on Study Days 5 through 9.
88946674|NCT01910493|Active Comparator|ART no SMS reminders|control group
88946675|NCT01910493|Active Comparator|PMTCT no SMS reminders|control group
89467380|NCT03393819|Experimental|Duraprep Surgical Solution|Surgical site (hip) is prepared with Duraprep (iodine-alcohol) prior to surgery according to package instructions.
89467381|NCT03393819|Experimental|Chloraprep Surgical Solution|Surgical site (hip) is prepared with Chloraprep (chlorhexidine-alcohol) prior to surgery according to package instructions.
89467382|NCT02360072||AR group|Allergic rhinitis without any typical asthma symptoms
88946676|NCT01910493|Experimental|SMS reminders to PMTCT cohort|experimental group
88946677|NCT01910493|Experimental|SMS reminders to ART cohort|experimental group
88946678|NCT01910506|Experimental|RDEA3170|
88946679|NCT01910532|Experimental|Clevidipine|Using Clevidipine for the treatment of acute hypertension defined SBP > 160 mmHg in patients who require an Intracranial Pressure Monitoring Device
88946680|NCT01910545|Experimental|OTS167IV|single arm
89467383|NCT02360072||Asthma|Accompanied by typical asthma symptoms and Δ FEV1≥12% in response to a short-acting bronchodilator or bronchial hyperreactivity(BHR) in the methacholine provocation test (PC20≤2.504mg)
89467384|NCT02360072||AR+Asthma|Diagnosed allergic rhinitis concomitant asthma symptoms
89467385|NCT02360072||Control group|non-atopic subjects with neither a history of rhinitis nor asthma
89467386|NCT03619187|Experimental|Single Arm|Study Product
89467387|NCT02360306|Active Comparator|Conventional EBUS|Subjects in this arm will have endobronchial ultrasound bronchoscopy done by the conventional EBUS scope rather than the hybrid EBUS scope. Subjects in this arm, like in the Hybrid EBUS arm, may or may not receive transbronchial forcep biopsies, airway brusings, and/or radial EBUS, depending on clinical need.
89467388|NCT02360306|Experimental|Hybrid EBUS|Subjects in this arm will have endobronchial ultrasound bronchoscopy done by the hybrid EBUS scope rather than the conventional EBUS scope. Subjects in this arm, like in the conventional EBUS arm, may or may not receive transbronchial forcep biopsies, airway brusings, and/or radial EBUS, depending on clinical need.
89467389|NCT02360150|Experimental|second propeller arm scanner|The experimental procedure is to conduct a second helical scanner strictly centered on the heart, 10 minutes after the first helix without inject contrast medium, to assess late enhancement to the inclusion visit.
89467390|NCT03393507|Experimental|apatinib combine with chemotherapy|
89467391|NCT03393507|Active Comparator|chemotherapy|
89467392|NCT01348139|Experimental|1|AZD3199 800 µg inhaled via single inhaler device (SID), single dose
89467393|NCT01348139|Experimental|2|AZD3199 880 µg inhaled via SID, single dose
89467394|NCT01348139|Experimental|3|AZD3199 1400 µg inhaled via SID, single dose
89467395|NCT01348139|Experimental|4|AZD3199 300 µg inhaled via Turbuhaler inhaler, single dose
89467396|NCT01348139|Experimental|5|AZD3199 1200 µg inhaled via Turbuhaler inhaler, single dose
89467397|NCT01348139|Placebo Comparator|6|Placebo inhaled via Turbuhaler inhaler and SID, single dose
89467398|NCT02359760|Experimental|Piezocision group|The experimental group will consist of 14 adults, subjects from 18 to 40 years-old (10 women, 4 men).
89467399|NCT02359760|No Intervention|conventional orthodontics|The control group will consist of 30 matched patients with the same inclusion and exclusion criteria, who have been already treated by conventional orthodontics in the orthodontic clinic of the University of Montreal.
89467400|NCT03393429|Active Comparator|DAVID assisted training|Group I: Training assisted by DAVID devices
89467401|NCT03393429|Placebo Comparator|training recommendation|"Group II: Training based on stay active recommendations"
89467402|NCT02355236|Experimental|Test Group|Naproxen/Esomeprazol 500/20mg and Comparator-Placebo for 12 weeks
89467403|NCT02355236|Active Comparator|Comparator Group|Celecoxib 200mg and Naxozol-Placebo for 12 weeks
89467404|NCT03393351|Experimental|Shared decision-making program|
89467405|NCT03393351|Active Comparator|Usual care|
89467406|NCT03619031|Experimental|LONG LEAVENING|Acute test meal
89467407|NCT03619031|Experimental|SHORT LEAVENING|Acute test meal
89467408|NCT03619031|Active Comparator|TRADITIONAL|Acute test meal
89467409|NCT02359682||Age 20-39|Patients aged from 20 to 39 years old.
89467410|NCT02359682||Age 40-59|Patients aged from 40 to 59 years old.
89467411|NCT02359682||Age 60-79|Patients aged from 60 to 79 years old.
89467412|NCT05169255|Experimental|Azithromycin|24 participants received azithromycin for 3 or 7 days
89467413|NCT05169255|Experimental|Amoxicillin|24 participants received amoxicillin for 3 or 7 days
89467414|NCT02359604|Other|Single Arm Study -microbiome|This is a single-arm study. The patients will serve as their own controls. The PPI administered for PPI-therapy is already FDA approved. A stool sample will be obtained for intestinal microbiome testing before PPI, under PPI and after PPI therapy.
89467415|NCT03410511|Experimental|Nicotine free intake|The participant will wean off nicotine during five days before the experimental session. At the start of the experimental session, participants will be exposed to acute propylene glycol/glycerol (mix 50:50) intake.
89467416|NCT03410511|Experimental|Nicotine intake|The participant will pursuit his regular nicotinic propylene/glycerol intake five days before the experimental session. At the start of the experimental session, participants will be exposed to acute propylene glycol/glycerol/nicotine (mix 50:50) intake.
89467417|NCT03410511|Experimental|Cessation intake|The participant will completely stop his regular nicotinic propylene/glycerol intake during five days before the session. At the start of the experimental session, participants will mimick intake with the device turns off.
89467418|NCT03126669|Active Comparator|Treratment|100% oxygen at 2 ATA at the hyperbaric chamber
89467419|NCT03126669|Placebo Comparator|Placebo|normal air, in the hyperbaric chamber
89467420|NCT02355314|Experimental|ICU patients requiring mechanical ventilation|
89467421|NCT02868229|Experimental|COR-001|
88946681|NCT01910558|Active Comparator|Alpha-cyclodextrin and digestible starch|Supplementation with three grams alpha cyclodextrin with three grams of digestible starch
88946682|NCT01910558|Experimental|Alpha-cyclodextrin|Supplementation with six grams of alpha-cyclodextrin
88946683|NCT01910558|Placebo Comparator|Digestible Starch|Supplementation with six grams of digestible starch
88956472|NCT05137119|Experimental|Penicillin-susceptible staphylococcus aureus (PSSA) - Interventional Arm (backbone therapy)|"Benzylpenicillin - Interventional Arm~Intravenous benzylpenicillin 1.8g (3 million units) every 4 or 6 hours. The minimum protocol duration of allocated study treatment is 14 days for those not allocated to early oral switch, and 5 days for those allocated to early oral switch. For patients with critical illness the intravenous benzylpenicillin administration doses will be adjusted."
89467422|NCT02868229|Placebo Comparator|Placebo|
89467423|NCT02355080|Experimental|On-site bundled rapid HIV/HCV testing|Participants will receive the on-site bundled rapid HIV/HCV testing intervention. In the intervention group, all patients will receive an offer to participate in rapid HIV/HCV testing. Those who accept this offer will: receive pre-test information about testing procedures and education, be tested, receive results during the same visit as testing, and be provided post-test counseling and support services by trained test counselors. Patients with a preliminary positive (i.e., reactive) HIV and/or HCV test result(s) will be actively linked immediately to a health care provider for further evaluation and confirmatory HIV and/or HCV RNA testing.
89467424|NCT02355080|Active Comparator|Standard of care (SOC)|Participants will receive the standard of care (SOC) at the study sites. The SOC entails venipuncture whole blood HIV testing + venipuncture whole blood HCV testing. Blood draws are sent to an external laboratory for processing, and patients must return for test results in another visit. Patients may not receive pre-test information or results and post-test counseling, especially if non-reactive or negative test result(s). Reflex testing is not standard practice, therefore some patients may require another visit and blood draw for confirmatory HIV and/or HCV RNA testing. Linkage to care in the SOC is accomplished by referral to a health care provider, either within the participating substance use disorder treatment organization or passive referral to other health facilities.
89467425|NCT05169021|Active Comparator|Amlodipine folic acid 5.8mg+intensive antihypertensive therapy|This group will receive intensive antihypertensive therapy (systolic blood pressure(SBP) <130 mmHg); with amlodipine folic acid 5.8mg.
89467426|NCT05169021|Active Comparator|Amlodipine folic acid 5.8mg+standard antihypertensive therapy|This group will receive standard antihypertensive therapy (SBP: 130-140 mmHg); with amlodipine folic acid 5.8mg.
89467427|NCT05169021|Active Comparator|Amlodipine+intensive antihypertensive therapy|This group will receive intensive antihypertensive therapy (systolic blood pressure(SBP) <130 mmHg); with amlodipine 5.0mg.
89467428|NCT05169021|Placebo Comparator|Amlodipine+standard antihypertensive therapy|This group will receive standard antihypertensive therapy (SBP: 130-140 mmHg); with amlodipine 5.0mg.
89467429|NCT02359292|Experimental|CHF 5993 HS 200/6/25 pMDI|High Strength fixed combination
89467430|NCT02359292|Active Comparator|CHF 5993 MS 100/6/25 pMDI|Medium Strength fixed combination
89467431|NCT02359292|Experimental|CHF 5993 HS 200/6/25 pMDI + Charcoal Block|High Strength fixed combination plus Charcoal Block
89467432|NCT02359292|Active Comparator|CHF 5993 MS 100/6/25 pMDI + Charcoal Block|Medium Strength fixed combination plus Charcoal Block
89467433|NCT02359292|Placebo Comparator|Placebo pMDI|Placebo
89467434|NCT05168553|Experimental|Revasularization|
89467435|NCT05168553|Active Comparator|Conventional endodontic treatment|
89467436|NCT02359214|Active Comparator|Vitamin D3 Supplement|This group will receive a daily dose of 5000IU (125µg) vitamin D3 (which is half of the recommended safe tolerable upper intake level of vitamin D for healthy individuals) for eight weeks.
89467437|NCT02359214|Placebo Comparator|Placebo|This group will receive 100% lactose placebo daily for eight weeks.
89467438|NCT04480437|Experimental|Study Intervention|mp-BUS data collection
89467439|NCT02359370|Active Comparator|Magnesium Group|Magnesium Sulphate was administered through continuous infusion, immediately before induction of anesthesia
89467440|NCT02359370|Active Comparator|Lidocaine Group|Lidocaine was administered through continuous infusion, immediately before induction of anesthesia
89467441|NCT02956967||Patients receiving Nivestim|
89467442|NCT02359448|Experimental|Melatonin|Patients will be prescribed and dispensed from pharmacy sustained -release Melatonin (Circadin) 2mg. This will be taken every night for twelve weeks.
88946684|NCT01910571|Experimental|P7435|"In Part A, there will be up to 6 cohorts of 8 subjects each (for the 2 cohorts undergoing food effect study, there will be 12 subjects in each cohort). At each dose level, every subject will participate in two periods (one with active, P7435 and the second period with matching placebo or vice versa) separated by appropriate wash-out period between the two periods. The randomization scheme will ensure that no subject undergoes the placebo period twice.~In Part B, there will be up to 3 cohorts of 10 subjects each. Each of the 3 cohorts will participate in two study periods of 10 days of dosing in each (one period with active, P7435 and the other period with matching placebo or vice versa) separated by appropriate wash-out period."
88946685|NCT01910571|Placebo Comparator|Placebo|"In Part A, there will be up to 6 cohorts of 8 subjects each (for the 2 cohorts undergoing food effect study, there will be 12 subjects in each cohort). At each dose level, every subject will participate in two periods (one with active, P7435 and the second period with matching placebo or vice versa) separated by appropriate wash-out period between the two periods. The randomization scheme will ensure that no subject undergoes the placebo period twice.~In Part B, there will be up to 3 cohorts of 10 subjects each. Each of the 3 cohorts will participate in two study periods of 10 days of dosing in each (one period with active, P7435 and the other period with matching placebo or vice versa) separated by appropriate wash-out period."
88946686|NCT01910584||Novasure treated group|patients diagnosed menorrhea were treated with novasure endometrial ablation
88946687|NCT01910597|Experimental|SBG|
88946688|NCT01910623||Patients being studied|APL patients previously enrolled in GIMEMA AIDA 0493 and AIDA 2000 studies.
88946689|NCT01910649|Experimental|Drisapersen|Extension phase of treatment. Intravenous dosing of drisapersen will be investigated as an alternative route of administration
88946690|NCT01910662|Experimental|Part A:|Subjects in the Part A will receive an ID injection of 0.1 mg KLH as 0.1 mL of KLH (1 mg/mL) in the upper right forearm and an ID injection of 0.1 mL of buffer in the lower right forearm and lower and upper left forearm on Day 1.
88946691|NCT01910662|Experimental|Part B:Cohort 1A|Subjects in the Part B Cohort 1A arm will receive a SC immunisation of 5 mg KLH in the right deltoid. On Day 15 subjects will return to the unit for an ID injection of 0.1 mg KLH as 0.1 mL of KLH (1 mg/mL) in the lower right and lower left forearm. On Day 43, 0.1mL of KLH (1 mg/mL) will be injected ID into the upper left forearm and the upper right forearm (The dose can be changed to either 5mg/1mg or 1mg/0.1mg depending on the results from the first 3 subjects in Cohort 1).
89467443|NCT02359526|Experimental|ILUVIEN 190 ug intravitreal implant|All patients will receive ILUVIEN 190 micrograms intravitreal implant in applicator with an initial release rate of 0.2 microgram per day. The implant will be administered by injection according to the method of administration defined in the SmPC (ILUVIEN SmPC). Only one eye of each patient will be treated with ILUVIEN.
89467444|NCT03396237||Group A|Case group contain cases of unexplained infertility women
89467445|NCT03396237||Group B|Control group contain fertile pregnant women
89467446|NCT03410433|Active Comparator|Silk 4.0|Silk suture
89467447|NCT03410433|Active Comparator|PG910 4.0|Vicryl Rapid suture
89467448|NCT03410433|Experimental|PP 4.0|Non-absorbable polypropylene monofilament
89467449|NCT03410433|Active Comparator|Silk 5.0|Silk suture
89467450|NCT03410433|Active Comparator|PG910 5.0|Vicryl suture
89467451|NCT03410433|Experimental|PP 5.0|Non-absorbable polypropylene monofilament
89467452|NCT03410433|Experimental|APG 5.0|Antibacterial Vicryl suture
89467453|NCT03410433|Experimental|ePTFE 5.0|expanded polytetrafluoroethylene
89467454|NCT03618953|Experimental|Arm 1 (Intravenous dosing)|"Fixed dose of Ad-E6E7 administered IM on study Day 1. Followed by one of 3 dose levels (escalation) of MG1-E6E7 administered as 4 infusion (IV) doses over 2 weeks starting at study day 15.~Fixed dose of atezolizumab administered IV every 3weeks starting at study day 43."
89467455|NCT03618953|Experimental|Arm 2 (Intravenous and Intra-tumoral injection dosing)|"Fixed dose of Ad-E6E7 administered IM on study Day 1. Followed by one of 2 dose levels (escalation) of MG1-E6E7 administered as 1 IV dose, starting at study day 15, followed by 2 intratumoral (IT) doses administered on study days 18 & 29.~Fixed dose of atezolizumab administered IV every 3weeks starting at study day 43."
89467456|NCT03147872|No Intervention|5% Oxygen|All patients' embryos will be cultured in 5% oxygen from day 1 through 3 of development. After day 3 of development, patients randomized to this arm will continue to have their embryos cultured at 5% oxygen until they are deemed to be clinically usable or not clinically usable (as per standard protocol).
89018434|NCT03761394|Experimental|Intervention Group for Extended Use|30-additional days of extended use of testing devices for adherence plus Kardia Mobile ECG device by AliveCor.
89018435|NCT03761394|No Intervention|Control Group for Extended Use|No device usage for 30-days following completion of the original 14-day period.
89018436|NCT03724318|Active Comparator|Closure|Patients randomized to the active Group will undergo closure of the left atrium appendage during Heart surgery by means of commercial clips
89018437|NCT03724318|No Intervention|Control|The left atrium appendage will remain open in patients randomized to the control group
89018438|NCT03721952|Experimental|Facilitator-Based Intervention|The 'Facilitator-Based Intervention' includes patient and family member subjects.
89018439|NCT03721952|No Intervention|Usual Care|The 'Usual Care' arm includes patient and family member subjects.
89018440|NCT03718065|Experimental|Lofexidine Men|Men will receive lofexidine (Lucemyra) for 5 weeks. Titration schedule is as follows: 0.36 mg on the first two evenings, 0.36 mg in the morning and evening on days 3 and 4; 0.36 mg in the morning, afternoon, and at bedtime on days 5 and 6; 0.36 mg in the morning and afternoon and 0.72 mg at bedtime on days 7 and 8; 0.36 mg in the morning and 0.72 mg in the afternoon and at bedtime on days 9 and 10, and 0.72 mg in the morning, afternoon and at bedtime on Day 11 and throughout the rest of the study.
89018441|NCT03718065|Experimental|Lofexidine Women|Women will receive lofexidine (Lucemyra) for 5 weeks. Titration schedule is as follows: 0.36 mg on the first two evenings, 0.36 mg in the morning and evening on days 3 and 4; 0.36 mg in the morning, afternoon, and at bedtime on days 5 and 6; 0.36 mg in the morning and afternoon and 0.72 mg at bedtime on days 7 and 8; 0.36 mg in the morning and 0.72 mg in the afternoon and at bedtime on days 9 and 10, and 0.72 mg in the morning, afternoon and at bedtime on Day 11 and throughout the rest of the study.
89018442|NCT03718065|Placebo Comparator|Placebo Men|Men will receive matching placebo for five weeks.
89018443|NCT03718065|Placebo Comparator|Placebo Women|Women will receive matching placebo for five weeks.
89467457|NCT03147872|Experimental|2% Oxygen|All patients' embryos will be cultured in 5% oxygen from day 1 through 3 of development. After day 3 of development, patients randomized to this arm will have their embryos cultured at 2% oxygen until they are deemed to be clinically usable or not clinically usable (per standard criteria).
89467458|NCT03396159|Experimental|mini fluid challenge|mini fluid will be given and stroke volume will be assessed before and after
89467459|NCT02354768|Experimental|lanreotide and anti-diarrheal treatments|"Lanreotide: 1 single injection at day 0 (lanreotide 120 mg)~Diosmectite (3 g) 6 / day for 72 hours (fromD0 to D3)~Chlorhydrate of Loperamide (2 mg capsule or tablet) 6 / day for 72 hours (D0 to D3)~hydration"
89467460|NCT02354768|Active Comparator|Current anti-diarrheal treatments alone|"Diosmectite (3 g) 6 / day for 72 hours (fromD0 to D3)~Chlorhydrate of Loperamide (2 mg capsule or tablet) 6 / day for 72 hours (D0 to D3)~Hydration"
89018444|NCT03701230|Experimental|low temperature rota-flush solution|A total of 66 patients are assigned to low temperature rota-flush solution group after randomization schedule.
89018445|NCT03701230|No Intervention|room temperature rota-flush solution|A total of 66 patients are assigned to room temperature rota-flush solution group after randomization schedule.
89018446|NCT03700567|Experimental|low temperature contrast|A total of 220 patients are assigned to low temperature contrast group after randomization schedule.
89018447|NCT03700567|No Intervention|room temperature contrast|A total of 220 patients are assigned to room temperature contrast group after randomization schedule.
89467461|NCT00000125|No Intervention|Observation|Close Observation.
89467462|NCT00000125|Other|Treatment|Participants treated with commercially available topical ocular hypotensive eye drops.
89467463|NCT03613441|Experimental|Mindful Awareness Practices (MAPs)|Mindful Awareness Practices is a mindfulness-based intervention developed at UCLA's Mindful Awareness Research Center. It is a weekly 2-hour, 6-session, group-based course in mindfulness meditation that is available in-person or online.
89467464|NCT03613441|No Intervention|Control|Waitlist control (intervention will be available to this group at the end of the study period)
89467465|NCT05168397||RV4857A arm|"Application of the product before and during each sun exposure, at least twice a day.~During sun exposures, the applications were renewed as often as necessary, in particular after swimming, perspiring, towelling, in order to ensure a good protection. On days of bad weather, the product was applied in the morning and at the beginning of the afternoon."
89467466|NCT02236897|Experimental|PET Scanning|Imaging of mGluR5 using PET scanning
89467467|NCT02348450|Experimental|Irinotecan plus Cisplatin|first line: irinotecan 65mg/m2 d1,8. Cisplatin 30mg/m2，d1,8, 21days/cycle×6 cycles Second-line: etoposide alone OR etoposide plus cisplatin, dosage will be same as first line or on investigator's discretion.
89467468|NCT02348450|Experimental|Etoposide plus Cisplatin|first line: etoposide 60mg/m2 d1-5 Cisplatin 75mg/m2，d1(recommended), or administer three times with same total daily dose , 21days/cycle×6 cycles Second-line: irinotecan alone or irinotecan plus cisplatin, dosage is same as first line or on investigator's discretion.
89018448|NCT03699020|Experimental|Acceptance and Commitment Therapy (ACT)|The intervention will consists of eight weekly two hour group ACT sessions led by trained lay personnel and followed by homework. ACT is a behavioral therapy.
89018449|NCT03699020|Experimental|Education Control|Consists of eight weekly two hour group chronic pain education sessions led by trained lay personnel and followed by homework.
89018450|NCT03689335|Active Comparator|Operative|Surgical fixation of the humeral shaft fracture
89018451|NCT03689335|Active Comparator|Non-operative|Conservative treatment of the humeral shaft fracture, using a humeral brace
89018452|NCT03684811|Experimental|Phase 1b Dose Confirmation Single Agent (Cohorts 1a-5a)|
89018453|NCT03684811|Experimental|Phase 2 Cohorts FT-2102 Single Agent (Cohorts 1a-5a)|
89018454|NCT03684811|Experimental|Phase 1b and 2 Cohorts Combination (Cohorts 1b and 3b)|
89018455|NCT03684811|Experimental|Phase 1b and 2 Cohort Combination (Cohort 2b)|
89467469|NCT03393273|Experimental|Elotuzumab|This is a single arm phase II trial to assess the Very Good Partial Response rate of a strategy involving autologous hematopoietic stem cell transplantation, after intensive treatment and followed by consolidation phase, with elotuzumab, dexamethasone, velcade, and thalidomide in elderly patients.
89467470|NCT02031653||Study Group|
89018456|NCT03684811|Experimental|Phase 1b and 2 Cohort Combination (Cohort 4b)|
89467471|NCT03613597|Experimental|Etoposide plus Lobaplatin group|Chemotherapy:etoposide plus lobaplatin (EL)
89467472|NCT03613597|Active Comparator|Etoposide plus Cisplatin group|Chemotherapy:etoposide plus cisplatin (EP)
89467473|NCT03393195|Experimental|Time-restricted eating plan|Participants in this group will be instructed to fast every day from 8pm until 12pm the following day. From 12pm until 8pm, participants can eat and drink whatever they want. During fasting hours, participants can drink water and black coffee.
89467474|NCT03393195|Active Comparator|Consistent Meal Timing Plan|Participants in this group will be instructed to eat three daily meals during specified eating times. Their first meal will be between 7am-11am. Second meal between 11am and 3pm, and third meal between 4pm-10pm. Participants will be encouraged to eat small snacks if needed so that they can eat their next meal during the specified window.
89467475|NCT02348372|Placebo Comparator|GSK1278863A Placebo|5, 25 and 100 mg matched
89467476|NCT02348372|Experimental|GSK1278863A 10mg|A round, biconvex, white film coated tablet
89467477|NCT02348372|Experimental|GSK1278863A 25mg|A round, biconvex, white film coated tablet
89467478|NCT02348372|Experimental|GSK1278863A 50mg|A round, biconvex, white film coated tablet
89467479|NCT02348372|Experimental|GSK1278863A 100mg|A round, biconvex, white film coated tablet
89467480|NCT02031731|Experimental|4 mg/kg Onartuzumab (MetMAb)|
89467481|NCT02031731|Experimental|15 mg/kg Onartuzumab (MetMAb)|
89467482|NCT02031731|Experimental|30 mg/kg Onartuzumab (MetMAb)|
89467483|NCT03614533|Experimental|Vi-Typhoid Conjugate Vaccine (Vi-TCV)|Children will receive a single 0.5-ml dose of Vi-TCV administered by the intramuscular route.
89467484|NCT03614533|Active Comparator|Inactivated Poliovirus Vaccine (IPV)|Children will receive a single 0.5-ml dose of Inactivated Poliovirus Vaccine (IPV) by the intramuscular route.
89467485|NCT03396003|Experimental|GALILEI G6 Lens Professional|The GALILEI G6 Lens Professional will measure anterior segment geometry and axial intra-ocular distances of the eye.
89467486|NCT03396003|Active Comparator|Oculus Pentacam AXL|The Oculus Pentacam AXL will measure anterior segment geometry and axial intra-ocular distances of the eye.
89467487|NCT03619109||Healthy Volunteers|No real intervention since samples from volunteers are not tested on Nanōmix eLab™ System near any volunteers. Leftover samples are stored at Sponsor for potential future analysis/ projects.
89467488|NCT03147404|Experimental|Avelumab|Avelumab 10 mg/kg i.v. every 2 weeks (Q2W)
88946692|NCT01910662|Experimental|Part B:Cohort 1B|Subjects in the Part B Cohort 1B arm will receive a SC immunisation of 5 mg KLH in the right deltoid on Day 1. On Day 15 subjects will return to the unit for an ID injection of 0.1 mg KLH in the lower right and lower left forearm. On Day 43 subjects will then receive an ID injection of 0.1 mg KLH in the upper right and upper left forearms (The dose can be changed to either 5mg/1mg or 1mg/0.1mg depending on the results from the first 3 subjects in Cohort 1).
88946693|NCT01910662|Experimental|Part B:Cohort 2|Subjects in the Part B Cohort 2 will receive an ID injection of 2TU (0.04 microg/mL) PPD in the upper right and upper left forearms on Day 1. On Day 3 (48 hours post challenge) If the induration is less than 6 mm, the subject will be re-challenged with 10 TU (0.04 microg/mL) PPD at a site at least 4 cm away from another challenge site. On Day 29 the subjects will have 2 ID injections of 2 TU or 10 TU (the same dose that produced an induration of 6 mm or more).
88946694|NCT01910662|Experimental|Part C: Cohort 1|Subjects in the Part C Cohort 1 will receive an ID injection of 0.1 mL PBS in the upper right forearm on Day 1. On Day 2 subjects will receive an ID injection of 0.1 ml PBS in the upper left forearm.
88946695|NCT01910662|Experimental|Part C: Cohort 2|Subjects in the Part C Cohort 2 will receive an ID injection of 2TU (0.04 microg/mL) PPD in the upper left forearms on Day 1. On Day 3 (48 hours post challenge) If the induration is less than 6 mm, the subject will be re-challenged with 10 TU (0.04 microg/mL) PPD at a site at least 4 cm away from another challenge site. On Day 29 the subjects will have 1 ID injections of 2 TU or 10 TU (the same dose that produced an induration of 6 mm or more).
89467489|NCT03614455|Experimental|Milademetan alone (A)|During Period 1, participants receive a single 100 mg milademetan oral dose on Study Day 1, with PK sampling to 168 hours post-dose (during the following 7-day washout period)
88946696|NCT01910675|Experimental|PCC group|Twenty patients in the PCC group receive 15 IU/kg of Octaplex concentrate and 2 g of Riastap concentrate. Additional fibrinogen is administered (if needed) to increase the baseline FIBTEM-MCF (at 5 min) to the target of 15 mm.
88946697|NCT01910675|Active Comparator|FFP group|Twenty patients in the FFP group receive 4 units of FFP (Octaplas). Additional fibrinogen (Riastab) is administered (if needed) to increase the baseline FIBTEM-MCF (at 5 min) to the target of 15 mm. The fibrinogen content of the FFP will be taken into consideration (2.1 g in 4 units of FFP).
88946698|NCT01910701|Experimental|Family Spirit Intervention|The Family Spirit intervention consists of 52 sessions (30-60 minutes in duration) delivered during a 39-month intervention phase and designed to positively impact a number of maternal and child behavioral and health outcomes.
89467490|NCT03614455|Other|Milademetan with itraconazole (AB)|During Period 2, participants receive itraconazole, 200 mg twice daily (BID) on Study day 8 and 200 mg once daily (QD) on Study Days 9 through 20, along with a single 100 mg milademetan dose on Day 14
89467491|NCT03614455|Other|Milademetan with posaconazole (AC)|During Period 2, participants receive 200 mg posaconazole three times daily (TID) on Study Days 8 through 20, along with a single 100 mg milademetan dose on Day 14
89467492|NCT03393117|Experimental|Liposomal Bupivacaine + Bupivacaine|This group will receive a long-acting pain medicine, Liposomal Bupivacaine, injected into the breast muscles during surgery. All patients will receive patient-controlled analgesia pump and oral narcotics as indicated post surgery.
89467493|NCT03393117|Active Comparator|Bupivacaine|This group will receive the same pain medication, Bupivacaine, but in the standard formulation, injected into the breast muscles during surgery. All patients will receive patient-controlled analgesia pump and oral narcotics as indicated post surgery.
89467494|NCT02236637||mCRPC patients|Patients with metastatic castration-resistant prostate cancer treated according to routine clinical practice
89467495|NCT02032225||CADASIL|patients with CADASIL
89467496|NCT03147326|Other|FDG-NaF-MRI|"All participants will undergo three project scans/the following interventions:~FDG-PET-CT NaF-PET-CT Whole-body MRI All participants will undergo a whole-body x-ray as part of clinical routine practice."
89467497|NCT02032303|Active Comparator|Ticagrelor|Patient randomized to Ticagrelor
89467498|NCT02032303|Active Comparator|Prasugrel|Patient randomized to Prasugrel
89467499|NCT04297293|Experimental|Ramosetron-ODT|
89467500|NCT04297293|No Intervention|Control|
89467501|NCT03147560|Experimental|Group 1|The sequential immunization strategy for group 1 on polio was Sabin IPV+ bOPV + bOPV.
89467502|NCT03147560|Experimental|Group 2|The sequential immunization strategy for group 2 on polio was Sabin IPV + Sabin IPV + bOPV.
89467503|NCT03147560|Experimental|Group 3|The sequential immunization strategy for group 3 on polio was Sabin IPV + Sabin IPV + Sabin IPV.
89467504|NCT03614377||Patients with low burden of sleep-disordered breathing|
89467505|NCT03614377||Patients with high burden of sleep-disordered breathing|
89467506|NCT02350790|Active Comparator|Robotic ablation|Half of the patients in the study will be randomized to robotic ablation of endometriosis with the argon beam coagulator (ABC).
89467507|NCT02350790|Active Comparator|Robotic Excision|Half of the patients in the study will be randomized to robotic excision of endometriosis.
89467508|NCT03392961|Experimental|IN-105 (Insulin Tregopil)|"Cohort1: Treatments A, B, and C: IN-105 administered at 30, 20 or 10 minutes before the ADA meal, respectively; Treatment D: Placebo administered at 20 minutes before the ADA meal.~Cohort 2: Treatments A, B, and C: IN-105 administered at 4, 5, and 6 hours after the previous ADA meal, respectively; Treatments D, E, and F: Placebo administered at 4, 5, and 6 hours after the previous ADA meal, respectively.~Cohort 3: For the first meal, IN-105 30 mg administered at the optimal pre meal time determined from Cohort 1 with ADA meal (Treatments A and D) or high fat meal (Treatments B and E) or high fiber meal (Treatments C or F)."
89467509|NCT03392961|Placebo Comparator|Placebo tablet|"Cohort1: Treatments A, B, and C: IN-105 administered at 30, 20 or 10 minutes before the ADA meal, respectively; Treatment D: Placebo administered at 20 minutes before the ADA meal.~Cohort 2: Treatments A, B, and C: IN-105 administered at 4, 5, and 6 hours after the previous ADA meal, respectively; Treatments D, E, and F: Placebo administered at 4, 5, and 6 hours after the previous ADA meal, respectively.~Cohort 3: For the first meal, IN-105 30 mg administered at the optimal pre meal time determined from Cohort 1 with ADA meal (Treatments A and D) or high fat meal (Treatments B and E) or high fiber meal (Treatments C or F)."
89467510|NCT02350946|Experimental|Cross over Oxytocin and Placebo|fMRI measurement and blood examinations following 26 IU Oxytocin (Syntocinon) on day 1 and following placebo on day 14
88946699|NCT01910714|Active Comparator|Health Education Control Condition|The health education control condition consists of team-building activities and viewing of educational videos on nutrition and fitness, environmental protection and nature. The control condition program will be delivered according to the same structure as the Focus on Youth intervention; daily for 60-90 minutes over the course of 8 days. Due to local staffing availability and the pilot nature of this research, youth in the control condition will not receive the control program in small-group peer format. Rather, youth will receive the control condition program in groups of approximately 30-50.
89467511|NCT02350946|Experimental|Cross over Placebo and Oxytocin|fMRI measurement and blood examinations following placebo on day 1 and following 26 IU Oxytocin (Syntocinon) on day 14
89467512|NCT00000371|Experimental|D-Cycloserine|Subjects were given 50 mg/day of D-Cycloserine for 24 weeks
89467513|NCT00000371|Placebo Comparator|Placebo|Participants were given 50 mg/day of Placebo for 24 weeks.
89467514|NCT04222647|Experimental|WO533|Formulation containing WO533 for intravaginal application
89467515|NCT03251989||1/Patient with a rare CNS diagnosis|A diagnosis of rare CNS Tumors
89467516|NCT02350712|Experimental|All Participants - Period 1|All participants receive patritumab with cetuximab plus platinum-based therapy (cisplatin or carboplatin) in Period 1 - Initial phase of the trial.
89467517|NCT02350712|Experimental|All Participants - Period 2|Participants deriving clinical benefit enter Period 2 - Extension phase, during which they continue to receive patritumab with cetuximab, but not platinum-based therapy.
89467518|NCT03614299||pSS cohort|Patients with pSS included in the study
89467519|NCT03618407||Oral oseltamivir group|Patients with influenza virus positive and early oral oseltamivir capsules
89467520|NCT03618407||Oral Lotus Capsules group|Patients with positive influenza virus and early oral administration of lotus extract capsules
89467521|NCT03618407||other group|Influenza virus positive patients who were not treated with oral lotus capsule or oseltamivir capsules early
89467522|NCT03618875|Active Comparator|ice|Patients were randomly assigned to receive an ice 5 minutes prior the IViT
89467523|NCT03618875|Placebo Comparator|placebo|Patients were randomly assigned to a room temperature patch (placebo) 5 minutes prior the IViT
89467524|NCT02867995|No Intervention|Control|No glaucoma drop aid control
89467525|NCT02867995|Active Comparator|Eye Drop Aids|Participants could be placed into one of the drop aid groups (Fabrication Autodrop Eye Drop Guide,Owen Mumford OP 6100 Autosqueeze, or the Simply Touch Eye Drop Applicator)
89467526|NCT03618797|Experimental|HL-PIF cap.160/2mg + Placebo|"Fenofibrate pellet (as micronized fenofibrate 160mg) and Pitavastatin Ca 2mg~once a day"
89467527|NCT03618797|Active Comparator|Livalo tab. 2mg + Placebo|"Pitavastatin ca 2mg~once a day"
89467528|NCT02350556|Other|hemiplegic patients|Dynamic Avoidance Task
89467529|NCT02350556|Other|healthy volunteers|Dynamic Avoidance Task
89467530|NCT03149432|Active Comparator|Reference analgesic|Gabapentin Rehabilitation Local care
89467531|NCT03149432|Experimental|reference analgesic and mirror therapy|Mirror Therapy Gabapentin Rehabilitation Local care
89467532|NCT03618329|Active Comparator|Prehabilitation|exercise, nutrition and anxiety reduction in the preoperative period
89467533|NCT03618329|No Intervention|No Prehabilitation|Not: exercise, nutrition and anxiety reduction in the preoperative period
88946700|NCT01910714|Experimental|Focus on Youth Intervention (FOY)|Focus on Youth is a community-based, eight session group intervention that provides youth with the skills and knowledge they need to protect themselves from HIV and other STDs. Focus on Youth uses fun, interactive activities such as games, role plays and discussions to convey prevention knowledge and skills pertaining to Protection Motivation Theoretical concepts. The intervention consists of 8 group sessions delivered daily over 8 days by two Apache facilitators to same-sex peer groups of 8-12 Apache youth. Each lesson lasts approximately 60-90 minutes. The goal of the sessions will be to teach youth about sexual and reproductive health with a specific focus on safe sex practices and sexual decision making.
88946701|NCT01910727|Experimental|Together on Diabetes-Hopkins|
88946702|NCT01910740|Experimental|Enhanced Physical Activity|Participants in the Enhanced Physical Activity group will receive a program of enhanced physical activity in addition to the usual care.
88946703|NCT01910740|Active Comparator|Usual Care|The Usual Care group will receive usual therapy provided by a multidisciplinary team and social interaction.
88946704|NCT01910753|Experimental|APA|Patient with neck cancer and accepting the physical activity program .
89467534|NCT03147014|Other|Maternal Hyperoxygenation|Maternal hyperoxygenation will be offered by administering 10 liters nasal cannula by face-mask (approximately 60% fiO2) for a minimum of 10 minutes.
89467535|NCT02031809||No additional unplanned major surgery|uneventfull intra-operative and postoperative course
89467536|NCT02031809||Additional unplanned major surgery|"Additional per-operative or post-operative unplanned major surgery such as unforeseen pneumonectomy, bilobectomy, lobectomy or additional segmentectomy, repair of major vessels or bronchi, bronchopleural fistula, unplanned surgery to other organs, within 30 days after the primary surgery.~These do not include:~Conversions without additional unplanned major surgery or suddne blood loss less than 500cc~Conversions or additional resection for unforeseen oncologic reasons.~Plasty, repair or sleeve resection of vessels after deliberate resection or transection for oncologic reasons"
88946705|NCT01910766|Experimental|Coenzyme Q10/CC group|"Intervention:~Coenzyme Q10 (CoQ10) and clomiphene citrate group (55 patients, 82 cycles) Patients in CoQ10/CC group took CC (Global Napi, Cairo, Egypt) 100 mg/day from cycle days 2-6, and CoQ10 Mepaco, Enshas Elraml, Sharkhia, Egypt), in a dose of 60 mg 3 times day capsules orally starting on cycle day 2 and continued till the day of human chorionic gonadotropin (hCG) administration"
89467537|NCT03618719||Obstructive sleep apnea|Patients with treatment-naive obstructive sleep apnea (OSA) who need continuous positive airway pressure (CPAP) therapy on clinical basis
89467538|NCT03618719||Control|Healthy controls without OSA
89467539|NCT05384483|Experimental|Cariprazine|Cariprazine 1.5 to 3 mg per day
89467540|NCT05384483|Placebo Comparator|Placebo|Matching placebo
89467541|NCT02354300||TCD Ultrasound|Transcranial doppler ultrasound monitoring during flow diverter placement.
89467542|NCT02354066|Experimental|Hallux valgus Surgery|Measurement of the Brake Response Time by Pat. undergoing hallux valgus surgery (first metatarsal osteotomy, Chevron, SCARF, Austin, etc.)
89467543|NCT02354066|Experimental|Hallux valgus and forefoot surgery|Measurement of the Brake Response Time by Pat. undergoing hallux valgus surgery (first metatarsal osteotomy; Chevron, Austin, SCARF, etc.) and additional forefoot surgery (PIP arthrodesis, second/third/etc. metatarsal osteotomy, etc.; Peg-in-Hole, WEIL-Osteotomy, etc.)
89467544|NCT02354066|Experimental|Control Run|Measurement of the Brake Response Time by Healthy Participants; control run; brake response time measurement with normal shoe and both foot orthoses
89467545|NCT03086629|Other|PCI Group|Participants who are patients of consultants randomized to this group will use the PCI during clinics.
89467546|NCT03086629|Other|Non PCI Group|Participants who are patients of consultants randomized to this group will not use the PCI during clinics.
89467547|NCT03077191||Quality of life|Quality of life of breast cancer patients treated with conservative surgery (quadrantectomy) and adjuvant hypofractionated whole breast radiotherapy according to the institutional standard regimen, to a total dose of 40 Gy in 15 fraction over 3 weeks will be measured with EORTC quality of life questionnaires QLQ-C30 and QLQ-BR23, before the start of the radiotherapy, at the end of the radiotherapy and subsequently at every follow-up visit (the first at 6 months after the end of the treatment, then annually for 5 consecutive years after the first follow up visit).
89467548|NCT05061563|Experimental|Period 1|A single dose of elinzanetant and an additional IV (microtracer dose) of [13C5]BAY 3427080 will be administered.
89467549|NCT05061563|Experimental|Period 2|Once daily oral dose of esomeprazole and a single oral dose of elinzanetant will be administered.
89018457|NCT03672773|Experimental|Treatment (temozolomide, talazoparib)|Participants receive temozolomide PO on days 1-5 and talazoparib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89018458|NCT03665337|Experimental|mTranS-C|Access to a mobile and computer accessible adaptation of Transdiagnostic Sleep and Circadian Intervention
89018459|NCT03665337|Active Comparator|Control|Access to a mobile and computer accessible control intervention that targets coping skills and sleep education.
89018460|NCT03661723|Experimental|Pembrolizumab + Radiation (lead-in)|"Pembrolizumab (200 mg) will initially be administered intravenously (IV) once every 3 weeks. (De-escalation dosing frequencies = once every 4 weeks and once every 6 weeks.)~Re-irradiation (35 Gy) will be administered to patients 5 days per week for 2 weeks"
89018461|NCT03661723|Experimental|Pembrolizumab + Bevacizumab + Radiation (lead-in)|"Pembrolizumab (200 mg) will initially be administered intravenously (IV) once every 3 weeks. (De-escalation dosing frequencies = once every 4 weeks and once every 6 weeks.)~Bevacizumab (15 mg/kg) will be administered intravenously (IV) once every 3 weeks~Re-irradiation (35 Gy) will be administered to patients 5 days per week for 2 weeks"
89018462|NCT03661723|Experimental|Pembrolizumab + Radiation|"Pembrolizumab (200 mg) will initially be administered intravenously (IV) once every 3 weeks~Re-irradiation (35 Gy) will be administered to patients 5 days per week for 2 weeks"
89018463|NCT03661723|Experimental|Pembrolizumab + Bevacizumab + Radiation|"Pembrolizumab (200 mg) will initially be administered intravenously (IV) once every 3 weeks~Bevacizumab (15 mg/kg) will be administered intravenously (IV) once every 3 weeks~Re-irradiation (35 Gy) will be administered to patients 5 days per week for 2 weeks"
89018464|NCT03635801||MyoVista 12 Lead (ECG) NSTEMI|"Patients enrolling in this clinical investigation will undergo a standard 12-lead ECG using the MyoVista 12-lead hs ECG device. An ECG is a quick, safe and painless test. No electricity is put into the body while it's carried out.~There may be some slight discomfort when the electrodes are removed from the skin - similar to removing a sticking plaster - and some people may develop a mild rash where the electrodes were attached.~An ECG is performed under controlled conditions."
89018465|NCT03634124|Experimental|interventional group|
89018466|NCT03629340|Experimental|Drug: Metformin|500mg PO (by mouth) BID (two times daily) x 1 week then increase to 1000mg PO BID x 11 weeks
89018467|NCT03629340|Placebo Comparator|Placebo Oral Capsule|Placebo capsule that is of identical size, shape, and color to experimental drug capsule PO (by mouth) BID (two times each day) for 12 weeks
89018468|NCT03598595|Experimental|Treatment (hydroxychloroquine, gemcitabine, docetaxel)|Participants receive hydroxychloroquine PO QD or BID on days 1-21, gemcitabine IV over 90 minutes on days 1 and 8, and docetaxel IV over 1 hours on day 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89018469|NCT03572738||Patients with HS|The set of all Hidradenitis Suppurativa patients (ICD-10 code: L73.2) who visited Wake Forest Baptist Medical Center's dermatology clinic during the last 5 years will either be recruited in person or be mailed the HS Severity Self-Assessment tool and a survey about their demographics, symptoms, treatments, psychological aspects, and lifestyle.
89537268|NCT05728905|Experimental|Therapeutic exercise|The patients assigned to this group performed a self-treatment program that included three coordination exercises, two post-isometric relaxation (contraction-relaxation) and one self-traction. All exercises were performed in front of a mirror. It was performed every 3 hours, 5 times a day, for 4 weeks. The patient was instructed and supervised by a physiotherapist until they were executed correctly. All participants were provided with a video where the procedure and dosage of each exercise was described in detail.
89018474|NCT03566043|Experimental|Part 1: RGX-121 Dose 1|1.3x10^10 GC/g brain mass of RGX-121
89018475|NCT03566043|Experimental|Part 1: RGX-121 Dose 2|6.5x10^10 GC/g brain mass of RGX-121
89467550|NCT03147092|Experimental|Hypertension group|Hypertensive patients will be counseled to initiate life style changes as weight loss, salt reduction, exercise, reduced alcohol consumption, smoking cessation and fresh fruits and vegetables in their diets. Drug treatment will be started for subjects that are not responding to nonpharmacological treatment. The anti-hypertensive medications will be Captopril 25Mg, Hydrochlorothiazide 25Mg Oral Tablet, atenolol and Losartan potassium 50 mg. All of these anti-hypertensive drugs are available in the PPP. If BP control is not yet obtained, other antihypertensive drugs will be requested: clonidine, spironolactone, hydralazine and amlodipine.
89018476|NCT03566043|Experimental|Part 1: RGX-121 Dose 2 Expanded Cohort|6.5x10^10 GC/g brain mass of RGX-121
89018477|NCT03566043|Experimental|Part 1: RGX-121 Dose 3|2.0x10^11 GC/g brain mass of RGX-121
89018478|NCT03566043|Experimental|Part 1: RGX-121 Dose 3 Expanded Cohort|2.9x10^11 GC/g brain mass of RGX-121 (transgene-specific PCR assay) equivalent to, 2.0x10^11 GC/g brain mass of RGX-121 (Poly-A-specific PCR assay)
89018479|NCT03566043|Experimental|Part 2: RGX-121 Pivotal Expansion|2.9x10^11 GC/g brain mass of RGX-121 (transgene-specific PCR assay)
89467551|NCT03613285|Active Comparator|conventional brackets|Conventional brackets with Mac Laughin bennette Trevisi (MBT) prescription
89467552|NCT03613285|Active Comparator|Smart clip passive self ligating brackets|Smart clip passive self ligating brackets with Mac Laughin bennette Trevisi (MBT) prescription
89467553|NCT03613285|Active Comparator|Empower active self ligating brackets|Empower active self ligating brackets with Mac Laughin bennette Trevisi (MBT) prescription
89467554|NCT03149588|Experimental|propofol|
89467555|NCT03149588|Experimental|sevoflurane|
89531372|NCT00706901|Active Comparator|Arm 3 TCC|Participants randomized to the Treatment Control Condition (TCC) received a psycho-educational group (e.g., addiction as a chronic disease, relapse prevention, developing a plan to prevent relapse) that was delivered with the aid of sequential standardized PowerPoint presentations. Group members were encouraged to ask questions and make comments. Therapists were encouraged to conduct the sessions using an instructional quality that minimized the use of GMI strategies. TCC consisted of four sessions, lasting 75 minutes, and was conducted on four consecutive days within the course of one week.
89018480|NCT03502018|Placebo Comparator|Saline|This arm will receive Saline along with Bupivacaine
89018481|NCT03502018|Experimental|Bupivacaine liposome|This arm will receive Exparel along with Bupivacaine
88946706|NCT01910766|Active Comparator|CC alone group|"Intervention:~CC (Global Napi, Cairo, Egypt) 100 mg/day from cycle days 2-6"
88946707|NCT01910779|Active Comparator|100 joule arm|100 joule as first biphasic shock energy
88946708|NCT01910779|Active Comparator|120 joule arm|120 joule as first biphasic shock energy
88946709|NCT01910805|Experimental|Lifestyle and Risk Awareness class|Women will attend a 3- and 9-month postpartum group nutrition and physical activity education class.
88946710|NCT01910805|No Intervention|Standard Care|Women will receive standard postpartum care for gestational diabetes mellitus.
88946711|NCT01910844|Experimental|Cisplatin - Metronomic Cyclophosphamide|Cisplatin 25 mg/m² from day 1 to day 3 every 3 weeks Metronomic Cyclophosphamide 150 mg from day 1 to day 14 every 3 weeks
89018482|NCT03484299|Other|Treatment|Irreversible electroporation and treatment with either FOLFIRINOX or Gemcitabine (based upon which chemotherapy regimen received prior to IRE)
89467556|NCT03613207|Experimental|Dermal pharmacokinetic measurement|"Measurement of dermal pharmacokinetic (PK) parameters (AUC, Cmax) within each subject.~For dermal PK measurement cutaneous interstitial fluid will be sampled using dermal open flow microperfusion (dOFM). Additionally 8 blood samples will be drawn to rule out systemic appearance of lidocaine/prilocaine.~Each subject will have 9 test sites in total which are treated with:~2 test sites: 15 mg/cm² lidocaine and prilocaine cream (2.5% lidocaine, 2.5% prilocaine, ACTAVIS LABORATORIES UT INC, US)~2 test sites: 10 mg/cm² lidocaine and prilocaine cream (2.5% lidocaine, 2.5% prilocaine, ACTAVIS LABORATORIES UT INC, US)~2 test sites: 5 mg/cm² lidocaine and prilocaine cream (2.5% lidocaine, 2.5% prilocaine, ACTAVIS LABORATORIES UT INC, US)~test sites: 10 mg/cm² Oraqix® gel (2.5% lidocaine, 2.5% prilocaine, Dentsply Pharmaceutical Inc., US/Dentsply DETRY GmbH, Germany)~2 test sites: untreated test site"
89467557|NCT02350322|Experimental|Schoolmeal with fatty fish|Fatty fish diet
89467558|NCT02350322|Experimental|Schoolmeal without fish|Meat/cheese diet (non-seafood)
89467559|NCT02350322|Experimental|Supplement|Omega-3 capsules
89467560|NCT02032381|Other|allogeneic hematopoietic stem cell|The eligible population for this study will consist of all children under 18 years who received allogeneic hematopoietic stem cell and evaluate of late pulmonary complications occurring in children treated with allogeneic hematopoietic stem cells.
89202130|NCT00782964||1|Outpatient with major depressive disorder, who has a change in pharmacological therapeutical plan after an incomplete response or intolerance to a treatment with an adequate dosage of an antidepressant (SSRI/NSRI) (20-40 mg fluoxetine, 75-225 mg venlafaxine or equivalent) for at least 6 weeks.
89202131|NCT00931671|Other|Exercise|Exercise
89467561|NCT03392883|Experimental|Digital Health Assisted Mental Healthcare|This Digital Health Assisted Mental Healthcare intervention will be based on the novel mobile-based platform (Laddr® from Square2 Systems).
89467562|NCT02350634|Experimental|Autopsy Cohort|End-of-life subjects (life expectancy < 6 months) consenting to brain donation at autopsy. Subjects will receive a single IV bolus injection of 370 MBq(10 mCi) of 18F-AV-1451.
89467563|NCT03613051||age band one|age band one ( from 3 to 6 years ) we test manual dexterity by posting coins with prefered hand and non prefered hand test balance by jumping on mats
89467564|NCT03613051||age band two|age band two ( from 7 to 10 years ) test manual dexterity by threading lace
89467565|NCT03613051||age band three|age band three ( from 11 to 18 years ) test manual dexterity by turning pegs test balance by zigzag hopping
89467566|NCT03159182|Experimental|Pressure garment and silicone insert|Custom measured pressure garment with a textile bonded silicone insert in either the distal or proximal portion of the pressure garment, to be worn 23 hours per day.
89467567|NCT03159182|Active Comparator|Pressure Garment|Custom measured pressure garment, to be worn 23 hours per day.
89467568|NCT03612739|Experimental|Cohort 1|5-azacytidine + 1x10^8 NKR-2 CAR-T Cells
89467569|NCT03612739|Experimental|Cohort 2|5-azacytidine + 3x10^8 NKR-2 CAR-T Cells
89467570|NCT03612739|Experimental|Cohort 3|5-azacytidine + 1x10^9 NKR-2 CAR-T Cells
89467571|NCT02350400|Experimental|DEBIRI|For unilobar disease, two treatments will be planned, separated by four weeks. For bilobar disease, there will be four treatments planned, alternating between right and left lobe, separated by 2 weeks duration.
89467572|NCT03612895|Experimental|Internal Care Coordination|The smoker will be connected to a Tobacco Care Coordinator who is based centrally within the health care system but has ready access via EHR, email, and telephone with staff in each primary care practice.
89467573|NCT03612895|Experimental|External Community Referral|"This intervention will connect the smoker directly via warm transfer to a the Massachusetts Smokers Helpline operated by National Jewish Health, which will provide its standard services to smokers."
89467574|NCT03612895|Other|Usual Care|Passive referral to quitline and referral to primary care physician.
89467575|NCT03149510|Experimental|Mobile Application|Participants will be using a mobile application, activity monitor and scale.
89467576|NCT03149510|No Intervention|Control Group|Participants will receive standard of care.
89467577|NCT03612817|Active Comparator|Tafluprost/timolol with PM dosing|Therapy with Tafluprost/timolol fixed combination drops dosed PM (20:00)
89467578|NCT03612817|Active Comparator|Tafluprost/timolol with AM dosing|Therapy with Tafluprost/timolol fixed combination drops dosed AM (08:00)
89467579|NCT03392805|Experimental|sedentary life style|
89467580|NCT03392805|No Intervention|physically active life style|
89202132|NCT00931749|Experimental|Low intensity Ultrasound group|
89467581|NCT02032459||Minority Women|Study data pulled from already collected data (N=1141 from the Camden Study of low income gravidae and minority gravidae (White, African-American and Hispanic) living in the northeastern United States (New Jersey).
89467582|NCT02347904|Experimental|Adjuvant S-1 and Oxaliplatin|Adjuvant treatment with s-1 and oxaliplatin after neoadjuvant chemoradiation and esophagectomy in patients with resectable esophageal cancer
89531373|NCT05040399|Other|Locking Compression Plates|Patients in whom we used Locking compression plates for sternal fixation
89531374|NCT05040399|Other|Wires|Patients in whom we used Sternal Wires for sternal fixation
89531375|NCT05051709|Active Comparator|Foot with no fusion|
89531376|NCT05051709|Active Comparator|Foot with fusion|
89531377|NCT03337373|Experimental|Cisatracurium|Patients who require paralysis with cisatracurium as part of their clinical care in ICU
89467583|NCT03990285|Other|[18F]Fluciclovine in glioblastoma|Axumin is a positron emitting radiopharmaceutical that has been studied in vivo in humans in a number of tumor types with positron emission tomography (PET/CT). 18F-Fluciclovine is a fluorine-18 labeled synthetic amino acid analog that is FDA approved as a PET imaging agent for prostate cancer recurrence, however, it has also been tested in other tumors. Investigators will use a typical dose of 18F-fluciclovine that is used for clinical studies in glioblastoma. This will be 5 mCi (approximate range for most studies is anticipated to be 5 mCi +/- 20%), but a lesser dose may be injected if, in the opinion of a Nuclear Medicine Authorized User, complete imaging data could be generated.
89467584|NCT03612427||Breastfed infants|Infants depending on breastfeeding S. Cholesterol S. Triglycerides S. HDL Cholesterol
89467585|NCT03612427||Formula-fed infants|Infants have formula feeding S. Cholesterol S. Triglycerides S. HDL Cholesterol
89467586|NCT03392727|Experimental|Study Box & Education Session|Parents are provided a baby box and infant health and safety products and participate in a face to face educational session
89467587|NCT03392727|Active Comparator|Community Box & Online Education|Parents are informed how to receive a free box from a community site and are provided a guide to online resources for prenatal and infant health promotion
89467588|NCT03612349|Other|Condition 1: All Products|Experimental Tobacco Marketplace Task is a behavioral economics task. During the task, participants purchase products from an online tobacco marketplace. In this condition, all tobacco products are available in menthol and non-menthol flavors.
89467589|NCT03612349|Other|Condition 2: No menthol LCCs|Experimental Tobacco Marketplace Task is a behavioral economics task. During the task, participants purchase products from an online tobacco marketplace. In this condition, the online tobacco marketplace does not include menthol flavored little cigars and cigarillos.
89467590|NCT03146858|Experimental|Enoxaparin|The patients will receive a 3-6 hour infusion of enoxaparin. The effects of the infusion will be assess when used on patients will acute heart attacks and undergoing emergency treatment with PPCI.
89467591|NCT03612661|Experimental|Intuitive Eating Group Intervention|Intuitive eating intervention delivered in a group format with 8-10 women, led by 2 facilitators.
89467592|NCT03612661|Experimental|Intuitive Eating Guided Self-Help|Participants in this condition engage in 8 weeks of self-study of the intuitive eating intervention have ~20 minute weekly phone call with a study interventionist.
89467593|NCT03408405|Experimental|Acthar Gel treatment group|Participants will be treated with 'Acthar Gel 80 UNT/ML Injectable Solution'. Initial dose for week 1 will be 50% of 80 units, injected twice per week. Week 2 is 75% of 80 units, week 3 and throughout treatment period (6 months in total) will be 80 units/ml twice per week.
89467594|NCT02350088|Active Comparator|Fast-track Surgery|probiotics,oral,b.i.d.
89467595|NCT02350088|Active Comparator|Traditional Group|placebo,oral,b.i.d.
89467596|NCT03408093||Interferon beta-1b|Patients with CIS, RRMS or SPMS who had more than 6 months in treatment
89467597|NCT03612115|Experimental|Neuromuscular electrical stimulation intervention|Neuromuscular electrical stimulation treatment
89467598|NCT03612115|No Intervention|Control|No additional intervention
89467599|NCT03149666||Evaluation of bitter taste|Participants will be evaluated as to the intensity of bitter taste when performing watery mouthwash with quinine.
89467600|NCT04679623|Experimental|Midazolam Injection|Midazolam injection, 10 mg
89467601|NCT04679623|Active Comparator|Seizalam™|Seizalam, 10 mg
89467602|NCT02353988|Experimental|bicalutamide|This is a multi-center, open-label, phase II study to evaluate the anti-tumor activity and safety of bicalutamide administered orally daily to patients with estrogen receptor (ER)-negative/ progesterone receptor (PgR)-negative/ androgen receptor (AR)-positive metastatic breast cancer. Eligible patients will receive bicalutamide at a dose of 150mg PO daily.
89467603|NCT02353988|Active Comparator|Physician's Choice|Treatment of the Physician's Choice defined as any single agent chemotherapy, hormonal treatment or biological therapy approved for the treatment of cancer; or palliative treatment or radiotherapy, administered according to local practice, if applicable
89467604|NCT03149354|Other|Patients with HIV|Patients with HIV
89467605|NCT03405675||SLAS 1|The subjects (N=2800) are recruited from all residents aged 55 years and above in Singapore in the areas covered by the South-East Community Development Council: Geylang, Aljunied, MacPherson, Marine Parade and Bedok (SLAS-I).
89467606|NCT03405675||SLAS 2|An additional 3200 subjects are recruited from residents in the Bukit Merah and Jurong (SLAS-II).
89467607|NCT03611803|Experimental|Ekso Group|
89467608|NCT03611803|Active Comparator|Control|
89467609|NCT03146780|Placebo Comparator|Conventional|
89467610|NCT03146780|Active Comparator|Digital 1|
89467611|NCT03146780|Active Comparator|Digital 2|
89467612|NCT03146780|Active Comparator|Digital 3|
89467613|NCT05383807|Experimental|Warna-Warni Waktu intervention|Participants in this condition are asked to view six, approximately five-minute videos (each with a number of associated short, interactive reinforcer activities), at a pace of one video per day, for 6 days.
89467614|NCT05383807|No Intervention|Waitlist control condition|These participants are not contacted during the intervention timeframe.
89467615|NCT03392571|Experimental|Resectable and borderline restable|"Potentially operable or borderline resectable pancreatic adenocarcinoma as assessed by standard CT criteria and histologically confirmed.~Patients receive 3 cycles of preoperative chemotherapy (NGC-triple regimen). The regimen consists of gemcitabine 800 mg/m2, Nab-paclitaxel 100 mg/m2and Cisplatin 25 mg/m2 given IV weekly x 2, every 3 weeks (one cycle).~Patients will be evaluated for adjuvant therapy within 12 weeks of surgery which will consist of Nab-paclitaxel, gemcitabine, and Cisplatin IV weekly x 2, every 3 weeks (one cycle) x 3 cycles."
89467616|NCT03112460||all patients|all of patients who went through basic and advanced cardiopulmonary resuscitations would be analyzed
89467617|NCT03612505|Active Comparator|Intervention|
89467618|NCT03612505|No Intervention|Control|
89467619|NCT03392493|Experimental|Group A|In the phase 1 :12 training sessions of Robot-assisted hand rehabilitation(60 minutes a time, 2 times a week); In the phase 2 :12 training sessions of Standard treatment only. (60 minutes a time, 2 times a week)
89467620|NCT03392493|Active Comparator|Group B|In the phase 1 :12 training sessions of Standard treatment only(60 minutes a time, 2 times a week) ; In the phase 2 :12 training sessions of Robot-assisted hand rehabilitation(60 minutes a time, 2 times a week)
89467621|NCT04656067|Active Comparator|Oxytocin(only)|oxytocin is given IV infusion 5-10 minutes before the start of skin incision in the Elective Cesarean Section
89467622|NCT04656067|Active Comparator|Tranexamic acid and Ethamsylate|Tranexamic acid and Ethamsylate are given IV slowly 5-10 minutes before the start of skin incision in the Elective Cesarean Section
89467623|NCT04226222||Triple negative Breast Cancer|Triple Negative Breast Cancer operatable from the outset
89467624|NCT03612037|Placebo Comparator|Control Phase|cellulose (600 mg)
89467625|NCT03612037|Experimental|Experimental Phase|alpha lipoic acid (600 mg)
89467626|NCT03395691|Active Comparator|The distal approach|The first two attempts via the distal approach will be performed . If the first two attempts failed, the subsequent attempts of venipuncture were performed using the proximal approach.
89467627|NCT03395691|Active Comparator|The proximal approach|The first two attempts via the proximal approach will be performed . If the first two attempts failed, the subsequent attempts of venipuncture were performed using the distal approach.
89467628|NCT02348138|Experimental|Home-based isometric handgrip training|All participants that will be assigned to home-based isometric handgrip training (HBT) will train three times per week for a total of 12 weeks, will perform a bout of isometric handgrip exercise: four sets of 2-min isometric contractions (using alternate hands) at 30% of maximal voluntary contraction; however, the training will be performed without daily supervision. Therefore, the subjects will receive a logbook to record the exercise sessions. In addition, visits will be scheduled at weeks 1, 3, 6, 9 and 11 to provide feedback to individuals and discuss potential problems in conducting training.
89467629|NCT02348138|Experimental|Supervised isometric handgrip training|All participants that will be assigned to supervised isometric handgrip training (ST) will train three times per week for a total of 12 weeks, will perform a bout of isometric handgrip exercise: four sets of 2-min isometric contractions (using alternate hands) at 30% of maximal voluntary contraction with. The training will be performed with daily supervision.
89467630|NCT02348138|No Intervention|Control group|Subjects randomized to the control group (CG) will be encouraged to increase the level of physical activity and make healthy eating, without, however, receive specific recommendations
89467631|NCT04713241|Active Comparator|Group A: SOC|Participants will receive the SOC and will also be asked to complete questionnaires to rate their symptoms
89467632|NCT04713241|Experimental|Group B: Electro-Acupuncture|Participants will receive the SOC + a daily 20-30 minute electro-acupuncture treatment from the time of randomization until the return of bowel function. The first treatment will be provided within 48 hours after the diagnosis of postoperative ileus. Participants will receive acupuncture every day until normal bowel movement function returns.
89467633|NCT02350166|Experimental|Laparoscopic group|Laparoscopic group, laparoscopic surgery or laparoscopic-assisted small-incision for resection of laparoscopic colorectal tumor combined with synchronously small-incision open resection of liver metastasis
89467634|NCT02350166|No Intervention|Conventional group|Conventional group, conventional laparotomy for simultaneously resection of both primary colorectal tumor and liver metastasis
89467635|NCT05168241|Experimental|1.the song/melodica group|"15 patients in the song/melodica group. Pre-tests were applied to the song/melodica group in the first interview, and training was given according to Pender's Health Promotion Model. In addition to the trainings, the experimental group was given a total of 40 minutes twice a day, a total of 2 sessions, melodica training for the melodica group, and song activity for the singing group. In addition, the song/melodica group was encouraged to work at home for at least 20 minutes every day by providing the necessary motivation for singing or playing the melodica. The patient was asked to record his practices by keeping a diary.~Two follow-ups were made by phone every 15 days, and the final tests were done face-to-face after 15 days. It tooks 10 weeks in total."
89531378|NCT05040555|Experimental|R-CDOP|Rituximab 375mg/m2, D0; Cyclophosphamide 750mg/ m2, D1; Doxorubicin hydrochloride liposome 30-35mg/ m2, D1; Vindesine 3mg/ m2, D1; Prednisone 60mg/ m2, D1~5.
88946712|NCT01910857|Experimental|Lifestyle counseling|Lifestyle counseling. 6 group meetings,facilitated by community health worker, focusing on lifestyle change, eg, weight loss, physical activity, low salt, stress reduction
89467636|NCT05168241|Other|2. the control group|15 patients in the control group. The control group was given pre-tests in the first interview, they were trained according to Pender's Health Promotion Model, they were followed up twice every 15 days by phone, and the post-tests were done face-to-face after 15 days, It tooks 10 weeks in total.
89467637|NCT02350244|Experimental|Experimental group|Subjects of the experimental group will have to follow an intervention for one month, consisting in active breaks from computer work
89467638|NCT02350244|Other|Control group|Control group patients had no intervention
89467639|NCT03886155||Trigger Finger Biopsy|Biopsy of trigger finger tenosynovial tissue during trigger finger release surgery sent to pathology for amyloid-specific analysis
89467640|NCT04203446||Adults with asthma or COPD|Adults (18-85 years old) with asthma or COPD diagnosed at least 3 months earlier, who are regularly treated with at least one inhlaer daily
89467641|NCT04447209||Child Health Clinic (CHC)|"Children attending CHC for routine vaccinations and follow-up in a tertiary center Parents will be counselled on food groups based on Infant and Young Children feeding practices.~Monthly telephone calls to collect data on dietary diversity - 4 telephone calls in total.~Anthropometric measurements and Blood investigations for hemoglobin and iron status at the start and end of study - optional"
89467642|NCT04447209||Community Children|"Children of urban poor families living in low-cost flats around Kuala Lumpur. Parents will be counselled on food groups based on Infant and Young Children feeding practices.~Monthly telephone calls to collect data on dietary diversity - 4 telephone calls in total.~Anthropometric measurements and Blood investigations for hemoglobin and iron status at the start and end of study - optional"
89467643|NCT04199624|Experimental|Experimental: omeprazole and ascorbic acid|
89467644|NCT04643353|Experimental|Non-ablative vaginal Erbium YAG laser treatment|"There are 3 visits where vaginal application of laser will be performed, with a 4-weeks interval. If needed, 3 extra laser applications can be added to the treatment (ie. with a maximum of 6 applications). Each application lasts around 15 minutes. The vaginal laser procedure will be performed in an outpatient setting, not requiring any specific preparation, analgesia or anesthesia, by one of two experienced operators.~Laser therapy is performed using a 2940 nm VEL (SP Spectro, Fotona, Slovenia)with SMOOTH mode setting, which enables non-ablative, thermal-only operation). The parameters are selected based on extensive preclinical and clinical studies.~Each laser treatment session consists of a full vaginal canal irradiation (using a 360° circular adapter), followed by additional irradiation of the prolapsed anterior wall (using a 90° angular adaptor) and concluded with irradiation of the vestibule area."
89467645|NCT04643353|Active Comparator|Pelvic floor exercises (PFE)|Standard PFE in Belgium are 9 sessions with a pelvic floor physiotherapist of choice, which can be extended by another 9 sessions, if clinically indicated. There are different strategies, though that will be on discretion of the physiotherapist. We will register the type of physiotherapy (standard (PFMT) versus assisted pelvic floor muscles training (APFMT)), number of completed sessions and duration of therapy. What is exactly done by the patient is registered as a variable.
89467646|NCT03395535|Experimental|'Laser-1st'|"Initial Selective Laser Trabeculoplasty (SLT) [PROCEDURE] followed by conventional medical therapy (eye-drops) as required.~All participants in this arm start their treatment pathway with SLT. If this does not reach the predefined, patient-specific target IOP then repeat laser (once only) is given. If the IOP target is then not reached additional treatment with all standard medications may be used and ultimately surgery (trabeculectomy with mitomycin C) as needed."
89537269|NCT05728905|Experimental|Therapeutic exercise + orthopedic manual therapy|The patients assigned to this group performed the exercise program and also received a manual therapy treatment applied by a physiotherapist. Two sessions were held per week for 4 weeks (8 sessions). Treatment consisted of traction, mobilization, and friction massage of the muscles of mastication.
89018483|NCT03471624|Experimental|Tenofovir Alafenamide for 24 months|Participants on any antiviral treatment for chronic HBV who plan to be switched by their physician to be treated with TAF 25 mg for 24 months.
89018484|NCT03441048|Experimental|Lintuzumab Ac225 (Dose 1 - 0.25 μCi/kg Ac-225 with 1.6 μg/kg lintuzumab)|Dose escalation for lintuzumab-Ac225 will be conducted according to a 3+3 design. CLAG-M chemotherapy will be administered at a fixed dose and schedule (cladribine 5mg/m^2/day IV over two hours on days 2-6; cytarabine 2 gm/m^2/day IV over four hours on days 2-6, starting two hours after the cladribine infusion is complete; mitoxantrone 10mg/m^2/day IV on days 2-4 and G-CSF at a dose of 300 µg on days 1-6). Lintuzumab-Ac225 will be administered as a single dose on day 8 of therapy.
89018485|NCT03441048|Experimental|Lintuzumab Ac225 (Dose 2 - 0.50 μCi/kg Ac-225 with 3.2 μg/kg lintuzumab)|Dose escalation for lintuzumab-Ac225 will be conducted according to a 3+3 design. CLAG-M chemotherapy will be administered at a fixed dose and schedule (cladribine 5mg/m^2/day IV over two hours on days 2-6; cytarabine 2 gm/m^2/day IV over four hours on days 2-6, starting two hours after the cladribine infusion is complete; mitoxantrone 10mg/m^2/day IV on days 2-4 and G-CSF at a dose of 300 µg on days 1-6). Lintuzumab-Ac225 will be administered as a single dose on day 8 of therapy.
89537270|NCT05728905|No Intervention|Control|The patients assigned to this group did not receive any type of intervention during the 4 weeks. They were asked not to change their habits or receive any other type of treatment.
89018486|NCT03441048|Experimental|Lintuzumab Ac225 (Dose 3 - 0.75 μCi/kg Ac-225 with 4.7μg/kg lintuzumab)|Dose escalation for lintuzumab-Ac225 will be conducted according to a 3+3 design. CLAG-M chemotherapy will be administered at a fixed dose and schedule (cladribine 5mg/m^2/day IV over two hours on days 2-6; cytarabine 2 gm/m^2/day IV over four hours on days 2-6, starting two hours after the cladribine infusion is complete; mitoxantrone 10mg/m^2/day IV on days 2-4 and G-CSF at a dose of 300 µg on days 1-6). Lintuzumab-Ac225 will be administered as a single dose on day 8 of therapy.
88946713|NCT01910857|No Intervention|Control|Standard care
89467647|NCT03395535|Active Comparator|Medicine-1st|"Conventional medical therapy [DRUG] without laser. All participants in this arm start their treatment pathway medical treatment. If the IOP target is then not reached, additional treatment with all standard medications may be used and ultimately surgery (trabeculectomy with mitomycin C) as needed.~During this pathway of treatment all commercially available medical treatments (eye-drops) are permitted according to a pre-specified step-wise intervention protocol described in detail in the publicly available trial protocol. This begins with prostaglandin analogues, then beta-blockers followed by alpha agonists or carbonic anhydrase inhibitors. The full range of available doses, treatments and drugs is beyond this short summary."
89018487|NCT03441048|Experimental|Lintuzumab Ac225 (Dose 4 - 1.00 μCi/kg Ac-225 with 6.4 μg/kg lintuzumab)|Dose escalation for lintuzumab-Ac225 will be conducted according to a 3+3 design. CLAG-M chemotherapy will be administered at a fixed dose and schedule (cladribine 5mg/m^2/day IV over two hours on days 2-6; cytarabine 2 gm/m^2/day IV over four hours on days 2-6, starting two hours after the cladribine infusion is complete; mitoxantrone 10mg/m^2/day IV on days 2-4 and G-CSF at a dose of 300 µg on days 1-6). Lintuzumab-Ac225 will be administered as a single dose on day 8 of therapy.
89202133|NCT00931749|Sham Comparator|Sham ultrasound group|
89467648|NCT03611491|Experimental|Princess® FILLER Lidocaine|Princess FILLER Lidocaine injections up to 10 ml given to the patients at baseline time point
89467649|NCT02748863|Placebo Comparator|Placebo|Placebo, provided in a 2 mL pre-filled syringe Placebo, provided in a 1 mL pre-filled syringe
89467650|NCT02748863|Experimental|Secukinumab 2 mL form|Secukinumab 300 mg, provided in a 2 mL pre-filled syringe
89467651|NCT02748863|Active Comparator|Secukinumab 1 mL form|Secukinumab 300 mg provided in 2 pre-filled syringes of 1 mL/150 mg (current approved form)
89467652|NCT02244554|Experimental|enLighten Laser Picosecond Pulse|Picosecond Pulse-duration with enLighten Q-switched Nd:YAG (1064 nm and 532 nm) laser treatment
89467653|NCT02244554|Experimental|enLighten Laser Nanosecond Pulse|Nanosecond Pulse-duration with enLighten Q-switched Nd:YAG (1064 nm and 532 nm) laser treatment
89467654|NCT03611413||ERAS programme|Patients who have been treated under an ERAS programm
89467655|NCT03611413||conventional care|Patients who have been treated under an conventional care
89467656|NCT03392337|Experimental|Open Label Narrowband UVB phototherapy|Open Label Narrowband UVB phototherapy for 12 weeks.
89467657|NCT03611179|Experimental|advanced ovarian cancer cases|patients with advanced ovarian cancer will receive Bevacizumab 15 mg/kg every 21 days with chemotherapy (Paclitaxel 175 mg/m2 & Carboplatin AUC 5 every 21 days)
89467658|NCT03126123|Other|acetic acid test|Patients will receive surgical treatment for anal condylomatosis and acetic acid on the mucosa of the anal canal before the surgical procedure
89467659|NCT02353676|Experimental|BUPIVACAINE GROUP|1.5 ml of 0.5% Bupivacaine solution to be injected into the operative site postoperatively.
89467660|NCT02353676|Placebo Comparator|PLACEBO GROUP|1.5 ml of saline solution to be injected into the opposite site postoperatively.
89467661|NCT03395457|Active Comparator|Care as usual|This is the care provided by the neurologist for chronic migraine.
89467662|NCT03395457|Experimental|Care as usual plus manual therapy|Other
89467663|NCT02032615|Active Comparator|Education plus Gudness Nutritional Bar|Subjects will receive education about anemia and will consume Gudness Nutrition bars for 3 months
89467664|NCT02032615|Placebo Comparator|Education with no nutrition bar|Subjects will receive education about anemia but will not receive nutrition bar
89467665|NCT02347748|Experimental|Group A - Reading pre-procedure script|Patients will be read a pre-procedure comfort talk script in the pre-procedure work-up area
89467666|NCT02347748|Experimental|Group B - Reading pre-extubation script|Patients will be read a pre-extubation script;
89467667|NCT02347748|Experimental|Group C - Reading 2 scripts|Patients will be read a pre-procedure comfort talk script in the pre-procedure work-up area Patients will be read a pre-extubation script
89202134|NCT00783042|Active Comparator|1|
89467668|NCT02347748|No Intervention|Group D|Patients will not be read any script
89467669|NCT02520375|Experimental|Prebiotic|This group will be administered a prebiotic mouthrinse and toothpaste
89467670|NCT02520375|Placebo Comparator|Control|This group will be administered a control mouthrinse and toothpaste
89467671|NCT03617627|Experimental|Experimental group|Patients will be included in a self-management intervention.
89467672|NCT03617627|No Intervention|Control group|Patients will receive a booklet with information.
89467673|NCT03611647|Active Comparator|Probiotic|
89467674|NCT03611647|Placebo Comparator|Placebo|
89467675|NCT03617549||All Participants|Mothers of singleton moderate preterm appropriate for Gestational Age (AGA) infants (29-32+6 weeks gestation in the neonatal intensive care unit at the Golisano Children's Hospital
89467676|NCT03395379||Group 1|RFA without air dissection protection
89467677|NCT03395379||Group 2|RFA with air dissection protection
89467678|NCT02347514|Experimental|Diabetes Group Visit|"Subjects in this arm will be asked to attend one group visit at their health center each month for six months. The group visits will involve various staff and providers at the health center who will teach them how to take care of their diabetes. Subjects will be scheduled to attend the same group visit appointments as the other subjects, and health center staff will encourage the group to share their own experiences about living with diabetes with the rest of the group.~If subjects at the health center additionally implementing the text-messaging intervention consent to enroll in the study, their phone number will also be entered into a secure system that will allow the group visit healthcare team to send them text messages during the course of the six months they are in the program. These text messages are intended to offer the subjects additional support in taking care of their diabetes."
89467679|NCT02347514|No Intervention|Usual care|Patients in the control arm will be selected after the follow-up period is over for the intervention arm. They will receive the care they normally receive at their health center.
89467680|NCT03392259|No Intervention|Control group|conventional treatment
89467681|NCT03392259|Experimental|App group|conventional treatment + use of smartphone app.
89467682|NCT03617393||Pulmonary Infection with DM group|Patients with diabetes and pulmonary infection.
89467683|NCT03617393||Pulmonary Infection group|Patients with pulmonary infection while the fasting blood-glucose in the normal range.
89467684|NCT03617393||DM group|Patients without pulmonary infection while the fasting blood-glucose > 8 mmol/L.
89467685|NCT03617393||Control group: normal people|Patients without pulmonary infection while the fasting blood-glucose in the normal range.
89202135|NCT00783042|Placebo Comparator|2|
88946714|NCT01910870|Experimental|Cisplatin - Metronomic Cyclophosphamide|Cisplatin 25 mg/m² (day 1 to day 3) every 3 weeks Metronomic cyclophosphamide 150 mg (day 1 to day 14) every 3 weeks
88946715|NCT01910883|Experimental|Group 1|Single doses of 200, 400 and 600 mg finafloxacin i.v.
88946716|NCT01910883|Experimental|Group 2|Single doses of 800 and 1000 mg finafloxacin i.v.
88946717|NCT01910883|Experimental|Group 3|Multiple doses of finafloxacin once daily (o.d.) for 7 days at dose levels of 600 mg i.v.
89467686|NCT02032849|Active Comparator|subglottic secretion drainage|The conventional method with a special tube to drainage subglottic secretion
89467687|NCT02032849|Experimental|Manual air-impingement operation|A method which we invented to clear subglottic secretion
89467688|NCT02347592|Active Comparator|straight Tenckhoff|The straight Tenckhoff catheter (sT) is the most common used catheter for peritoneal dialysis (PD).
89467689|NCT02347592|Active Comparator|self-locating catheter|A new, more expensive, self-locating catheter (sLC) has been developed by Di Paolo.
89467690|NCT03395301|Experimental|tubal occlusion|Fiber coils were inserted into the interstitial part of fallopian tubes, and IVF-ET was taken out in the following.
89467691|NCT03617315|Experimental|Hyaluronic Acid|One drop application of Hyaluronic acid + Galact-Xyloglucan with a dosage of 3 times a day for 45 days
89467692|NCT03617315|Experimental|CrossLinked Hyalurnic Acid|One drop application of Crosslinked Hylauronic Acid + Liposomes with a dosage of 3 times a day for 45 days
89467693|NCT02349932||Healthy Adults|The following samples will be collected: fecal, blood, and saliva
89467694|NCT05168007|Experimental|Cariprazine 3mg/day|WID-RGC20(Cariprazine) 3 mg/day
89467695|NCT05168007|Experimental|Cariprazine 6mg/day|WID-RGC20(Cariprazine) 6 mg/day
88946718|NCT01910883|Experimental|Group 4|Multiple doses of finafloxacin once daily (o.d.) for 7 days at dose levels of 600 mg i.v. (additional to Group 3)
88946719|NCT01910883|Experimental|Group 5|Multiple doses of finafloxacin once daily (o.d.) for 7 days at dose levels of 800 mg i.v.
89467696|NCT05168007|Placebo Comparator|Placebo|Placebo for WID-RGC20(Cariprazine) 3 mg/day or 6mg/day
89467697|NCT02032927|Active Comparator|Codeine/paracetamol|"The combination codeine/paracetamol,30 mg/500 mg,1 tablet every 8 hours, paracetamol 500 mg if NRS> 4, repeatable up to 3 times per day.~At any stage of the study, patients treated with combination codeine/paracetamol in case of ineffectiveness (NRS> 4) despite maximal dosage (2 tablets every 8 hours) and/or side effect, will be subject to the opioid switch and will start equianalgesic therapy with oxycodone/naloxone combination."
89467698|NCT02032927|Active Comparator|Oxycodone/Naloxone|Combination oxycodone /naloxone, 5 mg/2.5 mg, 1 tablet/day, paracetamol 500 mg if NRS> 4, repeatable up to 3 times per day.
88946720|NCT01910883|Experimental|Group 6|Multiple doses of finafloxacin once daily (o.d.) for 7 days at dose levels of 1000 mg i.v.
88946721|NCT01910896|Experimental|Overnight Intensive Patch|Overnight intensive patch (OIP), on polyolefin foam basis containing acrylate, extractum cepae and allantoin is a class I, CE (Conformité Européenne) marked medical device. Subjects will have their two scars randomized for Overnight Intensive Patch application versus no treatment.
88946722|NCT01910896|No Intervention|No treatment|Subjects serve as their own control. Eligible subjects have two comparable scars in same body regions, one scar will be treated with Overnight Intensive Patch, the second scar will not be treated.
88946723|NCT01910922||Repeated exposure Group (RE)|Exposure to basic salsify puree during E1-E8
89202136|NCT02556528|Experimental|Health Coaching|
89467699|NCT02353598|Experimental|Double-blind treatment window: Crenezumab dose level 1|Participants will recieve crenezumab dose level 1 once every 4 weeks.
89467700|NCT02353598|Experimental|Double-blind treatment window: Crenezumab dose level 2|Participants will receive crenezumab dose level 2 once every 4 weeks.
89467701|NCT02353598|Experimental|Double-blind treatment window: Crenezumab dose level 3|Participants will receive crenezumab dose level 3 once every 4 weeks.
89467702|NCT02353598|Placebo Comparator|Double-blind treatment window: Placebo|Participants will receive placebo matched to crenezumab once every 4 weeks.
89467703|NCT02353598|Experimental|Optional OLE window: Crenezumab|Participants will receive crenezumab dose levels 1 2, or 3 once in every 4 weeks.
89467704|NCT03392181|Experimental|18F-DCFPyL|
89467705|NCT03158324|Experimental|Advanced refractory solid tumors|Patients with advanced refractory solid tumors will be enrolled.
89467706|NCT03611257|Experimental|dRAST|"Hematologic patients with bacteremia will receive antibiotics based on dRAST results."
89467707|NCT03611257|Active Comparator|Current standard method|Hematologic patients with bacteremia will receive antibiotics based on current standard method results.
89467708|NCT03392103|Experimental|postoperative CRT|postoperative CRT: Treatment including postoperative radiotherapy (IMRT) with concurrent chemotherapy of Raltitrexed. Radiotherapy will be delivered to a planning target volume with a dose of 45-50.4Gy (1.8-2.0Gy daily) using with Intensity-Modulated Radiotherapy technique. During the radiation treatment, concurrent chemotherapy will be delivered (Raltitrexed, intravenous infusion, 3 mg/m2, on w1 and w4).
89467709|NCT03617081|Experimental|NNC0113-2023|Participants will receive increasing doses of NNC0113-2023 on day 1. Each participant will receive only a single dose.
89467710|NCT03617081|Placebo Comparator|Placebo|Participants will receive placebo (NNC0113-2023)
89467711|NCT03616925|Experimental|Platelet rich fibrin matrix|surgical open flap debridement with Application of Platelet rich fibrin matrix using Platelet Rich Fibrin Matrix kit in 15 intrabony defect sites
89467712|NCT03616925|Active Comparator|surgical open flap debridement|only surgical open flap debridement was done without application of Platelet rich fibrin matrix in 15 intrabony defect sites
89467713|NCT02349776|Experimental|All patients for allograft transplant|For the testimonial part all patients who have received an allograft transplant in the last five years will be eligible for participation if they have capacity to consent and can speak English fluently.
89467714|NCT03392025|Active Comparator|Flaxseed|Daily consumption of 30 grams flaxseed for 3 months
89467715|NCT03392025|Active Comparator|Flaxseed and the Mediterranean-like diet|Daily consumption of 30 grams flaxseed in adjunct to the Mediterranean-like diet for 3 months
89467716|NCT03392025|Placebo Comparator|Placebo|Daily consumption of Placebo for 3 months
89467717|NCT03610945|Experimental|EDP-305 and fluconazole interaction (Part 1)|
89467718|NCT03610945|Experimental|EDP-305 and quinidine interaction (Part 2)|
89467719|NCT03616847|Experimental|Standard care|Participants will have hallux valgus/hallux rigidus surgery using a calf tourniquet which will remain inflated until the wound is closed.
89467720|NCT03616847|Experimental|Tourniquet release|Participants will have hallux valgus/hallux rigidus surgery using a calf tourniquet which will be removed. There will be a five minute delay before the wound is closed.
88946724|NCT01910922||Flavour-flavour learning-salt (FFL-S)|Exposure to salty salsify puree during E1-E8
89467721|NCT02349854||Cases|patients with scalp itch and seborrheic dermatitis who will get biopsy
89467722|NCT02349854||Controls|patients without scalp itch and without seborrheic dermatitis who will get biopsy
89467723|NCT02032693|Experimental|Everycell™|Patient will take 1 tablet two times daily of Everycell™ (double-blind) for the 4-week treatment period.
89467724|NCT02032693|Placebo Comparator|Placebo|Patient will take 1 tablet two times daily of the placebo (double-blind) for the 4-week treatment period.
89537271|NCT02310269||Pasireotide|
88946725|NCT01910922||Flavour-flavour learning-nutmeg (FFL-N)|Exposure to nutmeg-flavored salsify puree during E1-E8
88946726|NCT01910935|Experimental|Physical activity prescription|24 weeks physical activity program. 1 hour, 3 times a week, moderate to vigorous intensity.
88946727|NCT01910935|No Intervention|No physical activity prescription|Provide information to patients about the benefits of physical activity and how to increase it safely.
89537272|NCT04489745|Experimental|SBRT and ADT|Patients undergo SBRT to a dose of 40 Gy in 5 fractions to prostate, and optional 25 Gy in 5 fractions to SVs and Pelvic LNs, with 9 months of Androgen Deprivation Therapy
89537273|NCT05728671|Experimental|IP2015_PO release form 1|Test formulation 1
89537274|NCT05728671|Experimental|IP2015_PO release form 2|Test formulation 2
89537275|NCT05728671|Experimental|IP2015_PO release form 3|Test formulation 3
89467725|NCT03391947|Experimental|semilunar coronally positioned flap|A semilunar incision will be done following the curvature of the gingival margin and ending about 2 to 3 mm short of the tip of the papillae. The most apical distance of this incision to the gingival margin will be obtained by adding the bone sounding measurement to the recession height. Perform a split-thickness dissection coronally from the incision, and connect it to an intrasulcular incision. The tissue will be collapsed coronally, covering the denuded root. The coronally repositioned gingival margin will be stabilized by coronally anchored suture with composite stops on the buccal surface of the tooth using flowable composite. Finally, the area will be covered with a periodontal dressing. This is called semilunar coronally positioned flap.
89531379|NCT03336281||Participants with Psoriatic Arthritis: Dermatologist Cohort|Participants who will receive ustekinumab (as a first or second line of biologic disease modifying anti-rheumatic drug [bDMARD] therapy) along with other co-medications as per clinical dematologist's discretion will be observed in this study. Ustekinumab will not be provided by the sponsor. The treatment by ustekinumab must have been decided by the physician prior to the decision to include the participant in the study. Only data available from a participant's source medical records will be collected. Additionally investigators will be asked to obtain (or record where available) Patient-Reported Outcome (PRO) data from participants participating in this study.
88946728|NCT01910948|Experimental|omega-3 polyunsaturated fatty acids|The included patients will be randomly divided into two groups A and B, two groups of patients 4 days before operation begin to give parenteral nutrition: A: the control group of normal intravenous nutrition. B: the trial group,add omega-3 polyunsaturated fatty acids 0.2 g/kg to parenteral nutrition, no use on the day of surgery, postoperative 2 days continue to add omega-3 polyunsaturated fatty acids 0.2 g/kg.
88946729|NCT01910961|Experimental|limb RIPC|limb RIPC protocol was applied after anesthetic induction and before the start of surgery. The limb RIPC was induced by placing a blood pressure cuff on the left upper arm of patient for three inflating-deflating cycles: 5 min inflating to 200 mmHg followed by a 5 min reperfusion with deflating the cuff.
88946730|NCT01910961|No Intervention|convention|Adult patients undergoing elective open abdominal aortic aneurysm repair received no treatment after induction of anaesthesia.The control group had an uninflated cuff placed on the left upper arm for 30 min.
88946731|NCT01910974|Experimental|endoscopic sub-mucosal dissection|
88946732|NCT01910987|Experimental|optimized retreatment, prolonged therapy|Patients will start therapy with retreatment with 6 cycles of bortezomib and dexamethasone (two 21-day cycles followed by four 35-day cycles) followed by a second randomization in a 1:1 ratio to 1 of 2 prolonged therapy schedules with bortezomib alone (Group A1: once weekly for the first 4 weeks in 35-day cycles; or Group A2: once every other week)
88946733|NCT01910987|Other|standard retreatment|Current Standard of Care: Patients will start retreatment with eight 21-day bortezomib and dexamethasone cycles, followed by posttreatment follow-up every 6 weeks.
88946734|NCT01911000|Experimental|RTHT|RT and hyperthermia after TACE in the unresectable HCC patients who combined with PVTT
88946735|NCT01911026|Experimental|Interventional|The investigational, or experimental arm, will receive standard written instructions on preparing for a colonoscopy plus interventional instructions from reinforcement educated nurse such as 'Reinforcement Nurse Education'
89202137|NCT00926913||Group 1|
89467726|NCT03391947|Active Comparator|coronally advanced flap|Coronally positioned flap will be initiated with two vertical incisions, extending from a mesial and distal linear angle at the cementoenamel junction (CEJ) and go beyond the mucogingival junction. A split thickness flap will be prepared by sharp dissection mesial and distal to the recession and connected with an intra crevicular incision. On the facial aspect of the tooth, a full thickness flap, approximately 3-4 mm apical to crest of alveolar bone. Then, the flap will be returned and sutured it at 1 mm coronal to the CEJ after de-epithelize the papillae. The coronally repositioned gingival margin will be stabilized by coronally anchored suture with composite stops on the buccal surface of the tooth using flowable composite and sutured in the papilla region and releasing incision. Finally, the area will be covered with a periodontal dressing.
89467727|NCT02349698|Other|Acute Lymphoblastic Leukemia|Acute lymphoblastic leukemia treated with chimeric antigen receptor modified T cells targeting CD19.
89467728|NCT02349698|Other|Chronic Lymphcytic Leukemia|Chronic lymphocytic leukemia with chimeric antigen receptor modified T cells targeting CD19.
89467729|NCT02349698|Other|Non-Hodgkin Lymphoma|Non-hodgkin lymphoma treated with chimeric antigen receptor modified T cells targeting CD19.
89467730|NCT03616769||quantiles of serum uric acid level|quantiles according to the patient's serum uric acid level
89467731|NCT03610867|Experimental|Furaprevir capsule (SAD)|single ascending oral dose (100 mg, 200 mg, 400 mg, and 600 mg) of TG-2349 (Furaprevir capsule)
89467732|NCT03610867|Placebo Comparator|Placebo (SAD)|"Single ascending oral dose of Furaprevir similar capsule.~."
89467733|NCT03610867|Experimental|Furaprevir capsule (MAD)|multiple ascending oral doses (200 mg, 400 mg, and 600 mg) of TG-2349 (Furaprevir capsule)
89467734|NCT03610867|Placebo Comparator|Placebo (MAD)|Multiple ascending oral doses of Furaprevir similar capsule
89467735|NCT05167851|Experimental|Lazertinib, a combination group of SBRT|"Lazertinib 240mg once a day(QD) oral(PO)~-If there is no disease progression or unacceptable toxicity, treatment is performed at 1 cycle (28 days) interval . This is expected to be an average of one year.~Stereotactic Body Radiation Therapy (SBRT) to oligometastatic sites SBRT(Stereotactic Body Radiation Therapy) will be delivered to the primary tumour and to all metastatic sites. SBRT(Stereotactic Body Radiation Therapy) will be delivered using risk-adapted SBRT with a maximum of 5 SBRT(Stereotactic Body Radiation Therapy) fractions."
89467736|NCT05167851|Active Comparator|Lazertinib single administration group|"* Lazertinib 240mg once a day(QD) oral(PO)~-If there is no disease progression or unacceptable toxicity, treatment is performed at 1 cycle (28 days) interval . This is expected to be an average of one year."
89467737|NCT02236715||Chronic Obstructive Airways Disease|
89467738|NCT02349620|Active Comparator|A:partialy edutolus patients|In this group surface treated implant with PRF will be inserted.Immediately after the surgery the implant stability will be measure with the Osstell mentor to verify the resonance frequency analysis (RFA), using the smart peg type 1, then stability will be measured every 2 weeks up to 3 months .Bone height will be measured in mesial and distal side immediately after placement and in months 3 and 6 with Intra Oral Peri Apical xray (IOPA x-ray)
89467739|NCT02349620|Placebo Comparator|B: partialy edutolus patients|In this group implant with out PRF will be inserted.Immediately after the surgery the implant stability will be measured with the Osstell mentor to verify the resonance frequence analysis (RFA ), using the smartpeg type 1, then stability will be measured every 2 weeks up to 3 months. Bone height was measured in mesial and distal side immediately after placement and in months 3 and 6 with IOPA xray
89467740|NCT02032771|Experimental|M22 IPL and ResurFX|The procedure will include an intense pulse light (IPL) treatment followed by fractional non-ablative (FNA) treatment.
89467741|NCT03823365|Experimental|Indolent NHL or CLL patients|Adults diagnosed with indolent non-Hodgkin lymphomas (iNHL) or chronic lymphocytic leukemia (CLL) in need of first line treatment consisting of either FCR or BR as per investigator assessment
88946736|NCT01911026|No Intervention|Standard preparation instructions|The control arm will receive written instructions on preparing for a colonoscopy per standard of care at Keimyung University Dongsan Medical Center
89467742|NCT03616691|Experimental|Atezolizumab|The dose level of atezolizumab proposed to be tested in this study is 1200 mg administered by IV infusion every 3 weeks (q3w)
89467743|NCT03616691|Experimental|Atezolimab+Bevacizumab|Once radiologic progression confirmed from atezolizumab monotherapy (stage 1), 1200mg of atezolizumab would be administered with 15mg/kg of bevacizumab as combination therapy (stage 2). Both of drugs are administered via intravenous infusion every 3 weeks.
89467744|NCT03158168|Experimental|study group|"The first group will receive Intralesional injection of Candidal antigen with a dose of (0.1ml -0.3ml) by insulin syringe in the largest wart at the first visit.( Only those patients who showed a positive response to the Candida test antigen).I njections will be repeated for all patients into the same lesion every 3 weeks for three treatment sessions. Follow up for next six months for any recurrences.~Storage: A 1ml multidose vial of candidal antigen (Candin) which is an intradermal test antigen, stored between 2c-8c."
89537276|NCT03065907|Active Comparator|Vision Rehabilitation Group 1|Vision rehabilitation assessment will be scheduled within 1 months of randomization; interventions will be scheduled and vision rehabilitation appointments will be scheduled accordingly.
88946737|NCT01911039|Experimental|Regulatory T Cells|Cohort 1 at 1x105 Treg cells/kg, Cohort 2 at 5x105 Treg cells/kg and Cohort 3 at 1.5x106 Treg cells/kg with an extension phase at the MTD (or maximum administered dose if the MTD is not reached).
88946738|NCT01911052|Experimental|Intervention|The investigational, or experimental arm, will receive standard written instructions on preparing for a colonoscopy plus intervention such as telephone based re-education by one investigator on the day before colonoscopy.
88946739|NCT01911052|No Intervention|Standard preparation instructions|The control arm will receive written instruction on preparing for a colonoscopy per standard of care at Keimyung University Dongsan Medical Center
88946740|NCT01911052|Experimental|Interventional|The investigational, or experimental arm, will receive standard written instructions on preparing for a colonoscopy plus intervention such as short message system based re-education by one investigator on the day before colonoscopy.
88946741|NCT01911078|Other|Renal Denervation Group|Subjects receiving renal denervation procedure.
88946742|NCT01911078|No Intervention|Control Group|"Subjects not receiving renal denervation procedure.~Subjects are randomized in a 3:1 ratio to either Renal Denervation Group or Control Group."
89018488|NCT03441048|Experimental|Lintuzumab Ac225 (Dose 5 - 1.25 μCi/kg Ac-225 with 8.0 μg/kg lintuzumab)|Dose escalation for lintuzumab-Ac225 will be conducted according to a 3+3 design. CLAG-M chemotherapy will be administered at a fixed dose and schedule (cladribine 5mg/m^2/day IV over two hours on days 2-6; cytarabine 2 gm/m^2/day IV over four hours on days 2-6, starting two hours after the cladribine infusion is complete; mitoxantrone 10mg/m^2/day IV on days 2-4 and G-CSF at a dose of 300 µg on days 1-6). Lintuzumab-Ac225 will be administered as a single dose on day 8 of therapy.
89018489|NCT03441048|Experimental|Lintuzumab Ac225 Recommended Phase 2 Dose (RP2D)|The maximum-tolerated dose for lintuzumab-Ac225 is defined as the highest level at which no more than one patient experiences a dose-limiting toxicity. The RP2D is defined as the dose level below the dose where two or more dose-limiting toxicities were observed. CLAG-M chemotherapy will be administered at a fixed dose and schedule (cladribine 5mg/m^2/day IV over two hours on days 2-6; cytarabine 2 gm/m^2/day IV over four hours on days 2-6, starting two hours after the cladribine infusion is complete; mitoxantrone 10mg/m^2/day IV on days 2-4 and G-CSF at a dose of 300 µg on days 1-6). Lintuzumab-Ac225 will be administered as a single dose on day 8 of therapy.
89018490|NCT03429907|Experimental|Mind-Body Exercises|"Participants do daily mind-body exercises for 14 days before starting chemotherapy. The exercises are presented on an online application (app) that runs on participant's personal electronic device (such as a mobile phone or tablet).~Questionnaires completed at baseline, at third and at last cycle of chemotherapy, and 6 months after chemotherapy."
89018491|NCT03429907|Other|Standard of Care|Questionnaires completed at baseline, at third and at last cycle of chemotherapy, and 6 months after chemotherapy.
89467745|NCT03158168|Active Comparator|control group|"The second group will receive an IL injection of 2%Zn sulfate with a dose of (0.1ml-0.3ml) by insulin syringe ,in the largest one .the wart is injected with the solution till blanching or bleb formation. Subcutaneous injections and acral parts such as fingers and toes will be avoided, as it may cause vascular necrosis [19]. Injections will be repeated for all patients into the same lesion every 2 weeks for three treatment sessions.Follow up for next six months for any recurrences.~Preparation of 2% zinc sulfate: A measure of 2g. of zinc sulfate powder is to be dissolved in 100 ml of sterile distilled water and autoclaved at 95c for 20 min(20)."
89018492|NCT03414983|Experimental|Arm A|Nivo + SOC
89018493|NCT03414983|Active Comparator|Arm B|SOC
89018494|NCT03411499|Experimental|Early surgery|Surgery within 72 hours from endocarditis diagnosis
89018495|NCT03411499|Active Comparator|Conventional therapy|Medical treatment and a possible delayed surgical intervention according to the current guidelines
89018496|NCT03398161|Experimental|Treatment (ultra low dose radiation therapy)|Patients undergo ultra low dose radiation therapy at the discretion of the treating physician.
89018497|NCT03396575|Experimental|Group A|TTRNA-DC vaccines with GM-CSF and TTRNA-xALT plus Td vaccine with Autologous Hematopoietic Stem cells (HSCs) during cycles of Dose-intensified TMZ
89018498|NCT03396575|Experimental|Group B|TTRNA-DC vaccines with GM-CSF and TTRNA-xALT plus Td vaccine with Autologous Hematopoietic Stem cells (HSCs) with Cyclophosphamide + Fludarabine Lymphodepletive Conditioning
89018499|NCT03395847|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 35 cycles in the absence of disease progression or unacceptable toxicity.
89467746|NCT03157154||First group|Haemophilia patients with history of either cardiovascular disease or atrial fibrillation undergoing an antiplatelet or anticoagulant prophylaxis
89202138|NCT00688688|Experimental|Mirabegron 50 mg|Participants received mirabegron 50 mg tablets and matching tolterodine extended release (ER) placebo capsules orally once a day for 12 months.
89202139|NCT00688688|Experimental|Mirabegron 100 mg|Participants received mirabegron 100 mg tablets and matching tolterodine ER placebo capsules orally once a day for 12 months.
89467747|NCT03157154||Control group|Haemophilia patient without such history or treatment matched on age and disease status (haemophilia A or B and the severity of the disease : severe, mild, minor).
89467748|NCT04282317|Other|Healthy Volunteer|This arm will enroll healthy volunteers as controls
89202140|NCT00688688|Active Comparator|Tolterodine ER 4 mg|Participants received tolterodine ER 4 mg capsules and matching mirabegron placebo tablets orally once a day for 12 months.
89018500|NCT03335670|Experimental|[68Ga]Pentixafor PET scan|4 mCi (range 3-5 mCi) of [68Ga]Pentixafor is administered intravenously over 1 minute using an infusion pump. PET imaging is performed from time of infusion for about 90 minutes. Approximately 12 blood samples (~ 1 tsp) will be taken for pharmacokinetic analysis.
89018501|NCT03304613|Active Comparator|Standard Web-based Cognitive Behavioral Therapy (e-CBT)|"Patients randomized to e-CBT will undergo Standard Web-based Cognitive Behavioral Therapy (e-CBT) Self-Management Program and meet with a study medical assistant (MA) for an orientation session. The MA provides an overview of the program, explains the rationale for treatment, and directs them to the FibroGuide website. FibroGuide features the CBT modules that will be used by both groups. Patients will complete one module per week. Materials needed for the 8-week intervention including the instructions for each activity and forms for the written aspects of an activity (worksheets) will be provided in the first visit and available online. The FibroGuide website evolved from the evidence-based website Living Well with Fibromyalgia that has established efficacy for improving functional status and reducing pain."
89202141|NCT00926991||traumatic rib fractures|
89202142|NCT00936819|Placebo Comparator|Plasma-Lyte A and 25% autologous plasma|
89467749|NCT04282317|Other|Gastroparesis Subjects|This arm will enroll a) patients with gastroparesis from type 1 diabetes and b) patients with gastroparesis from vagus nerve trauma
89467750|NCT02865499|Experimental|acarbose|all participants will receive acarbose
89467751|NCT04478552|Experimental|Intervention group|
89467752|NCT04478552|Placebo Comparator|Control group|
89467753|NCT04619953|Active Comparator|Postural Stability group (PSg)|The Postural Stability group (PSg) will perform 30 minutes of conventional neuromotor rehabilitation and 20 minutes of dynamic postural stability training.
89202143|NCT00936819|Experimental|Autologous EPCs|
89467754|NCT04619953|Active Comparator|Cognitive-Motor group (CMg)|The Cognitive-Motor group (CMg) performed 30 minutes of conventional neuromotor rehabilitation and 20 minutes of cognitive-motor training.
89467755|NCT02870933|Experimental|subject|this arm will receive Transepicardial with Transseptal CD 133+ Implantation
89467756|NCT02870933|No Intervention|control|this arm will not receive Transepicardial with Transseptal CD 133+ Implantation
89467757|NCT03156062|Experimental|study group|
89467758|NCT03156062|Active Comparator|control group|
88946743|NCT01911117||Cardiac Surgical Patients|"Patients who undergo cardiac surgery will be included in this study.~Patients undergo cardiac surgery and are over 18 years of age.~Patients need bypass machine for their cardiac surgery and traditional CO measurement.~Patients who are competent to understand the study and provide written informed consent and participate in outcome measurements."
88946744|NCT01911156|Other|Discontinue NA treatment|Subjects will not receive NA during the 72 week study period
89467759|NCT04269603|Other|30 healthy adult volunteers|Healthy adult volunteers without hemorrhagic diathesis.
89467760|NCT02031887|Experimental|Infant starter formula with synbiotics|Infant starter formula with synbiotics
89467761|NCT02031887|Active Comparator|Infant formula without synbiotics|Infant formula without synbiotics
89467762|NCT05167617|Experimental|Vitamin Deficiency|
89467763|NCT05239377||Baseline|Pre-prostatectomy conferences conducted without the use of digital support
89467764|NCT05239377||ISPM -MiProstate|Pre-prostatectomy conferences conducted with the use of digital support (ISPM- MiProstate)
89467765|NCT03146624|Experimental|attachment|attachment retained obturator
89467766|NCT03146624|Active Comparator|clasp|clasp retained obturator
89467767|NCT03616613||Men|Men born in 1952 in Barcelona in health areas depending from Hospital de la Santa Creu i Sant Pau.
89467768|NCT03616613||Women|Aleatory sample of women born in 1952 in Barcelona in health areas depending from Hospital de la Santa Creu i Sant Pau.
89467769|NCT02033161|Experimental|Internet-delivered CBT|
89467770|NCT02349464|Active Comparator|Intervention|For infants receiving pediatric care at one of the seven intervention practices, mothers will receive the Specialized Preterm Infant/Mother Dyad Lactation Support which includes home equipment and pediatric clinic-lactation support to support lactation for four months post-hospital discharge.
89467771|NCT02349464|No Intervention|Control|For infants receiving pediatric care at one of the seven control practices, mothers will receive standard support.
89467772|NCT03615365||Patients with moderate-to-severe COPD.|"Patients will be identified from the Cambridge COPD Centre. This unit sees patients following emergency admissions, GP referrals and has a regional referral base for complex COPD. Patients' medical records will be reviewed and classified according to GOLD criteria.~Patients will undergo a clinical assessment of COPD during screening at Addenbrooke's Hospital. All patients will be assessed five times: at the start, 2 weeks, 10 weeks, 18 weeks and at the end of the 26 week study period. A brief follow-up telephone review will be conducted approximately 2 weeks after the end of the monitoring period. At each assessment, capnometry measurements will be taken in addition to vital signs and pulse oximetry."
89467773|NCT05239065|Experimental|Personalized stress management nursing coaching with application of portable device|Arm (Tongji Hospital) All the participants will receive a paper-printed brochure introducing stress and stress management strategies and the instruction of using HUAWEI portable device at the recruitment. During the 3-month intervention phase, multiple formats of stress and stress management knowledge educations will be sent by the health educator on weekly basis. The participants will have personalized stress management nursing coaching and assistance of building up new life habits, they will be also encouraged to submit a weekly questionnaire for self-evaluation. Finally, participants from Tongji hospital will be involved in a social network to share their experience anonymously and gain knowledge from the group chat.
89467774|NCT05239065|Sham Comparator|Minimum information transfer and assistance of building up healthy life habits|Arm2 (Wuhan No1 Hospital) - The participants will only receive a paper-printed brochure introducing stress and stress management strategies and the instruction of using HUAWEI portable device at the recruitment. There is no recurrent knowledge education, interpersonal communications, data feedbacks with the participants during the 3-month intervention phase.
89467775|NCT03616457||All Study Participants|All study participants will undergo the same study procedures, including Automated Breast Ultrasound (ABUS).
88946745|NCT01911156|Other|NA treatment|Subjects will continue to receive their prescribed NA during the 72 week study period
88946746|NCT01911182|Experimental|Inhalation of low concentration of CO2|
88946747|NCT01911182|Active Comparator|caffeine only|
88946748|NCT01911208|Experimental|RECRUIT intervention|Clinical sites will work with the RECRUIT team to enhance and individualize their recruitment methods.
88946749|NCT01911208|Experimental|Control|Clinical sites can use which ever recruitment methods they prefer.
88946750|NCT01911234|Experimental|TNF-Kinoid|TNF Kinoid + ISA51
88946751|NCT01911234|Placebo Comparator|Placebo|Placebo + ISA51
88946752|NCT01911247|Experimental|Arm 1|
88946753|NCT01911286||Standard group|Apnea test according to the recommendation
88946754|NCT01911286||CPAP group|Apnea test with CPAP connection
88946755|NCT01911299|Experimental|Choline|Liquid glycerophosphocholine (GPC) supplement
88946756|NCT01911299|Placebo Comparator|Placebo|Liquid placebo supplement
88946757|NCT01911312|Experimental|Intervention|
88946758|NCT01911312|Active Comparator|Body Temperature Control|Stimulation performed with body temperature control
88946759|NCT01911325|Experimental|Phase Ib: Buparlisib + docetaxel|Buparlisib (BKM120) oral once daily: 80 mg and 100 mg dose levels to be tested in the dose escalation part of the trial in combination with docetaxel every three week intravenous (i.v.) infusion: 75 mg/m2 as per label.
88946760|NCT01911325|Experimental|Phase II: Buparlisib + docetaxel|Buparlisib oral once daily: MTD/RP2D mg to be tested in combination with docetaxel every three week i.v. infusion: 75 mg/m2 as per label.
88946761|NCT01911325|Placebo Comparator|Phase II: Placebo + docetaxel|Buparlisib matching placebo oral once daily to be tested in combination with docetaxel every three week i.v. infusion: 75 mg/m2 as per label.
89467776|NCT02349308||CentrosFLO Long Term Hemodialysis Catheter|Schedule placement of catheter. Arterial tip of the catheter should be placed at or just above the junction of the right atrium and superior vena cava, with the arterial lumen on the left side of the catheter. The venous limb will extend into the right atrium. Catheter will be locked with the usual heparin lock solution for a newly placed catheter (at least 500 units per lumen). Fluoroscopic images will document tip position.
89467777|NCT03615287||Group A|40 subjects undergoing Medical Treatment
89467778|NCT03615287||Group B|40 subjects undergoing Surgical Treatment
89467779|NCT03615287||Group C|40 control subjects
89467780|NCT03404739|Experimental|Single-dose group|Ceftazidime 2g at the start of POEM
89467781|NCT03404739|Active Comparator|Multiple-dose group|Ceftazidime 2g at the start of POEM plus additional 2 doses given every 12 hours after the procedure
89467782|NCT03155516|Experimental|GPM Ward|Good Pain management ward
89467783|NCT03155516|Active Comparator|Control Ward|Current practice controlled ward
89467784|NCT02031965|Experimental|Treatment (oncolytic HSV-1716)|Patients receive oncolytic HSV-1716 IT and peritumorally after undergoing surgical tumor resection. Patients also receive dexamethasone IV prior to and 6 and 12 hours after surgery.
89467785|NCT03395067|Active Comparator|Lifestyle counseling|
89467786|NCT03395067|No Intervention|Control group|
89467787|NCT02347280|Experimental|Loop ileostomy with colonic lavage|creation of a loop ileostomy, intraoperative colonic lavage with warmed polyethylene glycol via the ileostomy and postoperative antegrade instillation of vancomycin flushes into the diseased colon via the ileostomy
89467788|NCT02347280|Active Comparator|Total abdominal colectomy with end ileostomy|Removal of entire colon with preservation of rectal stump and construction of end ileostomy
89467789|NCT03404271|Placebo Comparator|Normal Diet|Participants in the normal diet (ND) group will follow a traditional dietary pattern, consisting of eating breakfast and continuing to eat throughout the day until the evening. Participants in this group will receive placebo capsules. Participants in all groups will follow an identical resistance training program and be provided with whey protein supplements.
88946762|NCT01911338|Experimental|Real Time Feedback|Before beginning practice, one of the teachers performed the manipulation and explained the graph parameters as real-time feedback to consider when interpreting the graph, leaving the graphic as the benchmark execution
89467790|NCT03404271|Experimental|Time-Restricted Feeding|Participants in the time-restricted feeding (TRF) group will consume all calories within an 8-hour period of time each day. Participants in this group will receive placebo capsules. Participants in all groups will follow an identical resistance training program and be provided with whey protein supplements.
88946763|NCT01911338|Active Comparator|Tradicional Learning Method|Two expert teachers in manual therapy provided indications and corrections to the group with a teacher - student ratio of 1:8
89467791|NCT03404271|Experimental|Time-Restricted Feeding plus HMB|Participants in the time-restricted feeding plus HMB (TRF+HMB) group will consume all calories within an 8-hour period of time each day. Participants in this group will receive HMB capsules. Participants in all groups will follow an identical resistance training program and be provided with whey protein supplements.
89467792|NCT03615209|Active Comparator|Transauricular vagus nerve stimulation|Non invasive vagus nerve stimulation will be conducted with Cerbomed NEMOS via the left ear.
88946764|NCT01911364|Experimental|BDP/FF/GB|CHF 5993 pMDI 100/6/12.5 mcg 2 inhalations b.i.d
88946765|NCT01911364|Active Comparator|Tiotropium|Tiotropium bromide 18 mcg
88946766|NCT01911364|Active Comparator|BDP/FF + Tiotropium|"BDP/FF pMDI 100/6/12.5 mcg 2 inhalations b.i.d and Tiotropium 18 mcg daily~BDP/FF/GB versus BDP/FF + Tiotropium"
88946767|NCT01911377|Active Comparator|Arm 1: Botulinum Toxin Type A|"200 units of Botulinum Toxin Type a will be administered intradermally to the allodynic area chosen for study.The allodynic area will be mapped, and the number of injections needed to cover the allodynic area without exceeding 40 injection sites will be determined.~All participants will receive a cream formulation of lidocaine and prilocaine (EMLA) applied to the painful area 60 minutes before the injections to minimize any discomfort caused by the injections."
88946768|NCT01911377|Placebo Comparator|Arm 2: Normal Saline for Injection|Normal saline for intradermal injection will be prepared by the Investigational Pharmacy in a manner as to be indistinguishable from active drug. The allodynic area will be mapped so as to determine the number of injections needed to cover the whole allodynic area without exceeding 40 injection sites. All participants will receive a cream formulation of lidocaine and prilocaine (EMLA) applied to the painful area 60 minutes before the injections to minimize any pain caused by the injections.
88946769|NCT01911416|Experimental|All participants|All participants on study
89202144|NCT00936819|Experimental|Autologous EPCs Transfected with human eNOS|
89467793|NCT03615209|Sham Comparator|Transauricular sham stimulation|Non invasive sham stimulation will be conducted with Cerbomed NEMOS via the left ear lobe.
89467794|NCT03149120|Experimental|Nivolumab|Nivolumab will be given as an intravenous infusion at a dose of 240 mg every 2 weeks for at least 6 months.
89467795|NCT03149120|Experimental|Nivolumab with Pazopanib|Pazopanib at a dose of 800mg by mouth daily.
89467796|NCT04849325|Experimental|IBS Titan|
89467797|NCT04849325|Active Comparator|Percutaneous Transluminal Angioplasty (PTA)|
89467798|NCT03403023|Experimental|DES treated patients|This single group of patients is imaged by the Tear Film Imager (TFI) device before and after treatment with Restasis, the treatment indicated for their condition.
89467799|NCT03155594|Experimental|Single arm|Patients in this trial will receive a FreeStyle Libre patch that continuously measures glucose in addition to their standard glucose monitoring.
89467800|NCT02864407||Vahelva® Respimat® (Tiotropium + Olodaterol fixed dose combination)|Korean patients with COPD who are newly prescribed with Vahelva® Respimat® (Tiotropium + Olodaterol fixed dose combination).
89467801|NCT03391791||Genetically engineered T Cell Receptor- treated|Long term follow-up of subjects with solid or hematological malignancies who have received lentivirus-mediated genetically engineered T Cell Receptors in a previous trial
89467802|NCT03149198|Experimental|Interventional group|Mat pilates exercises
89467803|NCT03149198|Active Comparator|Control group|Aquatic aerobic exercises
89467804|NCT03616301|Experimental|Clavamox, Powder for Oral Suspension, 400 mg + 57 mg / 5 ml|Clavamox, Powder for Oral Suspension, 400 mg + 57 mg / 5 ml is the test product. 14 of 28 subjects in each of two cohorts (total number of enrolled volunteers - 56) will be given single oral dose (5 ml containing 400 mg of amoxicillin and 57 mg of clavulanic acid) in period 1 and period 2 of the clinical part of the study.
89467805|NCT03616301|Active Comparator|Augmentin®, Powder for Oral Suspension, 400 mg + 57 mg / 5 ml|Augmentin®, Powder for Oral Suspension, 400 mg + 57 mg / 5 ml is the reference product. 14 of 28 subjects in each of two cohorts (total number of enrolled volunteers - 56) will be given single oral dose (5 ml containing 400 mg of amoxicillin and 57 mg of clavulanic acid) in period 1 and period 2 of the clinical part of the study.
89467806|NCT03149276||Limited English Proficiency Group|"LEP persons were identified by asking, What language would you like to receive medical information and services in? Patients were considered limited English proficient when a non-English language was preferred. Interventions included professional interpreter services and occupational therapy."
89202145|NCT00937053|Experimental|Hemoglobin below 120 g/dL|
89202146|NCT00937053|Active Comparator|Hemoglobin below 70 g/dL|
89018502|NCT03304613|Experimental|Resilience-Enhanced web-based CBT Program|"Patients randomized to PRISM will undergo Promoting Resilience through Innovative Self-Management (PRISM) and meet with the MA for an orientation session. The MA describes the program, explains the rationale for treatment, and directs them to the FibroGuide and PRISM websites. Materials and worksheets are provided in the first visit and available online. The e-CBT elements retained are the core elements of CBT for pain, while the resilience-based activities capitalize on the best practices for positive activities interventions including having multiple overlapping activities, making favored activities standard practice beyond the study and having a coaching component."
89018503|NCT03304613|No Intervention|Usual Care|Patients randomized to the usual care only group will have no contact with the study MAs. Usual care patients return for the same follow-up assessments (and electronic medical record review) at 8 weeks and at 6 and 12 months. Whereas major surgery including surgeries for pain, are exclusion criteria, spine and pain injections will be permitted.
89467807|NCT03149276||English Speaking Group|"English speaking persons were identified by asking, What language would you like to receive medical information and services in? Patients were considered English speaking when the English language was preferred. Intervention included occupational therapy."
89467808|NCT03391713|No Intervention|Control|No exposure to waiting room posters
89467809|NCT03391713|Active Comparator|Intervention|During the second half of the study (two weeks), there will be an education poster in the waiting room of the clinic, fashioned after the Face, Arms, Speech, Time (FAST) poster developed by the American Heart Association (AHA), but in Malay.
89467810|NCT03394989|Experimental|Test|Fluticasone propionate/salmeterol 100/50 µg
89467811|NCT03394989|Active Comparator|Comparator|Fluticasone propionate/salmeterol 100/50 µg
89467812|NCT03394989|Other|Placebo|Test Placebo
89467813|NCT02873429||Integrative Medicine (Complementary /Alternative)Group|Patients receiving chiropractic care, acupuncture, massage therapy, or meditation training for chronic pain
89467814|NCT02873429||Conventional Medicine Group|Patients receiving conventional medicine care (physical therapy, medication management, injections, etc.) for chronic pain.
89467815|NCT02033239|Experimental|FIAsp|Each subject will be randomised to a treatment sequence consisting of 8 treatment periods
89467816|NCT02033239|Active Comparator|NovoRapid®|Each subject will be randomised to a treatment sequence consisting of 8 treatment periods
89018504|NCT03301805|Experimental|BLEX 404 Oral Liquid|During Phase I study (dose escalation), a standard 3+3 design will be followed, and the dose range is 3 to 10 mg/kg BID. The recommended dose level (RDL) for the Phase II study is defined as the dose level with 0 to 1 DLT observed during cycle I of Gemcitabine monotherapy among 6 patients in the Phase I study.
89018505|NCT03298659|Experimental|Active iFR-guided revascularization|Decision to treat the nonculprit coronary stenosis if there is a significant pressure drop over the stenosis, as measured by intracoronary iFR assessment
89018506|NCT03298659|Active Comparator|Deferred CMR-guided revascularization|Decision to treat the nonculprit coronary stenosis if perfusion defect visible in corresponding coronary territory as visualized on stress perfusion CMR imaging
89018507|NCT03296774|Placebo Comparator|Usual Care|Usual postpartum care
89018508|NCT03296774|Experimental|Healthy Beyond Pregnancy|Web-based program for postpartum care and education and scheduling. Incentive for committing and returning for postpartum care.
89467817|NCT02353364|Experimental|Group A|Transfer of 1 or 2 biopsied euploid embryo of high morphological grade based on NGS testing using CNV-Seq (PGS)
89467818|NCT02353364|No Intervention|Group B|Transfer of 1 or 2 non-biopsied embryo of high morphological grade (no PGS)
89467819|NCT05167149|Experimental|Carbon nanoparticles group|
89467820|NCT05167149|Active Comparator|Indocyanine green group|
89467821|NCT03615131||MRI-TRUS fusion prostate biopsy|Single Arm Study, MRI and Prostate-Biopsy on same patient, individual patient acts as own control for intervention
89467822|NCT02033395||Participants exposed to tramautic event|
89467823|NCT02486302||Observation Group|
89467824|NCT02353286|Experimental|Post-cholecystecomy bile leak|Endoscopic insertion of biodegradable biliary stent
89467825|NCT02353286|Experimental|Benign biliary stricture|Endoscopic insertion of biodegradable biliary stent
88946770|NCT01911455|Active Comparator|acamprosate|The maximum dose of acamprosate to be used in this study is 666 mg three times daily (total 1998 mg/day) for subjects weight ≥ 50 kg and 1332mg for subjects that weigh < 50 kg.
89467826|NCT03394911|Experimental|Experimental Group|250mg p.o. of healthy adult male facial skin surface lipid liquid pheromone on fresh, new, just-purchased, un-chewed Wrigley's Rain #5 sugarless chewing gum vehicle. 15 pieces or divided as tolerated.
89467827|NCT03394911|Placebo Comparator|Placebo Group|Placebo identical to Experimental dose with randomly assigned identification numbers on unopened, unsealed key. Placebo and Experimental doses kept together and undifferentiable without the key being opened. Key available for opening 24/7 w/pharmaceuticals tech onsite. Keep pheromone/placebo doses under a fume hood. Wear 3M Versaflo activated charcoal filter supplied air respirator or equivalent to access.
89467828|NCT02033629|Active Comparator|Ce 1 ng/ml|TCI Remifentanil Ce 1 ng/ml
89467829|NCT02033629|Active Comparator|Ce 2 ng/ml|TCI Remifentanil Ce 2 ng/ml
89467830|NCT02033629|Placebo Comparator|Ce 3 ng/ml|Remifentanil Ce 3 ng/ml
89467831|NCT03148886|Experimental|PA intervention|The intervention consisted in a home-based adapted PA program defined at the inclusion, according to patient's capacities.
89467832|NCT03610243|Experimental|Self-administered acupressure|"The proposed self-administered acupressure intervention is patient-centered comprising four pre-selected acupoints that should be applied pressure on by all patients and a list of additional acupoints from which patients can choose two for self-administration according to the personalized recommendations of trainers. In this way, each patient will receive an individualized protocol (four pre-selected and two self-selected acupoints).~The intervention consists of: individual participant training (Two 2-hour one-on-one training sessions in week 1), self-practice (15 minutes of self-administered acupressure twice a day), and follow-up visits (a 1-hour follow-up visit at weeks 2, 3, and 4)."
88946771|NCT01911455|Placebo Comparator|Placebo|Placebo will be prescribed with the same frequency and duration as the acamprosate group.
88946772|NCT01911468|Active Comparator|metformin|In the metformin group metformin was initiated at a dose of 500 mg once per day and increased by 500 mg every 3 days up to 1000 mg BID per os.
88946773|NCT01911468|Active Comparator|liraglutide|In the liraglutide group liraglutide was initiated at a dose of 0.6 mg injected sc once per day and increased to 1.2 mg/day after 1 week.
88946774|NCT01911468|Active Comparator|metformin and liraglutide|In the metformin and liraglutide group metformin was initiated at a dose of 500 mg once per day and increased by 500 mg every 3 days up to 1000 mg BID per os. At the same time liraglutide was initiated at a dose of 0.6 mg injected sc once per day and increased to 1.2 mg/day after 1 week.
88946775|NCT01911481|Experimental|hydration|after recruitment the women in hydration group will be invited to drink 2 litres of water,in 2 hours
89202147|NCT04013997|Experimental|Exoskeletal-assisted walking training group|Prospective subjects were recruited following admission to the SCI inpatient unit at Mount Sinai Hospital. Attending physicians and rehabilitation clinicians identified patients admitted to the unit who may be eligible for the study.
89467833|NCT03610243|No Intervention|Wait-list control|The wait-list control group will be contacted in the third week to attend a health talk unrelated to symptom management.
88946776|NCT01911481|No Intervention|control|
88946777|NCT01911494|Experimental|Intervention|"The CLIP intervention consists of (i) community engagement including community leaders, the women of the communities themselves, and their mothers, husbands, and mothers-in-law, regarding pre-eclampsia, its origins, symptoms, signs, and potential consequences, pre-permissions for maternal transport, and fundraising activities around transport and treatment costs; (ii) provision of HDP oriented antenatal care through CLIP visits and use of CLIP PIERS on the Move mHealth tool (for risk stratification), and (iii) use of the CLIP package for women with a CLIP 'trigger' (i.e., oral antihypertensive therapy (methyldopa) when indicated, intramuscular (i.m.) magnesium sulfate when indicated; and appropriate referral to an CEmOC facility when indicated)"
88946778|NCT01911494|No Intervention|Control|Current standard of antenatal care
88946779|NCT01911507|Experimental|Treatment ( INCB028, erlotinib)|Patients receive INC280 PO BID and erlotinib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88946780|NCT01911520|Experimental|BMI < 50, Total Body Weight (TBW), 2mg/kg|Patients with a BMI < 50, who will be dosed according to total body weight.
88946781|NCT01911520|Experimental|BMI < 50, TBW, 4 mg/kg|Patients with a BMI < 50, who will be dosed according to total body weight.
88946782|NCT01911520|Experimental|BMI < 50, Ideal Body Weight (IBW), 2 mg/kg|Patients with a BMI < 50, who will be dosed according to ideal body weight.
88946783|NCT01911520|Experimental|BMI < 50, IBW, 4 mg/kg|Patients with a BMI < 50, who will be dosed according to ideal body weight.
88946784|NCT01911520|Experimental|BMI > 50, TBW, 2mg/kg|Patients with a BMI > 50, who will be dosed according to total body weight.
88946785|NCT01911520|Experimental|BMI > 50, TBW, 4mg/kg|Patients with a BMI > 50, who will be dosed according to total body weight.
89467834|NCT02033473|Experimental|Apelin|An apelin clamp in which an apelin infusion will be administered prior to reference clamp
89467835|NCT02033473|Placebo Comparator|Placebo|A clamp reference during which a placebo solution (saline solution) will be administered prior to apelin clamp
89467836|NCT03615989|Placebo Comparator|Exercise and Carbohydrate (CHO)|Participants had a fasted, baseline blood sample (10ml) taken upon arrival to the lab. They then completed a supervised resistance and plyometric exercise bout. Immediately following exercise, 50g of carbohydrate (maltodextrin) + water was consumed. Two more blood samples followed the exercise bout at 5 minutes post (10ml) and 1 hour post (10ml). An additional 50g of carbohydrate was consumed with water 1 hour post exercise. Two more fasting blood samples (10ml) were taken 24 and 48 hours later.
89467837|NCT03615989|Experimental|Exercise and Milk (Milk)|Participants had a fasted, baseline blood sample (10ml) taken upon arrival to the lab. They then completed a supervised resistance and plyometric exercise bout. Immediately following exercise, ~500 ml of skim milk was consumed. Two more blood samples followed the exercise bout at 5 minutes post (10ml) and 1 hour post (10ml). An additional 500 ml of skim milk was consumed 1 hour post exercise. Two more fasting blood samples (10ml) were taken 24 and 48 hours later.
89467838|NCT03391557|Experimental|Patients with the UE examination|Patients with enlarged intrathoracic lymph nodes(≥1cm) and/or 18-FDG high uptake (SUV Max > 2.5) without bleeding tendency, abnormal coagulation function and serious cardiac dysfunction were finally selected.
89467839|NCT03148808|Experimental|NVS Therapy|NVS Therapy will be delivered to de novo lesions in the superficial femoral artery (SFA) and proximal popliteal artery (PPA) during PTA in patients with symptomatic peripheral artery disease.
89467840|NCT02034097|Experimental|Cohort 1|Subjects with EGFRm NSCLC who have received clinical benefit (CR, PR, SD) for at least 4 months and then progressed on an EGFR-TKI within the last 30 days will receive 150 milligram (mg) erlotinib once daily (OD) and 45 mg foretinib OD as a combination therapy until disease progression
89467841|NCT02034097|Experimental|Cohort 2|Subjects with EGFR/WT NSCLC who have received clinical benefit (CR, PR, SD) for at least 2 months and then progressed on an EGFR-TKI within the last 30 days will receive 150 mg erlotinib OD and 45 mg foretinib OD as a combination therapy until disease progression.
89467842|NCT02034097|Experimental|Cohort 3|Subjects with NSCLC who are predicted to be sensitive to foretinib based on biomarkers identified with preclinical or clinical data will receive 60 mg foretinib OD as a monotherapy until disease progression
89467843|NCT03614897|Experimental|Education|Providers participating in education related to guidelines for treating patients at risk of falling
89467844|NCT05238051|No Intervention|Gastric residual volume group|Patients undergoing enteral nutrition with continuous infusion and intermittent gastric residual volume measurement in the intensive care unit
89467845|NCT05238051|Experimental|Non- Gastric residual volume group|Patients undergoing enteral nutrition with continuous infusion and intermittent gastric residual volume measurement was not measured in the intensive care unit
89467846|NCT03148730|No Intervention|manual group|This group will have a standard of care anesthesia. All the drugs, fluid and adjustement of ventilation settings will be done manually by the supervising anesthesiologist using the same drugs and fluids as the closed-loop group
89467847|NCT03148730|Experimental|automated closed-loop group|This group will have a fully automated anesthesia, analgesia , ventilation and fluid management using 3 indenpendent closed-loop systems same drugs used in both groups ( propofol and remifentanil, Plasmalyte and /or Voluven)
89467848|NCT03610477|Active Comparator|Medium Chain Triglyceride|Participants will be randomized to consume 5% of total energy intake from medium chain triglycerides.
89467849|NCT03610477|Placebo Comparator|Long Chain Triglyceride|Participants will be randomized to consume 5% of total energy intake from long chain triglycerides.
89467850|NCT03615833|Experimental|Patients with Vitamin D deficiency|Patients with Vitamin D deficiency, Administration of Cholecalciferol 2.5 mg (100 000 UI), once a month for 3 months
89467851|NCT03391401||Adip1|Patients with morbid obesity (i.e. BMI >35 kg/sqm) and age >18 scheduled for bariatric surgery (all standard procedures included)
89467852|NCT02347436||benign prostatic hypertrophy|patients who are diagnosed with lower urinary tract symptoms caused by prostatic hypertrophy, undergo transurethral resection of the prostate, and post-surgery 24-hr ambulatory blood pressure measurement.
89467853|NCT02347436||inguinal hernia or hydrocele|patients who are diagnosed with lower urinary tract symptoms caused by inguinal hernia or hydrocele, undergo surgical inguinal hernia repair or hydrocele repair, and post-surgery 24-hr ambulatory blood pressure measurement
89467854|NCT03615755|No Intervention|Standard Therapy|Standard Therapy (controlling blood sugar, antibiotic drug, ulcer debridement, wound care, offloading)
89206177|NCT00830934|Experimental|Group care|The second treatment group (group care group) will be assigned to weekly group exercise classes, focusing on core stability and strengthening exercises. Classes will last one hour and will be conducted for 4 weeks. In both treatment groups pain scores will be followed up for 1 week post last treatment.
89467855|NCT03615755|Active Comparator|Combination Therapy|Standard Therapy with adjuvant Hyperbaric Oxygen Therapy (Total 10 sessions, each session used pressure 2.4 ATA for 90 minutes per day)
89467856|NCT02747875|Active Comparator|Control - Fentanyl|Participants will receive 20 mcg/kg of fentanyl prior to surgical incision, over 20 minutes. The medication will be prepared as described and all research and staff personnel as well as the study participant will be blinded to treatment group assignment.
89467857|NCT02747875|Active Comparator|Treatment - Methadone|Participants will receive 0.3 mg/kg of methadone prior to surgical incision, over 20 minutes. The medication will be prepared as described and all research and staff personnel as well as the study participant will be blinded to treatment group assignment.
89467858|NCT03394833|Experimental|Preoperative fluids|40 individuals receiving preoperative colloid fluid bolus at 6 ml/kg LBW, (Gelofusine™, Fresenius Kabi AB, Sweden) before anesthesia induction by TCI (n = 20) or RSI (n =20).
89467859|NCT03394833|No Intervention|No preoperative fluids|40 individuals anesthetized by TCI (n = 20) or RSI (n =20) without preoperative fluids.
89467860|NCT02347358|Experimental|IV r-tPA with JRecanTM blood FR device|Dual IV r-tPA therapy and adjunctive treatment with JRecanTM blood flow recanalisation device
89467861|NCT02347358|Active Comparator|IV r-tPA|IV infusion of r-tPA
89467862|NCT03391323|Other|Medacta GMK Sphere® Medial-Pivot Knee Prosthesis|
89467863|NCT03391323|Other|Medacta GMK PS Posterior Stabilized Knee Prosthesis|
89537277|NCT03065907|Active Comparator|Vision Rehabilitation Group 2|Vision rehabilitation assessment will be scheduled within 7 months of randomization; interventions will be scheduled and vision rehabilitation appointments will be scheduled accordingly.
88946786|NCT01911520|Experimental|BMI >50, IBW, 2 mg/kg|Patients with a BMI > 50, who will be dosed according to ideal body weight.
88946787|NCT01911520|Experimental|BMI >50, IBW, 4 mg/kg|Patients with a BMI > 50, who will be dosed according to ideal body weight.
89467864|NCT03155282||Cirrhotic group|30 patients with cirrhosis will be evaluated by EUS-E to measure liver and spleen stiffness. Different cirrhosis etiologies will be included like cirrhosis induces by alcohol, virus, autoimmune, nonalcoholic steatohepatitis (NASH), cryptogenic, primary sclerosing cholangitis and primary biliary cirrhosis. The cirrhotic status will be determinate by clinical, biochemical and/or imaging methods (abdominal ultrasound or CT scan).
89467865|NCT03155282||Control group|30 normal patients with no history of liver disease (negative hepatitis B virus and hepatitis C virus serology, insignificant alcohol intake, normal ultrasound and laboratory), in whom a EUS has to be performed to evaluate a esophageal or gastric subepithelial lesion, chronic pancreatitis, will be evaluated by EUS-E to measure liver and spleen stiffness.
89467866|NCT03610321|Active Comparator|Statin group|Receiving statin treatment (atorvastatin 20 mg or rosuvastatin 10 mg, once daily, oral) only for 1 month.
89467867|NCT03610321|Experimental|Gefarnate group|Combined treatment with statins (atorvastatin 20 mg or rosuvastatin 10 mg, once daily, oral) and gefarnate (100 mg, three times daily, oral) for 1 month.
89467868|NCT03394755|Experimental|9.45 x 10^7 Thrombosomes/kg|Cohort 1
89467869|NCT03394755|Experimental|1.89 x 10^8 Thrombosomes/kg|Cohort 2
89467870|NCT03394755|Experimental|3.78 x10^8 Thrombosomes/kg|Cohort 3
89467871|NCT02236793|Experimental|BioChaperone PDGF-BB|BioChaperone PDGF-BB administered every other day at the dose of 4µg/cm² for 20 weeks or until wound closure, associated with Standard of Care
89467872|NCT02236793|Placebo Comparator|Standard of Care|Normal saline solution applied every other day at the same volume for up to 20 weeks, associated with standard wound care
88946788|NCT01911559||constipated quadriplegic CP children|In this study we included children with CP, in the manifestation of severe diplegia or quadriplegia, who do not currently use the standing-frame.
88946789|NCT01911572||Survivors|Individuals who have previously experienced an episode of invasive streptococcal infection or necrotising fasciitis.
88946790|NCT01911572||Family members|Parents of those survivors aged less than forty years without risk factors for streptococcal disease (forming mother-father-child trios), or first and second degree relatives of survivors from a family in which two or more individuals have been affected.
88946791|NCT01911585|Active Comparator|90 minute Prolonged Exposure Sessions|Prolonged Exposure Therapy for PTSD consists of 10 to 15 weekly or twice-weekly sessions, each lasting about 90 minutes, with 40 to 60 minutes imaginal exposure.
88946792|NCT01911585|Experimental|60 minute Prolonged Exposure Sessions|This treatment condition is a modified version of Prolonged Exposure therapy for PTSD. It consists of 10 to 15 weekly or twice-weekly sessions, each lasting about 60 minutes, with 20 minutes imaginal exposure.
88946793|NCT01911598|Experimental|A: MEHD7945A+ Cisplatin + 5-FU|Participants with previously untreated R/M SCCHN will receive MEHD7945A 1650 milligrams (mg) intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression, unacceptable toxicity, or protocol violation. Cisplatin will be administered as 100 milligrams per square meter (mg/m^2) IV infusion on Day 1 of Cycles 1 to 6. 5-FU will be administered as 1000 mg/m^2/day administered as continuous infusion over Days 1-4 of Cycles 1 to 6.
89206178|NCT00524134|Experimental|1|Carvedilol-CR up to 80mg daily, used as a P-glycoprotein inhibitor to increase drug concentrations in specific regions of the brain.
89467873|NCT02347046|Experimental|Moderately-decreased group|(eGFR: >=30mL/min/1.73m^2 and < 60mL/min/1.73m^2)
89467874|NCT02347046|Experimental|Slightly-decreased group|(eGFR: >=60mL/min/1.73m^2 and < 90mL/min/1.73m^2)
89467875|NCT02347046|Experimental|Normal group|(eGFR: >=90mL/min/1.73m^2)
89467876|NCT02451124|Experimental|Screening: non-endoscopic inflatable balloon for the esophagus|Patients undergo non-endoscopic brushing of the esophagus using a non-endoscopic inflatable balloon for the esophagus over 30-60 minutes followed by a standard esophagogastroduodenoscopy. Questionnaire administration will provide self-reported data on patient experiences. laboratory biomarker analysis of biopsy will confirm diagnosis.
89467877|NCT03391245||Cirrhotic patients with or without infection|"We will include admitted patients with liver cirrhosis irrespective of the underlying etiology during 6 months in Al Rajhi Tertiary Liver Hospital, Assiut, Egypt. They will be divided into 2 Groups. Group I: Cirrhotic patients with evidence of infections at any site and Group II: Cirrhotic patients without evidence of infections.~Diagnosis of infection will based on related clinical symptoms and signs with laboratory and radiological findings."
89467878|NCT03146234|Experimental|CAR-GPC3 T cells|"Autologous T Cells with a GPC3-redirected Chimeric Antigen Receptor. Route of administration: Intravenous injection.~Lymphodepletion conditioning regimen: A combination of fludarabine and cyclophosphamide will be administered at Day -6 to Day -3 prior to CAR-GPC3 T cells infusion."
89467879|NCT02236871|No Intervention|Control|Maintain current milk and milk product intakes.
89467880|NCT02236871|Active Comparator|2 servings|Participants will be asked to consume 1 milk (250 ml) plus a yogurt (100-175 g) or cheese (up to 50 g) to reach an average of 2 servings of milk or milk products/d.
89467881|NCT02236871|Active Comparator|4 servings|Participants will be asked to consume recommended servings of milk or milk products/d for their age, so they will receive 1 milk (250 ml), a yogurt (175 g) and cheese (50 g) or more. This would provide ≥ 3 servings/d.
89467882|NCT03401619||Osteoporosis With Cognitive impairment|
89467883|NCT03401619||Osteoporosis With Arterial stiffness|
89467884|NCT03401619||Osteoporosis|
89467885|NCT03401619||Normal|
89467886|NCT02349230|Experimental|Astym treatment|Astym treatment is a manual therapy intervention applied by certified therapists with specialized instruments
89467887|NCT02349230|Sham Comparator|Sham Astym|A sham Astym treatment applied with non-therapeutic pressure and
89206179|NCT00777023|Experimental|G-ER 1200 mg|Gabapentin extended-release (G-ER) 1200 mg
89467888|NCT02349230|No Intervention|Control|12 minutes of rest
88946794|NCT01911598|Experimental|B: MEHD7945A + Paclitaxel + Carboplatin|Participants with previously untreated R/M SCCHN will receive MEHD7945A 1650 mg IV infusion on Day 1 of each 21-day cycle until disease progression, unacceptable toxicity, or protocol violation. Carboplatin will be administered at a dose to achieve an area under the curve (AUC) of 6 milligrams/milliliter/minute (mg/mL/min) as an IV infusion on Day 1 of Cycles 1 to 6. Paclitaxel will be administered as 200 mg/m^2 IV infusion on Day 1 of Cycles 1 to 6.
88946795|NCT01911611|Placebo Comparator|Placebo|
89467889|NCT03400527|Experimental|Exercise|Participant will be pedaling a stationary exercise bicycle
88946796|NCT01911611|Experimental|RO6870868|
88946797|NCT01911624|Experimental|direct thrombin inhibition|dabigatran 110 mg BID, po argatroban (0.5 - 1 µg/kg/min) if peroral therapy is not possible
88946798|NCT01911624|Active Comparator|enoxaparin|enoxaparin 40 mg od, sc
88946799|NCT01911637|Experimental|VBY-036|VBY-036 10 mg, 30 mg, 100 mg, 300 mg, 600 mg, or 900 mg
88946800|NCT01911637|Placebo Comparator|Placebo|Placebo
88946801|NCT01911650|Experimental|Autologous Platlet Rich Plasma|This subject arm will receive one injection of autologous platelet rich plasma for the treatment of Achilles tendinopathy. In addition, they will be asked to undergo a palpatory exam of the Achilles tendon; complete Quality of Life Questionnaires at three different time points; and complete a 30 minute ultrasound imaging exam of the Achilles tendon.
88946802|NCT01911650|Other|Waitlist|Subjects in this arm will have already received standard of care interventions for Achilles tendinopathy with unsatisfactory outcomes. For this research they will be asked to undergo a palpatory exam of the Achilles tendon; complete Quality of Life Questionnaires at three different time points; and complete a 30 minute ultrasound imaging exam of the Achilles tendon.
88946803|NCT01911702|Active Comparator|Conventional Group|In this group patients receive volemic standard treatment (conventional)
88946804|NCT01911702|Active Comparator|Restrictive Group|In this group patients receive volemic small treatment (restrictive)
88946805|NCT01911715|Experimental|Single Oral MDV3100 dose|
88946806|NCT01911728|Experimental|Multiple doses of MDV3100|Multiple doses of MDV3100 and a single dose of pioglitazone and a single dose of cocktail containing -warfarin, omeprazole and midazolam
88946807|NCT01911741|Experimental|Treatment A|Single dose of 4 liquid-filled capsules of MDV3100 reference formulation
88946808|NCT01911741|Experimental|Treatment B|Single dose of 2 tablets of MDV3100 formulation tablet B
88946809|NCT01911741|Experimental|Treatment C|Single dose of 2 tablets of MDV3100 formulation tablet C
88946810|NCT01911754|Experimental|Influenza Vaccine|One dose of the vaccine will be administered at a volume of 0.5 mL by intramuscular injection on Day 1 and 22
88946811|NCT01911806|Experimental|Back care pillow & standard physical therapy treatment|standard physical therapy treatment for 6 sessions of treatment, each around 30 minutes, during a period of 2 weeks & back care pillow use during the day for 2 weeks
88946812|NCT01911806|Active Comparator|standard physical therapy treatment|standard physical therapy treatment for 6 sessions of treatment, each around 30 minutes, during a period of 2 weeks
89206180|NCT00777023|Experimental|G-ER 1800 mg|Gabapentin extended-release (G-ER) 1800 mg
89206181|NCT00777023|Placebo Comparator|Sugar Pill|Placebo 1200 mg or 1800 mg
89467890|NCT02353208|Active Comparator|Sham Feeding of Bacon Bits|"In addition to the standard procedure, subjects will be asked to perform sham feeding on two occasions: 1) Immediately after having swallowed the capsule and 2) One hour after having swallowed the capsule.~Sham feeding will be performed as follows: The patients will be asked to chew 10 times on a piece of bacon over a period of 30 seconds, prior to spitting saliva and bacon into a container. This will be repeated 10 times at one minute intervals.~The patient will then complete the capsule study as per the standard procedure.~Bacon bits will be a commercially available produce which has been deemed safe for sale in Canada."
89467891|NCT02353208|Placebo Comparator|Placebo|The control group will not chew bacon bits while undergoing capsule endoscopy.
89467892|NCT03399903|Experimental|Pentasa|40 participants will be randomized to take 1 gram of Pentasa, twice daily for 8 weeks
89467893|NCT03399903|Active Comparator|Align|40 participants will be randomized to take Align tablets, once daily for 8 weeks
89467894|NCT03148652|Experimental|Enhanced Intervention (CBT+working memory training)|A standard, manualized cognitive behavioral therapy-based intervention for individuals interested in quitting smoking plus computerized working memory training
89467895|NCT03148652|Placebo Comparator|Control Intervention Condition|Participants will receive a manualized cognitive behavioral therapy-based intervention
89467896|NCT03399825||Healthy controls|Children without eye disease
89467897|NCT03399825||Retinopathy of prematurity (ROP)|Previously preterm children with a history of ROP
89467898|NCT03399825||Diabetic retinopathy|Children with diabetes
88946813|NCT01911832|Experimental|Gastrectomy and subtotal gastrectomy|to compare the quality of life between esophagojejunostomy after total gastrectomy(TG group) and Roux-en-Y gastrojejunostomy after subtotal gastrectomy(SG group)
88946814|NCT01911832|Experimental|Wide and narrow reconstruction tube|to compare the quality of life between wide tube reconstruction after subtotal gastrectomy(WG group) and narrow tube reconstruction after subtotal gastrectomy(NG group) in Roux-en-Y gastrojejunostomy
88946815|NCT01911858|Experimental|Askina Calgitrol Paste|
89537278|NCT04392765|Other|Therapy arm|Six week use of eXciteOSA device. Once daily for 20 minutes.
88946816|NCT01911871||thalassemia|patients affected with thalassemia
88946817|NCT01911871||sickle cell disease|patients affected with sickle cell disease
88946818|NCT01911871||myelodysplasia|patients affected with myelodysplasia
88946819|NCT01911884|Other|Patients with a Rokitansky Syndrome|Patients with a Rokitansky Syndrome
88946820|NCT01911923|Active Comparator|No CPAP/PEEP and 100 % oxygen|This is the control group
88946821|NCT01911923|Experimental|CPAP/PEEP and 30 % oxygen|This is the intervention group
88946822|NCT01911936|Experimental|LJM716|
89537279|NCT05180123|Other|Patients after ACL reconstruction in adolescence|
89467899|NCT03391167|Sham Comparator|Control|Peroperative and postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed.
89467900|NCT03391167|Experimental|ESP Block|In addition to routine analgesic protocol; before anaesthesia induction; bilateral ultrasound guided erector spinae plane block (ESP) (intervention) will be performed via USG guidance at Th9 level.Standard Pain Followup and Monitorization will be performed.
89467901|NCT02346968||All study participants|Patients with end stage renal disease (ESRD) planned to undergo kidney transplantation.
89467902|NCT03391089|Experimental|BBL Experimental Navigation System|As this is a single arm trial, all participants receive treatment.
89467903|NCT03146468|Experimental|Nivolumab treatment arm|Nivolumab injection 3mg/kg intravenously every 2 weeks
89467904|NCT03391011|Experimental|BBL Experimental Navigation System|As this is a single arm trial, all participants receive treatment.
89467905|NCT02353130||Memantine-XR|Boys ages 8-12 with ASD treated with Memantine-XR daily for 8 weeks
89467906|NCT02033551|Experimental|Arm A - Veliparib Monotherapy|Subjects in this arm will be dosed with Veliparib continuous dosing.
89467907|NCT02033551|Experimental|Arm B - Veliparib in Combination with Carboplatin & Paclitaxel|Subjects enrolled will receive Veliparib in combination with Carboplatin and Paclitaxel and have an option to move to Veliparib monotherapy.
89467908|NCT02033551|Experimental|Arm C Veliparib in Combination with Modified FOLFIRI|Subjects will be given Veliparib in combination with modified FOLFIRI. The subject will have the opportunity to receive Veliparib as monotherapy.
89467909|NCT02450578|Experimental|Cohort 1a: DSM265/placebo, sporozoite inoculum|DSM265 400mg / placebo Day -1, sporozoite inoculum Day 0
89467910|NCT02450578|Active Comparator|Cohort 1b: Malarone, sporozoite inoculum|Malarone daily for 9 days from Day -1 to Day 7, sporozoite inoculum Day 0
89467911|NCT02450578|Experimental|Cohort 2: DSM265/placebo, sporozoite inoculum|DSM265 400mg / placebo Day -7, sporozoite inoculum Day 0
89467912|NCT02450578|Experimental|Cohort 3: DSM265 / placebo, sporozoite inoculum (Optional)|DSM265 400mg / placebo Day -X, sporozoite inoculum Day 0
89467913|NCT02346890|Experimental|AZD1722 alone|15 mg BID
89467914|NCT02346890|Experimental|AD1722 with Renvela|AZD1722 15 mg BID and Renvela 800 mg TID
89467915|NCT03980145|Active Comparator|Conventional Physical Therapy|Conventional physical therapy (CPT): CPT sessions will involve a 3-5 minute warm-up, stretching, progressive strength training exercises, and gait and balance training.40-43 Additional strategies for home exercises, energy conservation, fall prevention, and appropriate assistive devices (i.e., orthotics) will be provided.
89467916|NCT03980145|Experimental|End-Effector Robotic Training|G-EO training: Using the G-EO System, participants will be secured with the appropriate sized harness and attached to an overhead body-weight support system, with feet secured to pressure sensitive footplates. Each session will begin with a 3-5 minute warm-up in the continuous passive mode (cadence ~40-45 steps/minute). The participant will then be transitioned into the adaptive training phase for practicing repetitive floor walking and stair climbing for up to 30 minutes. During this phase, the force produced by the robot is modulated to support the effort of the patient in producing a typical walking pattern.
89467917|NCT03146390|Active Comparator|Essential oils (Listerine Mentol)|"a single mouthwash with 20 ml of essential oils for 30 seconds~20 ml rinses for 30 seconds with essential oils/2 times daily (1/0/1)."
89467918|NCT03146390|Placebo Comparator|Water|"a single mouthwash with 20 ml of sterile water for 30 seconds~20 ml rinses for 30 seconds with sterile water/2 times daily (1/0/1)."
89467919|NCT03146390|Experimental|Alcohol free essential oils|"a single mouthwash with 20 ml of alcohol free essential oils for 30 seconds~20 ml rinses for 30 seconds with alcohol free essential oils/2 times daily (1/0/1)."
89467920|NCT03610009|Active Comparator|2D ultrasound|Two-dimensional (2D) ultrasound is used to identify number and size of ovarian follicles, to select optimal day for triggering final oocyte maturation.
89467921|NCT03610009|Active Comparator|SonoAVC|SonoAVC is used to identify number and size of ovarian follicles, to select optimal day for triggering final oocyte maturation.
89467922|NCT02039180|Experimental|AZD3293 oral solution|single doses in random order in 3 study periods for each subject (Day 1 or Day 8 or Day 15)
89467923|NCT02039180|Experimental|AZD3293 tablet formulation A|single doses in random order in 3 study periods for each subject (Day 1 or Day 8 or Day 15)
89467924|NCT02039180|Experimental|AZD3293 tablet formulation B|single doses in random order in 3 study periods for each subject (Day 1 or Day 8 or Day 15)
89467925|NCT04924582|Experimental|Capacity Coaching|Participants randomized to the Capacity Coaching arm will receive three months of coaching with a Health and Wellness coach. They will receive one one-hour session and five half-hour sessions approximately two weeks apart.
89467926|NCT04924582|No Intervention|No Capacity Coaching|Participants randomized to the No Capacity Coaching arm will receive usual care.
89467927|NCT02346734|Active Comparator|MSHAT|The study participants will receive a clinical physical therapy evaluation and a physical therapy program to do at their own pace in the home and the intervention group will receive access to the MSHAT system via a website in which they will utilize each day. The study participants in the intervention group will login to the MSHAT system, go through a pre-exercise symptom diary to determine their eligibility to exercise, perform exercise while watching a video demonstration and report results real-time. The intervention group will also be able to send and receive messages via the MSHAT system. The time to complete the daily exercises will vary from patient to patient ranging for 10-30 minutes.
89537280|NCT05179811||Cohort|Patients with functional dysphonia using the Voice Handicap Index score.
88946823|NCT01911949|Experimental|Single shot femoral nerve block|Ultrasound guided Femoral Nerve Block-40ml of bupivacaine 0.5% with epinephrine
88946824|NCT01911949|Placebo Comparator|Placebo femoral nerve block|Sterile normal saline solution
88946825|NCT01911962||transabdominal laparoscope surgery|transabdominal laparoscope surgery
88946826|NCT01911962||transvaginal laparoscopic surgery|transvaginal laparoscopic surgery
88946827|NCT01911975|Placebo Comparator|Placebo|Patients with gain-of-function Nav 1.7 related small fiber neuropathy in this arm will receive placebo.
88946828|NCT01911975|Experimental|Lacosamide|Patients with gain-of-function Nav 1.7 related small fiber neuropathy in this arm will receive lacosamide.
89467928|NCT02346734|No Intervention|Control|The study participants randomized to group 2 will serve as the control. The study participants will receive a clinical physical therapy evaluation and a physical therapy program to do at their own pace in the home and will be given a paper diary to report their exercise completion. The control group will bring their paper diary showing their exercise completion results to their 3 month and 6 month follow-up visits.
89467929|NCT02346812|Experimental|Brassica|Brassica vegetables will be consumed daily as part of a controlled diet.
89467930|NCT02346812|Other|Control|Typical American diet will be consumed, without any Brassica vegetables.
89467931|NCT02449018|Experimental|QBW251|QBW251 will be provided to participants during 70 days
89467932|NCT02449018|Placebo Comparator|Placebo|Placebo will be provided to participants during 70 days
89467933|NCT03146312|Experimental|MVM/phytochemical supplement|a multi-vitamin, multi-mineral, phytochemical supplement
89467934|NCT03146312|Placebo Comparator|Placebo|a placebo tablet (microcrystalline cellulose) identical in size, shape and color to the treatment
89467935|NCT02859415|Experimental|Phase I/Escalating doses of Mithramycin|Escalating doses of Mithramycin
88946829|NCT01911988||Colon&Rectal Stage II /Stage III|
88946830|NCT01912001|Other|Telephone follow-up.|A member of the Home Dialysis team will telephone patients to follow-up on their symptoms, dialysis and care.
89467936|NCT02859415|Experimental|Phase II/Mithramycin administered at Maximum Tolerated Dose (MTD)|Mithramycin administered at MTD
88946831|NCT01912014|Experimental|Psychosocial support and counselling|There is only one arm as this is a pilot and feasibility study.
88946832|NCT01912027|Experimental|Arthroscopic Latarjet technique|Arthroscopic Latarjet technique
88946833|NCT01912027|Active Comparator|Open Latarjet technique|Open Latarjet technique
88946834|NCT01912053|Experimental|Therasphere®|Therasphere® in association with Gemcitabine and Cisplatin
88946835|NCT01912066|Experimental|Stillen|Patients taking a tab of Stillen and a tab of placebo drug and a tab of NSAID
88946836|NCT01912066|Active Comparator|Cytotec|The subjects taking a tab of Cytotec, a tab of placebo drug, and a tab of NSAID
89467937|NCT03390855|Experimental|Broccoli sprout and follow up|Daily consumption of 30 g of raw, fresh, broccoli sprouts, not cooked, during 10 weeks (70 days), followed by other 90 days of no ingestion of broccoli sprouts
89467938|NCT02346656||Treated subjects|All subjects recruited and treated with the Axium neurostimulator
89467939|NCT03943329|Active Comparator|Standard of Care|
89467940|NCT03943329|Experimental|Distal Targeting Treatment|
89467941|NCT02346500|Experimental|Transrectal ultrasound|TRUS and TRUS-Robot will be used during PVP
89467942|NCT02871791|Experimental|Palbociclib, Everolimus, Exemestane|"Palbociclib will be administered orally, 100mg, once daily for 21 consecutive days followed by a 7-day rest (28-day cycle)~Everolimus will be administered orally, 5mg, once daily on a 28 day schedule~Exemestane will be administered orally, 25mg, once daily on a 28 day schedule"
89467943|NCT02346578|Experimental|Enzalutamide|Enzalutamide 160 mg administered orally once a day as four 40-mg soft capsules
89467944|NCT02346578|Active Comparator|Flutamide|Flutamide 125 mg administered orally three times a day as one tablet after meal
89467945|NCT03399747|Experimental|Abb-R-CHOP|
89467946|NCT04446897|Experimental|mesenchymal stem cells|standard treatment according to clinical protocols plus mesenchymal stem cells
89467947|NCT04446897|Active Comparator|standard treatment|standard treatment according to clinical protocols
89467948|NCT02346266|Active Comparator|SMART|The intervention group of school-aged children will receive education on the F.A.S.T. (Face, Arm, Speech and Time) acronym, additional signs and symptoms of stroke and the need for immediate activation of Emergency Medical Services (EMS) by calling 911.
89467949|NCT02346266|No Intervention|Usual Care|This group will not receive stroke education.
89467950|NCT03112382|Active Comparator|zinc supplement plus vitamin A and E|patients will be receiving zinc supplement plus vitamin A and E for 3 months.
89467951|NCT03112382|Active Comparator|vitamin A and E|patients will be receiving equivalent dose of vitamin A and E only for 3 months
89467952|NCT03112382|No Intervention|no vitamins|patients will be observed for 3 months
89467953|NCT03399669|Experimental|gefitinib|Patients will be treated 250 mg/day of gefitinib orally (1 cycle for 28 days). Cycles were repeated until disease progression, unacceptable toxicity, or until the patient or the investigator requested therapy discontinuation.
89467954|NCT03148574|Experimental|misoprostol|intrauterine 400 microgram
89467955|NCT03148574|Active Comparator|oxytocin|intravenous infusion 10 units
89467956|NCT03390777|Active Comparator|surgery only|Surgery consisting in debridement/removal of affected tissue/s will be performed.
89467957|NCT03390777|Active Comparator|surgery and PRGF|Surgery consisting in debridement/removal of affected tissue/s will be performed. Platelet Rich Growth Factor (device) will be produced by a venous blood sampling of the patient and applied to the treated area
89467958|NCT03148340||VIPS monitoring group|The study population will consist of adult patients presenting for evaluation of acute brain pathology,
88946837|NCT01912092|Experimental|Askina Calgitrol Paste|
88946838|NCT01912105|Experimental|treatment|Airway Medix Closed Suction System
88946839|NCT01912105|Active Comparator|control|standard closed suctioning systems
88946840|NCT01912118|Experimental|PROPOFOL ONLY GROUP|In this study group measurements will be obtained before intubation or opioid administration. To that end plasma propofol concentration will be increased slowly from 0 to 4 μg/ml in steps of 0.5 μg/mL. After the highest target is reached, the propofol target concentration will be lowered to get a BIS value of 50. After 5-min, the laryngoscope will be inserted into the mouth. Next the laryngoscope will be removed. After 5-min the laryngoscope will be placed again and the patient will be intubated. This will be done without additional administration of muscle relaxant.
88946841|NCT01912118|Experimental|PROPOFOL + REMIFENTANIL TARGET A|The subject will be intubated according to the design of group 1. The propofol concentration will be 2-5 μg/kg, aimed at a BIS of 50, with 1 ng/ml remifentanil.
88946842|NCT01912118|Experimental|PROPOFOL + REMIFENTANIL TARGET B|The subject will be intubated according to the design of group 1. The propofol concentration will be 2-5 μg/kg, aimed at a BIS of 50, with 2 ng/ml remifentanil
88946843|NCT01912118|Experimental|PROPOFOL + REMIFENTANIL TARGET C|The subject will be intubated according to the design of group 1. The propofol concentration will be 2-5 μg/kg, aimed at a BIS of 50, with 3 ng/ml remifentanil.
89467959|NCT03390699|Experimental|before and after partial maxillectomy|Microbial profile among patients before and after partial maxillectomy
88946844|NCT01912118|Experimental|PROPOFOL + REMIFENTANIL TARGET D|The subject will be intubated according to the design of group 1. The propofol concentration will be 2-5 μg/kg, aimed at a BIS of 50, with 4 ng/ml remifentanil.
88946845|NCT01912118|Experimental|PROPOFOL + REMIFENTANIL TARGET E|The subject will be intubated according to the design of group 1. The propofol concentration will be 2-5 μg/kg, aimed at a BIS of 50, with 5 ng/ml remifentanil.
89467960|NCT03148028||PID IBD patients|patients with an immunodeficiency and inflammatory bowel disease phenotype
89467961|NCT04446741||Acute Myeloid Leukemia (AML)|Newly diagnosed or relapsed/resistant AML
89467962|NCT02343536|Experimental|Oral Azacitidine (CC-486) and R-CHOP|Will examine four escalating dose-levels of CC- 486 (100 mg, 150 mg, 200 mg and 300 mg).
89467963|NCT02343536|Active Comparator|R-CHOP|R-CHOP, (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) * rituximab, cyclophosphamide, doxorubicin, and vincristine are administered on Day 1; while prednisone is administered Days 1-5
89467964|NCT02343614|Experimental|ARM A|Patients undergoing treatment with oral celecoxib
89467965|NCT04446819|Other|Cohort|Patients diagnosed with solid tumors who are about to received albumin-binding paclitaxel monotherapy are recruited. Dominant hands and non-dominant hands are treated with small-size compression gloves and suitable-size compression gloves, respectively, during the administration of albumin-binding paclitaxel.
89467966|NCT02871635|Experimental|BI 695501|
89467967|NCT02871635|Active Comparator|HUMIRA + BI 695501|
89467968|NCT03147950|Active Comparator|Prone-Flexed PCNL|Prone-Flexed Position For Percutaneous Nephrolithotomy (PCNL)
89467969|NCT03147950|Active Comparator|Prone PCNL|Prone Position For Percutaneous Nephrolithotomy (PCNL)
89467970|NCT03390543|Experimental|Device group (Group D)|Arm Description: Patients in this group are assigned to receive internal jugular vein catheterization guided by ultrasound and simple needle guide device.
89467971|NCT03390543|Placebo Comparator|sono only group (Group S)|Patients in this group are assigned to receive internal jugular vein catheterization guided by ultrasound without simple needle guide device.
89467972|NCT04093700||SureLock All-Suture Anchor|Subjects that have been implanted with the SureLock All-Suture Anchor to repair the glenoid labrum
89467973|NCT03390465|Other|Arm1(N=6)|Fimasartan/Amlodipine combination drug, Hydrochlorothiazide
89467974|NCT03390465|Other|Arm2(N=6)|Fimasartan/Amlodipine combination drug, Hydrochlorothiazide
89467975|NCT03390465|Other|Arm3(N=6)|Fimasartan/Amlodipine combination drug, Hydrochlorothiazide
89467976|NCT03390465|Other|Arm4(N=6)|Fimasartan/Amlodipine combination drug, Hydrochlorothiazide
89467977|NCT03390465|Other|Arm5(N=6)|Fimasartan/Amlodipine combination drug, Hydrochlorothiazide
89467978|NCT03390465|Other|Arm6(N=6)|Fimasartan/Amlodipine combination drug, Hydrochlorothiazide
89467979|NCT05255198||Anterolateral approach|
89467980|NCT05255198||Direct anterior approach|
89467981|NCT03394677|Experimental|RVT-501 0.5% ointment|Subjects will receive RVT-501 0.5% ointment twice daily (BID) for 4 weeks.
89467982|NCT03394677|Placebo Comparator|RVT-501 vehicle ointment|Subjects will receive RVT-501 vehicle ointment twice daily (BID) for 4 weeks.
89467983|NCT02348996|Other|Clinical assessment|Patients would have dry weight determined by clinical evaluation (blood pressure levels, peripheral edema, pulmonary auscultation and symptoms).
89467984|NCT02348996|Experimental|Bioimpedance|Patients would have dry weight determined according to volume status with a body composition monitor (BCM)
89467985|NCT02342990|Experimental|Cluster B|After the first neuropsychological assessment (T1), children will start CogMed working memory training. Children will be retested (T2) about six or seven weeks later.
89467986|NCT02342990|Other|Cluster A|After the first neuropsychological assessment (T1), children will not start any training. Children will be retested (T2) about six or seven weeks later and will start CogMed working memory training. The group will be again retest (T3) after six or seven weeks after ended training.
89467987|NCT03390387|Experimental|Dexa intermittent|Induction therapy with intermittent Dexamethasone administration (1-15 days - 6 mg/m2, 15-22 day - pause, 22-29 days - 6 mg/m2).
89467988|NCT03390387|Active Comparator|Dexa constant|Induction therapy with continuous Dexamethasone administration (6 mg/m2 1-29 days).
89467989|NCT03390387|Active Comparator|Dexa|Therapy with Dexamethasone (6 mg/m2) as basic glucocorticoid preparation.
88946846|NCT01912118|Experimental|PROPOFOL TARGET BIS 30 + REMIFENTANIL TARGET C|The subject will be intubated according to the design of group 1. The remifentanil target will be 3 ng/ml remifentanil. The propofol concentration will aim a BIS of 30.
89467990|NCT03390387|Experimental|Medrol|Therapy with Methylprednisolone (60 mg/m2) as basic glucocorticoid preparation.
89467991|NCT03390387|Experimental|IDA|Induction and consolidation therapy with Idarubicin
89467992|NCT03390387|Active Comparator|DNR|Induction and consolidation therapy with Daunorubicin
89467993|NCT03390387|Experimental|Protocol Ib+|Two-phase induction therapy (additional second phase of induction - protocol Ib)
89467994|NCT03390387|Active Comparator|Protocol Ib-|Standard induction therapy (without second phase)
89467995|NCT03390387|Active Comparator|Bortezomib-|Consolidation therapy without Bortezomib
89467996|NCT03390387|Experimental|Bortezomib+|Consolidation therapy with Bortezomib 1.3 mg/m2 N12 (N4 in each reinduction)
89467997|NCT03146000|Experimental|lidocaine-prilocaine|women will receive 5 mg lidocaine-prilocaine cream topically on the episiotomy line
89467998|NCT03146000|Active Comparator|meloxicam|women will receive one 15 mg meloxicam rectal suppository
89467999|NCT02343146|Experimental|Type One Training (TOT)|The intervention group will receive the proposed intervention composed of peer parent consultants, telephone and in-person sessions with a trained interventionist, and SMS text messaging aimed at improving child glycemic control through improved nutrition and physical activity.
89468000|NCT02343146|No Intervention|Comparison|The comparison group will receive usual care with the diabetes team.
89468001|NCT03155438||Low responder|"Low responder : women aged 25-49 years old with less than 5 oocytes (1-4 oocytes) retrieved during controlled ovarian hyperstimulation~Oxidative stress-related gene expression and oocyte competence biomarkers will be performed to access the difference between low and normal responders."
89468002|NCT03155438||Normal responder|"Normal responder women aged 25-49 years old with 5-15 oocytes retrieved during controlled ovarian hyperstimulation~Oxidative stress-related gene expression and oocyte competence biomarkers will be performed to access the difference between low and normal responders."
89468003|NCT03125889|Experimental|Treatment Arm|Subjects will receive treatment with the AquaBeam System to remove prostatic tissue.
89468004|NCT02346188|Experimental|Ferrous fumarate|Tablet formulated as ferrous fumarate, 30 mg. Given once daily for 6 months.
89468005|NCT02346188|Experimental|Zinc oxide|Tablet formulated as zinc oxide, 30 mg. Given once daily by mouth for 6 months.
89468006|NCT02346188|Experimental|Ferrous fumarate and zinc oxide|Tablet, formulated as ferrous fumarate 30 mg plus zinc oxide 30 mg. Given once daily by mouth for 6 months.
89468007|NCT02346188|Placebo Comparator|Placebo|Sugar tablet formulated to look like the experimental arms of the study. Given daily by mouth for 6 months.
89468008|NCT05237817||Cerebral infarction Group|Patients with cerebral infarction, and enrolled in our emergency or clinical department.
89468009|NCT05237817||Intracerebral hemorrhage Group|Patients with intracerebral hemorrhage, and enrolled in our emergency or clinical department.
89468010|NCT05237817||Subarachnoid hemorrhage Group|Patients with subarachnoid hemorrhage, and enrolled in our emergency or clinical department.
89202148|NCT04013997|No Intervention|Matched control group|"Twenty inpatients with SCI were identified as the matched control group through reviewing an acute inpatient rehabilitation database of Uniform Data System for Medical Rehabilitation by a person blinded to the study.~The control group received a minimum of 15 hours of standard of care, including physical and occupational therapy, for acute inpatient rehabilitation per week. The control groups received the same amount of acute rehabilitation time per week as the intervention group."
89468011|NCT05166525|Active Comparator|Medically tailored meals only|Receive medically-tailored meals only (1 meal per day for total of 10 weeks) customized to the participant's nutrition-sensitive medical condition(s).
89468012|NCT05166525|Active Comparator|Medically tailored meals plus enhanced nutritional counseling|Receive medically-tailored meals only (1 meal per day for total of 10 weeks) with up to 3 remotely delivered enhanced nutritional counseling sessions that are customized to the participant's nutrition-sensitive medical condition(s).
89468013|NCT05166525|Placebo Comparator|Usual care|Receive usual standard of care.
89468014|NCT02477332|Experimental|QGE031 24 mg s.c. q4w|ligelizumab 24 mg injection subcutaneous every 4 weeks
89468015|NCT02477332|Experimental|QGE031 72 mg s.c. q4w|ligelizumab 72 mg injection subcutaneous every 4 weeks
89468016|NCT02477332|Experimental|QGE031 240 mg s.c. q4w|ligelizumab 240 mg injection subcutaneous every 4 weeks
89468017|NCT02477332|Active Comparator|Omalizumab 300 mg s.c. q4w|omalizumab 300 mg injection subcutaneous every 4 weeks
89468018|NCT02477332|Placebo Comparator|Placebo s.c. q4w|placebo injection subcutaneous every 4 weeks
89202149|NCT00931827||Group 1|
89468019|NCT02477332|Experimental|QGE031 120 mg s.c. s.d.|ligelizumab 120 mg injection subcutaneous single dose
89468020|NCT02346110|Active Comparator|Bupivacaine-adrenalin + sodium chloride|"Single shot saphenous block:~10 mL of 5 mg/mL bupivacaine with 5 μg/mL adrenalin = 50 mg bupivacain and 50 μg adrenalin~1 mL sodium chloride solution"
89202150|NCT00931827||Group 2|
89202151|NCT00664326|Experimental|Regorafenib (Stivarga, BAY73-4506)|Participants received Regorafenib 160 mg per os (po) every day (qd) for 3 weeks on 1 week off of every 4 week cycle
89468021|NCT02346110|Experimental|Bupivacaine-adrenaline + Dexamethasone|"Single shot saphenous block:~10 mL of 5 mg/mL bupivacaine with 5 μg/mL adrenalin = 50 mg bupivacain and 50 μg adrenalin~1 mL of 4 mg/mL dexamethasone = 4 mg dexamethasone"
88946847|NCT01912118|Experimental|PROPOFOL TARGET BIS 70 + REMIFENTANIL TARGET C|The subject will be intubated according to the design of group 1. The remifentanil target will be 3 ng/ml remifentanil. The propofol concentration will aim a BIS 70.
88946848|NCT01912131|Experimental|First 24 patients Cognitive interviewing|Part 1 - This first study phase will involve interviewing 24 patients to ask for their feedback on the appropriateness of questions being developed for use in the narrative interviewing in part 2 of the study. The cognitive interview will be audio-recorded. Demographics and ECOG performance status will be recorded prior to the cognitive interview.
88946849|NCT01912131|Active Comparator|usual care|As outlined ECOG performance status will be recorded at the time of registration without the subject's involvement. Quality of life, treatment satisfaction, distress and peacefulness will also be recorded at baseline. Subjects will neither be shown the goals-of-care (GOC) video nor undergo the narrative interview process - they will be contacted as per re-assessment.
88946850|NCT01912131|Experimental|video-only arm|As outlined ECOG performance status will be recorded at the time of registration without the subject's involvement. Quality of life, treatment satisfaction, distress and peacefulness will also be recorded at baseline. Subjects will be shown the goals-of-care (GOC) video but not undergo a narrative interview process - they will be contacted as per re-assessment.
88946851|NCT01912131|Experimental|combined narrative and video (P-COCC) arm|As outlined ECOG performance status will be recorded at the time of registration without the subject's involvement. Quality of life, treatment satisfaction, distress and peacefulness will also be recorded at baseline. subjects will watch the goals-of-care (GOC) video (described in detail in the next paragraph) and then be given the narrative question stem vetted/assessed in part 1 including any changes made to that stem in the process of Part 1 testing. Subjects in P-COCC arm will then be contacted for a telephone interview and audio-taping of their narrative. Interviews will be semi- structured and based off the narrative stem that subjects were previously given for review. Interviews will last approximately 30-45 minutes and will be conducted by staff from the MSKCC Department of Psychiatry & Behavioral Sciences.
88946852|NCT01912144|Other|coffee|Coffee beverage
88946853|NCT01912157|Placebo Comparator|No Intervention|The control condition are 3 sessions writing about individual time-management (placebo).
88946854|NCT01912157|Active Comparator|Expressive Writing|The intervention consists in 3 self-applied solitary written disclosure sessions (expressive writing).
88946855|NCT01912170|Experimental|fish oil|Patients will receive fish oil capsules, at a dose of 2g/day. Each 1g capsule will contain 220mg of EPA and 170mg of DHA
88946856|NCT01912170|Experimental|Flaxseed Oil|Patients will receive flaxseed oil capsule, at a dose of 2g/day. Each 1g capsule will contain 550mg of ALA
88946857|NCT01912170|Placebo Comparator|Placebo Supplementation|Patients will receive corn oil in the capsules at the same dose as fish oil. The corn oil will appear identical in size and color to the fish oil
88946858|NCT01912183|Active Comparator|Monitoring device in PHR|Both groups will receive routine clinical care in the pediatric weight management program at McMaster Children's Hospital. Children/youth in both groups will receive a physical activity and sleep monitor and access to their PHR. The Active Comparator group will not receive any feedback or communication outside of clinic visits from the clinical team regarding their goal progress.
88946859|NCT01912183|Experimental|Communication through PHR outside clinic|Both groups will receive routine clinical care in the pediatric weight management program at McMaster Children's Hospital. Children/youth in both groups will receive a physical activity and sleep monitor and access to their PHR. The experimental group will receive regular communication with /access to the clinical team through a secure portal within the PHR(i.e. 2 way communication, weekly feedback to the families on their goal progress).
89206182|NCT05062330|Experimental|Reproxalap Ophthalmic Solution (0.25%) administered 7 times over two consecutive days|
89468022|NCT03394599|Active Comparator|TheraTrainer Only|The 30 clients (15 per site) will have the opportunity to engage in cycling on the TheraTrainer only for the duration of their participation at the Geriatric program. Their carers will also be recruited.
89018509|NCT03288974||Post Marketing Survey of MM patients treated with POMALYST®|As a method of POMALYST® PMS, Drug Use Examination (DUE) is planned and designed to comply with the regulatory requirement in consequence of approval of a new drug in Korea. This DUE is a non-interventional, observational and post-marketing surveillance, which is conducted as a regulatory required procedure to evaluate product safety of a new drug treatment in clinical routine practice in Korea. And this DUE will be conducted in compliance with the local guideline [standard for Re-examination of New Drugs, etc.] as a post approval commitment.
89018510|NCT03272477|Active Comparator|Paclitaxel+Trastuzumab+Pertuzumab|"Neoadjuvant therapy: Trastuzumab and Pertuzumab in a 3-weekly schedule in combination with standard Taxane chemotherapy.~Adjuvant Therapy: Standard of care"
89018511|NCT03272477|Experimental|Endocrine+Trastuzumab+Pertuzumab|"Neoadjuvant therapy: Trastuzumab and Pertuzumab in a 3-weekly schedule in combination with endocrine therapy.~Adjuvant Therapy: Standard of care"
89018512|NCT03270631|No Intervention|Control|Multidisciplinary rehabilitation, no interventions
89468023|NCT03394599|Experimental|TheraTrainer + Motiview|The 30 clients (15 per site) will have the opportunity to engage in cycling on the TheraTrainer with the addition of Motiview (engaging videos to watching while cycling). Their carers will also be recruited.
89468024|NCT03390309|Other|Partially Hydrolyzed Formula|Infant was identified and got 1 or more scores by using infant feeding & stool pattern questionnaire at Visit 1 will be assigned into experimental group randomly
89468025|NCT03390309|Placebo Comparator|Normal Formula|Normal Formula
89468026|NCT02348528|Experimental|Lenalidomide and dexamethasone|"Cycle 1: 25 mg oral lenalidomide once daily on Days 1-21 every 28 Days and 40 mg oral dexamethasone on Days 8, 15, and 22. Cycle 2 and beyond: 25 oral lenalidomide once daily on Days 1-21 every 28 days and 40 mg oral dexamethasone once daily on Days 1, 8, 15, and 22.~The starting doses of Rd regimen will be the same last doses that the subjects received in Study CC-5013-MM-021, unless event(s) that require dose adjustments (dose modifications, reductions and interruptions) per protocol occurred prior to roll-over."
89468027|NCT03390231|Experimental|Stem Cell Educator|"The Stem Cell Educator (SCE) technology involves a closed-loop system that circulates a patient's blood through a blood cell separator, briefly cocultures the patient's immune cells with adherent CB-SCs in vitro, and returns only the educated immune cells to the patient's circulation. Several mechanistic studies with clinical samples and animal models have been conducted to demonstrate the proof of concept and clinical safety of SCE therapy. They suggest that SCE therapy may function via CB-SC induction of immune tolerance in the autoimmune T cells and pathogenic monocytes/macrophages that are encountered through the action of the autoimmune regulator (AIRE) and other molecular mechanisms. Following induction of immune tolerance in the immune cells, the immune balance and homeostasis may be restored when treated cells are returned in vivo."
89468028|NCT02345798|Active Comparator|Arm I (standard care)|Patients and caregivers receive standard care during routine clinic visits.
89468029|NCT02345798|Experimental|Arm II (video-assisted intervention)|Patients view Parts 1 and 2 of the video program, which focus on what to expect before surgery and after surgery in the hospital, on a tablet over approximately 8 minutes at a scheduled pre-operative visit. Patients then receive an educational handbook and discuss the video with a nurse. After surgery and before hospital discharge, patients view Part 3 of the video over approximately 6 minutes, which focuses on what to expect after going home.
89468030|NCT03390153|Experimental|semi flexible socket group|A new form of residuum containment is the semi-flexible carbon fiber prosthetic socket. A semi-flexible carbon fiber socket is constructed with the same security for the subject in mind, and is even more lightweight than a rigid socket. The carbon fiber and resin used in a semi-flexible socket may provide the same durability and stability as previous designs, but will deform, intentionally, without failing (breaking). This distinct feature of semi-flexible sockets makes them a potential option for people living with limb loss. By moving slightly with the residual limb, the socket-user-interface should experience fewer forces/stresses, and yield greater comfort for the prosthetic user.
89468031|NCT03390153|Active Comparator|rigid fiber socket group|A rigid carbon fiber socket is constructed for security and is mechanically lightweight to ensure stability and efficient build height. Carbon is used for its durability and stability. It proves to be a detriment in comfort and flexibility. The standard for carbon fiber weaves come in two forms: Unidirectional (UD) and Bidirectional (BD). UD carbon fiber has a zero-degree alignment, which is highly durable when compressed, but has low torsional durability. The BD carbon fibers are aligned in a 90 degree angle allowing for moderate compression and torsional strength. When oriented at 45 degrees to the line of progression, fibers become more flexible and exhibit greater torsional strength. Resins and glass composites are added to ensure security and sturdiness.
89468032|NCT02342756|Experimental|Group 1: CMV - HFOV|"Patients in group 1 will start with conventional mechanical ventilation with different values of PEEP (A-PEEP so that PLEEO = 0 cmH2O, B- PEEP so that PLEIO = 15 cmH2O, C- PEEP so that PLEEO = 0 cmH2O) and then will be ventilated with high frequency oscillatory ventilation (D- mPaw so that PL = 0 cmH2O, E- mPaw so that PL = 15 cmH2O, F- mPaw so that PL = 0 cmH2O)~Intervention: Device: Targeting transpulmonary pressure to avoid VILI"
89468033|NCT02342756|Experimental|Group 2: HFOV - CMV|"Patients in group 2 will start with high frequency oscillatory ventilation (D- mPaw so that PL = 0 cmH2O, E- mPaw so that PL = 15 cmH2O, F- mPaw so that PL = 0 cmH2O) and then will be ventilated with conventional mechanical ventilation with different values of PEEP (A-PEEP so that PLEEO = 0 cmH2O, B- PEEP so that PLEIO = 15 cmH2O, C- PEEP so that PLEEO = 0 cmH2O).~Intervention: Device: Targeting transpulmonary pressure to avoid VILI"
89468034|NCT02346032|Experimental|refametinib|refametinib medication
89468035|NCT02345954|Experimental|Supracervical Hysterectomy and Sacropexy|Laparoscopic Supracervical Hysterectomy and Sacropexy
89468036|NCT02345954|Experimental|Hysteropexy|Laparoscopic Hysteropexy
89468037|NCT02348294|Other|Healthy volunteers|Shear- force 19 newton and 3,9 kpa pressure for half an hour
89018513|NCT03270631|Experimental|FM and MCE|Subjects will have 4-5 times of fascial manipulation (FM) treatment and 4-6 times movement control exercises (MCE) at home to be done based on movement control testing (MCT). Both are given in 3 month period.
89018514|NCT03270631|Other|FM and sham-MCE|FM 4-5 times in 3 months and 4 general exercise prescription.
89018515|NCT03270631|Other|MCE and sham-FM|Sham-FM 4 times in 3 months including trigger point treatment in before decided points and 4-6 times MCE prescription and home exercises.
89018516|NCT03270631|Sham Comparator|Sham-MCE and sham-FM|4 general practice guiding and Sham-FM 4 times in 3 months including trigger point treatment in before decided points.
89018517|NCT03265314|Experimental|LeadHer|The LeadHer curriculum is presented to the target population over a total of 30 hours. The program addresses the following adult preparation subjects: Healthy relationships, Adolescent development, Healthy life skills, Educational and career success. The LeadHer curriculum is also accompanied by a mobile application.
89468038|NCT02348294|Other|Diabetes Mellitus type 2 without neuropathy|Shear- force 19 newton and 3,9 kpa pressure for half an hour
89468039|NCT02348294|Other|Diabetes Mellitus type 2 with neuropathy|Shear- force 19 newton and 3,9 kpa pressure for half an hour
89468040|NCT02348294|Other|Charcot Osteoarhtopathy|Shear- force 19 newton and 3,9 kpa pressure for half an hour
89468041|NCT02342834|No Intervention|Control|"During the control study, each subject ingest 500 ml of water 30 minutes before a standard 75 g Oral Glucose Tolerance Test"
89468042|NCT02342834|Experimental|Small mixed protein and lipid meal|"During the preload study, each subject ingest a small mixed meal 30 minutes before a standard 75 g Oral Glucose Tolerance Test. The meal is composed by 50 g of parmesan cheese, one small size boiled egg and 300 ml of water (250 kcal, 23 g protein, 17 g fat and 2 g of carbohydrate)."
89468043|NCT02342912|Experimental|Social Media Targeted Treatment|Participants randomly assigned to this treatment arm will receive weight loss materials via text messages, Facebook postings, on-line videos, and weekly reports. The topics relate to relate to behavioral and lifestyle changes associated with weight-loss (e.g., nutrition, exercise, social support, and self-monitoring). Calorie and physical activity targets also are set. Participants will receive a suggestion to track diet, physical activity, and weight.
89468044|NCT02342912|Experimental|Social Media Tailored Treatment|Participants randomly assigned to this treatment arm receive all of the same weight loss materials (as well as weight, calorie, and physical activity targets) as the Targeted group above. Weekly reports will be more personalized to help participants track diet, physical activity, and weight. Additionally, participants will be asked to report on their weight, exercise and calorie goals, and receive feedback.
89468045|NCT02342912|Active Comparator|Social Media Contact Control|Participants randomly assigned to this treatment arm receive health information via text messages, Facebook postings, on-line videos, and weekly reports. Topics relate to having a healthy body weight through a healthy mind, body, and energy. Some topics include stress management, importance of sleep, and importance of accepting one's body. Participants will receive a suggestion to track stress, body image, and energy levels.
89468046|NCT02345876||Dyslexic children|Longitudinal follow-up without intervention
89468047|NCT02345876||Normal reading children|Longitudinal follow-up without intervention
89468048|NCT02342600|Experimental|Trametinib with Pazopanib|Participants will take pazopanib (800mg) and trametinib (2mg) by mouth daily for a 28 day cycle.
89018518|NCT03265314|Placebo Comparator|Sassy Science|The Sassy Science curriculum is presented to the target population over a total of 30 hours. The program addresses the following subjects: States of Matter, Math, Engineering, Chemistry, Arts and Crafts, Sweet Treats and Celebrations. The curriculum does not have a mobile application.
89018519|NCT03261674|Experimental|CBTI|Patients in this arm will receive Cognitive Behavioral Therapy for Insomnia (CBT-I)
89018520|NCT03261674|Experimental|ABTI|Arousal-Based Therapy for Insomnia (ABT-I)
89018521|NCT03255070|Experimental|ARX788 Phase 1a (Dose Escalation)|ARX788 will be administered every 3 weeks (Q3W) or every 4 weeks (Q4W) via intravenous (IV) infusion. Patients will be enrolled into escalating dose levels during Dose Escalation period.
89018522|NCT03255070|Experimental|ARX788 Phase 1b (Dose Expansion)|ARX788 will be administered every 3 weeks (Q3W) via intravenous (IV) infusion. Patients will receive the maximum tolerated dose during the Dose Expansion period of the study.
89018523|NCT03253848||Observational (simplified guidelines and support)|Patients receive standard of care treatment for APL. Patients? doctors regularly discuss with an APL expert to identify and mange treatment.
89468049|NCT03147638|Experimental|1 month|patient treated with Anti coagulation for one month
89468050|NCT03147638|Active Comparator|3 months|standard of care , treatment for 3 months
89468051|NCT03147716|Active Comparator|Enrollment Flyer|Participants in this condition received one of the strategies in the Parent Engagement Package: an enrollment flyer that provided information about the Triple P Positive Parenting Program being offered at their child's school, including the location of meetings, free childcare, topics covered, choice of days/times and English or Spanish groups, and an enrollment form. Parents who returned the enrollment form received automated text, email and/or phone reminders and a confirmation letter prior to each parenting program session.
89468052|NCT03147716|Experimental|Enrollment Flyer & Testimonial Booklet|Participants in this condition received two of the strategies in the Parent Engagement Package: the enrollment flyer plus a two-page, testimonial booklet that included photos and quotes from parents and children describing benefits other parents reported after participating in the Triple P Positive Parenting Program and fun activities children reported about the childcare. The booklet also contained the location of meetings, free childcare, choice of days/times and English or Spanish groups, and an enrollment form.
89468053|NCT03147716|Experimental|Enrollment Flyer & Teacher Endorsement|Participants in this condition received two of the strategies in the Parent Engagement Package: the enrollment flyer plus a teacher endorsement of the Triple P Positive Parenting Program. The teacher also gave the participant a colorful brochure that included information about the location of meetings, free childcare, topics covered, choice of days/times and English or Spanish groups, and an enrollment form.
89468054|NCT03147716|Experimental|Enrollment Flyer & Engagement Call|Participants in this condition received two of the strategies in the Parent Engagement Package: the enrollment flyer plus an engagement call from a Triple P provider. Providers followed a manualized protocol for implementing the engagement call, which included strategies to increase parental motivation to participate in Triple P and reduce barriers to participation.
89468055|NCT03147716|Experimental|All Engagement Strategies|Participants in this condition received all engagement strategies in the Parent Engagement Package: enrollment flyer, testimonial booklet, teacher endorsement, and provider engagement call.
89018524|NCT03229356|No Intervention|Waitlist Control|BPA will be rolled out to waitlist control sites after 6 months
89468056|NCT02477020|Experimental|TAK-063 20 mg|TAK-063 20 mg, tablets, orally, once daily for up to 6 weeks. Dose may be titrated down to 10 mg/day, if intolerable.
89468057|NCT02477020|Placebo Comparator|Placebo|TAK-063 matching-placebo tablets, orally, once daily for up to 6 weeks.
89018525|NCT03229356|Active Comparator|Best Practices Advisory (BPA)|Clinicians will receive an email describing the BPA and order set, along with internet links to MD Quit Line without additional supplemental education.
89018526|NCT03229356|Active Comparator|BPA+ Enhanced Education|Clinicians will receive an email describing the new smoking BPA, educational materials offered, and a small tutorial on using the BPA and a new smoking cessation smart set in Epic. Education materials will include the educational hand out and academic detailing from Maryland Quit Line counselors.
89018527|NCT03176953|Experimental|prolonged exposure + topiramate|psychotherapy plus active medication
89018528|NCT03176953|Active Comparator|prolonged exposure + placebo|psychotherapy plus placebo medication
89018529|NCT03128775|Experimental|Nudge|This group will receive changes in the school environment (nudge strategies). Interventions regarding food consumption were based on nudge strategies to led students to eat more fruits and vegetables. To stimulate physical activity, several sports equipment (basketball hoops, volleyball nets, balls, ropes, shuttlecock and a lot of toys) are available for use in the school sports court.
89018530|NCT03128775|Experimental|Primary prevention|This group will receive educational activities in the classroom. Classroom-based educational activities will be based on an earlier study, called PAPPAS, which was developed in the same city and constituted a school-based intervention with the objective of reducing the consumption of sweetened beverages and biscuits and increase the consumption of fruits, vegetables and beans.
89018531|NCT03128775|Experimental|Primary prevention + nudge|This group will receive educational activities and in the classroomchanges in the school environment (nudge).
89018532|NCT03128775|No Intervention|Control|without any activity
89018533|NCT03110978|Experimental|Arm I (stereotactic body radiation therapy)|Patients undergo stereotactic body radiation therapy over 1-2 weeks.
89018534|NCT03110978|Experimental|Arm II (stereotactic body radiation therapy, nivolumab)|Patients undergo stereotactic body radiation therapy over 1-2 weeks. Beginning within 36 hours before or after the first fraction of stereotactic body radiation therapy, patients also receive nivolumab IV over 30 minutes on day 1. Cycles with nivolumab repeat every 4 weeks for up to 12 weeks in the absence of disease progression or unacceptable toxicity.
89018535|NCT03080974|Experimental|Single Arm|All patients undergoing irreversible electroporation will be treated with nivolumab
89018536|NCT03059563|Experimental|Varenicline|A standard dose titration regimen that is used for smoking-cessation will be followed. The pharmacist will prepare capsules of varenicline for each week of study participation. Under observation by a study clinician, participants will receive one capsule containing 0.5 mg VAR each day (0900 h) for 3 days, then one capsule containing 0.5 mg VAR twice daily (0900 h, 2100 h) for 4 days, and finally a capsule containing 1 mg VAR twice daily (0900 h, 2100 h) for the next 2 weeks.
89018537|NCT03059563|Placebo Comparator|Placebo|The same procedure used for varenicline treatment will be followed. The pharmacist will prepare capsules of placebo for each week of study participation. Under observation by a study clinician, participants will receive one capsule containing placebo each day (0900 h) for 3 days, then one capsule containing placebo twice daily (0900 h, 2100 h) for 4 days, and finally a capsule containing placebo twice daily (0900 h, 2100 h) for the next 2 weeks.
89468058|NCT03147794|Experimental|FES using MyndMove Technology|This is the only arm of the study. Participants will be provided with the FES intervention as part of the protocol.
89202152|NCT04015323|Experimental|IFC Therapy 2 kHz Arm|Subjects in this group will receive interferential current to their knees with a carrier frequency of 2 kHz
89206183|NCT05062330|Placebo Comparator|Vehicle Ophthalmic Solution administered 7 times over two consecutive days|
89468059|NCT02342522|Active Comparator|Remote ischemic conditioning|AutoRIC device will be placed on the upper arm and an active RIC protocol will be delivered (4x5 min cycles of inflation to 200mmHg and deflation) prior to PPCI.
89468060|NCT02342522|Sham Comparator|Sham control|Sham AutoRIC device will be placed on the upper arm and a sham RIC protocol will be delivered prior to PPCI.
89468061|NCT02342366|Placebo Comparator|Placebo|Placebo
89468062|NCT02342366|Experimental|GHB|GHB, Gamma-Hydroxybutyrate, two doses (20 and 35 mg/kg p.o.)
89468063|NCT02337296|Other|Phase 1 - Intervention|Five patients will be enrolled consecutively for the ADHERE intervention and be followed in order to refine the intervention as needed. This permits the investigation of the process of change at baseline, after the intervention, and across the phases.
89468064|NCT02337296|No Intervention|Phase 2 - Control Group|Following completion of Phase 1 and prior to initiation of enrollment in the intervention group, patients will be enrolled in the control group and will receive usual care.
89468065|NCT02337296|Experimental|Phase 2 - Intervention Group|Following enrollment of all control group patients, the intervention group will be recruited and enrolled and the ADHERE intervention will be conducted by the trained APRN interventionist at cancer center.
89018538|NCT03004287|Experimental|Study Treatment|"Induction Chemotherapy: Carfilzomib, Thalidomide, Dexamethasone, Daratumumab , CisPlatin, Adriamycin, Cyclophosphamide and Etoposide (KTD-Dara-PACE).~Autologous Stem Cell Transplant (ASCT) 1: Melphalan, Dexamethasone, ASCT.~Immunological Consolidation 1: Daratumumab.~Consolidation 1: Daratumumab, Carfilzomib, Dexamethasone (Dara-KD).~ASCT 2 (optional): Melphalan, Dexamethasone, ASCT.~Immunological Consolidation 2: Daratumumab.~Maintenance: Dara-KD alternating with Daratumumab, lenalidomide, and Dexamethasone (Dara-RD) in 3-month blocks.~Bortezomib may be substituted for carfilzomib throughout the regimen at the discretion of the treating physician."
89018539|NCT02986659|Active Comparator|Metformin then Placebo|Metformin dosing at 425, 850 and 1700 mg with GLUCOPHAGE® (metformin hydrochloride) Tablets. Treatment with metformin will be initiated at a dose of 425 mg (half pill) taken orally once a day at night for 7 days. After the week, the participant will be called to assess tolerance and will be asked to increase dose to one pill at night at a dose of 850 mg for one week. At the end of the second week, participants will be called again and if they tolerated the second dose, they will be asked to take two 850 mg pills, one in the morning and one at night, for a total dose of 1700 mg which is within the range of the usual effective dose of 1500 to 2000 mg/day for the remainder of the 3 months. Will then cross over to 3 months on placebo.
89018540|NCT02986659|Placebo Comparator|Placebo then Metormin|Dietary Supplement: Placebo with Methylcellulose capsules. Treatment with placebo will be initiated at a dose of a half pill taken orally once a day at night for 7 days. After the week, the participant will be called to assess tolerance and will be asked to increase dose to one pill at night for one week. At the end of the second week, participants will be called again and if they tolerated the second dose, they will be asked to take two pills, one in the morning and one at night for the remainder of the 3 months. After 3 months on placebo, participants will then cross over to 3 months of metformin as described in the other arm.
89018541|NCT02933489|Experimental|Arm A (DBT, AB-MR)|Participants undergo DBT followed by AB-MR for under 10 minutes on the same day or within 24 hours at baseline and then after 1 year.
89018542|NCT02933489|Experimental|Arm B (AB-MR, DBT)|Participants undergo AB-MR for under 10 minutes followed by DBT on the same day or within 24 hours at baseline and then after 1year.
89018543|NCT02837978|Experimental|Tacrolimus group|RA patients treated with tacrolimus, without MTX
89018544|NCT02837978|Active Comparator|Tacrolimus + MTX group|RA patients treated with tacrolimus and MTX
89018545|NCT02833402||UUI patients undergoing SNM|Urine specimens, questionnaire, and medical data will be collected from subjects that have UUI and are undergoing InterStim placement (SNM).
89018546|NCT02802423|Experimental|BLEX 404 Oral Liquid|During Phase I study (dose escalation), a standard 3+3 design will be followed, and the dose range is 3 to 10 mg/kg BID. The recommended dose level (RDL) for the Phase II study is defined as the dose level with 0 to 1 DLT observed during cycle I of Docetaxel monotherapy among 6 patients in the Phase I study.
89018547|NCT02777346|Experimental|Absorbable|Suture material: Polyglactin 910 thread (Vicryl Rapide®, Ethicon Inc).
89018548|NCT02777346|Active Comparator|Non Absorbable|Suture material: Polypropylene thread (Prolene®, Ethicon Inc).
89468066|NCT02862535|Experimental|Cohort 1: ADX|Participants will receive andecaliximab (ADX) 800 mg every 2 weeks on Days 1 and 15 of each 28-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
89468067|NCT02862535|Experimental|Cohort 2: ADX + S-1 + Cisplatin|Participants will receive ADX 800 mg every 2 weeks on Days 1 and 15 of each 28-day treatment cycle in combination with S-1 orally twice daily plus cisplatin chemotherapy (dosage and regimen will be based on participant condition, investigator discretion, institutional practice, and/or the in-country label) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
89468068|NCT02862535|Experimental|Cohort 3: ADX + S-1 + Oxaliplatin|Participants will receive ADX 1200 mg every 3 weeks on Day 1 of each 21-day treatment cycle in combination with chemotherapy (S-1 80 mg/day to 120 mg/day according to the body surface area orally twice daily for first 14 days of 21 day cycle plus oxaliplatin 100 mg/m^2) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study.
89018549|NCT02743806|Experimental|Vedolizumab 300 mg|Vedolizumab 300 mg, IV infusion, once every 8 weeks (Q8W) that maybe reduced to once every 4 weeks (Q4W) based on the investigator's judgment of participant's clinical status and acknowledged by the medical monitor for up to 6 years.
89018550|NCT02694666|Experimental|Vibration training group|The vibration group will receive 8-week controlled whole-body vibration training as the intervention on the Galileo Med L device
89468069|NCT02862535|Experimental|Cohort 4: ADX + Nivolumab|Participants will receive ADX 800 mg every 2 weeks followed by chemotherapy (nivolumab 3 mg/kg) on Days 1 and 15 of each 28-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
89468070|NCT02345564|Other|osteochondral lesions in knee/ankle|patients with traumatic and atraumatic osteochondral lesions in knee/ankle, implantation of MaioRegen fleece into osteochondral lesion
89468071|NCT02342210|Other|Group-A - Immediate Intervention|Immediate Mindfulness Ambassador Council for Early Psychosis (MAC-EP)
89468072|NCT02342210|Other|Group-B - Delayed Intervention|3 month treatment as usual waitlist followed by Mindfulness Ambassador Council for Early Psychosis (MAC-EP).
89468073|NCT02033707|Experimental|Male volunteers|Hallucinogens and psychoactive substances will be administered via capsule. Results will be compared between male and female participants.
89018551|NCT02694666|Placebo Comparator|Placebo training group|The placebo group will receive 8-week placebo training on the Galileo Med L device
89018552|NCT02693652|Experimental|CVI-HBV-002 (20ug, 3 shots)|"HBV surface antigen 20ug/dose~Intramuscular injection at 0, 1, 2 month"
89018553|NCT02693652|Experimental|CVI-HBV-002 (20ug, 6 shots)|"HBV surface antigen 20ug/dose~Intramuscular injection at 0, 1, 2, 3, 4, 5 month"
89018554|NCT02693652|Experimental|CVI-HBV-002 (40ug, 3 shots)|"HBV surface antigen 40ug/dose~Intramuscular injection at 0, 1, 2 month"
89018555|NCT02693652|Experimental|CVI-HBV-002 (40ug, 6 shots)|"HBV surface antigen 40ug/dose~Intramuscular injection at 0, 1, 2, 3, 4, 5 month"
89018556|NCT02692170|Experimental|CVI-HBV-001 (5 μg)|"HBV surface antigen 5 μg/dose~Intramuscular injection at 0, 1, 6th month"
89018557|NCT02692170|Experimental|CVI-HBV-001 (10 μg)|"HBV surface antigen 10 μg/dose~Intramuscular injection at 0, 1, 6th month"
89468074|NCT02033707|Experimental|Female volunteers|Hallucinogens and psychoactive substances will be administered via capsule. Results will be compared between male and female participants.
89468075|NCT02448706|Active Comparator|Hearing Aid Fitting Order A|High level of signal manipulation for 6 weeks, followed by a low level of signal manipulation for 6 weeks.
89468076|NCT02448706|Active Comparator|Hearing Aid Fitting Order B|Low level of signal manipulation for 6 weeks, followed by a low level of signal manipulation for 6 weeks.
89468077|NCT02337140|Experimental|Pacemaker|Patient who have been implanted with a pacemaker after TAVI
89468078|NCT02337140|Active Comparator|No Pacemaker|Patient who have not been implanted with a pacemaker after TAVI
89468079|NCT02039336|Experimental|Dacomitinib + PD-0325901|Dacomitinib: oral tablets PD-0325901: oral capsules
89468080|NCT02342054|Experimental|MRI-TRUS fusion guided Single Frac HDR|Patients treated with a Single Fraction Real-Time High-Dose-Rate (HDR 19Gy)
89468081|NCT03145844||Direct Acting Agents|No Intervention
89468082|NCT02341898|Experimental|Updated original programme|Educational programme for all nurses (90 min. single information session); training and structured support for nominated key nurses (one-day training workshop); provision of printed study material (evidence-based practice guideline; short versions for nurses, legal guardians, and others; information brochures for relatives); supportive material (poster, mugs etc.)
89468083|NCT02341898|Experimental|Concise updated programme|Training and structured support for nominated key nurses (one-day training workshop); nurses' training will be carried out by key nurses as facultative option; key nurses receive an additional train-the-trainer module to apply the educational programme; provision of printed study material (evidence-based practice guideline; short versions for nurses, legal guardians, and others; information brochures for relatives); supportive material (poster, mugs etc.)
89468084|NCT02341898|Active Comparator|Optimized usual care|Provision of printed study material (evidence-based practice guideline; short versions for nurses, legal guardians, and others; information brochures for relatives) only
89468085|NCT05255042||Trial Participants|"Overall Description of Trial Participants: The liver organ samples included in this project will be from patients undergoing elective surgery for a lesion in the liver in the HPB Unit of the Leicester General Hospital. No change in the surgical procedure or recruiting results from this study and the use of the samples.~Inclusion Criteria: The samples included in this project will be from patients undergoing elective liver surgery in the HPB Unit of the Leicester General Hospital. The criteria for inclusion of liver segment samples from radical surgery are adult age and presence of hepatic tissue in the discarded material after hepato-pancreato-biliary surgery.~Exclusion Criteria: The main exclusion criterion is acute invasive infection, but these patients are automatically excluded from major surgery. Vulnerable groups will not be recruited."
89468086|NCT02345096|Active Comparator|Saccharomyces cerevisiae CNCM I-3856|In this arm, subjects will be asked to consume one capsule of Saccharomyces cerevisiae CNCM I-3856 per day.
89468087|NCT02345096|Placebo Comparator|placebo|In this arm, subjects will be asked to consume one capsule of placebo per day.
89468088|NCT02345174|Experimental|Imaging Phase + Continuation Phase|In Part 1 of the study, participants will receive a dose of 89Zr-GSK2849330 (Dose 1), with an activity of no more than 37 MegaBequerel (MBq) and a variable total dose of GSK2849330. PET scans will be acquired within 7 days. Two weeks after Dose 1 participants will receive second dose of 89Zr-GSK2849330 (Dose 2) and a variable total dose of GSK2849330. Participants will continue to receive unlabelled GSK2849330 (in Part 2) either at established dose level or as decided by medical monitor.
89018558|NCT02692170|Experimental|CVI-HBV-001 (20 μg)|"HBV surface antigen 20 μg/dose~Intramuscular injection at 0, 1, 6th month"
89018559|NCT02692170|Experimental|CVI-HBV-001 (40 μg)|"HBV surface antigen 40 μg/dose~Intramuscular injection at 0, 1, 6th month"
89468089|NCT04935476|Active Comparator|Treatment|"Participants will receive standard of care and Dapsone per os (PO) twice daily for 21 days. If a dose is missed, it should not be replaced.~Dosage form: Dapsone oral tablet"
89018560|NCT02692170|Active Comparator|Conventional Hepatitis B vaccine (20 μg)|"HBV surface antigen 20 μg/dose~Intramuscular injection at 0, 1, 6th month"
89018561|NCT02668653|Experimental|Chemotherapy plus quizartinib|"Induction: up to 2 cycles with cytarabine and daunorubicin/idarubicin, followed by the experimental drug quizartinib~Consolidation: up to 4 cycles of cytarabine followed by the experimental drug quizartinib and/or hematopoeitic stem cell transplant~Continuation: up to 36 cycles with the experimental drug quizartinib"
89018562|NCT02668653|Active Comparator|Chemotherapy plus placebo|"Induction: up to 2 cycles with cytarabine and daunorubicin/idarubicin, followed by placebo~Consolidation: up to 4 cycles of cytarabine followed by placebo and/or hematopoeitic stem cell transplant~Continuation: up to 36 cycles with placebo"
89018563|NCT02661997|Experimental|Tai Chi Intervention|All components of the program derive from the classical Yang Tai Chi 108 postures, which has been shown to be a moderate intensity exercise. Each Tai Chi session will last 60 minutes, twice a week for 12 weeks. In the first session, the Tai Chi instructors will explain exercise theory and procedures of Tai Chi. In subsequent sessions, subjects will practice Tai Chi under the instruction of one of the Tai Chi instructors. Every session will include the following components: (1) warm up and a review of Tai Chi principles; (2) meditation with Tai Chi movement; (3) breathing techniques; and (4) relaxation. The investigators will instruct patients to practice at least 30 minutes a day at home throughout the intervention period and will provide them with training materials for home practice.
89468090|NCT04935476|Placebo Comparator|Control|"Participants will receive standard of care and placebo per os (PO) twice daily for 21 days. If a dose is missed, it should not be replaced.~Dosage form: Placebo oral tablet"
89018564|NCT02661997|Active Comparator|Wellness Intervention|The investigators will utilize a wellness education program for the control group because this approach has been successfully used in other Tai Chi studies from the investigators' team. Participants in the Wellness condition will also attend two 60-minute sessions per week for 12 weeks. The Wellness condition will correspond to the VA Whole Health Program to emphasize wellness across various domains (e.g., physical, emotional, and spiritual lives.) Each session will include a video clip as well as a brief mindfulness exercise that corresponds with the material being presented. The project coordinator for this study will provide the didactic lessons.
89018565|NCT02652052|Other|Group 1: Observational|Standard of Care - Observation Only
89468091|NCT04891016|Experimental|experimental group|patients received FLOT regimen on day 1 and toripalimab on day 3.
89468092|NCT04891016|Other|control group|patients received FLOT regimen and toripalimab on day 1.
89468093|NCT02868281|Experimental|Subjects recruited at ACT centers|For the subjects who will be recruited in the ACT centers, they will be treated based on the ACT score. If ACT score are = 25 for >=3 months then step-down the treatment; if ACT score >=20, <25 or ACT=25 for <3 months then there will be no change and if ACT score less than (<=) 19 then step-up the treatment.
89468094|NCT02868281|Active Comparator|Subjects recruited in the control centers|For subjects who will be recruited in the control centers, they will be treated based on doctor's subjective judgment.
89468095|NCT02476006|Experimental|Alirocumab|Participants received Alirocumab 150 milligram (mg) subcutaneously (SC) once every two weeks (Q2W) or 75 mg SC Q2W added to stable LMT up to a maximum of 120 weeks. Alirocumab dose was either up-titrated from 75 to 150 mg Q2W or down-titrated from 150 to 75 mg Q2W, based on Investigator judgment and treatment response.
89468096|NCT02344940|Experimental|toremifene|patients who will be treated with toremifene.
89468097|NCT02344940|Active Comparator|tamoxifen|patients who will be treated with tamoxifen.
89468098|NCT02341976|Other|Vibratory platform exercises|Vibratory platform exercises: different positions on a vibratory platform in different frequencies
89468099|NCT03615677|Experimental|LXI-15028 50mg group (n=130)|
89468100|NCT03615677|Active Comparator|Esomeprazole 40mg group (n=130)|
89468101|NCT03615443||Treatment-naive metastatic non-squamous NSCLC|
89468102|NCT02344862|Active Comparator|FYU-981 High dose|
89468103|NCT02344862|Active Comparator|FYU-981 Middle dose|
89468104|NCT02344862|Active Comparator|FYU-981 Low dose|
89468105|NCT02344862|Placebo Comparator|Placebo|
89468106|NCT03614429|No Intervention|Control|"Group 1: control group, n=50 Male patients undergoing aseptic surgery (regardless the procedure)~Inclusion criteria Male patients aged 20-50 years-old or older undergoing a sterile surgical procedure.~Exclusion criteria Unwilling patient for this procedure Patients with history of urethral surgery, urinary calculi, urethral structure, or ongoing pyospermia, prostatitis or pyuria will be excluded, and so will be patients undergoing non-sterile surgeries such as abscess drainage."
89468107|NCT03614429|Experimental|Ch group|"Group 2: Chlorhexidine group (Ch group), n=50 Male patients undergoing aseptic surgery (regardless the procedure)~Inclusion criteria Male patients aged 20-50 years-old or older undergoing a sterile surgical procedure.~Exclusion criteria Unwilling patient for this procedure Patients with history of urethral surgery, urinary calculi, urethral structure, or ongoing pyospermia, prostatitis or pyuria will be excluded, and so will be patients undergoing non-sterile surgeries such as abscess drainage."
89468108|NCT03111836|Sham Comparator|Control group|The Control group received limited to general information on blood pressure management
89468109|NCT03111836|Active Comparator|Expert-driven group|The intervention will consisted of pre-determined exercise and dietary goals (e.g. increase daily steps by 1000 steps, consuming 2-3 servings of fruit and vegetables per day).
89468110|NCT03111836|Active Comparator|User-driven group|The User-driven group received an intervention that enabled participants to select their areas of lifestyle change using text and video web links embedded in the email. The trans-theoretical model was used to inform the design of the User-driven program.
89468111|NCT03614117|Active Comparator|L.salivarius PS7 6-months|Lactobacillus salivarius PS7 during 6-months; approximately 1*10E9 colony forming unit (CFU) of L. salivarius PS7 in 1 sachet per day to be diluted in water by mouth for 6-months.
89468112|NCT03614117|Active Comparator|L. salivarius PS7 + placebo (3+3)|Lactobacillus salivarius PS7 during 3 months; approximately 1*10E9 CFU of L. salivarius PS7 in 1 sachet per day to be diluted in water by mouth for 3-months followed by 3 months oral administration of 1sachet per day of placebo supplement to be diluted in water.
89468113|NCT03614117|Placebo Comparator|Control group|Placebo supplement in 1 sachet per day to be diluted in water by mouth for 6-months.
89468114|NCT02341742||Patients|follow up of patients (children and adolescent) with inflammatory bowel disease in looking for the relationship between the bone mineral density and physical activity.
89468115|NCT03614351|Experimental|Physical Therapy plus Protein Supplement|Participants will be randomized to the protein supplementation group, PROT, and will receive education from a dietary counselor on how to monitor protein intake using a smartphone app.
89468116|NCT03614351|Active Comparator|Physical Therapy Control|Participants will be randomized to the enhanced-care control group, CONT, and will receive education from a dietary counselor on how to monitor protein intake using a smartphone app.
89468117|NCT02475850|Other|Fall prevention standard of care|"An evidence-based patient-centered intervention that will combine elements of a multifactorial, risk factor-based, standardly-tailored fall prevention strategy developed at Yale, practice guidelines offered by the CDC's STEADI toolbox and the joint American Geriatrics Society/British Geriatrics Society guidelines, and ACOVE practice change approach"
89468118|NCT02475850|Other|Control|Usual fall prevention care
89468119|NCT03614273|Active Comparator|Group 1 (HS)|Nebulized with 4 ml of 3% hypertonic saline for a duration of 20 minutes
89468120|NCT03614273|Active Comparator|Group 2 (Adr)|Nebulized with 0.1 mg/kg of adrenaline (non-racemic solution, 1:1000 concentration), which was diluted in normal saline to make it a 4 ml solution, for a duration of 20 minutes
89018566|NCT02652052|Experimental|Group 2: Dasatinib & Quercetin|Interventional: The drugs dasatinib and quercetin will be used in this arm
89468121|NCT02032121|Experimental|Intervention procedures|All the procedures will be completed for every subject
89468122|NCT02336984|Experimental|Combination Therapy|Combination Therapy: HER-2 pulsed DC1 vaccine with trastuzumab and pertuzumab.
89468123|NCT03613805|Active Comparator|Dexcom G5 - Eversense|Patients will wear first Dexcom G5 (Dexcom San Diego, CA, USA) transcutaneous sensor for 3 months, then Eversnese(Senseonics Inc, MD, USA) implantable sensor for 3 months Accuracy and efficacy will be evaluated
89468124|NCT03613805|Experimental|Eversense- Dexcom G5|Patients will wear first Eversense (Senseonics Inc, MD, USA) implantable sensor for 3 months, then Dexcom G5 (Dexcom San Diego, CA, USA) transcutaneous sensor for 3 months accuracy and efficacy will be evaluated
89468125|NCT03145610|Placebo Comparator|Placebo toothpaste|Fluoride toothpaste will be used by filling the individual silicone stent allowing it to come into contact with the implant area for 2 min.
89018567|NCT02649972|Experimental|Cobimetinib|This is an open-label, multicenter, phase II study exploring the efficacy and safety of single-agent Cobimetinib in patients with histiocytic disorders whose tumors are 1) BRAFV600 wildtype or 2) BRAFV600E mutant and are intolerant to, or unable to access, BRAF inhibitors. Visits during the treatment period are to be completed on Day 1, Day 15 (this visit can be by telephone), Day 29, and every 28 days thereafter. For patients treated on the study for six months, at the discretion of the Principal Investigator, visits can be spaced out to every 56 days (every 2 cycles instead of every cycle). After 24 cycles of treatment, if imaging demonstrates sustained stability in the opinion of the principal investigator, tumor assessments can be performed ever 1 year.
89468126|NCT03145610|Experimental|triclosan/copolymer/fluoride toothpaste|triclosan/copolymer/fluoride toothpaste will be used by filling the individual silicone stent allowing it to come into contact with the implant area for 2 min.
89468127|NCT03145922||Sarcoidosis|
89468128|NCT03145922||Healthy Controls|
89468129|NCT02341586|Experimental|Lucky Iron Fish|This group will receive a Lucky Iron Fish to use during cooking.
89468130|NCT02341586|Active Comparator|18 mg iron|This group will receive a daily oral iron supplement.
89468131|NCT02341586|Other|Control group|This group will receive nutrition education
89468132|NCT02336906|Active Comparator|Urotherapy + Constipation Treatment|This group will be treated with standard behavioral urotherapy in addition to receiving active stool softening with PEG3350 and standard constipation instruction.
89468133|NCT02336906|Other|Urotherapy alone|This group will receive standard behavioral urotherapy alone.
89468134|NCT03614039|Active Comparator|probiotic-smectite|Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) of gel per day.
89468135|NCT03614039|Placebo Comparator|placebo|Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) of gel per day.
89018568|NCT02615119|Experimental|Anorexia nervosa|Intravenous bolus infusions of isoproterenol (up to 4 micrograms per infusion) and normal saline.
89468136|NCT02341508|Experimental|Lpathomab|0.5 mg/kg Lpathomab, 1.0 mg/kg Lpathomab, 3.0 mg/kg Lpathomab, 10 mg/kg Lpathomab, 20 mg/kg Lpathomab,
89468137|NCT02341508|Placebo Comparator|Placebo|Saline solution for intravenous infusion
89468138|NCT03613571|Experimental|ILB|ILB treatment
89468139|NCT02341352|No Intervention|Control|Only behavioral education for Caregiver
89468140|NCT02341352|Experimental|fluoride varnish|fluoride varnish every 6 months
89468141|NCT02341352|Experimental|ImmunoglobulinY|anti-S.mutans Immunoglobulin yolk for everyday use
89468142|NCT02341352|Experimental|Probiotics|Probiotics use for 1 months
89468143|NCT03613883|Experimental|Primary Study Arm|The intervention is done to those patients that are managed by endovascular stent that is inserted in the parent artery to induce slowness in the blood flow thus initiate thrombosis in the aneurysmal sac.
89468144|NCT03613883|Experimental|Expanded Selection Arm|The intervention is done to the expanded selection arm and is managed by embolic materials (coils / glue) that occlude the aneurysm by proximal occlusion, proximal and distal occlusion or sac packing
89468145|NCT02344550|Experimental|Everolimus arm|Everolimus 10mg p.o. daily Letrozole 2.5 mg p.o. daily Leuprorelin (Leuprolide) 3.75mg SC every 4 weeks
89468146|NCT02344550|Active Comparator|Control arm|Letrozole 2.5 mg p.o. daily Leuprorelin (Leuprolide) 3.75mg SC every 4 weeks
89468147|NCT02419612|Experimental|Saxagliptin 5 mg/ dapagliflozin 10mg or Placebo|Saxagliptin 5 mg /dapagliflozin 10 mg Placebo once a day orally
89468148|NCT02419612|Experimental|Glimepiride or Placebo|Glimepiride or placebo 1mg or 2mg or 3mg or 4mg or 6mg once a day orally
89468149|NCT03612947|Active Comparator|Bupivacaine +magnesium sulphate|Ultrasound guided subcostal TAP block will performed on both sides using 20 ml volume (0.25 bupivacaine) plus 150 mg of MgSo4.
89468150|NCT03612947|Placebo Comparator|Bupivacaine only|Ultrasound guided subcostal TAP block will performed on both sides using 20 ml volume (0.25 bupivacaine).
89468151|NCT02341196|Experimental|CEA + Polyester patch|225 Patients
89468152|NCT02341196|Experimental|CEA + Patch Polyurethane|225 Patients
89468153|NCT03613415|Experimental|Expansion by Densah bur|"Scrubbing and draping of the patient in a standard fashion for intra oral procedures followed by local anesthesia administration to the patient.~A mid crestal flap will be reflected.~For both groups the implant manufacturer's pilot drill will be used to perform a standard osteotomy of 10 mm depth.~Sequential use of Densah bur under copious irrigation.~An implant of 3.9*10 mm will be inserted.~Smart peg will be placed on implant and Osstell will be used to record ISQ.~Healing collars will be placed on implants.~Flap will be prepared for closure and suturing."
89468154|NCT03613415|Active Comparator|Expander|"Scrubbing and draping of the patient in a standard fashion for intra oral procedures followed by local anesthesia administration to the patient.~A mid crestal flap will be reflected.~For both groups the implant manufacturer's pilot drill will be used to perform a standard osteotomy of 10 mm depth.~Sequential use of screw expanders.~An implant of 3.9*10 mm will be inserted.~Smart peg will be placed on implant and Osstell will be used to record ISQ.~Healing collars will be placed on implants.~Flap will be prepared for closure and suturing."
89468155|NCT03613337||current smokers|Current smokers are those who continued smoking cigarettes more than 1 cigarette pre month after first percutaneous coronary intervention (PCI) .
89018569|NCT02615119|Experimental|Generalized anxiety disorder|Intravenous bolus infusions of isoproterenol (up to 4 micrograms per infusion) and normal saline.
89468156|NCT03613337||nonsmokers|Nonsmokers are those who never smoked in their lifetime.
89468157|NCT03613337||former smokers|Former smokers are those who had quit smoking after percutaneous coronary intervention (PCI) , and smoked less than 1 cigarette pre month after first percutaneous coronary intervention (PCI)
88946860|NCT01912196|Experimental|MSI-195|"Patients randomized to the MSI-195 arm will receive treatment with 2 tablets (800 mg) of MSI-195 plus on-going antidepressant therapy (ADT).~MSI-195 800 mg (two tablets) taken orally once a day in the morning on an empty stomach with water (food should be avoided for at least 1 hr after taking the study drug)"
89468158|NCT02336828||MEWS alarm and mortality|Reach MEWS Alarm, Not reach MEWS Alarm, With 7 day mortality, Without 7 day mortality
89468159|NCT04913350|Experimental|Russian current and elbow support group|participants in the experimental group will apply elbow support and will receive Russian current on biceps and triceps muscles of the unaffected elbow three therapy sessions per week for 4 weeks.
89468160|NCT04913350|Active Comparator|elbow support group|Participants in this group will apply elbow support only.
89468161|NCT02447848|Experimental|sufentanil sublingual tablet 30 mcg|Patients may be administered one tablet every 60 minutes as needed during the study period
89468162|NCT02336516|Experimental|Azithromycin|ZITHROMAX ® 40mg/ml solution. DCI : Azithromycin . Pfizer ®
88946861|NCT01912196|Placebo Comparator|Placebo|"Patients randomized to the placebo arm will receive 2 tablets placebo plus on-going antidepressant therapy (ADT).~Placebo (two tablets) taken orally once a day in the morning on an empty stomach with water (food should be avoided for at least 1 hr after taking the study drug)."
88946862|NCT01912209|Experimental|My Everyday Health Group|Subjects in this group will be randomized to a web based diet and weight modification program (MyEveryday Health) and provided personal access codes. They will also continue to have access to the WebMD website provided as part of their employment with Baptist Health South Florida.
88946863|NCT01912209|No Intervention|WebMD Group|This group will continue to have access to a website that is available for use of all employees (WebMD) at Baptist Health South Florida. This is the care-as-usual arm.
88946864|NCT01912235|Active Comparator|Test Study 1: 2-15N glutamine|To determine the contributions make by glutamine to the provision of nitrogen for ornithine, citrulline and arginine syntesis in adults.
88946865|NCT01912235|Active Comparator|Test Study 2: 15N2 arginine &15N proline|administration of 15N2 arginine &15N proline to measure arginine and proline flux
88946866|NCT01912235|Active Comparator|Study Test 3: 1-13C glutamine|to determine to contribution of glutamine to the carbon skeleton of ornithine, citrulline and arginine in adults.
89468163|NCT02336516|Placebo Comparator|Glucose solution 10%|Glucose solution 10%
89468164|NCT02418910||bipolar outpatients|Patients with Bipolar Disorder in any clinical state
89468165|NCT02344706||Mini-EEG, NCSE|Unconscious patients due to seizures, of whom EEG is registered
89468166|NCT02039258|Experimental|Sequence AB|A single dose of CANA/MET XR FDC tablet of 150 mg/1,000 mg under fasted conditions (treatment A) followed by the same single dose under fed conditions (treatment B).
88946867|NCT01912248||Heart failure|strength training
89018570|NCT02615119|Experimental|Panic disorder|Intravenous bolus infusions of isoproterenol (up to 4 micrograms per infusion) and normal saline.
89018571|NCT02615119|Experimental|Major depressive disorder|Intravenous bolus infusions of isoproterenol (up to 4 micrograms per infusion) and normal saline.
89468167|NCT02039258|Experimental|Sequence BA|A single dose of CANA/MET XR FDC tablet of 150 mg/1,000 mg under fed conditions (treatment B) followed by the same single dose under fasted conditions (treatment A).
89468168|NCT03145454|Experimental|Pain detection|Electroencephalographical responses will be collected during surgical gesture by different intervention: electroencephalography helmet, dermal electrode, blood pressure sensors, pupillometry glasses and Holter.
89468169|NCT03145376||patients before and after TAVI/MitraClip|geriatric assessment of patients before and after TAVI/Mitraclip
88946868|NCT01912248||Heart Transplant recipients|strength training
88946869|NCT01912248||patients with ischemic heart disease|strength training
88946870|NCT01912261|Active Comparator|FeraMax|FeraMax Polysaccharide iron complex oral iron supplement 150mg one capsule orally daily
88946871|NCT01912261|Placebo Comparator|Placebo|one capsule orally daily
88946872|NCT01912300|Experimental|Lean adolescents|
88946873|NCT01912300|Experimental|Obese adolescents|
88946874|NCT01912326|Active Comparator|AF Suppression On|AF Suppression Algorithm On, optimized AF Pacemaker Programming
88946875|NCT01912326|Active Comparator|AF Suppression Off|AF Suppression programmed Off, Optimized Pacemaker Programming
88946876|NCT01912365||Above Elbow Cast + Collar/cuff|Participants randomized to this group will be treated with an Above Elbow Cast & collar/cuff for 3 weeks
89468170|NCT02344394|Other|Hybrid Ablation-cryoballoon alone|This group receives the hybrid surgical ablation (epicardial-endocardial ablation) with epicardial ablation and endocardial ablation consisting of pulmonary vein isolation with no further catheter ablation. This will be achieved using the nContact and Medtronic cryoballoon
89468171|NCT02344394|Other|Hybrid ablation-cryoballoon plus RF|This group receives the hybrid surgical ablation (epicardial-endocardial ablation) with epicardial ablation and endocardial ablation. Endocardial portion consists of pulmonary vein isolation using the cryoballoon with further catheter ablation, which may consist of ablation of complex fractionated electrograms and linear lesions. This will be achieved using the nContact and Medtronic Cryoballoon plus Thermocool Catheter.
89468172|NCT02342132|Experimental|Respiratoy Therapy Devices|Non-Invasive Bipap Ventilator, Mechanical Insufflator-Exsufflator, and High Frequency Percussive Oscillator are the three respiratory therapy devices that all participants will be using in a random order, in three consecutive days, one device per day.
89468173|NCT03115463|Experimental|OX25|Resuscitation will be initiated at 30% O2. Titration of oxygen during neonatal resuscitation: Intervention is target goal saturations which will be the 10th to 25th percentile saturations observed in healthy term newborns.
89468174|NCT03115463|No Intervention|OX50|Resuscitation will be initiated with 30% O2 and target goal saturations will be the approximated median SpO2 observed in healthy term newborns as per current NRP guidelines
89468175|NCT03115463|Active Comparator|OX75|Resuscitation will be initiated at 30% O2. Titration of oxygen during neonatal resuscitation: Intervention is target goal saturations which will be the 75th percentile saturations observed in healthy term newborns.
89468176|NCT02344082|No Intervention|Standard of Care|The control arm will receive face-to-face pharmacy clinic visits per usual care.
89468177|NCT02344082|Active Comparator|Intervention Arm|The intervention arm will receive pharmacy clinic visits plus additional telephone follow-up.
89468178|NCT02336126|Experimental|Biopsychological intervention|
89468179|NCT05254652|Experimental|Experimental: Duloxetine and Pregabalin|Experimental group will take medicine for 10 weeks from 2 weeks before surgery to 8 weeks after surgery. The group takes one pill of duloxetine 30 mg, one pill of pregabalin 150mg after breakfast and one pill of pregabalin 150 mg after dinner.
89468180|NCT05254652|Active Comparator|Active Comparator: Duloxetine|Active comparator group will take medicine for 10 weeks from 2 weeks before surgery to 8 weeks after surgery. The group takes only one pill of duloxetine 30 mg after breakfast.
89468181|NCT02343926|Experimental|Gemigliptin|GEMIGLIPTIN LS15-0444 administered once a day for 24 weeks as add-on therapy to metformin
89468182|NCT02343926|Active Comparator|Vildagliptin|Vildagliptin administered twice a day for 24 weeks as add-on therapy to metformin
89468183|NCT02343848|Experimental|treatment|smart bracelet.
89468184|NCT03112226|Active Comparator|GnRHant + E2|Single dose of GnRH antagonist degarelix acetate for depot injection (80mg) Transdermal estradiol add-back; Climara patch, 0.075mg/day, weekly for 12 weeks
89468185|NCT03112226|Placebo Comparator|GnRHant + Placebo|Single dose of GnRH antagonist degarelix acetate for depot injection (80mg) Transdermal placebo patch, weekly for 12 weeks
89468186|NCT02343770|Experimental|idiopathic juvenile arthritis|blood sample
89468187|NCT02343770|Other|control|blood sample
89468188|NCT03612869|Experimental|AAV SGSH gene therapy (LYS-SAF302)|One-time intracerebral administration of adeno-associated viral vector serotype rh10 containing the human N-sulfoglucosamine sulfohydrolase (SGSH) cDNA.
89468189|NCT02343692|Experimental|Radiofrequency abalation|"Intervention: Endoscopic Ultrasound (EUS) guided radiofrequency ablation (RFA) of cystic tumours of the pancreas~Device: An RFA generator (ERBE VIO 300D, Dolby medical products, Scotland)~Procedure: Delivery of sequential doses of electrical energy at 10W for a total of up to 4 minutes 30 seconds (3 x 90 second applications) to ablate the cystic lesion.~Ablation of cystic tumours of the pancreas"
89468190|NCT03618251||ischemic stroke|all patients with a suspicion of ischemic stroke
89468191|NCT02332616|Active Comparator|Methylprednisolone|Preoperative single high dose of Solu-Medrol 125 mg iv.
89468192|NCT02332616|Placebo Comparator|Isotonic Sodium Chloride|Preoperative single dose of isotonic Sodium Chloride
89468193|NCT02332148|Experimental|3Vm1001|3VM1001 topical cream containing 10 mg/day of copper, for 30 days
89468194|NCT02332148|Placebo Comparator|Placebo|Placebo for 3VM1001, topical cream without 3VM1001
89468195|NCT03618173|Experimental|dexamethasone|IV dexamethasone group : dexamethasone administrated at the induction of general anesthesia, at the dose of 0,2mg/kg (= 0,2mL/kg of a syringe with a 1mg/mL concentration) maximum 8mg (=8mL).
89468196|NCT03618173|Placebo Comparator|Placebos|IV placebo group : saline serum is administrated at the induction of general anesthesia, at the dose of 0,2mL/kg, maximum 8mL.
89468197|NCT02336048|Active Comparator|Placebo + Obinutuzumab + Chlorambucil|Participants will receive placebo and standard premedications on Days 1 and 2 of Cycle 1 (cycle length= 28 days) along with obinutuzumab and chlorambucil administered for 6 cycles.
89468198|NCT02336048|Experimental|Tocilizumab + Obinutuzumab + Chlorambucil|Participants will receive tocilizumab and standard premedications on Days 1 and 2 of Cycle 1 (cycle length= 28 days) along with obinutuzumab and chlorambucil administered for 6 cycles.
89468199|NCT03612401|Other|Neurogenic Bladder|Spinal Cord Injury patients with known neurogenic bladder on treatment with Anticholinergic Agents at baseline switched to mirabegron as the study intervention
89202153|NCT04015323|Experimental|IFC Therapy 4 kHz Arm|Subjects in this group will receive interferential current to their knees with a carrier frequency of 4 kHz
89202154|NCT04015323|Experimental|IFC Therapy 8 kHz Arm|Subjects in this group will receive interferential current to their knees with a carrier frequency of 8 kHz
89468200|NCT02335970|Experimental|Training group|Training program: Daily exercises for 3 months
89468201|NCT02335970|No Intervention|Controls|Standard care
89468202|NCT03612323|Experimental|Intra-ligamentary Piroxicam|Piroxicam is a long acting potent Non steroidal anti-inflammatory drug (NSAID)with half life of 50 hours in plasma, is given as intervention to assess the pain,will be administered by intra-ligamentary technique by injecting 0.4 milliliter (mL) of 20 milligram (Mg) piroxicam.
89468203|NCT03612323|Active Comparator|Intra-ligamentary Articaine|Articaine is a local anesthetic agent, will be administered by intraligamentary technique by injecting 0.4 milliliter (mL) of 4% articaine
88946877|NCT01912365||Long Arms Splint + Collar/Cuff|Participants randomized to this group will be treated with a long arm splint & collar/cuff for 3 weeks
88946878|NCT01912378|Experimental|Oxytocin Nasal Spray|40 IUs of Oxytocin nasal spray will be administered to both parents at one time during the lab visit.
88946879|NCT01912378|Placebo Comparator|Placebo nasal spray|40 IUs of Placebo nasal spray will be administered to both parents at one time during the lab visit.
89468204|NCT02332304|Other|Preterm fetus|Patients with pregnancies between 26 and 36 6/7 weeks of pregnancy. Before the birth, a sample of amniotic fluid was taken and analyzed using optical density at 650nm. A value above 0.15 was considered an indication of fetal lung maturity.
89468205|NCT02994719||Neurological Disease subjects|Parkinson's Disease and other Parkinsonian Disorders subjects. Other Parkinsonian Disorders include Atypical Parkinsonism such as Progressive Supranuclear Palsy, Multiple System Atrophy, Corticobasal Degeneration, Primary Gait Freezing Disorder, Indeterminate Parkinsonian Syndrome. During the first visit no intervention will take place. There is an optional second visit during which subjects with Parkinson's Disease are asked to come come off antiparkinson medication and if applicable, off both medication and deep brain stimulation.
89468206|NCT02994719||Healthy control subjects|The healthy control subjects will be age- and sex-matched to the Neurological Disease subjects.
89468207|NCT02994719||Ataxia Subjects|The ataxia subjects will participate in an additional cohort that will test and validate the gait model.
88946880|NCT01912391|Experimental|Selegiline|Transdermal Selegiline 12 mg patch Apply (1) patch daily
88946881|NCT01912391|Placebo Comparator|Placebo (for Selegiline)|Transdermal Placebo patch Apply (1) patch daily
88946882|NCT01912417|Experimental|Hemodialysis session with exercise|Patients were included in a randomly crossover study design such that each patient received one HD session with exercise (intervention) and the next session without exercise (control), alternating for six consecutive HD sessions.
89202155|NCT00778908|Experimental|A|Late-course accelerated hyperfractionated IMRT with concomitant cisplatin chemotherapy
89202156|NCT00778908|Other|B|Conventionally fractionated IMRT with concomitant cisplatin chemotherapy
89468208|NCT02994719||Huntington Disease Subjects|The Huntington Disease subjects will participate in an additional cohort that will test and validate the gait model.
89468209|NCT02340650||Bladder Cancer Patients|High resolution images of normal bladder tissue and suspicious bladder lesions will be collected from patients who present to the study site for clinical evaluation.
89468210|NCT03612167|Experimental|multi-modal cognitive intervention|a 12 consecutive 90-minute weekly cognitive groups that included cognitive training and rehabilitation, with activity-based cognitive exercises and discussions with a focus on applications of cognitive strategies in daily lives.
89468211|NCT03612167|Active Comparator|nutritional group|A quasi-experimental design with nonequivalent control was adopted in a senior center. The intervention for control group was a 12 consecutive 90-minute weekly nutritional groups that included nutrition classes (lecture and discussion).
89468212|NCT04686227||Group-1, women with normal uterus|
89468213|NCT04686227||Group-2, women with any uterine malformations|Group-2 is going to be sub-grouped according to ASRM and ESHRE classifications
89468214|NCT03612089||Low back pain group|Individuals with non-specific chronic low back pain
89468215|NCT03612089||Healthy control group|Healthy individuals without low back pain
89468216|NCT03612011|Experimental|Onco-Repair|Onco-Repair tube of 150 ml
89468217|NCT03612011|Placebo Comparator|Placebo|Placebo tube of 150 ml
89468218|NCT02340494|No Intervention|Control group|Women without access to the website.
89468219|NCT02340494|Experimental|Intervention group|Women with access to the website.
89468220|NCT05253950||Observational Group|A sample of 120 people was collected from all over Greece, more specifically 7.6% belong to the region of Attica, 7.6% belong to the region of Western Greece, 0.8% belong to the region of Thessaly, 32.8% belong to the region of Central Macedonia and 51.3% belong to the region of Crete .
89468221|NCT03611855|Experimental|BCI Rehabilitation|Patients trained on use of BCI-controlled orthotic device are given a device for home use. Patients are asked to use the device an hour per day, 5 days per week, for 12 weeks. During device use, patients are instructed via pre-programmed instructions on a tablet paired with the device to either rest or vividly imagine moving their affected hand. The device receives signals from a scalp electrodes within a headset the patient dons prior to use. The device interprets these signals and closes the patient's hand during a successful rest trial, and opens the patient's hand during a successful move trial.
89468222|NCT03611855|Active Comparator|Range of Motion Therapy|Active and Passive Range-of-Motion (AROM, PROM) therapy strategies are commonly prescribed by physical therapists for at-home post-stroke motor deficit rehabilitation that can be performed independently. Patients practice movement with joints and limbs affected by the stroke, either by using the unaffected limb (or the assistance of a caretaker) to stretch the affected limb (PROM) or by actively moving the affected limb (AROM). Patients are asked to perform this therapy one hour per day, 5 days per week, for 12 weeks.
89468223|NCT02335736|Active Comparator|Normal|Human menopausal gonadotrophin IM daily was administrated from day 2 of the cycle. The Gonadotropins releasing hormone antagonist GnRH ant (Cetrotide, Serono, Geneva, Switzerland) was given when the leading follicle was from 12 to 14 mm, at a daily dose of 0.25 mg SC.
88946883|NCT01912417|No Intervention|hemodialysis session without exercise|Each patient received one hemodialysis session without exercise
88946884|NCT01912430|Experimental|ICC (Integrated Care Coaching)|Received evidence-based, protocol-driven integrated care coaching intervention to improve chronic illness health outcomes (clinical, financial).
88946885|NCT01912430|Experimental|Control Group|Matched cohort by age and chronic illness diagnoses - no intervention
89468224|NCT02335736|Active Comparator|Poor responders|Human menopausal gonadotrophin IM daily was administrated from day 2 of the cycle. The Gonadotropins releasing hormone antagonist GnRH ant (Cetrotide, Serono, Geneva, Switzerland) was given when the leading follicle was from 12 to 14 mm, at a daily dose of 0.25 mg SC
89468225|NCT02335736|Active Comparator|Polycystic ovarian disease|Human menopausal gonadotrophin IM daily was administrated from day 2 of the cycle. The Gonadotropins releasing hormone antagonist GnRH ant(Cetrotide, Serono, Geneva, Switzerland) was given when the leading follicle was from 12 to 14 mm, at a daily dose of 0.25 mg SC
89468226|NCT02335814|Experimental|FLX925|
89468227|NCT03613259|Experimental|Diagnostic (fluorothymidine F-18 PET)|Patients receive fluorothymidine F-18 IV over 1 minute and undergo PET scan over 60 minutes 21 or less days prior to standard of care radiation therapy and 14 or less days prior to the standard of care surgery.
89468228|NCT03611699|Active Comparator|Umeclidinium bromide/vilanterol|Umeclidinium bromide/vilanterol (umeclidinium bromide 62.5 mcg; vilanterol 25mcg inhalation powder; trade name Anoro Ellipta) is a combination long-acting bronchodilator that acts to reduce the amount of air trapped in the lungs at the end of of expiration.
89468229|NCT03611699|Placebo Comparator|Placebo|A placebo inhaler will be administered to serve as a control comparator to the umeclidinium bromide/vilanterol inhaler.
89018572|NCT02615119|Experimental|Brain injury|Intravenous bolus infusions of isoproterenol (up to 4 micrograms per infusion) and normal saline.
89018573|NCT02615119|Active Comparator|Healthy comparison|Intravenous bolus infusions of isoproterenol (up to 4 micrograms per infusion) and normal saline.
88946886|NCT01912443||Bevacizumab Plus Chemotherapy|
89018574|NCT02558010|Experimental|Methadone Group|Patients will receive a total of 0.2mg/kg IV methadone intraoperative (0.1mg / kg preincision and 0.1mg/kg prior to emergence) with a maximum dosing of 20 mg.
89018575|NCT02558010|Active Comparator|Control Group|Patient will receive normal saline placebo initially, then morphine prior to emergence.
89468230|NCT02032355||hypotension|
89468231|NCT03095456|Experimental|Revefenacin|Active Revefenacin and placebo (in place of Spiriva Handihaler®)
89468232|NCT03095456|Active Comparator|Spiriva Handihaler®|Active Spiriva Handihaler® and placebo (in place of Revefenacin)
89468233|NCT03612557|Experimental|active treatment arm|penicillin G benzathine treatment
89537281|NCT02464865|Experimental|Thiamine 1|presence of severe symptoms and signs of thiamine deficiency: heart failure, convulsion, coma, loss of ankle and knee jerks with muscular wasting and paralysis (typically symmetrical foot- and wrist-drop)
89468234|NCT05253638|Experimental|study group|"Patients will be recruited from the Rheumatology, Rehabilitation Department from The in patient and out patient clinic of Assiut University Hospitals with an informed consent will be obtained from all patients.~Adult SLE patients >18 who fulfilled the 2012 systemic lupus international collaborating clinics (SLICC) criteria"
88946887|NCT01912469|Experimental|Traumeel|Traumeel tablets by mouth the total amount for 72 hours will be 26 tablets
88946888|NCT01912469|Placebo Comparator|Placebo|The Placebo tablets (300 mg lactose monohydrate and 1,5 mg magnesium stearate) by mouth the total amount for 72 hours will be 26 tablets
88946889|NCT01912482|Experimental|Cardiorespiratory training|The cardiorespiratory training group will undergo 18 sessions, these also periodized in a maximum six weeks, respecting the minimum weekly frequency of 3 sessions.
88946890|NCT01912482|Active Comparator|Ventilatory Training|The ventilatory training group will undergo 18 sessions, periodized in a maximum six weeks, respecting the minimum weekly frequency of three sessions.
88946891|NCT01912482|No Intervention|Crontrol Group|This condition will last six weeks, this period will be held six lectures sixty minutes long and periodization weekly.
88946892|NCT01912508||preterm labor|pregnant women with signs of preterm labor: uterine contractions or cervical shortening
89468235|NCT03611543||Screening Patients|100 Patients. Each patient who agrees to participate and is consented and is undergoing a routine screening mammogram will receive her normal 4 view 2D plus 3D combination imaging (Left Cranial Caudal (LCC), Left Mediolateral-Oblique (LMO), Right Cranial Caudal (RCC), Right Mediolateral-Oblique (RMLO)) mammogram, with the current standard paddle. In addition she will also receive a CC and a MLO in one of her breasts as determined by a randomization scheme with the new investigational curved paddle. The amount of compression applied to both mammograms will be that to achieve tautness.
89468236|NCT03611543||Diagnostic Patients|400 Patients. Patients who agree to participate, are consented and are undergoing a diagnostic exam will have her prescribed diagnostic 2D plus 3D combination imaging as well as a CC or MLO with both the standard paddle and the new investigational curved paddle compressed to tautness on the breast of interest. The order of the paddles will be randomized and the view (CC or MLO) will be based in the visibility of the area of interest for which the diagnostic imaging was ordered. (It is possible that one of the views is superior to assess the area of interest).
89468237|NCT03067844|Experimental|Alirocumab|Alirocumab 150 mg/mL, pre-filled auto-injector pen, every second week, starting at day 1 and up to week 50.
89468238|NCT03067844|Placebo Comparator|Placebo|Placebo, pre-filled auto-injector pen, every second week, starting at day 1 and up to week 50.
89468239|NCT02039882||Controls/Normals|control subjects without known cardiac disease, age ± 5 years and sex matched
89468240|NCT02039882||Acute Coronary Syndrome requiring Percutaneous Intervention|Subjects presenting to ER with Acute chest pain requiring cardiac catheterization
89468241|NCT02039882||Acute Coronary Syndrome, no intervention|Acute Coronary Syndrome, not requiring Percutaneous intervention
89468242|NCT02340572|Experimental|PRS-080#022-DP|hepcidin antagonist, single administration, ascending doses
89468243|NCT02340572|Placebo Comparator|PRS-080-Placebo#001|Comparotor treatment, single administration
89468244|NCT03105284|Active Comparator|Liposuction of fat|The intervention examined is the extraction method by liposuction.
89468245|NCT03105284|No Intervention|Excision of fat|Control group
89468246|NCT02340260|Other|High intensity interval training|High intensity interval training starts with warming up for 3 minutes at 70 % of maximum heart rate before treadmill training 10x1-minute intervals at 90 % of HRmax, with 75 seconds of active recovery at 70 % of HRmax between each interval. Exercise is completed with a three minute cool down. All training sessions are supervised by an exercise physiologist. Treadmill inclination and/or speed will be adjusted to make sure prescribed intensity is met throughout the intervention.
89468247|NCT02340260|Other|Sprint interval training|Sprint interval training starts with warming up for 3 minutes at 70 % of maximum heart rate before treadmill training 2x20 seconds of maximum intensity intervals, with 3 minutes and 20 seconds of active recovery at 70 % of HRmax between each interval, followed by 3 minutes cooling down at the same intensity. All training sessions are supervised by an exercise physiologist. Treadmill inclination and/or speed will be adjusted to make sure prescribed intensity is met throughout the intervention.
89468248|NCT02331758|Experimental|Lifestyle counseling|The investigators use several methods to educate patients of controllable factors like lifestyle counseling, and monitor the factors like BMI and other index until the statistics become normal.
89468249|NCT02331758|No Intervention|No treatment|Patients without any intervention and still have abnormal factors like BMI, etc.
89468250|NCT02340182|Experimental|Antibiotics|"All volunteers will self-administer the following antibiotics for 7 consecutive days (concomitantly):~Vancomycin 250mg 3dd2;~Ciprofloxacin 500mg 2dd1;~Metronidazole 500mg 3dd1."
89468251|NCT02331836|Active Comparator|Arc Endocuff (AEC 110, 120, 130, 140)|Endocuff-assisted colonoscopy Colonoscopy with the Endocuff attached at the distal tip of the scope
89468252|NCT02331836|Active Comparator|Cap|Cap-assisted colonoscopy Colonoscopy with the transparent Cap attached at the distal tip of the scope
89468253|NCT02331836|Active Comparator|Standard Colonoscope|Standard colonoscopy without any additional device
89468254|NCT05226182|Experimental|patients|"Implementation and visualisation of digital care path. Pre measurement: questionnaire quantifying patient involvement and experience on a 5-p Likert scale.~Post measurement: questionnaire quantifying patient involvement and experience on a 5-p Likert scale, questionnaire quantifying usability of the tool and in-depth interview."
89468255|NCT05226182|Experimental|healthcare professionals|"Implementation and visualisation of digital care path. Pre measurement: questionnaire quantifying communication needs and experiences on a 5-p Likert scale.~Post measurement: questionnaire quantifying communication needs and experiences on a 5-p Likert scale, questionnaire quantifying usability of the tool and in-depth interview."
89468256|NCT02339948|Active Comparator|SBRT only|Patients assigned to this arm receive 8.0 Gy per fraction for 5 fractions for a total of 40 Gy
89468257|NCT02339948|Active Comparator|IMRT plus SBRT Boost|Patients assigned to this arm receive 1.8 Gy per fraction for 25 fractions over 5 weeks for a total of 45.0 Gy followed by an SBRT boost of 5.5 Gy per fraction for 4 fractions after IMRT for a total of 22.0 Gy
89468258|NCT02339792|Other|Intervention|e-learning program of medical education, focused on teaching and implementing Comprehensive Geriatric Assessment (CGA) added to geriatric pharmacological notions (GPNs)
89468259|NCT02339792|Other|Control|e-learning program of medical education, focused on teaching only geriatric pharmacological notions (GPNs)
88946893|NCT01912508||control|pregnant women with no signs or symptoms of preterm labor
88946894|NCT01912521|Experimental|Intervention|This arm is eligible for participation in the Mfangano Health Net Microclinic Program, a social network-based educational program.
88946895|NCT01912521|No Intervention|Comparison|This arm is not eligible for participation in the intervention. Participants still have access to usual care at the Sena Health Center or their health facility of choice.
88946896|NCT01912534|Active Comparator|Valsartan|Subjects who tolerate active run-in and titration to target dose of valsartan will then undergo stratified randomization and begin blinded treatment with valsartan or matched placebo on maximal tolerated dose, according to their assigned treatment group. Treatment will continue for 2 years.
88946897|NCT01912534|Placebo Comparator|Placebo|Subjects who tolerate active run-in and titration to target dose of valsartan will then undergo stratified randomization and begin blinded treatment with valsartan or matched placebo on maximal tolerated dose, according to their assigned treatment group. Treatment will continue for 2 years.
88946898|NCT01912547||Blood draw for TEG analysis|TEG analysis of blood from patients at different points in time
89468260|NCT02339714|Experimental|Acupuncture combined moxibustion|Acupuncture at Hegu(LI4),Yingxiang(LI20),Chize(LU5),Sibai(ST2), Yintang(EX-HN3),Shangyingxiang(EX-HN8),Shangxing(GV23),Dazhui(Du14). Needle warming moxibustion at Dazhui(Du14). Patients will be treated once per day for 30 min, 3 times in a weeks for 4 weeks.
89468261|NCT02339714|Active Comparator|loratadine|Loratadine taken orally, 10mg/day in the morning
89468262|NCT02335190|Experimental|PSN block and RF ablation|Participants will first undergo a lidocaine block of the PSN at the lateral crest under ultrasound guidance. On a separate visit, participants will then undergo ablation of the PSN at the lateral crest under ultrasound-guidance.
89468263|NCT02339870|Experimental|Arm I (expressive disclosure)|Participants complete an anonymous 20 minute writing exercise at home on their computer once per week for 2 weeks (days 2, 9, and 16 for a total of 3 sessions). Participants write about their emotions pertaining to managing and providing care for the cancer patient.
89468264|NCT02339870|Experimental|Arm II (benefit finding)|Participants complete an anonymous 20 minute writing exercise at home on their computer once per week for 2 weeks (days 2, 9, and 16 for a total of 3 sessions). Participants write about any benefits that have arisen because of the cancer diagnosis.
89468265|NCT02339870|Sham Comparator|Arm III (control)|Participants complete an anonymous 20 minute writing exercise at home on their computer once per week for 2 weeks (days 2, 9, and 16 for a total of 3 sessions). Participants write about an emotionally neutral topic.
89468266|NCT02335112|Experimental|Group A|irreversible electroporation with voltage in level A for Unresectable Head and Neck Neoplasms
88946899|NCT01912573|Experimental|Intranasal (IN) naloxone|Intranasal (IN) naloxone as initial response to suspected opioid overdose
88946900|NCT01912573|Active Comparator|Standard of Care (TAU)|Standard of care (intravenous [IV], intramuscular [IM] or intraosseus [IO]delivery of naloxone) as initial response to suspected opioid overdose.
89018576|NCT02550548|Experimental|GIP infusion|During a 240 minute hyperglycemic clamp, subjects will have (after 90 minutes of the clamp) GIP infused at 4 incremental dosages, (initial dose will be 2.0 ng/kg/min, followed by 4.0, 8.0, and 16.0 ng/kg/min). Each dose will be infused continuously for 30 minutes, followed immediately by the next higher dose. The total time of this procedure is 240 minutes.
89468267|NCT02335112|Experimental|Group B|irreversible electroporation with voltage in level B for Unresectable Head and Neck Neoplasms
89468268|NCT02335112|Experimental|Group C|irreversible electroporation with voltage in level C for Unresectable Head and Neck Neoplasms
89468269|NCT02335034|Experimental|Study group|Intervention: study group will attend two days of classes (two months apart) with the seven professional teams, covering what is the disease arthritis, its causes and treatment options; what is disease, being ill, and the role of the patient in the treatment to obtain behavioral change; the importance of exercise in relieving symptoms, the importance of rest and proper ergonomics at home and at work; proper alimentation; the difference between labor work and regular physical activity as well as the importance of strength resistance and stretching exercises; and the importance of leisure. The second intervention verifies the acquired concepts.
89468270|NCT02335034|Experimental|Control Group|The control group will only make evaluations / consultations with all professional teams without classes for 2 years, then will attend the courses and will be followed by two more years.
89468271|NCT02334878|Experimental|Stem cells,Mesenchymal|Periurethral injection of autologous bone-marrow derived stem cells.
89468272|NCT02334878|Active Comparator|surgery (TVT)|Tension-free vaginal tape operation: a midurethral sling operation
89468273|NCT02331524|No Intervention|Control/Usual Care|Usual care only
89468274|NCT02331524|Experimental|Activity Feedback and Encouragement|Weekly Feedback about daily activity using the FitBit Zip
89468275|NCT02331524|Experimental|Health Coaching/Home Exercise|Weekly contact from physical therapist to develop and progress home exercise program and by health coach for goal setting and support
89018577|NCT02550548|Experimental|GLP-1 infusion|During a 240 minute hyperglycemic clamp, subjects will have (after 90 minutes of the clamp) GLP-1 infused at 4 incremental dosages, (initial dose will be 1.0 ng/kg/min, followed by 2.0, 3.0, and 4.0 ng/kg/min). Each dose will be infused continuously for 30 minutes, followed immediately by the next higher dose. The total time of this procedure is 240 minutes.
89018578|NCT02550548|Experimental|GIP + GLP-1 infusion|During a 240 minute hyperglycemic clamp, subjects will have (after 90 minutes of the clamp) GIP + GLP-1 infused simultaneously at 4 incremental dosages (doses will be half the amounts described above). These doses will be infused continuously for 30 minutes, followed immediately by the next higher doses. The total time of this procedure is 240 minutes.
89468276|NCT02339636||case group|100 patients with vulgaris psoriasi without arthritis
89468277|NCT02339636||control group|100 age-matched patients with other skin diseases without arthritis
89468278|NCT02581592|Experimental|Hepatic Impairment|Eight subjects with Moderate Hepatic Impairment (Child-Pugh B). Drug: TD-4208 175mcg, inhaled, single dose.
89468279|NCT02581592|Experimental|Normal Hepatic Function|Eight healthy participants matched to participants with moderate hepatic impairment. Drug: TD-4208 175mcg, inhaled, single dose.
89468280|NCT02578082|Experimental|Renal Impairment|Eight subjects with Severe Renal Impairment (eGFR <30 mL/min/1.73m2). Intervention is TD-4208, 175mcg, inhaled, single dose.
89468281|NCT02578082|Experimental|Normal Renal Function|"Eight healthy participants matched to participants with severe renal impairment.~Intervention is TD-4208, 175mcg, inhaled, single dose."
89468282|NCT02339324|Experimental|This study has one arm that consists of 3 phases or steps.|"Induction phase (first 6 weeks): Pembrolizumab and High Dose IFNα-2b (HDI) Pembrolizumab I.V. every 3-4 weeks for 2 doses concurrently with HDI I.V. x 5 consecutive days every week for 4 weeks, followed by S.C. every other day 3x each week for 2 weeks.~Surgery phase (week 6-8).~Maintenance phase (following recovery from surgery): Pembrolizumab I.V. infusion every 3 weeks given concurrently with HDI S.C. QOD (e.g. M,W,F) TIW every week for 46 additional weeks"
89468283|NCT02334956|Experimental|Patient|Patient with addiction
89468284|NCT02334956|Experimental|Control|healthy subject
89468285|NCT03105206||Low Pole Renal Calculus|patients with low pole renal calculus who are suitable to treat by flexible ureteroscopy
89018579|NCT02550548|Experimental|GIP + Ex-9 infusion|During a 240 minute hyperglycemic clamp, subjects will have (after 90 minutes of the clamp) GIP infused at 4 incremental dosages (as described above) with Ex-9 infused at a steady dose of 2.5 mcg/kg/min starting 90 minutes before the GIP infusion and maintained throughout the clamp experiment. The total time of this procedure is 240 minutes.
89018580|NCT02545673|Experimental|Enhanced Linkage|Participants will receive the enhanced linkage to care Intervention. Behavioral: Enhanced linkage to care Intervention Multiple sessions will focus on providing orientation to the HIV care system, counseling to help clients identify and reduce barriers to engagement in care, assistance disclosing and identifying a treatment supporter, and stigma reduction through increasing social support. The approach is guided by the HIV Stigma Framework.
89018581|NCT02545673|Active Comparator|Standard-of-care plus|Behavioral: Participants will receive the standard-of-care (paper-based referrals) plus return of CD4 test results to their home.
89018582|NCT02534233|Experimental|CryoBalloon ablation|Patients having ablation of dysplastic tissue in esophagus.
89018583|NCT02530502|Experimental|Treatment (RT, temozolomide, pembrolizumab)|"RT PORTION: Patients undergo focal RT over 42 days, and receive concurrent temozolomide PO QD on days 1-42 and pembrolizumab IV over 30 minutes on days 1, 22, and 43.~POST-RT: After completion of RT, patients receive temozolomide PO QD on days 1-5 and 29-34 of course 1 and days 1-5 and 29-33 of subsequent courses, and pembrolizumab IV over 30 minutes on days 1, 22, and 43. Treatment repeats every 9 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. After 6 courses, patients deriving benefit may continue to receive pembrolizumab for an additional 12 months."
89018584|NCT02494700|Experimental|Treatment (low dose orbital EBRT)|Patients undergo two fractions of low dose orbital EBRT on 2 consecutive days. Patients experiencing stable or progressive disease after 12-16 weeks of EBRT undergo additional low dose orbital EBRT over 10 fractions. Patients experiencing partial response or minimal response 1 year after EBRT also undergo low dose orbital EBRT over 10 fractions.
89018585|NCT02460783|Experimental|5-2 CR|Healthy living diet for 5 days/week; Calorie Restriction (530 Kcal in the form of a shake) for 2 days/week.
89018586|NCT02460783|Active Comparator|Healthy Living Diet|Healthy living diet for 7 days/week
89468286|NCT02334566|Experimental|NET TX|Behavioral intervention for PTSD (NET/KIDNET) with 8-12 sessions administered on a weekly basis.
89468287|NCT02334566|Active Comparator|Delayed TX|Behavioral intervention for PTSD (NET/KIDNET) with 8-12 sessions administered on a weekly basis, started following a three-month wait period
89468288|NCT02339480|No Intervention|Healthy volunteers|Healthy volunteers'hypothalamus picture of fMRI will compare with Obesity group' , no intervention and remaining unchanged lifestyle.
89468289|NCT02339480|Active Comparator|Obesity group|An intervention group of patients is put on a waiting list for massage therapy.Observing the Curative effect and hypothalamus picture of fMRI compare with healthy volunteers
89468290|NCT02418754|Experimental|REGN2176-3 (1 mg: 2 mg)|Intravitreal injection of REGN2176-3 (REGN2176 1 mg and REGN3 2 mg) every 4 weeks for 12 weeks. After Week 12, dosing was monthly up to Week 28, then criteria based re-dosing from Week 28-52.
89468291|NCT02418754|Experimental|REGN2176-3 (3 mg: 2 mg)|Intravitreal injection of REGN2176-3 (REGN2176 3 mg and REGN3 2 mg) every 4 weeks for 12 weeks. After Week 12, dosing was monthly up to Week 28, then criteria based re-dosing from Week 28-52.
89468292|NCT02418754|Experimental|Intravitreal Aflibercept Injection (IAI) 2 mg|IAI every 4 weeks for 12 weeks. After Week 12, dosing was monthly up to Week 28, then criteria based re-dosing from Week 28-52.
89468293|NCT02418754|Experimental|REGN2176-3 (3 mg: 2 mg) to IAI 2 mg|Intravitreal injection of REGN2176-3 (REGN2176 3 mg and REGN3 2 mg) every 4 weeks for 12 weeks. After Week 12, dosing was monthly with IAI 2 mg up to Week 28, then criteria based re-dosing from Week 28-52.
89468294|NCT02418754|Experimental|IAI 2 mg to REGN2176-3 (3 mg:2 mg)|IAI every 4 weeks for 12 weeks. After Week 12, dosing was monthly with REGN2176-3 (REGN2176 3 mg and REGN3 2 mg) up to Week 28, then criteria based re-dosing from Week 28-52.
89468295|NCT02334488|Active Comparator|Everolimus-Tacrolimus|"Tacrolimus (Prograf®) started at 0,1 mg/kg/day since Day0, then adapted to C0 concentration (4-7 ng/ml),~Everolimus (Certican®) started within 24h after reperfusion, to be adapted to C0 concentration (3-8 ng/ml)."
89468296|NCT02334488|Experimental|Everolimus-Mycophenolate sodium|"Everolimus (Certican®) started within 24h after reperfusion, to be adapted to C0 concentration (3-8 ng/ml),~Tacrolimus (Prograg®) started at 0,1 mg/kg/day from J0 then to be adapted to C0 concentration (4-7 ng/ml), then replacement by mycophenolate sodium (Myfortic®) at M3 (3 months visit) started at 1440 mg/day."
89468297|NCT03105050||Countries in Europe|All 51 countries will fill out their unique data on access to bariatric surgery in Europe
89468298|NCT02334644|Experimental|1|Probiotic Formula (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175)
89468299|NCT02334644|Placebo Comparator|2|Placebo
89468300|NCT02447458|Experimental|Cohort 1: MLN3126 300 mg|MLN3126 300 mg tablets, orally, fasting, once on Day 1.
89468301|NCT02447458|Experimental|Cohort 2: MLN3126 600 mg|MLN3126 600 mg tablets, orally, fasting, once on Day 1.
89468302|NCT02447458|Experimental|Cohort 3: MLN3126 1000 mg|MLN3126 1000 mg tablets, orally, fasting, once on Day 1. Participants returned to the clinic then received MLN3126 1000 mg tablets, orally, fed (30 minutes after the start of a high-fat breakfast), once on Day 1.
88946901|NCT01912586|No Intervention|Arm A|Patients receive no interventions for ED after laparoscopic surgery
88946902|NCT01912586|Experimental|Arm B|sildenafil 25mg/day nightly without vacuum erection device for 3 months after surgery within one or two weeks.
88946903|NCT01912586|Experimental|Arm C|sildenafil 25mg/day nightly and together with using vacuum erection device to make erections for 10-15 minutes/day for 3 months after surgery within one or two weeks.
88946904|NCT01912638|Experimental|Implantation of Ologen in trabeculectomy|Ologen Collagen Matrix is implanted in primary limbal-based trabeculectomy. It should be placed on the top of the loosely-sutured scleral flap before suturing of the conjunctiva thus preventing the collapse of the subconjunctival space.
89468303|NCT02447458|Experimental|Cohort 4: MLN3126 1500 mg|MLN3126 1500 mg administered orally as tablets, once on Day 1.
89468304|NCT02447458|Experimental|Cohort 5: MLN3126 2000 mg|MLN3126 2000 mg tablets, orally, fasting, once on Day 1.
88946905|NCT01912638|Active Comparator|Provisc in trabeculectomy|Provisc is used in primary limbal-based trabeculectomy. At the end of the surgery cohesive viscoelastic (Provisc) is injected under the scleral flap to prevent early hypotony.
88946906|NCT01912677|Active Comparator|Nifedipine|Women will receive an initial dose of oral nifedipine 10mg. If blood pressure exceeds 155mmHg systolic OR 105 mmHg diastolic after 1h, an additional 10mg dose can be provided each hour for two additional doses (30 mg total).
88946907|NCT01912677|Experimental|Methyldopa|Women will receive an initial dose of oral methyldopa 1000mg. No additional escalation in dose in the first 6 hours will be given.
88946908|NCT01912677|Experimental|Labetalol|Women will receive an initial dose of oral labetalol 200mg. If blood pressure exceeds 155mmHg systolic OR 105 mmHg diastolic after 1h, an additional 200mg dose can be provided each hour for two additional doses (600 mg total).
88946909|NCT01912690|Placebo Comparator|standard of care|
88946910|NCT01912690|Active Comparator|aerobic training only|
88946911|NCT01912690|Active Comparator|Aerobic and strength training|
88946912|NCT01912703||Preterm infants with IVH Grades I-II|Preterm infants (post-menstrual age 24-35 weeks) who were diagnosed with IVH Grades 1-2 in the neonatal intensive care unit (NICU).
88946913|NCT01912703||Control Group|Preterm infants (post-menstrual age 24-35 weeks) who had no imaging evidence of IVH in the neonatal intensive care unit (NICU).
88946914|NCT01912742|Experimental|Rapid weight loss group|The rapid weight loss group will follow a commercial very-low calorie diet (VLCD) during 4 weeks. The participants allocated to this group will follow a 550 (women) - 660 (men) kcal/day diet. The VLCD products provide 110kcal/pack and include a variety of milkshakes, smoothies and soups. In addition to VLCD products, calorie-free drinks and some low-starch vegetables (maximum 2 cups/day) will be allowed. Drinking at least 2.5 liters of non-caloric liquids will be recommended.
88946915|NCT01912742|Experimental|Slow weight loss group|The slow weight loss group will be prescribed an individualized low calorie diet (LCD) (1200-1500kcal/day), during 8 weeks, using meal replacements (such as smoothies, soups and cereal bars) and conventional foods. The macronutrient composition will be matched with that of the VLCD.
88946916|NCT01912755|Experimental|Articaine|injection of 1.8 mL buccal infiltrations of 4% articaine with 1:100,000 epinephrine in one tooth with a clinical diagnosis of symptomatic irreversible pulpitis.
88946917|NCT01912755|Active Comparator|Lidocaine|1.8 mL 2% lidocaine with 1:100,000 epinephrine injected as inferior alveolar nerve block in the mandible side with one tooth with a clinical diagnosis of symptomatic irreversible pulpitis.
88946918|NCT01912794|Experimental|Sensory Conditions|
89468305|NCT02447458|Experimental|Cohort 6|Did not take place due to termination of the study.
89468306|NCT02447458|Placebo Comparator|Placebo: Cohort 1-6|Placebo-matching MLN3126 tablets, orally, once on Day 1.
89468307|NCT02862457|Experimental|Part A Cohort 1: epacadostat 25 mg|Participants received 25 mg of epacadostat orally twice daily (BID) alone on Days 1-5 of Cycle 1 (28-day cycle) with a washout on Days 6 and 7. On Day 8 participants received a one-time intravenous (IV) infusion of 200 mg pembrolizumab while continuing to receive 25 mg of epacadostat BID on Days 8-28. For each 21-day cycle thereafter, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and received 25 mg of epacadostat BID on Days 1-21 for up to 35 cycles (approximately 2 years).
89537282|NCT02464865|Other|Non-thiamine|no symptoms and signs of thiamine deficiency
89537283|NCT02464865|Experimental|Thiamine 2|presence of mild symptoms and signs of thiamine deficiency; peripheral neuropathy alone (paraesthesia of hands and feet)
88946919|NCT01912820|Experimental|Arm I (quercetin, green tea extract)|Patients receive GT extract PO BID and quercetin PO BID for 3-6 weeks before undergoing prostatectomy.
88946920|NCT01912820|Placebo Comparator|Arm II (GT extract, placebo)|Patients receive GT extract PO BID and placebo PO BID for 3-6 weeks before undergoing prostatectomy.
88946921|NCT01912846|Sham Comparator|Attention usual care intervention|"Interventions includes prognosis disclosure and discussions of EOL care as needed as in current clinical practices.~Interventions of the attention usual care arm include a consistent master prepared nurse on the study team will provide the attention portion of the care and a workbook and a video with educational materials. The initial meeting will occur before the patient discharges from hospital and the usual care nurse will give patients and family caregivers a workbook and a video with educational materials on how to manage common symptoms and a comprehensive list of resources available, including patient support organizations, support and financial assistance through the social work department."
88956473|NCT05137119|No Intervention|No adjunctive treatment in combination with MRSA or MSSA or PSSA backbone therapy arm|"No adjunctive therapy + backbone therapy arm for MRSA or MSSA or PSSA~Participants with either MRSA or MSSA or PSSA will have no adjunctive therapy in combination with their backbone therapy arm."
89018587|NCT02437318|Experimental|fulvestrant + alpelisib|Alpelisib (300 mg; oral; once daily) in combination with fulvestrant (500 mg; intramuscular injection on Day 1 and Day 15 of Cycle 1, and then Day 1 of each subsequent 28-day cycle)
89018588|NCT02437318|Placebo Comparator|fulvestrant + placebo|Placebo (300 mg; oral; once daily) in combination with fulvestrant (500 mg; intramuscular injection on Day 1 and Day 15 of Cycle 1, and then Day 1 of each subsequent 28-day cycle)
89018589|NCT02305238|Experimental|2 Weeks adjustment|Participants received Aflibercept IVT injection at Week 0, Week 4, Week 8 and Week 16 followed by the variable treatment intervals with the criteria of Treat and Extend regimen. In the case the study eye of a participant met the criteria, the length of treatment interval was to be extended or shortened by 2 weeks from the last interval, respectively. Minimum/Maximum treatment interval is 8 weeks and 16 weeks during Week 16 to 96.
89018590|NCT02305238|Experimental|4 Weeks adjustment|Participants received Aflibercept IVT injection at Week 0, Week 4, Week 8 and Week 16 followed by the variable treatment intervals. In the case the study eye of a participant met the criteria of the shortening, the length of the treatment interval was to be shortened by 2 weeks. But when the last treatment interval for a participant was extended by 4 weeks from the second last interval, the treatment interval was shortened by 4 weeks. In the case the study eye of a participant met the criteria of the extension, the length of the treatment interval was to be extended by 4 weeks. But when a participant had a history of receiving treatment with interval shortened by 4 weeks during this study, the length of the extension was 2 weeks. Minimum/Maximum treatment interval is 8 weeks and 16 weeks during Week 16 to 96.
89468308|NCT02862457|Experimental|Part A Cohort 1: epacadostat 100 mg|Participants received 100 mg of epacadostat orally BID alone on Days 1-5 of Cycle 1 (28-day cycle) with a washout on Days 6 and 7. On Day 8 participants received a one-time IV infusion of 200 mg pembrolizumab while continuing to receive 100 mg of epacadostat BID on Days 8-28. For each 21-day cycle thereafter, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and received 100 mg of epacadostat BID on Days 1-21 for up to 35 cycles (approximately 2 years).
89468309|NCT02862457|Experimental|Part A Cohort 2: epacadostat 25 mg+pembrolizumab|For each 21-day cycle, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and received 25 mg of epacadostat orally BID on Days 1-21 for up to 35 cycles (approximately 2 years).
89468310|NCT02862457|Experimental|Part A Cohort 2: epacadostat 100 mg+pembrolizumab|For each 21-day cycle, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and received 100 mg of epacadostat orally BID on Days 1-21 for up to 35 cycles (approximately 2 years).
89468311|NCT02862457|Experimental|Part B Cohort 1: pembrolizumab+cisplatin+pemetrexed|For each 21-day cycle, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and 100 mg of epacadostat orally BID on Days 1-21 for up to 35 cycles (approximately 2 years). For the first 4 cycles, participants also received a one-time IV infusion of 75 mg/m^2 cisplatin and 500 mg/m^2 pemetrexed on Day 1. Treatment with epacadostat was stopped with protocol amendment 02.
89468312|NCT02862457|Experimental|Part B Cohort 2: pembrolizumab+carboplatin+pemetrexed|For each 21-day cycle, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and 100 mg of epacadostat orally BID on Days 1-21 for up to 35 cycles (approximately 2 years). For the first 4 cycles, participants also received a one-time IV infusion of Area Under the Curve (AUC) 5 carboplatin and 500 mg/m^2 pemetrexed on Day 1. Treatment with epacadostat was stopped with protocol amendment 02.
89468313|NCT02862457|Experimental|Part B Cohort 3: pembrolizumab+carboplatin+paclitaxel|For each 21-day cycle, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and 100 mg of epacadostat orally BID on Days 1-21 for up to 35 cycles (approximately 2 years). For the first 4 cycles, participants also received a one-time IV infusion of AUC 6 carboplatin and 200 mg/m^2 paclitaxel on Day 1. Treatment with epacadostat was stopped with protocol amendment 02.
89468314|NCT04103138|Experimental|EEG-Guided Anaesthesia|Patients will have Sedline EEG sensor placed and anaesthesia guided by the EEG characteristics, patient state index (PSI) and suppression ratio (SR), in addition to routine clinical parameters.
89468315|NCT04103138|Active Comparator|Routine Care|Patients will have Sedline EEG sensor placed but the monitor is concealed so the clinician is blinded to the EEG response. Anaesthesia is guided by routine clinical parameters.
88946922|NCT01912846|Experimental|Interactive advance care planning|The intervention aims at facilitating patients, families, and primary physicians to discuss the patient's wishes for EOL care by clarifying a terminally ill cancer patient's understanding of his/her prognosis and treatment options and her/his readiness for engagement in ACP, appropriately weighting the benefits and burdens of medical treatments at EOL, and clearly defining and documenting the patient's preferences so as to be readily available later for the patient's primary physician to guide EOL care decision-making which will honor the patient's preferences for EOL care.
89468316|NCT02334332|Active Comparator|Cohort I (standard care)|Participants receive standard post-operative care.
89468317|NCT02334332|Experimental|Cohort II (educational brochure)|Participants receive a 2-page educational brochure after surgery and prior to discharge home.
89468318|NCT02334254|Experimental|Dual antithrombotic therapy (DAT)|Dual Antithrombotic Therapy (DAT) regimen of rivaroxaban 2.5mg/5mg b.i.d. plus ticagrelor 90mg b.i.d.
89468319|NCT02334254|Active Comparator|Triple antithrombotic therapy (TAT)|Triple antithrombotic therapy (TAT) regimen of aspirin 100mg q.d., clopidogrel 75mg q.d. plus warfarin (INR 1.8-2.5).
89468320|NCT02447302|Experimental|Etrasimod Low Dose|Oral, low dose, daily for 12 Weeks
89468321|NCT02447302|Experimental|Etrasimod High Dose|Oral, high dose, daily for 12 weeks
89468322|NCT02447302|Placebo Comparator|Placebo|Oral, placebo, daily for 12 weeks.
89468323|NCT02033863||Cohort A|Varicocele arising from the spermatic vein(s) and pampiniform plexus, with or without concomitant diagnosis of infertility or subfertility
89468324|NCT02033863||Cohort B|Pelvic varices in females for the treatment of pelvic congestion syndrome (e.g., pelvic venous incompetence).
89468325|NCT02334410|No Intervention|Reference|
89468326|NCT02334410|Experimental|Whole body vibration (WBV)|Vibration therapy
89468327|NCT02482519|Other|10 day overfeeding/fasting|10 day high calorie diet followed by a 10 day fast
88946923|NCT01912859|Experimental|Nutrition/physical activity intervention|The intervention, Next Steps, comprises a network of community-led health maintenance programs offered to graduates of an initial intensive obesity course. These health maintenance programs will aim to help participants maintain and improve healthful behaviors and body mass indices.
88946924|NCT01912859|No Intervention|Usual care|"Participants in the No Intervention arm will not have access to the Next Steps programs and will receive only usual care through their health care clinic."
88946925|NCT01912885|Placebo Comparator|Group TENS 0-1|Electrodes will be fixated to one leg and sessions will be held once a week.
88946926|NCT01912885|Experimental|Group TENS 1-1|Electrical stimulation of the posterior tibial nerve of one leg once a week.
88946927|NCT01912885|Experimental|Group TENS 1-2|Electrical stimulation of the posterior tibial nerve of one leg twice a week.
88946928|NCT01912885|Experimental|Group TENS 2-1|Electrical stimulation of the posterior tibial nerve of two legs once a week.
88946929|NCT01912885|Experimental|Group TENS 2-2|Electrical stimulation of the posterior tibial nerve of two legs twice a week.
88946930|NCT01912898||1|
88946931|NCT01912937|Experimental|DCB Arm|Angioplasty treatment with the CVI Paclitaxel-Coated, Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter (CVI Paclitaxel-coated PTA Catheter)
88946932|NCT01912976|Experimental|Er:YAG AFL-PDT|Right leg on each patients was assigned a single session of Er:YAG AFL-PDT.
88946933|NCT01912976|Active Comparator|MAL-PDT|Left leg on each patient was selected to receive 2 sessions of MAL-PDT
88946934|NCT01911663|Experimental|KRG|500 mg Korea red ginseng (KRG)
88946935|NCT01911663|Placebo Comparator|Placebo|500 mg placebo (corn starch)
88946936|NCT01912989|Experimental|Lifestyle counseling|NOURISH+ plus motivational interviewing
88946937|NCT01913002|Experimental|Treatment A|LX4211 800 mg
88946938|NCT01913002|Experimental|Treatment B|LX4211 2000 mg
88946939|NCT01913002|Active Comparator|Treatment C|moxifloxacin 400 mg
88946940|NCT01913002|Placebo Comparator|Treatment D|Placebo
88946941|NCT01913015|Experimental|Arm I (abiraterone acetate, low then high fat breakfast)|Patients receive standard dose abiraterone acetate PO QD (held on days 2, 3, 9, and 10), and low-dose abiraterone acetate PO QD on days 3 and 10. Patients eat a low fat breakfast on day 3 and a high fat breakfast on day 10.
88946942|NCT01913015|Experimental|Arm II (abiraterone acetate, high then low fat breakfast)|Patients receive abiraterone acetate as in Arm I. Patients eat a high fat breakfast on day 3, and a low fat breakfast on day 10.
88946943|NCT01913028|Experimental|MEDI9929|Solution of MEDI9929, SC
88946944|NCT01913028|Placebo Comparator|Placebo|Placebo solution for MEDI9929, SC
88946945|NCT01913054|Active Comparator|Fentanyl & Propofol|0.02 ml/kg(1 μg/kg) fentanyl is diluted to 10 ml with normal saline and infused within 1 min, 4 min advance. 0.5 mg/kg(0.025 ml/kg) propofol is infused within 15 to 20 s. And then, depending on the randomized result, 0.5 mg/kg is given every time until the patient falls asleep. During the operation, 0.5 mg/kg is given when it is needed.
88946946|NCT01913054|Experimental|fentanyl, propofol & etomidate|0.02 ml/kg(1 μg/kg) fentanyl is diluted to 10 ml with normal saline and infused within 1 min, 4 min advance. 0.5 mg/kg(0.025 ml/kg) propofol is infused within 15 to 20 s. And then, depending on the randomized result, 0.5 mg/kg etomidate is given every time until the patient falls asleep. During the operation, 0.5 mg/kg etomidate is given when it is needed.
88956474|NCT05137119|Experimental|Adjunctive treatment in combination with MRSA or MSSA or PSSA backbone therapy arm|Adjunctive therapy + backbone therapy arm for MRSA or MSSA or PSSA Intravenous clindamycin (or lincomycin) 600mg every 8 hours for 5 days. No dosage adjustment is needed to renal impairment.
89468328|NCT02039570||haemorrhoids|The cohort contains only patients with symptomatic haemorrhoids - these patients will receive a transvaginal scan to examine their ovarian and internal iliac veins to ascertain whether there is any reflux
89468329|NCT02331602|Active Comparator|rivaroxaban|Patients are assigned to receive rivaroxaban 15mg once daily for 12 months according to a computer-generated randomization sequence at the central registration center. Patients with creatinine clearance 30-49 mL/min receive rivaroxaban 10mg once daily.
89468330|NCT02331602|Active Comparator|dabigatran|Patients are assigned to receive dabigatran 150mg twice daily for 12 months according to a computer-generated randomization sequence at the central registration center. Patients at a high risk of bleeding receive dabigatran 110mg twice daily.
89468331|NCT02454517|Experimental|Arm I (diet and exercise lifestyle intervention)|The goals of the diet and exercise lifestyle intervention is for patients to lose 7% total body weight. Patients meet with a nutritionist 11 times during the first 6 months to receive the structured diet and exercise instruction. Participants complete exercise sessions supervised by an exercise specialist, and will wear a heart rate monitor periodically during the study.
89468332|NCT02454517|Active Comparator|Arm II (control)|Patients receive an informational intervention along with a 20-30 minute individual session with a dietitian and a goal of 30 minutes of physical activity 5 days a week.
89468333|NCT02338934|Experimental|Cinacalcet with Vitamin D arm|Depending on the iPTH level and the serum calcium level they will be started on Cinacalcet 25mg OD and active Vitamin D will be adjusted. If Serum Cal <2.4 mmol/L - Start Cinacalcet 25mg OD & Increase active Vit D by 1 mcg/dose 3x/week Increase active Vit D by 1 mcg/dose 3x/week or Serum Ca 2.4-2.54 mmol/L- Start Cinacalcet 25mg OD and Maintain active Vit D dose OR if >2.54 mmol/L - Start Cinacalcet 25mg OD & Maintain active Vit D dose. Then they will go to maintenance phase.
89537284|NCT03066141||CAD with OSA|coronary artery disease with Obstructive sleep apnea
88946947|NCT01913067|Experimental|Cabazitaxel|Eligible patients will receive intravenous 25mg/m2 cabazitaxel every 3 weeks. Contrast-enhanced whole brain MRI will be performed every two cycles. Patients who show ≥50% volumetric reduction in the size of the brain lesion(s) will continue on cabazitaxel until disease progression or unacceptable toxicity. Patients who show evidence of disease progression and/or developed progressive neurological symptoms will be taken off study and offered whole brain irradiation. Patients who do not meet both criteria can have the choice either to continue on study drug or to be taken off study according to the investigator discretion.
88946948|NCT01913080|Active Comparator|Health Log|Patients who have a billing diagnosis RA (714.0)or seronegative inflammatory arthritis who are enrolled in the Brigham and Women's Rheumatoid Arthritis Sequential Study (BRASS)will be given the Health Log health management tool.
88946949|NCT01913080|No Intervention|Control Pill Box|Controls will be BRASS patients who continue to receive regular care and are also given a pill box instead of the Health Log health management tool.
88946950|NCT01913093||Leukemia survivors with neurocognitive deficit|"Leukemia survivors with neuro-cognitive deficit phenotype. Based on DIVERGET and other phenotyping tools, we will identify those with the deficit phenotype. This will be treated as case."
88946951|NCT01913093||Leukemia survivors without neurocognitive deficit|Leukemia survivors who did not show impaired neurocognitive function, compared to the Control group defined above.
88946952|NCT01913106|Experimental|HSV-tk + Valacyclovir and Brachytherapy|You will be given an antibiotic (Ciproflaxin) to take twice a day beginning the day before the procedure, and continuing for a total of 3 - 5 days. You will also be given 4 pills called (Valtrex) valacyclovir to take three times a day for 14 days, beginning the day before the procedure. You will be given a pill diary in which you will record each dose of valacyclovir that you take. You will receive brachytherapy (radioactive seed placement) the day after you begin taking your pills. After the radioactive seeds are placed, while you are still in the operating room, you will receive an injection into your prostate of 1 or 2 ml (one-fifth or two-fifths of a teaspoon) of a solution of the vector carrying the gene.
88946953|NCT01913119|Experimental|Romidepsin|"Day 1, 8, and 15 of a 28-day cycle Romidepsin Treatment is repeated until documented disease progression or unacceptable toxicity.~Dose and administration: 4-hour infusion of 14 mg/m2"
88946954|NCT01913145|Experimental|A1c, Self-collection, Blood sample|"Can a lay-persons safely and effectively self-collect a capillary blood sample of sufficient adequacy for A1c (HbA1c) testing in a clinical laboratory"
88946955|NCT01913171|Active Comparator|Walking|WALK. The participants were instructed to walk daily, at first week 12minutes/day, week II 16mins/day, week III 20mins/day, week IV 24 mins/day, week V 28mins/day, week VI 32mins/day at a pace that would moderately increase heart rate and result in sweating
88946956|NCT01913171|Active Comparator|Hula-hooping|HULA. The participants were instructed to hula hoop daily, at first week 6minutes/day, week II 8mins/day, week III 10mins/day, week IV 12 mins/day, week V 14mins/day, week VI 16mins/day
88946957|NCT01913184|Active Comparator|Continuous nebulization|Continuous nebulization with AKITA
88946958|NCT01913184|Experimental|Discontinuous nebulization|Discontinuous nebulization with AKITA
88946959|NCT01913197|Experimental|Pre-implant MRI images and planning|
88946960|NCT01913223|Experimental|submucosal dissection by dissector water jet|
88946961|NCT01913236|Experimental|Implementation intervention|Tailored implementation intervention to address determinants of practice in primary care
88946962|NCT01913236|No Intervention|Control|Treatment as usual provided by general practitioners to elderly patients with depression
88946963|NCT01913249|Experimental|Intervention|Seton through fistula 6 months prior to LIFT
88946964|NCT01913249|Active Comparator|Control|Seton through fistula 3 weeks prior to LIFT surgery
88946965|NCT01913262||IFH Patients on Depression Registry|Patients at the Institute for Family Health who have a diagnosis of depression active on their problem list or have had a diagnosis of depression used as an encounter diagnosis in the past year or patients with a PHQ-9 score greater than or equal to 10.
88946966|NCT01913288|Experimental|Biological Maternal Sounds|Daily Exposure to recorded mother's voice and heartbeat sounds via audio systems installed at the bedside
88946967|NCT01913288|Sham Comparator|Hospital Sounds|Exposure to standard hospital sounds; routine care.
88946968|NCT01913301|Experimental|Alagebrium|
88946969|NCT01913366|Experimental|CM-PST|If you are assigned to CM-PST, you will be working with the same care manager from your introductory session. The care manager will continue to work with you on your problem-solving plan. Additionally, you will receive case management services.
88946970|NCT01913366|Experimental|SG-PST|If you are assigned to SG-PST, you will continue to work on your problem-solving plan, using the self-guided materials provided to you during the introductory session. Additionally, you will be partnered with a senior peer counselor who will support you in your SG-PST efforts.
88946971|NCT01913379|Experimental|1: MDV3100|
88946972|NCT01913379|Experimental|2: MDV3100 and gemfibrozil|
89537285|NCT03066141||CAD without OSA|coronary artery disease without Obstructive sleep apnea
88946973|NCT01913379|Experimental|3: MDV3100 and itraconazole|
88946974|NCT01913392||morbidly obese, chronic renal disease|adult patients (> 18 years) who have stage 4 or 5 chronic renal disease (CrCl < 30 ml/min) who are being considered for possible future kidney transplantation. The study inclusion criteria are an indication for laparoscopic sleeve gastrectomy (BMI > 40 kg/m2, or BMI > 35 with at least one co-morbidity such as hypertension, dyslipidemia or diabetes)
88946975|NCT01913418|Active Comparator|Suan-Zao-Ren Tang|The SZRT formula used in this study is manufactured as a herbal extract powder from the good manufacturing procedures (GMP) of the certified company Kaiser Pharmaceutical Co., Ltd. (Taiwan). Granules were packed in aluminum foil packages and administered orally at a dose of 4 g, three times per day for four weeks.
89537286|NCT02466035|Experimental|Lactobacillus GG|Treatment with Lactobacillus rhamnosus GG
89468334|NCT03610087|Other|Low Intensity Intervention|The comparison group (low intensity) receives access to the e-platform and given an educational package with information about nutrition, physical activity, and smoking based on the NAVIGATE program (Mueser et al., 2015); i.e., a comprehensive program for implementing coordinated speciality care) with weekly e-mail reminders for 12 weeks. Participants receive access to online resources and free online webinars about these healthy behaviours.
89018591|NCT02234934|Experimental|Lentiviral G1XCGD Gene Therapy, Part A|Transplantation with autologous CD34+ stem cells corrected with X1XCGD lentiviral vector after myeloreductive conditioning
89018592|NCT02234934|Experimental|Lentiviral G1XCGD Gene Therapy, Part B|Transplantation with autologous CD34+ stem cells corrected with X1XCGD lentiviral vector after modified myeloreductive conditioning including increased monitoring and rescue treatment
89018594|NCT02175004|Experimental|Previous Placebo-Inotersen 300 mg|Participants received subcutaneous (SC) doses of 300 milligrams (mg) inotersen once weekly for up to 260 weeks. Participants who received inotersen-matching placebo in the previous study- ISIS 420915-CS2 (NCT01737398) were included in this group.
89018595|NCT02175004|Experimental|Previous Inotersen-Inotersen 300 mg|Participants received SC doses of 300 mg inotersen once weekly for up to 260 weeks. Participants who received inotersen in the previous study- ISIS 420915-CS2 were included in this group.
89018596|NCT02143050|Experimental|Dabrafenib, Trametinib and Metformin|Dabrafenib 150 mg PO BID until progression or unacceptable toxicity. Trametinib 2 mg PO QD until progression or unacceptable toxicity. Metformin 500 mg PO BID x 2 weeks, then 850 mg PO BID until progression or unacceptable toxicity.
89018597|NCT01957956|Experimental|Treatment (vaccine therapy and temozolomide)|"COURSE 1: Patients receive temozolomide PO daily on days 1-5.~COURSES 2-3: Patients receive temozolomide PO daily on days 1-5 and malignant glioma tumor lysate-pulsed autologous dendritic cell vaccine ID on days 1, 3, and 5.~COURSES 4-6: Patients receive temozolomide PO daily on days 1-5 and malignant glioma tumor lysate-pulsed autologous dendritic cell vaccine ID on day 1.~COURSES 7-12: Patients receive malignant glioma tumor lysate-pulsed autologous dendritic cell vaccine ID on day 1.~Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
89018598|NCT01863550|Experimental|Arm A (bortezomib, lenalidomide, dexamethasone)|Patients receive bortezomib SC or IV on days 1, 4, 8, and 11 of courses 1-8 and days 1 and 8 of courses 9-12; lenalidomide PO daily on days 1-14; and dexamethasone PO daily on days 1, 2, 4, 5, 8, 9, 11, and 12 of courses 1-8 and days 1, 2, 8, and 9 of courses 9-12. Treatment repeats every 3 weeks for 12 courses in the absence of disease progression or unacceptable toxicity.
89018599|NCT01863550|Experimental|Arm B (carfilzomib, lenalidomide, dexamethasone)|Patients receive carfilzomib IV over 30 minutes on days 1, 2, 8, 9, 15, and 16; lenalidomide PO daily on days 1-21; and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 4 weeks for 9 courses in the absence of disease progression or unacceptable toxicity.
89018600|NCT01863550|Experimental|Arm C (lenalidomide)|Patients receive lenalidomide PO daily on days 1-21. Treatment repeats every 4 weeks for 24 courses in the absences of disease progression or unacceptable toxicity.
89018601|NCT01863550|Experimental|Arm D (lenalidomide)|Patients receive lenalidomide PO daily on days 1-21. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
89018602|NCT01620203||Control|Matched group of control infants without diagnosis of intracranial hemorrhage
89018603|NCT01620203||Intracranial Hemorrhage|Group of preterm infant with diagnosis of intracranial hemorrhage.
89018604|NCT01465490|Experimental|Monitoring and Feedback Intervention|
89018605|NCT01465490|No Intervention|Treatment as usual|
89018606|NCT01334983|Experimental|REST|Participants instructed in individualized Rapid Easy Strength Training and pedometer-based walking programs
89018607|NCT01334983|No Intervention|Wait list control|Participants instructed in REST after completing week 8 outcome measures
89018608|NCT00866957||Patients with liver cancer|Patients diagnosed with liver cancer
89018609|NCT00091637|Placebo Comparator|1|Placebo infusion
89018610|NCT00091637|Experimental|2|Pexelizumab infusion
89018611|NCT02960633|Active Comparator|THA with Collar|THA with Collar
89018612|NCT02960633|Active Comparator|THA without Collar|THA without Collar
89018613|NCT01059825|Placebo Comparator|Placebo|Placebo for ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to sitagliptin, oral, once daily for 84 days
89537287|NCT02466035|No Intervention|Other formula|Children assuming other hypoallergenic formulas
89537288|NCT05728593|Active Comparator|study group|Participants (n=15) were randomly selected by the researchers using the coin toss method, and thus the participants were divided into two groups as study (n=8) and control group (n=7) The study group received parent-based occupational therapy, while the control group received standard occupational therapy.
89018614|NCT01059825|Experimental|Ertugliflozin 1 mg|Ertugliflozin 1 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days
89018615|NCT01059825|Experimental|Ertugliflozin 5 mg|Ertugliflozin 5 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days
89018616|NCT01059825|Experimental|Ertugliflozin 10 mg|Ertugliflozin 10 mg, placebo for ertugliflozin (25 mg), and placebo to sitagliptin, oral, once daily for 84 days
89018617|NCT01059825|Experimental|Ertugliflozin 25 mg|Ertugliflozin 25 mg, placebo for ertugliflozin (1 mg or 5 mg), and placebo to sitagliptin, oral, once daily for 84 days
89018618|NCT01059825|Active Comparator|Sitagliptin 100 mg|Sitagliptin 100 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), oral, once daily for 84 days
89018619|NCT00288899|Other|Arm 1|standard VA surgical iMedConsent process
89018620|NCT00288899|Experimental|Arm 2|enhanced version of VA surgical iMedConsent process (repeat-back)
89018621|NCT00321867|Active Comparator|1|Native tissue repair
89018622|NCT00321867|Experimental|2|Posterior repair with graft
89018623|NCT00288977|Experimental|islet cell transplant|
89018624|NCT00323076|Experimental|1|18F-FAZA PET Imaging
89018625|NCT00289055|Experimental|1|Cordis SMART™ Nitinol Stent
89018626|NCT00289055|Active Comparator|2|balloon angioplasty
89018627|NCT00289523||Escitalopram|
89018628|NCT00289523||Bupropion XL|
89018629|NCT00289523||Combination Therapy|Escitalopram and Bupropion XL
88946976|NCT01913418|Placebo Comparator|Suan-Zao-Ren Tang placebo|The Suan-Zao-Ren Tang placebo granules are prepared with 4 g starch inside the same colored and sized foil packages.
89468335|NCT03610087|Experimental|High Intensity Intervention|The intervention group (high intensity) receives a technology-enabled CCM intervention. Participants receive access to an online platform and infographic modules to learn more about nutrition, physical activity, and smoking cessation. Also, they are assigned a personal health coach who collaboratively schedules weekly virtual sessions via the platform to discuss the educational materials, goal setting and motivation, and provide support in the 12-week program. The participant's health coach reviews the participant's concerns and goals weekly with a virtual care team (VCT; including a psychiatrist, addictions specialist, nutrition specialist, peer mentor, and recreational therapist), who provides individualized recommendations to include in the participant's treatment plan. Participants have access to online resources and online webinars about nutrition, physical activity and smoking.
89468336|NCT02330900|No Intervention|Study group|Evaluation of interference
89468337|NCT03861039|Experimental|5 mg Tirzepatide|5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week. Participant received the following pre-treatment oral antihyperglycemic medication (OAM): Sulfonylurea, biguanide, alpha-glucosidase inhibitor, thiazolidinedione, glinide, or sodium-glucose cotransporter type 2 inhibitor.
89468338|NCT03861039|Experimental|10 mg Tirzepatide|10 mg tirzepatide administered SC once a week. Participant received the following pre-treatment oral antihyperglycemic medication (OAM): Sulfonylurea, biguanide, alpha-glucosidase inhibitor, thiazolidinedione, glinide, or sodium-glucose cotransporter type 2 inhibitor.
89468339|NCT03861039|Experimental|15 mg Tirzepatide|15 mg tirzepatide administered SC once a week. Participant received the following pre-treatment oral antihyperglycemic medication (OAM): Sulfonylurea, biguanide, alpha-glucosidase inhibitor, thiazolidinedione, glinide, or sodium-glucose cotransporter type 2 inhibitor.
89468340|NCT04365673||Readmitted|Patients that were readmitted within 30 days post hospital discharge
89468341|NCT04365673||Not readmitted|Patients that were not readmitted within 30 days post hospital discharge
89468342|NCT02334176|Active Comparator|single injection|Axillary plexus block performed with single injection dorsally to the artery
89468343|NCT02334176|Active Comparator|Double injection|Axillary plexus block performed with 2 injections: one over musculocutaneous nerve the second one dorsally to the artery
89468344|NCT02236975|Experimental|BuMA Supreme Biodegradable drug coating coronary stent system|Implant BuMA Supreme stent only
88946977|NCT01913431|Experimental|Baracle Tab.®|(It can be also placebo) dosage: 2 tablets daily for 48 weeks
88946978|NCT01913431|Experimental|Baraclude Tab.®|(It can be also placebo) dosage: 2 tablets daily for 48 weeks
88946979|NCT01913444|Experimental|Recombinant Antithrombin Infusion|The initial loading dose and maintenance continuous infusion will be calculated according to the following equations which are based on the patient's baseline AT activity level prior to ECMO. Loading dose(IU)=(100-baseline AT activity)/2.3 x Wt(kg). Maintenance Dose(IU/hour)=(100-baseline AT activity)/10.2 x Wt(kg). The loading dose will be administered as a 15-minute IV infusion once the patient is on ECMO. This will be followed by the maintenance continuous infusion. AT levels will be checked 2hours after the initiation of treatment. For AT levels that are <80% or >100%, the infusion rate will be increased or decreased, respectively, by 30% and a follow-up level will be checked 2hours after the adjustment. If the AT level is within goal range (80-100%), follow-up AT levels will be checked every 6hours unless dose adjustments are made. Once the patient is off ECMO, the continuous infusion will be discontinued and AT levels will no longer be checked.
88946980|NCT01913496|Placebo Comparator|Standard care|standard care ,without the web application ebalance
88946981|NCT01913496|Active Comparator|ebalance|using the ebalance application for 14 weeks
89468345|NCT02236975|Active Comparator|Resolute Integrity durable polymer stent system|Implant Resolute stent
88946982|NCT01913509|Experimental|Combined Therapy of FES and BAT|Patients with hemiplegic shoulder pain is applied functional electrical stimulation and bilateral arm training (FES-BAT) one hour daily, 3 days per week for 4 weeks and a total of 12 sessions to stimulate the supraspinatus muscle and the posterior deltoid muscle of the affected arm.
88946983|NCT01913509|Active Comparator|Conventional Rehabilitation|The stroke patients in CR group receive a structure protocol using electrical modality such as transcutaneous electrical nerve stimulation (TENS) and bilateral arm training (TENS-BAT) one hour daily, 3 days per week for 4 weeks and a total of 12 sessions.
88946984|NCT01913522|Experimental|Standard cryoablation|"Patients randomized to the standard group will undergo cryoablation with target duration of 240 seconds. Once PVI is achieved a single bonus application of 240 seconds will be delivered after the rewarming phase (to +20oC)."
89468346|NCT02338856|Experimental|MB12066 200mg|
89468347|NCT02338856|Placebo Comparator|Placebo|
88946985|NCT01913522|Active Comparator|Irrigated RF Ablation|Patients randomized to irrigated RF group will undergo standard wide circumferential PVI with an irrigated radiofrequency catheter
89468348|NCT03609931||Mitral Valve repair|Patients undergoing mitral valve repair
89468349|NCT02338778|Active Comparator|Control|Patients in this group will be receiving standard treatment according to National Comprehensive Cancer Network (NCCN) guide line
89468350|NCT02338778|Experimental|MV+control|Patients in this group will be receiving both standard treatment according to NCCN guide line and simultaneous injection of mix vaccine (MV)
88946986|NCT01913522|Experimental|Short Cryoablation|"Patients randomized to the multiple-freeze group will undergo cryoablation with target duration of 120 seconds. Once PVI is achieved a single bonus application of 120 seconds will be delivered after the rewarming phase (to +20oC)."
89018630|NCT00323661|Experimental|1|Rate-adaptation by Closed Loop Stimulation
89018631|NCT00323661|Active Comparator|2|Accelerometer based pacing rate adaptation
89468351|NCT03609307|Active Comparator|injection Combined Intravitreal bevacizumab and propranolol|patients receive two injections at each session Bavacizumab
89468352|NCT03609307|Active Comparator|injection Intravitreal bevacizumab|patients receive only Bevacizumab
89468353|NCT03399435|Experimental|Part A|8 cohorts are planned to be treated.
89468354|NCT03399435|Experimental|Part B|Part B will start at the earliest after 4 cohorts of Part A have been treated. Up to 8 cohorts are planned to be treated.
89468355|NCT03399435|Experimental|Part C|Part C will comprise 4 treatment groups. The neosaxitoxin dose will be the same in all 4 treatment groups.
89468356|NCT02338700|Active Comparator|Control|Patients in this group will be receiving standard treatment according to National Comprehensive Cancer Network (NCCN) guide line
89468357|NCT02338700|Experimental|MV+control|Patients in this group will be receiving both standard treatment according to NCCN guide line and simultaneous injection of mix vaccine (MV)
89468358|NCT01936688|Experimental|MK-3222 200 mg + Placebo to Etanercept|MK-3222 200 mg subcutaneously (SC) on Weeks 0, 4, 16, and 28 and, optionally, every 12 weeks thereafter until Week 220, plus etanercept placebo twice weekly up to Week 12, and then once weekly through Week 28.
89468359|NCT01936688|Experimental|MK-3222 100 mg + Placebo to Etanercept|MK-3222 100 mg SC on Weeks 0, 4, 16, and 28 and, optionally, every 12 weeks thereafter until Week 220, plus etanercept placebo twice weekly up to Week 12, and then once weekly through Week 28.
89468360|NCT01936688|Placebo Comparator|Placebo to MK-3222 + Placebo to Etanercept|Placebo to MK-3222 administered SC on Weeks 0 and 4 plus etanercept placebo twice weekly up to Week 12, then once weekly up to Week 28. Participants will be re-randomized 1:1 at Week 12 to receive MK-3222 high dose or MK-3222 low dose on Weeks 12, 16, and 28 and, optionally, every 12 weeks thereafter through Week 220.
89468361|NCT01936688|Active Comparator|Placebo to MK-3222 + Etanercept 50 mg|Matching placebo to MK-3222 SC on Weeks 0 and 4 and etanercept 50 mg twice weekly up to Week 12 and then once weekly through Week 28.
89468362|NCT03399357||≥ 65 Years old|Healthy community-dwelling elderly (men and women) age 65 and above who are eligible for influenza vaccine and fulfil inclusion and exclusion criteria
89468363|NCT04446663|Experimental|Toripalimab+induction chemotherapy +CCRT|"Patients will receive induction chemotherapy with Albumin-bound paclitaxel (260 mg/m2, d1 of every cycle) and cisplatin (80mg/m2, d1 of every cycle), every 3 weeks for 3 cycles before radiotherapy.~Then patients will receive definitive intensity-modulated radiotherapy (IMRT) of ≥66 Gy（2-2.2Gy/fx）.Concurrent cisplatin of 100mg/m2 will be administered every 3 weeks for 2 cycles during IMRT .~Toripalimab 240mg will be given every 3 weeks for 6 cycles, started on day 1 of induction chemotherapy"
89468364|NCT04446663|Active Comparator|induction chemotherapy +CCRT|"Patients will receive induction chemotherapy with Albumin-bound paclitaxel (260 mg/m2, d1 of every cycle) and cisplatin (80mg/m2, d1 of every cycle), every 3 weeks for 3 cycles before radiotherapy.~Then patients will receive definitive intensity-modulated radiotherapy (IMRT) of ≥66 Gy（2-2.2Gy/fx）.Concurrent cisplatin of 100mg/m2 will be administered every 3 weeks for 2 cycles during IMRT ."
89468365|NCT01861496|Experimental|LiPlaCis|Dose escalation of LiPlaCis - a liposomal formulation of cisplatin will be administered intravenously in cycles every 3 weeks on day 1, day 8. Upon the investigator's judgement the patient may continue treatment for more than 3 cycles when benefiting from the study drug.
89468366|NCT03399279|Experimental|Open flap debridement & perforated&Nano|Perforated collagen membrane and nano-hydroxyapatite and open flap debridement
89468367|NCT03399279|Active Comparator|Open flap debridment &Occlusive&Nano|Occlusive membrane and nano-hydroxyapatite and open flap debridement
89468368|NCT02333942||Alzheimer's Disease|Nautilus NeuroWaveTM System'
89468369|NCT02333942||Mild Cognitive Impairment|Nautilus NeuroWaveTM System'
89468370|NCT02333942||Frontotemporal Lobar Degeneration|Nautilus NeuroWaveTM System'
89468371|NCT02333942||Age-Matched Controls|Nautilus NeuroWaveTM System'
89468372|NCT02334020|Experimental|Training course|12 hour training course in Mental Health First-aid
89468373|NCT02334020|Other|Waiting list|Waiting list design, hence delayed offering of Mental Health First-aid
89468374|NCT02520219|Experimental|GDP+Endostar|"Patients in this group will be given conventional chemotherapy medicine:~GDP (gemcitabine+dexamethasone+cis-platinum)chemotherapy by treatment guidelines for Peripheral T-cell Lymphoma and Endostar."
89468375|NCT02520219|Active Comparator|GDP|"Patients in this group will be given conventional chemotherapy medicine:~GDP (gemcitabine+dexamethasone+cis-platinum) chemotherapy by treatment guidelines for Peripheral T-cell Lymphoma."
89468376|NCT02333786|Experimental|Infant|Radial artery or posterior tibial artery of patients younger than 1 year old are either cannulated with short-axis/out-of-plane or long-axis/in-plane US-guided arterial catheterization technique.
89468377|NCT02333786|Experimental|Preschool child|Radial artery or posterior tibial artery of patients older than 1 year old and younger than 5 years old are either cannulated with long-axis/in-plane or short-axis/out-of-plane US-guided arterial catheterization technique.
89468378|NCT02334098|Experimental|Omega-3 supplemented drink|A 200 ml. drink product with 1.1 grams of omega-3 from Smartfish (Smartfish: Forsiden in Norway).
89468379|NCT02334098|Placebo Comparator|Placebo Drink|exactly the same fruit drink contained in the same packaging, but will contain no omega-3.
89468380|NCT02334098|No Intervention|treatment-as-usual controls|No drinks are taken.
89468381|NCT03394287|Experimental|SHR-1210 +Apatinib daily dosing|SHR-1210 200mg(3mg/kg for patient whose weight is below 50kg) iv Q2W combination With Apatinib 250mg, po, daily dosing (d1-d14)
89468382|NCT03394287|Experimental|SHR-1210+Apatinib intermittent dosing|SHR-1210 200mg (3mg/kg for patient whose weight is below 50kg) iv Q2W combination With Apatinib 250mg, po, intermittent dosing(Continuous administration for 7 days every 14 days, d1-d7)
88946987|NCT01913548||Sickle Cell Disease (SCD)|Patients with sickle cell diseases, 16 years or older with 10-20 years of transfusion (defined as 0.2-0.6mg Fe/kg/day exposure with annual ferritin levels greater than 2500 in at least 60% of years of chronic transfusion); 0 to 9 years old at the initiation of chronic transfusions; no exchange transfusions in the previous 6 months; and iron overload documented by either liver biopsy, MRI or SQUID with estimated LIC (liver iron content) of greater than 7 mg/g dry wt in the previous 6 months or ferritin level greater than 1500mg/dl.
89468383|NCT02338622|Experimental|Schedule A: 4 days on, 3 days off|"300mg olaparib + intrapatient dose escalation of AZD5363 4 days on, 3 days off~Schema for dose escalation in schedule A (4-days-on, 3-days-off AZD5363)~-1. Olaparib: 200mg, AZD5363 240mg~Olaparib: 300mg, AZD5363 320mg~Olaparib: 300mg, AZD5363 400mg~Olaparib: 300mg, AZD5363 480mg"
89468384|NCT02338622|Experimental|Schedule B: 2 days on, 5 days off|"300mg olaparib + intrapatient dose escalation of AZD5363 2 days on, 5 days off~Schema for dose escalation in schedule B (2-days-on, 5-days-off AZD5363)~-1. Olaparib: 200mg, AZD5363 400mg~Olaparib: 300mg, AZD5363 480mg~Olaparib: 300mg, AZD5363 560mg~Olaparib: 300mg, AZD5363 640mg"
89468385|NCT02338466|Placebo Comparator|rt-PA|"Patients treated by thrombolysis with rt -PA within 4h30 of the onset of symptoms to a proximal middle cerebral artery occlusion visible on a MRI 1 are pre- included. A second MRI ( IRM2 ) is performed between 1 hour and 1.5 hours after administration of rt-PA in the usual way .~After the treatment by rt-PA, if there is no recanalization (TIMI score: 0,1, 2a), the patient is included. A patient included will be randomized either in the arm rt-PA treatment only or in the arm rt-PA + tenecteplase treatment. If he is included in the arm rt-PA only, he will not receive any other treatment for the study."
89468386|NCT02338466|Active Comparator|rt-PA + tenecteplase|"If patient is in the arm rt-PA + tenecteplase, he will receive tenecteplase (50UI/Kg) treatment. A third MRI will be performed at 24hour that will assess the recanalization status (TIMI), the final volume infarct and the hemorrhagic complications."
89468387|NCT03390075||ResearchNow NuVal shoppers|a convenience sample of 665 shoppers at two NuVal chains.
89468388|NCT05099510|Active Comparator|NatrunixTM|Each participant will receive one single subcutaneous injection of 200 mg (Cohort 1), 400 mg (Cohort 2), or 800 mg (Cohort 3) of NatrunixTM.
89468389|NCT05099510|Placebo Comparator|Placebo|Each participant will receive one single subcutaneous injection of placebo.
89468390|NCT03394209|Experimental|Favipiravir+oseltamivir|Favipiravir+oseltamivir will be given twice daily for a 10-day period.
89468391|NCT02333864||PWD testing POGO® BGMS|All enrolled persons with diabetes
89468392|NCT03399201|Active Comparator|General Anesthesia|Standard General Anesthesia will be applied.The change of the pulmonary functions will be evaluated via spirometer.
88946988|NCT01913548||Thalassemia Major (TM)|Patients with β-thalassemia major and transfusion-dependent E-beta THAL. 16 years or older with 10-20 years of chronic transfusion (defined above), 0 to 9 years old at the initiation of chronic transfusions, iron overload documented by either liver biopsy, MRI or SQUID with estimated LIC of greater than 7 mg/g dry wt in the previous 6 months.
88946989|NCT01913548||Diamond Blackfan Anemia (DBA)|Patients with DBA, 16 years or older with 10-20 years of transfusion, 0 to 9 years old at the initiation of chronic transfusions, iron overload documented by either liver biopsy, MRI or SQUID with estimated LIC of greater than 7 mg/g dry wt in the previous 6 months.
88946990|NCT01913561|Experimental|Master Caution Garment|"each patient will be connected simultaneously with two devices:~ECG gel electrodes~Master Caution Garment textile electrodes The two devices will be connected to hospital ECG telemetry."
88946991|NCT01913613|Experimental|Treatment|Treatment with the IASD device
88946992|NCT01913626|Experimental|cognitive group therapy|patient with subjective memory complains will participate in cognitive group therapy including eight meetings of practicing cognitive strategy to improve the memory .
88946993|NCT01913652|Experimental|Cabazitaxel|"INN: Cabazitaxel Cabazitaxel will be administered at a dose of 25 mg/m² by intravenous infusion, over 1 hour, on day 1 of each 21 day cycle.~Treatment should be administered until disease progression, unacceptable toxicity or patient's refusal."
88946994|NCT01913665|Active Comparator|B.Lactis|children with functional constipation
88946995|NCT01913665|Active Comparator|Inulin|children with functional constipation
88946996|NCT01913665|Active Comparator|B.Lactis+ınulin|children with functional constipation
89468393|NCT03399201|Active Comparator|Neuraxial Anesthesia|Neuraxial anesthesia will be applied. The change of the pulmonary functions will be evaluated via spirometer.
88946997|NCT01913665|Placebo Comparator|plasebo|children with functional constipation
88946998|NCT01913678|Active Comparator|Inulin|The participants will be given all dietary items in their diet. In the inulin arm, approximately 15 grams of inulin will be included in the diet.
88946999|NCT01913678|Active Comparator|Whole milk|The participants will be given all dietary items in their diet. In the whole milk arm, approximately 1 liter of whole milk will be included in the diet.
89202157|NCT00931905|Experimental|Homeopathic medication Plumbum metallicum|The homeopathic medication Plumbum metallicum 15CH was used, and was diluted and dynamized using the Hahnemann centesimal scale, whose matrix was obtained from the Schraiber laboratory in 4CH in 70% ethanol. From this solution, the matrix was elevated to 14CH in 70% ethanol. The 15CH dynamization was prepared in 30% ethanol, which was the recommended solution for administration.
89202158|NCT00931905|Placebo Comparator|hydroalcoholic solution|The placebo was composed of a hydroalcoholic solution also prepared in 30% ethanol.
89202159|NCT02561468|Experimental|Nefopam|20 mg nefopam in 100 ml normal saline is infused before starting operation.
89202160|NCT02561468|Placebo Comparator|Control|100 ml normal saline is infused before starting operation.
89202161|NCT02555748|Active Comparator|Pazopanib|"The daily dose of pazopanib will be the standard dose i.e. 800 mg once a day (2 tablets of 400 mg in one oral administration per day) administered each day, continuously, during the treatment phase (complete cycle will be defined as a 6-week period).~During the first stage of the study (Part I), adjustment of drug dose will be made according to individual patient tolerance to treatment evaluated by clinical and biological monitoring; During the second stage of the study (Part II), dose modification should also be performed according to individual patient tolerance to treatment evaluated by clinical and biological monitoring ans also by using the new Pharmacokinetic-Pharmacodynamic (PK-PD) Algorithm elaborated during the first part."
89468394|NCT02331056||thoracoscopic pulmonary lobectomy|to observe a fluid responsiveness in patients who receives scheduled thoracoscopic pulmonary lobectomy
89468395|NCT02331056||open pulmonary lobectomy(thoracotomy)|to observe a fluid responsiveness in patients who receives scheduled open pulmonary lobectomy(thoracotomy)
88947000|NCT01913678|Placebo Comparator|Complete diet|The participants will be given all dietary items in their diet.
89202162|NCT02555748|Active Comparator|Sunitinib|"Sunitinib will be administered at the standard dose of 50 mg, once daily during 4 consecutive weeks, followed by a wash-out period of 2 weeks (corresponding to a complete cycle of 6 weeks).~During the first stage of the study (Part I), dose adjustment of drug dose will be made according to individual patient tolerance to treatment evaluated by clinical and biological monitoring; During the second stage (Part II), dose modification should also be performed according to individual patient tolerance to treatment evaluated by clinical and biological monitoring ans also by using the new Pharmacokinetic-Pharmacodynamic (PK-PD) Algorithm elaborated during the first part."
89202163|NCT04014933||open-angle glaucoma|patients with a diagnosis of open-angle glaucoma, i.e. untreated IOP >21mmHg plus glaucomatous disc changes and/or visual field defects typical for glaucoma
89202164|NCT04014933||normal tension glaucoma|patients with a diagnosis of normal tension glaucoma, i.e. untreated IOP </=21mmHg plus glaucomatous disc changes and/or visual field defects typical for glaucoma
89202165|NCT04014933||healthy controls|individuals with normal optic disc and IOP </21mmHg and normal visual fields
89202166|NCT00751946|Active Comparator|1|12 weekly sessions of one-to-one TARGET (psychotherapy)
89202167|NCT00751946|Active Comparator|2|12 weekly sessions of one-to-one ETAU (psychotherapy)
89202168|NCT04059614|Active Comparator|"High flow nasal cannula (HFNC)"|"HFNC group: those who receive high-flow nasal cannula therapy"
89202169|NCT04059614|Experimental|conventional oxygen therapy (COT)|COT group: those who receive conventional oxygen therapy group
89468396|NCT02520453|Experimental|Durvalumab|Durvalumab 20 mg/Kg IV Q 4 weeks for 1 year, or until disease relapse or unacceptable toxicity
89468397|NCT02520453|Placebo Comparator|Placebo|Placebo Q 4 weeks for 1 year, or until disease relapse or unacceptable toxicity
89468398|NCT02331212||Ancillary-correlative (role of HAS2+ in CSCs)|Blood and bone marrow samples are collected and analyzed via flow cytometry and PCR. Cells are also transplanted into mice and studied.
89468399|NCT03399123|Experimental|Low tidal volume group|Use a low tidal volume(6'8ml/kg) ventilation mode during liver segmentation。
89202170|NCT00930345|Other|SUTENT before nephrectomy|
89202171|NCT00786006|Experimental|Arm 1|FOLFIRI.3
89202172|NCT00786006|Active Comparator|Arm 2|FOLFOX
89202173|NCT02562326|Experimental|BioChaperone insulin lispro|
89202174|NCT02562326|Active Comparator|Humalog®|
89202175|NCT00930501||Cancer patients|women 5-45 yr olf pre and post chemotherapy
89202176|NCT00783120|Experimental|1|10 Hz rTMS of left dorsolateral prefrontal cortex (DLPFC) (15 sessions/3 weeks, 1000 stimuli per session, stimulation intensity 110 % related to the individual resting motor threshold).
89202177|NCT00783120|Sham Comparator|2|placebo (sham)-rTMS of left DLPFC (15 sessions/3 weeks, 1000 stimuli per session)
89202178|NCT00746720|Experimental|A, 1|Study part 1 (n = 8)
89468400|NCT03399123|Active Comparator|Standard tidal volume group|Use a standard tidal volume(10'12ml/kg) ventilation mode during operation.
89468401|NCT02330744|Experimental|Approach-positive AAT|Computerized AAT procedure designed to increase automatic approach responses for positive social cues.
89468402|NCT02330744|Placebo Comparator|Control AAT|Computerized AAT procedure in which there is no contingency between arm movement and positive social cues.
89468403|NCT05043428|Experimental|Intervention Group|Those randomized to the intervention group will be asked to attend 16 online sessions (2 session/week). Each session will last one hour (total time: 16 hours. The exercise portion will be approximately 30 minutes of each session and led by a certified kinesiologist. These exercises are based on activities related to your daily life. As well, they will take part in peer support sessions. The peer support session will be approximately 30 minutes and be moderated by a behaviour change specialist who will also provide strategies to be active. In this peer support group, particpants will share and learn from other individuals living with COPD to help you stay active during and after the intervention. The online sessions will be video recorded to make sure that the program is delivered as designed.
89531380|NCT03336281||Participants with Psoriatic Arthritis: Rheumatologist Cohort|Participants who will receive ustekinumab (as a first or second line of bDMARD therapy) along with other co-medications as per clinical rheumatologist's discretion will be observed in this study. Ustekinumab will not be provided by the sponsor. The treatment by ustekinumab must have been decided by the physician prior to the decision to include the participant in the study. Only data available from a participant's source medical records will be collected. Additionally investigators will be asked to obtain (or record where available) PRO data from participants participating in this study.
89018632|NCT00289796|Active Comparator|Infanrix hexa Group|Subjects received a dose of hepatitis B vaccine at birth followed by immunization with 3 doses of Infanrix hexa™ (2, 4 and 6 months of age) and one booster dose of Infanrix hexa™ between 12 and 23 months of age. All vaccines were administered by deep intramuscular injection into the left anterolateral thigh.
89202179|NCT00746720|Placebo Comparator|A, 2|Study part 1 (n = 4)
89018633|NCT00323895|Experimental|1|group with intra-Cypher™ restenosis
89018634|NCT00323895|Active Comparator|2|group with intra-Taxus™ restenosis
89468404|NCT05043428|Active Comparator|Control Group|Those randomized to the control group will be asked to participate in an 8-week exercise program based on the exercise component of a standard home-based pulmonary rehabilitation program. During week 1 of the program, participants will receive a videocall via Microsoft Teams from the certified kinesiologist who will prescribe an exercise program, supervise the first exercise session, and provide a copy of Living Well with COPD, a list of strength exercises, and a home exercise diary. In weeks 2-8, participant exercises will be performed offline, on their own. Participants will be encouraged to engage in two or more exercise sessions per week, targeting both aerobic capacity and muscular strength, and document their exercise using a home diary. They will also receive a phone call once a week from the certified kinesiologist to discuss their exercise progress.
89468405|NCT02338388|Active Comparator|Single-layer unlocked closure|
89468406|NCT02338388|Active Comparator|Single-layer locked closure|
89468407|NCT02338388|Active Comparator|Double-layer closure|The first layer was continuous and unlocked and a second, continuous non-locking imbricating layer was applied over the first suture.
89468408|NCT02731755|Active Comparator|Oat intervention|67.7g oatflake and 22.5g oatbran concentrate - single intake (mixed with water)
89468409|NCT02731755|Placebo Comparator|Control|39.4g cream of rice, 6.1g sunflower oil, 29.5g skimmed milk, 5.6g pectin powder, 6.5g cellulose and mixed with water
89468410|NCT03389841|Active Comparator|Intervention|Education of the caregiver
89468411|NCT03389841|No Intervention|No intervention|Usual care
89468412|NCT03389763|Experimental|SPI-guided remifentanyl|remifentanyl solution will be administered intravenously at a rate 0,25 mcg/kg of body weight/minute, SPI will be monitored on-line; when delta SPI>15, infusion speed of remifentanyl will be increased by 50%
89468413|NCT03389763|Experimental|PRD-guided remifentanyl|solution remifentanyl solution will be administered intravenously at a rate 0,25 mcg/kg of body weight/minute, PRD measurement every 15 minutes; when PRD>5% infusion speed of remifentanyl will be increased by 50%
88947001|NCT01913704|Placebo Comparator|Placebo device|"The placebo comparator is a placebo version of the active device which is a system to deliver oxygen from an oxygen generator topically to the wound bed via a proprietary device.~The device will be applied to the wound and attached to the placebo oxygen generator and the generator switched on at the time of enrolment. Secondary dressings will then be applied. The device will be removed and reapplied at each dressing change for a treatment period of 6 weeks."
89468414|NCT03389763|Experimental|BBS-guided remifentanyl|BBS assessment every 5 minutes, solution remifentanyl solution will be administered intravenously at a rate 0,25 mcg/kg of body weight/minute; when BBS>2, infusion speed of remifentanyl will be increased by 50%
89468415|NCT01704404|Experimental|Dose 1 TD-4208|22 µg
89468416|NCT01704404|Experimental|Dose 2 TD-4208|44 µg
89468417|NCT01704404|Experimental|Dose 3 TD-4208|88 µg
89468418|NCT01704404|Experimental|Dose 4 TD-4208|175 µg
89468419|NCT01704404|Experimental|Dose 5 TD-4208|350 µg
88947002|NCT01913704|Active Comparator|NatroxTM Device|"A system to deliver oxygen from an oxygen generator topically to the wound via a proprietary device.~The NatroxTM oxygen delivery device will be applied to the wound and attached to the NatroxTM oxygen generator which will be switched on at the time of first dressing application at enrolment. Secondary dressings will then be applied. The device will be removed and reapplied at each dressing change for a treatment period of 6 weeks."
88947003|NCT01913743||MINDSETS|overweight/obese
88947004|NCT01913756|Experimental|Gouda-type cheese|80 g/day Gouda-type cheese
88947005|NCT01913756|No Intervention|Low cheese intake|
88947006|NCT01913756|Experimental|Gamalost (Norwegian traditional cheese)|50 g/day Gamalost
89468420|NCT01704404|Experimental|Dose 6 TD-4208|700 µg
89468421|NCT01704404|Placebo Comparator|Placebo|Placebo
89468422|NCT02866175|Experimental|Edoxaban Regimen|Participants will be randomized to receive edoxaban 60 mg once-daily or 30 mg once-daily and clopidogrel 75 mg once-daily (or in the presence of a documented clinical need prasugrel [5 mg or 10 mg once-daily] or ticagrelor [90 mg twice-daily] may be used) used.
89468423|NCT02866175|Active Comparator|Vitamin K Antagonist Regimen|Participants will be randomized to receive VKA in combination with clopidogrel 75 mg once-daily (or in the presence of a documented clinical need prasugrel [5mg or 10 mg once-daily] or ticagrelor [90 mg twice-daily] may be used) and aspirin (100 mg once-daily, for a minimum of 1 month and up to 12 months duration.
89468424|NCT03399045|Experimental|9-minute withdrawal group|Patients in 9-minute withdrawal group will be carefully observed for 9 minutes during the colonoscopy withdraw. A stop watch will be utilized to remind endoscopists the withdrawal time. The time to perform polyp biopsy will not be included in the 9 minutes.
89468425|NCT03399045|Active Comparator|6-minute withdrawal group|Patients in 6-minute withdrawal group will be carefully observed for 6 minutes during the colonoscopy withdraw. A stop watch will be utilized to remind endoscopists the withdrawal time. The time to perform polyp biopsy willwill not be included in the 9 minutes.
89468426|NCT02330822|Experimental|Hyaluronic Acid Group|In this Group, Hyaluronic acid will be injected following extraction.
89468427|NCT02330822|No Intervention|Traditional Extraction Group|In this group, traditional extraction procedures will be followed.
88947007|NCT01913769||Radiation therapy|Thoracic cancer patient s/p scheduled RT will be arranged to undergo Thallium-201 Myocardial Perfusion Study. The scheduled RT will be arranged by clinical judgments of radiation-oncologists. All of the patients will receive myocardial SPECT before and after the scheduled RT.
89468428|NCT02333396|Experimental|PICU Supports|Participants will receive the PICU Supports intervention.
88947008|NCT01913782||patients with low back pain|"Patients with disc herniation or radiculitis who are over 18 years of age.~Patients with a history of chronic function-limiting low back pain and lower extremity pain for at least one months' duration.~Patients who are competent to understand the study and provide written informed consent and participate in outcome measurements."
89018635|NCT00323895|Active Comparator|3|group with intra-BMS restenosis
89018636|NCT00289835|Experimental|PCI-stenting|Stenting the moderate SVG lesion with the paclitaxel stent
89468429|NCT02333396|Active Comparator|Educational Brochure|Participants will receive an educational brochure about the pediatric intensive care unit.
89202180|NCT00746720|Experimental|B, 1|Study part 2 (n = 20)
89468430|NCT02338310|No Intervention|No Aromatase Inhibitor|No aromatase inhibitor given around the time of surgery
88947009|NCT01913808|Experimental|Ferric carboxymaltose|Ferric carboxymaltose (Ferinject®, Vifor-France) was given as a single i.v. dose to correct the total iron deficit calculated by the Ganzoni formula (total iron deficit [mg] = 2.4 x patient's weight [kg] x (target Hb [13 g/dL] - current Hb [g/dL]) + 500 [mg iron stores]
88947010|NCT01913808|Active Comparator|Ferrous glycine sulphate|Ferrous glycine sulphate (Ferbisol-Bial Industrial Farmacéutica, Spain) was given as a once daily oral dose of 100 mg iron from the day of discharge (Day 7) to the rehabilitation visit 30 days after surgery
88947011|NCT01913834|Active Comparator|Forsteo|Synthetic PTH 1-34 Single dose Subcutaneous administration 20.0 micrograms
88947012|NCT01913834|Experimental|CP046 PTH CriticalSorb 22.5 R|Synthetic PTH 1-34 Single dose Nasal administration rexam device 22.5 micrograms
88947013|NCT01913834|Experimental|CP046 PTH CriticalSorb 45.0 R|Synthetic PTH 1-34 Single dose Nasal administration rexam device 45.0 micrograms
88947014|NCT01913834|Experimental|CP046 PTH CriticalSorb 90.0 R|Synthetic PTH 1-34 Single dose Nasal administration rexam device 90.0 micrograms
88947015|NCT01913834|Experimental|CP046 PTH CriticalSorb 90.0 O|Synthetic PTH 1-34 Single dose Nasal administration 90 micrograms
88947016|NCT01913847|Experimental|Sildenafil|Sildenafil 20 mg
88947017|NCT01913847|Placebo Comparator|Placebo|Placebo
88947018|NCT01913860|No Intervention|Control|Control group will receive usual care
88947019|NCT01913860|Active Comparator|Improve GP prescribing behaviour|Improve GP prescribing behaviour will be promoted through personalised audit and feedback reports, delivered through face to face workshops within practice.
88947020|NCT01913860|Active Comparator|Improved delayed GP prescribing|Improved delayed GP prescribing will be promoted through the antibiotic prescribing guidelines and personalised audit and feedback reports. Additional scientific evidence will be provided related to delayed prescribing.
88947021|NCT01913873|Experimental|Cardiac biomarkers concentration changes|"In 2012 the Third Global MI Task Force has presented a third universal definition of MI implying that MI associated with CABG is arbitrarily defined by elevation of cardiac biomarkers values > 10x99th percentile URL in patients with normal baseline cTn values (≤ 99th percentile URL), in addition with either (i) new pathological Q waves or new LBBB (left bundle branch block), or (ii) angiographic documented new graft or new native coronary artery occlusion, or (iii) imaging evidence of new loss of viable myocardium or new regional wall motion abnormality.~In this study we will measure the concentration changes over time of cardiac biomarkers (hs-cTN and CK-MB) and establish a threshold value for myocardial injury, diagnosed by ECG and approved -if necessary- by echocardiography."
88947022|NCT01913886|Experimental|MSCs injection|Injection of autologous bone marrow-derived mesenchymal cells
88947023|NCT01913899|Experimental|Mirror therapy|60 minutes of mirror therapy each day over a period of 14 days starting directly post surgically (24-48 hours after surgery)
88947024|NCT01913899|Active Comparator|Occupational/ physical therapy|60 minutes of occupational/ physical therapy each day over a period of 14 days starting 24-48 hours post surgically
88947025|NCT01913925|Active Comparator|Tyrosine-Containing Food Bar|150 mg/kg dose of tyrosine per administration, administered twice
88947026|NCT01913925|Placebo Comparator|Placebo bar|0 mg/kg dose of tyrosine per administration, administered twice
88947027|NCT01913964|Experimental|Acetyl-L-carnitine|2 g daily for 12 months
88947028|NCT01913964|Placebo Comparator|placebo|
88947029|NCT01913990|Other|Arm A: Standard Anti-emetic regimen|"The standard anti-emetic arm:~In this arm the treating medical oncologist will determine the choice of anti-emetic regimen that they perceive the patient would require and prescribe it. The treating physician will be blinded to result of the personalized composite emesis score. The physician may or may not choose to prescribe an NK-1 inhibitor as the study will not predetermine the type of anti-emetics used. In the event that the patient experienced chemo induced nausea and vomiting (CINV), modifications to the initial anti emetic regimen would be left to the treating physician."
88947030|NCT01913990|Experimental|Arm B: Dexamethasone, Ondansetron, Aprepitant|"The emesis risk model arm:~Prior to the start of intravenous chemotherapy an emesis risk score will be calculated for both acute and delayed emesis. The anti-emetic prophylaxis treatment will follow the emesis risk score. Whereby either an acute emesis score of ≥7 and/or a delayed emesis score of >16 will be considered high-risk. The anti-emetics will be prescribed reflecting this risk for pre-chemotherapy, 8 hrs post chemotherapy and day 2-3 post chemotherapy. Dexamethasone, Ondansetron and Aprepitant will be given in different combination and doses depending on what score the participant receives based on their responses to the diary. For subsequent cycle the anti-emetic score will be re-calculated prior to each cycle and the choice of anti-emetics adjusted if necessary."
88947031|NCT01914016|Other|prolonged walk|
88947032|NCT01914042|Experimental|Morphine|Morphine in changing dosages (range between 10-60 mg twice a day). Opioid titration proceeds as follows: starting at an oral dose of 10 mg twice per day, followed every 5 days by a dose increase of 10 mg twice per day until (1) adequate analgesia had been achieved (as determined by the patients), (2) side effects (severe sedation, nausea or vomiting, constipation, sleep disturbances) limited further titration, or (3) a total of 120 mg per day had been reached.
88947033|NCT01914042|Active Comparator|Milnacipran|Milnacipran (Ixel)- a serotonin-norepinephrine reuptake inhibitor (SNRI), will be administrated in changing dosages (range between 12.5-75 mg twice daily). SNRI titration proceeds as follows: starting at an oral dose of 12.5 mg twice per day, followed every 5 days by a dose increase of 12.5 mg twice per day until (1) adequate analgesia had been achieved (as determined by the patients), (2) side effects (severe sedation, nausea or vomiting, constipation, sleep disturbances) limited further titration, or (3) a total of 150 mg per day had been reached.
88947034|NCT01914055|Active Comparator|angio-guided thrombus aspiration|thrombus aspiration guided by angiography
89202181|NCT00746720|Placebo Comparator|B, 2|Study part 2 (n = 20)
89468431|NCT02338310|Experimental|Aromatase Inhibitor|Aromatase Inhibitor given perioperatively for 4 weeks (two weeks before and two weeks after surgery) Choice of AI is according to centre policy and may be either anastrozole (1mg/day) or letrozole (2.5mg/day)
89468432|NCT03389607||diabetic|the patients must have diabetic disease
89468433|NCT03389607||control|the patients must not have diabetic
89468434|NCT02817789|Active Comparator|Standard group|154 patients
89468435|NCT02817789|Experimental|Ticagrelor group|154 patients
89468436|NCT02333474|Active Comparator|control|Patients in this group will be receiving standard therapy according to National Comprehensive Cancer Network (NCCN) guide line Version 2.2014.
89468437|NCT02333474|Experimental|MV+control|Patients in this group will be receiving both standard therapy according to NCCN guide line Version 2.2014 and simultaneous injection of mix vaccine (MV). MV will be given
89468438|NCT05383625|Experimental|Quadrivalent vaccine|Patient receive 0.1 ml of quadrivalent HPV vaccine intralesional every two weeks
89468439|NCT05383625|Experimental|Bivalent Vaccine|Patient received 0.1 ml of bivalent HPV vaccine intralesional once every two weeks
89468440|NCT05383625|Placebo Comparator|Saline control|Patient received 0.1 ml of intralesional saline once every two weeks
89468441|NCT02330432|Experimental|Mycobacterium w group|Patients in the experimental arm (Mw) in addition to standard care will receive single daily dose of 0.3 mL of Mw (heat-inactivated Mw [0.5 × 10^9]; Cadila Pharma, Ahmedabad, India) in the deltoid region for 3 consecutive days
89468442|NCT02330432|Active Comparator|Best standard care|Best standard care for sepsis
89468443|NCT02337998|Experimental|Healthy men|each individual will serve as his own control by comparing baseline values to post intervention values
89468444|NCT02330354|Experimental|Intervention group|Centers in this group will participate in the Healthy Me, Healthy We program.
89468445|NCT02330354|Other|Control Group|Centers in this group will participate in the Healthy Me, Healthy We program after follow-up measures are collected.
89468446|NCT03125577|Experimental|4SCAR19 and 4SCAR20/CD22/CD30/CD38/CD70/CD123|Patients who have relapsed and refractory B cell malignancies after chemotherapy will be treated with CD19 and CD20/CD22/CD30/CD38/CD70/CD123-specific gene-engineered T cells.
89468447|NCT02330666|No Intervention|Comparison|Standard care
89468448|NCT02330666|Experimental|Intervention|Communication skills training Mission Possible: Parents & Kids Who Listen
89468449|NCT02039648|Active Comparator|Rumex acetosa L. extract|Rumex acetosa L. extract mouthrinse, 10 ml, tid, 3 min, 7 days
89468450|NCT02039648|Placebo Comparator|Placebo|Placebo mouthrinse, 10 ml, tid, 3 min, 7 days
89468451|NCT03389451|Experimental|68Ga PSMA PET scan|Ga-68 PSMA-HBED-CC PET
89468452|NCT02337842|Experimental|Cohort 1|N= 9 subjects will receive single oral dose of GII.4 CIN-1 at 10^3 RT-PCR units and N=1 single oral dose Placebo.
89468453|NCT02337842|Experimental|Cohort 2|N=9 subjects will receive single oral dose of GII.4 CIN-1 either at 10^2 or 5x10^3 RT-PCR units and N=1 single oral dose of Placebo.
89468454|NCT02337842|Experimental|Cohort 4|N=36 subjects will receive single oral dose of GII.4 CIN-1 at either 5x10^4 or 5x10^3 or 10^3 or 10^2 or 10^4 or 5x10^2 or 5x10^1RT-PCR units , N=4 subjects receive a single oral dose of Placebo
88947035|NCT01914055|Experimental|OCT-guided thrombus aspiration|thrombus aspiration guided by optical coherence tomography
89018637|NCT00289835|Other|Standard medical treatment|
89468455|NCT02337842|Experimental|Cohort 3|N=18 subjects will receive single oral dose of GII.4 CIN-1 at either 10^4, 10^3, 5x10^2 or 5x10^1 RT-PCR units and N=2 single oral dose of Placebo
89468456|NCT03610919|Experimental|Oxytocin nasal spray(5 doses)|Oxytocin nasal spray for 5 days, 24 IU per day
89468457|NCT03610919|Experimental|Oxytocin nasal spray(3 doses)|Oxytocin nasal spray or placebo nasal spray interleaved during the 5 days( on the 1st,3rd and 5th day),24 IU per day.
89468458|NCT03610919|Placebo Comparator|Placebo nasal spray(control group)|Placebo nasal spray for 5 days,24 IU per day.
89468459|NCT03385395|Experimental|OctaAlpha1|
89468460|NCT03385395|Active Comparator|Glassia®|
89468461|NCT02333318|Experimental|Single Dose_VVZ-149 injection|"Cohort A (50-64 years old), Cohort B (65-84 years old)~For 2.5, 5mg/kg~4-hr intravenous infusion of VVZ-149 injection~6 subjects will be administered within each age group. Total 24 subjects will participate."
89468462|NCT02333318|Experimental|Loading/Maintenance_VVZ-149 injection|"Cohort A (50-64 years old) This trial is conducted only in the Cohort A one week after the single IV infusion.~For Loading + Maintenance dose: 0.75 mg/kg+ 0.55 mg/kg/h, 1.5 mg/kg + 1.10 mg/kg/h~intravenous infusion~4 subjects will be randomly assigned within each dose group, respectively. Total 8 subjects will participate."
89468463|NCT02333318|Placebo Comparator|Loading/Maintenance_Placebo|"Cohort A (50-64 years old)~For Loading + Maintenance dose: 0.75 mg/kg+ 0.55 mg/kg/h, 1.5 mg/kg + 1.10 mg/kg/h~intravenous infusion~2 subjects will be randomly assigned within each dose group, respectively. Total 4 subjects will participate."
89468464|NCT03611387||Normal|Patients without any type of glaucoma
89468465|NCT03611387||Primary angle closure glaucoma|Patients with primary angle closure glaucoma
89468466|NCT03611387||Primary open-angle glaucoma|Patients with primary open-angle glaucoma
89468467|NCT03389373|Other|Child with full primary dentition|All children who match inclusion criteria are eligible to have a saliva sample obtained which will act as a proxy for bacterial levels. High bacteria levels are correlated with a higher risk of developing cavities.
89468468|NCT02032511||RAM Cannula Nasal Continuous Positive Airway Pressure|
89468469|NCT02032511||Infant Flow Nasal Continuous Positive Airway Pressure (NCPAP)|
89468470|NCT03385317|Experimental|Mindfulness|
89468471|NCT03610841||preterm labor|Workgroup consists of patients which diagnosed with preterm labor between the age of 21 and 34
89468472|NCT03610841||healthy|24-36 6/7 weeks of pregnant between the age of 21 and 34
88947036|NCT01914068|No Intervention|Control|No in hospital exercise training and no exercise advice.
88947037|NCT01914068|Active Comparator|Exercise Intervention|In hospital exercise training
88947038|NCT01914081|Active Comparator|Resveratrol|500 mg (1 capsule BID) of resveratrol for 12 months
88947039|NCT01914081|Placebo Comparator|Placebo|500 mg (1 capsule BID) of placebo for 12 months.
88947040|NCT01914107|Experimental|standard cancer pain care|the standard cancer pain care group: 1.will be follow-up by the cancer nurse once a week to acknowledge the cancer pain intensity, the current analgesic medication, and the side effects. and also give recommendations. 2.filled in the patient'diary and hand over to researchers.
88947041|NCT01914107|Experimental|real-time monitoring and instruction of cancer pain|"real-time monitoring and treatment instruction of cancer pain group~1.follow the same pattern of standard cancer pain care. 2. using the cloud computing concept system, install the software in the mobile phone of patients. the patients will fill in the content of brief pain inventory, medication and side effect, and upload to researchers every 2 days. 3. Researcher monitor the cancer pain treatment in realtime and give instructions."
88947042|NCT01914133|No Intervention|No Postprandial Hypotension (PPH)|Screening Meal Test performed and subject does not meet criteria for Postprandial Hypotension (PPH).
88947043|NCT01914133|Placebo Comparator|Placebo|Screening Meal Test performed and subject meets criteria for Postprandial Hypotension (PPH). At second Meal Test subject will receive a placebo and will take a placebo with the first bite of the next 3 meals.
88947044|NCT01914133|Active Comparator|Acarbose|Screening Meal Test performed and subject meets criteria for Postprandial Hypotension. During the second Meal Test subject will receive Acarbose 50mg and will take Acarbose 25mg with first bite of each of the next 3 meals.
89468473|NCT02330120|Experimental|propofol|Propofol infusion 0.5-2 mg/kg/h for sedation in mechanically ventilated patients
88947045|NCT01914146|Other|Before Initiation of Insulin Therapy|Study sessions will occur before the initiation of insulin therapy (no insulin). Initiation of insulin administration will be determined as part of standard of care by the subjects diabetologist in the VGH Diabetes Centre and not as part of participation in this study.
88947046|NCT01914146|Other|After Initiation of Insulin Therapy|Study session will take place 2-4 weeks after the initiation of insulin therapy. Initiation of insulin administration will be determined as part of standard of care by the subjects diabetologist in the VGH Diabetes Centre and not as part of participation in this study.
88947047|NCT01914172||Online web-based questionnaire|Up to 200 patients with KS/CHH will be recruited to complete an online web-based questionnaire (less than 30 minutes to complete)
88947048|NCT01914172||Patient focus group|Focus groups (90-120 minutes in duration) with 6-12 patients. Up to 36 patients total
88947049|NCT01914172||Online web-based evaluation of patient education materials|Up to 100 patients with KS/CHH will be recruited to complete an online web-based questionnaire to evaluate patient education materials (less than 15 minutes to complete)
88947050|NCT01914185|No Intervention|Comparison Schools|Regular health promotion activities
88947051|NCT01914185|Experimental|Comprehensive School Health (CSH)|Full time School Health Facilitator present in each school on a day-to-day basis for 3.5 years responsible for facilitating implementation of Comprehensive School Health
88947052|NCT01914198||Sleep study|Patients who are having a sleep study done at NCH to diagnose sleep apnea.
89468474|NCT02330120|Active Comparator|dexmedetomidine|dexmedetomidine infusion 0.2-0.7 mcg/kg/h for sedation in mechanically ventilated patients
89468475|NCT03389295|Experimental|Reduced Target Delineation and Radiation Doses|All patients were assigned to receive induction chemotherapy (IC) followed by IMRT with adjuvant chemotherapy (AC). IMRT was administered 2 weeks after IC, and AC was administered 1 month after IMRT. IC or AC (TPF regimen) comprised docetaxel (60 mg/m2/day, day 1), cisplatin (25 mg/m2/day, days 1-3), and 5-fluorouracil (500 mg/m2/day with a 120-h infusion) administered once every 3 weeks for two cycles. During radiotherapy, involved retropharyngeal lymph nodes and intracavity lesions of the primary tumor were delineated according to the post-IC volume, whereas the remainder of the involved tissues (eg, pterygopalatine fossa) of the primary tumor were delineated according to the pre-IC volume of the primary tumor as shown by MRI. Post-IC volumes of involved neck lymph nodes were used for delineation. The prescribed dose was 66 Gy to tumors above the slices of skull base or below the orapharynx with less than 5 mm retropharyngeal lymph nodes, or 70.4 Gy to tumors in other slices.
89468476|NCT02032589|Experimental|Self-generation treatment|self-generation strategy treatment, embedded within practice of various activities
89468477|NCT02032589|Placebo Comparator|memory training|Treatment consists on traditional memory training
89468478|NCT01592643|Experimental|Eye shield|Participants receive eye shield during PRK surgery
88947053|NCT01914211||Acute Normovolemic Hemodilution|Patients that receive acute normovolemic hemodilution prior to surgery.
88947054|NCT01914211||Tranexamic Acid|Patients that receive tranexamic acid during surgery.
88947055|NCT01914224|Experimental|Group 1|dietary education of low sodium and high potassium consumption
88947056|NCT01914224|Active Comparator|Group 2|dietary education of low sodium consumption only
88947057|NCT01914237|Experimental|Castor Stent Graft|To study the safety and efficacy of Castor single-branched stent graft system in endovascular repair of aortic dissection.
89468479|NCT02032745||Chemo-insensitive|Non-responders to chemotherapy (Probability for pathological negative nodal status)
89468480|NCT02032745||Chemo-sensitive|Responders to chemotherapy (Probability for pathological negative nodal status)
89468481|NCT03718988|Experimental|Meat Phase first|Participants will be asked to consume traditional meat products for 8 weeks, then switch to plant-based meat alternative products for another 8 weeks.
88947058|NCT01914250|Active Comparator|2|Topical Anesthetic, 2% Tetracaine oral gel - Group A Topical Anesthetic, 20% Benzocaine oral gel - Group B
88947059|NCT01914263|Experimental|cytokine induced killer cell|The eligible patients are infused a single dose of 8x10^9 CIK cells.
88947060|NCT01914263|No Intervention|Control|The eligible patients are followed up for 30 days without any treatment.
88947061|NCT01914289|Experimental|Resection|To observe prognosis of resection of icc
88947062|NCT01914289|Active Comparator|Radiotherapy|To observe the prognosis of radiotherapy treatment of icc
88947063|NCT01914302||Delica Lancing Device|Subjects in this group either use the Delica lancing device or a meter that requires 1.0 microliters of blood
88947064|NCT01914302||Freestyle Flash Lancing Device|Subjects in this group either use the Flash lancing device or a meter that requires 0.3/0.6 microliters of blood
88947065|NCT01914302||Easy Touch Lancing Device|Subjects in this group either use the Easy Touch lancing device or a meter that requires 0.3/0.6 microliters of blood
88947066|NCT01914302||Glucoject Lancing Device|Subjects in this group either use the Glucoject lancing device or a meter that requires 0.3/0.6 microliters of blood
88947067|NCT01914302||Microlet Lancing Device|Subjects in this group either use the Microlet lancing device or a meter that requires 0.3/0.6 microliters of blood
88947068|NCT01914302||Multiclix Lancing Device|Subjects in this group either use the Multiclix lancing device or a meter that requires 0.3/0.6 microliters of blood
88947069|NCT01914302||Fastclix Lancing Device|Subjects in this group either use the Fastclix lancing device or a meter that requires 0.3/0.6 microliters of blood
88947070|NCT01914302||Reli-On Lancing Device|Subjects in this group either use the Reli-On lancing device or a meter that requires 0.3/0.6 microliters of blood
88947071|NCT01914315|Experimental|Cardiac Rehabilitation|Patients randomized to the multidisciplinary cardiac management program at the cardiac rehabilitation center will undergo evaluation by a trained rehabilitation physician and physiologist. The evaluation will include medical history, physical examination, vitals, review of post discharge graded exercise stress test and nursing staff consultation. Exercise prescription will be based on a pre-specified protocol in accordance with ESC position paper on cardiac rehabilitation of patients with heart failure.
88947072|NCT01914315|Active Comparator|Internal Medicine|Following discharge, patients will return to the internal medicine (IM) outpatient clinics at 2-4 weeks, 3, and 6 months for consultation. These scheduled consultations will comprise of history taking, recording of any new events, physical examination and recommendations as clinically indicated.
88947073|NCT01914341|Experimental|Music|pentatonic live music
89468482|NCT03718988|Experimental|Plant Alternative Phase first|Participants will be asked to consume plant-based meat alternative products for 8 weeks, then switch to traditional meat products for another 8 weeks.
88947074|NCT01914341|No Intervention|control|no intervention
88947075|NCT01914380||Group 1|
89468483|NCT02647749|Experimental|Group 1 : Cardiac rythm radiofrequency ablation|Prospective recruitment
88947076|NCT01914419|Active Comparator|IV infusion|Oxytocin 10 IU will be administered by IV infusion according to randomization assignment as soon as possible after delivery of the baby.
88947077|NCT01914419|Active Comparator|IV bolus|Oxytocin 10 IU will be administered by IV bolus according to randomization assignment as soon as possible after delivery of the baby.
88947078|NCT01914419|Active Comparator|IM injection|Oxytocin 10 IU will be administered by IM injection according to randomization assignment as soon as possible after delivery of the baby.
88947079|NCT01914432|Experimental|YH16410|PO, Once Daily, 8 weeks
88947080|NCT01914432|Active Comparator|Rosuvastatin|PO, Once Daily, 8 weeks
88947081|NCT01914432|Active Comparator|Telmisartan|PO, Once Daily, 8 weeks
88947082|NCT01914432|Placebo Comparator|Placebo|PO, Once Daily, 8 weeks
88947083|NCT01914445|Experimental|Indigo Carmine|Indigo Carmine (2 mg per kilo) and 2nd half of PEG dose will be orally administered to patients prior to colonoscopy.
88947084|NCT01914458|Experimental|Low-dose computed tomography (LDCT)|Patients will have one baseline LDCT scan.
88947085|NCT01914471|No Intervention|Control|These schools did not receive the intervention.
88947086|NCT01914471|Experimental|Students for Nutrition and eXercise|These schools received the entirety of Students for Nutrition and eXercise, a middle-school-based obesity-prevention intervention combining school-wide environmental changes, multimedia, encouragement to eat healthy school cafeteria foods, and peer-led education and marketing
89018638|NCT00323934|Experimental|1|MGCD0103 Oral 2 times weekly
89018639|NCT04718259|Experimental|Group A|Will include patients who will receive bupivacaine intrathecal injection without adjuvant.
89468484|NCT02647749|Experimental|Group 1: Implantation or programming of a pacemaker|Prospective recruitment
89468485|NCT02647749|Experimental|Group 1: Risk of serious arrhythmias or sudden death|Prospective recruitment
89468486|NCT02647749|Active Comparator|Group 2: Cardiac rythm radiofrequency ablation|Retrospective recruitment
89468487|NCT02647749|Active Comparator|Group 2 : Implantation or programming of a pacemaker|Retrospective recruitment
88947087|NCT01914484|Experimental|Nilotinib with Ruxolitinib|"Nilotinib: Given that recommended dose of Nilotinib for imatinib failed CML patients is 400mg twice daily, Nilotinib dose will remain fixed at 400mg bid throughout the cycles.~Ruxolitinib: In the phase I part of the study, dose escalation will follow a 3+3 study design. Dose modifications will not occur, as the purpose of this study is to determine the maximum tolerated dose. Ruxolitinib will be given at one of 3 fixed dose levels for the duration of their treatment, either 10mg twice daily, 15mg twice daily or 20mg twice daily."
88947088|NCT01914497|Experimental|Acutus Medical System|Proprietary software algorithms will be used generate electrical activation maps based dipole density data acquired by the Acutus Medical Catheter during the procedures. These activation maps will then be applied to a 3D model of the endocardial surface to create a 3D activation map.
88947089|NCT01914523|Placebo Comparator|Macintosh|tracheal intubation will be performed using a Macintosh
88947090|NCT01914523|Active Comparator|King Vision|tracheal intubation will be performed using a King Vision
88947091|NCT01914523|Active Comparator|Glidescope|tracheal intubation will be performed using a Glidescope
88947092|NCT01914523|Active Comparator|AirTraq|tracheal intubation will be performed using a AirTraq
88947093|NCT01914536||Pompe patients|Adult onset pompe patients being or not treated with enzyme therapy replacement
88947094|NCT01914562|Experimental|OCA 10 mg while fasted|OCA 10 mg orally in the fasting state
88947095|NCT01914562|Experimental|OCA 10 mg while Fed|OCA 10 mg orally in the fed state
88947096|NCT01914562|Experimental|OCA 25 mg while fasted|OCA 25 mg orally in the fasting state
88947097|NCT01914562|Experimental|OCA 25 mg while Fed|OCA 25 mg orally in the fed state
88947098|NCT01914575|Experimental|Dipole Density Mapping|
88947099|NCT01914588|Experimental|Telemonitoring + Standard care|
88947100|NCT01914588|Active Comparator|Standard care|
88947101|NCT01914601|Active Comparator|Macintosh-King Vision|laryngoscopy will be performed with the Macintosh followed by the King Vision laryngoscope
89468488|NCT02647749|Active Comparator|Group 2 : Risk of serious arrhythmias or sudden death|Retrospective recruitment
89468489|NCT04003766|Active Comparator|Percutaneous Biopsy|"The subject would undergo the standard of care procedure for a percutaneous biopsy of the liver.~All percutaneous biopsies will be performed after administration of local anesthetic. No pre-procedure antibiotics will be administered. Subcostal or subxyphoid area will be cleaned and draped in the standard manner. 2% lidocaine solution will be injected subcutaneously using a 25-gauge needle and then administered into the subcutaneous tissue up to the liver capsule. A 16-gauge biopsy needle is inserted into the liver parenchyma under US or CT-guidance, with the location of needle placement left to the discretion of the performing radiologist. One or two core biopsy samples will be obtained. All procured specimens will be placed in a single specimen container of 10% formalin for tissue processing. When biopsy samples have been obtained, the patient will be taken to the recovery area for post-procedure monitoring."
89537289|NCT05728593|Active Comparator|control group|Participants (n=15) were randomly selected by the researchers using the coin toss method, and thus the participants were divided into two groups as study (n=8) and control group (n=7) The study group received parent-based occupational therapy, while the control group received standard occupational therapy.
89537290|NCT05173337|No Intervention|control group|Nefopam will not be administered in this group.
88947102|NCT01914601|Active Comparator|King Vision-Macintosh|laryngoscopy will be performed with the King Vision followed by the Macintosh laryngoscope.
88947103|NCT01914614||Working Poor Survivors|Low Wage workers
88947104|NCT01914614||Non-Working Poor Survivors|Higher-Wage Salary Workers
88947105|NCT01914627|Experimental|Loion|
88947106|NCT01914627|Active Comparator|SA-Gel|
88947107|NCT01914640||Healthy adults living in Turkey|The group was enrolled from the 24 provinces of the 7 regions of Turkey. At least 3 provinces were selected from each region by a random sampling method. The populations of these 7 regions were obtained from the records of the 2000 census. The study sample included males and non-pregnant females aged between 20 and 83 years. The populations of city centers, districts, and villages were classified by using the stratified sampling method and then were selected from the data collected from the household identification forms by random sampling. The geography of Turkey was classified into three groups according to altitude. Sea level was accepted as zero. 0-300 m was taken as coastal, 300-900 m as moderate
88947108|NCT01914653|Experimental|Pre-radiated|
88947109|NCT01914653|Experimental|Not radiated|
88947110|NCT01914653|Experimental|Post-radiated|
88947111|NCT01914692|Experimental|Somatostatin group|Patients with Advanced Gastric Cancer After D2 Lymph Node Dissection accept the Somatostatin medical therapy.
88947112|NCT01914692|Placebo Comparator|Blank group|Use the normal saline instead of somatostatin.
88947113|NCT01914705|Active Comparator|Landmark Procedure|Using Landmarks to guide SCVC placement
88947114|NCT01914705|Active Comparator|Ultrasound Guided Procedure|Using ultrasound to guide SCVC placement
88947115|NCT01914718|Experimental|DA-EPOCH-R|rituximab 375mg/m2 IV day 0, etoposide 50mg/m2/d CIV days 1-4, doxorubicin 10mg/m2/d CIV days 1-4, vincristine 0.4mg/m2/d CIV days 1-4, cyclophosphamide 750mg/m2 IV day 5, prednisone 50mg PO days 1-5 twice per day
88947116|NCT01914731|Experimental|Capsule|"Fecal microbiota transplant (stool transplant) from healthy, unrelated donor via frozen capsule"
88947117|NCT01914744|Experimental|entecavir|entecavir 0.5 mg/day PO
88947118|NCT01914744|Active Comparator|lamivudine|lamivudine 100 mg/day PO
89468490|NCT04003766|Active Comparator|Endoscopic-guided Ultrasound Biopsy|"The subject would undergo the standard of care procedure for an endoscopic-guided biopsy of the liver.~The left lobe of the liver is identified from the gastric lumen, EUS-guided fine needle biopsy (FNB) will be performed using a 19-gauge FNB needle, with the choice of needle type at the discretion of the performing endoscopist. Stylet will only be used to puncture the liver at the time of the first pass and then subsequently removed. No suction will be used. Fanning technique will not be used. A total of 10 to-and-fro needle movements will be performed during each pass. A total of two passes will be performed.All tissue specimens procured will be placed in a single specimen container of 10% formalin for tissue processing. When two passes are complete under EUS-guidance, the echoendoscope will be withdrawn from the patient and the patient will be taken to the recovery area for post-procedure monitoring."
89468491|NCT01511913||Ipilimumab treatment cohort of 1106 prospective participants|
89468492|NCT01511913||Non-Ipilimumab treatment cohort of 305 prospective participants|
89468493|NCT01511913||Retrospective cohort of 177 participants|
89468494|NCT02337608|Experimental|GLPG1205 100mg QD|GLPG1205 100mg daily dosing in the morning
89468495|NCT02337608|Placebo Comparator|Placebo|Placebo daily dosing in the morning
89468496|NCT03983564||All patients|Patients in this group will serve to validate the cutoff of the combination of the DES-OSA and BOSTON scores derived in the retrospective group.
89468497|NCT01500681||Maintenance PLEX|
89468498|NCT03398889||Unexplained Atherosclerosis phenotype|Residual score in linear regression >2
89468499|NCT03398889||Explained Atherosclerosis phenotype|Residual score in linear regression <-2, <2
89468500|NCT03398889||Protected Atherosclerosis phenotype|Residual score <-2
88947119|NCT01914770||Adults with systemic lupus erythematosus (SLE)|Subjects with SLE receiving ongoing stable SLE treatment
88947120|NCT01914783|Experimental|ultrafine particles|Subjects will be exposed to ultrafine particles for three hours in an exposure chamber. During that time participants will perform intermittent bicycle ergometer training. Training intensity is adjusted individually to increase ventilation to 20 l/min/m². During exposure, heart rate will be monitored continuously via ECG. Blood pressure will be measured every 15 minutes. Ultrafine elemental carbon black particles are generated using a commercially available electric spark generator. Particle number, mass, and size distribution will be monitored during exposure.
88947121|NCT01914783|Active Comparator|ultrafine particles and ozone|Subjects will be exposed to ultrafine particles for three hours in an exposure chamber. During that time participants will perform intermittent bicycle ergometer training. Training intensity is adjusted individually to increase ventilation to 20 l/min/m². During exposure, heart rate will be monitored continuously via ECG. Blood pressure will be measured every 15 minutes. Ultrafine elemental carbon black particles are generated using a commercially available electric spark generator. Particle number, mass, and size distribution will be monitored during exposure.Ozone is generated from medical oxygen in order to maintain a concentration of 250 ppb.
89018640|NCT04718259|Experimental|Group B|Will include patients who will receive bupivacaine and midazolam.
89018641|NCT00323973|Experimental|1|
89018642|NCT00323973|Placebo Comparator|2|Placebo
89018643|NCT00324012|Experimental|treatment|taxotere and cisplatin day one every three weeks
89468501|NCT01295697|Experimental|EZN-2208|Cytotoxic Agent
89468502|NCT03398811||"Group I the depot medroxy-progesterone acetate group"|where they will use Depot Medroxyprogesterone Acetate 150 mg injection every 3 month,
89468503|NCT03398811||"Group II Implanon group"|where they will have Implanon (etonogestrel implant) 68 mg implant
89468504|NCT03398811||group III (cerazette group)|where they are using Cerazette pills (desogestrel 75 µg l) one pill every day for 28 days without pill-free interval.
88947122|NCT01914783|Placebo Comparator|clean air|Subjects will be exposed to clean air for three hours in an exposure chamber controlled for temperature, humidity, and gas/particle composition. During that time they will perform intermittent bicycle ergometer training for 15 minutes alternating with 15 minutes rest. Training intensity is adjusted individually to increase ventilation to 20 l/min/m². During exposure, heart rate will be monitored continuously via ECG. The blood pressure will be measured in time intervals of 15 minutes.
89468505|NCT03398733|Other|continuous positive airway pressure|The CPAP treatment group received both baseline and CPAP treatment for 7 days preoperatively.
89468506|NCT01300143|Active Comparator|TACE|Patients will be treated by 2 or 3 cures of hyperselective TACE. The first one at week 0 and the second one at week 8. If required, a third cure of TACE could be done at week16.
89468507|NCT01300143|Experimental|TACE + RTC|Patients will be treated by one cure of TACE at week 0. Then, patients will be treated within two weeks by external conformational radiotherapy of 54 grey fractioned in 18 sessions during 3-4 weeks.
89468508|NCT01336205|Experimental|1|Oral Treatment
89468509|NCT01336205|Active Comparator|2|Oral treatment
89468510|NCT02333240|No Intervention|Usual care|"Women randomised to usual care will have their blood pressure monitored by their community midwife, and will have their anti-hypertensive medication adjusted by their general practitioner. There will be no intervention in this group.~All women will be followed up at ten days, four and six weeks, then three and six months postpartum and have their blood pressure measured by one of the study team."
89468511|NCT02333240|Experimental|Self-management|Self-management of postnatal anti-hypertensive treatment. Women will be provided with, and taught to use, a validated home blood pressure monitor, and perform daily BP readings. When treatment is discontinued we will ask them to continue daily BP measurements for 1 week. Provided these are <140/90 mmHg they will be asked to check their BP weekly for the remainder of the trial period. The self-monitoring BP data will be collated centrally through the use of a smart phone app or SMS based system. This service will respond to participants regarding the level of their BP and what action is required. Women in the self-management group will have an individualised medication adjustment schedule developed by the research team in conjunction with the participant's obstetric team.
89468512|NCT02033135|Experimental|Angioplasty with Zilver PTX|Angioplasty and stenting with a polymer free paclitaxel-eluting stent (Zilver-PTX) plus unsupervised exercise therapy, smoking cessation advice and best medical therapy.
89468513|NCT02033135|Active Comparator|Best medical treatment|Unsupervised exercise therapy, smoking cessation advice and best medical therapy.
88947123|NCT01914796|Placebo Comparator|Single ascending doses|
88947124|NCT01914796|Placebo Comparator|Measurement of eye blink rate|
89468514|NCT02865395|Experimental|Pre-operative Suppository|A B&O Suppository will be placed in the patient's rectum after the induction of anesthesia, but before the surgery.
89468515|NCT02865395|Active Comparator|Post-operative Suppository|A B&O Suppository will be placed in the patient's rectum while still under anesthesia, but after the surgery.
89468516|NCT02865395|Placebo Comparator|Rectal Exam|Patient's will be given a rectal exam after the procedure but while still under anesthesia to serve as a placebo.
88947125|NCT01914809|Experimental|group with a preeclampsia before 34 SA|
88947126|NCT01914809|Other|group with a normal pregnancy|
88947127|NCT01914822|Experimental|methylphenidate hydrochloride|The study will include two sessions which will be conducted at the same time of the day, one week apart from each other. Each session will last approximately 6 hours. In each session subjects will be exposed to baseline experimental pain models and auditory tests. Then they will receive either one MP SR 20 mg tablet or an identical looking placebo.
88947128|NCT01914822|Placebo Comparator|Sugar pill|The study will include two sessions which will be conducted at the same time of the day, one week apart from each other. Each session will last approximately 6 hours. In each session subjects will be exposed to baseline experimental pain models and auditory tests. Then they will receive either one MP SR 20 mg tablet or an identical looking placebo.
88947129|NCT01914835|Experimental|Motivational Chess & Active Control|Ten meetings of 90 minutes each.
88947130|NCT01914848|Active Comparator|Control Group|A routine care discharge planning with the social service
88947131|NCT01914848|Experimental|Advance Care Planning ACP|"Patient get a decision aid video and library and up to 3 consultations with qualified Advance Care Planning Facilitators.~--------------------------------------------------------------------------------"
88947132|NCT01914861||Men/Women, 21-65, following exposure to a traumatice event|
88947133|NCT01914874|Experimental|Mindfulness Meditation|12 weekly sessions in group format
88947134|NCT01914874|No Intervention|Wait-list|Patients will receive the mindfulness intervention after a 12-week wait period
89018644|NCT00303342|Experimental|mind body treatment|regulation of attention, respiration and posture
88947135|NCT01914887|Experimental|allogeneic ASCs|Treatment consists in a cell suspension (5 million cells/mL) in aseptic buffered solution containing human expanded adipose-derived stem cells (eASCs) of allogeneic origin in disposable vials with no preservative agents. The cells will be given in different sites within the affected colonic submucosa at a total dose of 60 million cells with the use of a colonoscope.
88947136|NCT01914913|Other|BMMNCs|BMMNCs
88947137|NCT01914939|Experimental|Social Skills Focused CBT|Twelve weekly 60-minute sessions of social skills focused CBT
88947138|NCT01914939|Active Comparator|Stress Management/Relaxation Training|Twelve weekly 60-minute sessions of stress management training
88947139|NCT01914939|Experimental|Oxytocin|Intranasal administration of 24 IU of oxytocin
88947140|NCT01914939|Placebo Comparator|placebo drug|Intranasal placebo drug
88947141|NCT01914952|Active Comparator|CaHMB Capsule|
89468517|NCT02327390|Experimental|X-ACT lymph node cell dose and schedule|"All patients will begin at dose level 1 and will be moved to higher dosing levels as long as the patient does not experience two or more dose limiting toxicities and maintains an acceptable performance status. A minimum of three patients will be enrolled per dose level and no patients will be enrolled on higher dose levels if dose limiting toxicities are encountered.~Dose level 1: 0.5 x 10^10 X-ACT cells. 2 infusions 4 weeks apart~Dose level 2: 1.0 x 10^10 X-ACT cells. 1 infusion~Dose level 3: 0.5 x 10^10 X-ACT cells. 4 infusions 4 weeks apart~Dose level 4: 1.0 x 10^10 X-ACT cells. 2 infusions 4 weeks apart~Dose level -1: 0.5 x 10^10 X-ACT cells. 1 infusion (if necessary)"
89468518|NCT02329496|Experimental|Lotus Valve and LOTUS Edge Valve System|Transcatheter aortic valve replacement (TAVR) with Lotus Valve System with the Next Generation Delivery System and LOTUS Edge Valve System
88947142|NCT01914952|Active Comparator|HMB free acid gelcap|
88947143|NCT01914952|Active Comparator|HMB free acid in water|
88947144|NCT01914952|Active Comparator|CaHMB powder in water|
88947145|NCT01914952|Active Comparator|HMB free acid (oral not in gelcap or water)|
88947146|NCT01914965|Active Comparator|Bupropion|First treatment group: 150 mg bupropion or placebo once daily for 2 weeks, followed by 300 mg bupropion or placebo once daily for subsequent 8 weeks (until week 10; visit 4) First tapering and washout: 150 mg bupropion or placebo once daily for 7 days followed by a washout phase of 1 week on placebo
88947147|NCT01914965|Placebo Comparator|Placebo|Second treatment group (crossover): placebo or 150 mg bupropion once daily for 2 weeks, followed by placebo or 300 mg bupropion once daily for subsequent 8 weeks (until week 22; visit 6) Second tapering placebo or 150 mg bupropion once daily for 7 days
88947148|NCT01914978|Experimental|Handbook|Food allergy handbook for parents
88947149|NCT01914978|Placebo Comparator|Treatment as usual|Food allergy treatment as usual
89468519|NCT03611231|Experimental|Experimental|chidamide
89468520|NCT02333084|Experimental|Joint Health Product|natural dietary supplement
89468521|NCT02333084|Placebo Comparator|Placebo|vegetable oil placebo
89468522|NCT02333084|Active Comparator|Combination with Omega-3|combination with omega-3 fish oil
89468523|NCT03610685|Placebo Comparator|Placebo|Participants will be given 2 weeks of placebo treatment. The placebo capsules will be taken once a day orally. The daily dose of placebo treatment will match the Prednisone dose for each participant.
89468524|NCT03610685|Active Comparator|Prednisolone|Participants will be given 2 weeks of prednisolone treatment. This is administered orally once a day. The daily dose is calculated according to 0.5mg/kg with a maximum dose of 40mg per day.
89468525|NCT02333006|Other|Traumatic brain injury questionnaires|Traumatic brain injury patients with anosognosia will answer to quetionnaires about Anosognosia compare to the answer of participant without neurological deficits
89468526|NCT02327234|Experimental|Ibuprofen|400mg (2X200mg) ibuprofen single dose once
89468527|NCT02327234|Placebo Comparator|Placebo|identical appearing lactose capsules single dose 2 capsules once
88947150|NCT01914991|Active Comparator|Control group|Conventional treatment: The treatment consisted of 10 minutes of local thermotherapy (paraffin), active exercises at the PIPJ and DIPJ (Distal interphalangeal joint), 3 sets of 15 repetitions of each exercise extending and flexing of the PIPJ with metacarpophalangeal joint from 0° to 90° respectively. Distal interphalangeal joint exercises were conducted with identical repetitions. The metacarpophalangeal joint and PIPJ exercises took place at 0 ° and involved stretching (5 sets of 3 reps, holding for 10 seconds) and Therapeutic U.S (0.8 w/cm2 / 7 minutes).
88947151|NCT01914991|Experimental|Experimental group|dynamic extension contracture orthotic. A mobilizing force of 250 - 300 gm/cm2 was set in each one. Patients were instructed to wear it for at least 6 hours per day and then removed it for ADL (Activity Daily Living). A static orthosis was constructed using orfitcast material to the maximum, pain-free length allowed by the tissues at night. Static and dynamic orthoses were checked once a week and adjusted as necessary.
88947152|NCT01915004|Other|Standard Invididual Urotherapy|Educational Intervention. Standard individual urotherapy (bladder re-training) occurs in the pediatric urology clinic.
88947153|NCT01915004|Experimental|Bladder Training Video|Experimental Educational Intervention. Participants will watch a 7 minute animated bladder training video.
89468528|NCT01123707|Experimental|Prior Aripiprazole/Escitalopram Combination Therapy|Aripiprazole capsules, orally at the daily dose of 3, 6, or 12 mg, in combination with escitalopram 10 or 20 mg orally, once daily in combination with escitalopram 10 or 20 mg (i.e., the final dose taken during the previous study), orally, once daily, for 36 weeks. Participants were titrated to the aripiprazole target dose of 12 mg/day at Week 1 if the initial 6 mg/day dose was tolerated. The dose adjustments were allowed for aripiprazole to establish the maximum tolerated dose (MTD) by Week 4. Participants who received aripiprazole/escitalopram combination therapy in the double-blind treatment period in previous studies were included in this group.
89468529|NCT01123707|Experimental|Prior Escitalopram|Aripiprazole capsules, orally at the daily dose of 3, 6, or 12 mg, in combination with escitalopram 10 or 20 mg orally, once daily in combination with escitalopram 10 or 20 mg (i.e., the final dose taken during the previous study), orally, once daily, for 36 weeks. Participants were titrated to the aripiprazole target dose of 12 mg/day at Week 1 if the initial 6 mg/day dose was tolerated. The dose adjustments were allowed for aripiprazole to establish the MTD by Week 4. Participants who received escitalopram in the double-blind treatment period in previous studies were included in this group.
89537291|NCT05173337|Experimental|nefopam group|Intravenous nefopam 20 mg will be administered twice, immediately after induction of anesthesia and at the end of surgery.
89537292|NCT03066921|Placebo Comparator|Placebo|Placebo packet will be given at a dose of one sachet thrice daily for 24 weeks; Placebo packet contain all excipients as present in packets (without the 3 strains of bacteria as mentioned above).
89202182|NCT00783276|Placebo Comparator|Sugar Pill|Placebo
89202183|NCT00783276|Active Comparator|SYN115|
89202184|NCT00932061|Active Comparator|Traditional Acupuncture|Acupuncture sites will be used for active intervention.
89202185|NCT00932061|Sham Comparator|Sham Treatment|Sham acupuncture is used.
89202186|NCT02562170|Active Comparator|TiLoop Bra|immediate breast reconstruction with an implant and TiLoop Bra
89202187|NCT02562170|Active Comparator|Protexa|immediate breast reconstruction with an implant and Protexa
89202188|NCT03538197|Other|SUICID ATTEMPT YOUNG PEOPLE|Suicide Re Attempts in Young Adults after first suicide attempt : socio-demographic, clinical and biological correlates
89202189|NCT00686972|Experimental|GLP-1|5 ng/kg/min, IV for 1 hour during each clamp study (7) over 2 year period.
89202190|NCT00937287||youth and caregivers|
89202191|NCT00665652|Experimental|Lenalidomide|
89202192|NCT00749294||Observation|
89202193|NCT00937365|Active Comparator|Exercise|Specific strengthening exercises demonstrated to improve pregnancy-related low back pain are taught to participants of this arm. Additionally, each participant will be evaluated and additional exercises will be prescribed relevant to her particular needs. Study participants of this arm are asked to perform the exercises at home at least once a day. Exercise is recorded in a diary. Participants follow the same study visit schedule as the two other arms.
89202194|NCT00937365|Experimental|Spinal Manipulation|Women randomized to this arm will be evaluated for spinal subluxations and, if appropriate, treated with chiropractic manipulation. Type of manipulation is determined by presentation. Woman may be manipulated with high velocity low amplitude thrust, blocking, activator, or other appropriate means of manipulating.
89202195|NCT00937365|Experimental|Neuroemotional technique (NET)|"Neuroemotional technique (NET) is a mind-body technique which combines elements of chiropractic medicine, Chinese medicine, and behavioral psychology. Muscle response testing, a form of functional neurology, and visceral somatic reflexes are used to ascertain whether the pain or dysfunction experienced by the participant has an emotional component. If an emotional component is present, it is identified and the original triggering occurrence is identified. The participant creates a snapshot of that original occurrence and while she holds that image in her mind spinal levels which innervate the associated organ are adjusted."
89202196|NCT02561390|Experimental|Skin prick test with aeroallergens|Mean wheal diameters of SPT with commercial and local American coakroach, house dust mite, cat, dog and mold
89202197|NCT02561390|Experimental|specific IgE measurement|specific IgE levels of commercial and local American coakroach, house dust mite, cat, dog and mold
89202198|NCT00937443||Walking Exercise Group|Walking Exercise Group versus Control Group
89202199|NCT00752024|Experimental|1|To position haematoma's location, drills several millimeter holes in the localization point of puncture, then insert the drainage tube to inhale haematoma, gives the filament resolver interrupted for liquefication drainage afterward.
89202200|NCT00752024|Active Comparator|2|In the treatment, under the convention we use the dehydrator for patients, the ultra early patient may use anti-filament medicinal preparation 6- amino-caproic acid 6-12g/d, intravenous drip, the period of revolution does not surpass for 24 hours, then just right for the illness treatment.
89202201|NCT00786084||1|Phase I patients who had a paraesophageal hernia repair with synthetic mesh.
89202202|NCT00786084||2|Phase I patients who had a paraesophageal hernia repair with small intestine submucosa mesh.
89202203|NCT04046952|Active Comparator|TR band only|Patients will have a TR band applied over the arteriotomy site and inflated with 15-18ml of air. After aspirating and clearing the contents of the sheath, the radial sheath will be removed. The TR band will be deflated until bleeding occurs, and 2 ml of air will be reintroduced to provide hemostasis. Patent hemostasis will be documented with plethysmography and oximetry as described below within 5 minutes after band application and removal, and within 30 min of discharge or after 24 hours. The TR band will be left inflated and in place for 60 minutes following the procedure for all patients (regardless of diagnostic or PCI procedure), after which full deflation attempts will commence.
89202204|NCT04046952|Experimental|Statseal with TR Band|Patients will have a Statseal Advance RAD (SS) disc applied after withdrawing the radial sheath 2-4 cm. A Tegaderm dressing will be applied to secure the disc position. The TR band will be applied over the SS disc with the center of the balloon (the green dot) over the center of the SS disc. The TR band will be inflated with 8cc of air (which is typically occlusive pressure), and the sheath removed. No deflation will occur immediately. After 20 minutes of pressure, 3 cc of air will be removed from the TR band. After an additional 40 minutes (60 minutes after procedure), the TR band will be completely deflated.
89202205|NCT00937599|Experimental|Brazil Nuts|The first group consumed the brazil nuts and the other group placebo (lactose pills)
89202206|NCT02555514||Knee Osteoarthritis|The study population consists of 100 enrolled patients with different stages of knee OA and varus malalignment >4° with respect to the mechanical loading axis of the lower extremity. A minimum of 40 patients are to be included per year, so that the study period will be planned from January 1st, 2015 to June 30th, 2017. Preliminary results will be reviewed by the end of every year and intermediate reports will be generated by the sub-study-groups
89202207|NCT00937677||1|63 patients with relapsing-remitting Multiple Sclerosis who are enrolled in the TOUCH program and have been taking Tysabri monotherapy for 2 years.
89202208|NCT00937677||2|22 age- and sex-matched normal controls who completed 1 year follow-up.
89202209|NCT00786162|Experimental|Intervention|Internet-based hypertension self-management platform
89018645|NCT00303342|Active Comparator|desensitization|mentation on insomnia behaviors and cognitive activity
89018646|NCT00303381|Experimental|Interferon-beta-1a, 44 microgram|
89018647|NCT00303381|Experimental|Interferon-beta-1a, 66 microgram|
89018648|NCT00303381|Placebo Comparator|Placebo|
89468530|NCT01123707|Experimental|Prior Aripiprazole|Aripiprazole capsules, orally at the daily dose of 3, 6, or 12 mg, in combination with escitalopram 10 or 20 mg orally, once daily in combination with escitalopram 10 or 20 mg (i.e., the final dose taken during the previous study), orally, once daily, for 36 weeks. Participants were titrated to the aripiprazole target dose of 12 mg/day at Week 1 if the initial 6 mg/day dose was tolerated. The dose adjustments were allowed for aripiprazole to establish the MTD by Week 4. Participants who received aripiprazole in the double-blind treatment period in previous studies were included in this group.
89468531|NCT01123707|Experimental|Prior Single-blind Escitalopram|Aripiprazole capsules, orally at the daily dose of 3, 6, or 12 mg, in combination with escitalopram 10 or 20 mg orally, once daily in combination with escitalopram 10 or 20 mg (i.e., the final dose taken during the previous study), orally, once daily, for 36 weeks. Participants were titrated to the aripiprazole target dose of 12 mg/day at Week 1 if the initial 6 mg/day dose was tolerated. The dose adjustments were allowed for aripiprazole to establish the MTD by Week 4. Participants who received escitalopram in the single-blind treatment period in previous studies were included in this group.
89468532|NCT03144752||Cohort 1: Participants between 8 to 14 weeks gestation|Cohort 1 will include female participants who present for the first prenatal visit which takes place between Weeks 8 and 14 at maternity practices associated with University of North Carolina (UNC) Women's Care. Biomarkers, medical and psychiatric history, and psychosocial measures will be evaluated and utilized in developing a predictive risk algorithm for perinatal depression.
89468533|NCT03144752||Cohort 2: Participants between 15 to 36 weeks gestation|Cohort 2 will include female participants enrolled at various points in their pregnancy from Week 15 up through 36 weeks gestation. Biomarkers, medical and psychiatric history, and psychosocial measures will be evaluated and utilized in developing a predictive risk algorithm for perinatal depression.
89468534|NCT02332772||Data Collection Endoscopy of Colon Polyps|Data collected from endoscopy reports and electronic medical record system to complete a descriptive analysis of the 1) demographics, 2) colonoscopy resection procedure, and 3) outcome of resection - immediate and delayed complications, tumor recurrence, and cancer during follow-up 01/01/2014 - 12/31/2025.
89468535|NCT02755103|Experimental|Women receiving MBRP plus TAU|Women will receive the Mindfulness Based Relapse Prevention (MBRP) plus treatment as usual (TAU less trauma focused group).
89468536|NCT02755103|No Intervention|Women receiving TAU|Women will only receive treatment as usual (TAU less trauma focused group).
89468537|NCT02329418|Experimental|Written document|Accompanying relatives with a written document when discussing withholding and withdrawing life-sustaining therapies . All other procedures are standard.
89468538|NCT02329418|Active Comparator|Standard|Discussing withholding and withdrawing life-sustaining therapies following standard procedure without written document
89468539|NCT01258803|Experimental|Sequence 1|Treatment Period 1: Placebo MDI with spacer; Treatment Period 2: MF/F MDI without spacer; Treatment Period 3: MF/F MDI with spacer; Treatment Period 4: F DPI
89468540|NCT01258803|Experimental|Sequence 2|Treatment Period 1: F DPI; Treatment Period 2: MF/F MDI without spacer; Treatment Period 3: MF/F MDI with spacer; Treatment Period 4: Placebo MDI with spacer
89018649|NCT00290420|Experimental|Chloroquine profilaxis|"Prevention: chloroquine profilaxis~Prevention of malaria attacks with chloroquine profilaxis taken once a week"
89018650|NCT00290420|No Intervention|No prevention|Treatment of malaria attack with chloroquine when they occur
89468541|NCT01258803|Experimental|Sequence 3|Treatment Period 1: MF/F MDI without spacer; Treatment Period 2: F DPI; Treatment Period 3: Placebo MDI with spacer; Treatment Period 4: MF/F MDI with spacer
89468542|NCT01258803|Experimental|Sequence 4|Treatment Period 1: Placebo MDI without spacer; Treatment Period 2: MF/F MDI with spacer; Treatment Period 3: F DPI; Treatment Period 4: MF/F MDI without spacer
89468543|NCT01258803|Experimental|Sequence 5|Treatment Period 1: MF/F MDI without spacer; Treatment Period 2: F DPI; Treatment Period 3: MF/F MDI with spacer; Treatment Period 4: Placebo MDI without spacer
89018651|NCT00303420|Active Comparator|1|Alteplase used by normal dwell procedure
89468544|NCT01258803|Experimental|Sequence 6|Treatment Period 1: MF/F MDI with spacer; Treatment Period 2: Placebo MDI without spacer; Treatment Period 3: MF/F MDI without spacer; Treatment Period 4: F DPI
89468545|NCT02327156|No Intervention|group L|receive 4 mL of levobupivacaine 0.75% plus hyaluronidase 15 IU diluted with 1mL normal saline
89468546|NCT02327156|Active Comparator|group LD|4 mL of levobupivacaine 0.75% plus hyaluronidase 15 IU and dexmedetomidine 20 μg diluted with 1mL normal saline
89018652|NCT00303420|Experimental|2|"Alteplase given by an new push protocol"
89018653|NCT00324129|Experimental|1|
89018654|NCT00324324|Active Comparator|moxifloxacin hydrochloride|Moxifloxacin 400 mg capsule orally once a day through D+100 after bone marrow transplant, then discontinue
89018655|NCT00324324|Placebo Comparator|Sugar pill|Placebo 1 capsule orally once a day through D+100 after bone marrow transplant, then discontinue
89018656|NCT00324363|Experimental|Exenatide|Placebo lead-in; exenatide 5 mcg for 4 weeks; exenatide 10 mcg for 12 weeks
89018657|NCT00324363|Placebo Comparator|Placebo|Placebo in volume equal to exenatide
89018658|NCT00291200||1|Participants with basic symptoms of psychosis
89018659|NCT00291200||2|Control participants
89468547|NCT02033291||Cortical stroke or primary intracerebral hemorrhage patients:|patients who have a clear clinical presentation of either cortical stroke or primary intracerebral hemorrhage confirmed on brain CT. The patients are eligible when the DCE-MRI scans can be performed within 0-6 weeks of the vascular event and on two subsequent days as the vascular permeability may change significantly on the timescale of weeks.
89468548|NCT02033291||cSVD patients|patients who present with a transient ischemic attack (TIA) and cSVD related abnormalities on brain MRI. TIA patients are defined as patients with stroke like symptoms that last no longer than 24 hours. MRI abnormalities include extended white matter lesions, (asymptomatic) lacunar infarcts, microbleeds and enlarged Virchow-Robin spaces. The patients are eligible when the first DCE-MRI scan can be performed 8-12 weeks after the TIA to avoid the acute phase, and the second MRI-scan within four weeks after the first.
88947154|NCT01915017|Experimental|Cognitive Behavior Therapy for Psychosis|Cognitive behavior therapy for psychosis is a manual-driven collaborative talk-therapy designed to help the individual identify appraisal biases and cognitive distortion, identify alternative explanations for events, and find ways to cope with the distress caused by persistent psychotic symptoms.
88947155|NCT01915017|Experimental|Cognitive Adaptation Training|CAT is a manual driven treatment using environmental supports such as signs, alarms, checklists, electronic devices, and the organization of belongings to bypass cognitive and motivational impairments and to cue and sequence adaptive behavior.
88947156|NCT01915017|Experimental|Multi-modal Cognitive Therapy|Combines Cognitive Behavior Therapy for Psychosis and Cognitive Adaptation Training into one home-delivered intervention
88947157|NCT01915017|Active Comparator|Treatment as Usual|Medication follow up and limited case management provided by the local community mental health center
88947158|NCT01915030|Experimental|High protein diet|High protein diet during caloric restriction
89468549|NCT02329340|Active Comparator|Am Academy of Pediatrics print materials|In-person session to read online version of American Academy of Pediatrics The Injury Prevention Program (TIPP sheets) childhood injury prevention print materials, followed by access to the TIPP sheets for 30 days.
88947159|NCT01915030|Placebo Comparator|Standard protein diet|Standard protein diet during caloric restriction
88947160|NCT01915043|Active Comparator|health education for lymphedema prevention|health education for lymphedema prevention
88947161|NCT01915043|Experimental|application smartphone-based group|Health education plus Smartphone-based application sample will have a reminder to do education everyday where patients will have to select if they have done or they haven´t done compliance
88947162|NCT01915056|No Intervention|Control Arm|Control Arm = Standard of Care. Patients who are randomized to the control arm will only have abnormal results on Geriatric Depression Scale (GDS) and cognitive evaluation communicated to their primary oncologist, as is customary. These results will be communicated to the primary team via electronic medical record and/or email communication. No other summary will be provided to oncologist.
88947163|NCT01915056|Experimental|Treatment Arm|Treatment Arm = Standard care plus GA results and recommendations. For patients assigned to the treatment arm, individuals will be offered the option of completing the GA during a visit with their primary oncologist, or attending an additional visit at the multidisciplinary geriatric oncology clinic (GA-driven intervention). The intervention consists of providing results of geriatric assessment in a summary to oncologists.
88947164|NCT01915069|Experimental|Cilostazol|The primary aim of the study is to assess the affects of oral Cilostazol taken at the FDA approved dose of 100mg PO bid on human oocyte maturation.
88947165|NCT01915082|Experimental|Azithromycin|"A first dose of azithromycin (25 mL po syrup = 1000 mg) will be given during preparation for subsequent lung transplantation (Day 0).~After lung transplantation, 'add on' treatment of azithromycin (6.25 mL = 250 mg) syrup will be given via (naso)gastric tube or per os every other day (days 1,3,5,7,9,11,13,15,17,19,21,23,25,27,29 and 31)."
88947166|NCT01915082|Placebo Comparator|Ora-Plus|"A first dose of placebo (25 mL po syrup) will be given during preparation for subsequent lung transplantation (Day 0).~After lung transplantation, 'add on' treatment of placebo (6.25 mL) syrup will be given via (naso)gastric tube or per os every other day (days 1,3,5,7,9,11,13,15,17,19,21,23,25,27,29 and 31)."
88947167|NCT01915121|Active Comparator|Education Intervention|In this session, participant will be provided with information about bladder cancer treatment options, and training tools directly related to Bladder Cancer.
88947168|NCT01915121|Placebo Comparator|Nutrition Intervention|In this session, participant will be provided with information about nutrition information directly related to bladder cancer recovery
88947169|NCT01915134|Experimental|EGP group|the group of participants who undergoing Recombinant Human Endostatin plus Gemcitabine and cisplatin chemotherapy
88947170|NCT01915134|Active Comparator|GP group|the group of participants who undergoing only Gemcitabine and cisplatin chemotherapy
88947171|NCT01915147|Experimental|OXN PR followed by OxyPR tablets|OXN PR followed by OxyPR tablets
88947172|NCT01915147|Experimental|OxyPR followed by OXN PR tablets|OxyPR followed by OXN PR tablets
88947173|NCT01915160|Active Comparator|treatment as usual|Trauma Focused- Cognitive Behavioral Therapy (TF-CBT)
88947174|NCT01915160|Experimental|tablet assisted therapy toolkit|electronically assisted Trauma Focused-Cognitive Behavioral Therapy (eTF-CBT)
88947175|NCT01915186|Experimental|Dihydroepiandrosterone (DHEA)|DHEA 25mg 3 times a day for 12 weeks
88947176|NCT01915186|Placebo Comparator|Placebo|Matched placebo capsules are given 3 times a day for 12 weeks
88947177|NCT01915199|Experimental|Intervention|Patients in this arm received a comprehensive intervention on hypertension through optimization of drug therapy, introduction of home blood pressure monitoring, and lifestyle guidance.
88947178|NCT01915199|No Intervention|Control|Patients randomized in this group did not receive any intervention and treatment continued according to conventional practice.
88947179|NCT01915264||Group 1|
89018660|NCT00303732|Experimental|PTK787, RAD001|PTK787 (vatalinib) 1000 mg daily, RAD001 (everolimus) 5 mg daily
89018661|NCT00324402||1|Healthy pregnant women, 18-40
89018662|NCT00303771|Active Comparator|LV5FU2 classique|LV5FU2 classique
89018663|NCT00303771|Experimental|LV5FU2 classique + irinotécan|LV5FU2 classique + irinotécan
89018664|NCT00303771|Active Comparator|LV5FU2 simplifié|LV5FU2 simplifié
89018665|NCT00303771|Experimental|LV5FU2 simplifié+ irinotécan|LV5FU2 simplifié + irinotécan
89018666|NCT00324480|Experimental|Treatment (chemotherapy, enzyme inhibitor)|Before beginning course 1 of study therapy, patients receive oral SAHA on days 1-3 in order to ensure tolerability of the drug. Beginning 1 week later, patients receive oral SAHA once daily on days 1-3 and 8-10 and fixed-dose alvocidib IV over 1 hour on days 2 and 9. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
89018667|NCT00303888|Experimental|Arm I|Patients receive docetaxel IV over 1 hour on days 1, 8, and 15 and oral placebo three times daily on days 1-21.
89018668|NCT00303888|Experimental|Arm II|Patients receive oral phenoxodiol three times daily on days 1-21 and docetaxel IV over 1 hour on days 1, 8, and 15.
89018669|NCT00324519|Active Comparator|Misoprostol Drug|This is the misoprostol drug.
89018670|NCT00324519|Experimental|The Foley Bulb|This is the experimental portion to test the Foley Bulb.
89018671|NCT00324558|Experimental|1|Bemiparin 3,500 IU
89018672|NCT00324558|No Intervention|Control|
89018673|NCT00304200|Experimental|Single arm, Open Label|Single arm, Open Label Temodar and Sutent
89018674|NCT00291941|Experimental|1|Henogen HB vaccine
89018675|NCT00291941|Active Comparator|2|Fendrix vaccine
89018676|NCT00291980|Experimental|1|HB-AS02V vaccine
89018677|NCT00291980|Active Comparator|2|HBVAXPRO vaccine
89018678|NCT00292019||Robotic prostatectomy|Patients who are eligible for a radical prostatectomy will have their surgery conducted with the aid of surgical robotics.
89018679|NCT00304317|Experimental|I|Celecoxib
89018680|NCT00304317|Placebo Comparator|II|Placebo
89018681|NCT00292097|Experimental|1|Early conversion from endotracheal intubation to percutaneous tracheostomy for ventilator support of trauma patients with severe brain injury
89018682|NCT00292097|Active Comparator|2|Conventional conversion from endotracheal intubation to percutaneous tracheostomy for ventilator support of trauma patients with severe brain injury
89468550|NCT02329340|Experimental|Family Safety 1-2-3|In-person session to view video and text-based interactive web site on injury prevention information and strategies, followed by 8 emails delivered over a 30-day period inviting participant to view additional child safety videos.
89018683|NCT00292253|Experimental|Rebif® with Rebiject™Mini|
89018684|NCT00292253|Active Comparator|Rebif® without Rebiject™Mini|
89018685|NCT00304434|Other|1|
89018686|NCT00304551|Experimental|1|
89018687|NCT00304551|Experimental|2|
89018688|NCT00304551|No Intervention|3|
89018689|NCT00292526|Experimental|enalapril arm|treatment with enalapril
89018690|NCT00292721|No Intervention|Control|
89018691|NCT00292721|Active Comparator|Celecoxib|
89018692|NCT00325182|Experimental|Intervention: Levetiracetam|Levetiracetam dose schedule Days 1-4 250 mg bid Days 5- 19 500 mg bid Days 20 -70 1000 mg bid Days 71-78 500 mg bid Days 79-85 250 mg bid Days 86-91
89018693|NCT00325182|Placebo Comparator|Historical controls|Historical controls from COMBINE study who receive a placebo
89018694|NCT04718324|Experimental|e-PROMS|Patients allocated to the e-PROMS arm will fill an online version of PROMS and then respond to the e-PREMS questionnaire.
89018695|NCT04718324|Active Comparator|p-PROMS|Patients allocated to the p-PROMS arm will fill in PROMS in paper form (p-PROMS) and then respond to the p-PREMS questionnaire.
89018696|NCT00325221|Experimental|Home Monitoring On|Home Monitoring activated after implantation (Intervention HM On)
89018697|NCT00325221|Experimental|Home Monitoring Off|Home Monitoring activated 9 months after implantation (Intervention HM Off)
89018698|NCT00293150|Active Comparator|Eplerenone|Eplerenone 25mg daily for 2 weeks Titrated to Eplerenone 50mg daily
89018699|NCT00293150|Placebo Comparator|Placebo|Placebo dosed daily
89018700|NCT00293228|Experimental|A|Recently converted contacts receiving isoniazid (5mg per kg up to 300 mg daily for 6 months) immediately after recruitment.
89018701|NCT00293228|Active Comparator|B|B. Recently converted contacts receiving isoniazid (5mg per kg up to 300 mg daily for 6 months) three months after recruitment.
89018702|NCT00293228|Experimental|C|C. Remote contacts receiving isoniazid (5mg per kg up to 300 mg daily for 6 months) immediately after recruitment
89018703|NCT00293228|Active Comparator|D|D. Remote contacts receiving isoniazid (5mg per kg up to 300 mg daily for 6 months) three months after recruitment.
89018704|NCT00293345|Experimental|Treatment (gemcitabine hydrochloride, triapine)|Patients receive 3-AP (TriapineÃÂ®) IV over 24 hours followed by gemcitabine hydrochloride IV over 100-125 minutes on days 1 and 8. Treatment repeats every 3 weeks for 12 courses in the absence of disease progression or unacceptable toxicity.
89018705|NCT00293618|Experimental|Intervention|Arm of anesthesiologists and senior residents who receive a patient's individual predicted PONV risk intraoperatively
89018706|NCT00293618|Active Comparator|Usual Care|Anesthesiologists and senior residents who provide usual care: they provide PONV prophylaxis as they always have
89018707|NCT00325494|Experimental|Cohort 1|MORAb-009 weekly dose of 12.5 mg/m^2
89018708|NCT00325494|Experimental|Cohort 2|MORAb-009 weekly dose of 25 mg/m^2
89018709|NCT00325494|Experimental|Cohort 3|MORAb-009 weekly dose of 50 mg/m^2
89018710|NCT00325494|Experimental|Cohort 4|MORAb-009 weekly dose of 100 mg/m^2
89018711|NCT00325494|Experimental|Cohort 5|MORAb-009 weekly dose of 200 mg/m^2
89018712|NCT00325494|Experimental|Cohort 6|MORAb-009 weekly dose of 400 mg/m^2
89018713|NCT00304863|No Intervention|Arm 1|This are will not receive Lactobacillus
89018714|NCT00304863|Experimental|Arm 2|This arm will receive lactobacillus
89018715|NCT00293735|Active Comparator|1. Labetolol|
89018716|NCT00293735|Active Comparator|2. Magnesium Sulfate|
89468551|NCT03610529|Experimental|ECG monitoring system CardioSenseSystem group|
89468552|NCT03610529|Active Comparator|ECG monitoring system Philips Intellivue|
89468553|NCT02039804|Experimental|Hyaluronic acid|Injectable hyaluronic acid.
89468554|NCT02039804|Active Comparator|Corticosteroids|Injectable corticosteroids.
89468555|NCT02865083|Active Comparator|Treatment|Subjects will receive use of the Traxi pannus retractor when undergoing cesarean section
89468556|NCT02865083|No Intervention|Standard|Patients will receive use of the standard of care option which is the montgomery straps
89468557|NCT03112070|Experimental|Water aerobic exercise session (WATER)|A continuous session of dynamic water aerobic exercise which consist of a dynamic warm-up period (5 minutes), an active exercise period (35 minutes), and a cooldown period (5 minutes) to total 45 minutes. Heart rate (HR) will be continuously measured with heart monitors (Polar) to confirm the intensity of the WATER session. The WATER intensity will be calculated according to the formula proposed by Kruel for exercise in an aquatic environment18 as follows: HR for exercise = % x (HRmax - ΔHR); % is the intensity of exercise; HRmax is the maximum HR (estimated by 220 - age); ΔHR represents the difference between resting HR on land and resting HR in the water environment. Exercise intensities: 55-60% HRmax during warm-up; 70-75% HRmax during active exercise; and 55-60% HRmax during cooldown.
89468558|NCT03112070|No Intervention|Control session (CONTROL)|A 45-min session with no exercise. During this session, participants will remain seated or standing as desired. They will read, talk, and drink water, but do nothing else.
89468559|NCT03385161|Active Comparator|botulinum toxin A|"Intraprostatic injection of botulinum toxin A (onabotulinumtoxinA; 100 IU) through transrectal ultrasonography.~One vial (100 IU) is dissolved in 10 ml saline and injected in the transition zone of each lobe of the prostate in 3 sites; basal, middle and apical.~one gm intramuscular ceftriaxone started and continued 3 days. A rectal enema performed the night before the procedure. The anal area sterilized A 21 gauge needle was introduced to the prostate."
89468560|NCT03385161|Active Comparator|Ethanol|"Intraprostatic injection of dehydrated ethanol through transrectal ultrasonography.~An amount equal to 25% of prostate volume was injected distributed over 6-8 sites among both prostatic lobes with an average of 2 ml per site.~one gm intramuscular ceftriaxone started and continued 3 days. A rectal enema performed the night before the procedure. The anal area sterilized A 21 gauge needle introduced to the prostate."
89468561|NCT02327000|Experimental|GLA5PR GLARS-NF1 tablet 150mg|GLA5PR GLARS-NF1 tablet 150mg/day(Pregabalin 150mg once a day, after meal)
89468562|NCT02327000|Experimental|GLA5PR GLARS-NF1 tablet 300mg|GLA5PR GLARS-NF1 tablet 300mg/day(Pregabalin 300mg once a day, after meal)
89468563|NCT02327000|Experimental|GLA5PR GLARS-NF1 tablet 450mg|GLA5PR GLARS-NF1 tablet 450mg/day(Pregabalin 150mg 1 tablet and Pregabalin 300mg 1 tablet, 1 times a day, after meal)
89468564|NCT02327000|Experimental|GLA5PR GLARS-NF1 tablet 600mg|GLA5PR GLARS-NF1 tablet 600mg/day(Pregabalin 300mg, 2 tablets 1 times a day, after meal)
89468565|NCT02032979|Experimental|FSHD patient|
89468566|NCT01036113|Experimental|Experimental: EZN-2208|Experimental: EZN-2208 EZN-2208 will be administered as an i.v. infusion on weekly basis for 3 weeks and repeated every 28 days.
89468567|NCT03111524|Active Comparator|Intervention school 1|All participants complete the questionnaire at baseline. The Classroom Communication Resource Intervention is administered by the teacher. The participants observe the intervention which is a social story (read by the teacher), the class performs a role-play (same plot as the story) and then the teacher facilitates and leads a semi-structured discussion. The intervention takes place in 1 classroom lesson only. No further intervention is completed.
89468568|NCT03111524|Active Comparator|Intervention school 2|All participants complete the questionnaire at baseline. The Classroom Communication Resource Intervention is administered by the teacher.The participants observe the intervention which is a social story (read by the teacher), the class performs a role-play (same plot as the story) and then the teacher facilitates and leads a semi-structured discussion. The intervention takes place in 1 classroom lesson only. No further intervention is completed.
89468569|NCT03111524|Active Comparator|Intervention school 3|All participants complete the questionnaire at baseline. The Classroom Communication Resource Intervention is administered by the teacher. The participants observe the intervention which is a social story (read by the teacher), the class performs a role-play (same plot as the story) and then the teacher facilitates and leads a semi-structured discussion. The intervention takes place in 1 classroom lesson only. No further intervention is completed.
89468570|NCT03111524|Active Comparator|Intervention school 4|All participants complete the questionnaire at baseline. The Classroom Communication Resource Intervention is administered by the teacher. The participants observe the intervention which is a social story (read by the teacher), the class performs a role-play (same plot as the story) and then the teacher facilitates and leads a semi-structured discussion. The intervention takes place in 1 classroom lesson only. No further intervention is completed.
89468571|NCT03111524|Active Comparator|Intervention school 5|All participants complete the questionnaire at baseline. The Classroom Communication Resource Intervention is administered by the teacher. The participants observe the intervention which is a social story (read by the teacher), the class performs a role-play (same plot as the story) and then the teacher facilitates and leads a semi-structured discussion. The intervention takes place in 1 classroom lesson only. No further intervention is completed.
89468572|NCT03111524|Placebo Comparator|control school 1|All participants complete the questionnaire at baseline. The Classroom Communication Resource Intervention is not administered by the teacher.
89018717|NCT00293774||Standard|Standard hip replacement subjects (polyethylene)
89018718|NCT00293774||Alternative Bearing|Subjects with ceramic on ceramic total hip replacement or metal on metal hip resurfacing.
89018719|NCT00293852|No Intervention|Usual Care|
89018720|NCT00293852|Experimental|Collaborative Care|
89018721|NCT00325533|Experimental|Screening & Enhanced Intervention|After an intensive 10-week baselne screening, the enhanced intervention group barbers will be trained to measure blood pressure and deliver health messages related to blood pressure control during each customer's visit.
89468573|NCT03111524|Placebo Comparator|control school 2|All participants complete the questionnaire at baseline. The Classroom Communication Resource Intervention is not administered by the teacher.
89468574|NCT03111524|Placebo Comparator|control school 3|All participants complete the questionnaire at baseline. The Classroom Communication Resource Intervention is not administered by the teacher.
89468575|NCT03111524|Placebo Comparator|control school 4|All participants complete the questionnaire at baseline. The Classroom Communication Resource Intervention is not administered by the teacher.
89468576|NCT03111524|Placebo Comparator|control school 5|All participants complete the questionnaire at baseline. The Classroom Communication Resource Intervention is not administered by the teacher.
88947180|NCT01915277|Experimental|Neonate dosing cohort 1|Neonate dexmedetomidine dosing cohort 1
88947181|NCT01915277|Experimental|Neonate dosing cohort 2|Neonate dexmedetomidine dosing cohort 2
88947182|NCT01915277|Experimental|Neonate dosing cohort 3|Neonate dexmedetomidine dosing cohort 3
89468577|NCT02033057|Experimental|Muscular electrostimulation.|The interventions is muscular electrostimulation.
88947183|NCT01915277|Experimental|Neonate dosing cohort 4|Neonate dexmedetomidine dosing cohort 4
88947184|NCT01915277|Experimental|Neonate dosing cohort 5|Neonate dexmedetomidine dosing cohort 5
88947185|NCT01915277|Experimental|Infant dosing cohort 1|Infant dexmedetomidine dosing cohort 1
88947186|NCT01915277|Experimental|Infant dosing cohort 2|Infant dexmedetomidine dosing cohort 2
88947187|NCT01915277|Experimental|Infant dosing cohort 3|Infant dexmedetomidine dosing cohort 3
88947188|NCT01915277|Experimental|Infant dosing cohort 4|Infant dexmedetomidine dosing cohort 4
89468578|NCT02329184|Experimental|MYK-461|
89468579|NCT02558699|Active Comparator|conventional group|Group operating the atrial fibrillation by physician's personal experience, not by virtual simulation.
89468580|NCT02558699|Experimental|3D atrial computer model|Group choosing choose the best effective rotor mapping by simulating 3D atrial computer model which consider patinet's heart size and shape.
88947189|NCT01915277|Experimental|Infant dosing cohort 5|Infant dexmedetomidine dosing cohort 5
88947190|NCT01915290||1600 elderly participants|Norwegian elderly population
88947191|NCT01915316||Prostate cancer|Men. Subjects have undergone primary and at least one secondary prostate biopsy with negative diagnostics. Elevated PSA (Prostate Specific Antigen), typically above 10 ng/mL.
88947192|NCT01915329|Experimental|Verum-RSS|RSS Stimulation with high frequency electric pulses
88947193|NCT01915329|Sham Comparator|Sham-RSS|Sham RSS Stimulation (no pulses are transmitted)
88947194|NCT01915342|Experimental|Focal muscle vibration|"Focal muscular vibration will be applied at mGCM of each subject for 10 minutes in each session.~Frequency: 40, 80, 120 Hz Amplitude: 0.1, 0.3, 0.5 mm"
88947195|NCT01915355|Experimental|Pulsed Dye Laser for fungus treatment|The purpose of this research is to investigate the use of the Candela V-beam Pulsed Dye Laser for the treatment of onychomycosis, a common nail fungus.
88947196|NCT01915368|Active Comparator|Stroke Management Program (SMP)|Participants will have usual care, and in addition, be provided with periodic information about their progress in the area of mobility using specialized activity monitors
88947197|NCT01915368|Experimental|Stroke Monitoring Program (SMonP)|Participants will have usual care, and in addition, be progressed according to customized protocols using feedback from specialized activity monitors
88947198|NCT01915368|Experimental|Stroke Supplementary Program (SSP)|Participants will have usual care, and in addition, will receive the same as the Stroke Monitoring Group, and also receive one additional hour of daily (5 times per week) physical exercise
88947199|NCT01915381|Active Comparator|Control group|follow up detraining effect of multimodal intervention
88947200|NCT01915381|Experimental|application smartphone-based group|Smartphone-based application group (SG) sample will have a reminder to do Phisical activity everyday where patients will have to select if they have done or they haven´t done physical activity.
88947201|NCT01915394||Hospitalized Respiratory Syncytial Virus Infected Newborns|All admitted newborns to the neonatal intensive care unit (NICU) will be enrolled in the study
88947202|NCT01915433|Experimental|Wahls Paleo Plus|Wahls Paleo Plus diet (ketogenic diet)
88947203|NCT01915433|Experimental|Wahls Diet|Wahls Diet (modified paleolithic diet)
88947204|NCT01915433|No Intervention|Usual Care|Control - usual care only.
88947205|NCT01915459|Experimental|Botulinum toxin type A(Botulax®)|Botulinum toxin type A
88947206|NCT01915459|Active Comparator|Botulinum toxin type A(Botox®)|Botulinum toxin type A
88947207|NCT01915472|Experimental|IMMU 130|
89468581|NCT02033603|Active Comparator|Femoral Nerve Block|Femoral Nerve block performed with 0.5% Ropivacaine 30mls (150mg)
89468582|NCT02033603|Active Comparator|Adductor Canal block|Adductor Canal block performed with 0.5% Ropivacaine 30mls (150mg)
89468583|NCT02326922|Experimental|Metraplant-E First prototype|Metraplant-E (first prototype) levonorgestrel-releasing intrauterine device
89468584|NCT02326922|Experimental|Metraplant-E second prototype|Metraplant-E (second prototype) levonorgestrel-releasing intrauterine device
89468585|NCT00862251|Experimental|Ezetimibe/simvastatin|
89468586|NCT00862251|Active Comparator|Doubling statin dose|
88947208|NCT01915485|Experimental|Lu 177|progressive metastatic medullary thyroid cancer
88947209|NCT01915524|Experimental|CV9202 and local radiation|"CV9202 consisting of 6 RNActive-derived molecules coding for 6 different NSCLC associated antigens.~local radiation (4x5 Gy)"
88947210|NCT01915537|Experimental|Infliximab group|Infliximab with MTX treatment
89537293|NCT03066921|Experimental|Probiotic packet|Probiotic formulation will be given at a dose of one packet thrice daily for 24 weeks, amounting to a total of 300 billion colony forming units(CFU)/day. Each packet contains 100 billion viable lyophilized bacteria of three strains of Lactobacillus viz Lactococcus lactis subsp. Lactis LL358 (BCRC910699)、Lactobacillus salivarius LS159 (BCRC910700) and Lactobacillus pentosus and excipients.
88947211|NCT01915537|Active Comparator|Classic DMARDs treatment group|Classic DMARDs treatment（MTX 、LEF 、HCQ 、 LEF ）
88947212|NCT01915550|Active Comparator|metformin|metformin was added without raising the insulin dose
88947213|NCT01915550|Active Comparator|Raising Insulin|insulin dose is raised
88947214|NCT01915576|Experimental|BAY1125976 [once daily, dose-esc.]|Oral administration once daily. Starting dose is 10 mg and will be escalated depending on any dose-limiting toxicities
88947215|NCT01915576|Experimental|BAY1125976 [twice daily, dose-esc.]|Oral administration twice daily. Starting dose is 40mg twice daily and will be escalated depending on any dose-limiting toxicities
88947216|NCT01915576|Experimental|BAY1125976 [MTD]|Oral administration of the defined MTD which shows optimal safety, PK profile, PD target inhibition and preliminary efficacy (once daily or twice daily) in different patient groups
88947217|NCT01915589|Experimental|Refametinib (BAY86-9766)|For purposes of data recording, the treatment period will be divided into 3-week cycles. Patients will continue on treatment until at least one of the following occurs (main criteria): Death Unacceptable toxicity Subject withdraws consent Substantial non-compliance with the protocol Treating physician determines discontinuation of treatment is in the subject's best interest. Radiological progression as determined by RECIST (Version 1.1) or mRECIST criteria or clinical progression (e.g. Eastern Cooperative Oncology group performance status - ECOG PS ≥3) patients may continue to receive study treatment if identified as having continued clinical benefit as judged by the treating physician.
89468587|NCT00862251|Active Comparator|Rosuvastatin|
89468588|NCT02329106|Experimental|NanoKnife LEDC System|Ablation with the NanoKnife Low Energy Direct Current (LEDC) System, alao called Irreversible electroporation (IRE), 90 pulses of 70 microseconds each in duration will be administered per electrode pair.
89468589|NCT02329106|No Intervention|Control|The patients without treatment
89468590|NCT03144986|Experimental|Deep insula-coil rTMS|"Active treatment phase consists of deep rTMS (18 Hz, 2 sec on, 20 sec off, over approximately 30 min) 5 times per week, for 6 weeks, for a total of 30 sessions as a part of an active treatment phase.~Maintaince treatment phase includes two sessions of rTMS (18 Hz, 2 sec on, 20 sec off, over approximately half an hour) weekly for the period of 6 weeks."
88947218|NCT01915602|Experimental|Refametinib and Sorafenib (Nexavar)|In Cycle 1 reduced sorafenib dose (600 mg daily; 200 mg in the morning + 400 mg in the evening) is administered, which is escalated to the standard dose in Cycle 2, if no Hand-foot skin reaction (HFSR), fatigue, or gastrointestinal (GI) toxicities of grade 2 or higher occur. For the purposes of data recording, the treatment period will be divided into 3-week cycles. Patients will continue on treatment until at least one of the following occurs (main criteria): Progressive Disease (PD) {PD as defined by mRECIST criteria or clinical progression [e.g. Eastern Cooperative Oncology Group performance status (ECOG PS) of ≥3], treatment may be continued past radiological progression, provided the patient derives clinical benefit as judged by the treating physician.}, Death, Unacceptable toxicity, Subject withdraws consent, Treating physician determines discontinuation of treatment is in the subject's best interest, Substantial non-compliance with the protocol
88947219|NCT01915628||BioMatrix Flex|percutaneous coronary intervention
88947220|NCT01915641|Active Comparator|group A|group A : CPAP treatment with optimal pressure for 1 month, repeat measurement change CPAP treatment to sham pressure 5cm H2O for 1 month, repeat measurement
88947221|NCT01915641|Sham Comparator|group B|group B : CPAP treatment with sham pressure for 1 month, repeat measurement change CPAP treatment with optimal pressure for 1 month, repeat measurement
89468591|NCT02329028||Prehospital mini-EEG|Feasibility of prehospital EEG device in unconscious patients.
89468592|NCT02332538|Active Comparator|Greenlight (532nm-laser) PVEP|532nm-laser photoselective vapo-enucleation of the prostate)
89468593|NCT02332538|Active Comparator|Holmium laser enucleation of prostate|Holmium-Yag laser enucleation of the prostate
89468594|NCT02332538|Active Comparator|Bipolar TURP|Bipolar transurethral resection of the prostate in saline
89468595|NCT00885963|Experimental|sapacitabine|"Part A (lead-in phase): Two dosing schedules, i.e., once daily (q.d.) or twice daily (b.i.d.) x 5 days/week x 2 weeks every 3 weeks will be evaluated.~Part B (Phase 2): Receive the recommended phase 2 dose of once daily or twice daily dosing schedule derived from Part A."
89468596|NCT02332694|Experimental|High intensity whole-body infrared heating|The participant will undergo the WBH intervention where subjects will be induced to levels of heat that increases core body temperature to approximately 37.5-38.5 °C.temperature.
89468597|NCT00725127|Active Comparator|1|100 mg/day ASA upon awakening.
89468598|NCT00725127|Active Comparator|2|100 mg/day ASA at bedtime
89468599|NCT02326766|Experimental|KRG|5g Korea red ginseng (KRG)
89468600|NCT02326766|Placebo Comparator|Placebo|5 g placebo (corn starch)
89468601|NCT02329262|Experimental|Mentoring to be Active|Trained teen mentors will deliver the physical activity curriculum to high school students in a school setting. Physical activity will be measured with accelerometers.
89468602|NCT02329262|Active Comparator|Planning to be Active|High school teachers will deliver the physical activity curriculum (usual care) to high school students enrolled in health education courses. Physical activity will be measured with accelerometers.
89468603|NCT00590109||1|
88947222|NCT01915654||Study population|The study involves patients operated in the cardiothoracic and cardio-vascular surgery department of Besançon University Hospital between December 2008 and May 2009 (study population) or between December 2007 and May 2008 and between December 2009 and May 2010 (reference population).
88947223|NCT01915654||Reference population|The study involves patients operated in the cardiothoracic and cardio-vascular surgery department of Besançon University Hospital between December 2008 and May 2009 (study population) or between December 2007 and May 2008 and between December 2009 and May 2010 (reference population).
89468604|NCT04949685||symptomatic plantar plate rupture|plantar plate repair operation for symptomatic lesser metatarsophalangeal joint instability
89468605|NCT03398577|Experimental|Intervention group|Eligible patients (HbA1C ≥ 7% and ≤ 9%) , who were allocated to the Intervention group will receive Dapagliflozin 10 mg in addition to oral anti-diabetic medication administered prior to study enrollment.
89468606|NCT03398577|Placebo Comparator|Control group|Eligible patients (HbA1C ≥ 7% and ≤ 9%) , who were allocated to the Control group will receive placebo in addition to oral anti-diabetic medication administered prior to study enrollment.
89468607|NCT03389061|Active Comparator|sofosbuvir/velpatasvir tablet|Single-dose sofosbuvir/velpatasvir as a whole tablet in a fasted state.
88947224|NCT01915667|Experimental|GLPG0634 capsule fasted|Single dose of GLPG0634 as capsules in fasted condition
88947225|NCT01915667|Experimental|GLPG0634 tablet fasted|Single dose of GLPG0634 as tablets in fasted condition
88947226|NCT01915667|Active Comparator|GLPG0634 tablet fed|Single dose of GLPG0634 as tablets in fed condition
88947227|NCT01915680||Glaucoma|
88947228|NCT01915680||Control|
88947229|NCT01915693|No Intervention|Arm A: Self-expanding metal stents (SEMS) (Control Arm)|SEMS insertion will be undertaken in accordance with standard local protocols. Covered or partially covered metal stents will be used and the length type and mode of stent placement will be selected by the clinician. Insertion will occur within two weeks of randomisation.
88947230|NCT01915693|Experimental|Arm B: SEMS plus external beam radiotherapy (Intervention Arm)|External beam radiotherapy (EBRT) is routinely available at regional cancer centres across the UK. For palliation of dysphagia in oesophageal cancer, a radiotherapy course delivering a tumour absorbed dose of 20Gy in 5 fractions or 30Gy in 10 fractions within 4 weeks of SEMS insertion.
89468608|NCT03389061|Experimental|sofosbuvir/velpatasvir crushed|Single-dose crushed sofosbuvir/velpatasvir in a fasted state.
89018722|NCT00325533|Active Comparator|Screening|After the intensive 10-week baseline BP screening (an intervention in itself), the barbershops in the comparison arm received a continual supply of American Heart Association pamphlets on Hypertension in African Americans.
89018723|NCT00294008||001|Risperdal Consta flexible dosage for 24 months
89018724|NCT00305097|Experimental|Caffeinated coffee|Caffeinated coffee
88947231|NCT01915706|No Intervention|Observation|Patients randomized to observation will be observed during the post-operative period for spontaneous Baerveldt-350 tube opening. The ripcord will not be removed unless deemed medically necessary by the study physician.
88947232|NCT01915706|Experimental|Ripcord removal|Patients randomized to intervention will have their ripcords removed in clinic at post-operative week 3.
88947233|NCT01915719|Experimental|Early non invasive ventilation|Early non invasive ventilation
88947234|NCT01915719|Active Comparator|Oxygen therapy only|Oxygen therapy only
88947235|NCT01915745|No Intervention|Usually health care|85 patients receive the usually health care. Then they are called during 10 minutes at 6 months to check if bone densitometry will be performed and if antiosteoporotic treatment will be initiated.
88947236|NCT01915745|Experimental|Short Message Service - SMS|85 patients receive 3 SMS (at 15 days, 5 weeks and 3 months) after consulting in the Emergency Department emergencies. Then they are called during 10 minutes at 6 months to check if bone densitometry will be performed and if antiosteoporotic treatment will be initiated.
88947237|NCT01915758|Experimental|occlusive patch 200 uL of clindamycin1%/tretinoin0.025% Gel|occlusive patch 200 uL of clindamycin1%/tretinoin0.025% Gel
88947238|NCT01915758|Placebo Comparator|occlusive patch 200uL of vehicle gel|occlusive patch 200uL of vehicle gel
88947239|NCT01915784|Experimental|Group A|Genuair® (Pressair™) first; Breezhaler® (Neohaler™) second
88947240|NCT01915784|Experimental|Group B|Breezhaler® (Neohaler™) first; Genuair® (Pressair™) second
88947241|NCT01915836|Experimental|Alpha game testers and questionaires|"This a video game designed to help smokers quit & remain non-smokers. Before the start the game,the participant will fill out a brief questionnaire.~It should take about 5 minutes to complete. Once this is done, the game play should last about 30 minutes & will present with different scenes. These scenes will show situations that may trigger smoking urges such as walking into a room where another person is smoking. In the game, the participant will be able to use different ways of coping with urges to smoke such as taking several deep breaths or listening to music. The participant will be asked to talk aloud about what they think of the game. The participant will be video &/or audio recorded while doing this. Once finished testing the game, we will then ask you a few questions about what you thought of the game. We will also ask you how relevant different situations are to you as a smoker or someone who is trying to avoid smoking. The entire visit is expected to last about 1.5 hours."
88947242|NCT01915875|Experimental|sophrology sessions|The sophrology is a dynamic method of physical and psychical relaxation
89018725|NCT00305097|Experimental|Decaffeinated coffee|Decaffeinated coffee
89018726|NCT00305097|Active Comparator|No coffee|
89018727|NCT00325689|Active Comparator|Quetiapine or Risperidone + Aripiprazole|
89018728|NCT00325689|Placebo Comparator|Quetiapine or Risperidone + placebo|
89018729|NCT00294125|Experimental|1|Participants will receive daily flavocoxid for 12 weeks.
89018730|NCT00294125|Placebo Comparator|2|Participants will receive placebo for 12 weeks.
89018731|NCT00294164|Experimental|Serostim® 4 mg daily|
89018732|NCT00294164|Experimental|Serostim® 4 mg alternate days|
89018733|NCT00294164|Placebo Comparator|Placebo|
89018734|NCT00325728|Experimental|Ramelteon 8 mg QD|
89468609|NCT02038868|Experimental|ASP4901 group|After the main enrollment, patients will receive an oral dose of ASP4901 once daily for 4 weeks (double-blind treatment period).
89468610|NCT02038868|Placebo Comparator|Placebo group|After the main enrollment, patients will receive an oral dose of placebo once daily for 4 weeks (double-blind treatment period).
89468611|NCT02038868|Active Comparator|Tamsulosin group|After the main enrollment, patients will receive an oral dose of tamsulosin once daily for 4 weeks (double-blind treatment period).
89468612|NCT03398499|Experimental|Magnetoledotherapy|Active ELF EMF Participants will receive active transcranial low frequency elec-tromagnetic field and magnetic induction (ELF EMF) and high energy LED light were used stimulation,Using the Viofor JPS device (Med & Live)
89468613|NCT03385083|Experimental|ACTIVITY TRACKER|Subjects in Cohort A will receive standard of care treatments in addition to a Fitbit Flex 2 activity tracker for six weeks and recommendation for daily step counts at initial visit. Cohort A will then meet with researchers via telehealth at 2 weeks and 4 weeks with researchers to review step counts and reaffirm targets. Subjects in Cohorts A will be reassessed in person at the conclusion of the six week period.
89468614|NCT03385083|Placebo Comparator|Control|Subjects in Cohort B will receive standard of care treatments in addition to a Fitbit Flex 2 activity tracker for six weeks and recommendation for daily step counts at initial visit. Subjects in Cohorts B will be reassessed in person at the conclusion of the six week period.
89468615|NCT02326688|Experimental|stroke patients|"Kinematic measurement of the amount of trunk displacement during a grasping task~Two separated measurements are recorded with a 6-hours interval~A third measurement provided by a second examinator is conducted"
89468616|NCT02326688|Experimental|control patients|"Kinematic measurement of the amount of trunk displacement during a grasping task~Two separated measurements are recorded with a 6-hours interval~A third measurement provided by a second examinator is conducted"
89468617|NCT03388983|Experimental|6-week prehabilitation group|6-week prehabilitation
89468618|NCT03388983|No Intervention|Control group|Patients will receive standard preoperative care (including information about the surgery from an orthopedic surgeon, and a pamphlet summarizing tips of maintaining proper posture and staying active). The usual postoperative care does not include routine rehabilitation program though a short course of rehabilitation may be given based on orthopedic surgeons' discretion.
89468619|NCT03388905|Experimental|Wearable Cardioverter Defibrillator group|
89468620|NCT02328794|Active Comparator|Control|Participants randomized to this arm will receive a standardized Vitality program aimed at promoting tobacco cessation. This program includes existing employee benefits for quitting and the use of text/email messages to encourage tobacco cessation. No incentives will be given to participants randomized to this arm. Free cessation aids will not be available to participants in this arm. They will receive compensation for completing study related activities (sample submissions).
89468621|NCT02328794|Experimental|E-cigarette free access|Participants randomized to this experimental arm will receive the standardized program including text/email messaging and will have access to free e-cigarettes only. These products can be ordered directly, free of charge, through the web-based interface. No incentives will be given to participants randomized to this arm. They will receive compensation for completing study related activities (sample submissions).
89468622|NCT02328794|Experimental|E-cigarette/NRT/Zyban/Chantix Choice|Participants randomized to this experimental arm will receive the standardized program including text/email messaging and will have access to free e-cigarettes, conventional Nicotine Replacement Therapy (NRT), Zyban, or Chantix. Each of these can be ordered directly, free of charge, through the web-based interface. No incentives will be given to participants randomized to this arm. They will receive compensation for completing study related activities (sample submissions).
89468623|NCT02328794|Experimental|Outcome Incentive arm|Participants randomized to this experimental arm will receive the standardized program and access to free e-cigarettes, NRT, Zyban, or Chantix. In addition, they will also be able to earn incentives across six months for testing negative for tobacco use (see Incentive payout, below). They will also receive compensation for completing study related activities (sample submissions).
89468624|NCT02328794|Experimental|Loss framing incentive arm|Participants randomized to this experimental arm will receive the standardized program and access to free e-cigarettes, NRT, Zyban, or Chantix. In addition they will also be able to earnincentives across six months through a pre-funded deposit or precommitment account. They will be notified that money has been placed into an account for them. At each time point they will lose a portion (see below) of this initial funding if they do not provide biochemical evidence of abstinence. They will also receive compensation for completing study related activities (sample submissions).
89468625|NCT03564080|No Intervention|Control - PAD|This group of patients will complete the 'standard care' of supervised exercise as recommended by NICE.
89468626|NCT03564080|Experimental|Combined - PAD and CAD|This group of PAD patients will exercise alongside CAD patients in an established supervised exercise programme (Cardiac Rehabilitation).
89468627|NCT03388827|Experimental|Laminaria|Laminaria tent was introduced in the cervical canal
89468628|NCT03388827|Active Comparator|Laminaria plus Misoprostol|Laminaria and Misoprostol were introduced
89468629|NCT02328716|Active Comparator|Comparator|Comparator
89468630|NCT02328716|Experimental|Experimental|Experimental
89468631|NCT03144284||dental interns|dental interns in pediatric dentistry department, faculty of dentistry, Cairo University.
89468632|NCT05077592|No Intervention|Control|Direct Wound closure
89468633|NCT05077592|Active Comparator|Intervention|The use of 10% surgical povidone iodine to wash the wound directly after fascial closure and before wound closure
89468634|NCT03398109|Experimental|Customized toric IOL|Customized toric IOL for post-Dalk atigmatism in cataract patients
88947243|NCT01915888||Complete Rotarix vaccination cohort|Subjects had received 2 doses of Rotarix within the vaccination window and the observation time is from the end of the vaccination window (8 months old for ACIP scenario, or 6 months old for PI scenario) to end of observation.
89018735|NCT00325728|Placebo Comparator|Placebo|
89468635|NCT03144362|Active Comparator|Bilateral Sliding Technique|
89468636|NCT03144362|Active Comparator|Unilateral Sliding Techniques|
89468637|NCT03144362|No Intervention|Standard care|
88947244|NCT01915888||Incomplete Rotarix vaccination cohort|Subjects had received one vaccination of Rotarix within the vaccination window and the observation time is from end of vaccination window (8 months old for ACIP scenario, or 6 months old for PI scenario)(if still observed) to end of observation.
89468638|NCT00038727|Active Comparator|1 Original Lifestyle|randomized to unmasked Intensive Lifestyle during the DPP and offered Intensive Lifestyle Group Session, DPPOS Group Lifestyle plus DPPOS Boost Lifestyle sessions in DPPOS Phase 1 and 2
89468639|NCT00038727|Active Comparator|2 Original Metformin|randomized to the masked metformin treatment group during DPP and continued open label in DPPOS. Participants were also offered Intensive Lifestyle Group Session, DPPOS Group Lifestyle in DPPOS Phase 1 and 2.
88947245|NCT01915888||Historical unvaccinated cohort|Subjects did not receive any Rotarix vaccine dose within the vaccination window and the observation time is from end of the vaccination window (8 months old for ACIP scenario, or 6 months old for PI scenario, if vaccination window ends on/before 12/31/2006) to end of observation.
88947246|NCT01915888||Contemporary unvaccinated cohort|Subjects did not receive any Rotarix vaccine dose within the vaccination window and the observation time is from end of the vaccination window (8 months old for ACIP scenario, or 6 months old for PI scenario, if vaccination window ends after 1/1/2007) to end of observation.
89468640|NCT00038727|Placebo Comparator|3 Original Placebo|randomized to masked placebo during DPP and offered Intensive Lifestyle Group Session, DPPOS Group Lifestyle in DPPOS Phase 1 and 2
89468641|NCT05077358|Experimental|Intracorporeal anastomosis|In this group, the anastomosis is performed inside the abdominal cavity with a laparoscopic technique. Specimen extraction will be done through Pfannenstiel incision or similar incision in lower abdomen.
89468642|NCT05077358|Active Comparator|Extracorporeal anastomosis|In this group, the anastomosis is performed by pulling out the bowel through a laparotomy.
88947247|NCT01915901|Experimental|bismuth subsalicylate (Pepto-Bismol®) + DMF|Subjects will receive dimethyl fumarate (DMF) and bismuth subsalicylate (Pepto-Bismol®).
88947248|NCT01915901|Experimental|Placebo + DMF|Subjects will receive dimethyl fumarate (DMF) and placebo.
88947249|NCT01915927|Other|1|Only 1 arm: treatment with MSC-AFP
89468643|NCT02864381|Experimental|Andecaliximab + Nivolumab|Andecaliximab 800 mg plus nivolumab 3 mg/kg administered every 2 weeks until disease progression, unacceptable toxicity, or withdrawal of consent (up to 34 weeks at the time of the primary efficacy analysis; up to 101 weeks at the time of the safety follow-up analysis).
89468644|NCT02864381|Active Comparator|Nivolumab|Nivolumab 3 mg/kg administered every 2 weeks until disease progression, unacceptable toxicity, or withdrawal of consent (up to 41 weeks at the time of the primary efficacy analysis; up to 97 weeks at the time of the safety follow-up analysis).
89468645|NCT05077202||ultra sound|lung ultrasound
88947250|NCT01915953||anemia|Measuring Hb valuse on anemia patients
88947251|NCT01915966|Experimental|Cardamom, ginger and orange juice gelatin|Dietary Supplement
89468646|NCT05077202||ct chest|patients had done CT chest already and we receive it from hospital files
89468647|NCT05230472|Active Comparator|simvastatin group|68 patients who had a ventilator associated pneumonia received simvastatin
88947252|NCT01915966|Active Comparator|Camomile infusion with lemon juice|Dietary Supplement
89468648|NCT05230472|No Intervention|control group|68 patients who had a ventilator associated pneumonia not received simvastatin
89468649|NCT05174325|Experimental|Arm 1|Pre-operative Sintilimab + chemotherapy
89468650|NCT03111368|Active Comparator|EUS- FNA Slow-pull|Endoscopic ultrasound-guided fine needle aspiration using a stylet slow-pull technique of solid pancreatic mass
89468651|NCT03111368|Active Comparator|EUS-FNA Negative Pressure|Endoscopic ultrasound-guided fine needle aspiration using negative pressure technique of solid pancreatic mass
88947253|NCT01915979|Experimental|Plasma rich in growth factors (PRGF)|This group will receive a total of three intraarticular injections of 6-8 ml. One injection every two weeks.
89468652|NCT03398031|Active Comparator|Magnesium supplement|90 female pregnant after ICSI after biochemical diagnosis of pregnancy will receive 500 mg magnesium supplement
89468653|NCT03398031|Placebo Comparator|placebo|90 female pregnant after ICSI after biochemical diagnosis of pregnancy will receive placebo oral tablet
89468654|NCT04149509||Exposed|Infants born ≥ 37 weeks gestation with second or third trimester opioid exposure as determined by maternal urine toxicology screen at delivery; maternal history; and/or infant urine, meconium, or umbilical cord toxicology screen.
89468655|NCT04149509||Unexposed - Controls|Infants born ≥ 37 weeks gestation with no antenatal drug exposure as determined by maternal urine toxicology screen at delivery and/or maternal history. We will match control infants to exposed infants based on Clinical Site and up to 60 days after the date of birth of the exposed infant , recruiting 1 control for every other exposed infant at each site.
89537294|NCT02464787|Experimental|Medical Students|Medical students willing to maintain the increased consumption of LifePak Nano dietary supplements, two twin-sachet packets of seven (7) supplements twice per day, for the entire eight-week experimental period, to maintain the logs and to report at each of the times that measurements will be made.
89537295|NCT05728515|Experimental|PET scan|Patients will receive an intravenous injection of 68Ga-NY104
89537296|NCT02464631|Active Comparator|Sofosbuvir + Ribavirin 1|Sofosbuvir + Ribavirin x 24 weeks
89537297|NCT02464631|Experimental|Sofosbuvir + Ribavirin 2|Sofosbuvir + Ribavirin x 36 weeks
89537298|NCT02464631|Experimental|Sofosbuvir + Ribavirin 3|Sofosbuvir + Ribavirin x 48 weeks
89537299|NCT03066687|Experimental|Treatment Sequence 1: Erdafitinib 9 mg|Participants will receive 9 milligram (mg) dose of erdafitinib under fasted condition [Treatment A] in Period 1, and under fed (with high-fat and high-calorie breakfast) condition [Treatment B] in Period 2. Each Treatment Period will be separated by a washout of at least 28 days.
89468656|NCT03111680|Experimental|intervention|this arm received an environmental intervention to make healthy eating and activity easier for residents
89468657|NCT03111680|No Intervention|control|the control participants received no interventions
89468658|NCT02039960||DAWN cases including all prescription drugs|This group will consist of all DAWN cases where prescription drugs are mentioned.
89468659|NCT02039960||All bupropion cases (including use of other drugs)|This group will consist of all DAWN cases where bupropion is mentioned and is a subset of Group 1.
89468660|NCT02039960||Burpropion Only Cases|This group will consist of all DAWN cases where burpropion is specifically the only drug mentioned within the case report, and is a subset of Group 2.
89468661|NCT05383313|Experimental|Psilocybin|25 mg, orally (capsule), single administration
89468662|NCT05383313|Active Comparator|Ketamine|250 mg, orally (capsule), single administration
89468663|NCT05383313|Placebo Comparator|Midazolam|5 mg, orally (capsule), single administration
89468664|NCT02328560||Paramedical ad consultation|Monitoring will be the same in the 2 groups; That paramedical consultation announcement is made in current practice.
89468665|NCT02328560||No paramedical ad consultation|Monitoring will be the same in the 2 groups
89468666|NCT02033681|Experimental|"One-per-mil Tumescent Solution"|
89468667|NCT02033681|Placebo Comparator|Saline Solution|
89468668|NCT02328248|Experimental|Biological patch|Use biological patch (Biodesign Surgisis Tissue Graft from Cook Biotech Incorporated) to repair hiatal hernia laparoscopically
89468669|NCT02328248|Placebo Comparator|Plastic patch|Use plastic patch (Parietex Composite from Sofradim Production) to repair hiatal hernia laparoscopically
89468670|NCT03610217|Experimental|Interstitial lung disease induction|
89468671|NCT03610217|Experimental|Pulmonary arterial hypertension|
89468672|NCT03610217|Experimental|Raynaud's phenomenon|
89468673|NCT03610217|Experimental|Digital ulcers|
89468674|NCT03610217|Experimental|Inflammatory arthritis|
89468675|NCT03610217|Experimental|Gastroesophageal reflux|
89468676|NCT03610217|Experimental|Bacterial overgrowth|
89468677|NCT03610217|Experimental|Constipation|
89468678|NCT03610217|Experimental|Skin involvement|
89018736|NCT00417794|Active Comparator|1|Atomoxetine HCL (Strattera)
89018737|NCT00417794|Placebo Comparator|2|
89018738|NCT00305175||Patients With Prior Hydroxyurea|Patients who have received hydroxyurea therapy before entering the study.
89018739|NCT00305175||Patients Without Prior Hydroxyurea|Patients who have not received hydroxyurea before study entry.
89202210|NCT00786162|Active Comparator|Control|Installation of BP cuff for communal use at the worksite
89468679|NCT03610217|Experimental|Pain|
89468680|NCT02328482|Experimental|Arm 1|Trehalose 30 g for IV infusion administered every week over an additional 52 weeks
89468681|NCT02328482|No Intervention|Arm 2|no-treatment concurrent control; follow-up over 52 weeks
89468682|NCT02328092|Active Comparator|Real group|The real group received biphasic rSMS using a Magstim Super Rapid (Magstim, Whitland, UK) stimulator connected to a 120-mm outer diameter figure-of-8 air film cooling coil positioned in the midline over the sacral vertebrae (approximately 5 cm above the natal cleft, which approximates to the level of S2). Stimulation was delivered at 15 Hz at 50% of maximum stimulator output (10 seconds on and 30 seconds off) with a total of 1500 pulses and the hand of the coil upward. The stimulation was repeated for 10 sessions, 5 sessions per week and 2 days off.
89468683|NCT02328092|Sham Comparator|Sham Group|The control group received sham rSMS stimulation using the same coil, the same session frequency, in the same setting, but the coil was tilted 90.
89468684|NCT02328170||EUROIMMUN Allergy|Immunoblot assay
89468685|NCT02328170||ImmunoCap|Fluoroallergosorbent test
89468686|NCT02860169|Experimental|Participants with cold and flu|Eligible participants with cold and flu were instructed to answer the self administered questionnaire and participate in the assessment that included Picture Rating, Picture Surfing Task, Questionnaire and VAS scales, Cognitive Function Assessment, RTI, AST, ERT , RVP
89468687|NCT02860169|Placebo Comparator|Healthy participants|Eligible healthy participants were instructed to answer the self administered questionnaire and participate in the assessment that included Picture Rating, Picture Surfing Task, Questionnaire and VAS scales, Cognitive Function Assessment, RTI, AST, ERT , RVP
89468688|NCT05069402|Experimental|Immunonutrition|Oral immunonutrition containing arginine, omega-PUFAs and antioxidants
89468689|NCT05069402|Active Comparator|High-protein diet|Oral nutrition with high-protein content
89468690|NCT05069402|Active Comparator|Standard nutrition|Oral nutrition with standard components
89468691|NCT03609983|Experimental|Daily Weighing|Participants will weigh themselves daily and receive feedback daily.
89468692|NCT03609983|Experimental|Weekly Weighing|Participants will weigh themselves weekly and receive feedback weekly.
89468693|NCT03609983|No Intervention|No Weighing|Participants will refrain from weighing themselves.
89468694|NCT05069090||Students and academics Universidad La Frontera|The intervention consists of social distancing measures to curb the viral transmission of SARS-CoV-2. The Araucanía region was subject to lockdown in a different moment than the Coquimbo region, creating exogenous variation.
89468695|NCT05069090||Students and academics Universidad Católica del Norte|The intervention consists of social distancing measures to curb the viral transmission of SARS-CoV-2. The Coquimbo region was subject to lockdown in a different moment than the Araucanía region, creating exogenous variation.
89468696|NCT03144050||0|Control - no diabetes
89468697|NCT03144050||1|Diabetes
89468698|NCT03144050||2|Diabetes w/neuropathy
89468699|NCT03144050||3|Diabetes with vascular disease
89468700|NCT03144050||4|Diabetes w/healed ulcer
89468701|NCT03144050||5|Diabetes with current ulcer
89468702|NCT02328638|Active Comparator|Manual-based Behavioral Treatment|up to 16 weekly behavioral therapy sessions (intervention) following the CHANGE obesity manual, lasting approximately 45 minutes and nutritional therapy sessions, lasting approximately 30 to 60 minutes.
89468703|NCT02328638|Placebo Comparator|Parent Education Program|up to 16 weekly behavioral therapy sessions following the parent education program
89468704|NCT03145220|Active Comparator|EA-230|Intravenous infusion of EA-230, 90 mg/kg/hour. Administered from start of surgical incision until stoppage of the cardio-pulmonary bypass pump, for a maximum of 4 hours.
89468705|NCT03145220|Placebo Comparator|Placebo|Intravenous infusion of NaCl (equivalent osmolarity with active intervention EA-230). Administered from start of surgical incision until stoppage of the cardio-pulmonary bypass pump, for a maximum of 4 hours.
89468706|NCT03144128|Placebo Comparator|Control (Ctl)|Standard of Care resistance exercise and timed protein supplementation with placebo capsule daily for 12 weeks
89468707|NCT03144128|Experimental|Vitamin D|Standard of Care resistance exercise and timed protein supplementation with 5,000IU vitamin D supplementation daily for 12 weeks
89468708|NCT02326532|Experimental|PRO data utilized|PRO data derived from the patient-completed MDHAQ/RAPID3 questionnaire will be collected from this arm and provided to the treating physicians.
89468709|NCT02326532|Sham Comparator|PRO data not utilized|PRO data derived from the patient-completed MDHAQ/RAPID3 questionnaire will be collected from this arm but will not be provided to the treating physicians.
88947254|NCT01915979|Active Comparator|Celestone cronodose (bethametasone)|This group will receive a total of three intraarticular injections of 2ml. One injection every two weeks.
88947255|NCT01915992|Other|Volunteer healthy|
89468710|NCT02326610|Active Comparator|hGH, ZOMACTON® (somatropin)|For infants in the treatment group receiving ZOMACTON® (somatropin) growth hormone by injection
89202211|NCT00778986|Experimental|remote monitoring|group of patients that will be using the heart failure remote patient monitoring system in addition to the usual care they receive at the University Health Network Heart Failure Clinic
89468711|NCT02326610|No Intervention|No human growth hormone|No growth hormone is given.
89468712|NCT00409773|Other|1|Arm 1: drug + comparator + Placebo
89468713|NCT00409773|Other|2|Arm 2: drug + comparator + Placebo
88947256|NCT01915992|Active Comparator|leukemia patient's|
89202212|NCT00778986|No Intervention|control|group of patients provided with usual care at the University Health Network Heart Failure Clinic
89202213|NCT00937755||olanzapine|olanzapine 10-20 mg/day
89468714|NCT00409773|Other|3|Arm 3: drug + comparator + Placebo
89468715|NCT00409773|Other|4|Arm 4: drug + comparator + Placebo
89468716|NCT00409773|Other|5|Arm 5: drug + comparator + Placebo
89468717|NCT02326376||CAPS patients|CAPS patients treated with anakinra, using the Kineret graduated syringe
89468718|NCT02034422|Experimental|Specific Aim #1|Specific Aim 1: Determine the consequences of oxidative stress on skeletal muscle afferent feedback and muscle blood flow during exercise in hypertension. Hypothesis: Afferent feedback sensitivity, determined by passive leg movement (isolation of mechanoreceptor sensitivity) and post exercise circulatory occlusion (isolation of metaboreceptor sensitivity) will be greater in hypertension leading to the exaggerated EPR. Muscle blood flow, assessed by Doppler ultrasound during multiple exercise intensities, will be impaired in hypertension leading to exercise intolerance. Reductions in oxidative stress, achieved by an oral antioxidant treatment (Vitamins C, E and alpha lipoic acid), will reduce afferent fiber sensitivity and improve muscle blood flow in hypertension. Additionally, venous endothelial cells will express elevated markers of oxidative stress providing novel evidence that the vascular endothelium contributes to the greater oxidative stress in hypertension.
89468719|NCT02034422|Experimental|Specific Aim #2|Specific Aim 2: Determine the remediable effect of combined antioxidant treatment and exercise rehabilitation in the treatment of hypertension. Hypothesis: Acute antioxidant treatment administered prior to exercise in hypertensive patients will ameliorate the exaggerated EPR resulting in a normal and safe blood pressure response to exercise-based rehabilitation. This two-pronged approach (antioxidants and exercise training) will result in a safely achieved reduction in skeletal muscle afferent feedback facilitating improved exercise tolerance, improved muscle blood flow and ultimately reduced cardiovascular risk in this population.
89468720|NCT02861807|Experimental|Active stimulation with mindfulness|Brain stimulation with mindfulness-based relapse prevention. Treatment sessions will be 2 hours for 8 sessions, with the first 30 minutes consisting of transcranial direct current stimulation (tDCS) with the current set to 2.0 milliamps (mA) and guided meditation practice.
88947257|NCT01916018|Other|hypothyroid group|Clinical exams radiologic exams Blood sample
88947258|NCT01916031|Experimental|Education|Upper Respiratory Infection education in Fall
88947259|NCT01916031|No Intervention|Standard Curriculum|
88947260|NCT01916044|Experimental|Lower Uterine Segment Ultrasound|Measure of Uterine Segment by Ultrasound
88947261|NCT01916044|No Intervention|control|no measure of Uterine Segment Ultrasound
88947262|NCT01916057|Experimental|18F-FDG PET Scan|18F-FDG PET Scan at Day 0 and M3
88947263|NCT01916070||patients with syncope|
88947264|NCT01916070||patients with near syncope|
88947265|NCT01916096||Delica 28g Depth 3 vs Delica 30g Depth 3|30 subjects with diabetes
89202214|NCT00937755||quetiapine|quetiapine 300-600 mg/day
89202215|NCT00937755||risperidone|risperidone monotherapy, 2-4 mg/day
89202216|NCT00786240|Experimental|A|
89202217|NCT00786240|Experimental|B|
89202218|NCT04498923||Bupivacaine with dexamethasone|"Ultrasound guided peripheral nerve block for upper or lower extremity was performed before orthopedic surgery using neurostimulator.~Twenty milliliters solution of bupivacaine 0,375% with dexamethasone was injected for one plexus or peripheral nerve."
89468721|NCT02861807|Sham Comparator|Sham brain stimulation with mindfulness|Brain stimulation with mindfulness-based relapse prevention. Treatment sessions will be 2 hours for 8 sessions, with the first 30 minutes consisting of transcranial direct current stimulation (tDCS) with the current set to ramp up to 2.0 milliamps (mA) and then ramp down to 0.0 mA and guided meditation practice.
89468722|NCT02325986|Experimental|Weekly PF with radiation|4 cycles of weekly cisplatin and fluorouracil (cisplatin 25mg/m2 on day 1, fluorouracil 1176mg/m2 on day 1-3, repeated weekly for 4 weeks) concurrently with Intensity-modulated radiation therapy (60Gy/28fr).
88947266|NCT01916096||Delica 28g Depth 5 vs Delica 30g Depth 5|30 subjects with diabetes
88947267|NCT01916096||Delica 28g Depth 7 vs Delica 30g Depth 7|30 subjects with diabetes
88947268|NCT01916096||Delica 28g Depth 3 vs Delica 33g Depth 3|30 subjects with diabetes
88947269|NCT01916096||Delica 28g Depth 5 vs Delica 33g Depth 5|30 subjects with diabetes
88947270|NCT01916096||Delica 28g Depth 7 vs Delica 33g Depth 7|30 subjects with diabetes
88947271|NCT01916135|Experimental|[18F]-SKI- 249380 and PET/CT scanning|Patients will receive an injection of up to 7.5 (0.5-7.5) mCi of [18F]-SKI- 249380, followed by serial PET/CT scanning and blood draws, over a period of 3.5 hours, on a single day. PET scans will be performed immediately, at approximately 90 minutes, and optionally at approximately 3 hours after injection of the radiotracer. Each patient will be offered the opportunity to repeat the 18F-SKI-249380 injection and subsequent set of post-injection PET-CT scans, once, on a separate date. Each patient may or may not be receiving treatment with dasatinib therapy at the time of 18F-SKI-249380 PET, for their first PET study, as well as repeat PET study, at the discretion of their oncologist according to best clinical judgment.
88947272|NCT01916161||IBD patients|Ambulatory patients attending IBD clinics at Leeds Teaching Hospitals
89468723|NCT02327780|Other|FODMAP diet|participants will be put on a low FODMAP diet.
89468724|NCT03610139|Active Comparator|low dose vitamin D3 supplementation|Patients in this group will take 800 IU daily dose of vitamin D supplementation. They will be kept on 800 IU for 6 months. If they still had low vitamin D at 3 months, they will be asked about their adherence to the supplement, the investigators will remind them to take it as prescribed, and the investigators will keep the 800 IU vitamin D supplement dose for another 3 months. If they were still deficient at 6 months, the investigators will switch them to 10,000 IU weekly dose.
89468725|NCT03610139|Experimental|high dose vitamin D3 supplementation|"Patients in this group will take 50,000 IU weekly dose of vitamin D supplementation. Patients who will reach normal serum vitamin D level, between 40-80 ng/ml, at 3 or 6 months will be asked to decrease their Vitamin D3 supplementation as follows: Those who will reach levels between 40-60ng/ml will be switched to 10,000 IU three times per week, and those who reach levels between 60-80 ng/ml will be switched to 10,000 IU once weekly.~If they did not have any improvement in their levels of vitamin D at 3 or 6 months, they will be asked about their adherence to the supplement and the investigators will remind them to take it as prescribed and the investigators will keep them at the 50,000 IU weekly dose."
89468726|NCT02327624|Active Comparator|Clopidogrel|The standard antiplatelet treatment for patients is pretreatment with aspirin and clopidogrel. In this trial patients will be randomised in clopidogrel orTicagrelor of two doses
89468727|NCT02327624|Experimental|Ticagrelor 60|Ticagrelor 60 is a new dosage to be tried in this trial.
89468728|NCT02327624|Experimental|Ticagrelor 90|Ticagrelor 90 is used following clopidogrel as maintenance therapy with aspirin 75 mg daily and clopidogrel 75 mg daily following PCI for at least 1 month.
89468729|NCT03388671|Active Comparator|TAB Block|Patients will recieve 0.3ml/kg bupivacaine 0.25% on each side for laparoscopically guided Transversus abdominis plane block.
89468730|NCT03388671|Active Comparator|Psoas Block|Patients will recieve 0.3ml/kg bupivacaine 0.25% on each side for laparoscopically guided psoas block.
89468731|NCT03609671|Experimental|Standard of Care + Intervention (Individualized Therapy)|Intervention (individualized therapy) plus Standard of Care, and the completion of a psychological questionnaire at chemotherapy start and at the end, approximately four to six months later.
89537300|NCT03066687|Experimental|Treatment Sequence 2: Erdafitinib 9 mg|Participants will receive 9 mg dose of erdafitinib under fed (high-fat and high-calorie breakfast) condition [Treatment B] in Period 1, and under fasted condition [Treatment A] in Period 2. Each Treatment Period will be separated by a washout of at least 28 days.
88947273|NCT01916174|Experimental|Insulin degludec/liraglutide, B5|Subjects will be randomly allocated to the two single dose administrations (one for each of the two IDegLira formulations) on the two separate dosing visits. The two administration days will be separated by a wash-out period of 7-15 days.
88947274|NCT01916174|Experimental|Insulin degludec/liraglutide, V2|Subjects will be randomly allocated to the two single dose administrations (one for each of the two IDegLira formulations) on the two separate dosing visits. The two administration days will be separated by a wash-out period of 7-15 days.
88947275|NCT01916187|Experimental|Imetelstat|285 mg/m2/dose, IV, for 2 hours. Days 1 and 8 every three weeks.
88947276|NCT01916200|Experimental|Paroxetine CR group|Paroxetine CR plus IBS regular treatment group
88947277|NCT01916200|No Intervention|Blank group|IBS regular treatment group
88947278|NCT01916213|Active Comparator|PICSI|PICSI dish ( MidAtlantic Diagnostics Inc) has been developed to select the specific sperm to be used for the ICSI procedure using the same principles as the Sperm Hyaluronan Binding Assay. HA-mediated ICSI sperm selection( PICSI) uses Falcon Petri dishes that feature three microdots of hyaluronan hydrogel attached to the interior bottom: mature, biochemically competent spermatozoa bind to hyaluronan, where they can be isolated and used for ICSI
88947279|NCT01916213|Active Comparator|ICSI|
89468732|NCT03609671|Other|Control Group: Standard of Care|Standard of Care plus the completion of a psychological questionnaire at the beginning of the chemotherapy and at the end, approximately four to six months later.
89468733|NCT02327936|Experimental|Fesoterodine 4mg|Fesoterodine 4 mg Po Die, dose could be increased to 8mg Po Die after 4 weeks, for a total of 8 weeks
89468734|NCT02327936|Active Comparator|Oxybutynin XL 10mg|Oxybutynin XL 10 mg Po Die, dose could be increased to 20 mg Po Die after 4 weeks, for a total of 8 weeks
89468735|NCT03384849||MRI patients|Up to 200 patients of different age, weight and sex, which undergo MRI examinations.
89537301|NCT04880577|Experimental|TAF|25 mg of daily TAF
89537302|NCT04880577|Placebo Comparator|Placebo|Placebo pill
89537303|NCT04353921||Single-Dose of Psilocybin|
88947280|NCT01916239|Experimental|Standard pomegranate extract formulation|Standard pomegranate extract formulation containing 20% punicalagin
89468736|NCT02327858|Experimental|Supportive text message group|Patients in all the intervention groups will receive twice daily supportive SMS text messages for 3 months .
89468737|NCT02327858|No Intervention|No supportive text message group|Patients in the control group will only receive a text message once every two weeks thanking them for participating in the study. The aim of this will be to help increase the retention rate for the study.
89468738|NCT03609905|Experimental|Intervention group|interventions: The MSCs of 5×10*7 will be given in different sites within colonic submucosa at a total 100 ml with the use of the colonoscope. Once every week，a total of two times. Conventional drug therapy (5-amino-salicylic acid or glucocorticoid) is used
89468739|NCT03609905|Other|Control group|interventions:Conventional drug therapy (5-amino-salicylic acid or glucocorticoid) is used
89468740|NCT02326142|Experimental|OBE001|
89202219|NCT04498923||Bupivacaine with dexamethasone and epinephrine|"Ultrasound guided peripheral nerve block for upper or lower extremity was performed before orthopedic surgery using neurostimulator.~Twenty milliliters solution of bupivacaine 0,375% with dexamethasone 0,02% and epinephrine 0,00018% was injected for one plexus or peripheral nerve."
89468741|NCT02326142|Placebo Comparator|Placebo|
89468742|NCT04486001|Experimental|Treatment Group|This is single arm study with only comparison to non-treated cohorts at site.
89537304|NCT04353921||Niacin-Control|
89537305|NCT04280211||COPD Group|Patients who are over 40 years old, diagnosed with COPD
88947281|NCT01916239|Experimental|Pomegranate extract formulation-1|New pomegranate extract formulation-1
88947282|NCT01916239|Experimental|Pomegranate extract formulation-2|New pomegranate extract formulation-2
88947283|NCT01916252|Active Comparator|MEL-200|bortezomib/lenalidomide/dexamethasone (VRD-GEM) induction treatment followed by high-dose melphalan-200 (MEL-200)
88947284|NCT01916252|Active Comparator|BUMEL|bortezomib/lenalidomide/dexamethasone (VRD-GEM) induction treatment followed by busulfan-melphalan (BUMEL) chemotherapy and consolidation with VRD-GEM
88947285|NCT01916265|Experimental|Glucagon level: 0,11 and 1 mg|Glucagon level: 0,11 and 1 mg
88947286|NCT01916265|Experimental|Glucagon level: 0,22 and 0,66 mg|Glucagon level: 0,22 and 0,66 mg
88947287|NCT01916265|Experimental|Glucagon level: 0,44 and 0,33 mg|Glucagon level: 0,44 and 0,33 mg
88947288|NCT01916291|Experimental|Propess insertion|
88947289|NCT01916343|Experimental|Study Laparoscopic Curriculum|Residents will perform a salpingectomy in the operating room, which will be video-recorded through the laparoscopic camera. The residents in the intervention group will then complete the salpingectomy at the conclusion of the curriculum. Following the completion of the curriculum, residents in the intervention group will undergo a multiple-choice examination as well as a repeat skills examination.
88947290|NCT01916343|No Intervention|Standard Clinical Education|Residents will perform a salpingectomy in the operating room, which will be video-recorded through the laparoscopic camera. The standard clinical education residents will perform the procedure as per standard of care.
88947291|NCT01916356|Experimental|educational video|Change in participant's infertility knowledge before and after watching the educational video covering the topics of basic reproductive biology, infertility etiologies, risk factors, treatments and common myths.
89537306|NCT04280211||Control Group|Healthy adults over 40 years old
89537307|NCT02465957|Experimental|aNK (NK-92)|aNK (activated NK-92, formerly Neukoplast)
88947292|NCT01916369|Experimental|CTX DP|Human neural stem cell product, single dose administered once only, increasing doses
88947293|NCT01916382|Experimental|Nitisinone|Homogentisic acid lowering drug intervention
88947294|NCT01916382|No Intervention|No treatment|comparrator
88947295|NCT01916395||Imitrex and Treximet|Imitrex 100mg as needed Treximet 85/500mg
88947296|NCT01916408|Active Comparator|Wobenzym plus|3 x 4 tablets of the study medication each day for the one week before and 3 x 2 tablets of the study medication each day for the two weeks after the marathon.
88947297|NCT01916408|Placebo Comparator|Placebo PL1|3 x 4 tablets of the study medication each day for the one week before and 3 x 2 tablets of the study medication each day for the two weeks after the marathon.
88947298|NCT01916421|Active Comparator|EZ Shot|
88947299|NCT01916421|Active Comparator|Expect™|
88947300|NCT01916421|Active Comparator|EchoTip® Ultra|
88947301|NCT01916434|Experimental|High Pufa Salmon Fillets|High EPA/DHA levels in feed and in salmon fillets (~15% of total feed fatty acids, equal to wild salmon), 2 salmon fillets per week for 18 weeks, on top of habitual fish consumption.
88947302|NCT01916434|Experimental|Sustainable PUFA salmon|'Sustainable' levels of EPA/DHA in feed and in salmon fillets (~6-8% of total feed fatty acids), 2 salmon fillets per week for 18 weeks, on top of habitual fish consumption
88947303|NCT01916434|Placebo Comparator|No salmon|The placebo group will continue to consume their habitual diet
88947304|NCT01916447|Experimental|TAS-102 and CPT-11 with or without Bevacizumab|
89202220|NCT00779064|Experimental|Arm 1|
89468743|NCT03142490|Experimental|Treatment|In vitro fertilization patients submitted to acupuncture as a complementary therapy. Patients in both groups will be evaluated by 4 different questionnaires.
89468744|NCT03142490|Active Comparator|Control|In vitro fertilization patients not submitted to acupuncture as a complementary therapy. Patients in both groups will be evaluated by 4 different questionnaires.
89468745|NCT03609515|Experimental|Patients with contract about patient-controlled admissions|Patients have a contract about short self-referred inpatient admissions in mental health services without approval by clinicians, for a maximum of 5 days and with a minimum of three weeks between such stays
89468746|NCT03384771||MBSR Students|community-dwelling adults who register for relevant MBSR courses at UMass CFM, UCSF, or participating community sites
89468747|NCT03384771||MBSR Teachers|those teaching MBSR courses at UMass CFM, UCSF, or participating community sites
89468748|NCT03384771||Raters|experience mindfulness teachers, recruited by invitation, who will participate in MBI-TAC training
89468749|NCT03388515|Experimental|SSS11, 1.5mg|SSS11, 1.5mg, iv, single dose at Day 1;
89468750|NCT03388515|Experimental|SSS11, 3.0mg|SSS11, 3.0mg, iv, single dose at Day 1;
89468751|NCT03388515|Experimental|SSS11, 6.0mg|SSS11, 6.0mg, iv, single dose at Day 1;
89468752|NCT03388515|Experimental|SSS11, 12.0mg|SSS11, 12.0mg, iv, single dose at Day 1;
89468753|NCT03388515|Experimental|SSS11, 24.0mg|SSS11, 24.0mg, iv, single dose at Day 1;
89468754|NCT03609827||Pediatric patients undergoing Hematopoietic Stem Cell Transplant|Children undergoing allogeneic hematopoietic stem cell transplant (alloHCT) at University of California, San Francisco Benioff Children's Hospital.
89468755|NCT05076968||Complete dentures fabricated by undergraduate students|
89468756|NCT05076968||Complete dentures fabricated by prosthodontists|
89468757|NCT03125733|Experimental|STESD|Submucosal tunneling endoscopic septum division
89468758|NCT03609749|Experimental|Mindfulness Training for Primary Care|"Experimental: Mindfulness Training for Primary Care For intervention description see Mindfulness Training for Primary Care (MTPC) in the study MINDFUL-PC: Integrating Mindfulness Into the Patient-Centered Medical Home (Phase 3). For the Mindfulness Training for Primary Care (MTPC) fMRI - arm, the investigators acquire pre-/post-intervention neuroimaging measures from subjects enrolled in this additional fMRI study."
89468759|NCT02858401|Experimental|Vesatolimod 1 mg (Cohort 1)|Vesatolimod 1 mg for 71 days, while continuing their existing ARV regimen
89468760|NCT02858401|Experimental|Vesatolimod 2 mg (Cohort 2)|Vesatolimod 2 mg for 71 days, while continuing their existing ARV regimen
89468761|NCT02858401|Experimental|Vesatolimod 4 mg (Cohort 3)|Vesatolimod 4 mg for 71 days, while continuing their existing ARV regimen
89468762|NCT02858401|Experimental|Vesatolimod 6 mg (Cohort 4)|Vesatolimod 6 mg for 127 days, while continuing their existing ARV regimen
89468763|NCT02858401|Experimental|Vesatolimod 8 mg (Cohort 5)|Vesatolimod 8 mg for 127 days administered following overnight fasting, while continuing their existing ARV regimen
89468764|NCT02858401|Experimental|Vesatolimod 10 or 12 mg (Cohort 6)|Vesatolimod 10 or 12 mg for 127 days administered following overnight fasting, while continuing their existing ARV regimen. Participants will receive 3 administrations of 10 mg, followed by 7 administrations of 12 mg (after review of 10 mg safety data)
89468765|NCT02858401|Experimental|Vesatolimod 12 mg (Optional Cohort 7)|Vesatolimod up to 12 mg for up to 127 days for up to 10 total doses administered following overnight fasting, while continuing their existing ARV regimen
88947305|NCT01916460|Experimental|Gastroparetic patient 19G|Endoscopic Ultrasound Fine Needle Aspiration of the gastric wall prior to surgical placement of gastric neurostimulator with 19-gauge fine core needle used for aspiration
88947306|NCT01916473|Active Comparator|Epidural analgesia|Epidural analgesia is provided with ropvacaine 0.2% given 6 hourly
89468766|NCT02858401|Experimental|Vesatolimod 6 mg with an acidic solution (Optional Cohort 8)|Vesatolimod 6 mg for 127 days for up to 10 total doses administered with an acidic solution (cranberry juice), while continuing their existing ARV regimen
89468767|NCT02858401|Experimental|Vesatolimod up to 12 mg (Cohort 9)|Vesatolimod up to 12 mg for 127 days for up to 10 total doses administered following a moderate-fat meal, after the review of the data from the highest tolerated fasted dose cohort while continuing their existing ARV regimen
89468768|NCT02858401|Placebo Comparator|Placebo (Cohorts 1-9)|Placebo to match vesatolimod for 71 or 127 days, while continuing their existing ARV regimen
89468769|NCT05024396|Experimental|maximum jump height|Two visits will take place 1-2 weeks apart. At the first visit, participants will complete 2x3 single-leg countermovement jumps measured by two subjects each. At the second visit, three jumps are completed measured by the first test subject.
89468770|NCT02236949|Experimental|Pain Practice Change Booster|Pain Practice Change Booster Intervention: 12 months after the EPIQ intervention, and every 4 months for 2 years, a 30-60 minute standardized booster session was delivered to a small group of champions in each hospital unit randomized to the intervention group. Two co-facilitators familiar with the EPIQ intervention conducted all booster sessions via teleconference. Booster sessions included reviewing the effectiveness knowledge translation strategies champions implemented over the past four months to sustain and improve targeted pain practices; determining the sustainability of the pain practice changes, developing a commitment to change plan of action for the next four months.
88947307|NCT01916473|Experimental|Continuous wound infusion|The continuous wound infusion consists of 0.376% ropivacaine infusion in the wound area at a rate 2 ml per hour.
89468771|NCT02236949|No Intervention|Usual Care Group|No interventions associated with the study were conducted on these units.
89468772|NCT03126825|Other|Conventional CI|The conventional CI group will receive the noise reduction on and off signal processing test programs. This is a within subject repeated measures design, so all subjects will receive the same testing but in a counterbalanced order.
88947308|NCT01916486|Experimental|Exercise training|Twice-weekly for the 6-month duration.
88947309|NCT01916486|Experimental|Complex mental and social activities|Twice-weekly for the 6-month duration.
88947310|NCT01916486|Active Comparator|Control: stretching and relaxation program|Twice-weekly for the 6-month duration.
89537308|NCT04248933|Experimental|"Peer-Delivered Behavioral Activation (Peer Activate)"|"Participants received a peer recovery specialist-delivered behavioral activation (BA) intervention (Peer Activate) to address barriers to retention in methadone treatment and increase substance-free, positive reinforcement to support retention."
89537309|NCT04680689||Fuse-Heart -SG 01|Study subjects with anatomically significant coronary lesions (at least 50% luminal narrowing) on native coronary arteries.
89202221|NCT00779064|Experimental|Arm 2|
89468773|NCT03126825|Other|Hybrid CI|The Hybrid CI group will receive the noise reduction on and off signal processing test programs. This is a within subject repeated measures design, so all subjects will receive the same testing but in a counterbalanced order.
89468774|NCT03144596|Experimental|Alfuzosin Hydrochloride|Alfuzosin hydrochloride 10 mg tablet by mouth, every 24 hours for 3 months
89468775|NCT03144596|Active Comparator|Tamsulosin Hydrochloride|Tamsulosin hydrochloride 0.4 mg tablet by mouth, every 24 hours for 3 months
89537310|NCT04680689||Fuse-Heart -SG 02|Study subjects surviving an acute myocardial infarction, revascularized or not.
89537311|NCT04489901|Experimental|Extra Virgin Olivei oil group|The women in the experimental (olive oil) group were asked to apply 10 cc (4 tablespoons) of extra virgin olive oil to the entire abdomen by hand without massaging twice a day in the morning and evening.
89537312|NCT04489901|No Intervention|Control group|The women in the control group did not undergo any intervention.
89468776|NCT02033915|Experimental|Interactive Discussion Group|The interactive discussion groups were held for six times (8-10 persons for each group). During the 50-60 minutes' discussion, the facilitators guided the participants to discuss a case vignette, focusing on the key issues of hospital suicide prevention, and to enhance their abilities of suicide risk identification and evaluation. Two research team members who served as facilitators led the group in a standardized manner.
89468777|NCT00127647|Experimental|1|montelukast sodium 5 mg, QD 2-weeks
89468778|NCT00127647|Experimental|2|montelukast sodium 10 mg QD 2-weeks
89468779|NCT00127647|Active Comparator|3|Pranlukast 225 mg BID 2-weeks
89468780|NCT03388437|Experimental|NI-NAVA|Initial setting; NAVA level of 2; PEEP of 5-6 cm H 2 O, apnea time 5-10 seconds, target Edi maximum between 10-15 and minimum < 5 for 72 hours post extubation
89468781|NCT03388437|Active Comparator|NIPPV|Initial setting; PIP can be increased by 2 cm H 2 O from the pre-extubation PEEP of 5-6 cm for 72 hours post extubation
89468782|NCT03111602|Experimental|interventional group|The interventional group was submitted to dietary orientation to restrict polyphenol-rich foods
89468783|NCT03111602|No Intervention|control group|healthy group as comparator
89468784|NCT03388359|Experimental|Allergic asthma|Bronchial asthma and sensitization to D. pteronyssinus allergen Interventions: Bronchial challenge with allergen (Dermatophagoides pteronyssinus, Dosimeter ProvoX (Ganshorns)); Eosinophil and linear bronchial smooth muscle cell or pulmonary fibroblast co-culture formation (eosinophils, fibrobralst, airway smooth muscle cells); Inhibition of Wnt and Smad signaling pathways; Extracellular matrix turnover and deposition assessment.
89202222|NCT04046874|Other|Usual Care|All patients were referred for the study by their General Practitioner (GP). GPs were encouraged to assess and treat their patients as usual and make all the referrals they think are appropriate for their patients.
89202223|NCT04046874|Other|Stratified Model of Care|A subgrouping tool helps guide clinical decision-making about treatment and onward referral (Start Back Screening Tool). Patients in each subgroup (low, medium or high risk of chronicity) are then managed according to a targeted treatment system of increasing complexity.
89468785|NCT03388359|Active Comparator|Healthy subjects|"Healthy subjects without allergic and other chronic respiratory diseases (control group).~Interventions: Bronchial challenge with allergen (Dermatophagoides pteronyssinus, Dosimeter ProvoX (Ganshorns)); Eosinophil and linear bronchial smooth muscle cell or pulmonary fibroblast co-culture formation (eosinophils, fibrobralst, airway smooth muscle cells); Inhibition of Wnt and Smad signaling pathways; Extracellular matrix turnover and deposition assessment."
89468786|NCT03111446|Active Comparator|Spinal Anesthesia|Spinal anesthesia will be used to anesthetize patients in this group for caesarian section
89468787|NCT03111446|Active Comparator|General Anesthesia|Standardized General Anesthesia will be used to anesthetize patients in this group for caesarian section
89468788|NCT04540523|Experimental|Exergaming intervention group|30 minutes of exergaming per session and 5 sessions of exergaming play per week for a 6-month period.
89468789|NCT04540523|Active Comparator|Traditional Physical Activity|Phone consultations and workshops for parents to offer 5 times, 30 minutes per session; traditional physical activity at home for 6 months.
89468790|NCT04540523|No Intervention|Attention control group|Continue with usual activities at home with emailed physical activity tips.
89468791|NCT02327546|Experimental|AKB-6548|AKB-6548
88947311|NCT01916499||"Switch trap-door re-implantation of the coronaries"|"Re-implantation of the coronary arteries into the neo-aortic sinuses through a trap-door as far distally as possible on the neo-aorta"
88947312|NCT01916499||"Switch non-trap-door re-implantation of the coronaries"|Re-implantation of the coronary arteries into the neo-aortic sinuses through small incisions or excision in the sinuses
89202224|NCT00789906||1|350 healthy women , aged from 18 to 89
89202225|NCT00789906||2|350 healthy men, aged from 18 to 89
89202226|NCT00932217|Active Comparator|filgrastim|patients mobilized with filgrastim
89202227|NCT00932217|Active Comparator|lenograstim|patients mobilized with lenograstim
89202228|NCT00786318|Experimental|ziprasidone|
89202229|NCT00786318|Active Comparator|Standard therapy|
89202230|NCT00783666|Experimental|1|Lactic Acid
89202231|NCT00566631|Experimental|Paliperidone Extended Release (ER)|
89202232|NCT00930735||Myocardial fibrosis, outcomes|Groups with none and variable amounts of myocardial fibrosis
89202233|NCT00932295|Active Comparator|Own brand cigarette|10 puffs from the participants own brand brand of cigarette (lit; 30 second inter puff interval)
89468792|NCT02327546|Experimental|AKB-6548 plus Ferrous Sulfate|AKB-6548 plus ferrous sulfate
89468793|NCT03388281||Patients with implanted pacemaker|Patients with implanted cardiac pacemaker registered in pacemaker database of the Department of Cardiology at the Medical University Vienna were included.
89468794|NCT03144830|Experimental|Overground walking program|Study participant will be involved in an indoor, overground walking program using an exoskeleton wearable walking device under the supervision of a physiotherapist.
89468795|NCT02034071|Experimental|DCCR Open Label - DCCR Double Blind|Patients are initiated on a DCCR dose of about 1.5 mg/kg (maximum starting dose of 145 mg) and are titrated every 14 days through 4 dose levels of DCCR. Patients will be up-titrated at each visit at the discretion of the investigator. Randomized to continue DCCR, at the same dose as they received on Day 69, in the Double-Blind, Placebo-Controlled, Randomized Withdrawal Extension
89468796|NCT02034071|Experimental|DCCR Open Label - Placebo Double Blind|Patients are initiated on a DCCR dose of about 1.5 mg/kg (maximum starting dose of 145 mg) and are titrated every 14 days through 4 dose levels of DCCR. Patients will be up-titrated at each visit at the discretion of the investigator. Randomized to receive placebo equivalent to the DCCR dose received on Day 69 in the Double-Blind, Placebo-Controlled, Randomized Withdrawal Extension
89468797|NCT04925336|Experimental|Experimental|Nociceptive intervention arm
88956475|NCT05137119|No Intervention|Continue intravenous antibiotic therapies (backbone +/- adjunctive therapy) - standard of care arm|"Backbone therapy arm for MRSA or MSSA or PSSA +/- adjunctive therapy will continue on intravenous antibiotic treatment for the length of time as per usual standard of care.~Participants eligibility is assessed at Day 7 (+/- 2 days) if eligible will be randomised if not eligible then eligibility will be assess again at Day 14(+/- 2 days). If eligibility is not met at day 14 then participant is excluded from this domain."
89202234|NCT00932295|Sham Comparator|Sham smoking|10 puffs from the participants own brand brand of cigarette (NOT lit; 30 second inter puff interval)
89468798|NCT03609437||ESUS patients|Acute ischemic stroke patients satisfying embolic stroke of undetermined source (ESUS) diagnostic criteria.
89468799|NCT03609437||Controls|Healthy volunteers (colleagues, friends, relatives and others).
89468800|NCT03609359|Experimental|Lenvatinib + Pembrolizumab|Lenvatinib and Pembrolizumab will be administrated simultaneously for advanced gastric cancer patients.
89468801|NCT03380793|Experimental|morinidazole|morinidazole and sodium chloride injection (500 mg intravenous, twice daily for 5-7 days) with aztreonam and (or) etimicin.
89468802|NCT03384615|Experimental|Compassion-focused therapy|
89537313|NCT04656587|Other|Standard Therapy (Control)|Standard status asthmaticus therapy with continuous beta-agonist, steroids and oxygen as needed.
89537314|NCT04656587|Experimental|Standard Therapy plus BPAP|Application of BPAP along with standard status asthmaticus therapy with continuous beta-agonist, steroids and oxygen as needed.
89537315|NCT02718131|Active Comparator|INFUSE Bone Graft (BMP-2)|Children with NF1 and tibial pseudarthrosis who require surgery will have the INFUSE bone graft added to their surgical protocol. After a standard surgical approach of resection of abnormal pseudarthrotic tissue, placement of a rigid intramedullary rod (of the surgeon's choice) and placement of autogenous bone graft from the iliac crest; in addition, the INFUSE bone graft in the form of a collagen sponge will be wrapped around the tibia during the surgical process.
89537316|NCT02718131|Placebo Comparator|Control Group|Children with NF1 and tibial pseudarthrosis who require surgery will receive the standard surgical protocol only. This includes resection of abnormal pseudarthrotic tissue, placement of a rigid intramedullary rod (of the surgeon's choice) and placement of autogenous bone graft from the iliac crest.
89537317|NCT02465879|Experimental|Therapist Triage|All subjects in this group will be triaged by an extended role occupational or physical therapist prior to their visit with the rheumatologist.
89537318|NCT03066765|Experimental|LTR Treatment|An implant device (Linguaflex Tongue Retractor) will be placed in the tongue and assessed for safety and efficacy
89537319|NCT02465723|Experimental|MRI with IVIM DW-MRI|Upon enrollment in the study, each patient will undergo a standard pre-treatment evaluation in the Radiation Oncology Clinic. Imaging will include MRI with IVIM DW-MRI (as a research exam). MR imaging will begin within 30 minutes (+/- 15 mins) of the completion of single-dose radiation or the first dose for patients treated with a multifractioned regime. Patients will have corresponding serum samples collected at approximately 1 hour before and 18-24 hours after the first radiation treatment. If radiation therapy occurs on a Friday, the collection of the serum 18-24 hours post-treatment may still be feasible. Patients will be treated with radiation therapy according to our standard clinical guidelines using one of several Varian megavoltage linear accelerators with on-board kilovoltage image-guidance capabilities, using established immobilization devices that are specific to the anatomical site treated at MD's discretion.
89537320|NCT03069261||Intervention - ICG angiography|ICG-angiography was used intraoperatively after placement of the flap at the recipient cite, evaluating the viability and perfusion of the flap. Poor perfused areas were excised
89537321|NCT03069261||Control - clinical assessment|A control group receiving identical operations but without ICG-angiography evaluation.
89537322|NCT04490213||hydrofibre, Aquacel|Study participants were previously treated on their donor sites with these CE-marked dressing products (RCT study published in 2014) and are now compared regarding scar outcome at the donor sites
89537323|NCT04490213||polyurethane foam, Allevyn|Study participants were previolsuy treated on their donor sites with these CE-marked dressing products (RCT study published in 2014) and are now compared regarding scar outcome at the donor sites
89537324|NCT04490213||porcine xenograft, Mediskin|Study participants were previolsuy treated on their donor sites with these CE-marked dressing products (RCT study published in 2014) and are now compared regarding scar outcome at the donor sites
89537325|NCT05728437|Experimental|Study group|This group includes 30 burned patients who will receive resistance exercises 8 weeks (3times/week) by using dumbbells and sand bags in addition to their physical therapy program (splinting, stretching ex. and ROM ex.) and medical treatment.
89537326|NCT05728437|No Intervention|Control group|This group includes 30 burned patients who will receive their physical therapy program (splinting, stretching ex., strengthening ex. and ROM ex.) and medical treatment.
89537327|NCT05728359||Cardiogenic shock and MI|Patients presenting with acute myocardial infarction and cardiogenic shock who are supported medically (ie. inotropes +/- intra aortic balloon pump only). N=50
89537328|NCT05728359||Cardiogenic shock and MI wtih ECMO|Patients presenting with acute myocardial infarction and cardiogenic shock who are supported medically with ECMO (+/- LV unloading device). N=50
89537329|NCT05728359||Cardiogenic shock and MI wtih Impella|Patients presenting with acute myocardial infarction and cardiogenic shock who are supported medically with Impella. N=50
89537330|NCT05728359||MI without cardiogenic shock|Patients presenting with acute myocardial infarction and cardiogenic shock as a control comparator
89537331|NCT05728359||Non ischemic Cardiogenic Shock ie myocarditis|Patients presenting with myocarditis and cardiogenic shock as a control comparator
89537332|NCT04562597|Placebo Comparator|Dose Response Curve Placebo|5 participants will be randomized to the placebo group to estimate the dose response curve and to identify the optimal dose.
89537333|NCT04562597|Active Comparator|Dose Response Curve N-acetylcysteine 50 mg/kg|5 participants will be randomized to the N-acetylcysteine 50 mg/kg group to estimate the dose response curve and to identify the optimal dose.
89537334|NCT04562597|Active Comparator|Dose Response Curve N-acetylcysteine 100 mg/kg|5 participants will be randomized to the N-acetylcysteine 100 mg/kg group to estimate the dose response curve and to identify the optimal dose.
89537335|NCT04562597|Active Comparator|Dose Response Curve N-acetylcysteine 150 mg/kg|5 participants will be randomized to the N-acetylcysteine 150 mg/kg group to estimate the dose response curve and to identify the optimal dose.
89468803|NCT03384615|No Intervention|Waitlist control group|
89468804|NCT04894448||PLWH|HIV positive
89468805|NCT04894448||Control|HIV negative
89468806|NCT02121275||Laparoscopic surgery|Patients undergoing laparoscopic surgery under general anaesthesia, patients undergo ultrasound of the lungs and electric impedance tomography at 4 times during anaesthesia
89468807|NCT03380715|Active Comparator|right nostril in patients with rhinitis|Intervention : Administration of either 4 sprays of nasal decongestions(Co-Phenylcaine(400mcl) (20mg lidocaine + 2mg phenylephrine) once into the right nasal cavity or
89468808|NCT03380715|No Intervention|Left nostril in patients with rhinitis|No nasal decongestion administration into the left nostril
89468809|NCT03380715|Active Comparator|Right nostril in patients with rhinitis|400mcl of co-phenylcaine (20mg of lidocaine + 2mg of phenylephrine) is added into the nasal nebuliser device (Rinowash Nebula, Air liquid medical systems) and the solution is diluted with 4.5cc of isotonic normal saline. This Mixture is then nebulised into the right nasal cavity for approximately 3 minutes.The seated patient's head is kept flexed and nebulizer device is kept sealed within the nasal cavity while the nebulisation is done and subsequently checking nasal resistance after nasal nebulisation.
89468810|NCT04833764|Experimental|Rosuvastatin|Subjects will receive 20 mg daily dose of rosuvastatin for at least 3 months
89468811|NCT03388125|Active Comparator|Injection Sclerotherapy|5% ethano lamine oleate
89468812|NCT03388125|Active Comparator|N-butyl-2-cyanoacrylate|N-butyl-2-cyanoacrylate injection group
88947313|NCT01916525|Experimental|Exercise based cardiac rehabilitation|Patients will receive written instructions and a referral to the exercise-based rehabilitation unit. The patient will be taught to use fitness room. Each session of training will be controlled by heart rate. Instruction will also be given for at-home training and filling in a training diary, and training will be scheduled at Verve once a week. On the first visit the patient will receive a device that measures physical activity during the study. Training will also be monitored from the training diary. Structured questionnaires will be used to check compliance and implementation of care will be determined from medication and other health-related habits once a month (during the first 6 months) and finally after 12 months.
88947314|NCT01916525|No Intervention|Control|A conventional post-acute care group treated according to finnish guidelines.
88947315|NCT01916538||Cases|Individuals with a current or past diagnosis of anorexia nervosa
88947316|NCT01916538||Controls|Individuals who have never been diagnosed with an eating disorder
88947317|NCT01916564|Active Comparator|Same-morning whole-dose|2-L PEG-ELS between 5 a.m. and 6 a.m. on the day of colonoscopy
88947318|NCT01916564|Active Comparator|Split-dose|1-L PEG-ELS between 8 p.m. and 8.30 p.m. on the day before and 1-L PEG-ELS between 5.30 a.m. and 6 a.m. on the day of colonoscopy
88947319|NCT01916577|Active Comparator|Plerixafor (Mozobil) Control Arm|Plerixafor mobilization of autologous CD117 stem cells: Plerixafor will be given at 240mcg/kg subcutaneously once to 5 normal control patients (volunteers) at time zero with blood collected for flow cytometric analysis for CD117+ peripheral blood cells prior to the dose and then again 8 hours after the dose
89468813|NCT03609281||Scheduled cesaren group|Patient delivered by elective cesarean section without labour pains
89468814|NCT03609281||Emergency cesarean group|Patients delivered by cesarean section due to an emergency
89468815|NCT04822376|Experimental|High risk arm|Mabs at day 0 and vaccine at week 6
89202235|NCT00932295|Experimental|Electronic cigarette Version One C7|"10 puffs from a so-called electronic cigarette named CROWN SEVEN (16 mg cartridge; 30 second inter puff interval)"
89202236|NCT00932295|Experimental|Electronic cigarette version 2: NJ|"10 puffs from a so-called electronic cigarette named NJOY (16 mg cartridge; 30 second inter puff interval)"
89468816|NCT04822376|Experimental|High risk arm (Immunological ancillary study)|Mabs at day 0 and vaccine at week 6
89468817|NCT04822376|Active Comparator|Control arm (Immunological ancillary study)|Vaccine at day 0 for contacts eligible for vaccination
89468818|NCT03388047|Experimental|Barrett's Esophagus patients|Multi-Spectral Endoscopic Imaging
89468819|NCT04314011|Experimental|HUC-MSCs Group|Human umbilical cord mesenchymal stem cells (1*10^6/kg cells): delivered via peripheral intravenous infusion.
89468820|NCT04314011|Placebo Comparator|Control Group|Placebo:normal saline delivered via peripheral intravenous infusion.
89468821|NCT05173545|Experimental|Mitoxantrone Hydrochloride Liposome Injection（12 mg/m2）|itoxantrone Hydrochloride Liposome Injection（12 mg/m2）
89468822|NCT05173545|Experimental|Mitoxantrone Hydrochloride Liposome Injection（16 mg/m2）|itoxantrone Hydrochloride Liposome Injection（16 mg/m2）
89468823|NCT05173545|Experimental|Mitoxantrone Hydrochloride Liposome Injection（20mg/m2）|itoxantrone Hydrochloride Liposome Injection（20 mg/m2）
89468824|NCT05173467|Experimental|Robot-assisted Invasion-controlled Surgery|
89468825|NCT05173467|Placebo Comparator|Traditional-open Surgery|
89468826|NCT03769701|Active Comparator|Group 1, SMGC four times/day|Women with GDM and SMGC 4 times/day; fasting and 1-hour post-prandial of breakfast, lunch and dinner
89468827|NCT03769701|Experimental|SMGC two times/day|Women with GDM and SMGC 2 times/day; pre-prandial and 1-hour post-prandial of breakfast, lunch or dinner alternating the meal each day.
89468828|NCT05173311|Experimental|Application use arm|The early childhood education and care (ECEC) professionals in the intervention arm groups were instructed to use the application with a tablet computer at least 1-2 times a week during the intervention period (3-4 weeks) and to record the number of tasks completed by their group in a logbook. In addition, we recommended that each group focus on at least six vegetables or fruits during the intervention period.
89468829|NCT05173311|No Intervention|Control arm|The control arm groups were instructed to continue their normal routines during the intervention period. They were instructed to refrain from introducing any novel food education methods during the intervention period.
89468830|NCT02857283|Experimental|Filtered Air, then Ozone|Participants in this arm will first receive filtered clean air followed by ozone
89468831|NCT02857283|Experimental|Ozone, then Filtered Air|Participants in this arm will first receive ozone followed by filtered clean air
89468832|NCT02327702|Experimental|Chinese naive pregnant chronice hepatitis B|Chinese naive pregnant chronice hepatitis B were enrolled to take emtricitabine (200 mg one time per day) till 48 weeks after delivery.
89468833|NCT02030210||cardiologists|
89468834|NCT02030210||study coordinators|
89468835|NCT02030210||registred nurses|
89468836|NCT03609775|Experimental|Treatment A (ethanol + ACT-541468)|5 h i.v. ethanol clamp at a level of 0.6 g/L in combination with a single oral dose of ACT-541468 (50 mg)
89468837|NCT03609775|Experimental|Treatment B (ethanol placebo + ACT-541468)|5 h i.v. placebo clamp in combination with a single oral dose of ACT-541468 (50 mg)
89202237|NCT04014699|Experimental|modified 2.2mm micoincision|
89202238|NCT04014699|Active Comparator|conventional 2.2mm microincision|
89202239|NCT00937911|Experimental|YM150 group|
89468838|NCT03609775|Experimental|Treatment C (ethanol + ACT-541468 placebo)|5 h i.v. ethanol clamp at a level of 0.6 g/L in combination with a single oral dose of matching ACT-541468 placebo
89468839|NCT03609775|Experimental|Treatment D (ethanol placebo + ACT-541468 placebo)|5 h i.v. placebo clamp in combination with a single oral dose of matching ACT-541468 placebo
89468840|NCT03690765||Endometriosis/Dydrogesterone|Females aged 18 to 45 years, suffering external genital endometriosis confirmed by laparoscopy, for whom were prescribed treatment with Duphaston®
89468841|NCT02033941|Active Comparator|Meganatural-Az Grapeseed Extract|Meganatural-Az® doses: 30mg / day for 2 weeks; 4 weeks of 600 mg/day, 4 weeks 1000mg / day
89468842|NCT02033941|Placebo Comparator|Placebo|Subjects receive capsules identical in appearance to the active agent with the same incremental schedule
89468843|NCT05383235|Experimental|Sexual offenders against children|sexual offenders against children
89468844|NCT05383235|Active Comparator|Healthy controls|Healthy controls
89468845|NCT03143972|Experimental|Dexmedetomidine only|"Dexmedetomidine will be administered by effect-site TCI according to the Hannivoort model extended with an effect-site rate constant of 0.0428min-1.~A stepwise increasing dosing regimen will be given, with concentrations targeting an effect site concentration of 1 ng/ml (40 min), 3 ng/ml (50 min), 4 ng/ml (40 min), 5 ng/ml (40 min) and 8 ng/ml (70 min)."
89468846|NCT03143972|Experimental|Remifentanil only|Remifentanil will be administered by effect-site TCI according to the Eleveld model. A stepwise increasing dosing regimen will be given, with concentrations targeting an effect site concentration of 1 ng/ml (12 min), 2 ng/ml (12 min), 3 ng/ml (12 min), 5 ng/ml (12 min) and 7 ng/ml (12 min).
89468847|NCT03143972|Experimental|Dexmedetomidine-Remifentanil interaction|"A fixed background dose of dexmedetomidine will be given, this will be calculated after the first 5 subjects completed the dexmedetomidine only session. It will be set to 50% of the observed mean EC50TOL (Tolerance of Laryngoscopy).~Remifentanil infusion will be administered by effect site TCI with stepwise increasing targets of 0.5 - 1.0 - 1.5 - 2.0 - 2.5 - 3.0 - 4.0 ng/ml, each lasting for 15 minutes."
89468848|NCT02237027|Experimental|TasP group|HIV positive female sex workers receiving TasP using ART regimen as per Benin guidelines
88947320|NCT01916577|Experimental|Plerixafor (Mozobil) Experimental Arm|Plerixafor mobilization of autologous CD117 stem cells: Plerixafor will be given at 240mcg/kg subcutaneously once to 5 COPD, 5 Cystic Fibrosis, and 5 Pulmonary Fibrosis patients (awaiting lung transplantation) at time zero with blood collected for flow cytometric analysis for CD117+ peripheral blood cells just prior to the dose and then again 8 hours after the dose
89468849|NCT02237027|Experimental|PrEP group|HIV negative female sex workers receiving PrEP using Truvada
89468850|NCT03608995|Experimental|Premaquick©|
89468851|NCT03608995|Other|Quikcheck|
89468852|NCT03380637||Pregnant and non-pregnant females|The pregnant females posted for elective lower segment cesarean section and non-pregnant females posted for elective surgeries are scanned by ultrasound in the pre recovery room. The visibility of the gastric antrum is assessed. The qualitative and quantitative assessment is made and is compared.
89468853|NCT03387969||meningitic group|Children suffering from fever , disturbed consciousnessand convulsion admitted in emergency department attending to assiut University Children Hospital aged between 2-18 years old
89468854|NCT02034227|Experimental|SG2000 - 15 µg/m2/day|Cohort 1 - will commence at 15 µg/m2/day intravenous doses of SG2000 until Maximum Tolerated Dose is determined.
89468855|NCT02034227|Experimental|SG2000 - 30 µg/m2/day|Cohort 2 - will commence at 30 µg/m2/day intravenous doses of SG2000 until Maximum Tolerated Dose is determined.
89468856|NCT03608917|Experimental|Treatment group|"Drug:Total Glucosides of Paeony (TGP)~Time Frame: Week0-week8 The 1st Week, TGP 0.6g , Bid, orally; 2nd to Week8 , TGP 0.6g , Tid, orally combined with NB-UVB phototherapy( 1 time every other day)~Time Frame: Week9-Week24 TGP, 0.6g, Tid, orally."
89468857|NCT03608917|Placebo Comparator|Control group|"Drug:Total Glucosides of Paeony (TGP) analogue~Time Frame:Week0-week8 The 1st Week, TGP analogue 0.6g , Bid, orally; 2nd to Week8, TGP analogue (0.6g , Tid, orally) combined with NB-UVB phototherapy( 1 time every other day)~Time Frame: Week9-Week24 TGP analogue, 0.6g, Tid, orally."
89468858|NCT02237105|Experimental|Cognitive Behavioral Therapy Group|This group will undergo Cognitive Behavioral Therapy (CBT) before having spinal surgery
89468859|NCT02237105|No Intervention|control group|This group will not undergo any psychological intervention before the spinal surgery.
88947321|NCT01916603|Experimental|Normative intervention|Normative intervention on diet & physical & breastfeeding: diet and physical activity counselling-support and breastfeeding promotion till 12 months postpartum
88947322|NCT01916603|No Intervention|Routine care|Routine antenatal care according to national guidelines
88947323|NCT01916642|Placebo Comparator|Control|0.9% Normal Saline is given instead of Lidocaine in the same volume and duration. Then, Etomidate 2mg intravenously every 15 seconds is given until the complete loss of consciousness as detected as the complete loss of eyelash reflex.
88947324|NCT01916642|Active Comparator|Lidocaine 1mg/kg|Lidocaine 1mg/kg is given intravenously within 2 minutes. Then, Etomidate 2mg intravenously every 15 seconds is given until the complete loss of consciousness as detected as the complete loss of eyelash reflex.
88947325|NCT01916642|Active Comparator|Lidocaine 1.5mg/kg|Lidocaine 1.5mg/kg is given intravenously within 2 minutes. Then, Etomidate 2mg intravenously every 15 seconds is given until the complete loss of consciousness as detected as the complete loss of eyelash reflex.
88947326|NCT01916642|Active Comparator|Lidocaine 2mg/kg|Lidocaine 2mg/kg is given intravenously within 2 minutes. Then, Etomidate 2mg intravenously every 15 seconds is given until the complete loss of consciousness as detected as the complete loss of eyelash reflex.
88947327|NCT01916642|Active Comparator|Lidocaine 2.5mg/kg|Lidocaine 2.5mg/kg is given intravenously within 2 minutes. Then, Etomidate 2mg intravenously every 15 seconds is given until the complete loss of consciousness as detected as the complete loss of eyelash reflex.
88947328|NCT01916694|Experimental|Smart phone app glucose monitoring|Home blood glucose monitoring results directly transmitted via a bluetooth enabled smart phone app to a central database to be reviewed by clinicians
89468860|NCT03380481||SECRETS-TCM|Stroke patients who treated by western medicine and/or traditional Chinese medicine in southern China
89468861|NCT04186819|Experimental|Patients|Single intravenous administration of rhPSMA-7.3 (18F) for PET Scan
88947329|NCT01916694|Active Comparator|Standard glucose monitoring|Home blood glucose monitoring results recorded by hand in a paper diary by the patient and reviewed by the clinical team in the outpatient clinic.
88947330|NCT01916707|Active Comparator|Standard Dosing|Patients will receive standard VTE prophylaxis of enoxaparin SQ every 12 hours.
89468862|NCT03384459|Experimental|Experimental group|"For a total period of 12 months, perform the 308-nm excimer laser treatment once a month.~At this time, the dose of the 308-nm excimer laser is based on the 50% of the maximum dose that the patient received for the treatment.~Check for signs of enlarged vitiligo lesions at 3-month intervals for a total period of 12 months.~If recurrence of vitiligo is observed during the follow-up period, visit the clinic and check for recurrence."
88947331|NCT01916707|Experimental|Weight Based Dosing|Patients will receive weight adjusted VTE prophylaxis of enoxaparin SQ every 12 hours.
88947332|NCT01916720|Experimental|SB-480848 40 mg|SB-480848 40 milligrams (mg) once a day (od) for 14 +/- 4 days followed by carotid endarterectomy. SB-480848 40 mg was administered as 2 SB-480848 20 mg tablets plus 2 placebo tablets.
89468863|NCT03384459|No Intervention|Control group|"Check for signs of enlarged vitiligo lesions at 3-month intervals for a total period of 12 months.~If recurrence of vitiligo is observed during the follow-up period, visit the clinic and check for recurrence."
89468864|NCT03143582|Experimental|Running group|13 week, bi-weekly running group
89468865|NCT03609125|Experimental|CBS eyedrop|The product is prepared from cord blood serum (CBS) analyzed in advance with regard to the content of specific neurotrophic growth factors.
89468866|NCT03387891||Cancer patients|Cancer patients admitted to hospital for treatment or monitoring of health condition
89468867|NCT04185259|Experimental|Acupuncture group|
89468868|NCT04185259|Sham Comparator|Sham acupuncture|
89468869|NCT04185259|No Intervention|Waitlist control group|Participants will receive no treatment for their heel pain for a period of 16 weeks after randomization, and subsequently have the option of 4 weeks (12 sessions) of acupuncture with free of charge at the end of follow-up.
89468870|NCT02034383|Experimental|Control|Diet will consist of a controlled diet without almonds for 3 weeks.
89468871|NCT02034383|Experimental|Whole Almonds|Diet will consist of a controlled diet with whole almonds for 3 weeks.
89468872|NCT02034383|Experimental|Roasted Whole Almonds|Diet will consist of a controlled diet with roasted whole almonds for 3 weeks.
88947333|NCT01916720|Experimental|SB-480848 80 mg|SB-480848 80 mg od for 14 +/- 4 days followed by carotid endarterectomy.SB-480848 80 mg was administered as 4 20 mg SB-480848 tablets.
88947334|NCT01916720|Placebo Comparator|Matching Placebo|Placebo for 14 +/- 4 days followed by carotid endarterectomy. Placebo was administered as 4 placebo tablets. Placebo tablets were identical in appearance to the SB-480848 20 mg tablets.
88947335|NCT01916733||Lower Extremity Bypass & open AAA|Lower Extremity Bypass (LEB) and open AAA patients will be placed on standard Fletcher Allen Health Care insulin protocol post op
88947336|NCT01916733||control|patients from the Vascular Study Group of New England centers without a defined program for glucose control after lower extremity bypass and open AAA repair will be used
88947337|NCT01916746|Experimental|transvaginal resection of pregnancy tissue|
89468873|NCT02034383|Experimental|Diced Almonds|Diet will consist of a controlled diet with diced almonds for 3 weeks.
89468874|NCT02034383|Experimental|Almond Butter|Diet will consist of a controlled diet with almond butter for 3 weeks.
89468875|NCT03387345|Experimental|bread-50/50-steelcut-80/20-flake-rice|25 g of available carbohydrate was delivered to participants via (1) white bread, followed by (2) 50/50 rice-barley mix, followed by (3) 100% steel cut barley, followed by (4) 80/20 rice-barley mix, followed by (5) 100% barley flakes, followed by (6) 100% rice
89468876|NCT03387345|Experimental|50/50-steelcut-80/20-flake-rice-bread|25 g of available carbohydrate was delivered to participants via (1) 50/50 rice-barley mix, followed by (2) 100% steel cut barley, followed by (3) 80/20 rice-barley mix, followed by (4) 100% barley flakes, followed by (5) 100% rice, followed by (6) white bread
89468877|NCT03387345|Experimental|steelcut-80/20-flake-rice-bread-50/50|25 g of available carbohydrate was delivered to participants via (1) 100% steel cut barley, followed by (2) 80/20 rice-barley mix, followed by (3) 100% barley flakes, followed by (4) 100% rice, followed by (5) white bread, followed by (6) 50/50 rice-barley mix
89468878|NCT03387345|Experimental|80/20-flake-rice-bread-50/50-steelcut|25 g of available carbohydrate was delivered to participants via (1) 80/20 rice-barley mix, followed by (2) 100% barley flakes, followed by (3) 100% rice, followed by (4) white bread, followed by (5) 50/50 rice-barley mix, followed by (6) 100% steel cut barley
89468879|NCT03387345|Experimental|flake-rice-bread-50/50-steelcut-80/20|25 g of available carbohydrate was delivered to participants via (1) 100% barley flakes, followed by (2) 100% rice, followed by (3) white bread, followed by (4) 50/50 rice-barley mix, followed by (5) 100% steel cut barley, followed by (6) 80/20 rice-barley mix
89468880|NCT03387345|Experimental|rice-bread-50/50-steelcut-80/20-flake|25 g of available carbohydrate was delivered to participants via (1) 100% rice, followed by (2) white bread, followed by (3) 50/50 rice-barley mix, followed by (4) 100% steel cut barley, followed by (5) 80/20 rice-barley mix, followed by (6) 100% barley flakes
89468881|NCT02034487||Boys with delayed puberty|Boys with no signs of puberty by an age that is -2 standard deviation below the population mean.
89468882|NCT04673006||anesthesiologists who will perform endotracheal intubation and extubation for general anesthesia|All anesthesiologists in this study will use face shield for facial protection. Face shield swab will be done before and after the procedures (intubation and extubation)
88947338|NCT01916759|Other|HIV uninfected adults|25 HIV uninfected adults enrolled at the Mulago National Referral Hospital complex in Kampala, Uganda will receive seasonal trivalent inactivated influenza vaccine (Vaxigrip®).
88947339|NCT01916759|Other|HIV infected adults on HAART|25 HIV infected adults enrolled at the Mulago National Referral Hospital complex in Kampala, Uganda will receive seasonal trivalent inactivated influenza vaccine (Vaxigrip®).
88947340|NCT01916759|Other|HIV-infected long-term non-progressors|10 HIV-infected long-term non-progressor adults enrolled at the Mulago National Referral Hospital complex in Kampala, Uganda will receive seasonal trivalent inactivated influenza vaccine (Vaxigrip®).
88947341|NCT01916772||cherubism patients|no interventions
89468883|NCT03608969||Study Group|Children with cerebral palsy aged 3-16 years will be evaluated in terms of the orofacial function using the Nordic Orofacial test- screening (NOT-S). Gross Motor Function Classification System (GMFCS), Manual Ability Classification System (MACS) level and Communication Function Scale (CFS) of child will be recorded. Oral health related quality of life will be assessed using the Parental- Caregiver Perceptions Questionnaire. Caries experience will be measured by identifying decayed, missing, and filled teeth for deciduous and permanent teeth (dmft)
89468884|NCT03609463|Experimental|Well-being and small change|Participants will be randomized to receive 4 individual 1-hour weekly sessions of the well-being intervention before starting the 12 individual 1-hour weekly sessions of the small change intervention in addition to the treatment as usual.
89468885|NCT03609463|Active Comparator|Small change|Participants will be randomized to receive 12 individual 1-hour weekly sessions of the small change intervention in addition to the treatment as usual.
89468886|NCT05172453||Nationwide hospital-based cohort|HBV-infected mother-infant pairs have been followed from registry to post vaccination serological test (PVST) in hospitals nationwide.
89468887|NCT05172453||Community-based cohort|HBV-infected mother-infant pairs have been followed from registry to post vaccination serological test (PVST) in Bao' an district, Shenzhen
89468888|NCT03143738|Experimental|continuous anesthesia of adductor canal|
89468889|NCT03143738|Experimental|continuous anesthesia of femoral nerve|
89468890|NCT03608891|Active Comparator|Control Arm|Conventional titanium miniplates
89468891|NCT03608891|Experimental|Intervention arm|Patient specific 3D plates
89468892|NCT03384303|Other|LBPL-RYGB|
89468893|NCT03384303|Other|S-RYGB|
89468894|NCT04393753|Experimental|domatinostat and avelumab|Single arm study of Domatinostat tablets in combination with avelumab infusion
89468895|NCT05080868||Infantile hemangioma with minimal or arrested growth|Epidemiological and clinical characteristics of infantile hemangioma with minimal or arrested growth.
89468896|NCT05080868||Classic infantile hemangioma|Epidemiological and clinical characteristics of classic infantile hemangioma.
89468897|NCT04647903|Experimental|Oral Placebo + Intranasal manipulated ADAIR|Oral Placebo + Intranasal manipulated ADAIR 30 mg
89468898|NCT04647903|Active Comparator|Oral Placebo + Intranasal crushed dextroamphetamine sulfate|Oral Placebo + Intranasal crushed dextroamphetamine sulfate IR 30 mg
89468899|NCT04647903|Experimental|Oral ADAIR + Intranasal Placebo|Oral ADAIR 30 mg + Intranasal Placebo
89468900|NCT04647903|Placebo Comparator|Oral Placebo + Intranasal Placebo|Oral Placebo + Intranasal Placebo
89468901|NCT04593225|Experimental|TAU + multicomponent treatment VIRTUAL SFCAMINA|VIRTUAL SFCAMINA is a multicomponent non-pharmacological program based on Pain Neuroscience Education (PNE), therapeutic exercise, Cognitive Behavioural Therapy (CBT) and Mindfulness Training
89468902|NCT04593225|Active Comparator|Treatment as Usual (TAU)|Treatment-as-Usual (TAU) consisted of the prescribed drugs adapted to the symptomatic profile of each patient and basic face to face and written advice on PNE and aerobic exercise adapted to the physical capacities of the patients at the beginning of the study.patient
89468903|NCT03608813||Controls|Healthy subjects
89468904|NCT03608813||Case|PCOS affected subjects
89468905|NCT03142256|Active Comparator|Incentivised - Conditional Cash Transfer|Cash incentive for good drug levels assed by Dried Blood Spot
89468906|NCT03142256|No Intervention|No incentive|Truvada 200Mg-300Mg Tablet
89468907|NCT04308655||Patient participants|This cohort will include pregnant patients with a history of opiate use disorder (OUD) who will be followed from the third trimester of pregnancy until five days postpartum.
89468908|NCT04308655||Provider participants|This cohort will include clinicians who provide care for pregnant patients with OUD. Providers will be interviewed and will complete one survey cross-sectionally.
89468909|NCT03387189||Quality Improvement Project|Quality Improvement Project: Regions Hospital
89468910|NCT03387189||No Quality Improvement Project|No Quality Improvement Project: The comparison group is Methodist Hospital, where the Quality Improvement project is not occurring.
89468911|NCT03142178|Experimental|Experimental 3VM1001 2g X 3 daily|3VM1001 active cream administered 2g cream three times daily for seven days
89468912|NCT03142178|Placebo Comparator|Placebo; 3VM1001 vehicle 2g X 3 daily|3VM1001 placebo vehicle administered 2g cream three times daily for seven days
89468913|NCT03142178|Experimental|Experimental 3VM1001 3g X 3 daily|3VM1001 active cream administered 3g cream three times daily for seven days
89468914|NCT03142178|Placebo Comparator|Placebo; 3VM1001 vehicle 3g X3 daily|3VM1001 placebo vehicle administered 3g cream three times daily for seven day
89468915|NCT03142178|Experimental|Experimental 3VM1001 3g x 4 daily|3VM1001 active cream administered 3g cream four times daily for seven days
89468916|NCT03142178|Placebo Comparator|Placebo; 3VM1001 vehicle 3g X 4 daily|3VM1001 placebo vehicle administered 3g cream four times daily for seven days
89468917|NCT01343459|Experimental|IOERT followed by hypofractionated WBRT|HIOB: IOERT of 11.1 Gy followed by WBRT with 15 times 2.7 Gy per fraction.
89468918|NCT03380403|Active Comparator|PDT|Methylene blue and Photon Irradiation , every each week, until total ulcer healing.
89468919|NCT03380403|Active Comparator|Ciprofloxacin|Diabetic foot patients were treated on conventional way, using antibiotics and surgery.
89468920|NCT03609229|Experimental|Study group|Abdominal Sacrocolpopexy with burch technique
89468921|NCT03609229|Active Comparator|control group|Abdominal Sacrocolpopexy without burch technique
89468922|NCT03143426|Experimental|3D laparoscopic cholecystectomy|Laparoscopic cholecystectomy will be performed under 3D visualisation.
89468923|NCT03143426|No Intervention|2D laparoscopic cholecystectomy|Laparoscopic cholecystectomy will be performed under 2D visualisation, the standard viewing method used during all laparoscopic surgeries currently.
89468924|NCT02034539|Experimental|VADOplex treatment|best medical treatment in combination with intermittent pneumatic foot compression by the VADOplex system for 4 - 6 hours/day until total wound closure of the target lesion is achieved with a maximum treatment of 24 weeks
89468925|NCT02034539|No Intervention|conservative treatment|best medical treatment of the target lesion alone
89468926|NCT03380325|Experimental|Iloprost first|Cross-over starts with iloprost intervention, then second clamp without iloprost.
89468927|NCT03380325|Experimental|Iloprost second|Cross-over starts without iloprost intervention, then second clamp with iloprost.
89468928|NCT02237053|Active Comparator|Glucagon with Octreotide and insulin|Overnight (10 hours) infusion of glucagon, then 3 hours infusion of glucagon with concurrent infusions of Octreotide and insulin.
89468929|NCT02237053|Placebo Comparator|Placebo, Glucagon with Octreotide and Insulin|Overnight (10 hours) infusion of saline, then 3 hour infusion of glucagon with concurrent infusions of Octreotide and insulin.
89468930|NCT02237053|Placebo Comparator|Placebo, with Octreotide and insulin|Overnight (10 hours) infusion of saline, then 3 hour infusion of saline with concurrent infusions of Octreotide and insulin.
89468931|NCT03142100||Hebrew speaking participants|Hebrew speaking bilateral-bimodal users will be assessed using cochlear implants and hearing aids
89468932|NCT03142100||Arabic speaking participants|Arabic speaking bilateral-bimodal users will be assessed using cochlear implants and hearing aids
88947342|NCT01916785|Experimental|A1|Arm A1: Dasatinib dose adjustment based on Cmin ≥3nM value analysed on blood after 7-10 days dasatinib 100mg intake
89468933|NCT05172219|Active Comparator|Message Type PNSL: Physician sender, No Survey Link|In this arm, the Physician is message sender and the message does not include a link to a survey that initiates asynchronous care.
89468934|NCT05172219|Active Comparator|Message Type PSL: Physician sender, Survey Link|In this arm, the Physician is message sender and the message does include a link to a survey that initiates asynchronous care.
89468935|NCT05172219|Active Comparator|Message Type SNSL: System sender, No Survey Link|In this arm, the Health System is message sender and the message does not include a link to a survey that initiates asynchronous care.
89468936|NCT05172219|Active Comparator|Message Type SSL: System sender, Survey Link|In this arm, the Health System is message sender and the message does include a link to a survey that initiates asynchronous care.
89468937|NCT03140930|Experimental|Duodenal tastants, ileal placebo|Duodenal infusion of combination of tastants (sweet, bitter and umami), ileal infusion of placebo (tap water)
89468938|NCT03140930|Experimental|Duodenal placebo, ileal tastants|Duodenal infusion of placebo (tap water), ileal infusion of combination of tastants (sweet, bitter and umami)
89468939|NCT03140930|Experimental|Duodenal tastants, ileal tastants|Duodenal infusion of combination of tastants (sweet, bitter and umami), ileal infusion of combination of tastants (sweet, bitter and umami)
89468940|NCT03140930|Placebo Comparator|Duodenal placebo, ileal placebo|Duodenal infusion of placebo (tap water), ileal infusion of placebo (tap water)
89468941|NCT04127825|Experimental|Acute Normovolemic Hemodilution (ANH)|Acute normovolemic hemodilution (ANH) is a blood conservation technique that entails the removal of blood from a patient shortly after induction of anesthesia, with maintenance of normovolemia using crystalloid and/or colloid replacement.
88947343|NCT01916785|Active Comparator|A2|Arm A2: Dasatinib standard dose (100mg/d) with Cmin ≥ 3nM analysed on blood after 7-10 days dasatinib 100mg intake
88947344|NCT01916785|Active Comparator|B|Arm B : Dasatinib standard dose with Cmin < 3nM analysed on blood after 7-10 days dasatinib 100mg intake
88947345|NCT01916798|Active Comparator|Intralipid infusion|100 Subfertile women aged 35-40 years with repeated implantation failure or recurrent miscarriage with positive natural killer cells undergoing ICSI cycle.
88947346|NCT01916798|No Intervention|Control group|100 Subfertile women aged 35-40 years with repeated implantation failure or recurrent miscarriage with positive natural killer cells undergoing ICSI cycle.
88947347|NCT01916837||Single arm|Fresh tumor specimens were sampled prior to adding any fixative and within one hour of breast cancer surgery.
88947348|NCT01916850|Experimental|LX4211 Low Dose|400 mg of LX4211 administered once daily for 10 consecutive days
88947349|NCT01916850|Experimental|LX4211 High Dose|800 mg of LX4211 administered once daily for 10 consecutive days
88947350|NCT01916850|Placebo Comparator|Placebo|Identical placebo administered once daily for 10 consecutive days
88947351|NCT01916863|Experimental|LX4211|400 mg of LX4211
88947352|NCT01916863|Active Comparator|Canagliflozin|300 mg canagliflozin
88947353|NCT01916863|Placebo Comparator|Placebo|LX4211 placebo
88947354|NCT01916876|No Intervention|Standard Care|At discharge, patients will be given a discharge plan by their attending caregiver as deemed appropriate.
89468942|NCT04127825|No Intervention|Standard of Care|Standard of care for blood volume maintenance during surgery
89468943|NCT03609151|Active Comparator|group A|laparoscopic hepatectomy (surgery)
89468944|NCT03609151|Experimental|group B|stereotactic body radiotherapy (SBRT)
89468945|NCT03384147|Experimental|Drinking|"Occasional drinkers assigned to start with a 3week drinking period (women 1 u/day - men 2 u/day)~Followed by crossover without washout to 3 week abstaining period"
89468946|NCT03384147|Experimental|Abstaining|"Habitual drinkers assigned to start 2 weeks of abstaining from alcohol~Followed by crossover without washout to 3 weeks drinking (women 1 u/day - men 2 u/day)"
89468947|NCT04964570|Experimental|Video and behavioral change module (BCM) + booster|Participants will watch the video and read the BCM twice (day 1 and day 14)
89468948|NCT04964570|Experimental|Video and behavioral change module (BCM)|Participants will watch the video and read the BCM once (day 1 only)
89468949|NCT04964570|No Intervention|Control|This arm will recieved the same length video with a content that is not related to mental health and no BCM
89468950|NCT02237131|Experimental|Oral contraceptives cyclic|Oral contraceptives containing 0.03 mg ethinyl estradiol and 3mg drospirenone will be administered. One tablet a day for 21 days followed by 7 days pill free. The regimen will be repeated for the duration of the trial.
89468951|NCT02237131|Active Comparator|Oral contraceptives continuous|Oral contraceptives containing 0.030 mg ethinyl estradiol and 3mg drospirenone will be administered. One tablet a day for the duration of the trial.
89468952|NCT03384069|Experimental|Group-based Cognitive Behavioral Therapy (CBT)|The Group-based CBT will incorporate psycho-education about cognitive behavioral skills and written materials to support learning and application of the psycho-educational content. The intervention will be culturally tailored to incorporate beliefs/attitudes, health literacy, effective communication, and motivational strategies, which focus on African Americans.
89468953|NCT03384069|Experimental|Phone-based Cognitive Behavioral Therapy (CBT)|This intervention will follow the same protocol as the group-based CBT, but without the opportunity for group-interaction. It will incorporate psycho-education about cognitive behavioral skills and written materials to support learning and application of the psycho-educational content. The intervention will be culturally tailored to incorporate beliefs/attitudes, health literacy, effective communication, and motivational strategies, which focus on African Americans.
89468954|NCT03384069|No Intervention|Standard of care|Participants will continue to receive care and follow up from their primary care providers, that incorporates general education regarding lifestyle activities and AD prevention.
89468955|NCT02734667|Experimental|CGM at diagnosis of T1D|Participants start non-adjunctive use of CGM at diagnosis of T1D and continue for 6 months.
89468956|NCT02734667|No Intervention|Usual Care|Participants receive usual care for T1D for 6 months post diagnosis.
89468957|NCT04997174||ERAS|Patients undergoing laparoscopic colorectal surgery with ERAS
89468958|NCT04997174||Non ERAS|Patients undergoing laparoscopic colorectal surgery without ERAS
89468959|NCT04997174||Open|Patients undergoing open colorectal surgery
89468960|NCT02237209|Experimental|RSV LID ΔM2-2 Vaccine|Participants will receive one dose of the RSV LID ΔM2-2 vaccine at study entry, delivered as nose drops.
89468961|NCT02237209|Placebo Comparator|Placebo Vaccine|Participants will receive one dose of placebo at study entry, delivered as nose drops.
89468962|NCT03383991|Experimental|Reverse Total Shoulder Arthroplasty|
89468963|NCT03383991|Active Comparator|Hemiarthroplasty|
89468964|NCT03387111|Experimental|NANT Squamous Cell Carcinoma (SCC) Vaccine|Combination of agents will be administered in this study: Aldoxorubicin HCl, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK, N-803, avelumab, bevacizumab, capecitabine, cetuximab, cisplatin, cyclophosphamide, fluorouracil, leucovorin, nab-paclitaxel, necitumumab, SBRT.
89468965|NCT04477070|Experimental|Air-polishing with ultrasonic debridement|Air-polishing with ultrasonic debridement
89468966|NCT04477070|Active Comparator|Conventional scaling and root planing.|Conventional scaling and root planing.
89468967|NCT03608293|Experimental|Smokers|Smokers outpatients at the Pneumology service from the HôpitalSaint-Philibert (Lomme, France) to whom a bronchoalveolar lavage will be performed
89468968|NCT03608293|Active Comparator|Non smokers|Non smokers outpatients at the Pneumology service from the HôpitalSaint-Philibert (Lomme, France) to whom a bronchoalveolar lavage will be performed
89468969|NCT03608501|Experimental|Ixazomib 4 mg + Thalidomide 100 mg + Dexamethasone 40 mg|Ixazomib 4 milligram (mg), capsule, orally, once on Days 1, 8 and 15 along with thalidomide 100 mg, tablet, orally, once daily and dexamethasone 40 mg, tablet, orally, once on Days 1, 8, 15 and 22 in a 28-day treatment cycle for up to 9 cycles or until withdrawal from the study in the treatment phase. Participants who complete treatment phase will be eligible to continue on to the maintenance phase of the study to receive ixazomib 4 mg, capsules, orally, once on Days 1, 8 and 15 of a 28-day treatment cycle for up to 24 months or until withdrawal from the study.
89468970|NCT04609436||Single arm|This is a single arm trial. The patient is his own control.
89468971|NCT03608761|Experimental|Rebamipide 2%|"- wash-out: 2 weeks~- rebamipide 2% four times a day for 3 months~- controls will be taken at day zero, 30 and 90.~- wash-out: 2 weeks~- autologous serum for 3 months"
89468972|NCT03608761|Experimental|Autologous serum|"- wash-out: 2 weeks~- autologous serum four times a day for 3 months~- controls will be taken at day zero, 30 and 90.~- wash-out: 2 weeks~- rebamipe 2% for 3 months"
89468973|NCT03608761|Experimental|autologous serum and rebamipide 2%|rebamipide 2% and autologous serum four times a day for 3 months separately by 1 minute between each other controls will be taken at day zero, 30 and 90. this group will not be crossed
89468974|NCT03383913|Experimental|Intervention|The intervention arm baseline visit will include: Institutional Review Board (IRB) consent, PROMIS measure baseline and outcome assessments, instructions on placement of Firstbeat device and use of Firsbeat journal, resting HRV recording using Firsbeat software for 15 minutes, saliva collection, and distribution of actigraph watch to quantify sleep quality. Participants placed in the intervention arm will receive 4-6 weeks of Heart Rate Variability Biofeedback training. All measures will be repeated at the end of the six week period.
89468975|NCT03383913|No Intervention|Control|The control arm baseline visit will include: Institutional Review Board (IRB) consent, PROMIS measure assessments, instructions on placement of Firstbeat device and use of Firsbeat journal, resting HRV recording using Firstbeat software for 15 minutes, saliva collection, and distribution of actigraph watch to quantify sleep quality. The control group will receive their usual care for SCD and complete baseline and post-baseline outcome assessments without any HRV-B training. All measures will be repeated at the end of the six week period.
89468976|NCT03608267|Experimental|Intervention|
89468977|NCT03383835|Experimental|Omega-3 Supplementation|Participants will take the dose of omega-3 supplementation (600mg DHA and 300mg EPA) daily for 6 months.
89468978|NCT04568174|Active Comparator|PPSGG|sterile liquid, one 1-hour infusion in SAD and multiple infusions in MAD. In SAD multiple cohorts being tested. Dosage and regime in MAD to be defined based on SAD outcome.
89468979|NCT04568174|Placebo Comparator|Placebo|standard PBS solution, pH 7.4, composed of disodium hydrogen phosphate dodecahydrate, potassium dihydrogen phosphate, sodium chloride, and water for injection
89468980|NCT02033447|Experimental|Magnetic Nanoparticle Injection|Patients undergoing radical cystoprostatectomy or prostatectomy
89468981|NCT02715115|Experimental|NNZ-2566|Glycyl-L-2-Methylpropyl-L-Glutamic Acid
89468982|NCT02715115|Placebo Comparator|Placebo (strawberry flavored solution)|Strawberry flavored solution and Water for Injection
88947355|NCT01916876|Other|Integrative medical follow-up package|"At discharge, patients will receive a discharge plan by their attending caregiver.~Thereafter, if randomised to this study arm they will receive the intervention as outlined elsewhere.~Integrated Medical Follow-up package"
88947356|NCT01916889|Experimental|RACY test|"4-question RACY delirium screening tool"
88947357|NCT01916902|Active Comparator|Ticagrelor- Delayed Administration|Subjects receive 180 mg of ticagrelor during cardiac catheterization after diagnostic angiography and prior to stenting. OCT is performed prior to and after coronary artery stenting.
88947358|NCT01916902|Active Comparator|Ticagrelor- Immediate Administration|Subjects receive 180 mg of ticagrelor immediately after study enrollment. OCT is performed prior to and after coronary artery stenting.
88947359|NCT01916915|Experimental|Tramadol 1|1 mg/kg tramadol + 0.25% levobupivacaine 4 ml/h infusion
88947360|NCT01916915|Experimental|Tramadol 2|2mg/kg tramadol + 0.25% levobupivacaine 4 ml/h infusion
88947361|NCT01916915|Placebo Comparator|Levobupivacaine|0.25% levobupivacaine 4ml/h infusion
88947362|NCT01916954|Active Comparator|3-day artemether-lumefantrine|Standard artemether-lumefantrine regimen (3-day treatment)
88947363|NCT01916954|Experimental|5-day artemether-lumefantrine|Artemether-lumefantrine extended regimen (5-day treatment)
88947364|NCT01916993|Experimental|Healthy Volunteers|single dose of NBI-98854 50 mg capsule
88947365|NCT01916993|Experimental|Mild Hepatic Impairment|single dose of NBI-98854 50 mg capsule
88947366|NCT01916993|Experimental|Moderate Hepatic Impairment|single dose of NBI-98854 50 mg capsule
88947367|NCT01916993|Experimental|Severe Hepatic Impairment|single dose of NBI-98854 50 mg capsule
88947368|NCT01917019|Placebo Comparator|Part A Placebo|Part A: All participants will receive placebo orally twice daily for the first 2 weeks and then be randomized to receive prolonged-release fampridine 10 mg or matching placebo tablets orally twice daily for up to 14 weeks.
88947369|NCT01917019|Experimental|Part A prolonged-release fampridine|Part A: All participants will receive placebo orally twice daily for the first 2 weeks and then be randomized to receive prolonged-release fampridine 10 mg or matching placebo tablets orally twice daily for up to 14 weeks.
88947370|NCT01917019|Experimental|Part B prolonged-release fampridine|Part B: Eligible participants will receive open label treatment with prolonged-release fampridine 10mg orally twice daily for up to 52 weeks.
88947371|NCT01917019|Experimental|Part C prolonged-release fampridine|Part C: Eligible participants will receive open label treatment with prolonged-release fampridine 10mg orally twice daily until marketed product is available.
88947372|NCT01917032|Active Comparator|Sprinkles|Micronutrient Powder Sprinkles 1 gram orally on weekdays during 11 weeks
88947373|NCT01917032|Placebo Comparator|Placebo|Maltodextrin 1 gram orally on weekdays during 11 weeks
88947374|NCT01917045|Experimental|low body fat percentage|body fat percentage less than 30%
89537336|NCT04562597|Active Comparator|Opioid Reduction with Optimal N-acetylcysteine Dose|Once the optimal N-acetylcysteine dose is identified, 15 additional participants will be randomized to the optimal dose to estimate the difference in opioid consumption between patients on placebo vs. the optimal dose. Primary and secondary outcomes will only be evaluated for the placebo group and optimal NAC group.
88947375|NCT01917045|Experimental|heigh body fat percentage|body fat percentage more than 30%
88947376|NCT01917058|Active Comparator|abatacept|
88947377|NCT01917058|Placebo Comparator|abatacept Subcutaneous vehicle|
88947378|NCT01917071|Experimental|Matched Group|Receives thoracic spine manipulation in the direction of motion limitation.
88947379|NCT01917097||Dexmedetomidine patients|Patients that received dexmedetomidine during their surgery.
88947380|NCT01917097||No Dexmedetomidine|Patients that didn't receive dexmedetomidine during surgery.
88947381|NCT01917110|Experimental|omafilcon A|Contact Lens Group
88947382|NCT01917110|Active Comparator|Spectacle Group|Prescription at Baseline
88947383|NCT01917123|Active Comparator|Stimol, Brachial Index, Powder agent|L-Citrulline malate,1gr,twice a day,2weeks
88947384|NCT01917123|Placebo Comparator|Placebo, Brachial Index, Powder agent|Placebo,1gr,twice a day,2weeks
89206184|NCT00297037|Active Comparator|1|"During the 6-week double-blind phase, all patients will be randomly assigned to receive either pimecrolimus 1% cream or its vehicle twice daily with occlusion on the affected areas. Topical application of pimecrolimus1% cream for oral erosive lichen planus for a duration of 6 weeks; ¼ gram of cream will be applied to each of the 2 sides of the mouth BID with a 2x2 gauze."
89468983|NCT04554836|Experimental|FOLFIRI + cetuximab|"Patients in Arm A will receive FOLFIRI + cetuximab until progressive disease (PD), unacceptable toxicity, withdrawal of informed consent or death, whatever occurs first. The recurrence of RAS-mutation without PD to switch back to FOLFIRI. In case of repeated conversion to RAS wild-type without PD, treatment will shift to FOLFIRI + cetuximab again, and so on. Switches of treatment will proceed until progressive disease (PD), unacceptable toxicity, withdrawal of informed consent or death, whatever occurs first.~[FOLFIRI = Irinotecan, Folinic acid (racemic), Fluorouracil (5-FU)]"
89468984|NCT04554836|Other|FOLFIRI|Patients in Arm B will continue therapy with FOLFIRI until PD, unacceptable toxicity, withdrawal of informed consent or death, whatever occurs first.
89468985|NCT03386955|Experimental|BPI-7711 treatment|"Phase I: Patients in dose escalation group will receive single dose of BPI-7711 on day -7 and start receive the 21 days/cycle continuous treatment once a day after 7 day washout period. Patients in the extension group will receive BPI-7711 once a day with the selected doses.~Phase IIa: Patients will receive BPI-7711 capsule(recommend phase 2 dose) as the first line treatment."
89468986|NCT04536272|Active Comparator|Target of 2-2.5 times baseline aPTT (usual care, about 60-75)|Administration of heparin during ECLS with an aPTT target of 2-2.5 times baseline.
89468987|NCT04536272|Active Comparator|Target of 1.5-2.0 times baseline aPTT (45-60 sec.)|Administration of heparin during ECLS with an aPTT target of 1.5-2.0 times baseline.
89468988|NCT04536272|Active Comparator|LMWH guided by weight and renal function.|Administration of LMWH guided by weight and renal function during ECLS.
89468989|NCT03608527|Experimental|Active motor treatment (AMT) group|15 people with multiple sclerosis performing a 8 week rehabilitative treatment based on task-oriented voluntary exercises (3 sessions/week).
89468990|NCT03608527|Active Comparator|Passive motor treatment (PMT) group|15 people with multiple sclerosis performing a 8 week passive mobilization delivered by a physical therapist (3 sessions/week).
89468991|NCT03380169|Experimental|Advance dressing|Prophylactic advance wound dressing
89468992|NCT03380169|Active Comparator|Conventional gauze dressing|Prophylactic conventional wound dressing
89468993|NCT02034721|Experimental|Protein supplementation|60 grams protein before, during, after eccentric exercise
89468994|NCT02034721|Placebo Comparator|Placebo|60 grams placebo before, during, after eccentric exercise
89468995|NCT04521842|Placebo Comparator|Standard size femoral head implant|Participants qualified to undergo total hip replacement who will receive standard femoral head size implant
89468996|NCT04521842|Active Comparator|Large size femoral head|Participants qualified to undergo total hip replacement who will receive large femoral head size implant
89468997|NCT03383601||Users of IQOS with HeatStick|Individuals (men and women) between the ages of 40 and 59 (inclusive) with a minimum of 10 pack-year smoking history who switched to and predominantly (>70%) use Heated Tobacco product IQOS/heatstick
89468998|NCT03383601||Smokers of combustible cigarettes|Individuals (men and women) between the ages of 40 and 59 (inclusive) who are currently smoking combustible cigarettes with a minimum of 10 pack-year smoking history
89468999|NCT02746679|Experimental|MBSR Group|The Mindfulness Based Stress Reduction program consisted of eight weekly sessions, each 2.5 hours long, and delivered on consecutive weeks.The Mindfulness Based Stress Reduction therapist participated in the mindfulness exercises with group members during the weekly sessions, and group members were instructed to practice these mindfulness exercises outside group meetings for at least 45 minutes per day, 6 days per week.Group members were taught three main varieties of mindfulness skills: the body scan exercise, sitting meditation, and yoga exercises.The daily homework exercises consisted of repeating body scan work, sitting meditation and yoga exercises at home to provide practice and generalization of the skills.
89469000|NCT02746679|No Intervention|wait-list control group|The patients assigned to the wait-list control group did not receive MBSR intervention for 8 weeks when participants in MBSR were engaged in the MBSR intervention.They only received conventional therapy.
89469001|NCT03380013|Experimental|OMT group|Osteopathic Manipulative Therapy (OMT); two treatments between day 4 and 7 of life
89537337|NCT04562597|Placebo Comparator|Placebo|15 Participants will be randomized to placebo to estimate the difference in opioid consumption between patients on placebo vs. the optimal dose. Primary and secondary outcomes will only be evaluated for the placebo group and optimal NAC group.
89469002|NCT03608215|Experimental|Active tDCS|The anode sponge electrode will be placed on the scalp over the left primary motor cortex (M1) and the cathode sponge electrode will be positioned over the right supraorbital cortex (SO). Active stimulation consists of 2 mA current applied continuously for 20 minutes.
89469003|NCT03608215|Sham Comparator|Sham tDCS|The anode sponge electrode will be placed on the scalp over the left primary motor cortex (M1) and the cathode sponge electrode will be positioned over the right supraorbital cortex (SO). The 2 mA current will be applied for 30 seconds at the beginning of the session.
89469004|NCT04138927|Experimental|Fostamatinib|"Subjects who at any time during the C-935788-057 study achieved a hemoglobin response will continue at their dose and regimen from the Week 22 visit in the C-935788-057 study.~All other subjects who enter the extension study will initially receive fostamatinib 100 mg PO bid. Starting at Week 4, the initial fostamatinib dose of 100 mg PO bid will be increased to fostamatinib 150 mg PO bid if subjects have adequately tolerated the study drug, based on the Investigator's judgment."
89469005|NCT04504604|Active Comparator|Cholangiocarcinoma|Eligible patients that present with Cholangiocarcinoma.
89469006|NCT04504604|Active Comparator|Cancer of Unknown Primary (CUP)|Eligible patients with cancer of unknown primary site (CUP).
89469007|NCT04504604|Active Comparator|Other remaining rare cancers (solid tumors & lymphomas)|Eligible patients that meet the definition of rare cancers (incidence of less than 6 per 100,000 in the United States).
89469008|NCT03610373|Experimental|Shared Decision Making|In this arm, parents and children will participate in a shared decision-making protocol with the clinician to plan their treatment. The treatment options available are established, evidence-based treatment techniques. The shared decision-making protocol was developed for this research project.
89469009|NCT03610373|Active Comparator|Clinician Guided|In this arm, the clinician will plan the treatment in consultation with their supervisor, and share the treatment plan with the parent and child. The parent and child will have the opportunity to ask questions about the treatment plan (and, if they do not agree, reject the treatment plan), but they are not actively involved in making each decision. This is more typical of usual care.
89018740|NCT00294203|Active Comparator|Epoetin Alfa group|Patients enrolled in the study will be randomized to receive either 40,000 units of epoetin alfa on day 1 and day 8. Hemoglobin, hematocrit, reticulocyte count, reticulocyte hemoglobin, and immature reticulocyte count will be measured on days 1, 4, 8, and once between post-operative days 20 and 30. Pre-operatively and between post-operative days 20 and 30 patients will complete a quality of live assessment tool (FACT-An) to assess their fatigue related to anemia.
89469010|NCT03610295|Experimental|PPI group|cataract extraction surgery with prophylactic peripheral iridectomy
89469011|NCT03610295|Active Comparator|historical control group|cataract extraction surgery
89469012|NCT03142022||SDB and lung transplantation|Polysomnography at 1 year after lung transplantation.
89469013|NCT02034643|Other|patients with single-lumen tube|Patients who required intraoperative TEE and single-lumen tube; balloon pressure adjustment before TEE probe insertion
89469014|NCT02034643|Other|patients with double-lumen tube|Patients who required intraoperative TEE and double-lumen tube; balloon pressure adjustment before TEE probe insertion
89469015|NCT02033525|Experimental|XCEL-M-ALPHA and standard rehabilitation|Intraarticular administration of XCEL-M-ALPHA followed by standard rehabilitation program
88947385|NCT01917149|Experimental|Metoprolol|Patients in the metoprolol group were started on 11.875-23.75mg of metoprolol succinct extended-release tablet once daily (11.875mg was recommended for patients with NYHA functional classes III-IV), and then doses were doubled every 2 weeks to achieve asymptomatic bradycardia (50-60 bpm of heart rate) over 4-6 weeks. Investigators were encouraged to up-titrate metoprolol to a maximum dose of 190mg whenever possible.
88947386|NCT01917149|Experimental|Low-dose valsartan|Patients randomized to low dose valsartan receive valsartan 80 mg until study completion.
88947387|NCT01917149|Experimental|Low dose Benazepril|Patients randomized to low dose Benazepril receive Benazepril 10 mg until study completion.
88947388|NCT01917149|Experimental|High dose valsartan|Patients randomized to high-dose valsartan were started on valsartan 80mg twice daily, and uptitrated to target doses within 7 days under in-hospital observation. The target high doses of valsartan is determined by left-ventricular end-diastolic diameter (LVEDD) (the maximal value of anteroposterior and lateral diameters) obtained by ECG at the randomization visit. A target dose of valsartan 320mg, 480mg, 640mg daily were assigned to patients with LVEDD of 50-59, 60-69, ≥70 mm respectively.
88947389|NCT01917149|Experimental|High dose Benazepril|Patients randomized to high-dose benazepril were started on benazepril 10mg twice daily, and uptitrated to target doses within 7 days under in-hospital observation. The target high doses of benazepril is determined by left-ventricular end-diastolic diameter (LVEDD) (the maximal value of anteroposterior and lateral diameters) obtained by ECG at the randomization visit. A target dose of benazepril 40mg, 60mg, 80mg daily were assigned to patients with LVEDD of 50-59, 60-69, ≥70 mm respectively.
88947390|NCT01917162|Other|Nelfilcon A/UltraFilcon B|Nelfilcon A contact lenses, followed by UltraFilcon B contact lenses. Each product worn bilaterally for one week in a daily wear, daily disposable modality.
88947391|NCT01917162|Other|UltraFilcon B/Nelfilcon A|UltraFilcon B contact lenses, followed by Nelfilcon A contact lenses. Each product worn bilaterally for one week in a daily wear, daily disposable modality.
88947392|NCT01917175||HIV+ patients with an estimated date of seroconversion|It was estimated that 564 individuals, will be enrolled at the Blood Bank Medical Centre, including 364 individuals already followed-up (former PRIMOCI ANRS 1220 cohort started in 1997) and 200 newly enrolled individuals in this study.
88947393|NCT01917201|Other|IVUS-guided group|The coronary stenting under IVUS-control (with VH or i-MAP) is carried out: a choice of length and diameter of stent - according to IVUS data. After the completion of implantation and postdilatation of stents the control IVUS (with VH or i-MAP) is being used, the optimality of stent implantation is also being assessed.If criteria of optimal implantation guided by IVUS were not achieved, additional impact is being made. In case of an additional impact the repeated control IVUS is being completed and the following results are being fixed. After control IVUS the OCT procedure is carried out. An additional impact based on OCT data is not being used.
88947394|NCT01917201|Other|Non-IVUS group|The coronary stenting under angiography control is carried out. After postdilatation control OCT is carried out. An additional impact based on OCT data is not being used.
88947395|NCT01917227|Experimental|Video|
88947396|NCT01917240|Experimental|Monophasic Media|Half of each patient's embryos will be randomly assigned to grow in monophasic media & the other half in sequential media. All embryos will undergo CCS & the best euploid embryo from each group will be transferred (DET). If there are only euploid embryos from one group, pt will have SET only (fresh or frozen)
88947397|NCT01917240|Placebo Comparator|Sequential Media|Half of each patient's embryos will be randomly assigned to grow in monophasic media & the other half in sequential media. All embryos will undergo CCS & the best euploid embryo from each group will be transferred (DET). If there are only euploid embryos from one group, pt will have SET only (fresh or frozen)
88947398|NCT01917253|Experimental|standard length catheter|Standard Device for peripheral vein cannulation
88947399|NCT01917253|Experimental|Long catheter|Standard Device for peripheral vein cannulation
88947400|NCT01917266||Concordant|
88947401|NCT01917266||Discordant|
88947402|NCT01917279|Active Comparator|Intermittent Capecitabine|Capecitabine 1000 mg/m2 twice daily on days 1-14 of each 3-week cycle.
89469016|NCT02033525|Active Comparator|standard rehabilitation|Standard rehabilitation program
89469017|NCT04638842|Experimental|Grief COVID intervention|Participants in this group will receive 12 sessions of a multi-component psychological intervention focused on the reduction of symptoms of anxiety, depression, hopelessness, and post-traumatic stress, and the increase of the quality of sleep and perception of the quality of life.
89469018|NCT04638842|No Intervention|Waiting List group|The participants in this group will not receive the treatment, just waiting list. They will be measured one time and then a second time 3 months after. Calculating when 3 months corresponding to 12 sessions will receive the intervention.
89469019|NCT02731131|Experimental|Group A: Monotherapy with Peginterferon alfa-2a|Participants will receive peginterferon alfa-2a alone, administered over 48 weeks.
89469020|NCT02731131|Experimental|Group B: Combination with Peginterferon alfa-2a + Ribavirin|Participants will receive combination therapy with peginterferon alfa-2a plus ribavirin, administered over 48 weeks.
89469021|NCT03608189||ACL injury subjects|Subjects with anterior cruciate ligament injuries.
89469022|NCT02746705|Active Comparator|Transcranial Direct Current Stimulation (tDCS)|
89469023|NCT02746705|Sham Comparator|Sham Transcranial Direct Current Stimulation (tDCS)|
89469024|NCT04585724|Experimental|Treatment (abemaciclib)|Beginning within 2 weeks prior to stereotactic radiosurgery, patients receive abemaciclib PO BID. Treatment continues in the absence of disease progression or unacceptable toxicity.
89469025|NCT04585724|Experimental|Treatment (palbociclib)|Beginning within 2 weeks prior to stereotactic radiosurgery, patients receive palbociclib PO QD on days 1-21. Treatment continues in the absence of disease progression or unacceptable toxicity.
89469026|NCT04585724|Experimental|Treatment (ribociclib)|Beginning within 2 weeks prior to stereotactic radiosurgery, patients receive ribociclib PO QD on days 1-21. Treatment continues in the absence of disease progression or unacceptable toxicity.
89469027|NCT03608111|Active Comparator|single task balance training|
89469028|NCT03608111|Active Comparator|dual task balance training|
89469029|NCT03386877|Experimental|Dental pulp stem cells|Test sites (n=15) Periodontal regeneration using micro-grafts of Dental pulp stem cells seeded onto collagen sponge
89469030|NCT03386877|Active Comparator|coagulum|control sites (n=14) Periodontal regeneration using coagulum and collagen sponge alone
89469031|NCT02237261|Experimental|Bendamustine, Bortezomib, Prednisone|Induction: Bortezomib: 1.3 mg/m2 subcutaneous for 7 days and Bendamustine: 90 mg/m2 intravenous for 2 days and in addition Prednison: : 60 mg/m2 per os for 4 days Consolidation: Bortezomib: 1.3 mg/m2 subcutaneous for 4 days and Bendamustine: 90 mg/m2 intravenous for 2 days and in addition Prednison 60 mg/m2 per os for 4 days
89469032|NCT03386643|Experimental|Bifidobacterium animalis subsp. lactis|"Intervention:~Bifidobacterium animalis subsp. lactis HN019"
89469033|NCT03386643|Active Comparator|Clobetasol propionate 0.05%|"Intervention:~Clobetasol propionate 0.05%"
88947403|NCT01917279|Experimental|Metronomic Capecitabine|Capecitabine 500 mg three times daily on days 1-21 of each 3-week cycle
88947404|NCT01917292|Other|Periodontal care|
88947405|NCT01917292|Experimental|One-Stage Full-Mouth Disinfection|
89537338|NCT04433637|Experimental|Nutrition Group|Pregnant women in the first experimental group were provided to consume cake and fruit juice 30 minutes before the NST procedure.
89537339|NCT04433637|Experimental|Video Group|The video, which contains information about the developments and changes occurring in the mother and the fetus during pregnancy, was watched for 15-20 minutes during the NST procedure, accompanied by music that provided relaxation.
89537340|NCT04433637|No Intervention|Control Group|No intervention was applied to the pregnant women in the control group.
89537341|NCT05728281|Other|Resumption of sexual intercourse recommended 4 weeks after hysterectomy|
89537342|NCT05728281|Other|Resumption of sexual intercourse recommended 8 weeks after hysterectomy|
89537343|NCT04554719|Experimental|68Ga-DOTA-FAPI PET/MR|Investigators select subjects from patients with suspected or diagnosed or treated malignant tumors who have completed 18F-FDG PET/CT imaging, focusing on malignant tumors with poor results of FDG PET/CT imaging, such as brain tumors, liver tumors, digestive system tumors and peritoneal, greater omentum, and mesenteric metastatic tumors. Patients undergo 68Ga-DOTA-FAPI PET/MR imaging within one week.
88947406|NCT01917305|Experimental|platform-switched implant|platform-switched implant
88947407|NCT01917305|Active Comparator|platform-matched implant|platform-matched implant
88947408|NCT01917318|Experimental|Iloperidone / Placebo|During 1st treatment period subjects will receive iloperidone. During 2nd treatment period subjects will receive placebo.
88947409|NCT01917318|Experimental|Placebo / Iloperidone|During 1st treatment period subjects will receive placebo. During 2nd treatment period subjects will receive Iloperidone.
88947410|NCT01917331|Experimental|Beclometasone/Formoterol/Glycopyrrolate|CHF 5993 pMDI 100/6/12.5 mcg 2 inhalations bid
88947411|NCT01917331|Active Comparator|Beclometasone/Formoterol|Foster® 100/6 mcg 2 inhalations bid
88947412|NCT01917357|Experimental|Quinvaxem in Uniject|"A single dose (0.5 mL) of Quinvaxem contains:~diphtheria antitoxin (>= 30 IU), tetanus antitoxin (>= 60 IU), whole-cell inactive pertussis bacteria (>= 4 IU), 10 mcg Hib oligosaccharide conjugate (approx. 25 mcg CRM197), 10 mcg Hepatitis B surface antigen~One dose of Quinvaxem given intramuscularly at Weeks 6, 10 and 14 by injection into the anterolateral region of the thigh using the Uniject pre-filled injection device"
88947413|NCT01917357|Active Comparator|Quinvaxem in single dose vials|"A single dose (0.5 mL) of Quinvaxem contains:~diphtheria antitoxin (>= 30 IU), tetanus antitoxin (>= 60 IU), whole-cell inactive pertussis bacteria (>= 4 IU), 10 mcg Hib oligosaccharide conjugate (approx. 25 mcg CRM197), 10 mcg Hepatitis B surface antigen~One dose of Quinvaxem given intramuscularly at Weeks 6, 10 and 14 by injection into the anterolateral region of the thigh using a needle and syringe from single dose vials"
89537344|NCT03068793||Patients with Recent Onset Schizophrenia|Individuals who have been diagnosed with Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder within the past five years and meet our research criteria for symptoms indicative of these diseases within the past five years.
89537345|NCT03068793||Patients with Major Depressive Disorder|Individuals who have been diagnosed with Major Depressive Disorder within the past five years and meet our research criteria for symptoms indicative of this disease within the past five years.
89537346|NCT03068793||Patients with Gambling Disorder|Individuals who have been diagnosed with Gambling Disorder within the past five years and meet our research criteria for symptoms indicative of this disease within the past five years.
88947414|NCT01917370||ICC patients|patients with intrahepatic cholangiocarcinoma treated by surgical treatment
88947415|NCT01917409|Experimental|conventional laryngoscopy|experimental conventional laryngoscopy group: laryngoscope is used to assist for nasotracheal intubation.
89469034|NCT02746627|Active Comparator|Education|Participants receive educational materials in the mail every 2 weeks for 8 weeks.
89469035|NCT02746627|Experimental|Positive Affect - Text|Participants receive positive affect intervention (weekly reminders to use gratitude, self-affirmations, parental affirmations, and gift cards) by SMS. Participants also receive educational materials in the mail every 2 weeks for 8 weeks.
89469036|NCT02746627|Experimental|Positive Affect - Phone|Participants receive positive affect intervention (weekly reminders to use gratitude, self-affirmations, parental affirmations) by phone. Participants receive small gifts in the mail every 2 weeks for 8 weeks. educational materials in the mail every 2 weeks for 8 weeks.
89469037|NCT04456166||Patient who received carbohydrate loading|Patients with diabetes mellitus type 2 who are planned to receive a carbohydrate beverage (400 ml (12.8% carbohydrates, 50 kcal/100 ml; Nucare NONPO Ⓡ , Daesang Wellife, Korea) before the operation and up to 2 hours before the induction of anesthesia outside this clinical study setting
89469038|NCT05172063||Persistent SARS-CoV-2 Infection Group|Pediatric Cancer patients with persistent SARS-CoV-2 infection
89469039|NCT05172063||SARS-CoV-2 Clearance Group|Pediatric Cancer patients who tested negative for SARS-CoV-2 within 14 days of diagnosis.
89469040|NCT02237287|Sham Comparator|wound dressing with VAC|After wound debridement wounds are treated for 2 weeks with VAC dressing alone
89469041|NCT02237287|Other|wound dressing with VAC and sNAG under Antiaggregation|In patients being under antiaggregation with Aspirin® 100mg daily, after wound debridement wounds are treated with VAC and sNAG
89469042|NCT02237287|Experimental|wound dressing with VAC and sNAG without antiaggregation|In patients NOT being under antiaggregation, after wound debridement wounds are treated with VAC and sNAG
89469043|NCT05171985|Experimental|Dexmedetomidine sedation group|72 cases sedated on Propofol infusion 50-200 mg/h + Fentanyl infusion 25-250 mcg/h guided by hemodynamics in addition to Dexmedetomidine infusion 0.2 - 1 mcg/kg/h, and also guided by hemodynamics.
89469044|NCT05171985|Other|control group|72 cases sedated on Propofol infusion 50-200 mg/h + Fentanyl infusion 25-250 mcg/h guided by hemodynamics
89469045|NCT02237365|Experimental|81mg aspirin|Aspirin 81mg daily for 60 days
89469046|NCT02237365|Experimental|1000mg aspirin|Aspirin 1000mg daily for 60 days
89469047|NCT02237365|Placebo Comparator|Placebo|Visually matched placebo daily for 60 days
89469048|NCT04396652|Experimental|Adductor canal block (ACB) group|Patients will receive ACB under ultrasound guidance in which the adductor canal was identified beneath the sartorius muscle and 20 ml of 0.25% Levobupivacaine will be injected in the canal
89469049|NCT04396652|Experimental|Peri-articular injection group|"Patients in group II will receive intraoperative peri-articular (cocktail) injection and will be performed by a single surgeon.~A periarticular cocktail injection consisting of 90 mL of normal saline, 17.5 mL of 0.5% levobupivacaine, 2 mL of ketorolac (30 mg), and 0.5mg (0.5mL) of adrenaline, The total volume of the cocktail will be 110 mL"
89469050|NCT04396652|Experimental|Adductor canal block and IPACK block group|Patients will receive ACB under ultrasound guidance in which the adductor canal was identified beneath the sartorius muscle and 20 ml of 0.25% Levobupivacaine will be injected in the canal IPACK block in which The ultrasound probe will be positioned in the popliteal crease, and needle will be inserted into the medial aspect of the knee from anteromedial to posterolateral direction in a plane between the popliteal artery and the femur and 15 ml of 0.25% Levobupivacaine will be injected
89202240|NCT00938067|Experimental|Staying Connected: Care Management|The intervention combines case management, psychopharmacological and culturally appropriate and individually tailored trauma support activities with evidence-based treatments.A key feature is the provision of a continuous healing relationship by a care management treatment team.The care manager, informed by the Native healer interviews, will provide a culturally appropriate and ongoing helping relationship to each intervention patient in the weeks and months post-injury and will remain in close contact with the trauma survivor subject for 6 months.Together, the care manager and trauma survivor subject will work on a plan to readjust to daily activities. The care management team will also coordinate psychopharmacological interventions for PTSD and related co-morbidities with primary care and or other community providers.
89469051|NCT03383367|Experimental|Tempo Colo|
89469052|NCT04499846||Diabetic patients following education|Patients will followed an educational intervention about physiopathology of diabetes and mechanisms of action of statins. A questionnaire will allow to measure compliance to the treatment.
89469053|NCT03379935||Bipolar radial head arthroplasty|Patients treated with bipolar head arthroplasty due to radial head fracture
89469054|NCT03379935||Unipolar radial head arthroplasty|Patients treated with unipolar head arthroplasty due to radial head fracture
89537347|NCT03068793||Patients with Post Traumatic Stress Disorder|Individuals who have been diagnosed with Post Traumatic Stress Disorder within the past five years and meet our research criteria for symptoms indicative of this disease within the past five years.
89537348|NCT03068793||Healthy Controls|Individuals who have not met criteria for a psychiatric, mood, or gambling disorder within their lifetime according to our research criteria for symptoms indicative of a psychiatric, mood, or gambling disorder.
89537349|NCT04504175|Experimental|Acute infusion|Acute phase: ketamine infusions twice a week for 4 weeks
88947416|NCT01917409|Experimental|video-stylet|experimental video-stylet group:video-stylet is used to guide nasotracheal tube into trachea
88947417|NCT01917435|Experimental|fiberoptic bronchoscope|Experimental: fiberoptic bronchoscope fiberoptic bronchoscope is used to facilitate for nasotracheal intubation.
88947418|NCT01917435|Experimental|video-stylet|Experimental: video-stylet video-stylet is used to facilitate for nasotracheal intubation.
88947419|NCT01917448|Sham Comparator|Control|The skin will be injected with local anesthetic without spinal block
88947420|NCT01917448|Active Comparator|Spinal morphine|0.15 mg spinal morphine
89469055|NCT02856113|Placebo Comparator|Placebo|Alogliptin matching-placebo tablets, orally, once daily (QD) for 52 weeks and background antidiabetic therapy (metformin and/or insulin), if applicable, maintained at the same dose throughout the first 26 weeks of the treatment period.
89469056|NCT02856113|Experimental|Alogliptin 25 mg|Alogliptin 25 mg tablets, orally, QD for 52 weeks and background antidiabetic therapy (metformin and/or insulin), if applicable, maintained at the same dose throughout the first 26 weeks of the treatment period.
89469057|NCT04471766|Experimental|Certified cloth face mask plus preventive information|Certified cloth face mask
89469058|NCT04471766|Active Comparator|Information on COVID-19 prevention|Advice on how to prevent COVID-19 according to the government´ policy.
89469059|NCT03386565|Active Comparator|control group|"Sodium chloride solution 10 mL IV just before induction of anesthesia~IV infusion during the surgery"
89469060|NCT03386565|Active Comparator|lidocaine group|"lidocaine 2 mg ̸ kg slowly IV just before induction of anesthesia~IV infusion during the surgery"
89469061|NCT04273724|Experimental|Geriatric assessment guided interventions|
89537350|NCT05724225||First group with atrial fibrillation disease|10 Atrial fibrillation(AF), predominant right atrial dilatation with at least moderate IT
89469062|NCT04055636||cancer survivors with heart failure and/or fatal arrhythmias|Patients undergoing cancer therapy for the last 3-4 years with signs of heart failure and/or life-threatening arrhythmias. Administered interventions: physical examination, echocardiography with speckle tracking analysis, 48-hour ECG monitoring, blood samples analysis for biochemistry, biomarkers of myocardial damage, fibrosis and inflammation.
89469063|NCT04055636||Cancer survivors without complications|Patients undergoing cancer therapy for the last 3-4 years without signs of heart failure and/or life-threatening arrhythmias. Administered interventions: physical examination, echocardiography with speckle tracking analysis, 48-hour ECG monitoring, blood samples analysis for biochemistry, biomarkers of myocardial damage, fibrosis and inflammation.
89469064|NCT04055636||Cancer patients before chemotherapy|Cancer patients before administered chemotherapy. Interventions: physical examination, echocardiography with speckle tracking analysis, 48-hour ECG monitoring, blood samples analysis for biochemistry, biomarkers of myocardial damage, fibrosis and inflammation.
89469065|NCT04055636||Patients with non-toxic dilated cardiomyopathy (control).|Patients with non-toxic dilated cardiomyopathy. Administered interventions: physical examination, echocardiography with speckle tracking analysis, 48-hour ECG monitoring, blood samples analysis for biochemistry, biomarkers of myocardial damage, fibrosis and inflammation.
88947421|NCT01917474|Experimental|Group A: Low-lipid diet|"Lifestyle counseling At the end of this run-in period all patients will be randomly attributed to one of the following two dietary regimens. Those in the experimental groupwill be given a low lipid diet with a lipid content < 20% of the total daily energy intake with the following composition:~Proteins (g) 77 (15% total energy intake) Lipids (g) 48 (22% total energy intake) Saturated (g) 9 (4% total energy intake) Monounsaturated (g) 31 (14% total energy intake) Polyunsaturated (g) 8 (4% total energy intake) Carbohydrates (g) 330 (63% total energy intake) Cholesterol (mg) 117 Fibres (g) 32 Total Energy (kcal) 1977"
88947422|NCT01917474|Active Comparator|normal lipid diet|"Patients in the active comparator will be given a diet with normal lipid intake and the following composition:~Proteins (g) 75 (15% total energy intake) Lipids (g) 67 (29% total energy intake) Saturated (g) 14 (6% total energy intake) Monounsaturated (g) 43 (19% total energy intake) Polyunsaturated (g) 10 (4% total energy intake) Carbohydrates (g) 307 (56% total energy intake) Cholesterol (mg) 128 Fibres (g) 32 Total Energy (kcal) 2048 lipid intake between 25-30% of the total daily energy intake."
88947423|NCT01917500||Cardiac ward 10 patients|10 patients from the cardiac ward.
88947424|NCT01917539|Sham Comparator|Sham Treatment|Sham light treatment will consist of applying the usual eye shields used for PLT, applying the usual skin gel to the facial region, and applying the cooling probe without application of pulsed light therapy treatment. All subjects will come for their initial visit where evaluation and treatment #1 will take place. They will also attend 3 follow-up visits spaced approximately 3-4 weeks apart during which they will have subsequent treatments and/or evaluations for their dry eyes. The visit duration will range from approximately 60-90 minutes per clinic visit.
88947425|NCT01917539|Experimental|Pulsed Light Therapy|All subjects will come for their initial visit where evaluation and treatment #1 will take place. They will also attend 3 follow-up visits spaced approximately 3-4 weeks apart during which they will have subsequent treatments and/or evaluations for their dry eyes. The visit duration will range from approximately 60-90 minutes per clinic visit.
88947426|NCT01917565||Airtraq laryngoscope group|The patients who will be intubated by using Airtraq laryngoscope
88947427|NCT01917565||Macintosh laryngoscope group|The patients who will be intubated by using Macintosh laryngoscope
88947428|NCT01917565||Fiberoptic bronchoscope group|The patients who will be intubated by using Fiberoptic bronchoscope
88947429|NCT01917578|Experimental|Half Cycles Group|Patients complete half of the whole cycles of neoadjuvant chemotherapy.
88947430|NCT01917578|Experimental|Whole Cycles Group|Patients complete whole cycles of neoadjuvant chemotherapy.
88947431|NCT01917591|Active Comparator|MariGen Wound|Fish derived extra cellular matrix
88947432|NCT01917591|Active Comparator|Oasis Sheet|Pig intestine derived extra cellular matrix
89469066|NCT05171829|Experimental|Intervention : Educational tool|self-tracking educational tool (diary)
89469067|NCT05171829|No Intervention|Control|
89469068|NCT02237339|Active Comparator|Allopurinol|Patients treated with Allopurinol 300mg daily for first month then 300mg twice daily for remainder trial.
89537351|NCT05724225||Second group with atrial fibrillation disease and tricuspid insufficiency|10 AF, predominantly right atrial dilatation without TI (or TI no more than mild)
88947433|NCT01917617|Experimental|Oral rehydration group（Short Hydration）|"Gemcitabine； gemzer Cisplatin；Cispulan Oral Rehydration Solution(ORS)；OS-1~Short hydration via oral rehydration solution (OS-1)~Cisplatin plus gemcitabine will be administered via infusion as follows; 500 ml of 0.9% saline including cisplatin (25 mg per square meter of body-surface area) over 1 hour followed by 250 ml of 0.9% saline including gemcitabine over 30 minutes. Before and after the infusion, each 500ml bottle of oral rehydration solution (OS-1) will be taken respectively."
88947434|NCT01917617|Active Comparator|Standard group（Long Hydration）|"Drug: Gemcitabine , Cisplatin~Other Names:~Gemcitabine； gemzer Cisplatin； Cispulan~Standard hydration via intravenous infusion~Cisplatin plus gemcitabine will be administered via usual infusion regimen by each hospital. In general, it is administered total 2 litters over 3 hours or more."
88947435|NCT01917630|Experimental|ALV003|
88947436|NCT01917630|Placebo Comparator|Placebo|
88947437|NCT01917643||Symbicort|BFC patients new to ICS/LABA and LAMA therapies
89469069|NCT02237339|Placebo Comparator|Placebo tablet|Microcrystalline cellulose one tablet daily for first month then twice daily for remainder of trial.
89469070|NCT03386331|Other|Diet and Exercise|
89469071|NCT02034929|Active Comparator|Endocuff-assisted colonoscopy|Endocuff-assisted colonoscopy
89469072|NCT02034929|Active Comparator|Standard colonoscopy|Standard Colonoscopy
89469073|NCT04048538|Experimental|Treatment Arm|Individuals who will receive access to the animated multimedia platform prior to their surgical procedure.
89469074|NCT04048538|Active Comparator|Control Arm|Individuals who will not receive access to the animated patient platform, and instead will receive the usual standard of care.
89469075|NCT02035007|Experimental|LV-EF > 50%|PiCCO catheter analysis of patients with coronary heart disease without impaired left ventricular function [LV-EF > 50%]
89537352|NCT05724225||Third group with AF and mitral insufficiency|10 AF, predominantly left atrial dilatation with at least moderate MI
89202241|NCT00938223|Active Comparator|4-peptide vaccine|Group A will receive 4 class I MHC-restricted synthetic melanoma peptides (1 each restricted by HLA-A1, -A3, and two restricted by HLA-A 2) and a tetanus helper peptide.
89202242|NCT00938223|Active Comparator|12-peptide vaccine|Group B will receive the 12 class I MHC-restricted synthetic melanoma peptides (4 each restricted to HLA-A1, -A2, and -A3) and a tetanus helper peptide.
88947438|NCT01917643||Spiriva|Tiotropium bromide patients new to ICS/LABA and LAMA therapies
89202243|NCT04014777|Experimental|NGM621 Cohort 1 Single Ascending Dose|NGM621 single IVT injection Cohort-Dose 1
89202244|NCT04014777|Experimental|NGM621 Cohort 2 Single Ascending Dose|NGM621 single IVT injection Cohort--Dose 2
89202245|NCT04014777|Experimental|NGM621 Cohort 3 Single Ascending Dose|NGM621 single IVT injection Cohort--Dose 3
89202246|NCT04014777|Experimental|NGM621 Cohort 4 Multiple Dose|NGM621 multiple IVT injection Cohort--Dose 4
89202247|NCT00930891|Active Comparator|Arm A|4 additional cycles of chemotherapy
89202248|NCT00930891|Experimental|Arm B|4 additional cycles of chemotherapy + bevacizumab
89202249|NCT00938301|Active Comparator|Treatment|2 cohorts will recieve single rising doses of PF-04455242 or placebo in a cross-over fashion.
89202250|NCT00938301|Placebo Comparator|Placebo|2 cohorts will receive single rising doses of PF-04455242 or placebo in a cross-over fashion.
89202251|NCT00938379|Experimental|20% deet insect repellent|experimental intervention
89202252|NCT00938379|Placebo Comparator|lotion without repellent active|
89202253|NCT00938535|Experimental|Obesity Prevention|
89202254|NCT00938535|No Intervention|Usual Care|This arm includes usual care.
89202255|NCT00661830|Experimental|1|Gemcitabine + Sorafenib
89202256|NCT00661830|Placebo Comparator|2|Gemcitabine + Placebo
89202257|NCT00932529|Active Comparator|Olanzapine|
89202258|NCT00932529|Active Comparator|Quetiapine|
89202259|NCT00932529|Active Comparator|Risperidone|
89202260|NCT00932529|Active Comparator|Ziprasidone|
89469076|NCT03143192|Experimental|Aflibercept with Micropulse Laser|Aflibercept 2mg (0.05mL) injected intravitreally every 4 weeks or as needed Micropulse Laser at initial visit and reassessed every 12 weeks.
88947439|NCT01917669||Lean Non-Diabetic Group|Variables measured will also include serum analyses (HbA1c, adiponectin, cholesterol) and patient vital signs.
88947440|NCT01917669||Pre-diabetics|These patients are anticipated to have elevated BMI, yet not be diabetics.
88947441|NCT01917669||Diabetic Patients|These patients will have good glucose control.
88947442|NCT01917669||Diabetic patients with poor glucocontrol|These patients are anticipated to have poor glucose control. They are usually taking insulin.
88947443|NCT01917695|Active Comparator|Concurrent Radical Chemoradiation|Paclitaxel(175 mg/sq.m) + Cisplatin (75 mg/sq.m) chemotherapy - 2 cycles of 3 weekly cycle Concurrent Radiotherapy - 50 Gy EBRT + Brachytherapy (7Gy HDR x 3 doses) All to be completed within 8-10 weeks
89202261|NCT00783744|Experimental|1|Insulin Glargine + Glimepiride + Metformin
89202262|NCT00783744|Active Comparator|2|Insulin monotherapy with premixed insulin NPH 30/70
89202263|NCT00932607|Active Comparator|Staloral Birch|"Start with 1 puff of Staloral Birch 10 I.R./ml on day one, 2 puffs on day two and increase by 2 puffs until at day six 10 puffs are reached. At day seven 1 puff of Staloral Birch 300 I.R./ml is taken, at day eight 2 puffs and day nine 4 puffs. From then on 4 puffs daily are taken.~Duration of treatment: 16-20 weeks per subject (at least 12 weeks for subjects with hazel or alder allergy)."
89202264|NCT00932607|Experimental|SUBLIVAC Birch|"Start with 1 drop daily of SUBLIVAC Birch and increase by 1 drop daily, until the maintenance dose of 5 drops is reached. This maintenance dose should then be taken daily.~Duration of treatment: 16-20 weeks per subject (at least 12 weeks for subjects with hazel or alder allergy)."
89202265|NCT00783822|Other|intervention|rapid genetic counseling and testing
89202266|NCT00783822|No Intervention|control|usual care
89202267|NCT00932685|Active Comparator|2. Video Game|
89202268|NCT00932685|Active Comparator|1. Midazolam 0.5mg/kg|
89202269|NCT05000346|Experimental|Experimental AQ001S 0.125 mg/mL quarter in die|AQ001S 0.125 mg/mL inhalation solution administered by inhalation 4 times a day
89202270|NCT05000346|Experimental|Experimental AQ001S 0.125 mg/mL bis in die|AQ001S 0.125 mg/mL inhalation solution administered by inhalation twice a day + placebo by inhalation twice a day
89202271|NCT05000346|Placebo Comparator|Comparator: placebo|No active drug - administered by inhalation 4 times a day
89202272|NCT00931125|Active Comparator|vitrectomy with ranibizumab|Patients receiving adjunct preoperative intravitreal ranibizumab (3±1 days) before vitrectomy surgery
89202273|NCT00931125|Placebo Comparator|vitrectomy without ranibizumab|Patients receiving sham treatment before vitrectomy as a comparator arm
89202274|NCT00786396|Experimental|DAART|Group that will be observed daily taking their medications for a period of six months. Followed by the remaining six months of the intervention in which the subject will take medications on their own.
89202275|NCT00786396|No Intervention|2|SAT (standard of care) group will take their medications as directed by their physicians for the period of one year.
89202276|NCT04014543|Experimental|Gastrostomy|"Gastrostomy involves creating an opening between the skin and the stomach. It allows the administration of nutrition solutes or food directly into the stomach without passing through the mouth and esophagus. It is a method widely used since the 1980s for enteral nutrition.~In the field of pediatrics, gastrostomy is considered in chronic diseases when enteral nutrition is necessary in the long term."
89202277|NCT00783900|Active Comparator|metoprolol|
89202278|NCT00783900|Active Comparator|biatrial pacing|
89202279|NCT00932841|Placebo Comparator|Placebo|
89202280|NCT00932841|Active Comparator|VSL#3 90 billion bacteria|
89202281|NCT00932841|Active Comparator|VSL#3 900 billion bacteria|
89202282|NCT00783978||1|Children with chronic lung disease
89202283|NCT00938613|Experimental|Captisol-Enabled Budesonide|32 ug/spray
89202284|NCT00938613|Active Comparator|Rhinocort Aqua|32 ug/spray
89202285|NCT00938613|Placebo Comparator|Placebo|posphate buffered saline
89202286|NCT00786552|Experimental|chemotherapy|
89202287|NCT00938691|Experimental|Tepha|
89202288|NCT00938691|Active Comparator|Vicryl|
89469077|NCT03143192|Sham Comparator|Aflibercept with Sham Laser|Aflibercept 2mg (0.05mL) injected intravitreally every 4 weeks or as needed Sham Laser at initial visit and reassessed every 12 weeks.
89469078|NCT04000685|Active Comparator|Yoga exercise group|Yoga program were applied all patients in this group accompanied by physiotherapist. Sessions included selected breathing, warm up and relaxation exercises.
89469079|NCT04000685|Active Comparator|Spinal stabilization exercise group|Spinal stabilization exercise with three different progressive phases were applied all patients in this group accompanied by physiotherapist.
89469080|NCT04000685|Active Comparator|aerobic walking exercise group|Aerobic walking exercise program applied all patients in this group accompanied by physiotherapist.
89469081|NCT03143348||Control/Nonsurgical|Infants with postnatally confirmed acyanotic congenital heart disease not expected to require surgery in the first six months of life.
89469082|NCT03143348||Surgery w/o bypass|Infants with postnatally confirmed congenital heart disease requiring cardiac surgery without cardiopulmonary bypass.
89469083|NCT03143348||Surgery w/ bypass|Infants with postnatally confirmed congenital heart disease requiring cardiac surgery with cardiopulmonary bypass.
89469084|NCT03985007|Experimental|CDIAG|Relapsed or refractroy acute myeloid leukemia patients reveive chidamide, decitabine combined with priming IAG regimen treatment.
89469085|NCT04285034||Ribavirin only|"Patients will receive ribavirin in accordance with Nigerian treatment guidelines. Patients will either receive the McCormick regimen or the Irrua regimen.~PK blood tests will be done on Day 1,2,5,6,10,11,12,13, discharge; Paxgene RNA blood test on day 1, 3, 5, discharge Haematocrit finger prick test on day 1,2, 5, 6, 10, discharge"
89469086|NCT04285034||Cardiocascular study only|Cardiac tests (NICAS (daily), ECG (Day 1, 5, 10, discharge), Echocardiogram (Day 1, 5, discharge), Ultrasound (Day 1, 3, 5, 7, 10), Endopat (Day 1 and discharge)) will be done throughout; Haematocrit finger prick test daily PAXgene RNA blood test on day 1, 5, discharge
89469087|NCT02034695||RAMP and Non-RAMP|
88947444|NCT01917695|Experimental|Neoadjuvant Chemoradiation + Radical Hysterectomy|Paclitaxel(175 mg/m2) + Cisplatin(75 mg/m2) chemotherapy - 2 cycles of 3 weekly cycle Concurrent Radiotherapy - 50 Gy EBRT - completed within 5 weeks Radical Hysterectomy - 3 weeks after completion of RT All to be completed within 8-10 weeks
89469088|NCT05161923||Per oral endoscopy myotomy|The per-oral endoscopic myotomy, or POEM, is a minimally invasive surgical procedure for the treatment of achalasia wherein the inner circular muscle layer of the lower esophageal sphincter is divided through a submucosal tunnel.[1] This enables food and liquids to pass into the stomach, a process that is impaired in achalasia. The tunnel is created, and the myotomy performed, using a flexible endoscope, meaning the entire procedure can be done without external incisions.
89469089|NCT03971084|Placebo Comparator|Sugar free gum without CPP-ACP|Sugar free gum without CPP-ACP, consumed 5 times a day, for 20 min each time, within 5 minutes after 3 main meals plus 2 snacks occasion, during 14 days.
89469090|NCT03971084|Active Comparator|Sugar free gum with CPP-ACP|Sugar free gum with 18.8 mg CPP-ACP per gum, consumed 5 times a day, for 20 min each time, within 5 minutes after 3 main meals plus 2 snacks occasion, during 14 days.
89469091|NCT03379779||Pneumonia patient with respiratory failure|Sputum and stool sampling day 1, 3 and 7 after enrolling into study
89469092|NCT02855411|Experimental|0.15 mg PF-04958242|Participants received 0.15 mg oral capsule, twice daily (BID) for 12 weeks
89469093|NCT02855411|Experimental|0.5 mg PF-04958242|Participants received 0.5 mg oral capsule, twice daily (BID) for 12 weeks
89469094|NCT02855411|Placebo Comparator|Placebo|Participants received matching placebo oral capsule, twice daily (BID) for 12 weeks
89469095|NCT03891368|Experimental|Virtual Learning Collaborative|The virtual learning collaborative (VLC) is an 18-month intensive training, skill building, and structured implementation process focused on reinforcing fidelity to the InSHAPE model.
88947445|NCT01917695|Experimental|Neoadjuvant Chemotherapy + Radical Hysterectomy|Paclitaxel(175 mg/m2) + Cisplatin (75 mg/m2) chemotherapy - 3 cycles of 3 weekly cycle Radical Hysterectomy - 3 weeks after completion of chemotherapy All to be completed within 8-10 weeks
88947446|NCT01917708|Experimental|Abatacept|4 doses of abatacept 10 mg/kg/dose will be given on days -1, +5, +14, and +28.
88947447|NCT01917721|Experimental|Doxycycline|These patients will receive doxycycline at the acute phase of their disease
88947448|NCT01917721|Active Comparator|Placebo|The comparative arm of the study will receive standard care and placebo for Kawasaki disease, but not doxycycline
88947449|NCT01917734||IM-SAM|Children 6-59 months with bilateral pitting edema, and/or WHZ < - 3 and/or MUAC < 115 mm.
88947450|NCT01917786||Dexmedetomidine patients|Surgical patients receiving dexmedetomidine.
88947451|NCT01917786||Control patients|Surgical patients not receiving dexmedetomidine.
88947452|NCT01917799|Experimental|Aspirin|75mg tab of aspirin once daily
89469096|NCT03891368|Active Comparator|Technical Assistance|"The technical assistance (TA) condition includes four scheduled conference calls between an InSHAPE expert TA coach and the agency's InSHAPE team, with the option for sites to request additional calls as needed through 18-months post-randomization."
89469097|NCT03379701||CRSwPolyps with no Eosonophilia|CRS patients with nasal polyposis, and no eosonophilia.
89469098|NCT03379701||CRSwPolyps with Eosonopholia|CRS patients with nasal polyposis and eosonophilia.
89469099|NCT03379701||CRS without Polyps|Patients with chronic rhinosinusitis and no nasalpolyposis.
89469100|NCT03379701||PCD|Patients with Primrary ciliary dyskinesia .
89469101|NCT03379701||AFRS|Patients with allergic fungal rhinosinusitis.
89469102|NCT03379701||allergic rhinitis|Patients with allergic rhinitis
89469103|NCT03379701||Control|Healthy subjects.
89469104|NCT04172324|Experimental|Hibbot|
89469105|NCT04172324|Active Comparator|Standard Care|
89469106|NCT03379623|Experimental|Intervention group|
89469107|NCT03379623|No Intervention|Usual care group|
89469108|NCT03607721|Experimental|DBS Patients Group|Body Motion Evaluation DARI
89469109|NCT03607721|Active Comparator|Control Group|Body Motion Evaluation DARI
89469110|NCT03308721|Experimental|NNC9204-1177|Dose trial with a sequential trial design
89469111|NCT03308721|Placebo Comparator|Placebo|
89537353|NCT05724225||Fourth group with atrial fibrillation and IM|10 AF, predominantly left atrial dilatation without MI (or no more than mild MI)
89469112|NCT04122482|Experimental|Intervention Group|In this arm, participants will be given access to the course material shortly after eligibility criteria is confirmed. They will be asked to complete post-measures questionnaires at 4 weeks and 8 weeks following completion of the course material.
89469113|NCT04122482|Experimental|Wait-list Control|In this arm, participants will be given access to the course material 8 weeks following confirmation of their eligibility. During, the 8-week waiting period they will be asked to complete questionnaires at 4 weeks and 8 weeks. At 8 weeks they will be given access to the course material and will be asked to complete the same questionnaires 4- and 8-weeks following completion of the course material.
89469114|NCT05152407|Experimental|Active serum on right|Right hemi face or skull will receive active serum (containing 0.3% MRB) / Left hemi face or skull will receive placebo serum for 6 months
89469115|NCT05152407|Experimental|Active serum on left|Left hemi face or skull will receive active serum (containing 0.3% MRB) / Right hemi face or skull will receive placebo serum for 6 months
89469116|NCT02745145|Experimental|Abituzumab 1500 milligram (mg)|
89469117|NCT02745145|Experimental|Abituzumab 500 mg|
89469118|NCT02745145|Placebo Comparator|Placebo|
89469119|NCT03646448|Experimental|Intervention group|Counseling based on Motivational Interviewing and elements of Cognitive Behavioral Therapy
89469120|NCT03646448|No Intervention|Control group|Control group receiving a booklet on problematic Internet use
89469121|NCT03383055|Experimental|CMV positive cohort|CMV-MVA Triplex vaccine administered on days 28 and 56 post-HCT
89469122|NCT03383055|Experimental|CMV negative cohort|CMV-MVA Triplex vaccine administered on days 28 and 56 post-HCT
89469123|NCT04083014|Experimental|study group|The treatment regimen is a single dose anti-CD20 antibody injection (500mg iv drip，day0) combined with bortezomib injection (1.3mg/m2 subcutaneous injection，twice a week for two weeks，day1，4，8，11). The treatment course will be repeated three months later.
89469124|NCT03386097||Type 2 diabetes patients|
89469125|NCT03386097||Healthy controls|
89469126|NCT03563066|Experimental|Benralizumab|Fixed dose 30mg benralizumab.
89469127|NCT03563066|Placebo Comparator|Placebo Control|Will appear identical in form to benralizumab arm.
89469128|NCT05152095|Experimental|Intervention|Self-administered Vaccaria seed tapes on auricular acupoints with pressure applied
89469129|NCT05152095|Sham Comparator|Sham|Self-administered plain tapes (without Vaccaria seed) on auricular acupoints without applying pressure.
89469130|NCT03606265|Experimental|App+Web|Treatment as usual + app Participants at this condition will receive the usual medical treatment for their pain but also they will be monitored daily using the Pain Monitor app. Alarms will be generated in the face of certain preestablished events. Physicians will be asked to call patients and change/stop treatment if an alarm is received.
89469131|NCT03606265|Active Comparator|Treatment as usual|Treatment as usual (waiting list) Patients at this condition will receive the usual medical treatment at the pain unit, but they will not be monitored daily using the app.
89469132|NCT03143114|Experimental|Myomectomy|Women will be subjected to laparotomy to remove the myomas
89469133|NCT03143114|No Intervention|Conservative management|Women will not be subjected to surgery (conservative management)
88947453|NCT01917799|Active Comparator|Aspirin + heparin|75mg tab of aspirin once daily + 0.4 mL/day of injection of low molecular weight heparin
88947454|NCT01917838|Experimental|MFG plus MyMFG|"MFG plus MyMFG will be tested and the aim is:~Greater quality of the Design and Do process rated by therapists, parents, and independent coders.~Greater quantity and quality of HW assignments rated by therapists and parents.~Greater quality of the Review process as rated by therapists, parents, and independent coders.~Greater satisfaction with treatment as rated by the parent, target child, and therapists."
88947455|NCT01917864|Experimental|iPad Application|Student participants will use specialized iPad software under the supervision of a speech-language pathologist over the course of 12 months, approximately one session per week, one hour per session.
88947456|NCT01917890|Experimental|Curcumin Group|"Patients undergo 74 Gy of intensity-modulated radiotherapy 5 times a week for 7-8 weeks.~Patients take 3 grams of curcumin (as 6 capsules 500 mg)"
88947457|NCT01917890|Placebo Comparator|Placebo|"Patients undergo 74 Gy of intensity-modulated radiotherapy 5 times a week for 7-8 weeks.~Patients take 3 grams of placebo (as 6 capsules 500 mg)"
88947458|NCT01917942|Active Comparator|Standard of Care|Standard of Care
88947459|NCT01917942|Experimental|Humidification|Humidification
88947460|NCT01917981|Experimental|Personal Heart Rhythm Monitor|Intermittent cardiac monitoring with a Personal Heart Rhythm Monitor for three months.
88947461|NCT01917994|Experimental|Text Messages + Appointment Reminders|Participants in the intervention arm will receive supportive, informational, or motivational text messages three times a week for one year in addition to text message reminders about HIV primary care appointments.
88947462|NCT01917994|Active Comparator|Appointment Reminders|Participants in the control arm will receive text messages reminding them of HIV primary care appointments 48 hours before the scheduled appointment.
89202289|NCT04046640||CSAP group|This group will include 40 patients with chronic stable angina pectoris (CSAP).
89469134|NCT03386019|Experimental|Sprinters|Sprinters will be recruited from the track and field team of National Taiwan Normal University (NTNU) in this study. After individuals' enrollments and baseline data collections, all subjects will receive all three different treatments (massage, cold water immersion and static stretching) in randomized orders a week apart, respectively. Outcome measures are: visual analogue scale (VAS) score, lower leg volume, pressure pain threshold and horizontal jump distance. All measurements will be recorded at baseline, immediately after exercise, immediately after treatment, and 10 minutes after treatment as the follow up.
89469135|NCT03111134|No Intervention|Routine Abdominal Closure|
89469136|NCT03111134|Experimental|New Abdominal Closure|modified component separation technique is used to abdomen closing.
89469137|NCT05151939||Patients with normal mediastinal and abdominal organ/anatomic strictures|Adult patients with normal mediastinal and abdominal organ/anatomic strictures after imaging test and EUS assessment due to chronic dyspepsia.
89537354|NCT05724225||Fifth group with tricuspid insufficiency|10 IT at least moderate to right ventricular remodeling in patients with pulmonary hypertension
89018741|NCT00294203|Placebo Comparator|Placebo group|Patients enrolled in the study will be randomized to receive either 40,000 units of placebo (saline) on day 1 and day 8. Hemoglobin, hematocrit, reticulocyte count, reticulocyte hemoglobin, and immature reticulocyte count will be measured on days 1, 4, 8, and once between post-operative days 20 and 30. Pre-operatively and between post-operative days 20 and 30 patients will complete a quality of live assessment tool (FACT-An) to assess their fatigue related to anemia.
89018742|NCT00294281|Experimental|1|Participants will undergo surgical implantation of the VNS system. This will be followed by a 2-week recovery period, then a 2-week period of gradually increasing the electrical output of the VNS system, and finally a 12-week VNS treatment period during which the electrical output level will remain constant. Follow-up will occur until Month 24.
89018743|NCT00294437|Experimental|zoledronic acid|Zometa® (zoledronic acid) in 100ml of calcium free solution i.v. as a 15 minute infusion every 3 months
89018744|NCT00294437|No Intervention|no intervention|no reference therapy
89018745|NCT00294866|Active Comparator|A|Receive Paricalcitol
89018746|NCT00294866|No Intervention|B|Paricalcitol on hold
89018747|NCT00326040|Experimental|A|
89018748|NCT02960477|Experimental|Pain Neuroscience education|A PNE session covers the neurobiology, neurophysiology and processing of pain. Topics addressed during the educational sessions will include the characteristics of acute versus chronic pain; how pain becomes chronic (plasticity of the nervous system, modulation, modification, central sensitization, etc.); potential sustaining factors of central sensitization like emotions, stress, pain cognitions, and pain behaviour; the decision to have shoulder surgery; surgical experiences and environmental issues' effects on nerve sensitivity; recovery after shoulder surgery; scientific evidence for the PNE content; and the opportunity to reflect and write questions to ask the surgeon prior to surgery.
89018749|NCT02960477|Active Comparator|Biomedical Education|A biomedical session covers the normal course of shoulder pain; anatomy, physiology and biomechanics of the shoulder; the expected course of postoperative shoulder pain; and the importance of self-care. Also, professional and leisure time activities will be discussed. Ergonomic advices will be given: e.g. how is the best way to catch a container, how I should move my shoulder in this sport/activity, what is a good work posture? The content of the biomedical education will be biomedically-/biomechanically-focussed.
89018750|NCT00326079|Active Comparator|1|
89018751|NCT00326079|Active Comparator|2|
89018752|NCT00326157|Experimental|1|AmBisome® will be administered for a duration of 8 weeks
89018753|NCT00295295|Experimental|Vibration|High frequency, low magnitude vibration at 30 Hz, 10 min/day using vibrating platform from Juvent Medical Inc.
89018754|NCT00295295|Active Comparator|Standing|Standing 10 min/day
89018755|NCT00305916|Active Comparator|1|conventional coronary angiography
89018756|NCT00305916|Experimental|2|multislice spiral computed tomography coronary angiography
89018757|NCT00295529|Experimental|Multifaceted Educational Intervention|Intervention group received an interactive workshop, portfolio of primary care appropriate genomics tools, and Gene Messengers
89018758|NCT00295529|No Intervention|No education|Educational materials at end of study
89018759|NCT00419601|Active Comparator|2|Fentanyl
89018760|NCT00419601|Experimental|1|Remifentanyl
89018761|NCT00295607|Active Comparator|1|
89018762|NCT00295607|Experimental|2|
89018763|NCT00306111|Experimental|Pegfilgrastim|Pegfilgrastim for stem cell mobilization (single arm)
89018764|NCT00306150|Experimental|Arm 1|
89018765|NCT00306150|Placebo Comparator|Arm 2|
89018766|NCT00306228|Active Comparator|bare-metal stent without tirofiban|implantation of a bare-metal stent with no tirofiban infusion after fibrinolysis
89018767|NCT00306228|Active Comparator|bare-metal stent with tirofiban|implantation of a bare-metal stent with tirofiban infusion after fibrinolysis
89018768|NCT00306228|Active Comparator|paclitaxel-eluting stent without tirofiban|implantation of a paclitaxel eluting-stent with no tirofiban after fibrinolysis
89018769|NCT00306228|Active Comparator|paclitaxel-eluting stent with tirofiban|implantation of a paclitaxel eluting-stent with tirofiban infusion after fibrinolysis
89018770|NCT00295763|Other|1|
89018771|NCT00417911|Active Comparator|No treatment|
89018772|NCT00417911|Experimental|Bortezomib consolidation|Bortezomib consolidation : 20 injections starting 3 months after ASCT
89018773|NCT00326469|Experimental|1|
89018774|NCT04718597||Open hernia repair|Patients who underwent inguinal hernia repair via an open Liechtenstein procedure
89018775|NCT04718597||Robotic assisted hernia repair|Patients who underwent inguinal hernia repair via robotic assisted laparoscopy
89018776|NCT00295802|Experimental|HIFU|Integrated Imaging High Intensity Focused Ultrasound using the Ablatherm Device
89018777|NCT00295802|Active Comparator|Cryotherapy|Endocare CRYOcare Cryosurgical and Galil Medical CRYO-HIT Systems (cryotherapy)
89018778|NCT00326586|Experimental|1|
89018779|NCT00326664|Experimental|Treatment (cediranib maleate)|Patients receive oral AZD2171 once daily on days 1-28. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
89018780|NCT00295919|Experimental|Single Group|
89469138|NCT03935906|Experimental|Reach Pathway|Community pharmacist will explain the risks of contracting HCV from current or historical intravenous drug use. OST patients will then meet with an outreach hepatology nurse specialist who will perform a diagnostic point-of-care (PoC) HCV test along with venepuncture for safety blood tests and confirmatory HCV RNA on the pharmacy premises. The nurse will return for a subsequent visit to prescribe (in the UK; in Australia prescribing is undertaken by qualified medic) and deliver HCV medication for participants who test positive, which will be dispensed alongside their OST schedule by their community pharmacist. The outreach nurse will return after approximately 14 days to confirm negative results, dispense medication for new patients with positive results (PCR positive but below limit of detection of POC test) and confirm follow up appointments where required. The RNA and PoC test will also be administered for sustained viral response at 12 weeks post treatment (SVR12).
89469139|NCT03935906|Experimental|Education-only Pathway|The community pharmacist will discuss the risks of contracting HCV through current or historical intravenous drug use. The community pharmacist will then advise participants on the nearest centre for HCV testing and treatment, as is standard of care for the countries included in this study. If they are referred from a REACH pharmacy, they will present a reply slip and/or the Patient Information Sheet to the nurse who will then consent the participant, perform HCV and safety blood tests, and complete the study paperwork. The participant's medication will be delivered to, and dispensed from, their community pharmacy alongside their OST. Participants will return to the local BBV clinic for an SVR12 test after completing treatment.
89469140|NCT05151861|Experimental|Experimental|Complete removal of pharmacological treatment
89469141|NCT05151861|Active Comparator|Control|Maintenance of pharmacological treatment
89469142|NCT03605875|Experimental|Web-App|A customized web-app tool to be used by patients to communicate concerns to their nephrologist
89469143|NCT03605875|Active Comparator|Paper|A customized paper tool to be used by patients to communicate concerns to their nephrologist
89469144|NCT03379467|Experimental|SMS Reminder|"Single SMS at each of the following times:~3 days before immunization~1 day before immunization~Day of immunization"
89537355|NCT05724225||Sixth group with mitral insufficiency|10 MI at least average from left ventricular remodeling from left ventricular dysfunction
89537356|NCT03068871|Experimental|CET|CET - Coping Effectiveness Training group.
89537357|NCT03068871|Experimental|ACT|ACT - Acceptance and Commitment Therapy group
88947463|NCT01918020|Experimental|Go Wild with Fruits and Veggies!|This group will receive nutrition education to learn about fruits and vegetables and physical activities right from the start of the experiment.
88947464|NCT01918020|Other|Go Wild with Fruits and Veggies! delayed|This group will only receive nutrition education about 4 months after the experiment starts.
88947465|NCT01918059|Experimental|Non-absorbable suture skin closure|The superficial eyelid skin will be repaired with simple interrupted sutures with non-absorbable suture (6-0 polypropylene) after repair of any deep component of the laceration.
88947466|NCT01918059|Experimental|Absorbable suture skin closure|The superficial eyelid skin will be repaired with simple interrupted sutures with absorbable suture (surgical gut) after repair of any deep component of the laceration.
88947467|NCT01918059|Experimental|Tissue Adhesive skin closure|The superficial eyelid skin will be repaired with layers of tissue adhesive (octyl-2-cyanoacrylate) after repair of any deep component of the laceration.
88947468|NCT01918098|Experimental|Oxycodone/naloxone prolonged release tablets|Dose strength:5/2.5 mg,10/5mg, 20/10mg,PO,q12h.daily dose from 10/5mg to 50/25mg.treatment duration:12 weeks
88947469|NCT01918098|Active Comparator|Oxycodone prolonged release tablets|Dose strength:5mg,10mg, 20mg,PO,q12h.daily dose from 10mg to 50mg.treatment duration:12 weeks
88947470|NCT01918111|Experimental|RD group|Renal denervation group
88947471|NCT01918111|Active Comparator|Control group|Control group
88947472|NCT01918124|Experimental|radiotherapy combined with chemotherapy|"Arm Label: radiotherapy combined with chemotherapy:~Radiotherapy:~Pelvic radiation to 45 Gy, 1.8 Gy per day, five days per week (25 fractions) or intensive modulated pelvic radiotherapy, with brachytherapy boost to the vagina if total abdominal hysterectomy and bilateral salpingo-oophorectomy was done in surgery, or with paraaortic radiation if paraaortic lymphnode metastases were found after surgery.~Cisplatin:~Two courses cisplatin (50mg/m2) given on days 1 and 28 during radiotherapy.~Cisplatin and Doxorubicin and Cyclophosphamide： Four courses of cisplatin (50mg/m2) and doxorubicin (60mg/m2) and cyclophosphamide (600mg/m2) given at 3 week intervals following completion of radiotherapy.~Paclitaxel and Carboplatin： Or four courses of Paclitaxel(135mg/m2) and carboplatin (AUC=5) given at 3 week intervals following completion of radiotherapy."
88947473|NCT01918137|Experimental|chocolate bar|
88947474|NCT01918137|Experimental|porridge|
88947475|NCT01918150|Experimental|TITAN 2 stent - Hexacath France|Patients receiving Titan 2 stents (percutaneous coronary intervention)
88947476|NCT01918150|Active Comparator|Cobalt-Chromium BMS - Any firm|Patients receiving Cobalt-Chromium Bare Metal Stents (free of any coating)(percutaneous coronary intervention)
88947477|NCT01918163|No Intervention|No Pills|Patients in this group will not receive Pomegranate pills.
88947478|NCT01918163|Active Comparator|Pomegranate pills|The reccruited patient will receive pomegranate pills every day for 12 weeks. The control group will not be exposed for the pills.
88947479|NCT01918176|Experimental|Fixed sequence crossover|All the subjects will undergo the treatment of Palbociclib alone first and then treatment of Palbociclib and Rabeprazole.
88947480|NCT01918202|Experimental|Cohort 1 - 20 mg|Cohort will include 4 HVs/completers who will receive a single 20 mg dose of PF-02545920.
88947481|NCT01918202|Experimental|Cohort 2 ( adaptive dose, optional)|Cohort 2 will include 4 HVs/completers who will receive a single dose of PF-02545920. The dose will be selected based on the results obtained for Cohort 1.
88947482|NCT01918202|Experimental|Cohort 3 ( adaptive dose, optional)|"Cohort 3 will include 4 HVs/completers who will receive a single dose of PF-02545920. The dose will be selected based on the results obtained for Cohort 1.~Dose options range from 30 mg to 10 mg, 5 mg, 2mg, 1 mg. This cohort is optional"
88947483|NCT01918228|Experimental|Intervention group|Talks on scientific status on back pain with the purpose of reducing LBP-related insecurity/fear, reducing the focus on the pain and providing participants with alternative explanation to their LBP. They were also provided with a folder (general stretching exercises) and had telephone access to health professional if they had questions about LBP during the follow-up year.
89469145|NCT03379467|Experimental|Interactive Reminder|"Single SMS at each of the following times:~3 days before immunization~1 day before immunization~Day of immunization On the day of immunization, study participants are required to respond back through SMS notifying us that child got vaccinated or if not, the reason for delay in immunization. In case of no response, 2 additional reminders will be sent at:~1 day after scheduled immunization date~1 week after scheduled immunization date"
89469146|NCT03379467|No Intervention|Control|Subjects in this arm will not receive any intervention
89469147|NCT05144607|No Intervention|Control group|Detection of patient-ventilator asynchronies through visual inspection of pressure and flow waveforms.
89469148|NCT05144607|Experimental|Pmus group|Detection of patient-ventilator asynchronies through visual inspection of estimated inspiratory muscle pressure curves, in addition to pressure and flow waveforms.
89469149|NCT03111056|Experimental|Web-Based Intervention|In an effort to reduce heavy drinking, participants will be asked to complete a daily monitoring assessment each morning for 14 days. Based on their responses, they will be provided a coping skill to either directly address their alcohol use or attempt to improve their emotion regulation and distress tolerance skills.
89469150|NCT03111056|No Intervention|Assessment Only Control|Participants will be asked to complete only the daily monitoring assessment each morning for 14 days.
89469151|NCT03115749|Other|Crohn's disease patient group|Intestinal biopsies during colonoscopy or biopsies taken on surgical specimen after intestinal resection
89469152|NCT03115749|Other|Ulcerative colitis patient group|Intestinal biopsies during colonoscopy or biopsies taken on surgical specimen after intestinal resection
89469153|NCT03115749|Other|Control group|Intestinal biopsies during colonoscopy or biopsies taken on surgical specimen after intestinal resection
89469154|NCT03140384|Active Comparator|Administration of oral Misoprostol|
89469155|NCT03140384|Active Comparator|Administration of Misoprostol vaginally|
89469156|NCT03140384|Active Comparator|Administration of buccal Misoprostol|
89469157|NCT05135403||ASSURE Registry Patients|Patient prescribed the ASSURE WCD who have also consented to participate in the ASSURE Patient Registry. Patients include those with reduced left ventricular ejection fraction (LVEF) and recent myocardial infarction, recent coronary revascularization, or new onset heart failure (HF) to allow for optimization of medical therapy and re-evaluation of cardiac function. Additional indications include ICD explant due to infection, postponed ICD implant, and pending heart transplant.
89469158|NCT05117307|Active Comparator|Group ESP|Ultrasound-guided erector spinae plane block with 20 ml %0.25 bupivacaine, per side
89469159|NCT05117307|Active Comparator|Group TFP|Ultrasound-guided Transversalis Fascia Plane Block block with 20 ml %0.25 bupivacaine, per side
89469160|NCT03739268|Active Comparator|sevelamer|Patients with type 2 diabetes treated with sevelamer
89469161|NCT03739268|Placebo Comparator|placebo|Patients with type 2 diabetes treated with placebo
89469162|NCT05109507|Experimental|Visitor Mindset|Single-session, self-guided web-based intervention (~30 to 45 minutes) hosted on Qualtrics with animated videos, audio-guided exercises, graphics, text-based material, and interactive questions. The intervention is designed to enhance emotional awareness, clarity, and acceptance, as well as modify beliefs about the duration and usefulness of negative emotions.
89469163|NCT05109507|Active Comparator|Relaxing with Nature|Single-session self-guided web-based intervention (~30 to 45 minutes) hosted on Qualtrics with videos (real-life images), text-based material, and questions. There are five videos showing different types of nature (e.g., forest scenes, beach scenes, etc.). Each video includes a sequence of pleasant nature photos (shown about 6 seconds each) with relaxing music in the background.
89469164|NCT02787590|Active Comparator|Simvastatin|A one month low dose phase of 40mg oral simvastatin daily will be followed by a 23 month high dose phase of 80mg oral simvastatin daily and a final two month phase off trial medication
89202290|NCT04046640||Healthy group|This group will include 40 healthy volunteers.
89202291|NCT00938769|Other|Self-Efficacy Training for Caregivers|The Enhanced Caregiver Training intervention will be delivered to informal caregivers of cancer patients before hospital discharge who are randomly selected to receive this intervention. Subjects in the treatment group will receive an individualized experiential caregiver training in strategies for managing patient's symptoms and in the use of pleasant imagery and muscle relaxation to manage stress.
89202292|NCT00938769|Other|Comparison Conditions for Caregivers|Subjects randomly selected to participate in the attention control training will receive an informational session about cancer and resources for support.
89469165|NCT02787590|Placebo Comparator|Matched Placebo|A one month low dose phase of 40mg matched placebo daily will be followed by a 23 month high dose phase of 80mg matched placebo daily and a final two month phase off trial medication
89469166|NCT04041674|Experimental|Group 1 (T1): DNA + MVA + Placebo (IM)|"Participants will receive 3 mg of GEO-D02 DNA by intramuscular (IM) injection at Months 0 and 2.~Participants will also receive 1×10^8 50% tissue culture infective dose (TCID50) of MVA/HIV62B plus placebo for B63521^11 gp120 plus placebo for IHV01, each by IM injection at Months 4, 6, and 10."
89469167|NCT04041674|Experimental|Group 2 (T1): DNA + MVA + Placebo (SC)|"Participants will receive 3 mg of GEO-D02 DNA by IM injection at Months 0 and 2.~Participants will also receive 1×10^8 TCID50 of MVA/HIV62B by IM injection plus placebo for B63521^11 gp120 by subcutaneous (SC) injection plus placebo for IHV01 by SC injection at Months 4, 6, and 10."
89018781|NCT04930809|Experimental|VER-01 single dose (2.5 mg THC)|PK profile is investigated after oral intake of a single dose VER-01 corresponding to 2.5 mg THC (Group A).
89469168|NCT04041674|Experimental|Group 3 (T2): DNA + MVA + IHV01 + B63|"Participants will receive 3 mg of GEO-D02 DNA by IM injection at Months 0 and 2.~Participants will also receive 1×10^8 TCID50 of MVA/HIV62B plus 150 mcg of B63521^11 gp120 plus 150 mcg of IHV01, each by IM injection at Months 4, 6, and 10."
89202293|NCT04047186|Experimental|neoadjuvant PD-1 group|receiving neoadjuvant therapy of programmed death-1 (pd-1) immune checkpoint inhibitor
89018782|NCT04930809|Experimental|VER-01 single dose (5 mg THC)|PK profile is investigated after oral intake of a single dose VER-01 corresponding to 5 mg THC (Group B).
89018783|NCT04930809|Experimental|VER-01 single dose (10 mg THC)|PK profile is investigated after oral intake of a single dose VER-01 corresponding to 10 mg THC (Group C).
89469169|NCT04041674|Experimental|Group 4 (T3): DNA + MVA +IHV01 + Placebo|"Participants will receive 3 mg of GEO-D02 DNA by IM injection at Months 0 and 2.~Participants will also receive 1×10^8 TCID50 of MVA/HIV62B plus placebo for B63521^11 gp120 plus 150 mcg of IHV01, each by IM injection at Months 4, 6, and 10."
89469170|NCT04041674|Experimental|Group 5 (T4): DNA + MVA +IHV01 (SC)+ B63 (SC)|"Participants will receive 3 mg of GEO-D02 DNA by IM injection at Months 0 and 3.~Participants will also receive 1×10^8 TCID50 of MVA/HIV62B by IM injection plus 150 mcg of B63521^11 gp120 by SC injection plus 150 mcg of IHV01 by SC injection at Months 4, 6, and 10."
89469171|NCT04446195|No Intervention|Control group|The control group received routine intestinal preparation education.
89469172|NCT04446195|Active Comparator|Experimental group|The experimental group was treated with routine intestinal preparation education and individualized intervention.
89469173|NCT04445727|Experimental|vitamin c|daily dose of 1000 mg vitamin c in order to regenerate collagen
89469174|NCT04445727|Experimental|spinal manipulation|Spinal manipulation in cervical and dorsal with high speed and short amplitude techniques
89469175|NCT04445727|Experimental|Transcutaneous electrical nerve stimulation (TENS)|electrotherapy for an analgesic purpose
89469176|NCT04445727|Experimental|manual therapy|manual muscle treatment for epicondyl musculature
89018784|NCT04930809|Experimental|VER-01 single dose (20 mg THC)|PK profile is investigated after oral intake of a single dose VER-01 corresponding to 20 mg THC (Group D).
89018785|NCT04930809|Experimental|VER-01 multiple dose (5 mg THC)|PK profile is investigated after oral intake of VER-01 corresponding to 5 mg THC in the morning and 5 mg THC in the evening on 4 consecutive days (Group E).
89469177|NCT03379155|Experimental|Active Group|Internet-based self-help
89469178|NCT03379155|No Intervention|Waiting List Group|
89469179|NCT03385941||Osteoporotic|Femal, 50-80 years of age with established diagnosis of osteoporosis, based on prior DXA scan with T-score <-2.0 at any site and/or history of fragility fracture
89469180|NCT03385941||Non-osteoporotic|Female, 27-40 years of age, no established history of osteoporosis
89018786|NCT04930809|Experimental|VER-01 multiple dose (10 mg THC)|PK profile is investigated after oral intake of VER-01 corresponding to 10 mg THC in the morning and 10 mg THC in the evening on 4 consecutive days (Group F).
89018787|NCT04930809|Experimental|VER-01 multiple dose (12.5 / 20 mg THC)|PK profile is investigated after oral intake of VER-01 corresponding to 12.5 mg THC in the morning and 20.5 mg THC in the evening on 4 consecutive days (Group F).
89018788|NCT04893057||Pregnant women|Women admitted to hospital for a live birth.
89018789|NCT04893057||Blood donors|Subjects qualified for whole blood donation
89018790|NCT00296153|Active Comparator|1|Omacor 1000mg x 4 / day
89018791|NCT00296153|Placebo Comparator|2|
89018792|NCT00418067|Active Comparator|Cypher|Sirolimus-eluting stent
89018793|NCT00418067|Active Comparator|Taxus Liberte|Paclitaxel-eluting stent
89018794|NCT00418067|Experimental|Endeavor|Zotarolimus-eluting stent
89018795|NCT04869969|Experimental|supine percutaneous nephrolithotomy|percutaneous nephrolithotomy to be done in the supine position
89018796|NCT04869969|Active Comparator|prone percutaneous nephrolithotomy|percutaneous nephrolithotomy to be done in the prone position
89018797|NCT00296309|Active Comparator|1|
89018798|NCT00296309|Experimental|2|
89469181|NCT03382743|Active Comparator|Group A (Lidocaine group)|5 sprays of endocervical Lidocaine 10% spray ( AstraZeneca, bedforshire) are used 3 minutes before office hysteroscopy
89469182|NCT03382743|No Intervention|Group B (control group)|office hysteroscopy is done without analgesia
89469183|NCT02976129|Experimental|V565|V565 three times a day (TID) PO for 6 weeks
89469184|NCT02976129|Placebo Comparator|Placebo|Placebo TID PO for 6 weeks
89469185|NCT02854631|Experimental|Selonsertib + Prednisolone|Selonsertib + prednisolone for 28 days
89469186|NCT02854631|Placebo Comparator|Prednisolone|Selonsertib placebo + prednisolone for 28 days
89469187|NCT02034773|Experimental|CC-220 0.3mg x 14 days|
89469188|NCT02034773|Experimental|CC-220 1mg x 28 days|
89469189|NCT02034773|Experimental|CC-220 0.3mg x 28 days|
89469190|NCT02034773|Experimental|CC-220 1mg x a total of 14 days|
89469191|NCT02034773|Experimental|Placebo|
89469192|NCT02034773|Experimental|CC-220 0.3mg (once every 3 days for 14 days)|
89469193|NCT02034773|Experimental|CC-220 1mg (once every 7 days for 28 days)|
89469194|NCT02034773|Experimental|CC-220 1mg (formulated and reference capsules)|
89469195|NCT02035163|Active Comparator|Two sites cryoablation group|Two ganglionic plexi around atrium was performed with 90-second cryoablation.
89469196|NCT02035163|No Intervention|Control group|No Intervention group
89469197|NCT03607643|Placebo Comparator|Colon: Chemo + Placebo|Standard of care chemotherapy for Stage IV colon or rectal cancer, will include leucovorin 350 mg/m2 IV over 2 hours Day 1, 5-FU 400 mg/m2 IV bolus followed 2400 mg/m2 IV over 46 hours, oxaliplatin 100 mg/m2 IV Day 1, bevacizumab 5 mg/kg IV day1. Irinotecan can be substituted for oxaliplatin.
89469198|NCT03607643|Experimental|Colon: Chemo + BRCX014|Cannabidiol (BRCX014) 200 mg daily plus Standard of care chemotherapy for Stage IV colon or rectal cancer, will include leucovorin 350 mg/m2 IV over 2 hours Day 1, 5-FU 400 mg/m2 IV bolus followed 2400 mg/m2 IV over 46 hours, oxaliplatin 100 mg/m2 IV Day 1, bevacizumab 5 mg/kg IV day1. Irinotecan can be substituted for oxaliplatin.
89469199|NCT03607643|Placebo Comparator|Rectal: Chemo + Placebo|Standard of care chemotherapy for Stage IV colon or rectal cancer, will include leucovorin 350 mg/m2 IV over 2 hours Day 1, 5-FU 400 mg/m2 IV bolus followed 2400 mg/m2 IV over 46 hours, oxaliplatin 100 mg/m2 IV Day 1, bevacizumab 5 mg/kg IV day1. Irinotecan can be substituted for oxaliplatin.
89469200|NCT03607643|Experimental|Rectal: Chemo + BRCX014|Cannabidiol (BRCX014) 200 mg daily plus Standard of care chemotherapy for Stage IV colon or rectal cancer, will include leucovorin 350 mg/m2 IV over 2 hours Day 1, 5-FU 400 mg/m2 IV bolus followed 2400 mg/m2 IV over 46 hours, oxaliplatin 100 mg/m2 IV Day 1, bevacizumab 5 mg/kg IV day1. Irinotecan can be substituted for oxaliplatin.
89469201|NCT03607643|Placebo Comparator|Multiple myeloma: Chemo + Placebo|Standard of care (SOC) chemotherapy for multiple myeloma will include a bortezomib-based regimen given at 1.3 mg/m2 on days 1, 4, 8 & 11 schedule to be repeated every 21 days.
89469202|NCT03607643|Experimental|Multiple myeloma: Chemo + BRCX014|Cannabidiol (BRCX014) 200 mg daily plus Standard of care (SOC) chemotherapy for multiple myeloma will include a bortezomib-based regimen given at 1.3 mg/m2 on days 1, 4, 8 & 11 schedule to be repeated every 21 days.
89469203|NCT03607643|Placebo Comparator|Pancreatic: Chemo + Placebo|Stage IV pancreatic cancer will include a gemcitabine-based regiment at 1000 mg/m2 day 1, 7, 15 of a 21-day cycle.
89469204|NCT03607643|Experimental|Pancreatic: Chemo + BRCX014|Cannabidiol (BRCX014) 200 mg daily plus Stage IV pancreatic cancer will include a gemcitabine-based regiment at 1000 mg/m2 day 1, 7, 15 of a 21-day cycle.
89469205|NCT03607643|Placebo Comparator|GBM: Chemo + Placebo|Standard of care chemotherapy for patients with glioblastoma multiforme includes concurrent radiation therapy (2 Gy per day for a total of 60 Gy) and temozolomide (75 mg per square meter of body-surface area per day, 7 days per week from the first to the last day of radiotherapy), followed by six cycles of adjuvant temozolomide (150 to 200 mg per square meter for 5 days during each 28-day cycle).
89469206|NCT03607643|Experimental|GBM: Chemo + BRCX014|Cannabidiol (BRCX014) 200 mg daily plus Standard of care chemotherapy for patients with glioblastoma multiforme includes concurrent radiation therapy (2 Gy per day for a total of 60 Gy) and temozolomide (75 mg per square meter of body-surface area per day, 7 days per week from the first to the last day of radiotherapy), followed by six cycles of adjuvant temozolomide (150 to 200 mg per square meter for 5 days during each 28-day cycle).
89018799|NCT00296348|Active Comparator|1|
88947484|NCT01918228|No Intervention|Control group|No intervention will be provided by the study team.
88947485|NCT01918241|Experimental|pegfilgrastim,30mcg/kg|On the 3rd day and 6th day in Cycle 2, mean after 48h and 120h of chemotherapy, subjects will be received PEG-rhG-CSF(sc) in a fixed time(9:00±30 min), and the dosage is 30 mcg/kg.
88947486|NCT01918241|Experimental|pegfilgrastim, 60mcg/kg|On the 3rd day in Cycle 2, mean after 48h of chemotherapy, subjects will be assigned to PEG-rhG-CSF(sc, single) in a fixed time(9:00±30 min), and the dosage is 60 mcg/kg.
88947487|NCT01918241|Experimental|pegfilgrastim,100mcg/kg|On the 3rd day in Cycle 2, mean after 48h of chemotherapy, subjects will be assigned to PEG-rhG-CSF(sc, single) in a fixed time(9:00±30 min), and the dosage is 100 mcg/kg.
88947488|NCT01918241|Experimental|filgrastim,5mcg/kg|On the 3rd day in Cycle 2, mean after 48h of chemotherapy, subjects will be assigned to controlled group with rhG-CSF(sc, once a day) in a fixed time(9:00±30 min), and the dosage is 5mcg/kg, rhG-CSF must be injected for a continous 14 days, or twice observed the results for ANC from the nadir to counts≥5.0×10^9/L, but at least 7 days.
88947489|NCT01918254|Experimental|Lumretuzumab Dose Escalation|Participants will receive escalating doses of lumretuzumab starting at 1000 mg IV (on Day 1, except Cycle 1 where lumretuzumab will be administered on Day 2) along with paclitaxel 80 mg/m^2 IV (on Days 1, 8, and 15), and pertuzumab 840 mg IV (on Day 1) initial dose followed by 420 mg IV, in each 21-day cycle. Participants will be treated until disease progression, unacceptable toxicities, and withdrawal from treatment for other reasons or death.
88947490|NCT01918254|Experimental|EPC1: Lumretuzumab (Prior Chemotherapy)|Extension phase Cohort 1 (EPC1): Participants will receive lumretuzumab 1000 mg IV (on Day 1) along with paclitaxel 80 mg/m^2 IV (on Days 1, 8, and 15), and pertuzumab 840 mg IV (on Day 1) initial dose followed by 420 mg IV, in each 21-day cycle. Participants will be treated until disease progression, unacceptable toxicities, and withdrawal from treatment for other reasons or death.
88947491|NCT01918254|Experimental|EPC2: Lumretuzumab (Without Prior Chemotherapy)|Extension phase Cohort 2 (EPC2): Participants will receive lumretuzumab 2000 mg IV (on Day 1) along with paclitaxel 80 mg/m^2 IV (on Days 1, 8, and 15), and pertuzumab 420 mg IV (on Day 1), in each 21-day cycle. Participants will be treated until disease progression, unacceptable toxicities, and withdrawal from treatment for other reasons or death. Only participants with no prior chemotherapy for metastatic disease and/or a maximum of only one prior chemotherapy regimen in adjuvant or neoadjuvant setting will be enrolled in this cohort.
88947492|NCT01918267||Cohort|
88947493|NCT01918280|Experimental|Young group|Patient aged 15-22 years for seminal analyses and testicular biopsy
88947494|NCT01918280|Other|Adult group|Patient aged 23-55 years for seminal analyses and testicular biopsy
89018800|NCT00296348|Experimental|2|
89202294|NCT00784056|Experimental|1|Lactic Acid (Dermacyd PH_DETINLYN Tangerine Mix)
89469207|NCT03496922|Experimental|Tobacco Products|Participants will be asked to sample ventilated and unventilated cigarettes (and possibly alternative nicotine products such as cigarillos). During the experimental sessions, they will be given the opportunity to purchase ventilated and unventilated cigarettes (and possibly alternative nicotine products) using an account balance in the Experimental Tobacco Marketplace. However, besides the required sampling session, participants will not be required to purchase any nicotine products.
89469208|NCT02855359|Experimental|denintuzumab mafodotin + RCHOP|Part A: denintuzumab mafodotin (SGN-CD19A) + RCHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)
89202295|NCT00540592|Experimental|Influenza vaccine GSK576389A formulation 1 Group|Subjects aged ≥65 years received one dose of formulation 1 of the adjuvanted influenza vaccine GSK576389A.
88947495|NCT01918293|Experimental|SMART arm|Using smartphone application for control of asthma
88947496|NCT01918293|No Intervention|conventional arm|non-using smartphone application for control asthma
89202296|NCT00540592|Experimental|Influenza vaccine GSK576389A formulation 2 Group|Subjects aged ≥65 years received one dose of formulation 2 of the adjuvanted influenza vaccine GSK576389A.
89202297|NCT00540592|Experimental|Influenza vaccine GSK576389A formulation 3 Group|Subjects aged ≥65 years received one dose of formulation 3 of the adjuvanted influenza vaccine GSK576389A.
88947497|NCT01918319|Experimental|Lifestyle intervention|The active intervention consisted of two major components: dietary counseling and physical activity. Dietary counseling was performed by trained dieticians on four separate occasions at 15, 20, 28 and 35 weeks gestation.
88947498|NCT01918319|No Intervention|Control|
88947499|NCT01918358|Experimental|Fixed-dose combination VR 160/20 mg-1|Fixed-dose combination VR 160/20 mg-1 is administered by mouth at Day 1, 8 and 15.
88947500|NCT01918358|Experimental|Fixed-dose combination VR 160/20 mg-2|Fixed-dose combination VR 160/20 mg-2 is administered by mouth at Day 1, 8 and 15.
88947501|NCT01918358|Experimental|Valsartan 160mg placebo + Rosuvastatin 20mg|Both Valsartan 160mg placebo and Rosuvastatin 20mg are administered by mouth at Day 1, 8 and 15.
88947502|NCT01918384|Experimental|NPC-14|Intravenous drip, QW, 36 weeks, Dose will be adjusted and maintained by therapeutic drug monitoring of peak serum levels of NPC-14
88947503|NCT01918384|Placebo Comparator|Placebo|Dose will be adjusted by volume of distribution (Vd) of patients in accordance with the NPC-14 dose regimen
88947504|NCT01918410|Active Comparator|Contact Lens with alginic acid|
88947505|NCT01918410|Placebo Comparator|Contact lens without alginic acid|
88947506|NCT01918423||Children of obese women from a RCT|Children born to obese women who were in the active intervention arm of the randomized controlled trial LiP. The lifestyle intervention during pregnancy consisted of two major components: dietary counseling and physical activity. Dietary counseling was performed by trained dieticians on four separate occasions at 15, 20, 28 and 35 weeks gestation.
88947507|NCT01918423||Children of obese mothers from a RCT, controls|Children born to obese mothers who were in the control arm of the randomized controlled trial LiP.
88947508|NCT01918423||Children born to normal weight women|Children born to women with a pregestationally normal BMI and who were not part of a lifestyle intervention programme during pregnancy.
88947509|NCT01918436|Experimental|TEAMS intervention|"Pre-school children age 3-6, from Region Zealand in Denmark, diagnosed with ADHD as primary diagnosis are offered participation in the RCT study of the TEAMS program.~The intervention groups participate in eight weekly group sessions consisting of separate parent- and children's groups.~In the child group, the children are introduced to games that are designed to enhance inhibitory control, working memory, attention, visuospatial abilities, planning, and motor skills. The parent group consists of psychoeducation and instructions in how to encourage playing these games with their children and how to support the child's development."
88947510|NCT01918436|Active Comparator|Control group|The control groups receive the standard treatment program, outlined by the clinical guidelines of Region Zealand, Denmark.
88947511|NCT01918449|No Intervention|Sleep Unit group|This group will have standard follow up in sleep unit at 1, 3 and 6 month. These patients will also be instructed in hygienic-dietary measures, standard care of cardiovascular risk factors and sleep hygiene counseling.
88947512|NCT01918449|Experimental|Primary Care group|This group will have standard follow up in primary care at 1, 3 and 6 month. These patients will also be instructed in hygienic-dietary measures, standard care of cardiovascular risk factors and sleep hygiene counseling.
88947513|NCT01918462||Alcoholic hepatitis|Patients with alcoholic hepatic; cases.
88947514|NCT01918462||Healthy controls|Persons undergoing hepatic resection; controls.
88947515|NCT01918475|Active Comparator|Carbetocin first|Subjects receive carbetocin 0.1 mg intravenously in the first session and placebo (NaCl 0.9%) in the second session
89018801|NCT04835376|Experimental|Randomized Crossover: Percussion Palm Cup Safety and Usability - Cup 1|The standard percussor palm cups are made out of a soft vinyl material molded into shape. The outer diameter of the infant palm cup is 1-3/4 inches and there is a 1-inch diameter pocket inside this product similar to a suction cup.
89202298|NCT00540592|Experimental|Influenza vaccine GSK576389A formulation 4 Group|Subjects aged ≥65 years received one dose of formulation 4 of the adjuvanted influenza vaccine GSK576389A.
89202299|NCT00540592|Experimental|Influenza vaccine GSK576389A formulation 5 Group|Subjects aged ≥65 years received one dose of formulation 5 of the adjuvanted influenza vaccine GSK576389A.
89202300|NCT00540592|Experimental|Influenza vaccine GSK576389A formulation 6 Group|Subjects aged ≥65 years received one dose of formulation 6 of the adjuvanted influenza vaccine GSK576389A.
89202301|NCT00540592|Experimental|Influenza vaccine GSK576389A formulation 7 Group|Subjects aged ≥65 years received one dose of formulation 7 of the adjuvanted influenza vaccine GSK576389A.
89469209|NCT02855359|Experimental|denintuzumab mafodotin + RCHP|Part A: denintuzumab mafodotin (SGN-CD19A) + RCHP (rituximab, cyclophosphamide, doxorubicin, and prednisone)
89469210|NCT02855359|Experimental|denintuzumab mafodotin + RCHOP or RCHP|Part B: denintuzumab mafodotin (SGN-CD19A) + RCHOP or RCHP
89469211|NCT02855359|Active Comparator|RCHOP|Part B: RCHOP alone: (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)
89469212|NCT01107821|Experimental|Engenex™-pump|Negative Pressure Wound Therapy with the Engenex™-pump and Bio-Dome™ Dressing
88947516|NCT01918475|Active Comparator|Placebo first|Subjects receive placebo (NaCl 0.9%) intravenously in the first session and carbetocin 0.1 mg in the second session
88947517|NCT01918488|Experimental|Nephropathy|Diabetics with diabetic nephropathy receiving first a standardized salt diet (200 mmol NaCl/day) for 4 days and then amiloride tablet 20 mg two times daily (morning and afternoon) for 2 days.
88947518|NCT01918488|Experimental|Control|Diabetics without nephropathy receiving a standardized salt diet (200 mmol NaCl/day) for 4 days, then amiloride tablet 20 mg two times daily (morning and afternoon) for 2 days.
88947519|NCT01918501|Experimental|Blood testing|Comparison of nutrition factors in MS patients and healthy volunteers as possibly source for the pathogenesis and for the remyelination process.
88947520|NCT01918540|Active Comparator|Hollow Centralizer|The stem used (MS30)was originally designed with a solid centralizer but has been redesigned to be used with a hollow centralizer.
88947521|NCT01918540|Active Comparator|Solid Centralizer|The stem used (MS30)was originally designed with a solid centralizer but has been redesigned to be used with a hollow centralizer.
88947522|NCT01918553|Experimental|Subject in the study ALIENOR|
88947523|NCT01918566|Placebo Comparator|300ml tap water|Single intragastric instillation of 300ml tap water via nasogastric tube
88947524|NCT01918566|Active Comparator|Glucose|Single intragastric instillation of 75g Glucose in 300ml tap water via nasogastric tube
88947525|NCT01918566|Active Comparator|Glucose plus Lactisole|Single intragastric instillation of 75g Glucose in 300ml tap water with 450ppm lactisole
88947526|NCT01918566|Active Comparator|Fructose|Single intragastric instillation of 25g Fructose in 300ml tap water via nasogastric tube
88947527|NCT01918566|Active Comparator|Glucose and Exendin|Single intragastric instillation of 75g glucose in 300ml tap water with 600pmol/kg/min exendin 9-39
88947528|NCT01918566|Sham Comparator|tap water, lactisole|Single intragastric instillation of 300ml tap water with 450ppm lactisole
88947529|NCT01918579|Experimental|CRP intervention|Patients will be tested by rapid POC CRP test
88947530|NCT01918579|No Intervention|Control|Patients will not be tested by rapid POC CRP test
88947531|NCT01918592|Experimental|MRI/PET|
88947532|NCT01918605|Experimental|Diluted spacer|Single dose of DuraSeal product with DuraSeal components diluted 1:1 in sterile saline injected between rectum and prostate
88947533|NCT01918605|Active Comparator|Non-diluted spacer|Single dose of DuraSeal product injected between rectum and prostate
88947534|NCT01918618||Levosimendan|study group
88947535|NCT01918618||No Levosimendan|Control group
88947536|NCT01918631|Active Comparator|Entecavir|Entecavir 0.5mg QD for 48 weeks
88947537|NCT01918631|Active Comparator|tenofovir disoproxil fumarate|tenofovir disoproxil fumarate 300mg QD for 48 weeks
88956476|NCT05137119|Experimental|Switch to oral antibiotics at trial day 7 (+/- 2 days) or Day 14 (+/- 2 days) if eligible.|"Switch from intravenous backbone antibiotic for MRSA or MSSA or PSSA to oral antibiotics at the treating clinicians discretion on trial Day 7 (+/- 2 days) or trial Day 14 (+/- 2 days).~Participants eligibility is assessed at Day 7 (+/- 2 days). If eligible will be randomised, if not eligible then eligibility will be assessed again at Day 14 (+/- 2 days). If eligibility is not met at day 14 then participant is excluded from this domain."
89018802|NCT04835376|Experimental|Randomized Crossover: Percussion Palm Cup Safety and Usability - Cup 2|This product was developed by MMRI personnel using a small custom 3D printed plastic handle and a 0.93-inch, single bellow, Buna-N rubber suction cup. The handle was made on the MMRI's 3D printer using ABS plastic and the suction cup was sourced from McMaster Carr (#5427A106). The handle is made up of three pieces; top, base and a pin that is designed to fix the top, base and suction cup to each other. There is a small hole through the pin which helps relieve some of the pressure that builds in the suction cup during use. It is not shown in the image to the right, but the handle will be coated in Plasti Dip for added user comfort.
89018803|NCT04835376|Experimental|Randomized Crossover: Percussion Palm Cup Safety and Usability - Cup 3|This product was developed by MMRI personnel using a large custom 3D printed plastic handle and a 0.93-inch, single bellow, Buna-N rubber suction cup. The handle was made on the MMRI's 3D printer using ABS plastic and the suction cup was sourced from McMaster Carr (#5427A106). The handle is made up of three pieces; top, base and a pin that is designed to fix the top, base and suction cup to each other. There is a small hole through the pin which helps relieve some of the pressure that builds in the suction cup during use. It is not shown in the image to the right, but the handle will be coated in Plasti Dip for added user comfort.
89018804|NCT00296426|No Intervention|Usual Care|control patients admitted to hospital floors received usual care
89018805|NCT00296426|Experimental|Intervention|computerized medication reconciliation tool and process redesign involving physicians, nurses, and pharmacists
89018806|NCT00326820|Experimental|Ibandronic Acid|50mg tablet once daily over 96 weeks
89202302|NCT00540592|Experimental|Influenza vaccine GSK576389A formulation 8 Group|Subjects aged ≥65 years received one dose of formulation 8 of the adjuvanted influenza vaccine GSK576389A.
89469213|NCT05084456|Experimental|Control|ModraDoc006/r will be administered in a continuous weekly dose of 30-20 mg without dose escalation. This is the established recommended phase II dose for patients with normal liver function based on previous phase I trials.
89469214|NCT05084456|Experimental|Child-Pugh class A|ModraDoc006/r administration will start treatment with a weekly BID dose of 20-10mg ModraDoc006 in combination with ritonavir. If toxicity is acceptable, after 4 weeks an intra-patient dose-escalation will be initiated, followed by the second dose escalation after another 4 weeks.
89469215|NCT05084456|Experimental|Child-Pugh class B|ModraDoc006/r administration will start treatment with a weekly QD dose of 20mg ModraDoc006 in combination with ritonavir. If toxicity is acceptable, after 4 weeks an intra-patient dose-escalation will be initiated, followed by the second dose escalation after another 4 weeks.
89469216|NCT02032004|Experimental|Allogeneic Mesenchymal Precursor Cells|Participants randomly assigned to treatment will undergo a single index cardiac catheterization involving transendocardial delivery of rexlemestrocel-L into the myocardium at a cell injection center by an interventional cardiology team not involved with review or assessment of subsequent study results.
89469217|NCT02032004|Sham Comparator|Control Treatment|Participants randomly assigned to control treatment will undergo a single cardiac catheterization involving a scripted sham cardiac mapping and cell delivery procedure at a cell injection center by an interventional cardiology team not involved with review or assessment of subsequent study results.
89469218|NCT02949297|Other|Ovation Alto Abdominal Stent Graft System|Endovascular repair of AAA using the Ovation Alto Abdominal Stent Graft System.
89469219|NCT03607903|Active Comparator|Subcutaneous adalimumab and placebo|adalimumab SC (40 mg in 0.4 mL) and saline ID (0.9%, 0.4 mL)
89469220|NCT03607903|Active Comparator|PLacebo and subcutaneous adalimumab|saline ID (0.9%, 0.4 mL) and adalimumab SC (40 mg in 0.4 mL)
89469221|NCT03607903|Experimental|Placebo and intradermal adalimumab|saline SC (0.9%, 0.4 mL) and adalimumab ID (40 mg in 0.4 mL)
89469222|NCT03607903|Experimental|Intradermal adalimumab and placebo|adalimumab ID (40 mg in 0.4 mL) and saline SC (0.9%, 0.4 mL)
89469223|NCT02035033||low calcium supplement|low calcium supplement
89469224|NCT02035033||Calcium intake 500-1000 mg per day|Calcium intake 500-1000 mg per day
89469225|NCT02035033||Calcium intake above 1000 mg per day|Calcium intake above 1000 mg per day
89469226|NCT03141866|Experimental|Exercise Intervention 1: Move It Or Lose It (MIOLI)|An established chair-based physical activity programme for older adults.
89469227|NCT03141866|Experimental|Exercise Intervention 2: Machine-based resistance training|Specialised, chair-based resistance training equipment for older adults.
89469228|NCT04445259||Critically Ill Patients with COVID-19|We plan to recruit patients who are admitted to intensive care units with COVID-19 diagnosis.
89469229|NCT04438850|Experimental|I_600|ivermectin 600 μg/kg daily for 5 consecutive days (I_600) + placebo
89469230|NCT04438850|Experimental|I_1200|ivermectin 1200 μg/kg daily at empty stomach with water for 5 consecutive days
89018807|NCT00326820|Active Comparator|Zoledronic Acid|4 mg via intravenous infusion (iv) over a minimum of 15 minutes in at least 100mls of saline every 4 weeks over 96 weeks
89018808|NCT00296465|Experimental|Lutrepulse® 5mcg IV|5.0 mcg Pulsatile GnRH (Lutrepulse®) administered intravenously via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks and oral placebo clomiphene citrate for 5 days
89018809|NCT00296465|Experimental|Lutrepulse® 10 mcg IV|10.0 mcg Pulsatile GnRH (Lutrepulse®) administered intravenously via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks and oral placebo clomiphene citrate for 5 days
89469231|NCT04438850|Placebo Comparator|Placebo|placebo
89469232|NCT03385863||early preterm infants with RDS|gestational age<34 weeks
89469233|NCT03385863||near term infants with RDS|34 weeks≤gestational age< 37 weeks
89469234|NCT03385863||term infants with RDS|Gestational age ≥ 37 weeks
89469235|NCT02035111|Experimental|Tianshu capsule|Four Tianshu capsules (0.34 g per capsule) by oral three times a day for 12 weeks.
89018810|NCT00296465|Experimental|Lutrepulse® 20 mcg SC|20.0 mcg Pulsatile GnRH (Lutrepulse®) administered subcutaneously via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks and oral placebo clomiphene citrate for 5 days
89018811|NCT00296465|Placebo Comparator|Placebo IV|Placebo Pulsatile GnRH (Lutrepulse®) administered intravenously via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks and oral placebo clomiphene citrate for 5 days
89018812|NCT00296465|Placebo Comparator|Placebo SC|Placebo Pulsatile GnRH (Lutrepulse®) administered subcutaneously via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks and oral placebo clomiphene citrate for 5 days
89018813|NCT00296465|Active Comparator|Clomiphene Citrate/Placebo IV|Oral clomiphene citrate (over encapsulated) for 5 days and Placebo Pulsatile GnRH (Lutrepulse®) administered intravenously via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks
89018814|NCT00296465|Active Comparator|Clomiphene Citrate / Placebo SC|Oral clomiphene citrate (over encapsulated) for 5 days and Placebo Pulsatile GnRH (Lutrepulse®) administered subcutaneously via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks
89018815|NCT00326976|Experimental|1|400 mg injected in 2 divided boluses
89018816|NCT00326976|Placebo Comparator|2|Matching placebo
89018817|NCT00296621|Experimental|1|
89018818|NCT00296621|Placebo Comparator|2|
89018819|NCT00296660||1|Proven acute HIV-1 infection
89018820|NCT00296660||1A|Sexual partners of members of Group 1
89018821|NCT00296660||2|Established HIV-infection
89018822|NCT00296660||3|HIV-1 uninfected
89018823|NCT04762407|Experimental|Sequence 1|Period 1 : Fasted state + HGP1910 + HGP1909, Period 2 : Fasted state + HCP1903
89018824|NCT04762407|Experimental|Sequence 2|Period 1 :Fasted state + HCP1903, Period 2 : Fasted state + HGP1910 + HGP1909
89018825|NCT04726956||case cohort|Pancreatic ductal adenocarcinoma patients (140)
89018826|NCT04726956||control cohort|healthy donors (140)
89018827|NCT04726956||Benign cohort|patients with Intraductal papillary mucinous tumor of the pancreas (IPMN), mucinous cystadenoma, or pancreatic cyst (30)
89018828|NCT04581486|Experimental|OMI intervention|Multimodal intervention based on optimal fluid viscosity adaptation (with Nutilis Clear®), optimal nutritional support with a triple adaptation of food (texture, (Nutilis Clear®)) caloric and protein content, organoleptic) + ONS depending on nutritional status and evaluation and optimal treatment of oral hygiene (tooth brushing + antiseptic mouthwash + professional dental cleaning)
89018829|NCT04581486|Other|Control intervention (standard clinical practice)|Standard clinical practice (fluid adaptation with Nutilis Powder® and simple texture adaptation (for solids (Nutilis Powder®))
89018830|NCT00296777|Experimental|escitalopram|escitalopram 10 mg/d, increasing by 10 mg/week if tolerated and not remitted to maximum dose of 40 mg/d
89018831|NCT00296777|Experimental|bupropion|bupropion XL 150 mg/d, increasing by 150 mg/d if tolerated and not remitted to maximum dose of 450 mg/d
89018832|NCT00296777|Experimental|imipramine|imipramine 50 mg/d for 3 days, then 100 mg/d for 4 days, then 150 mg/d for 3 days then 200 mg/d for 4 days then 250 mg/d for a week and then 300 mg/d thereafter, all dose increases if tolerated and not remitted
89018833|NCT00327054|Experimental|Nigella sativa seed|
89018834|NCT00327054|No Intervention|Control|
89018835|NCT00296855|Experimental|Arm 1|
89018836|NCT00296894|Experimental|1|Drug - adalimimab sc
89018837|NCT00296894|Placebo Comparator|2|Placebo
89018838|NCT00418106||1|Mothers who are pumping breast milk and who are willing to kangaroo hold their infant.
89018839|NCT00327093|Experimental|1|Bevacizumab
89018840|NCT00327093|Experimental|2|Cetuximab
89018841|NCT04708587|Active Comparator|dual anti-platelet therapy at least 6 months|
89018842|NCT04708587|Experimental|dual anti-platelet therapy 3months or less|
89018843|NCT00297128|Active Comparator|1|
89018844|NCT00327132|Experimental|Experimental Arm|
89018845|NCT00297206|Experimental|Cohort 1|Subjects in the age group of 2 to less than 6 years will be included
89018846|NCT00297206|Experimental|Cohort 2|Subjects in the age group of 1 to less than 2 years will be included
89018847|NCT00297206|Experimental|Cohort 3|Subjects in the age group of 6 months to less than 1 year will be included
89018848|NCT00297206|Experimental|Cohort 4|Subjects in the age group of 3 months to less than 6 months will be included
89018849|NCT00297206|Experimental|Cohort 5|Subjects in the age group of 1 month to less than 3 months will be included
89018850|NCT04478019|Other|Control > Active Intervention|Treatment is 3 weeks of standard personal protective equipment without any povidone-iodine (PI) or chlorhexidine gluconate (CHG) intervention (control), followed by a 2 weeks washout period, and 3 weeks of nasal (10% povidone-iodine swab sticks in each nostril) and CHG oral decolonization (swish and spit 15 ml 0.12% CHG oral rinse for 30 seconds, four times/day) procedures.
89018851|NCT04478019|Other|Active Intervention > Control|Treatment is 3 weeks of nasal (10% povidone-iodine swab sticks in each nostril) and CHG oral decolonization (swish and spit 15 ml 0.12% CHG oral rinse for 30 seconds, four times/day) procedures, followed by 2 weeks of washout, and 3 weeks of standard personal protective equipment without any PI or CHG intervention (control).
89018852|NCT00327210|Experimental|BGATHome|Blood Glucose Awareness Training at Home Internet Intervention
89018853|NCT00327210|No Intervention|Control|No intervention
89018854|NCT04392531|Active Comparator|Group A (control)|The control group will consist on the standard treatment that patients will receive according to hospital standard of care protocol.
89018855|NCT04392531|Experimental|Group B (experimental)|The experimental group will consist on cyclosporine added to the standard treatment that patients will receive according to hospital standard of care protocol.
89018856|NCT00297323||001|
89018857|NCT00327288|Experimental|A|Docetaxel plus imexon
89018858|NCT04344600|Experimental|Peginterferon lambda alfa-1a|peginterferon lambda-1a (Lambda) 180 micrograms by subcutaneous injection for participants who are not infected with SARS-CoV-2
89018859|NCT04344600|Placebo Comparator|Placebo|Placebo (saline) by subcutaneous injection for participants who are not infected with SARS-CoV-2
89018860|NCT04333134|Experimental|Dose level 1|Will enroll a single cohort of 12 healthy Caucasian subjects with an approximately one-to-one ratio of male to female subjectssubjects can be enrolled and dosed simultaneously.
89202303|NCT00540592|Active Comparator|Fluarix elderly Group|Subjects aged ≥65 years received one dose of Fluarix vaccine.
89469236|NCT02035111|Placebo Comparator|Sugar pill|Four sugar pills (0.34 g per capsule) by oral three times a day for 12 weeks.
89202304|NCT00540592|Active Comparator|Fluarix young Group|Subjects aged 18-40 years received one dose of Fluarix vaccine.
89202305|NCT03970395|Experimental|Osteopathic manipulative therapy|"Repositioning Therapy plus Osteopathic Manipulative Therapy (OMTh).~Osteopathic Manipulative Therapy. Participant OMT group receive 6 OMTh in 3 months, as follows: first at baseline, the second after 1 week, the third after 3 weeks, and then once every 3 weeks for three more visits."
89469237|NCT03378999|Placebo Comparator|Control|Placebo capsules containing microcrystalline cellulose
89469238|NCT03378999|Experimental|Rhodospirillum rubrum 0.25 gram/day|Capsules containing oven-dried Rhodospirillum rubrum, 0.25 gram/day
89469239|NCT03378999|Experimental|Rhodospirillum rubrum 0.5 gram/day|Capsules containing oven-dried Rhodospirillum rubrum, 0.5 gram/day
89469240|NCT03378999|Experimental|Rhodospirillum rubrum 1.0 gram/day|Capsules containing oven-dried Rhodospirillum rubrum, 1.0 gram/day
89469241|NCT03605797||No intervention|To study the indication and results of fixing the sacral fracture by tension band plating
89469242|NCT03865394|Experimental|Allogeneic ADSC cells in fibrin solution|"Application of allogeneic ADSC stem cells in fibrin gel, to cover wound surface with thin cells layer.~Therapy is based on standard procedure of diabetic foot ulcer treatment combined with application of allogeneic ADSC stem cells in fibrin solution onto the wound surface."
89469243|NCT03865394|Active Comparator|Standard care in diabetic foot ulcer with aplication of fibrin gel to cover wound surface.|Application of fibrin gel to cover wound surface.
89469244|NCT03605641|Experimental|JUUL electronic cigarette|JUUL electronic cigarette. Virginia Tobacco 5% tobacco-derived nicotine.
89469245|NCT03605641|Active Comparator|VUSE Solo electronic cigarette|Reynolds American International VUSE Solo electronic cigarette. Original flavor 4.8% tobacco-derived nicotine.
89469246|NCT03605641|Active Comparator|Conventional cigarette|Canadian purchased, store bought (not hand-rolled) conventional full-flavored cigarettes of subjects' preference.
89469247|NCT03093038|Active Comparator|H-MAX stem & Delta-TT cup + polyethylene|H-MAX femoral stem and the Delta-TT cup with polyethylene insert
89469248|NCT03093038|Experimental|H-MAX stem & Delta-TT cup + ceramic|H-MAX femoral stem and the Delta-TT cup with ceramic insert
89469249|NCT03093038|Experimental|C2 stem & Delta-TT cup + ceramic|C2 femoral stem and the Delta-TT cup with ceramic insert
89469250|NCT03605563|Experimental|FSN: Fu's subcutaneous needling|In this arm, the subjects will receive the intervention of FSN on Day1, Day2 and Day4, in total 3 treatments and will be arrange to take efficacy two assessment on Day8 and Day15, separately.
89469251|NCT03605563|Active Comparator|TENS: Transcutaneous Electric Nerve Stimulation|In this arm, the subjects will receive the intervention of TENS on Day1, Day2 and Day4, in total 3 treatments and will be arrange to take efficacy two assessment on Day8 and Day15, separately.
88956477|NCT05105477|Experimental|HPI Arm|AcumenTM HPI Software Feature to guide hemodynamic management in moderate-to-high-risk noncardiac surgery.
88956478|NCT05105477|Placebo Comparator|Non-HPI arm|Non-protocolized standard of care management per clinician and provider judgement
88956479|NCT05104775|Experimental|study treatment|Patients receive GNC-035 as a 24-hour continuous intravenous infusion (cIV, QD) for 2 weeks (a 2-week cycle). Participants with no intolerable AEs could continue for another three cycles.
89469252|NCT03382431|Experimental|PC786|Repeat dose
89469253|NCT03382431|Placebo Comparator|Placebo/vehicle|Repeat dose
89469254|NCT05083520||critical care patients|
89469255|NCT03141944||Apathetic patients|"De novo Parkinson's Disease patients with Apathy which participated in a former study and are under dopaminergic treatment at inclusion.~All patients will be evaluated with regard to apathy, depression, pain, behavior and personality. Primary outcome measure is the degree of Apathy by the Starkstein scale of apathy"
89469256|NCT03141944||Non-apathetic patients|"De novo Parkinson's Disease patients without Apathy which participated in a former study and are under dopaminergic treatment at inclusion.~All patients will be evaluated with regard to apathy, depression, pain, behavior and personality. Primary outcome measure is the degree of Apathy by the Starkstein scale of apathy"
89469257|NCT03605485|Experimental|Trial Continuous Positive Airway Pressure (CPAP) mask|Trial nasal pillows CPAP mask
89469258|NCT03125421|Other|control period|standard preventive methods of pressure sores in each center
88956480|NCT05101070|Experimental|Part A-1: S-531011 Monotherapy|Participants will receive escalating doses of S-531011 by intravenous infusion for up to approximately 12 months.
88956481|NCT05101070|Experimental|Part A-2: S-531011 + pembrolizumab|Participants will receive escalating doses of S-531011 in combination with pembrolizumab by intravenous infusion for up to approximately 12 months.
88956482|NCT05101070|Experimental|Part B: S-531011 Monotherapy|Participants will receive S-531011 at the the RP2D by intravenous infusion for up to approximately 12 months.
88956483|NCT05101070|Experimental|Part C: S-531011 + pembrolizumab|Participants will receive S-531011 at the RP2D in combination with pembrolizumab by intravenous infusion for up to approximately 12 months.
88956484|NCT05098938|Experimental|Acyclovir 50mg buccal/topical tablet treatment group|
88956485|NCT05098938|Placebo Comparator|Matching placebo group|
88956486|NCT05092958|Active Comparator|Arm A (avelumab)|Patients receive avelumab IV over 60 minutes on days 1 and 15 of each cycle. Cycles repeat every 28 days for 24 months in the absence of disease progression or unacceptable toxicity. Patients also undergo bone scan at screening and undergo CT or MRI and biospecimen collection throughout the trial.
88956487|NCT05092958|Experimental|Arm B (avelumab, cabozantinib)|Patients receive avelumab IV over 60 minutes on days 1 and 15 of each cycle and cabozantinib PO daily on days 1-28 of each cycle. Cycles repeat every 28 days for 24 months in the absence of disease progression or unacceptable toxicity. Patients also undergo bone scan at screening and undergo CT or MRI and biospecimen collection throughout the trial.
89469259|NCT03125421|Experimental|experimental period|experimental multifaceted preventive methods of pressure sores
89469260|NCT03605407|Experimental|Experimental group|Patient receiving one visit prior to hospital admission
89018861|NCT04303104|Active Comparator|Mobile ACF|Xpert Edge performed at point-of-care employing a low-cost panel van that is staffed by three health care workers. Patients identified with active TB will be initiated on TB treatment on the same day at the nearest clinic. On site HIV testing will also be offered. Thus, the interventional package is one of ACF + POC TB testing (TB testing by Xpert will occur on site at the van).
89018862|NCT04303104|Placebo Comparator|Centralised ACF|Similar to active arm but Xpert Ultra will be performed at a centralized laboratory (samples will be transported to the laboratory with results being available in a few days). Thus, the standard of care package is ACF + distant TB testing (TB testing by Xpert will occur at a distant laboratory site).
89018863|NCT00297362||Galantamine hydrobromide|
89469261|NCT03605407|No Intervention|Control group|Patient without receiving one visit prior to hospital admission
89018864|NCT05459220|Experimental|Treatment group A|SHR0410 Injection（Low Dose）
89018865|NCT05459220|Experimental|Treatment group B|SHR0410 Injection（High Dose）
89018866|NCT05459220|Placebo Comparator|Treatment group C|Placebo for SHR0410 Injection.
89018867|NCT04231773|Experimental|12.1% Oxygen and Inhaled Nitric Oxide|Moderate level of hypoxia (12.1% Oxygen) and Inhaled Nitric Oxide (40 ppm)
89018868|NCT04231773|Placebo Comparator|12.1 % Oxygen Placebo|Moderate level of hypoxia (12.1 % Oxygen) and Placebo (0 ppm Nitric Oxide)
89018869|NCT04231773|Experimental|13.6 % Oxygen and Inhaled Nitric Oxide|Severe level of hypoxia (13.6% Oxygen) and Inhaled Nitric Oxide (40 ppm)
89018870|NCT04231773|Placebo Comparator|13.6 % Oxygen and Placebo|Severe level of hypoxia (13.6% Oxygen) and Placebo (0 ppm Nitric Oxide)
89018871|NCT04224012|No Intervention|Conventional therapy group (control group)|patients of the control Group receive usual care
89018872|NCT04224012|Experimental|Interventional group (training group)|Specialized exercise and respiratory therapy for patients with pulmonary hypertension
89018873|NCT04207593|Active Comparator|Oxygen Therapy provided|Patients will be divided in a supplemental-oxygen group (primary intervention group) throughout the study
89018874|NCT04207593|Sham Comparator|no-supplemental-oxygen group (control group)|Patients of the control group will beginn the study without Oxygen Therapie and will be offered to participate in the interventional treatment arm after they have terminated the control period (partial cross-over; secondary intervention group).
89018875|NCT00297752|Active Comparator|'ceriumnitrate silversulfadiazine (flammacerium)|facial burns treatment with Cerium nitrate silver sulfadiazine
89018876|NCT00297752|Active Comparator|flammazine|facial burns treatment with silver sulfadiazine
89469262|NCT03141632|Active Comparator|Dulaglutide|Dulaglutide (Trulicity®) 1.5 mg in 0.5 ml, via Pen s.c. once weekly for 3 weeks.
89018877|NCT00297791|Other|1|surgery (open or laparoscopic) and observation
89018878|NCT00297869|No Intervention|1|
89018879|NCT00297869|Experimental|2|Electronic warnings when providers prescribe a potentially inappropriate medication or an excessively dosed medication (based on estimated creatinine clearance)
89018880|NCT05459103|Experimental|Intervention group|Participants in the intervention group received a 12-week bidirectional remote interaction intervention.
89018881|NCT05459103|Experimental|Control group|Participants in the control group received a 12-week unidirectional remote interaction intervention.
89018882|NCT00297947|Experimental|600 mg/day quetiapine (Group B)|Patients qualifying for the Double Blind Phase will be randomly assigned to 600 mg quetiapine (Group B) daily and treated on the assigned dose in a double-blind fashion for 8 weeks
89469263|NCT03141632|Placebo Comparator|Placebo|0.5 ml normal saline (0.9% sodium chloride), sc once weekly for 3 weeks.
89018883|NCT00297947|Experimental|1200 mg/day quetiapine (Group A)|Patients qualifying for the Double Blind Phase will be randomly assigned to high dose 1200 mg quetiapine daily (Group A) on the assigned dose in a double-blind fashion for 8 weeks
89018884|NCT05459025|Experimental|Aromatherapy yoga|Each intervention session lasted 90 min, between 6 p.m. and 7:30 p.m. The course was held in a yoga classroom once a week, in an area of 30 m × 35 m. Furthermore, the total intervention period lasted for 12 weeks.
89018885|NCT05459025|Active Comparator|Yoga|Each intervention session lasted 90 min, between 6 p.m. and 7:30 p.m. The course was held in a yoga classroom once a week, in an area of 30 m × 35 m. Furthermore, the total intervention period lasted for 12 weeks.
89018886|NCT04718714|Active Comparator|midazolam|postoperative ventilation and sedation with continuous intravenous infusion of midazolam only for 24 hours
89018887|NCT04718714|Active Comparator|propofol|postoperative ventilation and sedation with continuous intravenous infusion of propofol only for 24 hours
89018888|NCT04718714|Experimental|dexmedetomidine|postoperative ventilation and sedation with continuous intravenous infusion of dexmedetomidine only for 24 hours
89018889|NCT04718519||Migrant Workers|
89018890|NCT04009239|Experimental|Early Time Restricted Feeding|Consume meals for 7 days during an 8 hour window starting 1 hour after habitual wake time.
89018891|NCT04009239|Experimental|Mid-day Time Restricted Feeding|Consume meals for 7 days during an 8 hour window starting 6 hours after habitual wake time.
89018892|NCT00297986||1|healthy subjects
89018893|NCT05458635|No Intervention|HP without Pulmonary hypertion|HRCT chest , pulmonary functions and echocardiography
89018894|NCT05458635|Active Comparator|HP with Pulmonary hypertion|HRCT chest , pulmonary functions ,echocardiography and RT heart catheter in high echocardiographic probability of PH
89018895|NCT00298025|Experimental|Cetrotide®|
89018896|NCT00298025|Active Comparator|Antagon ™|
89469264|NCT04282239|Experimental|Pectoral nerves block type 2 (PECS2)|The intervention is the PECS2 block, a previously developed modality for preventing pain in the anterior chest. The medication used in the block is Ropivicaine 0.5%, Lidocaine 1% + 1:100,000 epinephrine, and 40 μg dexmedetomidine. Patients will receive a standard post-operative pain regimen per institutional protocol.
88947538|NCT01918657|Active Comparator|walnut powder|Subjects will be randomized in a 2:1 ratio into either an active treatment group (final dose 1500 mg walnut protein, n=20) or a placebo group (n=10). Subjects will undergo a one-day desensitization protocol designed to enable the subject to tolerate 6 mg of walnut protein or placebo (initial day escalation phase). After the initial escalation day achieving at least 1.5 mg and up to 6 mg of walnut protein or placebo, dosing build-up will occur every two weeks through dose 24 at 34 weeks. A maintenance dose will be given for 4 weeks followed by a 5 gram protein OFC to walnut and a 5 gram protein OFC to a second tree nut (at ~38 weeks), after which the study will be unblinded.
89202306|NCT03970395|Sham Comparator|Light Touch Therapy|"Repositioning Therapy plus Light Touch Therapy (LTT)~Participants to the LTT group receive the LTT protocol at the same date of the OMTh group."
89202307|NCT00790140|Active Comparator|Immunonutrition Prosure|This group of patients are to be given a tube feed enriched with 2.2 g Eicosapentaenoic Acid (EPA) per day for 5 days pre surgery and 21 days post surgery
89202308|NCT00790140|Placebo Comparator|Standard enteral nutrition Ensure Plus|This group are to be given a standard enteral tube feed without EPA for 5 days pre op and 21 days post surgery
89202309|NCT00565773|Experimental|Immunosuppressive medications|"Renal transplant recipients will be given an experimental combination of immunosuppressive drugs. Participants will receive a single dose of alemtuzumab on the day of transplantation and will receive belatacept and sirolimus for 1 year.~At the time of transplant, all patients will receive a single dose of 500 mg of methylprednisolone IV over 30 minutes, followed within 1 hour by an IV infusion of 30 mg of alemtuzumab over 3 hours."
89202310|NCT00932919|Experimental|Thought field therapy|24 randomly selected patients will be treated with 5 sessions of standard Thought field therapy.
89202311|NCT00932919|Active Comparator|Cognitive therapy|Treatment with Cognitive therapy, 12 sessions with manualized therapy according to David Clark's model.
89202312|NCT00932919|Other|Wait list|24 patients will be randomly selected to 3 months on a wait list, thereafter randomly selected to either Cognitive therapy or Thought field therapy.
89202313|NCT00570492|Placebo Comparator|Placebo nasal spray|
89202314|NCT00570492|Experimental|Fluticasone furoate nasal spray|
89202315|NCT00931281|Active Comparator|1|ABT-450/ritonavir
89202316|NCT00931281|Placebo Comparator|2|Placebo for ABT-450/placebo for ritonavir
89202317|NCT00933075|Experimental|Dermacyd Silver Frutal (Lactic Acid)|Dermacyd Silver Frutal (Lactic Acid) sample will be applied like a curative. Physiologic solution and mineral oil will be also usedas a control sample.
89202318|NCT04014855|Active Comparator|obese children 1|iron supplementation
89202319|NCT04014855|Active Comparator|obese children 2|lactoferrin supplementation
89202320|NCT00933153|Active Comparator|Meals on Wheels|Participants will receive two meals daily from Meals on Wheels.
89202321|NCT00933153|Experimental|Meals on Wheels + Ensure Plus supplement|Participants will receive two meals from Meals on Wheels daily plus Ensure Plus supplements with meals.
89202322|NCT00571922|Active Comparator|Acamprosate|
89202323|NCT00571922|Placebo Comparator|Placebo|
89202324|NCT00786630|Experimental|Case Management|
89202325|NCT00786630|Experimental|Facilitated Treatment Alliance|
89202326|NCT00933231|Active Comparator|Tacrolimus Standard Dose with ACEi/ARB|Participants receive a standard dose of tacrolimus with ACEi/ARB.
89202327|NCT00933231|Active Comparator|Tacrolimus Standard Dose without ACEi/ARB|Participants receive a standard dose of tacrolimus without ACEi/ARB.
89469265|NCT04282239|No Intervention|Control Group: standard post-operative pain regimen|Patients will receive a standard post-operative pain regimen per institutional protocol.
89202328|NCT00933231|Experimental|Tacrolimus Low Dose with ACEi/ARB|Participants receive a low dose of tacrolimus with ACEi/ARB.
89202329|NCT00933231|Experimental|Tacrolimus Low Dose without ACEi/ARB|Participants receive a low dose of tacrolimus without ACEi/ARB.
89202330|NCT00786708||NGAL|Urine that would otherwise be discarded will be obtained from a convenience sample of patients admitted to the hospital through the emergency room who meet the inclusion / exclusion criteria for this study.
89202331|NCT00746876|Active Comparator|Unipolar|15 patients randomized for treatment with a unipolar hip hemiarthroplasty
89202332|NCT00746876|Active Comparator|Bipolar|15 patients randomized for treatment with a bipolar hip hemiarthroplasty
89202333|NCT00790374|Experimental|Cohort 1|6 patients have been enrolled, the cohort has been completed.
89202334|NCT00790374|Experimental|Cohort 2|6 patients have been enrolled in cohort 2, the cohort has been completed.
89202335|NCT00790374|Experimental|Cohort 3|5 patients have been enrolled in cohort 3. The cohort was closed after the 5th patient enrolled.
89202336|NCT04054466|Experimental|Experimental group|Intervention with counselling designed
89202337|NCT04054466|Other|Control group|Intervention with habitual counselling
89202338|NCT00786786||1|Spinal Cord Injury
89202339|NCT03951532||children with hyperthyroidism|children and adolescents (6 months -17 years included) whose data are present in the SNIIRAM database (DCIR data) and beneficiaries of the general health insurance scheme during the study period (01/01/2006-31/12/2017)
89202340|NCT03489525|Experimental|Dose Escalation, MEDI2228, ADC|Single agent MEDI2228, ADC (antibody drug conjugate) will be administered to adult subjects with relapsed/refractory (R/R) multiple myeloma (MM).
89202341|NCT03489525|Experimental|Dose Expansion, MEDI2228, ADC|Single agent MEDI2228, ADC (antibody drug conjugate) will be administered to adult subjects with R/R MM in the dose-expansion cohort at the dose selected for evaluation in the dose-expansion phase.
89202342|NCT00784212|Experimental|Cohort 1|
89202343|NCT00784212|Experimental|Cohort II|
89202344|NCT00784212|Experimental|Cohort III|
89202345|NCT00752180|Experimental|Wosulin R|Wosulin R,Regular insulin for injection(Recombinant Human Insulin)(600 nmol/ml, 100IU/ml)in vials 10.0 ml given subcutaneously.
89202346|NCT00752180|Active Comparator|Actrapid|Actrapid, Regular insulin for injection (Recombinant Human Insulin) (600nmol/ml,100IU/ml)in vials 10.0 ml given subcutaneously.
89202347|NCT00784290|Experimental|1|Orantinib
89202348|NCT00752414|Experimental|1|MP-376 Inhalation Solution
89202349|NCT00752414|Placebo Comparator|2|Placebo
89202350|NCT00790530|Experimental|ATO-SR|Automated Telephone Outreach with Speech Recognition
89469266|NCT03605329|Other|Type 1 diabetic patients with OSAS|to explore the severity of NAC in case of OSAS
89202351|NCT00790530|No Intervention|Usual Care|Usual Care
89202352|NCT03396562||SCT Conditions|"Sex Chromosome Trisomies Conditions including Klinefelter (XXY), Trisomy X (XXX), XXY Syndromes.~Interventions: Longitudinal observational assessments of development and growth at ages: 2 months, 6 months, 12 months, 18 months, 24 months, 36 months, 48 months, and 5 or 6 years."
89469267|NCT02639078|Experimental|TD-0714|One time dosing in capsule formulation
89469268|NCT02639078|Placebo Comparator|Placebo|Placebo comparator one time dosing in capsule formulation
89469269|NCT03605251|Experimental|TAS5315 low dose group|TAS5315 low dose and Methotrexate as specified
89469270|NCT03605251|Experimental|TAS5315 high dose group|TAS5315 high dose and Methotrexate as specified
89469271|NCT03605251|Placebo Comparator|Placebo group|Placebo and Methotrexate as specified
89469272|NCT03141710|Experimental|12 type 2 diabetes patients|Long-term dietary (12 weeks) intervention of 20ml of prebiotic per day
89469273|NCT03605173|Experimental|free vitamin d|free vitamin is directly measured from blood serum using an ELISA kit
89469274|NCT03605173|Experimental|total vitamin d|Total vitamin d is measured routinely from blood serum
89469275|NCT03140618|Experimental|LEPPIC|The light and environment project in psychiatric inpatient care
88947539|NCT01918657|Placebo Comparator|placebo arm|Subjects will be randomized in a 2:1 ratio into either an active treatment group (final dose 1500 mg walnut protein, n=20) or a placebo group (n=10). Subjects will undergo a one-day desensitization protocol designed to enable the subject to tolerate 6 mg of walnut protein or placebo (initial day escalation phase). After the initial escalation day achieving at least 1.5 mg and up to 6 mg of walnut protein or placebo, dosing build-up will occur every two weeks through dose 24 at 34 weeks. A maintenance dose will be given for 4 weeks followed by a 5 gram protein OFC to walnut and a 5 gram protein OFC to a second tree nut (at ~38 weeks), after which the study will be unblinded. Placebo subjects that fail the OFC will be crossed over to active treatment and escalated as described to the 1500 mg target dose.
89469276|NCT03605095|Active Comparator|8 mg/ml nitroglycerin|Higher concentration of NO donor (Nitromint) vs dilution
89469277|NCT03605095|Active Comparator|1 mg/ml nitroglycerin|Lower concentration of NO donor (Nitropohl) vs physiological saline
89469278|NCT03140462||liver transplant patients and donors|To study clinical and genetic factors on tacrolimus dose normalized trough concentration.
88947540|NCT01918670||Pasteur|
88947541|NCT01918670||Grenoble|
88947542|NCT01918670||Nantes|
88947543|NCT01918670||Parly|
88947544|NCT01918670||Rennes|
88947545|NCT01918670||Rouen|
88947546|NCT01918696|Experimental|Anger Reduction Treatment|"This treatment consists of eight 15-minute sessions. Participants will read scenarios and imagine themselves in these situations: A driver does not let you over even though you have your blinker on. Next, another will appear to provide a less ambiguous interpretation. One letter will be missing from the key word of this sentence. The sentence will read They can't s_e you. The participant will fill in the missing letter (to form see). Next, this interpretation will be reinforced by requiring the participants to correctly answer yes or no to a comprehension question (Is the driver being disrespectful?). In each session 64 training scenarios will be presented. Participants will never see the same scenario twice over the course of the study."
89202353|NCT00786942|Active Comparator|1|autologous bone graft
89202354|NCT00786942|Experimental|2|without bone graft
89202355|NCT02193958|Experimental|Phase 1: Lowest dose of FF-10501-01|FF-10501-01 tablets BID every 14 days of a 28 day cycle.
89202356|NCT02193958|Experimental|Phase 1: 2x lowest dose of FF-10501-01|2x lowest dose of FF-10501-01 tablets BID every 14 days of a 28 day cycle.
89202357|NCT02193958|Experimental|Phase 1: 4x lowest dose of FF-10501-01|4x lowest dose of FF-10501-01 tablets BID every 14 days of a 28 day cycle.
89469279|NCT03382353|Active Comparator|No Treatment (NT)|Educational training
89469280|NCT03382353|Experimental|Partial Treatment (PT)|Nutritional supplementation & Counselling on a brain-healthy diet
89469281|NCT03382353|Experimental|Full Treatment (FT)|Nutritional supplementation & Counselling on a brain-healthy diet & Physical exercise training & Computerized cognitive training
89469282|NCT03140540|Active Comparator|Group A (stroke volume variation) guided fluid|Stroke volume variation guided intraoperative intravenous fluid will be administered.
89469283|NCT03140540|Active Comparator|Group B(Study group) TEE guided fluid|Transesophageal echocardiography will be used to guide the fluid therapy.
89469284|NCT05080478||Group A|patients receiving ticagrelor 90mg bid
89469285|NCT05080478||Group B|patients receiving clopidogrel 75mg qd
89469286|NCT03382197|Experimental|Nebulization|control intervention, will only perform nebulization;
89469287|NCT03382197|Experimental|Positive expiratory pressure valve|Intervention, will perform nebulization associated with positive expiratory pressure valve in the airways (EPAP)
89469288|NCT03382197|Experimental|Nonivasive ventilation|intervention, will perform nebulization associated with non-invasive ventilation Bi-level mode;
89469289|NCT03608449|Active Comparator|study group|after monitoring treatment outcomes for 4 weeks, treatment plan or psychotherpist will be changed according to scoring by the director of department.
89469290|NCT03608449|Placebo Comparator|control group|treatment as usual. treatment counitunes as usual without depending on monitoring treatment outcomes.
89469291|NCT03140774||Cohort 1: Phase 1 participants|Previously exposed to Ebola vaccine Ad26-ZEBOV and MVA-BN-Filo.
89469292|NCT03140774||Cohort 2: Received r-VSV-ZEBOV vaccine|Previously exposed to Ebola vaccine rVSV-EBOV.
89469293|NCT03140774||Cohort 3: Phase 2 participants|Previously exposed to Ebola vaccine Ad26-ZEBOV and MVA-BN-Filo
89018897|NCT03923439|Experimental|MRI protocol|For stroke patients, the follow-up MRI (named MRI-2) after successfully recanalized thanks to thrombectomy, intravenous thrombolysis or spontaneously, will be performed between 24h and 72h after recanalization on our new Canon 3T research magnet with high gradient system. Patients will be explored for a follow-up evaluation at 3 months with a final MRI (named MRI-3) that will be performed on the Canon 3T research magnet.
89469294|NCT03382119||Patients having Fontan cardiac surgery|"This group includes pediatric patients, aged 2-5 years, who have had a Fontan operation. This surgery corrects a heart defect found at birth in which the heart has only one ventricle.~Patients will have an Ultrasound with ARFI imaging."
89018898|NCT03917745|Experimental|eHealth mindfulness intervention group|8 weeks of internet mindfulness training
89018899|NCT03917745|No Intervention|Control group|Care as usual
89469295|NCT03382119||Patients with Liver disease|"This group includes pediatric patients, aged 2-5 years, who have chronic liver disease caused by biliary atresia.~Patients will have an Ultrasound with ARFI imaging."
89469296|NCT02853929|Experimental|dTpa Group|This group will consist of healthy male or female infants, aged 9 months at the time of enrollment, born to mothers who received a single dose of Boostrix during pregnancy and a dose of placebo immediately post-delivery. All enrolled subjects in this group who will come back for subsequent visit will receive a booster dose of Infanrix hexa co-administered with Prevenar 13 according to the routine national/local immunization or study procedure
89469297|NCT02853929|Active Comparator|Control Group|This group will consist of healthy male or female infants, aged 9 months at the time of enrollment, born to mothers who received a dose of placebo during pregnancy and single dose of Boostrix immediately post-delivery. All enrolled subjects in this group who will come back for subsequent visit will receive a booster dose of Infanrix hexa co-administered with Prevenar 13 according to the routine national/local immunization or study procedure
89469298|NCT05082974|Experimental|OC-01 (varenicline 0.6mg/ml) nasal spray|
89469299|NCT05082974|Placebo Comparator|Placebo (vehicle) nasal spray|
89469300|NCT03604471|Other|Atorvastatin|All patients using atorvastatin at any dose (usually ranging from 5 to 80 mg once-daily).
89469301|NCT02667639|Active Comparator|Treatment|A single dose of RPH-104 (4, 20, 40, 80 or 160 mg) will be administered subcutaneously.
89018900|NCT05458518|Active Comparator|Dressing removal at 24 hours|The wound dressing will be removed 24 hours after emergency cesarean delivery
89018901|NCT05458518|Placebo Comparator|Dressing removal at 48 hours|The wound dressing will be removed 48 hours after emergency cesarean delivery
89018902|NCT00298220|Active Comparator|training|tailored multi-component implementation program
89018903|NCT00298220|No Intervention|control|
89469302|NCT02667639|Placebo Comparator|Placebo|A single 0.9% sodium chloride injection will be administered subcutaneously.
89018904|NCT05458089||tuberculous pericarditis with 18F-FDG uptake|patients confirmed with tuberculous pericarditis presenting 18F-FDG uptake
89018905|NCT05458089||tuberculous pericarditis without 18F-FDG uptake|patients confirmed with tuberculous pericarditis presenting no 18F-FDG uptake
89018906|NCT00298259|Active Comparator|ORIF|open reduction internal fixation of fractured ribs in flail chest patients
89018907|NCT00298259|No Intervention|conservative management|current standard conservative management
89018908|NCT03826641|Experimental|Sequence 1|Period 1 : Fasted state + HCP1805, Period 2 : Fasted state + HCP1801
89018909|NCT03826641|Experimental|Sequence 2|Period 1 : Fasted state + HCP1801, Period 2 : Fasted state + HCP1805
89018910|NCT03826641|Experimental|Sequence 3|Period 1 : High fat diet + HCP1805, Period 2 : High fat diet + HCP1801
89018911|NCT03826641|Experimental|Sequence 4|Period 1 : High fat diet + HCP1801, Period 2 : High fat diet + HCP1805
89018912|NCT00298298|Experimental|1|5 million autologous, DNP-modified NSCLC cells
89018913|NCT00298298|Experimental|2|2.5 million autologous, DNP-modified NSCLC cells
89018914|NCT00298298|Experimental|3|0.5 million autologous, DNP-modified NSCLC cells
89469303|NCT02237443|Other|Post-induction|Anesthesia is induced with propofol and mask ventilation is commenced after patient is unresponsive to a jaw thrust prior to administration of rocuronium, vecuronium bromide, or succinylcholine
89469304|NCT03141398||High-Risk Group|The objective of the study to compare the efficiency of detecting glycemic abnormalities using Continuous Glucose Monitoring (CGMs) versus Oral Glucose Tolerance Test (OGTT) and HbA1C. versus T2* MRI of the pancreas (T2* MRI of the Pancreas) in high-risk patients due to insulin deficiency (potential beta cell injury) and those with insulin resistance and to study the different factors that may affect the glycemic control in these patients in relation to their results like the Dose of corticosteroids and chemotherapy in ALL and Hemoglobinopathies,Liver function in ALL and Hemoglobinopathies, and Serum ferritin in Hemoglobinopathies and their transfusion status.
89469305|NCT03733418||VIOLET participants|Neuropsychological evaluations will be conducted 12 (+/-4) months after randomization among a subset of 140 survivors enrolled in the VIOLET parent study at 7 (out of 42) PETAL sites.
89469306|NCT02237521||End-stage renal disease|Patients with normal glucose tolerance and end-stage renal disease
89469307|NCT02237521||Controls|Healthy controls with normal kidney function and normal glucose tolerance
89469308|NCT03607331|Experimental|Auricular vagus nerve stimulation|Auricular Concha Electro-acupuncture: twice a day at home as required, once in the morning and once in the evening, with 5 consecutive days per week for two months
89469309|NCT03607331|Active Comparator|Citalopram|citalopram for oral administration; 10mg for the first 1-3 days, 20mg for the following 4-7 days；40mg for the left days within two months
89469310|NCT03607955|Experimental|AVB-S6-500 + Paclitaxel + Carboplatin|"Paclitaxel will be given intravenously at a dose of 175 mg/m^2 on an outpatient basis over 3 hours on Day 1 of each 21-day cycle~Carboplatin will be given intravenously at a dose of AUC 6 over 30 minutes on Day 1 of each cycle of chemotherapy~AVB-S6-500 will be given at doses based on the dose escalation schema~The investigators will continue dosing AVB-S6-500 until 1 week prior to surgery and continuing after surgery. Maintenance dosing q2 weeks will begin with Cycle 7A/7B and be given every 2 weeks for 12 months through Cycle 19 (total of 13 maintenance cycles)."
89469311|NCT02067975|Other|Healthy Controls|All participants will receive both 6gm of tryptophan at least two weeks apart at time zero of 7 hour visits 2 and 3, and will also receive Placebo will be a liquid drink without tryptophan. 6mg at least two weeks apart at time zero of the 7 hour visits 2 and 3. The order in which participants receive either placebo or tryptophan will be randomized (ie. placebo first study visit day tryptophan on second study day, or tryptophan on first study day and placebo on second study day)
89469312|NCT02067975|Other|Schizophrenia Related Disorders|All participants will receive both 6gm of tryptophan at least two weeks apart at time zero of 7 hour visits 2 and 3, and will also receive Placebo will be a liquid drink without tryptophan. 6mg at least two weeks apart at time zero of the 7 hour visits 2 and 3. The order in which participants receive either placebo or tryptophan will be randomized (ie. placebo first study visit day tryptophan on second study day, or tryptophan on first study day and placebo on second study day)
89469313|NCT03143036|Experimental|Daratumumab, thalidomide and dexamethasone|
89469314|NCT03607253|Other|Men|Healthy young men aged between 18-25 years
89469315|NCT03607253|Other|Women|Healthy young women aged between 18-25 years
89469316|NCT03694418|Other|Cluster 1|Cluster 1 is 1 school on the Fort Peck Reservation that will be randomized into the intervention in 2019. Cluster 1 will receive all four levels of the intervention including: 1) A school-based SRH curriculum called Native Stand, designed to address individual-level factors that lead to sexual risk behaviors; 2) a family-level curriculum called Native Voices, tailored to increase communication between adult family members and youth about SRH topics; 3) a cultural mentoring component at the community level that pairs AI youth with adults and elders to discuss traditional AI beliefs and practices about SRH; and 4) a mobilizing strategy to activate a multi-sectoral network of youth-servicing organizations at the systems level in Fort Peck to coordinate SRH services for AI youth.
89469317|NCT03694418|Other|Cluster 2|Cluster 2 includes 2 schools on the Fort Peck Reservation that will be randomized in the intervention in 2019-2020. Cluster 2 will receive all four levels of the intervention including: 1) A school-based SRH curriculum called Native Stand, designed to address individual-level factors that lead to sexual risk behaviors; 2) a family-level curriculum called Native Voices, tailored to increase communication between adult family members and youth about SRH topics; 3) a cultural mentoring component at the community level that pairs AI youth with adults and elders to discuss traditional AI beliefs and practices about SRH; and 4) a mobilizing strategy to activate a multi-sectoral network of youth-servicing organizations at the systems level in Fort Peck to coordinate SRH services for AI youth.
89537358|NCT05720403|Experimental|pilates group|Pilates, which lasts for eight weeks, three days a week for 1 hour, will be carried out by Australian Pilates and Physiotherapy Institute certified and experienced Ph.D. Physiotherapist Halil Ibrahim Bulguroglu. The individuals in pilates exercise groups will be divided into six small groups to make the exercises more effective. In this study, the program will be 15 minutes of warm-up, 30 minutes of pilates, and 15 minutes cool-down and stretching exercises. The exercises will be performed in ten repetitions.
89018915|NCT03754140|Experimental|Polidocanol Injection|Polidocanol (3%) 0.1ml intralesional injection per 10mm diameter lesion
89018916|NCT00419640|Experimental|LAS + DAO ON|The right atrial lead is placed in the low atrial septal position and the DAO algorithm is turned ON.
89018917|NCT00419640|Experimental|LAS + DAO OFF|The right atrial lead is placed in the low atrial septal position and the DAO algorithm is turned OFF.
89018918|NCT00419640|Experimental|RAA + DAO ON|The right atrial lead is placed in the right atrial appendage position and the DAO algorithm is turned ON.
89018919|NCT00419640|Active Comparator|RAA + DAO OFF|The right atrial lead is placed in the right atrial appendage position and the DAO algorithm is turned OFF.
89018920|NCT03528486|Experimental|Music Training I|Participants will complete a type of music training including listening to music, learning about music, or learning to read music, or play a musical instrument.
89018921|NCT03528486|Active Comparator|Music Training II|Participants will complete a type of music training including listening to music, learning about music, or learning to read music, or play a musical instrument
89018922|NCT00298415|Active Comparator|A|Chemotherapy (mono)
89018923|NCT00298415|Experimental|B|Chemotherapy (doublet)
89018924|NCT04708392|Experimental|Tonic spinal cord stimulation|Patients are programmed with tonic (continuous) spinal cord stimulation for a period of four weeks.
89018925|NCT04708392|Experimental|Burst spinal cord stimulation|Patients are programmed with burst (intermittent) spinal cord stimulation for a period of four weeks.
89018926|NCT03517956|Experimental|Patients with FGFR1-4 - positive solid tumors|"Dose escalation:~The starting dose of the combination will be escalated in a stepwise fashion, escalating one drug at a time.~Dose expansion (urothelial cancer):~Patients in the dose expansion will be treated with the combination identified in the dose escalation part of the study."
89202358|NCT02193958|Experimental|Phase 1: 6x lowest dose of FF-10501-01|6x lowest dose of FF-10501-01 tablets BID every 14 days of a 28 day cycle.
89202359|NCT02193958|Experimental|Phase 1: 8x lowest dose of FF-10101-01|8x lowest dose of FF-10501-01 tablets BID every 14 days of a 28 day cycle.
89469318|NCT03694418|Other|Cluster 3|Cluster 3 are the remaining 2 schools on the Fort Peck reservation that will be randomized into the intervention in 2020-2021. Cluster 3 will receive all four levels of the intervention including: 1) A school-based SRH curriculum called Native Stand, designed to address individual-level factors that lead to sexual risk behaviors; 2) a family-level curriculum called Native Voices, tailored to increase communication between adult family members and youth about SRH topics; 3) a cultural mentoring component at the community level that pairs AI youth with adults and elders to discuss traditional AI beliefs and practices about SRH; and 4) a mobilizing strategy to activate a multi-sectoral network of youth-servicing organizations at the systems level in Fort Peck to coordinate SRH services for AI youth.
89202360|NCT02193958|Experimental|Ph 2a: FF-10501-01 at 8x in MDS/CMML|FF-10501-01 tablets BID every 21 days of a 28 day cycle.
89469319|NCT05080088||Colonoscopy Only Group|
89469320|NCT05080088||Artificial intelligence GI GENIUS ™ only Group|
88947547|NCT01918696|Active Comparator|Progressive Muscle Relaxation|"Participants will receive eight 15-minute sessions of PMR. They will listen to a PMR script (Kassinove & Tafrate, 2002). Participants will be asked to make sure they are sitting comfortably, close their eyes, and systematically tense and release 10 different muscle groups. At the end of this procedure, participants will create a plan for when they will use the exercise. They will then type out the sentence: When I feel [write the feeling you decided on], then I will use this relaxation technique. They will then be told, Now, go over what you have written and say it quietly to yourself until you can repeat it word for word without having to read what you have written."
88947548|NCT01918696|Placebo Comparator|Control Condition|To control for expectancy effects, participants assigned to the control condition will complete eight computerized sessions consisting of psychoeducation on healthy behaviors. These sessions will be matched for time with the active conditions, lasting 15 minutes each. Psychoeducation will cover the topics of exercise, diet, hygiene, social support, healthy activities, and sleep, and will be taken from protocols developed from our ongoing research. This psychoeducation is perceived as credible but has no detectable impact on behavior. After the post-treatment session, participants will be provided with the active ART treatment free of charge if they wish to receive it.
88947549|NCT01918709|Experimental|Valsartan 160mg, Rosuvastatin 20mg|Both Valsartan 160mg and Rosuvastatin 20mg are administered daily by mouth once a day for 7 days.
88947550|NCT01918709|Experimental|Rosuvastatin 20mg|Rosuvastatin 20mg is administered daily by mouth once a day for 7 days.
88947551|NCT01918709|Experimental|Valsartan 160mg|Valsartan 160mg is administered daily by mouth once a day for 7 days.
88947552|NCT01918722|Experimental|ICH-1|herbal medicine with Hirudo, Tabanus,8 herbals, promote blood circulation function
88947553|NCT01918722|Active Comparator|ICH-2|herbal medicine without Hirudo, Tabanus,Only 6 herbals
89202361|NCT02193958|Experimental|Ph1:8x lowest dose FF10101-01 for 21 day|FF-10501-01 tablets BID every 21 days of a 28 day cycle.
89469321|NCT05080088||Endoscopic Cap and Artificial Intelligence GI GENIUS ™ Group|
89537359|NCT05720403|No Intervention|control group|The group received breathing and relaxation exercises with a home program.
88947554|NCT01918722|Placebo Comparator|placebo herbal medicine|Placebo ：granula，dose twice a day by Oral or nasogastric tube for 10 days
88947555|NCT01918748|Experimental|MS & chronic stroke patients|"Intervention: 8 weeks of I-TRAVLE based training of proximal arm function, using the haptic master.~Each week participants will attend training sessions on 5 days per 2 weeks, during which they will train 2 times 30 minutes I-TRAVLE assisted therapy, of which 1x 30 minutes supervised self-training. The two times half an hour training sessions per day will be interspaced by at least half an hour to avoid (general) fatigue and overuse of the affected arm in the subjects."
89202362|NCT02193958|Experimental|Ph1: 8x lowest dose FF-10101-01 28 day|FF-10501-01 tablets BID every 28 days of a 28 day cycle.
89202363|NCT02193958|Experimental|Ph1: 10X lowest dose FF-10501-01 14 day|10x lowest dose of FF-10501-01 tablets BID every 14 days of a 28 day cycle.
89202364|NCT00686894|Experimental|Infliximab 5 mg/kg|Infliximab infusions: 5 mg/kg at weeks 0, 2, and 6.
89202365|NCT00328627|Placebo Comparator|Placebo|Alogliptin placebo-matching tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 26 weeks.
89469322|NCT03607097|Experimental|Secondary prevention of DRPs (medication code) (intervention)|The intervention consists of :1)Patient-centred prescription Espaulella-Panicot J model (review model that includes different strategies in a single intervention. It is performed by a multidisciplinary team, and allows them to adapt the pharmacological plan of patients with clinical complexity). 2)strategies to improve medication adherence
89469323|NCT03607097|No Intervention|Usual care (control group)|The patient is reviewed according to the standard procedure, consisting only on the review of the medical prescription in the emergency department by the pharmacist assisting the unit
89469324|NCT03381963||Aromatase inhibitors|
89469325|NCT03381963||Tamoxifen|
89469326|NCT03606863|Experimental|Perioperative peripheral parenteral nutrition|Perioperative peripheral parenteral nutrition during 4 days
89469327|NCT03606863|No Intervention|Standard fluid therapy|Standard fluid therap
89469328|NCT03381885|Experimental|Intervention Group|"A nudge grounded in behavioral economic theory (nudge=gentle incentive, preserving freedom of choice)"
89469329|NCT03381885|Placebo Comparator|Control|"No nudge"
89469330|NCT05082506|Experimental|Acupressure Group|Applicable to the acupressure group; Heart meridian 7th point (HT7), large intestine meridian 4th point (LI4) and pericardium 6th point (PC6), a total of three points will be applied. Afterwards, sequential (breathing rhythm) compressions will be applied to the determined acupressure points by the researcher without lifting the finger, taking into account the pain threshold of the individual who is applied with the thumb, with 10 seconds of pressure for two seconds of relief. Since the symmetry of the selected three different points on the other extremity will also be applied, a total of 12 minutes of compression will be applied to each point, provided that it is two minutes. Depending on the preparation and compression time on each point, the session duration of each patient will be approximately 16 minutes.
89469331|NCT05082506|Placebo Comparator|Sham Group|n the acupressure application to the Sham group, pressure will be exerted on the bone region where the meridians do not pass, parallel to the HT7, LI4, PC6 and points (approximately 1-1.5 cm away) (Figure 4). Before the application, the acupressure points will be heated for about 20 seconds and the tissue sensitivity will be reduced by rubbing and they will be made ready for the acupressure application. Afterwards, the acupressure points determined will be pressed with the thumb by the researcher with a lower intensity than the normal application pressure for two minutes. Similar to the acupressure group, the sham group will be applied to symmetrical points. In this direction, a session will last 16 minutes for each patient, as in the acupressure group, together with the duration of the pre-procedure preparation and applications.
89469332|NCT05082506|No Intervention|Control Group|Patients in the control group will not receive any intervention.
89469333|NCT03607877|Active Comparator|pedometer walking (PW)|15 minutes of warm-up activities, 30 minutes of walking, and 10 minutes to cool down for 3 months.
89469334|NCT03607877|Active Comparator|pedometer walking with training (PWT)|15 minutes of warm-up activities, 30 minutes of walking, and 10 minutes to cool down. Exercise intensity for the first four weeks was 50-55% heart rate reserve (HRR) with training for 3 months.
89469335|NCT03607877|Experimental|positive education and walking (PEPWT)|PEPWT: 15 minutes of warm-up activities, 30 minutes of walking, and 10 minutes to cool down for 3 months and six sessions of positive education.
89469336|NCT03381807|Experimental|TCRA and intrauterine infusion of hAESCs|hAESCs is infused into uterine cavity after TCRA.
89469337|NCT05078684|Active Comparator|Actual LGSB|"The patients will receive an actual LGSB procedure:~Using ultrasound navigation and an echo-contrast needle, 8ml of bupivacain (5%) will be applied to the site of the left ganglion stellate through an anterolateral approach in the neck region."
89469338|NCT05078684|Sham Comparator|Sham procedure|The procedure will be performed using the same instruments and anesthetic drug as the actual LGSB. However, the operator will apply only 0.5-1ml of the anesthetic drug and only subcutaneously to the site where an actual LGSB would be performed.
89469339|NCT03606707|Experimental|corticosteroid|steroid group, received intra-articular steroid injection for atlantoaxial joint. , in addition to methotrexate and chloroquine 400 mg per day.
89469340|NCT03606707|No Intervention|oral steroid|systemic group, received systemic steroid 20 mg/d , in addition to methotrexate and chloroquine 400 mg per day.
89469341|NCT03378687||status epileptius|Cases were patients 29 days to 18 years who were diagnosed with status epileptius in 35 hospitals in China between January 1， 2013 and December 31，2015.
89469342|NCT05080010|Experimental|3 cycles chemotherapy|Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first three months.
89469343|NCT03606005||Group 1: Allogeneic-HSCT recipients|Dyspnea [Modified Medical Research Council dyspnea scale (MMRC)], submaximal exercise capacity [6-minute walk test (6-MWT)], physical activity level [metabolic holter], quality of life [European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTCQOL)] and pulmonary functions [spirometry] were evaluated in allogeneic-HSCT recipients (.Vital signs, dyspnea and fatigue perception [Modified Borg Scale] were recorded as pre-post measurements of 6-MWT.
89469344|NCT03606005||Group 2: Healthy individuals|Healthy individuals were selected from individuals without known and diagnosed any chronic diseases. Similar measurements were applicated in healthy individuals.
89469345|NCT04255329|Other|Usual reading group|The leader of the activity reads aloud a text to four participants seated around the table. The readen text is a normal, currently used in a everyday life support such as a journal article. Consequently it is not previously adaptated to people with cognitive impairements. After the reading phase, the leader asks the participants the questions about the content.
89469346|NCT04255329|Other|Montessori reading roundtable group|The group counts four participants and one activity leader. Each person have the same Montessori reading roundtable book.
89469347|NCT03606629||Endoprosthesis implantation|Device implantation
89537360|NCT04433169|Experimental|Experimental group|ATRA 20 mg, three times a day (tid), for 28 consecutive days, 28 days per cycle (q4w), 6 planned cycles; combined with the treatment regimen chosen by the investigator since Day 6 of cycle 1.
89202366|NCT00328627|Experimental|Alogliptin 12.5 + Placebo|Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 26 weeks.
89469348|NCT03606551||New Orthodontic Patients|"New patient subjects who are just initiating full orthodontic treatment will have their premolars, canines, and incisors bonded with the EXD-959 Bracket System, using the related EXD-961 instruments, according to the manufacturer's IFU.~Their remaining teeth will be bonded with the brackets of the orthodontist's choice. Three of the 5 new patients recruited may be patients that the orthodontist will choose to initiate treatment with the EXD-959 study brackets being applied to the upper teeth only. Having this option will allow the investigators to recruit subjects with deeper over-bites where their standard of care would be to apply esthetic brackets on the upper teeth and metal brackets on the lower teeth."
89469349|NCT03606551||Intercept Orthodontic Patients-Progress|This group will include a minimum of three, and up to 5 patients at each study site who have moved into rectangular wires; and in whom, the orthodontist- investigator believes they will be able to evaluate rotation corrections using the EXD-959 Bracket System. For example, rotation correction of the upper central incisor which will test the width of the bracket's holding points in situations that have wide teeth and greater inter-bracket distance.
89469350|NCT03606551||Intercept Orthodontic Patients-Finishing|This group will include a minimum of three, and up to 5 patients per study site who are estimated to be within 4 months of completing their orthodontic treatment; and in whom, the orthodontist-investigator believes they will be able to evaluate both torque control and debonding experiences using the EXD-959 Bracket System.
89469351|NCT02030756|Active Comparator|Vibrating capsule|patients will receive vibrating capsule for 8 weeks of treatment [1 every 3 days (+/- 1 day)].
89469352|NCT02030756|Sham Comparator|sham non-vibrating capsule|patients will receive sham non-vibrating capsule for 8 weeks of treatment [1 every 3 days (+/- 1 day)].
89469353|NCT03385551||ARM 1|Patients who have been prescribed by the physician within the standard clinical practice 10 micrograms of estradiol vaginal tablets. One tablet intravaginally once daily for two weeks. Thereafter one tablet twice per week with at least a 3-days interval between treatments
89469354|NCT03385551||ARM 2|Patients who have been prescribed by the physician within the standard clinical practice promestriene 10mg./g vaginal cream. 1 gr. one application once daily intravaginally for two weeks. Thereafter one application twice per week with at least a 3-days interval between treatments
89469355|NCT02035319||capillary malformation treated by laser|capillary malformation treated by laser
89469356|NCT04217655|Experimental|Low-dose computed tomography group|Patients undergo low-dose computed tomography-guided lung biopsy for lung nodule on day 1.
89469357|NCT04217655|Active Comparator|Standard-dose computed tomography group|Patients undergo standard-dose computed tomography-guided lung biopsy for lung nodule on day 1.
89469358|NCT05079542|Experimental|Immediate implant placement|Implant is placed immediately after tooth extraction.
89469359|NCT05079542|Active Comparator|Delayed implant placement|Implant is placed 8 weeks after tooth extraction.
89469360|NCT05079542|Experimental|Lithium disilicate crown|Crown out of Lithiumdisilicate is inserted onto the implant.
89469361|NCT05079542|Active Comparator|Zirconia Crown|Crown out of Zirconia is inserted onto the implant.
88947556|NCT01918787|Experimental|repetitive TMS|repetitive TMS over dorsolateral prefrontal cortex, posterior superior temporal sulcus and inion as control
88947557|NCT01918813|Experimental|Preoperative MRSA nasal colonization|Interventions in arm of preoperative MRSA nasal colonization consisted of antibiotic prophylaxis with a single dose of vancomycin 1g in addition to cephalosporins, and topical decolonization of MRSA with application of 2% mupirocin ointment twice daily to nares for 5 days
88947558|NCT01918826|Active Comparator|TENS active|NEUROSTIMULATION TRANSCUTANEE AIMED ANALGESIC ACTIVE
88947559|NCT01918826|Placebo Comparator|TENS placebo|NEUROSTIMULATION TRANSCUTANEE AIMED ANALGESIC PLACEBO
88947560|NCT01918852|Active Comparator|Capecitabine|Capecitabine 1250 mg/m2 for patients < 70 years of age, and 1000 mg/m2 for patients ≥ 70 years of age, orally b.i.d. day 1-14 with or without bevacizumab 7.5 mg/kg i.v. day 1.
88947561|NCT01918852|Experimental|S1|S-1 30 mg/m2 orally b.i.d. irrespective of age, day 1-14 with or without bevacizumab 7.5 mg/kg i.v. day 1.
88947562|NCT01918865|Experimental|ISIS-PTP1BRx|Weekly Dosing for 26 Weeks
88947563|NCT01918865|Placebo Comparator|Placebo|Weekly Dosing for 26 Weeks
89469362|NCT03606473|Experimental|Prenatal cocaine exposed subjects|[C-11]NPA PET at baseline and post d-amphetamine
89469363|NCT03606473|Experimental|Comparison subjects|[C-11]NPA PET at baseline and post d-amphetamine
89469364|NCT03385473|Active Comparator|Pharmacological Adequation (PA)|Pharmacological adequation based on the Pharmacogenomic Index and therapeutic drug monitoring results.
89469365|NCT03385473|No Intervention|Standard of Care (SOC)|Without pharmacological adequation
89469366|NCT03316274|Experimental|Nivolumab (Cohort A-Safety)|All participants will receive 10mg in 1 mL injection into a single KS lesion in the skin, every 2 weeks for 4 doses.
89469367|NCT03316274|Experimental|Nivolumab (Cohort B-Expansion)|All participants will receive injection into up to two KS lesion in the skin, every 2 weeks for 4 doses. For participants in the expansion cohort whose injected lesion is improving as of week 26 and they also did not experience any serious adverse events (SAE), they can receive additional intra-lesional injections of nivolumab into up to 4 lesions every 2 weeks for up to 4 doses (for total up to 8 doses). The injected volume will not exceed 10 mg (or 1 mL) each time
89469368|NCT03606395|Experimental|Single ascending dose_healthy subjects|"NV-5138:~Single dose of 150, 300, 600, 1000, 1600 or 2400 mg single dose of placebo"
89202367|NCT00328627|Experimental|Alogliptin 25 + Placebo|Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 26 weeks.
89469369|NCT03606395|Experimental|Single dose in subjects with TRD|NV-5138 oral solution single dose (dose to be determined from Part A) single dose of placebo
89469370|NCT03252626|Active Comparator|Alprostadil|Based on the standard medical care, 2ml of Alprostadil
89469371|NCT03252626|Placebo Comparator|Normal saline|Based on the standard medical care, 2ml of 0.9% saline as the placebo
89469372|NCT03605615|No Intervention|CONTROL|In this group parturients will be attended in standardized manner, which in our hospital means a humanized approach with choice of position in socond stage and without routine episiotomy.
89469373|NCT03605615|Experimental|VOCALIZATION|In this group parturients will besides being be attended with our standar care, will receive training to vocalize during second stage.
89469374|NCT03375333||20GPs|20 general practitioners, who use ultrasound in the examination of patients.
89469375|NCT05072054|Experimental|Atorvastatin arm|Tablet Atorvastatin 40mg once daily at bed-time given for 6 months
89469376|NCT05072054|Active Comparator|Rosuvastatin arm|Tablet Rosuvastatin 20mg once daily at bed-time given for 6 months
89469377|NCT02035241|Experimental|Spices 1|220 ml test drink containing spices 1, acute study / one time administration
89469378|NCT02035241|Experimental|Spices 2|220 ml test drink containing spices 2, acute study / one time administration
89469379|NCT02035241|Experimental|Spices 3|220 ml test drink containing spices 3, acute study / one time administration
89469380|NCT02035241|Experimental|Herbs 1|220 ml test drink containing herbs 1, acute study / one time administration
89469381|NCT02035241|Experimental|Herbs 2|220 ml test drink containing herbs 2, acute study / one time administration
89469382|NCT02035241|Placebo Comparator|Placebo|220 ml control drink, acute study / one time administration
89469383|NCT03142880|Active Comparator|commonly hyperbaric ropivacaine group|This group will receive spinal anesthesia with commonly hyperbaric ropivacaine solution,which was made by adding 50% glucose to the plain ropivacaine commercially availablethe to make it's density is close to commonly hyperbaric bupivacaine.
89469384|NCT03142880|Experimental|marginally hyperbaric ropivacaine group|This group will receive spinal anesthesia with marginally hyperbaric ropivacaine,which was made by adding 5% glucose to the plain ropivacaine commercially availablethe to make it's density is slightly denser than cerebrospinal fluid but much less denser than commonly hyperbaric bupivacaine/ropivacaine.
89469385|NCT04019301|Experimental|Community-based Qigong Group|Participants randomized into this group follow one, 75 minutes class per week supplemented by home practice for 20 minutes on 3 additional days.
89469386|NCT04019301|Experimental|Internet-based Qigong Group|Participants randomized into this group follow two online sessions for 40 minutes each, also supplemented by home practice for 20 minutes on 3 additional days.
89469387|NCT04019301|No Intervention|Self-Care Control Group|The Self-care control group, will be requested not to practice any Qigong during the study. Participants will be provided with an educational book on caregiving that includes self-guided activities related to caregiving and caregiver health (The Caregiver Helpbook: Powerful Tools for Caregiving). The book's evidence-based program is designed to provide caregivers the tools to increase their self-care and their confidence to handle difficult situations, emotions, and decisions. In addition, study staff will call participants in the self-care control group once a month.
89469388|NCT03605537|Experimental|Stent|"Subjects will undergo repair of the choanal atresia in the operating room with a drug eluting stent placed at the end of the surgical procedure. They will return to the operating room in 3-5 weeks for repeat nasal endoscopy with possible balloon dilation, which is standard of care within our institution. At this time in the operating room the intervention arm will have the stent removed. Following removal of the stent, photodocumentation of the posterior nasal cavity and nasopharynx will take place to assess the size (standard of care).~Subjects will then follow up and undergo a bedside or outpatient nasal endoscopy and nasopharyngoscopy (standard of care) at the following approximate intervals 1 month, 6 months, 12 months (these are not exact time periods as clinic scheduling can sometimes be 2-3 months on either side of these time stamps)."
89469389|NCT03605537|No Intervention|No Stent|"Subjects will undergo repair of the choanal atresia in the operating room with no stent placed at the end of the surgical procedure. They will return to the operating room in 3-5 weeks for repeat nasal endoscopy with possible balloon dilation, which is standard of care within our institution. Photodocumentation of the posterior nasal cavity and nasopharynx will take place to assess the size (standard of care).~Subjects will then follow up and undergo a bedside or outpatient nasal endoscopy and nasopharyngoscopy (standard of care) at the following approximate intervals 1 month, 6 months, 12 months (these are not exact time periods as clinic scheduling can sometimes be 2-3 months on either side of these time stamps)."
89469390|NCT03605459|Experimental|Device use|"Only one treatment arm; the Comfort Plug™ is a device designed to control urinary incontinence in male subjects by being placed in the urethra to stop urine leakage."
89469391|NCT05013086|Experimental|1.11 GBq of 177Lu-AB-3PRGD2|The patients were intravenously injected with the dose about 1.11GBq (30 mCi) of 177Lu-AB-3PRGD2 and underwent 68Ga-RGD PET/CT scans before and after the treatment.
89469392|NCT03236870||Participants with moderate to severe plaque psoriasis in China|Participants with moderate to severe plaque psoriasis in China receiving adalimumab in daily clinical practice.
89469393|NCT03381495|Experimental|Epidural analgesia during labor|The epidural analgesia technique was used to maintain analgesia for parturients who request labor analgesia.First, we injected a test dose of 5ml 1% lidocaine . If not adverse effects were observed 10 minutes after the test dose, the parturient then received a bolus injection of an initial dose of 8-10 ml mixed liquids of 0.075% ropivacaine and 0.2ug/ml sufentanil citrate. We then connected the epidural catheter with a patient-controlled epidural analgesia (PCA) pump, which provided patients the same mixed solution at 8-10ml/h until the delivery of neonates.
89202368|NCT00328627|Active Comparator|Placebo + Pioglitazone 15|Alogliptin placebo-matching tablets, orally, once daily and pioglitazone 15 mg, tablets, orally, once daily for up to 26 weeks.
89018927|NCT00298532|No Intervention|standard therapy|"The use of a before-after controlled study design and 36-month time periods will mirror the approach of our Adult OPALS Study. The Control (before) Period represents the 36 months immediately prior to the introduction of ALS programs at each study community. The Intervention (after) Period is comprised of the 36 months immediately after each community has met all standards for a full ALS program, as defined below. Data will be pooled across communities but the start date for the periods will vary for each community as each will require different amounts of time to prepare their ALS program. A 6- to 36-month Run-in period will separate the Control and Intervention Periods and will allow for training and implementation of the ALS program. Data from the Run-in period will not be considered in the primary analysis. The study periods may be summarized as follows: a) Control (Before) Period b) Run-in Period c) Intervention (After) Period."
89018928|NCT03505476|Experimental|Study Participants|Device: Entac Medical device application Other: Patient Daily Assessment Other: Patient Discharge Assessment
89469394|NCT03381495|No Intervention|Non-epidural analgesia during labor|Women who refused epidural labor analgesia were included in the non-epidural analgesia group, and they don't receive epidural analgesia during labor
89469395|NCT03602417|Experimental|Flare type stent|Flare type stent (Taewoong medical) has a wide diameter at proximal end to prevent stent migration.
89469396|NCT03602417|Active Comparator|Conventional D-type stent|Conventional D-type (Taewoong medical) stent has a same diameter at both ends.
89469397|NCT03381417|Experimental|Pegcyte (Nanogen pegfilgrastim)|6 mg in each cycle
89469398|NCT03381417|Active Comparator|Neulastim (Roche pegfilgrastim)|6 mg in each cycle
89469399|NCT03059498|Active Comparator|unilateral PECS block patients|unilateral PECS I and II block using bupivacaine
89469400|NCT03059498|Active Comparator|bilateral PECS block patients|bilateral PECS I and II block using bupivacaine
89469401|NCT03548727|Experimental|Repeatability of FLT kinetics|Radiotracer: 18F-FLT Dose: 10 mCi Frequency: Two baseline PET/CT at baseline up to 3 days apart.
89469402|NCT03548727|Experimental|Pseudo-Simultaneous FMISO/FLT PET/CT Imaging|Radiotracer: 18F-FLT and 18F-FLT Dose and Frequency: 8 mCi 18F-FLT and 8 mCi 18F-FLT on Day1, the 8mCi 18F-FLT on Day2
89018929|NCT00298727|Active Comparator|1|SHIPS: Face-to-Face Workshop
89469403|NCT03142646|Experimental|IM19 CART|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by a single infusion of IM19CART cells administered intravenously.
89469404|NCT03602183|Experimental|Normal airway scenario|intubation in normal airway scenario
89469405|NCT03602183|Experimental|Tongue edema scenario|intubation in the tongue edema scenario. Tongue edema was obtain using simulator indicators
89469406|NCT03602183|Experimental|Spinal immobilization with normal airway scenario|intubation in spinal immobilization with normal airway scenario
89469407|NCT03602183|Experimental|Spinal immobilization with tongue edema scenario|endotracheal intubation with immobilized cervical spine and tongue edema scenario
89469408|NCT03378453|Other|NarCo|Narcolepsy type 1 over 65 years old
89469409|NCT03378453|Other|CoS|Cognitevement healthy controls
89469410|NCT03605225|Experimental|Cellphone application|Train of Four (TOF) ratio displayed by the Cellphone Application
89469411|NCT03605225|Active Comparator|Draeger TOF Scan|Train of Four (TOF) ratio displayed by the Draeger TOF Scan
89469412|NCT03142724|Experimental|[18F]MNI-968|To assess the safety and tolerability and to determine the radiation dosimetry of [18F]MNI-968.
89469413|NCT03541083|Experimental|Blinatumomab|After a 5-day steroid prephase patients will receive two weeks continuous infusion of blinatumomab. Then the first remission-induction course will be given after one week interruption. Subsequent therapy with 4 cycles of chemotherapy and two 4-week courses of blinatumomab will follow, and subsequently depending on risk group, eligibility and a suitable donor either allogeneic stem cell transplantation or 2 year maintenance treatment.
89018930|NCT00298727|Active Comparator|2|ePBL: Online Problem-Based Course
89018931|NCT05457894|Experimental|Flu-M, II trimester of pregnancy|Subjects during their II trimester of pregnancy (gestational age: 14-26 weeks), immunized once with the Flu-M vaccine.
89469414|NCT03605147|Experimental|CaHMB|CaHMB Group (n=60) will receive CaHMB twice a day and a late evening snack every night for 12 weeks. A specialized, ready-to-drink liquid with 34 kcal, 8.5 g carbohydrate, 1.5g calcium-HMB. The late evening snack is a drink with low-Glycemic Index carbohydrate with 112 kcal.
89469415|NCT03605147|Active Comparator|Control|Control Group (n=60) will receive placebo twice a day and placebo every night for 12 weeks with similar composition but without HMB. The late evening snack is a drink with low-Glycemic Index carbohydrate with 112 kcal.
89018932|NCT05457894|Active Comparator|Ultrix®, II trimester of pregnancy|Subjects during their II trimester of pregnancy (gestational age: 14-26 weeks), immunized once with Ultrix®.
89018933|NCT05457894|Experimental|Flu-M, III trimester of pregnancy|Subjects during their III trimester of pregnancy (gestational age: 27-32 weeks), will be immunized once with the Flu-M vaccine.
89018934|NCT05457894|Active Comparator|Ultrix®, III trimester of pregnancy|Subjects during their III trimester of pregnancy (gestational age: 27-32 weeks), immunized once with Ultrix®.
89018935|NCT03448653|Experimental|Colonoscopy with NBI|
89018936|NCT03439839|Experimental|Cohort 1: LNP023 200mg bid + SoC|Orally administered iptacopan 200 mg b.i.d. in Part 1 and Part 2
89018937|NCT03439839|Experimental|Cohort 2: LNP023 50mg/200mg bid + SoC|Orally administered iptacopan 50 mg b.i.d. for a minimum of 2 weeks in addition to SoC; this could be increased to iptacopan 200 mg b.i.d. at study day 15 or at any time later in the study if LDH was not within limit of normal or reduced by at least 60% as compared to baseline values.
89469416|NCT05079152|Experimental|Experimental group|Experimental Group (468 subjects) will receive: 1st dose : combined vaccination of COVAX+PPV23; 2nd dose: combined vaccination of COVAX+IIV4
89469417|NCT05079152|Active Comparator|Control group A|Control Group A (468 subjects) will receive: 1st dose: COVAX only; 2nd dose: COVAX only
89469418|NCT05079152|Active Comparator|Control group B|Control Group B (468 subjects) will receive: 1st dose: PPV23 only; 2nd dose: IIV4 only
89469419|NCT03605069|Other|First TWA (A)|"In each subject up to two target wound areas (TWA) are randomized, one each to active treatment or placebo.~In the first arm; randomization of the first selected TWA to active treatment or placebo"
88947564|NCT01918878|Experimental|Aflibercept (EYLEA)|Intravitreal injection of aflibercept (EYLEA) 2mg/0.05ml at enrolment (day 0), 4 weeks, 8 weeks, 16 weeks and 24 weeks. Aflibercept will be provided for total period of 24 weeks
88947565|NCT01918891|No Intervention|Usual Home Care|Regardless of study arm, all patients will receive usual home health services: a physician-ordered plan of care; skilled nursing and/or therapy services as prescribed by the MD; patient education, monitoring and hands-on care; and home health aide services depending on functional deficits and availability of unpaid caregivers.
88947566|NCT01918891|Experimental|Nurse Practitioner + Health Coach|The NP + HC arm will include the same protocol as the NP only arm plus 30 additional days of support. The HC will pick up the case after the initial 30 days and follow up with the plan of care jointly established by the patient, NP and HC. The focus will be on ongoing self-management coaching, providing preparation support for physician visits, and linking patient to additional community resources, as needed.
88947567|NCT01918891|Experimental|Nurse Practitioner Only|The NP only program will provide a 30 day intervention via in-home and telephone encounters for patients randomized to this group. In the first 30 days post-enrollment the NP will focus on medical case management and coordination with primary care providers and specialists, provide self-management coaching, and intervene if gaps in care are identified - all with a focus on BP reduction and preparing the patient for ongoing BP maintenance.
88947568|NCT01918904|Experimental|Sodium Thiosulfate|A small amount of 25% topical sodium thiosulfate cream twice daily (bid)
88947569|NCT01918904|Placebo Comparator|Placebo|A small amount of topical zinc oxide and aquaphor cream twice daily (bid)
88947570|NCT01918917|Active Comparator|Levobupivacaine|Intraarticular 19 ml 0.5% levobupivacaine and 1 ml 0.9% sodium chloride administered. postoperative morphine administered for analgesia
88947571|NCT01918917|Active Comparator|Dexmedetomidine|Intraarticular 19 ml 0.5% levobupivacaine and 1 ml (100 mcg/ml) dexmedetomidine administered, postoperative morphine used for analgesia
88947572|NCT01918943||PLIF and Aspen device patients|All patients will receive PLIF and Aspen device
88947573|NCT01918956|Active Comparator|conventional regimen of PURETHAL Birch|"Initial treatment:~6 incremental weekly subcutaneous doses of 0.05, 0.1, 0.2, 0.3, 0.4 and 0.5 ml PURETHAL Birch, 20.000 AUM/ml (week 1, 2, 3, 4, 5, 6).~Maintenance treatment:~0.5 ml PURETHAL Birch, 20.000 AUM/ml, in intervals according to registered scheme (week 8, 10, 12)."
88947574|NCT01918956|Experimental|rush regimen of PURETHAL Birch|"Initial treatment:~3 incremental weekly subcutaneous doses of 0.1, 0.3, and 0.5 ml PURETHAL Birch, 20.000 AUM/ml (week 1, 2, 3)~Maintenance treatment:~0.5 ml PURETHAL Birch, 20.000 AUM/ml, in 2-weekly intervals (week 5, 7, 9)."
89469420|NCT03605069|Other|Second TWA (B)|In each subject, in the second arm; allocation of the second selected target wound area (TWA) to the alternative treatment. Second arm in the same subject as the first arm.
89018938|NCT05457777|Experimental|Motivational interview group|Motivational interviews will be held to the participants with digital game addiction in this group.
89018939|NCT05457777|No Intervention|Control group|This group will be control group and any motivational interviews will not be held to the participants with digital game addiction in this group.
89018940|NCT00298883|Experimental|Treatment|This is a single arm, interventional trial.
89018941|NCT00298922|Active Comparator|Azithromycin|participants taking 500 mg tablets orally thrice weekly for 24 weeks
89018942|NCT00298922|Placebo Comparator|Placebo|Participants taking 500 mg tablets orally thrice weekly for 24 weeks
89018943|NCT05457738|Experimental|patients randomized to using the smartphone app|
89018944|NCT05457738|Active Comparator|patients randomized to not using the smartphone app|
89018945|NCT00299039|Active Comparator|1|
89018946|NCT00299039|Active Comparator|2|
89018947|NCT05457621|Experimental|Effaclar serum|Participants are asked to apply Effaclar serum once daily in the evening on the whole face avoiding contact with eyes for 2 months.
89469421|NCT02730819|Experimental|Illuminate Cream|Illuminate Cream is a skin-lightening formulation containing multiple drugs, including a retinoid, calcineurin inhibitor, anti-tyrosinase agent and sunscreen microfine zinc oxide. Approximately 0.5 grams to be applied topically to affected areas of skin once per day for 20 weeks.
89018948|NCT00299234|Placebo Comparator|2|placebo
89018949|NCT00299234|Experimental|1|atomoxetine
89018950|NCT00299273|Experimental|Low calorie high fat/protein diet|Low calorie high fat/protein diet
89018951|NCT05457543||Adult|A venous blood and capillary blood collection is taken from each participant and tested with investigative diagnostic tests.
88947575|NCT01918969||Blood donors|Blood donors with no exclusion criteria i.e with a very low probability to have an aortic aneurysm
88947576|NCT01918982||Aortic aneurysm|Patients with aortic aneurysm >30mm and < 50mm
88947577|NCT01918995|Experimental|Regadenoson low dose|Administered over approximately 10 seconds followed by 2 repeat low doses at 10 minute intervals
88947578|NCT01918995|Experimental|Regadenoson medium dose|Administered over approximately 10 seconds followed by 2 repeat medium doses at 10 minute intervals
88947579|NCT01918995|Experimental|Regadenoson high dose|Administered over approximately 10 seconds followed by 1 repeat high dose at 10 minute intervals
89018952|NCT00299390|Experimental|Sagopilone|
89018953|NCT00299429|Active Comparator|MIDCAB Surgery|MIDCAB Surgery
89018954|NCT00299429|Experimental|PCI with drug-eluting stent|PCI with DES
89018955|NCT02808585|Experimental|PB1046 Injection, 0.2 mg/kg|Four weekly doses of PB1046 Injection, 0.2 mg/kg
89018956|NCT02808585|Experimental|PB1046 Injection, 0.4 mg/kg|Four weekly doses of PB1046 Injection, 0.4 mg/kg
89018957|NCT02808585|Experimental|PB1046 Injection, 0.6 mg/kg|Four weekly doses of PB1046 Injection, 0.6 mg/kg
89018958|NCT02808585|Experimental|PB1046 Injection, 1.2 mg/kg|Four weekly doses of PB1046 Injection, 1.2 mg/kg
89018959|NCT02808585|Placebo Comparator|Placebo Comparator|Four weekly doses of Placebo (0.9% NaCl) Injection
89018960|NCT02751762||Prospective Longitudinal Cohort|Patients who have recently initiated long-term opioid therapy or initiated ER/LA opioid therapy
89018961|NCT02751762||Cross-sectional Cohort|Patients who have been treated with opioids (including at least one ER/LA opioid) for greater than one year
89018962|NCT05457348|Experimental|Group A:experimental group|those who receive planned incisions
89018963|NCT05457348|Active Comparator|Group B:Controlled group|the patients who were operated by conventional phacoemulsification
89018964|NCT00299819|Active Comparator|1|MEDI-545
89018965|NCT00299819|Active Comparator|2|MEDI-545
89469422|NCT03602027|Experimental|Anlotinib Plus Gefitinib|"This study will include a sequential evaluation of 3 subjects per dose group. low-dose groups: Anlotinib 8mg per day and Gefitinib. middle-dose groups: Anlotinib 10mg per day and Gefitinib. high-dose groups: Anlotinib 12mg per day and Gefitinib.~A dose limiting toxicity (DLT) event is defined as any of the following events:~CTCAE Grade 4 event (ANC<1000/ul, body temperature≥38.5°C);~Grade 3 non-hematologic toxicity (except for nausea and vomiting that could be improved with optimal supportive care, escalation of alkaline phosphatase) If a DLT is experienced in any dose group, the cohort will be expanded to 6 subjects. If 2 DLTs are experienced in any dose group, the dose escalation ceased. The MTD was defined as the dose having at most two out of six patients experience DLT."
89469423|NCT03141476|Other|Cefuroxime 1,5g|BMI <30kg/m*m
89469424|NCT03141476|Other|Cefuroxime 3g|BMI 30-50kg/m*m
89469425|NCT03141476|Other|Cefuroxime 4,5g|BMI >50kg/m*m
89469426|NCT03437889|Experimental|Epidural analgesia/anesthesia for childbirth|
89469427|NCT03601871|Active Comparator|Control group|Palonosetron 0.25 mg intravenously on day 1; or 1st-generation 5-HT3 antagonists (used as clinal routine) on day 1-3; Dexamethasone 12 mg by mouth or intravenously before chemotherapy on day 1 and 8 mg on days 2-4.
88947580|NCT01918995|Placebo Comparator|Placebo|Administered over approximately 10 seconds followed by 1 or 2 repeat doses at 10 minute intervals
89469428|NCT03601871|Experimental|Thalidomide group|Thalidomide 100 mg by mouth twice a day on days 1-5; Palonosetron 0.25 mg intravenously on day 1; or 1st-generation 5-HT3 antagonists (used as clinal routine) on day 1-3; Dexamethasone 12 mg by mouth or intravenously before chemotherapy on day 1 and 8 mg on days 2-4.
89469429|NCT03124485|Experimental|Endoscopic Sleeve Gastroplasty|A series of full thickness sutures done with Overstitch in the triangular stitch pattern as mentioned by Lopez-Nava[29] will be placed according to the APC markings. The suturing is initiated from the antrum distally and moved proximally towards the gastric fundus. A total of 6 to 8 plications are placed to reduce the gastric lumen. Five sham dressings would also be applied to patient's abdominal wall during the first week to minimize the bias in pain scoring.
89469430|NCT03124485|Active Comparator|Laparoscopic Sleeve Gastrectomy|Sleeve gastrectomy is then performed using lapaorscopic linear staplers, starting from a point 5-6cm proximal to the pylorus up to the angle of His along the left side of the Mid-sleeve tube. Haemostasis of the staple line is secured by suture plication with the Mid-sleeve tube in situ to ensure no compromise of the gastric tube lumen. All the wounds are closed with staples after local anaesthetic infiltration and covered with non-transparent dressings.
89469431|NCT02859038|Experimental|Upfront cytoreductive surgery|Upfront cytoreductive surgery with a maximal cytoreduction of complete gross resection within 3 weeks after biopsy, followed by at least 6 cycles of adjuvant chemotherapy.
89469432|NCT02859038|Active Comparator|Neoadjuvant chemotherapy|neoadjuvant chemotherapy with 3 cycles of chemotherapy, then followed by interval debulking surgery. The maximal time interval between course 3 chemotherapy and IDS is 6 weeks. And then 3 cycles of adjuvant chemotherapy.
89469433|NCT03381027|Experimental|Interventional Arm- Baby Massage|Interventional Arm= Baby Massage
89469434|NCT03381027|No Intervention|Control Arm- no Baby Massage|Control Arm= no Baby Massage
89469435|NCT02747576||Medulloblastoma Group|Medulloblastoma survivors, 30 between the ages of 12-20 years and 30 between 21-30 years.
89469436|NCT02747576||Control Group|Health comparison group frequency matched on age (30 between the ages of 12-20 years and 30 between 21-30 years), gender and race.
89469437|NCT03380949|Experimental|PPI (Pain Pupillary Index)|Opioid administration (remifentanil) in intervention group is guided by PPI derived from video-pupillometry performed with the AlgiScan™ by IDMed, Marseille, France. The device measures the degree of pupillary reflex dilation (PRD) following a nociceptive stimulation. It automatically increases the intensity of the electric stimulation from 10 to 60 mA and displays the PPI as numerical index between 0 and 10. A low PPI score indicates deep, a high score light analgesia. A PPI score of 2-3 is supposed to represent an optimal level of analgesia. A remifentanil bolus of 30 µg will be administered and the infusion rate of remifentanil will be increased by 0.03 µg/kg/min if PPI score is calculated more than 3. Remifentanil infusion will be decreased by 0.03 µg/kg/min if PPI score is <1.
89469438|NCT03380949|Experimental|SPI (Surgical Pleth Index)|Opioid administration (remifentanil) in intervention group is guided by SPI derived from photoplethysmography performed by the device CARESCAPE™ B650 Patient Monitor by GE Healthcare, Helsinki, Finland. Included in the monitoring system is a software that continuously calculates the SPI from normalized heart rate and pulse wave amplitude derived from finger plethysmography. The numerical index ranges between 0 (low sympathetic tone) and 100 (high sympathetic tone). A SPI score between 20 and 50 has been proposed as the target range. A remifentanil bolus of 30 µg will be administered and the infusion rate of remifentanil will be increased by 0.03 µg/kg/min if SPI score is calculated more than 50. Remifentanil infusion will be decreased by 0.03 µg/kg/min if PPI score is calculated below 20.
88947581|NCT01919008|Experimental|Group 1 (FK949E low dose tablet-first group)|"Days 1 and 2: One FK949E low dose tablet~Days 3 to 6: Three FK949E low dose tablets~Days 7 to 10: One FK949E high dose tablet"
88947582|NCT01919008|Experimental|Group 2 (FK949E high dose tablet-first group)|"Days 1 and 2: One FK949E low dose tablet~Days 3 to 6: One FK949E high dose tablet~Days 7 to 10: Three FK949E low dose tablets"
88956488|NCT05085327|Experimental|ChapStick Lip Moisturizer Original|Single topical application: 80 +/- 2 milligrams (mg) (2.0 +/- 0.05 mg per square centimeter [mg/cm^2]) of ChapStick Lip Moisturizer Original will be applied to the assigned test site using a fingercot. Test material will be evenly spread over the test site using light pressure for 35 +/- 15 seconds.
89018966|NCT00299819|Active Comparator|3|MEDI-545
89018967|NCT00299819|Active Comparator|4|MEDI-545
89018968|NCT00299819|Active Comparator|5|MEDI-545
89018969|NCT04716660||Women receiving epidural analgesia for labor|
89537361|NCT04433169|Active Comparator|Control group|The investigator chooses the treatment regimen based on the following regimens (including but not limited to: 1. VEGFR inhibitor; 2. chemotherapy).
89537362|NCT05711121|Active Comparator|S1 transforaminal|The group receiving S1 transforaminal epidural steroid injection
89537363|NCT05711121|Active Comparator|Caudal|The group receiving caudal epidural steroid injection
89537364|NCT02717195|Experimental|Prospective Confirmation (PC) Period|Single (patient)-blinded treatment period with risperidone or olanzapine for 6 weeks
89469439|NCT03380949|Experimental|NOL (Nociception Level)|Opioid administration (remifentanil) in intervention group is guided by NOL derived from finger photoplethysmography performed with the device PMD200™ manufactured by Medasense, Ramat Gan, Israel. The device continuously calculates the NOL with a multi-parametric approach from pulse rate, pulse rate variability, pulse wave amplitude, skin conductance level and fluctuations, skin temperature and finger motion. It is presented on a scale from 0 (no pain) to 100 (extreme pain). A NOL score between 10 and 25 has been proposed as the target range. A remifentanil bolus of 30 µg will be administered and the infusion rate will be increased by 0.03 µg/kg/min if NOL score is calculated more than 25. Remifentanil infusion will be decreased by 0.03 µg/kg/min if PPI score is calculated below 10.
89469440|NCT03380949|Active Comparator|Control|Opioid administration (remifentanil) in control group is guided according to standard clinical practice of the attending anesthesiologist based upon changes of heart rate, blood pressure, lacrimation and sweating of the patient.
89469441|NCT03604757|Experimental|PET/CT Imaging|
89469442|NCT03604679|Experimental|SyB C-0501|"SyB C-0501 (Oral Bendamustine) will be administered orally once a day (specified dose). The treatment period of 21 days (Cohort 1; 7 days of administration + 14 days of observation or Cohort 2; 14 days of administration + 7 days of observation or Cohort 3; 21 days of administration) constitutes 1 cycle.~Part 1: dose escalation to determine MTD, RD and dosing schedule Part 2: dose expansion at RD"
89469443|NCT02681120||High risk/BMI > 30|Women at elevated risk for breast cancer will have imaging (MRI and mammogram) pre-bariatric surgery and 1 year post-bariatric surgery, and blood and tissue collection (blood draw and biopsy) pre-bariatric surgery, 2 weeks post-bariatric surgery, and 1 year post-bariatric surgery.
89469444|NCT02681120||Women with normal BMI|Deidentified samples that were donated to the IU Komen Tissue Bank will be used for comparison to the high risk/BMI > 30 cohort.
89469445|NCT03124329|Experimental|Coronally Advanced Flap|
89469446|NCT03124329|Experimental|Vestibular Incision Subperiosteal Tunnel Access (VISTA)|
89469447|NCT03124329|Experimental|Intrasulcular tunneling|
89018970|NCT00299858|Active Comparator|Study Group|Patients will be given theophylline, titrated to optimal blood levels, for a period of 4 weeks.
89018971|NCT00299858|Placebo Comparator|Placebo group|Patients will receive placebo pills for a period of 4 weeks.
89469448|NCT03124329|Experimental|VISTA + Leukocyte-Platelet Rich Fibrin|
89469449|NCT05078372|Active Comparator|Ropivacaine and midazolam epidural administration|"An elastomeric pump was prepared for epidural infusion. This was prepared with 150 mg (20 ml) of 0.75% ropivacaine plus midazolam at 50 mcg / kg / 12 hrs. The solution was made up to 125 ml with physiological solution.~And 20 ml of physiological solution, was intraarticular administered as placebo."
89469450|NCT05078372|Active Comparator|Ropivacaine and midazolam intraarticular administration|"Ropivacaine 0.75% at 1.5 mg / kg was used with midazolam at 50 mcg / kg, to complete 20 ml of solution and was administrated on the knee articulation after tourniquet release.~And an elastomeric pump was prepared for epidural infusion, with 150 ml of physiological solution as placebo."
88947583|NCT01919034||Patients undergoing abdominal surgery|Patients undergoing abdominal surgery and using morphine pain control analgesia (PCA) device will be involved. Pre- and Post- operative (after anesthesia and at the end of surgery) blood sampling (total 30 ml) plus normal liver tissue (10mm3) e will be harvested. Above protein(TM, IL-20, HD) amount change will be measured (ELISA for TM, IL-20 (serum) or flowcytometry (white cells) for TM, HD, IL-20 expression, stain or blotting for skin tissue). Patients will be included in this branch to check the correlation between morphine consumption and protein expression. Pain questionnaire (BPI, McGill) will be applied for pain evaluation. 2-D gel analysis will also be applied to screen further possible molecules.
88947584|NCT01919047||Betanis group|Patients receiving Betanis for Overactive Bladder
89469451|NCT03601793|Experimental|Internet intervention with assistance|This arm is given access to the internet intervention Alcohol Help Center with email assistance from a health educator during the first two weeks after randomization.
88947585|NCT01919060||lesions in colon|
88947586|NCT01919060||lesions in extra-colon|
88947587|NCT01919073|Experimental|Immediate Treatment Group|The immediate treatment group will fill out the questions at the initial appointment and again after five treatment appointments. They will fill the questions out again at the first follow-up treatment appointment (approximately 4-5 months from the initial appointment), and then at the next (and last) follow-up appointment (approximately 7-8 months). The participants teacher will also be asked to fill out sets of questions.
88956489|NCT05085327|Experimental|ChapStick Lip Moisturizer Mint|Single topical application: 80 +/- 2 mg (2.0 +/- 0.05 mg/cm^2) of ChapStick Lip Moisturizer Mint will be applied to the assigned test site using a fingercot. Test material will be evenly spread over the test site using light pressure for 35 +/- 15 seconds.
89018972|NCT05455944|Active Comparator|Pregabalin Group|Patients received two capsules: one at the night of surgery, and the other at 2 hours before the surgery
89469452|NCT03601793|Active Comparator|Internet intervention without assistance|This arm is given access to the internet intervention Alcohol Help Center without any assistance from a health educator.
89469453|NCT03380871|Experimental|NEO-PV-01/Adjuvant + pembrolizumab + chemotherapy|Pembrolizumab at a dose of 200 mg administered by intravenous infusion (IV) plus chemotherapy with carboplatin (AUC 5) + pemetrexed (500 mg/m2) every 3 weeks for 4 cycles. At Week 12, all patients, regardless of their disease status, will receive NEO-PV-01 + adjuvant administered subcutaneously (one vial of pooled peptides per injection site) in up to four distinct sites (each extremity or flanks) while continuing therapy with pembrolizumab.
89469454|NCT02237495|Placebo Comparator|Saline|Normal saline as placebo is continuously infused right after anesthesia induction and lasts for 12 hrs with the same infusion rate as the comparator dexmedetomidine
89469455|NCT02237495|Experimental|dexmedetomidine|dexmedetomidine intravenous infusion starts right after anesthesia induction in the operating room and last for 12 hours into ICU with a infusion dose of 0.4 ug/kg/h. To avoid potential cause of bradycardia, no dexmedetomidine bolus is given.
88947588|NCT01919073|Active Comparator|Delayed Treatment Group|The wait list group will fill out the sets of questions again in 1-2 months. The question sets will then be completed again before beginning treatment four months from the initial completion and then again after five treatment appointments. The question sets will then be completed again at the first follow-up treatment appointment (approximately 8-9 months from the initial appointment) and at the next (and last) follow-up appointment (in about 11-12 months from the initial appointment).
89469456|NCT02486666|Experimental|Experimental Arm|"Experimental Arm:patients will not have any dose titration regardless of anti-Xa level.~Premature neonates will receive enoxaparin 2.0 mg/kg/dose rounded to nearest whole mg twice daily, while term neonates will receive enoxaparin 1.7 mg/kg/dose rounded to nearest whole mg twice daily. Children≥1 month corrected age will receive 1.5 mg/kg/dose twice daily (maybe rounded +/- 10% for convenience of dosing) while children≥2 month corrected age will receive 1.0 mg/kg/dose twice daily (maybe rounded +/- 10% for convenience of dosing)."
89469457|NCT02486666|Other|Control Arm|Control Arm: patients who will have dose titration based on anti-Xa levels to maintain a therapeutic range of 0.5-1.0 u/mL (standard of care).
89469458|NCT02237807|Experimental|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET of Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey one tablet, once
89469459|NCT02237807|Experimental|DYNABAC 250 MG ENTERIC COATED TABLET|DYNABAC 250 MG ENTERIC COATED TABLET of Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey, two tablets, once
89469460|NCT03366753|Experimental|Acute normovolemic hemodilution|acute normovolemic hemodilution by using hydroxyethyl starch
89469461|NCT03366753|Experimental|In-vitro hemodilution|adding additional hydroxyethyl starch for achieving further 30% dilution of whole blood sample which already underwent ANH of 4-6 ml/kg.
89469462|NCT03604367||GAITRite assessment|Subjects will undergo the GAITRite assessment of functional walking and then complete the Functional MRI Bipedal paradigm followed by questionnaires and assessments regarding the virtual environment.
88947589|NCT01919125|Experimental|Cohort 1: Child-Pugh Class A|Participants with mild hepatic impairment (Child-Pugh Class A score = 5-6) will receive a single dose of 100 mg IDX719 by mouth on Day 1.
88947590|NCT01919125|Experimental|Cohort 2: Child-Pugh Class B|Participants with moderate hepatic impairment (Child-Pugh Class B score = 7-9) will receive a single dose of 100 mg IDX719 by mouth on Day 1.
88947591|NCT01919125|Experimental|Cohort 3: Child-Pugh Class C|Participants with severe hepatic impairment (Child-Pugh Class C score = 10-15) will receive a single dose of 100 mg IDX719 by mouth on Day 1.
88947592|NCT01919138||severe sepsis, septic shock|
88947593|NCT01919151||Gastrointestinal cancer patients|Patients with radiological suspected cancer in the pancreas Patients with radiological suspected colorectal liver metastasis
89018973|NCT05455944|Placebo Comparator|Control Group|Patients received two capsules: one at the night of surgery, and the other at 2 hours before the surgery
89018974|NCT00300092|No Intervention|No antibioitcs|Group 1 received no antibiotics
89469463|NCT03125187|Experimental|Sodium heparin UQ First|The participants will receive the Sodium heparin UQ intravenous drug administration at first period and the Sodium heparin FK intravenous drug administration at second period
89469464|NCT03125187|Experimental|Sodium Heparin FK First|The participants will receive the Sodium heparin FK intravenous drug administration at first period and the Sodium heparin UQ intravenous drug administration at second period
89469465|NCT03299439|Experimental|acupuncture at highly sensitive points|Sterile, single-use filiform acupuncture needles (Hwato Needles, Sino-foreign Joint Venture Suzhou Hwato Medical Instruments Co., China) with a length of 40 mm and a diameter of 0.30 mm will be inserted to a depth of 15-30mm in five highly sensitive points.
89537365|NCT02717195|Experimental|Double-blind Treatment (DBT) Period, Lu AF35700 10 mg|Eligible patients from PC Period (based on criteria to which investigator and patient are blinded), will be randomly assigned (1:1:1) double-blind treatment in DBT Period, 10 weeks
89469466|NCT03299439|Active Comparator|acupuncture at lowly/non-sensitive points|Sterile, single-use filiform acupuncture needles (Hwato Needles, Sino-foreign Joint Venture Suzhou Hwato Medical Instruments Co., China) with a length of 40 mm and a diameter of 0.30 mm will be inserted to a depth of 15-30mm in five low/non-sensitive points.
89469467|NCT03299439|No Intervention|no acupuncture (waiting-list)|Patients in the waiting-list group will not receive any acupuncture intervention during the study.
89018975|NCT00300092|Active Comparator|Cephalexin|Group 2 received cephalexin at 50 mg/kg divided 3 times daily for 7 days
89018976|NCT00300131||1|Bioabsorbable Vascular Solutions (BVS) Everolimus Eluting Coronary Stent System
89469468|NCT03370029||Primary ciliary dyskinesia patients|Primary ciliary dyskinesia patients will be included in study. Inclusion and exclusion criteria were considered.
89469469|NCT03370029||Healthy individuals|Those without diagnosed chronic disease will be included in study. Inclusion and exclusion criteria were considered.
89469470|NCT02038946|Experimental|Arm 1: Nivolumab|Nivolumab 3 mg/kg injection by Intravenous for every 2 weeks until disease progression or discontinuation due to toxicity
89469471|NCT03377985|Active Comparator|axillary brachial plexus block group|Patients placed in the supine position with arm to be blocked abducted and externally rotated. After sterilization of the axilla ultrasound device with high frequency of 8-12 MHZ, linear transducer was put parallel to the anterior axillary fold at axilla to identify the axillary artery, lateral, medial and posterior cords of the brachial plexus in relation to the axillary artery. Lidocaine 1% was infiltrated subcutaneously 1 cm lateral to the probe, 7-10 ml of bupivacaine 0.5% was injected around each cord of the brachial plexus
89469472|NCT03377985|Active Comparator|supraclavicular brachial plexus block group|patients placed in the supine position with the head of the bed elevated 30 degrees and patient's head turned away from the side to be blocked after skin disinfection, ultrasound device was put transversely parallel to and above the middle third of the clavicle, the probe was tilted till identification of the subclavian artery, 1st rib, pleura and brachial plexus lateral to the subclavian artery and above the 1st rib. Lidocaine 1% was infiltrated subcutaneously 1 cm lateral to the lateral side of the probe. A needle was inserted in plane 1 cm lateral to the probe when adjacent to brachial plexus 25 ml of bubivacaine 0.5% was injected around the brachial plexus
89469473|NCT03377907|Active Comparator|Ketamine in hematoma block|Ketamine used in hematoma block
89469474|NCT03377907|Active Comparator|ketamine intravenous anesthesia|ketamine used in local intravenous anesthesia
89469475|NCT03377907|Active Comparator|lidocaine intravenous anesthesia|2.5 mg/kg of lidocaine 2% diluted with saline to a total volume of 40 ml.
89469476|NCT05082350|Experimental|Healthy Group,|Daily consumption of 4 cloves of black garlic, not cooked, during 12 weeks
89469477|NCT05082350|Experimental|Hypercholesterolemia|Daily consumption of 4 cloves of black garlic, not cooked, during 12 weeks
89469478|NCT05082272||Preterm neonates with bronchopulmonary dysplasia with pulmonary hypertension|Preterm neonates who continued need for respiratory support persisting at 36 weeks corrected postmenstrual age and diagnosed with pulmonary hypertension on echocardiographic examination
89469479|NCT05082272||Preterm neonates with bronchopulmonary dysplasia and without pulmonary hypertension|Preterm neonates who continued need for respiratory support persisting at 36 weeks corrected postmenstrual age and whose echocardiographic examination were normal
89469480|NCT05082272||Healty preterm neonates|preterm neonates with neither bronchopulmonary dysplasia nor pulmonary hypertension
89469481|NCT03143829|Experimental|Intervention group|electronic Symptom Self-Management Training- CINV (eSSET-CINV) is an educational intervention administered once at the start of treatment
89469482|NCT03143829|Active Comparator|Wait Control group|The Wait control group receives the electronic Symptom Self-Management Training- CINV (eSSET-CINV) at the last study visit. Outcomes will be compared to the Intervention group at the end of the study.
89018977|NCT01785459|Active Comparator|standard care|intravenous Prochlorperazine
89018978|NCT01785459|Experimental|treatment|0.5% bupivacaine
89018979|NCT00300326|No Intervention|1|Using the same knee implant with a conventional surgical technique.
89018980|NCT00300326|Active Comparator|2|Using the same knee implant using a computer-assist surgery group is the comparator
89469483|NCT03141554|Active Comparator|Treatment Sequence Group 1|"Treatment Sequence Group 1 = A -> B -> C~Treatment A = 1% Betadine® PVP-I based mouth wash and gargle~Treatment B = 0.2% Chlor-Rinse™ Chlorhexidine based mouth wash (no alcohol)~Treatment C = Normal saline gargle (lukewarm)."
89469484|NCT03141554|Active Comparator|Treatment Sequence Group 2|"Treatment Sequence Group 2 = B -> C -> A~Treatment B = 0.2% Chlor-Rinse™ Chlorhexidine based mouth wash (no alcohol)~Treatment C = Normal saline gargle (lukewarm).~Treatment A = 1% Betadine® PVP-I based mouth wash and gargle"
89469485|NCT03141554|Active Comparator|Treatment Sequence Group 3|"Treatment Sequence Group 3 = C -> A -> B~Treatment C = Normal saline gargle (lukewarm).~Treatment A = 1% Betadine® PVP-I based mouth wash and gargle~Treatment B = 0.2% Chlor-Rinse™ Chlorhexidine based mouth wash (no alcohol)"
89469486|NCT05082194||Balance in CAA|Each of the examined post-stroke patients (CAA) performed the given test twice, with the eyes open the first time and the eyes closed the second time. Moreover, both during the Unterberger functional test and the tests on the Biodex SD balance platform, the muscle tone was assessed in the subjects using the Luna EMG device. In both tests, the patients performed each of the tests 6 times, 3 with eyes open and 3 with eyes closed, on the same day.
89469487|NCT05082194||Balance in healthy participants|Each of the examined healthy participants performed the given test twice, with the eyes open the first time and the eyes closed the second time. Moreover, both during the Unterberger functional test and the tests on the Biodex SD balance platform, the muscle tone was assessed in the subjects using the Luna EMG device. In both tests, the subject performed each of the tests 6 times, 3 with eyes open and 3 with eyes closed, on the same day.
89537366|NCT02717195|Experimental|DBT Period, Lu AF35700 20 mg|Eligible patients from PC Period (based on criteria to which investigator and patient are blinded), will be randomly assigned (1:1:1) double-blind treatment in DBT Period, 10 weeks
89469488|NCT03375099|Experimental|Lethal Means Counseling|National Guard Personnel will receive a single 15-25 minute session of lethal means counseling. The session will focus on increasing the safety of current storage practices for personal firearms (e.g., storing unloaded in a secure location separate from ammunition) as well as planning to voluntarily and temporarily store firearms away from the home during any future hypothetical suicidal crisis. This intervention utilizes a motivational interviewing framework in an effort to remain sensitive to the views and culture of firearm owners.
89469489|NCT03375099|Active Comparator|Lethal Means Counseling plus Gun Locks|National Guard Personnel will receive a single 15-25 minute session of lethal means counseling. The session will focus on increasing the safety of current storage practices for personal firearms (e.g., storing unloaded in a secure location separate from ammunition) as well as planning to voluntarily and temporarily store firearms away from the home during any future hypothetical suicidal crisis. This intervention utilizes a motivational interviewing framework in an effort to remain sensitive to the views and culture of firearm owners. Individuals in this condition will also receive a free gun (cable) lock for each of their personal firearms.
89469490|NCT03375099|Active Comparator|Health and Stress Reduction|Individuals in this condition will take part in a single 15-25 minute session focused on reducing health vulnerabilities in one of four areas: diet, exercise, sleep, or stress. This condition is designed to control for the effects of active interaction with a clinicians (e.g. common factors). As with the experimental condition, this session will utilize a motivational interviewing framework.
89469491|NCT03375099|Active Comparator|Health + Stress Reduction plus Gun Locks|Individuals in this condition will take part in a single 15-25 minute session focused on reducing health vulnerabilities in one of four areas: diet, exercise, sleep, or stress. This condition is designed to control for the effects of active interaction with a clinicians (e.g. common factors). As with the experimental condition, this session will utilize a motivational interviewing framework. Individuals randomized to this condition will also receive a free gun (cable) lock for each of their personal firearms. This will control for whether the effect of the provision of gun locks is accounted for by the simultaneous use of lethal means counseling.
89469492|NCT03141164|Experimental|Training|Computerized vision training
89469493|NCT03141164|Sham Comparator|Control|Sham
89469494|NCT03375021|Experimental|Sequence 1 PL|Eligible subjects were randomized to Sequence 1 PL in which they received placebo (P) followed by crossover to CX717 200 mg low dose (L) of active treatment
89469495|NCT03375021|Experimental|Sequence 2 PH|Eligible subjects were randomized to Sequence 2 PH in which they received placebo (P) followed by crossover to CX717 800 mg High dose (H) of active treatment
88947594|NCT01919177|Active Comparator|Nitrate rich beetroot juice|Subjects with heart failure with preserved ejection fraction will receive 140 mL of Nitrate-rich concentrated beetroot juice (containing 12 mmol of NO-3). This will be a cross-over study. Therefore all subjects will receive both interventions, but the order of the interventions will be randomized.
88947595|NCT01919177|Placebo Comparator|Nitrate depleted beetroot juice|Subjects with heart failure with preserved ejection fraction will receive 140 mL of nitrate-depleted beetroot juice (containing <0.01 mmol of NO-3).This will be a cross-over study. Therefore all subjects will receive both interventions, but the order of the interventions will be randomized.
89469496|NCT03375021|Experimental|Sequence 3 LP|Eligible subjects were randomized to Sequence 3 LP in which they received CX717 200 mg Low dose (L) of active treatment followed by crossover to placebo (P)
88947596|NCT01919203|Experimental|group R|The starting dose of remifentanil is 0.5μg/kg and a step size was 0.05μg/kg.
88947597|NCT01919242||with morbidity|patients who suffered from any type of morbidity after surgery
88947598|NCT01919242||without morbidity|patients who did not suffer from any type of morbidity after surgery
88947599|NCT01919255|Active Comparator|Picolight + Coolprep (Day-Prior)|Picolight (1p/250cc, 5PM) + Coolprep (500cc x 2, 8PM)[Day-Prior]
88947600|NCT01919255|Active Comparator|Picolight + Clicolon (Day-Prior)|Picolight (1p/250cc, 5PM) + Clicolon (4T x 4, 8PM) [Day-Prior]
88947601|NCT01919255|Active Comparator|Picolight + Coolprep (Split-Dose)|Picolight (1p/250cc, 7PM) + Coolprep (500cc x 2, 5AM)[Split-Dose]
88947602|NCT01919255|Active Comparator|Picolight + Clicolon (Split-Dose)|Picolight (1p/250cc, 7PM) + Clicolon (4T x 4, 5AM)[Split-Dose]
88947603|NCT01919268|Experimental|Electrotherapy|Combination of active interferential current with exercises of the Pilates method. Patients will receive 18 sessions of treatment over a period of 6 weeks (3 sessions/week). The exercises of the Pilates method will be individualized to each patient's needs (pragmatic treatment).
88947604|NCT01919268|Active Comparator|Pilates|Combination of placebo interferential current with exercises of the Pilates method. Patients will receive 18 sessions of treatment over a period of six weeks (3 sessions/week). The exercises of the Pilates method will be individualized to each patient's needs (pragmatic treatment).
88947605|NCT01919281|Experimental|strength training|The subjects will attend for supervised training three sessions per week for 10 weeks (9-12). The strength training program involves dynamic contraction at intensities of 60 - 70 % of 1 repetition maximum (RM) to improve strength and muscle hypertrophy. Each session will contain 8 exercises on the major muscle groups. Each drill consists of 10-12 repetitions (reps) x 3 sets separated by one minute rest between sets.
88947606|NCT01919281|Experimental|interval training|"High intensity interval training (HIT) three times per week. The three weekly supervised HIT sessions will include two 4x4 min interval sessions and one 10x1 min session. The HIT consist of uphill treadmill running/walking."
88947607|NCT01919281|No Intervention|control|Based on the Norwegian recommendation we will encourage the control group to perform 60 minutes of physical activity at moderate to high intensity on a daily basis.
88947608|NCT01919294|Experimental|testosterone undecanoate|Open label testosterone injection. Testosterone Undecanoate (1 g in 4 ml oily base) will be given as slow (2 minute) intramuscular injections (Nebido, manufactured by Bayer-Schering). These will be administered by the study investigator or designated research nurse at time zero (baseline visit 2) and after 6, 18, 30 and 42 weeks.
88947609|NCT01919320||CSS Console TAH-t Patients|All TAH-t patients implanted while supported with the CSS Console who were enrolled in the INTERMACS Registry and implanted with the TAH-t on or after June 20, 2012.
89018981|NCT05451732|Experimental|Nanofat grafting|Nanofat grafting with tissue transfer by injection in the urethral stricture
89469497|NCT03375021|Experimental|Sequence 4 HP|Eligible subjects were randomized to Sequence 2 PH in which they received CX717 800 mg High dose (H) of active treatment followed by crossover to placebo (P)
89469498|NCT03141008||Ketogenic diet exposed group|"Fibroscan changes with different diets:~Patients in a weight loss program using a ketogenic diet. Will compare differences in Fibroscan and metabolic changes."
89469499|NCT03141008||NAFLD diet exposed group|"Fibroscan changes with different diets:~Patients in a NAFLD clinic using low calorie, low fat diet. Will compare differences in Fibroscan and metabolic changes."
89469500|NCT03377829|Experimental|Percutaneous laser ablation(PLA)|Eligible participants with PTMC will be randomly assigned to this group and undergo percutaneous laser ablation(PLA). All the process is under the detection of real-time ultrasound.After surgery, all the patients will accept contrast-enhanced ultrasound(CEUS), regular ultrasound follow-up, thyroid functional detection, fine-needle aspiration biopsy(FNAB), neck CT.Per and post-operative complications, need of drug treatment, length of hospital admission and customer satisfaction will be registered.
89469501|NCT03377829|Active Comparator|Surgery|Eligible participants with PTMC will be randomly assigned to this group and undergo total/subtotal thyroid surgery.
89469502|NCT04845308||Group 1|Patients operated with an early secondary alveolar grafting between the ages of 4 to 7 years with a 3D imaging (CT, CBCT or scan) performed between the ages of 8 to 11 years.
89469503|NCT04845308||Group 2|Patients operated with a late secondary alveolar graft between the ages of 8 to 11 years with a 3D imaging (CT, CBCT or scan) performed at least 1 year after the operation.
89469504|NCT04806074|Placebo Comparator|Single-moment, unspecified delivery of food literacy information|Non-specific food-related national and international guidelines were made digitally available in a website exclusively accessible to all the participants from the comparison group.
89469505|NCT04806074|Experimental|Personalised, weekly delivery of food literacy information matched with behaviour strategies|Food-related tips - including theoretical knowledge, practical competencies, and behaviours - from national and international guidelines were specifically matched with Behaviour Change Techniques from the BCT Taxonomy v1. These personalised material were made digitally available in a website exclusively accessible to all the participants from the experimental group. Presenting each week's topic, a small video featuring the lead psychologist was also made available each week.
89469506|NCT03369873|Experimental|Nursing Orientation with guidance manual|The patients received the nursing orientation with validated guidance manual of cardiac catheterization.
89469507|NCT03369873|No Intervention|Routine Nursing Orientation|The patients received the routine nursing orientation about cardiac catheterization.
89469508|NCT04754360||Atrial fibrillation|Adult patients with atrial fibrillation
89469509|NCT03369795|Experimental|Study Drug|Methotrexate 10mg
89469510|NCT03369795|Placebo Comparator|Placebo|Pills equivalent to other study arm (10 mg)
89469511|NCT04733924|Active Comparator|Withania somnifera 125 mg|One capsule before breakfast for 84 days
88947610|NCT01919320||C2 Driver System TAH-t Patients|200 TAH-t patients implanted while supported by the Companion 2 (C2) Driver System who were enrolled in the INTERMACS Registry and implanted with the TAH-t on or after June 20, 2012.
88947611|NCT01919320||All TAH-t Patient Records|All records for TAH-t patients enrolled in the INTERMACS Registry will be reviewed to support Objective 2 of the protocol.
88947612|NCT01919333||laparoscopic ovarian cystectomy|the group who laparoscopic ovarian cystectomy are performed for endometrioma
88947613|NCT01919333||laparoscopic non- ovarian pelvic surgery|the group whom laparoscopic non- ovarian pelvic surgery are performed
88947614|NCT01919346|Experimental|Eculizumab|Eculizumab 1200 mg (diluted in Sodium Chloride (NaCl) to 5mg/mL, volume = 240 mL) will be given intraoperatively at the time of transplantation prior to reperfusion of the renal allograft and again at 900 mg (diluted in NaCl to 5mg/mL, volume = 180 mL) 12-24 hours post-transplantation
88947615|NCT01919346|Placebo Comparator|Normal Saline|Administered at same volume and time as Experimental arm
89018982|NCT01539447|Active Comparator|Naproxen|• Group 1: Naproxen 500 mg twice daily for three weeks following surgery beginning postoperative day #1
89469512|NCT04733924|Active Comparator|Withania somnifera 250 mg|One capsule before breakfast for 84 days
89469513|NCT04733924|Placebo Comparator|Microcrystalline Cellulose|One capsule before breakfast for 84 days
89469514|NCT03374865||Video-mediated consultation|Consultations using Facetalk videocommunication software
89469515|NCT03374865||Face-to-face consultation|Traditional face-to-face consultations
89469516|NCT03377751|Experimental|Additional posterior wall isolation|Operator will perform pulmonary vein isolation (PVI) and additional posterior wall isolation if low voltage area exists more than 10% of the left atrium
89469517|NCT03377751|Experimental|Voltage-guided substrate homogenization|Operator will perform pulmonary vein antrum isolation (PVI) and additional substrate modification based on the degree of low voltage area.
89469518|NCT03377751|Active Comparator|PVI only group|Operator will perform PVI only
89469519|NCT03374787|Experimental|Fusion sound processor|The sound processor picks up the sound and transfer it to the implant that convert the sound to vibrations that are transmitted to the inner ear.
89469520|NCT03140306|Experimental|Low dose CT abdomen and pelvis|Low dose computed tomography
89469521|NCT03140306|Experimental|Control dose CT abdomen and pelvis|Control dose CT abdomen and pelvis
89469522|NCT03369561||normal cardiac patient|"Full history and clinical examination ECG on the left and right side Echocardiography and measurement of both left and right ventricular functions Laboratory investigation including cardiac enzymes, CK, CK MB, and cardiac troponin I.~Serum urea and creatinine and the calculated e GFR"
89469523|NCT05078216||Cancer patients|"The exercise program consisted of a 12-week supervised intervention, with twice per week sessions of 90 minutes, and was developed in a friendly and close environment, which promoted social interaction between participants. Apart from the twice-weekly supervised sessions, as early as the fifth week, one or two individualized home-based sessions were established for each patient in order to achieve his/her specific objectives with the help of any required supporting material such as documents and video references with exercise examples.~All sessions had the same structure: 10 min of warm-up at 60-70% maximal heart rate (MHR), followed by 60-70 minutes of specific training and 10 minutes of stretching exercises. At least, 20% of the total session time was based on cardiovascular work over 70% of the maximum heart rate (MHR)"
89469524|NCT03374709|Experimental|Treatment Group|This arm includes subjects who have been prescribed Oxtellar XR 150Mg Extended Release Tablets.
89469525|NCT05387330||CP-CML patients|Twenty five newly diagnosed CP-CML patients. Plasma sCD62L and serum SPARC levels were measured using commercially available ELISA kits
89469526|NCT05387330||Control|Ten matched controls were enrolled. Plasma sCD62L and serum SPARC levels were measured using commercially available ELISA kits
89469527|NCT02519751|Experimental|D3 Creatine followed by creatine supplementation|Every participant will be orally administered with 60mg of D3 Creatine in a fasted state in a non-gelatin capsule. Creatine supplemented throughout the study will be administered in the following doses-0.03, 0.035, 0.04, 0.045 g.kg.Lean mass/day, increasing on weekly basis. Final dose of 0.05 g.kg.Lean mass/day is then maintained throughout the study.
89469528|NCT05393492|Experimental|GREMO patients|"5 months of baseline : usual care of in a medico-social service (medical, social, neuropsychological and psychological),~5 months of dialectical behavior therapy (DBT)~-DBT skills training group : during 19 weeks~5 months of follow-up : usual care of + monthly reminders of DBT intervention skills"
89469529|NCT05393492|No Intervention|Controls without brain injury|People without brain injury used as controls for linguistic markers of emotional expression regulation and free will.
89469530|NCT05393492|No Intervention|GREMO patients' family|GREMO patients' relatives, without brain injury, living with the GREMO patient and ready to complete every day and adapted self-observational diary card similar to the one of the GREMO patient
89469531|NCT05393492|No Intervention|Qualitative research ABI patients and families|Patients and relatives followed by the same medico-social service but not meeting GREMO patients eligibility criteria, participating only in the qualitative research on free will and spirituality
89469532|NCT05393414|Experimental|Opioid Sparing Multimodal Regimen|After surgery, the experimental group will receive a combination of ketorolac 30 mg intravenous (IV) every six hours for patients younger than 65 years old or ketorolac 15mg IV every six hours for those older than 65 years old; and acetaminophen 1 gram by mouth (PO) every six hours up to 72 hours
89469533|NCT05393414|Experimental|Opioid Based Multimodal Regimen|After surgery, the control group will receive a combination of morphine 0.1 mg/kg IV every six hours and oxycodone combined with acetaminophen (2.5 mg / 325 mg) two tabs PO every six hours up to 72 hours
89469534|NCT03374397|Active Comparator|SurgiGuard|Surgiguard Non-woven Drug : SurgiGuard Non-woven 6g during surgery
89469535|NCT03374397|No Intervention|Bipolar electrocauterization|Bipolar electrocauterization during surgery Drug(-)
89469536|NCT05393336|Experimental|V-sitting posture stabilization|V sitting exercises will be administered where patients will be asked to lift the torso and legs while engaging the core and abdominal muscles.
89469537|NCT05393336|Experimental|modified clamshell exercises|Participants will perform modified clamshell exercises monitored visually and using a stabilizer pressure biofeedback unit.
89469538|NCT03377595|Experimental|TAP (Transversus Abdominis Plane) block|20-mL dose of EXPAREL 266 mg expanded in volume with 20 mL normal saline plus 20 mL 0.25% bupivacaine for a total volume of 60 mL m.A 2-point classic TAP block will be performed under ultrasound guidance within 1 hour (± 30 minutes) following skin incision closure of the C-section.
89469539|NCT03377595|Experimental|Wound infiltration|20 mL of EXPAREL 266 mg expanded in volume with 40 mL normal saline for a total volume of 60 mL, infiltrated in the fascia prior to skin closure with attention to infiltrate the angles of the incision.
89018983|NCT01539447|Placebo Comparator|Placebo|• Group 2: Placebo twice daily for three weeks following surgery beginning postoperative day #1
89469540|NCT05081960||Stone Formers|Individuals who have experienced at least one incidence of calcium-based kidney stones in the last 12 months
89469541|NCT05081960||Controls|Individuals who have never had a kidney stone in their lifetime.
89469542|NCT03377439||Group A|Participants with platelet counts <32×10^9/L.
89469543|NCT03377439||Group B|Participants with platelet counts between 32×10^9/L and 132×10^9/L.
89469544|NCT03377439||Group C|Participants with platelet counts >132×10^9/L.
89469545|NCT05387252|Experimental|Low volume mulberry juice|10 ml mulberry juice containing about 48 mg polyphenols
89469546|NCT05387252|Experimental|Middle volume mulberry juice|50 ml mulberry juice containing about 240 mg polyphenols
89469547|NCT05387252|Experimental|High volume mulberry juice|100 ml mulberry juice containing about 480 mg polyphenols
89469548|NCT03369483||CPAP|At the end of the abdominal surgical procedure, mechanical ventilation withdrawal and extubation, patients will receive Continuous Positive Airway Pressure CPAP). CPAP will be be delivered using any commercially available CPAP equipment. CPAP will be started as soon as possible after the end of surgery. The starting airway pressure (PEEP) will be 5 cmH2O. PEEP may be changed at the discretion of the responsible physician. The maximum permissible PEEP during the trial intervention period will be 10 cmH2O. CPAP may be continued after the four-hour trial intervention period has finished, at the discretion of the responsible physician.
89469549|NCT04108052|Other|Low dose CT scanner and Ultra low dose CT Scan|Thoracic low dose CT acquisition and Thoracic ultra-low dose CT acquisition
89469550|NCT03369327|Experimental|sofosbuvir/daclatasvir|Once daily fixed-dose combination pill of sofosbuvir and daclatasvir for 12 weeks if the patient is non cirrhotic and for 24 weeks if cirrhotic
89469551|NCT02034500|Experimental|S. sonnei 1790GAHB - 0.1 mcg - ID|Subjects enrolled in COHORT A receiving 3 injections of S. sonnei 1790GAHB - 0.1 mcg intradermally (ID)
89469552|NCT02034500|Experimental|S. sonnei 1790GAHB - 1 mcg - ID|Subjects enrolled in COHORT B receiving 3 injections of S. sonnei 1790GAHB - 1 mcg intradermally (ID)
89469553|NCT02034500|Experimental|S. sonnei 1790GAHB - 10 mcg - ID|Subjects enrolled in COHORT C receiving 3 injections of S. sonnei 1790GAHB - 10 mcg intradermally (ID)
89469554|NCT02034500|Experimental|S. sonnei 1790GAHB - 5 mcg - IN|Subjects enrolled in COHORT A receiving 3 injections of S. sonnei 1790GAHB - 5 mcg intranasally (IN)
89469555|NCT02034500|Experimental|S. sonnei 1790GAHB - 20 mcg - IN|Subjects enrolled in COHORT B receiving 3 injections of S. sonnei 1790GAHB - 20 mcg intranasally (IN)
89469556|NCT02034500|Experimental|S. sonnei 1790GAHB - 80 mcg - IN|Subjects enrolled in COHORT C receiving 3 injections of S. sonnei 1790GAHB - 80 mcg intranasally (IN)
89469557|NCT02034500|Experimental|S. sonnei 1790GAHB - 5 mcg - IM|Subjects enrolled in COHORT C receiving 3 injections of S. sonnei 1790GAHB - 5 mcg intramuscularly (IM)
89469558|NCT02034500|Placebo Comparator|Placebo - ID|2 subjects enrolled in each COHORT A, B and C receiving 3 injections of Placebo intradermally (ID). These were pooled in one Placebo group in the analyses
89469559|NCT02034500|Placebo Comparator|Placebo - IN|2 subjects enrolled in each COHORT A, B and C receiving 3 injections of Placebo intranasally (IN). These were pooled in one Placebo group in the analyses
89469560|NCT02034500|Placebo Comparator|Placebo - IM|2 subjects enrolled in COHORT C receiving 3 injections of Placebo intramuscularly (IM)
89469561|NCT05393102||Malignant liver nodules cohort|Participants with malignant liver nodules diagnosed by pathological biopsy.
89469562|NCT05393102||Benign liver nodules cohort|Participants with benign liver nodules diagnosed by pathological biopsy or imaging examination.
89469563|NCT05393102||Uncertain benign or malignant liver nodules cohort|Participants with liver nodules could not be diagnosed definitely by imaging examination and serum protein markers.
89469564|NCT03369171|Experimental|patients with MYO armband|
89469565|NCT02519517|Experimental|permissive hypercapnia|during one lung ventilation, right ventricular function was assessed by TEE and the effect of rising PCO2 appreciated
89469566|NCT03377283|Active Comparator|AP-KTx/LTx|Transplant recipients receiving an rATG-perfused kidney or liver
89469567|NCT03377283|Placebo Comparator|CP-KTx/LTx|Transplant recipients receiving a control-perfused kidney or liver.
89469568|NCT03140228|Experimental|I-Gel group|I-gel will be used for maintenance of airway during general anaesthesia
89469569|NCT03140228|Active Comparator|LMA ambu auraonce group|LMA ambu auraonce will be used for maintenance of airway during general anaesthesia
89469570|NCT03139760|Experimental|POWERSforID|POWERSforID intervention group
89469571|NCT03139760|No Intervention|Control|Usual clinical care
89469572|NCT02890797|Other|Bronchiolitis children|Under two years old patient with bronchiolitis will have thoracic radiology
89469573|NCT03955640|Experimental|Treatment (olaparib, hyperthermia)|Patients receive olaparib PO BID. Treatment continues for 4 weeks in the absence of disease progression and unacceptable toxicity. Beginning week 2, patients also undergo hyperthermia treatment over 1 hour twice weekly for 3 weeks in the absence of disease progression and unacceptable toxicity.
89469574|NCT03369093|Active Comparator|Ampicillin arm|Ampicillin arm: Patients will receive four doses of parenteral Ampicillin and single dose of Gentamicin daily for 3-5 days
89202369|NCT00328627|Experimental|Alogliptin 12.5 + Pioglitazone 15|Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 15 mg, tablets, orally, once daily for up to 26 weeks.
89469575|NCT03369093|Experimental|Amoxicillin arm|Amoxicillin arm: Patients will receive two doses of Amoxicillin and single dose of Gentamicin daily for 3-5 days
89202370|NCT00328627|Experimental|Alogliptin 25 + Pioglitazone 15|Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 15 mg, tablets, orally, once daily for up to 26 weeks.
89469576|NCT03369015|Experimental|Placebo, then 10 mg d-amphetamine, then 20mg d-amphetamine|
89469577|NCT03369015|Experimental|Placebo, then 20 mg d-amphetamine, then 10mg d-amphetamine|
89469578|NCT03369015|Experimental|10 mg d-amphetamine, then placebo, then 20mg d-amphetamine|
89469579|NCT03369015|Experimental|10 mg d-amphetamine, then 20mg d-amphetamine, then placebo|
89469580|NCT03369015|Experimental|20 mg d-amphetamine, then 10mg d-amphetamine, then placebo|
89469581|NCT03369015|Experimental|20 mg d-amphetamine, then placebo, then 10mg d-amphetamine|
89469582|NCT05178680|Experimental|relaxation session combining music and soft light|
89469583|NCT05178680|No Intervention|usual rest session|
89469584|NCT02038322|No Intervention|The Stork|Device - The Stork - complete kit (Conceptacle and Applicator)
88947616|NCT01919359|Experimental|Facial filler w/vitamin,Placebo/Resurfacing w/vitamin, placebo|Multizyme 150C 2 caps 2 times/day between meals Day of tx for 30 days Cyruta Plus 90T 1 cap 3 times/day 30 days before and after tx or Multizyme 150C 2caps 2 times/day between meals Day of Tx for 30 days; SHEP 2caps 2 times/day 30 days before and after Tx Cellular Vitality 90C 1cap 3 times/day 30 days before and after Tx
89202371|NCT00328627|Active Comparator|Placebo + Pioglitazone 30|Alogliptin placebo-matching tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.
89469585|NCT03140072|Experimental|AZD9898|In Part 1 of the study, 5 single dose cohorts are planned to be evaluated, where AZD9898 will be administered. Eight subjects will participate in each cohort. Within each cohort, 6 (alternatively 8 or 10) subjects will be randomized to receive a single dose of AZD9898. Fifteen asthma patients are planned to participate in 3 cohorts in Part 2. Five patients will participate in each cohort. Within each cohort, 4 (alternatively 6 or 8) patients will be randomized to receive a single dose of AZD9898. In Part 3, 3 dose cohorts are planned. Nine healthy subjects will participate in each cohort. Within each cohort, 6 (alternatively 8, 10 or 12) subjects will be randomized to receive AZD9898. The subjects taking part in one of the MAD cohorts under fasted conditions will also take part in Part 3B in order to explore the influence of food on the PK of AZD9898.
89537367|NCT02717195|Experimental|DBT Period, Continued treatment from PC Period|Eligible patients from PC Period (based on criteria to which investigator and patient are blinded), will be randomly assigned (1:1:1) double-blind treatment in DBT Period,10 weeks. Patients in this arm will continue with same the treatment and dose as at last visit of PC Period
89537368|NCT03066219|Active Comparator|BRM421 Ophthalmic Solution|The active control with BRM421 solution
89537369|NCT03066219|Placebo Comparator|Placebo|The vehicle solution
89469586|NCT03140072|Placebo Comparator|Placebo|In Part 1 of the study, 5 single dose cohorts are planned to be evaluated, where matching placebo will be administered. Eight subjects will participate in each cohort. Within each cohort, 2 (alternatively 3) subjects will be randomized to receive a single dose of matching placebo. Fifteen asthma patients are planned to participate in 3 cohorts in Part 2. Five patients will participate in each cohort. Within each cohort, one patient (alternatively 2 or 3 patients) will be randomized to receive a single dose of matching placebo. In Part 3, 3 dose cohorts are planned. Nine healthy subjects will participate in each cohort. Within each cohort, 3 (alternatively 4) subjects will be randomized to receive matching placebo.
89469587|NCT03374241|Experimental|Cohort 1|HM15211 or Placebo (single dose, subcutaneous injection)
89469588|NCT03374241|Experimental|Cohort 2|HM15211 or Placebo (single dose, subcutaneous injection)
89469589|NCT03374241|Experimental|Cohort 3|HM15211 or Placebo (single dose, subcutaneous injection)
89469590|NCT03374241|Experimental|Cohort 4|HM15211 or Placebo (single dose, subcutaneous injection)
89469591|NCT03374241|Experimental|Cohort 5|HM15211 or Placebo (single dose, subcutaneous injection)
89469592|NCT03890744|Experimental|ModraDoc006/r|Weekly ModraDoc006/r treatment as ModraDoc006 (oral docetaxel) 10mg tablets combined with ritonavir 100mg tablets
89469593|NCT03374163|Experimental|treatment group who recived intralipid|71 patients who recived intralipid on day of embryo transfer day, pregnancy day.
89469594|NCT03374163|No Intervention|control group|71 patient not recived intralipid
89469595|NCT03137732|Active Comparator|Surgeon-inserted|Rectus sheath catheter will be inserted under direct vision / palpation of the space at the end of the operation.
89469596|NCT03137732|Active Comparator|Anaesthetist-inserted|Rectus sheath catheter will be inserted under ultrasound guidance by the anaethetist.
89469597|NCT03374007|Experimental|GB226 1mg/kg single-dose|Geptanolimab, 1mg/kg, i.v., single-dose
89469598|NCT03374007|Experimental|GB226 3 mg/kg single-dose|Geptanolimab, 3mg/kg, i.v., single-dose
89469599|NCT03374007|Experimental|GB226 10mg/kg single-dose|Geptanolimab 10mg/kg, i.v., single-dose
89469600|NCT03374007|Experimental|GB226 1mg/kg multiple dosing, every 2 weeks|Geptanolimab, 1mg/kg, i.v., q2w*6
89469601|NCT03374007|Experimental|GB226 3mg/kg multiple dosing,every 2 weeks|Geptanolimab, 3mg/kg, i.v., q2w*6
89469602|NCT03374007|Experimental|GB226 10mg/kg multiple dosing, every 2 weeks|Geptanolimab,10mg/kg, i.v., q2w*6
89469603|NCT03374007|Experimental|GB226 280mg multiple dosing|Geptanolimab, 280mg, i.v., q3w
89469604|NCT03374007|Experimental|GB226 3mg/kg multiple dosing|Geptanolimab, 3mg/kg, i.v., q2w
89469605|NCT05392244||active group|Active PNS was defined as a serum albumin concentration of <2.5 g/dL and a urinary protein excretion of >40 mg/m2 per hour with high cholesterol levels.
89469606|NCT05392244||partial remission group|Partial remission PNS was defined as symptoms between active group and complete remission group.
89469607|NCT05392244||complete remission group|PNS in remission was defined as no proteinuria using the colorimetric qualitative test and a urinary protein/creatinine ratio of <0.2 on a random urine sample.
88947617|NCT01919359|Placebo Comparator|Soft Tissue filler sugar pill|"Placebo Analog 2tabs 2 times/day between meals; Day of tx for 30 days; Placebo Analog 1tab 3 times/day 30 days before and after tx or Placebo Analog (A) 2~1cap 2 times/day between meals; Day of Tx for 30 days Placebo Analog (B) 2caps 2 times/day 30 days before and after Tx Placebo Analog (C) 1cap 3 times/day 30 days before and after Tx"
88947618|NCT01919372|Active Comparator|Conventional assistance|Usual treatment of obesity in terms of monitoring lifestyle habits
89469608|NCT04525521||Non-Atopic Individuals|Individuals with no history of atopic dermatitis, food allergy, asthma, or allergic rhinitis will be recruited to this cohort. Skin studies (transepidermal water loss and skin tape strips) will be performed on the non-dominant hand at baseline, after hand sanitizer use, and after hand washing with soap and water.
89469609|NCT04525521||Individuals with Atopic Dermatitis|Individuals with history of atopic dermatitis will be recruited to this cohort. Skin studies (transepidermal water loss and skin tape strips) will be performed on the non-dominant hand at baseline, after hand sanitizer use, and after hand washing with soap and water.
89469610|NCT05392166|Active Comparator|case|
89469611|NCT05392166|Active Comparator|control|
89469612|NCT03139292|Experimental|ProSeal Laryngeal Mask Airway|Intravenous (0.02mg/kg Midazolam and 2 microgram/kg Fentanyl) and oxygen via a face mask will be administered. Two minutes later, general anesthesia will be induced using 2 mg/kg intravenous Propofol mixed with 25 mg Lidocaine Injected over 30 seconds, Mask ventilation commence and continue for at least 30 seconds until conditions are suitable for PLMA insertion
89469613|NCT03139292|Experimental|AmbuAuraGain Laryngeal Mask Airway|Intravenous (0.02mg/kg Midazolam and 2 microgram/kg Fentanyl) and oxygen via a face mask will be administered. Two minutes later, general anesthesia will be induced using 2 mg/kg intravenous Propofol mixed with 25 mg Lidocaine Injected over 30 seconds, Mask ventilation commence and continue for at least 30 seconds until conditions are suitable for AmbuAuraGain Laryngeal Mask Airway insertion
89469614|NCT03137654|Active Comparator|Affective Training|Subjects complete baseline assessment, 3 wks of training with versions of the tasks using emotionally-laden stimuli, and a post-training assessment. Subjects will be contacted monthly for 3 months after discharge for follow-up interviews.
89469615|NCT03137654|Active Comparator|Neutral Training|Subjects complete baseline assessment, 3 wks of training with versions of the tasks using neutral stimuli, and a post-training assessment. Subjects will be contacted monthly for 3 months after discharge for follow-up interviews.
89537370|NCT05594355|Experimental|Arm 1|Treatment with EGb 761® (TEBOFORTAN 240 mg) during 24 months.
88947619|NCT01919372|Experimental|Telemedic assistance|telemedical assistance with a technological system to provide a continuous monitoring of lifestyle habits and individualized treatment of obesity
88947620|NCT01919385|Experimental|type 1 diabetes|Predictive Low Glucose Minimizer (PLGM) System
88947621|NCT01919424|Active Comparator|'The English-Wright nebulizer'|The English-Wright nebulizer will be used to perform a methacholine challenge.
88947622|NCT01919424|Active Comparator|Trudell AeroEclipse*II BAN nebulizer|The Trudell AeroEclipse*II BAN nebulizer will be used to perform a methacholine challenge
88947623|NCT01919437|Experimental|Web-Enabled Cognitive Neuropsychological Evaluation System|
89469616|NCT03137654|No Intervention|Control (Non-active)|Subjects complete a baseline assessment and a secondary assessment approximately three weeks later. No active intervention is delivered. Subjects will be contacted monthly for 3 months after discharge for follow-up interviews.
89469617|NCT03136640|Experimental|ModraDoc006/r|Weekly ModraDoc006/r treatment as ModraDoc006 (oral docetaxel) 10mg tablets combined with ritonavir 100mg tablets
89469618|NCT03604237|Experimental|Targeted forceps biopsy|In this group, an endoscopist takes a forceps biopsy at depressed mucosa or large nodular area of large colorectal tumors after meticulous surface evaluation.
89469619|NCT03604237|No Intervention|Conventional forceps biopsy|In this group, an endoscopist takes a forceps biopsy at the most convenient area of large colorectal tumors.
89469620|NCT02675439|Experimental|Dose escalation monotherapy|ADU-S100 administered intratumorally on Days 1, 8 and 15 of each 28-day cycle until unacceptable toxicity, progressive disease and/or treatment is discontinued; starting dose 50 micrograms
89469621|NCT02675439|Experimental|Dose escalation combination|ADU-S100 administered intratumorally on Days 1 and 8 of each 21-day cycle (starting dose 200 micrograms) and ipilimumab, i.v., (3 mg/kg) on day 1 of each 21-day cycle for the first 4 cycles. Dosing is continued until unacceptable toxicity, progressive disease and/or treatment is discontinued
89469622|NCT02035423|Active Comparator|Male Guidance School|Non-Fortified Milk 120IU Milk 200IU Milk
89469623|NCT02035423|Active Comparator|Female Guidance|Non-fortified Milk 120IU Milk 200IU Milk
89469624|NCT02035423|Active Comparator|Male Highschool|Non-Fortified Milk 120IU Milk 200IU Milk
89469625|NCT02035423|Active Comparator|Female Highschool|Non-Fortified Milk 120IU Milk 200IU Milk
89469626|NCT03124641|Experimental|Hypothermic oxygenated perfusion (HOPE)|Application of Hypothermic machine perfusion (HOPE) for 1-2 hours
89469627|NCT03124641|Active Comparator|Conventional cold storage (CCS)|Conventional cold storage
89469628|NCT05104970|Active Comparator|SunnyD STAT softgel capsule|Cholecalciferol 200000 IU
89469629|NCT05104970|Placebo Comparator|Placebo SunnyD STAT softgel capsule|Olive oil only
89469630|NCT05104970|Active Comparator|SunnyD insta ampoule|Vitamin D3 200000 IU
89469631|NCT05104970|Placebo Comparator|Placebo SunnyD insta ampoule|Olive oil only
89469632|NCT03604081|Experimental|Intervention Group|One hour of intense massed practice of lower extremity either in the form of shaping or task practice
89469633|NCT03604081|Placebo Comparator|Control Group|Conventional physical therapy for 1 hour as per current standard of care that follows stroke clinical practice guideline.
89469634|NCT03368703|Experimental|COPD patients|COPD patients group
89469635|NCT03368703|Active Comparator|Healthy subjects|Healthy subject group, matched with COPD patients group on age, weight and BMI
89469636|NCT03604003|Experimental|bedtime dosing ARB for hypertension|bedtime administration of potassium losartan has benefit for the isolated nocturnal hypertension
89469637|NCT03604003|Experimental|bedtime dosing ARB for the prognosis|bedtime administration of potassium losartan has benefit for the prognosis of CKD patients
89469638|NCT05391854|Active Comparator|Pep2dia|
89469639|NCT05391854|Placebo Comparator|Placebo|
89469640|NCT03607669||Healthy Controls|Healthy volunteers of similar age and gender
89469641|NCT03607669||Ischaemic Cardiomyopathy|Patients with ischaemic cardiomyopathy and NYHA II-III heart failure
89469642|NCT03607669||Hypertrophic Cardiomyopathy|Patients with hypertrophic cardiomyopathy and NYHA II-III heart failure
89202372|NCT00328627|Experimental|Alogliptin 12.5 + Pioglitazone 30|Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.
89469643|NCT03607669||Dilated Cardiomyopathy|Patients with dilated cardiomyopathy and NYHA II-III heart failure
89469644|NCT02518581|Other|Doubly labelled water|
89469645|NCT05391776|Experimental|A single ascending dose of TST002 Intervenous Injection|Four single dose cohorts are designed in this study, 8 subjects will be enrolled in each cohort, Subjects in each dose group were randomized to receive TST002 or placebo in a ratio of 3:1.
89469646|NCT05391776|Placebo Comparator|A single ascending dose of placebo Intervenous Injection|Four single dose cohorts are designed in this study, 8 subjects will be enrolled in each cohort, Subjects in each dose group were randomized to receive TST002 or placebo in a ratio of 3:1.
89469647|NCT03607591|Active Comparator|Active rTMS group|One daily session: active 15Hz frequency, pulse intensity 100% of the rTMS, 60 pulses per train, inter-train pause of 15 sec, 40 stimulation trains for a total of 2400 pulses in 13 min of stimulation). 15 sessions (3 weeks of 5 consecutive daily sessions and 2 days of rest)
89469648|NCT03607591|Placebo Comparator|Placebo rTMS group|One daily session: inactive 15Hz frequency, pulse intensity 100% of the rTMS, 60 pulses per train, inter-train pause of 15 sec, 40 stimulation trains for a total of 2400 pulses in 13 min of stimulation). 15 sessions (3 weeks of 5 consecutive daily sessions and 2 days of rest)
89469649|NCT03364010|Experimental|Dyslexic and non dyslexic Children|Children aged 10-12 Evaluation of proprioception Evaluation of motor learning Evaluation of written language
89469650|NCT03607513|Experimental|Single Ascending Dose (SAD)|The SAD part will consist of 6 escalating dose cohorts and 1 fed cohort of healthy male participants, 2 dose escalating cohorts of healthy female participants, and 1 solid dose formulation (capsule) cohort of healthy male participants, who will be dosed after completion of the dose escalation cohorts. Participants in each cohort (except for the solid dose formulation cohort) will receive JNJ-64264681 or Placebo on Day 1, orally. In the solid dose formulation cohort, participants will receive JNJ-64264681 capsule on Day 1. Doses for the female cohorts and fed cohort will be selected based on safety, tolerability, pharmacokinetics (PK),and pharmacodynamic (PD) data from preceding cohorts and the dose for the solid dose formulation cohort will be selected and approximately equal to a dose previously studied in the single ascending dose cohorts.
89469651|NCT03607513|Experimental|Multiple Ascending Dose (MAD)|The MAD part will consist of 3 dose escalation cohorts of males and females. Participants will receive once-daily oral doses of JNJ-64264681 or placebo for 10 consecutive days.
89469652|NCT03373617||General anesthesia group|Patients in general anesthesia group are scheduled to undergo RIRS under general anesthesia.
89469653|NCT03373617||Spinal anesthesia group|Patients in spinal anesthesia group are scheduled to undergo RIRS under spinal anesthesia
89469654|NCT03607435|Experimental|Test Article Scanning|Spectroscopy for Analyte Quantification
89469655|NCT03122288|Experimental|Individualized Cognitive Training|Participants randomized to this arm will receive 20 hours of computerized cognitive training in the two predominate cognitive domains in which they experience deficits that contribute to their HIV-Associated Neurocognitive Disorder diagnosis.
89469656|NCT03122288|Other|No-Contact Control|Participants in this arm will not receive any experimental or sham contact. They will only participate in the Baseline and Posttest assessments.
89469657|NCT03368469|Experimental|transcranial direct current stimulation|Transcranial direct current stimulation (35 sq cm anode over left dorsolateral prefrontal cortex, 35 sq cm cathode over right supraorbital area, 1 mA current, 20 min per treatment session, 1 session per day, 10 treatment sessions over two weeks)
89537371|NCT05594355|No Intervention|Arm 2|No Treatment during 12 months and treatment with EGb 761® (TEBOFORTAN 240 mg) for the next 12 months.
89537372|NCT05646927||Group Child Preference|The children will prefer parents (mother or father) who will accompany them in the preoperative holding area and at induction.
89537373|NCT05646927||Group None|The parent of the children who will accompany them during the perioperative period will be determined according to randomization.
89537374|NCT04702919||Healthy volunteers|
88947624|NCT01919463|No Intervention|Control Group|Colonoscopy is completed without abdominal compression by GI assistants. Live image of magnetic endoscopic imaging system is shown to investigators for study but not to the colonoscopist for facilitating the intubation process.
88947625|NCT01919463|Experimental|Experimental Group 2 (Monitoring)|Colonoscopy is completed with abdominal compression by GI assistants. Live image of magnetic endoscopic imaging system is shown to investigators for study but not to the colonoscopist for facilitating the intubation process. The colonoscopist directs GI assistants to conduct compression by his subjective judgement.
88947626|NCT01919463|Experimental|Experimental Group 1 (Guiding)|Colonoscopy is completed with abdominal compression by GI assistants. Live image of magnetic endoscopic imaging system is shown both to investigators for study and to the colonoscopist for facilitating the intubation process. The colonoscopist directs GI assistants to conduct compression according to the guidance of magnetic endoscopic imaging system.
88947627|NCT01919476|Active Comparator|Control Meal: Bagel, cream cheese|Control meal consists of bagel with cream cheese and apple juice.
88947628|NCT01919476|Experimental|Almond Meal: Bagel, almond butter|Almond meal consists of bagel with almond butter and apple juice.
88947629|NCT01919502|Other|Semi-quantitative urine pregnancy test|Semi-quantitative urine pregnancy test (Quanti5 Multilevel hCG Pregnancy Test)
88947630|NCT01919515|Other|ZR Crown & Stainless Steel Crown|Each subject will have a maximum of one ZR Crown and one Stainless Steel Crown cemented on primary molars that are treatment planned for a crown.
88947631|NCT01919528|Experimental|axillary vein catheterization|central venous catheter placement into the axillary vein under ultrasound guidance
88947632|NCT01919541|Other|Prehabilitation|All patients will receive a prehabilitation program involving an individualized exercise and nutrition program 4 weeks before surgery. Whole body protein kinetics and insulin resistance will be determined at the beginning of the program and at the end of the program.
89469658|NCT03603769|Experimental|Group A: Food Supplement (Salmon Polar Lipids) Intervention|"Experimental: After fasting overnight, subjects will come to our metabolic unit where in a randomized and double blinded way they will be provided several versions of the food supplement either of stomach resistant (intestine release) or stomach non-resistant (stomach release) each containing either 0.25 (Low Dose) or 0.50 g (High Dose) of Salmon Polar Lipids (SPL)~Assessment & outcome measured: Blood samples will be taken from each subject at baseline (0 hours) and after 1-4 hours of the SPL-food supplement intervention. Aggregation of platelets will be assessed in these samples as previously described (see references 1-4), in order to evaluate the postprandial effects of this supplement on platelet aggregation.~Other blood coagulation parameters will also be evaluated, such as prothrombin time, fibrinogen, Activated partial thromboplastin time Plasma lipid profile (levels of plasma Total Cholesterol, LDL, HDL and Triglycerides) and serum CRP levels will also be assessed."
89469659|NCT03603769|Placebo Comparator|Group B: Consumption of Placebo Comparator|"Experimental: After fasting overnight subjects will come to the metabolic unit in UL at 08.00 am where in a randomized and double blinded way they will be provided a placebo capsule containing only glycerin.~Assessment & outcome measured: Blood samples will be taken from each subject at baseline (0 hours) and after 1-4 hours of the placebo administration. Aggregation of their platelets will be assessed as previously described (see references 1-4), in order to evaluate the postprandial effects of this supplement on platelet aggregation.~Other blood coagulation parameters will also be evaluated, such as prothrombin time, fibrinogen, Activated partial thromboplastin time Plasma lipid profile (levels of plasma Total Cholesterol, LDL, HDL and Triglycerides) and serum CRP levels will also be assessed."
89469660|NCT03052010|Other|PrEP for HIV-1 uninfected partners and ART for HIV-1 infected|Integrated PrEP as a bridge to ART HIV-1 prevention strategy
89469661|NCT03368391|Other|Sequence 1|"All participants will be exposed to all study medications during 3 subsequent visits with a 1 week washout between visits.~Sequence 1 participants will receive the drugs in the following sequence: 1) tetracaine HCl and oxymetazoline HCl 2) 3% mepivacaine 3) 2% lidocaine with 1:100,000 epi"
89469662|NCT03368391|Other|Sequence 2|"All participants will be exposed to all study medications during 3 subsequent visits with a 1 week washout between visits.~Sequence 2 participant will receive the drugs in the following sequence: 1) 2% lidocaine with 1:100,000 epi 2) tetracaine HCl and oxymetazoline HCl 3) 3% mepivacaine"
89469663|NCT03368391|Other|Sequence 3|"All participants will be exposed to all study medications during 3 subsequent visits with a 1 week washout between visits.~Sequence 3 participants will receive the drugs in the following sequence: 1) 3% mepivacaine 2) 2% lidocaine with 1:100,000 epi 3) tetracaine HCl and oxymetazoline HCl"
89469664|NCT02035501|Active Comparator|L-Tyrosine|
89469665|NCT02035501|Placebo Comparator|Placebo|
89469666|NCT03603691|Active Comparator|Modified Manual Muscle Test|The MMMT will be tested in a test-retest design
89469667|NCT03603691|Active Comparator|Neurostatus BMRC|The Neurostatus BMRC measures Strength and will be used in a test-retest design
89469668|NCT03603691|Active Comparator|MicroFET2|The MicroFET2 is a hand held dynamometer to measure strength
89469669|NCT02509442|Other|Diffusion of direct electric stimulation|Neurosurgery awakened
89469670|NCT03373305|Experimental|Treatment (brentuximab vedotin, lenalidomide)|Patients receive brentuximab vedotin IV over 30 minutes on day 1 and lenalidomide PO QD on days 1-14. Treatment repeats every 21 days for up to 17 courses in the absence of disease progression or unacceptable toxicity.
89469671|NCT03603613|Experimental|EPP: Entrepreneurship Programme|EPP: Entrepreneurship Programme: Youth randomized into the EPP-only arm will receive GIZ's employment programming within two weeks after the completion of the baseline assessments. The GIZ-supported EPP program includes six training modules. The modules include skills related to entrepreneurship, financial literacy, and skills building.
89537375|NCT05634915|Experimental|Individual dose of ATG|The total individual ATG dose was calculated based on population pharmacokinetic modeling. ATG was intravenously infused every day from day -5 to day -2.
89537376|NCT05634915|Active Comparator|ATG 10mg/kg|The total ATG dose was 10mg/kg. ATG was intravenously infused every day from day -5 to day -2.
89469672|NCT03603613|Experimental|EPP+YRI|EPP+YRI: Youth randomized into the EPP+YRI arm will begin the Entrepreneurship programme within two weeks of baseline assessments. The entrepreneurship modules will occur for 15 days for 5 hours each day, 5 days per week. Immediately following the EPP, youth will begin receiving the YRI. The YRI curriculum (12 modules), will be delivered twice weekly over the course of 6 weeks. Each session lasts approximately 90-minutes, with additional time taken as needed. These sessions assume a peer-to-peer group learning format deemed culturally appropriate for a setting like Sierra Leone where limited resources for mental health services exist. Once youth complete the YRI they will complete a post-intervention quantitative assessment.
89469673|NCT03603613|No Intervention|Control|Control: Youth randomized into the control arm will be quantitatively assessed at the same time points as youth randomized into the two treatment arms (baseline and post-intervention). Due to access to funding and feasibility, youth in the control arm will not have the opportunity to receive the YRI once the study period concludes. However, GIZ is conducting a phased roll out of their EPP programming, meaning they will offer their EPP throughout 2018 past their participation in Youth FORWARD. The list of youth from the control group will be provided to GIZ so they can participate in the future phases. Youth will also be compensated for their participation in our quantitative assessments.
89469674|NCT05391464|Active Comparator|Peripheral Nerve Block|Participants will receive an ultrasound-guided, single shot PNB using 30ml 0.5% bupivacaine with 10mg dexamethasone. The anatomic location of the block will be determined by the anesthesiologist and will vary according to fracture location and anticipated surgical approaches. Intraoperative sedation will be used at the discretion of the anesthetic team.
89469675|NCT05391464|Active Comparator|General Anesthesia +/- PNB|GA will be administered in the operating room by a nurse anesthetist, with support from the anesthesiologist. GA will be induced with propofol and fentanyl and maintained with sevoflurane or desflurane and fentanyl. Doses will be determined by the anesthesiology team.
89469676|NCT03607279||NGAL - retropubic radical prostatectomy|Plasma NGAL was determined at baseline, 6 and 12 hrs after induction of anaesthesia
89469677|NCT03607279||NGAL - robotic radical prostatectomy|Plasma NGAL was determined at baseline, 6 and 12 hrs after induction of anaesthesia
89469678|NCT03367767||1|Former AREDS2 and AREDS2 Follow-On participants
89469679|NCT03139214|Experimental|Intervention|Parenting intervention, 7 weekly sessions, each session 2 hours in length.
89469680|NCT03139214|No Intervention|Control|3 mailings about child development and stress management.
89469681|NCT03602443|Experimental|Experimental|This group will receive the LSVT(R)BIG Intervention first (4 weeks) and then cross over to the Waitlist Control (no intervention for 4 weeks).
89469682|NCT03602443|Other|Waitlist Control|This group will receive the Waitlist Control (4 weeks) and then cross over to receive the LSVT(R)BIG Intervention (4 weeks).
89469683|NCT03376815||prostate ,traditional sample method|Samples from 100 patients with prostate carcinoma were obtained by traditional sampling method
89469684|NCT03376815||prostate ,landscape sample method|Samples from 100 patients with prostate carcinoma were obtained by landscape sampling method to testify the clinical value and significance of tumor landscape pathological diagnosis .
89469685|NCT03376815||liver, traditional sample method|Samples from 100 patients with liver cancer were obtained by traditional sampling method.
89469686|NCT03376815||liver,landscape sample method|Samples from 100 patients with liver cancer were obtained by landscape sampling method to testify the clinical value and significance of tumor landscape pathological diagnosis .
89469687|NCT03376815||esophageal ,traditional sample method|Samples from 100 patients with esophageal carcinoma were obtained by traditional sampling method.
89469688|NCT03376815||esophageal ,landscape sample method|Samples from 100 patients with esophageal carcinoma were obtained by landscape sampling method to testify the clinical value and significance of tumor landscape pathological diagnosis .
89469689|NCT03376815||GIST,traditional sample method|Samples from 100 patients with gastrointestinal stromal tumor were obtained by traditional sampling method.
89469690|NCT03376815||GIST,landscape sample method|Samples from 100 patients with gastrointestinal stromal tumor were obtained by landscape sampling method to testify the clinical value and significance of tumor landscape pathological diagnosis .
89469691|NCT03376815||colorectal ,traditional sample method|Samples from 100 patients with colorectal carcinoma were obtained by traditional sampling method.
89469692|NCT03376815||colorectal ,landscape sample method|Samples from 100 patients with colorectal carcinoma were obtained by landscape sampling method to testify the clinical value and significance of tumor landscape pathological diagnosis .
89469693|NCT03376815||pancreatic ,traditional sample method|Samples from 100 patients with pancreatic carcinoma were obtained by traditional sampling method.
89469694|NCT03376815||pancreatic,landscape sample method|Samples from 100 patients with pancreatic carcinoma were obtained by landscape sampling method to testify the clinical value and significance of tumor landscape pathological diagnosis .
89469695|NCT03376815||lung cancer,traditional sample method|Samples from 100 patients with lung cancer were obtained by traditional sampling method.
89202373|NCT00328627|Experimental|Alogliptin 25 + Pioglitazone 30|Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.
89469696|NCT03376815||lung cancer,landscape sample method|Samples from 100 patients with lung cancer were obtained by landscape sampling method to testify the clinical value and significance of tumor landscape pathological diagnosis .
89469697|NCT03376815||Renal ,traditional sample method|Samples from 100 patients with renal carcinoma were obtained by traditional sampling method.
89469698|NCT03376815||Renal carcinoma,landscape sample method|Samples from 100 patients with renal carcinoma were obtained by landscape sampling method to testify the clinical value and significance of tumor landscape pathological diagnosis .
89469699|NCT03376815||Breast cancer,traditional sample method|Samples from 100 patients with breast cancer were obtained by traditional sampling method.
89469700|NCT03376815||Breast cancer,landscape sample method|Samples from 100 patients with breast cancer were obtained by landscape sampling method to testify the clinical value and significance of tumor landscape pathological diagnosis .
89469701|NCT03376815||cervical ,traditional sample method|Samples from 100 patients with cervical carcinoma were obtained by traditional sampling method.
89469702|NCT03376815||cervical ,landscape sample method|Samples from 100 patients with cervical carcinoma were obtained by landscape sampling method to testify the clinical value and significance of tumor landscape pathological diagnosis .
89469703|NCT03139136|Active Comparator|MBS2320|
88947633|NCT01919554|Placebo Comparator|Placebo Sub Lingual Immunotherapy Tablets (SLIT)|Placebo tablets Matching the HDM allergen extract Sub Lingual Immunotherapy Tablets
89469704|NCT03139136|Placebo Comparator|Placebo|
88947634|NCT01919554|Experimental|SLIT of HDM allergen extracts|Sublingual Immunotherapy Tablets of House Dust Mite allergen extracts
89469705|NCT03376737|Experimental|Apatinib + Pemetrexed|Apatinib + Pemetrexed
89469706|NCT03607201||Diabetic|History of diabetes prior to Acute Coronary Syndrome
89469707|NCT03607201||Non-diabetic|No documented history of diabetes prior to Acute Coronary Syndrome
89469708|NCT03139058|Other|prevalence of cirrhosis|Study the prevalence of cirrhosis in patients with VADS cancer
89469709|NCT03373227|Experimental|Prospective|25 adult male or female recipients of a heart transplant will be prospectively enrolled to once-daily therapy with Envarsus tablets. Time of initiation will follow current standard of care.
89469710|NCT03373227|No Intervention|Retrospective|25 age/gender-matched subjects who are receiving twice daily dosing with Prograf will be identified from the transplant center database and contacted to be consented, after which their results will be analyzed retrospectively.
88947635|NCT01919567||Normal team|"Subjects who have problem at third molar of impacted tooth need to receive a surgery with general anesthesia.~Subjects must:~Should have a blood exam (20ml) before the surgery.~Site staff must:~Collect subjects' saliva once a day (in the morning before breakfast) for 3 consecutive days.~Collect a 0.5x0.5Cm2 tissue sample around third molar during the surgery."
88947636|NCT01919567||Oral dysplasia|"Subjects who are diagnosed with dysplasia of oral cavity.~Subjects must:~Should have a blood exam (20ml/each time) before the surgery and 3 months after the surgery.~In the case the disease recurs after the surgery, subjects need to receive the surgery again and take another blood exam before the surgery and 3 months after the surgery.~Before the surgery site staff must:~Collect saliva once a day (in the morning before breakfast) for 3 consecutive days.~Collect a 0.5x0.5Cm2 tissue sample of the tumor during the surgery."
89469711|NCT03607123||Baseline|After implantation of pacemaker, the pacing mode and the lower rate of pacemaker will be set as VDD and 50/45 bpm respectively, to get the baseline burden of atrial fibrillation without atrial pacing. Except for beta-blockers digoxin, and CCB to control heart rate, anti-arrhythmic drugs (AAD) will not be prescribed. Patients who can not tolerate will drop out. After follow-up of at least 3 month, patients with AF lasting longer than one minute detected by pacemaker will go to next group / stage (Atrial Pacing, Step1).
89469712|NCT03607123||Atrial Pacing (Step 1)|After Baseline and after follow-up of at least 3 month, patients with AF lasting longer than one minute detected by pacemaker will come to this group /stage (Atrial Pacing). At this stage, the pacing mode and the lower rate of pacemaker will be set as DDD and 70/60 bpm respectively, to perform relatively high-rate atrial pacing. Except for beta-blockers digoxin, and CCB to control heart rate, anti-arrhythmic drugs (AAD) will not be prescribed. After follow-up of at least 3 month, patients with AF lasting longer than one minute detected by pacemaker will go to next group/stage (AAD, Step1).
89469713|NCT03607123||AAD (Step 2)|After Step 1, and after follow-up of at least 3 month, patients with AF lasting longer than one minute detected by pacemaker will come to this group/stage. Anti-arrhythmic drugs including propafenone, amiodarone and dronedarone will be prescribed. After follow-up of at least 6 month, patients with AF lasting longer than one minute detected by pacemaker will go to next group/stage (RFCA, Step3).
89469714|NCT03607123||RFCA (Step 3)|After Step 2, and after follow-up of at least 6 month, patients with AF lasting longer than one minute detected by pacemaker will come to this group/stage (RFCA, Step3). Patients will receive catheter ablation of AF, up to patients' willingness. After follow-up of at least 12 month, patients without AF lasting longer than one minute detected by pacemaker will go to next group/stage (SAFE PAF-SND II).
89469715|NCT03607123||SAFE PAF-SND II|After RFCA, and after follow-up of at least 12 month, patients without AF lasting longer than one minute detected by pacemaker will come to this group/stage (SAFE PAF-SND II). At this stage, the pacing mode and the lower rate of pacemaker will be set as VDD and 40 bpm respectively. If the patient can not tolerate, the the pacing mode and the lower rate of pacemaker will be set as DDD/DDDR and 60 bpm. If the patient has no symptom related to bradycardia, he/she will be followed up until the end of this study.
89469716|NCT02484716|Experimental|Timolol|Timolol 0.5% eye-drops solution packaged in a nasal spray device.
89469717|NCT02484716|Placebo Comparator|Placebo|NaCl solution packaged in a nasal spray device.
89469718|NCT03367611|Experimental|Immunochemical faecal occult blood test|All participants will collect a single faecal sample for haemoglobin measurement (immunochemical faecal occult blood test, iFOBT), and be examined by colonoscopy.
89469719|NCT03602365|Experimental|OXYGEN CONSUMPTION SINGLE ARM|Single arm Study Volunteer will h lie in supine posture for 20 min and oxygen consumption(VO2) will be measured in duplicate. Gentle Jogger (GJ) will be started in supine posture for 20 min and VO2 measured again in duplicate. The subject will be asked to sit in a chair for 20 min and VO2 will be measured in duplicate. Gentle Jogger (GJ) will be started in seated posture for 20 min and VO2 measured again in duplicate.
89469720|NCT03367455||ARIC and JHS participants|A combined cohort of Atherosclerosis Risk in Communities (ARIC) Study and Jackson Heart Study (JHS) participants
89469721|NCT03607045|Placebo Comparator|control group|bouquet technique
89469722|NCT03607045|Active Comparator|test group|headless screw
89469723|NCT03373149|Experimental|Growth hormone/HPuFSH/GnRH antagonist|The patients receive growth hormone
89469724|NCT03373149|Active Comparator|HPuFSH/GnRH antagonist|Growth hormone is not used
89469725|NCT03138902|Experimental|Glucose Tolerance Beverage|75 g. of a fruit punch flavored oral glucose solution
89469726|NCT03603379|Experimental|C225-ILs-dox i.v.|C225-ILs-dox administered intravenously
89469727|NCT05386784|Active Comparator|Raloxifen plus cholecalciferol|Raloxifene 60mg + Cholecalciferol 800 IU
89469728|NCT05386784|Active Comparator|Cholecalciferol|Cholecalciferol 800 IU
89469729|NCT03602287|Active Comparator|2% lignocaine|In the Lignocaine group, 2.5 ml of 2% of lignocaine is diluted with 2.5 ml of distilled water, and the 5ml solution will be injected into the Merocel pack 15 minutes before removal of the pack. Nothing will be done to the opposite nostril, which would act as a control.
89469730|NCT03602287|Placebo Comparator|Normal saline|In the Normal saline group, 5 ml of normal saline was injected into the Merocel pack 15 minutes before removal of the pack. Nothing will be done to the opposite nostril.
89469731|NCT03372915|Active Comparator|Standard Exposure|This arm will receive exposure therapy conducted according to standard care practices.
89469732|NCT03372915|Experimental|Exposure + Inhibitory Learning|This arm will receive exposure therapy conducted according to principles of inhibitory learning.
88956490|NCT05085327|Experimental|ChapStick Lip Moisturizer Black Cherry|Single topical application: 80 +/- 2 mg (2.0 +/- 0.05 mg/cm^2) of ChapStick Lip Moisturizer Black Cherry will be applied to the assigned test site using a fingercot. Test material will be evenly spread over the test site using light pressure for 35 +/- 15 seconds.
89469733|NCT03373929|Other|PFO Closure Rate|Evaluate closure rate of clinically relevant septal defects including PFO, ASD (less than 1 cm with redundant septal tissue), trans septal puncture sites, repair of ASA (when an appropriate PFO or small ASD defect is present) and rate of recurrent neurologic embolic event in patients with cryptogenic stroke and PFO
89469734|NCT03373929|Other|Published PFO Device Closure|Compare PFO closure rate and safety of closure of septal occluders in published PFO clinical trials.
89469735|NCT03606811|Active Comparator|fluroscopic guided block|
89469736|NCT03606811|Experimental|double modality guided block|
89469737|NCT03137498|Experimental|Lidocaine|Lidocaine 1.5mg/kg IVPB in 50ml normal saline over 10 minutes (active experimental) and normal saline 1ml intravenous push injection (placebo)
89469738|NCT03137498|Active Comparator|Ketorolac|Ketorolac 30mg (1ml) intravenous push injection (active intervention) and Normal saline 50ml IVPB over 10 minutes (placebo)
89469739|NCT03606733|Experimental|A custom made Suprachoroidal needle for macular diseases|A custom made 30 gauge needle offering 1000 micron penetration of the sclera at the parsplana
89469740|NCT05377814|No Intervention|Passive control|The (passive) control condition includes the same questionnaire as the experimental group, however participants are not presented with the intervention.
89469741|NCT05377814|Experimental|Intervention (volitional help sheet)|"Participants in the intervention group will be asked to form implementation intentions with respect to wearing face coverings. Participants will be presented with the stem If I am tempted not to wear a face covering consistently… and given 10 options with which to complete as many if-then plans as they like. These ten options have been taken from the literature and have been shown to be effective with respect to changing numerous behaviours, including self-harm, smoking, alcohol consumption and physical activity."
89469742|NCT03602209|Experimental|4 weeks of treatment|
89469743|NCT03602209|Active Comparator|6 weeks of treatment|
89469744|NCT05372822|Experimental|Burst SCS|Burst Spinal cord stimulation. SCS system implanted and burst stimulation given
89469745|NCT05372822|Sham Comparator|Sham SCS|Sham spinal cord stimulation. SCS system implanted but no stimulation given.
89469746|NCT03367377|Experimental|LY3209590|Escalating doses of LY3209590 administered by subcutaneous (SC) injection
89469747|NCT03367377|Active Comparator|Insulin glargine|Insulin glargine administered by SC injection
89469748|NCT03138980|Experimental|Mobile application|
89469749|NCT02519127|Experimental|Low glycaemic load diet|Subjects will be following a low glycaemic load diet, typically high in polyphenols, proteins, vegetables, pulses, fibres and nuts, and low in glycemic carbohydrates, for six continuous weeks.
89469750|NCT02519127|Experimental|Western diet|Subjects will be following a western diet, typically high in saturated fat, refined sugars and salt, and low in fruit and vegetables and fibers, for six continuous weeks.
89469751|NCT03602131|Experimental|ChiCGB|Treated with chidamide, cladribine, gemcitabine and busulfan(ChiCGB) therapy followed by autologous hematopoietic stem cell transplantation.
89469752|NCT03137420||Severely injured patients and their relatives|Severely injured patients (ISS > 16) and their relatives. Relatives are defined as on of the following: spouse/partner, son/daughter, parent, sibling, cousin.
89469753|NCT03137420||Monotrauma patients and theri relatives|Patients with isolated non-life threatening musculo-skeletal injuries and their relatives (control). Relatives are defined as on of the following: spouse/partner, son/daughter, parent, sibling, cousin.
89469754|NCT03376503|Experimental|Pegcyte (Nanogen pegfilgrastim)|pegcyte 6 mg in the first cycle
89469755|NCT03376503|Active Comparator|Neulastim (Roche pegfilgrastim)|Neulastim 6 mg in the first cycle
89469756|NCT03603067||monophthalmic group|The BCVA of the worse eye is less than 0.05 or CFOV is less than 5°. The better eye need to receive ocular surgery.
89469757|NCT03603067||Normal group|The BCVA of the worse eye is more than 0.3 and CFOV is more than 10°. One of two eyes need to receive ocular surgery.
89469758|NCT03138746||HBO|On day 2, the participant will undergo a 2-hour hyperbaric exposure breathing 100% oxygen
89469759|NCT03138746||Hyperbaric air|On day 2, the participant will undergo a 2-hour hyperbaric exposure breathing air
89469760|NCT05851599|Experimental|SKF7® - 375 mg|Patients who meet the entry criteria for the study will be randomized to receive 375 mg SKF7® for 16 weeks
89469761|NCT05851599|Experimental|SKF7® - 562.5 mg|Patients who meet the entry criteria for the study will be randomized to receive 562.5 mg SKF7® for 16 weeks
89469762|NCT05851599|Experimental|SKF7® - 750 mg|Patients who meet the entry criteria for the study will be randomised to receive 750 mg SKF7® for 16 weeks
89469763|NCT05851599|Placebo Comparator|Placebo|Placebo
89469764|NCT05851521|Experimental|Temporary prostatic stent (Exime®)|Post-operative placement of temporary prostatic stent (EXIME)
89469765|NCT05851521|Active Comparator|Indwelling catheter|Post-operative placement of indwelling catheter
88947637|NCT01919567||Oral cancer|"Subjects who suffer from oral cancer.~Subjects must:~Should have a blood exam (20ml/each time) before the surgery and 3 months after the surgery.~In the case the disease recurs after the surgery, subjects need to receive the surgery again and take another blood exam before the surgery and 3 months after the surgery.~Before the surgery site staff must:~Collect subjects' saliva once a day (in the morning before breakfast) for 3 consecutive days.~Collect a 0.5x0.5Cm2 tissue sample of the tumor during the surgery."
89469766|NCT05851495|No Intervention|home-based exercise groups|home exercise brochures were given to the home-based exercise groups according to their diagnosis at the end of the treatment. Then, all patients were called to the hospital for control after three months and the scale prepared by us and consisting of a total of 5 (five) questions was directed to the patients and it was determined how the exercises given were performed. Five different exercises were given to patients with low back and neck pain who participated in our study. The patients were asked to do these exercises 3 times a day for 10 repetitions. Cat-camel exercises, lumbar stretching, sit-ups, bridge building and back extensor strengthening exercises were given to patients with low back pain. For patients with neck pain, neck flexion-extension, neck lateral flexion, neck rotation, shoulder capsule stretching and shoulder flexion exercises were given.
89537377|NCT00701441||Control group: healthy individuals without OSA|healthy individuals without OSA who are matched in weight and age to the participating OSA patients
89469767|NCT05851495|Experimental|physiotherapists-led groups|The group involved in physiotherapists-led groups was shown the exercises in practice and under the supervision of the physiotherapist, the patients applied their exercises throughout their treatment. Then, all patients were called to the hospital for control after three months and the scale prepared by us and consisting of a total of 5 (five) questions was directed to the patients and it was determined how the exercises given were performed. Five different exercises were given to patients with low back and neck pain who participated in our study. The patients were asked to do these exercises 3 times a day for 10 repetitions. Cat-camel exercises, lumbar stretching, sit-ups, bridge building and back extensor strengthening exercises were given to patients with low back pain. For patients with neck pain, neck flexion-extension, neck lateral flexion, neck rotation, shoulder capsule stretching and shoulder flexion exercises were given.
89469768|NCT05851495|Experimental|home-based follow up groups|Home-based follow up groups, after the exercise training was given to the patients with a physiotherapist, daily text messages (SMS) were sent to the patients and the patients were reminded to do the exercises. Then, all patients were called to the hospital for control after three months and the scale prepared by us and consisting of a total of 5 (five) questions was directed to the patients and it was determined how the exercises given were performed. Five different exercises were given to patients with low back and neck pain who participated in our study. The patients were asked to do these exercises 3 times a day for 10 repetitions. Cat-camel exercises, lumbar stretching, sit-ups, bridge building and back extensor strengthening exercises were given to patients with low back pain. For patients with neck pain, neck flexion-extension, neck lateral flexion, neck rotation, shoulder capsule stretching and shoulder flexion exercises were given.
89469769|NCT05851482|Experimental|GERD|Patients with GERD symptoms
89469770|NCT05851456|Experimental|R130 Treatment Group|Every 7-14 days,1-6 ml R130 （concentration of 1x10^8 plaque-forming Units/mL,PFU/mL）will be injected intratumoral in patients with relapsed/refractory bone and soft tissue tumors.
89469771|NCT05851417|Experimental|Live donors|Live kidney donors (healthy volunteers).
89469772|NCT05851417|Experimental|Native kidney damage|Patients with native kidney damage (suspected active glomerular or interstitial lesion).
89469773|NCT05851417|Experimental|Kidney transplants|Patients with kidney transplant.
89469774|NCT05851404||South East Asian Region (SEAR)|Patients that underwent thyroidectomy for indeterminate thyroid nodules in the SEAR
89469775|NCT05851404||Americas Region (AMR)|Patients that underwent thyroidectomy for indeterminate thyroid nodules in the AMR
89469776|NCT05851404||Eastern Mediterranean Region (EMR)|Patients that underwent thyroidectomy for indeterminate thyroid nodules in the EMR
89469777|NCT05851404||the Europe Region (EUR)|Patients that underwent thyroidectomy for indeterminate thyroid nodules in the EUR
89469778|NCT05851404||Western Pacific Region (WPR)|Patients that underwent thyroidectomy for indeterminate thyroid nodules in the WPR
89469779|NCT05851391|Other|Burst Suppression EEG Target|Anesthetic will be titrated to achieve burst suppression on continuous EEG (50-99% attenuation/suppression) for 24 hours.
89469780|NCT05851391|Other|Seizure Suppression EEG Target|Anesthetic will be titrated to achieve seizure suppression on continuous EEG for 24 hours.
89469781|NCT05851339||PCNL|PCNL group applicants will answer SF-36 questionnaire
89469782|NCT05851339||RIRS|RIRS group applicants will answer SF-36 questionnaire
89469783|NCT05851274|Experimental|Transradial access|In this group, the transradial access (TRA) was used, which was to puncture the radial artery and insert a radial sheath to establish a surgical pathway for embolization of the aneurysm.
89469784|NCT05851274|Active Comparator|Transfemoral access|In this group, transfemoral access (TFA) was used to embolize the aneurysms, which was to puncture the femoral artery and insert the femoral sheath to establish a surgical pathway for embolizing the aneurysm.
89018984|NCT00300638||1- MRI and interviews|In our research, we are trying to understand where in the brain these emotional behaviors take place, and whether or not the brain functions differently for alcoholic and nonalcoholic individuals. We present emotional words and pictures on a computer screen, and using Magnetic Resonance Imaging (MRI) scans, we observe how the brain works when people purposefully respond to the words and pictures. Interviews, cognitive tests, and emotional measurements will also be done. Additionally, we are comparing brain structure and activation patterns in men and women, because there may be gender differences in responses to emotional stimuli.
89018985|NCT04718051|Experimental|Shen Pu Yang Gan Wan|Traditional Chinese Medicine
89018986|NCT04718051|Placebo Comparator|Placebo Comparator|Placebo Comparator
89018987|NCT04717167|Experimental|DN group|All identified MTrPs were inserted with a sterile filiform needle (0,30mm x 40mm or 0,30mm x 75mm, depending on the muscle) that moved up- and downwards until a local twitch response was elicited. When the repeated local twitch response fade away or the subject reported too much pain, the needle was removed. After the treatment, a 15 minutes break(51) was set up and the subjects were not permitted to use a hot pack or to stretch the muscle.
89018988|NCT04717167|Sham Comparator|Sham needling (SN) group|The SN technique was similar to DN, except for penetrating the muscle. In this technique, the needle only penetrated the skin and was therefore impossible to provoke a local twitch response.
89018989|NCT05373303|Experimental|Test Drug|Recombinant Human Erythropoietin Alfa, dosage : 50 IU/Kg body weight three times per week, and continued to titrated dose closely to achieve baseline Hb level 10-12g/dL
89202374|NCT00328627|Active Comparator|Placebo + Pioglitazone 45|Alogliptin placebo-matching tablets, orally, once daily and pioglitazone 45 mg, tablets, orally, once daily for up to 26 weeks.
89469785|NCT05851261|Placebo Comparator|PA3670 5 mg|Ten subjects will be randomly assigned in a ratio of 4:1 to receive 5 mg of PA3670 tablets or PA3670 placebo tablets. They will be administered a single dose and observed for four days.
89469786|NCT05851261|Placebo Comparator|PA3670 15 mg|Ten subjects will be randomly assigned in a ratio of 4:1 to receive 15 mg of PA3670 tablets or PA3670 placebo tablets. They will be administered a single dose and observed for four days.
89469787|NCT05851261|Placebo Comparator|PA3670 30 mg|Ten subjects will be randomly assigned in a ratio of 4:1 to receive 30 mg of PA3670 tablets or PA3670 placebo tablets. They will be administered a single dose and observed for four days.
89469788|NCT05851261|Placebo Comparator|PA3670 15 mg for 9days|Ten subjects will be randomly assigned at a 4: 1 ratio to receive either 15mg of PA3670 tablets or PA3670 placebo tablets, once daily for 9 days.
89469789|NCT05851261|Other|PA3670 15mg before and after meals|Ten subjects will be administered 15mg PA3670 after overnight fasting for 10 hours in the first cycle, and then will be administered 10mg PA3670 within 30 minutes after high-fat meal in the second cycle. They will receive a single dose in each cycle and will be observed for four days. The cleaning period between the two cycles is more than 7 days.
89469790|NCT05851261|Other|PA3670 15mg after and before meals|Ten subjects will be administered 15mg PA3670 within 30 minutes after the high-fat meal in the first cycle, and then will be administered 10mg PA3670 after overnight fasting 10 hours in the second cycle. They will receive a single dose in each cycle and will be observed for four days. The cleaning period between the two cycles is more than 7 days.
89469791|NCT05851248|Experimental|Buccal muco-gingival tissue graft|
89469792|NCT05851248|Active Comparator|Palatal connective tissue graft|
89469793|NCT05851235|Experimental|Colorectal cancer patients|Patients with colon or rectal cancer awaiting surgery
89469794|NCT05851131||Family physicians|Family physicians working in Turkey who gave consent to participate in the study.
89469795|NCT05851105|Experimental|Experimental|Three transfusion-dependent α-thalassaemia subjects aged 12-35 years will be reinfused with α-globin restored autologous hematopoietic stem cells modified with LentiHBA T>C
89469796|NCT05851092|Experimental|HRS-2189 Tablets|
89469797|NCT05851079||1. Stratified experimental design|Relying on the project's clinical multicenter to recruit patients for routine HPV screening in hospital outpatient clinics, for HPV high-risk type-positive subjects. The subjects with positive HPV types will continue to undergo TCT and colposcopic biopsy, and the remaining specimens after routine screening will be collected for high-throughput HPV typing and integrated assays. The sensitivity and accuracy of high-throughput HPV typing and integrated assays were compared with conventional screening methods.
89469798|NCT05851079||2. Parallel experimental design|A multicenter cohort of 12,000 permanent residents was recruited for routine cervical cancer screening(HPV+TCT combined screening), and the remaining specimens were collected after the conventional screening to test the indexes of high-throughput HPV typing and integrated assays. The sensitivity and accuracy of high-throughput HPV typing and integrated assays were compared with conventional screening methods.
89469799|NCT05851079||3. Prospective cohort study design:|Based on a multicenter cohort of cervical cancer screening based on the project group, 3000 cervical cancer patients with HPV-positive routine screening and colposcopic biopsies were enrolled. The cohort was followed up regularly for 3 years with routine HPV+TCT and colposcopy, and cervical biopsy if necessary. And specimens remaining after routine screening will be collected for testing of high-throughput HPV typing and integrated assays.
89469800|NCT05851053||Breast cancer survivors|Survivors of BC, diagnosed ≥11 years ago, who received chemotherapy and/or radiotherapy
89469801|NCT05851053||Reference population|Age and GP matched reference population without a history of cancer
89469802|NCT05851040||With Wheatgrass, tulsi formulation|People using Wheatgrass and Tulsi formulation or individual
89469803|NCT05851040||With Wheatgrass, tulsi formulation and allopathic drugs|People using Wheatgrass and Tulsi formulations or individuals with chronic disease medicine.
89469804|NCT05851040||Same age group not using any medication|
89469805|NCT05851027|Experimental|QL0911 Group 1|Starting dose 1μg/kg；PLT 100~200×10^9/L
89469806|NCT05851027|Experimental|QL0911 Group 2|Starting dose 2μg/kg；PLT 100~200×10^9/L
89469807|NCT05851027|Experimental|QL0911 Group 3|Starting dose 2μg/kg；PLT <100×10^9/L
89469808|NCT05851014|Experimental|GB491 combined with Letrozole|
89469809|NCT05851014|Placebo Comparator|Placebo combined with Letrozole|
89469810|NCT05851001|Experimental|Progressive muscle relaxation|"A CD recorded by the Turkish Psychological Association was provided to explain relaxation techniques to Progressive muscle relaxation group (PMR ) participants. The CD contains relaxation exercises instructions and there is relaxing music in the background. This CD consists of two parts. The first part(11 minutes) gives short information about the content and how exercises should be done. It consists of information about deep relaxation. In the second part, there are 27 minutes of relaxation exercises accompanied by command with background music.~PMR exercise consists of four stages: stretching-relaxation (1st stage -approximately 20 minutes), autogenic training - only relaxation (2nd stage approximately 10 minutes), deep breathing training-breathing relaxation (3rd stage approximately 3-4 minutes), rapid relaxation (4th stage--a few seconds)."
89469811|NCT05851001|Sham Comparator|Relaxation music|A CD recorded by the Turkish Psychological Association was provided to RM group participants. It consists of 30 minutes relaxing music only. The participant was asked to just listen to music with without working in a private room.
89469812|NCT05851001|No Intervention|Control|In this group, participant were assessed without any other intervention.
89469813|NCT05850975|Experimental|mindful breathing|
89469814|NCT05850975|Experimental|deep breathing|
89469815|NCT05850975|Experimental|cognitive therapy|
89469816|NCT05850975|Experimental|dare response|
89469817|NCT05850975|Experimental|defusion|
89469818|NCT05850975|Experimental|in flow with fear|
89469819|NCT05850975|Experimental|gratitude practice|
89469820|NCT05850975|Experimental|guided mindfulness|
89469821|NCT05850975|Experimental|muscle relaxation|
89469822|NCT05850975|Experimental|reframe your fears|
89469823|NCT05850975|Experimental|calming visualization|
89469824|NCT05850975|Experimental|reflective writing|
89469825|NCT05850975|Placebo Comparator|reading about anxiety|
89469826|NCT05850975|No Intervention|do what you would usually do|
89469827|NCT05850962|No Intervention|Standard MAP target|The comparator or the control group will be comprised of patients assigned to standard care, where vasopressor support will be titrated to maintain a default MAP of 65 mmHg, unless the treating clinician considers a different MAP target as more appropriate.
89537378|NCT00701441||OSA group|Patients in the OSA group receive CPAP for 12 weeks as part of their care. patients with OSA provide measures at baseline and after 12 weeks of CPAP treatment.
89537379|NCT05582031|Experimental|Regorafenib 90 mg + Tislelizumab 300 mg (Rego-Tisle)|The trial will include 8 cohorts of patients, with each cohort considered as a single-arm; all patients enrolled will be treated with regorafenib at a dose of 90 mg orally once daily, on days 1 to 21 of a 28 cycle in combination with tislelizumab 300 mg intravenously day 1 (of a 28 day cycle).
89469828|NCT05850962|Active Comparator|Individualised MAP target|"In the intervention arm, a patient's own pre-illness mean arterial pressure (MAP) would be targeted (range: 55-95 mmHg) during vasopressor support in ICU. The pre-illness MAP will be estimated from most recent pre-illness BP readings following a standardized method (Panwar et al,. Blood Press. 2017:1-9) and will be targeted for the duration of vasopressor therapy for up to a maximum of five days. The treating clinician can tailor these BP targets as deemed suitable for current clinical state. The type of vasopressor that will be used is at the discretion of the treating clinician.~Study intervention will cease if a patient is considered well enough by the treating clinician for discharge out of ICU. If a patient is transported out of ICU for procedural intervention, then standard (non-study) treatment should be provided."
89469829|NCT05850949|Experimental|Konjac-Grain|Without supplementation, followed by Supplementation with Konjac grain from PT. AMBICO
89469830|NCT05850936|Experimental|Intervention arm|medical reduction of IOP by eyedrops
89469831|NCT05850936|No Intervention|control arm|follow up without medication
89469832|NCT05850871|Experimental|CAZ/AVI plus Aztreonam|CAZ-AVI was administered at the dose of 2.5 g every 8 hours and ATM at the dose of 2 g every 8 hours
89469833|NCT05850871|Active Comparator|Conventional treatment|Other active antibiotics were administered, including colistin, tigecycline, fosfomycin, meropenem.
89469834|NCT05850858||Cirrhotic Patients with Spontaneous Bacterial Peritonitis|
89469835|NCT05850858||patient liver cirrhosis (child B,C)|
89469836|NCT05850858||normal individuals|
89469837|NCT05850845||CTX group in remission|The patients with idiopathic membranous nephropathy were divided into two groups: the group in remission and the group without remission after the application of cyclophosphamide. The pathological sections of the kidneys of the two groups were observed by microhyperspectral imaging system, and the differences between the two groups of patients under the spectrum were analyzed.
89469838|NCT05850845||CTX group without remission|The patients with idiopathic membranous nephropathy were divided into two groups: the group in remission and the group without remission after the application of cyclophosphamide. The pathological sections of the kidneys of the two groups were observed by microhyperspectral imaging system, and the differences between the two groups of patients under the spectrum were analyzed.
89469839|NCT05850832|Active Comparator|Group E|Esmolol group: patients received loading dose 1 mg/kg followed by maintenance dose of 30 μg/kg/min throughout the surgery
89469840|NCT05850832|Active Comparator|Group M|Magnesium sulphate group: patients received loading dose 40 mg/kg over a period of 15 mins and maintenance 15 mg/kg/h throughout the surgery.
89469841|NCT05850780|Experimental|Photobiomodulation|
89469842|NCT05850780|Active Comparator|Mineral Trioxide Aggregate (MTA)|
89469843|NCT05850754|Experimental|CBD Capsule|Participants will take capsules containing 50 mg of CBD daily for 4 weeks.
89469844|NCT05850754|Placebo Comparator|Placebo Capsule|Participants will take placebo capsules containing 0 mg of CBD daily for 4 weeks.
89469845|NCT05850702|Experimental|lidocaine|Intervention group
89469846|NCT05850702|Placebo Comparator|saline|control group
89469847|NCT05850650|Active Comparator|Controlled|The extraction socket will not receive a collagen sponge
89469848|NCT05850650|Experimental|Collagen|The extraction socket will receive a collagen sponge
89469849|NCT05850637|Experimental|Single Arm Ultra-hypofractionated|5 fractions of 5.7 Gy every other day in the breast or chest wall region, with or without the inclusion of regional lymph node drainage chains
89469850|NCT05850624|Experimental|ice massage|ice massage to hoku point for labor pain for 20 minutes
89469851|NCT05850624|Experimental|virtual animation|watching virtual animation for 20 minutes for labor pain
89469852|NCT05850624|No Intervention|Control Group|receiving standart care
89469853|NCT05850507|Experimental|Study Group|Intramuscular injection of 25μg/0.5ml Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells) in the deltoid muscle of the upper arm.
89469854|NCT05850507|Active Comparator|Control group|Intramuscular injection of 25 μg/0.5 ml recombinant novel coronavirus protein vaccine (CHO cells) into the deltoid muscle of the upper arm.
89469855|NCT05850468|Active Comparator|traditinal balanced anesthesia|fentanyl infusion after general anesthesia and erector spinea block
89469856|NCT05850468|Experimental|opioid free anesthesia|lidocaine and dextometidine infusion after general anesthesia and erector spinea block
89469857|NCT05850377||Participants with known or suspected High-Grade Gliomas|Patients with malignant gliomas undergoing neurosurgical procedures using 5-aminolevulinic acid (5-ALA)-based photodynamic therapy
89469858|NCT05850338|Experimental|Experimental|the autogenic relaxation exercise would be performed to intervention group. In the first interview, the introductory characteristics form was filled and the Menopause Specific Quality of Life Scale was completed. In addition, women were given training in line with the training booklet about the menopause period, autogenic relaxation exercise and cold pillow. After the training, autogenic relaxation exercise was taught accompanied by the autogenic relaxation exercise CD. The woman was informed about performing autogenic relaxation exercises 3 times a day and using a cold pillow when she experienced vasomotor symptoms. The autogenic relaxation exercise and cold pad application follow-up chart, which was prepared for the purpose of recording the applications, was given. The women were evaluated by being invited to the hospital at 4 and 8 weeks, and they filled out the Menopause Specific Quality of Life Scale during the follow-ups. The intervention was implemented for 8 weeks.
89202375|NCT00328627|Experimental|Alogliptin 12.5 + Pioglitazone 45|Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 45 mg, tablets, orally, once daily for up to 26 weeks.
89469859|NCT05850338|No Intervention|Control|After the women to be included in the control group were determined, individual interviews were conducted with the women in a separate room for orogenic relaxation. In the first interview, the introductory characteristics form was filled and the Menopause Specific Quality of Life Scale was completed. The women were evaluated by being invited to the hospital at 4 and 8 weeks, and they filled out the Menopause Specific Quality of Life Scale during the follow-ups. The women were followed for 8 weeks. No other intervention was applied to the women other than the standard care they received at the hospital. The women were called every week and their vasomotor symptoms were questioned.
89469860|NCT05850325|Other|Group 1: Elbow Flexed at 90 Degrees|subjects will be instructed to exercise the forearm with the elbow positioned by their side, in 90° of flexion.
89469861|NCT05850325|Experimental|Group 2: Elbow Fully Flexed|subjects will be instructed to exercise the forearm with their elbow fully flexed to achieve supination and the elbow extended to achieve pronation.
89469862|NCT06042686|Other|Repeated measures|Using a 2-day counterbalanced, within-subject repeated-measures design, 16 participants wore two mechanical compression devices, the commonly-used Kendall SCD Express 9525 (SCD) and the novel Recovery Force Movement and Compressions Device (RF-MAC) for 1 night each in their home while sleep was recorded with polysomnography. For each device, participants also completed questionnaires to assess usability, mobility, perceived noise disturbance, and perceived sleep disturbance.
89469863|NCT06042673|Experimental|Pomegranate seed oil|Participants will be asked to consume breakfast (0 minute) containing pomegranate seed oil
89469864|NCT06042673|Placebo Comparator|mixed vegetable oil|Participants will be asked to consume breakfast (0 minute) containing mixed vegetable oil
89469865|NCT06042660||newly diagnosed CML patients|
89469866|NCT06042582||Ulcerative Colitis (UC)|"subjects undergoing endoscopy and biopsies collection per standard of care~adult patients ≥18 and <60 years~clinical and endoscopic evaluation (Mayo score≥2)"
89469867|NCT06042582||Crohn's Disease (CD)|"subjects undergoing endoscopy and biopsies collection per standard of care~adult patients ≥18 and <60 years~clinical and endoscopic evaluation (Harvey-Bradshaw score ≥5 and overall simplified endoscopic score (SES-CD) >2)"
89469868|NCT06042582||NO UC/CD|"subjects undergoing endoscopy and biopsies collection (≥18 and <60 years) according to the normal clinical practice (as patients undergoing cancer surveillance, irritable bowel syndrome (IBS), diarrhea)~subjects not affected by UC or CD according to the previously reported clinical and endoscopic evaluation criteria"
89469869|NCT06042556|Experimental|Guide|Randomized to use of our IUD self-removal guide
88947638|NCT01919580||Normal team|"Subjects who have problem at third molar of impacted tooth need to receive a surgery with general anesthesia.~Subjects must:~Should have a blood exam (20ml) before the surgery.~Site staff must:~Collect subjects' saliva once a day (in the morning before breakfast) for 3 consecutive days.~Collect a 0.5x0.5Cm2 tissue sample around third molar during the surgery."
88947639|NCT01919580||Oral dysplasia|"Subjects who are diagnosed with dysplasia of oral cavity.~Subjects must:~Should have a blood exam (20ml/each time) before the surgery and 3 months after the surgery.~In the case the disease recurs after the surgery, subjects need to receive the surgery again and take another blood exam before the surgery and 3 months after the surgery.~Before the surgery site staff must:~Collect subjects' saliva once a day (in the morning before breakfast) for 3 consecutive days.~Collect a 0.5x0.5Cm2 tissue sample of the tumor during the surgery."
88947640|NCT01919580||Oral cancer|"Subjects who suffer from oral cancer.~Subjects must:~Should have a blood exam (20ml/each time) before the surgery and 3 months after the surgery.~In the case the disease recurs after the surgery, subjects need to receive the surgery again and take another blood exam before the surgery and 3 months after the surgery.~Before the surgery site staff must:~Collect subjects' saliva once a day (in the morning before breakfast) for 3 consecutive days.~Collect a 0.5x0.5Cm2 tissue sample of the tumor during the surgery."
88947641|NCT01919593|Experimental|2% Chlorhexidine Gluconate|apply 2% Chlorhexidine Gluconate in 70% Alcohol on skin before venipuncture
89469870|NCT06042556|No Intervention|No guide|Randomized to use of no additional resource
89469871|NCT06042504||Married students with no children|Submit Survey
89469872|NCT06042504||Married students with children|Submit Survey
88947642|NCT01919593|Active Comparator|10% povidone iodine|apply 10% povidone iodine on the skin before venipuncture
88947643|NCT01919632|Experimental|Lifestyle|The initial stage of the program consists of a health-behavior seminar and six weeks (twice a week for 90 minutes) of supervised endurance exercise (i.e. (?) jogging, nordic walking, cycling or swimming) in groups. In the second phase of the program, the participants receive a recommendation to continue exercise regularly unsupervised for one year, and receive monthly supervised exercise training sessions.
89469873|NCT06042504||Unmarried Students with children|Submit Survey
89469874|NCT06042504||Familial caregiver|Submit Survey
89469875|NCT06042504||Unmarried without kids|Submit Survey
89469876|NCT06042426|Experimental|Patients receiving intravenous dexamethasone|
88947644|NCT01919645|Experimental|Combined Training Group|"Combined Training - (strength + aerobics).~A combined training (CT)is performed, having aerobics exercises (AE)using a stationary bicycle and strength training in workout devices.~The strength training (ST) will be performed by isotonic exercises recruiting the main muscle groups. They exercises are: Chest Press, Leg Press, Vertical Traction, Leg Extension and Abdominal Crunch."
88947645|NCT01919645|Placebo Comparator|Control Group|The control group patients did not perform any intervention through physical exercises. They were oriented on Sleep Hygiene and were followed during the study. They were asked to come to the following visits (at weeks 8 and 16) and to 2 additional visits to get and then return the actigraph. During this period, they were followed through phone calls once a month and were asked for sleep hygiene and were reminded of their assessment dates.
88947646|NCT01919658|Active Comparator|proximal nerve block|The anesthesiologist will administer a proximal nerve block if specified in the randomization envelope.
88947647|NCT01919658|Active Comparator|distal nerve block|The anesthesiologist will administer a distal nerve block if specified in the randomization envelope.
88947648|NCT01919671|Experimental|Tongxinluo capsule|Tongxinluo capsule,4 granules,t.i.d. po,for 90 days
89469877|NCT06042426|Active Comparator|Patients receiving intravenous morphine and oral oxycodone|
89537380|NCT05581719|Experimental|Stage 1 (Allocetra-OTS monotherapy)|Dose escalation of Allocetra-OTS up to 10 x 10^9 cells by IV or IP administration.
89469878|NCT06042387||IBD Subjects|"Self-identify as:~Black, African, African American, Afro-Caribbean, Afro-Latino/a/x, or Hispanic/Latinx, Afro-Latino/a/x or any other Black or Latin or Indigenous ancestry~Available medical records to confirm IBD diagnosis (Crohn's disease, Ulcerative colitis, IBD undetermined (IBD-U)) Any age"
89469879|NCT06042387||Controls|"Self-identify as:~Black, African, African American, Afro-Caribbean, Afro-Latino/a/x, or Hispanic/Latinx, Afro-Latino/a/x or any other Black or Latin or Indigenous ancestry No personal history of IBD, no family history of IBD, no history of unexplained chronic diarrhea/blood in stool/anemia/abdominal pain/weight loss Any age"
89469880|NCT06042374|Experimental|Study group|The Progressive Core Stabilization Training was applied to study group as a group exercise with 5-10 athletes which was planned in the form of 3 days/week for a total of 9 weeks and 27 sessions.
89469881|NCT06042374|Sham Comparator|Control group|The athletes included in the CG performed only Standard Core Strengthening Exercises.
89469882|NCT06042361|Other|Intervention|All participants will receive the intervention of the Smokefree Implementation Framework and Toolkit
89469883|NCT06042348||Group 1|
89469884|NCT06042296||control group|group 1 -control group normal conjunctiva from 30 patients
89469885|NCT06042296||group 2 primary pterygia|primary pterygia samples from 30 patients
89469886|NCT06042296||group 3 recurrent pterygia|recurrent pterygia samples from 30 patients
88947649|NCT01919671|Placebo Comparator|placebo capsule|placebo capsule,4 granules,t.i.d. po,for 90 days
88947650|NCT01919684|Active Comparator|Active|LGD-6972
88947651|NCT01919684|Placebo Comparator|Placebo (Captisol®)|Vehicle Control (Captisol®)
88947652|NCT01919710|Experimental|rHSA/GCSF for injection|rHSA/GCSF Start from 300mcg
88947653|NCT01919736|Active Comparator|Moderate gait retraining|a moderate 7 degree toe-in modification
88947654|NCT01919736|Active Comparator|Mild gait retraining|A 2 degree toe-in gait retraining
88947655|NCT01919762||Bacteremia Positive Patients|"Symptomatic adult patients, confirmed via diagnostic blood culture and species identification followed by subsequent second blood culture results and species identification that are positive for each of the following species of bacteria (Target 6 Species).~Acinetobacter baumannii~Staphylococcus aureus~Klebsiella pneumonia~Pseudomonas aeruginosa~Enterococcus faecalis~Enterococcus faecium"
88947656|NCT01919762||Bacteremia Negative Patients|Adult patients confirmed via diagnostic blood culture and species identification and subsequent second blood culture and species identification as being negative for the Target 6 species
88947657|NCT01919788|Placebo Comparator|Control|"No insulin administered. Instead of insulin infusion, a small amount of saline is administered to keep the subject blinded.~Three muscle biopsies and two fat biopsies will be obtained. A palmitic acid tracer will be given to estimate fatty acid metabolism. Forearm pletysmography will be performed twice."
88947658|NCT01919788|Experimental|Insulin|Insulin (Insuman Rapid) is administered once as a bolus of 0,1 IU/kg. Three muscle biopsies and two fat biopsies will be obtained. A palmitic acid tracer will be given to estimate fatty acid metabolism Forearm pletysmography will be performed twice
89202376|NCT00328627|Experimental|Alogliptin 25 + Pioglitazone 45|Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 45 mg, tablets, orally, once daily for up to 26 weeks.
89469887|NCT06042244|Other|Control Group|Participants randomized to the control group will be put on a waitlist (passive control group) for 6 weeks. Upon completion of post-training assessment, participants in the control group will be able to receive the intervention, if they wish so.
89469888|NCT06042244|Experimental|Multimodal Exercise Group|Participants will complete 15 minutes of virtual reality treadmill training (VRTT), followed by 30 minutes of progressive evidence-based resistance training (RT), followed by other 15 minutes of VRTT.
89469889|NCT06042218|Experimental|Experimental group who trained one day a week|This intervention group will attend a weekly sixty-minute training session with the Xiaxi machine during the twelve weeks of the intervention. The sessions will include flexibility and strength-resistance work, as well as postural awareness.
89469890|NCT06042218|Experimental|Experimental group who trained two days a week|This intervention group will attend two weekly sixty-minute training sessions with the Xiaxi machine during the twelve weeks of the intervention. The sessions will include flexibility and strength-resistance work, as well as postural awareness.
89469891|NCT06042218|No Intervention|Control Group|They will not attend any type of intervention. They will continue to perform their daily activities without intervention.
89469892|NCT06042192|Experimental|TK-254RX applied to Lower Arm, Lower thigh or Ankle|"For Group1, TK-254RX will be applied to left and right side (total of two TK-254RX per day) of the following predetermined application site by subjects.~Day1: Lower Arm, Day2: Lower thigh, Day3: Ankle"
89469893|NCT06042192|Experimental|TK-254RX applied to Upper Arm, Upper thigh or Lower leg|"For Group2, TK-254RX will be applied to left and right side (total of two TK-254RX per day) of the following predetermined application site by subjects.~Day1: Upper Arm, Day2: Upper thigh, Day3: Lower leg"
89469894|NCT06042140|Experimental|NEOX Cord 1K applied fetoscopically|Patients intending to undergo open in-utero spina bifida repair will be offered to be screened for an alternative minimally invasive approach. All eligible pregnant mothers' fetuses within the trial will receive NEOX Cord 1K® as a spinal cord cover to close the developmental defect. In some cases, at the discretion of the Pediatric Neurosurgeon, NEOX Cord 1K® may be required to cover the skin. All eligible subjects meeting all inclusion criteria but none of the exclusion criteria may be enrolled.
89469895|NCT06042075||Health professionals|Health professionals working at Angers Maternity Unit include gynecologists, pediatricians, residents (gynecology and pediatric residents), childcare assistants, nursing auxiliaries and midwives.
89469896|NCT06042023|Experimental|Remote monitoring|Participants that consent to the study will undergo additional remote monitoring with the applied wearable sensor.
89469897|NCT06042010|Experimental|Test group|
89469898|NCT06042010|Active Comparator|control group|
89469899|NCT06041984|Experimental|Glycopyrrolate|Participants will receive intravenous glycopyrrolate 0.2 mg while receiving anesthetic.
89469900|NCT06041984|Placebo Comparator|Placebo|Participants will receive intravenous 1ml saline while receiving anesthetic.
89469901|NCT06041906||Neonate, Children, Adult with CPSS|
89469902|NCT06041893||ATG/LD-PTCy group|Patients undergoing haploidentical hematopoietic stem cell transplantation with ATG and low-dose post-transplant cyclophosphamide conditioning at the department of pediatrics, Samsung Medical Center
89469903|NCT06041763|Experimental|BEAR Implant|Adult patients with meniscus injury indicated for isolated meniscus repair. In the experimental group, the BEAR Implant will be utilized in the repair procedure.
89469904|NCT06041763|Active Comparator|Standard Repair|adult patients with meniscus injury indicated for isolated meniscus repair. In the standard repair group, participants will undergo an isolated meniscus repair without the implant.
89469905|NCT06041750||OSAS patients with postoperative pulmonary complication|American Society of Anesthesiologists (ASA) physical status I-III adult patients age between 18-65 years undergoing elective surgery with general anesthesia and diagnosis of OSAS will be recruited in this study. In this patient group, the incidence of postoperative early-period and long-term pulmonary complications will be investigated.
89469906|NCT06041724|Experimental|Envafolimab combined with recombinant human endostatin and first-line chemotherapy|
89469907|NCT06041698|Experimental|Group I (TXT-Chatbot )|Patients receive a text message notification and complete surveys through TXT-Chatbot Q2W for 6 months.
89469908|NCT06041698|Experimental|Group II (MyChart/Patient Portal)|Patients receive an email notification and complete surveys through MyChart/Patient Portal Q2W for 6 weeks.
89206185|NCT00297037|Placebo Comparator|2|"During the 6-week double-blind phase, all patients will be randomly assigned to receive either pimecrolimus 1% cream or its vehicle twice daily with occlusion on the affected areas. Topical application of pimecrolimus1% cream for oral erosive lichen planus for a duration of 6 weeks; ¼ gram of cream will be applied to each of the 2 sides of the mouth BID with a 2x2 gauze."
89469909|NCT06041633||Clinical|One hundred and thirty patients diagnosed with TMD constituted the study group (group I)
89469910|NCT06041633||Control|One hundred and thirty patients were excluded from having TMD based on the RDC/ TMD questionnaire, and these patients constituted the control group (group II).
89469911|NCT06041542||Case group|Collect video of hand grasping from patients with cervical spondylotic myelopathy through intelligent video analysis system.
89469912|NCT06041542||Control group|Collect video of hand grasping from normal people through intelligent video analysis system.
89469913|NCT06041542||Differentiate group|Collect video of hand grasping from Stroke and Parkinson's disease through intelligent video analysis system.
89469914|NCT06041529|Experimental|Telmisartan/Amlodipine/Chlorthalidonea 40/5/12.5 mg|Telmisartan/Amlodipine/Chlorthalidonea 40/5/12.5 mg will be orally administered during the study period
89469915|NCT06041529|Active Comparator|Telmisartan/Amlodipine/Hydrochlorothiazide 40/5/25 mg|Telmisartan/Amlodipine 40/5 mg and Hydrochlorothiazide 25 mg will be orally administered each during study period
89469916|NCT06041490|Experimental|multi-kinase inhibitors in combination with bevacizumab|TKI (Sorafenib 400mg, bid, po or Lenvatinib 8mg, qd, po if bodyweight less than 60 kg,12mg, qd, po if bodyweight more than 60kg or Donafenib：200mg, bid, po) + bevacizumab：7.5mg/kg, infusion, Q3w
89469917|NCT06041490|No Intervention|Without adjuvant therapy|No intervention.
89469918|NCT06041477|Experimental|concurrent treatment group|Participants receive two cycles of HAIC (the drugs are oxaliplatin 135mg/m2 over 3hrs, calcium folinic acid 400mg/m2 or levofolinic acid 200mg/ m2 over 1.5hrs, 5-FU 400mg/m2 over 2hrs, 5-FU 2400mg/m2 over 46hrs,every 4 weeks) in combination with targeted drug (lenvatinib 8mg/day) and immunotherapy (PD-1 antibody, dosage and frequency according to instructions), then evaluate the response of tumor, those who achieve complete response (CR) will receive surgical resection or follow-up, those with partial response (PR) or stable disease (SD) continue two cycles of combined therapy, and those with progress disease (PD) will be withdrawn and receive other treatments. After four cycles of combined therapy, second evaluation of efficacy will be performed, those who achieve CR will receive surgical resection or follow-up observation, and the other patients will be evaluated for the possibility of surgical resection or the subsequent treatment.
89469919|NCT06041477|Active Comparator|sequential treatment group|Participants receive two cycles of HAIC (drugs of oxaliplatin 135 mg/m2 over 3 hours; calcium folinic acid 400 mg/m2 or levofolinic acid 200 mg/m2 over 1. 5 hours, 5-FU 400 mg/m2 over 2 hours, and 5-FU 2400 mg/m2 over 46 hours,every 4 weeks), then evaluate the response of tumor, and those who achieve complete response (CR ) will receive surgical resection or follow-up, while other patients continue to receive two cycles of combination therapy, i.e. HAIC combined with targeted drug (levatinib 8mg/day) and immunotherapy (PD-1 antibody, dose and frequency according to instructions). After four cycles, a second efficacy assessment will be performed, and patients who achieve CR will undergo surgical resection or follow-up observation, and the other patients will be evaluated for the possibility of surgical resection or the subsequent treatment.
89469920|NCT06041464||cancer epithelial cell|cancer epithelial cells culture
89469921|NCT06041464||cancer fibroblast culture|cancer fibroblast cells culture
89469922|NCT06041451|Experimental|immunoglobulin group|This group of patients was treated with intravenous immunoglobulin(30g ivgtt qd) for 5 days
89469923|NCT06041451|Experimental|methylprednisolone group|This group of patients was treated with methylprednisolone 500 MG Injection
89469924|NCT06041451|No Intervention|control group|This group of patients was treated without immunoglobulin or hormone
89469925|NCT06041451|Experimental|mixed group|This group of patients was treated both with intravenous immunoglobulin and methylprednisolone.
89469926|NCT06041412||DPN group|Patients with type 2 diabetic peripheral neuropathy were categorized into the DPN group
89469927|NCT06041412||Diabetic group|patients with type 2 diabetes mellitus but not with DPN were distributed into the Diabetic group.
89469928|NCT06041412||control group|The other individuals without type 2 diabetes mellitus were selected as the control group
89469929|NCT06041399|Experimental|diabetic peripheral neuropathy group with hypoglycemic or lipid-lowering drugs.|Patients with type 2 diabetic peripheral neuropathy were categorized into the diabetic peripheral neuropathy group with hypoglycemic or lipid-lowering drugs group.The group treated with specific drug,like hypoglycemic or lipid-lowering drugs.
89469930|NCT06041399|No Intervention|diabetic peripheral neuropathy group without hypoglycemic or lipid-lowering drugs.|Patients with type 2 diabetic peripheral neuropathy were categorized into the diabetic peripheral neuropathy group without hypoglycemic or lipid-lowering drugs group.No hypoglycemic or lipid-lowering drugs were used in this group.
89469931|NCT06041399|Experimental|Diabetic group with hypoglycemic or lipid-lowering drugs.|Patients with type 2 diabetes mellitus but not with diabetic peripheral neuropathy were distributed into the Diabetic group with hypoglycemic or lipid-lowering drugs group. group.The group treated with specific drug,like hypoglycemic or lipid-lowering drugs.
89469932|NCT06041399|No Intervention|Diabetic group without hypoglycemic or lipid-lowering drugs.|Patients with type 2 diabetes mellitus but not with diabetic peripheral neuropathy were distributed into the Diabetic group without hypoglycemic or lipid-lowering drugs group.No hypoglycemic or lipid-lowering drugs were used in this group.
89469933|NCT06041386|Other|All Participants|All participants with clinical diagnosis of Severe asthma prescribed Mepolizumab as part of routine care.
89469934|NCT06041360||study group Study group(Group1)|"Thirty participants of the group will meet the following criteria Inclusion criteria:~Age ranges from 12 to 50 years old.~Disproportionate speech recognition score (SRS) with the hearing threshold level.~The auditory brainstem response (ABR) test with no waveform or, disturbed waves or, detectable wave V at high intense stimulus.~The otoacoustic emission (OAE) and/or cochlear microphonic (CM) potential may be present.~Exclusion criteria:~While the participants who have these criteria will be excluded from the study:~Consistent SRS and ABR response with hearing threshold level.~Abnormal finding in brain imaging.~Patients with history of diabetes and/or other causes of peripheral neuropathy."
89469935|NCT06041360||Control group (Group 2)|"Thirty participants have the following criteria:~Age and sex matched with the study group.~Patients with sensorineural hearing loss with degree of hearing matched with study group"
89469936|NCT06041321|Experimental|Reparel Sleeve|"Device size(s): Small, medium, large, x-large Device model(s): Reparel Leg Sleeve (full length) Description of each component: Fabric garment constructed of 41% Polyester embedded with a proprietary non-metal semiconductive nano-sized material, 13% Polyester, 27% Nylon, and 19% Lycra-Spandex. The top cuff of the garment has silicone grips to keep the garment from sliding down.~501k exempt: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/classification.cfm?ID=FQL Company Name: Challenger Health, LLC (dba Reparel) FDA Registration Number: 3012651665 Device Listing Number: D269770 Product Classification: Class I Medical Device, 510(k) exempt Product Code: FQL, Stocking/Medical Support"
89469937|NCT06041321|Placebo Comparator|Placebo Sleeve|Device size(s): Small, medium, large, x-large Device model(s): Generic Black Leg Sleeve Supplier: Jupin Group Co., Ltd. Description of each component: Fabric garment constructed of 80% polyester and 20% lycra
89469938|NCT06041295|Experimental|the cardiovascular surgery ICU nurse staff|on-the-job training of lung expansion therapy
89469939|NCT06041230|Active Comparator|Ultrasound guided ozone injection therapy|
89469940|NCT06041230|Active Comparator|Extracorporeal shock wave therapy|
89469941|NCT06041191||Children with GJH|Children who scored above 4 points in the hypermobility assessment made with the Beighton score were included in this group. sensory processing skills assessed with the Test of Sensory Functions in Infants
89537381|NCT05581719|Experimental|Stage 2.1 (Allocetra-OTS in combination with anti-PD-1 therapy)|Dose escalation of Allocetra-OTS up to 10 x 10^9 cells by IV or IP administration, with IV nivolumab 240 mg.
89469942|NCT06041191||Children without GJH|Children who scored below 4 points in the hypermobility assessment made with the Beighton score were included in this group. sensory processing skills assessed with the Test of Sensory Functions in Infants
89469943|NCT06041178|Experimental|scaling and root planing + 2.5% flurbiprofen on one site and placebo on contralateral site|Following scaling and root planing, the prepared 2.5% flurbiprofen was injected subgingivally in the selected deep pocket and the same was done with a placebo on the contralateral site
89469944|NCT06041178|Experimental|scaling and root planing + 98% aloe vera on one site and placebo on contralateral site|Following scaling and root planing, the prepared aloe vera was injected subgingivally in the selected deep pocket and the same was done with a placebo on the contralateral site
89469945|NCT06041178|Experimental|scaling and root planing + 2.5% flurbiprofen on one site and 98% aloe vera on contralateral site|Following scaling and root planing, the prepared 2.5% flurbiprofen was injected subgingivally in the selected deep pocket while the same was done with 98% aloe vera on the contralateral site
89469946|NCT06041165|Experimental|Experimental: JS401 injection|
89469947|NCT06041165|Placebo Comparator|Placebo|
89469948|NCT06041126||Group one|Patients with COPD according to the combined COPD assessment Global Intervention (GOLD) guidelines, participants who are in groups A and B (mild-moderate) will be included in group 1.
89469949|NCT06041126||Group two|"COPD patients according to the combined COPD assessment, according to the Global Intervention (GOLD) guidelines, participants who are in groups C and D (severe-very severe) will be included in group 2."
89469950|NCT06041061|Experimental|experiment group|According to the 0, 2, and 6 months immunization program, intramuscular injection of the upper arm deltoid muscle, 3 doses of the experiment vaccine
89469951|NCT06041061|Placebo Comparator|placebo|According to the 0, 2, and 6 months immunization program, intramuscular injection of the upper arm deltoid muscle, 3 doses of the placebo
89469952|NCT06041035|Experimental|QLS31905 + nab-paclitaxel + gemcitabine (Part A/B)|Pancreatic cancer participants will be treated with QLS31905 in combination with nab-paclitaxel and gemcitabine for part A of the study to establish the recommended dose of QLS31905 for part B. In part B, the participants will be treated with QLS31905 at a dose determined by the part A of the study in combination with nab-paclitaxel and gemcitabine.
89469953|NCT06041035|Experimental|QLS31905 + oxaliplatin + capecitabine (Part B)|In part B, gastric/gastroesophageal junction cancer participants will be treated with QLS31905 at dose determined by part A of the study in combination with oxaliplatin and capecitabine.
89469954|NCT06041035|Experimental|QLS31905 + gemcitabine+cisplatin(Part B)|In part B, other solid tumor participants including but not limited to biliary tract cancer will be treated with QLS31905 at dose determined by part A in combination with standard chemotherapy recommended by guidelines.QLS31905 plus gemcitabine+ cisplatin as the first-line treatment of advanced biliary tract cancer.
88947659|NCT01919788|Experimental|Insulin and glucose|"Insulin (Insuman rapid) is administered once as a bolus injection of 0,1 IU/kg and glucose is given at the same time to avoid hypoglycemia in this arm.~Three muscle biopsies and to fat biopsies is obtained. A palmitic acid tracer is given to estimate fatty acid metabolism Forearm pletysmography will be performed twice"
88947660|NCT01919827|Experimental|MSC endobronchial infusion|
88947661|NCT01919840|Active Comparator|Group C|• conventional protocol, volume replacement with massive bleeding.
88947662|NCT01919840|Experimental|Group ROTEM|• Protocol according to the different tests to be performed with thromboelastography
88947663|NCT01919853|Experimental|Mindfulness-Based Stress Reduction|The MBSR intervention is an 8-week course meeting 2 hours weekly. The curriculum is based on MBSR manuals with a brief CRF education component incorporated into the first and second class sessions, drawing from information from the National Comprehensive Cancer Network clinical practice guidelines for CRF. In general, the MBSR class includes guided meditation practice; mindful, gentle movement (hatha yoga); didactic material on self-regulatory responses to stress; and group discussion that includes the participants' growing incorporation of mindfulness in adapting to life experiences. Along with class time, each participant is asked to commit 20 minutes per day, six days per week to formal meditation practice using compact disk recordings of the teacher's voice.
88947664|NCT01919853|Active Comparator|Attention Control|"The attention control is an 8-week class meeting 2 hours weekly. The group sessions are supportive in tone, focus on pre-designated topics relevant to fatigue management (e.g., sleep hygiene, nutrition, exercise, emotional regulation), and involve weekly readings and open group discussion about session topics. This condition contains non-specific factors similar to MBSR (e.g., facilitator offering participants compassionate attention, empathy, genuine caring, and an opportunity to discuss what is important to them in a supportive environment); however, mindfulness is not presented/practiced in the group."
88947665|NCT01919866|Experimental|Transplantation of CD3/CD19 depleted stem cells|Patients receive a minimum dosage of 10x10E6/kg bodyweight CD3/CD19 depleted CD34+ stem cells. Maximum dosage of residual T cells will be 1x10E5/kg BW
89469955|NCT06040996|Experimental|IPSA|A new parent training program for parents with ADHD
89469956|NCT06040996|Other|Continued Routine Services|Continued Routine Services
89469957|NCT06040983|Experimental|FR-101 Dressing use|Subject will use FR-101 chest dressing on the target skin area accepted radiation therapy once every 2 days.
89469958|NCT06040944||Exposure 1|Schizophrenic patients that have been taking antipsychotic drugs inducing hyperprolactinemia (FGAs and the SGAs; amisulpride, risperidone and paliperidone) for at least 1 year
88947666|NCT01919879|Experimental|Arm A: Cetuximab + Afatinib|Afatinib 40 mg daily Cetuximab 500 mg/m2 every 2 weeks until progression
88947667|NCT01919879|Active Comparator|Arm B : Cetuximab alone|Cetuximab 500mg/m2 every 2 weeks until progression After progression: Cetuximab 500mg/m2 + Afatinib 40 mg per day until progression
88947668|NCT01919892|Experimental|Lithium 450-900mg/day|An Open-Label, 6-week Pilot Study of Flexible Dose of Lithium in Bipolar Depression: The Effectiveness of Lower Lithium Levels
89469959|NCT06040944||Exposure 2|Schizophrenic patients that have been taking antipsychotics sparing hyperprolactinemia (In SGAs; clozapine, quetiapine, olanzapine, ziprasidone and aripiprazole) for at least 1 year
89469960|NCT06040944||Non exposure (basline)|Newly diagnosed schizophrenic patients and/ or patients did not receive any psychiatric treatment for at least 1 year
89469961|NCT06040931|Active Comparator|Infrequent exacerbators (IFE) group|"15 patients with infrequent exacerbation (IFE) ≤1 exacerbation per year in the preceding 12 months before enrolment."
89469962|NCT06040931|Active Comparator|Frequent exacerbators (FE) group|"15 patients with frequent exacerbation(FE) ≥ 2 per year in the preceding 12 months before enrolment"
89469963|NCT06040892|Experimental|Group A|bilateral cochlear implant children with rehabilitation including 8 sessions with a spatialized sensory index
89469964|NCT06040892|Experimental|Group B|bilateral cochlear implant children with rehabilitation including initially 4 sessions without spatialized sensory cue followed by 4 sessions with spatialized sensory cue
89469965|NCT06040892|Active Comparator|Normal hearing volunteers|Children without known hearing loss
89469966|NCT06040879|Experimental|PENG BLOCK|receiving pain relief through PENG and LFCN block
89469967|NCT06040879|Active Comparator|PCA|receiving morphine PCA analgesia
89469968|NCT06040866|Experimental|Pain neuroscience education|In addition to the exercise training (stretching and relaxation exercises), which includes stretching and relaxation exercises routinely used in the field of physiotherapy and rehabilitation in primary dysmenorrhea, the patients in the pain neuroscience education arm will be given pain neuroscience education once a week for 2 weeks. Participants in the pain neuroscience education arm will be given pain neuroscience education once a week for 2 weeks after their first menstruation. The training will be repeated with a reminder session at the end of the 2nd menstruation.
89469969|NCT06040866|Active Comparator|Biomedical pain education|In the biomedical pain education arm, in addition to the exercise training (stretching and relaxation exercises) that includes stretching and relaxation exercises routinely applied in the field of physiotherapy and rehabilitation in primary dysmenorrhea, biomedical pain education will be given once a week for 2 weeks. Participants in the biomedical pain education arm will be given biomedical pain education once a week for 2 weeks after their first menstruation. The training will be repeated with a reminder session at the end of the 2nd menstruation.
89469970|NCT06040853|Experimental|tranexamic group|After intubation, intravenous 15mg/kg tranexamic acid will be given to the study group 10 minutes before the incision and 100 mg/h infusion will be administered until the skin is closed.
89469971|NCT06040853|Placebo Comparator|placebo group|The control group will be given intravenous 100 ml of saline
89469972|NCT06040814|Experimental|Rehabilitation Training|Rehabilitation Training is provided to patients with Liver Cirrhosis combined with sarcopenia.
89469973|NCT06040814|No Intervention|No-Rehabilitation Training|No extra training is provided to patients with Liver Cirrhosis combined with sarcopenia.
89469974|NCT06040788|Experimental|immediate implant placement with customized healing abutment|
89469975|NCT06040294|Experimental|dementia and disability simulation program (DDS)|DDS program consists of dementia virtual reality and disability simulation of activity design for seniors
89469976|NCT06040294|Active Comparator|dementia course with no DDS|Regular dementia course and group discussions of activity design for seniors with no DDS
89469977|NCT06039618||Referred to a Centre of Higher Level|Those are the newborns that were referred at the time of delivery or within one week after birth to centers of higher organizational level.
89469978|NCT06039618||Treated at the Centre of Admission|Those are the newborns that were not referred to other centers and were treated in the health facility were the birth took place, and hospitalized in the same center until discharge.
89469979|NCT06039228|Experimental|Intervention group|
89469980|NCT06038396|Experimental|Part A-Arm 1|Part A will follow the standard 3+3 dose escalation design, 3~6 participants will be allocated to the first dose group of RC118, and receive a treatment of RC118-ADC (1.0mg/kg) and Toripalimab (3.0mg/kg) followed by 14 days of dose limited toxicity (DLT) observation period.
89469981|NCT06038396|Experimental|Part A-Arm 2|Part A will follow the standard 3+3 dose escalation design, 3~6 participants will be allocated to the second dose group of RC118, and receive a treatment of RC118-ADC (1.5mg/kg) and Toripalimab (3.0mg/kg) followed by 14 days of dose limited toxicity (DLT) observation period.
88947669|NCT01919905|Active Comparator|High dose|High dose vitamin D group receiving Mozzarella cheese/pizza with 28000 IU vitD/serving once a week
88947670|NCT01919905|Placebo Comparator|Low dose|Low dose vitamin D group receiving Mozzarella cheese/pizza with 200 IU vitD/serving once a week
88947671|NCT01919918|Other|Heart Failure Patients|Patients with heart failure will undergo intervention of muscle contraction with metabolite solution administration. Maximal voluntary muscle contraction exercise with varying metabolite solution administration of adenosine triphosphate, lactate, and protons with phosphate buffer.
88947672|NCT01919918|Other|Control Participants|Healthy control participants will undergo intervention of muscle contraction with metabolite solution administration. Maximal voluntary muscle contraction exercise with varying metabolite solution administration of adenosine triphosphate, lactate, and protons with phosphate buffer.
88947673|NCT01919931||Candida Infection|Patients infected with Candida albicans
88947674|NCT01919931||No infection|Patients with no Candida albicans infection
88947675|NCT01919944|Experimental|VLY-686 20 mg|Single dose, 20 mg VLY-686, administered as two 10 mg VLY-686 oral capsules
89469982|NCT06038396|Experimental|Part A-Arm 3|Part A will follow the standard 3+3 dose escalation design, 3~6 participants will be allocated to the Thrid dose group of RC118, and receive a treatment of RC118-ADC (2.0mg/kg) and Toripalimab (3.0mg/kg) followed by 14 days of dose limited toxicity (DLT) observation period.
89469983|NCT06038396|Experimental|Part A-Arm 4|Part A will follow the standard 3+3 dose escalation design, 3~6 participants will be allocated to the last dose group of RC118, and receive a treatment of RC118-ADC (2.5mg/kg) and Toripalimab (3.0mg/kg) followed by 14 days of dose limited toxicity (DLT) observation period.
89537382|NCT05581719|Experimental|Stage 2.2 (Allocetra-OTS in combination with anti-PD-1 therapy)|Dose escalation of Allocetra-OTS up to 10 x 10^9 cells by IV or IP administration, with IV tislelizumab 200 mg.
89469984|NCT06038396|Experimental|Part B-Arm 1|Part B-Arm 1 will include approximately 20 patients with gastric cancer (including gastric esophageal junction). This subject group will receive RC118-ADC and Toripalimab (3.0mg/kg) Day 1 of every 14-day cycle. The starting dose of RC118-ADC for expansion will be derived from the RP2D determined during Part A.
89469985|NCT06038396|Experimental|Part B-Arm 2|Part B-Arm 1 will include approximately 20 patients with pancreatic cancer and other solid tumors. This subject group will receive RC118-ADC and Toripalimab (3.0mg/kg) Day 1 of every 14-day cycle. The starting dose of RC118-ADC for expansion will be derived from the RP2D determined during Part A.
89469986|NCT06037759||Cases (N=50):|Patients with incident ESKD managed by HD (n=50)
89469987|NCT06037759||Controls (N=50)|Patients with Incident ESKD managed by PD (n=20) Patients with CKD stage 3-4 (not on dialysis) with hypertension as a key risk factor for CKD and CVD (n=30)
89469988|NCT06037746|Experimental|Graston Group|Miyofascial release was performed by graston tool on the entire plantar fascia.
89469989|NCT06037746|Experimental|Percussive Massage Group|Miyofascial release was performed by theragun tool on the entire plantar fascia.
89469990|NCT06037746|No Intervention|Control Group|No application has been made.
89469991|NCT06036186|Experimental|BaroPacing treatment|Group 1 will use BaroPacing for the first 3 weeks (day 8 to day 28) and then switch to standard treatment for another 3 weeks (day 29 to day 49).
89469992|NCT06036186|Active Comparator|Standard treatment|Group 2 will use standard treatment for the first 3 weeks (day 8 to day 28) and then switch to BaroPacing for another 3 weeks (day 29 to day 49).
89469993|NCT06028776|Experimental|Intervention|This group will be offered 2 weekly sessions (45-60 min) of MS Ballroom Fitness for a period of 7 weeks. All other 'usual care' are allowed.
89469994|NCT06028776|No Intervention|Control|This group will continue their habitual living, also including whatever 'usual care' they participate in.
89469995|NCT06026423||Normal/uncomplicated healing process|100 women with a second-degree tear or episiotomy primarily sutured after labor: identified with a normal/uncomplicated healing process
89469996|NCT06026423||Dehisced wound treated with secondary resuturing|100 women with a second-degree tear or episiotomy: identified with a dehisced wound treated with secondary resuturing
89469997|NCT06026423||Dehisced wound treated with conservative management|100 women with a second-degree tear or episiotomy: identified with a dehisced wound treated with conservative management
89469998|NCT06019806|Experimental|postural correction group A|"Chin tuck (deep cervical flexor)~Strengthening shoulder retractors~Sternocleidomastoid muscle stretch~Pectoralis stretch"
89469999|NCT06019806|Active Comparator|Control group B|postural Correction education
89018990|NCT05373303|Active Comparator|Reference Drug|Recombinant Human Erythropoietin Alfa, dosage : 50 IU/Kg body weight three times per week, and continued to titrated dose closely to achieve baseline Hb level 10-12g/dL
89206186|NCT04093193|Experimental|Debridement group|Patients receive routine post-operative debridement at their Day 6, 30 and 60 follow up appointments.
89470000|NCT06019780|Experimental|Experimental interventional group A (Blood flow restriction training)|"Following exercise will be performed~Side lying external rotation~Prone horizontal abduction~Standing scaption with pneumatic cuff for blood flow restriction"
89470001|NCT06019780|Active Comparator|Control group B|"Following exercise will be performed~Side lying external rotation~Prone horizontal abduction~Standing scaption without blood flow restriction"
89470002|NCT06017323|Experimental|Dose Level 1:Proglumide TID with Gemcitabine and Nab-Paclitaxel|Proglumide given three times a day with gemcitabine and nab-paclitaxel
89470003|NCT06017323|Experimental|Dose Level 2:Proglumide BID with Gemcitabine and Nab-Paclitaxel|Proglumide given two times a day with gemcitabine and nab-paclitaxel
89018991|NCT00327600|Experimental|imexon + DTIC|
89470004|NCT06014788|Experimental|NPWTi|The whole wound was filled with black foam (Granufoam®, KCI). The instillation was performed via gravity from i.v. bag through a drain put within the foam. Chlorhexidine 0.1% 300 ml in 700 ml saline was used for continuous instillation three times daily (3 L per day) on the background of continuous pressure of 125 mmHg. The dressing changes were performed every 48-72 hours.
89470005|NCT06014788|Active Comparator|conventional NPWT|The wound was filled with black foam (Granufoam®, KCI) and covered with plastic folio. A continuous pressure of 125 mmHg was applied using the hospital suction system. The dressing changes were performed every 48 hours.
89470006|NCT06013592|Experimental|Healthy adults without obesity|Liquid meals with different caloric sizes (0-1800 kcal)
89470007|NCT06013592|Experimental|Healthy adults with obesity|Liquid meals with different caloric sizes (0-1800 kcal)
89470008|NCT06003985||Control|The control group will be comprised of patients who are not currently taking any GLP-1 agonist medications. Controls will receive the ultrasound exam to assess stomach contents.
89470009|NCT06003985||GLP-1 agonist intake|The GLP-1 agonist intake group will be comprised of patients who are currently taking any GLP-1 agonist medications. This group will receive the ultrasound exam to assess stomach contents.
89018992|NCT00300872|Active Comparator|1|Continuous positive airway pressure (CPAP)
89018993|NCT00300872|Sham Comparator|2|Sham Continuous positive airway pressure (CPAP)
89018994|NCT00300950|Active Comparator|1|Gencitabine
89018995|NCT00300950|Experimental|2|Gemcitabine with GI-4000
89206187|NCT04093193|No Intervention|Non Debridement Group|Patients will not receive debridement at any follow up visit after surgery. They will continue with saline irrigation.
89206188|NCT00292981|Experimental|C1 Esterase Inhibitor|
89470010|NCT06000501|Experimental|Adult ADHD Patients|Enrolled participants will begin with a two-week observation stabilization before starting treatment with Azstarys. Participants found to have ≥30% change in their total Adult ADHD Investigator Symptom Rating Scale (AISRS) scores during the two-week observation stabilization period treatment will be discontinued from the study. Remaining participants will be dispensed a three-week supply of Azstarys on a weekly basis.
89470011|NCT05999461||cases|behcet patients
89470012|NCT05999461||control|age and sex matched healthy volunteers
89470013|NCT05998031|Experimental|Active tDCS|AA neuroConn MR-safe 1x1 tDCS stimulator will be used to apply 12 minutes of 2.0 mA electrical current, with 30 seconds ramps up and 30 seconds ramps down. The electrical current will be applied by using two carbon rubber electrodes (one anode, one cathode) with added ten20 conductive paste. The electrode+paste will be affixed on the participant's scalp over the frontal cortices at F3 and F4 location (EEG 10-20 system). Inflow of current (anode) will occur at F4 location, and outflow of current will occur at F3 (cathode).
89470014|NCT05998031|Placebo Comparator|Sham tDCS|Sham stimulation will be performed with the same 1x1 device. Participants will receive 2 mA of direct current stimulation for 30 seconds with 30 seconds ramps up and down. This provides the tingling and prickling sensation on the scalp associated with tDCS while prevent delivering sufficient current (12 minutes) to penetrate the skull and stimulate the brain. Prep in sham conditions will be identical to active stimulation conditions. For each stimulation condition (active, sham), each participant will perform three runs of N-back working memory task (baseline/pre-stimulation, during stimulation, and after/post-stimulation) as detailed below. Sham efficacy will be evaluated as a direct comparison in N-back performance and connectivity results in active group versus sham group.
89470015|NCT05996874|Experimental|Semaglutide: 50 mL water and 30 minutes post-dose fasting|Participants will receive oral semaglutide D once daily for 10 days. Dose 1 of oral semaglutide D will be administered for the first 5 days followed by Dose 2 of oral semaglutide D for another 5 days with 50 mL water and 30 minutes post-dose fasting.
89470016|NCT05996874|Experimental|Semaglutide: 120 mL water and 30 minutes post-dose fasting|Participants will receive oral semaglutide D once daily for 10 days. Dose 1 of oral semaglutide D will be administered for the first 5 days followed by dose 2 of oral semaglutide D for another 5 days with 120 mL water and 30 minutes post-dose fasting.
89470017|NCT05996874|Experimental|Semaglutide: 50 mL water and 60 minutes post-dose fasting|Participants will receive oral semaglutide D once daily for 10 days. Dose 1 of oral semaglutide D will be administered for the first 5 days followed by Dose 2 of oral semaglutide D for another 5 days with 50 mL water and 60 minutes post-dose fasting.
89470018|NCT05996874|Experimental|Semaglutide: 120 mL water and 60 minutes post-dose fasting|Participants will receive oral semaglutide D once daily for 10 days. Dose 1 of oral semaglutide D will be administered for the first 5 days followed by Dose 2 of oral semaglutide D for another 5 days with 120 mL water and 60 minutes post-dose fasting.
89470019|NCT05996874|Experimental|Semaglutide: 50 mL water and 120 minutes post-dose fasting|Participants will receive oral semaglutide D once daily for 10 days. Dose 1 of oral semaglutide D will be administered for the first 5 days followed by Dose 2 of oral semaglutide D for another 5 days with 50 mL water and 120 minutes post-dose fasting.
89470020|NCT05996874|Experimental|Semaglutide: 120 mL water and 120 minutes post-dose fasting|Participants will receive oral semaglutide D once daily for 10 days. Dose 1 of oral semaglutide D will be administered for the first 5 days followed by Dose 2 of oral semaglutide D for another 5 days with 120 mL water and 120 minutes post-dose fasting.
89470021|NCT05994833|No Intervention|paper-based standard care exercise program|
89470022|NCT05994833|Experimental|VPT|
89470023|NCT05992701|Experimental|Directional deep brain stimulation|
89470024|NCT05987371|Experimental|TQC3721 Suspension for Inhalation (Twice a day)+ Salbutamol|TQC3721 suspension for inhalation, twice a day for 4 weeks, Salbutamol sulfate inhalation aerosol is used as required.
89470025|NCT05987371|Experimental|TQC3721 Suspension for Inhalation (Once a day)+ Salbutamol|TQC3721 suspension for inhalation, once a day for 4 weeks, Salbutamol sulfate inhalation aerosol is used as required.
89470026|NCT05987371|Placebo Comparator|TQC3721 matching placebo for inhalation (Twice a day)+ Salbutamol|TQC3721 suspension placebo for inhalation, twice a day for 4 weeks, Salbutamol sulfate inhalation aerosol is used as required.
89470027|NCT05987371|Placebo Comparator|TQC3721 matching placebo for inhalation (once a day)+ Salbutamol|TQC3721 suspension placebo for inhalation, once a day for 4 weeks, Salbutamol sulfate inhalation aerosol is used as required.
89470028|NCT05981898|Experimental|OPTIVF predicted drug dosage|This arm will use dosage, trigger predicted by Opt-IVF
89470029|NCT05981898|Active Comparator|Traditional drug treatment|Traditional drug treatment
89470030|NCT05972187|Experimental|Temperature and Humidity|32C or 25C and 30%RH or 70%RH
89470031|NCT05971498||cases|
89470032|NCT05971498||control|
88947676|NCT01919944|Experimental|VLY-686 50 mg|Single dose, 50 mg VLY-686, administered as one 50 mg VLY-686 oral capsule and one placebo capsule mimicking the VLY-686 50 mg capsule
89470033|NCT05968495|Experimental|Renuvion APR System Treatment|Subjects are receiving treatment with the Renuvion APR system following power-assisted liposuction in the abdomen per investigator standard of care. Subjects may also have other body areas treated at the same time.
88947677|NCT01919944|Experimental|VLY-686 100 mg|Single dose, 100 mg VLY-686, administered as two 50 mg VLY-686 oral capsules
88947678|NCT01919944|Placebo Comparator|Placebo|Single dose, placebo, administered as either two 10 mg oral capsules or two 50 mg oral capsules
88947679|NCT01919957|No Intervention|memory outcome|
88947680|NCT01919983||Primary Prevention of Sudden Cardiac Death|No intervention will be administered. This is an observational study testing the association of inflammation and cardiac sympathetic innervation using I-123-MIBG gamma scintigraphy
88947681|NCT01920009|Active Comparator|Pharmacy care group|patients in this group will receive two counseling sessions with a motivational interview.
88947682|NCT01920009|No Intervention|Controlgroup|patients in this group will receive usual care by pharmacists
88947683|NCT01920022|Experimental|Etonorgestrel and mifepristone|Quickstart, insertion of Nexplanon on the day of mifepristone in medical abortion
89470034|NCT05957770||cases|rheumatoid arthritis patients
88947684|NCT01920022|Active Comparator|mifepristone|Mifepristone on day 1. Nexplanon insertion at 3 weeks FU after the medical abortion
88947685|NCT01920074|Experimental|Rectiv|
89470035|NCT05957770||control|healthy subjects
89470036|NCT05955911|Experimental|Exercise|Moderate intensity treadmill walking (40%-59% of heartrate reserve).
89470037|NCT05955911|Other|Coloring|Coloring in an adult coloring book as a distraction activity
89470038|NCT05948787|Other|Intervention Group|Intervention group' Families take part in weekly sessions of Strong Families for 3 weeks. All family's complete measures again (Time 2, two weeks post intervention). All family's complete measures again (Time 3, 6 weeks post intervention)
89470039|NCT05948787|Experimental|Waitlist group' Families take part in weekly sessions of Strong Families after the data measures|Families in the RCT will be randomized to implementation of the Intervention or Waitlist group . Families will be allocated using online software (www.sealedenvelope.com). We are aware that randomization before recruiting participants can influence recruitment and dropout in the control arm. To minimize these issues, we have included costs for compensating families for participation in study measure completion and will instruct staff not to reveal family allocation until families have agreed to take part and before signing informed consent. This is an un-blinded trial. Research assistants, staff and families will be aware of participants' allocated condition during the trial.
89470040|NCT05944887|Active Comparator|Linisol|Patients will receive 1.5 mg/kg of intravenous linisol before propofol sedatation and gastroscope introduction
89470041|NCT05944887|Placebo Comparator|Sham|Patients will receive intravenous placebo (saline solution),before propofol sedation and gastroscope introduction
89470042|NCT05943275|Other|Patient with an indication for right heart catheterization|During the preparation of the subject on the cardiac catheterization table, a person specifically trained to the measurements of the medical device under test will be dedicated to this study. Once the skin has been cleaned with alcohol the device (magnet and micro-sensor encapsulated in the plastic support) will be placed on the subject's uninjured skin of the subject, on the path of the jugular vein. A second device will be placed at the level of the radial artery radial artery with the help of a bracelet. The signals will be recorded and observed on a screen for the duration of the invasive hemodynamic measurements, i.e. approximately 15 minutes.
89470043|NCT05937620|Experimental|Interventional arm|All patients will receive an injection of ICG and an injection of 99mTc nanocolloid albumin
89470044|NCT05914077|Experimental|Duodenopancreatic aspiration after secretin stimulation + EUS-FNA|Duodenopancreatic aspiration after secretin stimulation will be performed followed by endoscopic ultrasound-guided fine needle aspiration (EUS-FNA)
89202377|NCT02562248|Active Comparator|Intervention|Randomization is at the clinic level. Two clinics will be randomized to receive the revised module to screen for anxiety and ADHD among children who present with parental concern of disruptive behaviors. Parents who have concerns of disruptive behaviors will trigger the module and be administered both the Vanderbilt for ADHD and Screen for Childhood Anxiety Related Emotional Disorders (SCARED) screening tools.
89206189|NCT02598869|Active Comparator|Intravitreal triamcinolone|subjects will receive intravitreal injection of 2mg /0.05 ml of preservative free triamcinolone acetonide ( otherwise known as triesence)
89470045|NCT05914077|Experimental|EUS-FNA + duodenopancreatic aspiration after secretin stimulation|Endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) will be performed followed by duodenopancreatic aspiration after secretin stimulation
89470046|NCT05904834|Experimental|Flexibility training|The intervention group will undergo a flexibility training focused on hamstring extensibility. Each will they will take part in four stretching sessions besides the normal dance training.
89470047|NCT05904834|No Intervention|No training|The control group will continue with their training routine during the experiment.
89470048|NCT05896761|Experimental|Participants receiving CAB LA 400 milligrams (mg) and RPV LA 600 mg|Participants will receive an Intramuscular (IM) injection of CAB LA 400 mg on one lateral thigh and RPV LA 600 mg into the opposite lateral thigh on Day 1 in every 4 weeks (Q4W) for a total of 16 weeks during Thigh injection phase. Participants will then return to the clinic 4 weeks later to receive their first IM gluteal injection (at Week 16) of CAB LA 400 mg and RPV LA 600 mg during the Return to Gluteal Injection Phase. The subsequent gluteal injection will occur at Week 20.
89470049|NCT05896761|Experimental|Participants receiving CAB LA 600 mg and RPV LA 900 mg|Participants will receive an IM injection of CAB LA 600 mg on one lateral thigh and RPV LA 900 mg into the opposite lateral thigh on Day 1 in every 8 weeks (Q8W) for a total of 16 weeks during Thigh injection phase. Participants will then return to the clinic 8 weeks later receive their first IM gluteal injection (at Week 16) of CAB LA 600mg and RPV LA 900 mg during the Return to Gluteal Injection phase. The subsequent gluteal injection will occur at Week 24.
89470050|NCT05892770|Active Comparator|Botulinum toxin A injection|Botulinum toxin A injection into vocal cords for treatment of spasmodic dysphonia. This is the current standard of care for treatment of this disease process. This will be the control of the study.
89470051|NCT05892770|Experimental|"Botulinum toxin A injection +zinc supplementation"|Botulinum toxin A injection into vocal cords for treatment of spasmodic dysphonia, with subject taking zinc supplementation daily for the 5 days preceding the botox injection. This will be the experimental arm of the study.
89470052|NCT05854329|Experimental|Immersive Virtual Reality Exposure|Immersive Virtual Reality Dental Game for 15 minutes. Participants will be actively involved with the game, in placing restorations, scaling virtually playing the role of the dentist.
89470053|NCT05854329|Active Comparator|Non Immersive Virtual Reality Exposure|Participants will be made to watch dental related cartoon passively while sitting using the Virtual Reality device for 15 minutes.
89470054|NCT05854329|No Intervention|Control Group|Participants will be waiting for 15 minutes as usual prior to their treatment.
89470055|NCT05848063|Experimental|Group A: Global hip muscles strengthening exercises|Group A Group A will receive hot packs along with all hip muscle strengthening exercises. All exercises were performed for 3 sessions per week for 6 weeks. Outcome measures will be taken at baseline, in 3rd week, and at the end of the 6th week.
89470056|NCT05848063|Active Comparator|Group B: Hip abductors strengthening exercises|Group B will receive hot packs along with Hip abductors strengthening. A baseline assessment will be done on eligible participants. 3 sessions were given 3 days per week, Outcome measures will be taken at baseline, in 3rd week, and at the end of the 6th week.
89470057|NCT05842642|Placebo Comparator|Cervical treatment|A treatment of the cervical region will be done for 6 weeks, once a week, and they will be taught exercises to do at home.
89470058|NCT05842642|Experimental|Oculomotor treatment|An oculomotor treatment will be added to the treatment of the cervical group with specific exercises in the area. Once a week during 6 weeks
89470059|NCT05842057|Experimental|Membrane Arm: dHACM Group|Participants will undergo standard of care robot-assisted radical prostatectomy (RARP) surgery and the dehydrated Human Amnion Chorion Membrane (dHACM) membrane placed after removal of the prostate. Participants will be in the group for approximately 12 months.
89470060|NCT05842057|Other|Control Arm: No dHACM Group|Participants will undergo standard of care RARP surgery but will have no dehydrated Human Amnion Chorion Membrane (dHACM) placed after removal of the prostate. Participants will be in the group for approximately 12 months.
89470061|NCT05838664||AF patients unexposed to oral anticoagulants|
89470062|NCT05838664||AF patients exposed to VKA|
89470063|NCT05838664||AF patients exposed to apixaban|
89470064|NCT05838664||AF patients exposed to rivaroxaban|
89470065|NCT05838664||AF patients exposed to dabigatran|
89470066|NCT05836402|No Intervention|Control|-Usual diet.
89470067|NCT05836402|Experimental|Low Carbohydrate|"-Low-Carbohydrate Diet Intervention:Patients will receive a study kit. The kit will contain the following:~Instruction sheet containing medical food instructions and food journal and a web link to the weekly online journal~A 30-day supply of the medical food, KetoCitra, developed by Santa Barbara Nutrients, Inc. KetoCitra® is a ready-to-mix powder to be dissolved in water and taken twice per day with meals. KetoCitra® contains BHB, citrate, and a blend of minerals (potassium, calcium, magnesium) and is flavored with natural lemon flavor and stevia natural sweetener. KetoCitra® is sugar- and sodium-free and is intended to support the metabolic switch aimed for with the low-carbohydrate diet by providing exogenous BHB. (Package insert)"
89470068|NCT05834218|Experimental|split-body resistance training|"Split-group training regime:~Day 1 (Leg press, Stiffed-legged deadlift, Leg extension, Hip thrust) 3x12 repetitions for each exercise Day 2 ( Lat pulldown, Bench press, Cabled seated row)3x12 reps (Triceps press and biceps curls in cable (superset) Day 3 (Day 1 exercise repeated) Day 4 (Day 2 exercise repeated)"
89470069|NCT05834218|Active Comparator|Full body resistance training|"Full body training regime:~Day 1 (Leg press, Stiffed-legged deadlift, Leg extension, Hip thrust, Lat pulldown, Bench press, Cabled seated) 3x12 reps for each exercise, (Triceps press and biceps curls in cable (superset) Day 2 (Repeat first day exercise)"
89470070|NCT05834205|Experimental|Plyometric Training|"Plyometric training regime:~Ankle hops, jump squats, box jump, overhead medicine ball, plyometric push-up, rotational wall with 16x2 reps for week 1&2.~Ankle hops, jump squats, box jump, overhead medicine ball, plyometric push-up, rotational wall with 10x3 reps for week 3&4.~Ankle hops, jump squats, box jump, depth jump and alternate lunge jump, overhead medicine ball, plyometric push-up, rotational wall with 8x3 reps for week 5&6."
89470071|NCT05834205|Active Comparator|Drills|Fast bowling drills (hitting a target, football throw, fast bowler grip) and Ladder Drill
89470072|NCT05832008|Experimental|Clinician Nudge + Patient Nudge|"An EHR-prompt (pended order) will prompt clinicians in this arm when a patient is due for lung cancer screening or diagnostic follow-up.~Patients in this arm will receive messaging designed to increase awareness about the importance of annual screening and recommended follow-up"
89470073|NCT05832008|Experimental|Clinician Nudge Only|"Clinicians in this arm will not be prompted by a pended order when a patient is due for lung cancer screening or diagnostic follow-up.~Patients will receive usual care."
89470074|NCT05832008|Experimental|Patient Nudge Only|"Patients in this arm will receive messaging designed to increase awareness about the importance of annual screening and recommended follow-up.~Clinicians will receive usual care."
89470075|NCT05832008|No Intervention|Usual care (no nudges)|Patients and clinicians in this arm will receive usual care.
89470076|NCT05824416|Experimental|ALBA|25 minutes of therapy with ALBA and 20 minutes with conventional therapy per session for 5 days a week during 4 weeks.
89470077|NCT05824416|Active Comparator|Conventional Therapy|45 minutes conventional therapy per session for 5 days a week during 4 weeks.
89470078|NCT05810766|Experimental|mobilization with movement Group|"Week 1 & 2: mobilization with movement at glenohumeral joint for improving flexion, abduction internal and external rotation. 3 sets of painless glides of 10 repetitions will be given, with 1 minute rest between sets.~Week 2 & 4:MWM at glenohumeral joint and then we will add progression by adding glides at sternoclavicular and acromioclavicular joint.5 sets of painless glides of 10 repetitions will be given, with 3-minute rest between sets.~Week 3 & 6:MWM at glenohumeral joint and glides at sternoclavicular, acromioclavicular along with glides at scapulothoracic. 5 sets of painless glides for 10 repetitions were given. Progression can be introduced by increasing the number of repetitions performed exercises for 3 weeks."
89470079|NCT05810766|Other|conventional physical therapy|Hot pack for 15 minutes
89470080|NCT05805904|Experimental|Group 1|
89470081|NCT05805904|Experimental|Group 2|
89470082|NCT05798923|Experimental|LAM-001|
89470083|NCT05794347|Experimental|Group-A (Vertical sitting traction)|This session will be followed by the application of the continuous mechanical traction in the vertical sitting position with a belt around the chest. A total of 30 minutes session per day with 5 sessions per week for 12 weeks will be provided to the participants in this group
89470084|NCT05794347|Active Comparator|Group-B (supine lying traction)|Following the conventional treatment, continuous mechanical traction will be applied in the supine lying position with a traction force equal to 50% of the total body weight. A total of 20 minutes session per day with 5 sessions per week will be provided to the participants in group B.
88947686|NCT01920165||Full cohort|The population at risk for each time point is the number of children living in England aged 0-14 year
88947687|NCT01920360|Experimental|SULPHUROUS WATERS IMMERSION BATHS|The baths will be held in individual tubs, properly disinfected, supplied with sulphurous thermal water at a temperature 37-39 ° C, which encompass the optimum temperatures for therapeutic bath. The baths lasted for 20 minutes. The subjects will drink two cups of water, 300 ml before and after the baths, in order to avoid an imbalance water.
88947688|NCT01920360|Experimental|NOT SULPHUROUS WATERS IMMERSION BATHS|The baths will be held in individual tubs, properly disinfected, supplied with not sulphurous thermal water at a temperature 37-39 ° C, which encompass the optimum temperatures for therapeutic bath. The baths lasted for 20 minutes. The subjects will drink two cups of water, 300 ml before and after the baths, in order to avoid an imbalance water.
88947689|NCT01920360|Experimental|CONTROL GROUP|This group did not receive any treatment, only received some verbal directions as to the care that should be taken to prevent and control the knee pain.
88947690|NCT01920412|Experimental|Left Atrial Appendage Occluder|Adopted non-comparative arm on Left Atrial Appendage Occluder.
88947691|NCT01920516||Melphalan|"Day +1:~Intra femoral infusion of Melphalan at the dosage 1mg/ Kg~Intra femoral infusion of Melphalan Second ILI treatment can be repeated at side effects recovery ( following oncologist ' s planning of cure).~Day +30: The above procedure is repeated.~Day +90: In case of response, a third administration following the above procedures will be repeated."
88947692|NCT01920698|Experimental|MitraClip Device|Subjects randomized to the MitraClip Device group will undergo the MitraClip procedure in addition to optimal standard medical therapy.
89470085|NCT05772286|Experimental|763SIP8/MPLA-5 vaccine|Intramuscular injection of 100 μg of 763SIP8 protein adjuvanted with 500 μg MPLA liposomes will be administrated 4 times (day 0, week 8, week 24 and week 48).
89470086|NCT05767177|Experimental|High Carbohydrate Diet vs High Fat Diet|"In the current project, the situation applies to individuals with obesity (body mass index (BMI) 35 to 45 kg/m2). In one case the diet is of the type high-carbohydrate diet and in the other case high-fat diet. The idea is that the research subjects should subsist on these diets for the respective 14 days. The energy content of the diet periods must be the same and correspond to the participants' daily needs. Each participant is drawn to one diet for 2 weeks. After a break of at least 3 weeks, the second diet is taken for 2 weeks."
89470087|NCT05735379|Experimental|Deprescribing anticholinergic and sedative medications|Deprescribing plan targeting a reduction in drug burden index score of ≥ 0.5
89470088|NCT05731115|Experimental|Experimental Vaccine-lot 1|Participants (n=600) aged 40-65 years will receive one dose of 23-valent pneumococcal polysaccharide vaccine of commercial scale production lot 1.
89470089|NCT05731115|Experimental|Experimental Vaccine-lot 2|Participants (n=600) aged 40-65 years will receive one dose of 23-valent pneumococcal polysaccharide vaccine of commercial scale production lot 2.
89470090|NCT05731115|Experimental|Experimental Vaccine-lot 3|Participants (n=600) aged 40-65 years will receive one dose of 23-valent pneumococcal polysaccharide vaccine of commercial scale production lot 3.
89470091|NCT05709613|No Intervention|No feedback device|This group will have no access to the feedback device
88947693|NCT01920698|Other|Control|Patients randomized to the Control group will receive optimal therapy alone
88947694|NCT01920750|Experimental|Group 2|5 subjects will receive d single 0.1 ml intracutaneous injections of 3 titrated doses (1, 10, and 25 grams/ml) of MLCwA and one of mock antigen equally in two arms
88947695|NCT01920750|Experimental|Group 1|5 subjects received single 0.1 ml intracutaneous injections of 3 titrated doses (1, 10, and 25 grams/ml) of MLSA-LAM and one of mock antigen equally in two arms
88947696|NCT01920763||Surgical Patients|Patients with intracerebral hemorrhage who have been offered a parafascicular, minimally-invasive procedure for hematoma drainage, by the treating neurosurgeon.
88947697|NCT01920984|Experimental|pretreatment of bevacizumab|Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) 7 to 9 days before vitrectomy due to diabetic retinopathy.
89470092|NCT05709613|Experimental|Feedback device|This group will have access to the feedback device
88947698|NCT01920984|No Intervention|No pretreatment of bevacizumab|Patients will not receive bevacizumab pretreatment before vitreous surgery.
88947699|NCT01921127||Symbicort|BFC patients new to ICS/LABA therapies
88947700|NCT01921127||Advair|FSC patients new to ICS/LABA therapies.
88947701|NCT01921283|Experimental|BIS group|The BIS group (n=90) was monitored for sedation depth using BIS during ESD.
88947702|NCT01921283|Active Comparator|No-BIS group|The no-BIS group (n=90) was monitored by observer's assessment alertness/sedation scale (OAA/S).
88947703|NCT01921374|Experimental|sleep parameters|To assess the sleep parameters.
88947704|NCT01921374|Other|cardiovascular parameters|To assess the cardiovascular profile of control mothers and caregivers-mothers.
88947705|NCT01921374|Experimental|imflammatory and immunological profile|To assess the inflammatory profile of caregivers-mothers and control mothers
88947706|NCT01921374|Experimental|hormonal profile|To assess the hormonal profile of caregivers-mothers and control mothers.
88947707|NCT01921374|Experimental|metabolic profile|To assess the health profile of caregivers-mothers and control mothers.
88947708|NCT01921972|Active Comparator|Galantamine and Placebo|Subjects in this group will receive 4 weeks of 8 mg/day galantamine CR, followed by 4 weeks of 16 mg/day and from week 9 up to the end of the trial of 24 mg/day.
88947709|NCT01921972|Experimental|Galantamine and Memantine|Galantamine titration will be performed as described above. Memantine titration will be performed over 4 weeks in steps of 5 mg/day up to 20mg/day (10 mg b.i.d.). 50 % of this group will receive galantamine first, 50 % of the group will receive memantine first to allow for differential qualitative evaluation of tolerability of a combination therapy.
88947710|NCT01922362|Experimental|Negative pressure drainage system|Negative pressure drainage system
89470093|NCT05708638|Active Comparator|Patients who were assigned to have manual anesthesia induction group with propofol|Patients who were assigned to have a manual anesthesia induction group, propofol was administered 2-3 mg/kg in 1-2 minutes to achieve a level of hypnosis measured by bispectral index ( BIS ) of 35-60.
89537383|NCT04420169||PRE implementation communication protocol|
89537384|NCT04420169||POST implementation communication protocol|
88947711|NCT01922362|Active Comparator|Indirect wet dressing group|Indirect wet dressing
88947712|NCT01922414|Active Comparator|Laser|Patients will undergo Laser lithotripsy
88947713|NCT01922414|Active Comparator|Ultrasonic|Patients will undergo ultrasonic lithotripsy
88947714|NCT01922622||Bipolar hemiarthroplasty.|Group of patients who will stay in lateral position during whole surgery.
88947715|NCT01922622||Dynamic hip screw.|Group of patients who will be supine during surgery.
88947716|NCT01922830|Experimental|Bio-25 (Supherb)|"Bio-25 (Supherb) once daily (2 capsules -50 billion bacteria) for 6 months (or 4 weeks for healthy participants).~The Bio-25 (Supherb) is a probiotic supplement consisting of 11 different species of patented probiotic bacteria and over 25 billion active bacteria in each capsule. The bacteria in the formula are patented bacteria that have undergone drying, freezing, and double coating which ensures their survival under stomach acidity conditions and their enrooting in the intestines."
88947717|NCT01922830|Placebo Comparator|Placebo|"Identical placebo once daily (2 capsules) for 6 months (or 4 weeks for healthy participants).~The placebo supplementation is identical-looking to the Bio-25 supplement."
88947718|NCT01922882|Experimental|Amagugu Counseling Intervention|"The 'Amagugu' intensive 6 session home-based intervention. All 6 visits will be undertaken by a lay counsellor over a period of 8-10 weeks. The intervention includes 3 stages linked to the outcomes of the intervention:~family engagement, personal preparation, disclosure practice using intervention materials~health promotion training and a mother-child visit~play-for-communication and custody care planning"
88947719|NCT01922882|No Intervention|Standard of Care|"There is currently no Standard of Care in the South African DoH addressing the issue of parental disclosure of HIV status to HIV-uninfected children, beyond a recommendation to 'counsel to disclose'.~Therefore, for women who are randomized to the control group, we will ensure a Standard of Care for all mothers including a one-hour counselling session, focused specifically on disclosure, delivered at the primary health care facility as part of the HIV Programme.~We will orientate all health professionals in the enrolment clinic, including nurses, counsellors and community health care workers, on parental HIV disclosure, and provide a one-day training workshop (including training manual, role-plays and competency testing."
88947720|NCT01923168|Experimental|Alpelisib + Letrozole|Participants took alpelisib 300 mg once daily plus letrozole 2.5 mg once daily.
88947721|NCT01923168|Experimental|Buparlisib + Letrozole|Participants took buparlisib 100 mg once daily or 5 days on/2 days off plus letrozole 2.5 mg once daily.
88947722|NCT01923168|Placebo Comparator|Placebo + Letrozole|Participants took matching Placebo (of alpelisib 300 mg once daily/buparlisib 100 mg once daily or 5 days on/2 days off) plus Letrozole 2.5 mg once daily.
88947723|NCT01923454|Experimental|Paracentesis|"Immediate anterior chamber paracentesis (ACP) with a 30-gauge needle as an initial treatment for acute primary angle closure.~Acetamide, given in this study, is a standard treatment for acute angle-closure glaucoma. The participant will receive 1 tablet(250mg) at 1 hours after paracentesis. The following dose will be adjusted according to the level of IOP. The maximal dose is 4 tablets per day. It will be discontinued if the IOP is less than 21 mmHg.~All affected eyes will receive laser peripheral iridotomy with 24 hours after presentation. This a standard treatment for Acute angle-closure glaucoma"
88947724|NCT01923519|Experimental|allergic rhinitis|
88947725|NCT01923519|Experimental|allergic rhinitis and asthma|
88947726|NCT01923519|Experimental|witnesses|
88947727|NCT01923688|Experimental|Informatics Real-Time Alert|Alert/Nurse and Physician Intervention
88947728|NCT01923688|No Intervention|control-no intervention|
88947729|NCT01923701|Experimental|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy group receives group, individual, and family Cognitive Behavioral Therapy in addition to standard care.
88947730|NCT01923701|No Intervention|Monitoring|This group receives standard care only.
88947731|NCT01923935|Experimental|BUSULFEX®, Alkeran®|"BUSULFEX® 3.2 mg/kg/day iv once daily over 3 hours (day-6~day-4)~Alkeran® 70 mg/m2/day iv once daily over 30 minutes (day-3~day-2)"
88947732|NCT01923974|Placebo Comparator|Placebo|IV formulation
88947733|NCT01923974|Active Comparator|Melatonin 10 mg|IV formulation, Melatonin 10 mg
88947734|NCT01923974|Active Comparator|Melatonin 100 mg|IV formulation, Melatonin 100 mg
89470094|NCT05708638|Active Comparator|Patients who were assigned to have target controlled infusions ( TCI) induction with propofol|Patients who were assigned to have TCI induction had the target effect site concentration (Ce) of propofol (Ce) set at 3 μg ml-1 using the Schneider model and subsequently modified to achieve and maintain a level of hypnosis measured by BIS of 35-55
88947735|NCT01924013|Placebo Comparator|Group A|"Prenatal Period 0 IU; Postpartum Period 0 IU (placebo)~Overall:The Prenatal Period will start at enrolment (17-24 weeks gestation) and last until delivery. The Postpartum Period will last from delivery until 6 months postpartum."
88947736|NCT01924013|Experimental|Group B|Prenatal Period 4,200 IU/week of vitamin D3 (=600 IU/d); Postpartum Period 0 IU/week (placebo)
88947737|NCT01924013|Experimental|Group C|Prenatal Period 16,800 IU/week of vitamin D3 (=2,400 IU/d); Postpartum Period 0 IU/week (placebo)
88947738|NCT01924013|Experimental|Group D|Prenatal Period 28,000 IU/week of vitamin D3 (=4,000 IU/d); Postpartum Period 0 IU/week (placebo)
88947739|NCT01924013|Experimental|Group E|Prenatal Period 28,000 IU/week of vitamin D3 (=4,000 IU/d); Postpartum Period 28,000 IU/week(=4,000 IU/d)
88947740|NCT01924208|Active Comparator|Timothy|Allergen. Grazax® sublingual 75.000 SQ-T tablet (extracted from timothy, Phleum pretense), once daily until operation (ALK-Abelló, Hørsholm, Denmark) (n=30) .
88947741|NCT01924208|Active Comparator|Live attenuated influenza virus|Virus. Fluenz®, nasal live attenuated influenza vaccine, one 0.2 mL dose (MedImmune, Gaithersburg, USA) (n=60, 50:50 atopic:non-atopic).
88947742|NCT01924208|Active Comparator|Timothy + attenuated influenza virus|Allergen. Grazax® sublingual 75.000 SQ-T tablet (extracted from timothy, Phleum pretense), once daily until operation (ALK-Abelló, Hørsholm, Denmark) + Virus. Fluenz®, nasal live attenuated influenza vaccine, one 0.2 mL dose (MedImmune, Gaithersburg, USA) (n=30).
88947743|NCT01924208|No Intervention|No intervention|No intervention (n=60, 50:50 atopic:non-atopic).
88947744|NCT01924507|Experimental|CPAP|Patients with apnea will be treated with CPAP during the night.
88947745|NCT01924507|No Intervention|Control|One arm group will be control and will not receive CPAP treatment during the ICU admission.
88947746|NCT01924650|Experimental|PH-797804 PARTICLE SIZE 9-11UM|
89470095|NCT05695781|Active Comparator|BRM421 Ophthalmic Solution|
89470096|NCT05695781|Placebo Comparator|Vehicle|
89470097|NCT05680740|Experimental|VTAMA® (tapinarof) Cream 1%|VTAMA® (tapinarof) Cream 1% applied topically once daily
89470098|NCT05646771|Experimental|Partner-Supported|Dyads comprised of one Veteran and a cohabitating support person will participate in a behavioral weight management intervention.
89470099|NCT05639712|Placebo Comparator|Placebo|The patient is given standardized questions about their well-being and affective state before and after the administration of placebo (0.9% NaCl intravenously). This is carried out on the operating table right before anesthesia
89470100|NCT05639712|Active Comparator|Morphine 2.5 mg|The patient is given standardized questions about their well-being and affective state before and after the administration of morphine 2.5 mg intravenously. This is carried out on the operating table right before anesthesia
89470101|NCT05639712|Active Comparator|Morphine 5 mg|The patient is given standardized questions about their well-being and affective state before and after the administration of morphine 5 mg intravenously. This is carried out on the operating table right before anesthesia
89470102|NCT05639712|Active Comparator|Morphine 10 mg|The patient is given standardized questions about their well-being and affective state before and after the administration of morphine 10 mg intravenously. This is carried out on the operating table right before anesthesia
89470103|NCT05639712|Active Comparator|Oxycodone 2.5 mg|The patient is given standardized questions about their well-being and affective state before and after the administration of oxycodone 2.5 mg intravenously. This is carried out on the operating table right before anesthesia
89470104|NCT05639712|Active Comparator|Oxycodone 5 mg|The patient is given standardized questions about their well-being and affective state before and after the administration of oxycodone 5 mg intravenously. This is carried out on the operating table right before anesthesia
89470105|NCT05639712|Active Comparator|Oxycodone 10 mg|The patient is given standardized questions about their well-being and affective state before and after the administration of oxycodone 10 mg intravenously. This is carried out on the operating table right before anesthesia
89470106|NCT05639712|Active Comparator|Fentanyl 0.025 mg|The patient is given standardized questions about their well-being and affective state before and after the administration of fentanyl 0.025 mg intravenously. This is carried out on the operating table right before anesthesia
89470107|NCT05639712|Active Comparator|Fentanyl 0.05 mg|The patient is given standardized questions about their well-being and affective state before and after the administration of fentanyl 0.05 mg intravenously. This is carried out on the operating table right before anesthesia
89470108|NCT05639712|Active Comparator|Fentanyl 0.1 mg|The patient is given standardized questions about their well-being and affective state before and after the administration of fentanyl 0.1 mg intravenously. This is carried out on the operating table right before anesthesia
89470109|NCT05633784|Experimental|Intervention group|At the beginning and at the end of the 6-month study period, patients of the Intervention group will perform outpatient cardiological visits. During the 6-month they will be followed through a home remote teleassistance program, designed to provide multidisciplinary support.
89470110|NCT05633784|Active Comparator|Control group|At the beginning and at the end of the 6-month study period, patients of the Control group will perform outpatient cardiological visits. During the 6-month at home, patients will be followed in the usual care model by GP.
89470111|NCT05611242|Experimental|MT+CAT|Non-stenting group constitutes best medical management (BMM)+intra-arterial treatment (IAT) with mechanical thrombectomy (for IVO) added to extra-cranial proximal carotid occlusion angioplasty or aspiration (MT+CAT)
89470112|NCT05611242|Experimental|MT+CAS|Acute carotid stenting (ACS) approach constitutes BMM+IAT with acute carotid stenting (ACS) of the extracranial proximal carotid artery, spanning the cervical internal carotid artery (ICA), ICA origin, and the distal common carotid artery (CCA, across the bifurcation) as in the example of left (L) carotid stenting figure below (MT+CAS). Within the stenting arm, there will be 2 different subgroups based on the antiplatelet treatment protocol per the site standard of care (oral antiplatelet or IV antiplatelet medication (e.g., Cangrelor or others).
89470113|NCT05606601|Experimental|Intervention arm|Participants randomized into the intervention arm will be given immediate access to a fully functional version of the Minder app that includes baseline, interim and follow-up surveys and access to all app components and e-coaching.
89470114|NCT05606601|No Intervention|Control arm|Participants randomized into the control arm will be given access to a restricted version of the app that only includes access to a generic study introduction video and baseline and follow up survey assessments delivered via the app.
89470115|NCT05582694|Experimental|1|10 adults (>18 years of age) with human immunodeficiency virus (HIV) who demonstrate evidence of HIV-1 replication despite ongoing ART with documented genotypic and/or phenotypic resistance to multiple classes of HIV drugs (3 classes or more)
89470116|NCT05575570|Active Comparator|Pre-emptive AAA sac embolization|
89470117|NCT05575570|Sham Comparator|No pre-emtive AAA sac embolization|
89470118|NCT05569772|Active Comparator|semaglutide|semaglutide SC once weekly, up titration over 2 month period to 1mg/week (0.25mg once weekly, after 4 weeks 0.5mg once weekly and after 8 weeks the maintenance dose of 1mg once weekly), treatment duration of max. 3 years
89470119|NCT05569772|Placebo Comparator|placebo|placebo SC once weekly, the same dose-escalation regimen, using matching injections, treatment duration of max. 3 years
89470120|NCT05567783|Experimental|VIR-2482 (Dose 1)|
89470121|NCT05567783|Experimental|VIR-2482 (Dose 2)|
89470122|NCT05567783|Placebo Comparator|Placebo|
89470123|NCT05567094|Experimental|Dexamethasone|Patients will receive 0.2 mg/kg dexamethasone, administered as an intravenous bolus within 5 minutes after induction of anesthesia
89470124|NCT05567094|Placebo Comparator|Saline placebo|Patients will receive 2ml saline placebo, administered as an intravenous bolus within 5 minutes after induction of anesthesia
89470125|NCT05560243|Experimental|Intervention|Patients will receive a tobacco cessation intervention
89470126|NCT05555888|Experimental|Treatment Arm|A total of 34 patients will receive 5*5Gy short-course radiotherapy, followed by 4 cycles of CAPOX chemotherapy and PD-1 antibody, finally receive the TEM or TME surgery.
89470127|NCT05554211|Experimental|Experimental Breast|Participants will receive 50 ml of TxA and gentamicin to the assigned experimental breast.
89470128|NCT05554211|Placebo Comparator|Control Breast|Participants will receive a standard irrigation of 50 ml of 0.9% NS and gentamicin to the assigned control breast.
89470129|NCT05550584|Experimental|THRIVE|Ventilatory management during surgery provided by transnasal humidified rapid-insufflation ventilatory exchange.
89470130|NCT05550584|Active Comparator|Control|Ventilatory management during surgery provided by mechanical ventilation through laringeal mask
89470131|NCT05545111|Experimental|Dose Level A|Participant administered Dose Level A (6 weeks)
89470132|NCT05545111|Experimental|Dose Level B|Participant administered Dose Level B (6 weeks)
89470133|NCT05545111|Experimental|Dose Level C|Participant administered Dose Level C (6 weeks)
89470134|NCT05545111|Experimental|Dose Level D|Participant administered Dose Level D (6 weeks)
89470135|NCT05545111|Placebo Comparator|Placebo Schedule|Participant administered placebo (6 weeks)
89470136|NCT05529602|Experimental|post isometric relaxation exercises and core stability|for pain and disability secondary to SIJ dysfunction in postpartum females
89470137|NCT05529602|Other|conventional physical therapy|for management of lower back pain
89470138|NCT05526950|Active Comparator|Treated|"Treatment using the medical cytokine adsorption device in conjunction with lung transplantation"
89470139|NCT05526950|No Intervention|Non-treated|No additional treatment in conjunction with lung transplantation
89470140|NCT05522751|Experimental|AUD DBS|This is a single arm study. Participants will undergo baseline medical and psychiatric assessments, cognitive and behavioral testing, and positron emission tomography (PET) imaging. One to two weeks later, participants will undergo neurosurgical implantation of DBS electrodes in the limbic pallidum and a neurostimulator. Four weeks after DBS system implantation, the DBS system will be turned ON and the stimulation parameters optimized. Participants will be followed biweekly then monthly for repeat comprehensive assessments.
89470141|NCT05522296||Unvaccinated|Unvaccinated individuals who have risk factors for mpox infection and do not have a past history of mpox infection
89470142|NCT05522296||Vaccinated|Vaccinated individuals with smallpox and mpox vaccine (Live Modified Vaccinia Virus Ankara) who have risk factors for monkeypox infection and do not have a past history of mpox infection.
89470143|NCT05511467|Experimental|stroke group|
89470144|NCT05511467|Experimental|control group|
89470145|NCT05498402|Active Comparator|Bag-valve-mask ventilation|Providers will perform a cardiopulmonary resuscitation, and deliver ventilations using a bag-valve-mask
88947747|NCT01924650|Experimental|PH-797804 PARTICLE SIZE 9-11UM WITH SLS|
88947748|NCT01924650|Experimental|PH-797804 PARTICLE SIZE <= 20UM|
88947749|NCT01924650|Experimental|PH-797804 PARTICLE SIZE <= 20UM WITH SLS|
88947750|NCT01924650|Experimental|PH-797804 PARTICLE SIZE <= 5UM|
88947751|NCT01924650|Experimental|PH-797804 PARTICLE SIZE <= 5UM WITH SLS|
88947752|NCT01924676|Experimental|Treatment A|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
88947753|NCT01924676|Experimental|Treatment B|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
88947754|NCT01924676|Experimental|Treatment C|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
88947755|NCT01924741||ALPPS|ALPPS is the most recent modification of the techniques developed for Two-stage hepatectomies. ALPPS allows to remove an extensive part of the liver in two steps. In the first step the liver parenchyma is transected along the intended line of resection and the future liver remnant cleaned by partial resections from all tumor tissue in the case of bilobar tumors. To this a portal ligation of the larger liver lobe that will have to be removed is added. After a waiting period of 1-2 weeks the second step is performed in which the deportalized liver is removed to render the patient completely tumor-free. (Ann Surg 2012; 255(3):405-14.)
88947756|NCT01924923||Uveal Melanoma|Scheduled for enucleation surgery
88947757|NCT01925066|Experimental|Aerosolized Vancomycin|
88947758|NCT01925222||PCV-vaccinated infant, 3+1 schedule|
88947759|NCT01925222||PCV-vaccinated infant, 2+1 schedule|
88947760|NCT01925222||Control-vaccinated infant|
88947761|NCT01925222||PCV-vaccinated child, catch-up schedule|
88947762|NCT01925222||Control-vaccinated child, catch-up schedule|
88947763|NCT01925235||Control|patients with impaired renal function and a high risk of developing acute kidney injury undergoing TAVI and receiving standard care including pre-hydration 12 hours prior and 12 hours post procedure
89018996|NCT00301106|Experimental|adenovirus-mediated human interleukin-12|starting dose of ADV-hIL12 - 1 x 10 to the 10th power vp (virus particles) per patient, escalating in half-log increments up to 1 x 10 to the 13th power vp per patient, after which dose escalation will be at lower increments of 2 x 10 to the 13th power vp, to a maximum of 3.0 x 10 to the 13th power vp per patient.
89018997|NCT05366946||COPD - prevalence|Diagnosed with COPD (based on GOLD criteria and history of > 10 pack years of smoking) and no history of recent musculoskeletal injuries (within last 4 weeks) - prevalence study
89018998|NCT05366946||Healthy controls - prevalence|Not diagnosed with COPD or other respiratory conditions or recent musculoskeletal injuries (within last 4 weeks) - prevalence study
89018999|NCT05320302|Experimental|[11C]-Lu AF88370|Participants will receive [11C]-Lu AF88370 via an intravenous cannula on Day 1.
89019000|NCT04717206|Experimental|Plyomtric training to male badmninton players|Baseline assessment will be perfomimg on first day before intervention, 4 weeks plyometric training to male badminton players.
89470146|NCT05498402|Experimental|Supraglottic airway device ventilation|Providers will perform a cardiopulmonary resuscitation, and deliver ventilations using an i-gel® supraglottic airway device
89470147|NCT05481333|Experimental|IV Cohort 1|Single dose REGN7999 or Placebo; randomized 3:1
89470148|NCT05481333|Experimental|IV Cohort 2|Single dose REGN7999 or Placebo; randomized 3:1
89470149|NCT05481333|Experimental|IV Cohort 3|Single dose REGN7999 or Placebo; randomized 3:1
89470150|NCT05481333|Experimental|IV Cohort 4|Single dose REGN7999 or Placebo; randomized 3:1
89470151|NCT05481333|Experimental|IV Cohort 5|Single dose REGN7999 or Placebo; randomized 3:1
89470152|NCT05481333|Experimental|SC Cohort 1|Single dose REGN7999 or Placebo; randomized 3:1
89470153|NCT05481333|Experimental|SC Cohort 2|Single dose REGN7999 or Placebo; randomized 3:1
89470154|NCT05481333|Experimental|SC Cohort 3|Single dose REGN7999 or Placebo; randomized 3:1
89470155|NCT05475327|Other|Conventional Physical Therapy|Heat therapy and education regarding back care management.
89202378|NCT02562248|Active Comparator|Control|Randomization is at the clinic level. Two clinics will be randomized as the control clinics meaning that they will continue to provide care as usual for families who present to the clinic with concerns of disruptive behaviors. Currently, CHICA administers the Vanderbilt for ADHD screening tool.
89470156|NCT05475327|Experimental|Relaxation exercises|Progressive relaxation exercises along with Deep Breathing exercises.
89470157|NCT05474599|Experimental|Dry cupping therapy|For pain and severity of symptoms in primary dysmenorrhea.
89470158|NCT05474599|Other|Conventional physical therapy|For management of pain and severity of symptoms
89470159|NCT05463952|Experimental|ARV-471|Daily oral dosages of ARV-471
89470160|NCT05442554|Experimental|Brentuximab Vedotin 1.8 mg/kg|Brentuximab vedotin 1.8 mg/kg, IV on Day 1 of each 21-day cycle for up to a total of 16 cycles.
89470161|NCT05439876|Experimental|Melatonin|Melatonin
89470162|NCT05439876|Placebo Comparator|Placebo|Placebo
89470163|NCT05421910|Experimental|Early training group|The early group will receive robotic training combined with electrical stimulation as soon as possible after submission to the rehab center. With a frequency of three times a week for 3-5 weeks, dependent on the capabilities of the patients.
89470164|NCT05421910|Active Comparator|Late training group|The late training group will receive robotic training combined with electrical stimulation 3-5 weeks after submission to the rehab center. With a frequency of three times a week for 3-5 weeks, dependent on the capabilities of the patients.
89470165|NCT05419518|Experimental|Palliative radiation dose escalation|The prescribed dose is 50 Gy in 10 fractions. The total dose can be reduced to 40 Gy and the total number of fractions can be reduced to 8 fractions in non-spine metastases to achieve the normal tissue constraints.
89470166|NCT05419518|No Intervention|Therapeutic benefit|Radiation will be delivered as per protocol. For participants experiencing unacceptable toxicity related to study treatment, yet obtaining therapeutic benefit, participants will be allowed to continue treatment, if well tolerated at the discretion of the investigator.
89470167|NCT05414994||Cohort A|normal eyes with no ocular disease
89470168|NCT05414994||Cohort B|primary open angle glaucoma/Ocular hypertension defined as mild glaucoma which is well controlled with no more than one drop of prostaglandin use daily for the past 6 months
89470169|NCT05414994||Cohort C|non-infectious keratopathy not using any prescription medication (OTC artificial tears are acceptable)
89470170|NCT05414994||Cohort D|Dry AMD (age related macular degeneration)
89470171|NCT05414994||Cohort E|Wet AMD
89470172|NCT05414994||Cohort F|diabetic retinopathy, any stage
89019001|NCT04717206|Experimental|Plyomtric training to female badmninton players|Baseline assessment will be perfomimg on first day before intervention, 4 weeks plyometric training to female badminton players.
89019002|NCT00301535|Experimental|1|
89019003|NCT00301535|No Intervention|2|
89019004|NCT00301613|Active Comparator|Mycophenolate mofetil|
89019005|NCT00327873|Experimental|A|Oxygen
89019006|NCT00327873|Active Comparator|B|Medical Air
89019007|NCT00301652|Experimental|mycophenolate mofetil|
89019008|NCT00327912|Experimental|1|Laparoscopic Biliopancreatic diversion with Duodenal switch
89019009|NCT00327912|Active Comparator|2|Laparoscopic Roux-en-Y Gastric Bypass
89019010|NCT05252871|Experimental|Experimental: The specified PAL design wearers|Subjects who have been already wearing any from specified design type of PAL
89019011|NCT05252871|Active Comparator|The other PAL design wearers|Subjects who have been already wearing any from the other design type of PAL
89202379|NCT03977727|Experimental|Fiasp/Novolog|7 weeks on Fiasp® then crossover to 7 weeks on Novolog® in subjects on the 670g Hybrid Closed Loop Continuous Subcutaneous Insulin Infusion
89470173|NCT05412394|Experimental|Experimental|This is a one-arm study and the group of subjects are all experimental and will receive drug.
89019012|NCT00301769|Experimental|Arm I|Patients receive SJG-136 IV over 15 minutes on days 1-5. Courses repeat every 21 days in the absence of unacceptable toxicity or disease progression. Cohorts of 3-6 patients receive escalating doses of SJG-136 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. A total of 10 patients are treated at the MTD.
89019013|NCT00301847|Experimental|Arm I|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89470174|NCT05408559|Active Comparator|Avmacol ES|Processed SFN-rich extract will be purchased from Nutramax Laboratories, Inc. 2208 Lakeside Blvd Edgewood, MD 21040. Caplets containing SFN-rich broccoli sprout extracts will be obtained from Nutramax Labs. Study medication will be dispensed in sealed bottles with instructions to keep them in a household freezer. The size of the caplet will be about the size of a 1000 mg Vit C pill (about 2 cm in length). The participants will be dosed, based on weight, in a double-blind fashion with identical appearing placebo or SFN caplets. Participants will be instructed to take a daily dose for 24 weeks based on the participants weight. Two caplets for individuals <100 lb., three caplets for individuals 100-200 lb. and four caplets for individuals >200 lb. SFN (Avmacol Extra Strength) will be prescribed by a study physician, and will be dispensed by the study coordinators at TTUHSC Lubbock. Pill counts will be conducted to demonstrate compliance.
89470175|NCT05408559|Placebo Comparator|Placebo|Placebo caplets containing microcrystalline cellulose will be obtained from Nutramax Labs. Study medication will be dispensed in sealed bottles with instructions to keep them in a household freezer. The size of the caplet will be about the size of a 1000 mg Vit C pill (about 2 cm in length). The participants will be dosed, based on weight, in a double-blind fashion with identical appearing placebo or SFN caplets. Participants will be instructed to take a daily dose for 24 weeks based on the participants weight. Two caplets for individuals <100 lb., three caplets for individuals 100-200 lb. and four caplets for individuals >200 lb. Placebo will be prescribed by a study physician, and will be dispensed by the study coordinators at TTUHSC Lubbock. Pill counts will be conducted to demonstrate compliance.
89470176|NCT05408091|Experimental|Dose Level 1 - 1 mg/kg|Randomized 6:2 (TRL345:placebo) via IV infusion
89470177|NCT05408091|Experimental|Dose Level 2 - 10 mg/kg|Randomized 6:2 (TRL345:placebo) via IV infusion
89470178|NCT05385159|Experimental|ADSVF group|Adults with Scarred vocal folds, congenital (sulcus) or after phonosurgery
89470179|NCT05385159|Placebo Comparator|Placebo group|Adults with Scarred vocal folds, congenital (sulcus) or after phonosurgery
89470180|NCT05380440|Experimental|Pre-FAIR|Participants in this arm will receive the FAIR intervention.
89470181|NCT05380440|Active Comparator|Control|Participants in this arm will receive services standard case management and services .
89470182|NCT05374278|Experimental|Cohort 1 - dosimetry of [18F]RP-115 in healthy volunteers|Establish [18F]RP-115 safety in the clinic with male and female PET imaging.
89470183|NCT05374278|Experimental|Cohort 2B - [18F]RP-115 in patients with AD|Comparison of [18F]RP-115 PET binding between AD patients and age-matched cognitively normal controls and between AD and FTD
89470184|NCT05374278|Experimental|Cohort 2C - [18F]RP-115 in patients with FTD|Comparison of [18F]RP-115 PET binding between AD patients and age-matched cognitively normal controls and between AD and FTD
89470185|NCT05374278|Experimental|Cohort 2A - [18F]RP-115 in age-matched controls|Comparison of [18F]RP-115 PET binding between AD patients and age-matched cognitively normal controls and between AD and FTD
89470186|NCT05356481|Experimental|Experimental Group A|will recieve (low frequency segmental muscle vibration of 41 Hz over flexors muscles of upper limb Pectoralis minor, Biceps brachii, Flexor carpi muscle + general physical therapy session ) The transducer applied perpendicular to the muscle near its distal tendon insertion.The application consisted of 3 vibration sessions each with duration of 5 minutes for each muscle with 1 minute interval separated these sessions during the interval muscle vibration will interrupted and the subject will request to relax the muscle
89470187|NCT05356481|Experimental|Experimental Group B|group receive (low frequency segmental muscle vibration of 41 Hz over extensors muscles of upper limb Triceps brachii, Extensor carpi radialis longus & brevis + general physical therapy session ) The transducer applied perpendicular to the muscle near its distal tendon insertion The application consisted of 3 vibration sessions each with duration of 5 minutes for each muscle with 1 minute interval separated these sessions during the interval muscle vibration will interrupted and the subject will request to relax the muscle
89470188|NCT05346406|Active Comparator|Peripherally Inserted Central Catheter|
89470189|NCT05346406|Experimental|Long Peripheral Catheter|
89470190|NCT05319639|Experimental|POFI and Tislelizumab|"This study will include a sequential evaluation of 3 subjects per cohort. Irinotecan 135 → 150 and paclitaxel 45 → 67.5 → 90 mg/m2 on day 1.~The rest of regimen is that oxaliplatin (85 mg/m2) and Lev-leucovolin (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days. Tislelizumab 200mg，repeating the cycle every 14 days.~A dose limiting toxicity (DLT) event is defined as any of the following events in the first 4-week period:~CTCAE Grade 4 event (except for neutropenia lasting for ≤ 5 days); Grade 3 non-hematologic toxicity (except for nausea and vomiting that could be improved with optimal supportive care, escalation of alkaline phosphatase) If a DLT is experienced in any cohort, the cohort will be expanded to 6 subjects. If 2 DLTs are experienced in any cohort, the dose escalation ceased. The MTD was defined as the dose having at most two out of six patients experience DLT."
89019014|NCT00301886|Experimental|zoledronate|zoledronate
89470191|NCT05308511|Experimental|Swallowing order I|First swallow the trial device(PC-I) for examination, and then swallow the comparator device(COLON2) for examination at an interval of 2h.
89470192|NCT05308511|Experimental|Swallowing order II|First swallow the comparator device(COLON2) for examination, and then swallow the trial device(PC-I) for examination at an interval of 2h.
89470193|NCT05305950||Healthcare administrators|Healthcare administrators at MD Anderson Cancer Center and the sister institutions
89019015|NCT00301886|Experimental|ibandronate|ibandronate
89019016|NCT00301925|Active Comparator|Epi-CMF|
89470194|NCT05305950||Physicians/referring providers|Physicians/referring providers and the occupational therapy (OT) and physical therapy (PT) therapists at MD Anderson Cancer Center and the sister institutions
89470195|NCT05260684||Encorafenib + binimetinib|Encorafenib 450 mg once a day (QD) Binimetinib 45 mg twice a day (BID)
89470196|NCT05260684||Vemurafenib + binimetinib|Vemurafenib 960 mg twice a day (BID) for 28 days of 28 day cycle Cobimetinib 60 mg once a day (QD) for 21 days of 28 day cycle
89470197|NCT05260684||Dabrafenib + trametinib|Dabrafenib 150 mg twice a day (BID) Trametinib 2 mg once a day (QD)
89470198|NCT05224206|Sham Comparator|Sham iTBS/Active iTBS|Intermittent Theta Burst Stimulation (iTBS) or realistic sham iTBS will be applied to the left DLPFC. Both sessions will be one week apart.
89470199|NCT05224206|Active Comparator|Active iTBS|Intermittent Theta Burst Stimulation (iTBS) will be applied to the left DLPFC. Participants will receive daily sessions (on weekdays) for 6 weeks.
89470200|NCT05211440|Placebo Comparator|Placebo (Maltodextrin)|Subjects will be directed to consume 1 placebo capsule containing maltodextrin, twice daily, for 21 days.
89470201|NCT05211440|Experimental|BC-006|Subjects will be directed to consume 1 capsule containing BC-006, twice daily, for 21 days.
89470202|NCT05196646||(1) 10 preterm infants spontaneously breathing in-room air with no respiratory support|Group 1 will consist of 10 preterm infants spontaneously breathing in room air, with no respiratory support, in whom respiratory acoustic signals from the acoustic sensor will be compared with airflow measurements obtained using a pneumotachometer, i.e. the gold standard. Data will be acquired for 10 minutes.
89470203|NCT05196646||(2) 20 preterm infants spontaneously breathing in-room air with no respiratory support|Group 2 will consist of 20 preterm infants spontaneously breathing in room air, with no respiratory support, in whom respiratory acoustic signals from the acoustic sensor will be compared with airflow measurements obtained using a nasal temperature sensor. In addition, measurements of respiratory efforts will be obtained using the Respiratory Inductance Plethysmography (RIP), an inertial measurement unit (IMU) integrated within the acoustic sensor, and the Transthoracic Impedance (TTI) from the bedside monitor. Data will be continuously recorded for 3 hours.
89470204|NCT05196646||(3) 20 preterm infants on continuous positive airway pressure (CPAP) with cardiorespiratory events|Group 3 will consist of 10 preterm infants on CPAP with established cardiorespiratory events, in whom respiratory acoustic signals from the acoustic sensor will be continuously measured for 3 hours. In addition, measurements of respiratory efforts will be obtained using the Respiratory Inductance Plethysmography (RIP), an inertial measurement unit (IMU) integrated within the acoustic sensor, and the Transthoracic Impedance (TTI). Data will be continuously recorded for 3 hours.
89470205|NCT05165394|Placebo Comparator|Placebo|Participant follows Placebo schedule (57 days)
89470206|NCT05165394|Experimental|Antidepressant|Participant follows NBI-1065846 schedule (57 days)
89470207|NCT05163886|Experimental|LAM-002A|LAM-002A will be administered orally in five 25 mg capsules twice a day (250 mg total daily dose).
89470208|NCT05163886|Placebo Comparator|Placebo|Placebo matching LAM-002A will be administered orally in 5 capsules twice a day.
89470209|NCT05144334|Experimental|BTX-1188 Dose Cohort 1|Starting dose of BTX-1188 administered orally per dosing schedule
89470210|NCT05144334|Experimental|BTX-1188 Dose Cohort 2|First dose escalation of BTX-1188 administered orally per dosing schedule
89470211|NCT05144334|Experimental|BTX-1188 Dose Cohort 3|Second dose escalation of BTX-1188 administered orally per dosing schedule
89470212|NCT05144334|Experimental|BTX-1188 Dose Cohort 4|Third dose escalation of BTX-1188 administered orally per dosing schedule
89470213|NCT05144334|Experimental|BTX-1188 Dose Cohort 5|Fourth dose escalation of BTX-1188 administered orally per dosing schedule
89470214|NCT05144334|Experimental|BTX-1188 Dose Cohort 6|Fifth dose escalation of BTX-1188 administered orally per dosing schedule
89470215|NCT05144334|Experimental|BTX-1188 Dose Cohort 7|Sixth dose escalation of BTX-1188 administered orally per dosing schedule
89470216|NCT05142722|Placebo Comparator|Placebo|one placebo tablet once daily
89470217|NCT05142722|Experimental|obicetrapib 10mg|one 10mg obicetrapib tablet once daily
89470218|NCT05133531|Experimental|Cohort A|Randomized 1:1
89470219|NCT05133531|Experimental|Cohort B|Randomized 1:1
89470220|NCT05129904||Double plasma molecular absorption system treatment|Patients treat with DPMAS alone or in combination with plasma exchange
89470221|NCT05129904||Standard medical therapy|Patients with standard medical therapy except for DPMAS treatment or other artificial liver support system
89470222|NCT05120388|Experimental|Dietary addition of extra virgin olive oil|WHO diet with a daily addition of extra virgin olive oil
89470223|NCT05120388|No Intervention|No addition of extra virgin Olive Oil|WHO diet
89470224|NCT05115331|Active Comparator|Conventional Radiation Dose|8 Gy in a single fraction
89470225|NCT05115331|Experimental|Experimental Radiation Dose|16 Gy in 2 fractions
89470226|NCT05102721|Experimental|Experimental|Single arm, all patients serially enrolled to combination doses of Avelumab and Pepinemab
89470227|NCT05097573|Experimental|Venus Viva|The Venus Viva™ fractional RF device has been shown in clinical studies to improve various skin conditions related to aging and alter collagen structures such as wrinkles, rhytids, stretch marks and scars. Beginning with the Baseline visit (Visit 1), subjects will receive a total of 4 treatments approximately 4 weeks apart.
89470228|NCT05086471|Experimental|NaviCam SB|After gastrointestinal preparation, the enrolled patients swallow NaviCam SB and the PillCam SB3 capsules approximately 40 minutes apart in a randomized order for small bowel capsule endoscopy.
89470229|NCT05086471|Other|PillCam SB3|After gastrointestinal preparation, the enrolled patients swallow NaviCam SB and the PillCam SB3 capsules approximately 40 minutes apart in a randomized order for small bowel capsule endoscopy.
89470230|NCT05048784|Experimental|Treatment Sequence ABC|"Participants will be administered sotorasib dose A orally in the following order:~Treatment A - as 3 tablets (test 1)~Treatment B - as 8 tablets (reference)~Treatment C - as 3 tablets (test 2)"
89470231|NCT05048784|Experimental|Treatment Sequence BAC|"Participants will be administered sotorasib dose A orally in the following order:~Treatment B - as 8 tablets (reference)~Treatment A - as 3 tablets (test 1)~Treatment C - as 3 tablets (test 2)"
89470232|NCT05038228||NVAF High GI bleed risk|NVAF patients with a high risk of gastrointestinal bleeding
89470233|NCT05002569|Experimental|Arm A: Nivolumab Plus Relatlimab|Combination
89470234|NCT05002569|Experimental|Arm B: Nivolumab|Monotherapy
89470235|NCT04985799|Active Comparator|Gynecare TVT Exact sling|Participants who are planning surgery for SUI are randomized to have placement of Gynecare TVT Exact sling and followed postoperatively for 1 year.
89470236|NCT04985799|Active Comparator|Neomedic KIM sling|Participants who are planning surgery for SUI are randomized to have placement of retropubic Neomedic KIM sling and followed postoperatively for 1 year.
89470237|NCT04979962|Experimental|CAC Group|Inspection with computer assisted colonoscopy.
89470238|NCT04979962|No Intervention|CC Group|Inspection with conventional colonoscopy
89470239|NCT04970810|No Intervention|Attention Control|Subjects monthly calls similar in structure to the intervention arms, but without support. (attention placebo control)
89470240|NCT04970810|Active Comparator|My Diabetes Goal|My Diabetes Goal protocol
89470241|NCT04970810|Active Comparator|My Diabetes Goal + Community Rx|My Diabetes Goal protocol + Community Rx protocol
89470242|NCT04950504|Experimental|CNP-201 250 mg|200 mL intravenous infusion on Day 1 and Day 8: 250 mg CNP-201
89470243|NCT04950504|Experimental|CNP-201 450 mg|200 mL intravenous infusion on Day 1 and Day 8: 450 mg CNP-201
89470244|NCT04950504|Experimental|CNP-201 650 mg|200 mL intravenous infusion on Day 1 and Day 8: 650 mg CNP-201
89470245|NCT04950504|Placebo Comparator|Placebo|200 ml intravenous infusion on Day 1 and Day 8: CNP-201 Placebo
88947764|NCT01925235||RIPC|patients with impaired renal function and a high risk of developing acute kidney injury undergoing TAVI and receiving standard care including pre-hydration 12 hours prior and 12 hours post procedure plus ischemic preconditioning (intermittent arm ischemia through 4 cycles of 5-minute inflation and 5-minute deflation of a blood pressure cuff)
88947765|NCT01925365|Experimental|Wholegrain cereal oats|Volunteers had to consume wholegrain cereals oats (WGO)(45g/day) for six weeks followed by a four week wash out period.
88947766|NCT01925365|Placebo Comparator|Non wholegrain cereals|Volunteers had to consume non wholegrain cereals (NWG)(45g/day) for six weeks followed by a four week wash out period.
88947767|NCT01925625|No Intervention|Control|participants monitored for 10 years for lung cancer incidence.
88947768|NCT01925625|Active Comparator|Early CDT Lung Test|Early CDT lung blood test
88947769|NCT01925807|Experimental|Group Intervention|The intervention will consist of 6 psycho-educational group sessions for caregivers and 6 psycho-educational group sessions for adolescents. Adolescent and caregiver sessions will be held separately and will focus on different issues. For adolescents, the group sessions will focus on coping strategies and emotional regulation. For caregivers, the group sessions will be focused on attachment, family environment, and validation.
88947770|NCT01926262|Experimental|Physical Exercise Group|Specific Strength Training for the Neck and Shoulder muscles
88947771|NCT01926262|No Intervention|Reference group|No Specific Strength Training
88947772|NCT01926457|Experimental|First Trimester Treatment of Prediabetes|"Patients randomized to first trimester treatment will receive the following intervention immediately initiated upon diagnosis of prediabetes at <15 weeks 0 days gestation~diabetes education~blood glucose monitoring~medications as needed per California Diabetes and Pregnancy established protocol~growth ultrasounds~antenatal testing"
88947773|NCT01926457|Active Comparator|Third Trimester Treatment of Prediabetes|"Patients randomized to third trimester treatment will receive the following intervention to be initiated at 28 weeks of gestation~diabetes education~blood glucose monitoring~medications as needed per California Diabetes and Pregnancy established protocol~growth ultrasounds~antenatal testing"
88947774|NCT01926522|Experimental|Technological Rehabilitation|Experimental group receives a treatment of: 20 minutes of analyzing treadmill with feedback focused on symmetry and length of stride; 20 minutes of isokinetic dynamometric muscle strengthening of flexor and extensor muscles of tibiotarsal joint; 20 minutes of balance retraining on dynamic balance platform. Each patient receives 20 sessions over a period of 4 weeks (5 sessions per week).
88947775|NCT01926522|Active Comparator|Control Rehabilitation|Control group receives the same number of treatment sessions of same duration as those in the experimental group: activities targeted to improve the endurance (instead of analyzing treadmill ), manual exercises of lower limb muscle strengthening, stretching exercises (instead of dynamometer), gait retraining on the floor for 20 minutes and static and dynamic balance exercises in upright position (instead of dynamic balance platform).
88947776|NCT01926535|Experimental|Implant of amniotic membrane grafts|Amniotic membrane grafts were implanted in the affected eyes using topical anesthesia. Each graft was sutured to the bulbar conjunctive tissue using 10-0 nylon sutures and a reinforcement stitch was applied at the cornea
88947777|NCT01926535|Active Comparator|Therapeutic contact lenses|Therapeutic contact lenses were applied in all patients and the lenses were replaced every two months according to the pre-established gold standard for this procedure.
89470246|NCT04949854|Active Comparator|Control Arm B.Braun 6.35 cm 20 Gauge catheter|Device 6.35 cm 20 Gauge B. Braun catheter without guidewire
89470247|NCT04949854|Experimental|Experimental Arm B.D. Accucath 5.71 cm 20 Gauge catheter|Device BD 5.71 cm Accucath IV catheter with guidewire
89019017|NCT00301925|Experimental|Accelerated Epi-CMF|
89019018|NCT00301925|Experimental|Epi-Capecitabine|
89470248|NCT04940221|Experimental|Phone-delivered decision-counseling program for shared decision making in lung cancer screening|All individuals who are eligible for lung cancer screening according to USPSTF criteria were invited to participate in the study and all patients who accepted the invitation and consented were slated to receive the intervention which was a phone-delivered on line decision-counseling program (DCP) and there was no one randomized or enrolled into a control group, nor was anyone randomized or enrolled into a usual care group.
89470249|NCT04933448|Experimental|Prospective Intervention Group|Participants will receive standard of care for acute management of moderate to severe traumatic brain injury, together with a weight-based ketogenic diet added for up to fourteen days.
89470250|NCT04933448|No Intervention|Historical Control Group|Medical records of past TBI patients will be used as controls matched for age, gender, socioeconomic status (type of health care coverage including private insurance vs. government-funded coverage), lowest first 24 hour post-injury Glasgow Coma Score (GCS) (<8 or 8-12), and pre-injury school program (regular or special education).
89470251|NCT04919824|Experimental|Bipolar Knife|ESD procedure performed with a novel bipolar knife.
89470252|NCT04919824|Active Comparator|Monopolar Knife|ESD procedure performed with monopolar knives.
89470253|NCT04900675|Experimental|bright white light intervention|exposure to 5,000 lux with polychromatic white light with 5,300 Kelvin at eye level; light exposure starts immediately after awakening; light exposure takes place on weekdays (Monday till Friday) over a period of 3 weeks
89470254|NCT04900675|Placebo Comparator|dim reddish light intervention|exposure to 50 lux with polychromatic reddish light with 2,200 Kelvin at eye level; light exposure starts immediately after awakening; light exposure takes place on weekdays (Monday till Friday) over a period of 3 weeks
89470255|NCT04900675|No Intervention|no light intervention|no light intervention takes place in the morning; the study participants follow their natural rhythm of life
89470256|NCT04897542|Experimental|Patients will undergo a Gallium-68 NODAGA-JR11 PET/CT as well as a Gallium-68 DOTATATE PET/CT|"Each patient receive a single intravenous injection of Gallium-68 DOTATATE (40ug/150-200MBq) PET/CT, and undergo PET/CT scan at 40-60 min post-injection.~All patients have to do a Gallium-68 NODAGA-JR11 PET/CT scan (40ug/150-200MBq, 40-60 min post-injection) for comparison on the next day of DOTATATE scan."
89470257|NCT04894123|Experimental|trifluridine/tipiracil +/- oxaliplatin|"Trifluridine/tipiracil 35 mg/m² orally twice a day from day 1 to day 5 plus oxaliplatin 85 mg/m² intravenous at day 1 every 14 days.~If oxaliplatin is stopped for neurotoxicity, allergic reaction or other reason, or it is not indicated, patients will continue trifluridine/tipiracil in monotherapy 35 mg/m² orally twice a day between days 1-5 and days 8-12; repeated every 28 days."
89470258|NCT04885322|Experimental|DLPFC Stimulation|Intervention. 20 minutes of 2 mA direct current stimulation over the dorsolateral prefrontal cortex.
89470259|NCT04885322|Experimental|Occipital Stimulation|Intervention. 20 minutes of 2 mA direct current stimulation over the occipital cortex.
89470260|NCT04885322|Sham Comparator|Sham Stimulation|Placebo Comparator. 0.5-1 minutes of 2 mA direct current stimulation over the dorsolateral prefrontal cortex followed by 19-19.5 minutes of sham stimulation
89470261|NCT04884282|Experimental|Arm A - tedopi + docetaxel|Tedopi every 3 weeks plus docetaxel every 3 weeks only for 6 cycles, then maintenance with Tedopi alone every 6 weeks until the end of year 1, then every 12 weeks until disease progression, unacceptable toxicity or patient refusal.
89470262|NCT04884282|Experimental|Arm B - tedopi + nivolumab|Tedopi every 3 weeks plus nivolumab 360 mg every 3 weeks for 6 cycles, then maintenance nivolumab 360 mg every 3 weeks plus Tedopi every 6 weeks until the end of year 1, then every 12 weeks until disease progression, unacceptable toxicity or patient refusal
89470263|NCT04884282|Other|Arm C - docetaxel|Docetaxel every 3 weeks until disease progression, unacceptable toxicity, patient refusal, or for a maximum of 6 cycles (whichever comes first).
89470264|NCT04865276|Active Comparator|Intervention|Integrated tobacco cessation intervention delivered by Community Health Workers with the support of an App (mHealth) + Tobacco cessation program at the public health system
89470265|NCT04865276|Active Comparator|Control|Home visit by a Community Health Worker during which the participant is scheduled to attend the tobacco cessation program at the public health system
89019019|NCT00301925|Experimental|Accelerated Epi-Capecitabine|
89470266|NCT04863729|Experimental|Intervention|The program consists of 11 weekly sessions conducted with girls ages 10-14 and their female caregivers. 5 of the 11 sessions will be taught to groups of 9-13 girls and their female caregivers, and 6 of the sessions will be taught to individual girl/female caregiver dyads. The choice to use a mix of group- and individual sessions is based on findings from the formative phase indicating certain topics should be taught in groups (e.g. Navajo history and reproductive health 101), and certain topics be taught in individual dyads (e.g. family values and the clan system).
89470267|NCT04863729|No Intervention|Control|Girls and their female caregivers randomized to the control group will receive 4 retention incentives that are mailed to them monthly. These incentives will each be <$10 per dyad, examples include: water bottles, lanyards, pencil cases and tote bags. The control condition was selected by community members and allows for minimal contamination and/or overlap between the AB curriculum and control group
89470268|NCT04856904|Placebo Comparator|Trifarotene Vehicle Cream|
89470269|NCT04856904|Experimental|Trifarotene (CD5789) 50 mcg/g Cream|
89470270|NCT04849845|Experimental|Afrezza|The test product is defined as Afrezza [insulin human] inhalation powder administered using the Afrezza inhaler. In addition, subjects will take their personal basal insulin while enrolled in the study.
89470271|NCT04827615|Other|High Risk|"Group 2: Of all adults in (1), those at high risk of diabetes and hypertension, defined as having a score >4 based on the following criteria:~Age 40-49 years (+1), age ≥50 years (+2)~Used to smoke or use smokeless tobacco products or sometimes currently use (+1), currently use daily (+2)~Currently consume alcohol daily (+1)~Waist circumference 81-90 cm (women)/91-100 cm (men) (+1), >90 cm (women)/>100cm (men) (+2)~Physical activity <150 minutes per week (+1)~Parent and/or sibling with high blood pressure, diabetes, or heart disease (+2)"
89470272|NCT04827615|Other|Eligible adults|Group 1: All adults ≥30 years old living in the 12 target villages who meet eligibility criteria and provide informed consent
89470273|NCT04803877|Experimental|Regorafenib and Nivolumab|
89470274|NCT04796246|Experimental|Leap Motion Controller|Intervention Group: which will receive treatment with Leap Motion Controller
89470275|NCT04796246|Active Comparator|Conventional Physiotherapy|Control Group: who will receive treatment with conventional physiotherapy.
89470276|NCT04793750|Experimental|POC HIV VL Testing|Participants will receive the standard of care tests (DPP HIV-Syphilis Test System, OraQuick) plus the HIV POC VL test.
88947778|NCT01926561||Hypotensive bradycardic event|The participants are assigned to hypotensive bradycardic event (HBE) group when they experience signs or symptoms associated with syncope, hypotension, or bradycardia, which are treated with vasopressors or inotropics following sitting position after interscalene brachial plexus block is done. Otherwise, they are assigned to non-HBE group.
89470277|NCT04793750|Active Comparator|SOC HIV Testing|Participants will receive routine standard of care HIV testing.
89470278|NCT04774744|Experimental|Group I (digital health coaching program)|Patients receive the PACK Health digital health coaching program over 3 months consisting of communication initiated by either the PACK Health coach or the patient through either text, e-mail, or phone call, to provide education and support related to a specific topic such as fatigue, nutrition, or exercise.
89470279|NCT04774744|Active Comparator|Group II (standard of care support services)|Patients receive standard of care support services consisting of a telephone triage line that patients may call when experiencing physical or psychological concerns, or with any other questions related to their disease or treatment.
89470280|NCT04761549|Other|Adolescent Idiopathic Scoliosis|Questionnaires, Radiological EOS scan, 3D Dynamic Motion analysis
89470281|NCT04758871|Experimental|Dydrogesterone|Luteal phase support for hormone replacement therapy frozen embryo transfer cycles using dydrogesterone 10 mg 3 times daily
89470282|NCT04758871|Active Comparator|Micronized progesterone|Luteal phase support for hormone replacement therapy frozen embryo transfer cycles using micronized progesterone 2x200 mg twice daily vaginally
89470283|NCT04753736|No Intervention|No recurrent implantation failure|
89470284|NCT04753736|Experimental|Recurrent implantation failures|
89470285|NCT04753736|Experimental|Recurrent miscarriage|
89470286|NCT04740957|No Intervention|Observational cohort|"100 patients undergoing elective left colonic or rectal resection with a primary anastomosis will be recruited pre-operatively throughout the study period. This study will not affect or delay the intended treatment for study participants.~Patients will undergo serial endoscopic examination of the anastomosis post-operatively. Blood, urine, stool, and mucosal biopsies will be serially collected."
89470287|NCT04740957|Experimental|Distal limb feeding cohort|"This interventional arm will demonstrate the safety of re-introducing ileostomy effluent into the downstream (distal) limb of an ileostomy. The preliminary data will enable exploration of the association between microbiome and post-operative function and enable adequate powering of future interventional studies.~A subgroup of 20 patients undergoing a resection with a covering ileostomy will be recruited to the intervention arm. Complete healing of the colorectal anastomosis will first be confirmed by water-soluble contrast enema 8 weeks post-operatively (this is standard practice). Patients will be taught how to inject the output from the proximal ileostomy limb into the distal limb (this connects to the colon and thus the colorectal anastomosis) daily until the ileostomy closure date."
89470288|NCT04737603|Experimental|ED-initiated treatment with buprenorphine/naloxone.|A Clinical Opiate Withdrawal Score (COWS) score will be administered, and an induction dose of buprenorphine when COWS scores >=8. Participants who weigh > 70 kg and/or reported using ≥ 3 bags of heroin/day or its prescription opioid equivalent will receive 4 mg. After 1 hour an additional 4 mg will be administered for a total of 8 mg. Participants who weigh <= 70 kg and/or reported using ≤ 3 bags of heroin/day or its prescription opioid equivalent will receive 4 mg of buprenorphine. After 1 hour, an additional 2 mg will be administered for a total of 6 mg. Patients will be prescribed sufficient take-home daily doses (one-week supply) to ensure that the patient has adequate medication to receive 12-16 mg buprenorphine sublingual once daily. Parents of adolescents will also receive appropriate education on how to administer medication. Home induction instructions will be provided to patients and parents that arrive to the ED after an opioid overdose.
89470289|NCT04713787|Experimental|Group A|400 mg (4 capsules of 100 mg) of Oxfendazole administered orally as a single dose on Day 1. N=83.
89470290|NCT04713787|Experimental|Group B|800 mg (8 capsules of 100 mg) of Oxfendazole administered orally as a single dose on Day 1. N=83.
89470291|NCT04713787|Active Comparator|Group C|400 mg (1 tablet of 400 mg) of Albendazole administered orally as a single dose on Day 1. N=83.
89470292|NCT04700280|Experimental|GLPG3970|Participants will receive GLPG3970 400 milligrams (mg) (2 *200 mg tablet), orally, once daily for 12 weeks.
89470293|NCT04700280|Placebo Comparator|Placebo|Participants will receive placebo matched to GLPG3970 tablet, orally, once daily for 12 weeks.
89470294|NCT04679675|Active Comparator|Usual Care|
89470295|NCT04679675|Active Comparator|Education|
89470296|NCT04679675|Active Comparator|Direct Mail|
89470297|NCT04679675|Active Comparator|Opt-in|
89470298|NCT04660435||Women with ER+/Her2 negative metastatic breast cancer|Patients with ER+/HER2-negative metastatic breast cancer candidate to first-line treatment with a CDK4/6 inhibitor and an aromatase inhibitor as per standard clinical practice
89470299|NCT04648150|Experimental|VERUM|An active wave emission bracelet for a period of 2 months. Then delivery of a second active medical device for a period of 4 months
89470300|NCT04648150|Sham Comparator|SHAM|An inactive wave emission bracelet for a period of 2 months of use then delivery of an active medical device from M2 to M6 after inclusion.
88947779|NCT01927003|Experimental|Surgical flap|Dorsal digito-metacarpal flap is based on the dorsal digital artery and dorsal metacarpal artery.
88947780|NCT01927016||Esophagectomy for cancer|Patients operated on for a cancer of the esophagus, a Siewert I or II cancer of the oesophago-gastric junction
88947781|NCT01927185|Active Comparator|Long Axis strategy|The central venous catheterization will be performed by the long axis approach
88947782|NCT01927185|Active Comparator|Short Axis Strategy|The central venous catheterization will be performed by the short axis approach
88947783|NCT01927237|Experimental|HLR-first|"Patients in this arm will have the hypercapnia with low respiratory rate (HLR) strategy first. Once hypercapnia is achieved via inspired carbon dioxide, no additional changes will be made to the ventilator. Once steady-state is achieved, physiological measurements will be taken. The patient will be returned to baseline settings for a 15-minute rest period before starting the EHR strategy per the cross-over design."
88947784|NCT01927237|Experimental|EHR-first|"Patients in this arm will have the eucapnia with high respiratory rate (EHR) strategy first. Once hypercapnia is achieved via inspired carbon dioxide, respiratory rate will be increased until PetCO2 returns to baseline or up to 35 breaths per minute, as limited by the National Heart Lung and Blood Institute (NHLBI) ARDS Network protocol. fraction of inspired oxygen inspired oxygen fraction and set tidal volume will be maintained. Once steady-state is achieved, physiological measurements will be taken. The patient will be returned to baseline settings for a 15-minute rest period before starting the HLR strategy per the cross-over design."
88947785|NCT01927276|Placebo Comparator|Gluten Free Flour (Control)|Gluten Free Flour 10 grams daily
88947786|NCT01927276|Active Comparator|Wheat Flour|Wheat Flour 10 grams daily
88947787|NCT01927302|Experimental|Naming Deficits|Language treatment will focus on improving naming deficits in people who have aphasia. An experimental group will receive treatment focusing on naming objects and a control/natural history group will receive no treatment. Both groups will be assessed at baseline (week 0), at week 12, and at week 24.
89470301|NCT04626128|Experimental|Cohort 1 (Low Dose)|Subjects will receive a low dose of 0.03 mg CLS-AX
89470302|NCT04626128|Experimental|Cohort 2 (Low-mid Dose)|Subjects will receive a low-mid dose of 0.10 mg CLS-AX
89470303|NCT04626128|Experimental|Cohort 3 (High-mid Dose)|Subjects will receive a high-mid dose of 0.50 mg CLS-AX
89470304|NCT04626128|Experimental|Cohort 4 (High Dose)|Subjects will receive a high-mid dose of 1.0 mg CLS-AX
89470305|NCT04611997|Experimental|Group A|Laparoscopic gastrectomy group with the use of near-infrared imaging (ICG group)
89470306|NCT04611997|Placebo Comparator|Group B|Laparoscopic gastrectomy group without the use of near-infrared imaging (Non-ICG group)
89470307|NCT04595838|Experimental|Arm A:Best supportive oral care and Chemo Mouthpiece|Patients will receive best supportive oral care along with using the Chemo Mouthpiece device.
89470308|NCT04595838|Other|Arm B Best supportive oral care only|Patients will receive best supportive oral care only.
89470309|NCT04582435|Experimental|Insulin icodec|Participants will receive individualised weekly doses of insulin icodec
89470310|NCT04581850||PTSD patients|This group is composed of patients suffering from an active PTSD
89470311|NCT04581850||Control group (healthy individuals)|This group is composed of healthy individuals.
89470312|NCT04523571|Experimental|Low-dose, 18-55 years of age|
89470313|NCT04523571|Experimental|High-dose, 18-55 years of age|
89470314|NCT04523571|Placebo Comparator|Placebo, 18-55 years of age|
89470315|NCT04523571|Experimental|Low-dose, 65-85 years of age|
89470316|NCT04523571|Experimental|High-dose, 65-85 years of age|
89470317|NCT04523571|Placebo Comparator|Placebo, 65-85 years of age|
89470318|NCT04492995|Active Comparator|Radiotracer + TUMIR|TUMIR = transvaginal ultrsound-guided myometrial injection
89470319|NCT04492995|Experimental|(Radiotraces + ICG) + TUMIR|ICG =indocyanine green TUMIR = transvaginal ultrsound-guided myometrial injection
89470320|NCT04478630|Active Comparator|Peppermint Essential Oil|Usual care plus a personal pocket diffuser prepared with 14 drops of peppermint essential oil. Each subject will be instructed to inhale from the pocket diffuser beginning on the day of their chemotherapy (Day 1) and continue using the inhaler for the next three consecutive days (Day 1-Day 4).The subjects will remove the cover of the pocket diffuser, place the pocket diffuser approximately an inch away from their nose and inhale three times with deep breathing (i.e., three sniffs). Subjects will take 3 sniffs of the aromatherapy inhaler three times daily (morning, afternoon, and evening).The subjects will complete a Pre-treatment Assessment form before cycle of chemotherapy (total of 2), as well as 24 and 72 hours after each cycle of chemotherapy. The exact same procedures will be repeated during the participant's next cycle of chemotherapy, which is likely two or three weeks after the first one.
89470321|NCT04478630|Active Comparator|Ginger Essential Oil|Usual care plus a personal pocket diffuser prepared with 14 drops of ginger essential oil. Each subject will be instructed to inhale from the pocket diffuser beginning on the day of their chemotherapy (Day 1) and continue using the inhaler for the next three consecutive days (Day 1-Day 4). The subjects will remove the cover of the pocket diffuser, place the pocket diffuser approximately an inch away from their nose and inhale three times with deep breathing (i.e., three sniffs). Subjects will take 3 sniffs of the aromatherapy inhaler three times daily (morning, afternoon, and evening). The subjects will complete a Pre-treatment Assessment form before cycle of chemotherapy (total of 2), as well as 24 and 72 hours after each cycle of chemotherapy.The exact same procedures will be repeated during the participant's next cycle of chemotherapy, which is likely two or three weeks after the first one.
89470322|NCT04478630|Placebo Comparator|Pure Vanilla Extract (placebo-control)|Usual care plus a personal pocket diffuser prepared with 14 drops of pure vanilla extract (placebo). Each subject will be instructed to inhale from the pocket diffuser beginning on the day of their chemotherapy (Day 1) and continue using the inhaler for the next three consecutive days (Day 1-Day 4). The subjects will remove the cover of the pocket diffuser, place the pocket diffuser approximately an inch away from their nose and inhale three times with deep breathing (i.e., three sniffs). Subjects will take 3 sniffs of the aromatherapy inhaler three times daily (morning, afternoon, and evening). The subjects will complete a Pre-treatment Assessment form before cycle of chemotherapy (total of 2), as well as 24 and 72 hours after each cycle of chemotherapy. The exact same procedures will be repeated during the participant's next cycle of chemotherapy, which is likely two or three weeks after the first one.
89470323|NCT04448002|Experimental|AIM2ACT|AIM2ACT is the experimental arm for the trial. AIM2ACT is a dyadic mHealth intervention designed to sustain caregiver involvement and monitoring as well as guide dyads through collaborative asthma management.
89470324|NCT04448002|Active Comparator|mHealth Attention Control Condition|The mHealth attention control condition is the active comparator arm in the trial that accounts for staff attention and novelty of technology based asthma management intervention.
89470325|NCT04421820|Experimental|Part B - Dose Expansion - 1L Gastric Cancer (ARM I)|Arm closed to enrollment.
89470326|NCT04421820|Experimental|Part B - Dose Expansion - 2L Gastric Cancer (ARM II)|Open to enrollment.
89470327|NCT04421820|Experimental|Part B - Dose Expansion - 2L Pancreatic Cancer (ARM III)|Arm closed to enrollment.
89470328|NCT04421820|Experimental|Part B - Dose Expansion - 2L Colorectal Cancer (ARM IV)|Arm closed to enrollment.
89470329|NCT04421820|Experimental|Part B - Dose Expansion - 3L Colorectal Cancer (ARM VI)|Open to enrollment.
89470330|NCT04421820|Experimental|Part B - Dose Expansion - 2L Cholangiocarcinoma (ARM V)|Arm closed to enrollment.
89470331|NCT04421820|Experimental|Part A - Dose Escalation - Gastric Cancer|Arm closed to enrollment.
89470332|NCT04421820|Experimental|Part A - Dose Escalation - Pancreatic Cancer|Arm closed to enrollment.
89470333|NCT04421820|Experimental|Part A - Dose Escalation - Colorectal Cancer|Arm closed to enrollment.
89470334|NCT04421820|Experimental|Part A - Dose Escalation - Cholangiocarcinoma|Arm closed to enrollment.
89470335|NCT04410237|Experimental|Med-Jet|"The Med-Jet injector is a novel needle-free drug-delivery system, which we believe may be a solution to the impracticalities of ILTA for mild-to-moderate psoriasis. It uses regulated compressed air as a power source to accelerate an injectable fluid through a 0.005 orifice (6x smaller than a 30G needle) to penetrate the skin and deliver medication to a specific anatomical region.12 The drug-delivery device is highly configurable allowing adjustable depth and volume parameters.12 In addition, the high-performance design allows for triggering multiple injection sites rapidly which is practical when needing to treat large surface areas"
89470336|NCT04410237|Active Comparator|Traditional Syringe|TAC will be injected on a half-plaque while the control half of the plaque will be untreated. A standard sterile disposable 1 ml syringe and 30-gauge needle will be used to inject TAC.
89470337|NCT04369729||Post-Traumatic Headache|Individuals who have post-traumatic headache attributed to mild traumatic brain injury according to ICHD-3 diagnostic criteria
89470338|NCT04369729||Healthy Control|Healthy controls will have no history of traumatic brain injury and no history of migraine or other headaches
89470339|NCT04367090|Experimental|Pyrotinib and docetaxel plus trastuzumab|
89470340|NCT04361617|Active Comparator|Epigenetic age knowledge arm|Half of the intervention participants will be randomly selected to be informed of epigenetic age before the intervention.
89470341|NCT04361617|Active Comparator|No epigenetic age knowledge arm|The other half of intervention participants will not be informed of epigenetic age before the intervention.
89470342|NCT04346381|Experimental|camrelizumab combined with famitinib|Participants will receive camrelizumab on Day 1of each cycle and famitinib qd up to 2 years.
89470343|NCT04337450|Active Comparator|SOC|Standard-of-care (SOC)
89470344|NCT04337450|Experimental|DTG/3TC|Dolutegravir (DTG) and lamivudine (3TC) (known as DTG/3TC)
89470345|NCT04321993|Experimental|Baricitinib|Moderate and severe, not critical disease
89470346|NCT04321993|Experimental|Remdesivir|Moderate and severe, not critical disease
89470347|NCT04321993|Experimental|Remdesivir + baricitinib|Moderate and severe, not critical disease
89470348|NCT04321993|Experimental|Tocilizumab|Severe, critical disease
89470349|NCT04321993|No Intervention|Clinical standard of care|Moderate and severe, not critical disease AND severe, critical disease as applicable
89470350|NCT04307628|Active Comparator|Walnut|Eat 2 ounces of walnuts provided by the study. Eating any other nuts is to be avoided. Background diet will be low in polyphenols.
89470351|NCT04307628|Placebo Comparator|Nut-Free|Eating any other nuts is to be avoided. Background diet will be low in polyphenols.
89470352|NCT04233567|Experimental|Treatment (infigratinib)|Patients receive infigratinib PO QD on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89470353|NCT04212494|Experimental|Thrombus aspiration|Upfront manual thrombus aspiration followed by PCI
89470354|NCT04212494|Active Comparator|PCI Alone|PCI without upfront manual thrombus aspiration
89470355|NCT04170140||Prescribers of Dengvaxia|Healthcare professionals who are current or past prescribers of Dengvaxia
89470356|NCT04122001|Experimental|Active HD-tDCS+word intervention then Sham+word intervention|Participants will receive active HD-tDCS + Word List Learning Intervention (WordLLI) and then receive Sham + WordLLI after a three-month washout period.
89470357|NCT04122001|Experimental|Sham+word intervention then active HD-tDCS+word intervention|Participants will receive Sham + Word List Learning Intervention (WordLLI) and then active HD-tDCS + WordLLI after a three-month washout period.
88947788|NCT01927302|Experimental|Spelling and/or Writing Deficits|Language treatment will focus on improving writing and/or spelling deficits in people who have aphasia. An experimental group will receive treatment focusing on improving spelling abilities and a control/natural history group will receive no treatment. Both groups will be assessed at baseline (week 0), at week 12, and at week 24.
89470358|NCT04021914|Experimental|EnChroma glasses|EnChroma products improve brightness and color purity of primary colors for CVD people. Each participant with CVD will be provided EnChroma products to use indoors over the course of two weeks in the emergency department, educational settings, and in their personal life.
89470359|NCT04014322|Experimental|E-cigarette|All participants will be instructed to switch completely from combustible cigarettes to e-cigarettes for the next 8weeks. They will be assessed at baseline, 2 weeks, 4 weeks, 8 weeks, and 12 weeks.
89470360|NCT03988309|Active Comparator|"Test, subjects categorised as low risk or Not low risk"|"A clinical risk factor nomogram risk classification will be used in this study. The nomogram categorizes subjects as either low risk or not low risk categories. Low risk subjects satisfy all conditions and not low risk satisfies at least one of the conditions.The Cxbladder Triage test result will be provided to physicians for all low risk subjects on the test arm. If a low risk subject has a Cxbladder Triage negative test result then the indication is to rule out the subject without further assessment. The decision to rule-out or further evaluate is solely that of the physician and subject. If the low risk subjects are not Cxbladder Triage negative then a Cxbladder Detect test result will also be provided. The indication is further evaluation as per standard of care. Subjects categorised as not low risk will be evaluated as per standard of care. Note that Cxbladder test results will be available for eventual analysis for these subjects."
89470361|NCT03988309|No Intervention|Control|Subjects on the control arm will be on standard of care. Trial nomogram clinical risk factor categorization for control arm subjects will not be provided to the physician (but appropriate information will be collected on the CRF to enable sub-group analysis) No Cxbladder test results will be provided for control arm subjects. Note that Cxbladder test results will be available for eventual analysis for these subjects.
89470362|NCT03978988|Experimental|Thrombectomy + Carotid Stenting|"Intravenous thrombolysis will be administered if possible. Standard mechanical thrombectomy(MT) will be performed with a balloon Guide Catheter. MT technique will be left at the discretion of the operators.~Concerning the cervical disease, emergent carotid stenting will be performed if the patient is randomized in the intervention arm. The order to treat (head first or neck first), and the choice of a previous angioplasty of the extracranial carotid artery lesion will be left to the interventionist discretion. An intravenous bolus of 250mg of Aspirin (up to Imaging 24H) will be given at the end of the procedure in case of absence of complication.~Intravenous sedation or general anesthesia will be permitted.A second antiplatelet agent is used if a thrombus is formed : IV or nasogastric tube (choice by operator) A dual antiplatelet therapy is administered after 24H imaging follow-up excluding intracranial hemorrhagic complications (discretion of the local practice)"
89470363|NCT03978988|No Intervention|Thrombectomy alone|"Endovascular procedure:~Intracranial thrombectomy alone (carotid angioplasty may be performed)"
89470364|NCT03950427|Active Comparator|game-based Physical Activity Group|"The game-based physical activity group, will play active games using the Kinect for Xbox 360 game system or outdoors in a public park. Each game group will be facilitated by the study coordinator, the principal investigator or other study staff.~Participants in this group will also receive bupropion and counseling for smoking cessation."
89470365|NCT03950427|Placebo Comparator|Sedentary Videogame Group|"The sedentary videogame group will play games while seated using the Xbox 360 game system (without the Kinect sensor) or seated outdoors in a public park. Each sedentary videogame group will be facilitated by study staff.~Participants in this group will also receive bupropion and counseling for smoking cessation."
89470366|NCT03911505|Experimental|Cipaglucosidase Alfa (ATB200)/Miglustat(AT2221)|Participants received Cipaglucosidase Alfa (ATB200) co-administered with Miglustat (AT2221) capsule
89470367|NCT03909178|Active Comparator|Hip Arthroscopy Surgery with Acetabular Labral Repair|Hip Arthroscopy Surgery with Acetabular Labral Repair
89470368|NCT03909178|Active Comparator|Physical Therapy Focused on the Hip and Hemi-pelvis|Physical Therapy focusing on the hemipelvis strengthening, including the lower back, lower abdominal core, quadriceps, hamstrings, and gluteal muscles.
88947789|NCT01927302|Experimental|Sentence Processing|Language treatment will focus on improving sentence comprehension and production deficits in people who have aphasia. An experimental group will receive treatment focusing on improving sentence processing and a control/natural history group will receive no treatment. Both groups will be assessed at baseline (week 0), at week 12, and at week 24.
88947790|NCT01927354||Head and neck cancer|Subjects who suffer from oral cancer. Collect a 0.5x0.5Cm2 tissue sample of the tumor during the surgery.
88947791|NCT01927380||brachytherapy|males undergoing elective laparoscopic radical prostatectomy steep trendelenburg position with pneumoperitoneum
88947792|NCT01927445|No Intervention|Usual care|No standardized intervention for management of patients with atrial fibrillation. Instead participants receive interventions for management of chronic kidney disease.
88947793|NCT01927445|Experimental|quality improvement toolkit|The toolkit includes provider-focused strategies (education, audit and feedback, electronic decision support and reminders) plus patient-directed strategies (educational letters and reminders).
89470369|NCT03851588|Active Comparator|Supplementary dose|Dolutegravir-lamivudine-tenofovir fixed-dose combination tablet daily with an additional dolutegravir 50 mg dose taken 12 hours later.
89470370|NCT03851588|Placebo Comparator|Placebo dose|Dolutegravir-lamivudine-tenofovir fixed-dose combination tablet daily with placebo taken 12 hours later.
89470371|NCT03850600|Experimental|Diet-CD|dietary intervention: 8-10 weeks of diet intervention
89470372|NCT03850600|No Intervention|No-Diet-CD|Usual diet with no intervention
89470373|NCT03850600|No Intervention|No-Diet-Control|Unaffected controls at the same gestational stage will follow usual diet and no intervention
89470374|NCT03850444|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg by IV infusion on Day 1 every 3 weeks (Q3W) for a maximum of 35 cycles (21-day cycles). Participants who stop the initial course of pembrolizumab due to complete response or complete the initial course of pembrolizumab and have stable disease, but progress after discontinuation, are eligible for a second course of pembrolizumab for up to an additional 1 year (17 additional 21-day cycles).
89470375|NCT03850444|Active Comparator|SOC Treatment|Participants receive carboplatin at target dose Area Under the Curve (AUC 5) (maximum dose 750 mg) or AUC 6 (maximum dose 900 mg) + paclitaxel 200 mg/m^2 by IV infusion on Day 1 Q3W for a maximum of 6 cycles (21-day cycles) OR carboplatin target dose AUC 5 (maximum dose 750 mg) or AUC 6 (maximum dose 900 mg) + pemetrexed 500 mg/m^2 by IV infusion on Day 1 Q3W for a maximum of 6 cycles (21-day cycles). Participants with non-squamous histologies receive optional additional maintenance treatment with pemetrexed 500 mg/m^2 by IV infusion on Day 1 Q3W.
89470376|NCT03850379|Experimental|Levo|Levofloxacin 500 mg once daily
89470377|NCT03850379|Active Comparator|Cipro|Ciprofloxacin 500 mg BID
89470378|NCT03824483|Experimental|BOVEN regimen|"Patients will be given zanubrutinib (160mg by mouth BID) and obinutuzumab (1000mg IVPB on Days 1*, 8 and 15 of Cycle 1 and on Day 1 of Cycles 2 through 8) starting on Cycle 1 (28-day cycles). * On Cycle 1, obinituzumab will be administered in split dose at 100mg IVPB on Day 1 and 900mg IVPB on Day 2 in patients at increased risk for IRR (ALC >25,000 cells/ul or baseline lymph nodes >5 cm diameter). Venetoclax will be added to the regimen starting on Cycle 3, and will be incorporated into the regimen using the 5-week ramp-up schedule to mitigate the risk of tumor lysis syndrome (beginning at 20mg and gradually increasing to 400mg), and venetoclax will be administered a ta fixed dose level of 400mg by mouth daily of 28-day cycles thereafter."
89470379|NCT03820141|Experimental|Durvalumab + Trastuzumab + Pertuzumab|Durvalumab, trastuzumab, and pertuzumab will be administered on Day 1 every 3 weeks for 6 cycles. Trastuzumab will be administered as 8 mg/kg intravenous (IV) loading dose, followed by 6 mg/kg IV. Pertuzumab will be administered as 840 mg IV loading dose, followed by 420 mg. Durvalumab will be administered at a fixed dose of 1120 mg IV.
89470380|NCT03781804|Active Comparator|OPN-375 186 μg BID|OPN-375 186 μg BID x 24 Weeks
89470381|NCT03781804|Active Comparator|OPN-375 372 μg BID|OPN-375 372 μg BID x 24 Weeks
89470382|NCT03781804|Placebo Comparator|Placebo|Matching Placebo BID x 24 Weeks
89470383|NCT03742245|Experimental|Olaparib and Vorinostat|"Phase I: Olaparib and vorinostat will be orally administered for 4 28-day cycles. Dose levels (DLs) are as follows: DL -1, 100 mg twice daily (b.i.d.) olaparib and 300 mg for 5 consecutive days per week vorinostat; DL 0 (starting dose), 200 mg twice daily (b.i.d.) olaparib and 300 mg once daily (q.d.) vorinostat; DL 1, 300 mg b.i.d. olaparib and 300 mg q.d. vorinostat; and DL 2, 300 mg b.i.d. olaparib and 400 mg q.d. vorinostat.~Phase Ib: Olaparib and vorinostat will be administered at the maximum tolerated dose (MTD) determined in the Phase I portion of the study for 4 28-day cycles. Participants who derive clinical benefit (complete response, partial response, or stable disease) after 4 cycles will continue to receive study treatment until unacceptable toxicity or disease progression."
89019020|NCT00302237||1|1) To provide an ongoing post-market surveillance mechanism to document clinical outcomes. 2) To provide additional information that the RX ACCULINK™ and RX ACCUNET™ can be used safely by a wide range of physicians under commercial use conditions. 3) To evaluate the adequacy of Abbott Vascular's physician training program.
89019021|NCT05234775|Experimental|LIB003 (lerodalcibep) Process 1|300 mg LIB003 Process 1 drug product administered SC
89019022|NCT05234775|Active Comparator|LIB003 (lerodalcibep) Process 2|300 mg LIB003 Process 2 drug product administered SC
89470384|NCT03718312|Experimental|Arm 1|Patients with aortic clamping withpre-conditioning
89470385|NCT03718312|No Intervention|Arm 2|Patients with aortic clamping without pre-conditioning
89470386|NCT03706261|Experimental|Offspring Cohort|Racially/ethnically diverse subjects with or without a positive family history of Alzheimer's disease (AD) will have one PET scan with 18F-MK-6240 over a 30 to 60-minute scanning period, and one PET scan with 18F-Florbetaben over a 20-minute scanning period.
89470387|NCT03704662|Other|Stereotactic Body Radiation Therapy|Patients undergo Stereotactic Body Radiation Therapy (25 to 35 Gy over five fractions)
89470388|NCT03704662|Other|Preoperative Fractionated Radiation Therapy and Chemotherapy|Concurrent chemotherapy with radiation treatment (50.4 Gy over 28 fractions).
89470389|NCT03664648||Adult Pregnant Women Exposed to HEPLISAV-B|Adult women who received a dose of HEPLISAV-B within 28 days prior to conception or at any time during pregnancy.
89470390|NCT03648450||Propeller Smart Inhaler EMD|All enrolled participants will be given the Propeller Smart Inhaler electronic monitoring device to use for three months to track how often they are using their inhalers either for their regular medication or as a rescue dose.
89470391|NCT03624660|Experimental|HR-A (High-risk A)|"Prostate and proximal seminal vesicles: 2 cobalt gray equivalent per fraction to a total dose of 78 cobalt gray equivalent.~Simultaneous integrated boost to the IPT: 2.2 cobalt gray equivalent per fraction to a total dose of 85.8 cobalt gray equivalent."
89470392|NCT03624660|Experimental|HR-B (High-risk B)|"Prostate, proximal seminal vesicles, and pelvic nodes: 2 cobalt gray equivalent per fraction to a total does of 46 cobalt gray equivalent.~Prostate and proximal seminal vesicles: 2 cobalt gray equivalent per fraction to a total dose of 32 cobalt gray equivalent.~Entire uninvolved seminal vesicle when part of the seminal vesicle is involved with tumor: 2 cobalt gray equivalent per fraction to a total dose of 78 cobalt gray equivalent.~Simultaneous integrated boost to the IPT: 2.2 cobalt gray equivalent per fraction to a total dose of 85.8 cobalt gray equivalent."
89470393|NCT03619551|Experimental|Low Dose Busulfan|"Busulfan based preparative regimen targeted at area-under-the-curve (cAUC) exposure of 25-35 mg*h/L .~Randomization between the two dose levels will be done separately in each genotype stratum (RAG1/RAG2 and IL2RG/JAK3), using permuted blocks."
89470394|NCT03619551|Experimental|Medium Dose Busulfan|"Busulfan based preparative regimen targeted at area-under-the-curve (cAUC) exposure of 55-65 mg*h/L.~Randomization between the two dose levels will be done separately in each genotype stratum (RAG1/RAG2 and IL2RG/JAK3), using permuted blocks."
89470395|NCT03614026|Experimental|Teachers and Parents as Partners Intervention|Teachers and Parents as Partners will occur in a series of stages comprised of approximately four structured meetings over approximately 8 weeks. A Teachers and Parents as Partners consultant will meet together with a student's parent(s), teachers, other school personnel (as appropriate), and the student (as appropriate). The Teachers and Parents as Partners team will collaboratively address behavior problem solving objectives. Specific objectives include: identifying strengths and specific behaviors of concern, specifying alternative prosocial behaviors, creating measurable behavior goals, co-constructing behavior intervention/support plans to address the target concerns, creating sustainable conditions to support plan implementation at home and school, and evaluating the plan to assess progress toward goals.
89470396|NCT03614026|No Intervention|Business as usual control|In the business-as-usual control condition, participants will have access to any services that a school would routinely provide (e.g., develop and implement a behavior support plan) as well as services families can access in the community (e.g., mental health support).
89470397|NCT03581448|Experimental|Nerve Growth During Prosthesis Control|"Determine the optimum conditions that promote sensory restoration in limb-absent people, with an adaptive haptic feedback control law that mimics the experience of neural plasticity.~The intervention Sensory Restoration During Prosthesis Control will be used."
89470398|NCT03546972|Active Comparator|Group A (DPP)|Participants take part in DPP once a week over 1 hour for 16 weeks.
89470399|NCT03546972|Experimental|Group B (DPP-HT)|Participants take part in DPP once a week over 1 hour for 16 weeks and hunger training once a week during weeks 2-6.
89470400|NCT03522753|Experimental|Staples|For short single incisions, these patients will receive superficial closure using only metal skin staples. Closure will be performed by resident or fellow involved in the case.
89470401|NCT03522753|Active Comparator|Suture|For short single incisions, these patients will receive superficial closure using only nylon sutures. No metal skin staples will be used. Closure will be performed by resident or fellow involved in the case.
89470402|NCT03522753|Other|Half Staple Half Suture|Some patients will receive both nylon sutures and metal skin staples for superficial closure. If multiple incisions are involved, each incision will count as 1 in the alternation method (i.e. toe 1 will be all sutures, then toe 2 will be all staples). For long incisions, closure will alternate between nylon sutures and metal skin staples on the part of the incision which is closer (more proximal) or farther away (more distal) from the rest of the body.
89470403|NCT03507686|Experimental|BIIB111|Participants will receive a single dose of sub-retinal injection of BIIB111 in each eye at Day 0 separated by an interval of <6 months, 6-12 months, or >12 months.
89470404|NCT03506451|Other|Single arm non-therapeutic interventional study|All subjects who enroll on study will be asked to complete questionnaires at baseline before treatment starts; the questionnaires are repeated at one month, three and six months after radiation therapy has been completed. the demographics questionnaire is completed at baseline only; the FACT-HN is completed at all four time points.
89470405|NCT03471507|Experimental|Bonipar|
89470406|NCT03471507|Active Comparator|Diclofenac topical solution 1.5%|
89470407|NCT03459222|Experimental|Arm A|Relatlimab + Nivolumab + BMS-986205
89470408|NCT03459222|Experimental|Arm B|Relatlimab + Nivolumab + Ipilimumab
89470409|NCT03338894|Other|Yoga group|Each subject will serve as their own control
89470410|NCT03270072||Photon Therapy|The patients being treated on the Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial (NCT02603341) at Massachusetts General Hospital that were randomized to receive photon therapy.
89470411|NCT03270072||Proton Therapy|The patients being treated on the Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial (NCT02603341) at Massachusetts General Hospital that were randomized to receive proton therapy
89470412|NCT03250026|Experimental|Intervention (Workplace dialogue)|Intervention: Work place convergence dialogue contact
89470413|NCT03250026|Active Comparator|Care Manager|Intervention: Care Manager contact 12 weeks (Care as usual)
89470414|NCT03243734|Experimental|trūFreeze® System spray cryotherapy|trūFreeze® System spray cryotherapy as clinically indicated for symptom relief
89470415|NCT03138564|Experimental|SPIRIT Clinic|Patients at clinics that have been randomized to the SPIRIT arm will be given the option to participate in the intervention. SPIRIT is a two-session, 60-minute, structured psychoeducational intervention, targeting both patient and surrogate. Using a provider manual, the care provider follows six steps: 1) assessing illness presentation, 2) identifying gaps and concerns, 3) creating conditions for conceptual change, 4) introducing replacement information, 5) summarizing, and 6) setting goals and planning.
89470416|NCT03138564|Active Comparator|Comparison Condition Clinic|Patients at clinics that have been randomized to the control arm will be given the option to participate as a study control. The control clinics will have delayed implementation of the SPIRIT intervention.
89470417|NCT03137407|Experimental|DAXI 240 U|DaxibotulinumtoxinA for injection for the treatment of plantar fasciitis (PF) with 240 U
89470418|NCT03137407|Placebo Comparator|Placebo|Placebo Intramuscular Injection
89470419|NCT03114150|Experimental|Cardiorespiratory fitness training|Cardiorespiratory fitness training will be a 24-week supervised cycling program designed to improve cardiorespiratory fitness, with supervision directly from the research team. All participants will first receive a one-on-one orientation with an exercise training specialist that has been trained by Dr. Gary Pierce in monitoring an exercise program for healthy older adults. Training will start with a 5 minute-warm-up, 20 minutes moderate intensity cycling and 30 minutes light intensity cycling, and 5 minute cool-down per session, for 3 sessions/week. In each additional week, 6 minutes of moderate intensity cycling per session will be added, until the total time for moderate intensity is 50 minutes per session by the start of week 5 (with additional 5 minute warm-up and 5 minute cool-down).
89470420|NCT03114150|Active Comparator|Functional fitness training|Functional fitness training will be a 24-week supervised exercise program designed to focus on functional flexibility and mobility, with supervision directly from our research team. All participants will first receive a one-on-one orientation with an exercise training specialist that has been trained by Dr. Gary Pierce in monitoring an exercise program for healthy older adults. Training will start with a 5 minute-warm-up, 20 minutes of light intensity cycling and 20 minutes of dynamic stretching to increase range of motion and functional fitness, for 3 sessions/week. In each additional week, additional stretches will be added to maintain variety and improve flexibility of all major muscle groups.
89470421|NCT03063320|Active Comparator|Low Spice|The test meal (~1200kcal and 44g fat) will contain ~0.6g of spice blend
89470422|NCT03063320|Experimental|Moderate Spice|The test meal (~1200kcal and 44g fat) will contain ~3.7g of spice blend
89470423|NCT03063320|Experimental|Culinary Spice|The test meal (~1200kcal and 44g fat) will contain ~7.4g of spice blend
89470424|NCT02846103|Experimental|Biological samples|"Blood samples will be collected at baseline, after the first-line therapy and at 12 months.~Tumor tissues will be collected if available."
89470425|NCT02743494|Experimental|Nivolumab|
89470426|NCT02743494|Placebo Comparator|Placebo|
89470427|NCT02722538|Experimental|Residual Tumor following TURBT|TAR-200 is placed into the bladder through an inserter on Study Day 0 and is removed on Study Day 7. TAR-200 releases gemcitabine gradually during the 7 day indwelling time. A second TAR-200 is placed in the bladder on Study Day 21 and is removed on Study Day 28, which is the day of the Radical Cystectomy (RC).
89470428|NCT02722538|Experimental|No Residual Tumor Following TURBT|TAR-200 is placed into the bladder through an inserter on Study Day 0 and is removed on Study Day 7. TAR-200 releases gemcitabine gradually during the 7 day indwelling time. A second TAR-200 is placed in the bladder on Study Day 21 and is removed on Study Day 28, which is the day of the Radical Cystectomy (RC).
89470429|NCT02667873|Experimental|SL-801|The starting dose regimen of SL-801 (i.e., the dose regimen in Cohort 1) is 5 mg/day on Days 1-4 and 8-11 every 21 days. In the 2nd portion of the dose escalation stage, patients receive SL-801 PO once daily on days 1-2, 8-9, 15-16 and 22-23 of a 28-day cycle. The starting dose will be 70 mg/day (the next planned dose level).The SL-801 dose regimen for a particular patient is dependent on the cohort in which the patient is enrolled
89470430|NCT02531126|Experimental|RPC0163 (Ozanimod)|
89470431|NCT02401503|Experimental|Bendamustine + GA101 + ABT-199|"Bendamustine: 70mg/m² i.v. GA101: 1000 mg i.v. ABT-199: 20 - 400 mg p.o.~Possible Re-treatment of the included patients with GA101: 1000 mg i.v. and ABT-199: 20 - 400 mg p.o."
89470432|NCT02399423|Other|South Asian participants|30 South Asian male participants
89470433|NCT02399423|Other|European participants|30 European male participants
89470434|NCT02336282|Active Comparator|tDCS on Day 1|"On day one, participants will be randomized to receive the transcranial Direct Current Stimulation (tDCS) intervention. On day two, participants receive sham intervention.~On both days 1 and 2, within two hours of completing the intervention, participants will complete cognitive assessment.~In the second phase of the trial, participants will be evaluated over 5 weeks using a mobile tDCS device and Brain Games Stimulation twice per week. Within two hours of completing each tDCS session, participants will complete 20 minutes of cognitive training using a mobile application installed on an iPad. Cognitive assessment will be conducted pre- and post-intervention using remote assessment."
89470435|NCT02336282|Active Comparator|tDCS on Day 2|"On day one, participants will be randomized to receive sham intervention. On day two, participants receive the transcranial Direct Current Stimulation (tDCS) intervention.~On both days 1 and 2, within two hours of completing the intervention, participants will complete cognitive assessment.~The second phase of the trial will be conducted the same as for participants in the tDCS on Day 1 arm. Participants will be evaluated over 5 weeks using a mobile tDCS device and Brain Games Stimulation twice per week. Within two hours of completing each tDCS session, participants will complete 20 minutes of cognitive training using a mobile application installed on an iPad. Cognitive testing will be conducted pre- and post-intervention using remote assessment."
89470436|NCT02272998|Experimental|Treatment (ponatinib hydrochloride)|Patients receive ponatinib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89470437|NCT02272842|Experimental|Vitamin B12|A paste containing vitamin B12 2µg per 10 mL administered every day. The paste also contains 1 RDA of several other vitamins. The paste is produced by Compact (Norway / India)
89470438|NCT02272842|Placebo Comparator|Placebo|A paste containing no vitamin administered every day. The paste also contains 1 RDA of several vitamins, but no vitamin B12. The paste is produced by Compact (Norway / India)
89470439|NCT02258659|Experimental|Group A (radiation therapy alone)|Patients undergo radiation therapy once daily for weeks.
89470440|NCT02258659|Experimental|Group B (combination chemotherapy, low-dose radiation therapy)|Patients receive hydroxyurea PO BID on days 0-5, fluorouracil IV continuously on days 1-5, and paclitaxel IV over 60 minutes on day 1. Patients also receive low-dose radiation therapy BID on days 1-5. Treatment repeats every 14 days for 3 courses in the absence of disease progression or unacceptable toxicity.
89470441|NCT02258659|Experimental|Group C (combination chemotherapy, high-dose radiation)|"Patients receive hydroxyurea PO BID on days 0-5, fluorouracil IV continuously on days 1-5, and paclitaxel IV over 60 minutes on day 1. Patients also receive standard-dose radiation therapy BID on days 1-5. Treatment repeats every 14 days for up to 5 courses in the absence of disease progression or unacceptable toxicity.*~*NOTE: At the discretion of the PI, patients may receive cisplatin IV over 1-3 hours every 3 weeks during radiation therapy instead of paclitaxel and undergo daily radiation therapy."
89470442|NCT02064673|Active Comparator|Curcumin|Curcumin 500 mg orally twice a day
89470443|NCT02064673|Placebo Comparator|sugar pill|placebo orally twice a day
89470444|NCT01990300||Alogliptin/Pioglitazone combination tablets|Alogliptin/Pioglitazone combination tablets, taken orally, once daily for up to 12 months. Participants received interventions as part of routine medical care.
89470445|NCT01909934|Experimental|Brentuximab Vedotin 1.8 mg/kg|Participants received brentuximab vedotin 1.8 mg/kg as a 30 minute intravenous (IV) infusion on Day 1 of each 3 week cycle. Participants with stable disease or better and without unacceptable toxicity were to receive a minimum of 8 cycles with the opportunity to receive a maximum of 16 cycles.
89470446|NCT01811303|Experimental|D-fagomine|Measure the changes produced on the postprandial Glycaemic response to 50 g of sucrose containing 40 mg D-fagomine, in 200 ml water
89470447|NCT01811303|Placebo Comparator|Control|Sucrose 50 g without d-fagomine, in 200 ml water
89470448|NCT01740648|Experimental|Treatment (trametinib, fluorouracil, radiation, surgery)|"Patients receive trametinib PO (by mouth) QD (daily) on days -14 through -10 and 1-38 and fluorouracil IV continuously 5 days a week from days 1-38. Patients also undergo radiation therapy 5 days a week on days 1-33. Patients then undergo surgery 6-10 weeks later.~Patients achieving negative surgical margins after complete resection of tumor receive postoperative chemotherapy comprising leucovorin calcium IV over 2 hours and fluorouracil IV continuously over 46 hours on days 1 and 15 OR oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours and fluorouracil IV continuously over 46 hours on days 1 and 15. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity."
89470449|NCT01697566|Experimental|Metformin|"Participants gradually increase the dose of metformin by mouth as listed below:~Week 1: One capsule each day Week 2: One capsule 2 times each day Week 3: One capsule 3 times each day Week 4: Two capsules 2 times each day~After week 4, participant continues to take 2 capsules of metformin 2 times each day.~Each capsule is 425 mg."
89470450|NCT01697566|Experimental|Placebo + Lifestyle Intervention|Placebo taken by mouth twice daily for 4, 30 day cycles. Lifestyle intervention consists of 16 in-person sessions offered over a 4 month period.
89470451|NCT01697566|Experimental|Metformin + Lifestyle Intervention|"Participants gradually increase the dose of metformin by mouth as listed below:~Week 1: One capsule each day Week 2: One capsule 2 times each day Week 3: One capsule 3 times each day Week 4: Two capsules 2 times each day~After week 4, participant continues to take 2 capsules of metformin 2 times each day.~Each capsule is 425 mg.~Lifestyle intervention consists of 16 in-person sessions offered over a 4 month period."
89470452|NCT01697566|Placebo Comparator|Placebo|Placebo taken by mouth twice daily for 4, 30 day cycles.
89470453|NCT01638442|Experimental|Treatment A|Two 60 mg capsules (120 mg dose) of CHR-2797 administered orally with 240 mL room temperature tap water after an approximately 10 hour fast.
89470454|NCT01638442|Experimental|Treatment B|Two 60 mg capsules (120 mg dose) of CHR-2792 administered orally with 240 mL room temperature tap water within 30 minutes of receiving a high-fat meal.
89470455|NCT01368055|Experimental|Low Risk|70 Gy/CGE
89470456|NCT01368055|Experimental|Intermediate Risk|72.5 Gy/CGE
89470457|NCT01189708|Experimental|Mesh implantation|Ultrapro® Mesh implantation
89470458|NCT01189708|Active Comparator|Standard wound closure without a mesh|Standard wound closure
89470459|NCT01076400|Experimental|Part 1: adavosertib + topotecan/cisplatin|Part 1: Dose escalation study. adavosertib capsules will be administered in sequentially rising dose levels twice daily for a total of nine doses on Days 1-5 of a 21-day cycle. Topotecan will be administered at a dosage of 0.75 mg/m^2 by intravenous (IV) infusion over 30 minutes on Days 1-3 . Cisplatin will be administered at a dosage of 50 mg/m^2 by IV infusion over 30 minutes on Day 1.
89470460|NCT01076400|Experimental|Part 2: adavosertib + topotecan/cisplatin|Part 2: adavosertib capsules will be administered at the dose determined in Part 1 twice daily for a total of nine doses on Days 1-5 of a 21-day cycle. Topotecan will be administered at a dosage of 0.75 mg/m^2 by intravenous (IV) infusion over 30 minutes on Days 1-3. Cisplatin will be administered at a dosage of 50 mg/m^2 by IV infusion over 30 minutes on Day 1.
89470461|NCT01076400|Placebo Comparator|Part 2: Placebo to adavosertib + topotecan/cisplatin|Part 2: Placebo to adavosertib capsules will be administered twice daily for a total of nine doses on Days 1-5 of a 21-day cycle. Topotecan will be administered at a dosage of 0.75 mg/m^2 by intravenous (IV) infusion over 30 minutes on Days 1-3. Cisplatin will be administered at a dosage of 50 mg/m^2 by IV infusion over 30 minutes on Day 1.
89470462|NCT01000051|Experimental|Eltrombopag|Starting dose 50 mg/day orally for 8 weeks
89470463|NCT01000051|Placebo Comparator|Placebo|Once a day orally for 8 weeks
89470464|NCT00953160|Experimental|RF treatment|Abdomen, flank or thigh treated with RF device
89470465|NCT00934895|Experimental|Phase I / Phase II|"Phase I:~Abraxane will be given by IV for 30 minutes on the first day of the first three weeks of each 28 day cycle.~RAD001 will be given by tablet. The first group of patients will receive RAD001 once daily depending on side effects seen drug could be increased later to twice a day for a 28 day cycle.~Once a safe and effective drug range is established, the study moves into Phase II.~Phase II:~The maximum tolerated dose (established in Phase I) will be given as scheduled below and we will measure the effectiveness of the study drug combination.~Abraxane will be given by IV (intravenous infusion) for 30 minutes on the first day of the first three weeks of each 28 day cycle (Day 1, Day 8, and Day 15 of each cycle).~RAD001 will be given by tablet based on the dose established in the Phase I part of the study."
89470466|NCT00913497|Active Comparator|insulin glulisine|
89470467|NCT00913497|Active Comparator|insulin aspart|
89470468|NCT00911118|Experimental|Radiation|Patients enrolled in the study will undergo image-guided, intensity-modulated radiotherapy using the same equipment, techniques, and treatment-planning procedures as currently practiced as MSKCC. MSKCC patients will have the option of continued follow-up through MSKCC's established Prostate Survivorship Clinic for an indefinite period of time, meaning patients enrolled in the protocol will be encouraged to remain at MSKCC for life-long follow-up after their treatment. The standard assessments obtained in the Survivorship Clinic will not be altered. All protocol relevant data collected at these visits through month 60 will be used for protocol analysis.
89470469|NCT00874822||Berlin|Patients diagnosed with obstructive sleep apnea by polysomnography after being screened with the Berlin questionnaire.
89470470|NCT00693238|Experimental|Low Risk Proton Radiation|70 Gy/CGE in 28 fractions of 2.5 Gy/CGE/fx
89470471|NCT00693238|Experimental|Intermediate Risk Proton Radiation|72.5 GY/CGE in 29 fractions of 2.5 Gy/CGE/fx
89470472|NCT00556933|Experimental|Group 1|Kidney transplant recipients given a single large dose of rabbit anti-thymocyte globulin (rATG) and maintained on tacrolimus and sirolimus for chronic immunosuppression.
89470473|NCT00556933|Experimental|Group 2|Kidney transplant recipients given 4 small doses of rabbit anti-thymocyte globulin (rATG) and maintained on tacrolimus and sirolimus for chronic immunosuppression.
89470474|NCT00556933|Experimental|Group 3|Kidney transplant recipients given a single large dose of rabbit anti-thymocyte globulin (rATG) and maintained on tacrolimus and sirolimus for chronic immunosuppression until tacrolimus is replaced with mycophenolate mofetil after about 6 months.
89470475|NCT00556933|Experimental|Group 4|Kidney transplant recipients given 4 small doses of rabbit anti-thymocyte globulin (rATG) and maintained on tacrolimus and sirolimus for chronic immunosuppression until tacrolimus is replaced with mycophenolate mofetil after about 6 months.
89470476|NCT00503880|Experimental|Treatment|G-CSF 300 μg subcutaneously to begin one day prior to treatment and continued until ANC greater than 1.0 or recovers back to the patients baseline ANC for 3 days in a row subsequent to completion of chemotherapy (SOC) Low-dose Cytarabine 10 mg/m2 subcutaneously daily starting on day 1 for the first 5 consecutive days of the treatment course 2-4 hours following the end of the clofarabine infusion. (SOC) Clofarabine starting at dose level 0. Dose-10 mg/m2 IV over 1 hour daily starting on day 1 for the first 5 consecutive days of the treatment course The G-CSF and cytarabine doses are fixed. The dose of clofarabine is initially fixed. For the subsequent cohort, the dose of clofarabine will be advanced to the next dose level.
89470477|NCT00378326|Experimental|Tacrolimus|Tacrolimus at doses of 0.15- 0.3mg/kg/day in two divided oral doses, in conjunction with, initially, up to 60mg/day of oral prednisone
89470478|NCT00271739|Experimental|Telemedicine case management|Telemedicine visits conducted by a registered nurse (RN) with remote monitoring of blood pressure (BP) and blood glucose through the use of a telemedicine home unit (HTU).
89470479|NCT00271739|Active Comparator|Usual care|usual care by primary care provider
89470480|NCT00006478|Experimental|Effectiveness of Vaccine Therapy Following Chemotherapy & Peripheral Stem Cell Transplantation|"Phase II trial to study the effectiveness, safety & toxicity of vaccine therapy following chemotherapy and peripheral stem cell transplantation in treating patients who have non-Hodgkin's lymphoma.~Vaccinations begin at day 100 or up to 6 months after hematopoietic stem cell transplantation. Participants receive autologous lymphoma-derived idiotype vaccine plus keyhole limpet hemocyanin subcutaneously (SC) on day 1. Sargramostim (GM-CSF) SC is administered on days 1-4. Treatment repeats every 4 weeks for 4 doses, followed 12 weeks later by the fifth and final dose."
89470481|NCT05850221|Experimental|weight training|A prescribed 8-week training protocol
89470482|NCT05850221|No Intervention|no prescribed weight training|no prescribed weight training
89470483|NCT05850208|No Intervention|Routine treatment group|No special measures were taken and routine treatment was adopted
89470484|NCT05850208|Experimental|BMSCs group|BMSCs were transplanted on the basis of routine treatment: the transplanted cells were injected intravenously and transplanted in two times at a dose of 1 × 106/kg body weight, each volume was 80ml ± 5ml, and the time interval between two transplants was 1 week
89470485|NCT05850182|Experimental|Arm treated with lifestyle intervention|Patients with prostate cancer will receive a lifestyle intervention on diet and physical activity.
89470486|NCT05850169|Experimental|intervention group|"After completion of the initial assessments, the intervention group received 3 sessions per week of creative dance training for 4 weeks (12 sessions), with each session lasting approximately 40 minutes. The creative dance training took place in a 40-square-metre mirrored hall with a tatami mat on the floor. The training was conducted individually for each child in the IG. Different children's songs were selected for each session in harmony with the rhythm of the dance movements. In each session, 10 minutes of warm-up movements and 20 minutes of creative dance training were conducted, accompanied by songs. Meanwhile, materials such as spiky and heavy balls, ribbons, rhythm sticks and holihop were included in the application.~The creative dance training was planned by diversifying the 8 movement models (breath, tactile, core-distal, head-tail, upper-lower, body side, cross lateral and vestibular) of Brain Dance, which is a part of creative dance (Gilbert, 2002,2015)."
89470487|NCT05850169|No Intervention|Control group|
89470488|NCT05850143|Active Comparator|Oral Single dose dexamethsone in acute exacerbation of asthma|
89470489|NCT05850143|Active Comparator|Oral Multidose Prednisolone in acute exacerbation of asthma|
89470490|NCT05850117|Active Comparator|Tetracycline combined with levofloxacin quadruple therapy|esomeprazole 40mg twice a day + tripotassium dicitrate bismuthate 300mg four times a day+ tetracycline 500mg four times a day+ levofloxacin 500mg once a day
89470491|NCT05850117|Active Comparator|standard tincture quadruple therapy|"esomeprazole 40mg twice a day + tripotassium dicitrate bismuthate 300mg four times a day~+ tetracycline 500mg four times a day + metronidazole 250mg four times a day"
89470492|NCT05850117|Active Comparator|amoxicillin combined with levofloxacin quadruple therapy|esomeprazole 40mg twice a day + tripotassium dicitrate bismuthate 300mg four times a day+ amoxicillin 500mg four times a day+ levofloxacin 500mg once a day
89470493|NCT05850039||Study group|Patients with permanent or persistent AFib, undergoing surgical ablation, isolated or concomitant to valve surgery
89470494|NCT05850039||Mitral surgery control group|Patients undergoing isolated or concomitant mitral valve surgery
89470495|NCT05850039||Autoptic control group|Autopsy samples in subjects without arrhythmia
89470496|NCT05849974|Experimental|Hight Myopa|Large Cohort of patients with hight Myopa
89470497|NCT05849961||Prospective Subjects|Enrolled in the study pre-surgery. Subjects who agree to participate in the study that have not had surgery prior to being enrolled in the study.
89470498|NCT05849961||Retrospective to Prospective|Subjects enrolled in the study post- surgery then continue to participate in the study prospectively. Subjects who agree to participate in the study that have undergone surgery prior to enrollment in the study. Data for these subjects will collected from the subject's medical record for the time period prior to enrollment in the study containing data pertaining to the index surgery (retrospective data) and from the patient after they are enrolled in the study during the post-operative time period (prospectively).
89470499|NCT05849961||Retrospective Only Subjects|Subjects enrolled in the study post-study surgery with no intent to continue as prospective subjects. Patient's clinical record includes a signed HIPAA waiver allowing for the use of clinical record data for the purpose of clinical research outside of the operating institution.
89470500|NCT05849948|Experimental|choronobiological nutrition group|newborns were fed according to chronobiological nutrition
89470501|NCT05849948|No Intervention|control group|newborns will be fed in the order in which breastmilk is delivered to the hospital
89470502|NCT05849909||Stable Carotid Atherosclerotic Plaques|
89470503|NCT05849909||Unstable Carotid Atherosclerotic Plaques|
89470504|NCT05849883|Experimental|Omeprazole 20 mg capsules|Subjects were given a single dose of 20 mg omeprazole of either formulation (test or reference) with 240 ml of water
89470505|NCT05849883|Active Comparator|Losec® 20 mg capsules|Subjects were given a single dose of 20 mg omeprazole of either formulation (test or reference) with 240 ml of water
89470506|NCT05849870|Active Comparator|Comprehensive Geriatric Assessment (CGA)|Participants in this arm will undertake a Comprehensive Geriatric Assessment, and will be implemented based on Comprehensive Geriatric Assessment Toolkit for Primary Care Practitioners from the British Geriatrics Society. A personalised action plan will be developed and implemented based on the CGA.
89470507|NCT05849870|Experimental|Integrated Care for Older PEople (ICOPE)|Participants in this arm will undertake the assessment recommended by the World Health Organisation, and will be implemented by the publicly available app. A personalised action plan will be developed and implemented based on the ICOPE.
89470508|NCT05849870|Experimental|Identification and Management of frailty and sarcopenia|Participants in this arm will undertake the assessment recommended by the International Conference on Frailty and Sarcopenia Research Clinical Practice Guidelines for Identification and Management of physical frailty (ICFSR). A personalised action plan will be developed and implemented based on the ICFSR.
89470509|NCT05849870|Experimental|Functional Fitness Battery (FFB)|Participants in this arm will undertake a Functional Fitness Battery, comprising physical assessments on the intrinsic capacity, lifestyle and nutritional status
89470510|NCT05849870|No Intervention|Usual Care|Participants in this arm will not receive an intervention, but the usual care provided by the primary care provider.
89470511|NCT05849818|Experimental|Effect of fully immersive VR + school regular activities on cognitive functions of Down children|Children in this group will practice the same activities as control group in addition to virtual reality session using fully-immersive VRapeutic software gaming technology (Viblio module)for 20 min/3sessions/week for 8 weeks.
89470512|NCT05849818|No Intervention|Effect of school regular activities on cognitive functions of down children|Children in this group will practice their regular activities of school and daily living (receive no treatment).
89470513|NCT05849792|Experimental|Exercise group|Group where the participants realize an intervention based on exercise and psychology.
89470514|NCT05849792|No Intervention|Control|Group where the subjects do not realize the intervention.
89470515|NCT05849766|Placebo Comparator|Control|Group 1 received only standard therapy ACE/ ARB, BB, and diuretics
89470516|NCT05849766|Experimental|Interventional|Group 2 received dapagliflozin 10 mg once daily in addition to standard therapy ACE/ ARB, BB, and diuretics
89470517|NCT05849701|Active Comparator|Shock wave therapy group|Patients in this group were managed by shock wave therapy, using gymna Shock Master 500 with an input voltage of alternating current (AC) 220 Volte, 100 pulses at 0.13 m joule/mm at 3 Hz per session, for six weeks
89470518|NCT05849701|Active Comparator|Vacuum-assisted closure group|the patients in this group were treated by vacuum-assisted closure using KCI's Vacuum Assisted Closure Device, the pump delivered an intermittent negative pressure of -125 mmHg. The cycle was of seven minutes during which the pump was on for five minutes and off for two minutes, The dressings were changed on the fourth day.
89470519|NCT05849688|Active Comparator|Designed Physical Therapy Program|Boys with Duchenne muscular dystrophy will receive the designed physical therapy program for 1 hour/ session.
89470520|NCT05849688|Experimental|Bicycle Ergometry Training|Boys with Duchenne muscular dystrophy will receive the designed physical therapy program for 1 hour/ session in addition to bicycle ergometry training for 20 min./ session
89470521|NCT05849675|Experimental|Pitolisant|Two film-coated tablets (18mg x 2 [36mg]) for oral administration will be encapsulated in an opaque capsule.
89470522|NCT05849675|Placebo Comparator|Placebo|Two lactose film-coated tablets (2 x 65mg [125mg]) will be encapsulated in an opaque capsule (identical to the experimental arm drug).
89470523|NCT05849662|Experimental|Lower-risk patients|Lower-risk patients are defined as having a mutational burden of one clonal alteration AND a low DNA methylation classification.
89470524|NCT05849662|Experimental|High-risk patients|High-risk patients are defined as having as having a mutational burden of more than one clonal alteration AND/OR an intermediate or high DNA methylation classification.
89470525|NCT05849649|Experimental|BumptUp Mobile App|The intervention group will have full access to the BumptUp mobile app which includes exercise and dietary progress tracking, social support, evidence-based and safe exercise programming, videos, and symptom tracking.
89470526|NCT05849649|Active Comparator|Educational Brochure/ Attention Control|This group will receive evidence-based exercise education the form a one-time brochure.
89470527|NCT05849636|Experimental|ALERTA CANNABIS|The Experimental Group receives the ALERTA CANNABIS intervention, which consists of four sessions at school (baseline questionnaire, two sessions in three scenarios: at home, celebrations, and public places, and a final evaluation). The adolescents are provided with answers related to their views of each scenario; this information is used to provide highly specific feedback regarding their knowledge, risk perception, self-esteem, attitude, social influence (modelling, norms and social pressure), self-efficacy and action plans. The post-tests will be carried out at six and twelve months from the baseline.
88956491|NCT05085327|Active Comparator|SPF Standard|Single topical application: 80 +/- 2 mg (2.0 +/- 0.05 mg/cm^2) of SPF Standard will be applied to the assigned test site using a fingercot. Test material will be evenly spread over the test site using light pressure for 35 +/- 15 seconds.
89470528|NCT05849636|No Intervention|CONTROL|Control Group: The Control Group just completes the baseline and the evaluation questionnaires. Evaluation takes place after six and twelve months from baseline
89470529|NCT05849597|Experimental|Dexmedetomidine|Evaluate the effects of dexmedetomidine for sedation of patients in the intensive care unit after open heart surgery
89470530|NCT05849597|Active Comparator|Propofol|Compare the clinical outcomes of the experimental group with the standard of care, i.e. sedation with propofol
89470531|NCT05849571|No Intervention|No Intervention: Control group|"Consent is obtained with an informed consent form.~Patient identification form is filled.~The patient's mouth is evaluated using the World Health Organization Mucositis Classification and the International Pediatric Mucositis Rating Scale (ChIMES) before receiving chemotherapy. According to the World Health Organization Mucositis Classification, the frequency of oral care is decided.~The patient's mouth is evaluated using the World Health Organization Mucositis Classification and the International Child Mucositis Evaluation Scale (ChIMES) on days 0, 7, and 14, and after each assessment, the frequency of oral care is determined and applied for 21 days. The final assessment is made on Day 21.~The care given according to the frequency of oral care determined according to the score obtained by the patient in the World Health Organization Mucositis Classification is recorded on the Basic Oral Care Protocol Follow-up Chart."
89470532|NCT05849571|Experimental|Experimental: Experimental Group|Unlike the control group, the experimental group is rinsed with 5 ml of coconut 4 times a day.
89470533|NCT05849558|Experimental|Ursoplus® capsules (UDCA 250mg & Silymarin 140mg)|"Ursoplus® capsules: UDCA 250mg & Silymarin 140mg~2 Capsules every 12 hours"
89470534|NCT05849558|Active Comparator|UDCA 250mg|"UDCA capsules: UDCA 250mg~2 Capsules every 12 hours"
89470535|NCT05849558|Placebo Comparator|Placebo|"Placebo alone~2 Capsules every 12 hours"
89470536|NCT05849545|Experimental|Graston Tool|Graston instrument, 20 strokes per minute proximal to distal and 20 strokes per minute distal to proximal for a period of 3 minutes was given over the painful area. GT group protocol included the use application of IASTM along with the application of ice therapy at the end of the session. The assessment of patients was done at the initial and last visit before the completion of the treatment program. Three treatment sessions per week were given to each patient for a total of four weeks.
89470537|NCT05849545|Active Comparator|Neuromuscular Re-Education|General stretching and strengthening exercises for the neck muscles. The protocol of treatment for the NMR group included the use of the Neuromuscular re-education soft tissue mobilization technique (NMR) followed by active movements of the patient.
89470538|NCT05849519|Experimental|Intervention Group|Procedure:Coenzyme I for Injection,5mg，im，qd；Nacl，2ml，im，qd.
89470539|NCT05849519|Other|Control Group|Procedure: conventional treatment.
89470540|NCT05848960|Active Comparator|Mediterranean diet|Mediterranean diet
89470541|NCT05848960|Experimental|Mediterranean diet plus hypercaloric, hyperproteic oral supplement|Mediterranean diet plus hypercaloric, hyperproteic oral supplement
89470542|NCT05848479|Active Comparator|control group|Abdominal bracing
89470543|NCT05848479|Active Comparator|study group|Abdominal bracing and clamshell exercise
89470544|NCT05848271||HPDL deficiency|Patients with HPDL mutations
89470545|NCT05848193|Active Comparator|Standard of Care|Patients in the control group will receive standard of care for the treatment of post-concussion symptoms at our Integrated Adult Concussion Clinic
89470546|NCT05848193|Experimental|mHealth|Patients in the intervention group will use MyHeadHealth - an online application to help in the completion of their treatment plan
89470547|NCT05847725|Experimental|Elastic bandaging|Patients who have undergone TKA for primary knee OA
89470548|NCT05847725|Experimental|Short stretch bandaging|Patients who have undergone TKA for primary knee OA
89470549|NCT05847725|Experimental|Kinesio taping|Patients who have undergone TKA for primary knee OA
89470550|NCT05847296||Sarcopenia group|
88947794|NCT01927549|Active Comparator|Immediate multivessel PCI|After diagnostic angiography the culprit lesion is identified and PCI should be performed using standard techniques. The use of drug-eluting stents is recommended but not mandatory. All additional lesions in other major coronary arteries defined by a diameter >2 mm with high grade stenoses (>70% by visual assessment) should be intervened using standard techniques. Other major coronary arteries are defined by stenoses of other vessels and are not confined to a diagonal branch if the left anterior descending coronary artery was identified as the culprit lesion.
88947795|NCT01927549|Active Comparator|Culprit lesion only PCI|After diagnostic angiography the culprit lesion is identified and PCI of the culprit lesion should be performed using standard techniques. The use of drug-eluting stents is recommended but not mandatory. All other lesions should be left untreated in the acute setting. Complete revascularization of the non-culprit lesions may be performed at a later time point as staged procedure depending on remaining ischemia (as per guideline recommendations either by PCI or CABG).
88947796|NCT01927640|Experimental|Dexmedetomidine and intranasal cocaine|Intranasal cocaine administration (2 mg/kg) then Dexmedetomidine (0.3-0.6 mcg/kg) infusion
88947797|NCT01927640|Placebo Comparator|Normal saline and intranasal cocaine|Intranasal cocaine administration (2 mg/kg) then Saline (over 10 minutes I.V. infusion)
88947798|NCT01927679|Other|Antioxidant (LB) + control (UB)|Antioxidant will be weighed and applied to an area on the lower back (LB) to be exposed with visible light at a concentration of 2 mg/cm^2. Control will also be weighed and applied to an area of the upper back (UB) to be exposed with visible light at a concentration of 2 mg/cm^2. These will be applied according to the randomization scheme.
88947799|NCT01927679|Other|Antioxidant (UB) and Control (LB)|Antioxidant will be weighed and applied to an area on the upper back (UB) to be exposed with visible light at a concentration of 2 mg/cm^2. Control will also be weighed and applied to an area of the lower back (LB) to be exposed with visible light at a concentration of 2 mg/cm^2. These will be applied according to the randomization scheme.
88947800|NCT01927939||Histological proven breast cancer with bone lesion|
88947801|NCT01927965|Experimental|Minnelide™ 001|A Phase 1, Multi-Center, Open-label, Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of Minnelide™ given daily for 21 days followed by 7 days off schedule in patients with Advanced GI Tumors
88947802|NCT01928004|Experimental|implant placement|insertion of 2 interforaminal mandibular implants and conversion of the lower complete denture to an implant-overdenture
88947803|NCT01928004|Active Comparator|denture reline|conventional reline of mandibular complete denture
88947804|NCT01928108||iPhone Application|"Participants using an iPhone will download the waterlogged application and use this to track daily water intake for 1 week."
89470551|NCT05847296||Non sarcopenic group|
89470552|NCT05847283|Active Comparator|DPOS protocol|Women will receive oral Dydrogesterone 10mg (Duphaston 10mg) t.i.d daily from the first day of ovarian stimulation till the day of final oocyte maturation.
89470553|NCT05847283|Placebo Comparator|GnRH antagonist protocol|Women will receive GnRH antagonist (Ganirelix 0.25mg) once subcutaneously daily from day 5 of ovarian stimulation till the day of final oocyte maturation
89470554|NCT05846711|Active Comparator|Bedside BPPV diagnostics|Diagnostics of BPPV with manual tests using VNG goggles. The goggles will be added an IMU sensor detecting angulation and velocity (the physician will not get feedback from the sensor during the examination. This will only be used in later analysis).
89470555|NCT05846711|Active Comparator|TRV BPPV diagnostics|Diagnostics of BPPV using the TRV chair.
89470556|NCT05846126|Experimental|Telematic group|This program combines cognitive training, physical exercise, and mindfulness tasks delivered remotely to participants. The cognitive training includes 24 interactive sessions over 12 weeks aimed at training attention, memory, and executive function. The physical exercise program is personalized and includes balance work, stretching, and muscle strengthening exercises, with two sessions per week for 12 weeks. The mindfulness component adapts the Mindfulness-Based Stress Reduction program, including body scanning, seated meditation, and gentle Hatha yoga, with one supervised session per week via video call over 12 weeks. The program is designed for autonomous use by participants.
89470557|NCT05846126|Experimental|Immersive Virtual Reality group|"The sessions will consist of carrying out a face-to-face multimodal stimulation program with the application of MK360 immersive technology for the cognitive, emotional, behavioral, physical, functional - social areas. The multimodal intervention includes 24 interactive sessions two sessions per week, over 12 weeks. They will follow the following scheme:~Welcome and awareness of the here and now.~Physical activation.~Cognitive stimulation.~Relaxation techniques and Mindfulness.~Feedback and end of session.~During the intervention period, patients will be provided with a downloadable App with a username and password, so they can access it. From the App, they will view the tests to answer according to tempos and therapeutic direction."
89470558|NCT05846126|Active Comparator|Active control program|In paper or pdf format, patients in the active control group will receive guidelines for physical and cognitive stimulation to do autonomously at home. Patients in the active control group will receive guidelines for cognitive and physical stimulation and meditation exercises in paper or pdf format, to be done independently at home. They will be encouraged to do physical exercises, meditation, and cognitive activities two times a week.
89470559|NCT05845580|Experimental|Patient centered care|Patients concern of refusing statin therapy will initially be addressed.
89470560|NCT05845580|Active Comparator|Guideline-centered care|patients will be prescribed the standard of care regardless of their concerns toward statin therapy.
89470561|NCT05844956|Experimental|DZD8586|
89470562|NCT05844696|Sham Comparator|Sham stimulation|
89470563|NCT05844696|Experimental|continuous tDCS|
89470564|NCT05844696|Experimental|slow-oscillatory tDCS|
89470565|NCT05844345|Experimental|Hydrocolloid barrier group|Premature infants will firstly be assessed by two nurses with undergraduate degrees working in the clinic in terms of neonatal skin condition score, nasal injury score, neonatal stress level and comfort score before beginning NIMV support. The colloid tape will be cut to a t-shape to cover across the bridge of the nose and the nasal septum and philtrum and placed on the infant's face.
89470566|NCT05844345|Experimental|Facial Massage group|Premature infants will firstly be assessed by two nurses with undergraduate degrees working in the clinic in terms of neonatal skin condition score, nasal injury score, neonatal stress level and comfort score before beginning NIMV support. After beginning NIMV support, the researcher will perform facial massage 2 times in each 12-hour shift.
89470567|NCT05844345|No Intervention|Control group|Premature infants will firstly be assessed by two nurses with undergraduate degrees working in the clinic in terms of neonatal skin condition score, nasal injury score, neonatal stress level and comfort score before beginning NIMV support. After beginning NIMV support, no procedure apart from routine care will be performed. Routine care includes feeding every 3 hours, diaper care, position changes, changing the placement of probes and electrodes and confirming the position of the nasal cannula.
89470568|NCT05843968|Experimental|Rituximab|2 doses of rituximab 375 mg/m^2 (Maximum 500mg/day)at 6 months intervals
89470569|NCT05843968|Active Comparator|Mycophenolate Mofetil|MMF 20~30mg/kg/day，BID
89470570|NCT05843955||Women with Polycystic ovary syndrome (PCOS)|PCOS was diagnosed according to the revised 2003 Rotterdam Consensus as the presence of at least two of the following three criteria: (i)oligomenorrhoea or anovulation; (ii)clinical and/or biochemical signs of hyperandrogenemia and (iii)polycystic ovaries on ultrasound.
89470571|NCT05843279|Experimental|Myofunctional therapy|The intervention group receives myofunctional therapy sessions in which orofacial exercises are performed.
89470572|NCT05843279|Other|Breastfeeding session|In this group, a session is held in which the posture and attachment of the baby to the mother's chest is assessed and corrected.
89470573|NCT05843032|Experimental|Tongue tumor resection|
89470574|NCT05842369|Experimental|ADVOS|Application of the ADVOS device for
89470575|NCT05842369|Active Comparator|CVVHD|Application of CVVHD
89470576|NCT05841134|Experimental|Tislelizumab combined with CAPOX|Successfully screened subjects will receive 4 cycles of neoadjuvant therapy with tislelizumab combined with chemotherapy (CAPOX) before surgery； undergo radical surgery 4-6 weeks after the end of the last medication; tislelizumab will be given after surgery Monoclonal antibody ± chemotherapy adjuvant therapy (the investigator judges whether to add chemotherapy based on the patient's comprehensive condition), until disease progression or unacceptable toxicity, the longest treatment is 12 months.
89470577|NCT05840731|Experimental|Ashwagandha|"KSM-66 Ashwagandha is the active ingredient in Waithania somifera, a medicinal plant in Indian medicine. Ashwagandha is known as an adaptogen, an herb in capsule form that protects the body from stress.~After enrollment in the study, 50% of participants will be randomly assigned to take one capsule of KSM 66 Ashwagandha (300 mg) two times daily after breakfast and every night at bedtime with food, preferably 30 minutes before the anticipated sexual intercourse with a glass of water for 8 weeks."
89470578|NCT05840731|Placebo Comparator|Placebo|"Placebo means that the capsules will not contain Ashwagandha but some other inactive substance. By using placebo, investigators will know whether the positive results are because of Ashwagandha or are because of psychological factors. For example, the participant may feel that his or her condition is improved because he or she is expecting the capsules to be helpful.~After enrollment in the study, 50% of participants will be randomly assigned to take one capsule of placebo two times daily after breakfast and every night at bedtime with food, preferably 30 minutes before the anticipated sexual intercourse with a glass of water for 8 weeks."
89470579|NCT05837741|Active Comparator|Standard hypercaloric, hyperproteic oral supplement|Patients will receive 2 supplements per day (Standard hypercaloric, hyperproteic oral supplement)
88947805|NCT01928108||Android Application|"Participants using an Android cell phone will download the water your body application and use this to track daily water intake for 1 week."
88947806|NCT01928303||Chronic Pain Patients taking opioid medications|Oral fluid, blood and urine samples will be obtained from chronic pain patients who are taking pain medications from the opioid class of drugs.
88947807|NCT01928303||Negative controls|At least 10% of the total subject population. Chronic pain patients who are not taking pain medication from the opioid class of drugs.
88947808|NCT01928407|Experimental|ATAZANAVIR|The patient included in this Group 1 will receive their first antiretroviral regimen included : ATV + TDF/FTC (or Abacavir/Lamivudine, [ABC/3TC], if contre indicated of TDF/FTC) The dose : atazanavir/ritonavir 300/100mg/day and TDF/FTC 245 /200 mg day, 3 pills once a day, during 48 weeks during a meal
88956492|NCT05077774|Other|Harmony TPV System|Intervention Device: Harmony Transcatheter Pulmonary Valves and Delivery System
89470580|NCT05837741|Active Comparator|Leucin-enriched hypercaloric, hyperproteic oral supplement|Patients will receive 2 supplements per day (Leucin-enriched hypercaloric, hyperproteic oral supplement)
89470581|NCT05836948|Experimental|SHR-9839|three stages: dose escalation, dose expansion and efficacy expansion.
89470582|NCT05831878|Experimental|RC48-ADC|RC48-ADC as salvage treatment for HER2-low advanced breast cancer
89470583|NCT05827705||Group H|General anaesthesia was induced by Propofol (2 mg/kg) IV, Rocuronium (0.6 mg/kg) and Fentanyl (2 μg/kg) IV, and maintained with sevoflurane and Epidural anesthesia, intraoperative Hypotensive patients
89470584|NCT05827705||Group N|General anaesthesia was induced by Propofol (2 mg/kg) IV, Rocuronium (0.6 mg/kg) and Fentanyl (2 μg/kg) IV, and maintained with sevoflurane and Epidural anesthesia, intraoperative Non-Hypotensive patients
89470585|NCT05826197||Axillary lymph node metastasis|
89470586|NCT05826197||No axillary lymph node metastasis|
89470587|NCT05823454||Propofol|Intravenous infusion
89470588|NCT05823454||Dexmedetomidine|Intravenous infusion
89470589|NCT05823454||Esketamine|Intravenous infusion
89470590|NCT05823454||Sevoflurane|Inhalation anesthesia
89470591|NCT05823454||Remifentanil|Intravenous infusion
89470592|NCT05823207|Experimental|Sage essential oil|Sage essential oil is applied twice a day for a total of 6 drops for 5 days in each cycle.
89470593|NCT05823207|No Intervention|control group|No application was made to this group. Personal information form and PMS scale and quality of life scale will be applied to this group at the end of each cycle.
89470594|NCT05822115|Experimental|treated group|Breast reduction
89202380|NCT03977727|Experimental|Novolog/Fiasp|7 weeks on Novolog® then crossover to 7 weeks on Fiasp® in subjects on the 670g Hybrid Closed Loop Continuous Subcutaneous Insulin Infusion
89202381|NCT02563184|Active Comparator|COPD|Group will receive either the Fluzone Trivalent or Fluzone Quadrivalent.
89202382|NCT02563184|Active Comparator|Control|Group will receive either the Fluzone Trivalent or Fluzone Quadrivalent.
89202383|NCT00663858|Experimental|Cetrorelix 78+78|
89202384|NCT00663858|Experimental|Cetrorelix 78 + Placebo|
89202385|NCT00663858|Placebo Comparator|Placebo|
89202386|NCT00749372|Other|1|Patients who meet eligibility will be sent for radiographic imaging to include T2* cardiac and liver MRI to ascertain quantification of organ-specific iron concentrations as well as cardiac left ventricular ejection fraction.
89202387|NCT02562014|Other|Lean|Participants with body mass index <=25
89470595|NCT05821738|Experimental|Treatment Group|The treatment group will receive avapritinib orally. The dosage is 100mg to 300mg qd, allowed to combine with other chemotheray drugs.
89470596|NCT05816746|Experimental|Treatment group|Decitabine 10mg/d，VD d1-5; PD-1 200mg，d8
89019023|NCT05231889|Placebo Comparator|Below the shoulder vascular anomaly|If the standard J-tip guidewire does not cross a vascular anomaly located below the shoulder
89202388|NCT02562014|Other|Overweight|Participants with body mass index >25
89202389|NCT00787098|No Intervention|1|RA begins data collection with chart review for demographic and explanatory variables, collects data for baseline muscle strength. During standard care period, PM will obtain information about the plan for activity for enrolled patients (turning, complete or partial weight-bearing i.e., reverse Trendelenberg positioning, ROM, sitting and walking) through discussion with the direct providers. RA will interview one provider about factors which influence the decision to implement activity or provide bedrest, including the presence of orders for bedrest or physical therapy. If activity is planned, the PM will observe and record the type and duration of activity, drawing serum biomarkers 20 minutes before and 20 minutes after the activity. If no activity is planned or activity duration is less than 10 minutes, serum for only baseline inflammatory biomarkers will be drawn. The RA will collect outcomes data within 24 hours of discharge from the ICU.
89202390|NCT00787098|Experimental|2|Identical procedures for date recruitment, consent and data collection will occur. In this phase, the Project Manager will promote the use of the ETM protocol through coaching (e.g., reminding staff of benefits of mobility, identification of available resources, or suggesting cessation of bedrest orders) and by participating in planning at least one 20-minute activity.
89202391|NCT00749450|Experimental|Arm I|Patients receive OxMdG or XELOX combination chemotherapy for a total of 12 courses for treatment lasting a total of 24 weeks.
89202392|NCT00749450|Experimental|Arm II|Patients receive OxMdG or XELOX combination chemotherapy for a total of 6 courses for treatment lasting a total of 12 weeks.
89202393|NCT00795444|Experimental|Maraviroc|Adult patients with HIV infection and a viral load that has been suppressed for a long period (less than 50 copies/mL for at least 2 years) while on antiretroviral therapy.The treatment group will maintain the habitual antiretroviral therapy combined with maraviroc.
89202394|NCT00749528||1|Children vith recurrent wheezing
89202395|NCT00749528||2|Healthy children
89202396|NCT00790686|Experimental|1|Memokath 051
88947809|NCT01928407|Experimental|DARUNAVIR|The patients included in this Group 2 will receive their first antiretroviral regimen included Group 2 : DRV+ TDF/FTC (or ABC/3TC if contre-indicated of TDF/FTC) The dose : darunavir/ritonavir 800/100mg/day and TDF/FTC 245 /200 mg day, 4 pills once a day, during 48 weeks during a meal
88947810|NCT01928875|Experimental|Adequacy of Anesthesia (AoA) Monitoring|Adequacy of Anesthesia monitoring with SPI and Entropy
88947811|NCT01928875|Active Comparator|Routine (Standard) Anesthesia Monitoring|
88947812|NCT01929486|Experimental|<Phase Ia> Mogamulizumab 0.1mg/kg, 0.5mg/kg or 1.0mg/kg|<Phase Ia> Dose-escalation method with Mogamulizumab 0.1mg/kg, 0.5mg/kg or 1.0mg/kg. Mogamulizumab will be administered 8 times every week.
88947813|NCT01929486|Experimental|<Phase Ib> Mogamulizumab of the tolerated dose|<Phase Ib> Mogamulizumab of the tolerated dose in Phase Ia will be administered 8 times every week.
88947814|NCT01929486|Experimental|<Phase Ib> Mogamulizumab 0.1mg/kg|<Phase Ib> Mogamulizumab 0.1mg/kg will be administered 8 times every week.
88947815|NCT01929551|Other|Mango puree and pear juice beverage|Participants will drink 450 milliliters of the juice at time 0.
88947816|NCT01929551|Other|Commercial mango juice|Participants will drink 450 milliliters of the juice at time 0.
88947817|NCT01929551|Other|Fresh natural mango|Participants will eat 400 to 500 grams of frozen mango pulp, along with 250 milliliters of water at time 0.
88947818|NCT01929551|Other|Frozen natural mango|Participants will eat 400 to 500 grams of frozen mango pulp, along with 250 milliliters of water at time 0.
88947819|NCT01929551|Other|Processed natural mango pulp|Participants will eat 400 to 500 grams of frozen mango pulp, along with 250 milliliters of water at time 0.
89470597|NCT05949242|Active Comparator|OMNI canaloplasty with cataract surgery|participant will undergo OMNI canaloplasty with cataract surgery in one randomized eye
89470598|NCT05949242|Active Comparator|OMNI canaloplasty and Hydrus with cataract surgery|participant will undergo OMNI canaloplasty and Hydrus with cataract surgery in the contralateral eye
89470599|NCT05949229|Experimental|Duloxetine group (Group D)|patients received oral duloxetine 60 mg 2 hours just before operation.
89470600|NCT05949229|Placebo Comparator|Control group (Group C)|patients received an identical placebo pill 2 hours just before operation.
89470601|NCT05949216|Experimental|Musical engagement sessions|The single group of this study will participate in four musical engagement sessions as described in the intervention section.
89470602|NCT05949164||Group 1: Children able to answer questionnaires independently|Children who are deemed by a healthcare professional to be able to answer questionnaires independently (group 1) will be asked to complete self-reported questionnaires. Caregivers will also be asked to complete proxy-reported questionnaires.
89470603|NCT05949164||Group 2: Children unable to answer questionnaires|The caregivers of children who are deemed by a healthcare professional to be unable to answer questionnaires (group 2) will be invited to complete proxy-reported questionnaires only. There are no self-reported questionnaires for this group.
89470604|NCT05949151|Active Comparator|Group I|Patients received a complete removable mandibular implant supported overdenture
89470605|NCT05949151|Active Comparator|Group II|Patients received implant supported fixed bridge
89470606|NCT05949112|Experimental|Manual|Manual toothbrush
88947820|NCT01929551|Other|Mix of natural mango and pear|Participants will eat 400 to 500 grams of a mixture of fresh natural fruit containing mango (73%) and pear (27%), along with 250 milliliters of water at time 0.
88947821|NCT01929551|Other|50 grams glucose load|Participants will drink 250 milliliters of the standard glucose load at time 0.
88947822|NCT01929590|Active Comparator|PEG-3350 group 3|group 3: low-volume 2 L PEG-3350 solution (same day of the procedure 06:00-08:00 am).
88947823|NCT01929590|Active Comparator|PEG-3350 group 1|group 1 single dose (PEG-3350; PEG-4 L the day previous of the study, starting at 17:00 and finishing at 21:00 h)
88947824|NCT01929590|Experimental|PEG-3350 group 2|group 2: split-dose (PEG-3350 2 L the day before 17:00-19:00 h and 2 L same day of the procedure 06:00-08:00 am)
88947825|NCT01930006|Experimental|MGCD265|
88947826|NCT01930019|Experimental|OE|OE - obese patients (BMI>40) in which etomidate was used,
88947827|NCT01930019|Other|NE|NE - patients with normal body mass (BMI<25), in which etomidate was used,
88947828|NCT01930019|Experimental|OT|OT - obese patients in which thiopental was used,
88947829|NCT01930019|Other|NT|NT - patients with normal body mass, in which thiopental was used
88947830|NCT01930032||All subjects|
88947831|NCT01930084|Experimental|Combination intervention + incentives|"Point of care CD4+ after HIV diagnosis~Accelerated ART initiation~SMS appointment reminders~Non-cash financial incentives (FI)"
88947832|NCT01930084|Experimental|Combination intervention strategy(CIS)|"Point of care (POC) CD4+ after HIV diagnosis~Accelerated ART initiation~SMS appointment reminders"
88947833|NCT01930084|No Intervention|Standard of care (SOC)|Standard of care, no intervention
88947834|NCT01930097|Active Comparator|CHO-dependant bolus|"An insulin bolus dependant of carbohydrate content will be given after each meal.~Each subject insulin-to-carbohydrate ratio (U per 10g CHO) will be used to calculate the insulin bolus to be given. The dual-hormone closed-loop strategy will give the remaining insulin needed based on the sensor readings."
89019024|NCT05231889|Active Comparator|Above the shoulder vascular anomaly|If the standard J-tip guidewire does not cross a vascular anomaly located above the shoulder
89019025|NCT00328068||Back pain / peripheral arthritis|Patients with chronic back pain of unknown origin and onset of back pain <45 years of age or patients with peripheral arthritis / enthesitis / dactylitis of unknown origin and onset <45 years of age
89019026|NCT00302393|Active Comparator|IR-MPH|Immediate Release Methylphenidate administered before PET Scan
89470607|NCT05949112|Experimental|Mechanical|Mechanical toothbrush
89470608|NCT05949060|Experimental|Compassion Intervention|
89470609|NCT05949060|No Intervention|No Training|
89470610|NCT05948995|No Intervention|Conventional arm sling|Conventional arm sling Arm position : Internal rotation , Adduction
89470611|NCT05948995|Experimental|Abduction external rotational brace|Abduction external rotational brace Arm position : Abduction , External rotation
89470612|NCT05948982|Experimental|Human Umbilical Cord Mesenchymal Stem Cells|The trial was divided into three dose groups： Low-dose group: 1000000 cells/kg Medium-dose group: 2000000 cells/kg High-does group: 4000000 cells/kg
89470613|NCT05948969|No Intervention|Education alone|
89470614|NCT05948969|Active Comparator|Education + decision support to provide suggestions for care optimization|
89470615|NCT05948969|Active Comparator|Education + facilitated referral to cardiometabolic team-based center for care optimization|
89470616|NCT05948852|Experimental|Group A: SADI-S|SINGLE ANASTOMOSE DUODENAL SWITCH
89470617|NCT05948852|Active Comparator|Group B: OAGB|SINGLE ANASTOMOSE GASTRIC BY-PASS
89470618|NCT05948800|Experimental|Spraying group|The first group will use an isotonic seawater solution as a nasal spray for 10 days. The group with the isotonic seawater solution applied as a nasal spray will use it at least three times a day, and necessarily before exercise (about 20 minutes before).
89470619|NCT05948800|No Intervention|Non-spraying group|The control group will not use such a solution.
89470620|NCT05948774|Experimental|MT200605 for injection|The Single Ascending Dose (SAD) and Muliple Ascending Dose (MAD) stages were built up in the study. The MT200605 in SAD and MAD following Intravenous Infusion Administration by using infusion pump in Healthy Subjects.
89470621|NCT05948774|Placebo Comparator|MT200605 Placebo|The Single Ascending Dose (SAD) and Muliple Ascending Dose (MAD) stages were built up in the study. The MT200605 Placebo in SAD and MAD following Intravenous Infusion Administration by using infusion pump in Healthy Subjects.
89470622|NCT05948761|Placebo Comparator|Placebo|Hypoxic generator without active elements, pulsewise ventilation assured to ascertain blinding
89470623|NCT05948761|Experimental|Active intervention|FiO2 0.16 for 5 minutes interspersed with 5 minutes normoxia (intermittent hypoxia)
89470624|NCT05948735|Experimental|Physical Therapy Exercise and Dance Movement Therapy (PTE+DMT)|The intervention include 12 face-to-face group sessions of 45 minutes each, twice a week for 6 weeks. The intervention integrates Otago Exercise Program (OEP)-based techniques and DMT techniques to address the emotional experience that arises during physical exercise. This include encouragement for spontaneous and creative movement on the part of the participants, and an invitation to verbally share the feelings, sensations, and thoughts that arose in the participants following the movement. At the end of the sessions, participants will be instructed to perform nine exercises independently at home, at a minimum of twice per week for six months
89019027|NCT00302393|Active Comparator|Concerta|OROS Methylphenidate (Concerta) administered before PET Scan
89019028|NCT00328107|Experimental|Low Dose|Recombinant Trivalent Hemagglutinin Influenza Vaccine, 2004/05 formulation containing 45μg of each hemagglutinin derived from A/Wyoming/3/03(H3N2) and 15μg from A/New Caledonia/20/99(H1N1) and B/Jiangsu/10/03
89019029|NCT00328107|Experimental|Full Dose|Recombinant Trivalent Hemagglutinin Influenza Vaccine, 2004/05 formulation containing 45μg of each hemagglutinin derived from A/Wyoming/3/03(H3N2), A/New Caledonia/20/99(H1N1) and B/Jiangsu/10/03
89470625|NCT05948735|Active Comparator|Physical Therapy Exercise (PTE)|The intervention include 12 face-to-face group sessions of 45 minutes each, twice a week for 6 weeks. The intervention include OEP-based techniques only. At the end of the sessions, participants will be instructed to perform nine exercises independently at home, at a minimum of twice per week for six months.
89019030|NCT00328107|Placebo Comparator|Placebo|0.9% Sodium Chloride
89019031|NCT00328146||Observation of Sternal Re-entry|All subjects.
89019032|NCT00302471|Experimental|1600 mg twice a day|MK0429
89019033|NCT00302471|Experimental|200 mg twice a day|MK0429
89470626|NCT05948735|No Intervention|Control without intervention|Participants in the control group will be instructed to maintain their daily routine. At the end of the sessions, participants will be directed to independently perform nine exercises at home, a minimum of twice per week for six months.
89470627|NCT05948722|Experimental|Motivational Interview Group (MIG)|Participants assigned to this arm will complete three to five MI sessions
89470628|NCT05948722|Active Comparator|Conventional treatment group (CTG)|Participants assigned to this arm will receive the conventional treatment
89470629|NCT05948696||Horticultural participants|Inpatients with chronic schizophrenia who attend to a horticultural group therapeutic program.
89470630|NCT05948631|Experimental|MISC|Mediational Intervention for Sensitizing Caregivers (MISC): a program for mother and children where mothers become sensitized to the impact of their behavior on their children with the aim of improving quality caregiving and child outcomes.
89470631|NCT05948631|Active Comparator|Treatment as Usual|Treatment as Usual in the rehousing program. Mothers receive support in a domestic violence rehousing program to find work and housing.
89019034|NCT00302471|Experimental|800 mg twice a day|MK0429
89019035|NCT00302471|Experimental|400 mg twice a day|MK0429
89019036|NCT00302510|Placebo Comparator|immunoadsorption|
89019037|NCT00419913|Experimental|A|Dehydroepiandrosterone (DHEA) 25mg tid
89019038|NCT00419913|Placebo Comparator|B|
89019039|NCT00302549|Active Comparator|FK506|
89206190|NCT02598869|Active Comparator|posterior subtenon triamcinolone|subjects will receive posterior subtenon injection of 40mg /1 ml of preserved triamcinolone acetonide ( otherwise known as kenalog)
89470632|NCT05948527|Experimental|with mild Hypercapnia (Pco2 range 45-60 mmhg and power of hydrogen not less 7.30)|with mild Hypercapnia (Pco2 range 45-60 mmhg and power of hydrogen not less 7.30) of different pulmonary disorders
88947835|NCT01930097|Active Comparator|CHO-independent bolus|An insulin bolus independent of carbohydrate content will be given after each meal. The dual-hormone closed-loop strategy will give the remaining insulin needed based on the sensor readings.
89470633|NCT05948514||adult patients followed up in the nutrition and access device was inserted for parenteral nutrition|no intervention, observational study patients are enrolled, and followed up until a catheter related complication occurs
89470634|NCT05948488||Children with cystic fibrosis|Children over 8 and under 18 with cystic fibrosis. Children must be represented by their parent.
89470635|NCT05948449|Experimental|SOX+Cadonilimab（AK104）|3 cycles of neoadjuvant therapy: S-1: 40~60mg Bid，d1~14, q3w Oxaliplatin：130mg/m2，iv drip，d1, q3w Cadonilimab（AK104）:10mg/Kg,iv drip,d1,q3w
89470636|NCT05948423|Experimental|(Group A) Tissue Flossing + Conventional Therapy|"Tissue Flossing (3reps of 6 different active and passive movements, total 1-2 mints)~Hot Pack (10 mints)~PNF technique on Bicep, Tricep, pronator, Supinator muscle (3reps* 26sec, total 6 mints)~Joint Mobilization (3 reps of humeroulnar and radial head mobilization, total 6 mints) Total treatment duration was 24 mints."
89470637|NCT05948423|Active Comparator|(Group B) Conventional Therapy|"Hot Pack (10 mints)~PNF technique on Bicep, Tricep, pronator, supinator muscle (3reps* 26sec, total 6 mints)~Joint Mobilization (3 reps of humeroulnar and radial head mobilization, total 6 mints)~Total treatment duration was 24 mints."
89470638|NCT05948410||Study Group|Patients with an indication of invasive urodynamic study
89470639|NCT05948397||Study Group|Female patients admitted to urology outpatient clinic with mixed urinary incontinence.
89470640|NCT05948358||Females|18 Years to 45 Years (Adult )
89470641|NCT05948319|Active Comparator|myocardial performance and epicard thickness in obese pregnant women|obese pregnant versus normal-weight pregnant women were evaluated for MPI and fetal epicardial thickness
89470642|NCT05948319|Active Comparator|obese pregnant|obese pregnant versus normal-weight pregnant women were evaluated for MPI and fetal epicardial thickness
89470643|NCT05948280|Experimental|VR-supported mindfulness group|Participants in the intervention group will receive VR mindfulness intervention, consisting of four face-to-face sessions (twice a week for two weeks). During the first week, the interventionist will teach and guide the participant face-to-face. During the second week, participants will be required to practice VR on their own for self-help.
89470644|NCT05948280|Active Comparator|Mindfulness group|Participants in this group will receive a mindfulness exercise guided by the interventionist twice a week for two weeks.
89470645|NCT05948280|No Intervention|Control group|Participants in the control group will not receive mindfulness or mindfulness plus VR.
89470646|NCT05948254|Other|Triple Function Scan Body|Full arch implants were placed, a triple function scan Body and thus simplifying the workflow for full arch cases and reducing the number of visits to only 3 visits. Scan bodies were utilized for implant position scanning, facial scan alignment and as stoppers for jaw relation capturing as scan bodies were used as stoppers for jaw relation registration.
89470647|NCT05948241|Active Comparator|Standard treatment|The control group will undergo 1 consultation with the multidisciplinary team, offered as standard treatment at the Heart Failure outpatient clinic of the Institute of Cardiology, with the areas: medicine, nutritionist and psychology. Monitoring with a multidisciplinary team is the gold standard for monitoring patients with HF and its multiple comorbidities. These patients are followed up on average every 3 months in this outpatient clinic.
89470648|NCT05948241|Experimental|Online psychological support group|The intervention group, in addition to standard treatment, will have 1 weekly session in an online psychological support group of 45 minutes each, totaling 12 sessions in three months. The intervention will be carried out by research psychologists specializing in cardiology, with online consultations via whatsapp
88947836|NCT01930097|Active Comparator|Conventional treatment|Patients will use conventional pump therapy to regulate glucose levels
88947837|NCT01930110|Active Comparator|Single-hormone closed-loop system|In single-hormone closed-loop system, variable subcutaneous insulin infusion rate will be used to regulate glucose levels
88947838|NCT01930110|Active Comparator|Dual-hormone closed-loop system|In dual-hormone closed-loop system, variable subcutaneous insulin and glucagon infusion rates will be used to regulate glucose levels
88947839|NCT01930149|Experimental|Mailed patient outreach intervention|Participants randomized to this arm will receive mailed letter from health center that encourages cholesterol testing and describes the steps necessary to obtain the test at the patient's care site. Clinic staff will facilitate the ordering of tests for patients who may not have an office visit.
89470649|NCT05948228|Experimental|Application of bioactive gel on teeth in patients assigned for orthodontic treatment|Application of bioactive gel on labial/buccal surfaces of teeth is done according to manufacturer instructions using microbrush followed by light curing
89470650|NCT05948228|Active Comparator|Application of Fluoride on teeth in patients assigned for orthodontic treatment|Application of fluoride gel will be done using a gel loaded tray held in the mouth for 4 minutes .After removal of tray ,patients must spit out the residual gel. The use of suction is a must to avoid the problem of over ingestion
89470651|NCT05948215|Experimental|Jing Si Herbal Tea Liquid Packet|Participants received Jing Si Herbal Tea Liquid Packet 15 mg tablet orally once daily for 28 days.
88947840|NCT01930149|No Intervention|Usual Care Control Group|Participants randomized to this arm will receive usual care.
88947841|NCT01930201||Standard general anesthesia|Patients receiving standard of care.
88947842|NCT01930201||Caudal Epidural Block|Patients receiving a caudal epidural block in addition to standard of care.
88947843|NCT01930227|Experimental|TEAS Treatment|Patients were given 30min of TEAS at PC6 after spinal anesthesia
88947844|NCT01930227|Sham Comparator|Non-acupoint stimulation|Patients were given 30min of electrical stimulation at shoulder after spinal anesthesia
88947845|NCT01930227|No Intervention|Control|No stimulation was given
88947846|NCT01930240|Placebo Comparator|TRIA-662 Placebo|Single dose of nine placebo capsules matching TRIA-662 drug capsules
88947847|NCT01930240|Experimental|TRIA-662 Low Dose|Single-dose of TRIA-662 administered as three 30 mg TRIA-662 capsules and six matching placebo capsules
89019040|NCT04716855||Evaluation tests|RCS cases between the ages of 19-64 (n:40) who agreed to participate were included in the study. Pain severity (Visual Analogue Scale - VAS), range of motion (Universal Goniometer), muscle test (Manual muscle test), upper extremity functional status and disability (Quick-DASH questionnaire), physical activity level (International Physical Activity Questionnaire - UFAA) ) and quality of life (Short Form-36 - SF-36) were evaluated
89019041|NCT00419991|No Intervention|1 Tigecycline|
89019042|NCT02960321||CAG without PCI|Diagnostic coronary angiography only
89019043|NCT02960321||CAG with PCI|Diagnostic coronary angiography and subsequent percutaneous coronary intervention (PCI)
89019044|NCT04718090|Active Comparator|interscalene block|
89019045|NCT04718090|Active Comparator|PENG block|
89019046|NCT04716816|No Intervention|traditional treatment|received conventional analgesics.
89019047|NCT04716816|Experimental|Stripping massage|received SM twice daily in the active trigger points of the rhomboid for two weeks.
89019048|NCT00302627|Experimental|Pamidronate, Vitamin D, and Calcium|"60mg or 90mg given at baseline, 6,12,18, and 24 months~vitamin D 800 units/day~calcium carbonate 1500 milligrams/day"
89019049|NCT05129943|Active Comparator|active distraction group|local anesthesia with video game using VR device
89019050|NCT05129943|Active Comparator|passive distraction group|local anesthesia with cartoon video using VR device
89019051|NCT00302666|Sham Comparator|Arm 1|
89470652|NCT05948215|Placebo Comparator|Jing Si Herbal Tea Liquid Packet Placebo|Participants received Jing Si Herbal Tea Liquid Packet Placebo 15 mg tablet orally once daily for 28 days.
89470653|NCT05948202|Experimental|mPRT|mindfulness-enhanced Pivotal Response Treatment: group pivotal response training for parents that is supplemented with mindfulness strategies
89470654|NCT05948202|Active Comparator|pPRT|psychoeducation-enhanced Pivotal Response Treatment: group pivotal response training for parents that is supplemented with psychoeducation about stress and stress reduction
89470655|NCT05948150|Experimental|group not to use a breastfeeding pillow|In this arm, individuals are not provided with a breastfeeding pillow.
89470656|NCT05948150|Experimental|breastfeeding pillow group|In this arm, breastfeeding pillows are used for individuals
89470657|NCT05948137||Pheochromocytoma / paraganglioma|
89470658|NCT05948124|Experimental|L-Carnitine Group|Enrolled patients in this group who are on regular hemodialysis fulfilling our study's inclusion criteria with secondary carnitine deficiency(based on clinical manifestations and decreased serum level of L-carnitine ;serum free carnitine level less than 20 μmol/L) will receive intravenous L-carnitine (20 mg/kg dry body weight) after each dialysis session three times weekly for 6 months.
89470659|NCT05948124|Placebo Comparator|Placebo Group|enrolled patients in this group who will receive 5 ml intravenous isotonic saline after each dialysis session three times weekly for 6 months.
89470660|NCT05948072|Experimental|mFOLFOX6 + Cetuximab|Cetuximab + mFOLFOX6: Cetuximab (500mg/m2 IV ) will be given. Oxaliplatin (85 mg/m2 IV over 2 h on day 1), Leucovorin calcium (350 mg/m2 IV over 2 h on day 1) plus a bolus of 5FU (400 mg/m2) followed by a 46h-48h IV infusion of 5FU 2400 mg/m2 will be repeated for every 2 weeks. The regimens repeat every 2 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
89470661|NCT05948072|Active Comparator|mFOLFOX6|mFOLFOX6: Oxaliplatin (85 mg/m2 IV over 2 h on day 1), Leucovorin calcium (350 mg/m2 IV over 2 h on day 1) plus a bolus of 5FU (400 mg/m2) followed by a 46h-48h IV infusion of 5FU 2400 mg/m2 will be repeated for every 2 weeks. The regimens repeat every 2 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
89470662|NCT05948046||Training group|Patients with symptomatic convergence insufficiency who had received visual training
89019052|NCT00302666|Sham Comparator|Arm 2|
89019053|NCT05070741|Experimental|Heat Therapy Treatment|This study will recruit subjects to participate in heat therapy treatment at the University of Kansas Medical Center (KUMC). After pre-screening, informed consent, and enrollment, all subjects will have baseline laboratory assessments as well as an examination for neuropathy and a lower distal leg biopsy (3mm). Subjects will complete 12 heat therapy treatments over the course of 4 weeks. Within 24-48 hours after the last heat therapy experience, post-treatment laboratory assessments as well as an examination for neuropathy and a lower distal leg biopsy (3mm) will be performed.
89019054|NCT00418418|Active Comparator|A|Patient group receiving the stem cell injections during the CABG
89019055|NCT00418418|Placebo Comparator|B|The patient group receiving autologous serum injections during the CAGB operation
89019056|NCT00418496|Experimental|Aldekleukin Plus Dose Escalation Sorafenib|Patients will be admitted to a dedicated nursing unit for HD aldesleukin administration. Patients will receive bolus aldesleukin at a dose of 600,000 IU/Kg every eight hours on days 1-5 with a goal of 10-12 doses.
89019057|NCT05024721|Experimental|HIP2101|Taking HIP2101+HPP2102 once daily for 2 weeks.
89019058|NCT05024721|Active Comparator|RLD2101|Taking RLD21012101+HPP2101 once daily for 2 weeks.
89019059|NCT00302705|Active Comparator|Valsartan|160 mg/day on awakening
89470663|NCT05948046||Not training group|Patients with symptomatic convergence insufficiency who had not received visual training
89019060|NCT00302705|Active Comparator|Enalapril|10-20 mg/day on awakening
89019061|NCT00328419|Experimental|1|photoprotected parenteral nutrition
89019062|NCT00328419|Active Comparator|2|Non-photoprotected parenteral nutrition
89019063|NCT05015712|Experimental|moderate intensity continuous training|
89019064|NCT05015712|No Intervention|guideline control|Patients assigned to the guideline control just received 1-time advice on training according to guidelines.
89470664|NCT05948033|Experimental|CD70-targeting CAR-T cells|"Enrolled participants will be given a preconditioning regimen consisted of fludarabine and cyclophosphamide before the infusion of CD70-CAR T cells.~Enrolled patients in this arm will be administered CD70-CAR T cells in 3+3 based escalation manner."
89470665|NCT05947968|Experimental|Group A (Scapular PNF)|"will receive scapular proprioceptive neuromuscular facilitation exercise plus conventional treatment of lateral epicondylitis for 12 sessions (3 sessions per week for four weeks).~The conventional treatment of lateral epicondylitis will be:~Pulsed ultrasound over the lateral epicondyle for 5 min.~Five minutes of deep friction massage. It will be consisted of deep circular motions using the fingertips over the area of maximal tenderness at the lateral epicondyle.~Stretching exercise for extensor carpi radialis longus and brevis for 3 repetitions, each repetition will be 45 seconds with 30 seconds' rest.~Strengthening exercise for wrist extensors, eccentric exercise for wrist extensors will be as follow: 3 sets, 10 repetitions, 1 min rest interval between each set."
89470666|NCT05947968|Experimental|Group B (Shoulder exercises)|"will receive shoulder strengthening exercise plus conventional treatment of lateral epicondylitis for 12 sessions (3 sessions per week for four weeks).~Same conventional treatment in group (A)"
89470667|NCT05947916|Experimental|Intervention group|The intervention group will wear real-time CGM (120 cases) to monitor blood glucose and is required to use real-time-CGM more than 50% of the time every 4 weeks, the more the better.
89470668|NCT05947916|No Intervention|Control group|The control group will be followed up with traditional SMBG (120 cases) monitoring.
89470669|NCT05947877|Experimental|Non-pharmacological nursing pain management strategies|This arm considers conventional care.
89470670|NCT05947877|Experimental|Breast milk|This arm considers breast milk. The preterm infants were orally fed 2 ml of expressed breast milk through a syringe 2 minutes before heel stick over the anterior surface of the tongue, allowing for preterm infant swallowing rates over a period of 1-2 minutes. Thereafter, the bedside nurse conducts the heel lancing. When the mother is present with her preterm infant in the NICU, the breast milk was expressed by the mother and provided in a syringe at least 30 minutes before the intervention (n = 11). For the rest 10 preterm infants whose mothers were not present with them in the NICU, they send their breast milk to be kept in the NICU refrigerator. This milk was first warmed in room temperature 30 minutes before it was given to the preterm infant.
89470671|NCT05947877|Experimental|Oral sucrose|This arm considers oral sucrose. The researchers gave one ml of 24% oral sucrose to the preterm infant two minutes prior to the heel stick, drop-by-drop via syringe over the anterior surface of the tongue which enable the preterm infant to swallow rates over a period of 1-2 minutes. Conducting the heel stick procedure with lancet approximately two minutes after administering the sucrose. The pharmacy at the study site supplies the syringes containing the oral sucrose solution, solutions are prepared and packaged in an identical matter, the SR will label each syringe with the preterm infants' study number and name to ensure added protection.
88947848|NCT01930240|Experimental|TRIA-662 High Dose|Single dose of TRIA-662 administered as nine 30mg TRIA-662 capsules
88947849|NCT01930266|No Intervention|Observational|Patients will receive general dietary instructions with an annual follow-up. At this follow up, a repeat BMD, dietary and laboratory evaluation will be performed.
88947850|NCT01930266|Active Comparator|Interventional.|Patients will receive detailed dietary instructions with periodic (3 month) follow up. At the follow-up patients will be assessed whether they reached their calcium intake goals both quantitatively and whether appropriate calcium sources were utilized.
88947851|NCT01930266|Experimental|Active interventional|Patients will receive detailed dietary instructions and active follow up with diary and email reports. Inclusion in group C will be predicated upon intake of 100% DRI of calcium primarily by food sources, with the addition of Calcium Carbonate 600 mg, if necessary
88947852|NCT01930279||surface markers on T cells as assessed by FACS|
88947853|NCT01930292|Experimental|Part A: Debio 1143|Eligible participants receive Part A: Debio 1143 once daily for 5 consecutive days in each 21-day treatment cycle according to dose escalation rules (in combination with Paclitaxel and Carboplatin standard of care)
88947854|NCT01930292|Experimental|Part B: Lung Cancer|Participants with Lung Cancer receive Part B: Debio 1143 once daily for 5 consecutive days in each 21-day treatment cycle (in combination with Paclitaxel and Carboplatin standard of care)
88947855|NCT01930292|Experimental|Part B: Ovarian Cancer|Participants with Ovarian Cancer receive Part B: Debio 1143 once daily for 5 consecutive days in each 21-day treatment cycle (in combination with Paclitaxel and Carboplatin standard of care)
88947856|NCT01930292|Experimental|Part B: Breast Cancer|Participants with Breast Cancer receive Part B: Debio 1143 once daily for 5 consecutive days in each 21-day treatment cycle (in combination with Paclitaxel and Carboplatin standard of care)
89470672|NCT05947877|Experimental|KMC|This arm considers KMC. The preterm infants were randomized to the KMC intervention; the researchers explained to the mother that she and her preterm infants will be put in KMC position, where the diaper-clad infant was held upright, at an angle of approximately 60°, between the mothers' breasts, providing maximal skin-to-skin contact between mother and baby. A blanket was placed over the preterm infant's back, and the mother's clothes were wrapped around the neonate, the preterm infant will remain in KMC for 30 minutes before the lancing procedure, during, and at least 30 minutes after the heel lance.
89470673|NCT05947877|Experimental|Nesting position|This arm considers nesting position. Before heel lancing, the researchers prepared and arranged all the required nesting equipment from the NICU such as linen, small pillow, and blanket. Making the nest by folding the blanket form one corner, then placing it upright and laying the linen over the blanket. Positioning the preterm infant inside the nest in supine position, ensuring that the nest size is suitable for the preterm infant's body, neither too loose nor too tight during nesting position. Position the preterm infant first in supine position through wrapping infant with hand to midline the nest through putting small pillow under the preterm infant's shoulder to keep airway open, the nested infants were placed in nest, that helped to maintain and support them in a flexed position but still facilitated unrestricted movement of their body and limbs, supine nesting position conducting 30 minutes before heel lancing and, during, and after the procedure for 30 minutes.
89470674|NCT05947825|Experimental|Experimental: Combination of sitagliptin+ gemcitabine + nab-paclitaxel|"Drug: Sitagliptin Sitagliptin will be administered orally once a day at a dose of 100 mg depending on cohort assignment.~Drug: Gemcitabine Gemcitabine will be intravenously administered on Days 1 and 8 of every 21-day cycle at a dose of 1000 mg/m2 depending on cohort assignment.~Drug: Nab-Paclitaxel Nab-Paclitaxel will be intravenously administered on Days 1 and 8 of every 28-day cycle at a dose of 125 mg/m2 depending on cohort assignment."
89470675|NCT05947812|Experimental|Tafenoquine|Tafenoquine two tablets 1x/day on Days 1, 2, 3, and then weekly (Days 10 ± 1 day, 17 ± 2 days, 24 ± 2 days, 31 ± 2 days and 38 ± 2 days) until sustained clinical recovery
89470676|NCT05947812|Placebo Comparator|Placebo|Placebo two tablets 1x/day on Days 1, 2, 3, and then weekly (Days 10 ± 1 day, 17 ± 2 days, 24 ± 2 days, 31 ± 2 days and 38 ± 2 days) until sustained clinical recovery
89470677|NCT05947799|Other|Video medication module then text self-monitoring module|Patients are provided education via an online animated video on heart failure medications followed by a online text document on heart failure self-monitoring.
89470678|NCT05947799|Other|Text medication module then video self-monitoring module|Patients are provided education via an online text document on heart failure medications followed by a online animated video on heart failure self-monitoring.
89470679|NCT05947799|Other|Video self-monitoring module then text medication module|Patients are provided education via an online animated video on heart failure self-monitoring followed by a online text document on heart failure medications.
89470680|NCT05947799|Other|Text self-monitoring module then video medication module|Patients are provided education via an online text document on heart failure self-monitoring followed by a online animated video on heart failure medication management.
89470681|NCT05947773|Experimental|Robotically treated patient|They performed training with a robot 15 times over 3 weeks.
89470682|NCT05947773|Experimental|Walking training|Walking exercises were performed without a robot.
89470683|NCT05947773|Experimental|Control group|Physiotherapy treatment was carried out by the patients.
89470684|NCT05947708|Active Comparator|High FLow Rate|Flow Rate of 500ml/min or higher
89470685|NCT05947708|Active Comparator|Low Flow Rate|Flow Rate of 300ml/min
89470686|NCT05947682|Other|Adults who are planned to undergo plastic surgery|Adults who are planned to undergo plastic surgery for abdominal liposuction or lipoaspiration under general anaesthetic for their own care and who are voluntary for fat donation to contribute to the study
89470687|NCT05947669|Active Comparator|Standard of care - Methylprednisolone|Subjects are hospitalised Day 1 and for at least 4 days. It is accepted that participating centres handle the subjects on an outpatient basis as long as all study requirements are met. Methylprednisolone 80 mg intravenously (body weight 40-80 kg; methylprednisolone 1 mg/kg if body weight < 40 or > 80 kg) will be administered from Day 1 until mCTCAE ir-colitis/diarrhoea grade ≤ 2 and hereafter converted to oral prednisolone. During tapering, if ir-colitis/diarrhoea increases from grade 2 to ≥ grade 3, or from grade < 2 to ≥ grade 2, re-assessment including diagnostic workup will be performed, and the patient will be evaluated for rescue infliximab.
88947857|NCT01930318|Placebo Comparator|PCA,Placebo,Placebo|PCA for 2 days after operation, i.v placebo in 2 days after surgery and oral placebo in the day 3 to day 5 after surgery
88947858|NCT01930318|Placebo Comparator|PCA,placebo,tramadol|PCA for 2 days after operation, i.v placebo in 2 days after surgery, and oral tramadol in the day 3 to day 5 after surgery
88947859|NCT01930318|Experimental|PCA,parecoxib,placebo|PCA for 2 days after operation, i.v parecoxib in 2 days after surgery,and oral placebo in the day 3 to day 5 after surgery
88947860|NCT01930318|Experimental|PCA,parecoxib,celecoxib|PCA for 2 days after operation,i.v parecoxib in 2 days after surgery and oral celecoxib in the day 3 to day 5 after surgery
88947861|NCT01930331|Experimental|ARCO treatment|Patients in this treatment arm will receive on Day 0 a single dose of standard treatment of artemisinin/naphthoquine (in a fixed oral dose of ARCO tablets). Treatment will be given under supervision.
88947862|NCT01930331|Active Comparator|Eurartesim treatment|Patients in this treatment arm will receive a dose of dihydroartemisinin/piperaquine phosphate (in a fixed oral dose of Eurartesim tablets) over three days (0,1,2). Treatment will be given under supervision.
89019065|NCT00302822|Experimental|Intensification|lopinavir or efavirenz and emtricitabine/tenofovir and intensification with enfuvirtide (week 0 to 24)
89019066|NCT00302822|Active Comparator|Standard|lopinavir or efavirenz and emtricitabine/tenofovir
89019067|NCT00328458|Experimental|Cohort 1 Brain Tumors|The investigational drug - EPO906 will be administered as an intravenous infusion over five to ten minutes on weeks 1, 3 and 6, for the duration of radiation therapy up to a maximum of 7 weeks. Duration of therapy will be determined by disease cohort.
89019068|NCT00328458|Experimental|Cohort 2 Head and Neck Tumors|The investigational drug - EPO906 will be administered as an intravenous infusion over five to ten minutes on weeks 1, 3 and 6, for the duration of radiation therapy up to a maximum of 7 weeks. Duration of therapy will be determined by disease cohort.
89019069|NCT04716582|Experimental|SIT group|participants will sitting 4 hours continuously.
89019070|NCT04716582|Experimental|INTERRUPT group|participants will sitting 25 minutes with 5 minutes walking per half hour,40minutes walking in total
89019071|NCT04716582|Experimental|COGN group|participants will perform GED test as cognitive loading task during 4-hour sitting
89019072|NCT00302900|Experimental|1|Pre-donation water and muscle tension during donation
89019073|NCT00302900|Experimental|2|Pre-donation water
89019074|NCT00302900|Sham Comparator|3|Pre-donation muscle tension
89019075|NCT00302900|No Intervention|4|Standard donation
89019076|NCT04716621|Experimental|Early intervention|Three sites received the Pain Management Support System for Primary Care (PMSS-PC) integrated into the Electronic Health Record.
89019077|NCT04716621|Other|Delayed intervention|Delayed wait-list control group. Three additional sites received the intervention 6 months after the first arm.
89019078|NCT00303017|Experimental|flavocoxid|medical food
89019079|NCT00303017|Active Comparator|naproxen|NSAID
89019080|NCT00328497|Experimental|1|Panzem NCD will be dosed orally at a level of 1,000 mg, four times daily for 28 consecutive days and bevacizumab will be administered at a dose of 5 mg/kg as an intravenous bolus on Day 1 and Day 15 of the Treatment Period
89019081|NCT00303134|Experimental|Islet Cell Transplantation|
89019082|NCT00303212|No Intervention|UC|Usual HF guideline-base care
89019083|NCT00303212|Experimental|TM|Telemonitoring group plus usual guideline-based HF care
89019084|NCT00328575|Experimental|Intensity-Modulated Radiotherapy (IMRT)|Patients with brain metastases will be enrolled in one of three dose levels based on tumor size. For tumor size of 3 cm or less (maximum diameter in any dimension), doses of 47.5Gy, 52.5Gy, and 54.5Gy will be tested. For tumor size of greater than 3 cm (maximum diameter in any dimension), doses of 42.5Gy, 47.5Gy, and 52.5Gy will be tested.
89019085|NCT00303290|Experimental|PEG-Intron + ARA-C|Peg Interferon Alpha 2b (Peg Intron) 4.5 micrograms/kg once a week. ARA-C 10 mg under the skin daily.
89019086|NCT00328692|Experimental|2|
89019087|NCT00328692|Placebo Comparator|1|
89019088|NCT04718246|Other|Dental Implants in hyperlipidemia patients|Implants will be placed at T0, then Implant site exposure will take place 6 months following the implant placement. Insertion of the healing collars in order to obtain adequate soft tissue form for 1-2 weeks then the impressions (indirect, closed tray echnique) shall be taken to fabricate the final crowns, then the final crowns will be fitted in place.
89019089|NCT00303524|Experimental|1|Zoladex 3-month depot
89019090|NCT00303524|Experimental|2|Zoladex 1-month depot
89019091|NCT00303563|Experimental|1|
89019092|NCT00303563|Experimental|2|
89019093|NCT00303563|Experimental|3|
89019094|NCT00303563|Placebo Comparator|4|
89019095|NCT00328809|Experimental|Spirnolactone|
89019096|NCT00420030|Active Comparator|1|Arm 1 - routine upfront administration of Reopro (Abciximab)
89019097|NCT00420030|Other|2|Reopro (Abciximab) only if needed - according to physician
89019098|NCT00303758|Active Comparator|LV5FU2 simplifié + cisplatine puis gemcitabine si progression|LV5FU2 simplifié + cisplatine puis gemcitabine si progression
89019099|NCT00303758|Experimental|gemcitabine puis LV5FU2 simplifié + cisplatine si progression|gemcitabine puis LV5FU2 simplifié + cisplatine si progression
89019100|NCT00332280|Experimental|AMT2003|
89019101|NCT00303797|Experimental|Treatment (bortezomib, sorafenib tosylate)|"GROUP I (solid tumors-dose-escalation group): Patients receive oral sorafenib twice daily on days 1-21 and bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of sorafenib and bortezomib until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.~GROUP II (multiple myeloma or chronic lymphocytic leukemia-maximum tolerated dose [MTD] group): Patients receive oral sorafenib at the MTD twice daily on days 3-21 of course 1 and on days 1-21 of each subsequent course. Patients also receive bortezomib IV over 3-5 seconds at the MTD on days 1, 4, 8, and 11.~Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity."
89019102|NCT00303836|Experimental|Arm I|Patients undergo apheresis and in-vitro depletion of T-regulatory cells. Patients then receive a nonmyeloablative, lymphocyte-depleting preparative regimen comprising cyclophosphamide IV over 1 hour on days -8 and -7 and fludarabine IV over 15-30 minutes on days -6 to -2 followed by autologous T-regulatory-depleted lymphocytes IV over 20-30 minutes on day 0. Patients receive vaccination with gp100:209-217 (210M) and MART-1:27-35 peptides emulsified in Montanide ISA-51 subcutaneously (SC) on days 0-3, 20-23, 41-44, and 62-65. Patients also receive filgrastim (G-CSF) SC beginning on day 1 and continuing until blood counts recover.
89019103|NCT00303836|Experimental|Arm II|Patients receive treatment as in arm I. Patients also receive high-dose IL-2 IV over 15 minutes every 8 hours on days 0-4, beginning after the lymphocyte infusion. IL-2 treatment repeats every 3 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
89019104|NCT00303875|No Intervention|Wait-list control|Wait-list control received diet & exercise counseling during year 2 as a courtesy
89019105|NCT00303875|Experimental|Lifestyle counseling|subjects randomized to receive diet & exercise counseling for one year
89019106|NCT00420186|Experimental|1|
89019107|NCT00303992|Experimental|Trastuzumab and Irinotecan|
89470688|NCT05947669|Experimental|Treatment with infliximab|Infliximab will be administered Day 1 or latest Day 2 (within 48 hours). Infliximab infusion is handled as standard by skilled staff. A second dose of infliximab will be administered if ir-colitis/diarrhoea has not resolved to grade ≤ 2 on Day 7. Methylprednisolone 80 mg (body weight 40-80 kg; methylprednisolone 1 mg/kg if body weight < 40 or > 80 kg) intravenously is co-administered from Day 1 until mCTCAE ir-colitis/diarrhoea grade ≤ 2 and hereafter converted to oral prednisolone. Initial dosage of infliximab is 5 mg/kg. Dosage of infliximab for subjects referred to a second dose of infliximab will be left to the discretion of the treating physician. In the event of failure of infliximab, second line biological immunosuppressant treatment will also be left to the discretion of the treating physician.
89470689|NCT05947643|Experimental|Theophylline|Participants will dissolve the contents of the 400 mg theophylline capsules (experimental) into the sinus rinse bottle containing nasal saline.
89470690|NCT05947643|Placebo Comparator|Placebo|Participant will dissolve the contents of the identical-appearing lactose capsules (control) into the sinus rinse bottle containing nasal saline.
89470691|NCT05947630|Experimental|AFO (ankle foot orthosis) dynamic and correctional|Groep A with AFO (ankle foot orthosis) dynamic and correctional
89470692|NCT05947630|No Intervention|AFO or KAFO (knee ankle foot orthosis) correctional|Groep B with AFO or KAFO (knee ankle foot orthosis) and only correctional
89470693|NCT05947630|Experimental|KAFO dynamic and correctional|Groep C with KAFO dynamic and correctional
89470694|NCT05947630|No Intervention|KAFO correctional|Groep D with KAFO only correctional
89470695|NCT05947617|Experimental|Arm 1: Low Dose (1 ml) VIX001|Participants in this arm will receive intravenous injections of VIX001 at a low dose of 1 ml. The intervention involves the administration of VIX001 diluted in clinical standard saline.
89470696|NCT05947617|Experimental|Arm 2: Intermediate Dose (3 ml) VIX001|Participants in this arm will receive intravenous injections of VIX001 at an intermediate dose of 3 ml. The intervention entails the administration of VIX001 diluted in clinical standard saline.
89470697|NCT05947617|Experimental|Arm 3: High Dose (10 ml) VIX001|Participants in this arm will receive intravenous injections of VIX001 at a high dose of 10 ml. The intervention involves the administration of VIX001 diluted in clinical standard saline.
89470698|NCT05947604|Other|Dextromethorphan and Midazolam|"Drug drug interaction Dextromethorphan and Midazolam administrations~Dextromethorphan 15 mg syrup in fasted condition Period 1: Single oral dose of 15 mg administered on Day 1~Midazolam 5 mg syrup in fasted condition Period 1: Single oral dose of 5 mg administered on Day 8"
89470699|NCT05947604|Other|Acoziborole, Dextromethorphan and Midazolam|"Drug drug interaction Acoziborole, Dextromethorphan and Midazolam administrations~Acoziborole 960 mg (three tablets of 320 mg) for oral route in fasted condition Period 2: single oral administration on Day 12~Dextromethorphan 15 mg syrup in fasted condition Period 2: Single oral dose of 15 mg administered on Day 14~Midazolam 5 mg syrup in fasted condition Period 2: Single oral dose of 5 mg administered on Day 21"
89470700|NCT05947565|Active Comparator|Group 1|Invasive urodynamic study will be performed firstly in sitting position. Then, repeated in standing position.
89470701|NCT05947565|Active Comparator|Group 2|Invasive urodynamic study will be performed firstly in standing position. Then, repeated in sitting position.
89470702|NCT05947552||Chronic kidney disease Patients|Chronic kidney Disease Patients stage 3 to stage 5
89470703|NCT05947526||Women referring to infertility clinic for IVF treatment|Women who were referred to infertility clinic with complaint of not having baby go through IVF treatment, and having oocyte pick-up procedure with different sizes of ovarian follicles
89470704|NCT05947513|Experimental|Concurrent Curcumin Palliative Radiotherapy|Daily 1000 mg oral CGM Curcumin in two divided doses for seven days prior to the start of and for three to five weeks concurrently with palliative radiotherapy.
89470705|NCT05947487|Experimental|CD70-targeting CAR-T cells|"Enrolled participants will be given a preconditioning regimen consisted of albumin-bound paclitaxel, cyclophosphamide and fludarabine before the infusion of CD70-CAR-T cells.~Enrolled patients in this arm will be administered CD70-CAR-T cells in 3+3 based escalation manner."
89470706|NCT05947461|Experimental|diclofenac group|Patients without contraindications in diclofenac group received 100mg rectal diclofenac 30 mins before ERCP procedure.
89470707|NCT05947461|Active Comparator|Indomethacin group|Patients without contraindications in indomethacin group received 100mg rectal indomethacin 30 mins before ERCP procedure.
89470708|NCT05947383|Experimental|Psilocybin|
89470709|NCT05947383|Placebo Comparator|Placebo|
88947863|NCT01925976|Other|Individualized dietetic intervention|Behavioral: Individualized dietetic intervention-eating habits.
88947864|NCT01930344|Active Comparator|3D laparoscopic visual system|Laparoscopic cholecystectomy to be performed with 3D laparoscopic imaging system
88947865|NCT01930344|Placebo Comparator|2D Laparoscopic Visual System|Laparoscopic cholecystectomy to be performed using normal, 2D, laparoscopic visual system
88947866|NCT01930370|Experimental|Hemodialysis patients|Each patient will be evaluated during a total of 3.5 weeks correlating to routine dialysis treatment appointments. Each participant will start with low bicarbonate, followed by the washout phase (standard bicarbonate), then high bicarbonate, finishing with the follow up period. Dialysis prescription is standardized for each patient throughout the entire 3.5 week study period.
88947867|NCT01930383||Arm A|HCC patients who receive curative surgery or radiofrequency ablation therapy
88947868|NCT01930383||Arm B|patients who receive trans-arterial chemoembolization
88947869|NCT01930383||Arm C|patients who receive systemic therapy
88947870|NCT01930396|Experimental|Tinzaparin|
88947871|NCT01930396|Active Comparator|Unfractionated Heparin|
88947872|NCT01930409|Active Comparator|Education Only|"A 1 hour education session in the acute setting~A toolkit with education, exercise and self management instructions for after hip fracture"
88947873|NCT01930409|Experimental|Education + Telephone Follow-up|"A 1 hour education session in the acute setting~A telephone delivered self management program , including a toolkit (education, exercise and self management instructions for after hip fracture), support to take an active role in recovery, including setting and monitoring goals, problem solving mobility barriers, and guidance on the recovery process following a hip fracture."
88947874|NCT01930422|Experimental|Real tDCS|Direct transcranial electrical stimulation (tDCS procedure)
89470710|NCT05947370|Experimental|Berberine Chloride|This study employed a randomized, double-blind, placebo-controlled, two-period crossover design: subjects were randomized into two groups of equal size. The random allocation was conducted by asking volunteers to select the randomized number generated by computer. Each number represented placebo or BBR, and each group has the same number of numbers. The dosing sequence in the first group was oral BBR in the first cycle and oral placebo in the second cycle. The second group was administered placebo in the first cycle and BBR in the second cycle. Take the second dose 14 days after the first dose. After the last dose, continue to observe for 14 days to watch for side effects. On each experimental day, after an overnight fast, the subjects received a single oral dose of 1 g of BBR or a corresponding dose of the placebo.
89470711|NCT05947370|Placebo Comparator|Placebo control|This study employed a randomized, double-blind, placebo-controlled, two-period crossover design: subjects were randomized into two groups of equal size. The random allocation was conducted by asking volunteers to select the randomized number generated by computer. Each number represented placebo or BBR, and each group has the same number of numbers. The dosing sequence in the first group was oral BBR in the first cycle and oral placebo in the second cycle. The second group was administered placebo in the first cycle and BBR in the second cycle. Take the second dose 14 days after the first dose. After the last dose, continue to observe for 14 days to watch for side effects. On each experimental day, after an overnight fast, the subjects received a single oral dose of 1 g of BBR or a corresponding dose of the placebo.
89470712|NCT05947331|Active Comparator|Group I (Graded Anderson procedure)|patients with idiopathic infantile nystagmus related head turn corrected by graded Anderson procedure.
89470713|NCT05947331|Active Comparator|Group II (Kestenbaum procedure)|patients with idiopathic infantile nystagmus related head turn corrected by Kestenbaum procedure.
89470714|NCT05947318|Experimental|tACS - 70 Hz group|The group will receive the training program plus 20 minutes of tACS at 70 Hz in the C3 or C4 electrode position (depending of the hemiparetic arm) during a specific kinetic and kinematic tasks in every training session.
89470715|NCT05947318|Active Comparator|tACS - 7 Hz group|The group will receive the training program plus 20 minutes of tACS at 7 Hz in the C3 or C4 electrode position (depending of the hemiparetic arm) during a specific kinetic and kinematic tasks in every training session.
89470716|NCT05947318|Sham Comparator|tACS - sham group|The group will receive the training program plus 30 seconds of tACS at 70 Hz in the C3 or C4 electrode position (depending of the hemiparetic arm) in every training session.
89470717|NCT05947292||Nerve Block|Patients with femur fractures who receive a fascia-iliaca compartment nerve block as part of their care in the Emergency Department.
89470718|NCT05947292||No Nerve Block|Patients with femur fractures who receive only intravenous analgesia in the Emergency Department.
89470719|NCT05947253|Experimental|BUTYEKO BREATHING TECHNIQUE|First Group A 20 participants received Buyteko breathing technique while will be given 5 days per week
89470720|NCT05947253|Experimental|active cycle of breathing technique|Group B 20 participants received active cycle of breathing technique and session of 35min will be given 5 days per week
89470721|NCT05947240|Experimental|upper extremity aerobic exercises|The treatment group patients will perform upper extremity aerobic exercises by using an arm ergometer under the supervision of a physiotherapist. Training intensity will adjust according to 50 80 % of max HR or intensity of dyspnea to 4 points on modified Borg scale (MBS) for at least 15 45 min,3 times/week over 6 weeks.
89470722|NCT05947240|Experimental|active alternating movements for the upper limbs a|The control group patients will perform functional active alternating movements for the upper limbs at home involving three sets with 10 repetitions and a rest interval between 1- and 2-minute. Intervention will be for 3 times a week or 6 weeks.
89470723|NCT05947227|Experimental|manual chest physical therapy and Buteyko breathing technique|Group A will be treated with manual chest physical therapy and Buteyko breathing technique
89470724|NCT05947227|Experimental|manual chest physical therapy and Diaphragmatic breathing technique.|Group-B will be treated with manual chest physical therapy and Diaphragmatic breathing technique.
89470725|NCT05947175|Experimental|Experimental group - vertebral bone marrow (vBMA) clot|Bone allograft chips will be obtained from Istituto Ortopedico Rizzoli while vBMA will be harvested from each patient vertebral pedicle with the preparation of the site for pedicle screw insertion during spinal surgery. After the positioning of pedicle screws, the decompression of the cauda and nerve roots will be achieved with a hemilaminectomy and foraminotomy. vBMA clot associated with bone allograft chips will be opposed on the hemi-laminae and transvers process on the contralateral side of the hemilaminectomy. On the hemilaminectomy side, foramino-arthrectomy will be performed to insert the interbody fusion cage if necessary. After aspiration, the vBMA will be clotted and used for surgical procedure. vBMA clot associated to bone allograft chips will be applied on each side of the vertebra according to the number of segments to be fused.
89470726|NCT05947175|Active Comparator|Control - bone allograft chips|Bone allograft chips will be obtained from Istituto Ortopedico Rizzoli. In detail, conventional posterior approach for lumbar SF will be performed. After the positioning of pedicle screws, the decompression of the cauda and nerve roots will be achieved with a hemilaminectomy and foraminotomy. Bone allograft chips alone will be opposed on the hemi-laminae and transvers process on the contralateral side of the hemilaminectomy. On the hemilaminectomy side, foramino-arthrectomy will be performed to insert the interbody fusion cage if necessary.
88947875|NCT01930422|Sham Comparator|Placebo tDCS|Sham procedure
89470727|NCT05947110|Experimental|Plyo-HKT group|Participants in this group received the Plyo-HKT program
89470728|NCT05947110|Active Comparator|Control group|Participants in this group received the standard exercise program.
89470729|NCT05947097|Experimental|Mild Renal Impairment|
89470730|NCT05947097|Experimental|Moderate Renal Impairment|
88947876|NCT01930448||gastric bypass|Surgical group of obese patients with type 2 diabetes undergoing gastric bypass surgery
88947877|NCT01930448||gastric banding|surgical group of obese patients with type 2 diabetes undergoing gastric banding
88947878|NCT01930461|Experimental|SLIT (A)|SLIT tablets of HDM allergen extracts, 3 different doses (A)
88947879|NCT01930461|Experimental|SLIT (B)|SLIT tablets of HDM allergen extracts, 3 different doses (B)
88947880|NCT01930461|Experimental|SLIT (C)|SLIT tablets of HDM allergen extracts, 3 different doses (C)
88947881|NCT01930461|Placebo Comparator|Placebo|Placebo matching the SLIT tablets of HDM allergen extracts
88947882|NCT01930500|Experimental|Individual neuropsychological rehabilitation|12 times 90 minutes, once per week or once per two weeks, during 5 months
88947883|NCT01930500|Experimental|Group based neuropsychological rehabilitation|12 times 120 minutes + a brake, once per week or once per two weeks, during 5 months
88947884|NCT01930500|No Intervention|Control group|Control group does not receive neuropsychological rehabilitation or any other intervention during the first 5 months. After the control period they will be randomized to receive either individual or group based rehabilitation.
88947885|NCT01930526|Experimental|Pulmonary Rehabilitation|Patients will undergo the usual pulmonary rehabilitation programme but instead of two-legged cycling they will undergo single leg cycling where they cycle with one leg for 10-15mins and then the other in the same session.
88947886|NCT01930552|Experimental|Cohort 1|aflibercept IV infusion for 1 hour followed by FOLFIRI IV infusion every 2 weeks
89470731|NCT05947097|Experimental|Severe Renal Impairment|
89470732|NCT05947097|Experimental|Normal Renal function|
89470733|NCT05946928||Ozased group|50 patients premedicated with OZALIN® / OZASED®
89470734|NCT05946928||Control group|50 patients who did not receive any premedication
89470735|NCT05946291|Experimental|Standardized Patient Group|Standardized Patient: A pressure wound similar to reality will be created with the application of mulage on a standardized patient. In accordance with the scenario of a patient with a pressure wound, students will perform pressure wound evaluation and maintenance on a standardized patient in a simulation laboratory. Following the simulation application, student groups of eight to ten individuals will participate in a debriefing session.
89470736|NCT05946291|Active Comparator|Simulated Manneqquin Group|Simulated Mannequin: A pressure wound similar to reality will be created with the simulated mannequin mulage application. In accordance with the same scenario used in the experimental group, pressure wound evaluation and maintenance will be performed on the simulated mannequin in the simulation laboratory. Following the simulation application, student groups of eight to ten individuals will participate in a debriefing session.
89470737|NCT05944445||Single arm group|Adult critically ill patients admitted to ICU for different indications
89470738|NCT05944055||Overdose|Preterm born before 31 weeks of gestation with at least a 25OH-D measure above 120nmol/L before 36 weeks corrected age and no determination below 50nmol/L. Of note, 25OH-D determinations are routinely performed each month from the first month of life during the NICU hospitalization
89470739|NCT05944055||Control|"Preterm infants born before 31 weeks of gestation, who presented with a 25OH-D between 50 and 120nmol/L for all the 25OH-D measures during their hospitalization in the NICU setting.~Of note, 25OH-D determinations are routinely performed each month from the first month of life during the NICU hospitalization"
89470740|NCT05943886|Experimental|Single dose of 0.5 mg HEC88473|Healthy subjects, receiving a single dose of 0.5 mg HEC88473 (N=8) or placebo(N=2) after meal.
89470741|NCT05943886|Experimental|Single dose of 1.7 mg HEC88473|Healthy subjects, receiving a single dose of 1.7 mg HEC88473 (N=8) or placebo(N=2) after meal.
89470742|NCT05943886|Experimental|Single dose of 5.1 mg HEC88473|"Healthy subjects, receiving a single dose of 5.1 mg HEC88473 (N=8) or placebo(N=2) after meal.~Obese subjects, receiving a single dose of 5.1 mg HEC88473 (N=8) or placebo(N=2) after meal."
89470743|NCT05943886|Experimental|Single dose of 10.2 mg HEC88473|Healthy subjects, receiving a single dose of 10.2 mg HEC88473 (N=8) or placebo(N=2) after meal.
89470744|NCT05943886|Experimental|Single dose of 17.0 mg HEC88473|Healthy subjects, receiving a single dose of 17.0 mg HEC88473 (N=8) or placebo(N=2) after meal.
89470745|NCT05943886|Experimental|Single dose of 25.5 mg HEC88473|Healthy subjects, receiving a single dose of 25.5 mg HEC88473 (N=8) or placebo(N=2) after meal.
89470746|NCT05943886|Experimental|Single dose of 35.7 mg HEC88473|Healthy subjects, receiving a single dose of 35.7 mg HEC88473 (N=8) or placebo(N=2) after meal.
89470747|NCT05943886|Experimental|Single dose of 47.6 mg HEC88473|Healthy subjects, receiving a single dose of 47.6 mg HEC88473 (N=8) or placebo(N=2) after meal.
89470748|NCT05943886|Experimental|Single dose of 62.9 mg HEC88473|Healthy subjects, receiving a single dose of 62.9 mg HEC88473 (N=8) or placebo(N=2) after meal.
89470749|NCT05943886|Experimental|Single dose of 81.6 mg HEC88473|Healthy subjects, receiving a single dose of 81.6 mg HEC88473 (N=8) or placebo(N=2) after meal.
89470750|NCT05943886|Experimental|Multiple doses of 5.1 mg HEC88473|T2DM subjects, receiving a weekly dose of 5.1 mg HEC88473 (N=10) or placebo (N=2) for 5 consecutive weeks after meal.
89470751|NCT05943886|Experimental|Multiple doses of 15.3 mg HEC88473|T2DM subjects, receiving a weekly dose of 15.3 mg HEC88473 (N=10) or placebo (N=2) for 5 consecutive weeks after meal.
89470752|NCT05943886|Experimental|Multiple doses of 30.6 mg HEC88473|"T2DM subjects, receiving a weekly dose of HEC88473 (N=10) or placebo (N=2) for 5 consecutive weeks after meal.~The 30.6 mg cohort was administered by titration."
89470753|NCT05943886|Experimental|Multiple doses of 45.9 mg HEC88473|"T2DM subjects, receiving a weekly dose of HEC88473 (N=10) or placebo (N=2) for 5 consecutive weeks after meal.~The 45.9 mg cohort was administered by titration."
89470754|NCT05943886|Experimental|Multiple doses of 68.0 mg HEC88473|"T2DM subjects, receiving a weekly dose of HEC88473 (N=10) or placebo (N=2) for 5 consecutive weeks after meal.~The 68.0 mg cohort was administered by titration."
89470755|NCT05943067|Other|Single-arm|Donor lymphocytes from allogeneic donors depleted of CD45RA lymphocytes.
89470756|NCT05930704|Experimental|SHR-2017 injection|
88947887|NCT01930565|Experimental|LFCO application|We made LFCO application(Lactobacillus Fermented Chamaecypris obtusa) containing cream to one side of patients' face to monitor effectiveness and safety in acne treatment.
88947888|NCT01930565|Active Comparator|TTO application|To compare effectiveness and safety of new LFCO, we applied existing TTO containing cream to the other side of face in the same patients
89019108|NCT00304304|Active Comparator|Intervention - asthma education|CCC received asthma education in the first 6 months of the study
89470757|NCT05930704|Placebo Comparator|Placebo|
89470758|NCT05925049||Cohort 1: Naive Participants|Per standard of care, participants with MS enrolled in selected MS registries, who are natalizumab-naïve and other MS mAb-therapy-naive will receive natalizumab 300 mg, SC injection according to decision of the treating physician.
89470759|NCT05925049||Cohort 2: Natalizumab Experienced|Per standard of care, participants with MS enrolled in selected MS registries, who have previously received natalizumab IV will be switched from natalizumab IV to SC administration to receive natalizumab 300 mg, SC injection according to decision of the treating physician.
89470760|NCT05922787|Experimental|Experimental|Personal Information Form, Female Sexual Distress Scale-Revised (FSD-R),Arizona Sexual Experiences Scale (ASEX),Sexual Self-Confidences Scale (SSS) were utilized for the collection of research data. First of all, FSD-R was applied to the women, and the women who obtained a score above11.5 points or more from the FSD-R were invited to the study.Then, the Personal Information Form, ASEX, and SSS were first applied to the women invited to the study. Women in the experimental group received Reiki once a week for four weeks. No initiative was applied to the pregnant women in the control group. The FSD-R, ASEX and SSS were applied to all participant women after four weeks following the first application. The application of the measurement tools took 10-15 minutes.
89470761|NCT05922787|No Intervention|Control|The researchers applied no initiative to the control group, and the women in the control group solely had the routine checks. The women in the control group filled out all pretest forms(Personal Information Form, FSD-R, ASEX, SSS. The post-test forms (FSD-R, ASEX, SSS) were re-administered 4 weeks later to women who did not receive any intervention.
89470762|NCT05922007||Validation study|A total of 150 patients with chronic pain (18-65 years) will be included in the validation of the Czech version of the Patterns of Activity Measures-Pain scale (POAM-P/CZ). The reliability and validity study will have a cross-sectional design.
89470763|NCT05922007||Prospective quantitative study|For 150 patients with chronic pain aged 18-65 years, a questionnaire survey will be carried out using the questionnaire set three times, during the first regular check-up at the outpatient clinic and after at least 3 and 6 months, also during a regular check-up.
89470764|NCT05908097|Experimental|Virtual Reality|"Participants in this arm will receive the following interventions:~Treatment As Usual (Empty Virtual Reality Park) Virtual Reality Avatar (Intervention)"
89470765|NCT05908097|Placebo Comparator|Treatment As Usual (Control)|"Participants in this arm will receive the following interventions:~Treatment As Usual (Empty Virtual Reality Park)"
89470766|NCT05880914|Other|Bone-targeted management - prospective cohort|Participants diagnosed with a bone disorder related to chronic kidney disease (CKD) and undergoing a clinically indicated treatment for bone disease. Participants will have some questionnaires, research blood draws, bone scans and a bone biopsy. There will be a total of 4 visits over six months for data collection.
89470767|NCT05865743|Experimental|SDD treatment|Standard of care + SDD (an antibiotic drink of 10ml suspension containing amphotericin B (50 mg/ml), colistin sulphate (10 mg/ml), and tobramycin (8 mg/ml)
89470768|NCT05865743|No Intervention|Standard of care|Standard of care
89470769|NCT05862168|Experimental|Treatment|
89470770|NCT05860829|Experimental|Caregivers of children with Autism Spectrum Disorder (ASD)|Arm includes only the caregivers of children with ASD. The knowledge of caregivers of children with ASD regarding oral and nutritional health and the burdens they encounter in dealing and caring for these children will be assessed. Then, educating caregivers on diet diversities, and effective oral health education, expecting from it to the eating habits and oral hygiene of children living with autism.
89470771|NCT05839483|Experimental|CXCR4|scanned by 68Ga-PentixaFor PET imaging
89470772|NCT05838287|Active Comparator|Pioglitazone Administration Group|Pioglitazone 15mg/day titrated to 30 mg/day at week 2 and to 45 mg/day at week 4
89470773|NCT05838287|Placebo Comparator|Placebo/Control Group|Placebo
89470774|NCT05837052|Experimental|Serplulimab plus chemotherapy|Patients with unresectable NSCLC will receive 3-4 cycles of serplulimab plus chemotherapy as the conversion treatment (serplulimab 300mg d1 q3w; carboplatin (AUC 5) on day 1, and pemetrexed (500 mg/m2 for adenocar- cinoma) or nab-paclitaxel (260 mg/m2 for squamous carcinoma) d1 q3w), and then curative pneumonectomy will be provided for patients who are suitable for primary tumor resection. Locoregional ablative treatments will be performed for metastatic lesions. Maintenance treatment with PD-1 antibody q3w will continue up to 12 months or disease progression after surgery.
89470775|NCT05836506|Experimental|Part 1: Sequence A|In Period 1 on Day 1, participants will receive ABBV-903 Tablet Form 1 after fasting. In Period 2 on Day 1, participants will receive ABBV-903 Tablet Form 2 after fasting. Lastly, in Period 3 on Day 1, participants will receive ABBV-903 Tablet Form 1 after a high fat meal. Participants will be followed up for 30 days.
89470776|NCT05836506|Experimental|Part 1: Sequence B|In Period 1 on Day 1, participants will receive ABBV-903 Tablet Form 2 after fasting. In Period 2 on Day 1, participants will receive ABBV-903 Tablet Form 1 after fasting. Lastly, in Period 3 on Day 1, participants will receive ABBV-903 Tablet Form 1 after fasting. Participants will be followed up for 30 days.
89470777|NCT05836506|Experimental|Part 2: Sequence A|In Period 1 on Day 1, participants will receive ABBV-903 Tablet Form 1 after fasting. In Period 2 on Day 1, participants will receive ABBV-903 Tablet Form 2 after fasting. Lastly, in Period 3 on Day 1, participants will receive ABBV-903 Tablet Form 2 after a high fat meal. Participants will be followed up for 30 days.
89470778|NCT05836506|Experimental|Part 2: Sequence B|In Period 1 on Day 1, participants will receive ABBV-903 Tablet Form 2 after fasting. In Period 2 on Day 1, participants will receive ABBV-903 Tablet Form 1 after fasting. Lastly, in Period 3 on Day 1, participants will receive ABBV-903 Tablet Form 2 after fasting. Participants will be followed up for 30 days.
89470779|NCT05835921|Experimental|Virtual Reality|"Participants in this arm will receive the following interventions:~Virtual Reality Park Virtual Reality Avatar"
89470780|NCT05835921|Placebo Comparator|Treatment As Usual|"Participants in this arm will receive the following interventions:~Virtual Reality Park"
89019109|NCT00304304|Placebo Comparator|Wait-list control|CCC received asthma education in second 6 months of study
89019110|NCT00304382|Experimental|PPV-PCV|Patients receive Pneumovax, and 6 months later Prevnar
89470781|NCT05828719|No Intervention|Guideline-directed medical treatment group|In the GDMT group, medical treatment for patients with left ventricular dysfunction will be performed under current ACC/AHA/SCAI or ESC/EACTS guidelines for heart failure.
89019111|NCT00304382|Experimental|PCV-PPV|Patients receive Prevnar, and 6 months later Pneumovax
89019112|NCT00304382|Experimental|PCV-PCV|Patients receive Prevnar, and 6 months later Prevnar again
88947889|NCT01930578|Experimental|Treatment with 0.9% normal saline|1 litre of normal saline infused over minutes and BIS performed at baseline, and 5 minute intervals during infusion, then 5 minute interval readings for 15 minutes after the stop of the infusion.
88947890|NCT01930578|Experimental|Treatment with D5, 0.45 saline|1 litre of D5, 0.45 saline infused over minutes and BIS performed at baseline, and 5 minute intervals during infusion, then 5 minute interval readings for 15 minutes after the stop of the infusion.
88947891|NCT01930578|Experimental|Treatment with D5|1 litre of D5 infused over minutes and BIS performed at baseline, and 5 minute intervals during infusion, then 5 minute interval readings for 15 minutes after the stop of the infusion.
89470782|NCT05828719|Experimental|Revascularization group|"In the revascularization group, patients will undergo percutaneous coronary intervention (PCI) using standard techniques under current ACC/AHA/SCAI or ESC/EACTS guidelines. In the revascularization group, the procedure must be within 2 weeks of randomization.~Revascularization criteria is presented as below. Revascularization indication~Diameter stenosis >90% by visual assessment~Functionally significant stenosis (FFR≤0.80 or non-hyperemic pressure ratios≤0.89)~Chronic total occlusion with substantial ischemic territory. The below locations will be judged as having substantial ischemic territory.~Left main artery~Proximal to mid left anterior descending artery~Proximal left circumflex artery in left dominant coronary arterial system~Proximal to distal right coronary artery in right dominant coronary arterial system"
89470783|NCT05825066|Experimental|Neoadjuvant Chemotherapy (Gemcitabine and nab-Paclitaxel and mFOLFIRNIOX)|"Gemcitabine (1000 mg/m2 weekly, on day 1,8 and 15 OR 1000 mg/m2 weekly, on day 1 and 15 over 30 minutes after nab-paclitaxel infusion.~nab-Paclitaxel (125 mg/m2 weekly, on days 1,8, and 15 OR on days 1 and 15 as a 30-40 minute infusion administered first) for one month and then transition to mFOLFIRNIOX for one month~1 Cycle = 4 weeks: Day 1,8,15 in a 28 day cycle; 3 consecutive weeks (weeks 1, 2, and 3) of chemotherapy with 1 week off, OR~1 Cycle = 4 weeks: Day 1, 15 in a 28 day cycle; Every other week (weeks 1 and 3) of chemotherapy with 2nd and 4th week off~mFOLFIRINOX: Oxaliplatin, 85 mg/m² IV once every two weeks over 2 hours on Day 1 Irinotecan, 150 mg/m² IV once every two weeks over 90 minutes on Day 1 5-FU, 2,400 mg/m² IV once every two weeks over 46-48 hours administered via infusion Leucovorin, 400 mg/m2 IV every two weeks over 90 minutes on Day 1~Cycle = 4 weeks, administration on Day 1 and Day 15 of each mFOLIRINOX cycle"
89470784|NCT05813899|Experimental|Heat-treated PS23|PS23 heat-treated, 2 caps daily use
89470785|NCT05813899|Placebo Comparator|Placebo|The placebo , 2 caps daily use
89470786|NCT05813795|Experimental|C1- XW003 Low Dosage|XW003 with low dosage once weekly
89470787|NCT05813795|Placebo Comparator|C1-Placebo|Matched Placebo once weekly
89470788|NCT05813795|Experimental|C2- XW003 Medium Dosage|XW003 with medium dosage once weekly
89470789|NCT05813795|Placebo Comparator|C2-Placebo|Matched Placebo once weekly
89470790|NCT05813795|Experimental|C3- XW003 High Dosage|XW003 with high dosage once weekly
89470791|NCT05813795|Placebo Comparator|C3-Placebo|Matched Placebo once weekly
89470792|NCT05808010|Experimental|Mononuclear cells+Weifuchun+Hydrotalcite/L-Glutamine and Sodium Gualenate Granules|
89470793|NCT05808010|Experimental|Mononuclear cells|Mononuclear cells are obtained from umbilical cord blood by density gradient centrifugation
89470794|NCT05808010|Active Comparator|Weifuchun+Hydrotalcite/L-Glutamine and Sodium Gualenate Granules|Weifuchun is a kind of edible Chinese herbal prescription
89470795|NCT05799378|Experimental|Hydroxychloroquine (HCQ)|Patients will receive a 90-day supply of HCQ at their screening visit, at 2 months, 4 months, 6 months, 8 months, and 10 months. All patients will return their current supply along with a completed dosing diary at each visit and receive a new supply in exchange. The HCQ dose administered will match each patient's dosage of HCQ at enrollment.
89470796|NCT05799378|Placebo Comparator|HCQ-Matching Placebo|Patients will receive a 90-day supply of HCQ-matching placebo at their screening visit, at 2 months, 4 months, 6 months, 8 months, and 10 months. All patients will return their current supply along with a completed dosing diary at each visit and receive a new supply in exchange. The HCQ-matching placebo dose administered will match each patient's dosage of HCQ at enrollment.
88947892|NCT01930591|Active Comparator|Clopidogrel arm|Clopidogrel 300 mg before PCI followed by 75 mg po OD
88947893|NCT01930591|Experimental|Ticagrelor arm|Ticagrelor 180 mg before PCI followed by 90 mg po BID
88947894|NCT01930604|Active Comparator|Palmar hyperhidrosis, Botox (onabotulinumtoxinA)|Solution for injection, individual dosing, maximum dose 400 units, single treatment session.
88947895|NCT01930604|Placebo Comparator|Palmar hyperhidrosis, NaCl|Solution for injection, individual dosing, injection volume corresponding to active comparator, single treatment session.
88947896|NCT01930604|Active Comparator|Plantar hyperhidrosis, Botox (onabotulinumtoxinA)|Solution for injection, individual dosing, maximum dose 400 units, single treatment session.
88947897|NCT01930604|Placebo Comparator|Plantar hyperhidrosis, NaCl|Solution for injection, individual dosing, injection volume corresponding to active comparator, single treatment session.
89470797|NCT05794958|Active Comparator|Safety Run-in phase|First three patients (maximum of 6) will receive 0.5 x 106/kg CART cells (25% standard dose) as reinfusion product between days 7 through 14 if CRS/ICANS has resolved to a grade 1 or less.
89470798|NCT05794958|Experimental|Phase 1b|Up to 20 evaluable subjects will receive the target dose of AxiCel infusion to evaluate efficacy of Axi-Cel-2 in adults with high risk relapsed/refractory LBCL
88947898|NCT01930604|Active Comparator|Inguinal (groins/buttocks) hyperhidrosis, Botox (ona...)|Solution for injection, individual dosing, maximum dose 400 units, single treatment session.
88947899|NCT01930604|Placebo Comparator|Inguinal (groins/buttocks) hyperhidrosis, NaCl|Solution for injection, individual dosing, injection volume corresponding to active comparator, single treatment session.
88947900|NCT01930604|Active Comparator|Craniofacial hyperhidrosis, NeuroBloc/Myobloc (rima...)|Solution for injection, individual dosing, maximum dose 2500 units, single treatment session.
88947901|NCT01930604|Placebo Comparator|Craniofacial hyperhidrosis, NaCl|Solution for injection, individual dosing, injection volume corresponding to active comparator, single treatment session.
88947902|NCT01930604|Active Comparator|Truncal hyperhidrosis, NeuroBloc/Myobloc (rimabotulinumtoxinB)|Solution for injection, individual dosing, maximum dose 5000 units, single treatment session.
89019113|NCT00304382|Experimental|PCV only|Patients receive Prevnar only
89470799|NCT05780684|Experimental|Study Arm|All patients in this single-study arm will be exposed to the FOX regimen, an adaptively dose-escalated chemotherapy regimen. The FOX regimen is comprised of oxaliplatin 85 mg/m2 IV on Day 1; leucovorin calcium 350 mg IV on Day 1; and infusional 5-FU IV over 46 hours (Days 1 and 2) - starting at a dose of 2,400 mg/m2 and adaptively adjusted toward a maximum dose of 3,200 mg/m2 over Cycles 2-4 using a clinical algorithm.
89019114|NCT00328848|Experimental|Intervention care management|post dischsrge care management by a nurse care manager who performs in-home vistis and reports to a interdisciplinary team. Team generates care recommendations based on patient goals. PCP and care manager implement the care plan that is based on patient goals. Includes education, behavioral interventions, and coaching.
89470800|NCT05779995|Experimental|C1-XW001|Low dose of XW001 once daily
89470801|NCT05779995|Placebo Comparator|C1-Placebo|Matched Placebo once daily
89470802|NCT05779995|Experimental|C2-XW001|Medium dose of XW001 once daily
89470803|NCT05779995|Placebo Comparator|C2-Placebo|Matched Placebo once daily
89470804|NCT05779995|Experimental|C3-XW001|High dose of XW001 once daily
89470805|NCT05779995|Placebo Comparator|C3-Placebo|Matched Placebo once daily
89470806|NCT05758233|Experimental|Grup 1: Transversalis Fascia Plane Block (TFPB)|Transversalis Fascia Plane Block (TFPB)
89470807|NCT05758233|Experimental|Grup 2: Transversus Abdominis Plane Block (TAPB)|Transversus Abdominis Plane Block (TAPB)
89470808|NCT05754203|Experimental|Super-hyperfractionation Pulse Radiotherapy Combined With Immune Checkpoint Inhibitor|Radiotherapy design: a single dose of 0.5Gy, 16 consecutive pulses with an interval of 3 minutes (0.5Gy * 16F), total dose DT: 8Gy; Immunotherapy: PD-1/PD-L1 monoclonal antibodies conforming to CSCO guidelines for lung cancer indications, including Carrilizumab, Tirelizumab, Teripril, Paborizumab, etc., conventional therapeutic dose, Q3W, until progression or the investigator judges that there is no longer clinical benefit or intolerable side effects.
89470809|NCT05744427|Experimental|Dose escalation and expansion period|in dose escalation and expansion period，total 9 dose groups were designed. Subjects will be give dose 1.0, 2.1, 4.2, 5.3, 6.3, 7.3, 8.4, 9.4 and 10.5 mg/kg Q3W based on DLT results.
89470810|NCT05744427|Experimental|cohort 1 in phase II|Histologically and/or cytologically confirmed patients with unresectable locally advanced/metastatic breast cancer with low HER2 expression (IHC 1+ or IHC 2+ and FISH - or IHC 0) with an estimated sample size of about 30-50.
89470811|NCT05744427|Experimental|cohort 2 in phase II|Histologically and/or cytologically confirmed HER2 positive (IHC 3+ or FISH +) non-operable locally advanced/metastatic breast cancer with an expected sample size of about 30.
89470812|NCT05744427|Experimental|cohort 3 in phase II|Histologically and/or cytologically confirmed HER2 mutation patients (HER2 exon 19 or 20 mutation) with locally advanced inoperable/metastatic non-small cell lung cancer, with an estimated sample size of about 34 patients.
89470813|NCT05744427|Experimental|cohort 4 in phase II|Histologically and/or cytologically confirmed HER2 amplification (FISH +) patients with locally advanced/metastatic non-small cell lung , the expected sample size is approximately 34.
89470814|NCT05744427|Experimental|cohort 5 in phase II|Histologically and/or cytologically confirmed HER2 moderately and lowly in expression (HER2 IHC 2+ and FISH-，or IHC 1+) patients with locally advanced inoperable/metastatic gastric cancer or gastroesophageal borderline cancer, with an estimated sample size of about 34 patients.
89470815|NCT05744427|Experimental|cohort 6 in phase II|Histologically and/or cytologically confirmed HER2 moderately and highly in expression patients with solid tumors ( Excepted breast cancer, gastric/gastroesophageal junction cancer, and non-small cell lung cancer). Failured with systematic treatment , lack of effective treatment means, and the number of previous treatment lines does not exceed 3 lines, with an estimated sample size of about 34 patients.
89470816|NCT05742178|Experimental|Patient Navigation (PN)|Participants randomized to the PN arm will receive community health worker (CHW)-administered PN for cancer screening + social service needs + culturally and linguistically tailored cancer education. All individuals will complete a survey at baseline, 3 months, and 6 months.
89470817|NCT05742178|Active Comparator|Less Intensive (LI)|Participants randomized to LI arm will receive PN to social service needs + culturally and linguistically tailored cancer education materials. All individuals will complete a survey at baseline, 3 months, and 6 months. Once a participant randomized to the LI arm completes the 6-month survey, they will have the option to receive all navigational support provided by CHWs to individuals randomized to the PN arm.
89470818|NCT05718466|Experimental|Fractionated Radiosurgery and Bevacizumab|FRS and Bev followed by Bev combined either Irinotecan or Temozolamide or Carboplatin or Etoposide until progression
89470819|NCT05718466|Active Comparator|Bev with Chemo|Bev combined either Irinotecan or Temozolomide or Carboplatin or Etoposide until progression
89470820|NCT05704764|No Intervention|Minimally Enhanced TAU|Participants assigned to the minimally enhanced treatment-as-usual condition will receive an educational pamphlet about internalized stigma to read at their leisure and will be encouraged to continue in all their customary HIV- and substance use-related services.
89470821|NCT05704764|Experimental|ESS-HSU|Using the materials developed during study year one, up to nine approximately 60-90 minute sessions will be carried out with groups of 8-10 participants at a time randomized to receive ESS-HSU. Each by session will be administered by two facilitators and will be carried out over a virtual platform (e.g., Zoom, Teams). Any session hand-outs will be mailed and/or emailed to participants prior to each session and shared onscreen. Participants in the ESS-HSU condition may also receive study-provided tablet computers with data plans to facilitate their engagement in the intervention (as needed).
89470822|NCT05702723|Experimental|Smart-3RP|"Survivors-caregivers will be randomized together (dyad), stratified by survivor status: curvivor (participants who have completed curative therapy) or metavivor (participants will metastatic disease), using a random plan generator with 1:1 randomization. Participants will complete study procedures as outlined:~Baseline questionnaires.~9 virtual sessions of Smart-3RP.~3-month questionnaires.~Optional collections of hair samples at enrollment and 6-month follow-up period to measure cortisol concentration.~6-month questionnaires.~Optional exit interview with study staff."
89470823|NCT05702723|Active Comparator|Enhanced Usual Care|"Survivors-caregivers will be randomized together (dyad), stratified by survivor status (curvivor/metavivor), using a random plan generator with 1:1 randomization.~Participants will be referred to a 14-week online support group."
89019115|NCT00332397|Active Comparator|A|Rapamycin-eluting Stent (Cypher)
89470824|NCT05687643||Diabetic Foot Ulcer (DFU) group|"Inclusion criteria:~Age >18~A diagnosis of diabetes mellitus~A diagnosis of diabetic peripheral neuropathy~Recently healed plantar ulcer (within the last 3 months)"
89470825|NCT05687643||Low risk group|"Inclusion criteria:~Age >18~A diagnosis of diabetes mellitus~Low risk for DFU according to the NG19 guidelines (no risk factors for ulceration except callus alone)"
89470826|NCT05680155|Experimental|C1-XW003|High dosage of XW003 once weekly
89470827|NCT05680155|Placebo Comparator|C1-Placebo|Matched Placebo once weekly
89470828|NCT05680155|Experimental|C2-XW003|Low dosage of XW003 once weekly
89470829|NCT05680155|Placebo Comparator|C2-Placebo|Matched Placebo once weekly
89470830|NCT05680129|Experimental|B1: XW003+MET|High dosage of XW003 once weekly
89470831|NCT05680129|Experimental|B2: XW003+MET|Low dosage of XW003 once weekly
89470832|NCT05680129|Active Comparator|B3: Dulaglutide+MET|1.5mg Dulaglutide once weekly
89470833|NCT05640934|Active Comparator|Melatonin group|The patients will be given 5 mg melatonin the night before surgery, 12 hours before the scheduled time of surgery, followed by another 5 mg melatonin two hours before surgery.
89470834|NCT05640934|Placebo Comparator|Control group|The patients will be premedicated with placebo tablets, which will be administered at the same times as the melatonin group.
89470835|NCT05623579|Experimental|Intervention|Pain Education plus Exercise
89470836|NCT05623579|Active Comparator|Control|Exercise
89470837|NCT05598684||Cohort|Patient being treated with Humira® in whom the investigator has decided, with the patient's agreement and prior to enrolment, to replace Humira® with FK adalimumab
89470838|NCT05592301||Surgical patients|Patients undergoing major non-cardiac, non-vascular, and non-brain surgery who will be examined for a presence of PFO
89470839|NCT05561920||Adult laryngectomised patients|Patients who have undergone total laryngectomy and completed minimal their 6-month period without disease after surgery and post-operative treatments such as radiotherapy or chemotherapy
89470840|NCT05508009|Experimental|Cohort 1b: Conditioning Regimen A|An initial cohort of 4 patients will be enrolled as part of the initial Phase 1b safety run-in evaluation. Patients will undergo an αβdepleted hematopoietic stem cell transplant (HSCT) after receiving conditioning regimen A (conditioning regimen type is dependent on underlying disease and not part of the experimental goals). In the presence of donor myeloid engraftment, at least 3 months post-HSCT, patients will undergo a living donor kidney transplant (KT) using same donor as HSCT. In the absence of any clinical signs of kidney rejection, pharmacological immunosuppression (used for KT) will be tapered off by Day +90 post-KT.
89470841|NCT05508009|Experimental|Cohort 2a: Conditioning Regimen A|If the intervention is determined to be safe and non-futile, the study will continue to enroll eight more patients under Phase 2a following the same treatment as Phase 1b.
89470842|NCT05508009|Experimental|Cohort 1b: Conditioning Regimen B|An initial cohort of 4 patients will be enrolled as part of the initial Phase 1b safety run-in evaluation. Patients will undergo an αβdepleted hematopoietic stem cell transplant (HSCT) after receiving conditioning regimen B (conditioning regimen type is dependent on underlying disease and not part of the experimental goals). In the presence of donor myeloid engraftment, at least 3 months post-HSCT, patients will undergo a living donor kidney transplant (KT) using same donor as HSCT. In the absence of any clinical signs of kidney rejection, pharmacological immunosuppression (used for KT) will be tapered off by Day +90 post-KT.
88947903|NCT01930604|Placebo Comparator|Truncal hyperhidrosis, NaCl|Solution for injection, individual dosing, injection volume corresponding to active comparator, single treatment session.
89470843|NCT05508009|Experimental|Cohort 2a: Conditioning Regimen B|If the intervention is determined to be safe and non-futile, the study will continue to enroll eight more patients under Phase 2a following the same treatment as Phase 1b.
89470844|NCT05486676|Experimental|VR-Moodboost|All participants receive the same VR-Moodboost treatment, they only differ in the length of the baseline; 3 or 5 weeks.
89470845|NCT05476237|Active Comparator|TAU|Psychologists or PsyTechs in mental health services of primary care clinics will provide individual psychotherapy to depressed adolescents in the TAU arm. Local mental health professionals providing depression treatment in the TAU arm will not have been trained on IPT for adults or adolescents. Also, the two Ministry of Health psychologists trained as trainers of IPT-AG will not provide treatment in the TAU Arm.
89470846|NCT05476237|Experimental|IPT-AG|Group IPT-AG will be facilitated by the trained providers at each YFHS using the IPT-AG manual adapted to the Mozambican context. Adolescents will participate in 12 weekly sessions. The first and last sessions will be one-on-one with the provider. The first session is used for the participant and provider to develop a treatment plan and the last session is to prepare for treatment termination. All other sessions will be conducted in groups of 6-8 adolescents.
89470847|NCT05459298|Active Comparator|Usual care plus placebo|Infants will receive placebo (normal saline) in the first 28 days after birth. Care will be unaffected and provided based on the judgment of the attending neonatal faculty and NICU policies and routine practices. When the infant receives about 120 to 160 mL/kg/day of fortified milk at 24 kcal/ounce, the infant will receive supplementation with 400 IU/day of vitamin D as usual care.
88947904|NCT01930617||Trondheim|Burr hole surgery with passive subdural drainage
89470848|NCT05459298|Experimental|Usual care plus vitamin D supplementation|Infants will receive cholecalciferol 800 IU/day in the first 28 days after birth, given enterally four times per day (0.5mL per dose = 200 IU) until the infant is provided 400 IU/day (when feedings reach about 120 -160 mL/kg/day). At that point the study cholecalciferol will be reduced to 400 IU/day for a total supplementation of 800 IU/day.
89470849|NCT05455034|Experimental|Single-cell Sequencing of BLF to Guide the Treatment of Radiation Pneumonitis|Single-cell Sequencing of BLF is detected before treatment, and then patients will receive the treatment of Radiation Pneumonitis according to the result.
88947905|NCT01930617||Tromsø|Burr hole surgery with continuous irrigation
88947906|NCT01930617||Stockholm|Burr hole surgery with active subgaleal drainage
89470850|NCT05455034|Experimental|Single-cell Sequencing of BLF to Guide the Treatment of Immune Checkpoint Inhibitor Pneumonitis|Single-cell Sequencing of BLF is detected before treatment, and then patients will receive the treatment of Immune Checkpoint Inhibitor Pneumonitis according to the result.
89470851|NCT05444205|Experimental|Higher resources/lower challenges|Participants are assigned to this arm based on results of a brief screen; self-reports indicated that they did not posses any measured risk factors. Participants are provided with a choice of the following preventive interventions: Text4Baby/Bright by Text (depending on child age), Nurture Program, and/or Family Centers.
89470852|NCT05444205|Experimental|Lower Resources/Lower Challenges|Participants are assigned to this arm based on results of a brief screen; self-reports indicated that they were low-income, a teen parent, their newborn had health challenges (more than five weeks premature or a neonatal intensive care unit stay of longer than 4 weeks, or they reported mild parenting challenges. They did not endorse any more serious measured risk factors. Participants are provided with a choice of the following preventive interventions: Nurture Program and/or Video Interaction Project.
89470853|NCT05444205|Experimental|Moderate Challenges|Participants are assigned to this arm based on results of a brief screen; self-reports indicated that they had a history of mental health problems, low social support, or moderate parenting challenges. They did not endorse any more serious measured risk factors. Participants are provided with a choice of the following preventive interventions: Nurture Program and/or Video Interaction Project.
89470854|NCT05444205|Experimental|Serious Challenges|Participants are assigned to this arm based on results of a brief screen; self-reports indicated that they had a histories of involvement with child welfare, incarceration, opioid use disorder, recent homelessness, or that their child is displaying serious behavior problems. Participants are provided with a choice of the following preventive interventions: Smart Beginnings, Family Check-Up or if the child was less than two weeks old, Healthy Families America.
89470855|NCT05444127||Cases|patients with hepatic form of Wilson disease and those with neurological form
89470856|NCT05444127||controls|control population consulting in routine dental with panoramic dental imaging, outside of an emergency context
89470857|NCT05443698|Other|Ultrasound Device|All women who choose to enroll in the trial will undergo an at home transvaginal ultrasound guided by real-time remote supervision from a qualified and specially trained ultrasound technologist.
89470858|NCT05400577|Experimental|Sotorasib, 960 mg, oral daily dose for 4 weeks (28 days)|
89470859|NCT05396300|Experimental|Intravenous of CEA-targeted CAR-T|Infusion of CEA-targeted CAR-T cells by dose of 3-10x106 cells/kg
89470860|NCT05396300|Experimental|intraperitoneal injection of CEA-targeted CAR-T|Infusion of CEA-targeted CAR-T cells by dose of 3-10x106 cells/kg
89470861|NCT05374551|Other|All participants|All participants will complete all experimental conditions, which include transcranial magnetic stimulation (continuous theta-burst stimulation) to a brain region of experimental interest and to a control brain region.
89470862|NCT05372692|Experimental|Single-arm open clinical study|After blood collection from qualified subjects, lymphocytes will be pretreated，the subjects will then be treated with CAR T cells.
89470863|NCT05364450|Active Comparator|Enhanced Usual Care (EUC)|The EUC group will meet for a single 90-minute coaching session via Zoom Health.
89470864|NCT05364450|Active Comparator|Acceptance Commitment Therapy (ACT)|The ACT group will meet for 90-minute sessions via Zoom Health weekly for 6 weeks.
89470865|NCT05364450|Active Comparator|Cognitive Behavioral Therapy (CBT)|The CBT group will meet for 90-minute sessions via Zoom Health weekly for 6 weeks.
89470866|NCT05288777|Other|Her2/neu positive and lymph node positive|T-DM1/ trastuzumab emtansine infusion along with radiation to the breast or chest wall and lymph nodes
89470867|NCT05288777|Other|Her2/neu positive and lymph node negative|T-DM1/trastuzumab emtansine infusion along with radiation to the whole breast or chest wall
89470868|NCT05288777|Other|Her2/neu negative and lymph node positive|oral capecitabine twice per day along with radiation to the breast or chest wall and lymph nodes
89470869|NCT05288777|Other|Her2/neu negative and lymph node negative|oral capecitabine twice per day along with radiation to the whole breast or chest wall
89470870|NCT05264571||critically ill adult patients with intra-abdominal infection|"The ICCA study is an ancillary study of a non-interventional prospective cohort study (the pBDG2 study, NCT03997929) The pBDG 2 study has enrolled ICU patients with intra-abdominal infection requiring abdominal surgery. During the surgery, peritoneal fluid has been collected to identify the pathogens involved and guide anti-infective therapies. After the routine analyses, the remained peritoneal fluid was stored to create a biological collection.~This biological collection, in which the content of bacterias and yeasts is known, will be analysed with the calscreener."
89470871|NCT05254314|Experimental|Study Drug (Semaglutide)|Semaglutide 2.4mg once weekly
89470872|NCT05254314|Placebo Comparator|Placebo|Placebo 2.4mg once weekly
89470873|NCT05235750|Experimental|Writing|This is a single-group study with one arm only.
89531852|NCT05081934|Experimental|TAU + A-CRA|"Behavioral: A-CRA, a 12-14 weekly sessions long behavioral treatment for youth (ages 12-25) suffering from substance use disorder and co-occurring problems, i.e. criminal behavior. The aim is to increase constructive behavior that reduces the need of substances and creates a context where it is rewarding to stay sober. Individual functional analyses, goals and needs guides treatment planning and interventions.~TAU: interventions and treatments usually offered and delivered in institutional care. For example, Motivational Interviewing, MI, Cognitive Behavioral Therapy, CBT, Aggression Replacement Therapy, ART or Acceptance and Commitment Therapy, ACT. Further specification of TAU will be made in collaboration with the institutions included in the trial."
88947907|NCT01930630|Experimental|Extraesophageal saline injection (ESI)|Extraesophageal saline injection (ESI) guided by EUS in patients with advanced ESCC preoperatively
88947908|NCT01930656||Group A, B, C|Group A- American cut-point Group B- Translational approach cut-point Group C- Cost-effectiveness cut-point
88947909|NCT01930669|Other|All patients|To measure the autonomic nervous system activity elicited by a gravitational sympathetic stimulus in critically ill
88956493|NCT05065801|Experimental|GABRINOX|"D1, D8 and D15 GEMBRAX: Albumin bound paclitaxel 125mg / m² followed by Gemcitabine 1000mg / m² followed by 2 weeks of rest~D29 and D43 FOLFIRINOX: Oxaliplatin 85mg / m², Irinotecan 180mg / m², Folinic acid 400 mg / m², 5-fluorouracil 400mg / m² in bolus followed by continuous administration over 46h at 2400mg / m² followed by 2 weeks of rest"
89470874|NCT05167422|Experimental|Trusted Messenger|"The trusted messenger patient intervention will involve training a small number of staff trusted messengers to engage patients informally and assist with building vaccine confidence in brief one- on-one sessions, supported by trusted messengers weekly consultations with a content expert who can answer specific vaccine related questions that patients have over a 3-week period. Trusted messengers will be full time unit employees, selected with the assistance of the nursing supervisor for having excellent rapport with patients (assessed with the Nurse Coordinator Questionnaire) and for having been vaccinated. Mental health workers or nurses may serve in this role. Both inpatient units involved in this study will be grouped into the same vaccination cohort within the hospital, to provide patients in the intervention and the wait list similar opportunities to be vaccinated."
89470875|NCT05167422|No Intervention|Standard Care|After a 3-week study period, up to 24 patients on the second unit will receive the trusted messenger intervention and followed for a period of 3 weeks. The trusted messenger intervention will consist of staff who are trained to engage patients informally and assist building social norms for vaccine uptake supported by weekly and as-needed check-ins with a content expert who can answer specific vaccine related questions over a 3 week period.
89470876|NCT05156281|Experimental|Remibrutinib - Core|Remibrutinib tablet and matching placebo of teriflunomide capsule
89470877|NCT05156281|Active Comparator|Teriflunomide - Core|Teriflunomide capsule and matching placebo remibrutinib tablet
89470878|NCT05156281|Experimental|Remibrutinib - Extension|Participants on remibrutinib in Core will continue on remibrutinib tablet
89470879|NCT05156281|Experimental|Remibrutinib - Extension (on teriflunomide in Core)|Participants on teriflunomide in Core will switch to remibrutinib tablet
89470880|NCT05153174|Experimental|2 tablets of Sulforaphane|Participants will be given 2 extra strength tablets per day
89470881|NCT05153174|Experimental|4 tablets of Sulforaphane|Participants will be given 4 extra strength tablets per day
89470882|NCT05153174|Experimental|6 tablets of Sulforaphane|Participants will be given 6 extra strength tablets per day
89470883|NCT05101746|Experimental|Nitric oxide group|Participants in this group will receive Nitric Oxide (NO) while undergoing Cardiopulmonary bypass (CPB)
89470884|NCT05101746|Active Comparator|Standard of care cardiopulmonary bypass procedure|Participants in this group will receive standard of care
89470885|NCT05091580|Experimental|Intervention: Interpersonal Counseling for Depression|New adult TB patients with depressive symptoms (PHQ-9 > 10) will be offered 4-8 sessions of Interpersonal Counseling delivered by a trained lay counsellor.
89470886|NCT05091580|Other|Control: Enhanced Treatment as Usual|"New adult TB patients will be screened for depression and those with significant symptoms (PHQ-9 > 15 and/or suicidal ideation) will be referred to the clinic nurse for evaluation and referral to specialized mental health care as needed. Routine screening for depression is not a standard practice for TB patients; therefore assessment and referral is considered enhanced treatment as usual. Individuals will be interviewed at baseline and treatment completion."
89470887|NCT05090397|Experimental|Active|
89470888|NCT05090397|Sham Comparator|Sham|
89470889|NCT05089266|Experimental|CAR T cells|
89470890|NCT05027750|Experimental|Intervention|The selected womens were associated with obesity risk factors about obesity (overweight) or obese and between 18-49 years old) and randomly assigned to the experimental group. Obesity training consisting of a total of five sessions structured according to Theory of Planned Behavior was scheduled for the intervention group. Each session lasted for approximately 30 minutes.
89470891|NCT05027750|No Intervention|Control|The control group of the Randomized Controlled Trial (RCT) was composed of 39 womens (between 18-49 years old) randomly assigned to the control group who are BMI was between 25.0-29.9 or BMI was between ≥30.0 according to the risk rating scales. A standard obesity training consisting of a single session was scheduled for the control group.
88947910|NCT01930682|Experimental|Early post-fibrinolytic catheterisation|For STEMI Patients, alteplase is given as a intravenous bolus (8-mg) followed by 42 mg iv gtt in 90 min.Early routine catheterization after 3 hours but within 24 hours of the start of fibrinolytic therapy is performed, if required, PCI or, in case of insufficient ST resolution at 90 min,rescue PCI. The decision on rescue PCI will, however, be taken 90 min (or earlier if clinically indicated) after injection of alteplase according to the ST resolution (less than 50% reduction in ST-segment elevation).
88947911|NCT01930682|Other|Primary PCI|For STEMI Patients,primary PCI is performed without fibrinolytic therapy.
89470892|NCT04994405|No Intervention|Standard Pressure|The extremity tourniquet used during hand surgery for these participants will be the standard pressure of 250 mmHg.
89470893|NCT04994405|Experimental|Lower Tiered Pressures|The study intervention is the inflation of the extremity tourniquet to a pressure lower than the standard pressure of 250 mmHg during hand surgery for these participants determined by tiered guidelines based on systolic blood pressure (SBP).
89470894|NCT04971733|Experimental|Cohort A, Phase 1b and 2: E2814|Participants will receive E2814 as an intravenous infusion at set intervals over 12 weeks in Phase 1b and over 96 weeks in Phase 2.
89470895|NCT04971733|Experimental|Cohort B: E2814|Participants will receive E2814 as an intravenous infusion at set intervals over 52 weeks.
89470896|NCT04938453|Experimental|nintedanib 4 X 25 mg (T) then nintedanib 1 X 100 mg (R))|first test (T), then reference (R) treatment
89470897|NCT04938453|Experimental|nintedanib 1 X 100 mg (R) then nintedanib 4 X 25 mg (T)|first reference (R), then test (T) treatment
89470898|NCT04916067|Experimental|Intervention|Patients undergoing mesh implantation during ileostomy closure to reinforce the abdominal wall
89470899|NCT04876157|Experimental|Artificial intelligence-aimed ultrasound image interpretation|
88947912|NCT01930708|Experimental|DMF|120 mg capsule oral twice daily (BID) during the first week and 240 mg BID thereafter.
88947913|NCT01930721|Experimental|incision angle of 60 degrees|episiotomy incision angle will be defined as 60 degree as measured before cutting.
88947914|NCT01930721|Experimental|incision angle 40 degree episiotomy|incision angle of episiotomy will be defined as 40 degree as measured before cutting.
88947915|NCT01930734|Placebo Comparator|Normal Saline|"Normal Saline Placebo infusion containing Normal Saline NaCl 0.9% twice a week for a total duration of 6 months.~Placebo will be given at the same rate as the Dobutamine infusion, under the same measures."
89470900|NCT04874454|Experimental|vocal cord movement among the stroke patients|
89470901|NCT04817111|Other|Open Label - MIB-626|MIB-626
89470902|NCT04802681|Other|Wirecath - PressureWire X|Patients will undergo simultaneous FFR measurements with the Wirecath and PressureWire X simultaneously.
88947916|NCT01930734|Experimental|Dobutamine|Twice weekly, IV Dobutamine infusion up to 5mcg/Kg/min infusion, for the duration of 6 months. Medication will be administered under medical supervision and continues ECG and vital sign monitoring. Routine electrolyte and renal function testing will be performed and electrolytes corrected as indicated.
89470903|NCT04778982||dose-escalation Phase|KN026 20 mg/kg + palbociclib125 mg/day+Fulvestrant 500 mg (Patients with HR+/HER2-positive MBC )
89470904|NCT04778982||parallel-group expansion Phase|KN026 20 mg/kg + palbociclib +Fulvestrant 500 mg(Patients with HR+/HER2-positive MBC )
89470905|NCT04772781|Experimental|S (+) - Ibuprofen|
89470906|NCT04772781|Active Comparator|Ibuflex® - ibuprofen|
89470907|NCT04768608|Experimental|PD1-PSMA-CART|Patients undergo leukapheresis by receiving cyclophosphamide and fludarabine on days -6 to -4, and then receive PD1-PSMA-CART intravenous injection (IV) at split doses from day 0 on.
89470908|NCT04767373|Experimental|Clesrovimab|Participants receive a single intramuscular (IM) administration of clesrovimab on Day 1.
89470909|NCT04767373|Placebo Comparator|Placebo|Participants receive a single IM administration of placebo on Day 1.
89470910|NCT04765046|Other|BIS™ System|Enrolled subjects who are undergoing a standard of care elective surgery under general anesthesia, will be equipped with the BIS system to non-invasively measure and interpret brain waive activity directly related to the effects of anesthetic agents during the surgery duration.
89470911|NCT04756648|Experimental|CT0180 cells|CT0180 Cells infusion after lymphocyte-depleting with fludarabine and cyclophosphamide.
89470912|NCT04711603|Experimental|MR13A9/MR13A9|Patients are administered MR13A9 for 6 weeks (double-blind period), followed by MR13A9 for 52 weeks (open-label period).
89470913|NCT04711603|Placebo Comparator|Placebo/MR13A9|Patients are administered Placebo for 6 weeks (double-blind period), followed by MR13A9 for 52 weeks (open-label period).
89470914|NCT04699877|Experimental|Gilteritinib (Severe Renal Impairment)|Participants with severe renal impairment received a single oral dose of 20 milligrams (mg) of gilteritinib on day 1, under fasting conditions.
89470915|NCT04699877|Experimental|Gilteritinib (Normal Renal Function)|Participants with normal renal function received a single oral dose of 20 mg of gilteritinib on day 1, under fasting conditions.
89470916|NCT04699591|Other|Overall Study|Receive domperidone 4 times a day, weight-dependent dose
89470917|NCT04679948|Experimental|Cocktail/ Cocktail + BI 730357|Cocktail treatment will be followed by the Test treatment (Cocktail + BI 730357) in a fixed sequence. The treatment periods are separated by a wash-out phase of at least 20 days between the two cocktail administrations.
89470918|NCT04672616|Experimental|Group psychotherapy|Weekly group meeting w/psychotherapist: All the participants fulfilling the eligibility criteria are asked to take part in an additional Intervention. The Intervention is a weekly group Meeting with a psychotherapist to discuss issues or problems the group members have
89470919|NCT04653480|Experimental|Surufatinib, Toripalimab and Chemotherapy|Second line CRC patients received surufatinib 250mg po qd , toripalimab 3mg/kg ivgtt q2w and chemotherapy according to the first line treatment, until disease progression or intolerable toxicity
89470920|NCT04652219|Experimental|Patients with late malignant digestive tract tumor|Patients with late malignant digestive tract tumor, for example metastatic colorectal cancer, pancreatic cancer, gastric cancer and so on. because of this is a open, single arm trail, there is no control group.
89470921|NCT04647435|Experimental|APSCTC|Oral tablets every 6h for 3 days
88947917|NCT01930760|Experimental|Educational Intervention Group|
88947918|NCT01930760|Experimental|Behavioural Intervention Group|
88947919|NCT01930773|Experimental|Genotyping Arm|Rapid genotyping to select optimal P2Y12-inhibitor for PCI.
88947920|NCT01930773|Experimental|Phenotying Arm|The use of platelet function testing to select the optimal P2Y12-inhibitor for PCI.
88947921|NCT01930773|No Intervention|Conventional Arm|Regular approach for performing elective PCI.
89470922|NCT04647435|Active Comparator|Toragesic®|Oral tablets every 6h for 3 days
89470923|NCT04647435|Active Comparator|Tramal®|Oral tablets every 6h for 3 days
89470924|NCT04637529|Experimental|S (+) - Ibuprofen|S (+) - Ibuprofen (1 coated tablet) + placebo of Ibuvix® - ibuprofen (1 coated tablet) Every 6 hours for 28 days.
89470925|NCT04637529|Active Comparator|Ibuvix® - ibuprofen|Ibuvix® - ibuprofen (1 coated tablet) + placebo of S (+) - Ibuprofen (1 coated tablet) Every 6 hours for 28 days.
89470926|NCT04633291|Experimental|Novel swelling media|Participants underwent catheterization with the SpeediCath standard male catheter containing the novel swelling media. The catheterization was performed by a trained nurse.
89470927|NCT04633291|Active Comparator|Comparator swelling media|Participants underwent catheterization with CE-marked SpeediCath® standard male containing the original swelling media. The catheterization was performed by a trained nurse.
88947922|NCT01930786||onabotulinumtoxinA|onabotulinumtoxinA administered according to physician standard of care. All treatment decisions lie with the physician.
89019116|NCT00332397|Active Comparator|B|Zotarolimus-eluting Stent (Endeavor)
89019117|NCT00332397|Active Comparator|C|Rapamycin-eluting Stent
89470928|NCT04625803|Experimental|chemotherapy, PD-1 inhibitor and Apatinib|Participants received 5 preoperative cycles of PD-1 inhibitor and chemotherapy (mFOLFOX6), 2 months of apatinib, followed by surgery. Apatinib,PD-1 inhibitor and chemotherapy needed to be stopped for 4-6 months before operation. 1 month after surgery, 7 cycles of mFOLFOX6 combined with PD-1 monoclonal antibody were performed as adjuvant therapy.
89470929|NCT04574492||Participants receiving Upadacitinib|Participants receiving Upadacitinib for moderate to severe rheumatoid arthritis (RA).
89470930|NCT04528823|No Intervention|Standard care (control arm)|Strategy 1: Symptoms screen, CXR and TST (standard)
89470931|NCT04528823|Active Comparator|GeneXpert (GX)|Strategy 2: Symptoms screen, Genexpert and TST
89470932|NCT04528823|Active Comparator|CXR for all/NoTST|Strategy 3: Symptoms screen, CXR but NO TST
89470933|NCT04469517||HHT|patients with HHT
89470934|NCT04469517||control|persons age- and sex matched who do not suffer from HHT nor their first or second degree relatives
89470935|NCT04461171|Experimental|ERAS|Administration of a perioperative non-narcotic, multimodal pain management pathway.
89470936|NCT04461171|No Intervention|Non-ERAS (Conventional)|Administration of a conventional perioperative pain management pathway that consists of both narcotic and non-narcotic pain medications.
89470937|NCT04446117|Experimental|Experimental Arm|Subjects with mCRPC will receive cabozantinib 40mg oral, qd + atezolizumab 1200mg infusion, q3w
89470938|NCT04446117|Active Comparator|Control Arm|Subjects with mCRPC will receive active comparator of EITHER abiraterone 1000mg oral, qd + prednisone 5 mg oral, bid; OR enzalutamide 160mg oral, qd as designated by the Investigator prior to randomization
89470939|NCT04438525|Active Comparator|early maintenance phase|patients who reached the maintenance dose of venom immunotherapy one week (max. +3 weeks) before recruitment will be sting challenged
89470940|NCT04438525|Active Comparator|maintenance phase|patients who reached the maintenance dose of venom immunotherapy one year (+/- 2 months) before recruitment will be sting challenged
89470941|NCT04438525|Active Comparator|after stopping VIT|patients who finished venom immunotherapy two years (+/- 6 months) before recruitment (duration of VIT: at least 3 years) will be sting challenged
89470942|NCT04438525|Other|blood donors|patients with confirmed vespid venom allergy who have not undergone venom immunotherapy (blood donation necessary to perform BAT Inhibition test)
89470943|NCT04403919|Active Comparator|Revision total knee arthroplasty: control|
88947923|NCT01930812|Experimental|18F-NaF PET Imaging for Bone Scintigraphy|All participants will receive PET/CT Imaging using the investigational drug 18F-NaF and a 99mTc-medronate whole body bone scan with SPECT to compare the diagnostic ability of the two methods for the presence of bone metastases.
88947924|NCT01930838||Controls|Matched on age, sex and body mass index
88947925|NCT01930838||Gastric bypass operation|Patients with gastric bypass operation between 2006 and 2011 in The Central Denmark Region
89470944|NCT04403919|Experimental|Revision total knee arthroplasty: active|
89470945|NCT04403919|Active Comparator|Revision Total Hip Arthroplasty: control|
89470946|NCT04403919|Experimental|Revision Total Hip Arthroplasty: active|
89470947|NCT04397003|Experimental|Neoantigen DNA vaccine+durvalumab|"Patients will receive durvalumab (1500mg Q3W) in combination with standard of care carboplatin and etoposide for a total of 4 cycles given every 3 weeks~Beginning 4 weeks following Cycle 4 of carboplatin/etoposide/durvalumab, patients on will then receive 6 cycles of durvalumab 1500 mg with the polyepitope neoantigen DNA vaccine, both administered once every 4 weeks~Patients may then receive durvalumab every 4 weeks until disease progression or drug toxicity~Should a delay in vaccine preparation occur, patients will begin durvalumab and the vaccine will be added with the subsequent cycle."
88947926|NCT01930851||Gastric bypass|All gastric bypass operated patients in the Central Denmark Region 2006-2011
88947927|NCT01930864|Experimental|metfomin + irinotecan|Irinotecan 350mg/m² q21d + metformin up to 2500mg/d until disease progression, prohibitive toxicity or consent withdrawal
88947928|NCT01930877|Active Comparator|Lidocaine|Intravenous Lidocaine bolus of 1.5 mg/kg followed by infusion of 1.5 mg/kg/hr
88947929|NCT01930877|Placebo Comparator|Placebo|Normal saline placebo infusion
88947930|NCT01930916|Other|Not interventionnal|INR capillary measurement with INRatio 2 device antiphospholipid antibodies and lupus anticoagulant
88947931|NCT01930929||Bariatric surgery operated patients|All patients who have operated in the Central and North Denmark Region 2006-2011
88947932|NCT01930942|Experimental|preoperative concurrent chemoradiation|Radiation is given with 5000 cGy in 25 fractions (5 weeks). Concurrent chemotherapy consists of oxaliplatin (50 mg/m2 ) intravenously over 2 h on days 1, 8, 15, 22 and 29, and capecitabine (825 mg/m2 twice day) was given orally on each day of radiation.
88947933|NCT01930968||Ultrasound measurement|There is only 1 arm in this study. The ocular tumors will be imaged using ultrasound and the contrast agent. The patient's history will be noted, lung and heart auscultation will be performed, and blood pressure readings will be obtained to ensure the patient has no contraindications to using Definity®. If there are no contraindications, routine ocular ultrasonography, both A and B scans, will be performed using an Ellex Eye Cubed ultrasound machine. Definity® (the microbubble contrast agent) will be prepared per package instruction and the dose calculated according to the following formula: Patient weight (kg) X 10 microliters = Definity® dose. If necessary, a second 10 microliter/kg dose may be given 30 minutes after the first IV injection.
88947934|NCT01930994||Cohort 1|Twenty Sino-implant (II) and twenty Jadelle users enrolled 1-3 months before their 6-month insertion anniversary.
89470948|NCT04358029||COVID-19 patients|Patients who have been diagnosed with COVID-19 infection at Mount Sinai Hospital
89470949|NCT04358029||Influenza patients|Patients who have been diagnosed with Influenza infection at Mount Sinai Hospital
88947935|NCT01930994||Cohort 2|TwentySino-implant (II) and twenty Jadelle users enrolled 1-3 months before their 12-month insertion anniversary;
88947936|NCT01930994||Cohort 3|Twenty Sino-implant (II) and twenty Jadelle) users enrolled 1-3 months before their 24-month insertion anniversary
88947937|NCT01930994||Cohort 4|Twenty Sino-implant(II) and twenty Jadelle users enrolled 1-3 months before their 36-month insertion anniversary;
88947938|NCT01930994||Cohort 5|Forty Sino-implant (II) and forty Jadelle users enrolled 1-3 months before their 48-month insertion anniversary;
88947939|NCT01930994||Cohort 6|Forty Jadelle users enrolled 2-6 months before their 60-month insertion anniversary.
88947940|NCT01931007|Experimental|Autologous bone marrow concentrate|Subjects with symptomatic mild to moderate bilateral knee osteoarthritis will be enrolled in this study. Bone marrow will be aspirated from the patient's iliac crests and the cellular rich portion will be concentrated. Randomly, one knee will be injected with the autologous bone marrow aspirate concentrate. The contralateral knee will be injected with only sterile saline for placebo.
89206191|NCT04095455|Active Comparator|pectoral nerves block group|modified pectoral nerves block was performed on the side of surgery
89470950|NCT04358029||COVID-19 patients who were hospitalized with abnormal echocardiogram|Patients hospitalized for COVID-19 and who had an abnormal echocardiogram during hospitalization
89470951|NCT04358029||COVID-19 patients who were hospitalize with normal echocardiogram or no echocardiogram done|A matched cohort (for age, gender, troponin level, and days since hospital discharge) who did not have abnormalities on their echocardiograms (or who did not undergo echocardiogram) to ascertain that in this unusual disease, subjects did not develop echo abnormalities following hospital
89470952|NCT04266496|Other|<2 nocturnal voids|"All interventions in this group are done twice: Once before surgical intervention, and once 2 months after surgical intervention~Complete a 3 day Frequency Volume chart~Questionnaires: ICIG FLUTS/MLUTS, PSQI and CIVIQ2"
89470953|NCT04266496|Other|=> 2 nocturnal voids|"All interventions in this group are done twice: Once before surgical intervention, and once 2 months after surgical intervention~Complete a 3 day Frequency Volume chart and collection of the urine of the last day and night to complete osmolality and sodium testing.~Measuring the circumference off the lower limbs just after awakining and before falling asleep~Questionnaires: ICIG FLUTS/MLUTS, PSQI and CIVIQ2"
89470954|NCT04147260|Experimental|BI 730357 low dose|
89470955|NCT04147260|Active Comparator|Ciprofloxacin|
89470956|NCT04147260|Experimental|BI 730357 high dose|
89470957|NCT04147260|Placebo Comparator|Placebo|
89470958|NCT04134728|Experimental|GSK3196165 90 mg|Entire treatment period (24 Weeks): GSK3196165 90 mg SC injection once weekly. Participants will also receive a stable dose of csDMARD(s) as standard of care (SoC).
89470959|NCT04134728|Experimental|GSK3196165 150 mg|Entire treatment period (24 Weeks): GSK3196165 150 mg SC injection once weekly. Participants will also receive a stable dose of csDMARD(s) as SoC.
89470960|NCT04134728|Active Comparator|Sarilumab 200 mg|Entire treatment period (24 Weeks): Sarilumab 200 mg SC injection every other week + placebo SC injection in the intervening weeks. Participants will also receive a stable dose of csDMARD(s) as SoC.
89470961|NCT04134728|Placebo Comparator|Placebo sequence 1|From Week 0-11: Placebo SC injection once weekly. From Week 12 onwards: GSK3196165 90 mg SC injection once weekly. Participants will also receive a stable dose of csDMARD(s) as SoC.
89470962|NCT04134728|Placebo Comparator|Placebo sequence 2|From Week 0-11: Placebo SC injection once weekly. From Week 12 onwards: GSK3196165 150 mg SC injection once weekly. Participants will also receive a stable dose of csDMARD(s) as SoC.
89470963|NCT04134728|Placebo Comparator|Placebo sequence 3|From Week 0-11: Placebo SC injection once weekly. From Week 12 onwards: Sarilumab 200 mg SC injection every other week + placebo SC injection in the intervening weeks. Participants will also receive a stable dose of csDMARD(s) as SoC.
89470964|NCT04112043|Active Comparator|NR plus Walking Exercise|1,000 mg/day of NR combined with three days/week of supervised, center-based walking exercise (n=18)
89470965|NCT04112043|Active Comparator|Walking Exercise plus Placebo|1,000 mg/day of Placebo combined with three days/week of supervised, center-based walking exercise (n=18)
89470966|NCT04112043|Active Comparator|NR Alone|1,000 mg/day of NR
89470967|NCT03997968|Experimental|CYT-0851 dose escalation|Part A: CYT-0851 administered orally in rising doses QD or BID for 28 day cycles
89470968|NCT03997968|Experimental|CYT-0851 dose expansion|Part B: CYT-0851 administered orally at the selected Phase 2 dose for 28 day cycles
89470969|NCT03997968|Experimental|CYT-0851 and rituximab and bendamustine|Part C: Daily oral doses of CYT-0851 for 28 days in combination with rituximab on Day 1 and bendamustine on Days 1 and 2 of each 28 day cycle
89470970|NCT03997968|Experimental|CYT-0851 and gemcitabine|Part D: Daily oral doses of CYT-0851 for 28 days in combination with gemcitabine on Day 1, 8 and 15 of each 28 day cycle
89470971|NCT03997968|Experimental|CYT-0851 and capecitabine|Part E: Daily oral doses of CYT-0851 for 21 days in combination with capecitabine on Days to 14 of each 21 day cycle
89470972|NCT03995706|Experimental|Breast Brain Metastasis and Glioblastoma|Sacituzumab Govitecan treatment will be initiated with a 10mg/kg standard dose without any dose escalation on day-1, prior to surgery. Sacituzumab govitecan and will continue to be administered by IV infusion over 3 hours on Days 1 and 8 of a 21 day cycle post-operatively until progression.
89470973|NCT03984097|Experimental|Treatment Phase: TAK-079 and LenDex|TAK-079, subcutaneously, once weekly for 8 weeks, then once every 2 weeks for 16 weeks, and then once every 4 weeks thereafter, along with lenalidomide, orally, once daily for 21 days and dexamethasone, orally or intravenously, once on Days 1, 8, 15 and 22 in each 28-day treatment until progressive disease (PD) or unacceptable toxicity, withdrawal of consent, death, or termination of the study by sponsor for up to 2 years. The dosage of dexamethasone can be reduced for participants who are greater than (>) 75 years, have poorly controlled diabetes, or had prior intolerance to or AE from corticosteroid therapy.
89470974|NCT03984097|Experimental|Treatment Phase: TAK-079 and VRd|TAK-079 subcutaneously, once weekly for 8 weeks, then once every 2 weeks for 16 weeks, and then once every 4 weeks thereafter, along with bortezomib, subcutaneously, once on Days 1, 8, and 15, for a maximum of 8 cycles, lenalidomide, orally, once daily for 21 days, and dexamethasone, orally or intravenously, once on Days 1, 8, 15 and 22 in each 28-day treatment until PD or unacceptable toxicity, withdrawal of consent, death, or termination of the study by sponsor for up to 2 years. The dosage of dexamethasone can be reduced for participants who are >75 years, have poorly controlled diabetes, or had prior intolerance to or AE from corticosteroid therapy.
89470975|NCT03984097|Experimental|Safety Extension Phase: TAK-079 and, if applicable, backbone therapy (LenDex, VRd, or PomDex)|TAK-079 dosing and, if applicable, backbone therapy will be administered as per the schedule outlined in the parent study.
89470976|NCT03954184|No Intervention|TAU/Control|Sites in the Treatment as Usual (TAU)/Control Arm will receive product training/online support. Sites in the TAU/Control Arm will participate in a one-day product implementation or training session.
89531853|NCT05080608||Nerve injury|This is an interview study of patients with injury to the median, ulnar or digital nerve or brachial plexus injury.
88947941|NCT01931007|Placebo Comparator|Placebo|Subjects with symptomatic mild to moderate bilateral knee osteoarthritis will be enrolled in this study. Bone marrow will be aspirated from the patient's iliac crests and the cellular rich portion will be concentrated. Randomly, one knee will be injected with the bone marrow concentrate. The contralateral knee will be injected with only sterile saline for placebo.
88947942|NCT01931020|Active Comparator|Sucrose|1ml of 24%sucrose will be administered prior to heel lance
88947943|NCT01931020|Experimental|Glucose|1ml of 25% glucose will be administered prior to heel lance
88947944|NCT01931046|Experimental|Part 1|Treatment at one of three dose levels of Ad5-SGE-REIC/Dkk-3 in a sequential dose-escalating design with 4 cycles of therapy at each dose level permitted.
88947945|NCT01931046|Experimental|Part 2|Treatment with Ad5-SGE-REIC/Dkk-3 every 6-weeks for up to 4 cycles of therapy and may continue therapy if they have stable disease or are responding.
88947946|NCT01931072|Experimental|High-intensity interval training|The High-intensity interval training group was instructed to complete exercise sessions of 4x4-minutes intervals at 85-95% of maximal heart rate, 3 times a week for 8 weeks. This type of exercise include 10 minutes warm-up, followed by four intervals of four minutes high-intensity (85-95% of HRmax), with three minutes active breaks (70% of HRmax) between each interval, and ending with seven minutes cool-down. An exercise session last for 42 minutes, where the participants should breathe heavily and feel exhausted four times.
88947947|NCT01931072|Active Comparator|Moderate training|The moderate training group was instructed to complete exercise sessions of 50 minutes at 70% of maximal heart rate, 3 times a week for 8 weeks.
89470977|NCT03954184|Experimental|NIATx-TI Framework|Sites in the NIATx-TI Arm will receive product training/online support, and training in the NIATx-TI framework. The NIATx-TI framework will include a pre-implementation (planning) phase, and post-implementation (problem-solving) phase, with training delivered by a NIATx-TI coach.
89470978|NCT03903107|Placebo Comparator|Conventional Conduction System Pacing(CSP) using fluoroscopy|Subjects in this arm will receive Conduction System Pacing(CSP) using conventional fluoroscopy technique.
89470979|NCT03903107|Experimental|Fluoroless Conduction System Pacing(CSP) utilizing EAM with the CARTO 3 mapping system|Subjects in this arm will receive Conduction System Pacing(CSP) utilizing electroanatomic mapping system to eliminate or minimize fluoroscopic exposure.
89470980|NCT03887377|Experimental|Breast receiving botulinum toxin|"Following reconstruction one horizontal incisional wound will be selected to receive a series of botulinum toxin injections along the wound.~Injection abobotulinum toxin at time of surgery, single injection time with 30 gauge needle superficially, dosage determined by length of scar 5-15U per cm"
89470981|NCT03887377|Placebo Comparator|Breast receiving placebo|The other breast will be injected with bacteriostatic normal saline in a similar fashion to the other breast. The injector will be blinded to the contents of the syringe.
89470982|NCT03886272|Experimental|BI 730357 (Test)|
89470983|NCT03886272|Experimental|BI 730357 (Reference)|
89470984|NCT03859154||Viper bite victims|Snakebite victims in whom the snake has been brought and positively identified as Viperidae AND simultaneous aPTT has been sent AND consenting to be part of the study
89470985|NCT03859154||Nonvenomous snakebite|"age and gender matched victims of snake bite in whom the culprit snake brought along has been identified as a non venomous one.~AND consenting to be part of the study"
89470986|NCT03821376|Experimental|Renal malignancy|Patients with renal mass(es) identified by cross sectional imaging, specifically ultrasound following the intravenous injection of Lumason
89470987|NCT03767478|Sham Comparator|Control group|Best Medical Therapy + Sham Revitive Medic Coach (Sham Neuromuscular Electrical Stimulation Device) for 6 months
89470988|NCT03767478|Active Comparator|Intervention group|Best Medical Therapy + Revitive Medic Coach (Neuromuscular Electrical Stimulation Device) for 6 months
89470989|NCT03741478|Experimental|Metabolic Arm|"This arm includes a screening visit 1 and screening visit 2 to assess eligibility.~This arm then includes the pancreatic euglycemic clamp procedure at visits 1 to 3. Visits 1 to 3 each consist of 3 days (day 0, day 1, and day 2).~Olanzapine 2.5mg (or placebo) will be administered in doses of 5mg on day 0, 7.5mg on day 1, and 10mg on day 2.~Day 2 consists of the final dose of olanzapine (or placebo) and the pancreatic euglycemic clamp procedure and other assessment procedures.~On day 2, the participant is also randomized to and administered either intranasal insulin/Insulin Lispro 100 UNT/ML (or saline placebo) during the pancreatic euglycemic clamp procedure."
89470990|NCT03741478|Experimental|Cognitive and MRI Arm|"This arm includes a screening visit 1 and screening visit 2 to assess eligibility. This arm includes an MRI scan and cognitive testing at visits 1 to 4. Visits 1 to 4 each consist of 3 days (day 0, day 1, and day 2).~Olanzapine 2.5mg (or placebo) will be administered in doses of 5mg on day 0, and 10mg on day 1. Cognitive testing and MRI scanning then occur on day 2. On day 2, the participant is also randomized to and administered either intranasal insulin/Insulin Lispro 100 UNT/ML (or saline placebo) prior to conducting the MRI imaging and cognitive testing."
89470991|NCT03732833|Experimental|MT10109L Dose 1 + Placebo|MT10109L Dose 1 will be injected into the LCL and Placebo into the GL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period.
89470992|NCT03732833|Experimental|MT10109L Dose 1 + MT10109L Dose 2|MT10109L Dose 1 will be injected into the LCL and MT10109L Dose 2 into the GL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period.
89470993|NCT03732833|Placebo Comparator|Placebo|Placebo will be injected into the LCL and into the GL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period.
89470994|NCT03718494||Menopausal Hormone Therapy (mHT) Group|Women that participated in and completed the KEEPS study (NCT00154180) that were randomized to receive menopausal hormone therapy (mHT) will have a follow up brain Positron Emission Tomography (PET) imaging (F-18 Florbetapir PET or F-18 AV-1451 PET) and cognitive function testing.
88947948|NCT01931072|No Intervention|Control|The control group followed the baseline and follow-up tests, and was asked to live normally and not change their dietary pattern or exercise habits during their participation in this project. Based on the well-known beneficial effects of exercise on general health, it was regarded unethical to demand the control group to desist from any types of physical activity during the project period. They got no further follow-up on exercise.
89470995|NCT03718494||Placebo Group|Women that participated in and completed the KEEPS study (NCT00154180) that were randomized to receive placebo treatment will have a follow up brain Positron Emission Tomography (PET) imaging (F-18 Florbetapir PET or F-18 AV-1451 PET) and cognitive function testing.
89470996|NCT03702127|Experimental|TMS in patients with intracranial electrodes|We will administer TMS to neurosurgical patients with intracranial electroencephalography in order to better understand the effects TMS has on the human brain. Participants will receive both active and sham stimulation at varying points during the study.
89470997|NCT03669367|Experimental|abatacept|abatacept monotherapy (subcutaneous route).: 125 mg solution for injection in pre-filled syringe. In the first year (0-12 months) at a a dose of 125 mg per week (full dose) and in the second year (12-24 months) at a dose of 125 mg every other week (q2w) (optimized dose) injection) - 125 mg x week - subcutaneous use.
89470998|NCT03669367|Active Comparator|hydroxycloroquina|Hydroxyclorquina (Coated tablet)- (5 mg/Kg/day) monotherapy for 2 years (0-48 months)
89470999|NCT03630081|Experimental|WCK 4282 (FEP-TAZ) 4 g|WCK 4282 (FEP-TAZ) Pharmaceutical dosage form: Intravenous infusion Dosage: 4 g (2 g FEP and 2 g TAZ) IV q8h, infused over 90 min
89471000|NCT03630081|Active Comparator|Meropenem|Meropenem Pharmaceutical dosage form: Intravenous infusion Dosage: 1 g IV q8h, infused over 45 min
89471001|NCT03618381|Experimental|EGFR 806CAR(2G) -EGFRt|Autologous CD4+ and CD8+ T cells that have been genetically modified to express the EGFR 806CAR(2G) -EGFRt
89471002|NCT03618381|Experimental|EGFR806CAR(2G)-EGFRt and CD19CAR(2G)-T2A-HER2tG|Autologous CD4+ and CD8+ T cells that have been genetically modified to express the EGFR806CAR(2G)-EGFRt and CD19CAR(2G)-T2A-HER2tG
89471003|NCT03522688|Placebo Comparator|control group|The control group was given normal saline by constant intravenous (IV) infusion at a rate of 0.4mcg/kg/hour
89471004|NCT03522688|Active Comparator|treatment group|The treatment group was given dexmedetomidine by constant intravenous (IV) infusion at a rate of 0.4mcg/kg/hour
89471005|NCT03493919|Experimental|rMenB+OMV NZ Group|Participants vaccinated intramuscularly with Bexsero vaccine at Day 1 and Day 61 and blood samples were collected at Day -83, Day 8, and Day 98.
89471006|NCT03493919|Experimental|MenACWY 1 Group|Participants vaccinated intramuscularly with Menveo vaccine at Day 1 and blood samples were collected at Day -83, Day 8, and Day 151.
89471007|NCT03493919|Experimental|MenACWY 2 Group|Participants vaccinated intramuscularly with Menveo vaccine at Day 1 and blood samples were collected at Day -60, Day 31, and Day 151.
89471008|NCT03493919|Experimental|MenACWY 3 Group|Participants vaccinated intramuscularly with Menveo vaccine at Day 1 and blood samples were collected at Day -30, Day 61, and Day 151.
89471009|NCT03478917||Arm 1|Subjects previously enrolled onto protocol 05-H-0019 who were hospitalized with vasoocclusivecrisis.
89471010|NCT03431779|Experimental|Adipose derived stem cell transplantation via lipofilling|Liposuction of 60cc abdominal fat with its adipose derived stem cells which will be reinjected (10-20 cc) in the vestibular area after centrifugation for 3 minutes at 1000 rpm and decantation of oil and red blood cells.
89471011|NCT03431779|Active Comparator|Surgical excision|Excision of painful areas
89471012|NCT03356990|Experimental|Resistant Starch|"Intervention:~Dietary supplement will be taken every day for total of 2 weeks. Each participant will be take half the dose of Hi-Maze 260 or High RS Gummy Chews in the morning and the other half dose in the evening~Adult participants are asked to introduce in their diet 30 grams of high RS supplement each day of the diet period (2 weeks).~Children of age included between 5 and 9 years are asked to introduce in their diet 10 grams of high RS supplement each day of the diet period (2 weeks).~Children of age included between 10 and 17 years are asked to introduce in their diet 15 grams of high RS supplement each day of the diet period (2 weeks)."
89471013|NCT03326128|Active Comparator|BUP-300|Participants will receive Bupropion hydrochloride for 10 weeks and titrate to a maximum dose of 300 mg/day and will also receive standard smoking cessation counseling for 8 weeks.
89471014|NCT03326128|Experimental|BUP-450|Participants will receive Bupropion hydrochloride for 12 weeks and titrate to a maximum dose of 450 mg/day and will also receive standard smoking cessation counseling for 8 weeks.
89471015|NCT03280628|Active Comparator|Absorbable Sutures|Patients will have their laceration closed with sutures that absorb on their own and do not need to be removed.
89471016|NCT03280628|Experimental|Steri-Strips|"Patients will have their laceration closed with a special medical tape called Steri-Strips."
89471017|NCT03280628|Experimental|Dermabond|"Patients will have their laceration closed with a special skin glue called Dermabond"
89531854|NCT05078320|Experimental|Internet-delivered cognitive-behaviour therapy for adolescents with body dysmorphic disorder|Cognitive-behaviour therapy, Exposure and response prevention (ERP)
88947949|NCT01931098|Experimental|Glioblastoma or Gliosarcoma With No Prior Bevacizumab Exposure|Topotecan .25 mg and pazopanib 600 mg are administered orally daily until progression, up to one year.
89471018|NCT03277924|Experimental|Sunitinib and/or nivolumab plus chemotherapy in advanced STS and BS|C1-6: Adults, IP d1-14 sunitinib 37.5mg/d then MP sunitinib 25mg/d+nivolumab 240mg ev 2 weeks. Pediatrics, IP d1-14 sunitinib 25mg/d, if BSA>1.7 sunitinib 37.5mg/d and MP sunitinib 25mg/d+nivolumab (dose weight dependent). C7a level 0: Epirubicin 60mg/m2/d, d1,2, ifosfamide 3g/m2/d d1-3 and nivolumab 360mg. 3 or more DLTs level -1 same treatment than in level 0, but nivolumab 240mg. C7b level 0: Doxorubicin 75mg/m2/d, d1, dacarbazine 400mg/m2/d (also on d2) and nivolumab 360mg. 3 or more DLTs level -1 same tratment than in level 0, but nivolumab 240mg. GCSF support is mandatory. 1-year maintenance of nivolumab. C8 level 0: In the IP, CDDP 120mg/m2 (d1-2), doxorubicin 75mg/m2 in (d3-4 and d36-39), nivolumab 240mg (d5), and on d18,39,53 and methotrexate 12g/m2 on d22,29,57,64, surgery and MP with nivolumab on d210, every 2 weeks up to d364. 3 or more DLTs level -1, with nivolumab 360mg on d4,36, surgery and MP with nivolumab on d210, ev 3 weeks up to d364.
88947950|NCT01931098|Experimental|Glioblastoma or Gliosarcoma With Prior Bevacizumab Exposure|Topotecan .25 mg and pazopanib 600 mg are administered orally daily until progression, up to one year.
88947951|NCT01931111||Norwegian Elderly Population|
88947952|NCT01931124|Experimental|High Intensity Training|training at high intensities ranging from 85-95% of maximal heart rate
88947953|NCT01931124|Experimental|Moderate Intensity Training|training at intensities of 65-75% of maximal heart rate
88947954|NCT01931137|Experimental|Coating A|Each subject will in random order be allocated to three single-dose administrations of insulin 338 in a GIPET® I tablet with 3 different coatings, respectively, on three separate dosing visits (Visits 2, 3 and 4). Each of the three dosing days will be separated by a 3-week wash-out period (ranging from 20 to 28 days)
88947955|NCT01931137|Experimental|Coating B|Each subject will in random order be allocated to three single-dose administrations of insulin 338 in a GIPET® I tablet with 3 different coatings, respectively, on three separate dosing visits (Visits 2, 3 and 4). Each of the three dosing days will be separated by a 3-week wash-out period (ranging from 20 to 28 days)
88947956|NCT01931137|Experimental|Coating C|Each subject will in random order be allocated to three single-dose administrations of insulin 338 in a GIPET® I tablet with 3 different coatings, respectively, on three separate dosing visits (Visits 2, 3 and 4). Each of the three dosing days will be separated by a 3-week wash-out period (ranging from 20 to 28 days)
88947957|NCT01931176|Experimental|rDEN2Δ30-7169 vaccine|Participants will receive a single injection of the rDEN2Δ30-7169 vaccine at study entry.
88947958|NCT01931176|Placebo Comparator|Placebo|Participants will receive a single injection of placebo at study entry.
88947959|NCT01931189|Experimental|NI-071|
88947960|NCT01931189|Active Comparator|Infliximab|
88947961|NCT01931215|Active Comparator|morphine group|spinal anesthesia with intrathecal morphine
88947962|NCT01931215|Experimental|TAP group|TAP-block with ropivacaine and clonidine
89471019|NCT03176134|Experimental|Cohort 1: Tedizolid phosphate 6 to <12 Years|Participants will receive tedizolid phosphate once-daily single 200-mg dose (body weight ≥50 kg) or twice-daily 2-mg/kg doses (body weight 30 kg to <50 kg); or twice-daily 2.5-mg/kg doses (body weight 3.2 kg to <30 kg), by IV and/or oral suspension for 6 to 10 days.
89471020|NCT03176134|Active Comparator|Cohort 1 Comparator: 6 to <12 Years|Participants will receive comparator IV and/or oral per local standard of care for 10 to 14 days
89471021|NCT03176134|Experimental|Cohort 2: Tedizolid phosphate 2 to <6 Years|Participants will receive tedizolid phosphate once-daily single 200-mg dose (body weight ≥50 kg) or twice-daily 2-mg/kg doses (body weight 30 kg to <50 kg); or twice-daily 2.5-mg/kg doses (body weight 3.2 kg to <30 kg), by IV and/or oral suspension for 6 to 10 days.
89471022|NCT03176134|Active Comparator|Cohort 2 Comparator: 2 to <6 Years|Participants will receive comparator IV and/or oral per local standard of care for 10 to 14 days
89471023|NCT03176134|Experimental|Cohort 3: Tedizolid phosphate 28 Days to <2 Years|Participants will receive tedizolid phosphate once-daily single 200-mg dose (body weight ≥50 kg) or twice-daily 2-mg/kg doses (body weight 30 kg to <50 kg); or twice-daily 2.5-mg/kg doses (body weight 3.2 kg to <30 kg), by IV and/or oral suspension for 6 to 10 days.
89471024|NCT03176134|Active Comparator|Cohort 3: Comparator: 28 Days to <2 Years|Participants will receive comparator IV and/or oral per local standard of care for 10 to 14 days
89471025|NCT03176134|Experimental|Cohort 4: Tedizolid phosphate Birth to <28 Days Neonates|Participants will receive tedizolid phosphate ≤200 mg daily dose, IV and/or oral suspension for 6 to 10 days. Exact mg/kg dose is to be determined based on results of another study covering the age range.
89471026|NCT03176134|Active Comparator|Comparator: Birth to <28 Days (Term and preterm neonates)|Participants will receive comparator IV and/or oral per local standard of care for 10 to14 days
89471027|NCT03152786|Experimental|Group I (propranolol hydrochloride)|Patients receive propranolol hydrochloride PO 2 hours prior to standard of care prostatectomy.
89471028|NCT03152786|Active Comparator|Group II (no treatment)|Patients receive no treatment prior to standard of care prostatectomy.
88947963|NCT01931228|Experimental|MI-E plus manually assisted coughing|
88947964|NCT01931228|Experimental|Manually assisted coughing only|
88947965|NCT01931241|Experimental|Cohort 1, 500 mg|Cohort 1 receives SDD 500 mg AHRO-001; one week later receives MDD of 500 mg bid 7 days, then 500 mg tid 7 days
88947966|NCT01931241|Experimental|Cohort 2, 750 mg|Cohort 2 receives SD of 750 AHRO-001, then 7 days of 750 mg BID AHRO-001, then 7 days of 750 mg TID AHRO-001.
88947967|NCT01931241|Experimental|Cohort 3, 1000 mg|Cohort 3 identical design as Cohorts 1 and 2, but SD is 1000 mg AHRO-001.
88947968|NCT01931241|Experimental|Cohort 4, 21 day dosing|Cohort 4 receives 21 days tid administration of AHRO-001 using the best tolerated dose as determined by cohorts 1, 2 & 3
88947969|NCT01931241|Experimental|Cohort 5, 12 weeks dosing|Cohort 5 receives 12 weeks tid administration of AHRO-001 using the best tolerated dose as determined by the first 4 cohorts.
88947970|NCT01931267|Experimental|Tablet Computer Motivated Instruction|Using Tablet Computer Motivated Instruction to motivate patient learning breath skill and maintain practive. Research nurse will give 3 times instruction to patients during hospitalization. This arm estimated including 77 subjects.
88947971|NCT01931267|Active Comparator|systematic instruction|Research nurse give 3 times systematic instruction during hospitalization This arm estimated including 77 subjects.
89471029|NCT03089619|Active Comparator|Human-Spongiosa (IMP: drug)|Product Name: Human-Spongiosa,gefriergetrocknet, CHB / Pharmaceutical form: Granules / Routes of Administration: Dental use / Marketing authorisation number : 3004134.00.00 / Marketing Authorisation Holder: Institute of Transfusion Medicine, Tissue bank, Charité university of medicine Berlin / Used by socket preservation
89471030|NCT03089619|Active Comparator|collacone® (IMP: medical device)|Product Name: Collacone / Pharmaceutical form: Absorbable, local Hemostat, porcine collagen / Routes of Administration: Dental use / Medical device with a CE mark / Used by socket preservation
89471031|NCT03083366|Experimental|Sacral neuromodulation|Bilateral sacral neuromodulation will start within 3 months of spinal cord injury, as well as standard neurogenic bladder care.
89471032|NCT03083366|No Intervention|Standard care|Patients will receive standard neurogenic bladder care.
89471033|NCT03075176|Active Comparator|Wavefront optimized LASIK|Participants who chose to have LASIK surgery were assigned to have Wavefront optimized LASIK in one eye and Topography-guided LASIK in the other eye (randomly chosen).
89471034|NCT03075176|Active Comparator|Wavefront optimized Photorefractive Keratectomy|Participants who chose to have Photorefractive Keratectomy surgery were assigned to have Wavefront optimized Photorefractive Keratectomy in one eye and Topography-guided Photorefractive Keratectomy in the other eye (randomly chosen).
89471035|NCT03075176|Active Comparator|Topography-guided LASIK|Participants who chose to have LASIK surgery were assigned to have Topography-guided LASIK in one eye and Wavefront optimized LASIK in the other eye (randomly chosen).
89471036|NCT03075176|Active Comparator|Topography-guided Photorefractive Keratectomy|Participants who chose to have Photorefractive Keratectomy surgery were assigned to have Topography-guided Photorefractive Keratectomy in one eye and Wavefront optimized Photorefractive Keratectomy in the other eye (randomly chosen).
89471037|NCT03058146|Experimental|Mobile Health Walking Condition|Physically inactive older adults in this condition will perform 3 months of prescribed brisk walking (to increase cardio respiratory fitness) in their real world environments, using mobile health (mHealth) devices during each exercise session to achieve and maintain a minimum of 150 minutes of moderate to vigorous physical activity (MVPA) per week.
89471038|NCT03058146|Active Comparator|Healthy Aging Education Condition|The education control condition will provide participants with printed materials and homework assignments on issues related to successful aging, such as nutrition, social activity, cognitive and social engagement.
89471039|NCT02996773|Experimental|Cyclophosphamide and Bendamustine|"Experimental: Cyclophosphamide and Bendamustine Control: Cyclophosphamide~Interventions:~Drug: Bendamustine~Drug: Cyclophosphamide"
89471040|NCT02923011|Active Comparator|MRgFUS|Magnetic resonance-guided focused ultrasound ablation
89471041|NCT02923011|Active Comparator|CTgRFA|Computed tomography-guided radiofrequency ablation
89471042|NCT02918149|Other|Palpation Landmark Technique LP|Traditional landmark palpation technique will be used to perform LP
89471043|NCT02918149|Experimental|Ultrasound-Assisted Technique LP|Bedside ultrasonography exam will be used for identification of anatomic landmarks before performing LP
89471044|NCT02909179|Experimental|mCARE-II|mCARE-II supported service provision through existing community health workforce.
89471045|NCT02909179|No Intervention|Comparison|Standard of care, paper-based service provision through existing community health workforce.
89471046|NCT02851511|Experimental|Cognitive Training + Active Stimulation|This arm receives cognitive training combined with active tDCS.
89471047|NCT02851511|Experimental|Cognitive Training + Sham Stimulation|This arm receives cognitive training combined with sham tDCS.
89471048|NCT02851511|Experimental|Educational Training + Active Stimulation|This arm receives educational training combined with active tDCS.
89471049|NCT02851511|Experimental|Educational Training + Sham Stimulation|This arm receives educational training combined with sham tDCS.
89471050|NCT02827370|Experimental|Precision Nutrition (dietary intervention)|During chemotherapy, patients will receive dietary counseling based on the molecular pathways driving their specific breast cancers found through genetic testing. Nutritional recommendations will seek to down-regulate the dominant molecular drivers of an individual's breast cancer while they are receiving standard chemotherapy as outlined by their treating medical oncologist.
89471051|NCT02781129|Experimental|RNS® Neurostimulator|Subjects with pharmaceutically intractable seizures who have been implanted with a RNS® Neurostimulator.
89471052|NCT02727062||OM Pain Smartphone Application|This study examines whether the smartphone OM Pain App is a feasible and valid tool to assess pain from radiation-induced oral mucositis.
89471053|NCT02630147|Experimental|Vanilla, Then no vanilla night|"Participants were exposed to vanilla odor (2 mL of 2% vanillin on the bib, close to the face) on the first night (12-hour recording), and not exposed to vanilla on the third night (control night,12-hour recording)~No intervention, no recordings were made on the second night"
89471054|NCT02630147|Experimental|No vanilla, Then vanilla night|"Participants were exposed to the control condition on the first night, which consisted of no vanilla odor (12-hour recording), and then exposed to vanilla odor on the third night (2 mL of 2% vanillin on the bib, close to the face;12-hour recording)~No intervention, no recordings were made on the second night"
89471055|NCT02562157|Experimental|Patients with antro duodenal obstructions|NOTES gastroenteric anastomosis
89471056|NCT02538484|Active Comparator|Letrozole|Letrozole 2.5 mg by mouth daily for 30 days.
89471057|NCT02538484|Active Comparator|Fish Oil|Fish oil 2700 mg by mouth daily for 30 days.
89471058|NCT02538484|Active Comparator|Letrozole and Fish Oil|Letrozole 2.5 mg and Fish oil 2700 mg by mouth daily for 30 days.
89471059|NCT02484391|Experimental|Treatment (CPI-613, cytarabine, mitoxantrone hydrochloride)|See Detailed Description
89471060|NCT02478320|Experimental|Ilorasertib (ABT-348)|"Part 1 Dose of Ilorasertib: 200 mg administered by mouth twice daily on Days 1, 8, and 15 of each 28-day cycle.~Part 2 Expansion: Ilorasertib200 mg administered by mouth twice daily on Days 1, 8, and 15 of each 28-day cycle."
88947972|NCT01931280|Experimental|Lifestyle Counseling|Participants will obtain access to an internet-based educational intervention.
88947973|NCT01931280|No Intervention|Usual Care (Self-Directed)|Participants receive information via email on health related topics that surround pregnancy, physical activity, nutrition, and gestational diabetes.
88947974|NCT01931293|Experimental|HLA-DR and DQ antigens|Isolation of patient's lymphocytes from 10 cc of blood to determine the HLA-DR and DQ antigens at the first visit.
88947975|NCT01931319|Experimental|Intravenous Baclofen|Three single doses were evaluated using three cohorts (N=12 per cohort). Subjects received single doses of baclofen: 7.5, 11.5 or 15mg 10-minute intravenous infusion administered over 10 minutes by an infusion pump and 10, 15, or 20mg taken orally with a 48-hour washout phase between oral and intravenous arms of the study. Initially, 3 subjects received study drug at a given dose, after assessing the safety and tolerance of baclofen the additional 9 subjects received study drug.
88947976|NCT01931332|Active Comparator|Femoral Nerve Block with levobupivicaine|A single injection femoral nerve block (FNB) was performed in the supine position with a 50mm insulated needle (NanoLine, Pajunk, Geisingen, Germany) and peripheral nerve stimulator set at 1Hertz (Hz) with pulse width 0.1ms. Once a quadriceps muscle twitch was identified at a stimulated current between 0.2 and 0.5milliamperes (mA), 20mls of 0.375% levobupivacaine (75mg) was injected in fractionated amounts after negative aspiration
88947977|NCT01931332|Active Comparator|Intrathecal injection of diamorphine|500mcg of intrathecal diamorphine (ID) (dissolved in 0.5mls normal saline)
88947978|NCT01931345|Experimental|Motivational Interviewing Counseling|Counseling developed by the research team based on a motivational interviewing approach
88947979|NCT01931345|Active Comparator|Standard counseling|Counseling based on Quebec guidelines for rapid HIV testing
88947980|NCT01931358|Experimental|Group Ia|ALVAC-HIV at Weeks 0 and 4; ALVAC-HIV + AIDSVAX B/E at Weeks 12 and 24
88947981|NCT01931358|Placebo Comparator|Group Ib|ALVAC-HIV Placebo at Weeks 0 and 4; ALVAC-HIV Placebo + AIDSVAX B/E Placebo at Weeks 12 and 24
88947982|NCT01931358|Experimental|Group IIa|ALVAC-HIV at Weeks 0 and 4; ALVAC-HIV + AIDSVAX B/E at Weeks 12, 24 and 48
88947983|NCT01931358|Placebo Comparator|Group IIb|ALVAC-HIV Placebo at Weeks 0 and 4; ALVAC-HIV Placebo + AIDSVAX B/E Placebo at Weeks 12, 24 and 48
88947984|NCT01931358|Experimental|Group IIIa|ALVAC-HIV at Weeks 0 and 4; ALVAC-HIV + AIDSVAX B/E at Weeks 12 and 24; AIDSVAX B/E at Week 48
88947985|NCT01931358|Placebo Comparator|Group IIIb|ALVAC-HIV Placebo at Weeks 0 and 4; ALVAC-HIV Placebo + AIDSVAX B/E Placebo at Weeks 12 and 24; AIDSVAX B/E Placebo at Week 48
88947986|NCT01931358|Experimental|Group IVa|ALVAC-HIV at Weeks 0, 4 and 48; ALVAC-HIV + AIDSVAX B/E at Weeks 12 and 24
88947987|NCT01931358|Placebo Comparator|Group IVb|ALVAC-HIV Placebo at Weeks 0, 4 and 48; ALVAC-HIV Placebo + AIDSVAX B/E Placebo at Weeks 12 and 24
88947988|NCT01931371|Active Comparator|Recurrent anal fistula|Patients with a complex anal fistula that recurred after surgery with an Anal Fistula Plug or and Endorectal Advancement Flap
88947989|NCT01931371|Active Comparator|No recurrence of anal fistula|Patients with a complex anal fistula that did not develop recurrence after surgery with an Anal Fistula Plug or and Endorectal Advancement Flap
88947990|NCT01931384|Experimental|Intervention group|luteal phase support using Human chorionic gonadotrophin 1500 IU intramuscular injection will be given on the day of FET and 6 days later.
88947991|NCT01931384|Placebo Comparator|control group|normal saline (placebo) intramuscular injection will be given on the day of FET and 6 days later
88947992|NCT01931410|Placebo Comparator|sublingual|400 microgram mısoprostol will be administered sublıngually before elective caesarean
88947993|NCT01931410|Placebo Comparator|rectal|rectal 600 mgr misoprostol will be administered
88947994|NCT01931410|No Intervention|synpitan|
88947995|NCT01931423|Placebo Comparator|Drainage Group|early placental drainage plus cord traction
88947996|NCT01931423|No Intervention|Controlled Group|spontaneous removal placenta
89471061|NCT02311998|Experimental|Treatment (bosutinib, inotuzumab ozogamicin) Phase I Dose 1|Patients receive bosutinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive inotuzumab ozogamicin IV over 1 hour on days 1, 8, and 15. Patients with confirmed CR, CRi, CCyR and/or absence of MRD may receive inotuzumab ozogamicin IV on day 1 of subsequent cycles. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
89471062|NCT02311998|Experimental|Treatment (bosutinib, inotuzumab ozogamicin) Phase II|Patients receive bosutinib at the Maximum Tolerated Dose from the Phase I dose part, PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive inotuzumab ozogamicin IV over 1 hour on days 1, 8, and 15. Patients with confirmed CR, CRi, CCyR and/or absence of MRD may receive inotuzumab ozogamicin IV on day 1 of subsequent cycles. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
88947997|NCT01931449|Experimental|Modified digestive reconstruction|Modified method of digestive tract reconstruction: Evaluate the resectability; Remove pancreas head, gastric pyloric antrum, duodenum, distal common bile duct and regional lymph nodes; Reconstruct digestive tract with an independent intestinal loop and pancreas end.
88947998|NCT01931449|Active Comparator|Routine pancreatoduodenectomy|Routine digestive tract reconstruction: Evaluate the resectability; Remove pancreas head, gastric pyloric antrum, duodenum, distal common bile duct and regional lymph nodes;Reconstruct the common bile duct-jejunum and pancreatic duct-jejunum respectively.
89471063|NCT02311998|Experimental|Treatment (bosutinib, inotuzumab ozogamicin) Phase I Dose 2|Patients receive bosutinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive inotuzumab ozogamicin IV over 1 hour on days 1, 8, and 15. Patients with confirmed CR, CRi, CCyR and/or absence of MRD may receive inotuzumab ozogamicin IV on day 1 of subsequent cycles. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
89471064|NCT02311998|Experimental|Treatment (bosutinib, inotuzumab ozogamicin) Phase I Dose 3|Patients receive bosutinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive inotuzumab ozogamicin IV over 1 hour on days 1, 8, and 15. Patients with confirmed CR, CRi, CCyR and/or absence of MRD may receive inotuzumab ozogamicin IV on day 1 of subsequent cycles. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
89471065|NCT02252042|Experimental|Pembroliziumab|Participants will receive pembrolizumab 200 mg intravenous (IV) on Day 1 of each 3-week cycle for up to approximately 24 months. Eligible participants who stop pembrolizumab with Stable Disease (SD) or better but progress after discontinuation may be able to initiate a second course of pembrolizumab for up to approximately 1 additional year at the investigator's discretion.
89471066|NCT02252042|Active Comparator|Standard Treatment|Participants will receive standard treatment of either methotrexate 40 mg/m^2 IV (may be escalated to 60 mg/m^2 maximum dose) on Days 1, 8, and 15 of each 3-week cycle; or docetaxel 75 mg/m^2 IV on Day 1 of each 3- week cycle; or cetuximab 400 mg/m^2 IV loading dose on Day 1 and 250 mg/m^2 IV on Days 8 and 15 of Cycle 1, followed by cetuximab 250 mg/m^2 on Days 1, 8, and 15 of each subsequent 3-week cycle.
88947999|NCT01931488|Other|MIBG label with I123 or I124|evaluate the added value of PET-CT with 124I-MIBG tracer, compared to planar and SPECT imaging with the routine 123I-MIBG tracers/
88948000|NCT01931540|Experimental|Exercise Training - 17 offspring of OM|4 months exercise training, OM: Obese mothers
88948001|NCT01931540|No Intervention|11 non-frail controls (9 LM)|Studied only at baseline
88948002|NCT01931540|Experimental|Exercise Training - 20 offspring of LM|4 months exercise training, LM:Lean/Normal Mothers
88948003|NCT01931553|Experimental|Standardized attending morning rounds|"Pre-rounds discretion~Pre-rounds huddle~Bedside RN integration~Patient-centered rounding~Real-time order writing"
88948004|NCT01931553|No Intervention|Usual rounding practice|Usual rounding practice (as defined by each clinical team)
88948005|NCT01931579|Experimental|confocal endo-microscopy|confocal endo-microscopy : CELLVIZIO endo-microscopy procedure is performed in every patient using the same extended working channel as for navigational bronchoscopy.
88948006|NCT01931592|Active Comparator|ESBL eradication regimen|Fosfomycin-trometamol (3 g granules dissolved in 200 ml of water for oral administration every 72h) and colistin (2x106 IU oral solution dissolved in 50-100 ml of water given orally every 6 hours) and gentamicin (an 80 mg oral solution dissolved in 50-100 ml of water given orally every 6 hours) will be administered in a double-blind fashion for a total duration of 7 days (day 1-7). The placebo treatment will be identical in taste, consistency, colour and packaging. To include the oral cavity into the eradication regimen, all medications should be gargled for at least 10 seconds before being swallowed.
88948007|NCT01931592|Placebo Comparator|Placebo ESBL eradication|Placebo preparations of fosfomycin, gentamicin and colisitin, identical in taste, texture and color will be administered at the same rate as the active comparator medication.
88948008|NCT01931605|Experimental|Embolization procedure|selective prostatic arterial embolization using BeadBlock (Terumo) particules
88948009|NCT01931618|Active Comparator|Usual care|"Receives two interventions:~Online screening and feedback.~Online booklet."
88948010|NCT01931618|Experimental|Extended follow-up|"Receives two interventions:~Online screening and feedback.~Online multi session follow-up."
88948011|NCT01931644||Health Condition|Collect blood and other optional biospecimens from participants with a diagnosed health condition
88948012|NCT01931644||Healthy Control|Collect blood and other optional biospecimens from participants that have not been diagnosed with a health condition
88948013|NCT01931657|Experimental|Mifepristone prior to Mirena|Pretreatment with mifepristone prior to Mirena insertion
89471067|NCT02099058|Experimental|Monotherapy Telisotuzumab vedotin (21-day dosing cycles)|Telisotuzumab vedotin will be administered at escalating dose levels in 21-day dosing cycles. Additional subjects will be enrolled in an expansion cohort that will further evaluate Telisotuzumab vedotin.
89471068|NCT02099058|Experimental|Monotherapy Telisotuzumab vedotin(28-day dosing cycles)|Telisotuzumab vedotin will be administered at escalating dose levels in 28-day dosing cycles. Additional subjects will be enrolled in an expansion cohort that will further evaluate Telisotuzumab vedotin.
89471069|NCT02099058|Experimental|Monotherapy Expansion Cohort|Telisotuzumab vedotin will be administered every 14 days on a 28-day dosing cycle.
89471070|NCT02099058|Experimental|Arm A (Telisotuzumab vedotin plus Erlotinib)|Telisotuzumab vedotin to be evaluated with Erlotinib.
89471071|NCT02099058|Experimental|Arm D (Telisotuzumab vedotin plus Nivolumab)|Telisotuzumab vedotin to be evaluated with Nivolumab.
89471072|NCT02099058|Experimental|Arm E (Telisotuzumab vedotin plus Osimertinib)|Telisotuzumab vedotin to be evaluated with Osimertinib.
89471073|NCT01900847|Active Comparator|Morphine and placebo|Patient's will receive morphine during the usual course of their emergency department care and will receive a saline in a volume equivalent to the ketamine administered in the experimental arm of the stuy
89471074|NCT01900847|Experimental|Morphine and Ketamine|Patient's will receive a 0.3mg/kg dose of ketamine in addition to morphine given in the usual course of emergency department care
89471075|NCT01873924||Batten disease|Individuals with any form of Batten disease (Neuronal Ceroid Lipofuscinosis)
89471076|NCT01710007|Experimental|1PC002|2 mg 1PC002 once daily for 12 weeks.
89471077|NCT01710007|Active Comparator|Lipitor|10 mg atorvastatin once daily for 12 weeks.
89471078|NCT01633502|Placebo Comparator|Conventional circulatory support|Patients randomized to conventional circulatory support.
89471079|NCT01633502|Active Comparator|Impella|Patients randomized to Impella CP
89471080|NCT01608516|Experimental|68Ga-NODAGA-RGD radiotracer|All patients will undergo a 68Ga-NODAGA-RGD PET/CT, a 18F-FDG PET/CT, a MRI and a US.
89471081|NCT01357772|Experimental|Tamoxifen|tamoxifen at daily dose of 5 mg for a total treatment time of 3 years
89471082|NCT01357772|Placebo Comparator|placebo|placebo at daily dose of 5 mg for a total treatment time of 3 years
89471083|NCT00862407||1|Non-pulsatile Group (conventional)
89471084|NCT00862407||2|Pulsatile group (Alternate)
89471085|NCT00823277||1|Overweight and obese Children (BMI SDS > 90th percentile according to Danish BMI sheets) 5-20 Years of age. Recruited from the Paediatric department, University Hospital Holbaek, Region Zealand, Denmark, University of Copenhagen
89471086|NCT00811148||Tissue Bank|Collection of clinical data and tumor tissue removed during brain surgeries for future research.
89471087|NCT00378482|Experimental|1|Drug: CP-675,206 (Tremelimumab)
89471088|NCT05815459||Clinical Cases|Participants wear OCOsense during mood induction tasks tracking hedonic, self-reflective and autobiographical processes respectively. Participants also wear OCOsense whilst engaging in simple physical activities.
88948014|NCT01931657|Placebo Comparator|Placebo prior to Mirena|Pretreatment with placebo prior to Mirena insertion
89471089|NCT05815459||Control Cases|Participants wear OCOsense during mood induction tasks tracking hedonic, self-reflective and autobiographical processes respectively. Participants also wear OCOsense whilst engaging in simple physical activities.
89471090|NCT05813860|Experimental|Infliximab|Infliximab monotherapy, the first dose of 5 mg/kg of this product is provided, followed by the same dose at weeks 2 and 6 after the first dose and every 8 weeks thereafter.
89471091|NCT05813860|Active Comparator|Infliximab+azathioprine|Infliximab was given in combination with azathioprine, and Infliximab dosing was the same as in the experimental group, with azathioprine at 1-2 mg/kg/d.
89471092|NCT05799066|Experimental|Known RAPD|Participants with known RAPD will be administered the standard of care swinging light test and pupil measurements taken manually, then administered the light test using the VR HMD and ML.
88948015|NCT01931683|Experimental|remifentanil|LMA removal was accomplished when remifentanil was maintained a predetermined concentration throughout the emergence periods.
88948016|NCT01931696|Experimental|Verum acupuncture|Verum acupuncture treatment once every two days + Albuterol sulfate HFA (Ventolin®™ 100 mcg Inhalation Aerosol) as needed + Prednisone Acetate Tablets(H31020675, 5 mg oral tablet) for exacerbation
88948017|NCT01931696|Sham Comparator|Sham acupuncture|Sham acupuncture treatment once every two days + Albuterol sulfate HFA (Ventolin®™ 100 mcg Inhalation Aerosol) as needed + Prednisone Acetate Tablets(H31020675, 5 mg oral tablet) for exacerbation
88948018|NCT01931722|Active Comparator|Branched chain amino acid|Branched chain amino acid as food supplement
89471093|NCT05799066|Experimental|No Known RAPD|Participants with no known RAPD will be administered the standard of care swinging light test and pupil measurements taken manually, then administered the light test using the VR HMD and ML.
89471094|NCT05795569|Experimental|Intervention Group|
89471095|NCT05795569|Active Comparator|Control Group|
89471096|NCT05795023|Experimental|PD patients|Men and women with idiopathic PD (Hoehn & Yahr scale 1-3) aged 18-85 years
89471097|NCT05794360|Experimental|ACCELERATION|Both study arms occurred during participants' PE class, once a week for 45 minutes for 10 weeks. The ACCELERATION curriculum is designed to improve children's MVPA through learning and practicing new and challenging sport skills in a fun and free-will learning environment that includes not only school but also home environment. The ACCELERATION focuses on introducing the ball to the child at a basic level. Ball mastery is a soccer term that simply refers to the ability to manipulate and play with the ball using all parts of the foot. Since this program was an individual pursuit, not a team endeavor, it was imperative that each student has their own ball during the PE class. The trained undergraduate interns assisted PE teachers to deliver this program to classrooms assigned into the treatment arm. The program trains parents via virtual workshops on delivering the program at home.
89471098|NCT05794360|No Intervention|Standard PE|Classrooms assigned to the control group received a 45-minute weekly regular PE curriculum for 10 weeks designed to meet state-mandated requirements. For the same research school, a standard PE curriculum was also delivered by the same PE teacher who delivered the intervention curriculum. However, additional training and support were not provided to PE teachers for the implementation of a regular PE curriculum.
89471099|NCT05791604|Experimental|Probiotics group|Take probiotics during the study
89471100|NCT05791604|Experimental|Probiotics and prebiotics group|Take probiotics and prebiotics during the study
89471101|NCT05791604|No Intervention|Control group|Take placebo food during the study
89471102|NCT05788276|Active Comparator|Active treatment|165 patients
89471103|NCT05788276|Placebo Comparator|Control group|165 patients
89471104|NCT05786560|Experimental|Body image + nutrition education +self-compassion|For the treatment arm, girls will participate in the Body Project for about 30 minutes, then will be given about a 30 minute self-compassion-based nutrition education lesson. The nutrition topics will cover the basic biochemistry of nutrition, nutrition needs for teenage girls, and ways to find balance in eating, framed in the constructs of self-compassion. The three self-compassion constructs will be targeted in the following ways: (1) Mindfulness will involve bringing awareness to feelings and emotions about a time during the week where participants ate a food lower in nutritional value. (2) Common Humanity involves finding ways in which their experience connects to others and acknowledging that being human comes with imperfections. (3) Self-Kindness will involve having girls speak kind and understanding words to themselves as it relates to their eating-related downfall of the week.
89471105|NCT05786560|Active Comparator|Body image + nutrition education|For the control arm, participants will receive the same 30-minute Body Project class, then participants will be given a 30-minute nutrition education lesson. The nutrition lesson plans will have no components of self-compassion intertwined within the lesson, but the nutrition content will be the same as the treatment group.
89471106|NCT05785455|Active Comparator|Usual care|"Subjects will receive a health education program during 5 group sessions of 60 minutes, taught by physical therapists without training in pain neuroscience education.~All patients will receive 5 sessions, regardless of the group they belong to. Group education sessions will be in groups (of 5-6 patients), respecting the safety distance. Group sessions will be held in person, in small groups, at the health center, on a weekly basis. Both groups will receive online monitoring of the exercise program. An image with more information about the intervention and control is attached in Annex 2."
89471107|NCT05785455|Experimental|COGMO Intervention|Each subject will receive. a first individual session to assess their beliefs about pain and coping strategies, combining motivational interviewing and pain neuroscience education techniques, followed by 4 group sessions of 60 minutes, focused on the neurophysiology of pain and self-efficacy techniques in pain control, emphasizing . in two-way communication and followed by cognition targeted exercise therapy. These sessions will be taught by physiotherapists with specific training in motivational interviewing, pain neuroscience education and cognition targeted exercise
89471108|NCT05776706|Experimental|Single arm|"We will set up 2 navigation systems, newly developed AR-based navigation and conventional navigation system, to surgeries of all participants.~Surgeons will perform all surgical planning and operations with reference to the conventional navigation system. In this process, the errors of the existing navigation and the newly developed navigation will be measured and compared in 3D at several points, and the points are as follows:~Fiducial markers~Nasion~Tumor's margin (anterior, posterior, superior, inferior)"
88948019|NCT01931722|Active Comparator|Weight training|"Strength training will include a split-training program using all major muscle groups of the body on a three day on, one day off protocol. Muscle areas targeted on each training day will be as follows: Day1: chest, shoulder, triceps; Day2: back, biceps; Day3: legs and calfs; Day4: will be a rest day. On Day5: this cycle will begin again. A combination of free weights and machines will be used for each training day. Progressive overload protocol will be applied where the load used by every participant will be adjusted bi-weekly based on their 70% of 1RM (repetition maximum). Instruction will be provided for all exercises and professional trainers will oversee all training sessions."
88948020|NCT01931748|Experimental|UNCNT|6 times/ 12 days
88948021|NCT01931748|Active Comparator|MELSMON|6 times/ 12 days
88948022|NCT01931761|Experimental|[C14] selumetinib 75mg single dose|[C14] selumetinib 75mg single dose
88948023|NCT01931774||Acne Patients|
88948024|NCT01931774||Control Subjects|From General Population
88948025|NCT01931787|Experimental|Treatment (CPI-613)|Patients receive CPI-613 IV over 2 hours on days 1 and 4 of weeks 1-3. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
88948026|NCT01931800||Presenting patients a pneumonia pneumococcique|
88948027|NCT01931800||Patients presenting a bacteremia pneumococcique|
88948028|NCT01931800||Patients affected by pneumococcique meningitis|
88948029|NCT01931813||Infants likely to present febrile convulsions|
88948030|NCT01931826|Active Comparator|Endoscopic treatment alone|3 to 5 sessions of sclerotherapy till eradication of esophageal varices.
88948031|NCT01931826|Active Comparator|Total EGDS + endoscopy|Esophagogastric devascularization with splenectomy followed by endoscopic sclerotherapy of esophageal varices 2 months postoperatively.
88948032|NCT01931891||prreclampsia|
88948033|NCT01931917|Experimental|IY Parents and Babies Program|In the Incredible Years Parents and Babies Program, parents learn how to help their babies feel loved, safe, and secure. They learn how to encourage their babies' physical and language development. The parenting group format fosters peer support networks and shared learning. Trained Incredible Years facilitators use video clips of real-life situational vignettes to support the training and stimulate parenting group discussions and practice exercises with their babies. The program is group based with 6-8 mothers and partners attending 8 2 hour sessions with their babies.
88948034|NCT01931917|Active Comparator|Usual Care|Usual care consists of the elements that are being offered to all mothers in the participating municipalities which is 5 home visits by health visitors, a mothers group, a health nurse station and extra visits if needed.
88948035|NCT01931930|Experimental|Perilla extract|Experimental arm: Perilla extract
88948036|NCT01931930|Placebo Comparator|Maltodextrin|Placebo arm: Maltodextrin
89471109|NCT05770934|Experimental|home-based BFRE|"Patients in the home-based BFRE group will be carefully instructed in how to perform the exercise program with four weekly sessions for 12 weeks (48 training sessions within an 84-day period). Each session will consist of one lower-limb resistance training exercise: sit-to-stand from a ~43 cm high chair. The exercise will consist of four rounds interspaced by a 30-seconds rest pause. The first, second, and third round will consist of 30, 15, 15 repetitions, while the fourth round will be performed until volitional fatigue. The patients will be instructed to perform both the eccentric and concentric contractions at a steady 2-sec pace with, preferably, no time for relaxation in the transition from eccentric to concentric phase (i.e. the bottom is only kissing the chair before reversing the movement upwards). When a patient can perform more than 25 repetitions in the last round, they are encouraged to add external resistance corresponding to around 5 kg."
89471110|NCT05770934|No Intervention|Control Group|Patients in the control group will performed the same tests 12 months after surgery and 15 months after surgery as the intervention home-based BFRE group.
89471111|NCT05766956|Experimental|Advanced Care at Home (ACH)|Patients will receive inpatient hospitalization at home.
89471112|NCT05766956|Active Comparator|Traditional Inpatient (Brick-and-Mortar) Hospital Care|Patients will receive inpatient hospitalization at the hospital.
89471113|NCT05738694|Experimental|Neoadjuvant group|Neoadjuvant group will be given the neoadjuvant combination of axitinib plus Toripalimab + nephrectomy
89471114|NCT05738694|Active Comparator|Control group|The control group will be given nephrectomy alone.
89471115|NCT05731986|Active Comparator|Optimal stimulation (for a blood pressure response)|Stimulation will be applied during an orthostatic sit-up challenge, using the profile (stimulation site and parameters) that was chosen in the mapping sessions, for optimal modulation of systolic blood pressure.
89471116|NCT05731986|Sham Comparator|Sham stimulation|Sham stimulation will be applied during an orthostatic sit-up challenge. Sham stimulation will be delivered at a predetermined spinal location. Stimulation parameters, however, will be different from those chosen for the optimal stimulation, and sensation may be different as well.
89471117|NCT05727111|Experimental|HABIT-ILE therapy at home with a HABIT-ILE follow-up at home|2 weeks of HABIT-ILE (Hand-Arm Bimanual Intensive Therapy Including Lower Extremities) therapy at home followed by 9 weeks of HABIT-ILE follow-up at home
89471118|NCT05727111|Experimental|HABIT-ILE therapy at home followed by usual care|2 weeks of HABIT-ILE (Hand-Arm Bimanual Intensive Therapy Including Lower Extremities) therapy at home followed by 9 weeks of usual care
89471119|NCT05727111|Active Comparator|Classic HABIT-ILE therapy followed by usual care|2 weeks of classic HABIT-ILE (Hand-Arm Bimanual Intensive Therapy Including Lower Extremities) therapy on site followed by 9 weeks of usual care
89471120|NCT05727111|Active Comparator|Classic HABIT-ILE therapy with HABIT-ILE follow-up at home|2 weeks of classic HABIT-ILE (Hand-Arm Bimanual Intensive Therapy Including Lower Extremities) therapy on site followed by 9 weeks of HABIT-ILE follow-up at home
89471121|NCT05725499|Experimental|Participants with a chronic SCI (≥ 6 months after injury)|Participants will complete three days of baseline assessments (including a baseline orthostatic test and a day of neurophysiological mapping), five days of stimulation mapping to locate the optimal spinal sites for a blood pressure response, a day of testing with stimulation applied during an orthostatic provocation and a two-week (total of six days) training period with repeated exposure to stimulation, followed by two days of additional orthostatic tests (with and without stimulation)
89471122|NCT05723250|Experimental|Upfront Educational Intervention|Participants will receive a video-based intervention after completing baseline survey instruments and prior to retesting after 4-6 months.
89471123|NCT05723250|Experimental|Delayed Educational Intervention|Participants will complete baseline survey instruments and again complete surveys after 4-6 months. They will then receive the video-based educational tablet.
89471124|NCT05719103|Active Comparator|HFNC SP|HFNC flow at 60 L/min or maximum tolerable flow at supine position
89471125|NCT05719103|Active Comparator|HFNC PP|HFNC flow at 60 L/min or maximum tolerable flow at prone position
89471126|NCT05719103|Active Comparator|NIV SP|CPAP with full face mask at 10 cmH2O at supine position
89471127|NCT05719103|Active Comparator|NIV PP|CPAP with full face mask at 10 cmH2O at prone position
89471128|NCT05719103|Placebo Comparator|MC SP|Mask oxygen at supine position
89471129|NCT05719103|Placebo Comparator|MC PP|Mask oxygen at prone position
88948037|NCT01931943|Experimental|Selatinib Ditosilate Tablets|Selatinib Ditosilate either at 450,750,1000,1250mg, p.o. once daily
88948038|NCT01931969||IJVC intervention|
89471130|NCT05708521|Active Comparator|Standardized Prescription Group (SOP)|"All participants assigned to the SOP group will be treated as per the current status quo, in which they are given the standardized analgesic prescriptions following discharge from the hospital consisting of:~Acetaminophen 975 mg orally every 6 hours for 7 days~Ibuprofen 600 mg orally every 6 hours for 7 days~Hydromorphone 2-4 mg orally every 6 hours as needed, with a total dispense amount of 40mg.~The participants are not given instructions on how to taper their hydromorphone medication, which is the current status quo in our department."
89471131|NCT05708521|Experimental|Personalized Prescription Group (POP)|"All participants assigned to the POP group will receive pre-operative education on the medications that they will be given while they are inpatients and upon discharge, along with a pain medication card to aid their understanding. Medications upon discharge will be:~Acetaminophen 975mg orally every 6 hours for 1 week~Ibuprofen 600 mg orally every 6 hours for 1 week~Hydromorphone - Prescribed with a personalized schedule and tapering protocol based on the participant's last 24-hour in-patient use of opioids.~Participants in this arm will also receive tapering instructions as well as an education card to assist them with their tapering protocol upon discharge."
88948039|NCT01931982|Active Comparator|victoza|The study is a cross over study. Patients randomised to start with victoza are treated with victoza for 10 weeks. After a wash out period of 2 weeks they cross over to 10 weeks of no treatment
88948040|NCT01931982|No Intervention|No treatment|
88948041|NCT01932021|Experimental|adipose tissue grafting|
88948042|NCT01932034||Standard dosing|Vancomycin dosed and monitored according to standard practice
88948043|NCT01932034||BestDose Computer Software|Vancomycin dosed using BestDose computer software, targeting AUC rather than trough concentrations
89471132|NCT05707156||Low dose|Cumulative dose of corticosteroids 0-10 mg a day (prednisone equivalent) Prednisone: 0-10 mg OR, Dexamethasone: 0-1.5 mg OR, Prednisolone: 0-10 mg OR, Methylprednisolone: 0-8 mg
89471133|NCT05707156||Medium dose|"Cumulative dose of corticosteroids 10-20 mg a day (prednisone equivalent):~Prednisone: 11-20 mg OR, Dexamethasone: 1.6-3.0 mg OR, Prednisolone: 11-20 mg OR, Methylprednisolone: 9-16 mg"
89471134|NCT05707156||High dose|"Cumulative dose of corticosteroid >20 mg a day (prednisone equivalent):~Prednisone: > 20 mg OR, Dexamethasone: > 3.0 mg OR, Prednisolone: > 20 mg OR, Methylprednisolone: >16 mg"
89471135|NCT05702372|Experimental|Glucose as reference food|Eleven healthy, normal body weight adults (male: 4, female: 7) after 12hr fast, consumed 50g available carbohydrates from D-glucose, tested three times, in different visits as reference food; and 50g of available carbohydrates from crackers made by wheat, rye and sunflower flours, tested once, in different visits, along with 300mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min after food consumption. The first glucose sample was taken exactly 15min after the first bite of food or drink.
89019118|NCT00328887|Experimental|CD40 Gene Transfer|Recruitment will be random from the referral base of the investigators from the popula¬tion of individuals with esophageal cancer defined by the protocol inclu¬sion/exclusion criteria.
89471136|NCT05702372|Experimental|Cracker made by wheat flour|Eleven healthy, normal body weight adults (male: 4, female: 7) after 12hr fast, consumed 50g available carbohydrates from D-glucose, tested three times, in different visits as reference food; and 50g of available carbohydrates from crackers made by wheat, rye and sunflower flours, tested once, in different visits, along with 300mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min after food consumption. The first glucose sample was taken exactly 15min after the first bite of food or drink.
89471137|NCT05702372|Experimental|Cracker made by rye flour|Eleven healthy, normal body weight adults (male: 4, female: 7) after 12hr fast, consumed 50g available carbohydrates from D-glucose, tested three times, in different visits as reference food; and 50g of available carbohydrates from crackers made by wheat, rye and sunflower flours, tested once, in different visits, along with 300mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min after food consumption. The first glucose sample was taken exactly 15min after the first bite of food or drink.
89471138|NCT05702372|Experimental|Cracker made by sunflower flour|Eleven healthy, normal body weight adults (male: 4, female: 7) after 12hr fast, consumed 50g available carbohydrates from D-glucose, tested three times, in different visits as reference food; and 50g of available carbohydrates from crackers made by wheat, rye and sunflower flours, tested once, in different visits, along with 300mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min after food consumption. The first glucose sample was taken exactly 15min after the first bite of food or drink.
89471139|NCT05702359|Experimental|Glucose as reference food|Eleven healthy, normal body weight (male: 6, female: 5) adults after a 12hr fast, consumed 50g available carbohydrates from D-glucose, tested two times, in different visits as reference food, along with 300mL water. Fingertip capillary blood glucose samples were collected at baseline and 15, 30, 45, 60, 90, 120, 150, and 180 min after test drink consumption. Salivary insulin samples were collected at baseline, 15, 30, 45, 60, 90, 120, and 180 min after test drink consumption.
89471140|NCT05702359|Experimental|Control juice|Eleven healthy, normal body weight (male: 6, female: 5) adults after a 12hr fast, consumed 50g available carbohydrates from control mixed fruit juice (pomegranate, grape, apple and orange), tested once, in random order, along with 300mL water. Fingertip capillary blood glucose samples were collected at baseline and 15, 30, 45, 60, 90, 120, 150, and 180 min after test drink consumption. Salivary insulin samples were collected at baseline, 15, 30, 45, 60, 90, 120, and 180 min after test drink consumption.
89471141|NCT05702359|Experimental|Juice containing vitamin D3|Eleven healthy, normal body weight (male: 6, female: 5) adults after a 12hr fast, consumed 50g available carbohydrates from mixed fruit juice enriched with vitamin D3, tested once, in random order, along with 300mL water. Fingertip capillary blood glucose samples were collected at baseline and 15, 30, 45, 60, 90, 120, 150, and 180 min after test drink consumption. Salivary insulin samples were collected at baseline, 15, 30, 45, 60, 90, 120, and 180 min after test drink consumption.
89471142|NCT05702359|Experimental|Juice containing n-3 polyunsaturated fatty acids (PUFA)|Eleven healthy, normal body weight (male: 6, female: 5) adults after a 12hr fast, consumed 50g available carbohydrates from mixed fruit juice enriched with n-3 PUFA, tested once, in random order, along with 300mL water. Fingertip capillary blood glucose samples were collected at baseline and 15, 30, 45, 60, 90, 120, 150, and 180 min after test drink consumption. Salivary insulin samples were collected at baseline, 15, 30, 45, 60, 90, 120, and 180 min after test drink consumption.
89471143|NCT05702359|Experimental|Juice containing probiotics|Eleven healthy, normal body weight (male: 6, female: 5) adults after a 12hr fast, consumed 50g available carbohydrates from mixed fruit juice enriched with probiotics, tested once, in random order, along with 300mL water. Fingertip capillary blood glucose samples were collected at baseline and 15, 30, 45, 60, 90, 120, 150, and 180 min after test drink consumption. Salivary insulin samples were collected at baseline, 15, 30, 45, 60, 90, 120, and 180 min after test drink consumption.
89019119|NCT00328965|Other|Lacidipine|All subjects who meet eligiblity criteria receive 2mg for the first 4 weeks in an open manner. If target systolic blood pressure is not ahcieved, subject can increase the dose to 4mg and then 6mg consequently.
89019120|NCT00329004|Experimental|1|
89019121|NCT00332514|Other|Patients offered follow-up phone call|Patients offered follow-up telephone call
89019122|NCT00304772|Active Comparator|1|
89019123|NCT00304772|Active Comparator|2|
89019124|NCT00332670|Active Comparator|1|10.000lux bright blue light 1hour every morning 1 hour after wake-up time during three weeks
89019125|NCT00332670|Placebo Comparator|2|50lux dim red light 1 hour every morning 1 hr after wake-up time during 3 weeks
89019126|NCT00304850|Experimental|R+ / K+|
89471144|NCT05702359|Experimental|Juice containing probiotics, vitamin D3, and n-3 PUFA|Eleven healthy, normal body weight (male: 6, female: 5) adults after a 12hr fast, consumed 50g available carbohydrates from a mixed juice enriched with probiotics, vitamin D3, and n-3 PUFA, tested once, in random order, along with 300mL water. Fingertip capillary blood glucose samples were collected at baseline and 15, 30, 45, 60, 90, 120, 150, and 180 min after test drink consumption. Salivary insulin samples were collected at baseline, 15, 30, 45, 60, 90, 120, and 180 min after test drink consumption.
89471145|NCT05702307|Experimental|Glucose as reference food|Sixteen healthy, normal body weight adults after 12hr fast, consumed 50g available carbohydrates from D-glucose, tested three times, in different visits as reference food; and 50g available carbohydrates from tagliatelle control, 5% sunflower tagliatelle, 16% sunflower tagliatelle, 16% sunflower penne, and 16% sunflower fusilli, tested once, in different visits, along with 300mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose samples and measurements from continuous glucose monitoring system were taken at baseline, 15, 30, 45, 60, 90 and 120min after food consumption. The first glucose sample was taken exactly 15min after the first bite of food or drink.
89471146|NCT05702307|Experimental|Tagliatelle Control|Sixteen healthy, normal body weight adults after 12hr fast, consumed 50g available carbohydrates from D-glucose, tested three times, in different visits as reference food; and 50g available carbohydrates from tagliatelle control, 5% sunflower tagliatelle, 16% sunflower tagliatelle, 16% sunflower penne, and 16% sunflower fusilli, tested once, in different visits, along with 300mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose samples and measurements from continuous glucose monitoring system were taken at baseline, 15, 30, 45, 60, 90 and 120min after food consumption. The first glucose sample was taken exactly 15min after the first bite of food or drink.
89471147|NCT05702307|Experimental|5% sunflower tagliatelle|Sixteen healthy, normal body weight adults after 12hr fast, consumed 50g available carbohydrates from D-glucose, tested three times, in different visits as reference food; and 50g available carbohydrates from tagliatelle control, 5% sunflower tagliatelle, 16% sunflower tagliatelle, 16% sunflower penne, and 16% sunflower fusilli, tested once, in different visits, along with 300mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose samples and measurements from continuous glucose monitoring system were taken at baseline, 15, 30, 45, 60, 90 and 120min after food consumption. The first glucose sample was taken exactly 15min after the first bite of food or drink.
89471148|NCT05702307|Experimental|16% sunflower tagliatelle|Sixteen healthy, normal body weight adults after 12hr fast, consumed 50g available carbohydrates from D-glucose, tested three times, in different visits as reference food; and 50g available carbohydrates from tagliatelle control, 5% sunflower tagliatelle, 16% sunflower tagliatelle, 16% sunflower penne, and 16% sunflower fusilli, tested once, in different visits, along with 300mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose samples and measurements from continuous glucose monitoring system were taken at baseline, 15, 30, 45, 60, 90 and 120min after food consumption. The first glucose sample was taken exactly 15min after the first bite of food or drink.
89471149|NCT05702307|Experimental|16% sunflower penne|Sixteen healthy, normal body weight adults after 12hr fast, consumed 50g available carbohydrates from D-glucose, tested three times, in different visits as reference food; and 50g available carbohydrates from tagliatelle control, 5% sunflower tagliatelle, 16% sunflower tagliatelle, 16% sunflower penne, and 16% sunflower fusilli, tested once, in different visits, along with 300mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose samples and measurements from continuous glucose monitoring system were taken at baseline, 15, 30, 45, 60, 90 and 120min after food consumption. The first glucose sample was taken exactly 15min after the first bite of food or drink.
89471150|NCT05702307|Experimental|16% sunflower fusilli|Sixteen healthy, normal body weight adults after 12hr fast, consumed 50g available carbohydrates from D-glucose, tested three times, in different visits as reference food; and 50g available carbohydrates from tagliatelle control, 5% sunflower tagliatelle, 16% sunflower tagliatelle, 16% sunflower penne, and 16% sunflower fusilli, tested once, in different visits, along with 300mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose samples and measurements from continuous glucose monitoring system were taken at baseline, 15, 30, 45, 60, 90 and 120min after food consumption. The first glucose sample was taken exactly 15min after the first bite of food or drink.
89019127|NCT00304850|Experimental|R+ / K-|
89471151|NCT05702073|Experimental|INS068|
89471152|NCT05702073|Active Comparator|IGlar|
89471153|NCT05695872|Active Comparator|subtarsal approach|
89471154|NCT05695872|Active Comparator|conventional transconjunctival approach|
89471155|NCT05695872|Active Comparator|transconjunctival approach with Y- modification|
89471156|NCT05690282|No Intervention|Standard oral hydrocodone-acetaminophen post-op management|
89471157|NCT05690282|Active Comparator|Multimodal pain post-op management (Ibuprofen/Acetaminophen/GABAPentin/0.25%Bupivacaine)|
89471158|NCT05685576|Experimental|Ridge splitting and osseodensification with simultaneous implant placement|
89471159|NCT05677334|Experimental|Henagliflozin+ Continuous Subcutaneous Insulin Infusion|Combination therapy of Henagliflozin and Continuous Subcutaneous Insulin Infusion
89471160|NCT05677334|Active Comparator|Continuous Subcutaneous Insulin Infusion|Continuous Subcutaneous Insulin Infusion therapy alone
89019128|NCT00304850|Experimental|R- / K+|
88948044|NCT01932034||BestDose Computer Software 2|Vancomycin dosed using BestDose computer software, targeting AUC rather than trough concentrations and with computer-generated suggested optimal blood sampling times
88948045|NCT01932073|No Intervention|Control Group|Receives institutional skin care protocol
88948046|NCT01932073|Experimental|Treatment Group|Receives institutional skin care protocol and, when applicable (if skin reactions develop), Low-Level Laser Therapy
88948047|NCT01932086|Experimental|White rice|
88948048|NCT01932086|Experimental|Brown rice|
88948049|NCT01932086|Experimental|Black rice|
88948050|NCT01932086|Active Comparator|Bread|
88948051|NCT01932086|Active Comparator|Glucose solution|
89471161|NCT05676645||Participants|Breastfeeding women who have been prescribed (by a clinician independent from the study team) artemether-lumefantrine to treat uncomplicated malaria
89471162|NCT05669183||Peripheral VA ECMO|Femoral artery cannulation for veno-arterial extracorporeal membraneous oxygenation (VA ECMO)
89471163|NCT05669183||Central VA ECMO|Axillary artery cannulation for veno-arterial extracorporeal membraneous oxygenation (VA ECMO)
89471164|NCT05668845|Experimental|PG-ANB performed at the outset of LSG|PG-ANB is performed early in the procedure as a first step before starting the sleeve gastrectomy.
89471165|NCT05668845|Active Comparator|PG-ANB performed at the end of LSG|PG-ANB is performed at the end of the sleeve gastrectomy
89471166|NCT05664425|Experimental|Mechanical treatment arm + oral hygiene reinforcement|Subjects receive oral hygiene reinforcement, and additionally submucosal instrumentation with ultrasonics with a plastic tip.
89471167|NCT05664425|No Intervention|Oral hygiene reinforcement alone|Subjects receive oral hygiene reinforcement, but do not receive submucosal instrumentation.
89471168|NCT05659966|Experimental|Intervention|The intervention condition participants will be instructed to follow a plant-based diet. The intervention participants will receive weekly group classes for 3 months at a local restaurant and will receive guidance on how to choose foods to meet their nutrient needs that fit within the vegan diet. The intervention participants will receive a voucher each week for a free plant-based meal at the restaurant.
88948052|NCT01932138|Experimental|Enhanced CHW intervention|CHWs will 1) identify pregnant women through home visits and refer them to ANC; 2) inform pregnant women on antenatal care ANC and PMTCT; 3) visit women at home to ascertain ANC attendance; and 4) follow up women who have missed ANC or PMTCT appointments.
88948053|NCT01932138|Other|Standard of care|Clinic-based health workers follow-up patients who have missed scheduled PMTCT appointments (through telephone calls and/or in-person visits). The standard of care does not include any specific interventions to improve ANC attendance.
88948054|NCT01932151|Other|Terlipressin and albumin|Single-group study (Type-1 Hepatorenal Syndrome Associated With Active Infections) Terlipressin was initially given at a dose of 1 mg/4h as an intravenous bolus for 2 days. If at day 3 serum creatinine had decreased at least 25% of the pretreatment values, the dose of terlipressin was not modified. In the remaining patients, the dose was increased up to a maximum of 2 mg/4h. Terlipressin was given until serum creatinine had decreased below 1.5 mg/dL (133 µmol/L) or for a maximum of 14 days.
89471169|NCT05659966|Active Comparator|Control|Participants in the active control condition will receive meal vouchers to the restaurant. The active control condition participants will not receive any instruction to follow a particular diet or support. Participants in this condition will receive all intervention material and attend a class at the end of the study to learn about the intervention diet.
88948055|NCT01932177|Active Comparator|Schedule A|Everolimus run-in period followed by continuous administration of everolimus and sorafenib
88948056|NCT01932177|Active Comparator|Schedule B|Sorafenib run-in period followed by continuous administration of everolimus and sorafenib
88948057|NCT01932177|Experimental|Schedule C|Everolimus and sorafenib in alternance
88948058|NCT01932177|Experimental|Schedule D|Continuous administration of everolimus and intermittent administration of sorafenib
89019129|NCT00304850|Placebo Comparator|R- /K-|
89471170|NCT05658224|Active Comparator|Short education|Individuals receiving a short (1-minute) educational session on exercise-induced hypoalgesia
89471171|NCT05658224|Active Comparator|Long education|Individuals receiving long (10-15 minutes) educational session on exercise-induced hypoalgesia
89471172|NCT05656586||Participants|"Inclusion criteria for all aims/experiments~Receiving DBS therapy in GP for treatment of PD~Implanted with Medtronic Percept DBS system~At least 3 months since initial activation of the neurostimulator"
89471173|NCT05649449|Experimental|Experimental|Participants meet with self-directed care program staff called brokers to receive a program orientation, share perceptions of their current life situation and mental health status, and review past year behavioral health service use as well as participants' views of service helpfulness. This culminates in participants' choice of recovery goals and development of an individual budget to pay for for services and material goods directly related to recovery goals. After budget approval by the program supervisor, brokers make purchases. At quarterly meetings, brokers and participants discuss the latter's progress toward recovery goals and create the next quarter's budget. After receiving 12 months of SDC services, participants are helped to transition back to usual community mental health services.
89471174|NCT05649449|Active Comparator|Control|Subjects receive routine mental health care from community agencies consisting of outpatient services coordinated at community behavioral health programs.
89471175|NCT05646875|Experimental|post-ROSC|patients directly post-ROSC receiving HBOT
89471176|NCT05646875|Active Comparator|cardiac arrest survivors discharged home receiving HBOT|cardiac arrest survivors discharged home
89471177|NCT05646875|Active Comparator|healthy volunteers receiving HBOT|healthy volunteers receiving HBOT
89471178|NCT05646238|Experimental|intervention group|Students assigned to the experimental group will be divided into groups of 6-9. 3 psychoeducation sessions will be held with each group once a week for a total of 3 weeks. Group sessions are estimated to last between 60-75 minutes. Psychoeducational content based on Leventhal's Self-Regulation Model was prepared. In the first stage, cognitive bases of dysmenorrhea, in the second stage, strategies to cope with dysmenorrhea, and in the third stage, the effectiveness of coping strategies in dysmenorrhea will be discussed. In the second stage, the participants will be taught the progressive muscle relaxation exercise, which is among the strategies to cope with dysmenorrhea. Sessions will be held online.
89471179|NCT05646238|Active Comparator|control group|The control group will be given a online training of 30-45 minutes covering dysmenorrhea and coping in a single session. From the first menstrual cycle after the training session is completed, measurements will be made in 3 consecutive menstrual cycles.
89471180|NCT05645549|Experimental|Centering Pregnancy with Care Navigation for pregnant Marshallese women|Forty pregnant Marshallese women will be enrolled in the group prenatal intervention, Centering Pregnancy, with care navigation to determine the feasibility of the intervention and the preliminary effectiveness to improve maternal and infant health care outcomes.
89471181|NCT05645549|No Intervention|Pregnant Marshallese women enrolled in standard prenatal care|We will use a 1:1 propensity score matching with pregnant Marshallese women who completed standard prenatal care to compare their maternal and infant health care outcomes with those participants enrolled in the intervention.
89471182|NCT05643768|Experimental|High-resistance IMST|30 breaths/day (5 sets of 6 breaths, one minute of rest between sets), 5 days/week, 6 weeks
89471183|NCT05643768|Active Comparator|Low-resistance IMST|30 breaths/day (5 sets of 6 breaths, one minute of rest between sets), 5 days/week, 6 weeks
89471184|NCT05639881|Experimental|Experimental: Intervention|Subjects receive a brief intervention to improve their immune health literacy and self-management skills.
89471185|NCT05639881|Active Comparator|Services as Usual|Subjects receive routine mental health care.
89471186|NCT05631808||Lowest tertile|Participants with lowest tertile of EAT volume or attenuation among all eligible participants.
89471187|NCT05631808||Intermediate tertile|Participants with intermediate tertile of EAT volume or attenuation among all eligible participants.
89471188|NCT05631808||Highest tertile|Participants with highest tertile of EAT volume or attenuation among all eligible participants.
89471189|NCT05628831|Placebo Comparator|Traditional surgery|This group of patients will be treated with standard technique (vaginal hysterectomy with anterior and/or posterior vaginal repair) for pelvic organ prolapse .
89471190|NCT05628831|Active Comparator|vNOTES PREFAP|This group of patients will be treated with vNOTES aproach using autologous graft isolated from posterior rectus fascia for pelvic organ prolapse.
89471191|NCT05622409||Arm 1|Newly diagnosis arm (N=150): The study aims to obtain clinical information to correlate with genetic characterization of ATDGs of all types. Only patients with primary tumors that have recently received surgery are applicable.
89471192|NCT05622409||Arm 2|Post treatment arm 1 for training set (IDH-wild type ATDGs, N=50; IDH-mutant ATDGs, N=50): The study aims to compare the genetic differences of ATDGs in terms of IDH mutation status. Samples of primary tumors are preferred but can be replaced with recurrent ones. Paired samples are both eligible for typing if the recurrent diseases of IDH-mutant tumors possess potential altered genes (such as up grading per histology features).
89471193|NCT05622409||Arm 3|Post treatment arm 2 (recurrent ATDGs; N=25): The study will focus on recurrent diseases of ATDGs to study the consistency of genetic difference of the primary and the recurrent tumors. Tumor free is mandatory and needs to be documented after resection of the primary tumor. Patients remain eligible if IDH statuses are uncertain.
89471194|NCT05612646|Active Comparator|routine nursing and fake acupressure|control groups: receiving routine nursing and fake acupressure to improve constipation for 7 days during hospitalization.
89471195|NCT05612646|Experimental|acupressure|"The patients assigned to the experimental group received acupoint massage designed to improve constipation for 7 days during hospitalization. The selection of acupoints in this study includes Tianshu (double) (Tianshu, ST25: Stomach Meridian 25, the 25th point of the stomach meridian), Zhongwan (single) (Zhongwan CV12: Conception Vessel 12, the 12th point of the Ren meridian) ), Qihai Point (Single) (Qihai CV6: Meridian Vessel 6 Renmai 6th point) 3 points."
88948059|NCT01932190|Experimental|Early RRT strategy|"the early strategy : RRT is started immediately when a RIFLE F status is documented"
88948060|NCT01932190|Experimental|Delayed RRT strategy|"The delayed strategy : RRT (in patients who also present RIFLE F renal failure) is started only in case of occurrence of one or more of the Alert Criteria"
88948061|NCT01932203|Active Comparator|aspirin|aspirin 100mg by mouth once a day for 104 weeks
89471196|NCT05611021|Experimental|Walking Condition|In the walking condition, the patients will perform fifteen bouts of two minutes of treadmill walking with an interval of two minutes between bouts, at an intensity equivalent to 13-15 on Borg's subjective perceived exertion scale. The condition will have a total of sixty minutes of duration.
89471197|NCT05611021|Active Comparator|Arm-Cranking Condition|In the arm-cranking condition, the patients will perform fifteen bouts of two minutes of arm-cranking with an interval of two minutes between bouts, at an intensity equivalent to 13-15 on Borg's subjective perceived exertion scale. The condition will have a total of sixty minutes of duration.
89471198|NCT05611021|Sham Comparator|Control Condition|The control condition will consist of resting in the standing position for thirty minutes. The patients will be instructed to rest in the sitting position for two minutes at periods equivalent to the intervals from the exercise conditions, totalling sixty minutes of duration.
89471199|NCT05603286|Experimental|Home-monitoring arm|After inclusion, participants will skip one regular 3-monthly control visit and instead complete an online EQ-5D-Y-5L and JAMAR questionnaire. 5-7 months after inclusion, participants will be followed-up at the hospital and complete a questionnaire about their experiences with home-monitoring.
89471200|NCT05597202|Experimental|Treatment arm|Will receive semaglutide treatment for 6 months, at the highest tolerable dose, up to a maximum of 2.0mg weekly.
89471201|NCT05596903|Experimental|EMDR 2.0|EMDR 2.0 Online Group protocol will be administered.
89471202|NCT05596903|Active Comparator|Control|Mental Health Gap Action Programme (mhGAP) will be administered.
89471203|NCT05592912|Experimental|Low dose HydroLenz treatment|
89471204|NCT05592912|Experimental|High dose HydroLenz treatment|
88948062|NCT01932203|Experimental|Cilostazol|Pletaal SR 200mg by mouth once a day for 104 weeks
88948063|NCT01932216|Active Comparator|Single-site robotic cholecystectomy|Single-site cholecystectomy using da Vinci robotic assisted surgery
88948064|NCT01932216|Active Comparator|Multi-port laparoscopic cholecystectomy|Multi-port cholecystectomy using laparoscopic surgery
88948065|NCT01932229|Experimental|Afatinib treatment|
88948066|NCT01932255||prophylactic spinal tap|Microvascular decompression surgery approach at the Karolinska University Hospital, i.e. a small craniectomy (removal of bone without putting it back), and postoperatively serial prophylactic lumbar tap
88948067|NCT01932255||no prophylactic spinal tap|Microvascular decompression surgery approach at St Olavs Hospital Trondheim University Hospital and the University Hospital of North Norway, i.e. not comprising a policy of preventing CSF leak by performing prophylactic lumbar taps or its equivalents
88948068|NCT01932268|Experimental|Rifampicin|experimentally check a change of the colchicine concentration from baseline at 1,2,4,8,24 hours after taking Rifampicin
88948069|NCT01932281|Experimental|SierraSil|SierraSil will be given in a dosage of 3 to 5, 667 mg capsules, according to body weight, daily for 3 weeks.
88948070|NCT01932281|Placebo Comparator|Placebo|This is a sugar pill and will be given in a dosage of 3 to 5 capsules daily for 3 weeks.
88948071|NCT01932307|Experimental|PGY1 General Surgery Residents|All first year general surgery residents at the University of British Columbia
88948072|NCT01932320|Experimental|Part 1|Participants will receive single dose of all the 3 formulations of JNJ-40411813 (Formulation A: hard gelatin capsule filled with beads; Formulation B: immediate release tablet, and Formulation C: Nanosuspension formulation) without food in 3 periods (Period 1, Period 2, and Period 3). The sequences will be based on a computer-generated randomization schedule prepared by the sponsor before the study. Each period will be separated by a wash out period (no treatment) of at least 1 week.
88948073|NCT01932320|Experimental|Part 2|Participants will receive single dose of the selected solid dose formulation of JNJ-40411813 (Formulation A or Formulation B) from Part 1 without food and with food in 2 periods (Period 1 and Period 2). The sequences will be based on a computer generated randomization schedule prepared by the sponsor before the study. Each period will be separated by a wash out period of at least 1 week.
88948074|NCT01932320|Experimental|Part 3|Participants will receive single dose of the selected solid dose formulation of JNJ-40411813 (Formulation A or Formulation B) from Part 1 on two occasions (Day 1 and Day 10) without food along with ketoconazole from Day 6 to Day 14 with food.
88948075|NCT01932333|Experimental|Cohort 1|
88948076|NCT01932333|Experimental|Cohort 2|
88948077|NCT01932359|Active Comparator|rapidly absorbable suture (Vicryl Rapide)|
88948078|NCT01932359|Active Comparator|non-absorbable suture (Ethilon)|
88948079|NCT01932372||Tofacitinib (Xeljanz)|Tablets 5 mg BID
88948080|NCT01932372||Standard of Care|Standard of Care for Rheumatoid Arthritis
88948081|NCT01932385|Experimental|sorafenib|sorafenib 400mg, oral, twice a day until disease progression defined by RECIST.
88948082|NCT01932385|Active Comparator|Best Supportive Care|treatment mainly on nutrition and symptoms control
88948083|NCT01932398||ADHD|A diagnosis of ADHD, classified by the DSM-IV.
88948084|NCT01932398||no ADHD|No diagnosis of ADHD, classified by the DSM-IV.
88956494|NCT05065801|Active Comparator|FOLFIRINOX|D1, D15, D29 and D43 FOLFIRINOX: Oxaliplatin 85mg / m², Irinotecan 180mg / m², Folinic acid 400mg / m², 5-fluorouracil 400mg / m² as a bolus followed by continuous administration over 46h at 2.400mg / m² followed by 2 weeks of rest.
89471205|NCT05592912|Placebo Comparator|Control, i.e., no HydroLenz treatment|
89471206|NCT05591651|Experimental|Preparation with hyaluronic acid|Treatment of damaged nipple skin: Preparation with hyaluronic acid. The hyaluronic acid preparation will contain white vaseline and 0.2% sodium hyaluronate in a 30 g container.
89471207|NCT05591651|Experimental|Neutral Preparation without hyaluronic acid|Treatment of damaged nipple skin: Neutral preparation without hyaluronic acid. The neutral preparation will contain white vaseline only, in a 30 g container, and wiil have the same appearance and fragrance as the active preparation.
89471208|NCT05590130|Experimental|Nonin oximeter with a 90% SpO2 target|During this periods , oxygen will be administered in an manual titration with the FreeO2 device (fixed flow mode) to reach 90% of SpO2.
89471209|NCT05590130|Experimental|Philips oximeter with a 90% SpO2 target|During this periods, oxygen will be administered in a manual titration with the FreeO2 device (fixed flow mode), to reach 90% of SpO2.
89471210|NCT05590130|Experimental|Nonin oximeter with a 94% SpO2 target|During this periods , oxygen will be administered in a manual titration with the FreeO2 device (fixed flow mode) to reach 94% of SpO2.
89471211|NCT05590130|Experimental|Philips oximeter with a 94% SpO2 target|During this periods, oxygen will be administered in a manual titration with the FreeO2 device (fixed flow mode), to reach 94% of SpO2.
89471212|NCT05585502|Experimental|Training group|T2D patients and controls in the experimental group will undergo 50 telemedicine MOS sessions (15 minutes/day, 5 days/week, 10 weeks). Before the training period all subjects will participate to three different experimental sessions: during the first session a blood sample will be withdrawn and a skin biopsy will be taken; during the second session, muscle-tendon stiffness and muscle function will be evaluated; during the third session, the energy cost of walking will be determined at different speeds. After the training period and 5 weeks after the end of the training period, all subjects will repeat the second and the third sessions.
89471213|NCT05585502|No Intervention|Control group|T2D patients and controls in the control group will not perform any specific training. However, they will participate to the same three sessions as the experimental group.
89471214|NCT05585190|Other|Control|Subjects will not receive a sit/stand desk for the duration of the study and will be asked to follow their normal work day routine.
89471215|NCT05585190|Active Comparator|2-Hour Group|Sit-stand desk intervention group, subjects are asked to maintain the desk in the standing position at LEAST 2 hours each work day.
89471216|NCT05585190|Active Comparator|3-Hour Group|Sit-stand desk intervention group, subjects are asked to maintain the desk in the standing position at LEAST 3 hours each work day.
89471217|NCT05582759|Active Comparator|SH/ReadiWatchTM|Participants receive real-time feedback on sleep metrics and sleep hygiene education
89471218|NCT05582759|Experimental|teleCBT-I + SH/ReadiWatchTM|Participants receive real-time feedback on sleep metrics and sleep hygiene education plus cognitive cognitive behavioral therapy for insomnia
89471219|NCT05574504|Experimental|avelumab (PD-L1 inhibitor immunotherapy) + lurbinectedin|Phase II trial is designed to evaluate the combination of avelumab (800 mg IV every 2 weeks-(days 1,15, and 29 every 6 week cycle ) and lurbinectedin (3·2 mg/m2 lurbinectedin administered as a 1-h intravenous infusion once every 3 weeks-day 1 and 22 every 6 week cycle ) for those with stable or responding disease following 4-6 cycles of platinum-based firstline chemotherapy for mUC with stable or responding disease following 4-6 cycles of platinum-based firstline chemotherapy for mUC.
89471220|NCT05545670|Placebo Comparator|placebo|Group1: (Placebo, n=50) who will receive oral placebo tablet once daily FOR 6 MONTHS
89471221|NCT05545670|Active Comparator|allopurinol|Group 2:(Allopurinol n=50) who will receive oral allopurinol 300 mg daily for 6 months
89471222|NCT05541250|Experimental|Autologous Human Schwann Cell (ahSC) Group|Participants in this group will undergo a sural nerve biopsy followed by ahSC transplant
89471223|NCT05538858||Mechanical Ventilation|Cohort will undergo standard of care treatment utilizing a general anesthetic with mechanical ventilation for a surgical procedure.
89471224|NCT05538858||Control|Cohort will undergo standard of care treatment utilizing a regional or neuraxial anesthetic without mechanical ventilation for a surgical procedure.
89471225|NCT05529446|Experimental|intervention|This group will consist of twenty women with mild to moderate osteoarthritis suffering from pain. These women will perform strengthening exercises in addition to combination therapy 10 minutes for each session, 3 times per week, for 3 weeks.
89471226|NCT05529446|Sham Comparator|control|This group will consist of twenty women with mild to moderate osteoarthritis suffering from pain.These women will perform the same strengthening exercises as intervention group and receive sham combination therapy 10 minutes for each session, 3 times per week, for 2 weeks.
89471227|NCT05514106|Experimental|Myocardial 123I-MIBG scintigraphy imaging|Subjects with with normal neurologic functioning, REM sleep without atonia, RBD, parkinsonism, cognitive impairment, or some combination of these will undergo myocardial 123I-MIBG scintigraphy imaging
88948085|NCT01932424|Experimental|Single arm|The intervention in this study involves taking blood sample from an existing arterial line for measurement of blood propofol levels. The drug in evaluation is Propofol 2% (Diprivan 2%, Astra Zeneca UK) administered as a target controlled infusion using the commercially available paediatric TCI models (Paedfusor and Marsh models). The dose range is usually between a target concentration of 3-8 mcg/ml. However the anaesthetic management is not changed for the study. The blood concentrations of propofol will be measured using Pelorus 1500 (Sphere Medical, UK), a CE marked device. The anaesthetist will be blinded from the measurements, unless the measured value was outside the safe limit ( < 3 mcg/ml or > 10mcg/ml).
88948086|NCT01932450|Experimental|renal sympathetic denervation|One-time standard bilateral renal sympathetic denervation by catheter-based radiofrequency ablation and using antihypertensive drugs which at least include an angiotensin converting enzyme inhibitor (ACE-I) or an angiotensin II receptor blocker (ARB).
88948087|NCT01932450|Active Comparator|antihypertensive drugs|Blood pressure control in ADPKD patients with hypertension only using antihypertensive drugs which at least include an angiotensin converting enzyme inhibitor (ACE-I) or an angiotensin II receptor blocker (ARB)
88948088|NCT01932463|Experimental|ExAb;ate MRgFUS|
88948089|NCT01932476|Experimental|Celiac Disease Alone Gluten Challenge|
89471228|NCT05506085||Deep Brain Stimulation|Voice outcomes and Magnetic resonance imaging will be compared pre- and post-DBS (Deep brain stimulation) in patients with laryngeal dystonia and adductor laryngeal dystonia. The evaluators will be masked for analyzing the voice outcomes pre-and post-DBS
89471229|NCT05499767|Experimental|HEPPI|The HEPPI group attends weekly 90-minute intervention sessions at the participants' homes.
89471230|NCT05499767|No Intervention|Treatment as Usual (TAU)|The TAU group receives access to HEPPI at the end of the study.
89471231|NCT05487794|Experimental|Group 1 (T100)|
89471232|NCT05487794|No Intervention|Group 1 (T0)|
89471233|NCT05485493|Experimental|experimental group|The counseling program is 6 sessions, and it is the sessions will last 60-90 minutes on average once a week and be conducted via online video-conference applications. The first session is informing group members about emotional eating and solution-oriented approach, determining members' goals and expectations. Second session; It aims to ensure that emotions are noticed, to clarify the goals with the miracle question technique, and to focus on the solution by getting away from the problems. In the third session; Exception questions focus on recognizing exceptional situations, strengths, and skills. In the fourth session; It is aimed to discuss the existing coping methods of the group members, to recognize the useful coping methods and strengths and to increase their use. In the fifth session; focuses on designing a positive future and steps towards achieving a positive future. In the sixth session, the sessions are summarized by the group leader and members.
89471234|NCT05485493|Sham Comparator|control group|A one-session nutrition education will be given to the control group. Students will be informed about the emotional eating behavior and they will be informed about the physical exercise and nutrition regulation process. Measurements will be repeated at the end of the session and 2 weeks later.
89471235|NCT05481528|Experimental|Part 1 - Dose group 1|Single oral dose of elinzanetant or placebo.
89471236|NCT05481528|Experimental|Part 1 - Dose group 2|Single oral dose of elinzanetant or placebo
89471237|NCT05481528|Experimental|Part 1 - Dose group 3|Single oral dose of elinzanetant or placebo
89471238|NCT05481528|Experimental|Part 1 - Dose group 4|Single oral dose of elinzanetant or placebo
89471239|NCT05481528|Experimental|Part 2: Moxifloxacin - Placebo|Participants of Dose Groups 1 and 4 will receive a single dose of moxifloxacin in Period 1 and a single dose of placebo in Period 2.
89471240|NCT05481528|Experimental|Part 2: Placebo - Moxifloxacin|Participants of Dose Groups 1 and 4 will receive a single dose of placebo in Period 1 and a single dose of moxifloxacin in Period 2.
89471241|NCT05471999|Other|Patients with SBP|
89471242|NCT05457075||Case|Stage II-III rectal cancer patients who have neoadjuvant therapy
89471243|NCT05454943|Experimental|Standardized TRE protocol + External Support|Participants will be asked to follow a standardized 16:8 TRE protocol with an 11 am to 7 pm eating window for 16 weeks. Participants receive support to follow the TRE intervention from the study team which will include an initial consultation with a registered dietitian and ongoing tailored feedback via brief support calls from study staff at weeks 1, 3, 6, and 12.
88948090|NCT01932476|Sham Comparator|Celiac Disease Alone Sham Challenge|
88948091|NCT01932476|Experimental|Celiac Disease and T1D Gluten Challenge|
88948092|NCT01932476|Sham Comparator|Celiac Disease and T1D Sham Challenge|
89471244|NCT05454943|Experimental|Standardized TRE protocol + Peer Support|Participants will be asked to follow a standardized 16:8 TRE protocol with an 11 am to 7 pm eating window for 16 weeks. Each participant will be matched with another participant in the same group to provide peer-based support to adhere to TRE. Study staff will introduce pairs and provide an introduction to TRE and then pairs will meet by phone/video at weeks 1, 3, 6, and 12 at a minimum, with additional contact encouraged.
88948093|NCT01932489|Other|Sequencing of a metastatic lesion.|Biopsy of a metastatic lesion followed by a targeted cancer gene screen.
88948094|NCT01932502|Experimental|clonazepam conversion to clobazam (Onfi)|Subject's clonazepam will be converted to clobazam (Onfi). This is an open label study without placebo control.
88948095|NCT01932515|No Intervention|Screening|
88948096|NCT01932528|Experimental|500 mg LX606|All subjects will receive a single oral 500 mg dose of [14C]-LX1606.
89019130|NCT00305045|Active Comparator|High-frequency Left (HFL)|"Intensity: rTMS treatment intensity determined by using resting motor threshold (RMT). Subjects under age 65 will have treatment delivered at 100% of the RMT; those over age 65 will have treatment delivered at 120% of the RMT.~Site of Stimulation: left hemisphere of DLPFC.~Frequency: 10 Hz.~Duration: 29 - 5 second trains with 30 second inter-train interval."
89019131|NCT00305045|Active Comparator|Bilateral|"Intensity: rTMS treatment intensity determined by using resting motor threshold (RMT). Subjects under age 65 will have treatment delivered at 100% of the RMT; those over age 65 will have treatment delivered at 120% of the RMT.~Sites of Stimulation: right and left hemispheres of the DLPFC.~Frequency: 1 Hz over the right DLPFC followed by 10 Hz over the left DLPFC.~Duration: i) low-frequency right: 4 trains of 100 second duration and one train of 65 second duration, with a 30 second inter-train interval, followed by ii) HFL: 15 - 5 second trains with 30 second inter-train interval."
89019132|NCT00305045|Sham Comparator|Sham Stimulation|Stimulation will occur over the site of active treatment, but with only the side-edge resting on the scalp. It will be administered as HFL for 17 minutes, with the coil angled 45 degrees away from the skull in a single-wing tilt position. This method produces sound and some somatic sensation (e.g., contraction of scalp muscles) similar to those of active stimulation, but with minimal direct brain effects.
89471245|NCT05454943|Experimental|Personalized TRE protocol + External Support|Participants will be asked to follow TRE for 16 weeks with a protocol that is personalized to their preferences within the following pre-specified rules: 1) 8-10 hour eating window; 2) self-selected eating window start time as long as it ends ≥3h before bedtime; 3) if days off are required, aim to do so after following TRE for ≥5 successive days each week. Participants receive support to follow the TRE intervention from the study team which will include an initial consultation with a registered dietitian and ongoing tailored feedback via brief support calls from study staff at weeks 1, 3, 6, and 12.
89471246|NCT05454943|Experimental|Personalized TRE protocol + Peer Support|Participants will be asked to follow TRE for 16 weeks with a protocol that is personalized to their preferences within the following pre-specified rules: 1) 8-10 hour eating window; 2) self-selected eating window start time as long as it ends ≥3h before bedtime; 3) if days off are required, aim to do so after following TRE for ≥5 successive days each week. Each participant will be matched with another participant in the same group to provide peer-based support to adhere to TRE. Study staff will introduce pairs and provide an introduction to TRE and then pairs will meet by phone/video at weeks 1, 3, 6, and 12 at a minimum, with additional contact encouraged.
89471247|NCT05454943|No Intervention|Control Group|Participants will be asked to maintain their usual diet and physical activity patterns for 16 weeks. They will receive the same number and timing of calls from study staff as the other groups (at randomization, 1, 3, 6, 12 weeks).
89471248|NCT05454020|Experimental|A (XG004)|XG004 in two dose level (5% or 10%) will be applied to the targeted knee
88948097|NCT01932541|Experimental|Latuda (Lurasidone)|
88948098|NCT01932554|Experimental|Abciximab|"Abciximab will be administered as initial bolus of dose of 0.25 mg/kg, delivered via syringe pump over 15 minutes, followed by a continuous infusion of 0.125 microgram/kg/min (max of 10 micrograms/min) infused over the next 12 hours. Infusion to start within 16 hours of admission.~Patients will receive standard supportive care, including intravenous hydration, supplemental oxygen, incentive spirometry, ibuprofen, and parenteral narcotic pain medications (morphine, hydromorphone or fentanyl)"
89019133|NCT00305123||1|12,000 children 5 to 16 years of age attending the 4 public elementary schools in Djikoroni-para-Sébénikoro, Bamako, Mali.
89019134|NCT00305279|Active Comparator|1|
89019135|NCT00305279|Active Comparator|2|
89019136|NCT00305279|Active Comparator|3|
89019137|NCT00332904|Active Comparator|beta|patients with liver cirrhosis, treated with betablocker
89471249|NCT05454020|Placebo Comparator|B (Placebo)|Placebo in all cohorts will be applied to the targeted knee.
89471250|NCT05446792|Active Comparator|Pelvic floor muscle training (PFMT)|For the intervention of the PFMT group, which is non-invasive, a physical therapist experienced in this type of training will carry out the sessions, which will be individualized, in a specific room for care ocused on pelvic physiotherapy, with a stretcher, air conditioning and a lock on the door, for the patient to feel safe.
89471251|NCT05446792|Experimental|Pilates exercises (PE)|For the intervention of the PE group, in the first week the protocol will be used to familiarize the participants with the exercises, where the correct execution of the movements will be demonstrated and each principle of the method will be explained: concentration, centralization, precision, breathing, control and fluidity; and for familiarization with the correct voluntary contraction of the PFM. Participants in the PE group will be instructed and reminded to voluntarily contract the PFM during each repetition of the Pilates strengthening exercises. During the stretching exercises, the participant will be instructed not to perform the contraction. The springs will be changed according to the evolution of the participants, by replacing them with a spring of greater resistance. Basic equipment such as: Cadillac Trapezio, Combo Chair, Universal Reformer, Ladder Barrel and Wall Unit will be used.
89471252|NCT05445505|Active Comparator|Early-start single iTBS group|The intensive period: 2 weeks The maintenance period: 12 weeks
89019138|NCT00332904|Active Comparator|spiron|patients with liver cirrhosis, treated with aldosterone antagonist
89471253|NCT05445505|Active Comparator|Early-start double iTBS group|The intensive period: 2 weeks The maintenance period: 12 weeks
89471254|NCT05445505|Sham Comparator|Delayed-start single iTBS group|The intensive period: sham/iTBS, 2 weeks The maintenance period: daily sham/iTBS, 12 weeks
89471255|NCT05445505|Sham Comparator|Delayed-start double iTBS group|The intensive period: sham/iTBS, 2 weeks The maintenance period: twice daily sham/iTBS, 12 weeks
89471256|NCT05441722|Experimental|Exercise|"Participants will be invited to perform a bout of supervised moderate-intensity aerobic exercise. Patients receiving chemotherapy with sequential anthracycline-docetaxel will be offered the exercise before each docetaxel-containing infusion, whilst patients receiving weekly paclitaxel will perform the exercise every three weeks during treatment. Each session will comprise of moderate-intensity aerobic exercise on a cycle ergometer. Participants will perform a 5 to 10-minute warm-up.~Participants will then complete a 30-minute bout at 13-14 RPE whilst. This corresponds to a qualitative description of somewhat hard and equates to approximately 60% age-predicted heart rate reserve. Heart rate will be monitored continuously with a Polar heart rate monitor and RPE will be collected every 5-minutes. The resistance on the bike will be reduced if heart rate reserve is > 65% or RPE is > 14 on the 6-20 Borg scale. Each session will finish with a 5 min cool-down at low-intensity (≤ 11 RPE)."
89471257|NCT05441722|No Intervention|Control|"Participants allocated to this group will not receive a specific exercise intervention, but will be given a leaflet that provides general physical activity recommendations for cancer patients.~Recommendations will be based on published guidelines from the American College of Sports Medicine and American Cancer Society."
88948099|NCT01932554|Placebo Comparator|Placebo|"Inactive placebo will be administered as initial bolus followed by a continuous infusion over the next 12 hours, in syringes and volumes identical with the drug administered in the experimental arm. Infusion to begin within 16 hours of admission.~Patients will receive standard supportive care, including intravenous hydration, supplemental oxygen, incentive spirometry, ibuprofen, and parenteral narcotic pain medications (morphine, hydromorphone or fentanyl)"
88948100|NCT01932567|Experimental|Positive expiratory pressure|Use of positive expiratory pressure during 3 minutes
89471258|NCT05434728||Hypermobile EDS|Individuals with a confirmed diagnosis of hypermobile EDS
89471259|NCT05434728||Classical EDS|Individuals with a confirmed diagnosis of classical EDS
89471260|NCT05434728||Vascular EDS|Individuals with a confirmed diagnosis of vascular EDS
89471261|NCT05432765|Active Comparator|Physician Dosing|Subjects will continue per SOC, where the management of their immunosuppression regimen will be determined by their physician per center practices, including dd-cfDNA data.
89471262|NCT05432765|Experimental|PPM Dosing|Subjects will have dd-cfDNA data analyzed by PPM. Data, such as drug levels and regimens, will be used to fit a 2nd order polynomial for each patient to build patient-specific dose-response profiles with covariates that include the administered drugs tacrolimus, steroids, and MMF/MPA. PPM will be used to derive an optimal combination of tacrolimus, MMF/MPA, and prednisone to achieve minimal renal allograft injury, while staying within the therapeutic range of the medications. All else being equal, the most efficacious combination with the lowest dose of tacrolimus will be utilized.
89471263|NCT05431634|Placebo Comparator|Placebo|Placebo for ESK-001
89471264|NCT05431634|Experimental|Experimental Drug ESK-001|Experimental Drug ESK-001
89471265|NCT05417321|Experimental|HB0036|HB0036 IV every 3 weeks (q3w)
88948101|NCT01932567|Experimental|Incentive spirometry|Use of incentive spirometry during 3 minutes
88948102|NCT01932567|Experimental|manual airway clearance technique|Use of manual airway clearance technique during 3 minutes
88948103|NCT01932580|Other|FLOT chemotherapy|"Chemotherapy to be administered every 2 weeks for 4 cycles, before surgery. Then 4 more cycles will be given after surgery, at 2-week intervals.~5-FU 2600 mg IV/m2 in continuous infusion Leucovorin 200 mg IV/m2 Oxaliplatin 85 mg IV/m2 Docetaxel 50 mg IV/m2"
88948104|NCT01932593|Experimental|Infusion of autologous bone marrow|Bone marrow harvest under general anaesthetic and intravenous infusion of filtered but otherwise unselected autologous bone marrow
88948105|NCT01932593|Placebo Comparator|Placebo|
88948106|NCT01932632|No Intervention|Usual Care|This group will receive care as similar as possible to care that they received prior to the study beginning. Their attending MDs will be instructed and reminded to avoid making parallel changes in the prescribing for the control patients unless there is a specific medical indication to which they would normally respond with a medication reduction. No other reminders or prompts about the study will be provided for these patients.
89471266|NCT05413863|Experimental|Sequence: Biocon's Human Insulin R U-500-Biocon's Human Insulin R U-500- Humulin® R U-500|"Period 1:Biocon's Human Insulin R U-500 single subcutaneous dose of 0.3 IU/kg using a U-500 BD (Becton Dickinson) disposable syringe~Period 2:Biocon's Human Insulin R U-500 single subcutaneous dose of 0.3 IU/kg using a U-500 BD (Becton Dickinson) disposable syringe~Period 3:Humulin® R U-500 single subcutaneous dose of 0.3 IU/kg using a U-500 BD (Becton Dickinson) disposable syringe"
89019139|NCT00332904|No Intervention|control|patients with liver cirrhosis, no treatment
89019140|NCT00305435|Experimental|romiplostim (AMG-531)|
89471267|NCT05413863|Experimental|Sequence: Biocon's Human Insulin R U-500-Humulin® R U-500- Humulin® R U-500|"Period 1:Biocon's Human Insulin R U-500 single subcutaneous dose of 0.3 IU/kg using a U-500 BD (Becton Dickinson) disposable syringe~Period 2:Humulin® R U-500 single subcutaneous dose of 0.3 IU/kg using a U-500 BD (Becton Dickinson) disposable syringe~Period 3:Humulin® R U-500 single subcutaneous dose of 0.3 IU/kg using a U-500 BD (Becton Dickinson) disposable syringe"
89471268|NCT05413863|Experimental|Sequence: Biocon's Human Insulin R U-500-Humulin® R U-500-Biocon's Human Insulin R U-500|"Period 1:Biocon's Human Insulin R U-500 single subcutaneous dose of 0.3 IU/kg using a U-500 BD (Becton Dickinson) disposable syringe~Period 2:Humulin® R U-500 single subcutaneous dose of 0.3 IU/kg using a U-500 BD (Becton Dickinson) disposable syringe~Period 3:Biocon's Human Insulin R U-500 single subcutaneous dose of 0.3 IU/kg using a U-500 BD (Becton Dickinson) disposable syringe"
89471269|NCT05413863|Experimental|Sequence: Humulin® R U-500-Biocon's Human Insulin R U-500-Biocon's Human Insulin R U-500|"Period 1:Humulin® R U-500 single subcutaneous dose of 0.3 IU/kg using a U-500 BD (Becton Dickinson) disposable syringe~Period 2:Biocon's Human Insulin R U-500 single subcutaneous dose of 0.3 IU/kg using a U-500 BD (Becton Dickinson) disposable syringe~Period 3:Biocon's Human Insulin R U-500 single subcutaneous dose of 0.3 IU/kg using a U-500 BD (Becton Dickinson) disposable syringe"
89471270|NCT05413863|Experimental|Sequence: Humulin® R U-500 -Biocon's Human Insulin R U-500-Humulin® R U-500|"Period 1:Humulin® R U-500 single subcutaneous dose of 0.3 IU/kg using a U-500 BD (Becton Dickinson) disposable syringe~Period 2:Biocon's Human Insulin R U-500 single subcutaneous dose of 0.3 IU/kg using a U-500 BD (Becton Dickinson) disposable syringe~Period 3:Humulin® R U-500 single subcutaneous dose of 0.3 IU/kg using a U-500 BD (Becton Dickinson) disposable syringe"
89471271|NCT05413863|Experimental|Sequence: Humulin® R U-500-Humulin® R U-500-Biocon's Human Insulin R U-500|"Period 1:Humulin® R U-500 single subcutaneous dose of 0.3 IU/kg using a U-500 BD (Becton Dickinson) disposable syringe~Period 2:Humulin® R U-500 single subcutaneous dose of 0.3 IU/kg using a U-500 BD(Becton Dickinson) disposable syringe~Period 3:Biocon's Human Insulin R U-500 single subcutaneous dose of 0.3 IU/kg using a U-500 BD (Becton Dickinson) disposable syringe"
89471272|NCT05389865||Surgical cohort|Adult patients (18 years of age and above) who have had a surgical intervention on the proximal aorta in the three Scottish Cardiothoracic Surgery units based in Glasgow, Edinburgh, Aberdeen.
89471273|NCT05389865||Non-surgical cohort|"- Adult patients (18 years of age and above) who have a diagnosis of proximal aortopathy, but have not had surgical intervention (non-surgical/un-intervened proximal aortopathy). This cohort will be obtained from three sources:~Scottish national radiological database based on specific imaging codes~Regional genetic/inherited cardiac conditions services~Public Health Scotland via specific diagnostic ICD-10 codes."
89471274|NCT05389085|Other|Prospective non-blinded clinical study|All patients enrolled with with suspicious pigmented skin tumours will be scanned with reflectance confocal microscopy and photoacoustic imaging by an experienced examiner in a 30 minutes to 1-hour session. Subsequently, material for RNA and lipid analysis is obtained from tape-stripped lesional skin at the bedside. The skin tumors in patients enrolled will subsequently be treated according to hospital and national guidelines.
89471275|NCT05381467|Active Comparator|immediate implant placement with The Dual-Zone Therapeutic Concept|
89471276|NCT05381467|Experimental|Immediate implant placement with the bone shielding concept|
89531855|NCT05077254|Experimental|Pfizer-BioNTech COVID-19 Vaccine 2023-2024 + SOC IS Regimen|"Participants will receive a study dose (1 dose) of the Pfizer-BioNTech COVID-19 Vaccine 2023-2024 and will continue to take their standard of care transplant immunosuppressive medications without alterations in schedule and dosing.~SOC IS: Standard of Care transplant immunosuppression regimen"
88948107|NCT01932632|Experimental|Medication Minimization|"Initial Medication Review (IMR) Completed by Attending MD and identifies potential medications to be considered for minimization as well as those UNSUITABLE (as per usual MD opinion)~Orders-Medication Update (OMU) (ref form) The attending MD will have identified one or more medications to be considered for minimization and in the IMR suggested a time when a reduced dose will be reviewed (recommended every 4 weeks). Each review will generate an OMU. This process will be repeated for every participant in the Medication Minimization arm until all medications are marked as having no further changes, ie no need for further OMU. At that time a participant's record will be marked as having completed medication minimization."
88948108|NCT01932658|Experimental|Hematopoietic stem cell transplantation|Lymphoablation followed by autologous hematopoietic stem cell transplantation rescue.
88948109|NCT01932671||SMART|The SMART (Second Manifestation of ARTerial disease) cohort comprises patients at high-risk for or who have clinically manifest cardiovascular disease, including transient ischemic attack, cerebrovascular disease, peripheral artery disease, aneurysma aorta abdominalis, myocardial infarction, coronary ischemia for which coronary intervention is required, renal artery stenosis, diabetes mellitus, hyperlipidemia, hypertension, patients diagnosed with human immunodeficiency virus, pre-eclampsia, HELLP syndrome, abruption placentae and Intrauterine growth restriction in medical history. Participants are re-invited after 4 years for a second screening. This screening is performed to study the progression of atherosclerosis and evaluate the effects of the advice of the multidisciplinary team.
88948110|NCT01932684|Experimental|Incentive spirometry|Was utilized an incentive spirometer volume in this group.
88948111|NCT01932684|No Intervention|Control Group|
88948112|NCT01932684|Experimental|Breath Stacking|We used a face mask silicone connected to a check valve allowing only inspiration and is connected to a spirometer showed that the volume inspired by the individual.
88948113|NCT01932710|Experimental|White Blood Cell Transfusion|Patient receives white blood cells by vein from a volunteer donor. Each transfusion will take anywhere from 1 hour to several hours, depending on how treatment is tolerated. Patient receives a transfusion every 3-4 days (at least 2 a week) for up to 6 weeks.
88948114|NCT01932723|Experimental|Lumbar Stabilization Exercises & Control|Lumbar stabilization exercises daily, 10 repetitions each (three times a day) for three months consecutively. All exercises were performed to a count of 7 seconds.
88948115|NCT01932736|Experimental|healthy volunteers|healthy volunteers undergo pressure changes in ear canal
88948116|NCT01932749|Active Comparator|bilateral repetitive transcranial magnetic stimulation|"Bilateral protocol:~Motor threshold 100% /LDLPFC/10Hz/5 second duration/10 second intertrain/ Motor threshold 120% /RDLPFC/1Hz/10 second duration/2second intertrain/"
88948117|NCT01932749|Active Comparator|unilateral repetitive transcranial magnetic stimulation|"Unilateral protocol:~Motor threshold 120% /RDLPFC/1Hz/10 second duration/2second intertrain"
89471277|NCT05374499|Experimental|Liposomal bupivacaine|A double-blinded randomization process will be used to preoperatively assign patient's left or right side to receive either Exparel (Liposomal bupivacaine) (39.9 mg/3 mL) or standard bupivacaine (5 mg/mL). At the end of the mandibular third molar extraction surgical procedure and at least twenty minutes following the most recent administration of 2% lidocaine with 1:100,000 epinephrine (routine for this procedure), all patients will receive one side of their mandibular infiltrations with 3mL of 1.3% liposomal bupivacaine (Exparel).
89471278|NCT05374499|Active Comparator|0.5% bupivacaine with 1:200,000 epinephrine|A double-blinded randomization process will be used to preoperatively assign patient's left or right side to receive either Exparel (Liposomal bupivacaine) (39.9 mg/3 mL) or standard bupivacaine (5 mg/mL). At the end of the procedure and at least twenty minutes following the most recent administration of 2% lidocaine with 1:100,000 epinephrine (routine for this procedure), all patients will receive one side of their mandibular infiltrations with 3mL of diluted 0.5% bupivacaine with 1:200,000 epinephrine.
89471279|NCT05363527|Experimental|Endotoxin|Endotoxin 0.8 ng/kg body weight
89471280|NCT05363527|Placebo Comparator|Placebo|same volume of 0.9% saline
89471281|NCT05362721||Pressure-volume loop catheter|
89471282|NCT05358340|Experimental|Diagnostic (DSC MRI)|
89471283|NCT05357690|Experimental|Stellate ganglion block with local anesthetic|Subjects will receive a single injection of bupivacaine in a stellate ganglion block
89471284|NCT05357690|Sham Comparator|Stellate ganglion block with saline placebo|Subjects will receive a single injection of saline in a stellate ganglion block
89471285|NCT05356533|Active Comparator|Intervention|A total of 60 young adults will be randomized to the 4-week, web-based drinking to cope intervention.
89471286|NCT05356533|No Intervention|Assessment Control|A total of 60 young adults will be randomized to the assessment only control condition.
89471287|NCT05354882|Experimental|Intervention|Feasibility group. Single group (intervention group) will be given access to the DEFACTO intervention for twelve-weeks.
89471288|NCT05351216||Cases|Individuals diagnosed with KHE and treated with sirolimus. After immunoglobulin and flow cytometry assays, as well as outpatient evaluation and assessment, those participants will be vaccinated with live attenuated vaccines or inactivated vaccines in a timely order according to the advice. （Sirolimus Rapamycin 0.8mg/m2 bid po）
89471289|NCT05351216||Controls|Healthy children with no immunodeficiency disease, vaccinated according to the National Immunization Program. Particpants should be age-matched with the case group.
89471290|NCT05344352|Active Comparator|Mutistrain probiotic|
89471291|NCT05344352|Placebo Comparator|Placebo|
89471292|NCT05341154|Active Comparator|Ketamine group|"An anesthesiologist who is not involved in the study will prepare the intervention, ketamine1 mg/kg BW, in a standardized syringe with the same volume. Patients will be given the active comparator or placebo only once right before the induction of anesthesia.~All patients will be received standardized GA protocol as follows:~Induction with propofol (1-2 mg/kg body weight).~Esmeron (1 mg/kg body weight).~Isoflurane is a volatile anesthetic agent in 50% O2 and air.~Fentanyl (1 microgram/kg body weight) during induction of anesthesia and the total doses of fentanyl used during the operation will be recorded.~All patients received a combination of intravenous paracetamol 1 g and ketorolac 30 mg at the conclusion of surgery. This regimen will be repeated regularly every 8 h."
89471293|NCT05341154|Active Comparator|Dexmedetomidine group|"An anesthesiologist who is not involved in the study will prepare the intervention, Dexmedetomidine 1 μg/kg BW, in a standardized syringe with the same volume. Patients will be given the active comparator or placebo only once right before the induction of anesthesia.~All patients will be received standardized GA protocol as follows:~Induction with propofol (1-2 mg/kg body weight).~Esmeron (1 mg/kg body weight).~Isoflurane is a volatile anesthetic agent in 50% O2 and air.~Fentanyl (1 microgram/kg body weight) during induction of anesthesia and the total doses of fentanyl used during the operation will be recorded.~All patients received a combination of intravenous paracetamol 1 g and ketorolac 30 mg at the conclusion of surgery. This regimen will be repeated regularly every 8 h."
89471294|NCT05341154|Placebo Comparator|Placebo group|"An anesthesiologist who is not involved in the study will prepare the intervention, normal saline 0.9% in a standardized syringe with the same volume. Patients will be given the active comparator or placebo only once right before the induction of anesthesia.~All patients will be received standardized GA protocol as follows:~Induction with propofol (1-2 mg/kg body weight).~Esmeron (1 mg/kg body weight).~Isoflurane is a volatile anesthetic agent in 50% O2 and air.~Fentanyl (1 microgram/kg body weight) during induction of anesthesia and the total doses of fentanyl used during the operation will be recorded.~All patients received a combination of intravenous paracetamol 1 g and ketorolac 30 mg at the conclusion of surgery. This regimen will be repeated regularly every 8 h."
89471295|NCT05339061|Experimental|Physician-Modified Endograft|This is a single arm study used to evaluate the safety and effectiveness of fenestrated and branched techniques for the treatment of patients with a complex, juxtarenal, pararenal or thoracoabdominal abdominal aortic aneurysms (Extent I-V).
89471296|NCT05331599||Currently Depressed Participants|Individuals who are currently depressed and receive treatment through an antidepressant treatment
89471297|NCT05331599||Remitted Depressed Participants|Individuals who have achieved remission from depression within 4 months
89471298|NCT05331599||Remitted Depressed Elders|Individuals who no lifetime history of depression
89471299|NCT05331170|Active Comparator|Healthy|Subjects without asthma, COPD, rhinitis and with negative allergen test
89471300|NCT05331170|Active Comparator|Allergic Rhinitis|Subjects without asthma, COPD and with positive allergen test
89471301|NCT05331170|Active Comparator|Allergic Ashthma|Subjects with asthma and positive allergen test
89471302|NCT05330858|Experimental|ESK-001 Liquid|ESK-001 administered as an oral liquid
89471303|NCT05330858|Experimental|ESK-001 Tablet Fasted|ESK-001 administered as an oral tablet in the fasted state
89471304|NCT05330858|Experimental|ESK-001 Tablet Fed|ESK-001 administered as an oral tablet in the fed state
88948118|NCT01932775|Experimental|GlucoTab System|
88948119|NCT01932814||Aminoglycosides|have received aminoglycosides
88948120|NCT01932814||No Aminoglycosides|did not receive aminoglycosides
89471305|NCT05330858|Experimental|ESK-001 and Rabeprazole|ESK-001 administered as an oral tablet with rabeprazole
89471306|NCT05329389|Experimental|StoneMD|"Patients will receive standard recommendations of keeping diuresis at the level of 2.5 l/day and to use the StoneMD application on their smartphones after the surgery. Patients will use the section Water balance and follow the instructions during the 12 month after the surgery."
89471307|NCT05329389|Experimental|StoneMD & Schools of Patients|"Patients will receive standard recommendations of keeping diuresis at the level of 2.5 l/day and and recommendations to use the StoneMD application on their smartphones after the surgery. Patients will use the section Water balance and follow the instructions during the 12 month after the surgery. Additionally, patients will visit schools during a following year. Patients receive 4 consultations (one per 3 month)."
89471308|NCT05329389|Active Comparator|Recommendations only|Only fluid balance recommendations given at the day of discharge. Patients will receive recommendations of keeping diuresis at the level of 2.5 l/day after the surgery
89471309|NCT05328102|Experimental|Part 1|Drug: plamotamab administered at protocol defined dose in addition to tafasitamab (12 mg/kg intravenously) plus lenalidomide (25mg p.o.)
89471310|NCT05328102|Experimental|Part 2|Drug: plamotamab administered at protocol defined dose in addition to tafasitamab (12 mg/kg intravenously) plus lenalidomide 25mg (p.o.)
89471311|NCT05328102|Active Comparator|Part 2B|Drug: tafasitamab (12 mg/kg intravenously) plus lenalidomide 25mg (p.o.)
89471312|NCT05323344|Active Comparator|Neuro-physiotherapy|In intervention group I, patients will receive a one hour session of special Neuro-physiotherapy (NPT) twice per week with a total of 20 sessions over 10 weeks. In addition, patients will be instructed to a home-based training, so that they continue their training in between sessions and after completion of the 10 weeks intervention. NPT is designed to target the abnormal movements. It is based on previously established consensus recommendations and feasibility for a short (5 days) intervention was already tested. Adapted from Nielsen et al., each of our NPT sessions will include patient education, movement retraining and development of a self-management plan.
89471313|NCT05323344|Active Comparator|Combination of metacognitive therapy and Neuro-physiotherapy|In intervention group II, patients will be treated for 10 weeks by a combination of Metacognitive behavioral therapy (MCT) and Neuro-physiotherapy (NPT) (1 hour MCT and 1 hour NPT per week with a total of 20 treatment sessions over 10 weeks). The key feature during MCT sessions will be based on an attention training technique (ATT), which prevents or interrupts self-focused attention and reduces the overall level of preoccupation with the FMD. Patients will receive at least three competing sounds. Patients will be asked to practice the training with their eyes open and focused on a visual fixation point. Patients' self-reliance will be strengthened by an individualized cognitive self-training explained and practiced with the MCT therapist including an audio tape of the ATT training. This should be continued daily at home in between sessions and after completion of the 10 weeks intervention. Self-training will be documented in a daily training diary.
89471314|NCT05322785|Other|Single Visit breath collection|"Following informed consent, exhaled breath will be passively collected from subjects during quiet oral breathing through a simple mouthpiece or mask. Exhaled breath will be diverted into a collection device, which may include a bag, tube, or other device with minimal resistance. The collection process, including completing forms, will not exceed 30 minutes.~At no time will the patients be breathing anything other than ambient air with or without oxygen enrichment as clinically indicated. Inhaled air will not be manipulated."
89471315|NCT05317676|Active Comparator|Palmitoylethanolamide|300 mg PEA twice a day for a total of 600 mg PEA daily 2-month supply upon discharge
89471316|NCT05317676|Placebo Comparator|Placebo|1 placebo tablet twice a day for a total of 2 tablet placebo daily 2-month supply upon discharge
89471317|NCT05316259|Experimental|Group A（Dosing in the fasted state followed by fed dosing）|Dosing in the fasted state followed by fed dosing.A washout period of 14 days will be maintained between the 2 treatment periods.
89471318|NCT05316259|Experimental|Group B（Dosing in the fed state followed by fasted dosing）|Dosing in the fed state followed by fasted dosing.A washout period of 14 days will be maintained between the 2 treatment periods.
89471319|NCT05313815|Experimental|Moderate Hypofracitonated Boost to the Prostate with Pelvic Radiation Therapy|External beam radiotherapy- 60 Gy in 20 fractions to the prostate, 48 Gy in 20 fractions to the pelvis, 68 Gy in 20 fraction optional boost to prostatic dominant intraprostatic lesion, 55 Gy in 20 fraction optional boost to involved pelvic lymph nodes
89471320|NCT05312268|Other|Group A|Rasburicase treatment at week 1, 4 and 8 with stable dose oral urate-lowering therapy for 24 weeks.
89471321|NCT05312268|Other|Group B|Rasburicase treatment at week 12, 16 and 20 with stable dose oral urate-lowering therapy for 24 weeks.
89471322|NCT05311735|Other|Freeze-Dried Bone Allograft Control|-Control group (FDBA): extracted teeth will be discarded and sites will be grafted with FDBA.
88948121|NCT01932827||Canadian Consumer Monitor Panel|Canadian Consumer Monitor Panel is a online consumer monitor panel which answers surveys every 8-10 weeks about diet and health.
88948122|NCT01932840||Canadian Consumer Monitor Panel|Canadian Consumer Monitor Panel is an online panel which answer surveys every 8-10 weeks about diet and health
88948123|NCT01932853||Hemodialysis patients|Patients > 18y hemodialysis for at least 6 months at any center of Spain Fresenius Medical Care (FMC) meeting the inclusion criteria.
88948124|NCT01932866|Active Comparator|Control - diabetes risk score|the participants in the control group did not receive their diabetes risk score at the beginning of the trial, but did receive their scores to include baseline at the 12 and 24 week points.
88948125|NCT01932866|Experimental|Intervention - diabetes risk score|the subjects in the intervention arm received their diabetes risk scores at the beginning of the trial, 12 weeks and 24 weeks.
88948126|NCT01932892||Transhumeral prosthesis user|Transhumeral body-powered prosthesis user
88948127|NCT01932905|Active Comparator|deep rTMS-active doble coil|patients undergoing of deep rTMS real with doble coil
88948128|NCT01932905|Sham Comparator|deep rTMS-sham|patients undergoing to placebo deep rTMS
88948129|NCT01932905|Active Comparator|deep rTMS-active: H-coil|patients undergoing of deep rTMS real with H-coil
88948130|NCT01932918||PCA with morphine in liver transplant|Intravenous patient controlled analgesia with morphine was used for postoperative pain control in liver transplant recipients.
89019141|NCT00329472|Experimental|Gem/Cis|neoadjuvant chemotherapy: gemcitabine 1250mg/m2 D1,D8 & cisplatin 70mg/m2 , 2 cycles
89537385|NCT02465801|Experimental|Group 1|"Intervention: HSA-GCSF 1.2 mg~Drug: TE or TEC TE: Taxotere+Epirubicin Taxotere (75mg/m2) and Epirubicin (75mg/m2), IV on day 1 of each 21 chemotherapy cycle.~TEC:Taxotere+Epirubicin+Cyclophosphamide Taxotere (75mg/m2),Epirubicin (75mg/m2) and Cyclophosphamide (500mg/m2), IV on day 1 of each 21 chemotherapy cycle.~Recombinant Human Serum Albumin/Granulocyte Colony-Stimulating Factor Fusion Protein（1.2mg）will be injected subcutaneously at night o'clock a.m. in the 3rd and 7th day of per chemotherapy cycle. After the injection, stop administrating if Absolute Neutrophil Count (ANC) in peripheral blood exceeded 1.5×109/L at two contiguous times at least. If not up to standard, investigator should decide whether or not the third administration."
88948131|NCT01932918||PCA with ketorolac in liver transplant|Patient controlled analgesia with morphine and ketorolac was used for postoperative pain control in liver transplant and thoracic surgery patients.
88948132|NCT01932918||Intravenous PCA in thoracic surgery|Intravenous patient controlled analgesia was used for postoperative pain control in thoracic surgery patients.
88948133|NCT01932918||PCEA in thoracic surgery|Patient controlled epidural analgesia was used for postoperative pain control in thoracic surgery patients.
88948134|NCT01932931|Active Comparator|Cholecalciferol supplement (50ug)|Cholecalciferol supplement is given for 1 year through randomisation of both MDD patients and healthy controls.
88948135|NCT01932931|Placebo Comparator|Placebo|Placebo treatment (tablet) is given for 1 year through randomisation of both MDD patients and healthy controls.
88948136|NCT01932944||No treatment|
88948137|NCT01932957|Other|Laparotomy arm|Standard treatment
88948138|NCT01932957|Experimental|Laparoscopy arm|Treatment by laparoscopy
88948139|NCT01932983||TOF test|TOF - train of four test performed on patiens undergoing lumbar spine surgery where introperative neurophysiologic monitoring is applied. Stimulation of peripheral nerve - ulnar nerve resulting with muscle contractions and evaluation of responses by anesthesiologist and neurophysiologists. Stimulation with group of 0.2 millisecond pulses, spaced 500 millisecond apart, at a 2 Hz rate, current 20-60 mA to deliver four muscle contractions. Eligibility criteria included patients for study where subjective visual interpretation and quantitative interpretation of Adductor pollicis muscle responses is followed.
88948140|NCT01933022|Other|Single Arm: Eligard|Single Arm
88948141|NCT01933035||Immune Thrombocytopenics|The study shall be a single institution prospective cohort study. Comparison will be made among individuals with known ITP . Those with known hypo-proliferative forms of thrombocytopenia [aplastic anaemia, chemotherapy induced thrombocytopenia, and myelodysplastic thrombocytopenia, and a control population.
88948142|NCT01933035||Hypo-proliferative thrombocytopenics|The study shall be a single institution prospective cohort study. Comparison will be made between individuals with known ITP versus those with known hypo-proliferative forms of thrombocytopenia [aplastic anaemia, chemotherapy--induced thrombocytopenia, and myelodysplastic thrombocytopenia], and a control population.
88948143|NCT01933035||Control Pupulation|comprised of healthy individuals with normal platelet counts, to confirm normal values for MPC and MPM
88948144|NCT01933061|Experimental|Abraxane 150 mg/m² Intravenous (IV)|
88948145|NCT01933061|Experimental|CC-486 orally plus Abraxane IV|
88948146|NCT01933087|No Intervention|Control with no hand hygiene promotion|no implementation of hand hygiene promotion
88948147|NCT01933087|Experimental|Hand hygiene promotion|Intervention to promote hand hygiene which is based on the WHO multimodal hand hygiene improvement strategy.
88948148|NCT01933100|Experimental|Brown Rice Based-Meal|Macronutrient composition of experimental diet were carbohydrate 55~70%, protein 7~20%, fat 15~25%, fiber provided by the experimental diet was designed to adequate intake 20g/day for women
88948149|NCT01933100|Experimental|Polished Rice Based-Meal|Macronutrient composition of experimental diet were carbohydrate 55~70%, protein 7~20%, fat 15~25%, fiber provided by the experimental diet was designed to adequate intake 20g/day for women
88948150|NCT01933100|Experimental|Wheat Based-Meal|Macronutrient composition of experimental diet were carbohydrate 55~70%, protein 7~20%, fat 15~25%, fiber provided by the experimental diet was designed to adequate intake 20g/day for women
88948151|NCT01933126|Experimental|HCG administration|Intrauterine HCG injection
88948152|NCT01933126|Placebo Comparator|Placebo|G2 Medium
88948153|NCT01933139|Experimental|Audio-visual presentation|The intervention group will watch a 10-minute scripted video explaining the procedure, risks, benefits, expectations, and long term complications that relate to hysterectomies before face-to-face interaction with the surgeon. Patients in both arms will then sign the same standard pre-surgical informed consent form before undergoing the procedure.
88948154|NCT01933139|No Intervention|Control|standard physician interaction (control arm)
88948155|NCT01933152||Group 1|
88948156|NCT01933165|Other|LipiView|
88948157|NCT01933178|Other|Cirrus AS-OCT|
88948158|NCT01933191|Experimental|physical acticity|Experimental: Aerobic treadmill exercise (30 minutes, 70% VO2max)
88948159|NCT01933191|Placebo Comparator|placebo exercise|Aerobic treadmill exercise (30 minutes, 20% VO2max)
88948160|NCT01933204|Experimental|Acupuncture|Using basic points combined with additional points. Basic points are fixed, while additional points will be selected from a list of points categorized by syndrome differentiation.
88948161|NCT01933204|Active Comparator|Climen 21 Tablets|COMPOSITION 11 white tablets each containing estradiol-17-valerate 2 mg, plus 10 pink tablets each containing estradiol-17-valerate 2 mg and cyproterone acetate 1 mg.
88948162|NCT01933256|Experimental|600mg HIP2B|600mg HIP2B
88948163|NCT01933256|Placebo Comparator|Placebo|Placebo
88948164|NCT01933256|Experimental|400mg HIP2B|400mg HIP2B
88948165|NCT01933269|Experimental|FACBC|
89019142|NCT00329472|No Intervention|no neoadjuvant chemotherapy|
88948166|NCT01933282|Experimental|MESA chemotherapy|Methotrexate etoposide dexamethasone Polyehylene glycol-asparaginase Methotrexate 2g/ m2，IV d1 etoposide 100mg/ m2，VD d2，d3，d4 dexamethasone 20mg/ m2，VD d2，d3，d4，d5 Polyehylene glycol-asparaginase muscular injection 2500IU/ m2, d5
88948167|NCT01933308|Experimental|Continuous high intensity training-CT80|All arms will receive standardized comprehensive self-management teaching from health care practitioners. At program completion, all subjects will receive the same standardized exercise recommendations. The exercise training program will consist of cycling on a calibrated cycle ergometer at the target intensity, three sessions per week for 12 weeks. Sessions will include a 10-minute warm-up, a training phase at the target intensity, and a 5-minute cool-down. The duration of the training phase will be adjusted such that the total amount of work performed per session will be comparable between the three interventions. The training phase for the CT80 will consist of exercising at 80% of peak work rate (target training intensity) for 25 minutes, for a total session duration of 40 minutes.
88948168|NCT01933308|Experimental|Training at ventilatory threshold-CTVT|The exercise training program will consist of cycling on a calibrated cycle ergometer at the target intensity, three sessions per week for 12 weeks. Sessions will include a 10-minute warm-up, a training phase at the target intensity, and a 5-minute cool-down. The duration of the training phase will be adjusted such that the total amount of work performed per session will be comparable between the three interventions. The training phase for the CTVT will consist of exercising at the ventilatory threshold for a duration that will result in a total amount of work equivalent to the work that each patient would have done if he/she had been assigned to the CT80 arm. This approach has been used successfully in the past to isolate the effect of training intensity from that of total training dose.
88948169|NCT01933308|Experimental|Interval training-IT|The exercise training program will consist of cycling on a calibrated cycle ergometer at the target intensity, three sessions per week for 12 weeks. Sessions will include a 10-minute warm-up, a training phase at the target intensity, and a 5-minute cool-down. The training phase for the IT will consist of intervals of 30 seconds of exercise at 100% of work peak interspersed with intervals of 30 seconds of rest. This approach to IT was selected because it was successfully used by Vogiatzis et al. [33] and was shown to be as effective as continuous exercise training at a moderate intensity. As with the CTVT and CT80 arms, the duration of the training phase will be adjusted for the IT arm such that the total amount of work will be equivalent.
88948170|NCT01933321|Experimental|Intrathecal autologous stem cells|Intrathecal stem cells will be administered to patients that fulfill the inclusion criteria.
88948171|NCT01933347|Experimental|Gefitinib 250mg/d|Subjects will receive the oral administration of gefitinib 250mg/d until the tumor progression, perform scheduled visits in investigational sites at interview day and complete related examinations during follow-up period.
88948172|NCT01933360|Active Comparator|Misoprostol sublingual,1h|Administration of misoprostol sublingually 1h prior to surgery
88948173|NCT01933360|Active Comparator|Misoprostol sublingual. 3h|Administration of misoprostol sublingually 3h prior to surgery
88948174|NCT01933360|Active Comparator|Misoprostol vaginal,1h|Administration of misoprostol vaginally 1h prior to surgery
88948175|NCT01933360|Active Comparator|Misoprostol vaginal,3h|Administration of misoprostol vaginally 3h prior to surgery
88948176|NCT01933373|Active Comparator|Toupet|Laparoscopic Myotomy + Toupet 180 degree partial posterior fundoplication.
88948177|NCT01933373|Experimental|Dor|Laparoscopic Myotomy + Dor anterior partial fundoplication. 90 degree partial fundoplication being the standard of care.
88948178|NCT01933386|Other|SoundBite|SoundBite will be used for the first 30 days
88948179|NCT01933386|Other|Surgically Implanted BCD|The subject's own surgically implanted bone conduction device will be used for the first 30 days.
88948180|NCT01933412|Experimental|Sci-B-Vac Hepatitis B Vaccine|Sci-B-Vac Hepatitis B Vaccine
88948181|NCT01933412|Active Comparator|Engerix B Hepatitis B Vaccine|Engerix B Hepatitis B Vaccine
88948182|NCT01933438|Experimental|Sup-ER protocol|Early shoulder repositioning (Sup-ER Splint)
88948183|NCT01933438|Active Comparator|Control|Standard treatment
88948184|NCT01933451|Experimental|Restrictive intraoperative fluid therapy|To Keep intraoperative pulse pressure variation above 18%.
89471323|NCT05311735|Experimental|Mineralized Dentin Graft|-Test group I (mineralized tooth graft): extracted teeth will undergo the mineralization process according to the manufacture's guidelines. Procedure will be done in a specialized equipment for tooth graft preparation (Smart Dentin Grinder® (SDG) (KometaBio), and then sites will be grafted. Remaining graft will be stored appropriately for future grafting in the same patient (according to the guidelines)
88948185|NCT01933451|Other|Liberal intraoperative fluid therapy|To keep intraoperative pulse pressure variation below 13%.
88948186|NCT01933490|Other|a high carbohydrate test meal (control condition)|a high carbohydrate test meal (control condition)
88948187|NCT01933490|Active Comparator|high carbohydrate test meal after pre-treatment|a high carbohydrate test meal after pre-treatment with rapid acting aspart insulin (insulin condition)
88948188|NCT01933490|Active Comparator|high fructose low glucose test meal|high fructose , low glucose test meal with carbohydrate and caloric content similar to the control meal (fructose condition)
88948189|NCT01933503|Experimental|OCA 5 mg|OCA 5 mg, 1 mg by mouth followed by 2 days of no investigational product (IP); then OCA 5 mg by mouth for 14 days.
88948190|NCT01933503|Experimental|OCA 10 mg|OCA 10 mg, 1 mg by mouth followed by 2 days of no investigational product (IP); then OCA 10 mg by mouth for 14 days.
88948191|NCT01933503|Experimental|OCA 25 mg|OCA 25 mg, 1 mg by mouth followed by 2 days of no investigational product (IP); then OCA 25 mg by mouth for 14 days.
88948192|NCT01933516|Experimental|GP2013|
88948193|NCT01933529|Experimental|ARA 290|ARA 290, 4.0 mg, injected subcutaneously once every morning during 28 days.
88948194|NCT01933529|Placebo Comparator|Placebo|Placebo, injected subcutaneously once every morning during 28 days,
88948195|NCT01933542|Active Comparator|Chlorzoxazone|"Oral administration of chlorzoxazone 500 mg (two 250 mg tablets)~Morphine. Patient controlled intravenous morphine (PCA-pump), bolus 2.5 mg, lock-out-time 10 minutes. Concentration : Morphin 1 mg/ml.~Zofran 4 mg iv in case of moderate to severe nausea, supplemented by Zofran 1 mg iv if needed"
89019143|NCT02960399|Experimental|Antibody Deficient Patients|Zostavax® vaccine administered to antibody deficient patients 60 years of age and older.
88948196|NCT01933542|Placebo Comparator|Placebo|"Oral administration of two placebo tablets~Morphine. Patient controlled intravenous morphine (PCA-pump), bolus 2.5 mg, lock-out-time 10 minutes. Concentration : Morphin 1 mg/ml.~Zofran 4 mg iv in case of moderate to severe nausea, supplemented by Zofran 1 mg iv if needed"
88948197|NCT01933555|Experimental|Empowerment program|The hour intervention, delivered over a 11-week period, consisted of an empowerment and additional components adapted from Freedom program run to support domestic abused women.
88948198|NCT01933555|No Intervention|Control group|Standard care, which was routine check ups and care provided by health care professionals.
88948199|NCT01933568|Experimental|Radiation|combined CFRT and SABR with concurrent cisplatin
88948200|NCT01933581||ACS undergoing CA and PCI|Patients with Acute Coronary Syndrome undergoing coronary angiography and PCI
88948201|NCT01933607|Other|TOPS System|Post Marketing Study
88948202|NCT01933633|Experimental|Exercise|Regular exercise training for 10 weeks prior to assisted fertilisation
88948203|NCT01933633|No Intervention|Control|Standard care
88948204|NCT01933646||Cohort 1|
88948205|NCT01933659|Experimental|group A: DSW group|ingesting DSW 200 cc four times a day (one hour before meal and bed time);
88948206|NCT01933659|Placebo Comparator|group B: non-DSW group|ingesting non-DSW drinking water 200 cc four times a day (one hour before meal and bed time).
88948207|NCT01933685|Experimental|AIDSVAX B/E|AIDSVAX B/E at Weeks 0, 4, 24 and 48
88948208|NCT01933685|Placebo Comparator|AIDSVAX B/E Placebo|AIDSVAX B/E Placebo at Weeks 0, 4, 24 and 48
88948209|NCT01933698|Active Comparator|Amoxi-Ped|Single dose of 500 mg amoxicillin - AMOXI-PED - was administered after a 12-hour overnight fast.
88948210|NCT01933698|Active Comparator|Amoxil|Single dose of 500 mg amoxicillin - AMOXIL - was administered after a 12-hour overnight fast.
88948211|NCT01933711|Experimental|Rituximab maintenance|maintenance therapy with rituximab (375 mg/m2) administered every 3 months for 2 years.
88948212|NCT01933711|No Intervention|Observation|observational arm, no intervention
88948213|NCT01933737|Experimental|Kinesio Taping Group|The Kinesio Taping group (KTG) (n = 31 elderly women) were submitted to the protocol of applying Kinesio Taping for gastrocnemius muscle and the muscles of the median foot. The application of the tapes was bilateral limbs. The subjects were evaluated post-application and 48 hours after application of the tape.
88948214|NCT01933737|Experimental|Placebo tape group|The placebo tape group (PTG) (n = 31 elderly women) were submitted to the protocol of applying placebo tape (3M Micropore) for gastrocnemius muscle and the muscles of the median foot in the same way that KTG. The application of the tapes was bilateral limbs. The subjects were evaluated post-application and 48 hours after application of the tape.
88948215|NCT01932879|Experimental|Blackberry|Participants will consume blackberries twice/day as part of a 1-week controlled diet.
88948216|NCT01932879|Other|Control|Participants will consume jello twice/day as part of a 1-week controlled diet.
88948217|NCT01933750|No Intervention|Randomized/Control|7 patients randomized to deferred treatment/control cohort at the 3 sub-study control sites = 21
88948218|NCT01933750|Experimental|Non-Randomized/Treatment|Patients are non-randomized and if meet inclusion criteria receive the implantation of the PresVIEW device
88948219|NCT01933763|Experimental|Group A|Participants in Group A will consist of up to 6 sequential ascending dose cohorts. Each cohort will therefore receive 1 of 6 ascending dosing levels of the study drug (REGN1193) or placebo.
88948220|NCT01933763|Experimental|Group B|Participants in Group B will consist of up to 6 sequential ascending dose cohorts. Each cohort will therefore receive 1 of 6 ascending dosing levels of the study drug (REGN1193) or placebo.
88948221|NCT01933802|Experimental|autologous MSC-NP|intrathecal administration of autologous MSC-NP in three doses at three month intervals
88948222|NCT01933828|Active Comparator|OPEN lobectomy|Lobectomy and mediastinal lymph node dissection by thoracotomy with rib-spreading.
88948223|NCT01933828|Active Comparator|VATS lobectomy|Thoracoscopic minimally invasive lobectomy with thoracoscopic mediastinal lymph node dissection without rib-spreading.
88948224|NCT01933828|Other|ROBOT-assisted lobectomy|Robot-assisted lobectomy with mediastinal lymph node dissection (Robot group as clinical assignment in prospective Cohort).
88948225|NCT01933841||Days 1-30|Adult surgery patients whose operations occurred during Days 1-30 after monitoring is introduced in the PACU. Patients will have their TOF ratio measured and recorded using a TOF-Watch SX. The nurse will monitor the patient and notify the provider of the patient's TOF-ratio if appropriate.
88948226|NCT01933841||Days 31-60|Adult surgery patients whose operations occurred during Days 31-60 after monitoring is introduced in the PACU. Patients will have their TOF ratio measured and recorded using a TOF-Watch SX. The nurse will monitor the patient and notify the provider of the patient's TOF-ratio if appropriate.
88948227|NCT01933841||Days 61-90|Adult surgery patients whose operations occurred during Days 61-90 after monitoring is introduced in the PACU. Patients will have their TOF ratio measured and recorded using a TOF-Watch SX. The nurse will monitor the patient and notify the provider of the patient's TOF-ratio if appropriate.
88948228|NCT01933841||Days 91-120|Adult surgery patients whose operations occurred during Days 91-120 after monitoring is introduced in the PACU. Patients will have their TOF ratio measured and recorded using a TOF-Watch SX. The nurse will monitor the patient and notify the provider of the patient's TOF-ratio if appropriate.
88948229|NCT01933854||Riverside group|Women aged 20 years or over who are not pregnant living riverside area of the Amapa State Brazil.
88948230|NCT01933854||urban group|women aged 20years or over not pregnant and living urban area
88948231|NCT01933867|Experimental|Water immersion colonoscopy|Water immersion during colonoscope insertion and room air insufflation during colonoscope withdrawal.
88948232|NCT01933867|Active Comparator|Air insufflation colonoscopy|Standard room air insufflation during both colonoscope insertion and withdrawal.
88948233|NCT01933906|Experimental|P1101|"P1101 50µg s.c. will be administered every 2 weeks in addition to preexisting imatinib treatment. In the absence of dose limiting toxicities after 12 weeks, the dose will be escalated to 100µg every 2 weeks.~Maximum treatment duration will not expand 18 months."
88948234|NCT01933945||TACE + early Nexavar|Patients with early start of Sorafenib treatment. This cohort comprises all patients where the physician decides at the time of TACE non-eligibility to choose Sorafenib as the next treatment option (regardless of whether TACE treatment is continued or not).
89471324|NCT05311735|Experimental|Partial-Demineralized Dentin Graft|-Test group II (partial-demineralized tooth graft): extracted teeth will be undergone to partial-demineralized process, according to the manufacture's guidelines. Procedures will be done in a specialized equipment for tooth graft preparation (Smart Dentin Grinder® (SDG) (KometaBio), and then sites will be grafted. Remaining graft will be stored appropriately for future grafting in the same patient (according to the guidelines).
89471325|NCT05309395|Experimental|Food Rx- meal plans and groceries|These households will receive grocery delivery weekly for 6 months
89471326|NCT05309395|Active Comparator|Wait-listed control|These households will not receive grocery delivery for the first 6 months, but will get them the second six months after recruitment.
89471327|NCT05306509|Experimental|Nurse-initiated conversations for early integration of palliative care (NiCE)|Participants will receive nurse-initiated conversations facilitating early integration of palliative care in pediatric oncology.
89471328|NCT05306509|Other|Routine PPC|Participants will be scheduled to meet with the PPC team only when participants themselves, their families, or the attending oncologist requested an appointment.
89471329|NCT05296980|Experimental|REMINDER program online|The REMINDER program in this arm will be delivered by videoconferencing. It will integrate 20 sessions (with approximate length of 45-60 min), therapist-mediated, carried out twice a week, over a period of 12 weeks. Psychoeducation sessions and part of the reminiscence and memory strategies training sessions will be facilitated in groups, as means to promote social support and modeling, and the remaining will be individual sessions. Several activities aimed to promote personal development and definition and achievement of meaningful goals will be included in the program, and the program will be manualized to facilitate its future dissemination and implementation
89471330|NCT05296980|Experimental|REMINDER program face-to-face|The REMINDER program in this arm will be delivered face to face. It will integrate 20 sessions (with approximate length of 45-60 min), therapist-mediated, carried out twice a week, over a period of 12 weeks. Psychoeducation sessions and part of the reminiscence and memory strategies training sessions will be facilitated in groups, as means to promote social support and modeling, and the remaining will be individual sessions. Several activities aimed to promote personal development and definition and achievement of meaningful goals will be included in the program, and the program will be manualized to facilitate its future dissemination and implementation
89471331|NCT05296980|Sham Comparator|Brain psychoeducation program|The control condition will have the same length as the experimental harms, including 20 psychoeducation sessions, with information regarding dementia modifiable risk factors, information on healthy lifestyles, and brain health promotion.
89471332|NCT05295927|Experimental|Group A: EPI-7386 + Abiraterone Acetate Plus Prednisone (AAP)|Participants with metastatic castration-resistant prostate cancer (mCRPC) will receive EPI-7386 + AAP to determine the recommended phase 2 dose (RP2D) dose of EPI-7386 in combination with AAP in dose finding portion of the study. In dose expansion portion of the study, participants will receive EPI-7386 RP2D in combination with AAP.
89471333|NCT05295927|Experimental|Group B: EPI-3786 + Apalutamide|Participants with mCRPC will receive EPI-7386 + apalutamide to determine RP2D dose of EPI-7386 in combination with apalutamide in dose finding portion of the study. In dose expansion portion of the study, participants will receive EPI-7386 RP2D in combination with apalutamide.
89471334|NCT05293002|Experimental|Restorer Iliac Stent System|RESTORER Iliac Stent system for the treatment of Aorto-iliac lesions (TASC A, B, C and D) according to IFU
89471335|NCT05288673|Experimental|ALXN1210 400 mg|Participants received ALXN1210 every 28 days.
89471336|NCT05288673|Experimental|ALXN1210: 800 mg|Participants received ALXN1210 every 28 days.
89471337|NCT05288673|Placebo Comparator|Placebo|Participants received placebo every 28 days.
89471338|NCT05288660|Experimental|ALXN1210 200 mg|ALXN1210 was administered intravenously.
89471339|NCT05288660|Experimental|ALXN1210 400 mg|ALXN1210 was administered intravenously.
89471340|NCT05288660|Placebo Comparator|Placebo|Placebo was administered intravenously.
89471341|NCT05287243|Other|Inspiratory Muscle Training|involves the intervention portion of the study to improve strength of the cardiopulmonary system
89471342|NCT05279560|Experimental|Autologous intra-ovarian PRP injection|Study group, treated with autologous intra-ovarian PRP injection and undergoing a subsequent fresh ET-IVF/ICSI cycle in the third cycle after intervention
89471343|NCT05279560|Placebo Comparator|intra-ovarian saline solution (NaCL) injection|Control group, treated with intra-ovarian NaCl injection and undergoing a subsequent fresh ET-IVF/ICSI cycle in the third cycle after intervention
89471344|NCT05269472||Trigeminal Electrophysiology|
89471345|NCT05269472||Controls|
89471346|NCT05266365|Experimental|Video-based exercise group|Each subject in the video-based exercise group will receive a treatment protocol consisting of stretching exercises, strengthening exercises and functional exercises for knee and hip.
89471347|NCT05266365|Active Comparator|Standard exercise group|Each subject in the standard exercise group will receive a treatment protocol consisting of stretching exercises, strengthening exercises and functional exercises for knee and hip.
89019144|NCT02960399|Active Comparator|Healthy Subjects|Zostavax® vaccine administered per standard of care to healthy adults 60 years of age and older.
89471348|NCT05257577||Study group|Breast conserving surgery
89019145|NCT00329511|Active Comparator|A|methyldopa
89019146|NCT00329511|Active Comparator|B|clonidine patch
89019147|NCT00305552|Experimental|1|THALIDOMIDE
89471349|NCT05257460|Active Comparator|Closed-loop using standard rapid-acting insulin lispro|"Unsupervised home use of day and night hybrid closed loop insulin delivery system (CamAPS FX) for 8 weeks using standard rapid-acting insulin lispro.~The CamAPS FX closed-loop system comprises Dana insulin pump (Diabecare, Sooil, Seoul, South Korea) Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA), an Android smartphone hosting CamAPS FX Application with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump Glooko/Diasend cloud upload system."
89531856|NCT05077254|Experimental|Pfizer-BioNTech COVID-19 Vaccine 2023-2024 + SOC IS Reduction|"Participants will receive an additional dose (1 dose) of the Pfizer-BioNTech COVID-19 Vaccine 2023-2024, with concurrent reduction of their standard of care transplant immunosuppression regimen (IS), per protocol.~SOC IS Reduction: Standard of Care transplant immunosuppression regimen reduction, per protocol"
89019148|NCT00329589|Experimental|CNS|Velcade (bortezomib)
88948235|NCT01933945||TACE without early Nexavar|Patients without early start of Sorafenib treatment. This cohort comprises all patients where the physician decides at the time of TACE non-eligibility not to choose Sorafenib as the next treatment option. This cohort also includes patients with TACE non-eligibility for whom the decision to treat with Sorafenib is made at a later point in time, patients who are never treated with Sorafenib as well as patients for whom another systemic cancer treatment has been chosen be the physician either at time of TACE non-eligibility or at a later point in time.
89471350|NCT05257460|Experimental|Closed-loop using ultra-rapid insulin lispro|"Unsupervised home use of day and night hybrid closed loop insulin delivery system (CamAPS FX) for 8 weeks using ultra-rapid insulin lispro.~The CamAPS FX closed-loop system comprises Dana insulin pump (Diabecare, Sooil, Seoul, South Korea) Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA), an Android smartphone hosting CamAPS FX Application with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump Glooko/Diasend cloud upload system."
89471351|NCT05254626|Experimental|Diabetic Group 1|25 diabetic patients will be prescribed on dapagliflozin 10 mg - once daily (OD) - to be taken orally (PO) for 24 weeks
89471352|NCT05254626|Active Comparator|Diabetic Group 2|25 diabetic patients will be prescribed on Pioglitazone 30 mg - once daily (OD) - to be taken orally (PO) for 24 weeks
89019149|NCT00329589|Experimental|Head and Neck|Velcade (bortezomib)
89019150|NCT00329589|Experimental|Cervix|Velcade (bortezomib)
89471353|NCT05254626|Experimental|Non-diabetic Group 1|25 non-diabetic patients will be prescribed on dapagliflozin 10 mg - once daily (OD) - to be taken orally (PO) for 24 weeks.
89471354|NCT05254626|Active Comparator|Non-diabetic Group 2|25 non-diabetic patients will be prescribed on Pioglitazone 30 mg - once daily (OD) - to be taken orally (PO) for 24 weeks
88948236|NCT01933971|Other|Group 1: filgrastim 2.5 µg/kg/day for 7 consecutive days|"The test investigational product is BK0023. The reference product is Neupogen® 30, by Dompé Biotec S.p.A., Italy.~Both study treatments were administered according to a cross-over design in 2 subsequent periods separated by wash-out periods of at least 28 days.~The sites, where the injections are to be performed, are planned as follows:~st injection: upper part of the upper arm, posterior surface~nd injection: upper part of the thigh~rd injection: abdomen with the exception of the umbilical area~th injection: upper part of the contra-lateral upper arm, posterior surface~th injection: upper part of the contra-lateral thigh~th injection: abdomen with the exception of the umbilical area~th injection: upper part of the same upper arm, posterior surface as for the 1st injection."
88948237|NCT01933971|Other|Group 2: filgrastim 5 µg/kg/day for 7 consecutive days|"The test investigational product is BK0023. The reference product is Neupogen® 30, by Dompé Biotec S.p.A., Italy.~Both study treatments were administered according to a cross-over design in 2 subsequent periods separated by wash-out periods of at least 28 days.~The sites, where the injections are to be performed, are planned as follows:~st injection: upper part of the upper arm, posterior surface~nd injection: upper part of the thigh~rd injection: abdomen with the exception of the umbilical area~th injection: upper part of the contra-lateral upper arm, posterior surface~th injection: upper part of the contra-lateral thigh~th injection: abdomen with the exception of the umbilical area~th injection: upper part of the same upper arm, posterior surface as for the 1st injection."
89471355|NCT05253196|Experimental|Use of Foley Catheter Assistive Device|All participants will use Foley Catheter Assistive Device
89471356|NCT05252039|Experimental|Goals in Focus Therapy|Participants in this arm will receive 24 weekly sessions with Goals in Focus therapy (GiF) over 6 months.
89471357|NCT05252039|No Intervention|Waitlist Control|Participants in this arm will not receive any psychological treatment for 6 months. After 6-months, they will receive 24 sessions of Goals in Focus Therapy.
89471358|NCT05251311|Experimental|Social Risk Screening + Resource Map|Participants randomized to the experimental arm will receive a social risk assessment tool followed by an electronic resource map
89019151|NCT00329628|Experimental|Arm 1|
89019152|NCT00329628|Active Comparator|Arm 2|
89471359|NCT05251311|Active Comparator|Resource Map|Participants randomized to the active comparator group will receive only an electronic resource map
89471360|NCT05246085||Steroid|Subjects who take chronic swallowed topical steroids (i.e. budesonide or fluticasone) will be enrolled in the steroid cohort.
89471361|NCT05246085||Proton pump inhibitor|Subjects who take chronic proton pump inhibitors will be enrolled in the proton pump inhibitor cohort.
88948238|NCT01933971|Other|Group 3: filgrastim 10 µg/kg/day for 5 consecutive days|"The test investigational product is BK0023. The reference product is Neupogen® 30, by Dompé Biotec S.p.A., Italy.~Both study treatments were administered according to a cross-over design in 2 subsequent periods separated by wash-out periods of at least 28 days.~The sites, where the injections are to be performed, are planned as follows:~st injection: upper part of the upper arm, posterior surface~nd injection: upper part of the thigh~rd injection: abdomen with the exception of the umbilical area~th injection: upper part of the contra-lateral upper arm, posterior surface~th injection: upper part of the contra-lateral thigh."
88948239|NCT01933997|Experimental|MG01CI 1400 mg|
88948240|NCT01934023|Active Comparator|Varenicline|FDA approved smoking cessation medication
88948241|NCT01934023|Placebo Comparator|Placebo Sugar Pill|sugar pill
88948242|NCT01934036|Experimental|Obex, a nutritional supplement|Obex will be administered two sachets daily dissolved in a glass of water, 30 minutes before lunch and dinner during two months. Patients will be recommended to comply with a healthy lifestyle through diet and exercise.
88948243|NCT01934036|Placebo Comparator|Placebo|Placebo will be administered two sachets daily dissolved in a glass of water, 30 minutes before lunch and dinner during two months. Patients will be recommended to comply with a healthy lifestyle through diet and exercise.
88948244|NCT01934049|Active Comparator|Dexmedetomidine|Dexmedetomidine in dex group is administered as 1ug/kg by intravenous infusion 10 min and then 0.6 ug/kg until 30 minutes before the operation finishes.
88948245|NCT01934049|Placebo Comparator|Saline|Participants in con group receive placebo(saline) as the same dose at the same time as dex group.
88948246|NCT01934062||Surgical patients|Pediatric patients having surgery at Nationwide Children's Hosp. between 1/1/2013 & 7/31/2013.
88948247|NCT01934075|Experimental|Mental health treatment|Participants will receive twice-weekly exposure to 6 sessions of individual mental health treatment in a private room. Sessions will follow the intervention manual and be delivered by a full-time nurse facilitator who has a counseling background and receives supervision by a trained therapist.
88948248|NCT01934075|No Intervention|Standard of Care|Participants in the control condition will receive counseling that is the current standard of care for fistula patients at KCMC.
88948249|NCT01934088|Experimental|Propofol|Propofol in refract doses. Induction: 10-60 mg supplemented with 10-30 mg following an age correlated algorithm. Maintenance with refract bolus of 10-20 mg every 1-2 minutes after assessed need and condition
89531857|NCT05077254|Experimental|Moderna COVID-19 Vaccine 2023-2024 + SOC IS Regimen|"Participants will receive an additional dose (1 dose) of the Moderna COVID-19 Vaccine 2023-2024 and will continue to take their standard of care transplant immunosuppressive medications without alterations in schedule and dosing.~SOC IS: Standard of Care transplant immunosuppression regimen"
88948250|NCT01934088|Active Comparator|Fentanyl and Midazolam|0.025-0.05 mg of Fentanyl i.v. minimum 5 minutes before procedure as a single shot. Midazolam 1-2 mg i.v. for induction and 0.5-1 mg i.v. for maintenance after assessing needs and condition
88948251|NCT01934101|Experimental|CHR-5154|CHR-5154
88948252|NCT01934101|Placebo Comparator|Placebo|Placebo
88948253|NCT01934114||Under Treatment|Patients with locally advanced breast cancer, defined as being clinically appropriate for neoadjuvant therapy
89471362|NCT05241925|Experimental|Combined Training + Resistance Training|"Combined training (continuous aerobic + resistance) The protocol will consist of supervised exercise lasting 1h10min each session (5 min of warm-up, 30 min of aerobic exercise, 30 min of resistance exercise and 5 min of cool-down/relaxation).~And Resistance Training~- Resistance exercise will be performed at 70-80% of one repetition maximum (1-RM); 2 to 3 sets of 8 to 12 repetitions. The main muscle groups will be trained using training equipment with free weights and body mass of the participants. Exercises included leg extension, seated bicep curl, squat, seated triceps extension, sit-up, seated shoulder press, and standing pulldown"
89471363|NCT05241925|Experimental|Hitt Training + Resistance Training|"Combined training (high-intensity interval (IAI) + resistance) - Supervised exercise lasting 30 min each session (5 min warm-up, 20 min IAI and 5 min cool-down/relaxation).~And Resistance Training~- Resistance exercise will be performed at 70-80% of one repetition maximum (1-RM); 2 to 3 sets of 8 to 12 repetitions. The main muscle groups will be trained using training equipment with free weights and body mass of the participants. Exercises included leg extension, seated bicep curl, squat, seated triceps extension, sit-up, seated shoulder press, and standing pulldown"
89531858|NCT05077254|Experimental|Moderna COVID-19 Vaccine 2023-2024 + SOC IS Reduction|"Participants will receive a study dose (1 dose) of the Moderna COVID-19 Vaccine 2023-2024, with concurrent reduction of their standard of care transplant immunosuppression regimen (IS), per protocol.~SOC IS Reduction: Standard of Care transplant immunosuppression regimen reduction, per protocol"
89471364|NCT05216653|Experimental|Preoperative Short-course Radiation followed by Envafolimab plus CAPEOX|"The enrolled patients with MSS-type advanced middle-low rectal cancer will receive a combined regimen of neoadjuvant chemoradiotherapy combined with immunotherapy and total mesorectal excision (TME surgery).~Radiotherapy uses a short-range mode, irradiating the primary tumor and high-risk areas with dose of 25 Gy.~After radiotherapy, PD-L1 antibody (150mg/week, subcutaneous injection × 6 weeks) immunotherapy combined with two courses of CAPEOX chemotherapy was performed.~Two weeks after the end of the combined treatment plan in step 2), TME surgery is performed."
89471365|NCT05211791|Active Comparator|Group TEA|insertion of Thoracic epidural anesthesia plus GA with lung isolation using suitable size double lumen tube at level T6
89471366|NCT05211791|Active Comparator|Group ESB|U/S guided erector spinae block anesthesia using 15 ml local anesthesia plus GA with lung isolation using a suitable size double-lumen tube
89471367|NCT05211791|Active Comparator|Group PVB|U/S guided paravertebral block anesthesia using 15 ml local anesthesia as total volume plus GA with lung isolation using suitable size double lumen tube
89471368|NCT05196087||NIP IT!|Patients with early stage or locally advanced disease that is planned for or have undergone curative treatment will have next-generation sequencing (NGS)-based ctDNA analysis performed on blood samples to determine minimal residual disease (MRD). Blood samples, stool samples, and additional archival/fresh tumor specimens will be collected for banking and future research purposes.
89471369|NCT05181280|Experimental|Intervention|"Treatment: Standardized body image messaging targeting mothers. Following a similar model that has been used in previous studies testing the effect of traditional media exposure on body image and disordered eating behaviour, participants randomized to the treatment condition will have 1 exposure session per day over 5 days. Each exposure session will consist of 15 social media body message posts. Body image messaging targeting mothers will consist of mothers with ideal postpartum bodies and captions trending over the past 24 months."
89471370|NCT05181280|Placebo Comparator|Control|Control: Standardized infant feeding tips messaging. Participants randomized to the control will have 1 exposure session/day over 5 days. Each exposure will consist of 15 social media posts on infant feeding tips.
89471371|NCT05153720|Experimental|Ultrasound guided erector spinae plane block|Unilateral erector spinae plane block will be performed under ultrasound guidance
89471372|NCT05153720|Active Comparator|Ultrasound guided caudal block|Caudal block will be formed under ultrasound guidance
89471373|NCT05151094||Remdesivir exposure|Patients treated with remdesivir due to the COVID-19 infection
89471374|NCT05150587|Active Comparator|Rifaximin-Tested dose A|
89471375|NCT05150587|Active Comparator|Rifaximin-Tested dose B|
89471376|NCT05150587|Placebo Comparator|Placebo|
89471377|NCT05148468|Experimental|Active stimulation|During active stimulation phase, patients will receive through the spinal cord stimulator active tonic stimulation with amplitude set to 90% of paresthesia inducing threshold, therefore allowing blinding. Patients will be evaluated after a two week wash out period with no stimulation and after two weeks of continuous active stimulation.
89471378|NCT05148468|Sham Comparator|Sham stimulation|"During sham stimulation phase, patients will receive through the spinal cord stimulator a zero amplitude stimulation, therefore having no electrical current passing through epidural leads but with the program status still displayed as on if checked with patient's personal controller. Patients will be evaluated after a two week wash out period with no stimulation and after two weeks of continuous sham stimulation."
89471379|NCT05143229|Experimental|Dose level 1: alpelisib 250 mg plus sacituzumab govitecan 8 mg/kg|Alpelisib: 250 mg by mouth daily Sacituzumab govitecan: 8 mg/kg intravenous on days 1 and 8 of each 21 (+/-2) day cycle
89471380|NCT05143229|Experimental|Dose level 2: alpelisib 250 mg plus sacituzumab govitecan 10 mg/kg|Alpelisib: 250 mg by mouth daily Sacituzumab govitecan: 10 mg/kg intravenous on days 1 and 8 of each 21 (+/-2) day cycle
88948254|NCT01934114||Normal Cohort|Healthy female volunteers with breast size and epithelial integrity adequate to allow NIR imaging exams
88948255|NCT01934127|Experimental|Formulation 1 Group|Subjects in this group will receive two doses of GSK2789869A H7N1 vaccine formulation 1 at a 21 day interval
88948256|NCT01934127|Experimental|Formulation 2 Group|Subjects in this group will receive two doses of GSK2789869A H7N1 vaccine formulation 2 at a 21 day interval
88948257|NCT01934127|Experimental|Formulation 3 Group|Subjects in this group will receive two doses of GSK2789869A H7N1 vaccine formulation 3 at a 21 day interval
88948258|NCT01934127|Experimental|Formulation 4 Group|Subjects in this group will receive two doses of GSK2789869A H7N1 vaccine formulation 4 at a 21 day interval
89471381|NCT05143229|Experimental|Dose level 3: alpelisib 300 mg plus sacituzumab govitecan 10 mg/kg|Alpelisib: 300 mg by mouth daily Sacituzumab govitecan: 10 mg/kg intravenous on days 1 and 8 of each 21 (+/-2) day cycle
89471382|NCT05136742|Experimental|aerobic exercise and diet program|aerobic exercise with balanced restricted diet
89471383|NCT05136742|Active Comparator|diet program|balanced restricted diet
89471384|NCT05124522|Experimental|MSPA eClass|
89471385|NCT05124522|No Intervention|Waiting list|
89471386|NCT05120596|Experimental|T3P-Y058-739 Intravenous (IV)|Intravenous infusion
89471387|NCT05120596|Experimental|T3P-Y058-739 Intratumoural (IT)|Intratumoural injection
89471388|NCT05120596|Experimental|T3P-Y058-739 plus pembrolizumab|Intravenous infusion
89471389|NCT05119673|No Intervention|mono-plane sonographic view|Usual standard of care, in our institution, for difficult peripheral vascular access in the Emergency Department.
89471390|NCT05119673|Active Comparator|bi-plane sonographic view|
89471391|NCT05112783|Experimental|Henan Tuoren Endotracheal Tube group|Uses the Henan Tuoren endotracheal tube to assist the nasal tracheal tube passing the nasal cavity, oropharynx and advanced into the trachea
89019153|NCT00305669|Experimental|GM-CSF before surgery|GM-CSF dose prior to surgery- Cohort 1-GM-CSF 250mcg/m2 for 2 weeks Cohort 2-GM-CSF 250mcg/m2 for 3 weeks Cohort 3-GM-CSF 250mcg/m2 for 4 weeks Cohort 4-GM-CSF 125mcg/m2 for 4 weeks
89019154|NCT00333099|Placebo Comparator|nutrition|study of immuno-modulating enteral nutrition
89019155|NCT04716543||ILI Investigation|The suspected ILI cases will be first identified using the WHO clinical case definition of ILI and Covid 19 as either with:Acute onset of fever (> 37.5˚C axillary temperature or > 38˚C tympanic temperature) AND cough; OR Acute onset of ANY ONE OR MORE of the following signs or symptoms: Fever, cough, general weakness/fatigue, headache, myalgia, sore throat, coryza, dyspnoea, anosmia (loss of smell) or ageusia (loss of taste); with symptoms with onset within the last 10 days.
89471392|NCT05112783|Experimental|Smiths Portex Tracheal tubes group|Uses the Smiths Portex endotracheal tube to assist the nasal tracheal tube passing the nasal cavity, oropharynx and advanced into the trachea
89471393|NCT05099055|Experimental|Test group|Monitoring will be installed upon arrival.Metoclopramide 10 mg IV and Dexamethasone 4 mg will be given for nausea-prophylaxis. Patients may be given ondansetron 4 mg as rescue. Cefazoline 2G or clindamycin 900 mg will be given.A sterile spinal technique will be performed with a 25G Whitacre. Bupivacaine 12 mg (1.6 ml) will be drawn and given, along with dexmedetomidine 3 mcg (0.75 mL) previously blindly prepared for a total of 2.35 ml.Adequate blood pressure will be maintained with phenylephrine infusion or ephedrine IV. Glycopyrrolate 0.2 mg may be given for bradycardia.Once an adequate sensory block is obtained, the obstetrics team can perform the surgery.The patient will receive a dose of ketorolac 30 mg IV before leaving the PACU and then Naproxen 500 mg PO every 12 hours.She will receive acetaminophen 975 mg PO every 6 hours and hydromorphone 2-4 mg PO every 3 hours prn. Patients will also have access to a protocol for treatment of nausea and pruritus.
89471394|NCT05099055|Active Comparator|Control group|Monitoring will be installed upon arrival.Metoclopramide 10 mg IV and Dexamethasone 4 mg will be given for nausea-prophylaxis. Patients may be given ondansetron 4 mg as rescue. Cefazoline 2G or clindamycin 900 mg will be given.A sterile spinal technique will be performed with a 25G Whitacre. Bupivacaine 12 mg (1.6 ml) will be drawn and given, along with morphine 100 mcg, fentanyl 15 mcg and normal saline 0.25 ml previously blindly prepared for a total of 2.35 ml.Adequate blood pressure will be maintained with phenylephrine infusion or ephedrine IV. Glycopyrrolate 0.2 mg may be given for bradycardia.Once an adequate sensory block is obtained, the obstetrics team can perform the surgery.The patient will receive a dose of ketorolac 30 mg IV before leaving the PACU and then Naproxen 500 mg PO every 12 hours.She will receive acetaminophen 975 mg PO every 6 hours and hydromorphone 2-4 mg PO every 3 hours prn. Patients will also have access to a protocol for treatment of nausea and pruritus.
89471395|NCT05062525||Immunotherapy|
89471396|NCT05062525||Non-Immunotherapy|
89471397|NCT05042310|Experimental|LY3541860 (Part A)|Single doses of LY3541860 administered intravenously (IV) or subcutaneously (SC).
89471398|NCT05042310|Experimental|LY3541860 (Part B)|Multiple doses of LY3541860 administered either IV or SC.
89471399|NCT05042310|Placebo Comparator|Placebo (Part A)|Single doses of Placebo administered either IV or SC.
89471400|NCT05042310|Placebo Comparator|Placebo (Part B)|Multiple doses of Placebo administered either IV or SC.
89471401|NCT05041959|Other|Smoking Abstinence|Participants will abstain from smoking for 24 hours before one MRI scan. Smoking abstinence will be confirmed using exhaled carbon monoxide breath testing
89471402|NCT05041959|Other|Ad Lib Smoking|"Participants will continue smoking as usual (i.e. ad lib) before one MRI scan and smoke one additional cigarette immediately prior to scanning. Continued smoking will be confirmed using exhaled carbon monoxide breath testing."
89471403|NCT05037136||Ablation|Participants recruited from the LoTO_CASA_AF trial (ClinicalTrials.gov Identifier: NCT04280042) who underwent either conventional catheter ablation or thoracoscopic surgical ablation to treat their long standing persistent AF with be asked to continue downloading data from their implanted loop recorder and monitor their heart rate and physical activity level (step count) using a wrist worn activity tracker.
89471404|NCT05032170||Locator Group|The participant has a mandibular overdenture supported by two implants with locator attachments. The implants are scanned with each of two intraoral scanners both with and without the use of artificial landmarks. The implant scans are analyzed in terms of scanning accuracy (trueness and precision) by comparison with a reference model (3D implant positions in the working cast of the immediately loaded overdenture).
89471405|NCT05032170||Bar Group|The participant has a mandibular overdenture supported by two implants with a dolder bar attachment. The implants are scanned with each of two intraoral scanners both with and without the use of artificial landmarks. The implant scans are analyzed in terms of scanning accuracy (trueness and precision) by comparison with a reference model (3D implant positions in the working cast of the immediately loaded overdenture).
89471406|NCT05024344|Active Comparator|ESP Group|One 30mL syringe containing 30mL of 0.5% ropivacaine and 4 mg of dexamethosone-
89471407|NCT05024344|Sham Comparator|Sham Group|One 30mL syringe containing 30mL of preservative free normal saline
89471408|NCT05008900|Experimental|Surveillance|Patients with early biochemical relapse of prostate cancer following radical prostatectomy who have a PSA greater than or equal to 0.1 to less than 0.3 ng/mL with negative PSMA PET/CT will go on surveillance. Routine PSA will be conducted and a repeat PSMA PET/CT imaging will be conducted when the PSA rises to greater than 0.5 to less than 1.0 ng/mL.
89531859|NCT05073120||Piqray Prescriber's/HCP receiving the guide for hyperglycemia|HCPs prescribing Piqray in the EU/EEA provided with the Piqray Prescriber's/HCP Guide for hyperglycemia (educational material).
89019156|NCT00305747|Experimental|BR-DIM|BR-DIM will be administered at a starting dose of 75 mg po twice daily. Patients will be instructed to take tablets twice daily with 8 ozs. of water, with/without food. A study calendar will be provided and patients will be asked to fill the appropriate boxes when they take their study capsules. One treatment cycle is 28 days.
89019157|NCT00305825|Experimental|Study intervention|Patients receive bevacizumab IV over 30-90 minutes on day 1 and oral letrozole once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89019158|NCT00329706|Experimental|1|Experimental arm will have an immediate release of the PET report
89019159|NCT00329706|Active Comparator|2|Active Comparator arm will have a delayed release of 2 years
89019160|NCT00306137|Experimental|Arm 1|
89019161|NCT00306137|Placebo Comparator|Arm 2|
89471409|NCT05008900|No Intervention|Salvage radiotherapy|Patients with early biochemical relapse of prostate cancer following radical prostatectomy who have a PSA of greater than or equal to 0.1 to less than 0.3 ng/mL with negative PSMA PET/CT will receive salvage radiotherapy to the prostate bed. This radiotherapy may or may not include the pelvic lymph nodes.
89471410|NCT05006391|Experimental|Tele-Coaching (Online) Community-Based Exercise|This study involves two phases: a six month online Community-Based Exercise Intervention (Phase 1), followed by a six month Follow-Up Monitoring Phase (Phase 2).
89471411|NCT05002842|Experimental|Immediate Intervention|Those in the immediate intervention arm will begin the LovingKindess Meditation practice upon enrollment.
89471412|NCT05002842|Experimental|Delayed Intervention|Those in the deferred intervention arm will commence the LovingKindness Meditation practice intervention approximately 3 weeks (post 3 -week survey) after enrollment and participate three weeks thereafter.
89471413|NCT05000203|Experimental|Specific intervention for fear of childbirth|"Online education intervention Participants randomly assigned to the experimental group will be informed by telephone call of their inclusion in the first phase of the trial.~Participants in the intervention group will be encouraged to attend routine consultations with their midwife and obstetrician, as well as to take advantage of the group maternal education that participants usually develop in their health center.~Specific intranatal support~An experimental group will be carried out with a specific support intervention in the obstetric-gynecological emergency area that will supplement the one usually provided to all pregnant women.~At the end of the participant's stay within the emergency area due to hospital discharge, admission to the ward, or the end of the pregnancy, the collaborating midwife will fill out an online form designed to monitor the care offered. Said form will also be completed at the end of the work shift if the participant's care continues."
89471414|NCT05000203|Active Comparator|Routine intervention for fear of childbirth|"Usual care~Participants randomly assigned to the control group will be informed by telephone call of their inclusion in the first phase of the trial. The process under study will be explained in detail, resolving any doubts at that time.~Regular intranatal support~The participants in the control group will not be identified as pregnant women with fear of childbirth, and will receive the usual care in the obstetric-gynecological emergency area."
89471415|NCT04997304|Experimental|AirDuo and ProAir|This trial includes using the inhaler (AirDuo®) Digihaler™ and rescue inhalers (ProAir®) Digihaler™.
89471416|NCT04991324|Experimental|weekly supplementation|Weekly administration of a capsule containing 24'000 IU vitamin D, corresponding to a dose of approximately 3500 IU per day, as comedication to the usual treatment during 6 months.
89471417|NCT04991324|Active Comparator|monthly supplementation|Monthly administration of a capsule containing 24'000 IU vitamin D, corresponding to a dose of approximately 800 IU per day, as comedication to the usual treatment during 6 months.
89471418|NCT04991324|No Intervention|control group|Usual treatment without vitamin D supplementation.
89471419|NCT04984616|Experimental|ATORVASTATIN 40|40 mg Atorvastatin/day for 120 days P.O.
89471420|NCT04984616|Experimental|ATORVASTATIN 80|80 mg Atorvastatin/day for 120 days P.O.
89471421|NCT04984616|Placebo Comparator|Placebo|Placebo/day for 120 days P.O.
89471422|NCT04980521|Placebo Comparator|Print brochures|Participants assigned to the print brochure group will receive three educational print brochures about radon published by EPA via postal mails for three months (one per each month).
89471423|NCT04980521|Experimental|The radon app|Participants assigned to the radon app group will be asked to use the radon app for three months where they will be exposed to mobile friendly educational content that is repurposed from educational print brochures about radon published by EPA.
89471424|NCT04966481|Experimental|Arm 1: Palbociclib + Cetuximab|"Palbociclib by mouth 125 mg/daily on Days 1-21 of each 28 day cycle~Cetuximab: Initial dose 400mg/m^2 intravenous (IV); Subsequent doses 250 mg/m^2 IV, weekly"
89471425|NCT04966481|Active Comparator|Arm 2: Cetuximab|-Cetuximab: Initial dose 400mg/m^2 intravenous (IV); Subsequent doses 250 mg/m^2 IV, weekly
89471426|NCT04927533|Experimental|Older adults with psychiatric problems|The target group is a group of older adults with psychiatric problems (≥60 years old) admitted to a residential psychogeriatric department of the Psychiatric Clinic of the Alexians Care Group Tienen. The following exclusion criteria apply: a score of less than 21 on the MMSE (excluding dementia or other moderate to severe cognitive disorders), a mother tongue other than Dutch and having undergone surgery and/or chemotherapy in the last 3 months.
89471427|NCT04909216|Experimental|Mindful Attention Workshop|50 participants will be randomized to the Mindful Attention Training (MAT) workshop. The 90-minute workshop will be conducted in group, online format.
89471428|NCT04909216|No Intervention|Waitlist Control|"50 participants will be randomized to the waitlist control condition (as usual condition)."
89471429|NCT04904120|Active Comparator|[203Pb]VMT01 first|Participants randomized to this arm will receive imaging agent [203Pb]VMT01 and undergo SPECT/CT imaging first. Later, participants in this arm will receive [68Ga]VMT02 and undergo PET/CT imaging.
89471430|NCT04904120|Active Comparator|[68Ga]VMT02 first|Participants randomized to this arm will receive imaging agent [68Ga]VMT02 and undergo PET/CT imaging first. Later, participants in this arm will receive [203Pb]VMT01 and undergo SPECT/CT imaging.
89471431|NCT04877860|Experimental|Multimodal rehabilitation program + PNE (Therapeutic exercise, manual therapy and PNE)|Physical recovery program (multimodal) with a duration of 8 weeks. Three weekly sessions on alternate days lasting 60 minutes each one. 4 individual manual therapy sessions (1 session every 2 weeks). Access to the PaiNEd system.
89471432|NCT04877860|Active Comparator|Multimodal rehabilitation program + traditional biomedical information|Physical recovery program (multimodal) with a duration of 8 weeks. Three weekly sessions on alternate days lasting 60 minutes each one. 4 individual manual therapy sessions (1 session every 2 weeks). Dossier with traditional biomedical recommendations on the management of pain and disability.
88948259|NCT01934127|Experimental|Formulation 5 Group|Subjects in this group will receive two doses of GSK2789868A H7N1 vaccine formulation 5 at a 21 day interval
88948260|NCT01934127|Placebo Comparator|Placebo Group|Subjects in this group will receive two doses of placebo at a 21 day interval
88948261|NCT01934153|Experimental|Cohort A|Single dose of topical [14C]Umeclidinium was applied to the unoccluded axilla, and the drug which will be applied to the test site has to remain on the application site for 8 hrs
89019162|NCT00329940|Experimental|Letrozole|to evaluate the rheumatological tolerability of Femara
89471433|NCT04877860|Active Comparator|Control group|Information dossier with recommendations on pain control and dysfunction improvement.
89471434|NCT04871412|Experimental|Integrative Care (Treatment)|Participants in the Integrative arm will receive standard surgical and oncologic care at The Ottawa Hospital plus complementary care guided by a naturopathic doctor at The Centre for Health Innovation
89471435|NCT04871412|No Intervention|Standard Care (Control)|Participants in the control arm will receive standard surgical and oncologic care at The Ottawa Hospital
89471436|NCT04868877|Experimental|Part 2 NSCLC harboring EGFR exon 20 Insertion|Participants will receive intravenous infusion of MCLA-129 every two weeks at the recommended Phase II dose (RP2D).
89471437|NCT04868877|Experimental|Part 2 NSCLC harboring cMet exon 14 skipping mutation|Participants will receive intravenous infusion of MCLA-129 every two weeks at the recommended Phase II dose (RP2D).
89471438|NCT04868877|Experimental|Part 2 Select solid tumors harboring an EGFR or cMet driving mutation|Participants will receive intravenous infusion of MCLA-129 every two weeks at the recommended Phase II dose (RP2D).
89471439|NCT04868877|Experimental|Part 2 NSCLC First-line|Participants will receive intravenous infusion of MCLA-129 every two weeks at the recommended Phase II dose (RP2D) and Osimertinib orally once daily starting at a dose of 80mg.
89471440|NCT04868877|Experimental|Part 2 NSCLC Second-line or more|Participants will receive intravenous infusion of MCLA-129 every two weeks at the recommended Phase II dose (RP2D) and Osimertinib orally once daily starting at a dose of 80mg.
89471441|NCT04855331|Experimental|Laparoscopic pancreatoduodenectomy|Laparoscopic pancreatoduodenectomy following neoadjuvant chemotherapy for borderline resectable pancreatic cancer
89471442|NCT04855331|Active Comparator|Open pancreatoduodenectomy|Open pancreatoduodenectomy following neoadjuvant chemotherapy for borderline resectable pancreatic cancer
89471443|NCT04840901|Experimental|Lebrikizumab (Reference) - Pre-Filled Syringe with Needle Safety Device|2-mL (125 mg/mL) Lebrikizumab administered subcutaneously (SC) via pre-filled syringe with needle safety device (PFS-NSD).
89471444|NCT04840901|Experimental|Lebrikizumab (Test) - Autoinjector|2-mL (125 mg/mL) Lebrikizumab administered SC via autoinjector (AI).
88948262|NCT01934153|Experimental|Cohort B|Single dose of topical [14C]Umeclidinium was applied to the occluded axilla, and the drug which will be applied to the test site has remain on the application site for 8 hrs
88948263|NCT01934153|Experimental|Cohort C|Single dose of topical [14C]Umeclidinium was applied to the unoccluded palm, and the drug which will be applied to the test site has to remain on the application site for 8 hrs
89471445|NCT04826575|No Intervention|Control|No intervention will be done in this group.
89471446|NCT04826575|Experimental|Pre-Habilitation|Two weeks of high intensity respiratory muscle training, optional smoking cessation and psychological support.
89471447|NCT04818086|Active Comparator|Lemborexant Arm|Study Drug Dosage: 5 mg of lemborexant, and 10 mg of lemborexant combined with 16 mg/4 mg of buprenorphine-naloxone sublingually as a film.
89471448|NCT04818086|Placebo Comparator|Placebo Arm|Comparative placebo combined with 16 mg/4 mg of buprenorphine-naloxone sublingually as a film.
88948264|NCT01934153|Experimental|Cohort D|Single dose of topical [14C]Umeclidinium was applied to the occluded palm, and the drug which will be applied to the test site has to remain on the application site for 8 hrs
88948265|NCT01934166|Experimental|Nalmefene 18 mg|18 mg nalmefene corresponds to 20 mg nalmefene hydrochloride
88948266|NCT01934179||Ancillary-correlative (real-time PCR)|Patients undergo blood collection for analysis via real-time PCR at baseline, 3 months, and 6 months.
88948267|NCT01934205|Experimental|Part A(Cohort1)|Study BTZ116666 has two parts. Each part will consist of a maximum of 6 cohorts. Part A will be initiated with 4 initial cohorts/timepoints in order to minimize the number of healthy volunteers that undergo bronchoscopy in this study. After review of data from Cohorts 1 through 4 of Part A, the study team will determine if additional cohorts are needed to be studied in Part A and/ or if Part B is needed. If the study team determines that additional cohorts are needed, then only the necessary cohorts in Parts A and/or B will be executed. In Part A, participants will receive GSK2140944 1000 mg intravenous (IV) infusion over 2 hours x 1 dose
88948268|NCT01934205|Experimental|Part A (Cohort2)|In Part A, participants will receive GSK2140944 1000 mg intravenous (IV) infusion over 4 hours x 1 dose
89019163|NCT00333333||SGA infants|Infants who are thought to be small for gestational age (SGA)
89471449|NCT04812613||Photovoice|"Three youth community peer researchers from marginalized communities will be recruited and involved in every aspect of the project.~We will recruit 20 participants from marginalized communities with a current or past history of cannabis use, who can speak English, and who are between 16 and 26 years old.~Participants will receive training on study procedures, basics of photography and disposable camera to document their experiences with mental health and substance use over the span of two weeks. Community peer researchers and research team will conduct photoanalysis and creation of the description of the five photos chosen by each participant.~Duoethnographic dialogue: 10 youth participants will be paired with an older participant of TCAY study to have an open discussion to explore their experiences with cannabis and mental health. This conversation will be facilitated by community peer researcher, recorded and transcribed verbatim."
89531860|NCT05070546|Experimental|Cohort (C)1 Group (G)1: Healthy Adults, 18-59 Years (Respiratory Syncytial Virus [RSV] vaccine)|Participants will receive a single intramuscular (IM) injection of study vaccine on Day 1.
89531861|NCT05070546|Placebo Comparator|C1 G2: Healthy Adults, 18-59 Years (Placebo)|Participants will receive a single IM injection of matching placebo on Day 1.
89531862|NCT05070546|Experimental|C2 G3: High Risk Adult, 18-59 Years (RSV Vaccine)|Participants will receive a single IM injection of study vaccine on Day 1.
89202397|NCT02561936|Experimental|Panel 1: Group 1|Participants will receive Treatment A (25 milligram [mg] rilpivirine [RPV] formulated as the oral tablet under fed condition [standardized breakfast]) followed by Treatment D (25 mg RPV formulated as granules formulation G002 [10 g of 2.5 mg/g granules, dispersed in water] under fed [standardized breakfast]) followed by Treatment B (25 mg RPV formulated as dispersible tablet formulation G007 [10*2.5 mg tablets, dispersed in water] under fed condition) followed by Treatment C (25 mg RPV formulated as dispersible tablet formulation G009-01 [10*2.5 mg tablets, dispersed in water] under fed condition).
89471450|NCT04812613||Mix-method community based participatory action research|"Phase 1 study: we will conduct 50 semi-structured questionnaires. Data from the participants and literature will then be triangulated, coded, and analyzed using NVivo software. Researchers will transcribe interviews, create a code guide, code, analyze and report the data to appropriately inform the intervention (Phase 2).~Phase 2: 6 month follow-up with a questionnaire focused on socio-demographic data, questions on participants' smoking and other substance use habits, mental health, as well as questions on participants' social networks.. Participants will be informed that they can skip any of the questions if they are uncomfortable answering them. Qualitative data will be analyzed using NVivo, and quantitative data will be analyzed using SAS or R software. Phase 2 findings will be reported and submitted to an appropriate peer-review journal."
89471451|NCT04799431|Experimental|Neoantigen Vaccine with Poly-ICLC adjuvant and Retifanlimab|All participants receive this intervention.
89471452|NCT04798235|Experimental|TSHA-101|Subjects who will receive one-time intrathecal TSHA-101, brain volume based sliding scale for dosage
89471453|NCT04792853|Experimental|Tab-G (tablet-based group CBT education)|Tab-G participants will receive 4 weekly CBT(cognitive behavioral therapy)-based group learning sessions to encourage a simple walking activity through videoconferencing meetings in a group of 5 members. The educational materials emphasize shared goal setting and mutual reinforcement.
89471454|NCT04792853|No Intervention|Usual care group|A usual care group will receive general arthritis management education. Participant are instructed to maintain usual activity during the study period.
89471455|NCT04785872|Experimental|Intervention group|
89471456|NCT04785872|No Intervention|Control group|
89471457|NCT04768647||Main cohort|Main cohort of all patients
89471458|NCT04768647||Subgroup of patients with imbalance|Subgroup of patients with imbalance
89471459|NCT04766424|Experimental|Behavioral sleep extension group|Participants in the sleep extension group will receive a fitbit, weekly coaching calls and educational materials for 8 weeks. In months 3-6, they will receive educational materials and an email from the coach each month.
89471460|NCT04766424|Other|Health education|Participants in the health education group will receive 8 weekly health education emails and telephone calls to confirm their receipt and clarify any concepts from the materials. In months 3-6, they will receive monthly health education materials.
89471461|NCT04764539|Active Comparator|Stimuli administered via 2D format on an iPad Pro|Participants were given the Video-Assisted Speech Therapy (VAST) video-modeling stimuli in a 2D format (iPad Pro). Three children with ASD, between the ages of 4 and 8, participated in a 14-sessions-long study that utilized the tablet-based VAST application. Sessions were held twice a week with each lasting approximately 15 minutes (i.e. +/- 5 minutes).
89471462|NCT04764539|Active Comparator|Stimuli administered in 3D format via VR goggles and bone conduction headphones|Participants were given the Video-Assisted Speech Therapy (VAST) video-modeling stimuli in a VR format paired with a custom 3D-printed VR headset. Three children with ASD, between the ages of 4 and 8, participated in a 14-sessions-long study that utilized a 3D VR-integrated VAST prototype with bone conduction audio. Sessions were held twice a week with each lasting approximately 15 min (i.e. +/- 5 minutes).
89471463|NCT04738617|Experimental|Warm-up based on small-sided games|Intervention A is based on football-specific small-sided games (SSGs), consisting of 4 versus 4 matches (with mini-goals), performed in a 30 m by 24 m court (Giménez et al., 2018), using five sets of 90 seconds of work interspersed with 30 seconds of pause, in a total duration of 10 minutes.
89471464|NCT04738617|Experimental|Warm-up based on potentiation principles (e.g., speed, change of direction, plyometrics)|"Intervention B is based on speed, COD and plyometrics (i.e., a potentiation protocol), inspired by ideas presented by Howe, Coward, and Price (2017). Participants will perform five repetitions of the following exercises, in this order: unilateral hurdle hops and lateral hurdle hops with each lower limb; CMJ; broad jump; forward in and out; slalom jumps; lateral scissor jumps; single leg linear hops. Each intervention will last ~10 minutes and will be applied in the football field."
89471465|NCT04736537|Experimental|Healthy Controls|
89471466|NCT04726852||Patients|Patients having elective cardiac surgery
89471467|NCT04724668|Other|Morning light version+ Melatonin|Morning light version and melatonin 3mg capsule (3hrs before DLMO)
89471468|NCT04724668|Other|Morning light version+ Placebo|Morning light version and placebo capsule (3hrs before DLMO)
89471469|NCT04715659||COPD patients|
89471470|NCT04642053|Experimental|Immediate Treatment|Participants in the Immediate Treatment Group will receive DTTC Treatment four times per week (45-minute sessions each) for 8 weeks. Total duration will be 180 minutes/week over 32 sessions. Treatment will begin between 1-3 weeks following the diagnostic evaluation.
89531863|NCT05070546|Placebo Comparator|C2 G4: High Risk Adult, 18-59 Years (Placebo)|Participants will receive a single IM injection of matching placebo on Day 1.
89202398|NCT02561936|Experimental|Panel 1: Group 2|Participants will receive treatment B followed by treatment A then treatment C followed by treatment D.
89471471|NCT04642053|Experimental|Delayed Treatment|The Delayed Treatment Group serves as a control during the period in which participants are waiting to begin treatment. A delayed treatment onset is employed to control for maturation effects. Participants in the Delayed Treatment Group will receive DTTC Treatment four times per week (45-minute sessions each) for 8 weeks. Total duration will be 180 minutes/week over 32 sessions. Treatment will begin after an 8-week delay following the diagnostic evaluation.
89471472|NCT04640337|Experimental|Group E1: IPE applied, participants believe they are receiving IPE.|IPE will be applied following the standard protocol for PT. Participants will believe they are receiving IPE.
89471473|NCT04640337|Placebo Comparator|Group E2: IPE applied, participants believe they are receiving placebo.|IPE will be applied following the standard protocol for PT. Subjects will be led to believe that the intensity of the current is below the threshold necessary to cause changes in the tissue.
89471474|NCT04640337|Placebo Comparator|Group P1: IPE not applied, participants believe they are receiving IPE.|The needle will be inserted under the skin but the current will not be passing through. The subjects will see a shame video on the ultrasound screen so they will believe that the IPE is being performed.
89471475|NCT04640337|Placebo Comparator|Group P2: IPE not applied, participants believe they are receiving placebo.|The needle will be inserted under the skin, subjects will be led to believe that the intensity of the current is below the threshold necessary to cause changes in the tissue.
89471476|NCT04630015||Observational (surveys)|Patients complete surveys over 5-10 minutes at baseline (i.e. before participating in the program), and at 9 and 15 weeks follow up on the impact of COVID-19 on survivorship. Patients also complete a survey assessing how patients rate telehealth classes in the Survivorship Wellness program.
89471477|NCT04626271|Experimental|"ACR | U.S. Urine Analysis Test System"|Urine samples are collected and tested by a lay user, using the new home use device. The lay user test results are compared to the results obtained by testing the same urine sample on the comparison device.
89471478|NCT04622644|Experimental|Single Arm|All patients perform StrokeWave exam, after NCCT and before CTA acquisition.
89471479|NCT04609189|Experimental|Pearlium®/EffectiCal®|
89471480|NCT04609189|Active Comparator|Calcium Carbonate/Vitamin D3|
89471481|NCT04604795|Experimental|Part A:GSK3915393 DLs 1,3,4,intravenous (IV) microdose and placebo (Sequence A)|In Part A, participants will receive dose levels (DLs) 1, 3, 4, IV microdose of GSK3915393, and placebo in a pre-determined sequence (Sequence A). There will be a washout period of at least 7 days between each dose. Oral dose levels will be determined based on safety, tolerability and PK data.
88948269|NCT01934205|Experimental|Part A (Cohort3)|In Part A, participants will receive GSK2140944 1000 mg intravenous (IV) infusion over 8 hours x 1 dose
88948270|NCT01934205|Experimental|Part A (Cohort4)|In Part A, participants will receive GSK2140944 1000 mg intravenous (IV) infusion over 12 hours x 1 dose
88948271|NCT01934205|Experimental|Part A (Cohort5)|In Part A, participants will receive GSK2140944 1000 mg intravenous (IV) infusion. Optional Cohort or Part and will only be used if necessary. Sampling times are to be determined based on the review of preliminary PK results from prior study parts and/or cohorts.
88948272|NCT01934205|Experimental|Part A (Cohort6)|In Part A, participants will receive GSK2140944 1000 mg intravenous (IV) infusion. Optional Cohort or Part and will only be used if necessary. Sampling times are to be determined based on the review of preliminary PK results from prior study parts and/or cohorts.
88948273|NCT01934205|Experimental|Part B (Cohort1)|In Part B, participants will receive GSK2140944 1000 mg IV infusion, q12h x 5 doses. Optional Cohort or Part and will only be used if necessary. Sampling times are to be determined based on the review of preliminary PK results from prior study parts and/or cohorts.
88948274|NCT01934205|Experimental|Part B (Cohort2)|In Part B, participants will receive GSK2140944 1000 mg IV infusion over, q12h x 5 doses. Optional Cohort or Part and will only be used if necessary. Sampling times are to be determined based on the review of preliminary PK results from prior study parts and/or cohorts.
88948275|NCT01934205|Experimental|Part B (Cohort3)|In Part B, participants will receive GSK2140944 1000 mg IV infusion over, q12h x 5 doses. Optional Cohort or Part and will only be used if necessary. Sampling times are to be determined based on the review of preliminary PK results from prior study parts and/or cohorts.
88948276|NCT01934205|Experimental|Part B (Cohort4)|In Part B, participants will receive GSK2140944 1000 mg IV infusion over q12h x 5 doses. Optional Cohort or Part and will only be used if necessary. Sampling times are to be determined based on the review of preliminary PK results from prior study parts and/or cohorts.
88948277|NCT01934205|Experimental|Part B (Cohort5)|In Part B, participants will receive GSK2140944 1000 mg IV infusion over, q12h x 5 doses. Optional Cohort or Part and will only be used if necessary. Sampling times are to be determined based on the review of preliminary PK results from prior study parts and/or cohorts.
89471482|NCT04604795|Experimental|Part A:GSK3915393 DLs 1,2,4,IV microdose and placebo (Sequence B)|"In Part A, participants will receive dose levels 1, 2, 4, IV microdose of GSK3915393 and placebo in a pre-determined sequence (Sequence B).~There will be a washout period of at least 7 days between each dose. Oral dose levels will be determined based on safety, tolerability and PK data."
89471483|NCT04604795|Experimental|Part A:GSK3915393 DLs 1,2,3,IV microdose and placebo (Sequence C)|"In Part A, participants will receive dose levels 1, 2, 3, IV microdose of GSK3915393 and placebo in a pre-determined sequence (Sequence C).~There will be a washout period of at least 7 days between each dose. Oral dose levels will be determined based on safety, tolerability and PK data."
89531864|NCT05070546|Experimental|C3 G5: Adults, 65 Years and Older (RSV Vaccine)|Participants will receive a single IM injection of study vaccine on Day 1.
88948278|NCT01934205|Experimental|Part B (Cohort6)|In Part B, participants will receive GSK2140944 1000 mg IV infusion over, q12h x 5 doses. Optional Cohort or Part and will only be used if necessary. Sampling times are to be determined based on the review of preliminary PK results from prior study parts and/or cohorts.
88948279|NCT01934244||Per Protocol|All enrolled patients in which all inclusion/exclusion criteria were met and the NovaSure endometrial ablation was completed.
88948280|NCT01934244||Primary|All enrolled patients in whom the Novasure device was inserted.
88948281|NCT01934244||Intent to treat|All enrolled patients in which NovaSure device was attempted.
88948282|NCT01934257|Other|Marketed milk-based lactose-containing infant formula|
88948283|NCT01934257|Other|Marketed milk-based lactose-free infant formula|
88948284|NCT01934257|Other|Marketed soy-based lactose-free infant formula|
88948285|NCT01934270|Experimental|Anaerobic Test|
88948286|NCT01934283|No Intervention|operated patients|small bowel obstrucion patients who needed surgery for treatment of obstruction.
88948287|NCT01934322|Experimental|Case Management|"Furnish specific assistance and to provide referrals for the patients:~If the social determinants are not adequate, the team will lend assistance for obtaining income entitlements, health insurance coverage if eligible, stable housing, schooling for children, etc.~If there are mental disturbances, the team will refer to mental health departments inside the hospital, and if necessary, to a psychiatrist, psychologist or general practitioner (GP) out in the community.~If the patient presents risk behaviors, the team will refer to substance abuse services and links to community services in order to maintain continuity of care.~In case of somatic problems, the team will find a new GP or make contact with the previous provider, contingent on the patient's consent."
88948288|NCT01934322|No Intervention|Control|Patients randomized to control group (usual care) will receive standard emergency care by physicians (resident or attending physician) and nurses, without the case manager been involved. Nevertheless, the mobile team will take contact with each patient of the control group, giving them short information through a flyer (flyer) which will underline the existence of the mobile team, its addresses and telephone numbers.
88948289|NCT01934348|Experimental|Psychological First Aid|Behavioral intervention delivered to crime victims during 2-3 in-person interactions within 1 month of the assault.
88948290|NCT01934348|Active Comparator|Usual victim advocacy services|Standard victim advocacy services delivered to crime victims within 1 month of the assault.
88948291|NCT01934361|Experimental|Lomustine+ buparlisib (Phase Ib)|
88948292|NCT01934361|Experimental|carboplatin+ buparlisib (Phase Ib)|
88948293|NCT01934361|Experimental|lomustine+ buparlisib (Phase II)|
88948294|NCT01934361|Placebo Comparator|lumustine + placebo (Phase II)|
88948295|NCT01934361|Experimental|carboplatin+ buparlisib (Phase II)|
88948296|NCT01934374|Experimental|Stroke|On the 30th day post stroke (D30), the exjperimental group will start to receive the task-oriented lower extremity strengthening training (TOLEST) program for four weeks, one hour per session and three sessions per week. The TOLEST focuses on using task-specific circuit training combined with strengthening of bilateral lower limbs.
88948297|NCT01934374|No Intervention|Control|The control group will receive equal-dose exercises starting on D30, with the emphasis on stretching and non-functional movements of the affected lower extremity.
88948298|NCT01934413|Active Comparator|Technology-Enhanced TPC|In addition to receiving usual palliative care service in the hospital setting, Technology-Enhanced Transitional Palliative Care patients will receive Transitional Care from the Palliative Care consulting team beginning in the hospital within 24 hours of study enrollment and continuing post discharge for eight weeks in their homes in rural locations by means of video visits with the Palliative Care consulting team.
88948299|NCT01934413|Other|Usual standard of care|The control group will receive only the current standard palliative care service in the hospital setting, which includes standard in-hospital palliative care consultation and standard discharge planning.
88948300|NCT01934426||Admission High Risk|Admission High Risk
88948301|NCT01934439|Experimental|PAAD (Proximal Arm AMES Device)Treatments|"The PAAD flexes and extends the elbow, and it abducts and adducts the shoulder, where abduction is away from the side of the body, and adduction is towards it. Elbow extension occurs simultaneously with shoulder abduction, and elbow flexion occurs simultaneously with shoulder adduction. At the same time as the movements, vibrators are utilized to activate muscle spindle Ia receptors in the muscles of the arm to exaggerate the perception of movement."
88948302|NCT01934465||Avastin regimens|Patients who have either received or who are going to receive chemotherapy plus Avastin (bevacizumab)
88948303|NCT01934491|Experimental|Cognitive Training A|emotional memory training exercise
88948304|NCT01934491|Active Comparator|Cognitive Training B|memory training exercise
88948305|NCT01934530|Active Comparator|Connective Tissue Graft - Control|The donor tissue was harvested from tissue palatal to maxillary premolars and anterior to the mesial of the first molars. A horizontal incision corresponding to the width of the recipient bed plus 4mm was made 3 mm apical to the gingival margin. A small secondary vertical incision was tolerated on the mesial aspect of the surgical site to allow for a split thickness technique. The flap was then positioned over the graft and sutured with attempts to cover the grafted tissue to 2mm coronal to the implant/abutment interface pending flap tension. Follow up was monitored over 6 months at various time-points.
88948306|NCT01934530|Experimental|Alloderm - Test|ADM graft was prepared according to the manufacturer's instructions. The preparation requires rehydration in 50ml sterile saline or Ringers Solution for five minutes and repeated twice. The graft was then transferred to the recipient bed with the basement membrane side facing up and connective tissue on the periosteum. The allograft was trimmed to cover the defect dimensions up to the implant-abutment interface. There was a 4mm margin added to the width on each side to account for lateral contraction as with the connective tissue. With sterile moist gauze, pressure was applied to the graft for proper adaptation to the wound bed. The graft was sutured with a single sling and the flap with a double sling. Simple interrupted sutures were used to close vertical releases.
88948307|NCT01934543|Experimental|Polyunsaturated fatty acids diet|During 4 weeks, subjects eat a diet high in polyunsaturated fatty acids (percent of total caloric intake: 15.0% from proteins; 50.0% from carbohydrates; 35.0% from fat: 6.0% from saturated fat; 14.4% from monounsaturated fat; 12.6% from n-6 polyunsaturated fat).
89019164|NCT00333333||Pre-eclampsia exposed|Infants who are born to mothers who had pre-eclampsia
89471484|NCT04604795|Experimental|Part A:GSK3915393 DLs 2,3,4,IV microdose and placebo (Sequence D)|"In Part A, participants will receive dose levels 2, 3, 4, IV microdose of GSK3915393 and placebo in a pre-determined sequence (Sequence D).~There will be a washout period of at least 7 days between each dose. Oral dose levels will be determined based on safety, tolerability and PK data."
89471485|NCT04604795|Experimental|Part B: Cohort 1: Participants receiving GSK3915393 DL X|Participants will receive GSK3915393 dose level X twice daily during Part B of the study. Dose levels will be determined based on safety, tolerability and PK data from Part A.
89471486|NCT04604795|Placebo Comparator|Part B: Cohort 1: Participants receiving placebo|Participants will receive placebo matching GSK3915393 dose level X during Part B of the study.
89471487|NCT04604795|Experimental|Part B: Cohort 2: Participants receiving GSK3915393 DL Y|Participants will receive GSK3915393 dose level Y twice daily during Part B of the study. Dose levels will be determined based on safety, tolerability and PK data from Part A and Part B.
89471488|NCT04604795|Placebo Comparator|Part B: Cohort 2: Participants receiving placebo|Participants will receive placebo matching GSK3915393 dose level Y twice daily during Part B of the study
89471489|NCT04604795|Experimental|Part B: Cohort 3: Participants receiving GSK3915393 DL Z|Participants will receive GSK3915393 dose level Z twice daily during Part B of the study. Dose levels will be determined based on safety, tolerability and PK data from Part A and Part B.
89471490|NCT04604795|Placebo Comparator|Part B: Cohort 3: Participants receiving placebo|Participants will receive placebo matching GSK3915393 dose level Z twice daily during Part B of the study.
89471491|NCT04604795|Experimental|Part C: GSK3915393 IV/GSK3915393 IV+ITZ/GSK3915393+water/GSK3915393+GFJ/GSK3915393+ITZ (Sequence A)|Participants will receive GSK3915393 IV microdose in period 1 followed by combination of GSK3915393 IV microdose and itraconazole (ITZ) in period 2. Participants will then receive oral GSK3915393 plus water in period 3, oral GSK3915393 plus grape fruit juice (GFJ) in period 4 and oral GSK3915393 plus ITZ in period 5.
89471492|NCT04604795|Experimental|Part C: GSK3915393 IV/GSK3915393 IV+ITZ/GSK3915393+GFJ/GSK3915393+water/GSK3915393+ITZ (Sequence B)|Participants will receive GSK3915393 IV microdose in period 1 followed by combination of GSK3915393 IV microdose and ITZ in period 2. Participants will then receive oral GSK3915393 plus GFJ in period 3, oral GSK3915393 plus water in period 4 and oral GSK3915393 plus ITZ in period 5.
89471493|NCT04587128|Experimental|Cohort A: No Previous EGFR|"Participant who have not be previously exposed to anti-EGFR therapies and are in the first or second-line metastatic treatment setting.~Panitumumab (6mg/kg) or Cetuximab 500mg (per treating physician) on day 1 and 15 of a 28-day cycle"
89471494|NCT04587128|Experimental|Cohort B: Retreatment|"Participants with treatment refractory disease who have previously benefitted (greater than or equal to 4 months ago) from anti-EGFR therapy.~Panitumumab (6mg/kg) or Cetuximab 500mg (per treating physician) on day 1 and 15 of a 28-day cycle, +/- Irinotecan (180mg/m^2) every 2 two weeks per standard of care"
89471495|NCT04578314|Experimental|Relating module + Treatment as usual|Participants in this arm will receive 16 weekly sessions with Relating Therapy (RT) over 5 months in addition to their treatment as usual.
89471496|NCT04578314|Active Comparator|Treatment as usual|Treatment as usual will include medication management, supportive brief counselling sessions and various types of psychosocial (e.g. social work guided support, peer support) and monitoring provided by Mental Health Services, with individual and family psychological therapies offered occasionally. Individual therapies may include Cognitive Behavior Therapy or psychodynamic interventions.
89471497|NCT04574466|No Intervention|Enhanced Treatment As Usual (ETAU)|The control group will receive enhanced treatment as usual (ETAU). ETAU means that the research team will advise the participants to contact their doctor in case of physical or mental health problems. Moreover, the research team will hand over written information (official booklet) about the operating of the Swiss health care system. Adequate treatment will be provided by a physician, usually, a general practitioner who acts as a gate-keeper (an asylum seeker or refugee has to go first to his/her assigned GP in order to get access to the health care system).
89471498|NCT04574466|Experimental|Problem Management Plus|"The participants who are assigned to the intervention group will receive five sessions of PM+, a psychological intervention which has been developed by the WHO. PM+ is a new short, transdiagnostic (i.e., not specifically aimed at treating a certain mental disorder) program aiming to reduce common mental health symptoms and improve psychosocial functioning.~PM+ is a new, brief, psychological intervention program based on Cognitive Behaviour Therapy (CBT) techniques that are empirically supported and formally recommended by the WHO. The full protocol was developed by the WHO and the University of New South Wales, Australia. The manual involves the following empirically supported elements: problem solving plus stress management, behavioural activation, and accessing social support. These elements have been recommended in recent WHO guidelines. PM+ has proven to be effective by two randomized controlled trials (RCTs) in Kenya and Pakistan."
89471499|NCT04563273|Experimental|Healthy people aged 18-45|Healthy people aged 18-45 has 40 subjects,and it is considered as BCG purified protein derivative(BCG-PPD) skin test and Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10（EC） detection result all negative.
89471500|NCT04563273|Experimental|Healthy people aged 46-65|Healthy people aged 46-65 has 40 subjects,and it is considered as BCG purified protein derivative(BCG-PPD) skin test and Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10（EC） detection result all negative.
89471501|NCT04563273|Experimental|Healthy people aged 11-17.|Healthy people aged 11-17 40 subjects,and it is considered as BCG purified protein derivative(BCG-PPD) skin test and Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10（EC） detection result all negative.
89471502|NCT04563273|Experimental|Healthy people aged 6-10|Healthy people aged 6-10 has 40 subjects,and it is considered as BCG purified protein derivative(BCG-PPD) skin test and Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10（EC） detection result all negative.
89202399|NCT02561936|Experimental|Panel 1: Group 3|Participants will receive treatment C followed by treatment B then treatment D followed by treatment A.
89019165|NCT00329979||1|Radial access
89019166|NCT00329979||2|Femoral access
89019167|NCT00330018|Experimental|1|PO Valganciclovir
89019168|NCT00330018|Active Comparator|2|PO Acyclovir
89202400|NCT02561936|Experimental|Panel 1: Group 4|Participants will receive treatment D followed by treatment C then treatment A followed by treatment B.
89471503|NCT04560088|Experimental|Mindfulness|Mindfulness using an individual mobile health mindfulness-based intervention training. These sessions are intended to act as a general introduction to mindfulness meditation and incorporate techniques such as breath awareness and body scanning.
89471504|NCT04560088|Active Comparator|Breathing|Breathing control intervention will use an individual breathing app. The intervention is designed to be structurally equivalent to the mindfulness-based study intervention on key common factors of psychosocial interventions: (a) the number of sessions, (b) the length of sessions, and (c) delivery format.
89471505|NCT04553211|Experimental|Expedited Partner Therapy (EPT)|Participants in the EPT arm will receive up to five partner antibiotic treatment packets to deliver to their recent sexual partners following a diagnosis of gonorrhea (GC) and/or chlamydia (CT). The intervention will be repeated with all subsequent episodes of GC and/or CT infection during the 12-month follow-up period.
89471506|NCT04553211|No Intervention|Control|Participants in the control arm will receive standard-of-care counseling on partner notification following a diagnosis of gonorrhea (GC) and/or chlamydia (CT). The same counseling will be repeated with all subsequent episodes of GC and/or CT infection during the 12-month follow-up period.
89471507|NCT04552782|Experimental|Alcohol Cognitive Bias Modification (CBM) + PTSD CBM|
89471508|NCT04552782|Experimental|Alcohol CBM + PTSD Sham|
89471509|NCT04552782|Experimental|Alcohol Sham + PTSD CBM|
89471510|NCT04552782|Sham Comparator|Alcohol Sham + PTSD Sham|
89471511|NCT04539977|Experimental|LS-SCLC Surgery|"Induction therapy: TQB2450 1200mg, d1+carboplatin (AUC5) , d1+ etoposide 100mg/m2, d1,d2,d3, q3w, 4 cycles.~Surgery (decided by MDT) Maintenance therapy: Etoposide,100 mg/m2 , d1-3 + Carboplatin,AUC5 (ivgtt, q3w,Two cycles) + TQB24501200mg, d1 (ivgtt, q3w, 1 Year) or progression disease, or other discontinuation criteria (intolerant toxicity, no more clinical benefit, receiving another anti-tumor regimen [except radiotherapy], withdrawal of informed consent or death)."
89471512|NCT04539977|Experimental|LS-SCLC Radiotherapy|"Induction therapy: TQB2450 1200mg, d1+carboplatin (AUC5) , d1+ etoposide 100mg/m2, d1,d2,d3, q3w, 4 cycles.~Radiotherapy (decided by MDT) Maintenance therapy: Etoposide,100 mg/m2 , d1-3+Carboplatin,AUC5 (ivgtt, q3w,Two cycles)+TQB24501200mg, d1(ivgtt, q3w, 1 Year) or progression disease, or other discontinuation criteria (intolerant toxicity, no more clinical benefit, receiving another anti-tumor regimen [except radiotherapy], withdrawal of informed consent or death)."
89471513|NCT04538911|Experimental|Experimental group|30 tuberculosis patient were randomly assigned to the experimental group and the control group. The experimental group was injected with BCG-PPD drug once, while the control group was injected with BCG-PPD drug once
89471514|NCT04538911|Other|control group|30 tuberculosis patient were randomly assigned to the experimental group and the control group. The experimental group was injected with BCG-PPD drug once, while the control group was injected with BCG-PPD drug once
89471515|NCT04535141|Experimental|Olanzapine Arm|Olanzapine 5mg tablet with chemotherapy, and 3 days after
89471516|NCT04535141|Placebo Comparator|Placebo Arm|
88948308|NCT01934543|Experimental|Saturated fatty acids diet|During 4 weeks, subjects eat a diet high in polyunsaturated fatty acids (percent of total caloric intake: 15.0% from proteins; 50.0% from carbohydrates; 35.0% from fat: 13.4% from saturated fat; 15.3% from monounsaturated fat; 4.0% from n-6 polyunsaturated fat).
88948309|NCT01934569|Experimental|Active tratment|Pravastatin, midazolam, losartan, omeprazole, caffeine single dose alone or in combination with PF-05089771
88948310|NCT01934595|Experimental|Varying amounts of Beneprotein|1.5grams/kg/day, 2.0 grams/kg/day, and 2.5 grams/kg, day
88948311|NCT01934595|Active Comparator|1 Gram - Standard Therapy given in ICU|1 gram/kg/day of protein
88948312|NCT01934608|Experimental|Refill synch|Participants in this group will have their medication refill schedule synchronized.
88948313|NCT01934608|No Intervention|Control|Participants in this arm will receive usual care
88948314|NCT01934621|Experimental|Strategy Training|Strategy training is a form of meta-cognitive instruction that trains individuals with stroke-related cognitive impairments to identify and prioritize problematic daily activities, identify the barriers impeding performance, generate and evaluate their own strategies to address barriers, and apply these skills through iterative practice. Participants use printed workbooks to learn and apply this method.
88948315|NCT01934621|Placebo Comparator|Attention Control|The attention control intervention will control for the non-specific effects of strategy training. The therapists will administer the standardized and dose-matched protocol, using scripted open-ended questions to facilitate participants' reflections on their rehabilitation activities and experiences. In lieu of the strategy training workbook materials, participants will complete a daily journal, and discuss their entries during attention control sessions.
88948316|NCT01934634|Experimental|LCL161 +Gemcitabine +nab-Paclitaxel|LCL161 (tablets): 600, 1200, or 1800 mg once a week (Day 1, 8, 15) for 3 weeks, every 28 days Gemcitabine IV: 1,000 mg/m2 once a week (Day 1, 8, 15) for 3 weeks, every 28 days nab-paclitaxel IV: 100 or 125 mg/m2 once a week (Day 1, 8, 15) for 3 weeks, every 28 days
88948317|NCT01934673||Subjects with diabetes (type 2)|
88948318|NCT01934686||Subjects with diabetes mellitus (type 2)|
88948319|NCT01934699|Active Comparator|MRI-Arm|Myocardial vitality determination based on MRI diagnostics.
88948320|NCT01934699|Experimental|Echo-Arm|Myocardial vitality determination using echocardiography in combination with 2D-Strain Analysis.
88948321|NCT01934712|Experimental|FIAsp|Each subject will be randomly allocated to one of the two treatment sequences consisting of 2 dosing visits
88948322|NCT01934712|Active Comparator|NovoRapid®|Each subject will be randomly allocated to one of the two treatment sequences consisting of 2 dosing visits
88948323|NCT01934738|Experimental|Group 1: Cohort 1|
88948324|NCT01934738|Experimental|Group 1: Cohort 2|
88948325|NCT01934738|Experimental|Group 1: Cohort 3|
88948326|NCT01934738|Experimental|Group 2: Cohort 4|
88948327|NCT01934738|Experimental|Group 1: Cohort 5|
88948328|NCT01934738|Experimental|Group 2: Cohort 6|
88948329|NCT01934751|Other|Opioid dependent|Subjects with a possible opioid use disorder, as determined by positive responses on the eligibility form: has used opioids within the past 30 days, opioid use has been a problem, and at least one harmful consequence of opioid use has been present (eg. withdrawal symptoms, or problems with family, friends, work, money etc.).
89019169|NCT00333528|Experimental|1|Administration of one dose of the active drug (6 volunteers)
89471517|NCT04534595||Students attending SBHCs|The students enrolled in 5 schools with the school based health clinic implemented would be studied in terms of their experience during the COVID-19 pandemic.
89471518|NCT04534387|Experimental|Experimental Group|This group will receive the Spanish-Language Hearing Loss Toolkit materials.
89471519|NCT04534387|Active Comparator|Active Control Group|This group will receive standard of care Spanish language information from the American Speech-Language-Hearing Association (ASHA) Audiology Series
89471520|NCT04534023|Experimental|trial group|
89471521|NCT04534023|Placebo Comparator|control group|
89471522|NCT04511741||invasive mechanical ventilation|
89471523|NCT04511741||non invasive mechanical ventilation|
89471524|NCT04503317|Experimental|active acupuncture low level laser and aerobic exercise|active acupuncture, low level laser and aerobic exercise
89471525|NCT04503317|Active Comparator|aerobic exercise|aerobic exercise
89471526|NCT04493541|Experimental|BMS-986256|
88948330|NCT01934751|Other|Alcohol dependent|Patients who indicate they have a problem with alcohol will be asked to complete the AUDIT, a validated, 10-item instrument that measures the severity of an alcohol problem. The AUDIT enquires about core features of alcohol dependence, such as failure to fulfill obligations. A score of 8 or more indicates possible alcohol dependence.
88948331|NCT01934764||autoimmune disease|
89471527|NCT04493541|Placebo Comparator|Placebo|
88948332|NCT01934777|Experimental|TREATED GROUP|DHA 250 mg plus Vitamin E (39 UI) plus Choline 201 mg by mouth every day in association with lifestyle intervention [hypocaloric diet (25-30 Kcal/kg/day) or isocaloric (40-45 Kcal/kg/day) and physical activity] for 6 months
88948333|NCT01934777|Placebo Comparator|PLACEBO GROUP|placebo: this group will treated with identical placebo pearls given orally in association with lifestyle intervention [hypocaloric diet (25-30 Kcal/kg/day) or isocaloric (40-45 Kcal/kg/day) and physical activity] for 6 months
88948334|NCT01934803|Active Comparator|Zinc gluconate|Study participants will receive zinc gluconate supplements (15 mg for men and 12 mg for women) and will be instructed to take one pill daily for 18 months.
88948335|NCT01934803|Placebo Comparator|Placebo|Study participants will receive identically packaged placebo (sucrose) pills and will be instructed to take one pill daily for 18 months.
88948336|NCT01934816|Experimental|Glimepiride|4mg of Glimepiride once only before vascular testing and intradermal injections of GLP-1 and its analogues
88948337|NCT01934816|Placebo Comparator|Placebo tablet|Placebo tablet is given in the morning of the intradermal injections of GLP-1 and its analogues
88948338|NCT01934816|Active Comparator|Glyburide|10mg of Glyburide before study visit and intradermal injections of GLP-1 and its analogues
89471528|NCT04480918||Major Depressive Episode|After referral to the University of Iowa's Interventional Psychiatry Clinic, the patient will be clinically evaluated and, if appropriate, commence the procedural-based treatment course.
89471529|NCT04477109|Active Comparator|low level laser in addition to diet recommendations|The laser consists of a semiconductor and operates at a wavelength of 650 nanometre. The laser installed in the watch comprises 10 individual laser beams for the wrist and an additional adapter for nasal stimulation. The output power is 5 megawatt, but it can also be adjusted. The device operates at an ambient temperature of -20 to +40 ° C and a relative humidity of ≤ 85%. The laser watch can be used for a variable irradiation period of 10-60 min. the device will be applied on specific acupuncture points (N acupuncture point, Radial artery acupuncture points, and ulnar artery acupuncture points) combined with nasal laser irradiation at the same time, once per day, 3 times per week for three months
89471530|NCT04477109|Sham Comparator|sham laser application in addition to diet recommendations|while the control group will stick to the same line of treatment but with sham laser application
88948339|NCT01934829|Experimental|urea-based cream|Advanced HCC throughout China were treated with 10% urea-based cream 3 times per day plus best supportive care, starting on day 1 of sorafenib treatment, for up to 12 weeks
88948340|NCT01934829|Placebo Comparator|best supportive care|BSC included the ad libitum use of non-urea-based moisturizing creams, alcohol-free moisturizer and petroleum jelly. Once HFSR occurred, patients were allowed any cream, including urea based creams, as guided by the investigator
88948341|NCT01934842|Experimental|TAP20-C|TAP20-C
88948342|NCT01934842|Active Comparator|SAFE-T-FILL|SAFE-T-FILL
88948343|NCT01934907|Experimental|washed RBC|Packed RBCs are Washed and then, transfused.
88948344|NCT01934907|No Intervention|pack RBC|Packed RBCs are transfused.
88948345|NCT01934933|Active Comparator|celebrex|celebrex capsule, 0.2 gram bid, 52 weeks
88948346|NCT01934933|Active Comparator|Enbrel|etanercept injection, 25mg per injection, 50mg/week, 52 weeks
88948347|NCT01934933|Active Comparator|Enbrel plus Celebrex|50mg/week Enbrel by hypodermic injection plus Celebrex 0.2 gram bid, 52 weeks
88948348|NCT01934946|Experimental|comprehensive rehabilitation 10 days|comprehensive rehabilitation PT OT once per day for 10 times within 14 days hospitalization
88948349|NCT01934946|Placebo Comparator|home rehabilitation|home rehabilitation 6 times of PT home visit within 3 months after discharge
88948350|NCT01934959|Experimental|Probiotics|
88948351|NCT01934998||SCA6 and control|SCA6 and control
89471531|NCT04453709|Experimental|Problem Management Plus for Immigrants at family settings|PMP-I intervention aims to develop skills in coping adaptively in a new culture, seeking help and support for mental health problems, and other life skills opportunities that can help to improve their quality of life. PMP-I intervention includes stress management through breathing exercises and yoga, problem solving, behavioral activation, and skills to strengthen social support.
89471532|NCT04453709|Active Comparator|Talk program with Community Support Service Pamphlet (CSS)|Family receives pamphlet including list of community support service institutions that provide various health and well-being services.
88948352|NCT01934998||SCA6 or controls|Twelve SCA6 patients and 8 controls to be studied
88948353|NCT01935011||PD DBS 60 Hz, 130 Hz or DBS off|PD DBS on 60 Hz stimulation, 130 Hz stimulation or DBS off
88948354|NCT01935024|No Intervention|Normal Activity level|
88948355|NCT01935024|Active Comparator|Personalized Exercise Regimen|
88948356|NCT01935050|Experimental|Guided Cognitive-Behavioral Self-Help|All participants will receive the experimental intervention: Guided Cognitive-Behavioral Self-Help. The 10 patient treatment modules will incorporate exercise, behavioral activation, thought monitoring and restructuring, relaxation training, worry control, and sleep hygiene. The four caregiver educational modules will provide caregivers with the skills needed to facilitate patients' practice of treatment techniques learned in session. For example, caregivers will be taught to help patients identify negative thoughts and replace them with more balanced alternatives and will be given tools to assist patients complete therapy goals (i.e., exercise, socializing).
88948357|NCT01935063|Experimental|Cognitive Behavioral Couple Therapy|CBCT is a 12-session therapy that includes the following: re-conceptualize PVD as a multidimensional pain problem influenced by a variety of factors including thoughts, emotions, behaviours and couple interactions; psychoeducation about PVD and its impact upon sexuality, defining/working the sexual script, mindfulness techniques, communication skills training, and sexual approach/avoidance goals work, defusion and acceptance approaches to coping with pain, among others.
88948358|NCT01935063|Active Comparator|Topical lidocaine|Nightly applications of a 5% lidocaine ointment on the vulvar vestibule, at the entry of the vagina (50mg/g, Xylocaïne®, AstraZeneca, tube of 35g) for 12 weeks, as described by Zolnoun et al. (Zolnoun, Hartmann, & Steege, 2003).
88948359|NCT01935076||Obese mother/ Macrosomic baby|Obese mother that delivers a macrosomic neonate to understand the effects neonatal exposure to maternal obesity.
88948360|NCT01935076||Obese mother/ normal weight baby|Obese mother that delivers a normal weight neonate to understand effects neonatal exposure to maternal obesity.
88948361|NCT01935076||Normal weight mother/ Macrosomic baby|Normal weight mother that delivers a macrosomic neonate
88948362|NCT01935076||Normal weight mother/ Normal weight baby|Normal weight mother who delivered a normal weight neonate
88948363|NCT01935102||Chemotherapy|MBC patients treated with a first-line chemotherapy including paclitaxel without bevacizumab
88948364|NCT01935102||bevacizumab+chemotherapy|histologically confirmed HER2-negative MBC, treated with a first-line therapy including bevacizumab 10 mg/m2 i.v. on days 1 and 15 combined with first-line paclitaxel 90 mg/m2 i.v. on days 1, 8 and 15, every 4 weeks
88948365|NCT01935115|Active Comparator|Propofol|The control group will receive propofol 1 mg/kg and remifentanil 1 mcg/kg intravenously
88948366|NCT01935115|Experimental|Ketamine|Study group will receive ketamine 0.75 mg/kg and remifentanil 1 mcg/kg intravenously
88948367|NCT01935141|Experimental|Low-Dose IV Contrast|A single intravenous dose of 30 ml of Visipaque 320 non-ionic isoosmolar contrast agent will be given for each CT scan. The CT scan will be performed using a Siemens Sensation 64-MDCT scanner.
88948368|NCT01935141|Active Comparator|Full-Dose IV Contrast|A single intravenous dose of 100ml of Visipaque 320 non-ionic isoosmolar contrast agent will be given for each CT scan. The CT scan will be performed using a Siemens Sensation 64-MDCT scanner.
88948369|NCT01935154|Placebo Comparator|Placebo|Placebo will be administered evey 3 weeks from w0 to W15 than every 12 weeks until disease progression.
88948370|NCT01935154|Experimental|Vx-001|Vx-001 will be administered evey 3 weeks from w0 to W15 than every 12 weeks until disease progression.
88948371|NCT01935167|Experimental|A Group|DW1029M 600mg for 24 weeks
88948372|NCT01935167|Experimental|B Group|DW1029M 1200mg for 24 weeks
88948373|NCT01935167|Placebo Comparator|C Group|Placebo for 24 weeks
88948374|NCT01935193|Experimental|asa resistant|asa resistant patients receive endovenous infusion of lysine acetylsalicylate 288 mg and if asa resistance has been reversed they have been prescribed oral soluble salt of lysine acetylsalicylate.
88948375|NCT01935206|Placebo Comparator|Placebo|The effect of naloxone (2 mg/kg) on secondary hyperalgesia 168 hours after a first-degree burn-injury is compared to the placebo effect.
88948376|NCT01935206|Experimental|Naloxone (2 mg/kg)|The effect of naloxone (2 mg/kg) on secondary hyperalgesia 168 hours after a first-degree burn-injury is compared to the placebo effect.
88948377|NCT01935219|Experimental|Goal Management Training + Processing Speed Training|Group receives both Goal Management Training and as well as Processing Speed Training using DriveSharp software.
88948378|NCT01935219|Active Comparator|Processing Speed Training + Brain Health Workshop|Group receives both Processing Speed Training (using DriveSharp) and participates in a Brain Health Workshop that is matched to Goal Management Training for session length and contact with trainer.
88948379|NCT01935219|Placebo Comparator|Brain Health Workshop + computer assignments|Group participates in Brain Health Workshop and is provided with computer assignments to match for time spent on the computer in the other arms.
88948380|NCT01935232||Men|140 Men
88948381|NCT01935232||Female|500 Female
88948382|NCT01935245|Experimental|Mini extracorporeal circulation|Patients undergoing coronary artery bypass surgery on minimal extracorporeal circulation
88948383|NCT01935245|Active Comparator|Conventional extracorporeal circulation|Patients undergoing coronary artery bypass surgery on conventional extracorporeal circulation
88948384|NCT01935258|Experimental|Psychosomatic therapy|Psychosomatic therapy consists of a combination of information and education delivery, relaxation therapy and mindfulness, cognitive approaches and activating therapy. This multi-component approach is captured into a protocol in which therapists are able to modify the treatment in order to deliver a tailor-made treatment for patients with MUS. Psychosomatic therapy delivered by a psychosomatic therapist.
88948385|NCT01935258|Other|care as usual|Usual care of the general practitioner
88948386|NCT01935271|Experimental|Muscle Armor Supplement|Treatment with a commercially available over the counter nutritional supplement
88948387|NCT01935271|Placebo Comparator|Placebo|Sugar-based placebo drink mix
88948388|NCT01935284||Healthy Volunteers|
88948389|NCT01935297|Active Comparator|Exercise|8 weeks of supervised, structured, combined endurance and resistance training
88948390|NCT01935297|No Intervention|Control|Patients receive usual care, regular exercise is not recommended but also not prohibited
88948391|NCT01935310|Experimental|imiquimod use in photoaging|Evaluate the efficacy and safety of imiquimod as a treatment option for photoaging photoaging equal to or greater than 3.
88948392|NCT01935323|Experimental|High Intensity Interval Training|Participants will perform the HIIT protocol on an electronically-braked cycle ergometer (Quinton Excalibur, Quinton Instrument Company, Bothell, WA). Participants will perform a 20-minute protocol, consisting of four minutes of cycling at 15% of maximum anaerobic power (Max-AP) followed by 30 seconds at 85% of Max-AP. These workloads will be based upon pre-trial Wingate tests. This cycle was repeated four times within each protocol, ending with two minutes at 15% of Max-AP. This will be performed 3d/wk for 6wks, with at least 24 hrs between each session.
88948393|NCT01935323|Active Comparator|Moderate Intensity Training|Participants will perform 45-60 min (graduated over time to 60) of continuous cycling at 65% of VO¬2peak on a Monark cycle ergometer. Workload will be based upon pre-trial VO¬2peak testing. MIT exercise will be performed 5d/wk for 6wks.
88948394|NCT01935349||Diabetes mellitus (DM) and hypertension (HT)|Diabetes mellitus (DM) and/or hypertension (HT) patients in Hong Kong
88948395|NCT01935362|Placebo Comparator|placebo|Placebo administered to participant
88948396|NCT01935362|Active Comparator|Citrus supplement|Citrus supplement administered to participant
89531865|NCT05070546|Placebo Comparator|C3 G6: Adults, 65 Years and Older (Placebo)|Participants will receive a single IM injection of matching placebo on Day 1.
88948397|NCT01935375|Experimental|CNM Interpersonal Psychotherapy|CNM Interpersonal psychotherapy
88948398|NCT01935375|Active Comparator|Treatment as Usual|Treatment as Usual is psychotherapy with a mental health provider
88948399|NCT01935388|Experimental|Common canister|Use of a single MDI (instead of assigning each patient an individual MDI) for multiple mechanically ventilated patients. Inhalers will undergo a stringent cleaning protocol between administrations and storage.
88948400|NCT01935388|No Intervention|Control|Each patient will be assigned an individual inhaler as per standard of care practice.
89471533|NCT04384861|Experimental|ACTIVE|The ACTIVE arm of the project received the Mayo Clinic SMART training (1 two-hour in-person workshop) and access to the Mayo Clinic's SMART eLearning Support study modules (4 x 45 minute modules in weeks 1-4; 20 x 10 minute modules weeks 5-24)
89471534|NCT04384861|No Intervention|CONTROL|The CONTROL did not receive any interventions.
89471535|NCT04376346|Experimental|Intervention Arm|Participants in the intervention arm will complete the AIY-C curriculum that has been translated for mHealth delivery. This includes completing various activities such as completing their own risk assessment when it comes to AEP and setting goals for themselves.
89471536|NCT04376346|No Intervention|Control Arm|Participants in the control arm will complete activities that are carefully designed under different topics than the intervention arm. In this regard, participants will complete various activities such as quizzes, interactive games and videos. The investigators will ensure that participants in both arms will spend similar time on completing the activities.
89471537|NCT04374500|Experimental|Leptin infusion|This applies to protocol 1 when 10 healthy men got leptin infused locally in the forearm and forearm blood flow (FBF) was measured. The other forearm was used as the control.
89471538|NCT04374500|Experimental|Leptin infusion plus vasodilator infusion|This applies to protocol 2 when 10 healthy men got either a background infusion of leptin or saline locally in the forearm when measuring vasoresponse (FBF) to four vasodilatators. Each participant had two examinations with either leptin or saline and the order was randomised. The other forearm was used as the control.
89471539|NCT04374500|Experimental|Vasodilator infusion in CAD patients|This applies to protocol 3 when 83 men and women with known CAD (coronary artery disease) got three vasodilators locally infused in the forearm while measuring vasoresponse (FBF). The other forearm was used as the control.
88948401|NCT01935401||Women with Bulimia Nervosa|"fNIR~- Functional near-infrared spectroscopy measured-brain activity"
88948402|NCT01935401||Healthy Controls|"fNIR~- Functional near-infrared spectroscopy measured-brain activity"
88948403|NCT01935427||Volunteer test subjects|Healthy volunteer with no cardiovascular disease
88948404|NCT01935440|Active Comparator|Prevention & Testing Control|The comparison condition is focused on basic HIV risk reduction , safety and preventing drug overdose.
88948405|NCT01935440|Experimental|Prevention & Testing Intervention|The intervention condition is training on peer outreach skills which includes talking to HIV positive social network members about HIV care, medication adherence and HIV risk reduction.
88948406|NCT01935453|Experimental|Recombinant HSV-1 Injection|Intratumoral injection Single dose: 4 groups -- 106 pfu, 107 pfu, 108 pfu and 4×108 pfu Multiple dose (three injections, every 2 weeks): 2 groups -- 108, 108, 108pfu and 4×108, 4×108, 4×108pfu Continuous treatment: Upon 4 weeks follow-up after administration, if the investigator deems that continuous treatment will benefit subjects, continuous intratumoral injection may be given, and the interval between each injection will be 2 weeks.
88948407|NCT01935479|Experimental|AK159 SD 1|Single administration of AK159 dose level 1
88948408|NCT01935479|Experimental|AK159 SD 2|Single administration of AK159 dose level 2
88948409|NCT01935479|Experimental|AK159 SD 3|Single administration of AK159 dose level 3
88948410|NCT01935479|Experimental|AK159 SD 4|Single administration of AK159 dose level 4
88948411|NCT01935479|Active Comparator|MN-10-T SD|Single administration of teriparatide acetate
88948412|NCT01935479|Experimental|AK159 MD 1|Multiple administration of AK159 dose level 1
88948413|NCT01935479|Experimental|AK159 MD 2|Multiple administration of AK159 dose level 2
88948414|NCT01935479|Experimental|AK159 MD 3|Multiple administration of AK159 dose level 3
88948415|NCT01935479|Experimental|AK159 MD 4|Multiple administration of AK159 dose level 4
89471540|NCT04368689|Experimental|Floating|Participants have 3 Floatation sessions that last up to 90 minutes. Each spaced about a week apart.
89531866|NCT05061576|Active Comparator|Standard of care|Oral advice on exercise from a physician.
88948416|NCT01935479|Active Comparator|MN-10-T MD|Multiple administration of MN-10-T
88948417|NCT01935479|Placebo Comparator|Placebo MD|Multiple administration of placebo AK159
88948418|NCT01935492|Active Comparator|8 cycles of Paclitaxel & bevacizumab|8 cycles of Paclitaxel: 90 mg/m2 IV on days 1, 8 and 15 every 28 days & Bevacizumab: 10 mg/kg IV on days 1 and 15 every 28 days
88948419|NCT01935492|Active Comparator|2 x 4 cycles of Paclitaxel & bevacizumab|intermittent 2x4 cycles of Paclitaxel: 90 mg/m2 IV on days 1, 8 and 15 every 28 days & Bevacizumab: 10 mg/kg IV on days 1 and 15 every 28 days
88948420|NCT01935505||Consulting group|The physicians adopted a non-directive approach, included the five 'A' (ask, advice, assess, assist and arrange), assessing the stage of readiness in quitting smoking, strengthening clients' motivation to quit smoking using the five 'R' (relevance, risks, rewards, roadblocks and repetition) approach, and providing advice to overcome psychological craving, psychological dependence and social-cultural factors associated with tobacco dependency. Each smoker takes more than 30 min to complete the intervention.
88948421|NCT01935505||Drug intervention group|According to the smokers' level of nicotine dependency, disease history, cigarette consumption, prescription of drugs were provided, Nicotine Replacement Therapy, bupropion and varenicline.
88948422|NCT01935505||Telephone intervention group|Smokers received follow-up by a counselor at 1 week, 1, 3, 6 months and 1, 2 years using a detailed questionnaire by telephone interview. At each follow-up, we collected data, asked whether the smokers have any problem with drug use or other problems, provided problem-oriented suggestions or advice as appropriate, encouraged them to insist.
88948423|NCT01935505||Consulting+Telephone+Drug intervention|All the interventions above are include in this group
88948424|NCT01935518|Experimental|Fasudil|All the patients will take the fasudil treatment for 14 days (30mg twice a day, intravenous). 3 months later they will repeat the treatment mentioned before.
88948425|NCT01935531|Experimental|Diclofenac|3 % diclofenac in 2.5% hyaluronic acid gel (Solaraze® 3% gel) is applied twice daily in the treatment area. 3 % diclofenac in 2.5% hyaluronic acid gel (Solaraze® 3% gel) is to be applied 1cm beyond the single AK.
88948426|NCT01935544|Experimental|botulinum toxin injections|The main objective is to compare the efficiency of botulinum toxin injections depending on the localization technique: ultrasound vs. electrical stimulation.
88948427|NCT01935544|Other|ultrasound guidance|The secondary objective is to demonstrate less painful localization associated to ultrasound-guidance
88948428|NCT01935557|Active Comparator|Continuous heparin infusion group|continuous group is given an initial intravenous heparin 100u/kg and then maintain heparin infusion during procedural.
88948429|NCT01935557|Active Comparator|Intermittent heparin infusion group|Intermittent group is given an initial intravenous heparin 100u/kg. Then The ACT is tested every 30min with administration of additional heparin boluses and titration of the heparin drip based on the results and according to the judgment of the operating physician.
88948430|NCT01935570|Experimental|Magnesium|
89471541|NCT04366401|Active Comparator|Conventional Dietary Advice|"The control group will consist of participants diagnosed on the schizophrenic spectrum who will receive conventional dietary counseling (n=25) on an individual basis.~In the control group, data will be collected on the psychopathological state (PANSS and PSP scales), and blood analysis (hemogram, lipid profile, etc.). The measurements will be taken at the beginning (basal), at three and six months. The estimation of the intestinal microbiota and the usual nutritional pattern will also be evaluated at the beginning and at six months, using a stool test and a validated food frequency questionnaire, respectively. To assess the degree of adherence, GI participants will fill in a specific weekly record of the main dishes/foods consumed. At least, anthropometric parameters will also be analysed monthly (BMI, blood pressure, heart rate, abdominal perimeter)."
89531867|NCT05061576|Experimental|Active intervention|A leaflet with instructions and images on different forms of physical activities as well as clear recommendations on when to perform these.
88948431|NCT01935583|Experimental|Resilience/Adjustment Counseling|Intervention to promote resilience and adjustment (RAI) - The RAI was developed based upon considerable clinical experience and research review. The RAI is a structured approach to helping individuals after brain injury address issues related to resilience and adjustment to injury. The RAI is implemented in seven, 60-minute, in-person sessions.
88948432|NCT01935583|No Intervention|Waitlist Control|Individuals are randomly assigned to the treatment group or waitlist control (WLC) group. Individuals will complete the study measures on 2 occasions, 5 weeks apart. In fairness, WLC participants will then be offered the opportunity to participate in the intervention.
88948433|NCT01935596|Active Comparator|ropivacaïne 0,5%,|intrathecal administration of 15mg of ropivacaine 0.5%.
88948434|NCT01935596|Active Comparator|lévobupivacaïne 0,5%|intrathecal administration of 15mg of levobupivacaine 0.5%
88948435|NCT01935609|Experimental|Couples counseling|Intervention to promote couples' adjustment (TCI) - The TCI was developed based upon considerable clinical experience and research review. The TCI is a structured approach to helping couples after brain injury address issues related to relationship quality and emotional well-being. The TCI is implemented in five or six (optional parenting session) session. Each session is in-person and lasts for 120 minutes.
88948436|NCT01935609|No Intervention|Waitlist Control|Couples are randomly assigned to the treatment group or waitlist control (WLC) group. Couples will complete the study measures on 2 occasions, 5 weeks apart. In fairness, WLC couples will then be offered the opportunity to participate in the intervention.
88948437|NCT01935635|Experimental|HPDCs-T immune therapy combined with IFN|HPDCs-T immune therapy:one time every 2 weeks during 12 weeks to 36 weeks, about 2*105-1*106 cells per time,total 12 times; IFN therapy (Peg-IFN α-2b/2a):one time every 1 week according to the standards for 48 weeks
88948438|NCT01935635|Experimental|HPDCs-T immune therapy combined with ETV|HPDCs-T immune therapy:one time every 2 weeks during 12 weeks to 36 weeks, about 2*105-1*106 cells per time,total 12 times; Entecavir(ETV)therapy:0.5mg per day according guidelines for the treatment of chronic hepatitis B in the Asia Pacific Region
88948439|NCT01935635|Experimental|HPDCs-T immune therapy combined with LdT|HPDCs-T immune therapy:one time every 2 weeks during 12 weeks to 36 weeks, about 2*105-1*106 cells per time,total 12 times; Telbivudine(LdT)therapy:600mg per day according guidelines for the treatment of chronic hepatitis B in the Asia Pacific Region
88948440|NCT01935635|No Intervention|IFN treatment|IFN therapy (Peg-IFN α-2b/2a):one time every 1 week according to the standards for 48 weeks
88948441|NCT01935635|No Intervention|ETV treatment|Entecavir(ETV)therapy:0.5mg per day according guidelines for the treatment of chronic hepatitis B in the Asia Pacific Region
88948442|NCT01935635|No Intervention|LdT treatment|Telbivudine(LdT)therapy:600mg per day according guidelines for the treatment of chronic hepatitis B in the Asia Pacific Region
88948443|NCT01935648||Ropivacaine|Injection of local anaesthetic (ropivacaine) into the knee joint following hip arthroplasty. Total dose 200mls of 0.2% ropivacaine or 400mg at the time of surgery. This will be followed by a continuous infusion of 10mls/hour 0.2% ropivacaine for the subsequent 24 hours.
88948444|NCT01935674|Experimental|Switch ritonavir-boosted PI|Switch their existing ritonavir-boosted PI to another potent ART drug with lesser effects on serum cholesterol selected by the investigator.
88948445|NCT01935674|Experimental|Continue ritonavir-boosted PI+Rosuvastatin|Continue ritonavir-boosted PI-based ART and commence rosuvastatin 10 mg daily (5 mg daily in Asian participants).
88948446|NCT01935687|Experimental|Using of instrumented wheel and ergometer roller|The same patient will receive two types of tests: instrumented wheel and ergometer roller.
88948447|NCT01935726||Pulmonary fibrosis patients or their caretaker/supporter|Patients with pulmonary fibrosis of any cause (idiopathic, related to connective tissue disease [e.g., rheumatoid arthritis, systemic sclerosis/scleroderma, dermato-/polymyositis, sjogren's syndrome], familial or genetic) or the primary supporter/caregiver of a patient with pulmonary fibrosis
88948448|NCT01935739||Primary Breast Tumor|Primary breast tumor were test for HER2/neu status.
88948449|NCT01935739||Axillary Lymph Nodes.|Axillary Lymph Nodes were tested for HER2/neu status.
88948450|NCT01935752|Other|Fibromuscular dysplasia|Fibromuscular dysplasia:blood samples & vascular echotracking
88948451|NCT01935752|Other|healthy volunteer|healthy volunteer:blood samples & vascular echotracking
88948452|NCT01935752|Other|hypertensive patients|hypertensive patients:blood samples & vascular echotracking
89471542|NCT04366401|Experimental|Prebiotic/Probiotic Dietary Modulation|"In the intervention group (n=25), individual dietary counseling will be established through intensive nutritional counseling to provide a high prebiotic and probiotic food pattern.~In the experimental group, data will be collected on psychopathological status (Positive and Negative Syndrome Scale -PANSS- and Personal and Social Functioning Scale -PSP-), and blood tests (haemogram, lipid profile, etc.). The measurements will be taken at the beginning (basal), at three and six months. The estimation of the intestinal microbiota and the usual nutritional pattern will also be evaluated at the beginning and at six months, using a stool test and a validated food frequency questionnaire, respectively. To assess the degree of adherence, GI participants will fill in a specific weekly record of the main dishes/foods consumed. At least, anthropometric parameters will also be analysed monthly (BMI, blood pressure, heart rate, abdominal perimeter)."
89471543|NCT04359186|Experimental|Treatment Interruption Arm|
89471544|NCT04352530|Active Comparator|Rewind the Future|Fear appeal, video message to reduce sugar consumption or risk death
89471545|NCT04352530|Experimental|Hear No|"Video of spoken word poem from The Bigger Picture project, Hear No by Joshua Merchant; images of African-American male poet interspersed with images of environment"
88948453|NCT01935765|Experimental|Diabetes people|99 Type 1 diabetic patients aged 18 to 60 years, diagnosed since at least a year
88948454|NCT01935765|Experimental|healthy volunteers (controll group)|46 healthy volunteers matched by age, gender and body mass index
88948455|NCT01935804|Experimental|Experimental: 1|Pioglitazone given 30mg/once daily for 12 months.
88948456|NCT01935804|Active Comparator|Active comparator: 2|Metformin given 850 mg/twice daily for 12 months.
88948457|NCT01935817|Active Comparator|Silybin + vitamin E + phospholipids complex|Silybin 94 mg + vitamin E 90 mg + phospholipids 194 mg in one pill per day for 12 months
88948458|NCT01935817|Placebo Comparator|sugar pill|one placebo pill per day for 12 months
88948459|NCT01935830|Experimental|LAAM arm|"[11C]LAAM 15-20 mCi (maximum administered mass of 10 ug)~Efavirenz, oral capsules, 600 mg~Ritonavir, oral capsules, 100 mg"
88948460|NCT01935843|Experimental|Anti-tumor responses of CART-HER-2|
88948461|NCT01935856|Experimental|KHK7580|
88948462|NCT01935869|Experimental|LEO 90100|
88948463|NCT01935869|Placebo Comparator|Vehicle|
88948464|NCT01935869|Other|Petrolatum ointment|
88948465|NCT01935882|Active Comparator|Artemether-Lumefantrine|Artemether-Lumefantrine combination
88948466|NCT01935882|Experimental|Artemether-Lumefantrine-Primaquine 0.25|Artemether-Lumefantrine with a single dose of 0.25mg/kg primaquine
88948467|NCT01935882|Experimental|Artemether-Lumefantrine-Primaquine 0.4|Artemether-Lumefantrine with a single dose of 0.4mg/kg primaquine
88948468|NCT01935895||Exercise on Blood Pressure Reactivity|To test the hypothesis of the present study, volunteers were invited to participate in two randomly assigned visits in distint days, as follows: 1) combined resistance and aerobic exercises performed in a circuit mode; and 2) a control session without exercise. In both visits, blood pressure was measured at rest and at each 15 minutes post-session during 1 hour of recovery following the exercise and non exercise control sessions. In addition, blood pressure reactivity was evaluated using a cardiovascular stressor protocol (Cold Test Pressor) before and after the experimental sessions. The relationship between post-exercise blood pressure and blood pressure reactivity to stressor test was also examined.
88948469|NCT01935908|No Intervention|Control Group|The control group will not receive levetiracetam as seizure prophylaxis.
88948470|NCT01935908|Active Comparator|Treatment Group|levetiracetam 500mg in adults, twice daily, administered by mouth, per tube, or IV. The route of administration will be dependent upon the patient's clinical status and ability to tolerate each form. In descending order of preference, route of administration will be: oral, per tube, IV.
88948471|NCT01935960|Experimental|Arm I (retinoid 9cUAB30)|Participants receive retinoid 9cUAB30 PO QD on days 1 and 8-36. Treatment continues in the absence of unacceptable toxicity.
88948472|NCT01935960|Placebo Comparator|Arm II (placebo)|Participants receive a placebo PO QD on days 1 and 8-36.
88948473|NCT01935973|Active Comparator|Arm I (trametinib)|Patients receive trametinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving disease progression may cross over to Arm II.
88948474|NCT01935973|Experimental|Arm II (trametinib and Akt inhibitor GSK2141795)|Patients receive trametinib PO QD and Akt inhibitor GSK2141795 PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88948475|NCT01935986|Experimental|probiotic|dietary supplement
88948476|NCT01935986|Placebo Comparator|placebo|dietary supplement without probiotic
88948477|NCT01935999|Other|One piece closed pouch|One piece closed pouch
88948478|NCT01936012|Experimental|Lisinopril 10 mg tablets of PT Dexa Medica|Each tablet contains 10.89 mg lisinopril dihydrate that equal to 10 mg lisinopril. A single dose of lisinopril tablet of PT Dexa Medica was given to each of study subjects.
88948479|NCT01936012|Active Comparator|Lisinopril 10 mg tablets of PT Boehringer Ingelheim Indonesia|Each tablet contains 10.89 mg lisinopril dihydrate that equal to 10 mg lisinopril. A single dose of lisinopril tablet of PT Boehringer Ingelheim Indonesia was given to each of study subjects.
88948480|NCT01936025|Active Comparator|Sitagliptin|Placebo dextromethorphan + sitagliptin 100 mg
88948481|NCT01936025|Experimental|Dextromethorphan 30 mg + sitagliptin|Dextromethorphan 30 mg + sitagliptin 100 mg
88948482|NCT01936025|Experimental|Dextromethorphan 60 mg + sitagliptin|Dextromethorphan 60 mg + sitagliptin 100 mg
88948483|NCT01936025|Experimental|Dextromethorphan 90 mg + sitagliptin|Dextromethorphan 90 mg + sitagliptin 100 mg
88948484|NCT01936025|Experimental|Dextromethorphan 30 mg + placebo|Dextromethorphan 30 mg + placebo (sitagliptin)
88948485|NCT01936025|Experimental|Dextromethorphan 60 mg + placebo|Dextromethorphan 60 mg + placebo (sitagliptin)
88948486|NCT01936025|Experimental|Dextromethorphan 90 mg + placebo|Dextromethorphan 90 mg + placebo (sitagliptin)
88948487|NCT01936025|Placebo Comparator|Placebo|Placebo (dextromethorphan)+ placebo (sitagliptin)
88948488|NCT01936038|Placebo Comparator|Control Group|CPAP
89019170|NCT00333528|Placebo Comparator|2|Administration of placebo (2 volunteers)
88948489|NCT01936038|Experimental|EXPERIMENTAL GROUP|Upper Airway Toning for Improve the Compliance of CPAP
89471546|NCT04352530|Experimental|The Longest Mile|"Video of spoken word poem from The Bigger Picture Project, The Longest Mile by Tassiana Willis; images of African-American female poet interspersed with images of environment"
89471547|NCT04352530|Experimental|A Taste of Home|"Video of spoken word poem from The Bigger Picture Project, A Taste of Home by Monica Mendoza; images of Hispanic female poet interspersed with images of environment"
89471548|NCT04352530|Experimental|Lost in Translation|"Video of spoken word poem from The Bigger Picture Project, Lost in Translation by Yosimar Reyes; images of Hispanic male poet interspersed with images of environment"
89471549|NCT04352530|Experimental|Bottled Up|"Video of spoken word poem from The Bigger Picture Project, Bottled Up by Eileen Torrez; images of Hispanic female poet interspersed with images of environment"
89471550|NCT04352530|Experimental|The Corner|"Video of spoken word poem from The Bigger Picture Project, The Corner by Jose Vadi; images of Hispanic male poet interspersed with images of environment"
89471551|NCT04352530|Experimental|Thin Line|"Video of spoken word poem from The Bigger Picture Project, Thin Line by Ivori Holson; images of African-American female poet interspersed with images of environment"
89471552|NCT04326283|Experimental|Trametinib (0.5 mg)|One tablet of trametinib 0.5 mg per day
89471553|NCT04326283|Experimental|Trametinib (1 mg)|Two tablets of trametinib 0.5 mg per day
89471554|NCT04326283|Active Comparator|Riluzole (100 mg)|One tablet of riluzole 50 mg taken twice per day
89471555|NCT04314284|Other|Historical Control Survey|-The investigators will conduct a historic control survey of 80-100 recently diagnosed gynecologic, colorectal, and lung cancer patients. They can complete the survey in-person, over the phone, or online. The survey will take approximately 15 minutes to complete. It will ask about their knowledge of health insurance and confidence communicating about care costs.
89471556|NCT04314284|Experimental|I Can PIC|-Approximately 80-100 participants will use I Can PIC. This will take approximately 10-15 minutes. After their next appointment with their provider, they will complete a brief survey about their knowledge of health insurance and confidence communicating about care costs. This will take about 10 mins. Patient participants who choose to complete the study in person may view I Can PIC on a tablet provided in the clinic or at the office. Then after their appointment, they can complete the survey on a tablet provided in the clinic or at the office. If they choose to complete it over the phone, the investigators will email them the link to I Can PIC and then call them when it is time to complete the survey. If they wish to complete it online, the investigators will email them the link to I Can PIC, and then the survey after their appointment. After 3-6 months, participants will receive a 5-10 minute follow-up survey which they can complete in-person, online, or over the phone.
89471557|NCT04309682|Experimental|crestal sinus approach technique|Full thickness flap will be elevated at the edentulous site with two vertical releasing incision and then the preparation of osteotomy will be prepared following standard implant system protocol preparation of the osteotomy. Drilling will be done gently till reaching 0-1mm from the sinus floor, then implant placement will take place and the implant itself will be used to gently elevate the sinus up to 3-5mm
89471558|NCT04309682|Active Comparator|lateral sinus elevation technique|a full-thickness flap will be elevated at the edentulous site with two vertical releasing incisions extending to the vestibule for better reflection and exposure to the lateral wall of the sinus. The lateral antrostomy will be prepared in the lateral sinus wall using rotary bur no. 8 to provide adequate access to remove the thin to thick cortical bone and to expose the thin sinus membrane. The membrane will be elevated across the sinus floor and up the medial wall and this elevation must extend anteriorly-posteriorly to provide the exposed sinus floor. Drilling will be done gently till reaching 0-1mm from the sinus floor, then implant placement will take plac
89471559|NCT04288531||Pregnant and pregnant to be on iodine supplementation|Women in preconception, pregnant and lactating, receiving iodine supplementation
89471560|NCT04288531||Pregnant and pregnant to be not on iodine supplementation|Women in preconception, pregnant or lactating, not receiving iodine supplementation
89471561|NCT04288531||Women of childbearing age|Women of childbearing age not planning to become pregnant.
88948490|NCT01936051||OCD patients|OCD patients being treated with any dose of escitalopram
88948491|NCT01936064|Active Comparator|Jobelyn + Cyclophosphamide-Epirubicin6|Cyclophosphamide- Epirubicin 6 course regimen to be used with Jobelyn
88948492|NCT01936064|Active Comparator|Placebo + Cyclophosphamide- Epirubicin 6|Routine drugs for treatment of Breast Cancer used with Placebo
88948493|NCT01936077|Experimental|GnRH antagomnist hyper-responders|Those defined as hyper-responders will be given recombinant LH.
88948494|NCT01936090|Experimental|Treatment (bortezomib, TBI, melphalan, stem cell transplant)|"Conditioning regimen: Patients receive bortezomib IV on days -5 and -2, TBI BID on days -5 and -2, and melphalan IV over 1 hour on days -4 and -3.~Transplant: Patients undergo autologous bone marrow or peripheral blood stem cell transplant on day 0."
88948495|NCT01936103|Active Comparator|standard group|patients in this group received standard statin treatment： Atorvastatin statins 20mg / night .
88948496|NCT01936103|Experimental|intensive group|patients in this group received intensive statin treatment： Admission atorvastatin statins the 80mg, after surgery，atorvastatin 40mg / night，and until 30 days after the operation , and thereafter 20mg / night .
88948497|NCT01936116|Experimental|patients with intrauterine balloon catheter placement|In this group, during the procedure of sonohysterography balloon catheter is inflated in the uterine cavity
88948498|NCT01936116|Active Comparator|patients with intracervical balloon catheter placement|During the procedure of sonohysterography balloon catheter is inflated in the cervical canal
89019171|NCT03275753||Normal Population|VA of 20/25 or better in the study eye with no prior diagnosis of any retinal or ocular diseases
89019172|NCT03275753||Early Dry AMD Population|VA of 20/40 or better in the study eye with clinical diagnosis of early dry AMD
89019173|NCT03275753||Intermediate Dry AMD Population|VA of 20/40 or better in the study eye with clinical diagnosis of intermediate dry AMD
89019174|NCT03275753||Advanced Dry AMD Population|Clinical diagnosis of advanced dry AMD in the study eye
89471562|NCT04280965|Experimental|Quetiapine|Flexible dosing begins at 50 mg, titrating up to 100 mg at the end of week 2 with additional doses up to 400 mg per day if needed
89471563|NCT04280965|Active Comparator|Treatment As Usual (TAU)|Standard of care medications
89471564|NCT04266353|Experimental|Single arm|Participants with receive resveratrol at 150 mg daily for 6 weeks
89471565|NCT04253717|Experimental|Motor control exercise program|Participants will be physically trained during pregnancy and will receive the standard care including basic information on what to do when suffering from lumbopelvic pain.
89471566|NCT04253717|No Intervention|Control|Participants will receive the standard care including basic information on what to do when suffering from lumbopelvic pain.
89471567|NCT04231643|Experimental|Bipolar Disorder|adults with bipolar disorder
89471568|NCT04231643|Active Comparator|Healthy Volunteers|adults with no psychiatric disease
89471569|NCT04224974|Experimental|Other: Usual Care|
89471570|NCT04224974|Experimental|Behavioral: Usual Care + EASE Intervention-psy|EASE Intervention = EASE-psy + EASE-phys
89471571|NCT04216004|Experimental|Full-fat dairy|3x daily servings (cup-eq) of full-fat (3.25%) commercial cow's milk.
89471572|NCT04216004|Active Comparator|Non-fat diary|3x daily servings (cup-eq) of non-fat (0%) commercial cow's milk.
88948499|NCT01936129|Active Comparator|Copaxone|COPAXONE (glatiramer acetate) will be administered as a subcutaneous dose (20mg) once, one injection no later than 7 days from the initiation of the attack, and 1 more injection administered one week after the first injection.
88948500|NCT01936129|Placebo Comparator|Placebo|Placebo (buffered normal saline w/v)will be administered as a subcutaneous dose, one injection no later than 7 days from the initiation of the attack, and 1 more injection administered one week after the first injection.
88948501|NCT01936142|No Intervention|No RenalGuard|Control group will undergo CRT implantation without using RenalGuard
88948502|NCT01936142|Experimental|RenalGuard|Use of the RenalGuard system during CRT implantation
88948503|NCT01936155|Experimental|Oedema, Joint Mobility, Skin Oxygenation|Neuromuscular electrical stimulation (NMES) is to be applied using a custom-built, two-channel stimulator, Bioelectronics Research Cluster, National University of Ireland, Galway) with a frequency of 36 Hz, a balanced biphasic waveform with a pulse width of 350μs, a ramp up time of 500ms, a contraction time of 1s and a ramp down time of 500ms. Stimulation is to be applied every 20 seconds over a period of 90 minutes. Its affect on oedema reduction, joint mobility and skin oxygenation will be assessed both before and after its application.
88948504|NCT01936168|Active Comparator|RFA|Radiofrequency Ablation (RFA)
88948505|NCT01936168|Experimental|MOCA|Mechanochemical Endovenous Ablation (MOCA)
89471573|NCT04216004|Placebo Comparator|Non-dairy control|3x daily servings (cup-eq) of non-dairy sourced macronutrient composition of full-fat milk.
89471574|NCT04203823|Experimental|Algorithm Testing|"The main purpose of this cohort is to test the Digital Twin insulin delivery algorithm and the Meal Prediction algorithm~The study population will be enrolled as 2 separate cohorts to test each algorithms individually"
89471575|NCT04199910||Liver cirrhosis with spironolactone|
89471576|NCT04199910||Liver cirrhosis with rifaximin|
89471577|NCT04199910||Liver cirrhosis without spironolactone or rifaximin|
89471578|NCT04199910||Pneumonia|
89471579|NCT04199910||Crohn's disease|
89471580|NCT04199910||Ulcerative colitis|
89471581|NCT04197804||Tourette group|20 subjects with Tourette Syndrome undergoing an evaluation to identify the IQ. Subsequently, 4 tasks are presented. The 1st (with a duration of about 2 and a half minutes) and the 2nd (with a duration of about 2 minutes) concerning the motor field, the 3rd (with duration of about 1 minute) and the 4th (with duration of about 3 minutes) concerning the linguistic field.
89471582|NCT04197804||Control group|20 subjects without Tourette Syndrome subjected to an evaluation to identify the IQ. Subsequently 4 tasks are presented. The 1st (with a duration of about 2 and a half minutes) and the 2nd (with a duration of about 2 minutes) concerning the motor field, the 3rd (with duration of about 1 minute) and the 4th (with duration of about 3 minutes) concerning the linguistic field.
88948506|NCT01936194|Experimental|Docosahexaenoic Acid (DHA)|infants receiving capsule containing DHA.
89471583|NCT04171895||Enhanced Usual Care (EUC)|
89471584|NCT04171895||Communication Training|
89471585|NCT04626544||Dizziness|Patients with dizziness referred to a secondary referral center
89471586|NCT04626544||Healthy controls|Healthy controls without dizziness or neck pain symptoms for the last 3 months
89471587|NCT04171167|Active Comparator|Frequently treated acute rhino sinusitis|Does not meet the European position paper criteria of CRS: asymptomatic periods in between and no objective findings when entering the study.
88948507|NCT01936194|Other|High Olive Oil|infants receiving capsule without DHA and EPA.
88948508|NCT01936194|Experimental|DHA+EPA|infants receiving capsule containing DHA and EPA.
88948509|NCT01936207||One Group|
88948510|NCT01936220|Experimental|Continuity of specialized care|Continuity of specialized inpatient and outpatient care (relapse prevention)
88948511|NCT01936220|Experimental|Continuity of specialized care and parent groups|Continuity of specialized care combined with Parent groups
88948512|NCT01936220|Active Comparator|Treatment as usual|Discontinuity of care, relapse prevention as usual
88948513|NCT01936233|Experimental|Aspirin AND Lamivudine|
88948514|NCT01936233|Active Comparator|Lamivudine|
88948515|NCT01936246|Experimental|Increased protein|Full term infants will be on 4 g/kg/day of protein. Preterm infants will be on 4.5 g/kg/day of protein until term corrected age. Beneprotein powder will be used; if this is not tolerated, Complete Amino Acids will be used. Max protein will be 30 g/day. Increased protein will be given until 12 months corrected age.
89471588|NCT04171167|Active Comparator|CRSsNP|Meets the European position paper criteria of CRS. Zinreich modification of Lund-Mackey scoringing: Opacification score < 21 and obstruction score 0-8. No visible nasal polyps in endoscopy
89471589|NCT04171167|Active Comparator|Severe CRSsNP and CRSwNP|Meets the European position paper criteria of CRS and not included in the first two groups.
89471590|NCT04171167|No Intervention|Healthy volunteers|No nasal symptoms or complaints. No interventions done.
89471591|NCT04166695|Experimental|Monolithic / facially veneered zirconia|Participants receive one monolithic / facially veneered zirconia fixed partial denture.
89471592|NCT04166695|Other|Completely veneered CoCr|Control group. Participants receive one completely veneered metal ceramic fixed partial denture.
89471593|NCT04162899|Active Comparator|Active Comparator: SHR0302 dose A|Participants randomized in this arm will receive dose A of SHR0302 until end of study at week 12.
88948516|NCT01936246|No Intervention|Standard diet|Infants will be given a usual diet. If infants in this arm have poor growth, protein or caloric supplementation may be given per the discretion of the clinical team.
89471594|NCT04162899|Active Comparator|Active Comparator: SHR0302 dose B|Participants randomized in this arm will receive dose B of SHR0302 until end of study at week 12.
89471595|NCT04162899|Active Comparator|Placebo Comparator: Placebo|Participants randomized in this arm will receive Placebo of SHR0302 until end of study at week 12.
89471596|NCT04155346|Experimental|Facility-based prehabilitation (FBP)|"Exercise~Three supervised exercise training sessions of aerobic and resistance exercises. Includes high-intensity interval aerobic training and whole-body resistance exercises (60 min/session)~Specific exercises will also be prescribed to prepare regional and/or compensatory tissues for surgery~Exercise session will be supervised by a Registered Kinesiologist/Exercise Physiologist~Nutrition~Participants will receive an individualized nutrition assessment and counselling within the first week of prehabilitation and again in the week prior to surgery~All sessions will conducted by a Registered Dietitian (60 min/session)~Participants will also receive 20g of protein supplementation daily~Stress management and behavioural support~Participants will be scheduled for a psychoeducation session within the first week of prehabilitation and again in the week prior to surgery~All sessions will conducted by a psychologist (60 min/session)"
89471597|NCT04155346|Experimental|Home-based prehabilitation (HBP)|"Exercise~Three unsupervised, home-based exercise training sessions of aerobic and resistance exercises. Includes continuous moderate-intensity aerobic training and whole-body resistance exercises (60 min/session)~Specific exercises will also be prescribed to prepare regional and/or compensatory tissues for surgery~Exercise session will be supervised by a Registered Kinesiologist/Exercise Physiologist~Nutrition~Participants will receive an individualized nutrition assessment and counselling within the first week of prehabilitation and again in the week prior to surgery~All sessions will conducted by a Registered Dietitian (60 min/session)~Participants will also receive 20g of protein supplementation daily~Stress management and behavioural support~Participants will be scheduled for a psychoeducation session within the first week of prehabilitation and again in the week prior to surgery~All sessions will conducted by a psychologist (60 min/session)"
89471598|NCT04155346|No Intervention|Usual Care|- This group will receive no additional intervention from the routine care.
89471599|NCT04155112|Experimental|Physical activity (PA)|For 6 months, the participants will be recommended to increase physical activity to ≥ 150 min of moderate intensity or ≥ 75 min of vigorous intensity aerobic PA (or an equivalent combination) and ≥ 2 days of resistance exercise a week. The participants will take part in supervised group classes, twice per week. Each participant will receive a heart rate monitor to bring home and to use while reporting activity via a physical activity diary.
89471600|NCT04155112|Experimental|Hypocaloric Mediterranean diet (MeDi)|For 6 months, the participants will be recommended to consume a diet for 5-10% body weight loss. This diet will be based on the Mediterranean diet pattern. For the 6 months of the intervention, the participants will weigh themselves weekly and report their progress to the investigator. Adaptations to the diet will be made to ensure the goal of 5-10% weight loss is achieved. Each participant will receive a scale to bring home and to use while reporting weight loss.
89471601|NCT04155112|No Intervention|Control|At baseline, participants will receive usual care, which consists of general information regarding the importance of lifestyle for BP. This information will not be reinforced throughout the study duration.
88948517|NCT01936285|Placebo Comparator|Control group|Patients taking placebo
88948518|NCT01936285|Experimental|Colchicine|Active treatment group
88948519|NCT01936298|Experimental|A-ROM Continuous Passive Rehabilitation|The group of patients with Active Range Of Motion (A-ROM) is subjected to two session per day in the morning and in the afternoon over a period of two weeks (5 days per week). Each session is composed by 30 min of continuous passive motion rehabilitation and 60 min of physical and occupational therapy.
88948520|NCT01936298|Experimental|P-ROM Continuous Passive Rehabilitation|The group of patients with Passive Range Of Motion (P-ROM), i.e. without active movements of the hand at the baseline, is subjected to two session per day in the morning and in the afternoon over a period of two weeks (5 days per week). Each session is composed by 30 min of continuous passive motion rehabilitation and 60 min of physical and occupational therapy.
88948521|NCT01936311|No Intervention|Control Group|This group will receive usual care.
88948522|NCT01936311|Experimental|Self-Management Goal Elicitation|This group will receive usual care alongside a form that helps elicit self-management goals as well as preferred treatment modalities.
88948523|NCT01936337|Active Comparator|DLX105 Hydrogel|
88948524|NCT01936337|Placebo Comparator|Placebo Hydrogel|
88948525|NCT01936350|Experimental|Sildenafil|12 patients will be in this group. They will take a sildenafil 50mg.
88948526|NCT01936350|Placebo Comparator|Placebo|12 patients will be in this group, they will take placebo
88948527|NCT01936376||head & neck cancer patients, cisplatin treatment|
88948528|NCT01936376||cancer patients, no cisplatin, no nephrotoxic agent|
88948529|NCT01936402|Experimental|5-6cm Chest compression depth|"Control group is trained for 5-6cm Chest compression depth during education.~Depth 5-6cm, Rate 100-120/min, Full chest recoil"
88948530|NCT01936402|Experimental|6-7cm chest compression depth|"Experimental group is trained for 6-7cm Chest compression depth during education.~Depth 6-7cm, Rate 100-120/min, Full chest recoil"
88948531|NCT01936415|Experimental|Regenerex|One of the two prosthesis investegated
89471602|NCT04147871|Active Comparator|ADV7103 1.5 mEq/Kg/day|Patients receive ADV7103 twice a day.
89471603|NCT04147871|Active Comparator|ADV7103 3.0 mEq/Kg/day|Patients receive ADV7103 twice a day.
89471604|NCT04147871|Active Comparator|ADV7103 4.5 mEq/Kg/day|Patients receive ADV7103 twice a day.
89471605|NCT04147871|Placebo Comparator|Placebo|Patients receive placebo twice a day.
89471606|NCT04140032|Experimental|Intervention group|Centers in the group will participate in the A-B-C Healthy Me/Soy Saludable multi- component nutrition and physical activity preschool intervention.
89471607|NCT04140032|No Intervention|Control group|"Preschools in the group will continue with usual care practices. Control group preschools will receive intervention materials and accompanying instructions after follow-up measures are collected for each cohort."
89471608|NCT04129060|Experimental|Mecamylamine Challenge|One of the two study days will be the oral mecamylamine.
88948532|NCT01936415|Active Comparator|Vanguard|
88948533|NCT01936428|Other|interview|
88948534|NCT01936441|Experimental|Cognitive Behavioral Therapy-Insomnia (CBT-I)|"Participants will have contact with a menopause counselor 6 times over 8 weeks. The first session will be in-person at a private research office. All other contacts will be by telephone. Women unable to attend the in-person session will receive a phone call. All in-person and telephone consultations will be 20-30 minutes.~Participants will receive reading materials before each phone call relating to menopausal changes, menopausal changes in sleep and strategies for lessening menopause related sleep disturbances. A daily sleep diary will be completed each week during the 8-week intervention period. The day before each telephone session, the participant will email that week's completed diary to a secure email address accessible only by the counselor; women who are unable to use email will provide their data by telephone directly to the counselor. During the weekly telephone calls, the reading and materials will be discussed and the sleep diary will be reviewed."
88948535|NCT01936441|Placebo Comparator|Menopause Education Control (MEC)|Participants will have contact with a menopause counselor 6 times over 8 weeks. The first session will be in-person at a private research office. All other contacts will be by telephone. Women who are unable to attend the in-person session will receive a phone call. All in-person and telephone consultations are designed to last 20-30 minutes. Participants will receive information about menopausal changes and ways to develop symptom management strategies. Women in the MEC will keep a daily sleep diary. The day before each telephone session, the participant will email that week's completed diary to a secure email address accessible only by the counselor; women who are unable to use email will provide their data by telephone directly to the counselor. During the weekly telephone calls, the reading material will be discussed and the sleep diary will be reviewed.
88948536|NCT01936454||Cohort 1|n=20 women with insertion dates 3-5months prior to enrollment and followed for 2-6 months
88948537|NCT01936454||Cohort 2|n=20 women with insertion dates 9-11 months prior to enrollment and followed for 2-6 months
88948538|NCT01936454||Cohort 3|n=250 women with insertion dates 21-24 months prior to enrollment and followed through month 36
88948539|NCT01936454||Cohort 4|n=300 women with insertion dates 33-36 months prior to enrollment and followed through month 6
88948540|NCT01936493||Females with uterine fibroids|Participants will be females age of 18 or older who have be diagnosed with uterine leiomyoma. Study Subjects will be asked if mothers or siblings also have diagnosis of uterine leoimyoma (either past or present diagnosis) and these family members will be invited to participate in this trial. All participants will provide blood samples for serum aliquots for hormonal analysis and genomic DNA analysis, and will answer a baseline genetic epidemiology questionnaire.
88948541|NCT01936506|Experimental|Cognitive Training A|emotional memory training exercise
88948542|NCT01936506|Active Comparator|Cognitive Training B|memory training exercise
88948543|NCT01936545|Experimental|propofol|The anesthesia was maintained with propofol during liver transplantation.
88948544|NCT01936545|Active Comparator|Desflurane|The anesthesia was maintained with desflurane during liver transplantation.
88948545|NCT01936558||Amputees|Amputee with one arm or one leg amputated/ Far infrared ray to the phantom limb site
88948546|NCT01936558||Healthy subjects|Healthy subjects under 30 years old/ Far infrared ray to the sole
88948547|NCT06071780|Active Comparator|VCO contact lens|contact lens soaked in VCO
88948548|NCT06071780|Placebo Comparator|control contact lens|contact lens soaked in saline
88948549|NCT06071676|Other|conventional impression procedures|Implant analogues were screwed to the transfer copings inside the impression and the master cast were obtained. Attachments were screwed to the analogues and metal housing wasplaced on their position on master cast. Master cast will be scanned extra orally to obtain STL file of the master cast.
89019175|NCT00330096|Experimental|Hesperidin-rich food|
89019176|NCT00330096|Placebo Comparator|No intervention: Placebo|
89471609|NCT04129060|Experimental|Placebo Challenge|One of the two study days will be the oral placebo.
89471610|NCT04119284|Experimental|Anterior Vertebral Tethering|Anterior Vertebral Tether Vertebral body tethering done through anterior spine surgery under anesthesia.
89471611|NCT04117763|Experimental|Empagliflozin|Empagliflozin 25 mg once daily for 3 months
89471612|NCT04084119|Experimental|hypopressive abdominal exercise|Participants will perform an hypopressive abdominal exercise program consisting of 18 sessions (6 weeks), 3 times a week, 30 minutes each session.
89019177|NCT03275714|Active Comparator|People With a Bipolar Affective Disorder|
89019178|NCT03275714|Active Comparator|Control subjects without a psychiatric disorder|
89019179|NCT00330135|Experimental|1|Sodium hyaluronate 2.5 ml - 1 injection
89019180|NCT00330135|Placebo Comparator|2|Placebo injection - 1 injection
89471613|NCT04084119|Active Comparator|general strengthening exercise|Participants will perform a general strengthening exercise program consisting of 18 sessions (6 weeks), 3 times a week, 30 minutes each session.
89471614|NCT04078880|Experimental|Intervention (group A)|Patients who are subjected to the intervention, being iron plus ascorbic acid, other than the standard of care.
89471615|NCT04078880|No Intervention|Control (group B)|Patients who are not subjected to the intervention and follow the standard of care.
89019181|NCT03275558|Active Comparator|Axitinib|A single dose of Axitinib - 1 mg in a liquid form in the composition (Axitinib+Sunitinib+Pazopanib) of the nasal spray.
89019182|NCT03275558|Active Comparator|Sunitinib|A single dose of Sunitinib- 5 mg in a liquid form in the composition (Axitinib+Sunitinib+Pazopanib) of the nasal spray.
89471616|NCT04071574|Active Comparator|"Protocol A"|"Protocol with gonadotropins alone without agonist or antagonist:~Gonadotropin treatment begins after spontaneous menses. The gonadotropins (e.g. Menopur, 150-225IU) are injected daily from D2/3 of the cycle (Gonadotropin dose varies based on the follicular response). The moment to trigger ovulation by administration of HCG (e.g. Ovitrelle or Pregnyl, 10.000IU) is determined by monitoring ovulation (folliculogenesis) approximately 14 days after gonadotropins regimen and the presence of at least 3 follicles with 18 mm sizes and at least the levels of E2 reaches 250-300 pg/ml. 36 h after HCG triggering, the mature oocytes are retrieved."
89471617|NCT04071574|Active Comparator|"Protocol B"|"Short GnRH agonist protocol:~For the short GnRH agonist protocol, the administration of gonadotropins begins at the same time as that of the agonist, which makes it possible to take advantage of the action of endogenous gonadotropins released by the flare-up effect of the agonist. A low dose of GnRH agonist (e.g., triptorelin (Decapeptyl 0.1mg/day)) is administered in parallel to gonadotropin (e.g. Menopur, 150-225 IU) daily starting on cycle-day 2 (Gonadotropin dose varies based on the follicular development). Continual administration of GnRH agonist and gonadotropin lasts until HCG triggering (e.g. Ovitrelle or Pregnyl, 10.000IU), ~14 days post GnRH agonist regimen when follicles size reached 16-18 mm and at least the levels of E2 reaches 250-300 pg/ml. 36 h after HCG triggering, the mature oocytes are retrieved."
89471618|NCT04071574|Active Comparator|"Protocol C"|"Multiple-dose antagonist protocol:~For the GnRH antagonist protocol, a low dose of GnRH antagonist (0.25 mg/day) is administered. The protocol starts with the administration of gonadotropin (e.g. Menopur, 150-225 IU) daily which is initiated after monitoring of patients' follicles sizes on cycle-day 2/3 (Gonadotropin dose varies based on the follicular response). Almost after the 6th days of gonadotropin injection or when follicular size reaches more than or equal to 14 mm, GnRH antagonist (e.g., cetrorelix (cetrotide) or ganirelix (orgulatron) 0.25mg) begins by subcutaneous administration every day till HCG triggering (e.g. Ovitrelle or Pregnyl, 10.000IU). 36 h after HCG triggering, the mature oocytes are retrieved."
89471619|NCT04071574|Active Comparator|"Protocol D"|"Long GnRH agonist protocol:~For the long GnRH agonist protocol, a low dose of GnRH agonist (e.g., triptorelin (Decapeptyl 0.1mg)) is administered on cycle-day 21 followed by gonadotropin (e.g. Menopur, 150-225 IU) daily starting on cycle-day 2 after menses (Gonadotropin dose varies based on the follicular development). Continual administration of GnRH agonist and gonadotropin lasts until HCG triggering (e.g. Ovitrelle or Pregnyl, 10.000IU), ~14 days post GnRH agonist regimen when follicles size reached 16-18 mm. 36 h after HCG triggering, the mature oocytes are retrieved."
89471620|NCT04071574|Active Comparator|"Protocol E"|"Combined GnRH antagonist and agonist protocol:~For the combined protocol, it starts with the administration of gonadotropin (e.g. Menopur, 150-225 IU) daily which is initiated after monitoring of patients' follicles sizes on cycle-day 2/3 (Gonadotropin dose varies based on the follicular response). Almost after the 6th days of gonadotropin injection or when follicular size reaches more than or equal to 14 mm, GnRH antagonist (e.g., cetrorelix (cetrotide) or ganirelix (orgulatron) 0.25mg) begins by subcutaneous administration every day till GnRH agonist injection (e.g., triptorelin (Decapeptyl 0.1mg/day)). 36 h after agonist injection, the mature oocytes are retrieved."
89471621|NCT04065243|Active Comparator|Control group|Subjects in this group will have a daily energy intake equivalent of 100 % of their calculated normal daily energy intake.
89471622|NCT04065243|Experimental|Overfed group|Subjects in this group will have a daily energy intake equivalent of 150 % of their calculated normal daily energy intake.
89471623|NCT04005846|Other|Active tDCS first / Sham tDCS second|Receiving active tDCS during the first visit followed by sham tDCS on the next visit
89471624|NCT04005846|Other|Sham tDCS first / Active tDCS second|Receiving sham tDCS during the first visit followed by active tDCS on the next visit
89019183|NCT03275558|Active Comparator|Pazopanib|A single dose of Pazopanib-5 mg in a liquid form in the composition (Axitinib+Sunitinib+Pazopanib) of the nasal spray.
89019184|NCT03275519|Active Comparator|Antibiotics prophylaxis cohort|Subjects were prescribed prophylactic antibiotics after the hypospadias surgery.
89019185|NCT03275519|Active Comparator|Antibiotic-sparing cohort|Subjects were not prescribed prophylactic antibiotics after the hypospadias surgery.
89019186|NCT02956694|Experimental|Professional training|Professional e-learning program on shared decision making including two components: (1) a self-directed e-learning activity on shared decision making, lasting about 1 hour, that participants could complete in several sittings; and (2) five evidence summaries named Decision Boxes (DBs).
89471625|NCT04002362|Experimental|Children receiving triamcinolone acetonide|Pediatric participants with exacerbation-prone asthma will receive an intramuscular injection of triamcinolone acetonide and will be followed for 48 weeks.
89471626|NCT03995979|Experimental|Protein Restriction Group|Subjects will follow a 4 day protein restricted diet using Scandishake® mixed with almond milk which will be provided.
89471627|NCT03982186|Experimental|Arm 1: JNJ-73763989 (medium dose) + JNJ-56136379 + NA|Participants will receive medium dose of JNJ-73763989 along with JNJ-56136379 and nucleos(t)ide analog (NA) treatment (either entecavir [ETV], tenofovir disoproxil fumarate [TDF], or tenofovir alafenamide [TAF]) up to 48 weeks.
89471628|NCT03982186|Experimental|Arm 2: JNJ-73763989 (high dose) + Placebo + NA|Participants will receive high dose of JNJ-73763989 along with placebo for JNJ-56136379 and NA (either ETV, TDF, or TAF) up to 48 weeks.
89471629|NCT03982186|Experimental|Arm 3: JNJ-73763989 (medium dose) + Placebo + NA|Participants will receive medium dose of JNJ-73763989 along with placebo for JNJ-56136379 and NA (either ETV, TDF, or TAF) up to 48 weeks.
89471630|NCT03982186|Experimental|Arm 4: JNJ-73763989 (low dose) + Placebo + NA|Participants will receive low dose of JNJ-73763989 along with placebo for JNJ-56136379 and NA (either ETV, TDF, or TAF) up to 48 weeks.
89019187|NCT00330252|Experimental|Alemtuzumab & Rituximab|"Alemtuzumab Dosage will vary during Phase I of trial: Given intravenously on days 1, 3, and 5 for weeks one and two, on days 1 and 4 for weeks three and four and on day 1 for weeks five through eight. Participants may receive either one eight-week course of treatment or two eight-week courses of treatment (16 weeks)~Rituximab- Given intravenously on day 1 of every week for eight weeks (or 16 weeks)"
89471631|NCT03982186|Experimental|Arm 5: Placebo + JNJ-56136379 + NA|Participants will receive placebo for JNJ-73763989 and a fixed dose of JNJ-56136379 along with NA (either ETV, TDF, or TAF) up to 48 weeks.
89471632|NCT03982186|Placebo Comparator|Arm 6 (Control): Placebo + Placebo + NA|Participants will receive placebo for JNJ-73763989 and placebo for JNJ-56136379 along with NA (either ETV, TDF, or TAF) up to 48 weeks.
89471633|NCT03975985|Experimental|Core stability exercises|This group will be divided in two: core stability exercises (CSE) plus conventional therapy (CP) and CSE with transcutaneous electrical nerve stimulation (TENS) plus CP.
88948550|NCT06071676|Other|digital impression procedures|"A digital scanner (shining 3D scanner, Germany) was utilized to fabricate the definitive prostheses. The attachments were screwed to the implants intra orally and metal housing on their position which scanned by using intra oral scanner.~Intra oral scanner transformed into a virtual volume the three-dimensional geometry of dental arches using the principle of structured light. A scanning stitching strategy carried out by the same experienced investigator and applied to DIG group for the attachments on their position on implants.~The software automatically was applied a stitching algorithm in order to merge the two halves, based on the area between the two anterior implants, shared by both the separate scans.~The virtual model was created of the dental implant and attachments in position which used to obtain 3d printed master cast by using 3D printer (WANHAO desktop 3D printer, Zhejiang, China)."
89471634|NCT03975985|Active Comparator|Conventional physiotherapy (CP)|CP consists in a variety (or combination) of multiple components such as tone normalization, exercises for maintain range of motion, passive mobilization of hemiparetic side, postural control, gait re-education to walking/standing between parallel bars or with a therapist, rehabilitation of the activity of daily living, etc.
89471635|NCT03970252|Experimental|Treatment (nivolumab, mFOLFIRINOX)|Patients receive nivolumab IV over 60 minutes on day 1. Patients also receive fluorouracil IV over 10 minutes and over 46 hours, irinotecan hydrochloride IV over 90-120 minutes, leucovorin calcium IV over 120 minutes, and oxaliplatin IV over 120 minutes on days 1 and 15. Treatments repeat every 28 days for 3-6 cycles in the absence of disease progression or unacceptable toxicity. Within 2-4 weeks after treatment, patients with resectable disease undergo surgery. Within 8-12 weeks after surgery, patients with successful resection may receive 6 additional cycles of fluorouracil, irinotecan hydrochloride, leucovorin calcium, and oxaliplatin in the absence of disease progression or unacceptable toxicity.
89471636|NCT03949725|Experimental|Hans Kai program|The Hans Kai program is a peer-led, preventative, self-sustaining, community-based health promotion program for adults of all ages, genders, and socioeconomic circumstances who wish to maintain or improve their health. Hans Kai empowers individuals to take control of their own health and provides a unique opportunity for participants to have an active role in improving or maintaining their health and wellbeing.
89471637|NCT03949725|No Intervention|Wait list control|Participants in the waitlist control group will remain as close to a 'typical' community member as possible as they will be able to receive any health programming normally available to them in Winnipeg, except the Hans Kai program. Standard of care is made available to all members of the control group as related to the healthcare rights of Canadians and Manitobans holding a Manitoba health card. NorWest staff will provide support to the community members without a Manitoba health card in obtaining one. The only deviation from standard care in the waitlist control group will be the pre- and post-intervention visits during which the control participants will fill out self-report questionnaires and undergo physical assessments.
89471638|NCT03916809|Experimental|Active EMST + Standard Care|Patients randomized to the Active EMST + Standard Care arm (ACTIVE) will use the EMST150 device as packaged, i.e. following package instructions with a device that has its valve spring maintained.
89471639|NCT03916809|Sham Comparator|Sham EMST + Standard Care|Those randomized to the Sham EMST + Standard Care arm (SHAM) will use an EMST150 device that has been modified by removing the internal spring, which allows the valve to open in response to airflow through the device regardless of the amount of pressure generated.
89501980|NCT04280198|No Intervention|No Intervention: Group 1 - Control|Participants will attend three laboratory visits: baseline 1, baseline 2, and post-test. At baseline 2 and post-test, the primary outcome of child RRV of food vs. parent child interaction is measured. Other measures include child height and weight, child self-regulation, and parenting in the context of a parent-child interaction task. Participants in the control group will not be assigned to complete any intervention activities during the 4-week intervention phase (which takes place between baseline 2 and post-test visits); however, they will receive contacts from a member of the lab each week in the form of electronic reminders (i.e. texts) to remind them of their upcoming post-test laboratory appointment and will receive some intervention materials after the post-test assessment.
88948551|NCT06071663|Active Comparator|single visit|Necrotic primary molar treated in single visit
88948552|NCT06071663|Active Comparator|Two visits|Necrotic primary molar treated in two visits
88948553|NCT06071650|No Intervention|"Group A - Exercise to Rating of Perceived Exertion (RPE) - Control Group"|Participants prescribed moderate intensity aerobic exercise using their rating of perceived exertion (RPE) with a goal of sustaining an intensity level of 12 to 14 for their prescribed duration.
88948554|NCT06071650|Experimental|"Group B - Exercise to a Heart Rate (HR) Zone - Intervention Group"|Participants prescribed moderate intensity aerobic exercise using personalised heartrate zones with a goal of sustaining an intensity level by maintaining their heartrate above 50 percent of their heartrate reserve level for their prescribed duration.
88948555|NCT06071637|Active Comparator|Group A - single emission|"The application will be carried out with the DMC device, with a power of 100mW, with a beam area of 0.09842 cm² in each optical fiber.~Extraoral: A gallium and aluminum arsiade diode with emission of radiation in the infrared region of the electromagnetic spectrum (808 nm). An energy of 4J/point were determined, which will be applied punctually, with a distance between points of a maximum of 1cm, for 40s per point, totaling 9 points per region; Intraoral: An indium gallium aluminum phosphide diode with emission of radiation in the red region of the electromagnetic spectrum (660 nm). An energy of 1J/point were determined, which will be applied punctually, with a distance between points of a maximum of 1cm, for 10s per point, totaling 9 points per region ."
89019188|NCT04698473|Active Comparator|NCPAP|"Ventilator-derived NCPAP will be administered using binasal prongs. Standard Devices or infant flow-driver device. Initial NCPAP settings are: PEEP:6 cmH2O and FiO2: adjusted to keep preductal sPO2 between %90-94.~Failure is defined as FiO2 requirement of >%50, capillary blood gas obtained at the 4th hour of therapy showing pH<7.20 or pCO2>60 cmH2O."
88948556|NCT06071637|Experimental|Group B - double emission|"The application will be carried out with the DMC device, with a power of 100mW, with a beam area of 0.09842 cm² in each optical fiber.~Extraoral: An indium gallium aluminum phosphide diode and gallium aluminum arsiade with double radiation emission simultaneously in the red and infrared region of the electromagnetic spectrum (660 nm/808nm). An energy of 4J/point were determined, which will be applied punctually, with a maximum distance between points of 1cm, for 20s per point, totaling 9 points per region; Intraoral: An indium gallium aluminum phosphide diode and gallium aluminum arsiade with double radiation emission simultaneously in the red and infrared region of the electromagnetic spectrum (660nm/808nm). An energy of 1J / point (0.5J in the red and 0.5 in the infrared) were determined, which will be applied punctually, with a distance between points of no maximum 1cm, for 5s per point, totaling 9 points per region."
88948557|NCT06071598||CRC|CRC-affected patients stratified according to tumor stage (T0/T1-T4, M0/M1, N0/N1/N2)
88948558|NCT06071585||patients with Eosinophilic esophagitis (EoE)|
88948559|NCT06071585||patients with gastroesophageal reflux disease (GERD)|
88948560|NCT06071585||controls (patients without EoE e GERD)|
88948561|NCT06071559|Other|Obesitysurgery with diabetes|One group with obesity and concomitant type 2 diabetes
88948562|NCT06071559|Other|Obesitysurgery and non-diabetes|One group with obesity alone
88948563|NCT06071546|Experimental|Main arm|"one microperimetric examination with MAIA, one microperimetric examination with MAIA 2013 EDITION for agreement evaluation;~one additional microperimetric examination with MAIA and one additional microperimetric examination with MAIA 2013 EDITION for repetability evaluation."
88948564|NCT06071520||PTI patients treated with fostamatinib|Patient with criteria of PTI who has been treated with fostamatinib in the time described
88948565|NCT06071481|No Intervention|Arm-1|Standard supportive care ( Plenty of oral fluid, Tab. Paracetamol 500mg)
88948566|NCT06071481|Experimental|Arm-2|Standard supportive treatment + 2,00,000 IU Vitamin D oral solution
88948567|NCT06071481|Experimental|Arm-3|Standard supportive treatment + 4,00,000 IU Vitamin D oral solution
88948568|NCT06071403||60-70% group|We classified subjects into 3 groups by ((enteral feeding volume/total fluid volume)*100%).
88948569|NCT06071403||71-80% group|We classified subjects into 3 groups by ((enteral feeding volume/total fluid volume)*100%).
88948570|NCT06071403||81-90% group|We classified subjects into 3 groups by ((enteral feeding volume/total fluid volume)*100%).
88948571|NCT06071390|Experimental|Children watching animated- assisted video before endoscopy procedure|Inclusion criteria were children and mothers who voluntarily participated, who were aged 6-12 years, who know Turkish, and who do not have a vision or mental problem at a level to watch the image.
88948572|NCT06071390|No Intervention|Children not watching animated- assisted video before endoscopy procedure|Exclusion criteria were children and mothers who not voluntarily participated, who were not aged 6-12 years, who don't know Turkish, and who have a vision or mental problem at a level to watch the image.
88948573|NCT06071377||Individuals with sickle cell trait|
88948574|NCT06071234|Experimental|3D-printed group|The patient's breast blood supply was assessed preoperatively using 3D printing technology, and the flap was separated intraoperatively using a combination of cold knife and electrosurgical knife.
88948575|NCT06071234|Active Comparator|Normal group|Patients are not evaluated preoperatively using 3D printing technology and flap separation is performed using electrosurgical knife intraoperatively.
88948576|NCT06071169|Experimental|Intervention|progressive relaxation exercise group The nurses will perform the relaxation exercises 3 days a week for 5 weeks, 20 minutes in each practice.
88948577|NCT06071169|No Intervention|Control|Control group No application has been made.
88948578|NCT06071130|Experimental|Experiment 4A & 4B|Participants will attend for 3 sessions/week for 8 weeks. Instructors will conduct classes and maintain participant attendance records. Exercise components include flexibility, aerobics, strengthening, and physical activity logs. Classes begin and end with 10-minute warmups and cool downs. Participants are taught low-impact aerobic routines to maximize self-efficacy for physical activity maintenance after the program. This will include fitness walking that will progress from each participant's maximum capacity to the goal of 20 minutes of sustained walking. Participants will be instructed on how to gauge their exercise intensity and physical exertion. The strengthening focus of the program will improve independent functioning by targeting lower extremity strength with a graded, task-specific approach. Resistance will be progressively increased over the course of the program by adding weight. At the end of each exercise session, participants will log physical activity.
88948579|NCT06071091|Experimental|Intracranial stenting|Rescue Intracranial Stenting + best medical treatment
88948580|NCT06071091|Active Comparator|Best medical management alone|Best medical treatment with no additional thrombectomy passes
89531868|NCT05056753|Active Comparator|Investigational Device|The HWBV chair consists of a custom-made saddle-seat type of chair. The vibration actuators are embedded into the underside design of the chair. The base contains two vibrators, one for each side of the chair, and the chair is split in half vertically so that the vibrating actuators are able to send a harmonic vibration at alternating frequencies, upwards through each side of the chair. The HWBV system is considered a non-significant and non-substantial risk device.
88948581|NCT06071078|Experimental|DISCUSS announcement protocol|Model protocol for announcing decision of withholding and withdrawing life-sustaining treatments, with human simulation and the intervention of partner families in a simulation center and in situ, on the reduction of family stress following the announcement of a decision of withholding and withdrawing life-sustaining treatments in the emergency departments
88948582|NCT06071078|No Intervention|Control|Individuals will receive the usual practices.
88948583|NCT06071052|Experimental|TACE and HAIC Combined With Regorafenib for Liver Metastasis of Colorectal Cancer|liver metastasis of colorectal cancer patients who fail the second line, receive transhepatic artery irinotecan vehicle microsphere embolization and perfusion chemotherapy combined with regorafenib
88948584|NCT06071039|Experimental|3D Spacer Mattress|For the patients in this group, the mattress which developed by the researchers was used. Pressure level between the body and the mattress was measured throughout the surgery.
88948585|NCT06071039|No Intervention|Operating Room Mattress|For the patients in this group, the mattress which was in common use was used. The mattress used for the patients in this group was made up of foam. The pressure level between the body and the mattress was measured throughout the surgery.
88948586|NCT06071013|Experimental|Nintedanib + gefitinib/erlotinib/afatinib|Nintedanib will administered orally twice per day Gefitinib will administered orally once daily Erlotinib will administered orally once daily Afatinib will administered orally once daily
88948587|NCT06071000|Experimental|Experimental group|
88948588|NCT06071000|No Intervention|Control group|
88948589|NCT06070974||Single arm study|STEMI patients, who meet all the inclusion and none of the exclusion criteria, will be enrolled 3 days after PCI to study the correlation between exosome profile and severity of myocardial infarction
88948590|NCT06070948|Experimental|Regimen A|Participants will receive venetoclax dose A commercial formulation following a high-fat meal.
88948591|NCT06070948|Experimental|Regimen B|Participants will receive venetoclax dose B new formulation following a high-fat meal.
88948592|NCT06070948|Experimental|Regimen C|Participants will receive venetoclax dose A new formulation following a high-fat meal.
88948593|NCT06070948|Experimental|Regimen D|Participants will receive venetoclax dose B new formulation under fasted conditions.
88948594|NCT06070883|Other|Amniotic membrane|Amniotic membrane (AM) is the innermost layer of the placenta, which consists of a single layer of meta-bolically active epithelium, a thick basement membrane, and an avascular stromal matrix.It has been shown to exhibit a wide array of biological properties, including wound healing, anti-inflammatory, antimicrobial, and anti-angiogenic properties, amongst others
88948595|NCT06070857|Experimental|LV232|Subjects will receive LV232 orally for single dose.
88948596|NCT06070857|Experimental|Placebo|Subjects will receive placebo orally for single dose.
88948597|NCT06070844|Experimental|yoga nidra|yoga nidra
88948598|NCT06070844|No Intervention|control|control group
88948599|NCT06070831|Experimental|Inspiratory muscle training group (IMT)|Inspiratory muscle training at 50% of MIP, the training load was set each 2 weeks to keep 50% of MIP.
88948600|NCT06070831|Experimental|Expiratory muscle training group (EMT)|Expiratory muscle training at 50% of MEP, following the same rules as HIT.
88948601|NCT06070818|Experimental|Intervention|Healthy Body & Mind Program: In summary, the program includes two visits to the University of New South Wales (UNSW) Medicine & Health Lifestyle Clinic at the beginning and end of the program for Initial and Final Assessments, and two weekly sessions for 12 weeks (24 sessions in total) to the UNSW Medicine & Health Lifestyle Clinic to complete the Healthy Body & Mind Program. Participants will also be invited to take part in a focus group either at the clinic or online (via Teams/ zoom) at the end of the program.
88948602|NCT06070818|No Intervention|Wait-list control|Usual care. Participants will not be recruited if they are taking part in another research intervention or receiving treatment other than usual care.
88948603|NCT06070805||Non-depression group|The Hamilton Rating Scale for Depression (HAMD) will be applied to assess the depressive status of all enrolled patients. This scale consists of 24 survey items, each with a score of 0-4. Patients will be assigned to the nondepression group if their HAMD score was <8.
88948604|NCT06070805||Depression group|Patients will be assigned to the depression group if their score was ≥8.
89019189|NCT04698473|Active Comparator|NIPPV|"Ventilator-derived NIPPV will be administered using binasal prongs. Standard Devices or infant flow-driver device. Initial NIPPV settings are: PEEP:6 cmH2O, PIP: 15 cmH2O, Rate: 30-40/ bpm and FiO2: adjusted to keep preductal sPO2 between %90-94.~Failure is defined as FiO2 requirement of >%50, capillary blood gas obtained at the 4th hour of therapy showing pH<7.20 or pCO2>60 cmH2O."
89471640|NCT03915613|Experimental|Insulin|"Intranasal insulin will be made prepared from Humulin® R [insulin injection, human biosynthetic (rDNA Origin) REGULAR; 10 mL/vial, manufactured by Eli Lilly]. Each mL contains: 100 units of insulin injection, human biosynthetic (rDNA Origin) REGULAR. Nonmedicinal ingredients contain: glycerol, hydrochloric acid, m-cresol, sodium hydroxide and water for injection.~Unopened vials should be stored under refrigeration between 2°C and 8°C (36°F to 46°F) until the expiration date; do not freeze; keep away from heat and sunlight. Once punctured (in use), Humulin vials should be stored at room temperature <25°C (<77°F) and discarded after 28 days.~To obtain a dose Humulin R 160 U / placebo~16 sprays (0.1 mL/spray) are to be given per dose~This works out to 16 sprays split between each nostril such that each nostril receives 8 sprays.~The sprays will be administered between alternating nostrils"
89531869|NCT05056753|Sham Comparator|Control Device|The Control device is identical in construction to the Active device. The vibration mode, however, is a significantly different setting than that used by the Active version, so that the mechanoreceptors in the cervical spine are not effectively stimulated.
89531870|NCT05035641|Experimental|AND017 Dose A|AND017 will be administrated orally at dose A
89531871|NCT05035641|Experimental|AND017 Dose B|AND017 will be administrated orally at dose B
89531872|NCT05035641|Experimental|AND017 Dose C|AND017 will be administrated orally at dose C
89531873|NCT05035641|Placebo Comparator|Placebo|Placebo will be administrated orally
89531874|NCT05032950|Active Comparator|Treatment A|Midazolam orally
89531875|NCT05032950|Experimental|Treatment B|PF-07321332/ritonavir orally + Midazolam orally
89531876|NCT05032950|Active Comparator|Treatment C|Ritonavir orally + Midazolam orally
89531877|NCT05017740|Active Comparator|ICSI|
88948605|NCT06070792|Experimental|NEURO LINGUISTIC PROGRAM|"first experimental group. It will be administered to primiparous mothers after caesarean section in the first 48 hours after the sixth postoperative hour, once every eight hours, for a total of six times. Each session will last 20 minutes.~In the NLP application; firstly, the most frequently used visual, auditory and/or tactile representation system of the woman will be determined. Then, the internal and external reactions caused by the symptoms after caesarean section, her feelings and thoughts about her baby and breastfeeding will be combined with the anchoring technique. Then, with the swish technique, the existing negative emotions will be reduced and tried to be deleted from the most frequently used representation system. The woman's negative thoughts about breastfeeding will be changed in a positive direction with the belief change model."
88948606|NCT06070792|Experimental|PROGRESSIVE MUSCLE RELAXATION EXERCISES|"second experimental group. It will be administered to primiparous mothers after caesarean section in the first 48 hours after the sixth postoperative hour, once every eight hours, for a total of six times. Each session will last 20 minutes.~PMRE; All muscles of the body will be tried to be relaxed respectively with the commands given gradually."
88948607|NCT06070792|No Intervention|control|The control group will not receive NLP or PMRE.
88948608|NCT06070766||Chronic Pain|Drug: Ketamine The efficacy of the various approaches to prescribing Ketamine currently in use off-label. The focus will be to include ketamine research within the treatment plan of those with chronic conditions. A RIVER Ketamine protocol will be developed
88948609|NCT06070766||Anxiety|Drug: Ketamine The efficacy of the various approaches to prescribing Ketamine currently in use off-label. The focus will be to include ketamine research within the treatment plan of those with chronic conditions. A RIVER Ketamine protocol will be developed
88948610|NCT06070766||Veterans and First Responders|The efficacy of the various approaches to prescribing Ketamine currently in use off-label. The focus will be to include ketamine research within the treatment plan of those with chronic conditions. A RIVER Ketamine protocol will be developed
88948611|NCT06070766||Depression|Drug: Ketamine The efficacy of the various approaches to prescribing Ketamine currently in use off-label. The focus will be to include ketamine research within the treatment plan of those with chronic conditions. A RIVER Ketamine protocol will be developed
88948612|NCT06070766||Trauma|Drug: Ketamine The efficacy of the various approaches to prescribing Ketamine currently in use off-label. The focus will be to include ketamine research within the treatment plan of those with chronic conditions. A RIVER Ketamine protocol will be developed
88948613|NCT06070766||Auricular Chronic Pain|"Auricular Therapy (Ear acupuncture)~National Acupuncture Detoxification Association~Battlefield Acupuncture"
88948614|NCT06070766||Auricular Anxiety|"Auricular Therapy (Ear acupuncture)~National Acupuncture Detoxification Association~Battlefield Acupuncture"
88948615|NCT06070766||Auricular Depression|"Auricular Therapy (Ear acupuncture)~National Acupuncture Detoxification Association~Battlefield Acupuncture"
88948616|NCT06070766||Auricular Trauma|"Auricular Therapy (Ear acupuncture)~National Acupuncture Detoxification Association~Battlefield Acupuncture"
89019190|NCT04698707||lower limb lymphedema patients|This retrospective cohort study enrolled 131 lower limb lymphedema patients including 10 patients who have received VLNT as their primary lymphedema surgery showing minimal post-VLNT improvement (Group I) and 121 patients without previous lymphatic surgery (Group II).
89019191|NCT00451100|Experimental|Sugammadex|2.0 mg/kg Org 25969 (sugammadex)
89019192|NCT00451100|Active Comparator|Neostigmine|50 ug/kg neostigmine
89019193|NCT00420537|Active Comparator|mycophenolate|Mycophenolate mofetil with cyclosporine trough levels between 100 and 150
89019194|NCT00420537|Active Comparator|Everolimus|Everolimus with cyclosporine trough levels between 40 and 90 ng/ml
89019195|NCT00333684|Active Comparator|receive bioalcamid at baseline|half subjects received bioalcamid at baseline
89019196|NCT00333684|Active Comparator|Receive bioalcamid at 24 weeks|other half of subjets received bioalcamid at 24 weeks
89471641|NCT03915613|Placebo Comparator|Sterile Diluent|"Intranasal placebo will be prepared from Eli Lilly's sterile diluent used with Humulin® R (10 mL/vial, manufactured by Eli Lilly). Nonmedicinal ingredients contain: dibasic sodium phosphate, glycerin, liquefied phenol, metacresol, hydrochloric acid, sodium hydroxide and water for injection.~Unused sterile diluent should be kept at controlled room temperature until the expiration date. The USP defines controlled room temperature as (20° to 25°C [68° to 77°F]), with excursions permitted (15° to 30°C [59° to 86°F]). Once in-use, the sterile diluent vial should be used within 28 days.~Participants will follow the same dosage, frequency, and administration as Humulin:~16 sprays (0.1 mL/spray) are to be given per dose~This works out to 16 sprays split between each nostril such that each nostril receives 8 sprays.~The sprays will be administered between alternating nostrils"
89471642|NCT03914157|Active Comparator|15 patients with ARAS randomized to SWT|We will study 15 patients with ARAS randomized to SWT twice a week over 3 weeks. We will measure before and again 3 months after a 3-wk regimen renal cortical and medullary perfusion and function (multi-detector computed tomography [MDCT]), oxygenation, and fibrosis (magnetic resonance imaging [MRI]), urinary and plasma levels of renal injury markers, systemic endothelial function, and heart rate variability, an index of sympathetic activation.
89471643|NCT03914157|Sham Comparator|15 patients with ARAS sham|we will study 15 patients with ARAS randomized to or sham twice a week over 3 weeks. We will measure before and again 3 months after a 3-wk regimen renal cortical and medullary perfusion and function (multi-detector computed tomography [MDCT]), oxygenation, and fibrosis (magnetic resonance imaging [MRI]), urinary and plasma levels of renal injury markers, systemic endothelial function, and heart rate variability, an index of sympathetic activation.
89471644|NCT03896633|Active Comparator|Azopt 1% ophthalmic suspension|Ophthalmic suspension
89471645|NCT03896633|Experimental|Brinzolamide 1% ophthalmic suspension|ophthalmic suspension
89471646|NCT03890731|Other|Adult patients|Adult patients from completed Bayer-sponsored regorafenib trials who are benefitting from regorafenib treatment.
89471647|NCT03873051|Experimental|Challenge-Focused Program|This group will receive the challenge-focused group program
89471648|NCT03873051|Experimental|Rewards-Focused Program|This group will receive the rewards-focused group program
89471649|NCT03866564||Multi-Afflicted|Participants with multiple self reported afflictions will undergo comprehensive research health screenings including Echocardiography (to define cardiac dysfunction), Neuropsychological Testing (to define neurocognitive disease), Pain Catastrophizing Scale (to define chronic pain), and Nocturnal Polysomnography (to define sleep apnea).
89471650|NCT03866564||Un-Afflicted|Participants who report no afflictions will undergo comprehensive research health screenings including Echocardiography (to define cardiac dysfunction), Neuropsychological Testing (to define neurocognitive disease), Pain Catastrophizing Scale (to define chronic pain), and Nocturnal Polysomnography (to define sleep apnea).
89531878|NCT05017740|Active Comparator|PICSI|
89019197|NCT00451295|Placebo Comparator|1|
89019198|NCT00451295|Experimental|2|
89019199|NCT00451412|Experimental|Certoparin|
89019200|NCT00451412|Active Comparator|Unfractionated Heparin|
89471651|NCT03866564||Single Afflicted|Participants with one self reported afflictions will undergo comprehensive research health screenings including Echocardiography (to define cardiac dysfunction), Neuropsychological Testing (to define neurocognitive disease), Pain Catastrophizing Scale (to define chronic pain), and Nocturnal Polysomnography (to define sleep apnea).
89471652|NCT03857464|Other|Crossover Arm One|Hospital wards in this arm will use C. DIFF QUIK CHEK COMPLETE® for near-patient testing for the first phase of the crossover. For the second phase of the crossover, Arm One will utilize standard operating procedure testing for C. difficile infections using the centralized testing facilities.
89019201|NCT04717245|Active Comparator|Fractional CO2 LASER|Vaginal fractional CO2 LASER 3 sessions applications
89019202|NCT04717245|Active Comparator|Microablative fractional radiofrequency|Vaginal Microablative fractional radiofrequency 3 sessions application
89019203|NCT04717245|Active Comparator|Promestriene Vaginal|Promestriene vaginal use during 3 months
89019204|NCT03275441||Adult patients|Adult patients attending hospital for clinical visual electrophysiology.
89019205|NCT00333918|Experimental|1-bromfenac ophthalmic solution|sterile ophthalmic solution
89019206|NCT00333918|Placebo Comparator|2-placebo comparator|sterile ophthalmic solution
89019207|NCT04716738||Irritable Bowel Syndrome with Sexual Dysfunction|We use Rome IV criteria, scale bristol and the female sexual fuction to establish IBS and sexual dysfunction diagnosis, and SF-36 to determinated quality of life.
89019208|NCT04716738||Irritable Bowel Syndrome without Sexual Dysfunction|We use Rome IV criteria, scale bristol and the female sexual fuction to establish IBS and sexual dysfunction diagnosis, and SF-36 to determinated quality of life.
89019209|NCT00451568|Active Comparator|1|metformin
89019210|NCT00451568|Active Comparator|2|desorelle
89019211|NCT00451568|Active Comparator|3|desorelle + metformin
89471653|NCT03857464|Other|Crossover Arm Two|Hospital wards in this arm will utilize testing for C. difficile infections using the centralized testing facilities in phase 1 and will switch to using C. DIFF QUIK CHEK COMPLETE® for near-patient testing in phase 2 of the crossover design.
89019212|NCT04716465||Covid-19 infected patients|In this study male and female patients who were previously infected with covid-19 (symptomatic and asymptomatic) will be included. Patients will only be eligible if they had a positive covid-19 test before inclusion in the study. More specifically, only patients who had a positive COVID-19 test 2 to 8 weeks before study inclusion are eligible.
89019213|NCT00451646|Experimental|1|SMOFlipid
89019214|NCT00451646|Active Comparator|2|Intralipid
89019215|NCT04716348|Experimental|group A|suboccipital muscle energy technique
89019216|NCT04716348|Sham Comparator|group B|sham muscle energy technique
89019217|NCT00451841||1|Chronic cough caused by GERD
89019218|NCT00451841||2|Chronic cough without GERD
89019219|NCT00330798|Experimental|Nevanac|One drop, three times daily, in the assigned eye for the first three postoperative days
89019220|NCT00330798|Placebo Comparator|Acular LS|One drop, three times daily, in the assigned eye for the first three postoperative days
89019221|NCT00451880|Experimental|Arm 1|XL281 administered once a day
89471654|NCT03848715|Experimental|Endotoxin|Endotoxin 0.8 ng/kg body weight; 1 infusion
89471655|NCT03848715|Placebo Comparator|Placebo|same volume of 0.9% saline
89471656|NCT03847311|Placebo Comparator|Placebos|Subjects will receive sugar pill.
89471657|NCT03847311|Active Comparator|Sulfasalazine|Subjects will receive the active drug.
89471658|NCT03845543|Experimental|Luminor-14 paclitaxel eluting balloon|Pre-dilatation of 180 seconds with a standard non-drug-coated semi-compliant balloon followed by a dilatation with a Luminor-14 paclitaxel eluting balloon (3µg/mm² balloon surface).
89019222|NCT00451880|Experimental|Arm 2|XL281 administered twice a day
89471659|NCT03827889|Experimental|WMP of fluoride varnish|Whole mouth protocol group
89471660|NCT03827889|Experimental|TWLP of fluoride varnish|Tooth with lesion Protocol
89471661|NCT03827889|Active Comparator|DHP (educational intervention)|Diet and Hygiene guidance Protocol
89471662|NCT03826563|Placebo Comparator|Placebo|Subjects will receive pill placebo nightly
89471663|NCT03826563|Experimental|Melatonin|Subjects will receive oral melatonin tablets 2.5-10mg nightly for 2 weeks. All will receive melatonin 5mg for one week, then at the 1 week visit, the dose can be continued at 5mg or adjusted to 2.5mg or 10mg nightly based on clinical assessment of patient response and side effects.
89471664|NCT03823131|Experimental|Arm A: Tavo-EP, pembrolizumab, epacadostat|Tavo-EP will be injected intratumorally on Days 1, 5 and 8 every 6 weeks to up to 7 accessible lesions without exceeding 20 mL per day. Injected lesions will then be electroporated using the ImmunoPulse electroporation device. Pembrolizumab will be administered by a 30 minute IV infusion at a dose of 200 mg every 3 weeks. Epacadostat will be administered at the dose level determined in the dose escalation safety lead-in.
89471665|NCT03823131|Experimental|Arm B: Tavo-EP, pembrolizumab|Tavo-EP will be injected intratumorally on Days 1, 5 and 8 every 6 weeks to up to 7 accessible lesions without exceeding 20 mL per day. Injected lesions will then be electroporated using the ImmunoPulse electroporation device. Pembrolizumab will be administered by a 30 minute IV infusion at a dose of 200 mg every 3 weeks.
89531879|NCT05000788|Experimental|Qigong Group|
89531880|NCT05000788|Active Comparator|Exercise Group|
89531881|NCT04998097|Experimental|experimental (iTBS group)|device: Magstim Rapid2 Stimulator
89531882|NCT04998097|Sham Comparator|sham group|device shame Magstim Rapid2 Stimulator
89531883|NCT04997733|Experimental|Fecal microbiota|Patients receiving the fecal microbiota transplantation (FMT) in 3 times after inclusion and randomisation (endoscopic and oral)
89531884|NCT04997733|Sham Comparator|Sham-transplantation|Patients receiving the sham-transplantation in 3 times after inclusion and randomisation (endoscopic and oral)
89019223|NCT00451880|Experimental|Arm 3|XL281 administered once a day. Subjects in this arm will be dosed under fed conditions, fasted conditions, and with a concomitant single dose of 40 mg famotidine, during the second, third, and fourth week of the first cycle.
89019224|NCT00451997|Experimental|Gleevec + Low-Dose Ara-C|
89019225|NCT00452036||Minor head injury|patients with minor head injury
89019226|NCT00452036||minor head injury|patients with minor head injury
89019227|NCT00331032|Experimental|1: 3% w/w SPL7013 Gel|40 subjects VivaGel™.
89019228|NCT00331032|Placebo Comparator|2: Placebo|20 subjects placebo.
89471666|NCT03823131|Experimental|Arm C: Tavo-EP, pembrolizumab, CORVax|Tavo-EP will be injected intratumorally on Days 1, 5 and 8 every 6 weeks to up to 7 accessible lesions without exceeding 20 mL per day. Injected lesions will then be electroporated using the ImmunoPulse electroporation device. Pembrolizumab will be administered by a 30-minute IV infusion at a dose of 200 mg every 3 weeks. CORVax will be administered at a total dose of 0.2 mg of (S) protein plasmid in 120 microliter (uL) per lesion intratumorally into a maximum of 4 lesions of at least 0.3 mm in diameter for a total plasmid dose of 0.8 mg on treatment days 1 and 29 of cycle 1 followed by electroporation of the plasmid solution in infiltrated regions. On days when both tavo and CORVax is administered to the same lesions, tavo and CORVax will each be injected into the lesion followed by electroporation.
89471667|NCT03822091|Active Comparator|TERLIPRESSIN GROUP|
89471668|NCT03822091|Experimental|TERLIPRESSIN WITH NORADRENALINE GROUP|
89471669|NCT03798561|Experimental|82 µg/cm2 ASN008 TG or Placebo|PART A: ASN008 TG 82 µg/cm2 single application in 7 days or Placebo TG (6 subjects ASN008: 2 subjects placebo) (6:2)
89471670|NCT03798561|Experimental|164 µg/cm2 ASN008 TG or Placebo|PART A: ASN008 TG 164 µg/cm2 single application in 7 days or Placebo (6:2)
89471671|NCT03798561|Experimental|328 µg/cm2 ASN008 TG or Placebo|Part A: ASN008 TG 328 µg/cm2 single application in 7 days or Placebo (6:2)
89471672|NCT03798561|Experimental|492 µg/cm2 ASN008 TG or Placebo|Part A: ASN008 TG 492 µg/cm2 single application in 7 days or Placebo (6:2)
89471673|NCT03798561|Experimental|ASN008 TG TBD Cohort 1 or Placebo|Part B: ASN008 TG Cohort 1 daily application for 15 days or Placebo (9 subjects ASN008: 3 subjects Placebo) (9:3)
89471674|NCT03798561|Experimental|ASN008 TG TBD Cohort 2 or Placebo|Part B: ASN008 TG Cohort 2 daily application for 15 days or Placebo (9:3)
89471675|NCT03798561|Experimental|ASN008 TG TBD Cohort 3 or Placebo|Part B: Placebo TG Cohort 3 daily application for 15 days or Placebo (9:3)
89471676|NCT03785730|Experimental|Non-restorative cavity control - NRCC|Enlargement with metallic sandpaper associated with toothbrushing/1000 ppm fluoride toothpaste.
89471677|NCT03785730|Active Comparator|Resin composite restoration - RCR|Selective carious lesion removal and restoration with resin composite.
89471678|NCT03779711|Experimental|Treatment|Autologous (self) mononuclear cells derived from umbilical cord blood and that meet all release criteria are injected into the surface of the right heart muscle to achieve the target dose of 1-3 million cells per kilogram body weight . This is a one time treatment at the time of Stage II Glenn surgery .
89471679|NCT03779711|Active Comparator|Control|Clinical data will be collected before, during and after the Stage II surgical standard of care procedure. Requires additional imaging studies at 3 months that are not standard of care in addition to some blood tests that would be beyond standard of care. Information will be collected to document the clinical outcomes and will be compared with the information from the group receiving the investigational treatment used in this study.
89471680|NCT03754322|Active Comparator|Standard of care|One third of individuals get allocated to the standard of care arm. At each antenatal visit as per Ethiopian guidelines, pregnant women enrolled in the study will be submitted to the standard of care for malaria in pregnancy. If the pregnant mothers are symptomatic for malaria, they receive microscopy (blood smear for Plasmodium detection) and then are treated with anti-malarial therapy if microscopy is positive for Plasmodium. If it is negative they receive no treatment. If they are asymptomatic, they do not receive any further investigations or treatment in relation to malaria.
89471681|NCT03754322|Experimental|Intervention arm|The remaining two-thirds of participants will be actively screened (symptomatic and asymptomatic) for Plasmodium infection at each antenatal visit, using both LAMP and conventional techniques (microscopy and RDT). If either is positive, participants will be treated with antimalarial therapy according to Ethiopian Ministry of Health guidelines. If both are negative then they receive no treatment.
89471682|NCT03747133|Experimental|Stereotactic Ablative Radiotherapy|Adult patients with Kidney mass (either primary or metastasis) amenable to SABR
89471683|NCT03734393|Experimental|HIV D+/R+|HIV-infected individuals that accept an organ from an HIV-infected deceased donor - enrollment 40
89471684|NCT03734393|No Intervention|HIVD-/R+|HIV-infected individuals that accept an organ from an HIV-uninfected deceased donor and are randomized to participate in the full study arm, which includes research sample collection -enrollment 40
88948617|NCT06070766||Chronic Pain MH|4. Millennium Health The Phase 2 Protocol (P2P) has entered its 4th year of application in those with symptoms associated with all forms of traumatic brain injury (T.B.I.). Listening to any of the following Joe Rogan Experience podcasts, 1589, 1056, or 700, will provide a number of discussions on this topic. Since the 2020 pilot study with active duty Marines (U.S.M.C.), looking at the benefits of a 100% nutraceutical approach to T.B.I., precipitated changes in mental and physical health, we had the start to developing the P2P. With over 8,000 participants, we see the benefits derived from the 2023 Phase 2 Protocol.
89471685|NCT03734393|No Intervention|HIVD-/R+ (observational)|HIV-infected individuals that accept an organ from an HIV-uninfected deceased donor and randomized to observational group with limited data collection - enrollment 120
89471686|NCT03728504|Experimental|ASN002 40 mg|40 mg ASN002
88948618|NCT06070766||Anxiety MH|4. Millennium Health The Phase 2 Protocol (P2P) has entered its 4th year of application in those with symptoms associated with all forms of traumatic brain injury (T.B.I.). Listening to any of the following Joe Rogan Experience podcasts, 1589, 1056, or 700, will provide a number of discussions on this topic. Since the 2020 pilot study with active duty Marines (U.S.M.C.), looking at the benefits of a 100% nutraceutical approach to T.B.I., precipitated changes in mental and physical health, we had the start to developing the P2P. With over 8,000 participants, we see the benefits derived from the 2023 Phase 2 Protocol.
88948619|NCT06070766||Depression MH|4. Millennium Health The Phase 2 Protocol (P2P) has entered its 4th year of application in those with symptoms associated with all forms of traumatic brain injury (T.B.I.). Listening to any of the following Joe Rogan Experience podcasts, 1589, 1056, or 700, will provide a number of discussions on this topic. Since the 2020 pilot study with active duty Marines (U.S.M.C.), looking at the benefits of a 100% nutraceutical approach to T.B.I., precipitated changes in mental and physical health, we had the start to developing the P2P. With over 8,000 participants, we see the benefits derived from the 2023 Phase 2 Protocol.
88948620|NCT06070766||Tramua MH|4. Millennium Health The Phase 2 Protocol (P2P) has entered its 4th year of application in those with symptoms associated with all forms of traumatic brain injury (T.B.I.). Listening to any of the following Joe Rogan Experience podcasts, 1589, 1056, or 700, will provide a number of discussions on this topic. Since the 2020 pilot study with active duty Marines (U.S.M.C.), looking at the benefits of a 100% nutraceutical approach to T.B.I., precipitated changes in mental and physical health, we had the start to developing the P2P. With over 8,000 participants, we see the benefits derived from the 2023 Phase 2 Protocol.
89471687|NCT03728504|Experimental|ASN002 80 mg|80 mg ASN002
88948621|NCT06070753|Experimental|Participants undergo EVT plus Cerebrolysin|one group of patients should receive intravenous treatment with Cerebrolysin (30 ml/day) starting post EVT CT-Perfusion that will be performed not later than 3 hours from completion of EVT. Treatment will be continued for 10 consecutive days as one single daily infusion.
88948622|NCT06070740|Experimental|Combination therapy as first-line treatment|Durvalumab combined with XELOX chemotherapy as the first-line treatment
88948623|NCT06070727|Other|Metal framework group|group A: Patients will receive metallic framework with obturator for 6 months, then the metallic obturator will be replaced by PEKK obturator for another 6 months.
88948624|NCT06070727|Other|PEKK framework group|Group B: Patients will receive PEKK obturator for 6 months, then the same patients will receive metallic framework obturator for another 6 months.
88948625|NCT06070675|Other|Paper bladder diary (pBD)|Patients will complete the paper bladder diary at home for at least 2 consecutive days.
88948626|NCT06070675|Other|Automated bladder diary (autoBD)|Patients will complete the automated bladder diary (Minze Diary Pod) at home for at least 2 consecutive days.
88948627|NCT06070662||Suspected coronary microvascular disease confirmed at angiography (expected n=8)|Individuals with suspected coronary microvascular disease based on CT and MRI scans completed as part of the main research study. Those with confirmed coronary microvascular disease will complete an MRI scan as part of this pilot study and their CT scan will undergo additional analysis.
88948628|NCT06070662||Suspected coronary microvascular disease not confirmed at angiography (expected n=4)|Individuals with suspected coronary microvascular disease based on CT and MRI scans completed as part of the main research study. If this is not confirmed coronary microvascular disease they will not undergo any further investigations as part of this research study.
88948629|NCT06070662||Multivessel coronary artery disease (n=12)|Individuals with multivessel coronary artery disease, diagnosed based on CT and MRI scans completed as part of the main research study and confirmed at angiography.
88948630|NCT06070636|Experimental|bTAE-HAIC combined with Lenvatinib and Sintilimab|bTAE procedure was a 2.8-F microcatheter was super-selectively inserted into the tumor feeding artery using the coaxial technique. Then blank microspheres were used according to the tumor blood supply vessels (40-120um, 100-300um, 300-500um, 500-700um). Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin every 4 weeks. Lenvatinib 12 mg (or 8 mg) once daily (QD) oral dosing. Sintilimab, 200 mg intravenously every 3 weeks.
88948631|NCT06070571|Experimental|Intervention group|Bucco-adhesive films with Yarrow and Moringa extract nanoparticles
88948632|NCT06070571|Active Comparator|control group|Cholorohexiden oral gargles
88948633|NCT06070558|Other|Healthy|Healthy volunteers
88948634|NCT06070558|Other|Temporomandibular Joint Disorders|Patients with Temporomandibular Joint Disorders
89471688|NCT03728504|Placebo Comparator|Placebo oral tablet|Matching placebo for ASN002 doses
88948635|NCT06070545|Experimental|İntervention Group|Modified supine position care
88948636|NCT06070545|No Intervention|Control Group|Standard Care
88948637|NCT06070532|Experimental|Intervention group|12 female or male patients suffering from aging frailty
89471689|NCT03713853||Total hip arthroplasty + ORIF|Patients will receive acute primary total hip arthroplasty (THA) with open reduction internal fixation (ORIF) as a treatment for their acetabular fracture
89471690|NCT03713853||Surgical Fixation (ORIF)|Patients will receive open reduction internal fixation (ORIF) as a treatment for their acetabular fracture
89471691|NCT03703466|Experimental|200 mg Abemaciclib With a Meal|200 mg abemaciclib given twice a day (BID) orally with a meal.
89471692|NCT03703466|Experimental|200 mg Abemaciclib Without a Meal|200 mg abemaciclib given twice a day (BID) orally without a meal, taken in the modified fasted condition.
89471693|NCT03703466|Experimental|200 mg Abemaciclib Without Regard to Food|200 mg abemaciclib given twice a day (BID) orally without regard for food.
89019229|NCT00452075|Experimental|arm 1 medicine|erlotinib daily
89019230|NCT00331071||001|Ortho Evra transdermal patch containing 6 mg NGMN/0.75 mg EE worn for 1 week and replaced for 3 consecutive weeks fourth week is patch free
89471694|NCT03697772||multmorbid patients|patients with 2 chronic diseases (medical conditions requiring management for more than 6 months)
89019231|NCT00331071||002|Monophasic or triphasic Oral contraceptive tablet 35 mcg EE for 21 consecutive days followed by no or drug-free tablet for 7 days
89019232|NCT00452153|Experimental|Characterization Legionnella|Characterization Legionnella by polymerase chain reaction (PCR)
89019233|NCT02956889|Experimental|Vismodegib & Radiotherapy|"Radiotherapy (RT) will be administered with a total dose of 50 Gy/2.5 Gy per fraction over 4 weeks.~Treatment with Vismodegib will start within 4 weeks by the end of radiotherapy and will continue for 6 cycles"
89471695|NCT03677128|Experimental|mNavigator|Allied health providers will use mNavigator to guide diagnosis and treatment for pediatric cancer patients at Bugando Medical Centre (BMC).
89471696|NCT03677128|No Intervention|Historical controls|BL (DLBCL)/Rb retrospective patients (treated between 2015-2019) when standardized treatment protocols for BL (DLBCL) and Rb were introduced at BMC.
89471697|NCT03674697|Experimental|Active Treatment Group (Green LED)|Subjects will be exposed to a Green LED light for 8 weeks prior to surgery, during their hospital stay and for an additional 2 weeks after hospital discharge.
89471698|NCT03674697|Placebo Comparator|Control Group (White LED)|Subjects will be exposed to a White LED light for 8 weeks prior to surgery, during their hospital stay and for an additional 2 weeks after hospital discharge.
89471699|NCT03664544|Experimental|Subjects with severe hepatic impairment|HP PK MCI-186
89471700|NCT03664544|Experimental|Subjects with normal hepatic function|NHV PK MCI-186
89471701|NCT03561818|Experimental|Hospital-based group|2 months hospital-based pulmonary rehabilitation program
89471702|NCT03561818|Experimental|Home-based group|2 months home-based pulmonary rehabilitation program
89471703|NCT03534687|Experimental|Aerobic Exercise Group|Aerobic Exercise (AE) subjects will come in for supervised, aerobic exercise training sessions 5 days a week for 12 weeks. Training will progress from 55% VO2max for week 1 (40 min session), to 60-65% VO2max for week 2 (50 min session), to ~70% VO2max for all other weeks (50 min session). Subjects will perform a warm-up and cool down (~5 min each) that includes stretching exercises. Subjects will wear heart rate monitors during each training session to provide feedback of target heart rate. Intensity, duration, resting and exercise heart rates, and blood pressures will be recorded for each session. Follow-up VO2max tests will be performed at weeks 4 and 8 to monitor progress and adjust AE training intensity.
89019234|NCT03275363||Cognitively normal controls (CNC)|No subjective memory complaints Normal HK-MoCA Normal instrumental ADL All interventions as described
89019235|NCT03275363||Subjective cognitive decline (SCD)|Subjective memory complaints Normal HK-MoCA Normal instrumental ADL All interventions as described
89019236|NCT03275363||Mild cognitive impairment (MCI)|Subjective memory complaints Low HK-MoCA Normal instrumental ADL All interventions as described
89019237|NCT03275363||Alzheimer's dementia|Subjective memory complaints Low HK-MoCA Poor instrumental ADL Probable Alzheimer's disease All interventions as described except EEG with ERP
89471704|NCT03534687|No Intervention|Control Group|During the 12 week control period, subjects are to maintain their normal, daily-living activities. Control group participants will be given the option to enroll in the AE training group after completion of the original Control group trial period.
89019238|NCT03275363||Vascular dementia|Subjective memory complaints Low HK-MoCA Poor instrumental ADL Related to stroke / cerebrovascular disease All interventions as described except EEG with ERP
89019239|NCT03275324||Enrolled patients|Surgical patients meeting enrollment criteria
89019240|NCT04698512||Arteriovenous Fistuloplasty with MagicTouch™ Balloon|Patients above the age of 21 that have undergone AVF / AVG fistuloplasty with MagicTouch™ at Singapore General Hospital will be included in the study and followed up post-op for 12 months. Patients will be treated and followed-up following standard clinical care pathways.
89471705|NCT03531619||Dizziness|Patients referred to a neuro-otological clinic due to dizziness who answer that they do not suffer from neck pain
89471706|NCT03531619||Dizziness and neck pain|Patients referred to a neuro-otological clinic due to dizziness who answer that they suffer from neck pain
89471707|NCT03531619||Neck pain|Patients referred to a rehabilitation center due to neck pain who answer that they do not suffer from dizziness
89471708|NCT03531619||Neck pain and dizziness|Patients referred to a rehabilitation center due to neck pain who answer that the suffer from dizziness
89471709|NCT03531619||Healthy Control|Healthy Controls without neck pain or dizziness
89471710|NCT03521570|Experimental|Treatment (nivolumab, IMRT)|Patients receive nivolumab IV over 30 minutes on weeks -2, 0, 2, 4, and 6 and undergo IMRT once daily beginning on week 0 for up to 6-6.5 weeks. Beginning week 10, patients receive nivolumab IV over 30 minutes every 4 weeks for up to 10 courses in the absence of disease progression or unacceptable toxicity.
89471711|NCT03474185||Single Cohort|"The intervention for the entire cohort will be Taking Charge of your Heart Health Cardiac Education Classes, delivered via four 2.5-hour group-based classes at TotalCardiology Rehabilitation in Calgary, Canada. Classes review physiology, risk factors, medications, nutrition, exercise, and stress management. Patients are required to complete these classes prior to starting CR exercise sessions."
89019241|NCT04698668||1|Patients with pancreatic fluid collection treated with traditional EUS-drainage
89019242|NCT04698668||2|Patients with pancreatic fluid collection treated with fusion imaging
89019243|NCT04698551||16 pregnant women and their spouses|16 pregnant women and their spouses
89019244|NCT00334347|Active Comparator|Depakote ER|
89019245|NCT00334347|Active Comparator|Depakote DR|
89019246|NCT03275207|Placebo Comparator|control group|an equal volume of saline
89019247|NCT03275207|Experimental|dexmedetomidine|dexmedetomidine, 0.5ug/kg/h by intravenous infusion, intraoperative
89019248|NCT03275012|Experimental|Group 1|Gabapentin + Morphine
89019249|NCT03275012|Placebo Comparator|Group 2|Placebo + Morphine
89019250|NCT04698395|Experimental|HABIT-ILE|Baby HABIT-ILE (Hand-Arm Bimanual Intensive Therapy Including Lower Extremities) intervention during two weeks
89019251|NCT04698395|Active Comparator|Regular care|Usual customary care intervention during two weeks
89471712|NCT03468218|Experimental|Treatment (pembrolizumab, cabozantinib)|Patients receive pembrolizumab IV over 30 minutes on day 1 and cabozantinib PO QD on days 1-21. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
89471713|NCT03457168|Active Comparator|Intensive asleep SBP control|To reduce the asleep SBP mean up to a target <110 mmHg. Treatment of elevated asleep SBP mean
89471714|NCT03457168|Active Comparator|Conventional asleep SBP control|To reduce the asleep SBP mean up to a target <120 mmHg. Treatment of elevated asleep SBP mean
89471715|NCT03429816|Experimental|Interventional Arm|"Patients with locally advanced, resectable gastric or esophagogastric junction adenocarcinoma will receive a biopsy of the primary tumor, followed by standard-of care neoadjuvant systemic treatment; after neoadjuvant therapy tumor biopsies will be taken from different sites of the resection specimen.~Organoid cultures of pre-treatment tumor biopsies will be established and exposed to the same chemotherapy as the corresponding patient; in vitro response to treatment will be correlated with the in vivo response of patients.~Whole genome, methylome and RNA sequencing of tumors biopsies and organoids will be performed prior to as well as after systemic treatment."
89471716|NCT03408574|Experimental|Older Adults|Healthy adults aged 65-75 will participate in three study days where they are randomly assigned to receive either nicotine patch, oral mecamylamine, placebo and perform a working memory task during the fMRI. BOLD signal is the outcome measure.
89471717|NCT03408574|Experimental|Younger Adults|Healthy adults aged 18-30 will participate in three study days where they are randomly assigned to receive either nicotine patch, oral mecamylamine, or placebo and perform a working memory task during the fMRI.BOLD signal is the outcome measure.
89471718|NCT03404336|Experimental|Well-being therapy|WBT will be used as the only non-pharmacological therapeutic strategy and 8 sessions will be delivered every other week with a duration of 60 minutes each. The manualized WBT will be used (Fava, 2016). Thus, the initial phase will be concerned with self-observation of psychological well-being. Once the instances of well-being will be properly recognized, the patient will be encouraged to identify thoughts, beliefs, and behaviors leading to premature interruption of well-being (intermediate phase). The final part will involve cognitive restructuring of dysfunctional dimensions of psychological well-being and meeting the challenge that optimal experiences may entail.
89471719|NCT03404336|Placebo Comparator|Control condition|The control condition will include 8 be-weekly sessions based on Lifestyle and well-being National Institute for health and Care Excellence (NICE) guidelines (https://www.nice.org.uk/guidance/lifestyle-and-wellbeing) and on World Health Organization 12 steps to healthy eating (http://www.euro.who.int/en/health-topics/disease-prevention/nutrition/a-healthy-lifestyle). These sessions will inform participants about well-being and which lifestyles can influence it.
89471720|NCT03403933|Experimental|cardiopathic patients in hypovitaminosis|Didrogyl 10 ml: 10 drops a day to obtain levels of vitamin D > 30 ng /ml. Once these values are obtained lower the dose to 4-5 drops a day, with the aim, however, of keeping the plasma values between 30 and 60 ng/ml during 6 months of the study
89471721|NCT03397576|Experimental|ATHENA|Subjects in the experimental arm will participate in monthly group medication adherence counseling sessions within prison led by a nurse and peer educator. After prison release, subjects in the experimental group will participate in four home visits during which intervention staff (nurses and peer educators working in teams) will deliver individualized medication adherence counseling based on the Freirian educational model.
89471722|NCT03397576|No Intervention|Control|Subjects in the control group will receive standard care, which includes a referral for HIV care and ART if prescribed ART within prison.
89471723|NCT03385343|Experimental|VLE imaging of stage EAC|All subjects will receive VLE imaging for staging EAC. Volumetric laser endomicroscopy (VLE) is an imaging platform that uses infrared light to generate cross-sectional views of the human esophagus with microscopic resolution.
89471724|NCT03349996|Experimental|LifeStream Peripheral Stent Graft System|Patients treated with the LifeStream Peripheral Stent Graft System
89471725|NCT03341520|Experimental|interventional arm|Obinutuzumab Injection [Gazyva] 1000mg flat i.v. on week 1, 2, 3, 4, 8, 12, 16; Low dose radiation Therapy (LDRT) involved site 2 x 2 Gy in week 9
89471726|NCT03333551|Experimental|Patients with AL cardiac amyloid|Patients enrolled will be patients > 18 years of age with a clinical diagnosis of cardiac AL amyloidosis (typical echocardiographic or MRI findings, NT-ProBNP levels above 332 pg/mL, cardiac or extra cardiac histological evidence of light chain amyloidosis) with plans to undergo plasma cell directed chemotherapy.
89471727|NCT03326583|Experimental|Patiromer|"This arm is a 2 week observation period before the start of the Patiromer treatment phase, followed by a 12 week treatment phase, and 6 week no treatment observation phase.~Pre-Treatment (Wk 1-2): Observational period. Baseline sample collection of blood and stool. No medication.~Treatment (Wk 3-14): Participants will take 8.4 grams of Patiromer once daily for one week, during which serum potassium and gastrointestinal symptoms will be evaluated. If tolerated and in the absence of hypokalemia, the dose will be up-titrated to 16.8 grams once daily for the remaining 11 weeks. Blood and stool will be collected.~Post-Treatment (Wk 15-20): Observational period. No medication. Blood and stool will be collected."
88948638|NCT06070519|Experimental|Sigle arm study|HF patients who meets all the inclusion and none of the exclusion criteria
88948639|NCT06070480|Active Comparator|Spinal Anesthesia Group|Intraocular pressure values of the patients operated with spinal anaesthesia were measured
88948640|NCT06070480|Active Comparator|Desflurane Group|Intraocular pressure values were measured in patients operated under general anaesthesia with desflurane.
88948641|NCT06070480|Active Comparator|Propofol Group|Intraocular pressure values were measured in patients operated under general anaesthesia with desflurane.
89471728|NCT03286361|Experimental|BeGraft Peripheral + Stent Graft System|Patients treated with the BeGraft Peripheral Plus Stent Graft System
89471729|NCT03254940|Experimental|Arm 1: WT-SM-OR-SS-CS|Charge: weekly tracking, self-generated motivational messages, one reminder, summary score, compare to self
89471730|NCT03254940|Experimental|Arm 2: WT-SM-OR-SS-CG|Charge: weekly tracking, self-generated motivational messages, one reminder, summary score, compare to group
89471731|NCT03254940|Experimental|Arm 3: WT-SM-OR-SF-CS|Charge: weekly tracking, self-generated motivational messages, one reminder, specific goal feedback, compare to self
89471732|NCT03254940|Experimental|Arm 4: WT-SM-OR-SF-CG|Charge: weekly tracking, self-generated motivational messages, one reminder, specific goal feedback, compare to group
89471733|NCT03254940|Experimental|Arm 5: WT-SM-MR-SS-CS|Charge: weekly tracking, self-generated motivational messages, multiple reminders, summary score, compare to self.
89471734|NCT03254940|Experimental|Arm 6: WT-SM-MR-SS-CG|Charge: weekly tracking, self-generated motivational messages, multiple reminders, summary score, compare to group.
89471735|NCT03254940|Experimental|Arm 7: WT-SM-MR-SF-CS|Charge: weekly tracking, self-generated motivational messages, multiple reminders, specific feedback, compare to self
89471736|NCT03254940|Experimental|Arm 8: WT-SM-MR-SF-CG|Charge: weekly tracking, self-generated motivational messages, multiple reminders, specific feedback, compare to group
89471737|NCT03254940|Experimental|Arm 9: WT-EM-OR-SS-CS|Charge: weekly tracking, expert-generated motivational messages, one reminder, summary score, compare to self
89471738|NCT03254940|Experimental|Arm 10: WT-EM-OR-SS-CG|Charge: weekly tracking, expert-generated motivational messages, one reminder, summary score, compare to group
89471739|NCT03254940|Experimental|Arm 11: WT-EM-OR-SF-CS|Charge: weekly tracking, expert-generated motivational messages, one reminder, specific goal feedback, compare to self
89471740|NCT03254940|Experimental|Arm 12: WT-EM-OR-SF-CG|Charge: weekly tracking, expert-generated motivational messages, one reminder, specific goal feedback, compare to group.
89471741|NCT03254940|Experimental|Arm 13: WT-EM-MR-SS-CS|Charge: weekly tracking, expert-generated motivational messages, multiple reminders, summary score, compare to self
89471742|NCT03254940|Experimental|Arm 14: WT-EM-MR-SS-CG|Charge: weekly tracking, expert-generated motivational messages, multiple reminders,summary score, compare to group
89471743|NCT03254940|Experimental|Arm 15: WT-EM-MR-SF-CS|Charge: weekly tracking, expert-generated motivational messages, multiple reminders, specific goal feedback, compare to self
89471744|NCT03254940|Experimental|Arm 16: WT-EM-MR-SF-CG|Charge: weekly tracking, expert-generated motivational messages, multiple reminders, specific goal feedback, compare to group
89471745|NCT03254940|Experimental|Arm 17: DT-SM-OR-SS-CS|Charge: daily tracking, self-generated motivational messages, one reminder, summary score, compare to self.
89471746|NCT03254940|Experimental|Arm 18: DT-SM-OR-SS-CG|Charge: daily tracking, self-generated motivational messages, one reminder, summary score, compare to group
89471747|NCT03254940|Experimental|Arm 19: DT-SM-OR-SF-CS|Charge: daily tracking, self-generated motivational messages, one reminder, specific goal feedback, compare to self.
89471748|NCT03254940|Experimental|Arm 20: DT-SM-OR-SF-CG|Charge: daily tracking, self-generated motivational messages, one reminder, specific goal feedback, compare to group
89471749|NCT03254940|Experimental|Arm 21: DT-SM-MR-SS-CS|Charge: daily tracking, self-generated motivational messages, multiple reminders, summary score, compare to self
89471750|NCT03254940|Experimental|Arm 22: DT-SM-MR-SS-CG|Charge: daily tracking, self-generated motivational messages, multiple reminders, summary score, compare to group.
89471751|NCT03254940|Experimental|Arm 23: DT-SM-MR-SF-CS|Charge: daily tracking, self-generated motivational messages, multiple reminders, specific goal feedback, compare to self.
89471752|NCT03254940|Experimental|Arm 24: DT-SM-MR-SF-CG|Charge: daily tracking, self-generated motivational messages, multiple reminders, specific goal feedback, compare to group
89471753|NCT03254940|Experimental|Arm 25: DT-EM-OR-SS-CS|Charge: daily tracking, expert-generated motivational messages, one reminder, summary score, compare to self
89471754|NCT03254940|Experimental|Arm 26: DT-EM-OR-SS-CG|Charge: daily tracking, expert-generated motivational messages, one reminder, summary score, compare to group
89471755|NCT03254940|Experimental|Arm 27: DT-EM-OR-SF-CS|Charge: daily tracking, expert-generated motivational messages, one reminder, specific goal feedback, compare to self
89471756|NCT03254940|Experimental|Arm 28: DT-EM-OR-SF-CG|Charge: daily tracking, expert-generated motivational messages, one reminder, specific goal feedback, compare to group
89471757|NCT03254940|Experimental|Arm 29: DT-EM-MR-SS-CS|Charge: daily tracking, expert-generated motivational messages, multiple reminders, summary score, compare to self
89471758|NCT03254940|Experimental|Arm 30: DT-EM-MR-SS-CG|Charge: daily tracking, expert-generated motivational messages, multiple reminders, summary score, compare to group
89019252|NCT00334581|Experimental|1|Irbesartan 150mg
89471759|NCT03254940|Experimental|Arm 31: DT-EM-MR-GF-CS|Charge: daily tracking, expert-generated motivational messages, multiple reminders, specific goal feedback, compare to self
89471760|NCT03254940|Experimental|Arm 32: DT-EM-MR-GF-CG|Charge: daily tracking, expert-generated motivational messages, multiple reminders, specific goal feedback, compare to group.
89471761|NCT03248128|Experimental|Subjects receiving FF/VI in cohort A|Subjects will be randomized in 1:1 ratio to receive a FDC of FF/VI with a dose of 50/25 mcg administered once daily in the morning via ELLIPTA DPI.
89471762|NCT03248128|Active Comparator|Subjects receiving FF in cohort A|Subjects will be randomized in 1:1 ratio to receive FF with a dose of 50 mcg administered once daily in the morning via ELLIPTA DPI.
89471763|NCT03248128|Experimental|Subjects receiving FF/VI in cohort B|Subjects will be randomized in 1:1 ratio to receive a FDC of FF/VI with a dose of 100/25 mcg administered once daily in the morning via ELLIPTA DPI.
89471764|NCT03248128|Active Comparator|Subjects receiving FF in cohort B|Subjects will be randomized in 1:1 ratio to receive FF with a dose of 100 mcg administered once daily in the morning via ELLIPTA DPI.
89471765|NCT03222570|Experimental|IPT-A - possible augment with addl IPT-A|Adolescents begin with an initial treatment plan of 12 weekly sessions of interpersonal psychotherapy for depressed adolescents (IPT-A). Depressive symptoms will be assessed systematically over the course of therapy. If an adolescent demonstrates an insufficient response to IPT-A at one of these assessments, the dose of IPT-A will be increased by scheduling sessions twice per week for 4 weeks (16 sessions total).
89471766|NCT03222570|Experimental|IPT-A - possible augment with SSRI|Adolescents begin with an initial treatment plan of 12 weekly sessions of interpersonal psychotherapy for depressed adolescents (IPT-A). Depressive symptoms will be assessed systematically over the course of therapy. If an adolescent demonstrates an insufficient response to IPT-A at one of these assessments, treatment will be augmented by adding a selective serotonin reuptake inhibitor (SSRI).
89471767|NCT03222570|Active Comparator|Usual Care|Therapists will implement therapy procedures that they usually use and believe to be effective in clinical practice. Therapists will use whatever methods they usually use to make decisions regarding the frequency of therapy sessions and whether to refer the adolescent to start an SSRI.
88948642|NCT06070467||children and teenagers affected by Rare Eye Diseases|A Mixed Methods Research (MMR) using quantitative (QUAN) Vision Related-QoL (VR-QoL = FVQ-CYP and VQoL-CYP) tools and psychosocial PEM-CY, and qualitative (QUAL) socio-anthropologic investigations can capture reliably children's and teenagers' Patient-Reported Outcome (PRO).
88948643|NCT06070402|Experimental|Experimental group|Participants randomly assigned to this group will test the DIAL device for four weeks
88948644|NCT06070402|No Intervention|Control group|Participants randomly assigned to this group will not use the DIAL device
88948645|NCT06070324|Active Comparator|Prolene|This group of patients will have their periareolar incisions closed with 4-0 Prolene sutures which are non-absorbable (require removal) and require knot-tying.
88948646|NCT06070324|Active Comparator|Monocryl|This group of patients will have their periareolar incisions closed with 4-0 Monocryl sutures which are absorbable (do not require removal) and require knot-tying.
88948647|NCT06070324|Active Comparator|Stratafix|This group of patients will have their periareolar incisions closed with 4-0 Stratafix sutures which are absorbable (do not require removal) and do not require knot-tying.
88948648|NCT06070311|Active Comparator|Thymoquinone (0.5%) and Olive oil ointment|thymoquinone (0.5%) and olive oil ointment will be applied to fill the ethmoidal and different sinuses cavities of one randomly chosen side of the nose.
88948649|NCT06070311|No Intervention|No intervention|no intervention
88948650|NCT06070155|Experimental|Aerobic exercise three times a week|The participants will receive mild to moderate aerobic exercise for three weeks for 12 sessions.
88948651|NCT06070155|No Intervention|No Exercise group|This group will act as a control group.
88948652|NCT06070129||Patients with massive pulmonary embolism or high-risk patients|"Characterized by evidence of low-cardiac-output syndrome or clinical shock attributed to PE as the underlying cause, based on 1 or more of the following: systemic arterial systolic blood pressure<90 mm Hg, need for positive inotrope or systemic vasoconstrictor support, need for mechanical circulatory support, cardiac arrest, or profound bradycardia (heart rate<40 bpm).~CT pulmonary angiography demonstrating a thrombus which occludes greater than 50% of the pulmonary artery (PA) cross-sectional area or occludes two or more lobar arteries.~Echocardiography both Trans thoracic and Trans esophageal shows right ventricular (RV) systolic dysfunction, RV dilation, or a RV/left ventricular (LV) diameter ratio of >0.9 on four chamber view.~Elevated cardiac troponin T and I above normal limits."
88948653|NCT06070129||Patients with sub massive pulmonary embolism or intermediate -high risk|"Systolic blood pressure >90 mmHg and tachycardia (heart rate > 100 bpm).~CT pulmonary angiography shows that 30% to 50% of the pulmonary vasculature is occluded.~Echocardiography both Trans thoracic and Trans esophageal shows right ventricular (RV) systolic dysfunctions, RV dilation, or a RV/left ventricular (LV) diameter ratio of >0.9 on four chamber view.~Elevated cardiac troponin T and I above normal limits."
88948654|NCT06070064|Experimental|Music|"The music group will carry out an initial familiarisation session of the main study variables. Subsequently, through an incremental test, MR will be evaluated through the control of execution speed.~The heaviest load at which each participant could correctly lift with full knee extension shall be considered as their 1RM.~For lighter loads (average speed> 1.0 m-s-1), there will be 3 attempts per load.There shall be two attempts with medium loads(0.50 m-s-1 ≥ average speed ≤ 1.0 m-s-1); and only one for close to maximum loads (average speed < 0.50 m-s-1).~After the first 1RM visit described above, participants will complete two additional random counterbalanced visits, each with a different condition.~The music group started the whole evaluation process with the music conditioning factor present. After completion of the measurements and the necessary rest time, the measurement was repeated in the non-music condition."
88948655|NCT06070064|Experimental|Non-music|"The non-music group developed the same protocol but started the measurements without the presence of music."
88948656|NCT06070038|Experimental|Immediate Intervention Group|Immediate intervention group. Participants assigned to the immediate intervention group will be delivered materials over a three-month period as a series of four zoom hosted workshops, online content, and a social support group.
88948657|NCT06070038|Other|Waitlist Control Group|Wait-List Control Group. Participants in the follow-up group will be delivered intervention materials following the third data collection timepoint.
88948658|NCT06069986|Active Comparator|on pump CABG|using cardiopulmonary bypass
88948659|NCT06069986|Active Comparator|off pump CABG|without cardiopulmonary bypass
89471768|NCT03160456|Experimental|Transcutaneous electrical stimulation|The group of participants receiving continuous transcutaneous electrical stimulation will be trained on the device and settings will be recorded. The device is kept on all night and in the morning taken off with the hydrogel and disconnected. Bi-weekly phone calls and follow up visits at 6- and 12-weeks will be organized. At each visit comfort, compliance and adverse reactions will be recorded. At 12-weeks, the patients will be invited for a repeat assessment including polysomnography/home-based respiratory polygraphy during a night of electrical stimulation. Usage time of the device will be discussed with the patients and recorded.
88948660|NCT06069960|Experimental|Surgical group|SALT operation plan for patients who meet the enrollment conditions and successfully match the donor liver: Hemihepatectomy combined with left lateral lobe liver transplantation was performed first, and residual liver resection was performed after the graft grew to a sufficient functional liver volume.
89019253|NCT00334581|Experimental|2|Irbesartan 300mg
89471769|NCT03160456|Active Comparator|Continuous positive airway pressure (usual care)|Participants who will be randomized to the usual care group will be given their own CPAP device, as previously prescribed. Bi-weekly phone calls and follow up visits at 6- and 12-weeks will be organized. At the last visit, the patients will be studied during a repeat inpatient polysomnography/home-based respiratory polygraphy and the initial assessment will be repeated.
89471770|NCT03136328|Experimental|68Ga-DOTATOC PET/CT|Study participants will receive 68Ga-DOTATOC and undergo a PET/CT imaging study.
89471771|NCT03102580|Experimental|OA Care Plan Intervention|For intervention sites, the patient and surgeon will receive the OA Care Plan (currently under development). The OA Care plan with have Patient Reported Outcomes, feedback reports, and risk factors for shared decision making.
89471772|NCT03102580|No Intervention|Usual care|As collection of Patient Reported Outcomes (PROs) is considered standard of care in orthopedics (CMS mandate, Bundled Payment requirements, and reporting for Qualified Clinical Data Registry requirement for example), usual care patients and surgeons will have the ability to see PRO scores.
89471773|NCT03067272|Experimental|FemBloc® Permanent Contraceptive System|Treatment of women who desire permanent birth control (female sterilization) by occlusion of the fallopian tubes.
89471774|NCT03042494|Placebo Comparator|Control|Isocaloric food without the test prebiotic.
89471775|NCT03042494|Experimental|Prebiotic|Prebiotic consumed as one daily serving of 7 g in Group 1 and consumed as one daily serving of 2.5-3 g in Group 2.
89471776|NCT03026816|Experimental|Epidural Spinal Cord Stimulation|Epidural Spinal Cord Stimulation
89471777|NCT03017456|No Intervention|Usual Care (UC)|Patients in the UC arm will not receive the study intervention (behavioral) and instead will receive care according to usual practice. This usually involves a brief office visit (approximately 5-10 minutes) with pertinent history and physical examination related to surgical/radiation recovery, review of the pathology and general instructions regarding the next step in follow-up.
89531885|NCT04986904|Experimental|SHUTi (Sleep Healthy Using the Internet)|Participants will be assigned to the SHUTi (Sleep Healthy Using the Internet) online intervention. They will spend 1-2 hours each week for 6-9 weeks completing daily sleep diaries as well as interactive core content covering topics of sleep behaviors, sleep thoughts, sleep education, and relapse prevention. As users progress through the intervention, they will receive automated, tailored instructions for how to improve their sleep.
88948661|NCT06069947|Experimental|Surgical group|SALT operation plan for patients who meet the enrollment conditions and successfully match the donor liver: Hemihepatectomy combined with left lateral lobe liver transplantation was performed first, and residual liver resection was performed after the graft grew to a sufficient functional liver volume.
88948662|NCT06069921||maligant|female patients with US-visible solid maligant breast masses who underwent biopsy and/or surgical resection.
88948663|NCT06069921||benign|female patients with US-visible solid benign breast masses who underwent biopsy and/or surgical resection.
88948664|NCT06069908|Placebo Comparator|Complex Decongestive Treatment|Complex Decongestive Treatment (manual lymph drainage, skin care, special exercises, compression) approach. It will be applied 5 days a week for 3 weeks.
88948665|NCT06069908|Sham Comparator|Sham transcutaneous vagus nerve stimulation|In sham transcutaneous vagus nerve stimulation application, the device electrode will be placed in the superior scapha region of the outer ear, where the vagus nerve has no innervation, and no current will be given.Complex Decongestive Therapy and sham transcutaneous vagus nerve stimulation.It will be applied 5 days a week for 3 weeks.
88948666|NCT06069908|Active Comparator|Transcutaneous vagus nerve stimulation|Transcutaneous vagus nerve stimulation will be applied in addition to Complex Decongestive Therapy.It will be applied 5 days a week for 3 weeks.
88948667|NCT06069830|Experimental|Interim PET and EBV DNA-directed therapy|According to the interim PET and EBV DNA results, patients are divided into three cohorts: 1) cohort A: Deauville score 1-3 and EBV DNA negativity; 2) cohort B: Deauville score 1-3 and EBV DNA positivity; 3) cohort C: Deauville score 4-5.
88948668|NCT06069804|Experimental|The TR group|The respective drugs to be used for incision-site infiltration were prepared by an independent study investigator in the two groups: Participates will receive peri-incisional scalp infiltration with10 mg triamcinolone acetonide, 150 mg ropivacaine diluted to a total volume of 30 mL in 0.9% saline . The concentration of ropivacaine was 0.5% in both groups. The anesthesia protocol and monitoring were standardized for all patients. Monitoring, including blood pressure (BP), heart rate (HR), 5-lead electrocardiography (ECG), peripheral oxygen saturation (SpO2) and bispectral index (BIS) were continuously performed.
88948669|NCT06069804|Active Comparator|The R group|The respective drugs to be used for incision-site infiltration were prepared by an independent study investigator in the two groups: Participates will receive peri-incisional scalp infiltration with 150 mg ropivacaine diluted to a total volume of 30 mL in 0.9% saline in the control group. The concentration of ropivacaine was 0.5% in both groups. The anesthesia protocol and monitoring were standardized for all patients. Monitoring, including blood pressure (BP), heart rate (HR), 5-lead electrocardiography (ECG), peripheral oxygen saturation (SpO2) and bispectral index (BIS) were continuously performed.
88948670|NCT06069739|Experimental|Guided physical activity group|Guided-exercise of moderate intensity and frecuency, and incentive of autonomous physical activity proposals by the specialist.
88948671|NCT06069739|Active Comparator|Standard physical activity group|Standard physical activity without guided and incentives.
88948672|NCT06069700|Experimental|Individualized care program|"Participants in the individualized care stream, will be provided reassurance and psychoeducation via the bio-psycho-social model on understanding persistent symptoms consistent with usual care. Additionally, they will be afforded up to 12 treatments over the course of 6-weeks. Treatments will be standardized; however, given the heterogeneity of symptoms, components of the treatments will be individualized to the participants based on what subgroup they're classified into at baseline based on their initial clinical examination and self-reported dominant impairment. Regardless of subgroup classification, as part of individualized care, all patients will receive reassurance and psychoeducation about the bio-psycho-social understanding of persistent symptoms, including advice on adaptive illness behaviours, such as gradually resuming premorbid activities and avoiding excessive rest and all-or-nothing behaviour."
88948673|NCT06069700|Active Comparator|Usual care|"Active control - All participants in the active control group will receive 'usual care', (twice a week for 6 weeks), which will consist of reassurance and psychoeducation via the bio-psycho-social model on understanding persistent symptoms, including advice on adaptive illness behaviours, such as gradually resuming premorbid activities and avoiding excessive rest and all-or-nothing behaviour. Additionally, participants will be afforded weekly 20-minute supervised progressive sub-symptom aerobic exercise sessions at the KITE clinic under the supervision of study coordinator. They will be instructed to also perform daily 20-minutes of subsymptom aerobic exercise outside the supervised exercise sessions."
88948674|NCT06069661|Experimental|Single-Arm|Device: F2 Filter and Delivery System
88948675|NCT06069648|Placebo Comparator|control|factsheet about healthy living
88948676|NCT06069648|Experimental|printed decision aid|receive printed decision aid
88948677|NCT06069648|Experimental|mobile decision aid|receive mobile decision aid
88948678|NCT06069635|Experimental|Fatigue group|30 male players will be assessed for core endurance, balance and performance then fatigue protocol will be applied and measure for core endurance, balance and performance after fatigue
88948679|NCT06069635|Sham Comparator|Control group|30 players will be assessed for core endurance, balance and performance. Players will be assessed at baseline then take rest drink water and then measure for core endurance, balance and performance again .
88948680|NCT06069622||Overweight and Obese individuals|A group of overweight and obese men and women whose body mass index (BMI) is ≥30.0 kg/m2 or ≥27.0 kg/m2 with the presence of at least one of the following weight-related comorbidities (treated or untreated): hypertension, prediabetes, dyslipidemia, obstructive sleep apnea whose treating clinicians have elected to start on semaglutide.
88948681|NCT06069609|Experimental|Kalifilcon A Contact Lens for Astigmatism|
88948682|NCT06069609|Active Comparator|Commercially available contact lenses: Acuvue Oasys 1-Day for Astigmatism|
88948683|NCT06069583|Experimental|Support integrated in usual care|PWT1D participants will have access to Support as part of their regular care (their HCPs will use Support in their care). PWT1D participants in ARM 1 are followed in one of the 4 participating clinics either in-person or remotely or hybrid.
88948684|NCT06069583|Active Comparator|Support through independent access|PWT1D participants will have access to Support, independently from their regular care (they may initiate discussion about the platform with their diabetes care team who might register themselves on the platform, but will not prompt to any specific section on the platform and will not receive any training about the platform). PWT1D participants in ARM 2 can be followed in any other clinics in Canada.
88948685|NCT06068075|No Intervention|REG EWING or OSTEO: ctDNA EVALUATION|"This study involves collection of blood samples at pre-specified time points as well as collection of information about this disease.~For each timepoint, submit two tubes of blood (17 mL total or a little more than 3 teaspoons) per standard ctDNA workflow"
88948686|NCT06068075|Experimental|EWING ctDNA RETURN OF RESULTS|"This study involves collection of blood samples at pre-specified time points as well as collection of information about this disease.~For each timepoint, submit two tubes of blood (17 mL total or a little more than 3 teaspoons) to a commercial testing laboratory called Foundation Medicine and one tube of blood (10 mL or 2 teaspoons) to standard ctDNA workflow"
88948687|NCT06067594||MTC cases|• Cases: Patients who meet the above inclusion and exclusion criteria and have a diagnosis of medullary carcinoma by histology
88948688|NCT06067594||Controls|Controls: Patients who meet the above inclusion and exclusion criteria and do not have a diagnosis of medullary carcinoma by histology.
88948689|NCT06067113||Obese|Obese patients with an indication for bariatric surgery
88948690|NCT06067113||Controls|Age and sex-matched controls
88948691|NCT06066918|Experimental|Pregabalin|Pregabalin 75 mg X2
88948692|NCT06066918|No Intervention|No treatment|no treatment
88948693|NCT06066489|Experimental|Nurses|Nurses will be assessed first about their knowledge about VAP then they will receive an educational program about VAP and will be assessed immediately and 3 months after the program
88948694|NCT06066489|Experimental|newborns|the prevalence of VAP will be assessed among all ventilated newborns who will meet inclusion criteria in the study before implementing the program, immediately and 3 months after the program using PNU1
88948695|NCT06066307|Experimental|Olfactory training - Culinary arts students|Students in culinary skill training program will perform olfactory training by sniffing four specific essential oils twice daily, over the entire semester (4-month period). The odors will comprise four major odor categories: flowery (phenyl ethyl alcohol/rose), aromatic (eucalyptol), fruity (citronellal/lemon), and resinous (eugenol). They will be assessed before and after the school semester.
88948696|NCT06066307|No Intervention|Control group - Culinary arts students|Students in culinary skill training program will be assessed before and after the school semester, without any intervention throughout this period.
88948697|NCT06066307|Experimental|Olfactory training - Information Technology students|Students in Information Technology program will perform olfactory training by sniffing four specific essential oils twice daily, over the entire semester (4-month period). The odors will comprise four major odor categories: flowery (phenyl ethyl alcohol/rose), aromatic (eucalyptol), fruity (citronellal/lemon), and resinous (eugenol). They will be assessed before and after the school semester.
88948698|NCT06066307|No Intervention|Control group - Information Technology students|Students in Information Technology program will be assessed before and after the school semester, without any intervention throughout this period.
88948699|NCT06066294|Experimental|Regimen 1|WHO recommended PrEP Vaccination Schedule, 2 visits, 0.2ml 2 sites (0.1ml each site) on day 0 and day 7
88948700|NCT06066294|Active Comparator|Regimen 2|Government of India currently recommended PrEP Schedule, 0.1ml 3 visits, on day 0, day 7 and day 28
88948701|NCT06066281||Healthy volunteers|480 healthy subjects between the ages of 18 and 75, Italian native speakers, willing and able to comply with study procedures.
88948702|NCT06065592|Active Comparator|Non-Carriers of Targeted Gene-Related Polymorphisms (GRPs) in Cancer Patients|Cancer patients without any incidence of thromboembolism will be included if they are non-carriers of the targeted gene-related polymorphism (GRP).
88948703|NCT06065592|Active Comparator|Carriers of Targeted GRPs in Cancer Patients|Cancer patients without any incidence of thromboembolism will be included if they are carriers of the targeted gene-related polymorphism.
88948704|NCT06065592|Experimental|Carriers of Targeted GRPs in Cancer-Associated Thromboembolism Patients|Cancer patients with incidence of thromboembolism will be included if they are carriers of the targeted gene-related polymorphism.
88948705|NCT06065592|Experimental|Carriers of Targeted GRPs in Cancer-Associated Thromboembolism Patients Treated with Palbociclib|Cancer patients with incidence of thromboembolism will be included if they are carriers of the targeted gene-related polymorphism and will be subjected to Palbociclib treatment.
89019254|NCT00452465|Experimental|Intervention|A research nurse will meet with participants, complete a detailed nursing assessment and develop of a care plan to help connect participants with resources to allow them to stay in their homes longer.
89019255|NCT00452465|No Intervention|Control|Usual Care
89019256|NCT00452582|Experimental|Sildenafil|Orally administered sildenafil in addition to usual care.
89019257|NCT00452582|Active Comparator|Usual post-stroke care|Usual post-stroke treatment including physical, occupational, and speech therapy.
89019258|NCT00452660|Experimental|evaluating the effect of -Exjade|evaluating the effect of -Exjade (Deferasirox)_on oxidative stress parameters of blood cells in patients with Low risk Mylodysplastic syndrome ( MDS) with Iron over load
89019259|NCT03274973||Zomacton|
89019260|NCT00452777|Experimental|BVT.115959|Capsules containing 7 mg BVT.115959 administered orally three times daily
89019261|NCT00452777|Placebo Comparator|Placebo|Placebo capsules administered orally three times daily
89019262|NCT00334971|Other|1|Healthy Caucasian women 18-35 years old
89019263|NCT00334971|Other|2|Healthy African-American women 18-35 years old
89019264|NCT00334971|Other|3|Healthy Caucasian women 36-45 years old
89019265|NCT00334971|Other|4|Female fragile X premutation carriers 18-45 years old
89019266|NCT00452816|Experimental|Intervention|Intervention Group - Workplace Solutions Consulting
89019267|NCT00452816|Active Comparator|2|Delayed Intervention
89019268|NCT00335166|Experimental|1|
89019269|NCT00335166|Active Comparator|2|
89019270|NCT00335166|Placebo Comparator|3|
89019271|NCT03274934|Experimental|Face-to-face and online support group|Behavioral: Structured web- and mobile-based intervention with Youth COMPASS program to support adolescents' well-being, career preparation and life-control and subsequently support successful transition to upper secondary education. The Youth COMPASS is the five-week online program according to principles of Acceptance and Commitment Therapy aiming to enhance adolescents' psychological flexibility by guiding adolescents in exploring their values and setting goals and changing behaviors according to their goals (week 1), and learning acceptance defusion and mindfulness skills (weeks 2-3) and integrating these skills into their personal life (weeks 4-5). The participants in this condition receive weekly online support and feedback from their individually assigned coach. In addition, they meet their coach twice in the face-to-face meetings. The aim of the meetings is to increase adolescents' internal motivation and thereby participation in the program.
89019272|NCT03274934|Experimental|Only online support group|Behavioral: web- and mobile-based intervention with Youth COMPASS program to support adolescents' well-being, career preparation and life-control and subsequently support successful transition to upper secondary education. The Youth COMPASS is a five-week online program according to principles of Acceptance and Commitment Therapy aiming to enhance adolescents' psychological flexibility by guiding adolescents in exploring their values and setting goals and changing behaviors according to their goals (week 1), and learning acceptance defusion and mindfulness skills (weeks 2-3) and integrating these skills into their personal life (weeks 4-5). The participants in this condition receive weekly online support and feedback from their individually assigned coach.
89019273|NCT03274934|Experimental|Control group|Behavioral: No intervention, school counseling as usual
89019274|NCT00420576|Experimental|1|Low Dose Danggui Buxue Tang (1.5g)
89019275|NCT00420576|Experimental|2|Middle Dose Danggui Buxue Tang(3g)
89019276|NCT00420576|Experimental|3|High Dose Danggui Buxue Tang (6g)
89019277|NCT00420615|Experimental|Patupilone and Omeprazole|patupiloe + omeprazole
89019278|NCT00420615|Experimental|patupilone + midalzolam|patupilone + midalzolam
89019279|NCT00453167|Experimental|study arm|
89019280|NCT00420654|Active Comparator|A1|
89019281|NCT00420654|Placebo Comparator|A2|
89019282|NCT00420654|Other|A3|
89019283|NCT00453323|Experimental|study arm|
89019284|NCT04698083||Group1:normal SpO2(NS,n = 80) and low SpO2(LS, n = 80).|Patients with normal oxygen saturation (SpO2; ≥ 90%) who did not receive oxygen therapy and patients with low SpO2(<90%) who received nasal oxygen therapy were included in this study
89019285|NCT04698083||Group2:Rightward axis shift(Rws) and Leftward axis shift (Lws)|Both groups were divided into two main subgroups:patients with Rws and patients with leftward shift(Lws) of the QRS axis.The patient numbers were as follows: NS Rws (n=37),NS Lws(n=43),LS Rws (n=40),andLS Lws (n=40)
89019286|NCT00335595|Active Comparator|1|XELOXA
89019287|NCT00335595|Experimental|2|XELOXA-A
89019288|NCT00453635|Experimental|1|Docetaxel + Carboplatin + Herceptin (D/Carbo/Her)
89019289|NCT00453635|Experimental|2|Vinorelbine + Herceptin (VHer)
89019290|NCT00335751|Experimental|positron emission tomography computed tomography (PET/CT)|The first PET/CT scan will be performed as part of clinical evaluation of sarcoma; The second PET/CT scan will be performed 6 weeks after the start of chemotherapy treatment OR 6 weeks after the end of radiation therapy, to monitor response of sarcoma to treatment.
89019291|NCT04698278||Surgical Treatment Group|This is a prospective, single center, bilateral, non-randomized, open-label, observational clinical study. All patients will have had prior myopic Lasik and will receive a PanOptix Trifocal IOL in both eyes at the time of cataract surgery. These patients will then be followed for up to 6-months to assess their refractive predictability, quality of vision, spectacle independence, and overall patient satisfaction.
89019292|NCT04698200|Experimental|Blood pressure|Measurement of brachial, central and beat-to-beat blood pressure.
89019293|NCT00335985|Experimental|1|
89019294|NCT00335985|Placebo Comparator|2|
89019295|NCT00336102||Group 1 Breast Cancer Patient Cases|"Patients between the ages of 25 and 75, diagnosed with primary, operable, stage I-III B breast cancer with planned chemotherapy regimen Adriamycin / Cytoxan (AC) plus a taxane are trial candidates.~Will have physiologic testing at baseline to assess thyroid function and fatigue assessment and management inventory. Will follow-up on management of therapy complications for thyroid disorder if one identified or until off study."
89019296|NCT00336102||Group 2 Healthy Controls|"Controls will be women from the same general demographic area as Group 1 Cases, have no prior history of cancer and be within 5 years of the Group 1 case's age (+/- 5 years).~Will have physiologic testing at baseline to assess thyroid function and fatigue assessment and management inventory. Will follow-up on management of therapy complications for thyroid disorder if one identified or until off study."
89019297|NCT00453791|Experimental|Subjects receiving treatment sequence 1: Part 1|Eligible subjects will receive placebo followed by GW805858 with a starting dose of 150 micrograms administered using Metered Dose Inhaler (MDI).
89471778|NCT03017456|Active Comparator|SCP-Intervention vs usual care|behavioral intervention vs control Patients in the SCP-Int arm will be asked to attend a one-time appointment with a trained oncology nurse. The SCP-Int is comprised of a 30-minute nurse-led face-to-face intervention and the provision of a tailored PC-specific SCP (PC-SCP). Persistent effects and concerns that are identified will prompt the development of a tailored management plan captured within the PC-SCP. Relevant patient education materials will be linked electronically. Nurses will use motivational interviewing techniques to effective in increase healthy behaviors and empower the PC survivor to actively self-manage persistent treatment effects and to decrease their risk of late effects by providing effective health information, support, and self-management support.
89471779|NCT03011385|Experimental|Individual Planning|"The planning materials and forms have sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans.~Action plans (referring to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties, risky situations or temptations to not engage in physical activity) will be formed. Each participant will form their plans individually, without consulting the dyadic partner, but discussing the plans with the experimenter."
89471780|NCT03011385|Experimental|Dyadic Planning|"The planning materials and forms have sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans.~Action plans as well as coping plans will be formed. Both partners in the dyad jointly form one plan. This jointly developed plan is discussed with the experimenter.~The plan focuses on physical activity of only one person in the dyad. This target person will be selected jointly by the participants if both participants are healthy. If one participant has a chronic disease, e.g. diabetes or a cardiovascular disease, the plans are formed for the person with a disease."
89471781|NCT03011385|Experimental|Collaborative Planning|"The planning materials and forms have sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans.~Action plans and coping plans will be formed. Both partners in the dyad jointly form one plan. This jointly developed plan is discussed with the experimenter.~The plan focuses on physical activity of both persons within the dyad (both partners) and include some plans for joint physical activity."
89471782|NCT03011385|Active Comparator|Education|The education materials address physical activity and healthy nutrition guidelines for age groups and chronic disease. Participants receive a set of educational materials about types of physical activity (PA), PA intensity, exercise calorie expenditure, strength and endurance training, stretching, and general nutrition guidelines in terms of meal composition, and nutrients, meal frequency. The materials exclude any planning statements. The education is delivered by the experimenter to a partner-partner dyad and discusses individual guidelines for both dyadic partners.
89019298|NCT00453791|Experimental|Subjects receiving treatment sequence 2: Part 1|Eligible subjects will receive GW805858 with a starting dose of 150 micrograms followed by placebo administered using MDI.
89019299|NCT00453791|Experimental|Subjects receiving treatment sequence 1: Part 2|Eligible subjects will receive placebo followed by GW805858 with a starting dose of 150 micrograms administered using MDI.
89019300|NCT00453791|Experimental|Subjects receiving treatment sequence 2: Part 2|Eligible subjects will receive GW805858 with a starting dose of 150 micrograms followed by placebo administered using MDI.
89019301|NCT00453791|Experimental|Subjects receiving GW805858: Part 3|Eligible subjects will receive GW805858 1200 micrograms twice daily administered using MDI.
89019302|NCT00453791|Experimental|Subjects receiving placebo: Part 3|Eligible subjects will receive placebo administered using MDI.
89471783|NCT03006731|Experimental|High Intensity Training|High Intensity Interval Training patients will attend the centre 3 times/week for 24 weeks. All subjects will participate in MICE aerobic training 5 days/week in the first four weeks of the study to provide a foundation of fitness and endurance for the safe prescription of HIIT. Subsequently, the HIIT group will replace 3 MICE training days with 3 HIIT. HIIT sessions will include two 20 minute protocols; 30:60 second work:active rest ratio, and 120:180 second work:active rest ratio on a treadmill with a harness for fall protection. In addition to supervised exercise training (3 times/week), MICE will be conducted 2 times/week in the home/community, which has been shown to be both safe and effective
89471784|NCT03006731|Active Comparator|Moderate Intensity Exercise|Moderate Intensity Continuous Exercise patients will attend the centre 3 times/week for 24 weeks. Participants will be progressed to 30 to 60 minutes of continuous exercise at the heart rate that occurred at the anaerobic threshold on the exercise test. Participants will exercise on a treadmill with a harness ofr fall protection. In addition to supervised exercise training (3 times/week), MICE will be conducted 2 times/week in the home/community by both cohorts.
89471785|NCT02968784|Experimental|ExAblate MRgFUS|"Up to 50% of the prostate gland will be treated. Treatment will include the Index lesion which is visible on MRI + tumor free margins of 3-mm; tumor free margins will not extend beyond the posterior aspect of the prostate capsule.~Urethral and bilateral neurovascular bundle preservation will be preferred whenever clinically justified.~Additional foci in the same hemisphere that are confirmed by biopsy and are < Gleason Score 7 (up to 3+4 or 4+3) or suspected to be positive for malignancy based on multi parametric-MRI) will also be included in the treated volume, providing total treatment volume does not exceed 50% of the gland."
89471786|NCT02966782|Experimental|Venetoclax monotherapy (Cohort 1)|
89471787|NCT02966782|Experimental|Venetoclax + azacitidine (Cohort 2)|
89471788|NCT02966782|Experimental|Safety Expansion (Cohort 3)|
89471789|NCT02961283|Experimental|ASN003 Dose Escalation|Multiple ascending doses of ASN003 will be administered to determine the maximum tolerated dose (MTD).
89471790|NCT02961283|Experimental|ASN003 MTD - BRAFv600 melanoma|ASN003 administered at the MTD in subjects with BRAF v600 mutated metastatic melanoma
89471791|NCT02961283|Experimental|ASN003 MTD - BRAFv600 colon or lung cancer|ASN003 administered at the MTD in subjects with BRAFv600 mutated metastatic colorectal or non-small cell lung cancer.
89471792|NCT02961283|Experimental|ASN003 MTD - PIK3 pathway mutated cancers|ASN003 administered at the MTD in subjects who have mutations in PI3 kinase or loss of PTEN.
89471793|NCT02925650|Experimental|Low Dose|The study drug Posiphen dosage of 60mg is to be taken orally in divided doses, three times per day for a total 23-25 days.
88948706|NCT06065592|Experimental|Carriers of Targeted GRPs in Cancer-Associated Thromboembolism Treated with Anti-Coagulant|Cancer patients with incidence of thromboembolism will be included if they are carriers of the targeted gene-related polymorphism and will be subjected to anti-coagulant treatment.
88948707|NCT06062602|Experimental|TAK-676, Carboplatin, 5-FU, & Paclitaxel|Patients who are scheduled for surgical biopsy or tumor resection surgery will be injected at least four hours to up to four days prior to surgery using the CIVO device. Each needle of the CIVO device will deliver up to 8.3 microliters of solution, including a vehicle control (sterile saline) or subtherapeutic microdoses of TAK-676, carboplatin, 5-fluorouracil (5- FU), or paclitaxel as single agents or in combination. Each microdose is simultaneously injected in a columnar fashion through each of 8, 5, or 3 needles (in a device configuration determined by tumor dimensions) into a single solid tumor or effaced metastatic lymph node.
88948708|NCT06062472|Experimental|Probiotics|Probiotic capsules contain 10 billion CFU (colony forming units) of Lactobacillus paracasei, 2 caps daily use
88948709|NCT06062472|Experimental|Heat-Treated Probiotics|heat-treated probiotic capsule contain 10 billion of Lactobacillus paracasei, 2 caps daily use
88948710|NCT06062472|Placebo Comparator|Placebo|The placebo capsule contains microcrystalline cellulose, 2 caps daily use
88948711|NCT06062446|Experimental|Modified Lumbar Puncture|
88948712|NCT06062290||neonates|birth to <28 days
89471794|NCT02925650|Experimental|Medium Dose|The study drug Posiphen dosage of 120mg is to be taken orally in divided doses, three times per day for a total 23-25 days.
89471795|NCT02925650|Experimental|High Dose|The study drug Posiphen dosage of 180mg is to be taken orally in divided doses, three times per day for a total 23-25 days.
89471796|NCT02925650|Placebo Comparator|Placebo|The Placebo comparator is to be taken orally in divided doses, three times per day for a total 23-25 days.
88948713|NCT06062290||infants|28 days to ≤3 months
88948714|NCT06062290||toddlers|>3 months to ≤2 years
88948715|NCT06062290||children|>2 years to <5 years
88948716|NCT06061393|Active Comparator|venofer|Women with iron def. anemia aith hemoglobin level <9 gr/dl who will be traeted with venofer
88948717|NCT06061393|Active Comparator|Ferinject|Women with iron def. anemia aith hemoglobin level <9 gr/dl who will be traeted with ferinject
88948718|NCT06061107|Experimental|Handbook for Geriatric Prearranged Medical Care Consultation|"The experimental group utilized a cartoon version of the Advance Care Consultation for the Elderly manual to facilitate the ACP process, which encompassed three components: an introduction to ACP, an overview of terminal medical care, and a discussion about the participants' preferences for their past, current, and future required medical care."
89019303|NCT00336141|Experimental|Vorinostat|
89471797|NCT02914938|Experimental|ME-401 Alone|This arm is an open-label, dose escalation study to determine the safety, efficacy and pharmacokinetics of ME-401 along with the mBED, MTD, and DLTs. There are 4 planned cohorts which may enroll up to 61 subjects.
89471798|NCT02914938|Experimental|ME-401 in Combination with Rituximab|The second arm is an open label study to evaluate the safety, efficacy, and pharmacokinetics of ME-401 in combination with rituximab in subjects with various B-cell malignancies. There are two planned cohorts which may enroll up to 30 subjects.
89471799|NCT02914938|Experimental|ME-401 in Combination with Zanubrutinib|The third arm is an open label study evaluating the safety, efficacy, MTD, DLT and pharmacokinetics of ME-401 in combination with zanubrutinib in subjects with various B-cell malignancies. This arm will include 2 stages: a safety evaluation stage (cohort of 6-12 subjects) and a disease-specific expansion cohort stage (up to 74 subjects).
89471800|NCT02849457|Placebo Comparator|Vigabatrin or Placebo|Vigabatrin or Placebo is given for administration, the entire content of one sachet (500 mg active drug) is dissolved in 10 ml water for oral administration that is dosed according to body weight 50-150 mg/kg/day divided BID. Dosing will follow established recommended guidelines (50 mg/kg/day and increased as needed by 50 mg/kg/day every 3 days up to a maximum dose of 150 mg/kg/day, divided BID).
89471801|NCT02849457|Other|Vigabatrin|Vigabatrin open label is given for administration, the entire content of one sachet (500 mg active drug) is dissolved in 10 ml water for oral administration that is dosed according to body weight 50-150 mg/kg/day divided BID. Dosing will follow established recommended guidelines (50 mg/kg/day and increased as needed by 50 mg/kg/day every 3 days up to a maximum dose of 150 mg/kg/day, divided BID).
89471802|NCT02849457|No Intervention|Control Group|Enrolled subjects who never develop EEG abnormalities or clinical seizures
89471803|NCT02802631|Experimental|Minocin (minocycline) for Injection|Minocin (minocycline) for Injection was supplied as a sterile lyophilized powder in single-use 10-milliliter (mL) glass vials. Each vial contained 108 milligrams (mg) of minocycline hydrochloride equivalent to 100 mg of minocycline. Each cohort received one of the following dosages of Minocin (minocycline) for Injection: 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, or 600 mg. Within each cohort, participants received a single dose on Day 1, followed by 7 days of multiple doses (Days 4 to 10, given every 12 hours), followed by a single dose on Day 11.
89471804|NCT02802631|Placebo Comparator|0.9% Sodium Chloride Injection USP|Placebo was in the form of the same 100-mL bags of normal saline (0.9% Sodium Chloride Injection United States Pharmacopeia [USP]). Dosing was on the same schedule as participants randomized to Minocin (minocycline) for Injection.
89471805|NCT02770586|Other|Breast PET|Breast PET
89471806|NCT02757898|Experimental|Biotin-Labeled Red Blood Cell (RBC) Infusion|Blood will be drawn from participants and labeled with biotin before being re-infused back to the participant. Blood samples will be obtained weekly over 10 weeks.
89471807|NCT02754479|Experimental|Laser treatments|Each subject will receive a combination of 532 nm and/or 1064 nm Nd:YAG laser treatment
89471808|NCT02747888|No Intervention|Lower Suspected Familial Predisposition|"Lower Suspected Familial Predisposition~Screening and Enrollment:~Consent, Family HX, Medical HX, Blood/Saliva which will categorize by suspected hereditary predisposition: Based on family and medical history.~- Sample stored in Biorepository"
89471809|NCT02747888|Experimental|Higher Suspected Familial Predisposition|"Higher Suspected Familial Predisposition~Screening and Enrollment:~Consent, Family HX, Medical HX, Blood/Saliva which will categorize by suspected hereditary predisposition: Based on family and medical history.~- Specimen Testing and Analysis~•Referral to Genetic Counselor, if indicated"
89471810|NCT02730546|Experimental|Treatment (pembrolizumab, chemotherapy, radiation, surgery)|See Detailed Description
89471811|NCT02712255|Experimental|Individual Planning|"Participants are filling in the planning forms, referring to their individual physical activity. Both members of the dyad form their own, interdependent plans.~The following behavior change techniques (BCT) are included in the planning intervention protocol: action planning, barrier identification, prompting self-talk, relapse prevention/coping planning. Applications of all BCT included references to planning."
89471812|NCT02712255|Experimental|Dyadic Planning|"Participants are filling in the planning forms jointly. Planning refers to physical activity of only one person in the dyad, the patient. The partner is actively participating in forming plans by the patient.~The following BCT are included in the planning intervention protocol: action planning, barrier identification, prompting self-talk, relapse prevention/ coping planning. Applications of all BCT included references to planning"
89471813|NCT02712255|Experimental|Collaborative Planning|Participants are filling in the planning forms jointly. Planning refers to physical activity of both persons in the dyad (the patient and the partner). Physical activity may be performed jointly by both persons in the dyad. The following BCT are included in the planning intervention protocol: action planning, barrier identification, prompting self-talk, relapse prevention/ coping planning. Applications of all BCT included references to planning.
89471814|NCT02712255|Active Comparator|Education|The education group participants receive extended physical activity and healthy nutrition education program. The education includes: (1) the guidelines for physical activity and healthy nutrition, tailored to age and health status of the participant, (2) the examples of exercises and their metabolic equivalent; (3) information about healthy body mass and body composition.
89471815|NCT02693730||Healthy Control|Does not have diagnosis of irritable bowel syndrome (IBS) or inflammatory bowel disease (IBD) and is otherwise healthy and able to participate as defined by the exclusionary criteria.
89471816|NCT02693730||Irritable Bowel Syndrome (IBS)|Diagnosed with IBS and meets the Rome III criteria, in the absence of red flag signs (i.e., unexplained weight loss, bloody stool, fever, anemia)
89471817|NCT02693730||Ulcerative Colitis (UC)|Clinically and histologically confirmed diagnosis of ulcerative colitis
89471818|NCT02691689|Other|Patients with ASD or VSD and PAH|
89471819|NCT02672098|Experimental|HIPEC|A procedure in which the internal parts of your abdomen are bathed in a warm solution of anti-cancer medications for 90 minutes.
88948719|NCT06061107|No Intervention|Control group|No Intervention: standard clinical care
89019304|NCT00336180|Experimental|HW|The experimental group (HW) receives 18 classroom-based lessons on leisure motivation, life skills, and skills to avoid substance use and sexual risk.
89471820|NCT02669797|Experimental|EMI|EMI (Arm 1): (1) tailored ecological momentary intervention (EMI) prompts sent to parents targeting momentary behaviors (e.g., stress) around family meal quality and quantity for 16 weeks; and (2) a 8-week maintenance phase with EMI tips delivered on high stress days.
89471821|NCT02669797|Experimental|EMI + HV + Video feedback, Virtual|"EMI + HV + Video Feedback (Arm 2) education visits will all be delivered virtually, and the arm includes: (1) tailored ecological momentary intervention (EMI) prompts sent to parents targeting momentary behaviors (e.g., stress) around family meal quality and quantity for 16 weeks; (2) bi-weekly in-home educational visits (total of 8) with a community health worker (CHW) focusing on family meal quality (i.e., dietary quality, interpersonal quality) and quantity (i.e., frequency of family meals), and 8 weeks Try it Yourself activities that reinforce the messages and skills taught by a CHW (for a total of 16 weeks); (3) video feedback on a video-taped family meal delivered every other week during the in-home visit with the CHW; (4) a 8-week maintenance phase with EMI tips delivered on high stress days."
88948720|NCT06060938|Experimental|Risk stratified arm|"The intervention consists of calculation and communication of personal risk together with recommendations for the subsequent interval between screening visits.~Women in the intervention arm are offered a risk measurement and risk stratified screening accordingly with stratification into four risk groups: Low, intermediate, elevated and high risk. Depending on the risk group the women will be offered a mammography every 1-4 years. The high risk group will also be offered tomosynthesis. The risk estimation is based on the risk model, BOADICEA, which is the most comprehensive model currently available for breast cancer risk prediction. The model incorporates the most up to date polygenic risk score for breast cancer, based on 313 single nucleotide polymorphisms (SNP), as well as familial breast cancer history, reproductive history, lifestyle/hormonal risk factors, height, weight and mammographic density, obtained from image analysis of the mammogram."
88948721|NCT06060938|Active Comparator|Control arm|In the control arm, participants are assigned to the standard national screening program with biennial screening.
88948722|NCT06060171||Natural history|Natural history of the three common valvular lesions; aortic stenosis, aortic regurgitation and mitral regurgitation. Patients with mild, moderate and severe valvular heart disease (VHD) will be followed up at 1-year to measure progression in remodelling (hypertrophy, ischaemic, scar).
88948723|NCT06060171||Multisystem impact of VHD|Patients with severe symptomatic VHD will undergo non-invasive brain and cardiac magnetic resonance imaging (MRI) plus other non-invasive imaging tests to quantify small blood vessels across the cardiovascular system at baseline and at 6 months after surgical aortic valve replacement at which point a myocardial biopsy is taken.
88948724|NCT06060171||Response to intervention.|Patients with severe symptomatic VHD undergoing intervention will be followed up at 6 months to assess reverse remodelling after valve intervention. In those undergoing open-heart surgery, a myocardial biopsy will be taken to validate and complement non-invasive imaging.
88948725|NCT06059196|Active Comparator|Control - Standard contraceptive counseling|Standard contraceptive counseling, includes provider training on standard BCS+ counseling protocol and use of a companion mobile application to guide counseling
88948726|NCT06059196|Experimental|Intervention - Integrated contraceptive counseling|Integrated contraceptive counseling, includes provider training on ARCHES integrated in BCS+ counseling protocol and use of a companion mobile application to guide counseling
88948727|NCT06057272||Forensic Medicine|Individuals with unilateral lower extremity fractures who apply to the Department of Forensic Medicine for disability rate determination and reporting
88948728|NCT06057272||Orthopedic|In individuals with unilateral lower extremity fractures who apply to the Department of Orthopedics and Traumatology
88948729|NCT06057272||Healthy|The healthy counterparts of the patients in the forensic medicine and orthopedic population group.
88948730|NCT06056869|Active Comparator|buscopan group|will receive 2 ml (40 mg) of hyoscine butylbromide
88948731|NCT06056869|Placebo Comparator|control group|will receive 2 ml of normal saline
88948732|NCT06049524||Experimental group|Prior to surgery all included patients are asked to fill out questionnaires in written or electronic form to collect the information. Then the participating doctor conducts a test to determine the pain threshold for pressure pain. Further the scheduled surgical intervention is performed under spinal anesthesia.Intraoperative data are also entered to the database. After surgery the researcher provides the patient with a written or electronic form of a postoperative monitoring questionnaire. In the postoperative period, patients undergo analgesia according to the standard scheme. In case of ineffectiveness of the standard anesthesia regimen 100 mg of tramadol is administered to the patient. All patients are remotely monitored 30 days after surgery to collect postoperative data, and if there are any remaining symptoms or complaints, they are invited to the clinic for examination.
88948733|NCT06048328|Experimental|Intervention|peer-led, multi-session advocacy training group intervention
88948734|NCT06048328|No Intervention|Wait-list control|Usual care/no intervention
88948735|NCT06046300||Amputees|Individuals with a transtibial amputation
88948736|NCT06046300||Healthy|Healthy individuals
88948737|NCT06041282|Experimental|manipulation under anesthesia group|The patient underwent manipulation under anesthesia
88948738|NCT06041282|Active Comparator|Supervised home rehabilitation group|The patient underwent supervised home rehabilitation
88948739|NCT06037135|Experimental|dexmedetomidine group|In the dexmedetomidine group, dexmedetomidine is administered at a rate of 0.5 μg/kg/h immediately after anesthesia induction and continued until the completion of the surgery.
88948740|NCT06037135|Active Comparator|Control group|In the control group, a 0.9% normal saline infusion is initiated at the same rate immediately after anesthesia induction and continued until the end of the operation.
88948741|NCT06031974||DISCO Intervention|"Patients included to the DISCO-CT study and randomized to the experimental arm, ie. subjected to optimal medical treatment in accordance with European Society of Cardiology recommendations + DASH diet (Dietary Approaches to StopHypertension) and strict monitoring of eating and lifestyle behaviors~n=46"
89471822|NCT02669797|Experimental|EMI + HV + Video feedback, Hybrid|"EMI + HV + Video Feedback (Arm 3) education visits will be delivered virtually and in-home, and the arm includes: (1) tailored ecological momentary intervention (EMI) prompts sent to parents targeting momentary behaviors (e.g., stress) around family meal quality and quantity for 16 weeks; (2) bi-weekly in-home educational visits (total of 8) with a community health worker (CHW) focusing on family meal quality (i.e., dietary quality, interpersonal quality) and quantity (i.e., frequency of family meals), and 8 weeks Try it Yourself activities that reinforce the messages and skills taught by a CHW (for a total of 16 weeks); (3) video feedback on a video-taped family meal delivered every other week during the in-home visit with the CHW; (4) a 8-week maintenance phase with EMI tips delivered on high stress days."
89471823|NCT02649335|Active Comparator|Propranolol|Propranolol will be started at a dose of 40 mg and will be titrated based on pulse rate with target of 55-60 beats per minute or 20-25% reduction in heart rate and maximum tolerated dose.If any patients develop intolerable side effects, they will be withdrawn from the study.
89471824|NCT02649335|Active Comparator|Endoscopic variceal ligation (EVL)|Patients in EVL group will undergo regular sessions of UGIE with EVL till variceal eradication every 2- 4 weekly followed by 3 monthly for initial 6 months and 6 monthly in rest of the study period. If any patient develop acute variceal hemorrhage on follow up , will be treated inpatient with standard medical therapy (SMT) .
89471825|NCT02602262||HIV D+/R+|HIV-infected individuals who accept an organ from an HIV-infected deceased donor
89471826|NCT02602262||HIV D-/R+|HIV-infected individuals who accept an organ from an HIV-uninfected deceased donor
89471827|NCT02589496|Experimental|pembrolizumab|"Cohort A :gastric cancer patients Cohort B : MSI-H gastric cancer patients All Chort receive the following treatment.~Pembrolizumab 200 mg every 3 weeks"
89471828|NCT02309580|Experimental|Ibrutinib|This will be a standard dose-escalation study to determine the MTD of ibrutinib in relapsed/refractory PTCL or CTCL. At each dose 6 patients with TCL (PTCL or CTCL) will be enrolled. The first 6 patients will be enrolled at dose level 1. Dose escalation to the next dose level will proceed after DLT assessment of all 6 patients at the end of cycle 1 (28-days).
89471829|NCT02302742||Triple Negative Breast Cancer patients|No intervention
89471830|NCT02302742||Germline HBOC Mutation Carriers|No intervention
89471831|NCT02266121|Active Comparator|real tDCS|"Patients will receive non-invasive and painless brain stimulation over the rain areas involved in cognitive aptitudes.~tDCS will be applied during 20 minutes while patients will perform attentional, working memory and executive tasks"
89471832|NCT02266121|Placebo Comparator|Sham tDCS|"this will be exactly as for real tDCS unless that the tDCS will be rapidly turned off, unbeknown from patients-therapist-examinator (double-blind trial)"
89471833|NCT02213575|Other|Minocycline|Subjects will receive the dose of Minocycline determined to best lower BP and will undergo baseline and week 12-24 follow-up MRI and PET scans for changes in the paraventricular nucleus.
89471834|NCT02148796|Active Comparator|Broncho-Vaxom (BV)|One capsule of Broncho-Vaxom for children contains: 3.5 mg of lyophilized bacterial lysates of Haemophilus influenzae, Streptococcus (pneumonia, pyogenes and sanguinis (viridans)), Klebsiella (pneumoniae and ozaenae), Staphylococcus aureus and Moraxella catarrhalis. The content of the capsule will be mixed with a palatable liquid such as fruit juice.
89471835|NCT02148796|Placebo Comparator|Placebo|A placebo capsule will be used that will be indistinguishable from the active study drug.
89471836|NCT02139787|Experimental|Radio Story|Participants listen to a radio story about a family's' success with preventing or managing hypertension or obesity through diet and physical activity; the focus was for the entire family to implement healthful lifestyle behaviors so the children can learn as well.
89471837|NCT02139787|Active Comparator|Control -listened to a brochure|Participants received an audio version of a standard brochure about hypertension or obesity prevention.
89471838|NCT02133872|Other|Minocycline Dose Escalation|Subjects will receive minocycline 50mg if no mean daytime ABPM SBP decline =/> 5mm Hg; subjects will receive minocycline 100mg, if no mean daytime ABPM SBP decline =/> 5mm Hg BP subjects will receive minocycline 200 mg.
89471839|NCT02095249|Other|Pimonidazole|
89471840|NCT02086864|No Intervention|Usual care|
89471841|NCT02086864|Active Comparator|Individualized homeopathic medicine treatment|Participant will have a homeopathic consultation and be given a homeopathic medicine. Homeopathic medicines are chosen from those available for sale in Canada.
89471842|NCT02086864|Placebo Comparator|Unmedicated lactose/sucrose pill|Participant will receive a homeopathic consultation and receive an unmedicated lactose/sucrose pill.
89471843|NCT02069509||Control research participants|diagnosis of FRDA genetically excluded
89471844|NCT02069509||FRDA patients|with genetically confirmed diagnosis of FRDA
89471845|NCT02036476|Experimental|Cabozantinib|Cabozantinib 60 mg given orally daily for 28 days (4 weeks) each cycle. Participants were treated until disease progression, unacceptable toxicity or withdrawal for other reasons.
88948742|NCT06031974||Control|"Patients included to the DISCO-CT study and randomized to the control arm, ie. subjected to optimal medical treatment in accordance with European Society of Cardiology recommendations alone~n=46"
88948743|NCT06030050|Experimental|Treatment group|Intervention: Animal-assisted intervention (therapy dog visit) Frequency: 2 dog visits per week Duration: each visit is approx 10 mins long, study lasts 20 weeks
88948744|NCT06030050|No Intervention|Control group|Intervention: NONE - sit in waiting room like usual Frequency: 0 dog visits per week Duration: study lasts 20 weeks
88948745|NCT06024486||JIA cases|juvenile idiopathic arthritis cases
88948746|NCT06024486||CONTROL|age and sex matched healthy controls
89471846|NCT01832779||Achalasia subjects|Information about teh subject's medical history, leading up to the need for an Achalasia treatment, the procedure itself and how the subject does after the procedure, including after the subject gets home, will be collected. This will be done by gathering relevant information from the subject's medical chart and/or by talking with the subject prior to and after the subject's medical procedures. There are no specific study procedures or tests. All information collected is part of the subject's medical care and will be collected even if the subject is not in the study.
89471847|NCT01820884|Experimental|Total Hysterectomy (TH)|Patients may receive total hysterectomy (TH) and bilateral pelvic and para-aortic lymph node dissection (BPLND).
89471848|NCT01820884|Active Comparator|TH and bilateral salpingo-oophorectomy (TH/BSO)|Patients may receive total hysterectomy, bilateral salpingo-oophorectomy (BSO) and bilateral pelvic and para-aortic lymph node dissection.
89471849|NCT01820858|Experimental|Adjuvant Chemotherapy|Paclitaxel: 175 mg/m(2) intravenously (IV); followed by Paraplatin (Carboplatin Injection) AUC=5 IV. 3-6 cycles as necessary.
89471850|NCT01820858|Active Comparator|Adjuvant Radiotherapy|"Histopathological grade G3 and <50% myometrial invasion: Vaginal brachytherapy 5Gy, 3 times;~Histopathological grade G3 and vascular space involvement: Pelvic radiation 45-50 Gy;~≥50% myometrial invasion: Pelvic radiation 50 Gy + Vaginal brachytherapy 5Gy, 2-4 times."
89471851|NCT01755897|Experimental|Adjuvant Chemotherapy (Arm A)|Paclitaxel (T): 135-175 mg/m(2) intravenously (IV) on day 1, administrated intravenously over 3 hours; followed by cisplatin 75-85 mg/m(2) IV on day 2 and 3. Patients received at least 3 cycles at 4-week intervals beginning 2-3 weeks after surgery. 3-6 cycles as necessary.
89471852|NCT01755897|Active Comparator|Concurrent radiochemotherapy, CCRT (Arm B)|Pelvic RT is delivered using IMRT technique, 45～50.4 Gy/4～7 weeks, brachytherapy will been given as necessary. Cisplatin 35 mg/m(2) IV once a week. Total treatment time is 6-7 weeks.
89471853|NCT01738607|Placebo Comparator|Placebo|"basic recipe for juice and muffin recipe~abbreviated PLB"
89471854|NCT01738607|Experimental|Carboxymethylcellulose|"The supplements were prepared as two fruit juice mixtures (each 270 ml) providing 7 g total fiber/d) and two small muffins providing 9 g total fiber/d for 16 g of toal fiber daily.~abbreviated CMC"
88948747|NCT06016907|Other|Stepped care|Participants will receive up to two courses of treatment. All participants in stepped care will receive internet-delivered cognitive behavioral therapy (ICBT) in the first course (A). Participants with an insufficient treatment response will then be offered in-person cognitive behavioral therapy (CBT) in the second course (B). Even if participants are offered treatment in course B, participants are free to decline this offer, and will instead only be invited to the remaining outcome assessments.
88948748|NCT06016907|Other|Stratified care|Participants will receive up to two courses of treatment. In stratified care, in treatment course A, the investigators aim to offer around half of the participants ICBT and the other half in-person CBT (based on their risk of non-response). All participants in stratified care who do not sufficiently respond to treatment in course A will be offered personalized in-person CBT in course B. Even if participants are offered treatment in course B, participants are free to decline this offer, and will instead only be invited to the remaining outcome assessments.
89471855|NCT01738607|Experimental|Gum Arabic|"The supplements were prepared as two fruit juice mixtures (each 270 ml) providing 7 g total fiber/d) and two small muffins providing 9 g total fiber/d for 16 g of toal fiber daily.~abbreviated GA"
89471856|NCT01738607|Experimental|Psyllium|"The supplements were prepared as two fruit juice mixtures (each 270 ml) providing 7 g total fiber/d) and two small muffins providing 9 g total fiber/d for 16 g of toal fiber daily.~abbreviated as PSY"
88948749|NCT06012149|Experimental|Braining|A 12 week program where participants are encouraged to participate in physical exercise at the psychiatric unit.
88948750|NCT06012149|Active Comparator|Structured advice on physical activity|Health interview and a 12 week program where participants are encouraged to engage in physical exercise outside the psychiatric setting.
89206192|NCT04095455|Active Comparator|Ktamine plus Magnesium group|Patients received 40 mg/kg of magnesium sulphate infusion in 100cc normal saline, as a bolus dose, in addition to 0.2mg/kg of ketamine as a bolus dose, 15 min before the induction of general anesthesia. This was followed by intraoperative continuous infusion of 10 mg/kg/h of magnesium sulphate combined with infusion of 0.1mg/kg/h ketamine that was started before skin incision and continued until completion of skin closure via infusion pump
88948752|NCT06001671|Experimental|BEBT-109 120mg|BEBT-109 orally at an initial dose of 120 mg once daily.
88948753|NCT06001671|Experimental|BEBT-109 180mg|BEBT-109 orally at an initial dose of 180 mg once daily.
88948754|NCT06001671|Experimental|BEBT-109 240mg|BEBT-109 orally at an initial dose of 240mg (120mg bid) once daily.
88948755|NCT05994482||Older adults|Aim 1: Older adults with and without a prior history of precancerous polyps
88948756|NCT05994482||Older adults with prior polypectomy|Aim 2: Older adults with a prior history of precancerous polyps, exposed vs unexposed to surveillance colonoscopy
88948757|NCT05994482||Stakeholders|Aim 3: Veterans, clinical, and policy stakeholders who will provide input and participate in an expert panel to synthesis available evidence on pros/cons of surveillance in older adults.
89206193|NCT04095455|Active Comparator|Control Group|Normal saline infusion with similar rate and volume to KM infusion was used as a placebo
89471857|NCT01728259|Experimental|Treatment (pomalidomide, bortezomib, and dexamethasone)|Patients receive pomalidomide PO on days 1-21; bortezomib IV or SC on days 1, 8, and 15; and dexamethasone PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89471858|NCT01722604|Active Comparator|Azopt 1% ophthalmic suspension|Ophthalmic suspension
89471859|NCT01722604|Experimental|Brinzolamide 1% ophthalmic suspension|ophthalmic suspension
89471860|NCT01714050|Experimental|Cognitive-Behavioral Therapy (CBT)|"The CBT is a SAD-tailored version of Beck et al.'s (1979) cognitive therapy for depression called Coping with the Seasons (Rohan, 2008). The rationale addresses environmental changes, thoughts, and behaviors in SAD onset and maintenance. It seeks to change behaviors and thoughts to improve coping with winter. Behaviors that promote enjoyment in the winter are increased. Negative thoughts that interfere with self-esteem and negative thoughts about winter are identified and addressed. A relapse-prevention component addresses early identification of negative anticipatory thoughts about winter and SAD-related behavior changes, using the CBT skills learned to cope with subsequent winter seasons, and development of a personalized relapse-prevention plan. The CBT sessions are administered twice a week over 6 weeks (total of 12 sessions) with 4-8 participants per group. The CBT is led by one of three licensed Ph.D.-level psychologists working on the project."
89471861|NCT01714050|Experimental|Light Therapy (LT)|LT will be initiated at 30-minutes in the morning at home, first thing upon awakening, using a light box with an ultraviolet shield that emits 10,000-lux of white fluorescent light. After the first week, an M.D. light therapy consultant will recommend individually-tailored, clinical adjustments to the duration and timing of light use to maximize response and reduce any reported side effects. For each of the 6-weeks of LT, LT participants will complete a Light Therapy Side Effects Questionnaire to assess side effects attributed to LT. Participants will keep daily LT compliance diaries to record the timing and duration of LT. After the 6-weeks of monitoring, participants may choose to continue using the light box through April. We will offer LT participants who wish to use light therapy in the next fall/winter season access to our light boxes if they agree to followup with a physician or other qualified professional for monitoring and side effects management.
89471862|NCT01519843|Active Comparator|Real|Real tDCS
89471863|NCT01519843|Placebo Comparator|sham|Sham tDCS
89471864|NCT01503073|Active Comparator|Real stimulation|real NIBS
89471865|NCT01503073|Sham Comparator|Sham stimulation|sham NIBS
89471866|NCT01434043||Myocardial ischemia patients|
89471867|NCT01296022|Active Comparator|Subcutaneous ICD|Subcutaneous Implantable Cardioverter Defibrillator
89471868|NCT01296022|Active Comparator|Transvenous ICD|Transvenous Implantable Cardioverter Defibrillator
89471869|NCT01202994|Experimental|Flute|Flutemetamol PET scan.
89471870|NCT01075672|Experimental|Cognitive Behavioral Therapy|
89471871|NCT01075672|Experimental|Behavioral Medicine with Cognitive Behavioral Therapy|Participants enrolled in this arm of this study will be treated by the behavioral medicine interns with cognitive behavioral therapy focused on both their general health concerns and mental health concerns.
89471872|NCT00930943|Experimental|Oxymorphone ER 40 mg fed|Participants received 40 mg oxymorphone ER after a high-fat meal of approximately 1,010 kCal
88948758|NCT05994313|Experimental|Habitual potato consumption|At least 220g of white potatoes, including fresh and frozen, baked, boiled, and mashed potatoes, will be consumed in the evening meal, in replacement of non-nutrient-dense starchy staples, for 12 weeks.
88948759|NCT05994313|Active Comparator|Habitual non-nutrient-dense staple consumption|Isocaloric amounts of non-nutrient-dense starchy staples, such as white rice, white pasta, and white couscous, will be consumed in the evening meal for 12 weeks.
88948760|NCT05988164|Experimental|Eye mask Group|Patients in the intervention group will be given eye masks and asked to sleep with them at 22:00 or earlier. Researchers or nurses will assist patients who cannot wear an eye mask at night. To measure patients' perception of sleep quality, we will use the Richard-Campbell Sleep Scale. The following morning, we will complete the post-test Richard-Campbell Sleep Scale to assess sleep quality.
88948761|NCT05988164|No Intervention|control Group|The control group will undergo no intervention, and their sleep quality will be measured in the hospital setting using the Richard-Campbell Sleep Scale.
88948762|NCT05984524|Experimental|Gamma|8-week music-based intervention with gamma lights
88948763|NCT05984524|Placebo Comparator|Control|8-week music-based intervention with control lights
89471873|NCT00930943|Experimental|Oxymorphone ER 40 mg fasting|Participants received 40 mg oxymorphone ER after fasting for 8-12 hours
89471874|NCT00913939|Active Comparator|1: Salvage After EBRT|Patients with locally recurrent prostate cancer after radiotherapy will receive tumor-targeted salvage HDR brachytherapy. Arm 1 of the study will be coordinated and closely integrated with a separate concurrent study of MRI-guided prostate biopsy, which will be performed prior to accrual to Arm 1 of this trial (UHN 05-0641-C).
89471875|NCT00913939|Active Comparator|2: Boost to EBRT|Patients with locally advanced prostate cancer will receive a boost of prostate-targeted HDR brachytherapy during external beam radiotherapy.
89471876|NCT00845208|Active Comparator|Case Management|
89471877|NCT00845208|Experimental|Network Support|12 Weekly sessions intended to help patients change their social networks to be more supportive of abstinence
89471878|NCT00845208|Experimental|Network Support + Contingency Mgmnt|12 weekly sessions intended to help patients change their social networks to be more supportive of abstinence. Contingency management component added to reinforce efforts to make network changes.
89471879|NCT00670670|Experimental|1|CPP-ACP (GC Tooth Mousse)
89471880|NCT00670670|Experimental|2|CPP-ACP (GC MI Paste Plus)
89471881|NCT00670670|No Intervention|3|Control group
89471882|NCT00670618|Experimental|1|CPP-ACP (GC Tooth Mousse)
89471883|NCT00670618|Experimental|2|GCC-ACP (GC MI Paste Plus)
89471884|NCT00670618|Experimental|3|Fluoride (Elmex Medical Gel)
89471885|NCT00670618|No Intervention|4|Control group
89471886|NCT00643994|Experimental|CyberKnife Stereotactic Radiosurgery|36.25 Gy delivered in 5 fractions of 7.25 Gy per fraction in patients with low and intermediate risk prostate cancer.
89471887|NCT00643617|Other|Heterogeneous Dose|38 Gy delivered in 4 fractions of 9.5 Gy per fraction
89471888|NCT00618683|Other|Study Arm|Mapping and Ablation
89471889|NCT00535444|Active Comparator|Control|assisted appointment with physician
89471890|NCT00515281|Experimental|INO Treatment|The treatment group will receive iNO, combined with O2 or room air, until 33 weeks corrected age.
89471891|NCT00515281|Placebo Comparator|INO Control|INO will be given to infants in the control group for the first 7 days of the study gas, then O2 or room air, as clinically appropriate, on the 8th day, until 33 weeks corrected age
89471892|NCT00504582|Experimental|Fibrin Sealant|Tisseel applied externally to the dissected axillary area.
89471893|NCT00504582|No Intervention|No Fibrin Sealant|
89471894|NCT00486629|Experimental|Intervention|Lifestyle intervention
89471895|NCT00486629|No Intervention|Control|No intervention
89471896|NCT00353938|Experimental|Full Dose MDMA-assisted therapy (125 mg)|Three 8-hour sessions of MDMA-assisted therapy with 125 mg of MDMA, followed by a supplemental dose of 62.5 mg MDMA
89471897|NCT00353938|Active Comparator|Active Placebo MDMA-assisted therapy (25 mg)|Three 8-hour sessions of MDMA-assisted therapy with 25 mg of MDMA, followed by a supplemental dose of 12.5 mg MDMA
89471898|NCT00314366|Active Comparator|Stem Cell Therapy|Subjects are randomized to receive Stem Cell Therapy (treatment) at the time of enrollment where cells are delivered after NOGA mapping and cells injected with the Myostar catheter.
89471899|NCT00314366|Placebo Comparator|Control|"Placebo patients will receive injections of plasma (control) instead of stem cells. Placebo patients are able to crossover and receive active treatment at 6 months if they meet the criteria.~At 6 months, subject is offered stem cell therapy and then followed for 12 months."
89471900|NCT03266809||Breast Cancer Patients|"Eligible participants will be women aged 18 years or over who have the following main characteristics:~Early invasive breast cancer (stage I-III)~Due to start SAT (adjuvant or neoadjuvant chemotherapy +/- trastuzumab +/- pertuzumab)~WHO performance status 0-2."
89471901|NCT03372759|Active Comparator|study group air|airtamponade
89471902|NCT03372759|Sham Comparator|study group saline|saline
88948764|NCT05982184|Experimental|Music|Music intervention at home. Patients will be asked to listen to music using their own equipment three times a day. Starting approximately a week prior to surgery up to the day of surgery.
88948765|NCT05982184|No Intervention|Standard Care|Treatment as usual.
88948766|NCT05979519|Experimental|Grocery Prescription Program|Those randomized to the Grocery Prescription intervention will receive the Fresh Funds for Mom's through Instacart immediately
88948767|NCT05979519|Active Comparator|Standard Medical Care|the delayed control group will receive their usual care through their healthcare provider and then participate in Fresh Funds or MTM after the initial 12-weeks of intervention.
88948768|NCT05979519|Experimental|MTM (medically tailored frozen meals)|Those randomized to the MTM intervention will receive medically tailored frozen meals from Door Dash
88948769|NCT05977023|Experimental|NMDAE|An NMDA enhancer
88948770|NCT05977023|Placebo Comparator|Placebo|Placebo
88948771|NCT05968586|Experimental|Prone positioning|
88948772|NCT05968586|Active Comparator|Supine positioning|
88948773|NCT05946824|Experimental|1 - Prostate bed only recurrence|Patients with confirmed radiologic recurrence of their prostate cancer in the defined region of the previous prostate surgery - commonly referred to as the prostate surgical bed.
88948774|NCT05946824|Experimental|2- Pelvic nodal with or without a prostate bed recurrence|Patients who have a radiologic recurrence of prostate cancer in the pelvic node region
88948775|NCT05945641|Experimental|Low Load Resistance Training|LLRET - 12 weeks (2-3 times/week) 3 sets of Knee extension exercise (single leg) done at 30%1- RM. Performed to failure with 3 minutes of rest between sets, weight lifted will be adjusted throughout the study to keep repetitions completed in a 20-30 repetition range.
88948776|NCT05945641|Experimental|Sprint/High Intensity Interval Training|"SIT/HIIT- 12 weeks (2-3 times/week), mix of SIT and HIIT (8-15 sets/session). SIT -30 second Super Maximal Wingate style intervals performed on a Kicking ergometer (single leg) with 4 minutes rest provided between sets (number of interval ranges from 4-5), load determined from DEXA leg lean mass and will not be altered throughout training.~HIIT - 1-minute Submaximal efforts (90% single leg kicking ergometer VO2Peak Wattage) performed on a kicking ergometer (single leg) with 1 minute rest provided between sets (number of interval ranges from 8-10), if all sets completed wattage will be increased by 5watts for the next training session."
88948777|NCT05944133||Patients enrolled|Patients who are enrolled on health plans during active MOUD treatment.
88948778|NCT05944133||Patients who disenrolled|Patients who disenrolled from health plans during active MOUD treatment.
88948779|NCT05936177|Other|Education Group|The Education Group arm will involve participants who receive the osteoporosis education intervention, which includes a concise educational session delivered by a physiatrist, covering various topics related to osteoporosis. Participants in this arm will have the opportunity to enhance their knowledge and awareness of osteoporosis through the provided educational materials and interactive discussions.
88948780|NCT05936008|Active Comparator|Moderate intensity, continuous training (MICT)|After a 5-minute warm-up at 30% peak watts, MICT will consist of continuous exercise for 25 minutes at 55% of peak watts (range: 45%-65%). The average heart rate for each individual session should not exceed 70% (60-70%) of HR maximum to align with current exercise recommendations for stroke. An active cool-down (20% peak workload) at comfortable stepping pace occurs immediately after the intervention.
88948781|NCT05936008|Active Comparator|High intensity, interval exercise (HIIT)|"After the 5-minute warm-up at 30% peak watts, HIIT will consist of repeated 1-minute, high intensity bursts (on interval) alternated with 1-minute interval recovery (off interval) for 25 minutes. The on interval will begin at 70% of peak watts (range: 65%-95%) followed by the off interval at 10% of peak watts. The average HR for the on intervals will not exceed 85% age predicted maximum (75-85%). There will be 13 minutes of on and 12 minutes of off interval exercise. An active cool-down (20% peak workload) at comfortable stepping pace occurs immediately after the intervention."
89471903|NCT03137264||T790M positive|Patients determined to be T790M positive on cobas tissue and/or cobas plasma testing during Part 1 may be followed for clinical outcomes in Part 2, and will be treated in accordance with standard of care, which may include osimertinib.
89471904|NCT03137264||T790M negative|Patients determined to be T790M negative during Part 1 will not be followed for clinical outcomes in Part 2.
88948782|NCT05934331|Experimental|LM-302 in combination with Toripalimab|LM-302 (recombinant humanized anti-CLDN18.2 monoclonal antibody, MMAE conjugate), Toripalimab(recombinant humanized anti-PD1 monoclonal antibody)
88948783|NCT05928910|Experimental|SmileyScope VR Group|Participants in this group will wear the SmileyScope VR set during the PNE procedure for approximately 40 minutes.
88948784|NCT05928910|Experimental|No VR Group|Participants in this group will receive standard of care treatment.
88948785|NCT05925608|Experimental|Dose Escalation Cohort|The study will utilize a dose escalation study design with three patients at 20 million MSCs, three patients at 100 million MSC, and three patients at 200 million MSC to identify dose for Phase II. Prespecified DSMB review after each dose cohort of the Phase I, before moving to higher dose.
88948786|NCT05918692|Experimental|Escalation Phase|BMF-500 taken twice daily by participants who are not receiving drugs that inhibit CYP3A4 activity or who are receiving necessary azole antifungals that are moderate or strong CYP3A4 inhibitors excluding other moderate or strong CYP3A4 inhibitors.
88948787|NCT05918692|Experimental|Expansion Phase|BMF-500 taken twice daily by participants who are not receiving drugs that inhibit CYP3A4 activity or who are receiving necessary azole antifungals that are moderate or strong CYP3A4 inhibitors excluding other moderate or strong CYP3A4 inhibitors.
89202401|NCT02561936|Experimental|Panel 2: Group 1|Participants will receive Treatment E (25 mg RPV formulated as dispersible tablet formulation G007 or G009-01 or as granules formulation G002 [10*2.5 mg tablets or 10 g of 2.5 mg/g granules, dispersed in water] under fed [standardized breakfast] condition) followed by Treatment H (25 mg RPV formulated as dispersible tablet formulation G007 or G009-01 or as granules formulation G002 [10*2.5 mg tablets or 10 g of 2.5 mg/g granules, dispersed in water] under fed [yoghurt] condition) followed by Treatment F (25 mg RPV formulated as dispersible tablet formulation G007 or G009-01 or as granules formulation G002 [10*2.5 mg tablets or 10 g of 2.5 mg/g granules, dispersed in water] under fasted condition) followed by Treatment G (25 mg RPV formulated as dispersible tablet formulation G007 or G009-01 or as granules formulation G002 [10*2.5 mg tablets or 10 g of 2.5 mg/g granules, dispersed in water] under fed [standardized breakfast] condition).
89202402|NCT02561936|Experimental|Panel 2: Group 2|Participants will receive Treatment F followed by Treatment E then Treatment G followed by Treatment H.
89202403|NCT02561936|Experimental|Panel 2: Group 3|Participants will receive Treatment G followed by Treatment F then Treatment H followed by Treatment E.
89202404|NCT02561936|Experimental|Panel 2: Group 4|Participants will receive Treatment H followed by Treatment G then Treatment E followed by Treatment F.
88948792|NCT05907616|Experimental|pregnant Latina women|Pregnant Latina women in Hartford CT enrolled during the first or second trimester of pregnancy. Participants will be provided with up to three nutrition education sessions and will be sent text message reminders to redeem their incentives every month and to provide them with nutrition tips.
88948793|NCT05903885|Experimental|Onsite group|"The on-site distribution group will receive the Fecal Immunochemical Test (FIT) kits directly while visiting the Department of Motor Vehicles (DMV) location.~Participants in the on-site group will be guided through the process of receiving the FIT kits by trained staff present at the designated location. They will be given instructions on collecting the stool sample and using the FIT kit properly.~They will also be given a tailored educational brochure, reminder text messages, and phone calls within 3 weeks of the receipt of the FIT kit and post-navigation services for positive results."
89202405|NCT00790764|Placebo Comparator|Placebo|20 individuals will receive placebo.
89202406|NCT00790764|Experimental|MESENDO|"Active combination autologous stem cell therapy. 40 individuals will receive MESENDO in either the high or low dose treatment groups."
89471905|NCT03606655|Experimental|Kava|This is a single-arm pre- and post- Phase 0/1 study with one primary goal to explore the feasibility of recruitment of participants, adherence rate, acceptability of treatment and completion rate with 14 day dietary supplement kava treatment in head and neck cancer patients who continue to smoke. The other primary goal is to evaluate distribution of change in nicotine and NNK metabolism after 14 day kava treatment..
89471906|NCT03367221|Experimental|NAVA group|NAVA ventilation
89471907|NCT04477148|Active Comparator|Metallic Reusable(MR)|Patients in this group were intubated with reusable metallic blades
89471908|NCT04477148|Active Comparator|Metallic Disposable(MD)|Patients in this group were intubated with disposable metallic blades
89471909|NCT04477148|Active Comparator|Plastic Disposable(PD)|Patients in this group were intubated with disposable plastic blades
89471910|NCT03606577|Experimental|Carfilzomib, Daratumumab, Lenalidomide and Dexaméthasone|
89471911|NCT03601975|Experimental|anlotinib plus Gemcitabine/Cisplatin|patients receive anlotinib at 12mg QD (d1-d14)and gemcitabine (1000 mg/m² d1,8) or cisplatin (80mg/m² d1) every 3 weeks for every cycle
89471912|NCT03601975|Placebo Comparator|placebo plus Gemcitabine/Cisplatin|patients receive pacebo at 0mg QD (d1-d14)and gemcitabine (1000 mg/m² d1,8) or cisplatin (80mg/m² d1) every 3 weeks for every cycle
89471913|NCT04982666|Experimental|Whole-Food, Plant-Based Diet Group|Subjects with a known diagnosis of Crohn's disease will follow a whole-food, plant-based diet for a total of 12 weeks
88948794|NCT05903885|Active Comparator|Mailing group|"The mailing group participants will receive an initial letter from the the Nebraska Department of Health and Human Services (NE DHHS) asking whether they are interested in receiving Fecal Immunochemical Test (FIT) packets. For those who responded yes, NE DHHS will send FIT kits on behalf of the research team.~These participants will receive the FIT kits mailed to their provided addresses using the DMV database.~Participants in the mailing group will receive the FIT kits by mail along with detailed instructions on how to collect the stool sample and use the kit. The mailing group will also receive a tailored educational brochure, reminder text messages, and phone calls within three weeks of receipt of the FIT kit and post-navigation services in case of positive results."
88948795|NCT05900401|Experimental|Kidney and Stem Cell Recipients|Months-Years after standard transplant, patients will undergo bone marrow transplant (either from prospective collection of stem cells from their living donor, or from bone marrow collected at the time of deceased donation)
88948796|NCT05900401|Experimental|Kidney and Stem Cell Donors|PBSC will be collected from the LD via leukapheresis 1-4 weeks before the scheduled HSCT. The donor will first undergo standard GCSF mobilization: GCSF (can be TBO-GCSF) dosed at 10 mcg/kg/d (rounded to nearest pre-filled syringe) administered subcutaneously daily for 5 consecutive days. On the 5th day, the donor will undergo standard large volume leukapheresis. The target yield will be 2-3 x 106 CD34+ cells / kg of actual recipient body weight. A maximum of 3 days of pheresis will be allowed. A minimum of 2 x 106 CD34+ cells / kg of actual recipient body weight will be required to proceed
89471914|NCT04982666|Active Comparator|FODMAP Diet|Subjects with a known diagnosis of Crohn's disease will follow a FODMAP diet for a total of 12 weeks
89471915|NCT03137342|Experimental|Pepped on PrEP|"Using an efficient stepped care (adaptive) model, all participants will receive three sessions of PrEP-STEPS counseling for PrEP adherence delivered by a Masters-level or above therapist. Some individuals may require a more intensive approach. These participants will receive an additional seven counseling sessions of behavioral activation with integrated cognitive behavioral therapy (CBT) designed to reduce stimulant use and promote positive behaviors."
89471916|NCT03137342|No Intervention|Standard of Care|PrEP adherence counseling from the Miriam Hospital PrEP Clinic.
89471917|NCT03597841||Patients with CRKp BSI:Combination therapy|
89471918|NCT03597841||Patients with CRKp BSI: Monotherapy|
89471919|NCT04977206|No Intervention|No Intervention|Patients receiving usual care
89471920|NCT04977206|Experimental|Intervention|Patient's receiving care following nurse education on mutual goal-setting
89471921|NCT03602911|Other|Proof of Concept|The isotope 68Ga, available as NETSPOT and 18F-FDG-PET/CT per established protocol will both be administered
89471922|NCT03137186|Active Comparator|Investigational arm|Metformin will be added to standard of care
89471923|NCT03137186|No Intervention|Control arm|Patients will treated according to Standard of care only
89471924|NCT03602755||Patients with newly diagnosed transplant-ineligible MM|Adult Patients with newly diagnosed MM who were not suitable candidates for ASCT who started first-line treatment for the study disease in a routine clinical practice setting between 2012 and 2016, inclusive.
89471925|NCT05363852|Experimental|Emotional reaction|Physiological responses (cerebral blood flow, brain electrical activity, heart rate variability, and skin conduct-ance response) to visual word and picture stimuli
89471926|NCT03137030|Experimental|GRT7014 - 1 Tablet (Part 1)|"Abuse deterrent formulation of a fixed dose combination of hydrocodone bitartrate 5 mg/acetaminophen 325 mg immediate release (IR) tablet.~(GRT7014 - Abuse Deterrend Tablet)"
89471927|NCT03137030|Experimental|GRT7014 - 10 Tablets (Part 1)|"Abuse deterrent formulation of a fixed dose combination of hydrocodone bitartrate 5 mg/acetaminophen 325 mg immediate release (IR) tablet.~(GRT7014 - Abuse Deterrend Tablet)"
89471928|NCT03137030|Active Comparator|Norco - 1 Tablet (Part 1)|Norco fixed dose combination hydrocodone bitartrate 5 mg/acetaminophen 325 mg immediate release (IR) tablet (Norco 5Mg-325Mg Tablet).
89471929|NCT03137030|Active Comparator|Norco - 10 Tablets (Part 1)|Norco fixed dose combination hydrocodone bitartrate 5 mg/acetaminophen 325 mg immediate release (IR) tablet (Norco 5Mg-325Mg Tablet).
89471930|NCT03137030|Experimental|GRT7014 - 5 Tablets (Optional Part 2)|"Abuse deterrent formulation of a fixed dose combination of hydrocodone bitartrate 5 mg/acetaminophen 325 mg immediate release (IR) tablet.~(GRT7014 - Abuse Deterrend Tablet)"
88948797|NCT05898594|Experimental|Screening: Low-Dose Computed Tomography Screening|"Participants will undergo study procedures as outlined:~Complete questionnaires pre- and post- low-dose computed tomography (LDCT) test.~Visit Massachusetts General Hospital facility for a LDCT screening test."
88948798|NCT05893082|Experimental|Intervention|Placement of the F2 device in the aorta to cover the great cerebral vessels.
88948799|NCT05888506|Experimental|Ketone Ester|Participants will consume the supplement prior to bedtime. Nocturnal blood pressure, heart rate, and sleep characteristics will be assessed
88948800|NCT05888506|Placebo Comparator|Placebo Supplement|Participants will consume the supplement prior to bedtime. Nocturnal blood pressure, heart rate, and sleep characteristics will be assessed
88948801|NCT05883358||Kratom withdrawal|Kratom withdrawal syndrome patients, undergoing withdrawal therapy. On alternate weeks, each patient receives rotational treatment using Buprenorphine 5cmg/hr patch; or Clonidine tablet 0.1mg 4hourly; or combined Clonidine tablet 0.1mg 4hourly + Buprenorphine 5cmg/hr patch.
88948802|NCT05882916|Experimental|HIV self-test secondary distribution|The investigators will provide women who sell sex enrolled in the intervention arm with multiple World Health Organization (WHO) - and Kenya-approved oral fluid-based HIV self-test kits. Participants will be counseled to secondarily distribute self-tests to their male transactional sex partners. Self-test kits will contain instructions for use and tailored information on clinic locations and hours within the cluster, the benefits of early ART use, and the availability and benefits of PrEP.
88948803|NCT05882916|No Intervention|Usual care|No intervention, usual care provided at clinics in control communities
88948804|NCT05881473|Other|Group cervical: (control group):|This group includes (40) patients. The patient will be placed in a supine position with the head turned to the contralateral side for adequate exposure of the neck and the upper chest. A linear high-frequency ultrasound probe (6-13 MHz, Sonosite) will be placed at the lateral side of the neck over the midpoint of the sterno-cleido-mastoid muscle at the level of the cricoid cartilage, which corresponds with the C6 transverse process. Once the muscle is identified, the probe will then be moved posteriorly until the posterior tapering edge of the muscle is identified where the interscalene groove between the anterior and middle scalene muscles is identified. Then, the superficial cervical plexus (SCP) will be visualized. A five-cm block needle will then be introduced from lateral to medial using the posterior-in-plane technique until its tip is placed near the SCP above the prevertebral fascia.10 mL of 0.5% Bupivacaine will be deposited.
88948805|NCT05881473|Other|Group clavipectoral: (study group)|"This group includes (40) patients will have medial and lateral clavipectoral (CPB) block ultrasound guided using 20 ml Bupivacaine 0.5% for medial and lateral block equally after induction of general anesthesia.~The patient will be placed in a supine position with the head turned to the contralateral side, and the shoulder will be padded with a small pillow. a 6- to 13-MHz linear array probe will be used for regional anesthesia. During CPB, an ultrasound probe will be placed on both the inner and outer one-third of the anterior surface of the clavicle. Using the in-plane technique, a 22-gauge needle will be inserted and advanced into the space between the periosteum of the clavicle and clavipectoral fascia in a caudal to cephalad direction, and a total of 20 mL of 0.5% Bupivacaine will be equally injected medially and laterally"
88948806|NCT05875129|Experimental|Intervention arm|Participants (N=15) will will be provided with the VAVA prototype along with installation instructions to embed the VAVA within their homes. We provide them with a smart speaker running our intervention, a smart lamp, and a new router. They will be asked to trial the VAVA for a period of 2 weeks, a duration consistent with the primary stage of CBT-I treatment.
88948807|NCT05872022||Participants Exposed to Wegovy|Pregnant women who are exposed to Wegovy at any time during pregnancy for the treatment of obesity or overweight with at least one weight-related comorbid condition will be observed in this prospective observational study.
88948808|NCT05872022||Participants Unexposed to Wegovy or Other GLP-1 RAs|Pregnant women who have overweight with at least one weight-related comorbid condition or who have obesity at conception and who are not exposed to Wegovy or other GLP-1 RAs at any time during pregnancy but who may be exposed to other products for weight management will be observed in this prospective observational study.
88948809|NCT05870176|Active Comparator|Standard Referral|Provider education/training on referral process Patient education material on physical activity benefits Paper referral to LIVESTRONG at the YMCA Fitbit Activity Monitor
88948810|NCT05870176|Experimental|Enhanced Referral|Provider education/training on referral process Patient education material on physical activity benefits Patient decision aid on physical activity program choices Electronic referral to program of patient's choice Fitbit Activity Monitor
88948811|NCT05866315|Active Comparator|Group DLR|Administer desflurane at 1 MAC, adjust the dose by 1 vol% titration to maintain MAP and BIS levels, and remifentanil at 0.025 µg/kg/min.
89471931|NCT03137030|Active Comparator|Norco - 5 Tablets (Optional Part 2)|Norco fixed dose combination hydrocodone bitartrate 5 mg/acetaminophen 325 mg immediate release (IR) tablet (Norco 5Mg-325Mg Tablet).
89471932|NCT02237677||Post-traumatic stress disorder (PTSD)|Post-traumatic stress disorder (PTSD)
89471933|NCT02237677||Healthy Controls (HC)|Healthy Controls (HC)
89471934|NCT03597217|Experimental|Cohort A_Active|3 single doses treatment of PF-05221304
89471935|NCT03597217|Experimental|Cohort B_Active|Repeated doses of PF-05221304
89471936|NCT03597217|Placebo Comparator|Cohort B_Placebo|Repeated doses of placebo
89471937|NCT03596749|Experimental|Sevelamer Carbonate|Sevelamer carbonate will be given with fixed dose of 1600mg (p.o. b.i.d) with meals
89471938|NCT03596749|No Intervention|Control|blank-control
89471939|NCT01595061|Experimental|Treatment (IMRT, gemcitabine, cisplatin, surgery)|Patients undergo IMRT 5 days a week for 6 weeks. Patients also receive gemcitabine hydrochloride IV over 30 minutes and cisplatin IV over 60 minutes weekly for 6 weeks in the absence of disease progression or unacceptable toxicity. Within 6-8 weeks after completion of chemoradiation patients undergo local core biopsy to confirm response or surgical excision of gross residual disease in the vulva and/or inguinal-femoral lymph nodes.
89471940|NCT05088122||one group|
89471941|NCT03601819|Experimental|Pacritinib|200 mg twice daily (with possible dose reduction to 100 mg twice daily)
89471942|NCT04827602||Allergy tested group|Patients who have completed penicillin allergy testing
89471943|NCT03596047|Experimental|Standard treatment + Radial wave therapy|Sildenafil according to the degree of patient involvement + 6 sessions of radial waves.
89471944|NCT03596047|Placebo Comparator|Standard treatment + Placebo therapy|Sildenafil according to the patient's degree of affectation + 6 sessions of placebo therapy.
89471945|NCT03367143|Experimental|L-ICE|Lenalidomide 25mg/d po d1-10, Ifosfamide 1500mg/m2/d iv d1-3, Carboplatin 5*[GFR(ml/min)+25]mg/d iv d2, Etoposide 100mg/m2/d iv d1-3, Frequency every 21 days, Total cycles 4
89471946|NCT02519205||ED Nurses|ED triage nurses from Duke University Hospital (DUH) and Duke Regional Hospitals (DRH).
89471947|NCT03376347|No Intervention|Conventional arm|Institutional Standard of Care with intention to keep MAP> 65 mmHg. The FlotracIQ will be connected, but fully covered.
88948812|NCT05866315|Experimental|Group DHR|Administer desflurane at 1 MAC, adjusting the dose by 1 vol% titration to maintain MAP and BIS levels, and remifentanil at 0.3 µg/kg/min.
88948813|NCT05866315|Experimental|Group RHR|Administer remimazolam at a dose of 6 mg/kg/h initially, followed by 1 mg/kg/h, and remifentanil at 0.3 µg/kg/min.
88948814|NCT05863052||American Indian population|
88948815|NCT05863052||Caucasians treated with immunotherapy|
88948816|NCT05860504||Normal left ventricular systolic function|Patients with normal echocardiographic systolic function, defined as having left ventricular ejection fraction ≥ 50% and no regional hypokinesia
88948817|NCT05860504||Left ventricular dysfunction|Patients with echocardiographic left ventricular systolic dysfunction, defines as having left ventricular ejection fraction < 50% or left ventricular regional hypokinesia in at least two adjacent segments
89471948|NCT03376347|Active Comparator|Treatment arm|FlotracIQ with HPI algorithm.
89471949|NCT03372681|Experimental|Antiperistaltic|In this group patients undergo the distal gestrectomy with antiperistaltic Billroth II + Braun anastomosis
89471950|NCT03372681|Active Comparator|Isoperistaltic|In this group patients undergo the distal gestrectomy with isoperistaltic Billroth II + Braun anastomosis
89471951|NCT05087654|Experimental|Experimental group|Received the Combination of 3D VR and Hands-on Horticultural Activities.
89471952|NCT05087654|No Intervention|Comparison group|Received scheduled activities, such as physical fitness, paper cutting, etc., without any gardening activities.
89471953|NCT03376269|Active Comparator|Combined HBOT/psychotherapy|combined concurrent intervention of HBOT and creative art psychotherapy.
89471954|NCT03376269|Other|psychotherapy|single intervention with creative art psychotherapy
89471955|NCT04762316|Experimental|PP6 Drug|Use PP6 drugs to lose the size of Uterine Fibroids on Women the Pregnancy. Measuring the size of uterine fibroid. Monitor the disappearance of uterine fibroids from 4 - 40 weeks
89471956|NCT04762316|Placebo Comparator|PP6 Placebo|Use PP6 placebo to lose the size of Uterine Fibroids on Women the Pregnancy. Measuring the size of uterine fibroid. Monitor the disappearance of uterine fibroids from 4 - 40 weeks
89471957|NCT04109625|Experimental|Non-immunized Hepatitis B|subjects non-immunized against hepatitis B (naive)
89471958|NCT04109625|Experimental|Vaccine Hepatitis B|subjects vaccinated against hepatitis B
89471959|NCT04109625|Experimental|Ongoing, Old or cured Hepatitis B|subjects with hepatitis B (old or cured)
89471960|NCT05086718|Other|AB Gap Closure|Air Bone gap closure following surgery will be considered as successful outcome
89471961|NCT04074681|Experimental|Gambling Internet-based Protocol|Intervention group that carries out the Gambling Internet-based Protocol based on Cognitive and Behavioral Therapy (CBT) and receives support by the therapist (a weekly 10-minute phone call without clinical content). In addition, they will receive one notification per day to respond to the EMI questions at 8 PM. The EMI includes immediate automatic feedback depending on the participant's responses.
89471962|NCT04074681|No Intervention|Waiting List Control Group|Participants in a 12-week waiting list control condition. They will be offered the possibility of receiving the online treatment protocol after the waiting list period.
89471963|NCT03372447|Experimental|Megadose multivitamin complex|Intramuscular injection of hydroxocobalamin 10,000mcg, Thiamin 100mg, Pyridoxine 50mg
89471964|NCT03367065|Experimental|Dynamic contrast enhanced computerised tomography|
88948818|NCT05843799|Experimental|ILB-202|ILB-202 exosome with Clinical grade normal saline (0.9% sodium chloride for intravenous injection)
89471965|NCT04663256|Experimental|Cognitive Stimulation Group|This group receives physical training based on exercises for cognitive stimulation.
89471966|NCT04663256|No Intervention|Control Group|This group does not receive any treatment.
89471967|NCT04656158|Experimental|Therapeutic horticulture|handling (gardening equipment) and gardening task (outdoor and greenhouse tasks)
89471968|NCT04656158|Active Comparator|Handiwork|Handling tasks (materials) and handiwork (manufacturing of piece of wooden furniture)
89471969|NCT02519283|Active Comparator|Standard of Care|In keeping with the strategy-based pragmatic nature of the trial, the discharge procedures will largely be kept as they are in common practice. Investigators will standardize usual care for ED discharge to include HF medication reconciliation as well as encourage 7-day follow-up.
89471970|NCT02519283|Active Comparator|GUIDED-HF|GWTG:HF has been successfully implemented across multiple inpatient populations and health systems over the last decade and has been shown to improve HF disparities.
89471971|NCT03366909|Experimental|MBRP group|20 patients 2 groups of 10 patients
89471972|NCT03366909|Active Comparator|classic care in addictology center|20 patients
89471973|NCT03399578|Experimental|Group 1|Group 1 volunteers (n= 6) will be administered ChAdOx1 MERS, 5 x 10^9 vp through intramuscular route.
89471974|NCT03399578|Experimental|Group 2|Group 2 volunteers (n= 9) will be administered ChAdOx1 MERS, 2.5 x 10^10 vp through intramuscular route.
89471975|NCT03399578|Experimental|Group 3|Group 3 volunteers (n= 9) will be administered ChAdOx1 MERS, 5 x 10^10 vp through intramuscular route.
89471976|NCT03399578|Experimental|Group 4|Group 4 volunteers (n=6-12) will be administered ChAdOx1 MERS, 2.5 x 10^10 vp at week 0, followed by ChAdOx1 MERS, 2.5 x 10^10 vp at week 26. Both administrations will be given through intramuscular route.
88948819|NCT05843799|Placebo Comparator|Placebo|Clinical grade normal saline (0.9% sodium chloride for intravenous injection)
88948820|NCT05841212|Other|DBT for ADHD|"The intervention will consist of a DBT skills group. Its name, length, style and content will be guided by the viewpoints shared in the intervention planning focus group/ individual interviews, and taken into consideration alongside a clinical rational and the evidence-based content. It will include skills from all four of the DBT modules: Mindfulness, Distress Tolerance, emotion regulation and interpersonal effectiveness. There will be an emphasis on the skills relevant to ADHD symptoms plus a core psychoeducational component on ADHD symptoms. The intervention will be adapted from Rathus and Miller's (2014) DBT for adolescents (DBT-A) manual.~The group format will be didactic teaching with group discussion and experiential exercises to aid learning."
88948821|NCT05839119|Experimental|Treatment|"In patients with androgen receptor positive (AR+), pT2 - pT4, N0 - N1, M0 urothelial cell carcinoma (UCC) of the bladder. The study medication, Degarelix, will be administered concurrently with neoadjuvant gemcitabine/cisplatin.~SOC Neoadjuvant Chemotherapy: Gemcitabine/Cisplatin 21-day cycles (4 cycles total)~Gemcitabine: 1000 mg/m2 (IV) Days 1 and 8 of each cycle~Cisplatin: 70 mg/m2 (if borderline renal function: 35 mg/m2) (IV) Day 1 of each cycle (if borderline renal function, days 1 and 8 of each cycle).~Study Medication: Degarelix (SC) Every 28-days (3 cycles total) Day -7 to -2 of cycle 1, then as defined in the study calendar (approximately q28 days). initial dose is 240 mg administered as two 120 mg (3 mL) injections (SC), followed by subsequent doses at 80 mg (4 mL) administered as one injection (SC)"
88948822|NCT05832086|Experimental|Fasting Mimicking Diet|Intermittent fasting using a fasting mimicking diet
88948823|NCT05832086|Placebo Comparator|Standard Anti-Cancer Diet|Standard Anti-Cancer Diet
88948824|NCT05831735|No Intervention|Control|This group will be provided with a video showing the movement to do in case of pain, or endometriosis crisis
88948825|NCT05831735|Experimental|Physical activity|This group will be provided with a video showing the movement to do in case of pain, or endometriosis crisis + with 1h to 3 h of adapted physical activity delivered by videoconference.
89471977|NCT03399578|Experimental|Group 5|Group 5 volunteers (n=6-12) will be administered ChAdOx1 MERS, 2.5 x 10^10 vp at week 0, followed by ChAdOx1 MERS, 2.5 x 10^10 vp at week 4. Both administrations will be given through intramuscular route.
89471978|NCT03376113|Experimental|VHS group|Patients will be asked to make links between critical situations and appropriate solutions in the volitional help sheet (VHS).
89471979|NCT03376113|No Intervention|Control group|Patients will be asked to read the VHS. This is an active control group. That means all patients in this study will be exposed to situations and solutions in the VHS.
89471980|NCT03342950|Active Comparator|Active drug group|Treatment with the topical solution of clonidine + pentoxifylline (0.1%/5%)
89471981|NCT03342950|Placebo Comparator|Placebo group|Treatment with placebo solution with out active drug ingredients
89471982|NCT03376035|Active Comparator|Unilateral breast reconstruction|Temperature measurements are obtained from the reconstructed breast and compared to the non-reconstructed breast.
89471983|NCT03376035|Experimental|Bilateral breast reconstruction|Temperature measurements are obtained from both reconstructed breasts and the core temperature is measured as well for comparison.
89471984|NCT05086640|Experimental|Lemon foot|Application of Lemon in the Prevention of Blisters on one feet
89471985|NCT05086640|No Intervention|Control foot without lemon|No application of Lemon or any other prevention cream in the Prevention of Blisters on one feet
89471986|NCT04527159|Other|desensitizing agents (Fluoraphat Pro and VivaSens®)|"22 participants above the age of 18 years who presented to dental clinics in Riyadh Elm University with dentine hypersensitivity were randomly selected to participate in the study.~Each participant has at least two teeth with natural hypersensitivity which was not caused by any iatrogenic causes or bad oral habits, so there are 44 cases divided into two groups according to the material used, each group has 22 teeth, that make it applicable to apply the studied material with every patient on individual tooth with the same variables of the oral mouth. When teeth in the hypersensitivity group were evaluated for the level of DH, all teeth were found to have Grade 4 sensitivity."
88948826|NCT05831735|Experimental|Physical activity and education|This group will be provided with a video showing the movement to do in case of pain, or endometriosis crisis + with 1h to 3 h of adapted physical activity delivered by videoconference + 6 session of educational and discussion groups
88948827|NCT05824767|Experimental|Angiotensin II|For patients randomized to the intervention group, once the dose of background norepinephrine reaches ≥0.10 mcg/kg/min for ≥30 minutes, angiotensin II will be started at a dose of 20 ng/kg/min (recommended starting dose in package insert).Thereafter, angiotensin II and norepinephrine will both be titrated to mean arterial pressure (MAP) goal of >/= 65 mmHg according to the protocol titration scheme and in accordance with the University of New Mexico Hospital (UNMH) Nursing Department Titration Guideline. Angiotensin II treatment will be capped at 72 hours, at which point (if a second vasopressor is still needed) the patient will be started on an alternative agent.
89471987|NCT05086484||Endometriosis group|Women diagnosed with endometriosis.
89471988|NCT05086484||Control group|Women diagnosed without endometriosis.
89471989|NCT03366675|Experimental|AZD2811|AZD2811 200mg IV QD CnD1 & D4 every 4weeks
88948828|NCT05824767|No Intervention|Standard of Care (SOC)|Vasopressor therapy be titrated by the clinical team per usual SOC and UNMH Nursing Department Titration Guideline. using other available vasopressor agents (e.g., higher-dose norepinephrine, vasopressin, epinephrine, phenylephrine, and/or dopamine). To provide a comparator arm, patients in the SOC will have renin and DPP3 levels obtained at equivalent timepoints.
88948829|NCT05824351|Experimental|Tanzanian beeswax-pine adhesive|Each study subject will be tested with a thin ring of adhesive in the form of a Tanzanian beeswax-pine resin formula.
88948830|NCT05824351|Active Comparator|Domestic beeswax-pine adhesive|Each study subject will be tested with a thin ring of adhesive in the form of a domestic beeswax-pine resin formula.
88948831|NCT05824351|Active Comparator|Control|Each study subject will be tested with a thin ring of adhesive in the form of Hollister's AdaptTM Barrier Rings.
88948832|NCT05823376||Avatrombopag group|The duration of the study is 4 weeks, from +1 day to +28 days after UCBT, patients will be given Avatrombopag with a recommended dose of 40mg per day. After 28 days of administration, the patients may continue, change or discontinue medication based on the patients' platelet status.
88948833|NCT05819242||Healthy Adults|
88948834|NCT05819242||Rheumatoid Arthritis|
88948835|NCT05819242||Carpal Tunnel Syndrome|
88948836|NCT05816655|Experimental|Fulvestrant arm|fulvestrant + AI + ribociclib
88948837|NCT05816655|Active Comparator|Control arm|AI + ribociclib
88948838|NCT05811039|Experimental|Treatment|Treatment with RemoWax Oil
88948839|NCT05799209|Experimental|Reduced Environmental Stimulation Pool|floating supine in a pool for a prescribed amount of time (1 total session lasting 1 hour)
88948840|NCT05799209|Active Comparator|Zero Gravity Chair|floating supine in a zero-gravity chair for a prescribed amount of time (1 total session lasting 1 hour)
88948841|NCT05787379|Experimental|Providers receiving Long-COVID Concordant Care Training|Providers randomized to this arm will receive concordant care training.
88948842|NCT05787379|Active Comparator|Providers receiving Education Packet Training|Providers randomized to this arm will receive education packet training
88948843|NCT05787119|Experimental|Group 1|2 weeks Conventional therapy / 1 month ARMT / 4 weeks Conventional therapy
88948844|NCT05787119|Experimental|Group 2|3 weeks Conventional therapy / 1 month ARMT / 3 weeks Conventional therapy
88948845|NCT05787119|Experimental|Group 3|2.5 weeks Conventional therapy / 1 month ARMT / 3.5 weeks Conventional therapy
88948846|NCT05760521|Experimental|Arm A: Provider Educational Intervention|Providers receiving education/support from neurology teams, Adult Gerontological Nurse Practitioner (AGNP) assessments/recommendations, and training of office staff regarding ADRD and community resources support for patients/caregivers.
88948847|NCT05760521|No Intervention|Arm B: Provider Control|Providers receiving AGNP assessments/recommendations only.
89471990|NCT03136172||Premature infant|premature infants with 32 weeks or less gestational age or 1,500 g or less birth weight, who born in the Inha university hospital and admit to the neonatal intensive care unit of the Inha university hospital
89471991|NCT03372213||2003-2004|Adults 20-64 at or below 130% of the federal poverty level who completed one 24-hour dietary recall
89471992|NCT03372213||2005-2006|Adults 20-64 at or below 130% of the federal poverty level who completed one 24-hour dietary recall
89471993|NCT03372213||2011-2012|Adults 20-64 at or below 130% of the federal poverty level who completed one 24-hour dietary recall
88948848|NCT05754398|Other|Single group will receive the nurse-led intervention|A single group of community-dwelling older persons will receive a nurse-led intervention after an initial screening and eligibility checks.
88948849|NCT05741502|Experimental|Clozapine Arm|Patients will be on Clozapine for at least 6 months
88948850|NCT05741502|Active Comparator|Non-Clozapine arm|Patients will be on non-Clozapine antipsychotic for at least 6 months
88948851|NCT05729022|Placebo Comparator|Fluoroscopy|A local anesthetic (2% lidocaine), a 22G, 90mm needle (Quincke spinal needle) is inserted into the skin. Once the needle tip is in its target position, 0.5-5 cc of contrast (Omnipauqe) is injected. If the contrast spread along the spinal nerve into the epidural space, a mixture of 3 cc of 0.125% Marcaine and 40 mg of Depo-Medrol is injected or Diprofos (1/2 ampoule (2 ml) per level).
88948852|NCT05729022|Experimental|Ultrasound Microendoscopic|A US device with a curvilinear probe and with a microendoscope (EvoTouch+7 Star Scope), inserted into an 18G needle is used. This group will also receive one AP view fluoroscopy (as control) to check for the diffusion of the contrast material in the epidural space.
88948853|NCT05725070|Experimental|Drug|212Pb-NG001
88948854|NCT05716217|Experimental|Training group|
88948855|NCT05716217|No Intervention|Normal care|
88948856|NCT05711108||Long Term Care Residents Using Glucose Lowering Medication|
88948857|NCT05706727|Experimental|Mephentermine ( M group)|Group M
88948858|NCT05706727|Experimental|Phenylephrine ( P group )|Group P
88948859|NCT05705648|Experimental|Intervention|Medium chain triglyceride oil 15ml tid x 5 months
88948860|NCT05705648|Placebo Comparator|Placebo|Safflower oil 15mls tid x 5 months
89471994|NCT03372213||2013-2014|Adults 20-64 at or below 130% of the federal poverty level who completed one 24-hour dietary recall
89471995|NCT03366597|Experimental|Sevoflurane|Sevoflurane will be used as a narcotic drug in one group during cardiac surgery.
89471996|NCT03110120|Active Comparator|serratus|Serratus plane block and local control
89471997|NCT03110120|Sham Comparator|local|serratus control and local anesthesia
89471998|NCT04524975|Experimental|CD-008-0045 60 mg/day|Patients assigned to the CD-008-0045 60 mg/day group will receive 1 capsule of CD-008-0045 (20 mg) before breakfast, lunch, and dinner for 8 weeks
89471999|NCT04524975|Experimental|CD-008-0045 40 mg/day|Patients assigned to the CD-008-0045 40 mg/day group will receive 1 capsule of CD-008-0045 (20 mg) before breakfast and before dinner, and 1 placebo capsule before lunch for 8 weeks.
89472000|NCT04524975|Placebo Comparator|Placebo|Patients assigned to the Placebo group will receive 1 placebo capsule before breakfast, lunch, and dinner for 8 weeks.
89472001|NCT03109886|Experimental|Milciclib maleate|milciclib maleate ,10, 50 and 100 mg hard gelatine capsules , 100 mg once daily, for 4 consecutive days a week in a 4-week cycle (4 days on/3 days off x q4 wks) for a total of 12 weeks (i.e. 3 cycles)
89472002|NCT03110042||Observational Cohort|All patients will receive usual standard of care with the heart failure management including the routine supplemental oxygen therapy.
89472003|NCT03366519||patients with pulmonary embolism|patients with pulmonary embolism confirmed by tomography scan in emergency department
89472004|NCT03110198|Experimental|Mesalazine with hydrocortisone sodium succinate|Mesalazine（4g） with hydrocortisone sodium succinate (100mg ) enema
89472005|NCT03110198|Active Comparator|Mesalazine|Mesalazine （4g）enema
89472006|NCT03110198|Active Comparator|Hydrocortisone sodium succinate|Hydrocortisone sodium succinate (100mg ) enema
89472007|NCT04460781||1|Pregnant women from the VAP00003 Study and their offspring - Pregnant women from the VAP00003 Study (NCT03694392) between September 2018 and May 2020 (2 influenza seasons), and infants born from this cohort of pregnant women
89472008|NCT02519829|Active Comparator|Monocryl closure|"The skin incision is closed with monocryl dissolvable sutures and a topical adhesive (glue) called Dermabond and covered with a Tegaderm dressing.~Intervention: Monocryl closure, Tegaderm dressing"
89472009|NCT02519829|Active Comparator|Vicryl and staple closure|"The skin incision is closed with vicryl and staples and covered with a gauze dressing.~Intervention: Vicryl and Staple closure, Gauze dressing"
89472010|NCT05084690|Active Comparator|Resistance training control group|The resistance training control group will perform unilateral resistance training on their dominant arm. The training will be performed twice per week for four weeks totaling eight training sessions.
89472011|NCT05084690|Experimental|Resistance training with mirror illusion group|The resistance training with mirror illusion group will perform unilateral resistance training on their dominant arm. During training, they will view a mirror illusion of their exercising arm over their opposite, non-exercising arm. The training will be performed twice per week for four weeks totaling eight training sessions.
89472012|NCT03375957|Experimental|ATx201 2% Gel|
89472013|NCT03375957|Experimental|ATx201 4% Gel|
89472014|NCT03375957|Placebo Comparator|ATx201 Gel Placebo|
89472015|NCT03375879|Active Comparator|Bandage contact lens|Placing a bandage contact lens in one eye.
89472016|NCT03375879|No Intervention|Sham contact lens (immediate removal)|Sham contact lens will be placed on other eye, placing it and immediately removing it so patient does not know which eye will have a bandage contact lens.
88948861|NCT05701280|Experimental|DBS+Rehab|Active-DBS combined with motor rehabilitation
88948862|NCT05701280|Active Comparator|Rehab|Control-DBS combined with motor rehabilitation
88948863|NCT05700032|Experimental|high MI|patients receiving high MI impulses
88948864|NCT05700032|Active Comparator|low MI|patients receiving low MI impulses
89472017|NCT03366441|Experimental|Telephone group|The telephone group received telephone calls. All non-response and refusing donors were included for further follow-up. Donors who answered the phone call and agreed to be interviewed were asked the reasons why they had stopped donating according to a pre-designed questionnaire. All of the responsed donors were re-recruited by altruistic appeal.
89472018|NCT03366441|Experimental|SMS group|"The SMS intervention group received the following text message:Dear donors, Thank you for your donation through which your love brought hope to those helpless patients and your donated blood reignited the fire in their lives. If you can, please consider donating blood again to save a life. Thank you again for your support! . All donors either receiving or not receiving the message were included for further follow-up."
89472019|NCT03366441|No Intervention|Control group|No intervention will be giving to this group.
88948865|NCT05698927||Intrathecal Morphine Group|"Prosedure/Surgery: Regional block and Intrathecal Morphine Comparison~Comparing postoperative pain and opioid consumption in groups"
88948866|NCT05698927||Bilateral Erector Spinae Plane Block Group|"Prosedure/Surgery: Regional block and Intrathecal Morphine Comparison~Comparing postoperative pain and opioid consumption in groups"
88948867|NCT05695742||Active smokers|Having smoked at least 1 cigarette per day for at least 2 years.
88948868|NCT05695742||Pasive smokers|Being exposed to secondhand smoke for more than 15 minutes at home, school, office or anywhere in the past year, once a week.
88948869|NCT05695742||Non-smokers|Not being an active or passive smoker.
89472020|NCT03138824|Experimental|SPIES assisted TURBT|Storz Professional Image Enhancement System (SPIES) assisted transurethral resection of bladder tumour for Non-muscle invasive bladder cancer
89472021|NCT03138824|Experimental|WLI assisted TURBT|White Light Imaging (WLI) assisted transurethral resection of bladder tumour for Non-muscle invasive bladder cancer
89472022|NCT03366363|Experimental|Electro-acupuncture|"5 compulsory acupoints (ST35、EX-LE5、LR8、GB33 and Ashi) and 3 optional matching acupoints (stomach meridian syndrome：ST34、ST36、ST32、ST40、EX-LE2；gallbladder meridian syndrome：GB31、GB36、GB34、GB39、GB41；bladder meridian syndrome：BL39、BL40、BL57、BL60；San Yin meridian syndrome：LR7、SP9、SP10、KI10、SP4、SP6、LR3、KI3) will be chosen. Needles will be stimulated manually to achieve De Qi sensation and an electrical apparatus (Nanjing Jisheng Medical Co., Ltd., wave of 2/100Hz) will be then connected to the needles with alligator clips in pairs LR8-GB33 and two other matching acupoints. The stimulus intensity will be increased until the patient reports a strong but comfortable intensity. Patients will receive 30-minute, 24 sessions intervention over eight weeks."
89472023|NCT03366363|Experimental|manual acupuncture|Participants in the manual acupuncture group have the same schedule as the Electro-acupuncture group except that the electrical apparatus has working power indicator and sound without actual current output.
89472024|NCT03366363|Sham Comparator|sham acupuncture|Those in the sham acupuncture group receive shallow acupuncture at non-acupoints without manipulation，Deqi or actual current output.
89472025|NCT04345874|Experimental|Nutrition technical assistance|three encounters with Intervention team over three months: two virtual 60-90 minutes visits one-on-one with the FCCH each scheduled at the convenience of the provider and a 3- hour virtual group class with other providers.
89472026|NCT04345874|Experimental|Children's environmental health technical assistance|three encounters with Intervention team over three months: two virtual 60-90 minutes visits one-on-one with the FCCH each scheduled at the convenience of the provider and a 3- hour virtual group class with other providers.
89472027|NCT03366285||Fullterm infants|Quality of bonding is assessed at 6 to 8 years of age using the attachment story completion task. Infants are recruited from the local elementary school.
89472028|NCT03366285||Moderate to late preterm infants|"Bonding quality is assessed at 6 to 8 years of age using the attachment story completion task. Infants are recruited from former participants of the trauma and depression in late preterm parents study (TraDelPP) conducted 2010 to 2011."
89472029|NCT03366285||Preterm infants with skin to skin contact|"Bonding quality is assessed at 6 to 8 years of age using the attachment story completion task. Infants are recruited from former participants of the delivery room skin to skin study (deisy) who were randomized into the skin to skin contact group. The study was conducted from 2012 to 2015."
89472030|NCT03366285||Preterm infants with visual contact|"Bonding quality is assessed at 6 to 8 years of age using the attachment story completion task. Infants are recruited from former participants of the delivery room skin to skin study (deisy) who were randomized into the visual contact group. The study was conducted from 2012 to 2015."
89472031|NCT03375801|No Intervention|control group/pre intervention|the first 164 patients will receive care as usual and will make the decision together with their clinician without support of the decision aid. They will be asked to fill out the questionnaires.
89472032|NCT03375801|Experimental|intervention arm|another 164 patients will receive the decision aid as support for the decision making process with their clinician.
89472033|NCT04227860|Active Comparator|Group 1: G I primary KOA|Exercise and balance training
89472034|NCT04227860|Active Comparator|Group 2: G II primary KOA|Exercise and balance training
89472035|NCT04227860|Active Comparator|Group 3: G III primary KOA|Exercise and balance training
88948870|NCT05684783||Group 1 interviews|Care professionals with experience of being or working with Dementia Champions, and people affected by dementia who have received care from services with Dementia Champions.
88948871|NCT05684783||Group 2 interviews|Homecare professionals working in services where there are no Dementia Champions, and people affected by dementia who have received care from services with no Dementia Champions.
88948872|NCT05679388|Experimental|Study Group 1|"All study participants will receive a starting dose of relugolix (360 mg in the form of three 120 mg tablets) on Day 1 of the 29-day drug administration period. After Day 1, you will receive relugolix on its own or relugolix combined with another medication called itraconazole or ritonavir. The combination of medications you receive, the dosage for each medication, and when you take each medication will be based on the study group you are enrolled in.~Study Group 1 will receive:~Relugolix (360 mg) on Day 1~Relugolix (120 mg) on Days 2-7"
88948873|NCT05679388|Experimental|Study Group 2a|"All study participants will receive a starting dose of relugolix (360 mg in the form of three 120 mg tablets) on Day 1 of the 29-day drug administration period. After Day 1, you will receive relugolix on its own or relugolix combined with another medication called itraconazole or ritonavir. The combination of medications you receive, the dosage for each medication, and when you take each medication will be based on the study group you are enrolled in.~Study Group 2a will receive:~Relugolix (360 mg) on Day 1~Relugolix (120 mg) on Days 2-7~Itraconazole (200 mg) on Days 1-14"
89472036|NCT04227860|Active Comparator|Group 4: G IV primary KOA|Exercise and balance training
89472037|NCT03371901|Experimental|Physical therapy with BFR-LLST|
89472038|NCT03371589|Experimental|no P.O corticosteroids|Steroids injection
89472039|NCT03375567|Experimental|Guided Lesion Biopsies|After patients are treated with Carfilzomib Lenalidomide Dexamethasone (CRD), lesion biopsies will be performed per usual care. Patients will have biopsies performed on lesions using a novel image guided technique.
89472040|NCT03375567|Active Comparator|Standard Lesion Biopsies|After patients are treated with Carfilzomib Lenalidomide Dexamethasone (CRD), lesion biopsies will be performed per usual care. Patients will have biopsies performed on lesions using a novel image guided technique.
89472041|NCT03365973||Spinal metastases of breast cancer|Patients with potentially unstable spinal metastases of breast cancer
89472042|NCT03365895|Experimental|Diagnostic (non-enhanced MRI using MRN and DTI)|Patients undergo non-enhanced MRI of both lower extremities using MRN and DTI prior to initiation and after completion of standard of care chemotherapy.
89472043|NCT03365817|Experimental|Taper off|Decrease of opioid daily dose until discontinuation for up to six months.
89472044|NCT03365817|Active Comparator|Control Group|No changes on opioids and adjuvant medication for up to six months.
89472045|NCT03365739|Active Comparator|Active Comparator 1|Treatment - Mango (pulp/flesh-500 g)
89472046|NCT03365739|Active Comparator|Active Comparator 2|Mango (500 g) + Vitamin C (100 mg)
89472047|NCT03365739|Placebo Comparator|Control Comparator|Vitamin C (100 mg)
89472048|NCT03365661|Experimental|ALT-803|
89472049|NCT03371511||MiLC Cohort|"Participants donated HM from two consecutive pumping sessions at home. Women pumped once with their own pump and milk collection kit, and once with a sterile and sterile collection kit. Both pumping sessions occurred at participants' homes between 0700 and 1100 hours. The second pumping session occurred within 3 hr (+/- 30 min) after the beginning of the first. Randomization was used to determine which pump was used first. Women elected from which breast they donated their HM and were asked not to nurse on that side 2 hr before the first pumping session and not until after the second. Before women pumped with their own pump, swabs were taken of the breast from which HM was donated, the women's dominant hand, their own bottle/flange, their own pumps (port of pump and tubing), and their babies' mouths.~There was only one group but stratified enrollment was used to ensure equal numbers of women whose infants consumed HM only and women whose infants consumed HM and complementary foods."
89472050|NCT03365583||Vitamin B12 deficiency|"No intervention will be administered for this study. Serum vitamin B12 <203 pg/mL is considered as vitamin B12 deficiency.~Fecal microbiota composition will be analyzed with 16S rRNA sequencing. In a subgroup of infants (n=11), fecal samples will be recollected after the treatment as usual"
89472051|NCT03365583||Vitamin B12 sufficient|Serum vitamin B12 ≥203 pg/mL is considered as vitamin B12 sufficient Fecal microbiota composition will be analyzed with 16S rRNA sequencing.
89472052|NCT03365427|Experimental|Application Group|People in this arm will be introduced to an APP on smart phone, and receive lessons on how to use it on their own phones. The APP will be installed and prepare to use before surgery. People will be asked and monitored on-line to regularly use the APP.
89472053|NCT03365427|No Intervention|Convention Group|People in this arm receive exactly the same treatment and lessons on post-operative rehabilitation except the reach of the APP.
89472054|NCT03363789|Active Comparator|Brisement|Patients will receive a series of brisement injections for treatment of non insertional Achilles tendinosis.
89472055|NCT03363789|Active Comparator|Physical Therapy|Patients will undergo physical therapy for treatment of non insertional Achilles tendinosis.
89472056|NCT03365349|Experimental|living theatre|One session consisting for the patient of telling a story about his/her own life with diabetes , which is first written and then transformed to a script to be played by professional actors co-directed by the patient with the support of the Director to create a little play.
88948874|NCT05679388|Experimental|Study Group 2b|"All study participants will receive a starting dose of relugolix (360 mg in the form of three 120 mg tablets) on Day 1 of the 29-day drug administration period. After Day 1, you will receive relugolix on its own or relugolix combined with another medication called itraconazole or ritonavir. The combination of medications you receive, the dosage for each medication, and when you take each medication will be based on the study group you are enrolled in.~Study Group 2b will receive:~Relugolix (360 mg) on Day 1~Relugolix (120 mg) on Days 2-7~Ritonavir (100 mg tablets taken by mouth) on Days 1-14"
88948875|NCT05679388|Experimental|Study Group 3a|"All study participants will receive a starting dose of relugolix (360 mg in the form of three 120 mg tablets) on Day 1 of the 29-day drug administration period. After Day 1, you will receive relugolix on its own or relugolix combined with another medication called itraconazole or ritonavir. The combination of medications you receive, the dosage for each medication, and when you take each medication will be based on the study group you are enrolled in.~Study Group 3a will receive:~Relugolix (360 mg) on Day 1~Relugolix (120 mg) on Days 2-4~Itraconazole (200 mg tablets taken by mouth) on Days 1-14"
89472057|NCT03365349|Active Comparator|writing workshop|"one session consisting for the patient of writing a Letter to his/her own diabetes and then to read it to the group of patients and the healthcare providers."
89472058|NCT02852005|Experimental|Group 1: MVA/HIV62B + Placebo|Participants who received 3 sequential administrations of MVA/HIV62B in HVTN 205 will receive the MVA/HIV62B vaccine in their left deltoid at Months 0 and 4. They will receive placebo in their right deltoid at Months 0 and 4.
88948876|NCT05679388|Experimental|Study Group 3b|"All study participants will receive a starting dose of relugolix (360 mg in the form of three 120 mg tablets) on Day 1 of the 29-day drug administration period. After Day 1, you will receive relugolix on its own or relugolix combined with another medication called itraconazole or ritonavir. The combination of medications you receive, the dosage for each medication, and when you take each medication will be based on the study group you are enrolled in.~Study Group 3b will receive:~Relugolix (360 mg) on Day 1~Relugolix (120 mg) on Days 2-4~Ritonavir (100 mg) on Days 1-14"
88948877|NCT05634447|Experimental|Sequence 1|"Period 1: CKD-331, D337 - A single oral dose of 2 tablets under fasting condition~Period 2: CKD-391 - A single oral dose of 1 tablet under fasting condition~Period 3: CKD-331, D337 - A single oral dose of 2 tablets under fasting condition~Period 4: CKD-391 - A single oral dose of 1 tablet under fasting condition"
88948878|NCT05634447|Experimental|Sequence 2|"Period 1: CKD-391 - A single oral dose of 1 tablet under fasting condition~Period 2: CKD-331, D337 - A single oral dose of 2 tablets under fasting condition~Period 3: CKD-391 - A single oral dose of 1 tablet under fasting condition~Period 4: CKD-331, D337 - A single oral dose of 2 tablets under fasting condition"
88948879|NCT05628038|Experimental|Treatment arm|"The enrolled patients will receive 25-40Gy/5Fx irradiation or 15-30Gy/5Fx reirradiation (pelvic radiation history) for pelvic recurrence.~Patients (cohort A) will receive CAPOX, FOLFIRI or mFOLFOX6 chemotherapy based on previous adverse reactions to chemotherapy agents and at the discretion of the oncologist.~Patients (cohort B) will receive CAPOX, FOLFIRI, mFOLFOX6, mXELIRI, irinotecan and raltitrexed, or oxaliplatin and raltitrexed chemotherapy based on the first-line chemotherapy and previous adverse reactions to chemotherapy agents and at the discretion of the oncologist.~All metastasis sites will receive stereotactic ablative radiotherapy (SABR). SABR would be delivered between chemoimmunotherapy cycles. Five-fraction regimens (25-50Gy/5Fx) are delivered daily. Dose Constraints are based on SABR-COMET 10 trial."
88948880|NCT05626829|Experimental|Tranilast|concurrent Tranilast 100mg 3 times per day
88948881|NCT05626088||Retrospective Cohort|Participants diagnosed with UC or CD with prescription of vedolizumab, and were included in the PSP program (which has started in 2016) before the study starts will be observed retrospectively in this study.
89472059|NCT02852005|Experimental|Group 2: MVA/HIV62B + AIDSVAX B/E|Participants who received 3 sequential administrations of MVA/HIV62B in HVTN 205 will receive the MVA/HIV62B vaccine in their left deltoid at Months 0 and 4. They will receive the AIDSVAX B/E vaccine in their right deltoid at Months 0 and 4.
89472060|NCT02852005|Experimental|Group 3: MVA/HIV62B + Placebo|Participants who received 2 sequential priming administrations of JS7 DNA plasmid followed by 2 sequential boost administrations of MVA/HIV62B in HVTN 205 will receive the MVA/HIV62B vaccine in their left deltoid at Months 0 and 4. They will receive placebo in their right deltoid at Months 0 and 4.
89472061|NCT02852005|Experimental|Group 4: MVA/HIV62B + AIDSVAX B/E|Participants who received 2 sequential priming administrations of JS7 DNA plasmid followed by 2 sequential boost administrations of MVA/HIV62B in HVTN 205 will receive the MVA/HIV62B vaccine in their left deltoid at Months 0 and 4. They will receive the AIDSVAX B/E vaccine in their right deltoid at Months 0 and 4.
89472062|NCT02852005|Experimental|Group 5: Placebo + AIDSVAX B/E|Participants who received 2 sequential priming administrations of JS7 DNA plasmid followed by 2 sequential boost administrations of MVA/HIV62B in HVTN 205 will receive placebo in their left deltoid at Months 0 and 4. They will receive the AIDSVAX B/E vaccine in their right deltoid at Months 0 and 4.
88948882|NCT05626088||Prospective Cohort|Participants diagnosed with UC or CD with prescription of vedolizumab, and have participation in PSP after the study start will be observed prospectively in this study.
88948883|NCT05621018|Active Comparator|Intervention group|Patients will be introduced to Maze Out in an information meeting with the investigators and will afterwards receive a link with the game and a username. Each patient has to choose a code to start playing the game. The code will not be available for the investigators.
89472063|NCT03371277|Experimental|Arm1|patients with Parkinson's disease treated with deep brain stimulation.
89472064|NCT03371277|Experimental|Arm2|patients with Parkinson's disease treated without deep brain stimulation.
89472065|NCT03365271|Experimental|drainage|A drainage will be applied in this group.
89472066|NCT03365271|Active Comparator|without drainage|Non-drainage will be applied in this group.
89472067|NCT03601741|Active Comparator|Antimicrobial Stethoscope Diaphragm Covers|
89472068|NCT03601741|Active Comparator|Uncovered Stethoscopes|
89472069|NCT03365115|Active Comparator|intrathecal fentanyl|
89472070|NCT03365115|Active Comparator|intrathecal morphine|
89472071|NCT03365115|Experimental|intrathecal morphine and fentantyl|
89472072|NCT03365037|Experimental|Electret electrostatic physiotherapyFilm|Patients with acute soft tissue injury treated with electret electrostatic physiotherapyFilm
89472073|NCT03365037|Active Comparator|Fracture healing film|Patients with acute soft tissue injury treated with fracture healing film
89472074|NCT04524741|Experimental|left atrial appendage radiography|
89472075|NCT04524741|Experimental|intracardiac echocardiography guidance|
89472076|NCT03594877|Experimental|Psoriasis patients|Patients with verified diagnosis of psoriasis would be given standard treatment for the first 3 months, and then followed with the standard therapy accompanied with the sublimated mare milk supplement for additional 3 months.
89472077|NCT03594877|No Intervention|Healthy volunteers|Healthy patients will be enrolled in this study, and their gut microbiota composition as well as immune system indicators will be used for comparison with the psoriasis group.
89472078|NCT03364959|Experimental|Flixotide|Patients inhale first Flixotide and then Qvar
89472079|NCT03364959|Experimental|Qvar|Patients inhale first Qvar and then Flixotide
89472080|NCT02237755|Active Comparator|Clomiphene citrate|Administration of Clomiphene citrate in combination with gonadotropins according to a short stimulation GnRH antagonists protocol.
89472081|NCT02237755|Active Comparator|Gonadotropins|Patients in this group will be stimulated according to a short stimulation protocol with gonadotropins and GnRH antagonists.
89472082|NCT00642265|Experimental|1|operative treatment
89472083|NCT00642265|Active Comparator|2|conservative treatment
89472084|NCT03364725|Experimental|Open Label Treatment Arm|Treatment arm using Glecaprevir-pibrentasvir for treatment of all patients
89019305|NCT02273648||Orsiro|"Subjects requiring coronary revascularization with Drug Eluting Stents (DES) as well as Subjects presenting with~Diabetes (all types) at least 300 subjects should be included and analyzed in this segment~Small vessels (≤2.75 mm) approx. 150 subjects~Chronic total occlusion (CTO) approx. 50 subjects~Acute Myocardial Infarction (incl. STEMI and NSTEMI) approx. 100 subjects~Multivessels approx. 250 subjects~In stent restenosis approx. 100 subjects~Different type of DAPT interruption : <3 months, between 3 and 6 months, after 6 months approx. 300 subjects subjects who stopped <3 months"
89472085|NCT04524897|Other|The use of Triamcinolone Injection|Triamcinolone acetate (40 mg/mL)
89472086|NCT02237833||Septic shock and vasopressor|Measuring cerebral oxymetry (SCO2) first 24 hours in septic shock and given vasopressors.
89472087|NCT03364569||Participant with tranexamic acid.|The investigators followed the recommendations of one gram, two times a day, starting at the end of the surgery so as to avoid any adverse effects. The participants received two grams of Spotof ® (C.C.D laboratory, Portugal) as an oral liquid solution during three days.
89472088|NCT03364569||Participant without tranexamic acid.|This group concerns participants followed without acid tranexamic treatment. Investigators will observe the postoperative practices and complications observed, according to the surgical habits.
89472089|NCT03594799|Experimental|Bed Rest Control Group|60 days of strict head-down tilt bed rest
89472090|NCT03594799|Experimental|Cocktail intervention|60 days of strict head-down tilt bed rest along with a Cocktail supplementation composed of natural antioxidants XXS-2A-BR2 comprising vitamin E, Selenium and coupled with omega-3
89472091|NCT03363555|Experimental|SHR-1210|SHR-1210 injection, 200 mg/dose, intravenous infusion within 20-60 minutes.
89472092|NCT03363477|Experimental|AB treatment sequence|Period 1-Test Treatment A: enoxaparin (100 mg/mL) 100-mg SC injection, manufactured by Rovi (Spain) Period 2-Reference Treatment B: Clexane (100 mg/mL) 100-mg SC injection, manufactured by Sanofi (EU)
89472093|NCT03363477|Active Comparator|BA treatment sequence|Period 1-Reference Treatment B: Clexane (100 mg/mL) 100-mg SC injection, manufactured by Sanofi (EU) Period 2-Test Treatment A: enoxaparin (100 mg/mL) 100-mg SC injection, manufactured by Rovi (Spain)
89472094|NCT03601663|Experimental|Group 1|Participants in the main experimental group will receive a copy of the Canadian Physical Activity Guidelines that provide basic information about and recommendations for physical activity, a wearable activity tracker to support self-monitoring, and autonomy-support delivered through weekly emails to help enhance motivation for physical activity.
89472095|NCT03601663|Active Comparator|Group 2|Participants in this comparison group will receive a copy of the Canadian Physical Activity Guidelines that provide basic information about and recommendations for physical activity, and a wearable activity tracker to support self-monitoring. They will not receive any specific support to enhance motivation for physical activity.
89472096|NCT03601663|Active Comparator|Group 3|Participants in this information-only comparison group will receive a copy of the Canadian Physical Activity Guidelines that provide basic information about and recommendations for physical activity.
89472097|NCT03593941||Alzheimer's dementia and challenging behaviour symptoms|Care home residents >65y No interventions as this is a pilot project
89472098|NCT03593941||Alzheimer's dementia and no challenging behavioural symptoms|Care home residents >65y No interventions as this is a pilot project
89472099|NCT03593941||Older adults without dementia|Care home residents >65y No interventions as this is a pilot project
89019306|NCT00336219|Active Comparator|1|Pantoprazole 40 mg
89019307|NCT04698239|Experimental|Laser application ( BEFORE/AFTER)|"All patients will receive a maximum of 13 laser pulses in each lesion. We are going to make a comparison of the before and after the treatment, it is the patient himself who checks himself.~The number of lesions will be counted before treatment and after treatment(72-hour and 1-week ) . Adverse reactions will be collected at several visits as well, during the 2 weeks that the patient is included in the study."
89472100|NCT03601585|Experimental|Rolly Brush|Chew for 1 minute
89019308|NCT00336336|Experimental|1|N-3PUFA
89019309|NCT00336336|Placebo Comparator|2|
89019310|NCT00336336|Experimental|3|Rosuvastatin
89019311|NCT00336336|Placebo Comparator|4|
89019312|NCT00336375|Experimental|1|All treatment doses accompanied with intake of fatty food
89019313|NCT00336375|Active Comparator|2|All treatment doses not-accompanied with intake of fatty food.
89019314|NCT00336453|Experimental|FluBlok-22.5 μg, 6-35 months old|6-35 months old, FluBlok-22.5 μg of each recombinant hemagglutinin antigen: 2006-2007 formulation containing A/New Caledonia/20/99 (H1N1), A/Wisconsin/67/05 (H3N2), and B/Ohio/01/05 like viruses
89019315|NCT00336453|Experimental|FluBlok-45 μg, 6-35 months old|6-35 months old, FluBlok-45 μg of each recombinant hemagglutinin antigen: 2006-2007 formulation containing A/New Caledonia/20/99 (H1N1), A/Wisconsin/67/05 (H3N2), and B/Ohio/01/05 like viruses
89019316|NCT00336453|Active Comparator|TIV-7.5 μg, 6-35 months old|6-35 months old, 2006-2007 formulation of Fluzone, (sanofi-pasteur, Swiftwater, PA)-7.5 μg of each hemagglutinin antigen: A/New Caledonia/20/99 (H1N1), A/Wisconsin/67/05 (H3N2), and B/Malaysia/2506/2004 like viruses
89019317|NCT00336453|Active Comparator|TIV-15 μg, 36-59 months old|36-59 months old, 2006-2007 formulation of Fluzone (sanofi-pasteur, Swiftwater, PA)-15 μg of each hemagglutinin antigen: A/New Caledonia/20/99 (H1N1), A/Wisconsin/67/05 (H3N2), and B/Malaysia/2506/2004 like viruses
89472101|NCT03601585|Experimental|Chewing gum|Chew for 1 minute
89472102|NCT03601585|Experimental|Apple|Chew for 1 minute
89472103|NCT03601585|Active Comparator|Brush|brush for 1 minute
89019318|NCT00336453|Experimental|FluBlok-45 μg, 36-59 months old|36-59 months old, FluBlok-45 μg of each recombinant hemagglutinin antigen: 2006-2007 formulation containing A/New Caledonia/20/99 (H1N1), A/Wisconsin/67/05 (H3N2), and B/Ohio/01/05 like viruses
89019319|NCT00454025||Glaucoma|Patients with Glaucoma
89019320|NCT00454025||Healthy Patients|Patients without glaucoma
89019321|NCT00454064|Active Comparator|1|cognitive-behavioral treatment
89019322|NCT00454064|Active Comparator|2|cognitive-behavioral treatment with biofeedback elements
89019323|NCT00322062|Experimental|1|"1 pack (contains 4 (2 x PEG + E/P + 2 x Vitamin C/C) sachets)= 2L NRL994 . 2 sachets (one of each) will be dissolved in 1L of water. Each litre will be drunk within 1 hour. Furthermore, at least 1000ml (or more) of any additional clear fluid (except milk) has to be drunk after the 2L of NRL994."
89019324|NCT00322062|Active Comparator|2|1 pack consists of 2 flasks of 45ml. Each flask has to be dissolved within 125ml of water. Each intake of NaP solution has to be preceded and followed by 250ml (or more if necessary)of clear liquids(excluding milk)and a delay of at least 12 hours between the intake of the 2 x 45ml of NaP solution has to be completed. In addition, 750ml more of clear liquids (excluding milk)or more if needed must be drunk between the 2 intakes.
89019325|NCT00336648|Experimental|Gemcitabine + Avastin + Surgery|Gemcitabine plus Avastin-based chemoradiation followed by pancreaticoduodenectomy
89472104|NCT03364413||Chocolate|Participants will be asked to taste commercially available chocolate varying in sugar, fat and percent cocoa (milk, 70%, 85% and 90% cocoa).
89472105|NCT03601429|Experimental|Lactogyn|1 capsule of Lactogyn 2 times daily for the first 7 days then 1 time daily for 4 months
89472106|NCT03601429|Placebo Comparator|Placebo|1 capsule of Placebo Comparator 2 times daily for the first 7 days then 1 time daily for 4 months
89472107|NCT03124095|Experimental|Combined Exercise Group|The subjects of the combined training group will undergo the intervention three times a week for eight weeks. The combined group will carry out both resistance and aerobic exercises in the same session. The resistance training will be comprised by ten exercises which will alternate body segments with maximum repetitions in the first set and the lower limit of the repetitions interval in the next sets. Along the training, the number of series will be increased whereas the number of repetitions will be decreased. The intensity of the aerobic exercises will be based on the percentage of the heart rate of the anaerobic threshold on the first weeks and on the speed of the anaerobic and aerobic threshold on the last weeks
89472108|NCT03124095|No Intervention|Control Group|The control group will be advised not to change their health habits. After the intervention they will be invited to participate in a physical exercise program.
89472109|NCT03593707|Experimental|Metformin Alone|Metformin alone
89019326|NCT03274817|Active Comparator|Escitalopram|Escitalopram (lexapro) is presently the most widely used selective serotonin reuptake inhibitor (SSRI) antidepressant.
89019327|NCT03274817|Active Comparator|Venlafaxine|Venlafaxine is a norepinephrine, serotonin and dopamine reuptake inhibitor antidepressant.The specific form of venlafaxine which will be employed is Effexor XR (venlafaxine hydrochloride extended release capsules)
89019328|NCT03274817|Placebo Comparator|Placebo|Subjects randomized to group C will receive placebo tablets, which will be matched to the Lexapro and the Effexor XR as far as possible, and will also be administered on a once daily schedule at baseline.
89019329|NCT00230321|Experimental|Darbepoetin alfa|During the induction phase, the investigational agent DARBEPOETIN ALFA will be initiated at a dose of 4.5 ug/kg/week subcutaneously for 6 weeks. The dosage for the remaining treatment is dependent of patients response during the induction phase.
89472110|NCT03593707|Experimental|Metformin + PF-06865571|Co-administer metformin and PF-06865571
89472111|NCT03592537|Active Comparator|fentanyl|Group F: will receive intrathecal 0.5% bupivacaine (0.3 mg/kg) + (5ug) of fentanyl intrathecally
89472112|NCT03592537|Active Comparator|midazolam|Group M: will receive intrathecal 0.5% bupivacaine (0.3 mg/kg) + 0.5 mg of midazolam intrathecally
89472113|NCT03592537|Placebo Comparator|Bupivacaine|Group B:intrathecal 0.5% bupivacaine (0.3 mg/kg)
89019330|NCT02959632|Experimental|Patients receiving AAT|"Hospitalized patients receiving Animal Assisted Therapy (AAT).~Animal Assisted Therapy (Pet Visit) will be provided to the hospitalized patients."
89019331|NCT00322179||Obese|
89019332|NCT00322179||Non-Obese|
89472114|NCT02987582|Experimental|Emotion-focused mindfulness group|8-week mindfulness group
89472115|NCT03363009|Experimental|Connected device with close following|Data from connected devices (arm wrist watch, connected monitor of blood pressure, connected thermometer and pulse oximeter) will be analyzed every day and used for coaching
89472116|NCT03363009|Other|Connected device with standard coaching|Data from connected devices (arm wrist watch, connected monitor of blood pressure, connected thermometer and pulse oximeter) will be saved but not used for coaching
89472117|NCT02850536|Experimental|anti-CEA CAR-T cells|Three infusions of gene-modified anti-CEA T cells over the course of 3 weeks into the hepatic artery via a percutaneous approach along with low dose IL-2.
89472118|NCT02238223||Patients without experience in treatment with epinastine|
89472119|NCT03124017|Experimental|Alert Group|Electronic alert and the Geneva Risk Score calculation tool issued in the electronic patient chart
89472120|NCT03124017|No Intervention|Control Group|No electronic alert and no Geneva Risk Score calculation tool issued in the electronic patient chart
89472121|NCT05084612|Placebo Comparator|control group (S)|LMA will be placed using the standard Brain's insertion technique.
89472122|NCT05084612|Active Comparator|Rotational group (R)|LMA will be placed using a two Person Insertion with lateral rotation technique.
89472123|NCT03364179||young onset dementia|
89472124|NCT03364179||late onset dementia|
89472125|NCT03124173|Other|Behavioral Tasks|Each subject will conduct 4 sessions, i.e. a training session and three fMRI sessions. The first session will consist in training the subject to carry out the different behavioral tasks that he will then have to perform during the sessions of fMRI.
89472126|NCT04189562|Experimental|SMS Intervention|All parents of participants will receive customized text messages once a day, Sunday through Friday, for a duration of 9 months that will include reminders to adhere to the individualized medication regimen, reminders to call their clinician for a prescription refill followed by reminders to pick up medication from the pharmacy, and educational reminders about ADHD and its treatment.
89472127|NCT05077514|Experimental|Group A|
89472128|NCT05077514|Active Comparator|Group B|
89472129|NCT04527081|Experimental|Group A|
89472130|NCT04527081|Experimental|Group B|
89472131|NCT04527081|Experimental|Group C|
89472132|NCT03364101|Experimental|PowerOff|PowerOff is a nutraceutical and a blend of nine ingredients for sleep, including: melatonin; California Poppy; L-Cystine; Glycine; and Magnolia Officinalis
89472133|NCT03364101|Placebo Comparator|Placebo|The placebo pill will be manufactured at the same facility and appear identical in all aspects. However, the control agent will feature non-active ingredients with regards to sleep.Capsules will be instructed to commence on day 7 of the study after baseline appointment
89472134|NCT03362853|Experimental|Nemonoxacin 500Mg Capsule|
89472135|NCT03362853|Experimental|Nemonoxacin 750Mg Capsule|
89472136|NCT03362853|Placebo Comparator|Placebo oral capsule|
89019333|NCT00230438|Experimental|External Beam Radiation Therapy|
89019334|NCT00336843|Experimental|Zevalin-BuCyE|histologically confirmed, relapsed or refractory CD20 positive B-cell NHL including diffuse large B-cell, follicular, mantle cell, and Burkitt lymphomas.
89019335|NCT00230477|Active Comparator|Mono therapy|Hepsera
89472137|NCT03362853|Active Comparator|Moxifloxacin 400Mg Tablet|
89472138|NCT02849743|Experimental|Syntocinon (= Oxytocin), then Placebo|"Week 0 to Week 7: Intranasal oxytocin, administered 3 times per day (at mealtimes) for 8 weeks (dosage based on weight: 16 IU to 24 IU; dose escalation, if appropriate, occurs at 2 weeks)~Week 8 to Week 11: Washout~Week 12 to Week 20: Intranasal placebo, administered 3 times per day (at mealtimes) for 8 weeks (dosage based on weight: 16 IU to 24 IU; dose escalation, if appropriate, occurs at 2 weeks)~*Dose Escalation, as appropriate, at 2 Weeks"
89472139|NCT02849743|Experimental|Placebo, then Syntocinon (= Oxytocin)|"Week 0 to Week 7: Intranasal placebo, administered 3 times per day (at mealtimes) for 8 weeks (dosage based on weight: 16 IU to 24 IU; dose escalation, if appropriate, occurs at 2 weeks)~Week 8 to Week 11: Washout~Week 12 to Week 20: Intranasal oxytocin, administered 3 times per day (at mealtimes) for 8 weeks (dosage based on weight: 16 IU to 24 IU; dose escalation, if appropriate, occurs at 2 weeks)"
89472140|NCT05076812||Group 1 (Psoriasis only)|contains 24 psoriatic patients, Psoriasis Area Severity Index will be measured, also waist circumference, body mass index, blood pressure, fasting blood glucose and fasting lipid profile and finally: plasma level of interleukin 38
89019336|NCT00230477|Active Comparator|Combo therapy|
89019337|NCT00336882|Active Comparator|1|Midazolam at a dose of 0,03 mg/kg/hour with dose increasing of 0,02 mg/kg/hour until therapeutic effect.
89472141|NCT05076812||Group 2 (Psoriasis and metabolic syndrome)|contains 24 psoriatic patients with metabolic syndrome. Psoriasis Area Severity Index will be measured metabolic syndrome is diagnosed after measuring waist circumference, body mass index, blood pressure, fasting blood glucose and fasting lipid profile finally: plasma level of interleukin 38
89472142|NCT05076812||Group 3 (Metabolic syndrome only)|contains 24 patients with metabolic syndrome only. full dermatological examination to exclude psoriasis and other inflammatory skin disorders metabolic syndrome is diagnosed after measuring waist circumference, body mass index, blood pressure, fasting blood glucose and fasting lipid profile finally: plasma level of interleukin 38
89472143|NCT05076812||Group 4 (Healthy Controls)|contains 24 healthy control subjects full dermatological examination to exclude psoriasis and other inflammatory skin disorders metabolic syndrome is excluded after measuring waist circumference, body mass index, blood pressure, fasting blood glucose and fasting lipid profile finally: plasma level of interleukin 38
89472144|NCT04523883|Experimental|concurrent PD-1|Concurrent Immunotherapy With Postoperative Radiotherapy
89472145|NCT04523883|Active Comparator|Radiotherapy alone|Postoperative Radiotherapy alone
89472146|NCT03601351||TT|Tumor Tissue. Colon or rectum neoplasia stage II and III tumor tissue.
89472147|NCT03601351||NTT|Nontumorous Tissue. Colon or rectum neoplasia stage II and III adjacent nontumorous tissue.
89472148|NCT05063006|Experimental|LVAD pump speed dynamically adjusted|
89472149|NCT05063006|Active Comparator|LVAD pump at optimal resting speed|
89019338|NCT00336882|Experimental|2|Propofol at a dose of 1 mg/kg/hour with a dose increase of 1 mg/kg until therapeutic effect (with a maximum dose of 5 mg/kg/hour)
89019339|NCT00336921|Active Comparator|1|Alfuzosin 10mg
89019340|NCT00336921|Placebo Comparator|2|Placebo
89019341|NCT00336960|Experimental|treatment intervention|
89019342|NCT02960243|Sham Comparator|Bilateral Thalamic Vim OFF|"Participants with bilateral thalamic DBS will be tested four times over 90 minutes. The four tests will include the following in a randomized, double-blinded order:~First test: both stimulators on for 15 minutes Second test: left stimulator off, right stimulator on for 15 minutes Third test: left stimulator on, right stimulator off for 15 minutes Fourth test: both stimulators off for 15 minutes~In between switching to each test, there will be a 5 minute washout period."
89019343|NCT02960243|Experimental|Left Thalamic Vim ON|"Participants with bilateral thalamic DBS will be tested four times over 90 minutes. The four tests will include the following in a randomized, double-blinded order:~First test: both stimulators on for 15 minutes Second test: left stimulator off, right stimulator on for 15 minutes Third test: left stimulator on, right stimulator off for 15 minutes Fourth test: both stimulators off for 15 minutes~In between switching to each test, there will be a 5 minute washout period."
89472150|NCT04526457|Other|Standard of Care|Participants with suspected FH (LDL-C greater than 220 mg/dL) or a previous clinical diagnosis of FH and randomized to standard of care with lipid testing only.
89472151|NCT04526457|Other|Genetic Testing|Participants with suspected FH (LDL-C greater than 220 mg/dL) or a previous clinical diagnosis of FH randomized to genetic testing
89472152|NCT03587077|Experimental|study group|Women will receive vaginally one tablet misoprostol 200 mcg(Misotac; Sigma Pharma, SAE, EGYPT) plus one tablet isosorbide mononitrate 40 mg(Effox 40 mg; Minapharm). A trained clinical nurse will introduce the tablets, digitally without using speculum, 3 hours before IUD insertion into the posterior vaginal fornix of the woman while lying in the lithotomy position.
89019344|NCT02960243|Experimental|Right Thalamic Vim ON|"Participants with bilateral thalamic DBS will be tested four times over 90 minutes. The four tests will include the following in a randomized, double-blinded order:~First test: both stimulators on for 15 minutes Second test: left stimulator off, right stimulator on for 15 minutes Third test: left stimulator on, right stimulator off for 15 minutes Fourth test: both stimulators off for 15 minutes~In between switching to each test, there will be a 5 minute washout period."
89019345|NCT02960243|Experimental|Bilateral Thalamic Vim ON|"Participants with bilateral thalamic DBS will be tested four times over 90 minutes. The four tests will include the following in a randomized, double-blinded order:~First test: both stimulators on for 15 minutes Second test: left stimulator off, right stimulator on for 15 minutes Third test: left stimulator on, right stimulator off for 15 minutes Fourth test: both stimulators off for 15 minutes~In between switching to each test, there will be a 5 minute washout period."
89019346|NCT00418613|Experimental|1|MK0633
89019347|NCT00418613|Placebo Comparator|2|Placebo
89472153|NCT03587077|Placebo Comparator|control group|Women will receive vaginally one tablet misoprostol 200 mcg Plus one tablet placebo.A trained clinical nurse will introduce the tablets, digitally without using speculum, 3 hours before IUD insertion into the posterior vaginal fornix of the woman while lying in the lithotomy position.
89472154|NCT05090462||Standard surgical dressings (Clearpore)|
89472155|NCT05090462||NPWT dressing (PICO)|
89019348|NCT04715841||group A|Group A (Study group ) : 25 adolescent females suffering patellofemoral pain syndrome were recruited from the outpatient clinic of the faculty of physical therapy delta university in addition to the medical diagnosis was confirmed by consultant orthopedist using clinical and radiographic investigations .
89019349|NCT04715841||group B|Group B (Control Group):25 adolescent females with healthy knee joints with no clinical and radiographic evidence of patellofemoral pain syndrome , were recruited from the students of the faculty of physical therapy delta university .
89472156|NCT04524429||Pre-operative Group|This is the group of participants who suffer from obesity and are awaiting bariatric surgery.
89472157|NCT04524429||Post-operative Group|This is the group of participants who suffer from obesity and have received bariatric surgery.
89472158|NCT02238457|Active Comparator|Low dose losartan|Low dose losartan
89472159|NCT02238457|Active Comparator|High dose losartan|High dose losartan
89472160|NCT04524039|Experimental|iTBS stimulation|iTBS stimulation to left dorsolateral prefrontal cortex (DLPFC), twice daily, 10 days
89472161|NCT04524039|Sham Comparator|sham iTBS stimulation|sham iTBS stimulation to left dorsolateral prefrontal cortex (DLPFC), twice daily, 10 days
89472162|NCT05090306||Pregnant women in their first and second trimester|Pregnant women in their first and second trimester will be examined using two-dimensional echocardiography of the fetal heart.
89472163|NCT03601195||Subjects|Chinese women carrying multiple pregnancies
89472164|NCT02238535|Active Comparator|Ventavis + Warfarin|Patients in this group will receive drug treatment - ventavis (2,0 ml - 6 time per day - during 5 days). Warfarin - INR=2,0-3,0
89472165|NCT02238535|Active Comparator|Warfarin|Patients in this group will receive drug treatment according to up-to-date guidelines (Warfarin - INR=2,0-3,0)
89019350|NCT02960711|Experimental|METFORMIN (1700MG/DAY) + LIFESTYLE|METFORMIN: 2 tablets per day, one at breakfast (or lunch) and one at dinner, of either metformin (two 850 mg tablets/day) + participation in the life-style intervention activities
89019351|NCT02960711|Placebo Comparator|PLACEBO+ LIFESTYLE|Placebo: (two identical tablets) according to the blind assignment + participation in the life-style intervention activities
89019352|NCT02960711|Experimental|METFORMIN (1700 mg/day) alone|METFORMIN: 2 tablets per day, one at breakfast (or lunch) and one at dinner, of either metformin (two 850 mg tablets/day)
89019353|NCT02960711|Placebo Comparator|PLACEBO alone|Placebo: (two identical tablets) according to the blind assignment
89472166|NCT05090228||PVR/PPVI|Adult patients with congenital heart disease (GUCH) undergoing pulmonary valve replacement (PVR) or percutaneous pulmonary valve insertion (PPVI).
89472167|NCT03362697|Experimental|Probiotic|5*10^8 CFU of Lactobacillus reuteri DSM 16666/ATCC 55845 & Lactobacillus reuteri DSM 17938, PAC-A and Zinc
89472168|NCT03362697|Active Comparator|Antibiotic|Amoxicillin + clavulanic acid (500 mg twice daily) for seven days in patients with negative nitrites in dipstick or oral nitrofurantoin (200mg twice per day) for patients with positive nitrates in dipstick
89472169|NCT03371199|Active Comparator|Sodium arm|Sodium tablets
89019354|NCT00306644|Experimental|Arm 1|study drug
89472170|NCT03371199|Placebo Comparator|Placebo arm|Placebo tablets
89202407|NCT00752492|Active Comparator|Study intervention|Patient will be disconnected from the anesthetic circuit and connected to the resuscitation bag attached to the IH system. Ventilation will be assisted to maintain tidal volume of 8-10 mL/kg and respiratory rate of 20-25 breaths per minute to achieve minute ventilation of 15-20 L/min. Isocapnia manifold will maintain end-tidal PCO2 in range of 40-50 mm Hg.
89472171|NCT05033600|Experimental|Interventional - PEMF Therapy Recipients|90-minute sessions rendered twice weekly over three consecutive weeks. PEMFs are administered through electrodes attached to wrists, ankles and forehead of participant.
89472172|NCT02851069||Participants with Hepatitis C Virus Genotype 1 (HCV + GT1)|ABBVIE REGIMEN (ombitasvir/paritaprevir/ritonavir [25 mg/150 mg/100 mg once daily] with or without dasabuvir [250 mg twice daily]), and with or without weight-based ribavirin (± RBV; dosed 1,000 or 1,200 mg daily divided twice a day) for 12 or 24 weeks in HCV + GT1 participants.
89472173|NCT03362619|Experimental|CC-EIEs|Autologous cervical cancer specific engineered immune effectors (EIEs)
89472174|NCT02518815|Experimental|Prewarming group|Prewarmed for 20 minutes prior to OR using 3M Bair Paws System, a forced air warming blanket. This warming blanket was then used intraoperatively throughout the case.
89472175|NCT02518815|No Intervention|Control group|Patients received standard care, which is no active prewarming prior to OR. A full body, forced air warming blanket (same as treatment group) was used intraoperatively throughout the case.
89019355|NCT00337389|Experimental|1|CoFactor, 5-FU, Avastin
89019356|NCT00337389|Active Comparator|2|Leucovorin, 5-FU, Avastin
89202408|NCT02554968||Study participants|Study participants will complete study related documents including a demographics questionnaire and the shoulder-related patient reported outcome measures.
89202409|NCT00790920|Experimental|Desmoteplase|
89202410|NCT00790920|Placebo Comparator|Placebo|
89202411|NCT02563262|Other|body angles measurements during weightlessness|body angles : ankle, knee, hip, shoulder, elbow, wrist, and neck.
89472176|NCT03909074|Experimental|Experimental group|36-71 months old children-experimental EV71 vaccine.
89019357|NCT00306839|Other|1|Tissel group
89472177|NCT03909074|Active Comparator|Vaccine-controlled group|36-71 months old children-control EV71 vaccine.
89472178|NCT03909074|Active Comparator|Age-controlled group|6-35 months old children-experimental EV71 vaccine.
89472179|NCT03138668|Experimental|Low dose Ropivacaine|Perineural injection of 8 ml of Ropivacaine 0.75% at the lateral femoral cutaneous nerve
89019358|NCT00306839|Other|2|Suture group
89019359|NCT04715724|Experimental|Baby doll with remote controlled jaw|In this arm, participants will complete a simulation using the Newborn Oral Assessment and Latch Simulator (NORALSim), which is designed to look, feel, and weigh like a healthy human newborn. The NORALSim's jaw can be remotely operated by the user to demonstrate attachment at the breast.
89472180|NCT03138668|Experimental|High dose Ropivacaine|Perineural injection of 16 ml of Ropivacaine 0.75% at the lateral femoral cutaneous nerve.
89472181|NCT03371121|Other|Chondro-gide - Geistlich|Arthroscopic use of chondro-gide to treat symptomatic osteochondral talar lesion
89472182|NCT03601039|Experimental|Absnow Absorbable ASD Closure System|All subjects are implanted with Absnow Absorbable ASD Occluder
89472183|NCT03371043||users of analgesic medications|Children and adolescents who are users of analgesic medications, 2012 to 2015
89472184|NCT05089994|Experimental|Group 1 (QLBA) will include 30 patients|will receive ultrasound-guided anterior approach quadratus lumborum block
89472185|NCT05089994|Experimental|Group 2 (QLBI)will include 30 patients.|received ultrasound-guided intramuscular quadratus lumborum.
89472186|NCT05089838|Experimental|CMV-TCR-T cells|Patients who enrolled will receive one dose of CMV-TCR-T cells. The dosage ranges from 0.3×10^6 to 1×10^7 TCR+T/Kg.
89472187|NCT03370965|Experimental|Patients with optic neuritis|
89019360|NCT04715724|Active Comparator|Baby doll with hand controlled jaw|In this arm, participants will complete a simulation using a cloth baby with a puppet-style jaw which can be opened and closed by the user to demonstrate attachment at the breast.
89019361|NCT04715724|Active Comparator|Static baby doll|In this arm, participants will complete a simulation using a rigid, plastic baby with a static, open mouth.
89019362|NCT00306956|Experimental|A|Recommendation to offer a pacifier to 15 days old newborn infants with successful breastfeeding
89472188|NCT05013242|Active Comparator|group use GnRH|GnRH (zoladex 3.75mg) injection once every 4 weeks
89472189|NCT05013242|Active Comparator|Group use Visanne (dienogest 2mg) oral once daily for 12 weeks|Visanne (dienogest 2mg) oral once daily for 12 weeks
89472190|NCT03370887|Experimental|Low dose AZD8601 (3 mg)|8 patients will be randomised to receive 3 mg AZD8601
89019363|NCT00306956|Active Comparator|B|Recommendation not to offer a pacifier to normal newborn infant with successful breastfeeding at 15 days of age
89019364|NCT02960165|Experimental|Virtual interface group A|Older adults that started the practice on the virtual interface
89019365|NCT02960165|Experimental|Virtual interface group B|Older adults that started the practice on the virtual interface and then practiced on real task.
89019366|NCT02960165|Active Comparator|Real interface group A|Older adults that started the practice on the virtual interface
89019367|NCT02960165|Active Comparator|Real interface group B|Older adults that started the practice on the real interface and then practiced on virtual task.
89019368|NCT00307190||Binge Eating Disorder|Women with Binge Eating Disorder
89019369|NCT00307190||Controls|Weight, age, and gender-matched control subjects
89019370|NCT04717856|Other|drug users|
89019371|NCT04715607|Active Comparator|Nasopharyngeal swab, oropharyngeal swab, and salvia collection|"The participants will first be tested with nasopharyngeal swabs followed by oropharyngeal swab and saliva collection.~The collection material, virus transport medium and laboratory equipment for each method is the same in both arms"
89472191|NCT03370887|Experimental|High dose AZD8601 (30 mg)|8 patients will be randomised to receive 30 mg AZD8601
89472192|NCT03370887|Placebo Comparator|Placebo|8 patients will be randomised to receive placebo injections
89472193|NCT03590509|Experimental|Telemedicine Program*|"Integrated Telemedicine-Home Visitation* Program.~*After the approval of the study protocol, the home-visitation component of the integrated intervention was deemed not to be feasible with the available resources and personnel and has was not implemented"
89472194|NCT03590509|Active Comparator|Control|Usual Comprehensive Care
89472195|NCT03358173||Conservative Treatment|Standard protocol for conservative treatment will consist of the implementation of a sling and patient comfort. Pendulum or gentle Range of Motion (ROM) shoulder exercises may be implemented at any time as dictated by the attending surgeon.
89472196|NCT03358173||Operative Plate Fixation|The operating surgeon will determine the positioning of the patient for surgery. ORIF of the humeral shaft fracture will be carried out
89472197|NCT05005832||People participating in the walking pilgrimage|People taking part in the study will be healthy people without any existing systemic diseases and musculoskeletal injuries, and will not engage in professional physical activity. The age of the respondents will be in the range of 18-65 years and BMI in the range of 18-39. People who have valid medical examinations will be admitted to the tests, with no contraindications to physical activity.
89472198|NCT03362463||Acute Coronary Syndrom|acute coronary syndrome in a real-life setting for patients hospitalized with an ACS (i.e. STEMI, NSTEMI, unstable angina)
89472199|NCT04993898|Experimental|Plyometric training with warm up and cool down|"Plyometric training will include following exercises.~Squat to Squat Jump~Lunge to Plyo Lunge~Step Jack to Star Jumps~Plank to Plyo Spider Lunge~Plank to Frogger"
89472200|NCT04993898|Active Comparator|Conventional training with warm up & cool down|"Conventional training will include following exercises.~Squats~Single leg squat~Cork hip lift~Press ups"
89472201|NCT03370731|Experimental|Adenotonsillectomy|Surgical management, i.e. adenotonsillectomy, including adenoidectomy, tonsillectomy or adenoidectomy combined tonsillectomy
89472202|NCT03370731|Other|Nonsurgical management|Nonsurgical management, including nasal irrigation, inhaled corticosteroids etc.
89472203|NCT05089448|Active Comparator|The morning dosing group|After randomization, subjects will take alisartan 120 mg (Salubris, Shenzhen, China) once daily at 6:00-10:00. After 8 weeks of treatment, if the 24-hour ambulatory systolic BP remained ≥ 130 mmHg, alisartan will be doubled to 240mg. After 16 weeks of treatment, if the 24-hour ambulatory systolic BP remained ≥ 130 mmHg, amlodipine besylate 2.5 mg (Dawnrays, Suzhou, China) once daily will be added. The whole treatment duration will last for 24 weeks.
89472204|NCT05089448|Experimental|The bedtime dosing group|After randomization, subjects will take alisartan 120 mg once daily at 20:00-24:00. The follow-up plan is the same as the morning dosing group.
89472205|NCT03358095|No Intervention|Early surgery|Patients in this group proceed to pancreatic resection within 2 week of recruitment.
89472206|NCT03358095|Active Comparator|Preoperative biliary drainage|Endoscopic retrograde cholangiopancreatography (ERCP) is used to place an endoprosthesis to the biliary ducts to drain biliary stasis, and the patients proceed to pancreatic resection within 6 weeks of recruitment.
89472207|NCT04971122|Other|Trendeleburg -5 degree group,-10 degree group,-15 degree group|Norepinephrine was continuously pumped at 0.5ug/kg/min
89472208|NCT04955132|Experimental|E-learning|Participants (parents of food-allergic children) will use an E-learning platform on food allergies for one month.
89472209|NCT04955132|No Intervention|Standard care|Participants (parents of food-allergic children) will receive standard allergist consulting.
89472210|NCT04935944||Tube potential difference (FOV)|Using different FOV and mA values of the CBCT machine
89472211|NCT05088824||patients diagnosed with oblique inguinal hernia|
89472212|NCT03362385||OSA|
89472213|NCT03362385||Non-OSA|
89472214|NCT04918160||Conference Attendees|"Volunteering healthcare practitioners (medical doctor, nurse, nurse assistant, physiotherapist and psychotherapist) attending the FICS annual congress will be proposed to participate to the study.~After giving their consent, participants will be asked to perform a COVID-19 antigenic screening self-test at day 7 (+/- 1) of the last day of the meeting (June 11th 2021) and to fill a questionnaire at day 21 of the last day of the meeting (June 11th 2021)."
88948884|NCT05621018|Active Comparator|Control group|Patients will be introduced to Maze Out. 15 weeks later they will follow the same procedure as intervention group.
88948885|NCT05619146|Experimental|SCI subject|Subject with SCI
88948886|NCT05617625|Experimental|CD34+ Peripheral Blood Progenitor Cell (PBSC) Transplant with Busulfan/Melphalan/Fludarabine Regimen|"Cytoreduction therapy:~0.8 mg/kg q6h x 12 doses busulfan via IV injection~70 mg/m^2/day x 2 days melphalan via IV infusion over 30 minutes~25 mg/m^2/day x 5 days fludarabine vis IV infusion over 30 minutes~CD34+ selected, T-cell depleted, allogeneic PBSC transplant using CliniMACS system to select CD34+ cells"
88948887|NCT05612061|Experimental|Treatment Group|Receives Indigenous Recovery Planning (IRP) intervention, which includes 6 weekly group intervention sessions lasting about 2 hours each.
88948888|NCT05612061|No Intervention|Waitlist Control Group|Participants in the waitlist control group do not receive the intervention until after treatment group completes the intervention. Outcomes will be compared between the 2 study arms at baseline and at follow-up, at which point the treatment group will have completed the intervention and the waitlist control group will have not yet been exposed to the intervention, thereby serving as the control group.
88948889|NCT05597748|Active Comparator|Class II type A malocclusion - proclination of upper incisors indicated - No TADs|A hybrid Herbst appliance approach will be used (current available conventional treatment). The upper jaw component will be a maxillary expander secured on the first molar bands. The lower arch would have an uncemented lower acrylic full-coverage splint-type. In between Herbst-type pistons will be used. Upper brackets will be initially bonded and upper incisors proclined until normal inclination values are attained.
88948890|NCT05597748|Active Comparator|Class II type B malocclusion - proclination of upper incisors not indicated - No TADs|A hybrid Herbst appliance approach will be used (current available conventional treatment). The upper jaw component will be a maxillary expander secured on the first molar bands. The lower arch would have an uncemented lower acrylic full-coverage splint-type. In between Herbst-type pistons will be used.
88948891|NCT05597748|Experimental|Class II type A malocclusion - proclination of upper incisors indicated - TADs|A modified hybrid Herbst appliance approach (same hybrid Herbst appliance approach but with the addition of temporary anchorage devices (TADs) in both arches) will be used (alternative treatment). In the upper arch, the TADs would be inserted in the paramedical palatal area. In the lower arch, they would be inserted buccally between the roots of the lower second premolar and the first permanent molar. Elastomeric chains will be used to link these TADs to the first molars in the upper arch and to a buccal bottom on the lower canines. Upper brackets will be initially bonded and upper incisors proclined until normal inclination values are attained.
88948892|NCT05597748|Experimental|Class II type B malocclusion - proclination of upper incisors not indicated - TADs|CA modified hybrid Herbst appliance approach (same hybrid Herbst appliance approach but with the addition of temporary anchorage devices (TADs) in both arches) will be used (alternative treatment). In the upper arch, the TADs would be inserted in the paramedical palatal area. In the lower arch, they would be inserted buccally between the roots of the lower second premolar and the first permanent molar. Elastomeric chains will be used to link these TADs to the first molars in the upper arch and to a buccal bottom on the lower canines.
89472215|NCT04918160||Controls|"Volunteering healthcare practitioners (medical doctor, nurse, nurse assistant, physiotherapist and psychotherapist) not attending the FICS annual congress will be proposed to participate to the study. They will be recruited in the same medical departments as the Conference Attendees.~After giving their consent, controls will be asked to perform a COVID-19 antigenic screening self-test at day 7 (+/- 1) of the last day of the meeting (June 11th 2021) and to fill a questionnaire at day 21 of the last day of the meeting (June 11th 2021)."
88948893|NCT05595551|Experimental|"The intervention Aan Tafel in 1, 2, 3 euro"|The participants use the intervention program: the recipe booklets and the provided price guarantee for their meals.
88948894|NCT05595551|No Intervention|Control group|The participants are not registered to use the program and will be recruited in social organizations to match their sociodemographic profile as much as possible.
88948895|NCT05593770|Experimental|Fostamatinib|An investigational oral spleen tyrosine kinase inhibitor.
89472216|NCT03362307|Active Comparator|Laser Emitting group|subjects received Low-Level Laser and Light-Emitting Diodes after implant placement
89472217|NCT03362307|Placebo Comparator|Non Emitting group|In laser emitiiing group, subjects received Low-Level Laser and Light-Emitting Diodes after implant placement and in Non-emitting group,the same device was used while device was off.
89472218|NCT04445181||Patients with T2D|Active patients (defined as patients seen by an LMC endocrinologist between January 1, 2019 and December 31, 2019) with T2D (Type 2 Diabetes). Among the patients with T2D, those identified with CKD will be included in the renal registry.
89472219|NCT04445181||Healthcare providers|Healthcare providers caring for patients with CKD and T2D.
89472220|NCT05088590|Experimental|Growing Up Formula (GUF)|
88948896|NCT05593770|Placebo Comparator|Placebo|"Orange film-coated, plain, bioconvex tablets for fostamatinib.~For the purposes of interim and final analyses, the route and frequency of placebo will be ignored, and all placebo participants will be pooled together as a single group. In comparing an active drug versus placebo, only those placebo participants that were eligible for the active drug will be included."
88948897|NCT05555017|Active Comparator|Arm A: ADT|Patients in arm A will receive standard 6 months of ADT according to current clinical guidelines.
88948898|NCT05555017|Experimental|Arm B: ADT + PSMA radioguided surgery|Patients in arm B will receive standard 6 months of ADT according to current clinical guidelines, and will undergo 99mTechnetium (99mTc)-based PSMA-radioguided salvage surgery.
89472221|NCT05088590|Active Comparator|Standard Nutritional Supplement (NS)|
89472222|NCT02849509||Switch Patients / A|Patients with non-valvular atrial fibrillation (NVAF), currently on Vitamin K Antagonist (VKA) therapy, who are switched to Pradaxa.
89472223|NCT02849509||New Patients / B|Newly diagnosed NVAF patients who are treated with VKA or Pradaxa (VKA : Pradaxa = 1:1).
89472224|NCT03362229|Active Comparator|FIXATION|Medial malleolus fixation, with the method of fixation left to the surgeons discretion.
89472225|NCT03362229|Active Comparator|NON-FIXATION|A well reduced medial malleolus fracture is then left without fixation ie, non-operative management.
89472226|NCT00151424|Experimental|1|asenapine 5-10mg BID
89472227|NCT00151424|Placebo Comparator|2|Placebo
88948899|NCT05540275|Experimental|Cohort 1|Patients with bevacizumab-refractory recurrent glioma with PTEN or TERT gene mutations,determined according to the dynamics of TISF (Tumor in Situ Fluid) ctDNA.
88948900|NCT05540275|Experimental|Cohort 2|Patients with bevacizumab-refractory recurrent glioma without PTEN or TERT gene mutations,determined according to the dynamics of TISF (Tumor in Situ Fluid) ctDNA.
88948901|NCT05539391|Experimental|Treatment group|Combination rapid sequence intubation (RSI) with use of rocuronium and the bag-mask ventilation between induction and Gum Elastic Bougie GEB will be systematically used at the first attempt to facilitate intubation.
88948902|NCT05539391|Active Comparator|Control Group|Physicians will be reminded of the current recommendations for emergency intubation: Rapid sequence intubation (RSI) using succinylcholine and use of GEB to facilitate intubation in case of intubation failure under direct laryngoscopy.
88948903|NCT05535257|Experimental|Sequential Compression Device (SCD) on upper extremity|Subjects post stroke with upper extremity weakness have the SCD sleeve placed on the arm for up to 4 hours for one day only
89472228|NCT00151424|Active Comparator|3|olanzapine 10-20 mg QD
88948904|NCT05534750|Experimental|Tedizolid arm|Patients will be taken 1 tablet per day of 200 mg film-coated of Tedizolid (SIVEXTRO®), in the morning for 7 days. Then, the early bactericidal activity will be measured and compared to the other arms.
88948905|NCT05534750|Experimental|Linezolid arm|Patients will be taken 2 tablets per day of 600 mg film-coated of Linezolid (ZYVOXID®) in the morning for 7 days. Then, the early bactericidal activity will be measured and compared to the other arms.
89019372|NCT04715607|Active Comparator|Oropharyngeal swab, salvia collection, and nasopharyngeal swab|"The participants will first be tested with oropharyngeal swabs followed by saliva collection and nasopharyngeal swab.~The collection material, virus transport medium and laboratory equipment for each method is the same in both arms"
89019373|NCT04715607|Active Comparator|Salvia collection, nasopharyngeal swab, and oropharyngeal swab|"The participants will first be tested with saliva collection followed by nasopharyngeal swab and oropharyngeal swabs.~The collection material, virus transport medium and laboratory equipment for each method is the same in both arms"
89019374|NCT00340626||Control|healthy individuals with no history of oral cleftsto serve as controls
89019375|NCT00340626||Oral Cleft Family Members|individuals with unilateral or bilateral cleft lip with or without cleft palate and their unaffected relatives
89472229|NCT03370653|Experimental|Double-blind - odiparcil 1000 mg per day|2 tablets of odiparcil 250 mg per os, twice daily (BID)
89472230|NCT03370653|Experimental|Double-blind - odiparcil 500 mg per day|1 tablet of placebo and 1 tablet of odiparcil 250 mg per os, twice daily (BID)
89019376|NCT00337701|Experimental|1|
89472231|NCT03370653|Placebo Comparator|Double-blind - placebo|2 tablets of placebo per os, twice daily (BID)
89472232|NCT03370653|Experimental|Open Label - odiparcil 1000 mg per day|2 tablets of odiparcil 250 mg per os, twice daily (BID)
89472233|NCT04705532|Experimental|tDCS/music|active tDCS combined with music
89472234|NCT04705532|Experimental|sham tDCS/music|Sham tDCS combined with music
89472235|NCT04705532|Experimental|tDCS/white noise|active tDCS combined with white noise
89472236|NCT04705532|Experimental|sham tDCS/white noise|sham tDCS combined with white noise
89472237|NCT03600727|Experimental|Propofol group|Patients in this arm will be sedated by propofol.
89472238|NCT03600727|Experimental|Dexmedetomidine group|Patients in this arm will be sedated by dexmedetomidine.
89472239|NCT03370575|Experimental|ethiodized poppyseed oil|
89472240|NCT03370575|Active Comparator|the second-generation non-ionic monomer contrast|
89472241|NCT03138200|Other|Blood transfusion based on central venous oxygen saturation|
89472242|NCT03362151|Experimental|Regular pasta|Subjects will bolus rapid acting insulin per their carbohydrate ratio just prior to a meal of regular pasta. They will consume this meal on two separate occasions.
89472243|NCT03362151|Experimental|High protein pasta|Subjects will bolus rapid acting insulin per their carbohydrate ratio just prior to a meal of high protein pasta. They will consume this meal on two separate occasions.
89472244|NCT03362151|Experimental|White rice|Subjects will bolus rapid acting insulin per their carbohydrate ratio just prior to a meal of white rice. They will consume this meal on two separate occasions.
89472245|NCT03527654||Hispanic Immigrants|
89472246|NCT03584971||female patients|women in fertility treatment according to Long GnRH Agonist Protocol
89472247|NCT03584971||control group|random sample of male students
89472248|NCT04522011||Group A|D1/2 radical gastrectomy combines intraoperative hyperthermic intraperitoneal chemotherapy with docetaxel + oxaliplatin
89472249|NCT04522011||Group B|D1/2 radical gastrectomy combines postoperative hyperthermic intraperitoneal chemotherapy with docetaxel + oxaliplatin
89472250|NCT04522011||Group|without hyperthermic intraperitoneal chemotherapy
89472251|NCT03370497|Active Comparator|Whey protein hydrolysate|Whey protein hydrolysate (50 g) will be consumed by participants in the morning between 8-10 am after 8-14 h fasting. Blood samples, appetite scales and expired breath samples will be taken in a regular intervals for 2 h after ingestion.
89472252|NCT03370497|Experimental|Whey protein hydrolysate plus milk mineral supplement|Milk mineral supplement (equating to 1000 mg calcium) plus whey protein hydrolysate (50 g) will be consumed by participants in the morning between 8-10 am after 8-14 h fasting. Blood samples, appetite scales and expired breath samples will be taken in a regular intervals for 2 h after ingestion.
89472253|NCT03584893||Epidemiologic observational study cohort|All patients over 1 year old diagnosed as idiopathic bilateral juvenile cataracts will be included in the study at the study sites.
89472254|NCT03442946||INS|Patients in need of a cardiovascular surgery will be included in this observational study. The focus is on the nutrition therapies provided to these critically ill patients according to institutional or international nutrition guidelines, what ever applies for the participating sites.
89472255|NCT03357705|Experimental|synthetic|alveolar ridge preservation with synthetic bone
89472256|NCT03357705|Active Comparator|collagen|alveolar ridge preservation with bovine collagen
89472257|NCT03359642|Experimental|Patients with anti-TNF alpha|12 spondyloarthritis and 24 inflammatory bowel diseases patients (12 Crohn's disease and 12 ulcerative colitis), in which a first anti-TNF alpha treatment is indicated.
89472258|NCT03359642|Active Comparator|mirror group|"A mirror group of 12 spondyloarthritis and 24 inflammatory bowel diseases patients (12 Crohn's disease and 12 ulcerative colitis), in which an all but anti-TNF alpha or biotherapy treatment is indicated will be included to distinguish the specific effects on microbiota of anti-TNF alpha."
89472259|NCT03584581|Experimental|Olive polyphenols|
89472260|NCT03584581|Placebo Comparator|Control|
89472261|NCT04522245|Placebo Comparator|Control|Matched control group (Noom-branded 'healthy eating' short guide on weight loss).
89472262|NCT04522245|Experimental|Noom Health Weight Program|
89472263|NCT03362073|Experimental|Ketamine|continuous intravenous infusion of ketamine
89472264|NCT03584269|Experimental|NIV Device + LTOT|administration of ventilary support, without using an invasive artificial airway
89472265|NCT03584269|Active Comparator|LTOT|standard treatment, without NIV
89472266|NCT03325634|Experimental|Treatment (SBRT)|Patients undergo Stereotactic Body Radiation Therapy (SBRT) every other day for 3 fractions.
89472267|NCT03312842|Experimental|CS1001|
89472268|NCT03584191||People with Obesity|General population - potential participants will be recruited using various and numerous general population as appropriate in each country.
89472269|NCT03584191||Health Care Professionals|Health Care Professionals include primary care physicians and specialists who treat patients with obesity.
89472270|NCT04523805|Experimental|AUTJUDO-O1|"The judo sessions are performing in a large and well-ventilated space suitable for athletic activities in general and for judo in particular, such that the safety of the participants was maintained. Each participant is outfitted with a judogi (a traditional uniform consisting of a cotton jacket and trousers and a belt).~The sessions are 75 minutes in duration and were held once a week. Two judo teachers, with degrees in pedagogy and sports sciences and 7th and 6th degree black belts, respectively, led each session, and at least four volunteer judo instructors are present to lend support. The sessions are divided into warm-up, main exercise and cool-down activities. The instructional methodology apply the principles of gradual progression and the main exercise content of the sessions includes: different types of movements and falling techniques, ground control techniques, judo techniques and games."
89472271|NCT02238613|Experimental|radioactive stent|The radioactive stent carrying seeds iodine 125 is made of Polytetrafluoroethylene. It will be implanted in the common bile duct by ERCP(endoscopic retrograde cholangiopancreatography) of the irradiation group patients.
89472272|NCT02238613|Other|plastic stent|The plastic stent is made of polyethylene. It will be implanted in the common bile duct by ERCP(endoscopic retrograde cholangiopancreatography) of the conventional group patients.
89472273|NCT03361995|Experimental|Cooling + PCI|The subjects will be considered to be enrolled in the Test Arm of the trial when all inclusion and exclusion criteria have been met, the informed consent form has been signed, and randomization to the Test Arm of the trial to allow cooling with the Thermogard XP3 IVTM System before and after PCI.
89472274|NCT03361995|Active Comparator|PCI only|The subjects will be considered to be enrolled in the Control Arm of the trial when all inclusion and exclusion criteria have been met, the informed consent form has been signed, and randomization to the Control Arm of the trial to allow PCI only.
89019377|NCT00337701|Experimental|2|
89472275|NCT03357549|Experimental|Brief Motivational Intervention|The women of this group will receive a Brief Motivational Intervention during 20 or 30 minutes.
89472276|NCT03357549|Active Comparator|Breastfeeding education|The women of this group will receive a standard education about breastfeeding during 20-30 minutes
89472277|NCT03582865||responding|patients who received Tamoxifen 20 mg daily for at least 3 years with good response (no relapse) to tamoxifen. Both genotyping assessment and TDM of tamoxifen and its metabolites will be performed and correlated with the records. Follow up for these patients for further assessment of tamoxifen effectiveness will be carried out for 1- 2 years.
89472278|NCT03582865||relapse|patients who received Tamoxifen 20 mg daily for at least 3 years who were good responder to the drug but then the response has been diminished (relapse) and they have been shifted to another therapy. They will be exposed to genotyping study of CYP 2D6 to recognize the phenotyping style of that patient that may explain diminishing of response to tamoxifen therapy.
89472279|NCT03582865||tamoxifen resistant|patients who received Tamoxifen 20 mg daily for not more than 1 year with poor response to tamoxifen (early relapse) and clinically will be shifted to use another medication as they were diagnosed as tamoxifen resistant. Like the second group, they will be exposed to genotyping study of CYP2D6 with the same concept.
89472280|NCT03136250|Active Comparator|Group A (Control Group - Static Stretching)|(Control Group - Static Stretching + Standard Treatment)
89472281|NCT03136250|Experimental|Group B (Autogenic Inhibition MET)|(Autogenic Inhibition - PIR + Standard treatment)
89472282|NCT03136250|Experimental|Group C (Reciprocal Inhibition MET)|(Reciprocal Inhibition - RI + Standard treatment)
89472283|NCT04509375||Study Group|Premature babies in the first 28 postnatal days of life, with less than 32 gestational weeks or less than 1500 grams of birth weight, with documented anemia by current accepted transfusion guidelines of Turkish Neonatal Society
89472284|NCT03136406|Experimental|NANT Pancreatic Cancer Vaccine|"A combination of agents will be administered to subjects in this study:~cyclophosphamide, oxaliplatin, capecitabine, fluorouracil, leucovorin, nab-paclitaxel, bevacizumab, avelumab, ALT-803, aNK, GI-4000, and ETBX-011."
89472285|NCT03590197|Placebo Comparator|Control Arm|The patients in Control Arm will receive placebo with valproate (20 mg/kg).
89472286|NCT03590197|Experimental|Melatonin Arm|The Experimental Arm will receive tablet melatonin as an add-on to valproate. Melatonin will be prescribed 3 mg/day to the patients and will be advised to take 30 minutes before bedtime.
89472287|NCT04521465||NovaTears® + Omega-3|
89472288|NCT03136016|No Intervention|control|without any activity
89019378|NCT00307463|Active Comparator|strict volume control policy|strict volume control policy: Antihypertensive medicine will be stopped and strict volume control policy will be applied.
89019379|NCT00307463|Other|antihypertensive drugs administration|antihypertensive drugs administration: Antihypertensive medicine will be continued. Target BP will be 130/80 mmHg in both groups.
89202412|NCT03880214||stem cells transplanted pediatric patients|screen pediatric patients at least 3 months after they undergo allogeneic hematopoietic stem cells transplantation to detect any risk factors for developing oral manifestations of chronic graft -versus-host disease during this period
89202413|NCT04053218|Active Comparator|Exercise and supplement|Supervised aerobic exercise three times weekly and daily omega-3 supplements
89472289|NCT03136016|Experimental|educational activities|The students will receive educational activities in the classroom.
89472290|NCT03136016|Experimental|nudging|The students will receive changes in the school environment (nudge strategies);
89472291|NCT03136016|Experimental|nudging + educational activities|The students will receive educational activities and changes in the school environment.
89472292|NCT02035579|Experimental|Aerobic Training Intervention|Children with PCS who are eligible for the study will be randomized to a progressive, sub-symptom exacerbation, cycling aerobic training intervention or stretching comparison intervention. Children with PCS that meet criteria for the intervention trial will complete a baseline evaluation followed by a one week run-in-period (week 0-1) prior to their first intervention visit. After the initial intervention visit, weekly visits will be completed for at least 6 additional weeks (i.e., at least 6 weeks of aerobic training). An individualized home exercise program 5-6 days per week will also be developed. Children will be provided with a home stationary cycle to complete the home program.
89472293|NCT02035579|Experimental|Stretching Intervention|Children in the stretching intervention will complete a series of full body stretches of the shoulders, arms, chest, back, legs, and feet 5-6 days per week and will return weekly to review the stretching program. The minimum duration of the stretching intervention will also be 6 weeks
89202414|NCT04053218|Placebo Comparator|Placebo|Olive oil capsules. No supervised exercise but written recommendations for daily physical activity from the American Heart Association
89019380|NCT00421005|Experimental|1|Fluvastatin 80mg
89019381|NCT00421005|Active Comparator|2|Fluvastatin 20, tapered up according to LDL concentration
89019382|NCT00337896||observation|healthy adults ages 18-64 years, enrolled at Stanford University Hospital and participating in another clinical trial (DMID Protocol 04-062)
89019383|NCT00307502|Experimental|NVP|Nevirapine
89019384|NCT00307502|Experimental|EFV|Efavirenz
89019385|NCT00307502|Experimental|INV|Indinavir/ritonavir
89019386|NCT00307502|Experimental|NFV|Nelfinavir
89472294|NCT03357315|Experimental|Mix vaccine|In this group, the patients will receive mix vaccine. The check indexes are image examination (CT, MRI or PET scan) and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
89472295|NCT03357315|No Intervention|Control|In this group, the patients will receive no special treatment and as a control group. The check indexes are image examination (CT, MRI or PET scan) and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
89472296|NCT03135938|Active Comparator|Grading Inferior Oblique Anterior Transposition|in the classic group, IO muscle will be sutured to the sclera at the level of inferior rectus (IR) insertion at its temporal border, without considering the asymmetric DVD between the two eyes
89472297|NCT03135938|Active Comparator|Classic Inferior Oblique Anterior Transposition|in the grading group, IO muscle of the eye with more severe DVD will be sutured at the level of IR insertion and IO muscle of the eye with lower magnitude of DVD will be sutured 2mm posterior to the sclera to consider the preoperative DVD difference between the two eyes
89472298|NCT03582397|Experimental|Experimental|Subjects to receive virtual reality mirror therapy via WiseMind Software (Realiteer) 3x/week for 4 weeks.
89472299|NCT05057468|Experimental|Cyclosporine|2.5-5mg/kg of cyclosporine daily for 3 months
89472300|NCT05057468|Active Comparator|Rituximab|375 mg/ m2 weekly dose for a maximum of 4 weeks.
89472301|NCT03361839|Active Comparator|1|patients with RIF
89472302|NCT03361839|Placebo Comparator|2|fertile arm as r reference for result
89472303|NCT04509531|Experimental|Experimental: SA, ITP and Resilience|1 hour Wise intervention (based on SA, ITP and resilience) consisting on several tasks to be completed online individually.
89472304|NCT04509531|Other|Standard preventive intervention|1 hour educational intervention (about internet risks such as sexting and grooming) consisting on several tasks to be completed online individually.
89472305|NCT03296462|Experimental|Hip external rotation exercise (alone)|Standardised hip external rotation exercise training - over 12 week period
89472306|NCT03296462|Experimental|Hip external rotation + PFM exercises|Standardised hip external rotation plus pelvic floor muscle exercises - over 12 week period
89472307|NCT03296462|Active Comparator|pelvic floor muscle exercises (alone)|Standardised pelvic floor muscle exercises - over 12 week period (usual care)
89472308|NCT03600571|Experimental|AM groups in cadavers study|32 osteoarthritic knees of cadavers were randomly assigned to the AM group (injection medial from patella tendon towards intercondylar notch was performed with the target knee 90° flexion). Hyaluronic acid (HA) traced by methylene blue was injected into the knee, and the intra-articular distribution of HA was assessed using a five-point scale.
88948906|NCT05534750|Active Comparator|Standard quadruple therapy arm|"Patients will be taken :~ISONIAZIDE :~o A dosage of 3 to 5mg / kg / day for 7 days (to be taken in the morning on an empty stomach) of Isoniazid (RIMIFON®)~RIFAMPICINE :~o A dosage of 10mg / kg / day for 7 days (to be taken in the morning on an empty stomach)~ETHAMBUTOL :~o A dosage of 15-20mg / kg / day for 7 days (to be taken in the morning on an empty stomach) of Ethambutol~PYRAZAMIDE :~o A dosage of 20-25mg / kg / day for 7 days (to be taken in the morning on an empty stomach) of Pyrazinamide~Then, the early bactericidal activity will be measured and compared to the other arms."
88948907|NCT05526924|Experimental|Dose-Finding Group 1: Dose Level 1 (Part 1 of Study)|"The purpose of part 1 is to determine the best tolerated dose of study drugs with the least side effects. Dose escalation means that some participants will receive a different (higher) dose than other participants depending on when they join the study. This is to determine side effects at different doses and find a dose that will be safe to give to all participants. Participants in this group will receive:~One dose of tislelizumab (200 mg) 15 days before chemoradiotherapy (CRT) given intravenously (by IV), which means through a vein.~Chemoradiotherapy over a period of 5 weeks. During each cycle of CRT, participants will receive:~Pamiparib (20 mg daily on days 0-5 of each cycle) along with 5FU and hydroxyurea for 5 days.~Radiation will also be given two times a day for 5 days~After CRT, participants will rest for roughly 8 days without study drugs or radiation then they will receive tislelizumab (200 mg) for 12 months by IV over 30 minutes every 6 weeks."
89019387|NCT00307502|Experimental|SQV|Saquinavir/ritonavir
89019388|NCT00307502|Experimental|LPV|Lopinavir/ritonavir
89019389|NCT00307502|Experimental|ATV|Atazanavir
89472309|NCT03600571|Experimental|MMP groups in cadavers study|32 osteoarthritic knees of cadavers were randomly assigned to the MMP group (injection medial under horizontal patella midline was administrated with the lower limb extension). Hyaluronic acid (HA) traced by methylene blue was injected into the knee, and the intra-articular distribution of HA was assessed using a five-point scale.
89472310|NCT03600571|Experimental|AM groups in random controlled trial|50 patients with unilateral mKOA were enrolled and randomly into the AM group (injection medial from patella tendon towards intercondylar notch was performed with the target knee 90° flexion).The clinical outcomes of 5-weekly injections of HA were evaluated by WOMAC and Lequesne index. The follow-up times were at weeks 1, 2, 3, 4, 5, 14, and 24 after the injections.
89472311|NCT03600571|Experimental|MMP groups in random controlled trial|50 patients with unilateral mKOA were enrolled and randomly into the MMP group (injection medial under horizontal patella midline was administrated with the lower limb extension).The clinical outcomes of 5-weekly injections of HA were evaluated by WOMAC and Lequesne index. The follow-up times were at weeks 1, 2, 3, 4, 5, 14, and 24 after the injections.
89019390|NCT00307502|Experimental|ATV/rtv|Atazanavir/ritonavir
89472312|NCT02518503||High potency statin users|Exposure will be defined as a new prescription for a high dose statin (high doses of rosuvastatin, high doses of atorvastatin, and high doses of simvastatin) between 1 January 1997 and 31 March 2011, or 1 year after the beginning of data availability.
89472313|NCT02518503||Low potency statin users|Exposure will be defined as a new prescription for a low dose statin (all doses of fluvastatin, all doses of pravastatin, all doses of lovastatin; low doses of atorvastatin and simvastatin) between 1 January 1997 and 31 of March 2011, or 1 year after the beginning of data availability.
89472314|NCT03136874||Donors who procreated|
89472315|NCT03136874||Donors who don't procreated|
89472316|NCT02238691|Experimental|Mask ventilation with PEEP|15 subjects will undergo anesthetic induction with application of PEEP of 10 cm H2O during mask ventilation.
89472317|NCT02238691|No Intervention|Mask ventilation without PEEP|15 subjects will undergo anesthetic induction without PEEP during mask ventilation.
89019391|NCT00307502|Experimental|Fos-APV|Fos-amprenavir/ritonavir
89019392|NCT00307502|Experimental|TPV|Tipranavir/ritonavir
89019393|NCT00307502|Experimental|DRV|Darunavir/ritonavir
89019394|NCT00340860||Norweigian Population-Based Pregnancy Cohort|Norwegian-speaking pregnant women, their children born post enrollment, and enrolled children's fathers
89019395|NCT00340977||Case-Control Parent-Triad|Norwegian infants born with cleft lip or palate over a 5 year period
89019396|NCT00337974|Experimental|Experimental Treatment|Computerized Plasticity-Based Adaptive Cognitive Training
89019397|NCT00337974|Active Comparator|Active Control|Educational DVDs
89019398|NCT00337974|No Intervention|No Contact Control|
89019399|NCT00341016||Cohort of Chernobyl cleanup workers (liquidators) in Ukraine|Cases with leukemia and related diseases, and matched controls in the cohort
89019400|NCT04715919||Patients in ICU|ICU patients with COVID-19
89019401|NCT04715919||Patients in Hospital Ward|Patients with COVID-19 in hospital wards
89019402|NCT00307853|Active Comparator|1|TraumeelS
89019403|NCT00307853|Placebo Comparator|Placebo|
89019404|NCT00307892|Active Comparator|A|TRAUMEEL S
89019405|NCT00307892|Placebo Comparator|B|comparable placebo remedy (injection and oral)
89019406|NCT00308009|Active Comparator|1|Group I, Prolapse repair and TVT concomitantly
89019407|NCT00308009|Active Comparator|2|Group II, Prolapse repair and TVT 3 months afterwards if necessary
89019408|NCT00341094||Main UkrArm|Subjects exposed to I131 before the age of 18 years
89019409|NCT00341094||Ukraine in utero|Subjects exposed to I131 in utero
89019410|NCT00338130|Active Comparator|1|Temozolomide
89019411|NCT00338130|Experimental|2|AZD6244
89019412|NCT00308165|Experimental|Topotecan|Once a plastic catheter is placed, within 24 hours of placement, the catheter will be connected to a small pump at the bedside, and the convection-enhanced delivery of the Topotecan will begin. The Topotecan will be infused for 4 to 5 days after which time the catheters will simply be pulled out. Patients will be monitored with blood tests and MRI scans during the treatment and at different time periods during the following months.
89019413|NCT00338208|No Intervention|No training|Subjects will be fitted with low vision devices; no extra training will be provided.
89019414|NCT00338208|Experimental|Training in the Use of Low Vision Devices|Subjects will be fitted with low vision devices and will receive 6 training sessions with prescribed devices for up to 1 hour each time
89019415|NCT00418652|No Intervention|No TMS stimulation|The patients performed 2 tasks: a study and a control assignments with no TMS stimulation.
89019416|NCT00418652|Experimental|TMS over the dorsal stream|The patients performed 2 tasks: a study and a control assignments under TMS stimulation over the dorsal stream area (PO3 EEG site).
89019417|NCT00418652|Sham Comparator|TMS over the vertex|The patients performed 2 tasks: a study and a control assignments under TMS stimulation over the vertex area.
89019418|NCT00418769|Experimental|Nilotinib Tablet Formulations|
89019419|NCT00418769|Active Comparator|Established Nilotinib Capsule Formulation|
89019420|NCT00308204|Experimental|Raptiva|raptiva injection
89019421|NCT00425334|Experimental|Hemospan (MP4OX)|4.3 g/dL MalPEG-Hb solution
89019422|NCT00425334|Active Comparator|Control|Ringer's lactate
89019423|NCT04715802||PAAG removal + Immediate implant reconstruction|Patients who had a one-stage operation comprising gel removal and immediate breast reconstruction.
89019424|NCT04715802||PAAG removal + Delayed implant reconstruction|Patients who had a two-stage operation comprising gel removal and delayed breast reconstruction at least 3 months later. The first included maximal gel removal and purulent tissue debridement, if necessary. Thereafter, patients were invited for a clinical follow-up and discussion about DBR 3 months later. The latter was offered as a second stage in those opting for it.
89019425|NCT04715802||PAAG removal + No breast reconstruction|Patients who only underwent surgical PAAG removal without breast reconstruction.
89019426|NCT04715802||PAAG removal + Delayed autologous fat grafting reconstruction|Patients who underwent a two-stage operation comprising surgical PAAG removal and autologous fat injection at least 3months later. Usually, the amount of transplanted fat was 150-200mL/side. A multilayer and multi-tunnel injection method was commonly used.
89019427|NCT04715802||PAAG removal + breast reconstruction with implants|Patients who underwent surgical PAAG removal with immediate or delayed implant breast reconstruction.
89019428|NCT04715802||Primary breast augmentation with implants|Patients who had undergone conventional breast augmentation(BA) with implants during the study period who matched the study cohort by age(±5 years).
89019429|NCT00308438|Experimental|1|All subjects in the study dosed at 0.1 mg/kg teduglutide
89019430|NCT00338325|Experimental|Treatment|50% randomized to receive treatment: reading pre-operatively
89019431|NCT00338325|No Intervention|Control|50% randomized to receive no intervention pre-operatively: no reading
89019432|NCT00341328|Experimental|1|In one arm the patient will receive intradermal Mycobacterium W Vaccine along with Category I ATT drugs according to RNTCP guidelines
89019433|NCT00341328|Placebo Comparator|2|In this Arm patient will receive Placebo along with Category I ATT drugs according to RNTCP guidelines
89019434|NCT00338364|Experimental|Treatment|50% randomized to receive distraction during painful procedure
89019435|NCT00338364|No Intervention|Control|50% randomized to receive no distraction during painful procedure
89019436|NCT00308789|Experimental|1|Biphasic NCPAP
89019437|NCT00308789|Active Comparator|2|Continuous CPAP
89019438|NCT00341406||Healthy volunteers|healthy, non-overweight or other medical conditions
89019439|NCT00341406||Patients overweight|Those who are generally healthy but overweight
89019440|NCT00341406||Patients with health conditions|Those with diabetes and cardiovascular disease.
89019441|NCT00308906||1|Hospitalized, untreated infants and children
88948908|NCT05526924|Experimental|Dose-Finding Group 2: Dose Level 2 (Part 1 of Study)|"The purpose of part 1 is to determine the best tolerated dose of study drugs with the least side effects. Dose escalation means that some participants will receive a different (higher) dose than other participants depending on when they join the study. This is to determine side effects at different doses and find a dose that will be safe to give to all participants. Participants in this group will receive:~One dose of tislelizumab (200 mg) 15 days before chemoradiotherapy (CRT) given intravenously (by IV), which means through a vein.~Chemoradiotherapy over a period of 5 weeks. During each cycle of CRT, participants will receive:~Pamiparib (20 mg twice daily on days 0-5 of each 14 -day cycle) along with 5FU and hydroxyurea for 5 days.~Radiation will also be given two times a day for 5 days~After CRT, participants will rest for roughly 8 days without study drugs or radiation then they will receive tislelizumab (200 mg) for 12 months by IV over 30 minutes every 6 weeks."
89472318|NCT04509297|Experimental|High protein milk|Experimental: High protein milk consumption This arm involved High protein milk whole consumption concomitant with 6 weeks of resistance training. Subject ingested consumed 1 x 250 mL immediately after resistance training and 1 x 250 mL half an hour before bedtime.
89472319|NCT04509297|Placebo Comparator|Placebo|This arm involved consumption of a maltodextrin drink with a 9% solution with a vanilla flavor concomitant with 6 weeks of resistance training. Subject ingested consumed 1 x 250 mL immediately after resistance training and 1 x 250 mL half an hour before bedtime. drink r
89472320|NCT03600493|Active Comparator|Dexemetomidine|Dexmedetomidine 1 mcg/kg over 10 min followed by 0.4 mcg/kg/hr. till the start of wound closure.
89472321|NCT03600493|Active Comparator|Lidocaine|Lidocaine prepared in a syringe with the same volume of Dexmedetomidine to assure blinding given as 1mg/kg over 10 min followed by 1mg/kg/hr till the start of wound closure.
89472322|NCT03138356|Experimental|Cohort 1 Treatment A|"Single-dose of saxagliptin (2.5 mg), dapagliflozin (5 mg), metformin (1000 mg) XR (Extended-release) FDC (Fixed-dose combination) tablet administered orally under fasted condition. Within each cohort, subjects will be randomized to 1 of 6 treatment sequences, each subject will receive 3 single-dose treatments in either a fasted or fed-state.~The treatment sequences are (ABC), (ACB), (BAC), (BCA), (CAB) or (CBA)."
89472323|NCT03138356|Experimental|Cohort 1 Treatment B|"Single-dose of saxagliptin (2.5 mg), dapagliflozin (5 mg), metformin (850 mg) XR FDC tablet, administered orally under fasted condition. Within each cohort, subjects will be randomized to 1 of 6 treatment sequences, each subject will receive 3 single-dose treatments in either a fasted or fed-state.~The treatment sequences are (ABC), (ACB), (BAC), (BCA), (CAB) or (CBA)."
89472324|NCT03138356|Active Comparator|Cohort 1 Treatment C (Reference product)|"Single-dose of Onglyza® (2.5 mg saxagliptin), Forxiga® (5 mg dapagliflozin) and Glucophage XR® (2 x 500 mg metformin XR) co-administered under fasted condition. Within each cohort, subjects will be randomized to 1 of 6 treatment sequences, each subject will receive 3 single-dose treatments in either a fasted or fed-state.~The treatment sequences are (ABC), (ACB), (BAC), (BCA), (CAB) or (CBA)."
89472325|NCT03138356|Experimental|Cohort 2 Treatment D|"Single-dose of saxagliptin (2.5 mg), dapagliflozin (5 mg), metformin (1000 mg) XR FDC tablet administered orally under fed condition. Within each cohort, subjects will be randomized to 1 of 6 treatment sequences, each subject will receive 3 single-dose treatments in either a fasted or fed-state~The treatment sequences are (DEF), (DFE), (EDF), (EFD), (FDE) or (FED)."
89472326|NCT03138356|Experimental|Cohort 2 Treatment E|"Single-dose of saxagliptin (2.5 mg), dapagliflozin (5 mg), metformin (850 mg) XR FDC tablet, administered orally under fed condition. Within each cohort, subjects will be randomized to 1 of 6 treatment sequences, each subject will receive 3 single-dose treatments in either a fasted or fed-state.~The treatment sequences are (DEF), (DFE), (EDF), (EFD), (FDE) or (FED)."
89472327|NCT03138356|Active Comparator|Cohort 2 Treatment F (Reference Product)|"Single-dose of Onglyza® (2.5 mg saxagliptin), Forxiga® (5 mg dapagliflozin) and Glucophage XR® (2 x 500 mg metformin) co-administered under fed condition. Within each cohort, subjects will be randomized to 1 of 6 treatment sequences, each subject will receive 3 single-dose treatments in either a fasted or fed-state.~The treatment sequences are (DEF), (DFE), (EDF), (EFD), (FDE) or (FED)."
89472328|NCT03138356|Experimental|Cohort 3 Treatment G|"Single-dose dapagliflozin (5 mg) / metformin (1000 mg) XR FDC tablet administered orally under fed condition. Within each cohort, subjects will be randomized to 1 of 6 treatment sequences, each subject will receive 3 single-dose treatments in either a fasted or fed-state.~The treatment sequences are (GHI), (GIH), (HGI), (HIG), (IHG) or (IGH)."
89472329|NCT03138356|Experimental|Cohort 3 Treatment H|"Single-dose dapagliflozin (5 mg) / metformin (850 mg) XR FDC tablet administered orally under fed condition. Within each cohort, subjects will be randomized to 1 of 6 treatment sequences, each subject will receive 3 single-dose treatments in either a fasted or fed-state.~The treatment sequences are (GHI), (GIH), (HGI), (HIG), (IHG) or (IGH)."
89472330|NCT03138356|Active Comparator|Cohort 3 Treatment I (Reference Product)|"Single-dose Forxiga® (5 mg dapagliflozin) and Glucophage XR® (2 x 500 mg metformin) co-administered under fed condition. Within each cohort, subjects will be randomized to 1 of 6 treatment sequences, each subject will receive 3 single-dose treatments in either a fasted or fed-state.~The treatment sequences are (GHI), (GIH), (HGI), (HIG), (IHG) or (IGH)."
89472331|NCT03577951|Experimental|high position space group|The left and right Trocar meet at the level of the sternum angle and begin to establish the operating space.
89472332|NCT03577951|Experimental|low position space group|The left and right Trocar meet under the sternum angle and begin to establish the operating space.
89472333|NCT03137966|Active Comparator|Deferoxamine|Patients will be randomised to treatment with Deferoxamine (n=87). Deferoxamine (0.66mg/ml) will be applied locally as a gel (3 times a week) for a period of maximum three months or until intact skin.
89019442|NCT00308906||2|Aminoglycoside treated infants and children without renal injury
89019443|NCT00308906||3|Aminoglycoside treated infants with renal injury
89019444|NCT00308945|Experimental|2|cross-over comparison of two substances
89019445|NCT00308945|Experimental|1|
89019446|NCT00338481|Active Comparator|1|
89019447|NCT00338481|Active Comparator|2|
89019448|NCT00338520||Healthy Controls (HC)|Healthy control children will be enrolled from out-patient well-baby visits.
89472334|NCT03137966|Placebo Comparator|Placebo|Patients will be randomised to treatment with placebo (n=87). Placebo will be applied locally as a gel (3 times a week) for a period of maximum three months or until intact skin.
89472335|NCT02035657|Experimental|GLA-SE|Glucopyranosyl Lipid A in Stable Emulsion
89472336|NCT03577873|Placebo Comparator|gallbladder preserved|Patients with stones in their bile ducts and gallbladders will keep gallbladders in stay after clearance of bile duct stones with ERCP.
89472337|NCT03577873|Experimental|cholecystectomy|Patients with stones in their bile ducts and gallbladders will undergo cholecystectomy after clearance of bile duct stones with ERCP.
89472338|NCT03357237|Experimental|XYLOGLUCAN|treatment regimen with oral rehydration solution and xyloglucan
89472339|NCT03357237|Placebo Comparator|PLACEBO|rehydration solution and placebo.
89472340|NCT03138434||Optimization phase|The first five patients will be included for the optimization of the MRI sequences. This is to ensure that a standard protocol will work for different sizes of AAA. These patients will only be scanned once.
89472341|NCT03138434||Study phase|"This phase will commence after the optimization phase. This phase is where we want to assess the feasibility, reproducibility and association with disease severity between MRI parameters and AAA.~These twenty patients will be scanned twice, with an interval of 1 week ± 5 days.~The study will be completed when we have 20 patients with 2 scans for each sequence, or when a maximum number of 30 patients in the study phase have been scanned."
89472342|NCT04521387|Experimental|N1 Platelet Rich Plasma (PRP)|2ml of autologous platelet rich plasma injection
89472343|NCT04521387|Active Comparator|N2 Corticosteroid (CS)|2ml of 7mg Betamethasone injection
89472344|NCT04521387|Active Comparator|N3 Hyaluronic Acid (HA)|2ml of 40mg hyaluronic acid with mannitol injection
89472345|NCT04521387|Placebo Comparator|N4 Saline (NaCl)|2ml saline (0,9%NaCl) injection
89472346|NCT03579979|Experimental|Self control|"During the operation, with the fluorescent molecular imaging instrument, the imaging agent (indocyanine green) is illuminated by the probe distance to the tissue surface 10-30cm, and is excited to produce the near infrared fluorescence of the specific wavelength (the human eye is not visible). The system uses a photoelectric coupler to collect the light of the specific spectrum, and the image is collected by the method of correction. The operation was performed to achieve real-time display of lesions.~The injection points were selected subcutaneously around the areola or the periphery of the tumor. 1% methylene blue 0.5ml was injected at each point, with a total of 2-3 points. Within 5 minutes, 2.5mg/ml ICG 0.5ml was injected at each point, with a total of 2-3 points."
89472347|NCT04967612|Experimental|Virtual implantation of diffractive optical lens design A|
89472348|NCT04967612|Experimental|Virtual implantation of diffractive optical lens design B|
89472349|NCT04967612|Experimental|Virtual implantation of diffractive optical lens design C|
89472350|NCT03600415|Experimental|Order A|The participants will be tested in Zurich (Low altitude: 470m above sea level) and consecutively at High Altitude(Säntis; 2500m above sea Level)
89472351|NCT03600415|Experimental|Order B|The participants will be tested at High Altitude (Säntis; 2500m above sea level) and consecutively in Zurich (Low altitude; 470m above sea level).
89472352|NCT03361761||experimental|therapeutic coordination apartments with formalized/official Health education program
89472353|NCT03361761||active comparator|therapeutic coordination apartments without formalized/official Health education program
89472354|NCT04838444|Experimental|VLA1553|
89202415|NCT01060735|Experimental|Larger doses of vitamin D supplementation|The subjects enrolled in this arm will be supplemented during the third trimester of pregnancy with 2000IU vitamin D per day
89472355|NCT04509063|Other|Detailed information about screening harms|
89472356|NCT04509063|Other|Non-detailed information about screening harms|
89472357|NCT03600337|Experimental|Experimental Condition|Working to Optimize Wellness in Teens with PCOS
89472358|NCT03600337|No Intervention|Control Condition|Participants in this arm will receive treatment as usual and will be given the intervention after 1 month assessments are completed for the intervention group
89472359|NCT03601559|Active Comparator|Lactobacillus paracasei Lpc-37|Probiotic
89472360|NCT03601559|Placebo Comparator|Placebo|Inert placebo
89472361|NCT03577717|Experimental|computerized cognitive training|"participants will be trained by the Cookies for the brainy day, including memory, attention, calculation, executive functions, and language training."
89472362|NCT03577717|Active Comparator|occupational therapy|participants will receive craft activities of occupational therapy, such as weaving, origami etc.
89472363|NCT03110588|Experimental|PACE with Cabazitaxel @ 15 mg/m2|The drugs to be administered are: prednisone 5 mg orally twice daily, abiraterone 1000 mg orally once daily, enzalutamide 160 mg orally once daily, and cabazitaxel intravenous infusion at 15 mg/m2 every 3 weeks.
89472364|NCT03110588|Experimental|PACE with Cabazitaxel @ 20 mg/m2|The drugs to be administered are: prednisone 5 mg orally twice daily, abiraterone 1000 mg orally once daily, enzalutamide 160 mg orally once daily, and cabazitaxel intravenous infusion at 20 mg/m2 every 3 weeks.
89472365|NCT04509141|Active Comparator|acupuncture|acupuncture three times a week
89472366|NCT04509141|Active Comparator|standard treatment for migraine by neurologist|standard treatment for migraine that was given by a neurologist
89472367|NCT03604133||Patients receiving ICD devices|
89472368|NCT03604055|Other|Endobronchial hamartomas treatment|After removal of endobronchial lesions, cryotherapy is applied to the area of origin. Recurrences are followed. Recurrences are recorded as poor results, compared with good results.
89472369|NCT04509219|Experimental|Participants treated with MP pulse|Selected participants will be given MP pulse treatment
89472370|NCT04524182|Other|control group|There was no intervention in the control group during the study (At the end of study all patients were received home-based exercise)
89472371|NCT04524182|Experimental|mobilization group|"Lumbo-sacral mobilization was applied to the mobilization group. Lumbo-sacral mobilization techniques were applied for 10 minutes to lumbo-sacral region in the supine position.~(At the end of study all patients were received home-based exercise)"
89472372|NCT04444635|Active Comparator|Serratus Anterior Plan block plus fentanyl infusion|The patients will receive serratus anterior block in addition to continous intraoperative fentanyl infusion.
89472373|NCT04444635|Active Comparator|Fentanyl infusion only|The patient will receive fentanyl infusion only.
89472374|NCT03577561|No Intervention|Control group A|Control group A: 1 -year historical data (2016/2017) The blood sampling error rate in the interns receiving proficiency based progression training in 2018 will be compared to historical data on doctors who would have received whatever training they would normally undergo as a part of their existing training program. It will not differ from what they would normally receive at that institution.
89472375|NCT03577561|Active Comparator|Control Group B|Control group B (2017/2018) In a pilot project in July 2017, 46 interns received the phlebotomy proficiency based progression training at CUH. The error rates in the interns in 2017 will be compared to the newly trained interns in 2018 to determine the effectiveness of the training over time. The intervention is the proficiency based progression training programme in phlebotomy.
89472376|NCT03577561|Active Comparator|Interventional Group|"The blood sampling error rate of doctors in training provided with the intervention i.e. improved proficiency based progression training programme will be analysed from July 10th 2018 until the study ends.~The proficiency based progression training will consist of an online eLearning module to teach the doctors the correct process to take blood in the hospital. The doctors will then have to attend a face to face training day on a simulation ward where they will be asked to take blood according to a metric of 77 steps with less than 13 errors and no critical errors. Finally, the doctors will be observed taking blood on the ward and again must take it to a proficient standard."
89472377|NCT03601403|No Intervention|CONTROL GROUP|Received the standard medical and pharmacological care provided by the hospital
89472378|NCT03601403|Experimental|Inhaler technique|The intervention group received the standard medical and pharmacological care provided by the hospital. In addition, a tablet-assisted training on the use of inhalers, which included an explanation of the use of inhalers together with a ventilatory re-education program.
89472379|NCT04443621||participants with early stage dementia|Subjects with diagnosed any type of dementia at an early phase (MMSE score 20 - 25 points) - for longitudinal study (three phasis).
89472380|NCT04443621||participants without dementia|Subjects without dementia with MMSE score 26 - 30 points (for validation of ACE-III).
89472381|NCT03603821||LUTS male|Clinical assesment of males older than 50 years with lower urinary tract symptoms presumably related to benign prostate enlargement
89472382|NCT03361683|Experimental|High-flow nasal oxygen|Randomized patients will receive oxygen through a high flow nasal device capable of delivering humidified, heated air at an output rate of 40 L/min
89472383|NCT03361683|Active Comparator|Conventional oxygen|Randomized patients will receive oxygen through a Venturi mask at an air flow of 15 L/min
89472384|NCT03579823|Experimental|AVT02 100 MG/ML|Single subcutaneous injection of 40 mg of AVT02 (100MG/ML)
88948909|NCT05526924|Experimental|Dose-Finding Group 3: Dose Level 3 (Part 1 of Study)|"The purpose of part 1 is to determine the best tolerated dose of study drugs with the least side effects. Dose escalation means that some participants will receive a different (higher) dose than other participants depending on when they join the study. This is to determine side effects at different doses and find a dose that will be safe to give to all participants. Participants in this group will receive:~One dose of tislelizumab (200 mg) 15 days before chemoradiotherapy (CRT) given intravenously (by IV), which means through a vein.~Chemoradiotherapy over a period of 5 weeks. During each cycle of CRT, participants will receive:~Pamiparib (40 mg twice daily on days 0-5 of each 14 -day cycle) along with 5FU and hydroxyurea for 5 days.~Radiation will also be given two times a day for 5 days~After CRT, participants will rest for roughly 8 days without study drugs or radiation then they will receive tislelizumab (200 mg) for 12 months by IV over 30 minutes every 6 weeks."
88948910|NCT05526924|Experimental|Dose Expansion Group ( Part II of Study)|Part 2 (dose expansion phase): The purpose of this part is to continue to evaluate the dose of study drugs that is the best tolerated and has the least side effects. This part will start once the dose is selected from part 1. Enrollment in this part of the study is dependent on when participants join the study. Approximately 18 subjects will be enrolled in Part 2.
89472385|NCT03579823|Active Comparator|Adalimumab 100 MG/ML [HUMIRA]|Single subcutaneous injection of 40 mg of Adalimumab (100MG/ML) [HUMIRA]
89472386|NCT04444011|Experimental|Anaprazole Sodium enteric-coated tablet|Administered orally twice daily (e.g., 8am,8pm) for 5 consecutive days in 1 of 4 treatment periods of cohort 1 ( only once on the morning of D5 of treatment periods), one tablet each time.
88948911|NCT05517122|Experimental|Nicotinamide (NAM)|
88948912|NCT05517122|Experimental|Nicotinamide Riboside (NR)|
88948913|NCT05517122|Experimental|Nicotinamide Mono Nucleotide (NMN)|
88948914|NCT05517122|Placebo Comparator|Microcrystalline cellulose|
88948915|NCT05516940||Caesarean-section|125 subjects will be selected who have delivered infants by Caesarean-section.
88948916|NCT05516940||Normal delivery|125 subjects will be selected who have delivered infants by vaginal/normal deliveries
88948917|NCT05515991|Experimental|SUPPORT-DIALYSIS with Access to Output Report and Information Hub|Feasibility of SUPPORT-Dialysis at Toronto General Hospital
88948918|NCT05515991|Experimental|SUPPORT-DIALYSIS Only|Usual Treatment at Humber River Hospital
88948919|NCT05515575|Experimental|Niraparib|This study will utilize Simon's two-stage design: 16 patients will be enrolled in the first portion of this study. If 4 or more patients are progression-free at 12 weeks, an additional 16 patients will be enrolled for a total of n = 32 patients enrolled.
88948920|NCT05501366|Experimental|BHB Mono-ester 180mg/kg|
88948921|NCT05501366|Experimental|BHB mono-ester 360mg/kg|
89472387|NCT04444011|Experimental|Amoxicillin capsules|"Administered orally twice daily (e.g., 8am,8pm) for 5 consecutive days in 1 of 4 treatment periods of cohort 1 ( only once on the morning of D5 of treatment periods), 2 capsules each time."
88948922|NCT05501366|Experimental|C8 Ketone Di-ester 180mg/kg|
89472388|NCT04444011|Experimental|Clarithromycin tablet|"Administered orally twice daily (e.g., 8am,8pm) for 5 consecutive days in 1 of 4 treatment periods of cohort 1 ( only once on the morning of D5 of treatment periods), 2 tablets each time."
89472389|NCT04444011|Experimental|Anaprazole + Amoxicillin +Clarithromycin|"Cohort 1: Administered orally twice daily (e.g., 8am,8pm) for 5 consecutive days in 1 of 4 treatment periods ( only once on the morning of D5 of treatment periods).~Cohort 2: Administered orally on an empty stomach once on the morning of D1 of treatment periods"
89472390|NCT04444011|Experimental|Anaprazole + Amoxicillin +Clarithromycin+Bismuth|Administered orally on an empty stomach once on the morning of D1 of treatment periods in cohort 2
89472391|NCT03600181||orotracheal intubation|Patients admitted in ICU and planned to be intubated. Non-invasive sensor capable of measuring ORI (RAD - 97 pulse co-oximeter; Rainbow® Sensor, R2-25, Revision L, Masimo Corp.) will be applied to the third or fourth finger on the contralateral side of the inflatable cuff for non-invasive blood pressure monitoring.
89472392|NCT03603743|Experimental|high intensity interval training|high intensity interval training: two sets of 8-min intervals at 100% of peak power output (PPO). Each interval set was composed of repeated bouts of 30 s at 100% of PPO interspersed by 30 s of passive recovery in the seated position. Four minutes of passive recovery were allowed between the two sets.
88948923|NCT05501366|Experimental|C8 Ketone Di-ester 360mg/kg|
88948924|NCT05501366|Experimental|AcAc Di-ester 180mg/kg|
88948925|NCT05501366|Experimental|AcAc Di-ester 360mg/kg|
88948926|NCT05501366|Experimental|(R)-1,3 butanediol 180mg/kg|
88948927|NCT05501366|Experimental|(R)-1,3 butanediol 360mg/kg|
88948928|NCT05501366|Placebo Comparator|Control|
88948929|NCT05496491|Experimental|Neoadjuvant Chemoradiotherapy and Consolidation Chemotherapy|"The experimental group will receive the standard 5-week neoadjuvant chemoradiotherapy (CRT). Thereafter, all patients will commence consolidation chemotherapy. At the 6th week after the end of CRT, patients will undergo MRI re-staging: In case of non-response (mrTRG 5) they will be submitted immediately to surgery, and, subsequently, excluded from the trial.~In case of response (mrTRG 2-4) they will receive consolidation chemotherapy for the whole waiting period between the end of CRT and surgery - 12 weeks."
88948930|NCT05496491|Active Comparator|Neoadjuvant Chemoradiotherapy and Adjuvant Chemotherapy|The control group will receive the standard 5-week neoadjuvant chemoradiotherapy regimen. Six weeks after completion the patient will be re-staged with rectal MRI and depending on the response will be operated (TME): immediately in case of non-response (mrTRG 5) or after an additional 6-week delay (overall 12 weeks after the end of chemoradiotherapy) in case of partial response (mrTRG 2-4). Adjuvant chemotherapy will be, also, administered.
88948931|NCT05488522|Experimental|study treatment plan|Patients will be enrolled in a Rolling 6 clinical trial design1. This study design retains sensitivity to identifying DLTs while having the benefit of decreasing accrual time given the long DLT period required to assess radiation toxicity. In this trial design, up to 6 patients can be enrolled at a time onto a dose level while awaiting DLT assessment. Established rules guide the decision for enrolling onto the current, next highest, or previous dose level based on the number of participants currently enrolled in a given cohort, the number of radiation-attributable dose-limiting toxicities (ra-DLTs) observed, and the number of patients with immature toxicity data. If the MTD is not reached after 6 patients have enrolled on dose level 3 (three 17Gy fractions of SBRT) and have completed toxicity evaluations, then the recommended phase 2 dose will be determined based on an analysis of the efficacy of the combination
88948932|NCT05480605||Experimental Group|Children with autism ages 6-13
88948933|NCT05480605||Control Group|Typically developing children ages 6-13
88948934|NCT05456958|Experimental|Amygdala|PTSD participants will receive a neurofeedback signal reflecting amygdala activity.
88948935|NCT05456958|Experimental|Posterior cingulate cortex (PCC)|PTSD participants will receive a neurofeedback signal reflecting PCC activity.
88948936|NCT05456958|Experimental|Sham-control|PTSD participants will receive a sham neurofeedback signal, i.e., from a successful participant in one of the experimental arms.
88948937|NCT05454488|Experimental|Focal therapy Treatment|Cryoablation is a procedure in which special needles are inserted into the tumor site.
88948938|NCT05445726|Active Comparator|Healthy|Generally healthy participants that are able to participate in study procedures (i.e. laying down, sitting up, shaving chest hair for ECG/Test device placement if needed).
88948939|NCT05445726|Active Comparator|Atrial Fibrillation Diagnosis|Participants with a diagnosis of atrial fibrillation that are able to participate in study procedures (i.e. laying down, sitting up, shaving chest hair for ECG/Test device placement if needed).
88948940|NCT05445492|Experimental|Healthy Cohort|The target population for this cohort is healthy adult volunteers who do not have preexisting heart or lung conditions or illness. The goal is to recruit a participant population with a range of body types and BMIs and an approximately even split of genders and compare the reference device measurements to the test device.
88948941|NCT05445206|Experimental|Health Adult|The target population is healthy adult volunteers who do not have preexisting heart or lung conditions or illness. The goal is to recruit a participant population with a range of body types and BMIs and an approximately even split of genders.
88948942|NCT05433025|Experimental|Intervention|Cervigard Neck Collar, which is a device used to treat neck pain caused by forward head posture.
88948943|NCT05433025|No Intervention|Waitlist Control|This group will receive no intervention for 6 weeks after enrollment. They will receive the device after 6 weeks.
88948944|NCT05396794||Control Group|If the patient is in group 1, she will get standard education for weight loss, which will be provided by her Gynecologic Oncologist. This will take about 15 minutes.
89202416|NCT01060735|No Intervention|Conventional vitamin D supplementation|Regular supplementation during pregnancy with 400IU vitamin D
89472393|NCT03603743|Active Comparator|moderate intensity and continuous exercise|moderate intensity and continuous exercise: 30 minutes at 60% of PPO.
89019449|NCT00338520||Uncomplicated Malaria (UM)|Febrile children admitted to the hospital with Plasmodium falciparum parasitemia, no other cause of fever identified, no evidence of severe malaria (as listed in Study Protocol, Section 5.2 under exclusion criteria for UM), and no co-infection with other malaria species will be enrolled in the UM group.
89472394|NCT02238769||Hepatocellular Carcinoma|18F-FluoroethylCholine PET will show the difference between HCC lesions and normal liver tissue
89472395|NCT04443387|Active Comparator|Asthmatic low vitamin D on treatment|asthmatic patient low vitamin D level received treatment for Vitamin D 50000IU weekly
89472396|NCT04443387|Placebo Comparator|Asthmatic low vitamin D on placepo|asthmatic patient low vitamin D level received placepo
89019450|NCT00338520||Cerebral Malaria (CM)|Comatose children admitted to the hospitals will be evaluated by the house physician and/or member of the study team. If lumbar puncture is obtained, the parent or guardian will be approached for permission to enroll the child into the study. Parasitemic children with no other cause of coma identified will included in the CM group.
89472397|NCT03601169|Experimental|Low Dose MMFS-205-SR|Low dose, oral MMFS-205-SR twice daily (1,000 or 1,500 mg/day total, depending on lean body mass: ~22mg/kg LBM/day) for 6 weeks
89472398|NCT03601169|Experimental|High Dose MMFS-205-SR|High dose, oral MMFS-205-SR twice daily (1,500 or 2,000 mg/day total, depending on lean body mass: ~33mg/kg LBM/day) for 6 weeks
89472399|NCT03601169|Placebo Comparator|Placebo|Oral inactive placebo twice daily for 6 weeks
89472400|NCT02932592|Experimental|Dysglycemic group|"Patients with dysglycemia (not diabetic patients) will be undergone a monitoring of blood glucose with a device till the discharge of the patient.~Then, an oral glucose tolerance test (OGTT) will be done to categorize the patient as having impaired fasting glucose (IFG) or impaired glucose tolerance (IGT), or diabetes mellitus."
89472401|NCT02518737||GIP-receptor deficient|Persons with a mutation (Glu354Gln) causing their GIP-receptor to loose function.
89472402|NCT02518737||Controls|Matched controls, with a normal functioning GIP-receptor.
89472403|NCT03579745|Active Comparator|Conventional lingual mechanics|
89472404|NCT03579745|Experimental|Lever arm lingual mechanics|
89472405|NCT03603587|Experimental|Patients who will benefit from the removal of a scalp tumour|"Patients who will benefit from the removal of a scalp tumour in the alopecic zone will be recruited in the dermatology department of the St-Etienne University Hospital.~They will have biopsy, blood sample, examination of the scalp, questionnaire on sun exposure, Norwood scale, scinexa score, questionnaire of clinicals signs and questionnaire of the history of the hair loss."
89472406|NCT02316236|Experimental|dexmedetomidine loading dose|dexmedetomidine is given at load dose
89472407|NCT02316236|Experimental|dexmedetomidine sustaining dose|dexmedetomidine is given at sustaining dose
89472408|NCT04521075|Experimental|Treatment Arm|Combination treatment: anti PD1 + FMT by capsules
89472409|NCT03577249|Experimental|Single arm|
89472410|NCT03601091|Active Comparator|PR|PRECEDEX 200 mcg 2 ml,0,3 mcg/kg/h, intravenous continue infusion, 4 hours.
89472411|NCT03601091|Active Comparator|DO|DORMICUM 5MG/5 ML, 0,1 mg/kh/h, intravenous continue infusion for 4 hours
89472412|NCT03549559|Active Comparator|Healthy Subjects|Healthy subjects will receive an IV injection of 11C-Martinostat and undergo simultaneous PET-MRI.
89472413|NCT03549559|Active Comparator|Diabetes Patient Subjects|Patient subjects with diabetes will receive an IV injection of 11C-Martinostat and undergo simultaneous PET-MRI.
89472414|NCT03549559|Experimental|Aortic Stenosis Patient Subjects|Patient subjects with aortic stenosis will receive an IV injection of 11C-Martinostat and undergo simultaneous PET-MRI before and after transcatheter valve replacement.
89472415|NCT04508829|Experimental|Anti-EGFR arm|In the induction chemotherapy phase, TP regimen (Docetaxel 75mg/m2, D1 + DDP 25mg/m2, D1-3, repeat every 3 weeks) or TPF regimen (Docetaxel 75mg/m2, D1 + DDP 25mg/m2, D1-3+5-FU 750mg/m2, CIV, 120h, repeat every 3 weeks) will be used. Cetuximab 400mg/m2 will be used one week before radiotherapy and 250mg/m2/week during IMRT, or nimotuzumab 200mg/week; meanwhile, cisplatin 80mg/m2 will be used every 3 weeks.
89472416|NCT04479176||Drip-method group|Transnasal SPGB was performed by a single pain clinician. After the patient was placed in a supine and neck-extended position, 2 mL of 2% mepivacaine was placed in a syringe connected to a 16-gauge Angiocath sheath. The sheath of the Angiocath was inserted through the nostril, and 2% mepivacaine was dripped into the nostrils with the patient in a supine position. The mepivacaine drip on the nasal pharynx was maintained for 10 min. A drip of 2% mepivacaine was delivered to the nostril, where the pain was dominant. In cases of bilateral pain, mepivacaine drip was administered to both nostrils.
89472417|NCT04479176||Topical-method group|Transnasal SPGB was performed by a single pain clinician. The posture was the same as that in the drip method. A cotton tip applicator soaked with 2% mepivacaine was inserted vertically into the nostril. After the cotton tip applicator made contact with the posterior wall of the middle turbinate, the cotton tip applicator was fixed for 10 min. A cotton tip applicator was inserted into the nostril, where the pain was dominant. In cases of bilateral pain, two applicators were inserted into both nostrils.
89472418|NCT03603431|Experimental|Single Ascending Dose - MRG-110|Intradermal injection of MRG-110 at two wound sites and intradermal injection of placebo at two other wound sites
89472419|NCT03603431|Placebo Comparator|Single Ascending Dose - Placebo|Intradermal injection of placebo at four wound sites
89472420|NCT03603431|Experimental|Multiple Ascending Dose - MRG-110|Intradermal injection of MRG-110 at two wound sites and intradermal injection of placebo at two other wound sites
89472421|NCT03603431|Placebo Comparator|Multiple Ascending Dose - Placebo|Intradermal injection of placebo at four wound sites
89472422|NCT02239081|Experimental|CTP-730, 5 mg|oral suspension, once daily.
89472423|NCT02239081|Experimental|CTP-730, 10 mg|Oral Suspension, once daily.
89472424|NCT02239081|Experimental|CTP-730, 20 mg|Oral Suspension, once daily.
89472425|NCT02239081|Experimental|CTP-730, 30 mg|Oral Suspension, once daily.
89019451|NCT00338520||Non-malaria CNS disease (NMC)|Children without parasitemia and diagnosed with a non-malaria cause of coma or CNS disease will be enrolled in the non-malaria CNS disease group.
89019452|NCT00309101|Experimental|1. tacrolimus|
89019453|NCT00309218|Active Comparator|A|Steroid withdrawal
89019454|NCT00309218|Placebo Comparator|B|continuos Steroid treatment
89472426|NCT02239081|Experimental|CTP-730, 40 mg|Oral Suspension, once daily.
89019455|NCT00338559||LMA group|Patients in which laryngeal mask airway (LMA) is used.
89019456|NCT00338559||ET group|Patients in which endotracheal tube (ET) is used.
89019457|NCT00309296|Experimental|Longitudinal Care|One year of combined behavioral and pharamcological tobacco dependence treatment, with interim smoking reduciton for smokers who fail initial quit attempt.
89019458|NCT00309296|Active Comparator|Usual Care|Evidence based, state-of-the-science tobacco treatment; combined behavioral and pharmacological treatment for 8 weeks
89019459|NCT00309413|Active Comparator|1|Cannabidiol/Placebo
89019460|NCT00309413|Placebo Comparator|2|Placebo/Cannabidiol
89019461|NCT04715880|Active Comparator|Paravertebral Block (PVB) group|"Under complete aseptic precaution, Patient will be in lateral decubitus position a paravertebral catheter will be placed by the surgeon before closure of thoracotomy wound. The catheter will be introduced percutaneously through 18 gauge needle into the pleural cavity.~The tip of catheter will be loaded by anaesthesiologist with 0.25 % isobaric bupivacaine with 20 ml followed by continuous infusion with bupivacaine 0.25 % at 6-8 ml per hour"
89019462|NCT04715880|Active Comparator|Paravertebral block/Intercostal Block (PVB/ICB) group|Under complete aseptic precaution, patient will be in lateral decubitus position a paravertebral catheter will be placed by surgeon into pleural cavity and will not be loaded with bolus dose. At the end of surgery the (consultant anaesthesiologist) will perform intrathoracic unilateral intercostal nerve block two level above and two level below and at site of incision with 4 ml per level of 0.25 % bupivacaine followed by continuous infusion with 0.25 % bupivacaine at 6-8 ml/hour through catheter placed in paravertebral space.
89019463|NCT00309491|Experimental|Group I|Tamoxifen alone
89019464|NCT00309491|Experimental|Group II|Tamoxifen + Aminoglutethimide
89019465|NCT02960048|Active Comparator|Anterior repositioning splint|"A 2-mm-thick, hard, clear sheet of resin will be adapted to the maxillary arch .~Small amount of self-curing acrylic will be added to the anterior portion of the appliance as a stop for the lower incisor. The area of this stop is approximately 4 to 6 mm. The patient is instructed to protrude the mandible slightly and to open and close the mouth In this position.~Self-curing acrylic will be added to the occluding surface of the appliance. All occluding areas, except the contact on the anterior stop .~Excess acrylic surrounding the centric contacts is removed with a hard rubber wheel on a lathe."
89202417|NCT00747032|Active Comparator|1|NYC 0462 Ointment
89202418|NCT00747032|Placebo Comparator|2|Placebo
89472427|NCT02239081|Experimental|CTP-730, 50 mg|Oral Suspension, once daily.
89472428|NCT02239081|Experimental|CTP-730, 60 mg|Oral Suspension, once daily.
89472429|NCT04521309|No Intervention|Control|Standard care only n = 10 patients.
89472430|NCT04521309|Experimental|IVIG dose: 0.15 g/kg|Standard Care + Single dose of 0.20 g/Kg anti-COVID-19 IVIG (experimental drug prepared at DUHS) n= 10 patients
89472431|NCT04521309|Experimental|IVIG dose: 0.20 g/kg|Standard Care + Single dose of 0.25 g/Kg anti-COVID19 IVIG (experimental drug prepared at DUHS) n= 10 patients
89472432|NCT04521309|Experimental|IVIG dose: 0.25 g/kg|Standard Care + Single dose of 0.30 g/Kg anti-COVID19 IVIG (experimental drug prepared at DUHS) n= 10 patients
89472433|NCT04521309|Experimental|IVIG dose: 0.30 g/kg|Standard Care + Single dose of 0.35 g/Kg anti-COVID19 IVIG (experimental drug prepared at DUHS) n= 10 patients
89472434|NCT02239159|No Intervention|Control|Electrodes will be attached, but stimulation will not be given
89472435|NCT02239159|Sham Comparator|Non-acupoint TES|TES is for transcutaneous electric stimulation.Stimulation will be given through electrodes attached to non-acupoints
89472436|NCT02239159|Experimental|Acupoint TES|Transcutaneous stimulation will be given through acupoints
89472437|NCT03600935|Experimental|Vancouver Clinical Pathway|The Vancouver Clinical Pathway utilizes objective anatomical and functional screening criteria as well as strict peri-procedural guidelines to determine if next day discharge home is appropriate.
89472438|NCT04521153|Experimental|Experimental group|Preoperative camrelizumab combined with apatinib mesylate (q2w, 2 cycles) → radical surgery → postoperative TACE treatment → sequential camrelizumab and apatinib mesylate (q3w, at least 6 cycles) (Note: Surgery within 2-4 weeks after the last administration of neoadjuvant therapy, postoperative TACE treatment at least 4 weeks after surgery, and camrelizumab combined with apatinib mesylate within 2 weeks after TACE treatment)
89472439|NCT04521153|Active Comparator|Control group|Radical surgery→postoperative TACE treatment
89472440|NCT04362566|Active Comparator|Bupivicaine|Scalp flap: 2.5cc bupivacaine for 0-10cm2, additional 1cc for each additional 10cm2 up to max 5cc, Ear flap or wedge repair: 2.5cc bupivacaine for 0-10cm2, additional 1cc for each additional 10cm2 up to max 5cc Nose flap, 2.5cc bupivacaine for 0-10cm2, additional 1cc for each additional 10cm2 up to max 5cc. Split volume between nose and donor site for melolabial interpolated flap Paramedian forehead flap: 5cc split between forehead donor site and nasal recipient site: 4cc forehead, 1cc nose Cartilage alar-batten graft (ear donor site) 1cc at auricular donor site in addition to bupivacaine used for nasal reconstruction, if any, that qualifies above Cheek Mustarde flap: 2.5cc bupivacaine for 0-10cm2, additional 1cc for each additional 10cm2 up to max 5cc Lip flap, wedge repair, Abbe flap: 2.5cc bupivacaine for 0-10cm2, additional 1cc for each additional 10cm2 up to max 5cc
89472441|NCT04362566|Placebo Comparator|Placebo saline|Saline in the same volume as described above for bupivicaine
89202419|NCT00683774|Experimental|PCOS subjects|PCOS subjects given diazoxide
89202420|NCT00683774|Active Comparator|Normal subjects|Normal subjects given diazoxide
89202421|NCT03741907|Experimental|FAUCS|French Ambulatory C-section
89472442|NCT02239237||Compound Kuh-seng Injection|Compound Kuh-seng Injection will be given to the patients, and the investigators will record all the information including ADR, application of Compound Kuh-seng Injection and the combined medications, etc.
89472443|NCT02237885|Experimental|Neurofeedback|
89472444|NCT03354507|Experimental|Sodium Bicarbonate|"Patients will receive sodium bicarbonate for 4 weeks, based on pre-calculated weight based doses. Patients are selected if they have metabolic acidosis at baseline.~< 24 kg : 1/4 teaspoon bid. 24 - 42 kg : 1/2 teaspoon bid. > 42kg : 3/4 teaspoon bid."
89472445|NCT03354507|No Intervention|Control|Patients will not receive treatment if they do not have metabolic acidosis at baseline.
89202422|NCT03741907|Active Comparator|MLC|Gold Standard
89202423|NCT00787410|Experimental|1|
89472446|NCT03579589|Active Comparator|Sugammadex|"If spontaneous recovery has reached second twitch after TOF: 2 mg/kg~If spontaneous recovery has reached between 1-2 post-tetanic counts but no twitch responses to TOF: 4 mg/kg~When there is a clinical need to reverse NMB within 3 min of a single dose of rocuronium (1.2 mg/kg): 16 mg/kg"
89472447|NCT03579589|Active Comparator|Neostigmine|50 µg. Kg-1 will be administered after spontaneous recovery has reached fourth twitch after TOF in accordance with our institutional standard procedures and published literature.
89472448|NCT03600025|Other|non-randomized|Responses will be compared before and after vaccination
89472449|NCT03600623|Experimental|Folfirinox + SBRT|Folfirinox comprises the following: Fluorouracil 2,400 mg/m2 intravenously over 48 hours Days 1-3 and 15-17 every 4 weeks; Folinic acid 400 mg intravenously on Days 1 and 15 every 4 weeks; Oxaliplatin 85 mg/m2 intravenously on Days 1 and 15 every 4 weeks; and Irinotecan 180 mg/m2 intravenously on Days 1 and 15 every 4 weeks. Radiation will begin at the completion of cycle 2 if chemotherapy toxicity permits and will last over a period of 5 days.
89472450|NCT03600623|Experimental|Gemcitabine-nab Paclitaxel + SBRT|Gemcitabine-nab Paclitaxel comprises the following: Gemcitabine 1000 mg/m2 on Days 1, 8, and 15 every 4 weeks; nab Paclitaxel 125 mg/m2 on Days 1, 8, and 15 every 4 weeks. Radiation will begin at the completion of cycle 2 if chemotherapy toxicity permits and will last over a period of 5 days.
89472451|NCT02201810|Experimental|2nd level intervention: Rate Reduction|Rate reduction intervention
88948945|NCT05396794||Video Group|If the patient is in group 2, she will get standard education for weight loss provided by her Gynecologic Oncologist. Then she will be asked to view a 15-minute video to get information regarding obesity, the relationship of obesity and endometrial cancer, and the safety and benefits of bariatric surgery. These will take about 30 minutes.
88948946|NCT05392608|Experimental|Arm A (one-arm study)|Alpelisib plus fulvestrant beyond progression
88948947|NCT05385315||Parkinson's Disease, de novo|patients with de novo PD, without dopaminergic treatment
88948948|NCT05385315||Parkinson's Disease, advanced stage|PD patients with diagnosis >5years, with dopaminergic treatment and motor fluctuations.
88948949|NCT05385315||Multiple system atrophy|patients with multiple system atrophy
88948950|NCT05368025||Newly diagnosed Oropharyngeal cancer patients|Newly diagnosed oropharyngeal cancer patients will be enrolled into the study. Patients will receive both mobile health systems and be asked to complete swallowing exercises and report symptoms daily for a period of 6 months. Following completion of the study, this group will be interviewed individually to gain insight into the user experience of using both systems
88948951|NCT05360160|Experimental|SNDX-5613|Capsules by mouth 2 times every day (about 12 hours apart).
88948952|NCT05360160|Experimental|Venetoclax|Tablets by mouth on Days 1-14 of each cycle.
88948953|NCT05360160|Experimental|ASTX727|Tablets by mouth on Days 1-5 of each cycle.
88948954|NCT05356936|Experimental|Vitamin K2(MK-7) and Vitamin D3|Participants randomized to this group will receive Vitamin K2 (MK-7) and Vitamin D3 by mouth.
88948955|NCT05356936|No Intervention|Control|Participants to this group will receive no intervention.
88948956|NCT05355051|Experimental|Pembrolizumab plus Azacitidine|Pembrolizumab by vein over about 30 minutes every 3 weeks. Azacitidine by vein over about 60-90 minutes on Days 1-7 of each 28-day study cycle
88948957|NCT05353738||Patients with severe neuromuscular disease|Patient with severe neuromuscular disease and having received vaccination with the Moderna vaccine
88948958|NCT05353738||Patients groupe témoins négatif|Patient having had a blood sample taken as part of the treatment for virological analysis before anti-COVID 19 vaccination
88948959|NCT05353738||Patients groupe témoins positif|Patient having had a blood sample taken as part of the treatment for virological analysis following infection with the omicron variant.
88948960|NCT05339451||Severe/Deep infiltrating endometriosis|Endometriosis stage III/IV according to rASRM.
88948961|NCT05339451||Minimal/mild endometriosis|Endometriosis stage I/II according to rASRM
88948962|NCT05339451||Controls|Women operated for other benign gynecological diseases and have no signs of endometriosis perioperatively.
88948963|NCT05337826|Experimental|Single Arm|
88948964|NCT05329792|Experimental|Treatment arm with L19IL2 /L19TNF|70 patients will be enrolled and treated with a mixture of L19IL2 and L19TNF once weekly for 4 consecutive weeks. The total dose/volume will be distributed among the target lesions defined at screening via single or multiple intralesional injections, according to lesions' size and number.
88948965|NCT05322343||Prospective cohort|The general population from the age of 55.
88948966|NCT05313204||Pregnant with Multiple Sclerosis|Pregnant individuals (> 13 weeks) with a Multiple Sclerosis diagnosis.
88948967|NCT05313204||Pregnant without Multiple Sclerosis|Pregnant individuals (> 13 weeks) without Multiple Sclerosis.
88948968|NCT05313204||Postpartum with Multiple Sclerosis|Postpartum individuals (< 1 year since delivery) with a Multiple Sclerosis diagnosis.
88948969|NCT05313204||Postpartum without Multiple Sclerosis|Postpartum individuals (< 1 year since delivery) without Multiple Sclerosis.
88948970|NCT05305144|Experimental|ophthalmological and vascular assessments|This single-center national interventional study aims to collect ophthalmological (retinal image acquisition) and blood pressure (vascular assessment) data from 400 young adults from the Bordeaux bio-Share cohort, during two visits taking place one year apart.
89202424|NCT02555124|Experimental|Cohort A|Participants will receive single oral dose of 5 milligram (mg) of JNJ-42847922 or Placebo on Day 1, fasted condition.
89202425|NCT02555124|Experimental|Cohort B|Participants will receive single oral dose of 20 mg of JNJ-42847922 or Placebo on Day 1, fasted condition.
89202426|NCT02555124|Experimental|Cohort C|Participants will receive single oral dose of 40 mg of JNJ-42847922 or Placebo on Day 1, fasted condition.
89202427|NCT03989557|Experimental|Monitoring Arm|Randomization: based on light transmittance aggregometry, modified dose of antiplatelet therapy(aspirin and ticagrelor) was used for high platelet reactivity(HPR) patients with intracranial stent placement, and standard antiplatelet regimen(aspirin and clopidogrel) was used in non-HPR patients.
89472452|NCT02201810|Experimental|2nd level intervention: Recycling|Recycling Group
89472453|NCT02201810|Experimental|2nd level intervention: Choice|Choice Group
89472454|NCT03600545|Experimental|Active|4 weeks daily practice of the brain exercises
89472455|NCT03600545|No Intervention|control|no brain exercises
89472456|NCT02518347|Experimental|FDS-Strawberry|Freeze-dried strawberry powder (50g/d)
89472457|NCT02518347|Placebo Comparator|Placebo|Powder matched for carbohydrates and fiber in the strawberries
88948971|NCT05298709|Experimental|Hypercarbia/Hypocarbia/resting state during fMRI|"During real time fMRI, all subjects will completed breathing tasks though a mask that supplies gas mixtures using the RespirAct™ Gas Control System (Thornhill Medical). The RespirAct™ is a computer-controlled gas blender providing carbon dioxide (CO2), oxygen (O2) and nitrogen for a subject to inhale while breathing for the purpose of controlling the concentrations of the respective blood gases.~For hypocarbia, subjects will be instructed to pace their breathing to 16- 20 breaths-per-minute to achieve a stable target end-tidal CO2 between 30 and 40 mm Hg.~Hypercarbia will be induced by increasing CO2 concentration and flow rate of the gas mixture until a desired ETCO2 level between 40 and 50 mm Hg has been reached.~There will also be a 10 minutes rest period during which respiratory rate and heart rate will be monitored continuously."
88948972|NCT05294081|Experimental|Exposure (EXP)|Exposure in vivo for fear avoidant chronic low back pain patients. This treatment means that the individual is exposed to movements and tasks that have been avoided due to fear of (re)injury. The treatment begins after three educational lessons including the rational and developing a fear hierarchy. Exposure phase includes 10 exposures sessions which are highly individualized. Behavioral experiments can be included to correct catastrophic misinterpretations. The main purpose of this intervention type is to reduce pain related disability via diminishing fear avoidance.
88948973|NCT05294081|Active Comparator|Cognitive Behavioural Therapy (CBT)|Cognitive behavioural psychotherapy for fear avoidant chronic low back patients. The therapy is modularized in three main parts. The educational lesson is followed by the module graded activity which represents the behavioral part of the program. The second module comprises relaxation. And the last part contains cognitive interventions. Cognitive behavioural intervention techniques are employed to support the patient in the process of coping with chronic pain: i.e. reduction of disability and improving functional ability.
88948974|NCT05291923||Post whipple's procedure patients|
88948975|NCT05280600||NMDAR-antibody encephalitis|Children and young people (ages 8-24 years) with a diagnosis of NMDAR-antibody encephalitis.
88948976|NCT05280600||Antibody-negative autoimmune encephalitis|Children and young people (ages 8-24 years) with a diagnosis of autoantibody-negative but probable autoimmune encephalitis or definite autoimmune limbic encephalitis.
88948977|NCT05280600||Healthy control|Healthy children and young people (ages 8-24 years).
88948978|NCT05252442||Pre-COVID-19|
88948979|NCT05252442||COVID-19|
88948980|NCT05252442||COVID-19 vaccination roll-out|
88948981|NCT05245500|Experimental|Phase 1/1B|Dose Escalation/Evaluation
88948982|NCT05245500|Experimental|Phase 2|MRTX1719 RP2D administered to separate cohorts of patients with selected solid tumor malignancies with MTAP homozygous deletion to include the following: Mesothelioma, Pancreatic Adenocarcinoma, NSCLC, Malignant Peripheral Nerve Sheath Tumor, Other Solid Tumors
88948983|NCT05243641|Experimental|Part 1b (dose escalation)|This portion of the study will enroll a maximum of 27 patients in the dose-finding trial including the possibility of adding up to 6 additional ER+ patients in a safety assessment of aromatic inhibitor treatment
88948984|NCT05243641|Experimental|Part 2 (dose expansion)|This portion of the study will enroll a maximum of 29 patients
89472458|NCT03603197|Experimental|BP-C1|Patients allocated to BP-C1 arm will be treated for 32 consecutive days. Patients who respond to treatment and do not experience untolerated toxicity will be invited to participate in the BMC2011-02 study, where they are offered to continue treatment with BP-C1.
89472459|NCT03603197|Placebo Comparator|Placebo|Patients allocated to Placebo arm will be treated for 32 consecutive days. Thereafter the patients will cross over to 32-day treatment with BP-C1. Patients who respond to treatment and do not experience untolerated toxicity will be invited to participate in the BMC2011-02 study, where they are offered to continue treatment with BP-C1.
88948985|NCT05229679|Experimental|HPV-based screening|Women 23-29 invited to cervical screening will have their samples analyzed for HPV.
89472460|NCT02848729|Experimental|Treatment A: Oral Acetaminophen|Treatment A = 4 repeat doses of 1,000 mg oral acetaminophen (2 x 500 mg tablets) and an IV infusion of saline every 6 hours (Hours -6, 0, 6, and 12), and 2 infusions of intravenous (IV) morphine (0.125 mg/kg) at Hours 0 and 6
88948986|NCT05224336|Experimental|Psilocybin|Participants will receive 25mg oral psilocybin one day to two weeks after baseline psychophysical and fMRI testing. Psychophysical and fMRI testing will then be employed one day to two weeks after drug administration.
89472461|NCT02848729|Experimental|Treatment B: IV Acetaminophen|Treatment B = 4 repeat doses of IV acetaminophen (1,000 mg/100 mL) and 2 placebo tablets every 6 hours (Hours -6, 0, 6, and 12), and 2 infusions of IV morphine (0.125 mg/kg) at Hours 0 and 6.
89472462|NCT02518659|Other|Inulin|Intervention by inulin, max 20gr per day
89472463|NCT02518659|No Intervention|No Inulin|Same Patients of arm inulin. Here the phase without inulin supplementation (own controls)
89538479|NCT02457689|Placebo Comparator|Group 1 (Transcutaneous and Placebo)|Group 1 (Transcutaneous and Placebo) Participants will receive 1.0ml intramuscular injections of the vaccine Sodium Chloride BP into the upper thigh. Participants will also have a further 0.2ml of Sodium Chloride BP delivered transcutaneously. An area of skin of approximately 4 x 4cm will be photographed and prepared first. During this preparation, the area is shaved to remove the hair, and then superglue is applied to remove the top layer of skin (like waxing). The vaccine is spread onto the skin surface. Once applied, the area is covered with a comfeel bandage, the investigator will ask volunteers to not engage in strenuous exercise, shower, or bathe for 24 hours afterwards.
89472464|NCT03135782|Experimental|Health Services Research (Chart review, training, coaching)|"MEDICAL CHART REVIEW: Medical charts from patients with diagnoses of head and neck cancer, lung cancer, prostate cancer, or breast cancer are reviewed at months 1-12 to determine the frequency of tobacco assessments and documentation of discussions with patients regarding tobacco use and utilization of cessation resources as before and after the proposed training.~PROVIDER TRAINING: Providers undergo training to use patient coaching such as the 5A's (Ask, Advise, Assess, Assist, and Arrange), to conduct regular tobacco intake assessment using motivational interviewing techniques. Providers also undergo training to use public/community tobacco cessation resources for patients ready to quit within six weeks, and have access to pharmacy residents for ad-hoc prescribing questions.~PATIENT COACHING: Patients attend 4 phone or in-person motivational interviewing coaching sessions over 30-45 minutes for 6-8 weeks or longer as needed."
89472465|NCT03600467|Experimental|Adrogen Postive Solid Tumours|
89472466|NCT03361449|Active Comparator|Group 1|training with kinesthetic ability trainer.
89472467|NCT03361449|Active Comparator|Group 2|Flamingo exercise
89472468|NCT03361449|Active Comparator|Group 3|training with kinesthetic ability trainer and Flamingo exercise
89472469|NCT03577093||ischemic stroke|acute ischemic stroke patients within 6h after stroke onset
88948987|NCT05224336|Placebo Comparator|Niacin|Participants will receive 100mg oral niacin one day to two weeks after baseline psychophysical and fMRI testing. Psychophysical and fMRI testing will then be employed one day to two weeks after drug administration.
88948988|NCT05191719|Active Comparator|Botox|
88948989|NCT05191719|Experimental|Neurotomy|
88948990|NCT05179785|Experimental|Left vLPFC cTBS/right dlPFC iTBS/left Som cTBS|"A random number sequence will be generated for randomization of the 3 EEG/TBS session order to which each participant is assigned:~left vlPFC cTBS (cTBS applied to the left ventrolateral prefrontal cortex) right dlPFC iTBS (iTBS applied to the right dorsolateral prefrontal cortex) left Som cTBS (cTBS applied to the left somatosensory cortex)"
88948991|NCT05179785|Experimental|Left vLPFC cTBS/left Som cTBS/right dlPFC iTBS|"A random number sequence will be generated for randomization of the 3 EEG/TBS session order to which each participant is assigned:~left vlPFC cTBS (cTBS applied to the left ventrolateral prefrontal cortex) left Som cTBS (cTBS applied to the left somatosensory cortex) right dlPFC iTBS (iTBS applied to the right dorsolateral prefrontal cortex)"
88948992|NCT05179785|Experimental|left Som cTBS/right dlPFC iTBS/Left vLPFC cTBS|"A random number sequence will be generated for randomization of the 3 EEG/TBS session order to which each participant is assigned:~left Som cTBS (cTBS applied to the left somatosensory cortex) right dlPFC iTBS (iTBS applied to the right dorsolateral prefrontal cortex) left vlPFC cTBS (cTBS applied to the left ventrolateral prefrontal cortex)"
88948993|NCT05179785|Experimental|left Som cTBS/Left vLPFC cTBS/right dlPFC iTBS|"A random number sequence will be generated for randomization of the 3 EEG/TBS session order to which each participant is assigned:~left Som cTBS (cTBS applied to the left somatosensory cortex) left vlPFC cTBS (cTBS applied to the left ventrolateral prefrontal cortex) right dlPFC iTBS (iTBS applied to the right dorsolateral prefrontal cortex)"
88948994|NCT05179785|Experimental|right dlPFC iTBS/left Som cTBS/Left vLPFC cTBS|"A random number sequence will be generated for randomization of the 3 EEG/TBS session order to which each participant is assigned:~right dlPFC iTBS (iTBS applied to the right dorsolateral prefrontal cortex) left Som cTBS (cTBS applied to the left somatosensory cortex) left vlPFC cTBS (cTBS applied to the left ventrolateral prefrontal cortex)"
88948995|NCT05179785|Experimental|right dlPFC iTBS/Left vLPFC cTBS/left Som cTBS|"A random number sequence will be generated for randomization of the 3 EEG/TBS session order to which each participant is assigned:~right dlPFC iTBS (iTBS applied to the right dorsolateral prefrontal cortex) left vlPFC cTBS (cTBS applied to the left ventrolateral prefrontal cortex) left Som cTBS (cTBS applied to the left somatosensory cortex)"
88948996|NCT05166499|Active Comparator|Hydroxy Methyl Butyrate|
88948997|NCT05166499|Other|Balanced Amino Acid Mixture|
88948998|NCT05160675||Group 1|Group 1: 690 healthy infants and their mother followed from birth to 12 months
88948999|NCT05160675||Group 2|Group 2: 690 healthy infants and their mother followed from 6 months to 3 years of age
88949000|NCT05157100|Experimental|Ingrezza|Participants will receive Ingrezza orally once daily for 12 weeks.
88949001|NCT05149937|Experimental|Interventional group|Implementation of interprof Home measures to improve cooperation between nursing services, general practitioners and members of the therapeutic professions in the care of people living at home with care needs.
88949002|NCT05143619||Observational (surveys)|Participants complete surveys immediately after completion of a HCC diagnostic guideline webinar, monthly thereafter, and again at 6 months.
88949003|NCT05134142||Observational (Physical tests, questionnaires, record review)|Patients undergo physical performance assessments and complete quality of life assessments and questionnaires pre-hemipelvectomy, at 6 weeks post-hemipelvectomy, and then every 3 months up to 12 months and yearly thereafter for 10 years. Patients who are 1 year out from surgery complete pain-related questionnaires once. Patients who have already undergone hemipelvectomy prior to enrollment undergo medical record review.
89202428|NCT03989557|Experimental|Conventional Arm|Randomization: without light transmittance aggregometry, standard antiplatelet regimen was used for unruptured aneurysm patients with intracranial stent.
89472470|NCT03577093||control|healthy controls
89472471|NCT03600389|Experimental|Intervention Arm (Implementing Patient Priorities Care)|Aligning healthcare recommendations to achieve patients' specific health outcome goals within the context of what patients are willing and able to do.
89472472|NCT03600389|No Intervention|Control Arm (Not Implementing Patient Priorities Care)|Routine Care
89202429|NCT00787488|Experimental|1|Chemotherapy plus Hyperthermia
89202430|NCT01054495|Active Comparator|Acupuncture|Needle acupuncture at acupuncture point pericardium 6
89202431|NCT01054495|Sham Comparator|Sham acupuncture|Non-penetrating sham needling at acupuncture point pericardium 6
89472473|NCT04520529|Other|Patients with primary cutaneous lymphoma|
88949004|NCT05133804|Experimental|Treatment with Reboxetine and Methylphenidate|"During the first 3 weeks of the study, subjects in the active treatment group will take reboxetine at a dose of 4mgper day, with the instructions to start at 2mg per day for 3 days and then increase the dosage to 4mg per day for 26 days, i.e. until completion of the study.~On day 22 of the study, the patients will take the first dosage of10mg Ritalin or a placebo, and remain in the clinic for 2 hours to guard safety and guidance during possible occurrence of side effects such as anxiety, palpitations, etc. During the observation time in the clinic, 6 Ritalin IR 10mg and 3 Reboxetine 4mg pills will be handed out to the participants. These pills will be taken at the responsibility of the subject at8:00 AM (Ritalin and Reboxetine) and at noon (Ritalin only) at the following three days."
88949005|NCT05133804|Placebo Comparator|Treatment with Placebo|The patients will take placebos according to the medication schedule of the treatment group.
89472474|NCT02437435|Experimental|Reproductive Technique Gimilio|"Patient supine, legs in triple flexion, feet on table, controlling legs left hand and right hand bent on uterine body contact.~Both hands catch utero withdrawal into one on another with arms outstretched. Fixed uterus right hand, left hand, with levers legs combines lateroflexion-rotation parameters of lumbar spine to improve uterine ligaments stretch, repeat technique to tissue relaxation. Then perform massage-cranial caudo zigzag with anteroposterior thrust. (overall hemodynamic maneuver). Finally do anteroposterior pumping about uterine body generating positive and negative pressures.~Hand therapist will keep in touch at all times on the suprapubic region of the patient."
89472475|NCT02437435|Placebo Comparator|Placebo Intervention|The researcher puts his right hand on the right shoulder of the patient for 20 times Metronome.
89472476|NCT03600311|Placebo Comparator|Energy Balance|Participants will be in energy balance and consume 1.2 g/kg BW protein. They will be provided 30 g of maltodextrin following exercise.
89472477|NCT03600311|Active Comparator|Caloric Restriction and CHO Supp|Participants will be calorie restricted to 15 kcal/kg FFM/day and consume 1.2 g/kg BW protein. They will be provided 30 g of maltodextrin following exercise.
89472478|NCT03600311|Experimental|Caloric Restriction and PRO Supp|Participants will be calorie restricted to 15 kcal/kg FFM/day and consume 1.2 g/kg BW protein. They will be provided 30 g of whey protein following exercise.
88949006|NCT05131321||Group A: Fusion Group|Primary arthrodesis: Subjects allocated to the fusion group will have insertion of a retrograde locked calcaneal nail. Tibiotalar joint preparation, bone grafting, subtalar preparation, and fibulectomy will not be performed unless deemed necessary by the treating surgeon.
89472479|NCT03599557|Experimental|Intervention|Arm 1 will receive the STOP-HPV communication intervention
89472480|NCT03599557|No Intervention|Control|Arm 2 will receive standard of care
89472481|NCT03354351||NB-Group|Stepped-care model comprising a hierarchy of interventions, from the least to the most intensive, matched to the cardiac man's needs. The model involves three steps: Step 1 (therapist-guided and self-guided 3-session psychoeducational program), Step 2 (Group sessions involving care partners), and Step 3 (individual or dyadic (patient and care Partner) sessions. As such, if following Step 1, the mental-health symptoms of men with HD do not sufficiently subside, as identified by the screening tests, participants will qualify for Step 2. Following Step 2, men who continue to meet criteria for a clinically significant mood, anxiety, or post-traumatic stress disorder on the screening tests (PHQ9, MRDS, DASS 21, IES-R, CIS), will be invited to receive services at Step 3.
89472482|NCT03354351||ON-Group|Stepped-care model where men will need to follow a sequential treatment (Step 1 (self-guided), Step 2 (Group sessions), and Step 3 (individual or couple sessions). As such, if following Step 1, the mental-health symptoms of men with HD do not sufficiently subside, as identified by the screening tests, participants will qualify for Step 2. Following Step 2, men who continue to meet criteria for a clinically significant mood, anxiety, or post-traumatic stress disorder on the screening tests (PHQ9, MRDS, DASS 21, IES-R, CIS), will be invited to receive services at Step 3.
89472483|NCT03354351||QC-Group|Standard Stepped-care model where men will need to follow a sequential treatment (Step 1 (self-guided), Step 2 (Group sessions), and Step 3 (individual or couple sessions). As such, if following Step 1, the mental-health symptoms of men with HD do not sufficiently subside, as identified by the screening tests, participants will qualify for Step 2. Following Step 2, men who continue to meet criteria for a clinically significant mood, anxiety, or post-traumatic stress disorder on the screening tests (PHQ9, MRDS, DASS 21, IES-R, CIS), will be invited to receive services at Step 3.
88949007|NCT05131321||Group B: Internal Fixation|ORIF will be performed using modern techniques for timing and staging of fixation, soft tissue and fibula management, surgical approaches, reduction techniques, and plate choice.
88949008|NCT05127421|Experimental|Double-blind Period: vehicle cream or Ruxolitinib cream 1.5% BID|Participants will be treated with ruxolitinib cream 1.5% or vehicle cream twice a day (BID) in a double-blind fashion.
88949009|NCT05127421|Experimental|Open Label Extension: Ruxolitiib cream 1.5%|Patients will be treated with Ruxoltinib cream 1.5% twice per day (BID) during the open label extension period. Participants who complete the double-blind period will continue into this open-label extension period for an additional 4 weeks of treatment.
88949010|NCT05126797|Other|3D printed stent+ MDASI-3D Oral Stents Questionnaire|Patients wear a customized 3D printed oral stent over 5-10 minutes in the supine position at the time of radiation simulation, before starting radiation therapy, and in the 3rd to 5th week of radiation therapy. Patients may also optionally wear the commercially-made stent called TruGuard at these timepoints. Ancillary Studies (MDASI-3D Oral Stents Questionnaire)
89202432|NCT01054495|Placebo Comparator|Laser acupuncture|Laser stimulation at acupuncture point pericardium 6
89202433|NCT00790998|Experimental|Moxidectin|Moxidectin 8mg
89202434|NCT00790998|Active Comparator|Ivermectin|Ivermectin 150 mcg/kg
89472484|NCT03354195|Active Comparator|Group 1|"Group 1 - intact ACL ligament will be accepted as functionally intact~unicompartmental knee arthroplasty with the Mako Robotic Arm-assisted system."
88949011|NCT05115656|Experimental|Online group intervention 1|Participants in group 1 meet weekly online for a 2-hour group sessions for 10 weeks where the instructor will provide leadership in discussions, which will include practice of basic routines. Participants will also be asked to do 20-30 minutes of daily activities/exercises, where they will be asked to practice mental exercises.
88949012|NCT05115656|Active Comparator|Online group intervention 2|Similar to group 1, participants will meet weekly online or in person for 2-hour group sessions for 10 weeks where the instructor will provide leadership in discussions, which will include practice of basic routines. Participants will also be asked to do 20-30 minutes of daily activities/exercises, where they will be asked to practice mental exercises.
88949013|NCT05112133|Placebo Comparator|Control|Water administrated just before a meal
88949014|NCT05112133|Experimental|Mulberry leaf extract before|250 mg of Mulberry leaf extract was administered before a standard meal
88949015|NCT05112133|Experimental|Mulberry leaf extract during|250 mg of Mulberry leaf extract was administered during a standard meal
88949016|NCT05109364|Experimental|terazosin therapy extension|Primary procedures in this study are MIBG scan, DAT scan, NM-MRI, and terazosin medication. Subjects will return for research visits and imaging every six months for three years. The investigators hypothesize that the rate of decline in DAT scan123I-Ioflupane uptake will be slower in subjects who have received the alpha1- adrenergic receptor antagonist terazosin, resulting in a decreased clinical conversion rate to parkinsonism.
88949017|NCT05106257|Experimental|Condition #1|Education = short Walking training = on Inhaler training = on Caregiver support = on
88949018|NCT05106257|Experimental|Condition #2|Education = short Walking training = on Inhaler training = on Caregiver support = off
88949019|NCT05106257|Experimental|Condition #3|Education = short Walking training = on Inhaler training = off Caregiver support = on
88949020|NCT05106257|Experimental|Condition #4|Education = short Walking training = on Inhaler training = off Caregiver support = off
88949021|NCT05106257|Experimental|Condition #5|Education = short Walking training = off Inhaler training = on Caregiver support = on
88949022|NCT05106257|Experimental|Condition #6|Education = short Walking training = off Inhaler training = on Caregiver support = off
88949023|NCT05106257|Experimental|Condition #7|Education = short Walking training = off Inhaler training = off Caregiver support = on
88949024|NCT05106257|Experimental|Condition #8|Education = short Walking training = off Inhaler training = off Caregiver support = off
88949025|NCT05106257|Experimental|Condition #9|Education = long Walking training = on Inhaler training = on Caregiver support = on
88949026|NCT05106257|Experimental|Condition #10|Education = long Walking training = on Inhaler training = on Caregiver support = off
88949027|NCT05106257|Experimental|Condition #11|Education = long Walking training = on Inhaler training = off Caregiver support = on
88949028|NCT05106257|Experimental|Condition #12|Education = long Walking training = on Inhaler training = off Caregiver support = off
88949029|NCT05106257|Experimental|Condition #13|Education = long Walking training = off Inhaler training = on Caregiver support = on
89202435|NCT01057459||Ancillary-Correlative (biomarkers and treatment outcomes)|Genomic DNA is extracted from previously collected blood samples for KIR and HLA genotyping and polymorphism analysis.
89472485|NCT03354195|Active Comparator|Group 2|"Group 2 - intact but fibrillated (frayed) ligament) will be accepted as functionally intact~unicompartmental knee arthroplasty with the Mako Robotic Arm-assisted system."
88949030|NCT05106257|Experimental|Condition #14|Education = long Walking training = off Inhaler training = on Caregiver support = off
88949031|NCT05106257|Experimental|Condition #15|Education = long Walking training = off Inhaler training = off Caregiver support = on
88949032|NCT05106257|Experimental|Condition #16|Education = long Walking training = off Inhaler training = off Caregiver support = off
88949033|NCT05097716|Experimental|Ritlecitinib and tolbutamide|In Period 1, participants will be dosed with a single administration of tolbutamide 500 mg tablet on Day 1. Period 1 will be immediately followed by Period 2 with no washout. In Period 2, participants will be dosed with oral 200 mg ritlecitinib QD for 10 days followed by administration of a single dose of 500 mg tolbutamide oral tablet within approximately 5 minutes after administration of a 200 mg dose of ritlecitinib on the morning of Day 10.
88949034|NCT05086016|Experimental|All treated|The All Treated (AT) population is defined as all subjects who signed informed consent, meet eligibility criteria and for whom a procedure was begun (defined as the initiation of vascular access with the Renata Minima system).
88949035|NCT05084963|Experimental|Arm 1: IRL201104 Dose A|IRL201104 IV on Days 0, 7, and 14
88949036|NCT05084963|Experimental|Arm 2: IRL201104 Dose B|IRL201104 IV on Days 0, 7, and 14
88949037|NCT05084963|Placebo Comparator|Arm 3: Placebo|Placebo IV on Days 0, 7, and 14
89472486|NCT03354195|Active Comparator|Group 3|"Group 3 - nearly completely torn ligament (>50% and disrupted) will be deemed as having functionally absent ACLs~unicompartmental knee arthroplasty with the Mako Robotic Arm-assisted system."
89472487|NCT04562324|Experimental|Experimental:|NF group participants receive 24 min NF sessions over the Motor sensory Cortex, 2-3 days per week, for 2 weeks combine a selective serotonin reuptake inhibitor (SSRI) or a serotonin or norepinephrine reuptake inhibitors (SNRI) or benzodiazepines or tricyclic antidepressants or other antidepressants or antipsychotics or other sedative-hypnotics
89472488|NCT04562324|Experimental|Healthy Experimental:|Participants receive 24 min NF sessions over the Motor sensory Cortex, 2-3 days per week, for 2 weeks
89472489|NCT04562324|Sham Comparator|Healthy Sham Comparator|Sham group participants receive 24 min NF sessions with pseudo-random numbers, 2-3 days per week, for 2 weeks
89472490|NCT04562324|Sham Comparator|Sham Comparator|Sham Comparator: Sham group participants receive 24 min NF sessions with pseudo-random numbers, 2-3 days per week, for 2 weeks combine a selective serotonin reuptake inhibitor (SSRI) or a serotonin and norepinephrine reuptake inhibitors (SNRI), benzodiazepines, tricyclic antidepressants, other antidepressants, antipsychotics, other sedative-hypnotics
89472491|NCT03599921||Family-based Treatment|Participants will receive family-based treatment.
88949038|NCT05071703|Experimental|Trilaciclib, carboplatin, etoposide, Topotecan|Trilaciclib plus Carboplatin combined with Etoposide OR Topotecan (ES-SCLC patients)
88949039|NCT05071300|Experimental|Eplontersen|Eplontersen will be administered by subcutaneous (SC) injection once every 4 weeks for up to 3 years (157 weeks).
88949040|NCT05058989||Pregnant women who are aged between 18 to 47 years old (childbearing age).|These patients must be willing to be followed up for 1 year and agreeing to give the informed consent. Recruitment period will take up to three months. Follow up period will be conducted at the end of first, second and third trimester and three months after giving birth.
88949041|NCT05054998|Experimental|Diagnostic (fludeoxyglucose F-18, PET/MRI)|Patients receive fludeoxyglucose F-18 IV over approximately 1 minute and undergo a PET/MRI scan over 70 minutes. Within 5 hours of receiving fludeoxyglucose F-18, patients undergo a repeat PET/MRI scan over 30 minutes. Scans take place within 2 weeks before scheduled surgery and within 4-6 weeks after radiation treatment.
88949042|NCT05053555|Experimental|Group A (Prospective cohort )|20 patients, will undergo initial diagnostic workup, staging and treatment per institutional standard of care. Intervention: High dose rate brachytherapy (HDRBT)
88949043|NCT05053555|Experimental|Group B( Retrospective chart review )|40 patients who meet same eligibility criteria, but did not receive HDRBT between 1/1/2000 and 1/1/2021.
89202436|NCT02555046|No Intervention|General Anaesthesia|EVAR-treatment is preformed with the patient in General Anaesthesia
89472492|NCT03599921||Enhanced Cognitive behavioral therapy|Participants will receive enhance cognitive behavioral therapy.
89472493|NCT03599921||Family-based Treatment for ARFID|Participants will receive family-based treatment modified for Avoidant/Restrictive Food Intake Disorder (ARFID).
89472494|NCT03599921||FBT + UP for ARFID|Participants will receive family-based treatment with the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in Children and Adolescents, named FBT + UP for ARFID.
89472495|NCT04520295||HER2 positive cohort|
89472496|NCT04526366||The study population|All (full scientific) study designs and publication types written in English and reporting Bland-Altman test results (or other tests suggesting the presence of the required data) between simultaneous, paired, polysomnography (PSG)-derived AND Continuous Positive Airway Pressure (CPAP)-derived data describing sleep disordered breathing.
89472497|NCT03603119|Active Comparator|Group A|Dexamethasone-ondansetron
89472498|NCT03603119|Experimental|Group B|Midazolam
89472499|NCT03356847|Experimental|SISA implant|
89472500|NCT03603041|No Intervention|Control|These participants will maintain their daily food and exercise routine and will receive no intervention.
89472501|NCT03603041|Experimental|Whey Protein Supplementation|Participants will receive protein supplementation daily for 16 weeks.
89472502|NCT03603041|Experimental|Omega-3 Fatty Acids (O3FA)|Participants will receive O3FA supplementation daily for 16 weeks.
89472503|NCT03603041|Experimental|Whey Protein and O3FA|Participants will receive protein and O3FA supplementation daily for 16 weeks.
89472504|NCT03603041|Placebo Comparator|Whey Protein and Placebo Fat Source|Participants will receive protein and placebo fat source supplementation daily for 16 weeks.
89472505|NCT03123627|Experimental|New profilaxis|Prophylaxis is discontinued when the patient developed CMV-specific cellular immunity.
89472506|NCT03123627|Active Comparator|Profilaxis recommended by TTS|Valganciclovir prophylaxis until day +90 as recommended by the International Consensus document of the TTS.
89472507|NCT03138044|Experimental|Combined Treatment|The Combined Treatment: patients undergo a surgical operation of ipsilateral liver lobe devascularization and four weeks later after the operation percutaneous alcohol injection sessions.
89472508|NCT03602963||Dexcom G5 mobile CGM system|Children (6 to 18 years) with type 1 diabetes mellitus treated with insulin injections and wearing a FreeStyle Libre Flash glucose sensor that will switch to the Dexcom G5 mobile glucose monitoring system.
89472509|NCT03580551|Experimental|Intervention Group|Ten participants from each racial group (Black/White) will be assigned to the Intervention, which will receive the home-based DVD Chair Exercise Program. This is the group that will receive the chair exercise intervention upon enrollment.
89472510|NCT03580551|Active Comparator|Waitlist Control Group|Ten participants from each racial group (Black/White) will be assigned to the Waitlist Control Group, which will receive the home-based DVD Chair Exercise Program at the end of 8 weeks.
89472511|NCT05737472|Active Comparator|Standard RUTF|The standard RUTF dose is according to weight as per the WHO 2013 guideline, thus 150-220Kcal/kg/day. A child will receive a weekly ration for 8 consecutive weeks from enrolment.
89472512|NCT05737472|Experimental|High-protein RUTF|The high-protein RUTF dose is according to weight as per the WHO 2013 guideline, thus 150-220Kcal/kg/day. A child will receive a weekly ration for 8 consecutive weeks from enrolment.
89472513|NCT03602807|Experimental|Active treatment|
89472514|NCT03356769|Experimental|experimental：asprin & AEDS|Aspirin 5mg/kg，maximum 300mg; once a day plus AEDS
89472515|NCT03356769|Placebo Comparator|control: placebo & AEDS|placebo 5mg/kg，maximum 300mg; once a day plus AEDS
89472516|NCT03136952||Pediatric children under 1 yrs old|Observation study of two measurement points of cerebral oxygenation
89472517|NCT03602729|No Intervention|Group 1|No study related education given
89472518|NCT03602729|Experimental|Group 2|Written BF education
89472519|NCT03602729|Experimental|Group 3|Verbal BF education
89472520|NCT03602729|Experimental|Group 4|Video BF education
89472521|NCT05737394|Experimental|Laparoscopy-guided TAP Block|Patients will receive surgically-placed TAP block right after pneumoperitoneum induction and before Trocar insertion with levobupivacaine 0.25%, 0.5 ml/kg.
89472522|NCT05737394|Active Comparator|Ultrasound-guided TAP Block|Patients will receive ultrasound-guided TAP block performed after anesthetic induction and before surgical incision with levobupivacaine 0.25%, 0.5 ml/kg.
89472523|NCT03356691|No Intervention|Control group|No intervention.
89472524|NCT03356691|Experimental|Complementary Spiritist Therapy|"Prayer, Spirit education, Spiritist passe and magnetized water"
89472525|NCT03356691|Other|Prayer|Prayer during 1-2 minutes
89472526|NCT03356691|Other|"Spiritist passe"|"Spiritist passe during 5-10 minutes."
89472527|NCT03356691|Placebo Comparator|Laying on of hands with intent to heal|laying on of hands with intent to heal during 5-10 minutes.
89472528|NCT03356691|Other|Fluid water or magnetized water|Spiritist healers laying on of hands hands on the glass of water and desire health, restoration of balance and health for the patient.
89472529|NCT03356691|Other|Non-fluidic water|individuals receive water without fluidification (no laying on of hands hands on the glass of water).
88949044|NCT05047302|Experimental|Treatment|The goal of the BlueLeaf System is to percutaneously form one or more functional, autogenous deep venous valves and restore venous competence.
89472530|NCT03602651||MAGZEN®|All patient will be treated with MAGZEN® and will be evaluated with the Hamilton-anxiety scale (HAM-A)
89472531|NCT05737316|Experimental|Combat PD|Combat PD is an aerobic exercise programme hosted on a mobile application.
89472532|NCT05737316|Active Comparator|Usual Care|Home exercises based on a standard PD exercise booklet, consisting mainly of range of motion and stretching exercises
89472533|NCT02237963||Posterolateral thoracotomy|Surgeons perform a posterolateral thoracotomy
89472534|NCT02237963||Axillary thoracotomy|Surgeons perform an axillary thoracotomy
88949045|NCT05035706|Experimental|Treatment (biopsy, biospecimen collection)|Patients undergo biopsy prior to radiation therapy and 7-14 days after radiation therapy. Patients also undergo blood sample collection prior to therapy (within 7 days of starting radiation therapy), 1 and 7 days post completion of radiation therapy. Patients' photographs of the biopsy site are taken before and at 4-6 weeks post completion of radiation, and their medical records are reviewed for up to 2 years.
88949046|NCT05035667||Observational (questionnaires)|Patients complete questionnaires over 30 minutes about level of anxiety and social media use and management.
88949047|NCT05034393||Patients with de novo or recurrent HR-positive HER2-negative mBC|Patients diagnosed with de novo or recurrent HR-positive HER2-negative mBC from January 2018 to December 2020
89472535|NCT04508439|Experimental|Prophylactic enexaparin|Enoxaparin dose of 1mg / kg / dose twice daily
89472536|NCT04508439|Active Comparator|Therapeutic Enoxaparin|Enoxaparin dose of 1mg / kg / dose daily
89472537|NCT04088552|Experimental|ActuaYa Arm|Participants will receive educational sessions, facilitated discussions and an exercise program.
89472538|NCT03602573||pre-menopause|
89472539|NCT03602573||post-menopause|
89472540|NCT02237573|Experimental|Intervention|Written medical report and standardized medical advices
89472541|NCT02237573|Active Comparator|Control|Standardized medical advice only
89472542|NCT02237651||topical anesthesia multi-use device|anesthesia with multi-use device (Laryngeal atomizer, Karl Storz, Tuttlingen, Germany
89472543|NCT02237651||topical anesthesia Intranasal Mucosal Atomization|single-use product (LMA® MAD Nasal™ Intranasal Mucosal Atomization Device, Teleflex medical, Kernen Germany) for topical anesthesia
89472544|NCT03356613||focus group of paramedical staff from Nancy|During the focus group, the psychologist researcher asks the group a series of question about their views and opinions on research and how to make it.
89472545|NCT03356613||focus group of paramedical staff from Metz|During the focus group, the psychologist researcher asks the group a series of question about their views and opinions on research and how to make it.
89472546|NCT03356613||focus group of paramedical staff from Dijon|During the focus group, the psychologist researcher asks the group a series of question about their views and opinions on research and how to make it.
89472547|NCT03356613||focus group of paramedical staff from Bar-le-Duc|During the focus group, the psychologist researcher asks the group a series of question about their views and opinions on research and how to make it.
89472548|NCT03356613||Test of the tool by paramedical staff center 1|Paramedical staff who didn't participate to the focus group, will test the GenI tool to generate research ideas.
89472549|NCT03356613||Test of the tool by paramedical staff center 2|Paramedical staff who didn't participate to the focus group, will test the GenI tool to generate research ideas.
89472550|NCT02237729|Experimental|PF-06410293|
89472551|NCT02237729|Active Comparator|Adalimumab-US|
89472552|NCT02237729|Active Comparator|Adalimumab-EU|Adalimumab-EU will be administered as a single 40 mg, subcutaneous dose
89472553|NCT02238041||GlucoClear System|
89472554|NCT04508127||Active Procedure|The patients will receive targeted Percutaneous Spinal Cord Stimulation at suitable DRG with Axium SCS system as part of their standard treatment for lumbar pain. The lead placement will happen in 2 stages. First stage involves placement of leads and an externalised device and is a trial stage. Patient deemed to have a good response to first stage will proceed to the second stage to have the permanent implant. Again this is part of our standard care. Normally our drop out rate after first stage is less than 10% and these patients will not have subsequent tests including PET-CT scan and questionnaires.
89472555|NCT02238119|Experimental|tiotropium + formoterol|
89472556|NCT02238119|Active Comparator|tiotropium|
89472557|NCT02238119|Active Comparator|formoterol|
89472558|NCT03598985||Patients with CAI|"Patients referred with a confirmed diagnosis of CAI, with a Cumberland Ankle Instability tool score lower than 27 points. Patients should have had a recurrent sprain within the previous year.~Patients will have their balance assessed using the Myankle smartphone application simultaneously with Biodex balance system assessment."
89472559|NCT03598985||Healthy participants|"Healthy participants who are not complaining of pain and have not be exposed to trauma, injury or undergone surgery for the lower quadrant of the body.~Participants will have their balance assessed using the MyAnkle smartphone application simultaneously with Biodex balance system assessment."
89472560|NCT04508205|Experimental|Subjects with redness and bumps and/or blemishes|Topical administration twice daily for 12 weeks
89472561|NCT03598907||Standard management of coagulopathy|"The first group of existing ,,standard care - the approach to bleeding patient will be based on clinical experience of the anaesthetist, practically meaning administering crystalloids, colloids (hydroxyethyl starch or gelatin), fresh frozen plasma and erythrocytes to restore normovolemia and platelets, fibrinogen, prothrombin complex concentrate, von Willebrand factor, tranexamic acid, all products giving ,,blindly when it comes to diagnosis and treatment of coagulopathy."
89472562|NCT03598907||POC management of coagulopathy|"group of ,,point-of-care approach to the diagnosis and treatment of perioperative bleeding and coagulopathy will be conducted on the basis of the results of the POC methods ROTEM, PFA 200 and Multiplate (prothrombin complex concentrate, fibrinogen, platelets, von Willebrand factor, tranexamic acid). A solution of 5% albumin and erythrocytes (to keep haemoglobin level over 100 g/l as it is critical for normal primary haemostasis) will be used to keep normal circulating volume and to compensate for perioperative blood loss."
89472563|NCT03354117|Experimental|Ulipristal 30mg plus Meloxicam 15mg|Each study participant will complete one menstrual cycle without medication. Her second menstrual cycle, each study participant will receive ulipristal acetate plus meloxicam at peak fertility.
89472564|NCT03360981|Active Comparator|diabetics incretin-users (arm 1)|epicardial tissue biopsy, and than treated by incretin therapy plus standard anti ischemic therapy.
89472565|NCT03360981|Placebo Comparator|diabetics never-incretin-users (arm 2)|epicardial tissue biopsy, and than treated by standard hypoglycemic drug therapy plus standard anti ischemic therapy.
89472566|NCT03360981|No Intervention|non diabetics (arm 3)|non diabetics, treated by coronary artery bypass grafting (CABG), receiving epicardial tissue biopsy, and than treated by standard anti ischemic therapy.
89472567|NCT03597815||DME positive, OSA positive|Visit 1: Baseline DME Treatment. Includes first EYELEA(aflibercept) injection. (DME positive patients will receive a minimum of 6 injections with the first five occurring at 1-month intervals and the sixth occurring two months after the fifth. Further injections will be provided at the discretion of the ophthalmologist in according to the treat and extend protocol of Eylea to ensure the DME is resolved by the end of the study.) Each injection is 2 mg (0.05 mL). Visit 2: Diagnosis of OSA - Overnight sleep study Visit 3: 1 month follow up post-CPAP initiation Visit 4: 6-month visit post DME initial treatment Visit 5: 2-3 month follow up - titration study (at sleep lab) Visit 6: 12-month visit post DME initial treatment in the OSA- group and at least 3 months post CPAP initiation in the OSA+ group Visit 7: 12-month sleep apnea follow up
89472568|NCT03597815||DME positive, OSA negative|Visit 1: Baseline DME Treatment Includes first EYELEA(aflibercept) injection. (DME positive patients will receive a minimum of 6 injections with the first five occurring at 1-month intervals and the sixth occurring two months after the fifth. Further injections will be provided at the discretion of the ophthalmologist in according to the treat and extend protocol of Eylea to ensure the DME is resolved by the end of the study.) Each injections is 2 mg (0.05 mL). Visit 2: Diagnosis of OSA - Overnight sleep study Visit 3: 6-month visit post DME initial treatment Visit 4: 12-month visit post DME initial treatment in the OSA- group and at least 3 months post CPAP initiation in the OSA+ group
89472569|NCT03597815||DME negative (NPDR positive), OSA positive|no injections needed. Visit 1: Baseline NPDR diagnosis Sleep lab visits Visit 2: Diagnosis of OSA - Overnight sleep study Visit 3: 1 month follow up post-CPAP initiation Visit 4: 2-3 month follow up - titration study Visit 5: 12-month sleep apnea follow up
89472570|NCT03597815||DME negative (NPDR positive), OSA negative|no injections needed. Visit 1: Baseline NPDR diagnosis Visit 2: Diagnosis of OSA - Overnight sleep study
88949048|NCT05032105|Experimental|Intervention|Unilateral Magnetic Resonance Imaging-guided Focused Ultrasound Ablation (MRgFUSA) of the anterior nucleus of the thalamus (ATN)
88949049|NCT05020002||Single biofluid collection|We will ask eligible volunteers to provide a single urine sample and undergo a single blood draw.
88949050|NCT05020002||Serial biofluid and muscle function testing|We will ask eligible volunteers to provide a urine sample, a blood sample, and undergo standard muscle function tests once every six months over a two-year period, and undergo pulmonary function tests and electrocardiogram once per year for two years.
89202437|NCT02555046|Experimental|Local Anaesthesia|EVAR-treatment is preformed with the patient in Local Anesthesia
89202438|NCT00787878||A|
88949051|NCT05020002||Biofluid and muscle tissue biopsy|We will ask eligible volunteers to provide a urine sample and undergo a muscle biopsy once.
88949052|NCT05019625||Single biofluid collection|We will ask eligible volunteers to provide a single urine sample and undergo a single blood draw.
88949053|NCT05019625||Serial biofluid and muscle function testing|We will ask eligible volunteers to provide a urine sample, a blood sample, and undergo standard muscle function tests once every six months over a two-year period, and undergo pulmonary function tests and electrocardiogram once per year for two years.
88949054|NCT05019625||Biofluid and muscle tissue biopsy|We will ask eligible volunteers to provide a urine sample and undergo a muscle biopsy once.
88949055|NCT05019625||Ultrasound and myography testing|We will ask eligible volunteers to provide a single urine sample, a single blood draw, and undergo ultrasound and electrical impedance myography studies once.
88949056|NCT05006248|Active Comparator|Conventional robotic continuous passive movement training|The participants will be single-blinded and wear the M1 robotic device on their affected/weaker foot, and complete up to 30 minutes of continuous passive movement per training session. The participants will complete 12 training sessions.
89202439|NCT00787878||B|
89202440|NCT00787878||C|
89206194|NCT04095299|Active Comparator|A: Standard chemoradiotherapy|50.4 Gy to the tumor and elective volume. The dose is given in 28 fractions on weekdays concomitantly with capecitabine 825 mg/m2 twice daily on weekdays.
89206195|NCT04095299|Experimental|B: High-dose radiotherapy|62 Gy to the clinical tumor volume and 50.4 Gy to the elective volume. The dose is given in 28 fractions on weekdays concomitantly with capecitabine 825 mg/m2 twice daily on weekdays
89206196|NCT00296725|Experimental|fluoxetine / Imipramine|fluoxetine or Imipramine
89019466|NCT02960048|Experimental|Stabilizing splint|"A 2-mm-thick, hard, clear sheet of resin will be adapted to the maxillary arch .~Small amount of self-curing acrylic will be added to the anterior portion of the appliance as a stop for the lower incisor. The area of this stop is approximately 4 to 6 mm. The patient should be instructed to close in Centric relation . Self-curing acrylic will be added to the occluding surface of the appliance. All occluding areas, except the contact on the anterior stop .~Excess acrylic surrounding the centric contacts is removed with a hard rubber wheel on a lathe. All areas, except labial to the mandibular canines, are flattened to the contact marks. This area will create the eccentric guidance."
89019467|NCT00309569|Experimental|A (pre- + postoperative chemotherapy)|3 cycles CMF (cyclophophamide + Methotrexat + 5-Fluorouracil) followed by surgery. Subsequently node-positive patients received 3 cycles anthracycline-based chemotherapy regime EC (epirubicin + cyclophosphamide) and node-negative patients another 3 cycles CMF.
89019468|NCT00309569|Experimental|B (conventional postoperative chemotherapy)|Surgery followed by 3 cycles CMF (cyclophophamide + Methotrexat + 5-Fluorouracil). Subsequently node-positive patients received 3 cycles anthracycline-based chemotherapy regime EC (epirubicin + cyclophosphamide) and node-negative patients another 3 cycles CMF.
89019469|NCT00338715|Experimental|A|Prophylactic Pulmonary Vein Isolation in Addition to CABG for the prevention of postoperative Atrial Fibrillation
89019470|NCT00309647|Experimental|H5N1 Formulation 1 Group|Subjects in this group received 2 doses of H5N1 adjuvanted formulation 1 vaccine at a 21-day interval
89019471|NCT00309647|Experimental|H5N1 Formulation 2 Group|Subjects in this group received 2 doses of H5N1 adjuvanted formulation 2 vaccine at a 21-day interval
89019472|NCT00309647|Experimental|H5N1 Formulation 3 Group|Subjects in this group received 2 doses of H5N1 adjuvanted formulation 3 vaccine at a 21-day interval
89019473|NCT00309647|Experimental|H5N1 Formulation 4 Group|Subjects in this group received 2 doses of H5N1 adjuvanted formulation 4 vaccine at a 21-day interval
89019474|NCT00309647|Active Comparator|H5N1 Formulation 5 Group|Subjects in this group received 2 doses of H5N1 formulation 5 vaccine at a 21-day interval
89019475|NCT00309647|Active Comparator|H5N1 Formulation 6 Group|Subjects in this group received 2 doses of H5N1 formulation 6 vaccine at a 21-day interval
89019476|NCT00309647|Active Comparator|H5N1 Formulation 7 Group|Subjects in this group received 2 doses of H5N1 formulation 7 vaccine at a 21-day interval
89019477|NCT00309647|Active Comparator|H5N1 Formulation 8 Group|Subjects in this group received 2 doses of H5N1 formulation 8 vaccine at a 21-day interval
89206197|NCT00625872|Active Comparator|Treatment Group|Somatropin for 12 months
89019478|NCT00341835||High risk lung cancer families|Individuals from families with a high risk of lung cancer, both affected and unaffected family members
89019479|NCT00418847|Experimental|1|
89019480|NCT00341952||Cases|individuals diagnosed with incident, first primary non-Hodgkin lymphoma
89472571|NCT02876315|Experimental|Redoxon VI|2 film coated tablets Redoxon VI oral intake daily for 12 weeks
89472572|NCT02876315|Placebo Comparator|Placebo|2 film coated tablets placebo oral intake daily for 12 weeks
89206198|NCT00625872|Other|Control Group|In the first 6 months no intervention, afterwards Somatropin for 12 months
89472573|NCT03356457|Active Comparator|DCA in T1DM with severe hypoglycemia|12 T1DM subjects (C-peptide negative, HbA1c <7.5%) with a history of severe hypoglycemia and hypoglycemia unawareness as assessed by the Guy's and Thomas' Minimally Modified Clarke Hypoglycemia Survey, the Gold Score and the Edinburgh Hypoglycemia Survey and as evidenced by interview and glucose log and/or continuous glucose monitoring will receive a single dose of 12.5mg/kg dichloroacetate (DCA).
89472574|NCT03356457|Placebo Comparator|Placebo in T1DM with severe hypoglycemia|12 T1DM subjects (C-peptide negative, HbA1c <7.5%) with a history of severe hypoglycemia and hypoglycemia unawareness as assessed by the Guy's and Thomas' Minimally Modified Clarke Hypoglycemia Survey, the Gold Score and the Edinburgh Hypoglycemia Survey and as evidenced by interview and glucose log and/or continuous glucose monitoring will receive a placebo oral capsule.
89472575|NCT03356457|Active Comparator|DCA in healthy control subjects|12 non-diabetic healthy subjects (fasting plasma glucose < 100 mg/dL, HbA1c < 6.0%), who are matched for age, gender, and weight to T1DM subjects, to serve as controls for the study. Each subject will receive a single dose of 12.5mg/kg dichloroacetate (DCA).
89472576|NCT03356457|Placebo Comparator|Placebo in healthy control subjects|12 non-diabetic healthy subjects (fasting plasma glucose < 100 mg/dL, HbA1c < 6.0%), who are matched for age, gender, and weight to T1DM subjects, to serve as controls for the study will receive a placebo oral capsule.
89472577|NCT03356379|Experimental|Patients|Patients suspected of PES will have a transcutaneous oximetry test during tiptoeing
89472578|NCT03356379|Sham Comparator|Controls|Healthy asymptomatic athletes will have a transcutaneous oximetry test during tiptoeing
89472579|NCT03595241|Experimental|Group A - active treatment|
89472580|NCT03595241|No Intervention|Group B - conservative management|
89472581|NCT03595085|Experimental|catheter directed interventions|Those patients will undergo catheter directed fragmentation followed by local thrombolysis using streptokinase
89472582|NCT03595085|Active Comparator|systemic thrombolysis|Those patients will receive systemic streptokinase
89472583|NCT04507971|Experimental|MET-3 2.5 g daily for 4 weeks|MET-3 is composed of twenty-two strains of bacteria and was designed to treat metabolic syndrome. The strains that were selected are based on strains that are known butyrate producers, associated with healthy subjects and improved gut barrier function. MET-3 is provided in capsule form and 5 capsules will be swallowed by each subject once daily for 4 weeks.
89472584|NCT04507971|Experimental|MET-5 2.5 g daily for 4 weeks|MET-5 is a new product composed of twenty-six strains of bacteria isolated from the stool of a different healthy donor than MET-3. Although it is expected to work in a similar fashion to MET-3, it contains some strains that are unique in comparison to the original MET-3 formulation and have been associated with leanness in the scientific literature. MET-5 is provided in capsule form and 5 capsules will be swallowed by each subject once daily for 4 weeks.
89472585|NCT03356301|Experimental|Triathletes|Every triathlete will realize three cardiac MRI exams.The second of those will be done at the fitness peak, 2-3 weeks before the main objective of the sports season. Training will be increased between the study beginning and the first MRI, and the second exam. After each cardiac MRI, an applanation tonometry examination will aslo be performed.
89472586|NCT03356301|Experimental|Controls|Every control subject will also realize three cardiac MRI exams if possible at the same time as the triathletes.They must be not engaged in physical activity more than 150 minutes a week on average. After each cardiac MRI, an applanation tonometry examination will aslo be performed.
89202441|NCT00354679|Experimental|Irinotecan, Cisplatin, Bevacizumab, Radiotherapy, & Surger|"Induction therapy: Patients receive cisplatin IV over 30 minutes and irinotecan hydrochloride IV over 30 minutes on days 1, 8, 22, and 29. Patients also receive bevacizumab IV over 30-90 minutes on days 1 and 22.~Combination therapy and radiotherapy: Patients receive cisplatin and irinotecan hydrochloride as in induction chemotherapy on days 43, 50, 64, and 71. Patients also receive bevacizumab IV over 30-90 minutes on days 43 and 64. Patients undergo external beam radiotherapy 5 days a week for 6 weeks beginning on day 43. Surgery: Patients undergo surgery 6-8 weeks after finishing combination therapy and radiotherapy.~Maintenance therapy: Approximately 6 weeks after surgery, patients receive bevacizumab IV over 30-90 minutes every 3 weeks for 6 months"
89472587|NCT03594851|Experimental|Administration of individualized advice|"Administration of individualized advice to improve the quality of older people's sleep, based on the following interventions :~Pittsburgh Sleep Quality Index, Sleep diary, Mini Mental State Examination, Autonomy assessment (Katz Index of Independence in Activities of Daily Living~& Lawton Instrumental Activities of Daily Living), Neuropsychiatric Inventory (Cummings) for the caregiver, if applicable, Mini Zarit Caregiver Burden Scale, for the caregiver, if applicable, Cornell Scale for Depression in Dementia, Quality of Life in Alzheimer's Disease, Neuropsychiatric Inventory"
89472588|NCT00158756|Experimental|Tritanrix™-HepB+Rotarix™ Group|Subjects received 3 doses of Tritanrix™-HepB vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Rotarix™ vaccine at 3 and 4.5 months of age.
89019481|NCT00341952||Controls|individuals identified in the same geographical areas without non-Hodgkin lymphoma or othercancers
89472589|NCT00158756|Experimental|Tritanrix™-HepB+Placebo Group|Subjects received 3 doses of Tritanrix™-HepB vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Placebo for Rotarix™ vaccine at 3 and 4.5 months of age.
89472590|NCT00158756|Active Comparator|Zilbrix™+Rotarix™ Group|Subjects received 3 doses of Zilbrix™ vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Rotarix™ vaccine at 3 and 4.5 months of age.
89472591|NCT00158756|Active Comparator|Zilbrix™+Placebo Group|Subjects received 3 doses of Zilbrix™ vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Placebo for Rotarix™ vaccine at 3 and 4.5 months of age.
89472592|NCT00158756|Active Comparator|Triple Antigen™+Engerix™-B Group|Subjects received 3 separate doses of Triple Antigen™ and Engerix™-B vaccines at 3, 4.5 and 6 months of age, intramuscularly into the left and right anterolateral thighs, respectively.
89472593|NCT03353883|Active Comparator|(Group A) Midluteal Triptorelin depot|infertile women with impaired ovulation who will be subjected to Triptorelin sustained release(Decapeptyl depot 375 mg one injection )at D-21 of previous menstrual cycle Hormon Replacement Therapy (HRT)Cyclo-Progynova (estradiol, norgestrel)(Group A). All patients received the same luteal support in the form of intravaginal progesterone two day before embryos transfer until blood pregnancy test was performed 14 days later. The classic Testart slow freezing and rapid thawing protocol was applied on stage-2 PN embryos. Endometrial thickness was measured in the midsagittal plane using transvaginal ultrasound (TVU). Clinical pregnancy was diagnosed by measurement of β-HCG level and was confirmed 2-weeks later by TVU.
89537386|NCT02465801|Experimental|Group 2|"Intervention:HSA-GCSF 1.5 mg~Drug: TE or TEC TE: Taxotere+Epirubicin Taxotere (75mg/m2) and Epirubicin (75mg/m2), IV on day 1 of each 21 chemotherapy cycle.~TEC:Taxotere+Epirubicin+Cyclophosphamide Taxotere (75mg/m2),Epirubicin (75mg/m2) and Cyclophosphamide (500mg/m2), IV on day 1 of each 21 chemotherapy cycle.~Recombinant Human Serum Albumin/Granulocyte Colony-Stimulating Factor Fusion Protein（1.5mg）will be injected subcutaneously at night o'clock a.m. in the 3rd and 7th day of per chemotherapy cycle. After the injection, stop administrating if Absolute Neutrophil Count (ANC) in peripheral blood exceeded 1.5×109/L at two contiguous times at least. If not up to standard, investigator should decide whether or not the third administration.~Intervention: Drug: TE or TEC"
89537387|NCT02465801|Active Comparator|Group 3|"Intervention: GCSF~Drug: TE or TEC TE: Taxotere+Epirubicin Taxotere (75mg/m2) and Epirubicin (75mg/m2), IV on day 1 of each 21 chemotherapy cycle.~TEC:Taxotere+Epirubicin+Cyclophosphamide Taxotere (75mg/m2),Epirubicin (75mg/m2) and Cyclophosphamide (500mg/m2), IV on day 1 of each 21 chemotherapy cycle.~Recombinant Human Granulocyte Colony-Stimulating Factor Injection (5μg/kg/day) will be injected subcutaneously at night o'clock a.m. from the 3rd of per chemotherapy cycle. After the injection, stop administrating if Absolute Neutrophil Count (ANC) in peripheral blood exceeded 1.5×109/L at two contiguous times at least. The maximum of usage was continuous 14 days.~Intervention: Drug: TE or TEC"
89472594|NCT03353883|Active Comparator|(Group B)first day Triptorelin depot|infertile women with impaired ovulation who will be subjected toTriptorelin sustained release(Decapeptyl depot 375 mg one injection) at D-1 of menses then Cyclo-Progynova (estradiol, norgestrel) (Group B). All patients received the same luteal support in the form of intravaginal progesterone two day before embryos transfer until blood pregnancy test was performed 14 days later. The classic Testart slow freezing and rapid thawing protocol was applied on stage-2 PN embryos. Endometrial thickness was measured in the midsagittal plane using transvaginal ultrasound (TVU). Clinical pregnancy was diagnosed by measurement of β-Human Chorionic Gonadotropin level and was confirmed 2-weeks later by TVU.
89472595|NCT03360669|Experimental|Sequence: Clinical/Research|Participants assigned to this arm will have their blood pressure measured in a clinical setting first, and in a research setting second. The sequence randomization corresponds to the intervention. Visits will be at least a day apart but within a two-week period. During the clinical visit, they will have their blood pressure measured with the Omron HEM-907, an automated office blood pressure (AOBP) device. During the research setting, participants will be guided through a series of research-driven steps such as study questionnaires and completion of consent forms. They will have their blood pressure measured in both arms with a mercury sphygmomanometer, and then 3 measurements with a mercury sphygmomanometer. AOBP measurements (Omron HEM-907) will be performed at the end of the visit.
89472596|NCT03360669|Active Comparator|Sequence: Research/Clinical|Participants assigned to this arm will go through the same measurements and procedures exception made of the research-first and clinical-second sequence. The intervention to which they are randomized corresponds to the sequence of the visits.
89472597|NCT03110276|Experimental|EYP001a|
89472598|NCT03110276|Placebo Comparator|Placebo|
89472599|NCT03356067|Sham Comparator|Esophago-gastro-duodenoscopy|Standard endoscopic examination of the upper GI tract with flexible endoscope.
89472600|NCT03356067|Experimental|Gastric endoscopic peroral pyloromyotomy|Experimental per-oral endoscopic myotomy of the pyloric sphincter
89472601|NCT03355989|Experimental|Low Flat Rate without Lottery|The intervention consists of receiving a small cash incentive of $0.80 on every vaccine along with 3 SMS reminders before, at and after the due date. The incentive will be sent via mobile top - up.
88949057|NCT05006248|Experimental|Visual Feedback|The participants will be single-blinded and wear the M1 robotic device in transparency mode on their affected/weaker foot, and complete up to 30 minutes of training with visual biofeedback (games). The participants will complete 12 training sessions. The transparency mode of the robotic device compensates for its weight and friction so that the participant does not feel weight while moving the device.
88949058|NCT05006248|Experimental|Haptic and Visual Feedback|The participants will be single-blinded and wear the M1 robotic device in assistance mode on their affected/weaker foot, and complete up to 30 minutes of training with visual biofeedback (games). The participants will complete 12 training sessions. The assistance mode of the robotic device applies assistive/resistive torque based on muscle activity.
88949059|NCT04989959|Experimental|Pre-Surgical|Patients with suspected RCC planned for surgery
88949060|NCT04989959|Experimental|Metastatic or VHL Syndrome|Patients with metastatic ccRCC or VHL syndrome and RCC
88949061|NCT04989959|Experimental|Planned belzutifan treatment|Patients with VHL syndrome with RCC, CNS hemangioblastoma, and/or pancreatic neuroendocrine tumor(s) planning to start belzutifan.
88949062|NCT04973852|Experimental|Exoskeleton|5 sessions of overground ambulation with wearable exoskeleton where heart rate is monitored over each session.
88949063|NCT04971200|Experimental|Vitiligo Patients on Tildrakizumab|
88949064|NCT04931225|Experimental|Landiolol injection|Intravenous Landiolol injection (from 0.5 to 10 µg/kg/min during 12 hours) up to a 15% decrease in HR on microcirculatory vascular reactivity.
88949065|NCT04931225|No Intervention|Usual tachycardia management|No treatment, usual tachycardia management.
88949066|NCT04906512|Experimental|3M™ Tegaderm™ CHG I.V. Securement Dressing|The primary purpose of 3M™ Tegaderm™ CHG I.V. Securement Dressing is to secure devices to skin; and secondly, the dressing contains an antimicrobial ingredient that inhibits microbial regeneration. This product is used to cover and protect the catheter sites on the body surface and to secure devices to skin and is available in a variety of models and sizes.
89019482|NCT00341991||1|Cases from hospitals
89472602|NCT03355989|Experimental|Low Flat Rate with Lottery|The intervention consists of a 20% chance of receiving a small cash incentive of $4.00 on every vaccine along with 3 SMS reminders before, at and after the due date. The incentive will be sent via mobile top - up.
89472603|NCT03355989|Experimental|Low Sharp Rate without Lottery|The intervention consists of receiving a small cash incentive of $0.75 on the BCG/Penta-1/Penta-2 vaccine and $1.00 on the Measles-1/Measles 2 vaccine along with 3 SMS reminders before, at and after the due date. The incentive will be sent via mobile top - up.
89472604|NCT03355989|Experimental|Low Sharp Rate with Lottery|The intervention consists of a 20% chance of receiving a small cash incentive of $3.75 on the BCG/Penta-1/Penta-2 vaccine and $5.00 on the Measles-1/Measles 2 vaccine along with 3 SMS reminders before, at and after the due date. The incentive will be sent via mobile top - up.
89472605|NCT03355989|Experimental|High Flat Rate without Lottery|The intervention consists of receiving a large cash incentive of $2.40 on every vaccine along with 3 SMS reminders before, at and after the due date. The incentive will be sent via mobile top - up.
89472606|NCT03355989|Experimental|High Flat Rate with Lottery|The intervention consists of a 20% chance of receiving a large cash incentive of $12.00 on every vaccine along with 3 SMS reminders before, at and after the due date. The incentive will be sent via mobile top - up.
89202442|NCT00683696|Experimental|CRT=ON|Cardiac Resynchronization Therapy activated.
89202443|NCT00683696|Active Comparator|CRT=OFF|Cardiac Resynchronization Therapy deactivated.
89202444|NCT00345631|Active Comparator|Manual Compression|Manual compression (MC)
89202445|NCT00345631|Experimental|Vascular Closure Device|Vascular Closure Device (VCD)
89202446|NCT00540514|Experimental|Albumin-bound paclitaxel + Carboplatin|Participants received albumin-bound paclitaxel (ABRAXANE®) 100 mg/m^2 administered as an intravenous infusion over 30 minutes on Days 1, 8, and 15 of each 21-day cycle. Carboplatin was given at an Area Under the Curve (AUC) = 6 mg*min/mL on Day 1 only of each 21-day cycle, beginning immediately after the completion of albumin-bound paclitaxel administration. Participants could continue treatment at the investigator's discretion until disease progression, development of an unacceptable toxicity, or withdrawal of consent.
89202447|NCT00540514|Active Comparator|Paclitaxel + Carboplatin|Participants received 200 mg/m^2 paclitaxel (Taxol®) administered by intravenous infusion followed by carboplatin at AUC = 6 mg*min/mL on Day 1 of a 21 day cycle. Participants could continue treatment at the investigator's discretion until disease progression, development of an unacceptable toxicity, or withdrawal of consent.
89202448|NCT00752960||A|Patients receiving olanzapine
89202449|NCT00752960||B|patients receiving risperidone
89202450|NCT00752960||C|Patients receiving quetiapine
89202451|NCT00752960||D|Patients receiving aripiprazole
89202452|NCT00752960||E|patients receiving ziprasidone
89202453|NCT00663702|Experimental|1|
89202454|NCT03986281|Active Comparator|Omron HeartGuide Smartwatch|Readings from the Omron HeartGuide Smartwatch
89202455|NCT03986281|Active Comparator|Arterial Line|Readings from the arterial line
88949067|NCT04906512|Active Comparator|3M™ Tegaderm™ Transparent Film Dressing 1626W|Transparent dressing, i.e. CHG-free transparent dressing, can be used to cover and protect catheter sites on the body surface and to secure devices to skin, without any antibacterial ingredients, and are the currently most commonly used transparent dressings in DVC care in China.
88949068|NCT04905277|Experimental|Atenolol|Study subjects will take Atenolol 50 mg daily over 2 years
89019483|NCT00341991||2|Controls from the general populations
89202456|NCT02022592|Experimental|Lormetazepam|The patient is treated on ICU not longer than 2 days. Dosage requirements according to Summary of product characteristics (Sedalam®).
89202457|NCT02022592|Active Comparator|Midazolam|The patient is treated on ICU not longer than 2 days. Dosage requirements according to Summary of product characteristics (Midazolam-ratiopharm®, Midazolam-hameln®).
89202458|NCT00683618|Experimental|1|Rosuvastatin 5mg qd
89202459|NCT00683618|Experimental|2|Rosuvastatin 10mg qd
89202460|NCT00683618|Active Comparator|3|Atorvastatin 10mg qd
89202461|NCT01057537|Experimental|polypill|Red Heart Pill Version 1 and Red Heart Pill Version 2. In general, participants with a history of coronary heart disease will be given version 1, and those with a history of stroke or cerebrovascular disease will be given version 2.
89202462|NCT01057537|Active Comparator|Usual Care|Participants in the usual care arm will take their usual cardiovascular medications. The participants will be seen as needed by their usual doctor between study visits.
89202463|NCT00795756|Experimental|Intrathecal DepoCyte|I.t. DepoCyte 50 mg admninistered x6-8 (depending on immunophenotypic disease subset) during induction/consolidation/eraly maintenance phases
89202464|NCT00795756|Active Comparator|Triple intrathecal therapy (TIT)|Methotrexate 12,5 mg + Cytarabine 50 mg + Prednisolone 40 mg injected intrathecally x12 during indiction/consolidation phases
89202465|NCT04058522|Experimental|Group Physiotherapy|1 class per week for 6 weeks (30 min length) aiming for 5-10 participants per class. Classes included advice on the nature of the condition and exercises for scapulo-humeral mobility, scapulo-humeral stability and specific rotator cuff rehabilitation exercises
89202466|NCT04058522|Active Comparator|Routine Physiotherapy|Individual physiotherapy sessions: 6 sessions weekly (30 min) for 6 weeks. Treatment was based on evidence-based guidelines for the treatment of shoulder impingement (CSP 2005) and consisted of mobilisation techniques, supervised exercises and stretches.
89202467|NCT04004026||Multiple sclerosis patient|First day, first evaluator will perform all tests, and second day, second evaluator will perform 3 m backwards walk test.
89202468|NCT00795834|Placebo Comparator|Beverage|
89202469|NCT00795834|Active Comparator|High Polyphenol Beverage|
89202470|NCT00749840||HIV Care Questionnaire|Patients with a new diagnosis of HIV infection.
89472607|NCT03355989|Experimental|High Sharp Rate without Lottery|The intervention consists of receiving a large cash incentive of $2.25 on the BCG/Penta-1/Penta-2 vaccine and $3.00 on the Measles-1/Measles 2 vaccine along with 3 SMS reminders before, at and after the due date. The incentive will be sent via mobile top - up.
89019484|NCT00341991||3|Biological Samples
89472608|NCT03355989|Experimental|High Sharp Rate with Lottery|The intervention consists of a 20% chance of receiving a large cash incentive of $11.25 on the BCG/Penta-1/Penta-2 vaccine and $15.00 on the Measles-1/Measles 2 vaccine along with 3 SMS reminders before, at and after the due date. The incentive will be sent via mobile top - up.
89472609|NCT03355989|Experimental|Easypaisa Flat Rate without Lottery|The intervention consists of receiving a large cash incentive of $2.40 on every vaccine along with 3 SMS reminders before, at and after the due date. The incentive will be sent via mobile money transfer i.e. easypaisa
89472610|NCT03355989|Experimental|Easypaisa Flat Rate with Lottery|The intervention consists of a 20% chance of receiving a large cash incentive of $12.00 on every vaccine along with 3 SMS reminders before, at and after the due date. The incentive will be sent via mobile money transfer i.e. easypaisa
89472611|NCT03355989|Experimental|SMS Reminder Only|The intervention consists of only sending 3 SMS reminders before, at and after the due date.
89472612|NCT03355989|No Intervention|Control|No intervention will be provided either in the form of cash incentive or reminder SMS. Vaccination facilities will be provided as per usual.
89472613|NCT04071782|Experimental|SELUTION Drug Coated Balloon|Study participants will undergo lower limb angioplasty using SELUTION DCB, which is coated with sirolimus.
89472614|NCT03353727|Experimental|Orthoptic rehabilitation|
89472615|NCT04034576|Experimental|TAU + mindfulness intervention|The mindfulness-based intervention consists of three five to ten minutes session-introducing interventions (mindful walking, body scan, breathing space). At the beginning of each of the 24 therapy sessions patients receive one of the three mindfulness interventions. Each intervention is instructed for four sessions consecutively and eight sessions in total. After completion of the mindfulness intervention, the regular therapy session begins.
89472616|NCT04034576|Active Comparator|TAU + relaxation intervention|The relaxation interventions (progressive muscle relaxation (PMR), imagery journey, walking relaxation) are parallelized to the three mindfulness-based interventions. At the beginning of each of the 24 therapy sessions, patients receive one of the three relaxation interventions. Each intervention is instructed for four sessions consecutively and eight sessions in total. After completion of the relaxation intervention, the regular therapy session begins.
89019485|NCT00338832|Experimental|1|Participants will receive the Physically Ready for Invigorating Movement Every Day program
88949069|NCT04905277|Placebo Comparator|Placebo|Study subjects will take a placebo daily over 2 years
88949070|NCT04892472|Experimental|Arm 1: Treatment Group|Pembrolizumab (MK-3475) and TTFields
89019486|NCT00338832|Active Comparator|2|Participants will receive the Program for Activity, Leisure Skills, and Socialization
88949071|NCT04892472|Experimental|Arm 2: Control Group|Pembrolizumab (MK-3475)
88949072|NCT04889911|Experimental|Narrative Enhancement and Cognitive Therapy- Young Adult, Combined with Coordinated Specialty Care|NECT is a structured, 20-session group-based treatment called that combines psychoeducation, cognitive restructuring, and elements of narrative psychotherapy. NECT-YA will be modified to meet the needs of people who have experienced an FEP and may have fewer sessions or be provided in individual format or via telehealth for this study. NECT-YA will be offered to participants who are also receiving treatment within Coordinated Specialty Care programs for First Episode Psychosis.
88949073|NCT04889911|Active Comparator|Coordinated Specialty Care|Coordinated Specialty Care is an evidence-based treatment for FEP that includes multiple treatment components. The FEP programs in at the recruiting site follow the Coordinated Specialty Care model.
88949074|NCT04888312|Experimental|Intravenously administered mitazalimab given in combination with chemotherapy|Mitazalimab, a human monoclonal antibody targeting CD40, administered intravenously every 14 days, in combination with standard of care chemotherapy modified FOLFIRINOX.
89019487|NCT00338871|Experimental|study|home exercise
89019488|NCT00338871|No Intervention|control|regular therapy
89019489|NCT00310115||Smoking Prevention Usual Care|Arm I (usual care): Self-help materials and brief relapse prevention advice based on Treating Tobacco Use and Dependence Clinical Practice Guideline.
89472617|NCT04034576|Other|Treatment as usual|Standard cognitive behavior therapy treatment, based on the individualized case conception of the trainee therapist, is conducted during the whole treatment sessions. No particular session-introductions are applied.
89472618|NCT03353649|Experimental|Binge Eating Group|"(1) exposing subjects to specific stimulus sets relevant to the sample that may promote engagement of appetitive drives (images of highly palatable foods for obese individuals), and (2) exposing them to an instructional manipulation designed to engage self-regulatory processes in the presence of these stimulus sets. Specifically, participants in this sample will be exposed to images of food and control non-food images. In different trials, subjects will be given a now cue instructing them to engage with the immediate hedonic properties of the stimulus or a later cue instructing them to imagine the long-term consequences of using the stimulus.~This arm includes fMRI and the now vs. later cue intervention"
89472619|NCT03353649|Experimental|Smoking Group|"(1) exposing subjects to specific stimulus sets relevant to the sample that may promote engagement of appetitive drives (tobacco-related images or smokers), and (2) exposing them to an instructional manipulation designed to engage self-regulatory processes in the presence of these stimulus sets.~A similar approach to the Binge Eating sample will be used for the smoking sample using two stimulus sets. Instead of foods and non-food control images, smokers will see smoking-related images and the same control non-food non-smoking images as the Binge Eating sample.~This Arm includes fMRI and the now vs. later cue intervention"
89472620|NCT04519125|Experimental|Intervention|Tenofovir/ Emtricitabine ( 300 mg / 200 mg daily during 60 days) + Personal Protective Equipment (PPE)
89472621|NCT04519125|Placebo Comparator|Placebo|(1 tablet daily during 60 days) + Personal Protective Equipment (PPE)
89472622|NCT03353571|Other|C3 PATIENT PARTICIPANTS|This single arm prospective study is designed to produce valid scientific evidence regarding safety and efficacy of the C3 in establishing urinary drainage and allowing the control of micturition when indwelling for up to 7 days in patients. The total study population will initially include 50 subjects with open enrollment of additional subjects.
89472623|NCT04519281||Group (A)|consists of 50 patients undergoing open heart surgeries who will receive IV ascorbic acid
89472624|NCT04519281||Group (B)|consists of 50 patients undergoing open heart surgeries who will not receive ascorbic acid or will receive a placebo (Control Group).
89472625|NCT03353493|Experimental|MBCT + TAU|Mindfulness-based Cognitive Therapy (MBCT) a 8 week group based intervention delivered according to the protocol by Segal, Williams and Teasdale (2013) plus treatment as usual (TAU) . TAU is restricted to antidepressant medication and no psychological therapy.
89472626|NCT03353493|Other|TAU|Treatment as Usual (TAU). TAU is restricted to antidepressant medication and no psychological therapy.
89019490|NCT00310115||MRP|Arm II (motivational relapse prevention [MRP]): Same intervention as usual care, plus 30 minutes telephone counseling at 34 & 36 weeks gestation then at 2, 4, 7, & 16 weeks postpartum.
89019491|NCT00310115||Enhanced MRP +|Arm III (enhanced MRP [MRP+]): Same intervention as usual care and telephone counseling as MRP, plus 1 hour in-person counseling at 30-33 weeks gestation & 8 weeks postpartum.
89019492|NCT00418730|Experimental|1|
89019493|NCT00418730|Active Comparator|2|
89019494|NCT00418730|Placebo Comparator|3|
88949075|NCT04880083|Experimental|Formula-Fed (FF) Group|Subjects will be fed commercial bovine milk-based, whey-predominant, α-lactalbumin-enriched term formula with high sn-2 palmitate fat blend, supplemented with oligofructose for 6 weeks.
89019495|NCT00339027||Preschool children|Children aged 3-5 years who are enrolled in federally-subsidized early care and education centers in underserved communities in Miami-Dade County
89019496|NCT00342108|Experimental|1|Diagnosis: CP, moderate to severe MR and CVI
89019497|NCT00342108|Experimental|2|Diagnosis: CP, Moderate to severe MR, no visual impairment
89019498|NCT00342147||1|This is a high risk population of families for NPC
89019499|NCT00310544|Experimental|Arm 2|
89019500|NCT00310544|Experimental|Arm 1|
89019501|NCT00310661|Placebo Comparator|Placebo|Placebo hard gelatin capsules matching the investigational medication
89019502|NCT00310661|Experimental|Sarizotan HCI|Sarizotan HCI is administered at various doses ranging from 2-7mg.
89472627|NCT03360435||Participants with transdermal patches|All study subjects will belong to the same group. This group will undergo bariatric surgery and will use a transdermal patch for vitamin and mineral supplementation post operatively. The transdermal patch will be the Patch MD MultiVitamin Plus patch
89472628|NCT02730195|Experimental|Pioglitazone & TKI therapy|Patients receive pioglitazone PO QD on days 1-28. Patients also start or continue the same tyrosine kinase inhibitor (TKI) therapy at the pre-discontinuation doses. Courses repeat every 28 days for 6 months in the absence of disease progression or unacceptable toxicity.
89472629|NCT03360357|Experimental|guided drills|These people will be going through all the guided drills before being evaluated.
89472630|NCT03360357|No Intervention|Self-trained|These people will watch a video and be able to practice by themselves without having any direction regarding how and what to practice.
89472631|NCT04444557||Turkish hemodialysis patients|Turkish patients undergoing in-center hemodialysis
89472632|NCT04444557||Temporarily protected Syrian hemodialysis patients|Temporarily protected Syrian patients undergoing in-center hemodialysis
89019503|NCT00421044|Experimental|Arm A (Normal liver function)|
89019504|NCT00421044|Experimental|Arm B (Mild liver dysfunction)|
89019505|NCT00421044|Experimental|Arm C (Moderate liver dysfunction)|
89019506|NCT04715256|Experimental|KCNQ1 mutated subjects|"This arm includes :~KCNQ1-mutated subjects with long QT Romano-Ward syndrome~KCNQ1-mutated subjects without phenotypic expression of the Romano-Ward syndrome~family relatives of a KCNQ1-mutated enrolled subject, carrying the KCNQ1 family mutation"
89019507|NCT04715256|Sham Comparator|Healthy subjects|Healthy subjects will be matched to KCNQ1 subjects. The matching factors will be age per decade (18-28 years, > 28-38 years, > 38-48 years), gender and body mass index (BMI: ≤ 24.9 kg/m2; 25-29.9 kg/m2; > 30 kg/m2).
89019508|NCT00310778|Experimental|1|treatment
89019509|NCT00310895|Experimental|Dose escalation|Treatment Schedule 3 will consist of dosing on Days 1, 4, 8, and 11 of each 21 day cycle (3 weeks equals 1 cycle) and Treatment Schedule 4 will consist of dosing on Day 1 of each 28 day cycle (4 weeks equals 1 cycle)
89472633|NCT03353337|Experimental|aerobic exercise|Cycling at the intensity of 50%-70% of maximum heart rate (220-age) for 30 mins per day, 4 days per week, last for 1 month.
89472634|NCT03353337|Placebo Comparator|Placebo controlled group|General intensity activities of recreation therapy, including Handicraft manufacture, reading activity, singing entertainment, walking.
89472635|NCT03123159||HBV Infected patients|chronic HBV patients who will undergo standard of care FDA approved antiviral therapy to treat HBV infections. Will have blood drawn to be tested using the DxN HBV Assay. Study is observational and results will not be used to manage patient care.
89472636|NCT03123237|Placebo Comparator|Control|"control will be subjected to:~• Quantitative Tc99m DMSA renal scan using SPECT technique."
89019510|NCT00421122|Active Comparator|1|Bricasol®
88949076|NCT04880083|No Intervention|Breast-Fed (BF) Group|Subjects will continue exclusive/ predominant breastfeeding for 6 weeks. Breastmilk may be consumed directly from the breast or breast milk may be expressed and fed through infant feeding bottle.
88949077|NCT04857671|Experimental|Botulinum toxin A injections|Botulinum toxin A (Botox)
88949078|NCT04857671|Placebo Comparator|placebo injections|Isotone saline water
89472637|NCT03123237|Active Comparator|Diabetic|"diabetic cases will be subjected to:~• Quantitative Tc99m DMSA renal scan using SPECT technique."
88949080|NCT04855864|Other|BCR TKA|Patients with intact and functional ACL and PCL will be treated with the BCR design
88949081|NCT04855864|Other|BCS TKA|Patients with an afunctional or absent ACL and/or PCL will be treated with the BCS design
88949082|NCT04855864|Other|PS TKA|Patients with an afunctional or absent ACL and/or PCL will be treated with the PS design
88949083|NCT04853004||Study cohort|Personnel in health and care in Stockholm County, who have previously participated in a study where data on sick leave, SARS-Cov2 infections and SARS-CoV2 antibody levels were collected and documented form the study cohort.
88949084|NCT04836637|Placebo Comparator|Product with placebo (no calcium supplementation).|Maltodextrin with 0 mg calcium in capsules and sachets consumed orally daily for one year.
88949085|NCT04836637|Active Comparator|Product with calcium-carbonate|800 mg calcium as calcium-carbonate in capsules and sachets consumed orally daily for one year.
88949086|NCT04836637|Experimental|"Product with calcium-enriched permeate Capolac"|800 mg of calcium from calcium-enriched permeate in capsules and sachets consumed orally daily for one year.
89472638|NCT03123237|Active Comparator|Hypertensive|"hypertesive cases will be subjected to:~• Quantitative Tc99m DMSA renal scan using SPECT technique."
89019511|NCT00421122|Experimental|2|Bricasol® + Pulmicort®
88949087|NCT04836637|Experimental|"Product with calcium-enriched permeate Capolac and Inulin"|800 mg of calcium from calcium-enriched permeate and 12 g inulin in capsules and sachets consumed orally daily for one year.
88949088|NCT04828083|Active Comparator|Ultrasound-guided adductor canal block with local anesthetic|Single shot Ultrasound-guided adductor canal block with 0.5% ropivacaine 30 ml
88949089|NCT04828083|Sham Comparator|Ultrasound-guided adductor canal block with saline|Single shot Ultrasound-guided adductor canal block with 30 mL of normal saline (Sodium chloride)
88949090|NCT04826068|Experimental|Emotional Processing|The intervention looks at emotional processing of face interpretation.
88949091|NCT04826068|Placebo Comparator|Control intervention|The control group is seeing the same faces and are asked questions regarding them.
89019512|NCT00421122|Experimental|3|Bricasol® + Symbicort®
89472639|NCT03123237|Active Comparator|Diabetic & Hypertensive|"Diabetic & Hypertensive cases will be subjected to:~• Quantitative Tc99m DMSA renal scan using SPECT technique."
89472640|NCT03360279|Active Comparator|Regular balloon|Use the regular balloon to perform standard balloon angioplasty.
89472641|NCT03360279|Active Comparator|DCB (paclitaxel-coated balloon)|Use DCB (paclitaxel-coated balloon) to perform additional balloon angioplasty.
89472642|NCT03353103|Active Comparator|symptomatic|
89472643|NCT03353103|Active Comparator|asymptomatic|
88949092|NCT04825678|Experimental|Erenumab|
89472644|NCT03360123|Active Comparator|Midazolam Hydrochloride 2Mg/mL Syrup|"The participants in this arm will receive midazolam+nitrous oxide at the 1st dental appointment.~Dosage: Midazolam: Midazolam HCl Syrup 0.5mg/kg (Max: 15mg) taken 10-15 minutes prior to dental treatment."
89472645|NCT03360123|Active Comparator|Triazolam 0.125 MG|The participants in this arm will receive triazolam+nitrous oxide at the 1st dental appointment. Dosage: Triazolam: 0.125mg tablet taken 30 minutes prior to dental treatment.
88949093|NCT04808700|Other|Focal cartilage lesion|Patients with focal cartilage lesions who underwent a knee surgery using the Episealer implant
88949094|NCT04808505|Experimental|Cohort 1: Cipaglucosidase Alfa/Miglustat in ERT-experienced pediatric IOPD subjects|Pediatric IOPD subjects 6 months to <18 years experiencing clinical decline
88949095|NCT04808505|Experimental|Cohort 2: Cipaglucosidase Alfa/Miglustat in ERT-naïve pediatric IOPD subjects|Pediatric IOPD subjects <6 months
88949096|NCT04805346|Experimental|Therapeutic Group|With the patient sitting upright in bed or a chair, the remote ischemic conditioning intervention will consist of 4 automatic cycles of upper arm blood pressure cuff inflation to 200 mm Hg for 5 minutes to induce transient, noninjurious, limb ischemia, followed by cuff deflation for 5 minutes, for a total of 35 minutes (autoRIC®, Cellaegis Devices, Mississauga, ON, Canada). The remote ischemic preconditioning cycles will be performed by trained research personnel prior to each cycle of chemotherapy (total treatments variable based on chemotherapy protocol).
89019513|NCT00425295|Active Comparator|1|
89019514|NCT00425295|Experimental|2|
89019515|NCT00339222||1|Melanoma-prone families from dermatology clinics.
89019516|NCT00311129|Experimental|Arm 1|
89019517|NCT00311129|Active Comparator|Arm 2|
89019518|NCT00342342||Beaver Dam Eye Study|Individuals over 45 years of age enrolled in Beaver Dam Wisconsin
89472646|NCT04523415||patients wiht CT data|all patients with CT data are enrolled with this research, and the classification about proximal humeral fractures are identified.
89472647|NCT03360045|Active Comparator|Tranexamic acid group|500mg tranexamic acid is sprayed in the nose by atomizer spray, and then is applied nasal compression by manually.
89472648|NCT03360045|Placebo Comparator|Placebo group|5ml normal saline is sprayed in the nose by atomizer spray, and then is applied nasal compression by manually.
89472649|NCT03360045|Active Comparator|Merocel Group|Merocel packing is applied.
89472650|NCT03123003|Experimental|SonicBone Ultrasound|Assessment of bone age by SonicBone Ultrasound will compared to wrist X-ray assessment
89472651|NCT03123081|Experimental|Umbilical Cord Milking|Umbilical Cord Milking involves milking 30 cm length of cord at birth, after initiation of ventilation.
89472652|NCT03123081|No Intervention|Immediate Umbilical Cord Clamping|Procedure: No Intervention: Immediate Umbilical Cord Clamping or Immediate Cord Clamping.
89472653|NCT04444089|Experimental|conventional group, CG|receives Ringer's lactate solution at a rate of 4 ml/kg/h for the first-10 kg of body weight, 2 ml/kg/h for the second-10 kg of body weight, and 1 ml/kg/h for each further kg of body weight. The deficit volume is calculated as the maintenance volume multiplied by fasting hours and given as follows: 50% of the volume in the first hour, 25% of the volume in the second hour, and 25% of the volume in the third hour, in addition to the aforementioned maintenance volume
89472654|NCT04444089|Experimental|restricted group, RG|Patients in the RG receives Ringer's lactate solution at a rate of 3 ml/kg/h from the start to the end of surgery.
89472655|NCT04507737|Experimental|Critical Care Outreach Team Model|When a patient deteriorates and is in need of a Rapid Response Team, this arm will deploy a Critical Care Outreach Team Model consisting of an ICU-trained Nurse with the on-duty physician of the general ward and a nurse from the general ward.
89472656|NCT04507737|No Intervention|Medical Emergency team Model|When a patient deteriorates and is in need of a Rapid Response Team, this arm will deploy a Medical Emergency Team Model, consisting of an ICU-trained Doctor as well as an ICU-trained Nurse with the on-duty physician of the general ward and a nurse from the general ward.
89472657|NCT03353025|Experimental|transsphenoidal surgery treatment|Transsphenoidal surgery treat non-invasive prolactinoma by experienced neurosurgeon
89472658|NCT03353025|Experimental|dopamine agonist treatment|Minimum effective dose of dopamine agonist, bromocriptine, treat non-invasive prolactinoma
89472659|NCT03355755|Experimental|Interventional Group|All participants will be included in the interventional group. Intervention will consist of walking exercise using the EksoGT exoskeleton for supported walking, running SmartAssist software.
89472660|NCT03355677|Active Comparator|Case finding clinics|The visit will be a minimum 90 minutes long at the participants own GP surgery. This will include a respiratory assessment including spirometry will performed by a RT Respiratory Nurse Specialist (RNS) and where possible a Practice Nurse or Nurse Practitioner will attend. The visit will consist of objective measurements, investigations and questionnaires
89472661|NCT03355677|Placebo Comparator|Case finding Usual care|In the control arm of the study, practices will continue with usual care according to national guidance for case finding for COPD (NICE, 2010). Matched practices will have their eligible population identified through electronic searches based on data routinely recorded in primary care run in the HHRa. Case finding yield will be measured as the percentage of patients from the eligible population identified with a respiratory diagnosis in the 12 months from study beginning to study end.
88949097|NCT04805346|No Intervention|Control Group|A control group will undergo a similar procedure, but the cuff will not be inflated.
88949098|NCT04788654|Active Comparator|Pharmacological group|Pharmacological analgesia will be performed
88949099|NCT04788654|Experimental|Pharmacologican and surgical group|Pharmacological and surgical analgesia will be performed.
88949100|NCT04781647|Active Comparator|ABI-H0731 + ETV|Participants with cHBV will receive ABI-H0731 with ETV for 48 weeks, followed by ETV alone for 12 weeks
88949101|NCT04781647|Experimental|ABI-H0731 + ETV + Peg-IFNα|Participants with cHBV will receive ABI-H0731 with ETV and Peg-IFNα for 24 weeks, followed by ABI-H0731 with ETV for 24 weeks, followed by ETV alone for 12 weeks
88949102|NCT04781647|Active Comparator|ETV + Peg-IFNα|Participants with cHBV will receive ETV and Peg-IFNα for 24 weeks, followed by ABI-H0731 with ETV for 24 weeks, followed by ETV alone for 12 weeks
88949103|NCT04777084|Experimental|Cohort A|Cohort A is evaluating the efficacy and safety of IBI318 in combined with lenvatinib in advanced NSCLC patients who had failed first-line PD-1/PD-L1 inhibitor therapy.
88949104|NCT04777084|Experimental|Cohort B|Cohort B is the efficacy and safety of advanced NSCLC with EGFR-sensitive mutation /ALK fusion after EGFR-TKI /ALK-TKI treatment resistance.
88949105|NCT04777084|Experimental|Cohort C|Cohort C is the efficacy and safety of first-line treatment of advanced NSCLC with negative PD-L1 expression and EGFR, ALK, and ROS1 wild-type.
88949106|NCT04776824||Patients with confirmed amyloidosis|Confirmed diagnosis of amyloidosis w/wo cardiac involvement
88949107|NCT04770246|Experimental|TAS-117 Dose Escalation Daily Dose Regimen (Part A: safety lead-in)|Advanced or metastatic solid tumors irrespective of gene alterations
89202471|NCT01563952|Active Comparator|Non-IVUS guided endeavor-R group|2x2 randomization by the treatment of IVUS-guided intervention vs. Non-IVUS guided intervention and the types of the implanted DES, Endeavor-R vs. Nobori.
89537388|NCT04908839||case: patient with otosclerosis|Diagnosis of otosclerosis with indication for primary stapedial surgery by the combination of arguments
89537389|NCT04908839||case: otosclerosis patient with surgery|otosclerosis patient with surgery
89537390|NCT04908839||controle: Absence of known otological pathology|Absence of known otological pathology
89537391|NCT04339439|No Intervention|Closure without vessel loop|These patients will receive standard of care closure of the carpal tunnel release incision.
88949108|NCT04770246|Experimental|TAS-117 Dose Escalation Intermittent Dose Regimen (Part A: safety lead-in)|Advanced or metastatic solid tumors irrespective of gene alterations
88949109|NCT04770246|Experimental|TAS-117 Dose and Regimen Confirmation (Part A: safety lead-in)|Advanced or metastatic solid tumors with germline PTEN inactivating mutations
88949110|NCT04770246|Experimental|TAS-117 Phase 2 (Part B)|Advanced or metastatic solid tumors with germline PTEN inactivating mutations
88949111|NCT04768569|Active Comparator|Zonisamide Pre-op + Placebo Post-op|For subjects randomized to zonisamide pre-op, the pre-op package will contain one zonisamide capsule (100 mg PO) and the post-op package will contain one placebo capsule that looks, smells, and tastes the same as zonisamide capsules.
89202472|NCT01563952|Experimental|IVUS guided endeavor-R group|2x2 randomization by the treatment of IVUS-guided intervention vs. Non-IVUS guided intervention and the types of the implanted DES, Endeavor-R vs. Nobori.
89202473|NCT01563952|Active Comparator|Non-IVUS guided Nobori group|2x2 randomization by the treatment of IVUS-guided intervention vs. Non-IVUS guided intervention and the types of the implanted DES, Endeavor-R vs. Nobori.
89472662|NCT03355677|Active Comparator|At Risk Case clinics|The complex case clinic will be a minimum 120 minute appointment at the participants own GP surgery. The intervention will include an initial assessment by a RT Respiratory Nurse Specialist (RNS) and followed by a joint assessment by a respiratory physician (RP) working alongside a practice clinician (GP and/or Practice Nurse/Nurse Practitioner). The visit will consist of objective measurements, investigations and questionnaires as outlined in section 3 below. A personalised disease management and action plan will be agreed jointly between the RT, practice clinician and participant. The practice clinician will undertake the necessary tasks required for the agreed management plan. The clinical responsibility for the participant will remain with the GP practice.
89472663|NCT03355677|Placebo Comparator|At Risk Usual Care|In the control arm of the study, practices will continue with usual care according to national guidance for the management of COPD and asthma . A cohort of patients matched for practice and for age, sex, disease condition and, where possible, disease control will be identified. This cohort will be monitored against markers of sub-optimal disease (medication usage, exacerbations, unscheduled visits to the practice, attendance or admission to hospital).
89472664|NCT03355599|Other|3d camera|3d camera
89472665|NCT03355521|Experimental|Nordic walking Experimental|Experimental: Nordic walking Training The total period of training was composed by 9-week of walking with poles, two sessions per week. The cycles were divided into four microcycles composed of three training sessions. Each training session took 60 min. Nordic walking aerobics training was used during the training period. These exercises were performed alternating volume and intensity. The training session was divided into three stages: (a) stretching, joint mobility, and heating; (b) main part (NW); (c) return to the calm and ultimate stretching.
89472666|NCT03355521|Active Comparator|Free walking|Free walking Training The total period of training was composed by 9-week of walking without poles, two sessions per week. The cycles were divided into four microcycles composed of three training sessions. Each training session took 60 min. Free walking aerobics training was used during the training period. These exercises were performed alternating volume and intensity. The training session was divided into three stages: (a) stretching, joint mobility, and heating; (b) main part (FW); (c) return to the calm and ultimate stretching.
88949112|NCT04768569|Placebo Comparator|Placebo Pre-op + Placebo Post-op|For the subjects randomized to placebo, both pre- and post-op packages will contain placebo capsules that looks, smells, and taste the same as zonisamide capsules.
88949113|NCT04768569|Active Comparator|Placebo Pre-op + Zonisamide Post-op|For subjects randomized to zonisamide post-op, the pre-op package will contain one placebo capsule and the post-op package will contain one zonisamide capsule (100 mg PO).
88949114|NCT04759664|Experimental|LUT014 Gel (Dose 1)|
89472667|NCT03355443|Active Comparator|Re-examination Group|Routine intubation is performed. After cecal intubation, the cecum and ascending colon is examined with colonoscope tip in forward direction for the first time. Re-intubation is performed after the first examination of the cecum and ascending colon, and then this region of the large bowel is re-examined in the same fashion. After that, the rest of the colon is examined in routine method.
89472668|NCT03355443|Experimental|Retroflexion Group|Routine intubation is performed. After cecal intubation, the cecum and ascending colon is examined with colonoscope tip in forward direction for the first time. Re-intubation is performed after the first examination of the cecum and ascending colon, and then this region of the large bowel is re-examined with the colonoscope tip in reverse direction (retroflexion fashion). After that, the rest of the colon is examined in routine method.
89472669|NCT04516395|Experimental|Optimal antibiotic combination regimens|The patients in the groups will be given the optimal antibiotic combination regimens.
89472670|NCT04516395|Other|Standard antibiotic regimens|The patients in the groups will be given the standard antibiotic regimens.
89472671|NCT04507035|Experimental|Anlotinib group|After 2 cycles of anlotinib treatment, we evaluate the therapeutic effect of tumor treatment: If it achieve downgrading and is operable, surgical treatment will be performed; if it is still inoperable and could accept radiotherapy, radiotherapy and chemotherapy will be combined with oral chemotherapy of anlotinib until the end of radiotherapy. Efficiency and side effects will be evaluated within 3 months after therapy. Finally, the survival is in follow-up.
89472672|NCT03352947|Active Comparator|Continuous (Standard)|Dabrafenib 150mg twice daily 12 hours apart, on days 1-28 of a 28 day cycle plus Trametinib 2mg once daily, on days 1-28 of a 28 day cycle
89472673|NCT03352947|Experimental|Intermittent (experimental)|Dabrafenib 150mg twice daily 12 hours apart, on days 1-21 of a 28 day cycle plus Trametinib 2mg once daily, on days 1-14 of a 28 day cycle
89472674|NCT02730351|Experimental|FF/VI 100/25 mcg + Placebo DISKUS®/ ACCUHALER®|Randomised subjects will receive FF/VI 100/25 mcg once daily via ELLIPTA inhaler and placebo twice daily via DISKUS / ACCUHALER for 2 weeks in Period 1. There will be a washout period of 2 weeks between treatment periods in which subjects will receive FP 250 mcg twice daily. Subjects will receive FP 250 mcg twice daily via DISKUS inhaler and placebo once daily via ELLIPTA inhaler for 2 weeks in Period 2.
89537392|NCT04339439|Experimental|Closure with vessel loop|These patients will receive closure of the carpal tunnel release incision with a vessel loop placed under the sutures.
88949115|NCT04759664|Experimental|LUT014 Gel (Dose 2)|
88949116|NCT04759664|Placebo Comparator|Placebo|
88949117|NCT04743791|Active Comparator|Dupilumab|Two injections of Dupilumab will be administered at Week 0/Visit 3 as a loading dose. Subsequently one injection of Dupilumab will be given every 2 weeks ± 3 days at home by the patient. The doses of investigational product must be separated by ≥11 days to avoid an overdose.
88949118|NCT04743791|Placebo Comparator|Placebo|Two injections of placebo will be administered at Week 0/Visit 3 as a loading dose. Subsequently one injection of placebo will be given every 2 weeks ± 3 days at home by the patient. The doses must be separated by ≥11 day.
88949119|NCT04737330|Active Comparator|Investigational Arm|Investigational Arm - Secukinumab 300 mg s.c. at Baseline, Week 1, Week 2, Week 3, Week 4, Week 8, Week 12
88949120|NCT04737330|Placebo Comparator|Control Arm - placebo|Control arm - placebo s.c. at Baseline, Week 1, Week 2, Week 3, Week 4, Week 8, Week 12
88949121|NCT04734210|Experimental|SURF-200 (0.02% betamethasone sodium phosphate in vehicle)|One drop twice daily (BID) in the study eye for 14 days.
89472675|NCT02730351|Experimental|FP 250 mcg + Placebo ELLIPTA®|Randomised subjects will receive FP 250 mcg twice daily via DISKUS inhaler and placebo once daily via ELLIPTA inhaler for 2 weeks in Period 1. There will be a washout period of 2 weeks between treatment periods in which subjects will receive FP 250 mcg twice daily. Subjects will receive FF/VI 100/25 mcg once daily via ELLIPTA inhaler and placebo twice daily via DISKUS inhaler for 2 weeks in Period 2.
89472676|NCT03359655|Active Comparator|Rectal misoprostol|200 mcg of misoprostol will be administered rectally- 2 hours previously. This intervention will be performed by a third party health professional who will be blinded to the procedure.
89472677|NCT03359655|Active Comparator|Rectal hyoscine butyl bromide|10 mg hyoscine butyl bromide administered rectally- 2 hours previously. This intervention will be performed by a third party health professional who will be blinded to the procedure.
88949122|NCT04734210|Experimental|SURF-200 (0.04% betamethasone sodium phosphate in vehicle)|One drop BID in the study eye for 14 days.
88949123|NCT04734210|Placebo Comparator|Vehicle|One drop BID in the study eye for 14 days.
88949124|NCT04732130|Active Comparator|Time-Restricted Feeding|Participants in the time-restricted feeding are instructed to eat ad libitum from 12:00 to 20:00 daily, and fast from 20:00 to 12:00 daily for 4 weeks.
88949125|NCT04732130|Active Comparator|Alternate Day Fasting|Participants in the alternate day fasting group are instructed to eat every second day ad libitum, but to abstain from calorie intake on fast days (100 % restriction) for 4 weeks.
88949126|NCT04732130|No Intervention|Control|Participants in the control group are instructed to maintain their habitual diet regimen.
88949127|NCT04727528|Experimental|Open-label correction phase (up to 48 hours)|"All eligible patients will receive SZC 10 g TID for up to 48 hours. Patients with POCT (Point-of-Care-Test) K+ ≥5.1 mmol/L after 24 hours will continue on SZC 10 g TID for another 24 hours. Patients who achieve normokalemia (defined as POCT K+ between 3.5 and 5.0 mmol/L inclusive) after receiving SZC 10 g TID for up to 48 hours will proceed to randomization.~Patients with POCT K+ <3.5mmol/L at any time during the open-label phase will be withdrawn from study treatment and will be followed per protocol."
88949128|NCT04727528|Experimental|Randomized, placebo controlled phase (Day 2 or 3 to Day 29)|Patients will be randomized to SZC 10 g QD or placebo 10 g QD. The dose of SZC/placebo will be titrated by increasing or decreasing the dose by 5 g increments at 1-week intervals to between 5 g every other day (QOD) and 15 g QD of the randomized phase to maintain normokalemia by POCT K+.
88949129|NCT04724980|Experimental|Adjuvant PRGN-2012|Four PRGN-2012 administrations (on days 1, 15, 43, and 85) via subcutaneous injection.
88949130|NCT04716998|Experimental|MesenCure treatment|"Clinical interventions:~Health questionnaire, respiratory rate, heart rate, blood pressure, RA O2 saturation, x-ray.~Blood tests: leukocyte and lymphocyte count, CRP, D-Dimer, renal and liver function, optional: cytokine levels."
88949131|NCT04714450|No Intervention|MMST control|
88949132|NCT04714450|Experimental|MMST+|
88949133|NCT04711837|Experimental|HSK3486|HSK3486 for induction of general anesthesia.
88949134|NCT04711837|Active Comparator|Propofol|Propofol for induction of general anesthesia.
88949135|NCT04693377|Active Comparator|Arm A (SBRT)|Patients undergo stereotactic body radiation therapy for 1 fraction.
88949136|NCT04693377|Experimental|Arm B (cryoablation, SBRT)|"Patients undergo cryoablation. Within 10 days after cryoablation, patients undergo stereotactic body radiation therapy for 1 fraction. Alternatively, patients may receive stereotactic body radiation therapy initially, followed by cryoablation."
88949137|NCT04682678|Sham Comparator|OFF STIM|without stimulation
88949138|NCT04682678|Active Comparator|ON STIM|stimulation with the most effective parameters
88949139|NCT04680611||Patients with severe eosinophilic asthma Phase 1|Patients with severe eosinophilic asthma on Nucala(R) treatment
88949140|NCT04680611||Patients with severe eosinophilic asthma Phase 2|Patients with severe eosinophilic asthma to start Nucala(R) treatment
88949141|NCT04680611||Partners of patients with severe eosinophilic asthma Phase 2|Partners of patients with severe eosinophilic asthma to start Nucala(R) treatment
88949142|NCT04680611||Phase 3: Patients with severe eosinophilic asthma from Phase 2|A sub-group of patients who participate in Phase 2
88949143|NCT04680611||Phase 3: Partners of patients in Phase 3|Partners of the sub-group of patients who participate in Phase 3
89472678|NCT03359655|No Intervention|Sham administration|A rectal examination will be performed by a third party health professional who will be blinded to the procedure. No drug will be administered
88949144|NCT04676425|Experimental|Moderate Hepatic Impairment Participants|Participants with hepatic impairment will receive a single dose of MK-8189 4 mg orally on Day 1.
88949145|NCT04676425|Experimental|Healthy Participants|Healthy participants will receive a single dose of MK-8189 4 mg orally on Day 1.
88949146|NCT04674189|Experimental|CVnCoV: Group 1, Lot 1|Participants in Group 1 will be vaccinated with CVnCoV 12 µg mRNA on Day 1 and Day 29 in the deltoid area, preferably in the non-dominant arm.
88949147|NCT04674189|Experimental|CVnCoV: Group 2, Lot 2|Participants in Group 2 will be vaccinated with CVnCoV 12 µg mRNA on Day 1 and Day 29 in the deltoid area, preferably in the non-dominant arm.
88949148|NCT04674189|Placebo Comparator|Placebo|Participants will receive a placebo on Day 1 and Day 29 in the deltoid area, preferably in the non-dominant arm.
88949149|NCT04670198|Experimental|Intervention|The intervention arm will receive the Youth Empowerment Skills (YES) programme.
88949150|NCT04670198|Other|Waiting-list control|The waiting-list control arm will receive usual care for six months before receiving the Youth Empowerment Skills (YES) programme.
88949151|NCT04661891|Experimental|Healthy Participants|The investigators will look at muscle activity of healthy participants from eight lower limb muscles during functional tasks (e.g. single-joint movement, walking, squatting, cycling).
88949152|NCT04661891|Experimental|Clinical Participants|The investigators will look at muscle activity of participants post-stroke from eight lower limb muscles during functional tasks (e.g. single-joint movement, walking, squatting, cycling).
88949153|NCT04652765|No Intervention|Standard of care (SOC)|SARS-CoV-2 positive participants will receive SOC therapy alone.
88949154|NCT04652765|Active Comparator|SOC plus camostat|SARS-CoV-2 positive participants will receive SOC therapy as well as camostat for 7 days.
88949155|NCT04652765|Active Comparator|SOC plus camostat and bicalutamide|SARS-CoV-2 positive participants will receive SOC therapy as well as camostat and bicalutamide for 7 days.
89472679|NCT03359577|Experimental|Psorax35|Food supplement Psorax35 capsules containing fish roe extract high in eicosapentaenoic acid (EPA)/docosahexaenoic acid (DHA) phospholipid. Dose: 10 capsules of 590 mg. Route of administration: oral.
89472680|NCT03359577|Placebo Comparator|MCT oil|Placebo capsules containing coconut oil high in caprylic acid C8:0 and capric acid C10:0 (Medium Chain triglycerides (MCT) oil). Dose: 10 capsules of 590 mg: Route of administration: oral.
89472681|NCT03355287|Placebo Comparator|Traditionally Threshed Teff (TTT)|The control group will consume injera based on teff threshed under the hooves of cattle. We plan to have a certain number of teff flour suppliers, where the teff is traditionally threshed and contains at least 50 mg Fe per 100 g flour.
89472682|NCT03355287|Experimental|Lab Threshed Teff (LTT)|The intervention group will consume injera based on teff flour that has been lab threshed using a modern teff threshing machine.
88949156|NCT04642430|Active Comparator|Apixaban group|"5 mg PO, twice daily for 12 months of treatment. A dose reduction* to 2.5 mg twice daily will apply if patients meet 2 of 3 following criteria: age > 80 years; weight < 60 kg; creatinine >133 micromol/L.~*Patients with AF who are receiving DOAC should have their renal function assessed at baseline and at least annually"
88949157|NCT04642430|Active Comparator|Rivaroxaban Group|"20 mg PO, once daily for 12 months of treatment. A dose reduction* to 15 mg daily will apply to patients with creatinine clearance <50 ml/min.~*Patients with AF who are receiving DOAC should have their renal function assessed at baseline and at least annually"
89472683|NCT03355287|Active Comparator|Fortified Lab Threshed Teff (FTT)|This arm will be the positive control group consuming Ferrous Sulphate drops ( with injera that consist of lab-threshed teff. The Fe drops have to be consumed with the meal and will provide an additional 6 mg of Ferrous sulfate to the diet of the children.
89472684|NCT03352869|Experimental|Exenatide|Drug: Byetta Generic name: Exenatide Dosage form: 5ug and 10ug Dosage: 10-20ug/day Frequency: twice a day Duration: 3 months
89472685|NCT03352869|Active Comparator|Metformin|Drug: Glucophage Generic name: Metformin Dosage form: 500mg Dosage: 1500-2000mg/day Frequency: 500mg three times a day/1000mg twice a day Duration: 3 months
89472686|NCT03352869|Experimental|Combination|Drug: Byetta and Glucophage Generic name: Exenatide Dosage form: Exenatide 5ug and 10ug; Metformin 500mg Dosage: Exenatide10-20ug/day; Metformin 1500-2000mg/day Frequency: Exenatide twice a day; Metformin 500mg three times a day/1000mg twice a day Duration: 3 months
89472687|NCT03352791|Active Comparator|DSM-H Hospice Edition|training, assigning of champions to serve as mentors and performance improvement leads, and workflow changes including caregiver education pamphlets, interdisciplinary care plans, treatment algorithms, and assessment instruments.
89472688|NCT03352791|Active Comparator|Control Arm|Usual Care
89472689|NCT03359499|Experimental|Bacillus clausii|Bacillus clausii administered orally for two weeks plus standard dietary advice for non-constipated irritable bowel syndrome
89472690|NCT03359499|Other|Antispasmodic|Trimebutine administered orally for two weeks plus standard dietary advice for non-constipated irritable bowel syndrome
89472691|NCT03123315|Experimental|Cook Bush DL™ Ureteral Illuminating Catheter|As part of this study an additional tool will be used during the hysterectomy. This tool is called a Cook Bush DL™ Ureteral Illuminating Catheter, which is a lighted ureteral stent. This is a very thin tube that goes into the ureter. A urologist, who is an expert at placing these devices, will insert a stent into each ureter during surgery. The lighted stents will help effectively find the ureters and keep track of them during the surgery. This same procedure is already being done in many other forms of abdominal surgery to help find the ureter. The stents will be removed before the surgery is complete and treatment will not differ in any other way.
89472692|NCT04506801|Placebo Comparator|Placebo|liquid oral formulation 9 drops once a day
89472693|NCT04506801|Experimental|Probiotic|The probiotic contained Lactobacillus acidophilus LA3; 1 · 1011 CFU / g, Bifidobacterium animalis subsp. Lactis BLC1; 1.5 · 1011 CFU / g and Lactobacillus casei BGP93 2 · 1011cfu / g in the form of a liquid oral formulation
89472694|NCT04512183|Experimental|High-Fidelity Simulation|First, students will go through an inverted class on sepsis. Then, they will be submitted to high-fidelity simulation scenarios to care for patients with sespe. After the scenario, the students' physiological parameters (blood pressure, heart rate, body temperature, respiratory rate and oxygen saturation) will be measured. After the scenario, students will go through a reflective debriefing session.
89472695|NCT04512183|Active Comparator|Low-Fidelity Simulation|First, students will go through an inverted class on sepsis. Then, they will be submitted to low-fidelity simulation scenarios to care for patients with sespe. After the scenario, the students' physiological parameters (blood pressure, heart rate, body temperature, respiratory rate and oxygen saturation) will be measured. After the scenario, students will go through a feedback session.
88949158|NCT04630431|Experimental|Part I (questionnaire, medical record review)|Patients complete a questionnaire about their preferences, understanding, and attitudes regarding clinical trials. Patients also have their medical records reviewed.
88949159|NCT04630431|Active Comparator|Part II: Arm A (clinical trial education, standard of care)|Patients undergo clinical trial education via a video and educational booklet and then standard of care follow-up on study.
89472696|NCT03352635||Native Hawaiians|One parent of Hawaiian descent.
89472697|NCT03352635||Japanese Americans|Two parents of Japanese descent.
89472698|NCT03352635||Non-Hispanic Whites|Two parents of non-Hispanic white descent.
89472699|NCT03359343||experts|In this group, two experts distinguish a set of polyps on LCI images as adenoma or non-adenoma.
89472700|NCT03359343||non-experts|In this group, two non-experts distinguish the set of polyps(the same to experts group) on LCI images as adenoma or non-adenoma.
89472701|NCT03359343||Computer-aided diagnosis system|In this group, a newly developed computer-aided diagnosis system will be used to distinguish a set of polyps as adenoma or non-adenoma.
88949160|NCT04630431|Experimental|Part II: Arm B (clinical trial education, navigation)|Patients undergo clinical trial education via a video and educational booklet and then undergo patient navigation with active clinical trial matching and receive clinical trial information through the electronic medical record portal on study.
88949161|NCT04624750|Other|Cohort 1 and 2|7 patients aged 12 to < 18 years , inclusive in cohort-1 7 patients aged 6 to < 12 years, inclusive in cohort-2
88949162|NCT04614467|Experimental|GCSF-mobilized autologous CD34+ cells|
88949163|NCT04614467|Placebo Comparator|Placebo|
89202474|NCT01563952|Experimental|IVUS guided Nobori group|2x2 randomization by the treatment of IVUS-guided intervention vs. Non-IVUS guided intervention and the types of the implanted DES, Endeavor-R vs. Nobori.
89537393|NCT02465645|Experimental|Carvedilol + Simvastatin|"Carvedilol will be administered orally at a start dose of 3.125 mg twice daily per day. After 1 week, this will increased to a dose of 6.25 mg twice daily per day. Target dose of 12.5 mg twice daily per day will be started after 2 weeks if systolic blood pressure does not fall below 90 mm Hg and HR 55-60/min.~Simvastatin will be administered orally at a start dose of 20 mg for 15 days followed by 40 mg OD for the next 3 months. Along with Simvastatin, Carvedilol will be administered orally at a start dose of 3.125 mg twice daily per day. After 1 week, this will increased to a dose of 6.25 mg twice daily per day. Target dose of 12.5 mg twice daily per day will be started after 2 weeks if systolic blood pressure does not fall below 90 mm Hg and HR 55-60/min."
89537394|NCT02465645|Active Comparator|Carvedilol|Carvedilol will be administered orally at a start dose of 3.125 mg twice daily per day. After 1 week, this will increased to a dose of 6.25 mg twice daily per day. Target dose of 12.5 mg twice daily per day will be started after 2 weeks if systolic blood pressure does not fall below 90 mm Hg and HR 55-60/min.
89537395|NCT04157205|Experimental|Test arm|All patients. Single arm study
89537396|NCT02465411|Experimental|Long-term CGM|Continuous glucose monitoring with DexCom G4 platina or later generations during 12 months following participation in the CGMMDI trial
89537397|NCT04294277|Experimental|Treatment arm|Treatment with Pemigatinib at the protocol-defined dose administered orally once daily as continuous therapy schedule until 12 months.
89537398|NCT03065829|Experimental|ASSIST|The ASSIST intervention will deliver daily doses of MMT and vary dose intensity of all components each day based on the subject's biophysical data. Across a 30-day period, the ASSIST intervention will capture and analyze data to deliver on-demand MMT, guided practices to promote sleep hygiene and physical activity. Each day, subjects will receive at least one prompt to practice MMT (about 5 minutes at a time). However, based on the subject's biophysical sensor data, subjects could receive a maximum of 5 alerts or prompts per day from the device to enhance stress reduction, sleep hygiene, or physical activity.
88949171|NCT04595422|Experimental|Call center staff (educational intervention)|Participants undergo training consisting of a 60-minute educational session.
88949172|NCT04595422|Experimental|Callers substudy (LCS educational materials, questionnaire)|Participants are referred to lung cancer screening educational materials. Participants also complete questionnaires at 1 week and 6 months after referral to educational materials.
88949173|NCT04594005|Experimental|abemaciclib+paclitaxel|
89202475|NCT00795912|Active Comparator|1|Atorvastatin titrated from 10-40 mg/day over 3 months and maintained at 40mg/day for a further 3 months
89202476|NCT00795912|No Intervention|2|Usual medical care of heart failure
89202477|NCT00753194||1|"Newborns that show a Pass On the newborn hearing screening program before hospital discharge"
89202478|NCT00753194||2|"Newborns that show a fail and will be retested in 15 days."
89202479|NCT03211702||Elderly DLBCL patients|Elderly DLBCL patients (age>=65 years) treated with R-CHOP chemotherapy
89202480|NCT02562794|Experimental|Intervention|Family Strengthening Intervention-Refugees. A total of 20 Somali Bantu and 20 Bhutanese refugee families will participate in a Family Strengthening Intervention adapted for use with refugees.
89202481|NCT02562794|No Intervention|Control|A total of 20 Somali Bantu and 20 Bhutanese refugee families will receive services as usual.
89202482|NCT05360134|Experimental|Carica Papaya Arm|1100mg of Carica Papaya Leaf extract administered three times daily for upto one week preoperatively and from post-operative day 3 to day 7.
89202483|NCT05360134|Placebo Comparator|Placebo Arm|Placebo administered 3 time daily for upto one week preoperatively and from post-operative day 3 to day 7.
89202484|NCT00788034|Experimental|Lu AA21004|
89202485|NCT00788034|Placebo Comparator|Placebo|
88949174|NCT04591977|Experimental|Self-Sampling Kit|Self-Sampling kit (Evalyn Brush) to collect samples for analysis for HPV/Cervical cancer screening.
88949175|NCT04580732|Active Comparator|Active|Subjects randomized to the Active group, programming parameters will be set, and therapy will be delivered for a minimum of 2-hours per day for the duration of the study.
88949176|NCT04580732|Placebo Comparator|Delayed|The delayed group will begin 2-hour stimulation/day at the 3-Month visit.
89202486|NCT04058444|Experimental|ERAS Group|Perioperative management follows the ERAS (Enhanced Recovery After Surgery) protocol
89202487|NCT04058444|Experimental|Control Group|Perioperative management follows the conventional program
89202488|NCT05208814|Experimental|Renal Insuffiency|Subjects with various degrees of renal insuffiency
89202489|NCT05208814|Experimental|healthy subjects|healthy subjects
89202490|NCT04004884||UPA Treatment|Women who had completed a full 12-week treatment course of Ulipristal Acetate for symptomatic uterine fibroids since September 2018
89202491|NCT00688064|Experimental|1|Adapalene-BPO + Doxycyline
89202492|NCT00688064|Active Comparator|2|Vehicle + Doxycycline
89202493|NCT00788112|Experimental|Vorinostat|
89202494|NCT04058600|Experimental|Virtual Reality|The patients will be exposed to a virtual reality software that simulates the environment of the hospital, from admission to the operating room and the recovery room.
89202495|NCT04058600|No Intervention|Control|Patients in this group are not exposed preoperatively to the virtual reality software and are given the standard therapy and cares for their disease.
89202496|NCT00788190|Other|Surgery|Surgical intervention to reduce Distal Radius Fracture
89202497|NCT00788190|Other|Conservative Treatment|Conservative treatment of Distal Radius Fractures
89202498|NCT00749918|Experimental|1|Each subject was evaluated and data was collected before and after the intervention
89202499|NCT00791310|Experimental|TEP|Performance of of TEP coupled to scanner X
88949177|NCT04578665|Experimental|Healthy Participants Ankle Robot (M1)|The investigators will look at how the task performance and motor performance of individuals in dyadic physical interactions are affected.
88949178|NCT04578665|Experimental|Healthy Participants Bilateral Lower Limb Exoskeleton (H3/X2)|The investigators will look at how the task performance and motor performance of individuals in dyadic physical interactions are affected.
88949179|NCT04578665|Experimental|Clinical Populations Ankle Robot (M1)|The investigators will look at how the task performance and motor performance of individuals in dyadic physical interactions are affected.
88949180|NCT04578665|Experimental|Clinical Populations Bilateral Lower Limb Exoskeleton (H3/X2)|The investigators will look at how the task performance and motor performance of individuals in dyadic physical interactions are affected.
88949181|NCT04574193|Experimental|Continuing Care App|Participants will receive the Continuing Care app, in addition to usual care at the treatment program (12-weeks of weekly group cognitive behavioral therapy).
88949182|NCT04574193|Active Comparator|Treatment As Usual|Participants will only receive 12-weeks of weekly group cognitive behavioral therapy.
88949183|NCT04570761|Experimental|ON-Stim|acoustic stimulation
88949184|NCT04570761|Sham Comparator|OFF-Stim|no acoustic stimulation
88949185|NCT04560595|Experimental|Caffeine Reduction Manual, Immediate Treatment Group|"Weekly caffeine consumption is to be measured before and after using the caffeine reduction program, which has been summarized in a Guide to Caffeine Reduction and Cessation manual to help people reduce their caffeine use. Those in the immediate treatment group will receive the guide immediately after screening."
88949186|NCT04560595|Experimental|Caffeine Reduction Manual, Delayed Treatment Group|"Weekly caffeine consumption is to be measured before and after using the caffeine reduction program, which has been summarized in a Guide to Caffeine Reduction and Cessation manual to help people reduce their caffeine use. Those in the delayed treatment group will receive the guide seven weeks after screening."
88949187|NCT04537429|Experimental|Eptinezumab|
88949188|NCT04528719|Experimental|Cohort 1: Dose A in Younger Adults|Single injection of Dose A of mRNA-1345 or matching-placebo on Day 1.
88949189|NCT04528719|Experimental|Cohort 2: Dose B in Younger Adults|Single injection of Dose B of mRNA-1345 or matching-placebo on Day 1.
88949190|NCT04528719|Experimental|Cohort 3: Dose B in Younger Adults|Three total injections, 1 injection of either Dose B of mRNA-1345 or matching-placebo per day on Day 1, Day 57, and Day 113.
88949191|NCT04528719|Experimental|Cohort 4: Dose C in Younger Adults|Single injection of Dose C of mRNA-1345 or matching-placebo on Day 1.
88949192|NCT04528719|Experimental|Cohort 5: Dose D in Children|Three total injections, 1 injection of either Dose D of mRNA-1345 or matching-placebo per day on Day 1, Day 57, and Day 113.
88949193|NCT04528719|Experimental|Cohort 6: Dose G in Children|Three total injections, 1 injection of either Dose G of mRNA-1345 or matching-placebo per day on Day 1, Day 57, and Day 113.
88949194|NCT04528719|Experimental|Cohort 7: Dose A in Older Adults|Two total injections, 1 injection of either Dose A of mRNA-1345 or matching-placebo per day on Day 1 and approximately 12 months later. Participants will receive second booster injection of Dose A of mRNA-1345 at Month 24.
88949195|NCT04528719|Experimental|Cohort 8: Dose B in Older Adults|Two total injections, 1 injection of either Dose B of mRNA-1345 or matching-placebo per day on Day 1 and approximately 12 months later. Participants will receive second booster injection of Dose A of mRNA-1345 at Month 24.
88949196|NCT04528719|Experimental|Cohort 9: Dose C in Older Adults|Two total injections, 1 injection of either Dose C of mRNA-1345 or matching-placebo per day on Day 1 and approximately 12 months later. Participants will receive second booster injection of Dose A of mRNA-1345 at Month 24.
88949197|NCT04528719|Experimental|Cohort 10: Dose E in Older Adults|Two total injections, 1 injection of either Dose E of mRNA-1345 or matching-placebo per day on Day 1 and approximately 12 months later. Participants will receive second booster injection of Dose A of mRNA-1345 at Month 24.
88949198|NCT04528719|Experimental|Cohort 11: Dose F in Older Adults|Two total injections, 1 injection of either Dose F of mRNA-1345 or matching-placebo per day on Day 1 and approximately 12 months later. Participants will receive second booster injection of Dose A of mRNA-1345 at Month 24.
88949199|NCT04528719|Experimental|Cohort 12: Dose E in Women of Child-Bearing Potential|Single injection of Dose E of mRNA-1345 or matching-placebo on Day 1.
88949200|NCT04528719|Experimental|Cohort 13: Dose F in Women of Child-Bearing Potential|Single injection of Dose F of mRNA-1345 or matching-placebo on Day 1.
88949201|NCT04528719|Experimental|Cohort 14: Dose A in Women of Child-Bearing Potential|Single injection of Dose A of mRNA-1345 or matching-placebo on Day 1.
88949202|NCT04528719|Experimental|Cohort 15: Dose B in Japanese Older Adults|Single injection of Dose B of mRNA-1345 or matching-placebo on Day 1.
88949203|NCT04521764|Experimental|Treatment (MV-s-NAP)|Patients receive MV-s-NAP intratumorally (IT) on day 1 in the absence of disease progression or unacceptable toxicity. After 1 cycle of treatment, patients who experience disease progression proceed to follow-up. Patients who achieve CR, PR, or SD receive MV-s-NAP IT every 21 days for up to 3 additional cycles in the absence of disease progression or unacceptable toxicity.
88949204|NCT04517643|Experimental|Therasphere Therapy|All participants will receive the Therasphere Therapy.
88949205|NCT04512911|Active Comparator|Patients who didn't fail AAD|This group of patients will be randomized to 3 subgroups: 1) Endocardial ablation; 2) Endocardial - Epicardial ablation; 3) Antiarrhythmic medications
88949206|NCT04512911|Active Comparator|Patients who failed AAD|This group of patients will be randomized to 2 subgroups: 1) Endocardial ablation; 2) Endocardial - Epicardial ablation
88949207|NCT04501133|Experimental|Healthy Participants|Healthy participants without motor disorders and medications influencing brain functions will be scanned with MRI and undergo PES and/or single pulse TMS during several visits, each with different stimulation patterns, while HD-EMG is recorded.
88949208|NCT04501133|Experimental|Patients|Participants with Parkinson's Disease or essential tremor will be scanned with MRI and undergo PES and/or single pulse TMS during several visits, each with different stimulation patterns, while HD-EMG and EEG are recorded.
89019519|NCT00342342||Framingham Eye Study|Subset of individuals from the Framingham Heart Study who received eye examinations
89202500|NCT03050476|Experimental|bRESCAP|Bolus of 1000 IU of bovine intestinal alkaline phosphatase on induction of anaesthesia, followed by an infusion with a sum of 10,000 IU/day over the next 24, 48, or 96 hours.
89472702|NCT03352479|Other|Opioids Prescribed|Each participant in the study will be given an envelope for return of unused opioids. The percentage of returned number of opioids will be calculated based on the number prescribed
89472703|NCT03359265|Active Comparator|Test|The test group used underpants made of precious metal fibers (germanium, titanium and phosphorus), developed by Green Energy Nano Technology Co., Ltd.
89472704|NCT03359265|Placebo Comparator|Control|The control group used commercially available underpants.
89472705|NCT03355131|Experimental|Adapted NASA's Mission X program|Adapted NASA's Mission X program for the intervention group
89472706|NCT03355131|No Intervention|Mission X Control|no intervention
89472707|NCT03355053|Active Comparator|Dexmedetomidine (Dex) very-low dose group|"Study drug will be administered by the patient's nurse. Study drugs (50 mL of 4 ug/ ml dexmedetomidine hydrochloride or 50 ml normal saline (NS)) will be provided as clear solutions in identical 60 mL syringes. In each study arm patients will receive a continuous overnight infusion of study drug (Dex or placebo) at 0.075 ml/kg/h Dex or NS from 8PM until 7AM, for 7 consecutive nights or until leaving the ICU, depending on randomization group, as follows:~1) Group 1: Dex at 0.1 mcg/kg/h from 8PM until 7AM"
89472708|NCT03355053|Active Comparator|Dexmedetomidine (Dex) low dose group|"Study drug will be administered by the patient's nurse. Study drugs (50 mL of 4 ug/ ml dexmedetomidine hydrochloride or 50 ml normal saline (NS)) will be provided as clear solutions in identical 60 mL syringes. In each study arm patients will receive a continuous overnight infusion of study drug (Dex or placebo) at 0.075 ml/kg/h Dex or NS from 8PM until 7AM, for 7 consecutive nights or until leaving the ICU, depending on randomization group, as follows:~2) Group 2: NS at 0.3 mcg/kg/h from 8PM until 7AM"
89472709|NCT03355053|Placebo Comparator|Usual care + placebo group|"Study drug will be administered by the patient's nurse. Study drugs (50 mL of 4 ug/ ml dexmedetomidine hydrochloride or 50 ml normal saline (NS)) will be provided as clear solutions in identical 60 mL syringes. In each study arm patients will receive a continuous overnight infusion of study drug (Dex or placebo) at 0.075 ml/kg/h Dex or NS from 8PM until 7AM, for 7 consecutive nights or until leaving the ICU, depending on randomization group, as follows:~3) Group 3: NS at 0.075 ml/kg/h from 8PM until 7AM."
89472710|NCT03354975|Experimental|Experiential Training|
89472711|NCT03354975|Active Comparator|Training-as-usual|
89472712|NCT04511559||chronic gastritis|This group will include 80 patients with chronic gastritis and the diagnoses will be based on the British Society of Gastroenterology guidelines.
89472713|NCT04511559||Moderate to severe atrophy/intestinal metaplasia/|This group will include 80 patients with Moderate to severe atrophy/intestinal metaplasia/ and the diagnoses will be based on British Society of Gastroenterology guidelines.
89472714|NCT04511559||gastric cancer|This group will include 380 patients with gastric cancer and the diagnoses will be based on British Society of Gastroenterology guidelines.
89472715|NCT03359187|Active Comparator|Normal saline with salt/Soda|Normal saline with salt/soda rinse 4 times a day/everyday and for each time 15 ml.
89472716|NCT03359187|Experimental|Clinacanthus nutans|Clinacanthus nutans in form of mouth wash rinse 4 times a day/everyday and for each time 15 ml.
89472717|NCT03359187|Experimental|Boesenbergia rotunda|Boesenbergia rotunda in form of mouth wash 4 times a day/everyday and for each time 15 ml.
89472718|NCT04506723|Experimental|Patients with urolithiasis|Patients with confirmed urolithiasis who is assigned to PCNL.
89472719|NCT04506723|Active Comparator|Patients without urolithiasis|Patients with renal tumor without urolithiasis in history who is assigned to partial or radical nephrectomy due to renal tumor.
89472720|NCT03354819|Experimental|Modified MBCT|A group-based, 10-week, 7-session modified Mindfulness Based Cognitive Therapy (MBCT) will be adopted in the MBCT intervention group with a group size of 15-20. The program includes different mindfulness activities (such as mindful eating and mindful walking) and peer sharing.
89472721|NCT03354819|Active Comparator|SIRE on dementia|The frequency of the Social Interactions and Routine Education (SIRE) program is the same as that of modified MBCT which consists of seven sessions (weekly for the first four sessions and bi-weekly for the last three sessions) and each session will last about two hours for 10 weeks with group size 15-20.
88949209|NCT04492540|Other|aerobic exercise and MIND diet program|the aerobic exercise in form of treadmill training intensity of exercise moderate intensity, target heart rate (THR) will be 60-70% of heart maximum (HR MAX), time of session 60 min initial 10 min warm up exercise on treadmill in low intensity and target phase 40 min intensity will increase until patient reach to THR then intensity decrease until session will be ended by cooling down phase for 10 min . The volunteers will perform exercise 3 times per week for 12 weeks
88949210|NCT04492540|Other|The Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) diet program|the control group will receive MIND diet program for 12 weeks
88949211|NCT04489589|Experimental|Midodrine|Midodrine 10mg PO/NG q8h
88949212|NCT04489589|Placebo Comparator|Placebo|Microcrystalline cellulose PO/NG q8h
88949213|NCT04471987|Experimental|Treatment|"The study will take place in two stages:~In the dose escalation part, participants will be enrolled in cohorts and will be treated with different doses of IL12-L19L19 in order to identify a RD to be further explored in the subsequent dose expansion part. In the dose escalation part, patients will be treated in cohorts of 1 to 6 patients with escalating doses of IL12-L19L19 until the MAD is reached.~Following successful identification of the RD, the study will proceed with a dose expansion part and 40 patients will be treated at the RD dose level."
89202501|NCT03050476|Placebo Comparator|Placebo|Bolus of of media on induction of anaesthesia, followed by an infusion of media over the next 24, 48, or 96 hours.
88949214|NCT04464785||Treatment|Subjects who receive the CentriMag Circulatory Support System
88949215|NCT04464473|Experimental|FPl-TMS|Transcranial magnetic stimulation to the lateral frontal pole. 600 pulses delivered in 50 Hz bursts every 5 Hz for 40 seconds at 80% of active motor threshold.
88949216|NCT04464473|Experimental|MFG-TMS|Transcranial magnetic stimulation to the middle frontal gyrus. 600 pulses delivered in 50 Hz bursts every 5 Hz for 40 seconds at 80% of active motor threshold..
89202502|NCT00791544|Experimental|Dose Level -1|0.5 mg/kg AVE1642 single agent at cycle 1 with sorafenib at cycle 2
89472722|NCT04511091||Vats Group|patients underwent planned VATS lobectomy for NSCLC from the Italian VATS Group Database (a validated, risk-adjusted, prospective, outcomes-based program with 50 participating hospitals in Italy) were included in the analysis.
89472723|NCT04506489||Psychological investigation|
89472724|NCT03359031|No Intervention|No patient education|This group of patients will not receive any additional information beyond standard of care educational pamphlets provided by the hospital.
89472725|NCT03359031|Other|Patient education|This group of patients will be given a pamphlet on pain control, narcotic medication, and compartment syndrome including its pathophysiology, signs/symptoms, and treatment.
89472726|NCT04506333|Experimental|Small Cuff|"Participants with an upper-arm circumference of 6.3-9.4 may be placed in the small cuff arm."
89472727|NCT04506333|Experimental|Medium Cuff|"Participants with an upper-arm circumference of 9.0-14.6 may be placed in the medium cuff arm."
89472728|NCT04506333|Experimental|Lage Cuff|"Participants with an upper-arm circumference of 12.2-17.7 may be placed in the large cuff arm.~The large cuff arm will use an adaptive study design. Per the AAMI/ESH/ISO standards, at least 1/6 of participants must fall into each cuff size arm for that cuff size, and of the participants assigned to each cuff size, at least 40% of those must fall in the upper and lower half of the cuff's size range. However, we do not anticipate many participants in our age range falling in the upper half of the large cuff size range (upper arm circumference > 14.95).~Because of this, our plan is to validate the large cuff, but if enrolling a patient with a large cuff would require additional patients be enrolled to reach 1/6 of the total sample, the large cuff will be dropped from consideration and the validation completed with only the small and medium cuffs."
89472729|NCT04443933||Cerebral Small Vessel Disease|In this group, patients are diagnosed with cerebral small vessel disease preoperatively using multimodal MRI.
89472730|NCT04443933||non-Cerebral Small Vessel Disease|In this group, cerebral small vessel disease is ruled out by preoperative multimodal MRI.
89472731|NCT03352167||ED Hjoerring|
89472732|NCT03352167||ED Aalborg|
89472733|NCT03352167||ED Aarhus|
89472734|NCT03352167||ED Herning|
89472735|NCT03352167||ED Aabenraa|
89472736|NCT03352167||ED Odense|
89472737|NCT03352167||ED Slagelse|
89472738|NCT03352167||ED Koege|
88949217|NCT04464473|Active Comparator|S1-TMS|Transcranial magnetic stimulation to primary somatosensory cortex. 600 pulses delivered in 50 Hz bursts every 5 Hz for 40 seconds at 80% of active motor threshold..
89472739|NCT04443777|Active Comparator|Sulphonylurea Group|Gliclazide 60 mg (Diamicron® MR) will be orally administered as matched capsules (same color, flavor, smell and size) 8 hours before the beginning of exercise session.
89472740|NCT04443777|Placebo Comparator|Placebo Group|Placebo (starch, sodium lauryl sulfate and Aerosil) will be orally administered as matched capsules (same color, flavor, smell and size) 8 hours before the beginning of exercise session.
89472741|NCT04511169|Experimental|remainder|The participants who are inactive for more than 48 hours after recieving new content will recieve a remainder, in the format of a text message and an email.
89472742|NCT04511169|No Intervention|non-remainder|The participants who are inactive for more than 48 hours after recieving new content will NOT recieve a remainder, in the format of a text message and an email.
89472743|NCT04523103|No Intervention|Control group|Standard ICSI procedure. The MII oocytes that failed fertilization in IVF cycles were injected with activating sperm.
89472744|NCT04523103|Experimental|A1 assisted activation|The MII oocytes that failed fertilization in ICSI cycles were activated in calcium ionophore A23187 activation solution for two times.
89472745|NCT04523103|Experimental|A2 assisted activation|Fertilization failure MII oocytes were collected in ICSI cycles. After CaCl2 was injected, the oocytes were transferred into the calcium ionophore A23187 solution for two times.
88949218|NCT04460352|Active Comparator|Control arm (A)|"Neoadjuvant chemoradiotherapy followed by esophagectomy.~Radiotherapy: 1.8 Gy fractions 5 days per week in 23 fractions to a total dose of 41.4 Gy.~Chemotherapy: Carboplatin AUC 2 + Paclitaxel 50mg/m2 weekly x 5 (day 1, 8, 15, 22, 29), starting on the first day of radiotherapy.~Esophagectomy: Within 8 weeks of termination of chemoradiotherapy,"
88949219|NCT04460352|Experimental|Experimental arm (B)|"Definitive chemoradiotherapy followed by surveillance, and esophagectomy only in case of residual or recurrent locoregional cancer.~Radiotherapy: Two alternative schemes:~1.8 Gy fractions five days per week in 28 fractions to a total dose of 50.4 Gy.~2.0 Gy fractions five days per week in 25 fractions to a total dose of 50 Gy.~Chemotherapy: Three alternative regimens:~1. Platin-Taxane Regimen: Carboplatin AUC 2 + Paclitaxel 50mg/m2 on day 1 weekly during the full course of radiotherapy.~2a. Platinum-Fluoropyrimidine Regimen: Cisplatin 75mg/m2 weeks 1 and 5 + 5-fluorouracil 1000 mg/m2/day by continuous infusion weeks 1 and 5.~2b. FOLFOX: Oxaliplatin 85 mg/m2, calcium folinate 200 mg/m2 and 5-fluorouracil 400 mg/m2 weeks 1, 3 and 5 + 5-fluorouracil 800 mg/m2 by continuous infusion weeks 1, 3 and 5."
88949220|NCT04445831|Placebo Comparator|Placebo|Placebo administered at predefined time points over a 48-week period.
88949221|NCT04445831|Experimental|ACI-35.030 - Low dose|Active vaccine administered at predefined time points over a 48-week period.
88949222|NCT04445831|Experimental|ACI-35.030 - Medium dose|Active vaccine administered at predefined time points over a 48-week period.
88949223|NCT04445831|Experimental|ACI-35.030 - High dose|Active vaccine administered at predefined time points over a 48-week period.
88949224|NCT04445831|Experimental|JACI-35.054 - Low dose|Active vaccine administered at predefined time points over a 48-week period.
89472746|NCT04523103|Experimental|A3 assisted activation|Fertilization failure MII oocytes were collected in ICSI cycles. Mechanical activation was done for the MII oocytes, and then the oocytes were transferred into the calcium ionophore A23187 solution for two times.
89472747|NCT03358953|Other|Electronic Cigarettes|Participants wishing to quit tobacco smoking have an equal chance of being assigned to the electronic cigarette arm. They are supplied with a second generation e-cigarette to support their quit attempt with standard of care once weekly support sessions from NHS smoking cessation services.
89472748|NCT03358953|Other|Nicotine replacement patches|Participants wishing to quit tobacco smoking have an equal chance of being assigned to the nicotine replacement patch arm (standard care). They are supplied with a second generation e-cigarette to support their quit attempt with standard of care once weekly support sessions from NHS smoking cessation services.
89472749|NCT03352089||Aortic stenosis group|Patients with severe aortic stenosis >70 years of age referred for aortic valve intervention
89472750|NCT03352089||Healthy volunteer group|Patients with no history of symptoms to suggest current cardiovascular disease >70 years of age
89472751|NCT04509999|Experimental|Standard of care and Experimental treatment of Bicalutamide|Each subject will be administered bicalutamide 150 mg daily at 1:1 randomization for up to 4 weeks.
89472752|NCT04509999|Placebo Comparator|Standard of Care and Placebo|Each subject will be administered placebo as formulated at 1:1 randomization for up to 4 weeks.
89472753|NCT04509921|No Intervention|symptoms group|The asthma treatment adjustments guided by GINA guidelines
89472754|NCT04509921|Experimental|BHR group|The asthma treatment adjustments additionally taking account to the results of the bronchial hyperresponsiveness test
89472755|NCT04522869|Experimental|Umbilical cord blood - derived mesenchymal stem cells|17 patients with BA underwent Kasai operation and then will received two doses of UC-MSCs at 1x106 cells/kg (body weight) administered via hepatic artery
89472756|NCT04522869|No Intervention|Control group|17 patients with BA will be conducted Kasai operation only
89472757|NCT04506021||Bicarbonate Ringer's Solution|"According to the choices of the patients' immediate family members, patients will be divided into Bicarbonate Ringer's Solution.~drug dosage form: Solution, Intravenous infusion. the drug dosage frequency and duration were no intervention"
89472758|NCT04506021||Other Crystalloid|"According to the choices of patients' immediate family members, patients will be divided into Other Crystalloid.~drug dosage form: Solution, Intravenous infusion. the drug dosage frequency and duration were no intervention"
89472759|NCT04509453|Experimental|McGRATH|
89472760|NCT04509453|Active Comparator|Macintosh|
89472761|NCT04505943|Experimental|isonicotinic acid hydrazide|2vaginal tablet of isonicotinic acid hydrazide inserted by the study nurse12 hours before IUD insertion.
89472762|NCT04505943|Active Comparator|dinoprostone|2 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia & Upjohn, Puurs, Belgium) inserted by the study nurse 12 hours before IUD insertion.
89472763|NCT04505943|Active Comparator|misoprostol|2 vaginal tablet of misoprostol (200 mcg) (Misotac®; Sigma Pharma, SAE, Egypt) inserted by the study nurse 12hours before IUD insertion.
89472764|NCT03358719|Experimental|Treatment (CDX-1401, poly ICLC, decitabine, nivolumab)|Patients receive DEC-205/NY-ESO-1 fusion protein CDX-1401 intracutaneously and poly ICLC SC on day -14, on day 15 of courses 1-4, and then on day 1 of every 4 courses thereafter. Patients also receive nivolumab IV over 30 minutes on days 1 and 15 and decitabine IV over 1 hour on days 1-5. Courses with nivolumab and decitabine repeat every 4 weeks in the absence of disease progression or unaccepted toxicity.
89472765|NCT03358641||Wuchuan residents|All residents that meet the criteria can be enrolled in this group, receiving a home interview (including IPA-Q to assess the level of physical activity) and a weight-bearing posteroanterior semiflexed view of radiographs at tibiofemoral (TF) joints at baseline and 3 years later.
89472766|NCT04505475||Direct oral anticoagulants|Patients taking dabigatran, ravaroxaban or apixaban
89202503|NCT00791544|Experimental|Dose Level 1|1 mg/kg AVE1642 single agent at cycle 1 with sorafenib at cycle 2
89202504|NCT00791544|Experimental|Dose Level 2|3 mg/kg AVE1642 single agent at cycle 1 with sorafenib at cycle 2
89472767|NCT04505475||Vitamin K antagonists|Patients taking acenocoumarol with therapeutic INR levels (2.0-3.5)
89472768|NCT01376349|Experimental|Arm I low dose DHEA|Participants apply a low dose (3.25 mg) of vaginal prasterone (dehydroepiandrosterone [DHEA]) gel once daily (QD), at bed time, for 12 weeks. Treatment continues until unacceptable adverse events or patient refusal to continue participation on the study.
89472769|NCT01376349|Experimental|Arm II high dose DHEA|Participants apply a high dose (6.5 mg) of vaginal DHEA gel QD, at bed time, for 12 weeks. Treatment continues until unacceptable adverse events or patient refusal to continue participation on the study.
88949225|NCT04445831|Experimental|JACI-35.054 - Medium dose|Active vaccine administered at predefined time points over a 48-week period.
88949226|NCT04431609||CAROtid WEB associated with cerebral infarction|french multicentric cohort that collects retrospectively and prospectively purely observational data on patients with cerebral infarction associated with a carotid web. Diagnostic, therapeutic or follow-up strategies will be at the discretion of the Stroke Unit taking care of the patient.
88949227|NCT04419181|Experimental|Pathologic complete response (pCR)|Participants will receive four cycles of TCHP [docetaxel (Taxotere®), carboplatin, trastuzumab (Herceptin®), pertuzumab], followed by surgery. Participants who achieve pathologic complete response will receive infusions of trastuzumab every 3 weeks for a total of 12 cycles/infusions.
88949228|NCT04419181|Experimental|Residual Disease|Participants will receive four cycles of TCHP [docetaxel (Taxotere®, carboplatin, trastuzumab (Herceptin®), pertuzumab], followed by surgery. Participants who have residual disease may be offered two more cycles of TCHP in the adjuvant settings (optional) per treating oncologist's discretion and then will receive infusion of Trastuzumab Emtansine (TDM1) plus pertuzumab every three weeks for a total of 12 cycles/infusions.
89472770|NCT01376349|Placebo Comparator|Arm III placebo|Participants apply a vaginal placebo gel QD, at bed time, for 12 weeks. There is an Optional Continuation Phase (for placebo arm only): Participants apply a high dose of vaginal DHEA gel QD, at bed time, for 12 weeks. Treatment continues until unacceptable adverse events or patient refusal to continue participation on the study.
89202505|NCT00791544|Experimental|Dose Level 3|6 mg/kg AVE1642 single agent at cycle 1 with sorafenib at cycle 2
89202506|NCT00791544|Experimental|Dose Level 4|12 mg/kg AVE1642 single agent at cycle 1 with sorafenib at cycle 2
89202507|NCT00791544|Experimental|Dose Level 5|18 mg/kg AVE1642 single agent at cycle 1 with sorafenib at cycle 2
89472771|NCT04504695||Thrombectomy group|Major patients requiring management for endovascular thrombosis
89472772|NCT04504695||Aneurysm group|Major patients requiring management for an intracranial aneurysm
89472773|NCT03350685||Classic Whipple's disease (CWD)|"Classic Whipple's disease (CWD), defined as~duodenal biopsy positive by PAS/immunohistochemistry~or blood positive by PCR"
89472774|NCT03350685||Focal Whipple's disease (FWD)|"Focal Whipple's disease (FWD), defined as~joint fluid positive by PCR~but duodenal biopsy negative by PAS/immunohistochemistry"
88949229|NCT04388852|Experimental|Treatment (valemetostat, ipilimumab)|Patients receive valemetostat PO QD on days 1-21 and ipilimumab IV over 90 minutes on day 1 of cycles 1 and 3. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89472775|NCT03350685||Chronic T. whipplei-associated arthritis (CTWA)|"Chronic T. whipplei-associated arthritis (CTWA) defined as chronic arthritis and~duodenal biopsy, stool, or saliva positive by PCR~duodenal biopsy negative by PAS/immunohistochemistry~joint fluid negative by PCR"
89472776|NCT04505787|Experimental|Esflurbiprofen hydrogel patch|"Esflurbiprofen hydrogel patch 165 mg (EFHP) (Teikoku Seiyaku Co.), transdermal patch containing 165 mg S-flurbiprofen, once daily consecutive application over 14 days; each patch to be applied for 24 h, application site: outer ankle (same site and position for all applied patches)"
89472777|NCT04505787|Active Comparator|Froben|"Froben 100 mg comprimidos revestidos (Abbott Laboratórios, Lda., Portugal), immediate release tablets containing 100 mg flurbiprofen, oral multiple dose administration of 1 tablet three times daily (TID) over 4 consecutive days after a light meal"
89472778|NCT04445337|Experimental|Open Label SGB|Initial perineural bolus injection - clonidine 100 mcg, Decadron PF 5mg, and 0.25% bupivacaine 5 ml will be used for SGB block.
89472779|NCT03351855|Experimental|HPV-CTLs|Autologous or allogenic HPV specific cytotoxic lymphocytes
89472780|NCT03350373|Experimental|Fasted dosing followed by fed dosing|Dosing of FYU-981 in the fasted state followed by fed dosing
89472781|NCT03350373|Experimental|Fed dosing followed by fasted dosing|Dosing of FYU-981 in the fed state followed by fasted dosing
89472782|NCT03351777|Experimental|PR022 topical gel, 0.05%|Applied twice daily for 28 days
89472783|NCT03351777|Experimental|PR022 topical gel, 0.1%|Applied twice daily for 28 days
89472784|NCT03351777|Placebo Comparator|PR022 topical gel vehicle|Applied twice daily for 28 days
89472785|NCT03350295|Experimental|GRP1 - Assess relative bioavailability(3-way cross-over)|"GROUP 1 (Treatments A, B, C) All 3 treatments in Group 1 consist of a dose of 120 mg nifurtimox (4 x 30 mg tablets). Participants received the 3 treatments in one of six treatment sequences under fed condition.~Treatment A, dose administration with fast in vitro dissolution characteristics Treatment B, dose administration with medium in vitro dissolution characteristics Treatment C, dose administration with slow in vitro dissolution characteristics"
89472786|NCT03350295|Experimental|GRP2 - Assess relative bioavailability (2-way cross-over)|"GROUP 2 (Treatments D and E) Participants received the 2 treatments in one of two treatment sequences under fed condition.~Treatment D, a single dose 30 mg nifurtimox dose with medium in vitro dissolution characteristics Treatment E, a single dose of 120 mg nifurtimox"
89472787|NCT04523025||Low NLR-ratio|Patients with low NLR ratio (NLR<3)
89472788|NCT04523025||High NLR-ratio|Patients with high NLR ratio (NLR≥3)
89472789|NCT04505241|Experimental|Adaptive Goal-Setting|Participants in this condition will receive daily step goals calculated as the 60th percentile of their last 9 days of available daily steps data. Goals will be transmitted over text message, and will be accompanied by information about the participant's steps on the previous day and whether they met their goal the previous day.
89472790|NCT04505241|Experimental|Static Goal-Setting|Participants in this condition will receive daily a uniform daily goal of 10,000 steps per day. Participants will receive daily texts including information about the participant's steps on the previous day, whether they met their goal the previous day, and encouraging them to continue striving for 10,000 steps each day.
89472791|NCT04522635|Active Comparator|albumin|albumin (100 ml of Grifols 25%) given intravenously at the start of IHD
89472792|NCT04522635|Placebo Comparator|normal saline|0.9% sodium chloride (normal saline (NS)) given intravenously at the start of IHD
89472793|NCT03350139||Patients treated with gamma knife radiosurgery|Collection of non-genetic, chronobiological, therapeutic and co-morbidities
89472794|NCT03350061|Experimental|SENSY benefit|Sensory feedback elicited by intraneural stimulation will be provided by SENSY with and without the leg prosthesis to improve walking ability, increase embodiment, and reduce metabolic cost, cognitive load and phantom pain.
89472795|NCT03349983|Experimental|MVA-BN-Brachyury/ FPV-Brachyury|
89472796|NCT03358485|Experimental|Aolanti Weikang tablets|3，6 or 8 Aolanti Weikang tablets each time,tid
89472797|NCT03358485|Placebo Comparator|Placebo|3,6 or 8 tablets each time,tid
88949230|NCT04386317|Experimental|terazosin therapy|Daily oral doses of adrenergic blocker 5 mg or 10 mg. The dosage will be gradually increased from the initial recommended starting dose of 1 mg daily at bedtime and titrated stepwise to 2mg, 5mg or 10 mg weekly, according to patient tolerability, as measured by subjective complaints, arterial blood pressure and heart rate. The target dose will be 5 mg or 10 mg daily based on subject's tolerability.
88949231|NCT04380857|Experimental|Dexamethasone ophthalmic insert 0.4 mg|Dexamethasone ophthalmic insert 0.4 mg
89472798|NCT04522401||People aged 65 and over|"People aged 65 and over who have had a gerontological evaluation Bien vieillir at the St-Etienne University Hospital Day Hospital."
89472799|NCT03349827|Experimental|Experimental|HIPEC with Docetaxel/ Lobaplatin at the time of fist surgery and twice repeat within one week after the surgery, following 2 cycles of 3-week Oxaliplatin/S1 chemotherapy combined with Apatinib and 1 cycles of 3-week Oxaliplatin/S1 chemotherapy. The second surgery, exploratory laparoscopy or laparotomy, is carried out one week later after the series of systemic chemotherapy.
89472800|NCT04503915|Experimental|Constant group|Women will receive oral estradiol valerate (Progynova®; Bayer Schering Pharma AG, Berlin, Germany) 3 mg bid for 14 days for endometrial priming from the second or third day of the menstrual cycle.
89472801|NCT04503915|Active Comparator|Step -up group|Women will receive estradiol valerate 2mg once daily for 4 days from the second to fifth day,followed by 2mg bid for 4 days from the sixth to ninth day and then 3mg bid for 6 days from tenth to fifteenth day of menstrual cycle.
88949232|NCT04380857|Active Comparator|Topical prednisolone acetate ophthalmic drops|topical prednisolone acetate ophthalmic drops
88949233|NCT04327570||ICU-hospitalised COVID-19 patients|COVID-19 positive patients hospitalised in intensive care ('severe disease').
89019520|NCT04715412|Other|Study group|"The standard training sessions were conducted for individual patient by the transplant physician to explain rejections, infections and tumor risks, post-transplant medication. After discharge, all patients had scheduled follow-up visits at the outpatient clinic of the transplant center, where immune suppressant blood levels were measured and their dosing adjusted accordingly. Patients also had the opportunity to discuss any concern of their condition or drug therapy with the transplant physician in charge.~in addition to this standard transplant training, patients received intensified care by a dedicated clinical pharmacist combining educational and technical interventions aiming at achieving and maintaining adherence to his/her prescribed medication and improving health outcomes."
89019521|NCT00342381|Active Comparator|3.4 diaminopyridine|Single dose 3,4 diaminopyridine
88949234|NCT04327570||ward-hospitalised COVID-19 patients|COVID-19 positive patients requiring hospitalisation,not on intensive care department ('non-severe').
89019522|NCT00342381|Placebo Comparator|Placebo|Two tablets identical to active treatment
89472802|NCT04522479|No Intervention|prolonged protocol of early follicular phase|Inject a full dose of GnRH-a in 1st-3rd day of menstruation (leuprorelin acetate, injection, 3.75mg), the level of E2, P, LH in peripheral blood and the number of follicles in bilateral internal ovarian sinuses were monitored 32-38 days after the depression. If the pituitary desensitization was achieved, Gn (recombinant human follicle stimulating hormone or urofollicle stimulating hormone, injection, 75-300iu) was used for contralled hyperstimulation, when the diameter of 2 follicles was ≥ 18mm，hCG (human chorionic gonadotropin, injection, 4000-10000IU) was used to trigger and retrieve the oocyte. Selective single blastocyst transplantation was performed on the 4th-6th day after the oocyte retrieved. β-hCG was detected on the 12th day after embryo transplantation, and pregnancy or not was judged. If patients get pregnancy, follow-up was continued until the 42nd day after baby delivery.
89472803|NCT04522479|Experimental|prolonged protocol of middle luteal phase|Inject a full dose of GnRH-a in 21st-23rd day of menstruation (leuprorelin acetate, injection, 3.75mg), the level of E2, P, LH in peripheral blood and the number of follicles in bilateral internal ovarian sinuses were monitored 32-38 days after the depression. If the pituitary desensitization was achieved, Gn (recombinant human follicle stimulating hormone or urofollicle stimulating hormone, injection, 75-300iu) was used for contralled hyperstimulation, when the diameter of 2 follicles was ≥ 18mm，hCG (human chorionic gonadotropin, injection, 4000-10000IU) was used to trigger and retrieve the oocyte. Selective single blastocyst transplantation was performed on the 4th-6th day after the oocyte retrieved. β-hCG was detected on the 12th day after embryo transplantation, and pregnancy or not was judged. If patients get pregnancy, follow-up was continued until the 42nd day after baby delivery.
89472804|NCT03351465|Experimental|CALM|The intervention for this study, CALM Tools for Living-Il, is a computer-assisted cognitive-behavioral therapy for anxiety and depression that guides both the patient and CALM specialist. It is a reformulation of CALM Tools for Living that directly incorporates our previously optional modules for depression into the main program. The computerized/internet format is designed to retain the fidelity of CBT when delivered by novice clinicians. The program is intended to be delivered in 6 to 8 sessions, although flexibility is allowed. Participants in the intervention group will be visited by the calm specialist weekly between 6 and 8 times prenatally;postpartum visits will vary based on continuing assessment of symptoms.
89472805|NCT03351465|No Intervention|Treatment as Usual|Participants will receive pre-natal care as usual, and will be visited at 4 time points by the graduate student researchers: baseline, 12 weeks post baseline, and 10 weeks postpartum.
89472806|NCT04503837|Experimental|Intervention|Personalized Mobile Phone Video Recording in addition to Standard care
89472807|NCT04503837|No Intervention|Control|Standard care alone
89472808|NCT04504851|Active Comparator|Arm A (Standard of Care)|Standard combination treatment for pulmonary TB of 8 weeks rifampicin, isoniazid, pyrazinamide, ethambutol, then 16 weeks rifampicin, isoniazid
89472809|NCT04504851|Experimental|Arm B (Standard of Care plus Rosuvastatin)|Standard combination treatment for pulmonary TB of 8 weeks rifampicin, isoniazid, pyrazinamide, ethambutol PLUS rosuvastatin, then 16 weeks rifampicin, isoniazid
89472810|NCT03349749||Patients undergoing fluid resuscitation|Adult patients in the intensive care unit (ICU) undergoing fluid resuscitation guided by the LiDCOplus haemodynamic monitor.
89472811|NCT03351309|Experimental|Telephone-based cognitive behavioral therapy|Telephone-based cognitive behavioral therapy (CBT) intervention - Four session protocol plus routine perioperative management.
89472812|NCT03351309|No Intervention|Treatment as Usual|Treatment as Usual (TAU) - Routine perioperative management.
89472813|NCT04504617|Experimental|Intervention Group|This group will consist of six kebeles with a total of 90 pairs of mothers and their children that will receive the nutrition education intervention to enhance complementary feeding practices first. The six lessons will be delivered in a period of 6 weeks. Before the intervention this groups will be assessed with the baseline assessment. After the intervention, this group will be assessed in three time points (post-intervention, follow-up 1 and follow-up 2).
89019523|NCT00311558|Experimental|SSG & INF|1 arm study: SSG & interferon
89202508|NCT00791544|Experimental|Combination cohort 1|AVE1642 selected dose in combination with sorafenib
89472814|NCT04504617|Active Comparator|Delayed Intervention Group|This arm will consist of the six kebeles with a total of 90 pairs of mothers and their children that will not receive the intervention immediately. This group will first complete the baseline and the second assessment. After the second assessment, this group will receive the nutrition education intervention to enhance complementary feeding practices. After the intervention, this group will be assessed in two additional time points (post-intervention and follow-up 1).
88949235|NCT04307836|Experimental|DENEX Renal denervation|Subjects are treated with the renal denervation procedure after randomization and maintained baseline anti-hypertensive medications
88949236|NCT04307836|No Intervention|Control group|Subjects are not treated with the renal denervation, not sham, after randomization and maintained baseline anti-hypertensive medications
89472815|NCT03351153|Other|X-ray group|In the X-ray group, the changes in femoral head height were measured with X-ray in an anteroposterior position of the pelvis (healthy and affected sides of the hip) at preoperative 1 week.
89472816|NCT03351153|Other|CT group|In the CT group, changes of femoral head height were measured with CT scan on bilateral hips (healthy side and affected side) at preoperative 1 week.
89472817|NCT03351153|Other|Specimen group|In the specimen group, femoral head on the affected side was resected during surgery and directly measured with a ruler and vernier caliper.
89472818|NCT04504461||Laparoscopic Inguinal Hernioplasty. Ambulatory|Laparoscopic Inguinal Hernioplasty performed in ambulatory surgery center
89472819|NCT04504461||Laparoscopic Inguinal Hernioplasty. Hospital Stay|Laparoscopic Inguinal Hernioplasty that have to stay at least 24 hours at the hospital
89472820|NCT03349203|Experimental|Icotinib|Patients with EGFR-mutant stage IIIB or oligometastasis Non-small Cell Lung Cancer which can be potentially radical treated by surgery are arranged to receive Icotinib with a dose of 125 mg three times per day orally for 8 weeks before surgery and 2 years as adjuvant therapy after surgery or till progressive disease or unaccepted toxicity.
89472821|NCT04504539|Experimental|mOPV with FIPV|mOPV vaccine will be given at birth, 6 weeks, 10 weeks and 14 weeks of age along with a single dose of FIPV at 14 weeks of age.
89472822|NCT04504539|Experimental|bOPV with FIPV|bOPV vaccine will be given at birth, 6 weeks, 10 weeks and 14 weeks of age along with a single dose of FIPV at 14 weeks of age.
89472823|NCT04504539|Experimental|mOPV with fIPV|mOPV vaccine will be given at birth, 6 weeks, 10 weeks and 14 weeks of age along with a two doses of fIPV at 6 weeks and 14 weeks of age.
89472824|NCT04504539|Experimental|bOPV with fIPV|bOPV vaccine will be given at birth, 6 weeks, 10 weeks and 14 weeks of age along with a two doses of fIPV at 6 weeks and 14 weeks of age.
89472825|NCT03350841|Experimental|Revascularization|platelet rich plasma injected in the canals
89472826|NCT03350841|Active Comparator|root canal treatment|endodontic treatment obturated with gutta percha
89472827|NCT03350763|Experimental|Plastic biliary stent|A plastic (ie Tannenbaum 10 Fr) biliary stent is used to achieve biliary decompression
89472828|NCT03350763|Experimental|Self-expandable metallic biliary stent|A self-expandable metallic biliary stent is used to achieve biliary decompression
89472829|NCT03101787|No Intervention|CCPR protocol|"Preclinical Cardiopulmonary resuscitation (CPR) by emergency medical services (EMS) and rapid transport to the emergency department with ongoing mechanical CPR and advanced cardiac life support (ACLS).~Clinical Upon the patient's arrival, the standard of care (CCPR) will be continued according to ERC guidelines.~No special preparations for the trial are needed before the patient's arrival."
89472830|NCT03101787|Experimental|ECPR protocol|"Preclinical Cardiopulmonary resuscitation (CPR) by emergency medical services (EMS) and transport to the emergency department with ongoing mechanical CPR and advanced cardiac life support (ACLS).~Clinical The ECPR team is mobilized while the patient is transported to the hospital. Initiation of extracorporeal cardiopulmonary resuscitation (ECPR).~Time from arrest to start of cannulation is < 60 minutes."
89472831|NCT03349125||Collar On|Individuals who have been referred for videoflouroscopic swallow study (VFSS) as per standard of care, with a stable cervical injury, will have trials of liquids and solids with the Cervical Brace (Collar) on.
89472832|NCT03349125||Collar Off|Individuals who have been referred for videoflouroscopic swallow study (VFSS) as per standard of care, with a stable cervical injury, will have trials of liquids and solids with the Cervical Brace (Collar) off.
89472833|NCT03349047|Active Comparator|Behavioral Intervention|Behavioral Intervention Group - Education regarding nut allergy and will also have contact with nut.
89472834|NCT03349047|Placebo Comparator|Control|Education regarding nut allergy
88949237|NCT04307485|Active Comparator|standard dose ticargrelor based DAPT therapy|treated with ticagrelor 90mg and aspirin 100mg after PCI for 12 months as the standard group
88949238|NCT04307485|Experimental|low dose ticargrelor based DAPT|treated with ticagrelor 60mg plus aspirin 100 mg for 11 months after one month standard DAPT treatment
88949239|NCT04299620|Experimental|Diagnostic (TRUS)|Patients may undergo TRUS prior to standard-of-care radical prostatectomy. Following radical prostatectomy, removed glands are scanned and micro-US, standard of care mpMRI, and whole mount images are analyzed and compared.
88949240|NCT04284267|No Intervention|Healthy Control|This group consists of individuals with no psychiatric diagnosis.
88949241|NCT04284267|Experimental|Bipolar Group|This group consists of individuals with a diagnosis of bipolar disorder who have been randomized to receive high-dose TMS (i.e., 1800 pulses) and sham TMS.
89472835|NCT05452863|Active Comparator|Automatic oxygen supply|Oxygen will be supplied by the O2matic device
89472836|NCT05452863|Placebo Comparator|Manual oxygen supply|Oxygen will be supplied by nurse adjustments in the usual way
89472837|NCT02518035|Placebo Comparator|Control|No silicone gel treatment after remove of stitches
89472838|NCT02518035|Experimental|Experimental|Silicone gel applied for twice per day
89537399|NCT03065829|Experimental|Attention-Control|This intervention exposes subjects to the wearable technology without the self-management components to minimize novelty effects. Subjects assigned to this condition will wear the device for 30 days, which offers them an opportunity to experientially learn to self-monitor and employ self-regulatory skills by viewing the display biophysical data. Subjects in this condition will not receive any prompts from the device.
89537400|NCT02465021|Experimental|Snack bar 1|Dietary intervention: 190 Kcal, 12g fat, 14g carbohydrate, 5g fibre, 6g sugar, 10g protein
89472839|NCT03030261|Experimental|Elotuzumab + Pomalidomide + Dexamethasone|"Patients will receive 2-6 cycles of salvage/induction per standard of care. After protocol version 02/13/2020, patients may have already received their induction therapy prior to enrolling in the study.~Following induction, patients will undergo standard of care ASCT melphalan conditioning (ASCT). Administration of melphalan and the second ASCT will be done as part of routine care and procedures are not dictated by this protocol.~Continuation therapy with Elo-Pom-Dex will begin between Days 80 and 120 following the second ASCT:~10 mg/kg of elotuzumab on Days 1 and 15 for Cycles 1-6 followed by 20 mg/kg on Day 1 for Cycles 7+~2 mg pomalidomide daily on Days 1-21 of all cycles~40 mg dexamethasone on Days 1 and 15 of all cycles for Cycles 1-6 followed by 40 mg on Day 1 for Cycles 7+~Continuation therapy may continue until relapse or progression."
89472840|NCT03348813|Experimental|HIV/STI Prevention Intervention|Two-session, small group HIV/STI prevention intervention.
89472841|NCT03348813|Active Comparator|General Health Control Intervention|Two-session, small group general health promotion intervention.
89472842|NCT02176161|Experimental|Surgery - High Risk, Undetectable prostate-specific antigen (PSA)|
89472843|NCT02176161|Experimental|Radiation - Rising PSA|
89472844|NCT02176161|Experimental|Surgery - Rising PSA|
89472845|NCT04504305|Active Comparator|Neuropaway|
89472846|NCT04504305|Placebo Comparator|Microcystalline cellulose|
89472847|NCT03348735|Experimental|Lidocaine patch 5%|Lidocaine 5% medicated plasters will be applied daily, during 12 consecutive hours.
89472848|NCT03348735|Experimental|Capsaicin 8% patch|Capsaicin 8% patches need to applied in a hospital setting during 1 hour. Re-application of these capsaicin patches will be performed upon re-occurrence of painful symptoms (mostly after 12 weeks - so not after a fixed time interval). Application of capsaicin patches will be carried out in a hospital setting (+/- 3 hours procedure).
89472849|NCT03348735|Active Comparator|Pregabaline|Oral treatment with pregabalin (75mg capsules) will be used at optimized doses to best match clinical practice in Europe. In European clinical practice, up-titration of the dose is often carried out over a longer time-period. This study thus includes up-titration schedule for pregabalin over a period of 4 weeks. If patients develop side-effects during the intake/uptitration of pregabalin this treatment can be stopped and switched to gabapentin (300mg capsules). Gabapentin will always be the back-up treatment for failed systematic treatment with pregabalin. Dose of gabapentin will be uptitrated to maximum 1200mg per day.
89472850|NCT03348657|Other|Music intervention Group|Patients who participated to at least one music session provided by volunteers while being admitted to the geriatric assessment unit. Participation to the music sessions was voluntary.
89472851|NCT03348657|No Intervention|Control Group|Patients who did not want to participate to the music sessions provided by volunteers while being admitted to the geriatric assessment unit
89472852|NCT03348579||The before period|The before period (control phase) will consist of all consecutive patients admitted to the participating ICUs before the national guidelines publication concerning hospital-acquired pneumonia.
89472853|NCT03348579||The second period|"Intensive care units are randomized in two groups:~Standard training: The centers will receive the text of the recommendation electronically. The principal investigator of each center will then train doctors, interns, nurses and physiotherapists to the use of these recommendations (team leader). A computer presentation common to all the centers will be used and a communication strategy vis-à-vis the other caregivers of the investigative services will be put in place. All doctors, interns and nurses must have attended this theoretical training during the awareness phase."
89472854|NCT03348579||The third and final period|The third and final period will consist of all consecutive patients admitted to the participating ICUs after the formal training.
89472855|NCT01797003|Active Comparator|Opening wedge HTO|Opening wedge high tibial osteotomy using Puddu plate
89472856|NCT01797003|Active Comparator|Closing wedge HTO|Closing wedge high tibial osteotomy using cramp fixation
89472857|NCT04501029|Experimental|Gimatecan group|In Phase Ib study, patients will receive gimatecan at different dose level (0.4mg/m2, 0.6mg/m2,0.8mg/m2, oral, every 4 weeks) until progressive disease (PD).In Phase II study, patients will receive gimatecan at recommended phase II dose level.
89472858|NCT01700673|Experimental|Myeloablative BMT|Azacitidine and sargramostim after myeloablative stem cell transplant
89472859|NCT01700673|Experimental|Non-myeloablative BMT|Azacitidine and sargramostim after non-myeloablative stem cell transplant
89472860|NCT01700673|Experimental|Standard consolidation|Azacitidine and sargramostim after standard consolidation
89472861|NCT00923871|Experimental|Cone Beam CT|
89472862|NCT03347097|Experimental|TIL cells|10 days after the end of chemotherapy or radiotherapy，the 300ml TIL cells ( TIL saline + 0.25% human serum albumin) was injected intravenously 2 times every 30 days .
89472863|NCT03347097|Experimental|PD1-TIL cells|10 days after the end of chemotherapy or radiotherapy，the 300ml PD1-TIL cells ( PD1-TIL saline + 0.25% human serum albumin) was injected intravenously 2 times every 30 days .
89472864|NCT00158600|Active Comparator|alglucosidase alfa|Intravenous (IV) infusions of alglucosidase alfa at 20 milligrams (mg)/kilogram (kg) of body weight every other week (qow) for 78 weeks.
89472865|NCT00158600|Placebo Comparator|Placebo|Intravenous (IV) infusions of placebo every other week (qow) for 78 weeks.
89472866|NCT03898154|Experimental|Glucocorticoid (GC) group|Intraoperative: Single intraoperative dose of 10 mg intravenous dexamethasone Postoperative: A 6-day oral methylprednisolone (oral GC) taper course. The oral GC taper course begins on the day of surgery and includes 24mg on day 1, 20mg on day 2, 16mg on day 3, 12mg on day 4, 8mg on day 5, and 4mg on day 6
89472867|NCT03898154|No Intervention|Control (non-GC) group|No GC administration
89472868|NCT02517801|Experimental|Anthocyanin capsules|Chronic intake of 2 capsules for 30 days (2x daily)
89472869|NCT02517801|Placebo Comparator|placebo capsules|Chronic intake of 2 capsules for 30 days (2x daily)
89472870|NCT02517957|Experimental|Qinzhuliangxue Keli|Qinzhuliangxue Keli(common name: QZLX particles, shenzhen China resources san-jiu pharmaceutical trading co., LTD.), loratadine tablets placebo (common name: LLTD piece, Shanghai schering pharmaceutical co., LTD.)
89472871|NCT02517957|Active Comparator|loratadine tablets|Qinzhuliangxue Keli placebo (common name: QZLX particles, shenzhen China resources san-jiu pharmaceutical trading co., LTD.),Loratadine tablets (common name: LLTD piece, Shanghai schering pharmaceutical co., LTD.).
89472872|NCT02517957|Active Comparator|Qinzhuliangxue and loratadine|Qinzhuliangxue Keli (common name: QZLX particles, shenzhen China resources san-jiu pharmaceutical trading co., LTD.), loratadine tablets (common name: LLTD piece, Shanghai schering pharmaceutical co., LTD.).
89472873|NCT05735288||Haemodialysis patients|Haemodialysis patients attending haemodialysis in an outpatient setting in Beaumont Hospital, Ireland.
89472874|NCT02517879|Experimental|Group 1 - 1-3 days|Community health worker hang-up visit 1-3 days after the community point distribution
89472875|NCT02517879|Experimental|Group 2 - 5-7 days|Community health worker hang-up visit 5-7 days after the community point distribution
89472876|NCT02517879|Experimental|Group 3 - 10-12 days|Community health worker hang-up visit 10-12 days after the community point distribution
89472877|NCT02517879|Experimental|Group 4 - 15-17 days|Community health worker hang-up visit 15-17 days after the community point distribution
89472878|NCT02517879|Placebo Comparator|Group 5 - No hang-up visit|Did not receive any hang-up visit after the community point distribution
89472879|NCT03137810|Experimental|placental cord drainage|In 90 women after vaginal delivery of the baby, the placental end of the cut umbilical cord 1st will be clamped for few seconds and then unclamped and left open to drain blood in a vessel until flow stoped. This will prevent the drained blood from getting mixed with blood lost in the 3rd stage.
89472880|NCT03137810|Active Comparator|Non placental cord drainage|In 90 women after vaginal delivery of the baby placental end of the cut umbilical cord will be kept clamped.
89472881|NCT02517723|Experimental|SIC + NET|Waiting List + Standard Inpatient Care + Narrative Exposure Therapy
89472882|NCT02517723|Active Comparator|SIC + DBT|Waiting List + Standard Inpatient Care + Dialectical Behavior Therapy
89472883|NCT03888716|Experimental|KL1333|25 and 100 mg KL1333 encapsulated tablets for daily oral dosing
89472884|NCT03888716|Placebo Comparator|Matching placebo|25 and 100 mg KL placebo encapsulated tablets for daily oral dosing
89472885|NCT03841682|Experimental|I-CARE2 Intervention|"Participants should continue with their usual medical care. Additionally, participant receive the I-CARE2 intervention.~Trained health coaches deliver the I-CARE2 intervention over 6 months. The intervention provides 9 individual counseling sessions on problem solving treatment and behavior counselling to manage mood and lose weight (4 weekly, 2 biweekly, and then 3 monthly; 1 hour each), 11 home-viewed GLB videos (weekly; 20-30 minutes each), and self-study and self-monitoring activities. Throughout the intervention, participants are asked to wear and sync a study-provided Fitbit pedometer, and to log their weight, minutes of physical activity, and dietary intake using the Fitbit website or mobile app."
89472886|NCT03841682|No Intervention|Usual Care|Participants should continue with their Usual Medical Care. Additionally, participants receive information on wellness and behavioral health promotion at UI Health and a Fitbit pedometer.
89472887|NCT04503369||EMS crews|Crews of Emergency Medical Services
89472888|NCT03348267|Experimental|Protein|On the match day, 25g of protein consumed immediately after the match and then 30g at 3h (+3h) and 25g at 6h (+6h). On each day of the remaining days, 20 g of protein consumed with breakfast.
89472889|NCT03348267|Active Comparator|Placebo|On the match day, 500 ml received received orally immediately post-match and then at +3h and +6h. On the remaining days, 500 ml daily with breakfast.
89472890|NCT05734976|Experimental|Electro-Acupuncture can modulate the levels of pro-inflammatory metabolites|the disproportionate inflammatory response presented by chronic and acute inflammation as is the case in patients with stroke. In addition, the evaluation of the risk factors associated with the presence of metabolites such as cholesterol and fatty acids will provide us with an adequate diagnosis of the influence that these risk factors have on the blood vessels and the vascular endothelium.This is the group that receives real electroacupuncture, applied to selected acupuncture points both on the arms and legs, and on the scalp. All procedures were carried out with disposable needles measuring 0.25 mm in diameter (32-gauge) and 44 mm in length.
89472891|NCT05734976|Sham Comparator|The design and conduct randomized clinical trial using electroacupunture|efficacy and effectiveness of electroacupuncture in a clinical trial in electroacupuncture: design of control group and treatment group (including sharm acupuncture) and develop in this study the measurements in the patients and perform everything to the highest standards in both treatment procedures and measurement of results. Randomized controlled trail: intervention strategy and implementation.Also called Sham because it does not receive real stimulation from an acupuncture point, it is 1 cm away from the meridian. All procedures were carried out to a depth of 0.5 cm with disposable needles
88949242|NCT04271488|Experimental|Cohort A: Mild Hepatic Impairment (Child Pugh Class A)|Participants with mild hepatic impairment will receive a single 35 milligram (mg) tablet of tasurgratinib in the morning with 150 milliliters (mL) of water following an overnight fast of at least 10 hours.
88949243|NCT04271488|Experimental|Cohort B: Moderate Hepatic Impairment (Child Pugh Class B)|Participants with moderate hepatic impairment will receive 10 mg dose of tasurgratinib as capsule (2 capsules each of 5 mg) in the morning with 150 mL of water following an overnight fast of at least 10 hours.
88949244|NCT04271488|Experimental|Cohort C: Healthy Participants (Control)|Healthy participants matched to participants with hepatic impairment in Cohorts A and B (matched with regards to age, race, gender and body weight) will receive a single 35 mg tablet of tasurgratinib in the morning with 150 mL of water following an overnight fast of at least 10 hours.
88949245|NCT04265274|Experimental|Disulfiram, vinorelbin, cisplatin, copper|Vinorelbine 25mg/m2 day 1 and 8, Cisplatin 75mg/m2 day 1, every 3 weeks, Disulifiram um 400mg daily and 2 mg of elementary Copper daily, continuously.
88949246|NCT04264260|Experimental|colchicine group|The participants will receive colchicine starting from 2 tablets after meal twice per day (total 2 mg). The dose will be adjusted ranging from total minimum 1.5 mg to maximum 3 mg per day based on the condition and tolerance of the participant. One cycle of treatment is defined as 4 days treatment and 3 days off. The participants will receive repeated cycles till the participants quit the trial.
89202509|NCT00791544|Experimental|Combination cohort 2|AVE1642 selected dose in combination with erlotinib
89537401|NCT02465021|Experimental|Snack bar 2|Dietary intervention: 200 Kcal, 15g fat, 12g carbohydrate, 5g fibre, 4g sugar, 8g protein
89537402|NCT02465021|Experimental|Snack bar 3|Dietary intervention: 210 Kcal, 16g fat, 12g carbohydrate, 2g fibre, 6g sugar, 6g protein
89537403|NCT02465021|Experimental|Control 1|Dietary intervention: Water (500 g)
88949247|NCT04255199|Experimental|Intervention|Primary care and urgent care clinicians randomized to the intervention arm will receive two to three visits with a standardized patient instructor who will physicians how to facilitate patient acceptance of a watchful waiting strategy with regard to spinal imaging in the context of acute low back pain.
89472892|NCT05734976|No Intervention|Arm type Methodological challenge in design|Electroacupuncture treatment, develops different groups study are three; electroacupuncture group or real treatment,1st control group or Participants in the sham group also received 24 sessions of acupuncture treatment; however, needling was performed 1 cm away from the real acupoints and 2nd control group or non-penetration needles. Access to medical records; to collect data and store it securely and anonymously.this group will receive treatment at 6 acupuncture points, but without penetration, without electroacupuncture, this is why it is called the control group. Use disposable needles too
89472893|NCT05243745|Experimental|Test Product|Participants will dose the toothbrush provided with a strip of dentifrice (a full brush head) on each brushing occasion. Test product is a combination toothpaste of 3% methyl vinyl ether/maleic anhydride co-polymer (PVM/MA) + 5% Potassium Nitrate (KNO3). Participants will brush their two selected 'test teeth' first, followed by the whole mouth for one timed minute, twice daily (morning and evening); Participants will be permitted to rinse with water post-brushing.
89472894|NCT05243745|Active Comparator|Comparator 1|Participants will dose the toothbrush provided with a strip of dentifrice (a full brush head) on each brushing occasion. Comparator 1 toothpaste is containing 3% PVM/MA. Participants will brush their two selected 'test teeth' first, followed by the whole mouth for one timed minute, twice daily (morning and evening); participants will be permitted to rinse with water post-brushing.
89472895|NCT05243745|Active Comparator|Comparator 2|Participants will dose the toothbrush provided with a strip of dentifrice (a full brush head) on each brushing occasion. Comparator 2 toothpaste is containing 5% KNO3. Participants will brush their two selected 'test teeth' first, followed by the whole mouth for one timed minute, twice daily (morning and evening); participants will be permitted to rinse with water post-brushing.
88949248|NCT04255199|Placebo Comparator|Control|Primary care and urgent care clinicians randomized to the control arm will receive a single visit with a standardized patient who simulates a visit with patient with acute low back pain but will deliver no instruction on patient communication or other content.
89472896|NCT05243745|Other|Negative Control|Participants will dose the toothbrush provided with a strip of dentifrice (a full brush head) on each brushing occasion. Negative control is regular fluoride toothpaste. Participants will brush their two selected 'test teeth' first, followed by the whole mouth for one timed minute, twice daily (morning and evening); participants will be permitted to rinse with water post-brushing.
89472897|NCT04500717|Active Comparator|Almonertinib 110mg PO once daily|Almonertinib 110mg PO once daily.
89472898|NCT04500717|Experimental|Almonertinib plus carboplatin and pemetrexed|Almonertinib 110mg PO once daily in combination with pemetrexed (500 mg/m2) plus carboplatin (AUC=5) on Day 1 of 21day cycles (every 3 weeks) for 4-6 cycles, followed by Almonertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.
89472899|NCT01680458||fluconazole|Infant Subjects who are treated with fluconazole
88949249|NCT04254094||Early onset dementias (EOD)|Prospective multicenter cohort of EOD patients with a three-year follow-up in tertiary Reference Memory centers
88949250|NCT04225806|Experimental|Investigational|Subjects will be treated with the investigational device and followed per protocol.
88949251|NCT04218708|Active Comparator|counseling + nicotine replacement therapies NRT|A research assistant (RA) trained in motivational interviewing and qualitative methods will support the PI to deliver counseling sessions and conduct interviews. Briefly, during each visit, with help of the RA, participants will provide exhaled CO and saliva cotinine test, and complete surveys in REDCAP using a tablet, allowing programmed logic checks and skip patterns to minimize burden. The RA will also deliver brief motivational counseling tailored to the participant's readiness to quit and arm in the study (NRT). Participants will also receive their NRT to last them to the following visit based on their baseline smoking.
89202510|NCT00753350|Experimental|1|Sensate™ anti-Obesity device
88949252|NCT04218708|Active Comparator|Counseling + Standardized Research E-cigarettes (SREC)|Participants in the SREC arm to practice using the SREC and give them instructions to return with their SREC and used refill tanks on every visit. A research assistant (RA) trained in motivational interviewing and qualitative methods will support the PI to deliver counseling sessions and conduct interviews. Briefly, during each visit, with help of the RA, participants will provide exhaled CO and saliva cotinine test, and complete surveys in REDCAP using a tablet, allowing programmed logic checks and skip patterns to minimize burden. The RA will also deliver brief motivational counseling tailored to the participant's readiness to quit and arm in the study (SREC). Participants will also receive their SREC to last them to the following visit based on their baseline smoking.
88949253|NCT04189588|Active Comparator|Cohort A|Cetirizine HCl 10 mg/mL: a single 1 mL injection.
88949254|NCT04189588|Active Comparator|Cohort B|Diphenhydramine 50 mg/mL: a single 1 mL injection.
88949255|NCT04176419|Experimental|Treatment Group|"Perioperative intervention (preoperative acetaminophen, gabapentin, and celecoxib and intraoperative ketamine and lidocaine).~The Investigational Drug Service will mix and prepare the study medications necessary for each participant. An Investigational Drug Service staff member will deliver the oral medications to the nursing team in the preoperative holding unit and the IV medications to the anesthesia team in the OR unit."
89019524|NCT00311597|Experimental|Single fractionated radiation adjusted for tumor size|Single fractionated radiation adjusted for volume of tumor tissue encompassed by desired isodose line
89019525|NCT00311675|Experimental|1|
89202511|NCT00753428||Baseline evaluation|Prior to the implementation of the pilot project of giving routine HAART as a method of PMTCT, a minimum of 387 households with children under the age of two will be sampled within each community, for a total of 1,548 households for the first round.
89206199|NCT00523978|Experimental|Experimental|Experimental subjects received cryoablation intended to isolate the pulmonary veins and ablate arrhythmia foci. If necessary, experimental subjects were allowed a previously failed Study Atrial Fibrillation Drug (AF Drug).
89472900|NCT03348189||Observational|Healthy males and females
89472901|NCT03348111|Experimental|Air-polishing device|Air polishing of the implant surface and/or elimination of the intrapocket biofilm using the air abrasion device Air-Flow Master Piezon®
89472902|NCT03136718||First-time hearing aid users|Individuals using hearing aids for the first-time (or if previous users, have not having worn hearing aids for more than 3 years) will have access to the mobile-enabled RLOs (mRLOs) intervention, which will be given to the participants shortly after their hearing aid is fitted.
89472903|NCT03346317|Experimental|dried biological amnion graft|patients, who are with IUA, treated by uterine application of disposable balloon uterine stent + amnion membrane following hysteroscopic adhesiolysis.
89472904|NCT03346317|Experimental|estrogen|patients, who are with IUA, treated by uterine application of disposable balloon uterine stent+ hormones (estradiol valerate tablets+dydrogesterone Tablets) following hysteroscopic adhesiolysis.
89472905|NCT04885790||Bronchiectasis|Children with bronchiectasis
89472906|NCT02517333|Other|Proof-of-principle (PoP)|"Proof-of-principle phase of the study. All participants undergo the exercise intervention as part of the feasibility.~Screen within Year 9 Class~Targeted recruitment for those scoring in bottom 5th percentile~Invite students to take part in 6-week intervention~Enroll students participating~Pre-intervention assessment~Start 6-week Epic Club gym intervention (1-2 times weekly for 45-60 mins) consisting of 30 min cardiovascular exercise and 25-30 min strength/resistance and weight training~Post-intervention assessment~Exit to longer-term sport/physical activity"
89472907|NCT01550432|Experimental|High-Dose Glutathione|2,260 mg/day
89472908|NCT01550432|Experimental|Low-Dose Glutathione|1,130 mg/day
89472909|NCT01550432|Experimental|High-Dose N-Acetylcysteine|1,200 mg/day
89472910|NCT01550432|Experimental|Low-Dose N-Acetylcysteine|600 mg/day
89472911|NCT01550432|Placebo Comparator|Placebo|Volume of liquid placebo product comparable to glutathione and 1 or 2 placebo pills/day.
89472912|NCT04502277|Experimental|Flucanazole|The Objective of This Study Was an Open-label, Randomized, 2-way Crossover to Compare the Single-dose Relative Bioavailability of Flucanazole 40mgm/ml 35 ml Suspension and to measure AUC at 0, 1 , 4 , 8, 12, 16 , 20 and 24 hours Under Fed Condition
89472913|NCT04502277|Active Comparator|Diflucan|The Objective of This Study Was an Open-label, Randomized, 2-way Crossover to Compare the Single-dose Relative Bioavailability of Diflucan 40mgm/ml 35 ml Suspension and to measure AUC at 0, 1 , 4 , 8, 12, 16 , 20 and 24 hours Under Fed Condition
89472914|NCT05732090|Experimental|Control group (A)|control group will received therapeutic exercise program with pulmonary training by incentive mechanical respiratory training spirometer (3 sessions/week/two months).
89472915|NCT05732090|Experimental|study Group (B)|study group will received the same intervention in control group in addition to diaphragmatic myofascial release (3 sessions/week/two months).
89472916|NCT03347019|Experimental|accelerated rehabilitation after surgery|patients were included progressive rehabilitation programme first week after arthroscopic bankart repair consisting of passive shoulder range of motion exercises, scapular retraction exercises. The exercise programme progressed from active range of motion exercises to resistive and plyometric shoulder exercises. Patients were followed for six months.
89472917|NCT03347019|Experimental|delayed rehabilitation after surgery|Patients were not allowed to start passive shoulder exercises first three weeks after surgery. Patients were included progressive rehabilitation programme third week after arthroscopic bankart repair consisting of passive shoulder range of motion exercises, scapular retraction exercises. The exercise programme progressed from active range of motion exercises to resistive and plyometric shoulder exercises. Patients were followed for six months.
89472918|NCT05730608|Other|Primary breast cancer|"Patients diagnosed with new breast cancer determined to have high risk disease by a multidisciplinary team."
89472919|NCT05730608|Other|Recurrent breast cancer|Patients with suspected or proven locoregional recurrent breast cancer.
89472920|NCT02517255|Experimental|Cardiac Magnetic Resonance Imaging|Cardiac MRI will be performed within 7 days of rescue percutaneous coronary intervention (PCI) and after 3 and 6 months.
89472921|NCT02574026|Experimental|Psychomotor tasks|20 healthy subjects and 10 tetraplegic patients will participate to acquisition of MEG, EEG, MRI data during a motor tasks
89472922|NCT02517489|Experimental|Hydrocortisone|Patients in the treatment group will receive intra-venous hydrocortisone (in addition to the standard treatment of severe Community-Acquired Pneumonia (CAP)
89472923|NCT02517489|Placebo Comparator|Placebo|Patients of the control group will receive an intravenous placebo by intravenous route (in addition to the standard treatment of severe Community-Acquired Pneumonia (CAP)
89472924|NCT04882748|Active Comparator|Control|In the control arm, patients were laid down on the robot platform. Physiotherapists identified the trigger points and the robot was connected, providing the expected noise and vibration, but the air pressure was not applied. Thermotherapy and rehabilitation exercises were provided, as is the standard treatment for NSLBP at the Rehabilitation Service.
89472925|NCT04882748|Experimental|Robot massage|In the robot arm, a physiotherapist with more than 15 years of experience identified the trigger points in the patient, programmed the robot, and applied robot-controlled air pressure massage for 10 minutes. The ADAMO robot applies an air current to the trigger points on the back of the patient, guided by cameras and computer programs (https://adamorobot.com/). Thermotherapy and rehabilitation exercises were also applied.
89472926|NCT05719766|No Intervention|Routine follow-up group|
89472927|NCT05719766|Experimental|IBD Disease Management Research Group|
89472928|NCT03351543|Experimental|Exposed group|these volunteers receive microbial inoculate
89472929|NCT03351543|No Intervention|control|these volunteers do not receive microbial inoculate
89472930|NCT04850144|Experimental|Tiotropium Easyhaler Product variant D|
89472931|NCT04850144|Experimental|Tiotropium Easyhaler Product variant E|
89472932|NCT04850144|Experimental|Tiotropium Easyhaler Product variant F|
89472933|NCT04850144|Experimental|Tiotropium Easyhaler Product variant G|
89472934|NCT04850144|Experimental|Tiotropium Easyhaler Product variant H|
89472935|NCT04850144|Active Comparator|Spiriva HandiHaler|
89472936|NCT04850144|Experimental|Tiotropium Easyhaler Product variant F administered with oral activated charcoal|
89472937|NCT02517411|Experimental|Experimental group|COPD patients with stable disease will be recruited and they will receive physiotherapy added to standard care.
89472938|NCT02517411|Other|Control group|COPD patients with stable disease will be recruited and they will receive standard care.
89472939|NCT04543136|Active Comparator|Intermittent catheter; SpeediCath® Standard male|Participants underwent two catheterizations with standard of care intermittent catheter: The first was performed by a trained nurse, the second by the participant later the same day.
89472940|NCT04543136|Experimental|New intermittent catheter Variant 1 for males|Participants underwent two catheterizations with the new intermittent catheter Variant 1 for males: The first was performed by a trained nurse, the second by the participant later the same day.
89472941|NCT04543136|Experimental|New intermittent catheter Variant 2 for males|Participants underwent two catheterizations with the new intermittent catheter Variant 2 for males: The first was performed by a trained nurse, the second by the participant later the same day.
89472942|NCT05585073||qualified of D2 Lymph node dissection group|
89472943|NCT05585073||not-qualified D2 Lymph node dissection group|
89472944|NCT04796870|Experimental|Experimental: Online Brain and Balance Training|Individuals that meet the inclusion/exclusion criteria and enrolled in the study will participate in a 8-week virtual balance and cognitive training intervention performed three times a week.
89472945|NCT02517177|Other|Cardiovascular parameters measurements|
89472946|NCT04746404||Control group|Control group : Major borderline patients followed up at the Health Unit of the Villeneuve-lès-Maguelone Remand Prison
89472947|NCT04746404||Test group|Test group : Major borderline patients followed up at the Health Unit of the Villeneuve-lès-Maguelone Remand Prison
89019526|NCT00311753|Experimental|1|Certoparin
89472948|NCT04590794||covid 19|Patients admitted with covid 19
89472949|NCT00709761|Experimental|Single Arm|Single arm combination therapy of Lap and NabPaclitaxel combination
89472950|NCT01792310|Experimental|Dose Cohort 1|Intervention: LAM561. 7 dose cohorts of up to 6 patients have been performed in the dose escalation phase. The starting dose cohort received 250 mg twice daily.
89472951|NCT01792310|Experimental|Dose Cohort 2|Intervention: LAM561. 500 mg twice daily
89472952|NCT01792310|Experimental|Dose Cohort 3|"Intervention: LAM561.~1g twice daily"
89472953|NCT01792310|Experimental|LAM561 Dose Cohort 4|Intervention: LAM561. 2g twice daily
89472954|NCT01792310|Experimental|LAM561 Dose Cohort 5|Intervention: LAM561. 4g twice daily
89472955|NCT01792310|Experimental|LAM561Dose Cohort 6|Intervention: LAM561. 4g three times daily
89472956|NCT01792310|Experimental|LAM561 Dose Cohort 7|Intervention: LAM561. 8g twice daily
89472957|NCT01792310|Experimental|LAM561 Dose Expansion cohort. Glioma|Intervention: LAM561 at the MTD: 4g three times daily. Up to 10 patients with malignant glioma.
89472958|NCT01792310|Experimental|LAM561 Dose Expansion cohort. Non-glioma|Intervention: LAM561 at the MTD: 4g three times daily. Up to 10 patients with other advanced solid tumours that are suitable for biopsy.
89472959|NCT01789346|Other|532nm KTP|Cutera ExcelV 532nm potassium titanyl phosphate (KTP) laser
89472960|NCT01789346|Active Comparator|595nm PDL|Cynosure Cynergy 595nm pulsed-dye (PDL) laser
89472961|NCT05584839||carpal tunnel syndrome|"Admitted to outpatient clinics with symptoms of CTS~Findings of CTS in physical examination~CTS diagnosis was confirmed by nerve conduction study~KTS grade mild or moderate~He has not received physical therapy for this reason in the previous 1 year~No steroid injection and no treatment for neuropathic pain (pregabalin, gabapentin, etc.)"
89472962|NCT02516943|Active Comparator|Control|The patient were retrospectively included according to the last digit of their admission number (odd number). The had arterial blood gas analysis every 4 hour during the ICU stay.
89472963|NCT02516943|Active Comparator|Guideline|The patient were prospectively included and they had arterial blood gas analysis following the pathological- based guidelines for arterial blood gas analysis in patients aftercardiac surgery
89472964|NCT05377892|Experimental|Intervention|Subjects receiving high protein followed by reduced protein diet
89472965|NCT02516865|Experimental|Group 1|
89472966|NCT02516865|Experimental|Group 2|
89472967|NCT02516865|No Intervention|Group 3|
89472968|NCT04208906|Experimental|Children with congenital cardiac disease|Pediatric patients aged < 7 years undergoing cardiac surgery
89472969|NCT03348033|Experimental|Chronic Myeloid Leukemia + NK cell|"Starting on Day -7, G-CSF daily by vein until post nadir of absolute neutrophil counts (ANC) are equal or over 1000. Day -6 to Day -2 Fludarabine administrated by vein at 30 mg/m^2. Four hours later Cytarabine administrated by vein at 2 g/m^2. Natural killer (NK) cell infusion Days 0 to 14 for 6 doses total.~NK Cell infusion on Days 0 to 14 for 6 doses total."
89472970|NCT03347955|Experimental|Neural implantation group|Human embryonic dopamine neurons were implanted into brains of half the randomized participants (n = 20). Participants were evaluated at baseline, 4, 8, and 12 months after surgery.
88949256|NCT04176419|Placebo Comparator|Control Group|"Perioperative placebo~Placebo oral drugs will be encapsulated versions provided by the Investigational Drug Service and will appear identical to the interventional oral drugs. Placebo IV infusions will be prepared by Investigational Drug Service as per institutional guidelines and will appear identical to the interventional IV drugs."
88949257|NCT04163172|Active Comparator|Elbow hemiarthroplasty|The Latitude anatomical hemiarthroplasty (WRIGHT -Memphis, Tennessee) for distal humeral fractures.
88949258|NCT04163172|Active Comparator|Open reduction and internal fixation|Double plating (Synthes - Switzerland and West Chester, Pennsylvania, United States) for distal humeral fractures.
88949259|NCT04162210|Experimental|Participants receiving Belantamab mafodotin|Participants will receive belantamab mafodotin single agent dose on Day 1 of Q3W
88949260|NCT04162210|Active Comparator|Participants receiving pom/dex|Participants will receive pomalidomide daily on Days 1 to 21 of each 28-day cycle, with dexamethasone once weekly on Days 1, 8, 15 and 22.
88949261|NCT04157101|Experimental|Health Coaching|The 12-session remote health coaching intervention assists Veterans in developing and maintaining health behaviors that meet their life goals. Veterans begin by discussing their symptoms, the impact of their symptoms, and their beliefs about Pain-CMI. Next, the Veteran identifies discrepancies between where they are and where they want to be for 5 lifestyle factors. The first half of treatment focuses on providing education about the 5 lifestyle factors. Veterans are introduced to behavior change/health coaching principles. The major focus is on behavior change and development of long-term healthy habits. During the last session, Veterans develop a long-term plan to maintain behavioral changes after the 12-week program and identify the skills that they can utilize moving forward.
88949262|NCT04157101|Placebo Comparator|Supportive Psychotherapy|"Our control will be supportive psychotherapy which will focus on discussing weekly stressors in a supportive, non-directive way. Session content is patient-driven, and sessions focus on emphasizing the patients' strengths, following patients' emotional affect, and building a therapeutic alliance. Participants will be asked to generate the topic they would like to discuss for the session and will complete a worksheet between sessions noting emotional events throughout their week (A time when I felt stressed was . ) in order to help identify experiences for discussion in session. The control consists of 12 weekly sessions delivered via telephone or video and will be delivered by bachelor's, or master's level providers."
88949263|NCT04154488|Experimental|Mavorixafor|"Part 1: Adult participants and adolescent participants who weigh more than 50 kilograms (kg) will receive mavorixafor 400 milligrams (mg) (4 capsules of 100 mg each), orally once on Day 1. Adolescents weighing less than or equal to 50 kg will receive mavorixafor 200 mg (2 capsules of 100 mg each), orally once on Day 1.~Part 2: Eligible participants from Part 1 will receive once daily dosing of mavorixafor for 6 months."
88949264|NCT04149171|Experimental|conventional treatment|red blood cells (RBC), Tranexamic acid (TXA) and Fibrinogen Concentrate (FC)
88949265|NCT04149171|Active Comparator|conventional treatment added to Crystalloids and TXA|administration of Crystalloids and TXA
88949266|NCT04147585|Experimental|Intervention Arm|Three cycles of a 5-day Intermittent Reduced Calorie Diet
88949267|NCT04147585|No Intervention|Control Arm|Regular Diet
88949268|NCT04144894|Other|Healthy Controls|
88949269|NCT04144894|Other|Vascular Surgery Subjects|
88949270|NCT04111822|Active Comparator|Conventional treatment of septic shock|Conventional treatment of septic shock according to current management guidelines
89472971|NCT03347955|Sham Comparator|Sham Surgery group|This group (n = 20) received sham surgery with a steel frame affixed to their heads and four burr holes drilled into their foreheads without crossing the blood/brain barrier. Participants were assessed at baseline, 4, 8, and 12 months after surgery.
89472972|NCT05584761|Experimental|experimental group|"unrelated umbilical cord blood stem cell microtransplantation combined with AZA/AZA+ based treatment.~A single unit of unrelated umbilical cord blood was reinfused within 24-72 hours after the end of AZA or chemotherapy, and the longest delay was 96 hours after the end of chemotherapy. The umbilical cord blood was matched at 0-3/10 locus.~Specific treatment options:~AZA monotherapy:~Azacitidine 75mg·m-2·d-1, d1-d7, subcutaneous injection;~VA :~Azacitidine 75mg·m-2·d-1, d1-d7, subcutaneous injection; Venetoclax (VEN) 100mg d1,200mg d2,400mg d3 to d14, orally.~VAH:~Azacitidine 75mg·m-2·d-1, d1-d7, subcutaneous injection; Venetoclax (VEN) 100mg d1, 200mg d2,400mg d3 to d14, orally. Homoharringtonine injection (HHT) 2-3mg d1 to d14 was intravenously injected. During the period, the medication time was adjusted according to the patient's blood condition and complications"
88949271|NCT04111822|Experimental|Current management plus ascorbic acyd,thiamine and vitamin C|"Conventional treatment of septic shock according to current management guidelines associated with:~i. Hydrocortisone 50 mg every 6 hours for 7 days or until discharge from the ICU with subsequent withdrawal in descending pattern for 3 days ii. Vitamin C (ascorbic acid) 1.5 gr diluted in 100 ml of 5% SG every 6 hours for 4 days (16 doses) iii. Thiamine 200 mg diluted in 100 ml of SG 5% or SF 0.9% every 12 hours for 4 days iv. Measurement of vitamin C levels prior to administration of the first dose of vitamin C"
88949272|NCT04086264|Experimental|Regimen A (Closed to Enrollment)|IMGN632, administered intravenously on Day 7 of a 28 day cycle at 0.015 mg/kg, 0.045 mg/kg, or 0.09 mg/kg, in combination with azacitidine, administered subcutaneously or intravenously daily at 75 mg/m2 on Days 1 to 7 of a 28 day cycle. Cycle 1 azacitidine dose in subsequent cohorts may be reduced.
89472973|NCT05584605|Experimental|aerobic treadmill training|Progressive graded, high-intensity aerobic treadmill training is delivered over 36 sessions at a frequency of 3x per week for 30-50 minutes of training per session over a period of 3 months. If possible, the training intensity is progressed from 40% to 80% of heart rate reserve, according to the supervising therapist.
89472974|NCT05584605|Active Comparator|stretching exercise|The control intervention includes stretching exercise therapy similarly heart rate controlled within limits up to 20% of heart rate reserve over 36 sessions at a frequency of 3x per week for 30 minutes.
89472975|NCT04137458|Experimental|Participants|The investigator will withdraw biological samples and a biological and DNA bank will also be realized
89472976|NCT03346785|Experimental|Food Photography|Participants will engage in food photography on their smart phones while eating
89472977|NCT03346785|Experimental|Non-Food Photography|Participants will engage in non-food photography on their smart phones while eating
89472978|NCT03346785|Experimental|No Phone Use|Participants will not use their smart phones while eating
89472979|NCT03605264||Slow Graft Function|Slow Graft function(SGF) is defined as a failure of serum creatinine to fall by 70% at postoperative day 7 after renal transplantation.
89472980|NCT03605264||Immediate Graft Function|Immediate graft function(IGF) is defined as a fall of serum creatinine of 70% at postoperative day 7 after renal transplantation.
89472981|NCT02516787|Other|EEG and NIRS measurements|
88949273|NCT04086264|Experimental|Regimen B (Closed to Enrollment)|IMGN632, administered intravenously on Day 7 of a 21 day cycle at 0.015 mg/kg, 0.045 mg/kg, or 0.09 mg/kg, in combination with venetoclax, administered orally daily at 100 mg on Day 1, 200mg on Day 2, and 400 mg on the day 3 up to Day 21 of a 21 day cycle. Alternate schedules with reduced venetoclax administration may be explored.
89019527|NCT00311753|Active Comparator|2|Heparin
89019528|NCT00339534||Cases|Cases were recruited at Korle Bu Teaching Hospital in Accra, Ghana, between 2008 and 2012.
89019529|NCT00339534||Controls|Controls were selected in a population-based component using a probability sample designed with the 2000 Ghana Population and Housing Census data between 2004 and 2006.
89019530|NCT00311792|Experimental|1|Simulator training
89202512|NCT00753428||Following implementation|Two years after full implementation of the pilot project of giving routine HAART for PMTCT across all sites, a minimum of 387 households with children under the age of two will be sampled within each community, for a total of 1,548 households. [Note: At time of implementation, we used the same sampling frame for each community. Because of the population increased observed in parts of Kafue, the final number of households significantly exceeded the minimum threshold.]
89202513|NCT00990028|Experimental|Rosuvastatin|20 mg oral during 10 days
89202514|NCT00990028|Placebo Comparator|Placebo|
89202515|NCT04052906|Experimental|Intervention Group|Planned Inhaler Medication Training
89202516|NCT04052906|No Intervention|Control Group|usual care
89472982|NCT02516631|Active Comparator|Oral (A)|One tablet of Angusta™ (25 µg) or 1/8 of a tablet of Cytotec® (25 µg).
89472983|NCT02516631|Active Comparator|Oral (B)|Two tablets of Angusta™ 25 µg or ¼ of a tablet of Cytotec®.
89472984|NCT02516631|Active Comparator|Sublingual (C)|Two tablets of Angusta™ (total dose of 50 µg) or ¼ of a tablet of Cytotec® (50 µg.
89472985|NCT02516475|Active Comparator|zinc sulfate|1 zinc sulfate capsule for 15 weeks
89472986|NCT02516475|Placebo Comparator|starch|1 corn starch capsule for 15 weeks
89472987|NCT05083286|Active Comparator|OLD (4 U per 0.1 mL)|The total BOTOX dose will be 20U divided into 5 injections. Each injection will receive a total of 0.5 mL.
89472988|NCT05083286|Active Comparator|COLD (4 U per 0.02 mL group)|The total BOTOX dose will be 20U divided into 5 injections. Each injection will receive a total of 0.1 mL.
89472989|NCT02516397|Experimental|Omnia group|After 2 weeks of run-in period, subjects take 2 Omnia pills per meal (3 meals a day) for 12 weeks.
89472990|NCT02516397|Placebo Comparator|Placebo group|After 2 weeks of run-in period, subjects take 2 Placebo pills per meal (3 meals a day) for 12 weeks.
89472991|NCT05026424|Placebo Comparator|Active Comparator: Oral Nutrition Supplement Control|The control study intervention is an oral drink that contain protein, carbohydrate and fat and are intended for use as supplemental nutrition.
89537404|NCT02465021|Experimental|Control 2|Dietary intervention: White bread (190 Kcal, 2g fat, 37g carbohydrate, 2g fibre, 3g sugar, 6g protein)
89472992|NCT05026424|Active Comparator|Active Comparator: Oral Nutrition Supplement Test|The test study intervention is an oral drink that contain protein, carbohydrate and fat and are intended for use as supplemental nutrition for people living with diabetes.
89472993|NCT03121911|Experimental|Group 1 - Interval Training (IT)|"All participants will be submitted to several exams of cardiac and pulmonary functions. Then, group 1 (IT) will participate in a physical training program for 12 weeks and will be re-evaluated after this period. After discharge, they will be monitored for an aditional period of 6 months, with returns every two months to measure the energy expenditure (accelerometer). At the end of this period all the tests will be repeated.~Each exercise session will last for 60 minutes and will be divided into three parts as follows: warm up (10 minutes); interval training (IT) - 30 minutes of IT performed in a cycle ergometer, divided into 6 levels of intensity based on the ventilatory anaerobic threshold found in CPET (70%, 80%, 100% and 110%); cooling down (10 minutes)."
89472994|NCT03121911|Experimental|Group 2 - IT + IMT|"All participants will be submitted to the same evaluations before and after training, and 6 months after discharge. Group 2 (IT + inspiratory muscle training (IMT)) will participate in a 12 week physical training program. After discharge, they will be monitored for an aditional period of 6 months, with returns every two months to measure the energy expenditure.~The group 2 will perform the IMT session at the end of the warm-up exercises, prior to the beginning of the IT on a cycloergometer. IMT session consists of 2 series of 12 inspirations with a 60% of MIP. Participant will be asked to inhale quickly and deeply, as quickly as possible, with a 2 minutes interval between series. All the others exercises will be identical between group 1 and 2."
89472995|NCT03121911|No Intervention|Group 3 - Absence of rehabilitation|Group 3 (absence of rehabilitation) will be made up of those patients who for any reason do not agree to participate in the rehabilitation program, such as those who do not live in the city, and will remain without intervention. All participants in this group will perform all the evaluations procedures, comprised of: heart rate variability, hematological and biochemical profile, erythrocytes membrane deformability and stability, inflammatory markers, respiratory pressures, plethysmography, spirometry, carbon monoxide diffusion capacity, ankle brachial index, electrical bioimpedance, echocardiogram, quality of life questionnaires (SF-36 and MacNew QLMI), cardiopulmonary exercise testing and constant load tests.
88949274|NCT04086264|Experimental|Regimen C - Frontline (Enrolling) & Relapsed / Refractory (Closed to Enrollment)|IMGN632, administered intravenously on Day 7 of a 28 day cycle at 0.015 mg/kg or 0.045 mg/kg, in combination with azacitidine, administered subcutaneously or intravenously daily at 35-75 mg/m2 given for Days 1 to 7 of a 28 day cycle and venetoclax, administered orally daily at 100 mg on Day 1, 200mg on Day 2, and 400 mg on Day 3 up to Day 28 of a 28 day cycle. Alternate schedules with reduced venetoclax administration or reduced azacitidine dose or administration may be explored.
88949275|NCT04086264|Experimental|Regimen D (Closed to Enrollment)|IMGN632, administered intravenously on Day 1 of a 21 day cycle at 0.045 mg/kg, as a monotherapy for Fit and Unfit MRD+ patients.
89472996|NCT02239315|Experimental|Tumor RNA Disruption Assay™ (RDA)|Tumor RNA Disruption Assay™ (RDA) to generate RDA score from fine needle aspiration biopsy samples of breast cancer obtained 7-14 days after the first, second and third cycles of neoadjuvant chemotherapy; and, if there is a change of chemotherapy regimen, after the first cycle of the new chemotherapy.
89472997|NCT03423680|Experimental|Abilify (Tablet)|
89472998|NCT03423680|Placebo Comparator|Placebo of Abilify (Tablet)|
89472999|NCT02239393|Experimental|Autologous Mesenchymal Stem Cells|At week 0 a single infusion of either ex-vivo expanded autologous MSC or suspension media will be administered intravenously at a dose of 1 to 2 x 1000000 MSC/Kg body weight. At week 24, another infusion will be performed for cross-over re-treatment: at week 24 treatments will be reversed compared to week 0.
89473000|NCT02239393|Experimental|Suspension media|At week 0 a single infusion of either ex-vivo expanded autologous MSC or suspension media will be administered intravenously at a dose of 1 to 2 x 1000000 MSC/Kg body weight. At week 24, another infusion will be performed for cross-over re-treatment: at week 24 treatments will be reversed compared to week 0.
89473001|NCT05584371|Experimental|Exogenous ketosis|Intake of 10 grams of beta-hydroxybutyrate free of alcohol and salt.
89473002|NCT05094830|Experimental|Stomach Intestinal Pylorus Sparing (SIPS)|Patients undergoing SIPS procedure as their bariatric surgery of choice.
89473003|NCT02516319|Active Comparator|Serial Blood Draws|Cohorts 3 and 4 - weight based doses of ICG dye followed by serial blood draws at 5, 10, 15 and 20 minutes post ICG injection.
89473004|NCT02516319|Experimental|Liver Funtion Test Dye Detection Monitor|All cohorts receive continuous LFT monitoring post ICG injection.
89473005|NCT04443543|Experimental|Arm 1|"Arm 1 includes patients with MSS/pMMR. In this arm, patients receive consolidation chemotherapy after neoadjuvant chemoradiation (nCRT). The chemotherapy regimens either XELIRI or FOLFIRINOX, and the cycles of chemotherapy depend on patient tumor responses. For patients who reach cCR will enter the W&W cohort and omit radical surgery, while those without cCR will receive radical surgery."
89537405|NCT02465021|Experimental|Control 3|Dietary intervention: Soft baked pretzel (190 Kcal, 2g fat, 38g carbohydrate, 2g fibre, 6g sugar, 4g protein)
89537406|NCT03068637|Experimental|Care planning platform usage|This intervention will focus on the use of the Carevive care planning software for multiple myeloma patients age 65 and older who are at a treatment decision-making timepoint.
89537407|NCT02464241||normal control|normal control
89537408|NCT02464241||patients|patients with optic or macular pathology or amblyopia
88949277|NCT04079465|Active Comparator|O2matic|Usual care plus O2matic controlled oxygen therapy for a maximum of 24 hours or until weaning from oxygen supplementation
88949278|NCT04079465|No Intervention|Manual|Usual care plus manual controlled oxygen therapy by nursing staff. O2matic is used in monitoring mode to measure SpO2 continuously.
88949279|NCT04066114|Experimental|lulizumab pegol + novel ISR|lulizumab pegol + novel ISR: lulizumab pegol plus immunosuppressive regimen (anti-thymocyte globulin (rabbit), steroids,) belatacept, tocilizumab, and everolimus)
89473006|NCT04443543|Experimental|Arm 2|"Arm 2 includes patients with MSI-H/dMMR status. In this arm, patients receive consolidation immunotherapy of 3 cycles of tislelizumab after nCRT. For patients who reach cCR will enter the W&W cohort and omit radical surgery, while those without cCR will receive radical surgery."
89473007|NCT04874948|Experimental|Single oral administration of 500 mg BTZ-043 containing 3.7 MBq of [14C]BTZ-043|4 subjects to receive a single oral administration of 14C-labeled radioactive 500mg BTZ-043
89473008|NCT02516085|Experimental|L-arginine and metformin|7.5 g L-arginine p.o. and 500 mg metformin p.o. per day (3x 2.5 g, respectively 3x 250 mg) for 16 weeks
89473009|NCT03298256||Lenke type 1 AIS|Patients will be given a new prescription for a custom made Boston type thoracic-lumbo- sacral-orthosis (TLSO) braces. All patients will undergo low dose biplanar X-rays using the EOS ® machine system.
89473010|NCT05069493||Tension-free|Hiatal hernia repair by tension-free mesh closure
89473011|NCT05069493||Suturing|Hiatal hernia repair by simple suturing of the diaphragmatic
89473012|NCT02515929|Experimental|Oligomeric Proanthocyanidins|90 mg exocian cran 408 plus 120mg Vitamin C, 1 tablet by mouth, every 24 hours for 21 days
89473013|NCT02515929|Placebo Comparator|Placebo|Similar organoleptic experimental arm,1 tablet by mouth, every 24 hours for 21 days
89473014|NCT03347721|Active Comparator|Lidocaine gel|
88949280|NCT04060862|Experimental|Phase 1b and Phase 3: Ipatasertib + Palbociclib +Fulvestrant|
88949281|NCT04060862|Placebo Comparator|Phase 3: Placebo + Palbociclib + Fulvestrant|
88949282|NCT04040881|Experimental|Remote monitoring using Smartphone|Patients will be provided with a Global System for Mobile communications (GSM) accelerometer-equipped Android smartphone (specific model to be decided) with an installed open source, freely available pedometer application (Google Fit, Google, CA, United States) which will record their daily steps. Patients will receive daily calls from a research assistant to document the presence of clinically significant chemotherapy-related toxicity.
88949283|NCT04040569|Experimental|Single-fraction stereotactic partial breast radiotherapy|The primary objective is to escalate the dose of 1 fraction stereotactic partial breast radiotherapy utilizing the MR Linac,Gammapod or Cyberknife system to an ablative dose in the pre-operative setting to the primary tumor without exceeding the maximum tolerated dose in patients with early stage breast cancer.
88949284|NCT04010461|Experimental|TMS to dlPFC, without a concurrent task|TMS (intermittent theta burst stimulation) will be applied to the dlPFC, when subjects are in a resting state
88949285|NCT04010461|Experimental|TMS to vertex, without concurrent task|TMS (intermittent theta burst stimulation) will be applied to the cerebral vertex, when subjects are in a resting state
88949286|NCT04010461|Experimental|TMS to dlPFC, during task|TMS (intermittent theta burst stimulation) will be applied to the dlPFC, when subjects are engaged in the n-back working memory task
88949287|NCT03995108|Experimental|Mavorixafor|Participants (adults and adolescents [12 to 17 years of age weighing >50 kilograms [kg]) will receive mavorixafor 400 milligrams (mg) once daily (QD) orally for 52 weeks in the Randomized Placebo-Controlled Period. Adolescents weighing ≤50 kg will receive mavorixafor 200 mg QD. Participants who complete the Randomized Placebo-Controlled Period or are granted Early Release due to recurrent or significant infections, as adjudicated by a blinded, independent adjudication committee (AC), will be offered the opportunity to enroll in the Open-Label Period and receive treatment with mavorixafor 400 mg once daily orally until commercial availability or study termination by the Sponsor.
88949288|NCT03995108|Placebo Comparator|Placebo|Participants will receive placebo matching to mavorixafor QD orally for 52 weeks in the Randomized Placebo-Controlled Period. Participants who complete the Randomized Placebo-Controlled Period or are granted Early Release due to recurrent or significant infections, as adjudicated by a blinded, independent AC, will be offered the opportunity to enroll in the Open-Label Period and receive treatment with mavorixafor 400 mg once daily orally until commercial availability or study termination by the Sponsor.
88949289|NCT03985423|Experimental|Emapalumab|Patients were administered Emapalumab-Lzsg by intravenous (i.v.) infusion over a period of 1 to 2 hours, at an initial dose of 6 mg/kg and continued at 3 mg/kg, every 3 days for the first 2 weeks (Study Day [SD] 15), and then twice-a-week. If the treating physician deemed appropriate, the dose of emapalumab could be increased (up to 10 mg/kg), guided by clinical and laboratory response.
89473015|NCT03347721|Placebo Comparator|Lubricant Gel|
89473016|NCT03347643|Active Comparator|tDCS with real stimulation|A total of 25 patients will be allocated into active comparator with real stimulation with tDCS.
89473017|NCT03347643|Sham Comparator|tDCS with sham stimulation|A total of 25 patients will be allocated into sham comparator with sham stimulation with tDCS.
89473018|NCT03346005|Experimental|Adult patients with positive FIT test|Adult patients with a positive FIT-test will breath into an e-nose device for 5 minutes.
89473019|NCT02848651|Experimental|Atezolizumab|Participants received 1200 milligrams (mg) of atezolizumab administered by intravenous infusion every 21 days until disease progression, loss of clinical benefit, or unacceptable toxicity (up to a total of 2 years of atezolizumab treatment).
89473020|NCT00709059||PegIntron Plus Rebetol|Previously untreated patients infected with HCV genotype 1, 4, 5, or 6.
89473021|NCT03345927||high cardiovascular risk group|no intervention
89019531|NCT00311792|Active Comparator|2|Traditional Clinical education at operating room
89019532|NCT00311831|Active Comparator|1|
89019533|NCT00311831|Experimental|2|
89019534|NCT00342771||NCI Maryland pop-based controls|population-based controls
89473022|NCT04500561|Experimental|YY-20394|YY-20394 tablets will be given daily for 21 days in 21-day cycles until there appears evidence of progressive disease, intolerable toxicity, or the subject discontinues from the study treatment for other reasons
89473023|NCT05094752|Experimental|Intervention group|Vibration treatment will last eight weeks for each patient, with 4 sessions per week, 30 minutes per session. Subjects of the intervention group will receive proprioceptive stimulations set to create illusions of movement.
89473024|NCT05094752|Sham Comparator|Control group|Vibration treatment will last eight weeks for each patient, with 4 sessions per week, 30 minutes per session. Subjects of the control group will receive sham stimulations.
89473025|NCT04507256|Experimental|AZD7442|Participants will receive AZD7442 doses across five fixed-dose cohorts via intravenous (IV) infusions (three cohorts will be administered sequentially, and one cohort will receive co-administration of AZD8895 + AZD1061, mixed into a single infusion) and direct gluteal intramuscular (IM) injections (administered sequentially).
89473026|NCT04507256|Placebo Comparator|Placebo|Placebo will be administered to participants across five fixed-dose cohorts similar to the active treatment.
89473027|NCT05094674|Other|Participants who require a diagnostic or screening COVID-19 RT-PCR test|Participants who require a diagnostic or screening COVID-19 RT-PCR test, presenting at Tameside and Glossop Integrated Care NHS Foundation Trust aged 18 years or over
89473028|NCT04468490||GROUP A: Patients adherent to BTcP European Guidelines|
89473029|NCT04468490||GROUP B: Patients non Adherent to BTcP European Guidelines|
89473030|NCT05094596|Experimental|Standart treatment group|Standard treatment in accordance with our national COVID-19 diagnosis and treatment guide
89473031|NCT05094596|Experimental|Montelukast sodium 10 mg treatment|Received 10 mg/day oral montelukast in addition to standard treatment
89473032|NCT05094596|Experimental|Montelukast sodium 20 mg treatment|Received 10 mg/day oral montelukast in addition to standard treatment
89473033|NCT04500249|Experimental|CPB|cervical plexus block was performed with 0,5% bupivacaine using Moore's technique
89473034|NCT04500249|Experimental|CPB with SPI guided analgesia|cervical plexus block was performed with 0,5% bupivacaine using Moore's technique alongside with SPI-guided rescue analgesia using 1% lidokaine and intravenous fentanyl
89473035|NCT04500249|Experimental|CPB plus SPI guided analgesia plus carotid artery block|cervical plexus block was performed with 0,5% bupivacaine using Moore's technique combined ith US-guided carotid artery block alongside with SPI-guided rescue analgesia using 1% lidokaine and intravenous fentanyl
89473036|NCT04921293|Active Comparator|Standard Diet|Standard diet incorporating current recommendations for heart failure (low sodium and liquids) and supplementation with bitter taste placebo.
89473037|NCT04921293|Experimental|Endogenous Ketosis|Ketogenic diet incorporating current recommendations for heart failure (<50gr of carbohydrates, low sodium, and liquids) for 10 days.
89019535|NCT00342771||NCI-Maryland Prostate Cancer Cases|prostate cancer cases
89019536|NCT00339573||National Housing Stock|The target population of this study was the national housing stock (1998-1999) ofapproximately 95 million housing units.
89019537|NCT00311948|Active Comparator|Telephone counseling + interactive website|Teen has access to interactive website and receives tailored telephone counseling
89019538|NCT00311948|Other|Control with interactive website|Teen only has access to interactive website.
89019539|NCT00339612||HIV-infected children who acquired HIV infection through mothe|HIV-infected children in who acquired HIV infection through mother-to-child transmission (MTCT).
89019540|NCT00342849|Experimental|1|Scuccimer Treatment Group
89473038|NCT04921293|Experimental|Exogenous ketosis|Standard incorporating current recommendations for heart failure (low sodium and liquids) and supplementation with exogenous ketones (ketone monoester) for 10 days.
89019541|NCT00342849|Placebo Comparator|2|In order to provide placebo with an odor comparable to that of succimer, the Drug Distribution Center will place a small canister containing 200 mg of active drug into each bottle of placebo drug. A canister containing 200 mg of placebo will be placed inside each bottle of succimer so that all bottles will appear the same.
89206200|NCT00523978|Active Comparator|Control|Control Subjects were treated with an AF Drug (flecainide, propafenone, or sotalol) that they had not previously failed.
89473039|NCT05094518|Experimental|Reminder|Participants will fill the sociodemographic and health history form. Participants will receive reminders in the form of push notifications for prenatal checkup dates automatically generated according to their pregnancy start data or initial check-up appointment for 6 months. Reminders will be sent at the following intervals: 1) 2 weeks before the appointment, 2) 1 day before the appointment, and 3) on the day of appointment. After this date, participants will receive push notifications asking whether they went to the appointment or not weekly for 1 month. This reminder algorithm will be used for each prenatal checkup for a total of four appointments: once in first trimester, once in second trimester and two in third trimester, using the World Health Organization and Turkish Ministry of Health prenatal checkup calendar. At the end of 6 months of follow up period, participants will be contacted via phone call to ask for any remaining appointments or unanswered notifications.
89473040|NCT05094518|No Intervention|Informed Control No Reminder|Participants will fill the sociodemographic and health history form. Their contact information will be gathered. Participants will be contacted at the end of 6 months and will be asked about the number of the prenatal care appointments they have attended during their pregnancy.
89473041|NCT05094518|No Intervention|Uninformed Control No Reminder|"Participants will fill the sociodemographic and health history form. No contact information will be gathered. The purpose of this arm is to estimate the true baseline for the number of visits without any extra attention given by the medical staff."
89473042|NCT04413188|Experimental|A warm foot bath group|65years, relative independent in daily life activities and literate, having a PSQI score of 5 or more and no communication problems.
89206201|NCT02599727|Experimental|Active Isometric exercise|Subjects performing the isometric exercises intervention
89206202|NCT02599727|Active Comparator|No exercise|Subjects not performing the isometric exercises intervention
89473043|NCT04413188|No Intervention|Control group|65years, relative independent in daily life activities and literate, having a PSQI score of 5 or more and no communication problems.
89473044|NCT04500327|Experimental|CPAP users|The Drive app will be used by CPAP users to identify any major issues with the usability and functionality of the app when used with CPAP therapy.
89473045|NCT05581017||No PBD|Patients without preoperative biliary drainage before pancreaticoduodenectomy
89473046|NCT05581017||PBD < 2 months|Patients who had undergone preoperative biliary drainage and the pancreaticoduodenectomy was in 2 months after the drainage.
89473047|NCT05581017||PBD ≥ 2 months|Patients who had undergone preoperative biliary drainage and the pancreaticoduodenectomy was at 2 months or later after the drainage.
89473048|NCT03345693|Experimental|Treated with MoTrack Therapy|Patients receive the MoTrack Therapy device to assist them in their at-home therapy exercises. The patient is instructed to use the MoTrack Therapy device when they want to do their at-home therapy exercises. The patients therapy in the clinic is not affected.
89473049|NCT04401956|Active Comparator|Gluten free bread with added gluten|Bread will be eaten by the participants for 4 consecutive days.
89473050|NCT04401956|Active Comparator|Gluten free bread with added FODMAPs|Bread will be eaten by the participants for 4 consecutive days.
89473051|NCT04401956|Experimental|Traditional manufactured wheat bread|Bread will be eaten by the participants for 4 consecutive days.
89473052|NCT04401956|Experimental|Traditional manufactured spelt bread|Bread will be eaten by the participants for 4 consecutive days.
89473053|NCT04401956|Experimental|Conventional manufactured wheat bread|Bread will be eaten by the participants for 4 consecutive days.
89473054|NCT04401956|Experimental|Conventional manufactured spelt bread|Bread will be eaten by the participants for 4 consecutive days.
89473055|NCT05578365|Experimental|Pilates Group|Pilates method exercise program, performed online, 8 weeks long, twice a week + information on self-management and pain education once a week.
89473056|NCT05578365|Active Comparator|Control Group|Information on self-management of low back pain, pain education, and changes in lifestyle habits once a week during 8 weeks.
89473057|NCT04541186|Active Comparator|Main Study|The cohort will include subjects with SHTG without concurrent fibrate therapy and will consist of 5 treatment groups to compare 4 dose levels/regimens of BIO89-100 versus placebo.
89473058|NCT04541186|Active Comparator|Fibrate Expansion Study|The cohort will include subjects with SHTG on stable background fibrate therapy and with a baseline MRI PDFF ≥6%, and will consist of 2 treatment groups comparing one dose regimen of BIO89 100 versus placebo.
89473059|NCT04500015|Experimental|INH|3 vaginal tablet of isonicotinic acid hydrazide self-inserted by the patient 12 hours before IUD insertion.
89206203|NCT00296647|Active Comparator|patch|
89473060|NCT04500015|Placebo Comparator|Placebo Comparator|3 tablet of placebo self-administered by the patient 12 hours before IUD insertion
89473061|NCT05093738|Experimental|Rehabilitation Group|Refugee Children taking cognitive rehabilitation
89473062|NCT05093738|No Intervention|Control Group|Refugee Children not taking cognitive rehabilitation
89537409|NCT05530317|Experimental|Cardiac Rehabilitation|Participants will undergo 12 weeks of standard of care cardiac rehabilitation.
89537410|NCT04872257|Experimental|Oral Vitamin D + NB-UVB Phototherapy|
89206204|NCT00296647|Active Comparator|nicotine lozenge|
89537411|NCT04872257|Placebo Comparator|Placebo + NB-UVB Phototherapy|
88949290|NCT03978793||MyTPill|Participants receive digital pills for three months, have a 2-week washout, then switch to Wisepill.
89473063|NCT04844229|No Intervention|Control group|21 patients will receive conservative management for PDPH in the form of oral paracetamol 1000 mg/8hours, and caffeine 300-500 mg/day, 1000 mL 0.9% normal saline infusion over the initial 4 hours with increasing oral fluids and bed rest to be maintained. After 6 hour of starting treatment if the above measures failed to control pain with the VAS ≥ 4 non-steroidal anti-inflammatory drugs (NSAID) will be added in the form of ketorolac 30 mg IV which can be repeated every 12 hours if needed. Participants will be followed up after 1 hour, 6 hours and 24 hours with assessment of VAS score, modified Lybecker clas¬sification score and TCD parameters. EBP will be considered after 24 hours of treatment if pain still not controlled with VAS ≥ 4 and modified Lybecker clas¬sification score ≥ 2 and after patients' consent.
88949291|NCT03971734|Experimental|Arm 1 regadenoson 0.05mg|"Approximately 10 minutes prior to undergoing the research MRI, patients will be administered a single dose of regadenoson at their assigned dose level, under the supervision of a cardiologist.~The research MRI scan will be performed immediately following administration of regadenoson and appropriate monitoring of vital signs and 12-lead electrocardiography on a similar machine as the pre-enrollment eligibility MRI scan, using the same administered dose of gadolinium and acquisition parameters.~The research MRI will consist of DCE perfusion MRI for estimation of Ktrans and will be performed with co-administration of standard doses of gadolinium following regadenoson dose.~Regadenoson 0.05mg"
89473064|NCT04844229|Active Comparator|Interventional group|"21 patients will receive the same conservative management as in control group together with bilateral transnasal sphenopalatine ganglion block.~After one hour Participants who will show improvement in pain scores will be followed up after 6 hours and 24 hours, while, patients who will show persistent headache will be subjected for bilateral ultrasound guided greater occipital nerve block.~then these patients will be assessed after 1 h, 6 h, and 24 h of the block. If still suffering epidural blood patch will be indicated and performed after gaining patients' consent."
89473065|NCT01678820|Experimental|Sitagliptin/Simvastatin FDC|Sitagliptin 100 mg/simvastatin 40 mg FDC plus placebo to sitagliptin plus placebo to simvastatin administered orally once daily in the evening for 16 weeks. Participants will continue on their stable pre-screening metformin dose and dosing regimen of >=1500 mg daily for the duration of the study. Participants may receive glimepiride 1 mg once daily or 2 mg once daily (may be up-titrated to 6 mg once daily) as rescue therapy.
89473066|NCT01678820|Active Comparator|Sitagliptin|Sitagliptin 100 mg plus placebo to simvastatin plus placebo to sitagliptin/simvastatin FDC administered orally once daily in the evening for 16 weeks. Participants will continue on their stable pre-screening metformin dose and dosing regimen of >=1500 mg daily for the duration of the study. Participants may receive glimepiride 1 mg once daily or 2 mg once daily (may be up-titrated to 6 mg once daily) as rescue therapy.
89473067|NCT01678820|Active Comparator|Simvastatin|Simvastatin 40 mg plus placebo to sitagliptin plus placebo to sitagliptin/simvastatin FDC administered orally once daily in the evening for 16 weeks. Participants will continue on their stable pre-screening metformin dose and dosing regimen of >=1500 mg daily for the duration of the study. Participants may receive glimepiride 1 mg once daily or 2 mg once daily (may be up-titrated to 6 mg once daily) as rescue therapy.
89473068|NCT02515695|Experimental|0.5 MIU i.v. and 1.5 MIU s.c.|"All 12 subjects participated in 4 periods, receiving 4 different doses of interferon beta-1a from 2 of the 4 possible pairs of treatments.~The number of treatment sequences was limited to 6 and the subjects were randomized among the 6 sequences, as one male and one female per sequence. Thus 6 subjects received each dose. The washout period between two injections (Day 1 of subsequent periods) was of 7 days or more."
89473069|NCT02515695|Experimental|1 MIU i.v. and 3 MIU s.c.|"All 12 subjects participated in 4 periods, receiving 4 different doses of interferon beta-1a from 2 of the 4 possible pairs of treatments.~The number of treatment sequences was limited to 6 and the subjects were randomized among the 6 sequences, as one male and one female per sequence. Thus 6 subjects received each dose. The washout period between two injections (Day 1 of subsequent periods) was of 7 days or more."
89473070|NCT02515695|Experimental|2 MIU i.v. and 6 MIU s.c.|"All 12 subjects participated in 4 periods, receiving 4 different doses of interferon beta-1a from 2 of the 4 possible pairs of treatments.~The number of treatment sequences was limited to 6 and the subjects were randomized among the 6 sequences, as one male and one female per sequence. Thus 6 subjects received each dose. The washout period between two injections (Day 1 of subsequent periods) was of 7 days or more."
89473071|NCT02515695|Experimental|4 MIU i.v. and 12 MIU s.c.|"All 12 subjects participated in 4 periods, receiving 4 different doses of interferon beta-1a from 2 of the 4 possible pairs of treatments.~The number of treatment sequences was limited to 6 and the subjects were randomized among the 6 sequences, as one male and one female per sequence. Thus 6 subjects received each dose. The washout period between two injections (Day 1 of subsequent periods) was of 7 days or more."
89473072|NCT03347487|Experimental|Deep Brain Stimulation of Bilateral Habenula|
89473073|NCT03979430|Other|Intervention|There is only one arm with the intervention.
89473074|NCT02515539|Experimental|CardiAQ TMVI System (Transapical & Transfemoral DS)|CardiAQ TMVI System using either the Transapical or Transfemoral Delivery System
89537412|NCT02464319|Active Comparator|Experimental: hrIL-2 active|Intervention：Add hrIL-2 according to the protocol to original treatment. HrIL-2 active: 1 million U doses of human recombinant interleukin-2 s.c. injection
89537413|NCT02464319|Placebo Comparator|Placebo Comparator: hrIL-2 placebo|1 million U doses of placebo s.c. injection
89537414|NCT05603637|Active Comparator|Radiofrequency ablation arm|Patients will undergo pulmonary vein isolation by means of radiofrequency energy. The ablation will be done using SmartTouch ablation catheter (Biosense Webster, USA).
88949292|NCT03971734|Experimental|Arm 2 regadenoson 0.1mg|"Approximately 10 minutes prior to undergoing the research MRI, patients will be administered a single dose of regadenoson at their assigned dose level, under the supervision of a cardiologist.~The research MRI scan will be performed immediately following administration of regadenoson and appropriate monitoring of vital signs and 12-lead electrocardiography on a similar machine as the pre-enrollment eligibility MRI scan, using the same administered dose of gadolinium and acquisition parameters.~The research MRI will consist of DCE perfusion MRI for estimation of Ktrans and will be performed with co-administration of standard doses of gadolinium following regadenoson dose."
89206205|NCT00296647|Active Comparator|bupropion|
89473075|NCT03888560|Experimental|Micro-osteoperforations|Lower arch, 2 MOPs vertically at interdental area bilaterally mesial to lower 6's ; mesial to lower 1st premolar; mesial to lower 2's and between the lower 1's..The start date of lower labial segment alignment (T1) was recorded after insertion of the lower 0.014'' NiTi archwire. Participants were reviewed every 6 weeks and repeated MOPs were performed for the experimental group until the completion of lower labial segment alignment (LLS), which is when the Little's irregularity index scores one, indicating a minimum irregularity of ≤ 2 mm contact point displacement, based on the contact point displacements of the mandibular anterior segment, from canine to canine.
89473076|NCT03888560|No Intervention|control|Conventional orthodontic treatment without any aid in tooth acceleration method / device
89473077|NCT04500093|Experimental|Capsulotomy with Repair|Repair after capsulotomy in direct anterior hip arthroplasty
89473078|NCT04500093|Active Comparator|Capsuloectomy|Capsuloectomy in direct anterior hip arthroplasty
89473079|NCT04413500|Experimental|adaptive intervention|The patients will receive various adaptive digital interventions through mobile app.
89473080|NCT03346629|Experimental|Mifepristone + Misoprostol|Intervention: 200mg mifepristone followed 24-48 h later with 400mcg misoprostol (repeat Q3)
89473081|NCT04501965|Active Comparator|Hydroxychloroquine/Azythromycin|Patients received Hydroxychloroquine 200 mg tablet orally 3 times daily for 10 days and Azythromycine 250 mg orally at the rate of 2 tablets the first day, then one tablet for 5 days
89473082|NCT04501965|Experimental|Quinquina/Azythromycin|Patients receive 3.5g tea bags of Cinchona/Stevia powder orally at the rate of 3 tea bags per day for 10 days
89473083|NCT04501965|Experimental|4plants/Azythromycin|Participants received 4Plants powder in a 3.5g tea bag orally three times daily for 10 days and Azythromycine 250 mg orally at the rate of 2 tablets the first day, then one tablet for 5 days
89473084|NCT03122067|Experimental|oxytocin group|male participants with oxytocin treatment
89473085|NCT03122067|Placebo Comparator|placebo group|male participants with placebo treatment
89473086|NCT03718520||prenatal exposed to cannabis|50 mother-infant pairs with self-reported maternal chronic cannabis use during pregnancy
89473087|NCT03718520||prenatal not-exposed to cannabis|60 mother-infant pairs with no self-reported maternal cannabis use during pregnancy
89473088|NCT03347409|No Intervention|Standard Perioperative (SP) care|
89473089|NCT03347409|Experimental|ERAS protocol|
89473090|NCT04502901|Experimental|Experimental Group -KX0826|KX0826 is tropically applied to the scalp of healthy male subjects once a day for 14 days. The applied dosage cohorts are 2.5mg, 5mg, 10mg and 20mg.
89473091|NCT04502901|Placebo Comparator|Control Group- Placebo|Placebo is tropically applied to the scalp of healthy male subjects once a day for 14 days.
89019542|NCT00339651||Cases|Women in one large U.S. health care plan. Cases will consist of women who developed endometrial carcinoma or censored complex atypical hyperplasia at least 1 year after receiving a diagnosis of endometrial hyperplasia.
89473092|NCT04536194|Experimental|norepinephrine|infusion of norepinephrine with a adjusted dose to elevate 10% of mean arterial pressure
89473093|NCT04536194|Active Comparator|Dopamine|infusion of dopamine with a adjusted dose to elevate 10% of mean arterial pressure
89206206|NCT00296647|Active Comparator|patch + lozenge|
89473094|NCT04502511||Adult critically ill patients in the ICU|Acutely admitted to the ICU
89473095|NCT03242720|Active Comparator|Active Positive Airway Pressure|Active positive airway pressure for treatment of Obstructive Sleep Apnea
89473096|NCT03242720|Sham Comparator|Sham Positive Airway Pressure|Sham positive airway pressure for treatment of Obstructive Sleep Apnea
89473097|NCT03347175|Experimental|Volume controlled ventilation|Intervention1: Ventilation with Volume controlled ventilation
89473098|NCT03347175|Active Comparator|Pressure controlled ventilation|Intervention2: Ventilation with Pressure controlled ventilation
89473099|NCT03347175|Active Comparator|CPAP mode|Intervention3: Ventilation with Continuous Positive Airway Pressure mode only
89473100|NCT04462172|Experimental|Synthes Femoral Neck System (FNS)|Synthes Femoral Neck System (FNS) was developed with the intention to combine advantages of DHS (dynamic hip screw) and MCS (multiple cancellous screw). The FNS implants consist of plates, bolts, locking screws and antirotating-screws. The plate consists of a small base plate with one or two locking holes and a barrel portion. The barrel allows for gliding of the head elements while restricting rotation around the head-neck axis, so FNS is a fixed-angle gliding fixation device that allows for controlled collapse of the femoral neck, like DHS. The FNS was also designed to minimize implant footprint on the bone with its compact design, like MCS. Furthermore, the FNS was designed to reduce the length of incision necessary for implant insertion when compared to DHS. This new concept of femoral neck fracture fixation still emphasizes the biology of fracture healing by initial fracture compression.
89206207|NCT00296647|Active Comparator|buproion + lozenge|
89206208|NCT00754013|Active Comparator|Donepezil|
89473101|NCT04462172|Active Comparator|Multiple cancellous screws (MCS)|Multiple cancellous screws (MCS) fixation is the most common and classic method to deal with femoral neck fractures which is less invasive and retains more viable bone, compared with dynamic hip screw (DHS) fixation that appears biomechanically more stable. In this study, three cancellous screws with an inverted triangle pattern are used to fix the fracture of femoral neck.
89473102|NCT03122769|Experimental|11C-metformin|All participants allocated to the study will be included in this arm
89473103|NCT03286088|Other|Group A|TransEsophageal Echocardiography + TransThoracic Echocardiography
89473104|NCT03286088|Other|Group B|TransEsophageal Echocardiography + TransThoracic Echocardiography + cardiac Magnetic Resonance
89473105|NCT03286088|Other|Group C|TransEsophageal Echocardiography + TransThoracic Echocardiography + MitraClip
89473106|NCT05376020|Experimental|Densah Burs|Intervention Group
89473107|NCT05376020|Active Comparator|Conventional Burs|Control Group
89473108|NCT03121833|Experimental|Endostar & AIM regimen / GT regimen|Endostar & AIM regimen / GT regimen; Endostar 15mg, into 500ml 0.9% sodium chloride intravenous infusion of 3 ~ 4h, d1 ~ d14, 21-28 days for a cycle; AIM regimen is Pirarubicin (THP) + Ifosfamide (IFO), the specific dose is IFO 8-12g / m2, given 4-5 days; THP 75mg / m2, given 1-2 days; 21-28 days for a cycle; GT regimen is Docetaxel (TXT) + Gemcitabine (GEM), specific dose of Gemcitabine 1000mg / m2 (D1, D8) and Docetaxel 75mg / m2 (D8); 21-28 days for a cycle; Preferred AIM regimen, AIM regimen chemotherapy failure or can not tolerate anthracycline chemotherapy in patients with GT regimen.
89473109|NCT03121833|Placebo Comparator|Placebo & AIM regimen / GT regimen|Placebo + AIM regimen / GT regimen; Placebo is 500ml 0.9% sodium chloride, Intravenous 3 ~ 4h, d1 ~ d14, 21-28 days for a cycle; The chemotherapy regimen is the same as the experimental group.
89473110|NCT04440644||Patients|patients with amyotrophic lateral sclerosis
89473111|NCT04440644||Healthy control|healthy control participants
89473112|NCT03121755||Sangre Por Salud cohort members|Subjects entered in the Sangre Por Salud Biobank
89473113|NCT03121521|Experimental|melatonin|Melatonin 10mg/d p.o.
89473114|NCT03121521|Placebo Comparator|placebo|placebo 10mg/d p.o.
89473115|NCT03121443||Patient position|Perfusion index
89473116|NCT04437992||Pregnant women|"Pregnant women resident in the Emilia Romagna region who access the combined test at regional counseling centers and hospital prenatal clinics.~Women able to understand the information, participate in pre-test counseling and provide informed consent."
89473117|NCT05585931|Experimental|Cohort 1|9 subjects receive 10 mg TPN171H for Period 1; Placebo for Period 2
89473118|NCT05585931|Experimental|Cohort 2|9 subjects receive Placebo for Period 1; 10 mg TPN171H for Period 2
89473119|NCT02643056|Experimental|Panitumumab|6 mg/kg per administration
89473120|NCT02515617|Active Comparator|Period with endotracheal tubes not allowing SSD|During this period, patients will be intubated with standard endotracheal tubes not allowing Subglottic Secretions Drainage
89473121|NCT02515617|Experimental|Period with endotracheal tubes allowing SSD|During this period, patients will be intubated with specific endotracheal tubes allowing Subglottic Secretions Drainage
89473122|NCT05098808||Dysphagia mild|Able to start oral feeding after assessment
89473123|NCT05098808||Dysphagia severe|Non oral feeding and high risk of aspiration
89473124|NCT04586829|Active Comparator|Conventional diet|Conventional diet. (50% carbohydrate, 30% lipids, 20% protein). Current dietary recommendations from official guidelines will be reinforced.
89473125|NCT04586829|Experimental|Ketogenic diet|Tailored ketogenic diet. Participants will be allowed to chose their meals as long as they consume less than 50gr of carbohydrates per day.
89473126|NCT02515461|Experimental|Intervention: Low energy shockwave therapy|Low energy shockwave therapy performed on both kidneys applying 3000 shocks on each kidney.
89473127|NCT04499703||Group 1|Subjects with normal macular thickness in one or both eyes.
88949293|NCT03971734|Experimental|Arm 3 regadenoson 0.2mg|"Approximately 10 minutes prior to undergoing the research MRI, patients will be administered a single dose of regadenoson at their assigned dose level, under the supervision of a cardiologist.~The research MRI scan will be performed immediately following administration of regadenoson and appropriate monitoring of vital signs and 12-lead electrocardiography on a similar machine as the pre-enrollment eligibility MRI scan, using the same administered dose of gadolinium and acquisition parameters.~The research MRI will consist of DCE perfusion MRI for estimation of Ktrans and will be performed with co-administration of standard doses of gadolinium following regadenoson dose."
89473128|NCT04499703||Group 2|Subjects with center-involving macular edema due to wAMD in one or both eyes
89473129|NCT04499703||Group 3|Subjects with center-involving macular edema due to DR or RVO in one or both eyes
89473130|NCT05079308|Experimental|Filtering face piece with peripheral sealing device|Individuals using the Filtering face Piece (FFP2) with the Peripheral Sealing Device (AMS).
89473131|NCT05079308|Active Comparator|Filtering face piece without peripheral sealing device|Individuals using the Filtering face Piece (FFP2) without the AMS;
89473132|NCT05079308|Experimental|IIR surgical mask with peripheral sealing device|Individuals using the Surgical mask (SM) with the AMS;
89473133|NCT05079308|Active Comparator|IIR surgical mask without peripheral sealing device|Individuals using the Surgical mask (SM) without the AMS;
89473134|NCT05079308|Experimental|Filtering face piece with IIR surgical mask|individuals using a FFP2 with a SM over it, simultaneously, without the AMS.
89473135|NCT04169594||Stroke|Unilateral hemiplegic stroke patients
89473136|NCT04169594||Amputee|Unilateral transtibial amputee patients
89473137|NCT04413422||propofol|Those patients planned for general surgery, who received propofol as an induction agent for general anesthesia.
89473138|NCT04413422||etomidate|Those patients planned for general surgery, who received etomidate as an induction agent for general anesthesia.
89473139|NCT04413422||thiopental|Those patients planned for general surgery, who received thiopental as an induction agent for general anesthesia.
89473140|NCT02238145||Chronic Obstructive Airways Disease|
89019543|NCT00339651||Controls|Women in one large U.S. health care plan. Controls will consist of individually matched women who received a diagnosis of endometrial hyperplasia at the same age and date as the cases and were cancer-free and hysterectomy-free until the date at which the index cases were diagnosed with endometrial carcinoma or censored complex atypical hyperplasia.
89473141|NCT03579355|Experimental|DFND Program|"Dentist Fighting Nicotine Dependence, (DFND) intervention program consisted primarily of a 10-session curriculum, each session lasting about an hour. The curriculum was comprehensive and incorporated information about tobacco and its adverse health effects, social influences, and social competence skills. DFND was administered over 5 weeks, at a rate of 2 sessions per week. Each session lasts an hour. Fourteen classrooms in four schools represented the experimental arm and received DFND."
89473142|NCT03579355|No Intervention|Informational Booklet|Fourteen classrooms in four schools represented the No Intervention arm (control). They received only an informational booklet about tobacco adverse health effects.
89473143|NCT05098418||2015|total number of poisoned patients in 2015, including their demographic data
89473144|NCT05098418||2016|total number of poisoned patients in 2016, including their demographic data
89473145|NCT05098418||2017|total number of poisoned patients in 2017, including their demographic data
89473146|NCT05098418||2018|total number of poisoned patients in 2018, including their demographic data
89473147|NCT05098418||2019|total number of poisoned patients in 2019, including their demographic data
89473148|NCT02512731|Active Comparator|Goal directed fluid therapy using esophageal doppler monitor|The esophageal doppler monitor directs the fluid therapy.
89473149|NCT02512731|No Intervention|Fluid therapy using standard management|The esophageal doppler monitor is in place however blinded to the healthcare providers, fluid management is as per standard clinical practice.
89473150|NCT03345459|Experimental|Internet-Based Treatment (ICare)|ICare Prevent is a 7-week internet-based treatment for depression that is primarily cognitive behavior therapy but targets broad-based mechanisms related to college students.
89473151|NCT03345459|No Intervention|Usual Care|Participants are notified that they have elevated distress, and additionally, they are provided a list of on-campus and community resources.
89473152|NCT03577015||critically ill patients at risk for DIC|patients 18 years or older with a condition potentially associated with DIC, admitted to intensive care: severe infection/sepsis, solid tumor, hematologic malignancies, trauma, obstetric complications, acute pancreatitis
89473153|NCT04550637||Anticoagulant therapy after percutaneous left atrial appendage|Oral apixaban
89473154|NCT03576781|Experimental|Real iTBS to the DLPFC|One session of real intermittent Theta Burst Stimulation (iTBS) will be delivered to the left dorsolateral prefrontal cortex (dlPFC) (20 trains of stimulation over dlPFC (middle frontal gyrus) (F3); each train: 3 pulse bursts presented at 5Hz, 15 pulses/sec for 2 sec, 8 sec rest, 200 pulses/train; 110% RMT, MagPro; 600 pulses total)
89473155|NCT03576781|Sham Comparator|Sham iTBS to the DLPFC|One session of sham intermittent Theta Burst Stimulation (iTBS) will be delivered to the left dorsolateral prefrontal cortex (dlPFC) (20 trains of stimulation over dlPFC (middle frontal gyrus) (F3); each train: 3 pulse bursts presented at 5Hz, 15 pulses/sec for 2 sec, 8 sec rest, 200 pulses/train; 110% RMT, MagPro; 600 pulses total)
89473156|NCT03576781|Experimental|Real cTBS to the MPFC|One session of real continuous Theta Burst Stimulation (cTBS) will be delivered to the left medial prefrontal cortex (mPFC) (1 train of stimulation over the left frontal pole (FP1); each train: 3 pulse bursts presented at 5Hz, 15 pulses/sec for 40 sec, 600 pulses/train, 110% RMT, MagPro; 600 pulses total)
89473157|NCT03576781|Sham Comparator|Sham cTBS to the MPFC|One session of sham continuous Theta Burst Stimulation (cTBS) will be delivered to the left medial prefrontal cortex (mPFC) (1 train of stimulation over the left frontal pole (FP1); each train: 3 pulse bursts presented at 5Hz, 15 pulses/sec for 40 sec, 600 pulses/train, 110% RMT, MagPro; 600 pulses total)
89473158|NCT03345381|Experimental|SKY + ASTM + usual care|Sudarshan Kriya Yoga (SKY) followed by Automatic Self Transcending Meditation (ASTM) plus usual care
89473159|NCT03345381|Active Comparator|Usual Care|Treatment as usual
89473160|NCT03576703|Experimental|EX+H2O|Exercise and diet that did not include SSB
89473161|NCT03576703|Experimental|EX+SSB|Exercise and diet that includes SSB
89473162|NCT03576703|No Intervention|CONTROL|No exercise and diet that did not include SSB
89473163|NCT03345303|Experimental|Bortezomib treatment|'Bortezomib Injectable Solution
89473164|NCT03345303|No Intervention|supportive care|supportive care
89473165|NCT03574909|Experimental|Treatment Arm|"Treatment Arms: Tromalyt® 150mg prolong release capsule for oral ingestion. The capsule contains 150mg of anti-platelet agent acetylsalicylic acid, maize starch and Sucrose 20:80. The capsule also contains Copovidone (Kollidon VA-64), Eudragit L, Ethylcellulose and Triacetin. The capsule is made with gelatin, erythrosine, quinoline yellow, titanium dioxide. Tromalyt® is trademark of Meda Pharma SL (Reg 59.210).~There is no requirement for the first dose to be administered in the clinic under observation.~The dosing frequency is once daily. Subjects will be instructed to take the study medication at the same time each day.~No specific precautions are required in relation to concomitant food intake."
89473166|NCT03574909|Placebo Comparator|Control Arm|"Placebos to be used are hard gelatin capsules (Sanitatis®) for patients randomized to the placebo arm. These capsules are externally identical to Tromalyt capsule. The capsules contain 198mg microcrystalline cellulose and 2mg of magnesium stearate (Sanitatis®) Placebo: There is no requirement for the first dose to be administered in the clinic under observation.~The dosing frequency is once daily. Subjects will be instructed to take the study medication at the same time each day.~No specific precautions are required in relation to concomitant food intake."
89473167|NCT03345225|Active Comparator|Control Group|Participants will be randomized to receive DEB-TACE utilizing a standard endhole microcatheter
89473168|NCT03345225|Experimental|Surefire Group|Participants will be randomized to receive DEB-TACE utilizing the Surefire Infusion System
89473169|NCT03576625|Placebo Comparator|High oleic sunflower oil (HOSO)|30 ml HOSO emulsion (equivalent to 9.9 ml oil) in a single dose, 56 days
89473170|NCT03576625|Experimental|Buglossoides oil emulsion|30 ml Buglossoides oil emulsion (equivalent to 9.9 ml oil) in a single dose, 56 days
89473171|NCT02512653|Experimental|1|Cupressus arizonica allergen extract at 4 different concentrations. Positive control. Negative control
89473172|NCT03579199|Experimental|exploration of abdominal cavity using a NIR/ICG camera|
89473173|NCT03579043|Experimental|Nutritive Sweetener|Participants will consume 36 ounces of Coke daily for three consecutive days.
89473174|NCT03579043|Experimental|Non-Nutritive Sweetener|Participants will consume 36 ounces of Diet Coke daily for three consecutive days.
88949294|NCT03971734|Experimental|Arm 4 regadenoson 0.4mg|"Approximately 10 minutes prior to undergoing the research MRI, patients will be administered a single dose of regadenoson at their assigned dose level, under the supervision of a cardiologist.~The research MRI scan will be performed immediately following administration of regadenoson and appropriate monitoring of vital signs and 12-lead electrocardiography on a similar machine as the pre-enrollment eligibility MRI scan, using the same administered dose of gadolinium and acquisition parameters.~The research MRI will consist of DCE perfusion MRI for estimation of Ktrans and will be performed with co-administration of standard doses of gadolinium following regadenoson dose."
89473175|NCT03579043|Experimental|Carbonated Water|Participants will consume 36 ounces of carbonated water daily for three consecutive days.
89473176|NCT02660138|Experimental|600 U Dysport® Group|
89473177|NCT02660138|Placebo Comparator|600 U Dysport® Placebo Group|
89473178|NCT02660138|Experimental|800 U Dysport® Group|
89473179|NCT02660138|Placebo Comparator|800 U Dysport® Placebo Group|
89473180|NCT04499469|Experimental|Spreader Graft|Placement and attachment with 5.0 polydioxanone (PDS) suture 2 grafts in the middle third of the nose
89473181|NCT04499469|No Intervention|Without Spreader Graft|No engraftment in the middle third
89473182|NCT03576469|Experimental|C1-esterase inhibitor [recombinant] (C1-INH-R)|"Single-site, open-label arm to evaluate the benefit of C1-INH-R in subjects on IVIG therapy who experience ADRs. The study will have 2 periods:~6 - 8 weeks - subjects will receive 2 infusions of IVIG~9 - 12 weeks - subjects will receive 3 infusions of C1-INH-R prior to IVIG infusion"
89473183|NCT02181751||Treatment Group|Children in the Treatment Group will receive treatment for a Trauma Focused Cognitive Behavioural Therapy Group.
89473184|NCT02239003|Experimental|DAOIB|250-1500 mg/day, oral, for 24 weeks
89473185|NCT02239003|Placebo Comparator|Placebo|placebo, oral, for 24 weeks
89473186|NCT03574831||Stretta|Radio Frequency Ablation (RFA) using a Stretta device.
89473187|NCT03947918|Experimental|Short sleep|No more than 8 hours of sleep for 4 consecutive nights.
89473188|NCT03947918|Experimental|Long sleep|At least 10 hours of sleep for 4 consecutive nights
88949295|NCT03971734|Experimental|Arm 5 regadenoson 0.7mg|"Approximately 10 minutes prior to undergoing the research MRI, patients will be administered a single dose of regadenoson at their assigned dose level, under the supervision of a cardiologist.~The research MRI scan will be performed immediately following administration of regadenoson and appropriate monitoring of vital signs and 12-lead electrocardiography on a similar machine as the pre-enrollment eligibility MRI scan, using the same administered dose of gadolinium and acquisition parameters.~The research MRI will consist of DCE perfusion MRI for estimation of Ktrans and will be performed with co-administration of standard doses of gadolinium following regadenoson dose."
88949296|NCT03971734|Experimental|Arm 6 regadenoson 1.0mg|"Approximately 10 minutes prior to undergoing the research MRI, patients will be administered a single dose of regadenoson at their assigned dose level, under the supervision of a cardiologist.~The research MRI scan will be performed immediately following administration of regadenoson and appropriate monitoring of vital signs and 12-lead electrocardiography on a similar machine as the pre-enrollment eligibility MRI scan, using the same administered dose of gadolinium and acquisition parameters.~The research MRI will consist of DCE perfusion MRI for estimation of Ktrans and will be performed with co-administration of standard doses of gadolinium following regadenoson dose."
89202517|NCT05361226|Experimental|s-CAIS (static computer aided implant surgery)|For the s-CAIS group, Cone Beam Computed Tomography (CBCT) and full-arch optical scan were performed to provide digital information for implant planning software (coDiagnostix 9, Dental Wings GmbH, Chemnitz, Germany). The virtual implant was set on a three dimensional (3D) virtual jaws according to the prosthetically driven protocol by one postgraduate dentist and was confirmed by one experienced dentist. Static surgical template covering on occlusal part of 4 teeth anteroposteriorly was then fabricated via 3D printing machine (surgical guide resin, Form 2, Formlabs, Somerville, Massachusetts, USA). This surgical template would be used during surgery.
89206209|NCT00754013|Placebo Comparator|Placebo|
89473189|NCT03905720|No Intervention|Treatment As Usual|Participants will receive routine care consisting of usual analgesic medications for pain in adults with cancer.
89473190|NCT03905720|Active Comparator|Acupuncture|Along with routine pain medications, participants will be offered daily acupuncture treatments for up to four days.
89473191|NCT03905720|Active Comparator|Pain Counseling|Along with routine pain medications, participants will receive evidence-based psychosocial support through education and counseling provided by qualified study staff.
89473192|NCT03905720|Active Comparator|Acupuncture and Pain Counseling|Along with routine pain medications, participants will be offered daily acupuncture treatments and pain counseling for up to four days as described above.
89473193|NCT05097950|Active Comparator|Intervention Group|Administration of 1 gr paracetamol I.V
89473194|NCT05097950|Placebo Comparator|Control Group|Administration of 100 ml. sodium chloride 0.9% IV
89473195|NCT05375786||COVID-19 infections|"SARS-Cov-2 RNA positive~without symptom or with mild clinical manifestations"
89473196|NCT05097638||Cured pulmonary Tuberculosis patients|6 months after a completed course of anti-tuberculosis therapy
89473197|NCT05097560|Experimental|HFNC group|"Set FiO2 28%~Titrate the flow of HFNC at the highest tolerated value up to 60 L/min"
89473198|NCT05097560|Active Comparator|VM group|- Keep FiO2 constant with VM and HFNC during the two trial
89473199|NCT05097248|Experimental|Camrelizumab, Liposomal doxorubicin and Losartan|Participants receive intravenous camrelizumab (200 mg, Q3W) and liposomal doxorubicin (40 mg, Q3W for 6 weeks) plus oral losartan (50 mg loading dose followed by 100 mg QD, Q3W, until discontinuation of liposomal doxorubicin).
89473200|NCT04413812|Experimental|Experimental Group|The experimental group will participate in a 3-months training programme focusing on health competence related outcomes.
89473201|NCT04413812|No Intervention|Control Group|The control group does not participate in the exercise programme but undergoes identical outcome assessments.
89473202|NCT01603394|Experimental|Pregabalin (300-600 mg/day; 150 mg/day starting dose)|
89473203|NCT03352778||IMRT|
89473204|NCT03352778||2DRT|
89473205|NCT03340844|Experimental|No Touch (NT)|Pancreatic and Periampullary Tumors resection by no-touch technique
89473206|NCT03340844|Active Comparator|Superior Mesenteric Artery First (SMA)|Pancreatic and Periampullary Tumors resection by superior Mesenteric Artery First technique
89473207|NCT03265496|Experimental|study procedure|Clinical exam. Liquid biopsy. Diagnostic exam (biopsy and imagery). 1st line treatment. tumor evaluation. Biopsy
89473208|NCT03197090|Experimental|Zenicor ON|Patients allocated to the experimental group will undergo systematic short ECG monitoring
89473209|NCT03197090|No Intervention|Zenicor OFF|In patients allocated to the control group, usual diagnostic procedures for detection of atrial fibrillation will be employed according to ESC Guidlines.
89473210|NCT02837432|Other|Healthy|Healthy individuals will receive both the placebo and hydrocortisone interventions in a randomized order
89473211|NCT02837432|Other|Depression|Individuals with depression will receive both the placebo and hydrocortisone interventions in a randomized order
89473212|NCT02729025|Placebo Comparator|Placebo|Participants received placebo to evolocumab by subcutaneous injection once a month (QM) for 12 weeks.
89473213|NCT02729025|Experimental|Evolocumab 420 mg QM|Participants received 420 mg evolocumab by subcutaneous injection once a month (QM) for 12 weeks.
89473214|NCT02640248||Cuff ETT|
89473215|NCT02379572|Experimental|iMRI-guided surgery|Resection of Glioblastomas with iMRI-guidance
89473216|NCT02379572|Active Comparator|5-ALA-guided surgery|Resection of Glioblastomas with 5-ALA-fluorescence-guidance
89473217|NCT02515149|No Intervention|Standard of care|Referral laboratory based CD4 measurement after home-based HIV testing
89473218|NCT02515149|Experimental|Point of care|POC CD4 testing after home-based HIV testing
88949297|NCT03971734|Experimental|Arm 7 regadenoson 1.4mg|"Approximately 10 minutes prior to undergoing the research MRI, patients will be administered a single dose of regadenoson at their assigned dose level, under the supervision of a cardiologist.~The research MRI scan will be performed immediately following administration of regadenoson and appropriate monitoring of vital signs and 12-lead electrocardiography on a similar machine as the pre-enrollment eligibility MRI scan, using the same administered dose of gadolinium and acquisition parameters.~The research MRI will consist of DCE perfusion MRI for estimation of Ktrans and will be performed with co-administration of standard doses of gadolinium following regadenoson dose."
89202518|NCT05361226|Active Comparator|c-LIS (conventional laboratory-guided implant surgery)|"For the c-LIS group, a radiographic template (ORTHO Plast, prominent®, Chonburi, Thailand) was fabricated covering on occlusal part of 4 teeth anteroposteriorly according to diagnostic wax-up on the study model. A radiographic marker (gutta percha) was then filled in the created hole of the template and for used while taking CBCT image to verify marker position.~Next, a study model was scanned by laboratory surface scan (D900m, 3Shape, Copenhagen, Denmark). The STL file was imported to 3D printing devices and the resin model was fabricated (Dental LT clear resin, Form 2, Formlabs, Somerville, Massachusetts, USA).~Next, the same template that had been used for CBCT was used to place implant replicas in a resin model. The position of the implant replicas in the models were assumed as pre-operative planned implant position."
89473219|NCT05092334|Experimental|Proprioceptive exercises|"Group A treated with proprioceptive exercises. proprioception exercises included.~Head relocation it involve the practice of relocating head back to natural head posture and to predetermined positions in range first with eyes open using feedback from a laser attached to their head and then with closed all active movement of cervical flexion extension lateral flexion and rotations were used.~Gaze stability oculomotor exercises commencing with eyes movement with the head stationary, progressing to movement of head with visual fixation on a target.~Eye head coordination exercises, commenced with rotation of eyes and head to the same side in both right and left directions. Then progressed with both eyes and head move in opposite direction"
89473220|NCT05092334|Experimental|Strengthening exercises|Group B treated with strengthening exercises which are performed with prone and supine position by placing a towel under head, press towel for 5 seconds with 10-12 repetitions ,one set in a week for six weeks for cervical muscles
89473221|NCT02512185||Chemotherapy|Men starting first-line chemotherapy for mCRPC (typically Docetaxel and Prednisone)
89473222|NCT02512185||Abiraterone|Men with mCRPC starting Abiraterone
89473223|NCT02512185||Enzalutamide|Men with mCRPC starting Enzalutamide
89473224|NCT02512029|Experimental|TBI Subjects|Subjects with history of recent subacute Traumatic Brain Injury (TBI) will receive a single IV injection, 370 megabecquerel (MBq) [10 millicurie (mCi)] of 18F-AV-1451 2 to 6 weeks following injury. They will return for a follow-up injection approximately 6 months following injury.
89473225|NCT02512029|Experimental|Control|Cognitively healthy volunteer subjects will receive a single IV injection, 370 megabecquerel (MBq) [10 millicurie (mCi)] of 18F-AV-1451.
89473226|NCT05599971|Active Comparator|Group A|15 patients will receive intralesional 0.1 mL of combined digoxin and furosemide, with maximum 5 warts per session.
89473227|NCT05599971|Active Comparator|Group B|15 patients will receive intralesional injection of 5- Fluorouracil (50mg/ml) in full concentration into the wart using a 27- gauge insulin syringe till the entire lesion begins to puff up. The maximum dose injected per session will be 2ml of 5-FU.
89473228|NCT05599971|Placebo Comparator|Group c|15 patients will receive intralesional saline.
89473229|NCT05093816|Experimental|Common Elements Tooplbox|
89019544|NCT00312065|Experimental|Patient|Once stabilized, a trimmed reflective shield to cover only the probe itself will be placed over the thermistor probe. Changes in measured skin temperature and warmer power output will be recorded non-invasively, as well as the time taken to reestablish baseline status. A full-sized reflective shield will then be placed over the thermistor probe and the same observations recorded, then repeated 15 minutes later. At the time of a subsequent routine change in thermistor position, the same procedure will be followed, but omitting the intermediate step of using the smaller trimmed shield. Continuous core temperatures will be monitored via a short rectal probe during the study periods.
89473230|NCT05093816|No Intervention|Wait-list control|
89473231|NCT02512263|Experimental|Intervention group|They will have to do all the tests and to follow the home-based training program during 9 weeks.
89473232|NCT02512263|No Intervention|control group|They will have to do all the tests but not to follow the home-based training program.
89473233|NCT05033912|Experimental|Treatment Sequence 1|Subjects will receive daily doses of matching placebo for CST-2032 and CST-107 on Day 1, 1mg CST-2032 & 3mg CST-107 on Day 2, 3mg CST-2032 & 3mg CST-107 on Day 3, & 9mg CST-2032 and 3mg CST-107 on Day 4.
89473234|NCT05033912|Experimental|Treatment Sequence 2|Subjects will receive daily doses of 1mg CST-2032 & 3mg CST-107 on Day 1, 3mg CST-2032 & 3mg CST-107 on Day 2, & 9mg CST-2032 and 3mg CST-107 on Day 3, and matching placebo for CST-2032 and CST-107 on Day 4.
89473235|NCT05033912|Experimental|Treatment Sequence 3|Subjects will receive daily doses of 3mg CST-2032 & 3mg CST-107 on Day 1, & 9mg CST-2032 and 3mg CST-107 on Day 2, matching placebo for CST-2032 and CST-107 on Day 3, and 1mg CST-2032 & 3mg CST-107 on Day 4.
89473236|NCT05033912|Experimental|Treatment Sequence 4|Subjects will receive daily doses of 9mg CST-2032 and 3mg CST-107 on Day 1, matching placebo for CST-2032 and CST-107 on Day 2, 1mg CST-2032 & 3mg CST-107 on Day 3, and 3mg CST-2032 & 3mg CST-107 on Day 4.
89473237|NCT02514915|Other|Stereotactic Radiosurgery|Subjects will receive stereotactic radiosurgery prior to resection
89473238|NCT05017922|Experimental|combined group|unresectable hepatocellular carcinoma patients who received TACE plus endoscopic therapy
89473239|NCT05017922|Other|control group|unresectable hepatocellular carcinoma patients who only received TACE
89473240|NCT02515071|Experimental|Nitrate rich beetroot juice|Concentrated, beetroot juice is a rich source of dietary nitrate.
89473241|NCT02515071|Placebo Comparator|Nitrate depleted placebo beetroot juice|Placebo beetroot juice is identical to active beetroot juice in every way except nitrate content.
89473242|NCT02514759|Experimental|The Teen Outreach Program|TOP is a youth development and service learning program for youth designed to reduce teenage pregnancy and increase school success by helping youth develop a positive self-image, life management skills, and realistic goals. The TOP program model consists of three components implemented in school, after school, or in community settings over nine months: (1) weekly curriculum sessions, (2) community service learning, and (3) positive adult guidance and support. The TOP Changing Scenes Curriculum is separated into four age-/stage-appropriate levels, Level 1 is typically for youth ages 12 or 13 and Level 4 is typically for youth age 17. The intended program dosage for each participant is a minimum of 25 weekly sessions (one per week at 40-50 minutes each) and at least 20 hours of community service learning over nine months. One or two facilitators, who plan the order of sessions based on the needs and interest of youth, implemented TOP in a group of 10 to 25 youth.
89473243|NCT02514759|No Intervention|Control group|The control group received business as usual.
89473244|NCT04981574|Experimental|A group: neck pain|
89473245|NCT04981574|Experimental|B group: low back pain|
89473246|NCT02511873|Experimental|Fycompa|Fycompa dose is chosen based on tolerability and efficacy. 2mg to 8mg daily for 6 weeks then washed out.
89473247|NCT02511873|Placebo Comparator|Placebo|Inactive ingredient equal to 2mg tablets
89473248|NCT04936490|Experimental|Crocin|
89473249|NCT04936490|Placebo Comparator|Placebo|
89473250|NCT02514993||Study group|Inclusion criteria for the study were (a) sternal fracture and concomitant thoracic spine fracture, (b) Injury Severity scale (ISS) ≥ 16, (c) age under 50 years, (d) presence of a whole body computed-tomography (CT-scan) performed at admission of the patient to the hospital.
89473251|NCT02514993||Control group|The inclusion criteria for the control group included: (a) Thoracic spine fracture without concomitant sternal fracture, (b) ISS ≥ 16, (c) age under 50 years, (d) presence of a whole body computed-tomography (CT-scan) performed at admission of the patient to the hospital.
89537415|NCT05603637|Experimental|Pulsed- field ablation arm|Patients will undergo pulmonary vein isolation by means of pulsed-field ablation. The ablation will be done using Farawave ablation catheter (Boston Scientific, USA).
89537416|NCT03065751|Active Comparator|TPE|
89019545|NCT00339690|Experimental|Test Kit Homes|Households assigned to use the in-home test kit.
89019546|NCT00312260|Experimental|1|
89019547|NCT00312260|Active Comparator|2|
89019548|NCT00312299|Experimental|Arm 1 A - Square edge PMMA IOL|50 patientes will recieve square edge PMMA IOL
89473252|NCT04626986|Experimental|microwave ablation|Microwave ablation（MWA）refers to all electromagnetic methods of inducing tumor destruction by using devices with frequencies greater than or equal to 900MHz. The rotation of dipole molecules accounts for most of the heat generated during MWA. Water molecules as dipoles attempt to continuously reorient at the same rate in microwave's oscillating electric field. As a result of microwave transmission, the water molecules flip back and forth billions of times a second. The vigorous movement of water molecules produce friction and heat, thus inducing cellular death via coagulation necrosis. The microwave unit (KY-2000, Kangyou Medical, Nanjing, China) is capable of producing 100 Watts of power at 2450 MHz.The needle antenna has a diameter of 1.6 mm (16G) and a length of 10 cm. The active tip length is 3mm and 5mm.
89473253|NCT04626986|Active Comparator|breast conserving surgery|Breast-conserving surgery refers to the removal of the primary tumor and adjacent breast tissue, supplemented by postoperative radiotherapy.Its principle is to remove the primary tumor completely while meet patient's cosmetic satisfaction.The combined treatment of early breast cancer with radiotherapy and chemotherapy is the same as radical surgery or modified radical surgery in terms of local and regional control rate and long-term survival rate. Breast conserving surgery and postoperative comprehensive treatment have become one of the main methods for the treatment of early breast cancer.
89473254|NCT02511951|Experimental|one-layer duct-to-mucosa anastomosis|one-layer duct-to-mucosa anastomosis is used for pancreaticojejunostomy after pancreaticoduodenectomy.
89473255|NCT02511951|Active Comparator|two-layer duct-to-mucosa anastomosis|two-layer duct-to-mucosa anastomosis is used for pancreaticojejunostomy after pancreaticoduodenectomy.
89473256|NCT04438070|Placebo Comparator|Daily active screening only|
89473257|NCT04438070|Experimental|Daily active screening and self-collected nasal swab|
89473258|NCT04438070|Experimental|Daily active screening and self-collected oral-nasal swab|
89473259|NCT04438070|Experimental|Daily active screening and nurse collected nasopharyngeal swab|
89473260|NCT02511795|Experimental|AZD1775 (6 doses/week) + Olaparib|"In this Arm, AZD1775 will be given twice daily over 3 days (6 doses) on Days 1-3 of Week 1 and Days 8-10 of Week 2. Olaparib will be given orally BID on Days 1-14.~All patients will enter an olaparib sub-study in order to assess multiple dose pharmacokinetics of olaparib prior to entering the main study. In the olaparib PK sub-study patients will take olaparib for 3 consecutive days and venous blood samples will be collected on Day 3. The PK sub-study must be initiated 10 days prior to the Cycle 1 Day 1 administration of the AZD1775 and olaparib combination. The patient will experience a short gap in treatment (approximately 4-5 days) between Day 3 of the olaparib PK sub-study and Cycle 1 Day 1 AZD1775 and olaparib combined dosing."
89473261|NCT02511795|Experimental|AZD1775 (10 doses/week) + Olaparib|"In this Arm, AZD1775 will be given twice daily over 5 days (10 doses) on Days 1-5 of Week 1 and Days 8-12 of Week 2. Olaparib will be given orally BID on Days 1-14.~All patients will enter an olaparib sub-study in order to assess multiple dose pharmacokinetics of olaparib prior to entering the main study. In the olaparib PK sub-study patients will take olaparib for 3 consecutive days and venous blood samples will be collected on Day 3. The PK sub-study must be initiated 10 days prior to the Cycle 1 Day 1 administration of the AZD1775 and olaparib combination. The patient will experience a short gap in treatment (approximately 4-5 days) between Day 3 of the olaparib PK sub-study and Cycle 1 Day 1 AZD1775 and olaparib combined dosing."
89473262|NCT04796636|Experimental|Intermediate dose|"Sodium ascorbate (vitamin C) is provided by the manufacturer (Orthomolecular Medisearch Laboratory P/L, Braeside, Victoria, Australia) as 30 grams in 100 ml.~30 gram load over 2 hours (T = 0 - 2 hours)~30 gram infusion over 6 hours (T = 2-8 hours) which will be repeated at 14, 26 and 38 hours"
89473263|NCT04796636|Experimental|High dose|"Sodium ascorbate (vitamin C) is provided by the manufacturer (Orthomolecular Medisearch Laboratory P/L, Braeside, Victoria, Australia) as 30 grams in 100 ml.~30 gram load over 2 hours (T = 0 - 2 hours)~60 gram infusion over 6 hours (T = 2-8 hours) which will be repeated at 14, 26 and 38 hours"
89473264|NCT04796636|No Intervention|Usual care|Usual care for septic shock. No vitamin C will be given
89473265|NCT04501809|Active Comparator|Group I (Misoprostol group):|seventy-nine patients will receive a loading dose of moistened misoprostol tablets ( Cytotec pfizer 400 mg) inserted vaginally and it will be followed by maintenance dose (200 mg) after six hours and repeated every 4 hours till the start of effective uterine contraction with maximum five doses in 24 hours duration .
89473266|NCT04501809|Active Comparator|Group II (Combined group):|seventy- nine patients will get intracervical Foleys Catheter insertion .a 16F (french units) Foley catheter will be introduced into the cervical canal to induce cervical ripping. The catheter will be fixed through inflation of the balloon with 30 milliliters of sterile solution when the catheter will be beyond the internal cervical os. After six hours of Foleys catheter fixation, we will start infusion of 10 international units (IU) of oxytocin on 500 ml ringer lactate by rate 125 ml\hr followed by one hour rest to allow diuresis. Increased gradually of oxytocin dose by 5 IU each time until achieving regular uterine contraction, maximum five doses in twenty -four hours duration.
89473267|NCT04718636|Experimental|Administration of OC alone, then progress to OC in combination with CC-99677|Oral Contraceptive (OC) and CC-99677 will be administered daily
89473268|NCT02514681|Active Comparator|Trastuzumab + chemotherapy|Trastuzumab + chemotherapy Chemotherapy regimen is chosen from the following; Docetaxel, Paclitaxel, nab-paclitaxel ,Vinorelbine, Eribulin, Capecitabine or Gemcitabine
89473269|NCT02514681|Experimental|Trastuzumab+ pertuzumab + chemotherapy|Trastuzumab+ pertuzumab + chemotherapy Chemotherapy regimen is chosen from the following; Docetaxel, Paclitaxel, nab-paclitaxel, Vinorelbine, Eribulin, Capecitabine or Gemcitabine
89473270|NCT04444700|Experimental|Therapeutic anticoagulation|Therapeutic anticoagulation with LMWH or UFH (high dose nomogram). The choice of LMWH versus UFH will be at the clinician's discretion and dependent on local institutional supply. Therapeutic anticoagulation will be administered until discharged from hospital, 28 days or death. If the patient is admitted to the ICU or requiring ventilatory support, we recommend continuation of the allocated treatment as long as the treating physician is in agreement.
89473271|NCT04444700|No Intervention|Standard care|Administration of LMWH, UFH or fondaparinux at thromboprophylactic doses for acutely ill hospitalized medical patients, in the absence of contraindication, is considered standard care.
89537417|NCT03065751|No Intervention|Kontroll|
89473272|NCT04501575|Experimental|Osteopathic consultation|It consists of 1 session. Each osteopathic session is based on a structural evaluation and treatment tailored to the participant-specific complains
89473273|NCT04501575|Sham Comparator|Osteopathic sham consultation|Osteopathic Sham treatment was applied using manual contact on specific bony surfaces using very light pressure. The practitioner was counting the seconds up to 1 minute between the areas where to apply the light touch without any intention to treat or diagnose.
89473274|NCT04501575|No Intervention|Usual Care|Participants will be on a waiting list, and meanwhile, they are advised to deal with their pain in the way they would, but without using any sort of Manual Therapy.
89019549|NCT00312299|Active Comparator|1B|In group 1, 50 eyes will receive round edge PMMA IOL
89473275|NCT02511639|Experimental|Arm A: Everolimus & Aromatase inhibitors|Everolimus 10 mg po daily + Aromatase inhibitors (Exemestane 25 mg po daily or Letrozole 2.5 mg po daily or Anastrozole 1 mg po daily)
89019550|NCT00312299|Experimental|2A|In group 2, 50 eyes will receive square edge PMMA IOL
89019551|NCT00312299|Active Comparator|2B|In group 2, 50 eyes will receive acrysof IOL
89019552|NCT00339768|Experimental|Amox/omepr|2 weeks; placebo controlled
89019553|NCT00339768|Experimental|Garlic|Supplement for 7 years; placebo controlled
89019554|NCT00339768|Experimental|Vitamins|Supplement for 7 years; placebo controlled
89019555|NCT00312455|Experimental|1|Drug Treatment
89019556|NCT00312455|Placebo Comparator|2|Placebo treatment
89019557|NCT00339885||AADM|Family and Population based individuals
89019558|NCT00339885||Action-LADA|Population based individuals
89019559|NCT00339885||D2D 2004|Population based individuals
89019560|NCT00339885||DIAGEN (Dresden Biobank)|Population based individuals
89019561|NCT00339885||FINRISK 1987|Population based individuals
89019562|NCT00339885||FINRISK 2002|Population based individuals; Test DNA
89019563|NCT00339885||Fusion 1|Affected-sib pair (ASP) families and elderly controls
89019564|NCT00339885||Fusion 2|275 Replication ASP Families; Trios
89019565|NCT00339885||Fusion 3|Siblings of FUSION1 families; Spouses, Offspring of 291 FUSION 1 families; Spouses, Offspring of Elderly Controls; Other F1 relatives
89019566|NCT00339885||Fusion 4/5|Spouses, Offspring of FUSION 1 and 2 Families
89019567|NCT00339885||FUSION Finnish Groups|Family and Population based (including METSIM and DR's EXTRA): Tissue samples
89019568|NCT00339885||Health-2000|Population based individuals
89019569|NCT00339885||HUNT 2|Population based individuals
89019570|NCT00339885||METSIM|Population based individuals
89019571|NCT00339885||Savitaipale|Population based individuals
89019572|NCT00339885||UEF - Laakso|Monogenic disease individuals and family members
89473276|NCT02511639|Active Comparator|Arm B: Aromatase inhibitors|Aromatase inhibitors (Exemestane 25 mg po daily or Letrozole 2.5 mg po daily or Anastrozole 1 mg po daily)
89019573|NCT00343200|Placebo Comparator|Placebo|
89019574|NCT00343200|Experimental|Sildenafil|
89019575|NCT00312962|Active Comparator|1|Participants will use commercially available computer games
89019576|NCT00312962|Experimental|2|Participants will receive targeted cognitive training with neuroplasticity-based software created by Posit Science Corporation
89019577|NCT00343239|Experimental|Docetaxel/Cisplatin/Fluorouracil (DCF)|DCF combination for three 21-day cycles unless a disease progression is observed at the tumor assessment scheduled after the second cycle or due to patient intolerability
89019578|NCT00313157|Active Comparator|Metoprolol|Treatment with Metoprolol 100 mg x 1 for three weeks
89019579|NCT00313157|Active Comparator|Diltiazem|Treatment with Diltiazem 360 mg x 1 for three weeks
89019580|NCT00313157|Active Comparator|Verapamil|Treatment with Verapamil 240 mg x 1 for three weeks
89019581|NCT00313157|Active Comparator|Carvedilol|Treatment with Carvedilol 25 mg x 1 for three weeks
89019582|NCT00343395|Active Comparator|Avandamet|AVANDAMET 2/500 mg
89019583|NCT00343395|Placebo Comparator|Placebo|
89019584|NCT00347763|No Intervention|control|no active fly spray intervention
89019585|NCT00347763|Active Comparator|intervention|aerial spray of permethrin daily for two weeks and weekly as needed by assessment of fly density
89019586|NCT00313235|Experimental|DC Vaccine and Cyclophosphamide|"Autologous dendritic cells (DC) are derived from PBMC, cultured with cytokines, pulsed ex vivo with irradiated allogeneic (Colo 829) melanoma cells. About 15 x 10^6 dendritic cells will be injected subcutaneously, in 3 separate sites (3.3 ml/site).~Patients will receive a total of 7 doses of the vaccination. Each individual dose will be administered at weeks: 0, 2, 4, 6, 11, 14, and 18. Patients with SD, PR according to RECIST criteria may receive 4 more vaccines at 36, 48, 60 and 72 weeks. Patients with CR will receive 4 additional vaccines at 36, 48, 72, and 96 weeks.~CPA will be administered 300mg/m2, intravenously over a 2-hour infusion 24 hours prior to DC vaccinations # 1, 3, 5, 6 and 7. Frequency of CPA administration might be increased based on their T cell measure."
89019587|NCT04715334|Experimental|Single arm study|The intervention is the Mollii suit which is fitted and programmed by the Mollii suit distributor, Inerventions and will be administered by trained physiotherapists from KKH. Participants will be involved in the Intervention phase of the study for 4 weeks with treatment duration of 60 min/ session every day.
89019588|NCT00347997|Experimental|LASIK|LASIK correction of myopia and myopic astigmatism
89019589|NCT00348036|Experimental|Group therapy|Participants will receive interpersonal group therapy.
89019590|NCT00348036|Active Comparator|Control|Participants will receive information only on PTSD.
89019591|NCT00348075|Experimental|Neurovision|
89019592|NCT00313430||Dialysis patients|
89019593|NCT00313430||with or wthout glucose added to dialysis fluid|
89019594|NCT00348153|Experimental|Adalimumab + corticosteroids + immunosuppressive treatments|Adalimumab 40 mg eow, stable immunosuppression, corticosteroids in 1 mg/kg/Bodyweight (max. 80 mg) and taper
89019595|NCT00348153|Active Comparator|immunosuppressive treatment + corticosteroids|corticosteroids upped to 1mg/kg/Bodyweight and taper, stable immunosuppressive treatment
89537418|NCT02464397|Experimental|OPTIMAX-BAS 1|Titanium-nitride-oxide coated cobalt-chromium OPTIMAX™ bio-active stent (BAS). Patients will have OCT follow-up 1 month after the index procedure.
89473277|NCT03068000|Experimental|Judo training|Judo intervention will take place twice a week, lasting 50 minutes per session, for 3 months, divided into general exercises: warm-up and stretching specific to the sport; Specific exercises of the sport: shock absorption, falls cushioning (Ukemi-waza), immobilization techniques (hon-kesa-gatame and tate-shiho-gatame) and projection (o-soto-gari, o-goshi, ashi-guruma, koshi-guruma, tai-otoshi and others); And fight simulation: randori.
89473278|NCT03068000|Active Comparator|Ball games|The Ball Games will take place twice a week, with a duration of 50 minutes per session, for 3 months, divided into general exercises: heating and specific stretching with ball; Specific exercises of the sport: fundamentals of sports with ball, exercises with ball; And games: games will be given at the end of the lesson to work out all the fundamentals and specific exercises in general.
89473279|NCT02514603|Experimental|Prexasertib|Prexasertib intravenously (IV) on day 1 of a 14 day cycle. Treatment with prexasertib may continue until disease progression, unacceptable toxicity, or other discontinuation criteria are met.
89473280|NCT05091320|Active Comparator|Mechanical thrombectomy|this arm will include all patient underwent mechanical thrombectomy, either alone or after failure of medical treatment.
89473281|NCT05091320|Active Comparator|medical managemnet|this arm will include all patients who received medical treatment only, either anti-platelet or alteplase.
89473282|NCT02511483|Placebo Comparator|IV-PCA morphine + Placebo PO|"Pain control after surgery will be performed through IV-PCA morphine. Placebo will be administered with the same schedule of Propranolol in the experimental arm.~Parallel evaluation of Quantitative Sensory Testing (QST), Psychometric assessment and COMT-haplotypes will be included along the trial."
89473283|NCT02511483|Experimental|IV-PCA morphine + Propranolol PO|"The morning of the surgery a dose of Propranolol 20 mg PO will be administered. After surgery pain control will be performed with IV-PCA morphine; in addition a second dose of Propranolol 20 mg PO will be administered .~During the first and second postoperative day Propranolol 30 mg PO (BID) will be administered. Parallel assessment of Quantitative Sensory Testing (QST), Psychometric assessment and COMT-haplotypes will be included along the trial."
89473284|NCT05091164|Experimental|Moderate obstructive sleep apnea syndrome patient under hypnosis|"Patients suffering from moderate obstructive sleep apnea syndrome. It is proposed to induce in the patient a hypnotic trance leading to intense muscle relaxation, capable of reproducing in the upper airways.~The type of collapsibility thus obtained, classified according to Kezirian (6), will allow specific management by OAM in the event of predominant anteroposterior stenosis."
89473285|NCT04501341|Experimental|BM-MNC experimental|Autologue bone marrow mononuclear cell
89473286|NCT04501341|Experimental|UC-MSC|Umbilical cord mesenchymal stem cell
89473287|NCT04437758|Experimental|Hydrolyzed collagen and Vitamin C powder mix|20 g hydrolyzed collagen + 50 mg vitamin C (ascorbic acid) pre-packed powder diluted in 250 ml (8 oz) of water
89473288|NCT04437758|Placebo Comparator|Maltodextrin powder|20 g maltodextrin pre-packed powder diluted in 250 ml (8 oz) of water
89473289|NCT04429802|Placebo Comparator|Placebo|Placebo is an opaque empty gel capsule obtained from the UZ Gasthuisberg pharmacy. These capsules are composed of 100% gelatine that will rapidly dissolve (disintegration time is 15 minutes) in the stomach without affecting the gastric motor function.
89473290|NCT04429802|Experimental|Prucalopride|2 mg, Resolor®, Shire, Belgium Prucalopride (2 mg) is rapidly absorbed; after a single oral dose of 2 mg Cmax was attained in 2-3 hours. The absolute oral bioavailability is >90%. Concomitant intake of food does not influence the oral bioavailability of prucalopride.
89473291|NCT02511405|Experimental|Arm 1|VB-111 + Bevacizumab
89473292|NCT02511405|Active Comparator|Arm 2|Bevacizumab
89473293|NCT04387760|Experimental|Hydroxychloroquine|Hydroxychloroquine is widely used to treat autoimmune diseases, due to its immunomodulatory properties, such as systemic lupus erythematosus and rheumatoid arthritis, with an excellent safety profile. In vitro studies have suggested that their mode of action in COVID-19 disease is blockade of SARS-CoV-2 transport from endosomes to endolysosomes, which appears to be a requirement to release the viral genome.
89473294|NCT04387760|Experimental|Favipiravir|Favipiravir is an antiviral drug that it is a pyrazinecarboxamide derivative with activity against influenza viruses, west nile virus, yellow fever virus, foot and mouth disease virus as well as against flaviviruses (i.e. arenaviruses, bunyaviruses and alphaviruses).
89473295|NCT04387760|Active Comparator|Standard clinical care|Supportive care according to local guidelines
89473296|NCT02514291|Experimental|Sleep intervention|Standard pediatric neurology care plus education and augmented support around adequate sleep habits, appropriate daylight exposure, and beneficial and safe physical activity tailored to each epileptic child's capabilities.
89473297|NCT02514291|No Intervention|Standard care|Standard pediatric neurology care
89473298|NCT05375396|Active Comparator|Streptococcus salivarius M18 lozenges|Streptococcus salivarius M18 lozenges containing dairy based Streptococcus salivarius M18
89473299|NCT05375396|Active Comparator|Streptococcus salivarius M18 dairy free lozenges|Streptococcus salivarius M18 lozenges containing dairy free Streptococcus salivarius M18
89473300|NCT02511327||Preterm born infants of vaccinated women|Preterm born infants (< 37 weeks of gestation) whose mothers have received an acellular pertussis vaccine during pregnancy, within the national recommended vaccination programme. Infant vaccination against pertussis is performed according to the national recommended schedule.
89473301|NCT02511327||Term born infants vaccinated women|Term born infants (>= 37 weeks of gestation) whose mothers have received an acellular pertussis vaccine during pregnancy, within the national recommended vaccination programme. Infant vaccination against pertussis is performed according to the national recommended schedule.
89473302|NCT02511327||Term born infants unvaccinated women|Term born infants (>= 37 weeks of gestation) whose mothers have not received an acellular pertussis vaccine during pregnancy. Infant vaccination against pertussis is performed according to the national recommended schedule.
89473303|NCT02511327||Preterm born infants unvaccinated women|Preterm born infants (< 37 weeks of gestation) whose mothers have not received an acellular pertussis vaccine during pregnancy.Infant vaccination against pertussis is performed according to the national recommended schedule.
89473304|NCT02511171|No Intervention|No intervention|Subjects do not receive osteopathic care
89473305|NCT02511171|Experimental|Cranial osteopathic manipulative treatment|Subjects receive individualised osteopathic treatment
89473306|NCT05091086|Active Comparator|Persistent treatment of Denosumab:|persistent denosumab for 7 years
89473307|NCT05091086|Experimental|Alternating treatment of Denosumab and Zoledronic acid|alternating treatment of Denosumab and Zoledronic acid for 7 years
89473308|NCT02511249||cohort|"1 evaluation day : The evaluation team included a neuropsychologist, a speech therapist and either a pediatric neurologist or a pediatric physical and rehabilitation medicine practitioner.~tests carried out : Global intellectual functioning (WISC-IV), Oral language (N-EEL), Gross and fine motor abilities (clinical examination, Box & Block test, 9 Hole Peg test)"
89473309|NCT05091008|Active Comparator|HCV without co-morbidities|Ledipasvir-Sofosbuvir fixed-dose combination one tablet (90 mg Ledipasvir, 400 mg Sofosbuvir), orally once daily at a fixed time with or without food for 12 weeks
89473310|NCT05091008|Active Comparator|HCV with co-morbidities|Ledipasvir-Sofosbuvir fixed-dose combination one tablet (90 mg Ledipasvir, 400 mg Sofosbuvir), orally once daily at a fixed time with or without food for 12 weeks
89473311|NCT03346551|Experimental|women with postnatal depression|
89473312|NCT03346551|Other|women without postnatal depression|
89473313|NCT02918084|Sham Comparator|ARM A|Adjuvant chemotherapy → Aromatase inhibitors x 5 yrs (sequential arm)
89473314|NCT02918084|Experimental|ARM B|Adjuvant chemotherapy + Aromatase inhibitors x 5 yrs (concurrent arm)
89473315|NCT03346473||Adolescents aged 12-15 years in LMICs|No interventions administered
89473316|NCT02514213|Experimental|Arm A|2mg INO-5150 and electroporation device CELLECTRA®-5P
89473317|NCT02514213|Experimental|Arm B|8.5mg INO-5150 and electroporation device CELLECTRA®-5P
89473318|NCT02514213|Experimental|Arm C|2mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5P
89473319|NCT02514213|Experimental|Arm D|8.5mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5P
89473320|NCT02514135||Elevated Intra-abdominal Pressure|Patients with intra-abdominal pressure > 12 mmHg at any time throughout admission
89473321|NCT02514135||Normal Intra-abdominal Pressure|Patients with intra-abdominal pressure < 12 mmHg throughout admission
89473322|NCT02513979|Active Comparator|angiotensin type II receptor antagonists|Hypertensive patients treated with angiotensin type II receptor antagonists
89473323|NCT02513979|No Intervention|No treatment|Normotensive patients
89473324|NCT01603082|Experimental|Ticagrelor|Ticagrelor - 180 mg loading dose
89473325|NCT01603082|Active Comparator|Clopidogrel|Clopidogrel - 600 mg loading dose
89473326|NCT02511093|Experimental|TBC intervention|"A structured collaborative intervention delivered by trained nurses of ambulatory clinics and by community pharmacists working in collaboration with physicians during 6-month of follow-up includes:~BP measurements;~an educational and counselling intervention on patient adherence;~an educational and counselling intervention on lifestyle (physical activity and diet).~Physicians adjust antihypertensive medications based on nurse and pharmacist feedback."
89473327|NCT02511093|No Intervention|Usual care|
89473328|NCT04499313|Active Comparator|Group A: Dexamethasone|Dexamethasone (20 mg/iv/daily/from Day 1 of randomization, followed by a tapering dose according to the patient's condition.
89473329|NCT04499313|Active Comparator|Group B: Methylprednisolone|Methylprednisolone Sodium Succinate at a dose of 0.5mg/kg (Injectable solution)
89473330|NCT04331756|Other|Guiding Emergence From Anaesthesia Without Tragus Pressure|Monitoring of patients and removal of laryngeal mask airway (LMA) as per routine practice in post anaesthesia care unit (PACU)
89473331|NCT04331756|Experimental|Guiding Emergence From Anaesthesia With Tragus Pressure|Tragus pressure documentation of planes of emergence from anaesthesia - regular 3-5 minutes follow up with Tragus pressure till removal of airway device or rejection of it by patient
89473332|NCT02514057||Healthy|Volunteers over 18 years
89473333|NCT02514057||Gastrointestinal disorders|Over 18 and with any gastrointestinal or liver disorder
89473334|NCT02514057||Non-gastrointestinal disorders|Over 18 and with any medical condition requiring hospital attention in which there is no primary gastrointestinal or liver disease
89473335|NCT04499625|Other|Control - Lateral window|Standard surgical technique to access maxillary sinus for sinus floor augmentation procedure.
89473336|NCT04499625|Experimental|Test - Hydrodynamic transalveolar approach|Novel transalveolar approach (using an ultrasonic device) to access maxillary sinus for sinus floor augmentation procedure.
89473337|NCT05376956|Experimental|Muscle Energy Technique|Using Muscle Energy Technique in Individuals With Hamstring Shortness
89473338|NCT05376956|Experimental|Proprioception neuromuscular facilitation (PNF)|Using proprioception neuromuscular facilitation (PNF) in Individuals With Hamstring Shortness
89473339|NCT02510937|Experimental|Low dose CC-90001|Low dose (100 mg) CC-90001 administered orally once daily (QD) for 12 continuous weeks
89473340|NCT02510937|Experimental|High dose CC-90001|High-dose (200 mg) CC-90001 administered orally Once Daily (QD) for 12 continuous weeks
88949298|NCT03875092|Experimental|Pembrolizumab + Chemotherapy|Participants receive pembrolizumab 200 mg by intravenous (IV) infusion prior to chemotherapy on Day 1 of each 21-day cycle for up to 35 cycles PLUS Investigator's choice of paclitaxel (200 mg/m^2 by IV infusion on Day 1 of each 21-day cycle for 4 cycles) or nab-paclitaxel (100 mg/m^2 by IV infusion on Days 1, 8, 15 of each 21-day cycle for 4 cycles) PLUS carboplatin Area Under the Curve (AUC) 6 by IV infusion on Day 1 of each 21-day cycle for 4 cycles.
89473341|NCT05090930|Active Comparator|Intervention team (1/1 group)|"An extracorporeal hemoperfusion device will be installed in the device of the extracorporeal life support system for heart failure...~(10 patients)"
89473342|NCT05090930|Active Comparator|Intervention team (1/2 group)|An extracorporeal hemoperfusion device will be installed in the device of the extracorporeal life support system for pulmonary failure (10 patients).
89473343|NCT05090930|Active Comparator|Intervention team (1/3 group)|An extracorporeal hemoperfusion device will be installed in patients before/during the implantation of a left ventricular accessory (5 patients).
89473344|NCT05090930|Active Comparator|Intervention team (1/4 group)|An extracorporeal hemoperfusion device will be installed in patients during operations with prolonged artificial circulation, hypothermia, and circulatory arrest. (25 patients).
89473345|NCT05090930|Active Comparator|Intervention team (2/1 groups)|"An extracorporeal hemoperfusion device will be installed in the device of the extracorporeal life support system for heart failure.~(10 patients)"
89473346|NCT05090930|Active Comparator|Intervention team (2/2 groups)|"An extracorporeal hemoperfusion device will be installed in the device of the extracorporeal life support system for pulmonary failure.~(10 patients)"
89473347|NCT05090930|Active Comparator|Intervention team (2/3 groups)|An extracorporeal hemoperfusion device will be installed in patients before/during the implantation of a left ventricular accessory (5 patients)
89473348|NCT05090930|Active Comparator|Intervention team (2/4 groups)|An extracorporeal hemoperfusion device will be installed in patients during operations with prolonged artificial circulation, hypothermia, and circulatory arrest. (25 patients)
89473349|NCT02510859|Experimental|Systematic nutritional consultation at home|"Patients will be followed by a dietician at the patient's home at weeks 2 (S2) and 4 (S4) of radiotherapy, then at the end of radiotherapy at T0. Monitoring will be continued 15 days after the end of irradiation and then one month (T1 and 2 months (T2). A personalized follow will be performed and a document entitled Dietary own program will be given to the patient."
88949299|NCT03875092|Active Comparator|Chemotherapy|Participants receive normal saline by IV infusion prior to chemotherapy on Day 1 of each 21-day cycle for up to 35 cycles PLUS Investigator's choice of paclitaxel (200 mg/m^2 by IV infusion on Day 1 of each 21-day cycle for 4 cycles) or nab-paclitaxel (100 mg/m^2 by IV infusion on Days 1, 8, 15 of each 21-day cycle for 4 cycles) PLUS carboplatin AUC 6 by IV infusion on Day 1 of each 21-day cycle for 4 cycles.
88949300|NCT03863041|Other|Additional MRI SCAN sequence|Additional sequence performed during MRI scan
88949301|NCT03862833|Experimental|experimental group|"Zoledronic acid and IL-2 Zoledronic acid: 4 mg~Three IL2 levels will be tested:~Level 1: 2 millions UI/Infusion Level 2: 4 millions UI/Infusion Level 3: 6 millions UI/Infusion"
88949302|NCT03862833|No Intervention|control group|no experimental treatment
88949303|NCT03859063|Experimental|Intervention|Regular follow up by a community based stroke coordinator
88949304|NCT03859063|Active Comparator|Control|Usual care
88949305|NCT03856892|Experimental|Active Study Group|"Participants randomized to the Active Study Group are asked to follow a daily routine of the three protocols of psycho-physical yoga component techniques: Slow Engaged Dynamic Asana (SEDA), Breath Regulated Engaged Meditation (BREM), Sound Heart Engaged Meditation (SHEM). This intervention involves more hours in daily practice to equate to a high dose of breath and meditative techniques."
88949306|NCT03856892|Active Comparator|Active Control|"Participants randomized to the Active Control study arm are asked to follow a daily routine of low-to mid-intensity body posture practice that is body-based and has minimal breath or meditative elements. This intervention involves fewer hours in daily practice to equate to a medium dose of body focused techniques"
89473350|NCT02510859|No Intervention|Traditional nutritional follow up|Traditional nutritional follow up that is to say with a nutritional consultation before starting treatment and then when necessary on medical advice
88949307|NCT03856892|No Intervention|Passive Control|Participants randomized to the Passive Control study arm do not receive a study intervention.
89019596|NCT00313508|Experimental|A: Peptide-pulsed DC, ALI and Low Dose Fludarabine|Fludarabine: 5 mg/m^2/day, Auto Lymphocyte Infusion, DC Infusion
89473351|NCT02510781|Experimental|A group|docetaxel+carboplatin+trastuzumab
89473352|NCT02510781|Active Comparator|B group|Epirubicin+docetaxel+trastuzumab-docetaxel+trastuzumab
89473353|NCT03578653|Experimental|Merging Yoga and Occupational Therapy for Parkinson disease|The group participates in three assessment periods: August, October, and December. Then in October-December the group will receive group occupational therapy and recommended community adaptive yoga programming 2x/week for 8 weeks.
89473354|NCT03121599|Experimental|18F-FLT PET/CT|"Patients undergo 18F-FLT (3'-18Fluoro-3'-deoxy-Lthymidine) PET/CT (Positron Emission Tomography/ Computed Tomography) at baseline. No specific dietary restrictions or hydration are required for FLT-PET scans, however, patients will be urged to drink plenty of water before and after the PET studies. [18F] FLT will be prepared by the cyclotron core facility and assessed for quality control following good manufacturing practice criteria. The radiopharmaceutical will immediately be brought to the Molecular Imaging and Therapy Service Radiopharmacy for dispensation in the PET suite. For each scan, patients will receive approximately up to 370 MBq (target of 10 mCi) [18F] FLT by intravenous infusion."
89473355|NCT03576235|Experimental|a treatment group|PG102P 1.5 g/day
88949308|NCT03847467|Experimental|2'-Fucosyllactose|"Phase I: 36 young adult participants aged 18-25 years. Group 1: 1 gm per day n=12 (6UC/6CD) Group 2: 5 gm per day n=12 (6UC/6CD) Group 3: 10 gm per day n=12 (6UC/6CD)~Phase II (post Phase I interim safety analysis): 120 participants aged 11-25 years Group 1: 1 gm per day n=40 (20UC/20CD) Group 2: 5 gm per day n=40 (20UC/20CD) Group 3: 10 gm per day n=40 (20UC/20CD)"
89473356|NCT03576235|Placebo Comparator|a control group|placebo
89473357|NCT02510547|Active Comparator|CrossBoss Catheter|Crossing the CTO with upfront use of the CrossBoss catheter
89473358|NCT02510547|Active Comparator|Antegrade Wire Escalation Strategy|Crossing the CTO with upfront antegrade wire escalation strategy
89473359|NCT04437524|Active Comparator|balance-proprioception exercises group|balance-proprioception exercises group
89473360|NCT04437524|Active Comparator|aerobic exercises group|aerobic exercises group
89473361|NCT03576079|Experimental|Laser therapy|12 laser sessions over 3 months
89473362|NCT03576079|Active Comparator|anterior re-positioning splint therapy|anterior re-positioning splint worn for 8 hours during night time for 3 months
89473363|NCT03576079|Placebo Comparator|inactive laser therapy|placebo laser for 12 sessions over 3 months
89473364|NCT02035735|Experimental|Videoendoscopy with WL and NBI|The day before the laryngoscopy under general anesthesia (LGA), two endoscopies by two different physicians were performed for each patients and recorded: the first one with white light (WL) and the second one with NBI (NBI).
89473365|NCT02513589|Experimental|Experimental arm|
89473366|NCT03575923||Intervention site 1|2 planted trees; bulb planting
89473367|NCT03575923||Comparison site 1A|
89473368|NCT03575923||Comparison site 1B|
89473369|NCT03575923||Intervention site 2|12 planted trees; bulb planting; artificial tree decorations (string lights)
88949309|NCT03847467|Placebo Comparator|Placebo|"Phase I: 20 young adult participants age 18-25 years dosed at 2 gm placebo per day. (10UC/10CD)~Phase II (post Phase I interim safety analysis): 40 participants age 11-25 years dosed at 2 gm placebo per day. (20UC/20CD)"
88949310|NCT03829319|Experimental|Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Lenvatinib|Participants receive carboplatin Area Under Curve 5 mg/mL/min (AUC5) or cisplatin 75 mg/m^2 via intravenous (IV) infusion on Day 1 of each 3-week cycle (Q3W) for 4 cycles PLUS pemetrexed 500 mg/m^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS lenvatinib via oral capsule once daily for up to 2 years.
88949311|NCT03829319|Placebo Comparator|Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Placebo|In Parts 1 and 2: Participants receive carboplatin AUC5 or cisplatin 75 mg/m^2 via IV infusion Q3W for 4 cycles PLUS pemetrexed 500 mg/m^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS (Part 2 only) placebo matching lenvatinib via oral capsule once daily for up to 2 years.
88949312|NCT03824652|Experimental|Usual Diet + Walnuts|Usual diet with the addition of two ounces of walnuts daily, phone counseling with dietitian, for 4-10 weeks
88949313|NCT03824652|Active Comparator|Usual Diet|Usual diet for 4-10 weeks
88949314|NCT03800823|Experimental|Parent group & mHealth component|The intervention in the present study is a 10 week parent training group session (More and Less Program) followed by a 6-month mobile phone based intervention. Both components aim to develop healthy lifestyle behaviours regarding dietary habits and physical activity in 2-6 year olds. The intervention is delivered towards the parents.
88949315|NCT03800823|Active Comparator|Standard care|Standard care for overweight and obesity
88949316|NCT03776318||Safety Group|STX-015-18-01 Clonidine Micropellet long-term safety follow-up
88949317|NCT03776318||Sham Control|STX-015-18-01 Sham control long-term safety follow-up
88949318|NCT03774485||Healthy controls|Record gastrointestinal motility by G-Tech Gutcheck Myoelectric recording device in healthy controls. The investigator does not change the routine medical care of study participants.
88949319|NCT03774485||Crohn's disease (remission state)|Record gastrointestinal motility by G-Tech Gutcheck Myoelectric recording device in subjects with Crohn's disease (remission state). The investigator does not change the routine medical care of study participants.
89019597|NCT00313508|Experimental|B: Peptide-pulsed DC, ALI and High Dose Fludarabine|Fludarabine: 25 mg/m^2/day, Auto Lymphocyte Infusion, DC Infusion
89019598|NCT00343980|Experimental|A|
89473370|NCT03575923||Comparison site 2A|
89473371|NCT03575923||Comparison site 2B|
89473372|NCT03575923||Intervention site 3|3 planted trees; artificial tree decorations (string lights, tree socks)
89473373|NCT03575923||Comparison site 3A|
89473374|NCT03575923||Comparison site 3B|
89473375|NCT03575923||Intervention site 4|8 planted trees; bulb planting; artificial tree decorations (string lights, tree socks)
89473376|NCT03575923||Comparison site 4A|
89473377|NCT03575923||Comparison site 4B|
89473378|NCT03575845|Experimental|Occupational therapy informed yoga|Occupational therapists adapted postures to meet the abilities and rehabilitation needs of individual breast cancer survivors engaging in group-delivered yoga sessions
89473379|NCT03949868|Experimental|High Mindfulness|All participants in this condition will complete all measures online and over the phone at two points in time, including one narrative response at T1. They will also be instructed to complete a mindfulness intervention at home and respond to diary-type text messaging questions (all including questions about memory performance) twice daily for six days.
89473380|NCT03949868|Experimental|Low Mindfulness|All participants in this condition will complete all measures online and over the phone at two points in time, including one narrative response at T1. They will also be instructed to respond to diary-type text messaging questions (some related to memory performance) twice daily for six days.
89537419|NCT02464397|Active Comparator|SYNERGY-EES 1|SYNERGY™ everolimus eluting stent (EES). Patients will have OCT follow-up 1 month after the index procedure.
89019599|NCT00343980|Active Comparator|B|
89019600|NCT00313976|Experimental|Arm 1|
89473381|NCT03949868|Active Comparator|Active control|All participants in this condition will complete all measures online and over the phone at two points in time, including one narrative response at T1. They will also be instructed to respond to diary-type text messaging questions (none about memory performance) twice daily for six days.
89473382|NCT03574675|Experimental|Order Sham/Hypoxia|"The participants will be consecutively exposed to shamed hypoxia (FiO2: 20.9%) equivalent to sea level and to simulated altitude (FiO2: 15.1%) equivalent to 2500m above sea level administered by an altitude simulator (Altitrainer, SMTEC) with a facemask."
89473383|NCT03574675|Experimental|Order Hypoxia/Sham|"The participants will be consecutively exposed to hypoxia (FiO2: 15,1%) equivalent to 2500m above sea level and to shamed hypoxia (FiO2: 20.9%) equivalent to sea level administered by an altitude simulated (Altitrainer, SMTEC) with a facemask."
89473384|NCT02513901|Experimental|Chidamide|"Step 1 - Six participants will receive Chidamide 10 mg twice a week(BIW) for 4 consecutive weeks.~Step 2 - Another six participants will receive Chidamide 30 mg twice a week(BIW) for 4 consecutive weeks.~Participants will be enrolled into Step 1 first; if the dose given to Step 1 is well tolerated and no safety concerns are noted, Step 2 will be enrolled."
89019601|NCT00313976|Experimental|Arm 2|
89019602|NCT00314054|Experimental|1|HCV-796 1000mg single dose
89019603|NCT00348387|Experimental|Group 1|
89019604|NCT00348387|Active Comparator|Group 2|
89019605|NCT00314171|Experimental|Brinzolamide + Timolol|
89019606|NCT00314171|Active Comparator|Dorzolamide + Timolol|
89019607|NCT00344214|Experimental|1|Participants will receive the tri-focal cognitive behavioral therapy - social skills training counseling program
89019608|NCT00344214|Active Comparator|2|Participants will receive the standard care comparison condition
89019609|NCT00344253|Experimental|1|Interferon beta 3x weekly
89019610|NCT00344253|Active Comparator|2|Methotrexate sc 20 mg weekly
89473385|NCT04535258|Other|First-movers|The first four alcohol clinics offers internet-based treatment to the patients who chooses the proportion of internet-based sessions.
89473386|NCT04535258|Other|Second-movers|After three months, the next five alcohol clinics offers internet-based treatment to the patients who chooses the proportion of internet-based sessions.
89473387|NCT04535258|Other|Third-movers|After three months, the next five alcohol clinics offers internet-based treatment to the patients who chooses the proportion of internet-based sessions.
89473388|NCT04535258|Other|Fourth-movers|After three months, the last four alcohol clinics offers internet-based treatment to the patients who chooses the proportion of internet-based sessions.
89537420|NCT02464397|Experimental|OPTIMAX-OCT 6|Titanium-nitride-oxide coated cobalt-chromium OPTIMAX™ bio-active stent (BAS). Patients will have OCT follow-up 6 months after the index procedure.
89537421|NCT02464397|Active Comparator|SYNERGY-EES 6|SYNERGY™ everolimus eluting stent (EES). Patients will have OCT follow-up 6 months after the index procedure.
89537422|NCT02464475|Experimental|OMT|
89019611|NCT04715295|Experimental|Doxycyclin and Rivaroxaban|Oral Doxycyclin 200 mg daily for 7 days with or without Rivaroxaban
89019612|NCT04715295|Active Comparator|National Standard|Hydroxychloroquine 400 mg daily for 5 days in combination with Azithromycin 500 mg on day 1 and 250 mg daily from day 2 through day 5
89019613|NCT00348621|Active Comparator|Visual impairment intervention program|enhanced access to eye care services
89019614|NCT00348621|No Intervention|Usual care|family and nursing home was apprised of ocular exam results; eye care services left to family/nursing home arrangements
89019615|NCT00344565|Placebo Comparator|Placebo|Placebo, was matched to modafinil up to 400 mg/day. Patients also receive motivational interviewing and Cognitive Behavioral Therapy-Relapse Prevention (CBT-RP)
89019616|NCT00344565|Active Comparator|Modafinil|Modafinil (Active comparator). Patients received motivational interviewing and Cognitive Behavioral Therapy--relapse prevention (CBT-RP)
89019617|NCT00348699|Experimental|Treatment (AFP464)|Patients receive AFP464 IV over 3 hours on days 1, 8, and 15. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
89019618|NCT00348738|Experimental|1|Patients assigned to this group are receiving Erythropoietin medication
89019619|NCT00348738|No Intervention|2|control group receiving no treatment
89019620|NCT00315029|Experimental|1|Receives combined patient centred intervention
89019621|NCT00315029|No Intervention|2|Standard treatment
89019622|NCT00348777|Active Comparator|1|group with 18 days thermal cure
89019623|NCT00348777|Sham Comparator|2|group with no thermal cure but only access 3 days to watering place 6 months after inclusion
89019624|NCT04715490|Experimental|The Multimedia Symptom Management Program Intervention|The program is composed of two parts: 1) a face-to-face presentation about the contents of the program, and 2) structured telephone support.
89019625|NCT04715490|Active Comparator|Control group|Participants in the control group will be provided with the HF handbook at the beginning of the 3-month period, and also will be received usual care, which included medical consultations, and two telephone calls.
89019626|NCT02960126|Active Comparator|Intervention: Clopidogrel|Case management with clopidogrel 75mg once daily is provided for stroke prevention in AF patient.
89019627|NCT02960126|Experimental|Control: Aspirin|Usual care with aspirin 100mg once daily is provided for stroke prevention in AF patient.
89537423|NCT02464475|Sham Comparator|Sham|
89473389|NCT03575689|Experimental|Splint|A. The Doyle splint will be places in both nostrils of the patient after septoplasty. The doyle splints will be removed 6 days after surgery as per standard of care. No other procedures will be changed during the surgery.
89473390|NCT03575689|No Intervention|No Splint|B. No Doyle splints will be placed in the nostrils of the patient after septoplasty. All standart of care visits will remain the same.
89473391|NCT02510469|Experimental|Apatinib Maintenance Therapy After Adjuvant Chemotherapy|Apatinib Mesylate Tablets 500 mg qd p.o. after XELOX Adjuvant Chemotherapy (Capectabine 1000mg/m2 po bid d1-14, oxaliplatin 130mg/m2 iv d1, q21d)
89473392|NCT02510469|No Intervention|Only Adjuvant Chemotherapy|No Intervention After XELOX Adjuvant Chemotherapy (Capectabine 1000mg/m2 po bid d1-14, oxaliplatin 130mg/m2 iv d1, q21d)
89473393|NCT03578575|Experimental|Danggui Buxue Tang group|Use Danggui Buxue Tang 5g/time, 3 times a day, for 12 weeks.
89473394|NCT03578575|Placebo Comparator|Placebo group|Use Placebo 5g/time, 3 times a day, for 12 weeks.
89473395|NCT02513511|Experimental|Hypnosis|the investigators will put the patient into a hypnotic state and analyze laryngoscopy under hypnosis, followed by intubation.
89473396|NCT02510313|No Intervention|Classic VUP (Control)|Families receive benefits (cash) in exchange for state-sanctioned labour intensive work.
89473397|NCT02510313|No Intervention|Expanded VUP|Families receive benefits (cash) in exchange for state-sanctioned flexible labour within close proximity (2 km) to household. Eligible for variation of minimum graduation package benefits, such as asset transfer, financial literacy, skills training, sensitizations.
89473398|NCT02510313|Experimental|Sugira Muryango & Classic VUP|Families receive combination of Sugira Muryango and benefits (cash) in exchange for state-sanctioned labour intensive work.
89473399|NCT02510313|Experimental|Sugira Muryango & Expanded VUP|Families receive combination of Sugira Muryango and benefits (cash) in exchange for state-sanctioned flexible labour within close proximity (2 km) to household. Eligible for variation of minimum graduation package benefits, such as asset transfer, financial literacy, skills training, sensitizations.
89473400|NCT03574519|Experimental|Non-contingent incentives and weekly feedback|Participants will receive payment for participating in the study (regardless of goal attainment) and will receive weekly updates about their performance.
89473401|NCT03574519|Experimental|Non-contingent incentives and daily feedback|Participants will receive payment for participating in the study (regardless of goal attainment) and will receive daily updates about their performance.
89473402|NCT03574519|Experimental|Contingent incentives and weekly feedback|Participants will receive payment for meeting their daily goals and will receive weekly updates about their performance.
89473403|NCT03574519|Experimental|Contingent incentives and daily feedback|Participants will receive payment for meeting their daily goals and will receive daily updates about their performance.
89473404|NCT02510391|Experimental|PIPA|Modularized treatment for anxiety in children ages 3-7 years old
89473405|NCT03575455|Experimental|Exercise|"Concussed participants will participate in a single 20' bout of treadmill walking at either 40% or 60% of the age-predicted HRmax.~Healthy participants will participate in a single 20' bout of treadmill walking at either 40% or 60% of the age-predicted HRmax."
89473406|NCT03575455|No Intervention|Seated Control|"Concussed participants will participate in a single 20' treatment session of seated rest.~Healthy participants will participate in a single 20' treatment session of seated rest."
89473407|NCT02510235|Experimental|Lubricin|Lubricin 150 µg/ml eye drops solution
89019628|NCT00348855|Experimental|1|"Intervention with one day training, electronic device to measure bood pressure, leaflet with goals and drug strategies according to guidelines, six specific cardiovascular consultations during two years, feed back on results of the intervention group at inclusion, year 1 and year 2.~Specific consultations will be focused on goals to be reach, compliance, exercise and diet."
89019629|NCT00348855|No Intervention|2|
89473408|NCT02510235|Active Comparator|Sodium Hyaluronate|Sodium hyaluronate 0.13% eye drops
89473409|NCT03575377|Experimental|Deterra Bag|These families will receive a Deterra® bag (a drug Disposal Aid) and instructions on its use by a research team member.
89473410|NCT03575377|No Intervention|Control|These families will receive routine postoperative instructions only.
89473411|NCT05081336||High-intensity statin|
89473412|NCT05081336||High-intensity statin plus ezetimib|
89473413|NCT05081336||High-intensity statin plus ezetimib plus PCSK9 inhibitor|
89473414|NCT03575299|Experimental|Study group|Patients will be treated with anti-tuberculosis drugs, and meanwhile will be treated with Allogeneic γδT cells.
89473415|NCT03575299|Placebo Comparator|Control Group|Patients will be treated with anti-tuberculosis drugs, and meanwhile will not be treated with allogeneic γδT cells.
89473416|NCT03712982|No Intervention|Waitlist Control|All participants in this condition will complete all measures online at three different points in time, including one narrative response at T2.
89473417|NCT03712982|Experimental|Attention to Variability - Patient Only|All participants in this condition will complete all measures online at three different points in time, including one narrative response at T2. They will also be instructed to complete a mindfulness intervention at home and respond to diary-type text messaging questions twice daily for two weeks (14 days).
89473418|NCT03712982|Experimental|Attention to Variability - Partner Only|All participants in this condition will complete all measures online at three different points in time, including one narrative response at T2. Partners of the infertile women will also be instructed to complete a mindfulness intervention at home and respond to diary-type text messaging questions twice daily for two weeks (14 days).
89473419|NCT03712982|Experimental|Attention to Variability - Patient & Partner|All participants in this condition will complete all measures online at three different points in time, including one narrative response at T2. All participants (patients and partners) will also be instructed to complete a mindfulness intervention at home and respond to diary-type text messaging questions twice daily for two weeks (14 days).
89473420|NCT03712982|Active Comparator|Infertility Stories - Reading|All participants in this condition will complete all measures online at three different points in time, including one narrative response at T2. They will also be instructed to do an at-home reading activity several times over a period of 2 weeks.
89473421|NCT02239549|Experimental|Jumbo cold forceps polypectomy group|Polypectomy conducted with jumbo cold forceps
89473422|NCT02239549|Experimental|Cold snare polypectomy group|Polypectomy conducted with cold snare
89202519|NCT00663234|Experimental|Age 10 to 14|Participants ages 10 to 14 years receiving oral atorvastatin for 48 weeks while on a stable antiretroviral regimen
89473423|NCT03578497|Experimental|IL-1 receptor antagonist Anakinra 100 mg|Anakinra (Kineret®; r-metHuIL-1ra, Swedish Orphan Biovitrum AB) is a recombinant, non-glycosylated form of the human IL-1Ra in a 100 mg/ 0.67 ml solution for subcutaneous injection. Anakinra/Kineret® is supplied in single use prefilled glass syringes with 27 gauge needles as a sterile, clear, colorless-to-white, preservative free solution for daily s.c. administration over a time period of 28 days.
89473424|NCT03710876|Active Comparator|Treatment Group|rAd-IFN (Study Day 1) + celecoxib oral product (Study Days 1 to 14) + gemcitabine (Study Days 14 and 21 [i.e., Days 1 and 8 of the first gemcitabine treatment cycle], gemcitabine will be repeated every 3 weeks until disease progression/early termination [ET]
89473425|NCT03710876|Placebo Comparator|Control Group|Celecoxib oral product (Study Days 1 to 14) + gemcitabine (Study Days 14 and 21 [i.e., Days 1 and 8 of the first gemcitabine treatment cycle], gemcitabine will be repeated every 3 weeks until disease progression/ET.
89473426|NCT03578341|Experimental|Colostrum|Group 1:(Colostrum): Preterm infants under 32 SDG will receive orally colostrum 0.3 mL every 4 h during three days.
89473427|NCT03578341|Placebo Comparator|Placebo|Group 2: (Placebo): Preterm newborns under 32 SDG who will receive orally sterile water 0.3 mL every 4 h during three days.
89473428|NCT02513433|Active Comparator|Bupivacaine & Levobupivacaine|Bupivacaine 15 ml 0.5% and Levobupivacaine 15 ml 0.5% in epidural route before surgery
89473429|NCT02513433|Active Comparator|Bupivacaine & Ropivacaine|Bupivacaine 15 ml 0.5% and Ropivacaine 15 ml 0.75% in epidural route before surgery
89473430|NCT02513433|Active Comparator|Ropivacaine & Levobupivacaine|Ropivacaine 15 ml 0.75% and Levobupivacaine 15 ml 0.5% in epidural route before surgery
89473431|NCT03567590|Experimental|Pulsed Radiofrequency Group|This group will undergo pulsed radiofrequency treatment.
89473432|NCT03567590|Active Comparator|Nerve Block Group|This group will undergo nerve block treatment.
89473433|NCT03780387|Experimental|Inhaled Allergen Challenge|Felis Catus sensitive, mild asthmatics will undergo inhaled allergen challenge.
89473434|NCT02846779|Active Comparator|Low intensity|All participants randomized to this arm will receive quarterly educational mailings and limited telephonic outreach delivered by a pharmacist focused on insulin adherence and glycemic control.
89473435|NCT02846779|Experimental|Moderate intensity|Participants will receive all intervention components as in the low-intensity arm but will receive more frequent pharmacist follow-up and the option of enrolling in a text-messaging program. The pharmacist will also provide limited follow-up with the participant's provider. Only 60% of participants randomized will be targeted to receive the intervention based on adherence risk score.
89473436|NCT02846779|Experimental|High intensity|Participants will receive all intervention components as in the moderate-intensity arm but will receive more frequent pharmacist follow-up. The pharmacist will also provide more follow-up with the participant's provider and/or pharmacist. Only 40% of participants randomized will be targeted to receive the intervention based on adherence risk score and baseline disease control.
89473437|NCT02510157|Active Comparator|dexamethasone|Dexamethasone is administered intravenously before induction of anaesthesia. Deep neuromuscular blockade is induced with rocuronium and is assessed by acceleromyography (post-tetanic count stimulation) on the ulnar nerve of the patient's hand. At the end of surgery, sugammadex 4 mg/kg is administered to reverse neuromuscular blockade.
89473438|NCT02510157|Placebo Comparator|normal saline|Normal saline is administered intravenously before induction of anaesthesia. Deep neuromuscular blockade is induced with rocuronium and is assessed by acceleromyography (post-tetanic count stimulation) on the ulnar nerve of the patient's hand. At the end of surgery, sugammadex 4 mg/kg is administered to reverse neuromuscular blockade.
89473439|NCT05376332|Experimental|Sonomyographic control|Sonomyographic control involves the use of ultrasound signals from muscle deformation to control a prosthetic hand.
89473440|NCT05376332|Active Comparator|Myoelectric control|Myoelectric control involves the use of surface electromyography signals from muscle activation to control a prosthetic hand.
89473441|NCT03478592|Experimental|reference technique slow freezing|In reference technique slow freezing arm, embryon will be frozen with the conventional slow freezing procedure with the Freezal device apply a slow decreasing in temperature with moderate cryoprotector concentration
89473442|NCT03478592|Experimental|vitrification technique|In vitrification technique arm, embryon will be frozen with automated vitrification system
88949320|NCT03774485||Crohn's disease (flare state)|Record gastrointestinal motility by G-Tech Gutcheck Myoelectric recording device in subjects with Crohn's disease (flare state). The investigator does not change the routine medical care of study participants.
88949321|NCT03755388|Experimental|Episealer group|Subjects with a focal cartilage lesion of the distal femur in which biological surgical methods have failed or are not eligible
88949322|NCT03747159|Experimental|BLM+RTX treatment arm|"Intervention 1 Belimumab injection: subcutaneous weekly injections with 200mg belimumab (BML) for the duration of the entire study period of two years.~Intervention 2 Rituximab infusion: Two intravenously infusions of 1000mg rituximab (RTX) at week 4 and week 6 after the start of belimumab.~Intervention 3: Standard of care: induction therapy with three intravenously infusions methylprednisolone of 1000mg (or 500mg if weight is below 60kg), oral prednisolone 60mg with a quick tapering scheme to reach 5mg in 10 weeks and mycofenolate mofetil start dosis 500mg twice daily with maximum dosis of 2000mg twice daily depending on tolerance and area under curve (AUC) aimed at 60mg*hour/L."
89202520|NCT00663234|Experimental|Age 15 to 23|Participants ages 15 to 23 years receiving oral atorvastatin for 48 weeks while on a stable antiretroviral regimen
89202521|NCT00683384||1|
89202522|NCT00753662|Active Comparator|1|15 patients in group 1 will be treated with 1Hz frequency
89202523|NCT00753662|Active Comparator|2|15 patients in group 2 will be treated with 1Hz frequency 10Hz
89202524|NCT00753662|Sham Comparator|3|15 patients in group 3 will be treated with SHAM (1Hz/10Hz)
89473443|NCT03344978|Active Comparator|Cardboard Cot Care|Stable infant will be nursed in a cardboard cot, lined with reflective film for 24 hour period of time. Infant's axillary temperature will be taken at 1 hour after randomization, at 6 hours after randomization, and 24 hours after randomization. After 24 hours, infant will be swapped to the other arm (Incubator Care), and back for a total of 2 24-hour periods in each arm.
89019630|NCT00344721|Active Comparator|EPA/DHA/flaxseed|Study patients in the active comparator arm will take four soft-gel capsules containing omega-3 fatty acids (a nutritional supplement) orally daily for 3 months. Each daily dose contains eicosapentaenoic acid (450 mg), docosahexaenoic acid (300 mg) and flaxseed oil (1000 mg).
89019631|NCT00344721|Placebo Comparator|Wheat germ oil|Study patients in the placebo arm will take four doses of soft-gel capsules containing wheat germ oil orally daily for 3 months.
89473444|NCT03344978|Placebo Comparator|Incubator Care|Stable infant will be nursed in an incubator for 24 hour period of time. Infant's axillary temperature will be taken at 1 hour after randomization, at 6 hours after randomization, and 24 hours after randomization. After 24 hours, infant will be swapped to the other arm (Cardboard Cot Care), and back for a total of 2 24-hour periods in each arm.
89473445|NCT03345147||Normal Vitamin A intake|Normal Vitamin A intake will be assessed by a questionnaire directed to the consumption of food items with high VA content on the 7 days prior to the questionnaire. The daily consumption will be assessed on average. A child is assigned to Normal Vit. A consumption if daily Vit. A is between 250 and 600 micrograms per day.
89473446|NCT03345147||High Vitamin A intake|High Vitamin A intake will be assessed by a questionnaire directed to the consumption of food items with high VA content on the 7 days prior to the questionnaire. The daily consumption will be assessed on average. A child is assigned to High Vit. A consumption if daily Vit. A is above 900 micrograms per day.
89473447|NCT05375318||Adults patients with astrocytoma grade 4|
89473448|NCT03662919||Flixabi|Infliximab naive participants or participants who were previously treated with other infliximab biologics will receive Flixabi (infliximab) as prescribed by physician according to the local prescribing procedures.
89473449|NCT03662919||Imraldi|Adalimumab naive participants or participants who were previously treated with other adalimumab biosimilars will receive Imraldi (adalimumab) as prescribed by physician according to the local prescribing procedures.
89473450|NCT05375240|No Intervention|Blank-control group|Patients will receive standard treatment.
89473451|NCT05375240|Experimental|Oropranolol group|Propranolol will be administered at a dose of 10mg*3/day over a course of 7 consecutive days after stroke onset.
89473452|NCT05375240|Experimental|Propranolol + ceftriaxone group|Propranolol will be administered at a dose of 10mg*3/day combined with 2g/day ceftriaxone over a course of 7 consecutive days after stroke onset.
89473453|NCT00406393|Active Comparator|Tacrolimus/Methotrexate|Patients will be given Tacrolimus and Methotrexate for GVHD prophylaxis.
89473454|NCT00406393|Experimental|Tacrolimus/Sirolimus|Patients will be given Tacrolimus and Sirolimus for GVHD prophylaxis.
89473455|NCT05065892|Experimental|Hypertension group|Hypertension group will enroll 330 subjects with hypertension (aged 60 years or older).
89473456|NCT05065892|Experimental|Diabetes Mellitus group|Diabetes group will enroll 330 subjects with diabetes (aged 60 years or older).
89019632|NCT00344760|Active Comparator|Standard Treatment|Efavirenz 600mg once daily, Lamivudine 300mg once daily and Tenofovir 300mg once daily
89019633|NCT00344760|Experimental|Standard Treatment Plus Enfuvirtide|Efavirenz 600mg once daily, Lamivudine 300mg once daily, Tenofovir 300mg once daily and enfuvirtide 90mg subcutaneously twice a day until the viral load is less than 50copies for 2 consecutive visits or 12 weeks (whichever comes first).
89019634|NCT00348894|Experimental|Open Treatment|[S,S]-reboxetine
89473457|NCT05065892|Experimental|Combined Disease group|Combined Diseases group will enroll 300 subjects with both hypertension and diabetes (aged 60 years or older).
89473458|NCT05065892|Active Comparator|Healthy people group|Healthy people group will enroll 480 subjects with no medical history of hypertension or diabetes (aged 60 years or older).
89473459|NCT02513355|Experimental|NP(Changchun marina+cisplatin)+Endostar|Patients in this group will be given conventional chemotherapy medicine,NP plan (Changchun marina+cisplatin)recommended by treatment guidelines for Advanced non small cell lung cancer. Endostar 15mg/m2, 21 days per cycle, 4 to 6 cycles;Changchun marina;25mg/m2,d1 and d8,cisplatin 80mg/m2,d1, q21d×4
89473460|NCT02513355|Experimental|TP(Taxol+cisplatin or parapl) +Endostar|"Patients in this group will be given conventional chemotherapy medicine,TP(Taxol+cisplatin)recommended by treatment guidelines for Advanced non small cell lung cancer.~Endostar 15mg/m2, 21 days per cycle, 4 to 6 cycles; Taxol;135-175mg/m2,d1,cisplatin or parapl 75mg/m2,d1,q21d×4."
89473461|NCT03574285|Experimental|Anpl-one SR Tab. 300mg|Anpl-one SR Tab. 300mg tablets followed by Sarpodipil SR Tab. 300mg tablets
89473462|NCT03574285|Active Comparator|Sarpodipil SR Tab. 300mg|Sarpodipil SR Tab. 300mg tablets followed by Anpl-one SR Tab. 300mg tablets
89473463|NCT05051930|Experimental|TQC3721 suspension for inhalation|Participants will receive 0.2 mg/1.0 mg/3.0 mg/6.0 mg/12.0 mg/24.0 mg single dose of TQC3721 suspension for inhalation on Day 1.
89473464|NCT05051930|Placebo Comparator|TQC3721 suspension placebo for inhalation|Participants will receive 0mg single dose of TQC3721 suspension placebo for inhalation on Day 1.
89473465|NCT02509923|Experimental|1|3-way cross-over, Z-215 10 mg/day / Z-215 20 mg/day / Rabeprazole Sodium 10 mg/day
89473466|NCT02509923|Experimental|2|3-way cross-over, Z-215 20 mg/day / Z-215 40 mg/day / Rabeprazole Sodium 20 mg/day
89473467|NCT02509923|Experimental|3|3-way cross-over, Z-215 20 mg/day (before breakfast) / Z-215 20 mg/day (after breakfast) / Rabeprazole Sodium 10 mg/day (after breakfast)
89019635|NCT00348894|Other|Standard Care|Standard Care
89019636|NCT00315575||1|Individuals with high risk for Alzheimer's disease
89473468|NCT03578263|Experimental|carbetocin arm|carbetocin 100 µg diluted in 10 ml normal saline and administered slowly (over 30-60 seconds) intravenously by anesthetist after the birth of the baby
89473469|NCT03578263|Active Comparator|oxytocin and ergometrine arm|oxytocin 5 I.U which was diluted in 10 ml normal saline and administered slowly over (30-60 seconds) intravenously by anesthetist plus intramuscular ergometrine 0.2 mg after the birth of the baby
89473470|NCT05031182|Placebo Comparator|Laparoscopy|In this Arm, patient will have the traditional hysterectomy by laparoscopy. This is the type of surgery that we realize everyday.
89473471|NCT05031182|Active Comparator|vNOTES|In this Arm, patient will have the hysterectomy by vNOTES (vaginal natural orifices Transluminal surgery). It's the new type of surgery that we want prove the no-inferiority.
88949323|NCT03747159|No Intervention|Standard of Care treatment arm|"Intervention 1: Standard of care: induction therapy with three intravenously infusions methylprednisolone of 1000mg (or 500mg if weight is below 60kg), oral prednisolone 60mg with a quick tapering scheme to reach 5mg in 10 weeks and mycofenolate mofetil start dosis 500mg twice daily with maximum dosis of 2000mg twice daily depending on tolerance and area under curve (AUC) aimed at 60mg*hour/L.~Optional intervention: (if patients flare or are non-responders on mycofenolate mofetil + prednisolone) : Two intravenously infusions of 1000mg rituximab at week 4 and week 6 after the start of belimumab."
88949324|NCT03735628|Experimental|Dose escalation|"Copanlisib:~45 mg (dose level -1) or 60 mg (dose level 1) on Day 1, Day 8 and Day 15 (28 day cycle)~Nivolumab:~240 mg on Day 15 of Cycle 1 and on Day 1 and Day 15 of subsequent cycles (28 day cycle)."
88949325|NCT03735628|Experimental|Dose expansion|"Copanlisib:~Recommended phase 2 dose established in the phase 1b part on Day 1, Day 8 and Day 15 (28 day cycle)~Nivolumab:~240 mg on Day 15 of Cycle 1 and on Day 1 and Day 15 of subsequent cycles (28 day cycle)."
88949326|NCT03727100|Active Comparator|Clonidine Micropellets|single dose injection into the lumbar epidural space
88949327|NCT03727100|Sham Comparator|Sham Control|non-epidural needle placement
88949328|NCT03720275|Experimental|patients with chronic neuropathy of unknown aetiology|For the 130 patients with chronic neuropathy of unknown aetiology, the diagnosis of TTR-FAP will be performed using standard procedures following international recommendations, requiring genetic analysis of the TTR gene.
88949329|NCT03694938|Experimental|Magnetic resonance imaging|Annual MRI during 3 years
88949330|NCT03694691|Experimental|Biopsy|Biopsies taken at protocol specified time points
88949331|NCT03685331|Experimental|Phase I Level 0|"(28-day cycle)~Olaparib 300 mg by mouth twice a day, days 1-28; fulvestrant 500 mg intramuscularly, Day 1 + 500 mg intramuscularly Cycle 0 Day 15; palbociclib 75 mg by mouth daily, days 1-21, beginning at cycle 1"
88949332|NCT03685331|Experimental|Phase I Level 1|"(28-day cycle)~Olaparib 300 mg by mouth twice a day, days 1-28; fulvestrant 500 mg intramuscularly, Day 1 + 500 mg intramuscularly Cycle 0 Day 15; palbociclib 100 mg by mouth daily, days 1-21, beginning at cycle 1~Treatment continues until disease progression, unacceptable toxicity, withdrawal of consent, or other protocol-mandated study removal."
88949333|NCT03685331|Experimental|Phase I Level 2|"(28-day cycle)~Olaparib 300 mg by mouth twice a day, days 1-28; fulvestrant 500 mg intramuscularly, Day 1 + 500 mg intramuscularly Cycle 0 Day 15; palbociclib 125 mg by mouth daily, days 1-21, beginning at cycle 1~Treatment continues until disease progression, unacceptable toxicity, withdrawal of consent, or other protocol-mandated study removal."
88949334|NCT03685331|Experimental|Phase II|"(28-day cycle) Olaparib 300 mg by mouth twice a day, days 1-28; fulvestrant 500 mg intramuscularly once monthly on Day 1 of each cycle + 500 mg intramuscularly on Cycle 1 Day 15; palbociclib dose as per maximum tolerated dose determined during Phase I, by mouth daily, days 1-21~Treatment continues until disease progression, unacceptable toxicity, withdrawal of consent, or other protocol-mandated study removal."
88949338|NCT03634072|Other|PVR Arm|PVR arm will undergo PVR via catheter or surgery
88949339|NCT03634072|No Intervention|No PVR|No PVR group will continue with medical management
88949340|NCT03621540|Active Comparator|Verum arm|25 min anodal tDCS + adaptive working memory training
88949341|NCT03621540|Sham Comparator|Sham arm|sham tDCS + adaptive working memory training
88949342|NCT03605719|Experimental|Arm 1|Patients receive dexamethasone IV on days 1, 2, 8, 9, 15, and 16, carfilzomib IV over 30 minutes on days 1, 2, 8, 9, 15, and 16, and nivolumab IV over 30 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88949343|NCT03605719|Experimental|Arm 2|Patients receive dexamethasone IV on days 1, 2, 8, 9, 15, and 16, pelareorep IV on days 1, 2, 8, 9, 15, and 16, carfilzomib IV over 30 minutes on days 1, 2, 8, 9, 15, and 16, and nivolumab IV over 30 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88949344|NCT03605719|Experimental|Arm 3 (expansion)|Patients receive dexamethasone IV on days 1, 2, 8, 9, 15, and 16, pelareorep IV on days 1, 2, 8, 9, 15, and 16, carfilzomib IV over 30 minutes on days 1, 2, 8, 9, 15, and 16, and nivolumab IV over 30 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88949345|NCT03602391|Experimental|SCP Plus|
88949346|NCT03602391|No Intervention|Services as usual|
88949347|NCT03593993||Surgical Cohort|Blood, cerebrospinal fluid, and tumor tissue will be obtained from each participant on this arm.
88949348|NCT03547050||Patients diagnosed with RE|People who meet the eligibility requirements and have been diagnosed with rolandic epilepsy.
88949349|NCT03547050||Controls|People without a lifetime history of seizures.
89473472|NCT02507661|Experimental|alveolar ridge preservation - 2 months|preservation of alveolar ridge with beta tricalcium phosphate + collagen - 2 months
89473473|NCT02507661|Active Comparator|no-preservation of alveolar ridge - 2 months|no-preservation of alveolar ridge - 2 months
89473474|NCT02507661|Experimental|preservation of alveolar ridge - 4 months|preservation of alveolar ridge with beta tricalcium phosphate + collagen - 4 months
89473475|NCT02507661|Active Comparator|no-preservation of alveolar ridge - 4 months|no-preservation of alveolar ridge - 4 months
89473476|NCT02507661|Experimental|preservation of alveolar ridge - 9 months|preservation of alveolar ridge with beta tricalcium phosphate + collagen - 9 months
89473477|NCT02507661|Active Comparator|no-preservation of alveolar ridge - 9 months|no-preservation of alveolar ridge - 9 months
89473478|NCT05009966|Experimental|SYSA1801 for injection|"Stage I: Dose Escalation and dose expansion： Dose Escalation：SYSA1801 will be administered intravenously (IV) at different dose levels, including 0.5, 1, 2, 3, 4.5 and 6 mg/kg according to a modified 3+3 dose-escalation design. Accelerated dose titration design will be used for the first 2 dose levels (0.5 and 1 mg/kg), and then traditional 3+3 dose escalation design will be used for the following levels (2, 3, 4.5 and 6 mg/kg).~Dose expansion: SYSA 1801 will be administered at up to dose levels which is equal or lower than MTD IV infusion. Each dose level contains no more than 12 subjects (including subjects in dose escalation) Stage II: Extension cohort This cohort will comprise subjects with Claudin 18.2 positive GC or GEJ adenocarcinoma, pancreatic cancer or other solid cancer with prior failure of, progression on, or intolerance to, standard therapy.~The starting dose of SYSA1801 for expansion will be derived from the RP2D determined during Stage I"
89473479|NCT02509611|Experimental|Immediate treatment|Participants who are randomly assigned to the immediate treatment group will receive 60-minute biweekly Hatha yoga for 12 weeks.
89473480|NCT02509611|Active Comparator|Waitlist control|Participants who are randomly assigned to the wait-list group will receive no intervention during the first 12 weeks. Not only will they serve as the comparative group, they will also serve as their own control and receive the same yoga intervention at the end of 12 weeks when the immediate treatment group completed their program.
89473481|NCT03174002|Experimental|Low oxygenation target|Partial pressure of oxygen in arterial blood (PaO2) 8 kPa (60 mmHg)
89473482|NCT03174002|Active Comparator|High oxygenation target|Partial pressure of oxygen in arterial blood (PaO2) 12 kPa (90 mmHg)
89473483|NCT02509533|Experimental|V.A.C.® Therapy|In this arm, investigators will use the V.A.C.® Therapy after a transplants of leg ulcers.
89473484|NCT02509533|Active Comparator|usual dressing method (compresses)|In this arm, investigators will use the usual dressing method after a transplants of leg ulcers.
89473485|NCT03572257|Experimental|Quetiapine (0.5 mg/kg TID x 10 days)|This study group will receive treatment with quetiapine after diagnosis of pediatric delirium. Group assignment will be blinded.
89473486|NCT03572257|Placebo Comparator|Placebo|This study group will receive a placebo treatment after diagnosis of pediatric delirium. Group assignment will be blinded.
89473487|NCT03572179|Active Comparator|Treatment Group|After finishing orthodontic treatment, all patient will receive a modified indirect technique for bonding fixed mandibular retainer and the key of modification is the fabrication of 3D printed digital positioning tray for placement of retainer with holes for composite pads for its direct application using 3 shape Ortho analyser Software ® instead of conventional indirect retainer fabrication method
89473488|NCT03572179|No Intervention|Control Group|All patients of this group will follow conventional steps of direct bonding procedure of fixed mandibular retainer
89473489|NCT04498143|Experimental|"Project SAVE (Stop Adolescent Violence Everywhere) SSI"|SAVE is a ~30-minute, self-administered, web-based program that uses components of cognitive behavior therapy and dialectical behavior therapy designed to decrease self-injurious behaviors in youth. The Project SAVE SSI has 4 general content sections: (1) explaining the science behind how changing your actions (i.e. decreasing self-injurious behaviors) can positively impact your emotions over time; (2) providing scientific evidence and testimonials from other teens that have successfully decreased their self-injurious behaviors and noticed positive change as a result; (3) evidence-based tips for overcoming common obstacles to decreasing self-injurious behaviors in day to day life; and (4) offering an opportunity for youth to share their own thoughts and advice on what they have learned with other teenagers who are facing similar challenges.
89473490|NCT04498143|Active Comparator|"Supportive Therapy (Share Your Feelings) SSI"|Supportive Therapy SSI (Schleider & Weisz, 2018): ~30-minute, self-administered, web-based program that uses components of supportive therapy to encourage feelings sharing. The supportive therapy SSI encourages participants in the control group to identify and express their feelings by (1) explaining why sharing feelings is natural, important, and helpful and (2) including testimonials from teens who have shared their feelings with close others.
89473491|NCT05374772||Patient with COVID-19|Mild to moderate COVID-19 patient with at least one risk factor for serve COVID-19 illness or death.
89019637|NCT00315575||2|Individuals with low risk for Alzheimer's disease
89019638|NCT00315692||Premenopausal women|
89019639|NCT00315692||Postmenopausal women|
89473492|NCT02239705||Fluid challenge|Patients whose clinical conditions require bolus of fluids infusion to correct blood pressure and cardiac output
89019640|NCT00349050|Active Comparator|1|laboratory pain assessment
89019641|NCT00349050|Active Comparator|2|transcranial magnetic stimulation
89019642|NCT00349089|Active Comparator|1|Cisplatin/Vinorelbine
89019643|NCT00349089|Experimental|2|Cisplatin/Pemetrexed
89019644|NCT00349167|Experimental|PR-104|PR104 was administered as a 1-hr IV infusion every 21 days at doses ranging from 135 to 1400 mg/m2
89019645|NCT00349206|Experimental|Arm 1|Patients receive temsirolimus IV over 30 minutes on days 1, 8,15, and 22 and oral sorafenib once or twice daily on days 1-28.
89019646|NCT00421395|Experimental|multi|escalating in increments of 2.5 mCi/m2
89019647|NCT00315926|Experimental|Melatonin|
89019648|NCT00315926|Placebo Comparator|Placebo|
89473493|NCT02239705||Inotropic infusion|Patient whose clinical conditions require inotropic agents infusion to correct blood pressure and cardiac output
89019649|NCT00421434|Experimental|Nitazoxanide-Peginterferon|One oral nitazoxanide 500 mg tablet with food twice daily for 12 weeks followed by 36 weeks of one oral nitazoxanide 500 mg tablet plus weekly injections of 180 µg peginterferon alfa-2a.
89019650|NCT00421434|Experimental|Nitazoxanide-Peginterferon-Ribavirin|One oral nitazoxanide 500 mg tablet with food twice daily for 12 weeks followed by 36 weeks of one oral nitazoxanide 500 mg tablet plus weekly injections of 180 µg peginterferon alfa-2a plus oral ribavirin 1000 mg (body weight <75 kg) or 1200 mg (body weight ≥75 kg) daily in two divided doses.
89019651|NCT00421434|Active Comparator|Peginterferon-Ribavirin|Weekly injections of 180 µg peginterferon alfa-2a plus oral ribavirin 1000 mg (body weight <75 kg) or 1200 mg (body weight ≥75 kg) daily in two divided doses for 48 weeks.
89019652|NCT06165796||previous LASIK group|
89019653|NCT06165796||previous non-LASIK group|
89019654|NCT06165731|Experimental|Diaphragmatic Breathing Exercise (DB)|Participants will undergo a total of 10 minutes of at-home diaphragmatic breathing exercises (5 minutes in the morning and 5 minutes in the evening) with the practice of standard bladder hygiene recommendations. Participants will exercise daily for a total of 4 weeks and complete daily exercise logs.
89019655|NCT06165731|Active Comparator|Educational Handout (EH)|Participants assigned to this group will participate in the usual standard care of bladder hygiene, which will include common practices of timed voiding, reduction in constipation, avoidance of bladder irritants, daily recommended aerobic exercise, adequate hydration, and appropriate perineal hygiene. Participants will practice standard bladder hygiene recommendations daily for a total of 4 weeks.
89019656|NCT06165692|Experimental|Test Group|Placement of PRF in the post-extraction socket after third molar surgery
89019657|NCT06165692|No Intervention|Control Group|No positioning PRF in the post-extraction socket after third molar surgery
89019658|NCT06165666|Experimental|intervention group (EG)|The participants will receive as a therapeutic approach 3 physical therapy sessions/week of 40' duration, for 10 weeks.
89019659|NCT06165666|Active Comparator|control group (CG)|The participants will receive as a therapeutic approach 3 physical therapy sessions/week of 40' duration, for 10 weeks.
89019660|NCT06165588||Cyclists|Elite cyclists participating in the Tour de France
89019661|NCT06165523|Placebo Comparator|Water|Water
89019662|NCT06165523|Experimental|Flavored Kefir|1% Lowfat Kefir manufactured by Lifeway Kefir and containing 18 g of CHO, 10 g of protein, and 2 g of fat
89019663|NCT06165523|Active Comparator|Flavored Milk|1% Lowfat Milk manufactured by Prairie Farms and containing 24 g of CHO, 8 g of protein, and 2.5 g of fat
89019664|NCT06165510|Experimental|Convergent AF Ablation with Left Atrial Appendage Exclusion|"Two Staged Convergent AF Ablation Procedure~Stage 1 - Minimally Invasive Surgical Epicardial Ablation Procedure with concomitant LAA exclusion (LARIAT procedure)~Stage 2 - Percutaneous Endocardial Catheter Ablation"
89019665|NCT06165510|Active Comparator|Standard Endocardial Catheter Ablation|Standard Endocardial Catheter Ablation
89019666|NCT06165497|Experimental|Mindfulness, 5 minutes, male voice|Mindfulness meditation, 5 minutes duration, with a male speaker.
89019667|NCT06165497|Experimental|Mindfulness, 10 minutes, male voice|Mindfulness meditation, 10 minutes duration, with a male speaker.
89019668|NCT06165497|Experimental|Mindfulness, 5 minutes, female voice|Mindfulness meditation, 5 minutes duration, with a female speaker.
89019669|NCT06165497|Experimental|Mindfulness, 10 minutes, female voice|Mindfulness meditation, 10 minutes duration, with a female speaker.
89019670|NCT06165497|Experimental|Self-compassion, 5 minutes, male voice|Self-compassion meditation, 5 minutes duration, with a male speaker.
89019671|NCT06165497|Experimental|Self-compassion, 10 minutes, male voice|Self-compassion meditation, 10 minutes duration, with a male speaker.
89019672|NCT06165497|Experimental|Self-compassion, 5 minutes, female voice|Self-compassion meditation, 5 minutes duration, with a female speaker.
89019673|NCT06165497|Experimental|Self-compassion, 10 minutes, female voice|Self-compassion meditation, 10 minutes duration, with a female speaker.
89019674|NCT06165497|Experimental|Gratitude, 5 minutes, male voice|Gratitude meditation, 5 minutes duration, with a male speaker.
89019675|NCT06165497|Experimental|Gratitude, 10 minutes, male voice|Gratitude meditation, 10 minutes duration, with a male speaker.
89473494|NCT02509299|Experimental|Experimental group 1|patients will be involved in the Physiotherapy program 1. The program included 15 minutes of deep breathing exercises and 20-30 minutes of limb exercises. The exercises included global active range of motion (ROM) exercises and muscle strengthening like upper and lower limbs flexion-extension do single-leg stance, and sit to stand exercises added to standard treatment.
89473495|NCT02509299|Experimental|Experimental group 2|patients will be involved in the physiotherapy program 2. The program was a combined intervention including the Control Group treatment plus neuromuscular stimulation therapy on quadriceps accompanied by lower limb exercises.
89473496|NCT02509299|Other|Control group|patients will receive standard medical treatment without physiotherapy intervention.
89019676|NCT06165497|Experimental|Gratitude, 5 minutes, female voice|Gratitude meditation, 5 minutes duration, with a female speaker.
89473497|NCT03140696|Experimental|Chicken egg alone|A chicken egg alone will be offered for 2 days by mouth for once a day
89473498|NCT03140696|Experimental|Egg and RUSF|A chicken egg and Ready to use supplementary food (RUSF) will be offered for 2 days by mouth for once a day
89473499|NCT03140696|Experimental|Egg and breast milk|A chicken egg and Mother's breast milk will be offered for 2 days by mouth for once a day
89473500|NCT02509377|Experimental|BMI 35.0 to 40.0|"Mothers who meet all inclusion exclusion criteria for open fetal repair of myelomeningocele except BMI.~These mothers have a BMI between 35.0 and 40.0"
89473501|NCT02845375|Placebo Comparator|PLACEBO|Placebo (normal saline) will be administered following a period of muscle relaxation after which respiratory measurements will be obtained.
89473502|NCT02845375|Other|NEOSTIGMINE|intravenous neostigmine will be administered following a period of muscle relaxation after which respiratory measurements will be obtained.
89473503|NCT02845375|Experimental|SUGAMMADEX|intravenous sugammade will be administered following a period of muscle relaxation after which respiratory measurements will be obtained.
89473504|NCT02979860|No Intervention|Typical sleep schedule|"Children in this arm will be asked to maintain their current sleep schedule. No prescription will be provided other than to sleep how they typically would sleep."
89473505|NCT02979860|Experimental|Enhance time in bed by 90 min/night|Sleep duration - 90 minutes: Children in this arm will be asked to get into bed and to turn their lights out 90 minutes earlier than their typical bedtime. Bedtimes and wake times will remain consistent across the 4-week experimental phase of the study.
89473506|NCT02979860|Experimental|Enhance time in bed by 45 min/night|Sleep duration - 45 minutes:Children in this arm will be asked to get into bed and to turn their lights out 45 minutes earlier than their typical bedtime. Bedtimes and wake times will remain consistent across the 4-week experimental phase of the study.
89473507|NCT02979860|Experimental|Regularize sleep schedule|Sleep timing: Children in this arm will be asked to get into bed at a consistent bedtime each night and wake at a consistent time each morning such that time in bed achieved during baseline is maintained during the 4-week experimental phase; only timing of bedtimes/wake times will be manipulated in this arm.
89473508|NCT02507271|Experimental|Experimental Group|
89019677|NCT06165497|Experimental|Gratitude, 10 minutes, female voice|Gratitude meditation, 10 minutes duration, with a female speaker.
89019678|NCT06165497|Other|Internet-as-usual, 5 minutes|Participants will be instructed to use the internet as they typical do for 5 minutes.
89473509|NCT02507271|Placebo Comparator|Control Group|
89473510|NCT02240563|Experimental|Low-level laser therapy|This group of patients was treated with a continuous wave diode laser device (830 nanometer, infrared) with a beam area of 0.002827 cm2 using the punctual method on the continuous emission mode at an output power of 50 milliwatts and a fluence of 707 Joules/cm2 six years before.
89473511|NCT02240563|Placebo Comparator|Non laser ordinary red light|This group of patients was treated using the same method and equipment, except that a non laser ordinary red light, an output power of 0.1 Watt and a fluence of 1.41 Joules/cm2 and an irradiance value of 0.0002827 Watts/cm2 (the placebo), indistinguishable from the laser beam, was used. Therefore, the patients were blinded to which treatment they received.
89473512|NCT03344679|Other|Control group|Bupivacaine 0.25% for pectoral nerve block.
89473513|NCT03344679|Other|Adenosine|Bupivacaine 0.25% with added Adenosine 12mg for pectoral nerve block.
89473514|NCT03344679|Other|Magnesium sulphate|Bupivacaine 0.25% with Magnesium sulphate 500 mg for pectoral nerve block.
89473515|NCT03572101||Calgary Patient Cohort|Patients with advanced colorectal cancer who are recruited from Calgary, Canada before, during, and after an early palliative care pathway becomes the new standard of care in Calgary.
89019679|NCT06165497|Other|Internet-as-usual, 10 minutes|Participants will be instructed to use the internet as they typical do for 10 minutes.
89019680|NCT06165445|Active Comparator|conventional tDCS group|The conventional tDCS group will receive 30 session of 20-minute stimulation at 2 mA intensities using standard electrodes (7 x 5 cm) over the target region
89019681|NCT06165445|Active Comparator|multi-channel tDCS group|The multi-channel tDCS group will receive 30 session of 20-minute stimulation at 2 mA intensities using 8 electrodes (2.5 x 2.5 cm) over the target region
89473516|NCT03572101||Calgary Caregiver Cohort|Caregivers of patients with advanced colorectal cancer who are recruited from Calgary, Canada before, during, and after an early palliative care pathway becomes the new standard of care in Calgary.
89019682|NCT06165445|Placebo Comparator|sham tDCS group|The conventional tDCS group will receive 30 session of 20-minute placebo stimulation using standard electrodes (7 x 5 cm) over the target region
89019683|NCT06165432|Active Comparator|Drug Arm :Topical benzocaine|since its a split mouth study one half of the hard palate will receive topical benzocaine i.e Group A
89019684|NCT06165432|Active Comparator|Topical ice|Other half of the palate will receive topical ice i.e Group B
89019685|NCT06165393|Experimental|Slow-release CHO-AA|Alginate encapsulated Carbohydrates and Amino Acids
89019686|NCT06165393|Experimental|Slow-release CHO|Alginate encapsulated Carbohydrates
89019687|NCT06165393|Active Comparator|CHO|Carbohydrates only
89019688|NCT06165315|Experimental|Parenting Program|This community-based group parenting program aims improve caregiver knowledge, attitudes, and practices on nurturing care to ultimate improve early childhood development. A secondary aim of the program is to support caregiver psychosocial wellbeing. The curriculum covers various topics relating to responsive caregiving, early learning, child protection, maternal and child health and nutrition, and caregiver mental health. Intervention will be delivered through existing community group networks. Each parenting group will comprise of 10 caregivers that will be facilitated by trained volunteers.
89019689|NCT06165315|No Intervention|Waitlist-Control|Villages in the control group will not immediately receive the parenting program. Instead, they will receive whatever standard of care services are delivered at the community-level (e.g., routine services from community health volunteers that are primarily focused on maternal and child health and nutrition). After endline data collection is completed for the trial, then villages in the control group will receive the parenting program.
89019690|NCT06165289|Experimental|PRP high concentration group|Endoscopic balloon dilatation combined with autologous platelet-rich plasma (PRP) injection with high concentration (platlet 2*10^6/μL)
89473517|NCT03572101||Edmonton Patient Cohort|Patients with advanced colorectal cancer who are recruited from Edmonton, Canada during the same time period (no palliative care pathway introduced).
89473518|NCT03572101||Edmonton Caregiver Cohort|Caregivers of patients with advanced colorectal cancer who are recruited from Edmonton, Canada during the same time period (no palliative care pathway introduced).
89473519|NCT03344601|No Intervention|Reference Cohort|A 12-month longitudinal evaluation of physical fitness and physical activity assessments in a cohort of individuals with HD (n=60) recruited from the Enroll-HD platform study.
89473520|NCT03344601|Experimental|Physcial Activity Intervention|Participants will be recruited from the Enroll-HD platform study and will be individually randomised (1:1) to a 12-month physical activity and coaching intervention.
89019691|NCT06165289|Experimental|PRP low concentration group|Endoscopic balloon dilatation combined with autologous platelet-rich plasma (PRP) injection with low concentration (platlet 1*10^6/μL)
89473521|NCT03344601|No Intervention|Activity as usual control|Participants will be recruited from the Enroll-HD platform study and will be individually randomised (1:1) to continue with physical activity as usual for 12 months
89473522|NCT02259829|Experimental|Telmisartan/Amlodipine fixed dose combination|
89473523|NCT02259829|Active Comparator|Telmisartan and Amlodipine monocomponents|
89473524|NCT03344523|Experimental|standard treatment + Iron succinylate|1 bottle orally, twice daily, take orally before meals
89473525|NCT03344523|Placebo Comparator|standard treatment + placebo|1 bottle orally, twice daily, take orally before meals
89473526|NCT02658734|Experimental|Trastuzumab emtansine|
89473527|NCT03574051|Experimental|Probiotic|Taking probiotics containing Bifidobacterium infantis, Lactobacillus acidophilus and Enterococcus faecalis for 30 days
89473528|NCT03344445|No Intervention|traditional vist|Patients receive traditional anesthesiologist visit
89473529|NCT03344445|Experimental|video-assisted|Patients watch the video, then an anesthesiologist visit
89473530|NCT03572023|Active Comparator|MINOCA|"This group will include patients with myocardial infarction with non-obstructive coronary arteries (MINOCA).~Integrative characterization of MINOCA patients:~The following interventions will be administered: MSCT, CMR, SPECT, Blood tests, Genetic tests."
89473531|NCT03572023|Active Comparator|MI with coronary obstruction|"This group will include patients with myocardial infarction and obstructive coronary arteries.~Characterization of MI patients with coronary obstruction:~The following interventions will be administered: MSCT, CMR, SPECT, Blood tests, Genetic tests."
89473532|NCT03346707||10.5 Tesla|
89473533|NCT05098964|Experimental|Study Group (pedometer)|Participants received an Omron HJ 321 pedometer (Omron Healthcare Co Ltd, Kyoto, Japan) and were asked to walk at home at the fastest step pace as possible, for at least 30 minutes every day, up to 6 weeks.
89473534|NCT05098964|Experimental|Control Group|participants received supervised exercise training at outpatient clinics for total 18 sessions (3 weekly sessions for 6 weeks).
89473535|NCT03458299|Experimental|Motivational Interviewing|The MI intervention will incorporate open-ended questions, personalized feedback, and discussion about participants' alcohol use and drug, associated risk behaviors (e.g., drinking and driving), and the consequences of these behaviors. Individual MI procedures will incorporate the core principles of MI described by Miller and Rollnick, including expressing empathy, developing discrepancy, rolling with resistance, and supporting self-efficacy. Therapist interventions will be tailored to the participants' readiness to change/current stage of change (pre-contemplation, contemplation, preparation, action, maintenance, and relapse).
89473536|NCT03458299|Experimental|Psychoeducation|The Psychoeducation session will consist of therapist assisted viewing and discussion of four educational DVDs about adolescent alcohol use, drug use, and driving under the influence provided by Human Relations Media, Mount Kisco, NY (hrmvideo.com).
89473537|NCT04501107|Experimental|BioChaperone insulin lispro reconstituted with Humalog® (IMP1)|Subcutaneous administration of Biochaperone insulin lispro formulation made from a freeze-dried of BioChaperone reconstituted with Humalog® at a dose of 0.2 U/Kg Body Weight (BW).
89473538|NCT04501107|Experimental|Ready-to-use BioChaperone insulin lispro (IMP2)|Subcutaneous administration of ready-to-use Biochaperone insulin lispro formulation at a dose of 0.2 U/Kg BW.
89019692|NCT06165276|Experimental|Group 1|Adults receiving Low Dose TetraMen-T with adjuvant
89019693|NCT06165276|Experimental|Group 2|Adults receiving High Dose TetraMen-T without adjuvant
89019694|NCT06165276|Experimental|Group 3|Toddlers receiving Low Dose TetraMen-T with adjuvant
89019695|NCT06165276|Experimental|Group 4|Toddlers receiving High Dose TetraMen-T without adjuvant
89019696|NCT06165276|Experimental|Group 5|Infants receiving Low Dose TetraMen-T with adjuvant. Subjects were to receive a booster dose of the same formulation at age 13 months
89473539|NCT04501107|Active Comparator|US-approved Humalog® (IMP3)|Subcutaneous administration of US-approved Humalog® at a dose of 0.2 U/Kg BW.
89473540|NCT04501107|Active Comparator|EU-approved Humalog® (IMP4)|Subcutaneous administration of EU-approved Humalog® at a dose of 0.2 U/Kg BW.
89019697|NCT06165276|Experimental|Group 6|Infants receiving Low Dose TetraMen-T with adjuvant. Subjects were to receive a booster dose of the same formulation at age 13 months
89473541|NCT03143985|Experimental|Vactosertib + Pomalidomide|"Vactosertib tablets, taken once daily for the first and second dose levels and twice a day for third and fourth dose level levels for 5 days followed by 2 days without treatment, repeated for 28-day cycles until evidence of progressive disease, intolerable toxicity, or participant discontinuation.~For dose escalation - dosing initiated at 60 mg once daily by oral administration and will be increased to determine MTD. Provisional subsequent doses are 60, 120, once daily and 100 mg and 200 mg twice daily on days 1-5, 8-12, 15-19 and 22-26. Extension cohorts will enter at 200 mg twice daily (i.e. if MTD not defined) for 12 months until progression or intolerable toxicity.~POM is administered orally (4 mg/day daily on Days 1 - 21 days). Treatment will occur in a suitable outpatient ambulatory care setting that is equipped for monitoring of patients with hematopoietic malignancies undergoing early clinical trial research."
89473542|NCT02663336||CKD patients|Patients with chronic kidney disease, with diagnosed arterial hypertension and normal blood pressure during office blood pressure measurement. Comparison of ambulatory blood pressure (ABPM) with office blood pressure measurements (OBPM).
89473543|NCT02885714|Placebo Comparator|Group I|Placebo surgery + supervised specific exercises
89473544|NCT02885714|Active Comparator|Group II|Rotator cuff repair + supervised specific exercises
89473545|NCT02507193|Active Comparator|Open reduction internal fixation(ORIF)|This surgical intervention is performed using a plate and screws.Under general anesthesia, an incision is made at the site of the break or injury, and the fracture is carefully re-aligned . The plate and screws are installed, and the incision is closed with staples or stitches. Synthes and Stryker plate and screws will be used.
89473546|NCT02507193|Active Comparator|Intermedullary (IM) Nail|This surgical intervention is performed using an intermedullary nail. Under general anesthesia, an incision is made at the site of the break or injury, and the fracture is carefully reduced. The nail in inserted through the medullary canal after proper imaging for accurate placement. The incision is closed with staples or stitches. Acumed fibula nail will be used.
89473547|NCT05091944|Experimental|intervention|usual care plus web-based birth decision aid
89473548|NCT05091944|No Intervention|control|ususal care
89473549|NCT02605148|Experimental|Gluten free diet|Gluten free diet during 18 months. The subjects will be referred to a nutritionist every 6 months. Vitamin D 800 U Daily, Omega 3 fatty acids and probiotics as nutritional supplements.
89473550|NCT02605148|Active Comparator|Normal diet|Normal diet. Vitamin D 800 U Daily, Omega 3 fatty acids and probiotics as nutritional supplements.
89473551|NCT02462330|Placebo Comparator|Placebo comparator|injection of human albumin 4%
89473552|NCT02462330|Experimental|Autologous MSC from bone marrow|intramyocardial injection of 6.10e7 stem cells
89473553|NCT02395640|Experimental|XELOX|oxaliplatin 130mg/m2 d1； capecitabine 1000mg/m2 Bid po，d1-14；
89473554|NCT02395640|Active Comparator|EOX|Epirubicin 50mg/m2 d1； oxaliplatin 130mg/m2 d1； capecitabine 1000mg/m2 Bid po，d1-14；
89473555|NCT02507037|Experimental|gum+PEG|used 2L PEG+sugarless gum
89473556|NCT02507037|Placebo Comparator|PEG|only used 2L PEG
89473557|NCT05100758|Experimental|Active Hexose Correlated Compound|The participants will be given Active Hexose Correlated Compound as a capsule 3 gram/ daily for 6 months
89473558|NCT05100758|No Intervention|Control Group|Participant will be given only the tuberculosis and antiretroviral treatment
89473559|NCT02501343|Experimental|Sodium bicarbonate|High acid load meal (Western style meal) with Sodium bicarbonate (Sodibic 840mg*2)
89019698|NCT06165276|Experimental|Group 7|Infants receiving High Dose TetraMen-T without adjuvant. Subjects were to receive a booster dose of the same formulation at age 13 months
89019699|NCT06165276|Active Comparator|Group 8|Infants receiving Menjugate ®. Subjects were to receive a booster dose of low-dose adjuvanted TetraMen-T at age 13 months. Routine vaccines were deferred.
89473560|NCT02501343|Placebo Comparator|Placebo|High acid load meal (Western style meal) with sodibic-matching placebo
89473561|NCT05097092|Experimental|Immobilization control|The immobilization control group will undergo arm immobilization. Immobilization will be implemented with four weeks of muscle unloading with a sling and swathe on the nondominant arm. The sling will suspend the arm at the elbow joint with the elbow in a flexed position at 90°, the swathe will then wrap around the participant to fix the arm against the body.
89473562|NCT05097092|Experimental|Immobilization with unilateral training|The immobilization with unilateral training group will undergo arm immobilization for four with a sling and swathe on the nondominant arm. The sling will suspend the arm at the elbow joint with the elbow in a flexed position at 90°, the swathe will then wrap around the participant to fix the arm against the body. The free (non-immobilzed) arm of this group will undergo heavy strength training twice per week throughout the immobilization period. The training will consist of unilateral dumbbell shoulder press and biceps curl.
89473563|NCT02508831|Experimental|Bilateral amputation of upper limb|Patients with bilateral amputation of upper limb will receive a double upper limb allograft
89019700|NCT06165237|Experimental|BR6001-1+BR6001-2|
89473564|NCT02508909|Experimental|Videoscopic ilioinguinal lymphadenectomy for melanoma|Melanoma groin lymph node metastasis.
89202525|NCT04003714|Experimental|Repetitive Transcranial Magnetic Stimulation Group|Patients in r-TMS group received r-TMS 20-min (1000 pulses) daily session, 5 days per weeks, for a total of 10 sessions.
89473565|NCT02509143|Experimental|High-dose acupuncture with intravenous infusion of ramosetron|Three sessions of acupuncture on the points of Stomach 36 (ST36), Stomach 37 (ST37), Liver 3 (LR3), Large Intestine 11 (LI11), Large Intestine 4 (LI4), Spleen 6 (SP6), Spleen 4 (SP4), Pericardium 6 (PC6), Heart 8 (HT8), and Gall Bladder 41 (GB41) within 48 hours after surgery
89473566|NCT02509143|Active Comparator|P6 stimulation with intravenous infusion of ramosetron|P6 stimulation by wearing a study wristband within 48 hours after surgery
89473567|NCT02509143|Active Comparator|Intravenous infusion of ramosetron|A mixture of standard antiemetic medication (5-Hydroxytryptophan receptor antagonist; ramosetron hydrochloride 0.3 mg) and analgesics, including anon-steroidal anti-inflammatory drug (NSAID) (ketorolac tromethamine 120 mg), and a semi-synthesized opioid (oxycodone 20 mg), will be infused by intravenous patient-controlled analgesia (1ml bolus/20 min lockout, 1ml/hr continuous infusion).
89473568|NCT02507115|Experimental|TMAP|Alcohol-related Text messages 4 days/week for 6 weeks
89473569|NCT02507115|Sham Comparator|Control|Motivational Text messages 4 days/week for 6 weeks
89473570|NCT05100680|Active Comparator|Multicomp group|Food supplement - 2 capsules / day containing together: 20 mg coenzyme Q10,500 mg methyl sulfonyl methane (MSM), 100 mg L-proline, 10 mg L-cysteine (as HCl monohydrate), 2 mg thiamine , 2.4 mg riboflavin, 19 mg niacin, 8.5 mg pantothenic acid, 2.3 mg vitamin B6, 0.15 mg, biotin, 0.0125 mg vitamin B12, 80 mg vitamin C, 5.5 mg vitamin A , 22 mg vitamin E, 10 mg zinc, 0.07 mg selenium, 1.1 mg copper.
89473571|NCT05100680|Placebo Comparator|Placebo group|Placebo - 2 capsules / day containing modified starch
89473572|NCT02508987||Group 1|"Periodontal status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions as periodontally healthy.Periodontal status was determined by evaluating the following clinical parameters: Silness & Löe plaque index; Löe & Silness gingival index; probing pocket depth; clinical attachment level; bleeding on probing.~Obesity was diagnosed according to World Health Organization criteria using body mass index. 18.50-24.99 kg/m2: Normal-weight"
89019703|NCT06165198|Experimental|Closed-loop tACS stimulation based on addiction-induced states|In the initial phase of this study, participants will be subjected to individual closed-loop tACS interventions at varying frequencies for one-week intervals. Concurrently, they will be exposed to MA-related cue paradigms to induce brain addiction states, while scalp EEG signals are collected. Stimulation will be initiated only upon identifying specific neural signals associated with MA cues, aiming to ascertain the optimal frequency for single-session closed-loop tACS stimulation that could elicit individual neurological responses. Subsequently, we will embark on a longitudinal closed-loop tACS intervention control study for MA dependents at one-week intervals, which involves addiction-induced closed-loop tACS stimulation, random time-point stimulation, and traditional continuous stimulation, to rectify potential sequence effects and delineate the disparities in neurological and behavioral impacts between discrete and continuous stimulations based on brain states.
89202526|NCT04003714|Sham Comparator|Sham Group|Control group received sham r-TMS with the same protocol.
89473573|NCT02508987||Group 2|"Periodontal status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions as gingivitis. Periodontal status was determined by evaluating the following clinical parameters: Silness & Löe plaque index; Löe & Silness gingival index; probing pocket depth; clinical attachment level; bleeding on probing.~Obesity was diagnosed according to World Health Organization criteria using body mass index.~18.50-24.99 kg/m2: Normal-weight"
89206210|NCT04094987|Experimental|Quadratus Lumborum block|We will use the ultrasound guided anterior Quadratus Lumborum Block.A peripheral nerve block catheter will be placed between the quadratus lumborum muscle and the psoas muscle with ultrasound
89473574|NCT02508987||Group 3|"Periodontal status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions as 'generalized chronic periodontitis'. Periodontal status was determined by evaluating the following clinical parameters: Silness & Löe plaque index; Löe & Silness gingival index; probing pocket depth; clinical attachment level; bleeding on probing.~Obesity was diagnosed according to World Health Organization criteria using body mass index.18.50-24.99 kg/m2: Normal-weight"
89473575|NCT02508987||Group 4|"Periodontal status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions as either 'periodontally healthy'. Periodontal status was determined by evaluating the following clinical parameters: Silness & Löe plaque index; Löe & Silness gingival index; probing pocket depth; clinical attachment level; bleeding on probing.~Obesity was diagnosed according to World Health Organization criteria using body mass index. 30.00-34.9 kg/m2: Obesity class I"
89473576|NCT02508987||Group 5|"Periodontal status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions as 'gingivitis'. Periodontal status was determined by evaluating the following clinical parameters: Silness & Löe plaque index; Löe & Silness gingival index; probing pocket depth; clinical attachment level; bleeding on probing.~Obesity was diagnosed according to World Health Organization criteria using body mass index. 30.00-34.9 kg/m2: Obesity class I"
89473577|NCT02508987||Group 6|"Periodontal status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions as 'generalized chronic periodontitis'. Periodontal status was determined by evaluating the following clinical parameters: Silness & Löe plaque index; Löe & Silness gingival index; probing pocket depth; clinical attachment level; bleeding on probing.~Obesity was diagnosed according to World Health Organization criteria using body mass index. 30.00-34.9 kg/m2: Obesity class I"
89473578|NCT05100446|Active Comparator|Treatment with Pylera (r) + esomeprazole 40mg|
89473579|NCT05100446|Active Comparator|Treatment with high-dose amoxicillin + esomeprazole 40mg|
89473580|NCT02501577|Experimental|SAD 1|FOI for placement
89473581|NCT02501577|Experimental|SAD 2|FOI für placement
89473582|NCT02506803|Experimental|NAC-GEMABR|Neoadjuvant chemotherapy 2 courses of NAC-GEMABR for subsequent 10 patients.
89473583|NCT02844439|Experimental|Glioblastoma|The single arm design assessing progression-free survival at 6 months (PFS-6) in the overall population with the ability to detect a rate of 25% is appropriate as a preliminary test of activity in patients with glioblastoma. The sample size of this study is also designed to permit the comparison of results with EGFR amplified and non-amplified tumors, as well as EGFRvIII mutated versus wild-type. The sample size is adequate to characterize the safety profile in patients with glioblastoma.
89473584|NCT02501499||Breastfeeding Buddies participants|Mothers that participated in Me Breastfeed workshops. Half will have been in the education-only group and half will have a buddy/peer support person in addition to the workshop.
89473585|NCT02501499||Volunteer Focus Group|Breastfeeding buddies volunteers that deliver education and support programs.
89473586|NCT05096000|Experimental|InterMob: a behavioral and economical intervention|"6 months of free transport/bicycle (12.5 Adding objects in the BCT, Michie et al., 2011)~Two meetings with a coach :~st meeting: discussion about the motivations to change (motivational interviewing and 5.2 Salience of consequences, BCT), personalized advice of transport (4.1 Instruction on how to perform the behavior, BCT), mobility change goals, and action planning (1.1 Goal setting and 1.4 Action planning, BCT), solutions to possible obstacles (1.2 Problem solving, BCT)~nd meeting: discussion about the goals and the obstacles lived and resolved. If needed, personalized transport advice is given.~Goals notebook to fill up for 6 months (goals need to be set every 2 weeks and obstacles if experienced)~Weekly SMS during 6 months, prompting a) to set and adapt goals (1.7 Review outcome, BCT) and b) to do a self-feedback related to mobility change (e.g. a more important well-being) (2.4 Self-monitoring of outcomes, BCT's taxonomy)"
88949350|NCT03483337||recurrent or metastatic head and neck cancer patients|Patients will be imaged on a 1.5 T or 3 T MR scanner. Patients will receive a test-retest DWI scan in on session prior to start of treatment. Patients who will be receiving radiation therapy treatment at Memorial Sloan Kettering's main campus, will also be imaged weekly during their course of treatment.
88949351|NCT03483337||head and neck cancer or thyroid cancers (differentiated and undifferentiated)|All patients, irrespective of treatment regimen, will be imaged on a 1.5T or 3T MR scanner prior to treatment initiation. Follow up imaging for patients undergoing surgery only will be as per clinical standard of care and not on this protocol. Patients undergoing treatment in radiation oncology and/or medicine will have imaging studies during week 2 of treatment. If patients receive 70Gy, they will also receive a scan during week 4 of treatment, if needed by treating physician. Scans will be performed to derive MRI biomarkers indicative of therapeutic mechanisms of action or efficacy will also be performed.
88949352|NCT03467919|Experimental|MFAT(Micro Fragmented Adipose Tissue)|Intra-articular knee injection of autologous Micro Fragmented Adipose Tissue harvested from the thigh using tumescent lipoaspiration and processing with minimal manipulation. This harvested tissue will then be injected into the patient's knee.
88949353|NCT03467919|Active Comparator|Conventional therapy|Intra-articular injection of corticosteroid (Triamcinolone 40mg).
89473587|NCT05096000|Other|Air pollution information: an informational group|"Active control group focused on air pollution information:~Two meetings with a coach:~st meeting: Discussion about air pollution (definition, sources, population most affected, levels in Grenoble, the consequences on health, pollution peaks), air pollution and car use (video about the pollution exposure of car drivers and the consequences of fine particles) and, a discussion about the benefit and disadvantages of using a car (5.2 Salience of consequences according to BCT's taxonomy)~nd meeting: Discussion about air quality during the last weeks and they check the quality of air of the last week.~Observation notebook to fill up for 6 months (quality of air in Grenoble and the pollution peaks every 2 weeks)~Weekly SMS during 6 months prompting a) to write down the air quality of the air every two weeks and b) write down any pollution peak announced in the television/radio/telephone"
89473588|NCT04559126|Experimental|EDP-297 SAD Cohorts|EDP-297 Dose 1, Dose 2, Dose 3, Dose 4, Dose 5 and Dose 6 oral solution, once daily in one single administration
89473589|NCT04559126|Experimental|EDP-297 MAD Cohorts|EDP-297 Dose 1, Dose 2 and Dose 3 oral solution, once daily for 14 days
89473590|NCT04559126|Placebo Comparator|EDP-297 SAD Placebo Cohort|Matching placebo, oral solution, once daily in one single administration
89473591|NCT04559126|Placebo Comparator|EDP-297 MAD Placebo Cohort|Matching placebo, oral solution, once daily for 14 days
89473592|NCT03571867||group Sugammadex|After surgery, while the TOF count was 2/4, the residual muscle relaxation was antagonized with 2 mg/kg iv sugammadex + 0.01 ml/kg saline in Group S
89473593|NCT03571867||group Neostigmine|After surgery, while the TOF count was 2/4, the residual muscle relaxation was antagonized with 0.02 mg/kg neostigmin+0.01 mg/kg atropine in Group N.
89473594|NCT04531592|Experimental|VPA plus SOC|A single dose of 140 mg/kg of VPA plus standard of care
89473595|NCT04531592|Placebo Comparator|Placebo plus SOC|A single dose of isotonic saline solution plus standard of care
89473596|NCT03571711||Meropenem therapy in SBP|Patients in a tertiary care Hospital with meropenem injection due to spontaneous bacterial Peritonitis.
89473597|NCT01677182|Experimental|Ramelteon SL (Dose 1)|Ramelteon SL tablets, sublingual, once daily, at night time for up to 6 weeks.
89473598|NCT01677182|Experimental|Ramelteon (Dose 2)|Ramelteon SL tablets, sublingual, once daily, at night time for up to 6 weeks.
89473599|NCT01677182|Placebo Comparator|Placebo|Ramelteon SL placebo-matching tablets, sublingual, once daily, at night time for up to 6 weeks.
89473600|NCT02843659|Experimental|BMS-931699|Subcutaneous weekly injection + daily oral placebo tablets
88949354|NCT03455725|Active Comparator|CardiAMP cell therapy system|"Roll-in phase:~Up to 10 subjects with refractory chronic myocardial ischemia CCS class III-IV will be treated in an unblinded, uncontrolled roll-in phase.~In the subsequent randomized phase:~Up to 333 subjects with refractory chronic myocardial ischemia CCS class III-IV will be randomized. Up to 222 Subjects will be randomized to treatment with the CardiAMP cell therapy system."
89473601|NCT02843659|Experimental|BMS-986142|Daily oral tablets + subcutaneous placebo (weekly) injection
89473602|NCT02843659|Placebo Comparator|Placebo|Weekly subcutaneous placebo injection +daily oral placebo tablets
89473603|NCT05099744|Experimental|Electrostimulation Therapy|Participants will undergo six electrostimulation sessions, which will take place once a week and will last 20 minutes. Participants complete a set of questionnaires at the following times: pre-test (T0), post-test (T1), and 1-month post-intervention follow-up (T2). The first session will include a psychoeducational component, where it will be explained that psychological morbidity and stress influence the immune system, with repercussions on QoL.
89473604|NCT05099744|Experimental|Relaxation + Electrostimulation Therapy|Participants have sessions of relaxation and electrostimulation therapy during 20 minutes. They will receive two sessions in the same week, one of electrostimulation therapy and another of relaxation. Also, participants complete a set of questionnaires at the following times: pre-test (T0), post-test (T1), and 1-month post-intervention follow-up (T2).
89473605|NCT05099744|Active Comparator|Relaxation (standard)|Participants will receive relaxations sessions weekly, and complete a set of questionnaires at the following times: pre-test (T0), post-test (T1), and 1-month post-intervention follow-up (T2).
89473606|NCT05099744|Placebo Comparator|Placebo|Participants will be connected to the handles but will not receive any frequency during the 20 minutes. The sessions will take place at the same location and with the same weekly frequency as EG1 and EG2. Also, they will complete a set of questionnaires at the following times: pre-test (T0), post-test (T1), and 1-month post-intervention follow-up (T2).
88949355|NCT03455725|Sham Comparator|Sham procedure control|"Randomized phase:~Up to 333 subjects with refractory chronic myocardial ischemia CCS class III-IV will be randomized. Up to 111 subjects will be treated with a Sham Treatment (no introduction of trans endocardial delivery catheter and no administration of autologous cells)"
89206211|NCT01062919|Experimental|Epidural analgesia group|patients in the epidural analgesia group will receive ropivacaine 0.2% through the epidural catheter, normal saline in the wound catheter and PCA with morphine.
89473607|NCT05104190|Experimental|plastic wafers group|"In one arm/ group 1 (plastic wafers group), debonding was done by open mouth technique. All brackets were removed using same plier i.e. angled direct bracket remover. Figure pressure in the apical direction was applied concomitantly applied to stabilize each tooth. Loose cotton was used between thumb and tooth during debonding. Arch wires and ligatures were not removed during debonding.~Patient pain score during procedure was measured using visual analogue scale ranging from zero to one hundred (0-100) In"
89473608|NCT05104190|Experimental|finger pressure group|In another arm/ group 2( finger pressure group) brackets were removed in the same way with the same debonding plier as in group 1 but soft acrylic sheets folded 4 times were placed between upper and lower dentition with the patient biting on this wafer. Wires and ligatures were left tied to brackets during debonding. After the procedure, patient was asked about pain using visual analogue scale.
89538480|NCT02457689|Active Comparator|Group 2 (Transcutaneous and Active)|Group 2 (Transcutaneous and Active) Participants will receive 1.0ml intramuscular injections of the GTU®-MultiHIV B Clade Vaccine (2 mg/ml) into the upper thigh. Participants will also have a further 0.2ml of the vaccine (2mg/ml) delivered transcutaneously. An area of skin of approximately 4 x 4cm will be photographed and prepared first. During this preparation, the area is shaved to remove the hair, and then superglue is applied to remove the top layer of skin (like waxing). The vaccine is spread onto the skin surface. Once applied, the area is covered with a comfeel bandage, the investigator will ask volunteers to not engage in strenuous exercise, shower, or bathe for 24 hours afterwards.
89473609|NCT03570541|Active Comparator|Active|"Active bilateral ultrasound-guided transmuscular quadratus lumborum (TQL) block. 60 mL ropivacaine 0,375% single shot.~Every six hours postoperative, all patients are administered 1 g of acetaminophen.~In both arms morphine will be administered IV as part of a patient controlled analgesia (PCA)-pump regimen or additionally after contact with the nursing staff as it is the standard treatment.~On the day of surgery, postop day 1+2 and day 10-14, all patients will have blood samples taken for immunological analysis.~On the day of surgery, postop day 1+2 and day 10-14, all patients are asked to fill out a Quality of recovery-15 questionaire.~Before surgery, and 3, 6 and 24 hours postop. All patients are tested for orthostatic hypotension."
89473610|NCT03570541|Placebo Comparator|Placebo|"Placebo bilateral ultrasound-guided transmuscular quadratus lumborum (TQL) block. 60 mL saline single shot.~Every six hours postoperative, all patients are administered 1 g of acetaminophen.~In both arms morphine will be administered IV as part of a patient controlled analgesia (PCA)-pump regimen or additionally after contact with the nursing staff as it is the standard treatment.~On the day of surgery, postop day 1+2 and day 10-14, all patients will have blood samples taken for immunological analysis.~On the day of surgery, postop day 1+2 and day 10-14, all patients are asked to fill out a Quality of recovery-15 questionaire.~Before surgery, and 3, 6 and 24 hours postop. All patients are tested for orthostatic hypotension."
89473611|NCT05374382|Experimental|Strengthening|Participants received a 9-weeks strengthening-based prehabilitation program before ACL reconstruction, followed by a standardized post-operative rehabilitation program
89473612|NCT05374382|Active Comparator|Conventional|Participants received a 9-weeks conventional prehabilitation program (targeting pain knee mobility) before ACL reconstruction, followed by a standardized post-operative rehabilitation program
89473613|NCT05374382|No Intervention|Control|No prehabilitation program Participants received only a standardized post-operative rehabilitation program
89473614|NCT00708435|Experimental|Beriplex® P/N|
89473615|NCT00708435|Active Comparator|Fresh frozen plasma|
89473616|NCT04437290||Alzheimer disease|The group is composed of individuals with a consensus diagnosis of amnestic mild cognitive impairment (MCI) or amnestic multimodal MCI or dementia primarily attributed to Alzheimer's disease (AD), as determined by the UW ADRC Clinical Core. They will have age of presentation > 55 years, sporadic onset, CDR (Clinical Dementia Rating Scale) score 0.5-1.0, and sufficient English competency to complete a standardized cognitive testing battery. All will have no contraindication to MRI and will have had an MRI scan in the UW ADRC Imaging and Biomarker Core. These participants will undergo PET scanning with the investigational tau tracer [18F] MK6240
89473617|NCT02841787|Experimental|Individual Internet Intervention (III)|"Coached internet intervention based on the principles of cognitive behavioral therapy (CBT) for depressed older adults delivered individually by 2 clinical psychologists.~(iCBT for late life depression without social network included.)"
89473618|NCT02841787|Experimental|Internet Intervention+Peer Supp.(II+PS)|"Coached internet intervention based on the principles of cognitive behavioral therapy (CBT) for depressed older adults delivered with peer support; group moderation was provided by 2 clinical psychologists.~(iCBT for late life depression with social network included.)"
89473619|NCT02841787|No Intervention|Waitlist Control (WLC)|Waiting period, no intervention administered. WLC participants received access to the III following the 8-week waiting period.
89473620|NCT05104034|Experimental|Screening group|Inform the elderly about the results of the screening and recommend those with moderate to high risk of fracture to receive active examination and treatment.
89473621|NCT05104034|Experimental|Multi-discipline intervention|Introduce integrated services of health education, nutrition, rehabilitation, medication evaluation and other multi-specialties to assist study participants with health promotion
89473622|NCT05104034|Placebo Comparator|Delayed intervention|receive general care after collecting basic information, and provide health education related information such as osteoporosis sarcopenia. After two year's follow-up, multi-disciplinary team intervention service will be implemented.
89473623|NCT05374226|Experimental|JS019 0.3 mg/kg|repeat dose every 21 days up
89473624|NCT05374226|Experimental|JS019 1 mg/kg|repeat dose every 21 days up
89473625|NCT05374226|Experimental|JS019 3 mg/kg|repeat dose every 21 days up
89473626|NCT05374226|Experimental|JS019 10 mg/kg|repeat dose every 21 days up
89473627|NCT02508753|Experimental|CXA-101/tazobactam therapeutic dose|
89473628|NCT02508753|Experimental|CXA-101/tazobactam supra-therapeutic dose|
89473629|NCT02508753|Active Comparator|Moxifloxacin|
89473630|NCT02508753|Placebo Comparator|Placebo|
89473631|NCT02506647|Experimental|Sequence 1|Gan & Lee insulin glargine followed by Lantus
89473632|NCT02506647|Active Comparator|Sequence 2|Lantus followed by Gan & Lee insulin glargine
89473633|NCT02190097|Experimental|paleolithic diet|subjects in this arm are given detailed instructions and coaching in following a paleolithic type diet for 4 months, with the option to continue for another 4 months. studies of ovarian and metabolic parameters will be done at baseline, 2 and 4 months
89473634|NCT02190097|Active Comparator|American Diabetes Association diet|subjects in this arm are given detailed instructions and coaching in following an ADA type diet for 4 months, with the option to switch over to the paleolithic diet arm for another 4 months. studies of ovarian and metabolic parameters will be done at baseline, 2 and 4 months
89473635|NCT02508597|Other|Physicians receiving smoking cessation training|On the training day, the investigators will explain at the beginning of the workshop the purpose of the training, and the details of the brief smoking cessation intervention to all physicians who attend the training workshop.
89473636|NCT02508519|Experimental|Zonal|The zonal acupuncture group will receive a treatment according to a zonal method and a pain level will be estimated by the investigator according to a visual analog pain scale (VAS) before and 10 minutes and 15 minutes after the beginning of the treatment and the change of the pain level will be recorded. If possible the pain level will be measured again approximately 24 hours after the treatment and the change of the pain level will be again recorded.
89473637|NCT02508519|Experimental|Balance|The balance acupuncture group will receive a treatment according to a balance method, and a pain level will be estimated according to a visual analog pain scale (VAS) before and 10 minutes and 15 minutes after the beginning of the treatment and the change of the pain level will be recorded. If possible the pain level will be measured again approximately 24 hours after the treatment and the change of the pain level will be again recorded.
89473638|NCT02508519|No Intervention|Control|The control group will provide only the estimation of the the pain level according to a visual analog pain scale (VAS) but receive no acupuncture treatment. Then if possible the pain level will be measured again approximately 24 hours after the first measurement and the change of the pain level will be recorded.
89473639|NCT02571530|Experimental|Intra-arterial Cerebral Infusion of Trastuzumab|Super-selective Intra-arterial Cerebral Infusion of Trastuzumab After Blood-Brain Barrier Disruption
89473640|NCT02508441|Experimental|Andes-1537 for Injection|Part 1 is an open-label, dose-escalation study. Part 2 is an open-label, dose-expansion study.
89473641|NCT05108402|Experimental|Bottle of water|"After inclusion in the study, the patients are phenotyped between V1 and V4. Following this, they will be separated into 2 groups: NaCl sensitive patients and non-NaCl sensitive patients. The non-sensitive group will drop out of the study, while the others will be randomized to one of the 2 treatment arms: bottle of water or sachet of salt."
89473642|NCT05108402|Active Comparator|Salt sachet|"After inclusion in the study, the patients are phenotyped between V1 and V4. Following this, they will be separated into 2 groups: NaCl sensitive patients and non-NaCl sensitive patients. The non-sensitive group will drop out of the study, while the others will be randomized to one of the 2 treatment arms: bottle of water or sachet of salt."
89473643|NCT05108402|Other|No treatment|"After inclusion in the study, the patients are phenotyped between V1 and V4. Following this, they will be separated into 2 groups: NaCl sensitive patients and non-NaCl sensitive patients. The non-sensitive group will drop out of the study, while the others will be randomized to one of the 2 treatment arms: bottle of water or sachet of salt."
89473644|NCT02501187|Experimental|Patients operated for ptosis by levator advancement|patients undergoing surgical repair for aponeurotic ptosis by the procedure- levator advancement.
89473645|NCT02501187|Experimental|Patients operated for ptosis by white line advancement|patients undergoing surgical repair for aponeurotic ptosis by the procedure- white line advancement
89473646|NCT02501187|Experimental|Patients operated for ptosis by Müller resection|patients undergoing surgical repair for aponeurotic ptosis by the procedure- Müller's muscle-conjunctival resection.
89473647|NCT05108324|Experimental|zygomatic implant|patients receiving 2 zygomatic implants with 2 conventional implant in anterior region
89473648|NCT05108324|Active Comparator|conventional implant|patients receiving 4 conventional implant 2 in anterior region and 2 in posterior region with immediate loading
89473649|NCT04495647|Experimental|WB-EMS_frail|
89473650|NCT04495647|Active Comparator|WB-EMS_robust|
89473651|NCT04495647|Active Comparator|WB-EMS_young|
89473652|NCT05108168||infiltrative cardiomyopathy|infiltrative cardiomyopathy
89473653|NCT02501031|Experimental|Flaxseed (ground)|
89473654|NCT02501031|No Intervention|Usual diet|
88949356|NCT03454646|Experimental|Group randomized for continuing treatment|"Group who continues the cholinesterase inhibitors (CI). The treatment is one of the CI (donepezil, galantamine or rivastigmine) with market authorization and commercialized for more than 15 years in France. The choice of the treatment will be done by the specialist according to his habits; the specialist will monitor the treatment as usual.~All randomised patients will then be followed-up for two years with regular assessment of judgment criteria every 6 months."
89473655|NCT05103488|Experimental|Intervention|"Comprehensive palliative care (CPC) is multidisciplinary inpatient care that aims to respond to patients' suffering in many aspects: physical, psychological, social, and spiritual. It is basically a standard palliative care service in Vietnam with additional psychosocial and spiritual support with a multidisciplinary approach. CPC is provided by seven doctors, 20 nurses, two social workers, a pharmacist, and a psychologist. CPC could go parallel with oncology care or be the primary care for patients.~The psychosocial and spiritual supports are mainly provided by social workers. Psychologist and religious will get involved when patient need advance care. The psychosocial intervention is individualized for each patient based on their individual situation, issues, and decision."
89473656|NCT05103488|Other|Control|Patients who are randomized to the control group will receive the standard palliative care in Vietnam. They can assess to the same palliative care for their physical symptoms as patients in the intervention group do. They can also access psychosocial and spiritual support from the resources that available for them before entering to the study. If they request for social or financial support, their care team can reach out to the social work departments. Patients who are in need can receive mental health care from psychiatrists from the psychiatrist unit at UMC.
88949357|NCT03454646|No Intervention|Group randomized for stopping treatment|Group who stops the CI. No placebo will be given, over 2 years All randomised patients will then be followed-up for two years with regular assessment of judgment criteria every 6 months.
89473657|NCT02506725|Experimental|Prenatal Care in groups|We will do prenatal care using centering care pregnancy methodology in 10 sessions
89473658|NCT02506725|No Intervention|Control Group|We will do in this arm conventional Prenatal care available in the family clinics
89473659|NCT04526054|Other|anosmic or normosmic COVID-19 patients|Patients will undergo ENT exams, olfactometry and MRI.
89473660|NCT03343275|Experimental|Experimental|"Dietary supplement : Lit-Control® pH Down~Pharmaceutical form: capsules~Administration : oral~Dose: 3 capsules/day.~• Sanitary product : Lit-Control® pH Meter~In vitro diagnosis sanitary product~Use:Urinary pH evaluation"
89473661|NCT03343275|Placebo Comparator|Placebo|"Placebo:~Pharmaceutical form: capsules~Administration : oral~Dose: 3 capsules/day.~• Sanitary product : Lit-Control® pH Meter~In vitro diagnosis sanitary product~Use:Urinary pH evaluation"
89473662|NCT04379024|Experimental|Immediate active agent|Duavee. One capsule daily for 6 months (+/- 1 month) of Duavee (Bazedoxifene 20 mg plus conjugated estrogens 0.45 mg)
89473663|NCT04379024|Other|Delayed active agent|No intervention for first 6 months. Then option to receive daily Duavee for 6 months.
89473664|NCT04497831|Experimental|Study Drug|Morphine hydrochloride
89473665|NCT04497831|Placebo Comparator|Placebo|Placebo
89473666|NCT04498689|Experimental|camrelizumab + nab-paclitaxel + gemcitabine|PD-1 Monoclonal Antibody Camrelizumab at 200 mg on Day 1 and 15 nab-paclitaxel at 100 mg/m2 on Day 1, 8, and 15; gemcitabine at 1000 mg/m2 on Day 1, 8, and 15
89473667|NCT01376037|Placebo Comparator|inactive placebo laser device|The inactive placebo laser device looks identical to the active laser device, but does not emit any therapeutic light output.
89473668|NCT01376037|Active Comparator|Erchonia ML Scanner (MLS)|The Erchonia ML Scanner (MLS) is a low level laser light therapy device comprising 4 independent rotating diodes, each emitting 17mW 635nm of red laser light. The diodes are mounted in scanner devices positioned 120 degrees apart from each other, tilted at a 30 degree angle. The Erchonia® MLS is activated for 20 minutes per arm during which time the 4 rotating diodes create a spiraling circle pattern that is totally random and independent from the others. These patterns overlap each other to guarantee total coverage within the target area. The total laser energy the test subject is exposed to per treated arm is approximately 3.94 joules per square centimeter. Six procedures are administered evenly across 2 weeks.
89473669|NCT05103098|Experimental|misoprostol 400 mcg|"All patients will receive three doses of sublingual misoprostol every four hours The first dose of misoprostol 400 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of the second dose will be given upon sending home.~Two doses of misoprostol 800 mcg each (2 tablets of 200 mcg per dose). Paracetamol, eight hourly, will be provided as an analgesic or antipyretic. A specimen bottle to collect the POC if passed out. Two pairs of disposable gloves. Pre-filled histopathological examination form to be sent to the laboratory together with the products of conception"
89473670|NCT05103098|Active Comparator|misoprostol 800 mcg|"All patients will receive three doses of sublingual misoprostol every four hours The first dose of misoprostol 800 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of the second dose will be given upon sending home.~Two doses of misoprostol 800 mcg each (four tablets of 200 mcg per dose). Paracetamol, eight hourly, will be provided as an analgesic or antipyretic. A specimen bottle to collect the POC if passed out. Two pairs of disposable gloves. Pre-filled histopathological examination form to be sent to the laboratory together with the products of conception"
89473671|NCT03121287||Lung or Esophageal Patients|Patients with lung or esophageal cancer undergoing conventionally-fractionated radiation therapy. Interventions to be administered include: Imaging Biomarkers using Volumetric CT Scans, Pulmonary using Pulmonary Function Test & 6Minute Hall Walk, Imaging using Cardiac MRI, Specimen Collection using Blood Draws.
89473672|NCT04272008|Active Comparator|Annovera (alone)|Annovera without tampon use
89473673|NCT04272008|Active Comparator|Annovera with tampon use|Annovera with tampon use
89473674|NCT03121131|Other|Accurate Clinical Exam Findings|Radiologists will be provided with accurate clinical exam data.
89473675|NCT03121131|Other|Inaccurate Clinical Exam Findings|Radiologists will be provided with purposefully incorrect clinical exam data
89473676|NCT03121131|Other|No Clinical Exam Findings|Radiologists will be not be provided with any clinical exam data
89473677|NCT04147832||HIV-1|HIV-1+, males, females, transgender, ≥18 years of age, seen at any AHF clinic within the last two years and whose care is documented in the AHF electronic health records system.
89473678|NCT03120897|Experimental|Test group|The subjects will be enrolled into the test group and will receive RAM sensor.
89473679|NCT03343119||Hospitalised patients|No intervention
89473680|NCT03343119||Healthy volunteers|No intervention
89473681|NCT03343119||Dog owners (healthy volunteers)|No intervention
89473682|NCT03343119||Veterinarians (healthy volunteers)|No intervention
89473683|NCT03343119||Pig farmers (healthy volunteers)|No intervention
89473684|NCT05107622|Experimental|FMUD+Probiotic|FMUD+Probiotic (n=30): full-mouth ultrasonic periodontal debridement associated with administration of probiotic formulation twice a day for 30 days.
89473685|NCT05107622|Placebo Comparator|FMUD+Placebo|FMUD+Placebo (n=30): full-mouth ultrasonic periodontal debridement associated with administration of placebo formulation, twice a day for 30 days.
89473686|NCT02506179||Open-label cohort|Patients will be followed for 52 weeks post initiation of adalimumab (Week 0).
88949358|NCT03431896||Primary|"1.) To evaluate the relative amount of misfolded ATTR oligomers in asymptomatic ATTR amyloid genetic carriers and correlate their levels with clinical symptoms and outcomes.~Determine if misfolded ATTR oligomers are elevated compared to healthy control data obtained by Scripps during probe development~Describe the levels longitudinally~Determine if treatment with ATTR-specific medications (examples: diflunisal, doxycycline, ursodiol, tauroursodeoxycholic acid (TUDCA), green tea extract, curcumin, tafamidis, inotersen, patisiran) lead to reduction in the probe levels in those with elevated levels at baseline"
89473687|NCT05107388|Experimental|Continuous interstitial glucose measurements|Variations of interstitial glucose are measured during 14 days with FreeStyle Libre Pro
89473688|NCT05103020|Experimental|HAI oxaliplatin and systemic FOLFIRI plus targeted therapy (bevacizumab or cetuximab)|HAI-oxaliplatin + Systemic FOLFIRI + target agent (bevacizumab or cetuximab)
89473689|NCT05103020|Active Comparator|Systemic FOLFIRI plus targeted therapy (bevacizumab or cetuximab)|IV FOLFIRI+ target agent (bevacizumab or cetuximab)
89473690|NCT04495491||Pupillary block group|According to the configurations of angle closure, the pupillary block group is defined as the iris bombe.
89473691|NCT04495491||plateau iris group|According to the configurations of angle closure, the plateau iris group is defined as the thickness of the peripheral iris.
89473692|NCT04495491||mixed mechanism group|According to the configurations of angle closure, the mixing mechanism group is defined as the iris bombe plus thickening of the peripheral iris.
89473693|NCT05107076||STEMI patients who underwent PPCI|"2D Echocardiography with color Doppler assessment will be done within 24 h after PPCI~Biochemical measurements:~Peripheral blood samples were obtained within 48 hours after acute MI, and the serum will be frozen at -70°C until tested for Galactin-3 level.~Follow up 2D Doppler echocardiography will be repeated at 40 days of the event."
88949359|NCT03407469||Questionnaires|Questionnaires completed at the time participant joins this study and then about 30 days, 3 months, 6 months, and 12 months after that. Questionnaires will be about quality of life and experiences with treatment for venous thromboembolism (VTE).
88949360|NCT03401762|Experimental|Chronic stroke MCI Electromyogram (EMG) pairs|Decoupling 2 muscles at a time with MCI
89473694|NCT04495335|Experimental|Test Group (TG)|The study included test group with Photobiomodulation treatment after dental implant surgery
89473695|NCT04495335|Active Comparator|Control Group (CG)|The control group consisted of laser application without energy delivery to the tissue.
89473696|NCT04498455|Placebo Comparator|Placebo|Dietary Supplement: Placebo
89473697|NCT04498455|Active Comparator|Prebiotin|Dietary Supplement: Prebiotin (oligofructose enriched inulin)
89473698|NCT03344367|Experimental|JWCAR029|The safety and efficacy of JWCAR029 will be evaluated in a standard 3+3 dose escalation approach. 5 CAR T dosage will be tested in this study: 1×10^7, 2.5×10^7, 5×10^7, 1×10^8, 1.5^108 CAR+ T cells.
89473699|NCT03344289|Experimental|Linked color imaging|When the patient is randomized for LCI, the imaging mode is switched to LCI and colonoscopic inspection will take place during withdrawal of the endoscope
89473700|NCT03344289|Active Comparator|High definition white light|When the patient is randomized for HD-WLE, the imaging mode is switched to HD-WLE and colonoscopic inspection will take place during withdrawal of the endoscope.
89473701|NCT02657408|Experimental|BI 1026706|
89473702|NCT02657408|Experimental|Placebo|
89473703|NCT02841709|Experimental|Sequence 1|Each subject participates in 5 treatment periods. On the evening of the first 2 days of each period they receive one dose (D) of ACT-541468 or placebo orally in the following order: D4, D2, D3, D1 and P, with D4 = the highest dose (50 mg) and D1 the lowest dose (5 mg). Each treatment period is separated from the next one by a 5- to 12-day washout.
89473704|NCT02841709|Experimental|Sequence 2|Each subject participates in 5 treatment periods. On the evening of the first 2 days of each period they receive one dose (D) of ACT-541468 or placebo orally in the following order: D2, P, D4, D3 and D1, with D4 = the highest dose (50 mg) and D1 the lowest dose (5 mg). Each treatment period is separated from the next one by a 5- to 12-day washout.
89473705|NCT02841709|Experimental|Sequence 3|Each subject participates in 5 treatment periods. On the evening of the first 2 days of each period they receive one dose (D) of ACT-541468 or placebo orally in the following order: D3, D1, D2, P and D4, with D4 = the highest dose (50 mg) and D1 the lowest dose (5 mg). Each treatment period is separated from the next one by a 5- to 12-day washout.
89473706|NCT02841709|Experimental|Sequence 4|Each subject participates in 5 treatment periods. On the evening of the first 2 days of each period they receive one dose (D) of ACT-541468 or placebo orally in the following order: P, D4, D1, D2, D3, with D4 = the highest dose (50 mg) and D1 the lowest dose (5 mg). Each treatment period is separated from the next one by a 5- to 12-day washout.
89473707|NCT02841709|Experimental|Sequence 5|Each subject participates in 5 treatment periods. On the evening of the first 2 days of each period they receive one dose (D) of ACT-541468 or placebo orally in the following order: D1, D3, P, D4 and D2 with D4 = the highest dose (50 mg) and D1 the lowest dose (5 mg). Each treatment period is separated from the next one by a 5- to 12-day washout.
89473708|NCT02506491|Experimental|Pilates exercise program|Incorporate Pilates principles to stimulate core muscles in a dynamic and static way, and exercising arms and legs complementarity with balance as an essential part of standing exercises.
89473709|NCT02506491|Experimental|Muscular exercise program|To train core muscles in a dynamic and static way, and exercising arms and legs complementarity with balance as an essential part of standing exercises.
89473710|NCT02506491|Active Comparator|Control group|Healthy active but nonexercising old women
89473711|NCT02501109|Experimental|Group A|Healthy volunteers will receive Aripiprazole Oral Soluble Film(OSF) 10mg orally a single of dose within 28 days with water.
89473712|NCT02501109|Experimental|Group B|Healthy volunteers will receive Aripiprazole Oral Soluble Film(OSF) 10mg orally a single of dose within 28 days without water.
88949361|NCT03401762|Experimental|Chronic stroke MCI EMG triplets|Decoupling 3 muscles at a time with MCI
89473713|NCT02501109|Experimental|Gruop C|Healthy volunteers will receive the reference drug Abilify tab. 10mg orally a single of dose within 28 days with water.
88949362|NCT03401762|Experimental|Chronic stroke MCI while reaching|Decoupling muscles with MCI while reaching to targets
88949363|NCT03401762|Sham Comparator|Chronic stroke Sham MCI|Sham control group
88949364|NCT03401762|Experimental|Acute stroke MCI|Decoupling muscles with MCI in acute stroke subjects
89473714|NCT03938246|Experimental|TVB-2640|Subjects randomly assigned to receive the study drug will take TVB-2640 tablet orally every day for 12 week treatment period. The dose is to be taken at the same time of the day, with each dose separated by 24 hours (±4 hours).
88949365|NCT03401762|Sham Comparator|Acute stroke Sham MCI|Acute stroke subjects sham comparator
88949366|NCT03336268|Experimental|POINT|This arm will be offered both POINT services (in addition to standard emergency care) and enrollment in study data collection. If they choose to enroll in POINT, they may choose whether or not to enroll in data collection, as it is not required. Should they enroll in data collection, they will be consented and enrolled in the research study as a participant in the POINT study arm.
88949367|NCT03336268|No Intervention|Standard Care|This arm will only be offered enrollment in study data collection, as they will receive standard emergency care. If they choose to enroll, they will be consented in the research study as the Standard Care arm.
88949368|NCT03328026|Experimental|SV-BR-1-GM, retifanlimab combination original sequence|Subjects will be treated with the SV-BR-1-GM regimen in combination with retifanlimab with cycles every 3 weeks
88949369|NCT03328026|Experimental|SV-BR-1-GM, retifanlimab combination alternative sequence|"Subjects will be treated with the SV-BR-1-GM regimen in combination with retifanlimab as follows:~Cycle 1: SV-BR-1-GM only Cycle 2: resume retifanlimab on Day 2±1 Cycle 3 and beyond: retifanlimab can be administered on Day -2, Day 0, 1, 2, or 3."
88949370|NCT03324932|Other|AI+denosumab VS only AI|We compare AI intake+denosumab injection and AI intake only in patients with normal BMD to whom Letrozole or Arimidex will be administered as postoperative endocrine therapy, and we assess the efficacy of denosumab injection on bone loss by adjuvant endocrine therapy.
89473715|NCT03938246|Placebo Comparator|Placebo|Subjects randomly assigned to placebo will receive placebo tablets orally once a day under the same conditions and frequency as described for TVB-2640.
89473716|NCT03938246|Experimental|Cross over to TVB-2640|At Catalina Research Institute, a subset of subjects who received placebo in the single-blind Cohorts 1 and 2 at that site will be recruited to an open label cross over Cohort 3 where they will receive the study drug (TVB-2640 tablet) orally every day for 12-week treatment period. Additional patients from outside the pool of previous placebo subjects may be needed to meet the enrollment target.
89473717|NCT04498533|Active Comparator|B (brace) group|The patients in the B group were informed about the application of the forearm strap (counterforce brace). Patients were advised to wear the counterforce brace for three weeks continuously.
89473718|NCT04498533|Active Comparator|KT (kinesio tape) group|In the KT group, a standard 2-inch (5 cm) Kinesio®Tex tape (Kinesio Holding Corporation, Albuquerque, New Mexico, USA) was used with techniques of muscle inhibition and fascia correction. Kinesio tape was applied once a week for four weeks.
89473719|NCT02245399|Experimental|A canola oil enriched mediterranean diet|Participants will be advised to consume, a low-carbohydrate diet (26-32% of calories), high in vegetable protein (28-32%) and fat (41-45%) with canola as the major component (10%). Carbohydrate sources will feature viscous fiber-containing foods (including psyllium cereal, oats and barley) and low-starch vegetables (emphasizing okra and eggplant) for the relatively limited amount of carbohydrate.
89473720|NCT02245399|Active Comparator|A high wheat fiber diet|Participant will be advised to consume a high carbohydrate diet (58% carbohydrate, 16% protein and 25% fat) emphasizing whole wheat/whole grain cereals and increased high fiber alternatives, with fruits and vegetables.
89473721|NCT05060666|Experimental|Ivermectin|2 doses of ivermectin at day 0 and day 2
89473722|NCT05060666|Placebo Comparator|Placebo|2 doses of placebo at day 0 and day 2
89473723|NCT02508129|Experimental|Brief Behavioral Treatment for Insomnia|Brief Behavioral Treatment for Insomnia (BBTI) employs behavioral strategies for managing insomnia and is administered in 4 brief weekly contacts with a therapist via online web conferencing.
89473724|NCT02508129|Experimental|Sleep Healthy Using the Internet (SHUTi)|SHUTi is an automated, interactive, personalized web-based program for improving insomnia through the use of Cognitive-Behavioral Therapy strategies for insomnia.
89473725|NCT02508129|Placebo Comparator|Enhanced Usual Care (EUC)|EUC involves the primary care physician's current treatment; feedback to patients and providers on assessment and treatment recommendations; an educational video from Emmi Solutions, Inc.
89473726|NCT05106842|Active Comparator|Hydrotherapy after Rotator Cuff Repair|The participants will start with passive mobilization right after surgery for 4 weeks. Intervention in hydrotherapy will follow after that.
89473727|NCT05106842|Active Comparator|Classical Land Based Rehabilitation after Rotator Cuff Repair|The participants will start with passive mobilization right after surgery for 4 weeks. Intervention in classic dry land based rehabilitation will follow after that.
89473728|NCT03573895|Experimental|Foam-Roller|
89473729|NCT03573895|Experimental|Neuromuscular Stretching|
89473730|NCT03573895|Experimental|Pasive stretching|
89473731|NCT03573895|No Intervention|Control|
89473732|NCT02508051|No Intervention|No daily emails|The usual care group will receive no intervention except for a reminder every six months to take a test of journal-based CME questions from 2 anesthesiology journals
89473733|NCT02508051|Placebo Comparator|Article email links|The email link group will get e-mailed web links to different specific articles, including articles on which the CME questions are based, published in 2 anesthesiology journals Monday through Friday with a reminder to take the same test every six months
89473734|NCT02508051|Experimental|Blog email links|The experimental group will get e-mailed web links to blogs Monday through Friday based on the same specific articles as in group 2; each daily blog will focus on a specific article, including articles on which CME questions are based, the blogs will have web links to the articles on which they are based and every six months group 3 will get a reminder to take the same test.
89473735|NCT04991168||Diabetic patients over 18 from the CHU Lapeyronie|Diabetic patients over 18 from the CHU Lapeyronie
89473736|NCT02507895|Experimental|MI-BCI training|subjects will undergo 12 sessions over 4 weeks of MI-BCI training
88949371|NCT03297645|Experimental|Arm 1|school + asthma education + home environment remediation
88949372|NCT03297645|Experimental|Arm 2|asthma education + home environment remediation
88949373|NCT03297645|Active Comparator|Arm 3|enhanced standard of care
89473737|NCT04935320|Experimental|Oral Solution Fasted|HTL0016878.HCl 10 mg, single dose, oral solution, fasted
89473738|NCT04935320|Experimental|Oral Capsule Fasted|HTL0016878.citrate 10 mg, single dose, oral capsule, fasted
89473739|NCT04935320|Experimental|Oral Capsule Fed|HTL0016878.citrate 10 mg, single dose, oral capsule, fed
89473740|NCT02506335|Other|Hep quant cholate testing|diagnostic measure of liver function
89473741|NCT04875104|Active Comparator|Invisalign|Patients treated with Invisalign aligners
89473742|NCT04875104|Experimental|Spark|Patients treated with Spark aligners
89473743|NCT04875104|Experimental|Quicksmile|Patients treated with Quicksmile aligners
89473744|NCT04875104|Experimental|ClearCorrect|Patients treated with ClearCorrect aligners
89473745|NCT01353859|Experimental|Single Arm|
89473746|NCT03344133|Experimental|Exercise|4-week moderate intensity exercise programme
89473747|NCT03344133|No Intervention|Control|4 weeks of habitual life style
89473748|NCT02507817||31-32 with Mg for neuroprotection|"Women in 31-32 weeks gestation that where treated with Magnesium Sulphate for neuroprotection.~blood sample and tissue sample (placenta)."
89473749|NCT02507817||33-34 without Mg for neuroprotection|"Women in 33-34 weeks gestation that per protocol are not entitled for treatment with Magnesium Sulphate for neuroprotection.~blood sample and tissue sample (placenta)."
89473750|NCT02507817||PET with Mg after 34 weeks|"Women that had severe preeclamsia and where treated with Magnesium Sulphate for seizure prophylaxis and delivere after 34 weeks of gestation.~blood sample and tissue sample (placenta)."
89473751|NCT02507817||control|"Low risk pregnanacies in similar weeks to group 3 that did not require any special teatment and delivered after 34 weeks of gestation.~blood sample and tissue sample (placenta)."
89473752|NCT02238197||Chronic Obstructive Pulmonary Disease|
89473753|NCT02500953|Experimental|Japanese male single fasted ASP dose-1|ASP3325 will be administered as a single oral dose with 240 mL of water to subjects who have been fasting from 22:00 on the day before administration.
89473754|NCT02500953|Experimental|Japanese male single fasted ASP dose-2|ASP3325 will be administered as a single oral dose with 240 mL of water to subjects who have been fasting from 22:00 on the day before administration.
89473755|NCT02500953|Experimental|Japanese male single fasted ASP dose-3|ASP3325 will be administered as a single oral dose with 240 mL of water to subjects who have been fasting from 22:00 on the day before administration.
89473756|NCT02500953|Experimental|Japanese male single fasted ASP dose-4|ASP3325 will be administered as a single oral dose with 240 mL of water to subjects who have been fasting from 22:00 on the day before administration.
89473757|NCT02500953|Experimental|Japanese male single fasted ASP dose-5|ASP3325 will be administered as a single oral dose with 240 mL of water to subjects who have been fasting from 22:00 on the day before administration.
89473758|NCT02500953|Experimental|Japanese male single fasted ASP dose-6|ASP3325 will be administered as a single oral dose with 240 mL of water to subjects who have been fasting from 22:00 on the day before administration.
89473759|NCT02500953|Experimental|Japanese male single fasted ASP dose-7|ASP3325 will be administered as a single oral dose with 240 mL of water to subjects who have been fasting from 22:00 on the day before administration.
89473760|NCT02500953|Experimental|Japanese female single fasted ASP dose-3|ASP3325 will be administered as a single oral dose with 240 mL of water to subjects who have been fasting from 22:00 on the day before administration.
89473761|NCT02500953|Experimental|Japanese female single fasted ASP dose-5|ASP3325 will be administered as a single oral dose with 240 mL of water to subjects who have been fasting from 22:00 on the day before administration.
89019704|NCT06165185|Experimental|Water|"At intervention day 1, during a maximum time period of 20 minutes, subjects will ingest 1 L of water (still bottled water) to map the acute water effect on the vasopressin marker copeptin (repeated blood sampling every 30 minutes for 4 hours). Day 1 then continues with the rest of the daily intake, i.e., 2 L of extra water (i.e. in addition to each subject's habitual food and fluid intake).~Intervention day 2-7: 3 L extra water per day in addition to each subject's habitual food and fluid intake."
89206212|NCT01062919|Experimental|Wound Group|patients in the epidural analgesia group will receive ropivacaine 0.2% through the wound catheter, normal saline in the epidural catheter and PCA with morphine.
89473762|NCT02500953|Experimental|Caucasian male single fasted ASP dose-3|ASP3325 will be administered as a single oral dose with 240 mL of water to subjects who have been fasting from 22:00 on the day before administration.
89473763|NCT02500953|Experimental|Caucasian male single fasted ASP dose-5|ASP3325 will be administered as a single oral dose with 240 mL of water to subjects who have been fasting from 22:00 on the day before administration.
89473764|NCT02500953|Experimental|Japanese male single fed ASP dose-5|ASP3325 will be administered as a single oral dose with 240 mL of water to subjects after a meal.
89473765|NCT02500953|Experimental|Japanese male single fasted placebo|Placebo will be administered as a single oral dose with 240 mL of water to subjects who have been fasting from 22:00 on the day before administration.
89473766|NCT02500953|Experimental|Japanese female single fasted placebo|Placebo will be administered as a single oral dose with 240 mL of water to subjects who have been fasting from 22:00 on the day before administration.
89473767|NCT02500953|Experimental|Caucasian male single fasted placebo|Placebo will be administered as a single oral dose with 240 mL of water to subjects who have been fasting from 22:00 on the day before administration.
89473768|NCT02500953|Experimental|Japanese male single fed placebo|Placebo will be administered as a single oral dose with 240 mL of water to subjects after a meal.
89473769|NCT02500953|Experimental|Japanese male multiple ASP dose-3|ASP3325 will be administered as multiple oral doses with 240 mL of water, three times a day, just after a meal.
89473770|NCT02500953|Experimental|Japanese male multiple ASP dose-4|ASP3325 will be administered as multiple oral doses with 240 mL of water, three times a day, just after a meal.
89473771|NCT02500953|Experimental|Japanese male multiple ASP dose-5|ASP3325 will be administered as multiple oral doses with 240 mL of water, three times a day, just after a meal.
89473772|NCT02500953|Experimental|Japanese female multiple ASP dose-3|ASP3325 will be administered as multiple oral doses with 240 mL of water, three times a day, just after a meal.
89473773|NCT02500953|Experimental|Japanese female multiple ASP dose-4|ASP3325 will be administered as multiple oral doses with 240 mL of water, three times a day, just after a meal.
89473774|NCT02500953|Experimental|Japanese female multiple ASP dose-5|ASP3325 will be administered as multiple oral doses with 240 mL of water, three times a day, just after a meal.
89473775|NCT02500953|Experimental|Japanese male multiple Placebo|Placebo will be administered with 240 mL of water, three times a day, just after a meal.
88949374|NCT03266783|Active Comparator|Apixaban group|10 mg orally (PO), twice a day (BID) for 1 week, then 5 mg PO BID for 3 months of treatment
88949375|NCT03266783|Active Comparator|Rivaroxaban group|15 mg orally (PO), twice a day (BID) for 3 weeks, then 20 mg PO once a day (OD) for 3 months of treatment
88949376|NCT03242343|Experimental|VasQ device implantation|"Main study cohort: Prospective, multi-center, single-arm, open label, enrolling patients referred to surgical creation of new brachiocephalic fistula (BCF). The VasQ will be applied to the AV fistula in all patients. The primary effectiveness endpoint for this trial will be measured at 6 months and compared to a performance goal (PG). Safety will compare descriptively between AE rates for Steal, Infection, Aneurysm and Seroma. Patients will be followed up for an additional 18 months for a total of 2 years. Additionally, this trial has several secondary endpoints.~Supplementary study cohort: 15 patients will be prospectively enrolled which are referred to surgical creation of a new forearm arteriovenous fistula. VasQ will be applied to the AV fistula in all patients. Patients will be followed in the same manner as in the Main study cohort, however, the data will be reported separately and not be part of the analysis sets for the study primary and secondary endpoints."
88949377|NCT03231735|Other|Mid frequency ventilation|Mid frequency ventilation delivered at rates > 60 per minute and ≤ 150 per minute, with patient triggered ventilation and pressure support.
89473776|NCT02500953|Experimental|Japanese female multiple Placebo|Placebo will be administered with 240 mL of water, three times a day, just after a meal.
89473777|NCT02500953|Experimental|Japanese male ASP dose-5 before a meal|ASP3325 will be administered with 240 mL of water, three times a day, for 2 days.
89473778|NCT02500953|Experimental|Japanese male ASP dose-5 during a meal|ASP3325 will be administered with 240 mL of water, three times a day, for 2 days.
89473779|NCT02500953|Experimental|Japanese male ASP dose-5 after a meal|ASP3325 will be administered with 240 mL of water, three times a day, for 2 days.
89473780|NCT03592433|Experimental|I Can PIC|The I Can PIC website will be provided to participants randomized to the experimental/intervention group.
88949378|NCT03231735|Other|Standard frequency ventilation|Standard frequency ventilation delivered at rates < 60 per minute and ≥ 20 per minute, with patient triggered ventilation and pressure support.
88949379|NCT03219359|Experimental|Experimental|Hematopoietic Stem Cell Transplant followed by maintenance Vedolizumab
88949380|NCT03180034|Experimental|Arm I (Gardasil, DTaP)|Participants receive Gardasil IM at month 0 and DTaP IM at month 6.
89473781|NCT03592433|No Intervention|Attention Control|Participants randomized to the attention control group will be provided a link to a website developed by the American Cancer Society Cancer Action Network.
89473782|NCT05342714|Experimental|RIC group|Participants in the experimental group receive both RIC and standard clinical therapy. The RIC treatment is composed of 5 cycles of bilateral upper limb ischemia for 5 minutes followed by reperfusion for another 5 minutes performed twice a day for a total of 180 consecutive days.The procedure was performed by using an electric autocontrol device with cuffs that inflated to a pressure of 200 mmHg during the ischemic period and deflated during the reperfusion (Patent No.CN200820123637.X, China).
89473783|NCT05342714|No Intervention|Control group|Participants in the control group receive standard clinical therapy.
89473784|NCT03592355|Experimental|Intervention|"If enrolled in the intervention arm, the following steps will occur:~The Brigham Health Virtual Care team will work with the clinician toward immediate on-boarding (software training, hardware setup, technical support) as per their usual process.~The clinician will schedule virtual visits as s/he and/or her/his department see fit. Virtual visits occur on an already-in-use Partners- and Brigham-approved video platform."
89473785|NCT03592355|No Intervention|Control|"If enrolled in the control arm, the following steps will occur:~Three months from the time of the follow-up email, the Brigham Health Virtual Care team will work with the clinician toward immediate on-boarding (software training, hardware setup, technical support) as per their usual process.~The clinician will schedule virtual visits as s/he and/or her/his department see fit. Virtual visits occur on an already-in-use Partners- and Brigham-approved video platform."
89473786|NCT03571243||smokers|no intervention
89473787|NCT03571243||never-smokers|no intervention
89473788|NCT02500875|Experimental|PTNiA|"Topical negative pressure therapy with instillation of saline solution (6 times daily).~During the instillation of saline solution, aspiration is stopped for 10-15 minutes and subsequently the device is programmed to exert a sub atmospheric pressure in aspiration of at least 50 mmHg up to a maximum of 200 mmHg.~The change of dressing is carried out on the first day after the application of the device, and thereafter, as needed (approximately every 3 or 4 days)."
88949381|NCT03180034|Experimental|Arm II (Cervarix, DTaP)|Participants receive Cervarix IM at month 0 and DTaP IM at month 6.
88949382|NCT03180034|Active Comparator|Arm III (Gardasil)|Participants receive Gardasil IM at month 0 and 6.
88949383|NCT03180034|Active Comparator|Arm IV (Cervarix)|Participants receive Cervarix IM at month 0 and 6.
88949384|NCT03180034|No Intervention|Arm V (epidemiologic survey)|A concurrent epidemiologic survey for HPV status among two groups of unvaccinated women. Survey participants are followed for two study visits six months apart to determine their HPV DNA status, with no further follow-up. These women will be offered HPV vaccination (Cervarix) at the two study visits.
88949385|NCT03169712|Active Comparator|CBT for PTSD|15 sessions of trauma-focused CBT
88949386|NCT03169712|Experimental|Imagery Rehearsal Therapy + CBT for PTSD|5 sessions of IRT + 15 sessions of trauma-focused CBT
88949389|NCT03121352|Experimental|Carboplatin + Nab-paclitaxel + Pembrolizumab|Combination therapy of Carboplatin, Nab-paclitaxel, and Pembrolizumab
88949390|NCT03114501|Experimental|Yoga Program Group|"Participants take part in the partner-based yoga program.~Questionnaire completed during each week of radiation therapy about participant's feelings about the yoga sessions.~Questionnaires completed before first radiation treatment, during week 3 of radiation therapy, and again after completion of treatment schedule (usually 6 weeks later)."
88949391|NCT03114501|Experimental|Waitlist Control Group (WLC)|"Participants receive standard of care.~Questionnaires completed before first radiation treatment, during week 3 of radiation therapy, and again after completion of treatment schedule (usually 6 weeks later).~After the study has been completed, participant and caregiver/alternative caregiver offered the opportunity to take part in the partner-based yoga program."
88949392|NCT03113929||Alcoholic Liver Disease Patients|
88949393|NCT03108456|Active Comparator|Orbital Atherectomy (OA)|The Diamondback 360® Coronary Orbital Atherectomy System (OAS) will be used for orbital atherectomy (OA) vessel preparation prior to implantation of a drug-eluting stent.
88949394|NCT03108456|Active Comparator|Conventional Balloon Angioplasty|Coronary balloons cleared or approved for commercial use by the Food and Drug Administration will be used for conventional balloon angioplasty prior to implantation of a drug-eluting stent.
88949395|NCT03086421||Brain Tumor Participants|Participants with a diagnosis of brain tumor who are between the ages of 4 and 6 years old and are 6 to 12 months post-completion of treatment. They will complete several standard questionnaires.
89538481|NCT02457689|Placebo Comparator|Group 3 (Electroporation and Placebo)|Group 3 (Electroporation and Placebo) Participants will receive 1.0ml intramuscular injections of Sodium Chloride BP into the upper thigh using the ICHOR TriGridTM delivery system for intramuscular (TDS-IM) delivery with electroporation. Electroporation (EP) improves the delivery of the product into muscle cells, by delivering an electrical pulse with the injection using a hand held device that is pressed against your thigh. This will cause a muscle twitch with a sharp cramp-like feeling in the thigh lasting a few seconds. Once the procedure is carried out, the muscle will feel sore for up to 72 hours. The investigator will ask volunteers not to engage in any strenuous exercise for at least 24 hours after the procedure.
88949396|NCT03086421||Solid Tumor Participants|Participants with a diagnosis of non-Central Nervous System (non-CNS) solid tumor who are between the ages of 4 and 6 years old and are 6 to 12 months post-completion of treatment. They will complete several standard questionnaires.
88949397|NCT03073577|Experimental|Treatment Group|PKX-001 will be supplemented to islet preservation CMRL-1066 medium at final concentration of 3 mg/mL during islet isolation process. On the day of transplantation, preserved islets supplemented with PKX-001 are collected and washed with Transplant Media, which does not contain PKX-001, as a standard procedure. The isolation team will evaluate the final islet product based on standard assays. Islets are maintained for minimal 6 hours up to 72 hours in supplemented CMRL1066-based media containing PKX-001 until the time of transplant. When product release minimal criteria are met, islets will be clinically transplanted into patients intraportally.
88949398|NCT03069469|Other|Experimental Treatment|"Dose Escalation Phase: Increasing doses of DCC-3014 beginning at 10 mg QD for 28 day cycles until disease progression or unacceptable toxicity.~Expansion Phase: Dosing of different patient cohorts at the dose level determined from the Dose Escalation Phase of the study."
88949399|NCT03066206|Experimental|Treatment (poziotinib)|Patients receive poziotinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88949400|NCT03051074|Experimental|Floating|The participant will float supine in water with a high concentration of Epsom salt for up to 90 minutes on three separate occasions
88949401|NCT03051074|Active Comparator|Comparison condition|The participant will watch a relaxing 90 minute film as a comparison condition
88949402|NCT02975882|Experimental|Treatment (nab-rapamycin, temozolomide, irinotecan)|Patients receive nanoparticle albumin-bound rapamycin IV over 30 minutes on days 1 and 8 beginning on cycle 1. Patients also receive temozolomide PO and irinotecan hydrochloride PO on days 1-5 beginning on cycle 2. Treatment repeats every 21 days for up to 35 cycles in the absence of disease progression or unacceptable toxicity.
88949403|NCT02965755|Other|Genetic profiling|All participants will undergo genetic profiling. Archival tissue will be requested to undergo routine review for possible treatment recommendations. Blood samples will be obtained to study research correlates (plasma tumor DNA, ptDNA) and tissue comparison.
88949404|NCT02938130|Other|Wellness Programs|Community Partners and Community LIFE programs
88949405|NCT02916550|Experimental|Breathing exercise|Participants will perform a paced breathing intervention (slow breathing) prompted by pseudorandomized remote reminders (scheduled reminders plus non scheduled reminders), through cellular phone application.
88949406|NCT02911064||Assessment Questionnaires|Questionnaires completed before and after inpatient rehabilitation. Questionnaires ask about daily living activity performance, expectation of how well daily living activities will be performed after completion of inpatient rehabilitation, symptoms experienced in the past 24 hours, and physical, functional, social, and emotional well-being.
88949407|NCT02871921|Experimental|Conversational Engagement|Participants engage in 30-minute face-to-face communications with study staff through internet/webcam 4 times per week for 24 weeks (6 months). Under an exploratory aim, a limited number of participants will be further followed by sustaining dose of 2 times per week of 30 minutes session for additional 24 weeks (6 months). Conversational staff will facilitate content-standardized but naturalistic-style social engagement. Staff and participants will engage in conversation about a wide variety of topics that are culturally and personally relevant and interesting to participants. Each day, participants will be able to choose from topic options. Participants will also receive a phone call once per week that lasts approximately 10 minutes; interviewers ask brief questions to monitor participant social activities and health conditions.
88949408|NCT02871921|No Intervention|Control Group|Participants will receive a phone call once per week that lasts approximately 10 minutes; interviewers ask brief questions to monitor participant social activities and health conditions
88949409|NCT02827032|Experimental|MobiusHD™|The MobiusHD device is a self-expanding nitinol implant that is delivered intravascularly to the internal carotid sinus via the delivery catheter.
88949410|NCT02818283|Experimental|Soy Pretzel-Short Feasibility|6 week intervention involving daily consumption of soy pretzel (two packets, 5 oz./packet) for 28 days. Participants will follow a legume-free diet which restricts the consumption of legume foods (soy, beans, peas, peanuts, and lentils) during the study period. This arm will precede the longer 28 week study
88949411|NCT02818283|Active Comparator|Soy Pretzel|28 week intervention involving daily consumption of soy pretzel (two packets, 5 oz./packet) for 12 weeks. Participants will follow a legume-free diet which restricts the consumption of legume foods (soy, beans, peas, peanuts, and lentils) during the study period. Participants will be randomized to start with soy pretzel or wheat pretzel arm and crossover to the other pretzel at week 14.
88949412|NCT02818283|Placebo Comparator|Wheat Pretzel|28 week intervention involving daily consumption of wheat pretzel (two packets, 5 oz./packet) for 12 weeks. Participants will follow a legume-free diet which restricts the consumption of legume foods (soy, beans, peas, peanuts, and lentils) during the study period. Participants will be randomized to start with soy pretzel or wheat pretzel arm and crossover to the other pretzel at week 14.
88949413|NCT02811133|Experimental|Inositol|Subjects will receive inositol
88949414|NCT02790021|No Intervention|Complex decongestive therapy|Group A will continue complex decongestive therapy consisting of skin care, manual lymphatic drainage, and compression therapy using compression stockings.
88949415|NCT02790021|Experimental|Lymphaticovenous anastomosis (LVA)|Group B will undergo an LVA procedure under local anesthesia in surgical daycare setting. Patients are not allowed to wear compression stockings or have decongestive therapy for four weeks after the surgery.
88949416|NCT02784119|Experimental|temporary porto-caval shunt|patients in whom temporary porto-caval shunt is performed during orthotopic liver transplantation
89473789|NCT02500875|Experimental|PTNiB|"Topical negative pressure therapy with instillation of Amukine Med 0,05% (6 times daily).~During the instillation of Amukine Med 0,05%, aspiration is stopped for 10-15 minutes and subsequently the device is programmed to exert a sub atmospheric pressure in aspiration of at least 50 mmHg up to a maximum of 200 mmHg.~The change of dressing is carried out on the first day after the application of the device, and thereafter, as needed (approximately every 3 or 4 days)."
89473790|NCT02500875|Active Comparator|PTN|"Topical negative pressure therapy (without instillation). The device is programmed to exert a sub atmospheric pressure in aspiration of at least 50 mmHg up to a maximum of 200 mmHg.~The change of dressing is carried out on the first day after the application of the device, and thereafter, as needed (approximately every 3 or 4 days)."
89473791|NCT04436588||DDX3X|DDX3X
89473792|NCT03592199|Experimental|1st Line Sunitinib and 2nd Line Axitinib|1st line sunitinib on a 4/2 schedule followed by axitinib 5 mg twice a day on 2nd line therapy
89473793|NCT02245867|Experimental|Phase Ia|"Administration of Chimeric Fibril-Reactive Monoclonal Anti-body 11-1F4:~A 1-patient cohort will be infused with 0.5 mg/m2 of Ch 11-1F4 and, if tolerated, the doses in the next patients will be increased to 5, 10, 50, 100, 250, and finally, 500 mg/m2. All individuals will be evaluated prior to treatment, after infusion weekly for four weeks, as well as at 8 weeks."
89473794|NCT02245867|Experimental|Phase Ib|"Administration of Chimeric Fibril-Reactive Monoclonal Anti-body 11-1F4:~Subjects will receive four weekly infusions of the monoclonal anti-body at Dose Level 1 (0.5 mg/m2). If tolerated, the doses in the next patients will be increased to 5, 10, 50, 100, 250, and finally, 500 mg/m2. When the highest tolerated dose is reached without toxicity in 2 patients, an additional 4 patients will be enrolled and infused at that dose. Escalation or de-escalation will continue until we have determined the highest dose level at which less than 2 patients experience toxicity. All individuals will be evaluated prior to each course of treatment, as well as at weeks 5, 8, and 12."
89473795|NCT02506413|Other|MNCH Intervention Package|"The division assigned to this arm received a comprehensive Maternal and Newborn Health (MNH) intervention package using the 'MamaToto Process'. Key intervention activities included:~engaging district leaders in district health system strengthening;~strengthening health facility-based MNH services; and~establishing a Maternal, Newborn, and Child Health focused lay Community Health Worker program."
89473796|NCT03591809|Experimental|combined exercise training group|The combined exercise training group will be given combined exercise training, consisting of Pilates and aerobic exercise, three times during 8 weeks.
89473797|NCT03591809|No Intervention|Control group|The patients in the control group will not apply an exercise training.
89473798|NCT02507739|Other|possibility to walk during labor|possibility to walk during labor
89473799|NCT02507739|Other|no possibility to walk during labor|no possibility to walk during labor
89473800|NCT03573661|Experimental|Breast Cancer Locator (BCL)|The Breast Cancer Locator (BCL) uses 3D printing to create a bra-like plastic form that matches the breast surface when the patient is in the supine MRI (and surgical) position. This locator will be constructed pre-operatively, sterilized and provided to the surgeon at the time of procedure.
89473801|NCT02507583|Experimental|Cohort 1|After protocol amendment dated 11 May 2017, all subjects enrolled into the trial will receive 20 chambers for 48 hours.
89473802|NCT02246101||WTC responders|WTC responders who were enrolled in the WTC-CHEST program.
89473803|NCT02506023|Active Comparator|Hemophilia A carriers with mild mutation|Hemophilia A carriers with a mild type mutation will be given a single intravenous dose of 0.3mcg/kg of DDAVP (Desmopressin).
89473804|NCT02506023|Active Comparator|Hemophilia A Carriers with severe mutation|Hemophilia A carriers with a severe type mutation will be given a single intravenous dose of 0.3mcg/kg of DDAVP (Desmopressin).
89473805|NCT02506023|Active Comparator|Control|Subjects with a mild qualitative platelet dysfunction will be given a single intravenous dose of 0.3mcg/kg of DDAVP (Desmopressin).
89473806|NCT04876196|Active Comparator|Intervention Group|Web-based intervention (Selfapy for Bulimia Nervosa)
89473807|NCT04876196|No Intervention|Waitlist Control Group|12-week waiting period
89473808|NCT03828461|Experimental|BITS + VR|Facilitated group therapy with behavioral practice; 16 weeks
89473809|NCT04497441||Netizens|Internet users in Al Qassim province region are the target study population for this study. This Cross sectional study utilizes an electronic google form to get responses from netizens of Al Qassim province of Saudi Arabia regarding the perception of COVID-19 information and information sources. All the questions in the survey are compulsory answerable questions. The settings in the google form are set so that a single respondent can limit the survey response to single time. The Google form link is shared to the netizens of Al Qassim province across relevant Social media platforms.
88949417|NCT02784119|No Intervention|no temporary porto-caval shunt|patients in whom temporary porto-caval shunt is not performed during orthotopic liver transplantation
88949418|NCT02775435|Experimental|Pembrolizumab + Chemotherapy|Participants receive pembrolizumab 200 mg by intravenous (IV) infusion prior to chemotherapy on Day 1 of each 21-day cycle for up to 35 cycles PLUS Investigator's choice of paclitaxel (200 mg/m^2 by IV infusion on Day 1 of each 21-day cycle for 4 cycles) or nab-paclitaxel (100 mg/m^2 by IV infusion on Days 1, 8, 15 of each 21-day cycle for 4 cycles) PLUS carboplatin AUC 6 by IV infusion on Day 1 of each 21-day cycle for 4 cycles.
88949419|NCT02775435|Active Comparator|Chemotherapy|Participants receive normal saline by IV infusion prior to chemotherapy on Day 1 of each 21-day cycle for up to 35 cycles PLUS Investigator's choice of paclitaxel (200 mg/m^2 by IV infusion on Day 1 of each 21-day cycle for 4 cycles) or nab-paclitaxel (100 mg/m^2 by IV infusion on Days 1, 8, 15 of each 21-day cycle for 4 cycles) PLUS carboplatin AUC 6 by IV infusion on Day 1 of each 21-day cycle for 4 cycles.
88949420|NCT02766933||hepatitis B cohort|CBCHB employees and/or spouses found to be hepatitis B surface antigen positive on screening
89473810|NCT04395599|Experimental|COVID19 patients undergoing visceral surgery|
89019705|NCT06165185|Experimental|Coffee|"At intervention day 1, during a maximum time period of 20 minutes, subjects will ingest 4 dL of coffee to map the acute coffee effect on the vasopressin marker copeptin (repeated blood sampling every 30 minutes for 4 hours). Day 1 then continues with the rest of the daily intake, i.e., 6dL of extra coffee (i.e. in addition to each subject's habitual food and fluid intake).~Intervention day 2-7: 1 L extra coffee per day in addition to each subject's habitual food and fluid intake."
89019706|NCT06165185|Experimental|Control|"At intervention day 1, during a maximum time period of 20 minutes, subjects will ingest just 10 ml of water to map the acute effect on the vasopressin marker copeptin (repeated blood sampling every 30 minutes for 4 hours). Day 1 then continues with each subject's habitual food and fluid intake.~Intervention day 2-7: Each subject's habitual food and fluid intake."
89019707|NCT06165172|Experimental|Intervention|Active treatment with MyoRegulator® device
89019708|NCT06165146|Experimental|Repaglinide - Period 1|Single dose of repaglinide administered orally.
89019709|NCT06165146|Experimental|Pirtobrutinib - Period 2|Multiple doses of pirtobrutinib administered orally.
89019710|NCT06165146|Experimental|Pirtobrutinib + Repaglinide - Period 2|"Pirtobrutinib administered in combination with repaglinide orally.~There will be a washout period of 11 days between the dose of repaglinide from Period 1 to 2."
89473811|NCT02246179|Experimental|1: AFXL + AHES|This test region will be pretreated with a fractional carbon dioxide laser (ablative fractional laser; AFXL) with a 120 μm spot at 5% density and a pulse energy of 2.5 mJ/microbeam, single pulse at t0 in a subject blinded fashion. Articaine hydrochloride 40 mg/ml and epinephrine 10 μg/ml solution (AHES) will be applied at this test region at t1.Ten minutes after AHES application (incubation time; under occlusion), a pain stimulus will be given at t11 to the subject at the test region using AFXL at 5% density and 35 mJ/microbeam.
89473812|NCT02246179|Experimental|2: AFXL + EMLA|This test region will be pretreated with a fractional carbon dioxide laser (ablative fractional laser; AFXL) with a 120 μm spot at 5% density and a pulse energy of 2.5 mJ/microbeam, single pulse at t0 in a subject blinded fashion. Eutectic mixture of lidocaine 25 mg/g and prilocaine 25 mg/g cream (EMLA cream) will be applied at this test region at t1.Ten minutes after EMLA cream application (incubation time; under occlusion), a pain stimulus will be given at t11 to the subject at the test region using AFXL at 5% density and 35 mJ/microbeam.
89473813|NCT02246179|Sham Comparator|3: Sham AFXL + AHES|"A pass with a fractional carbon dioxide laser with a 120 μm spot at 5% density and a pulse energy of 2.5 mJ/microbeam, single pulse will be given at the area right adjacent to this test region (sham AFXL) at t0 in a subject blinded fashion. Articaine hydrochloride 40 mg/ml and epinephrine 10 μg/ml solution (AHES) will then be applied at this test region on the intact skin at t1. Ten minutes after AHES application (incubation time; under occlusion), a pain stimulus will be given at t11 to the subject at the test region using AFXL at 5% density and 35 mJ/microbeam."
89019711|NCT06165133|Experimental|Non-Surgeon Physician|The intervention arm is a mesh inguinal hernia repair performed by a non-surgeon physician (NSP). These are medical officers who have finished a 2-year mandatory house job. The medical officers will be trained to perform inguinal hernia repair by a certified surgical trainer in Ghana.
89019712|NCT06165133|Placebo Comparator|Control: Surgeon|The control is a mesh inguinal hernia repair performed by a fully trained surgeon, defined as one who is accredited as fully trained with the Ghana College of Physicians and Surgeons, West African College of Surgeons, or equivalent. A trained surgeon will be assisted by an NSP who has completed the TIGER training programme. We anticipate that at least 5-10 fully trained surgeons will take part in the control arm.
89019713|NCT06165120|Active Comparator|group A; Bracka's repair group|This group will undergo Bracka's repair using preputial graft in treatment of proximal hypospadias with marked ventral curvature
89019714|NCT06165120|Active Comparator|group B; STPIF repair group|This group will undergo STPIF repair using preputial flap in treatment of proximal hypospadias with marked ventral curvature
89019715|NCT06165107||Ischemic stroke|"We retrospectively gathered information on patients admitted for acute first-ever ischaemic stroke between January 2012 and January 2022. The following individuals were excluded from the study: 1) Those under 18 years of age; and 2) Pregnant women.~The variables gathered included the primary test parameters of patients within 24 hours of admission, encompassing age, gender, smoking and alcohol consumption status, arterial blood pressure, fat-related indicators, comorbidities, and the primary treatments administered within the initial 24 hours."
89019716|NCT06165094||Diagnosed with supraclavicular LNM|There was no intervention(s) in any group
89019717|NCT06165094||Diagnosed with paraesophageal LNM|There was no intervention(s) in any group
89019718|NCT06165042|Experimental|Glass hybrid restorative system|(Equia Forte, GC Europe, Leuven, Belgium)
89019719|NCT06165042|Experimental|Fluoride varnish + Glass hybrid restorative|Fluoride varnish (SDI Riva Star)+ Glass hybrid restorative (Equia Forte, GC Europe, Leuven, Belgium)
89019720|NCT06165003|Experimental|Experimental group|Peripheral Intravenous Catheter Insertion Procedure - Broselow Band Selection - Experimental Group Urinary Catheter Insertion Procedure - Broselow Tape Selection - Experimental Group Aspiration process - Broselow Band Selection - Experimental group Nasogastric/Orogastric Catheter Insertion Procedure - Broselow Band Selection - Experimental Group
89019721|NCT06165003|No Intervention|Control Group|Peripheral Intravenous Catheter Insertion Procedure - Routine Application - Control Group Urinary Catheter Insertion Procedure - Routine Application - Control Group Aspiration process - Routine Application - Control Group Nasogastric/Orogastric Catheter Insertion Procedure - Routine Practice - Control Group
89019722|NCT06164990|Experimental|PEKK (Pekkton) framework|PEKK (Pekkton) framework in mandibular implant-supported complete fixed dental prostheses with All-on-four treatment concept and evaluated regarding peri-implant tissue health
89019723|NCT06164977|Other|Chronic total coronary occlusion|Participants who underwent percutaneous coronary intervention for chronic total coronary occlusion revascularization with bioresorbable scaffold.
89019724|NCT06164912|Active Comparator|TMS Neurofeedback|Participants in this Arm will receive TMS neurofeedback
89019725|NCT06164912|Placebo Comparator|TMS Pseudofeedback|Participants in this Arm will receive TMS with pseudofeedback
89019726|NCT06164899||Patients with bilateral knee osteoarthritis treated with hyaluronic acid injection|"Patients with bilateral osteoarthritis treated with hyaluronic acid injection treated within the research protocol OA-bi-blind"
89473814|NCT02246179|Sham Comparator|4: Sham AFXL + EMLA|"A pass with a fractional carbon dioxide laser with a 120 μm spot at 5% density and a pulse energy of 2.5 mJ/microbeam, single pulse will be given at the area right adjacent to this test region (sham AFXL) at t0 in a subject blinded fashion. Eutectic mixture of lidocaine 25 mg/g and prilocaine 25 mg/g cream (EMLA cream) will then be applied at this test region on the intact skin at t1. Ten minutes after EMLA cream application (incubation time; under occlusion), a pain stimulus will be given at t11 to the subject at the test region using AFXL at 5% density and 35 mJ/microbeam."
89473815|NCT02507427|Experimental|Nerve monitoring arm|They will receive pelvic autonomic nerve monitoring and mapping using NIM-Eclipse (Medtronic) during robot-assisted laparoscopic prostatectomy.
89473816|NCT02238275||Patients with hypertension|
89473817|NCT03344055|Active Comparator|Colonoscopy with Endocuff Vision (ECV)|ECV-assisted colonoscopy ( with the use of Endocuff Vision (ECV) Second generation)
89473818|NCT03344055|No Intervention|Standard colonoscopy|Standard colonoscopy (without the use of Endocuff Vision (ECV) Second generation)
89473819|NCT03589235|Experimental|A Platelet-Rich Fibrin dressing|A Platelet-Rich Fibrin dressing (PRF) will be used in both donor and receiving sites after a free gingival graft.
89473820|NCT03589235|Experimental|A non-eugenol-based dressing|A non-eugenol-based dressing (Coe-Pak™) will be used in both donor and receiving sites after a free gingival graft.
89473821|NCT04602104|Experimental|Phase 1: hMSC-Exos low dose|hMSC-Exos low-dose group
89473822|NCT04602104|Experimental|Phase 1: hMSC-Exos medium dose|hMSC-Exos medium-dose group
89473823|NCT04602104|Experimental|Phase 1: hMSC-Exos high dose|hMSC-Exos high-dose group
89473824|NCT04602104|Experimental|Phase 2: hMSC-Exos dosage 1|basic treatment+hMSC-Exos (a quarter of MTD/day)
89473825|NCT04602104|Experimental|Phase 2: hMSC-Exos dosage 2|basic treatment+hMSC-Exos (MTD/day)
89473826|NCT04602104|Placebo Comparator|Phase 2: control group|basic treatment+normal saline
89473827|NCT04495101|Experimental|Prolastin 120 mg/kg + Standard Medical Treatment|Subjects will receive Prolastin, two intravenous infusion (IV) doses of 120 milligram per kilogram (mg/kg), based upon the subject's body weight, on Day 1 and Day 8. Subjects will also receive all standard of care interventions while hospitalized, from Day 1 to Day 29.
89473828|NCT04495101|Active Comparator|Standard Medical Treatment|Subjects will receive all standard of care interventions while hospitalized, from Day 1 to Day 29.
89473829|NCT04394117|Active Comparator|Standard Care + Angiotensin Receptor Blocker (ARB)|Participants will receive an Angiotensin Receptor Blocker on top of the standard care provided by their institution.
89473830|NCT04394117|Placebo Comparator|Standard Care + Placebo|Participants will receive a placebo on top of the standard care provided by their institution.
89473831|NCT04745078|Active Comparator|Carboxy30|carboxy30
88949421|NCT02685826|Experimental|Cohort A: High risk, TNE|"High risk, transplant non-eligible [TNE], newly diagnosed multiple myeloma (NDMM) participants who were administered~Intravenous (IV) durvalumab at 1500 mg on Day 1 of each 28-day cycle~Oral lenalidomide (LEN) 25 mg/day (adjust per the creatinine clearance [CrCl]) value on Days 1 to 21 of each 28-day treatment cycle~Oral dexamethasone (dex) 40 mg/day (≤ 75 years old) or 20 mg/day (> 75 years old) on Days 1, 8, 15, and 22 of each 28-day cycle"
88949422|NCT02685826|Experimental|Cohort B: >=65 years old, TNE|">= 65 years old, transplant non-eligible [TNE], newly diagnosed multiple myeloma (NDMM) participants who were not high risk were administered~Intravenous (IV) durvalumab at 1500 mg on Day 1 of each 28-day cycle~Oral lenalidomide (LEN) 25 mg/day (adjust per the creatinine clearance [CrCl]) value on Days 1 to 21 of each 28-day treatment cycle~Oral dexamethasone (dex) 40 mg/day (≤ 75 years old) or 20 mg/day (> 75 years old) on Days 1, 8, 15, and 22 of each 28-day cycle, up to 12 cycles"
88949423|NCT02685826|Experimental|Cohort C: High risk, Post-transplant|"High risk, post-transplant NDMM participants were administered the following as maintenance therapy:~Intravenous (IV) durvalumab at 1500 mg on Day 1 of each 28-day cycle~Oral lenalidomide (LEN) 10 mg/day on Days 1 to 21 of each 28-day treatment cycle"
88949424|NCT02684162|Experimental|Treatment (guadecitabine, DLI)|Patients receive guadecitabine SC QD on days 1-5. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive DLI IV over 10-30 minutes on day 6 of cycles 2, 4, and 6 in the absence of disease progression or unacceptable toxicity.
89473832|NCT04745078|Active Comparator|Carboxy60|carboxy60
89473833|NCT02242123||Study group|Symptomatic patients, with weakly positive serum anti-tTG and evidence of mild intestinal histology damage (grade 1-2) at first evaluation.
89473834|NCT02242123||Control group|Symptomatic patients, with weakly positive serum anti-tTG and evidence of intestinal villous atrophy (intestinal histology damage grade 3) at first evaluation.
89473835|NCT02500485|Experimental|SHR3824 20mg/SP2086 100mg|One 100-mg tablet of SP2086 once daily on Day 1,2,3,4 followed by two 10-mg tablets of SHR3824 once daily on Day 11,12,13,14, followed by one 100-mg tablet of SP2086 and two 10-mg tablets of SHR3824 on Day 15,16,17,18.
89473836|NCT04628546|Experimental|Intervention|
89473837|NCT04628546|No Intervention|Assessment Only|
89473838|NCT03589079||Monogenic Disorder|Participants exhibiting clinical phenotypes suggestive of an underlying novel monogenic disorder, with/without the presence of familial recurrence of the phenotype and/or parental consanguinity will be included. Sanger and/or Next generation Sequencing (NGS) - Panel/WES/WGS approaches will be used to facilitate identification of de novo/inherited variants in the child/proband.
89473839|NCT02243059|Experimental|GDF-MRI|"In this pilot study, all included patients will undergo conventional MRI with contrast enhancement (gadofosveset trisodium) and diffusion weighted MRI.~Ablavar™ solution contains 244 mg/mL (0.25 mmol/mL) gadofosveset trisodium. 0.03 mmol/kg of gadofosveset will be administered by manual injection as a single intravenous bolus injection over a period of time up to 30 seconds followed by a 25-30 ml saline flush. In practice, this comes down to the maximum of one vial for one patient (one vial contains 10 ml solution, which contains a total of 2.50 mmol of gadofosveset trisodium equivalent to 2.27 g of gadofosveset)."
89473840|NCT02500563|Active Comparator|Amino acid based infant formula|
89473841|NCT02500563|Experimental|Extensively hydrolyzed casein infant formula|
89473842|NCT02500563|Other|Mother's own breast milk|
89473843|NCT02500329|Experimental|gemigliptin|gemigliptin for 4 weeks
89473844|NCT02500329|Active Comparator|acarbose|acarbose for 4 weeks
89473845|NCT02243137|Active Comparator|prasugrel and acetylsalicylic|single dose of prasugrel 60 mg orally and 300 mg acetylsalicylic acid orally
89473846|NCT02243137|Experimental|lysine acetylsalicylate and prasugrel|single dose of prasugrel 60 mg oral and lysine acetylsalicylate 450 mg intravenous
89473847|NCT03343977|Experimental|Every two weeks docetaxel|50 mg/m2 of docetaxel will be given on day 1 every 14 days over one hour IV infusion for up to 9 cycles (1 cycle = 14 days)
89473848|NCT03343977|Active Comparator|Every three weeks docetaxel|75 mg/m2 of docetaxel will be given on day 1 every 21 days over one hour IV infusion for up to 6 cycles (1 cycle = 21 days)
89473849|NCT02850965|Experimental|BI 695501|
89473850|NCT02850965|Active Comparator|Humira|
89473851|NCT03571087|Experimental|HL140 5/10|Treatment(W0~W8), Extension(W9~W20): : 6Tab./q.d. HL140 5/10(Rosuvastatin5mg/Ezetimibe10mg)
89473852|NCT03571087|Experimental|HL140 10/10|Treatment(W0~W8), Extension(W9~W20): : 6Tab./q.d. HL140 10/10(Rosuvastatin10mg/Ezetimibe10mg)
89473853|NCT03571087|Experimental|HL140 20/10|Treatment(W0~W8), Extension(W9~W20): : 6Tab./q.d. HL140 20/10(Rosuvastatin20mg/Ezetimibe10mg)
89473854|NCT03571087|Experimental|Rosuvastatin 5mg → HL140 5/10|"Treatment(W0~W8): 6Tab./q.d. Rosuvastatin 5mg~Extension period(W9~W20): 6Tab./q.d. HL140 5/10(Rosuvastatin5mg/Ezetimibe10mg)"
89473855|NCT03571087|Experimental|Rosuvastatin 10mg → HL140 10/10|"Treatment(W0~W8): 6Tab./q.d. Rosuvastatin 10mg~Extension period(W9~W20): 6Tab./q.d. HL140 10/10(Rosuvastatin10mg/Ezetimibe10mg)"
89473856|NCT03571087|Experimental|Rosuvastatin 20mg → HL140 20/10|"Treatment(W0~W8): 6Tab./q.d. Rosuvastatin 20mg~Extension period(W9~W20): 6Tab./q.d. HL140 20/10(Rosuvastatin20mg/Ezetimibe10mg)"
89473857|NCT04557644|Active Comparator|medical staff treating patients with scabies|
89473858|NCT04557644|Active Comparator|family infested with scabies|
89473859|NCT03571009|Experimental|utilization of PAAS|conventional treatment utilization of PAAS
89473860|NCT03571009|No Intervention|Conventional care|conventional treatment only
89473861|NCT02381522|Active Comparator|Remote Ischemic Pre-conditioning|Remote Ischemic Pre-conditioning group will receive 4 cycles of lower extremity occlusion of perfusion by blood pressure cuff inflated to 20 mmHg higher than systolic and confirmed by doppler.
89473862|NCT02381522|Sham Comparator|Sham RIPC|Sham procedure group will receive 4 cycles of inflation of lower extremity blood pressure cuff but it will be 20mmhg lower than systolic BP and hence not occlude the vessel.
89473863|NCT01375959|Experimental|Resveratrol|resveratrol 500 mg capsules, 3 each day for 6 weeks
89473864|NCT01375959|Placebo Comparator|Placebo|matching placebo capsule containing lactose, 3 each day for 6 weeks
89473865|NCT03581669||THA + cerclage acetabulum|
89473866|NCT03570853|Experimental|Intervention|Participants will receive the 8-week SMART-3RP intervention within a few weeks of enrolling in the study.
89473867|NCT03570853|No Intervention|No Intervention|Participants will not receive the SMART-3RP program and will only complete study questionnaires..
89473868|NCT02238353|Experimental|azelastine + fluticasone|azelastine 137 µg + fluticasone 50 µg combined applied twice daily one puff in each nostril duration: 4 weeks
89202527|NCT02561312||RMPET|For rapid manual partial exchange transfusion, participants with a weight >50kg, 500 ml of whole blood is removed from the participant via a single lumen central venous line, followed by infusion of 500 ml of saline. A 30 second wait time is utilized for equilibration to occur. A second 500 ml aliquot is removed, and then two units of packed red blood cells (PRBC) are infused. (This is customized for a patient with large red blood cell mass). For participants <50 kg, the individual exchange aliquots are adjusted to 10 ml/kg or normal saline and PRBC.
89202528|NCT02561312||Simple Transfusion|For simple transfusion, the volume of packed red blood cells (PRBC) to be transfused in the participant is 10-15 cc/kg. No normal saline exchange is required. All blood is transfused through a single lumen central venous line.
89202529|NCT05361148||DIVIDS (Delhi Infant Vitamin D Supplementation) study, India|"The DIVIDS cohort were born low birth weight (LBW, <2.5 kg) at term in 2007-2010. They had monthly follow-up until 6m then at 5 and 11 years. Anthropometry was collected at all visits, body composition in the 5 and 11 years, and blood samples at 6 months and 5 and 11 years. For SAMPA, the DIVIDS cohort acts as a positive control since we expect adverse long-term non-communicable disease consequences of being born LBW.~Sample numbers at previous follow-ups and expected:~Birth: 2079 total, all LBW~Age 5 y: 911 total, 764 (84%) BMIZ>-2, 138 (15%) BMIZ -2 to -3, 9 (1%) BMIZ<-3~Age 11 y (ongoing): 647 total, 482 (75%) BMIZ>-2, 117 (18%) BMIZ -2 to -3, 48 (7%) BMIZ<-3~Expected for SAMPA: 800 total"
89202530|NCT05361148||SAM (Severe Acute Malnutrition) Lusaka|"This group comprises children with or without prior MALN in early childhood. Some are from a study which identified 1195 children with MALN (mean age 16 months, 11.6% HIV-infected) in a house-to-house survey in a low-income area, Misisi, Lusaka in 2009. Some children are from a study of body composition and indicators of chronic diseases (HbA1c, lipids); 100 were hospitalised with MALN when < 2 years and 76 are never-malnourished neighbourhood controls.~Sample numbers at previous follow-ups and expected:~Age < 2 y: 400 total, 200 WHZ<-3, 200 well-nourished~Age 9 y: 186 total, 110 previous MALN, 76 no MALN; currently 17 (9%) BMIZ <-2~Expected for SAMPA: 400 total"
89202531|NCT05361148||CICADA (Chronic Infections, Co-morbidities and Diabetes in Africa), Mwanza, Tanzania|"The CICADA cohort comprises HIV-infected and uninfected recruited since 2010. CICADA involved 3 annual visits for data on HbA1c, OGTT, insulin, anthropometry, body composition, and diabetes lifestyle risk factors. CICADA has the most detailed longitudinal diabetes data of the project cohorts, archived fasting samples, and are the oldest so have had longer to develop diabetes; therefore, this cohort will be used for the in-depth and longitudinal components (hypotheses 3 and 4).~Sample numbers at previous follow-ups and expected:~12 y prior: 447 total, 300 (67%) BMI > 18.5 kg/m2, 74 (17%) BMI 17 to 18.5 kg/m2 73 (16%) BMI <17 kg/m2~10 y prior: 704 total, 304 (43%) BMI 17 to 18.5 kg/m2, 400 (57%) BMI<17 kg/m2~3 y prior: 1947 total, 1519 (78%) BMI > 18.5 kg/m2, 275 (14%) BMI 17 to18.5 kg/m2, 152 (8%) BMI <17 kg/m2~Expected for SAMPA: 1200 total"
88949425|NCT02662907|Experimental|Aspirators Group|"Participants receive modified barium swallow at baseline and after 8 weeks of using the expiratory muscle strength training (EMST) device. Participants given neurocognitive exams at baseline. Questionnaires completed about symptoms and quality of life at baseline, after 8 weeks of using the EMST device, and 12 months after completing the study.~Participant uses the EMST device at home on a 5-5-5 schedule (5 repetitions, 5 sets, 5 days per week) for 8 weeks.~Digital manometer used to test how forcefully participant is able to exhale and cough at baseline, and one time each week for 8 weeks while using the EMST device."
88949426|NCT02662907|Other|Non-Aspirators Group|Participants receive modified barium swallow at baseline. Participants given neurocognitive exams at baseline. Questionnaires completed about symptoms and quality of life at baseline and at 12 months.
88949427|NCT02659800|Experimental|Arm A - Low Dexamethasone (LD)|"Patients receive single dose of NT-I7 IM. Treatment continues in the absence of disease progression or unacceptable toxicity. Dose Escalation~Laboratory Biomarker Analysis Correlative Studies"
88949428|NCT02659800|Experimental|Arm B High Dexamethasone (HD)|"Patients receive single dose of NT-I7 IM. Treatment continues in the absence of disease progression or unacceptable toxicity. Dose Escalation~Laboratory Biomarker Analysis Correlative Studies"
88949429|NCT02659800|Experimental|Arm A1 (LD) Control - Placebo|"Patients receive single dose Placebo IM (blinded). Patients also on Dexamethasone </=0.75mg daily Treatment continues in the absence of disease progression or unacceptable toxicity. Pilot~Laboratory Biomarker Analysis Correlative Studies"
89473869|NCT02238353|Placebo Comparator|placebo|twice daily one puff in each nostril duration: 4 weeks
89473870|NCT04426292|Other|General arm|All patients follow this arm. Patients will undergo 3 blood sample testings at 3 different time points and have to fill in a questionnaire at 3 different time points
88949430|NCT02659800|Experimental|Arm A2 (LD) MTD|"Patients receive single dose MTD NT-I7 IM determined in Arm A (Blinded) . Patients also on Dexamethasone <=0.75mg daily Treatment continues in the absence of disease progression or unacceptable toxicity. Pilot~Laboratory Biomarker Analysis Correlative Studies"
88949431|NCT02659800|Experimental|Arm B1 HD MTD|"Patients receive single dose MTD NT-I7 IM determined in Arm B (Blinded) . Patients also on Dexamethasone >= 4mg daily Treatment continues in the absence of disease progression or unacceptable toxicity. Pilot~Laboratory Biomarker Analysis Correlative Studies"
88949432|NCT02658981|Experimental|A1 Anti-LAG-3|"Patients receive Anti-LAG-3 monoclonal antibody BMS-986016 IV over 60 minutes and on days 1 and 15. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.~Pharmacological Study~Laboratory Biomarker Analysis"
89473871|NCT02496273|Experimental|CEA Specific CTL|Patients receiving CEA-specific CTLs as therapy for Gastric Cancer
89473872|NCT03570775|Experimental|"Neomedlight Sleeping bag phototherapy"|Phototherapy device with LED light + fiber optic mesh
89473873|NCT03570775|Active Comparator|Conventional phototherapy|LU-6T model: phototherapy device with six fluorescent tubes, four white and two blue, with adjustment of inclination and height incorporated.
89473874|NCT04482686|Experimental|Active Arm|Patients will be treated with a combination of Ivermectin, Doxycycline, Zinc, Vitamin D3 and Vitamin C
89473875|NCT04482686|Placebo Comparator|Placebo|Placebo and Vitamin D3, Vitamin C, and Zinc
89473876|NCT03580889|Active Comparator|Atropine sulphate|Atropine 5 mcg/kg diluted in normal saline to total volume of 2 ml is given intravenous 1 minute after giving intrathecal Bupivacaine 0.5% (Heavy) and patients vitals such as blood pressure, heart rate, SPO2 are monitored every 1 minute for 5 minutes ,then every 5 minutes for 30 minutes then every 10 minutes till end of surgery. Patient shifted to PACU where above vitals are monitored for 2 hrs then shifted to ward. Mean while any adverse outcomes such as nausea, vomiting, sweating, dry mouth is noted and treated accordingly
89473877|NCT03580889|Active Comparator|Glycopyrrolate|Glycopyrrolate 2.5 mcg / kg diluted in normal saline to total volume of 2 ml is given intravenous 1 minute after giving intrathecal Bupivacaine 0.5% (Heavy) and patients vitals such as blold pressure, heart rate, SPO2 are monitored every 1 minute for 5 minutes ,then every 5 minutes for 30 minutes then every 10 minutes till end of surgery. Patient shifted to PACU where above vitals are monitored for 2 hrs then shifted to ward. Mean while any adverse outcomes such as nausea, vomiting, sweating, dry mouth is noted and treated accordingly.
89473878|NCT03580889|Active Comparator|Normal Saline|Normal saline 2 ml is given intravenous 1 minute after giving intrathecal Bupivacaine 0.5% (Heavy) and patients vitals such as blold pressure, heart rate, SPO2 are monitored every 1 minute for 5 minutes ,then every 5 minutes for 30 minutes then every 10 minutes till end of surgery. Patient shifted to PACU where above vitals are monitored for 2 hrs then shifted to ward. Mean while any adverse outcomes such as nausea, vomiting, sweating, dry mouth is noted and treated accordingly.
89473879|NCT02500017|Experimental|Melatonin|A commercially available rapid-release formulation of melatonin (5 mg) capsules to be administered once a day for a total of 8 weeks
89473880|NCT02500017|Placebo Comparator|Placebo|Matching placebo capsules to be administered once a day for a total of 8 weeks
89473881|NCT03415867|Experimental|Dose escalation sequential cohorts|Glasdegib will be self-administered orally once daily in the morning as monotherapy in continuous 28-day treatment cycles for a maximum of 24 cycles. Those patients enrolled in the trial that obtain objective clinical benefit under treatment with glasdegib (defined as the achievement of at least a partial response at one or more target organs), will be allowed to proceed to a slow dose withdrawal phase over a period of 6 months after the end of Cycle 24. The dose reduction scheme is fully detailed in the protocol.
89473882|NCT03815669||Arthroscopic subacromial decompression|Patients referred to arthroscopic subacromial decompression
89473883|NCT04200482|Active Comparator|Arm A (low dose nutrition and PA class, eHealth intervention)|Participants attend one diet and physical activity class delivered remotely via Zoom and receive an eHealth communication intervention for 6 months.
89473884|NCT04200482|Experimental|Arm B (high dose nutrition and PA class, eHealth intervention)|Participants attend 12 twice monthly diet and physical activity online sessions delivered remotely via Zoom and receive an eHealth communication intervention for 6 months.
89473885|NCT02505633|Experimental|2P2I group|subcutaneous injection is done widely. A nerve stimulating needle (Stimuplex insulated needle; D Plus B. Braun, Melsungen, Germany) attached to a nerve stimulator (Stimuplex HNS12; B. Braun, Melsungen, Germany) is advanced via an ultrasound in-plane approach. After the needle is penetrated the nerve sheath with a direction of downward, the nerve stimulator is then turned on. If hand muscle twitching is observed even at 0.3 mA, LA 15 mL (lidocaine mixed with epinephrine) is injected. After that, the stimulating needle is re-advanced at the behind site of the initial puncture site. And the needle is penetrated the nerve sheath with a direction of upward, and then the same process is performed and LA 15 mL is injected.
89473886|NCT02505633|Active Comparator|1P1I group|After subcutaneous injection of 1 mL of 2% lidocaine, a nerve stimulating needle (Stimuplex insulated needle; D Plus B. Braun, Melsungen, Germany) attached to a nerve stimulator (Stimuplex HNS12; B. Braun, Melsungen, Germany) is advanced via an ultrasound in-plane approach from lateral to medial direction. After the needle is penetrated the nerve sheath, the nerve stimulator is then turned on, and the stimulation current starts at 0.5mA. If hand muscle twitching is observed even at 0.3 mA, local anesthetics 30 mL (lidocaine mixed with epinephrine) is injected.
89473887|NCT03580577||Cirrhotic with venous thromboembolism|"cirrhotic patients with a venous thromboembolic event (including deep venous thrombosis, pulmonary embolism, acute non-malignant portal vein thrombosis, splenic vein, inferior vena cava thrombosis or mesenteric vascular occlusion).~Each patient will subjected to through history taking and careful examination to detect and risk factors also laboratory work to detect thrombocytopenia, disease severity, coagulation status thrombelastography before starting anticoagulants.~Patients will start treatment with anticoagulants therapy after liaise with the specialized physician.~Protein C, protein S and antithrombin III level will be assessed 3 months after the acute thrombotic event and 1 month of vitamin K antagonist (VKA) withdrawal."
89473888|NCT03580577||Cirrhotic without venous thromboembolism|"cirrhotic patients without any thrombotic events Each patient will subjected to through history taking and careful examination to detect and risk factors.~- Protein C, protein S and antithrombin III level will be assessed at baseline."
89473889|NCT02248519|Active Comparator|Open Gastrectomy|Patients allocated to the 'Open Gastrectomy' group will receive distal or total gastrectomy via laparotomy. This group is considered the control group
89473890|NCT02248519|Experimental|Laparoscopic Gastrectomy|Patients allocated to the 'Laparoscopic Gastrectomy' group will undergo distal or total gastrectomy via laparoscopy.
89473891|NCT03570307|Other|drug treatment|Misoprostol for uterine evacuation
89473892|NCT03570307|Other|surgical treatment|dilatation and curettage for uterine evacuation
89473893|NCT04001426|Experimental|Monitoring during activation of the FemPulse System|Subjects will undergo non-invasive monitoring during activation of the FemPulse System.
89473894|NCT03587441|Active Comparator|The Intervention Group (N)|Neostigmine Methylsulfate intervention : A one milliliter syringe will contain 20 µg of Neostigmine methyl sulfate. 0.5 mg ampule (1 ml) will be diluted in 4 ml dextrose 5% to make a solution of 100 µg/ml, 0.2 ml of this solution will be added to 2.5 ml of hyperbaric bupivacaine 0.5 % used for intrathecal injection.
89473895|NCT03587441|Placebo Comparator|The Control Group (P)|Dextrose 5% in water intervention : an equal volume (0.2 ml) of dextrose 5% will be added to 2.5 ml of hyperbaric bupivacaine 0.5 % used for intrathecal injection.
89473896|NCT05102396|Experimental|Topical oxybutynin spray|Participants with axillary hyperhidrosis will receive topical oxybutynin spray (10%) in an appropriate dose of 2 puffs in each armpit twice a day for 42 days.
89473897|NCT05102396|Placebo Comparator|Topical placebo spray|Participants with axillary hyperhidrosis will receive topical placebo spray in an appropriate dose of 2 puffs in each armpit twice a day for 42 days.
89473898|NCT05102396|Active Comparator|Oral oxybutynin|Participants with axillary hyperhidrosis will receive oral oxybutynin for 42 days as follows: during the first week, participants will receive 2.5 mg of oxybutynin once a day in the evening; from the 8th to the 14th day, they will receive 2.5 mg twice a day; and from the 15th day to the end of the 42nd day of treatment, they will receive 5 mg twice a day.
89473899|NCT01165645|Experimental|Arm I|Patients receive oral lopinavir and ritonavir twice daily for 28 days in the absence of disease progression or unacceptable toxicity.
89473900|NCT01165645|No Intervention|Arm II|Patients receive no therapy.
89473901|NCT03579953|Experimental|Real cTBS to MPFC|One session of real cTBS treatment delivered to the medial prefrontal cortex (MPFC) (2 trains of stimulation over the MPFC as defined by EEG coordinates (FP1); each train: 120 sec, 3 pulse bursts presented at 5Hz, 15 pulses/sec, 1800 pulses/train, 60 sec intertrain interval; 110% RMT, MagPro X100 Cool Coil; 3600 pulses total).
89473902|NCT03579953|Sham Comparator|Sham cTBS to MPFC|One session of sham cTBS treatment delivered to the medial prefrontal cortex (MPFC) (2 trains of stimulation over the MPFC as defined by EEG coordinates (FP1); each train: 120 sec, 3 pulse bursts presented at 5Hz, 15 pulses/sec, 1800 pulses/train, 60 sec intertrain interval; 110% RMT, MagPro X100 Cool Coil; 3600 pulses total).
89473903|NCT05331794|Experimental|"Experimental: BIOFIT-Park outdoor fitness equipment"|"Refers to an arm that trains on the BIOFIT-Park line of outdoor fitness equipment that is currently under development and testing."
89473904|NCT05331794|Experimental|Experimental: Gym park equipment|Refers to an arm that trains on gym park equipment
89473905|NCT03570073|Active Comparator|Manual vitrification|
89473906|NCT03570073|Experimental|Automatic vitrification|
89473907|NCT03569995|Experimental|Induction+Consolidation chemotherapy|"[Induction phase]~① After induction therapy (Rituximab-Methotrexate) 2 times, first evaluation~Complete, partial response or stable disease-> next step~Progressive disease-> eliminated~② After Induction therapy (Rituximab-Methotrexate) was added 3 times (total 5 times), 2nd evaluation~Complete response -> consolidation therapy(Rituximab-Cytarabine) progress~Partial response or stable disease-> Rituximab-Methotrexate 2 additional administrations~Progressive disease-> eliminated~③ After Induction therapy (Rituximab-Methotrexate) was added twice (7 times in total), 3rd evaluation~Complete, partial response or stable disease-> consolidation therapy(Rituximab-Cytarabine)~Progressive disease-> eliminated"
89473908|NCT03815162|Experimental|High Flavanol Cocoa extract|278mg total flavanols (38.3mg epicatechin) per opaque cellulose capsule 3 capsules consumed once per day (836 mg total flavanols; 115mg epicatechin) for 3 months
89473909|NCT03815162|Placebo Comparator|Alkalised cocoa|0mg total flavanols (0mg epicatechin) per opaque cellulose capsule 3 capsules consumed once per day (0mg total flavanols; 0mg epicatechin) for 3 months
89473910|NCT02238431|Experimental|Lucrin depot, artificial cycle start|intramuscular administration of Lucrin depot (half dose of 3.75mg) on the 5th day following oocyte retrieval
89473911|NCT02238431|Active Comparator|OCP active, artificial cycle start|to take active OCP tablets (1 per day) from the 10th day following oocyte retrieval for at least 21 days
89473912|NCT02238431|Experimental|Natural, menstrual period|to wait for the second bleed to commence the artificial FET cycle
89473913|NCT02246335|Active Comparator|Control group|Hemiarthroplasty
89473914|NCT02246335|Active Comparator|Treatment group|Total hip arthroplasty
89473915|NCT05122598|Active Comparator|Computerized Olfactory Training (COT) Device with olfactory stimulants|COT device with olfactory stimulants consists of daily 40 cycles of intervention with a combination of olfactory stimulation and training tasks, lasting ~45 minutes, delivered once daily over 6 months period by the participant or their partner/caregiver.
88949433|NCT02658981|Experimental|A2 Anti-CD137 (Urelumab)|"Patients receive Anti-CD137 (Urelumab) IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 15 courses in the absence of disease progression or unacceptable toxicity~Pharmacological Study~Laboratory Biomarker Analysis"
88949434|NCT02658981|Experimental|B1 Anti-LAG3 + Anti-PD-1 (nivolumab)|"Patients receive Anti-PD-1 (nivolumab) IV over 60 minutes and anti-LAG-3 monoclonal antibody BMS-986016 IV on days 1 and 15. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.~Pharmacological Study~Laboratory Biomarker Analysis"
89473916|NCT05122598|Sham Comparator|Sham/COT Device|This is COT device that uses compressed room air scented with phenylethylamine (rose scent) instead of olfactory stimulants and has shape pattern matching tasks instead of cognitive tasks, in order to blind users to their treatment assignment. Similar to the COT, sham COT will be used daily for 45 minutes.
89473917|NCT02238509|Experimental|lapatinib and trastuzumab|ARM A: Lapatinib and trastuzumab (experimental arm). Patients with hormone receptor (HR) positive breast cancer will also receive endocrine therapy at the physician's discretion (preferred choice with fulvestrant).
89473918|NCT02238509|Experimental|trastuzumab plus chemotherapy|ARM B: Trastuzumab plus chemotherapy (control arm). Any type of chemotherapy in combination with trastuzumab will be allowed at the physician's discretion.
89473919|NCT04022954||Inquiry™ AFocusII™ Double Loop|The Inquiry™ AFocus™ catheters are for recording intracardiac signals and cardiac stimulation during diagnostic electrophysiological studies. The Inquiry™ AFocus™ catheters are for use in mapping atrial regions of the heart.
89473920|NCT04022954||Advisor™ HD Grid, Sensor Enabled™|The Advisor™ HD Grid Mapping Catheter, Sensor Enabled™, is indicated for multiple electrode electrophysiological mapping of cardiac structures in the heart with recording or stimulation only. This catheter is intended to obtain electrograms in the atrial and ventricular regions of the heart.
89473921|NCT03573271|Experimental|Micro-coring of facial/neck skin with MCD|Micro coring of facial and neck skin will be conducted in up to 2 treatments and followed 90 days post treatment with MCD
88949435|NCT02658981|Experimental|B2 Anti-CD137 + Anti-PD-1|"Patients receive Anti-PD-1 (nivolumab) IV over 60 minutes on days 1 and 15 and Anti-CD137 (urelumab) IV on day 1. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.~(2pts enrolled before the Anti-CD137 antibody (BMS-663513 - urelumab) treatment arm closed by BMS on 10/16/18 due to closure of BMS Urelumab development program. Subjects currently on treatment may continue.)~Pharmacological Study~Laboratory Biomarker Analysis"
89473922|NCT03568981||Partial Breast Irradiation (PBI)|Patients receiving 5-fraction stereotactic partial breast irradiation for breast cancer
89473923|NCT03568981||Whole Breast Irradiation (WBI)|Patients receiving whole breast irradiation for breast cancer
89473924|NCT02238821||resectable colorectal cancer|
89473925|NCT03584048||HIV-1|HIV-1+, males, females, transgender, ≥18 years of age, residing in the Charlotte Metropolitan Area and with at least a single entry in the EHR in the last 2 years.
89473926|NCT03573193|Active Comparator|study group:|ridge preservation alveolar ridge socket preserved using alloplastic material beta tri calcium phosphate type
89473927|NCT03573193|Other|control group|ridge preservation (alveolar ridge socket preserved using xenograft material Bio-oss type
88949436|NCT02658981|Experimental|Intratumoral Studies|"Patients pre-operatively receive either anti-LAG-3 monoclonal antibody BMS-986016 (Arm A1), or urelumab (Arm A2), or nivolumab and anti-LAG-3 monoclonal antibody BMS-986016 as in Part B (B1)), or nivolumab and urelumab as in Part B (B2). Within 45 days of surgical resection, patients post-operatively receive drug from one of the four arms.~(3pts enrolled before the Anti-CD137 antibody (BMS-663513 - urelumab) treatment arm closed by BMS on 10/16/18 due to closure of BMS Urelumab development program. Subjects currently on treatment may continue.)"
88949437|NCT02592291|Experimental|MHealth Group|Participants randomized into this group will use the mHealth system throughout the study in conjunction with their standard of care
88949438|NCT02592291|No Intervention|Control|Participants randomized into this group will not use the mHealth system throughout the study, but will continue with their standard of care.
88949439|NCT02575794|Experimental|Treatment (terameprocol)|"Patients receive terameprocol PO QD on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Pharmacological Study"
89202532|NCT05361148||NUSTART Lusaka|"We will trace and recruit 200 previously malnourished HIV-infected adults from the NUSTART Lusaka participants plus 100 non-HIV-infected neighbourhood controls to the SAMPA study. As for NUSTART Mwanza, there was a high mortality rate during the first 12 weeks of ART.~Sample numbers at previous follow-ups and expected:~10 y prior: 1111 total, 437 (39%) BMI 17 to 18.5 kg/m2, 674 (61%) BMI<17 kg/m2~Expected for SAMPA: 300 total"
89473928|NCT03579407|Active Comparator|Traditional Open Ended Trocar|Patients will undergo bone marrow aspiration using the Jamshidi bone marrow aspiration needle. This needle is the traditional trocar with an open end. 50-60 mL will be collected and concentrated with a centrifuge.
89473929|NCT03579407|Experimental|Fenestrated Blunt Trocar|Patients will undergo bone marrow aspiration using the Marrow Cellution bone marrow aspiration needle. This needle has several fenestrations along the trocar through which the bone marrow is aspirated. Approximately 8-10 mL of high concentrate bone marrow will be collected, which will not be concentrated.
89473930|NCT03579914|Placebo Comparator|Placebo group|Patients receive intravenous placebo injection.
89473931|NCT03579914|Experimental|Intravenous metoprolol group|Patients receive intravenous metoprolol injection.
89473932|NCT03579914|Experimental|RIC group|Patients receive RIC treatment.
89473933|NCT03579914|Experimental|Intravenous metoprolol and RIC group|Patients receive intravenous metoprolol injection and RIC treatment.
88949440|NCT02481349|Experimental|Arm I (couple-based Hatha yoga program)|Patients and their partners attend up to 15, 45-60 minute sessions of Hatha yoga over the course of radiation therapy 5 times a week for 5-6 weeks. The program comprises four main components: joint loosening with breath synchronization; postures with deep relaxation techniques; breath energization with sound resonance; and meditation. At the fifth session, patients and their partners receive a DVD and are encouraged to practice on their own (individually and/or together) on the days when they do not meet with the instructor.
88949441|NCT02481349|Active Comparator|Arm II (waitlist control)|Patients receive standard of care provided by the health care team and complete questionnaires before and after radiation therapy.
88949442|NCT02403505|Experimental|Assess for HPV Antigen Presentation Therapeutic Biological Product Mix activity|9vHPV Vaccine 1.0 mL add into BCG Organism 50 MG
89473934|NCT03573037|Experimental|1-month anticoagulation group|Anticoagulation using warfarin or non-VKA oral anticoagulant for 1 month after radiofrequency catheter ablation of paroxismal atrial fibrillation and then stop anticoagulation.
88949443|NCT02240472|No Intervention|Axillary clearance|Patients in this arm will be treated by completion axillary clearance after a sentinel node biopsy showing 1-2 nodes with macrometastasis
88949444|NCT02240472|Experimental|No axillary clearance|Patients in this arm will not undergo further axillary surgery after a sentinel node biopsy showing 1-2 nodes with macrometastasis
88949445|NCT02236910|Experimental|Primary Therapy with Lu-DOTA-TATE|Lu-DOTA-TATE (Lutetium-177 Octreotate) will be administered by intravenous infusion to participants who have not been previously treated with Lu-DOTA-TATE
88949446|NCT02236910|Experimental|Secondary Therapy with Lu-DOTA-TATE|Patients who have received previous treatment with Lu-DOTA-TATE (Lutetium-177 Octreotate) under the special access program are eligible to be treated in this study. Patients will receive Lu-DOTA-TATE by intravenous infusion.
88949447|NCT02140021|Experimental|Screening (biospecimen collection)|Patients undergo collection of anal, cervical, vaginal, and oral samples during their scheduled pelvic exam.
88949448|NCT02107105||Observational (questionnaire)|Patients complete quality of life questionnaires over 20-30 minutes at baseline, 6 and 12 months after surgery, and 2, 3, 4, and 5 years after surgery.
88949449|NCT02046057|Experimental|PNB of SLN|Percutaneous core biopsy of sentinel node prior to standard sentinel node dissection
89202533|NCT05361148||St-ATT (Starting Anti-TB Treatment) Cohort, Philippines|"Between Aug 2018 and Feb 2020, the St-ATT cohort recruited 900 adults within 5 days of starting a new 6 or 9 month anti-TB regimen in three provinces: Cebu, Negros Occidental and Metro Manila, encompassing urban, peri-urban and rural populations. 17% had HbA1c >=7.0% (probable diabetes in TB) with an additional 30% with HbA1c 5.8%-7.0% ('prediabetes'/mild TB-induced hyperglycaemia). Post-treatment follow-up is ongoing. This cohort will be involved in in-depth analyses for hypothesis 3.~Sample numbers at previous follow-ups and expected:~1-2 y prior: 900 total, 495 BMI >18.5 kg/m2, 189 (21%) BMI 17.0 -18.5 kg/m2, 216 (24%) BMI <17 kg/m2~Expected for SAMPA: 600 total"
89473935|NCT03573037|Active Comparator|2-month anticoagulation group|Anticoagulation using warfarin or non-VKA oral anticoagulant for 2 months after radiofrequency catheter ablation of paroxismal atrial fibrillation and then stop anticoagulation
89473936|NCT03586271||trifocal lens|trifocal lens implantation(AT Lisa tri 839MP)
89473937|NCT03586271||bifocal lens 1|bifocal lens implantation(Diff-aay)
89473938|NCT03586271||bifocal lens 2|bifocal lens implantation(ReSTOR +3.0D)
89473939|NCT03586271||bifocal lens 3|bifocal lens implantation(ReSTOR +2.5D)
89473940|NCT03585413|Active Comparator|Specific Micronutrient-probiotic-combination|"Intake of one micronutrient capsule three times daily and probiotic powder twice daily starting on the first day after hospital discharge until 12 weeks postoperatively.~The micronutrient capsules consist of vitamins, minerals, phytochemicals and bioactive substances. The probiotic supplement is a powder of 10 different species of probiotic bacteria."
89473941|NCT03585413|Placebo Comparator|Micronutrient-placebo-combination|"Intake of one micronutrient capsule three times daily and placebo powder twice daily starting on the first day after hospital discharge until 12 weeks postoperatively.~The micronutrient-control-combination consists of a micronutrient capsule (vitamins and minerals) but without phytochemicals and bioactive substances, and a placebo powder manufactured to mimic the probiotic powder."
89473942|NCT03449264|Experimental|Biological collection|"samples of different natures:~Tissue samples (tumor tissue and healthy tissue) frozen and secured in paraffin collected during surgery.~Blood samples taken at different times. During the blood samples taken for diagnosis and / or treatment, additional samples for research purposes will be carried out.~In parallel to this biological collection, standardized clinical data will be entered into a database"
89473943|NCT03568903|Experimental|Intervention group|Comprehensive physical therapy intervention in small groups (3 members), altogether 16 sessions were performed during a period of 8 weeks (twice a week). Each session lasted 1 hour.
89473944|NCT03568903|No Intervention|Control group|Control group members did not receive any specific intervention during study period, but if needed, medical treatment (medication, it's dosage etc) of Parkinson Disease was changed during study period. They were assigned to individual therapy after the study period.
89473945|NCT03568825|Experimental|Number of Osteopatic Manual Therapy|Intervention: OMT. Osteopatic Manual treatment consisting of Thoracic spine, Diaphragm mobilisation, Traction of the cardia and posture correction.
89473946|NCT03568825|Experimental|Interval in days between each OMT|Intervention: OMT. The time between each OMT's is calculated by the study design. Each OMT intervantion consists of Thoracic spine and Diaphragm mobilisation, Traction of the cardia and Posture correction.
89473947|NCT03569683|Experimental|Interventional Single arm|"Group A- Diode laser biostimulation on surgical site immediately after external bevel gingivectomy and on 1st,3rd, and 7th day after surgery.~Group B- Hyaluronic acid (Gengigel) topical application on surgical site immediately after external bevel gingivectomy and on 1st,3rd, and 7th day after surgery.~Group C- Herbal gel (Hiora SG) topical application on surgical site immediately after external bevel gingivectomy and on 1st,3rd, and 7th day after surgery."
89473948|NCT05079074||Patients with late-stage metastatic breast cancers.|This cohort included patients with late-stage metastatic breast cancers and their disease progressed after at least two-line treatment.
89473949|NCT03569605|Active Comparator|Self-help|Participants will receive an individual session, Fitbit activity tracker, and access to a secret Facebook group.
89473950|NCT03569605|Experimental|Intervention|Participants will receive an individual session, Fitbit activity tracker, and access to a secret Facebook group, behavioral lessons, adaptive physical activity goals, tailored feedback summaries, and text messages.
89473951|NCT05101304||HEAR(Healthcare European Amyloidosis Registry)-Retrospective Cohort|Retrospective collection of deceased patients data with inclusion criteria
89473952|NCT05101304||HEAR(Healthcare European Amyloidosis Registry)-Retrospective-Prospective Cohort|Retrospective and prospective collection of patient data and real-life follow-up of patients from the date of inclusion Living patients who met the inclusion criteria
89473953|NCT05101304||HEAR(Healthcare European Amyloidosis Registry)-Prospective Cohort|Prospective data collection and real-life follow-up of patients from the date of inclusion These patients are either newly followed in the centre with the inclusion criteria
89473954|NCT03569527|Active Comparator|Kiwifruit|Treating chronic constipation with 2 kiwifruit (6g fiber) per day
89473955|NCT03569527|Active Comparator|Psyllium fiber|Treating chronic constipation with 24g psyllium fiber (6g fiber) per day
89473956|NCT03569527|Active Comparator|Prune|Treating chronic constipation with 100g dried plums (6g fiber) per day
89473957|NCT05277428|Experimental|Lactobacillus Plantarum APsulloc 331261(GTB1)|Take GTB1 capsule once daily for 4 weeks
89473958|NCT05277428|Placebo Comparator|Placebo|Take placebo capsule once daily for 4 weeks.
89473959|NCT00708201|Experimental|Alvimopan|"12 milligrams (mg)~Alvimopan, 12mg, capsule. Administered orally. One 30 minutes to 5 hours before the scheduled start of surgery on Day 0, and twice daily beginning on Postoperative Day 1 (POD 1) until hospital discharge or for a maximum of 7 days (up to 15 doses) of postoperative treatment"
89473960|NCT00708201|Placebo Comparator|Placebo|"300 mg polyethylene glycol in a capsule~Administered orally at least 30 minutes and no later than 5 hours before the scheduled start of surgery on Day 0. On Day 1, a single dose of placebo was given twice a day for a maximum of 7 days in hospital after surgery."
89473961|NCT03339440|Experimental|Intervention Group|Patients in this group will be receiving the Hearts and Parks intervention.
89473962|NCT03339440|No Intervention|Control Group|Patients in this group will continue receiving standard of care.
89473963|NCT03572959|Active Comparator|comparison group (active control)|0.1 % topical triamcinolone acetonide preparation (Kenacourt-A Orabase Pomad, DEVA HOLDINGS A.S., Istanbul, Turkey) was used where the patients' were instructed to apply the gel 4 times daily, with no food or fluid taken one hour after application. Patients used the medication for 4 weeks , and if extension of treatment was required after that period , patients were instructed to apply miconazole oral gel (JANSSEN-CILAG Pty Ltd 1-5 Khartoum Road North Ryde NSW 2113 Australia) four times a day for one week to protect from superimposed fungal infections.15
89473964|NCT03572959|Experimental|experimental group|"OLP lesions were irradiated with a 970-nm diode laser (SIRO Laser Advance class III b, SIRONA, Germany) with a 2 W irradiation power in a continuous non-contact mode. The laser beam was delivered using a fiber-optic tip with a 320 µm diameter with defocused mode directed at the lesions plus 0.5 cm peri- lesional tissues with a slight overlapping in order to evenly distribute energy covering all the lesional and peri-lesional tissues until blanching of the area was observed.14 Diode laser was calibrated to an output power of 3W, frequency of 30 Hz, energy of 180 joule and time interval of 8 minutes divided into 4 sessions , two min each with one minute rest in between to allow for tissue relaxation.~Irradiation was done twice weekly for two months until the resolution of signs for a maximum of ten sessions.11 After each session, patients were advised to have a cold diet and use chlorhexidine oral gel postoperatively twice a day to the lesion for one week."
89473965|NCT03291002|Experimental|Cohort A|Dose escalation of CV8102
89473966|NCT03291002|Experimental|Cohort B|Optional expansion cohorts of CV8102
89473967|NCT03291002|Experimental|Cohort C|Dose escalation of CV8102 + anti-PD-1 therapy
89473968|NCT03291002|Experimental|Cohort D|Optional expansion of CV8102 + anti-PD-1 therapy
89473969|NCT03568747|Experimental|NIV plus oxygen therapy|noninvasive ventilation (dual-limb NIV) is given at peak exercise until the borg scale reaches it's baseline point
89202534|NCT05361148||CLHNS (Cebu Longitudinal Health and Nutrition Survey), Philippines|"The cohort was recruited in 1983-84. Since the original follow-up to age 2 years, there have been 8 follow-up surveys including in 2019 when 1300, ~40% of the initial cohort, were available. Loss from the cohort over time is mostly from out-migration and those remaining are more rural and of lower socioeconomic status. In follow-up surveys, data collection included: anthropometry, diet (24-hr recall), health history, blood pressure and other chronic disease risk factors, school achievement, and, for older ages, reproductive history. This cohort represents our longest follow-up of MALN diagnosed by anthropometry resulting primarily from poor nutrition, not specific severe infections.~Sample numbers at previous follow-ups and expected:~Birth: 28 LBW of the 144 with childhood MALN~Age < 2 y: of 420 total to be included, 144 (34%) WHZ<-3~Expected for SAMPA: 420 total"
89473970|NCT03568747|Experimental|oxygen therapy|oxygen therapy is given at peak exercise until the borg scale reaches it's baseline point
89473971|NCT02500251|Experimental|Group A (5 subjects)|Subjects will receive bortezomib and plasmapheresis.
89473972|NCT02500251|Experimental|Group B (5 subjects)|Subjects will receive belimumab, bortezomib, and plasmapheresis.
89473973|NCT02500251|Experimental|Group C (5 subjects)|Subjects will receive belimumab, bortezomib, rituximab, and plasmapheresis.
89473974|NCT03572881|Experimental|Asymptomatic|
89473975|NCT03572881|Experimental|Symptomatic|
89473976|NCT03928730|Other|Group I|Inflammatory swellings
89473977|NCT03928730|Other|Group II|Cystic swellings
89473978|NCT03928730|Other|Group III|Lymph node swellings
89473979|NCT03928730|Other|Group IV|Benign swellings
89473980|NCT03928730|Other|Group V|Malignant swellings
89473981|NCT03568591|Experimental|Intervention Group (Treatment)|A treatment group cohort who have self-referred for the psychosensory therapy intervention (Havening Techniques).
89473982|NCT03568591|No Intervention|Control Group (Waiting List)|Self-referral waiting list cohort (usual care).
88949450|NCT01993810|Active Comparator|Arm I (photon beam radiation therapy and chemotherapy)|"Patients undergo photon beam radiation therapy 5 days per week for a total of 35 fractions and receive either paclitaxel* IV over 1 hour and carboplatin* IV weekly during radiation therapy or etoposide IV on days 1-5 and 29-33 and cisplatin IV on days 1, 8, 29, and 36. Patients with non-squamous cell cancer may receive pemetrexed IV and carboplatin IV on every 21 days. Patients who receive paclitaxel and carboplatin must complete 2 courses of consolidation therapy.~CONSOLIDATION THERAPY: Beginning 3-6 weeks after chemoradiotherapy, patients receive either paclitaxel IV over 3 hours and carboplatin IV on day 1 or durvalumab IV every 2 weeks. Treatment repeats every 21 days for 2 courses or every 2 weeks for up to 12 months for durvalumab in the absence of disease progression or unacceptable toxicity. Patients with non-squamous cell carcinoma may receive durvalumab or pemetrexed IV and carboplatin IV on day 1 every 21 days for up to 4 courses."
89473983|NCT03568513|Experimental|Treatment|Patients in the treatment arm with weight between 35 kg to 50 kg will receive 50 mg capsule of curcumin twice a day (maximum dose 2.8 mg/kg/day, which is within the GRAS approved dose) and those over 50 kg in weight will receive three curcumin capsules a day (maximum dose 3 mg/kg/day, within GRAS recommended dose). Study duration will be 8 weeks.
89473984|NCT03568513|Placebo Comparator|Placebo|Patients in the placebo arm will receive a capsule which has similar size, shape and color of the curcumin capsule. The placebo capsule will contain inert food powder. Study duration will be 8 weeks.
89473985|NCT02982668|Active Comparator|Full enteral feeding|The caloric goal of the first day is one-third of caloric requirements, the second day is half of caloric requirements, the third day is 70-100% and sustained for 1 week. Protein requirements are calculated at 1.2 to 1.5 g per kilogram of body weight per day.
89473986|NCT02982668|Experimental|Modified full enteral feeding|Consistent with full enteral feeding plan, preventively add metoclopramide or mosapride everyday to improve gastrointestinal (GI) motility.
89473987|NCT02982668|Experimental|Permissive underfeeding|The caloric goal of the first day is one-third of caloric requirements, the second day is 40-60% and sustained for 1 week. Protein requirements are calculated at 1.2 to 1.5 g per kilogram of body weight per day.
89473988|NCT02848313|Experimental|Intermediate AMD - HRD without GA|"Participants had one 1 eye with intermediate age-related macular degeneration with high-risk drusen without geographic atrophy [GA]), i.e. the presence of either at least 1 large (≥125 μm) druse or multiple medium-size (63-124 μm) drusen.~Participants received 40 mg dose of elamipretide administered once daily as a 1.0mL SC injection."
89473989|NCT02848313|Experimental|Intermediate AMD with NCGA|"Participants had 1 eye with intermediate AMD with noncentral geographic atrophy [NCGA]; i.e. evidence of GA with cumulative area ≥1.27 mm2 (approximately 0.5 disc area[DA]) by fundus autofluorescence (FAF) that spared the fovea (defined as retinal pigment epithelium (RPE) and outer retina intact by spectral-domain optical coherence tomography [SD-OCT]).~Participants in this arm also received 40 mg dose of elamipretide administered once daily as a 1.0mL SC injection."
89202535|NCT00788346|Experimental|Computerized Alerts|Computerized Clinical Decision Support to clinician at the time of prescribing
89473990|NCT02496117|Active Comparator|RNS-checked RDN|20 patients with hypertension will be enrolled undergoing RNS-checked RDN
89473991|NCT02496117|Experimental|RNS-guided RDN|20 patients with hypertension will be enrolled undergoing RNS-guided RDN
89473992|NCT03071965|Experimental|Cohort 1|Participants completed protocol NTMT-01. All participants received surgery to implant NT-501. All participants received ciliary neurotrophic factor (CNTF).
89473993|NCT03071965|Experimental|Cohort 2|Participants completed protocol NTMT-02. Participants received surgery to implant NT-501 or sham surgery to mimic implant procedure. Participants that received NT-501 implant were exposed to ciliary neurotrophic factor (CNTF).
89473994|NCT03584867|Experimental|study Group|refresher CPR
89473995|NCT03584867|No Intervention|control|NO refresher
89473996|NCT02247973|Experimental|Mesenchymal stem cells|Intravenous bone marrow derived mesenchymal stem cells infusion from related donor to patients with severe aplastic anemia.
89473997|NCT02495961||Low risk population|Colombian children, between 6 and 12 years old, regular students of a Primary school.
89473998|NCT02495961||High risk population|Mexican children, between 6 and 12 years old, regular students of a Primary school.
89473999|NCT05001932|Active Comparator|Multifocal|Patients will receive a multifocal lens bilateral (Alcon Vivity).
89474000|NCT05001932|Active Comparator|Mono-vision|Patients will receive a monofocal lens bilateral. Target refraction for the dominant eye will be -0.25D and for the non-dominant myopia of -2.50D.
89474001|NCT05001932|Active Comparator|Minimono-vision|Patients will receive a monofocal lens bilateral. Target refraction for the dominant eye will be -0.25D and for the non-dominant -1.25D.
89474002|NCT05001932|Active Comparator|Monofocal|Patients will receive a monofocal lens bilateral. Target refraction will be -0.25D.
89474003|NCT03572803|Active Comparator|Group of Dry Needling|"They will receive a treatment of dry needling, guided by ultrasound, together with a self-treatment program at home based on eccentric exercises and stretching.~The needle will get in the relevant zone of treatment. The punction will be realized using Hong's technique (fast in-out). Three needle insertions will be carried out in the target area during 3 seconds"
89474004|NCT03572803|Active Comparator|Group of electrolysis|"They will receive a treatment of Intratissue Percutaneous Electrolysis, guided by ultrasound, together with a self-treatment program at home based on eccentric exercises and stretching.~The needle will get in the relevant zone of treatment. The punction will be realized simulating Hong's technique (fast in-out). Three needle insertions will be carried out in the target area during 3 seconds and 3mA each one."
89474005|NCT03572803|Sham Comparator|Control Group|They will receive a treatment of punction sham, guided by ultrasound, together with a self-treatment program at home based on eccentric exercises and stretching.
89019727|NCT06164899||Patients with bilateral knee osteoarthritis treated with BMAC injection|"Patients with bilateral knee osteoarthritis treated with autologous bone marrow concentrate injection treated within the research protocol OA-bi-blind"
89202536|NCT00788346|Experimental|Alerts PLUS Detailing|Computerized Clinical Decision Support to clinician at the time of prescribing PLUS one group academic detailing session
89202537|NCT00788346|No Intervention|Usual Care|Usual Care
89202538|NCT00753740|Experimental|12mg/m2/dose|12mg per meter squared per dose
89202539|NCT00753740|Experimental|15mg/m2/dose|15mg per meter squared per dose
89202540|NCT00753740|Placebo Comparator|Placebo|5% dextrose infusion (placebo)
89474006|NCT03584633|Other|Lymphedema|The subjects with lymphedema will be exercising on a Nu-Step exercise machine that will exercise their arms and legs simultaneously for five-minute intervals. Every five minutes their limbs will be imaged with Indocyanine Green Lymphography.
89474007|NCT02500095|No Intervention|Control|12 hours of fasting
89202541|NCT00326911|Experimental|cetuximab + bevacizumab + gemcitabine|Cetuximab 400 mg/m2 weekly (over 120 minutes) on day 1 of cycle 1 with subsequent weekly infusions of 250 mg/m2 (over 60 minutes), followed by bevacizumab 10 mg/kg (over 60 minutes) on day 1 and repeated every 2 weeks, and gemcitabine 1000 mg/m2/minute over 100 minutes weekly x 3 of 4 weeks. All medications will be administered by intravenous infusion on the same day. The order of study drug administration will be cetuximab, bevacizumab, and gemcitabine. On day 1 of cycle 1, one hour must elapse between administration of cetuximab and bevacizumab.
88949451|NCT01993810|Experimental|Arm II (proton beam radiation therapy and chemotherapy)|"Patients undergo proton beam radiation therapy 5 days per week for a total of 35 fractions and receive either paclitaxel* and carboplatin*, etoposide and cisplatin, or pemetrexed and carboplatin (for non-squamous cell cancer patients only) as in Arm I. Patients who receive paclitaxel and carboplatin must complete 2 courses of consolidation therapy.~CONSOLIDATION THERAPY: Beginning 3-6 weeks after chemoradiotherapy, patients receive either paclitaxel IV over 3 hours and carboplatin IV on day 1 or durvalumab IV every 2 weeks. Treatment repeats every 21 days for 2 courses or every 2 weeks for up to 12 months for durvalumab in the absence of disease progression or unacceptable toxicity. Patients with non-squamous cell carcinoma may receive durvalumab or pemetrexed IV and carboplatin IV on day 1 every 21 days for up to 4 courses."
88949452|NCT01962415|Experimental|UCBT:transfusion dependent anemias or increased rejection risk|Day -21 to -19: Alemtuzumab + Hydroxyurea; Day -18 to -10: Hydroxyurea; Day -9 to -5: Fludarabine + Hydroxyurea; Day -4 to -3: Melphalan; Day -2: Thiotepa; Day -1: Rest; Day 0: Transplant
88949453|NCT01962415|Experimental|BMT, PBSCT and not transfusion dependent UCBT|Start of conditioning to Day -15: Hydroxyurea; Day -14 to -13: Alemtuzumab + Hydroxyurea; Day -12 to -10: Hydroxyurea; Day -9 to -5: Fludarabine + Hydroxyurea; Day -4 to -3: Melphalan; Day -2: Thiotepa; Day -1: Rest; Day 0: Transplant
88949454|NCT01950351|Experimental|Treatment (proton beam radiation therapy)|Patients undergo proton beam radiation therapy in 15 fractions over 5-6 weeks.
88949455|NCT01919619|Experimental|Treatment (lenalidomide and ipilimumab)|Patients receive lenalidomide PO QD on days 1-21 of courses 1, 3, 5 and 7. Beginning 1-3 days after the last dose of lenalidomide patients receive one dose of ipilimumab IV over 90 minutes of courses 2, 4, 6 and 8. Treatment repeats every 28 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
88949456|NCT01918527|Other|A, Conventional treatment|Operation + 4 or 8 cycles of adjuvant chemotherapy, if indicated.
88949457|NCT01918527|Other|B, Neoadjuvant chemotherapy|3 cycles of neoadjuvant chemotherapy + operation. Adjuvant chemotherapy only if indicated.
88949458|NCT01851369|Experimental|1|combination treatment with oral TRC102 and oral TMZ for days 1-5 of 28-day cycles
88949459|NCT01792531|Experimental|Treatment focus - Parenting vs lifestyle|To determine the effectiveness of two obesity treatment interventions: 1) parent training group (n=90) and 2) standard treatment with focus on lifestyle (n=90). The two treatment conditions will be evaluated with respect to child weight status (BMI SDS; primary outcome), psychosocial and metabolic health, lifestyle choices, and family functioning (secondary outcomes). This design will allow us to assess whether a program targeting only parents and focusing on parenting practices will result in better outcomes than treatment as usual emphasizing lifestyle changes.
88949460|NCT01792531|Experimental|Length of treatment|To understand the influence of treatment duration by comparing the effectiveness of two obesity treatment interventions: the parent training group administered for 12 wks only (n=45) and the parent training group with booster sessions which include additional booster sessions at 8-week intervals for the following year (n=45). Thus we will randomize families to either a group with booster sessions or without. This design will allow us to evaluate if prolonged care is necessary to maintain intervention effects, or if a 12-week program is equally effective.
88949461|NCT01731236|Active Comparator|Carnitine (No antibiotics, No aspirin)|L-Carnitine 500 mg capsule by mouth, twice daily for 2 months. No aspirin for 1 month prior to starting study and remains off aspirin during study.
88949462|NCT01731236|Active Comparator|Choline (No Antibiotics, No aspirin)|Choline 500 mg capsule by mouth, twice daily for 2 months. No aspirin for 1 month prior to starting study and remains off aspirin during study.
88949463|NCT01731236|Active Comparator|Antibiotics|"Antibiotics (Ciprofloxacin, Vancomycin, Metronidazole and Neomycin) Drug: Ciprofloxacin 500 mg, po, twice daily for 7 days (Other Names: Cipro)~Drug: Metronidazole 500 mg, po, twice daily for 7 days (Other Names: Flagyl, Noritate, Rosadan, Vandazole, Flagyl ER, Vitazol)~Drug: Vancomycin 125 mg, po, 4 times daily for 7 days (Other Names: Vancocin, Vancocin HCl, Pulvules, Vancoled, Novaplus, PremierPro Rx, Vancomycin HCl)~Drug: Neomycin 1 gram, po, four times daily for 7 days (Other Names: Aminoglycoside)"
88949464|NCT01731236|Active Comparator|Choline and Aspirin|"Choline supplement 500 mg capsule by mouth, twice daily for 2 months Drug: aspirin 81 mg by mouth, daily for 3 months (on aspirin for 1 month prior to starting study and 2 months with Choline supplementation during study)~Other Names:~Ecotrin, Bufferin, Ascriptin, Fasprin, Norwich Aspirin, Durlaza, Bayer Genuine Aspirin, Genacote, Bayer, Halfprin, Aspirtab, Aspir Low, Aspir-Trin"
88949465|NCT01731236|Active Comparator|Carnitine and Aspirin|"Carnitine supplement 500 mg capsule by mouth, twice daily for 2 months Drug: aspirin 81 mg by mouth, daily for 3 months (on aspirin for 1 month prior to starting study and 2 months with Carnitine supplementation during study)~Other Names:~Ecotrin, Bufferin, Ascriptin, Fasprin, Norwich Aspirin, Durlaza, Bayer Genuine Aspirin, Genacote, Bayer, Halfprin, Aspirtab, Aspir Low, Aspir-Trin"
88949466|NCT01627093||Observational (questionnaire, medical chart review)|Patients complete questionnaires over 30 minutes before treatment begins, at each visit during treatment, and again at all follow-up visits related to treatment. Patients also have their medical records reviewed.
88949467|NCT01590069|Experimental|Treatment (aerosolized aldesleukin)|Patients receive aerosolized aldesleukin QD on days 1-21. Courses repeat every 28 days in the absence of disease progression of unacceptable toxicity.
88949468|NCT01529593|Experimental|Temsirolimus + Metformin|Starting dose of Temsirolimus 25 mg by vein weekly. Metformin titrated over 3 weeks at 500 mg by mouth daily. Four weeks of treatment constitute 1 cycle. Cycle one (1) however, will be 6 weeks long to allow for metformin titration.
88949469|NCT01504789|Experimental|Cultural Related Material Group|Patients will be randomized to receive either culturally adapted AI materials or non-culturally adapted SI materials. Intervention materials will be mailed to patients every 2 weeks. Based on the results of the fitness tests, a specific exercise program will be presented. The research staff will call about every 2 weeks to check that materials were received and have been sent back whatever materials are due. The phone call should take no more than 15 minutes. At 6 months after the follow-up visit, a packet of follow-up questionnaires about physical activity and quality of life will be mailed or given over the phone. The questionnaire packet will be mailed with a postage-paid return envelope. It should take about 10 minutes to complete the questionnaires.
89019728|NCT06164886||Sperimental|Patient on the waiting list for scheduled surgical admissions
89474008|NCT02500095|Experimental|Fasting and saline|72 hours of fasting and concomitant saline
89474009|NCT02500095|Experimental|Fasting and GHR blockade|72 hours of fasting and concomitant Growth hormone receptor (GHR) blockade with Pegvisomant (Somavert) for inhibition of the fasting-induced GH secretion
89474010|NCT05233215|Experimental|GROW Support Program|"Patient participants will fill out questionnaires about emotional and physical health with responses used to develop an individualized survivorship plan conducted through 1x monthly virtual or in-clinic check-ins as well as GROW support meetings as needed for 6 months.~Caregiver participants will fill out questionnaires used to develop patient individualized survivorship plan and participate in 1x monthly check-in meetings with patients or separately for 6 months."
89474011|NCT03577925||HSIL|the patients with HSIL
88949470|NCT01504789|Experimental|Non-Cultural Related Material Group|Patients will be randomized to receive either culturally adapted AI materials or non-culturally adapted SI materials. Intervention materials will be mailed to patients every 2 weeks. Based on the results of the fitness tests, a specific exercise program will be presented. The research staff will call about every 2 weeks to check that materials were received and have been sent back whatever materials are due. The phone call should take no more than 15 minutes. At 6 months after the follow-up visit, a packet of follow-up questionnaires about physical activity and quality of life will be mailed or given over the phone. The questionnaire packet will be mailed with a postage-paid return envelope. It should take about 10 minutes to complete the questionnaires.
88949471|NCT01504789|Active Comparator|Waitlist Group|Patients may choose to participate in the exercise program after 16-week assessment. After 4 months of exercise, all the follow-up tests repeated. Exercise recommendation then given, and all of the intervention materials.
88949472|NCT01446133|Experimental|Untreated 65 +|"Patients with untreated SLL/CLL with indications for treatment that are age 65 or older.~Rituximab (375 mg/m2) will be given intravenously on Day 1, Day 8, Day 15 and Day 22 and then continued once every 4 weeks during cycles 3-12 (+ 7 days). Rituximab will not be given in Cycle 2. Lenalidomide will be started on Day 9 of cycle 1 at the dose of 10 mg/day and will be continued daily. Treatment duration will be 12 cycles and it will be possible to continue beyond 12 cycles if there is a significant benefit such as an ongoing Partial Response or Complete Response."
88949473|NCT01446133|Experimental|Prior Treatment Any Age|"Patients of any age with previously treated CLL/SLL and recurrent disease.~Rituximab (375 mg/m2) will be given intravenously on Day 1, Day 8, Day 15 and Day 22 and then continued once every 4 weeks during cycles 3-12 (+ 7 days). Rituximab will not be given in Cycle 2. Lenalidomide will be started on Day 9 of cycle 1 at the dose of 10 mg/day and will be continued daily. Treatment duration will be 12 cycles and it will be possible to continue beyond 12 cycles if there is a significant benefit such as an ongoing Partial Response or Complete Response."
88949474|NCT01340742|Active Comparator|1|Arm remote preconditioning
88949475|NCT01340742|Placebo Comparator|2|Control group.
88949476|NCT01295645|Experimental|Standard of Care + Cidofovir|Cidofovir 0.5 mg/kg IV 3 x week for 4 weeks
88949477|NCT01295645|Active Comparator|No Cidofovir|Standard of Care: Pharmacologic management of pain, spasms, and urinary urgency with medications, hyper-hydration, or continuous bladder irrigation.
88949478|NCT01254903|Experimental|Stereotactic Radiosurgery (SSRS)|Target dose of 18 or 24 Gy to spine in single session of radiation treatment.
88949479|NCT01234025|Experimental|Part 1 Cohort 1|
88949480|NCT01234025|Experimental|Part 1 Cohort 2|
88949481|NCT01234025|Experimental|Part 2 Arm A|
88949482|NCT01234025|Experimental|Part 2 Arm B|
88949483|NCT01187199|Experimental|Carboplatin Group|Carboplatin: Starting dose AUC 2 by vein on day 1 of a 21 day cycle. Temsirolimus: Starting dose 12.5 mg by vein given on day 1, 8, and 15 of a 21 day cycle. Bevacizumab: Starting dose 5 mg/kg given by vein on day 1 of a 21 day cycle.
88949484|NCT01187199|Experimental|Paclitaxel Group|Paclitaxel: Starting dose 30 mg/m2 given by vein on day 1 of a 21 day cycle. Temsirolimus: Starting dose 12.5 mg by vein given on day 1, 8, and 15 of a 21 day cycle. Bevacizumab: Starting dose 5 mg/kg given by vein on day 1 of a 21 day cycle.
88949485|NCT01187199|Experimental|Sorafenib Group|Sorafenib: Starting dose 200 mg by mouth daily for a 21 day cycle. Temsirolimus: Starting dose 12.5 mg by vein given on day 1, 8, and 15 of a 21 day cycle. Bevacizumab: Starting dose 5 mg/kg given by vein on day 1 of a 21 day cycle.
88949486|NCT01177683|Experimental|Arm 1|Bendamustine in combination with bortezomib and pegylated liposomal doxorubicin.
88949487|NCT01084252|Experimental|Phase 1:Isatuximab <=1 mg/kg Q2W|Participants with CD38+ hematological malignancies (HM), received Isatuximab at any one of the dose less than or equal to (<=) 1 milligram per kilogram (mg/kg) (i.e. either 0.0001 mg/kg or 0.001 mg/kg or 0.01 mg/kg or 0.03 mg/kg or 0.1 mg/kg or 0.3 mg/kg or 1 mg/kg) as intravenous (IV) infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal by participant, investigator's decision, and/or availability of study drug (maximum exposure: 120 weeks).
88949488|NCT01084252|Experimental|Phase 1: Isatuximab 3mg/kg Q2W|Participants with CD38+ HM, received Isatuximab 3 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator's decision, and/or availability of study drug (maximum exposure: 120 weeks).
89474012|NCT03577925||stage IA1 cervical squamous cancer|the patients with stage IA1 cervical squamous cancer
89019729|NCT06164873|Placebo Comparator|Placebo|
89019730|NCT06164873|Experimental|IBI362|
89019731|NCT06164860|Other|Group A|started with MD
89019732|NCT06164860|Other|Group B|started with KD
89019733|NCT06164834|Active Comparator|Clopidogrel 75 mg|Oral administration of clopidogrel 75 mg tablet once daily for 7 days
89019734|NCT06164834|Experimental|Clopidogrel 75 mg + Tegoprazan 25 mg|Oral administration of clopidogrel 75 mg tablet and tegoprazan 25 mg tablet once daily for 7 days
89019735|NCT06164834|Experimental|Clopidogrel 75 mg + Esomeprazole 20 mg|Oral administration of clopidogrel 75 mg tablet and esomeprazole 20 mg tablet once daily for 7 days
89019736|NCT06164808|Other|Active device engagement|All subjects will wear either the Holter monitor and the HeartWatch or the Sirona event recorder and the HeartWatch
89019737|NCT06164756||Experimental: Ketamine Infusion|Participants who received 6 infusions of ketamine (0.5 mg/kg IV, up to 60 mg total), administered over 40 minutes while on continuous cardiac monitoring and oximetry in the ongoing clinical trial (KET-PD trial; NCT04944017, HIC 2000030394)
89019738|NCT06164756||Placebo Comparator: Saline Infusion|Participants who received 6 infusions of placebo (saline IV), administered over 40 minutes while on continuous cardiac monitoring and oximetry in the ongoing clinical trial (KET-PD trial; NCT04944017, HIC 2000030394)
89019739|NCT06164730|Experimental|Cohort 1: Single Ascending Dose Escalation|Participants will receive a single dose of VERVE-102.
89019740|NCT06164730|Experimental|Cohort 2: Single Ascending Dose Escalation|Participants will receive a single dose of VERVE-102.
89019741|NCT06164730|Experimental|Cohort 3: Single Ascending Dose Escalation|Participants will receive a single dose of VERVE-102.
89019742|NCT06164730|Experimental|Cohort 4: Single Ascending Dose Escalation|Participants will receive a single dose of VERVE-102.
89019743|NCT06164717|Experimental|Auditory feedback perturbation during speech|The intervention consists of manipulating real-time auditory feedback during speech production. In our lab, such feedback perturbations can be implemented with either a stand-alone digital vocal processor (a device commonly used by singers and the music industry) or with software-based signal processing routines (see Equipment section for details). Note that the study does not investigate the efficacy of these hardware or software methods to induce behavioral change in subjects' speech. Rather, the study addresses basic experimental questions regarding the general role of auditory feedback in the central nervous system's control of articulatory speech movements.
89019744|NCT06164717|Experimental|Visual feedback perturbation during reaching|The intervention consists of manipulating real-time visual feedback during upper limb reaching movements. In our lab, such feedback perturbations can be implemented with a virtual reality display system.
89019745|NCT06164717|Experimental|Deep brain stimulation|This intervention consists of toggling the deep brain stimulation (DBS) implant ON/OFF prior to participation in the speech auditory-motor learning tasks and speech sequence learning tasks. This intervention can be implemented by the subject themselves as all patients have a hand- held controlled that they use to switch stimulation ON/OFF.
89019746|NCT06164665|Active Comparator|Pioglitazone|Pioglitazone administered as a 15 mg oral dose per day for 5 days
89019747|NCT06164665|Placebo Comparator|Placebo|Microcrystalline cellulose pill administered as an oral dose per day for 5 days
89019748|NCT06164652|Experimental|Healthy adults (M/V/X, 18-80)|
89019749|NCT06164639||Reflux aspiration group|Reflux aspiration group
89019750|NCT06164639||Non-reflux aspiration group|Non-reflux aspiration group
89019751|NCT06164600|Experimental|Bovine Colostrum group|Thirty Patients will receive oral bovine colostrum sachets daily for one month in a dose of 1 sachet per day for children less than 2 years and 2 sachets per day for children older than 2 years.They will be instructed to take each sachet on an empty stomach at least 30 min before meals after being added to 50 ml of neutral (previously boiled) water with continuous mixing until being dissolved.
89019752|NCT06164600|Placebo Comparator|Control group|Thirty Patients will receive oral placebo sachets daily in a similar dose for the same duration. They will be instructed to receive it similarly to the experimental group.
89019753|NCT06164535|Placebo Comparator|Control Group|35 patients will be given placebo (only adjust their drugs to control blood glucose level)
89019754|NCT06164535|Experimental|DPPI Group|35 T2DM patients will be given DPP4Is once or twice daily
89019755|NCT06164535|Experimental|DPPI + metformin group|35 T2DM patients will be given DPP4Is + metformin once or twice daily
89019756|NCT06164509|Active Comparator|Alphintern|Group A will receive (Alphintern® tablet, Amoun, Egypt),
89019757|NCT06164509|Active Comparator|Alzyme Max|Group B will receive (Limitless Allzyme Max®, tablet, Eva, Egypt)
89019758|NCT06164509|No Intervention|Placebo|Group C will not receive medication
89019759|NCT06164483||Control|Healthy patients between 20 and 40 years
89019760|NCT06164483||MS group|Patient with Relapsing Remitting MS age between 20 and 40 years
89019761|NCT06164418|Placebo Comparator|a nanohybrid resin composite material with a universal adhesive|Each patient will randomly receive one cervical restoration with one of the tested restorative systems
89019762|NCT06164418|Active Comparator|a nanohybrid resin composite material with a fluoride-releasing universal adhesive|Each patient will randomly receive one cervical restoration with one of the tested restorative systems
89019763|NCT06164418|Placebo Comparator|ion-releasing restorative material with a universal adhesive|Each patient will randomly receive one cervical restoration with one of the tested restorative systems
89019764|NCT06164418|Active Comparator|ion-releasing restorative material with a fluoride-releasing universal adhesive|Each patient will randomly receive one cervical restoration with one of the tested restorative systems
89202542|NCT00326911|Active Comparator|cetuximab + bevacizumab|Cetuximab 400 mg/m2 weekly (over 120 minutes) on day 1 of cycle 1 with subsequent weekly infusions of 250 mg/m2 (over 60 minutes), followed by bevacizumab 10 mg/kg (over 60 minutes) on day 1 and repeated every 2 weeks. Both medications will be administered by intravenous infusion on the same day. The order of study drug administration will be cetuximab and bevacizumab. On day 1 of cycle 1, one hour must elapse between administration of cetuximab and bevacizumab.
89474013|NCT04497207||Keratoconus|"Those with a clinical diagnosis of keratoconus such as:~a) the presence of a central protrusion of the cornea with Fleischer ring, Vogt striae, or both by slitlamp examination.(b) an irregular cornea determined by distorted keratometry mires and distortion of retinoscopic red reflex or both in addition to the following topographic findings as summarized by Pińero and colleagues: focal steepening located in a zone of protrusion surrounded by concentrically decreasing power zones, focal areas with dioptric (D) values >47.0D, inferior- superior(I-S) asymmetry measured to be > 1.4 D or angling of the hemimeridians in an asymmetric or broken bowtie pattern with skewing of the steepest radial axis (SRAX) 2."
89474014|NCT04497207||Subclinical keratoconus|Defined as subtle corneal tomographic changes as the aforementioned keratoconus abnormalities in the absence of slit- lamp or visual acuity changes typical of keratoconus (subclinical keratoconus).
89474015|NCT04497207||Normal|This group comprised refractive surgery candidates and subjects applying for a contact lens fitting with a refractive error of less than 8.0 D sphere with less than 3.0 D of astigmatism and without clinical, topographic or tomographic signs of keratoconus nor suspected keratoconus.
89474016|NCT02398526||Radium-223 dichloride|Male patients with a diagnosis of CRPC with symptomatic bone metastases without known visceral metastases will be enrolled after the decision for treatment with Radium-223 has been made by the attending physician according to his/her medical practice.
89474017|NCT05354479|Active Comparator|Expressed breast milk|Babies will get only expressed breast milk.
89474018|NCT05354479|Experimental|paracetamol plus expressed breast milk|Babies will get expressed breast milk plus paracetamol
89474019|NCT02505321|Experimental|fATDIVA - OTTT (Cases)|"Individuals identified with the polygenic lipodystrophy genetic variants of interest will undergo the Oral Triglyceride Tolerance Test (OTTT) plus an abdominal fat biopsy (optional). Case/control status will be unblinded at analysis."
89474020|NCT02505321|Experimental|fATDIVA - OTTT (Controls)|"Control individuals carrying the average number of risk alleles and matched to individuals identified with the polygenic lipodystrophy genetic variants of interest for gender, age and BMI, will undergo the Oral Triglyceride Tolerance Test (OTTT) plus an abdominal fat biopsy (optional). Case/control status will be unblinded at analysis."
89474021|NCT04873310|Experimental|Triple P online with professional support|In the online version with professional support, the psychologist in charge will have the role of monitoring the autonomous work of the participants during the 8 sessions, as well as answering questions and doubts that the participants may have regarding the program and its implementation.
89474022|NCT04873310|Experimental|Triple P online without professional support|In the version without professional support, the role of the psychologist in charge will be to keep the platform updated so that the person who self-administers the intervention does not have technical problems associated with the platform.
89474023|NCT04873310|No Intervention|Control group|Control group without any intervention.
89474024|NCT03579095|Experimental|American ginseng|200mg Cereboost and Maltodextrin
89474025|NCT03579095|Placebo Comparator|Placebo|Placebo
89474026|NCT05354401|Active Comparator|Obese|Obese subjects ages 10-18 years with OSA will be recruited from sleep clinic. As per standard clinic care, once a subject is diagnosed with OSA on a PSG they are reviewed in sleep clinic to discuss CPAP therapy. Families will be approached to participate in this study during the subject's regularly scheduled clinical visit. Obese subjects meeting eligibility criteria will be recruited from the sleep clinic. The patients agreeing to CPAP therapy will be invited to take part in the study.
89474027|NCT05354401|Active Comparator|CMC|As per current standard clinical care, CMC diagnosed with moderate to severe OSA following a clinically indicated baseline PSG who have had a previous adenotonsillectomy or who are not considered candidates for surgery are reviewed in sleep clinic to discuss the prescription of CPAP for OSA. CMC subjects' meeting eligibility criteria will be recruited from the sleep clinic. The patients agreeing to CPAP therapy will be invited to take part in this study.
89474028|NCT04805762||Children with overweight or obesity following the lifestyle intervention YCND|Children with overweight or obesity that are participant of the lifestyle intervention YCND
89474029|NCT03577847||1|Intervention group: Stroke patients investigated with rural CT scanning at HSS, Ål. Patients living in the municipalities of Hol, Ål, Gol, Hemsedal and Nes.
89019765|NCT06164379|Experimental|Finerenone group|After the induction period of two weeks, the patients with primary aldosteronism were randomized in an equal ratio to receive finerenone 10mg once daily. Patients received the initial dose (10mg, week 0) of drug for the first two weeks of randomized treatments period. Thereafter, the dose of finerenone would not be changed for the adequate blood pressure (BP) control and the normal serum potassium. For patients not meeting BP < 140/90mmHg and the serum potassium ≥ 3.5 mmol/L, the dose of finerenone would be increased to 20mg once daily for the second 2 weeks later (week 2) and 30 mg 4 weeks later (week 4), respectively. The whole treatment period was 8 weeks. if blood pressure > 160/110 mmHg during the clinical trial, amlodipine 5 mg once was added.
89474030|NCT03577847||2|Control-group: Stroke patients with similar transportation time to hospital, but no access to rural CT scanning. Patients living in the municipalities of Nore- and Uvdal, Vang, Øystre and Vestre Slidre, Lesja, Vågå, Lom, Dovre, Skjåk and Sel.
89474031|NCT02495649|Other|[18F]-DOPA|evaluate the added value of PET-CT with [18F]-DOPA tracer for Assessment of the Myocardial Sympathetic Denervation in patients with or suspected with Parkinson's disease.
89474032|NCT04749446||Breast sarcoma|This cohort include patients affected by breast sarcoma, referred to participating Institutions between January 2000 and June 2020.
88949489|NCT01084252|Experimental|Phase 1: Isatuximab 5 mg/kg Q2W|Participants with CD38+ HM, received Isatuximab 5 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator's decision, and/or availability of study drug (maximum exposure: 120 weeks).
89474033|NCT03568357||Reoxygenation|After one minute of full bypass, fraction of inspired oxygen (FiO2) in liberal group was increased at increments of 0.1 per minute to reach a FiO2 target of 40%-80% adjusted reoxygenation to maintain PO2 in the range of 250mm Hg-300 mm Hg or more during the bypass.
89474034|NCT02495727|Experimental|Control Group|This group will undertake two-weeks of step-reduction to <1,500 steps per day, followed by two-weeks of strength training exercise (6 sessions).
89474035|NCT02495727|Experimental|Pre-Training Group|This group will undertake four weeks of strength training exercise (10 sessions) before two-weeks of step-reduction to <1,500 steps per day, followed by two-weeks of strength training exercise (6 sessions).
89474036|NCT02495727|Experimental|Exercise Snacking Group|This group will undertake home-based 'exercise snacks' of simple lower limb movement (5 minutes, 3 times a day) whilst undertaking two-weeks of step-reduction to <1,500 steps per day, followed by two-weeks of strength training exercise (6 sessions).
89474037|NCT02495805|Active Comparator|adductor canal block (ACB)|Subjects randomized to this groups receive a continuous proximal adductor canal block (ACB) during surgery.
89474038|NCT02495805|Active Comparator|femoral nerve block (FNB)|Subjects randomized to this groups receive a continuous femoral nerve block (FNB) during surgery.
89474039|NCT04732988|Experimental|HSG4112 30 mg Single Dose|Single oral dosing of HSG4112 30 mg
89474040|NCT04732988|Placebo Comparator|Placebo 30 mg Single Dose|Single oral dosing of Placebo 30 mg
89474041|NCT04732988|Experimental|HSG4112 60 mg Single Dose|Single oral dosing of HSG4112 60 mg
89474042|NCT04732988|Placebo Comparator|Placebo 60 mg Single Dose|Single oral dosing of Placebo 60 mg
89474043|NCT04732988|Experimental|HSG4112 120 mg Single Dose|Single oral dosing of HSG4112 120 mg
89474044|NCT04732988|Placebo Comparator|Placebo 120 mg Single Dose|Single oral dosing of Placebo 120 mg
88949490|NCT01084252|Experimental|Phase1:Isatuximab (CD38+HM and Standard Risk Multiple Myeloma)|Participants with CD38+ HM along with participants with standard risk multiple myeloma were included this arm and, received Isatuximab 10 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator's decision, and/or availability of study drug (maximum exposure: 120 weeks).
88949491|NCT01084252|Experimental|Phase 1:Isatuximab (CD38 + HM and High Risk Multiple Myeloma)|Participants with CD38+ HM along with participants with high risk multiple myeloma, received Isatuximab 10 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator's decision, and/or availability of study drug (maximum exposure: 120 weeks).
88949492|NCT01084252|Experimental|Phase 1: Isatuximab 10 mg/kg QW|Participants with CD38+ HM, received Isatuximab 10 mg/kg, as IV infusion QW, i.e. on Day 1 and 8 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator's decision, and/or availability of study drug (maximum exposure: 120 weeks).
89474045|NCT04732988|Experimental|HSG4112 240 mg Single Dose (Fasted)|Single oral dosing of HSG4112 240 mg under fasted conditions
89474046|NCT04732988|Experimental|HSG4112 240 mg Single Dose (Fed)|Single oral dosing of HSG4112 240 mg under fed conditions
89474047|NCT04732988|Placebo Comparator|Placebo 240 mg Single Dose|Single oral dosing of Placebo 240 mg
89474048|NCT04732988|Experimental|HSG4112 480 mg Single Dose|Single oral dosing of HSG4112 480 mg
89474049|NCT04732988|Placebo Comparator|Placebo 480 mg Single Dose|Single oral dosing of Placebo 480 mg
88949493|NCT01084252|Experimental|Phase 1: Isatuximab 20 mg/kg Q2W|Participants with CD38+ HM, received Isatuximab 20 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator's decision, and/or availability of study drug (maximum exposure: 120 weeks).
89202543|NCT00990262||Acute Chest Pain|Patients who presented to the emergency department with acute chest pain, with negative initial biomarkers and normal or non-ischemic ECG
89202544|NCT00747110|Experimental|A|9mg budesonide OD
89202545|NCT00747110|Active Comparator|B|3g mesalazine OD
89474050|NCT04732988|Experimental|HSG4112 720 mg Single Dose|Single oral dosing of HSG4112 720 mg
89474051|NCT04732988|Placebo Comparator|Placebo 720 mg Single Dose|Single oral dosing of Placebo 720 mg
89474052|NCT04732988|Experimental|HSG4112 240 mg Multiple Dose|Once-daily multiple oral dosing of HSG4112 240 mg for 14 days
89474053|NCT04732988|Placebo Comparator|Placebo 240 mg Multiple Dose|Once-daily multiple oral dosing of Placebo 240 mg for 14 days
89474054|NCT04732988|Experimental|HSG4112 480 mg Multiple Dose|Once-daily multiple oral dosing of HSG4112 480 mg for 14 days
89474055|NCT04732988|Placebo Comparator|Placebo 480 mg Multiple Dose|Once-daily multiple oral dosing of Placebo 480 mg for 14 days
89474056|NCT05354011|Experimental|Kinesiotaping|Kinesiotape will be applied toward the start of the week, to remain on for 5 days with a multi day rest for an aggregate of about a month.
89474057|NCT05354011|Experimental|Active Release Technique|kinesiotaping and active release technique will be applied 3 times a week for 2 week
89474058|NCT02505399|Experimental|ticagrelor|"In the intervention group, Ticagrelor will be administered orally, according to the following scheme:~180 mg the evening preceding (and at least 6 hours before) rotational atherectomy (Day -1),~90 mg the following morning (D Day before rotational atherectomy and angioplasty),~90 mg the following evening (D Day after rotational atherectomy and angioplasty),~90 mg twice daily the day after the procedure of rotational atherectomy and angioplasty (Day +1)."
89474059|NCT02505399|Active Comparator|clopidogrel|"In the control group, Clopidogrel will be administered orally, according to the following scheme:~300 mg the evening preceding (and at least 6 hours before) rotational atherectomy (Day -1),~75 mg the following morning (D Day before rotational atherectomy and angioplasty),~0 mg the following evening (D Day after rotational atherectomy and angioplasty),~75 mg once daily the day after the procedure of rotational atherectomy and angioplasty (Day +1)."
89474060|NCT04814498|Experimental|Geneva cocktail (less fexofenadine) & BLD-0409|Following an overnight fast of at least 10 hours, subjects will be administered IP in a fixed sequence.
89474061|NCT03572725|Active Comparator|Gas tamponade|Gas as intraocular tamponade.
89474062|NCT03572725|Experimental|Air tamponade|Air as intraocular tamponade.
89474063|NCT02728089|Experimental|MK-7625A|MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g) administered as an intravenous (IV) infusion every 8 hours for 7 days. The dose may be reduced to 750 mg (ceftolozane 500 mg/tazobactam 250 mg) for participants with a creatinine clearance (CrCl) of 30-50 mL/min.
89474064|NCT04436900|Experimental|Intervention group|20 patients (40 eyes) with PDR underwent PRP with ARC with a spot number of 1,200 to 1,500 per eye and spot size 500 micron with a duration of 200 ms.
89474065|NCT03567187|Experimental|Iovera|"The iovera° device consists of a reusable, portable hand-piece, along with a single-patient use sterile smart Tip (cryoprobe) and disposable nitrous oxide (N2O) cartridges (cryogen). The smart tip is composed of closed-tip stainless steel needles, thereby fully enclosing the cryogen. There are 2 types of smart tips that will be utilized during this study, depending on the depth of the nerves being treated. The shorter smart tip comes in 2 variants - three X 6.9 mm or 8.9 mm, 27-gauge needles, with an attached skin warmer to prevent damage to the underlying skin. The longer smart tip also comes in 2 variants - 55 mm 22-gauge needle or a 90 mm 20G needle.~The effect is by initiation of a cooling cycle, by fully inserting the smart tip into the procedure site and activating the cryogen flow. As the gas travels through the length of the needle, an ice ball develops around the needle freezing the surrounding tissue."
89474066|NCT02505243||HCV patients|HCV patients treated with direct acting antivirals and ribavirin
89474067|NCT05110118|Experimental|LY01008|Single intravenous injection of LY01008 3 mg/kg for 90 min(±1 min).
89474068|NCT05110118|Active Comparator|Avastin|Single intravenous injection of Avastin 3 mg/kg for 90 min(±1 min).
89474069|NCT03567967|Experimental|San Francisco|Each study participant will receive four paper vouchers per month for a total of six months. Each of these vouchers can be redeemed for fresh or frozen fruits and vegetables at a number of specified local corner stores, supermarkets, or farmer's markets. The San Francisco participants will receive and spend these vouchers in an environment which has implemented a sugar-sweetened beverage tax.
89474070|NCT03567967|Active Comparator|Los Angeles|Each study participant will receive four paper vouchers per month for a total of six months. Each of these vouchers can be redeemed for fresh or frozen fruits and vegetables at a number of specified local corner stores, supermarkets, or farmer's markets. The Los Angeles participants will receive and spend these vouchers in an environment which has NOT implemented a sugar-sweetened beverage tax.
89474071|NCT04443075||exposed group|The exposed group consists of the frontline medical workers who take part in the medical team to support Wuhan.
89474072|NCT04443075||non-exposed group|This group includs medical workers who didn't join in the medical team to support Wuhan.
89474073|NCT05106530||Coronary Artery Ectasia patients|
89474074|NCT05106530||Normal coronary artery patients|
88949494|NCT01084252|Experimental|Phase 1: Isatuximab 20 mg/kg QW|Participants with CD38+ HM, received Isatuximab 20 mg/kg, as IV infusion QW, i.e. on Day 1 and 8 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator's decision, and/or availability of study drug (maximum exposure: 120 weeks).
89202546|NCT00796458|Active Comparator|Arm I|Patients continue to receive LHRH-A therapy until disease progression.
89202547|NCT00796458|Experimental|Arm II|Patients receive LHRH-A therapy as in arm I. Patients also receive docetaxel IV on day 1. Treatment with docetaxel repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
89474075|NCT03042169|Active Comparator|continuation of chemotherapy|"Patients assigned to arm A will continue to receive the same chemotherapy regimen they received before randomization. Chemotherapy should be restarted between D1 and D30 after randomization.~In case of poor tolerance to the induction chemotherapy, alternative chemotherapy regimen might be discussed, according to local standards and national guidelines (www.tncd.org)."
89474076|NCT03042169|Experimental|surgical removal of the primary tumour and treatment of the metastatic site followed by chemotherapy|"Patients assigned to arm B will undergo gastrectomy (subtotal or total according to the location of the primary tumour) between D1 and D30 after randomization.~Subtotal gastrectomy is recommended if it allows a complete resection of the primary tumour to limit postoperative morbidity in such metastatic situations, based on the results of REGATTA"
89474077|NCT02495571|Experimental|ALS Patients|Study Group: Evaluation of the cough reflex and the voluntary cough by spirometer and nebulizer
89474078|NCT02495571|Other|Healthy Subjects|Control group matched by aged and sex with the study group
89474079|NCT03572647|Experimental|Test ERITROMAX|Blausiegel Industria e Comercio Ltda. Recombinant Human Erythropoietin (ERITROMAX)
89474080|NCT03572647|Active Comparator|EPREX|Janssen-Cilag Recombinant Human Erythropoietin (EPREX)
89202548|NCT00753818|Experimental|1|
89202549|NCT00753818|Experimental|2|
89202550|NCT00753818|Experimental|3|
89202551|NCT00753818|Other|4|Control
89206213|NCT00523744|Experimental|Amlodipine(AML)+olmesartan, AML+valsartan, AML+valsartan+HCTZ|During the Treatment Phase 1, participants received 1 week of treatment with olmesartan 10 mg and amlodipine 5 mg once daily in free combination, followed by three weeks of treatment with olmesartan 20 mg plus amlodipine 10 mg once daily in free combination. During the treatment Phase 2 of the study participants received amlodipine 10 mg plus valsartan 160 mg for 4 weeks. During the Extension Phase, participants received 4 weeks treatment with amlodipine 10 mg plus valsartan 160 mg plus hydrochlorothiazide (HCTZ) 12.5 mg.
88949495|NCT01084252|Experimental|Phase 2 Stage 1a: Isatuximab 3 mg/kg Q2W|Participants with multiple Myeloma received Isatuximab 3 mg/kg, as IV infusion on Day 1 and Day 15 of each 28-day cycle until unacceptable adverse event (AE), disease progression, poor compliance to the study protocol, study termination or lost to follow up (maximum exposure: 77 weeks).
88949496|NCT01084252|Experimental|Phase 2 Stage 1a: Isatuximab 10 mg/kg Q2W|Participants with multiple Myeloma received Isatuximab 10 mg/kg, as IV infusion on Day 1 and Day 15 of each 28-day cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination or lost to follow up (maximum exposure: 77 weeks).
88949497|NCT01084252|Experimental|Phase2 Stage1a:Isatuximab 10mg/kg Q2W; Then Q4W|Participants with multiple Myeloma received Isatuximab 10 mg/kg, as IV infusion Q2W, i.e. on Day 1 and Day 15 of Cycle 1 and 2 (each cycle 28 days), then every 4 week (Q4W), i.e. on Day 1 of each 28-days cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination or lost to follow up (maximum exposure: 77 weeks).
88949498|NCT01084252|Experimental|Phase 2 Stage 1b: Isatuximab 20mg/kg QW and Then Q2W|Participants with multiple Myeloma received Isatuximab 20 mg/kg, as IV infusion QW, i.e. on Day 1, 8, 15 and 22 of Cycle 1 and 2 (each cycle 28 days), then Q2W, i.e. on Day 1 and Day 15 of each 28-days cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination or lost to follow up (maximum exposure: 53 weeks).
88949499|NCT01084252|Experimental|Phase 2 Stage 2: Isatuximab Alone|Participants with relapsed or relapsed/refractory multiple myeloma (RRMM), received Isatuximab 20 mg/kg, as IV infusion on Day 1, 8, 15 and Day 22 of Cycle 1 (28 days) and then on Day 1 and 15 of each subsequent 28-day cycles until unacceptable AE, disease progression, poor compliance to the study protocol, study termination, lost to follow up or investigator's decision maximum exposure: 97 weeks).
88949500|NCT01084252|Experimental|Phase 2 Stage 2: Isatuximab + Dexamethasone|Participants with relapsed or RRMM, received Isatuximab 20 mg/kg, as IV infusion on Day 1, 8, 15 and Day 22 of Cycle 1 (28 days) and then on Day 1 and 15 of each subsequent 28-day cycles along with dexamethasone: tablet or as IV infusion (40 mg/day for less than [<] 75 years of age; 20 mg/day [greater than or equal to [>=] for 75 years of age) on Days 1, 8, 15 and 22 of each 28 days cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination, lost to follow up or investigator's decision (maximum exposure: 97 weeks).
88949501|NCT00993044|Experimental|Single Arm|
88949502|NCT00955045|Experimental|istradefylline|
88949503|NCT00887302||Restricted food intake without rerouting food flow cohort|Obese non-diabetic patients and diabetic patients undergoing gastric band surgery will be studied before they have surgery, 1 week after the band is adjusted to restrict food intake and again after they have lost the weight equal to that which gastric bypass patients loose 3 months after surgery (to match data we already have in the current study). All patients will be studied with an intravenous glucose tolerance test to measure insulin sensitivity and IV glucose-induced insulin secretion and a meal challenge to measure the secretion of metabolites and peptides.
88949504|NCT00887302||Response to meal when a portion of the stomach is excluded from food flow cohort|Obese-diabetic patient undergoing gastric sleeve surgery will be studied before they have surgery, 1 week after surgery and again 3-6 months after surgery (to match data we already have in the current study). The patient will be studied with an intravenous glucose tolerance test to measure insulin sensitivity and insulin secretion and a meal challenge to measure the secretion of metabolites and peptides.
89474081|NCT04125446||Cancer in pregnancy chemo treated|Patients that received at least one of the following treatments: Carboplatin, Cisplatin, Cyclophosphamide, Paclitaxel and/or anthracyclines, the latter being the most given type of CT during pregnancy
89474082|NCT04125446||Cancer in Pregnancy not chemo treated|Women who were not treated with CT during pregnancy, including those who were solely surgically treated or did not receive any treatment during pregnancy, will be included in the CT-unexposed control arm
89474083|NCT04125446||healthy pregnancies|A group of healthy pregnant women without cancer will form the second control group
89474084|NCT02495493|Experimental|Induction DCS chemotherapy|"Induction chemotherapy -- S-1 35mg/m2 bid day 1-14~Docetaxel 30 mg/m2 day1, 8~Cisplatin 30 mg/m2 day1, 8~Chemoradiotherapy : S-1 20 mg/m2 bid (Day 1-14, 21-28) cisplatin (30 mg/m2/day, Day 1,8, 21,28), Radiotherapy 45 Gy"
89474085|NCT02495181|Sham Comparator|Aflibercept Monotherapy|IVT Aflibercept 2 mg + Sham PDT
89474086|NCT02495181|Active Comparator|Aflibercept + verteporfin PDT|IVT Aflibercept 2 mg + Verteporfin PDT
89474087|NCT05109572||Hospitalized group|Hospitalized patient (HP) stayed in hospital during the Covid-19 pandemic period
89474088|NCT05109572||Non-hospitalized with Emergency care|Emergency care plan made but no hospitalization was included to this study during the Covid-19 pandemic period
89474089|NCT05109572||Non-hospitalized and non-emergency care|Patients who neither apply to the emergency department nor are hospitalized was included to this study during the Covid-19 pandemic period
89474090|NCT02499861|Experimental|Decitabine and Genistein|continuous 24 hours Intravenous decitabine followed by oral genistein for 20 days.
89474091|NCT05106140||Stroke Participants|This group will include stroke survivors from the Calgary Stroke Program who are over 18 years of age.
89206214|NCT04094831|Active Comparator|Intervention arm|Intervention group (Health education through CKD campaign and mHealth) technology
89206215|NCT04094831|Active Comparator|Control|No intervention
89474092|NCT05106140||Control Participants|This group will include healthy individuals from the community who are matched for age and sex to stroke participants.
89474093|NCT05519319|Active Comparator|Photodynamic therapy(PDT)|The PDT optical fiber was inserted through the dilation catheterand advanced toward the bile duct stenosis point under visual-radiography. The dilation catheter was then withdrawn to leave the PDT optical fiber directly across the stricture. Photoactivation was performed at 640 nm using a diode laser at a light dose of 180 J/cm2at power density of300 mW/cm2 and irradiation time of 600 s.
89474094|NCT05519319|Active Comparator|Radiofrequency ablation(RFA)|An RFA electrode (Habib EndoHPB, EMcision, HitchinHerts, UK) was advanced along the guide wire into the bile duct and to the biliary stricture under X-ray fluoroscopic guidance. A 400 kHz RF generator (RITA 1500X, Angio Dynamics, USA) was connected for RFA at 7-10 W for 90 seconds.
89474095|NCT05519319|Active Comparator|RFA+PDT|The PDT optical fiber was inserted through the dilation catheterand advanced toward the bile duct stenosis point under visual-radiography. The dilation catheter was then withdrawn to leave the PDT optical fiber directly across the stricture. Photoactivation was performed at 640 nm using a diode laser at a light dose of 180 J/cm2at power density of300 mW/cm2 and irradiation time of 600 s. After that An RFA electrode (Habib EndoHPB, EMcision, HitchinHerts, UK) was advanced along the guide wire into the bile duct and to the biliary stricture under X-ray fluoroscopic guidance. A 400 kHz RF generator (RITA 1500X, Angio Dynamics, USA) was connected for RFA at 7-10 W for 90 seconds.
89474096|NCT05109182|Experimental|Intervention (3D model + CT for surgical planning)|Patients in this arm will receive a 3D model which will be used in addition to the CT scan for surgical planning.
89474097|NCT05109182|No Intervention|Control (CT for surgical planning)|Patients in this arm will only have the a CT scan used for surgical planning.
89474098|NCT02840461|Experimental|Ivermectin Cream, 1%|test product, manufactured by Actavis Laboratories UT, Inc.
89206216|NCT00831012|Experimental|Group 1|Group 1 will consist of healthy participants receiving an immunization of 10^3 PFU rDEN3delta30/31-7164
89019766|NCT06164379|Active Comparator|Spironolactone group|After the induction period of two weeks, the patients with primary aldosteronism were randomized in an equal ratio to receive spironolactone 20mg once daily. Patients received the initial dose (20mg, week 0) of drug for the first two weeks of randomized treatments period. Thereafter, the dose of spironolactone would not be changed for the adequate blood pressure (BP) control and the normal serum potassium. For patients not meeting BP < 140/90mmHg and the serum potassium ≥ 3.5 mmol/L, the dose of finernone would be increased to 40mg once daily for the second 2 weeks later (week 2) and 60 mg 4 weeks later (week 4), respectively. the whole treatment period was 8 weeks. if blood pressure > 160/110 mmHg during the clinical trial, amlodipine 5 mg once was added.
89019767|NCT06164366|Experimental|0 Degrees Group|dentures will be printed at a 0 degrees build angle
89019768|NCT06164366|Active Comparator|45 Degrees Group|dentures will be printed at a 45 degrees build angle
89019769|NCT06164353|Active Comparator|bovine xenograft covered with a collagen membrane|"The same procedure of implant placement will be performed but xenograft will be used for augmentation.~In both groups, the placed graft will be covered with a collagen membrane. Finally, tension free wound closure will be attained after periosteal releasing incision and suturing using 5/0 proline interrupted sutures.~An immediate postoperative CBCT scan will be done following the surgical procedure."
89019770|NCT06164353|Experimental|Partially demineralized dentin graft covered with a collagen membrane|The stored tooth will undergo grinding using the tooth transformer device. The produced particulate dentin graft will be of a particle size 400-800 µm. Afterwards, these particles will undergo partial demineralization by immersion in in 2% HNO3 for 10 minutes. Then, it will be washed twice using phosphate buffered saline. The exposed implant threads will be covered by partially demineralized autogenous dentin graft in the test group
89019771|NCT06164327|Experimental|BEBT-908 combined with R|"BEBT-908 for Injection,dosage of administration:22.5mg/m^2，frequency and duration of administration:on the 1st,3rd,5th,8th,10th and 12th days of each cycle in the 1st to 6th cycles,and 21 days as a cycle.~Rituximab Injection,dosage of administration:375 mg/m^2,frequency and duration of administration:on the 1st day of each cycle, and 21 days as a cycle."
89019772|NCT06164327|Experimental|BEBT-908 combined with R-GemOx|"BEBT-908 for Injection,dosage of administration:15mg/m^2，frequency and duration of administration:on the 1st,3rd,5th,8th,10th and 12th days of each cycle in the 1st to 6th cycles,and 21 days as a cycle.~Rituximab Injection,dosage of administration:375 mg/m^2,frequency and duration of administration:on the 1st day of each cycle in the 1st to 6th cycles, and 21 days as a cycle.~Gemcitabine Hydrochloride for Injection，dosage of administration:1g/m^2,frequency and duration of administration:on the 2nd day of each cycle in the 1st to 6th cycles, and 21 days as a cycle.~Oxaliplatin Injection,dosage of administration:100mg/m^2,frequency and duration of administration:on the 2nd day of each cycle in the 1st to 6th cycles, and 21 days as a cycle."
89019773|NCT06164327|Experimental|BEBT-908 combined with R-ICE|"BEBT-908 for Injection,dosage of administration:15mg/m^2，frequency and duration of administration:on the 1st,3rd,5th,8th,10th and 12th days of each cycle in the 1st to 6th cycles,and 21 days as a cycle.~Rituximab Injection,dosage of administration:375 mg/m^2,frequency and duration of administration:on the 1st day of each cycle in the 1st to 6th cycles, and 21 days as a cycle.~Etoposide Injection,dosage of administration:100mg/m^2，frequency and duration of administration:on the 1st,2nd and 3rd days of each cycle in the 1st to 6th cycles,and 21 days as a cycle.~Ifosfamide for Injection,dosage of administration:5000mg/m^2,frequency and duration of administration:on the 2nd day of each cycle in the 1st to 6th cycles, and 21 days as a cycle.~Carboplatin Injection，dosage of administration:based on AUC=5, single dose ≤800 mg，frequency and duration of administration:on the 2nd day of each cycle in the 1st to 6th cycles, and 21 days as a cycle."
89019774|NCT06164327|Experimental|BEBE-908 monotherapy (alternative cohort 1)|BEBT-908 for Injection,dosage of administration:22.5mg/m^2，frequency and duration of administration:on the 1st,3rd,5th,8th,10th and 12th days of each cycle in the 1st to 6th cycles,and 21 days as a cycle.
89019775|NCT06164327|Experimental|BEBT-908 combined with R-GemOx（alternative cohort 2）|"BEBT-908 for Injection,dosage of administration:22.5mg/m^2，frequency and duration of administration:on the 1st,3rd,5th,8th,10th and 12th days of each cycle in the 1st to 2nd cycles,and 21 days as a cycle.~Rituximab Injection,dosage of administration:375 mg/m^2,frequency and duration of administration:on the 1st day of each cycle in the 3rd to 6th cycles, and 21 days as a cycle.~Gemcitabine Hydrochloride for Injection，dosage of administration:1g/m^2,frequency and duration of administration:on the 2nd day of each cycle in the 3rd to 6th cycles, and 21 days as a cycle.~Oxaliplatin Injection,dosage of administration:100mg/m^2,frequency and duration of administration:on the 2nd day of each cycle in the 3rd to 6th cycles, and 21 days as a cycle."
89019776|NCT06164288|Experimental|hAESCs injection|Intravenous reinfusion of human amniotic epithelial cell injection, the number of injections is single
89019777|NCT06164249|Experimental|Nordic|Training regimens composed of nordic exercise
89019778|NCT06164249|Experimental|Deadlift|Training regimens composed of deadlift exercise
89019779|NCT06164249|No Intervention|Control|Training regimens composed of no exercise
89019780|NCT06164223|Experimental|Experimental|Group to which VR Baby Pump will be applied
89019781|NCT06164223|No Intervention|Control|An intervention will not be applied.
89019782|NCT06164158|Experimental|Study Group|Half were made to watch the procedural videos and learn the steps of the procedure and then made to perform procedure
89019783|NCT06164158|Experimental|Control Group|Other half group did not watch the procedural videos and were made to perform procedure.
89019784|NCT06164106|Experimental|Virtual Crisis Response Planning|The virtual crisis response planning (CRP) session will last between 30 minutes to 1-hour and be conducted via doxy.me with a trained study therapist. The virtual CRP is primarily text-based, instead of verbal, and utilizes the chat feature on doxy.me. CRP involves the following standard suicide intervention strategies: supportive listening, provision of crisis resources, and referral to a mental health professional (if not already established). The CRP active component involves a collaborative process in which the therapist invites the participant to share the events, symptoms, and contextual factors leading up to and surrounding their suicidal crisis. Next, the participant identifies their personal warning signs, self-management coping skills, reasons for living, and sources of social support. The participant types the components on a template via the white board feature on doxy.me. The CRP will be saved and serve as a concrete reference for participants in the real-world.
89474099|NCT02840461|Active Comparator|SoolantraTM (ivermectin) Cream, 1%|reference product, manufactured by Galderma Laboratories, L.P.
89019785|NCT06164106|Active Comparator|In-Person Crisis Response Planning|The in-person crisis response planning (CRP) session will last between 30 minutes to 1-hour. The in-person CRP will follow the same protocol and include the same treatment components as the virtual CRP. However, it will occur face-to-face, instead of on doxy.me, with a trained study therapist. The treatment components, outlined under the virtual CRP arm description, are written by the participant on an index card. The index card serves as a concrete reference for participants in the real-world.
89019786|NCT06164106|Active Comparator|Virtual Crisis Risk Counseling|The crisis risk counseling session will last between 30 minutes to 1-hour. It will occur virtually on doxy.me with a trained study therapist. It will include the following standard suicide intervention strategies: supportive listening, provision of crisis resources, and referral to a mental health professional (if not already established). The therapist will conduct a semi-structured suicide risk assessment interview, after which participants will complete a self-guided safety plan worksheet via the white board feature. The worksheet will take approximately 10-minutes to complete and will be done independently.
89019787|NCT06164093|Other|Subjects once received LPCs transplantation treatment|The patients who have participated in the clinical trial of autologous transplantation of P63+ LPCs for treatment of bronchiectasis, and actually received LPCs transplantation treatment. (n = 15)
89019788|NCT06164093|Other|Subjects providing samples of surgically resected bronchiectasis lesions|The bronchiectasis patients who could provide samples of surgically resected lung lesions. (n = 5)
89019789|NCT06164080|No Intervention|Antenatal corticosteroid non-administration|Pregnant women who did not use antenatal corticosteroid before 34 weeks
89019790|NCT06164080|Active Comparator|Antenatal corticosteroid administration|Pregnant women using antenatal corticosteroids for any reason before 34 weeks
89019791|NCT06164067||Pregnant women who abort within 24 hours|Group 1 treatment was completed in the first 24 hours ( who were completely aborted and removed the fetal material and its attachments )
89019792|NCT06164067||Pregnant women who abort within 24- 48 hours|Group 2 consisted of patients who needed additional cycles and aborted within 24-48 hours.
89019793|NCT06164054|Experimental|Virtual Reality Rehabilitation Therapy|Experimental group.
89019794|NCT06164054|Active Comparator|Traditional Therapy|Control group.
89019795|NCT06164041|No Intervention|Control Group|The control group did not use any of the research mobile applications, but were measured at pre, post and post 2. They continued attending physical education classes normally and practicing their sports activities.
89019796|NCT06164041|Experimental|"Cardiovascular training through the application MapMyWalk"|"The adolescents who used this application were required to record their weekly workouts. To do this, before starting the workout, they entered the application, selected walking and started the record. The application included different warnings and alerts to encourage the practice of physical activity. Each week they had to make a weekly report with the distance covered."
89019797|NCT06164041|Experimental|"Cardiovascular training through the application Strava"|"The adolescents who used this application were required to record their weekly workouts. To do this, before starting the workout, they entered the application, selected walking and started the record. The application included different warnings and alerts to encourage the practice of physical activity. Each week they had to make a weekly report with the distance covered."
89474100|NCT02840461|Placebo Comparator|Placebo/Vehicle cream|Placebo, manufactured by Actavis Laboratories UT, Inc.
89474101|NCT03343821||Frail elderly patient|
89474102|NCT05108792||Patients deceased following a decision to limit or stop therapeutics|a
89474103|NCT03343743|Other|Hydration|Patients were instructed to drink at least 2 L/day of a hypotonic, oligomineral water low in sodium and minerals (fixed residue at 180°C <200 mg/L) for at least 12 months
89019798|NCT06164041|Experimental|"Cardiovascular training through the application Pacer"|"The adolescents who used this application were required to record their weekly workouts. To do this, before starting the workout, they entered the application, selected walking and started the record. The application included different warnings and alerts to encourage the practice of physical activity. Each week they had to make a weekly report with the distance covered."
89019799|NCT06164041|Experimental|"Cardiovascular training through the application Pokémon Go"|This application is considered immersive as teenagers enter a virtual world. In it, the distance traveled in the real world was accounted for in the video game, also appearing different Pokémon that they could capture, making the gaming experience more playful. In the same way, the teenagers had to keep a weekly record of the distance traveled.
89019800|NCT06164015||Recurrent Miscarriage group (study group)|Group of women who have experienced 2 or more pregnancy loss of less than 24 weeks gestation.
89019801|NCT06164015||Fertile population group (control group)|Group of women with proven fertility with at least one child born at full term
89474104|NCT03567811|Other|Chronic Fatigue Syndrome|"Inclusion and exclusion criteria based on 1994 Center for Disease Control (Fukuda) criteria of persistent, disabling, moderate to severe fatigue that was relieved by rest, plus at least 4 of the 8 following ancillary features: cognitive dysfunction affecting short term memory or concentration, sore throat, sore lymph nodes, sore muscles, sore joints, headache, sleep disturbance, and exertional exhaustion (post-exertional malaise). Intervention: Procedure/Surgery: Submaximal bicycle exercise stress test on Days 1 and 2"
89474105|NCT03567811|Other|Sedentary Control|Subjects who lived a sedentary lifestyle, did not meet Chronic Fatigue Syndrome criteria, and did not have any exclusionary chronic medical, psychiatric or other conditions were our Sedentary Control subjects. By design, this control group included controlled Type II diabetes and thyroid disease, chronic idiopathic fatigue, hypertension (other heart disease excluded) and other stable medical conditions. This variety of subjects were included to prevent ceiling (CFS) vs. floor (control) effects if the control group had totally pristine subjects with zero health issues. Intervention: Procedure/Surgery: Submaximal bicycle exercise stress test on Days 1 and 2
89019802|NCT06164002|Experimental|Group (I)|"Patients will be prepared with vertical feather edge margin design."
89019803|NCT06164002|Experimental|Group (II)|"Patients will be prepared with horizontal shoulder margin design."
89019804|NCT06164002|Experimental|Subgroup (A)|Patients will receive zirconia ceramic crowns
89019805|NCT06164002|Experimental|Subgroup (B)|Patients will receive hybrid ceramic crowns.
89019806|NCT06163989|Experimental|TheaLoz Duo in first month, crossover to saline control in second month|The TheaLoz Duo eyedrop will be prescribed and used by the participant for 1 month. At the second visit 1 month later, the participant will return the TheaLoz Duo eyedrop bottle, and be prescribed saline control eyedrops and used by the participant for another 1 month. At the third and final visit 1 month later, the participant will return the saline eyedrop bottle and complete the study visits.
89019807|NCT06163989|Active Comparator|Saline control in first month, crossover to TheaLoz Duo in second month|The saline control eyedrop will be prescribed and used by the participant for 1 month. At the second visit 1 month later, the participant will return the saline eyedrop bottle, and be prescribed TheaLoz Duo eyedrop and used by the participant for another 1 month. At the third and final visit 1 month later, the participant will return the TheaLoz Duo eyedrop bottle and complete the study visits.
89019808|NCT06163976||ICU Survivor|Elderly patients admitted to intensive care unit and discharged alive
89474106|NCT03341871||HCV Genotypes 1, 2, 3, 4, 5, or 6 participants|Participants receiving combination therapy with the glecaprevir plus pibrentasvir (GLE/PIB) regimen according to the current local label.
89474107|NCT03567031|Experimental|Main Arm|In each patient, under ongoing standard general anesthesia in a stable state, EtCO2 is manually modified to reach predefined values, and after waiting until cerebral blood flow has reached steady state, NIRS and DTC values are noted.
89019809|NCT06163976||ICU Mortality|Elderly patients admitted to intensive care unit and died during ICU stay
89019810|NCT06163963|Experimental|Sentinel Lymph Node Mapping With Double Tracer in Endometrium Cancer (Single Arm)|Sentinel Lymph Node Mapping With Double Tracer and Double Injection Sites in Early-Stage Endometrium Cancer (Single Arm)
89019811|NCT06163950|Experimental|Patients with cerebral palsy|A specially adapted recumbent cycle ergometer with the ability to quickly transform into an isometric dynamometer will be used to assess fatigability development during a task to failure. Throughout the task, which consists of blocks of 3 minutes, neuromuscular assessments will take place to determine the evolution of fatigability and its peripheral and central determinants.
89474108|NCT05108714|Experimental|Group 1. Left arm.|Healthy subjects, who underwent the following intervention: intradermal injection of lidocaine hydrochloride injectable solution via MicronJet600 microneedle device at the site of antecubital fossa of the left arm, followed by the insertion of 18G catheter in a cubital vein.
89474109|NCT05108714|Placebo Comparator|Group 1. Right arm.|Healthy subjects, who underwent the following intervention: intradermal injection of sterile saline via MicronJet600 microneedle device at the site of antecubital fossa of the right arm, followed by the insertion of 18G catheter in a cubital vein.
89474110|NCT05108714|Experimental|Group 2. Left arm.|Healthy subjects, who underwent the following intervention: intradermal injection of lidocaine hydrochloride injectable solution via MicronJet600 microneedle device at the site of antecubital fossa of the left arm, followed by the insertion of 18G catheter in a cubital vein.
89474111|NCT05108714|Active Comparator|Group 2. Right arm.|Healthy subjects, who underwent the following intervention: insertion of 18G catheter in a cubital vein at the site of antecubital fossa of the right arm, without any prior intervention.
89474112|NCT02505165|Experimental|Parent Uncertainty Intervention|A pediatric cancer-specific, clinic based, six-module interdisciplinary uncertainty intervention. Modules one through three target uncertainty prevention. Modules four through six target uncertainty responses for situations in which uncertainty cannot be prevented or avoided.
89019812|NCT06163950|Active Comparator|Healthy people|A specially adapted recumbent cycle ergometer with the ability to quickly transform into an isometric dynamometer will be used to assess fatigability development during a task to failure. Throughout the task, which consists of blocks of 3 minutes, neuromuscular assessments will take place to determine the evolution of fatigability and its peripheral and central determinants.
88949505|NCT00887302||Response to meal when a portion of the GI tract is excluded from food flow cohort|"In approximately 6 patients/year our surgeons have to insert a gastrostomy tube into the bypassed stomach of gastric bypass patients. This provides a unique opportunity to see the changes in metabolites and peptides in blood in response to a meal delivered to the bypassed stomach, duodenum and proximal jejunum. Since we can not anticipate which patients will require this procedure, we cannot do tests before surgery, but we will do four tests post-operatively: (1) an IV glucose tolerance test, (2) an oral meal challenge (with Hi-cal), and (3) a meal challenge (identical to that given orally/Hi-Cal) delivered through the gastrostomy tube.~Gastrostomy subjects will also have a 4) test, a 75 gram dextrose meal challenge."
89202552|NCT05359744|Experimental|Elite cyclists, male|Bicycle ergometer-based exercise testing. 15 min aerobic warm-up phase (2 W/kg) followed by a standardized but individualized ramp-bicycle ergometer protocol to reach maximal exercise capacity after 8 - 12 minutes. The exclusively aerobic energy supply during warm-up will be assessed by constant respiratory quotient and constant arterial lactate concentration (<0.5 mmol in the last 5 min). During exercise, respiratory gas exchange, heart rate, blood pressure, ECG and ratings of perceived exertion will be continuously monitored. Venous blood specimens will be collected before exercise (baseline), at the end of the warm-up as well as 2 min, 10 min, and 30 min in recovery.
89202553|NCT05359744|Experimental|Recreational athletes, male|Bicycle ergometer-based exercise testing. 15 min aerobic warm-up phase (1 W/kg) followed by a standardized but individualized ramp-bicycle ergometer protocol to reach maximal exercise capacity after 8 - 12 minutes. The exclusively aerobic energy supply during warm-up will be assessed by constant respiratory quotient and constant arterial lactate concentration (<0.5 mmol in the last 5 min). During exercise, respiratory gas exchange, heart rate, blood pressure, ECG and ratings of perceived exertion will be continuously monitored. Venous blood specimens will be collected before exercise (baseline), at the end of the warm-up as well as 2 min, 10 min, and 30 min in recovery.
89202554|NCT05359744|Experimental|Recreational athletes, female|Bicycle ergometer-based exercise testing. 15 min aerobic warm-up phase (1 W/kg) followed by a standardized but individualized ramp-bicycle ergometer protocol to reach maximal exercise capacity after 8 - 12 minutes. The exclusively aerobic energy supply during warm-up will be assessed by constant respiratory quotient and constant arterial lactate concentration (<0.5 mmol in the last 5 min). During exercise, respiratory gas exchange, heart rate, blood pressure, ECG and ratings of perceived exertion will be continuously monitored. Venous blood specimens will be collected before exercise (baseline), at the end of the warm-up as well as 2 min, 10 min, and 30 min in recovery.
89202555|NCT05359744|No Intervention|Control, male|Venous blood specimens will be collected at the same time points in the absence of exercise.
89202556|NCT00747188|Experimental|2|
89202557|NCT00747188|No Intervention|A, 2, III|
89202558|NCT04046016|Experimental|Subjects|A total of two subjects were enrolled. Those are breast cancer patients.
89202559|NCT01057615|Experimental|Active Fish Oil + Vitamin C Placebo|Fifteen subjects will take 10 active fish oil capsules per day and 2 vitamin C placebo capsules per day for 3 weeks.
89202560|NCT01057615|Experimental|Fish Oil Placebo + Active Vitamin C|Fifteen subjects will take 10 fish oil placebo capsules per day and 2 active vitamin C capsules per day for 3 weeks.
89202561|NCT01057615|Experimental|Active Fish Oil + Active Vitamin C|Following a 2-week washout period, all subjects from the other two arms (n=30) will take 10 active fish oil capsules per day and 2 active vitamin C capsules per day for 3 weeks.
89202562|NCT04046718|Experimental|electroacupuncture|the study group received electroacupuncture stimulation at different points
89202563|NCT04046718|No Intervention|control group|a control group with no intervention
89202564|NCT02561858|Experimental|acid load test|
89202565|NCT05124418|Other|Palatal masticatory mucosa thickness measurement|
89202566|NCT00788424|Experimental|AS101 Cream|Twice daily topical application of AS101 cream on the psoriatic lesions for approx. 12 weeks is expected to clear the treated area.
89202567|NCT00788424|Experimental|Placebo|Twice daily topical application on the psoriatic lesions for 8 weeks will serve as control group.
89202568|NCT00747422|Experimental|I|
89202569|NCT04003870|Experimental|Runner|Subject will undergo an assessment wearingeither the CASO or the HL. Sequence of CASO of HL will be randomly allocated.
89202570|NCT00796536|Experimental|1|Participants will undergo 12 weeks of group cognitive behavioral therapy (CBT) and a pre- and post-intervention MRI brain scan.
89202571|NCT00796536|Active Comparator|2|Participants will received 12 weeks of pain education and a pre- and post-intervention MRI brain scan.
89202572|NCT04057274|Experimental|Exercise assessment|The exercise condition will involve venous blood samples being drawn immediately before and after a single bout of moderate-intensity aerobic interval exercise.
89202573|NCT04057274|No Intervention|Resting assessment|The resting condition will involve venous blood samples being drawn before and after 60 minutes of seated rest.
89202574|NCT02686060|Experimental|in-line filters|0.2 micron positively charged PALL Corporation filters for parenteral nutrition (Posidyne® NEO Intravenous Filter Set) and 1.2 micro IV in-line filters used for lipid administration (Lipipor™ NEO Filters for Neonatal Parenteral Nutrition)
89202575|NCT02686060|No Intervention|without in-line filters.|
89202576|NCT00791856|Active Comparator|1|28 cm2 testosterone patch
89202577|NCT00791856|Experimental|2|14 cm2 testosterone patch
89202578|NCT02561780|Active Comparator|Curriculum|"The curriculum is a mental health literacy resource designed to inform high school curricula and contains six distinct modules: 1) stigma of mental illness; 2) understanding mental health and mental illness; 3) information on specific mental illnesses; 4) experiences of mental illness; 5) seeking help and finding support; and 6) the importance of positive mental health.~A research assistant trained teachers on The Curriculum Guide content in a half-day session. Teachers implemented The Curriculum Guide, which requires approximately 6 hours of classroom time, during regular instruction of the Healthy Living course."
89019813|NCT06163937|Experimental|Glucose as reference food|Ten healthy, normal-weight adults after 10-14 hours of fasting, consumed 50g available carbohydrates from D-glucose, tested three times, in different visits as reference food; and 50g available carbohydrates from orange juice and mixed fruit juice (consisted of apple, orange, grape, and pomegranate), each tested once, in different visits, along with 300mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min after beverage consumption. The first glucose sample was taken exactly 15min after the first sip of drink.
89019814|NCT06163937|Experimental|Orange juice|Ten healthy, normal-weight adults after 10-14 hours of fasting, consumed 50g available carbohydrates from D-glucose, tested three times, in different visits as reference food; and 50g available carbohydrates from orange juice and mixed fruit juice (consisted of apple, orange, grape, and pomegranate), each tested once, in different visits, along with 300mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min after beverage consumption. The first glucose sample was taken exactly 15min after the first sip of drink.
89019815|NCT06163937|Experimental|Mixed fruit juice|Ten healthy, normal-weight adults after 10-14 hours of fasting, consumed 50g available carbohydrates from D-glucose, tested three times, in different visits as reference food; and 50g available carbohydrates from orange juice and mixed fruit juice (consisted of apple, orange, grape, and pomegranate), each tested once, in different visits, along with 300mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min after beverage consumption. The first glucose sample was taken exactly 15min after the first sip of drink.
89019816|NCT06163911||No myocardial contractility abnormalities|
89019817|NCT06163911||Myocardial contractility abnormalities|
89019818|NCT06163885|Experimental|peer-supported training group|Peer-supported training groups consist of 36 people. Participants in this group will receive a four-hour stoma care skill training from their peers. The group's knowledge and skills in stoma care were evaluated by two independent observers
89019819|NCT06163885|Experimental|flipped classroom training group|flipped classroom training groups consist of 35 people. Participants in this group will receive a four-hour stoma care skill training from their educator. The group's knowledge and skills in stoma care were evaluated by two independent observers
89019820|NCT06163885|No Intervention|Control group|Control training groups consist of 35 people. Participants in this group will receive a four-hour stoma care skill training from their educator. The group's knowledge and skills in stoma care were evaluated by two independent observers
89019821|NCT06163833|Placebo Comparator|1-control (placebo)|Administration: once (bolus), intravenous, 36mL
89019822|NCT06163833|Experimental|2-MSCs 80*10^6|Administration: once (bolus), intravenous, 36mL
89019823|NCT06163833|Experimental|3-MSCs 160*10^6|Administration: once (bolus), intravenous, 36mL
89019824|NCT06163781|Experimental|Blood culture taken based on machine learning tool|
89019825|NCT06163781|No Intervention|Blood culture taken based on the treating physician|
89019826|NCT06163768|Other|insulin|This is a prospective study, without intervention in the clinical treatment plan at the hospital
89019827|NCT06163755|Experimental|Group- 1, Morphine Group|Morphine 3mg group+0.5% Bupivacaine (total volume 5ml) for Intra-articular knee injection.
89019828|NCT06163755|Active Comparator|Group- 2 , DepoMedrol ( Methylprednisone) Group|(control Group - Standard of care ) - DepoMedrol 40mg + 0.25% Bupivacaine (total Volume 5 ml) for Intra-articular knee injection.
89019829|NCT06163716|No Intervention|Regular health advice control (RHA) group.|Participants randomized to the control group followed preventive programs already ongoing at their Primary Care Unit regarding physical activity, socialization, and smoking and alcohol usage. Visits to the GP and nurse depended on personal demands and necessities; nevertheless, annual consultation was recommended for all patients over 60 years old.
89019830|NCT06163716|Experimental|Multidomain intervention (MD-Int) group|The MD-Int program was designed to provide tools and routines that participants could incorporate into daily living activities and reinforce the social environment. Although the program included standardized guidelines and exercises, each participant was considered individually, adapting nutritional requirements and physical and cognitive activity according to individual needs and abilities. This methodology is based on the FINGER trial design but has been adapted to local resources and the healthcare system. GPs and nurses were involved in the follow-up visits. Most intervention activities were carried out at the local Primary Care Centre. Local town hall resources such as group activities for older adults at the municipality sports centre and current outdoor sports activities were incorporated in the study.
89474113|NCT02505165|Other|Education/Support Only|"Sessions in this condition aim to provide education on cancer etiology, medical treatments, side effects, potential short- and long-term effects of treatment and resources that are often helpful to parents of children with cancer. Information presented will be based upon, Young People with Cancer: A Handbook for Parents, a parent resource developed by the National Cancer Institute. Parents will also be provided with relevant educational brochures from COG. Each session will also include a structured set of questions that will facilitate discussion. All ESO interventionists will be trained in non-directive approaches including reflective listening. Content provided in the ESO sessions will offer valuable information to parents without providing the specific skills of the IMPACT."
89474114|NCT04500626|Experimental|HBOT|These patients will receive hyperbaric oxygen therapy (HBOT) in addition to usual treatment for COVID-19. HBOT sessions will be 75 minutes in length at a pressure of 2.0 ATA.
89474115|NCT04500626|No Intervention|Control|These patients will receive usual treatment for COVID-19, including oxygenation at normal atmospheric pressure (normobaric oxygenation).
89474116|NCT02495415|Experimental|Fenretinide emulsion|Patients enrolled will receive 600 mg fenretinide/m2/day on Day 1, followed by 1200 mg fenretinide/m2/day on Days 2 - 5 as a continuous intravenous infusion via central line over 5 days. Cycles are repeated every 3 weeks.
89474117|NCT03572569||Index patients|Patients ≤18 years with primary cardiomyopathy
89474118|NCT03572569||First-degree family members|Parents and siblings of index patients
89474119|NCT05106062|Experimental|Remote Monitoring follow up|This group will turn on the RM function 0 to 45 days after defibrillator implantation. Patient should be seen at clinic once a year, or if there is any adverse event notification
88949506|NCT00761618|Experimental|Arm 1 - Daily|Intrapleural Catheters (IPC) drained every day
88949507|NCT00761618|Experimental|Arm 2 - 3 Times a Week|IPC drained 3 times a week
89019831|NCT06163664|Experimental|Intervention|Intervention with 1 week use of ChatGPT
89019832|NCT06163664|Active Comparator|Delayed control|No ChatGPT use for 1 week and intervention after 1 week
89019833|NCT06163638|Experimental|Intergenerational movement program|This group will receive the intergenerational physical activity program. There are 4 components, which consist of an educational session for grandparents and parents (1), group-based movement sessions for grandparents and grandchildren once a week during 6 weeks (2), home-based physical activities for both grandparents and grandchildren (3) and community-based activities for both grandparents and grandchildren (4).
89019834|NCT06163638|No Intervention|Control group|This group will receive no treatment during the intervention period. Grandparents and grandchildren will receive the home-based physical activities, but without setting goals to not trigger their awareness to be more co-physically active.
89019835|NCT06163625|Experimental|Depression Group|
89019836|NCT06163625|Other|Control Group|
89019837|NCT06163612||Healthy controls, or people who do not have depression.|
89019838|NCT06163612||People diagnosed with MDD and a history of suicide attempt|
89019839|NCT06163612||People diagnosed with MDD without a history of suicide attempt|
89019840|NCT06163586|Experimental|Intervention|This group will receive structured neonatal touch or massage therapy from a certified NICU provider. Therapy will given 3 days a week for 5 to 15 minutes for a minimum of 4 weeks. We will also be collecting data to assess pain and stress responses during the period immediately before, during, and shortly after the therapy. This includes assessment of crying/irritability, behavior state, facial expression, extremities tone, and vital signs (heart rate, breathing rate, and oxygen levels).
89019841|NCT06163586|No Intervention|Control|This group will receive standard NICU care, no different than if they were not enrolled in the study.
89019842|NCT06163573|Experimental|N-TEC|N-TEC is based on autologous nasal chondrocytes expanded and further cultured on type I/III collagen membranes for 2 weeks to allow cells to produce extracellular matrix containing cartilage specific proteins. The IMP is implanted in the knee at the patellofemoral joint.
89019843|NCT06163573|Active Comparator|Platelet Rich Plasma|Total of 3 injections of about 5 ml each of platelet rich plasma (PRP), autologous Conditioned Plasma ACP®, Arthrex, one injection per week for three consecutive weeks.
89019844|NCT06163547|No Intervention|Arm 1 - Surgery - No embolization (control)|Patients who undergo surgical treatment will be randomized into receiving embolization within 72 hours post-surgery (Arm 2) or no-embolization post-surgery (conventional management, Arm 1). Patients will be randomized at rate of 2 MMA embolization to 1 conventional management.
89019845|NCT06163547|Experimental|Arm 2 - Surgery - MMA embolisation|Patients who undergo surgical treatment will be randomized into receiving embolization within 72 hours post-surgery (Arm 2) or no-embolization post-surgery (conventional management, Arm 1). Patients will be randomized at rate of 2 MMA embolization to 1 conventional management.
89019846|NCT06163547|Active Comparator|Arm 3 - No surgery - Embolization accepted|Patients who are excluded for surgery due to significant medical contraindications or patients who refuse surgery, will be considered for embolization only. Embolization accepted : Arm 3.
89019847|NCT06163547|No Intervention|Arm 4 - No surgery - Embolization not accepted|Patients who are excluded for surgery due to significant medical contraindications or patients who refuse surgery, will be considered for embolization only. Embolization refused : Arm 4.
89019848|NCT06163209||Suspected nasal fracture|Patients with a history of recent nasal trauma.
89019849|NCT06158867||FMD WK|
89202579|NCT02561780|Active Comparator|Curriculum +eLearning Follow-up|"The curriculum is a mental health literacy resource designed to inform high school curricula and contains six distinct modules: 1) stigma of mental illness; 2) understanding mental health and mental illness; 3) information on specific mental illnesses; 4) experiences of mental illness; 5) seeking help and finding support; and 6) the importance of positive mental health.~A research assistant trained teachers on The Curriculum Guide content in a half-day session. Teachers implemented The Curriculum Guide, which requires approximately 6 hours of classroom time, during regular instruction of the Healthy Living course. Students are asked to complete follow-up modules online. These modules are only accessible after completion of the Healthy Living course."
88949508|NCT00579644|Active Comparator|1 Methotrexate* & minocycline|"Methotrexate Dosing:~1)initial dose of methotrexate for all patients will be 10 mg/week. 2)2 month: dose of MTX will remain at 10 mg/week if full remission criteria are met; otherwise, increased to 15 mg/week.~3)4 month: dose of MTX will remain at its current level if full remission criteria are met; otherwise, be increased to 20 mg/week.~4)6, 8 and 10 month: If the patient has fallen below full remission criteria and is not already receiving the maximum dose of 20 mg/week,dose will be increased to 20 mg/week. If the patient meets ACR 50 criteria prednisone will be tapered by 1mg/month 5)12 month evaluation: End of the blinded portion of the study. minocycline dosage 200 mg"
89019850|NCT06158867||Placebo|
89019851|NCT06158412|Experimental|ATRA in Combination with a KPD Regimen|All-trans Retinoic Acid plus the KPD Regimen
89019852|NCT06158399|Experimental|ARCHOP|Azacitidine in combination with R-CHOP
89019853|NCT06158386|Experimental|Chidamide combined with Linperlisib|
89019854|NCT06158165||General Anesthesia|Patients undergoing elective unilateral total knee arthroplasty with tourniquet application under the general anesthesia technique
89019855|NCT06158165||Combined Spinal Epidural Anesthesia|Patients undergoing elective unilateral total knee arthroplasty with tourniquet application under the combined spinal epidural anesthesia technique
89019856|NCT06156475|Experimental|Proprioception Exercise Group|Wand exercises and Proprioception exercises
89019857|NCT06156475|Active Comparator|Proprioception exercises with Electromyographic Biofeedback|Wand exercises and Proprioception exercises with Electromyographic Biofeedback
89019858|NCT06156423|Experimental|Motor Control Rehabilitation|
89019859|NCT06156423|Active Comparator|Standard Rehabilitation|
89019860|NCT06156280|Experimental|TQH2929 Injection (1 mg/kg)|TQH2929 Injection 1 mg/kg is administered as a single dose.
89019861|NCT06156280|Experimental|TQH2929 Injection (3 mg/kg)|TQH2929 Injection 3 mg/kg is administered as a single dose.
89019862|NCT06156280|Experimental|TQH2929 Injection (10 mg/kg)|TQH2929 Injection 10 mg/kg is administered as a single dose.
89474120|NCT05106062|No Intervention|Conventional Follow up|This group will not turn on remote monitoring function of defibrillator. Patient should be seen at clinic according to center's custom but no longer than 6 months between each visit
89474121|NCT02499939|Active Comparator|Standard Care|Participants in this group will receive standard education about CIPN and therapeutic exercises to carry out at home.
89474122|NCT02499939|Experimental|Experimental: Ultrasound Therapy|Participants in this group will receive standard education about CIPN and therapeutic exercises to carry out at home. Participants in this group will also undergo 10 daily treatments of ultrasound therapy (e.g., Monday to Friday for two weeks) that is administered to their toes and fingers. The ultrasound therapy will be administered over the first two weeks of the intervention period.
89474123|NCT03572491|Experimental|Allantoic split inactivated seasonal influenza vaccine|A allantoic split inactivated seasonal influenza vaccine has been prepared on eggs and is made from inactivated parts of the following influenza virus strains: NYMC X-275 (A/PR/8/34 (M, PB2, PA, NS, NP genes) и A/Michigan/45/2015 (PB1, HA, NA genes)), NYMC X-263В (A/PR/8/34 (PB1, PB2, PA, NS, NP, М genes) и A/Hong Kong/4801/2014 (HA, NA genes)), NYMC BX-35 (B/Lee/40 (NP gene), B/Panama/45/90 (PB2, М genes) и B/Brisbane/60/2008 (HA, NA PB1, PA, NS genes)).
89474124|NCT02505009|Experimental|entecavir pretreated vaccine arm|Arm A,case group: 75 cases will be enrolled to receive Engerix-B injection and compared with histological non-vaccine treated controls
89474125|NCT02505009|Experimental|tenofovir pretreated vaccine arm|Arm B case group: A total of 50 patients will be randomized into case (vaccine) and control group according to age, gender, pretreatment HBV DNA level.
89474126|NCT02505009|Active Comparator|Entecavir pretreated control arm|Arm A control group: Age, gender and pretreatment DNA matched histological controls
89474127|NCT02505009|Active Comparator|tenofovir pretreated control arm|Arm B control group: A total of 50 patients will be randomized into case (vaccine) and control group according to age, gender, pretreatment HBV DNA level.
89474128|NCT03567733||Coronary Artery Disease|Drug- eluting Stent
89474129|NCT04420208|Experimental|Modified Pap test|Adding a non-painful event after the most uncomfortable phase of Pap smear.
89474130|NCT04420208|No Intervention|Traditional Pap test|Traditional Pap-smear procedure as control.
89474131|NCT05353543|Experimental|Acupuncture (strong reaction acupoints) group|This group will include 40 patients with MDD who will be treated with acupuncture and SSRIs antidepressants. Strong reaction acupoints selected in the first part of the study will be stimulated. The oral dose of SSRIs antidepressants will be determined by the clinical specialist.
89474132|NCT05353543|Experimental|Acupuncture (weak reaction acupoints) group|This group will include 40 patients with MDD who will be treated with acupuncture and SSRIs antidepressants. Weak reaction acupoints selected in the first part of the study will be stimulated. The oral dose of SSRIs antidepressants will be determined by the clinical specialist.
89474133|NCT05353543|Experimental|Sham acupuncture group|This group will include 40 patients with MDD who will be treated with sham acupuncture and SSRIs antidepressants. The sham acupuncture will be needled on the points 1cm lateral to strong reaction acupoints. The oral dose of SSRIs antidepressants will be determined by the clinical specialist.
89474134|NCT02499627|Experimental|Bendamustine + Brentuximab for 6 cycles|Bendamustine 90 mg/m2 d1-2. Brentuximab vedotin 1.8 mg/kg d1.Every 21 days for 6 cycles.
89474135|NCT03567655|Experimental|Single group|Farlutal tab. 500mg/ Pfizer to be administered
89474136|NCT02505087|Active Comparator|Placebo followed by N-Acetylcysteine|Arm receiving placebo for 6 months, then N-Acetylcysteine (NAC) for 6 months.
89474137|NCT02505087|Experimental|N-Acetylcysteine followed by Placebo|Arm receiving N-Acetylcysteine (NAC) for 6 months and then placebo for 6 months.
89474138|NCT02505087|No Intervention|Healthy volunteers|The purpose of this group is to collect reference values for biochemical markers.
89474139|NCT05105828||post Hepatitis C patients with hepatocellular carcinoma|post Hepatitis C patients with hepatocellular carcinoma above 18 years
89474140|NCT05105828||control group|post Hepatitis C patients without hepatocellular carcinoma above 18 years
89474141|NCT03566875|Experimental|Total knee arthroplasty with the Stryker's MAKO™ system|The total knee arthroplasty is performed with Stryker's MAKO™ robotic system. It allows to place precisely the prosthetic implants.
89474142|NCT03566875|Active Comparator|Total knee arthroplasty with mechanical ancillary|The total knee arthroplasty is performed using a mechanical ancillary. It's the conventional method.
89474143|NCT02499705|Experimental|Sucralose|Flavored beverage with sucralose.
89474144|NCT02499705|Experimental|Sucrose|Flavored beverage with sucrose.
89474145|NCT02499705|Experimental|Sucralose + maltodextrin|Flavored beverage with Splenda + maltodextrin .
89474146|NCT04288544|Active Comparator|Experimental: Intervention group|The patients get 1x 5,3g per day the microalgae Phaeodactylum tricornutumover for two weeks.
89474147|NCT04288544|Active Comparator|Omega-3 capsules|The patients get one capsule per day of the Omega-3-fatty acid capsules for 2 weeks.
89474148|NCT04288544|Experimental|sea fish (facultative)|as positive control, one portion of fish is eaten per week for 2 weeks after the Intervention of 8 weeks and 2 wash out (omega 3 must not be eaten).
89474149|NCT02499549|Experimental|10% Cocamide diethanolamine 8 hours|Cocamide DEA topical lotion applied 8 hours/overnight with drying
89474150|NCT02499549|Experimental|10% Cocamide diethanolamine 2 hours|Cocamide DEA topical lotion applied 2 hours with drying, repeated after 7 days
89474151|NCT02839681|Experimental|1/Safety Run-in Arm|Subjects will be dosed with the higher of the 2 possible anetumab ravtansine doses (dose level 1) evaluated on the study
89474152|NCT02839681|Experimental|2/Phase 2 Arm|Subjects will be dosed with anetumab ravtansine at the recommended phase 2 dose (dose level 1 if no more than 1 dose limiting toxicity (DLT) occurred in the safety run-in arm, or at dose level -1 otherwise)
89474153|NCT05105204||Individuals need intra-arterial catheter at the radial artery for blood pressure monitoring|Individuals who requiring the use of intra-arterial catheter at the radial artery for continuous blood pressure monitoring for at least two hours as part of their planned care.
89474154|NCT02494947|Experimental|interval training|high intensity interval-based aerobic exercise
89474155|NCT02494947|Other|controls|usual care
89474156|NCT02504463|Experimental|Samidorphan IV|Samidorphan solution for IV administration
89474157|NCT02504463|Experimental|Samidorphan sublingual|[14c]-Samidorphan for sublingual administration
89474158|NCT02504463|Experimental|Samidorphan oral|[14c]-Samidorphan for oral administration
89474159|NCT03566719|Experimental|Intervention group|
89474160|NCT03566719|No Intervention|Control group|
89474161|NCT04437212|Experimental|Toripalimab Group|All patients will receive radiation therapy scheme: 41.4Gy in 23 fractions over 5 weeks, concurrently with 5 cycles of paclitaxel/cisplatin (paclitaxel 45mg/m2 and cisplatin 25 mg/m2) on days 1, 8, 15, 22,29 and 2 cycles of toripalimab 240 mg every 3 weeks after chemoradiotherapy. Esophagectomy is performed 6-8 weeks after CRT completion and after operation patients received 4 cycles of toripalimab 240 mg every 3 weeks for adjuvant treatment.
89474162|NCT03566641|Experimental|Negative pressure wound therapy|This group of patients will receive negative pressure wound therapy (prevena) as their postoperative wound care method.
89474163|NCT03566641|Active Comparator|standard care dressing|This group of patients will receive standard care dressing as their postoperative wound care method.
88949509|NCT00579644|Active Comparator|2 Methotrexate|"Methotrexate Dosing:~Initial evaluation: The dose of methotrexate for all patients will be 10 mg/week.~2 month evaluation: The dose of MTX will remain at 10 mg/week if full remission criteria are met; otherwise, it will be increased to 15 mg/week.~4 month evaluation: The dose of MTX will remain at its current level if full remission criteria are met; otherwise, it will be increased to 20 mg/week.~6, 8 and 10 month evaluations:~If the patient has fallen below full remission criteria and is not already receiving the maximum dose of 20 mg/week, the dose will be increased to 20 mg/week.~If the patient meets ACR 50 criteria prednisone will be tapered by 1mg/month~12 month evaluation: End of the blinded portion of the study."
89019863|NCT06156280|Experimental|TQH2929 Injection (20 mg/kg)|TQH2929 Injection 20 mg/kg is administered as a single dose.
89019864|NCT06156280|Experimental|TQH2929 Injection (30 mg/kg)|TQH2929 Injection 30 mg/kg is administered as a single dose.
89474164|NCT02494635||Diagnostic (ultrasound, biomarker studies)|Previously collected tumor tissue samples, bladder washings, and urine cells are stained with calcium dye, washed and immersed in external buffer solution, and then transferred to the ultrasound imaging system. Tissue, bladder wash cells and urine cells samples are also analyzed for biomarkers of invasiveness derived from or related to REST gene via qRT-PCR, Western blot, and FISH.
89474165|NCT04123496|Experimental|Dose 1|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 1 is 5 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
89474166|NCT04123496|Experimental|Dose 2|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 2 is 10 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
89474167|NCT04123496|Experimental|Dose 3|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 3 is 15 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
89474168|NCT04123496|Experimental|Dose 4|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 4 is 20 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
89474169|NCT04123496|Experimental|Dose 5|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 5 is 25 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
89474170|NCT04123496|Experimental|Dose 6|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 6 is 30 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
89474171|NCT04123496|Experimental|Dose 7|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 7 is 35 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
89474172|NCT04123496|Experimental|Dose 8|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 8 is 40 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
89474173|NCT04123496|Experimental|Dose 9|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 9 is 45 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
89474174|NCT04123496|Experimental|Dose 10|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 10 is 50 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
89474175|NCT03566563||Ex-Drug Users|These are ex drug users residing at halfway houses
89474176|NCT03568279|Active Comparator|Control|The attending anesthesiologist provided intubation without two-handed jaw thrust.
89474177|NCT03568279|Experimental|Two-hand|The attending anesthesiologist provided intubation with two-handed jaw thrust.
89474178|NCT03341793|Experimental|Muscle secretion|Characterize the changes in muscle secretion induced by bariatric surgery and determine their role in improving the insulin sensitivity of skeletal muscle and insulin secretion by B cell responsible for the remission of diabetes mellitus.
89474179|NCT04105712|Experimental|Pre and Post Dietary Change (within subjects)|Participants do an initial call for baseline data. Then the active assessment period (pre / post dietary change) begins. Pre - dietary change procedure is 5 days of standard high HP diet while completing daily electronic assessments of withdrawal, ecological momentary assessments, and a phone appointment. Post - dietary change is 5 days of lower HP diet (food provided for 3 of 5 days) while completing daily electronic assessments of withdrawal, ecological momentary assessments, and a phone appointment. Daily assessments of affect, craving, and withdrawal are all virtual. On day 4-5 of post assessment, participants complete a food journal to report foods they ate to ensure compliance to low HP food diet. The pre / post-dietary change phone appointments include 1) psychosocial stress task, 2) cue reactivity task, 3) questionnaires 4) self-reported weight. Participants may also complete a follow up period of questionnaires every other day and self-report weight at the end of follow up.
89474180|NCT03566407|Other|Single Group|This is a prospective, longitudinal descriptive study of subjects with diagnosed Crohn's disease. Blood samples for measurement of protein biomarkers (serology), fresh whole blood for detection of gene polymorphisms, and stool samples for detection and assessment of microbiome and host DNA will be collected, and colonoscopy will be performed.
89474181|NCT04061954|Experimental|Intervention group|"Families in the intervention group received:~Parents participate in a group intervention once a week for about 20 weeks, including psychoeducation on mental health and drug and alcohol abuse, anger management, family planning, parenting skills, communication skills, and dealing with couples conflicts~Family visits to address topics as family cohesion, intra-familial communication and psychological basic need of children~Trauma-focused therapies~Parents receive training regarding agriculture and micro credit projects, and financial assistance~One child per family receives a social skill training group preparing them for returning to school~Access to schools and school material~If needed medical assistance is provided~If needed legal assistance is provided"
89474182|NCT04061954|No Intervention|No intervention group|The control group was invited to participate in three interviews getting small amounts of money (~2,5 €) as decompensation of their time.
89474183|NCT02499471|Other|Before levothyroxine therapy 137.75 μg|18F-FDG PET CT scan after mild cold exposure 6.8 ± 2.8 weeks after thyroidectomy, when plasma free T4-levels were at the minimum, before daily levothyroxine therapy 137.75 ± 25.75 μg.
89474184|NCT02499471|Other|After levothyroxine therapy 137.75 μg|18F-FDG PET CT scan after mild cold exposure four to six months after the initial measurements, after daily levothyroxine therapy 137.75 μg (fT4 levels 23.1 ± 3.9 pmol/L, TSH 0.5 ± 0.6 mU/L)
89474185|NCT03566329|Active Comparator|Magnesium sulphate|50 mg/kg over 10 minutes loading followed by 15mg/kg/hr infusion
88949510|NCT00116272||Etanercept-Exposed|Pregnant women with a current diagnosis of rheumatoid arthritis (RA), juvenile rheumatoid arthritis (JRA), ankylosing spondylitis (AS), psoriatic arthritis (PsoA) or psoriasis (PsO) who used etanercept in the first trimester of pregnancy for any length of time.
88949511|NCT00116272||Diseased Controls|Pregnant women with a current diagnosis of RA, JRA, AS, PsA, or PsO who did not use etanercept or any tumor necrosis factor (TNF) antagonist during pregnancy.
88949512|NCT00116272||Non-Diseased Historical Comparison|Pregnant women not diagnosed with RA, JRA, AS, PsoA, or PsO who did not use etanercept or any TNF antagonist at any time in pregnancy and were not exposed to any known human teratogen during pregnancy. This cohort consists of historical controls enrolled in other pregnancy outcome studies selected to match pregnant women in the exposed cohort.
88949513|NCT00080886|Other|Arm 1|"Participants receive rituximab IV over approximately 3-4 hours once weekly for 2 weeks followed 1 week later by hematopoietic stem cell or bone marrow harvest.~Participants then receive a third dose of rituximab IV over approximately 3-4 hours on day -7 or -6. Patients also receive high-dose chemotherapy comprising carmustine IV on day -6, cytarabine IV and etoposide IV twice daily on days -5 to -2, and melphalan IV on day -1. Participants undergo autologous hematopoietic stem cell transplantation on day 0. Participants who have less than a complete remission at day 100 post-transplantation receive 4 additional doses of rituximab IV over approximately 3-4 hours once weekly for 4 weeks. Participants are followed at day 100, at 1 year, and then annually thereafter."
89019865|NCT06156280|Experimental|TQH2929 Injection (40 mg/kg)|TQH2929 Injection 40 mg/kg is administered as a single dose.
89474186|NCT03566329|Active Comparator|lidocaine hydrochloride|1.5mg/kg loading followed by 2mg/kg/hr infusion
89474187|NCT03566329|Placebo Comparator|NaCl 0.9% normal saline|Normal saline infusion with the same rate as the study drugs
89474188|NCT03824990|No Intervention|Before-intervention phase|All the healthy infants who were admitted from March 2018 to August 2018 to the Well Baby nurse of different hospitals.
89474189|NCT03824990|Experimental|Intervention phase|All the healthy infants who were admitted from September 2018 to February 2019 to the Well Baby nurse of different hospitals.During this phase,multiple intervention bundles of quality improvement will be implemented.
89474190|NCT03824990|Experimental|Sustainability intervention phase|All the healthy infants who were admitted from March 2019 to August 2019 to the Well Baby nurse of different hospitals.In the Sustainability intervention phase,multiple intervention bundles of quality improvement will be continuous implemented.
89474191|NCT02499315|Experimental|AMG 357|
89474192|NCT02499315|Placebo Comparator|Placebo|
89474193|NCT03566251|Experimental|Multiple Sclerosis|Patients with confirmed diagnosis of clinically definite MS, Expanded Sisability Status Scale range of 0.5-4 who are able to walk independently.
89474194|NCT03566251|No Intervention|Healthy individuals|29 healthy volunteers with matching ages and genders
89474195|NCT02504385|Experimental|Virtual Reality Timocco|The study group will integrate the use of Timocco in occupational therapy sessions. The session will begin with 15 minutes of spatial activity involving sensory-motor practice, 15 minutes of activity in a virtual environment, and 15 minutes of structured activity at a desk.
89474196|NCT02504385|Active Comparator|Conventional OT intervention|The control group will be given conventional occupational therapy without using Timocco. In order to ensure that the therapy sessions in this group have a structure similar to that one used in the study group, each session will include 25 to 30 minutes of spatial sensory-motor activity, followed by 15 to 20 minutes of structured practice at a desk.
89474197|NCT05047016|Other|Dynamic consent arm|Subjects will receive a virtual investigational product once daily. Subjects also need to measure their body temperature once daily at the scheduled timepoint.
88949514|NCT01936571||NSCLC|The cohort consists of approximately 250 patients. As a rule of thumb 5-10 events per variable are needed to avoid overfitting a model. To model 6 clinical variables + 9 biomarker variables 75-150 events are needed. Assuming a two-year survival of 40%, the calculated (constant) hazard rate is 0.46 per year. With an inclusion rate of 50 patients per year, and a follow-up time varying between 0.5 and 4 year, at the time of analysis (November/December 2013) it is expected that there will be 138 events available for analysis.
88949515|NCT01936584||TAPP repair|TAPP repair for inguinal hernia
88949516|NCT01936584||TEP repair|TEP repair for inguinal hernia
88949517|NCT01936597|Active Comparator|Single set (control Arm)|method of external cardiac massage incentive based on a single set. Intervention : Therapeutic and preventive strategies
88949518|NCT01936597|Experimental|Controller|Audio continuous guidance method by the controller. Intervention : Therapeutic and preventive strategies
88949519|NCT01936597|Experimental|Audio|Audio continuous guidance method by the controller relayed by an audio. Intervention : Therapeutic and preventive strategies
88949520|NCT01936610|Experimental|role play|In this method, researcher with two other co-researchers played 3 scenarios in 7 steps (for each scenario)including warm up, selecting participant, preparing the scene, preparing observers, play ,discussion and evaluation and generalization to education about advantages and disadvantages of normal delivery and cesarean section .
88949521|NCT01936610|Experimental|lecture|describe the advantages and disadvantages of normal delivery and cesarian section
88949522|NCT01936636||Cancer patients treated for BTcP|"All patients 18 years of age and older with breakthrough cancer pain (BTcP) who are registered in the Transmucosal Immediate Release Fentanyl (TIRF) Risk Evaluation and Mitigation Strategy (REMS) Access program and receiving Abstral® under the direction of a TIRF REMS Access program-registered physician are eligible for the study.~Patients or their proxy with a witness must be able to sign written informed consent to participate in the study; and the patient may also use a proxy caregiver to assist in the completion of the study questionnaires."
88949523|NCT01936675|No Intervention|Framingham Risk Score|Patients in this arm will receive their Framingham Risk Score of having a heart attack.
89474198|NCT02499237|Active Comparator|Denosumab|Patients with low bone mass, being treated only with denosumab in the past, who will receive another year of treatment with denosumab and subsequently discontinue treatment for one year
89474199|NCT02499237|Experimental|Denosumab plus zoledronic acid|Patients with low bone mass, being treated only with denosumab in the past, who will receive a single infusion of zoledronic acid and subsequently discontinue treatment for another year
89474200|NCT03566095|Active Comparator|Coaching and Voices for Food Kit|The treatment communities received community coaching from an Extension Professional or Educator in the use of the Voices for Food kit.
88949524|NCT01936675|Active Comparator|Framingham and Genetic Risk Score|Patients in this arm will receive their Framingham Risk Score as well as their Genetic Risk Score of having a heart attack.
88949525|NCT01936701|Other|acrylic 3-piece IOL|same-day bilateral cataract surgery with implantation of intraocular lens Domilens KS-XS in one eye
89474201|NCT03566095|Sham Comparator|Voices for Food Kit|The comparison community received the Voices for Food kit.
89474202|NCT03565861|Placebo Comparator|Placebo|Placebo intravenous 30 minute infusion on day 1
89474203|NCT03565861|Experimental|NP10679 5 mg|NP10679 5 mg intravenous infusion on day 1
89474204|NCT03565861|Experimental|NP10679 15 mg|NP10679 15 mg intravenous infusion on day 1
89474205|NCT03565861|Experimental|NP10679 50 mg|NP10679 50 mg intravenous infusion on day 1
89474206|NCT03565861|Experimental|NP10679 100 mg|NP10679 100 mg intravenous infusion on day 1
89474207|NCT03565861|Experimental|NP10679 200 mg|NP10679 200 mg intravenous infusion on day 1
88949526|NCT01936701|Other|silicone 3-piece IOL|same-day bilateral cataract surgery with implantation of intraocular lens Domilens KS-3Ai in one eye
89019866|NCT06156280|Placebo Comparator|Placebo Injection|Placebo injection is administered as a single dose or multiple doses (once every two weeks).
89474208|NCT03565861|Experimental|NP10679 300 mg|NP10679 300 mg intravenous infusion on day 1
89474209|NCT02499393|Experimental|TH+MgSO4|Therapeutic hypothermia plus magnesium sulphate intravenous infusion Neonates who were randomized to the study group (TH+MgSO4) received three 250 mg/kg doses of magnesium sulfate given as one - hour continuous infusion spaced 24 hours apart on three consecutive days. 20% Magnesium Sulfuricum (Polpharma), 2 g /10 ml were used.
89474210|NCT02499393|No Intervention|TH- therapeutic hypothermia|therapeutic hypothermia without magnesium sulphate
89474211|NCT04873622|Experimental|RESTORE intervention|Participants who screen eligible and consent will receive RESTORE with guidance.
89474212|NCT03341559||With Existing Diabetic Ulcers|Current DFU
89019867|NCT06156280|Experimental|TQH2929 Injection (900 mg)|TQH2929 Injection 900 mg is administered once every two weeks.
89019868|NCT06156280|Experimental|TQH2929 Injection (1500 mg)|TQH2929 Injection 1500 mg is administered once every two weeks.
89019869|NCT06156280|Experimental|TQH2929 Injection (1800 mg)|TQH2929 Injection 1800 mg is administered once every two weeks.
89019870|NCT06155695|Experimental|Auditory Control Enhancement (ACE)|tDCS + ACCT
89019871|NCT06155695|Sham Comparator|Sham tDCS + ACCT|Sham tDCS + ACCT
89019872|NCT06153888|Active Comparator|Standard hemodialysis prescription|Short dialysis time and higher ultrafiltration rate/hour dialysis (speed) is used
89202580|NCT02561780|No Intervention|Teaching As Usual (Control)|Schools randomized to this arm of the study received the unadulterated Healthy Living course, taught as usual.
89474213|NCT03341559||Diabetic Ulcers in remission|DFU in remission
89019873|NCT06153888|Experimental|Modified hemodialysis prescription|Prolonged dialysis time and less ultrafiltration rate/hour dialysis
89019874|NCT06153394|Experimental|Redesca|Patients in the extended thromboprophylaxis group will receive Redesca (enoxaparin sodium for injection) (40mg) once a day, starting on the day of surgery, for 90 days postoperatively.
89019875|NCT06153394|Active Comparator|Fragmin|Patients in the standard of care group will receive Fragmin (daletparin) (5,000 I.U) once a day, starting on the day or surgery, for 30 days postoperatively.
89019876|NCT06153225|Experimental|Sub study 1|All subjects will receive 4 study products (300ml each) on 4 different visits in a randomized order. In total in both arms combined, 7 products will be tested.
89019877|NCT06153225|Experimental|Sub study 2|All subjects will receive 4 study products (300ml each) on 4 different visits a randomized order. In total in both arms combined, 7 products will be tested.
89019878|NCT06152835||Breastfeeding Italian women|Italian women, aged 20-40 years who breastfeed children born at full term
89019879|NCT06151275||Colonoscopy|18-95 years old patients apply our endoscopy unit for colonoscopy will be included in our study. Patients that have colonic resection history will be excluded from study.
89019880|NCT06151119||suspected or confirmed myelofibrosis|Patients with suspected or confirmed myelofibrosis;
89019881|NCT06151119||primary/secondary myelofibrosis|Patients with primary/secondary myelofibrosis who were not treated with ruxolitinib.
89202581|NCT00796692|Experimental|Group 2|Low molecular weight heparin
89474214|NCT03565705||Spinal anesthesia with propofol sedation|Patients receive spinal anesthesia for analgesia to undergo open abdominal prostatectomy. Ventilation is secured via a laryngeal mask under propofol sedation and no muscular blocking is necessary.
89474215|NCT03565705||General anesthesia|General anesthesia is conducted with a combination of intravenous opioid (sufentanil) and neuromuscular blocking agent for open abdominal prostatectomy. Patients receive an induction bolus of propofol, undergo tracheal intubation and maintenance of sedation by sevoflurane.
89474216|NCT04849598|Experimental|ESWT Order A and B|First Endurance Shuttle Walk Test using the automatic oxygen titration (O2matic) with the target range being 90 - 94% SpO2, the second Endurance Shuttle Walk Test using the prescribed constant flow oxygen therapy.
89474217|NCT04849598|Experimental|ESWT Order B and A|First Endurance Shuttle Walk Test using the prescribed constant flow oxygen therapy, the second Endurance Shuttle Walk Test using the automatic oxygen titration (O2matic) with the target range being 90 - 94% SpO2.
89474218|NCT04849598|Experimental|Stairs Order A and B|First Stair Walking Test using the automatic oxygen titration (O2matic) with the target range being 90 - 94% SpO2, the second Stair Walking Test using the prescribed constant flow oxygen therapy.
89474219|NCT04849598|Experimental|Stairs Order B and A|First Stair Walking Test using the prescribed constant flow oxygen therapy, the second Stair Test using the automatic oxygen titration (O2matic) with the target range being 90 - 94% SpO2.
89474220|NCT03341481|Experimental|Femaltiker|7.7 g of Femaltiker twice a day for 14 days of the trial.
89474221|NCT03341481|Placebo Comparator|placebo|7.7 g placebo 14 days of the trial.
89474222|NCT03565627|Experimental|Exercise app|7 Minute Workout Challenge by Fitness Guide Inc.
89474223|NCT03565627|Experimental|Running App|One You Couch to 5K by Public Health England
89474224|NCT02504307|Experimental|Inspiron|Sirolimus Eluting Stent Inspiron
89474225|NCT02504307|Active Comparator|Cronus|Bare Metal Stent
89474226|NCT03567499|Experimental|Part A: Sequence 1|Subjects in sequence 1 will receive matching placebo in period 1 followed by GSK3039294 200 milligrams (mg) in Period 2 followed by GSK3039294 600 mg in Period 3 once daily orally. There will be a minimum of 7-day washout period between each treatment session. Each treatment session will consist of 7 days of dosing.
89474227|NCT03567499|Experimental|Part A:Sequence 2|Subjects in sequence 2 will receive GSK3039294 600 mg in period 1 followed by matching placebo in Period 2 followed by GSK3039294 200 mg in Period 3 once daily orally. There will be a minimum of 7-day washout period between each treatment session. Each treatment session will consist of 7 days of dosing.
89474228|NCT03567499|Experimental|Part A: Sequence 3|Subjects in sequence 3 will receive GSK3039294 200 mg in period 1 followed by GSK3039294 600 mg in Period 2 followed by matching placebo in Period 3 once daily orally. There will be a minimum of 7-day washout period between each treatment session. Each treatment session
89474229|NCT03567499|Experimental|Part A: Sequence 4|Subjects in sequence 4 will receive GSK3039294 600 mg in period 1 followed by GSK3039294 200 mg in Period 2 followed by matching placebo in Period 3 once daily orally. There will be a minimum of 7-day washout period between each treatment session. Each treatment session will consist of 7 days of dosing.
89474230|NCT03567499|Experimental|Part A: Sequence 5|Subjects in sequence 5 will receive GSK3039294 200 mg in period 1 followed by matching placebo in Period 2 followed by GSK3039294 600 mg in Period 3 once daily orally. There will be a minimum of 7-day washout period between each treatment session. Each treatment session will consist of 7 days of dosing.
89474231|NCT03567499|Experimental|Part A: Sequence 6|Subjects in sequence 6 will receive matching placebo in period 1 followed by GSK3039294 600 mg in Period 2 followed by GSK3039294 200 mg in Period 3 once daily orally. There will be a minimum of 7-day washout period between each treatment session. Each treatment session will consist of 7 days of dosing.
89474232|NCT03567499|Experimental|Part B: Sequence 1|Subjects in sequence 1 will receive matching placebo in period 1 followed by GSK3039294 (dose level to be decided on results of Part 1) in Period 2 once daily orally. There will be a minimum of 7-day washout period between each treatment session. Each treatment session will consist of 7 days of dosing.
88949527|NCT01936714|Other|HF easyTip 2.2mm|The phacoemulsifications tip used was the easyTip 2.2mm tip (Oertli Instruments, Berneck, Switzerland). The cristaline lens was divided into four quadrants using an aspiration flow rate of 10ml/min and vacuum of 70 mmHg. The quadrants were aspirated using the following linear power and fluidic settings: aspiration flow rate 45ml/min, vacuum 600 mmHg, bottle height 100cm.
88949528|NCT01936714|Other|LF easyTip 2.2mm|The phacoemulsifications tip used was the easyTip 2.2mm tip (Oertli Instruments, Berneck, Switzerland). The cristaline lens was divided into four quadrants using an aspiration flow rate of 10ml/min and vacuum of 70 mmHg. The quadrants were aspirated using the following linear power and fluidic settings: aspiration flow rate 20ml/min, vacuum 400 mmHg, bottle height 100cm.
88949529|NCT01936727|Other|HF easyTip 2.2mm|The phacoemulsifications tip used was the easyTip 2.2mm tip (Oertli Instruments, Berneck, Switzerland). The cristaline lens was divided into four quadrants using an aspiration flow rate of 10ml/min and vacuum of 70 mmHg. The quadrants were aspirated using the following linear power and fluidic settings: aspiration flow rate 50ml/min, vacuum 600 mmHg, bottle height 100cm.
88949530|NCT01936727|Other|infusion asissted easyTip|The phacoemulsifications tip used was an infusion assisted easyTip 2.2mm (Oertli Instruments, Berneck, Switzerland). The cristaline lens was divided into four quadrants using an aspiration flow rate of 10ml/min and vacuum of 70 mmHg. The quadrants were aspirated using the following linear power and fluidic settings: aspiration flow rate 50ml/min, vacuum 600 mmHg, bottle height 100cm.
88949531|NCT01936740|Other|HF easyTip 2.2mm|The phacoemulsifications tip used was the easyTip 2.2mm tip (Oertli Instruments, Berneck, Switzerland). The cristaline lens was divided into four quadrants using an aspiration flow rate of 10ml/min and vacuum of 70 mmHg. The quadrants were aspirated using the following linear power and fluidic settings: aspiration flow rate 45ml/min, vacuum 600 mmHg, bottle height 100cm.
89019882|NCT06151106|Experimental|Chidamide combined with Duvillisib|
89202582|NCT00796692|Active Comparator|Group 1|Unfractionated heparin(UFH)
89474233|NCT03567499|Experimental|Part B: Sequence 2|Subjects in sequence 2 will receive GSK3039294 (dose level to be decided on results of Part 1) in period 1 followed by matching placebo in Period 2 once daily orally. There will be a minimum of 7-day washout period between each treatment session. Each treatment session will consist of 7 days of dosing
89474234|NCT04632290|Experimental|All participants|All participants receive the same intervention.
89474235|NCT02504229|Experimental|Chemotherapy+DC-CIK|Combined treatment group:mononuclear cells were obtained aseptically with blood cell separator composition spheresis 1 day before SOX program chemotherapy, cultured DC-CIK cells. SOX program was acted on Day 2. Cells were cultured 14d,2 times back to the patient.A 21d was a cycle, then evaluated the therapeutic effect after two cycles.
89474236|NCT02504229|Active Comparator|Chemotherapy alone|Chemotherapy: two groups were treated with SOX program,specific drugs:Venoclysis of oxaliplatin 130mg/㎡;Day 1; Tegafur,Gimeracil and Oteracil Porassium Capsules 80mg/㎡/d,two oral/d;Day 1 to 12; 21d as one cycle of treatment, evaluated the therapeutic effect after two cycles.
89474237|NCT04625738|Experimental|MSC Arm|"Ex vivo expanded Wharton's Jelly derived mesenchymal stem cells will be infused at day 0, day 3 and day 5 (+/- 1 day), in patients with moderate to severe ARDS with a mechanical ventilation.~day 0: 1.10^6 MSC/kg day 3: 0.5. 10^6 MSC/kg day 5: 0.5 . 10^6 MSC/kg"
89474238|NCT04625738|Placebo Comparator|Placebo Arm|Only the vehicle solution, without MSCs, containing albumin 4% , NaCl 0,9% and ACD will be injected to patients at day 0, 3 and 5 (+/-1 day).
89474239|NCT03567343|Active Comparator|Proprietary Spearmint Extract Blend|"Subjects randomized into the active treatment group will be asked to consume 500 mg/day of the Proprietary Spearmint Extract Blend blend by mouth every night 30 mins before bed, complete a sleep diary upon waking and wear a Fitbit Charge 2 device for sleep monitoring for 30 days.~A subset of this group will undergo 2 overnight polysomnography studies"
89474240|NCT03567343|Placebo Comparator|Control|"Subjects randomized into the active treatment group will be asked to consume 500 mg/day of the excipient, microcrystalline cellulose by mouth every night 30 mins before bed, complete a sleep diary upon waking and wear a Fitbit Charge 2 device for sleep monitoring for 30 days.~A subset of this group will undergo 2 overnight polysomnography studies"
88949532|NCT01936740|Other|HF easyTip 2.8mm|The phacoemulsifications tip used was the easyTip 2.8mm tip (Oertli Instruments, Berneck, Switzerland). The cristaline lens was divided into four quadrants using an aspiration flow rate of 10ml/min and vacuum of 70 mmHg. The quadrants were aspirated using the following linear power and fluidic settings: aspiration flow rate 50ml/min, vacuum 600 mmHg, bottle height 100cm.
88949533|NCT01936753|Experimental|Mentor Mother Peer Support|This is an enhanced behavioral intervention. Mentor Mothers trained with a standard study curriculum are assigned to pregnant HIV-positive women accessing care at Primary Healthcare Centers in study communities. Under close daily supervision, Mentor Mothers provide support and counseling for the mother-infant pairs until the exposed infant is 12 months old. Study participants in this arm also receive standard of care PMTCT services.
88949534|NCT01936753|No Intervention|Routine Peer Support|Pregnant HIV-positive women receive standard-of-care PMTCT services (drugs, appointments, tests). These women are, per routine, assigned peer counselors who are also HIV-positive women with PMTCT experience but who do receive little or no standardized formal training, and are not closely supervised.
89474241|NCT03567343|Active Comparator|Proprietary Blend And Melatonin|Subjects randomized into the active treatment group will be asked to consume 500 mg/day of the proprietary spearmint extract blend and 1 Mg of melatonin by mouth every night 30 mins before bed, complete a sleep diary upon waking and wear a Fitbit Charge 2 device for sleep monitoring for 30 days.
89474242|NCT03567343|Active Comparator|Melatonin|Subjects randomized into the active treatment group will be asked to consume 1 Mg of melatonin by mouth every night 30 mins before bed and complete a sleep diary upon waking and wear a Fitbit Charge 2 device for sleep monitoring for 30 days.
89474243|NCT02503917||Healthy volunteers|Healthy female adult volunteers
89474244|NCT02503917||Cervical cancer patients|Patients receiving radiotherapy for cervical cancer at the Royal Marsden who will receive a planning CT scan and daily CBCT scanning as part of their treatment.
89474245|NCT04595864|Experimental|treatment group|Transarterial chemoinfusion (TAI) with mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)
89474246|NCT04595864|No Intervention|control group|no neo-adjuvant treatment before operation
89474247|NCT05353309|Active Comparator|Angioplasty DSA|"Reference procedure (DSA), comprising: production of fluoroscopy images for placement of endoluminal material and navigation, subtracted angiography with placement of flaps to reduce the field of rays (collimation ) for visualization of the arterial axis (in low dose, pulsed with maximum collimation), the realization of possible oblique incidences (external iliac), the catheterization with or without placement of a post-inflation stent, then the realization of a second subtracted control angiogram."
89474248|NCT05353309|Experimental|Angioplasty DSA+Fusion|Procedure under study (DSA+Fusion), including: production of fluoroscopy images for placement of the endoluminal material and navigation, 2 fluoroscopy images specifically for image fusion registration (from the images scanner), selective angiography under fluoroscopy with collimation to improve registration (in low dose mode, pulsed with maximum collimation), if possible no oblique views (3D markers of the fusion), with or without placement of post-inflation stent followed by subtracted control angiography
89474249|NCT03341325|Experimental|animal-assisted intervention|the intervention is a real animal is presented in different forms to the participants
89474250|NCT03341325|Active Comparator|control intervention|the control intervention is a stuffed toy animal is presented in different forms to the participants
88949535|NCT01936779|Active Comparator|Dietary supplement: fatty acid active|4g/day n-3 fatty acids for 8 weeks
88949536|NCT01936779|Placebo Comparator|Dietary supplement: fatty acid placebo|4g/day olive oil for 8 weeks
88949537|NCT01936792||mild traumatic brain injury|Subjects with mild traumatic brain injury
88949538|NCT01936792||Controls|Controls with no premorbid health conditions
88949539|NCT01936805|Active Comparator|Rosuvastatin|A 40 mg loading dose of rosuvastatin was administrated 24 h before the PCI.
88949540|NCT01936805|Placebo Comparator|Control|A loading dose of placebo was administrated 24 h before the PCI.
88949541|NCT01936922|Experimental|Virtual reality device (GaitAid®)|This will be a within-subjects design. Each subject will first walk in a controlled laboratory setting as she or he would in daily life. After this, each participant will walk while using the virtual reality device (GaitAid®) for a brief period of time. The session will end with walking as usual.
88949542|NCT01936961|Experimental|CTLA-4 Antibody + hypofractionated radiotherapy|Hypofractionated radiotherapy completed at least 3 days prior to receipt of CTLA-4 Antibody
88949543|NCT01937013|Experimental|Intranasal Oxytocin|Participants will be randomized to receive 72 IU intranasal oxytocin on either study visit 2 or 3
89474251|NCT04583462|Experimental|Metformin|Metformin, started at 500 mg per day per os and titrated up to 2000 mg during 2 years (increase of 500 mg every two weeks)
89474252|NCT04583462|Placebo Comparator|Placebo|Placebo (coated tablet similar to metformin tablet titrated following the same schedule as in the experimental arm), started at 500 mg per day per os and titrated up to 2000 mg during 2 years (increase of 500 mg every two weeks)
89474253|NCT03564925|Active Comparator|Wide area circumferential ablation|Device:Smart Touch® Irrigated Tip Ablation Catheter in combination with 3D mapping system CARTO or any future development generations of this product line, provided they are CE marked and the centre has the experience of at least 10 procedures before including a patient into the study.
89474254|NCT03564925|Experimental|Cryoballoon ablation|Device: ArcticFront® Cardiac CryoAblation Catheter System with the FlexCath Steerable Sheath or ArcticFront® Advance Cardiac CryoAblation Catheter System with the FlexCath Steerable Sheath or any future development generations of this product line, provided they are CE marked and the centre has the experience of at least 10 procedures before including a patient into the study.
89474255|NCT03121053|Active Comparator|sodium bicarbonate|250ml 1.4% sodium bicarbonate 1 h before TAVR
89474256|NCT03121053|Active Comparator|hypotone saline|0.65% sodiumchloride 1 ml/kg/h for 12 h before and 12 h after TAVR
89474257|NCT04456322|Experimental|RT plus Nimotuzumab|Patients with pretreatment plasma EBV DNA<1500 copy/ml and up to CR/PR according to RECIST and the EBV DNA reduced to undectable(0 copy/mL ) after two cycle induction chemotherapy ( TPF :Paclitaxel liposome135mg/m2 d1+DDP 25mg/m2 d1-d3+ 5-FU 750mg /m2/day civ120h, every 3 weeks for 2 courses) will have nimotuzumab (200mg, once a week during radiotherapy, a total of 7 weeks)
89019883|NCT06151080|Experimental|LO-CHOP|Lenalidomide combined with G-CHOP
89474258|NCT04456322|Active Comparator|RT plus Cisplatin|Patients with pretreatment plasma EBV DNA<1500 copy/ml and up to CR/PR according to RECIST and the EBV DNA reduced to undectable(0 copy/mL ) after two cycle induction chemotherapy( TPF :Paclitaxel liposome135mg/m2 d1+DDP 25mg/m2 d1-d3+ 5-FU 750mg /m2/day civ120h, every 3 weeks for 2 courses) will have concurrent cisplatin (100mg/m2, every three weeks,D1,D22,D43 of intensity modulated radiotherapy) )
89474259|NCT03564847|Experimental|LTP Plus|LTP Plus Participants will receive the intervention over 4 months Weekly sessions for 2 months and fortnightly for next two months by trained non-specialists/community health workers.
89474260|NCT03564847|No Intervention|Treatment As Usual (TAU)|Treatment as Usual (TAU) group will receive routine care and their follow up will be done at 4th and 6th month post randomization.
89474261|NCT02503761|Active Comparator|Infusion arm|Infants will receive a loading dose of 20 mg/kg/dose every 8 hours for sepsis and 40 mg/kg/dose every 8 hours in meningitis and pseudomonas infection. Each dose will be infused over four hours.
89474262|NCT02503761|Active Comparator|Bolus group|Infants will receive a loading dose of 20 mg/kg/dose every 8 hours for sepsis and 40 mg/kg/dose every 8 hours in meningitis and pseudomonas infection. Each dose will be infused over thirty minutes.
89474263|NCT03565549|Experimental|Mnemonic|Intervention group will receive a mnemonic aid to remember the CCHR
89474264|NCT03565549|Active Comparator|CCHR rule|The control group will receive the CCHR only
89474265|NCT03341169|Experimental|Glutamine|Intravenous glutamine infusion perioperatively for 18 hours (8 hours before surgery and 10 hours after induction of anesthesia)
89474266|NCT03341169|Placebo Comparator|Placebo|
89474267|NCT03341091|Experimental|Tai-chi group|"16-week 10-step simplified Tai-chi programme.~Two 1-hour sessions of centre-based Tai-chi training and a minimum of three 30-minute Tai-chi sessions at home on a weekly basis."
89474268|NCT03341091|No Intervention|Control group|"Group recreational activities and continue their usual lifestyles and levels of physical activity as usual for 16 weeks.~Two 1-hour sessions of group recreational activities on a weekly basis."
89019884|NCT06150859|Experimental|Experimental: Ayahuasca-assisted constructivist therapy.|Constructivist psychotherapy will be delivered over 9 online psychotherapeutic sessions interconnected in 3 modules to process trauma, restore attachment security and reconstruct the self. One preparation session and two integration sessions after two ayahuasca administrations are included to the experimental group.
89474269|NCT02676193|Experimental|Australian Packs|The intervention to be administered to participants randomized to this group is the purchase of their US brand of cigarettes packaged using standard Australian marketing for three months.
89474270|NCT02676193|Experimental|Blank Packs|The intervention to be administered to participants randomized to this group is the purchase of their US brand of cigarettes packaged using blank packaging for three months. Blank packaging will indicate participants brand and will not have any brand-related images or labels.
89474271|NCT02676193|No Intervention|American Packs|Participants assigned the nonintervention group will purchase their US brand of cigarettes in the standard American packaging for three months.
89474272|NCT05105126|Experimental|Active tDCS first|"[Active stimulation first, then crossover to Sham stimulation]~Each participant will receive BOTH sham or active tDCS but the order of each will be randomized. The active tDCS and sham are procedurally identical. Participants in both arms will have the initial tingling sensation and the active tDCS stimulation will CONTINUE for 20 minutes at 1 mA (milliamps). All tDCS sessions will occur during ABA therapy."
89474273|NCT05105126|Sham Comparator|Sham tDCS first|"[Sham stimulation first, then crossover to Active stimulation]~Each participant will receive BOTH sham or active tDCS but the order of each will be randomized. The active tDCS and sham are procedurally identical. Participants in both arms will have the initial tingling sensation, except in sham stimulation, the current will be DISCONTINUED after 30 seconds while the power indicator remains on for the remainder of 20 minutes at 0 mA (milliamps). All tDCS sessions will occur during ABA therapy."
89474274|NCT03565471||ASD patients with surgical closure|"Patients diagnosed with an ASD who have had a surgical closure of the defect more than 3 years ago.~Echocardiography, right side catheterization, exercise testing and Holter monitoring are performed on all participants."
89474275|NCT03565471||ASD patients with transcatheter closure|"Patients diagnosed with an ASD who have had a transcatheter closure of the defect more than 3 years ago.~Echocardiography, right side catheterization, exercise testing and Holter monitoring are performed on all participants."
89474276|NCT03565471||Controls|"Controls who do not have any cardiac or pulmonary diagnoses nor use prescription drugs that may affect the cardiopulmonary function.~Echocardiography, right side catheterization, exercise testing and Holter monitoring are performed on all participants."
89474277|NCT04988360|Experimental|Group A: HMD first|Those assigned to group A will use the head-mounted display (HMD) VR intervention first. Caregivers will be trained to use the HMD-system and asked to use that system for the duration of T1 (weeks 1 & 2). At the end of T1 they will be asked to complete standardized questionnaires and will participate in a semi-structured interview about their experiences. At the beginning of T2 (weeks 3 & 4), they will then be trained to use the tablet-system, which will be used for the duration of T2. At the completion of T2, the dyad will again complete the same standardized questionnaires and will participate in a semi-structured interview about their experiences. Each session is expected to include 20 minutes of VR exposure. Each session throughout T1 and T2 is to be video-recorded by the caregiver-participant so that reactions and interactions can later be analyzed.
89474278|NCT04988360|Experimental|Group B: Tablet first|Those assigned to group B will use the tablet VR intervention first. Caregivers will be trained to use the tablet-system and asked to use that system for the duration of T1 (weeks 1 & 2). At the end of T1 they will be asked to complete standardized questionnaires and will participate in a semi-structured interview about their experiences. At the beginning of T2 (weeks 3 & 4), they will then be trained to use the HMD-system, which will be used for the duration of T2. At the completion of T2, the dyad will again complete the same standardized questionnaires and will participate in a semi-structured interview about their experiences. Each session is expected to include 20 minutes of VR exposure. Each session throughout T1 and T2 is to be video-recorded by the caregiver-participant so that reactions and interactions can later be analyzed.
89474279|NCT03120585|Experimental|Fluid Management Intervention|Restricting IV fluids to infants with respiratory distress to mimic fluid intake of normal healthy breast fed infants (less fluid that current standard of care)
89474280|NCT03120585|No Intervention|Control Group|Infants with respiratory distress will receive standard of care fluid management.
89474281|NCT03565393|Placebo Comparator|Fibersol-2|Receive Fibersol-2 twice daily
89474282|NCT03565393|Placebo Comparator|Placebo|Receive placebo twice daily
89474283|NCT02503995|Active Comparator|No intervention|Participants not undertaking any additional exercise
89474284|NCT02503995|Experimental|Water-based exercise group|Participants assigned to a water-based exercise group
89474285|NCT02503995|Experimental|Land-based exercise group|Participants assigned to a land-based exercise group
89474286|NCT03565081|Experimental|PWS elastic band training group|Genetically confirmed diagnosis of PWS participants were recruited. The PWS participants needed to have sufficient command of the Mandarin language to understand the study information and motivated to conduct the training program.
89474287|NCT02503605|Active Comparator|Biosimilar recombinant FSH|Under current practice, 65 participants will be stimulated with 150 international units (IU)/day biosimilar recombinant FSH, .Daily doses of 0.25 miligrams gonadotropin-releasing hormone (GnRH) antagonist will start on day 6 of stimulation. From this day may also vary the dose of recombinant FSH biosimilar according ovarian response. In the presence of 3 or more follicles ≥17 mm, a single dose of 0.1 miligram GnRH agonist will be administered for triggering final oocyte maturation
89474288|NCT02503605|Active Comparator|Urinary FSH|Under current practice, 65 participants will be stimulated with 150 IU/day of urinary FSH. Daily doses of 0.25 miligrams gonadotropin-releasing hormone (GnRH) antagonist will start on day 6 of stimulation From this day may also vary the dose of urinary FSH according ovarian response. In the presence of 3 or more follicles ≥17 mm, a single dose of 0.1 miligram GnRH agonist will be administered for triggering final oocyte maturation
89474289|NCT04495023||Group 1 (Kidney transplanted patients)|Group 1: Kidney transplanted patients requiring oncologic or non-oncologic left elective colectomy All kidney transplanted patients requiring oncologic or non-oncologic left elective colectomy between 01 January 2004 and 31 December 2015.
89474290|NCT04495023||Group 2 (Non-transplanted patients)|Group 2 : Non-transplanted patients requiring oncologic or non-oncologic left elective colectomy Non-transplanted patients requiring oncologic or non-oncologic left elective colectomy between 01 January 2004 and 31 December 2015.
89474291|NCT03341013|Experimental|Sequence 1|formulation 2 on Day 1 and formulation 3 on Day 10
89474292|NCT03341013|Experimental|Sequence 2|formulation 3 on Day 1 and formulation 2 on Day 10
89474293|NCT03340935|Experimental|Fasting mimicking diet|Fasting mimicking diet (FMD)
89474294|NCT04097912||Low-dose aspirin users|Patients who receive low-dose aspirin (75-100mg) for either the primary or secondary prevention of cardiovascular disease (CVD).
89474295|NCT04966676|Experimental|Non-Small cell Lung Cancer|"Nivolumab, intravenously (given by vein), once every 3 weeks Ipilimumab, intravenously (given by vein), once every 6 weeks~Participants will have blood samples taken for cell free deoxyribonucleic acid (cfDNA) testing.~If there is an increasing or stable tumor cfDNA, platinum-doublet chemotherapy will be given."
89474296|NCT03340857|Experimental|Intelligent electric bicycle (VELIS) sessions|Intelligent electric bicycle (VELIS) sessions with an instructor, twice a week for 6 weeks
89474297|NCT04040816|Experimental|Dose A|Dose A SAP-001 versus placebo
89474298|NCT04040816|Experimental|Dose B|Dose B SAP-001 versus placebo
89474299|NCT04040816|Experimental|Dose C|Dose C SAP-001 versus placebo
89474300|NCT04040816|Experimental|Dose D (allopurinol patients)|Dose D SAP-001 versus placebo in gout patients who remain on allopurinol
89474301|NCT03340779|Experimental|Norepinephrine alone|Administration of norepinephrine with increasing dose
89474302|NCT03340779|Active Comparator|Norepinephrine plus Dobutamine|Administration of norepinephrine and dobutamine
89474303|NCT05104580||Group 1|High pre-PCI PPG index and high post-PCI QFR
89474304|NCT05104580||Group 2|Low pre-PCI PPG index and high post-PCI QFR
89474305|NCT05104580||Group 3|Low post-PCI QFR regardless of pre-PCI PPG index
89474306|NCT02503371||Women under IVF stimulation at the begining and end|Coagulation parameters will be measured for all parturients at the beginning and conclusion of an IVF simulation cycle with the use of thromboelastogram
89474307|NCT04040738|Active Comparator|Upper extremity surgery under general anaesthesia|Fentanyl 2 mcg/kg iv, propofol 2 mg/kg iv induction, 1MAC sevoflurane maintenance
89474308|NCT04040738|Active Comparator|Upper extremity surgery under regional anaesthesia|Bupivacaine brachial plexus block 0.4 ml/kg of 0.33% solution
89474309|NCT05104424|Active Comparator|adult post covid-19 recovered 22 patients with smell and taste dysfunction take quadruple therapy|adult patients recovered postcovid-19 taking the quadruple therapy zinc 50 mg , gabapentin 300 mg , 40 I.U rapid insulin , 3 times small cube of ice in the mouth Questionnaires will be administered pre- and post-treatment to assess the change in measures. The mean values between groups will be compared.
89474310|NCT05104424|Placebo Comparator|patients taking zinc only with smell training on volatile oils|these 22 adult patients on zinc 50 mg and smell training on 4 volatile oils
89474311|NCT04497129|Experimental|ROMTech PortableConnect|Rehabilitation Using the ROMTech PortableConnect Device
88949544|NCT01937013|Placebo Comparator|Saline Nasal Mist|Participants will be randomized to receive intranasal saline mist (placebo) on opposite visits from the interventional drug visit 2 or 3
89474312|NCT04497129|Active Comparator|Traditional Rehabilitation & Continuous Passive Motion Device|Combination of OPPT and HHPT in conjunction with CPM device usage
89474313|NCT05087732|Experimental|Stylage® M Lidocaïne|STYLAGE® M Lidocaine is a hyalorunic acid injectable gel with Lidocaine hydrochloride whose intended purpose is the filling of skin depressions on the face by dermal injection.
88949545|NCT01937065||No treatment|
89474314|NCT05087732|Active Comparator|Stylage® M|STYLAGE® M Lidocaine is a hyalorunic acid injectable gel whose intended purpose is the filling of skin depressions on the face by dermal injection.
89474315|NCT03340701|Other|Vaginal Progesterone|micronized progesterone vaginal suppository 200mg
89474316|NCT04758962|Experimental|1 µg CoV2 SAM (LNP) Group|Participants aged 18-50 years, allocated in the 1 µg COV2 SAM (LNP) Group receive 2 doses of 1 µg CoV2 SAM (LNP) vaccine 30 days apart, at day 1 and day 31 and are followed up until the study end.
89474317|NCT02503683|Active Comparator|ALN-AAT|
89474318|NCT02503683|Placebo Comparator|Sterile Normal Saline (0.9% NaCl)|
89474319|NCT03453866|Experimental|Warmed Arthroscopic Fluids|Arthroscopic Fluids will be warmed to 38 degrees Celsius during procedure with active warming device. Temperature will be measured in real time.
89474320|NCT03453866|Active Comparator|Room Temperature Arthroscopic Fluids|Arthroscopic fluids will be kept at room temperature and will not be warmed per current standard of care. Temperature will be measured in real time.
89474321|NCT02494479|Active Comparator|50mg of Purisol daily|One (1) 50 mg tablet of Prurisol and one (1) matching placebo tablet given AM and two (2) matching placebo tablets given PM for 84 (± 3) days
89474322|NCT02494479|Active Comparator|100mg of Purisol daily|One (1) 50 mg tablets of Prurisol and one (1) matching placebo tablet given twice daily (AM and PM) for 84 (± 3) days
89474323|NCT02494479|Active Comparator|200mg of Purisol daily|Two (2) 50 mg tablets of Prurisol given twice daily (AM and PM) for 84 (± 3) days
89474324|NCT02494479|Placebo Comparator|Placebo daily|Two (2) placebo tablets given twice daily (AM and PM) for 84 (± 3) days
89474325|NCT05070494|Other|้healthy subject with standard dose trivalent influenza vaccine|้healthy volunteer that received Egg-derived standard dose trivalent influenza vaccine (surface antigen, inactivated) ( 0.5 ml : 15 mcg/strain)
89019885|NCT06150859|Active Comparator|Constructivist Psychotherapy|"Constructivist Psychotherapy will be delivered over 9 online psychotherapeutic sessions interconnected in 3 modules to process trauma, restore attachment security and reconstruct the self.~Once the follow-up period is over (3 months), participants have the option of receiving 2 administrations of ayahuasca if the severity of grief is high."
89019886|NCT06150859|Other|No treatment|"Participants received no treatment during the 9-week Control Period.~Once the follow-up period is over (3 months), participants have the option of receiving 2 administrations of ayahuasca if the severity of grief is high."
89019887|NCT06150755|Placebo Comparator|mplant supported overdenture by ball attachment|immediate loaded implant supported overdenture by ball attachment
89019888|NCT06150755|Active Comparator|implant supported overdenture by bar|immediate loaded implant supported overdenture by intraoral welding titanium bar splinted two implant
89019889|NCT06150248|Other|Intervention group|"Intervention group: Participants assigned to the intervention group will receive educational intervention program to improve their knowledge and promote lifestyle adherence in terms of healthy diet behaviour and physical activity among the undergraduate students. This program will include educational booklets and educational classes include six weeks of in-person education sessions and six weeks of social media messaging. The course will include six weekly teaching units (lectures and group discussions, 45-60 minutes each):~Topic 1: To understand the causes and prevention strategies for overweight and obesity.~Topic 2: To understand food based approaches to reduce or prevent overweight and obesity.~Topic 3: To understand the importance of regular physical activity. Topic 4: To demonstrate how snacking can be a healthy habit. Topic 5: To learn how to read and interpret food labels. Topic 6: To understand how to prepare healthy meals."
89019890|NCT06150248|Other|Control group: No Intervention|Participants randomized to the control group in this study will not receive any intervention (They will have their regular curriculums and normal physical activity routine).
89019891|NCT06149741|Experimental|Left-sided loop colostomy|Left-sided loop colostomy matured in left iliac fossa after complete splenic flexure mobilisation, mesorectal excision and anastomosis
89019892|NCT06147284|Experimental|Traditional exercise|This is an intervention with six 90-minute sessions. Progressive traditional exercise including warm-up exercises, resistance training, stretching routines, and cool-down exercises will be introduced. Both face-to-face and home-based online modes of delivery are available.
89019893|NCT06147284|Experimental|Yoga intervention|The intervention, comprising six 90-minute sessions, will be delivered by a trained mindful yoga instructor in group format. The intervention is based on our previously tested mindfulness yoga programme for people with PD (31). Following a universal Hatha Yoga practice, the session comprises mindfulness practice of yoga sequence, breathing exercise, and guided meditation. Both face-to-face and home-based online modes of delivery are available.
89019894|NCT06147284|Experimental|Arts-based intervention|Participants in the six 90-minute sessions in this intervention will be engaged in art-making processes through multiple art modalities such as visual arts, dance/ movement, music, drama, and creative writing. Each section is usually structured with Filling-in - greetings and check-in, Bridging - warm-up, Decentering - arts making and appreciation, Harvesting - sharing and response, and Closure. Both face- to-face and home-based online modes of delivery are available.
89202583|NCT00750074||1|"During volume assist-control ventilation, a 0.4 second end-inspiratory pause will be set and the following pressures measured: peak pressure; plateau pressure; and PEEP. The following ventilator settings will be recorded: inspiratory flow; expired tidal volume; and rate. The presence or absence of autoPEEP will be noted.~During pressure-control ventilation, the flow versus time waveform will be printed from the ventilator using a conventional computer printer for later analysis. The following ventilator settings will be recorded: inspiratory pressure; PEEP; and expired tidal volume."
89202584|NCT00540436|Experimental|GSK1325760A|Single arm safety and efficacy
89019895|NCT06147284|Experimental|Somatic intervention|The intervention involves six 90-minute sessions led by a trained somatic practitioner in group format. Participants will be guided to bring awareness to their body and to connect with their internal sensations through exploring imageries related to their somatic experiences. They will also learn some somatic techniques that enable them to use their bodies more effectively. Both face-to-face and home- based online modes of delivery are available.
89019896|NCT06142409|Active Comparator|Active arm|Enzyme-containing lozenge
89474326|NCT05070494|Active Comparator|ESRD patient with standard dose trivalent influenza vaccine|ESRD patient that received Egg-derived standard dose trivalent influenza vaccine (surface antigen, inactivated) ( 0.5 ml : 15 mcg/strain)
89019897|NCT06142409|Placebo Comparator|Placebo arm|Placebo lozenge
89019898|NCT06132789|Experimental|Essen Experimental Group (18-60 years old)|The subjects received 1 dose of 1mL Rabies Vaccine（Human Diploid Cell）for Human Use,Freeze-dried each at day 0, 3, 7, 14 and 28, with a total of 5 doses
89019899|NCT06132789|Experimental|Essen Experimental Group (10-17 years old)|The subjects received 1 dose of 1mL Rabies Vaccine（Human Diploid Cell）for Human Use,Freeze-dried each at day 0, 3, 7, 14 and 28, with a total of 5 doses
89019900|NCT06132789|Experimental|Zagreb Experimental Group (18-60 years old)|The subjects received 2 doses of 1mL Rabies Vaccine（Human Diploid Cell）for Human Use,Freeze-dried on day 0, 1 dose on day 7 and 1 dose on day 21, a total of 4 doses.
89019901|NCT06132789|Experimental|Zagreb Experimental Group (10-17 years old)|The subjects received 2 doses of 1mL Rabies Vaccine（Human Diploid Cell）for Human Use,Freeze-dried on day 0, 1 dose on day 7 and 1 dose on day 21, a total of 4 doses.
89019902|NCT06125925|Experimental|Radiofrequency catheter ablation (RFCA)|Radiofrequency ablation is adopted in the study, instead of cryo ablation, surgical ablation or pulsed field ablation. 3-dimensional model is constructed after transseptal puncture. Circumferential pulmonary vein isolation (CPVI) is performed with irrigated contact force catheter. Previously published STABLE-SR approach is recommended as the ablation strategy beyond CPVI.
89019903|NCT06125925|Active Comparator|Medical therapy|AADs should be prescribed according to the current guidelines, such as amiodarone, dronedarone, or propafenone. In brief, rhythm control is preferred, including electric cardioversion. However, rate control should be considered if rhythm control is contraindicated, intolerated or unpreferred by patients.
89019904|NCT06124677||Patients|Patients who received intravitreal faricimab injections between May and September, in 2023. and conform the inclusion/exclusion criteria.
89019905|NCT06120647||Sarcopenic obesity|Age: 70-80 years Men, ALM/W < 25.7 %, body fat % > 35 Women, ALM/W < 19.7 %, body fat % > 40
89019906|NCT06120647||Non-sarcopenic obese|Age: 70-80 years Men, ALM/W > 25.7 %, body fat % > 35 Women, ALM/W > 19.7 %, body fat % > 40
89019907|NCT06120647||Non-sarcopenic lean|Age: 70-80 years Men, ALM > 7.0 kg/m2, body fat % < 25 Women, ALM > 5.5 kg/m2, body fat % < 32
89019908|NCT06120647||Young lean|Age: 18-40 years Men, ALM > 7.0 kg/m2, body fat % < 25 Women, ALM > 5.5 kg/m2, body fat % < 32
89019909|NCT06118892|Experimental|MISHA Knee System|
89019910|NCT06105684|Experimental|Low dose capecitabine (Xeloda)|1000 mg capecitabine daily by mouth.
89019911|NCT06099678|Experimental|Elastic Band Training|This group will perform moderate intensity, whole-body elastic band training.
89019912|NCT06099678|Experimental|Elastic Band Training with Maximal Mental Effort|This group will perform moderate intensity, whole-body elastic band training with maximal mental effort during muscle contraction.
89019913|NCT06099678|No Intervention|Control|This group will not perform any training and maintain their regular level of physical activity.
89019914|NCT06096246|Active Comparator|Experimental: DCCV + PVI|"An implantable loop recorder will be inserted in the pre pectoral area with local anaesthetic at least one week before the randomisation.~Two femoral sheaths will be inserted at the groin area in all patients on the day of the procedure prior randomisation. This will be utilised as the access route for cardiac catheter insertion for ablation and for phrenic nerve pacing during the procedure.~DC cardioversion (DCCV) plus Pulmonary Vein Isolation - At the end of pulmonary vein isolation, DCCV is performed (if the patient is still in AF)."
89019915|NCT06096246|Sham Comparator|DC cardioversion (DCCV) + Sham procedure|"An implantable loop recorder will be inserted in the pre-pectoral area with local anaesthetic at least one week before the randomisation.~Two femoral sheaths will be inserted at the groin area in all patients on the day of the procedure prior randomisation. This will be utilised as the access route for cardiac catheter insertion for intermittent phrenic nerve pacing during the procedure.~DC Cardioversion and Sham procedure will be performed after randomisation. Intermittent phrenic nerve pacing will be employed for the sham group through the femoral venous sheath using a quadripolar catheter."
89019916|NCT06082310|Experimental|High Intensity Interval Training - Biking (HIITBIKE)|Cycling exercise: 5 min warm-up + 9-12 x [45 seconds at 80% of HRmax followed by 1 minute 30 seconds of active recovery at a power equivalent to 40% of HRmax].
89019917|NCT06082310|Experimental|High Intensity Interval Training - Running (HIITRUN)|Running exercise: 5 min warm-up + 9-12 x [45 seconds at 80% of HRmax followed by 1 minute 30 seconds of active recovery at a treadmill speed equivalent to 40% of HRmax].
89019918|NCT06075823|Experimental|Interventional|TEER + Optimal Medical Therapy
89019919|NCT06075823|Active Comparator|Control|Optimal Medical Therapy alone
89019920|NCT06059443|Experimental|mLab App Plus|Participants randomized to intervention will receive standard of care counseling, complete online surveys, be provided with the mLab App Plus, and a box of condoms. The intervention arm will also complete two HIV/Syphilis Ab Combo Rapid Tests (DPP® HIV-Syphilis Test) at their baseline (first test) and 3-month follow- up (second test) appointments.
89019921|NCT06059443|No Intervention|Standard of Care|Participants randomized to standard care will receive standard of care counseling, complete online surveys and be sent an email with links to mobile-optimized online prevention information, including Pre-Exposure Prophylaxis(PrEP) and HIV/STI testing information found on the Centers for Disease Control (CDC) website, and a box of condoms.
89474327|NCT05070494|Experimental|ESRD patient with double dose trivalent influenza vaccine|ESRD patient that received Egg-derived double dose trivalent influenza vaccine (surface antigen, inactivated) total 1 ml ( 1 ml /(30 mcg/strain)
89474328|NCT05070494|Experimental|ESRD patient with double dose - booster trivalent influenza vaccine|ESRD patient that received Egg-derived double dose trivalent influenza vaccine (surface antigen, inactivated) ( 1 ml /(30 mcg/strain) and booster with Egg-derived double dose trivalent influenza vaccine (surface antigen, inactivated) ( 1 ml /(30 mcg/strain) at next 6 months after first dose
89474329|NCT03340623||Mammary reconstruction by DIEP with venous coupler|
89474330|NCT03340623||Mammary reconstruction by DIEP without venous coupler|
89474331|NCT02498535|Experimental|Nitric oxide gas at 160 ppm|Nitric oxide gas at 160 ppm inhaled four times daily for 30 min delivered with air as the carrier via nasal inhalation for a total of 7.5 days. Total dose of 2400 ppm hours.
89474332|NCT02498535|Placebo Comparator|Breathing 20.3% oxygen|Breathing 20.3% oxygen inhaled four times daily for 30 min delivered with air as the carrier via nasal inhalation for a total of 7.5 days.. 100% nitrogen will be injected into the breathing circuit (instead of 99.5% nitrogen and 0.5% NO).
89474333|NCT04497051||Embolized patients|subjects receiving preoperative embolization for aggressive spinal debulking surgery
89474334|NCT04727138|Experimental|EXS21546 Powder for Oral Suspension|EXS21546 Powder for Oral Suspension
89474335|NCT04727138|Placebo Comparator|Placebo|Placebo Powder for Oral Suspension
89474336|NCT04727138|Experimental|EXS21546 Granule in Capsule|EXS21546 Granule in Capsule
89474337|NCT03342885|Experimental|Intervention group|Participants enrolled into the intervention group receive specific sleep ergonomics guidance
89474338|NCT03342885|Active Comparator|Control group|Participants enrolled into the control group will receive general sleep ergonomics guidance
89474339|NCT02498457|Active Comparator|low calcium dialysis|patients in this group will be dialyzed using a dialysate with a calcium concentration 1.25mmol/L.
89474340|NCT02498457|Other|Routine dialysis|Patients in this groups will be dialyzed using routine dialysate with a calcium concentration 1.5mmol/L.
89474341|NCT01676012||five types of bronchoscopy|"Bronchoscopy will be performed in a standardized order using five different imaging modes.~Standard white light videobronchoscopy (WLB)~High Definition -Bronchoscopy~HD-bronchoscopy + surface enhancement (iScan-surface)~HD-bronchoscopy + tone enhancement (iScan-tone)~Auto Fluorescence Bronchoscopy (AFB - SAFE3000) in dual video mode"
89474342|NCT03340545|Other|Healthy Individuals|Healthy individuals will be imaged for comparison purposes
89474343|NCT03340545|Other|Disc Herniation|Subjects diagnosed with Intervertebral Disc Herniation will be imaged to evaluate sensitivity of the proposed method.
89019922|NCT06058949|Experimental|Health Protection and Promotion Program|
89474344|NCT04889846|Experimental|SAFE early intervention group|A family collaborative treatment program based on sensory strategies, activity-based motor training and environmental enrichment principles was created for the infants in the treatment group. Within the scope of the SAFE treatment approach, appropriate activities were explained to the families. Families were asked to do these activities every day for 10 weeks. The compliance of the families with the program was monitored every week via phone calls or the WhatsApp phone program. In addition, families were asked to keep a diary and note the duration of the activity. The homes of the families in the treatment group were visited at least once. During this visit, home environment was evaluated. In order to create an enriched home environment, families were informed about the toys and materials that can be obtained. The family's questions about the program were answered.
89474345|NCT04889846|Experimental|Control group|Within the scope of this study, the infants in the control group were given an NDT-based family training program in accordance with their corrected months and current functional levels. In this context, appropriate activities were taught to families. Families were asked to do these activities every day for 10 weeks. The compliance of the families with the program was monitored every week via phone calls or the WhatsApp phone program. In addition, families were asked to keep a diary and note the duration of the activity. One visit was made to the homes of the families in the control group. The family's questions about the program were answered.
89474346|NCT02498301|Experimental|Rifaximin 550 mg once/day|rifaximin, 550 mg, once daily, by mouth
89474347|NCT02498301|Experimental|Rifaximin 550 mg twice/day|rifaximin, 550 mg, twice daily, by mouth
89474348|NCT02498301|Placebo Comparator|Placebo|Placebo pills, twice daily, by mouth
89474349|NCT03343665|Experimental|Nivolumab 40 mg|Experimental: Nivolumab Nivolumab 40 mg IV over 60 minutes on day 1. Treatment repeats every 14 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
89474350|NCT02733614|Experimental|SRX246|SRX246 160 mg BID, oral administration, capsules, daily for 8 weeks
89474351|NCT02733614|Placebo Comparator|Placebo|oral administration, capsules, daily for 8 weeks
89474352|NCT03340467|Experimental|CGM patch|Patient receives four models of CGM patches. Adhesion sites are randomly allocated (1 on each upper arm, 2 on the abdomen).
89019923|NCT06058949|Active Comparator|General Health Program|
89019924|NCT06050616||binge eating disorder|Participants with a current binge eating disorder, as assessed by the Eating Disorder Diagnostic Screen (DSM-5 version). These participants have been recruited as part of the STRATIFY study. An additional 30 participants will be recruited in this study to enlarge the sample size, using the same study procedure and assessments in the STRATIFY study.
89019925|NCT06050616||anorexia nervosa|Participants with current anorexia nervosa, as assessed by the Eating Disorder Diagnostic Screen (DSM-5 version).. These participants have been recruited as part of the STRATIFY study. Their data will be used in this study.
89202585|NCT00754286|Experimental|Aromatherapy|Participants will be given aromatherapy wand at the onset of their chemotherapy treatment.
89474353|NCT05435001|Experimental|OSAS disease status|The dependent variable was diseased status (OSAS +/-). The independent variables analyzed were age, sex, body mass index (BMI), and for HRV variables, their day and night values and the differences between their night and day values (D[D/N]), as night mean HR, D[D/N] mean HR, night r-MSSD, D[D/N] r-MSSD, night SDNN, D[D/N] SDNN, night SDNN index, D[D/N] SDNN index, night SDANN, and D[D/N] SDANN.
89474354|NCT03340389|Experimental|cataract surgery|cataract extraction and intraocular implantation
89474355|NCT04760444|Experimental|Peer Leader Diabetes Self-Management Support (PLDSMS)|Participants in the PLDSMS arm will receive 10 hours of group diabetes self-management education (DSME) with a certified diabetes care and education specialist. After the DSME group sessions, the group will complete 6 1-hour weekly diabetes self-management support (DSMS) session led by two peer leaders.
89474356|NCT04760444|Active Comparator|Control Group|Participants in the control group will receive 10 hours of group diabetes self-management education (DSME) with a certified diabetes care and education specialist.
88949546|NCT01937078|Active Comparator|active|Famotidine will be administered at total daily doses of 80, 120mg, or 160mg per day. Each patient will be randomized to receive each active dose of famotidine (80, 120, or 160mg/d and placebo). Each patient will receive 4 randomized treatment phases - three famotidine (one at each of the dose levels) and one placebo.
89474357|NCT03340311|Other|Pre-Post|"(Phase one): Each participant will receive usual care (four weeks). Four weeks of glucose logs will be collected at patient's provider visits and completeness recorded.~(Phase two): Each participant will receive a BG5 wireless glucose meter with supplies enough for four weeks. Each participant will download the iGluco application to their smartphone. Education will be given on the monitor and iGluco application use. Four weeks of glucose logs will be collected at patient's provider visits and completeness recorded.~At the conclusion of phase 2, the participants will be asked to complete a satisfaction survey about the care received and their preference of monitors."
89474358|NCT04496583|Active Comparator|Fluid Balance Depletive Strategy Group|Patients with fluid overload under a depletive strategy to attain a predetermined negative balance
89474359|NCT04496583|Experimental|Preload Responsiveness Depletive Strategy Group|Patients with fluid overload under a depletive strategy to attain a state of preload responsiveness
89474360|NCT03340233|Experimental|Group 1|Group 1 includes 25 healthy subjects recruited in Year 1 to undergo cardiac MRI without contrast.
89474361|NCT03340233|Experimental|Group 2|Group 2 includes 25 healthy subjects recruited in Year 2 to undergo cardiac MRI without contrast.
89474362|NCT03340233|Experimental|Group 3|Group 3 includes 33 patients with Heart Failure with Preserved Ejection Fraction (HFpEF) who will undergo cardiac MRI at baseline and at six months to assess diagnostic sensitivity of MRI measurement.
89202586|NCT00754286|Placebo Comparator|Placebo|Participants will be given the placebo wand at the onset of their chemotherapy treatment. Placebo wands will look identical to the scented wands but will not contain a scent.
88949547|NCT01937091||Participants in trials|Participated in a trial of HAART for duration of > 48 weeks.
88949548|NCT01937091||Non-participants in trials|Never participated in clinical trials of HAART Must have been offered participation in a clinical trial and declined
88949549|NCT01937104|Experimental|Group 1|"Drug: Desflurane Anesthesia with desflurane in both Group 1 and Group 2 - adjust minimum alveolar concentration (MAC) to maintain bispectral index (BIS) between 40-60~Drug: Remifentanil Adjuvant continuous administration~- adjust effect site concentration to maintain changes of vital sign below 20%~Device: Ultrasonographic measurement of ONSD~Procedure/Surgery: Mechanical ventilation Maintain the end-tidal carbon dioxide partial pressure between 35 and 40 mmHg and peak inspiratory pressure below 30 cmH2O.~Trendelenburg position - 30 degree"
89474363|NCT02907788||Cystic Fibrosis patients|Patient with cystic fibrosis diagnosed by Heel-prick screening
89474364|NCT02907788||non-CF patients|Children who undergo bronchoscopy for another reason, without CF: eg gastro-esophageal reflux.
88949550|NCT01937104|Experimental|Group 2|"Drug: Desflurane Anesthesia with desflurane in both Group 1 and Group 2 - adjust MAC to maintain BIS between 40-60~Drug: Remifentanil Adjuvant continuous administration~- adjust effect site concentration to maintain changes of vital sign below 20%~Device: Ultrasonographic measurement of ONSD~Procedure/Surgery: Mechanical ventilation Maintain the end-tidal carbon dioxide partial pressure between 35 and 40 mmHg and peak inspiratory pressure below 30 cmH2O.~Reverse Trendelenburg position - 30 degree"
89474365|NCT03342807|Experimental|Group Insulin|
89474366|NCT03342807|Experimental|Group Aphesis|
89474367|NCT02498379|Experimental|Cu[64]-25%CANF-Comb|Single IV injection of 4-8 mCi Cu[64]-25%CANF-Comb followed by PET-CT scan at 1-4 hours, 5-10 hours, and 22-26 hours or 46-50 hours post injection.
89474368|NCT02503293|Other|Chrono Super PID then Generic Syringe - Gammanorm|"Each patient will receive the study treatment using each of the two studied delivery devices according to the sequence randomly assigned based on a cross-over design:~• Chrono Super PID then Generic Syringe-Gammanorm"
89474369|NCT02503293|Other|Generic Syringe then Chrono Super PID - Gammanorm|"Each patient will receive the study treatment using each of the two studied delivery devices according to the sequence randomly assigned based on a cross-over design:~• Generic Syringe then Chrono Super PID-Gammanorm"
89474370|NCT04718558||Patients aged between 3-24 month and undergoing cleft palate surgery|
89474371|NCT04661306|Experimental|SHUTi|
89019926|NCT06050616||bulimia nervosa|Participants with current bulimia nervosa, as assessed by the Eating Disorder Diagnostic Screen (DSM-5 version). These participants have been recruited as part of the STRATIFY study. Their data will be used in this study.
88949551|NCT01937143|Placebo Comparator|Control|General information about infant immunizations at birth of a newborn infant
88949552|NCT01937143|Active Comparator|Low intensity intervention|Pamphlet with information about pain management during infant immunizations at birth of a newborn infant
88949553|NCT01937143|Active Comparator|High intensity intervention|Pamphlet and video with information about pain management during infant immunizations at birth of a newborn infant
89019927|NCT06050616||healthy controls|Healthy controls are selected from the IMAGEN study at the third follow-up (~age 22 years) who do not exhibit any psychiatric disorder. Their data will be used in this study. IMAGEN and STRATIFY are sister studies that employ matched study protocols.
89474372|NCT04700462|Experimental|Sm-EMA|Participants will receive the Self-monitoring ecological momentary assessment behavior change tool.
89474373|NCT05233059|Active Comparator|Walking|The walking group will receive a tailored FitEx for endometrial cancer survivors, including cancer specific newsletters.
89474374|NCT05233059|Experimental|Walking Plus Yoga|The walking group will receive a tailored FitEx for endometrial cancer survivors with yoga cuing and yoga-based newsletters.
89474375|NCT03340077|Experimental|MOR Toolkit|Medicines Optimisation Review consultation + My clinical companion (patient questionnaire about their medications)
89474376|NCT03340077|Active Comparator|Standard of Care|Current standard of care for patients with HIV receiving antiretroviral therapy, which consists of a phamacists review of ART prescriptions.
89474377|NCT04496661|Experimental|tDCS over M1 and PES|Anodic transcranial direct current stimulation (tDCS) over right primary motor cortex (M1) and PES (20Hz and 330ms) placed at the height between the T12 and S1 vertebrae in order to cover the entire lumbar area . Duration: 30 minutes.
89474378|NCT04496661|Experimental|tDCS over DLPFC and PES|Anodic transcranial direct current stimulation (tDCS) over left dorsolateral prefrontal cortex (DLPFC) and PES (20Hz and 330ms) placed at the height between the T12 and S1 vertebrae in order to cover the entire lumbar area . Duration: 30 minutes.
88949554|NCT01937169|Experimental|Drug + motor task|"Each participant will undergo physical examination by an doctor. Then, the participant will receive the Fitbit device with instructions for proper use. The next stages will take place at the participant's home environment.~Each participant will monitor motor activity in hours prior to sleep and at night for assessing baseline activity level. After 3 nights of monitoring, each participant will be administered with a quarter of a Dopicar pill (4th night) and half a Dopical pill (5th night), measuring different dose effect on motor activity during sleep.This group will be administered with a quarter of a Dopicar pill, 1 hour prior to sleep. After 15 minutes, participants in this group will perform a motor task (e.g., walking) for 30 minutes."
89474379|NCT04496661|Sham Comparator|Sham tDCS and PES|Sham tDCS and PES stimulation. Anodic transcranial direct current stimulation (tDCS) over right primary motor cortex (M1) and PES (20Hz and 330ms) placed at the height between the T12 and S1 vertebrae in order to cover the entire lumbar area. The currents will be turned off automatically after 30 seconds. Duration: 30 minutes.
89474380|NCT05112068||Control group|
89474381|NCT05112068||Experimental group|
89474382|NCT05112224|Experimental|Educational Intervention|An educational program based on HBM that was conducted using five one-hour sessions.
88949555|NCT01937169|Placebo Comparator|Placebo + motor task|"Each participant will undergo physical examination by an doctor. Then, the participant will receive the Fitbit device with instructions for proper use. The next stages will take place at the participant's home environment.~Each participant will monitor motor activity in hours prior to sleep and at night for assessing baseline activity level. After 3 nights of monitoring, each participant will be administered with a quarter of a Dopicar pill (4th night) and half a Dopical pill (5th night), measuring different dose effect on motor activity during sleep. This group will be administered with a quarter of a Placebo pill, 1 hour prior to sleep. After 15 minutes, participants in this group will perform a motor task (e.g., walking) for 30 minutes."
89474383|NCT05112224|No Intervention|Control|Control group only received the education program provided by the dental clinic.
89474384|NCT03342729|Experimental|Intervention Group|Immediate exposure to the 10-week Aging Mastery Program (AMP)
89474385|NCT03342729|Placebo Comparator|Wait-list Group|Class to start 3 months after the Intervention Group
89474386|NCT05112146|Placebo Comparator|Control 10|100 ml Water taken 10 min before standard meal
89474387|NCT05112146|Experimental|Whey protein isolate 10|10 g whey protein isolate diluted in 100 ml taken 10 min before standard meal
89474388|NCT05112146|Experimental|Whey protein microgel 10|10g whey protein microgel in 100 ml taken 10 min before standard meal
89474389|NCT05112146|Placebo Comparator|Control 30|100 ml Water taken 30 min before standard meal
89474390|NCT05112146|Experimental|Whey protein isolate 30|10 g whey protein isolate diluted in 100 ml taken 30 min before standard meal
89474391|NCT05112146|Experimental|Whey protein microgel 30|10g whey protein microgel in 100 ml taken 30 min before standard meal
89019928|NCT06041672|Experimental|Warm Water Hand Baths|Patients in the experimental group have their hand immersed in warm water (40°C) for ten minutes.
89474392|NCT04593914|Experimental|Cavilon Advanced Skin Protectant|"Cavilon Advanced Skin Protectant forms a film barrier intended to protect intact or damaged skin. It is effective in conditions where skin is frequently or continuously exposed to moisture and caustic irritants such as feces, digestive fluids, wound drainage and urine. Cavilon Advanced Skin Protectant also can be used in areas exposed to friction and shear from bedding, clothing, shoes or any other material that would rub against the skin.~The skin barrier protectant will be applied on the irradiated skin from the third week of radiotherapy until 1 week after the final radiotherapy session."
89474393|NCT04523090|Experimental|Nitazoxanide|Nitazoxaninde, 1000mg (2pills), oral, twice daily for 7 days. To be taken with food.
89474394|NCT04523090|Placebo Comparator|Placebo|Placebo, 2 pills, oral, twice daily for 7 days. To be taken with food.
89474395|NCT04947488|Active Comparator|Bioarginina C|vials based on L-arginine and liposomal vitamin C
89019929|NCT06041672|No Intervention|Routine care|Including preoperative instructions, postoperative care, and monitoring of vital signs.
89474396|NCT04947488|Placebo Comparator|Placebo|vials without L-arginine and liposomal vitamin C
89474397|NCT02727777|Experimental|Aggressive Non-Hodgkin Lymphoma (NHL) - TAK228|"Phase II - Aggressive NHL: Diffuse Large B Cell Lymphoma (DLBCL), Mantle Cell Lymphoma (MCL), Transformed Large Cell Lymphoma, and Follicular Lymphoma (FL) grade 3b Group~Participants take TAK-228 1 time every day of a 28 day cycle.~Treatment continues until progression of disease occurs, or a maximum of 12 months of treatment.~Participant checks blood sugar every day before TAK-228 dose."
89202587|NCT00796770|Experimental|Dendritic Cell Vaccine|Autologous dendritic cells generated using GM-CSF and interferon alpha, loaded with HIV lipopeptides and activated with lipopolysaccharide
89019930|NCT06029842|Other|the intervention group|this group received the collaborative care between the clinical pharmacist and physicians in a medical center
88949556|NCT01937169|Sham Comparator|Dopicar + Sham task|"Each participant will undergo physical examination by an doctor. Then, the participant will receive the Fitbit device with instructions for proper use. The next stages will take place at the participant's home environment.~Each participant will monitor motor activity in hours prior to sleep and at night for assessing baseline activity level. After 3 nights of monitoring, each participant will be administered with a quarter of a Dopicar pill (4th night) and half a Dopical pill (5th night), measuring different dose effect on motor activity during sleep. This group will be administered with a quarter of a Dopicar pill, 1 hour prior to sleep. After 15 minutes, participants in this group will perform a non-motor task (e.g., crossword puzzle) for 30 minutes."
88949557|NCT01937182|Active Comparator|Selective Serotonin Reuptake Inhibitors|Intervention Drug: Citalopram
88949558|NCT01937182|Placebo Comparator|Placebo|Intervention Drug: Placebo
88949559|NCT01937208|Experimental|high-dose|concurrent chemoradiation:CT:DDP 25mg/m2 D1+docetaxel 25mg/m2 D1,Weekly for 5 wks;RT：60Gy/30F/6W(3D-CRT or IMRT).Then,2 cycles consolidation chemotherapy were used:DDP 75mg/m2 D1+docetaxel 75mg/m2 D1, Q3W
88949560|NCT01937208|Active Comparator|standard dose|concurrent chemoradiation:CT:DDP 25mg/m2 D1+Docetaxel 25mg/m2 D1,Weekly for 5 wks;RT：50Gy/25F/5W(3D-CRT or IMRT).Then,2 cycles consolidation chemotherapy were used:DDP 5mg/m2 D1+Docetaxel75mg/m2 D1, Q3W
88949561|NCT01937221||mild cognitive impairment|
88949562|NCT01937221||mild to moderate cognitive impairment|
88949563|NCT01937221||normal or control group|
88949564|NCT01937234|Active Comparator|Metoclopramide|Intravenous injection of 10mg metoclopramide
88949565|NCT01937234|Placebo Comparator|Placebo|Intravenous injection of 0.9% sodium chloride
89474398|NCT02727777|Experimental|Indolent Non-Hodgkin Lymphoma (NHL) - TAK228|"Phase II - Indolent NHL: Follicular Lymphoma (FL) grade 1-3a, Small Lymphocytic Lymphoma (SLL), Marginal Zone Lymphoma (MZL) Group~Participants take TAK-228 1 time every day of a 28 day cycle.~Treatment continues until progression of disease occurs, or a maximum of 12 months of treatment.~Participant checks blood sugar every day before TAK-228 dose."
89019931|NCT06029842|No Intervention|the control group|this group received the standard care of physicians in a medical center without clinical pharmacist interventions
89019932|NCT06028282||Radioiodine I-131 (RAI)|oral administration of radioiodine I-131 (RAI) to patients with well-differentiated thyroid cancer
89202588|NCT00788658|Placebo Comparator|Diet modifications|Diet consultation and life style modifications for 6 sessions
89202589|NCT00788658|Active Comparator|Cognitive therapy|6 sessions of cognitive behavioral therapy
89202590|NCT00792012|Experimental|Glioblastoma Multiforme Patients|Hypofractionated Intensity-Modulated Radiation Therapy (Hypo-IMRT) Combining with Temozolomide (TMZ) Chemotherapy
89202591|NCT02562950|Experimental|Midazolam and 500 mg GLPG1837|Each subject will receive a single oral dose of midazolam (2 mg) on 2 occasions (Days 1 and 12) and multiple oral doses of GLPG1837 (250 mg b.i.d daily for 10 days) from Days 2 to 11.
89474399|NCT02727777|Experimental|Hodgkin Lymphoma - TAK228|"Phase II - Hodgkin Lymphoma Group~Participants take TAK-228 1 time every day of a 28 day cycle.~Treatment continues until progression of disease occurs, or a maximum of 12 months of treatment.~Participant checks blood sugar every day before TAK-228 dose."
89474400|NCT04522778|Experimental|Device|Those in the device arm will be given two wearable central line securement devices and the investigators will encourage continuous wear throughout the duration of the study.
89474401|NCT04522778|Active Comparator|Traditional Securement Dressing|Those is the non-device arm will continue to wear a traditional central line securement dressing as is the standard of care.
89474402|NCT03342651|Other|Observational research|Vitamin D levels and respiratory complications; observational research.
89474403|NCT04819568|Experimental|Terlipressin Bolus Arm|
89474404|NCT04819568|Active Comparator|Terlipressin Continuous Infusion Arm|
89474405|NCT02502981|Experimental|CKD stage 2 & 3|"Patients with CKD stage 2 & 3 (eGFR 30-89ml/min/1.73m2) will be randomly assigned to receive either spironolactone or chlortalidone in a PROBE design.~Subjects will undergo cardiac MRI, carotid femoral pulse wave velocity, 24 hour ambulatory blood pressure monitoring, blood tests for renal function and spot urine analysis for proteinuria (albumin:creatinine ratio) at baseline and after 40 weeks of allocated treatment. Additional blood tests for renal function and potassium level will be assessed at week 1,2,4,8 and 20."
89474406|NCT04230746|Placebo Comparator|Placebo|Participants will be recruited and enrolled. Participants will be surveyed regarding environmental, health, and behavioral practices. (Instrument 1) . Then a clean catch urine specimen will be collected. Participants will be provided with placebo to be taken twice daily. This will be considered day 0. Participants will then be instructed to take the study drug twice daily and return on Day 2, Day 5, Day 10, Day 30, and Day 180 for additional clean-catch urine specimen.
89474407|NCT04230746|Experimental|Bactrim|Participants will be recruited and enrolled. Participants will be surveyed regarding environmental, health, and behavioral practices. (Instrument 1) . Then a clean catch urine specimen will be collected. Participants will be provided with Bactrim 800/120 to take twice daily. This will be considered day 0. Participants will then be instructed to take the study drug twice daily and return on Day 2, Day 5, Day 10, Day 30, and Day 180 for additional clean-catch urine specimen.
89474408|NCT02498223|Experimental|research arm|50 subjects (healthy soldiers, male and female) from combat units will undergo the experiment protocol.
89474409|NCT04681196||patients affected by OSA treated with CPAP / paradox effect group|patients with obstructive sleep apnea, exhibiting persistent obstructive events and paradoxical obstruction when wearing oronasal masks during CPAP, that were fully recovered with the shift to nasal one with the same or also lower pressure
89474410|NCT04681196||patients affected by OSA treated with CPAP / control group (no paradox effect)|patients with obstructive sleep apnea, with no obstructive events when wearing oronasal masks during CPAP
89474411|NCT02494245|Active Comparator|Intervention|128 participants will take part in the STARFISH intervention
89474412|NCT02494245|No Intervention|Control|Participants allocated to the control group will be given a booklet with general advice on physical activity.
89474413|NCT04633772|Placebo Comparator|Placebo|
88949566|NCT01937325|Active Comparator|Ivacaftor|150mg orally twice daily
88949567|NCT01937325|Placebo Comparator|Placebo|Matching placebo
88949568|NCT01937338|Experimental|AZD7624|
88949569|NCT01937338|Placebo Comparator|Placebo|
88949570|NCT01937416|Experimental|autologous bone marrow mononuclear cells|Bone marrow come from the patients himself/herself. With a conventional method and reagent,Ficoll, mononuclear cells were isolated with deleting erythrocyte by density gradient centrifugation.
88949571|NCT01937429|Experimental|Colonoscopy with blue indigo Carmin®|Patients undergoing from a colonoscopy with instillation of tepid water (30°C) tinged with indigo Carmin® (0,08/1000) during the endoscope insertion from the anus to the caecum, and with insufflation of air only during withdrawal from the caecum to the anus.
89474414|NCT04633772|Experimental|Angiotensin-(1-7)|
89474415|NCT03339687|Experimental|Induction of Open Mindset|Psychological Intervention. Participants are asked to work on a brief paper-and-pencil task that has been shown to induce a Deliberative Mindset according to the Mindset theory of action phases (Gollwitzer & Keller (2016). Mindset Theory. In: V. Zeigler-Hill, T.K. Shackelford (eds.), Encyclopedia of Personality and Individual Differences. New York: Springer).
88949572|NCT01937429|Active Comparator|Standard colonoscopy|Standard colonoscopy with insufflation of air
88949573|NCT01937442|Experimental|Thalidomide Celgene™ 200mg once daily|5-day period of thalidomide treatment
88949574|NCT01937455|Experimental|Group A|rAAV1-PG9DP or placebo (v:p = 3:1)
88949575|NCT01937455|Experimental|Group B|rAAV1-PG9DP or placebo (v:p = 3:1)
88949576|NCT01937455|Experimental|Group C/C1|rAAV1-PG9DP or placebo (v:p = 3:1 in Group C, and v:p = 9:3 in Group C1)
88949577|NCT01937455|Experimental|Group D/D1|rAAV1-PG9DP or placebo (v:p = 3:1 in Group D, v:p = 4:1 in Group D1)
88949578|NCT01937481|Experimental|Nutrition and Physical Activity|The Food Friends programs
88949579|NCT01937481|No Intervention|Control|Control group
89474416|NCT03339687|Experimental|Induction of a Closed Mindset|Psychological Intervention. Participants are asked to work on a brief paper-and-pencil task that has been shown to induce an Implemental Mindset according to the Mindset theory of action phases (Gollwitzer & Keller (2016). Mindset Theory. In: V. Zeigler-Hill, T.K. Shackelford (eds.), Encyclopedia of Personality and Individual Differences. New York: Springer).
89474417|NCT04610840|Active Comparator|Direct puncture|Direct puncture of the caliceal system performed under ultrasound or Xray control
88949580|NCT01937494|Experimental|asthma patients|patients who show a positive response at the first dos of histamine challenge test will be enrolled
88949581|NCT01937533||Cervical Cancer|Patients with presumed early cervical cancer being considered for curative surgery
88949582|NCT01937546|Active Comparator|Anterior shoulder|Primary delivery of the anterior shoulder of the fetus
88949583|NCT01937546|Experimental|Posterior shoulder|Primary delivery of the posterior shoulder of the fetus
89019933|NCT06024174|Experimental|Part 1: DDI Cohort|
89019934|NCT06024174|Experimental|Part 1: Dose Escalation|
89019935|NCT06024174|Experimental|Part 2: Dose Expansion|
89019936|NCT06014723||Observation group|The observation group received early submaximal balloon angioplasty and medical therapy.
89019937|NCT06014723||Control group|The control group received only medical therapy.
89019938|NCT06004830|Experimental|Spironolactone|Participants will receive a prescription for spironolactone
89474418|NCT04610840|Active Comparator|Non-direct puncture|Puncture of the caliceal system performed under ultrasound or Xray control and retrograde contrast
89474419|NCT03339609||Immediate uroflow/EMG testing|Participants performed two direct repetitions of uroflowmetry in combination with EMG.
89474420|NCT03339609||uroflow measurement beforehand|Participants performed a preceding measurement of isolated uroflowmetry, followed by two randomized measurements of either isolated uroflowmetry or uroflowmetry with EMG.
89474421|NCT02502591|Experimental|intervention|Additional pain relief (a Pudendal Nerve Block (PNB)) will be administered during surgery in addition to routine care.
89474422|NCT02502591|No Intervention|control|routine care only
89474423|NCT05111444|Other|Camrelizumab+Pyrotinib + Chemotherapy|Camrelizumab (200 mg) will be administered intravenously [IV] on day 1 of each 3-week cycle. Pyrotinib (320 mg) will be administered orally once daily [QD] on every 21 days. Chemotherapy will either be XELOX, SOX or TS.
89474424|NCT03339531|Experimental|2D radiotherapy|Patients with prostate cancer were treated with 2D-radiotherapy
89474425|NCT03339375||control|Monitoring arterial pressure, central venous pressure and pulse pressure variation
89474426|NCT03339375||esophagela Doppler|Monitoring arterial pressure, central venous pressure Insertion of esophageal Doppler probe to patient Monitoring stroke volume, cardiac output, corrected flow time from esophageal Doppler Use stroke volume optimization goal directed therapy protocol
89474427|NCT02498691|Experimental|Type exposed|endometriosis
89474428|NCT02498691|Experimental|Type unexposed|Without endometriosis
89474429|NCT05110820||Acute CO poisoning|A diagnosis of CO poisoning was made according to medical history and carboxyhaemoglobin >5% (>10% in smokers).
89474430|NCT02497989|Experimental|Inter-personal Communication (IPC)|Interpersonal communication will entail delivery of intervention massages that are custom-made to address individual participants' specific barriers and facilitators of VMMC. RAs will discuss with uncircumcised men why they have not gone for VMMC using the 'VMMC Demand Creation Toolkit'. The aim will be to fully address their barriers and re-enforce their facilitators. RAS will be trained behavioral counselors, circumcised men, female partners, CHWs, or any other cadre of individuals identified during the formative phase.
89474431|NCT02497989|Experimental|Dedicated Service Outlets (DSO)|RAs shall visit all households with eligible men to inform them about the availability of, and give information on location of DSO sites in the Location. DSOs are sites: where services are offered exclusively to men aged ≥25 years by male service providers in the same age bracket; providing services in the evenings/weekends/designated days of the week, and through special mobile services for older men. DSO sites we will strive to shorten the waiting time to ≤ three hours. They will be informed that all other VMMC sites continue to serve all men regardless of age (i.e., including older men) while DSO sites will only serve men aged ≥25 years. RAs will respond to questions using 'All You Need to Know About VMMC' booklet, the same way current recruiters do.
89474432|NCT02497989|Experimental|Combined IPC & DSO|Both Inter-personal Communication (IPC) and Dedicated Service Outlets (DSO) interventions (as described above) will be implemented concurrently. This will be done to determine the effect of both interventions delivered jointly compared to each delivered singly, and compared to no intervention.
89474433|NCT02497989|No Intervention|Control|In these Locations, participants will only be given the 'All You Need to Know About VMMC' booklet at the time of enrollment, which is the standard of care.
89474434|NCT04598204|Experimental|Treatment Arm|To treat the enrolled patients with oral rapamycin at an initial dosage of 0.8mg/m2, once daily for children under 3 years old and twice daily (every 12 hours) for those above 3 years, and adjust the dosage to target a trough concentration of rapamycin in plasma as 10-15ng/ml （OR 15-20ng/ml if the efficacy of treatment is not satisfactory）. One course lasts for 12weeks and no more than 4 course is given.
89474435|NCT03769688|Experimental|Cervicovaginal secretions|Participants will receive standard of care antibiotics (vaginal Metronidazole gel). After standard antibiotic treatment, participants will receive a single intravaginal dose of cervicovaginal secretions (10 mg in 1 ml total volume, 0.9 ml normal saline).
89474436|NCT03769688|Placebo Comparator|Saline placebo|Participants will receive standard of care antibiotics (vaginal Metronidazole gel). After standard antibiotic treatment, participants will receive a single intravaginal dose of sterile saline placebo (1 ml total volume).
89474437|NCT02502825|Experimental|asthma|methacholine(0.031-16mg/ml) bronchial provocation tests. this is a crossover,normal-control study. nebulized with Wright nebulizer for 2 minutes with an output of 0.13ml/min.
89202592|NCT02562950|Experimental|Midazolam and 1000 mg GLPG1837|Each subject will receive a single oral dose of midazolam (2 mg) on 2 occasions (Days 1 and 12) and multiple oral doses of GLPG1837 (500 mg b.i.d daily for 11 days) from Days 2 to 12.
89019939|NCT06004180|Experimental|Lu AF28996|Participants will receive ascending oral doses of Lu AF28996 OD for 14 days (Day 1 to Day 14). From Day 15, the participant will initiate down-titration of Lu AF28996 as per investigator's judgement.
89019940|NCT05984810|Experimental|10mg, administered 3-5 days before surgery|"Drug: SGM-101 Intravenous single injection of the targeted NIR fluorophore SGM-101. This targeted 700nm fluorophore developed by SurgiMab S.A.S., Montpellier, France.~Device: Intraoperative near-infrared fluorescence imaging Intraoperative imaging will be performed with the following CE-marked near-infrared (NIR) fluorescence imaging system: Quest Spectrum imaging platform (v2/3.0). With a NIR-imaging system a potential fluorescent signal of the tumor can be evaluated. Furthermore, the Quest Spectrum platform will also be used for evaluation of ex-vivo fluorescence of resected tissue on the back table (Back table imaging) and pathology department (ex-vivo imaging), which shall be performed during and after every procedure."
89019941|NCT05980806|Experimental|Selinexor 60 mg (Arm 1)|Participants will receive selinexor 60 milligrams (mg) oral tablets once weekly (QW) (Days 1, 8, 15, and 22 of each 28-day cycle) until PD, intolerable toxicity, or until they meet the criteria for discontinuation of study treatment, death, or withdrawal of consent, whichever comes first and followed by optional add-on medication dosing may be initiated based on Spleen Volume Reduction (SVR) values.
89202593|NCT02599948||Patients hospitalised in ICU|Patients hospitalised in ICU
89019942|NCT05980806|Experimental|Selinexor 40 mg (Arm 2)|Participants will receive selinexor 40 mg oral tablets QW (Days 1, 8, 15, and 22 of each 28-day cycle) until PD, intolerable toxicity, or until they meet the criteria for discontinuation of study treatment, death, or withdrawal of consent, whichever comes first and followed by optional add-on medication dosing may be initiated based on SVR values.
89019943|NCT05980806|Experimental|Selinexor 60 mg (Optional Expansion Arm)|Participants will receive selinexor 60 mg oral tablets QW (Days 1, 8, 15, and 22 of each 28-day cycle) until PD, intolerable toxicity, or until they meet the criteria for discontinuation of study treatment, death, or withdrawal of consent, whichever comes first. Optional add-on medication (ruxolitinib [5 mg or 10 mg twice daily], pacritinib [200 mg twice daily], or momelotinib [200 mg once daily]) may be initiated for participants whose SVR is less than (<) 10% at Week 12 or <35% at Week 24 based on the participants platelet count values (i.e., ruxolitinib if platelets greater than or equal to [>=] 50 x 10^9/L, pacritinib if platelets <50 x 10^9/L, momelotinib if platelets is >=50 x 10^9/L and hemoglobin level is < 10 gram per deciliter [g/dL]).
89019944|NCT05980806|Experimental|Selinexor 40 mg (Optional Expansion Arm)|Participants will receive selinexor 40 mg oral tablets QW (Days 1, 8, 15, and 22 of each 28-day cycle) until PD, intolerable toxicity, or until they meet the criteria for discontinuation of study treatment, death, or withdrawal of consent, whichever comes first. Optional add-on medication (ruxolitinib [5 mg or 10 mg twice daily], pacritinib [200 mg twice daily], or momelotinib [200 mg once daily]) may be initiated for participants whose SVR is <10% at Week 12 or <35% at Week 24 based on the participants platelet count values (i.e., ruxolitinib if platelets >= 50 x 10^9/L, pacritinib if platelets <50 x 10^9/L, momelotinib if platelets is >=50 x 10^9/L and hemoglobin level is < 10 g/dL).
89019945|NCT05979051|Experimental|Treatment group A|SHR-1703
89019946|NCT05979051|Placebo Comparator|Treatment group B|SHR-1703 Placebo
89019947|NCT05972122|Placebo Comparator|Group S = SPSIPB group|A high-frequency linear US probe (11-12 MHz, Vivid Q) will be covered with a sterile sheath, and an 80 mm block needle (Braun 360°) will be used. The procedure will be performed with the patient in the lateral decubitus position. After the scapula is shifted slightly laterally, the US probe is placed sagittal at the upper corner of the spina scapula, and the serratus posterior superior muscle is visualized with the third rib. The in-plane technique will be used. The block needle will be advanced in the craniocaudal direction to enter between the serratus posterior superior and the third rib. The block location will be confirmed by injecting 5 ml of saline between the rib and the muscle. After the block location is confirmed, 30 ml of 0.25% concentration bupivacaine will be used.
89019948|NCT05972122|Other|Group C = Control group|The intercostal infiltration with 30 ml of 0.25% concentration of bupivacaine will be performed by the surgical team.
89019949|NCT05965570|Experimental|Brensocatib + Clarithromycin|Participants will receive a single oral dose of brensocatib in the morning on Days 1 and 13 after an overnight fast, and oral doses of clarithromycin, twice daily (BID), with food on Days 8 to 19. On Day 13, brensocatib will be coadministered with the morning dose of clarithromycin. Clarithromycin can be taken with food, with the exception of the morning dose on the day of coadministration with brensocatib (Day 13), which will be taken after an overnight fast.
89019950|NCT05959421|Experimental|Booster|Participants will receive ERVEBO® (rVSV∆G-ZEBOV-GP) ≥72 million pfu/mL primary immunization And a single booster immunization with the same dose of study vaccine as the primary dose (≥72 million pfu/mL) at month 6 following primary vaccination
89019951|NCT05959421|Experimental|no Booster|Participants will receive ERVEBO® (rVSV∆G-ZEBOV-GP) ≥72 million pfu/mL primary immunization only
89019952|NCT05950191|Experimental|PermaNet Dual|long lasting insecticidal nets with chlorfenapyr-pyrethroid
89019953|NCT05950191|Active Comparator|PermaNet 3.0|long lasting insecticidal nets with PBO-pyrethroid
89019954|NCT05949918|Experimental|Precontemplation, Contemplation, Preparation, Action, and Maintenance-based intervention|The intervention that would consider the Processes of Change that people use when they would be in the Precontemplation Stage of Change.
89019955|NCT05949918|Experimental|Contemplation-based intervention|The intervention that would consider the Processes of Change that people use when they would be in the Contemplation Stage of Change.
89019956|NCT05949918|Experimental|Preparation-based intervention|The intervention that would consider the Processes of Change that people use when they would be in the Preparation Stage of Change.
89019957|NCT05949918|Experimental|Action-based intervention|The intervention that would consider the Processes of Change that people use when they would be in the Action Stage of Change.
89019958|NCT05949918|Experimental|Maintenance-based intervention|The intervention that would consider the Processes of Change that people use when they would be in the Maintenance Stage of Change.
89019959|NCT05949892|Experimental|A healthy diet|"This arm will focus on the following:~Eating lots of vegetables and fruit Choosing whole grain foods Eating protein foods Limiting highly and ultra-processed foods Highly processed foods Making water your drink of choice Salt, sodium and potassium Refraining from added sugars"
89019960|NCT05949892|Experimental|Healthy Weight Management|"This arm will focus on the following:~Physical Activity for a Healthy Weight Preventing Weight Gain Choosing an Eating Plan to Prevent Weight Gain Balancing Food and Activity for Healthy Weight"
89019961|NCT05949892|Experimental|Physical Activity|"This arm will focus on the following:~Step 1: Make a commitment Step 2: Take stock of where you are Step 3: Set realistic goals Step 4: Identify resources for information and support Step 5: Continually check in with yourself to monitor your progress. Revisit the goals you set for yourself in Step 3 and evaluate your progress regularly"
89019962|NCT05949892|Experimental|Stress management|"This arm will focus on the following:~Stress relief Relaxation techniques Meditation Mindfulness exercises"
89019963|NCT05949892|Experimental|Smoking Cessation and Avoidance|"This arm will focus on the following:~Second-hand smoke Offering option to avoid secondhand smoke"
89474438|NCT02502825|Experimental|normal controls|methacholine(0.031-16mg/ml) bronchial provocation tests. this is a crossover,normal-control study. nebulized with Devilbiss646 nebulizer for 2 minutes with an output of 0.13ml/min
89474439|NCT04572776|Experimental|Resiniferatoxin|Single dose of Resiniferatoxin (25 mcg in 3 mL) injected epidurally
89474440|NCT04572776|Active Comparator|Standard of Care|Standard of care treatment as determined by the investigator
89019964|NCT05949086|No Intervention|Work Chat Later|This group will not receive Work Chat during the study, but will receive Work Chat access after data collection is complete.
88949584|NCT01937572|Experimental|Computer-aided TKA|The Visionaire system is a computer-aided system utilizing MRI of the knee prior to TKA surgeries. This technology achieves accurate rotational and A-P position. All of the commonly-referred anatomical landmarks (AP axis, epicondylar axis) are analyzed pre-operatively, allowing for the proper positioning of the implant for each patient.
88949585|NCT01937572|Other|Conventional TKA|A conventional TKA utilizes a jig system based on either intra-medullary or extra-medullary guides. No knee MRI is utilized for a conventional TKA.
88949586|NCT01937585|Active Comparator|CDC brochure only condition|Receipt of CDC brochure by female partners of African American men designed to provide African American men information and guidance concerning whether to undergo PSA and/or DRE screening for prostate cancer
88949587|NCT01937585|Experimental|Partner and CDC brochure condition|Receipt of a brochure designed for female partners of African American men designed to provide information about prostate cancer screening and strategies for influencing her mate to schedule a discussion with a health care provider about whether to undergo prostate cancer screening, in combination with receipt of the comparator brochure (CDC brochure for African American about prostate cancer screening).
88949588|NCT01937611|Experimental|Dexmedetomidine|dexmedetomidine 1μg•kg-1
89202594|NCT00747578||1|"AS patients who fit the modified New York criteria (1984)~Exclusion criteria :~Patients who have cognitive impairment.~Patients who have overlapping syndrome of any 2 of the 3 rheumatic disease (eg. RA overlapping with SLE).~Patients who are less than 18 years old or older than 65 years old.~Patients who visited rheumatologists in the outpatient clinics of the Division of Rheumatology at Taichung Veterans General Hospital for less than 4 times in 2008."
89202595|NCT00747578||2|"RA patients who fit the American College of Rheumatology (ACR) criteria (1987)~Exclusion criteria :~Patients who have cognitive impairment.~Patients who have overlapping syndrome of any 2 of the 3 rheumatic disease (eg. RA overlapping with SLE).~Patients who are less than 18 years old or older than 65 years old.~Patients who visited rheumatologists in the outpatient clinics of the Division of Rheumatology at Taichung Veterans General Hospital for less than 4 times in 2008."
89202596|NCT00747578||3|"SLE patients who fit the ACR revised criteria for the classification of SLE (1997)~Exclusion criteria :~Patients who have cognitive impairment.~Patients who have overlapping syndrome of any 2 of the 3 rheumatic disease (eg. RA overlapping with SLE).~Patients who are less than 18 years old or older than 65 years old.~Patients who visited rheumatologists in the outpatient clinics of the Division of Rheumatology at Taichung Veterans General Hospital for less than 4 times in 2008."
89202597|NCT00788814|Other|Control|Control group
89202598|NCT02567110||Participants with Major Depression|Participants with major depression will complete neurocognitive and psychiatric assessments, complete self-report forms and undergo Magnetic Resonance Imaging scans. Blood and spinal fluid specimens will also be collected for estimation of inflammatory markers.
89202599|NCT02567110||Participants without Depression|Participants without depression will complete neurocognitive and psychiatric assessments, complete self-report forms and undergo Magnetic Resonance Imaging scans. Blood and spinal fluid specimens will also be collected for estimation of inflammatory markers.
89202600|NCT00754754|Experimental|Brain Retraction Monitoring Sensor|
89202601|NCT00792090|Experimental|1|Fermented milk
89202602|NCT00792090|Active Comparator|2|Standard milk
89202603|NCT00747656||1|3 lead ECG subjects with chest pain and suspected ischemia transported to the nearest receiving ED and not eligible for bypass based on transport time
89202604|NCT00747656||2|3 lead ECG subjects with chest pain and suspected ischemia transported to the nearest receiving ED and eligible for bypass based on transport time, if 12 lead PHECG was possible
89202605|NCT00747656||3|12 lead ECG subjects with prehospital notification transported to nearest receiving ED adn not eligible for bypass to PCI center based on transport time
88949589|NCT01937611|Active Comparator|midazolam|midazolam 0.03 mg•kg-1
88949590|NCT01937637|Other|Behavioral Intervention for Dyspnea|"In the first intervention session, enrolled participants will learn breathing and relaxation exercises designed to relieve breathlessness. The nurse practitioner will also provide handouts with directions for these exercises, an audio-recording with the relaxation exercises, and worksheets for daily home practice. During the second session, participants will again meet with the nurse practitioner to review the study exercises and to address any difficulties participants may have experienced in practicing the skills.~All participants will complete questionnaires before and after the study intervention as well as a brief follow-up interview with the research assistant to obtain feedback about ways to improve the intervention to relieve breathlessness in patients with lung cancer."
89202606|NCT00747656||4|12 lead PHECG subjects with prehospital notification bypassed past the nearest receiving ED to the PCI center.
89202607|NCT00792168|Active Comparator|1. Venlafaxine|
89202608|NCT00792168|Placebo Comparator|2. Placebo|
89202609|NCT02554188|Placebo Comparator|Control|Participants will receive Seasonal influenza (flu) vaccine.
89202610|NCT02554188|Experimental|Diet|Participants will consume 2 cycles of a 5-day low calorie fasting-mimicking diet with approximately 3 weeks of gap period prior to receiving standard Seasonal influenza (flu) vaccine.
89202611|NCT00687440|Experimental|Caelyx, Docetaxel, Trastuzumab|"Stage 1: subjects will receive Caelyx one day every 3 weeks in combination with docetaxel one day every 3 weeks and trastuzumab once weekly during 6 cycles. At the end of this stage, based on the number of cardiac events, subjects will proceed to a second stage or restart with a lower dose of Caelyx.~Stage 2: subjects will be treated with the recommended dose of Caelyx (defined in the first stage) in combination with docetaxel and trastuzumab."
89202612|NCT02554734|Experimental|Levodopa standard carbidopa|Levodopa, carbidopa, ODM-104
89202613|NCT02554734|Experimental|Levodopa modified carbidopa|Levodopa, carbidopa, ODM-104
89202614|NCT02554734|Active Comparator|Stalevo|Levodopa, carbidopa, entacapone
89202615|NCT00990496|Experimental|GBM Treatment|
89202616|NCT00754910||Group 1|Patients receive porfimer sodium IV over 3-5 minutes and undergo irradiation with red light 48 hours later. Patients receive 2 more treatments at 2-day intervals.
89202617|NCT00755066|Experimental|F|Fluticasone propionate 200 µg intranasal
89474441|NCT03342495|Experimental|Patient Navigator Arm|"Patient Navigator (Social Worker) will assist youth adapt and attach to adult delivered healthcare for up to 24 months.~Participants will receive 5 issues of a provincial generic newsletter on topics around transition.~Participants will be asked to complete a health questionnaire at baseline and 4 more times during 24 months.~Participants will be asked to complete a transition readiness questionnaire at baseline and 4 more times during 24 months.~Participants will be provided the opportunity to journal online about their experiences.~Up to 100 participants will be provided the opportunity to be interviewed at baseline and end of study about their transition experience."
89474442|NCT03342495|Other|Usual Care Arm|"Youth will receive usual care from their pediatric clinics in preparation and transfer to adult care.~Participants will receive 5 issues of a provincial generic newsletter on topics around transition.~Participants will be asked to complete a health questionnaire at baseline and 4 more times during 24 months.~Participants will be asked to complete a transition readiness questionnaire at baseline and 4 more times during 24 months.~Participants will be provided the opportunity to journal online about their experiences."
89474443|NCT05110664||Cohort/Intervention 1|Meal test
89474444|NCT05110664||Cohort/Intervention 2|Ad libitum meal
89474445|NCT05104346|Placebo Comparator|Patients in group I (G1) had AA prior to the era of COVID|Patients in group I (G1) had AA prior to the era of COVID
89474446|NCT05104346|Active Comparator|patients in group II (G2) had AA during COVID|patients in group II (G2) had AA during COVID
89474447|NCT03343587|Experimental|LY3375880 Single Dose|Single dose of LY3375880 administered IV or SC
89474448|NCT03343587|Placebo Comparator|Placebo Single Dose|Single dose of placebo administered IV or SC
89474449|NCT03343587|Experimental|LY3375880 Multiple Dose|Multiple doses of LY3375880 administered IV or SC
89474450|NCT03343587|Placebo Comparator|Placebo Multiple Dose|Multiple doses of placebo administered IV or SC
89474451|NCT02502513|Experimental|Intervention|"Brief computerized intervention (computer game Tetris) plus usual care in the maternity department and completion of intrusive memory diary"
89474452|NCT02502513|No Intervention|Control|Usual care in the maternity department plus completion of intrusive memory diary
89474453|NCT03338985|Experimental|"Group cases patients"|patients with endometrial hyperplasia or endometrial cancers
89474454|NCT05100914|Experimental|Couple-based family nursing|Women and their spouses were provided couple-based family nursing based on dignity and respect, information sharing, participation and collaboration for 30-60 minutes with couple-based interviews for arm rehabilitation. Arm rehabilitation begins within 48 hours postoperatively, and each movement should be incrementally increased in terms of exertion and repetition until the patient reaches 10 repetitions, 2-3 times daily, for one month.
89474455|NCT05100914|Active Comparator|Treatment as usual|All women in the control group received hospital standard operative care, and couples attended a routine, 30-60-minute presentation about rehabilitation after breast surgery without any specific couple-based dyad interview.
89474456|NCT03338907|Experimental|Oxycarbon (5% CO2 + 95% O2)|Patients will be mechanical ventilated with Oxycarbon (5%CO2 +95% O2) after normocapnia is reached until FeO2 is stable for at least 1 min ≥ 80%. At timepoint 1 immediately prior apnea NIRS and vital parameters will be registered and an bloodsample will be drawn.
89202618|NCT00755066|Placebo Comparator|P|Placebo intranasal spray
89202619|NCT00990574|Active Comparator|spinal anesthesia group (SAG)|Participants will undergo the standard procedures involved in placement of a spinal anesthetic in the sitting position.
89202620|NCT00990574|Active Comparator|The WSCG (wiley spinal catheter group)|The WSCG (wiley spinal catheter group) will undergo the standard procedures involved in placement of a spinal anesthetic in the sitting position.
89202621|NCT00659490|Experimental|AZD1940|AZD1940 800ug given predose
89202622|NCT00659490|Active Comparator|Naproxen|Naproxen 500mg given pre-surgery
89202623|NCT00659490|Placebo Comparator|Placebo|Placebo given pre-surgery
89202624|NCT00792246|Experimental|graft versus host disease|Patients receiving oral voriconazole will be switched to intravenous voriconazole. Pharmacokinetics will be determined after each formulation.
89202625|NCT00792246|Experimental|No graft versus host disease|Patients receiving oral voriconazole will be switched to intravenous voriconazole. Pharmacokinetics will be determined after each formulation.
89474457|NCT03338907|Placebo Comparator|Control (95% O2)|"Same procedure as arm active comparator"
89474458|NCT03338751|Active Comparator|Hearing Assistance Device (HAD) First|Tablet, loaded with REDCap will generate a random number that determines the order of test administration with the HAD first or second. Participants randomized to HAD first will use a Hearing Aid Device.
89474459|NCT03338751|Active Comparator|No Hearing Assistance Device (HAD) First|Sham hearing aid device
89474460|NCT03338517|Active Comparator|Study group|Helium Neon Laser
89474461|NCT03338517|No Intervention|Control group|No intervention
89474462|NCT04989374||CD patients treated with WMT|the gastrointestinal experts decided the treatment plan according to the patient's condition and the patient's wishes, these CD patients treated with WMT
89474463|NCT04989374||CD patients treated without WMT|the gastrointestinal experts decided the treatment plan according to the patient's condition and the patient's wishes, these CD patients treated without WMT
89474464|NCT04989374||UC patients treated with WMT|the gastrointestinal experts decided the treatment plan according to the patient's condition and the patient's wishes, these UC patients treated with WMT
89474465|NCT04989374||UC patients treated without WMT|the gastrointestinal experts decided the treatment plan according to the patient's condition and the patient's wishes, these UC patients treated without WMT
89474466|NCT03338439||CSII|CSII: patients with continuous subcutaneous insulin infusion
89474467|NCT03338439||MDI|MDI: patients with multi-daily injections
89474468|NCT02498145|Experimental|Nicotine e-cigarette|Patients will receive nicotine patch and intensive counseling plus e-cigarette with nicotine.
89474469|NCT02498145|Active Comparator|Non-nicotine e-cigarette|Patients will receive nicotine patch and intensive counseling plus e-cigarette without nicotine.
89474470|NCT02497911|Experimental|Adductor Canal Catheter|Postoperatively, patients will be brought to the PACU. The needle insertion site, approximately 10cm proximal to their operative knee, will be exposed. A sterile field will be utilized and the femoral artery is identified with a high frequency linear transducer proximal to the operative knee. 18g insulated Tuohy needle will be inserted in an out-of-plane approach through the sartorius muscle to a final location in close proximity to the saphenous nerve. Once satisfied with needle placement and following negative aspiration, 15 cc's of 0.5% ropivicaine will be injected through the needle under visualization. A 20-g multi-orifice catheter will be inserted approximately 4 cm beyond the needle tip and secured.
88949591|NCT01937650|Active Comparator|Radiotherapy plus metronidazole|Participants in the intervention arm received 1gm (2 suppositories) of metronidazole per rectum 30 minutes before radiotherapy for every other radiotherapy session with two rest days of Saturday and Sunday. The standard radiotherapy regimen for advanced cancer of the cervix composed of two phases of radiotherapy was used; phase 1 was tele-therapy via parallel-opposed portals from Co-60 radiation source, with a total dose of 50 Gy given in 25 fractions of 2 Gy/day for five weeks. The patients were then given a break of 1-4 weeks before getting the second phase of treatment. Phase 2 was brachy-therapy from a Cs-137 source, whereby a single dose of 30Gy was delivered at point A at a rate of 2.55 Gy/ hour for 7 hours and 50 minutes, via a uterine Tandem and two vaginal Ovoids.
89202626|NCT00797004||endoscopic sinus procedure candidates|
89474471|NCT02497911|Experimental|Intraarticular Catheter|Intra-articular catheters will be placed by the surgeon at the end of the procedure, before wound closure. A bupivacaine 0.5% infusion will be admin through the On-Q system and continued for 48 hours postoperatively.
89474472|NCT04187300|Experimental|DV3396|Semaglutide administered with the DV3396 pen-injector (Formulation D)
89474473|NCT04187300|Experimental|PDS290|Semaglutide administered with the PDS290 pen-injector (Formulation B)
89474474|NCT00707577|Experimental|Internet-based maintenance program|9-month Internet based self-monitoring maintenance program to track weight, exercise, and food logs
89474475|NCT00707577|No Intervention|Control|No maintenance program provided
89474476|NCT04914650|Experimental|Telerehabilitation intervention|
89474477|NCT02502279|No Intervention|Control|Engström Datex-Ohmeda ICU Ventilator: Pediatric patients under general anesthesia will be mechanically ventilated with the conventional ventilator parameters with 0 PEEP/CPAP.
89474478|NCT02502279|Active Comparator|Lung Recruitment- PEEP group|Engström Datex-Ohmeda ICU Ventilator: Pediatric patients under general anesthesia will be mechanically ventilated with the conventional ventilator parameters plus lung recruitment manoeuvre with peak inflation pressure 35 cmH2O for 15 seconds followed by PEEP until extubation delivered by the ventilator.
89474479|NCT02502279|Active Comparator|Lung Recruitment- PEEP and CPAP group|"Engström Datex-Ohmeda ICU Ventilator: Pediatric patients under general anesthesia will be mechanically ventilated with the conventional ventilator parameters plus~lung recruitment manoeuvre with peak inflation pressure 35 cmH2O for 15 seconds followed by PEEP until extubation delivered by the ventilator.~Postoperative CPAP mask immediately after extubation"
89474480|NCT02497833|Placebo Comparator|control|the participants in this arm are instruted to consume placebo capsules
88949592|NCT01937650|Placebo Comparator|Radiotherapy alone|Participants in the control arm received 500mg (two suppositories) of paracetamol as a placebo on similar days. This was in addition to the standard radiotherapy administration in two phases as described above.
88949593|NCT01937663|Experimental|KWA-0711 Dose1|
88949594|NCT01937663|Experimental|KWA-0711 Dose2|
88949595|NCT01937663|Experimental|KWA-0711 Dose3|
88949596|NCT01937663|Experimental|KWA-0711 Dose4|
88949597|NCT01937676||Adults admitted to ER|All adult patients admitted to emergency department during the study period.
88949598|NCT01937689|Experimental|Pyrotinib|Each subject will receive a single dose of pyrotinib on day 1, followed by 4-day observation period, and then subject will receive pyrotinib once daily for 28 days during cycle 1.Each cycle will consists of 28 days.
88949599|NCT01937702|Experimental|Anti-diabetes medication|Insulin
88949600|NCT01937728|Active Comparator|A: Peg-interferon alpha-2a & Ribavirin|Arm A: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 24 weeks with a follow-up period of 24 weeks.
88949601|NCT01937728|Experimental|B: Peg-interferon alpha-2a & Ribavirin|"Arm B: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 36 weeks with a follow-up period of 24 weeks.~(Patients who have HVL and an RVR will be randomized into arm B or arm C with a ratio of 1:1)"
88949602|NCT01937728|Experimental|C: Peg-interferon alpha-2a & Ribavirin|"Arm C: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 48 weeks with a follow-up period of 24 weeks.~(Patients who have HVL and an RVR will be randomized into arm B or arm C with a ratio of 1:1)"
88949603|NCT01937728|Active Comparator|D: Peg-interferon alpha-2a & Ribavirin|"Arm D: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 48 weeks with a follow-up period of 24 weeks.~(Patients who do not achieve a RVR but have HCV RNA PCR-seronegative at week 12 of treatment)"
88949604|NCT01937728|Experimental|E: Peg-interferon alpha-2a & Ribavirin|"Arm E: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 48 weeks with a follow-up period of 24 weeks.~(Patients who do not achieve a RVR and remain HCV RNA PCR-seropositive at week 12 of treatment will be randomized into arm E or arm F a ratio of 1:1)"
89474481|NCT02497833|Experimental|treatment|the participants in this arm are instruted to consume retinoic acid capsules
89474482|NCT02493933|Active Comparator|Phytoestrogen|Patients received oral PE 120 mg/ day in the form of dry coated tablets (Klimadynon, Bionorica, Germany) 2 tablets three times daily from day 1 to day 12 as adjuvant to CC in the follicular phase of the cycle.
89474483|NCT02493933|Active Comparator|Isosorbid mononitrate|Patients received in addition to CC 20 mg Isosorbid mononitrate (ISMN) tablet (EFFOX, Minapharm Co., Egypt under licence of Shwartz pharma,Germany) applied vaginally from day 1 to day 12 of the cycle.
89474484|NCT02493933|Active Comparator|N-Acetyl cysteine|Patients received supplementation to CC with NAC 1200 mg/day orally (N-acetyl cysteine, Sedico, Cairo, ARE) sachets 200 mg each, as two sachets thrice daily from day 1 to day 12 of the cycle.
89474485|NCT02494011|Experimental|traditional exercise (group I)|"Mobilization:2 strokes per one second and repeated 6 times during session~stretching exercise: 15 to 20 minutes~passive range of motion: 5 minutes at beginning and at end~active range of motion: 20 repetition~oedema control: 15s active contraction of fingers of 15s relax for 3 times"
89474486|NCT02494011|Experimental|russian current stimulation (group II)|The frequency was 2.5 kHz for 15 minutes
89474487|NCT02494011|Experimental|CKC (group III)|"wall press exercise - plyometric exercise-Quadruped rhythmic stabilization- press up exercise~closed kinetic chain exercises performed 10 times and each week 2 more repetitions added as a progression"
89474488|NCT02502201|Active Comparator|six-minute walk study indoors first|Participants randomized to indoor six-minute walk test first
89474489|NCT02502201|Experimental|six-minute walk study outdoors first|Participants randomized to outdoor six-minute walk test first
89474490|NCT02502201|Active Comparator|six-minute walk study indoors second|Participants randomized to indoor six-minute walk test second
89474491|NCT02502201|Experimental|six-minute walk study outdoors second|Participants randomized to outdoor six-minute walk test second
89474492|NCT03338283|Experimental|Electromassage|"Electromassage and conservatory treatment. All subjects will be received a conservatory treatment (1h and 40 min) and electro-massage (10min).~The protocol will consist of six sessions, twice a week for three weeks. The duration will be 1 hour and 40 min for the conservatory treatment and 10 min for the electro-massage."
89474493|NCT03338283|Active Comparator|Conservatory Treatment|The control protocol will combine: (a) thermotherapy with infrared application; (b) active, self-assisted and isometric shoulder exercises, including Codman's pendulum exercises; (c) manual therapy, always in a pain-free range of movement; and (d) ultrasound in pulsatile mode over the acromium and scapulohumeral area.
89474494|NCT04864964|Other|combined conventional and pulsed radiofrequency of trigeminal nerve nucleus|"The technique of the CCPRF is described as follows;~the classic Hartle technique is used to reach the Gasserian ganglion~Sensory stimulation with the RF equipment is conducted and parathesia of the affected branch is achieved at 0.1-0.2 V (50 Hz), keeping in mind that the mandibular part of the Gasserian ganglion is ventrolateral and the ophthalmic rootlets are postrolateral. Motor pre-stimulation (2 Hz) is achieved with masseter contraction at 0.1-0.3 V .~After sensory and motor stimulation, RF therapy is conducted by use of the RF generator , in the sequence:~Conventional RF 1st lesion at 60 °C for 60 s then 2nd lesion at 65°C for 60 seconds then 3rd lesion at 70°C for 60 seconds~Finally, PRF is applied for 360 second repeated at 45 V, with a pulse width of 10 ms and a pulse frequency of 4 Hz. The cut-off needle tip temperature is set at 42 °C.~Before withdrawal of needle 1 cc xylocaine 1% + 0.5 cc dexamethasone 4mg to be given ."
89474495|NCT04790240|Active Comparator|Inflammation (I)|"Upper respiratory inflammation.~Fever.~Lower respiration inflammation."
89474496|NCT04790240|Active Comparator|Inflammation (II)|Cough, chest pain
89474497|NCT04790240|Active Comparator|Inflammation (III)|"Metabolites~Clots"
89474498|NCT02502357|Experimental|Healing Statements|Patients in the healing statements group will be read healing statements during anesthesia induction, prior to undergoing surgery.
89474499|NCT02502357|No Intervention|No Healing Statements|Patients in the no healing statements group will not be read healing statements during anesthesia induction prior to undergoing surgery. They will receive standard of care.
89474500|NCT04386980|Experimental|Resiniferatoxin|12.5 ug of Resiniferatoxin in 5 mL volume administered once intra-articularly
89474501|NCT04386980|Placebo Comparator|Placebo|5 mL of diluent in normal saline administered once intra-articularly
89474502|NCT02493699|Experimental|Exercise|physical exercise- based intervention (Karate techniques training)
89474503|NCT02493699|No Intervention|Control|Not participating in physical exercise- based intervention (Karate techniques training)
89474504|NCT02497599|Experimental|Intraoperative dual-modality imaging|Patients receive a single intravenous dose of Indium-111-DOTA-Girentuximab-IRDye800CW. At day 4 or 5 after antibody injection a whole body planar scan and SPECT/CT scan will be acquired. At day 7 standard of care (partial) nephrectomy will be performed. This will be extended with the use of dual-modality imaging.
89474505|NCT04314050|Active Comparator|tramadol|1,5 mg /kg tramadol will perform intraoperatively in 100 ml saline within 15 minutes at 30 minutes before surgery completed. In addition, 1 gr paracetamol will be given intraoperatively.
89474506|NCT04314050|Active Comparator|dexmedetomidine|1 mcg/kg dexmedetomidine bolus will perform after anesthesia induction and followed by infusion of 0.5 mcg/kg/h until 30 minutes before surgery completed. In addition, 1 gr paracetamol will be given intraoperatively.
89474507|NCT04314050|Placebo Comparator|control|1 gr paracetamol will perform intraoperatively
88949605|NCT01937728|Experimental|F: Peg-interferon alpha-2a & Ribavirin|"Arm F: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 72 weeks with a follow-up period of 24 weeks.~(Patients who do not achieve a RVR and remain HCV RNA PCR-seropositive at week 12 of treatment will be randomized into arm E or arm F a ratio of 1:1)"
88949606|NCT01937754|Active Comparator|Nitric Oxide supplement|
88949607|NCT01937754|Placebo Comparator|Placebo|
88949608|NCT01937767|Active Comparator|Propofol|Induction: Propofol, fentanyl, rocuronium. Maintenance: Sevoflurane, remifentanil.
88949609|NCT01937767|Experimental|Remimazolam 6 mg/kg/hr|Induction: Remimazolam 6 mg/kg/hr, fentanyl, rocuronium. Maintenance: Remimazolam up to 2 mg/kg/hr titrated to effect, remifentanil.
89474508|NCT04496193|Experimental|Group lower dose ropivacaine with dexamethasone|Quadratus lumborum block was administered with 0.25% Ropivacaine 20 ml + dexamethasone 0.8 ml (4mg) at the end of surgery
89474509|NCT04496193|Active Comparator|Group higher dose ropivacaine with N/S|Quadratus lumborum block was administered with 0.5% Ropivacaine 20 ml + N/S 0.8 ml at the end of surgery
88949610|NCT01937767|Experimental|Remimazolam 12 mg/kg/hr|Induction: Remimazolam 12 mg/kg/hr, fentanyl, rocuronium. Maintenance: Remimazolam up to 2 mg/kg/hr titrated to effect, remifentanil.
88949611|NCT01937793|Active Comparator|effortful swallowing exercise|Subjects in the arm are asked to do the effortful swallowing exercise at home for 8 weeks. The training frequency is to exercise 3-4 days/week, 3 times/day, 10 repetitions per time. Besides the at home exercise, each subject is scheduled to meet the investigator at the hospital at weekly basis to discuss and review his/her exercise practice.
88949612|NCT01937793|Active Comparator|Mendelsohn swallowing exercise|Subjects in the arm are asked to do the Mendelsohn swallowing exercise at home for 8 weeks. The training frequency is to exercise 3-4 days/week, 3 times/day, 10 repetitions per time. Besides the at home exercise, each subject is scheduled to meet the investigator at the hospital at weekly basis to discuss and review his/her exercise practice.
88949613|NCT01937806|Experimental|besifovir 150mg|Besifovir 150 mg q.d. + Placebo of Tenofovir Disoproxil Fumarate 300 mg q.d. + L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d.
89474510|NCT04496193|Placebo Comparator|Group lower dose ropivacaine with N/S|Quadratus lumborum block was administered with 0.25% Ropivacaine 20 ml + N/S 0.8 ml at the end of surgery
89474511|NCT02502123||OnabotulinumtoxinA (BOTOX®)|Patients diagnosed with chronic migraine headache treated with BOTOX® as standard of care in clinical practice. No intervention was administered in this study.
89474512|NCT03892616|Experimental|A - B - C|
89474513|NCT03892616|Experimental|D - A - B|
89474514|NCT03892616|Experimental|E - B - A|
89474515|NCT03892616|Experimental|C - A - D|
89474516|NCT03892616|Experimental|A - E - C|
89474517|NCT03892616|Experimental|E - D - A|
89474518|NCT03892616|Experimental|B - C - D|
89474519|NCT03892616|Experimental|C - E - B|
89474520|NCT03892616|Experimental|B - D - E|
89019965|NCT05949086|Experimental|Work Chat Now|Behavioral: Work Chat: An Interactive Virtual Workday Work Chat will be a simulation training using virtual characters to role-play conversations. It will contain conversations with a coworker, a customer, and a supervisor within a workplace setting.
89474521|NCT03892616|Experimental|D - C - E|
89474522|NCT03892616|Experimental|C - B - A|
89474523|NCT03892616|Experimental|A - E - D|
89474524|NCT03338127||Participants|all patients recruited in the trial will be investigated for renal function test
89474525|NCT04689542|Experimental|Surgical Facemask|The surgical facemask will be worn during the sit-to-stand test
89474526|NCT04689542|No Intervention|Control|No facemask will be worn during the sit-to-stand test
89474527|NCT02502045|Experimental|Morning Simulated Sunlight|Timed morning simulated sunlight (Philips Wake Up Light, Model HF3520) peaking at 300 lux delivered over a 40 minute ramp between 5-9 a.m. for 14 consecutive days. A flexible window of has been allowed to accommodate participants and care routines.
89474528|NCT02502045|Placebo Comparator|Non-Therapeutic Red Light|Non-therapeutic red light control at 5 lux will be used as the control condition
89474529|NCT04602650||Type 2 Diabetic|Type 2 diabetic individuals of Mexican descent.
89474530|NCT04602650||Non-diabetic Controls|Non-diabetic individuals of Mexican descent.
89474531|NCT02493543||Spinal cord injury|Patients (n=90) will undergo a common arm blood collection to determine autoantibody profiles in serum. This procedure will be performed twice: after recruitment and 3 months later.
89474532|NCT02493543||Controls|Control subjects (n=20) will undergo a common arm blood collection to determine autoantibody profiles in serum. This procedure will be performed only once.
89474533|NCT04517474|Experimental|CANreduce with psychological support|Adherence-focused guidance enhanced web-based self-help for the reduction of cannabis use with psychological support
89474534|NCT04517474|Experimental|CANreduce without psychological support|Adherence-focused guidance enhanced web-based self-help for the reduction of cannabis use without psychological support
89474535|NCT04517474|No Intervention|Treatment as usual|Users will be prompt to a web with a list of the treatment centers nearby their postal code
89474536|NCT03120819|Active Comparator|Oncologist Recommendation only|Medical providers in this study provide a standardized brief recommendation for exercise to a consenting patient during a clinical visit. Patients randomized to this arm receive a packet that contained a study information sheet and standard published exercise information materials. The standard materials consisted of publicly available exercise recommendations for cancer survivors from the American Cancer Society (ACS). The packet of exercise information intended to represent general information about exercise and cancer that would be readily available to patients through the internet, a medical clinic, or cancer support services.
89474537|NCT03120819|Experimental|Oncologist Recommendation + DVD|Participants in this arm receive the same oncologist's recommendation and written materials as the comparator group and also received an instructional yoga DVD. Inclusion of the video is intended to provide patients with a tool for following the oncologist's exercise recommendation. The instructional video contains a brief introduction from a breast cancer survivor, who was also featured in the exercise portion of the DVD, and safety information about lymphedema from a lymphedema therapist. The exercise program is a 30-minute, low intensity, restorative yoga program to improve whole body flexibility and to be safe for participants who were in active treatment for cancer and/or who had metastatic disease. Women are encouraged to use the DVD at least 3 times per week.
89474538|NCT03343509|Experimental|Group A - Oral|Oral metronidazole 400mg 3 times a day for 7 days Placebo ointment applied 3 time times a day for 7 days to affected region
89474539|NCT03343509|Experimental|Group B - Topical|Topical metronidazole ointment 10% 3 times a day for 7 days Oral placebo tablets 3 times a day for 7 days
89474540|NCT02501889|Experimental|Walnut-rich weight loss diet arm|Participants will have an individualized reduced-calorie diet prescription and weight loss counseling session with the project coordinator, who is a registered dietitian. Composition of prescribed diets will be based on individual preferences. During the 6-month intervention, study subjects will participate in individualized counseling and group sessions, with in-person, telephone, email and text message contacts to provide support and behavioral guidance and strategies. All participants will have contact with the project coordinator a minimum of every 1-2 weeks. Walnuts will be provided to participants in the walnut-rich study arm.
89474541|NCT02501889|Active Comparator|Standard weight loss diet arm|Participants will have an individualized reduced-calorie diet prescription and weight loss counseling session with the project coordinator, who is a registered dietitian. Composition of prescribed diets will be based on individual preferences. During the 6-month intervention, study subjects will participate in individualized counseling and group sessions, with in-person, telephone, email and text message contacts to provide support and behavioral guidance and strategies. Participants assigned to this arm will be instructed to abstain from the consumption of nuts during the study. All participants will have contact with the project coordinator a minimum of every 1-2 weeks.
89019966|NCT05943756|Experimental|Signature Strengths|In this arm, participants would participate in in an intervention program meant to improve well-being in individuals who have sustained a brain injury.
89202627|NCT00539500|Experimental|Transplantation CD133+ cells|Stem Cell Transplantation of CD133+ cells using the ClinicMACS in combination with Carboplatin + Etoposide + Melphalan
89202628|NCT00662532|Experimental|Minocycline HCl|1 mg microspheres of minocycline hydrochloride
89474542|NCT03338049|Other|Veran System|Staged biopsy sampling methodology. If lymph node staging is negative, EMN-bronchoscopy will be performed. If EMN-bronchoscopy is negative, EMN-TTNA will be performed
89474543|NCT03337971|Placebo Comparator|PLACEBO|"Intervention: Dietary Supplement: PLACEBO A group of subjects ingesting a liquid beverage (0.3g per kg body mass ; 1.2kcal/kg body mass) at 10:00pm, 3h post-absorptive of a standardised evening meal.~Samples for the measurement of biomarkers of change in the rate of bone turnover appearing in the blood to be collected for the immediate 4h, and excreted in urine, 24h post-ingestion"
89474544|NCT03337971|Active Comparator|Milk-based protein matrix|"Intervention: Dietary Supplement: MBPM A group of subjects ingesting a liquid beverage (0.3g per kg body mass ; 1.2kcal/kg body mass) at 10:00pm, 3h post-absorptive of a standardised evening meal.~Samples for the measurement of biomarkers of change in the rate of bone turnover appearing in the blood to be collected for the immediate 4h, and excreted in urine, 24h post-ingestion"
89474545|NCT04516148|Experimental|Antibiotics|Patients randomized to the treatment arm of the study will have orders placed by a physician on the clinical team, with preparation and delivery of the antibiotics dose by the pharmacy following standard procedures. Antibiotic administration will occur after induction of anesthesia, with delivery by the Anesthesia staff no more than one hour prior to incision. Those with known allergy to beta-lactams will receive clindamycin instead of cefazolin.
89474546|NCT04516148|No Intervention|Standard of Care|Patients randomized to the standard of care arm of the study will receive no perioperative antibiotic administration and will proceed with routine pre-operative care.
89474547|NCT03337893||Breastfed|The kids who breastfed
89474548|NCT03337893||non-breastfed|The kids who did not breastfed
89474549|NCT03342573|Experimental|Single Arm|Patients with a biopsy proven diagnosis of PRP
89474550|NCT03343353|Experimental|LED red group (630nm)|The leds will initially be measured in the photobiophysics laboratory of the University of São Paulo - Ribeirão Preto, regarding wavelength parameters, beam divergence, nominal power and fluency. The application will be in the graft donor area (scalp) of burn patients. The applied fluence will be 4J / cm2.
89474551|NCT03343353|Experimental|LED infrared group (940nm)|The leds will initially be measured in the photobiophysics laboratory of the University of São Paulo - Ribeirão Preto, regarding wavelength parameters, beam divergence, nominal power and fluency. The application will be in the graft donor area (scalp) of burn patients. The applied fluence will be 4J / cm2.
89474552|NCT03343353|Sham Comparator|Group Sham|This group will not receive irradiation by led light. You will only receive the routine care of the hospital unit to which you are hospitalized. These patients will be evaluated in the same way as the other two intervention groups, and also by a blind evaluator.
89474553|NCT03337815|Active Comparator|Treatment of MTX and TwHF placebo|Patients were treated with Methotrexate (MTX) and Tripterygium wilfordii Hook F（TwHF）placebo.
89474554|NCT03337815|Experimental|Treatment of TwHF and MTX placebo|Patients were treated with Tripterygium wilfordii Hook F（TwHF）and Methotrexate (MTX) placebo.
89474555|NCT03575936|Active Comparator|Standard of Care Group|Standard of Care arm. Pharmacist intervention in clinic
89474556|NCT03575936|Experimental|Home Monitoring Group|Pharmacist intervention with home INR monitoring
89474557|NCT03974048||Trauma patients|All trauma patients admitted to Rigshospitalet's trauma center will have a blood sample taken during the initial treatment and 30 days after the trauma.
89474558|NCT03974048||Patients admitted for elective orthopedic surgery|The patients will have a blood sample taken before and after surgery and again 30 days after the surgery.
89474559|NCT02497053|Experimental|Arm A|Four cycles of pemetrexed/platinum
89474560|NCT02497053|Active Comparator|Arm B|Six cycles of pemetrexed/platinum
89474561|NCT03120975|Experimental|Computerized decision support|
89474562|NCT03120975|Active Comparator|Standard antibiotic stewardship|
89474563|NCT04417556|Experimental|Sleep Measurement|Sleep Measurement arm, sleep are simultaneously measured using polosomgraphy, actigraphy and Thai-version Richards Campbell Sleep Questionnaire.
89474564|NCT02501967|Experimental|COMET|The intervention consists of completion of the tool (COMET) by means of a 30 minute telephone interview prior to the primary care visit and provision of the tool's output to the patient and primary care physician. The COMET tool takes information about the patient's medications and chronic conditions from the electronic health record, and then supplements this with information obtained by a telephone interview assessing the patient's cognition, social supports, medication adherence, home medication regimen, medication side effects, and health status. In addition, there is a chart review screen to record renal function, blood pressure, and hemoglobin A1C. All of this information is run through a set of algorithms to identify medication reconciliation errors and potentially inappropriate medications.
89474565|NCT02501967|No Intervention|Usual Care|
89474566|NCT04353206|Experimental|Intubated COVID-19 patients in the ICU|Mechanically ventilated intubated patients with respiratory failure due to COVID-19
89474567|NCT03337737|Placebo Comparator|Placebo|Placebo will be composed of microcrystalline cellulose in a gel capsule
89202629|NCT00662532|No Intervention|No Intervention|Control group receiving no drug intervention
89202630|NCT00686036|Experimental|vandetanib|300 mg orally, once daily for up to 18 months
89202631|NCT00686036|Placebo Comparator|Placebo|orally, once daily for up to 18 months
89202632|NCT00788970|Experimental|Acupressure|Acupressure adjuvant therapy
89474568|NCT03337737|Active Comparator|Extreme Endurance|Dietary Supplement manufactured by LifeSpan International LLC
89474569|NCT03337659|Experimental|FICare Intervention Group|Study participants received Family Integrated Care (intervention) while their infant(s) was/were admitted to a Level II NICU.
89474570|NCT03337659|No Intervention|FICare Control Group|Study participants received standard care while their infant(s) was/were admitted to a Level II NICU.
89474571|NCT04352816|Experimental|Control Group|Participants who do not receive an ICD therapy and have normal Echocardiogram findings and no evidence of arrhythmia will form this group. These participants will receive an MCG scan in addition to their standard care plan We will record the findings of any/all investigations participants receive as per their standard care plan, such as imaging providing left ventricular ejection fraction and usual care blood tests although their research activity/involvement in the trial will cease after the baseline observation. There will be no follow up. We aim to recruit 210 participants to this group to match the anticipated size of the group who receive an ICD but don't receive a shock.
89474572|NCT04352816|Experimental|Observation group|The participants who go on to receive an ICD therapy, as part of standard care, will constitute the 'Observation' group. These participants will undergo an MCG, lying and standing blood pressure and undertake a quality of life questionnaire. Participants in this group will undergo additional blood tests, circulating vascular biomarkers such as (High sensitivity Troponin, Nt pro BNP, CRP, High sensitivity CRP, mRNA, IL-6). All scans and tests that are conducted as part of standard care for evaluation of requirement of ICD implantation will be collected, for example; Echocardiographic, CMRI or MUGA measurements of the heart chambers and function. We will record these findings as this will enable us to substratify patients according to different degrees of cardiac dysfunction
89474573|NCT04352816|Experimental|Device in situ group|"To achieve the secondary objectives of exploring whether features consistent with arrhythmogenesis are extractable from MCG scans on participants with ICDS and pacemakers in situ, the investigators will recruit an additional 30 participants separate from the main trial. Twenty participants will be recruited from the ICD clinic. These participants, who have already had an ICD implanted will be selected with a 50:50 split as to whether they have had previous therapy from the ICD. The presence of an ICD can impact the analysis of MCGs in these patients due to the background signal noise subtraction required to obtain a usable signal. We will use these scans to trial different signal noise reduction strategies. These will be analysed to determine whether the features seen in the main trial can be extracted from this data set.~10 participants will be recruited who have got an upgrade from a pacemaker to an ICD."
89474574|NCT04496505|Sham Comparator|Control Arm|Participants will use a sham device twice per day for 16 minutes per day for 8 weeks. They will be assessed for symptoms of depression at baseline, along with symptoms every two weeks thereafter until the 8 week mark. Participants will also be assessed for anxiety, irritability, future orientation, quality of life, and rumination.
89474575|NCT04496505|Experimental|Treatment Arm|Participants will use a device twice per day for 16 minutes per day for 8 weeks. They will be assessed for symptoms of depression at baseline, along with symptoms every two weeks thereafter until the 8 week mark. Participants will also be assessed for anxiety, irritability, future orientation, quality of life, and rumination.
89474576|NCT03337581|Sham Comparator|group 1.1|Normal saline group
89474577|NCT03337581|Experimental|group 1.2|0.25μg/kg dexmedetomidine group
89474578|NCT03337581|Experimental|group 1.3|0.5μg/kg dexmedetomidine group
89474579|NCT03337581|Experimental|group 1.4|0.75μg/kg dexmedetomidine group
89202633|NCT00788970|Placebo Comparator|Placebo acupressure|Sham acupressure adjuvant therapy
89202634|NCT00788970|No Intervention|No treatment|Wait list group (no treatment)
89474580|NCT03337581|Experimental|group 1.5|1.0μg/kg dexmedetomidine group
89474581|NCT02496975|Experimental|Cyclosporine A|Participants assigned to this group will receive 2.5mg/kg load then 5mg/kg qd continuous infusion x 3 days (72hours)
89474582|NCT02496975|Active Comparator|Placebo|Participants assigned to this group will receive 2.5mg/kg load then 5mg/kg qd continuous infusion x 3 days (72hours)
89474583|NCT02496897|Experimental|FP-02.2 Low Dose|A low dose of the FP-02.2 vaccine.
89474584|NCT02496897|Experimental|FP-02.2 High Dose|A high dose of the FP-02.2 vaccine.
89474585|NCT02496897|Experimental|FP-02.2 Low Dose with IC31® Adjuvant|A low dose of the FP-02.2 vaccine with IC31® Adjuvant.
89474586|NCT02496897|Experimental|FP-02.2 High Dose with IC31® Adjuvant|A high dose of the FP-02.2 vaccine with IC31® Adjuvant.
89474587|NCT02496897|Placebo Comparator|Placebo|Placebo component.
89474588|NCT02496897|Experimental|IC31® Adjuvant|IC31® Adjuvant alone.
89474589|NCT03337503|Experimental|THC and CDB in a 1 to 1 ratio|"Post a self-titrating schedule of medical cannabis oil, subjects take 1 capsule three times a day at 6 hour intervals.~2.5 mg THC with 2.5 mg CBD capsule"
89474590|NCT03337503|Experimental|THC and CBD in a 1 to 2 ratio|"Post a self-titrating schedule of medical cannabis oil, subjects take 1 capsule three times a day at 6 hour intervals.~2.5 mg THC with 5 mg CBD capsule"
89474591|NCT03337503|Experimental|high CBD with trace THC|"Post a self-titrating schedule of medical cannabis oil, subjects take 1 capsule three times a day at 6 hour intervals.~20 mg CBD with traces of THC"
89202635|NCT00990730||rheumatoid arthritis subjects|60 subjects with rheumatoid arthritis, defined by American College of Rheumatology Criteria, enrolled in the UCSF RA cohort
89202636|NCT00990730||healthy controls|20 matched controls without rheumatoid arthritis
89202637|NCT00792324|Active Comparator|Group 1|Four 100mg Etravirine tablets plus one Efavirenz (EFV) placebo tablet once daily
89202638|NCT00792324|Active Comparator|Group 2|One 600mg EFV tablet plus four Etravirine placebo tablet tablets once daily
89202639|NCT00990808|Experimental|Panel A|Period 1: atorvastatin + placebo to MK0859; Period 2: atorvastatin + MK0859
89202640|NCT00990808|Experimental|Panel B|Period 1: placebo to atorvastatin + placebo to MK0859; Period 2: MK0859 + placebo to atorvastatin
89474592|NCT03337503|Placebo Comparator|placebo|"Post a self-titrating schedule of carrier oil, subjects take 1 capsule three times a day at 6 hour intervals.~carrier oil capsule"
89474593|NCT02501655|Active Comparator|Phase 1|Jet Nebulizer - control group
89474594|NCT02501655|Experimental|Phase 2|Mesh nebulizers
89474595|NCT03337425|Experimental|psychoeducational groups|Psychoeducational group therapy and standard treatment (ADHD treatment as usual)
89474596|NCT03337425|Active Comparator|Waiting list|Waiting list and standard treatment (ADHD treatment as usual)
89474597|NCT01675622|Experimental|Oxycodone Capsules for cancer pain|
89474598|NCT01675622|Active Comparator|Morphine tablets for cancer pain|
89474599|NCT02496741|Experimental|Metformin and chloroquine combination|"Metformin will be administered in a 3+3 dose-escalation schedule.~Chloroquine will be administered in a fixed dose."
89474600|NCT04496037||Standard of care (SOC)|See NCT03994783
89474601|NCT04496037||Rituximab + SOC (SOCR)|See NCT03994783
89474602|NCT03777332|Experimental|(Cohort 1) Pegcetacoplan, 15 mg/100 μL, monthly for up to 60 months|
89474603|NCT03777332|Experimental|(Cohort 2) Pegcetacoplan, 15 mg/100 μL, monthly for up to 36 months|
89474604|NCT03777332|Experimental|(Cohort 2) Pegcetacoplan, 15 mg/100 μL, every other month for up to 36 months|
89474605|NCT02501421|Active Comparator|TB/FLU-04L|Live recombinant influenza vectored tuberculosis vaccine
89474606|NCT02501421|Placebo Comparator|Placebo|Buffer
89474607|NCT03724916|Placebo Comparator|Pooled Placebo|TAK-079 placebo-matching injection, subcutaneously, once every 3 weeks in combination with principal investigator-directed background therapy for SLE for up to 12 weeks. Placebo data will be pooled across all the dose levels.
89474608|NCT03724916|Experimental|TAK-079 45 mg|TAK-079 45 mg injection subcutaneously, once every 3 weeks in combination with principal investigator-directed background therapy for SLE for up to 12 weeks.
89474609|NCT03724916|Experimental|TAK-079 90 mg|TAK-079 90 mg injection subcutaneously, once every 3 weeks in combination with principal investigator-directed background therapy for SLE for up to 12 weeks.
89474610|NCT03724916|Experimental|TAK-079 135 mg|TAK-079 135 mg injection subcutaneously, once every 3 weeks in combination with principal investigator-directed background therapy for SLE for up to 12 weeks.
89474611|NCT03342339|Other|patients with Parkinson's disease|"cognitive examination : mini mental test of Parkinson, Hospital Anxiety and Depression Scale, 5 words by Dubois, fast test frontal assessment, Trail Making Test~viewing of video : scale of differential emotions and Positive and Negative Affect Scale~Test of Iowa Gambling Task"
89474612|NCT03342339|Other|witnesses|"cognitive examination : mini mental test of Parkinson, Hospital Anxiety and Depression Scale, 5 words by Dubois, fast test frontal assessment, Trail Making Test~viewing of video : scale of differential emotions and Positive and Negative Affect Scale~Test of Iowa Gambling Task"
89474613|NCT04183166|Experimental|Arm A : Early study treatment initiation|TG4050 treatment initiation at completion of primary treatment
89474614|NCT04183166|Experimental|Arm B: Study treatment initiation at recurrence|TG4050 treatment initiation at the time of recurrence
89474615|NCT03337269|Other|Control|Subject does not receive an educational intervention
89474616|NCT03337269|Other|Educational video|Subject watches an educational video
89474617|NCT03337269|Other|Educational handout|Subject reads an educational handout
89474618|NCT02493465|Experimental|LVH everolimus|Progression of left ventricular hypertrophy in recipients of kidney transplant after conversion of immunossupression from azathioprine to everolimus.
89474619|NCT04161716|Experimental|NIRS module|Each patient has a NIRS module during a diagnosis urodynamic assessment provided for by the usual practice.
89474620|NCT03342261||HCV patients with mixed cryoglobulinemia|HCV patients with or without HIV presenting a mixed cryoglobulinemia and treated with direct-acting antiviral agents
89474621|NCT03963206|Other|Cabozantinib group|patients will receive Cabozantinib (within the framework of its MA) (an ECG is added)
89202641|NCT00750230|Experimental|NEM Treatment|NEM, 500 mg, once daily, orally for 30 days.
89474622|NCT04495569|Experimental|Group/Cohort A|A single intramuscular injection of SYN023 at 0.3mg/kg
89474623|NCT04495569|Experimental|Group/Cohort B|A single intramuscular injection of SYN023 at 0.3mg/kg combined with the Chinese licensed Vero Cell Rabies Vaccine (following the PEP (Post-exposure Prophylaxis) recommendation)
89474624|NCT03923972||Patients with chronic kidney disease|Patients with non dialysis dependent chronic kidney disease stages 4-5, patients on renal replacement therapy treated with peritoneal dialysis or hemodialysis, patients after renal transplantation
89474625|NCT03923972||Nephrologists|physicians treating patients with chronic kidney disease
89474626|NCT03923972||Nephrology nurses|nurses caring for patients with chronic kidney disease
89474627|NCT03923972||heads of Nephrology departments|Medical and/or administrative directors of e nephrology department with knowledge of the healthcare system in their country
89474628|NCT04511624|Experimental|Cohort 1|IBI112 SC dose1
89474629|NCT04511624|Experimental|Cohort 2|IBI112 SC dose2
89474630|NCT04511624|Experimental|Cohort 3|IBI112 SC dose3
89202642|NCT00797082|Experimental|1|"MRI = Myocardial Perfusion Stress and MPS = Myocardial Perfusion Scintigraphy~Diabetic patients~Coronary insufficiency"
89202643|NCT00755144|Experimental|1|ROCC
89474631|NCT04511624|Experimental|Cohort 4|IBI112 IV dose4
89474632|NCT04511624|Experimental|Cohort 5|IBI112 IV dose3
89474633|NCT04511624|Experimental|Cohort 6|IBI112 SC dose5
89474634|NCT04511624|Experimental|Cohort 7|IBI112 IV dose5
89474635|NCT03120429|Experimental|Fish group|subjects will have 3 x 150 g lean fish/ week at main meal
89474636|NCT03120429|Experimental|Control group|subjects will have no seafood.
89474637|NCT04608890||Long-standing T1D patients|Patients with long-standing type 1 diabetes
89474638|NCT04608890||Healthy volunteers|Healthy volunteers
89474639|NCT03337191|Active Comparator|ultrasound guided caudal block|Caudal block was performed by ultrasound guided with %0,125 levobupivacaine + 10 mq/kg morphine
89474640|NCT03337191|Active Comparator|conventional caudal block|Caudal block was performed by conventional method with %0,125 levobupivacaine + 10 mq/kg morphine
89474641|NCT03854552|Experimental|BI 764198|Single rising oral doses
89474642|NCT03854552|Placebo Comparator|Placebo|Single rising oral doses
89474643|NCT04494243|Experimental|AD-214/Rabeprazole|Period 1 : Test Drug(AD-214 10/600mg) Period 2 : Reference Drug(Rabeprazole 10mg)
89474644|NCT04494243|Experimental|Rabeprazole/AD-214|Period 1 : Reference Drug(Rabeprazole 10mg) Period 2 : Test Drug(AD-214 10/600mg)
89474645|NCT03337035|Active Comparator|oral probiotics and oxytocin spray|Subjects will receive oral probiotics, 2 pills per day, for 28 weeks. For the last 12 weeks, subjects will also receive intranasal oxytocin spray at the following dose: 4 IU in week 1, 8 IU in week 2, 16 IU in week 3, and 24 IU in weeks 4-12.
89474646|NCT03337035|Placebo Comparator|oral placebo and oxytocin spray|Subjects will receive oral placebo, 2 pills per day, for 28 weeks. For the last 12 weeks, subjects will also receive intranasal oxytocin spray at the following dose: 4 IU in week 1, 8 IU in week 2, 16 IU in week 3, and 24 IU in weeks 4-12.
89474647|NCT03547076|Experimental|Focused ultrasound diagnostics|"Intervention: Focused ultrasound Diagnostics~All participants will first be examined twice with handheld ultrasound, With separate examinations performed by general practioners and nurses (random order). Both will utilize automatic analyses of left ventricular function and telemedicine support for best possible diagnosis of heart failure. Subsequently, reference imaging and diagnostics will be performed by experts (cardiologists). Handheld ultrasound examinations will be compared to Reference."
89474648|NCT02493387|Experimental|Exercise group|The group-based exercise program consists of 60-minute sessions twice a week for 3 months, including central circulatory exercise performed on an ergometer cycle and muscle training, and one or two occasions of home-based exercise. The exercise program are designed after the patients requirements and with the intensity 13-17 on the RPE 6-20 scale
89474649|NCT02493387|Active Comparator|PAP group|The patients randomized PAP will receive a PAP prescription and a physical activity diary. The PAP and physical activity diary will be followed up at 6 and 12 weeks after the inclusion.
89474650|NCT02491905|Experimental|low dose HL tablet|HL tablet which contains 66.7mg of active compound by oral administration, twice daily in an hour after meal
89474651|NCT02491905|Experimental|high dose HL tablet|HL tablet which contains 200mg of active compound by oral administration, twice daily in an hour after meal
89474652|NCT02491905|Placebo Comparator|placebo group|Placebo by oral administration, twice daily in an hour after meal
89474653|NCT03539666|Experimental|Pork|Standard American Diet with meat source: lean pork. Diet adheres to 2015-2020 Guidelines for Americans.
89474654|NCT03539666|Experimental|Poultry|Standard American Diet with meat source: chicken. Diet adheres to 2015-2020 Guidelines for Americans.
89474655|NCT05232747||Study|Participants' pain level and pain-related behaviors will be questioned.
89474656|NCT03526172||Control|Patients undergoing HTO without the inclusion of any bone wedge
89474657|NCT03526172||Allograft|Patients undergoing HTO with the inclusion of an allograft bone wedge
89474658|NCT03331029|Other|transesophageal echocardiography|Comparison of 3D Ultrasound with transesophageal echokardiography
89474659|NCT03640988|Experimental|dermaPACE|Non-sterile, single, Benchtop System that is comprised of a dermaPACE Control Console, PACE Applicator and foot pedal. The PACE applicator uses shockwave technology on acute and chronic defects.
89474660|NCT05464797|Placebo Comparator|Control group|
89474661|NCT05464797|Experimental|Direct Pulp Capping group|
88949614|NCT01937806|Active Comparator|Tenofovir 300mg|Placebo of Besifovir 150 mg q.d. + Tenofovir Disoproxil Fumarate 300 mg q.d. + Placebo of L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d.
89474662|NCT05464797|Experimental|Partial Pulpotomy group|
89474663|NCT05464797|Experimental|Complete Pulpotomy group|
89474664|NCT05464797|Experimental|Root canal treatment group|
89474665|NCT05464641|Active Comparator|preoperative|preoperative The Oxford Knee Score (OKS) is a 12-item patient-reported PRO, low score worse.
89474666|NCT05464641|Active Comparator|postoperative|postoperative The Oxford Knee Score (OKS) is a 12-item patient-reported PRO, low score worse.
89474667|NCT03330873|Experimental|Foley catheter|After the completion of hysteroscopic adhesiolysis, Foley catheter was inserted and inflated with normal saline which was removed on the 7th day after surgery.
89474668|NCT03330873|Experimental|Disposable balloon uterine stent|After the completion of hysteroscopic adhesiolysis, disposable balloon uterine stent was inserted and inflated with normal saline which was removed on the 7th day after surgery.
89474669|NCT04596254|Other|Juice Intake|
89474670|NCT05073536|Experimental|mini-sized MCE|Participants in this group underwent examination of mini-sized MCE.
89474671|NCT05073536|Other|normal-sized MCE|Participants in this group underwent examination of normal-sized MCE.
89474672|NCT02496819|Experimental|Metacognitive self-regulated learning intervention|It involves training of daily tasks using a self-correct strategy. Participants' performance will be video-taped and they will then watch the video playback for reflection and self-correction under the guidance of the occupational therapist.
89474673|NCT02496819|Experimental|Sensory Integration intervention|It involves active, fun physical activity completing 8 stations of activities involving tactile, proprioceptive and vestibular tasks. Frequent breaks will be given to avoid exhaustion and fatigue throughout the activities.
89474674|NCT02496819|Active Comparator|Activity-Based Intervention|It provides constructional, drawing and crafts activity. Participants are guided to complete these tasks
89474675|NCT03255590|Experimental|Finger Dexterity Training|"Chronic stroke patients (i.e. great than 6 months) with ischemic stroke confirmed by CT or MRI, residual unilateral upper extremity weakness, able to give informed consent, and able to understand the tasks involved.~Participants trained for 5 consecutive days, 3 to 4 h/d, on a multi-finger piano-chord-like task that cannot be performed by compensatory actions of other body parts (e.g., arm). Participants had to learn to simultaneously coordinate and synchronize multiple fingers to break unwanted flexor synergies."
89474676|NCT02496507|Experimental|Intervention|Provision of a sit-stand workstation for use at work.
89474677|NCT02496507|No Intervention|Control|Participants were asked to maintain their normal work practices and received no intervention. Participants were offered the opportunity to have a sit-stand workstation installed for 8 weeks after all data collection.
89474678|NCT03125798|Experimental|LigaSure|In this arm, LigaSure™ will be used for mediastinal lymph nodes dissection, according to standard surgical technique.
89474679|NCT03125798|Active Comparator|Monopolar electrocautery|In this arm, conventional monopolar electrocautery will be used for mediastinal lymph nodes dissection, according to standard surgical technique.
89474680|NCT03342183|Experimental|Intervention Arm|RIPC stimulus will be applied prior to the first intervention visit, using a previously validated (for cardiac protection in HD patients) standard dose (four cycles of cuff inflation to the lower limb of the patient and inflating at 200mmHg for five minutes, with five minutes' deflation). To be administered on a monthly basis from the baseline visit to the year 1 visit.
89474681|NCT03342183|Sham Comparator|Control Arm|Sham procedure in which the blood pressure cuff will be applied to the lower limb and inflated to 40mmHg for five minutes and deflated for five minutes with the cycle repeated a total of four times prior to dialysis. To be administered on a monthly basis from the baseline visit to the year 1 visit.
89474682|NCT03025100||Prospective|A sample of 120 patients aged 60 years or older admitted to General Medicine at Duke University Hospital will be enrolled in the prospective cohort study. A convenience sample will be derived from a randomized daily list of general medicine admissions; weekend admissions will be excluded as these patients will not be captured within 24 hours of hospital admission.
89474683|NCT03342105|Experimental|Cettum (Electrical moxibustion)|The patients in this group will receive Cettum (Electrical moxibustion) treatment applied by a certified Korean Medicine Doctor with more than 6 years of traditional Korean medicine college education.
89474684|NCT03342105|Active Comparator|Acupuncture|The patients in this group will receive acupuncture treatment applied by a certified Korean Medicine Doctor with more than 6 years of traditional Korean medicine college education.
89474685|NCT02496429|Other|BrownieForSymphony use|Each participant will use the BrownieForSymphony pumpset
89474686|NCT02496351|Active Comparator|TENS INTERVENTION|In the immediately postoperative of limb amputation, TENS will be use in this patients during 24 hours. The intensity of the impulse will be determined in a test carried out 3 days before surgery. The other parameters will be continuous, biphasic, compensated and symmetric impulse, frequency of 80 Hz, time impulse between 250 and 290 microseconds, modulation time 5´´
89474687|NCT02496351|Placebo Comparator|TENS NO INTERVENTION|In the immediately postoperative of limb amputation, TENS will be use in this patients during 24 hours, but in this case TENS just will be on. No intensity impulse should be programmed.
89474688|NCT03336957|Experimental|Pregnant group|Test group, non-surgical periodontal therapy (NPT) consisted of scaling and oral hygiene instruction was applied. IL- 1β AND IL-10 in the GCF and Cg A in saliva samples were taken before and after periodontal treatment.
89474689|NCT03336957|Active Comparator|Non-Pregnant|Control group, non-surgical periodontal therapy (NPT) consisted of scaling and oral hygiene instruction was applied. IL- 1β AND IL-10 in the GCF and Cg A in saliva samples were taken before and after periodontal treatment.
88949615|NCT01937819|Experimental|SMART arm|Using SMARTPHONE application for self judging bowel preparation
88949616|NCT01937819|No Intervention|Conventional arm|Non-using SMARTPHONE application for bowel preparation
89202644|NCT00755144|Active Comparator|2|LCS
89202645|NCT00792402||1 control group|Computerized data collection of outcome measures in usual care
89202646|NCT00792402||2 intervention group|Computerized data collection of outcome measures and interviews to clinicians which are using a computerized Heart Failure guideline in their daily practice.
88949617|NCT01937832|Active Comparator|Ertapenem|
88949618|NCT01937832|Experimental|Faropenem|
88949619|NCT01937858||Normal renal function|
88949620|NCT01937858||Stage 2 and 4 and 5 chronic kidney disease|
88949621|NCT01937858||End stage renal disease on hemodialysis|
88949622|NCT01937897|Experimental|Left-Sided Massage|Unilateral massage on the left side of the body.
88949623|NCT01937897|Active Comparator|Right-Sided Massage|Unilateral massage on the right side of the body.
89202647|NCT00682448|Active Comparator|1|Olanzapine plus metformin: olanzapine plus metformin 500 mg titrated up to but no greater than 2,000 mg based upon fasting blood glucose during study visits over six months.
89202648|NCT00682448|Placebo Comparator|2|Olanzapine plus Drug: Placebo. Subjects will remain on olanzapine plus placebo for 6 months.
89474690|NCT03330717|Placebo Comparator|General anesthesia|Patients will undergo oncologic breast surgery on general anesthesia.
89474691|NCT03330717|Experimental|Hypnosis sedation|Patients will undergo oncologic breast surgery on hypnosis sedation.
89474692|NCT03330717|Experimental|General anesthesia with preoperative session of hypnosis|Patients interested in hypnosis but too anxious to have surgery while on hypnosis sedation will undergo surgery on general anesthesia but will have a preoperative session of hypnosis relaxation using technology of virtual reality
89474693|NCT02655224|Experimental|Relugolix 40 mg|Relugolix placebo-matching tablet, orally, once daily before breakfast for 3 to 6 weeks in the run-in period, followed by relugolix 40 mg, tablet, orally once daily before breakfast for 12 weeks.
89474694|NCT02655224|Placebo Comparator|Placebo|Relugolix placebo-matching tablet, orally, once daily before breakfast for 3 to 6 weeks in the run-in period, followed by relugolix placebo-matching tablet, orally once daily before breakfast for 12 weeks.
89202649|NCT00797238||NSCLC stage III|Taiwanese NSCLC patients with stage III
88949624|NCT01937897|Sham Comparator|Bi-Lateral Massage|Traditional massage on the back of the body.
88949625|NCT01937910|Experimental|Stroke Group|Participants in the stroke group will complete 10 training sessions of the TRAIT task.
88949626|NCT01937910|Active Comparator|Matched Healthy Control Group|Participants in the Matched Healthy Control group will complete 10 sessions of the TRAIT task
88949627|NCT01937936|Experimental|CBT|Cognitive Behavioral Therapy (CBT)
88949628|NCT01937936|Active Comparator|Education|Health Education
88949629|NCT01937988|Experimental|Doula Arm|Women in the doula arm will have standard procedure protocol with addition of doula support at the time of the procedure.
88949630|NCT01937988|No Intervention|Control Group|Women in the control arm will have standard procedure protocol at the time of the procedure.
88949631|NCT01938027|Experimental|Transanal total mesorectal excision|Laparoscopy-assisted transanal total mesorectal excision
88949632|NCT01938053|Other|Reminder card with no number|Patients receive a card to remind them of the time frame for results but no number is listed.
88949633|NCT01938053|Other|Card with number|Patients receive a card to remind them of the time frame for results but and a number to call for results is listed
89202650|NCT04003792|Experimental|single arm prospective trial|
89202651|NCT00747890|Active Comparator|I|
89202652|NCT00747890|Other|II|
89202653|NCT00789048|No Intervention|Surgeon doesn't see|The surgeon doesn't see the radiograph prior to surgery
89202654|NCT00789048|Experimental|Surgeon does see|The surgeon can see the radiograph prior to surgery
89202655|NCT00990886|Experimental|001|Oxybutynin chloride 15 mg once daily for 12 weeks
89202656|NCT00990886|Placebo Comparator|002|Placebo Once daily for 12 weeks
89202657|NCT00755300||1|Standard Total Knee Replacement
89202658|NCT00755300||2|Computer Guided Knee Replacement
89202659|NCT00755378|Experimental|1|
89202660|NCT00755378|Placebo Comparator|2|
89202661|NCT00789204|Experimental|GPR|Global Postural Re-Education
89202662|NCT00789204|Active Comparator|SEP|Standard Exercise Programm
89019967|NCT05943756|Active Comparator|TBI Education Course|In this arm, participants would participate in in an intervention program meant to improve well-being in individuals who have sustained a brain injury.
89019968|NCT05937373|Experimental|Continuous Glucose Monitor|CGM placed preoperative to monitor blood glucose and insulin correction to achieve perioperative glucose management
89019969|NCT05937373|Active Comparator|Standard of Care|no study intervention-conventional glucose management per subjects medical providers as standard of care
89019970|NCT05930613|Experimental|1|Certolizumab (CIMZIA® ; TNF-α antagonist )
89019971|NCT05930613|Placebo Comparator|2|Placebo (NaCl 0.9 % solution)
89019972|NCT05912738||Postherpetic neuralgia patient NO1|Postherpetic neuralgia patients often experience unilateral symptoms, with lesions predominantly occurring on one side of the chest wall. Therefore, the investigators can perform muscle elastography using ultrasound on both the unaffected side and the affected side of the patient to study the changes in muscle elasticity on the affected side.
89019973|NCT05912738||Postherpetic neuralgia patient NO2|Postherpetic neuralgia patients often experience unilateral symptoms, with lesions predominantly occurring on one side of the chest wall. Therefore, the investigators can perform muscle elastography using ultrasound on both the unaffected side and the affected side of the patient to study the changes in muscle elasticity on the affected side.
89019974|NCT05912738||Postherpetic neuralgia patient NO3|Postherpetic neuralgia patients often experience unilateral symptoms, with lesions predominantly occurring on one side of the chest wall. Therefore, the investigators can perform muscle elastography using ultrasound on both the unaffected side and the affected side of the patient to study the changes in muscle elasticity on the affected side.
89019975|NCT05912738||Postherpetic neuralgia patient NO4|Postherpetic neuralgia patients often experience unilateral symptoms, with lesions predominantly occurring on one side of the chest wall. Therefore, the investigators can perform muscle elastography using ultrasound on both the unaffected side and the affected side of the patient to study the changes in muscle elasticity on the affected side.
89019976|NCT05912738||Postherpetic neuralgia patient NO5|Postherpetic neuralgia patients often experience unilateral symptoms, with lesions predominantly occurring on one side of the chest wall. Therefore, the investigators can perform muscle elastography using ultrasound on both the unaffected side and the affected side of the patient to study the changes in muscle elasticity on the affected side.
89019977|NCT05912738||Postherpetic neuralgia patient NO6|Postherpetic neuralgia patients often experience unilateral symptoms, with lesions predominantly occurring on one side of the chest wall. Therefore, the investigators can perform muscle elastography using ultrasound on both the unaffected side and the affected side of the patient to study the changes in muscle elasticity on the affected side.
89019978|NCT05912738||Postherpetic neuralgia patient NO7|Postherpetic neuralgia patients often experience unilateral symptoms, with lesions predominantly occurring on one side of the chest wall. Therefore, the investigators can perform muscle elastography using ultrasound on both the unaffected side and the affected side of the patient to study the changes in muscle elasticity on the affected side.
89019979|NCT05912738||Postherpetic neuralgia patient NO8|Postherpetic neuralgia patients often experience unilateral symptoms, with lesions predominantly occurring on one side of the chest wall. Therefore, the investigators can perform muscle elastography using ultrasound on both the unaffected side and the affected side of the patient to study the changes in muscle elasticity on the affected side.
89019980|NCT05912738||Postherpetic neuralgia patient NO9|Postherpetic neuralgia patients often experience unilateral symptoms, with lesions predominantly occurring on one side of the chest wall. Therefore, the investigators can perform muscle elastography using ultrasound on both the unaffected side and the affected side of the patient to study the changes in muscle elasticity on the affected side.
89019981|NCT05912738||Postherpetic neuralgia patient NO10|Postherpetic neuralgia patients often experience unilateral symptoms, with lesions predominantly occurring on one side of the chest wall. Therefore, the investigators can perform muscle elastography using ultrasound on both the unaffected side and the affected side of the patient to study the changes in muscle elasticity on the affected side.
89019982|NCT05912426|Experimental|Reduced-sodium potassium-enriched salt|Reduced-sodium potassium-enriched salt
89019983|NCT05910008|Experimental|O-Arm stereotactic imaging|Imaging is performing directly in the operating room.
89019984|NCT05910008|Active Comparator|Standard stereotactic imaging|Imaging is performing in Radiology department.
89019985|NCT05909878|Experimental|Virtual Reality Distraction|Use of Virtual Reality (VR) before the MRI.
89019986|NCT05909878|Active Comparator|Standard Treatment|Standard Treatment used at the radiology department.
89019987|NCT05908149|Experimental|HEMIPLEGIC PATIENTS|HEMIPLEGIC PATIENTS WITH PES EQUINUS WILL BE EXAMINED BY GAIT ANALYSIS WITH AND WITHOUT THE INSOLE SPLINT, RANDOMLY
89019988|NCT05905133|Experimental|CBP-201|The subjects will receive CBP-201 600 mg (4 mL in total, 2 injections of 2 mL each in different sites) on Day1, begin to receive a subcutaneous injection of CBP-201 300 mg (2 mL) from Week2, and receive CBP-201 300 mg (2 mL) every 2 weeks thereafter until Week10.
89019989|NCT05903807|Experimental|Ovarian cancer or high risk of ovarian cancer|Patients with newly diagnosed ovarian cancer or high risk of ovarian cancer undergo FAPI PET/CT in addition to conventional imaging
89019990|NCT05901415|Experimental|A Modified Semi-supine Position of Combined Anterior Lumbar and Lateral Sacral Plexus Block|Patients were placed in a supine position with a small pad put under the upper body at the surgical side, then they received a combined anterior lumbar and lateral sacral plexus block.
89019991|NCT05901415|Sham Comparator|A classical Position of Combined Anterior Lumbar and Lateral Sacral Plexus Block|Patients received a combined anterior lumbar and lateral sacral plexus block in a lateral position.
89019992|NCT05899387||BC, mastectomy and implant|Women with first diagnosis of breast cancer or DCIS and planned skin-sparing mastectomy and implant placement
89019993|NCT05899387||BC and mastectomy|Women with first diagnosis of breast cancer or DCIS and planned simple mastectomy
89202663|NCT01899976|Other|X-Suit NIR Covered Biliary Stent|Stent implantation in the biliary tree
89202664|NCT00797394|Experimental|Treated|
89202665|NCT00797394|Active Comparator|Control|
89202666|NCT00792480|Experimental|Intensive Counseling Group|
89474695|NCT04494477|Experimental|The IN•clued program|The IN•clued program for youth consists of a three-hour in-person workshop for youth which includes lessons about safe sex practices and self-efficacy at healthcare centers, exam room roleplays, and a discussion on patient rights. Youth receive a Zine, or a magazine-style booklet, that they may take home. They also receive a list of local healthcare providers that highlights those that have participated in the IN•clued healthcare provider workshop or have had training on working with the LGBTQ population. Program youth can also receive text messages with health tips and reminders to visit a healthcare center.
89474696|NCT04494477|No Intervention|Control|"The youth control group receives a 10-minute presentation and a list of local sexual healthcare providers, with no indication of which providers have been trained to be more LGBTQ friendly and accepting. This 10-minute presentation is a part of a longer three-hour activity unrelated to sexual health or accessing sexual healthcare. During the three-hour session, the list of approved activities includes but is not limited to:~Films by, and for, LGBTQ youth about sexual orientation and gender identity;~Community scavenger hunts;~Poetry slams;~Discussions about relationships; and~Activities related to the appreciation of individuals' unique strengths."
89474697|NCT04494321|Active Comparator|Reference 1 Symbicort Inhaler 160/4.5μg|Reference 1: Symbicort Inhaler (Budesonide/ Formoterol, 160/4.5μg), Single dose, 8 puffs
89474698|NCT04494321|Experimental|SYN010 HFA Inhaler|SYN010 HFA (Budesonide/ Formoterol, 160/4.5μg), Single dose, 8 puffs
89474699|NCT04494321|Active Comparator|Reference 2 Symbicort Inhaler 160/4.5μg|Reference 2: Symbicort Inhaler (Budesonide/ Formoterol, 160/4.5μg), Single dose, 8 puffs
89474700|NCT04494165|Experimental|Aromatherapy Group|In addition to the standard physical therapy session, 30 patients in this group received a total of six sessions of lumbar massage for three weeks with frankincense and myrrh essential oils, two sessions per week (2nd and 5th days of each week), each lasting 15 minutes. During the massage, an average of 3ml mixture prepared by adding 2% frankincense oil and 2% myrrh essential oil to jojoba carrier oil was used as an oil mixture.
89474701|NCT04494165|Placebo Comparator|placebo group|In addition to the standard physical therapy session, 31 patients in this group received a total of six sessions of lumbar massage for three weeks with jojoba oil, two sessions per week (2nd and 5th days of each week), each lasting 15 minutes.
89474702|NCT04494165|No Intervention|control group|30 patients in this group received standard physical therapy sessions, and no massage was applied.
89474703|NCT03330483||Female Speedicath nelathon|Evaluation of pain or discomfort in female patients at/during/after Speedicath nelathon-tip catheter insertion
89474704|NCT03330483||Female nelathon|Evaluation of pain or discomfort in female patients at/during/after standard nelathon-tip catheter insertion
89474705|NCT03330483||Male Speedicath tiemann|Evaluation of pain or discomfort in male patients at/during/after Speedicath tiemann-tip catheter insertion
89474706|NCT03330483||Male tiemann|Evaluation of pain or discomfort in male patients at/during/after standard tiemann-tip catheter insertion
89474707|NCT01675544||Heart Failure Admission|Patients admitted for acute decompensated heart failure
89474708|NCT03330327|Experimental|Part 1|Intravenous (IV) infusion of HM12470
89474709|NCT03330327|Experimental|Part 2: Sequence 1|Intravenous (IV) infusion of HM12470
88949634|NCT01938092|Active Comparator|Diazepam|Participated will be instructed to insert one 10mg tablet vaginally 1-2 times per day as needed for pain.
88949635|NCT01938092|Placebo Comparator|Placebo|Participated will be instructed to insert one 10mg tablet vaginally 1-2 times per day as needed for pain.
88949636|NCT01938105|Experimental|Nimotuzumab+chemoradiotherapy|
89474710|NCT03330327|Experimental|Part 2: Sequence 2|Intravenous (IV) infusion of HM12470
89474711|NCT03336879|Experimental|Active rTMS (15 Hz)|The intervention will be Repetitive Transcranial Magnetic Stimulation. Each patient will receive active stimulation targeting the left dorsolateral prefrontal cortex (lDLPFC) with a frequency of 15 Hz and 100% of the individual resting motor threshold, for a total of 40 trains (60 stimuli per train, inter-train interval of 15 second, total duration 13 minutes). Each session will be repeated twice/daily for 10 consecutive days for 2 weeks, during the continued treatment phase. Following this, the participants will receive the maintenance intervention of 2 sessions per week for 3 months (rTMS follow-up), at the same parameters described above. Device: MagPro R30 with the Cool-B80 figure-of-eight coil (MagVenture, Falun, Denmark).
89474712|NCT05116124||Group 1 - uncomplicated appendicitis|
89474713|NCT05116124||Group 2 - complicated appendicitis|
89474714|NCT03330171|Other|HIV-unexposed children|HIV-unexposed children enrolled in a randomized open label study on the pneumococcal conjugate vaccine (PCV1+1) will be invited to participate in this study. Children enrolled in the PCV1+1 study will receive all vaccines included in the South African public immunization program. Measles vaccine (0.5 mL, subcutaneous injection) will be adminstered at 6 months of age and 12 months of age. Varicella vaccine (0.5 mL, subcutaneous injection) or Hepatitis-A vaccine (0.5 mL, intra-muscular injection) will be administered to the participants at 18 months of age as an additional benefit for participating in the study.
88949637|NCT01938118|Experimental|Obesity Prevention Group|Mothers and families receive a developmentally appropriate educational intervention designed to promote healthy lifestyle behaviors for prevention of excessive weight gain between birth to 15 months of life. Educational content is delivered through eight home visits, five newsletters and twice weekly text messages. At several time points the mother identifies another family member/caregiver to actively participate in the program with her.
88949638|NCT01938118|Active Comparator|Injury Prevention Group|Mothers and families receive a developmentally appropriate educational intervention designed to promote automobile and home safety behaviors for prevention of childhood injury. Educational content is delivered through eight home visits, five newsletters and twice weekly text messages. At several time points the mother identifies another family member/caregiver, who is only asked to complete surveys/assessments.
88949639|NCT01938131|Placebo Comparator|placebo|Patients in this group will be subjected to a treatment with muscle released in which the probe of CroSystem instrument will be approached to the quadriceps, without making contact. The instrument in these conditions emits a buzz but not provokes muscle vibration
89019994|NCT05899387||High risk for BC|healthy women with high risk for breast cancer and planned bilateral risk-reducing mastectomy and implant reconstruction
88949640|NCT01938131|Experimental|repeated Muscle Vibration|The patients will be subjected to 3 daily applications of rMV of 10 minutes each, for 3 consecutive days. Between two successive applications will be observed a break of at least 15 seconds. The probe of the specific instrument (Cro ® System) will be placed near the supero-medial margin of the patella, on both quadriceps
88949641|NCT01938144|Experimental|Treatment A|IBU 200 mg/ PE 10 mg
88949642|NCT01938144|Experimental|Treatment B|IBU 200 mg/ PE 10 mg/CHLOR 4 mg
88949643|NCT01938144|Active Comparator|Treatment C|Acetaminophen 500 mg
88949644|NCT01938157|Experimental|High Risk Breast Cancer Patients|High Risk Breast Cancer Patients (all subjects)
88949645|NCT01938183|Placebo Comparator|Full-mouth PD+placebo gel|Full-mouth periodontal debridement using an ultrasonic device in a single session for approximately 1 hour + trays with 3 g of placebo gel (semi-solid suspension containing carbopol), overnight, during seven days.
88949646|NCT01938183|Active Comparator|Full-mouth PD+Metronidazole tablet|Full-mouth periodontal debridement using an ultrasonic device in a single session for approximately 1 hour + single oral dose of 750 mg tablets/day at night, during seven days.
88949647|NCT01938183|Active Comparator|Full-mouth PD+Metronidazole benzoate gel|Full-mouth periodontal debridement using an ultrasonic device in a single session for approximately 1 hour + trays with 3 g of 15% Mtz benzoate gel (semi-solid suspension containing carbopol), overnight, during seven days.
89019995|NCT05899387||Cosmetic breast surgery|healthy women planned for plastic breast implant surgery
88949648|NCT01938196|Experimental|KWA-0711 Dose1|
88949649|NCT01938196|Experimental|KWA-0711 Dose2|
88949650|NCT01938196|Experimental|KWA-0711 Dose3|
88949651|NCT01938196|Experimental|KWA-0711 Dose4|
88949652|NCT01938196|Placebo Comparator|Placebo|
88949653|NCT01938209|Experimental|seated general thoracic spine manipulation|seated general thoracic spine manipulation
88949654|NCT01938209|Experimental|supine specific thoracic spine manipulation|Specific supine manipulation
88949655|NCT01938235|Experimental|Exenatide|"o Exenatide at a dose of 1.5 µg IV over 30 min followed by 1.2 µg/hr IV for 1.5 h (Rate1), followed by 1.9 µg/hr IV* for 22 h (Rate 2)~*Once the creatinine clearance is available, if the value is <60 mL/min, the rate at 2 hours will be maintained at Rate 1 for the duration of the infusion. If the value becomes available after the 2-hour point, and the rate has already been changed to Rate 2, the infusion will be titrated back down to Rate 1 if the creatinine clearance is <60 mL/min.~If the creatinine clearance is <30 mL/min, the infusion will be discontinued and the patient will otherwise continue with all study procedures.~A bolus administration of study medication is initiated preferably prior to reperfusion, or, if not possible, up to 30 minutes after the start of reperfusion to avoid delays in door-to-door balloon times."
88949656|NCT01938235|Placebo Comparator|Placebo|o Placebo bolus over 30 min followed by placebo infusion at 'Rate 1' for 1.5 h, followed by 'Rate 2' for 22 hours*.
88949657|NCT01938274|Experimental|Educational intervention|Patients in this group will receive a brief educational intervention to assist them in setting the appropriate expectations for leisure activity after surgery with respect to the type, amount, intensity, and duration of activity.
88949658|NCT01938274|No Intervention|Control group|No intervention will be received. Patients will receive a written version of the education intervention at the end of the study.
88949659|NCT01938287|Experimental|SENSIMED Triggerfish|
88949660|NCT01938300|Experimental|Magnesium|"Magnesium sulfate infusion during a operation period.~Infusion regimen:~Bolus 50 mg/kg of magnesium sulfate in 100 ml normal saline over 15 minutes~Infusion 15 mg/kg/h of magnesium sulfate throughout the operation"
88949661|NCT01938300|Placebo Comparator|Control|administration of normal saline as a same volume of magnesium sulphate as a same method.
88949662|NCT01938313|Active Comparator|ERAS perioperative cares|Patients planned to undergoing laparoscopic gastrectomy, following the ERAS protocols.
88949663|NCT01938313|Active Comparator|Conventional perioperative cares|Patents will be managed by our hospital's critical pathways.
88949664|NCT01938339|Experimental|PET/MR|Multi-radiotracer PET/MR will be performed to compare the accuracy of tumor detection in patient with primary prostate cancer
88949665|NCT01938352|Experimental|CR8020|CR8020 administered as a single 2-hour intravenous infusion
88949666|NCT01938352|Placebo Comparator|Placebo|Placebo administered as a single 2-hour intravenous infusion
88949667|NCT01938365||Diabetes|
88949668|NCT01938365||Normal glucose regulation|
88949669|NCT01938404||Octaplas|Patients receiving Octaplas for the treatment of Thrombotic Thrombocytopenic Purpura (TTP) undergoing therapeutic plasma exchange (TPE) procedures
88949670|NCT01938404||standard plasma products|Patients receiving standard plasma products (e.g., FFP, etc) for the treatment of Thrombotic Thrombocytopenic Purpura (TTP) undergoing therapeutic plasma exchange (TPE) procedures
88949671|NCT01938417||adult patients treated with Osteoset® T (tobramycin sulfate)|10 g or 20 g of Osteoset® T
88949672|NCT01938443|Experimental|Part 1|Part 1 will determine the MTD and RP2D based on the safety and tolerability of GSK2256098 administered with trametinib. Subject will be administered starting dose of 1.0 mg OD trametinib combined with 500 mg BID GSK2256098. Dose escalation will continue until the MTD is established.
88949673|NCT01938443|Experimental|Part 2|Based on determination of combination dose regimen in Part 1, dose expansion cohorts for Part 2 will be opened.
88949674|NCT01938456|Experimental|Trametinib + Docetaxel + Filgrastim|Participants will receive Trametinib once daily for 21 days of each cycle + Intravenous Docetaxel once every three weeks over at least a one-hour infusion + Filgrastim (growth factor) subcutaneous injection once daily for prophylactic use.
88949675|NCT01938469|Other|Solid Meal|Participants in this group will be administered only solid meals on both study visits completed before surgery (T0) and 12-15 months after (T1).
88949676|NCT01938469|Other|Liquid Meal|Participants in this group will be administered only liquid meals on both study visits completed before surgery (T0) and 12-15 months after (T1).
88949677|NCT01938482|Experimental|Part 1|Subjects will receive 0.3% or 1% GSK1940029 (or matching vehicle), as a single App 24h (22.5h) application to 400 cm^2 (0.3%), 400 cm^2 (1%) or 1200 cm^2 (1%), respectively, in each of three sequential cohorts
88949678|NCT01938482|Experimental|Part 2|Subjects will receive 0.3% or 1% GSK1940029 (or matching vehicle), as 14 daily App24h (22.5h) application to 400 cm^2 (0.3%), 400 cm^2 (1%) or 1200 cm^2 (1%), respectively, in each of three sequential cohorts
88949679|NCT01938508|Experimental|Test|Minocycline 100 mg capsules Darier SA Dermatological Laboratories de CV (Micromycin ®).
88949680|NCT01938508|Experimental|Reference|Minocycline 100 mg capsules (Micocin ®) Marketed and distributed by Triax Pharmaceuticals
88949681|NCT01938521|Experimental|Red Grape Cells (RGC)|Red Grape Cells (RGC) 1000 mg powder once daily by mouth for three month
88949682|NCT01938521|Placebo Comparator|Placebo (for Red Grape Cells (RGC))|Placebo (for Red Grape Cells (RGC)) similar powder to mimic 1000 mg of Red Grape Cells (RGC), once daily by mouth for three month
88949683|NCT01938534|Experimental|Experimental|"Omeprazole 30mg twice Clarithromycin 500mg twice Amoxicillin 1000mg twice~for 10 days"
88949684|NCT01938534|Active Comparator|Control|Tetracycline 500mg four times Omeprazole 30mg twice Bismuth 600mg twice Metronidazole 500mg three times for 10 days
88949685|NCT01938560||Physicians|Retigabine Physicians (e.g. neurologists/epileptologists/neurosurgeons) who have prescribed retigabine at least once in the last 12 months.
88949686|NCT01938560||Pharmacists|Pharmacists who have dispensed an anti-epileptic drug (AED) at least once in the last 3 months.
88949687|NCT01938586||Surgical excision|
88949688|NCT01938612|Experimental|MEDI4736 Q2W|Evaluate MEDI4736 given every 2 weeks
88949689|NCT01938612|Experimental|MEDI4736 Q3W|Evaluate MEDI4736 given every 3 weeks
88949690|NCT01938612|Experimental|MEDI4736 Dose Expansion|evaluate MEDI4736 given every 2 weeks
88949691|NCT01938612|Experimental|MEDI4736 Q4W|Evaluate MEDI4736 given every 4 weeks
88949692|NCT01938612|Experimental|MEDI4736 combined with another drug|evaluate MEDI4736 in combination with another drug given every 4 weeks
88949693|NCT01938638|Experimental|BAY1143572 [continuous]|BAY1143572 will be administered from cycle 1, day 1 (C1D1) onwards once daily continuously
88949694|NCT01938638|Experimental|BAY1143572 [on/off]|BAY1143572 will be administered from C1D1 in a 3 days on/4 days off schedule
88949695|NCT01938651|Experimental|Diagnostic (7T ultra high-field MRI/MRS)|Patients undergo measurement of tumor perfusion and permeability using DCE-MRI, tumor cellularity using DW-MRI, phospholipid metabolism using 31P MRS, macromolecular content using MT-MRI, and cellular protein content using CEST-MRI. All of these procedures are integrated into a single MRI exam lasting under 60 min.
88949696|NCT01938690|Sham Comparator|Sham stimulation|Sham stimulation on the scalp of unaffected brain
88949697|NCT01938690|Experimental|transcranial magnetic stimulation|transcranial magnetic stimulation on unaffected brain
88949698|NCT01938729|Experimental|HAI with FLOXURIDINE & DEXAMETHASONE & GEMCITABINE|"This is an open-label single arm study. multi-institution phase I dose escalating trial of adjuvant HAIP FUDR and Gemcitabine chemotherapy after curative resection of ICC. Hepatectomy with or without bile duct reconstruction and pump placement are performed. The patients will start therapy 4 weeks postoperatively. They will receive HAI FUDR/Dex and systemic gemcitabine in the following dose escalation levels of gemcitabine. The dose of HAI FUDR will be fixed. A classic 3+3 cohort dose escalation scheme will be used to identify the MTD of the combination.~Level 1: Systemic gemcitabine 650mg/m^2 Day 1 and 15 and HAI FUDR/Dex 0.12mg/kg/day Day 1-14 Level 2.Systemic gemcitabine 800mg/m^2 Day 1 and 15 HAI FUDR/Dex 0.12 mg/kg/day Day 1-14 Level 3. Systemic gemcitabine 1000mg/m^2 Day 1 and 15 HAI FUDR/Dex 0.12 mg/kg/day Day 1-14"
88949699|NCT01938755|Experimental|levobupivacaine I|group that was administered levobupivacaine plus 60mg dextrose
88949700|NCT01938755|Experimental|levobupivacaine II|group that was administered levobupivacaine plus 80 mg dextrose
88949701|NCT01938755|Experimental|levobupivacaine III|group that was administered levobupivacaine plus 100 mg dextrose
88949702|NCT01938768||Tranexamic acid|patients with multiple trauma who received tranexamic acid on the scene
88949703|NCT01938768||Non tranexamic acid|patients with multiple trauma who did not receive tranexamic acid on the scene
88949704|NCT01938781|Active Comparator|Entecavir monotherapy|entecavir, 0.5mg, qd, oral, for 2 years.
88949705|NCT01938781|Experimental|Entecavir plus peg-IFN Therapy|entecavir combined peg-IFN in the middle 1 year.
88949706|NCT01938807|Experimental|Intervention|The intervention group receives the CareCoach mobile application
88949707|NCT01938807|Active Comparator|Control|The control group receives standard care.
88949708|NCT01938820|Active Comparator|Entecavir Therapy|"Entecavir monotherapy:~entecavir, 0.5mg, qd, oral, for 2 years."
88949709|NCT01938820|Experimental|Entecavir plus Thymosin-α|entecavir plus Thymosin-α 1.6μg, Twice a week, ih, in the middle of 1 year.
88949710|NCT01938859|Experimental|Lithium combined with SGAs|SGAs (Second Generation Antipsychotics), quetiapine adjunctive to lithium therapy
88949711|NCT01938859|Experimental|lithium combined with TCM|TCM (Traditional Chinese Medicine), Shuganjieyu capsule adjunctive to lithium therapy.
88949712|NCT01938859|Active Comparator|Lithium monotherpy|Lithium monotherapy
88949713|NCT01938872||PEB angioplasty|paclitaxel eluting balloon angioplasty in below-the-knee lesions
88949714|NCT01938898|Other|Potential NICOLA Participants|All potential participants identified through the sampling strategy and contacted to take part in the NICOLA study
89474715|NCT03330171|Other|HIV-exposed children|A cohort of HIV-exposed children will be recruited. Measles vaccine (0.5 mL, subcutaneous injection) will be adminstered at 6 months of age and 12 months of age. Varicella vaccine (0.5 mL, subcutaneous injection) or Hepatitis-A vaccine (0.5 mL, intra-muscular injection) will be administered to the participants at 18 months of age as an additional benefit for participating in the study.
89474716|NCT05118542|Active Comparator|PTU Group|Propylthiouracil (PTU) was given with adjusted dosage according to patient clinical assessment at every visit by their own endocrinologist
89474717|NCT05118542|Active Comparator|Methimazole Group|Methimazole was given with adjusted dosage according to patient clinical assessment at every visit by their own endocrinologist
89474718|NCT03336801|Active Comparator|Sevoflurane|Intervention Back surgery and sevoflurane.
89474719|NCT03336801|Active Comparator|Propofol|Intervention Back surgery and propofol.
89474720|NCT05115578||Group I TCI effect-site target infusion of 1.5 ng/ml of remifentanil|Group I of 35 patients received a constant TCI effect-site target infusion of 1.5 ng/ml of remifentanil for 25 min.
89474721|NCT05115578||Group II TCI effect-site target infusion of 1.5 ng/ml of remifentanil + 1 mg Midazolam iv|Group II of 35 patients received a constant TCI effect-site target infusion of 1.5 ng/ml of remifentanil for 25 min with a bolus of 1 mg of midazolam previous to the remifentanil infusion
89474722|NCT05115578||Group III Control|Group III of 30 patients. The same TCI system provided the saline solution in the control group under an equivalent simulation profile to the remifentanil administration
89474723|NCT03325179|Experimental|participants received treatment|100 participants who are diagnosed as simple obesity under the standards of... are planned to enrolled in the trial. Each will receive Thread-embedding therapy.
89474724|NCT03336723|Experimental|Experimental Group|Two piece zirconia dental implants place subcrestally with a healing abutment at baseline (T0) and rehabilitated with a zirconia dental crown T3 3 Measures on the IL1b and IL6 at T0 baseline , T2 2 month and T3 at crown placement.Microbiological samples at T2 and T3.
89474725|NCT03336723|Active Comparator|Control Group|Two piece titanium dental implants place subcrestally with a healing abutment at baseline (T0) and rehabilitated with a zirconia dental crown T3 3 Measures on the IL1b and IL6 at T0 baseline , T2 2 month and T3 at crown placement.Microbiological samples at T2 and T3.
89474726|NCT05115500|Experimental|ADC Combined With Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2|
89474727|NCT02490891|Experimental|PET scan with RGD K5 imaging|PET scan with RGD K5 tracer will be performed before and after two cycles of chemotherapy
89474728|NCT05115344|Experimental|flonoltinib 25mg|1 case，The starting dose，Take the medicine once on D1 ，D 5 through 21.
89474729|NCT05115344|Experimental|flonoltinib 50mg|6 case，Increasing dose，Take the medicine once on D1 ，D 5 through 21.
89474730|NCT05115344|Experimental|flonoltinib 100mg|6 case，Increasing dose，Take the medicine once on D1 ，D 5 through 21.
89474731|NCT05115344|Experimental|flonoltinib 150mg|6 case，Increasing dose，Take the medicine once on D1 ，D 5 through 21.
89474732|NCT05115344|Experimental|flonoltinib 225mg|6 case，Increasing dose，Take the medicine once on D1 ，D 5 through 21.
89474733|NCT05115344|Experimental|flonoltinib 325mg|6 case，Increasing dose，Take the medicine once on D1 ，D 5 through 21.
89474734|NCT05115266|Experimental|Experimental group (EG)|Receive animal-assisted therapy and usual treatment (ATT)
89474735|NCT05115266|Active Comparator|Control group|Receive usual treatment
89474736|NCT03329859|Experimental|Interventional arm|"High resolution standardized laparoscopic cholecystectomy Patients in which laparoscopic cholecystectomy was performed after high Resolution standardization and Training of the OR Team according to the Standard."
89474737|NCT03329859|Active Comparator|Control arm|No 'High resolution standardized laparoscopic cholecystectomy' Patients in which laparoscopic cholecystectomy was performed in the conventional way without prior standardization
89474738|NCT02636036|Experimental|enadenotucirev and nivolumab|
89474739|NCT03336567||Subjects with hematological malignancies|It will include subjects with Refractory Diffuse Large B-cell Lymphoma and Multiple Myeloma, Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) and/or who participated in a CAR-T clinical trial or autologous treatment. Subjects will undergo a telephonic interview for up to 90 minutes.
89474740|NCT03336567||Subjects with NSCLC or soft-tissue sarcoma|It will Include subjects with NSCLC on second or later-line therapy or soft-tissue sarcoma on second or later line therapy. Subjects will undergo a telephonic interview for up to 90 minutes.
89474741|NCT03336567||Oncologists from academic centers with CGT experience|It will include oncologists using TCR therapies, CAR-T or participating in CAR-T or TCR therapy clinical trials. Oncologists will undergo a telephonic interview for up to 60 minutes.
89474742|NCT03336567||Oncologists from community clinics|It will include oncologists from community clinics who evaluate, prescribe, treat, and actively interact with subjects with NSCLC or soft tissue sarcoma, who have used immuno-oncology (IO) therapies. Oncologists will undergo a telephonic interview for up to 60 minutes.
89474743|NCT03329781|Experimental|Trial|350 mg of BCM-95, 1 capsule per day, for 21 days.
89474744|NCT03329781|Placebo Comparator|Control|350 mg of starch, 1 capsule per day, for 21 days
89474745|NCT02437604|Experimental|Treatment A|Fp MDPI 200 mcg, 1 inhalation
89474746|NCT02437604|Experimental|Treatment B|FS MDPI 200/12.5 mcg, 1 inhalation
89474747|NCT02437604|Active Comparator|Treatment C|fluticasone propionate (FLOVENT DISKUS) 250 mcg, 2 inhalations
89474748|NCT02437604|Active Comparator|Treatment D|fluticasone propionate/salmeterol (ADVAIR DISKUS) 500/50 mcg, 1 inhalation
89474749|NCT03325023|Active Comparator|Active Comparator:|Dietary modification + Probiotic supplementation (Sanprobi Super Formula)
89474750|NCT03325023|Placebo Comparator|Placebo Comparator|Dietary modification + placebo.
89474751|NCT02315144|Experimental|TV48108 - Healthy Volunteers|Stage 1 is a randomized, placebo-controlled, double-blind, single-dose study. Healthy subjects will be randomized to receive a single inhaled dose of TV48108 120 µg
89474752|NCT02315144|Placebo Comparator|Placebo - Healthy Volunteers|Placebo
89474753|NCT02315144|Experimental|TV48108 15 µg COPD|Stage 2 consists of a 2-period open-label study with an ipratropium bromide reference to evaluate the single administration of 3 ascending doses of inhaled TV48108 in COPD patients.
89474754|NCT02315144|Experimental|TV48108 60 µg COPD|Stage 2
89474755|NCT02315144|Experimental|TV48108 120 µg COPD|Stage 2 .
89474756|NCT03324945|Experimental|Neurocognitive Assessment +/- FMRI|All participants receive pre- and post-chemotherapy neurocognitive assessments. A sequentially-assigned subset also receive pre- and post-chemotherapy Functional Magnetic Resonance Imaging (FMRI) procedures.
89474757|NCT05118464|Experimental|Children with cancer|The arm of the research will consist of pediatric patients aged 6-18 years who have been diagnosed with cancer in Afyonkarahisar Health Sciences University, Health Application and Research Center, Department of Pediatric Hematology-Oncology Clinics and who come for outpatient treatment.
88949715|NCT01938911|Experimental|Hypertensives with oxytocin and social support|80 hypertensive non-smoking medication-free men will be randomly assigned to receive intranasal OT (24 IU) or placebo 50 min before stress, and either social support (SS) from their best friend during the preparation period of the stress protocol or no social support.
89474758|NCT03329703|Experimental|Immediate-Treatment|This group will receive Project UPLIFT immediately after completing surveys.
89474759|NCT03329703|Active Comparator|Waitlist Control|This group will receive Project UPLIFT after waiting approximately 3 months to begin the intervention.
88949716|NCT01938911|Experimental|Hypertensives with oxytocin without social support|80 normotensive non-smoking medication-free men will be randomly assigned to receive intranasal OT (24 IU) or placebo 50 min before stress, and either social support (SS) from their best friend during the preparation period of the stress protocol or no social support.
88949717|NCT01938911|Experimental|Hypertensives without oxytocin with social support|80 hypertensive non-smoking medication-free men will be randomly assigned to receive intranasal OT (24 IU) or placebo 50 min before stress, and either social support (SS) from their best friend during the preparation period of the stress protocol or no social support.
88949718|NCT01938911|Placebo Comparator|Hypertensives without oxytocin or social support|80 hypertensive non-smoking medication-free men will be randomly assigned to receive intranasal OT (24 IU) or placebo 50 min before stress, and either social support (SS) from their best friend during the preparation period of the stress protocol or no social support.
88949719|NCT01938911|Experimental|Normotensives with oxytocin and social support|80 hypertensive non-smoking medication-free men will be randomly assigned to receive intranasal OT (24 IU) or placebo 50 min before stress, and either social support (SS) from their best friend during the preparation period of the stress protocol or no social support.
88949720|NCT01938911|Experimental|Normotensives with oxytocin without social support|80 hypertensive non-smoking medication-free men will be randomly assigned to receive intranasal OT (24 IU) or placebo 50 min before stress, and either social support (SS) from their best friend during the preparation period of the stress protocol or no social support.
88949721|NCT01938911|Experimental|Normotensives without oxytocin with social support|80 hypertensive non-smoking medication-free men will be randomly assigned to receive intranasal OT (24 IU) or placebo 50 min before stress, and either social support (SS) from their best friend during the preparation period of the stress protocol or no social support.
89474760|NCT05117216|Experimental|Parental Vigilant Care|3 sessions of group parental training
89474761|NCT05117216|Active Comparator|Technological Parental Monitoring|The installation of filtering devices on adolescents' mobile phones and setting them for reducing time use and prohibiting inappropriate content
89474762|NCT05117216|Active Comparator|PVC + TPM|combining both group parental training and installation of filtering devices
89474763|NCT05117216|No Intervention|Control|Control group that did not receive any intervention
89474764|NCT03329625|Experimental|Pathways Triple P|Families randomized to the Pathways Triple P received a 14 week home based intervention.
89474765|NCT03329625|Active Comparator|Services as Usual|Families randomized to the services as usual condition received services as usual through the Missouri Children's Division
89474766|NCT05114954|Experimental|Experiment group|Patients treated with PFA catheter.
89474767|NCT02493309|Experimental|Prolonged sitting|
89474768|NCT02493309|Active Comparator|Light activity breaks|
89474769|NCT03329547|Experimental|Subjects receiving treatment sequence AB|Eligible subjects will receive treatment sequence AB; A= SKF101804 cefixime 400 mg test capsules and B= cefixime 400 mg reference capsules. Subjects will receive single oral dose of treatment A in treatment period 1 on Day 1 and treatment B in treatment period 2 on Day 1. Treatment periods 1 and 2 will be separated by a washout period of 7 to 14 days.
89474770|NCT03329547|Experimental|Subjects receiving treatment sequence BA|Eligible subjects will receive treatment sequence BA; B= cefixime 400 mg reference capsules and A= SKF101804 cefixime 400 mg test capsules. Treatment periods 1 and 2 will be separated by a washout period of 7 to 14 days. Subjects will receive single oral dose of treatment B in treatment period 1 on Day 1 and A in treatment period 2 on Day 1. Treatment periods 1 and 2 will be separated by a washout period of 7 to 14 days.
89474771|NCT05107232|Other|Participants|Patients and Healthy volunteers included will have an MRI
89474772|NCT05463627||BMI<24 kg/m2|women diagnosed with PCOS with BMI<24 kg/m2
89474773|NCT05463627||BMI24-28 kg/m2|women diagnosed with PCOS with BMI24-28 kg/m2
89474774|NCT05463627||BMI>28 kg/m2|women diagnosed with PCOS with BMI>28kg/m2
89474775|NCT01975298|Experimental|Laquinimod 0.6 mg|
89474776|NCT01975298|Experimental|Laquinimod 1.2 mg|
89474777|NCT01975298|Active Comparator|Avonex®|
88949722|NCT01938911|Placebo Comparator|Normotensives without oxytocin or social support|80 hypertensive non-smoking medication-free men will be randomly assigned to receive intranasal OT (24 IU) or placebo 50 min before stress, and either social support (SS) from their best friend during the preparation period of the stress protocol or no social support.
89474778|NCT05114642|Experimental|Skeletal Class III Malocclusion Treatment with Face Mask Group|In patients with skeletal class III malocclusion (ANB angle < 0,0) due to maxillary deficiency, rapid maxillary expansion appliances prepared on dental plaster models made of acrylic material covering all the upper dental posterior tooth surfaces were applied before the upper jaw was orthopedically brought forward with a face mask. This process was stopped when the expansion was made so that the palatal tubercles of the maxillary permanent first molars align with the buccal tubercles of the mandibular permanent first molars. Immediately afterwards, the petit-type face mask was applied to the hooks of the maxillary expansion device with the help of elastic bands and used continuously for at least 18 hours a day. After obtaining a positive overjet, the face mask appliance was used at night to ensure retention, and then the treatment was terminated.
89474779|NCT05114642|No Intervention|Control Group|A control group was formed from patients in the same age group who had skeletal class III malocclusion due to maxillary growth deficiency but were not treated. In this way, the changes that occurred in the normal process in the head, craniocervical postures, pharyngeal airway and hyoid bones of the patients whose growth and development continued could be distinguished.
89474780|NCT03324867|Experimental|Intranasal Insulin 40 IU|40 IU of Humulin-R via nose Before surgery and everyday after surgery up to POD 7
89474781|NCT03324867|Placebo Comparator|Intranasal Normal Saline|Normal Saline via nose Before surgery and everyday after surgery up to POD 7
89474782|NCT03329391|Experimental|Intervention Group|The intervention group will receive a 8-week nurse-led psychosocial care group,which involve 90 minutes session every week.
89474783|NCT03329391|No Intervention|Control Group|The control group will receive usual care, which refers to the pharmacological therapy provided by psychiatrists in the Psychiatric Department.
89474784|NCT05084534|Experimental|Midodrine hydrochloride plus standard medical treatment|"Standard Medical Treatment will be continued in all, which includes,~To continue restriction of sodium to < 2meq/kg/day~To continue maximum tolerable dose of diuretics~Repeat LVP with infusion of albumin (8 g/L) performed for tense, symptomatic ascites~Albumin infusion for serum albumin <2.5g/dl - dose 1g/kg/day (maximum 20g/day)~Midodrine starting at 0.25mg/kg/day in divided doses, increased to 0.5mg/kg/day after 7 days if MAP does not increase by >10% (maximum dose - 15mg/day)~Midodrine dosage will be decreased by 25% in case of arterial hypertension (>95th centile BP for the age)"
89474785|NCT05084534|Other|Standard medical treatment|"Standard Medical Treatment will be continued in all, which includes,~To continue restriction of sodium to < 2meq/kg/day~To continue maximum tolerable dose of diuretics~Repeat LVP with infusion of albumin (8 g/L) performed for tense, symptomatic ascites~Albumin infusion for serum albumin <2.5g/dl - dose 1g/kg/day (maximum 20g/day)"
89474786|NCT03329235|Experimental|Intraosseous and intra-articular|injection of PRP 2 ml
89474787|NCT03329235|Active Comparator|intra-articular PRP|injection PRP 2 ml
88949723|NCT01938924|No Intervention|No intervention|No intervention
88949724|NCT01938924|Active Comparator|GekoTM|geko applied to bypass limb
88949725|NCT01938937|Experimental|Transcranial bright light exposure|Transcranially administered bright light exposure for 12 minutes
88949726|NCT01938937|Sham Comparator|Transcranial sham exposure|Transcranially administered sham exposure for 12 minutes
88949727|NCT01938950|Active Comparator|Aerobic Exercise|Participants will perform aerobic exercise using treadmills and/or ellipticals at 40-65% of VO2peak, three times per week, for 60 minutes/session.
88949728|NCT01938950|Active Comparator|Resistance Exercise|Participants will perform 2 sets (8-12 repetitions per set) of 8 exercises to the point of failure using weight stack equipment, three times per week, for 60 minutes/session. 2 sets of push-ups and sit-ups will also be performed.
88949729|NCT01938950|Active Comparator|Aerobic and Resistance Exercise|Participants will perform aerobic exercise using treadmills and/or ellipticals for 30 min at 40-65% of VO2peak and thereafter, perform 1 set of each of the above 10 resistance exercise for 30 min.
88949730|NCT01938963|No Intervention|Care as usual|
89474788|NCT03329235|Active Comparator|Intra-articular injection of HA|injection of HA 2 ml
89474789|NCT03336099|Experimental|Spa Treatment|Bicarbonate and sulfurated water cares in Vals-les-Bains thermal cure center, massage, cataplasm.
89474790|NCT05046548|Experimental|Vaccine|"At Stage I:~Group 1 - 10 volunteers, Vaccine 0.5 ml, 14 days interval, post-vaccination observation period of 28 days.~At Stage II:~Group 1 - 140 volunteers,Vaccine0.5 ml, 14 days interval, post-vaccination observation period of 28 days.~At Stage III:~Group 3 - 150 volunteers, Vaccine 0.5 ml, 14 days interval, post-vaccination observation for 6 months."
89474791|NCT05046548|Placebo Comparator|Placebo|"No active ingredient in the placebo~At Stage I:~Group 2 - 5 volunteers, Placebo 0.5 ml, 14 days interval, post-vaccination observation period of 28 days.~At Stage II:~Group 2 - 45 volunteers, Placebo 0.5 ml, 14 days interval, post-vaccination observation period of 28 days.~At Stage III:~Group 4 - 50 volunteers, Placebo 0.5 ml, 14 days interval, post-vaccination observation period of 6 months."
89474792|NCT03336021|Experimental|Intervention|FAS program
89474793|NCT03336021|No Intervention|Comparison|Comparison group
89474794|NCT02491281|Experimental|LNA043|LNA043 given intra-articularly
89474795|NCT02491281|Placebo Comparator|Placebo|Placebo given intra-articularly
89474796|NCT04645316|Active Comparator|Sevoflurane|Sevoflurane will use for anesthesia maintenance for liver donor hepatectomy surgery
89474797|NCT04645316|Active Comparator|Desflurane|Desflurane will use for anesthesia maintenance for liver donor hepatectomy surgery
89019996|NCT05890105|Experimental|Cohort 1|Single dose administration of PF-07853578 and placebo. Participants will receive up to 4 dose levels of PF-07853578 and up to 2 dose levels of matching placebo.
89019997|NCT05890105|Experimental|Cohort 2|Single dose administration of PF-07853578 and placebo. Participants will receive up to 4 dose levels of PF-07853578 and up to 2 dose levels of matching placebo.
89019998|NCT05890105|Experimental|Cohort 3|Single dose administration of PF-07853578 and placebo. Participants will receive up to 4 dose levels of PF-07853578 and up to 2 dose levels of matching placebo.
89474798|NCT04645316|Placebo Comparator|Total intravenous anesthesia|Total intravenous anesthesia (propofol/remifentanyl) will use for anesthesia maintenance for liver donor hepatectomy surgery
89474799|NCT05114408|Experimental|Trimodal prehabilitation|Patients qualified for elective surgery that meet criteria for prehabilitation
89474800|NCT03324789|Experimental|Single Implant Partial Over-denture|The design will be as follows; two rests on principle abutments and lingual plate major connector, single implant in the symphyseal region.
89474801|NCT03324789|Active Comparator|Conventional Partial Denture|patients will receive conventional partial denture with double Aker clasp on mandibular second premolar and first molar, with no indirect retention and lingual plate as major connector .
89474802|NCT03335943|Experimental|CDA-2 (Cell Differentiation Agent 2)|Patients will be given CDA-2 therapy.
89474803|NCT01843634|Experimental|ODSH|
89474804|NCT03324555|Experimental|ORIC-101|
89474805|NCT03328923|Experimental|500mg brown seaweed powder|2 x 250mg capsules InSea2® (brown seaweed powder)
89474806|NCT03328923|Placebo Comparator|Placebo|2 x capsules microcrystalline cellulose (bulking agent) (0mg InSea2®)
89474807|NCT05113628|No Intervention|anatomical identification|thyroidectomy was done with identification of both RLN and parathyroid gland done on anatomical basis
89474808|NCT05113628|Sham Comparator|methylene blue identification|thyroidectomy was done with identification of both RLN and parathyroid gland done using methylene blue spray (0.5 ml methylene blue 2% was diluted by 5ml normal saline) was sprayed over the lower thyroid pole and the perilobar area
89474809|NCT05113472||Ecuadorian Healthcare Workers|All individuals involved were part of the first phase of the national COVID-19 vaccination plan in our country and were contacted through a local registry established by a local private university.
89474810|NCT05464485||ACL hamstring reconstructions using semitendinosus (ST) tendon only|
89474811|NCT05464485||ACL hamstring reconstructions using semitendinosus and gracilis (ST/G) tendon|
89474812|NCT04445090|Experimental|Single Rising Dose part: BI 1569912|
89474813|NCT04445090|Placebo Comparator|Single Rising Dose part: Placebo|
89474814|NCT04445090|Experimental|Bioavailability and Food effect part: BI 1569912|This part follows the SRD part; open-label, randomised, single-dose, intraindividual, six-sequence, three-way crossover
89474815|NCT03335709|Experimental|ADL intervention|The participants are assigned to an eight-week intervention program aiming at enhancing ADL ability. The program consists of a minimum of five and a maximum of eight sessions; Session one - First meeting and occupational therapy evaluation (mandatory), Session two - Goal setting and clarifying reasons for problems related to ADL (mandatory), Session three- seven - Interventions aiming at enhancing ADL ability (Number of sessions can vary. However, a minimum of two sessions are mandatory), Session eight - Re-evaluation (Mandatory)
89474816|NCT03324399|Experimental|High Amino Acid levels|"Comparison between high amino acid levels and low amino acid levels of clinical global assessments, muscle strength and spasticity and functional assessments.~Patients taking proprietary probiotic"
89474817|NCT03324399|Experimental|Low Amino Acid levels|"Comparison between high amino acid levels and low amino acid levels of clinical global assessments, muscle strength and spasticity and functional assessments.~Patients taking proprietary probiotic"
89474818|NCT04247750|Experimental|Open label trial|Sirolimus 0.5 mg tablets
89474819|NCT03335631|Experimental|Group-supervised|This intervention arm will include 3 group, supervised sessions per week for 6 months with a certified exercise specialist. Supervised sessions will be delivered in a group format with 4-8 participants per group. Flexibility training will include stretching for 5-10 minutes at the beginning and end of each session. Aerobic training will involve 30 minutes of low-impact step aerobics. Resistance training will be conducted using resistance bands, a stability ball, and an exercise mat with 8 prescribed exercises that target the major muscle groups. Participants will be encouraged to perform exercises independently on additional days, for a total of 4-5 days per week of exercise.
89474820|NCT03335631|Experimental|Home-based|The same protocol and training frequency as the supervised programs described above will be followed. However, all exercises will be completed independently by participants. Specific exercises in the aerobic program may be modified to accommodate patient preference (same target heart rate range as the supervised group). Participants will be supported with smartphone technology and remote 'health coaches' during the intervention phase. This will help to ensure participant adherence, appropriate progression, and safety.
89474821|NCT05117606|Other|Vitalsigns|Data from patients (heart rate, respiration, movement, blood pressure) is measured with traditional, standard hospital equipment in parallell with data from LYNG mat captured non-intrusively in the same session.
88949731|NCT01938963|Experimental|Collaborations in Health (COACH)|COACH integrates the care provided by the older person's primary care provider (PCP) with that delivered by an Aging Worker (AW; a lay member of the village's Aging Association), supervised by a psychiatrist consultant. Based on chronic disease management principles, the PCP is trained to use evidence based practice guidelines for treatment of both HTN and depression, and provided with access to mental health consultation regarding optimal management of the patient's depression. The AW is trained to conduct a systematic assessment of the older person's social context to identify and reduce social and environmental barriers to treatment adherence and response. AWs participate with the PCP in developing multi-disciplinary care plans for their shared patients, reinforce treatment adherence and adoption of healthy behaviors, and emphasize activation and engagement of the older person in activities designed to improve their connectedness to others and to the community.
88949732|NCT01938976|Experimental|Adolescent Asthma Action|Adolescent Asthma Action in Jordan (TAJ) Plus the added class smoke free pledge will be implemented in high schools in Jordan and will be compared to the TAJ alone for its efficacy in decreasing smoking rates, lowering CO1 levela and nicotine dependence.
88949733|NCT01938976|Experimental|TAJ|TAJ Plus the class smoke free pledge will be implemented in high schools in Jordan and compared to TAJ alone
89019999|NCT05879679||Binge Eating Disorder|Participants with a binge eating disorder (DSM-5 criteria)
89474822|NCT03328767|Experimental|Early activity and Mobilisation intervention|Patients will be randomised within 48 hrs of commencing ECMO. Patients unable to initially receive active physical training will receive passive physical training for a minimum of 20 minutes and a maximum of one hour per day to maintain joint and muscle activity until active physical training is commenced. The intervention involves a progression of exercises with the objective of rehabilitating the patient at the highest level of exercise possible for the patient for the longest period of time that can be tolerated (up to 60 minutes) at each session, based on our published ICU mobility scale now used internationally in ICU trials. This is performed with or without IMV (including both endotracheal tubes or tracheostomies).
89474823|NCT03328767|No Intervention|Standard Care|The control group will receive standard care from physiotherapy staff not involved in delivering the intervention. We have previously established that standard care in Australia for a patient receiving prolonged IMV (control group intervention) frequently involves no active exercise out of bed.
89474824|NCT02493231|Active Comparator|Nefopam|The generic name is 'ACUPAN'. It is infused during operation. A induction dose is 0.3mg/Kg. A maintenance dose is 65 mcg/kg/hr
89474825|NCT02493231|Active Comparator|Ketamine|It is infused during operation. A induction dose is 0.3 mg/Kg. A maintenance dose is 3 mcg/kg/hr
89474826|NCT02493231|Placebo Comparator|Saline|It is infused during operation. A induction volume is 3mL A maintenance dose is 10mL/hr
89474827|NCT04075682|No Intervention|Standard cigarette packs (control)|Participants will be provided with a 2 week supply of their preferred brand of cigarettes, with the only alteration being the small health warning message on the side of the pack, whose textual content will be the same as that used for the pictorial warning label conditions.
89474828|NCT04075682|Experimental|Cigarette packs with inserts only|Participants will be provided with a 2 week supply of their preferred brand of cigarettes, with packs altered to include inserts with four different rotating messages to promote response efficacy beliefs (2 inserts on the benefits of cessation) or self-efficacy to quit (2 inserts with cessation tips).
89474829|NCT04075682|Experimental|Cigarette packs with pictorial warnings only|Participants will be provided with a 2 week supply of their preferred brand of cigarettes, with packs altered to include four different rotating pictorial warnings showing the consequences of smoking and that cover 50% of the front and back of the pack.
89474830|NCT04075682|Experimental|Cigarette packs with inserts and pictorial warnings|Participants will be provided with a 2 week supply of their preferred brand of cigarettes, with packs altered to include inserts with four rotating efficacy messages (see description above) and four rotating pictorial warnings (see above).
89020000|NCT05879679||Bulimia Nervosa|Participants with a bulimia nervosa (DSM-5 criteria)
89020001|NCT05879146|Experimental|nirogacestat|Participants will take nirogacestat by mouth every day of each 28-day study cycle. Based on when you enroll in this study, you will take nirogacestat either 1 time a day at about the same time each day OR 2 times a day, about 12 hours apart.
89020002|NCT05878236||Acute Pancreatitis|Patients meeting Revised Atlanta Criteria for diagnosis of acute pancreatitis
89474831|NCT03328689|Experimental|Physical activity in the community|The physical activity program will include an individualized exercise program delivered in community exercise facility plus education..
89474832|NCT03328689|Active Comparator|Control group standard care|Participants from the control group will receive no additional intervention other than being encouraged to continue with their physiotherapists or chiropractor recommendation which will often include recommendation to keep activity, home exercise programs and advice to engage in physical activity.
88949734|NCT01939015|Active Comparator|Standard titanium miniplate- single non compression miniplate|fixation will be perform by A single non compression miniplate with 4-hole 2-mm using 2-mm monocortical screws at superior border of the mandible according to ideal lines of osteosynthesis.
88949735|NCT01939015|Experimental|three dimensional titanium miniplate|3D curved strut miniplate* (Universal Mandible System, Stryker-Lei binger, Freiburg, Germany) , installed and stabilized with monocortical screws. The 3D plate will be place in such a way that a horizontal bar is perpendicular and a vertical bar is parallel to the fracture line.
88949736|NCT01939041|Experimental|Robot-assisted therapy with InMotion3 (IMT)|We will use the InMotion3 Wrist Robot (Figure 1) for the IMT group. During the InMotion3 therapy (IMT) session, participants will receive 5-minute of muscle tone normalization preparation and passive range of motion, then a 70-minute robot-assisted training followed by a 15-minute functional training. During the robot-assisted training, only the paretic hand will be trained and the participant will rest the forearm and hand on a cradle and the wrist and hand in a fixed positions. During the practice, a visual display will provide online visual feedback of accuracy and coordination success. And summary scores regarding movement accuracy and movement smoothness will be shown on the display periodically. After each IMT session, a 15 min functional task practice will be provided as described in the previous paragraph.
88949737|NCT01939041|Experimental|Robot-assisted therapy with Bi-Manu-Track (BMT)|During the Bi-Manu-Track training (BMT), participant will use both nonparetic and paretic hands. Participants will receive 5-munite of muscle tone normalization preparation and passive range of motion, then will practice about 5-minute in Mode 1, 25-minute in Mode 2, and 5-minute in Mode 3 in wrist and forearm respectively. The training repetitions of each mode fall within the range of the protocols used in previous studies which would not cause adverse events (Hesse et al., 2005). The total minutes of each robot-assisted will be 70 minutes. After each BMT session, a 15 min functional task practice will be provided based on the same principles as the one in the IMT group.
88949738|NCT01939041|Active Comparator|Control intervention group (CI)|The control group's therapy will be designed to control for the duration and intensity of the robot-assisted training (90 min/day, 5 days/wk, for 4 wk). The therapeutic activities in the control group will involve passive range of motion, weight bearing, stretching, strengthening of the paretic arm, gross motor activities, coordination tasks, unilateral and bilateral fine motor tasks, transition, mobility, and posture/balance.
88949739|NCT01939054|Experimental|Nimotuzumab,docetaxel,capecitabine|Nimotuzumab 400mg/w,IV,once a week and Docetaxel 75 mg/m2,IV,D1, every 21 days a cycle and Capecitabine 1000mg/m2, orally, twice daily, D1-D14
88949740|NCT01939054|Active Comparator|docetaxel,capecitabine|Docetaxel 75 mg/m2,IV,D1, every 21 days a cycle and Capecitabine 1000mg/m2, orally, twice daily, D1-D14
89474833|NCT02993107|Other|Group 1 (Placebo Crossovers)|Subjects who complete the placebo arm of ARC003 and consent to enroll in ARC004 (Group-1) will cross over to active treatment with AR101 using the same dosing regimen used in ARC003 in open-label fashion. Group 1 subjects may also be assigned to cohorts which test the gradual lengthening of dosing intervals. Following the completion of their longest tested dosing interval, Group 1 subjects will undergo an exit double-blinded placebo-controlled food challenge (DBPCFC).
89474834|NCT02993107|Other|Group 2 (Active Rollovers)|Subjects who successfully complete the active arm of ARC003 and consent to enroll in ARC004 (Group-2) will consecutively enter treatment with AR101 in one of three cohorts which will test alternate dosing intervals. There will be a DBPCFC at the completion of the subject's longest tested dosing interval.
88949741|NCT01939067|Other|HHHFNC|"Treatment of respiratory distress by Heated Humidified High Flow Nasal Cannula (HHHFNC).~Escalation of the ventilatory support per protocol and the attending physician."
88949742|NCT01939067|Other|NCPAP|"Treatment of respiratory distress by nasal continuous positive airway pressure (NCPAP).~Escalation of the ventilatory support per protocol and the attending physician."
88949743|NCT01939080|Active Comparator|Medical supervision|Exercise training with supervised sessions Classics training
88949744|NCT01939080|Active Comparator|No medical supervision|Exercise training without supervised sessions Classics training
88949745|NCT01939093|Experimental|Quetiapine|Quetiapine 100 mg per day is taken orally once a day for four weeks. The dose is increased every 5 days until no psychotic symptom is observed.
88949746|NCT01939093|Active Comparator|Haloperidol|Haloperidol 2 mg per day is taken orally once a day for four weeks. The dose is increased every 5 days until no psychotic symptom is observed.
88949747|NCT01939119||retinal vascular occlusion|Patients with retinal vascular occlusion undergo a hematocrit dependent 5 day hemodilution
88949748|NCT01939132|Experimental|H.P. Acthar Gel SQ injection|Open-label H.P. Acthar Gel 80 units subcutaneously twice weekly for 12 weeks with a 12 week extension.
88949749|NCT01939171|Placebo Comparator|Non treated|Cadaver donor is cared and treated as usual protocol
88949750|NCT01939171|Experimental|TREATED|Cadaver donor receives one dose of thymoglobulin of 3 mg/kg iv in 2 hours after ganglia extraction and 3- 6 hours prior to organ procurement.
88949751|NCT01939210|Experimental|Arm I (breathing training sessions)|Patients participate in 3 50-minute breathing training sessions, including a psycho-educational component and meditation-based breathing training, over 10 days. Patients then undergo 4D-CT on day 14 and undergo image-guided SBRT or standard radiation therapy 5 times a week for up to 5 fractions or 25 fractions, respectively.
88949752|NCT01939210|Active Comparator|Arm II (control)|Patients receive standard care over 10 days. Patients then undergo 4D-CT on day 14 and undergo image-guided SBRT or standard radiation therapy 5 times a week for up to 5 fractions or 25 fractions, respectively.
88949753|NCT01939236|Experimental|traditional Chinese medicine|Subjects were treated with TCM 2 times per day for 28 days according to syndrome differentiation. For example, the syndrome of one patient with chronic heart failure is qi deficiency and blood stasis. He will take drug of qi deficiency and blood stasis 2 times per day for 28 days.
88949754|NCT01939236|Placebo Comparator|placebo (gummeline)|Subjects were treated with placebo 2 times per day for 28 days according to syndrome differentiation. For example, the syndrome of one patient with chronic heart failure is qi deficiency and blood stasis. He will take drug of qi deficiency and blood stasis 2 times per day for 28 days.
89474835|NCT05112692|Active Comparator|PPOS group|Patients will be coadministered with Human Menopausal Gonadotrophin (HMG) 150-225 international unit/day (IU/d) via intramuscular injection and oral DYG 20mg/d from menstrual cycle day 3 (MC3) to the day of triggering. The starting dose of HMG is 150IU/day for patients with a high antral follicle count >20 or slightly elevated basal FSH (7-10IU/L), and a daily dose of 225IU HMG is used for the other patients. The dose will be adjusted after day 5 of stimulation based on the ovarian response as assessed by serum hormone levels and transvaginal ultrasonography
89474836|NCT05112692|Active Comparator|GnRH antagonist|In the fixed GnRH antagonist protocol, daily s.c. administration of Cetrotide 0.25 mg will be initiated at 6th day of stimulation. HMG (150-225IU) will be administered daily from menstrual cycle day 3, and follicular monitoring will be performed every 2 to 3 days after 5 days of injections. The dose of hMG will be adjusted according to the ovarian response, as monitored by ultrasonography and the measurement of serum sex steroids. Treatment with hMG and GnRH antagonist will continue daily until the day when final oocyte maturation is triggered
89474837|NCT03328533|Active Comparator|Phenylephrine|Will receive spinal anesthesia using Bupivacaine. Then, phenylephrine infusion by a starting rate of 0.75 mcg/Kg/min. The rate will be then adjusted according to the patient blood pressure. The infusion will stop in case of reactive hypertension. The infusion will start again when blood pressure returns to normal reading. Infusion will be increased by 20% if hypotension occurred.
89474838|NCT03328533|Experimental|Norepinephrine|Will receive spinal anesthesia using Bupivacaine. Then, norepinephrine bitartrate infusion by a starting rate of 0.1 mcg/Kg/min (equivalent to norepinephrine base of 0.05 mcg/Kg/min). The rate will be then adjusted according to the patient blood pressure. The infusion will stop in case of reactive hypertension. The infusion will start again when blood pressure returns to normal reading. Infusion will be increased by 20% if hypotension occurred.
89474839|NCT05105594|Active Comparator|Study Group|People who have lymphedema
89474840|NCT05105594|Active Comparator|control group|healty people
89474841|NCT03324321|Experimental|Hyperventilation Protocol|This will involve sustained periods of 90-seconds of hyperventilation at two levels (-5mmHg and -10mmHg below baseline EtCO2) to a maximum lower level threshold of EtCO2 24mmHg/CBFV 33cm/s regulated using a metronome. Two-minute washout periods of normal respiration will be allowed between successive measurements. Each incremental reduction in pCO2 will be repeated on two occasions during the same session. Further assessments will be conducted 10-14 days following baseline assessments.
89474842|NCT05117372|Active Comparator|Patients treated with with immunotherapy and developing diffuse infiltrative lung disease|Group 1: Patients treated for cancer with immunotherapy and developing diffuse infiltrative lung disease
89474843|NCT05117372|Placebo Comparator|Patients not treated with immunotherapy and requiring carcinologic lobectomy|Group 2: Patients with lung cancer not treated with immunotherapy and requiring carcinologic lobectomy
89474844|NCT05353777|Experimental|Levita Robotic Platform|
89474845|NCT03324243|Experimental|Crenolanib|
89474846|NCT05117138|Experimental|NSCLC/HNSCC：AMT-116 CAR-T cells|Patients with moderate or far advanced non-small cell lung carcinomav or head and neck Squamous Cell Carcinoma.
89474847|NCT05117138|Experimental|MEL：AMT-253 CAR-T cells|Patients with moderate or far advanced melanoma.
89474848|NCT05353699|Experimental|Intervention groups|
89474849|NCT05353699|No Intervention|Control groups|as same as before
89474850|NCT03324165|No Intervention|Usual Care Arm|Patients randomized to Usual Care Arm will be managed as per current best practice that is based on the individual doctor's discretion.
89474851|NCT03324165|Experimental|Intervention Arm|Patients randomized to Intervention Arm will be managed as per the proposed algorithm, which is based on the computation of Alvarado Score.
89474852|NCT02493075|Experimental|CF guided group|Ablation will be performed with smart-touch catheter.The operator will kown the real-time contact force (CF), ablation time, FTI, etc during the procedure.
88949755|NCT01939106|Other|One Piece Drainable Pouch|This is a one piece drainable pouch designed for the purpose of collecting stool from subjects with an ileostomy stoma
88949756|NCT01939249|Active Comparator|Abbott Laboratories Xience|Subjects assigned to Abbott Laboratories Xience can be treated with either the Xience Prime or Xience Xpedition drug eluting stent (DES).
88949757|NCT01939249|Experimental|Biotronik Orsiro|Subjects assigned to Biotronik Orsiro will be treated with Biotronik Orsiro
88949758|NCT01939262|Experimental|Vegan Diet|Limitation of Animal Fat and Protein in the Diet. Animal products were proscribed and the use of unrefined foods was encouraged. Participants were asked to limit high-fat plant foods, such as nuts, avocados, and refined oils. There was no restriction in energy intake, were encouraged to eat freely and not count calories.
88949759|NCT01939262|Placebo Comparator|Control|Subjects maintained their existing diet without modification.
88949760|NCT01939327|Experimental|Lenalidomide/Rituximab|Association of Lenalidomide and Rituximab
88949761|NCT01939379|Active Comparator|15ml ropivacaine|Depending on what dose of ropivacaine the subject is randomized to he/she could receive the 15ml dose injected into the catheter every 6 hours
88949762|NCT01939379|Active Comparator|30ml ropivacaine|If the subject is randomized to 30ml ropivacaine he/she will be injected through the catheter every 6 hours.
89020003|NCT05878106|No Intervention|Control Group|They receive physical activity and nutrition recommendations.
89474853|NCT02493075|Active Comparator|Usual ablation group|Although we use the same catheter,operator will be blinded to CF data during the procedure.
89474854|NCT03564769|Experimental|Intervention Arm 1|Individuals randomized to intervention group 1 will have participated in the AAD SPOTmeⓇ skin cancer screening program in either 2016 or 2017 AND will receive additional skin cancer screening educational materials.
89474855|NCT03564769|Experimental|Intervention Arm 2|Individuals randomized to intervention group 2 will have participated in the AAD SPOTmeⓇ skin cancer screening program in either 2016 or 2017 only.
89474856|NCT05101538||patients and controls|AN patients and controls are recruited, studied using imaging and followed for 5 years
89474857|NCT02492919|Experimental|Medixair®|Cardiac reanimation unit bed with Medixair®
89474858|NCT02492919|No Intervention|NO Medixair®|Cardiac reanimation unit bed with NO Medixair®
89474859|NCT05101226|Experimental|Intervention in person|The participants in this group will receive 8 weeks of yoga classes, that they attend in person.
89474860|NCT05101226|Experimental|Intervention online|The participants in this group will receive 8 weeks of yoga classes, that they attend online via zoom.
89474861|NCT05101226|Other|Waiting list control in person|The waiting list control in person group will participate in person in the same yoga classes as the intervention in person group but only after the first group has finished the intervention
89474862|NCT05101226|Other|waiting list control online|The waiting list control online group will participate online in the same yoga classes as the intervention online group but only after the first group has finished the intervention
89474863|NCT03324087||Adult patients with ITP|The investigators are undertaking a multi-center, prospective trail of 1000 adult ITP patients and use SF-36 and ITP-PAQ questionnaires to assess the HRQoL in patients with ITP in the real world, and analyze the influencing factors of HRQoL so as to provide a sufficient basis for clinical decision making.
89474864|NCT03324009|Experimental|2-stage screen|All patients will be enrolled in the two-stage cervical cancer screening protocol
89474865|NCT02838901|Experimental|Beet It Beetroot Juice|70 cc (3.8 millimoles nitrate) Beet It organic beetroot juice once a day for 30 days. Vitamin C 500 mg (tablets) will be given along with each dose of the juice.
89474866|NCT02838901|Placebo Comparator|Beet It Beetroot Juice Placebo|70 cc Beet It organic beetroot juice (placebo) once a day for 30 days. The placebo beet juice is identical in appearance and taste with nitrate removed. Vitamin C 500 mg (tablets) will be given along with each dose of the juice.Beet It Placebo Beetroot juice.
89474867|NCT05098106||Pneumonia patients with ARDS|Patients in the perioperative/intensive care setting with pneumonia-induced ARDS requiring bronchoscopy.
89474868|NCT05098106||Ventilated patients without ARDS|Patients without ARDS on mechanical ventilation.
89474869|NCT03328299|Active Comparator|Dexmedetomidine group|patients were given ultrasound guided TAP-block with 20 ml of 0.5 % bupivacaine + dexmedetomidine 1 μg•kg-1 diluted in 20 ml saline
89474870|NCT03328299|Placebo Comparator|bupivacaine group|patients will given ultrasound guided TAP-block with 20 ml of 0.5 % bupivacaine
89474871|NCT05097872|Active Comparator|Real diet|Diet excluding the trigger nutrient identified by an acute mucosal reaction in CLE
89474872|NCT05097872|Sham Comparator|Sham diet|Diet excluding a sham nutrient without acute mucosal reaction in CLE
89474873|NCT05097872|Active Comparator|Wheat exclusion diet|In patients without identified trigger nutrient (i.e. no acute mucosal reaction to any nutrient), wheat will be excluded as an empirical diet in crossover fashion with soy.
89474874|NCT05097872|Active Comparator|Soy exclusion diet|In patients without identified trigger nutrient (i.e. no acute mucosal reaction to any nutrient), wheat will be excluded as an empirical diet in crossover fashion with soy.
88949763|NCT01939392|Experimental|Renal Denervation|Subjects randomized to the Renal Denervation arm will receive bilateral renal ablation with the OneShot system and be maintained on antihypertensive medication.
89474875|NCT05091554|No Intervention|Single visit control|"The root canals were obturated in the same session using cold lateral compaction technique with AH Plus sealer (Dentsply DeTrey, Konstanz, Germany), Protaper Universal gutta-percha (ProTaper Universal gutta-percha, Dentsply) and .02 tapered auxiliary gutta-percha (Diadent, Chongju, Korea) cones. Residual gutta-perchas in the access cavity were removed with the aid of heated hand tools. The quality of root canal filling was checked with periapical radiographs.~The pulp chamber was filled with flowable composite resin (Filtek Ultimate Flowable, 3M-ESPE, St. Paul, MN, USA) and nanohybrid composite resin (3M-ESPE) using an incremental technique.~Intraoral cryotherapy was not applied."
89474876|NCT05091554|Experimental|Single visit 15 minutes cryotherapy|"The root canals were obturated in the same session using cold lateral compaction technique with AH Plus sealer (Dentsply DeTrey, Konstanz, Germany), Protaper Universal gutta-percha (ProTaper Universal gutta-percha, Dentsply) and .02 tapered auxiliary gutta-percha (Diadent, Chongju, Korea) cones. Residual gutta-perchas in the access cavity were removed with the aid of heated hand tools. The quality of root canal filling was checked with periapical radiographs.~The pulp chamber was filled with flowable composite resin (Filtek Ultimate Flowable, 3M-ESPE, St. Paul, MN, USA) and nanohybrid composite resin (3M-ESPE) using an incremental technique.~15 minutes intraoral cryotherapy was applied."
89474877|NCT05091554|Experimental|Single visit 30 minutes cryotherapy|"The root canals were obturated in the same session using cold lateral compaction technique with AH Plus sealer (Dentsply DeTrey, Konstanz, Germany), Protaper Universal gutta-percha (ProTaper Universal gutta-percha, Dentsply) and .02 tapered auxiliary gutta-percha (Diadent, Chongju, Korea) cones. Residual gutta-perchas in the access cavity were removed with the aid of heated hand tools. The quality of root canal filling was checked with periapical radiographs.~The pulp chamber was filled with flowable composite resin (Filtek Ultimate Flowable, 3M-ESPE, St. Paul, MN, USA) and nanohybrid composite resin (3M-ESPE) using an incremental technique.~30 minutes intraoral cryotherapy was applied."
89474878|NCT05091554|No Intervention|Multiple visit control|"Root canals were filled with calcium hydroxide paste (Kalsin, Turkey), prepared according to the rate recommended by the manufacturer using a lentulo spiral (Dentsply Sirona, Switzerland) 2 mm from the working length. Sterile dry cotton pellets were placed in the pulp chamber, then the access cavity was sealed with a temporary filling material and occlusion was checked.~Intraoral cryotherapy was not applied. Patients were given an appointment 7 days later for second visit. In this appointment, patients were anesthetized, the tooth was isolated with rubber dam, the temporary filling material was removed. Then calcium hydroxide paste was removed by using the last instrument used to prepare the root canals at the working length during the first appointment using sufficient irrigation.~The final irrigation protocol was repeated. Root canal fillings and permanent restorations were completed by applying the same techniques as in single session groups."
89474879|NCT05091554|Experimental|Multiple visit 15 minutes cryotherapy|"Root canals were filled with calcium hydroxide paste (Kalsin, Turkey), prepared according to the rate recommended by the manufacturer using a lentulo spiral (Dentsply Sirona, Switzerland) 2 mm from the working length. Sterile dry cotton pellets were placed in the pulp chamber, then the access cavity was sealed with a temporary filling material and occlusion was checked.~15 minutes intraoral cryotherapy was applied. Patients were given an appointment 7 days later for second visit. In this appointment, patients were anesthetized, the tooth was isolated with rubber dam, the temporary filling material was removed. Then calcium hydroxide paste was removed by using the last instrument used to prepare the root canals at the working length during the first appointment using sufficient irrigation.~The final irrigation protocol was repeated. Root canal fillings and permanent restorations were completed by applying the same techniques as in single session groups."
89474880|NCT05091554|Experimental|Multiple visit 30 minutes cryotherapy|"Root canals were filled with calcium hydroxide paste (Kalsin, Turkey), prepared according to the rate recommended by the manufacturer using a lentulo spiral (Dentsply Sirona, Switzerland) 2 mm from the working length. Sterile dry cotton pellets were placed in the pulp chamber, then the access cavity was sealed with a temporary filling material and occlusion was checked.~30 minutes intraoral cryotherapy was applied. Patients were given an appointment 7 days later for second visit. In this appointment, patients were anesthetized, the tooth was isolated with rubber dam, the temporary filling material was removed. Then calcium hydroxide paste was removed by using the last instrument used to prepare the root canals at the working length during the first appointment using sufficient irrigation.~The final irrigation protocol was repeated. Root canal fillings and permanent restorations were completed by applying the same techniques as in single session groups."
89474881|NCT03564301|Active Comparator|Metronidazole 250mg|Systemic antibiotic: Metronidazole 250mg , 2 capsules three times a day, for 7 days.
89474882|NCT03564301|Placebo Comparator|Placebo|Placebo: same shape, size and dosis as test
89474883|NCT03335397|Experimental|M-learning group|Participants receive mobile app (m-learning application) with interactive content (quiz).
89474884|NCT03335397|Other|Control group|Participants receive traditional learning process (books, journals available in the University library).
89474885|NCT03328143|Experimental|Treatment with Lavender|Lavender (Lavandula angustifolia) aromatherapy will be administered at regular intervals using a nasal inhaler.
89474886|NCT05079854|Active Comparator|INTRACAMERAL MOXIFLOXACIN|After the surgery, the antibiotic is intracameral administered, Moxifloxacin 0.5% 0.1mL.
89474887|NCT05079854|Active Comparator|TOPICAL MOXIFLOXACIN|After the surgery, the antibiotic is topical administered, Moxifloxacin 0.5% 0.1mL.
89474888|NCT03323931|Active Comparator|(1) standard therapy|Standard therapy based on Applied Behavioral Analysis (ABA) and Cognitive-Behavior-Therapy (CBT). It implies structured activities in which the therapist reinforces the adaptive behavior of the child.
88949764|NCT01939392|No Intervention|Optimal Medical Therapy|Subjects randomized to the control arm will be maintained on antihypertensive medications.
88949765|NCT01939418|Experimental|RAD001|gemcitabine 800mg/m2, D1 and D8 iv. every 3 weeks. cisplatin 30mg/m2, D1 and D8 iv. every 3 weeks. RAD001 5mg QD. po.
88949766|NCT01939431||Advanced|advanced stage podoconiosis
88949767|NCT01939431||Control|non-podoconiosis controls
88949768|NCT01939431||Early|early stage podoconiosis
88949769|NCT01939444|Experimental|naloxone intranasal|2.0 mg by the nasal route
88949770|NCT01939444|Active Comparator|naloxone intravenous|1.0 mg intravenous
88949771|NCT01939457|Experimental|misoprostol|400 mcg misoprostol sublingually
88949772|NCT01939470||Native American Women|Native American Women over the age of 50 yrs
88949773|NCT01939483|Experimental|Treatment (irinotecan hydrochloride)|"Patients receive irinotecan hydrochloride IV over 90 minutes on days 1, 8, 15, 22, and 29. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.~This arm also includes laboratory biomarker analysis as an intervention."
88949774|NCT01939509|Experimental|Atenolol-Bisoprolol|
88949775|NCT01939522|Experimental|Prevenar13® (13-valent pneumococcal conjugate vaccine)|Prevenar13 administered as a single dose, 0.5ml Intramuscular liquid form intervention at baseline.
88949776|NCT01939535||Women with endometriosis|Women with endometriosis with the intention of surgery - no intervention
88949777|NCT01939561|Active Comparator|Lamotrigine|Participants are taken oral tablets Lamotrigine once daily. The dosis is escalating every other weeks, from 25 mg - 50 mg - 150 mg- 300mg during the period of 8 weeks.
88949778|NCT01939561|Placebo Comparator|Placebo|Participants are taken oral tablets placebo once daily. The dosis is escalating every other weeks, from 25 mg - 50 mg - 150 mg- 300 mg during the period of 8 weeks.
88949779|NCT01939574|Experimental|Chemoradiation & Adjuvant Therapy:|"Concurrent chemoradiation Therapy:~Radiation therapy:2 Gy will be given daily 5 days per week for a total of 60 Gy over 6 weeks.~Temozolomide from day 1 of radiotherapy to the last day of radiation at a daily oral dose of 75 mg/m2 for a maximum of 49 days.~Bevacizumab will be administered intravenously on days 1 and 15 of each 28-day cycle,at the beginning of the 4th week of radiation. The dose will be 10 mg/kg.~Adjuvant Therapy:~Temozolomide once per day for 5 consecutive days of a cycle. The starting dose for the first cycle will be 150 mg/m2/day, with a single dose 200 mg/m2/day in subsequent cycles if no treatment-related adverse events> grade 2 are noted.~Bevacizumab will be administered intravenously on days 1 and 15 of each 28-day cycle. The dose will be 10 mg/kg."
88949780|NCT01939587|Experimental|PBF-680 5 mg|5 mg of PBF-680
88949781|NCT01939587|Experimental|PBF-680 20 mg|20 mg of PBF-680
88949782|NCT01939587|Placebo Comparator|Placebo|Placebo
88949783|NCT01939600|Experimental|All subjects|All subjects will undergo all 4 treatments, starch-free breakfast, Hi-Maize 260, Hylon VII and Amioca in randomized order
88949784|NCT01939613||Parkland group|Extensive burn patients are resuscitated with Parkland formula.In the first 24h of resuscitation,crystalloids were infused as the main fluid.
88949785|NCT01939613||TMMU group|Extensive burn patients are resuscitated with Third Military Medical University (TMMU) formula as a modified EVANS formula routinely used in China. In the first 24h of resuscitation, crystalloids and colloids were infused together.
88949786|NCT01939626|Experimental|Single-step medium|embryos will be cultured in a single-step medium for 5 days with no change
88949787|NCT01939626|Other|Control|Embryos cultured in two Culture media for 5 Days.
89474889|NCT03323931|Experimental|(2) robot--enhanced intervention|A treatment developed on the same principles as standard therapy, based on Applied Behavioral Analysis (ABA) and Cognitive-Behavior-Therapy (CBT). It implies structured activities in which the robotic agent reinforces the adaptive behaviors of the child, under the supervision of the therapist.
89474890|NCT05116436||Patient with idiopathic scoliosis|
89474891|NCT05116436||Healthy related patients|
89474892|NCT03335319|Experimental|Periodized Exercise Training Regime|The ET program will be carried out 3 times a week (60 minutes per session) on non-consecutive days for 48 weeks and supervised for both groups. Exercise prescription will be gradually progressed through various combinations of duration, frequency and/or intensity of training. Over the 1st-15th exercise sessions: MCT and anatomical resistance training; from the 16th-30th session: combined ET with HIIT and hypertrophy; from the 31st-45th exercise session, after the adjustments of the respectively time point assessments: MCT and maximal strength; from the 46th-60th exercise sessions: HIIT with hypertrophy; at the end of the 60th session until the end (6 months has passed): the same exercise prescription will repeat all over again at the same order.
89474893|NCT03335319|Active Comparator|Non Periodized Exercise Training Regime|participants will do a combined ET regime (aerobic and RT). Aerobic component: combine moderate to vigorous exercises 3 d.wk-1 on nonconsecutive days, for 20 min per session, involving major muscle groups using the available ergometers to perform continuous and rhythmic activities in nature. Resistance component: RT should be performed after the aerobic component of the exercise session to allow for adequate warm-up. Initial load should be trained initially with one set of 10-15 repetitions that can be lifted without straining (~30%-40% 1RM for the upper body; ~50%-60% 1 RM for the lower body). Each major muscle group should be trained initially with one set; multiple set regimens may be introduced later as tolerated. It will be performed 8-10 exercises of the major muscle groups.
89474894|NCT05116358|Active Comparator|Active|An active phototherapy device
89474895|NCT05116358|Sham Comparator|Sham (Placebo)|An inactive device
88949788|NCT01939639|Experimental|Oxytocin|24 IU Oxytocin, intranasal application 30 min prior to the experiment
88949789|NCT01939639|Placebo Comparator|Placebo|intranasal application, sodium chloride solution, 3 puffs per nostril
88949790|NCT01939652|Active Comparator|Drag: Crystalloids and Colloids|Drag: Crystalloids and Colloids Intraoperative 10 ml/kg/per hour, postoperative 70-100 ml/per hour
88949791|NCT01939652|Experimental|Standard fluid regime|Drag: Crystalloids and Colloids Intraoperative 15 ml/kg/per hour, postoperative 150-200 ml/per hour
88949792|NCT01939691|Experimental|Difluprednate|Difluprednate 0.05% ophthalmic emulsion 4 times a day until Week 4, then decrease according to protocol (if resolution of edema at 4 weeks, decrease to 1 drop per day until Week 6, then stop; if not resolved, continue at 4 times a day until 6 weeks and then decrease to 1 drop per day until Week 8 if resolved, then stop). If macular edema not resolved (or reoccurs) by Week 8, treat per best medical judgement.
88949793|NCT01939691|Experimental|Nepafenac plus Prednisolone acetate|Nepafenac 0.1% 3 times a day until resolution; prednisolone acetate 1% 4 times a day until Week 4, then decrease according to protocol (if resolution of edema at Week 4, decrease to 1 drop per day until Week 6, then stop; if not resolved, continue at 4 times a day until Week 6, then decrease to 1 drop per day until Week 8, then stop). If macular edema not resolved (or reoccurs) by Week 8, treat per best medical judgement.
88949794|NCT01939691|Experimental|Difluprednate plus Nepafenac|Nepafenac 0.1% 3 times a day until resolution; Difluprednate 0.05% ophthalmic emulsion 4 times a day until Week 4, then decrease according to protocol (if resolution of edema at 4 weeks, decrease to 1 drop per day until Week 6, then stop; if not resolved, continue at 4 times a day until 6 weeks and then decrease to 1 drop per day until Week 8 if resolved, then stop). If macular edema not resolved (or reoccurs) by Week 8, treat per best medical judgement.
88949795|NCT01939704|No Intervention|Pediatric Primary Care Control|Baseline survey with a social needs assessment, health care status, health care satisfaction and health care utilization assessment and two telephone-based follow up surveys at 3 and 6 months.
88949796|NCT01939704|No Intervention|Pediatric Urgent Care Control|Baseline survey with a social needs assessment, health care status, health care satisfaction and health care utilization assessment and two telephone-based follow up surveys at 3 and 6 months.
88949797|NCT01939704|Experimental|Pediatric Primary Care Intervention|Baseline survey that includes social needs assessment, health care status, health care satisfaction and health care utilization assessment; 30 minute on-site intervention, twice monthly follow-up phone calls for up to 3 months to help address social needs
89020004|NCT05878106|Experimental|Resistance training group|They will perform resistance training and placebo in the supplementation.
89474896|NCT05116280||TJA|"patients with primary osteoarthritis of the knee and hip who underwent elective primary total hip and total knee arthroplasty.~MACE and pulmonary embolism were recorded"
89474897|NCT03327987||31-90 days|Patient 31-90 days after transplantation receiving standard of care annual 2017-2018 influenza vaccine.
89474898|NCT03327987||91-180 days|91-180 days after transplantation receiving standard of care annual 2017-2018 influenza vaccine.
89474899|NCT03327987||181-365 days|181-365 days after transplantation receiving standard of care annual 2017-2018 influenza vaccine.
89474900|NCT05106452||Group ANI|
89474901|NCT05106452||Group Control|
89474902|NCT03335241|Experimental|Arm 1: Fludarabine and Pegylated liposomal doxorubicin|
89474903|NCT03335241|Active Comparator|Arm 2: Pegylated liposomal doxorubicin|
89474904|NCT03525860|Experimental|Acupuncture Treatment|"20 subjects will be treated with standard of care and acupuncture.~Will complete Symptom and Pain questionnaire (VAS) and a Was It Worth It (WIWI) questionnaire each day of study participation (3 days)."
89474905|NCT03525860|No Intervention|No Intervention|"20 subjects will be treated with standard of care only.~Will complete Symptom and Pain questionnaire (VAS) each day of study participation (3 days)."
89474906|NCT03327831|Experimental|Open Label Treatment Arm|This study has a single, open label treatment arm. Patients will have topical aminolevulinic acid applied to the actinic keratoses in the treatment area (face/scalp) and will spend 2 hours outdoors in the shade to activate the medication. The patient then follow up in clinic 3 months and 6 months after their treatment to have the number of actinic keratoses counted.
89474907|NCT03327753|Experimental|Motor control exercises|A primary goal of the motor control exercise program is to regain control and coordination of the spine and pelvis using principles of motor learning such as segmentation and simplification. The whole intervention is based on assessment of the individual patient's motor control impairments and the patient's individual treatment goals (set collaboratively with the therapist).
89474908|NCT03327753|Experimental|Graded activity|A primary goal of the graded activity program is to increase activity tolerance by performing individualized and submaximal exercises in addition to ignoring illness behaviors and reinforcing well behaviors. The intervention uses cognitive behavioral approaches to deal with fear of movement and self efficacy.
89474909|NCT05042180|Experimental|Virtual Reality Cognitive Behavioral Therapy (VRCBT)|The VR exposure is performed to induce alcohol craving and high-risk induced reactions during the therapy session, in order to trigger a lifelike response to alcohol, while the therapist is present and able to train the participant in applying CBT-based coping strategies to deal with the alcohol cravings.
89474910|NCT05042180|Active Comparator|Cognitive Behavioral Therapy (CBT)|CBT is made up of the following elements: i) recognition (ii) avoiding and (iii) overcoming drinking cravings in high-risk situations with the aim of preventing relapse.
89474911|NCT05099900||Pre-pregnancy|
89474912|NCT05099900||During pregnancy|
89474913|NCT05099900||Post-pregnancy|
89474914|NCT02578394|Active Comparator|Group A|Anakinra 100mg and Placebo Depo-Medrone
89474915|NCT02578394|Active Comparator|Group B|Depo-Medrone 120mg and Placebo (Anakinra)
89474916|NCT04493229|Experimental|Oxytocin|Oxytocin IM injection will be given per randomization prior to first outpatient physical therapy session
89474917|NCT04493229|Active Comparator|Placebo|Placebo IM injection will be given per randomization prior to first outpatient physical therapy session
89474918|NCT04984148||Trial cohort：Chemoradiotherapy followed by immunotherapy|"Contrast-enhanced thoracic CT: before, during and after radiotherapy~Radiomics~PD-L1 testing (Histological analysis of biopsy)~Molecular Markers (Histological analysis of biopsy)"
89474919|NCT03120273|Experimental|Dexlansoprazole Injection|15mg q12h,30mg q12h,15mg qd,30mg qd in dexlansoprazole treatment arm for 5 days
89474920|NCT03120273|Active Comparator|Lansoprazole Injection|30 mg q12h in lansoprazole treatment arm for 5 days.
89474921|NCT02122718|Experimental|Allopurinol|
89474922|NCT02122718|Placebo Comparator|Placebo|
89474923|NCT04244084|Experimental|MMH-407|Tablet for oral use. One tablet per intake. On day 1, five tablets are taken in the first 2 hours (one tablet every 30 min), followed by three more tablets regularly spaced during the rest of the day. From day 2 through 5, one tablet is administered three times daily. The drug is administered not during meals (i.e. between the meals or 15-30 minutes before meal). The tablet should be held in mouth until complete dissolution.
89474924|NCT04244084|Placebo Comparator|Placebo|According to the scheme of receiving MMN-407 until the end of the study.
89474925|NCT04979156||SOLTIVE™ Thulium Laser Fiber En Bloc Resection of Bladder Tumors|SOLTIVE™ Thulium Laser Fiber En Bloc Resection of Bladder Tumors
89474926|NCT04974476|Experimental|In-person exercise training group|participants in this group will receive in person exercise HIIT training 3 days a week for 12 weeks
89474927|NCT04974476|Experimental|Virtual exercise training group|participants in this group will receive virtual exercise HIIT training 3 days a week for 12 weeks
89474928|NCT04513652|Experimental|AG-920|Articaine Sterile Topical Ophthalmic Solution (AG-920) is a sterile, isotonic, non-preserved aqueous solution containing the active ingredient Articaine HCl 8%, Boric Acid, Mannitol, Sodium Acetate Trihydrate, Glacial Acetic Acid, and Edetate Disodium Dihydrate. The product formulation is adjusted to pH 4.5 to 5.0. Each subject randomized to AG-920 will receive a single dose of 2 drops 30 seconds apart from a single vial into study eye.
89474929|NCT04513652|Placebo Comparator|Placebo|Placebo ophthalmic solution is identical to the active product, with the exception of the active ingredient. Each subject randomized to placebo will receive a single dose of 2 drops 30 seconds apart from a single vial into study eye.
88949798|NCT01939704|Experimental|Pediatric Urgent Care Intervention|Baseline survey that includes social needs assessment, health care status, health care satisfaction and health care utilization assessment; 30 minute on-site intervention, twice monthly follow-up phone calls for up to 3 months to help address social needs
88949799|NCT01939717|Other|Dance group|Participants allocated to this group will continue with their usual care and participate in a set dancing class.
88949800|NCT01939717|No Intervention|Control group|Participants allocated to this group will act as a control group and continue to receive their usual care only.
88949801|NCT01939730|Experimental|Rituximab + GM-CSF|All patients receive one (1) course of therapy consisting of four (4) doses of rituximab, a single dose 375 mg/m^2 administered once weekly for 4 weeks along with GM-CSF 250 mcg subcutaneously three times weekly (tiw) for 8 weeks, starting 1 hour before the first dose of rituximab. In selected cases, the GM-CSF starts 1 week before, or 1 day after, the first rituximab dose.
88949802|NCT01939743|Experimental|diclofenac suppository plus lidocaine gel|Intervention Drug with local anaesthetic
88949803|NCT01939743|Other|Lidocaine gel only|Used as local aneaethetic as a part of institutional prostate biopsy protocol
88949804|NCT01939756|Experimental|Intravesical baobab oil|Intravesical instillation of 50 ml sterile Baobab natural oil. After draining of the bladder, the suspension is infused intravesically through a Foley catheter. The solution is retained in the bladder for 60 min, followed by emptying of the bladder and removal of the catheter.
89020005|NCT05878106|Experimental|Resistance training and creatine supplementation group|They will perform the same resistance training and will also receive creatine supplementation
89020006|NCT05877014|Experimental|Unipolar interlocking group|
89474930|NCT04234802|Active Comparator|HEAT intervention group|Workers in the intervention group will receive the HEAT training, and supervisors in the intervention group will receive the HEAT awareness application and training on how to use it.
89474931|NCT04234802|No Intervention|Comparison group|The comparison group will not be offered HEAT trainings or the HEAT awareness application. They will be offered an alternative training on another topic.
89474932|NCT02060162||HIV/HBV co-infected|150-200 patients in Zambia and 250-300 across all sites
89474933|NCT02060162||HIV mono-infected|700-750 patients in Zambia and 1600-1700 across all sites
89474934|NCT00706797|Active Comparator|Usual care|Utilized Disease-Modifying Antirheumatic Drugs (DMARDs) from a list of the 6 most commonly prescribed in the participating countries (Methotrexate, sulfasalazine, hydroxychloroquine, leflunomide, cyclosporine A and gold).
89474935|NCT00706797|Active Comparator|ETN + MTX|Etanercept (ETN) 50 milligrams (mg) sub-cutaneous (SC) injection once weekly (pre-filled syringe) plus continuation of current dose of Methotrexate (MTX) either oral (PO), SC, or intramuscular (IM).
89474936|NCT03323697|Experimental|Herbal|SZ-05 (2.5 gr; 3 capsules twice a day)
89474937|NCT03323697|Active Comparator|Selective serotonin reuptake inhibitor|Escitalopram (10 mg capsule plus 5 placebo capsules)
89474938|NCT00706641|Experimental|Experimental: Neoadjuvant Dasatinib + Radical Cystectomy|Dasatinib 100 mg PO qd x 4 weeks followed by radical cystectomy 8-24 hours post last administered dasatinib dose
89474939|NCT05465499||Patient|Patient baseline data were taken from the examination at the anesthesiology outpatient clinic. (N=41)
89474940|NCT05465499||Doctor|Consists of specialist and resident anesthesiology, orthopaedic surgery and traumatology, obstetrics and gynaecology, urology. (N=110)
89474941|NCT05465499||Healthcare worker|Consists of nutritionists, pharmacists, surgical nurses, anesthesiologists, and recovery room nurses.(N=56)
89474942|NCT02491203|No Intervention|Usual care|All study participants in the control group will receive a 4-week written home exercise program (e.g. GRASP) , i.e. the usual care discharge home program.
88949805|NCT01939782|Experimental|Type 2 diabetic patients (T2D)|"In type 2 diabetic patients (T2D), the investigators will evaluate the metabolic clock gene expression in PBC and serum glucose, insulin, triglycerides, free fatty acids (FFA), cortisol intact GLP-1, triglycerides ,cortisol, plasma free fatty acids (FFA l and DPP4 plasma activity in two different occasions:~No Breakfast (NoB): fasting until lunch at 12:00~Yes Breakfast (YesB): eating breakfast at 8:30 and lunch at 12:00 In both occasions the blood samples for glucose and insulin, cortisol and intact GLP-1 will be taken after overnight fast at 8:30 and thenat 8:30, 9:00, 10:30, 12:00, 12:30, 14:00 and 15:30. The samples for clock genes and for DPP4 plasma activity will be taken at 8:30, 12:00 (before lunch) and at 15:30 (3 1/2 h after lunch)."
88949806|NCT01939782|Active Comparator|Healthy No Diabetics|"In healthy No Diabetics,: the investigators will evaluate the metabolic clock gene expression in PBC and serum glucose, insulin, triglycerides, free fatty acids (FFA), cortisol intact GLP-1, triglycerides ,cortisol, plasma free fatty acids (FFA l and DPP4 plasma activity in two different occasions:~No Breakfast (NoB): fasting until lunch at 12:00~Yes Breakfast (YesB): eating breakfast at 8:30 and lunch at 12:00 In both occasions the blood samples for glucose and insulin, cortisol and intact GLP-1 will be taken after overnight fast at 8:30 and thenat 8:30, 9:00, 10:30, 12:00, 12:30, 14:00 and 15:30. The samples for clock genes and for DPP4 plasma activity will be taken at 8:30, 12:00 (before lunch) and at 15:30 (3 1/2 h after lunch)."
88949807|NCT01939795|No Intervention|Healthy People|Control group
88949808|NCT01939795|Experimental|Untrained CRT|Untrained CRT patients
88949809|NCT01939795|Experimental|Exercise trained + CRT|Exercise-trained CRT patients
88949810|NCT01939808|Other|Wrist splinted in extended position|We propose to carry out a study to compare the outcomes (grip strength and range of movement) of flexor tendon repair in two groups of patients: one with wrists splinted in a neutral position and the other splinted in an extended position during their postoperative rehabilitation
88949811|NCT01939808|Other|Wrist Splinted in the Neutral postion|We propose to carry out a study to compare the outcomes (grip strength and range of movement) of flexor tendon repair in two groups of patients: one with wrists splinted in a neutral position and the other splinted in an extended position during their postoperative rehabilitation
88949812|NCT01939821|Experimental|Educational and counselling program|In addition to educational meeting and printed educational material the investigators will include the use of local opinion leaders and educational outreach
88949813|NCT01939821|Active Comparator|Educational program|The investigators want to organize the educational meetings as an interactive workshop that target knowledge, attitudes, and skills at the individual healthcare professional/peer group level.
88949814|NCT01939821|No Intervention|Control group|The control group will not receive any educational program. It represents the present real life in nursing homes.
88949815|NCT01939834|Experimental|AAA Control|"Subjects will use their home insulin pump along with a continuous glucose monitor (CGM) receiver. A CGM will be worn for 7 days prior to the study admission. Four fingersticks completed each day and carbohydrates will be recorded in bolus calculator of their insulin pump prior to each meal.~Subjects will be asked to provide the study team their insulin pump data on Day 2 or 3 to ensure accuracy of data collection. Subjects will be asked to submit insulin pump, glucometer, and CGM data 1-2 days prior to their admission and again the evening prior to the study admission at a Research House.~During the Experimental Admission, the AAA system will be tested using the DiAs platform. Subjects will participate in 45 minutes of exercise during the 40 hour admission (n=36). A subset (n=5-7) will continue with 5 nights of consecutive closed loop control (23:00-07:00)."
89020007|NCT05877014|Active Comparator|Bipolar interlocking group|
89020008|NCT05873816|Experimental|ProtEmbo - Cerebral Embolic Protection|Subjects will undergo TAVR following placement of the ProtEmbo cerebral embolic protection device.
89474943|NCT02491203|Experimental|Telerehabilitation system|Participants in the experimental group will receive four weeks written home exercise program provided by a clinician, i.e. usual care discharge home program plus virtual reality (VR) and telerehabilitation system. The intensity and choice of game for the home program will be determined by the therapist based on the patient's abilities, interests, motivation and fatigue. The patient's performance for the VR home program will be monitored asynchronously and the program adapted to ensure it remains at an appropriate level for the patient.
89474944|NCT03335085|Active Comparator|Oxytocin|Single dose of intranasally administered 24 IU of Oxytocin (Syntocinon-Spray Novartis, Switzerland)
89474945|NCT03335085|Placebo Comparator|Placebo|All ingredients except for oxytocin.
89474946|NCT03327363|Experimental|ICT base monitoring group|In the ICT-based centralized monitoring group, both subjects and medical staff receive feedback regarding decreased lung function and exacerbation in asthma symptoms in the form of text messages
89474947|NCT03327363|Placebo Comparator|control group|Use standard asthma treatment
89474948|NCT03323619||GA|No intervention. General anesthesia is decided by the physicien according to his usual practice
89474949|NCT03323619||LASed|No intervention. Local anesthesia with sedation is decided by the physicien according to his usual practice
89474950|NCT03323541||Group of patients treated with Zarxio|All consecutive patients, treated for lymphoma or myeloma, which underwent autologous stem cell transplantation in the University Hospital of Brest. All these patients were treated with biosimilars of Filgrastim: Zarzio®.
89474951|NCT03335007|Experimental|Aceclofenac|Aceclofenac 100 mg tablet
89474952|NCT03335007|Placebo Comparator|Placebo|Placebo
89474953|NCT03327285|Experimental|C-CAR011|The amount of cells received：1.0-5.0×10^6 CAR+T cells/kg
89474954|NCT01362530|Experimental|Aprepitant Regimen|"Cycle 1:~Participants 12 to 17 years of age, Day 1: aprepitant 125 mg capsule orally (PO) + ondansetron, Days 2 to 3: aprepitant 80 mg capsule PO. Participants 6 months to <12 years of age, Day 1: aprepitant powder for suspension (PFS), 3.0 mg/kg (up to 125 mg) + ondansetron, Days 2 to 3: aprepitant PFS, 2.0 mg/kg (up to 80 mg).~Optional Cycles 2-6:~Open-label aprepitant administered in the same manner as in Cycle 1."
89474955|NCT01362530|Placebo Comparator|Control Regimen|Cycle 1: Participants 12 to 17 years of age, Day 1: matching placebo for aprepitant 125 mg capsule oral (PO) + ondansetron Days 2 to 3: matching placebo for aprepitant 80 mg capsule PO. Participants 6 months to <12 years of age, Day 1: matching placebo PFS: 3.0 mg/kg (up to 125 mg) + ondansetron, Days 2 to 3: matching placebo PFS: 2.0 mg/kg (up to 80 mg). Optional Cycles 2-6: Open-label aprepitant administered in the same manner as in Cycle 1.
89474956|NCT02492685|Experimental|Contrast enhanced EUS group|Contrast enhanced EUS with quantitative analysis
89474957|NCT03327207||Study group|Children who receive Growth hormone treatment. Non Interventional
89474958|NCT03327207||Control group|Healthy children . Non Interventional
89474959|NCT04494399|Active Comparator|Treatment group|5-day course of daily subcutaneous injection of interferon β-1b 2mL (16 million IU) consecutively and oral ribavirin 400mg twice daily plus standard care
89474960|NCT04494399|No Intervention|Control group|Standard care alone
89474961|NCT01758614|Experimental|bypass group|all the participants in this group will be performed EC-IC bypass surgery
89474962|NCT01758614|Active Comparator|medical group|all the participants in this group will be given medical therapy including aspirin 100mg per day or clopidogrel 75mg per day
89474963|NCT03334929|Experimental|Virtual Reality intervention|Participants will be wearing Virtual Reality headset called Oculus gear equipped with Samsung galaxy S7 during the trigger point injections. The VR app chosen is called Relax VR - Rest, Relaxation & Meditation, which will provide a calm beach scene with waves and soothing musics.
89474964|NCT03334929|No Intervention|control|Participants in this group will receive trigger point injections without any intervention. The trigger point injections will be performed in daily manner.
89474965|NCT03334773|Experimental|Intervention group|Nutrition education (group inclusive of education materials)
89474966|NCT03334773|No Intervention|Control group|Only receives education materials
89474967|NCT05120726|Experimental|Treatment Arm|Patient's pyoderma gangrenosum wounds are treated surgically with EpiFix (dehydrated human amnion/chorion membrane). In another surgery about one week later, we will be covering the treated wounds with split-thickness skin grafts. During each surgery, we will be collecting wound samples for genetic analysis. Routine post-surgery clinic visits will be used to monitor wound healing over a 6-month period.
89474968|NCT02490657|Experimental|Iloprost group|
89474969|NCT02490657|Placebo Comparator|normal saline|
89474970|NCT05120492|Experimental|Surgical weight loss|sleeve gastrectomy + dietary and lifestyle counseling prior to total knee replacement
88949816|NCT01939834|Active Comparator|CGM + insulin pump at home|"The experimental and control admissions (40hr admissions) are exactly the same except for the study admission. During the Control Admission, subjects will use their home insulin pump along with a continuous glucose monitor receiver without running any specialized mathematical equations.~The active comparator for subjects participating in 5 consecutive nights of closed loop control will be the sensor-augmented pump therapy at home."
88949817|NCT01939847|Experimental|Molecular prolfiling in tissue|Participant's tumor will be analyzed by Foundation Medicine on their FoundationOne platform - a targeted whole exome sequencing of 182 cancer related genes (3,230 exons) as well as 37 introns from 14 genes commonly rearranged or altered in cancer via next-generation sequencing technology to provide a molecular profile for a possible treatment suggestion
88949818|NCT01939847|No Intervention|Molecular prolfiling in blood|Participant's blood sample will be analyzed by Foundation Medicine on their FoundationOne platform - a targeted whole exome sequencing of 182 cancer related genes (3,230 exons) as well as 37 introns from 14 genes commonly rearranged or altered in cancer via next-generation sequencing technology; however, this is just being done to see if it is possible to generate similar results in blood samples. We do not yet know if blood sample results may be used for treatment decision (this will be tested in a future study) and results will not be given to participants; therefore, no treatment suggestion will be given.
88949819|NCT01939860|No Intervention|Usual pharmacy care|Participants will not receive any structured written education on hypertension and its treatment
88949820|NCT01939860|Experimental|usual pharmacy care plus structured information|Participants will be provided with validated verbal and written information on hypertension and its treatment, including information about class (es) of anti-hypertensive medication(s) used by each patient, and their common side-effects. The written material will be based on validated patient information leaflets from the British Heart Foundation and the Blood Pressure Association.
88949821|NCT01939873|Experimental|KRISTELLER|Uterine fundal pressure
88949822|NCT01939873|No Intervention|Control group|
88949823|NCT01939886|Experimental|Artemether- Lumefantrine|Treatment with artemether-lumefantrine (AL; Coartem; Novartis Pharma), administered as half a tablet (20 mg of artemether and 120 mg of lumefantrine) per 5 kg of body weight in a 6-dose regimen (at enrolment and 8, 20, 32, 44, and 56 h [+/-90 min] after the initiation of treatment). AL is currently the first line treatment in Tanzania Other Name: Coartem;
89474971|NCT05120492|No Intervention|Standard of Care|dietary and lifestyle counseling prior to total knee replacement
89474972|NCT03326973||online or telephone survey|This is a cross-sectional survey. Our main method of communication with patients will be email. Participants will complete a single online or telephone survey at a minimum of 12 months post initial treatment of checkpoint inhibitors and remain on maintenance therapy.
89474973|NCT03334383|Experimental|Sponge group|Patients offered surgery with the retractor sponge
89474974|NCT03334383|No Intervention|Control group|Patients receiving standard care: surgery in Trendelenburg position
89474975|NCT03326817|Active Comparator|Control Group|This group will receive standard care.
89474976|NCT03326817|Experimental|Soft Robotic Glove Group|This group will receive standard care and soft robotic therapy (continuous passive motion device developed by National University of Singapore).
89474977|NCT05120414|Active Comparator|Control|patients in control group did balance exercises for period of 4 weeks (10 repetitions in each set, 3 sets per session, 1 session daily, 3 days weekly.) The exercises included standing with feet together, Standing in Tandem position, Standing eye open to eye closed, multidirectional functional reach during standing, March in place and walk sideways.
89474978|NCT05120414|Experimental|Experimental|Experimental group received ankle strategy exercises in addition to balance exercises for a period of 4 weeks (10 repetitions in each set, 3 sets per session, 1 session daily, 3 days weekly). Ankle strategy exercises included raising and lowering heels and forefeet, heel to toe walking, stepping up and down and right and left and diagonal inclination of body during standing.
89474979|NCT04494087|Active Comparator|Hernia video|The video of the intervention group will provide a short (< 5 min) summary explaining the basic principles of endoscopic extraperitoneal hernia repair, its possible complications and the postoperative course. After carefully watching the video, participants should be able to correctly answer to a multiple-choice test consisting of 12 questions related to the aforementioned topics.
89474980|NCT04494087|Placebo Comparator|Mock video|"This video is a general documentation of the typical day of surgery in the day clinic. The information is essentially limited to the pictorial representation of the individual wards which the patient will pass through during the operation (arrival at the clinic, admission, transport to the operating theatre, recovery room, discharge).~The video explicitly does not transport any information that could be helpful for answering the quiz questions or for medical understanding of the operation itself."
89474981|NCT04494087|Sham Comparator|Control group|The link of the third group leads to a digital version of the information sheet, which has already been discussed with all patients during the informed consent discussion. The digital version of the informed consent form allows the patient to read the information again. The third group thus corresponds to the standard of care.
89474982|NCT04442841|Experimental|Single arm (vaccine)|No further description
89474983|NCT03323229|No Intervention|Usual care (control group)|Patient receives care as usual.
89474984|NCT03323229|Experimental|Enhanced communications & ultrasound|The paramedic will record a brief video summary of the patient's condition, then remotely supported point of care ultrasound scans will be performed, and both file types sent to the hospital for review and feedback from the consultant.
89474985|NCT03323073|Active Comparator|Bipolar disorder type I or II|a single resting state fMR for patients with bipolar disorder type I or II with acute depressive state
89474986|NCT03323073|Active Comparator|Unipolar disorder|a single resting state fMR for patients with monopolar disorder with acute depressive state
89474987|NCT03323073|Other|Healthy volunteers|a single resting state fMRI for subjects without psychiatric disorders assessed by the SCID
89474988|NCT03334227|Experimental|High-Flow nasal cannula (HFNC)|"Treatment with HFNC will be adjusted for SpO2 >92%, even with FiO2 of 0.21, if needed.~The rationale for this HFNC dosage is that minute ventilation can be already reduced with 30 L/min, but functional residual capacity and oxygenation maximally improve at higher flow. On the contrary, flow >50 L/min is uncomfortable for many patients.~In the case of clinical intolerance, flow will be reduced to 40, 30 or 20 L/min. Yet it is not tolerated, HFNC will be stopped and patients will receive conventional oxygen if required, but will be evaluated as in the HFNC group by intention to treat."
89474989|NCT03334227|No Intervention|Conventional therapy|"Patients assigned to the conventional treatment will receive the standard care given at hospital which consists of adding oxygen on nasal prongs or Venturi mask only if hypoxemia is suggested by SpO2 < 92% by pulse oximetry.~Target for oxygenation in both arms is SpO2 between 92% and 95%. SpO2 >95% without oxygen supply is acceptable. On the contrary, SpO2 <92% may be acceptable when needed for medical reasons, mainly chronic hypercapnic patients."
89474990|NCT02491125|Placebo Comparator|Placebo|12 weeks placebo maltodextrin 15g/day ( 5 g in beverage, to be consumed three times a day)
89474991|NCT02491125|Experimental|soluble wheat bran fibre|12 weeks soluble wheat bran fibre 15g/day (5 g in beverage, to be consumed three times a day)
89474992|NCT02492607|Active Comparator|Standard treatment|"Standard treatment according to local policy. This can be either wide local excision only, wide local excision and radiotherapy, or mastectomy. Hormonal therapy is also allowed.~Follow-up:by annual digital mammography for a period of 5 years and a digital mammography at 7 and 10 years."
89474993|NCT02492607|Experimental|Active surveillance|Active surveillance : monitoring by annual digital mammography for a period of 5 years and a digital mammography at 7 and 10 years.
89474994|NCT04326686|Other|N-of-1 study|For 24 weeks, each participant will measure their blood pressure and respond to questionnaires daily, and visit the institute to provide a blood sample every 4 weeks. The study is split into three 8-week phases, the first of which will start when each participant is enrolled. For the first 8-week observation phase (A1) the participant is instructed to continue with their usual diet and exercise habits. For the second 8-week intervention phase (B), the participant will be provided with wholegrains and nuts and recommended to substitute these in place of refined grains and other snacks, respectively. They will also receive dietary advice for following the Dietary Approaches to Stop Hypertension (DASH) diet. For the final 8 week follow-up period (A2), provision of wholegrains and nuts will cease but the participant will continue with measurements at the same frequency as previously.
88949824|NCT01939886|Active Comparator|Drug: Mefloquine-Artesunate, an alternative ACT|Treatment with the paediatric fixed dose combination Mefloquine-Artesunate (MQ-AS; Artequin; Mepha, Aesch, Basel, Switzerland, artesunate (50 mg/day) and mefloquine (125 mg/day) fixed dose formulation (stick pack) once daily for 3 consecutive days, given in three daily doses. The weight range of enrolled children is chosen to be recommended for this fixed dose combination. MQ-AS is available in Kenya as Artequin and has been extensively tested in uncomplicated malaria in children.
89206217|NCT00831012|Experimental|Group 2|"Group 2A will consist of healthy participants who will receive an immunization of 10^5 PFU of rDEN3delta30/31-7164 vaccine or placebo. Group 2A participants will be enrolled if less that 90% of Group 1 participants seroconvert to DEN3 by Study Day 42.~Group 2B will consist of healthy participants who will receive an immunization of 10^1 PFU of rDEN3delta30/31-7164 vaccine or placebo. Group 2B participants will be enrolled if more that 90% of Group 1 participants seroconvert to DEN3 by Study Day 42."
89474995|NCT04501484|Experimental|Treatment Group|Participants will undergo a thalamotomy contralateral to their previous treatment with MRgFUS using ExAblate Neuro 4000 device (InSightec Ltd, Tirat Carmel, Israel).
88949825|NCT01939912|Experimental|Stimulation of carotid body chemoreceptors|Adenosine boluses will be administered through an intravascular catheter used to administer the contrast agent during the carotid artery arteriography.
89202667|NCT00792480|No Intervention|Routine care group|"The routine care group took part in an initial physical exam and history, routine labs, and routine visits per American College of Obstetrics & Gynecology (ACOG) standards. The only counseling on diet and exercise during pregnancy was that included in our standard prenatal booklet What to do When You're Having a Baby by Gloria Mayer (Institute for Health Advancement, 2003, La Habra, CA). At each routine obstetric appointment, the participant's weight was measured recorded in the medical chart. The healthcare provider did not counsel the participant regarding any changes in diet or lifestyle."
89202668|NCT00681824|Experimental|FS VH S/D 500 s-apr|Application of FS VH S/D 500 s-apr on top of suture
89474996|NCT04323566|Experimental|Treatment-first arm|Participants receive i.v. infusions with 500 mg Rituximab at 0 and 4 months, followed by placebo infusions (NaCl) at 8 and at 12 months, Pre-treatment prior to all four infusions consists of injection Solu-Medrol 125 mg i.v., tablet Paracetamol 1000 mg p.o. and tablet Cetirizin 10 mg p.o.
89474997|NCT04323566|Experimental|Placebo-first arm|Participants receive placebo (NaCl) i.v. infusions at 0 and 4 months, followed by 500-mg-Rituximab infusions at 8 and 12 months. Pre-treatment prior to all four infusions consists of injection Solu-Medrol 125 mg i.v., tablet Paracetamol 1000 mg p.o. and tablet Cetirizin 10 mg p.o.
89474998|NCT02491047|Experimental|BonyPid-1000|Implantation of BonyPid-1000 medical device, constructed of bone filler coated with controlled release antibiotic formulation, concomitantly with standard of care treatment (SOC)
89474999|NCT02491047|Other|Study control arm|Standard of care treatment (SOC) only
89475000|NCT03326739|Active Comparator|Ultrasound Guided A-Line Placement|Patients in this group will have ultrasound guided arterial line placement.
89475001|NCT03326739|Active Comparator|Landmark Guided A-line Placement|Patients in this group will have landmark guided arterial line placement.
89475002|NCT04864184|Experimental|Breathing intervention|Participants will complete 2-minute breathing exercises following the Breathing App every 15 minutes during a 4-hour postprandial period following high-fat meal consumption.
89475003|NCT03334071|Active Comparator|Exercise Intervention|Patients in the intervention arm will participate in a supervised in-hospital, exercise training program on a cycle ergometer before and during chemotherapy. At week 5-6 there will be a transition period of in-hospital to home-based exercise training (at this point we will perform the exercises that they will perform at home in the in-hospital environment to ensure that the patient understands the home-based exercise training programme) and then week 7-12 will be home-based exercise training only with telephone support.
89475004|NCT03334071|No Intervention|Negative Control|Patients in the control arm will not undergo an exercise training program.
89475005|NCT03334071|No Intervention|Observational|Patients who do not enrol in RCT will be enrolled in the observational arm
89475006|NCT04828460||Kidney transplant recipients who receive Covid-19 vaccine|
89475007|NCT03109119|Active Comparator|Group S|These patients will be induced and maintained with sevoflurane during anaesthesia.
89475008|NCT03109119|Sham Comparator|Group P|These patients will be induced and maintained with propofol during anaesthesia.
88949826|NCT01939925|Experimental|New plain language summary format|New plain language summary format of a Cochrane systematic review
88949827|NCT01939925|Active Comparator|Current plain language summary format|Plain Language Summary format for the public currently in use in Cochrane systematic reviews
88949828|NCT01939951|Active Comparator|Activation Energy Serum|Activation Energy Serum 7 or 21 drops twice daily for 4 weeks
89202669|NCT00681824|Active Comparator|Standard of Care (Control group)|The treatment of the control group consisted of Standard of Care (SoC) which was defined as the closure of a dura defect by suturing in a patch of autologous fascia, pericranium or suturable collagen based dura substitute.
89202670|NCT00797472|Active Comparator|Arm I: R-mabHD|Anti-hodgkin disease agent
89475009|NCT04826666||Groups/Cohorts|The Principal Investigator propose to conduct a retrospective observational cohort study of all consecutive adult patients who underwent a liver transplantation between July 2008 and January 2021 at the Centre hospitalier de l'Université de Montréal (CHUM).
89475010|NCT03333993|Experimental|Intervention Group|Patients in this group will be submitted to 10 sessions of Mat Pilates exercises, performed twice a week, lasting 60 minutes, for a period of 5 weeks (from the beginning to the end of radiotherapy). The program will consist of group sessions of up to 4 patients, supervised by a specialized physiotherapist. In addition, they will be guided to follow with the home exercises, according to the institutional routine.
89475011|NCT03333993|Active Comparator|Control Group|Patients assigned to this group will not participate in the Mat Pilates exercises and will be instructed to maintain the home exercises for upper limbs, guided by physiotherapists in the postoperative period, according to the institutional routine.
89475012|NCT05119946|Experimental|Suicide prevention video|In this group, in addition to receiving the standard of care for their suicidality, the participants will also view a suicide prevention video.
89475013|NCT05119946|Active Comparator|Standard suicide treatment|In this group, participants will only receive the standard of care for their suicidality, which can include medications and/or therapy. The care will be determine by their attending physician.
88949829|NCT01939951|Placebo Comparator|Placebo|sugar pill
88949830|NCT01939964|Active Comparator|Activation Mist|Liquid mist preparation to be sprayed topically on wrinkle areas
89202671|NCT00797472|Active Comparator|Arm II: ABVD|
89206218|NCT01068145|Experimental|Very low dose SCH 527123|
89206219|NCT01068145|Experimental|Low dose SCH 527123|
88949831|NCT01939964|Placebo Comparator|Placebo|sugar pill
88949832|NCT01939990|Active Comparator|Nebivolol|Group A will be given Nebivolol 5 to 10mg per day
88949833|NCT01939990|Placebo Comparator|Placebo|Group B will be given Placebo.
88949834|NCT01940003|No Intervention|Control|Usual care of service Institute of Medicine Professor Fernando Figueira(IMIP) prenatal
89206220|NCT01068145|Experimental|Medium dose SCH 527123|
89475014|NCT03326661|Active Comparator|Needle aspiration|Patients treated with aspiration will receive standard antibiotic treatment according to clinical guidelines: Penicillin and metronidazole or Clindamycin alone in case of penicillin allergy. These patients will be treated in the outpatient clinic and will be examined again the day after inclusion. Aspiration will be done if necessary. At this first control visit the clinician will schedule the next visit based on findings.
89475015|NCT03326661|Active Comparator|Tonsillectomy a chaud|Patients treated with tonsillectomy a chaud are admitted for intra-venous treatment with penicillin and metronidazole until surgery. Antibiotic treatment is discontinued after surgery and the patient may be discharged from the hospital the day after surgery.
89475016|NCT03322839|Experimental|Multifaceted implementation strategies|The school-management will participate in a one-day training. In addition each intervention school will form an implementation team that is responsible for the implementation of the guideline within their school. The implementation teams will participate in 4-5 workshops in order to support the implementation process.
89475017|NCT03322839|Active Comparator|Single implementation strategy|The control-schools will only receive training to the school-management.
89475018|NCT04363814|Experimental|Bactek-R|Subject included in the experimental group will receive Bactek- R.The dose consists on 3 spray puff every 6 hours for 2 weeks.
89475019|NCT04363814|No Intervention|Control|Subject included in the control group will receive standard therapy for COVID-19.
89475020|NCT05119634|Experimental|case group|patients will receive whole body vibration training 3 days in a week for 8 weeks
89475021|NCT05119634|Active Comparator|control group|participants will receive a home based exercise program
89475022|NCT03322761|Experimental|Systematic exercise training|Two weekly supervised aerobic exercise trainings for 48 weeks. The training will be planned by exercise physiologists, and performed in a progressive manner.
89475023|NCT03322761|Active Comparator|Educational program|Educational program on physical activity and health, consisting of four educational sessions in the intervention period.
89475024|NCT03322761|No Intervention|Standard treatment alone|Data from The Danish MS Registry will serve as control-data for standard treatment alone.
89475025|NCT03333759|Experimental|Laser Treatment|"Patients will receive one laser treatment (week 0) with the Erbium YAG laser at a 2940nm wavelength (Alma - Harmony XL Laser) and parameters corresponding with their acne scar severity. They will then return to the clinic 1, 4 and 8 weeks (7, 30, and 56 days + 7 days) after the treatment for their scars to be evaluated under optical coherence tomography.~Laser parameters are as follows:~iPixelEr 2940nm Erbium:YAG Module: mild scars: 7 by 7 (7X7) mm tip, energy 1400-1600 millijoules/P (mJ), pulse energy 5 Hz, 2-6 stacks, pulse mode L, 2-3 passes, 10% overlap moderate scars: 7X7 mm tip, energy 1600-1800 mJ/P, pulse energy 5 Hz, 2-6 stacks, pulse mode L, 2-3 passes, 10% overlap severe scars: 7X7 mm tip, 1800-2000 mJ/P, pulse energy 5 Hz, 2-6 stacks, pulse mode L, 2-3 passes, 10% overlap"
89475026|NCT02703116|Experimental|Alcohol Use BI|Those who are randomized to the intervention will complete eSBI, an electronic brief intervention for substance use, which is comprised of 11 topical areas, each with a single webpage, in a motivational interviewing (MI) format. MI is a client-centered behavioral change approach.
89475027|NCT02703116|Active Comparator|Nutrition Intervention|Those randomized to the control will complete the attention control modules, a non-active brief time-matched attention control intervention of equal length (i.e., encouraging nutrition).
89475028|NCT02490579||Facebook Survey Group|"During June, 2015, approximately 1200 women will be recruited through Facebook advertisements targeted at English-speaking women age 18-50 years living in the United States. Advertisements will contain 3 key features: an image, a caption, and ad copy followed by a link to the survey website. Individuals who click on the study link in the advertisement will be redirected to the study's Qualtrics web page where they will take a 15 web-page, multiple choice survey developed by the research team. The survey covers these domains: reaction to video, understanding of core message, self-efficacy around lifestyle behaviors, attitudes, beliefs and intentions regarding vaccination during pregnancy, key health information sources during pregnancy, and demographics."
89475029|NCT02490579||Clinical Survey Group|During June-August, 2015, approximately 500 women will be recruited at routine obstetric visits to the University of Michigan's outpatient clinics. Women who check in for an Ob appointment will be offered the opportunity to participate in an anonymous online survey. Individuals who express interest in participating will be provided with a laptop and headphones and directed to the survey Qualtrics site where they will take a 15 web-page, multiple choice survey developed by the research team. The survey covers these domains: reaction to video, understanding of core message, self-efficacy around lifestyle behaviors, attitudes, beliefs and intentions regarding vaccination during pregnancy, key health information sources during pregnancy, and demographics.
88949835|NCT01940003|Experimental|Aquatic exercise|Pool-based exercise classes will be completed in groups of 4 to 6 participants under the instruction of a physiotherapist. The exercise program will be conducted three times per week and each session lasting 45 minute. This will be conducted since GDM diagnosis (26-28th gestational week) to the end of the third trimester (38-39th gestational week). Thus, an average of 30 training sessions will be planned for each pregnant woman.
89475030|NCT02490579||Social Network Group|Once a pregnant participant completes the survey, she will be asked to provide her email address. If she is willing to do so, Qualtrics will automatically send her an email containing a weblink to the survey for her social network. She can then provide this link to 1 or 2 social network members that she feels influence her health behaviors during pregnancy. These members are asked similar questions about their response to the video, as well as some additional questions about how they advise their pregnant person about different health topics. It is necessary to provide a unique weblink to her, so that the survey responses from the pregnant woman and her unique social network members can be linked.
89475031|NCT03326505|Active Comparator|Injection of Umbilical cord derived UC- MSCs|Allogenic Umbilical Cord derived stem cells injected intrathecally to enrolled MS patients
89475032|NCT03326505|Active Comparator|injection of UC- MSCs and SPT|Allogenic Umbilical Cord derived stem cells injected intrathecally to enrolled MS patients along with a supervised physical therapy program
89475033|NCT03326505|Active Comparator|Supervised Physical Therapy (SPT)|Supervised physical therapy program without stem cells
89475034|NCT02654054|Placebo Comparator|Placebo|Placebo for both elagolix twice daily (BID) and norethindrone acetate (E2/NETA) once daily (QD)
89475035|NCT02654054|Experimental|Elagolix|Elagolix 300 mg BID and placebo for E2/NETA (estradiol 1.0 mg/norethindrone acetate 0.5 mg) QD
89475036|NCT02654054|Experimental|Elagolix + E2/NETA|Elagolix 300 mg BID and E2/NETA (estradiol 1.0 mg/norethindrone acetate 0.5 mg) QD
89475037|NCT03326427|Experimental|Skill Training Group|A twelve sessions protocol of the Skill Training Group of the Dialectical Behavior Therapy.
89475038|NCT03326427|Active Comparator|Treatment as Usual|Patients will have one psychiatric session to control their medication adherence.
89475039|NCT03186404|Placebo Comparator|Placebos|Placebos
89475040|NCT03186404|Experimental|Statin|Atorvastatin 40mg
89475041|NCT02492373|Active Comparator|laser+steroid 2 days before and after laser|Before lentigines' treatment with Qs Nd:YAG 532 nm laser, topical 0.05% Clobetasol propionate ointment was applied 2 days on the lesion. Then applied 2 days after the treatment.
89475042|NCT02492373|Other|laser+steroid 2 days after laser|Controlled side. Applied topical 0.05% Clobetasol propionate ointment only 2 days after the laser treatment
89202672|NCT00991042|Other|cytokine levels|Serum levels of pro-inflammatory cytokines were measured using the Enzyme Linked Immuno Sorbent Assay (ELISA) technique in 23 patients with pain due to herniated disk disease (G1) as well as in 10 control healthy subject
89475043|NCT05119322|Experimental|GlutenDetect home urine test|The GlutenDetect home urine test group will receive home use tests for GIP detection in urine to self-monitor the GFD. Tests will be used at their discretion, but using at least 8 tests during the study period (1/week), so that they may receive immediate qualitative feedback regarding the presence of biomarkers of gluten exposure in their urine and they will have to register the results obtained. Additionally, patients will collect a urine and a stool sample every 4 weeks to evaluate their adherence to the GFD in the laboratory.
89475044|NCT05119322|No Intervention|Control group|The control group will not receive any home urine tests but will collect a urine and a stool sample every 4 weeks with the purpose of evaluating their adherence to the GFD in the laboratory.
89475045|NCT03326349|Experimental|Guttmann, NeuroPersonalTrainer|Guttmann NeuroPersonalTrainer (GNPT) 5 days per week over 6 weeks.
89475046|NCT03326349|Sham Comparator|Ictus.online|Itus.online 5 days per week over 6 weeks
89475047|NCT03073070|Experimental|Biotin labeled RBCs in 4-10 year old diabetes children|Biotin labeled autologous RBCs will be transfused to the subjects
89020009|NCT05873816|Active Comparator|Sentinel - Cerebral Embolic Protection|Subjects will undergo TAVR following placement of the Sentinel cerebral embolic protection device.
89475048|NCT03073070|Experimental|Biotin labeled RBCs in 10-18 year old diabetes children|Biotin labeled autologous red blood cells will be transfused to the subjects
89475049|NCT03326271||Lubinus SP2 stem|Patients treated with a cemented Lubinus SP2 stem for a femoral neck fracture. Both total hip arthroplasty and hemiarthroplasty are included.
89475050|NCT03326271||Exeter stem|Patients treated with a cemented Exeter stem for a femoral neck fracture. Both total hip arthroplasty and hemiarthroplasty are included.
89202673|NCT00789282|Active Comparator|Usual Care Group|The 'usual care' study arm (control) will reflect current patterns of care for patients with thpe 2 diabetes in the Capital Health region
89202674|NCT00789282|Experimental|Enhanced Care Group|In the enhanced care group(intervention arm) the participants will receive a multifactorial intervention with three main components that include: optimized medical management, 2) support for development of enhanced patient self management skills, and 3) organized proactive follow-up by chronic disease management teams to support improvement in care.
89202675|NCT00681668|Experimental|Quetiapine Fumarate 150 - 800mg|Quetiapine 150-800mg
89475051|NCT05122364|Active Comparator|Telerehabilitation group|Group of cochlear implanted children who will take sessions online by the Arabic online program that will be designed
89202676|NCT00792558|Experimental|Single Arm|
89206221|NCT01068145|Experimental|High dose SCH 527123|
89206222|NCT01068145|Placebo Comparator|Placebo to match SCH 527123|
89475052|NCT05122364|Placebo Comparator|Face to Face group|Group of cochlear implanted children who will take sessions face to face in the classical way (control group)
89475053|NCT03322683|Experimental|EXPERIMENTAL GROUP|The intervention for this group consisted of 5 massage sessions with the PHYSIUM device for a month.
89475054|NCT03322683|Experimental|CONTROL GROUP|"The multimodal physical therapy program includes 10 sessions of:~ultrasound pulsatil therapy (US) for 10 minutes.~transcutaneous electric nerve stimulation (TENS) for 20 minutes.~massage for 20 minutes."
89475055|NCT05119244|Experimental|cannabis smokers|
89475056|NCT05119244|Experimental|Tobacco smokers|
89475057|NCT05119244|Experimental|Non-smoking patients|
89475058|NCT03333681|Experimental|Refractory rheumatoid arthritis patients|Autologous mesenchymal stem cells
89475059|NCT05099432|Experimental|CARMA Technique|All included participants undergo polyp resection using standard of care polypectomy techniques, followed by the CARMA technique
89475060|NCT03326115|Experimental|Peer Visitation Program (PVP)|Participants in this group will begin participation in the Peer Visitation Program (PVP) beginning at amputation date with the initiation window ranging from immediately pre-operative to 7 days post operative.
89475061|NCT03326115|No Intervention|Delayed Peer Visitation (NoPVP)|Not participating in a Peer Visitation Program for 60 days post-operatively, followed by participation and completion in a PVP 60 days later than the PVP group for a total of 120 days.
89475062|NCT03333603|Experimental|esomeprazole|esomeprazole 40mg /tab oral Day1-Day14 then 40mg/2 tab oral Day15-Day56
89475063|NCT02701556|Experimental|Bausch & Lomb (B&L) NNR06 Multi-Purpose Solution (MPS)|B & L investigational NNR06 used as a rub care regimen (Test)
89475064|NCT02701556|Active Comparator|COMPLETE MPS|B&L Multi-Purpose Solution as a rub care regimen (Control)
89475065|NCT03333525|Experimental|Insulin dose-CARB counting HPM group|HPM (high protein meal), contained 36 g protein,17 g fat, 70 g carbohydrate and 11.5 g fiber, was given to the subjects in breakfast meal (08.30 h) in the hospital. The glycaemic index (GI) of meal was 60.40. The insulin dose for meal was calculated according to the carbohydrate counting (insulin-to-carbohydrate ratio-ICR).Capillary blood glucose values were collected and recorded before (0 min) and every 30 minutes thereafter for 240 minutes.
89475066|NCT03333525|Experimental|Insulin dose-CARB counting HPFM group|HPFM (high protein-high fat meal), contained 36 g protein,30 g fat, 70 g carbohydrate and 11.5 g fiber, was given to the subjects in breakfast meal (08.30 h) in the hospital The glycaemic index (GI) of meal was 60.40. The insulin dose for meal was calculated according to the carbohydrate counting (insulin-to-carbohydrate ratio-ICR).Capillary blood glucose values were collected and recorded before (0 min) and every 30 minutes thereafter for 240 minutes.
89475067|NCT03333525|Experimental|Insulin dose-CARB+FPU counting-HPFM|HPFM (high protein-high fat meal), contained 36 g protein,30 g fat, 70 g carbohydrate and 11.5 g fiber, was given to the subjects in breakfast meal (08.30 h) in the hospital. The glycaemic index (GI) of meal was 60.40. The insulin dose for meal was calculated according to the carbohydrate counting plus fat-protein counting (insulin-to-carbohydrate ratio-ICR and fat-protein unit-FPU).Capillary blood glucose values were collected and recorded before (0 min) and every 30 minutes thereafter for 240 minutes.
89475068|NCT03333525|Active Comparator|Insulin dose-CARB counting SM group|SM (standart meal), contained 24 g protein,17 g fat, 70 g carbohydrate and 11.5 g fiber, was given to the subjects in breakfast meal (08.30 h) in the hospital. The glycaemic index (GI) of meal was 60.40. The insulin dose for meal was calculated according to the carbohydrate counting (insulin-to-carbohydrate ratio-ICR and fat-protein unit-FPU).Capillary blood glucose values were collected and recorded before (0 min) and every 30 minutes thereafter for 240 minutes.
89475069|NCT03333447||Study Population|Patients of any age or gender with confirmed diagnosis of type 1 Gaucher disease, treated with VPRIV® at the beginning of the study. Patients should have one MRI data in the 5 previous years before starting VPRIV® treatment (up to 3 months after initiation of VPRIV®.
89475070|NCT03322371|Other|Health Subjects in Sleep Lab|Adult patients (> 18yrs old) scheduled for a standard of care PSG (sleep study) lasting at least 8 hours for any condition. Patients will undergo simultaneous 2-lead limited EEG recording with experimental device. 2-lead limited electroencephalography recording
89475071|NCT03322371|Other|ICU patients, not sedated or ventilated|Adult ICU patients (> 18yrs old) anticipated to stay in the ICU overnight (minimum 8 hours) with a Glasgow Coma Scale of 13 or greater, not intubated and not sedated. Patients will undergo simultaneous 2-lead limited electroencephalography recording
88949836|NCT01940016|Experimental|Arm I (health coach)|Participants participate in a 12-week physical activity intervention (walking program)and receive health mail messages via IVR system and from a health coach. Participants in this arm of the study, interacted with the IVR system and had the option of interacting with the health coach.
89206223|NCT01068145|Experimental|Low dose SCH 527123 (Part 2)|
89475072|NCT03322371|Other|ICU patients, sedated and ventilated|Adult ICU patients (> 18yrs old) who are intubated, sedated, ventilated, and anticipated to stay in the ICU overnight (minimum 8 hours). Patients will undergo simultaneous 2-lead limited electroencephalography recording
89475073|NCT03333369|Active Comparator|Madopar Arm|A single dose of a cachet filled with 200 mg levodopa/50 mg benserazide
89475074|NCT03333369|Placebo Comparator|Placebo Arm|A single dose of a cachet filled with Dextrose
89475075|NCT03333291|Experimental|Fecal transplantation|Duodenal transfer of healthy donor fecal suspension
89475076|NCT03333213|Experimental|Gua Sha therapy|Patients' backs were first covered with Tumarol N Balsam. The study physician then applied a round-edged instrument (the inside smooth edged lip of a metal cap) to patients' skin in downward strokes. Patients were treated twice with a 7-day interval.
89475077|NCT03333213|No Intervention|Waitlist control group|Treatments in the control group were not regulated but patients were asked to continue their self-directed medical care. They were offered the Gua Sha therapy once the trial was concluded.
89475078|NCT03325803|Experimental|150μm-AFL-PDT|
89475079|NCT03325803|Experimental|350μm-AFL-PDT|
89475080|NCT03325803|Experimental|500μm-AFL-PDT|
89475081|NCT02653664|Experimental|Condition #1: PsychoEducation (ED)|Condition #1 will include 8 90-minute group sessions that will educate the subject about chronic pain, discuss the impact of pain, and inform the subject of different ways to manage it in hopes of decreasing pain and its impact on the subject's life. Participants in this condition will be given pre-recorded audio recordings of the content of the sessions to listen to.
89475082|NCT02653664|Experimental|Condition #2:Self-Hypnosis Training (HYP)|In condition #2, the facilitator will perform a standard hypnotic short induction followed by therapeutic suggestions, including post-hypnotic suggestions. Participants will relax in a comfortable position with their eyes closed and will simply listen to the clinician read a standardized hypnotic script that will include an induction followed by suggestions for decreased pain and improvement in co-morbid symptoms (e.g., improved mood and optimism, relaxation, sleep quality).
89475083|NCT02653664|Experimental|Condition #3: Mindfulness Meditation (MM)|In condition #3, the facilitator will teach participants Vipassana meditation, which is the specific form of mindfulness meditation (MM) typically implemented in mindfulness research. The emphasis is placed upon developing focused attention on an object of awareness, such as the breath. This focus is then expanded to include a more open, non-judgmental monitoring of any sensory, emotional, or cognitive events. Time will also be devoted to problem solving around any difficulties with MM practice.
89475084|NCT05465343|Experimental|Furmonertinib|Furmonertinib 160mg orally QD
89475085|NCT04494009|Experimental|INCMGA00012 군|INCMGA00012 500 mg iv every 4 weeks for up to 12 months
89475086|NCT04494009|No Intervention|Observation arm|followed up every 12 weeks for up to 12 months
88949837|NCT01940016|Active Comparator|Arm II (no coach condition)|Participants participate in a 12-week physical activity intervention (walking program)and receive health mail messages via IVR system. Participants in this arm of the study only interacted with the IVR system.
88949838|NCT01940042|Experimental|maneuver group|In the intervention group, CO2 was removed by means of Trendelenburg position (30 degrees) and a pulmonary recruitment maneuver consisting of five manual inflations of the lung.
88949839|NCT01940042|No Intervention|clasical group|no additional action will be taken after the operation
88949840|NCT01940055|Experimental|Experimental group|Dual Task Treadmill Walking Exercise Program
88949841|NCT01940055|Active Comparator|Control group|Dual task recumbent cycling exercise program
88949842|NCT01940068|Experimental|New Thickened Amino acid based formula|
88949843|NCT01940068|Active Comparator|Amino acid based formula|
88949844|NCT01940081||Group A: Nonischemic cardiomyopathy - not admitted for surgery|"Patients with nonischemic cardiomyopathy with:~documented ventricular arrhythmia or~suspected ventricular arrhythmia (e.g. because of out-of-hospital cardiac arrest, palpitations or syncope) or~high risk for ventricular arrhythmia (LVEF ≤ 35%) or~intermediate risk for ventricular arrhythmia (LVEF ≤ 50% and late enhancement on contrast-enhanced MRI)~who are not admitted for cardiac surgery"
88949845|NCT01940081||Group B: Nonischemic cardiomyopathy -admitted for surgery|"Patients with nonischemic cardiomyopathy with:~documented ventricular arrhythmia or~suspected ventricular arrhythmia (e.g. because of out-of-hospital cardiac arrest, palpitations or syncope) or~high risk for ventricular arrhythmia (LVEF ≤ 35%)~who are admitted for cardiac surgery (e.g., mitral valve annuloplasty or CorCap)"
88949846|NCT01940081||Group C: Controls|"Patients without nonischemic cardiomyopathy (controls) who are admitted for:~Coronary artery bypass graft surgery and who do not have prior myocardial infarction~Aortic valve replacement"
88949847|NCT01940107|Other|Control Group (CG)|Control Group, which were subjected only to evaluations and to no exercise
88949848|NCT01940107|Experimental|Study Group (SG)|Study group (SG), was oriented to perform domiciliary exercises for the upper limbs.
88949849|NCT01940133|Experimental|PQR309|Different dose evaluation
88949850|NCT01940159|Active Comparator|Active Comparator: SEP-363856|Dosing will be initiated at 25 mg SEP-363856 as a single oral dose. Subsequent cohorts will be dosed at 50, 100, and 150 mg of SEP-363856
88949851|NCT01940159|Placebo Comparator|Placebo|Matched placebo.
88949852|NCT01940172|Experimental|Birinapant with Conatumumab|
89020010|NCT05873816|No Intervention|Control Arm|Subjects will undergo TAVR without embolic protection.
89475087|NCT05465187||Patients|Adults patients aged for more than 18 years old, admitted in an intensive care unit in Grand-Est region in France, for whom a decision of withholding or withdrawing of life-sustaining therapy is taken during the month of study.
89475088|NCT05121662||Individuals with Multiple Sclerosis (MS)|Individuals with MS on B-cell depleting therapy, non-cell depleting therapy, or no therapy.
89475089|NCT03325725|Experimental|NewBreez LD Intra-laryngeal implant|
89475090|NCT02623244||ovarian endometrioma|Women with ovarian endometrioma noted by ultrasonography.
89202677|NCT00539188|Experimental|N-Acetylcysteine|Patients randomized to this arm will receive N-Acetylcysteine augmentation, at a standard dose (3000 mg daily), in addition to the medication regimen they are on at enrollment
89475091|NCT02623244||The control group|Women with age and body mass index matched and without ovarian endometrioma in ultrasonography
89475092|NCT03325569|Active Comparator|NGT|NGT - normal glucose tolerance. Women with PCOS and normal glucose tolerance
89475093|NCT03325569|Active Comparator|IGH|IGH - impaired glucose homeostasis Women with PCOS and impaired glucose homeostasis - that means impaired fasting glucose or impaired glucose tolerance.
89475094|NCT03924362|Active Comparator|Simultaneous Bilateral PCNL|Patients undergo simultaneous bilateral PCNL.
89475095|NCT03924362|Active Comparator|Unilateral PCNL|Patients undergoing unilateral staged PCNL.
89475096|NCT03325491|Experimental|Acipimox plus exercise training|The active supplement will contain the prescription drug Acipimox (250 mgs) , a nicotinic acid precursor traditionally used to lower blood lipid levels. The supplement will be administered 3 times per day, for 6 weeks.
89475097|NCT03325491|Placebo Comparator|Placebo plus exercise training|The placebo supplement will contain only cellulose microcrystalline. This is an inert substance widely used in many pill and tablet formulations. It is an insoluble fibre and is not absorbed into the blood stream therefore is unlikely to cause toxicity when taken orally.
89475098|NCT04150562|Experimental|Arm 1- Experimental Treatment: Safety Run-in|Interleukin 15 (IL-15) by continuous intravenous (CIV) infusion at escalating doses of 2 and 4 mcg/kg/day on days 1-5 of each 28-day cycle (max 4 cycles) with avelumab by intravenous (IV) infusion at a dose of 800mg on Day 8 and 22 of each cycle
89475099|NCT04150562|Experimental|Arm 2-Experimental Treatment: Dose Expansion|Interleukin 15 (IL-15) by continuous intravenous (CIV) infusion at 4 mcg/kg/day on days 1-5 of each 28- day cycle (max 4 cycles) with avelumab by intravenous (IV) infusion at a dose of 800mg on Day 8 and 22 of each cycle
89475100|NCT04442529|No Intervention|Control|Pregnant women will receive prenatal care as usual.
89475101|NCT04442529|Experimental|Intervention|Pregnant women will receive the 12-session Mothers and Babies intervention
89475102|NCT03325413|No Intervention|Control|Usual care with assessment only (no study-related intervention)
89475103|NCT03325413|Other|Implementation|Implementation of intervention measures
89475104|NCT03325413|Other|Full-scale intervention|
89475105|NCT03332823|Experimental|SME Ambassadors training & program|- SME Ambassadors will participate in train-the-ambassador workshops and provide voluntary services and promote mental well-being activities to vulnerable groups.
89475106|NCT05002790|Experimental|Data collection|All 20 anticipated subjects to be scanned under MRI, with data collected and analysed together
89206224|NCT01068145|Experimental|Medium dose SCH 527123 (Part 2)|
88949853|NCT01940224|Active Comparator|Pregabalin & Morphine|Administration of pregabalin 300 mg to patients undergo laparoscopic colorectal surgery.Patients receive oral Pregabalin 150 mg the night before surgery, and another one dose of 150 mg 1 hour prior to surgery. Postoperative administration of morphine via PCA pump for 48 hours
88949854|NCT01940224|Placebo Comparator|Placebo & Morphine|Administration of placebo to patients undergo laparoscopic colorectal surgery.Patients receive oral Placebo the night before surgery, and another one dose 1 hour prior to surgery.Postoperative administration of morphine via PCA pump for 48 hours
89020011|NCT05861778|Experimental|89Zr-girentuximab|A single administration of 37 MBq (+/-10%) 89Zr-girentuximab, containing a mass dose of 10 mg of girentuximab
89475107|NCT03325335|Active Comparator|Midazolam premedication group (Group P)|Patients of group P were premedicated with intramuscular midazolam 0.05 mg/kg 30 minutes before surgery.
89475108|NCT03325335|Other|Control group (Group N)|Patients of group N were not premedicated with midazolam (Do not use placebo). [Treatment of Glycopyrrolate (0.2 mg, IM) 30 minutes prior to surgery is not intervention because it is a routine practice of this center. (-> removed from interventions)]
89475109|NCT05121116|Experimental|Active intervention condition|Participation in an 8-week, online, self-directed MBSR program.
89475110|NCT05121116|No Intervention|Waitlist control condition|Participants in the waitlist control condition received no active intervention during the trial period but received a link to the MBSR program after completing the post-intervention assessments.
89475111|NCT03322059|Active Comparator|Control|"The core intervention will include educational materials, access to a basic smartphone app and a Fitbit.~Participants will receive a weekly email with a step goal that will increase 10% beyond the previous weeks values."
89475112|NCT03322059|Experimental|Intervention|"The core intervention will include educational materials, access to a basic smartphone app and a Fitbit. Participants will receive a weekly email with a step goal that will increase 10% beyond the previous weeks values.~Participants will be in the form of a charitable donation in their name to a cancer charity."
89475113|NCT03332745||Severe aortic stenosis|Patients with severe aortic stenosis who are scheduled to undergo aortic valve replacement surgery
89475114|NCT03332745||Control group|Patients scheduled to undergo non-aortic valve cardiac or elective ascending aortic surgery
89475115|NCT02044328|Experimental|Icotinib|Patients receive icotinib 125 mg three times daily as adjuvant chemotherapy with for 18 months after surgery.
89475116|NCT03332511|Experimental|Investigational arm|Oral nilotinib 300mg twice daily with a 12-hour interval
89475117|NCT05114720|Experimental|standard adjuvant chemotherapy plus moxifloxacin|"Standard adjuvant chemotherapy (Taxanes combined with cyclophosphamide or doxorubicin combined with cyclophosphamide followed by taxanes) plus antibiotic (moxifloxacin)~Other Name: docetaxel 75mg/m^2, or nab-paclitaxel 260mg/m^2, IV, days 1, cycled every 21 days cyclophosphamide 1000 mg/m^2, IV, days 1, cycled every 21 days; or doxorubicin 60mg/m^2, IV, days 1, combined with cyclophosphamide 600 mg/m^2, IV, days 1, followed by docetaxel 75mg/m^2, or nab-paclitaxel 260mg/m^2, IV, days 1; plus Moxifloxacin 0.4 PO once daily days 1-5; cycled every 21 days"
89475118|NCT05114720|Placebo Comparator|standard adjuvant chemotherapy plus placebo|"Standard adjuvant chemotherapy (Docetaxel combined with cyclophosphamide or doxorubicin combined with cyclophosphamide followed by docetaxel) plus placebo~Other Name: docetaxel 75mg/m^2, or nab-paclitaxel 260mg/m^2, IV, days 1 cyclophosphamide 1000 mg/m^2, IV, days 1, cycled every 21 days; or doxorubicin 60mg/m^2, IV, days 1, combined with cyclophosphamide 600 mg/m^2, IV, days 1, followed by docetaxel 75mg/m^2, or nab-paclitaxel 260mg/m^2, IV, days 1; plus Placebo 0.4 PO once daily days 1-5; cycled every 21 days"
89475119|NCT05113550||Young group|patients < 70 years of age
89475120|NCT05113550||Elderly|Patients ≥ 70 years of age)
89475121|NCT04493697|Active Comparator|Experimental 1|A ThermoNeuroModulation device will be worn by the participant that delivers warm waveforms in one ear (42 °C) and cool waveforms (17 °C) in the other ear.
89475122|NCT04493697|Placebo Comparator|Experimental 2|A ThermoNeuroModulation device will be worn by the participant that will neither warm nor cool.
89475123|NCT02488629|Experimental|SCB01A|This study is a single arm, open-label, Phase II trial
89475124|NCT05111054|Experimental|Low-Load|Acute resistance exercise performed at 30% 1RM
89475125|NCT05111054|Active Comparator|High-Load|Acute resistance exercise performed at 80% 1RM
89475126|NCT04493463|Experimental|methylprednisolone + ropivacaine + saline|The local infiltration solution in the methylprednisolone plus ropivacaine with saline group (treatment group) will consist of 1 ml of 40 mg methylprednisolone plus 15ml of 1% ropivacaine and 14 ml saline.
89475127|NCT04493463|Active Comparator|ropivacaine + saline|The local infiltration solution in the ropivacaine plus saline group (control group) will consist of 15 ml of 1% ropivacaine and 15ml saline.
89475128|NCT04493073|Active Comparator|Trabectulectomy with mitomycin|Mitomycin-C Kyowa® (Biochem Pharmaceutical Industries, India) 10 mg vial 2 mg/ml concentration
89475129|NCT04493073|Active Comparator|Trabectulectomy with Ologen implants|Ologen Collagen Implant (Aeon Astron Europe, Netherlands) - three-dimensional collagen- GAG implant >90% lyophilized porcine atelocollagen and <10% lyophilized porcine GAG 12 mm in diameter with 1 mm of thickness and 6 mm in diameter with 2 mm of thickness
89475130|NCT00748904|Experimental|A|35 patients receiving rifaximin
89475131|NCT00748904|Experimental|B|35 patients receiving lactulose
89475132|NCT03332433|No Intervention|Control group|Oxygen(2L/min) supplied with nasal catheter
88949855|NCT01940237|Experimental|Interpersonal Psychotherapy (IPT)|Interpersonal psychotherapy (IPT) is a brief, manualized therapy that has shown efficacy in the treatment of major depressive disorder (MDD) in several controlled trials. This study will test the efficacy of IPT in a group of prostate, colorectal, lung and pancreatic cancer patients with a diagnosis of major depressive disorder.
88949856|NCT01940250|Placebo Comparator|Sterile water|"Sterile water will be packaged identically to the active comparator.~Each patient randomized to the placebo arm of the trial will receive a loading dose of 0.5ml/kg intravenous over 20 minutes , followed by a maintenance dose of 0.3 ml/kg/hr to 0.5 ml/kg/hr randomly adjusted by an independent doctor to mimic adjustments made in the active comparator arm for 72 hrs."
89475133|NCT03332433|Experimental|High-flow nasal cannula group|Oxygen(up to 60L/min) supplied with high-flow nasal cannula
89475134|NCT00219830|Experimental|1 - home-based walking program|Based on medical record held in general practice, patients who had not attended a formal cardiac rehabilitation program after myocardial infarction and were enrolled in home-based walking programme
89475135|NCT00219830|No Intervention|2 - cardiac rehabilitation|Based on medical record held in general practice, patients who are identified as having attended a Cardiac Rehabilitation program following myocardial infarction - 'usual care'
89475136|NCT05071742||IBD group|According to the consensus opinions on diagnosis and Treatment of Inflammatory Bowel Disease (Beijing, 2018) formulated by Chinese Society of Gastroenterology, Chinese Medical Association The diagnosis of IBD was confirmed by clinical, laboratory, radiographic, digestive endoscopy and histopathological examination.
89475137|NCT05071742||control group|During the same period, healthy subjects were collected from the physical examination center of our hospital as subjects of the normal control group. Infectious diarrhea, ischemic bowel disease, radiation enteritis, gastrointestinal tumor, diabetes, systemic lupus erythematosus, rheumatoid arthritis and autoimmune thyroiditis were excluded from all clinical examinations before inclusion.
89475138|NCT03321903||1: Intraoral Squamous Cell Carcinomas|Intraoral squamous cell carcinomas that are resected and receive adjuvant radiation therapy. These patients may receive a Carlo Erba Ink injection before surgical tumor resection, after tumor resection (in the postsurgical radiation field), or in both instances. Patients whose tumor is within 5 mm of the surface will have injections of India ink into the tumor itself and measurements made in the tumor prior to surgery. Patients whose tumor is deeper than 5 mm of the surface could participate only in the measurements of the postsurgical radiation field. EPR Oximetry measurements will be made in the tumor and/or, if applicable, over the course of radiation in the postsurgical radiation field as appropriate.
89475139|NCT03321903||2: Cutaneous Malignant Tumors|Patients with primary cutaneous malignant tumors (including but not limited to squamous cell carcinoma, basal cell carcinoma, or melanoma) whose tumor is within 5 mm of the surface and whose treatment plan includes surgical resection and/or postsurgical radiation therapy. These patients may receive a Carlo Erba Ink injection before surgical tumor resection, after tumor resection (in the postsurgical radiation field), in both the tumor and the postsurgical radiation field, or in the tumor prior to radiation therapy. EPR Oximetry measurements will be made in the tumor and/or, if applicable, over the course of radiation in the tumor or postsurgical radiation field as appropriate.
89475140|NCT03321903||3: Breast Cancers|Breast cancer patients whose treatment plan includes surgical resection followed by radiation therapy. All patients who receive a surgical resection will receive a Carlo Erba Ink injection in the radiation field after sufficient healing has occurred to the area to be injected, as determined in consultation with the treating physicians, and using topical anesthetic or local anesthetic, if the patient so desires. All patients in this cohort will be expected to agree to a minimum of one EPR Oximetry measurement in the planned radiation field prior to radiation and a minimum of one measurement made over the course of radiation therapy.
89020012|NCT05850988|Active Comparator|Group Eighty|Patients in Group E will receive %80 oxygen for 3 minutes during preoxygenation
89020013|NCT05850988|Active Comparator|Group Hundred|Patients in Group H will receive %100 oxygen for 3 minutes during preoxygenation
89020014|NCT05849779|Experimental|Inhaled sedation with sevoflurane|Sevoflurane as vaporized via the Anesthesia Conserving Device (Sedaconda-ACD-S, Sedana Medical, Danderyd, Sweden).
89020015|NCT05849779|Active Comparator|Intravenous sedation|The investigators will not mandate the sedative type, but rather encourage the use of sedatives that are already routinely used in participating ICUs (typically a benzodiazepine, propofol, or dexmedetomidine, i.e. drugs approved for sedation).
89475141|NCT03321903||4: Other tumors|Other tumors within 5 mm of the surface, whose planned treatment includes radiotherapy of the tumor and does not include a planned resection of the tumor. As these other qualifying malignancies are expected to occur only rarely, they will be grouped into a single cohort despite potential varied histology. These patients will receive a Carlo Erba Ink injection in their tumor prior to radiation therapy. All patients in this cohort will be expected to agree to a minimum of one EPR Oximetry measurement in the planned radiation field prior to radiation and a minimum of one measurement made over the course of radiation therapy.
89475142|NCT04993430|Experimental|Group A|HRS8807 monotherapy dose escalation
89475143|NCT04993430|Experimental|Group B|HRS8807 monotherapy dose expansion
89475144|NCT04993430|Experimental|Group C|HRS8807 in combination with SHR6390 dose escalation
89475145|NCT04993430|Experimental|Group D|HRS8807 in combination with SHR6390 dose expansion
89475146|NCT02492061|Active Comparator|Demand creation|In the intervention arm, demand creation for couples' HCT is done using small group (comprising about 20 people), couple-focused or men-only, interactive sessions. A senior counselor facilitates the sessions in which the advantages and fears associated with couples' HCT are discussed with invited couples or men. The sessions are reinforced by testimonies from couples or men who have ever tested as a couple. Attending couples or men receive couple invitation coupons inviting them to test for HIV together with their partners at a designated health facility in the community.
89475147|NCT02492061|No Intervention|Standard of care|In the standard of care arm, participants receive general adult health talks to educate them about the importance of HIV testing (including couples' HCT) but no invitations are issued to invite couples to test for HIV together with their partners at a designated health facility. However, couples can seek HCT out of their own volition. The sessions are not stratified by marital status, and attendants include all those who are willing and are able to attend.
89020016|NCT05848440|Experimental|Part A|Participants will be administered single ascending SC doses of AZD9550 or a placebo.
89020017|NCT05848440|Experimental|Part B|Participants will be administered one SC dose of AZD9550 or a placebo.
89475148|NCT04411550|Experimental|HLX11 group|HLX11 are given intravenous infusion at a single dose of 420 mg, and the administration time is 60 min (± 10 min).
89475149|NCT04411550|Active Comparator|CN-Perjeta group|CN-Perjeta are given intravenous infusion at a single dose of 420 mg, and the administration time is 60 min (± 10 min).
89475150|NCT04411550|Active Comparator|EU-Perjeta group|EU-Perjeta are given intravenous infusion at a single dose of 420 mg, and the administration time is 60 min (± 10 min).
89475151|NCT04411550|Active Comparator|US-Perjeta group|US-Perjeta are given intravenous infusion at a single dose of 420 mg, and the administration time is 60 min (± 10 min).
89475152|NCT03320499||echo doppler at the bed|
89475153|NCT03320499||echo doppler in the vascular exploration platform|
89475154|NCT04984382|Experimental|After receiving standardized training on Helicobacter pylori eradication|After the gastroenterologists receive standardized training to eradicate Helicobacter pylori, they recruit Helicobacter pylori-positive patients for treatment.
89475155|NCT04984382|No Intervention|Before receiving standardized training on Helicobacter pylori eradication|Gastroenterologists recruited patients with Helicobacter pylori positive for treatment before receiving standardized training on Helicobacter pylori eradication.
89020018|NCT05848440|Experimental|Part C|Participants will be administered one IV dose of AZD9550 or a placebo.
89020019|NCT05847634||Acute Respiratory Distress Syndrome|Adults admitted to ICU with ARDS confirmed according to Berlin Definition
89020020|NCT05847569|Active Comparator|Group I (low dose belantamab mafodotin)|Patients receive low dose belantamab mafodotin intravenously (IV) on day 1 of each cycle. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. All patients undergo a CT scan, a MRI scan, or a PET/CT scan during screening and patients with plasmacytoma (a MM tumor in bone or soft tissue) also undergo imaging scans on study. Patients undergo bone marrow aspirate and biopsy during screening and on study as well as collection of blood samples throughout the trial.
89202678|NCT00539188|Placebo Comparator|placebo|Patients randomized to this arm will receive placebo, formulated to be indistinguishable from N-Acetylcysteine, in addition to the medication regimen they are on at study enrollment.
89202679|NCT00681590|Active Comparator|1|vitamin D (cholecalciferol) 400 IU daily orally - low dose
89202680|NCT00681590|Active Comparator|2|vitamin D (cholecalciferol) 2000 IU daily orally - high dose
89206225|NCT01068145|Experimental|High dose SCH 527123 (Part 2)|
89206226|NCT01068145|Placebo Comparator|Placebo (Part 2)|
89475156|NCT03321825|Experimental|Belotero® Volume Lidocaine|Subdermal injection
89475157|NCT03321825|No Intervention|No treatment|
89475158|NCT03332199|No Intervention|Control|Participants in the control group received standard treatment from oncologists and nurses at Hanoi Medical University Hospital.
89475159|NCT03332199|Experimental|Intervention|In addition to standard care provided by oncologists and nurses at Hanoi Medical University Hospital as described above, participants assigned to the intervention group received the psychoeducational intervention delivered by the nurse researcher.
89475160|NCT03322449|Experimental|Animal Diet|during this Arm, the participants will receive a diet enriched in animal products
89475161|NCT03322449|Experimental|Plant Diet|during this Arm, the participants will receive a diet enriched in plant products
89020021|NCT05847569|Experimental|Group II (low dose and high dose belantamab mafodotin)|Patients receive belantamab mafodotin IV on day 1. Cycle repeats at 3 weeks for the next cycle and then every 6 weeks for subsequent cycles in the absence of disease progression or unacceptable toxicity. All patients undergo a CT scan, a MRI scan, or a PET/CT scan during screening and patients with plasmacytoma (a MM tumor in bone or soft tissue) also undergo imaging scans on study. Patients undergo bone marrow aspirate and biopsy during screening and on study as well as collection of blood samples throughout the trial.
89020022|NCT05844566|Other|Decision Support System (DSS)|Patients of this cohort are seen at a site randomised to the availability of the DSS. These patients will be provided routine clinical care including local/national prescribing guidelines during the course of the study. In addition to routine clinical care, the DSS which is available online, is a tool intended for clinicians to estimate the clinical benefit of any LLT regimen, whether monotherapy or combination therapies.
89475162|NCT05230160|Experimental|Intervention Group|The IF group will fast for 16 consecutive hours on 6 days per week with an 8-hour eating window (e.g., eat from 10 a.m. to 6 p.m.). The IF group will consume their habitual diet in terms of food choices and energy intake, but only during the 8-hour and full-day non-fasting periods. An RD will meet virtually with participants in the IF group at baseline to teach them the fasting protocol and how to manage energy intake and hunger, as well as to reinforce the requirement to not change habitual dietary practices. The research coordinator will call patients every two weeks to assess for changes in medications, compliance with the fasting protocol, and symptoms (assessed monthly) using the modified HBI.
89020023|NCT05844566|No Intervention|Non-Decision Support System (Non-DSS)|Patients of this cohort are seen at a site randomised to no availability of a DSS (Non-DSS). These patients will be provided routine clinical care including local / national prescribing guidelines during the course of the study.
89020024|NCT05829044|Experimental|Testing non-visual light impacts on pupil response, circadian timing, and hormones|"Pupillometry on day 1 in afternoon and evening and on day 2 in morning and evening. Participants will be randomized to one of 8 different light stimuli within the pupillometry~Red light exposure on night 1 to determine circadian timing~Blue/green light exposure on night 2 to compare hormone response during blue/green light to that during red light on night 1"
89020025|NCT05826002|Active Comparator|Digital insomnia intervention|This group receives the following combination of treatment features: optimized graphical user interface (no), adaptive treatment strategy (no), daily prompts (no).
89202681|NCT01920724||wasting, obesity, stunting, normal|wasting (BMI for age Z-scores < -2 SD), normal (-1 SD ≤ BMI for age Z-scores ≤ +1 SD), obesity (BMI for age Z-scores > +2 SD), and stunting (HAZ < -2 SD).
89475163|NCT05230160|No Intervention|Standard Medical Care Group|The control group will continue with their habitual dietary pattern. The research coordinator will call patients at baseline and every two weeks to assess for changes in medications and symptoms (assessed monthly) using the modified HBI.
89475164|NCT04109378|Active Comparator|Patients operated with conventional laparoscopic technique|Patients operated with conventional laparoscopic technique for colorectal DIE
89475165|NCT04109378|Active Comparator|Patients operated with NOSE laparoscopic technique|Patients operated with NOSE technique for colorectal DIE
89475166|NCT03320421|Experimental|SIB group|"Radiation therapy:~daily 5 days per week for 3 weeks. 43.5 Gy in 15 fractions to the whole breast 49.5 Gy in 15 fractions to the tumor bed boost"
89475167|NCT02492217|Experimental|Adalimumab|Adalimumab will be provided to trial participants as 0.8 ml single dose pre-filled syringes containing 40mg adalimumab each. A kit will be dispensed to he subject every two weeks, each kit containing one syringe.
89475168|NCT05229926||Patient Group|Patients who previously were hospitalized during the COVID-19 pandemic, receiving mock care inside the CareCube
89475169|NCT05229926||Patient Caregiver Group|Caregivers/family/friends of patients previously hospitalized during the COVID-19 pandemic, communicating with the patient inside the CareCube
89475170|NCT05229926||Heathcare Provider Group|Physicians, Certified Registered Nurse Anesthetists, RNs, Certified Nursing Assistants who will perform routine clinical care tasks, including passing food and medicines, drawing blood, inserting an IV. To simulate intubation, a mannequin will be used.
89475171|NCT03332043|Experimental|HIRREM|Subjects in the experimental arm will receive an in-office, open-label course of acoustic stimulation linked to brain activity (High-resolution, relational, resonance-based, electroencephalic mirroring, HIRREM).
89475172|NCT03332043|Active Comparator|Ambient Nature Sounds|Subjects in the active comparator arm will receive an in-office, open-label course of acoustic stimulation not linked to brain activity (ambient natures sounds).
88949857|NCT01940250|Active Comparator|Magnesium sulphate|"Each patient randomized to the treatment arm of the trial will receive a loading dose of 50mg/kg intravenous over 20 minutes (0.5ml/kg), followed by a maintenance dose of 30-50 mg/kg/hr (0.3 ml/kg/hr to 0.5 ml/kg/hr) for 72 hrs.~The maintenance dose will be determined by increasing the loading infusion dose 0.1 ml/kg/hr (10mg/kg/hr) every 15 minutes to a maximum dose of 0.5 ml/kg/hr (50 mg/kg/hr), with the following caveats:~If the systolic BP decreases to < 90th percentile for age, gender and length the dose will be reduced by 1 stage every 15 mins~If the systolic BP increases to the levels detailed in the study protocol for treatment failure, action will be taken as indicated~If the systolic BP decrease rapidly more than 25% over 15 minutes~If the plasma Mg level > 2.5 mmol/l or < 1.8 mmol/l a 25% increase or decrease in the infusion rate will be implemented as appropriate."
89475173|NCT05229848|Active Comparator|3D electroanatomical mapping alone|Patients who are diagnosed with typical right sided flutter who are scheduled for an ablation procedure will be enrolled. Informed consent will be obtained from each of them prior to the procedure. Patients will be randomly assigned to undergo either 3D electroanatomical mapping alone vs ICE plus 3D electroanatomical mapping guided CTI ablation. Operators will plan to alternate each case with the use of ICE + 3D mapping and 3D mapping alone with one method followed by the other for randomization. All patients will have the standard access sheaths placed in the right femoral vein.
89475174|NCT05229848|Experimental|ICE plus 3D electroanatomical mapping|Patients who are diagnosed with typical right sided flutter who are scheduled for an ablation procedure will be enrolled. Informed consent will be obtained from each of them prior to the procedure. Patients will be randomly assigned to undergo either 3D electroanatomical mapping alone vs ICE plus 3D electroanatomical mapping guided CTI ablation. Operators will plan to alternate each case with the use of ICE + 3D mapping and 3D mapping alone with one method followed by the other for randomization. All patients will have the standard access sheaths placed in the right femoral vein. The group randomized to ICE catheter placement will have a left femoral 11F sheath placed in addition.
89475175|NCT02488395||de novo Parkinson's patients|"This group includes de novo Parkinson's patients who have just been diagnosed and not started their treatment at the inclusion.~This group will perform three fMRI sessions at different crucial steps of their normal follow up with a neurologist. Their visual abilities will be tested with an ophthalmologic evaluation and their sensitivity to contrast with a visual psycho-physics test."
89475176|NCT02488395||matching controls|"This group includes age-matching control participants to the first Parkinson group.~This group will perform one fMRI session. Their visual abilities will be tested with an ophthalmologic evaluation and their sensitivity to contrast with a visual psycho-physics test."
89475177|NCT05229536|Experimental|High dose Group|Meningococcal ACYW135 Polysaccharide Conjugate Vaccine, 40μg/dose
89475178|NCT05229536|Experimental|Low dose Group|Received Vaccine: Meningococcal ACYW135 Polysaccharide Conjugate Vaccine, 20μg/dose
89475179|NCT02490735|No Intervention|No-CIK|After accepting chemotherapy, patients will regularly follow up.
88949858|NCT01940263|Placebo Comparator|Placebo|placebo 320 mg daily for twelve weeks
88949859|NCT01940263|Experimental|Anthocyanin|Drug: MEDOX (natural purified anthocyanin) anthocyanin 320 mg daily for twelve weeks.
88949860|NCT01940289|Active Comparator|asymptomatic subjects attending podiatry clinic for nail care|Algometric meter readings for perception of pain These subjects will have an algometric pressure threshold meter reading taken during their routine treatment visit to establish Algometric meter readings for perception of pain
88949861|NCT01940289|Active Comparator|forefoot pain|Algometric meter readings for perception of pain forefoot pain severity measured by both VAS and algometric pressure meter
88949862|NCT01940302|Experimental|LEHEL multi-nutrients supplement|75 g/d of LEHEL supplementation along with oral hypoglycemic agents such as glibenclamide and/or metformin.
89020026|NCT05826002|Active Comparator|Digital insomnia intervention + optimized user interface|This group receives the following combination of treatment features: optimized graphical user interface (yes), adaptive treatment strategy (no), daily prompts (no).
89020027|NCT05826002|Active Comparator|Digital insomnia intervention + adaptive treatment strategy|This group receives the following combination of treatment features: optimized graphical user interface (no), adaptive treatment strategy (yes), daily prompts (no).
89020028|NCT05826002|Active Comparator|Digital insomnia intervention + optimized user interface, adaptive treatment strategy|This group receives the following combination of treatment features: optimized graphical user interface (yes), adaptive treatment strategy (yes), daily prompts (no).
89020029|NCT05826002|Active Comparator|Digital insomnia intervention + daily prompts|This group receives the following combination of treatment features: optimized graphical user interface (no), adaptive treatment strategy (no), daily prompts (yes).
89020030|NCT05826002|Active Comparator|Digital insomnia intervention + optimized user interface, daily prompts|This group receives the following combination of treatment features: optimized graphical user interface (yes), adaptive treatment strategy (no), daily prompts (yes).
89475180|NCT02490735|Experimental|CIK|After accepting chemotherapy, patients will receive at least 3 cycles of Cytokine-induced Killer Cells treatment per year
89475181|NCT03331887|Active Comparator|E-max CAD crowns retained with Fiber Reinforced Composite Post|"The modulus of elasticity of FRC post is (18-22 GPa) resembling that of dentin. Ideally the remaining tooth, the fiber post and the composite cement create a monoblock in which the loads are uniformly dissipated, ensuring a behavior similar to healthy teeth with a lower risk of root fracture. Using lithium disilicate e.max restorations is documented in literature as a successful restoration."
89475182|NCT03331887|Experimental|E-max CAD Endocrowns|Endocrowns have several advantages over conventional crowns like adequate function and esthetic with less chair time reduced number of interfaces in the restorative system. Stress concentration is less because of the reduction in the nonhomogenous material present. The preparation design is conservative compared to the traditional crown. Supragingival margin prevents interferences with periodontal tissues so involvement of the biological width is minimal. The application and polymerization of resins is also better controlled. Emax ceramic material have a high mechanical strength and are capable of being acid etched, with the adhesive capacity of adhesive systems and resinous cements, made it possible to restore endodontically treated teeth, without cores and intraradicular posts.
89475183|NCT04830956|Experimental|Sequence 1|FID123238 in 4 specification levels (minimum, moderate, moderate plus, maximum) and Systane hydration applied to the ocular surface in 1 of 5 randomized sequences. 1 application per product.
89475184|NCT04830956|Experimental|Sequence 2|FID123238 in 4 specification levels (minimum, moderate, moderate plus, maximum) and Systane hydration applied to the ocular surface in 1 of 5 randomized sequences. 1 application per product.
89475185|NCT04830956|Experimental|Sequence 3|FID123238 in 4 specification levels (minimum, moderate, moderate plus, maximum) and Systane hydration applied to the ocular surface in 1 of 5 randomized sequences. 1 application per product.
89475186|NCT04830956|Experimental|Sequence 4|FID123238 in 4 specification levels (minimum, moderate, moderate plus, maximum) and Systane hydration applied to the ocular surface in 1 of 5 randomized sequences. 1 application per product.
89475187|NCT04830956|Experimental|Sequence 5|FID123238 in 4 specification levels (minimum, moderate, moderate plus, maximum) and Systane hydration applied to the ocular surface in 1 of 5 randomized sequences. 1 application per product.
89475188|NCT02488161||Patients with colorectal cancer|One cohort of patients with colorectal cancer, studied before the intervention, and one month, one year, two years, three years and five years after.
89020031|NCT05826002|Active Comparator|Digital insomnia intervention + adaptive treatment strategy, daily prompts|This group receives the following combination of treatment features: optimized graphical user interface (no), adaptive treatment strategy (yes), daily prompts (yes).
89020032|NCT05826002|Active Comparator|Digital insomnia intervention + optimized user interface, adaptive treatment strategy, daily prompts|This group receives the following combination of treatment features: optimized graphical user interface (yes), adaptive treatment strategy (yes), daily prompts (yes).
89020033|NCT05815836||Acute Ischemic Stroke|504 patients admitted to a specialized stroke service because of an acute ischemic stroke. The circulating proteome and metabolome as well as specific molecular targets of interest (i.e. NfL) will be assessed upon admission (day 1), the next morning (day 2), day 3, day 7 (or day of discharge if earlier), and day 90. Routinely collected clinical data including from neuroimaging will be collected throughout hospitalization. Clinical follow-up will be performed at 3 months.
89020034|NCT05815836||Acute Intracerebral hemorrhage|130 patients admitted to a specialized stroke service because of an acute intracerebral hemorrhage. The circulating proteome and metabolome as well as specific molecular targets of interest (i.e. NfL) will be assessed upon admission (day 1). Routinely collected clinical data including from neuroimaging will be collected throughout hospitalization.
89020035|NCT05815836||Stroke Mimics|51 patients admitted to the emergency department because of acute stroke-like symptoms caused by epileptic seizures, migraine attacks, or other stroke-mimicking diseases. The circulating proteome and metabolome as well as specific molecular targets of interest (i.e. NfL) will be assessed upon admission (day 1), the next morning (day 2), day 3, day 7, and day 90. Routinely collected clinical data including from neuroimaging will be collected throughout hospitalization.
89020036|NCT05815836||Healthy subjects|102 subjects without acute neurological symptoms. The circulating proteome and metabolome as well as specific molecular targets of interest (i.e. NfL) will be assessed.
89020037|NCT05809414|Experimental|Amantadine|
89020038|NCT05809414|Placebo Comparator|Placebo|
89020039|NCT05809414|Experimental|TMS|
89020040|NCT05809414|Sham Comparator|TMS sham|
89020041|NCT05795517|Experimental|HSK31679 low dose|
89020042|NCT05795517|Experimental|HSK31679 medium dose|
89020043|NCT05795517|Experimental|HSK31679 high dose|
89020044|NCT05795517|Placebo Comparator|Placebo|
89020045|NCT05795517|Active Comparator|Ezetimibe|
89475189|NCT04810910|Experimental|Personalized neoantigen vaccines|"iNeo-Vac-P01 (peptides)： 4 x 300 mcg per peptide given on days 1, 4, 8, 15, 22, 52, and 82 for a total of 7 doses;~GM-CSF: 4 x 40 mcg (total dose 160 mcg) given on days 1, 4, 8, 15, 22, 52, and 82 for a total of 7 doses"
89475190|NCT03331809|Active Comparator|Control|
89475191|NCT03331809|Experimental|Two-hand|
89475192|NCT04791722|Active Comparator|Wave 1|Properties in Wave 1 (n=4) will implement a smoke-free policy on January 1, 2020.
89475193|NCT04791722|Experimental|Wave 2|Properties in Wave 2 (n=4) will implement a smoke-free policy on May 1, 2020.
89475194|NCT04791722|Experimental|Wave 3|Properties in Wave 3 (n=4) will implement a smoke-free policy on October 1, 2020.
89475195|NCT02488083|Experimental|all subjects treated by UltraShape|all the patients undergo fat reduction treatment by UltraShape
89475196|NCT03320265|Experimental|PC-mAb|Phosphorylcholine human monoclonal antibody, i.v. infusions
89475197|NCT03320265|Placebo Comparator|Placebo|Placebo to PC-mAb, i.v. infusions
89020046|NCT05789784|Experimental|mymobility Physical Therapy|The mymobility Physical Therapy cohort will complete an identical protocol to the Standard Office-based Physical Therapy cohort with one exception: the mymobility cohort's therapy for the entire duration of the protocol is administered at home through the mymobility application. This cohort initiates use of the mymobilty application one postoperative day 1. Exercises and restrictions are described in-depth in the Study Protocol document.
89020047|NCT05789784|Active Comparator|Standard Office-based Physical Therapy|The Standard Office-based Physical Therapy cohort completes an identical protocol to the mymobility Physical Therapy cohort with one exception: rather than through use of the mymobility application, the Standard Office-based Physical Therapy cohort's protocol is administered through the traditional means of an exercise handout for postoperative day 1 through 2 weeks followed by formal office-based physical therapy for the duration of the protocol. Exercises and restrictions are described in-depth in the Study Protocol document.
89020048|NCT05774756|Experimental|Setemelanotide|Randomized 2:1 (Setmelanotide: Placebo)
89020049|NCT05774756|Placebo Comparator|Placebo|Randomized 2:1 (Setmelanotide: Placebo)
89020050|NCT05761613|Active Comparator|Endotracheal Tube with Subglottic Secretion Drainage|All patients in this arm will be intubated with an ETT with subglottic secretion drainage
89020051|NCT05761613|Active Comparator|CeraShield Endotracheal Tube|All patients in this arm will be intubated with a ceragenin coated ETT
89475198|NCT04631588|Experimental|Open Label BOTOX|Participants will receive BOTOX at Baseline (Day 1)
89475199|NCT04631588|Experimental|Double-Blind Randomized BOTOX|Participants will receive BOTOX at Baseline (Day 1)
89475200|NCT04631588|Placebo Comparator|Double Blind Randomized Placebo|Participants will receive placebo at Baseline (Day 1)
89475201|NCT02492139|Other|Pumping|Each particpant will pump with the current pumpset one week and then two weeks with the pumpset
89475202|NCT04591886|Experimental|mind. body. voice.|The 10-week mind. body. voice. program
89475203|NCT04591886|No Intervention|Control|Assessment-only control
89020052|NCT05758376|Experimental|Recovery Bridge|Open trial single arm pilot study
89020053|NCT05755165|Active Comparator|Depression|Adolescent depression
89020054|NCT05755165|Active Comparator|Depression, adjusted|Adolescent depression, impacted by racism
89020055|NCT05755165|Active Comparator|Control|Control condition
89020056|NCT05739942|Experimental|[177Lu]Lu-NeoB in Combination with Radiotherapy (RT) and Temozolomide (TMZ)|In newly diagnosed glioblastoma
89020057|NCT05739942|Experimental|[177Lu]Lu-NeoB as Single Agent|In recurrent glioblastoma
89475204|NCT02490501|Active Comparator|SC0806|Intervention with SC0806 (implantation of device with FGF1 and peripheral nerves) in addition to rehabilitation
89475205|NCT02490501|Other|Controls|Rehabilitation only
89475206|NCT03331653|Experimental|Dry Needling and Ischemic Compression at the Trigger Point|Dry Needling and Ischemic Compression at the Trigger Point
89475207|NCT03331653|Active Comparator|Intervention at 1.5 cm from the Trigger Point|Dry Needling and Ischemic Compression at 1.5 centimeters from the Trigger Point
89475208|NCT03321669|Active Comparator|Increased Fat Diet|
89475209|NCT03321669|Sham Comparator|Low Fat Diet|
89475210|NCT05229380||saccharin test|"The patients with SPT less than 20 minutes are considered to have a normally functioning ET.~The patients with SPT between 20- 45 minutes are considered to have a partial dysfunction of ET .~The patients with SPT more than 45 minutes are considered to have a gross dysfunction of the ET ."
89020058|NCT05725408|Experimental|Telehealth Group|Participants will be randomized to the telehealth group where they will attend weekly group intervention sessions online through the Zoom platform. Participants will be emailed or mailed materials for session since they will not be attending in-person. Participants will not be asked to attend any sessions or portions of the study in-person.
89020059|NCT05725408|Active Comparator|In-Person Group|Participants will be randomized to the in-person group where they will attend weekly group intervention sessions at a building on the Texas A&M University campus. Participants will be emailed or provided session materials when they arrive for sessions. After the first session, they will not be attending any online sessions.
89020060|NCT05723510|Experimental|Edoxaban 60mg|Multiple dosing of edoxaban alone once daily for 5 days
89020061|NCT05723510|Experimental|Edoxaban 60mg + Tegoprazan 50mg|Multiple dosing of edoxaban once daily in combination with tegoprazan once daily for 5 days
89475211|NCT05229380||methylene blue test|"The patients with methylene blue clearance time less than 10 minutes are considered to have a normally functioning ET.~The patients with methylene blue clearance time between10 to 20 minutes are considered to have a partial dysfunction of ET.~The patients with methylene blue clearance time more than 20 minutes are considered to have a gross dysfunction of the ET ."
89020062|NCT05723510|Experimental|Apixaban 5mg|Multiple dosing of apixaban alone twice daily for 5 days
89020063|NCT05723510|Experimental|Apixaban 5mg + Tegoprazan 50mg|Multiple dosing of apixaban twice daily in combination with tegoprazan once daily for 5 days
89020064|NCT05723510|Experimental|Rivaroxaban 20mg|Multiple dosing of rivaroxaban alone once daily for 5 days
89020065|NCT05723510|Experimental|Rivaroxaban 20mg + Tegoprazan 50mg|Multiple dosing of rivaroxaban once daily in combination with tegoprazan once daily for 5 days
89475212|NCT02490423|Active Comparator|Nudges Intervention|The intervention arm will employ standard cardiovascular clinical care plus the combination of the MoBe Maps Patient Activation Platform with the Intermountain Risk Score to personalize and deliver motivational nudges to each participant.
89475213|NCT02490423|No Intervention|Standard of Care|The standard of care arm will utilize Intermountain cardiovascular clinical program care processes as they are in place today for treatment of the study subjects.
89475214|NCT03320187|Experimental|Group A|Nitroglycerin as Nitroderm TTSⓇ skin patch is applied on the upper chest alongside with regular induction of labor protocol ( 3gm/ 8 hours DinoprostoneⓇ vaginal tablet in the posterior vaginal fornix)
89475215|NCT03320187|Placebo Comparator|Group B|Placebo patch is applied on the upper chest alongside with regular induction of labour protocol ( 3gm/ 8 hours DinoprostoneⓇ vaginal tablet in the posterior vaginal fornix)
89475216|NCT04511156|Experimental|Foundational Helping Skills|The Foundational Helping Skills training will be intervention to be evaluated in this study. The Foundational Helping Skills is a flexible curriculum, with an approximate 3-day (20 hour) duration to be modified based on context and personnel. The Foundational Helping Skills is a human-centered design competency-based training in foundational helping skills. The training curriculum has been developed in a modular format, with each module relating to specific foundational helping skills (e.g., non-verbal communication, confidentiality, etc). The training curriculum can be found. The general training outline includes two days of foundational helping skill modules, brief role-play competency assessments at the end of each foundational helping skills training day to inform trainers which competencies need remediation, and a half-day of training that involves a remediation of the specific foundational helping skills that have been identified via the brief role-play assessments.
89475217|NCT04530812|Experimental|Arm I (commercial kefir beverage)|Patients consume commercial kefir beverage daily for 3 months.
89475218|NCT04530812|Active Comparator|Arm II (usual diet)|Patients maintain usual diet for 3 months.
89475219|NCT04529876||Tofacitinib|Reference group
89475220|NCT04529876||Abatacept|Exposure group
89475221|NCT03320031|Experimental|combined group|Drug: linagliptin&premixed insulin Treated with linagliptin 5mg/d combined with premixed insulin for 12 weeks.
89475222|NCT03320031|Active Comparator|linsulin group|Drug: premixed insulin Treated with premixed insulin for 12 weeks.
89475223|NCT04510922|Experimental|Droxidopa|100-600mg droxidopa TID
89475224|NCT05465031|Experimental|Experimental: Sacubitril/Valsartan|After assessment of the tolerance of the drug during the single-blind period, during the which the starting dose of the drug of 100 mg b.i.d. should be increased after two weeks to the target dose 200 mg b.i.d, the patients will be randomized in 1:1 ratio to either intervention or placebo group. In the experimental arm, the patients after randomization will receive the dose 200 mg b.i.d of sacubitril/valsartan for the course of the study. If the patients does not tolerate the target dose of 200 mg b.i.d., the reduction of the drug dose to 100 mg b.i.d. will be possible at the discretion of the physician-in-charge.
89475225|NCT05465031|Placebo Comparator|Placebo|After assessment of the tolerance of the drug during the single-blind period, during the which the starting dose of the drug of 100 mg b.i.d. should be increased after two weeks to the target dose 200 mg b.i.d, the patients will be randomized in 1:1 ratio to either intervention or placebo group. In the placebo arm, the paitents will receive the matching placebo with an identical strategy of dose reduction as in the intervention group, at the discretion of the physician-in-charge.
89475226|NCT04510844|Experimental|Study Drug Group|Participants who will receive a shot of the Evolocumab at Visit 3 and self-administer the rest of the shots at visit 4-7.
89020066|NCT05717400|Experimental|DAA therapy plus Bevacizumb and Atezolizumab|Participants will receive bevacizumab and atezolizumab about every 3 weeks as part of the standard of care HCC treatment that is managed by your cancer doctor. In addition, Participants will continue receiving your standard of care DAAs (either sofosbuvir + velpatasvir or sofosbuvir + velpatasvir + voxilaprevir)
89020067|NCT05709782|Experimental|Group 1 (Therapeutic Cohort)|Participants in Group 1 will receive spine radiosurgery on the MR LINAC machine, along with imaging scans using the same machine.
89020068|NCT05709782|Experimental|Group 2 (Imaging-only Cohort)|Participants in Group 2 will receive spine radiosurgery using a standard radiation therapy machine and have the opportunity to get imaging on the MR LINAC.
89020069|NCT05709210|Other|Memory complaint|
89020070|NCT05709210|Other|Mild cognitive decline|
89020071|NCT05709210|Other|Alzheimer's Disease|
89020072|NCT05704920|Experimental|IA Group|Patients with at least one nodule (> 6mm) for whom the multidisciplinary team meeting discussion is informed of the AI-based analysis of their chest computed tomography
89020073|NCT05704920|Other|Group not IA analysis|Patients with at least one nodule (> 6mm) for whom the multidisciplinary team meeting discussion is not informed of the AI-based analysis of their chest computed tomography
89020074|NCT05704647|Experimental|Relatlimab+Nivolumab|Participants will receive nivolumab in combination with relatlimab by vein over about 30 minutes on Day 1 of each 28-day study cycle. You may receive up to 25 doses of the study drugs.
89475227|NCT04510844|Placebo Comparator|Placebo group|Participants who will receive a Placebo shot at Visit 3 and self-administer the rest of the shots at visit 4-7.
89475228|NCT05464953|Active Comparator|Formulated Posterior Sub Tenon Triamcinolone|
89475229|NCT05464953|Active Comparator|Posterior Sub Tenon Triamcinolone alone|
89475230|NCT05464953|Active Comparator|suprachoroidal Triamcinolone|
89475231|NCT02491749|Experimental|Ultra Fast-Track Anesthesia|Patients who fulfilled the extubation criteria were extubated at the end of surgery and transferred to the ICU for follow up.
89475232|NCT02491749|Experimental|Conventional|patients who did not fulfill extubation criteria were left intubated and sedated and transferred to the ICU for later management
89475233|NCT04443296|Experimental|CCRT+TIL|Cisplatin based concurrent chemoradiotherapy(CCRT) combined with tumor-infiltrating lymphocyte (TIL)
89475234|NCT03331575|Experimental|Arm1(Hypofractionated Radiotherapy)|Hypofractionated Radiotherap（PTV-G60.5Gy/22Fx, 2.75Gy/Fx; PTV-C 49.5Gy/22Fx, 2.25Gy/Fx）, with concurrent chemotherapy : Cisplatin(20 mg/m2 d1) Docetaxel (20 mg/m2 d1),weekly, 6 cycles )
89475235|NCT03331575|Placebo Comparator|Arms2（Conventional Radiotherapy）|Conventional Radiotherapy（PTV-G60Gy/30Fx,2Gy/Fx; PTV-C 50.4Gy/30Fx, 1.8Gy/Fx）, with concurrent chemotherapy : Cisplatin(20 mg/m2 d1) Docetaxel (20 mg/m2 d1),weekly, 6 cycles )
89475236|NCT03321435||placenta previa group|
89475237|NCT03321435||Normal control group|
89475238|NCT04243070|Other|3-channel Holter ECG recording for EPS patient|Patients participating in an EPS will undergo a 3-channel Holter ECG recording in parallel to the standard 12-channel Holter ECG recording during the EPS followed by an optional 24 h observation period
89475239|NCT04243070|Other|12-channel Holter ECG recording for non-EPS patients|Patients scheduled for a follow-up for their heart disease will undergo a 12-channel Holter ECG recording while participating in a Body Motion test followed by a 24 h observation period
89475240|NCT03756740|Experimental|Telerehabilitation|After each face to face session the patient will receive the exercises ordered by the physical therapist to perform at home. The exercises will be sent as a video to his/her mobile or e-mail according to the subject's preference. The exercises will be previously recorded and accompanied with a verbal explanation and instructions on how to correctly perform the exercises, paying close attention to specific points. In total, there will be 10 videos of exercises found effective for LBP patients.. After each face to face meeting, the physical therapist will choose from these 10 videos suitable exercises for the patients.
89475241|NCT03756740|Active Comparator|Control|"After each face to face session the patient will receive the exercises ordered by the physical therapist to perform at home.~subjects will receive the same exercises given to experimental group according to the results of the face to face meeting. The exercises will be shown as printed pictures on paper"
89475242|NCT02727699|Experimental|Xanamem™|Oral Xanamem™ capsules 10mg, to be administered once daily
89202682|NCT04980456|Other|TOTAL30, then Biofinity|Lehfilcon A contact lenses worn first, followed by comfilcon A contact lenses as randomized. Each study product will be worn bilaterally (in both eyes) for approximately 30 days for at least 10 hours per day during waking hours only. CLEAR CARE will be used for daily cleaning and disinfection.
89202683|NCT04980456|Other|Biofinity, then TOTAL30|Comfilcon A contact lenses worn first, followed by lehfilcon A contact lenses, as randomized. Each study product will be worn bilaterally (in both eyes) for at least 10 hours per day during waking hours only. CLEAR CARE will be used for daily cleaning and disinfection.
89202684|NCT05359432|Experimental|Empagliflozin|
89475243|NCT02727699|Placebo Comparator|Placebo|Matching placebo which is identical in appearance to the test product except that it contains no active ingredient, to be administered once daily
89475244|NCT05228600|Experimental|YL-13027|"YL-13027 is a novel small molecule TGF-βR1 inhibitor. 1.1.1. Chemical Properties~Chemical Name:~6-(5-fluoro-2-(6-methylpyridin-2-yl)phenyl)imidazo[1,2-a]pyridine-3-carboxamide Molecular Formula C20H15FN4O Molecular Weight 346.36 Formulation YL-13027 is provided as pink film coated tablets for oral administration in two strengths, 30 mg and 120 mg.~Packaging and Storage YL-13027 tablets are packaged (30 tablets/bottle) in the 45 mL opaque HDPE bottles with child resistant polypropylene caps, induction-sealed inner polypropylene liners. YL-13027 tablets should be protected from light in a closed container and stored at room temperature.~Stability The shelf-life of YL-13027 oral tablets is tentatively set at 24 months when stored at room temperature."
88949863|NCT01940302|No Intervention|Control|Received only oral hypoglycemic agents.
89475245|NCT04408898|Experimental|ADP-A2M4 T cells in combination with pembrolizumab|
89475246|NCT03747926|Experimental|BI 705564|
89475247|NCT03747926|Placebo Comparator|Placebo|
89475248|NCT03331419||Males with Chronic Fatigue Syndrome|Two brief high effort exercise tests on consecutive days in our laboratory in order to provoke abnormalities in ME/CFS patients with respect to autonomic function, symptom exacerbation, and activity limitations.
89475249|NCT03331419||Females with Chronic Fatigue Syndrome|Two brief high effort exercise tests on consecutive days in our laboratory in order to provoke abnormalities in ME/CFS patients with respect to autonomic function, symptom exacerbation, and activity limitations.
88949864|NCT01940315|Active Comparator|rBV A/B|0.5 mL dose of rBV A/B (40 µg) will be administered intramuscularly (IM) in a three-dose dosing schedule given at Days 0, 28 ± 5 days, and 182 ± 9 days
88949865|NCT01940315|Placebo Comparator|Placebo|0.5 mL dose of placebo will be administered intramuscularly (IM) given at Days 0, 28 ± 5 days, and 182 ± 9 days
89202685|NCT05359432|Experimental|Vildagliptin|
89475250|NCT03543722|Experimental|National Career Coach Program|This program has four main components: a 4-day in-person introductory seminar held in Alpharetta, GA, up to 18 months of job coaching provided by telephone and Skype, a human capital fund to pay for expenses of securing a job (e.g., travel, clothing, computers, professional organization fees), and an opportunity for two years to earn a bonus for employment earnings above a certain level.
89020075|NCT05696977|Active Comparator|Obese nephrotic patients with BMI>25 kg/m2|"Nephrotic obese patients receive Cyclosporine capsule initially according to weight-based dose then modifying the dose according to targeted therapeutic level.~To determine the best weight can be used to get the targeted therapeutic level. Correlate with the lipid profile, fat percentage and other anthropometric measures."
89020076|NCT05696977|Other|Non obese nephrotic patients with BMI<25 kg/m2|Nephrotic non-obese patients receive Cyclosporine capsule initially according to weight-based dose then modified dose according to targeted therapeutic level.
89020077|NCT05695040|Experimental|dietary workshop conducted on the 15th postoperative day|
89020078|NCT05695040|No Intervention|Standard care|
89020079|NCT05689892|Experimental|Intervention group|Participants who have been diagnosed with IBD and are recommended a new biologic therapy will be recruited to this arm. Participants and their families will be referred to a decision coach (DC), who will provide support in gaining knowledge of treatment and care options. They will also be given decision aids (DA) as outlined in the study description.
89020080|NCT05689892|No Intervention|Comparator group|Participants who have been recommended a new biologic therapy within the last 12 months and have commenced treatment will be recruited to this arm.
89202686|NCT00755456|Active Comparator|Glucose solution|
89020081|NCT05689684|Active Comparator|Hybrid Product: Aarabinogalactan (AG)+xylan-oligosaccharides (XOS) +AXOS|Daily 2x 5g Hybrid Product, produced by Carbiotix AB. Hybrid Product is available as powder, which can be easily dissolved in water.
89202687|NCT00755456|Experimental|Glucose and L-carnitine solution|
89020082|NCT05689684|Placebo Comparator|Placebo|Daily 2x 5g maltodextrin. Maltodextrin is available as powder, which can be easily dissolved in water.
89020083|NCT05678218||Presumed resectable perihilar, intrahepatic or mid-common bile duct (CBD) cholangiocarcinoma|
89020084|NCT05677204||Acute Achilles tendinopathy|No intervention will be given
89202688|NCT00789516||1|Normal control
89202689|NCT00789516||2|B thalassemia regular transfusion
89202690|NCT00789516||3|B thalassemia post transplantation
89202691|NCT00755534|Experimental|1|Irinotecan+Erbitux -> XELOX+Erbitux
89202692|NCT00755534|Experimental|2|XELOX+Erbitux ->Irinotecan+Erbitux
89020085|NCT05676294|Experimental|Olanzapine|olanzapine oral tablet, 5mg, once prior to surgery
89202693|NCT00326599|Experimental|Arm I|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, carboplatin IV over 30 minutes on day 1, and oral AZD2171 once daily on days 1-21. Treatment repeats every 21 days for up to 6 courses. Patients achieving stable disease, partial response, or complete response after 6 courses of therapy receive AZD2171 alone as above. Treatment with AZD2171 repeats every 21 days in the absence of disease progression or unacceptable toxicity.
89475251|NCT03543722|Active Comparator|Local Community Resources Program|Consists of referral to three local face-to-face service providers offering veterans training, financial assistance, and paid work experiences: The Department of Veterans Affairs Compensated Work Therapy Program, the state Vocational Rehabilitation program, and the Department of Labor America's Job Center.
89475252|NCT02490345|Active Comparator|Gabapentin Administration|gabapentin 600mg orally every 8 hours x 48 hours
89475253|NCT02490345|Placebo Comparator|Placebo|Placebo , 1 tablet, orally every 8 hours x 48 hours
89475254|NCT03319641|Experimental|PSMA-PET/CT scan|PSMA-PET/CT imaging in advanced ACC/SDC
89475255|NCT05228054|Experimental|Laser 1940nm|Patients with hemorrhoidal deasease 2-3 st. who will be treated with laser 1940nm
89475256|NCT05228054|Active Comparator|sclerotherapy|Patients with hemorrhoidal deasease 2-3 st. who will be treated with sclerotherapy
89020086|NCT05676294|Placebo Comparator|Placebo|placebo oral tablet once prior to surgery
89020087|NCT05665088|Experimental|Cohort 1- 40 Micrograms|Sublingual film containing 40 Micrograms Dexmedetomidine
89020088|NCT05665088|Experimental|Cohort 2- 60 Micrograms|Sublingual film containing 60 Micrograms Dexmedetomidine
89020089|NCT05665088|Placebo Comparator|Placebo|Sublingual Placebo film
89020090|NCT05665049|No Intervention|Control Group|Only educational materials focused on the benefits of exclusive breastfeeding and the current international recommendations are provided.
89020091|NCT05665049|Experimental|Intervention Group 1 - Non-Conditional Social Transfer|Educational materials focused on the benefits of exclusive breastfeeding and the current international recommendations are provided. At the baseline visit, participants are told that at the 6-month visit, they will receive a gift of their choice - which is meant to show our appreciation and support for their efforts in breastfeeding.
89020092|NCT05665049|Experimental|Intervention Group 2 - Conditional Social Transfer|Educational materials focused on the benefits of exclusive breastfeeding and the current international recommendations are provided. At the baseline visit, participants are told that at the 6-month visit, they will receive a gift of their choice if they are still exclusively breastfeeding.
89202694|NCT00326599|Active Comparator|Arm II|Patients receive gemcitabine and carboplatin as in arm I. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
89202695|NCT00797550|Active Comparator|Control|The Control arm of the study will receive bone autograft.
89202696|NCT00797550|Experimental|Treatment|The Treatment arm of the study will receive single level posterolateral spinal fusion between L1 to S1 levels with implantation of BRC product.
89202697|NCT05004688|Experimental|BCG|Active BCG immunization
89202698|NCT00797628|Experimental|Information Prescription|"Providers will give usual care to patients who smoke and a paper prescription with the name and url of the Smoking Coach website. The smoking coach website is a tailored, public health intervention for smoking cessation."
89202699|NCT00797628|Experimental|QUIT-PRIMO|Providers will give usual care to patients who smoke and then refer patients to the online smoking cessation system electronically.
89202700|NCT00750386|Experimental|1|Paclitaxel/Carboplatin
89202701|NCT00539032|Experimental|Group 1: Menactra® Booster Group|Participants who had received 2 doses of quadrivalent (A, C, Y, and W-135) meningococcal polysaccharide vaccine before age 2 years received a booster vaccination with Menactra® vaccine.
89475257|NCT02487927||Weaning success|patients pass SBT and weaning without any ventilation in 48 hours
89475258|NCT02487927||weaning failure|patients do not pass SBT or ventilation with any ventilation in 48 hours
89475259|NCT03991286|Placebo Comparator|Placebo|"Drug: Placebo~Ovulatory Agent:~Clomiphene Citrate"
89475260|NCT03991286|Experimental|experimental|"Drug: Astaxanthin 8mg~Drug: Ovulatory Agent Clomiphene Citrate"
89475261|NCT03331263|Experimental|Abdominal application of 2% CHG|
89475262|NCT03331263|Experimental|Groin application of 2% CHG|
89475263|NCT03331263|No Intervention|Control treatment with no application|
89475264|NCT04111016||Participants able to access the intervention|These group sessions will be delivered by government health workers, and include behavioral recommendations about responsive stimulation, nutrition, water, sanitation and hygiene, lead poisoning prevention, and maternal mental health. Pregnancy groups and caregiver-child groups will be held separately, and mothers and caregivers who attend sessions will receive simple toys and books to use during some of the intervention sessions, which they will be permitted to take home with them. In addition, mothers and caregivers who attend intervention sessions will receive 30 sachets containing 1 gm multiple micronutrient powder (MNP) per month. Beginning as soon as pregnancy is confirmed, health workers will facilitate pregnant women in receiving the Iron and Folic acid supplements already provided by the Government of Bangladesh and will continue the supplementation up to three months post-partum period.
89475265|NCT02487693|No Intervention|RFA alone|Patients undergo radiofrequency ablation alone.
89475266|NCT02487693|Experimental|RFA+CIK|Autologous cytokine-induced killer cells were transfer via venous one week after RFA Interventions
89475267|NCT03943082|Active Comparator|Cohort A : Usual Care (FRP Only)|Patients or parents/legal guardians of patients receive FRP brochure at the time of iMPACT consent.
89475268|NCT03943082|Experimental|Cohort A: Usual Care + Intervention (FRP + Follow-up)|Patients or parents/legal guardians of patients receive FRP brochure at the time of iMPACT consent and a follow-up phone call on day 3 after iMPACT consent.
89475269|NCT02490033|Other|Contact force unblinded|
89475270|NCT02490033|Other|Contact force blinded|
89475271|NCT02490033|Other|ECI unblinded|
89475272|NCT02490033|Other|ECI blinded|
89475273|NCT02490267||1|children with primary or secondary glaucoma
89475274|NCT02490267||2|children w/ cataract or previously treated for cataract
89475275|NCT02490267||3|children w/ microphthalmia, anophthalmia or coloboma
88949866|NCT01940328||Decompensated CHF|patients with acute pulmonary congestion or pulmonary edema
88949867|NCT01940328||Compensated CHF|patients with significant stable left HF (NYHA II-III) who are on optimal medical treatment for CHF, and are without clinical or laboratory evidence of pulmonary congestion
88949868|NCT01940328||Non CHF patients|patients without CHF and without uncontrolled hypertension.
88949869|NCT01940367|Active Comparator|PTNS Arm|Subjects randomized to the PTNS arm will undergo PTNS treatment once weekly for 30 minutes for 12 weeks total. If at 12 weeks they are considered to have a positive response to therapy, they will continue maintenance therapy in a tapered fashion: subjects will come in every 2 weeks for the next 8 weeks for 30 minute treatments (4 visits total), then every 3-4 weeks for 30 minute treatments for the remaining 32 weeks of the year (8-10 visits).
88949870|NCT01940367|Active Comparator|TENS Arm|Subjects randomized to the TENS arm of the study will begin therapy after their baseline evaluation is complete. They will be issued a home TENS device (EMPI TENS Select) and will administer self-treatment daily for 2 hours per day (1 hour in the morning and 1 hour in the evening) for a total of 12 weeks. If they are considered to have a positive response with TENS treatment, subjects will continue by weaning use over a three-month time period. They will begin with 3 x per week for 1 month, then 2 x per week for 1 month, then 1 x per week for 1 month, all at 2 hours per day.
88949871|NCT01940393|Active Comparator|Cetirizine|Cetirizine
88949872|NCT01940393|Active Comparator|Desloratadine|desloratadine
88949873|NCT01940393|Active Comparator|Fexofenadine|Fexofenadine
88949874|NCT01940393|Active Comparator|Ebastine|ebastine
88949875|NCT01940393|Active Comparator|Bilastine|bilastine
88949876|NCT01940406|Experimental|Stimulation procedure|Stimulation procedure
88949877|NCT01940419|Active Comparator|Tranexamic Acid|1g Tranexamic acid iv just before surgery
89475276|NCT02490267||control group|age matched children without eye and vision problems.
89475277|NCT02490189|Experimental|Mindfulness-Based Intervention|Participants in the mindfulness-based intervention arm will receive 12 weekly sessions of 2 to 2.5 hours duration. The intervention will be delivered in a group format. Participants will be assigned weekly homework.
89475278|NCT02490189|Active Comparator|Cognitive Behavior Group Therapy|Participants in the cognitive behavior group therapy arm will receive 12 weekly sessions of 2 to 2.5 hours in duration. Participants will be assigned weekly homework.
89475279|NCT04436120|Other|Tumor biopsy and blood draw|Tumor biopsy and blood draw
89475280|NCT02491827||Cellvizio mini laser probe|Cellvizio mini laser probe will be administered via the endoscopic device used for the neurosurgical procedure to provide confocal laser endomicroscopy in patients requiring neurosurgery due to glioma multiforme or subcranial tumors
89475281|NCT03319563|Experimental|local anesthetic-epinephrine group|"after general anesthesia, the Infiltration cocktail was done by the surgeon at three levels:~Subcutaneous: before incision at a volume 20 ml/10 cm/side.~Muscular Paravertebral: before opening the thoracolumbar fascia, using the same previous volume.~Neural paravertebral: after exposure of the transverse processes. A volume of 5 ml/per each process of the same cocktail, 1 cm deep to the surface of the corresponding process before pedicular screws fixation after negative blood aspiration."
89475282|NCT03319563|Placebo Comparator|saline group|after general anesthesia, the same infiltration volume and technique using normal saline.
89475283|NCT02485119|Experimental|BAY94-9343|"Cohort 1: Safety, tolerability and PK of 4.5 mg/kg dose given Q3W. Proceeding to Cohort 2 or not will be decided based on both safety variables during Cycle 1 (21 days) of 3 to 6 subjects in Cohort 1 and PK obtained from Cycle 1 (at least Day 1 to Day 5).~Cohort 2: Safety, tolerability and PK of 6.5 mg/kg dose given Q3W. Whether recruitment will be continued up to 9 subjects for Cohort 2 or not will be decided based on safety variables during Cycle 1 (21 days) of the first 3 subjects in Cohort 2. The safety and tolerability of 6.5 mg/kg will be assessed based on the data of 9 subjects during Cycle 1 in Cohort 2, and considering long term toxicity, the safety and tolerability of BAY94-9343 will be assessed all safety data by the end of 3 cycles in Cohort 2."
89475284|NCT03153020||Cohort of patients with stroke or transient ischemic attack|The cohort will be constituted of all consecutive patients admitted for a stroke or transient ischemic attack by the Rhône's emergency medical help service (SAMU), or in one of the emergency unit or stroke unit of the Rhône area, and presenting a symptom-onset (the last time the patient was seen without deficit) less than 24 hours.
89475285|NCT04060940|Experimental|Emotion Regulation Therapy: 8-session version|All participants will be randomly assigned to an 8-session or 16-session version of ERT with equal probability. Participants assigned to the 8-session version of ERT will receive 8 sessions of individualized therapy, each of which is 1-1.5 hours, on a weekly basis. Sessions 1-5 will be 1 hour long, sessions 6 and 7 will be 1.5 hours long, and session 8 will be one hour long, resulting in a total required time commitment of 9 hours over the course of 8 weeks.
89475286|NCT04060940|Experimental|Emotion Regulation Therapy: 16-session version|All participants will be randomly assigned to an 8-session or 16-session version of ERT with equal probability. Participants assigned to the 16-session version of ERT will receive 16 sessions of individualized therapy, each of which is 1-1.5 hours, on a weekly basis. Sessions 1-9 will be 1 hour long, sessions 10-13 will be 1.5 hours long, and sessions 14-16 will be 1 hour long, resulting in a total required time commitment of 18 hours over the course of 16 weeks.
89475287|NCT02490111|Experimental|DWJ1319 300 mg BID|DWJ1319 300 mg, orally, twice daily (BID) for up to 12 months
89475288|NCT02490111|Experimental|DWJ1319 300 mg QD|DWJ1319 300 mg, orally, once daily (QD), and DWJ1319 placebo-matching capsules, orally, once daily for up to 12 months
89475289|NCT02490111|Placebo Comparator|Placebo|Placebo, orally, twice daily (BID) for up to 12 months
89475290|NCT03316365|Experimental|Continuous RAS|The experimental group (continuous treatment) trained daily with RAS for 24 weeks.
89475291|NCT03316365|Active Comparator|Intermittent RAS|The control group (intermittent treatment) trained with RAS for 8 weeks, discontinued training for 8 weeks, and resumed training with RAS for 8 weeks.
89475292|NCT05190224|Experimental|Experimental-|All participants will be included in this arm
89475293|NCT02484573|Experimental|Propanolol|Patients will take the non-selective beta blocker propranolol for approximately 4 weeks starting immediately after endoscopy for esophageal variceal ligation. Patients will be initiated on a dose of 20mg by mouth every 12 hrs before titration to maximum tolerated dose. Patients will undergo testing before and after treatment for the variables listed in the outcomes section below.
89475294|NCT02489955|Experimental|AUC group|
89475295|NCT02489955|Active Comparator|Trough dose monitoring|
88949878|NCT01940419|Placebo Comparator|Placebo|sterile sodium chloride 9mg/ml iv
88949879|NCT01940432|Experimental|electroacupuncture group|Bilateral BL33 are given acupuncture of 50-60mm with 30-45°angle to inward and downward. Bilateral BL35 are given acupuncture of 50-60mm to outward and upward. The electric stimulator is applied to bilateral BL33 and BL35.Every session lasts for 30 min per day.The participants are treated continuously for 8 weeks for 3 sessions a week, 24 sessions for each patient in all.
88949880|NCT01940432|Experimental|pelvic floor muscle training group|Standing/sitting/lying on back, knees bent to chest. A set consists of three contractions, each lasting 10s, with a 10s break between contractions. Counting or measuring the duration of contractions and breaks is accomplished without effort by taking advantage of the duration of normal breaths. As most men take about 10 breaths per minute, each breath can be used as 6s timing device.The participants are treated continuously for 8 weeks for 3 sessions a week, 24 sessions for each patient in all.
88949881|NCT01940445|Experimental|ResurFX treatment|Fractional Non Ablative (NA) treatment on one side of the face with the M22 ResurFX module
88949882|NCT01940445|Experimental|M22 ResurFX and QS treatment|Fractional NA treatment with the M22 ResurFX followed by Q-Switched (QS) laser treatment (SST) on one side of the face
88949883|NCT01940536|Active Comparator|Tranexamic Acid|1g tranexamic acid, intravenous, at time of sudy enrollment and again a surgical incision
89475296|NCT03784430|Active Comparator|Implant|Immediate dental implant placement
89475297|NCT03784430|Experimental|Implant+CTG|Immediate dental implant placement with CTG.
89475298|NCT03319485|Experimental|ExAblate Pallidotomy|ExAblate treatment for Advanced Idiopathic Parkinson's Disease
89475299|NCT03319485|Sham Comparator|Sham ExAblate Pallidotomy|Sham (fake) treatment
89475300|NCT02484495|Experimental|Program evaluation in intervention areas|"A quasi-experimental matched-control cluster design will be used in which outcomes are compared in intervention and non-intervention areas. The program evaluation will have three points of data collection to assess effect of the program on the nutritional status of children 6-29 months. Sixty intervention clusters have been purposively selected whereas the data will be collected from randomly selected subjects. The following interventions will be provided:~Processed complementary food rations will be distributed to all children 6-23 months of age, from a grain bank based on bartering of raw materials.~Monthly 15 sachets of MNP will be provided to all children 6-23 months of age with the instruction to add them to their complementary food, to enable point-of-use fortification."
89475301|NCT02484495|No Intervention|Non intervention areas|A quasi-experimental matched-control cluster design will be used in which outcomes will be compared in intervention and non-intervention clusters. The program evaluation will have three points of data collection to assess effect of the program on the nutritional status of children 6-29 months. Matching sixty non-intervention clusters have been purposively selected out of the predetermined non- intervention districts whereas study subjects will be randomly selected from the identified clusters on a population based sampling method both groups. These non-intervention areas do not get processed complementary food rations and do not receive MNPs.
89475302|NCT03734744|Experimental|Adults with Cystic Fibrosis|CF adults with vitamin D insufficiency or deficiency will receive 300,000-600,000 IU vitamin D3 (cholecalciferol)
89475303|NCT03734744|Experimental|Non-CF Controls with Low vitamin D|Non-CF controls with vitamin D insufficiency or deficiency will receive 300,000-600,000 IU vitamin D3 (cholecalciferol)
89475304|NCT03316287|Experimental|Hearing aid + mobile phone|
89475305|NCT03316287|Experimental|Hearing aid + mobile phone + biosensor|
89475306|NCT03731546|No Intervention|Group A|Placental insufficiency and ICC : Immediate cord clamping after delivery of the fetus in preterm infants with placental insufficiency
89475307|NCT03731546|Active Comparator|Group B|Placental insufficiency and DCC: Cord clamping 60 seconds after delivery of fetus in preterm infants with placental insufficiency
89475308|NCT03731546|Active Comparator|Group C|Normal placenta with DCC:Cord clamping 60 seconds after delivery of fetus in preterm infants without placental insufficiency
89475309|NCT03319329||critically ill adult patients|"Part I: A cross-sectional study to compare validity of several predictive equations used to predict REE in critically ill adult patients for staying ≤ 5 days, 6 - 10 days and > 10 days by using indirect calorimetry (IC) as the reference standard.~Part II: To develop predictive equation for the estimation of energy requirement by identifying variables that might influence REE of mechanically ventilated critically ill patients.~Part III: To validate the newly developed predictive equation for the estimation of energy requirement by using Ten fold cross-validation approach"
89475310|NCT04715126|Active Comparator|Oxyjun (Extract of Terminilia Arjuna).|
89475311|NCT04715126|Placebo Comparator|Placebo (Microcrystalline cellulose)|
89475312|NCT02487537|Placebo Comparator|Non-sweetened soft drink|4-week-intervention with one liter of custom-made soft drink per day; soft drink does not contain glucose or any kind of sweet tasting substance
89475313|NCT02487537|Active Comparator|Sweetened soft drink|4-week-intervention with one liter of custom-made soft drink per day, soft drinks contains an amount of sweetener, which is isosweet compared to 100 g of sucrose in one liter of beverage
89475314|NCT04636502||Cohort|Participants who had treated with fSCIG (HyQvia) for not more than 27 months and SCIG 20% (Cuvitru) for not more than 35 months.
89475315|NCT02484105|Experimental|Comforting Conversation|Conversation according to the initital qualitative study.
89475316|NCT02484105|Active Comparator|Standard Communication|Standard information prior to and during endoscopy.
89475317|NCT02487459|Experimental|BPX-501 and AP1903|"Three cohorts, 3 patients each, will receive two infusions (at the same dose) of BPX-501.~If needed to treat aGVHD, a single dose of AP1903 will be administered IV."
89020093|NCT05662241|Experimental|ZB012|Obexelimab administered as an SC injection.
89475318|NCT03319095|No Intervention|Control|Control group: participants will receive only verbal instructions on PFM anatomy and function during the first assessment when women will be required to contract their pelvic floor muscle. The participants will have no contact with the service until the second assessment
89475319|NCT03319095|Active Comparator|Intervention|Intravaginal Electrical Nerve Stimulation: participants will be submitted to Intravaginal Electrical Nerve Stimulation
89475320|NCT03321279|No Intervention|Control|Participants' daily step counts will be for weeks 2-13 after hospital discharge. Participants will be asked to complete surveys at 5, 9 and 13 weeks post-discharge.
89475321|NCT03321279|Experimental|Intervention|Participants' daily step counts will be monitored for weeks 2-13 after hospital discharge. Participants will have a weekly step goal that increases from baseline by 10% each week of the intervention (12 weeks). Participants will engage in a social incentive-based gamification based on points and levels that leverages loss aversion, which has been demonstrated to motivate behavior change more effectively with losses than gains. Participants will receive daily feedback for the step counts and weekly feedback for levels. Participants will be asked to identify a support partner, who will receive weekly reports with the the participant's points and levels balance.
89475322|NCT02489643|Experimental|Receiving training|Patients will be visited and receive information about the prescribed topical treatment according to the normal course and procedure of an outpatient visit at our institution. At the end of the visit, they will also receive practical instructions on dosages and application modalities of the topical therapy.
89475323|NCT02489643|No Intervention|No-receiving training|
89475324|NCT03315819|Experimental|Bankart repair|Arthroscopic repair of anterior capsulo-labral lesions using the Bankart technique. The procedure must be performed within 15 days of dislocation.
89475325|NCT03315819|Active Comparator|Immobilization interne rotation|Immobilization of the shoulder during 3 weeks
89475326|NCT03576716|Experimental|Study Population|D6-25-hydroxyvitamin D3 with vitamin D3
89475327|NCT03319017||Multiple-trauma patients|The patients who are diagnosed with multiple-trauma and have blood test in an emergency room. The patients with multiple-trauma are defined as the patients who have trauma in more than two regions.
89475328|NCT04505072|Experimental|PR-ESSENCE treatment|PR-ESSENCE treatment 10 weeks
89475329|NCT04505072|Active Comparator|Control|Treatment as usual 10 weeks
88949884|NCT01940536|Placebo Comparator|Placebo Injection|Placebo injection (normal saline) a time of study enrollment and again at time of surgical incision
88949885|NCT01940549|Sham Comparator|Trauma Focused Therapy + Sham tDCS|Trauma Focused Therapy will be conducted during the delivery of sham Transcranial Direct Current Stimulation
88949886|NCT01940549|Active Comparator|Trauma Focused Therapy + active tDCS|Trauma focused therapy will be conducted while active Transcranial Direct Current Stimulation is applied
88949887|NCT01940562|Experimental|Eltrombopag|"Pediatric patients undergoing allogeneic UCB transplantation will receive eltrombopag from day +1 until platelet count has exceeded 50,000/microliter for 14 consecutive days without platelet transfusion.~Starting doses are 100 mg/d for children >40 kg body weight (BW), 50 mg/d for children 20-40 kg BW, and 2 mg/kg/d for children <20 kg BW.~If unsupported platelet count has not reached the threshold of 20,000/microliter, doses will be escalated every 2 weeks up to maximal doses of 200 mg/d for children ≥ 40 kg BW, 150 mg/d for children 20-40 kg BW and 3.5 mg/kg for children <20 kg BW."
88949888|NCT01940575|Active Comparator|Restylane®|Inject Restylane® on right or left nasolabial fold
88949889|NCT01940575|Experimental|SkinPlus-Hyal®|Inject SkinPlus-Hyal® on right or left nasolabial fold
88949890|NCT01940588||Neuropsychoanalytic treatment|Outpatient detoxification, intensive neuropsychoanalytic therapy, low dose naltrexone, monthly evaluations for six months - case series approach.
88949891|NCT01940601|Experimental|Balugrastim 300 ug/kg|Balugrastim 300 μg/kg subcutaneously (SC) administration once per chemotherapy cycle, approximately 24 h after chemotherapy, up to 4 cycles
88949892|NCT01940601|Experimental|Balugrastim 670 μg/kg|Balugrastim 670 μg/kg (maximum 40 mg) SC administration once per chemotherapy cycle, approximately 24 h after chemotherapy, up to 4 cycles
88949893|NCT01940601|Active Comparator|Filgrastim 5 μg/kg|Filgrastim will be administered at a dose of 5 μg/kg SC once a day for at least 5 consecutive days or until absolute neutrophil count (ANC) has returned to ≥2*10^9/L for each chemotherapy cycle up to 4 cycles. The maximum period of filgrastim administration is 14 days in each cycle.
88949894|NCT01940627|Experimental|Ubiquinol|Firemen consuming 200 mg ubiquinol/day during two weeks
89475330|NCT02484183|No Intervention|Low-flow oxygen|Low-flow oxygen supplementation if respiratory danger signs are present or if their oxygen saturation is <90%. Respiratory danger signs include any of the following: grunting, severe chest indrawing, very fast breathing (>70 breaths/minute if 1-11 months; >60 breaths/minute if 12-59 months), nasal flaring, stridor in a calm child, or apnea. Low-flow oxygen given by an oxygen concentrator with a nasal cannula. Low-flow is 0.5 liters per minute (LPM) for patients 1-2 months, and 1-2 LPM for patients 2-59 months. For 2-59 month olds oxygen can be increased to a maximum of 2 LPM to maintain a 90% saturation or treat respiratory danger signs.
89475331|NCT02484183|Experimental|bubble CPAP|Bubble continuous positive airway pressure (bCPAP) patients are eligible if respiratory danger signs are present or if oxygen saturation is <90%. bCPAP will be initiated at 7 centimeters (cm) water (H20) if 1-2 months of age or 8cm H20 if 2-59 months of age using the minimum oxygen flow necessary to achieve these pressures. Gradual weaning can be attempted after 24-48 hours of treatment. All changes will be followed by 60 minutes of monitoring.
89475332|NCT04620434||patient|39 patients who are planning surgeries that require general anesthesia and tracheal intubation
89475333|NCT02487381|Experimental|THC|Subjects receive 20 mg delta-9-tetrahydrocannabinol (2 capsules containing 10 mg each) and corresponding cannabidiol placebo capsules.
89475334|NCT02487381|Experimental|CBD|Subjects receive 800 mg cannabidiol (4 capsules containing 200 mg each) and corresponding delta-9-tetrahydrocannabinol placebo capsules.
88949895|NCT01940627|Placebo Comparator|Control|Firemen consuming placebo capsules during two weeks
88949896|NCT01940640|Experimental|DHA supplementation|mothers consuming 900 mg DHA/day and their neonates.
88949897|NCT01940640|Active Comparator|Control|follow on capsules without probiotics
89475335|NCT02487381|Experimental|CBD+THC|Subjects receive 800 mg cannabidiol (4 capsules containing 200 mg each) and 20 mg delta-9-tetrahydrocannabinol (2 capsules containing 10 mg each) a
89475336|NCT02487381|Placebo Comparator|Placebo|Subjects receive corresponding delta-9-tetrahydrocannabinol and cannabidiol placebo capsules
89475337|NCT04606706|Experimental|Maternal, lactating mother & young child (Intervention)|mHealth education intervention for 6 months
89475338|NCT04606706|No Intervention|Maternal, lactating mother & young child (Control)|Conventional health education
89475339|NCT02487849|Experimental|HIPEC|If patient is eligible - secondary cytoreductive operation will be followed by HIPEC with 800 mg/m² body surface (KOF) Carboplatin with closed technique.
89475340|NCT04435730||Group 1|45 patients with cutaneous psoriasis with no musculoskeletal manifestations.
89475341|NCT04435730||Group 2|45 patients with psoriatic arthritis fulfilling CASPAR criteria of PsA
89475342|NCT04435730||Group 3|45 patients with subclinical psoriatic arthritis (patients with cutaneous psoriasis and musculoskeletal manifestations but not fulfilling CASPARcriteria of PsA).
89475343|NCT04435730||Group 4|45 sex and age matched healthy controls
89475344|NCT02489877||Multiple Sclerosis|Patients diagnosed with Multiple Sclerosis
89475345|NCT02489877||without Multiple Sclerosis|Healthy individuals without neurological disease associated
89475346|NCT02489877||with other neurological diseases|Patients diagnosed with the following diseases: Lateral Amniotrofic Sclerosis, Headache , Parkinson's disease, Dementia and Epilepsy.
89475347|NCT04504448|Experimental|HNC664 capsules|HNC664 capsules,single ascending doses Single dose
89475348|NCT04504448|Placebo Comparator|HNC664 placebos|HNC664 placebos,single ascending doses Single dose
89475349|NCT04504448|Experimental|HNC664 capsules FED|HNC664 capsules,food effect,Single dose
88949898|NCT01940653|Other|Progesterone|Group A receives 5 days of micronized progesterone vaginally (Utrogestan® ((Utrogestan, Besins International). On the 5th (group A) of progesterone supplementation, the cryopreserved-thawed day 3 embryo is transferred.
88949899|NCT01940653|Active Comparator|progesterone 3 days|Group B receives 3 days of micronized progesterone vaginally. On the 3rd day of progesterone supplementation, the cryopreserved-thawed day 3 embryo is transferred.
88949900|NCT01940666||Controls|patients who have all androgens (TT, A4, FAI, and DHEA-S) lower than their cut-off values
88949901|NCT01940666||Total Testosterone >= 2.39|Patients who have only total testosterone higher than its cut-off value; (TT) >=2.39
88949902|NCT01940666||Androstenedione >= 2.99|Patients who have only androstenedione higher than its cut-off value; (A4) >=2.99
88949903|NCT01940666||Free Androgen Index >= 6.53|Patients who have only free androgen index higher than its cut-off value; (FAI) >=6.53
89475350|NCT02484339|Experimental|Treatment Group A|"Radium-223 dichloride (Xofigo®) 55 kilobecquerel (kBq)/kgbw (6 i.v. injections every 4 weeks)~External beam radiotherapy (EBRT)->conventional or high dose radiotherapy"
89475351|NCT02484339|Other|Treatment Group B|External beam radiotherapy (EBRT) ->conventional or high dose radiotherapy
89475352|NCT04021550|Experimental|Combined Treatment|Subjects will be given 80 mg/day Telmisartan + 600 mg/day Alpha-Lipoic Acid. Subjects will also be prescribed CPAP therapy by their physician. Subjects will be instructed to use their CPAP device according to their physician's guidelines.
89475353|NCT04021550|Placebo Comparator|Placebo Control|Subjects will be given placebo capsules. Subjects will also be prescribed CPAP therapy by their physician. Subjects will be instructed to use their CPAP device according to their physician's guidelines.
88949904|NCT01940666||DHEAs >= 181.55|Patients who have only dehyroepiandrosterone sulfate higher than its cut-off value; (DHEA-S)>=181.55
88949905|NCT01940679|Experimental|Fresh meat stick|Fresh meat stick w/ encapsulated 600 mg EPA/DHA; product frozen immediately after production.
88949906|NCT01940679|Experimental|Stored meat stick|Stored meat stick with encapsulated 600 mg EPA/DHA; stored at 100F for 3 months after production
88949907|NCT01940679|Experimental|Fresh pound cake|Fresh pound cake w/ encapsulated 600 mg EPA/DHA; product frozen immediately after production.
88949908|NCT01940679|Experimental|Stored pound cake|Stored pound cake with encapsulated 600 mg EPA/DHA; stored at 100F for 3 months after production.
88949909|NCT01940692|Active Comparator|Intravenous tranexamic acid|Will receive 1.5g intravenous tranexamic acid preoperatively
88949910|NCT01940692|Experimental|Intra-articular tranexamic acid|Will receive 3g intra-articular tranexamic acid after wound closing
89020094|NCT05662241|Placebo Comparator|Placebo|Placebo administered as an SC injection.
89020095|NCT05661669|Experimental|Ketamine|This arm will receive ketamine (n=25)
89020096|NCT05661669|Placebo Comparator|Placebo|This arm will receive the saline placebo (n=25)
89475354|NCT02489565|No Intervention|Tertiary care|Outpatient from tertiary care with discharge criteria who remains in the tertiary care.
88949911|NCT01940718|Experimental|Transdermal Testosterone|Transdermal Androgel 1.62% (20.25 mg testosterone = 1 pump actuations) to be applied once daily for 3.5 months. Initial dose will be at lowest level, 20.25 mg testosterone with dosing adjustments given in 20.25 mg testosterone increments.
88949912|NCT01940731|Experimental|Colistimethate sodium|
88949913|NCT01940744|Experimental|Prescriptive Mobilization|"The prescriptively applied non-thrust manipulation will be involve a central lumbar posterior-anterior directed at L4 and L5. The therapist will place the hypothenar eminence of 1 hand over the spinous process of L4. With the elbows remaining extended, the therapist will deliver a low-velocity, high amplitude oscillatory force (at approximately 2 Hz) directed at L4 for a total 60 seconds (Figure 1). Following a 30-second rest the therapist will perform a similar set of oscillations directed at L5. A second set of oscillations will then be performed in a similar manner at L4 and L5. Patients will be seen for 4 visits."
89020097|NCT05655494|Experimental|Stand-alone Portal|The standard of care condition will include a portal that provides patients with access to existing online cancer clinical trial resources in one location. This includes links to pages with basic information about cancer clinical trials, ongoing studies, enrollment opportunities for existing institutional research registries, and contact information for study coordinators.
89475355|NCT02489565|Experimental|Primary care|Outpatient discharge from tertiary care to a primary care near the patient's home with the support of telemedicine.
89475356|NCT02489253||polygenic hypercholesterolemia|patients with high cholesterol level where no mutation was found in their FH-causing genes and had to gene score in their six LDL-C raising gene score undergo a carotid ultrasound, a CT coronary angiogram and a blood test
89475357|NCT02489253||monogenic FH|patients with a mutation in FH-causing gene undergo a carotid ultrasound, a CT coronary angiogram and a blood test
89475358|NCT02489487|Experimental|VM-1500 + Raltegravir|VM-1500 40 mg in combination with 400 mg Raltegravir
89475359|NCT02489487|Experimental|VM-1500 +Darunavir|VM-1500 40 mg in combination with 600 mg Darunavir boosted with 100 mg Ritonavir
89475360|NCT02489487|Experimental|VM-1500|VM-1500 40 mg alone
89475361|NCT04503746|Placebo Comparator|Placebo|Placebo twice a day
89475362|NCT04503746|Experimental|ALH-L1005 600 mg|ALH-L1005 300 mg twice a day
89475363|NCT04503746|Experimental|ALH-L1005 1,200 mg|ALH-L1005 600 mg twice a day
89475364|NCT02096354|Experimental|RRx-001 followed by irinotecan|Once-weekly intravenous RRx-001 at a dose of 4 mg on Days 1, 8, 15, and 22 of a 4-week cycle. On progression and if eligible, patients will receive irinotecan (with or without bevacizumab)
89475365|NCT02096354|Active Comparator|Regorafenib followed by irinotecan|Regorafenib daily on Days 1- 21 of a 4-week cycle. On progression and if eligible, patients will receive irinotecan (with or without bevacizumab)
89475366|NCT02007980||Patients with indwelling ureteral stent|Patients with existing indwelling ureteral stent, no additional treatment
89475367|NCT03177746|Experimental|Dapoxetine/Tadalafil 30/20 mg film coated tablet|
89475368|NCT02484027|Experimental|statin-therapy|Rosuvastatin orally at a dose of 20mg daily is assigned to patients immediately for the first 3 days of hospitalization. From the fourth day onward, rosuvastatin 10 mg daily will be administered for 1 year.
89475369|NCT02484027|Sham Comparator|non-statin-therapy|No statins is assigned to patients for the first 3 days of hospitalization. From the fourth day onward, rosuvastatin 10 mg daily will be administered for 1 year.
89475370|NCT04318496|Experimental|Acupuncture with press tack needle group (Acu)|the press tack needles (PYONEX Φ0.20×0.6 mm made by Seirin Corporation) has a diameter of 0.2 mm and length of 0.6 mm will be used on the following bilateral points; GB 36 (Waiqiu), GB 34 (YangLingQuan), ST 36 (Zusanli), LI 4 (HeGu), LU 7 (LieQue), TH 5 (Waiguan) press tack needles retention time will be 4 days.
89475371|NCT04318496|Placebo Comparator|Placebo group (Con)|The pess tack placebo is PYONEX sticker and pack that is identical to the press needle, except that the needle part was removed. The acupuncturist will apply the stickers on the following bilateral acupoints: GB 36 (Waiqiu), GB 34 (YangLingQuan), ST 36 (Zusanli), LI 4 (HeGu), LU 7 (LieQue), TH 5 (Waiguan) press tack stickers retention time will be 4 days.
89475372|NCT02483715|Experimental|High-dose dual therapy|group A-high-dose dual therapy ( rabeprazole 20 mg, tablet, qid + amoxicillin 750 mg, capsule, qid for 14 days)
89475373|NCT02483715|Active Comparator|Bismuth-containing quadruple therapy|group B-bismuth-containing quadruple therapy (rabeprazole 20 mg, tablet, bid + tripotassium dicitrate bismuthate 300 mg, tablet, qid + metronidazole 250 mg, tablet, qid + tetracycline 500 mg qid, capsule, for 10 days)
89475374|NCT03090230|Experimental|Relay Pro Thoracic Stent-Graft System|The Relay Pro arm includes subjects who receive the device to treat traumatic injury of the descending thoracic aorta with the RelayPro Thoracic Stent-Graft System
89475375|NCT02483793|Active Comparator|Oxybutynin group|This group will be prescribed oxybutynin as well as standard narcotic pain medications. Oxybutynin will be prescribed based off of standard dosing. Patients who are unable to swallow pills will be given oxybutynin elixir (0.5mg/kg/day, divided TID). Patients who are able to swallow pills will be given oxybutynin 5mg either BID or TID.
89475376|NCT02483793|Active Comparator|Tamsulosin group|This group will be prescribed tamsulosin and standard narcotic pain medication. Patients will be given tamsulosin 0.4mg at bedtime. This dosage has been used in other studies for children age ≥ 4.
89475377|NCT02483949|No Intervention|Control|
89475378|NCT02483949|Experimental|Intervention|Lifestyle intervention with peer-counseling follow-up
89475379|NCT03200288|Experimental|HL-01|Single 2 ml intra-articular injection of HL-01 (solution of high and low molecular weight hyaluronic acid (HA))
89475380|NCT03200288|Placebo Comparator|Placebo|Single 2 ml intra-articular injection of Placebo (physiological solution)
89475381|NCT03318471|Active Comparator|Group M|received 50 mg/kg MgSo4 in 100 ml 0.9 NaCl 15 minutes prior to anesthesia induction over 15 minutes
89475382|NCT03318471|Placebo Comparator|Group S|received 100 ml 0.9% NaCl 15 minutes prior to anesthesia induction over 15 minutes.
89475383|NCT03175796|Experimental|IMH-HV Treatment Group|Infant Mental Health-Home Visiting. Weekly home visits for up to one year by a trained IMH-HV treatment provider. Treatment delivery consistent with the IMH-HV manual.
89475384|NCT03175796|No Intervention|Treatment as Usual Control Group|No intervention provided as part of participation in this study; families are free to access community resources including any available treatment(s) in the community.
89475385|NCT02489409|Experimental|Experimental group|Gemcitabine (Gem): 1.0 m/m2, iv 0.5h, d1, 8; Navelbine (NVB): 40 mg/d, iv, d1, 8; Platinum (DDP): 30 mg/m2, iv 3h, d1-3; Xeloda Tablets: 2 000 mg/m2, po, d1-14; EndostarTM Injection: 210 mg in 279 mL normal saline (NS), continuous pump, d1-d10 (2.5 mL/h).
89475386|NCT02489409|Active Comparator|Control group|Gemcitabine (Gem): 1.0 m/m2, iv 0.5h, d1, 8; Navelbine (NVB): 40 mg/d, iv, d1, 8; Platinum (DDP): 30 mg/m2, iv 3h, d1-3; Xeloda Tablets: 2 000 mg/m2, po, d1-14.
89475387|NCT02797574|Active Comparator|Vitiligo Diagnosed Group|Clinically diagnosed with non-segmental vitiligo
89475388|NCT02797574|Active Comparator|Healthy Control Group|20 normally pigmented control subjects who are between the ages of 18 and 50
89475389|NCT03930602|Experimental|BMS-986165+Fluvoxamine|
89475390|NCT03930602|Experimental|BMS-986165 only|
89475391|NCT03930602|Experimental|Fluvoxamine only|
89475392|NCT02489175|Experimental|Stomaplasty KoringTM group|The KoringTM is a stomaplasty ring made of propylene, flexible and non-absorbable. It is fixed to the anterior sheath of the abdominal wall in order to prevent PSH.
89475393|NCT02489175|No Intervention|No preventive measure|In these patients, the stoma creation will be traditional, with no mesh implanted
89475394|NCT02729636|Experimental|FES:a|The group will be treated with multipad electrical stimulation device.
89475395|NCT02729636|Active Comparator|control|The group will be treated with conventional treatment.
89475396|NCT02943980|Experimental|CMAC Videolaryngoscope|tracheal intubation using CMAC
89475397|NCT02943980|Experimental|Macintosh laryngoscope|tracheal intubation using Macintosh laryngoscope
89475398|NCT02483871|Experimental|Rosuvastatin|Two Cohorts, one at 20 mg and one at 40 mg will enroll in a dose escalation of rosuvastatin
89475399|NCT02489019|Placebo Comparator|Control|Individuals assigned to this condition will receive 0.9 mcg/kg sodium chloride (NaCL)
89202702|NCT00539032|Experimental|Group 2: Menactra® Primary Vaccine (Control) Group|Participants who had not previously been given any meningococcal vaccine (meningococcal vaccine naive) received a primary vaccination with Menactra® vaccine.
89475400|NCT02489019|Experimental|Low Dose|Individuals assigned to this condition will receive 1 mcg/kg fentanyl
89475401|NCT02489019|Experimental|High Dose|Individuals assigned to this condition will receive 2 mcg/kg fentanyl
89475402|NCT02604446|Experimental|Tapentadol|depot Tapentadol in addition to usual pain treatment
89475403|NCT02604446|Active Comparator|Oxycodone|depot Oxycodone in addition to usual pain treatment
89475404|NCT02604446|Placebo Comparator|Placebo|depot glucose placebo in addition to usual pain treatment.
89475405|NCT02847637|Active Comparator|Arm C (Control): No Prophylaxis, Then Emicizumab|Participants who had received episodic treatment with FVIII prior to study entry were randomized to continue episodic FVIII treatment when they started the trial. After completing 24 weeks of no prophylaxis (i.e., episodic FVIII treatment) on study, then they were given the opportunity to switch to emicizumab prophylaxis of 3 mg/kg subcutaneously (SC) once per week (QW) for 4 weeks, followed by maintenance dosing of 3 mg/kg emicizumab SC once every 2 weeks (Q2W). Upon implementation of protocol version 4 (20-Dec-2019), treatment duration was extended. During this study prolongation, each participant was given the option to choose a preferred emicizumab dosing regimen among those permitted and continue on that dosing regimen until discontinuation from the study.
89475406|NCT02847637|Experimental|Arm A: Emicizumab 1.5 mg/kg QW|Participants who had received episodic treatment with FVIII prior to study entry were randomized to receive emicizumab prophylaxis at a dose of 3 milligrams per kilogram (mg/kg) subcutaneously (SC) once per week (QW) for 4 weeks, followed by maintenance dosing of 1.5 mg/kg emicizumab SC QW. Upon implementation of protocol version 4 (20-Dec-2019), treatment duration was extended. During this study prolongation, each participant was given the option to choose a preferred emicizumab dosing regimen among those permitted and continue on that dosing regimen until discontinuation from the study.
89475407|NCT02847637|Experimental|Arm B: Emicizumab 3 mg/kg Q2W|Participants who had received episodic treatment with FVIII prior to study entry were randomized to receive emicizumab prophylaxis at a dose of 3 mg/kg subcutaneously (SC) once per week (QW) for 4 weeks, followed by maintenance dosing of 3 mg/kg emicizumab SC once every 2 weeks (Q2W). Upon implementation of protocol version 4 (20-Dec-2019), treatment duration was extended. During this study prolongation, each participant was given the option to choose a preferred emicizumab dosing regimen among those permitted and continue on that dosing regimen until discontinuation from the study.
89475408|NCT02847637|Experimental|Arm D: Emicizumab 1.5 mg/kg QW (Pre-study FVIII Prophylaxis)|Participants who had received FVIII prophylaxis prior to study entry were enrolled to receive emicizumab prophylaxis at a dose of 3 mg/kg subcutaneously (SC) once per week (QW) for 4 weeks, followed by maintenance dosing of 1.5 mg/kg emicizumab SC QW. Upon implementation of protocol version 4 (20-Dec-2019), treatment duration was extended. During this study prolongation, each participant was given the option to choose a preferred emicizumab dosing regimen among those permitted and continue on that dosing regimen until discontinuation from the study.
89475409|NCT05399199|Experimental|study group|
89475410|NCT05399199|No Intervention|control group|
89475411|NCT02483559|Other|Amber Lenses|Participants will be randomized to participate in the amber lens condition first or second. Outcome measures to assess the effects of wearing amber lenses to block the blue light spectrum of light includes mood and sleep rating questionnaires (Positive and Negative Affect Scale, PANAS; Leeds Sleep Evaluation Questionnaire) as well as measuring the levels of melatonin the body is producing while wearing the glasses.
89475412|NCT02483559|Other|Placebo Lenses|Participants will be randomized to participate in the placebo lens condition first or second. Outcome measures to assess the effects of wearing placebo lenses to allow all spectrums of light includes mood and sleep rating questionnaires (Positive and Negative Affect Scale, PANAS; Leeds Sleep Evaluation Questionnaire) as well as measuring the levels of melatonin the body is producing while wearing the glasses.
89475413|NCT05345353||The Aarhus Protocol, Aarhus municipality:|Children with obesity who participated in a family-centered multicomponent lifestyle intervention - The Aarhus Protocol, Aarhus Municipality
89475414|NCT05345353||The Randers Protocol, Randers municipality:|children with obesity who participated in a family-centered multicomponent lifestyle Intervention - The Randers Protocol: Randers Municipality
89475415|NCT05345353||No intervention|Children with obesity who didn't participate in a lifestyle intervention delivered by the municipality.
89475416|NCT05352607|Experimental|TENS group|"TENS group will receive the conventional physiotherapy treatment plus TENS. TENS is most commonly used directly on affected muscles in patients with CP. The device will be used from Cosmogamma company (MIXING 2 (EVO): COMBINED THERAPY). It consists of 3 parts: the stimulator part, electrode and connected wires. Strap or plaster for electrodes adhesive with gel. Electrode diameter (6×4.5 cm). The program will be (Pain therapy - TENS - Free program - Modify -Parameter's setup).~Parameter setup (pulse frequency= 100 Hz, pulse duration= 250 μs, time=30 minutes and the intensity according to patient to feel tingling sensation only and no muscle contraction)."
89475417|NCT05352607|Active Comparator|Control group|The Control group will receive the conventional physiotherapy treatment for upper limb spasticity only.
89475418|NCT02314910||Failed implant|There is only one group, being the group of patients of which the oral implant needed to be removed for clinical reasons.
89475419|NCT03564535|Experimental|SELF FIXATING GROUP|Monofilament polyester mesh with polylactic acid (PLA) microgrips of size 11*15 will be used. It is an isoelastic large-pore knitted fabric with a density of 73g/m2 at implantation and 38g/m2 after microgrips absorption which will be at 18 months. The resorbable micro grips provide immediate adherence to surrounding muscle and adipose tissue during the initial days post hernia surgery, serving as an alternate method of fixation to traditional sutures, tacks, staples, or fibrin sealants. No additional tacks, staples, sutures, or fibrin sealant will be used.
89475420|NCT03564535|Active Comparator|TACKER FIXATION GROUP|Patients will be undergoing mesh ﬁxation with non-absorbable tacks. The tacks would be used such that they avoid bony prominences and vascular and neural structures. One or two tacks will be put at the Cooper's ligament and another applied laterally superior to the iliopubic tract in the anterior abdominal wall. In any patient, the maximum number of tacks applied will not exceed three.
89475421|NCT00706095|Experimental|E7389 1.4 mg/m^2|
89020098|NCT05655494|Experimental|Portal with Virtual Community Health Educator (vCHE)|The virtual community health educator condition will provide all information in standard of care with the addition of a virtual community health educator. Patients will have the opportunity to choose which virtual community health educator will provide digital navigation. The choices will include at least four English-speaking and four Spanish-speaking virtual community health educators representing different genders and racial/ethnic backgrounds.
89475422|NCT00706095|Experimental|E7389 1.1 mg/m^2|
89475423|NCT00706095|Experimental|E7839 0.7 mg/m^2|
89475424|NCT05352997||Group 1: on-target beta-lactams serum concentration|Patients with on-target beta-lactams serum concentration during 1st dosing
89475425|NCT05352997||Group 2: off-target beta-lactams serum concentration|Patients with off-target beta-lactams serum concentrations during 1st dosing
89475426|NCT05352997||Group 3: off-target beta-lactams plasma concentration:|Patients with high beta-lactams plasma concentrations during 1st dosing
89475427|NCT02486913|No Intervention|Conventional Health Check|Patients undergoing conventional National Health Service Health Check
89475428|NCT02486913|Experimental|Enhanced Health Check|Patients undergoing National Health Service Health Check enhanced by risk report
89475429|NCT05352841||Caries free children|Children old 72 months or younger with no caries lesion
89475430|NCT05352841||Children with severe form of early childhood caries|Children with severy form of early childhood caries, S-ECC are those having 3 to 5 years , and have more than four, five and six tooth surfaces affected in the primary front teeth at 3, 4 and 5 years, respectively. Caries in children under 3 years of age involving one or more smooth surfaces and in children under 6 years of age affecting one or more smooth surfaces in the front teeth or total dmfs score equal or higher than 6 would be also classified as S-ECC.
89475431|NCT02486835|Experimental|"Cough Syrup for adults and children"|Marked (authorized) medical device acting by protecting the oropharynx, in a non pharmacological way, to reduce cough. It contains honey, plantago lanceolata, thymus vulgaris.Dosage form: syrup Dosage: 5 ml three times a day. Frequency: the duration of the study for each patient is 4 nights, 3 days.
89475432|NCT02486835|Placebo Comparator|Placebo|The placebo intervention is a syrup of same taste and colour without the protective components. Dosage form: syrup. Dosage: 5 ml three times a day Frequency: the duration of the study for each patient is 4 nights, 3 days.
89475433|NCT05708287|Experimental|all patients|
89475434|NCT01084382|Active Comparator|Arthrospira platensis supplement|
89475435|NCT01084382|Placebo Comparator|Protein/Dextran supplemented|
89475436|NCT00584246|Experimental|1|Pregabalin (Lyrica)
89475437|NCT00584246|Placebo Comparator|2|Placebo
89475438|NCT03321123|Experimental|CRA treatment|"The drug for this trial is autologous T cells transduced with the lentiviral vector pLTG1563 (MB-CART19.1). The dose is 2x10e6 ~2x10e7 MB-CART19.1/kg.~A leukapheresis for the patient will be performed for MB-CART19.1 generation. All patients will receive lymphodepleting chemotherapy with fludarabine 30 mg/m2/d intravenously (iv) on days -5,-4,-3 and -2 cyclophosphamide 500 mg/m2/d iv on day -3,-2 before CAR T cell transfer to enhance the in vivo expansion of CAR T cells."
89475439|NCT03564457||One group of 20.000 patients|No interventions will take place as this is an observational study
89475440|NCT05124314|Experimental|Mifepristone and Misoprostol|Patients receive oral mifepristone (600 mg) 48 hours before medical treatment with vaginal misoprostol (800 mcg repeated after 24 hours if no pregnancy tissue is lost).
89475441|NCT05124314|Active Comparator|Misoprostol|Medical treatment with vaginal misoprostol (800 mcg repeated after 24 hours if no pregnancy tissue is lost).
89475442|NCT04413032|Experimental|Patients with MS|30 Patients with MS will use the DreaMS App over a study duration of 6 weeks.
89475443|NCT04413032|Experimental|Healthy Volunteers|30 Healthy Volunteers will use the DreaMS App over a study duration of 6 weeks.
89475444|NCT02486991|Active Comparator|Tunnel + AlloDerm®|A coronally positioned tunnel (CPT) technique for root coverage will be used alone with acellular dermal matrix (AlloDerm®).
89475445|NCT02486991|Experimental|Tunnel + AlloDerm® + Verticals|The use of intramucosal vertical incisions in addition to a coronally positioned tunnel (CPT) technique for root coverage will be used with acellular dermal matrix (AlloDerm®).
89475446|NCT04436354|Experimental|vaginoscopic office hysteroscopy in the trendelenburg position|
89475447|NCT04436354|Experimental|vaginoscopic office hysteroscopy in lithotomy position|
89475448|NCT02837731|Experimental|Treatment Starling SV monitor|A dynamic assessment of fluid responsiveness using the Starling SV monitor will be performed at every clinical decision point for the first 72 hours of study enrollment. Examples of a clinical decision point include a mean arterial pressure (MAP) of < 65, the decision to give additional fluid volume, and the decision to either escalate or wean vasopressors. Fluid responsiveness will be assessed using a passive leg raise (PLR) to guide corresponding treatment.
89475449|NCT02837731|No Intervention|Control|No required therapeutic protocol will be used for patient treatment, and is determined per the discretion of the physician and hospital standards.
89475450|NCT03315663|Active Comparator|Sweetch App + DBWS|Participants receive usual care for prediabetes management. In addition, participants will be randomized to receive the Sweetch app plus weight monitoring via digital body weight scale (DBWS).
89475451|NCT03315663|Active Comparator|Sweetch App Alone|Participants receive usual care for prediabetes management. In addition, participants will be randomized to receive the Sweetch app alone.
89475452|NCT02483325|Other|Busulfan with adapted doses|Conditioning regimen for allogeneic transplant (Busulfan, Thymoglobuline and Fludarabine)
89475453|NCT02486679|Active Comparator|PGE2|Patients allocated to vaginal PGE2 (Prostin) for cervical ripening
89475454|NCT02486679|Active Comparator|Foley catheter|Patients allocated to foley catheter placement for cervical ripening
89475455|NCT04211090|Experimental|Camrelizumab with pemetrexed / carboplatin|Camrelizumab with pemetrexed / carboplatin in patients with brain metastases of driven gene-negative, non-squamous non-small cell lung cancer
89475456|NCT02486445|Experimental|Rivaroxaban|Rivaroxaban 15 mg every 12 hours until the completion of the diagnostic work-up, which should not exceed 24 hours.
89202703|NCT00797706|Placebo Comparator|Vehicle|
89202704|NCT00797706|Experimental|Low dose|
89475457|NCT02836873|Active Comparator|Bexagliflozin tablets, 20 mg|Each subject will receive a bexagliflozin tablet, 20 mg, once daily for the duration of the study.
89475458|NCT02836873|Placebo Comparator|Placebo tablets|Each subject will receive a placebo (inactive) tablet once daily for the duration of the study.
89475459|NCT03318237||Patients with focal epilepsy|Patients undergoing ultra high field MRI of the brain
89475460|NCT04538534|Experimental|nicardipine and isosorbide dinitrate|"A Cocktail of 1 mg of Isosorbide Dinitrate associated to 1 mg of nicardipine will be put in a syringe than diluted in saline serum to have a volume of 3cc.~The obtained solution will be administered in an intra-arterial fashion via the trans-radial sheath after randomization."
89475461|NCT04538534|Active Comparator|isosorbide dinitrate|Isosorbide Dinitrate: 1 mg will be diluted in saline solution as to have a 3cc volume The obtained solution will be administered in an intra-arterial fashion via the trans-radial sheath after randomization
89475462|NCT03318159|Other|posaconazole prophylaxis group|aplastic anemia / hypoplastic myelodysplastic syndrome patients undergoing antithymocyte globulin treatment and receiving posaconazole as prophylaxis antifungal agent
89475463|NCT03740984|Experimental|Hypnosis / Hypnotherapy|Hypnosis intervention has been created by a certified hypnosis therapist (Prof. Reinhard) has been audio-recorded. The hypnosis intervention is based on the patient's happy place as well as many other interventions which all focus on support and wellbeing (total recording time ca. 4 ½ hours). All patients are advice to start with the beginning, however during the course of chemotherapy they are allowed to skip mp3 files, if they prefer to listen to a new intervention.
89475464|NCT03740984|Experimental|Music therapy|"For the music therapy the following music recordings have been used. All patients were allowed to skip tracks if they did not like to listen to that particular track.~Purple Waves - Berlin Symphonic Film orchestra / Christopher Franke - Pacific Coast Highway Black Garden View - Berlin Symphonic Film orchestra / Christopher Franke - Pacific Coast Highway Sunset Destination - Berlin Symphonic Film orchestra / Christopher Franke - Pacific Coast Highway Crystal Tree - Berlin Symphonic Film orchestra / Christopher Franke - Pacific Coast Highway Best nature sounds / Ocean Volume 2 - Best Relaxation Music - Deep Sleep Top 10 Serse: Aria Ombra mai Fu - Andreas Scholl, Akademie für Alte music Berlin - Händel Johann Sebastian Bach: Jesus Bleibet Meine Freude (Studio) - Eduard Stan - Piano Recital Mozart: Concerto pour violon no 4 en re majeur, KV (Köchel listing) 218 - Christian Ferras; Pietro Argento; Orchestra Scarlatti di Nap - La fete a Stradivarius~... etc."
89475465|NCT03740984|Placebo Comparator|Standard therapy|In this standard therapy the patient listens to a short explanation that they were randomized into the control arm and that they are allowed to listen to silence (tracks with no music or intervention).
89475466|NCT03315585|Experimental|Steep Pulse Device|Applying the steep pulse to treat the patients with Prostate cancer
89475467|NCT03318081|Active Comparator|cognitive function rehabilitation group|The main content of cognitive function rehabilitation esecutive function,including working memory,sustained attention, response inhibition function and cognitive flexibility, 45 minutes a day over 6 weeks period.
89475468|NCT03318081|Active Comparator|cognitive bias modification group|The main content of cognitive bias modification groups were changing ATS related attention bias, 45 minutes a day over 6 weeks period.
89475469|NCT03318081|No Intervention|control group|Participants only accept the regular scheduled in the compulsory isolated detoxification center
89475470|NCT03315507|Experimental|PB1046 Injection|PB1046 Subcutaneous Injection
88949914|NCT01940744|Active Comparator|Pragmatic Mobilization|The pragmatically applied non-thrust manipulation will be based on the original concepts outlined by Maitland and will of consist of passive, low velocity, oscillatory movements within the physiological range of the joint, applied to the comparable spinal level of the patient (defined as the spinal level that reproduced the patient's familiar pain). The techniques will be modified based on clinician assessment and patient feedback and consist of Grade I through Grade IV movements. Since the pragmatic approach is clinician-driven, no time limit will be placed on the application and the number of mobilizations used will depend on the patient feedback (the exact definition of a pragmatic treatment). Patients will be seen for 4 visits.
88949915|NCT01940783|Other|Intervention|All participants in the study will receive one pre-operative MRI, prior to cochlear implantation, and two cone-beam computed tomography scans, after cochlear implantation
88949916|NCT01940796|Experimental|Brentuximab Vedotin|The dose of brentuximab Vedotin will be based on the cohort the participant is enrolled on. Dosing will be based on the participant's weight prior to each dose. Actual weight will be used except for participants weighing > 100 kg. The dose for participants weighing > 100 Kg will be calculated based on a weight of 100 kg. The dose should be rounded to the nearest whole number of milligrams. Brentuximab vedotin will be administered over approximately 30 minutes IV.Up to five dose levels will be tested in cohorts of 3-6 participants each. Once the maximum tolerated dose (MTD) is established, 10 more participants will be treated at the MTD for analysis of efficacy.
88949917|NCT01940848|Experimental|STW5|2/3 patients with irritable bowel syndrome will be randomized in this arm
89475471|NCT05123924||POMS Group|Individuals in the POMS group will be evaluated in terms of respiratory capacity, respiratory muscle strength and fatigue.
89475472|NCT05123924||Control Group|Individuals in the control group will be evaluated in terms of respiratory capacity, respiratory muscle strength and fatigue.
89475473|NCT03320889|Other|Pamphlets plus Review with Expert Educator|Educational Intervention includes Pamphlets plus Review with Expert Educator
88949918|NCT01940848|Placebo Comparator|Placebo|1/3 patients with irritable bowel syndrome will be randomized in this arm
88949919|NCT01940861||Traumatic brain injury|
88949920|NCT01940874||Cerebral oximetry|
88949921|NCT01940913|Active Comparator|Probiotics|
88949922|NCT01940913|Placebo Comparator|Placebo|
88949923|NCT01940926|Experimental|68Ga-BNOTA-PRGD2|In patients with RA, single dose intravenous injection of nearly 111 MBq 68Ga-BNOTA-PRGD2 will be given at 30 minutes before PET/CT scanning to determine 68Ga-BNOTA-PRGD2 uptake in joints.
88949924|NCT01940952|Active Comparator|Zydena 50mg|Zydena (Udenafil) 50mg + Donepezil 5mg or 10mg
89475474|NCT03320889|Other|Pamphlets only|Educational Intervention includes Pamphlets only
89475475|NCT03315429|Other|Stress testing arm|Stress testing of patients with functional mitral regurgitation.
89475476|NCT02724410|Active Comparator|home intravenous ertapenem and PICC|Placement of peripheral inserted central catheter (PICC) and completion of ten day antibiotic treatment with home (IV) ertapenem (Drug Class:carbapenem antibiotic) (15 mg/kg IV every twelve hours not to exceed 1 gm/day for ages <13; age 13 or greater, then 1 gm daily)
89475477|NCT02724410|Experimental|home oral amoxicillin-clavulanate|Completion of ten day antibiotic treatment with home oral amoxicillin-clavulanate(Drug Class:beta lactam antibiotic)(15mg/kg every eight hours or 22.5mg/kg extended release tablets every twelve hours).
89475478|NCT03564223||Parents/Guardians|"Parents/Guardians aged over 18, attending Great Ormond Street Hospital Outpatients.~Intervention: Administer questionnaire to review and decide on significance of each of 30 child health concerns"
89475479|NCT03564223||Paediatricians|"Paediatricians working at Great Ormond Street Hospital NHS Foundation Trust.~Intervention: Administer questionnaire to review and decide on significance of each of 30 child health concerns"
89475480|NCT03320811||"group celiac disease"|
89475481|NCT03320811||"group no celiac disease"|
89475482|NCT02486523|Active Comparator|Control group|"Outpatient management of children diagnosed with severe acute malnutrition.~Interventions allocated:~Behavioral: Group discussions after successful discharge Procedure/Surgery: Outpatient Therapeutic Programme"
89475483|NCT02486523|Experimental|Intervention group|"Outpatient management of children diagnosed with severe acute malnutrition + household WASH package~Interventions allocated:~Behavioral: Hygiene promotion sessions Device: Household WASH package The content of the kit: soap and aquatab for 3 months, 20 liters Jerry can, a cup, a plastic kettle for hand washing and the instructions leaflet.~Behavioral: Household visits during the OTP phase Behavioral: Group discussions after successful discharge Procedure/Surgery: Outpatient Therapeutic Programme"
89475484|NCT04435886|Experimental|Probiotic group|A multi-strain probiotic
89475485|NCT04435886|Placebo Comparator|Placebo group|Identical placebo
89475486|NCT02486601|Experimental|nab-paclitaxel + FOLFOX|nab-paclitaxel + FOLFOX nab-paclitaxel: 150 mg/m2 D1 every 2 weeks Leucovorin: 400 mg/m2 D1 every 2 weeks Oxaliplatin: 85 mg/m2 D1 every 2 weeks 5-FU infusion: 2400mg/m2 48h infusion every 2 weeks 6 pre-operative cycles 6 post-operative cycles (optional)
89475487|NCT02487069|Experimental|MSD group|The patients will received HSCT from MSD.
89475488|NCT02487069|Experimental|MUD group|The patients will received HSCT from MUD.
89475489|NCT02487069|Experimental|HRD group|The patients will received HSCT from HRD.
89475490|NCT05123456|Experimental|Patient operated with isolated ACL knee reconstruction|
89475491|NCT05123456|Experimental|Patient operated with ACL and ALL knee reconstruction|
89475492|NCT03564379|Experimental|Part 1: Single Dose Part|Participants will receive a single oral dose of 25 mg JNJ-42165279 or placebo tablet under fasted condition in the morning on Day 1.
89475493|NCT03564379|Experimental|Part 2: Multiple Dose Part|After a washout period of at least 10 days, same participants from Part 1 will receive multiple daily dosing of 25 mg JNJ-42165279 or placebo tablet for 10 days.
89475494|NCT03317847|Experimental|Bromfenac|Patients randomized to this arm will receive Bromfenac 0.09 % Ophthalmic Solution BID for 2 weeks
89475495|NCT03317847|Active Comparator|Dexamethasone|Patients randomized to this arm will receive Dexamethasone 0.1 % Ophthalmic Suspension QID for one week and BID for the following week
89475496|NCT02675192||Proof cohort : muscular assessment|"Clinical examination : Body weight, BMI, cardiac frequency, muscular examination,...~Blood appraisal : glycaemia, lipidic appraisal, leptin, albumin, coagulation, metabolome and epigenetic tests,...~Urinary collection : metabolome tests~Maximal voluntary quadriceps strength (MVC)~Checking muscle functional skills~Muscular biopsy"
89475497|NCT03315351|Experimental|Study Procedure|Brachytherapy. PET-scan.
89475498|NCT01342081|Experimental|1|DE-111 ophthalmic solution
89475499|NCT01342081|Active Comparator|2|Tafluprost ophthalmic solution 0.0015%
89475500|NCT01342081|Active Comparator|3|Concomitant use of tafluprost ophthalmic solution 0.0015% plus timolol ophthalmic solution 0.5%
89475501|NCT02518087|Experimental|CPB-oXiris®|Non emergent cardiac surgery patients requiring expected CPB time > 90 minutes: double valve replacement or valve replacement plus coronary arterial bypass graft (CABG).
89475502|NCT02518087|No Intervention|CPB-Standard|Non emergent cardiac surgery patients requiring expected CPB time > 90 minutes: double valve replacement or valve replacement plus coronary arterial bypass graft (CABG).
89020099|NCT05650970|Active Comparator|routinely treated control group|Unlike the study group, radial nerve mobilization will not be included in the treatment program of this group. only massage, ice and activity modification training will be included.
89020100|NCT05650970|Experimental|radial nerve mobilization study group|The treatment program of this group will include massage, radial nerve mobilization, ice and activity modification training.
89475503|NCT05123378|Experimental|Phase 1 Implementation|Campwood District and District 3C begin NCHAP implementation in May 2018.
89475504|NCT05123378|Experimental|Phase 2 Implementation|District 3AB and District 2 begin NCHAP implementation in November 2018.
89020101|NCT05649072|Other|Genetic Testing and Counseling|Participants will be given a saliva collection kit to collect a saliva sample for hereditary cancer and genetic testing. The kit includes all standard paperwork and instructions for collecting the sample and shipping the kit back to the genetic testing company (Invitae).
89020102|NCT05649072|Other|Screening Form|Participants will complete a screening form to assess your risk of hereditary breast and colorectal cancers.
89020103|NCT05641896|Experimental|[18F]FAPI-74 PET/CT|Patients receive [18F]FAPI-74 intravenously followed by PET/CT 60 minutes (+/-10minutes) later
89020104|NCT05636722|Experimental|Intervention group|Participants in this group (all participants) were asked to complete a questionnaire before and after (6 weeks after baseline) using the online self-help intervention (unguided web-based intervention).
89020105|NCT05629845|Active Comparator|EUS-guided therapy group|EUS would be performed with a curvilinear echoendoscope based on protocol described in our prior study. Because EUS-guided glue injection can be applied to both EV and GV and is less technically demanding than coiling or the combination approach, it is chosen as the EUS guided intervention in our study. The target EV or GV size will be measured by the caliper function on the EUS machine. After confirmation of blood flow in the target varix by Doppler, EUS-guided glue injection would be performed for EV or GV ≥ 3mm in diameter using a standard 19G needle. Each injection will contain a 1.2ml mixture of 0.5ml glue (Histoacryl, n-butyl-2-cyanoacrylate, B. Braun Surgical, Germany) + 0.7ml lipiodol. Flow obliteration in the treated varix will be confirmed on EUS Doppler. If blood flow is still observed on Doppler after the first injection, additional injection of glue-lipiodol mixture would be repeated (up to 4 doses) until flow obliteration is achieved.
89020106|NCT05629845|Active Comparator|Conventional endoscopic therapy group|In patients with prior EV bleeding, EV with high-risk stigmata (regardless of size) or EV of medium or large size detected on study EGD will be treated with VBL using a multi-band ligator fitted on the gastroscope for secondary prevention. In patients with prior GV bleeding, if compressible GV suggestive of incomplete obliteration from prior glue treatment is noted on study EGD, cyanoacrylate glue injection using a 1.2ml mixture of 0.5ml glue (Histoacryl, n-butyl-2-cyanoacrylate, B. Braun Surgical, Germany) + 0.7ml lipiodol will be performed for secondary prevention.
89020107|NCT05626582|Experimental|Pain Stimulus - Learning Only|Capsaicin combined with heat applied to intact skin
89020108|NCT05626582|Experimental|Pain Stimulus - Learning and Retention|Capsaicin combined with heat applied to intact skin
89020109|NCT05626582|No Intervention|No Stimulus|Nothing applied to skin
89020110|NCT05625776|Experimental|Pain Stimulus|Capsaicin combined with heat applied to intact skin
89020111|NCT05625776|Active Comparator|Distractor Somatosensory Stimulus|Sensory transcutaneous electrical nerve stimulation (TENS) applied to intact skin
89020112|NCT05625776|No Intervention|No Stimulus|Nothing applied to skin
89020113|NCT05624944|Experimental|Mild hepatic impairment|Patients with mild hepatic impairment will receive a single-dose of 5 mg of TS-142
89020114|NCT05624944|Experimental|Moderate hepatic impairment|Patients with moderate hepatic impairment will receive a single-dose of 5 mg of TS-142
89020115|NCT05624944|Experimental|Normal hepatic function|Subjects with normal hepatic function will receive a single-dose of 5 mg of TS-142
89020116|NCT05610891|Experimental|Pediatric High-Grade Glioma Patients|Two dosing cohorts will be explored; patients in the first arm will receive two doses, 20 mCi/m2 each, separated by 14 days for two cycles, with a third optional cycle. Patients in the second arm will receive two doses, 10 mCi/m2 each, separated by 14 days for three cycles with a fourth optional cycle.
89020117|NCT05605691|Experimental|Renuvion APR System Treatment|Subject will be treated with the Renuvion APR system in the lower eyelid (periorbital) area.
89475505|NCT05123378|Experimental|Phase 3 Implementation|District 4 begins NCHAP implementation in September 2020.
89475506|NCT05123378|Experimental|Phase 4 Implementation|Owensgrove District and Commonwealth District begin NCHAP implementation in April 2021.
89020118|NCT05591924||ESTABLISH|Adults over 18 years of age admitted to the ICU within 48 hours and whose presentation to the Emergency Department was within 72h of ICU admission.
89020119|NCT05591924||Healthy Controls|Adults over 18 years of age with no infectious symptoms, interaction with the health care system, or antimicrobial use in the past 14 days and no history of immunosuppression.
89020120|NCT05591196|Active Comparator|Activity Based Rehabilitation|Activity Based Rehabilitation is comprised of intensive, progressive, functional task practice. The protocol consists of repetitive activities of gross upper limb movement, isolated finger movements, bimanual task performance, simple and complex pinch, and grip performance. Several activities with various difficulty levels are designated for each category, and the participant will perform 1-2 activities within each category in each rehabilitation session. Rehabilitation sessions will be three times per week, 90 minutes per session for six weeks (total of 18 sessions).
89202705|NCT00797706|Experimental|High dose|
89202706|NCT00685802|Experimental|Cilostazol 50 mg Tablets|A single dose of cilostazol (2 x 50 mg tablets) administered after an overnight fast of at least 10 hours.
89202707|NCT00685802|Experimental|Cilostazol (Pletal® ) 50 mg Tablets|A single dose of Cilostazol (Pletal® tablets, 2 x 50 mg ) administered after an overnight fast of at least 10 hours.
89202708|NCT00991198|Experimental|A|Aria Regimens 0.5% conc
89202709|NCT00991198|Experimental|B|Aria Regimen (5 products) 0.25% conc
89475507|NCT05123378|Experimental|Phase 5 Implementation|District 1 begins NCHAP implementation in January 2022.
89475508|NCT03315273|Experimental|Traumatic brain injury|"Patients who have suffered a traumatic brain injury will be assessed with a test battery including~a motor imagery ability questionnaire (MIQ-rs)~a mental rotation test~a chronometry test (TDMI)"
89475509|NCT03315273|Active Comparator|Control|"Healthy volunteers matched for age, sex and educational level will be assessed with the same test battery including~a motor imagery ability questionnaire (MIQ-RS)~a mental rotation test~a chronometry test (TDMI)"
89475510|NCT03563833|Other|Minimal Flow Anesthesia|"Minimal Flow Anesthesia (50% O2, 50% air), Desflurane (MAC = 4,5). In hypotensive anesthesia application; Remifentanil will be used at infusion rates of 0.025-0.1μg / kg / min after a loading dose of 1 μg / kg / min, with mean Arterial Pressure 55-65 mmHg.~Before the induction of anesthesia and 30 minutes of anesthesia, 2 ml of venous blood sample will be taken from the patients and simultaneous tissue oxygen saturation will be recorded. Serum thiol disulfide levels obtained from the blood sample of the recipient will be studied in the biochemistry research laboratory using the method developed by Erel et al."
89475511|NCT03563833|Other|High Flow Anesthesia|"High Flow Anesthesia (50% O2, 50% air), Desflurane (MAC = 4,5) In hypotensive anesthesia application; Remifentanil will be used at infusion rates of 0.025-0.1μg / kg / min after a loading dose of 1 μg / kg / min, with mean Arterial Pressure 55-65 mmHg.~Before the induction of anesthesia and 30 minutes of anesthesia, 2 ml of venous blood sample will be taken from the patients and simultaneous tissue oxygen saturation will be recorded. Serum thiol disulfide levels obtained from the blood sample of the recipient will be studied in the biochemistry research laboratory using the method developed by Erel et al."
89475512|NCT03317769|Experimental|Experimental Treatment|Computerized cognitive training for 18 hours and structured social skills training for 9 hours over a 9 week period.
89475513|NCT03317769|Active Comparator|Active Comparator|Commercially-available computerized training for 18 hours and 9 hours of unstructured support group sessions over a 9 week period.
89475514|NCT03563989|Experimental|Stentys Xposition S Self-Apposing stent|STENTYS Xposition S Sirolimus Eluting Self-Apposing Coronary Stent System
89475515|NCT03563989|Active Comparator|Conventional Balloon-expandable stent|Conventional Balloon-expandable drug eluting stents in effect at the time of the study, in compliance with applicable contracts made between Hospital and suppliers.
89475516|NCT03318627|Other|Tension Measuring|Measuring intraoperative tension of rotator cuff tendon with sterile spring Balance.
89475517|NCT03317691||ST segment Elevation Myocardial Infarction|ST segment Elevation Myocardial Infarction patients' diagnosis was confirmed by coronary artery angiography. The prior surgery electrocardiogram need to be collected.
89475518|NCT02310620|Experimental|Cognitive Training|
89475519|NCT02483169|Experimental|Cilostazol+ Probucol|100mg cilostazol bid plus probucol plus placebo of aspirin
89475520|NCT02483169|Active Comparator|Aspirin + Probucol|aspirin plus placebo cilostazol plus probucol
89475521|NCT02483169|Experimental|Cilostazol|cilostazol plus placebo of aspirin
89475522|NCT02483169|Active Comparator|Aspirin|aspirin plus placebo of cilostazol
89475523|NCT02483091|Experimental|Multifaceted KT intervention|Webinars, online vignettes and e-module, copy of guideline recommendations
89475524|NCT02483091|No Intervention|Control|Printed copy of guideline recommendations
89475525|NCT02489097|Active Comparator|Nitrous Oxide|Receives a mixture of 70% Nitrous Oxide in 30% Oxygen
89475526|NCT02489097|Placebo Comparator|Air/Oxygen (placebo)|Receives a mixture of 70% Air in 30% Oxygen
89475527|NCT02488707|Active Comparator|LISR group|Cases which undergo rectal resection with laparoscopic intersphincteric resection.
89475528|NCT02488707|Active Comparator|TAMIS Group|Cases with rectal cancer which undergo Transanal minimally invasive Total mesorectal excision.
89475529|NCT02203682|Experimental|Doxycycline|Tablets Doxycycline 50 mg PO per day for 12 weeks
89475530|NCT02203682|Placebo Comparator|Placebo|Tablet placebo for 12 weeks
89475531|NCT02483013|Active Comparator|Whitening dentifrices|Two groups used whitening dentifrices, three times per day during four weeks
89475532|NCT02483013|Placebo Comparator|Placebo|One group used conventional dentifrice, three times per day during four weeks
89475533|NCT01869530||Healthy children|
89475534|NCT02256800|Experimental|UGT1A1 genotyping (6,6)|The investigators will escalate the dosage of irinotecan from 180mg/m2 to 260 mg/m2
89475535|NCT02256800|Experimental|UGTA1T1 genotyping (6,7)|The investigators will escalate the dosage of irinotecan from 180mg/m2 to 240 mg/m2
89475536|NCT02256800|Experimental|UGTA1T1 genotyping (7,7)|The investigators will escalate the dosage of irinotecan from 120mg/m2 to 180 mg/m2
89475537|NCT02256800|Experimental|UGT1A1 non-genotyping|The investigators will maintain the dosage of irinotecan by 180mg/m2
89202710|NCT00991198|Placebo Comparator|C|Aria Regimen Control without O2
89475538|NCT03320655|Active Comparator|Combined Aerobic Training|The subjects will perform in ST part, always only 1 set in the 6 machines early mentioned. During the first and second week they will do 12 repetitions at 40% - 50% of 1 RM. In the third and fourth week progress to 10 repetitions at 60%-70% of 1 RM, and in the second and third month, 8 repetitions at 70%-80% of 1 RM. In the AT part the HIIT protocol is based on a ratio 2 min : 1 min. Consisted of 10 interval training periods (2 min of high intensity at 85% - 90% of heart rate reserve (HRreser) and 9 pauses (1 min in passive pause) between interval training periods. During the first week of training will start with a continuous training, in the second week will start with 5 intervals of HIIT, and in the second and third months they are doing the 10 stages of HIIT.
89475539|NCT03320655|Experimental|Combined Strength Training|During the first and second week subjects will perform 1 sets with 12 repetitions at 40% - 50% of 1 RM in the 6 machines mentioned before. In the third and fourth week strength exercises progress to 2 sets of 10 repetitions, at 60%-70% of 1 RM, and in the second and third month consists of 3 sets at 8 repetitions, at 70%-80% of 1 RM. In the AT part the HIIT protocol is based on a ratio 2 min : 1 min. Consisted of of 5 interval training periods (2 min of high intensity: 85% - 90% of HRreser) and 4 pauses (1 min in passive pause) between interval training periods. During the first week of training will start with a continuous training, in the second week will start with 3 intervals of HIIT, and after the third/fourth week they are doing the 5 stages of HIIT.
89475540|NCT03315195|Experimental|Preoperative oral nutritional supplement|Oral nutritional supplement 500 kcal/day for 14 days and dietary advice
89475541|NCT03315195|No Intervention|Conventional treatment|Dietary advice
89475542|NCT00821522|Active Comparator|Preconditioning|
89475543|NCT00821522|No Intervention|Control|Standard clinical management during cardiac surgery.
89475544|NCT01341457|Experimental|LY2603618 + Gemcitabine|"Gemcitabine 1000 milligrams per meter squared (mg/m^2) administered intravenously on days 1, 8 and 15 of at least one 28-day cycle. 170 or 230 mg LY2603618 administered intravenously on days 2, 9 and 16 of at least one 28-day cycle.~Participants experiencing benefit may continue on the combination therapy until discontinuation criteria are met."
89475545|NCT02488473|Experimental|Ropivacaine + Dexmedetomidine|Adductor Canal Block 20 ml Ropivacaine 5mg/ml + 1 ml Dexmedetomidine 100ug/ml
89475546|NCT02488473|Placebo Comparator|Ropivacaine + Placebo|Adductor Canal Block 20 ml Ropivacaine 5mg/ml + 1 ml Saline
89475547|NCT05128292|Experimental|CoQ10 plus selenium|"Nutraceutical intervention:~400 mg/day CoQ10 soft gel capsula (Bio-Quinone active 100 mg b.i.d) plus 200 microgram organic selenium yeast tablet (SelenoPrecise 100 microgram b.i.d.) over 8 weeks"
89475548|NCT04492137|Experimental|Ultra Early NKF group|Patients submitted to Ultra early NKF in a consecutive fashion by an expert endoscopist
89475549|NCT04492137|No Intervention|Standard cannulation techniques group (including double-guidewire-assisted cannulation)|Patients submitted to standard cannulation techniques (including double-guidewire-assisted cannulation) in a consecutive fashion by an expert endoscopist
89475550|NCT05458791||Standard Dose Intra-arterial Perfusion|All patients will undergo standard of care interventional treatment for liver cancer. The procedure will take place utilizing fluoroscopic and CT guidance. During their procedure, patients will have intra-arterial CT perfusion maps derived of the liver including the region of the tumor. (n=10)
89475551|NCT05458791||Low Dose Intra-arterial Perfusion|Investigate the impacts on contrast and radiation doses and the robustness of reconstruction algorithms on intra-arterial CT perfusion using a lower radiation dose technique. (N=10)
89475552|NCT05103956||Group A (Study Group)|HEMOPATCH® (Sealing / hemostatic patch of collagen and e polyethylene glycol)
89475553|NCT05103956||Group B (Control Group)|No hemostatic or the standard (ligatures and oxidized cellulose regenerated).
89475554|NCT02480127|Experimental|Endometrial injury|In the intervention group, endometrial sampling is obtained twice by Pipelle [one in the follicular phase (during 8-9 or 11- 13 day in the beginning of buserelin cycle) and the last in the luteal phase (during 19-21 or 20-23 day) preceding the embryo transfer cycle preceding the embryo transfer cycle]. Blood samples (5- 10 cc) are taken in the both groups twice (one on the 9-8 or 11- 13 day and 19-21 or 20-23 day preceding the embryo transfer cycle).
89475555|NCT02480127|No Intervention|Control|In the control group endometrial sampling will be done only in the luteal phase of the cycle preceding the embryo transfer cycle. Blood samples (5- 10 cc) are taken twice (one on the 9-8 or 11- 13 day and 19-21 or 20-23 day preceding the embryo transfer cycle).
89475556|NCT03979742|Experimental|MC001|UCBMNC (MC001) transplant+Locomotor training
89475557|NCT03979742|Other|No treatment|No surgery, no transplant, locomotor training only
89475558|NCT03317301|Experimental|Experimental|Experimental: 2 times a day(Day, Night), 2 weeks of treatment / Day: HL151 (1Tab)+Talion Tab (Placebo)(1Tab), Night: HL151 (Placebo)(1Tab)+Talion Tab (Placebo)(1Tab)
88949925|NCT01940952|Placebo Comparator|Placebo|Placebo + Donepezil 5mg or 10mg
88949926|NCT01940952|Active Comparator|Zydena 100mg|Zydena (Udenafil) 100mg + Donepezil 5mg or 10mg
88949927|NCT01940965|Experimental|Lixisenatide + Biguanide|52-week treatment with Lixisenatide in combination with biguanide (usual maintenance dose in the label)
89202711|NCT01054651|Experimental|Artesunate+Sulfamethoxypyrazine/pyrimethamine|
89202712|NCT01054651|Active Comparator|Praziquantel|
89475559|NCT03317301|Active Comparator|Active comparator|Comparator: 2 times a day(Day, Night), 2 weeks of treatment / Day: HL151 (Placebo)(1Tab)+Talion Tab (1Tab), Night: HL151 (Placebo)(1Tab)+Talion Tab (1Tab)
89475560|NCT05463471|Experimental|sodium acetate ringer|
89475561|NCT05463471|Active Comparator|albumin|
89475562|NCT03317145|Active Comparator|Arm A (NMES followed by IPC)|Arm A (NMES followed by IPC). Following baseline blood flow measurements using ultrasound, the neuromuscular electrostimulation (NMES) device will be fitted and allowed to operate for 10 minutes. Blood flow measurements will then be repeated. The NMES device will be removed. After a 30 minute rest period, the intermittent pneumatic compression (IPC) device will be fitted, activated for 10 minutes and then blood flow measurements repeated.
89475563|NCT03317145|Active Comparator|Arm B (IPC followed by NMES)|Arm B (IPC followed by NMES). Following baseline blood flow measurements using ultrasound, the intermittent pneumatic compression device (IPC) will be fitted and allowed to operate for 10 minutes. Blood flow measurements will then be repeated. The IPC device will be removed. After a 30 minute rest period, the neuromuscular electrostimulation (NMES) device will then be fitted, activated for 10 minutes and then blood flow measurements repeated
89475564|NCT03971708|Other|Ropivacaine|This is the control where patients will receive ropivacaine via the TAP block infusion post-operatively.
89475565|NCT03971708|Active Comparator|Lidocaine|This is the study arm where patients will receive lidocaine via the TAP block infusion post-operatively.
89475566|NCT02480205|Experimental|NeuroBox to deliver the NeuroPAP|
89475567|NCT02832037|Experimental|BI 425809 dose 1|
89475568|NCT02832037|Experimental|BI 425809 dose 2|
89475569|NCT02832037|Experimental|BI 425809 dose 3|
89475570|NCT02832037|Experimental|BI 425809 dose 4|
89475571|NCT02832037|Placebo Comparator|Placebo|
89202713|NCT04961554||Adult patients presenting with limited mouth opening|Adult patients presenting with limited mouth opening not allowing intubation by videolaryngoscopy, on mandibular surgical pathology requiring general anesthesia.
89475572|NCT03970226|Experimental|Tocilizumab Administration: Phase 0|In Phase 0, patients will receive one dose of tocilizumab prior to surgery.
89475573|NCT03970226|Experimental|Tocilizumab Administration: Feasibility Phase|During the Feasibility Phase, patients will receive tocilizumab every 2 weeks for up to 13 cycles (approximately 1 year). Patients will be followed for up to 5 years.
89475574|NCT02480361|Experimental|Acupuncture|The patients who were received acupuncture after gastric cancer surgery
89475575|NCT02480361|No Intervention|Non-acupuncture|The patients who were not received acupuncture after gastric cancer surgery
89475576|NCT02482857|Experimental|Acetylsalicylic acid 75 mg twice daily|Aspirin 75 mg BID is a new experimental dosing regimen which has shown improved efficiency regarding laboratory parameters in several studies, mainly in diabetic patients.
89475577|NCT02482857|Active Comparator|Acetylsalicylic acid 160 mg once daily|Aspirin 160 mg OD is an accepted and used dosage after CABG.
89475578|NCT02482857|Active Comparator|Acetylsalicylic acid 75 mg once daily|Aspirin 75 mg OD is an accepted and used dosage after CABG.
89475579|NCT04202276|Other|Patients with GERD|The data of Food frequency questionnaire (FFQ), 24-hours oesophageal pH-impedance examination, GERD-Q questionnaire to be performed in children and adolescents with GERD.
89475580|NCT04202276|Other|Control group|The same examinations as in experimental group are to be performed in patients of the control group (no GERD according to the results of the examination): Food frequency questionnaire (FFQ), 24-hours oesophageal pH-impedance examination, GERD-Q questionnaire.
89475581|NCT03316989||obese children|Children and adolescents with BMI according to the CDC greater that 95%ile
89475582|NCT03316989||normal weight|Children and adolescents with BMI according to the CDC less than the 85%ile
89475583|NCT03316989||obese with the MetS|obese children with metabolic syndrome compared to obese children with out the MetS and normal weight children
89475584|NCT03316755|No Intervention|without pamphlet|a group not exposed to pamphlet
89475585|NCT03316755|Experimental|With pamphlets|a group exposed to pamphlet
89475586|NCT02480049|Experimental|A Test|test drug (Asmakast)1 tablet contains 10 mg Montelukast
89475587|NCT02480049|Active Comparator|B Reference|reference drug (Singulair) 1 tablet contains 10 mg Montelukast
89475588|NCT02479971|Active Comparator|Normal saline irrigation|An irrigation of the entire abdominal cavity with 500 ml normal saline will be performed.
89475589|NCT02479971|Experimental|Clindamycin-gentamicin irrigation|An irrigation of the entire abdominal cavity with 500 ml gentamicin and clyndamycin solution will be performed.
89475590|NCT02486055|Active Comparator|Cohort 1|In Cohort 1, doses of BPM31510 Oral Nanosuspension 4% will be administered two times per day before the morning and evening meals with no less than 8 and no more than 10 hours between doses. Immediately after administration, subjects will ingest 6 ounces of tap or bottled water. Solid food and drinks, other than water should be restricted to 2 hours before and 1 hour after dosing.
89475591|NCT02486055|Active Comparator|Cohort 2|In Cohort 2 doses BPM31510 Oral Nanosuspension 4% will be administered three times per day before meals, with no less than 4 and no more than 6 hours between doses. Immediately after administration, subjects will ingest 6 ounces of tap or bottled water. Solid food and drinks, other than water should be restricted to 2 hours before and 1 hour after dosing.
89475592|NCT03314883|Experimental|D-US ARF|Diaphragmatic evaluation, i.e thickening fraction (%) and excursion (millimeters), will be performed 3 times in the first two hours after acute hypoxic - hypercapnic respiratory failure (ARF) patients admission
89475593|NCT02486289|Experimental|NBMI (Emeramide) 100mg|NBMI oral capsules 100mg administered once daily. Double dummy used for blinding i.e. 2 x 50mg NBMI + 1 x 200mg placebo capsule equals in total 3 capsules administered daily.
89475594|NCT02486289|Experimental|NBMI (Emeramide) 300mg|NBMI oral capsules 300mg administered once daily. Double dummy used for blinding i.e. 2 x 50mg NBMI + 1 x 200mg NBMI capsule equals in total 3 capsules administered daily.
89475595|NCT02486289|Placebo Comparator|Placebo|Placebo oral capsules administered once daily. Double dummy used for blinding i.e. 2 x 50mg size + 1 x 200mg size placebo capsules equal in total 3 capsules administered daily.
89475596|NCT03314727|No Intervention|Control group|Drink 200 ml soup with no added salt
89475597|NCT03314727|Experimental|High salt (NaCl) intake|Group 2: Drink 200 ml soup with 3 g added salt Group 3: Drink 200 ml soup with 3 g added salt plus 500 ml water Group 4: Drink 200 ml soup with 3 g added salt plus 750 ml water
89475598|NCT02485821|Experimental|Estradiol + Misoprostol|100 patient will receive single dose vaginal estradiol 50mcg tablet (Ethinyl Estradiol manufactured by KAHIRA Pharmaceutical company) and vaginal misoprostol 25mcg tablet (Vagiprost manufactured by ADWIA Pharmaceutical company), misoprostol alone will repeated every 6hours up to five doses.
89475599|NCT02485821|Placebo Comparator|Placebo + Misoprostol|100 patients will receive placebo vaginally and misoprostol 25 mcg which will be repeated every 6 hours up to five doses.
89475600|NCT02485977||Pulmonary Hypertension|Adult patients with pulmonary hypertension referred for cardiac catheterization in the PI institution
89475601|NCT03314649||Observational study|Patients with gastric cancer and non-cancerous disease planned to have laparotomy
89475602|NCT05127668|Experimental|Airglove arm|Participants on the airglove arm were subjected to warming of their forearms using the Airglove device at 38.5oC.
89475603|NCT05127668|Experimental|Warm-water Immersion arm|Participants on the WWI arm were subjected to warming by immersing their forearms into a bucket of warm water at 38.5oC.
89475604|NCT02485665|No Intervention|Kegel exercise education|Prostate cancer patients of control group will received Kegel exercise education for pelvic floor muscle exercise (PFME) to improve the post-prostatectomy incontinence after robot-assisted laparoscopic radical prostatectomy.
89475605|NCT02485665|Experimental|Extracorporeal biofeedback device|Prostate cancer patients of intervention group will received extracorporeal biofeedback device (Any Kegel) for pelvic floor muscle exercise (PFME) to improve the post-prostatectomy incontinence after robot-assisted laparoscopic radical prostatectomy.
89475606|NCT05078294||Cases|Patients treated as monotherapy with phototherapy, cyclosporine, methotrexate, azathioprine, mycophenolate, dupilumab, baricitinib, upadacitinib, or tralokilumab for the treatment of moderate to severe atopic dermatitis.
89475607|NCT02479815|Other|1gm MNP, 15 sachets per month|Quasi experimental matched control cluster design where for every child 1gm Micronutrient Powder (MNP) for two days, is given which totlas to 15 sachets per month
89475608|NCT02482545|Experimental|Breakfast Meal Replacement|Once daily of a powdered meal replacement (high fat, high protein) will be consumed, mixed with water, at breakfast.
89475609|NCT02482545|No Intervention|Control|No placebo or intervention
89475610|NCT05037110|Experimental|Physical activity group|
89475611|NCT05037110|Experimental|Chemosensory training group|
89475612|NCT05037110|No Intervention|Control group|For 12 weeks, continue the participant's routine (no intervention). This is done remotely. Then, every two weeks, complete an online follow-up questionnaire (15 minutes each).
89475613|NCT02485743|Active Comparator|Active Diet Products|A range of products that will be provided as part of a weight maintenance diet which contain active ingredients aimed at increasing satiety (such as inulin, β-glucan, protein and mycoprotein). All ingredients are accepted food ingredients approved for human consumption in Europe.
89475614|NCT02485743|Placebo Comparator|Placebo Diet Products|A range of products matching those provided in the Active Diet which will be provided as part of a weight maintenance diet but do not contain additional ingredients aimed at improving satiety (food matrices will be the same - e.g. shakes, cheeses etc but without active ingredients).
89475615|NCT04119830|Experimental|Treatment (rintatolimod, pembrolizumab)|Patients receive rintatolimod IV over 30 minutes on days 1-3 and pembrolizumab IV over 30 minutes on day 3. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Beginning in cycle 4, patients receive rintatolimod IV over 30 minutes and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 24 months from the first dose in the absence of disease progression or unacceptable toxicity.
89475616|NCT03314571||non applicable|
89475617|NCT04049786|Active Comparator|Simvastatin - Healthy volunteers|Adult patients (18-65 years old) with body mass index < 25 kg/mˆ2 treated with a single oral dose of 40 mg simvastatin for Pk analysis. Blood samples collected for blood tests, genomics and transcriptomic analysis
89475618|NCT04049786|Active Comparator|Carvedilol Study - Healthy volunteers|Adult patients (18-65 years old) with body mass index < 25 kg/mˆ2 treated with a single oral dose of 25 mg carvedilol for Pk analysis. Blood samples collected for blood tests, genomics and transcriptomic analysis
89475619|NCT04049786|Active Comparator|Simvastatin - Obese|Adult patients (18-65 years old) with body mass index > 30 kg/mˆ2 treated with a single oral dose of 40 mg simvastatin for Pk analysis. Blood samples collected for blood tests, genomics and transcriptomic analysis.
89475620|NCT04049786|Active Comparator|Carvedilol study - Obese|Adult patients (18-65 years old) with body mass index > 30 kg/mˆ2 treated with a single oral dose of 25 mg carvedilol for Pk analysis. Blood samples collected for blood tests, genomics and transcriptomic analysis.
89475621|NCT04049786|Active Comparator|Simvastatin - Post-RYGB|Adult patients (18-65 years old) previously submitted to RYGB surgery treated with a single oral dose of 40 mg simvastatin for Pk analysis. Blood samples collected for blood tests, genomics and transcriptomic analysis.
89475622|NCT04049786|Active Comparator|Carvedilol - Post-RYGB|Adult patients (18-65 years old) previously submitted to RYGB surgery treated with a single oral dose of 25 mg carvedilol for Pk analysis. Blood samples collected for blood tests, genomics and transcriptomic analysis.
89475623|NCT04039100|Experimental|Family Caregiver Ambassador Support|Intervention group: caregivers of newly diagnosed patients (n=30), former family caregivers as ambassadors (n=20)
89475624|NCT03316677|Other|colorectal resection and anastamosis|"Intraoperative testing of colorectal anastomoses~Insert a Foley catheter through the anus into the rectum.~Insufflate the Foley balloon with 5 cc of air.~fill the pelvic space with 500 CC of warm saline~Insufflate air into the rectum up to a pressure of 35 mmH2o as measured by external manometer~Remove the saline from the pelvic space.~Inject methylene blue in to the rectum up to a pressure of 35 mmH2o measured by external manometer~Remove the methylene blue from rectum.~NB the above procedures are standard practice for assessing the quality of colorectal anastomoses during colorectal surgery.~The purpose of the study is to compare these standard methods of evaluation to determinant which method is superior"
88949928|NCT01940965|Experimental|Lixisenatide + TZD|52-week treatment with lixisenatide in combination with TZD (usual maintenance dose in the label)
88949929|NCT01940965|Experimental|Lixisenatide + alpha-GI|52-week treatment with Lixisenatide in combination with alpha-GI (usual maintenance dose in the label)
89475625|NCT02482077|Experimental|SOF+RBV 8 wk|Participants will receive SOF+RBV for 8 weeks.
89475626|NCT02482077|Experimental|SOF+RBV 12 wk|Participants will receive SOF+RBV for 12 weeks.
89475627|NCT02482077|Experimental|SOF+DCV 8 wk|Participants will receive SOF+DCV for 8 weeks.
89475628|NCT02482077|Experimental|SOF+DCV 12 wk|Participants will receive SOF+DCV for 12 weeks.
89475629|NCT02482077|Experimental|LDV/SOF 8 wk|Participants will receive LDV/SOF for 8 weeks.
89475630|NCT02482077|Experimental|LDV/SOF 12 wk|Participants will receive LDV/SOF for 12 weeks.
89475631|NCT03316599|Experimental|Ficlatuzumab + Gemcitabine and Nab-Paclitaxel|"Ficlatuzumab will be administered intravenously days 1 and 15 of a 28 day cycle~Gemcitabine 1000 mg/m2 and Nab-Paclitaxel 125mg/m2 will be administered IV days 1, 8, and 15 of a 28 day cycle.~Dosage of Ficlatuzumab is determined by dose level to which the patient is assigned at time of enrollment."
89475632|NCT02482155|Experimental|ibuprofen|ibuprofen 400 mg granules, oral solution, single administration under fasting conditions
89475633|NCT01675154|Placebo Comparator|SLx-4090 placebo/Orlistat Placebo|"Slx-4090(placebo) is dosed as 4 tablets of 50 mg, three times per day with meals.~Orlistat (placebo) is dosed as 2 capsules of 60 mg, three times per day with meals.~This trial is adaptive design/flexible design. The participants were either randomized from the start of the study or after the completion of each treatment."
89475634|NCT01675154|Experimental|Orlistat/placebo|Orlistat two capsules 60mg each, three times per day with meals. Placebo for SLx-4090, 4 tablets 50mg each, three times per day with meals. This trial is adaptive design/flexible design. The participants were either randomized from the start of the study or after the completion of each treatment.
89475635|NCT01675154|Experimental|Orlistat placebo /SLx-4090|Orlistat placebo 2 capsules, 60mg each three times per day with meals. Slx-4090 4 tablets, 50mg each. three times per day with meals. This trial is adaptive design/flexible design. The participants were either randomized from the start of the study or after the completion of each treatment.
89475636|NCT01675154|Experimental|Orlistat/SLx-4090|Orlistat, 2 capsules 60 mg each, three times per day with meals. SLx-4090 4 tablets 50mg each, three times per day with meals. This trial is adaptive design/flexible design. The participants were either randomized from the start of the study or after the completion of each treatment.
89475637|NCT02481999||Study group: Patients|"470 children for elective surgery 0,5 to 8 years~Analysis of EEG data will divided in four age-related groups because of the different baseline EEG activity:~0.5 - 12 month: 5-7 Hz activity / blocked by eye opening~12 - 36 month: 7-8 Hz activity / Variability 5 - 10 Hz~3 - 6 years: 8 Hz activity / amplitude 100µV~6 - 8 years 10Hz activity / amplitude 100 µV"
88949930|NCT01940965|Experimental|Lixisenatide + Glinide|52-week treatment with Lixisenatide in combination with glinide (usual maintenance dose in the label)
89475638|NCT02481999||Control group: Healthy children for POCD assessment|80 healthy children (siblings of study group children and children from Kindergarten) 0,5 to 8 years with no operation
89475639|NCT03316521|Experimental|Single Ascending Dose (SAD)|"In the SAD arm subjects will be sequentially included in one of up to six cohorts (dose levels). All cohorts will include at least four subjects each. Additional subjects may be added in any cohort if necessary.~AMY-101 will be administered as a SQ or IV injection. Subjects in each cohort will be dosed sequentially, to allow for close safety monitoring. Between each cohort, safety data will be analyzed, evaluated and reviewed by the internal Safety Review Committee. Subsequent dose levels will be administered until either the maximum tolerated dose (MTD) or the study maximum dose (SMD) is reached based on specified dose escalation criteria."
89475640|NCT03316521|Experimental|Multiple Dose (MD)|Depending on the results of the SAD, multiple doses of AMY-101 will be administered at the dose which has been identified as the dose which saturates target C3, for a duration that results to an exposure level equivalent to the maximum exposure achieved in the SAD. The dose and dosing interval will be determined based on the PK data obtained in the SAD part of the study. Each MD cohort will include at least four subjects and may be expanded with additional subjects if necessary. Between each cohort, safety data will be analyzed, evaluated and reviewed by the internal Safety Review Committee.
89475641|NCT02485431|Experimental|Deflazacort, fasted|36mg of Deflazacort with 240 ml of room-temperature, non-carbonated water in Fasted state.
89475642|NCT02485431|Experimental|Deflazacort, high-fat meal|36mg of Deflazacort with 240 ml of room-temperature, non-carbonated water with high fat meal served 30 minutes prior to dosing.
89475643|NCT02485431|Experimental|Deflazacort, crushed, fasted|36mg of Deflazacort crushed and mixed with apple sauce.
89475644|NCT02485431|Experimental|Deflazacort alternate strength,fasted|Investigational Formulation Deflazacort tablet (6 X 6mg).
89475645|NCT02485431|Experimental|Deflazacort suspension with apple juice|Deflazacort oral suspension (36mg) mixed with 100ml apple juice in fasted state.
88949931|NCT01940978|Placebo Comparator|Control|Methylphenidate ER QD placebo BID
88949932|NCT01940978|Active Comparator|Methylphenidate ER, cyproheptadine 2.5mg|Methylphenidate ER QD cyproheptadine hydrochloride 2.5mg BID
88949933|NCT01940978|Active Comparator|Methylphenidate ER, cyproheptadine 5mg|Methylphenidate ER QD cyproheptadine hydrochloride 5.0mg BID
88949934|NCT01941004|Experimental|double blinded Fingolimod 6 mos + open label fingolimod 6 mos|Randomized to 6 month (180 days) 0.5 mg fingolimod + 6 month (180 day) open label 0.5mg fingolimod capsules for oral administration once daily
88949935|NCT01941004|Placebo Comparator|Placebo 6 mos + open label fingolimod 6 mos|Randomized to 6 month (180 days) matching placebo + 6 month (180 day) open label 0.5mg fingolimod capsules for oral administration once daily
88949936|NCT01941017||Minimal or mild endometriosis|Patients with minimal or mild endometriosis diagnosed via laparoscopy.
88949937|NCT01941017||Tubal obstruction without endometriosis|Patients with tubal obstruction due to infection or adhesion with absent evidence for endometriosis on laparoscopy
88949938|NCT01941056|Experimental|Treatment (CMV-MVA Triplex vaccine)|Participants receive multi-CMV epitope modified vaccinia Ankara vaccine IM followed by a booster injection 28 days later in the absence of unacceptable toxicity.
88949939|NCT01941069|Active Comparator|Internalizing Disorders|Students identified as being at-risk for or meeting criteria for Internalizing Disorders will assigned to this intervention arm. They will receive the FRIENDS for Life intervention. FRIENDS is a group Cognitive Behavioral Therapy (CBT) intervention, based on a theoretical model, which addresses cognitive, physiological and behavioral processes that are seen to interact in the development and perpetuation of excessive anxiety.
88949940|NCT01941069|Active Comparator|Externalizing Disorders|Students identified as being at-risk for or meeting criteria for Externalizing Disorders will be assigned to this intervention arm. They will receive the Coping Power Program (CPP) intervention. CPP is a cognitive-behavioral, multi-component group intervention for elementary and middle school students at risk for externalizing behavior disorders. In addition to anger management, the CPP includes units on goal setting, emotional awareness, relaxation training, social skills training, problem solving, and handling peer pressure.
88949941|NCT01941082|Experimental|Part A: RO6867461|Single doses
88949942|NCT01941082|Experimental|Part B: RO6867461|Multiple doses
88949943|NCT01941121|Experimental|Linkage to PrEP or Care|Subjects screened for HIV at any CCTG consortium site will be offered Linkage to PrEP or Care, depending on HIV status. After results are received, HIV testers will obtain verbal consent from the subject to connect with the ALERT Specialist, or otherwise offer the subject the ALERT Specialist contact information. When contacted, the ALERT Specialist will coordinate with the subject the scheduling of the PrEP or Care visit, and remain in contact to ensure linkage.
88949944|NCT01941134|Experimental|Gastric bypass COC|"This is a before-and-after comparison. Women will enroll prior to planned gastric bypass surgery and complete one cycle of oral contraceptive use and evaluation. There will then be no more study procedures/interventions until 3-4 months after surgery. At that time, women will complete the second cycle of OC use and evaluation. Study participation is then complete.~Intervention: Ethinyl estradiol-levonorgestrel(EE 20mcg/LNG 150mcg)"
88949945|NCT01941147|Experimental|Pulsed ELF-MF|Nine patients will be treated daily for 5 consecutive days, starting within 48 h from the onset of stroke. Three dose cohorts of three patients each, will be stimulated with pulsed ELF-MF at increasing daily exposure (45, 120, 240 min).
88949946|NCT01941160|Experimental|Amoxicillin/Clavulanic Acid and Lacidofil® STRONG|Participants are provided in double blinded fashion Lacidofil® STRONG to take with antibiotics
88949947|NCT01941160|Placebo Comparator|Placebo|Participants are provided in double blinded fashion placebo to take with antibiotics
88949948|NCT01941173|Experimental|Treatment (ziv-aflibercept, FOLFIRI)|Patients receive ziv-aflibercept IV over 15-30 minutes followed by FOLFIFRI chemotherapy comprising leucovorin calcium IV over 2 hours, irinotecan hydrochloride IV over 90 minutes, and fluorouracil IV over 46 hours on day 1. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.
88949949|NCT01941199|Experimental|D → M → D+M|D : DA-1229 5mg qd, M : metformin 1000mg bid
89206227|NCT05428475|Experimental|[18F]FDG-PET Scan|Participants with unclear symptoms of cognitive impairment who will undergo the [18F]FDG-PET scan (185 MBq of [18F]FDG administered once during study).
89475646|NCT02485509|Experimental|20 mg VM-1500/Placebo Healthy group|VM-1500 20 mg or placebo single dose.
89475647|NCT02485509|Experimental|40 mg VM-1500/Placebo Healthy group|VM-1500 40 mg or placebo single dose.
89475648|NCT02485509|Experimental|20 mg VM-1500/Placebo Patient group|VM-1500 20 mg or placebo once daily for 7 days.
89475649|NCT02485509|Experimental|40 mg VM-1500/Placebo Patient group|VM-1500 40 mg or placebo once daily for 7 days.
89475650|NCT02744755|Experimental|GP2017|Group 1 will receive treatment with 40mg GP2017 (Adalimumab - GP2017) by subcutaneous injection every other week up to 24 weeks (Study Period 1) at which patients achieving at least a moderate clinical response continue treatment with 40mg GP2017 subcutaneous injection every other week up to 48 weeks (Study Period 2).
89475651|NCT02744755|Active Comparator|US Licensed Humira|Group 2 will receive treatment with 40mg Humira® (Adalimumab - US licensed Humira®) by subcutaneous injection every other week up to 24 weeks (Study Period 1) at which patients achieving at least a moderate clinical response will be switched to treatment with 40mg GP2017 subcutaneous injection every other week up to 48 weeks (Study Period 2).
89475652|NCT03314493|Experimental|Spironolactone group|Spironolactone oral tablet 25mg/day, for 12 months
89475653|NCT03314493|No Intervention|Control group|No spironolactone use
89475654|NCT02485587|Experimental|Individualized Arousal-Biofeedback|"After a pre-training assessment at baseline, subjects will be randomized to either treatment arm or treatment as usual. Subjects in the experimental condition will receive 20 sessions of arousal (electrodermal activity) feedback, 1 session/week. Each session will last about 1 hour. After the first 10 sessions (10 weeks after the beginning of the training phase), parents/caregivers will be asked to evaluate behavioral measures of aggression.~After training completion (approximately 20 weeks after the beginning of the training phase), subjects will undergo post-treatment assessment (week 20/21) and follow up (6 months after the end of the training phase)."
89475655|NCT02485587|Active Comparator|Treatment as usual|After a pre-training assessment at baseline, subjects will be randomized to either treatment arm or treatment as usual. Subjects in the comparator condition will receive several appointments together with their parents/caregivers or group trainings over a timeframe of 20 weeks. Within the sessions, the investigators will focus on psychoeducational issues and provide general counseling for the families. After 10 weeks, parents/caregivers will be asked to evaluate behavioral measures of aggression. After 20 weeks, subjects will undergo post-treatment assessment (week 20/21) and follow up (6 months after the end of the treatment phase).
89475656|NCT02485587|No Intervention|Typically developing (TD) control group|Healthy, typically developing children will only undergo baseline assessment (observational) for comparison
89475657|NCT02479893||cold snare polypectomy|CSP: In this group polyps will be removed with the cold snare polypectomy technique, as a single piece. Additionally, a 1-2mm of normal tissue around the small polyp will also be ensnared in the CSP.
89475658|NCT02479893||hot snare polypectomy|HSP: In this group polyps will be removed with the hot snare polypectomy technique as a single piece with a electrosurgical snare and monopolar current with a setting of 30-35 W in the endocut function.
89475659|NCT02479893||APC polyp destruction-polypectomy|APC: In APC group polyps will be cauterized by application of high power argon plasma coagulation on small waves at 50-60W and flow at 2lt/min,as result the polyp destruction.
89475660|NCT03924752|Experimental|Healthy individuals using powered exoskeleton|This study will be conducted on a sample population of able-bodied subjects (single arm). Each subject will test with each condition of the exoskeleton (repeated measures).
89475661|NCT02479659|No Intervention|Control|Facilities in this arm maintained status quo HIV testing and routine childhood immunization services
89475662|NCT02479659|Experimental|Simple Intervention|This included: 1) HIV testing commodity reinforcement and 2) a policy reinforcement meeting
88949950|NCT01941199|Experimental|D → D+M → M|D : DA-1229 5mg qd, M : metformin 1000mg bid
88949951|NCT01941199|Experimental|M → D → D+M|D : DA-1229 5mg qd, M : metformin 1000mg bid
88949952|NCT01941199|Experimental|M → D+M → D|D : DA-1229 5mg qd, M : metformin 1000mg bid
88949953|NCT01941199|Experimental|D+M → M → D|D : DA-1229 5mg qd, M : metformin 1000mg bid
88949954|NCT01941199|Experimental|D+M → D → M|D : DA-1229 5mg qd, M : metformin 1000mg bid
88949955|NCT01941212|Active Comparator|Music therapy and Behavioral therapy|Music and behavioral therapy
88949956|NCT01941212|Active Comparator|Music only|Music therapy without behavioral therapy
88949957|NCT01941212|No Intervention|Control|Patients will not listen to music neither will get music therapy
88949958|NCT01941225|Placebo Comparator|Placebo|Nebulized normal saline. Single administration
88949959|NCT01941225|Experimental|Inhaled iloprost 5.0 mcg|Single administration
88949960|NCT01941238||Insulin pump|
88949961|NCT01941238||MDI|
89202714|NCT04059692|Experimental|Cervical manipulation intervention|"To perform the evaluation and detect the cervical vertebral level with mobility restriction, with the patient in supine position, a cervical examination is carried out to determine the mobility restriction, both in flexo-extension, as in inclination and rotation. To check the level of restriction, the post-anterior sliding test is performed.~The manipulation is performed following the criteria of thrust manipulations. A maximum of 3 manipulations are applied in total per subject, one for each level (high level C1-C2, medium level C3-C6, and low level C7), if necessary."
89475663|NCT02479659|Experimental|Comprehensive Intervention|This arm included: 1) HIV testing commodity reinforcement, 2) a policy reinforcement meeting, 3) community sensitization, 4) Opt-out HIV testing for mothers and newborns, and 5) Operational support for service integration
89475664|NCT03912350|Experimental|Test group|Participants with moderate hepatic impairment.
89475665|NCT03912350|Active Comparator|Reference group|Healthy pariticipants with normal hepatic function.
89475666|NCT03563755|Experimental|Cognitive Bias Modification (CBM) + Treatment as usual|Participants will receive access to a 3-week online training programme alongside their usual treatment.
89475667|NCT03563755|No Intervention|Treatment as usual|Participants will continue to receive their usual treatment.
89475668|NCT01849627|Experimental|Low-ED|This condition will focus lowering on the energy density of the diet of the diet. This prescription does not include goals for any other nutrients, thus there are no energy goals.
89475669|NCT01849627|Experimental|Energy Balance|This condition will focus have an energy balance prescription. Participants will be asked to consume a daily energy intake at estimated energy needs for weight loss maintenance.
89475670|NCT03314415|Experimental|Early robotic intervention|Participants randomized to the early robotic intervention will attend robotic assistance sessions for a two-week period earlier in the study (during the first half of the study, approximately). Each participant will attend ten 15-minute robotic assistance sessions to interact with a robot (Aldebaraan Nao H25).
89475671|NCT03314415|Experimental|Late robotic intervention|Participants randomized to the late robotic intervention will attend robotic assistance sessions for a two-week period later in the study (during the latter half of the study, approximately). Each participant will attend ten 15-minute robotic assistance sessions to interact with a robot (Aldebaraan Nao H25).
88949962|NCT01941264|Active Comparator|community based screening and treatment|CHWs will identify pregnant women in the village and encourage to go to the antenatal care clinic, furthermore, once a month the community health worker will screen the pregnant women for malaria with a rapid diagnostic test and treat with artemether-lumefantrine in case of a positive test result.
88949963|NCT01941264|No Intervention|Control|All pregnant women will be identified in the study area and asked for participation to the study. No intervention will take place.
88949964|NCT01941290||Orsiro|
88949965|NCT01941303||Advanced stage non-small cell lung cancer patients|
89206228|NCT00824928||Observational|Patients with locally recurrent prostate cancer that have chosen salvage cryotherapy
89020121|NCT05591196|Experimental|Non-invasive Electrical Spinal Cord Stimulation + Activity Based Rehabilitation|Non-invasive electrical spinal cord stimulation will be performed using surface electrodes placed over the skin of the neck. Biphasic rectangular pulses of 1 millisecond per phase duration will be delivered with a 10 kiloHertz overlapping frequency and between 20-120 Hertzz burst frequency. Non-invasive electrical spinal cord stimulation will be paired with Activity Based Rehabilitation sessions. Stimulation plus rehabilitation sessions will be three times per week, 90 minutes per session for six weeks (total of 18 sessions).
89475672|NCT03801200|Experimental|Apatinib combined with Radiotherapy|"Drugs: Apatinib Apatinib (500 mg/d) was given orally for one week before the brain radiotherapy, and then, continued to be administered at the same way during the brain radiotherapy period (3 weeks). It was given for another one week after the end of the brain radiotherapy.~Radiotherapy: Intensity-modulated radiotherapy (IMRT).~According to the patients KPS score, GPA score, the number and size of metastatic lesions can be selected:~37.5Gy/15 fractions of whole brain irradiation for multiple brain metastases were more than 5;~The whole brain was irradiated with 37.5Gy/15 and simultaneous integrated boost dose of 52.5Gy/15 to patients with 1-5 metastatic lesions."
89475673|NCT03801200|No Intervention|Radiotherapy alone|"Radiotherapy: Intensity-modulated radiotherapy (IMRT).~According to the patients KPS score, GPA score, the number and size of metastatic lesions can be selected:~37.5Gy/15 fractions of whole brain irradiation for multiple brain metastases were more than 5;~The whole brain was irradiated with 37.5Gy/15 and simultaneous integrated boost dose of 52.5Gy /15 to patients with 1-5 metastatic lesions."
89475674|NCT03563911|Experimental|Brief Mindfulness-Based Intervention|Those assigned to the Brief Mindfulness-Based Intervention (BMBI) Arm will receive BMBI.
89475675|NCT03563911|Active Comparator|Control/Nutrition Education|Those assigned to the Control/Nutrition Education Arm will receive the nutrition education intervention.
89475676|NCT02485197|Other|Low 25(OH)D|We will recruit individuals with low 25(OH)D (<30ng/mL).
89475677|NCT02485197|Other|High 25(OH)D|"We will recruit individuals with higher 25(OH)D (at least 20ng/mL units higher then that of the low 25(OH)D group)."
89475678|NCT04234178|Active Comparator|Dural puncture epidural|2 µg/ml fentanyl + %0,125 bupivacaine (20 ml) to epidural
89475679|NCT04234178|Active Comparator|Combined spinal-epidural with epidural volume extension|10 µg fentanyl + 2 mg bupivacaine to intrathecal 7.4 ml saline volume to epidural
89475680|NCT01356589||Cohort|
89475681|NCT02485041|Experimental|M→D→D+M|Mirodenafil(M) in period 1, Dapoxetine(D) in period 2, Dapoxetine+Mirodenafil(D+M) in period 3
89475682|NCT02485041|Experimental|M→D+M→D|Mirodenafil(M) in period 1, Dapoxetine+Mirodenafil(D+M) in period 2, Dapoxetine(D) in period 3
89475683|NCT02485041|Experimental|D→M→D+M|Dapoxetine(D) in period 1, Mirodenafil(M) in period 2, Dapoxetine+Mirodenafil(D+M) in period 3
89475684|NCT02485041|Experimental|D→D+M→M|Dapoxetine(D) in period 1, Dapoxetine+Mirodenafil(D+M) in period 2, Mirodenafil(M) in period 3
89475685|NCT02485041|Experimental|D+M→M→D|Dapoxetine+Mirodenafil(D+M) in period 1, Mirodenafil(M) in period 2, Dapoxetine(D) in period 3
89206229|NCT01063231|Experimental|1|Subjects that are indicated for colonoscopy, who are suspected or known to suffer from large bowel diseases.
89475686|NCT02485041|Experimental|D+M→D→M|Dapoxetine+Mirodenafil(D+M) in period 1, Dapoxetine(D) in period 2, Mirodenafil(M) in period 3
89475687|NCT02481843||Hyperoxia|2-hours of hyperoxia (FiO2 = 1.0)
89475688|NCT02481843||Control|2-hours control without hyperoxia
89475689|NCT01246297|Other|Control|Usual Care
89475690|NCT01246297|Active Comparator|Pulmonary Rehabilitation|Pulmonary Rehabilitation consists of twice weekly exercise classes with an educational component.
89475691|NCT03563599|Experimental|Telacebec (Q203) tablet|
89475692|NCT03563599|Active Comparator|Rifafour e-275|
89475693|NCT04282694||High risk (former) smokers|"Subjects at high risk of lung cancer screened by the medical team of the AOUPR or by GPs to join the prevention program.~Inclusion criteria~Age between 50 and 75 years~Equivalent tobacco intoxication of ≥ 15 cigarettes per day for ≥25 years or ≥ 10 cigarettes per day for ≥30 years~Status of current smoker or ex-smoker for <10 years.~Exclusion criteria~• Personal history of cancer within the prior 5 years"
89475694|NCT02484963|Experimental|zolpidem|Tablet zolpidem 5mg once daily will be given for 4 weeks
89475695|NCT02484963|Placebo Comparator|Placebo|One tablet of placebo will be given for 4 weeks
89475696|NCT03316443|Active Comparator|(Group G)|Glidescope group: 45 patients will be intubated by Glidescope (Group G). For endotracheal intubation with glidoscope, size 3 blade will be used in all of the cases. Glidoscope will be advanced gently in the oral cavity (in the midline) and walked down the tongue. The scope will be further advanced into the vallecula and gentle lifting force will be applied for visualization of the glottis. Endotracheal tube will be loaded on specific rigid stylet with 60 degree bent and will be advanced into the trachea by the same operator.
89475697|NCT03316443|Experimental|(Group M)|Macintosh group: 45 patients will be intubated by Macintosh laryngoscope (Group M).The patient will be intubated by suitable sized tube (in males 8 mm and in females 7.5 mm internal diameter). In Macintosh group we will use a blade size 3 at first, the laryngoscope will be advanced in patient mouth displacing the tongue laterally till the laryngoscope reach the vallecula and then gentle lifting will be applied till visualization of the laryngeal inlet then the tube will be advanced
89475698|NCT04116242||cirrhosis of the liver, stadium Child A|sampling of biological material and health related data collection longitudinally in 6-monthly intervals up to 36 months
89475699|NCT04116242||cirrhosis of the liver, stadium Child B|sampling of biological material and health related data collection longitudinally in 6-monthly intervals up to 36 months
89537424|NCT04970121|Experimental|Duloxetine arm|Chemotherapy regimens consisting of taxanes will be used according to treatment specifications. Subjects require therapeutic intervention for painful peripheral neuropathy will receive duloxetine 20 mg (orally, once daily) as the starting dose for 1 cycle of 7 days; the current dose will be maintained for effective pain control (NRS ≤ 3 points) and increased by 20 mg at the next cycle assessment for ineffective pain control (NRS > 3 points) up to a maximum dose of 60 mg (orally, once daily). Duloxetine administration will be maintained until the uncontrolled pain (under the condition of treatment with duloxetine at its maximum dose), intolerable toxicity, completed antineoplastic therapy or subject loss of visit, death, withdrawal of informed consent, or other conditions occur. The administration of duloxetine is up to a maximum of 12 weeks.
89537425|NCT04856657||Session 1: tACS at IAPF + 2 Hz|Participants in this arm will undergo tACS at a frequency 2 Hz above their IAPF during stimulation session 1. They will undergo tACS at a frequency 2 Hz below their IAPF during stimulation session 2.
89537426|NCT04856657||Session 1: tACS at IAPF - 2 Hz|Participants in this arm will undergo tACS at a frequency 2 Hz below their IAPF during stimulation session 1. They will undergo tACS at a frequency 2 Hz above their IAPF during stimulation session 2.
89537427|NCT03065595|Placebo Comparator|Intervention|Ophicephalus striatus extract
89537428|NCT03065595|Active Comparator|Control|Placebo drug
89537429|NCT02463929|Experimental|diphenhydramine|Subject sedated with sevoflurane, and given bilateral extraoral infraorbital block with 0,125% bupivacaine. Subject injected 0,5mg/kg diphenhydramine intravenously, 15 minutes prior to discontinuation of sevoflurane. If subject develop agitation, 0,1 mg/kg ketamine is administered
89537430|NCT02463929|Placebo Comparator|control|Subject sedated with sevoflurane, and given bilateral extraoral infraorbital block with 0,125% bupivacaine. Subject injected 0,5cc/kg normal saline intravenously, 15 minutes prior to discontinuation of sevoflurane. If subject develop agitation, 0,1 mg/kg ketamine is administered
89537431|NCT02465255|Experimental|Ketorolac|Ketorolac 0.5 mg/kg administrated by sublingual route
89537432|NCT02465255|Active Comparator|Tramadol|Tramadol 2.0 mg/kg administrated by sublingual route
89537433|NCT02465255|Active Comparator|Acetaminophen (paracetamol)|Acetaminophen (paracetamol) 20.0 mg/kg administrated by sublingual route
89020122|NCT05590260|Experimental|IV iron arm|Which will result in receipt of a single-dose IV iron infusion between 6 and 48 hours after delivery and prior to discharge from the facility; folate tablets per local guidelines.
89020123|NCT05590260|Active Comparator|Oral iron comparator arm|Oral iron tablets (containing 60 mg of elemental iron (± folate as per local guidelines)) to be taken at a treatment dose of twice daily for 6 weeks.
89020124|NCT05589480||postoperative recurrence|
89020125|NCT05589480||postoperative non-recurrence|
89020126|NCT05567315|Active Comparator|Oocyte puncture with local anaesthesia alone|
89020127|NCT05567315|Experimental|Oocyte puncture with local anaesthesia and additional virtual reality hypnosis|
89206230|NCT02599103|Placebo Comparator|fat-free milkshake|
89206231|NCT02599103|Active Comparator|Olive oil|
89537434|NCT02463851|Active Comparator|AF-Ablation with Multi-electrode catheter|Regular AF-ablation with a multi-electrode ablation catheter
89537435|NCT02463851|Active Comparator|AF-Ablation with Contact Force single-tip electrode|Regular AF-ablation with a regular Contact Force single-tip ablation catheter
89537436|NCT02464709|Experimental|Actinic keratosis patients|Participant's AKs in facial skin or scalp are first clinically graded and demarcated in two symmetric treatment areas on different sides of face. The areas will be curettaged thinly and next a SPF20 sun protection cream is applied on all sun-exposed areas of the skin. Then a 0,25mm-thick layer of BF-200 ALA (aminolevulinic acid) gel is applied on one treatment side and MAL (methyl 5-aminolevulinate) cream on the other side. The sides will be randomized and the participant doesn't know which side is treated with which light sensitizer. After appropriate absorption time of 30 minutes the patients will be taken to the hospital balcony or yard for 2 hour illumination with natural daylight to accomplish the phototoxic reaction. Maximum dosage of light sensitizer will be 2 grams.
89206232|NCT02599103|Experimental|soybean oil|
89537437|NCT02464085||Longitudinal evaluation of recovery|Stroke survivors with subacute and severe upper limb disability
89537438|NCT05510973|No Intervention|Control|standard of care
89537439|NCT05510973|Experimental|Intervention|Enhanced package of AHD care
89537440|NCT02462915|Experimental|i-gel, an brand of supraglottic airway device|a supraglottic airway devices with a gastric suction channel
89537441|NCT02462915|Experimental|endotracheal tube|traditional use for protect airway during the surgery
89537442|NCT03064893|Active Comparator|Dermacell|Device for immediate implant based breast reconstruction
89020128|NCT05566561|Active Comparator|Group PSCB = Parasartorial compartment block group|After placing the linear ultrasound probe in the middle of the anterior superior line to the patella and spina drug, the probe will be advanced cephalad to visualize the intermediate femoral cutaneous nerve over the satrorious. Then the block will be applied. Three injections will be made with a single needle entry in the same imaging. The procedure will be completed by applying the first injection to the femoral triangle (10 ml of local anesthetic solution), the second injection to the subsartorial region (10 ml of local anesthetic solution) lateral to the femoral artery, and the third injection to the suprasartorial region (10 ml of local anesthetic solution) (total 30 ml of 0.25% solution). concentration bupivacaine). The block location will be confirmed by injecting 2 ml of saline in every three injections.
89020129|NCT05566561|Active Comparator|Group C = Control group|Wound infiltration will be applied by the surgical team
89020130|NCT05557279|Other|Intervention Group|All participants will receive 500 mg NDS-446 daily for 12 weeks
89020131|NCT05541484|Other|Group A: Usual care followed by usual care plus dapagliflozin|10 persons with T1D will check capillary beta hydroxybutyrate (BOHB) and concomitant breath acetone (BrAce) 2 - 3 times daily for 2 weeks during usual care, then undergo an insulin withdrawal visit. Subsequently, the Group A patients will repeat the paired measurements of BOHB and BrAce, 2 - 3 times daily for 2 weeks during usual care plus treatment with the SGLT2i dapagliflozin, 10 mg taken orally daily, followed by an insulin withdrawal visit.
89020132|NCT05541484|Other|Group B: Usual care plus dapagliflozin followed by usual care|10 persons with T1D will check capillary beta hydroxybutyrate (BOHB) and concomitant breath acetone (BrAce) 2 - 3 times daily for 2 weeks during usual care plus treatment with the SGLT2i dapagliflozin, 10 mg taken orally daily, then undergo an insulin withdrawal visit. Subsequently, the Group B patients will repeat the paired measurements of BOHB and BrAce, 2 - 3 times daily during usual care alone followed by an insulin withdrawal visit.
89020133|NCT05540340|Experimental|Pharmacokinetic directed melphalan|This is a feasibility study of pharmacokinetic (PK)-directed Captisol Enabled (CE) melphalan dosing to target an AUC of 8.5 (+/- 1.5) using a population PK model in lymphoma patients receiving BEAM [carmustine (BCNU) (B), etoposide (E), cytarabine (Ara-C) (A), and melphalan (M)], followed by autologous hematopoietic cell transplantation (AHCT). This study will enroll 20 patients with lymphoma planned for BEAM-AHCT. Carmustine IV will be given on day -6, followed by etoposide IV and cytarabine IV from day -5 to -2 as per the MSK inpatient or outpatient standard of care. The calculated melphalan dose based on population PK model to achieve the proposed melphalan target exposure [8.5 (+/- 1.5) mg*h/L], will be administered on day -1, and six peripheral blood samples of 5 ml in lithium heparin tubes will be collected at 5, 15, 30, 40, 75, and 150 minutes after the melphalan, for PK testing to determine if the goal AUC was achieved.
89020134|NCT05538351||Fluid assessment|All patients enrolled in this study will have a clinical assessment to identify hydration status, patient reported signs and symptoms of hydration and Bioimpedance using the Body composition Monitor (BCM).
89020135|NCT05527886|Experimental|Group 1|Randomized AAROM, Slow Load, or Plyometric intervention
89020136|NCT05527886|Experimental|Group 2|Randomized AAROM, Slow Load, or Plyometric intervention
89020137|NCT05527886|Experimental|Group 3|Randomized AAROM, Slow Load, or Plyometric intervention
89475700|NCT04116242||cirrhosis of the liver, stadium Child C|sampling of biological material and health related data collection longitudinally in 6-monthly intervals up to 36 months
89475701|NCT04116242||cirrhosis of the liver, acutely decompensated|sampling of biological material and health related data collection on days 1 (Baseline), 3, 7, and 14. If acutely decompensated patients re-compensate they will be followed 6-monthly for up to 36 months
89475702|NCT04116242||acute liver failure|sampling of biological material and health related data collection on days 1 (Baseline), 3, 7, and 14. If acutely decompensated patients re-compensate they will be followed 6-monthly for up to 36 months
89475703|NCT04116242||healthy controls|sampling of biological material and health related data collection on day 1 (Baseline)
89475704|NCT05713773|Active Comparator|Test product 1 (T1)|Aphaia Pharma (APH)-001A: glucose coated beads containing 8 g glucose and caffeine anhydrous
89475705|NCT05713773|Active Comparator|Test product 2 (T2)|APH-001B: glucose coated beads containing 8 g glucose and caffeine anhydrous
89475706|NCT05713773|Active Comparator|Test product 3 (T3)|APH-001C: glucose coated beads containing 8 g glucose and caffeine anhydrous
89475707|NCT05713773|Active Comparator|Test product 4 (T4)|APH-001D: glucose coated beads containing 8 g glucose
89475708|NCT05713773|Active Comparator|Test product 5 (T5)|APH-001E: uncoated beads containing 8 g glucose and caffeine anhydrous
89020138|NCT05521464|Active Comparator|Group 1|Cast by Plaster of Paris
89020139|NCT05521464|Experimental|Group 2|Robert Jones bandage
89020140|NCT05517850|Active Comparator|Therapist-guided|12 weeks of therapist-guided, exposure-based intervention via tha internet, with comprehensive material
89020141|NCT05517850|Experimental|Self-guided|12 weeks of self-guided, exposure-based intervention via the internet, with shortened and improved material
89020142|NCT05511961|Experimental|Intervention arm|Immediate referral to local budget and debt counselling service and a copy of 'Your child, your money', a financial guidance book for new parents
89020143|NCT05511961|Active Comparator|Waitlist-control arm|Immediately given a copy of 'Your child, your money' book, and referral to local budget and debt counselling service after a period of 3 months
89020144|NCT05509036||Critically ill patients|Critically ill adults > 50 admitted to the ICU and receiving a life support intervention
89475709|NCT02830087|Active Comparator|220 mmHg tourniquet cuff pressure|Thigh tourniquet cuff inflated to 220 mmHg.
89020145|NCT05506631|Experimental|Outpatient cervical ripening|Placement of transcervical Foley balloon for cervical ripening in outpatient setting
89475710|NCT02830087|Active Comparator|250 mmHg tourniquet cuff pressure|Thigh tourniquet cuff inflated to 250 mmHg
89475711|NCT02830087|Active Comparator|275 mmHg tourniquet cuff pressure|Thigh tourniquet cuff inflated to 275 mmHg
89475712|NCT02830087|Active Comparator|300 mmHg tourniquet cuff pressure|Thigh tourniquet cuff inflated to 300 mmHg
89475713|NCT02830087|Active Comparator|325 mmHg tourniquet cuff pressure|Thigh tourniquet cuff inflated to 325 mmHg
89475714|NCT02830087|Active Comparator|350 mmHg tourniquet cuff pressure|Thigh tourniquet cuff inflated to 350 mmHg
89475715|NCT02481765|Experimental|Direct current Stimulation|High definition transcranial direct current stimulation (HD-tDCS)
89475716|NCT05126654|Experimental|COPD with PHGG|COPD patient PHGG 5g/day for 1 month
89475717|NCT05126654|No Intervention|COPD without PHGG|COPD patient without PHGG 5g/day for 1 month
89475718|NCT05126654|Active Comparator|Healthy with PHGG|Healthy PHGG 5g/day for 1 month
89475719|NCT05126654|No Intervention|Healthy without PHGG|Healthy without PHGG 5g/day for 1 month
89020146|NCT05506631|Active Comparator|Inpatient cervical ripening|Placement of transcervical Foley balloon for cervical ripening in inpatient setting
89020147|NCT05499182||Teens|Teens are: 1) Male 2) Aged 13-17; 3) self-identified as Hispanic/Latino; 4) diagnosed with Major Depressive Disorder or Persistent Depressive Disorder/Dysthymia; and 5) referred to psychotherapy or prescribed medication for depression. Teens will be excluded if they are experiencing intense psychological distress or imminent thoughts of suicide.
89020148|NCT05499182||Parents|Parents will 1) Be parents or legal guardians of teens; and 2) Speak and read English or Spanish.
89020149|NCT05499182||Healthcare Providers|Healthcare providers will 1) Self-identify as regularly providing clinical care to Latino adolescents with depression; and 2) be in a role in which they can refer to or provide depression treatment.
89020150|NCT05483608|Experimental|Vertical climbing ergometer exercise|8 weeks of 3 times per week (24 sessions in total) of 30 minutes of vertical climbing ergometer exercise using the CLMBR. Intensity will be prescribed at a level of 12 to 14 on the Borg Rate of Perceived Exertion Scale.
89020151|NCT05483608|Active Comparator|Recumbent cycling|8 weeks of 3 times per week (24 sessions in total) of 30 minutes of recumbent cycle ergometer exercise. Intensity will be prescribed at a level of 12 to 14 on the Borg Rate of Perceived Exertion Scale.
89020152|NCT05483491|Experimental|KK-LC-1 TCR-T cells|Subjects will receive a conditioning regimen, KK-LC-1 TCR-T cells, and aldesleukin.
89475720|NCT02481921|Experimental|MEDIC-HF|Group clinic or shared medical appointment of Education & Intervention in Heart Failure
89475721|NCT02481921|No Intervention|Usual Care|Usual care in heart failure
89475722|NCT05126498||Cohort 2018|All surgically treated patients in the surgical audits for lung cancer surgery (DLCA-S), Upper gastrointestinal cancer surgery (DUCA), pancreatic cancer surgery (DPCA), hepatobiliary surgery (DHBA), colorectal cancer surgery (DCRA), hip fracture surgery (DHFA), aortic aneurysm surgery (DSAA), and bariatric surgery (DATO), from the participating hospitals in 2018
89537443|NCT03064893|Active Comparator|Alloderm|Device for immediate implant based breast reconstruction
89537444|NCT02463617|Other|PD patients|
89202715|NCT04059692|Placebo Comparator|Placebo intervention|This group will receive 15 minutes of sham techniques in a supine position over the stretcher. First, a series of short-time and no pressure contact with physiotherapist´s hands is performed in several points of head and shoulders for 10 minutes. Subsequently, light touch is applied on standardized anatomic areas, for 2 minutes each time.
89202716|NCT00789594|Experimental|Laboratory Monitoring|Laboratory Monitoring
89202717|NCT00789594|Experimental|Result management|Result management
89202718|NCT00789594|Experimental|Both interventions|Both laboratory monitoring and result management interventions
89202719|NCT00789594|No Intervention|Usual care|Usual care
89202720|NCT00354601|Experimental|Weekly Docetaxel and Capecitabine|Weekly Docetaxel and Capecitabine
89202721|NCT00792792||Tissue transfer skin flap|Modulated Imaging Spectroscopy
89202722|NCT01563640|Placebo Comparator|normal school uniforms|washing only
89202723|NCT01563640|Experimental|insecticide-treated school uniforms|washing and insecticide treatment
89202724|NCT00792870|Experimental|SURI Enhanced|
89202725|NCT00792870|Active Comparator|SURI Standard|
89202726|NCT00750620|Experimental|1. Severe renal impairment|severe renal impairment
89202727|NCT00750620|Experimental|2. Moderate renal impairment|moderate renal impairment
89475723|NCT05126498||Cohort 2019|All surgically treated patients in the surgical audits for lung cancer surgery (DLCA-S), Upper gastrointestinal cancer surgery (DUCA), pancreatic cancer surgery (DPCA), hepatobiliary surgery (DHBA), colorectal cancer surgery (DCRA), hip fracture surgery (DHFA), aortic aneurysm surgery (DSAA), and bariatric surgery (DATO), from the participating hospitals in 2019
89202728|NCT00750620|Experimental|3. Mild renal impairment|mild renal impairment
89202729|NCT00750620|Experimental|4. Normal renal function|normal renal function
89202730|NCT03827473|Experimental|Arm A (ADT, docetaxel)|Participants receive androgen deprivation therapy (ADT) per standard of care and docetaxel IV over 1 hour on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
89202731|NCT03827473|Experimental|Arm B (ADT, abiraterone acetate, prednisone)|Participants receive androgen deprivation therapy (ADT) per standard of care, abiraterone acetate PO daily, and prednisone PO twice daily. Treatment continues in the absence of disease progression or unacceptable toxicity.
89202732|NCT00800592|Active Comparator|10 mg sildenafil bolus|10 mg sildenafil bolus
89202733|NCT00755690|Active Comparator|1|"High/ Low Phosphate diet I. A five-day low phosphate diet / A five-day low phosphate diet with the addition of a phosphate binder / A five-day high phosphate diet.~II. A five-day low phosphate diet / A five-day high phosphate diet / A five-day low phosphate diet with the addition of a phosphate binder III. A five-day high phosphate diet / A five-day low phosphate diet with the addition of a phosphate binder / A five-day low phosphate diet.~IV. A five-day high phosphate diet / A five-day low phosphate diet / A five-day low phosphate diet with the addition of a phosphate binder.~V. A five-day low phosphate diet with the addition of a phosphate binder / A five-day low phosphate diet / A five-day high phosphate diet.~VI. A five-day low phosphate diet with the addition of a phosphate binder / A five-day high phosphate diet / A five-day low phosphate diet."
89202734|NCT00755690|Active Comparator|2|High/ Low Phosphate diet
89202735|NCT00755690|Active Comparator|3|High/ Low Phosphate diet
89202736|NCT00991354|Experimental|Group 1|Participants will receive 3 mg of PENNVAX-B vaccine or placebo at Months 0, 1, and 3.
89537445|NCT05505123|Experimental|sevoflurane|induction and maintenance with sevoflurane
89202737|NCT00991354|Experimental|Group 2|Participants will receive 3 mg of PENNVAX-B vaccine and 1 mg of IL-12 vaccine or placebo at Months 0, 1, and 3.
89202738|NCT00991354|Experimental|Group 3|Participants will receive 3 mg of PENNVAX-B vaccine and 1 mg of IL-12 vaccine or placebo at Months 0, 1, and 3.
89202739|NCT00800670|Experimental|Lower dose|Lower dose of Ad5Ag85A: 10^8pfu
89202740|NCT00800670|Experimental|Higher dose|Higher dose of vaccine Ad5Ag85A: 10^9pfu
89202741|NCT05360836|Active Comparator|Group 1|Conservative Treatment Program
89475724|NCT05126498||Cohort 2020|All surgically treated patients in the surgical audits for lung cancer surgery (DLCA-S), Upper gastrointestinal cancer surgery (DUCA), pancreatic cancer surgery (DPCA), hepatobiliary surgery (DHBA), colorectal cancer surgery (DCRA), hip fracture surgery (DHFA), aortic aneurysm surgery (DSAA), and bariatric surgery (DATO), from the participating hospitals in 2020
89020153|NCT05482425|Other|Autologous facial fat graft injection- washed fat|Washed fat injected into both the left and right sides of the face.
89475725|NCT05713617|Experimental|Intervention group|Participants will receive 10 remote sessions with the curriculum with a promotora, and 3 in-person group workshops.
89475726|NCT05713617|No Intervention|control group|Participants will receive community services as usual
89475727|NCT02829775|Experimental|Interferon Alfa-2A in Cancer Participants|Participants who responded to interferon alfa-2A (either pegylated interferon alfa-2A or recombinant interferon alfa 2A) treatment during the parent study will continue to receive the same treatment in this study. Pegylated interferon alfa-2A will be administered subcutaneously once weekly and recombinant interferon alfa 2A will be administered subcutaneously once daily, until disease progression, withdrawal, or death whichever occurs first (up to approximately 3 years).
89475728|NCT05504655||Observational NAC group|Based on a FDA approved 3-bag regime, NAC (Molecular weight:163) was administrated intravenously, initially 150 mg/kg in 200 mL of 0.9%NaCL for 60 minutes (first bag), followed by 50 mg/kg in 500 mL of 0.9%NaCL for 4 hours (second bag), and then 100 mg/kg in 1000 mL of 0.9%NaCL for 16 hours (third bag)
89475729|NCT05504655||Observational Non NAC group|N-acetylcysteine given IV at 600 mg every 12 hours till discharge from ICU.
89475730|NCT03488030||All Participants|Participants diagnosed with moderate to severe UC or CD from the 7 participating sites will be observed on Day 1 for cross-sectional evaluation of disease activity, treatment patterns, burden of disease and quality of life along with retrospective data collection for previous 3 years from the date of UC or CD diagnosis until Day 1 to assess the IBD treatments, medical history and comorbidities, treatment patterns and use of health resources.
89475731|NCT03563521||Atopic, eosinophilic|
89475732|NCT03563521||Atopic, non-eosinophilic|
89475733|NCT03563521||Non-atopic, eosinophilic|
89475734|NCT03563521||Chronic rhinosinusitis with/without nasal polyposis|
89475735|NCT03563521||Non-atopic, non-eosinophilic|
89475736|NCT03563521||Control|Without asthma, atopy and eosinophilia
89475737|NCT02476695||S0/1|S0 = no fibrosis and S1 = portal fibrosis without septa
89475738|NCT02476695||S2|S2 = portal fibrosis with few septa
89475739|NCT02476695||S3|S3 = numerous septa without cirrhosis
89475740|NCT02476695||S4|S4 = liver cirrhosis (compensatory stage)
89475741|NCT02476773|Experimental|Group 1|"5 subjects will receive 10µg Na-APR-1 (M74)/Alhydrogel with Sterile Saline Placebo administered to the alternate arm.~5 subjects will receive 10µg Na-APR-1 (M74)/Alhydrogel with 100µg Na-GST-1/Alhydrogel plus GLA-AF administered to the alternate arm."
89475742|NCT02476773|Experimental|Group 2|"5 subjects will receive 10µg Na-APR-1 (M74)/Alhydrogel plus GLA-AF, with Sterile Saline Placebo administered to the alternate arm.~5 subjects will receive 10µg Na-APR-1 (M74)/Alhydrogel plus GLA-AF, with 100µg Na-GST-1/Alhydrogel plus GLA-AF administered to the alternate arm."
89475743|NCT02476773|Experimental|Group 3|"5 subjects will receive 30µg Na-APR-1 (M74)/Alhydrogel, with Sterile Saline Placebo administered to the alternate arm.~5 subjects will receive 30µg Na-APR-1 (M74)/Alhydrogel, with 100µg Na-GST-1/Alhydrogel plus GLA-AF administered to the alternate arm."
89475744|NCT02476773|Experimental|Group 4|"5 subjects will receive 30µg Na-APR-1 (M74)/Alhydrogel plus GLA-AF, with Sterile Saline Placebo administered to the alternate arm.~5 subjects will receive 30µg Na-APR-1 (M74)/Alhydrogel plus GLA-AF, with 100µg Na-GST-1/Alhydrogel plus GLA-AF administered to the alternate arm."
89475745|NCT02476773|Experimental|Group 5|"5 subjects will receive 100µg Na-APR-1 (M74)/Alhydrogel, with Sterile Saline Placebo administered to the alternate arm.~5 subjects will receive 100µg Na-APR-1 (M74)/Alhydrogel, with 100µg Na-GST-1/Alhydrogel plus GLA-AF administered to the alternate arm."
89475746|NCT02476773|Experimental|Group 6|"5 subjects will receive 100µg Na-APR-1 (M74)/Alhydrogel plus GLA-AF, with Sterile Saline Placebo administered to the alternate arm.~5 subjects will receive 100µg Na-APR-1 (M74)/Alhydrogel plus GLA-AF, with 100µg Na-GST-1/Alhydrogel plus GLA-AF administered to the alternate arm."
89475747|NCT05126186|Experimental|haplo-SCT with PTCy|haploidentical (haplo) related donor Stem Cell Transplantation (haplo-SCT) with administration of post-transplantation cyclophosphamide (PTCy, which targets alloreactive T cells generated early after an HLA-mismatched transplant, sparing regulatory T cells and leaving unaffected the non-dividing hematopoietic stem cells)
89475748|NCT05403164||Periodontitis|Patients with periodontitis which is defined by interdental clinical attachment loss (CAL) ≥ 2 non-adjacent teeth, or Buccal or Oral CAL ≥ 3 mm with probing pocket depth (PPD) > 3 mm is detectable at ≥2 teeth. All patients should be indicated for periodontal surgery.
89475749|NCT05403164||Healthy periodontium|Healthy periodontium is defined by absence of CAL, PPD ≤3 mm, bleeding on probing <10%, and no evidence of radiological bone loss. Gingival samples are collected from subjects referred for gingivectomy for esthetic reasons such as crown lengthening, gummy smile or prior to teeth extraction for orthodontic treatment.
89020154|NCT05482425|Other|Autologous facial fat graft injection-unwashed fat|Unwashed fat injected into both the left and right sides of the face.
89020155|NCT05479123|Experimental|ter in die (TID)three times a day|
89020156|NCT05479123|Experimental|bis in die (BID)twice a day|
89020157|NCT05479123|Active Comparator|Control|
89020158|NCT05476549|Experimental|Lemon verbena|
89020159|NCT05476549|Placebo Comparator|Placebo|
89020160|NCT05471557|Experimental|Pain Stimulus|Capsaicin combined with heat applied to intact skin
89020161|NCT05471557|Active Comparator|Distractor Somatosensory Stimulus|Sensory transcutaneous electrical nerve stimulation (TENS) applied to intact skin
89020162|NCT05471557|No Intervention|No Stimulus|Nothing applied to skin
89202742|NCT05360836|Active Comparator|Group 2|Conservative Treatment + Motor Imagery Program
89475750|NCT04500860|Active Comparator|Group A Tadalafil 5 mg|30 patients subjected to Daily dose of tadalafil 5mg
89475751|NCT04500860|Active Comparator|Group B Tolterodine|30 patients subjected to tolterodine 4 mg daily
89475752|NCT04500860|Placebo Comparator|Group C placebo|30 patients subjected to placebo daily
89475753|NCT05125874|Experimental|V-01 COVID-19 Vaccine|One dose administrated by intramuscular injection
89475754|NCT05402696||Large non-pedunculated colorectal polyp (LNPCP)|Patients referred to St. Paul's Hospital for endoscopic management of a large (≥20mm) non-pedunculated colorectal polyp (LNPCP).
89475755|NCT05430789|Experimental|Intervention group|5As brief advice + Self-help ebooklet + Nurse-led mHealth intervention
89475756|NCT05430789|Active Comparator|Control group|5As brief advice + Self-help ebooklet + Text messaging
89475757|NCT02479503||French Adult Heart Transplantation Center|All center performing adult heart transplantation in France in 2015.
89475758|NCT02479581|Experimental|ERAS group|Perioperative management follows the Enhanced Recovery after Surgery（ERAS） program
89475759|NCT02479581|Experimental|Conventional control group|Perioperative management follows the conventional program
89475760|NCT05389592|Experimental|Double-active|Active transcranial electrical stimulation and cognitive training.
89475761|NCT05389592|Sham Comparator|Cognitive training-only|Sham transcranial electrical stimulation and cognitive training.
89475762|NCT02479347|Experimental|Chloraprep|Preoperative skin preparation with chlorhexidine 2% in alcohol 70% solution
89475763|NCT02479347|Active Comparator|Povidone-iodine|Preoperative skin preparation with povidone-iodine 10% solution
89475764|NCT05125718|Experimental|test group (antimicrobial peptide)|Half of the dentition will receive scaling and root surface debridement within a week followed by the application of antimicrobial peptide gel Ace Helper™ into the site with pocket depth >5mm until overflow noticed. Antimicrobial peptide (AMP) will be reapplied for 2 more times at an interval of 3 days. Antimicrobial peptide gel Ace Helper™ contained 0.85% synthetic AMP (TAPS-18) designed based on the basic structure of cathelicidin, hydroxyethyl cellulose, and purified water.
89475765|NCT05125718|Sham Comparator|control group (normal saline)|Half of the dentition will receive scaling and root surface debridement within a week followed by the irrigation of 0.9% normal saline into the site with pocket depth >5mm. Normal saline irrigation will be repeated for 2 more times at an interval of 3 days.
89475766|NCT01355497|Experimental|GTx-024 3mg once daily|subjects will be randomized to receive GTx-024 3mg sofgel capsule once daily for the duration of the trial
89475767|NCT01355497|Placebo Comparator|placebo|subjects will be randomized to receive matching placebo once daily for the duration of the trial
89475768|NCT04859972||Patients diagnosed with IBS|Patients diagnosed with IBS within primary care in Region Örebro County between 2015- 2019, identified by ICD-code K.58.
89475769|NCT02481609|Experimental|NAC arm|Topical intranasal N-acetyl cysteine (NAC 200 mg/2 ml vials) BID for one month
89475770|NCT04076540|Experimental|AZD4041|
89475771|NCT04076540|Placebo Comparator|Placebo|
89475772|NCT05373225|Experimental|Shock wave Therapy|This group will be composed of subjects who represented the experimental group 1. They will receive shock wave therapy
89475773|NCT05373225|Experimental|Acetic acid shockwave phonophoresis therapy|This group will be composed of subjects who represented the experimental group 2. They will take 6 sessions with Time between sessions 5-7 days plus exercise and dietary advice
89475774|NCT05373225|Active Comparator|conventional physical therapy program|"This group will be composed of subjects who represented the control group~Exercise program:~Standing calf-stretching exercise~Towel stretch: stretching exercise~Ice bottle~Towel pickup exercise~Marble pickups exercise~Calf raises exercises -Static and dynamic balance exercise"
89475775|NCT02479191||Female (Treatment Group)|Device: Ovation Abdominal Stent Graft Platform
89475776|NCT02479191||Male (Control Group)|Device: Ovation Abdominal Stent Graft Platform
89475777|NCT01355575|Experimental|Rifaximin for 6-weeks followed by 6-week observation period|All patients receiving 6 weeks Rifaximin 400mg twice daily, followed by a 6 week observation period.
89475778|NCT05125640|Experimental|Treatment A|"Progesterone 200 mg Soft Capsule (JSC Farmak, Ukraine)"
89475779|NCT05125640|Active Comparator|Treatment B|Utrogestan® 200 mg Soft Capsule (Manufacturer by: Cyndea Pharma, S.L., Spain, MAH: Laboratoires Besins International, France)
89475780|NCT03314259|Experimental|Tamsulosin|Patients will then consume oral tamsulosin 0.4mg every morning daily for 5 days prior to elective surgery
89475781|NCT03314259|Placebo Comparator|Placebo|Patients will then consume placebo every morning daily for 5 days prior to elective surgery
89475782|NCT05125406|Experimental|Exposure therapy using Virtual Reality (ETVR)|
89475783|NCT05125406|No Intervention|No exposure therapy with Virtual Reality.|
89475784|NCT03563443||Bladder cancer patients|Diagnosed bladder cancer patients who are being monitored will be the experimental group to develop the LOI panel, and subsequent cohort will be used to confirm the sensitivity and specificity of this urinary analysis.
89206233|NCT02599103|Experimental|fried soybean oil|
89206234|NCT02599103|Experimental|palm oil|
89206235|NCT02599103|Experimental|fried palm oil|
89475785|NCT03563443||Non-cancer participants|Patients being treated for other diseases but without any tumor or healthy participants will provide a negative control to provide data for developing the LOI diagnostic panel
89475786|NCT02479269|Experimental|intervention|Aerobic exercise+ blood sampling
89475787|NCT02479269|No Intervention|control|Blood sampling
89475788|NCT03929042|Experimental|Posture Correction Girdle|Our research team has designed a prototype of posture correction girdle based on the clinical, textile science, material and ergonomics engineering analyses as an alternative to hard brace for AIS. The design of the posture correction girdle incorporates different mechanisms, such as 1) compression and pulling forces through a close fit of the intimate apparel, 2) lumbar flexion by using supporting belt, 3) transverse forces applied by inserting pads inside the pocket lining by using the principle of the 3-point pressure system.
89537446|NCT05505123|Experimental|propofol|induction and maintenance with propofol
89475789|NCT02481687||Ulcerative colitis|"Consecutively admitted patients with active ulcerative colitis, confirmed by histopathology.~I-SCAN and pCLE will be applied in all patients."
89475790|NCT02481687||Crohn's disease|"Consecutively admitted patients with active Crohn's disease, confirmed by histopathology.~I-SCAN and pCLE will be applied in all patients."
89475791|NCT02479425|Active Comparator|3 point turning|patients nursed by the traditional re-positioning (two hours on back, two hours on right and two hours on left).
89475792|NCT02479425|Experimental|2 points turning|patients nursed on the right and left side sonly in 30ْ avoiding the back
89475793|NCT02826421|Experimental|UltraSert Preloaded Delivery System|Preloaded IOL delivered via a 2.2 mm clear corneal incision during cataract surgery
89475794|NCT02826421|Active Comparator|iTec Preloaded Delivery System|Preloaded IOL delivered via a 2.2 mm clear corneal incision during cataract surgery
89475795|NCT02826421|Active Comparator|iSert Preloaded Delivery System|Preloaded IOL delivered via a 2.2 mm clear corneal incision during cataract surgery
89475796|NCT02826421|Active Comparator|Monarch III D Manual IOL Delivery System|Manually loaded IOL delivered via a 2.4 mm clear corneal incision during cataract surgery
89475797|NCT02476461|Active Comparator|xiapex|1: xiapex: 0,58 mg clostridium histolyticum administered in the dupuytrens cord as discribed in producers manual
89475798|NCT02476461|Experimental|PNF|percutaneous needle fasciotomi is performed at affected cords
89475799|NCT05224765||Geriatric patients that attended fall prevention discharge class|recidivism rates of MDMC-qualified G60 patients that attended fall prevention discharge class per hospital protocols
89475800|NCT05224765||Geriatric patients that did not attend fall prevention discharge class|recidivism rates of MDMC-qualified G60 patients that did not attended fall prevention discharge class per hospital protocols
89475801|NCT05466357|Experimental|Intracapsular excision of pituitary tumor|Literature review was conducted to calculate the excision rate, postoperative recurrence rate and postoperative endocrine improvement of previous endoscopic intracapsular excision of pituitary tumor.
89475802|NCT04703816|Experimental|Intervention arm|Physicians in the intervention arm will receive the training program consisting of two half-day group workshops with a review of the skills needed to build effective patient relationships and a discussion of difficult consultations.
89475803|NCT04703816|No Intervention|Control arm|Physicians in the control group will not receive any specific intervention at this stage.
89475804|NCT04642274|Experimental|ERAS|
89475805|NCT04642274|No Intervention|Control|
89475806|NCT02476227|Experimental|Visitag group|Ablation using CARTO system. Visitag module: automated algorithm to collect RF ablation points using Visitag module. Criteria of ablation point: catheter stability range of motion ≤2.5mm, catheter stability time >15sec, contact force >5g over >50% of time. Optimal contact force suggested: 10-40g.
89475807|NCT02476227|Active Comparator|Control group|Ablation using CARTO system. Manual collection of RF ablation points by operator or by assistant. Optimal contact force suggested: 10-40g.
89475808|NCT02476305|Experimental|cryoablation|patients undergo cryoablation procedure for desmoid tumor
89475809|NCT04547738||Tuberculosis (TB) index patients|- Patients (older than 5 years) diagnosed with TB before initiation of TB treatment
89206236|NCT02599103|Experimental|camellia oil|
89206237|NCT02599103|Experimental|fried camellia oil|
89475810|NCT04547738||TB contacts|- Children (5-17 years old), who had contact with TB index patients
89475811|NCT02481453|Experimental|Rapamycin|rapamycin 1 mg/ml oral solution, 2 mg/day (2 ml/day), once a day, during one year
89475812|NCT02481453|Placebo Comparator|Placebo|Placebo oral solution, 2 ml/day, once a day, during one year
89475813|NCT02481531|Active Comparator|Previously marketed infant formula|Cow's milk-based infant formula
89475814|NCT02481531|Experimental|Previously marketed formula using a similar protein|Cow's milk-based infant formula
89475815|NCT02476383|Active Comparator|augmented spinal manipulative therapy|Participants in this group will receive spinal manipulative therapy provided by a practitioner interacting in a warm and friendly way who is free to respond to participant conversation. Participants in this group will receive information about the effectiveness of spinal manipulative therapy for some individuals experiencing low back pain.
89475816|NCT02476383|Active Comparator|neutral spinal manipulative therapy|Participants in this group will receive spinal manipulative therapy provided by a practitioner engaging in minimal interaction. Participants in this group will not receive information about the effectiveness of spinal manipulative therapy for some individuals experiencing low back pain.
89475817|NCT04492527|Experimental|Telehealth coaching sessions|Receives the Telehealth-delivered coaching sessions.
89475818|NCT05713539|Experimental|Cooled metal placed on skin|Metal is placed onto the skin at a temperature of -2 degrees Celsius for 30 seconds. A thermal imaging camera will be used to identify how long it takes for the skin to return to its initial temperature.
89475819|NCT05335005|Experimental|MK-2060|MK-2060 administered via intravenous (IV) infusion on days 1, 3, and 5 during the first week and on day 8 during the second week.
89475820|NCT02825251|Experimental|Faster-acting insulin aspart CSII|
89475821|NCT02825251|Active Comparator|NovoRapid® CSII|
89475822|NCT05449197||Community pharmacists chosen by the patient with haemophilia A for dispensing Emicizumab|
89537447|NCT03064815|Experimental|Spondylarthropathies with GI symptoms|Subjects in this arm will have spondylarthropathies and gastrointestinal symptoms and will undergo a colonoscopy, videocapsule endoscopy, biomarker testing (PROMETHEUS® IBD sgi Diagnostic™ and fecal calprotectin)
89537448|NCT03064815|Experimental|Spondylarthropathies without GI symptoms|Subjects in this arm will have spondylarthropathies without gastrointestinal symptoms and will undergo a colonoscopy, videocapsule endoscopy, biomarker testing (PROMETHEUS® IBD sgi Diagnostic™ and fecal calprotectin)
89537449|NCT03065439|Experimental|STarT Back Tool group 3|Patients scored as high risk patients by the STarT Back Tool
89475823|NCT05415111|Active Comparator|Subepithelial connective tissue group (SCTG)|"A SCTG will be harvested from the patient's palate with a dimension dependent on the size of the peri-implant osseous defect. The technique of harvesting a soft tissue grafting is well described and established in the literature. Following the administration of local anesthesia, the SCTG will be harvested using a single incision technique. The periosteum will be left intact. The thickness of the SCTG will be at least 1.5mm. A cross suture will be used to close the palatal incision.~The SCTG will be placed on the buccal exposed implant threads (above the DBBM-C) exceeding 1mm in a coronal and apical direction, 3mm in a mesial and distal direction and then immobilized using a horizontal mattress connecting it to the lingual or palatal flap. The flaps are then closed primarily and tension-free following a horizontal periosteal releasing incision."
89475824|NCT05415111|Active Comparator|Volume stable Collagen Matrix group (VCMX)|A VMCX (FibroGide®) will be hydrated in sterile saline, trimmed and adjusted to a dimension dependent on the size of the osseous peri-implant defect. The VCMX will then be placed as described above and then immobilized using a horizontal mattress connecting it to the lingual or palatal flap. The flaps are then closed primarily and tension-free following a horizontal periosteal releasing incision.
89475825|NCT05415111|Sham Comparator|No soft tissue augmentation (GBR)|No barrier membranes will be placed. After filling the defect with the bone substitute, the flaps are closed primarily and tension-free following a horizontal periosteal releasing incision.
89020163|NCT05461820|Active Comparator|Conventional treatment group|According to the thyroid function, if the initial free thyroxine(FT4) ≥ 3 times the normal value, the initial dose of methimazole is 30mg/ day, the thyroid function will be tested every four weeks, and the dose will be reduced when thyroid stimulating hormone(TSH) > normal lower limit or free triiodothyronine(FT3) < normal lower limit or FT4 < normal lower limit. The dose will be reduced according to the clinical routine, specifically, every day (30 mg→20 mg→10 mg→5mg→2.5 mg) If the initial FT4 is less than 3 times the normal value, the initial dose of methimazole is 15mg/ day, and the thyroid function is tested every four weeks. When TSH is greater than the normal lower limit or FT3 is less than the normal lower limit or FT4 is less than the normal lower limit, the dose will be reduced according to the clinical routine, specifically every day for 24 months. If TSH > 100 mIU/L occurs during the treatment, the reduction speed will be accelerated, and 1-2 dose levels can be skipped.
89020164|NCT05461820|Active Comparator|Intensive treatment group|If the initial FT4≥ 3 times of normal value, the initial dose of methimazole was 30mg/ day, and the thyroid function and antibodies were detected every four weeks. When TSH≥4.2 mIU/L, the amount of methimazole began to decrease, specifically in a daily manner (30 mg→20 mg→15mg). The dose was maintained after the decrease to 15 mg. In the case of hypothyroidism, levothyroxine was added until the three antibodies (TPOAb, TGAb and TRAb) were negative. The dose was maintained for six months, and then the doses of methimazole and levothyroxine were gradually reduced until drug discontinuation (each month). If the initial FT4 was less than 3 times of normal level, the initial dose of methimazole was 15 mg/ day, and levothyroxine was added when hypothyroidism occurred. After all three antibodies were negative, the doses were gradually reduced to the point of drug discontinuation.
89020165|NCT05459324|Experimental|Study Group|Twenty-four patients offered SCS for standard of care were also invited to participate in this study, in which a study electrode was temporarily placed intraoperatively and neuromonitoring was done per our routine standard-of-care
89020166|NCT05454969|Active Comparator|One-4-ALL Initiative|The health app arm will pilot the intervention and key outcome measures will be compared between the Health App group and the placebo control.
89020167|NCT05454969|Placebo Comparator|Control|Will receive standard care.
89020168|NCT05450198|Experimental|Dose Escalation Panel A|Participants are randomized to low dose MK-6194 or placebo, administered every 2 weeks (q2w).
89020169|NCT05450198|Experimental|Dose Escalation Panel B|Participants are randomized to medium dose MK-6194 or placebo administered q2w.
89020170|NCT05450198|Experimental|Dose Escalation Panel C|Participants are randomized to high dose MK-6194 or placebo administered q2w.
89020171|NCT05450198|Experimental|Expansion Panel D|Participants are randomized to medium dose MK-6194 or placebo administered q2w.
89020172|NCT05450198|Experimental|Expansion Panel E|Participants are randomized to a dose less than or equal to high dose MK-6194 or placebo administered q2w.
89020173|NCT05450198|Experimental|Expansion Dose F|Participants are randomized to a dose less than or equal to high dose MK-6194 or placebo q2w.
89020174|NCT05449756||Children who participated in randomised clinical trail, called TEMPO, in their first year of life|Children who participated in randomised clinical trail, called TEMPO, in their first year of life
89020175|NCT05445947|Experimental|Intervention Group|Educators working at childcare centers in the intervention group will be trained and provided with ongoing coaching in the EASEL Approach.
89020176|NCT05445947|No Intervention|Control Group|Educators in the control group will continue with business-as-usual. Control group educators will be offered the opportunity to receive training in the EASEL Approach after completion of the trial.
89020177|NCT05444972||Participants Undergoing Chart Review|Participants treated for myelofibrosis undergoing chart review.
89020178|NCT05429255|Experimental|Aerobic Training|"Participants will be given a stationary exercise bike for home use. They will be instructed to use the exercise bike five times a week for thirty-minute sessions. The exercise intensity prescription will be based on the subject's maximum heart rate based on age. The exercise program will start at 60% of max heart rate, and then will be increased by steps of 5% intensity every 2 weeks until participants reach 30 minutes of training at 80% intensity. In addition, rate of perceived exertion (Borg scale) will be assessed at each training session. Participants will be contacted weekly by email or phone to answer any questions about the exercise protocol and will be instructed to log each training session.~Subjects will record duration of exercise, perceived exertion, average heart rate, maximum heart rate, and distance.~Subjects will be asked to use the bike for 1 month"
89206238|NCT02599103|Experimental|tallow|
89206239|NCT02599103|Experimental|fried tallow|
89475826|NCT04491981|Experimental|Encapsulated Glass Ionomer Cement|Repair of restorations in primary molars using a high viscosity glass ionomer cement (RIVA Self Cure - SDI)
89475827|NCT04491981|Experimental|Composite resin|Repair of restorations in primary molars using a composite resin (Filtek Bulk Fill- 3M ESPE)
89475828|NCT02478801|Experimental|Endurance trained|subjects will receive different levels of amino acids intakes varying from 0.2 to 2.8 g/kg/day.
89202743|NCT03983395|Experimental|Part 1: Cohort 101 - ISB 1302 250 ng/kg|Cohort 101, subjects will be administered ISB 1302 by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. Dose on D1, D8, D15, D22 is 250 ng/kg
89202744|NCT03983395|Experimental|Part 1: Cohort 201 - ISB 1302 325 ng/kg|Cohort 201, subjects will be administered ISB 1302 by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. Dose on D1, D8, D15, D22 is 325 ng/kg
89202745|NCT03983395|Experimental|Part 1:Cohort 301- ISB 1302 325 ng/kg-D1;425 ng/kg -D8,D15,D22|Cohort 301, subjects will be administered ISB 1302 by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at escalating dose levels. Dose of GBR 1302 is 325 ng/kg on D1 and 425 ng/kg on D8, D15, D22
89202746|NCT03983395|Experimental|Part 1:Cohort 401- ISB 1302 325 ng/kg-D1;550 ng/kg -D8,D15,D22|Cohort 401, subjects will be administered ISB 1302 by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at escalating dose levels. Dose of ISB 1302 is 325 ng/kg on D1 and 550 ng/kg on D8, D15, D22
89202747|NCT03983395|Experimental|Part1Cohort501-ISB1302 325ng/kgD1;550 ng/kg D8;700 ng/kgD15,22|Cohort 501, subjects will be administered ISB 1302 by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at escalating dose levels. Dose of ISB 1302 is 325 ng/kg on D1 and 550 ng/kg on D8, and 700 ng/kg on D15, D22
89202748|NCT03983395|Experimental|Part1Cohort601-ISB1302 325ng/kgD1;550 ng/kg D8;900 ng/kgD15,22|Cohort 601, subjects will be administered ISB 1302 by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at escalating dose levels. Dose of ISB 1302 is 325 ng/kg on D1 and 550 ng/kg on D8, and 900 ng/kg on D15, D22
89202749|NCT03983395|Experimental|Part 1 Cohort 701- ISB 1302 escalating doses,1200 ng/kg D15,22|Cohort 701, subjects will be administered ISB 1302 by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at escalating dose levels. Dose of ISB 1302 is 325 ng/kg on D1 and 700 ng/kg on D8, and 1200 ng/kg on D15, D22
89475829|NCT02478957|Experimental|PA101|PA101, 40 mg administered via inhalation three times daily for 6 weeks
89475830|NCT02478957|Placebo Comparator|Placebo|Placebo, administered via inhalation three times daily for 6 weeks
89475831|NCT02481063|Active Comparator|Eccentric|6 Weeks Training with eccentric Overload (Squat with Yoyo Technology) 3 Consecutive Days Running 1 hour at 80% of Maximus Heart Rate
89475832|NCT02481063|Active Comparator|Control|3 Consecutive Days Running 1 hour at 80% of Maximus Heart Rate
89475833|NCT03563365|Experimental|Replenix|Replenix power of 3 cream with Resveratrol applied twice daily
89475834|NCT03563365|Experimental|Replenix and Adapalene and Benzoyl Peroxide gel|Replenix power of 3 cream with Resveratrol applied twice daily and Adapalene and Benzoyl Peroxide Gel, 0.1%/2.5% applied once daily
89475835|NCT03563365|Active Comparator|Adapalene and Benzoyl Peroxide gel|Adapalene and Benzoyl Peroxide Gel, 0.1%/2.5% applied once daily
89537450|NCT03065439|Experimental|STarT Back Tool groups 1+2|Patients scored as low risk or medium risk patients by the STarT Back Tool
89537451|NCT02463695|Experimental|vestibular deficit|"Initial clinical assessment including otoneurological examination, pure tone audiometry, tympanometry vestibular screening tests and Magnetic Resonance Imaging as clinically indicated.~The cortical vestibular evoked potentials will add approximately add an extra 30 minutes to the test sequence but is minimally invasive and will not cause any pain or discomfort. It will be conducted on both the affected and non-affected ears."
88949966|NCT01941316|Experimental|Phase II|"Phase II: Stratified, single arm trial using a starting dose of 20/36 mg/m2 of carfilzomib and 125 mg/m2 of irinotecan, in small cell lung cancer patients who have relapsed on a prior platinum regimen.~Stratification for phase II component:~Platinum sensitive disease: initial response to platinum-based chemotherapy with progression > 90 days after last treatment.~Platinum refractory disease: No response to platinum-based chemotherapy or progression within 90 days of completing platinum-based therapy. Subjects that progressed during or within one month of completion of platinum-based chemotherapy will be excluded."
88949967|NCT01941329|Experimental|Ranimizumab + Panretinal photocoagulation (PRP)|3 Intravitreous injections of ranibizumab combined with standard PRP (2 ± 1 weeks after injection), at month-0, month-1 and month-2 that can be repeated after month-3, with always at least 1 month of interval between injections.
88949968|NCT01941329|Active Comparator|Panretinal photocoagulation (PRP)|"Panretinal photocoagulation treatment (PRP) between month-0 and month-2, with 1 mandatory laser session in month-0 and more laser sessions as needed until Month-2 to complete the PRP treatment.~After completing the PRP treatment, PRP sessions can be repeated from Month-3 to Month-11."
88949969|NCT01941342|Active Comparator|Pancreatoduodenectomy|Instant pancreatoduodenectomy within one week after diagnosis including: Evaluate the resectability; Remove pancreas head, gastric pyloric antrum, duodenum, distal common bile duct and regional lymph nodes; Reconstruct digestive tract.
88949970|NCT01941342|Experimental|ENBD and Pancreatoduodenectomy|"Consistent ENBD (Endoscopic Nasobiliary Drainage) for 3 weeks or drainage until bilirubin level decreases to 200μmol per liter or below then perform pancreatoduodenectomy including:~Evaluate the resectability; Remove pancreas head, gastric pyloric antrum, duodenum, distal common bile duct and regional lymph nodes; Reconstruct digestive tract."
89475836|NCT02475993|Experimental|SMART app|SMART, a mobile phone-based self-monitoring service to enhance outpatient treatment in chronic illness will be tested for its utility to help reduce acute care utilization rates for patients given SMART following acute care visits at the Sickle Cell Day Hospital. SMART will enable symptom monitoring with a particular emphasis on pain measures, co-symptoms, and related interventions aided by provider daily monitoring and support guided by patient report via SMART to provide a Sickle Cell Disease Information interchange (SCDi) service. Instead of using their current routine of triaging phone messages daily, assessing patients' need for intervention, providers will instead monitor patients' entries via SMART daily.
89202750|NCT03983395|Experimental|Part 2 (Dose Expansion) -ISB 1302 at the MTD and/or RP2D dose|Subjects treated with ISB 1302 at the MTD and/or RP2D dose in separate groups in the Q1W and/or the Q2W dose regimen.
89475837|NCT02475993|No Intervention|Standard of care control group|The control group will get standard of care, including a printed plan for medications to be taken, phone number to call for questions or issues, and the return date for visit
89475838|NCT02259907|Experimental|KUC 7483 CL|single rising doses
89475839|NCT02259907|Experimental|KUC 7483 CL, fed|dosing after high fat meal
89475840|NCT02259907|Placebo Comparator|Placebo|
89475841|NCT02475915|Experimental|ART + VHM|"Group 1: Combination Antiretroviral Therapy prescribed at week 0 for a period of 10 weeks. Likely consisting of two NRTI such as tenofovir and emtricitabine and an NNRTI, such as efavirenz. For subjects on NNRTI therapy, a protease inhibitor, such as darunavir will be substituted for the NNRTI 2 weeks prior to treatment interruption.~Plus: 3 X 14-day cycles of vorinostat administered at weeks 0, 4 and 8; hydroxychloroquine and maraviroc prescribed at week 0 for a period of 10 weeks."
89475842|NCT02475915|Active Comparator|ART alone|Group 2: Combination Antiretroviral Therapy prescribed at week 0 for a period of 10 weeks. Likely consisting of two NRTI such as tenofovir and emtricitabine and either an NNRTI, such as efavirenz. For subjects on NNRTI therapy, a protease inhibitor, such as darunavir will be substituted for the NNRTI 2 weeks prior to treatment interruption.
89475843|NCT02480985|Other|Pituitary function evaluation|Exams performed according to a determined schedule following admission in the intensive care unit in order to determine the risk factors and the outcome associated with pituitary disorders.
89475844|NCT05180149||Psychedelics-only Group|"A group of participants who reported using in their past psychedelic substances only (both classical and non-classical psychedelics are included). Specifically, in the current study this group included reports on the following substances:~Psilocybin (magic mushrooms, truffles) LSD (acid) Mescaline (peyote, san pedro) Dimethyltryptamine (DMT) Ayahuasca 5-MeO-DMT 3-MMC Ibogaine Salvia Phenethylamines (2C family)"
89020179|NCT05429255|Active Comparator|Exergame Training|"The Nintendo wii system will be used as the rehabilitation exergame system in the study. Wii-fit games will be used and the subjects will be shown to system at the initial assessment. Participants will be instructed to play 30 minutes a day, 5 days per week for 1 month. Participants will be contacted weekly by email or phone to answer any questions about the exercise protocol and will be instructed to log each training session.~Subjects will record duration of exercise, perceived exertion, balance challenge, and which games they played."
89020180|NCT05425992||Patients treated in CCBD|Patients who are currently receiving therapy at the Center for Cancer and Blood Disorders
89020181|NCT05425862|Experimental|Treatment with both talazoparib and pidnarulex|At the time of registration, patients will be assigned to the specific dose-schedule of talazoparib and pidnarulex depending on where the study is at in terms of dose-escalation or dose-expansion
89020182|NCT05415774|Active Comparator|S Stimulation|Standard STN DBS defined as high frequency at 130Hz stimulation
89475845|NCT05180149||Stimulants-only Group|"A group of participants who reported using in their past drugs identified as stimulating compounds only (both recreational and prescribed usages are included). Stimulating compounds are considered, in the context of the current study, substances that increase the overall activity of the central nervous system. Specifically, in the current study this group included reports on the following substances:~Cocaine Crack Amphetamines Methamphetamines Prescription stimulants (e.g., Adderall, Ritalin, Concerta)"
89475846|NCT05180149||Depressants-only Group|"A group of participants who reported using in their past drugs identified as depressing compounds only (both recreational and prescribed usages are included). Depressing compounds are considered, in the context of the current study, substances that decrease the overall activity of the central nervous system. Specifically, in the current study this group included reports on the following substances:~Benzodiazepines Opiates (recreational use of heroin, opium, hydrocodone, oxycodone, oxymorphone, codeine, fentanyl) Prescription opioids"
89475847|NCT05180149||Cannabinoids Group|"A group of participants who reported using in their past cannabinoids compounds only (both recreational and prescribed usages are included). Specifically, in the current study this group included reports on the following substances:~THC (cannabis, marijuana) CBD Medical Cannabis (both THC and CBD)"
89475848|NCT05180149||Psychedelic and Non-psychedelic Substances Group|"A group of participants who reported using in their past drugs identified as psychedelics and stimulants and/or depressants (both recreational and prescribed usages are included). In this group participants will be included who reported using at least one non-psychedelic drug additionally to a psychedelic one. Specifically, the following options were provided:~Psychedelic compounds:~Psilocybin (magic mushrooms, truffles) LSD (acid) Mescaline (peyote, san pedro) Dimethyltryptamine (DMT) Ayahuasca 5-MeO-DMT 3-MMC Ibogaine Salvia Phenethylamines (2C family)~Non-psychedelic compounds:~THC (cannabis, marijuana) Medical Cannabis (both THC and CBD) CBD MDMA (ecstasy) Ketamine Cocaine Crack Amphetamines Methamphetamines Prescription stimulants (e.g., Adderall, Ritalin, Concerta) Benzodiazepines Opiates (e.g., heroin, opium, hydrocodone, oxycodone, oxymorphone, codeine, fentanyl) Prescription opioids"
89475849|NCT05180149||Substance-naive Group|"A group of participants who reported no past experience with any of the substances listed in the current study nor reported using other substances (excluding alcohol and nicotine). Participants will be assigned to this group if and only if they choose the None of the above option from the Substance Use Survey (item 1)."
89475850|NCT02475525|Experimental|Arginine enriched oral nutritional supplement group|Patients randomised to the oral nutritional supplement group will continue their normal diet. In addition, this group will commence taking oral nutritional supplement twice daily 5 days prior to surgery and continued for 4 weeks post surgery. Intake of nutritional drink will be suspended during their fasting period prior to surgery and will commence once surgery is completed and group are able to tolerate food post surgery. Wound examination will take place at 1 and at 4 weeks post surgery by the tissue viability nurse specialist who will be blinded to the treatment. Patient adherence to the study protocol with the nutritional supplement regimen will be recorded daily by the patient for four the four weeks the supplement is provided.
89475851|NCT02475525|No Intervention|Control|This group will continue on their normal diet before and after surgery. Normal diet will be suspended during their fasting period prior to surgery and will re commence once surgery is completed and group are able to tolerate food post surgery. Wound examination will take place at 1 and at 4 weeks post surgery by the tissue viability nurse specialist who will be blinded to the treatment.
89475852|NCT03110575|Experimental|TNX-102 SL|2 x TNX-102 SL, 2.8 mg tablets taken daily at bedtime for 12 weeks
89475853|NCT02475603|Experimental|tourniquet|Total knee arthroplasty will be performed with tourniquet
89475854|NCT02475603|Experimental|non-tourniquet|Total knee arthroplasty will be performed without tourniquet
89475855|NCT02479035|Active Comparator|Red raspberry meal 1|~125 g fresh weight (1 cup equivalent)
89475856|NCT02479035|Active Comparator|Red raspberry meal 2|~250 g fresh weight (2 cup equivalent)
89475857|NCT02479035|Placebo Comparator|Control meal|0 g red raspberry
89475858|NCT03563287|Experimental|Phenotyping cocktail of 9 CYP probe drugs before surgery|
89475859|NCT03563287|Experimental|Phenotyping cocktail of 9 CYP probe drugs 1 year after surgery|
89020183|NCT05415774|Experimental|C1 Stimulation|Combined high frequency stimulation of the STN and SNr using an interleaved pulses at 125Hz
89475860|NCT05384847|Experimental|Experimental Phase IA|In Phase IA two participants (1 and 2) will receive ascending dose levels of the study drug (5 µg T3 orally twice daily for the first 2 days and 10 µg T3 orally twice daily for the next 3 days).
89020184|NCT05415774|Experimental|C2 Stimulation|Combined low frequency stimulation of the SNr at 60Hz and high frequency stimulation of the STN
89020185|NCT05413681|Active Comparator|metabolic myopathy|a supra-maximal exercise test on a cycloergometer.
89020186|NCT05413681|Placebo Comparator|Control : Healthy volonteers|a supra-maximal exercise test on a cycloergometer.
89020187|NCT05413668|Experimental|RVP-001 group|4 Cohorts of 6 subjects each will receive RVP-001 at doses of 2, 4, 7 and 12 mg Mn/kg.
89020188|NCT05413668|Placebo Comparator|Placebo group|4 Cohorts of 2 subjects each will receive placebo (saline).
89020189|NCT05413551|Experimental|Rapid acetylator|Participants will receive 1 standard dose (Day 0), followed by 1 higher dose (Day 7), follow by 2 standard doses (Days 14 and 21).
89020190|NCT05413551|Active Comparator|Intermediate acetylator|Participants will receive 4 standard doses (Days 0, 7, 14 and 21).
89020191|NCT05413551|Experimental|Slow acetylator|Participants will receive 2 standard doses (Days 0 and 7), followed by 1 lower dose (Day 21), follow by 1 standard dose (Day 21).
89020192|NCT05413278|Other|Training|Patient education, empowerment, and information
89020193|NCT05409664|Experimental|webMFT|Survivors randomized to webMFT will receive the evidence-based intervention for moderate-to-vigorous physical activity (MVPA) promotion that consists of MVPA counseling matched to patients' motivational readiness, and self-monitoring of MVPA (via Fitbit Inspire 2). The goal for the 3-month program will be to gradually increase the amount of moderate-intensity aerobic exercise that is performed, to the current national recommendations of at least 150 minutes of MPVA per week. Our goal is to promote aerobic exercise that is safe and enjoyable, such as walking.
89020194|NCT05409664|Active Comparator|MVPA tracking|These survivors will be asked to self-monitor moderate-to-vigorous physical activity (MVPA) participation by wearing the Fitbit Inspire 2 each day over 12 weeks. This group will not receive the MVPA counseling from the coaches.
89020195|NCT05408169|No Intervention|Control|
89020196|NCT05408169|Experimental|1-week deadline, no planning sheet|
89020197|NCT05408169|Experimental|2-week deadline, no planning sheet|
89020198|NCT05408169|Experimental|4-week deadline, no planning sheet|
89020199|NCT05408169|Experimental|No deadline, with planning sheet|
89475861|NCT05384847|Experimental|Experimental Phase IB|In Phase IB, dose adjustments will be calculated while accounting for laboratory and safety data from the first two participants (Phase IA) for the remaining 3 participants within the treatment arm of Phase I. Participants 3 to 5 will receive 10 µg T3 orally twice daily on day 1 and 20 µg T3 twice daily from day 2 to 5.
89475862|NCT05384847|Placebo Comparator|Control Group-Phase IA and IB|The control group will have testing as the experimental group but will not be given any medications.
89475863|NCT05384847|Experimental|Experimental Phase II|Patients who were enrolled in the open-label control group of Phase I and who have completed the 3-month follow-up will be permitted to enroll in Phase II. This Phase will start treatment after completion of Phase I and approval from the Data and Safety Monitoring Board (DSMB) to proceed with a single cohort that will receive a stable dose of the study drug (20 µg T3 orally twice daily for 5 days).
89020200|NCT05408169|Experimental|1-week deadline, with planning sheet|
89020201|NCT05408169|Experimental|2-week deadline, with planning sheet|
89020202|NCT05408169|Experimental|4-week deadline, with planning sheet|
89020203|NCT05407818|Experimental|JNJ-63733657|Participants will receive a single dose of JNJ-63733657 as an intravenous (IV) infusion on Day 1.
89020204|NCT05401071|Experimental|Short Regimen with Rifapentine 10mg/kg|Intervention: Short Regimen with Rifapentine 10mg/kg consists of two periods of 17- 26 weeks. The first is an intensive phase of 8 weeks, and included rifapentine, isoniazid, pyrazinamide, and moxifloxacin. This is followed by a continuation phase of 9 weeks with the following agents: rifapentine, isoniazid and moxifloxacin (extended up a maximum of 18 weeks if no smear conversion at the end of 8 weeks or the tuberculosis cavity is not closed at the end of 17 weeks).
89020205|NCT05401071|Experimental|Short Regimen with Rifapentine 15mg/kg|Intervention: Short Regimen with Rifapentine 15mg/kg consists of two periods of 17- 26 weeks. The first is an intensive phase of 8 weeks, and included rifapentine, isoniazid, pyrazinamide, and moxifloxacin. This is followed by a continuation phase of 9 weeks with the following agents: rifapentine, isoniazid and moxifloxacin (extended up a maximum of 18 weeks if no smear conversion at the end of 8 weeks or the tuberculosis cavity is not closed at the end of 17 weeks).
89020206|NCT05401071|Active Comparator|Standardized Regimen|Intervention：World Health Organization (WHO) Standardized Regimen group consists of 26 weeks with two phases of treatment. The first is an intensive phase of 8 weeks, and included rifampicin, isoniazid, pyrazinamide, and ethambutol. This is followed by a continuation phase of 18 weeks with the following agents: rifampicin and isoniazid.
89020207|NCT05401071|Experimental|Short Regimen with Rifapentine 20mg/kg|Intervention: Short Regimen with Rifapentine 20mg/kg consists of two periods of 17- 26 weeks. The first is an intensive phase of 8 weeks, and included rifapentine, isoniazid, pyrazinamide, and moxifloxacin. This is followed by a continuation phase of 9 weeks with the following agents: rifapentine, isoniazid and moxifloxacin (extended up a maximum of 18 weeks if no smear conversion at the end of 8 weeks or the tuberculosis cavity is not closed at the end of 17 weeks).
89020208|NCT05398302|Experimental|Diagnostic (image-guided biopsy)|Patients undergo an image-guided biopsy at baseline and 2-4 weeks after cycle 2 of 177Lu-PSMA-617 therapy.
89020209|NCT05394337|Experimental|Atezolizumab|Atezolizumab will be administered at a fixed dose of 1200 mg Q3W (1200 mg on Day 1 of each 21 day cycle),
89020210|NCT05394337|Experimental|Tiragolumab|Tiragolumab will be administered at a fixed dose of 600 mg intravenously Q3W on Day 1 of each 21-day cycle.
89020211|NCT05375162|Experimental|Exp Condition 1|Research participant receives the Core Intervention + E-Coach + General Mindfulness Training + MVPA Specific Mindfulness Training + Buddy
89020212|NCT05375162|Active Comparator|Exp Condition 2|Research participant receives the Core Intervention + E-Coach + General Mindfulness Training + MVPA Specific Mindfulness Training
89020213|NCT05375162|Active Comparator|Exp Condition 3|Research participant receives the Core Intervention + E-Coach + Buddy
89020214|NCT05375162|Active Comparator|Exp Condition 4|Research participant receives the Core Intervention + E-Coach
89020215|NCT05375162|Active Comparator|Exp Condition 5|Research participant receives the Core Intervention + E-Coach + General Mindfulness Training + Buddy
89020216|NCT05375162|Active Comparator|Exp Condition 6|Research participant receives the Core Intervention + E-Coach + General Mindfulness Training
89020217|NCT05375162|Active Comparator|Exp Condition 7|Research participant receives the Core Intervention + E-Coach + MVPA Specific Mindfulness Training + Buddy
89020218|NCT05375162|Active Comparator|Exp Condition 8|Research participant receives the Core Intervention + E-Coach + MVPA Specific Mindfulness Training
89020219|NCT05375162|Active Comparator|Exp Condition 9|Research participant receives the Core Intervention + General Mindfulness Training + Buddy
89020220|NCT05375162|Active Comparator|Exp Condition 10|Research participant receives the Core Intervention + General Mindfulness Training
89020221|NCT05375162|Active Comparator|Exp Condition 11|Research participant receives the Core Intervention + MVPA Specific Mindfulness Training + Buddy
89020222|NCT05375162|Active Comparator|Exp Condition 12|Research participant receives the Core Intervention + MVPA Specific Mindfulness Training
89475864|NCT02480907|Active Comparator|Workshop Group|Parents of ~ 40 children and adolescents within the age group of 10-18 years suffering from anorexia or bulimia nervosa will be involved in the workshop support group for parents for a period of three months, including a written manual, a DVD (Digital Video Disc) with additional information and weekly workshops. Over the course of three months, parents will participate at the 8 workshop sessions and get the manual to read and the DVDs to use at home to illustrate workshop contents with examples and video clips.
89020223|NCT05375162|Active Comparator|Exp Condition 13|Research participant receives the Core Intervention + General Mindfulness Training + MVPA Specific Mindfulness Training + Buddy
89020224|NCT05375162|Active Comparator|Exp Condition 14|Research participant receives the Core Intervention + General Mindfulness Training + MVPA Specific Mindfulness Training
89020225|NCT05375162|Active Comparator|Exp Condition 15|Research participant receives the Core Intervention + Buddy
89020226|NCT05375162|Active Comparator|Exp Condition 16|Research participant receives the Core Intervention
89475865|NCT02480907|Active Comparator|Internet-based support group|Parents of ~ 40 children and adolescents within the age group of 10-18 years suffering from anorexia or bulimia nervosa will be involved in the Internet-based support group for parents, including material from the manual and the DVD and additional information available online within a structured program. Over the course of three months, parents will get access to the 8 support sessions online with the instruction to work out the program at home. Additionally email support is offered after completing each session.
89475866|NCT02480907|No Intervention|Control group - TAU|Parents of ~ 40 children and adolescents within the age group of 10-18 years suffering from anorexia or bulimia nervosa will get treatment as usual and take part in conventional parental intervention groups.
89475867|NCT03831529||ICU older patient|Older patient (> 65 years old) admitted to ICU with severe acute cholangitis
89475868|NCT03826225||Study Cohort|All participants are considered to be in the study cohort and will have the study device placed externally on their skin in order to collect human ECG data.
89475869|NCT02479113||Lean with normal glucose tolerance|"Pregnant women who are lean with normal glucose tolerance~- Bloods will be taken at 12 - 32 weeks, at 36 weeks/ delivery"
89475870|NCT02479113||Obese with Normal glucose tolerance|"Pregnant women who are obese with normal glucose tolerance~- Bloods will be taken at 12 - 32 weeks, at 36 weeks/ delivery"
89475871|NCT02479113||Gestational diabetes mellitus|"Pregnant women who have Gestational Diabetes Mellitus~- Bloods will be taken at 12 - 32 weeks, at 36 weeks/ delivery"
89020227|NCT05372887|Experimental|TNX-102 SL, 5.6 mg|2 x TNX-102 SL, 2.8 mg Tablets taken sublingually each day at bedtime for 12 weeks.
89475872|NCT03825991||Control group|Cohort 1 is a a control group matched 1:5 to the exposed group on sex and age. This group i randomly assigned via Statistics Denmark and does not have a diagnosis of back pain in the time period 2008-2013. They do however have another diseases registered in the Danish Patient Registry, which only contains information on patients having had contacts with the hospital sector i Denmark. Used for study 1.
89475873|NCT03825991||Specific back pain (unexposed)|Cohort 2 consists of patients registered with one of the following diagnosis in the time period 2008-2013 in Denmark: Spinal Disc Herniation DM51.1 and Spinal stenosis DM48.0 (ICD-10 classification).
89475874|NCT03825991||Unspecific back pain (exposed)|Cohort 3 consists of patients registered with one of the following diagnosis in the time period 2008-2013 in Denmark: Other intervertebral disc disorders DM51*-51.1, Dorsalgia DM54, Other disorders of muscle DM62, Postprocedural musculoskeletal disorders not elsewhere classified DM96 and Segmental and somatic dysfunction DM99 (ICD-10 classification)
89020228|NCT05372887|Placebo Comparator|Placebo|2 x Placebo Tablet taken sublingually each day at bedtime for 12 weeks.
89020229|NCT05371964|Experimental|Imetelstat + Ruxolitinib|"Part 1: Participants who have received ruxolitinib orally (PO) as part of standard of care (SOC) for at least 12 weeks prior to Screening will be enrolled. After enrollment, participants will initiate imetelstat therapy. Dose levels of imetelstat may include 4.7, 6, 7.5, 9.4mg, until a RP2D is established.~Part 2: Janus kinase (JAK) inhibitor naïve participants will receive initial treatment with ruxolitinib for at least 12 weeks, including 4 weeks at a stable dose, followed by imetelstat treatment at the RP2D in combination with ruxolitinib."
89020230|NCT05351879|Experimental|GAD-Alum (DIamyd) 40 μg/mL and Vitamin D|"Patients with a Vitamin D level <100 nmol/L (40 ng/mL) at screening will receive oral Vitamin D supplementation (2000 IU daily) for 60 days, starting 30 days prior to the injection.~On Visit 2 (Day 0), patients eligible for the study will receive one intralymphatic injection of 4µg Diamyd."
89020231|NCT05348603|No Intervention|No Intervention|*No intervention.
89020232|NCT05348603|Experimental|Traditional Letter Only|*A mailed letter will invite the patient to set up a research profile in their patient portal.
89020233|NCT05348603|Experimental|Direct to Patient Message Only|*An e-mail sent to the patient will inform the patient that there is a message pending in their patient portal regarding opportunities to participate in research.
89475875|NCT03825991||Total population (DM*)|Cohort 4 is the total population including all BPD diagnosis in the time period 2008-2013 in Denmark. This cohort will be used as basis for study 2 and 3, although de definitions of the groups specific back pain (unexposed) and unspecific back pain (exposed) will used in sub-analysis.
89475876|NCT02478567|Experimental|Scapular Training|Initiated scapular training exercise for the first 4 weeks followed by addition of rotator cuff exercises the next four weeks
89475877|NCT02478567|Experimental|Rotator Cuff Training|initiated rotator cuff training exercise for the first 4 weeks followed by addition of scapular training exercises the next four weeks.
89475878|NCT04856527|Experimental|Experimental Group|Participants will receive physical therapist support to reduce postural sway while completing a precision aiming task in virtual reality, whether or not they require the support.
88949971|NCT01941342|Experimental|EBD and Pancreatoduodenectomy|"Consistent EBD (Endoscopic Biliary Drainage) for 3 weeks or drainage until bilirubin level decreases to 200μmol per liter or below then perform pancreatoduodenectomy including:~Evaluate the resectability; Remove pancreas head, gastric pyloric antrum, duodenum, distal common bile duct and regional lymph nodes; Reconstruct digestive tract."
89475879|NCT04856527|No Intervention|Control Group|Participants will receive no physical therapist support while completing the task.
89475880|NCT02478411|Experimental|Cycle ergometer physiotherapy|15 minutes of cycle ergometer physiotherapy plus 15 minutes of conventional physiotherapy, once daily, five days a week, as long as patients remain in the intensive care unit
89475881|NCT02478411|Active Comparator|Conventional physiotherapy|30 minutes of conventional physiotherapy, once daily, five days a week, as long as patients remain in the intensive care unit
89475882|NCT02478879|Experimental|ZP-PTH Patch|Intradermal microneedle patch coated with 40 mcg of PTH, applied intracutaneously to the abdomen daily for 30 minutes, 14 days of treatment
88949972|NCT01941342|Experimental|PTCD and Pancreatoduodenectomy|"Consistent PTCD (Percutaneous Transhepatic Cholangial Drainage) for 3 weeks or drainage until bilirubin level decreases to 200μmol per liter or below then perform pancreatoduodenectomy including:~Evaluate the resectability; Remove pancreas head, gastric pyloric antrum, duodenum, distal common bile duct and regional lymph nodes; Reconstruct digestive tract."
88949973|NCT01941355|Experimental|Exercise training, psycho-educative|
88949974|NCT01941355|Experimental|Psycho-educative component|
88949975|NCT01941355|Experimental|Exercise training component|
89475883|NCT02478879|Active Comparator|FORTEO(R) Pen|Marketed FORTEO 20 mcg, administered daily as a subcutaneous injection to the abdomen or thigh for 14 days of treatment.
89475884|NCT03563053|Experimental|active drug|~14-22 mg dexamethasone sodium phosphate (DSP)
88949976|NCT01941355|No Intervention|Usual care|
88949977|NCT01941368|No Intervention|Control|Individuals assigned to Control Group will undergo baseline testing and then be asked to continue their normal exercise routine for 4 weeks and will undergo post-testing (visits 16 and 17) after this time period.
88949978|NCT01941368|Placebo Comparator|Placebo + High-Intesnity Interval Training (HIIT)|On training days, individuals will consume 1 gram of placebo 30 min prior to training, 1gram placebo 1 hour post training, and 1gram placebo 3 hours post training. On non-training days, individuals will consume placebo 3 times per day (8am, 12pm and 4pm).
88949979|NCT01941368|Active Comparator|HMB-FA + HIIT|On training days, individuals will consume 1 gram HMB-FA 30 min prior to training, 1gram HMB-FA 1 hour post training, and 1gram HMB-FA 3 hours post training. On non-training days, individuals will consume HMB-FA 3 times per day (8am, 12pm and 4pm).
89475885|NCT02478645|Experimental|ramosetron 0.3|
89475886|NCT02478645|Active Comparator|ramosetron 0.45|
89475887|NCT02478645|Active Comparator|ramosetron 0.6|
89475888|NCT02475447|Placebo Comparator|Placebo|Placebo-matched tablets twice daily for 4 weeks.
89475889|NCT02475447|Experimental|Asimadoline|Asimadoline tablets twice daily (5 mg total daily dose) for 8 weeks.
89475890|NCT05872009||Women with gestational diabetes|Any treatment. N=200.
89475891|NCT05872009||Control group|Gestational-age matched, euglycemic, normotensive pregnant women (n=150)
89475892|NCT05871957||Serum vitamin D deficiency in Hashimoto's thyroiditis during hypothyroidism|Serum vitamin D levels are lower than normal
89475893|NCT05871957||Patients with normal serum vitamin D during hypothyroidism in Hashimoto's thyroiditis|Serum vitamin D levels are within normal limits
88949980|NCT01941381||Type B tympanogram|Patients with a clinical diagnosis of acute otitis media and a B type curve with tympanometry.
88949981|NCT01941381||Type A/C tympanogram|Patients with a clinical diagnosis of acute otitis media and a type A or C curve with tympanometry
89475894|NCT05871944|Active Comparator|control group|kalternborn joint mobilization techniques will be administered for total of 8 weeks at the rate of 2 session per week.
89475895|NCT05871944|Experimental|experimental group|Post stretch facilitation technique will be administered for total of 8 weeks at the rate of 2 session per week.
89475896|NCT05871918|Experimental|TCbHP|"Experimental group (TCbHP) :~Taxotere (75mg/m2) + Carboplatin (AUC=5)~Trastuzumab 6mg/kg(initial dose 8mg/kg)~Pertuzumab 420mg(initial dose 840mg)~1/21d times 6 cycle"
89475897|NCT05871918|Placebo Comparator|ddEC-THP|"Epirubicin (90mg/m2)+ cyclophosphamide (600mg/m2) 1/14d×4 cycle~Taxol (80mg/m2) 1/7d x 12w~Trastuzumab 6mg/kg(initial dose 8mg/kg) 1/21d ×4 cycles~Pertuzumab 420mg(initial dose 840mg) 1/21d x 4 cycles"
89475898|NCT05871879||All adult patients who underwent urologic procedures|The included procedures included all urologic oncology surgeries, suburethral sling placement, laparoscopic pyeloplasty, transurethral resection of the prostate, transurethral resection of the bladder tumor, ureteroscopy, hydrocelectomy, orchiectomy, spermatocelectomy, epididymectomy, and varicocelectomy.
89475899|NCT05871827||Traditional Overlay|Subjects who underwent THA without use of computer navigation
89475900|NCT05871827||Computer Navigation|Subjects who underwent THA with use of computer navigation
89475901|NCT05871775|Experimental|Personalized exercise|
89475902|NCT05871775|Active Comparator|Stabilization exercise|
89475903|NCT05871775|Active Comparator|General exercise|
89475904|NCT05871723||Stroke Patients|Patients diagnosed with stroke.
89475905|NCT05871710||Patients in need of pulmonary rehabilitation or already receiving pulmonary rehabilitation.|Native Turkish-speaking patients in need of pulmonary rehabilitation or already receiving pulmonary rehabilitation.
89475906|NCT05871710||Health personnel working in the field of pulmonary rehabilitation.|Native Turkish-speaking health personnel working in the field of pulmonary rehabilitation.
89475907|NCT05871697||Patients with spinal cord injury|Patients who have spinal cord injury.
89475908|NCT05871671|Active Comparator|Control group|The control group shall consist of a minimum of 40 patients with a confirmed diagnosis of COPD and osteoporosis or osteopenia. This group which shall consist of patients who do not wish to participate in Pulmonary Rehabilitation but show the wish to form part of this study, or participants who are on the waiting list to be enrolled into the Rehabilitation classes, shall act as a control for the study and therefore not undergo PR and the following maintenance home exercise programme until completion of the study. All patients were medically stable and referred by their caring respiratory consultant.
89475909|NCT05871671|Experimental|Active group|The active group shall consist of a minimum of 40 patients with a confirmed diagnosis of COPD and osteoporosis or osteopenia. All patients shall receive a 16-week twice weekly PR programme which shall be followed by a 36-week maintenance home exercise programme. All patients were medically stable and referred by their caring respiratory consultant.
89475910|NCT05871658|Experimental|the electroacupuncture group|electroacupuncture were inserted into bilateral Zusanli (ST36), Sanyinjiao (SP6), Hegu (LI4) and Quchi (LI11), and Yintang (EX-HN3). Electroacupuncture parameters selected the sparse wave, the frequency was 4 Hz, the stimulation intensity was tolerated by the patient.
89475911|NCT05871658|Sham Comparator|the sham electroacupuncture group|According to the previous trial,[19] sham acupoints were 1cm away from the level of the acupoints used in the EA group, which avoided the area corresponding to any of the 14 meridians of TCM. The insertion of the needle was shallower (less than 0.2cm) and had similar pain to that of normal needle insertion. The stimulation intensity was 0mA. However, the model of electroacupuncture, the frequency, and duration of treatment in the SEA group were identical in the TA group.
89475912|NCT05871645|Experimental|Jakarta Surgical Uterine Conservation (JSICA) technique|Cipto Mangunkusumo General Hospital's novel uterine preservation technique based on standard procedure
89475913|NCT05871645|Active Comparator|Standard Hysterectomy|Surgery to remove the uterus
89475914|NCT05871593|Other|Molecular genetic diagnostic|Next-Generation-Sequencing (NGS)-methods
89475915|NCT05871554|No Intervention|Waitlist|Participants are allocated to a waitlist condition where they participate in surveys for 11 weeks. Participants receive access to the treatment modules after completing the final survey after the 11th week.
89475916|NCT05871554|Experimental|Treatment|Participants are allocated to a treatment condition where they participate in surveys and online video modules for 11 weeks.
89475917|NCT05871528||No hemorrhagic transformation|Patients with ischemic stroke treated with intravenous thrombolysis and no hemorrhagic transformation (IH1 or IH2 are allowed)
89475918|NCT05871528||Local hemorragic transformation|Patients with ischemic stroke treated with intravenous thrombolysis and hemorrhagic transformation PH1 or PH2
89475919|NCT05871528||Remote hemorrhage|Patients with ischemic stroke treated with intravenous thrombolysis and remote hemorrhage in areas without evident ischemia (rPH)
89475920|NCT05871502|Experimental|Subcutaneous blood glucose monitoring device|After signing the informed consent and before the start of the endovascular procedure, a subcutaneous blood glucose monitoring device will be implanted, which will be removed on day 15 (or at hospital discharge if this takes place before 15 days).
89475921|NCT05871463|Experimental|Exosome|Standard medication + MSC-derived exosomes at a final dose of 40mg in three weeks
89475922|NCT05871450|Experimental|Participants living in Host Towns|Participants live in Host Towns, where a delegation of athletes are hosted for one week. Furthermore, Host Town coordinator organize several inclusive events.
89475923|NCT05871450|No Intervention|Participants not living in Host Towns|Participants where no delegeation of athletes are hosted and no inclusive events are organized by Host Town coordinator.
89475924|NCT05871359|Active Comparator|tDCS group|transcranial Direct Current Stimulation group (tDCS group) : patients carry out activities in Dual Task associated with tDCS real.
89475925|NCT05871359|Sham Comparator|Sham group|Sham group: patients carry out activities in Dual Task associated with tDCS sham.
89475926|NCT05871294|Experimental|Acoustic stimulation therapy|Patients in this group will receive acoustic stimulation therapy.
89475927|NCT05871294|Experimental|Repetitive transcranial magnetic stimulation therapy|Patients in this group will receive repetitive transcranial magnetic stimulation therapy.
89475928|NCT05871281|Active Comparator|Pelvic floor muscle training group|All subjects attended individual physiotherapy procedures, the duration of one of which was 60 minutes. One woman was assigned a total of 8 contact procedures over four weeks. During the individual procedures, exercises were selected and modified according to the women's ability to perform them. All women were taught correct abdominal breathing while lying down, to activate the abdominal muscles. Also, all were trained to perform Kegel exercises, explaining their benefits. In order to diversify and modify the exercises, they were performed with auxiliary means, i.e. using balls, gymnastic sticks, a bench, elastic bands, a physiotherapy wall, yoga blocks, rollers, weights and an aerial yoga band.
89475929|NCT05871281|Experimental|Pelvic floor muscle electrostimulation group|Electrostimulation was performed with a Kegel 8 home elektrostymulator. The subjects were prescribed two electrostimulation programs: PO3 in the morning and PO10 in the evening. The duration of the PO3 program was 45 minutes, and was intended for general strengthening of the pelvic floor muscles. The duration of the PO10 program is 40 minutes. and it is prescribed for stress incontinence. Duration of interventions 4 week.
88949982|NCT01941394|Experimental|With MSC|infusion of Mesenchymal stem cells at dose 1 mln cells per kg
88949983|NCT01941394|No Intervention|Without MSC|Without MSC infusion
89475930|NCT05871229|Experimental|Study group|Lumoral and standard treatment
89475931|NCT05871229|Other|Control group|Standard treatment only
89475932|NCT05871216||Joint Hypermobility Syndrome|Patients suffering from Joint Hypermobility Syndrome with a moderate/severe degree of joint hypermobility (Beighton-Horan Joint Mobility Index score 3-9)
89475933|NCT05871203||Postoperative acute kidney injury|
89475934|NCT05871203||Postoperative non-acute kidney injury|
89475935|NCT05871190|Active Comparator|Test group|I-PRF is placed on the wound site after a gingivectomy with the conventional method and closed with a periodontal dressing
89475936|NCT05871190|Placebo Comparator|control group|closure of the wound site with only a periodontal dressing after a gingivectomy with the conventional method.
89020234|NCT05348603|Experimental|Chatbot Only|*A real-time, interactive chatbot on the patient portal will encourage research participation and direct patients to learn more about research opportunities and trials that match their interests.
89020235|NCT05348603|Experimental|Banner Only|"*Banner-type advertisements will appear during routine viewing and use of of the patient's portal for their our medical/clinical care inform patients of research opportunities."
89020236|NCT05348603|Experimental|Traditional Letter + Direct to Patient Message|"A mailed letter will invite the patient to set up a research profile in their patient portal; AND~An e-mail sent to the patient will inform the patient that there is a message pending in their patient portal regarding opportunities to participate in research."
89020237|NCT05348603|Experimental|Traditional Letter + Chatbot|"A mailed letter will invite the patient to set up a research profile in their patient portal; AND~A real-time, interactive chatbot will encourage research participation and direct patients to learn more about research opportunities and trials that match their interests."
89475937|NCT05871112||Patella positioning after TKR + FUZION|Patients who underwent TKR - femoral component rotation established with a use of a dynamic tensioner (FUZION)
89475938|NCT05871112||Patella positioning after standard TKR|Patients who underwent standard TKR performed with measured resection technique
89475939|NCT05871099|Experimental|Experimental group|Experimental group receive laparoscopic (robotic) D2 surgery plus HIPEC2 times plus systemic chemotherapy 6~8 cycles.
89475940|NCT05871099|No Intervention|Control group|Control group receive laparoscopic (robotic) D2 surgery + systemic chemotherapy 6-8 cycles
89475941|NCT05871073|Experimental|Ropivacaine 0.75% Injectable Solution|Wound Infiltration for Postoperative Analgesia After Spinal Surgery
89475942|NCT05871073|Experimental|Dexamethasone 8mg|Wound Infiltration for Postoperative Analgesia After Spinal Surgery
89475943|NCT05871047||practical group|
89475944|NCT05871047||non-practical group|
89475945|NCT05871034|Other|Control group|Control group who have cataract without Open Angle glaucoma Will under go phacoemulsification cataract surgery
89475946|NCT05871034|Other|Open Angle glaucoma group|patients who have cataract and Open Angle glaucoma Will undergo phacoemulsification cataract surgery
89475947|NCT05871021|Experimental|75 Gy with two cycles of bevacizumab|
89475948|NCT05870969||Patients with very high risk for HCC according local guideline|
89475949|NCT05870969||Patients with high risk for HCC according local guideline|
89475950|NCT05870969||Patients with medium risk for HCC according local guideline|
89475951|NCT05870969||Patients with low risk for HCC according local guideline|
89475952|NCT05870904|Experimental|Dry Needling Group|Received dry needling through the insertion of fusiform needle for the trigger point release on 3 days a week aimed at pain relief.
89020238|NCT05348603|Experimental|Traditional Letter + Banner|"A mailed letter will invite the patient to set up a research profile in their patient portal; AND~Banner-type advertisements during routine viewing and use of of the patient's portal for their our medical/clinical care inform patients of research opportunities."
89020239|NCT05348603|Experimental|Direct to Patient Message + Chatbot|"An e-mail sent to the patient will inform the patient that there is a message pending in their patient portal regarding opportunities to participate in research; AND~A real-time, interactive chatbot will encourage research participation and direct patients to learn more about research opportunities and trials that match their interests."
89475953|NCT05870904|Active Comparator|Ischemic Compression Group|Received ischemic compression release through thumb pressure for trigger points on 3 days a week.
89475954|NCT05870878|Experimental|Standard care and additional lifestyle program|3 lifestyle group sessions (1 physical and 2 online) and additional online platform and individual consultation given at the research center by trained employees
89475955|NCT05870878|Other|Standard care|Individual consultation given at the research center by trained employees
89475956|NCT05870852|Experimental|ESWT|All individuals who will participate in the study will be treated once a week for 4-5 minutes in total 3 times with ESWT. 2000 impulses will be applied on calcinosis with 2.4 bar pressure and 5.0 Hz frequency.
89475957|NCT05870852|Experimental|ESWT+PNF|PNF stretching techniques will be applied in addition to ESWT. PNF stretching techniques: It will be done with isometric contraction for 10 seconds against maximum resistance. 8-10 repetitions will be done. A 10-second listening interval will be left for active relaxation of the patient between the applications. PNF application will be done by the physiotherapist once a week. You will be asked to do the PNF stretching exercises taught once daily as a home program.
89475958|NCT05870813||AI+OFS|adjuvant treatment with aromatase inhibitor + OFS (ovarian function suppression)
89475959|NCT05870813||TAM|Patients started the adjuvant treatment with Tamoxifen ± OFS
89475960|NCT05870774|Active Comparator|First group|The patients underwent implant placement in combination with an increase in the thickness of soft tissues using a free connective tissue graft from the tuberosity area of the upper jaw
89475961|NCT05870774|Experimental|Second group|"The patients underwent implant placement in combination with an increase in the thickness of soft tissues using collagen matrix Fibro-Gide"
89475962|NCT05870696||negative|normal:no findings on colonoscopy hyperplastic polyps: inflammatory or hyperplastic polyps low-risk adenoma:1 or 2 adenoma(s), ≤10 mm in size, non-advanced
89475963|NCT05870696||Positive|"advanced adenoma Advance adenoma, including the following subcategories:~Adenoma with carcinoma in situ/high grade dysplasia, any size~Adenoma, villous growth pattern (>25%), any size~Adenoma > 1.0 cm in size~Serrated lesion, > 1.0 cm in size early stage CRC: CRC stage I advanced stage CRC: CRC stage II-IV"
89475964|NCT05870657||Overall cohort|Patients receiving inclisiran
89475965|NCT05870644|Experimental|Exercise in room temperature at 25 degree Celsius.|The participants received a moderate exercise program of cycling at moderate intensity (50-60% HRR) for 60 minutes in room temperature at 25 degree Celsius.
89475966|NCT05870644|Experimental|Exercise in room temperature at 34 degree Celsius.|The participants received a moderate exercise program of cycling at moderate intensity (50-60% HRR) for 60 minutes in room temperature at 34 degree Celsius.
89475967|NCT05870631|Experimental|Group A|Group with DTap vaccination produced by Chendu Institute of Biological Products Co., Ltd
89475968|NCT05870631|Experimental|Group B|Group with DT vaccination
89475969|NCT05870618|Experimental|Group A|Group with DTap vaccination produced by Wuhan Institute of Biological Products Co., Ltd
89475970|NCT05870618|Experimental|Group B|Group with DT vaccination
89475971|NCT05870501|Experimental|Ketamine followed by midazolam|Ketamine 0.5mg/kg (three IV infusions) followed by midazolam 0.045mg/kg (three IV infusions)
89475972|NCT05870501|Experimental|Midazolam followed by ketamine|Midazolam 0.045mg/kg (three IV infusions) follower by ketamine 0.5mg/kg (three IV infusions)
89475973|NCT05870475|Experimental|pegylated interferon α-2b in combination with ruxolitinib group|Pegylated interferon α-2b in combination with ruxolitinib group: Pegylated interferon α-2b at a starting dose of 180ug, subcutaneous injection once a week; ruxolitinib at a starting dose of 10mg, orally administered twice daily.
89475974|NCT05870475|Active Comparator|Pegylated interferon α-2b group|"Pegylated interferon α-2b group: Starting dose of 180ug, subcutaneous injection once a week.~If complete hematological remission is not achieved after 12 weeks of treatment with pegylated interferon α-2b alone, cross-over to the pegylated interferon α-2b plus ruxolitinib group is allowed; if ruxolitinib is not tolerated, cross-over to the pegylated interferon α-2b alone group is allowed."
89475975|NCT05870449|Experimental|trial group|
89475976|NCT05870449|Active Comparator|control group|
89475977|NCT05870436||Positive group|The group that conducted the Methacholine Choline Provocation Test with Positive result
89475978|NCT05870436||Negative group|The group that conducted the Methacholine Choline Provocation Test with negative result
89475979|NCT05870423|Experimental|PRRT + olaparib 100mg q.d.|administration of the standard therapy of 7.4GBq 177lu-dotatate with the additional study medication olaparib 100mg q.d.
89475980|NCT05870423|Experimental|PRRT + olaparib 100mg b.i.d.|administration of the standard therapy of 7.4GBq 177lu-dotatate with the additional study medication olaparib 100mg b.i.d.
89475981|NCT05870423|Experimental|PRRT + olaparib 200mg b.i.d.|administration of the standard therapy of 7.4GBq 177lu-dotatate with the additional study medication olaparib 200mg b.i.d.
89475982|NCT05870423|Experimental|PRRT + olaparib 300mg b.i.d.|administration of the standard therapy of 7.4GBq 177lu-dotatate with the additional study medication olaparib 300mg b.i.d.
88949984|NCT01941407|Experimental|Association eribulin and bevacizumab|Drug: eribulin 1,23mg/m²; d1 and d8 in IV, all 3 weeks until 6 cycles or progression Drug: bevacizumab 15m/kg ; d1 in IV, all 3 weeks until 6 cycles or progression or toxicity
88949985|NCT01941420||1 Blood cardioplegia|Blood cardioplegia
88949986|NCT01941420||2 Crytalloid Cardioplegia|Crytalloid Cardioplegia
88949987|NCT01941433|Experimental|Arthritis Health Journal|Participants in this group will use the Arthritis Health Journal in the first 6 months of study.
88949988|NCT01941433|Other|Control|Participants in this group will receive a delayed intervention. They will receive usual care for the first 6 months of study, during which time they will contribute control data, and they will use the Arthritis Health Journal in the second 6 months of study, during which time they will contribute intervention data.
89475983|NCT05870397|Placebo Comparator|Recheck time is at 4 to 6 weeks after the eradication therapy|All cases are administered the same eradication regimen: amoxicillin 1000 mg, clarithromycin 500mg, rabeprazole 10mg, and colloidal bismuth 200 mg each given twice a day for 14 days. Urea breath tests were administered at 4 to 6 weeks( as guildeline suggested) after the treatment.
89475984|NCT05870397|Active Comparator|Recheck time is at 6 to 8 weeks after eradication therapy|All cases are administered the same eradication regimen: amoxicillin 1000 mg, clarithromycin 500mg, rabeprazole 10mg, and colloidal bismuth 200 mg each given twice a day for 14 days. Urea breath tests were administered at 6 to8 weeks after the treatment.
88949989|NCT01941459||1 Custodiol|Custodiol
89475985|NCT05870397|Active Comparator|Recheck time is at 8 to 10 weeks after eradication therapy|All cases are administered the same eradication regimen: amoxicillin 1000 mg, clarithromycin 500mg, rabeprazole 10mg, and colloidal bismuth 200 mg each given twice a day for 14 days. Urea breath tests were administered at 8 to 10 weeks after the treatment.
89475986|NCT05870371|Experimental|Feldenkrais Awareness Through Movement|Application of the Feldenkrais Awareness Through Movement technique in group sessions.
89475987|NCT05870371|Active Comparator|Acupuncture and Stretching|Acupuncture protocol in combination with stretching exercises.
89475988|NCT05870358|No Intervention|fmSRP|27 patients with diabetic periodontitis underwent full mouth scaling and root planning (fmSRP) alone
89475989|NCT05870358|Active Comparator|fmSRP-mel|28 patients with diabetic periodontitis were administered systemic melatonin tablets (6 mg daily, for 30 days) immediately after fmSRP.
88949990|NCT01941459||2 Blood cardioplegia|Blood cardioplegia
88949991|NCT01941511|Experimental|Rivipansel/Placebo/Moxifloxacin|Rivipansel 4.8 gA IV infusion over 20 minutes Phosphate Buffered Saline (PBS) IV infusion over 20 minutes Moxifloxacin (Avelox) 400 mg single oral dose
88949992|NCT01941524|Active Comparator|Poractant goup|Newborns, who will be monitored by amplitude integrated electroencephalography (aEEG) and near infrared spectroscopy (NIRS) during poractant instillation.
88949993|NCT01941524|Active Comparator|Beractant group|Newborns who will be monitored by aEEG and NIRS during beractant instillation
88949994|NCT01941550|Other|Cabazitaxel chemotherapy|"Patients undergo 6 cycles Cabazitaxel chemotherapy. Cabazitaxel suspension is given once per cycle as infusion intravenously, 1 mg/square meter.~For max. 6 times at all."
89475990|NCT05870306|Other|PVI alone|High-density voltage mapping using a multipolar catheter (PentaRay or OctaRay, Biosense Webster, Diamond Bar, CA, USA) will be performed during AF. PVI will be performed with the standard protocol. If needed electrical cardioversion will be performed after PVI ablation. A 10-minute waiting period after isolation of each ipsilateral PV pair was applied to assess for acute reconnections. Additional RF applications were performed if needed at reconnection sites until PVI was achieved.
89537452|NCT02463695|Active Comparator|otologically normal controll|Normative data will be collected from 36 normal ears from subjects that have no history of audiovestibular symptoms and are not being investigated for any balance disorders. The cortical vestibular evoked potentials will be recorded from both ears
89537453|NCT02462525|Experimental|ABBV-838 dose escalation|Varying doses of ABBV-838
89475991|NCT05870306|Experimental|PVI PLUS HSC ABLATION|After standard PVI isolation point-by point ablation targeting HSC-EGMs will be performed. HSC-EGMs with a distance less than 5 mm between them will be addressed with a single application. The ablation index will be defined based on the LA wall thickness (LAWT) at the location of the HSC-EGM: LAWT < 1mm: 300 f, LAWT 1-2 mm: 350 f, LAWT 2-3 mm: 400 f and LAWT >3 mm: 450 f. This is the experimental intervention added to pulmonary veins isolation. This intervention, in terms of risks, is superimposable to the ablation of CFAEs or rotational activity, which are stablished techniques for PsAF catheter ablation
89475992|NCT05870163||RefluxStop patients|
89475993|NCT05870163||Nissen fundoplication patients|
89475994|NCT05870137|Active Comparator|Standard care|Standard care was delivered by the participants with access to didactic instruction and telephonic support. Participants had access to all resources through standard ward base computer systems. Access to senior support through telephone call using a bleep/on call system standard to practice within the institution.
89475995|NCT05870137|Experimental|Mixed reality - HoloLens2TM Supported care|HL2 supported care made all of these resources available through interaction with the HL2 device. Participants had access to all resources through the Mixed reality device (HoloLens2). Access to senior support through using the HL2 device.
89475996|NCT05870072|Experimental|Dual task training (balance exercises combined with cognitive task) group|
89475997|NCT05870072|Experimental|Kinesthetic motor imagery training group|
89475998|NCT05870072|Active Comparator|Balance exercises (Control) group|
89475999|NCT05870059|Experimental|propolis|5 ml of 20% propolis mouthwash twice a day.
89476000|NCT05870059|Active Comparator|chlorhexidine|5 ml of 0.2% chlorhexidine mouthwash twice a day.
89476001|NCT05870020|Experimental|Adults with dystono-diskinetic syndrome treated by depp brain stimulation in the unit.|
89476002|NCT05870007|No Intervention|Control group|Standard treatment alone
89476003|NCT05870007|Active Comparator|Atorvastatin|Standard treatment + Atorvastatin 20mg QD
89476004|NCT05870007|Active Comparator|Atorvastatin AND Alkali|Standard treatment + Atorvastatin 20mg QD + Sodium Bicarbonate therapy up to 1800mg per day
89476005|NCT05869981||Postpartum women|Postpartum women (6-8 weeks to 6 months after delivery) Age 25-35 years
89476006|NCT05869253|Experimental|children diagnosed with ADHD|After completing an eligibility assessment, adequate participants will go through baseline assessment and 12 weeks of waiting without receiving intervention; b) pre-test, before first treatment session, end of 12 week waiting period; c) post-test after 12 weeks of intervention; d) post intervention assessment, three months follow up
89476007|NCT05868460|Experimental|Group A (High Intensity Laser Therapy Group)|patients will receive HILT in addition to traditional physical therapy exercise program
89476008|NCT05868460|Placebo Comparator|Group B (Placebo-Control Group)|patients will receive placebo HILT in addition to traditional physical therapy exercise program
89476009|NCT05866653|Active Comparator|Control Arm|This group will consist of 45 patients who are scheduled to receive oxaliplatin based chemotherapy regimen. After receiving 2 cycles of chemotherapy usually patient develops OIPN. Patients who will develop OIPN with pain intensity ≥4 in VAS scores will be included. The patients will be treated with one lidocaine transdermal patch/day for 12 hours for 10 days as add on therapy with standard treatment by oncologist.
89476010|NCT05866653|Placebo Comparator|Placebo Arm|This group will consist of 45 patients who are scheduled to receive oxaliplatin based chemotherapy regimen. After receiving 2 cycles of chemotherapy usually patient develops OIPN. Patients who will develop OIPN with pain intensity ≥4 in VAS score will be included. The patients will be treated with one placebo patch/day for 12 hours for 10 days as add on therapy with standard treatment by oncologist.
89476011|NCT05861700|Active Comparator|Group 1: B) Dbic 35 -30 mmol/L C) Dbic 30- 35 mmol/L|"Week 1 - a constant Dbic 35 mmol/L -Treatment A. Week 2 - Dbic 35 mmol/L for the first two hours followed by 30 mmol/L for the remainder of the treatment- Treatment B.~Week 3 - a constant Dbic 35 mmol/L (wash-out period). Week 4 - Dbic 30 mmol/L for the first two hours followed by 35 mmol/L for the remainder of the treatment -Treatment C."
89476012|NCT05861700|Active Comparator|Group 2: C) Dbic 30- 35 mmol/L B) Dbic 35 -30 mmol/L|"Week 1 - a constant Dbic 35 mmol/L -Treatment A. Week 2 - Dbic 30 mmol/L for the first two hours followed by 35 mmol/L for the remainder of the treatment- Treatment C.~Week 3 - a constant Dbic 35 mmol/L (wash-out period). Week 4 - Dbic 35 mmol/L for the first two hours followed by 30 mmol/L for the remainder of the treatment -Treatment B."
89476013|NCT05859867|Experimental|Children resident in the Municipality of Mondovì (Intervention group)|"Recruiting of 1000 children (more or less) with ages between 0 and 5 years resident in the Municipality of Mondovì.~Eligible subjects are children with a date of birth between 1/1/2018 and 31/12/2022 (subjects born in 5 years prior to the start of the project), plus a cohort of newborn between 01/1/2023 and 21/6/2023.~Children of both sex and of any ethnicity could be enrolled in the trial.~Moreover, parents of eligible and enrolled children are also considered in-study subjects."
89476014|NCT05859867|No Intervention|Children resident in the Municipality of Savigliano (Control group)|"Recruiting of 1000 children (more or less) with ages between 0 and 5 years resident in the Municipality of Savigliano.~Eligible subjects are children with a date of birth between 1/1/2018 and 31/12/2022 (subjects born in 5 years prior to the start of the project), plus a cohort of newborn between 01/1/2023 and 21/6/2023.~Children of both sex and of any ethnicity could be enrolled in the trial.~Moreover, parents of eligible and enrolled children are also considered in-study subjects."
89476015|NCT05852015|Active Comparator|Treatment-as-Usual (TAU)|TAU consists of weekly outpatient-based group therapy
89476016|NCT05852015|Experimental|TAU Plus Digital Mindfulness-Based Treatment|TAU consists of weekly outpatient-based group therapy. The digital mindfulness-based treatment is multimedia app-based program teaching mindfulness skills.
89476017|NCT05851807||Patints with COVID-19 History|Patients with infected with COVID-19 in any time.
89202751|NCT00747968|Active Comparator|glp-1-analogue|During hyperglycemic clamp and GLP-1-analogue versus placebo infusion 15 patients will be heart OR CNS-PET scanned
89476018|NCT05851807||Patints without COVID-19 History|Patients without COVID-19 history.
89476019|NCT05851664|Active Comparator|Group Direct laryngoscopy (DL)|Group DL: intubated with direct laryngoscopy type Macintosh.
89476020|NCT05851664|Experimental|Group vidéo Laryngoscopy (VL)|Group VL: intubated with a video laryngoscope type McGrath
89537454|NCT02462525|Experimental|ABBV-838 plus pomalidomide/dexamethasone|ABBV-838 to be evaluated with pomalidomide/dexamethasone.
89476021|NCT05845879||"Women who planned to deliver at the brith center un nid pour naître"|"Women who planned to deliver at the brith center un nid pour naître"
89476022|NCT05842252|Experimental|greater trochanter transfer and subtrochanteric valgus osteotomy|greater trochanter transfer, subtrochanteric valgus osteotomy fixation by Wagner & TB and Locked plate
89476023|NCT05820828|No Intervention|Control group|Patient will during extracorporeal circulation be monitored and held in the range of > 300 mL in the venous reservoir. Patient will recieve fluid if needed to maintain correct level (crystalloids, colloids or erytrocytes depending on patients clinical status).
89476024|NCT05820828|Experimental|Interventional group|Patient will during extracorporeal circulation be monitored and held in the range of 200 - 300 mL in the venous reservoir. To maintain correct level of volume, any excessive fluid will be drained into a sterile infusion bag during extracorporeal circulation. After the surgery, the patient will recieve the volume to ensure correct volume status.
89476025|NCT05816460|Experimental|Digital Cognitive Behavioural Therapy for Insomnia (dCBT-I)|Digital Cognitive Behavioural Therapy for Insomnia (dCBT-I) will be provided on an online digital platform called Sleepio (BigHealth Ltd). Sleepio delivers fully automated CBT-I through 6 sessions, lasting an average of 20 minutes each, over the course of 6 weeks.
89476026|NCT05816460|Active Comparator|Sleep Hygiene Education (SHE)|The Sleep Hygiene Education (SHE) provided is based on recognised sleep hygiene advice and will consist of behavioural recommendations concerning lifestyle and environmental factors associated with sleep and insomnia. SHE will be delivered electronically.
89476027|NCT05802030|Experimental|Plyometric training|The 8 weeks of plyometric training included push-ups and medicine ball exercises for the upper limbs and jumping, hopping exercises for the lower limbs. Exercises for the upper limbs were immediately followed by lower-limb exercises, with no intervening rest periods.
89476028|NCT05802030|Active Comparator|Routine training|During the intervention, the control group just continued with their routine training regime (e.g., normal fitness training, and injury prevention drills), twice a week, for the duration of the experiment.
89476029|NCT05790577|Active Comparator|Metformin 30% and 2% Nicotinamispde|Metformin 30% plus Nicotinamide 2% in the reatment of Melasma
89476030|NCT05790577|Active Comparator|Kligman formula|Kligman formula in the treatment of Melasma
89476031|NCT05778838|Placebo Comparator|Control|Will receive IV vasopressor infusion only
89476032|NCT05778838|Active Comparator|Midodrine|Will receive oral midodrine 10 mg/ 8 hours in addition to IV vasopressor infusion till the end of treatment (subject remaining vasopressor-free for 24 consecutive hours).
89476033|NCT05771701|Experimental|Lateral epicondylitis patients|Patients that are diagnosed with lateral epicondylitis.
89476034|NCT05769413||Patients with human immunodeficiency virus infection|Patients with human immunodeficiency virus infection
89476035|NCT05769400||Patients wiht Hepatitis C Virus Infection|Patients with hepatitis c virus infection.
89476036|NCT05768737||Patients wiht Hepatitis B Virus Infection|Patients with hepatitis b virus infection.
89476037|NCT05763615|Experimental|Patients|Children aged 1 to 5 benefiting from a 3T MRI at the Necker Enfants-Malades hospital as part of the initial assessment of a tumor or cervico-facial malformation and at the first postoperative follow-up MRI if indicated for the care during a period of 12 months.
89476038|NCT05763615|Experimental|Control patients|Children aged 1 to 5 benefiting from a 3T MRI at the Necker Enfants-Malades hospital as part of the initial assessment of an ENT pathology other than that of the patient group.
89476039|NCT05757544|Experimental|Dose optimization phase (open label): IV Ganaxolone bolus (variable) followed by infusion (variable)|
89537455|NCT04111419|Experimental|Intensive blood pressure and cholesterol control|
89537456|NCT04111419|Active Comparator|Intensive blood pressure and routine cholesterol control|
89476040|NCT05757544|Experimental|Double-blind phase: IV Ganaxolone + SOC|
89476041|NCT05757544|Placebo Comparator|Double-blind phase: IV Placebo + SOC|
89476042|NCT05748392|Other|Veraflo™ Cleanse Choice Complete™ Dressing Use with Assessments|Subject will have Veraflo™ Cleanse Choice Complete™ dressing applied and used per instructions for use. 3D imaging and wound / peri-wound skin characteristics will be taken during the treatment.
89476043|NCT05740943|Experimental|Treatment Arm|Patients will receive 12-week induction Lorlatinib followed by radical surgery or local radiotherapy or continue Lorlatinib through MDT and optional consolidation lorlatinib for up to 2 years.
89476044|NCT05738785||Home health care patients|Home health patients registered in the Anatolian side of Istanbul
89476045|NCT05732220|Experimental|EMA+ group|EMA assessment + EMA-based cessation counselling
89476046|NCT05732220|Active Comparator|EMA group|EMA assessment only + Usual peer counselling
89476047|NCT05732220|Active Comparator|Control|Usual peer counselling
89537457|NCT04111419|Active Comparator|Routine blood pressure and intensive cholesterol control|
89537458|NCT04111419|Active Comparator|Routine blood pressure and cholesterol control|
89476048|NCT05715645|Experimental|Block at the Adductor Canal + Infiltration between Popliteal Artery and Posterior Capsule|Adductor canal block analgesia associated with infiltration between the popliteal artery and the posterior capsule
89476049|NCT05715645|Active Comparator|Block at the Adductor Canal + High Volume Local Infiltration Analgesia|Adductor canal block analgesia associated with surgical periarticular infiltration
89476050|NCT05709600|Active Comparator|Fasting mimicking diet|Human fasting mimicking diet (Prolon®) for five days prior to living kidney donation in donor: Day 1 of Prolon® supplies ~4600 kJ, day 2-5 provide ~3000kJ.
89476051|NCT05709600|Active Comparator|Ketogenic diet|Isocaloric, ketogenic diet 7 days prior to living kidney donation in the kidney donor with below 5% of energy from carbohydrate (<20g/day), approximately 15% from protein (<100g/day) and 80% from fat (>125g/day) without changes in caloric supply calculated by the Mifflin-St.Jeor formula achieved by the KetoCal 4:1 formula diet (Nutricia Milupa GmbH, Erlangen, Germany).
89476052|NCT05709600|Active Comparator|Dietary restriction of sulfur containing amino acids|Isocaloric, dietary restriction of sulfur containing amino acids in the donor without changes in caloric supply calculated by the Mifflin-St.Jeor formula achieved by the X Met X Cys Maxamaid formula diet (Nutricia Milupa GmbH, Erlangen, Germany).
89476053|NCT05709600|Active Comparator|Control-Group|Healthy, low-fat, moderate protein and high carbohydrate diet in the donor as described in the current nutritional recommendations of the American Diabetes Association achieved by the Fortimel® diet (Nutricia Milupa GmbH, Erlangen, Germany)
89476054|NCT05688943|Active Comparator|General Anesthesia|This arm will receive general anesthesia for vNOTES surgery.
89476055|NCT05688943|Experimental|Spinal Anesthesia|This arm will receive spinal anesthesia for vNOTES surgery.
89476056|NCT05673915|Experimental|tDCS Treatment A (Low Amplitude)|Subjects with focal epilepsy that is not well-controlled on anti-seizure medications will receive 2 different treatments periods, each lasting 2 months, of transcranial direct current stimulation (tDCS). The initial treatment stimulation will be completed during the first 2-months.
88949995|NCT01941576|Experimental|rhBNP Group|Patients after corrective repair of Tetralogy Of Fallot will be treat with routinely therapy, including inotropics and diuretics, combined a rhBNP infusion 24 hours after operation. The dose of recombinant human brain natriuretic peptide (rhBNP) will be 1.5 mcg/kg for loading, followed by continuous infusion recombinant human brain natriuretic peptide 0.01-0.01mcg/kg/min for 72 hours.
89476057|NCT05673915|Experimental|tDCS Treatment B (High Amplitude)|Subjects with focal epilepsy that is not well-controlled on anti-seizure medications will receive 2 different treatments periods, each lasting 2 months, of transcranial direct current stimulation (tDCS). The last treatment stimulation will be completed during the following 2-months.
89476058|NCT05661539||non-pregnant|negative b-hCG results 9 days after embryo transfer.
89476059|NCT05661539||pregnant with obstetric complications|Patients with a positive pregnancy result who develop obstetric complications such as preeclampsia, eclampsia, fetal growth restriction, oligohydramnios, polyhydramnios, preterm birth, gestational diabetes mellitus, antenatal bleeding and etc. after the 20th gestational weeks.
89476060|NCT05661539||pregnant without obstetric complications|Patients who have positive pregnancy results and do not have any obstetric complications such as preeclampsia, eclampsia, fetal growth restriction, oligohydramnios, polyhydramnios, preterm birth, gestational diabetes mellitus, antenatal bleeding and etc. during pregnancy.
89476061|NCT05657561|Experimental|early mobilization|"Patients in the intervention group will be given Early Mobilization Training in the preoperative preparation unit in the preoperative period."
89476062|NCT05657561|No Intervention|routine clinical care|Patients in the control group will receive routine clinical care .Routine post-operative mobilization procedure will be delivered by clinic doctors and nurses
89476063|NCT05648617|Active Comparator|Protein Supplement group|Participants will receive 30g of SUSTINEX Hydrolyzed Whey Protein supplement. The participants will be asked to add it to their soft food or their beverages to reach the goal of consuming 30g daily for 12 weeks (3months).
88949996|NCT01941576|Placebo Comparator|Placebo Group|Patients after corrective repair of Tetralogy Of Fallot will be treat with routinely therapy, including inotropics and diuretics, combined a placebo infusion 24 hours after operation.
88949997|NCT01941602||prophylactic|Prophylactic treatment with drugs to prevent venous thromboembolism in patients operated with open surgery for intracranial meningioma at the Department of neurosurgery at Karolinska Hospital, Stockholm, Sweden
88949998|NCT01941602||non-prophylactic|No use of prophylactic treatment with drugs to prevent venous thromboembolism in patients operated with open surgery for intracranial meningioma at the Departments of neurosurgery at University Hospital North Norway (UNN) and St.Olavs University Hospital (Tromsø and Trondheim respectively, both Norway)
88949999|NCT01941654|Experimental|preemptive local ablative therapy|
88950000|NCT01941667|Experimental|Daily Messages, virtual home visits|"Intervention includes: Measuring daily weights, 24 hour intake, heart rate, oxygen level~Daily messages requesting weight, intake, pulse ox and pulse are automated~Virtual home visits occur twice weekly where the investigators see the infant and families."
89476064|NCT05648617|No Intervention|control group|Receive no intervention- usual care, will receive the standard care of the clinic without supplemented with PS.
89476065|NCT05638919||Oral Antiviral Group|Study participant initiated with oral antiviral (nirmatrelvir plus ritonavir or molnupiravir) for the treatment of COVID-19
89476066|NCT05638919||Non Oral Antiviral Group|Study participant not initiated with oral antiviral for the treatment of COVID-19
89476067|NCT05637879|Active Comparator|Active Drug|Glecaprevir 100 mg/Pibrentasvir 40 mg, 3 oral tablets once daily for 8 weeks.
89476068|NCT05637879|Placebo Comparator|Placebo|Placebo, 3 oral tablets once daily for 8 weeks.
89476069|NCT05634031|Experimental|Patients with INOCA|Patients to undergo coronary angiogram and/or coronary CT angiogram for suspected ischemic symptoms of angina and dyspnea but do not have obstructive epicardial coronary artery disease.
89476070|NCT05631405|Placebo Comparator|Placebo|
89476071|NCT05631405|Experimental|Intervention|
89476072|NCT05628207||4 hospitals using CDS TBI|healthcare system leveraging the rigorous approach, SCALED (SCaling AcceptabLE cDs), to guide CDS scaling across the system in VTE prevention.
89476073|NCT05628207||3 hospitals not using CDS TBI (control)|healthcare system not leveraging the rigorous approach, SCALED (SCaling AcceptabLE cDs), to guide CDS scaling across the system in VTE prevention.
88950001|NCT01941667|Placebo Comparator|Usual Care|Infants will have usual care as defined by cardiology.
88950002|NCT01941680||ZPI|Zidovudine 1000mg/day : Retrovir® 250mg/day) PegINF (Pegasys®) 180μg x1 injection/week
88950003|NCT01941680||ZPI+CHOP-21|"Zidovudine 1000mg/day : Retrovir® 250mg/day) PegINF (Pegasys®) 180μg x1 injection/week~CHOP-21 Day1 = day 21 (3 cycles)~Day 1 Cyclophosphamide : 750 mg/m2, Doxorubicine : 50 mg/m2, Vincristine : 1,4mg/m2, Prednisone : 100mg/day PO.~day 2-Day 5 Prednisone~1mg/kg/day PO."
89202752|NCT00747968|Placebo Comparator|placebo|During hyperglycemic clamp and GLP-1-analogue versus placebo infusion 15 patients will be CNS OR heart-PET scanned.
89202753|NCT00793026|Experimental|1|Dermacyd Breeze Pocket BR (Lactic Acid)
89476074|NCT05625477|Experimental|TNM002 low dose|Participants receive a single intramuscular injection of TNM002 with low dose on Day 1
89476075|NCT05625477|Experimental|TNM002 medium dose|Participants receive a single intramuscular injection of TNM002 with medium dose on Day 1
89476076|NCT05625477|Experimental|TNM002 high dose|Participants receive a single intramuscular injection of TNM002 with high dose on Day 1
89476077|NCT05625477|Active Comparator|Human Tetanus Immunoglobulin (HTIG)|Participants receive a single intramuscular injection of human tetanus immunoglobulin 250 IU on Day 1
89476078|NCT05625477|Placebo Comparator|Placebo|Participants receive a single intramuscular injection of placebo on Day 1
89476079|NCT05625230|Experimental|Behavior activation-PLUS T-RAC|Behavioral: Behavior activation/BA plus T-RAC Each session is focused on reviewing the activity log, planning anti-depressant activities for the next week, and finding support for the implementation of the activity. After activity planning, the participants will follow an XboxKinect exergame for 10 minutes, an actfulness exercise and will imagine one planned activity using dynamic imagery. From session 2 restructuring action memories are added.
89476080|NCT05625230|Active Comparator|Arm 2 Behavioral activation|"Behavioral: Behavior activation/BA Participants in the behavioral activation arm will undergo a BA procedure. A therapist will administer an 8 sessions behavioral activation intervention based on the manual used in the COBRA trial.~Each session is focused on reviewing the activity log, planning anti-depressant activities for the next week, and finding support for the implementation of the activity."
89476081|NCT05621655|Experimental|Mid dose in toddlers (7-71 months old, 3 doses)|Mid dose recombinant trivalent rotavirus subunit vaccine in toddlers aged 7-71 months on Day 0, 28 and 56, intramuscularly injected.
89476082|NCT05621655|Experimental|Mid dose in toddlers (7-71 months old, 2 doses)|Mid dose recombinant trivalent rotavirus subunit vaccine in toddlers aged 7-71 months on Day 0 and 28, intramuscularly injected.
89476083|NCT05621655|Experimental|High dose in toddlers (7-71 months old, 3 doses)|High dose recombinant trivalent rotavirus subunit vaccine in toddlers aged 7-71 months on Day 0, 28 and 56, intramuscularly injected.
89537459|NCT02462447||Prostate Cancer|Subjects will receive two PET/CT examinations, one with 11C-sarcosine and one with 11C-choline. These scans will take 30-45 minutes each.
89537460|NCT02462447||Healthy Volunteer|Subjects will receive one PET/CT examination, with 11C-sarcosine. This scan will take approximately 90 minutes.
89202754|NCT00797940|Experimental|Single Arm|Up to 42 subjects with first recurrence or progression of GBM
89202755|NCT00800748|Experimental|Group A|Participants with genotype 1, 4, 5 or 6 received peginterferon alfa-2a 180 mcg SC qw + ribavirin 1000-1200 mg PO daily (dependent on body weight) for 48 weeks.
89202756|NCT00800748|Experimental|Group B|Participants with genotype 2 or 3 received peginterferon alfa-2a 180 mcg SC qw + ribavirin 800 mg PO daily for 24 weeks.
89202757|NCT00800748|Experimental|Group C|Participants with HIV co-infection received peginterferon alfa-2a 180 mcg SC qw + ribavirin 800 mg PO daily for 48 weeks.
89202758|NCT00345397|Experimental|Subjects Receiving PEC Tube|Percutaneous Endoscopic Colostomy Tube (PEC) Placement
89476084|NCT05621655|Experimental|High dose in toddlers (7-71 months old, 2 doses)|High dose recombinant trivalent rotavirus subunit vaccine in toddlers aged 7-71 months on Day 0 and 28, intramuscularly injected.
89476085|NCT05621655|Placebo Comparator|Placebo in toddlers (7-71 months old, 3 doses)|Placebo in toddlers aged 7-71 months on Day 0, 28 and 56, intramuscularly injected.
89476086|NCT05621655|Placebo Comparator|Placebo in toddlers (7-71 months old, 2 doses)|Placebo in toddlers aged 7-71 months on Day 0 and 28, intramuscularly injected.
89476087|NCT05621655|Experimental|Mid dose in infants (6-12 weeks of age, 3 doses at 4-week intervals)|Mid dose recombinant trivalent rotavirus subunit vaccine in infants aged 6-12 weeks on Day 0, 28 and 56, intramuscularly injected.
89476088|NCT05621655|Experimental|Mid dose in infants (6-12 weeks of age, 3 doses at 8-week intervals)|Mid dose recombinant trivalent rotavirus subunit vaccine in infants aged 6-12 weeks on Day 0, 56 and 112, intramuscularly injected.
89476089|NCT05621655|Experimental|High dose in infants (6-12 weeks of age, 3 doses at 4-week intervals)|High dose recombinant trivalent rotavirus subunit vaccine in infants aged 6-12 weeks on Day 0, 28 and 56, intramuscularly injected.
89476090|NCT05621655|Experimental|High dose in infants (6-12 weeks of age, 3 doses at 8-week intervals)|High dose recombinant trivalent rotavirus subunit vaccine in infants aged 6-12 weeks on Day 0, 56 and 112, intramuscularly injected.
89476091|NCT05621655|Placebo Comparator|Placebo in infants (6-12 weeks of age, 3 doses at 4-week intervals)|Placebo in infants aged 6-12 weeks on Day 0, 28 and 56, intramuscularly injected.
89476092|NCT05621655|Placebo Comparator|Placebo in infants (6-12 weeks of age, 3 doses at 8-week intervals)|Placebo in infants aged 6-12 weeks on Day 0, 56 and 112, intramuscularly injected.
89476093|NCT05594329|Experimental|Experimental meal 1|Instant noodle soup containing 2 servings of dried Pleurotus oyster mushroom.
89476094|NCT05594329|Experimental|Experimental meal 2|Instant noodle soup containing 1 serving of dried Pleurotus oyster mushroom.
89476095|NCT05594329|Experimental|Experimental meal 3|Instant noodle soup containing 0.5 serving of dried Pleurotus oyster mushroom.
89476096|NCT05594329|Placebo Comparator|Control meal|Instant noodle soup containing cornflour and maltodextrin in a 2.5:1 ratio.
89476097|NCT05590780||Control|Evaluation of plasma cfDNA levels
89476098|NCT05590780||Periodontitis|Evaluation of plasma cfDNA levels
89476099|NCT05590780||Cardiovascular disease|Evaluation of plasma cfDNA levels
89476100|NCT05590780||Periodontitis + cardiovascular disease|Evaluation of plasma cfDNA levels
89476101|NCT05581095|Active Comparator|Mindful Eating Self-Help Book Only|"Participants will be invited to read about and practice a variety of mindful eating-related strategies over the course of 10 weeks based on Dr. Michelle May & Dr. Kari Anderson's self-help book entitled, Eat What You Love, Love What You Eat for Binge Eating. Participants will also be asked to complete a weekly electronic log describing their experiences with the weekly mindfulness-based practices."
89476102|NCT05581095|Experimental|Mindful Eating Self-Help Book + Smartphone App|"Participants will be invited to read about and practice a variety of mindful eating-related strategies over the course of 10 weeks based on Dr. Michelle May & Dr. Kari Anderson's self-help book entitled, Eat What You Love, Love What You Eat for Binge Eating. In addition, participants will be asked to use the companion Am I Hungry? Mindful Eating Virtual Coach smartphone application three times daily. Participants will also be asked to complete a weekly electronic log describing their experiences with the weekly mindfulness-based practices."
89476103|NCT05579743|No Intervention|Standard care|Patients randomized to receive standard of care will be provided with a wound care plan at the time of enrollment, and then follow-up in clinic on a biweekly basis (week 2, 4, 6, 8, 10, 12) for a wound check and care plan update as needed.
88950004|NCT01941680||ZPI +DHAP-21|"Zidovudine 1000mg/day : Retrovir® 250mg/day) PegINF (Pegasys®) 180μg x1 injection/week~DHAP Day 1= day 21 (3 cycles) Day 1 : Cisplatina 100 mg/m2 Day 2 and day 3 : Aracytine 2000mg/m2/day Day 1-day 4 : Dexamethasone 40mg"
89206240|NCT04352140|Experimental|Dominant hand|Subject scheduled to undergo an elective surgical procedure will have TetraGraph device lead placement on the dominant hand, ToFscan placed on non-dominant hand
89476104|NCT05579743|Experimental|Remote wound monitoring technology|Enrolled patients (and their caregivers, if applicable) are given an in-person training on how to use the smartphone app to self-assess their wound during regular dressing changes. Wound assessments are electronically transmitted to a secure, dedicated portal up to once a week for remote review by the study doctors. In-person follow-up is monthly (at the time of enrollment, week 4, week 8, and week 12).
89476105|NCT05579236||Patient Participants|Patient participants will have a diagnosis of mild cognitive impairment or prodromal / mild Alzheimer's Disease. Participants with a global CDR score of 0.5 and 1 will be recruited in a minimum of a 2:1 ratio respectively in the study.
89476106|NCT05579236||Study Companions|Study companions will have sufficient knowledge on the patient participant's condition to complete companion assessments of the patient, in the investigator's judgement, for example they may be carers of the patients.
89476107|NCT05569538|Experimental|Cohort A (Patients refractory to, relapsed or intolerant of ruxolitinib):|"Bomedemstat : The starting dose of bomedemstat at Initial Treatment Period Cycle 1 Day 1 will be 0.4 mg/kg daily for all patients in Cohort A. The first up-titration is not permitted until Initial Treatment Period Cycle 2 Day 1; thereafter, the dose may be up-titrated no more frequently than every 4 weeks from the prior up- or down-titration (note: down-titrations may occur at any time (or the current dose maintained) in the best interest and safety of the patient), to a target platelet count range of 50-100 x 10^9/L.~Ruxolitinib: Patients will continue their prior, stable dose of ruxolitinib. This same dose will be continued throughout the study unless dose modification is required because of toxicity."
88950005|NCT01941693|Experimental|Integrated care|"Integrated care:~Intervention for co-morbid alcohol dependence and anxiety or mood disorder. Trained therapists will deliver specific Cognitive Behavioural Therapy based upon interventions that have been supported by randomised controlled trials for alcohol use, anxiety, and depressive disorders."
88950006|NCT01941693|Active Comparator|Usual care|Usual care
89537461|NCT05473923|Experimental|Receiving chemotherapeutic or targeted drugs recommended by molecular tumor board.|These drugs included all the FDA-approved drugs that have been used in treating gliomas. A single drug or a drug combination for a specific patient will be recommended by the molecular tumor board, comprising neurooncologists, neurosurgeons, pharmacologists, cancer biologists, radiologists and bioinformaticians, will recommend , based on their expertise, patients willingness as well as evidences from PTCs-drug screening and bioinformatic prediction for drug response.
89537462|NCT02462681|Active Comparator|bupivacaine group in paravertebral block|patients will be received 20 ml of bupivacaine 0.25% paravertebrally, divided into 3-4 ml in each level
89537463|NCT02462681|Active Comparator|bupivacaine + 0.5 mg/kg ketamine group in paravertebral block|patients will be received 20 ml of bupivacaine 0.25% + 0.5 mg/kg ketamine paravertebrally divide into 3-4 ml in each level
88950007|NCT01941706|Experimental|Project UPLIFT (Treatment)|Participants randomly assigned to the Treatment group receive the UPLIFT Intervention immediately after completing the Baseline Assessment. Participants can chose to participate in the Web- or phone-delivery of UPLIFT.
88950008|NCT01941706|Experimental|Project UPLIFT (TAU Waitlist Control)|Participants randomly assigned to the Treatment-as Usual (TAU) Waitlist Control group will also receive the UPLIFT intervention. However, TAU Waitlist Control participants will begin the Intervention 8 weeks after completing the Baseline Assessment. During the initial 8 weeks, participants in this group will continue whatever treatment they are currently undergoing to prevent or treat mild depressive symptoms. Participants can chose to participate in the Web- or phone-delivery of UPLIFT.
89476108|NCT05569538|Experimental|Cohort B (Cohort B will consist of 10 patients who are JAK inhibitor naïve):|"Bomedemstat: The starting dose of bomedemstat at Initial Treatment Period Cycle 1 Day 1 will be 0.4 mg/kg daily for all patients in Cohort B. The first up-titration is not permitted until Initial Treatment Period Cycle 2 Day 1; thereafter, the dose may be up-titrated no more frequently than every 4 weeks from the prior up- or down-titration (note: down-titrations may occur at any time (or the current dose maintained) in the best interest and safety of the patient), to a target platelet count range of 50-100 x 10^9/L.~Ruxolitinib: Patients will start treatment with ruxolitinib at Initial Treatment Period Cycle 1 Day 1. The starting dose of ruxolitinib will be 10 mg BID. This same dose will be continued throughout the study unless dose modification is required because of toxicity."
89476109|NCT05564312||non-pregnant|Negative b-hCG results 9 days after embryo transfer.
89476110|NCT05564312||pregnant|Positive b-hCG results 9 days after embryo transfer.
89476111|NCT05551052||Next-Gen CRC Screening Test|Adults 45 years of age and older who are at average risk of developing colorectal cancer and eligible for a screening colonoscopy
89476112|NCT05526014||non-pregnant|negative b-hCG results 9 days after embryo transfer.
89476113|NCT05526014||pregnant with obstetric complications|Patients with a positive pregnancy result who develop obstetric complications such as preeclampsia, eclampsia, fetal growth restriction, oligohydramnios, polyhydramnios, preterm birth, gestational diabetes mellitus, antenatal bleeding and etc. after the 20th gestational weeks.
89476114|NCT05526014||pregnant without obstetric complications|Patients who have positive pregnancy results and do not have any obstetric complications such as preeclampsia, eclampsia, fetal growth restriction, oligohydramnios, polyhydramnios, preterm birth, gestational diabetes mellitus, antenatal bleeding and etc. during pregnancy.
89476115|NCT05517148|Experimental|Mindfulness-based Stress Reduction by Therapeutic VR|47 participates were randomized and allocated to this treatment group. During the study, seven individuals were lost, and a total of 40 nurses participated in the final statistics. Of the seven individuals lost, two withdrew from the intervention due to personal reasons, while the remaining five terminated the intervention due to COVID-19 infection. The therapeutic intervention consisted of an eight-week group intervention that included the same amount of contact and meditations as MBT.
89476116|NCT05517148|Other|Mindfulness-based Stress Reduction|Received the same mindfulness therapy training audio as the other set, but did not watch the 3D scene on the VR device. At the end of the study, we will compensate them and let them use VR for relaxation training according to their wishes.
89476117|NCT05586724|Active Comparator|Micronized progesterone in continuous combination with oral estrogen|Capsule 100 mg mP (Utrogestan®) orally per day in continuous combination with 1 mg encapsulated estradiol (Estrofem®)
89476118|NCT05586724|Active Comparator|Norethisterone acetate in continuous combination with oral estrogen|Capsule 0.5 mg NETA/ 1 mg estradiol (Activelle®) orally per day (encapsulated and identical to Estrofem® and one matched placebo to Utrogestan.
89476119|NCT05515952|Other|Active TBS-Sham TBS|Active TBS in block one, Sham TBS in block two
89476120|NCT05515952|Other|Sham TBS-Active TBS|Sham TBS in block one, Active TBS in block two
88950009|NCT01941732|Experimental|Sildenafil|motor function to be tested before and after challenge with 100 mg sildenafil after taking normal anti-PD medication, and Again after discontinuation of anti-PD medication for 12 h
88950010|NCT01941758|Experimental|Basic science (trivalent influenza vaccine)|Patients receive trivalent influenza vaccine on day 1.
88950011|NCT01941771|Active Comparator|Arm A|Vinorelbine (Navelbine Oral) 60 mg/m2 day 1 and day 8 Plus Capecitabine (Xeloda) 1000 mg/m2 2 times daily day 1 to 14 in a 3 weekly schedule.
88950012|NCT01941771|Experimental|Arm B|Oral Vinorelbine (Navelbine oral) 50 mg 3 times weekly, monday, wednesday and friday plus Capecitabine (Xeloda) 1000 mg/m2 2 times daily day 1-14 in a 3 weekly schedule.
88950013|NCT01941784|Experimental|Supportive care (health education program)|See Detailed Description.
89476121|NCT05505045|Experimental|Treatment Group: Cognitive Orientation to daily Occupational Performance (CO-OP)|Each CO-OP session will last 60 minutes and subjects will complete one session per week over the course of 10 weeks. All sessions will be delivered remotely via the Zoom platform.
89476122|NCT05505045|Active Comparator|Attention Control Group|Each session will last 60 minutes and subjects will complete one session per week over the course of 10 weeks. All sessions will be delivered remotely via the Zoom platform.
89537464|NCT02462681|Active Comparator|bupivacaine + 1 mg/kg ketamine group in paravertebral block|patients will be received 20 ml of bupivacaine 0.25% + 1mg/kg ketamine paravertebrally divide into 3-4 ml in each level
89537465|NCT03064581|Experimental|Intervention|Gender-specific culturally tailored social-support informed educational intervention session.
89537466|NCT03064581|No Intervention|Control|Usual care with delayed intervention at the end of study.
88950014|NCT01941797|Experimental|Peri-implant mucosa|
88950015|NCT01941797|Active Comparator|periodontal mucosa|
88950016|NCT01941810|Experimental|Supportive care (bovine lactoferrin supplement)|Patients receive bovine lactoferrin supplement PO TID for 1 month.
88950017|NCT01941823||Carnitine CRRT, prospective|CRRT patients given carnitine in TPN as part of clinical protocol. Will evaluate total and free, carnitine and acylcarnitine profile as well as cardiac function by standard and speckle tracking echo weekly during CRRT.
88950018|NCT01941823||CRRT Control, retrospective|Retrospective control group, CRRT patients who did not receive carnitine supplementation during CRRT and had carnitine levels measured and echo performed during CRRT.
89476123|NCT05500651|Experimental|Experimental group|Dance and movement therapy is planned to be applied once a week as a total of 12 sessions of 60 minutes. First session; meeting, warming up, determining the group rules, explaining the principles, determining the expectations activities. Subsequent sessions; The greeting is completed with warm-up, initiation, continuation and closing activities. During the warm-up phase, the whole group comes together to form a circle, generally standing, in order to ensure the group dynamic. It starts with simple warm-up exercises such as breathing and muscle relaxation and continues with body awareness exercises. In the continuation (development of themes) stage, practices are included according to the characteristics and needs of the group.
89476124|NCT05500651|No Intervention|Control group|
89476125|NCT05485558|Placebo Comparator|Control group|15 patients will receive standard antiepileptic drug plus placebo capsules for 6 months.
89476126|NCT05485558|Active Comparator|N-acetyl cysteine group|15 patients will receive 10 mg/kg of N-acetyl cysteine capsules together with their standard antiepileptic drug for 6 months.
89476127|NCT05485558|Active Comparator|N-actyl cysteine group|15 patients will receive 40 mg/kg of N-acetyl cysteine capsules together with their standard antiepileptic drug for 6 months.
89476128|NCT05479058|Experimental|Filgotinib 200 mg|"Participants will receive filgotinib 200 mg and placebo to match filgotinib 100 mg. Participants will receive blinded treatment until primary analysis time point (after last participant completes Week 48 post baseline visit or has completed Week 12 post re-escalation visit, or after last follow-up of participant who discontinues prior to Week 48, whichever comes last), with exception of participants with endoscopic score (ES)-confirmed UC flare who will be switched to open-label 200 mg filgotinib q.d. for at least 12 weeks and may continue treatment in case of response until the end of the study.~Participants, who are blinded at the time of the primary analysis time point, will receive open-label filgotinib 200 mg q.d.~The maximum duration of the treatment will be 216 weeks."
89476129|NCT05479058|Experimental|Filgotinib 100 mg|"Participants will receive filgotinib 100 mg and placebo to match filgotinib 200 mg. Participants will receive blinded treatment until primary analysis time point (after last participant completes Week 48 post baseline visit or has completed Week 12 post re-escalation visit, or after last follow-up of participant who discontinues prior to Week 48, whichever comes last), with exception of participants with ES-confirmed UC flare who will be switched to open-label 200 mg filgotinib q.d. for at least 12 weeks and may continue treatment in case of response until the end of the study.~Participants, who are blinded at the time of the primary analysis time point, will receive open-label filgotinib 100 mg q.d.~The maximum duration of the treatment will be 216 weeks."
89476130|NCT05468034|Experimental|Exercise Intervention|Eligible and consented participants randomized to the exercise arm (EX) will work with an exercise trainer 3x weekly for 16 weeks. Training sessions are 60 min. Schedules are determined by participant and trainer with oversight by the study team, ideally occurring at similar times each day in line with IBC theory. Each training session will be delivered virtually over a HIPAA compliant IU Health Zoom platform. The virtual exercise sessions include 3 parts: cardiovascular exercise, resistance training, and balance or stretching exercise. During sessions, patients will wear provided heart rate monitors with a training goal of moderate intensity, defined as 40-60% of heart rate reserve. Based on the participant's rate of perceived exertion (RPE), heart rate, and individual response during each session, trainers will follow an algorithm designed by the PI and collaborators to progress or regress intensity level. Participant will attend a class on creating and maintaining behavior changes.
89476131|NCT05468034|No Intervention|Usual Care|Participants randomized to usual care (UC) will receive care per their treatment team. UC participants are encouraged to exercise but will not be provided components of the intervention. Participants in the UC arm will be given usual care handouts at baseline from the American College of Sports Medicine.
89476132|NCT05446857|Experimental|Active Drug|All enrolled participants will receive Glecaprevir/Pibrentasvir
89476133|NCT05443074|Active Comparator|Face to face intervention group|This group will be composed of participants who will receive face to face physiotherapy instruction session.
89476134|NCT05443074|Experimental|Remote intervention group|This group will be composed of participants who will receive real time remote physiotherapy instruction session.
89476135|NCT05443074|Active Comparator|Control group|This group will be composed of participants who will not receive any type of physiotherapy instruction session during the period of the study.
89476136|NCT05441774|Sham Comparator|Sham stimulation plus sham imagery|Double sham group: Stimulator electrodes will be applied to earlobe (sham stimulation); imagery task will involve a 'draw-a-face-in-imagination' (sham imagery) task.
89476137|NCT05441774|Other|Active stimulation plus sham imagery|Single (imagery) sham group: Stimulator electrodes will be applied to the tragus (active stimulation); 'draw-a-face-in-imagination' (sham imagery) task.
88950019|NCT01941823||ICU Control (non-CRRT), prospective|Critically ill ICU patients not receiving any exogenous carnitine, and not receiving CRRT, will have total and free carnitine and acylcarnitine profile measured weekly during CRRT.
89476138|NCT05441774|Other|Sham stimulation plus active self-compassion imagery|Single (stimulation) sham group: earlobe (sham) stimulation; imagery task will involve directing compassion to the self (self-compassion, active imagery).
89476139|NCT05441774|Active Comparator|Active stimulation plus active self-compassion imagery|Double active group: tragus (active) stimulation; self-compassion (active imagery)
89476140|NCT05435469||Questionnaires assessed adolescents|① Teenagers aged 14-25. ② Chinese nationality, who has lived in China since the outbreak of the COVID-19 epidemic, and has experienced or is experiencing the epidemic and its normalization. ③ Have the normal cognitive ability, expression ability, and social participation ability.
89476141|NCT05433909|Experimental|Endometriosis group|The endometriosis group will include women who will undergo surgery for endometriosis.
89476142|NCT05433909|Experimental|Control Group|The control group include women who will undergo surgery for other gynecological diseases in which the presence of endometriosis will be excluded during the operation.
89476143|NCT05425524|Experimental|Care Bundle Group|Treatment step by step we have 5 steps STEP 1: Leptospirosis suspected case STEP 2: Investigations STEP 3: Antibiotics within 1 hour after Hemocultures were taken STEP 4: Intravenous Fluid STEP 5: Stage-Base Management of AKI (KDIGO)
89476144|NCT05425524|No Intervention|Control Group|
89476145|NCT05383196|Experimental|DOSE ESCALATION ONVANSERTIB + PACLITAXEL|"In the phase 1b, dose escalation/de-escalation will be managed using a BOIN design to identify the RP2D.~The study is divided into three time periods: a screening period; a treatment period; and a post-treatment follow-up period.~The names of the study interventions involved in this study are:~Onvansertib~Paclitaxel"
89476146|NCT05383196|Experimental|DOSE EXPANSION RP2D ONVANSERTIB + PACLITAXEL|"The study is divided into three time periods: a screening period; a treatment period; and a post-treatment follow-up period.~The names of the study interventions involved in this study are:~Onvansertib~Paclitaxel"
89476147|NCT05319548|Active Comparator|Starting with Purple-Red Carrot Juice|Participants are randomized to consume purple-red carrot juice first (250 mL) in under 2 minutes. They will crossover to red carrot juice and to purple carrot juice.
89476148|NCT05319548|Active Comparator|Starting with Purple Carrot Juice|Participants are randomized to consume purple carrot juice first (250 mL) in under 2 minutes. They will crossover to red carrot juice and to purple-red carrot juice.
89476149|NCT05319548|Active Comparator|Starting with Red Carrot Juice|Participants are randomized to consume red carrot juice first (250 mL) in under 2 minutes. They will crossover to purple-red carrot juice and to purple carrot juice.
89476150|NCT05313295|Experimental|Home-based Physiotherapy|Two days a week of physical therapy (mobilizations, manual therapy, stretching, respiratory techniques) + 3 hours extra of home-based physiotherapy (stretching, active mobilizations)
89476151|NCT05313295|Active Comparator|Usual physiotherapy|Two days a week of physical therapy (mobilizations, manual therapy, stretching, respiratory techniques)
89476152|NCT05310448|Experimental|Treatment (tumor treating fields)|After completion of standard of care radiation therapy, patients wear the Optune device for 18 hours per day for 12 months in the absence of disease progression or unacceptable toxicity.
89476153|NCT05302505|Experimental|Simulation|"Theoretical training in e-learning for nurses on :~arteriovenous fistula puncture~use of ultrasound with echoreferencing and ultrasound guidance~therapeutic communication~And simulation-based training (procedural) on :~arteriovenous fistula puncture~use of ultrasound with echoreferencing and ultrasound guidance~therapeutic communication"
89476154|NCT05302505|No Intervention|Control|"Theoretical training for nurses in e-learning on :~arteriovenous fistula puncture~use of ultrasound with echoreferencing and ultrasound guidance~therapeutic communication"
89476155|NCT05285605||Emergency Contraceptive Group|Group of participants receiving emergency contraception in the form of 3 packages of ulipristal acetate to use at home if needed.
89476156|NCT05268289|Active Comparator|Iptacopan + standard of care (part 1)|Iptacopan + standard of care
89476157|NCT05268289|Placebo Comparator|Placebo matching iptacopan + standard of care (part 1)|Placebo matching iptacopan standard of care
89476158|NCT05268289|Active Comparator|Iptacopan + standard of care (part 2)|Iptacopan + standard of care
89476159|NCT05268289|Active Comparator|Iptacopan + placebo (part 2)|Iptacopan + placebo standard of care
88950020|NCT01941849|Experimental|Vandetanib + 131I-mIBG|"Vandetanib (100, 200 or 300 mg once daily) in combination with 131I-mIBG radiation therapy (activity to be prescribed to deliver whole body absorbed dose of 0.5 Gy) on day 1 of each 12-weekly cycle.~Patients will receive up to 4 cycles of vandetanib in combination with 131I-mIBG."
89206241|NCT04352140|Experimental|Non-dominant hand|Subject scheduled to undergo an elective surgical procedure will have TetraGraph device lead placement on the non-dominant hand, ToFscan placed on dominant hand
89476160|NCT05268289|Active Comparator|Placebo matching iptacopan + standard of care (part 2)|Placebo matching iptacopan + standard of care
89476161|NCT05244083|Experimental|Experimental Group|The experimental group will perform a 5-week motor program consisting of 4 bimanual exercises with mirror therapy, to be done at home 30 minutes a day, 5 days a week.
89476162|NCT05244083|Active Comparator|Control Group|The control group will perform a 5-week motor program consisting of 4 bimanual exercises without mirror therapy, to be done at home 30 minutes a day, 5 days a week.
89476163|NCT05219448|Experimental|Education and self-efficacy coaching|This arm will receive education, behavior change support in the form of self-efficacy coaching, and introduction of sugar-free water enhancers.
88950021|NCT01941862|Experimental|Anxiety Risk Reduction|The anxiety risk reduction condition will be a combination of psychoeducation plus Cognitive Bias Modification (CBM-I) for anxiety sensitivity (AS). The psychoeducational component will focus on the nature of stress and its effect on the body. Interoceptive exposure (IE) exercises, designed to correct the conditioned fear to these bodily sensations, will be explained and practiced.
88950022|NCT01941862|Experimental|Mood Risk Reduction|The mood risk reduction condition will be a combination of psychoeducation plus Cognitive Bias Modification (CBM-I) for perceived burdensomeness and thwarted belongingness. The psychoeducational component will focus on dispelling myths related to burdensomeness and belongingness and describe their role in the development of mood symptoms.
88950023|NCT01941862|Experimental|Combined Risk Reduction|The combined intervention will involve all of the interventions in the anxiety and mood risk reduction conditions and thus will not be matched for length.
88950024|NCT01941862|No Intervention|Repeated Contact Control|"Participants assigned to the repeated contact group will be assigned a personal study coordinator. The coordinator will contact them at specific intervals during the study. The rationale for these contacts will be provided (e.g., checking in on their status and helping to administer some brief measures). During the three weeks (corresponding to treatment session intervals for those in one of the active treatment conditions), the study coordinator will contact the participant once per week for a brief phone check in where suicide risk will be evaluated. Participants in the control group will also meet with their study coordinator during each of the scheduled follow-up visits."
88950025|NCT01941888|Experimental|propofol|Patients in Group Propofol(n=70) were seated with propofol target concentration 1.2-1.6 µg/ml. Patients in both groups undergoing CS received also iv fentanyl (1μg/Kg) for pain control.
88950026|NCT01941888|Active Comparator|midazolam|Control Group: patients in Group midazolam (n=70) were sedated with midazolam 0.04 mg/kg if aged< 70 - 0.03 mg/kg if aged> 70. Patients in both groups undergoing CS received also iv fentanyl (1μg/Kg) for pain control.
88950027|NCT01941901|Experimental|Calcium electroporation|"The metastases will be treated with intratumoral injection of calcium chlorid followed by electrotransfer.~It is a once-only treatment. Calcium chlorid concentration: 9mg/ml. Total dose: 0,5ml/cm3 tumor volume."
89202759|NCT00793260|Active Comparator|Usual Support Group|Predictive models in the Usual-Support Group were aimed at identifying individuals through medical claims and administrative data (such as hospitalization notification). The output of the predictive models is a rank-ordered, or stratified, list of individuals who have support needs. These lists were then used to generate outbound mail, interactive voice response (IVR) calls or calls by health coaches.
89476164|NCT05219448|No Intervention|Comparison|This arm will have the outcomes assessed but will not receive relevant parts of the intervention (education, behavior change support, and introduction of sugar-free water enhancers) until the end of the study.
89476165|NCT05210088|Experimental|PHASE 1- Dose escalation protocol|"4-step dose-escalation protocol with increasing doses of intermittent hypoxia and continuous reassessment of safety criteria (primary endpoint).~Hypoxic conditioning will be performed in three one-hour sessions per week, performed non-consecutively, for 8 weeks. The hypoxic stimulus will be intermittent, and each session will consist of 7 cycles of 5 minutes of hypoxia alternating with 3 minutes of normoxia (FiO2 = 21%). The subjects will be installed in a semi-recumbent position, at rest in a quiet environment.~For hypoxic exposure, the inspired fraction of oxygen (FiO2) will be set individually to achieve the targeted level of desaturation (Pulse Oxygen Saturation, SpO2) continuously monitored: 90% for stage 1 (n=1 patient), 85% for stage 2 (n=3 patients), 80% for stage 3 (n=3 patients), 75% for stage 4 (n=3 patients)."
89476166|NCT05210088|Active Comparator|PHASE 2 - Intermittent hypoxia group|"Group exposed to an intermittent hypoxic stimulus (n=20, target pulsed saturation in dioxygen 75%).~The device used is a gas mixer already in use in the unit and used in current clinical practice and research in our team (Altitrainer®, Sport and Medical TEChnologies S.A. (SMTEC S.A.), Switzerland). The hypoxic stimulus will be obtained by having the subject inhale a gas mixture enriched in nitrogen by means of a mask, in variable proportion according to the desired degree of hypoxia.~Hypoxic conditioning will be performed in three one-hour sessions per week, performed non-consecutively, for 8 weeks. The hypoxic stimulus will be intermittent, and each session will consist of 7 cycles of 5 minutes of hypoxia alternating with 3 minutes of normoxia (FiO2 = 21%). The subjects will be installed in a semi-recumbent position, at rest in a quiet environment.~For hypoxic exposure, the FiO2 will be set individually to achieve the targeted level of desaturation."
89476167|NCT05210088|Sham Comparator|PHASE 2 - Sham (Normoxia) group|Normoxia group (n=10, FiO2 = 21%). The same setting will be used as in the Intermittent hypoxia group, but subjects will breathe ambient air throughout the conditioning procedure.
89476168|NCT05179733|Experimental|ZR2|six courses of zanubrutinib, rituximab and lenalidomide
89476169|NCT05179733|Active Comparator|R-miniCHOP|six courses of rituximab combined with low-dose CHOP
89476170|NCT05178797|Experimental|K-tapping and exercise (Group A)|Group A will be given kinesiology taping technique and exercise therapy
89476171|NCT05178797|Active Comparator|Compression decongestive therapy (Group B )|Group B will be given compression decongestive therapy (manual lymphatic drainage, short stretch bandage and exercise therapy)
89476172|NCT05154825||Spine Surgery Participants|Spine surgical candidates that will be receiving posterior only surgery for spinal deformity
89202760|NCT00793260|Experimental|Enhanced Support Group|The Enhanced-Support Group intervention used more sophisticated predictive models, more extensive outreach to engage individuals, and provided tighter feedback loops to inform the care support process.
89206242|NCT02548494|Placebo Comparator|Control Group|The control group will receive all traditional methods of treatment for DKA including iv insulin, correction of fluid loss, and electrolyte correction, including a placebo subcutaneous injection.
89206243|NCT02548494|Experimental|Treatment Group|The study group will receive the same treatment including iv insulin, correction of fluid loss, and electrolyte correction, but will be supplemented with a subcutaneous glargine injection.
89206244|NCT05049148|Other|Patients requirering brain/medullary tumors excision|All patients requirering a surgery for brain or medullar excision
89476173|NCT05154708||Patient Group - Phase 1|15 to 30 patients are expected in Phase 1 for the identification of needs and expectations in relation to a systematic electronic assessment of symptoms by the patients themselves
89476174|NCT05154708||Health Professionals Group - Phase 1|15 to 30 healthcare professionals are expected to participate in Phase 1 regarding the identification of needs and expectations in relation to a systematic electronic assessment of symptoms by the patients themselves
89476175|NCT05154708||Patient Group - Phase 2|50 à 60 patients were expected to test a systematic electronic assessment
89476176|NCT05152303|Experimental|A：Remimazolam Tosilate|
89476177|NCT05152303|Experimental|B：Remimazolam Tosilate|
89476178|NCT05149664|Experimental|VibratoSleeve TUS|Subjects will receive 30 TUS treatments, each one lasting 90 minutes on the calf of a leg with peripheral arterial disease.
89476179|NCT05096273|Experimental|CPT- Pain relief lotion|During the initial visit participant will do the cold pressor test twice to assess catastrophic symptom expectations. After completing the 1st CPT, participants will be randomized to receive a pain relief lotion or pain sensitivity lotion. Participants will then repeat the CPT with the lotion applied to their hand.
89476180|NCT05096273|Experimental|CPT- Pain sensitivity lotion|During the initial visit participant will do the cold pressor test twice to assess catastrophic symptom expectation. After completing the 1st CPT, participants will be randomized to receive a pain relief lotion or pain sensitivity lotion. Participants will then repeat the CPT with the lotion applied to their hand.
88950028|NCT01941901|Active Comparator|Electrochemotherapy with bleomycin|"The metastases will be treated with intratumoral injection of bleomycin followed by electrotransfer.~It is a once only treatment. bleomycin concentration: 1000 IU/ml. Total dose: o,5 ml/cm3 tumor volume."
88950029|NCT01941914|Experimental|Calcium electroporation|"The keloid will be treated with intratumoral injection of calcium chloride followed by electrotransfer. It is a once only treatment.~Calcium chlorid concentration is 9 mg/ml Total dose is 0,5ml/cm3 tumor volume."
88950030|NCT01941953|Experimental|Metformin and Flourouracil|
88950031|NCT01941966|Experimental|Chemo-radiotherapy|Capecitabine, PO, 825mg/m2 Mitomycin C, IV, 15 mg/m2 Radiotherapy - 50,4 - 54 Gy
88950032|NCT01941979|Experimental|Adjuvant therapy|"5-FU, Leucovorin and Oxaliplatine (FLOX) OR Capecitabine and Oxaliplatin (CAPOX)~NOTE: If the patient was randomized for the arm experimental, the investigator can choose between intravenous (IV) treatment or oral treatment (PO). Both are considered equal by the principal investigator."
88950033|NCT01941979|No Intervention|Observation|
88950034|NCT01941992|Experimental|SAMITAL® sachets, oral suspension|SAMITAL® sachets for oral suspension, 20 mL, four times a day.
88950035|NCT01941992|Placebo Comparator|Placebo sachets|Placebo sachets for oral suspension, 20 mL, four times a day.
88950036|NCT01942018|Experimental|EGOO|Patients presenting with symptomatic gastroesophageal junction outflow obstruction (EGOO)who will be treated with Per oral endoscopic myotomy (POEM)
88950037|NCT01942031|Experimental|structured collegial feed back|Structured feed back and information about stroke to the primary care center, to physicians and head of the center
88950038|NCT01942031|No Intervention|Control group|No structured feed back on stroke prevention. Ordinary educational activities only.
88950039|NCT01942044|Experimental|Promus element|Promus element is a thin struts, 2-link design, evelolimus-eluting stents.
88950040|NCT01942044|Active Comparator|Xience Prime|Xience Prime is a thin struts, 3-link design, evelolimus-eluting stents.
88950041|NCT01942044|Active Comparator|Nobori|Nobori is a thick struts, 2-link design, biolimus-eluting stents.
88950042|NCT01942057||School Grades 1+2|Children currently enrolled in grades 1 and 2
88950043|NCT01942057||School Grades 6+7|Children currently enrolled in grades 6 and 7
88950044|NCT01942057||School Grades 11+12|Children currently enrolled in grades 11 and 12
88950045|NCT01942070|Experimental|Bioresorbable vascular scaffold|Bioresorbable vascular scaffold (BVS)
88950046|NCT01942070|Active Comparator|Everolimus-eluting stent|Durable polymer everolimus-eluting metallic stent (EES)
88950047|NCT01942083|Experimental|OPB-111077|orally, once daily
88950048|NCT01942096||Competitive swimmers|Swimmers performing at national or international level
88950049|NCT01942096||Competitive indoor athletes|Indoor athletes performing at national or international level
88950050|NCT01942096||Healthy control individuals|Individuals performing sports at a recreational level
89476181|NCT05096273|Active Comparator|ReACT for PNES- Booster therapy sessions|After completing the 12 therapy sessions, half of the participants will be randomized to receive 2 booster therapy sessions, 3 months and 9 months after the 12th ReACT treatment session.
89476182|NCT05096273|Experimental|ReACT for PNES- No Booster therapy sessions|After completing the 12 ReACT treatment sessions, half of the participants will be randomized to not receive the 2 booster therapy sessions.
88950051|NCT01942109|Active Comparator|Furosemide|This group will receive furosemide as a diuretic treatment
88950052|NCT01942109|Experimental|Torasemide|This group will receive torasemide as a diuretic treatment
88950053|NCT01942174|Other|Immediate group|"For these patients, the methotrexate treatment is initiated in the same time that the antipneumococcal vaccination by Prevenar13. A revaccination by Pneumo23/Pneumovax is administred 2 months after the first vaccination.~Interventions : biological/vaccine and drug"
88950054|NCT01942174|Experimental|period group|"Methotrexate treatment is initiated 1 month later the first antipneumococcal vaccination by Prevenar13.~A revaccination by Pneumo23/Pneumovax is administred 2 months after the first vaccination~Interventions : biological/vaccine and drug"
88950055|NCT01942187|Active Comparator|Medication Augmentation|Medication augmentation with aripiprazole (Abilify) starting at 5mg/day, and increasing weekly in 5mg increments to a maximum of 15mg (10mg/day is the target dose). Under conditions of nonresponse after 6 weeks, aripiprazole will be switched for bupropion (Wellbutrin), starting at 150mg, and possibly increasing to 300mg after 2 weeks.
88950056|NCT01942187|Active Comparator|Problem Solving Therapy|Treatment for 12 weeks with weekly sessions of Problem Solving Therapy, with a trained therapist.
88950057|NCT01942200||Carcinoma, Oxaliplatin onkovis (Oxaliplatin)|Treatment in combination therapy for adjuvant treatment of colon carcinoma of stage III (Dukes C) after complete removal of the primary tumor, as well as for treatment of metastasizing colorectal carcinoma.
89476183|NCT05096273|No Intervention|Healthy Control|Healthy controls are matched to participants with PNES based on age (+ or - 1 year), gender, race and family income. Healthy controls and their parent come for 1 baseline laboratory visit and a follow up visit 13 weeks after the baseline visit. These visits will be identical to baseline and follow-up visits of children with PNES.
89476184|NCT05083247|Active Comparator|Arm A|mFOLFIRINOX (oxaliplatin: 85 mg/m2, CPT-11: 165-180 mg/m2, folinic acid: 400mg/m2 and 5FU 2000-2400 mg/m2/46 h) regimen for 8 cycles every 2 weeks; or*Gemcitabine-Nab-P: gem: 1000 mg/m2 weekly 3 w/4; nab-P: 125 mg/m2 3 w/4 for 4 cycles in case of unfit for mFFX).
89476185|NCT05083247|Experimental|Arm B|mFOLFIRINOX for 6 cycles (or for 3 cycles Gemcitabine-Nab-P: gem: 1000 mg/m2 weekly 3 w/4; nab-P: 125 mg/m2 3 w/4 in case of unfit for mFFX) +Isotoxic high-dose SBRT: 5 x 7Gy with Simultaneous Integrated Boost (SIB) up to maximum 55Gy (= 1 week; starting ideally 2 weeks and maximum within 4 weeks after the end of chemotherapy)
88950058|NCT01942213||Subjects receiving Ranibizumab|150 Subjects diagnosed with Neovascular Age-Related Macular Degeneration receiving Ranibizumab 0.5 mg administered by intravitreal injection.
88950059|NCT01942213||Subjects receiving Aflibercept|150 Subjects diagnosed with Age-related Macular Degeneration receiving Aflibercept 2 mg administered by intravitreal injection
88950060|NCT01942239|Active Comparator|CGM-group|CGM-group: the intervention(s) to be administered is Continuous glucose monitoring with real time glycemia each 5 minutes
88950061|NCT01942239|No Intervention|IGM-group|IGM-group: the intervention(s) to be administered is intermittent capillary glucose testing (IGM-group) associated with a blind-CGMS to detect retrospectively missed hypoglycemia
89476186|NCT05076110|Active Comparator|Standard of Care Group|Subjects will receive standard of care pain medication Oxycodone for pain control following hip arthroscopy procedure
89476187|NCT05076110|Experimental|Non-Opiate Pain Control Group|Subjects will receive a non-opiate pain control regime using Ibuprofen, Gabapentin, Acetaminophen, Methocarbamol for pain control following hip arthroscopy procedure.
89476188|NCT05070390|Experimental|Panel A- Moderate RI|Single dose of MK-0616 10 mg
89476189|NCT05070390|Experimental|Panel B- Healthy Controls|Single dose of MK-0616 10 mg
89476190|NCT05069584|Experimental|transperineal biopsy|The strategy evaluated is based on performing targeted and systematized prostate biopsies performed by the transperineal route. Biopsy must be performed as part of the usual treatment for prostate cancer diagnosis.
89476191|NCT05069584|Active Comparator|transrectal biopsy|The comparison strategy is based on performing targeted and systematized prostate biopsies performed by the transrectal route. Biopsy must be performed as part of the usual treatment for prostate cancer diagnosis.
89476192|NCT05063838|Experimental|Pharmacogenomic group|The perioperative (anesthetic and postoperative pain management) plan for each patient will be determined preoperatively by the treating anesthesia team. Thereafter, the pharmacogenomic results of the patient will be released and a personalised anesthetic plan formulated based on international pharmacogenomic guidelines. The treating anesthesia team will then modify the perioperative care plan based on the patients' pharmacogenomic results and the international pharmacogenomic guidelines.
89476193|NCT05063838|No Intervention|Control group|Perioperative care will be managed according to current 'standard care' practice at Peter MacCallum Cancer Centre.
89476194|NCT05048680|Experimental|Hypoxia - Rest|Sessions of intermittent hypoxia at rest; 3 sessions/week; 8 weeks. To be compared with the placebo (normoxia) group at rest.
89476195|NCT05048680|Placebo Comparator|Normoxia - Rest|Sessions of normoxia at rest; 3 sessions/week; 8 weeks.
89476196|NCT05048680|Experimental|Hypoxia - Exercise|Sessions of exercise training under hypoxia; 3 sessions/week; 8 weeks. To be compared with the placebo (exercise under normoxia) group.
89476197|NCT05048680|Active Comparator|Normoxia - Exercise|Sessions of exercise training under hypoxia; 3 sessions/week; 8 weeks.
89476198|NCT05174650|Experimental|Combined treatment with Atezolizumab and Derazantinib|Treatment with Atezolizumab 1200 mg i.v. every 3 weeks and Derazantinib 300 mp p.o. once daily for a maximum of 96 weeks or until disease progression or unacceptable toxicity or study termination
89476199|NCT05020353|Experimental|Investigational Device|Observed self-test of oral fluid with the OraQuick HIV Self-Test
89476200|NCT05006339|Experimental|Dental Monitoring|Orthodontic retention review via dental monitoring only
89476201|NCT05006339|Active Comparator|Clinic Review|Orthodontic retention review via in-office visits as per routine care
89476202|NCT04998357|Experimental|Transplantation|Endovascular infusion
89476203|NCT04986579|Experimental|ERIBULIN WITH PAXMAN SCALP COOLING SYSTEM (PSCS)|"Participants will use Paxman Scalp Cooling System (PSCS) on days 1, 8 and 21 of each of their standard of care (SOC) treatment cycles with Eribulin.~Study cyle is 21 days with total number of cycles based on discretion of treating provider up to 2 years."
88950062|NCT01942291|Experimental|Niacin/Laropiprant|Extended-release niacin 1g/day associated with Laropiprant 1g/20mg (ERN/LRPT, Cordaptive, Merck, Sao Paulo, Brazil)
88950063|NCT01942291|Experimental|Niacin|Extended-release niacin 1g/day alone (ERN, Metri, Libbs Farmaceutica, Sao Paulo, Brazil)
88950064|NCT01942304|Active Comparator|Anorganic bovine bone mineral in direct sinus augmentation|Anorganic bovine bone mineral
88950065|NCT01942304|Experimental|Alloplastic bone putty in direct sinus augmentation|Alloplastic bone putty
88950066|NCT01942317|Experimental|Balneotherapy|16 balneotherapy treatments, each of 45 minutes, twice a week, for 8 consecutive weeks
88950067|NCT01942317|No Intervention|Physiotherapy|16 physiotherapy treatments (no balneotherapy), each of 45 minutes, twice a week, for 8 consecutive weeks
88950068|NCT01942330|No Intervention|Traditional Laparoscopic-Assisted Colectomy|
88950069|NCT01942330|Experimental|Transvaginal Laparoscopic-Assisted Colectomy|Laparoscopic-Assisted Natural Orifice Surgery
89476204|NCT04986579|Active Comparator|ERIBULIN WITHOUT PAXMAN SCALP COOLING SYSTEM (PSCS)|"Participants will not use Paxman Scalp Cooling System (PSCS) during their standard of care (SOC) treatment with Eribulin.~Study cyle is 21 days with total number of cycles based on discretion of treating provider up to 2 years."
88950070|NCT01942343|Active Comparator|Arm 1 : Droperidol 1,25 mg|
88950071|NCT01942343|Active Comparator|Arm 2 : Droperidol 0,625 mg|
89476205|NCT04986579|Experimental|SACITUZUMAB GOVITECAN WITH PAXMAN SCALP COOLING SYSTEM (PSCS)|"Participants will use Paxman Scalp Cooling System (PSCS) on days 1 and 21 of each of their standard of care (SOC) treatment cycles with SACITUZUMAB GOVITECAN.~Study cyle is 21 days with total number of cycles based on discretion of treating provider up to 2 years."
89476206|NCT04986579|Active Comparator|SACITUZUMAB GOVITECAN WITHOUT PAXMAN SCALP COOLING SYSTEM (PSCS)|"Participants will not use Paxman Scalp Cooling System (PSCS) during their standard of care (SOC) treatment with SACITUZUMAB GOVITECAN.~Study cyle is 21 days with total number of cycles based on discretion of treating provider up to 2 years."
88950072|NCT01942343|Active Comparator|Arm 3 : Odansetron 4 mg|
88950073|NCT01942356|Experimental|RL-TIVA Group|Propofol, ketamine and sufentanil administration for a TIVA (total intravenous anesthetic) will be administered using a Harvard 33 syringe pump connected via a RS 232 interface to the study computer running the RL (Reinforcement Learning) control software. This software platform will collect real time vitals and BIS valises and steer the target controlled infusion pumps and the closed loop controllers. The anesthesiologist will provide interventions based on protocol for TIVA - Hypotension, TIVA - Hypertension, TIVA - Bradycardia and TIVA - Tachycardia .
88950074|NCT01942356|Active Comparator|Manual TIVA Group|Manually titrated TIVA (total intravenous anesethetic) with proposal, ketamine and sufentanil will be administered using an Alaris infusion pump titrated by the anesthesiologist based on blood pressure and heart-rate as is traditionally done and is standard of care with intravenous anesthetics. The anesthesiologist will provide interventions based on protocol for TIVA - Hypotension, TIVA - Hypertension, TIVA - Bradycardia and TIVA - Tachycardia .
88950075|NCT01942356|Active Comparator|Inhaled Sevofluorane Group|An inhaled anesthetic with Sevofluorane will be titrated between 0.8-1.5 MAC (minimum alveolar concentration) by the anesthesiologist based on heart rate and blood pressure which is standard of care for inhaled anesthetics. The anesthesiologist will provide interventions based on protocol for INH - Hypotension, INH - Hypertension, INH - Bradycardia and INH - Tachycardia .
88950076|NCT01942369||Deep Infiltrating Endometriosis (DIE)|
88950077|NCT01942382|Experimental|Treatment A|Participants will receive 4 injections of paliperidone palmitate 150 milligram in the deltoid muscle on Days 1, 8, 36, and 64.
88950078|NCT01942382|Experimental|Treatment B|Participants will receive 4 injections of paliperidone palmitate 75 milligram in the deltoid muscle on Days 1, 8, 36, and 64.
88950079|NCT01942382|Experimental|Treatment C|Participants will receive 4 injections of paliperidone palmitate 75 milligram in the gluteal muscle on Days 1, 8, 36, and 64.
89206245|NCT02548416|Active Comparator|PEEP group|Induction and maintenance of anaesthesia in a conventional manner. Peroperative ventilatory settings using positive end-expiratory pressure.
89476207|NCT04986579|Experimental|TRASTUZUMAB DERUXTECAN WITH PAXMAN SCALP COOLING SYSTEM (PSCS)|"Participants will use Paxman Scalp Cooling System (PSCS) on days 1, 8 and 21 of each of their standard of care (SOC) treatment cycles with TRASTUZUMAB DERUXTECAN.~Study cyle is 21 days with total number of cycles based on discretion of treating provider up to 2 years."
89476208|NCT04986579|Active Comparator|TRASTUZUMAB DERUXTECAN WITHOUT PAXMAN SCALP COOLING SYSTEM|"Participants will not use Paxman Scalp Cooling System (PSCS) during their standard of care (SOC) treatment with TRASTUZUMAB DERUXTECAN.~Study cyle is 21 days with total number of cycles based on discretion of treating provider up to 2 years."
89476209|NCT04967703|Experimental|Ultrasound therapy protocol|Patients in group A received ultrasound therapy protocol with the following parameters (1 MHz frequency, intensity of 1.5 W/cm2 and use of continuous mode of ultrasound for 5 minutes).
89476210|NCT04967703|Experimental|Radial shock wave therapy protocol|Patients in group B received radial shock wave therapy protocol with the following parameters: (1) the energy level was 0.12 mJ/mm2 equivalent to 2.5 bar intensity, (2) the number of shoots was 2000, (3) the frequency was 8 Hz.
89020240|NCT05348603|Experimental|Direct to Patient Message + Banner|"An e-mail sent to the patient will inform the patient that there is a message pending in their patient portal regarding opportunities to participate in research AND~Banner-type advertisements during routine viewing and use of of the patient's portal for their our medical/clinical care inform patients of research opportunities."
89020241|NCT05348603|Experimental|Chatbot + Banner|"A real-time, interactive chatbot will encourage research participation and direct patients to learn more about clinical trial opportunities and trials that match their interests; AND~Banner-type advertisements during routine viewing and use of of the patient's portal for their our medical/clinical care will inform patients of research opportunities."
89020242|NCT05348603|Experimental|Traditional Letter + Direct to Patient Message + Chatbot|"A mailed letter will invite the patient to set up a research profile in their patient portal; AND~An e-mail sent to the patient will inform the patient that there is a message pending in their patient portal regarding opportunities to participate in research; AND~A real-time, interactive chatbot will encourage research participation and direct patients to learn more about research opportunities and trials that match their interests."
89476211|NCT04967703|Experimental|Combined therapy protocol|Patients in group C received a combination of both ultrasound therapy and radial shock wave therapy protocol.
89476212|NCT04967222|Experimental|Cognitive Reappraisal-by-Distancing (CRD)|Subjects will be coached to use cognitive reappraisal-by-distancing to downregulate their negative reactions to aversive emotional pictures usng practice pictures.
89476213|NCT04967222|Active Comparator|Control Downregulate Condition (CD)|Subjects will be coached to practice their customary emotion regulatory techniques in a treatment occurring twice a week for 6 weeks.
89476214|NCT04954391|Active Comparator|PRF one nerve|Ultrasound guided PRF neuromodulation of suprascapular nerve and block axillary nerve, and articular branch of the lateral pectoral nerve with ropivacaine and dexamethasone
89476215|NCT04954391|Active Comparator|PRF three nerves|Ultrasound guided PRF neuromodulation of suprascapular, axillary nerves, and articular branch of the lateral pectoral nerve
89476216|NCT04951687|Experimental|Active: Ecologic Barrier©|"Dietary supplement: Ecologic Barrier©~Ingredients: maize starch, maltodextrin, vegetable protein, potassium chloride, magnesium sulphate, manganese sulphate, and probiotic bacteria (B. bifidum W23, B. lactis W51, B. lactis W52, L. acidophilus W37, L. brevis W63, L. casei W56, L. salivarius W24, Lc. lactis W19, Lc. lactis W58).~Subjects will consume 2g (5 billion CFU)/day of Ecologic Barrier©. The intervention is a powder which is sealed in sachets and an be stored at room temperature by participants. Subjects are to mix into warm water and drinking alongside a meal."
89476217|NCT04951687|Placebo Comparator|Placebo|"Dietary supplement: placebo powder~Ingredients: maize starch, maltodextrin, vegetable protein, potassium chloride, magnesium sulphate, manganese sulphate.~As with the active treatment, the intervention is a powder which is sealed in sachets and an be stored at room temperature by participants. Subjects are to mix into warm water and drinking alongside a meal."
89476218|NCT04939441|Experimental|TAF group|TAF [Vemlidy® 25mg QD] monotherapy
89476219|NCT04937738|Active Comparator|XELOX|Oxaliplatin 130 mg/m2, d1 Capecitabine 1000 mg/m² two times per day (BID), d1-14, every 3 weeks (q3w) 4 cycles (12 weeks) pre-OP and 3 cycles (12 weeks) post-OP
89476220|NCT04937738|Experimental|FLOT|Docetaxel 50mg/m2, d1 5-FU 2600 mg/m², d1 Leucovorin 200 mg/m², d1 Oxaliplatin 85 mg/m², d1 every two weeks (q2w) 4 cycles (8 weeks) pre-OP and 4 cycles (8 weeks) post-OP
89476221|NCT04890925|No Intervention|Control group|Women who have experienced intimate partner violence but no sustained brain injury (Brain Injury Severity Assessment; BISA = 0)
89476222|NCT04890925|Experimental|Community Support Network (CSN) intervention group|The SOAR Community Support Network (CSN) intervention includes cognitive training, aerobic exercise, mindfulness meditation, counselling, quality of life tracking.
89476223|NCT04890925|Active Comparator|Usual care|Participants in this group will receive dose-equivalent usual care
89476224|NCT04884178|Experimental|Trifocal Preloaded IOL Delivery System|Bilateral trifocal IOLs implanted through preloaded IOL Delivery System in the capsular bag in the posterior chamber of the eye during cataract surgery
89476225|NCT04868968|Experimental|DFV890|DFV890
89020243|NCT05348603|Experimental|Traditional Letter + Direct to Patient Message + Banner|"A mailed letter will invite the patient to set up a research profile in their patient portal; AND~An e-mail sent to the patient will inform the patient that there is a message pending in their patient portal regarding opportunities to participate in research; AND~Banner-type advertisements during routine viewing and use of of the patient's portal for their our medical/clinical care inform patients of research opportunities."
89020244|NCT05348603|Experimental|Traditional Letter + Chatbot + Banner|"A mailed letter will invite the patient to set up a research profile in their patient portal; AND~A real-time, interactive chatbot will encourage research participation and direct patients to learn more about research opportunities and trials that match their interests.~AND~*Banner-type advertisements during routine viewing and use of of the patient's portal for their our medical/clinical care inform patients of research opportunities."
89476226|NCT04860505|Experimental|Doxycycline and Biktarvy|Participants will take both study drugs simultaneously at home approximately 1 hour before Visit 2 and will be instructed to take a timestamped photograph or videotape of themselves taking the dose.
89020245|NCT05348603|Experimental|Direct to Patient Message + Chatbot + Banner|"An e-mail sent to the patient will inform the patient that there is a message pending in their patient portal regarding opportunities to participate in research; AND~A real-time, interactive chatbot will encourage research participation and direct patients to learn more about research opportunities and trials that match their interests; AND~Banner-type advertisements during routine viewing and use of of the patient's portal for their our medical/clinical care inform patients of research opportunities."
89020246|NCT05348603|Experimental|Traditional Letter + Direct to Patient Message + Chatbot + Banner|"A mailed letter will invite the patient to set up a research profile in their patient portal; AND~An e-mail sent to the patient will inform the patient that there is a message pending in their patient portal regarding opportunities to participate in research; AND~A real-time, interactive chatbot will encourage research participation and direct patients to learn more about research opportunities and trials that match their interests; AND~Banner-type advertisements during routine viewing and use of of the patient's portal for their our medical/clinical care inform patients of research opportunities."
89020247|NCT05340790|Experimental|Antimicrobial Peptide PL-18 Vaginal Suppositories|Dose 1 to 5 of Antimicrobial Peptide PL-18 Vaginal Suppositories
89020248|NCT05340790|Placebo Comparator|Placebo dose|Placebo dose 1 to 5 of Antimicrobial Peptide PL-18 Vaginal Suppositories
89020249|NCT05323630|Other|Procedure with the Renuvion APR System in the labia|The labia procedure utilizing the Renuvion APR system will be performed per the investigator's standard clinical practice.
89020250|NCT05323474|Experimental|Standard rehabilitation|Classical rehabilitation carried out by a physiotherapist with an evaluation at 6 months post-surgery to authorize the return to sport.
89020251|NCT05323474|Active Comparator|Optimized rehabilitation|Classical rehabilitation carried out by a physiotherapist + expert physiotherapist performing monthly clinical and functional assessments with recommendations for exercises and running program sent to the physiotherapist.
89476227|NCT04840680||Participants With MM|Participants with MM who are newly prescribed and will start treatment with ixazomib citrate in a real-world clinical practice setting will be observed prospectively for up to 6 years 11 months.
89476228|NCT04836858|Experimental|CMK389 high dose|Active
89476229|NCT04836858|Placebo Comparator|Placebo high dose|Placebo
89476230|NCT04836858|Experimental|CMK389 low dose|Active
89476231|NCT04836858|Placebo Comparator|Placebo low dose|Placebo
89476232|NCT04809870||LC (liver cirrhotic patients)|Patients with concomitant liver cirrhosis
89476233|NCT04809870||Non-LC (non liver cirrhotic patients)|Patients without concomitant liver cirrhosis
89476234|NCT04809792|Experimental|Head and neck cancer|In this arm patients with head and neck cancers treated with SBRT are recruited.
89476235|NCT04800341||Patients ESADA follow-up|Patients included in the ESADA European database and contacted by phone for the collection of cardiovascular and metabolic events, incident cancers and deaths, through a structured questionnaire.
89476236|NCT04784390|Active Comparator|Patching|Patching of the sound eye (fellow eye) - patients will have their sound eye (fellow eye) patched 2 hours per day 7 days a week for 16 weeks.
89476237|NCT04784390|Experimental|Binocular video games|Binocular video games - patients will play 1 hour of binocular video game of choice (Dig Rush and/or Monster Burner) a day 7 days a week for 8 to 12 weeks.
89476238|NCT04742465|Experimental|Augmented reality|"Augmented reality technological assistance for the movements of people with Alzheimer's disease or MCI in a controlled environment.~The ARIADE project will take place in a controlled and reproducible ecological environment (Ker Lann gymnasium) and will aim at assessing the effectiveness of Augmented Reality assistance, that of the devices for detecting wandering, the safety of the patient when traveling with an Augmented Reality headset, and his acceptance of the device.~Three routes each comprising seven intersections, i.e. a location requiring a decision on navigation, will allow us in 20 patients to objectively compare the three different visual aids offered in augmented reality, i.e. arrows, light path, animated companion."
89476239|NCT04724018|Experimental|Dose Escalation Sacituzumab Govitecan (SG) and Enfortumab vedotin-ejfv (EV),|Participants will be given the study drugs Enfortumab Vedotin and then Sacituzumab Govitecan on Days 1 and 8 of a 21-day study cycle. Dose escalation and de-escalation for the Sacituzumab Govitecan (SG) and Enfortumab vedotin-ejfv (EV) combination will be guided using the Bayesian optimal interval (BOIN) design with up to 4 dose level escalations.
88950080|NCT01942395|Active Comparator|DASH/Sodium-Restricted Diet Intervention|Each patient will eat 3 weeks of the provided DASH/SRD diet for 21 days. The diet is patterned after the intervention in the DASH-Sodium trial (Sacks FM et al. New Engl J Med 2001;344(1):3-10). The diet is designed, prepared, and packaged by research dietitians and all food and beverages are provided for study participants. At enrollment patients will be randomized to the DASH/SRD or Control Diet for 21 days and then cross over to the other for 21 days. Immediately following the provided DASH/SRD and Control Diet, patients will be instructed to adhere to the DASH/SRD for an additional eight weeks with dietary support.
89476240|NCT04719910|Experimental|Study group|The study group will watch 15 minute long videos of cooking and preparing the food of the patient's preferred type of food prior to be taken to the operating room.
89476241|NCT04719910|Placebo Comparator|Placebo group|The control group will watch 15 minute long non-food related videos.
89476242|NCT04713592|Experimental|Risankizumab|Participants will receive risankizumab for 52 weeks
89476243|NCT04713592|Placebo Comparator|Placebo|Participants will receive placebo for 16 weeks followed by risankizumab for 36 weeks.
89476244|NCT04704401||Patients PWV follow-up|"Patients included in the meta-analysis sleep apnea syndrome and arterial stiffness and contacted by phone for the collection of cardiovascular and metabolic events, incident cancers and deaths, through a structured questionnaire."
89476245|NCT04687176|Experimental|Oral arsenic trioxide, all-trans-retinoic acid, ascorbic acid (AAA)|"Induction: Oral arsenic trioxide 10mg daily (0.16mg/kg/day in patients < 18 years-old, all-trans retinoic acid (ATRA) [45mg/m^2 (25mg/m^2 per day in patients < 18 years-old) in 2 divided doses) and ascorbic acid 1g daily (15mg/kg/day in patients < 18 years-old) for 42 days Consolidation: Oral arsenic trioxide daily, ATRA, and ascorbic acid daily for 14 days every 28 days for 2 cycles.~Maintenance: Oral arsenic trioxide, ATRA and ascorbic acid daily for 2 weeks every 8 weeks for a total of 2 years (i.e. for 12 cycles in total)."
89476246|NCT04676815||NBI PATIENT|Diagnostic Test: NBI in combination with electronic bronchoscope
89476247|NCT04676815||Non-NBI PATIENT|Diagnostic Test: Electronic bronchoscope without NBI
89476248|NCT04667065|Other|Physical activity with smartwatch before bronchial cancer surgery|
89476249|NCT04653831|Other|Standard of Care - Control|Standard of care (Soc) according to current guidelines and the discretion of treating physician.
89476250|NCT04653831|Experimental|Pirfenidone Treatment|"In addition to SoC, Pirfenidone 2,403 mg administered orally or per nasogastric tube as 801mg TID, for 4 weeks.~Pirfenidone dose will be 2,403mg daily, from day one of admission to the ICU, titrated over 3 days:~Day 1 - 801mg x 1/d (801mg) Day 2 - 801mg x 2/d (1,602 mg) Day 3 - 801mg x 3/d (2,403 mg) Feeding and medication delivery will be upon the discretion of the treating physician according to tolerability. Powdered 801mg tablets will be administered through the nasogastric tube: Each tablet will be crushed and dissolved in 20cc of water. The nasogastric tube will be flushed afterwards to avoid obstruction..~If the patient is able to swallow and the nasogastric tube is removed, pirfenidone will continue to be delivered orally."
89476251|NCT04635800|Experimental|Cohort 1|Cohort 1; open-label, non-randomized, single administration
89476252|NCT04635800|Experimental|Cohort 2|Cohort 2; open-label, non-randomized, single administration
89476253|NCT04635800|Experimental|Cohort 3|Cohort 3, open-label; non-randomized, single administration
89476254|NCT04635800|Experimental|Cohort 4|Cohort 4, open-label, non-randomized, single administration
89476255|NCT04597632|Experimental|brolucizumab 6 mg|Participants will receive brolucizumab 6 mg/0.05 mL solution by intravitreal injection in a Treat-to-Control regimen with injection intervals from 4 up to 20 weeks. Intervals may be changed in steps of 4 weeks at a time per investigators' decisions determined by the disease activity.
89476256|NCT04579198|Experimental|Families receiving intervention|
89476257|NCT04517500|Experimental|Home-base pulmonary rehabilitation with mindful breathing modu|Subjects will complete in a home-based pulmonary rehabilitation program and in addition will complete a mindful breathing practice using a module on a computer tablet.
89476258|NCT04517500|Active Comparator|Home-base pulmonary rehabilitation|Subjects will complete 12 week home-based pulmonary rehabilitation with health coaching
89476259|NCT04512638|Active Comparator|Conservative treatment|Amoxicillin-based antibiotics and chlorhexidine oral rinse. Minor debridement. Primary wound closure is not part of this treatment strategy.
89476260|NCT04512638|Experimental|Minimally invasive approach + LPRF|Amoxicillin-based antibiotics and chlorhexidine oral rinse. Minimally-invasive surgical treatment, including sequestrectomy, debridement of soft tissue, and application of LPRF membranes before tension-free wound closure is obtained. Marginal resection of all necrotic bone is not part of this treatment strategy.
89020252|NCT05321563|No Intervention|Observation Phase|Schools will continue to apply their standard disciplinary response to school-based substance use infractions during the 'unexposed' study period.
89476261|NCT04512638|Experimental|Primary surgical management|Amoxicillin-based antibiotics and chlorhexidine oral rinse. Removal of the necrotic bone without excessive resection of healthy bone. Buccal mucoperiosteal flaps will be used to achieve a tension-free mucosal coverage.
89476262|NCT04510428|Experimental|OSIG-Eye Drop|Ocular Surface Immune Globulin (OSIG) eye drops 4 mg/ml (0.4%) four times a day for 8 weeks
89476263|NCT04510428|Placebo Comparator|Placebo-Eye Drop|Normal Saline Eye Drops (0.9% NaCl) four times a day for 8 weeks
89476264|NCT04485416|Experimental|Treatment group|Subjects will receive eltrombopag
89476265|NCT04473599|Active Comparator|Uniform Random|Participants will receive supportive text-messages for a period of 2 months. These text-messages have two categories: behavioral activation (BA) and coping skills. In this arm, participants will receive one of these types of messages daily on a random schedule in random time periods throughout the day.
88821620|NCT03277105|Active Comparator|Dara IV|Participants will receive daratumumab for intravenous infusion (Dara IV) 16 mg/kg once weekly in Cycle 1 and 2, every 2 weeks in Cycle 3 to 6, every 4 weeks on Day 1 in Cycle 7 and thereafter until disease progression, unacceptable toxicity or the end of study. The duration for each cycle is 4 weeks. For Participants still receiving treatment with Dara-IV at the time of Protocol Amendment 4 the duration of infusion may be shortened to a 90-minute infusion or participants will have the option to switch to Dara 1800 mg subcutaneous (SC) on Day 1 of any cycle, at the discretion of the investigator.
89476266|NCT04473599|Experimental|Reinforcement Learning|In this arm we will test a reinforcement learning (RL) algorithm with a learned decision mechanism for the timing and type of text-messages. The algorithm learns from previous data (which messages were sent, what was the participants' mood) to maximize an increase in participants' mood.
89476267|NCT04473599|Active Comparator|Mood ratings only|In this arm, participants will monitor their mood and receive random feedback based on mood responses.
89476268|NCT04437303|Active Comparator|Continuation of oral anticoagulants|
89476269|NCT04437303|Active Comparator|Interruption of oral anticoagulants|
89476270|NCT04431063|Experimental|Sutured Stump|The group consist of subject with distal stump suturing of perobeus longus agains peroneus brevis in ACL Reconstruction Case
89476271|NCT04431063|No Intervention|Unsutured Stump|The group consist of subject without distal stump suturing of peroneus longus agains peroneus brevis in ACL Reconstruction Case
89476272|NCT04420728|Experimental|Early auto-mode enabled|Auto mode continuous glucose monitoring enabled 2-10 days post-partum
89476273|NCT04420728|Active Comparator|Delayed auto mode enabled|Auto mode continuous glucose monitoring enabled 12 weeks post-partum
89476274|NCT04411693|Active Comparator|Group A: Intravitreal Dexamethasone Implant|Subjects in this arm will be given intravitreal Dexamethasone implant injection at month 0. PRN intravitreal Dexamethasone implant injections will be given for persistent edema, if it has been 10 weeks or more since last implant injection. If it has been less than 10 weeks since last implant injection, subjects will receive PRN intravitreal Aflibercept for persistent edema.
89476275|NCT04411693|Active Comparator|Group B: Intravitreal Aflibercept|Subjects in this arm will be given Intravitreal aflibercept at month 0. PRN intravitreal Aflibercept will be given at months 1-6 for persistent edema.
89476276|NCT04399967|Experimental|Intervention Group|Chat-based support+ COVID-19 specific advice + AWARD advice + COVID-related health warning leaflet + referral card + COSH booklet
89476277|NCT04399967|Experimental|Control Group|Text-based support + AWARD advice + warning leaflet + referral card + COSH booklet
89476278|NCT04380740|Placebo Comparator|Standard GVHD Prophylaxis + Abatacept + Placebo|Standard GVHD prophylaxis of calcineurin inhibitor (cyclosporine or tacrolimus) and methotrexate + 4 doses of Abatacept (investigational product) + 4 doses of Placebo.
89476279|NCT04380740|Experimental|Standard GVHD Prophylaxis + Abatacept Extended dosing|Standard GVHD prophylaxis of calcineurin inhibitor (cyclosporine or tacrolimus) and methotrexate + 8 doses of Abatacept.
89476280|NCT04377100||Adults 18 and over|Adults 18 and over
89476281|NCT04360460|Experimental|Experimental|Virtual reality followed by translation into related functional tasks in a real life setting for 2 weeks + conventional therapies
89476282|NCT04360460|Active Comparator|Control|Virtual reality followed by translation into non-related functional tasks in a real life setting for 2 weeks + conventional therapies
89476283|NCT04274335|Experimental|Intravenous tranexamic acid|
89476284|NCT04274335|Experimental|Intramuscular tranexamic acid|
89476285|NCT04274335|Experimental|Oral liquid tranexamic acid|
89476286|NCT04274335|No Intervention|No tranexamic acid|
89476287|NCT04252950|Experimental|CB-SET Treatment|Participants randomized to this group will receive a community-based structured exercise therapy (CB-SET) along with the standard of care (revascularization)
89476288|NCT04252950|Active Comparator|Control|Participants randomized to this group will receive standard of care (revascularization)
89476289|NCT04248283|Experimental|Adjustable Continence Therapy for Women|Implantation of the Adjustable Continence Therapy for the treatment of female SUI.
89476290|NCT04238767||HIV-1-positive individuals|HIV-1-positive individuals eligible to receive a DTG-based ART regimen at enrolment.
89476291|NCT04235972|Other|Arthrodesis surgery patients|A follow-up consultation is organized which includes: A clinical examination with standard data collection as well as a face and profile radiograph of the operated wrist.
89476292|NCT04207203|Other|Single arm study|During 3 weeks, SZC will be prescribed to normalize plasma potassium to 3.5 to 5.0 mml/L, and a diet with energy 25-35 kcal/kg/day and protein 0.6 to 0.8 g/kg/day and with low K content will be prescribed. At the end of the first 3 weeks, the patients will initiate a healthy diet containing 3700 to 4000 mg/potassium for 3 weeks (healthy diet phase). A food basket containing fruits, vegetables, whole grains, nuts, white meat, fish and eggs in amounts adequate for the patient will be provided. Serum K will be monitored to promote serum K between 3.5 to 5.0 mmol/L and adjustments in the dose of SZC will be performed according to the drug label. During stabilization and healthy diet phases, serum K will be measured every 72 hours until serum K is normalized and after that, once per week.
88950081|NCT01942395|Active Comparator|Control Diet Intervention|Patients will consume 3 weeks of a specially prepared diet that will be patterned on the information we collected using Food Frequency Questionnaires during our pilot study. The diet is designed, prepared, and packaged by research dietitians and all food and beverages are provided for study participants. At enrollment patients will be randomized to the DASH/SRD or Control Diet for 21 days and then cross over to the other for 21 days. Immediately following the provided DASH/SRD and Control Diet, patients will be instructed to adhere to the DASH/SRD for an additional eight weeks with dietary support.
88950082|NCT01942395|No Intervention|Healthy Control|Fifteen healthy age-matched and 10 young healthy control patients will be recruited. Age-matched healthy control subjects will undergo testing before and after 3 weeks of eating their habitual diet. Young healthy control subjects will only require 1 study visit with no dietary intervention.
88950083|NCT01942408|No Intervention|Standard care group|Patients will undergo an initial PVI procedure. Further management will be determined by AF recurrences at the responsible Consultant's discretion as per standard care.
88950084|NCT01942408|Active Comparator|Repeat study group|Following an initial PVI procedure, all patients (regardless of early AF recurrence) will undergo a repeat electrophysiology (EP) study at 8-10 weeks post-initial PVI, with repeat PVI of any PV reconnection identified
88950085|NCT01942421|Experimental|Cultivated mucosal epithelial transplant|Cultivated mucosal epithelial transplantaion to limbal deficiency patients
89476293|NCT04206735|Experimental|Interprofessional Education (IPE)|Each hospital needs to assign a 'COPD-NIV' team of champions to lead the implementation strategy at the local level. We will provide virtual or in-person (if safety permits) training for the COPD-NIV teams (one RT, one RN, and one MD). The training will consist of NIV knowledge and skills through the principles of IPE and teamwork. We will use the train the trainer method; after we train the COPD-NIV team champions, the champions will promote and hold training sessions for their peers in person (if safety permits, 2-3 times a month for 4 months). At present, we are providing these training sessions as prerecorded content available whenever the clinician is available. Champions will promote the training to their clinicians for the first 4 months and then at 6 and 12 months for new staff.
89476294|NCT04203004|Experimental|HOPE-CytoSorb|Patients transplanted with livers preserved by HOPE with cytokine filtration by CytoSorb, a CE approved medical device for extracorporeal cytokine removal
89476295|NCT04203004|No Intervention|HOPE-standard|Patients transplanted with livers preserved by HOPE without cytokine filtration
89476296|NCT04200872||biological adjuvants|patients with aseptic pseudarthrosis clinically treated with biological adjuvants
89476297|NCT04200872||without biological adjuvants|patients with aseptic pseudarthrosis clinically treated without biological adjuvants
89476298|NCT04180059|Experimental|CTL 19 : T cell therapy|Level 1: 1 x 104 cells/kg of recipient, Level 2: 5 x 104 cells/kg, Level 3: 25 x 104 cells/kg, Level 4: 50 x 104 cells/kg, Level 5: 100 x 104 cells/kg.
89476299|NCT04177355|Experimental|Part A, Group 1 (T1): BG505 SOSIP.664 gp140 + 3M-052-AF + Alum|Participants will receive 100 mcg of BG505 SOSIP.664 gp140, admixed with 1 mcg of 3M-052-AF and 500 mcg of Aluminum Hydroxide Suspension (Alum), as one intramuscular (IM) injection at Months 0 and 2.
89476300|NCT04177355|Placebo Comparator|Part A, Group 1 (P1): Placebo|Participants will receive placebo as one IM injection at Months 0 and 2.
89476301|NCT04177355|Experimental|Part A, Group 2 (T2): BG505 SOSIP.664 gp140 + 3M-052-AF + Alum|Participants will receive 100 mcg of BG505 SOSIP.664 gp140, admixed with 5 mcg of 3M-052-AF and 500 mcg of Alum, as one IM injection at Months 0 and 2.
89476302|NCT04177355|Placebo Comparator|Part A, Group 2 (P2): Placebo|Participants will receive placebo as one IM injection at Months 0 and 2.
89476303|NCT04177355|Experimental|Part B, Group 3 (T3): BG505 SOSIP.664 gp140 + CpG 1018 + Alum|Participants will receive 100 mcg of BG505 SOSIP.664 gp140, admixed with 300 mcg of CpG 1018 and 500 mcg of Alum, as one IM injection at Months 0, 2, and 6.
89476304|NCT04177355|Placebo Comparator|Part B, Group 3 (P3): Placebo|Participants will receive placebo as one IM injection at Months 0, 2, and 6.
89476305|NCT04177355|Experimental|Part B, Group 4 (T4): BG505 SOSIP.664 gp140 + 3M-052-AF + Alum|Participants will receive 100 mcg of BG505 SOSIP.664 gp140, admixed with either 1 mcg or 5 mcg of 3M-052-AF (the highest tolerated dose from Part A), and 500 mcg of Alum, as one IM injection at Months 0, 2, and 6.
89476306|NCT04177355|Placebo Comparator|Group 4 (P4): Placebo|Participants will receive placebo as one IM injection at Months 0, 2, and 6.
89476307|NCT04177355|Experimental|Part B, Group 5 (T5): BG505 SOSIP.664 gp140 + GLA-LSQ|Participants will receive 100 mcg of BG505 SOSIP.664 gp140, admixed with GLA-LSQ (GLA 5 mcg, and QS-21 2 mcg), as one IM injection at Months 0, 2, and 6.
89476308|NCT04177355|Placebo Comparator|Part B, Group 5 (P5): Placebo|Participants will receive placebo as one IM injection at Months 0, 2, and 6.
89476309|NCT04177355|Experimental|Part B, Group 6 (T6): BG505 SOSIP.664 gp140 + Alum|Participants will receive 100 mcg of BG505 SOSIP.664 gp140, admixed with 500 mcg of Alum, administered as one IM injection at Months 0, 2, and 6.
89476310|NCT04177355|Placebo Comparator|Part B, Group 6 (P6): Placebo|Participants will receive placebo as one IM injection at Months 0, 2, and 6.
89476311|NCT04177355|Experimental|Part C, Group 7 (T7): BG505 SOSIP.664 gp140 + Alum|Participants will receive BG505 SOSIP.664 gp140, 100 mcg admixed with 3M-052-AF, 3 mcg and Alum, 500 mcg to be administered as one 0.5-mL dose intramuscularly (IM) at months 0, 2, and 6.
89476312|NCT04177355|Placebo Comparator|Part C, Group 7 (P7): Placebo|Participants will receive placebo as one IM injection at Months 0, 2, and 6.
89476313|NCT04177355|Experimental|Part C, Group 8 (T8): Trimer 4571 + Alum|Participants will receive Trimer 4571, 100 mcg admixed with 3M-052-AF, 5 mcg and Alum, 500 mcg to be administered as one 0.5-mL dose IM at months 0, 2, and 6.
89476314|NCT04177355|Placebo Comparator|Part C, Group 8 (P8): Placebo|Participants will receive placebo as one IM injection at Months 0, 2, and 6.
89476315|NCT04166110|Active Comparator|Physician's prescription|Antibiotic treatment duration according to physician, following the French national guidelines: 7 to 14 days.
89476316|NCT04166110|Experimental|Duration according to stability|"Antibiotic treatment duration is variable. Interruption of treatment is based on the patient reaching stability criteria (body temperature ≤ 37.8°C; heart rate ≤ 100/min; systolic blood pressure ≥ 90mmHg, oxygen saturation ≥ 90%).~Minimum of duration of antibiotic treatment: 3 days."
89476317|NCT04154514|Experimental|Delivering FES to stroke survivors|"In stroke survivors, normal and abnormal muscle synergies will also be determined from their walk EMGs. Our proposed FES intervention involves delivering stimulations to muscles with waveforms generated from the activations of all the normal synergies not observed in each stroke survivor. We are going to employ the wearable to deliver personalized muscle-synergy-based FES stimulations to multiple groups of leg muscles on the stroke-affected side of elderly chronic stroke survivors as they walk on a treadmill/overground for gait rehabilitation. We hypothesized that the subject will essentially be walking with his/her abnormal muscle pattern superimposed with the artificially introduced normal muscle pattern coming from FES."
89476318|NCT04154514|Experimental|Delivery no current FES to stroke survivors (Sham group)|In stroke survivors, normal and abnormal muscle synergies will also be determined from their walk EMGs. Our proposed FES intervention involves delivering stimulations to muscles with waveforms generated from the activations of all the normal synergies not observed in each stroke survivor. Additionally, we are going to introduce a sham group. We are going to employ the wearable to multiple groups of leg muscles on the stroke-affected side of elderly chronic stroke survivors without any stimulation as they walk on a treadmill or overground for gait rehabilitation. The purpose of the sham group is to empirically validate the effectiveness of the FES wearable.
89476319|NCT04125277|Experimental|Imaging|One visit to either the UMCG or Amsterdam UMC-location VUMC is required for the FES-PET scan, and possibly one additional visit for an FDG-PET. A FES- or FDG-PET scan plus low dose CT will each induce an extra radiation burden of about 6.1 mSv (210 MBq injected for an average patient of 70 kilogram body weight).
89476320|NCT04063865|Active Comparator|Control Arm|Tacrolimus as maintenance immunosuppression
89476321|NCT04063865|Experimental|Study Arm|Everolimus monotherapy maintenance immunosuppression
89476322|NCT04053764|Experimental|crizanlizumab + standard of care|5 mg/kg by intravenous (i.v.) infusion at Week 1 Day 1, Week 3 Day 1 and Day 1 of every 4-week cycle until Week 51 in addition to their usual standard of care treatment.
89476323|NCT04053764|Active Comparator|standard of care|Patients in the standard of care alone arm will continue to receive their usual standard of care treatment.
89476324|NCT04046562|Active Comparator|PAW plus standard of care|Each PAW session will include handouts and worksheets to assist with new strategies as well as homework. Strategies taught within PAW will be integrated with the skills taught in weight management. For example, pain diaries will be kept along with food and exercise logs to examine relationships among pain, eating and activity.
89476325|NCT04046562|Placebo Comparator|Pain education plus standard of care|For those randomized into the information-only group, sessions will be delivered in the same manner. Sessions will cover general pediatric pain management but no behavioral or cognitive skills training will be taught.
89476326|NCT04001205||No oral anticoagulation|Patients without oral anticoagulation for AF
89476327|NCT04001205||Oral anticoagulation|Patients with long term oral anticoagulation
89476328|NCT03994211|Experimental|Part A (core phase)|60 mg pamiparib administered orally on Days 1 and 10 fasting 8 hours pre-dose 600 mg rifampin once a day from days 3 to 11 in the fasted state (at least 2 hours predose)
89476329|NCT03994211|Experimental|Part B (core phase)|Single dose of 20 mg pamiparib orally in the fasted state (at least 8 hours predose) on days 1 and 7 200 mg itraconazole once a day approximately 30 minutes after completing a meal Day 3 to day 8
89476330|NCT03994211|Experimental|Extension phase|60 mg pamiparib orally twice a day in 28-day cycles until progression of disease
89476331|NCT03916562|Experimental|Healthy Participants|The investigators will determine how asymmetric walking constraints influence spatiotemporal coordination, energetic cost, and dynamic balance in healthy individuals. The investigators will manipulate spatiotemporal coordination using a special treadmill. Energetic cost will be quantified using expired gas analysis and inverse dynamic approaches. Stability will be evaluated by characterizing participants' ability to recover from unexpected perturbations.
89476332|NCT03916562|Experimental|Post-stroke Participants|The investigators will determine how different patterns of coordination during walking influence energetic cost and dynamic balance in people post-stroke. The investigators will manipulate coordination using a special treadmill. Energetic cost will be quantified using expired gas analysis and inverse dynamic approaches. Stability will be evaluated by characterizing participants' ability to recover from unexpected perturbations.
89531892|NCT04914793|No Intervention|Reference phase|"At the start (month 0), a point prevalence surveys (PPS) on hospital antimicrobial use are performed (more details on conduct of PPS are given in following section) to collect baseline data before introducing paper-based guidelines.~All medical doctors of each participating hospital are asked to complete an AMS knowledge survey and pre-prescribing guidelines survey after PPS is conducted. Then, paper-based prescribing guidelines in both adult and paediatric versions (one adult guideline and one paediatric guideline) are distributed to all doctors at participating hospitals, followed by guideline introductory session of the guidelines. After introduction of the paper-based guidelines, all six hospitals are formally included in the reference period."
88950086|NCT01942447|Experimental|FMT|FMT
88950087|NCT01942447|Active Comparator|Standard|Vancomycin
88950088|NCT01942460|Experimental|Ferumoxytol|
89476333|NCT03910660|Other|Phase 1b|"Patients will be observed for dose-limiting toxicity (DLT) during Cycle 1. 3 patients will be treated initially with 0.4 mg BXCL701 plus PEMBRO:~If there are no DLTs, the dose of BXCL701 will be escalated to 0.6 mg in the next cohort.~If ≥1/3 of patients has a DLT in Cycle 1, either 3 patients (if 1 experience a DLT) or 6 to 9 patients (if 2 or 3 experiences a DLT) will be added at the 0.4 mg dose.~At the 0.4mg dose:~If <1/3 of the patients experience a DLT, consideration will be given to dose to 0.6 mg BXCL701 plus PEMBRO.~If 1/3 of the patients experience a DLT, the Phase 2a can commence. If >1/3 of the patients experience a DLT, a discussion will be held as to how to proceed.~Following 0.6 mg dose. If there are no DLTs, the Phase 2a can commence. If ≥1/3 patients have a DLT in Cycle 1, after a discussion, 6 to 9 patients will be added at the 0.6 mg dose.~For this cohort of 6 to 9 patients:~If </=1/3 of the patients experience a DLT, the Phase 2a can commence"
89476334|NCT03910660|Other|Phase 2a|After assessment of the safety and confirmation of the BXCL701/+PEMBRO dose schedule to be used in the subsequent stage, the Phase 2a will begin. Eligible patients will receive BXCL701 QD on Days 1 to 14 of a 21-day cycle plus PEMBRO 200 mg administered IV on Day 1 every 21 days.
89476335|NCT03910660|Other|Phase 2b combination|"Upon completion of the Phase 2a and achievement of the protocol required composite responses for a given histologic subtype, the Phase 2b enrollment will begin for that subtype. Eligible patients will be randomized to receive:~• Combination therapy of BXCL701 on Days 1 to 14 of a 21-day cycle plus PEMBRO 200 mg administered IV on Day 1 of every 21 days."
89476336|NCT03910660|Other|Phase 2b monotherapy|"Upon completion of the Phase 2a and achievement of the protocol required composite responses for a given histologic subtype, the Phase 2b enrollment will begin for that subtype. Eligible patients will be randomized to receive:~Monotherapy BXCL701 on Days 1 to 14 of a 21-day cycle. Upon radiographic disease progression with monotherapy, crossover to combination treatment is allowed."
89476337|NCT03837756|Placebo Comparator|Arm A: Placebo/Placebo|This arm will receive placebo (sterile saline) for both Lefitolimod and 3BNC117 + 10-1074.
89476338|NCT03837756|Active Comparator|Arm B: Lefitolimod/Placebo|This arm will receive Lefitolimod and placebo (sterile saline) for 3BNC117 + 10-1074.
89476339|NCT03837756|Active Comparator|Arm C: Placebo/3BNC117 + 10-1074|This arm will receive 3BNC117 + 10-1074 and placebo (sterile saline) for Lefitolimod.
89476340|NCT03837756|Active Comparator|Arm D: Lefitolimod/3BNC117 + 10-1074|This arm will receive both Lefitolimod and 3BNC117 + 10-1074.
89476341|NCT03829644|Experimental|Intervention|Participants in the intervention arm will be fitted with a semi-rigid prefabricated lumbar brace (Horizon 627 Lumbar Brace, Aspen Medical Company, Oak Canyon, Irvine, CA 92618) in addition to their current back pain management program.
89476342|NCT03829644|No Intervention|Control|Participants in this arm will be instructed to follow their current back pain management program.
89476343|NCT03818607|Other|T (ABP 959) / R (eculizumab)|ABP 959 for 52 weeks in Period 1 followed by eculizumab for 26 weeks in Period 2
89476344|NCT03818607|Other|R (eculizumab) / T (ABP 959)|Eculizumab for 52 weeks in Period 1 followed by ABP 959 for 26 weeks in Period 2
89206246|NCT02548416|Active Comparator|Control group zero PEEP|Induction and maintenance of anaesthesia in a conventional manner. Peroperative ventilatory settings using zero end-expiratory pressure.
89476345|NCT03811275|Experimental|Sequence #1|Participants will receive nine 30 minute sessions (over 3 weeks) of intervention A followed by nine 30 minute sessions (over 3 weeks) of intervention B.
89476346|NCT03811275|Experimental|Sequence #2|Participants will receive nine 30 minute sessions (over 3 weeks) of intervention B followed by nine 30 minute sessions (over 3 weeks) of intervention B.
89476347|NCT03797963|Active Comparator|PBM+ACB|Porcine bone mineral (Symbios Xenograft) + autogenous cortical bone
89476348|NCT03797963|Experimental|ABB+ACB|Anorganic bovine bone (BioOss Xenograft) + autogenous cortical bone
89476349|NCT03796156|Experimental|Aspirin|75mg of non enteric coated or dispersible aspirin once daily added to usual medications
88950089|NCT01942473|Experimental|Automated FiO2 control|Infants will be changed to a specific ventilator device approved for clinical use in neonates in Germany (Avea, Carefusion 234 GmbH Hoechberg, Germany), which is capable to automatically adjust the FiO2 based on readings of an incorporated SpO2 monitoring device. Infants will be allowed to adjust for at least 2h using the ventilator settings as chosen by the clinical team responsible. Thereafter, data will be recorded for 24h experimental time.
89476350|NCT03796156|No Intervention|Usual care|Usual medications only
89476351|NCT03767595|Experimental|ProACT Adjustable Continence Therapy for Men|Patients implanted with ProACT Adjustable Continence Therapy for Men
89476352|NCT03737292|Experimental|Exparel|Intercostal injection of 266mg of Exparel diluted to 30 ml.
89476353|NCT03737292|Active Comparator|Bupivacaine|Intercostal injection of 0.5% Bupivacaine 2 mg/kg dose diluted to 30 ml.
89476354|NCT03732586|Experimental|Omega 5 fatty acid supplement|20 patients will be assigned to traditional treatment with prednisone 40 mg per day plus dietary supplement with omega 5 fatty acid
89476355|NCT03732586|Placebo Comparator|PLACEBO|20 patients will be assigned to traditional treatment (prednisone 40 mg per day) plus placebo
89206247|NCT00752219|Experimental|NXL104/CAZ/MTZ|NXL104/ceftazidime + metronidazole
89206248|NCT00752219|Active Comparator|Meropenem|
89206249|NCT00827268|Other|Arm 1|Repeated probes every 8 hours of treatment (1/week)
89206250|NCT00825006|No Intervention|Control|Dual site pacing (LV tip electrode and RV tip electrode)
89476356|NCT03724929|Experimental|Ulcerative Colitis patients|"To determine if the best cut-off points of vedolizumab (VDZ) trough levels measured at W6 capable to identify UC patients who will achieve a clinical response at week 10 with VDZ and also the best cut-off points of VDZ trough levels measured at W14 capable to identify UC patients who will achieve a clinical remission to maintenance therapy with VDZ :~Blood samples will be systematically collected at W0, W2, W6, W14 and W52 for vedolizumab pharmacokinetic parameters, including the vedolizumab trough levels and the specific anti-vedolizumab antibody. A supplementary blood sample will be collected at W10 which is the point where a significant greater number of patients were in remission.~Rectosigmoidoscopy will be performed in each center at time points W0, W10 and W52, to evaluate treatment efficacy.~In cases of loss of response, rectosigmoidoscopy will be performed before and four weeks after optimization."
89476357|NCT03713450|Experimental|Control with imaging guidance|
89476358|NCT03713450|Active Comparator|Control without imaging guidance|
89476359|NCT03710460|Experimental|Dapagliflozin|Dapagliflozin capsules, 10 mg, one per day before breakfast during 12 weeks.
89476360|NCT03710460|Experimental|Dapagliflozin plus metformin XR|Dapagliflozin plus metformin XR capsules, 10/1000 mg, one per day before breakfast during 12 weeks.
89476361|NCT03710460|Experimental|Metformin XR|Metformin XR capsules, 1000 mg, one per day before breakfast during 12 weeks.
89476362|NCT03650894|Experimental|Nivolumab, Ipilimumab, and bicalutamide|Participants will receive nivolumab plus ipilimumab combination therapy. Participants should receive nivolumab at a dose of 240 milligrams (mg) fixed dose as a 30-minute intravenous (IV) infusion prepared in 50 milliliter (ml) normal saline (NS) every 2 weeks until progression. Participants should receive ipilimumab at a dose of 1 mg/kilogram as a 30-minute IV infusion prepared in 50 ml NS every 6 weeks. All subjects will take bicalutamide 150mg (3 x 50mg tablets) daily.
89476363|NCT03606694|Experimental|Dihydromyricetin|Dihydromyricetin capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.
89476364|NCT03606694|Experimental|Metformin|Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.
89476365|NCT03546881|Experimental|Arm with fusion imaging guidance technology|arm with fusion imaging guidance technology to perform the endovascular surgery, in addition to the traditional 2D X-ray screen system.
89476366|NCT03546881|Active Comparator|Arm without fusion imaging guidance technology|arm without fusion imaging guidance technology, using the traditional 2D X-ray screen system, to perform the endovascular surgery.
89476367|NCT03544281|Experimental|Arm A: Belantamab mafodotin+lenalidomide +dexamethasone|"Participants will receive SINGLE full dose of belantamab mafodotin as 2.5 mg/kg and 1.9 mg/kg on Day 1 of every 28-day cycle as a 30-60 min infusion.~SPLIT: belantamab mafodotin will be administered in two equal divided doses, 2.5 mg/kg SPLIT dose of a 1.25 mg/kg dose on Day 1 and a 1.25 mg/kg dose on Day 8 of each 28-day cycle.~STRETCH: belantamab mafodotin will be administered as 1.9 mg/kg dose on Day 1 of every alternate 28-day cycles (C1, C3, C5, C7 and so on.) Participants will also receive Lenalidomide 25 mg or 10 mg orally daily, on Days 1-21 of each 28 day cycle with Dexamethasone, 40 mg weekly per oral (PO)/intravenously (IV) on Days 1,8,15, & 22 of each cycle."
89476368|NCT03544281|Experimental|Arm B: Belantamab mafodotin+bortezomib+dexamethasone|Participants will receive SINGLE full dose of belantamab mafodotin as 3.4 mg/kg; 2.5 mg/kg; 1.9 mg/kg on Day 1 of each 21-day cycle. SPLIT: belantamab mafodotin will be administered in two equal divided doses: 3.4 mg/kg SPLIT as 1.7 mg/kg dose on Day 1 & 1.7 mg/kg dose on Day 8; 2.5 mg/kg SPLIT dosing as 1.25 mg/kg dose on Day 1 & 1.25 mg/kg dose on Day 8 of each 21-day cycle. STRETCH: belantamab mafodotin will be administered as single dose of 2.5 mg/kg on Day 1 of every alternate 21-day cycles (C1,C3,C5,C7 & so on), 1.9 mg/kg administered on Day 1 of every alternate 21-day cycles (C1,C3,C5,C7 and so on). Step Down(S/D) STRETCH=belantamab mafodotin 2.5 mg/kg dose will be administered on Day 1 C1 followed by 1.9 mg/kg starting dose on Day1 of alternate 21-day cycles C3 onwards (C3,C5,C7, & so on). Bortezomib will be administered at 1.3 mg/m^2 SC/IV on Days 1,4,8, & 11 of every 21-day cycle. Dex will be administered at 20 mg PO or IV on Days 1,2,4,5,8,9,11, & 12 of every 21-day cycle.
89476369|NCT03529045||VNS Therapy|Any approved VNS Therapy System (according to local regulations) may be used in this registry.
88950090|NCT01942473|Placebo Comparator|Manual Adjustment|Infants will be exposed to the first study phase (clinical routine or automated FiO2 adjustment) for 24 h and then will be switched to the alternate mode (automated FiO2 adjustment or clinical routine) for another 24 h.
88950091|NCT01942499|Other|Community Exercise Group|Community-based exercise program for one year
88950092|NCT01942499|No Intervention|Usual Care|
88950093|NCT01942512||ARETA|All patients with intracranial aneurysms, ruptured or unruptured, treated by endovascular treatment
88950094|NCT01942525||Intrauterine growth restriction|birth weight <10th percentile first intervention: aEEG second intervention: assessment of neurodevelopmental follow-up
88950095|NCT01942525||Appropriate for gestation age|control group with birth weight >10th percentile first intervention: aEEG second intervention: assessment of neurodevelopmental follow-up
88950096|NCT01942538|Experimental|rTMS-rTMS|subjects receiving real rTMS treatment and real rTMS maintenance sessions
88950097|NCT01942538|Sham Comparator|sham - sham|subjects receiving sham treatment and presenting a clinical improvement : they will be submitted to sham maintenance sessions
88950098|NCT01942538|Sham Comparator|rTMS-sham|subjects receiving sham rTMS maintenance sessions after successful real rTMS treatment
88950099|NCT01942538|Experimental|rTMS|real rTMS for 3 weeks but without clinical improvement
88950100|NCT01942538|Sham Comparator|sham|sham treatment for 3 weeks without clinical improvement
88950101|NCT01942551|Experimental|tadalafil, dutasteride|
88950102|NCT01942551|Experimental|dutasteride, tadalafil|
89476370|NCT03512002|Active Comparator|HIRREM|High-resolution, relational, resonance-based, electroencephalic mirroring (HIRREM) is a novel, noninvasive, closed-loop, brainwave mirroring, acoustic stimulation neurotechnology to support relaxation and auto-calibration of neural oscillations, using auditory tones to reflect brain frequencies in near real time.
89476371|NCT03512002|Other|Continued Current Care|Participants will continue their current care.
89476372|NCT03481530||Blinded|Continuing Glucose Monitoring System will be blinded
89476373|NCT03481530||Unblinded|Continuing Glucose Monitoring System will be open. Participant can review results if they choose.
89020253|NCT05321563|Experimental|Intervention Phase|Schools will have the opportunity to deliver the iDECIDE curriculum in lieu of or as part of the standard disciplinary response to school-based substance use infractions during the 'exposed' study period.
89476374|NCT03467906||Weight loss < median of group|Sleeve gastrectomy surgery patients will take part in in-laboratory assessment. Based on 1-year post-surgical weight loss, a median split will be done to allocate subjects to one of two groups.
89476375|NCT03467906||Weight loss > median of group|Sleeve gastrectomy surgery patients will take part in in-laboratory assessment. Based on 1-year post-surgical weight loss, a median split will be done to allocate subjects to one of two groups.
89476376|NCT03387579|Experimental|Smoflipid 20%|Patients randomized to this arm will receive the composite fish oil lipid, Smoflipid, at standard dosing up to 3 g/kg/day. Patients will be started on a dose of 1 g/kg/day and titrated up to maximum dose. As enteral nutrition is advanced the lipid dose will be weaned per study protocol and dietary recommendations.
89476377|NCT03387579|Experimental|Intralipid 20% Reduction|Patients randomized to this arm will receive soy-based lipid (Intralipid) at a dose of 1 g/kg/day throughout their enrollment in the study.
89476378|NCT03387579|Other|Intralipid 20% Historic|Patients who retrospectively received soy-based lipid (Intralipid) at standard dosing of 2-3 g/kg/day were eligible for inclusion. Patients in this group were matched to prospective patients based on diagnosis, gestational age, and length of lipid therapy.
89476379|NCT03339635|Experimental|Testosterone gel|Patients will be randomized to treatment with transdermal testosterone gel (Androgel) once daily during 20 weeks, followed by 20 weeks of active Androgel treatment in all participants.
89476380|NCT03339635|Placebo Comparator|Placebo gel|Patients will be randomized to treatment with placebo gel once daily during 20 weeks, followed by 20 weeks of active Androgel treatment in all participants.
89476381|NCT03260387||TPIAT|patients undergoing total pancreatectomy with islet autotransplant.
89206251|NCT00825006|Experimental|Triple site pacing|Triple site pacing(LV tip electrode,RV tip electrode and RV ring electrode)
89020254|NCT05317936|Experimental|Pirtobrutinib+venetoclax|Pirtobrutinib by mouth at the same time each day Venetoclax by mouth at the same time each day.
89020255|NCT05315544|Experimental|CSI pVAD|
89476382|NCT03218475|Experimental|MR Guided Focused Ultrasound|
89476383|NCT03174327|Other|Hepatic Transplantation|
89476384|NCT03119597|Placebo Comparator|Placebo|Formulation containing approximately 4.79g Fructose+ 4.52g Glucose+ 45mg Vitamin C
89476385|NCT03119597|Experimental|Wild Blueberry Power-13g|Formulation containing approximately 250mg of anthocyanin+ 4.79g Fructose+ 4.52g Glucose+ 45mg Vitamin C
89476386|NCT03094884|Experimental|Pulsed Low dose radiation with Carboplatin/Paclitaxel|Pulsed Low Dose Radiation concurrent with Carboplatin and Paclitaxel
89476387|NCT03076489|Experimental|high consumption habits|high consumption habits of fatty and sugary foods
89476388|NCT03076489|Experimental|low consumption habits|low consumption habits of fatty and sugary foods
89476389|NCT03059108|Experimental|Early Loading|Implant early loading: prosthesis delivery 4 weeks after implant placement
89020256|NCT05291546|Experimental|Part A|Single ascending dose (SAD) of REGN9035 or matching placebo given by intravenous (IV) administration.
89020257|NCT05291546|Experimental|Part B|Selected doses of REGN5381 or matching placebo given by IV administration followed by selected doses of REGN9035 and/or matching placebo via IV infusion
89476390|NCT03059108|Active Comparator|Conventional Loading|Implant conventional loading: prosthesis delivery 8 weeks after implant placement
89476391|NCT03046199|No Intervention|Control|
89476392|NCT03046199|Experimental|Questionnaire|
89476393|NCT03046199|Experimental|Coordination|
89476394|NCT03046199|Experimental|Questionnaire + coordination|
89476395|NCT03029390|Experimental|Berberine hydrochloride|"Berberine capsules, 500 mg, three per day before each meal during 12 weeks.~The patients will have a forced titration period:~First week they will receive one 500 mg capsule before breakfast Second week they will receive two 500 mg capsules (before breakfast and meal) From the third week until the end of the study, they will be receive three 500 mg capsules (before each meal)"
89476396|NCT03029390|Experimental|Metformin|"Metformin capsules, 850 mg, two per day before breakfast and dinner and one placebo capsule before lunch during 12 weeks.~The patients will have a forced titration period:~First week they will receive one 850 mg capsule before breakfast Second week they will receive one 500 mg capsules (before breakfast) and one placebo capsule (before meal).~From the third week until the end of the study, they will be receive two 850 mg capsules (before breakfast and dinner) and one placebo capsule (before meal)."
89476397|NCT02975674|Experimental|MT-12 dental implant|MT-12 dental implant with Morse taper implant-abutment connection
89476398|NCT02975674|Active Comparator|CON.INT dental implant|CON.INT dental implant with internal hexagon implant-abutment connection
89476399|NCT02975245||Men receiving chemotherapy|Semen collection and analysis
89476400|NCT02923063|Experimental|Combined Aerobic and Resistance Exercise|Exercise will be supervised by exercise trainers 3 days per week for 12 weeks via videoconferencing. Each session will start at 30 minutes in duration and include either high-intensity interval targeting a relative perceived exertion (RPE) of greater than 14 (on a scale of 6-20) or strength training (RPE 12-14) or power walking (RPE 12-14). Each 1 week of supervised sessions will alternate with 1 week of self-directed sessions with mid-week trainer check-in.
89476401|NCT02923063|No Intervention|Usual Care|"The control group will receive a one-time counseling session on appropriate dietary and physical activity recommendations. They will receive a Go4Life Workout to go sample exercise routing created by the national institutes on aging (NIA)."
89476402|NCT02889458||Case|"Inclusion Criteria~Female~aged 18 or above~Chinese~Usually residing in Hong Kong (Definition: Having stayed in HK for at least three months during the six months before the reference time-point)~Able to speak Cantonese~Newly diagnosed with breast cancer or DCIS in 24 weeks~Exclusion Criteria~- Undergoing treatment for any non-breast cancer~Subjects will complete a structured interview with a questionnaire with research assistants' aid. Specimen of blood, normal breast tissue and tumour tissue will be collected."
89476403|NCT02889458||Control|"Inclusion Criteria~Female~aged 18 or above~Chinese~Usually residing in Hong Kong~Able to speak Cantonese~Exclusion Criteria~- History of any cancer~Subjects will complete a structured interview with a questionnaire with research assistants' aid. Specimen of blood will be collected."
89476404|NCT02822144|Experimental|general anesthesia|General anesthesia with etomidate, succinylcholine, propofol and remifentanil
89476405|NCT02822144|Experimental|sedation|Sedation with remifentanil and local anesthesia with lidocaine
89476406|NCT02802397|Other|Cases|"Cases and controls will benefit, as usual in France concerning infertility etiology examinations, of a follicle antral count by transvaginal ultrasound and AMH measurement.~At baseline, physicians will complete a short questionnaire to check the inclusion criterion, the results of the measurement of follicle count and hormone measurement (including AMH). Cases and controls will respond to self-administered questionnaire at inclusion with information about their medical history, their demographics, their tobacco and alcohol consumption, their occupation and products handled in the workplace. Blood samples (for measure of persistent organic pollutants and heavy metals) and urine (for measure of metabolites of glycol ethers) will be collect at baseline. Occupational exposures to solvents will be defined using job exposures matrices. The risk of decreased ovarian reserve will be analyzed using logistic regressions for each exposure of interest adjusting for potential confounders."
88950103|NCT01942564||Case Subjects|"Age 18 years or older~Had a head injury that occurred at least 6 months prior to entering study~Have found lights more bothersome since injury"
88950104|NCT01942564||Control Subjects|"Age 18 years or older~Have not had a previous head injury~Have had a full eye examination at Ohio State University College of Optometry during last 6 months."
88950105|NCT01942278|No Intervention|Usual Care|Care is delivered according to baseline standard practice
88950106|NCT01942278|Experimental|BHOMA|Care is delivered according to the BHOMA intervention
88950107|NCT01942577|No Intervention|No treatment|
88950108|NCT01942577|Active Comparator|NoSting|
88950109|NCT01942629||Lung adenocarcinoma|"This group will include 100 patients with lung adenocarcinoma, the clinical outcomes will be retrospectively assessed.~at the same time 2 histopathological slides will be retrieved and stained for known markers as well as to P63."
88950110|NCT01942629||Breast adenocarcinoma|"This group will include 100 patients with breast adenocarcinoma, the clinical outcomes will be retrospectively assessed.~at the same time 2 histopathological slides will be retrieved and stained for known markers as well as to P63."
88950111|NCT01942629||Pancreatic ductal adenocarcinoma|"This group will include 100 patients with pancreatic ductal adenocarcinoma, the clinical outcomes will be retrospectively assessed.~at the same time 2 histopathological slides will be retrieved and stained for known markers as well as to P63."
88950112|NCT01942655|Experimental|Patients with recto-colic biopsies prescribed|45 patients
88950113|NCT01942681|Other|Propiverine Hydrochloride Administration|Administration of Propiverine Hydrochloride for 12 weeks
88950114|NCT01942746|Active Comparator|Blueberry Juice|Commercially prepared single strength blueberry juice which was composed of a 50:50 blend of two highbush blueberry species (Vaccinium corymbosum L. 'Rubel' and V. ashei Reade 'TifBlue'). Volunteers consumed 300 mls of juice/day (247-271 mg anthocyanins (as C3G) daily) while on this intervention, for either 3 weeks (Blueberry Juice S2) or 12 weeks (Blueberry Juice L1).
88950115|NCT01942746|Active Comparator|Blueberry Capsules|Commercially prepared single strength blueberry juice which was composed of a 50:50 blend of two highbush blueberry species (Vaccinium corymbosum L. 'Rubel' and V. ashei Reade 'TifBlue')was freeze dried to a powder and encapsulated in gelatin capsules (Blueberry Capsules S2). Volunteers consumed 3 capsules/daily (7.11mg anthocyanin (as C3G eq) for 3 weeks.
88950116|NCT01942746|Placebo Comparator|Placebo|Volunteers consumed in S2 three placebo capsules daily for 3 weeks. In L1 volunteers consumed 300ml placebo juice for twelve weeks. Placebo products contained no anthocyanins.
88950117|NCT01942746|No Intervention|Washout (S2 and L1)|Washout periods involved no study products. Washout was 3 weeks in S2 and or 8 weeks (L1) in duration.
89476407|NCT02802397|Other|Controls|"Cases and controls will benefit, as usual in France concerning infertility etiology examinations, of a follicle antral count by transvaginal ultrasound and AMH measurement.~At baseline, physicians will complete a short questionnaire to check the inclusion criterion, the results of the measurement of follicle count and hormone measurement (including AMH). Cases and controls will respond to self-administered questionnaire at inclusion with information about their medical history, their demographics, their tobacco and alcohol consumption, their occupation and products handled in the workplace. Blood samples (for measure of persistent organic pollutants and heavy metals) and urine (for measure of metabolites of glycol ethers) will be collect at baseline. Occupational exposures to solvents will be defined using job exposures matrices. The risk of decreased ovarian reserve will be analyzed using logistic regressions for each exposure of interest adjusting for potential confounders."
89476408|NCT02684955||Cerebral spectroscopy + pupillometry|During CPR, rSO2 will be monitored continuously as well as quantitative measurements of the pupillary light reaction every 5 minutes.
89476409|NCT02565680|Placebo Comparator|placebo|tablets of Xyzall 5mg/ day during 5 days + placebo 40mg/ day during 4 days
89476410|NCT02565680|Experimental|prednisone|tablets of Xyzall 5 mg/j during 5 days + prednisone 40 mg/ day during 4 days
89476411|NCT02558946|Active Comparator|Physical Therapy Treatment Group|Written and verbal information on performing Kegel exercises (exercises that aim to strengthen pelvic floor muscles) will be provided at the pre-op clinic visit. The treatment group will receive pelvic floor muscle training through a course of three one-hour sessions with a trained pelvic floor physical therapist in addition to the current standard information from their surgeon. The physical therapy sessions will be conducted at 1-6 weeks preoperative, 7-10 days postoperative, and 4-8 weeks postoperative .
89476412|NCT02558946|Active Comparator|Control Group|Written and verbal information on performing Kegel exercises (exercises that aim to strengthen pelvic floor muscles) will be provided at the pre-op clinic visit.
89476413|NCT02487160|Experimental|SBL-3 multifocal intraocular lens|The SBL-3 intraocular lens will be implanted after the cataractous natural lens has been removed, in those patients randomized into this group
89476414|NCT02487160|Active Comparator|Control monofocal intraocular lens|The Control intraocular lens will be implanted after the cataractous natural lens has been removed, in those patients randomized into this group
89476415|NCT02422615|Experimental|Ribociclib + fulvestrant|Ribociclib was administered orally at a daily dose of 600mg for 21 consecutive days within a 28-day cycle. This treatment was combined with fulvestrant, which was administered via intramuscular injections of 500mg every 28 days starting on Day 1 of each cycle. Additionally, an extra dose of fulvestrant was given on Day 15 of Cycle 1. For participants who did not tolerate the protocol-specified dosing schedule, dose adjustments were permitted in order to allow the patient to continue the study treatment.
89476416|NCT02422615|Placebo Comparator|Placebo + fulvestrant|"Placebo was administered orally for 21 consecutive days within a 28-day cycle. This treatment was combined with fulvestrant, which was administered via intramuscular injections of 500mg every 28 days starting on Day 1 of each cycle. Additionally, an extra dose of fulvestrant was given on Day 15 of Cycle 1. For participants who did not tolerate the protocol-specified dosing schedule, dose adjustments were permitted in order to allow the patient to continue the study treatment.~Participants were unblinded after the implementation of protocol amendment 4 (29-Jan-20) and were given the option to crossover to treatment with ribociclib and fulvestrant."
89476417|NCT02382406|Experimental|Arm A: Phase I Dose Finding Cohort|"Twelve subjects will be enrolled and treated with carboplatin AUC 6 IV on Day 1, nab-paclitaxel 100 mg/m^2 IV on Day 1, Day 8, and Day 15, pembrolizumab 2* mg/kg IV on Day 1 for 4 cycles. pembrolizumab (Phase I) treatment for Cohort 1 will continue for a maximum duration of 4 21-day cycles~Phase I, Cohort 1 Maintenance Therapy:~Participants who have confirmed CR, PR, or SD (non-progression) after 4 cycles, maintenance therapy with MK-3475 2* mg/kg will continue on D1 of each 21-day cycle. Treatment will continue until progression of disease, unacceptable toxicity, or a maximum of 2 years from C1D1.~If unacceptable toxicity is seen in Phase I Cohort 1, 12 additional participants will be enrolled in Cohort 2 and treated with carboplatin AUC 6 IV on D1, nab-paclitaxel 100 mg/m2 IV on D1, D8, and D15, MK-3475 2*mg/kg IV on D1 starting C2. MK-3475 (Phase 1) treatment for Cohort 2 will continue for a maximum duration of 3 21-day cycles (C2-4 only)."
88950118|NCT01942759||Histologic grade|According to the modified criteria of Bloom and Richardson grading system: grade 1, 2 and 3
89476418|NCT02382406|Experimental|Arm B: Phase II Investigational Treatment|"Subjects will be treated with carboplatin AUC 6 given IV on Day 1, nab-paclitaxel 100 mg/m^2 given IV on Day 1, Day 8, and Day 15, and pembrolizumab 200mg IV on Day 1 of each cycle. Pembrolizumab Phase II treatment will continue for a maximum duration of 4 cycles (cycle = 21 days).~Maintenance Therapy For participants who have confirmed CR, PR, or SD (non-progression) after 4 cycles of induction therapy, maintenance therapy with MK-3475 2* mg/kg will continue on Day 1 of each 21-day cycle. Treatment will continue until progression of disease, unacceptable toxicity, or for a maximum of 2 years from C1D1.~*As additional data from ongoing trials becomes available, the dose of MK-3475 may be adjusted."
89476419|NCT02203669|Active Comparator|Structured In-Office Therapy|Structured In-Office Therapy: Study subjects will receive structured, therapist-supervised occupational/physical therapy twice per week for four (4) weeks. Each visit will last approximately sixty (60) minutes. Patients in this arm will receive therapy instruction by a certified occupational therapist on upper extremity stretching, relaxation, cardio rehabilitation, and strength training. These patients will also receive exercise and stretching handouts to use at home between therapy visits. Will complete the DASH at week 1 and week 4.
89476420|NCT02203669|No Intervention|No therapy|Study subjects in this arm will not receive post-operative occupational /physical therapy. Will complete the DASH at week 1 and week 4.
89020258|NCT05285813|Experimental|AML MRD cohort only|Each study cycle is 28 days. Vibecotamab by vein (IV) over about 2 hours On Days 1, 3, 5, 8, 15 and 22 of Cycle 1 and then on Days 1, 8, 15 and 22 of Cycles 2-4.
89476421|NCT02203669|Active Comparator|Home Therapy|Home Therapy: Study subjects will receive a handout of exercises adapted for post-operative breast reconstruction patients along with an instructional handout for stretching complied by a certified occupational therapist to complete independently at home for four (4) weeks. Will complete the DASH at week 1 and week 4.
89476422|NCT02186587|Other|ConforMIS|Subjects who receive a ConforMIS custom total knee implant.
89476423|NCT02134327|Experimental|Premedication with Midazolam|
89476424|NCT02112331|Experimental|Raw human milk / pasteurized human milk|"Raw human milk compared to pasteurized human milk. Two meals administration (20mL/kg) per day during 6 days in a randomized order, with an intragastric tube : one with raw milk and one with pasteurized milk.~In order to characterise gastric effluents at different postprandial times after ingestion and to measure gastric lipolysis and proteolysis, at each administration two gastric samples will be collected with the intragastric tube :~one before the meal,~and one either 35, 60 or 90 minutes (randomized time frame) after the meal."
89476425|NCT02112331|Experimental|Pasteurized human milk / pasteurized-homogenized human milk|"Pasteurized human milk compared to pasteurized-homogenized human milk. Two meals administration (20mL/kg) per day during 6 days in a randomized order, with an intragastric tube : one with pasteurized milk and one with pasteurized-homogenized milk.~In order to characterise gastric effluents at different postprandial times after ingestion and to measure gastric lipolysis and proteolysis, at each administration two gastric samples will be collected with the intragastric tube :~one before the meal,~and one either 35, 60 or 90 minutes (randomized time frame) after the meal."
89476426|NCT02101268|Experimental|Arm 1: Momelotinib|Participants will receive open-label momelotinib for 24 weeks during the randomized treatment phase, after which they will be eligible to receive momelotinib in an extended treatment phase for up to an additional 204 weeks.
89476427|NCT02101268|Active Comparator|Arm 2: Best Available Therapy (BAT)|Participants in the BAT treatment arm will receive open-label treatment at doses and schedules determined by the investigator in accordance with standard of care. Therapy may be changed at any time during the study except during the screening period. After completion of the randomized treatment phase, participants will be eligible to receive momelotinib for the duration of the study during the extended treatment phase for up to 204 weeks.
89476428|NCT02063113|No Intervention|NA/NA|
89476429|NCT02045446|Active Comparator|Maintenance chemotherapy|FDA approved drugs for the study population: Bevacizumab, Docetaxel, Erlotinib, Gemcitabine, Pemetrexed
89476430|NCT02045446|Experimental|Stereotactic Body Radiation Therapy|consolidative Stereotactic Body Radiation Therapy (SBRT) plus maintenance chemotherapy
89476431|NCT01898650|Experimental|craniofacial abnormalities|Subjects with craniosynostosis or other craniofacial abnormalities associated with ICP who will undergo an MR scan.
89476432|NCT01880515|Experimental|Tetracycline|Patients will receive tetracycline 250mg every 12 hours for 1 month plus general dermatological recommendations (sunscreen and emollient cream)
89476433|NCT01880515|No Intervention|No Tetracycline|This arm only with general dermatologic recommendations. Patients in this arm can receive tetracycline after week 4 of assessment only if rash grade 3-4 occur
89476434|NCT01817517|Experimental|Deep Brain Stimulation implant|Unblinded treatment arm, thalamic DBS for Tourette syndrome.
89476435|NCT01783145||Patients|Patients with disseminated TC who have finished their chemotherapy, if needed followed by surgery, and who are in complete remission and currently in active follow-up.
88950119|NCT01942759||Axillary metastasis|Group A: axillary lymph node metastasis Group B: no axillary lymphatic metastasis
88950120|NCT01942759||Modified Nottingham prognostic index|"NPI = pathological tumour size (cm) × 0.2 + lymph node stage (1, 2 or 3) + histological grade (1, 2 or 3)~The cut-off points of the index were 3.4 and 5.4 to divide patients into the good (≤3.4), moderate (3.41-5.4) and poor (>5.4) prognostic groups"
88950121|NCT01942759||Oestrogen receptor status|Negative Positive
88950122|NCT01942759||Progesterone receptor status|Negative Positive
88950123|NCT01942759||HER-2 neu status|Negative Positive
88950124|NCT01942772|Experimental|experimental test of healthy subjects|wearing experiment，motion experiment
89476436|NCT01780883|Placebo Comparator|Placebo|5 tablets of placebo once a day, an hour before falling asleep, for 6 weeks.
89476437|NCT01780883|Experimental|2 mg melatonin|1 tablet of 2mg melatonin and 4 tablets of its placebo once a day, an hour before falling asleep, for 6 weeks.
89476438|NCT01780883|Experimental|4 mg melatonin|2 tablets of 2mg melatonin and 3 tablets of its placebo once a day, an hour before falling asleep, for 6 weeks.
89476439|NCT01780883|Experimental|10 mg melatonin|5 tablets of 2mg melatonin once a day, an hour before falling asleep, for 6 weeks.
89476440|NCT01747291||Atypical femur fracture cohort|
89537467|NCT04129151|Experimental|PALBOCICLIB and GANITUMAB|"The research study procedures include screening for eligibility and study treatment including evaluations for testing and follow up visits.~The study treatment will be 12 months in duration and follow up will be one year from when the participant receives the last dose of study drug.~The names of the study drugs involved in this study are:~Palbociclib-Oral, per protocol pre determined dosage, once a day for 21 days~Ganitumab-Intravenous, per protocol predetermined dosage, twice per cycle~Cycle is 28 days"
88950125|NCT01942798|Active Comparator|Cognitive Games|"The Cognitive Games group will receive 40 minute supervised group training three times per week for a period of four weeks. The group for the first week will be held at the clinic, while the remaining three weeks be conducted at the subject's home and supervised by the Trainer remotely using a tablet with video conferencing capability. At the end of the four-week Supervised Phase, subjects will retain the Wii units and they will be encouraged to use the program on their own for an additional period of four weeks (Unsupervised Phase).~Subjects in the control group will play cognitive oriented video games using Wii Big Brain Academy Degree program. BigBrain™ is a video gaming system which has games and exercises to improve cognitive function(identify, memorize, analyze, compute, and visualize). Subjects use the Wii handheld remote to participate in the games by pointing and clicking the remote to select on-screen answers in response to on-screen questions."
88950126|NCT01942798|Experimental|WiiNWALK Intervention|"The intervention group will also receive 40 minute supervised group training three times per week for a period of four weeks. Interventions conducted over the first week will be held at the clinic, while the remaining three weeks be conducted at the subject's home and supervised by the Trainer remotely. At the end of the four-week Supervised Phase, subjects will retain the Wii units and they will be encouraged to use the program on their own for an additional period of four weeks (Unsupervised Phase).~The WiiNWALK protocol consists of performing Nintendo WiiFit activities. Subjects stand on the WiiFit balance board and interact with the WiiFit games through weight shifting or by using the Wii handheld remote control. The intervention protocol will include selected exercises consisting of: 1) Yoga 2) Balance Tasks 3) Strength training and 4) Aerobics.~At the in-clinic sessions in Vancouver, a motion-sensing device will also record video and skeleton data of the participant."
88950127|NCT01942811|Experimental|Intervention|The Quit Using Drugs Intervention Trial (QUIT) experimental arm includes: screening, very brief clinician advice, and telephone drug-use health education to reduce 'at risk' drug use and thus interrupt progression from casual or episodic abuse to dependence.
88950128|NCT01942811|No Intervention|Control|Usual care and a health education booklet and video on cancer prevention
88950129|NCT01942824|Experimental|Intervention|Text Message
89476441|NCT01668719|Active Comparator|Arm I (bortezomib, lenalidomide, dexamethasone)|"INDUCTION: Patients receive bortezomib SC or IV on days 1, 4, 8, and 11; lenalidomide PO QD on days 1-14; and dexamethasone PO or IV on days 1, 2, 4, 5, 8, 9, 11, and 12. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity (patients who received a course of chemotherapy prior to registration will begin protocol treatment with course 2 and receive a total of 7 courses of protocol therapy).~MAINTENANCE: Patients receive bortezomib SC or IV on days 1, 8, and 15; lenalidomide PO QD on days 1-21; and dexamethasone PO on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
89476442|NCT01668719|Experimental|Arm II (bortezomib, lenalidomide, dexamethasone, elotuzumab)|"INDUCTION: Patients receive bortezomib, lenalidomide, and dexamethasone as in Arm I. Patients also receive elotuzumab IV on days 1, 8, and 15 of courses 1 and 2 and on days 1 and 11 of courses 3-8. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive bortezomib, lenalidomide, and dexamethasone as in Arm I. Patients also receive elotuzumab IV on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
89476443|NCT01642901|Experimental|Zoledronic Acid 5 mg IV infusion|Single infusion of 5 mg intravenous zoledronic acid given within 21 days of acute traumatic spinal cord injury.
89476444|NCT01642901|Placebo Comparator|normal saline 0.9%|Infusion of normal saline of equivalent volume to reconstituted zoledronic acid, given only once and run over 2 hours, to occur within 21 days of acute traumatic spinal cord injury.
88950130|NCT01942824|No Intervention|Usual Care|
88950131|NCT01942850||No Treatment|Collect pilot data on the performance of the ICARS in patients younger than 10 years of age, as well as to introduce definitions for the various clinically defined stages of AT, and attempt to develop descriptors of change that could help in the assessment of patients longitudinally.
88950132|NCT01942863|Experimental|water exchange single balloon enteroscopy|
89476445|NCT01488045|Active Comparator|Fentanyl and Midazolam|Fentanyl and Midazolam sedation for colonoscopy discomfort
89476446|NCT01488045|Active Comparator|Propofol|Propofol sedation for colonoscopy discomfort
89476447|NCT01090479|No Intervention|Control|This group will perform an ordinary shower the night prior and the morning of their scheduled surgery date.
89476448|NCT01090479|Experimental|2% Chlorhexidine cloth|This group will use the 2% chlorhexidine wipes the night prior as well as the morning of their surgery date.
89476449|NCT01045525|Experimental|Phlebotomy + lifestyle and diet advices|
89476450|NCT01045525|Active Comparator|Lifestyle and diet advices|
89537468|NCT02462369|Experimental|Saxagliptin|Saxagliptin 5mg/d, 52 weeks
89537469|NCT02462369|Active Comparator|glimepiride|glimepiride 1~4mg/d,52 weeks
89537470|NCT04072835|Experimental|Etripamil NS 70mg|Patients will self-administer etripamil NS.
89476451|NCT00946712|Experimental|Arm I (chemo +/- bevacizumab)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes with or without bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. After completion of 6 courses, patients receiving bevacizumab may continue to receive bevacizumab (as above) in the absence of disease progression or unacceptable toxicity.
89476452|NCT00946712|Experimental|Arm II (chemo, cetuximab, +/- bevacizumab)|Patients receive paclitaxel and carboplatin with or without bevacizumab as in Arm I. Patients also receive cetuximab IV over 1-2 hours on days 1, 8, and 15. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. After completion of 6 courses, patients may continue to receive cetuximab with or without bevacizumab (as above) in the absence of disease progression or unacceptable toxicity.
89476453|NCT00772200||Observational (neuropsychological and behavioral tests)|Parent and child participants complete the COG Standard Neuropsychological and Behavioral Battery at approximately 9, 30, and 60 months post-diagnosis in a 1-2 hour testing session conducted by a neuropsychologist or psychologist. The Battery consists of measures of intelligence, processing speed, attention, memory, language preference, behavioral/social/emotional function, executive function, adaptive function, and quality of life.
89476454|NCT00656669|Experimental|1|The study will be conducted in 3 sequential treatment segments.
89476455|NCT03070951|Experimental|OBE2109 dose 1 (100mg) + Placebo Add-back|
89476456|NCT03070951|Experimental|OBE2109 dose 1 (100mg) + Add-back|
89476457|NCT03070951|Experimental|OBE2109 dose 2 (200mg) + Placebo Add-back / OBE2109 dose 2 (200 mg) + Add-back|
88950133|NCT01942863|Active Comparator|CO2 insufflation single balloon enteroscopy|
88950134|NCT01942876|Experimental|Intervention|The Quit Using Drugs Intervention Trial (QUIT) experimental arm includes: screening, very brief clinician advice, and telephone drug-use health education to reduce 'at risk' drug use and thus interrupt progression from casual or episodic abuse to dependence.
88950135|NCT01942876|Sham Comparator|Control|This arm will receive a sham telephone intervention of equivalent duration on health behavior maintenance.
88950136|NCT01942889|Active Comparator|Antioxidant Supplementation|Vitamin antioxidant and trace elements combination that won't exceed the maximal nutritional dose recommended in France (Vit E, vit C, Selenomethionine, Zinc gluconate).
88950137|NCT01942889|Placebo Comparator|Placebo|Placebo
88950138|NCT01942902|Experimental|Continuous Glucose Monitoring System|
88950139|NCT01942915|Experimental|umbilical cord blood mononuclear cells|Umbilical Cord blood come from healthy puerpera. Erythrocyte in umbilical cord blood was separated and deleted through sedimentation. Mononuclear cells in umbilical cord blood were then isolated with a conventional method and reagent,Ficoll,by density gradient centrifugation.
88950140|NCT01942928|Active Comparator|Usual NHS care|
89476458|NCT03070951|Experimental|OBE2109 dose 2 (200mg) + Add-back|
89476459|NCT03070951|Placebo Comparator|Placebo + Placebo Add-back / OBE2109 dose 3 (200mg) + Add-back|
89476460|NCT04759339|Experimental|AG-920|Subjects will receive a single dose of articaine sterile topical ophthalmic solution in one eye only. The study eye will be randomized. The single dose will be administered by the clinic staff as two drops in study eye 30 seconds apart.
88950141|NCT01942928|Active Comparator|Usual NHS Care plus Osteopathic Manipulative Therapy|
88950142|NCT01942941|Experimental|geko™ electrical stimulation|Applied to stimulate peroneal nerve unilaterally
88950143|NCT01942967||Preterm ≤ 32 weeks GA, on CPAP|Preterm infants less than 32 weeks gestational age requiring CPAP as a mode of respiratory support and admitted in the NICU.While the baby is on CPAP,tissue oxygen saturation monitoring will be started by applying NIRS(Near Infrared Spectroscopy Monitoring) sensors to the forehead and the abdomen. After 3 hours,echocardiography(including Superior Mesenteric Artery Doppler) will be done while the baby is on CPAP. Then, using the same machine, the mode of respiratory support will be changed to TrPA. After another three hours,another echocardiography will be done,then NIRS monitoring will be stopped and the mode of respiratory support will be changed back to CPAP.
88950144|NCT01942980|Other|conventional postoperative whole-brain radiation therapy|conventional postoperative whole-brain radiation therapy (40 Gy in 20 fractions of 2 Gy)
88950145|NCT01942980|Other|whole-brain radiation therapy with hippocampal avoidance|Radiation therapy with hippocampal avoidance
88950146|NCT01943006|Experimental|Hirudoid cream|"Patient treated with Hirudoid cream 0.3% Mucopolysaccharide polysulfate~Twice daily"
88950147|NCT01943006|Placebo Comparator|Placebo|"Patients treated with placebo cream without active substance~Twice daily"
88950148|NCT01943019|Experimental|Linagliptin|Linagliptin daily
88950149|NCT01943032||Primary Breast Tumor|Immunohistochemical staining of paraffin embedded tissue blocks of primary breast tumor for estrogen and progesterone receptors was performed.
88950150|NCT01943032||Axillary Lymph Nodes.|Immunohistochemical staining of paraffin embedded tissue blocks of axillary lymph nodes for estrogen and progesterone receptors was performed.
88950151|NCT01943045|Experimental|NGM282 Dose 1|NGM Dose 1
88950152|NCT01943045|Experimental|NGM282 Dose 2|NGM Dose 2
88950153|NCT01943045|Experimental|NGM282 Dose 3|NGM Dose 3
88950154|NCT01943045|Placebo Comparator|Placebo|Placebo
88950155|NCT01943058|Experimental|Arm A (megestrol acetate)|Patients receive megestrol acetate PO BID for up to 18 months in the absence of disease progression or unacceptable toxicity.
88950156|NCT01943058|Experimental|Arm B (levonorgestrel-releasing IUS)|Patients receive levonorgestrel-releasing IUS with continuous release for up to 18 months in the absence of disease progression or unacceptable toxicity.
88950157|NCT01943071|Experimental|Day care for patients with dementia|Day care for patients with dementia
88950158|NCT01943071|No Intervention|Care as usual|Care as usual
88950159|NCT01943084|Experimental|Norditropin®|
88950160|NCT01943084|Active Comparator|Genotropin®|
88950161|NCT01943123|Experimental|probiotic drink|experimental group (30 subjects) were given 50 ml of probiotic drink for 6 months on daily basis
88950162|NCT01943123|Placebo Comparator|plain, unsweetend, unflavored pasturised milk|control group/ placebo group (30 subjects) were given pasteurized milk (50 ml) for 6 months on regular basis
89476461|NCT01338493||lumbar spinal arthroplasty + Maverick™|Patients requiring total disc replacement
89476462|NCT01362296|Experimental|GSK1120212|Oral once daily
89476463|NCT01362296|Active Comparator|docetaxel|IV once every 3 weeks
89476464|NCT01338415|Experimental|bosentan 2mg/kg b.i.d.|Patients who received 2 mg/kg bosentan twcie daily (b.i.d.) during the FUTURE 3 core study and continued with the same dose regimen during the extension study
89476465|NCT01338415|Experimental|bosentan 2mg/kg t.i.d.|Patients who received 2 mg/kg bosentan 3 times a day (t.i.d.) during the FUTURE 3 core study and continued with the same dose regimen during the extension study
89476466|NCT04353128|Experimental|Melatonin|2 mg of melatonin orally before bedtime for 12 weeks
89476467|NCT04353128|Placebo Comparator|Placebo|Identically looking placebo orally before bedtime for 12 weeks
89476468|NCT05334823|Experimental|pCAR-19B cells|Infusion of pCAR-19B cells by dose of 0.6-2 x106 cells/kg
89476469|NCT05125172|Active Comparator|Internal focus of attention group|"Participants will be given instructions that make them think about their body's movements.~Participants will complete the external focus group second in the cross over."
89476470|NCT05125172|Experimental|External focus of attention group|"Participants will be given instructions that make them think about an outside target or outcome.~Participants will complete the internal focus group second in the cross over."
89476471|NCT05125094||Non-Gadoxetic MRI for diagnosis|the patients with HCC follow up with Non-Gadoxetic MRI for diagnosis
89476472|NCT05125094||Gadoxetic MRI for diagnosis|the patients with HCC follow up with Gadoxetic MRI for diagnosis
89476473|NCT04312490|Experimental|patients|all patients with myocarditis
89476474|NCT04609891|Experimental|Avatrombopag Tablets Oral|When patient is diagnosed with thrombocytopenia induced by chemotherapy of malignant tumor, avatrombopag will be given to patients as a therapeutic plan.
89476475|NCT03562819||NSCLC|Non-small cell lung cancer
89476476|NCT04263350|Experimental|Treatment A:Fixed- dose combination mini-tablet|
89476477|NCT04263350|Experimental|Treatment B: Separate products taken at the same time|
89476478|NCT05258149|Experimental|TEST/CONTROL/CONTROL|Eligible subjects will be randomized into the sequence TEST/CONTROL/CONTROL.
89476479|NCT05258149|Experimental|CONTROL/TEST/TEST|Eligible subjects will be randomized into the sequence CONTROL/TEST/TEST
89476480|NCT03490682|Active Comparator|Non-pregnant control|adult females aged less than 40 years, not currently pregnant, without significant medical history (American Society of Anesthesiologists ASA 1), fasting for at least 6 hours for solids and 1 hour for clear fluids.
89476481|NCT03490682|Active Comparator|Pregnant control|adult females aged less than 40 years, pregnant in the third trimester (gestation greater than 32 weeks on the day of the study) according to dates and the calculation of term established at the start of the pregnancy by an obstetrician, without significant medical history (American Society of Anesthesiologists ASA 1), fasting for at least 6 hours for solids and I hour for clear fluids.
89476482|NCT03490682|Experimental|Analgesia|adult females aged less than 40 years, without significant medical history (American Society of Anesthesiologists ASA 1), in labour in the delivery suite, with a working epidural, having consumed solid food more than 6 hours before inclusion in the study and clear fluids more than 1 hour before inclusion in the study, and allowed to ingest solids during labour (cervical dilatation strictly less than 8cm) conforming to local protocols.
89476483|NCT03490682|Experimental|Parturient|adult females aged less than 35 years, without significant medical history (American Society of Anesthesiologists ASA 1), in labour in the delivery suite, without any epidural analgesia, having consumed solid food more than 6 hours before inclusion in the study and clear fluids more than 1 hour before inclusion in the study, and allowed to ingest solids during labour (cervical dilatation strictly less than 8cm) conforming to local protocols.
89476484|NCT03562585||Efficacy of immunoassay in liver fibrosis|efficacy of immunoassay in liver fibrosis in patients with CHB
89476485|NCT03463850|Experimental|Non-fracture|subjects without a lumbar fracture will have a Dexa scan and Dual Energy CT (DECT) scan for observation/evaluation
89476486|NCT03463850|Experimental|Fracture|subjects with one or more lumbar fractures will have a Dexa scan andDual Energy CT (DECT) scan for observation/evaluation
89476487|NCT04237844||no BPD|In preterm infants(GA<32 weeks and hospital day>14 days )，infants without BPD
89476488|NCT04237844||classic BPD|In preterm infants(GA<32 weeks and hospital day>14 days )，There are clinical manifestations and imaging evidence of RDS after birth, the condition is not relieved, FiO2 lasts >25%
89476489|NCT04237844||BPD after RDS|In preterm infants(GA<32 weeks and hospital day>14 days )，There are clinical manifestations and imaging evidence of RDS after birth. FiO2<23% within 7 days, and the condition is aggravated to FiO2>25%.
88950163|NCT01943136|Experimental|papaya 1% extract ointment|papaya 1% extract ointment twice a day for 1 week
88950164|NCT01943136|Active Comparator|mupirocin 2% ointment|mupirocin 2% ointment twice a day for 1 week
88950165|NCT01943162|Experimental|SMART-CPT|CPT with additional elements of cognitive rehabilitation
88950166|NCT01943162|Active Comparator|CPT|Standard Cognitive Processing Therapy
88950167|NCT01943175||Genetic High Risk|
88950168|NCT01943175||Healthy Control|
88950169|NCT01943188|Experimental|Treatment (SBRT, autologous PBMC infusion)|"SBRT: Patients undergo standard of care SBRT over 1-2 weeks according to tumor volume and location.~LYMPHODEPLETION: Beginning 3 weeks later, patients receive cyclophosphamide PO BID for 3 days.~REINFUSION OF PBMC: Within 3-14 days of completing lymphodepletion with cyclophosphamide , patients undergo autologous PBMC infusion."
88950170|NCT01943201|Experimental|new bedsheet|new bedsheet
88950171|NCT01943201|Placebo Comparator|conventional bedsheet|conventional bedsheet
88950172|NCT01943214||Type II DM body constitution|Type II diabetes mellitus, body constitution
88950173|NCT01943240|Experimental|Group A|Paravertebral peripheral nerve blockade with with 4 mL of 0.5% ropivacaine at each of six levels, plus 10 cc of 0.375% ropivacaine for pectoral nerve block
89476490|NCT04237844||Delayed BPD|In preterm infants(GA<32 weeks and hospital day>14 days )，There is no RDS performance after birth, FiO2 lasts <25%
89476491|NCT04237844||Early, lethal BPD|In preterm infants(GA<32 weeks and hospital day>14 days )，Some infants who die before 36 weeks PMA (between 14 days of postnatal age and 36 weeks) due to persistent parenchymal lung disease and respiratory failure that can not be attributable to other neonatalmorbidities
89476492|NCT05124938||Group 1|Healthy individuals
89476493|NCT05124938||Group 2|patients with localized thyroid malignancy
88950174|NCT01943240|Active Comparator|Group S|Paravertebral peripheral nerve blockade with 4 mL of 0.5% ropivacaine at each of six levels, plus 10 cc of normal saline for pectoral nerve block.
88950175|NCT01943253|Active Comparator|Conventional ESD|Conventional ESD: Conventional ESD technique using IT2-Knife, Dual-Knife, Hook-Knife (Olympus Europe, Hamburg, Germany) ERBE VIO 300D (V2.1.4) RF-surgery system (ERBE Elektromedizin GmbH, Tübingen, Germany) Injection of fluid: Syringe
88950176|NCT01943253|Active Comparator|Hybridknife ESD|"Group 2: Water-jet assisted HybridKnife® ESD technique using HybridKnife® (Erbe Elektromedizin GmbH, Tübingen, Germany) ERBE VIO 300D (V2.1.4) RF-surgery system (ERBE Elektromedizin GmbH, Tübingen, Germany)~Injection of fluid: Integrated in HybridKnife® with ERBEJet 2 water-jet surgery system (ERBE Elektromedizin GmbH, Tübingen, Germany)"
88950177|NCT01943266|Experimental|protein intake|protein intake randomly fed from deficient to excess
89020259|NCT05285813|Experimental|MDS post-HMA failure cohort only|Each study cycle is 28 days. Vibecotamab by vein (IV) over about 2 hours On Days 1, 3, 5, 8, 15 and 22 of Cycle 1 and then on Days 1, 8, 15 and 22 of Cycles 2-4.
89476494|NCT05124938||Group 3|patients with metastatic thyroid malignancy
89476495|NCT03187028|Active Comparator|Diet only|Diet counseling will be delivered using visual communication (e.g., Skype). Participants will be provided a computer tablet for the intervention with participants randomized to receive diet counseling.
89020260|NCT05281809|Experimental|Treatment Arm|CAR -T-cell collection, infusion
89476496|NCT03187028|Experimental|Diet + Exercise|Diet and exercise counseling will be delivered using visual communication (e.g., Skype). Participants will be provided a computer tablet for the intervention with participants randomized to receive diet and exercise counseling also receiving a fitness bracelet to facilitate counseling by the certified Cancer Exercise Trainer.
89476497|NCT02259985|Experimental|Itasetron tablet fed|
89476498|NCT02259985|Active Comparator|Itasetron tablet fasted|
89476499|NCT02259985|Active Comparator|Itasetron infusion fasted|
89476500|NCT04010396||Recipients of Bovine Graft|Recruitment and informed consent procedure for blood sampling to conduct immunological testing. In addition a questionnaire on QOL (SF-12) will be used to evaluate the most actual quality of life of these patients.
89476501|NCT04010396||Recipients of Mechanical Graft|Recruitment and informed consent procedure for blood sampling to conduct immunological testing. In addition a questionnaire on QOL (SF-12) will be used to evaluate the most actual quality of life of these patients.
89476502|NCT05124626|Active Comparator|One bar|MIRPE utilizing just one metallic bar
89476503|NCT05124626|Active Comparator|Two bars|MIRPE utilizing two metallic bars fixed with the bridge device
89476504|NCT01371643|Active Comparator|Medical treatment by Octreotide LAR|Medical therapy with Octreotide LAR 30 mg/month for 3 months preceding surgery
89476505|NCT01371643|Active Comparator|Surgical debulking followed by Octreotide LAR|Surgical debulking of pituitary tumor followed by Octreotide LAR if not surgically cured
89476506|NCT03056222|Active Comparator|HeartLight® EGLA|Participants will be treated with the endoscopically guided laser ablation catheter
89476507|NCT03056222|Active Comparator|Contact Force Sensing Irrigated RF ablation|Participants will be treated with a contact force sensing irrigated radiofrequency ablation catheter
89476508|NCT04390477|Experimental|Probiotic|1 pill od containing 1x10E9 cfu of the probiotic
89476509|NCT04390477|No Intervention|Control|No treatment
89476510|NCT04046809|Experimental|Study Treatment|500 ml oral solution containing citicoline free acid 50 mg/ml.
89476511|NCT04046809|Placebo Comparator|Placebo|500 ml oral solution indistinguishable from active product in appearance and taste
89476512|NCT03719456|Experimental|Flexible ureteroscope|
89476513|NCT03023462|Active Comparator|Transmuscular Quadratus lumborum Block|A single shot unilateral transmuscular Quadratus lumborum Block with Ropivacaine 7,5 mg/ml, 20 ml
89476514|NCT03023462|Active Comparator|TAP Block|A single shot unilateral TAP block with Ropivacaine 7,5 mg/ml, 20 ml
89476515|NCT04412798|Other|group 1|orange juice concentrate
89476516|NCT04412798|Other|Group 2|Sugar-sweetened orange-flavoured beverage
89476517|NCT04412798|Other|Group 3|Whole orange juice with skin removed
89476518|NCT02824952|Experimental|Tagrisso 80 mg|80 mg of Tagrisso(AZD9291) will be given every day for 6 or 12 weeks.
89476519|NCT01371565|Experimental|mifepristone|
89476520|NCT03714854|Active Comparator|Deep brain stimulation ON|Patients will undergo every experimental tasks with their DBS stimulator in ON and OFF positions. Order of ON/OFF conditions will be counterbalanced between patients.
89476521|NCT03714854|Placebo Comparator|Deep brain stimulation OFF|Patients will undergo every experimental tasks with their DBS stimulator in ON and OFF positions. Order of ON/OFF conditions will be counterbalanced between patients.
89476522|NCT03662906|Experimental|Electroacupuncture|Bilateral Shenshu (BL23), Ciliao (BL32), Zhongliao (BL33), Huiyang (BL35), and Sanyinjiao (SP6) will be inserted by the needles (0.30 mm in diameter, 75 mm in length or 0.40 mm diameter, 100 mm in length, Hwato Brand, Suzhou Medical Appliance Factory, China).
89476523|NCT03662906|Sham Comparator|Sham electroacupuncture|Sham Bilateral Shenshu (BL23), Ciliao (BL32), Zhongliao (BL33), Huiyang (BL35), and Sanyinjiao (SP6) will be inserted by the needles (0.20 mm in diameter, 25 mm in length, Hwato Brand, Suzhou Medical Appliance Factory, China).
89020261|NCT05280613|Experimental|Family Check-Up|"Families randomized to the Family Check-Up arm will be connected with a clinician who will provide the Family Check-Up. The Family Check-Up® (FCU) is an ecologically sensitive, evidence-based intervention that was developed to decrease childhood EBP by 1) assessing known ecological (child, family and contextual) risk and protective factors; 2) engaging parents in a tailored plan to enhance positive parenting and family management skills; and 3) connecting families to a tailored suite of child and family services and supports. Services may include an evidence-based suite of parenting sessions (Everyday Parenting Curriculum [EPC]) created by FCU developers for direct tailoring to the FCU feedback session."
89020262|NCT05280613|Active Comparator|Treatment as Usual|Treatment as Usual participants will be connected to a Family Service Coordinator within the Autism Program, who can direct the family to appropriate services and resources. Services may include consultation on child behaviours, workshops on various topics, parenting programs, Applied Behaviour Analysis, support groups, and group recreational programs. Families in the treatment as usual arm will be offered the Family Check-Up upon completion of the study.
89020263|NCT05271552|Experimental|Cohort 1- 40 Micrograms|Sublingual film containing 40 Micrograms Dexmedetomidine
89020264|NCT05271552|Experimental|Cohort 2- 60 Micrograms|Sublingual film containing 60 Micrograms Dexmedetomidine
89020265|NCT05271552|Placebo Comparator|Placebo|Sublingual Placebo film
89020266|NCT05268224||Dense Breast|Women mammographically categorized as having either heterogeneously dense or extremely dense breast tissue.
89020267|NCT05267951|Experimental|Open-loop Stimulation|Continuous stimulation
89020268|NCT05267951|Experimental|Close-loop Stimulation|Intended movement-based stimulation.
89020269|NCT05249088|Experimental|Protocolised reduction of non-resuscitation fluids|Participants receive non-resuscitation fluids according to a pre-defined protocol starting within two hours of randomization. The intervention is continued for the duration of the ICU admission up to a maximum of 90 days.
89476524|NCT03818425||Clinical Population|In- and Out-Patients diagnosed with depression (F32, F33), anxiety disorder (F40, F41; ICD-10) or posttraumatic stress disorder (F43.1; ICD-10)
89476525|NCT03818425||Healthy Controls|Subjects with no previous or actual mental disorder
89476526|NCT04093843|Experimental|TMS|Open label single arm study to determine safety and effectiveness of TMS for post stroke depression
89476527|NCT03598478|Experimental|TC-MPT group|Tai Chi-muscle power training group
89476528|NCT03598478|Active Comparator|TC group|Tai Chi group
89476529|NCT03598478|Active Comparator|MPT group|Muscle power training group
89476530|NCT03598478|No Intervention|Control group|Usual medical care is allowed.
89476531|NCT05347940|Experimental|Study group (A)|Study group (A):15 patient received traditional physical therapy program in addition to motor imagery in form of mirror therapy.
89476532|NCT05347940|Experimental|Study group (B)|Study group (B):15 patient received traditional physical therapy program only.
89476533|NCT02035969|No Intervention|Conventional treatment (CT)|Treatment according to the National Treatment Guidelines in Vietnam including treatment counseling and clinical follow up every three months. The caretaker of the child is responsible that the child will take the drugs and is provided with a pre-packed dosage form for easy remembering
89476534|NCT02035969|Experimental|Enhanced Treatment Support (ETS)|Treatment according to the National Treatment Guidelines in Vietnam including treatment counselling and clinical follow up every three months. In addition adherence support is provided according to the description under intervention.
89476535|NCT05121584|Experimental|Kinder Krown|Anterior primary teeth which restored by a Kinder Krown zirconia crown as a final restoration
89476536|NCT05121584|Active Comparator|NuSmile|Anterior primary teeth which restored by a NuSmile zirconia crown as a final restoration
89476537|NCT02821819|Experimental|Random start ovarian stimulation|"Egg-donors will be assigned to random start ovarian stimulation: During follicular phase starting at day 5,7,9,11 or 13 of the menstrual cycle and during luteal phase at luteinizing hormone (LH) peak +3,+5,+7,+9 or +11. They will receive urinary follicle stimulating hormone (FSH) 150-225 International units / daily (IU/d) and five days later the gonadotropin-releasing hormone (GnRH) antagonist: cetrorelix acetate 0,25 mg/d will be added until achieving criteria for receiving triptorelin 0,2 mg to induce final follicular maturation. Egg collection will take place 36 hours later.~Interventions:~Random start ovarian stimulation~Gonadotrophins: Urinary FSH 150-225 IU/d~GnRH antagonists: Cetrorelix 0,25 mg/d~GnRH agonist for triggering: Triptorelin 0,2 mg single dose"
89476538|NCT04500548|Experimental|Dose level -1 (nivolumab)|"PART I: Patients undergo collection of tissue samples for TMB level. Patients with elevated TMB may be eligible for Part II.~PART II: Patients receive nivolumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity."
89476539|NCT04500548|Experimental|Dose level 1 (nivolumab, ipilimumab)|"PART I: Patients undergo collection of tissue samples for TMB level. Patients with elevated TMB may be eligible for Part II.~PART II: Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive nivolumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days for up to 23 cycles in the absence of disease progression or unacceptable toxicity."
89020270|NCT05249088|Other|Usual Care|Participants receive non-resuscitation fluids according to local routines.
89476540|NCT05707819||Sintilimab+Chemoradiotherapy|Patients will receive 3 cycles of induction chemotherapy with gemcitabine and cisplatin and concurrent cisplatin-radiation plus Sintilimab, and then receive 11 cycles of Sintilimab after intensity-modulated radiotherapy (IMRT). All patients will receive IMRT. Sintilimab will begin on day 1 of induction chemotherapy and continue every 3 weeks for 17 cycles.
89476541|NCT02273336||Ancillary-Correlative (comprehensive genomic analysis)|Tissue and blood samples are analyzed via next generation sequencing and whole exome sequencing.
89476542|NCT03034538|Active Comparator|100mg|Zonegran 100mg
89476543|NCT03034538|Active Comparator|200mg|Zonegran 200mg
89476544|NCT02766998|Experimental|Preserved umbilical vein|Preserved umbilical vein as shunt/conduit
89476545|NCT02468180|Active Comparator|BRTO|Balloon-occluded retrograde transvenous obliteration
88950178|NCT01943279|Active Comparator|Standard Follow-up (SFU)|Women selecting SFU at either site (BCBC or CIHC) will schedule their in-person follow-up appointment before leaving the BCBC clinic on Study Day 1, when they receive their medication. In-person follow-up appointment will be scheduled for Study Day 15 (± 3 days)where, as per usual care, includes a history and a Post-abortion Checklist, transvaginal ultrasound, and a bimanual exam to confirm successful pregnancy expulsion.
89476546|NCT02468180|Active Comparator|NBCA|Endoscopic cyanoacrylate injection
89476547|NCT01836068|Experimental|Enfuvirtide monotherapy|Enfuvirtide 90 mg subcutaneously every 12 hours will be also be administered during any periods when oral medications are not expected to be tolerated for ≥ 24 hours, or during periods when ART is held due to interactions with conditioning regimens in patients who require ritonavir-boosted PI containing ART regimens.
88950179|NCT01943279|Experimental|Remote Follow-up (RFU)|On Study Day 1 in both sites, women selecting RFU will receive 3 laboratory requisition forms for serum β-hCG testing and will be instructed to have testing done at a laboratory site of her choice on Study Day 10-12. The follow-up telephone appointment will be scheduled to take place on Study Day 15 (±3 days). For the follow-up telephone appointment, the research nurse/nurse practitioner will calculate the percentage fall in the β-hCG value. She will contact the subject by phone at the specified time, take a history of the timing of misoprostol use, resulting symptoms and complete the symptom Post-abortion Check-list. The research nurse/nurse practitioner, in consultation with the clinic physician if necessary, will confirm the information, determine whether other follow-up is required.
88950180|NCT01943305|Experimental|Test arm|A total of 100 healthy adults, pre-screened to be negative for anti-dengue antibodies will be enrolled upon written informed consent. 75 subjects in the test arm will received 2 doses of inactivated Japanese Encephalitis vaccine and 1 dose of Yellow Fever vaccine.
88950181|NCT01943305|Experimental|Control arm|A total of 100 healthy adults, pre-screened to be negative for anti-dengue antibodies will be enrolled upon written informed consent. 25 subjects in the control arm will not receive Japanese Encephalitis vaccine but will receive 1 dose of Yellow Fever vaccine.
88950182|NCT01943331||patients admitted to ICU|
88950183|NCT01943357|Experimental|Diabetes Self-Management Program|Behavioral: Diabetes Self Management Program. Consists of either a six-week small-group face-to-face program with two peer leaders or an six-week peer-facilitated Internet-based program.
88950184|NCT01943370|Experimental|Early saline irrigation|Initiation of early saline irrigation
88950185|NCT01943370|Active Comparator|Late or Routine Saline Irrigation|Routine initiation of saline irrigation
88950186|NCT01943383||Diuretic|Patients who received a diuretic drug during the parent trial are eligible for participation.
88950187|NCT01943396|Experimental|Rheohemapheresis|Each treated patient will receive a series of 8 rheohemaphereses (cascade filtration) within 10 weeks. Best-corrected visual acuity, electroretinography and drusenoid retinal pigment epithelium detachment area will be examined. Changes of selected special immunologic parameters will be measured.
88950188|NCT01943396|No Intervention|without rheohemapheresis|Into the group the patients will be randomized with the same disease but without rheohemapheresis
88950189|NCT01943409|Active Comparator|Intralipid|Patients will receive Intralipid, which is the standard lipid emulsion used in the hospital
88950190|NCT01943409|Experimental|ClinOleic|Patients that are randomized to receive ClinOleic as a lipid emulsion in their PN, instead of Intralipid. ClinOleic is approved by Health Canada. The amount of calories from the lipid emulsion will be equivalent in the standard of care group and in the ClinOleic group.
89476548|NCT05053880|Experimental|1b dose exploration|1b dose exploration for 18 patients - The starting dose of ACT001 will be administered in combination with a single intravenous (IV) infusion of Pembrolizumab. After recovery from surgical resection, dosing will resume on a 3 weekly cycle and will consist of Pembrolizumab (standard dosing) and daily ACT001. Evaluation of a dose level of at least three (3) patients after completing one cycle of treatment post-surgery is required prior to commencing the next dose level.
89476549|NCT05053880|Experimental|2a- Randomized/Two-treatment Arm|30 Patients will be randomized to Arm A or Arm B at a ratio of 1 (Arm A) : 2 (Arm B). 10 patients will be randomized to the Pembrolizumab only arm (Arm A) and 20 patients will be randomized to the ACT001 plus Pembrolizumab arm (Arm B).
89476550|NCT04973540|Experimental|IBS Angel|Iron Bioresorbable Scaffold System
89476551|NCT05134376|Experimental|Workgroup|During the repair of the mediolateral episiotomy, the pregnant women included in the study group will be shown a video accompanying the acemaşîrân office with sterile virtual reality glasses with a view of nature.
89476552|NCT05134376|No Intervention|Control|Unlike the experimental group, only video and music applications will not be applied to the pregnant women included in the control group. Other applications will be done in the same way.
89476553|NCT03926611|Experimental|LOU064 Arm 1|10 mg LOU064 qd capsule once daily
89476554|NCT03926611|Experimental|LOU064 Arm 2|35 mg capsule qd LOU064 once daily
89476555|NCT03926611|Experimental|LOU064 Arm 3|100 mg capsule qd LOU064 once daily
88950191|NCT01943422|Experimental|Vemurafenib + IFNα-2b (10 MU/m2/d)|"Vemurafenib + High-dose Interferon alfa-2b (10 MU/m2/d)~IFNα-2b will be administered intravenously for 5 consecutive days (Monday through Friday) every week for 4 weeks (induction)~Vemurafenib will be dosed continuously at the standard Food and Drug Administration (FDA) approved dose of 960mg twice a day orally without dose interruption except for toxicities attributable to this agent."
89476556|NCT03926611|Experimental|LOU064 Arm 4|10 mg capsule LOU064 bid
89476557|NCT03926611|Experimental|LOU064 Arm 5|25 mg capsule LOU064 bid
89476558|NCT03926611|Experimental|LOU064 Arm 6|100 mg capsule LOU064 bid
89476559|NCT03926611|Placebo Comparator|Placebo Arm|Participants took matching placebo twice daily
89476560|NCT05134298||Study Kohort|As specified by study population, inclusion and exclusion criteria
89476561|NCT05134220||Chronic Kidney Disease (CKD) patients with acute coronary syndrome|"The CKD patients with or without dialysis who admitted to coronary care unit with chest pain consistent with ACS with any of following features :~Electrocardiogram (ECG) changes:~ST elevation.~ST depression.~T wave inversion.~recent left bundle branch block.~Troponin elevation."
89476562|NCT05134220||Chronic Kidney Disease (CKD) patients without acute coronary syndrome|The CKD patient with or without dialysis with no previous history of ACS.
89476563|NCT01423682|Placebo Comparator|Healthy subjects|
89476564|NCT01423682|Active Comparator|Rotator cuff tendinopathy|
89476565|NCT01272999||1|Otitis media cases
89476566|NCT05129852|Active Comparator|sage oil group|The participants in the sage oil massage group (30 participants in total) had pain in the first 3 days of their menstrual cycle; when the pain started, pain levels were scored by the participants using visual analog scale (VAS). In addition, their blood pressure, body temperature, and pulse rate were measured. The researchers massaged the abdomen with sage oil for 30 minutes, and 30 minutes after the massage, VAS evaluation and blood pressure, body temperature, and pulse rate measurements were performed again. This application was repeated for two menstrual periods.
89476567|NCT05129852|Active Comparator|Reiki group|visual analog scale (VAS) pain scores were also evaluated in the Reiki group (30 participants) when the pain started. The participants experienced pain on the first 3 days of their menstruation. Their blood pressure, body temperature, and pulse rate were also measured. Reiki was applied by a researcher with a Reiki certificate. Thirty minutes after the Reiki application, VAS evaluation and blood pressure, body temperature, and pulse rate measurements were repeated. This application was repeated for two menstrual periods.
89476568|NCT05129852|No Intervention|control group|Similarly, in the control group (30 participants),visual analog scale (VAS) pain scores were evaluated when the pain started on the first three days of their menstruation, and their blood pressure, body temperature, and pulse rate were measured. No application was performed; they were only asked to rest. VAS evaluation and blood pressure, body temperature, and pulse rate measurements were performed again after 30 minutes. These measurements were repeated for two menstrual cycles.
89476569|NCT05129774|Experimental|radical surgery with PALND|
89476570|NCT05129774|Active Comparator|radical surgery without PALND|
89476571|NCT03954379|Active Comparator|Group C ( Comparator Group )|Standard of care: Adductor Canal Block(ACB), Spinal Anesthesia (SA) and Peri-op Pain management
89476572|NCT03954379|Experimental|Group S ( Study Group )|iPACK and multi-modal analgesic regimen
89476573|NCT05134064||PCa patients underwent 1 h p.i. PSMA PET/CT imaging and 3 h p.i. PSMA imaging|
89476574|NCT02036125|Experimental|Ultrasound guided injection|Ultrasound guided injection of 40 mg of methylprednisolone
89476575|NCT02036125|Active Comparator|Blind injection|Blind injection of 40 mg of methylprednisolone
89476576|NCT05403866|Experimental|LT3001 Drug Product|Administered by intravenous infusion
89476577|NCT05403866|Placebo Comparator|Placebo|Administered by intravenous infusion
89476578|NCT05707507|Active Comparator|Outpatient antimicrobial therapy|Included patients will receive outpatient antimicrobial therapy according to their infectious disease.
89476579|NCT05707507|Other|Inpatient antimicrobial therapy|Included patients will receive intrahospital antimicrobial therapy according to their infectious disease.
89476580|NCT05133752|Experimental|Nemonoxacin|
89476581|NCT05129072|Experimental|kalifilcon A Daily Disposable Toric LD213001 lens|kalifilcon A Daily Disposable Toric LD213001 lens in SKUs +6D, +3D, 0D, -3D, -6D, and -9D
89476582|NCT04847102|Experimental|Study group|
88950192|NCT01943422|Experimental|Vemurafenib + IFNα-2b(15 MU/m2/d)|"Vemurafenib + High-dose Interferon alfa-2b (15 MU/m2/d)~IFNα-2b will be administered intravenously for 5 consecutive days (Monday through Friday) every week for 4 weeks (induction)~Vemurafenib will be dosed continuously at the standard Food and Drug Administration (FDA) approved dose of 960mg twice a day orally without dose interruption except for toxicities attributable to this agent."
89476583|NCT04847102|Placebo Comparator|Control group|
89476584|NCT02818777|Experimental|cannabidiol|"GWP42003-P oral solution, is purified cannabidiol (purity of ≥98%, 100 mg/ml cannabidiol in sesame oil with anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring).~Started at 5 mg/kg/day and is increased by 2.5-5 mg/kg at 3-5 day intervals to a target dose of 20 mg/kg/day."
89476585|NCT05128916|Active Comparator|Intralesional PRP|Patients with onychomycosis will receive intralesional injections of PRP.
89476586|NCT05128916|Active Comparator|Oral terbinafine|Patients with onychomycosis will receive oral terbinafine 250 mg daily
89476587|NCT05128916|Active Comparator|Intralesional PRP + Oral terbinafine|Patients with onychomycosis will receive intralesional PRP in addition to oral terbinafine 250 mg daily.
89476588|NCT02036047|Experimental|Exclusive cold polypectomy snare|All colorectal polyps up to 10 mm found except for tiny hyperplastic polyps in the rectum and distal sigmoid colon are removed using an exclusive cold polypectomy snare (Exacto cold snare). The technique is cold snare resection of the polyp without tenting without electrocautery and then suction of the transected polyp into a trap followed by submission to the histological evaluation. The hemostatic clipping is not performed after cold snare polypectomy.
89476589|NCT02036047|Active Comparator|regular polypectomy snare|All colorectal polyps up to 10 mm found except for tiny hyperplastic polyps in the rectum and distal sigmoid colon are removed using a regular polypectomy snare. The technique is cold snare resection of the polyp without tenting without electrocautery and then suction of the transected polyp into a trap followed by submission to the histological evaluation. The hemostatic clipping is not performed after cold snare polypectomy.
89476590|NCT05128760||Patients with COVID-19 and aPL positivity|Patient with COVID-19 and aPL test positivity
89476591|NCT05128760||Patients with COVID-19 without aPL positivity|
89476592|NCT05128760||APS patients|
89476593|NCT05128760||Healthy control|
89476594|NCT05128760||Disease control|
89020271|NCT05245097|Experimental|Intervention Group|"The intervention group will be assigned a Tango Belt to be worn around the waist for up to 24 hours a day (removed for bathing, charging of device and upon request) for 6 months. The Tango Belt (the Device) is a wearable belt designed to enable safer mobility of geriatric individuals (≥ 65 years of age) at risk for fall injury by mitigating major hip injuries due to falls by deploying an airbag around the hips upon sensing a serious hip-impacting fall-in-progress to protect the hips from ground impact forces."
89020272|NCT05245097|No Intervention|Control Group|The the clinical site's electronic medical record (EMR) database will be reviewed determine their long-term care patient population's initial eligibility for meeting the study inclusion criteria beginning at the time frame 6 months prior to the institutional review board (IRB) approval date. Subjects eligible for the control group must meet the requirements of the inclusion and exclusion criteria except for the waist circumference and need for consent. Eligible subjects' electronic health records will be mined for the baseline, midpoint, and final study metrics.
89476595|NCT05133050|Experimental|Experimental group|Drug: Ramipril The initial dose of ramipril is 2.5 mg /d. The blood pressure, blood potassium and blood creatinine is measured every 1-2 weeks. If the blood pressure is normal, the dose of ramipril is adjusted to 5 mg /d after 2 weeks. If the blood pressure is low, the dose of ramipril is reduced to 1.25 mg /d until the blood pressure becomes normal, otherwise, stop ramipril using. If the blood potassium is high (>5.5mmol/L), the dose of ramipril is reduced to 1.25 mg /d until the blood potassium becomes normal, otherwise, stop ramipril using. If the blood creatinine is higher before therapy (≥30%), the dose of ramipril is reduced to 1.25 mg /d until the blood creatinine becomes normal, otherwise, stop ramipril using.
89476596|NCT05133050|No Intervention|Control group|No angiotensin converting enzyme inhibitor (ACEI) and other renin-angiotensin system inhibitors (including angiotensin II receptor antagonists, etc.) treatment.
89476597|NCT05132972|Experimental|Treatment|Group receiving standard COVID-19 treatment and UCMSC infusion
89476598|NCT05132972|Sham Comparator|Control|Group receiving standard COVID-19 treatment and normal saline infusion
89476599|NCT04835480|Experimental|OsrHSA Group|OsrHSA (10g or 20g), IV, qd
89476600|NCT04835480|Active Comparator|HSA Group1|HSA (10g or 20g), IV, qd
89476601|NCT04495634|Experimental|Head Trauma or Brain Bleed|Medically stable patients who have undergone conventional head CT imaging undergo imaging within 24 hours using the s-HCT system.
89476602|NCT04160078|Experimental|Mindfulness Intervention Arm|A stress reduction plus sleep education intervention to improve sleep health
89476603|NCT02817841|Experimental|15 mg E4/3 mg DRSP|15 mg estetrol (E4)/3 mg drospirenone (DRSP) combined oral contraceptive
89476604|NCT05132894||Novice Runners|1-5 miles / week 18+ yo
89476605|NCT05132894||Moderate Runners|6-15 miles / week 18+ yo
89476606|NCT05132894||Advanced Runners|16+ miles / week 18+ yo
89476607|NCT02036905|Experimental|Cervical and thoracic mobilization|Cervical and thoracic mobilization: described as a repetitive low-velocity oscillatory movement applied to a joint segment. It is graded 1-4 based on the size of the amplitude and where in range it is being applied. The mobilization technique chosen will be based on the examination and clinical reasoning process of the therapist. The cervical and thoracic mobilization will be applied to the most provocative level.
89476608|NCT02036905|Experimental|Cervical and thoracic manipulation|Cervical and thoracic manipulation: is defined as high-velocity low-amplitude thrust at end range of a particular spinal segment. The therapist performs this technique by taking up all available slack at a particular segment and applying a high-velocity thrust through the end-range restriction. The manipulation technique will be chosen based on the examination and clinical reasoning process of the therapist.
89476609|NCT05128448|Experimental|Mobilisation with movement (MWM)|"With the participant standing, the restricted shoulder will rest on the clinician's shoulder in the following starting position: 90 degrees of glenohumeral abduction and 90 degrees of elbow flexion and hand holding a treatment belt. The belt will loop around the clinician and patient and will be held by the participant's contralateral hand. The clinician will apply and sustain a pain free caudal or posterolateralcaudal humeral head mobilisation force (whichever is more comfortable to the subject), followed by an active internal rotation (IR) performed by the patient. The IR movement will be performed to a pain free end of range. If possible, an overpressure with be requested, this is achieved by pulling the belt with the contralateral hand. The overpressure should not produce pain, if it does, it will not be performed.~3 sets of 8 repetitions will be applied, sustaining the end of available range for 2 seconds. An interval of 45 seconds will be respected amongst the repetitions."
89476610|NCT05128448|Active Comparator|Cross-body stretch|With the participant standing, the restricted shoulder will be self-stretched by conducting a horizontal adduction in 90 degrees of shoulder flexion to a level tolerated by the participant. This position will be held for thirty seconds and repeated four times. An interval of forty five seconds will be respected amongst the repetitions.
89476611|NCT05120102|Experimental|Experimental side of the arch|The right or left side of the patients maxillary arch selected by randomization
89476612|NCT05120102|No Intervention|Placebo side of the arch|The right or left side of the patients maxillary arch selected by randomization
89476613|NCT05403788|Experimental|Intervention with virtual reality|Each subject will receive a single session of exercises with the OCULUS QUEST2 (OCULUS VR, USA) and a hand tracking software (Hand Physics Lab, Holonautic, Switzerland). Brain function monitoring will be made by an EEG system ENOBIO 20 (Neuro-electrics, Spain) positioned over subject head. Intervention consisted of exercises with upper limbs and visual feedback. These activities were projected stereoscopically on VR googles.
89476614|NCT03764761|Experimental|AAC Intervention|Participants will use AAC technology of different designs delivered on iMacs or Surface tablets
89476615|NCT05132738|Experimental|Ripretinib treatment group|
89476616|NCT02036203|Experimental|SCu300A IUB|
89476617|NCT02036203|Active Comparator|TCu380A|
89020273|NCT05235009||Sub-Study 1|"Adults >= 18 years old with cancer or imminent cancer diagnosis (cases) versus cancer-free and no imminent cancer diagnosis (controls).~Sub-Study 1 is intended for the development of 3 free GAGome MCED tests."
89020274|NCT05235009||Sub-Study 2|"Adults between 35 - 80 years old asymptomatic for cancer and with no recent history of cancer (> 5 years since curative-intent treatment for cancer).~Sub-Study 2 is intended for the validation of the combined free GAGome MCED test (primary endpoint) and the plasma and urine free GAGome MCED tests (secondary endpoints)."
89020275|NCT05228964|Experimental|Open-label focused ultrasound|Focused ultrasound at a 10 Hz pulse repetition frequency, 5% duty cycle, and 720 mw/cm squared de-rated spatial peak temporal average intensity, delivered over 10 min once a day, five days a week for 3 weeks.
89020276|NCT05224362|Experimental|Hip Region|"Pre intervention: Force plate Posturography Pre selected exercises (8) will be performed by the participant using an elastic resistance band anchored from ground level and placed the hip region.~Warm up: 5-10 mins~Exercises:~Forward step, forward tandem steps, forward tandem hold, Upper body rotation, side steps. backward step, backward tandem walk, backward tandem hold. Cool down. Post intervention- Force plate Posturography and a Semi-structured Interview schedule"
89020277|NCT05224362|Experimental|Chest Region|"Pre intervention: Force plate Posturography Pre selected exercises (8) will be performed by the participant using an elastic resistance band anchored from ground level and placed the chest region (using velcro on a chest harness/training vest).~Warm up: 5-10 mins~Exercises:~Forward step, forward tandem steps, forward tandem hold, Upper body rotation, side steps. backward step, backward tandem walk, backward tandem hold. Cool down. Post intervention- Force plate Posturography and a Semi-structured Interview schedule"
89020278|NCT05224362|Placebo Comparator|No elastic band|"Pre intervention: Force plate Posturography Pre selected exercises (8) will be performed by the participant.~Warm up: 5-10 mins~Exercises:~Forward step, forward tandem steps, forward tandem hold, Upper body rotation, side steps. backward step, backward tandem walk, backward tandem hold. Cool down. Post intervention- Force plate Posturography and a Semi-structured Interview schedule"
89020279|NCT05222750||Pre-COVID-19|
89476618|NCT04640714|Experimental|CONTINUity of care Under Management by Video visits (CONTINUUM-V)|"Participants with advanced cancer will receive a video visit conducted by an oncology Nurse Practitioner (NP) within three (3) business days of hospital discharge.~The visit will involve: (1) reconcile medications, (2) manage symptoms, (3) review the post-hospital care plan for hospitalization-specific issues, and (4) schedule follow-up with the outpatient oncology team.~Participant and clinician may also be interviewed for their feedback on the video visit.~The ultimate goal of the intervention is to improve patients' confidence in managing their health condition and reduce burdensome health care utilization after discharge, particularly reducing 30-day hospital readmissions."
89476619|NCT05132426|Experimental|OMT Intervention Arm|"Myofascial release of the thoracic inlet is a treatment involving gentle pressure applied to shoulders and neck to move the tissue in different directions.~Pectoral traction will have the doctor gently grasp and slowly pull the armpit area with a slow pulling force applied towards the shoulders.~Diaphragm release with MFR consists of the doctor touching below the ribs on each side and gently applying pressure to move the tissue from side to side.~Fascial release of the breast will have the doctor encircling the breast with their hands and inducing anterior traction. The doctor then induces motion in all directions. The doctor will then locate the affected spot and use a direct stripping motion from the base of the breast toward the areola until the restriction is released.~Thoracic pump has the doctor placing their hands over the chest wall on each side and applying pressure and releasing pressure several times to generate a pumping action of about 100 times per minute."
89476620|NCT05132426|Sham Comparator|OMT Sham Arm|"MFR of the thoracic inlet Sham: Operator's hands would encircle the thoracic inlet and would feel for somatic dysfunction in the area but would refrain from treating this area.~Pectoral traction Sham: The doctor would contact the armpit area and diagnose the somatic dysfunction, but unlike the treatment group they would not do any treatment.~Diaphragm release with MFR Sham: The doctor's hands are placed just below the ribcage and will feel for the direct restrictive barriers but will not augment the release.~Fascial release of the breast Sham: The doctor would encircle the breast with their hands but would not induce motion or engage any direct barriers. The operator will find the barrier in the tissue but will refrain from treating it.~Thoracic pump Sham: The doctor will hold their hands in place over the chest wall but will not try to affect the breathing motion and will not resist the upward motion of the rib cage during inhalation."
89476621|NCT05132270|Experimental|Combination of hydroxyurea and thalidomide|Hydroxyurea was continued at a dose of 10-20 mg/kg/day for 6 months and then thalidomide was added orally at a dose of 2-5mg/kg/day for 6 months.
89476622|NCT02814565|Experimental|Cyclobenzaprine HCl 15 mg|Cyclobenzaprine Hydrochloride (HCl) extended-release, 15 mg capsules, orally, once daily for 14 days.
89476623|NCT02814565|Placebo Comparator|Placebo|Cyclobenzaprine HCl extended release placebo-matching capsules, orally, once daily for 14 days.
89476624|NCT05132192||PVT|Patients with pretransplant portal vein thrombosis
89476625|NCT05132192||non-PVT|Patients without pretransplant portal vein thrombosis
89020280|NCT05222750||COVID-19|
89020281|NCT05222750||COVID-19 vaccination roll - out|
89020282|NCT05215769|Experimental|Health services research (video)|Patients participate in a video intervention session and complete questionnaires at baseline, after participating in the video intervention, and after receiving NGS results.
89020283|NCT05215678||INKA participants|Individuals eligible and accepting participation in the INKA trial (NCT05172843)
89020284|NCT05215678||n-INKA participants|Individuals eligible and declining participation in the INKA trial (NCT05172843)
89020285|NCT05211336|Experimental|1: VIPOR|VIPOR (venetoclax, ibrutinib, prednisone, obinutuzumab, lenalidomide) in 21-day cycles for up to 6 cycles
89206252|NCT02599805|Experimental|Natrox treatment group|In this group, all subjects will have the Natrox™ ODS will be applied to the ulcer and attached to the active Natrox™ Oxygen Generator using the tubing provided or regular dressing will be used. Dressings according to the standard practice guidelines will be used. Patients in this group will continue to receive treatment as described by the diabetic foot ulcer standard of care. The ulcer will be photographed at biweekly intervals for a period of 8 weeks to analyze ulcer surface area using a standardized digital imaging software.
89020286|NCT05209594|Experimental|Healthy Relationships Program (HRP) for 2SLGBTQIA+ Youth|Students in grades 9 to 12 participating in GSAs where the HRP for 2SLGBTQIA+ Youth is being implemented.
89476626|NCT05121038|Experimental|Cohort 1 Pancreatic Cancer|Biopsy for tissue immune profile if archived tissue not available. Folfirinox infusion for 3 cycles followed by a repeat biopsy for a second tissue immune profiling. Folfirinox plus CEND1 infusion for 3 cycles. Seventy-two hours after last infusion participant will have surgery.
89476627|NCT05121038|Experimental|Cohort 2 Peritoneal Mets|Biopsy for tissue immune profile if archived tissue not available. Folfirinox plus Panitumumab (if RAS/BRAF) infusion for 3 cycles followed by a repeat biopsy for a second tissue immune profiling. Folfirinox plus Panitumumab (if RAS/BRAF positive) and CEND1 infusion for 3 cycles. Seventy-two hours after last infusion participant will have surgery.
89476628|NCT05121038|Experimental|Cohort 3 Oligomets Colon Cancer|Biopsy for tissue immune profile if archived tissue not available. Folfirinox plus Panitumumab (if RAS/BRAF) infusion for 3 cycles followed by a repeat biopsy for a second tissue immune profiling. Folfirinox plus Panitumumab (if RAS/BRAF positive) and CEND1 infusion for 3 cycles. Seventy-two hours after last infusion participant will have surgery.
89476629|NCT05106374||Observational (questionnaire, assessment, biospecimen)|Patients complete questionnaires over 30-40 minutes about daily activity and feelings, complete thinking and walking tests over 10 minutes, and undergo collection of blood samples before the first dose of chemotherapy and 90, 180, and 365 days after first dose of chemotherapy. Patients with non-small lung cancer also undergo collection of stool sample.
88950193|NCT01943422|Experimental|Vemurafenib + IFNα-2b (20 MU/m2/d)|"Vemurafenib + High-dose Interferon alfa-2b (20 MU/m2/d)~IFNα-2b will be administered intravenously for 5 consecutive days (Monday through Friday) every week for 4 weeks (induction)~Vemurafenib will be dosed continuously at the standard Food and Drug Administration (FDA) approved dose of 960mg twice a day orally without dose interruption except for toxicities attributable to this agent."
89476630|NCT05705713|Experimental|Cases|48 participants with burn injuries associated with inhalation lung injuries were recruited from the burn department.
89476631|NCT05705713|Active Comparator|Control|10 participants with burn injuries NOT associated with inhalation lung injuries were recruited from the burn department.
89476632|NCT05097794|Experimental|Sequence BR1015-1/BR1015-2/BR1015-1 + BR1015-2|"A total of 32 subjects will be enrolled in one sequence group. The investigational products (IPs) will be administered according to the treatment groups(BR1015-1, BR1015-2, BR1015-1 + BR1015-2) assigned to one sequence group in Period 1, Period 2, and Period 3.~Period 1(BR1015-1): BR1015-1(Fimasartan 60mg) - 1 tablet QD, five-day repeated-dose~Period 2(BR1015-2): BR1015-2(Indapamide 1.5mg) - 1 tablet QD, five-day repeated-dose~Period 3(BR1015-1 + BR1015-2): BR1015-1 (Fimasartan 60mg) 1 tablet + BR1015-2 (Indapamide 1.5mg) 1 tablet QD, five-day repeated-dose~Washout period between Period 1 and Period 2: five days~Washout period between Period 2 and Period 3: two days"
89476633|NCT02036281|Experimental|SP-SAP ARM|The first subject will be enrolled in the 1-mcg SP-SAP cohort. A percutaneous intraspinal catheter will be placed at the L5-S1 interspace and the catheter advanced 4-5 cm into the intrathecal space under fluoroscopic guidance. To confirm location, CSF will be aspirated and radioopaque contrast dye injected. 1-mL study drug will be mixed with 1-mL patient CSF fluid and administered intrathecally via the catheter. The catheter will be flushed with 1 mL bolus of saline. Four hours after injection (+15 min), the catheter will be removed and the exit site treated with Neosporin ointment and sterilely dressed. Subjects will be monitored in the recovery room for 4 hours and in the hospital for 24 hours and discharged home. Patients only receive a single IT dose.
89476634|NCT02036359|Active Comparator|erlotinib|Patients in erlotinib arm will take erlotinib 150mg/day for 9 weeks unless disease progression, unacceptable toxicity or death.
89476635|NCT02036359|Active Comparator|Chemotherapy|"Patients in chemotherapy arm will then receive 3 cycles (9 weeks) of chemotherapy with docetaxel 35mg/m2 IV on day 1 and day 8, and cisplatin 75mg/m2 on day 8.~Treatment failure will include patients who fail to complete 3 cycles (9 weeks) of study treatments due to disease progression or unacceptable toxicity.~Patients with no disease progression after terminating study treatment will undergo surgical resection and be followed until disease progression is noted, or study end. Survival will be recorded and analyzed.~If progressive disease or unacceptable toxicity occurs during study treatments, patients will be treated at discretion of investigator according to local protocol."
89476636|NCT04884386|Experimental|robot-assisted gait training|
89476637|NCT04884386|Active Comparator|conventional locomotion therapy|
89476638|NCT03817333||ACOS smoking history >20 pack-years|Subjects with asthma-COPD overlap syndrome
88950194|NCT01943487|Experimental|1: verapamil + EC905|
88950195|NCT01943500||Cancer or no prior history of cancer|Confirmed patients with breast, prostate, or colorectal cancer (OR) subjects with no prior history of cancer
88950196|NCT01943513|Experimental|BIIB023|Participants receive intravenous (IV) infusions of BIIB023
88950197|NCT01943513|Placebo Comparator|Placebo|Participants receive intravenous (IV) infusions of placebo
88950198|NCT01943578||lung cancer patients|Non Small Cell Lung Cancer, Small Cell Lung Cancer
88950199|NCT01943604|Experimental|Experimental|"Nutella Breakfast~Waffle Breakfast"
88950200|NCT01943617|Active Comparator|Entecavir Therapy|Entecavir, 0.5mg, qd, oral, for 2 years
89476639|NCT03817333||IRAO smoking history <5 pack-years|Subjects with an incomplete reversibility of airway obstruction
89476640|NCT02036437|Experimental|Cases|A dose of 20ug is required obtained by dissolving the 200ug tablet (Misotac® Sigma Pharmaceutical Industries) in 200 ml water (1ug per ml), the solution is shaked well before each administration. The solution will be orally administrated every two hours (max. 12 hrs) until adequate uterine contractions obtained (3 per 10 minutes each lasting 40-60 seconds) and then stopped. The initial dose will be increased to 40 ml (40ug) after two doses if there are no contractions. The timing and strength of contractions will be assessed by abdominal palpation. If the contractions are inadequate, augmentation of the active phase of labor will be attempted by hourly-titrated oral misoprostol (20 ml) +/- amniotomy.
89476641|NCT02036437|Active Comparator|Control|Dinoprostone 3 mg (Dinoglandin® Alexandria Co. for Pharmaceuticals) will be inserted in the posterior vaginal fornix and repeated after six hours if contractions are inadequate (i.e. two doses maximum). If the contractions become inadequate, augmentation of the active phase of labor will be attempted by Syntocinon (oxytocin) infusion +/- amniotomy.
88950201|NCT01943617|Experimental|Entecavir plus thymosin therapy|Entecavir plus thymosin-α 1.6μg, Twice a week, ih, in the middle one year
88950202|NCT01943630|Active Comparator|AS101|Topical 15% AS101 gel, once a day (overnight)
88950203|NCT01943630|Placebo Comparator|Vehicle|Vehicle, Once a day topical application (Overnight)
88950204|NCT01943656|Experimental|Tobii™ Eyegaze System|Single arm, open label study.
88950205|NCT01943669|Experimental|ReWalk™ device|Self-controlled group; single cohort.
88950206|NCT01943682|Experimental|CPX-351|CPX-351 is made up of two chemotherapy drugs that patients may have already received called cytarabine and daunorubicin that are now packaged together. Subjects will receive a single course of CPX-351 administered on Days 1, 3, and 5.
88950207|NCT01943708|Active Comparator|Continuous positive airway pressure (CPAP) device.|Standard CPAP therapy
88950208|NCT01943708|Experimental|Auto-CPAP device (SPAP).|Novel Auto-CPAP algorithm
88950209|NCT01943721|Experimental|VISION5 Product|VISION5 Product in both eyes
88950210|NCT01943734|Experimental|Lifestyle counseling|Information passed on anthropometric assessment
88950211|NCT01943760|Active Comparator|tramadol wound infiltration|2 mg / kg of tramadol diluted in 5 ml of 0.9% saline solution wound infiltration 20ml of 0.9% saline solution intravenously
88950212|NCT01943760|Experimental|tramadol intravenous administration|2 mg / kg of tramadol diluted 20ml of 0.9% saline solution intravenously 5 ml of 0.9% saline solution wound infiltration
88950213|NCT01943773|Experimental|Prehabilitation|The intervention will consist of nine 45 minute long physical therapy sessions. Sessions will occur three times weekly at the patient's home.
88950214|NCT01943773|Experimental|No Prehabilitation|The control group will undergo routine pre-operative management.
89206253|NCT02599805|No Intervention|Control group|"All subjects in this group will receive the Diabetic foot ulcer standards of care which include:~Full medical assessment in all cases.~Surgical operation/Intervention where indicated.~Local treatment of the ulcer (debridement followed by ulcer care according to modern ulcer healing standards and management of diabetes.) The ulcer will be photographed at biweekly intervals for a period of 8 weeks to analyze ulcer surface area using a standardized digital imaging software."
88950215|NCT01943786||FOLFIRI + Cetuximab|Patients with advanced colorectal cancer and wild-type KRAS will receive FOLFIRI + Cetuximab according to regular clinical practice
88950216|NCT01943812|Experimental|Substituted FET cycle and GnRHa|Substituted FET GnRH-a 2 bolus two days before Estradiol 6 mg Progesterone (Crinone) 180 mg
88950217|NCT01943812|Active Comparator|Substituted FET cycle|substituted FET cycle Estradiol Progesterone
88950218|NCT01943838|Experimental|SAR245408 polymorph E tablets|Escalating doses of SAR245408 polymorph E tablets, once daily dosing with morning meal every day for two 28-days cycles
88950219|NCT01943877|Experimental|Propolis|
88950220|NCT01943877|Sham Comparator|scaling and root planing|
88950221|NCT01943890|Experimental|Physiotherapy and hypertonic saline|Chest physiotherapy integrated with inhalation of hypertonic saline
89020287|NCT05209594|Active Comparator|Regular GSA Programming|Students in grades 9 to 12 participating in regular GSA programming.
89476642|NCT02650466|Experimental|Nanopulse treatment|The study will be a single center, open label, non-randomized clinical trial that will provide efficacy data for the treatment of common warts by the Nanopulse system in terms of efficacy and cosmetic outcome with 1 - 4 application (treatment) sessions. All subjects will receive a minimum number of applications per discrete skin wart lesion. Up to 4 warts per subject will be treated with the Nanopulse device. The wart will be debulked to the point of pinpoint bleeding prior to the initial application. The subject will return after 1 week for an evaluation visit and at 4 weeks for a second treatment and 2 additional monthly treatments if warranted. If the subject is declared clinically clear at any of the application visits, they will be placed into follow up. The minimum number of treatments per wart is one and the maximum is 4. They will return at the 12 week point post last visit for final assessment and evaluation.
89476643|NCT02036593|Experimental|Walk Your Heart to Health intervention|"Participants were randomized into one of two groups: intervention and lagged intervention. The intervention group completed the 8 week Walk Your Heart to Health intervention, followed by a second wave of data collection for both initial and lagged intevention groups. The lagged intervention group then completed the 8 week Walk Your Heart to Health intervention. Both groups continued walking for another 24 weeks.~Walking group sessions conducted 3 times per week for 32 weeks."
89476644|NCT02036593|Other|Walk Your Heart to Health lagged|"Participants were randomized into one of two groups: intervention and lagged intervention. The intervention group completed the 8 week Walk Your Heart to Health intervention, followed by a second wave of data collection for both initial and lagged intevention groups. The lagged intervention group then completed the 8 week Walk Your Heart to Health intervention. Both groups continued walking for another 24 weeks.~Walking group sessions conducted 3 times per week for 32 weeks."
89476645|NCT03562429|Experimental|TGF group (study group)|Use TGF to treat osteoarthritis of the knee, 5g/time, 3 times a day, for 12 weeks.
89476646|NCT03562429|Placebo Comparator|TGFP group (placebo group)|Use TGFP to treat osteoarthritis of the knee, 5g/time, 3 times a day, for 12 weeks.
89476647|NCT02036671|Experimental|EndoAVF|The FLEX System will be used to percutaneously create a fistula in CKD patients who require hemodialysis vascular access
89476648|NCT05697445|Experimental|Cranial Mobilization and Exercises Group|
89476649|NCT05697445|Active Comparator|Exercises Group|
89476650|NCT02815735|Experimental|comfilcon A|Participants wear comfilcon A lens for 4 weeks during the cross over study.
89476651|NCT02815735|Active Comparator|lotrafilcon B|Participants wear lotrafilcon B lens for 4 weeks during the cross over study.
89476652|NCT04677218|No Intervention|First Group|First group of fixation will be standar procedure ( without knotted and retensioned the hamstring autograft after tibial fixation)
89476653|NCT04677218|Experimental|Second Group|In the second group, the hamstring autograft will be retensioned after tibial fixation.
89476654|NCT04677218|Active Comparator|Third Group|In the third group, the hamstring autograft will be knotted and retensioned after tibial fixation.
89476655|NCT05027360||Acute heart Failure AHF|AHF diagnosis, defined as rapid onset or worsening of symptoms and/or signs of HF
89476656|NCT02036983|Active Comparator|Ultrasound guided bilateral TAP block|Ultrasound guided TAP Block with local anesthetic and dexamethasone.
88950222|NCT01943903||Cohort 1 - Standard of Care|Subjects will be referred for non-invasive and/or invasive testing and evaluation. Prior to treatment of each subject considered for percutaneous coronary intervention (PCI) and/or coronary artery bypass grafting (CABG), the investigator and the institution's heart team will review clinical data and results of the diagnostic tests to recommend a treatment strategy, according to the institution's standard practice. Cohort 1 of the study is an observational evaluation of resource utilization and outcomes based on standard practice for diagnosis and treatment of subjects with symptomatic suspected CAD and intermediate likelihood of obstructive CAD. Subjects will be followed for one year after enrollment.
88950223|NCT01943903||Cohort 2 - FFRCT-guided|Subjects will be referred for non-invasive and/or invasive testing and evaluation. Prior to treatment of subjects considered for PCI and/or CABG, the investigator and the institution's heart team will review the results of all available diagnostic tests, including cCTA and FFRCT, and will recommend a treatment strategy accordingly. FFRCT is a non-invasive method to evaluate the hemodynamic significance of coronary artery lesions. FFRCT calculates FFR from subject-specific cCTA data using computational fluid dynamics under rest and simulated maximal coronary hyperemic conditions. FFRCT values range between 0 and 1, and values ≤0.80 are considered hemodynamically (HD)-significant.
88950224|NCT01943942|Experimental|A (reference)/ B (test)|initial administration of reference and cross-over to test
88950225|NCT01943942|Experimental|B (test)/ A (reference)|initial administration of test and cross-over to reference
88950226|NCT01943955|Experimental|home-based computer gaming|computer gaming, balance exercises carried out at home for 20 minutes 5 days/week and monitored by a physical therapist.
88950227|NCT01943968|Other|Systemic sclerosis patients|Systemic sclerosis patients will have blood tested for fibrotic enzyme levels
88950228|NCT01943981||Optimal/inappropriate exercise response|
88950229|NCT01944007|Experimental|CLP 15 g Fed|Cross-Linked Polyelectrolyte (CLP) Study medication delivered q.i.d just before each of 4 standardized meals/snack
88950230|NCT01944007|Experimental|CLP 25 g Fed|Cross-Linked Polyelectrolyte (CLP) Study medication delivered q.i.d just before each of 4 standardized meals/snack
88950231|NCT01944007|Experimental|CLP 7.5 g Fed|Cross-Linked Polyelectrolyte (CLP) Study medication delivered q.i.d just before each of 4 standardized meals/snack
88950232|NCT01944007|Experimental|CLP 15 g fasted|Cross-Linked Polyelectrolyte (CLP) Study medication delivered q.i.d 1 hour prior to 4 standardized meals/snack
88950233|NCT01944033|Active Comparator|Group Terbutaline|Group Terbutaline received 5 mg Terbutaline sulfate (2ml) and 3ml serum saline in nebulization repeated three times during 1 hour and every 4 hours during the first 24 hour protocol
89206254|NCT04774354||Abdominal surgery|POSSUM, the P-POSSUM and the Charlson comorbidity index will be calculated and compared to the outcomes obtained in our center.
89476657|NCT02036983|Active Comparator|Instillation of surgical site with local anesthestic.|Instillation of surgical site under direct visualization with local anesthetics and dexamethasone.
89476658|NCT02036983|Placebo Comparator|Control Group|Standard anesthetic technique
88950234|NCT01944033|Experimental|Group Terbutaline/IB|Group Terbutaline/Ipratropium Bromide received combination of 5 mg Terbutaline (2ml) and 0.5 mg Ipratropium bromide (2ml) and 1ml serum saline in nebulization repeated threeand every 4 hours during the first 24 hour protocol
89476659|NCT03814915||Study 1 - Prediabetes|"The primary objective of Study 1 is to collect biosamples and information that might yield novel, predictive biomarkers for glycaemic deterioration in non-diabetic high-risk participants.~Participants in Study 1 were recruited from existing prospective cohort studies in or around each of the following European cities: Malmö, Sweden (Malmö Diet and Cancer Study); Amsterdam, The Netherlands (Hoorn Study); Copenhagen, Denmark (Inter99); and Kuopio, Finland (METSIM). A clinically practicable screening tool (DIRECT-DETECT) was used to identify at-risk participants from existing cohort studies, who were then recruited into this new prospective cohort study (Study 1)."
89476660|NCT03814915||Study 2- Diabetic|The primary objective of Study 2 is to collect biosamples and information that might yield novel, predictive biomarkers for glycaemic deterioration in people who have recently been diagnosed with type 2 diabetes. Participants in Study 2 of DIRECT are recruited from or nearby each of the following European cities: Malmö, Sweden; Amsterdam, the Netherlands; Copenhagen, Denmark; Exeter, UK; Newcastle, UK; Dundee, UK. Potential participants are recruited through targeted searches of existing databases and research registers combined with person-to-person contact at educational clinics and through routine retinal screening programmes.
89476661|NCT04990310|Experimental|Study Participants|On Day 1, participants will receive a single oral dose of [14C]-CORT113176 450 mg (3 X 150 mg lipid formulation capsules) in the fed state.
89476662|NCT05020652|Experimental|TQ05105 tablets + Hydroxyurea blank tablets|Take TQ05105 Tablets + Hydroxyurea blank tablets orally on an empty stomach, with an interval of at least 8 hours, and the best interval is 12 hours. Every 4 weeks is a period of administration
89476663|NCT05020652|Active Comparator|TQ05105 blank tablets + Hydroxyurea tablets|Take TQ05105 blank tablets + Hydroxyurea tablets orally on an empty stomach, with an interval of at least 8 hours, and the best interval is 12 hours. Every 4 weeks is a period of administration
89476664|NCT03562351|Experimental|Verbal Instructions on use of RM|Caregivers will undergo an educational intervention with typical training with verbal instructions and use of a rectal diazepam trainer.
89476665|NCT03562351|Experimental|Video on use of RM|Caregivers will undergo an educational intervention with training by watching an instructional video regarding rescue medication administration
89476666|NCT03562351|Experimental|Mannequin on use of RM|Caregivers will undergo an educational intervention with training by use of a mannequin to practice administering the rescue medication
89476667|NCT04853498|Experimental|TQB3720 tablets|TQB3720 tablets administered orally, once daily in 28-day cycle.
89476668|NCT05689177|Experimental|Booster dose administration to younger participants|Participants 18-25 y.o. take a booster dose of vaccine against COVID-19 (Soberana Plus (FINLAY-FR-1A), Republic of Cuba)
89476669|NCT05689177|Experimental|Booster dose administration to older participants|Participants 26-80 y.o. take a booster dose of vaccine against COVID-19 (Soberana Plus (FINLAY-FR-1A) Republic of Cuba)
89476670|NCT02475291||Significant coronary lesions|Significant lesions with more than 70% diameter stenosis at proximal major coronary arteri(es).
89476671|NCT05108012|Experimental|Test group|The investigators will inject the activated NK cells, 1-3 times with weekly interval into tumor cavity.
89476672|NCT02036749|Active Comparator|quadratus lumborum block (nerve block)|quadratus lumborum block with ropivacaine
89476673|NCT02036749|Placebo Comparator|sham block|QL block with saline
89476674|NCT04818320|Experimental|Favipiravir|Favipiravir treatment group (with standard of care),
89476675|NCT04818320|No Intervention|Control|No favipiravir given. Standard of care only
89476676|NCT02475135|Experimental|Panel 1: Group 1|Subject will receive a single oral tablet of fixed dose combination (FDC) containing darunavir (DRV)/ cobicistat (COBI)/emtricitabine (FTC) /tenofovir alafenamide (TAF) (D/C/F/TAF) under fed conditions (standardized regular breakfast, test Panel 1) on Day 1 of treatment period 1 and by FDC of elvitegravir (EVG)/cobicistat (COBI)/emtricitabine (FTC)/ tenofovir alafenamide (TAF) (E/C/F/TAF) under fed conditions (standardized regular breakfast, reference Panel 1) on Day 1 of treatment period 2.
89476677|NCT02475135|Experimental|Panel 1: Group 2|Subject will receive a single oral tablet of FDC containing E/C/F/TAF under fed conditions (standardized regular breakfast, reference Panel 1) on Day 1 of treatment period 1 and a single oral tablet of FDC containing D/C/F/TAF under fed conditions (standardized regular breakfast, test Panel 1) on Day 1 of treatment period 2.
89476678|NCT02475135|Experimental|Panel 2: Group 1|Subject will receive a single oral tablet of D/C/F/TAF under fed conditions (standardized regular breakfast, test Panel 2) on Day 1 of treatment period 1 and a single oral tablet of DRV, a tablet of emtricitabine/ tenofovir alafenamide (FTC/TAF) and a tablet of COBI under fed conditions (standardized regular breakfast, reference Panel 2) on Day 1 of treatment period 2.
89476679|NCT02475135|Experimental|Panel 2: Group 2|Subject will receive a single oral tablet of DRV, a tablet of FTC/TAF and a tablet of COBI under fed conditions (standardized regular breakfast, reference Panel 2) on Day 1 of treatment period 2 and a single oral tablet of D/C/F/TAF under fed conditions (standardized regular breakfast, test Panel 2) on Day 1 of treatment period 2.
88950235|NCT01944072|Other|60%|aerobic exercise training intensity of 60%Wmax
88950236|NCT01944072|Other|80%|aerobic exercise training intensity of 80%Wmax
88950237|NCT01944085|Active Comparator|Acetaminophen|Acetaminophen was administered 1 hour prior to pin removal (weight dependent dose)
88950238|NCT01944085|Active Comparator|Ibuprofen|Ibuprofen was administered 1 hour prior to pin removal (weight dependent dose)
88950239|NCT01944085|Placebo Comparator|Vitamin C (Placebo)|Vitamin C was administered 1 hour prior to pin removal (weight dependent dose)
88950240|NCT01944111|Experimental|Plication|Prospective clinical trial comparing Standard Adustable Gastric Banding versus experimental Adjustable Gastric Banding
88950241|NCT01944124|Experimental|Exercise Prescription + Mobile Health|Received a tailored exercise prescription and mobile health technology kit to track blood pressure, blood glucose, physical activity and body weight.
88950242|NCT01944124|Active Comparator|Exercise Prescription|Received a tailored exercise prescription only.
88950243|NCT01944137|No Intervention|Standard Care|Participant will receive standard cancer care
89476680|NCT02475135|Experimental|Panel 3: Group 1|Subject will receive a single oral tablet of D/C/F/TAF under fasted conditions (test Panel 3) on Day 1 of treatment period 1 and a single oral tablet of D/C/F/TAF with a standardized high-fat breakfast (reference Panel 3) on Day 1 of treatment period 2.
89476681|NCT02475135|Experimental|Panel 3: Group 2|Subject will receive a single oral tablet of D/C/F/TAF with a standardized high-fat breakfast (reference Panel 3) on Day 1 of treatment period 1 followed by a single oral tablet of D/C/F/TAF under fasted conditions (test Panel 3) on Day 1 of treatment period 2.
89476682|NCT02478333|Experimental|ALS-008176 (250 mg) or Placebo|Participants will receive ALS-008176, 250 milligram (mg) or placebo oral suspension once on Day 1 under fasted conditions.
89476683|NCT02478333|Experimental|ALS-008176 (500 mg) or Placebo|Participants will receive ALS-008176, 500 milligram (mg) or placebo oral suspension once on Day 1 under fasted conditions.
89476684|NCT02478333|Experimental|ALS-008176 (750 mg) or Placebo|Participants will receive ALS-008176, 750 milligram (mg) or placebo oral suspension once on Day 1 under fasted conditions.
89476685|NCT05118620|Experimental|Active Treatment|This group will receive a single injection PENG nerve block of bupivacaine 0.375% (20 mL)
89476686|NCT05118620|Placebo Comparator|Placebo|This group will receive a single injection PENG nerve block with normal saline (20 mL)
89476687|NCT02814643|Experimental|Benralizumab|1 mL fill volume administered every 4 weeks for 3 doses (Weeks 0, 4, and 8). Patients will receive 1 dose of seasonal influenza virus vaccine Intramuscular (IM) at Week 8.
89476688|NCT02814643|Placebo Comparator|Placebo|1 mL fill volume administered every 4 weeks for 3 doses (Weeks 0, 4, and 8). Patients will receive 1 dose of seasonal influenza virus vaccine Intramuscular (IM) at Week 8.
89476689|NCT05105516|Other|Ablation|Comparison between different sites of ablation
89476690|NCT05368233|Experimental|ERAS protocol without the use of of abdominal drain in the perforated peptic ulcer patient|"Tracheal intubation. Short acting anesthetic agents,avoid opioid agents . Omental patch repair without placement of sub hepatic drain. Bilateral Transverse abdominis plane block/ Rectus sheath block immediately after surgery.~Abdominal drain will not be placed Post operative nausea and vomiting prophylaxis. Encourage to mobilize out of bed after effect of general anesthesia has weaned off.~Initiation of feeding-Oral sips on day 1, step up day 2 onward. Removal of nasogastric tube-immediately after surgery after aspirating the gastric content through nasogastric tube.~Removal of urinary catheter-after weaning from the effect of general anesthesia.~Avoid opioid analgesics."
89476691|NCT05368233|Active Comparator|ERAS protocol with the use of of abdominal drain in the perforated peptic ulcer patient|"Tracheal intubation. Short acting anesthetic agents, avoid opioid agents. Omental patch repair with placement of sub hepatic drain. Bilateral Transverse abdominis plane block/ Rectus sheath block immediately after surgery.~Abdominal Drains will be placed and removed at anytime within 24 hrs and to not remove if the output is bilious or pus.~Post operative nausea and vomiting prophylaxis. Encourage to mobilize out of bed after effect of general anesthesia has weaned off.~Initiation of feeding-Oral sips on day 1, step up day 2 onward. Removal of nasogastric tube-immediately after surgery after aspirating the gastric content through nasogastric tube.~Removal of urinary catheter-after weaning from the effect of general anesthesia.~Placing Sub hepatic drain intraoperatively. Avoid opioid analgesics."
89476692|NCT02036827|Active Comparator|moderate NMB + standard pressure|Investigators will administrate rocuronium until moderate neuromuscular blockade (Train of Four >=1, Post-tetanic count>=8) is established. And pneumoperitoneum will be maintained with standard-pressure 14 mmHg.
89476693|NCT02036827|Active Comparator|deep NMB + standard pressure|Investigators will administrate rocuronium until deep neuromuscular blockade (Train of Four=0, Post-tetanic count<=3) is established. And pneumoperitoneum will be maintained with standard-pressure 14 mmHg.
89476694|NCT02036827|Active Comparator|deep NMB + low pressure|Investigators will administrate rocuronium until deep neuromuscular blockade (Train of Four=0, Post-tetanic count<=3) is established. And pneumoperitoneum will be maintained with standard-pressure 8 mmHg.
89476695|NCT02475213|Experimental|Cohort 1: enoblituzumab 3 mg/kg plus pembrolizumab 2 mg/kg|enoblituzumab 3 mg/kg IV weekly plus pembrolizumab 2 mg/kg IV every 3 weeks
89476696|NCT02475213|Experimental|Cohort 2: enoblituzumab 10 mg/kg plus pembrolizumab 2 mg/kg|enoblituzumab 10 mg/kg IV weekly plus pembrolizumab 2 mg/kg IV every 3 weeks
89476697|NCT02475213|Experimental|Cohort 3: enoblituzumab 15 mg/kg plus pembrolizumab 2 mg/kg|enoblituzumab 15 mg/kg IV weekly plus pembrolizumab 2 mg/kg IV every 3 weeks
89476698|NCT02475213|Experimental|Cohort 4: enoblituzumab 15 mg/kg plus MGA012 375 mg|enoblituzumab 15 mg/kg IV weekly plus MGA012 375 mg
89476699|NCT02474979|Experimental|CBPM-system|CBPM-system (Continuous Bedside Pressure Mapping System): the bed is equipped with a pressure sensing mat including thousands of sensors. It is connected with a monitor that continuously registers the pressure between the body and the bed surface (interface pressure). The pressure is indicated by colors, where warmer colors indicate higher pressure. The CBPM-system will be used in addition to standard pressure ulcer prevention (PU reducing mattress, floating heels, repositioning).
89476700|NCT02474979|Experimental|Control|Standard pressure ulcer prevention (PU reducing mattress, floating heels, repositioning).
89476701|NCT05256056|Experimental|Group A|patients will be injected with 20 cc of 0.25% Bupivacaine
89476702|NCT05256056|Experimental|Group B|patients will be injected with 30 cc of 0.25% Bupivacaine.
89476703|NCT02480673|Experimental|Free diet plus Chia|This subjects will consume 1 cookie oatmeal with chia before breakfast and dinner for 90 days without changing their diet
88950244|NCT01944137|Experimental|Nursing Intervention|Participants will receive 4 planned phone calls from nurse practitioners during their first 2 cycles of chemotherapy
89476704|NCT02480673|Experimental|Normocaloric diet plus chia|This subjects will consume 1 cookie oatmeal with chia before breakfast and dinner for 90 days along with a normocaloric diet
89476705|NCT02480673|Active Comparator|Normocaloric diet plus oatmeal|This subjects will consume 1 cookie oatmeal before breakfast and dinner for 90 days along with a normocaloric diet
89476706|NCT02480673|Active Comparator|Normocaloric diet|This subjects will only go under a normocaloric diet for 90 days
89476707|NCT02724111|Experimental|deep neuromuscular blockade|This arm will be given sufficient dose of rocuronium. In this Arm group, rocuronium will be administered to maintain deep neuromuscular blockade [NMB] (train-of-four [TOF] count 0, post-tetanic count [PTC] of 1-2 twitches) until the end of surgery and the reversal of NMB will be performed by sugammadex 4 mg/kg at the end of surgery'.
89476708|NCT02724111|Active Comparator|restricted neuromuscular blockade|This arm will not be given sufficient dose of rocuronium. In this Arm group, sugammadex will be administered according to the prescribing indications (4 mg/kg for deep neuromuscular blockade [NMB] state or 2 mg/kg for moderate NMB or less) to reverse the NMB 10 min after position change (sugammadex 10 min after position change [a prone position]). Thereafter, muscle relaxants will not be injected any more throughout the surgery except the following situations: If the patients show any body movement during surgery or if surgeons express any complaint about muscle tone (the muscle tone: grade 3), rescue rocuronium 5 mg will be administered and the number of body movements and rescue rocuronium administration (dose) will be recorded.
89476709|NCT02649218|Experimental|Ligelizumab|QGE031 240 mg s.c. q4w x 13 treatments
89476710|NCT02480751|Experimental|1: Exprimental (TRK-100STP)|high dose
89476711|NCT02480751|Experimental|2: Exprimental (TRK-100STP)|low dose
89476712|NCT02480751|Placebo Comparator|3: Placebo Comparator|Placebo
89476713|NCT04930016||Former DIQOL intervention group|In the present follow-up study no interventions are administered. This group encompasses patients who had been part of the intervention group of the completed RCT DIQOL with the following intervention: Patients answered QoL questionnaires after surgery and at 3, 6, 12, and 18 months postoperatively. Results were transferred to a QoL-profile consisting of 13 QoL scales. Three experts with various professional background used the individual patient's QoL-profile and clinical and sociodemographic information to generate a QoL-report including therapy recommendations which was sent to the patient's doctor. Specific therapeutic options for the treatment of QoL had been defined: pain therapy, psychotherapy, social support, nutrition counseling, stoma care, physiotherapy, and fitness.
89476714|NCT04930016||Former DIQOL control group|In the present follow-up study no interventions are administered. This group encompasses patients who had been part of the control group of the completed RCT DIQOL: Patients answered QoL questionnaires after surgery and at 3, 6, 12, and 18 months postoperatively but their doctor neither received a QoL-profile nor a QoL-report.
89476715|NCT04227314|Experimental|Apremilast|apremilast: 30 mg twice daily during a 12 week double blind placebo controlled period, then 30 mg twice daily during an additional 12 week active treatment period
89476716|NCT04227314|Placebo Comparator|Placebo|Placebo: 30 mg twice daily during the initial 12 week double blind placebo controlled period
89476717|NCT02480517|Experimental|Investigational Therapy (Surround Sound)|Investigational Therapy using external focused ultrasound
89476718|NCT02480517|Sham Comparator|Sham Control|Blinded Sham Control Arm
89476719|NCT04223648|Experimental|Treatment|"Subjects will receive 1 cycle of tremelimumab/durvalumab~Subjects will undergo resection to obtain tumor for generation of autologous tumor infiltrating lymphocytes (TIL) cultures and blood draw to obtain peripheral blood mononuclear cell (PBMC)s~TIL and PBMC will undergo immunoselection based on binding to an anti-programmed cell death 1 (PD-1) antibody and then will be expanded ex vivo.~Subjects will receive 3 cycles of ipilimumab/nivolumab~• Subjects will undergo staging with computer tomography (CT) chest/abdomen/pelvis and brain magnetic resonance imaging (MRI) or CT scan.~subjects with stable disease will continue with nivolumab monotherapy; Subjects with progressive disease will proceed to cell therapy."
89476720|NCT04165148|Experimental|Low Impact Laparoscopy|Low Impact Laparoscopy is a minimally invasive technique that combines low pressure insufflation (with the Intelligent Flow System (iFS) AirSeal® system) and microcoelioscopy (with specific microtrocards and laparoscopic instruments).
89476721|NCT04165148|Active Comparator|conventional laparoscopy|conventional laparoscopy
89206255|NCT03856476||Dyslipidemia group|Children and adolescents with dyslipidemia
89206256|NCT03856476||Control group|Children and adolescents without dyslipidemia
89476722|NCT02814175|Active Comparator|Part 1: MTX Escalated Dose|Methotrexate (MTX) escalated to 20 - 25 mg or highest tolerable dose every week (ew)
89476723|NCT02814175|Experimental|Part 1: ADA + MTX|Adalimumab (ADA) 40 mg every other week (eow) in combination with MTX 15 mg ew
89476724|NCT02814175|Active Comparator|Part 2: MTX Escalated Dose|Participants achieving minimal disease activity (MDA) at Week 16 on MTX escalated to 20 -25 mg or highest tolerable dose ew, continued with the same MTX dose
89476725|NCT02814175|Active Comparator|Part 2: ADA + MTX Escalated Dose|Participants not achieving MDA at Week 16 on MTX escalated to 20 - 25 mg or highest tolerable dose ew, received ADA 40 mg eow in combination with MTX 20 - 25 mg or highest tolerable dose ew
89476726|NCT02814175|Experimental|Part 2: ADA|Participants achieving MDA at Week 16 on ADA 40 mg eow plus MTX 15 mg ew, had MTX completely withdrawn at Week 16 and continued receiving ADA as monotherapy
89476727|NCT02814175|Experimental|Part 2: ADA ew + MTX|Participants not achieving MDA at Week 16 on ADA 40 mg eow plus MTX 15 mg ew, had ADA escalated to 40 mg ew in combination with MTX 15 mg ew
89476728|NCT04696484|Experimental|Intervention|coopeRATE Prompt
89476729|NCT05714397|Experimental|Cingal Injection|Cingal will be administered by fellowship-trained physicians through ultrasound-guided injection using a 20-gauge needle into the joint space of the knee under sterile conditions. The needle track will be anesthetized with local anesthetic.
89476730|NCT04511858|Experimental|Running endurance|Athletes wiil run for 5 hours in a row.
89476731|NCT04511858|Experimental|Cycling endurance|Athletes wiil cycle for 5 hours in a row.
89476732|NCT02475057|Experimental|Degarelix (LHRH antagonist)|Degarelix (LHRH antagonist) EndoPAT2000
89476733|NCT02475057|Active Comparator|LHRH agonist|LHRH agonist at the discretion of the treating Urologist/Oncologist EndoPAT2000
89476734|NCT04906070|Experimental|HB-001 DaRT Seeds|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds
89476735|NCT02047435|Experimental|Information, event and workshops at a cartoon museum|
89476736|NCT02047435|Active Comparator|Information and event at a cartoon museum|
89476737|NCT02037139|Active Comparator|Control (screening)|screening only (standard care control)
89476738|NCT02037139|Active Comparator|Educational brochure|Screening + illustrated educational brochure
89476739|NCT02037139|Experimental|Education|Screening + illustrated educational brochure + an in-person educational intervention
89476740|NCT02474667|Active Comparator|BB3|Administered IV for 30 min within 24 hours after transplantation and around 24 hours after previous dosing 3 days in a row
89206257|NCT02598791|Active Comparator|IIGI+GIP|4 hour i.v. infusion of glucose-dependent insulinotropic polypeptide (4 pmol/kg/min) during isoglycemic conditions
89476741|NCT02474667|Placebo Comparator|Normal Saline|Administered IV for 30 min within 24 hours after transplantation and around 24 hours after previous dosing 3 days in a row
89476742|NCT04436432||Assessment|Children with ASD ages 3-5 years at baseline
89476743|NCT02047669|Experimental|Biopsychosocial|Biopsychosocial intervention with Individually tailored physical exercises and stress management
89476744|NCT02047669|Active Comparator|Reference|"Reference group receiving usual care in terms of standard workplace ergonomics and physical exercises"
89476745|NCT03096080|Experimental|Cohort 1|Single 0.25 mg/kg dose of tesevatinib
89476746|NCT03096080|Experimental|Cohort 2|Single 0.50 mg/kg dose of tesevatinib
89476747|NCT03096080|Experimental|Cohort 3|Single 1.00 mg/kg dose of tesevatinib
89476748|NCT02037217|Experimental|ExAblate Treatment|
89476749|NCT02474745|Experimental|INTERVENTION GROUP|"Directed open-glottis pushing (with prolonged exhalation) must be explained to the women and professionals as follows:~After inhaling deeply, the patient will exhale while pulling in her stomach in such a way they she can use the contraction of her abdominal muscles to help the fetus descend through the birth control. She should push as long as possible"
89476750|NCT02474745|Other|CONTROL GROUP|"Directed closed-glottis pushing (pushing while holding one's breath) should be explained to the women and professionals as follows:~After inhaling deeply, the patient should push very hard downwards to the perineum, while holding the inhaled breath in her lungs. She should push as hard and as long as possible."
89476751|NCT02047825|Experimental|Experimental group|The patients included in this group will receive an intensive intervention based on upper limbs intervention with exercises added to the usual treatment they receive.
89476752|NCT02047825|Active Comparator|Control group|Patients with multiple sclerosis not included in the intensive intervention. They receive the usual treatment of occupational and physical therapy.
89476753|NCT02478177||Stroke|Patients who had an acute ischemic stroke while taking one of the novel oral anticoagulants or patients who had an intracerebral hemorrhage while taking warfarin or one of the novel oral anticoagulants
89476754|NCT01335997|Experimental|ERN/LRPT/SIM → ERN/LRPT+SIM|Weeks 0-4 (Period 1): Participants will take ERN/LRPT/SIM 1 g/10 mg and SIM-matching placebo tablets daily; Weeks 5-12 (Period 2): Participants will be advanced to ERN/LRPT/SIM 2 g/20 mg and SIM-matching placebo tablets daily; Weeks 13-20 (Period III): Participants will crossover to ERN/LRPT 2 g + SIM 20 mg coadministration treatment.
89476755|NCT01335997|Active Comparator|ERN/LRPT+SIM → ERN/LRPT/SIM|Weeks 0-4 (Period I): Participants will take ERN/LRPT co-administered with SIM (ERN/LRPT 1g + SIM 10 mg tablets) daily; Weeks 5-12 (Period II): Participants will be advanced to ERN/LRPT 2 g + SIM 20 mg daily; Weeks 13-20 (Period III): Participants will crossover to the ERN/LRPT/SIM 2 g/20 mg combination treatment and SIM-matching placebo tablets.
88950245|NCT01944150|Active Comparator|TENS|Patients with only transcutaneous electrical nerve stimulation (TENS),
88950246|NCT01944150|Experimental|TENS and hypnosis.|Patients with transcutaneous electrical nerve stimulation (TENS) and hypnosis simultaneously
88950247|NCT01944163|No Intervention|Usual care|GP provide care as usual to their CLBP patients.
88950248|NCT01944163|Other|Referral arm|GP are randomized in clusters either to use or not to use the CaFaSpA referral model. The CaFaSpA referral models consists out of four variables, a positive ASAS IBP questionnaire, a positive family history for SpA, a good reaction to NSAIDs and back pain duration longer than 5 years. If at least two out of four variables are present a referral to the rheumatologist is advised.
89476756|NCT02472561|Experimental|Mobile Health Application Group 1|"Participants will wear a Fitbit Physical Activity Monitor to objectively quantify physical activity patterns. Once a week (± 3 days) during the 12 week mHealth intervention patients will measure and download their blood pressure and blood glucose (if diabetic) by means of a mHealth blood pressure cuff and mHealth glucometer. Medication adherence will be measured at baseline and 12-weeks by the Morisky Medication Adherence Scale-8 (MMAS-8) questionnaire. Each participant will be provided with a electronic version of the book titled, Your COMPLETE and EASY GUIDE to Understanding Peripheral Artery Disease; patients will be asked to read approximately one chapter per week for educational purposes."
89476757|NCT02472561|No Intervention|Usual Care Group 2|"Participants will follow standard care as ordered by their individual, treating physician. Each participant will be given a paperback copy of the book, Your COMPLETE and EASY GUIDE to Understanding Peripheral Artery Disease. All participants will be contacted by study personnel in order to schedule visits at baseline and 12-weeks for the outcome assessments."
89476758|NCT02048137|Active Comparator|Active transcranial direct current stimulation|
89476759|NCT02048137|Sham Comparator|Sham transcranial direct current stimulation|
89476760|NCT03784118|Experimental|Children|Children who are followed up after arterial catheterization for evaluation of complications, using ultrasonography
89476761|NCT02048215|Active Comparator|Ephedrine + Caffeine + diet|Ephedrine 20 mg + Caffeine 200 mg capsule t.i.d. for one month plus hypocaloric diet
89476762|NCT02048215|Placebo Comparator|Placebo + diet|Similarly-looking placebo capsule t.i.d. for one month plus hypocaloric diet
89476763|NCT04849832|Experimental|SIC|4mg of Fe will be given as 102 mg of SIC as a solution
89476764|NCT04849832|Experimental|SIC + tea|4 mg of Fe will be given as 102 mg of SIC as a solution along with 200 ml of black tea
89476765|NCT04849832|Active Comparator|FeSO4|4 mg of Fe will be given as Ferrous sulfate solution
89476766|NCT04849832|Active Comparator|FeSO4 + tea|4 mg of Fe will be given as Ferrous sulfate solution along with 200 ml of black tea
89476767|NCT02048293|Active Comparator|Group O|Remifentanyl innovative molecule = Ultiva®
89476768|NCT02048293|Active Comparator|Group A|Remifentanyl comparator A = Remifentanil Laboratorios Chalver de Colombia S.A.
88950249|NCT01944176|Experimental|Simvastatin|simvastatin 20 mg/d is randomized to treat COPD patients for 4 weeks
88950250|NCT01944176|Placebo Comparator|B1-6-12|B1-6-12 one tablet a day is randomized to give to COPD patients for 4 weeks
89206258|NCT02598791|Active Comparator|IIGI+GLP-1|4 hour i.v. infusion of glucagon-like peptide-1 (1 pmol/kg/min) during isoglycemic conditions
89476769|NCT02048293|Active Comparator|Group B|Remifentanyl comparator B = Fada Remifentanilo
89476770|NCT05712993|Experimental|transcoronoid|participants are TN patients complain TN without secondary causes of trigeminal neuralgia underwent V2 targeting through coronoid notch
88950251|NCT01944189|Experimental|Food Supplement|"Population PK Study will enroll 70 children receiving standard AL dose at 0, 8, 24, 36, 48, 60 hour with recommended milk or maize porridge plus oil. Both foods contain sufficient fat therefore will contribute to pool evaluations as a single cohort.~A subset, 48 children will have participated in nested comparative bio-availability study as follows Standard arm children receiving single dose with milk (12) Standard arm children receiving double dose with milk (12) Experimental arm children receiving single dose with maize porridge plus oil (12) Experimental arm children receiving double dose with maize porridge plus oil (12) The rest, 22 children will have participated exclusively in PPK, receiving appropriate single or double dose with milk similar to those in standard arm"
88950252|NCT01944189|Experimental|Food Supplement Arm|"Population PK Study will enroll 70 children receiving standard AL dose at 0, 8, 24, 36, 48, 60 hour with recommended milk or maize porridge plus oil. Both foods contain sufficient fat therefore will contribute to pool evaluations as a single cohort.~A subset, 48 children will have participated in nested comparative bio-availability study as follows Standard arm children receiving single dose with milk (12) Standard arm children receiving double dose with milk (12) Experimental arm children receiving single dose with maize porridge plus oil (12) Experimental arm children receiving double dose with maize porridge plus oil (12) The rest, 22 children will have participated exclusively in PPK, receiving appropriate single or double dose with milk similar to those in standard arm"
89476771|NCT05712993|Experimental|infrazygomatic anterior out of plane|participants are TN patients complain TN without secondary causes of trigeminal neuralgia underwent V2 targeting through infrazygomatic anterior out of plane
89476772|NCT05252247|Experimental|Conditions|Participants will attend three sessions where two consist of immobilisation or exercise interventions.
89476773|NCT02050009|Experimental|Treatment (metformin hydrochloride, carboplatin, paclitaxel)|Patients receive metformin hydrochloride BID on days 1-21, paclitaxel IV over 3 hours on day 1, and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
89476774|NCT02474823|Other|Sleep Apnea assessment|all participants are in the same arm & undergo the same assessments: PSG, HST, ESAP
89476775|NCT02050087|Active Comparator|3 weeks with simple sling|Early motion after arthroscopic rotator cuff repair.
89476776|NCT02050087|Active Comparator|6 weeks with neutral brace|Delayed motion after arthroscopic rotator cuff repair.
89476777|NCT03095768|Experimental|Intervention|Lifestyle Education and Cooking Demonstration
89476778|NCT02050165|Experimental|KIND Bar|Daily inclusion of KIND Bars with almonds as a primary ingredient as part of the participant's usual diet, with diet counseling to adjust for the calories from the KIND Bars. KIND Bars that we will use in the study will include: Dark Chocolate Chili Almond; Cranberry Almond; Almond Walnut Macadamia; Pomegranate Blueberry Pistachio; Nut Delight; Fruit and Nut Delight; Almond and Apricot; Blueberry Pecan and Fiber.
89476779|NCT02050165|Experimental|Typical American Snack|Daily inclusion of conventional snacks (as part of the participant's usual diet, with diet counseling to adjust for the calories from the snacks. The snacks will consist of cookies considered to be conventional snack foods that are nutrient-dilute (i.e. relatively low in nutrients) and energy-dense (i.e., relatively high in kcal). Examples of conventional snack foods will include: Nabisco Snackwell Creme Sandwich 1.7 oz pack, Nabisco Newtons Fig 2 oz pack, Nabisco Cips Ahoy! Chocolate Chip 1.4 oz pack, and Nabisco Oreo Double Stuff Chocolate 1.3 oz pack.
89476780|NCT04800614|Experimental|Fasted dosing followed by fed dosing (high-fat meal) followed by fed dosing (low-fat meal)|Dosing in the fasted state followed by fed dosing after high and low fat meals
89476781|NCT04800614|Experimental|Fasted dosing followed by fed dosing (low-fat meal) followed by fed dosing (high-fat meal)|Dosing in the fasted state followed by fed dosing after low and high fat meals
88950253|NCT01944202|Experimental|Educational Intervention|"Physicians in the intervention arm receive the following multi-faceted educational intervention on transthoracic echocardiogram appropriateness: 1) a lecture at the beginning of the study period, which describes the Appropriate Use Criteria (AUC) for echocardiography and highlights common clinical scenarios for which outpatient TTEs are ordered, 2) an electronic pocket card via email that provides tips on appropriate ordering of TTEs, and 3) an individualized monthly feedback report that categorized TTEs ordered over the preceding month. The feedback reports contains the number of TTEs ordered during the month and how many are classified as appropriate, inappropriate, or uncertain based on the 2011 AUC."
88950254|NCT01944202|No Intervention|Control group|Physicians in the control arm have their TTE orders tracked and classified, but do not receive any feedback on their ordering behavior.
89476782|NCT04800614|Experimental|Fed dosing (high-fat meal) followed by fasted dosing followed by fed dosing (low-fat meal)|Dosing after a high-fat meal followed by doing in the fasted sate followed by dosing after a low-fat meal
89476783|NCT04800614|Experimental|Fed dosing (high-fat) followed by fed dosing (low-fat) followed by dosing in the fasted state|Fed dosing (high-fate meal) followed by fed dosing (low-fate meal) followed by dosing in the fasted state
89476784|NCT04800614|Experimental|Fed dosing (low-fat) followed dosing in the fasted state followed by fed dosing (high fat)|Fed dosing (low-fat) meal followed dosing in the fasted state followed by fed dosing (high-fat meal)
89476785|NCT04800614|Experimental|Fed dosing (low-fat) followed by fed dosing (high-fat) followed by dosing in the fasted state|Fed dosing after a low-fat and high-fate meals followed by dosing in the fasted state
89476786|NCT02050243|Experimental|5ALA|All included patients will receive 20mg/kg of 5ALA (oral suspension) about 3 hours prior to surgery
89476787|NCT02050399|Active Comparator|Healthy subjects|15 men, 45 and 65 years old. After initial evaluation, clinical exercise testing, cardiopulmonary exercise testing, carotid ultrasound, laboratory tests (biochemical blood) and isometric exercise protocol will be performed.
89476788|NCT02050399|Experimental|Coronary disease with Type 2 Diabetes|15 men, 45-65 years old, with coronary artery disease and type 2 diabetes will perform clinical exercise testing, cardiopulmonary exercise testing, carotid ultrasound, laboratory tests (biochemical blood), clinical autonomic tests and isometric exercise protocol will be performed.
89476789|NCT02050399|Experimental|Coronary disease without Type 2 Diabetes|15 men, 45-65 years old, with coronary artery disease will perform clinical exercise testing, cardiopulmonary exercise testing, carotid ultrasound, laboratory tests (biochemical blood) and isometric exercise will be performed.
89476790|NCT03357380|Experimental|Semaglutide|Semaglutide will be initiated with a starting dose of 0.05 mg/day for the first 4 weeks. The dose will be increased every 4 weeks until the target dose of 0.4 mg/day has been reached.
89476791|NCT03357380|Placebo Comparator|Placebo|Placebo will be initiated with a starting volume corresponding to 0.05 mg/day of semaglutide for the first 4 weeks. The volume will then be increased every 4 weeks until the target volume corresponding to 0.4 mg/day of semaglutide has been reached.
89476792|NCT02050477|Experimental|Laparoscopic Vertical Gastroplasty|
88950255|NCT01944215|Active Comparator|Arm 4 - Fast vs Fast + External Heating|MBI will be performed in 52 subjects after an overnight fast with 4-6 mCi Tc-99m sestamibi. The subject will receive the usual Mayo gown for breast imaging. A skin temperature sensor will be taped to the anterior of one breast and skin temperature will be recorded. The subject will be asked to sit for 15 minutes in the waiting room prior to injection of the Tc-99m sestamibi. Just prior to injection, skin temperature will be recorded again. After completion of the first study the subject will then be given a warm towel robe and a small heating pad to be placed over the chest area. After 30 minutes, skin temperature will be recorded again immediately prior to injection of the second dose of Tc-99m sestamibi. The second MBI study will then be performed.
89476793|NCT02472483|Experimental|bipolar disorder|"Cognitive and Behavior Therapy (CBT) : 20-weeks CBT~+ Mindfulness Based Cognitive Therapy (MBCT) : 8-weeks MBCT"
89476794|NCT02472483|Experimental|anxious disorders|"Cognitive and Behavior Therapy (CBT) : 20-weeks CBT~+ Mindfulness Based Cognitive Therapy (MBCT) : 8-weeks MBCT"
89476795|NCT02472483|Experimental|alcohol disorder|"Cognitive and Behavior Therapy (CBT) : 20-weeks CBT~+ Mindfulness Based Cognitive Therapy (MBCT) : 8-weeks MBCT"
89476796|NCT04717154|Experimental|Treatment arm|"Combinatory regimen of nivolumab 3mg/kg and ipilimumab 1mg/kg, followed by nivolumab 480mg flat dose (Q4w) to up to one year.~This regimen will be given to participants in both cohort 1 and 2."
89020288|NCT05201183|Experimental|Fludarabine + Total Marrow Irradiation|Fludarabine will be administered sequentially after the administration of TMI. TMI will be delivered on Days -11, -10, -9, -8, and -7 (1.4-2.2 gray (GY)/fraction, twice a day) followed by fludarabine on Days -6, -5, -4, -3, and -2 (150 mg/m2, 30 mg/m2/day)
89476797|NCT02050555|Placebo Comparator|Koji-extracted beverage|100ml/day for 12 weeks
89476798|NCT02050555|Experimental|Koji-extracted beverage fermented with LP28|100ml/day for 12 weeks. 1x10^11 cells (LP28)/day
89476799|NCT02474511||general anesthesia|In this group，the patient is received radiofrequency ablation under general anesthesia.
89476800|NCT02474511||local anesthesia|In this group，the patient is received radiofrequency ablation under local anesthesia.
89476801|NCT03608540|Experimental|Intervention|Suturing system with suture apposition then bulging formation then cutting the lesion
89476802|NCT03561961|Active Comparator|Moderate Hypo-fractionation|In arm 1 of the study, patients who are randomized to receive moderately hypo-fractionated RT will receive a total dose of 66-68 Gy in 25# to the primary over 5 weeks, with treatment being delivered daily. All patients will receive a dose of 50 Gy in 25# to the pelvis. Boost to gross nodal disease will be considered based on the response to hormonal therapy to a dose of 60-66 Gy/25# as a simultaneous integrated boost(SIB).
89476803|NCT03561961|Experimental|Extreme Hypo-fractionation|In Arm 2 of the study, patients who are scheduled to receive SBRT will receive a course of 5 fractions of radiation; each fraction size will be 7.00-7.25 Gy. The total dose will be 35-36.5 Gy. All patients will receive a dose of 25 Gy in 5 # to the pelvis. Boost to gross nodal disease will be considered based on the response to hormonal therapy to a dose of 30-35 Gy/5# as a simultaneous integrated boost(SIB).The 5 treatments will be scheduled to be delivered alternate day over approximately 7-10 days. An option of equivalent biological dose using 35-36.5 Gy in 5 weekly fractions may be allowed for multicentric accrual in the future.
89476804|NCT03108963|Experimental|L-carnitine and Metformin|L-carnitine and Metformin in Obese PCOS Women trying induction of ovulation with clomiphene citrate.
89476805|NCT03108963|Active Comparator|placebo|placebo was given toObese PCOS Women trying induction of ovulation with clomiphene citrate.
89476806|NCT04697654|Experimental|TLC19 (low dose)|TLC19 2ml single dose
89476807|NCT04697654|Experimental|TLC19 (medium dose)|TLC19 4ml single dose
89476808|NCT04697654|Experimental|TLC19 (high dose)|TLC19 6ml single dose
89476809|NCT04697654|Sham Comparator|TLC19 Vehicle (low dose)|TLC19 Vehicle 2ml single dose
89476810|NCT04697654|Sham Comparator|TLC19 Vehicle (medium dose)|TLC19 Vehicle 4ml single dose
89476811|NCT04697654|Sham Comparator|TLC19 Vehicle (high dose)|TLC19 Vehicle 6ml single dose
89476812|NCT02050633||Severe cranial trauma|This is a cohort of adult patients who have suffered a severe TBI between 1 July 2005 and 1 May 2007.
89476813|NCT02474433|Active Comparator|PO Misoprostol|Patients assigned to PO Misoprostol (Cytotec) 400 mg once, 2-4 hours prior to hysteroscopy
89476814|NCT02474433|Active Comparator|PV Misoprostol|Patients assigned to PV Misoprostol (Cytotec) 400 mg once, 2-4 hours prior to hysteroscopy
89476815|NCT02474433|Active Comparator|Buccal Misoprostol|Patients assigned to buccal Misoprostol (Cytotec) 400 mg once, 2-4 hours prior to hysteroscopy
89476816|NCT04812002|Experimental|Double medicine combined|participants received 200mg of PD-1 inhibitors combined 15mg of bevacizumab per square body surface area intravenously every 3 weeks
89476817|NCT02050711|Other|Usual care|Patients will receive usual care from their general practitioners/pulmonologists.
89476818|NCT02050711|Experimental|Pulmonary rehabilitation|Patients will enrol in a 12-week PR program consisting on exercise training (3 times a week) and psychoeducation (once a week).
89476819|NCT02474277|Other|30 sec chair stand test|all patients in this Group receives a diagnostic test for functional impairment
89476820|NCT03813589||PMK patients|Patients already implanted with double chamber pacemaker able to detect automatically congestive heart failure and collect atrial events.
88950256|NCT01944215|Active Comparator|Arm 3 - Fasting vs. Fasting + Caffeine|MBI will be performed in 52 subjects after an overnight fast with 4-6 mCi Tc-99m sestamibi. The subject will then be instructed to consume 200 mg caffeine in tablet form. This is equivalent to the caffeine content of an 8 oz brewed coffee from Starbucks. After 45 minutes after consumption of the caffeine tablet, patients will receive a second injection of 4-6 mCi Tc-99m sestamibi and a repeat MBI study will be performed.
88950257|NCT01944215|Active Comparator|Arm 2-Resting vs. Exercising|MBI will be performed in 25 subjects after an overnight fast with 4-6 mCi Tc-99m sestamibi. Patients will then be asked to perform moderate exercise on a treadmill for 6-10 minutes at a level of 70%-80% of maximum predicted heart rate. At ~10 minutes, patients will receive a second injection of 4-6 mCi Tc-99m sestamibi and a repeat MBI study will be performed.
88950258|NCT01944215|Active Comparator|Arm 1-Fasting vs. Fed|MBI will be performed in 25 subjects after an overnight fast with 4-6 mCi Tc-99m sestamibi. Patients will then be instructed to consume 8-16 fluid oz of Ensure (350-700 calories). At 30 minutes after consumption of the meal, patients will receive a second injection of 4-6 mCi Tc-99m sestamibi and a repeat MBI study will be performed.
88950259|NCT01944228|Experimental|Vagal Nerve Stimulation|30 minutes of vagal nerve stimulation using a catheter in the IJV
88950260|NCT01944228|Sham Comparator|Sham stimulation|Catheter placed in the IJV without stimulation
89476821|NCT04557254||silver-triclosan graft implantation (SynG group)|
89476822|NCT04557254||standard Dacron graft implantation (DacrG group)|
89476823|NCT02051491|Active Comparator|BP-NCPAP|Nasal BP-NCPAP will be delivered using the Infant Flow® SiPAP™ and either nasal prongs or mask interface. A blood gas (arterial if an arterial line exists, or a capillary sample) will be drawn at the time of NCPAP failure (time 0) unless one was done within 1 hour preceding the randomization. The blood gas will then be repeated at 1 hour and recorded along with transcutaneous carbon dioxide (TcCO2) monitor data (if available). Initial settings of BP-NCPAP will be a lower level PEEP of 5 cm water (H2O) and a higher level PEEP of 8 cm H2O at a cycle rate of 20 per minute with 1 second at the higher PEEP per cycle. The settings can then be adjusted and titrated up to a maximum of 7 and 10 cm H2O for the lower and higher PEEPs respectively at a maximum rate of 30 cycles per second based on fraction of inspired oxygen (FiO2) requirements.
89476824|NCT02051491|Experimental|NIHFV|NIHFV will be provided using the Drager VN500, using either nasal prong or mask interfaces.A blood gas (arterial if an arterial line exists, or a capillary sample) will be drawn at the time of NCPAP failure (time 0) unless one was done within 1 hour preceding the randomization. The blood gas will then be repeated at 1 hour and recorded along with TcCO2 monitor data (if available). Initial settings for NIHFV arm will be MAP of 8 cm H2O, frequency of 10 Hz, and amplitude of 20 cm H2O. The maximum allowable MAP will be 10 cm of H2O. The range of frequency allowed will be 6 - 14 Hz. Both frequency and amplitude will be adjusted to try and achieve palpable/visible chest movement and to achieve target CO2 levels for the particular patient.
89476825|NCT03424460|Experimental|population 1-A1 : DM1 with VTE|Myotonic dystrophy type 1 patients with a history of venous thromboembolism (pulmonary embolism and/or deep vein thrombosis)
89476826|NCT03424460|Active Comparator|population 1-B1 : DM1 without VTE|Myotonic dystrophy type 1 patients without a history of venous thromboembolism
89476827|NCT03424460|Active Comparator|population 1-C1 : Healthy volunteers|Healthy volunteers without any medical history or treatment
89476828|NCT03424460|Experimental|population 2-A2 : DM1 liver samples|Liver samples of patients with myotonic dystrophy type 1
89476829|NCT03424460|Active Comparator|population 2-B2 : Healthy liver samples|Liver samples from patients without any medical history
89476830|NCT05712837|Active Comparator|Group A 25% TCA|25% TCA peel Patients of group A were treated with 25% TCA peel and patients at 2-week intervals for a total of 12 weeks. Clinical evaluation was done at the end of therapy after 12-weeks of treatment.
89476831|NCT05712837|Active Comparator|Group B 30% SALICYLIC ACID|30% SA peels Patients of group B were treated with 30 % salicylic acid peel and patients at 2 weeks interval for a total of 12 weeks.clinical evaluation was done at the end of therapy after 12 weeks of treatment
89476832|NCT02050789|No Intervention|Usual Care Arm|Programs will continue adhering to current ACGME requirements.
89476833|NCT02050789|Experimental|Intervention Arm|The intent of the intervention arm is to allow flexibility in surgical resident duty hours and improve continuity of care.
89476834|NCT03267914|Experimental|Tray group|Control intervention Patients will use the custom-made tray to apply the fluoride locally to the teeth and wear for 5 minutes each day.
89476835|NCT03267914|Active Comparator|Brush group|Patients will brush with the fluoride for 2 minutes each day.
89476836|NCT05712213||pIPOM Group|Laparoscopic Incisional Hernia repair was performed with closure of fascia with non-absorbable suture (pIPOM)
89476837|NCT05712213||sIPOM Group|Laparoscopic Incisional Hernia was performed without fascia closure (sIPOM)
89476838|NCT02472327|No Intervention|Typical Care|These patients will receive normal peripartum care and support.
89476839|NCT02472327|Experimental|Pre-operative support|These patients will receive additional emotional support prior to undergoing an unplanned cesarean section during labor.
88950261|NCT01944241||Women with cervical surgery|The cases will include women who have had cervical surgery, either LLETZ or cone biopsy
88950262|NCT01944241||women with no surgery|controls will be women who have attended colposcopy but who have not had surgery.
89476840|NCT02464202|Experimental|stereolithography tooth replica|stereolithographic tooth replica used as a guide for tooth autotransplantation decreases extra-alveolar time and reduces trauma to periodontal ligament tissue therefore increasing the success rate after transplantation
89476841|NCT02472249|Experimental|Norepinephrine intra-arteriel/hepatic|This is the only arm of this study. These patients will receive 24 micrograms of norepinephrine in the hepatic artery with subsequent CT perfusion imaging to evaluate liver blood flow.
89476842|NCT02313194|Experimental|Stimulation|Determine if epidural stimulation can improve motor function.
89476843|NCT02332226|Experimental|Representational approach|Four sessions with a nurse. For each session, the parent identifies an area where he/she needs more information. The nurse and the parent jointly survey the parent's knowledge of the area and discusses consequences of knowledge gaps or misunderstandings. Then, new information is introduced and benefits from the new information is discussed.
89476844|NCT02332226|No Intervention|Control|Standard care as per ward protocol.
89476845|NCT01733420|Experimental|Biodentine|Pulpotomy using Biodentine as pulpotomy medicine.
89476846|NCT01733420|Active Comparator|White Mineral trioxide Aggregate (MTA)|Pulpotomy using white MTA as pulpotomy medicine.
89476847|NCT01733420|Active Comparator|Tempophore|Pulpotomy using Tempophore as pulpotomy medicine in a control group.
89476848|NCT01144520||Normoglycemic|Healthy subjects that do not have diabetes
89476849|NCT01144520||Type II Diabetes (HbA1c <7 or 7%)|Subject that have Type II Diabetes with good glucose control with glycated hemoglobin (HbA1c <7 or 7%)
89476850|NCT01144520||Type II Diabetes (HbA1c between 7.1-9)|Subjects with Type II Diabetes with moderate glucose control (HbA1c between 7.1-9)
89476851|NCT01144520||Type II Diabetes (HbA1c >9%)|Subjects with Type II Diabetes with poor glucose control (HbA1c >9%)
89476852|NCT04435652|Experimental|Experimental: Cohort A|Participants receive QL1604 and nab-paclitaxel on Days 1, 8, and 15 of each 28-day cycle. If not disease progression after 4 cycles, participants receive QL1604 monotherapy until disease progression、unacceptable toxicity or up to 2 years.
89476853|NCT04435652|Experimental|Experimental: Cohort B-arm1|Participants receive QL1604 and nab-paclitaxel on Days 1, 8, and 15 of each 28-day cycle. If not disease progression after 4 cycles, participants receive QL1604 monotherapy until disease progression、unacceptable toxicity or up to 2 years.
89476854|NCT04435652|Experimental|Experimental: Cohort B-arm2|Participants receive paclitaxel on Days 1, 8, and 15 of each 28-day cycle until disease progression or unacceptable toxicity.
89476855|NCT02474043|Active Comparator|Usual care|Standard health education and prevention counseling by trained staff
89476856|NCT02474043|Experimental|Hep-Net Intervention|Computerized tailored behavioral intervention
88950263|NCT01944254|Active Comparator|random to respiration|Cardiac output measurement at random to respiration
88950264|NCT01944254|Experimental|timed with expiration start|Cardiac output measurement synchronised at start of expiration.
88950265|NCT01944254|Experimental|timed to instructed exhalation|Cardiac output measurement timed to instructed exhalation. The patient will receive instructions to exhale slowly using a peak expiratory flow (PEF)-flute and the cardiac output measurement will be started (i.e bolus given) at the start of expiration.
88950266|NCT01944267|Active Comparator|Apically positioned flap|"Standard TUSDM Periodontology Clinic procedures will be followed. Local anesthesia will be achieved. Center of implant fixtures will be located. Crestal incision thru the center of implant fixture will be made. Implant fixture will be uncovered and healing abutment/s will be inserted. Horizontal incision at approximately 0.5mm coronal to buccalmucogingival junction will be made 1 tooth mesial to 1 tooth distal to the treating area.~No vertical incision will be made Gingiva coronal to horizontal incision will remain intact Partial thickness flap will be prepared and displaced apically approximately 7mm from the horizontal incision and secured with sutures.~Prepared surgical area will be measured apico-coronally and mesio-distally."
88950267|NCT01944267|Active Comparator|Free Gingival Graft|"Standard Clinic procedures followed. Local anesthesia achieved. Center of implant fixtures located. Crestal incision thru center of fixture will be made.~Implant fixture uncovered and healing abutment/s inserted. Horizontal incision at approx 0.5mm coronal to buccalmucogingival junction will be made 1 tooth mesial to 1 tooth distal to the treating area.~No vertical incision made. Gingiva coronal to horizontal incision remains intact.~Partial thickness flap prepared and displaced apically approximately 7mm from horizontal incision; secured with sutures. Prepared recipient bed measured apico-coronally and mesio-distally. Masticatory mucosa from palate of treating side (Right or Left) harvested according to size measured from recipient bed with width of approximately 5mm at line of measurement. Harvested graft material will be transplanted on recipient bed, lined with initial horizontal incision line with sutures"
89206259|NCT02598791|Placebo Comparator|IIGI+NaCl (placebo)|4 hour i.v. NaCl (placebo) during isoglycemic conditions
89206260|NCT02598791|Active Comparator|IIGI+GIP+GLP-1|4 hour co-infusion of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1
89206261|NCT02598791|Other|50 g OGTT|50 g oral glucose tolerance test (OGTT)
89476857|NCT02473887|Experimental|gastroenteritis with persistent vomiting.|patients with gastroenteritis with persistent vomiting received single dose of intravenous ondansetron form orally after being flavored with 1:1 ORA-sweet, the dose of ondansetron was determined based on the patient presenting weight.
89476858|NCT02478021|Experimental|Hydrocortisone|10 mg hydrocortisone
89476859|NCT02478021|Placebo Comparator|Placebo|1 pill Placebo
89476860|NCT01952522|Experimental|Weighted brace|
89476861|NCT01952522|Placebo Comparator|non weighted brace|
89476862|NCT02477865|Experimental|PEX168(100µg)|PEX168(100µg),100µg,Subcutaneous injection,once a week,for 52 weeks.
89476863|NCT02477865|Experimental|PEX168(200µg)|PEX168(200µg),200µg,Subcutaneous injection,once a week,for 52 weeks.
89476864|NCT02477865|Placebo Comparator|Placebo|Placebo,0.5ml,Subcutaneous injection,once a week for 24 weeks,followed by PEX168(100µg or 200µg) qw sc for 28 weeks.
89476865|NCT04441190|Experimental|Digital Action Observation Therapy (Digital AOT)|The common categories of motor actions and tasks will be selected and included in this group: (a) active range of motion (AROM) exercises, (b) reaching movement or object manipulation, and (c) upper-limb functional tasks.
89476866|NCT04441190|Experimental|Digital Mirror Therapy (Digital MT)|The common categories of motor actions and tasks will be selected and included in this group: (a) active range of motion (AROM) exercises, (b) reaching movement or object manipulation, and (c) upper-limb functional tasks.
89476867|NCT04441190|Active Comparator|Conventional Occupational Therapy|The common categories of motor actions and tasks will be selected and included in this group: (a) active range of motion (AROM) exercises, (b) reaching movement or object manipulation, and (c) upper-limb functional tasks.
88950268|NCT01944267|Active Comparator|Apically positioned flap with Mucograft|"Standard TUSDM Periodontology Clinic procedures followed. Local anesthesia achieved.~Center of implant fixtures will be located. Crestal incision thru the center of implant fixture will be made. Implant fixture will be uncovered and healing abutment/s will be inserted. Horizontal incision at approximately 0.5mm coronal to buccalmucogingival junction will be made 1 tooth mesial to 1 tooth distal to the treating area.~No vertical incision will be made. Gingiva coronal to horizontal incision will remain intact. Partial thickness flap will be prepared and displaced apically approximately 7mm from the horizontal incision and secured with sutures.~Prepared recipient bed will be measured apico-coronally and mesio-distally. Mucograft material will be prepared according to the manufacturer's instruction and trimmed as the size measured from the recipient and be placed and secured on the recipient bed with sutures."
89476868|NCT05419245||Freeman-Sheldon syndrome Classic Type|"Patients who have all features required by the Stevenson criteria, including: very small mouth (microstomia); whistling-face appearance (pursed lips); H or V shaped chin dimple; very obvious down-slanting crease from the nostril to the corners of the mouth (nasolabial creases); and restricted movement in joints (contractures) of two or more body areas, often hands and feet, with fingers and toes frequently overlapping."
89476869|NCT05419245||Freeman-Sheldon syndrome Craniofacial Type|"Patients who have only the face and skull physical findings required by the Stevenson criteria, including: very small mouth (microstomia), whistling-face appearance (pursed lips), H or V shaped chin dimple, very obvious down-slanting crease from the nostril to the corners of the mouth (nasolabial creases)."
89476870|NCT05419245||Freeman-Sheldon syndrome Mixed Type|Patients who have the face and skull physical findings required by the Stevenson criteria and some but not all required joint problems.
89476871|NCT05419245||Sheldon-Hall syndrome|Patients who have all features required by the Stevenson criteria, including: small mouth (not microstomia); neck webbing (pterygium colli); small but prominent chin; very obvious down-slanting crease from the nostril to the corners of the mouth (nasolabial creases); and restricted movement in joints (contractures) of two or more body areas, often hands and feet, with fingers and toes frequently overlapping.
89476872|NCT05419245||Distal Arthrogryposis Type 1|Patients with features consistent with this diagnosis, including restricted movement in joints (contractures) of two or more body areas, often hands and feet, with fingers and toes frequently overlapping.
89476873|NCT05419245||Distal Arthrogryposis Type 3|Patients with features consistent with this diagnosis, including: gap in the roof of the mouth (cleft palate); drooping eyelid (blepharoptosis); and spine curve problems; and restricted movement in joints (contractures) of two or more body areas, often hands and feet, with fingers and toes frequently overlapping.
89476874|NCT04497350|Experimental|Transcranial Magnetic Stimulation|All patients are required to have an advanced MRI of the brain including a structural T1, volume measurements of various brain regions, ASL, and BOLD sequences. Patients will also undergo an in-scanner task designed to activate key neurofunctional regions of interest.
89476875|NCT04497350|Experimental|Theta Burst Stimulation|All patients are required to have an advanced MRI of the brain including a structural T1, volume measurements of various brain regions, ASL, and BOLD sequences. Patients will also undergo an in-scanner task designed to activate key neurofunctional regions of interest.
89476876|NCT02472093|Active Comparator|Physical exercises treatment|The types of exercises included: low-impact to moderate aerobic training (gradually starting from 50% of the Fc max to 70%-80% of Fc max); walking fast in a circle, alternating with periods of going up and down the stairs (3 steps for 10 minutes) for a total of 20 consecutive minutes; posture exercises for the back and proprioceptive exercises for the trunk in the supine position to improve axial stability, including diaphragmatic breathing.
89476877|NCT02472093|Experimental|Perceptive Rehabilitation Treatment|Perceptual surfaces is a therapeutic system that is based on the interaction between the patient's back or painful area and a support surface, composed of small latex cones with various dimensions (height: 3-8 cm; base diameter: 2-4 cm) and elasticities. The inferior bases of these cones are applied to a rigid wood surface using elastic strips; usually, over 100 cones are used for each session. Patients were asked to lie down supine on the surface that was formed by the smoothed apex of these cones, creating reaction forces to the patient's weight, generated by the interaction with the cones.
89476878|NCT02472093|Active Comparator|Control group|The control group did brief educational sessions.
88950269|NCT01944280|Experimental|intervention|The intervention group will receive a 20 minute massage during each hemodialysis treatment for 2 weeks. Most patients receive dialysis 3 times per week resulting in 6 massage sessions. The massage will include both feet and legs up to and including the knee. Massage will include general light centripetal friction and point compression to bellies and myotendinous junction of muscles of the foot and calf not to exceed a perceived pain of 6 on a scale of 1 to 10, 10 being most severe and 1 being no pain.
88950270|NCT01944280|No Intervention|control|usual care
88950271|NCT01944306||Low birth-weight, obese|
88950272|NCT01944306||Low birth-weight, normal body weight|
88950273|NCT01944306||Normal birth-weight, obese|
88950274|NCT01944306||Normal birth-weight, normal body weight|
88950275|NCT01944384|Experimental|aldactone|aldactone 25 mg for 6 months
88950276|NCT01944384|No Intervention|without aldactone|
88950277|NCT01944397||Atrial fibrillation|Patients with a diagnosis of atrial fibrillation recorded in primary or secondary care during the study period.
88950278|NCT01944410|Experimental|traumatic bone cyst|Patients with traumatic bone cyst defect are injected with PRP
88950279|NCT01944436||Parkinson's Disease Dementia|"Participants in the Parkinson's Disease Dementia group:~Must be taking a stable parkinsonian medication~Must have a diagnosis of clinically definite Parkinson's disease >1 year prior to cognitive deficit with at least two of the following symptoms: asymmetric resting tremor, rigidity or bradykinesia, and definite motor response to dopaminergic agents.~Response to cholinesterase inhibitor over a period of six months will be monitored."
88950280|NCT01944436||Dementia with Lewy Bodies|"Participants in the Dementia with Lewy Bodies group:~Diagnosis of clinically probable or possible Dementia with Lewy bodies with at least 1 of the following: Marked fluctuations in cognition, visual hallucinations or spontaneous parkinsonism.~Response to cholinesterase inhibitor over a period of six months will be monitored."
89206262|NCT00827346|Active Comparator|Group 1|600-mg double dose
88950281|NCT01944449|Experimental|Whey Protein (WPC) at breakfast|The subjects in Whey Protein (WPC) group will consume WPC (35gr) powder in bottles mixed with 250 ml milk, making a total of 42 g protein, at breakfast, for 12 weeks.
88950282|NCT01944449|Experimental|Other Protein Sources at breakfast|The subjects will consume also 42 g protein at breakfast but from different source, for 12 weeks.
88950283|NCT01944449|Active Comparator|Low Protein at breakfast|The subjects will consume 17 g protein breakfast namely from soy for 12 weeks.
88950284|NCT01944488|Experimental|GnRH intervention|All participating subjects are assigned to receive an intravenous GnRH agonist injection.
88950285|NCT01944501|Active Comparator|Transcranial Magnetic Stimulation|Patients receiving real transcranial magnetic stimulation
88950286|NCT01944501|Placebo Comparator|Sham TMS|Patients receiving sham transcranial magnetic stimulation
88950287|NCT01944501|Active Comparator|Transcranial Direct Current Stimulation|Patients receiving real transcranial direct current stimulation
88950288|NCT01944501|Placebo Comparator|Sham TDCS|Patients receiving sham transcranial direct current stimulation
89476879|NCT02472171|Experimental|Group 1|"Order of treatments:~A. High saturated fat meal, placebo powder and sunflower oil B. High saturated fat meal, blueberry powder and sunflower oil C. High saturated fat meal, placebo powder and DHA"
88950289|NCT01944514||Ischaemic cardiomyopathy group|Patients with ischaemic cardiomyopathy attending for ICD implantation / Ventricular tachycardia stimulation testing as part of ICD risk stratification
88950290|NCT01944514||Non-ischaemic cohort|Patients attending for ICD implantation / ventricular tachycardia stimulation test who do not have ischaemic cardiomyopathy.
89476880|NCT02472171|Experimental|Group 2|"Order of treatments:~A. High saturated fat meal, placebo powder and sunflower oil C. High saturated fat meal, placebo powder and DHA B. High saturated fat meal, blueberry powder and sunflower oil"
89476881|NCT02472171|Experimental|Group 3|"Order of treatments:~B. High saturated fat meal, blueberry powder and sunflower oil A. High saturated fat meal, placebo powder and sunflower oil C. High saturated fat meal, placebo powder and DHA"
89476882|NCT02472171|Experimental|Group 4|"Order of treatments:~B. High saturated fat meal, blueberry powder and sunflower oil C. High saturated fat meal, placebo powder and DHA A. High saturated fat meal, placebo powder and sunflower oil"
89476883|NCT02472171|Experimental|Group 5|"Order of treatments:~C. High saturated fat meal, placebo powder and DHA B. High saturated fat meal, blueberry powder and sunflower oil A. High saturated fat meal, placebo powder and sunflower oil"
89476884|NCT02472171|Experimental|Group 6|"Order of treatments:~C. High saturated fat meal, placebo powder and DHA A. High saturated fat meal, placebo powder and sunflower oil B. High saturated fat meal, blueberry powder and sunflower oil"
89476885|NCT00071552|Experimental|Qvar|Qvar 160 mcg twice daily
89476886|NCT00071552|Active Comparator|Flovent Diskus|Flovent Diskus 200 mcg twice daily
89476887|NCT05164263|Experimental|Empagliflozin naive uncontrolled T2DM on oral anti-diabetics & lifestyle modifications for 3 months|"Type 2 diabetic males & females between 18-65 years.~HbA1c: 7.0% - 10%~eGFR ˃60 mL/min/1.73m2.~Patient who will give informed consent"
89476888|NCT05136014||General cohorte|patient with non-small cell lung cancer undergoing surgical resection in the thoracic surgery department of the Nancy CHRU
89476889|NCT04767711|Active Comparator|L. reuteri|Capsules of freeze-dried L. reuteri 6475 of 5x10E9 colony-forming units (CFU) mixed with maltodextrin powder and 200 IU of cholecalciferol, taken twice daily for 30 days, yielding a total daily dose of 1x10E10 L.reuteri CFU and 400 IU of cholecalciferol per day. Oral glucocorticoid 25 mg daily for 7 days.
89476890|NCT04767711|Placebo Comparator|Placebo|Placebo product identical to the active product (L. reuteri) in taste and appearance but without the active component, orally twice daily, for 30 days.The placebo product contains 200 IU cholecalciferol per dose, yielding a total dose of cholecalciferol of 400 IU per day. Oral glucocorticoid 25 mg daily for 7 days.
89476891|NCT04273178|Experimental|Escalating prophylaxis|For all patients without documented proven or probable invasive fungal disease (IFD), patients will receive fluconazole during the treatment in the laminar air flow units (LAF). After discharged from LAF units, patients will receive anti-mold prophylaxis in case of haplo-identical or HLA-matched unrelated donor transplantation to d+100 without active acute GVHD (aGVHD). In case of active aGVHD, the prophylaxis treatment will be extended until recovery of aGVHD and tapering of immunosuppression. In case of HLA-matched sibling donor, fluconazole will be continued to d+100 and anti-mold prophylaxis will be given in case of active aGVHD.
89476892|NCT02473809|Experimental|Liraglutide|"Liraglutide (Victoza), subcutaneous 1,8 mg once daily for 180 days"
89476893|NCT02473809|Placebo Comparator|Placebo|Saline, subcutaneous once daily for 180 days
89476894|NCT02725671|Other|Cardiogoniometry and ECG Assessment|The same patient will undergo both advanced ECG assessment using cardiogoniometry and standard ECG
89476895|NCT05131334|Other|intervention group|The pilot study applied an open-label, unblinded, repeated measures design with three time points of pupillometry measurements at two testing days. Patient serving as their own controls
88950291|NCT01944514||Control group|Patients attending for electrophysiological study with no conditions that place them at risk of sudden cardiac death.
88950292|NCT01944540|Active Comparator|conventional ESD|Conventional ESD arm indicates the group in which conventional ESD method is applied for the dissection of colorectal neoplasm.
88950293|NCT01944540|Experimental|Optimized ESD with snaring|Optimized ESD with snaring arm indicates the group in which optimized ESD with snaring method is applied for the dissection of colorectal neoplasm.
88950294|NCT01944553|Experimental|prospective|Single Arm
88950295|NCT01944579|Experimental|Control-Blackberry|Participants will receive a controlled diet with the control food (jello) first and then cross over to the controlled diet with blackberries.
89476896|NCT02446990|Experimental|Ivabradine|
89476897|NCT02446990|Placebo Comparator|Placebo|
88950296|NCT01944579|Experimental|Blackberry-Control|Participants will receive a controlled diet with blackberries first and then cross over to the controlled diet with the control food (jello).
88950297|NCT01944592|Experimental|Gynaecology Training Associates (GTA's)|Final year (Year 5) medical undergraduates embarking upon their O&G clinical placement trained in pelvic examination with GTA's
89476898|NCT04272632|Experimental|4 ml/kg group|4 ml/kg compound sodium chloride (0.85% NaCl, 0.03% KCl, and 0.033% CaCl2) was given immediately after spinal anesthesia.
89476899|NCT04272632|Experimental|8 ml/kg group|8 ml/kg compound sodium chloride (0.85% NaCl, 0.03% KCl, and 0.033% CaCl2) was given immediately after spinal anesthesia.
88950298|NCT01944592|Active Comparator|Manikin training|Final year (Year 5) medical undergraduates embarking upon their O&G clinical placement trained in pelvic examination on manikins.
88950299|NCT01944605||Cardiac Arrest patients undergoing Therapeutic Hypothermia|Cardiac Arrest subjects with Return Of Spontaneous Circulation (ROSC) and undergoing treatment with Therapeutic Hypothermia will undergo sampling of blood, stool, and expired gas data at physiologically predetermined time points.
89476900|NCT04272632|Experimental|12 ml/kg group|12 ml/kg compound sodium chloride (0.85% NaCl, 0.03% KCl, and 0.033% CaCl2) was given immediately after spinal anesthesia.
89476901|NCT02471703||SMF mini-stem hip replacement recipient|Received the device via total hip arthroplasty
89476902|NCT04269824|Experimental|Intervention Group|Residents of the peri-urban ward randomized to this group will receive the norm and network-centric intervention package that includes individual, household, group and community-level interventions. No hardware will be provided. Behavior change components will focus on shifting empirical expectations of improved sanitation behaviors in their wards as well as building capacity to achieve toilet construction and behavioral goals.
89476903|NCT04269824|No Intervention|Control Group|Residents of these wards will not receive any intervention. They may be exposed to other WASH interventions promoted by the government and/or other parties independent of this study.
89476904|NCT04413110||Non-subjective cognitive impaired|Cases of migraine and non-subjective cognitive impaired
89476905|NCT04413110||Subjective cognitive impaired|Cases of migraine and subjective cognitive impaired
88950300|NCT01944618||T2DM patients newly prescribed Forxiga|A post-marketing evaluation of the safety of Forxiga (10 mg tablets, orally once daily for 6 months) through an observational prescription adverse event monitoring program (registry-based monitoring program) is warranted to assess real-world incidence of adverse events in routine clinical practice.
89476906|NCT04413110||Control group|Age and sex matched healthy controls
89476907|NCT03976934|Active Comparator|Tamsulosin group|administration of 0,4mg of tamsulosin 24 hours before surgery and 0,4mg 6 hours before surgery
89476908|NCT03976934|Placebo Comparator|Placebo group|administration of placebo 24 and 6 hours before surgery
89476909|NCT02725515|Experimental|XmAb5871|XmAb5871 administered by IV infusion for up to a total of 16 infusions
89476910|NCT02725515|Placebo Comparator|Placebo|Placebo to match XmA5871 administered by IV infusion for up to a total of 16 infusions
89476911|NCT05130554|Experimental|XEN45|The effect of XEN45 surgery on patients with primary open-angle glaucoma
89476912|NCT04912024||Tablo Hemodialysis System|Participants who were prescribed acute intermittent renal replacement therapy on the Tablo Hemodialysis System at a dialysate flow rate of 300 mL/min
89476913|NCT04912024||Conventional Hemodialysis System|Participants who were prescribed acute intermittent renal replacement therapy on conventional hemodialysis systems (Non-Tablo) with dialysate flow rates of ≥ 500 mL/min
89476914|NCT02416180|Experimental|SERETIDE EVOHALER|Subjects will switch from their current usual maintenance treatment of SERETIDE via DISKUS Inhaler to an equivalent dose of SERETIDE via the MDI (EVOHALER) at Visit 1. Subjects will use the MDI as 2 inhalations twice daily for approximately 14 days. Subjects will revert back to using SERETIDE DISKUS Inhaler again from Visit 2 (after 14 days) starting with the next scheduled dose.
89476915|NCT02471937|Experimental|Pregnant women negative for GBS colonization|Only women negative for GBS during all the study will be included.
89476916|NCT05130320||Asthma biologics|120 people receiving asthma biologics (monoclonal antibodies)
89476917|NCT05130320||Asthma inhalers|40 people receiving asthma inhalers
89476918|NCT05130320||Steroid tablets|40 people needing daily steroid tablets to control their asthma
89476919|NCT05130320||Healthy Control|50 age-matched healthy people
89476920|NCT05130242||Cement-augmented Pedicle Screws (CPS) Group|
89476921|NCT05130242||Hybrid Construct (HC) group|
89476922|NCT02473510|Experimental|Trivalent Influenza Vaccine|A single dose of 10^(7.0 +/- 0.5) fluorescent focus units (FFU) per strain of trivalent influenza vaccine will be administered as intranasal spray on Day 1.
89476923|NCT02473510|Placebo Comparator|Placebo|A single dose of placebo matched to trivalent influenza vaccine will be administered as intranasal spray on Day 1.
89476924|NCT02473575|Experimental|Caffeine gum|caffeine (300 mg) in gum form x 1 ingestion
89476925|NCT02473575|Placebo Comparator|Placebo gum|placebo gum consumed x 1 ingestion
89476926|NCT02473575|No Intervention|Non-intervention group|A third group of runners will be used to adjust for changes in environmental conditions. They will complete 2 runs without consuming either placebo or experimental treatment
89476927|NCT02473731|Experimental|A|Treatment with KTN3379 in HPV positive head and neck cancer patients
89476928|NCT02473731|Experimental|B|Treatment with KTN3379 in HPV negative head and neck cancer patients
89476929|NCT03952286|Experimental|Intervention|ED-Dispensing with home and school supervision
89476930|NCT03952286|Other|Control|ED-Dispensing with home supervision
89476931|NCT02471625||Traumatic Brain Injury|Men and women ages 18-65 with suspected acute head trauma within 24-72hrs. of presentation, scoring a 3-15 on initial evaluation on GCS scale.
89476932|NCT02471625||Control|Men and women ages 18-65 with no history of head trauma and a score of 15 on the GCS scale.
88950301|NCT01944657|Active Comparator|Standard Medication Monotherapy Group|A group of 15 patients will receive only standard antidepressant medication treatment.
88950302|NCT01944657|Active Comparator|Supplemental TMS plus Medication Group|A group of 15 patients will receive supplemental transcranial magnetic stimulation (TMS) plus standard antidepressant medication.
89476933|NCT05135234|Experimental|Muscular Exercise|Increased level of low effort muscular activity
89476934|NCT05092724|No Intervention|standard protocol of manaegement|
88950303|NCT01944683|Experimental|GGF2|"Patients will be randomized to receive GGF2 or Placebo and on study day 3 administered a single IV infusion.~Each patient will receive 5 oral doses of Midazolam syrup on study day 1 and days 4 through 7 respectively."
88950304|NCT01944683|Placebo Comparator|Placebo|"Patients will be randomized to receive GGF2 or Placebo and on study day 3 administered a single IV infusion.~Each patient will receive 5 oral doses of Midazolam syrup on study day 1 and days 4 through 7 respectively."
89476935|NCT05092724|Active Comparator|fetal blood|
89476936|NCT05682885|Experimental|Axillary lymph node dissection with LBS|70 subjects will be needed for each group. A standard mastectomy or lumpectomy incision is made and ALND will be done in the same incision. The lymphatic vessels and lymph nodes will be resected using a near-infrared (NIR) camera. To locate lymphatic vessels, a microscope with ICG lymphography navigation is employed. LBS was performed by making intima-to-intima anastomosis between the afferent lymphatic vessels and the recipient's veins, or to the efferent lymphatic vessels. The anastomosis patency will be assessed by observing the ICG fluorescent flow. After surgery, follow-up will be done every 2 months and every 3 months in the second year. UEL index, ICG lymphography, and quality of life evaluation will be done. The cumulative incidence of BCRL, the free survival time of BCRL, and subclinical lymphedema (SCL) progression will be reported descriptively. BCRL risk factors and collateral lymphatic pathway will be observed as well.
89476937|NCT05682885|No Intervention|Axillary lymph node dissection without LBS|70 subjects will be needed for each group. A standard mastectomy or lumpectomy incision is made and ALND will be done in the same incision. After primary breast cancer removal, a standard ALND level I, II, and if necessary, level III is performed. After surgery, follow-up will be done every 2 months and every 3 months in the second year. History taking, physical examination, radiology and histopathology examination, UEL index, and ICG lymphography evaluation will be done during follow-up. Each subject will complete the lymphedema quality of life questionnaire. The cumulative incidence of BCRL, the free survival time of BCRL, and SCL progression will be reported descriptively. BCRL risk factors and collateral lymphatic pathway will be observed as well.
89476938|NCT03770546|Experimental|Osteoarthritis - Amnion Injection|BioDRestore Elemental Tissue Matrix is a morselized, flowable tissue allograft derived from human amniotic tissues.
89476939|NCT03770546|Active Comparator|Osteoarthritis - Betamethasone Injection|Betamethasone Sodium Phosphate and Betamethasone Acetate injection (To clarify, this is one formulation/injected solution, not separate solutions/interventions)
89476940|NCT03770546|Experimental|Adhesive Capsulitis - Amnion Injection|BioDRestore Elemental Tissue Matrix is a morselized, flowable tissue allograft derived from human amniotic tissues.
89476941|NCT03770546|Active Comparator|Adhesive Capsulitis - Betamethasone Injection|Betamethasone Sodium Phosphate and Betamethasone Acetate injection (To clarify, this is one formulation/injected solution, not separate solutions/interventions)
89476942|NCT05077046|Experimental|Intervention first arm|"Due to the counter-balanced design of this study all participants will experience both an interventional and a control period. Within the intervention first arm participants will be asked to execute the assessment trial / test battery with the intervention pen first. After a wash-out period, the participants will execute the same assessment trial / test battery with the control pen."
89476943|NCT05077046|Experimental|Control first arm|"Due to the counter-balanced design of this study all participants will experience both an interventional and a control period. Within the control first arm participants will be asked to execute the assessment trial / test battery with the control pen first. After a wash-out period, the participants will execute the same assessment trial / test battery with the intervention pen."
89206263|NCT00827346|Active Comparator|Group 2|600/600-mg double loading dose (first dose 600 mg given immediately upon arrival at the hospital and the second dose 600 mg, 3 hours after the first loading dose for a total of 900 mg
89476944|NCT03137576|Active Comparator|Paravertebral block (PVB)|"Intraoperative pain management~Sedation~Continuous monitoring of sedation with bispectral index. Sedation is achieved with propofol 1% (target bispectral index: 50-70), plus on-demand remifentanyl (50 mcg/ml in TCI, dose target Cet 2-8 ng/ml).~Paravertebral Block~Post operative pain management~Continuous infusion of Tramadol 200 mg or Ketorolac 60 mg~Rescue analgesia with Morphine (0.1 mg/kg) a single time every 24 hours, and/or Tramadol 100 mg up to three times every 24 hours and/ or Ketorolac 30 mg up to three times every 24 hours"
88950305|NCT01944696|Active Comparator|continuous (uninterrupted) phototherapy|standard phototherapy
88950306|NCT01944696|Experimental|15 minute per hour cycled phototherapy|15 minute per hour cycled phototherapy
89476945|NCT03137576|Experimental|Erector Spinae Plane Block (ESPB)|"Intraoperative pain management~Sedation~Continuous monitoring of sedation with bispectral index. Sedation is achieved with propofol 1% (target bispectral index: 50-70), plus on-demand remifentanyl (50 mcg/ml in TCI, dose target Cet 2-8 ng/ml).~Erector Spinae Plane Block~Post operative pain management~Continuous infusion of Tramadol 200 mg or Ketorolac 60 mg~Rescue analgesia with Morphine (0.1 mg/kg) a single time every 24 hours, and/or Tramadol 100 mg up to three times every 24 hours and/ or Ketorolac 30 mg up to three times every 24 hours"
89476946|NCT05134844|Experimental|Halliwick Snoezelen Group|Hydrotherapy in a multi-sensory Snoezelen environment
89476947|NCT05134844|Experimental|Land Snoezelen Group|Land multi-sensory Snoezelen environment
89476948|NCT05134766||PCR positive|Those with a condition of the first SARS-CoV-2 PCR test result was positive. Based on data recorded in the period between 01 January 2021 to 30 June 2021
89476949|NCT05134766||PCR negative|Those with a condition of the first SARS-CoV-2 PCR test result was negative. Based on data recorded in the period between 01 January 2021 to 30 June 2021
89476950|NCT05134766||IgA/IgG positive|Those with a condition of the first IgA or IgG test result was at least once positive.
89476951|NCT05134766||IgA/IgG negative|Those with a condition of the first IgA and IgG test results were both negative
89476952|NCT05134766||Prevention only|Those with a condition of the first SARS-CoV-2 PCR test result was negative AND IgG /IGA negative.
89476953|NCT05134766||W/Symptoms|Those that reported at least one positive symptom. Based on data recorded in the period between 01 January 2021 to 30 June 2021
89476954|NCT03734042|Experimental|PRP group|These patients will receive platelet rich plasma intrauterine infusion at day 11
89476955|NCT03734042|Placebo Comparator|Control group|These patients will receive intrauterine normal saline infusion at day 11
89476956|NCT03704168|Experimental|CRYOABLATION ARM|
89476957|NCT02477943||Injured and Matched Control Subject Pool|Injured subjects consist of athletes who are head injured and meet the inclusion/exclusion criteria. Injured subjects will be tested within 72 hours (3 days) of injury and at specified time points post injury. Matched control subjects will be tested at the same time intervals as the injured subject. BrainScope Battery will be performed at each time point and consists of the following components: brain electrical activity (EEG), neurocognitive performance assessment, balance/sway measurement, and clinical symptoms/assessments. In addition, a subset of injured and matched control subjects will receive advanced MRI/DTI neuroimaging at time of injury and following RTP.
89476958|NCT02477943||Pre-Season and Post-Season Subject Pool|This subject pool will consist of uninjured (not head injured) contact and non-contact athletes and will be tested at two time points - pre-season and post-season. These subjects will perform the same BrainScope Battery as the injured and matched control subjects at each time points.
89206264|NCT00827346|Active Comparator|Group 3|Clopidogrel 900mg
89476959|NCT03383900|Experimental|G-IMT|The experimental group will first carry out a diaphragmatic reeducation program, followed a posteriori by an inspiratory muscle training program use progressive resistance loads up to 80% of the PImax during the 8 weeks
89476960|NCT03383900|Placebo Comparator|Gn-IMT|The Gn-IMT will use by an inspiratory muscle training program use resistance loads up to 20% PImax during the 8 weeks.
89476961|NCT05341323|Active Comparator|Group K1 Ketamine|pre-incisional submucosal infiltration of ketamine .5 mg/kg in the Peritonsillar area
89476962|NCT05341323|Active Comparator|Group B1 Bupivacaine|pre-incisional submucosal infiltration of Bupivacaine .25 % in the Peritonsillar area
89476963|NCT05115734||Short stayers|Determination of the acylcarnitine profile during the 5 days following discharge of a short stay in ICU (maximum 2 days)
89476964|NCT05115734||Long stayers|Determination of the acylcarnitine profile during the year following discharge of a prolonged stay in ICU (7 days or more)
89476965|NCT02471859|Experimental|Part A: GDC-3280|Participants in multiple cohorts and treatment periods will receive single doses of GDC-3280 under fed/fasting conditions.
89476966|NCT02471859|Placebo Comparator|Part A: Placebo|Participants in multiple cohorts and treatment periods will receive single doses of placebo under fed/fasting conditions.
89476967|NCT02471859|Experimental|Part B: GCD-3280|Participants in different cohorts will receive GDC-3280 in multiple ascending doses under fed/fasting conditions.\n
89476968|NCT02471859|Placebo Comparator|Part B: Placebo|Participants in different cohorts will receive placebo in multiple ascending doses under fed/fasting conditions.\n
89476969|NCT05080400|Experimental|Gellan gum|White rice cooked with gellan gum
89202761|NCT00756080|Experimental|1|After receiving a 7-day oral supplementation with citrulline, each subject will be admitted to the Clinical Investigation Unit for a half day, after an overnight fast,and will receive a 5-h intravenous infusion of L-[1-13C]leucine (i.e.; leucine labeled with 13C, a stable isotope of carbon) from 8 am to 1 pm. At regular intervals throughout the isotope infusion, blood will be obtained to measure 13C-enrichment in plasma a-keto-isocaproate, the keto acid of leucine, using gas chromatography-mas spectrometry. Simultaneously, 13C-enrichment will be measured in aliquots of expired air CO2 using isotope ratio mass spectrometry, and total CO2 production (VCO2) will be measured using direct calorimetry, respectively. The subject will then leave the hospital, take no treatment for13 days (wash-out period). The study will then be repeated a second time in an identical fashion, after a second 7-day period of oral supplementation with placebo, as a cross-over study design will be used.
89476970|NCT05080400|Placebo Comparator|Control|White rice cooked without gellan gum
89476971|NCT02473419||Vayarin|Vayarin x 16 weeks
89476972|NCT02473419||Placebo|Placebo x 16 weeks
89476973|NCT02473419||Vayarin and Placebo|Placebo x 8 weeks and then Vayarin x 8 weeks
89476974|NCT03381092||invasive breast cancer|Patients with invasive breast cancer who have clinically negative axilla and receive neoadjuvant treatment followed by sentinel lymph node biopsy are eligible for this study.
89476975|NCT04622865|Experimental|Masitinib plus Isoquercetin plus Best Supportive Care|"Patients will receive oral masitinib dose of 3 mg/kg/day for 4 days then 4.5 mg/kg/day.~The dose of isoquercetin will be 1 g/day by oral route. Best Supportive Care is best available therapy at the choice of the investigator, including, but not limited to, oxygenation, analgesics, anti-thrombotics, anti-viral drugs, or biologics drugs."
89476976|NCT04622865|Active Comparator|Best Supportive Care|Best Supportive Care is best available therapy at the choice of the investigator, including, but not limited to, oxygenation, analgesics, anti-thrombotics, anti-viral drugs, or biologics drugs.
89476977|NCT02473185|Experimental|Methylphenidate|Methylfenidate 20 mg Tablet single-dose per os
89476978|NCT02473185|Placebo Comparator|Placebo|Placebo 20 mg Tablet single-dose per os
89476979|NCT02477787|Experimental|treatment|patients will receive donor-derived NK cell infusion after haploidentical HCT
89476980|NCT02477787|No Intervention|control|patients will undergo haploidentical HCT but not receive donor-derived NK cells after HCT
88950307|NCT01944735|Experimental|Active|Once daily oral capsule containing 50 or 100 mg of CTX-4430
88950308|NCT01944735|Placebo Comparator|Placebo|Once daily oral capsule containing mannitol, visibly identical to CTX-4430 capsules
88950309|NCT01944748|Experimental|Family Mediation|Families receive FARS family mediation program after completing baseline survey.
88950310|NCT01944748|No Intervention|Wait-list control|Families receive FARS family mediation program after completing baseline, 6-week and 12-week surveys.
88950311|NCT01944787|Active Comparator|Routine|IV Hydration at 125 cc hour
88950312|NCT01944787|Experimental|Intervention|IV Hydration at 250 cc hour
88950313|NCT01944813|Experimental|Intervention: ACP conversation|Intervention: Advance Care Planning conersation between a healtprofessionel and a patient about end-of-life discussions.
88950314|NCT01944813|No Intervention|No intervention: usual care|No intervention just usual care
88950315|NCT01944826||Tako-Tsubo And Cancer Registry|
88950316|NCT01944852|Experimental|2 icodextrin bags/day|2 icodextrin bags + 1 glucose per day
88950317|NCT01944852|Active Comparator|1 icodextrin bag/day|1 icodextrin bag + 2 glucose bags per day
88950318|NCT01944865|Experimental|Interval Training|The INTV consisted of 7 to 10 repetitions of 4-6 min at the highest intensity sustainable, and in the last 30 s of each repetition was performed a maximal sprint, the active recovery was 4-6 min in intensity from 10 to 15 of scale of perceived exertion CR100.
88950319|NCT01944865|Experimental|Intermittent Training|The riders completed 8 to 12 repetitions of 30 s all-out with 4 min of active recovery (10-15 on the CR100 scale).
89476981|NCT02445586|Experimental|Pertuzumab in Combination with Trastuzumab and Docetaxel|Participants will receive pertuzumab in combination with trastuzumab and docetaxel every 3 weeks until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
89476982|NCT02471547|No Intervention|TURBT ONLY|"A total of 150 patients in this arm will be divided into five follow-up sub groups according to pathology reports.~Group 1 - Primary Low risk patients Group 2 - Primary Intermediate risk patients Group 3 - Primary High risk patients Group 4 - Recurrent Intermediate risk patients Group 5 - Recurrent Intermediate risk patients"
89476983|NCT02471547|Experimental|BWT with Mitomycin-C prior TURBT|"A total of 150 patients in this arm will be divided into five follow-up sub groups according to pathology reports.~Group 1 - Primary Low risk patients Group 2 - Primary Intermediate risk patients Group 3 - Primary High risk patients Group 4 - Recurrent Intermediate risk patients Group 5 - Recurrent Intermediate risk patients"
89476984|NCT02477631|Experimental|Deferiprone|patient treated with study drug
89476985|NCT01674062|Experimental|Pertuzumab + Trastuzumab (Cohorts 1 and 2)|Females with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer will receive dual-agent treatment with pertuzumab and trastuzumab. Trastuzumab will be administered IV as 2 milligrams per kilogram (mg/kg) once weekly, or as 6 mg/kg every 3 weeks, beginning on Day 1 of Cycle 1. Pertuzumab will be administered IV at a loading dose of 840 mg followed by a standard dose of 420 mg every 3 weeks, beginning on Day 2 of Cycle 1. Thereafter, both medications will be administered on Day 1 of each 3-week cycle. Treatment will continue for a minimum of 8 cycles and may be extended until disease progression, intolerable toxicity, or death.
89476986|NCT01674062|Experimental|Pertuzumab +/- Trastuzumab (Cohort 3)|Females with HER2-positive metastatic breast cancer will receive single-agent treatment with pertuzumab. Pertuzumab will be administered IV at a loading dose of 840 mg followed by a standard dose of 420 mg every 3 weeks, administered on Day 1 of each 3-week cycle. Participants with documented disease progression may have trastuzumab added to the regimen, per the dosing schedule described for Cohorts 1 and 2, to receive dual-agent treatment until disease progression, intolerable toxicity, or death.
89476987|NCT02473029||Cases|Patients admitted to a tertiary hospital, with a clinical suspicion of Horton disease
89476988|NCT02472873|Experimental|study group - sclerotherapy|Aspiration and Sclerotherapy of endometriomas.
89476989|NCT02472873|Other|control group - cystectomy|cystectomy of endometriomas.
89476990|NCT02472886|Experimental|LDV/SOF|Treatment-naive participants with genotype 1 HCV infection without cirrhosis will receive LDV/SOF FDC for 8 weeks.
89476991|NCT02472886|Experimental|LDV/SOF Coinfected with HIV-1|Treatment-naive participants with genotype 1 HCV infection without cirrhosis and who are coinfected with HIV-1 will receive LDV/SOF FDC for 8 weeks.
88950320|NCT01944904|Placebo Comparator|Sugar Pill|Subjects will be asked to take the dietary supplement daily for 8 weeks. Blood samples will be taken at screen, baseline and week 8. An oral glucose tolerance test will be taken at baseline and week 8. Additionally subjects will be asked to collect their stool samples at Baseline, week 4, and 8. Subjects will also undergo a test to determine their body composition at baseline and week 8. Subjects will be asked to keep a diary of their bowel habits and any symptoms that might be related to the supplement. Subjects will be asked to recall the foods that they have eaten in the past 24 hours and to avoid any foods that contain XOS and probiotic bacteria during the study.
88950321|NCT01944904|Active Comparator|XOS 2.8|Subjects will be asked to take the dietary supplement daily for 8 weeks. Blood samples will be taken at screen, baseline and week 8. An oral glucose tolerance test will be taken at baseline and week 8. Additionally subjects will be asked to collect their stool samples at Baseline, week 4, and 8. Subjects will also undergo a test to determine their body composition at baseline and week 8. Subjects will be asked to keep a diary of their bowel habits and any symptoms that might be related to the supplement. Subjects will be asked to recall the foods that they have eaten in the past 24 hours and to avoid any foods that contain XOS and probiotic bacteria during the study.
88950322|NCT01944917||Chronic musculoskeletal pain|Chronic musculoskeletal pain - treated with electromagnetic field Chronic musculoskeletal pain - placebo
88950323|NCT01944943|Experimental|Vismodegib|Vismodegib 150 mg will be administrated orally at a dosage of 150 mg (1 capsule) once a day during 12 months.
88950324|NCT01944982|Experimental|Activated natural killer cells|Activated natural killer cells
88950325|NCT01944995|Experimental|group B|
88950326|NCT01944995|Experimental|group A|
88950327|NCT01945008||Hepatitis-C infected patients|Patients with Hepatitis-C infection untreated at the enrolment
89476992|NCT02472886|Experimental|LDV/SOF+RBV Retreatment|Participants with genotype 1 or 3 HCV infection who failed to achieve SVR12 in Gilead Study GS-US-334-0119 will receive LDV/SOF FDC + RBV for 12 weeks.
89476993|NCT05283356|Active Comparator|Acetylsalicylic acid 100mg/day|Aspirin 100 mg/day after TAVI
89476994|NCT05283356|Experimental|Ticagrelor 60mg twice per day|Ticagrelor 60 mg twice per day after TAVI
89476995|NCT05067465|Experimental|Milk and dairy products|"Standardized diet over five days (n = 40) - composed of cow milk, cheese, cream cheese, cream, valess milk schnitzel~Test meal on day 6 (n = 12) - composed of milk, cheese, cream cheese, cream"
89476996|NCT05067465|Experimental|Whole-grain products (rich in soluble fibers)|"Standardized diet over five days (n = 40) - composed of oatmeal, oat bran, oat milk, whole wheat pasta, whole wheat bread, hummus~Test meal on day 6 (n = 12) - composed of oatmeal, oat bran, oat milk"
89476997|NCT05067465|Experimental|Sausage and processed meat (pork)|"Standardized diet over five days (n = 40) - composed of Lyoner (pig), Viennese (pig), minced meat (pig)~Test meal on day 6 (n = 12) - composed of Lyoner (pig), Viennese (pig)"
89476998|NCT05067465|Experimental|Meat-free sausage and meat alternatives (based on egg, pea, soy)|"Standardized diet over five days (n = 40) - composed of Mortadella (egg-based), Viennese (egg-based), vegan mince (soy-based)~Test meal on day 6 (n = 12) - composed of Mortadella (egg-based), Viennese (egg-based)"
89476999|NCT03351218|Other|Patients|25 patients with cervical and 25 patients with myoclonus dystonia
89477000|NCT03351218|Other|Controls|50 healthy volunteers matched to patents ( age, sex)
88950328|NCT01945021|Experimental|Crizotinib|Single-arm trial whereby all consented, enrolled, eligible patients receive crizotinib
88950329|NCT01945047|Experimental|Ketamine|During Phase 1 patients will be randomly assigned to receive ketamine or active placebo.
88950330|NCT01945047|Active Comparator|Midazolam|In phase 1 patients will be randomized to receive active placebo
89477001|NCT02472652|Other|Abilify Maintena|Subjects will be switched to Abilify Maintena (Aripiprazole) LAI monthly doses of 400mg, 300mg, 200mg or 160mg and have their sexual functioning reevaluated over a 3 month period to determine if there is any significant sexual functioning improvement.
89477002|NCT04410848||All patient with suspicion of choledocholithiasis|Patient with the suspect of common biliary duct stone for pain type colic in the right upper quadrant abdomen, the elevation of bilirubin, alkaline phosphatase, pancreatitis, dilated common bile duct and cholangitis. According to the criteria to assign the risk of choledocholithiasis. We are going to validate a scale based on intelligence artificial compared to the clinical predictor.
89477003|NCT05276336|Experimental|Intervention Group|Subjects will receive radiofrequency turbinate reduction done in the outpatient clinic, followed by pharmacology treatment (intranasal steroid and AH-1) for 8 weeks.
89477004|NCT05276336|Active Comparator|Control Group|Subjects in the control group will receive only the pharmacology treatment for 8 weeks.
89477005|NCT05274698|Experimental|Group A (Experimental group):|This group includes 30 patients with adhesive capsulitis who will receive muscle energy techniques 1 session per day, 5 days a week for 8 weeks in addition to their conventional physical therapy program (Mobilization exercises, Posterior capsule stretching, and Range of motion exercises).
89477006|NCT05274698|Other|Group B (Control group):|This group includes 30 patients with adhesive capsulitis who will receive their conventional physical therapy program (Mobilization exercises, Posterior capsule stretching, and Range of motion exercises) 1 session per day, 5 days a week for 8 weeks.
88950331|NCT01945060|Experimental|heart rate Control to Range System (hrCTR) THEN No heart rate Control to Range System (hrCTR)|The Diabetes Assistant (DiAs) Control-to-Range system is notified of heart rate during exercise. The study team member will activate and deactivate a heart rate button when the subject's heart rate exceeds and then returns below 140 beats per minute.
88950332|NCT01945060|Placebo Comparator|No heart rate Control to Range System (hrCTR) THEN heart rate Control to Range System (hrCTR)|Using the DiAs Platform, the Control-to-Range system is not notified of the heart rate during exercise. Heart rate not of interest in this arm.
88950333|NCT01945073|No Intervention|Control (RC)|Routine clinical care with no intervention
88950334|NCT01945073|Experimental|Educational Booklet (BK)|Routine clinical care and educational booklet (BK) given
89477007|NCT02910752|Experimental|"CLAM|PBSC"|CLAM chemotherapy with mobilized PBSC infusion: Cladribine 5mg/m2 + cytarabine 1.5g/m2 + mitoxantrone 10mg/m2 from D1 to D5
89477008|NCT02807857|Other|Patients' heart failure and non-heart failure|No treatments are stipulated by this protocol - patients' HF and non-HF treatments will be observed throughout the study. The patients' treatment is entirely in the discretion of the primary care physicians
89477009|NCT04568798|Active Comparator|Sana Device|The Sana Device is an externally worn mask that physically contacts the skin of the face. The Sana Device delivers Audio Visual Stimulation (AVS) in the form of coordinated pulses of light (through closed eyelids) and sound at various frequencies.
89477010|NCT04568798|Sham Comparator|Sana Sham Device|The sham treatment device is designed to copy the look and feel of the Sana therapy to a degree that it would be indistinguishable from the true treatment. The sham treatment delivers a series of Audio-Visual Stimulation (AVS) in the form of pulses of light (through closed eyelids) and sound, but that offer no therapeutic effect.
89477011|NCT05243186|Experimental|MPH walking|The participants will be instructed to work while taking Methylphenidate and walking on a treadmill workstation
89477012|NCT05243186|Placebo Comparator|MPH sitting|The participants will be instructed to work while taking Methylphenidate and sitting at a desk
89477013|NCT05243186|Placebo Comparator|No MPH walking|The participants will be instructed to work without taking Methylphenidate while walking on a treadmill workstation
89477014|NCT05243186|Placebo Comparator|No MPH sitting|The participants will be instructed to work without taking Methylphenidate while sitting at a desk
89477015|NCT02856074|Experimental|Ischemic stroke patients|
89477016|NCT02808182|Other|A0: PET/scan with [11C] palmitate|A bolus of 180 MBq of [11C]-acetate at time 90min and PET acquisition
89477017|NCT02808182|Other|A1: PET/scan with [11C] palmitate|A bolus injection of 180 MBq of [11C]-acetate at time 90min, followed by PET acquisition
89477018|NCT02808182|Other|B0: PET/scan with [18F]-FTHA|At time 0, a standard liquid meal will be drunk over 20 minutes with 70 MBq of 18FTHA . PET acquisition at time 90 min.
89477019|NCT02808182|Other|B1: PET/scan with [18F]-FTHA|At time 0, a standard liquid meal will be drunk over 20 minutes with 70 MBq of 18FTHA followed by a PET acquisition at time 90 min.
89477020|NCT04695704|Experimental|Montelukast|10mg oral montelukast once daily for 28 days.
88950335|NCT01945073|Experimental|Educational Booklet and Counselling (CB)|Routine clinical care, aided by formal counselling and active discussions from the educational booklet (CB)
88950336|NCT01945099|Active Comparator|ePID closed loop system without hyaluronidase|Hyaluronidase will not be given while subject uses ePID closed loop system
89477021|NCT04695704|Placebo Comparator|Placebo|oral placebo once daily for 28 days.
89477022|NCT02051569|Experimental|Tryptophan first|Tryptophan is given for the first 14 days, 6 times 500mg per day. Placebo is given 6 times per day for the second 14 days.
89477023|NCT02051569|Experimental|Tryptophan second|Placebo is given 6 times per day for the first 14 days. Tryptophan is given for the second 14 days, 6 times 500mg per day.
89477024|NCT02048527|Active Comparator|Global|In vitro embryo culture in single-step medium (Global)
89477025|NCT02048527|Active Comparator|Origio|In vitro embryo culture in sequential media (Origio)
89477026|NCT04497272|Other|The metabolomic signature of COVID-19 patients|It will consist in the collection of 1 additional tubes at their blood draw and 1 urine sample.
89477027|NCT02048605|Experimental|Psycho-social (CBT) based training|Psycho-social Training in Neurological Diseases - Parkinson's Disease ( Training according to Ellgring et al., 2006)
89477028|NCT02048605|Placebo Comparator|Unspecific group training|"Health Enhancement Program~The validation of an active control intervention for Mindfulness Based Stress Reduction (MBSR) (MacCoon et al., 2012)"
89477029|NCT02648438|Experimental|Treatment sequence 1|Treatment Period 1:AZD7594 Solution for infusion (150 μg intravenous formulation) Treatment Period 2:AZD7594 Inhalation powder (400 μg) by dry powder inhaler (DPI) Device 1 (monodose inhaler) Treatment Period 3:AZD7594 Inhalation powder (400 μg) by DPI device 2 (multiple-dose inhaler) Treatment Period 4:AZD7594 Oral suspension (1200 μg oral formulation)
89477030|NCT02648438|Experimental|Treatment sequence 2|Treatment Period 1:AZD7594 Solution for infusion (150 μg intravenous formulation) Treatment Period 2:AZD7594 Inhalation powder (400 μg) by dry powder inhaler (DPI) Device 1 (monodose inhaler) Treatment Period 3:AZD7594 Pressurized inhalation suspension (400 μg) by pressurized metered-dose inhaler (pMDI) Treatment Period 4:AZD7594 Oral suspension (1200 μg oral formulation)
89477031|NCT02051725|Experimental|Active life-style intervention|"The active life-style intervention is designed as 12-week structured and progressive heavy-resistance power training combined with recommended everyday physical activity."
89477032|NCT02051725|No Intervention|Control|The control group is offered to enroll in the same active life-style intervention after the end of the 12-week control period. During the control period this group is asked to maintain the habitual life style.
88950337|NCT01945099|Experimental|ePID closed loop system with hyaluronidase at infusion site|Hyaluronidase will be injected at insulin pump infusion site prior to the time that subject uses ePID closed loop system
89477033|NCT02591420|Experimental|Group 1: immediate ART and placebo infusion|Participants will start ART and will receive a single infusion of placebo at Day 0.
89477034|NCT02591420|Experimental|Group 2: immediate ART and VRC01 infusion|Participants will start ART and receive a single infusion of VRC01 at Day 0.
89477035|NCT02591420|Experimental|Group 3: immediate VRC01 infusion and subsequent ART|Participants will receive a single infusion of VRC01 on Day 0 followed by ART initiation on Day 7.
89477036|NCT02050945|Experimental|Patients with COPD|Patients with COPD are to be trained 3 times a week for 8 weeks
89477037|NCT02050945|Active Comparator|Control patients with COPD|Control patients with COPD are to be trained 3 times a week for 8 weeks
89477038|NCT05218538||Learning e-cohort|Includes the entire population within Clalit Healthcare's electronic records database which spans from the year 2000 to 2021.
89477039|NCT05218538||FIB-4 score group|One of the two validation population invited to the clinic. The FIB-4 score group are individuals invited by their score.
89477040|NCT05218538||Model based group|"One of the two validation population invited to the clinic:~The Model based group are individuals invited by their predicted time-to-event to liver cirrhosis diagnosis."
88950338|NCT01945099|Experimental|ePID closed loop system with hyaluronidase co-formulation|Hyaluronidase-insulin co-formulation will be used in study pump while subject uses ePID closed loop system
88950339|NCT01945125|No Intervention|THW Group|Patients under THW stimulation for RIT
88950340|NCT01945125|Other|rhTSH Group|Patients under rhTSH stimulation for RIT
88950341|NCT01945151|Experimental|Group 1 (G1) NMES is applied in the spastic antagonist muscle|The parameters considered for the application of NMES are: frequency of 50Hz, the wavelength of 350m / s, 10 seconds of contraction of 20 seconds of rest to total 15 minutes. During the application of NMES patients will be positioned supine on the bed with knees flexed semi supported on roller positioning. The G1 apply NMES on the motor point of the tibialis anterior and triceps surae lengthening held along with the contraction (reciprocal inhibition).
88950342|NCT01945177|No Intervention|white light endoscopy|white light endoscopy
88950343|NCT01945177|Active Comparator|narrow band imaging|narrow band imaging
88950344|NCT01945190|Experimental|True before sham electroacupuncture|Crossover design, individuals randomized to receive either true or sham acupuncture in first study day, and on the second study day whichever intervention was not administered on the first study day.
88950345|NCT01945190|Experimental|Sham before true electroacupuncture|Crossover design, individuals randomized to receive either true or sham acupuncture in first study day, and on the second study day whichever intervention was not administered on the first study day.
88950346|NCT01945203||PD-ABI|"Patients at National Taiwan University Hospital (NTUH)~Patients who have received PD more than 3 months~Patients who sign the informed consents~Patients who aged between 20-90 years."
88950347|NCT01945229||Hyperthyroid patients|Patients with hyperthyroidism admitted for treatment with radioiodine or antithyroid drugs
88950348|NCT01945255||HD-ABI|"Patients at National Taiwan University Hospital (NTUH)~Patients who have received PD more than 3 months~Patients who sign the informed consents~Patients who aged between 20-90 years"
88950349|NCT01945268|Experimental|influenza vaccine|Participants at high risk for adverse vascular events will be immunized with 0.5 ml dose of inactivated trivalent influenza vaccine
88950350|NCT01945268|Placebo Comparator|placebo vaccination|Participants at high risk for adverse vascular events will be immunized with a 0.5 ml dose of sterile saline inactivated during the influenza season.
88950351|NCT01945320||HD-BCM|"Patients at National Taiwan University Hospital~Patients who have received HD more than 3 months~Patients who sign the informed consents~Patients who aged between 20-90 years"
88950352|NCT01945333|Active Comparator|Brain Basics for Impaired Tone Matchers|Cognitive remediation includes sensory processing training
88950353|NCT01945333|Active Comparator|Brain Basics for Intact Tone Matchers|Cognitive remediation includes sensory processing training
88950354|NCT01945333|Active Comparator|Brain Training for Impaired Tone Matcher|Cognitive remediation does not include sensory processing training
88950355|NCT01945333|Active Comparator|Brain Training for Intact Tone Matchers|Cognitive remediation does not include sensory processing training
88950356|NCT01945346|Experimental|PRX167700|
88950357|NCT01945346|Placebo Comparator|Placebo|
88950358|NCT01945359||Relapsing Remitting MS (RRMS)|
88950359|NCT01945372|Experimental|EEG NeuroFeedback - real feedback|Thw women in the experimental group will receive accurate realtime feedback corresponding to their performance on the task.
88950360|NCT01945372|Sham Comparator|EEG NeuroFeedback - sham feedback|The women in the sham group will receive neural feedback from another person in the study, thus unrelated to their mental practice
88950361|NCT01945385|Experimental|Video intervention|Participants will view a seven - minute theory-based video of patient testimonials about their own postabortal LARC uptake.
88950362|NCT01945385|No Intervention|Control|Patients will view a 7 minute video about stress management delivered by local psychologist.
89020289|NCT05183841|Active Comparator|Bronchodilator|The intervention will be a combination of 2 drugs, ipratropium (20 mcg) and fenoterol (50mcg). Ipratropium is an anticholinergic bronchodilator, and fenoterol is a beta-agonist bronchodilator. The medication will be delivered to the patient via an inhaler device with spacer, at leat 20 minutes before the constant load exercise test (CLET). Patient will be asked for a total exhalation, followed by an appropriate spacer mouthpiece placement and the first of eight puffs (30 seconds interval between puffs) will be delivered through the opposite extremity of the spacer. Patient will be instructed to perform five tidal volume breaths for each puff.
89020290|NCT05183841|Placebo Comparator|Placebo|The placebo will be delivered via an inhaler device with spacer (identical to the bronchodilator device), at least 20 minutes before the constant load exercise test (CLET). Patient will be asked for a total exhalation, followed by an appropriate spacer mouthpiece placement and the first of eight puffs (30 seconds interval between puffs) will be delivered through the opposite extremity of the spacer. Patient will be instructed to perform five tidal volume breaths for each puff.
89477041|NCT02051803|Experimental|Distress Tolerance Treatment for Weight Concern (DT-W)|DT-W is delivered over a 9 week period with 1 1-hr individual session during week 1, 8 weekly 1.5-hr group counseling sessions during weeks 2-9, and 1 20-minute individual telephone session during week 4. Session content includes distress tolerance intervention for weight concern plus standard behavioral smoking cessation treatment. Participants also receive 8 weeks of nicotine patch.
89020291|NCT05183841|No Intervention|Control|A paired healthy control group will be assessed by a constant load exercise test (75% from maximal load achieved on the cardiopulmonary exercise test) concomitant to the optoelectronic plethysmography to compare mechanical respiratory parameters to the bronchiectasis patients during the placebo assessment. In addition they will also use an accelerometer for 7 consecutive days.
89477042|NCT02051803|Active Comparator|Health Education (HE)|HE is delivered over a 9 week period with 1 1-hr individual session during week 1, 8 weekly 1.5-hr group counseling sessions during weeks 2-9, and 1 20-minute individual telephone session during week 4. Session content includes smoking health education program plus standard behavioral smoking cessation treatment. Participants also receive 8 weeks of nicotine patch.
89477043|NCT05217758|Experimental|Mifepristone|Glucocorticoid Receptor (GR) blockade using the generic drug mifepristone
89020292|NCT05174221|Experimental|Mezagitamab|Mezagitamab, subcutaneous injection, once weekly for 8 weeks then once every 2 weeks for 16 weeks in the Main Study. Same dosing regimen will be repeated in LTE Retreatment Period.
89477044|NCT05217758|Placebo Comparator|Placebo|
89477045|NCT05135390|Experimental|HSK21542|0.3 μg/kg
89477046|NCT05135390|Experimental|Placebo|Placebo
89477047|NCT03723512|Experimental|Whole group|Whole group
89477048|NCT02051023|Experimental|FML 0.1% eyedrops|FML (fluorometholone) 0.1% eyedrops 4 times a day in both eyes for 22 days
89477049|NCT02051023|Active Comparator|Liquifilm artificial tears eyedrops|Topical application 4 times a day in both eyes for 22 days
89477050|NCT02415556|Experimental|Type 2 Diabetes Mellitus - Insulin|40 IU of regular human insulin once daily over 24 weeks
89477051|NCT02415556|Placebo Comparator|Type 2 Diabetes Mellitus - Placebo|Intranasal sterile saline once daily over 24 weeks
89477052|NCT02415556|Experimental|Control - Insulin|40 IU of regular human insulin once daily over 24 weeks
89477053|NCT02415556|Placebo Comparator|Control - Placebo|Intranasal sterile saline once daily over 24 weeks
89477054|NCT05138198|Experimental|Mediterranean Diet & Physical Activity|Nutrition with a Physical Activity component. 10-week intervention implementing the Mediterranean Diet.
89477055|NCT05138198|Active Comparator|Usual Care|Usual care involves one-on-one monthly nutrition counseling
89477056|NCT02471235|Experimental|Intervention group|The physiotherapist will provide every patient an individualized physical training programme that fits their cardiopulmonary status. Patients will have the training as out-patient in the physiotherapy department for 4-8 sessions, 2 hours each time, 1-2 times weekly. Home exercise will be taught. Our case manager will give phone calls to the subject every 2 weeks to provide support and reinforcement for having continuous exercise at home for one year. Patients will be invited to attend reinforcement out-patient physiotherapy training once very month or every 2 months if they are willing to attend.
89477057|NCT02471235|No Intervention|Control group|The control group will receive no physiotherapy training by physiotherapist and no phone calls from case manager for reinforcement of home exercise. .
89477058|NCT02051881|Other|Biopsies|Intestinal biopsies were taken in patients who underwent endoscopy.
89477059|NCT02051959|Active Comparator|Crossover 1a: anodal stimulation of M1 + sham|"6 amputees will undergo 8 active treatments of 20 min 2mA anodal stimulation of M1 localized to the contralateral amputation area followed by 8 sham treatments.~Total duration and frequency of treatments: 8 weeks, 2 sessions per week.~Each session will last approximately one hour which will consist of:~EEG and pain measurements~20 minutes of stimulation~EEG and pain measurements after completion of stimulation"
89477060|NCT02051959|Active Comparator|Crossover 1b: sham + anodal stimulation of M1|"6 amputees will undergo 8 sham treatments followed by 8 active treatments of 20 min 2mA anodal stimulation of M1 localized to the contralateral amputation area.~Total duration and frequency of treatments: 8 weeks, 2 sessions per week.~Each session will last approximately one hour which will consist of:~EEG and pain measurements~20 minutes of stimulation~EEG and pain measurements after completion of stimulation"
89020293|NCT05168033|Experimental|Motor imagery training|"In addition to classic rehabilitation the experimental group will be assigned to motor imagery training.~This training will take place at 3 specific periods (4 weeks) during the rehabilitation process:~MI 1: immediately postoperative; MI 2: return to run; MI 3: change of directions and cutting;~To complete a motor imagery training session, participants of the experimental group will have to watch video clips in which rehabilitation exercises or sport specific situations will be shown. After watching, participants will have to mentally imagine they are performing these exercises themselves without actually moving. During each of the 3 motor imagery periods, subjects will be required to complete 20 sessions of 10-15 minutes each."
89020294|NCT05168033|Active Comparator|Classic rehabilitation|This group will follow the classic rehabilitation pathway after anterior cruciate ligament reconstruction.
89020295|NCT05162404|Experimental|Video Intervention|The intervention in this study is a TED-talk style video series designed to provide patient education on cancer, care coordination, and self-advocacy. The content is designed to provide both a background about cancer disease and to address each of the specific domains in care coordination (CCI). The development of video contents was informed by our prior/current research in rural care coordination and components of evidence-based interventions including the patient navigator training by the George Washington University Cancer Institute, Imi Hale (the Native Hawaiian Cancer Network), and a supportive care intervention by Mokuau et al. As the target population of this intervention is rural patients, videos include some rural-specific considerations related to care coordination.
89020296|NCT05159934|Active Comparator|Nicotine|Experimental Session 2 will determine if smokers can discriminate 0.05, 0.025, and 0.0125 mg nicotine/pulse of nicotine from saline.
89477061|NCT02051959|Active Comparator|Crossover 2a: cathodal stimulation of M1 + sham|"6 amputees will undergo 8 active treatments of 20 min 2mA cathodal stimulation of M1 localized to the contralateral amputation area followed by 8 sham treatments.~Total duration and frequency of treatments: 8 weeks, 2 sessions per week.~Each session will last approximately one hour which will consist of:~EEG and pain measurements~20 minutes of stimulation~EEG and pain measurements after completion of stimulation"
89477062|NCT02051959|Active Comparator|Crossover 2b: sham + cathodal stimulation of M1|"6 amputees will undergo 8 sham treatments followed by 8 active treatments of 20 min 2mA cathodal stimulation of M1 localized to the contralateral amputation area.~Total duration and frequency of treatments: 8 weeks, 2 sessions per week.~Each session will last approximately one hour which will consist of:~EEG and pain measurements~20 minutes of stimulation~EEG and pain measurements after completion of stimulation"
89477063|NCT05418621|Experimental|Enamel Matrix Derivative application|"At the completion of the subgingival instrumentation, in all sites with PPD>6 mm, a solution of 24% EDTA, will be first applied with a sterile syringe with a thin blunt tip (25GX1/4). The tip will be inserted in the gingival crevice and run apically on the instrumented root taking particular care in not penetrating the underlying soft tissues. The sites will be then copiously rinsed with both water-spray and by 5 sec passage of ultrasonic instrument's fine tip in the site with no contact to the root surface. After irrigation, a thorough drying of the site will be performed with an air-spray and a section of an orthodontic floss will be placed in all sites and left in the site for 1 minute at least. Thus, once Superfloss is removed in the test group, EMD (Emdogain FL®, Institute Straumann AG, Basel, Switzerland) will be applied with a dedicated syringe until overflowing from the pocket border, taking particular care in avoiding trauma to the tissues."
89477064|NCT05418621|Placebo Comparator|Saline application|"At the completion of the subgingival instrumentation, in all sites with PPD>5 mm, a solution of 24% EDTA , will be first applied with a sterile syringe with a thin blunt tip (25GX1/4). The tip will be inserted in the gingival crevice and run apically on the instrumented root taking particular care in not penetrating the underlying soft tissues. The sites will be then copiously rinsed with both water-spray and by 5 sec passage of ultrasonic instrument's fine tip in the site with no contact to the root surface. After irrigation, a thorough drying of the site will be performed with an air-spray and a section of an orthodontic floss will be placed in all sites and left in the site for 1 minute at least. Thus, once Superfloss is removed in the control group, a lavage of sterile saline will be applied with a syringe with a thin blunt tip until overflowing from the pocket border, taking particular care in avoiding trauma to the tissues."
89477065|NCT02048683|Experimental|burn ICU patients|Determination of plasmatic concentrations of sevoflurane at different times of a short term sedation of sevoflurane in burn versus non burn ICU patients
89477066|NCT02048683|Other|non burn ICU patients|Determination of plasmatic concentrations of sevoflurane at different times of a short term sedation of sevoflurane in burn versus non burn ICU patients
89477067|NCT02048761|Placebo Comparator|Placebo Group|After debridement, placebo gel was applied into the periodontal pockets with a syringe and a blunt canula.
89477068|NCT02048761|Active Comparator|1% Metformin|After debridement, 1% Metformin gel was applied into the periodontal pockets with a syringe and a blunt canula.
89477069|NCT04491903|Experimental|REBOA|
89477070|NCT02048839||Radiel Intervention group and their children|Participated the Radiel- intervention study (2008-2011) in the Intervention group: Lifestyle counselling during and after pregnancy (up to 1 year post partum)
89477071|NCT02048839||Radiel Control Group with their children|Control group in the Radiel- intervention study.
89477072|NCT03108729|Experimental|eslicarbazepine acetate|elicarbazepine acetate, once daily flexible dosing
89477073|NCT02048917|Experimental|High Intensity Counseling + Long Acting NRT + PRN NRT|High Intensity Counseling + Long Acting NRT + PRN NRT
89477074|NCT02048917|Experimental|High Intensity Counseling + bupropion + PRN NRT|High Intensity Counseling + bupropion + PRN NRT
89477075|NCT02048917|Experimental|High Intensity Counseling + varenicline + PRN NRT|High Intensity Counseling + varenicline + PRN NRT
89477076|NCT02048917|Experimental|High Intensity Counseling + Long Acting NRT|High Intensity Counseling + Long Acting NRT
89477077|NCT02048917|Experimental|High Intensity Counseling + bupropion|High Intensity Counseling + bupropion
89477078|NCT02048917|Experimental|High Intensity Counseling + varenicline|High Intensity Counseling + varenicline
89477079|NCT02048917|Experimental|Low Intensity Counseling + Long Acting NRT + PRN NRT|Low Intensity Counseling + Long Acting NRT + PRN NRT
89020297|NCT05159934|Placebo Comparator|saline|Saline will compared to different nicotine doses. Nicotine doses: 0.05, 0.025, and 0.0125 mg nicotine/pulse of nicotine from saline.
89020298|NCT05159518|Experimental|PRT2527|PRT2527 will be administered by intravenous infusion
89477080|NCT02048917|Experimental|Low Intensity Counseling + bupropion + PRN NRT|Low Intensity Counseling + bupropion + PRN NRT
89477081|NCT02048917|Experimental|Low Intensity Counseling + varenicline + PRN NRT|Low Intensity Counseling + varenicline + PRN NRT
89020299|NCT05121376|Experimental|BMN 331|AAV Gene Therapy Infusion
89020300|NCT05120427|No Intervention|Control|Access to standard care.
89206265|NCT00827346|Active Comparator|Group 4|First dose 600 mg given immediately upon arrival at the hospital and the second dose 300 mg, 3 hours after the first loading dose for a total of 900 mg
89020301|NCT05120427|Experimental|LNS only|Children in this arm will receive lipid-based nutrient supplements (LNS) for 12-18 months. LNS are 20 g/~110 calorie nutrient supplements that provide energy, protein, essential fatty acids and a wide range of micronutrients critical for children ages 6 to 24 months of age. They are designed to complement diets without displacing breastmilk and local dietary preferences and can be mixed into the child's meal or eaten directly from the sachet. The LNS used in this study will be Nutributter plus.
89020302|NCT05120427|Experimental|Growth Charts Only|Children in this arm will receive a growth chart that can be installed at children's homes. Growth charts have been locally developed to allow parents an easy assessment of their children's height at their home. Charts will be placed on walls inside homes and will provide parents the opportunity to measure their child whenever they want, and will also contain information on the most suitable local foods as well as the importance of diverse diets and frequent feeding. After the home installation of growth charts, caregivers will be given a short introduction on how to use them and on how to interpret the measurements by study staff.
89020303|NCT05120427|Experimental|LNS and Growth Charts|Children in the combined arm will receive both growth charts and LNS.
89020304|NCT05081076|Active Comparator|Glazed surface|One side of the zirconia crown will receive glazed surface treatment according to standard laboratory procedure and manufacturer's recommendations (Ceramill Stain & Glaze Kit).
89020305|NCT05081076|Experimental|Polished surface|The contralateral side of the zirconia crown will receive polished surface treatment (polishing rubbers kit in the sequence indicated by the manufacturer - EVE DIACERA Finishing and Polishing Kit, EVE Ernst Vetter GmbH - Germany).
89020306|NCT05081050||10-year Patients|Clinical and image examination to assess single crowns on short (6-mm) implants in the posterior region of the maxilla and mandible, according to functional, biological and technical variables, patient's satisfaction and quality of life.
89477082|NCT02048917|Experimental|Low Intensity Counseling + Long Acting NRT|Low Intensity Counseling + Long Acting NRT
89477083|NCT02048917|Experimental|Low Intensity Counseling + bupropion|Low Intensity Counseling + bupropion
89477084|NCT02048917|Experimental|Low Intensity Counseling + varenicline|Low Intensity Counseling + varenicline
89477085|NCT04492982|Active Comparator|Yoga|60 minute sessions of guided yoga in small group format
89020307|NCT05078957||Frail PLWH|
89020308|NCT05078957||Pre frail PLWH|
89020309|NCT05078957||No frail PLWH|
89020310|NCT05075382||Pilot group|Group of 40 patients that will act as observationnal group for this study
89477086|NCT04492982|Active Comparator|Distress Tolerance|60 minutes sessions of guided didactic distress tolerance skill building in small group format
89477087|NCT04492982|No Intervention|Treatment as Usual|Those recruited through Student Health and Wellness will complete the university standard BASICS intervention.
89477088|NCT02472951|Active Comparator|Type 2 diabetic subjects|
89477089|NCT02472951|Active Comparator|Prediabetic subjects|
89477090|NCT02472951|Active Comparator|Healthy subjects|
89477091|NCT02472717|Experimental|Interventional arm|liraglutide 0.6mg sc daily for 1 week, 1.2mg sc daily for 11 weeks
89477092|NCT02472717|Placebo Comparator|Placebo arm|Placebo sc daily for 12 weeks, volume titration at week 2 to mirror liraglutide arm
89020311|NCT05063981||CRSwNP|10 patients with severe refractory eosinophilic asthma plus CRSwNP
89020312|NCT05063981||No CRSwNP|10 patients with severe refractory eosinophilic asthma and no CRSwNP
89020313|NCT05057182|Experimental|BNT162b2|BNT162b2 mRNA vaccine (Cominarty®, BioNTech/Fosun Pharma), one dose (0.3mL after dilution) contains 30 micrograms of COVID-19 mRNA Vaccine embedded in lipid nanoparticles.
89020314|NCT05057169|Experimental|BNT162b2 third dose after two doses of BNT162b2|
89020315|NCT05057169|Experimental|CoronaVac third dose after two doses of BNT162b2|
89020316|NCT05057169|Experimental|BNT162b2 third dose after two doses of CoronaVac|
89020317|NCT05057169|Experimental|CoronaVac third dose after two doses of CoronaVac|
89020318|NCT05050942|Experimental|CAM2029|
89020319|NCT05050942|Active Comparator|Octreotide LAR or lanreotide ATG|
89020320|NCT05050617||Acute Pulmonary Embolism|Subjects in this single cohort will undergo point-of-care echocardiography at the time of presentation and subsequent follow up to assess for short term adverse events or complications.
89020321|NCT05030909|Experimental|transdiagnostic group protocol|The study will run two gender-specific treatment groups (8 participants each) recruited from the community, with one individual session (for information, consent and initial data collection) and 6 group sessions. Both groups will receive the same intervention. A second round of recruitment will run later with anticipated n of 32 in the experimental arm.
89477093|NCT02037373||Octaplas™|Patients treated with Octaplas™ infusion solution for IV administration as prescribed by their treating physician.
89477094|NCT02037373||Plasma|Patients treated with regular plasma (e.g., fresh frozen plasma (FFP) and other FDA and American Association of Blood Banks (AABB) approved plasma products).
89477095|NCT04427150|Experimental|Auditory Training Group|12 hours of psychoacoustic training over 8 weeks
89477096|NCT04427150|Active Comparator|Other Training Group|12 hours of non-psychoacoustic training over 8 weeks
89477097|NCT04427150|No Intervention|TD Group|
89477098|NCT02048995||Bipolar Depressed|Bipolar Depressed - are participants with Bipolar Disorder Type I or II and a current episode of major depression which is confirmed on the SCID interview
89477099|NCT02048995||Healthy Comparator|Healthy Comparator - are participants without mental disorders, alcohol or substance disorders confirmed by the SCID-interview
89477100|NCT02049073|Experimental|Zonisamide|Zonisamide 100 mg or 200 mg pill administered orally every day for 2 weeks
89477101|NCT02049073|Experimental|Methylprednisolone|Methylprednisolone 32 mg or 64 mg pill administered orally once
89477102|NCT02049073|No Intervention|Control|no medication
89477103|NCT04518345|Experimental|Treatment (dubermatinib)|"FLT3 AML WITH RELAPSED/REFRACTORY DISEASE:~INDUCTION: Patients receive dubermatinib PO QD on days 1-21. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients with clinical or hematologic response and not transplant eligible may continue dubermatinib until loss of response/clinical benefit. Patients with clinical or hematologic response and transplant eligible may continue dubermatinib until one week prior to admission."
89477104|NCT02260063|Experimental|Epinastine syrup|
89477105|NCT02260063|Active Comparator|Epinastine tablets|
89477106|NCT05151302|Other|completion of the computer vision symptom scale questionnaire, italian version|video display terminal (VDT) workers completed the questionnaire
88950363|NCT01945398|Experimental|Inspiratory Muscle Training (IMT)|Patients from the inspiratory muscle training group will utilize a linear pressoric resistance equipment with an inspiratory charge of 30% of maximum inspiratory pressure (adjusted weekly), during 7 days of the week, session duration of 30 minutes, during 8 weeks.
88950364|NCT01945398|Placebo Comparator|Sham IMT|Patients in the placebo group will be submitted to inspiratory muscle training with the same equipment as the intervention group, however without a resistance generating spring.
88950365|NCT01945411|Experimental|Experimental|the length between incisor and mandible angle
88950366|NCT01945411|Active Comparator|Active comparator|the length between mouth corner-mandible angle
88950367|NCT01945424||Pregnancy Cases|Pregnant women exposed to Sanofi Pasteur's Quadrivalent Influenza Vaccine (QIV)
88950368|NCT01945437|Placebo Comparator|Control|Control group receive same volume of normal saline as in the magnesium group
88950369|NCT01945437|Experimental|magnesium|This group receive magnesium sulfate perioperatively.
88950370|NCT01945450|Active Comparator|Antibiotic prophylaxis|antibiotic prophylaxis as following: 24 hours coverage with Ampicillin 2 grams*4, Gentamycin 240 mg*1, Clindamycin 600 mg*3
88950371|NCT01945450|No Intervention|No treatment|No antibiotics
88950372|NCT01945476|Experimental|midazolam|midazolam group
88950373|NCT01945476|Active Comparator|normal saline|control group
88950374|NCT01945502||nasal packing with dry packs|
88950375|NCT01945502||nasal packing with wet packs|
88950376|NCT01945502||nasal packing with Benzidamin-Clorhexsidin damped packs|
88950377|NCT01945502||no nasal packing|
88950378|NCT01945515|Experimental|Robot + anodal tDCS|Robotic-assisted gait training for 45 min after anodal tDCS on impaired motor cortex for 20 min
88950379|NCT01945515|Sham Comparator|Robot + sham tDCS|Robotic-assisted gait training for 45 min after sham tDCS on impaired motor cortex for 20 min
88950380|NCT01945528|Experimental|US-guided tenotomy with PRP|ultrasound guided percutaneous tenotomy with PRP injection each alternate week for a total of two interventions
88950381|NCT01945528|Active Comparator|US-guided tenotomy with lidocaine|ultrasound-guided percutaneous needle tenotomy with lidocaine injection each alternate week for a total of two interventions
88950382|NCT01945541|No Intervention|standard fluid management|postoperative BMC measurements
88950383|NCT01945541|Active Comparator|body composition monitoring preoperative|pre and postoperative BCM measurements
88950384|NCT01945554|Experimental|Cervical disc herniation|Patients with cervical disc herniation and compression of nerve roots C3-C8.
88950385|NCT01945554|Experimental|Lumbar disc herniation|Patients with lumbar disc herniation and compression of nerve roots L1-S1.
88950386|NCT01945567|Experimental|Dorsal zona incerta|Up to 3 mA, 60 us, 130 Hz deep brain stimulation
88950387|NCT01945567|Experimental|Caudal zona incerta|Up to 3 mA, 60 us, 130 Hz deep brain stimulation
88950388|NCT01945567|Experimental|Empirical deep brain stimulation|Empirical unblinded deep brain stimulation programming using any posterior subthalamic area electrode contact(s) and stimulation parameters to optimise clinical outcome.
88950389|NCT01945606|Experimental|Placebo and BAY1067197|Patients will get both treatment 1 and 2
88950390|NCT01945632|No Intervention|no treatment|Control group with no treatment.
88950391|NCT01945632|Experimental|root planing (gracey curettes)|treatment with root planing using conventional gracey curettes
88950392|NCT01945632|Experimental|Vertically oscillating ultrasonic device|Treatment done with vertically oscillating ultrasonic device
88950393|NCT01945632|Experimental|Device: piezoelectric ultrasonic scraper|Treatment using a piezoelectric ultrasonic scraper
88950394|NCT01945645|Experimental|Intervention|The Ready to Act programme aimed to promote health-related action competence including motivation, informed decision-making, action experience and social involvement The intervention was delivered across a number of primary care settings including the GP office, health centre and pharmacy. The programme consisted of two individual counselling interviews and eight group sessions, which totalled 18 hours within a three month period.
88950395|NCT01945684|Experimental|Botulinum toxin type A (DWP450)|DWP450: Botulinum toxin type A
88950396|NCT01945684|Active Comparator|Botulinum toxin type A (Botox®)|Botox®: Botulinum toxin type A
88950397|NCT01945697||normal oral mucosa|
88950398|NCT01945697||oral precancerous lesion or oral cancer|
88950399|NCT01945723||Healthy volunteers|Healthy volunteers
88950400|NCT01945736||Cohort 1|> or = 90 days to < 2 years on enteral methadone. Dose schedule is per routine medical care.
88950401|NCT01945736||Cohort 2|2 years to < 6 years on enteral methadone. Dose schedule is per routine medical care. Will include overweight children with BMI for age of 85 - 95 percentile, or obese children BMI for age > or = to 95 percentile.
88950402|NCT01945736||Cohort 3|6 years to < 18 years on enteral methadone. Dose schedule is per routine medical care. Will include overweight children with BMI for age of 85 - 95 percentile, or obese children BMI for age > or = to 95 percentile.
88950403|NCT01945749|Experimental|Intraarticular steroid + Exercise|Intra-articular corticosteroid treatment with subsequent exercise therapy. Exercise therapy is commenced 2 weeks after injection
89020322|NCT05030909|Other|Waitlist control|At both recruitment rounds, we will recruit 16 young people to receive the same intervention at a later stage. We will ask them to complete data collection at the same timepoints as the experimental arm participants to compare intervention effect size but will offer them the intervention afterwards so they still have access to the group. Data collected from them in the group will be used to assess feasibility and acceptability but not treatment effect size comparison.
89020323|NCT05030220||Phase 1|51 subjects with serum levels of testosterone, free testosterone, and sex hormone binding globulin as well as the SpCuV from the cultures obtained in clinic, immediately pre-operative skin cultures, and incised wound cultures.
89477107|NCT02037685|Active Comparator|Usual care|Subjects randomized to usual care will receive a brochure once a year on the importance and impact of controlling cardiovascular risk factors, tips to improve statin adherence and smoking cessation strategies and public services. Subjects will also receive a letter every 6 months to remind about study participation along with educational material.
89020324|NCT05030220||Phase 2|Subjects enrolled to help determine if preoperative serum testosterone levels are associated with risk for shoulder PJI in patients undergoing primary shoulder arthroplasty and if preoperative serum testosterone levels are predictive of bacterial load of deep tissue cultures taken at the time of revision shoulder arthroplasty in patients undergoing primary shoulder arthroplasty.
89020325|NCT05004675|Experimental|lerodalcibep|300 mg SC dosed monthly
89020326|NCT05004675|Active Comparator|inclisiran|284 mg SC dosed Day 1 and Day 90
89020327|NCT05002218|Experimental|Aerobic Training|Participants will be given a stationary exercise bike for home use. They will be instructed to use the exercise bike five times a week for thirty-minute sessions. The exercise intensity prescription will be based on the subject's VO2max determined on pre-test day. The exercise program will start at 60% of intensity per session, and then will be increased by steps of 5% intensity every 2 sessions until participants reach 30 minutes of training at 80% intensity. Participants will be contacted weekly by e-mail or phone to answer any questions about the exercise protocol and will be instructed to log each training session. Subjects will record duration of exercise, perceived exertion, average heart rate, maximum heart rate, and distance.
89020328|NCT05002218|Active Comparator|Balance Training|A physical therapist will tailor a home balance training program for each participant based on pre- training capabilities. Subjects will be asked to perform exercises five times a week for thirty-minute sessions. Both dynamic and static exercises will be performed in sitting and standing positions. Exercises will start with stabilizing in a challenging static position and progress to dynamic arm and leg movements in the same or modified position. Participants will be contacted weekly by e-mail or phone to answer any questions about the exercise protocol and will be required to log their exercise effort in terms of frequency and level of balance challenge.
89020329|NCT04998578|Active Comparator|Microneedling- Group A|Participants will only perform microneedling
89020330|NCT04998578|Active Comparator|Microneedling and outpatient Cosmetics- Group B|Microneedling associated with the use of outpatient cosmetics
89477108|NCT02037685|Experimental|Motivational Interviewing (MINT)|"The MINT intervention will consist of 6 to 9 telephone encounters between a counselor trained in Motivational interviewing. All subjects in the MINT arm will be contacted every 3 months; however subjects who are not filling medication appropriately will receive additional calls.~Each telephone encounter will last from 20 to 30 minutes and have a patient centered approach having the following basic structure and goals:~Establishing a connection and reinforcing autonomy: .~Empathizing with ambivalence and rolling with resistance.~Coach the subject towards expressions of commitment."
89477109|NCT03561727|Experimental|Mass closure technique|Abdominal cavity will be closed by a single layer of 2 continuous sutures beginning on the opposite ends of the wound towards the median line and involving peritoneum, transversalis fascia, posterior and anterior layer of rectus abdominis muscle fascia and, in case of incisions beyond the lateral border of rectus abdominis muscle, also the oblique abdominal muscles fascia.
89477110|NCT03561727|Active Comparator|Layered closure technique|Abdominal cavity will be closed with two separate layers of continuous sutures. The first layer will include peritoneum, transversalis fascia and posterior layer of the rectus abdominis muscle fascia. In case of incisions not exceeding the lateral border of rectus abdominis muscle, the second layer will involve only the anterior layer of the rectus abdominis muscle fascia. In case of incisions exceeding the lateral border of rectus abdominis muscle, the second layer will include internal oblique abdominal muscle fascia, external oblique abdominal muscle fascia and anterior layer of the rectus abdominis muscle fascia.
89477111|NCT04398914|Experimental|Pyrotinib, trastuzumab, pertuzmab and paclitaxel|"Prior to surgery: pyrotinib, trastuzumab, pertuzumab and nab-paclitaxel for 4 cycles (1 cycle = 21 days).~After surgery：~if non-tpCR：chemotherapy with epirubicin and cyclophosphamide (EC), followed with pertuzumab and trastuzumab up to 1 year total; or T-DM1 for 14 cycles.~if tpCR: chemotherapy 0-4 cycles according to physician's choice, followed with pertuzumab and trastuzumab up to 1 year total."
89020331|NCT04998578|Active Comparator|microneedling and home use cosmetics - Group C|Microneedling associated with home use cosmetics
89020332|NCT04998578|Active Comparator|Non-ablative radiofrequency - Group D|Participants will perform only non-ablative radiofrequency
89020333|NCT04996758|Experimental|Toripalimab and Anlotinib Combination Treatment|Patients receive toripalimab at a dose of 240 mg on day 1 and anlotinib at a dose of 12 mg before breakfast for once-daily on days 1-14. Treatment cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity
89477112|NCT04398914|Active Comparator|Trastuzumab, pertuzmab and paclitaxel|"Prior to surgery: trastuzumab, pertuzumab and nab-paclitaxel for 4 cycles (1 cycle = 21 days).~After surgery：~if non-tpCR：chemotherapy with epirubicin and cyclophosphamide (EC), followed with pertuzumab and trastuzumab up to 1 year total; or T-DM1 for 14 cycles.~if tpCR: chemotherapy 0-4 cycles according to physician's choice; followed with pertuzumab and trastuzumab up to 1 year total."
88950404|NCT01945749|Active Comparator|Intraarticular saline+Exercise|Combined intra-articular saline injection and subsequent exercise therapy. Exercise therapy is commenced 2 weeks after injection
88950405|NCT01945762||1. patient cohorts (40 patients/cohort)|RET positive patient cohorts
88950406|NCT01945762||2. patient cohorts (40 patients/cohort)|RET negative patient cohorts
88950407|NCT01945788|Active Comparator|Teriparatide Forteo|20 micrograms/day plus calcium and vitamin D
88950408|NCT01945788|Experimental|Teriparatide Osteofortil|20 micrograms/day plus calcium and vitamin D
88950409|NCT01945801|Active Comparator|Lasilactone|Dosage form: One capsule taking in the morning Dosage: furosemide, 20mg, and spironolactone, 100 mg. Frequency and duration: One capsule daily for 7 days.
88950410|NCT01945801|Placebo Comparator|placebo pill|One capsule taking in the morning. Frequency and duration: One capsule daily for 7 days.
88950411|NCT01945801|Active Comparator|Sodium-Restricted Diet|The diet group will receive a regimen with a prescribed intake of three grams of sodium per day
88950412|NCT05410990||mortality, MACE (+)|patients with all-cause mortality within the first 6 months of index hospitalization and MACE (major adverse cardiovascular events)
88950413|NCT05410990||mortality, MACE (-)|patients without all-cause mortality within the first 6 months of index hospitalization and MACE (major adverse cardiovascular events)
88950414|NCT05410834||Individuals with polycystic ovarian syndrome|Individuals with a documented diagnosis of polycystic ovarian syndrome
88950415|NCT05410834||Individuals without polycystic ovarian syndrome|Individuals without a known diagnosis of polycystic ovarian syndrome but with regular menstrual cycles
88950416|NCT05410769|Experimental|PD patients|The intervention envisaged by the study takes place in the form of interviews, self-reports, and measurement of the heart rate variability.
88950417|NCT05410769|Experimental|patient's caregivers|The intervention envisaged by the study takes place in the form of interviews, self-reports, and measurement of the heart rate variability.
88950418|NCT05410717|Experimental|CAR-NK cell therapy group|Appropriate patients who could benefit from the Claudin6, GPC3, Mesothelin, or AXL targeting CAR-NK cell therapy against solid cancers are chosen to be the CAR-NK cell therapy group.
88950419|NCT05410717|Experimental|IL7/CCL19 secreting CAR-NK cell therapy group|Appropriate patients who could benefit from the Claudin6, GPC3, Mesothelin, or AXL targeting CAR-NK cell therapy against solid cancers are chosen to be the IL7/CCL19 secreting CAR-NK cell therapy group.
88950420|NCT05410717|Experimental|PD1/PDL1/CTLA4-scfv secreting CAR-NK cell therapy group|Appropriate patients who could benefit from the Claudin6, GPC3, Mesothelin, or AXL targeting CAR-NK cell therapy against solid cancers are chosen to be the PD1/PDL1/CTLA4-scfv secreting CAR-NK cell therapy group.
88950421|NCT05410717|Experimental|CAR-NK cell plus CBD therapy group|Appropriate patients who could benefit from the Claudin6, GPC3, Mesothelin, or AXL targeting CAR-NK cell therapy against solid cancers are chosen to be the CAR-NK cell plus CBD therapy group.
88950422|NCT05410717|Experimental|CAR-NK cell plus NAD therapy group|Appropriate patients who could benefit from the Claudin6, GPC3, Mesothelin, or AXL targeting CAR-NK cell therapy against solid cancers are chosen to be the CAR-NK cell plus NAD therapy group.
88950423|NCT05410704|Experimental|Study Group|Pelvic floor muscle exercises and diaphragmatic breathing exercises will be performed 3 times a week for 12 weeks. New York Posture Rating Scale and SF-36 will be applied before and after the study. International Physical Activity Questionnaire and Pelvic Floor Impact Questionnaire will be applied before the study.
88950424|NCT05410704|No Intervention|Control Group|No intervention. New York Posture Rating Scale and SF-36 will be applied before and after the study. International Physical Activity Questionnaire and Pelvic Floor Impact Questionnaire will be applied before the study.
88950425|NCT05410691|No Intervention|Conventional|AVF/AVG cannulation by renal nurses in standardised manner
88950426|NCT05410691|Active Comparator|ultrasound guided|AVF/AVG cannulation by renal nurses by handheld US device
88950427|NCT05410678|Experimental|renal stent group|Acute coronary patients treatment with renal stent
88950428|NCT05410678|Active Comparator|BMCS group|Acute coronary patients treatment with bare-metal stent
88950429|NCT05410665||Sepsis group|Adult septic patients admitted into the intensive care unit (ICU) of Nanjing First Hospital. The diagnostic criteria for sepsis were in accordance with the surviving sepsis guidelines.
88950430|NCT05410665||Control group|Baseline data (including age, sex, body-mass index, disease severity scores) matched adult non-septic critical patients in our ICU.
88950431|NCT05410639|Experimental|Study group|Parents of premature infants in the experimental group received online education consist of information to support infants motor,social-communication development.and to manage the parents stress.
88950432|NCT05410639|Placebo Comparator|Control group|The parents of premature babies in the control group did not receive any education programs
88950433|NCT05410626|Experimental|original|This study use 18 and 36 mg of original prolong-release methylphenidate. Dosing of Medication is equivalent to immediate-release. Medication administration is once daily in the morning.
88950434|NCT05410626|Active Comparator|generic|This study use 18 and 36 mg of generic prolong-release methylphenidate. Dosing of Medication is equivalent to immediate-release. Medication administration is once daily in the morning.
88950435|NCT05410613|Experimental|combined electromagnetic field and a plantar resistance|
88950436|NCT05410613|Experimental|electromagnetic field|
89477113|NCT03561649|Experimental|Adalimumab|"Adalimumab is not the experimental study drug. This treatment justifies the inclusion of patients and is used in accordance with its marketing authorization.~The patients will be seen as part of their follow-up consultation in Rheumatology.~Modality of administration: The baseline visit should take place no more than 4 weeks before the start of adalimumab treatment, 40mg every 2 weeks, subcutaneously, in accordance with Summary of Product Characteristics.~At baseline and 6 months follow-up visits, a single blood draw for the biomarker dosage will be added to the standard patient health care follow-up. The clinical examination will also be performed at these two visits, and the clinical response will be assessed after 6 months of adalimumab treatment at M6 follow-up visit."
89477114|NCT03108651|Active Comparator|Case|Motivational message will be administrated.
89477115|NCT03108651|No Intervention|Control|Motivational message will not be administrated.
89477116|NCT05138042|Experimental|Intervention side|Breast cancer patients wore frozen glove on the dominant hand for 90 minutes during their weekly treatment with paclitaxel (80 mg/m2). Treatment was continued for 12 weeks, with their non-dominant hand as the control side
89477117|NCT05138042|No Intervention|Control side|Breast cancer patients wore frozen glove on the dominant hand for 90 minutes during their weekly treatment with paclitaxel (80 mg/m2). Treatment was continued for 12 weeks, with their non-dominant hand as the control side
89477118|NCT02807623|Experimental|Ibuprofen|Randomized and double blinded study participants assigned to Group A intervention will receive an oral NSAID of ibuprofen 800 mgs three times a day for 48 hours.
88950437|NCT05410613|Active Comparator|conservative treatment for the ulcer|
88950438|NCT01944358||Taiwan AIDS study group|
88950439|NCT05410535|Experimental|Patients who received UDCA 600mg|Patients who participated in PEGASUS-D clinical trial and received UDCA 600mg
88950440|NCT05410535|Experimental|Patients who received UDCA 300mg|Patients who participated in PEGASUS-D clinical trial and received UDCA 300mg
88950441|NCT05410535|Placebo Comparator|Patients who received Placebo|Patients who participated in PEGASUS-D clinical trial and received Placebo
88950442|NCT05410522|Experimental|Experimental lung transplant|The training time will be 30 minutes in the morning and 30 minutes in the afternoon with a total daily work time of 60 minutes. The frequency of work will be different in each session, seeking in the morning routine a vascularization and improvement of muscle trophism and in the afternoon an aerobic endurance, activation of the working capacity of the tonic muscles to improve the stabilizing muscles and postural fitness.
88950443|NCT05410522|No Intervention|Control lung transplant|Electro stimulation therapy will not be performed.
88950444|NCT05410483|Experimental|Docetaxel dose level|Initial dose of 60mg/m2 and increase the remaining dose gradient by 5 mg/m2
88950445|NCT05410470||MF patients who received ruxolitinib treatment|
88950446|NCT05410444|Active Comparator|The control group|The control group received routine indwelling catheterization, the catheter was continuously opened, and the indwelling catheter was replaced every 7 days. When the bladder function returned to normal, the catheter was removed.
88950447|NCT05410444|Experimental|The study group|The observation group, namely intermittent catheterization group, was given one-to-one training and education to patients and their families before the implementation of the project. Frequency and timing of intermittent catheterization: it is recommended to catheterize once every 4 hours and no more than 6 times every 24 hours. If the residual urine volume decreases, the number of catheterization can be appropriately reduced; Before each catheterization, urinate by yourself. The derived urine volume is the residual urine volume. The total amount of urine shall not exceed the safe capacity of the bladder.
88950448|NCT05410405|Experimental|8 millimeter implants|implant insertion with piezo surgical osteotomy and with osseodensification drills
88950449|NCT05410405|Experimental|10 millimeter implants|implant insertion with piezo surgical osteotomy and with osseodensification drills
88950450|NCT05410314||cHL (85%) and DLBCL (15%)|Patients enrolled in this study are cHL (85%) and DLBCL (15%) long-term survivors, treated mainly with ABVD+ radiotherapy (not under diaphragmatic and pelvic irradiation), without relapse (during quinquennial follow-up) who are followed at the clinic dedicated to fertility in oncology of our Department, which is a regional referral center for this purpose. Therefore, the investigators conducted a prospective observational controlled study on two groups: the first one (A group) underwent oral supplementation with MIC for 12 months; the second group (B group) underwent follow-up without any nutritional supplement for 12 months
88950451|NCT05410275|Experimental|Rivaroxaban|"Rivaroxaban 5 mg daily, administered orally, during 3 consecutive days. After a wash-out period of 4 days, Rivaroxaban 10 mg daily, administered orally, during 3 consecutive days.~After a wash-out period of 4 days, Rivaroxaban 15 mg daily, administered orally, during 3 consecutive days."
89477119|NCT02807623|Placebo Comparator|Placebo|Randomized and double blinded study participants assigned to Group B intervention will receive an oral placebo three times a day for 48 hours starting immediately after influenza vaccine receipt.
89477120|NCT02807623|Experimental|Compound Exercise of Push-ups|Randomized study participants assigned to Group C will perform an exercise intervention of push-ups immediately after influenza vaccine receipt.
88950452|NCT05410119|Experimental|Resilience group|
88950453|NCT05410119|Active Comparator|Controlled group|
88950454|NCT05410093|Experimental|Patients who taking Resveratrol|Take RES (250mg, NuMedica, FDA approved) at a dose of 250mg per day for three months
88950455|NCT05410093|Active Comparator|Patients who taking VitE|Take vitamin E at a dose of 100 mg per day for three months
88950456|NCT05410067|Experimental|Cervicothoracic Junction Mobilization Technique|"It is a part of manual therapy technique. Maitland mobilization to the C7- T1 level, according to their primary movement restriction (for flexion-extension restriction- central PA glide, for rotation restrictions unilateral PA glide) is given.For central PA glide, a central pressure angled towards the participant's head was given with overlapping thumbs of the therapist placed on the spinous process of C7.~Dosage:~Glide would be given according to the nature, intensity and severity of the patient's pain. 30 sec bouts with 3 sets &amp; 2 reps. Total 2-3 min duration. 2 sessions per week for 3 weeks."
88950457|NCT05410067|Experimental|Eccentric Muscle Energy Technique|"Eccentric muscle energy technique would be applied to the patient's cervical spine. The cervical spine would be brought to the barrier of motion in each plane i.e. flexion/extension, lateral bending and rotation. Then patient would be asked to push their heads into the direction opposite that of the barrier.~Dosage:~The therapist provided isometric resistance for 3- 5 seconds, after which the subjects relaxed their muscles completely and the therapist applied stretch. This is applied for generalized cervical movements in each plane like Flexion, Extension, Side Bending~&amp; Rotation. 3-5 repetitions with 2-3 sets were performed. Total duration: 3-5 min 2 sessions per week for 3 weeks."
88950458|NCT05410041|Experimental|CAR-NK-CD19 Cells|After preconditioning with chemotherapy, CAR-NK-CD19 Cells will be evaluated.
88950459|NCT05409950|Active Comparator|Study group: implants were inserted using socket shield technique at the esthetic zone|
89202762|NCT00756080|Placebo Comparator|2|After receiving a 7-day oral supplementation with placebo, each subject will be admitted to the Clinical Investigation Unit for a half day, after an overnight fast,and will receive a 5-h intravenous infusion of L-[1-13C]leucine (i.e.; leucine labeled with 13C, a stable isotope of carbon) from 8 am to 1 pm. At regular intervals throughout the isotope infusion, blood will be obtained to measure 13C-enrichment in plasma a-keto-isocaproate, the keto acid of leucine, using gas chromatography-mas spectrometry. Simultaneously, 13C-enrichment will be measured in aliquots of expired air CO2 using isotope ratio mass spectrometry, and total CO2 production (VCO2) will be measured using direct calorimetry, respectively. The subject will then leave the hospital, take no treatment for13 days (wash-out period). The study will then be repeated a second time in an identical fashion, after a second 7-day period of oral supplementation with citrulline, as a cross-over study design will be used.
89202763|NCT00798252|Experimental|Arm A (Capecitabine + Brivanib alaninate)|
89202764|NCT00798252|Experimental|Arm B (Doxorubicin + Brivanib alaninate)|
89202765|NCT00798252|Experimental|Arm C (Ixabepilone + Brivanib alaninate)|
89202766|NCT00798252|Experimental|Arm D (Docetaxel + Brivanib alaninate)|
89202767|NCT00798252|Experimental|Arm E (Paclitaxel + Brivanib alaninate)|
89202768|NCT00748046|Experimental|Radium-223 chloride (Xofigo, BAY88-8223)|The patients will receive Radium-223 chloride as an escalating dose of either 50, 100 or 200 kBq/kg b.w. (0.0014, 0.0027 or 0.0054 mCi/kg).
89202769|NCT00326209|Experimental|Encapsulated Mesalamine Granules (eMG)|Participants will receive eMG 1.5 grams (4 capsules of eMG 0.375 grams each) QD orally in the morning for up to 24 months.
89202770|NCT00537940|Active Comparator|A|
89477121|NCT05137964||Vitamin D Deficient|deficiency (<20ng/ml)
89477122|NCT05137964||Vitamin D Sufficient|sufficiency (>30ng/ml)
89477123|NCT05137340|Experimental|NCPAP group|Participants enrolled spontaneously breathing preterm infants born between 24 and 29.9 weeks' gestational age with signs of respiratory distress syndrome. The initial respiratory support mode of premature infants assigned to NCPAP group was NCPAP. Patients diagnosed with NRDS on NCPAP were given a therapeutic dose of pulmonary surfactant via MISA within 120 minutes after birth. NCPAP group ventilator parameter setting: PEEP 6cmH2O (adjustment range 6-8cmH2O), FiO2 adjustment range 0.21-0.40, in order to achieve postnatal target oxygen saturation.
88950460|NCT05409950|No Intervention|Control group: implants were inserted using conventional immediate technique|
88950461|NCT05409755|Active Comparator|Fractional microneedling radiofrequency|Device
88950462|NCT05409755|Active Comparator|Fractional microneedling radiofrequency followed by minoxidil application|Device and drug
88950463|NCT05409755|Active Comparator|Minoxidil|Topical drug
88950464|NCT05409742|Active Comparator|Modified Hall technique|
88950465|NCT05409742|Experimental|Hall Technique|
88950466|NCT05409703|Experimental|The Effect of Reiki on Executive Nurses on Psychological Empowerment, Happiness|Reiki application will take 45 minutes.
88950467|NCT05409703|No Intervention|The Effect of Reiki on Executive Nurses on Emotion Management and Work Engagement|No treatment was applied to the patients in the control group other than their routine care.
89020334|NCT04991805||Benralizumab|Patients who have received Benralizumab.
89202771|NCT00537940|Active Comparator|B|
89202772|NCT00661362|Experimental|1|Metformin + Saxagliptin
89477124|NCT05137340|Active Comparator|NIPPV group|Participants enrolled spontaneously breathing preterm infants born between 24 and 29.9 weeks' gestational age with signs of respiratory distress syndrome. The initial respiratory support mode of premature infants assigned to NIPPV group was NIPPV. Patients diagnosed with NRDS on NIPPV were given a therapeutic dose of pulmonary surfactant via MISA within 120 minutes after birth. The initial ventilator parameters of NIPPV group were as follows: PEEP 6cmH2O (adjustment range 6-8cmH2O), PIP15cmH2O (regulation range 15-20cmH2O), inspiratory time 0.3s (regulation range 0.3-0.4s), respiratory rate 30 beats/min (regulation range 20-40 beats/min), and FiO2 regulation range 0.21-0.40 in order to achieve postnatal target oxygen saturation.
89477125|NCT04386590|Sham Comparator|'Sham' manual therapy plus Pulmonary Rehabilitation (PR)|Treadmill walking, upper body exercise machine, light weight training and bicycle. These exercises are supervised. In addition to the standard exercise therapy, all participants will undergo a 20-minute session consisting of discussion with the patient and 11 minutes of detuned ultrasound, which has been used in previous studies to account for time and attention for the patient. The detuned ultrasound procedure is to apply the ultrasound gel and turn the machine on, but set the intensity at zero (0) W/cm2
89477126|NCT04386590|Experimental|Manual therapy plus Pulmonary Rehabilitation (CMT+|Manual therapy is made up of gentle Effleurage and cross-fibre friction massage applied to the muscles of the posterior chest wall. Manual Therapy consists of two separate manipulations (Grade V mobilization). Each manipulation involves the delivery of a high-velocity low amplitude (HVLA) posterior to anterior force directed at the inter-vertebral, costo-vertebral and costo-transverse joints. The first manipulation is delivered at the level of the upper/middle thoracic spine while the second is at the level of the middle/lower thoracic spine. In addition to the MT, the participant will also undergo Pulmonary Rehab as previously described.
89477127|NCT02471157||Eugonadal|Eugonadal men
89477128|NCT02471157||Hypogonadal|Hypogonadal men
89477129|NCT02052037|Experimental|Egg inclusion|Participants will meet with a registered dietitian and receive instructions for including 2 eggs per day (10 to 14 eggs/week) in their meal plan, while preserving an isocaloric condition relative to the egg exclusion phase. The study dietitian will provide individualized guidance to participants on how to make room for eggs in their diet, while giving them latitude in determining how to adjust for the extra calories from the eggs, to better approximate real-world conditions.
89477130|NCT02052037|Experimental|Egg exclusion|"Participants will meet with the dietitian and receive relevant meal planning guidance and instructions to avoid eggs and specific egg-containing products.~During both intervention phases, study participants will be advised to eat to their usual state of fullness, and dietary monitoring and weighing will be conducted to ensure that an isocaloric condition is maintained."
89477131|NCT02470923|Other|Group 1|Usual care including medical advice to quit and confrontation with abnormal spirometry results if relevant.
89477132|NCT02470923|Other|Group 2|Intensive counseling (15 minutes) by a smoking cessation counselor including confrontation with abnormal spirometry results if relevant, and follow up for at least 5 weeks after discharge (will be done weekly by phone for five consecutive weeks).
89477133|NCT02470923|Other|Group 3|Intensive counseling (15 minutes) by a smoking cessation counselor including confrontation with abnormal spirometry results if relevant, offering and providing nicotine replacement therapy (NRT) and follow up (will be done weekly by phone for five consecutive weeks).
89477134|NCT02037841|Experimental|Nursing-driven Asthma protocol|Children randomized to the intervention group will have their β2-agonist medication weaned by the nurse, according to the steps outlined in the clinical pathway. The nurse will ensure that the patient's family is booked for asthma teaching, and will also remind the physicians to fill out an asthma action plan on discharge. Detailed information as to when to contact physicians in the event of an acute deterioration of the patient is included in the clinical pathway.
89477135|NCT02037841|No Intervention|Physician-driven asthma management|Patients in the control group will continue receiving the current standard of care, which consists of physicians weaning the β2-agonist medication when called to the bedside by the nurse or when deemed necessary by a physician
89477136|NCT04358198|Experimental|GIM patient|The patients with GIM will be assessed at both GIM and normal mucosa during endoscopy.
89477137|NCT04345952|Experimental|Calm Meditation|Participants in the Calm group will be asked to use the Calm app ad libitum during their time spent receiving chemotherapy at the Mays Cancer Center (~2 hours) and while at home between treatment cycles ad libitum. Participation will be measured during the entire intervention using internal tracking systems within the app (i.e., # of times logged in, type of meditation accessed, time spent meditating, date and time of meditation accessed). This data will be provided to us through data coordinator of the app.
89477138|NCT04345952|No Intervention|Usual Care|The usual care control group will not be offered anything to listen to during their chemotherapy treatment cycles or when they are between chemotherapy treatment cycles. They will receive their treatment as intended without any additional intervention.
89477139|NCT02049229|Experimental|OPTIMAX stent|Patients randomised to receive titanium-nitride-oxide coated OPTIMAX-stent
89477140|NCT02049229|Active Comparator|SYNERGY stent|Patients randomised to receive everolimus-eluting, biabsorabble polymer coated stent
89477141|NCT02477475||NEXIUM|Oral dose 20mg/day
89020335|NCT04991805||Other biologics|Patients who have received non benralizumab biologics.
89020336|NCT04991805||Non-biologic|Patients who have received non biologic drug.
89020337|NCT04986657|Experimental|Patients: ChromoSeq|ChromoSeq will be performed on bone marrow DNA from consented patients in parallel with the standard of care cytogenetics, FISH, and the MyeloSeq gene panel obtained from that sample, in a CLIA licensed environment using CLIA-compliant ChromoSeq procedures.
89020338|NCT04986657|No Intervention|Stakeholders (Treating Physicians)|-Stakeholders (treating physicians) will complete surveys/questionnaires. As of protocol amendment 10/31/2023, the stakeholders (treating physicians) will no longer be completing surveys/questionnaires.
89020339|NCT04977414|No Intervention|Waitlist control group|Hospitals assigned to this group will be placed in on a waitlist to receive the training intervention at a later date
89020340|NCT04977414|Experimental|"Making data count intervention group"|The Making Data Count training intervention was designed by NHS-Improvement to improve knowledge about SPC charts and to increase their uptake. Training sessions are tailored for two sets of attendees: board members and data analysts. Board member and analyst training sessions are delivered as close as possible in time, typically within the same month. Training sessions for board members are usually delivered over about one-and-a-half hours and focus more heavily on the benefits of control charts compared to other charts. Training sessions for analysts are usually delivered over three hours and focus more heavily on the structure and interpretation of the individual and moving range charts (X-mR charts).
89020341|NCT04974567||Women recently diagnosed with breast cancer who have not undergone any treatment.|Tear sample collection
89020342|NCT04969874|Other|remote follow-up|patients with chronic disorders on sequelae of anti-cancer treatments after an intensive rehabilitation stay will undergo 5 months of remote follow-up with speech therapists including questionnaires and interview
89020343|NCT04965246|Experimental|Physical activity|the physical activity intervention will be structured to increase light-intensity aerobic physical activity, to achieve a total of 150 minutes per week. The intervention will also include weekly support calls from research staff to improve compliance to physical activity
89020344|NCT04965246|Other|Usual care|Participants randomized to the usual care control group will serve as the control group for 15 weeks, and receive no intervention during this time.
89020345|NCT04959331|Active Comparator|Short-course fosfomycin|3 g of fosfomycin once daily for two days (sachets)
89020346|NCT04959331|Active Comparator|Short-course nitrofurantoin|Five-day nitrofurantoin 100 mg t.i.d. (pills)
89020347|NCT04959331|Active Comparator|Short-course pivmecillinam|Three-day pivmecillinam 400 mg. t.i.d. (pills)
89020348|NCT04959331|Active Comparator|Single-dose fosfomycin|Single 3 g dose of fosfomycin (sachet)
89020349|NCT04948775|Experimental|Intervention Group|Cervical Stabilization Exercise Group
89020350|NCT04948775|No Intervention|Control Group|Control Group
89020351|NCT04916951|No Intervention|Amoxicillin - standard-of-care dose|Obtain amoxicillin plasma concentrations in patients already receiving amoxicillin
89020352|NCT04916951|No Intervention|Cephalexin - standard-of-care dose|Obtain cephalexin plasma concentrations in patients already receiving cephalexin
89020353|NCT04916951|Experimental|Amoxicillin - study dose|Obtain amoxicillin plasma concentrations after a study-administered dose of amoxicillin
89020354|NCT04916951|Experimental|Cephalexin - study dose|Obtain cephalexin plasma concentrations after a study-administered dose of cephalexin
89020355|NCT04912076|Experimental|BM41|"9 treatment visits where subcutaneous injections with solution of the test drug BM41 (adsorbed to aluminium hydroxide) in a blinded fashion starting with 12.5 nanogram increasing to 20 microgram which is maintenance dose. Subsequently 3 maintenance doses will be given.~Please look at the results in the original article."
89020356|NCT04912076|Placebo Comparator|Placebo|Placebo consisting of only aluminium hydroxide will be administered blinded in amounts according to BM41.
89020357|NCT04912076|Active Comparator|Alutard|Alutard SQ (ALK) will serve as the comparator and administration is open. Up-dosing is performed according to the official cluster scheme, reaching maintenance of 100.000 SQ-E
89020358|NCT04898413|Experimental|Group-based acceptance and commitment therapy (ACT)|Participants assigned to the group-based ACT intervention will receive eight sessions through face-to-face or Zoom video conferencing over the course of four months. Participants will also receive individualized support between sessions to help them better understand the program using phone or Zoom video conferencing. If participants' care recipient hopes to receive psychological treatment, they will be invited to participate in a group-based reminiscence therapy held once or twice a month, each lasting about 60-90 minutes, over the course of about three months.
89020359|NCT04898413|Active Comparator|Group-based cognitive behavior therapy (CBT)|Participants assigned to the group-based CBT intervention will receive eight sessions through face-to-face or Zoom video conferencing over the course of four months. Participants will also receive individualized support between sessions to help them better understand the program using phone or Zoom video conferencing. If participants' care recipient hopes to receive psychological treatment, they will be invited to participate in a group-based reminiscence therapy held once or twice a month, each lasting about 60-90 minutes, over the course of about three months.
89020360|NCT04897269|No Intervention|Control group|In the control group, the patients will be indicated with standard protocol, micronized progesterone (Cyclogest pessary) 400mg two times per day for 14 days, without any progesterone supplementation. If the beta-hcg test is positive, the patients will be treated with the same protocol and followed till 7 weeks of pregnancy when the fetal heart can be confirmed
89020361|NCT04897269|Experimental|Study group|In the interventional group,the patients will be indicated with standard protocol, micronized progesterone (Cyclogest pessary) 400mg x 2 per day for 14 days, supplemented with intramuscular progesterone (Progesterone 25mg/ml) 25 mg x 2 at one time per day for 14 days. If the beta-hcg test is positive, the patients will be treated with the same protocol and followed till 7 weeks of pregnancy when the fetal heart can be confirmed
89020362|NCT04891419|Experimental|JUVÉDERM® VOLUMA® with Lidocaine|Participants will be treated with JUVÉDERM® VOLUMA® with Lidocaine injectable gel in temple. Participants are eligible for touch up treatment
89477142|NCT02052115|Other|Exercise and weight loss|12 month exercise and weight loss intervention
89477143|NCT02471001||Heart Surgery Using Heart-lung Machine|All patients who scheduled for an elective heart surgery in Royal Infirmary of Edinburgh using a heart-lung machine and the administration of ether-like anaesthetic, isoflurane will be recruited in this study. The medical and surgical care plans for participants remain as usual in this study with an exception being two additional blood samples of about two-teaspoonful in volume will be collected from an in-placed catheters in vein and aorta.
89477144|NCT02805907|Experimental|Intervention Group (IG)|Calcifediol (Hidroferol®) in 16,000-IU ampoules taken weekly by the oral route
89020363|NCT04891419|No Intervention|Control- No treatment|No treatment is administered. Optional treatment at month 6.
89020364|NCT04881565|Experimental|Reactive balance training plus functional electrical stimulation|
89477145|NCT02805907|Placebo Comparator|Control Group (CG)|Placebo in a presentation with an identical appearance taken weekly by the oral route
89477146|NCT04308902||Children previously enrolled in the OptiMoM Fortifier Study|This is an observational study of children who were previously enrolled in a trial (Bovine vs. Human Milk-Based Fortifier Study) between 2014 and 2016 during which time they were randomized to have their feeds (mother's own milk or pasteurized donor breastmilk) nutrient enriched with a human milk-based fortifier or a bovine protein-based fortifier.
89477147|NCT04308902||Term-born Comparison|This is an observational study of children born at full term (>= 37 weeks gestation) and weighing more than 2500g. These children will be recruited from the communities in which the OptiMoM participants live.
89477148|NCT02470845|Experimental|Tian Jiu group|The TJ group will undergo a 4-week treatment with herbal patches one session per week and a 4-week post-treatment follow-up, of one assessment session per week. Participants in the TJ group will be treated with herbal patches of Tian Jiu group on five acupoints on the back.
89537471|NCT03587831|Experimental|VSG + LSM|"Procedure/Surgery: Vertical Sleeve Gastrectomy will be performed using five laparoscopic ports. The short gastric and epiploic vessels will be taken down With a 40 French Bougie in place, the greater curvature will be excised starting 6 cm proximal to the pylorus.~Behavioral: Lifestyle Modification Counseling - The intensive lifestyle intervention will align with methods listed in the LSM arm description. However, participants assigned to the VSG will not have calorie ceilings during the first 6 months of rapid weight loss, and they will receive additional instruction regarding food volume and adequate protein intake."
89537472|NCT03587831|Active Comparator|LSM|Behavioral: Lifestyle Modification Counseling - The intensive lifestyle intervention is modeled after the LookAHEAD trial, with modules modified for participants undergoing surgery, and designed to produce maximum achievable weight loss. Both groups will increase their level of moderate-intensity physical activity (such as walking) to a total of 325 minutes per week. All lifestyle-medical management participants will be given calorie intake targets of 1200, 1500, or 1800 kilocalories per day, depending on body weight, with the goal of producing a weight loss of 1 to 2 pounds per week. There will be 24 weekly counseling meetings during the first 6 months, bi-weekly meetings between months 7 and 9, and monthly meetings between months 10 and 12.
89537473|NCT02463383|Experimental|Sequence 1|"Ibuprofen Tab 400MG~Placebo Tab"
89537474|NCT02463383|Experimental|Sequence 2|"Placebo tab~Ibuprofen Tab 400MG"
89537475|NCT02463461|Experimental|ActiSleep Activity Monitor|Subjects placed in this group will given an ActiSleep Activity Monitor for the one night of the study.
89537476|NCT02463461|Experimental|Jawbone Activity Monitor|Subjects placed in this group will given a Jawbone Activity Monitor for the one night of the study.
89537477|NCT02463461|Experimental|Actiwatch 2 Activity Monitor|Subjects placed in this group will given an Actiwatch 2 Activity Monitor for the one night of the study.
89537478|NCT02463461|Experimental|FitBit Activity Monitor|Subjects placed in this group will given a FitBit Activity Monitor for the one night of the study.
89537479|NCT02463461|Experimental|Actigraph by Ambulatory Monitoring Activity Monitor|Subjects placed in this group will given an Actigraph by Ambulatory Monitoring Activity Monitor for the one night of the study.
89537480|NCT04828629||Identification of prognostic factors in patients who have recovered from COVID-19|Selected prognosis factors will be analyzed in patients who have recovered from COVID-19
89537481|NCT03268109||people living with HIV|subjects infected with HIV and with cognitive complaints
89537482|NCT03268109||control subjects|subjects not infected with HIV and with cognitive complaints
88950468|NCT05409677||1-month survivors; 1-month non-survivors|Depending on mortality within 1 month, the patients were divided into two groups named 1-month survivors and 1-month non-survivors.There was no intervention other than normal treatment
88950469|NCT05409625|Experimental|Young adults|Participants aged between 18 and 30 years old without chronic diseases but with two caries lesions or more
88950470|NCT05409586||no recurrence|Patients who recovered after IGM treatment and had no signs of relapse
88950471|NCT05409586||recurrence|Patients whose symptoms reappear 3 months after IGM treatment
88950472|NCT05409560||Cold water swimmers|swimmers participating in the 6-hour cold water swim, qualifying for the English Channel Swim
89537483|NCT05419557|Active Comparator|Intervention|12 week virtual family-based health eating program
89537484|NCT05419557|No Intervention|Comparison|Standard in-office counseling about diet
89537485|NCT03065673|Active Comparator|Potassium Oxalate 5% gel|The patient will receive the application of potassium oxalate 5% gel on vestibular surface teeth, for 10 minutes.
89537486|NCT03065673|Placebo Comparator|Placebo gel|The patient will receive the application placebo gel on vestibular surface teeth, for 10 minutes.
88950473|NCT05409521|Experimental|Tape Group|Kinesio taping will be applied on thoracic region
88950474|NCT05409521|Placebo Comparator|Placebo Group|Placebo taping will be applied on arm region
88950475|NCT05409469||Chinese patients with aortic dissection|Clinical characteristics, management patterns and outcomes of type A aortic dissection in China.
88950476|NCT05409469||American patients with aortic dissection|Clinical characteristics, management patterns and outcomes of type A aortic dissection in the United States.
88950477|NCT05409417|Experimental|Tislelizumab Combined With chemotherapy|Tislelizumab Combined With XELOX and Bevacizumab or Tislelizumab Combined With FOLFOX and Cetuximab
88950478|NCT05409339|Experimental|"Caffeine-Caffeine (Condition Caffeine)"|Through the 9-day pre-ambulatory, 2-day laboratory, and 7-day post-ambulatory parts, participants received 150 mg caffeine x 3 times daily.
88950479|NCT05409339|Experimental|"Caffeine-Placebo (Condition Withdrawal)"|During the 9-day ambulatory part, participants received 150 mg caffeine x 3 times daily, followed by a switch to placebo (150 mg mannitol) from the 2nd intake of the 9th day onward, through the laboratory and the post-ambulatory parts.
88950480|NCT05409339|Placebo Comparator|"Placebo (Condition Placebo)"|Through the 9-day ambulatory and 2-day laboratory, and 7-day post-ambulatory parts, participants received 150 mg mannitol x 3 times daily.
88950481|NCT05409326|Experimental|TQH2722 injection|Participants will receive single dose of TQH2722 injection under fasted condition (Single Ascending Dose(SAD) Cohorts 50mg, 150mg, 300mg, 600mg, 1200mg) on Day 1, or will receive multiple doses of TQH2722 injection once every 14 days under fasted condition (Multiple-Dose Administration (MAD) Cohort 150mg, 600mg) on Day 1-43.
89020365|NCT04881565|Active Comparator|Reactive balance training|
89537487|NCT04006223||11C-PIB or 18F-florbetapir PET/MR|Patients suspected of or diagnosed with systemic amyloidosis will be scanned by 11C-PIB or 18F-florbetapir PET/MR twice. One is before biopsy and treatment, and the other is after at least half a year of treatment.
89537488|NCT03108365|Experimental|Axiostat|"Size: 1 x 1 cm~Chitosan based haemostatic dressing"
89537489|NCT03108365|Active Comparator|Cotton Gauze|Size: 1 x 1 cm
89537490|NCT02628873|Experimental|Arm 1 (HyCoSy followed by HSG)|HyCoSy procedure followed by HSG procedure
89537491|NCT02628873|Experimental|Arm 2 (HSG followed by HyCoSy)|HSG procedure followed by HyCoSy procedure
89537492|NCT02463149|Experimental|Youth Chef Academy|Receives intervention
89537493|NCT02463149|No Intervention|Control|Usual classroom curriculum
89537494|NCT02462993|Experimental|Aloe vera group|Group recieving scaling and root planing and aloe vera gel local drug delivery
89537495|NCT02462993|No Intervention|SRP group|Group recieving only scaling and root planing
89537496|NCT03063333|Experimental|Coping-oriented hypnosis|
89537497|NCT03063333|Placebo Comparator|Neutral hypnosis|
89537498|NCT03063333|No Intervention|current treatment only|
89537499|NCT02935283||OTCD participants|Female carriers of ornithine transcarbamylase deficiency (OTCD) or males with late onset presentation of OTCD who can undergo MRI and behavioral testing
89537500|NCT02935283||Normal controls|Healthy males or females without known medical or metabolic disorder (control group) who can undergo MRI and behavioral testing
89537501|NCT02935283||HA recovery group|Female carriers of ornithine transcarbamylase deficiency (OTCD) or males with late onset presentation of OTCD or participants with CPS-1 who have had a recent hyperammonemic episode who can undergo MRI and behavioral testing
89537502|NCT02935283||Distal UCD|Males and females with ASSD and ASLD who can undergo MRI and behavioral testing
89537503|NCT02871167|Experimental|Oocyte/embryo cryopreservation|"Controlled ovarian hyperstimulation (COH)~Oocyte/embryo freezing"
89537504|NCT03981549|Active Comparator|Immediate Cellular Therapy / Deferred Sham Therapy|"At baseline: Bone marrow aspiration followed by intravitreal injection of CD34+ cells.~At 6 months: Sham bone marrow aspiration and sham intravitreal injection."
89537505|NCT03981549|Sham Comparator|Immediate Sham Therapy / Deferred Cellular Therapy|"At baseline: Sham bone marrow aspiration followed by sham intravitreal injection.~At 6 months: Bone marrow aspiration followed by intravitreal injection of CD34+ cells."
89537506|NCT04657133|Experimental|Intervention group|Subjects in the intervention group will receive remote ischemic conditioning and standard background medical treatment.
89537507|NCT04657133|Placebo Comparator|Sham group|Subjects in the placebo group will receive sham remote ischemic conditioning and standard background medical treatment alone.
89537508|NCT03922139|Experimental|Botox|"Ultrasound guided 1 mg/1 mL injection.~25 units of Botox will be injected 2 cm proximal and 2 cm distal to the midpoint of the tibialis anterior muscle."
89537509|NCT04728243|Experimental|WHO QualityRights|Mental health professionals assigned to the experimental arm will be enrolled in the WHO QualityRights online training.
89537510|NCT04728243|Placebo Comparator|WHO Coronavirus Disease of 2019 (COVID19)|Mental health professionals assigned to the control arm will be enrolled in the WHO novel coronavirus 2019 online training series.
89202773|NCT00661362|Placebo Comparator|2|Metformin + Placebo
89202774|NCT00991432||INFUSE® Bone Graft|all study participants will receive INFUSE® Bone Graft
89537511|NCT03063177|Experimental|1840Newtons/s(N/s);125ms;250 Newtons(N)|Participants will receive a spinal manipulative therapy of 20 Newtons (N) preload leading to a peak force of 250N over 125ms (rate of force application of 1840N/s).
89020366|NCT04852302|Experimental|Arm 1|Remote CALM therapy for participants with newly or recurrent PCNST
89537512|NCT03063177|Experimental|920N/s;125ms;135N|Participants will receive a spinal manipulative therapy of 20N preload leading to a peak force of 135N over 125ms (rate of force application of 920N/s).
89537513|NCT03063177|Experimental|920N/s;250ms;250N|Participants will receive a spinal manipulative therapy of 20N preload leading to a peak force of 250N over 250ms (rate of force application of 920N/s).
89202775|NCT00748202|Active Comparator|1|intravenous administration of C1-Inhibitor, after the end of the first observation period (at least after 7 days), each arm switches cross-over to the alternative administration mode not investigated so far
89202776|NCT00748202|Active Comparator|2|subcutaneous administration of C1-Inhibitor. After the end of the first observation period (at least after 7 days), each arm switches cross-over to the alternative administration mode not investigated so far.
89202777|NCT00325897|Active Comparator|Azithromycin, 250 mg|Macrolide Antibiotic (Azithromycin)
89202778|NCT00325897|Placebo Comparator|Placebo|Inactive
89202779|NCT00756392|Other|1|
89202780|NCT03989089|Experimental|Pembrolizumab single agent|Pembrolizumab 200 mg will be given intravenously every 3 weeks , on Day 1 on each 3 week cycle. Pembrolizumab can be given up to 35 adminstration (2 years).
89202781|NCT00756626|Experimental|1|Intervention group receives bottle weaning intervention from WIC nutritionist
89202782|NCT00756626|No Intervention|2|Control standard of care
89202783|NCT00793338|Experimental|Sildenafil|All patients will receive open-label treatment with sildenafil.
89537514|NCT03063177|No Intervention|control|Spinal stiffness will be assessed at each sesssion, however, participants won't receive any spinal manipulative therapy.
89537515|NCT02462213||Amyloidosis|Patients being managed for amyloidosis without prior history of cardiac involvement
89537516|NCT02462213||Cardiac amyloidosis|Patients being managed for cardiac amyloidosis
89537517|NCT03064347|Active Comparator|Coated Sucrose plus Whole Milk|200kcal sucrose plus whole milk powder in enteric coating as single dose
89537518|NCT03064347|Placebo Comparator|Non Coated Sucrose plus Whole Milk|200kcal sucrose plus whole milk powder with separate enteric coating materials as single dose
89537519|NCT03064347|Active Comparator|Enteric Coated Sucrose|200kcal sucrose in enteric coating as single dose
89537520|NCT03064347|Placebo Comparator|Non-Enteric Coated Sucrose|200kcal sucrose with separate enteric coating materials as single dose
89537521|NCT03064347|Active Comparator|Enteric Coated Whey Protein|200kcal whey protein in enteric coating as single dose
89537522|NCT03064347|Placebo Comparator|Non-Enteric Coated Whey Protein|200kcal whey protein with separate enteric coating materials as single dose
89537523|NCT03064347|Active Comparator|Enteric Coated Pea Protein|200kcal pea protein in enteric coating as single dose
89537524|NCT03064347|Placebo Comparator|Non-Enteric Coated Pea Protein|200kcal pea protein with separate enteric coating materials as single dose
89537525|NCT03063099|Experimental|ReNu™ Injection|ReNu™ is an allograft tissue composed of particularized amniotic membrane and cell from the amniotic fluid.
89477149|NCT02470845|Sham Comparator|Placebo-control group|The placebo-control group will undergo a 4-week treatment with placebo patches one session per week and a 4-week post-treatment follow-up, of one assessment session per week. Participants in this group will be treated with placebo patches of placebo-control group on the same acupionts as the TJ group.
88950482|NCT05409326|Placebo Comparator|Placebo to match TQH2722|Participants will receive single dose of matching placebo under fasted condition (Single Ascending Dose(SAD) Cohorts 50mg, 150mg, 300mg, 600mg, 1200mg) on Day 1, or will receive multiple doses of matching placebo once every 14 days under fasted condition (Multiple-Dose Administration (MAD) Cohort 150mg, 600mg) on Day 1-43.
88950483|NCT05409313|Experimental|EBP and SDM training group|A total of 36 nurses will be received EBP and SDM training program.
88950484|NCT05409313|Active Comparator|SDM training group|A total of 36 nurses will be received SDM training alone.
89477150|NCT02470845|No Intervention|Waitlist-control group|The waitlist-control group will receive no treatment during the first 4 weeks but, beginning with the 5th week this group will receive TJ treatment for four weeks as compensatory.
89477151|NCT05137106|Experimental|Active Dry Needling|Active dry needling (ADN). Intramuscular insertion Intervention/treatment. All participants in this group received an ADN session with an intramuscular insertion of a 25 mm X 0.22 mm JEMCO acupuncture needle into the infraspinatus muscle. The dry needling was performed with the rapid entry and exit technique.
88950487|NCT05409248|Experimental|Experimental Group|Online games designed to target specific cognitive skills such as attention, perception, or inhibition). Activities' difficulty will be automatically adjusted accordingly to each participant's performance, always demanding a maximum cognitive effort.
89202784|NCT00756704|No Intervention|Baseline Period|
89202785|NCT00756704|Experimental|Intervention Period|
89202786|NCT00798408|Experimental|1|Participants will maintain current physical activity and take a fluid supplement.
89477152|NCT05137106|Sham Comparator|Sham Dry needling|Sham dry needling (SDN). All participants in this group received one session of SDN with a 25 mm X 0.22 mm JEMCO acupuncture needle over the infraspinatus region. To ensure that the blunt needles did not puncture the skin during the experimental session (and for patient comfort), each needle was individually cut and polished and checked for sharpness against the investigator's fingertip. As a precaution against infection, each patient was treated with a separate dummy needle.
89202787|NCT00798408|Experimental|2|Participants will maintain current physical activity and take a solid supplement.
89477153|NCT02477397|Experimental|Spiromax Budesonide/formoterol|1. In Group A, Patients will be treated with Spiromax® budesonide/formoterol 160/4.5 μg two inhalations twice daily + Spiromax® budesonide/formoterol 160/4.5 μg as needed with a maximum of 8 additional inhalations daily.
89477154|NCT02477397|Active Comparator|Diskus Fluticasone/salmeterol|2. In group B, Patients will be treated with Diskus® fluticasone/salmeterol 500/50 μg one inhalation twice daily + salbutamol 100 μg as needed with a maximum of 8 inhalations daily.
89477155|NCT05131724|Active Comparator|Treadmill training|The treadmill training would be 10 sessions over 2 weeks with 30 minutes for each session (5-min warm-up; 20 min gait training; 5-min cool-down). During the sessions, treadmill speed will be maintained at 60 to 80% of the maximum speed established on an exertion test. The child will walk at 60% maximum speed in the first and final five minutes and 80% in the middle 20 minutes.
89477156|NCT05131724|Experimental|Virtual reality|Infants in the TTVR group will perform gait training on the treadmill simultaneously with virtual reality.
89477157|NCT02037451|Experimental|intervention group|intervention group which receive auditory cueing while performing movement
89477158|NCT02037451|No Intervention|Control group|control group which performing movement after listen to required movement rhythm.
89202788|NCT00344773|Experimental|Gefitinib|Gefitinib 250mg tablet once daily
89202789|NCT02561546|Experimental|TAE plus p53 gene therapy|Trans-catheter embolization (TAE) combined with recombinant adenoviral human p53 gene (rAd-p53) will be given one per month
89477159|NCT02469675|Experimental|All subjects|"All subjects undergo same full protocol, including different combinations of stimulation on different days:~Transcranial Magnetic Stimulation Cervical Transcutaneous Stimulation Median Nerve Stimulation"
89477160|NCT04365777||Awake State|OAA/S=5
89477161|NCT04365777||Sedation State|OAA/S=3
89477162|NCT04365777||Unconsciousness State|OAA/S=1
89202790|NCT02561546|Active Comparator|Trans-catheter embolization|Trans-catheter embolization (TAE) will be given once per month
89477163|NCT02051179||Replacement amalgam|Replacement The clinicians totally removed and replaced the defective restorations. After completing the cavity preparations, the tooth was restored with a new AM (Original D). Bonding agents and/or liners underneath the amalgam restorations were not used in this trial. Rubber dam isolation was used for all restorative treatments. .
89477164|NCT02051179||Repair Amalgam|The clinicians (PV and CM) used Carbide burs (330-010 Komet, Brasseler GmbH Co. Postfach 160.32631, Lemgo, Germany) to explore the defective margin, carious lesion or anatomic form of the restorations. Part of the restorative material adjacent to the defect was removed as an exploratory proceedure thus allowing a proper evaluation and subsequent diagnosis of the extent of the defect. Provided that the defect was limited and localized, the clinician then removed any defective tooth tissue. Mechanical retention was employed inside the existing AM restoration. Rubber dam isolation was used for this procedure. Repair of the restorations was carried out with a dispersed-phased amalgam (Original D, Wyckle Research Inc, Carson City, NV, USA).
89477165|NCT05096078|Active Comparator|Diet Group|Individuals will receive only dietary treatment that the dietitian deems appropriate for 6 weeks.
89477166|NCT05096078|Experimental|Exercise Group|In addition to the 6-week diet program that the dietitian deems appropriate, a circuit exercise program will be applied for 6 weeks. The circuit exercise program will consist of a medium-intensity circuit training for 50 minutes, 3 days a week, detailing the main muscle groups of the patients (chest, back, biceps, triceps, deltoid, quadriceps, thigh and calf muscles). Exercise intensity will be monitored using Borg's scale of perceived exertion, with a target intensity of 12 to 14. 8 exercises will be given in a continuous, circuit-type manner with short 1-minute rests.
89477167|NCT02052271|Experimental|Essential tremor|cerebellar stimulation
89477168|NCT02052271|Placebo Comparator|Placebo arm|placebo stimulation
89477169|NCT04280276|Active Comparator|Group 1 - Patients with high IPV (designated as ≥ 30%).|Patients with high IPV (designated as ≥ 30%).
89477170|NCT04280276|Active Comparator|Group 2 - patients with normal IPV (< 30%).|Patients with normal IPV (< 30%). Will assess risk of subclinical acute rejection in patients with high IPV compared to normal IPV. All tacrolimus 12 h trough levels in patients with stable allograft function at least 3 months post-transplant.
89477171|NCT03561571|Active Comparator|Butter based breakfast|
89477172|NCT03561571|Active Comparator|Chocolate spread based breakfast|
89537526|NCT04545047||Exposed|Veterans who received COVID-19 convalescent plasma therapy within 2 days of eligibility
89537527|NCT04545047||Unexposed|Veterans who did not receive COVID-19 convalescent plasma therapy
89202791|NCT00991588||PCL, posterolateral reconstruction|All patients who are entered into study who receive a PCL and/or posterolateral knee ligament reconstruction
89477173|NCT02723175|Experimental|Sham tDCS Stimulation|"30 minutes of the sham transcranial Direct Current Stimulation~Transcranial Direct Current Stimulation: Transcranial Direct Current Stimulation is a minimally invasive technique that uses a small amount of electricity (2mA) to temporarily stimulate specific brain areas in awake people."
89477174|NCT02723175|Experimental|Anodal tDCS Stimulation of DLPFC|"30 minutes of the active transcranial Direct Current Stimulation (tDCS)~Transcranial Direct Current Stimulation: Transcranial Direct Current Stimulation is a minimally invasive technique that uses a small amount of electricity (2mA) to temporarily stimulate specific brain areas in awake people."
89477175|NCT02052349|Experimental|Arm 1: ABT-333|A single centre, open-label, 4-treatment, 3-period, 4-sequence incomplete randomised, single dose crossover study in healthy subjects.
89477176|NCT05058326||TEST GROUP|Women with fecal incontinence referred to outpatients clinic.
89477177|NCT02051413|Other|Venlafaxine extended release|Venlafaxine extended-release, flexible dose
89477178|NCT05305976|Experimental|Ambulant Group|Individuals unable to walk according to the Brooke Function Classification System
89477179|NCT05305976|Experimental|Non-ambulant Group|Individuals who can walk according to the Brooke Function Classification System
89477180|NCT02470767||DOAC treated patients|Patients diagnosed with Non-Valvular Atrial Fribilation at risk of stroke or systemic embolism treated in primary care centres with DOAC.
89477181|NCT02477241|Other|Healthy female subjects|Healthy female subjects with or without overactive bladder undergoing functional MRI brain and urodynamic study.
89477182|NCT02049541|Experimental|Treatment (PI3K inhibitor BKM120, rituximab)|Patients receive BKM120 PO daily and rituximab IV. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with asymptomatic progression may continue treatment for up to 12 months. Pharmacodynamic samples from peripheral blood (for those with peripheral blood involvement) and bone marrow aspirate (for all patients) are drawn at baseline. Patients will undergo correlative studies to include bone marrow biopsy at study enrollment, and at the time of complete remission.
89477183|NCT05026112||DCM with MSF (MSF+)|Patients with dilated cardiomyopathy and midwall septal fibrosis identified in a previous cardiac MRI scan
89477184|NCT05026112||DCM without MSF (MSF-)|Patients with dilated cardiomyopathy but without midwall septal fibrosis on previous cardiac MRI scan
89477185|NCT05026112||Control - MSF+|Control healthy volunteers (HV) to the MSF+ cohort
89477186|NCT05026112||Control - MSF-|Control healthy volunteers (HV) to the MSF- cohort
89477187|NCT02052427|Experimental|ADRCs|"Adipose-Derived Regenerative Cells (ADRCs) processed by the Celution System:~0.8 x 10^6 cells/kg body weight (not to exceed 80.0 x 10^6 cells)~Delivered via the MYOSTAR™ Injection Catheter in 15 intramyocardial injections"
89477188|NCT02052427|Placebo Comparator|Placebo|"Placebo - Physiological Solution~Inactive substance (Lactated Ringers + autologous blood)~Delivered via the MYOSTAR™ Injection Catheter in 15 intramyocardial injections"
89477189|NCT02470611|Experimental|Sodium Alendronate|Adjunctive use of 1% sodium alendronate gel as part of periodontitis treatment
89477190|NCT02470611|Placebo Comparator|Placebo|Adjunctive use of placebo gel as part of periodontitis treatment
89477191|NCT02049619|No Intervention|Control|Following endotracheal intubation, no pharyngeal pack was inserted into the hypopharynx.
89477192|NCT02049619|Experimental|pharyngeal pack|Following endotracheal intubation, one saline soaked, gauze pharyngeal pack was inserted into the hypopharynx under direct vision using McGill's forceps. The packs were tied to the endotracheal tube and their placements were documented on the scrub nurse's count board.
89477193|NCT02470689|Active Comparator|Diacerin cream 1%|
89477194|NCT02470689|Placebo Comparator|ultraphil cream|
89477195|NCT05305898|Experimental|Metformin group|"Patients from metformin group will receive metformin 3 x 850 mg (after titration period) for 2 years (3 x 500 mg for first 6 weeks) with 6 months follow-up after treatment cessation."
89477196|NCT05305898|No Intervention|No metformin group|"Patients form no metformin group will be observed for 2 years and 6 months, which cover the same period like for patients from metformin group."
89477197|NCT02049697|Experimental|14C-JNJ-39823277|
89477198|NCT03561493|Experimental|zumba exercise group|Participants will engage in 16 classes of 60-minute Zumba® fitness for two consecutive menstrual cycles (an 8-week period, twice weekly). Each class was one h in length and a recovery period of at least 48 h was taken between classes.
89477199|NCT03561493|No Intervention|non zumba exercise group|The participants in the control group did not receive any intervention.
89477200|NCT05005676|Experimental|adductor pollicis AP|Measurement site: M.adductor pollicis of both arms.
89477201|NCT05005676|Experimental|Corrugator supercilii CS|Measurement site: M. corrugator supercilii at both sides
89477202|NCT02052505|No Intervention|Usual care|The patients will receive the usual care when admitted. This includes an examination by a physician, a medication review and the physician will prescribe medications for the patients as well as other necessary interventions.
89477203|NCT02052505|Experimental|Medication review|The patients will receive the usual care when admitted. This includes an examination by a physician, a medication review and the physician will prescribe medications for the patients as well as other necessary interventions. Following this (usual care) a trained nurse will perform a medication review and discuss the observations with a physician.
89477204|NCT02469831|Active Comparator|group D|deep neuromuscular block by rocuronium defined :post tetanic (PTC) >1 but no response to a train of four (TOF) stimulation.
89477205|NCT02469831|Active Comparator|group I|intermediate neuromuscular block by rocuronium defined as TOF count of 1-3.
89477206|NCT05305742|Experimental|Protaper Ultimate|
89477207|NCT05305742|Active Comparator|Protaper Gold|
89477208|NCT02049775|Experimental|NBI|
89477209|NCT02469909|Other|immediate decannulation|In the immediate decannulation group - the tracheostomy tube is removed and the patient would be monitored overnight in an intermediate monitored unit. On the next day a clinical evaluation would be held, and the patient would be discharge or transferred to his department according to the clinical course of the patient
89202792|NCT02554344|Experimental|All Patients|Fourteen subjects with histologically confirmed squamous CIN3 will be enrolled in a single arm study. All patients will receive 500 mg of curcumin administered orally, twice a day for 12 weeks upon enrollment on trial.
89477210|NCT02469909|Other|Gradual tracheostomy tube decrease|In the gradual decannulation group The tracheostomy tube will be reduced in 2 sizes compared with the initial inner diameter of the tube. The patients will remain with the reduced tube for 48 hours, and the tube will be removed if the patients would meet pre-decannulation evaluation
89477211|NCT04999904|Experimental|Uneven Treadmill Arm|Uneven Treadmill Intervention with up to twelve sessions over approximately six weeks and Standard of Care Physical Therapy with an 18 month follow-up period
89477212|NCT04999904|Active Comparator|Control Arm|Standard of Care Physical Therapy over approximately six weeks with an 18 month follow-up period
89477213|NCT02049853|No Intervention|default group|"Patients with the randomization result default group receive standard diagnostics"
89477214|NCT02049853|Active Comparator|POCT group|"patients with the randomization result POCT group receive a NTproBNP measurement with point of care device Cobash232 in the ambulance vehicle"
89477215|NCT04985084|Experimental|The intervention group|A 4-week dietary behavioral intervention provided by a registered nurse who has received nutrition training.
89477216|NCT04985084|Other|Usual care|General dietary advice provided by the ward nurses.
89477217|NCT04211246|Active Comparator|Standard group|Fraction of inspired oxygen (FiO2) is titrated guided by SpO2.
89477218|NCT04211246|Experimental|ORI group|Fraction of inspired oxygen (FiO2) is titrated guided by SpO2 and ORI
89477219|NCT02995005|Experimental|Tenofovir Disoproxil Fumarate|Women early in pregnancy (end of first or beginning second trimester) will be treated with TDF to determine the efficacy of this strategy to bring >=95% of women to undetectable HBV DNA levels at delivery.
89477220|NCT05305274||2019 screening|34,400 schoolchildren with a 36-month follow-up from 2019 to 2021.
89477221|NCT05305274||2020 screening|34,400 schoolchildren with a 36-month follow-up from 2019 to 2021.
89477222|NCT05305274||2021 screening|34,400 schoolchildren with a 36-month follow-up from 2019 to 2021.
89477223|NCT02052817|Active Comparator|Control|Debridement and standard of care in off-loading on control patients
89477224|NCT02052817|Experimental|Toad Brace|Debridement and fitting of Toad Brace
89477225|NCT04182386||rPVE|Right portal vein embolization. All patients subjected to selective right portal vein embolization prior to planned hepatobiliary surgery.
89477226|NCT04182386||rPVE+S4|Right portal vein embolization including segment 4 portal vein branches. All patients subjected to selective right portal vein embolization including segment 4 portal vein branches prior to planned hepatobiliary surgery.
89477227|NCT03561415|Experimental|Universal posaconazole prophylaxis|Universal posaconazole prophylaxis: All patients will start posaconazole modified release tablet (300mg daily ) between Day 4 and Day 14 post lung or heart-lung transplantation for 3 months.
89477228|NCT03561415|Experimental|Pre-emptive posaconazole therapy|Pre-emptive posaconazole therapy: Posaconazole will be started if a fungal pathogen is identified or there is serological evidence of a fungal pathogen in the absence of any evidence of invasive fungal disease and given for 3 months.
89477229|NCT02477007|Experimental|Ibuprofen+placebo of paracetamol|Patients will receive in addition to morphine (usual care) ibuprofen and placebo of paracetamol
89477230|NCT02477007|Experimental|Paracetamol + placebo of ibuprofen|Patients will receive in addition to morphine (usual care) paracetamol and placebo of ibuprofen
89477231|NCT02477007|Experimental|Paracetamol + ibuprofen|Patients will receive in addition to morphine (usual care) paracetamol and ibuprofen
89477232|NCT02477007|Placebo Comparator|Placebo of paracetamol + placebo of ibuprofen|Patients will receive morphine alone(usual care).
89477233|NCT04173182||Inflammation on pCLE|Patients with inflammatory findings in the peridiverticular and colonic mucosa (crypt fusion and distortion, bright epithelium, and dilated-prominent branching vessels)
89477234|NCT04173182||No inflammation on pCLE|Patients with normal findings on pCLE evaluation of the peridiverticular and colonic mucosa (absence of inflammation)
89202793|NCT00750854|Experimental|NEM Treatment 1|NEM Formulation X (#0802), 500 mg, once daily, orally
89202794|NCT00750854|Experimental|NEM Treatment 2|NEM Formulation Y (#0505), 500 mg, once daily, orally
89202795|NCT02554422|Experimental|PalpEar|Intraoperative palpation of the ossicles using the PalpEar device, to measure mobility of the ossicle chain.
89477235|NCT02052973|Experimental|Propolis varnish|Saliva and oral biofilm will be collected before and in regular times after the application of the propolis varnish. This data will be compared in order to evaluate the probable reduction of Streptococcus mutans in saliva and oral biofilm.
89477236|NCT02477085||all women with an induced labor|prospective population-based cohort of all women who have an induced labor during one month in seven perinatal networks
89477237|NCT02053519|Active Comparator|Vigantol Oil, (Vitamin D3)|Oral Vigantol Oil 5 mls, (100 000 iu of Vitamin D). First dose at randomisation, 7 -28 days prior to commencing standard Hepatitis C treatment for Hepatitis C Genotypes 1 or 3 . Thereafter monthly with concurrent Hepatitis C treatment.
89477238|NCT02053519|Placebo Comparator|MyGliol Oil|Matched placebo. Subjects randomised to this arm will take 5 mls of active Placebo, (Mygliol oil), 7 - 28 days prior to commencing active Hepatitis C treatment and thereafter 5 mls monthly concurrent with Hepatitis C treatment for the duration of the study
89477239|NCT02053597|Experimental|doxorubicin and paclitaxel|All patients will receive four cycles of doxorubicin (A) (50 mg/m2) and paclitaxel (P) (200 mg/m2), given on a three-weekly basis for four cycles, followed by weekly paclitaxel (P) (80 mg/m2) for twelve weeks.
89477240|NCT02801617|Experimental|Sequence 1 (PRO-067)|"study subjects will be allocated to receive PRO-067 QD for 30 days, after which they will be crossed over to the other medication (GAAP Ofteno®) for another 30 days. The Intraocular pressure-reducing effect of the medications will be assessed by the reduction in IOP after each medication compared to baseline.~Washout period: 21 hours"
89477241|NCT02801617|Active Comparator|Sequence 2 (GAAP Ofteno®)|"study subjects will be allocated to receive GAAP Ofteno® QD for 30 days, after which they will be crossed over to the other medication (PRO-067) for another 30 days. The Intraocular pressure-reducing effect of the medications will be assessed by the reduction in IOP after each medication compared to baseline.~Washout period: 21 hours"
89477242|NCT02056015|Experimental|[68Ga]MLN6907|
89020367|NCT04848506|Experimental|CK-3773274 up to 20 mg|Patients in this arm take daily dose of CK-3773274. Each patient will start at the lowest prespecified dose and titrate up to their maximum tolerated dose.
89020368|NCT04832724|Experimental|Commercial Formulation Dose 1|Dose 1 of RGX-314
89020369|NCT04832724|Experimental|Clinical Formulation Dose 1|Dose 1 of RGX-314
89020370|NCT04832724|Experimental|Commercial Formulation Dose 2|Dose 2 of RGX-314
89020371|NCT04832724|Experimental|Clinical Formulation Dose 2|Dose 2 of RGX-314
89020372|NCT04832087||Cohort A|Participants with SBS who started Teduglutide after FDA approval (May 2019)
89020373|NCT04832087||Cohort B|Subjects who participated in any of the teduglutide pediatric clinical trial studies (TED-C13-003, TED-C14-006, SHP633-303, or SHP633-304) and subsequently started therapy with teduglutide
89020374|NCT04828018||Key Staff|Key Staff will take part in one interview lasting up to 60 minutes
89020375|NCT04828018||In-Pensioners|Royal Hospital Chelsea In-Pensioners will take part in one interview lasting up to 90 minutes and complete n=2 Quality of Life Questionnaires (ICECAP-A and WHOQOL-BREF) at the start of their qualitative interview.
89020376|NCT04828018||New In-Pensioner|New In-Pensioners wil be asked to complete a total of n=4 Quality of Life Questionnaires (ICECAP-A and WHOQOL-BREF), n=2 on admission to Royal Hospital Chelsea and n=2 six months after admission.
89020377|NCT04820283|Experimental|Care manager intervention (nurse)|
89020378|NCT04820283|Active Comparator|Internet-based CBT|
89020379|NCT04818060||Low Risk of Motor Diagnosis|Approximately 52 participants who have a low probability of motor diagnosis based on the multivariate risk score.
89020380|NCT04818060||High Risk of Motor Diagnosis|Approximately 102 participants who have a high probability of motor diagnosis based on the multivariate risk score.
89020381|NCT04818060||Stage I or II Huntington's Disease|Approximately 52 participants who are living with diagnosed stage I or stage II Huntington's Disease.
89020382|NCT04818060||Healthy Controls|Approximately 52 participants who are age-, ethnicity-, and education-matched healthy controls.
89020383|NCT04806893|Experimental|LIB003 (lerodalcibep)|300 mg subcutaneously monthly (Q4W)
89020384|NCT04806893|Placebo Comparator|Placebo|matching placebo subcutaneously monthly (Q4W)
89020385|NCT04799912|Experimental|Elective labor induction|Elective labor induction via oxytocin between 39 weeks of gestation and 0 day and 39 weeks of gestation and 4 days for women with favorable cervix. Those with an unfavorable cervix (Bishop score < 6) will first undergo cervical ripening (method left to the discretion of the practitioner) in conjunction with or followed by oxytocin stimulation unless a contraindication arises. Except for elective induction of labor between 39 weeks of gestation and 0 day and 39 weeks of gestation and 4 days, the obstetrical management will not be modified compared to routine obstetrical management.
89020386|NCT04799912|No Intervention|Expectant management|Standard follow-up visits until at least 41 weeks of gestation and 0 day without elective labor induction unless a medical indication is present. Antepartum fetal testing will be initiated no later than 41 weeks of gestation and 1 day according to policies at each center (according to the French guidelines). If still pregnant, women will undergo induction at 41 weeks of gestation and 6 days (according to the French guidelines)
89020387|NCT04797247|Experimental|LIB003 (lerodalcibep)|300 mg subcutaneously monthly (Q4W)
89020388|NCT04797247|Placebo Comparator|Placebo|matching placebo subcutaneously monthly (Q4W)
89020389|NCT04797104|Experimental|LIB003 (lerodalcibep)|300 mg (1.2 mL) SC Q4W
89020390|NCT04797104|Placebo Comparator|Placebo|1.2 mL SC Q4W
89020391|NCT04783402|Experimental|e-OTCAT|The experimental group will receive the e-OTCAT program that consists of a 12-week videoconference-based occupational therapy intervention at the same time women with breast cancer receive chemotherapy.
89202796|NCT00750932||T|Control
89202797|NCT00750932||M|Minor with cystic fibrosis
88950488|NCT05409248|Active Comparator|Control Group|Online painting and artistic games designed not to target the specific cognitive skills at test. Activities' duration will match those of the experimental group, and its difficulty will be constant through the intervention.
88950489|NCT05409222||Cohort 1A: preventive salpingo-oophorectomy with hormone replacement therapy|Healthy carriers who decide undergo preventive surgery and opt to have hormone replacement therapy
88950490|NCT05409222||Cohort 1B: preventive salpingo-oophorectomy without hormone replacement therapy|Healthy carriers who decide undergo preventive surgery and reject hormone replacement therapy
88950491|NCT05409222||Cohort 2: without preventive salpingo-oophorectomy|Healthy carriers who decide not to proceed to preventive surgery
88950492|NCT05409209||Carotid plaque length|Patients underwent carotid ultrasonography and first coronary angiography simultaneously
89202798|NCT00750932||A|Adult with cystic fibrosis
89477243|NCT02056093|Experimental|Intubated patients|Intubated patients: The three modes (PSV, PAV, NAVA) will be applied in random order to each mechanically ventilated patient included in the study.
89477244|NCT02056249||Healthy, lean subjects|Volunteers without anemia (hematocrit), diabetes (A1c), use of illicit drugs and antidepressants, or any other major health issues.
89477245|NCT02056327||Oral appliance with monitoring suite|Subjects will sleep with a standard oral appliance with the newly developed monitoring suite embedded within it for 1-2 nights while being monitored with standard in lab polysomnography or home sleep testing.
89477246|NCT04140968|Experimental|Utrogestan|300mg Utrogestan (1 tablet 100mg + 1 tablet 200mg)by mouth,every day in the second and third menstrual cycle daily from cycle day 15 to 26.
89477247|NCT05042804|Experimental|Machine Learning Assistance|Clinicians in the Anesthesia Control Tower will review patient data using the electronic health record and using AlertWatch, and they will also view the machine learning display. They will then predict how likely the patient is to experience postoperative death and postoperative acute kidney injury.
89477248|NCT05042804|No Intervention|No Assistance|Clinicians in the Anesthesia Control Tower will review patient data using the electronic health record and using AlertWatch, but they will not view the machine learning display. They will then predict how likely the patient is to experience postoperative death and postoperative acute kidney injury.
89477249|NCT02896556|Experimental|Resin infiltrate|This is a single-arm study. Resin infiltration technique will be performed to all patients.
89477250|NCT04383938|Experimental|Safety Lead In|Patients with advanced solid tumors. Up to 3 dose levels evaluated.
89477251|NCT04383938|Experimental|Expansion 1|Patients with advanced gastric cancer.
89477252|NCT04383938|Experimental|Expansion 2|Patients with advanced urothelial/bladder cancer.
89477253|NCT04383938|Experimental|Expansion 3|Patients with advanced NSCLC.
89477254|NCT01334515|Experimental|Disease measured by standard radiographic criteria|Treatment (hu14.18-Interleukin 2(IL2) fusion protein and isotretinoin). Patients receive sargramostim (SC [preferred]) or IV over 2 hours on days 1-2 and 8-14, hu14.18-IL2 fusion protein IV over 4 hours on days 4-6, and isotretinoin PO twice daily on days 11-24. Treatment repeats every 28 days for 4-10 courses in the absence of disease progression or unacceptable toxicity. Patients in stratum-1 who achieve stable disease (SD) after course 4 are removed from protocol therapy. Patients in stratum-2 who achieve SD after course 4 receive 2 additional courses of study treatment. Patients may undergo blood and bone marrow sample collection periodically for correlative studies.
89477255|NCT01334515|Experimental|Disease evaluable only by I-MIBG or BM histology|Treatment (hu14.18-Interleukin 2(IL2) fusion protein and isotretinoin). Patients receive sargramostim (SC [preferred]) or IV over 2 hours on days 1-2 and 8-14, hu14.18-IL2 fusion protein IV over 4 hours on days 4-6, and isotretinoin PO twice daily on days 11-24. Treatment repeats every 28 days for 4-10 courses in the absence of disease progression or unacceptable toxicity. Patients in stratum-1 who achieve stable disease (SD) after course 4 are removed from protocol therapy. Patients in stratum-2 who achieve SD after course 4 receive 2 additional courses of study treatment. Patients may undergo blood and bone marrow sample collection periodically for correlative studies.
89477256|NCT02802319|Experimental|Test: Porcine Xenograft (Zcore)|Ridge preservation bone grafting surgery with porcine xenograft (Zcore)
89020392|NCT04783402|Other|Control Group|At the beginning of chemotherapy, the participants allocated to the control group will only receive an educational handbook containing information about most frequent side-effects of cancer and cancer treatments, plus standard care for these patients.
89202799|NCT01055041|Experimental|inhaled budesonide and formeterol plus oral montelukast|1st two weeks -run in period .All three participants prescribed Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day Next 8 weeks- Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day plus tablet montelukast (10 mg/day)orally in the evening
89202800|NCT01055041|Experimental|inhaled budesonide and formeterol plus oral doxophylline|1st two weeks -run in period, all three participants prescribed Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day Next 8 weeks
89202801|NCT01055041|Experimental|Doubling the dose of inhaled budesonide and formeterol|1st two weeks -run in period all the participants prescribed Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day Next 8 weeks- Metered dose inhaler (budesonide 200 mcg /puff + formeterol 6 mcg/puff) two times a day plus metered dose inhaler of budesonide (200 mcg/puff) two times a day
89202802|NCT02561624|Experimental|Intervention|Use of behaviour change communication via text messages to pregnant women receiving an electronic voucher for long lasting insecticide treated nets redemption through antenatal clinics.
89202803|NCT02561624|No Intervention|Control|Control group receives no behaviour change communication via text message, but receives an electronic voucher for long lasting insecticide treated nets redemption through antenatal clinics.
89202804|NCT01060813|Active Comparator|Exercise + Leucine|Patients will receive leucine 10 g/d po + exercise for 3 months
89202805|NCT01060813|Active Comparator|Leucine without exercise|patients will receive leucine 10 g/d po
89202806|NCT00793416|Experimental|ShuntCheck measure|All patients will have ShuntCheck measurements along with radionuclide shunt patency testing.
89202807|NCT00748280|Experimental|1|ORCT
89202808|NCT00748280|Experimental|2|PCEM/PMTA
89202809|NCT00798642|Active Comparator|Hypnotherapy|
89202810|NCT00798642|Placebo Comparator|Standard care|
89202811|NCT00798642|Placebo Comparator|Mind Body Therapy|
89202812|NCT00325819|Active Comparator|Acetaminophen|Children were randomized 1:1 to receive up to five doses of acetaminophen (10-15mg per kg) or placebo following routine vaccinations.
89477257|NCT02802319|Active Comparator|Active Control: Bovine Xenograft (Bio-Oss)|Ridge preservation bone grafting surgery with bovine xenograft (Bio-Oss)
89477258|NCT02053129|Other|HIV negative pregnant women|Pregnant women who are HIV negative attending their first ANC visit
89477259|NCT02053129|Other|HIV positive pregnant women|Pregnant women who are HIV positive accessing antenatal care.
89477260|NCT02415400|Active Comparator|Apixaban|5 mg or 2.5 mg Apixaban tablets orally twice per day
89477261|NCT02415400|Active Comparator|Vitamin K Antagonist|VKA tablets orally once daily
89477262|NCT02415400|Placebo Comparator|Acetylsalicylic acid film coated tablet|81 mg Acetylsalicylic acid film coated tablet orally once daily
89477263|NCT02415400|Placebo Comparator|Placebo matching Acetylsalicylic acid film coated tablet|Placebo matching Acetylsalicylic acid film coated tablet once daily
89477264|NCT02053675|Other|Vasopressin|
89477265|NCT02037997|Experimental|combination with Erlotinib|Erlotinib 150mg qd combination with docetaxel 75mg/m2 or pemetrexed 500mg/m2
89477266|NCT02037997|Active Comparator|sequential chemotherapy for Erlotinib|docetaxel 75mg/m2 or pemetrexed 500mg/m2，after PD，Erlotinib 150mg qd
89477267|NCT02056405|Placebo Comparator|Placebo|Placebo arm: intake of placebo (Lactose). 1 pill of the same characteristics as Mosapride every 8 hs with 30 ml tap water. This will begin on postoperative day 1 until discharge from Hospital or unacceptable toxicity develops.
89477268|NCT02056405|Active Comparator|Mosapride|Mosapride arm: intake of active drug (Mosapride). 15 mg per day divided into 3 oral intakes of 5 mg each (1 pill of Mosapride every 8 hs with 30 ml tap water). This treatment will begin on postoperative day 1 until discharge from Hospital or unacceptable toxicity develops.
89477269|NCT02056483|Experimental|Screening-based nurse navigation|Based on systematic screening for psychological and physical symptoms as well as health behavior a nurse navigator will refer to and monitor use of appropriate rehabilitation programs
89477270|NCT02056483|No Intervention|Usual care|Usual care
89477271|NCT02056561||TIVA (group T n: 15)|Group T were given propofol infusions of 12 mg/kg/hr for the first 10 minutes, 9 mg/kg/hr for the second 10 minutes and 6 mg/kg/hr after that. Patients were ventilated with 50% air and 50% O2 mix at 6 L/min flow.
89477272|NCT02056561||Sevoflurane (group S n: 15)|Group S were ventilated with 2% sevoflurane, 50% air and 50% O2 mix at 6 L/min flow.
89477273|NCT02056561||Desflurane (group D n: 15)|Group D cases were given 6% desflurane 50% air and 50% O2 mix at 6 L/min flow.
89477274|NCT05655637|Experimental|Treatment Group|There will be one group, and study will be Quasi Experimental Study. Treatment will be given to all 28 participants, 3 sessions in a week for 4 weeks. Pre and Post treat-meant evaluation will be checked by CFQR+14. All patients will be treated with exercise program of Active cycle breathing techniques(ACBT), Pursed lip breathing, Endurance Exercise 20 to 30 min ( walking, cycling) and strength training with Thera-Bands (Bilateral arm raising, Bilateral knee extension). Exercise capacity will be measured with 6MWT. Dyspnea and fatigue will be measured with Borg scale.
89477275|NCT02053207|Experimental|Cog-Train Intervention|
89477276|NCT02056717|Experimental|Dexamethasone group|
89477277|NCT02056717|Placebo Comparator|Control group|
89477278|NCT04194801|Experimental|Phase Ib: Fisogatinib (BLU-554) 400mg in combination with Sugemalimab (CS1001) 1200mg|
89477279|NCT04194801|Experimental|Phase Ib: Fisogatinib (BLU-554) 600mg in combination with Sugemalimab (CS1001) 1200mg|
89477280|NCT04194801|Experimental|Phase II: Fisogatinib (BLU-554) 600mg in combination with Sugemalimab (CS1001) 1200mg|
89537528|NCT03065361||Group A|"Group composed of 21 children and adolescents aged between 9 and 19 years old, treated by hemodialysis in two hospitals of Belo Horizonte. Just in case of some evidence of difference in the results within group A, because of the two types of dialysis (via fistula or catheter), this group can be subdivided in subgroups A1 (n=10) and A2 (n=11), respectively.~Group A was already on hemodialysis, the intervention was not performed by the researcher. Our goal was only to evaluate some characteristics of these individuals."
88950493|NCT05409196|Experimental|ShigETEC vaccine|"In Stage 1 subjects will be allocated randomly to one of four study cohorts to receive a single oral dose of one of four escalating dose levels of ShigETEC vaccine (ShigETEC 1x10^9 CFU, ShigETEC 1x10^10 CFU, ShigETEC 5x10^10 CFU, ShigETEC 2x10^11 CFU). 8 subjects per dose group will be administered.~Subjects in Stage 2 will be enrolled sequentially by group and allocated randomly to one of three study cohorts determined from Stage 1 to receive either two, three or four doses of the 5x10^10 ShigETEC vaccine at 3-day interval. 8 subjects per dose group will be administered."
88950494|NCT05409196|Placebo Comparator|Placebo|"In Stage 1: 4 subjects in each dose group will receive a single oral dose of placebo~In Stage 2: 4 subjects in each cohort will either receive 2, 3 or 4 doses of placebo at 3-day intervals."
88950495|NCT05409170||pre-covid group|Each surgical procedure was considered an independent event. , the January 2016-December 2019 and January 2020-December 2021 intervals were defined as pre-COVID and COVID periods, respectively.
88950496|NCT05409170||covid group|Each surgical procedure was considered an independent event. , the January 2016-December 2019 and January 2020-December 2021 intervals were defined as pre-COVID and COVID periods, respectively.
88950497|NCT05409144|Experimental|Thoracic epidural infusion group|Patients will receive thoracic epidural preoperative
88950498|NCT05409144|Experimental|Erector Spinae Plane Block group|Patients will receive Ultrasound-guided Erector Spinae Plane Block preoperative with an injection of 30 ml levobupivacaine 0.25% and insertion of a catheter
88950499|NCT05409144|Experimental|Serratus Anterior Plane Block group|Patients will receive Ultrasound-guided Serratus Anterior Plane Block preoperative with an injection of 30 ml levobupivacaine 0.25%.
88950500|NCT05409092|Experimental|Astaxanthin|The astaxanthin capsules will contain 8 mg of astaxanthin from freshwater algae in starch beadlets. Ingested daily for 4 weeks.
88950501|NCT05409092|Placebo Comparator|Placebo|The placebo capsules will contain just the starch beadlets with natural red coloring from the pitaya fruit. Ingested daily for 4 weeks.
88950502|NCT05409053|Active Comparator|screw fixation|lateral condyle humerus fracture open reduction and internal fixation by canullated screws
88950503|NCT05409053|Active Comparator|k wire fixation|lateral condyle humerus fracture open reduction and internal fixation by K wire
89202813|NCT00325819|Placebo Comparator|Placebo|Children were randomized 1:1 to receive up to five doses of acetaminophen (10-15mg per kg) or placebo following routine vaccinations.
89202814|NCT00751010||1|In a mailed survey (Part 1 of this study), 127 women with a documented diagnosis of IC agreed to be contacted for an in-office examination.
88950504|NCT05409053|Other|Conservative management|Undisplaced fractured treated conservatively by above elbow slab
88950505|NCT05409053|Other|Closed reduction and percutaneous pinning|Undisplaced fractured treated closed reduction and percutaneous pinning
88950506|NCT05407272|Experimental|Shared mode intervention group (experimental group)|Methods of collecting cases The subjects whose identity card numbers last in odd numbers are in the experimental group and even numbers are in the control group. They are randomly divided into two groups - the shared mode intervention group (experimental group) and the home care routine care group (control group). The experimental group was given a weekly sharing mode intervention for six weeks, 20-60 minutes per week; the control group was given the home health education manual in the third week.
88950507|NCT05407272|Active Comparator|home care routine care group (control group)|Methods of collecting cases The subjects whose identity card numbers last in odd numbers are in the experimental group and even numbers are in the control group. They are randomly divided into two groups - the shared mode intervention group (experimental group) and the home care routine care group (control group). The experimental group was given a weekly sharing mode intervention for six weeks, 20-60 minutes per week; the control group was given the home health education manual in the third week.
88950508|NCT05405335|Experimental|Prone Positioned Group|"Intermittent prone positioning for a total of eight hours per day for seven days. Each cycle of prone positioning should not be less than 30 minutes and note more than 3 hours at one time.~Rest of the treatment as per protocols of the institution"
88950509|NCT05405335|No Intervention|Control Group|Treatment as per institutional protocols- the protocols does not involve prone positioning of the patients
88950510|NCT05398952||Long-COVID|Patients with previous COVID-19 disease, and having long COVID symptoms 3 months after the active infection.
88950511|NCT05398952||Post-COVID-19 without long-COVID syndrome|Patients with previous COVID-19 disease, without long COVID symptoms
88950512|NCT05398952||IcMP (positive control)|Patients with ischemic heart disease without COVID-19 disease, and vaccinated at least with one injection
89206266|NCT02549274|Experimental|self-rehabilitation + physiotherapy|Patients will have, in addition to conventional physiotherapy, to visit two training sessions in self-rehabilitation at the hospital. They will then perform a self-rehabilitation / day session.
88950513|NCT05398952||Healthy (negative control)|Healthy individuals without COVID-19 disease, and vaccinated at least with one injection
88950514|NCT05397054|Experimental|Investigator|Education, Reformulation, Environmental change, Used salt meter
88950515|NCT05397054|Active Comparator|Control|standard treatment with standard education
88950516|NCT05395897||New users|Users without any reimbursement for psychotropic drugs before the beginning of the coronavirus crisis.
88950517|NCT05395897||Actual or former users|Users without at least one reimbursement for psychotropic drugs before the beginning of the coronavirus crisis.
88950518|NCT05387278|Experimental|Experimental/treatment arm|
88950519|NCT05387278|Placebo Comparator|Placebo|
89206267|NCT02549274|Active Comparator|physiotherapy|Patients will have only conventional physiotherapy
88950520|NCT05357924|Active Comparator|robotic-assisted laparoscopy|The robotic-assisted resection of endometriosis will be performed using the da Vinci Surgical System Si (Intuitive Surgical) using up to five ports as needed. An umbilical port was placed for the laparoscope (10/12 mm), a 5-mm port for the assistant, and two to three ports (5/8 mm) for the robotic arms.
88950521|NCT05357924|Active Comparator|conventional laparoscopy|Laparoscopic-assisted cystectomy of endometrioma will be performed using up to four 5-mm ports, including an umbilical port and additional ports as dictated by each individual surgery.
89477281|NCT02056795|Experimental|Electroacupuncture|Subjects will do balance assessment in lab. In treatment room, practitioner will clean insertion area with alcohol swab, allow adequate time to dry, and insert 2 Asia-Med Special No 16 (0.30x30mm) needles: one at proximal insertion of fibularis longus anterior to fibular neck, in proximity to common fibular nerve (GB-34); one over sinus tarsi and lateral ligaments of ankle mortise (GB-40). Needles will be inserted approximately 1-2cm, connected for 10 min at 2Hz to electrical stimulation (ITO ES-130, 500 ohm test load, 1 to 500Hz). Needles will disposed of in sharps container. Area will be wiped with long handled cotton swab, pressure will be applied for 2 seconds. Subjects will be asked to slowly get up from table and return to lab for second balance assessment.
89477282|NCT02056795|Sham Comparator|Control|As with experimental group, controls will do balance assessment pre- and post-intervention. Streitberger placebo needles (Asia-Med, 0.03 x 30 mm), blunted with a telescoping mechanism, will be used. Subjects will feel slight prick, and shaft will telescope into handle, creating illusion of skin penetration. Needles will be held in place by plastic ring covered by a bandage. They are validated for blinding. They will be placed over non-traditional acupuncture points on medial aspect of leg, in direct opposition to treatment group needles. Needle placement is not intended to produce therapeutic outcome. The needles will be connected to a wire, which will be turned on for 10 minutes but no stimulation will be felt.
89477283|NCT02802865|Active Comparator|Letrozole|Letrozole 2.5 mg orally for 5 days on cycle days 3-7
89477284|NCT02802865|Experimental|Letrozole + Clomiphene|Letrozole 2.5 mg orally for 5 days on cycle days 3-7 AND Clomid 50 mg orally for 5 days on cycle days 3-7
89477285|NCT02414932|Experimental|Ketamine|Ketamine (ketamine hydrochloride 0.5 mg/kg; Pfizer Healthcare Ireland)) will be made up as a 50 ml colourless saline solution and administered as a slow infusion over 40 minutes using an intravenous infusion pump. A course of up to four once-weekly infusions will be administered. Infusions will be discontinued by the Anaesthetist if there are persisting haemodynamic changes (i.e. heart rate >110/minute or systolic/diastolic blood pressure (BP) >180/100 or >20% increase above pre-infusion BP for more than 15 minutes) that do not respond to beta-blocker therapy.
89477286|NCT02414932|Active Comparator|Midazolam|Midazolam (0.045 mg/kg; Roche Products Ireland Ltd) will be made up as a 50 ml colourless saline solution and administered as a slow infusion over 40 minutes using an intravenous infusion pump. A course of up to four once-weekly infusions will be administered.
89477287|NCT02476929|Active Comparator|Nasal nitrous oxide|Mesurement of Nasal nitrous oxide in all groups: allergic rhinitis, non-allergic rhinitis, nasosinusal polyps and healthy group
89477288|NCT02476929|Active Comparator|Electronic nose|Measurement with the Electronic nose in all groups: allergic rhinitis, non-allergic rhinitis, nasosinusal polyps and healthy group.
89477289|NCT02038387|Experimental|Diet|
89477290|NCT02056951|Active Comparator|Multidisciplinary rehabilitation|The central objective of inpatient multidisciplinary orthopedic rehabilitation (MOR) is to improve functional health with the main focus on restoring and improving work ability. A MOR lasts on average 23 days with a total extent of therapy of 48 hours on average. MOR is provided by a multiprofessional team consisting of physicians, psychologists, sport therapists, physiotherapists, occupational therapists, masseurs, social workers, dieticians and nurses. The interventions are carried out mainly in open groups.
89477291|NCT02056951|Experimental|Interprofessional rehabilitation|The central objective of the interprofessional rehabilitation (PASTOR) is the development of active self-management of chronic non-specific low back pain. PASTOR is matched to the MOR with respect to the total duration and total extent of therapy, the included professions and the interventions dimensions (physical, psychological). The differences between PASTOR and MOR are characterized by, a) an integrative combination of profession related modules within a comprehensive and consistent treatment approach, b) an interprofessional and collaborative teamwork based on profession related modules, c) the use of standardized methods, media and materials by all professions in the therapeutic team d) a highly structured and detailed manual for the entire treatment process. The interventions are carried in fixed groups with eight to twelve participants.
89477292|NCT02057029|Other|BCI Assay Results|The Breast Cancer Index (BCI) is a novel gene expression-based prognostic predictor for ER positive cancers and is provided through a CLIA certified commercial laboratory. It is an RT-PCR assay that can be performed on formalin fixed paraffin embedded sections of archived tissues. Participants will work in concert with a physician to determine future treatment options based on BCI results.
89477293|NCT02555319|Experimental|Transcatheter Pulmonary Valve|Transcatheter Pulmonary Valve (TaeWoong Medical Co., Ltd. Korea)
89477294|NCT02470533|Active Comparator|Transarterial chemoembolization|Chemoembolization will be performed through a transarterial route delivering drug eluting beads, i.e. hydrogel-based microspheres (Biocompatibles UK, Ltd, HepaSphere Biosphere Medical) loaded with the chemotherapeutic agent doxorubicin.
89477295|NCT02470533|Experimental|Stereotactic body radiation therapy|Risk-adapted dose prescription for delivering the highest possible tumor dose not exceeding the maximum dose in 6 fractions of 8-9 Gy, while hepatic normal tissue complication probability (NTCP) < of 5%
89477296|NCT02053987|Experimental|Stroke rehabilitation|
89477297|NCT02053987|No Intervention|Control Group|This group will undergo rehabilitation as per the current stroke rehabilitation pathway.
89477298|NCT02054065|No Intervention|Control|Normal care conditions, no computer-based physician alert.
89477299|NCT02054065|Experimental|CAUTI Decision Support|Decision support aimed at preventing Catheter Associated Urinary Tract Infections (CAUTIs)
88950522|NCT05356520|Experimental|The experimental group|Endoscopic ivor-Lewis operation was performed for siwert type II adenoma at the esophagogastric junction
88950523|NCT05356520|Active Comparator|The control group|Laparoscopic transabdominal enlarged gastrectomy for siwert TYPE II adenoma at the esophagogastric junction was performed
88950524|NCT05334550|Experimental|Intervention group|Allocated to intervention group through randomization process.
88950525|NCT05334550|No Intervention|Control group|Allocated to control group through randomization process.
88950526|NCT05326919||Acute myeloid Leukemia (AML)|"Standard and routine care.~For storage,limited volumes of blood or bone marrow aspirate will be added to usual sampling and stored."
88950527|NCT05326919||Acute lymphoblastic leukemia (ALL)|"Standard and routine care.~For storage,limited volumes of blood or bone marrow aspirate will be added to usual sampling and stored."
89206268|NCT00997750|Experimental|Lornoxicam|Lornoxicam 8mg/day and 12mg/day for 15 days
89477300|NCT02054143|Experimental|Sevoflurane|Sevoflurane was administered to all patients at 1 minimal alveolar concentration (MAC) after the intubation occured until the patient was extubated.
89477301|NCT05313867|Placebo Comparator|Placebo|1 sequence of 10 tablets containing only excipients
89477302|NCT05313867|Experimental|Trace elements|Nutri VX1 in a single dose (1 sequence of 10 tablets). Nutri VX1 is a complex of trace elements with the status of a food supplement.
89477303|NCT02054221|Other|extended myectomy + MVreplacement|"Procedure: extended myoectomy, mitral valve surgery~Will be included in a group of 41 patients with obstructive hypertrophic cardiomyopathy and severe mitral insufficiency. Intraoperatively for all patients will be executed TEE to calculate the volume of excision. All patients will be performed extended myoectomy with full isscheniem subvalvular apparatus and mitral valve replacement.~Evaluation results will be made myoectomy as TEE and direct tensiometer."
89477304|NCT02054221|Other|extended myectomy + MVrepair|"Procedure: extended myoectomy, mitral valve surgery~Will be included in a group of 41 patients with obstructive hypertrophic cardiomyopathy and severe mitral insufficiency. Intraoperatively for all patients will be executed TEE to calculate the volume of excision. All patients will be performed extended myoectomy which supplemented resection and release of the papillary muscles and the mitral valve repair. Results of mitral valve repair will be more appreciated intraoperatively. In case of unsatisfactory MV repair will reconnect the device artificial circulation and mitral valve replacement. There after, patients will be moved to the first group.~Evaluation results will be made myoectomy as TEE and direct tensiometer ."
89477305|NCT02058667|Experimental|Paclitaxel+Initial Radiation+Boost|Paclitaxel twice weekly + Initial Fields Radiation + Boost Radiation (10Gy)
89477306|NCT02470455||Normoglycemic group|25 patients were recruited who were on Atorvastatin and with normal blood glucose and Hb1Ac level.
89477307|NCT02470455||Prediabetic with normal GTT|25 patients were recruited who were on Atorvastatin and with fasting blood sugar level 100-125 mg/dl with normal GTT.
89477308|NCT02470455||Prediabetic with impaired GTT|25 patients were recruited who were on Atorvastatin and with fasting blood sugar level 100-125 mg/dl with impaired GTT.
89477309|NCT02057263|Experimental|Alendronate and Hepatitis B Vaccine|Participants in the experimental arm will receive 4 alendronate doses during their Hepatitis B vaccination course.
89477310|NCT02057263|Experimental|Sugar Pill and Hepatitis B Vaccine|Participants in the experimental arm will receive placebo doses during their Hepatitis B vaccination course.
89477311|NCT02057419||Contraceptive Method|"Protocol 1: 3-month use period for each of 3 contraceptive methods, randomly ordered. intravaginal ring, oral contraceptive pill, spermicide+condom; dosage and frequency as instructed...~Protocol 2: 3-month use period for 1st randomly assigned contraceptive method. At end of use period, user chooses to continue on 1st method or to switch to 2nd randomly assigned method for remaining 3-month use-period."
89477312|NCT02057419||Sexual Lubricant Method|3-month use period for each of 3 sexual lubricant methods, randomly ordered. gel formulation, film formulation, insert formulation; dosage and frequency as instructed
89477313|NCT02058745|Active Comparator|CAU+ (Enhanced Care as Usual)|CAU+ (Enhanced Care as Usual) is defined as the care received from the care recipient's oncologist supplemented by unlimited access to three components of the study website: caregiver guides, links to web-based resources, and a basic friends and family page for the 10 month duration of the study.
89477314|NCT02058745|Experimental|CAU+ and SmartCare|CAU+ (Enhanced Care as Usual) for eight weeks, followed by eight weeks of SmartCare. SmartCare is a web-based, nurse guided intervention for caregivers based on the Representational Approach of symptom management.
89477315|NCT02058745|Experimental|CAU+ and Beating the Blues and SmartCare|CAU+ (Enhanced Care as Usual) and Beating the Blues concurrently for eight weeks, followed by SmartCare for eight weeks. Beating the Blues is an established, web-based, self-directed, cognitive behavioral therapy for managing depressive symptoms.
89477316|NCT05550909|Active Comparator|artesunate-amodiaquine (ASAQ)|Subjects will receive artesunate-amodiaquine (ASAQ) daily for 3 days.
89477317|NCT05550909|Experimental|ASAQ with 0.25mg/kg primaquine (PQ)|Subjects will receive artesunate-amodiaquine (ASAQ) daily for 3 days and a single dose of 0.25mg/kg primaquine (PQ) on the first day of ASAQ treatment.
89477318|NCT05550909|Active Comparator|Artemether-Lumefantrine (AL)|Subjects will receive artemether-lumefantrine (AL) twice daily for 3 days.
89477319|NCT05550909|Experimental|Artemether-Lumefantrine-Amodiaquine (ALAQ)|Subjects will receive artemether-lumefantrine (AL) and amodiaquine (AQ) twice daily for 3 days.
89477320|NCT05550909|Experimental|Artemether-Lumefantrine-Amodiaquine (ALAQ) with 0.25 mg/kg primaquine (PQ)|Subjects will receive artemether-lumefantrine (AL) and amodiaquine (AQ) twice daily for 3 days and a single dose of 0.25mg/kg primaquine (PQ) on the first day of ALAQ treatment.
89477321|NCT02057497||Healthy volunteers|Considered generally healthy based on medical history and physical examination as per discretion of the investigator
89477322|NCT02057497||Type 1 Diabetes|T1DM diagnosed clinically prior to start of trial examinations
89477323|NCT02057497||Type 2 Diabetes|T2DM diagnosis prior to the start of trial examinations
88950528|NCT05326919||High-risk myelodysplastic syndrome (MDS)|"Standard and routine care.~For storage,limited volumes of blood or bone marrow aspirate will be added to usual sampling and stored."
88950529|NCT05326919||Myeloproliferative neoplasm -related myelofibrosis|"Standard and routine care.~For storage,limited volumes of blood or bone marrow aspirate will be added to usual sampling and stored."
88950530|NCT05286502||Adults 18 years old or older|
88950531|NCT05281302|No Intervention|Control patients|Patient receiving no additional treatment to conventional occupational therapy sessions
88950532|NCT05281302|Experimental|left-NMV|"Patient will be equipped with vibratory stimulators during conventional occupational therapy sessions.~Only the left-side NMV vibrator will be activated."
88950533|NCT05281302|Sham Comparator|left-NMV + sham-tDCS|"Patient will be equipped with vibratory stimulators and with electrodes form sham-tDCS during conventional occupational therapy sessions.~Only the left-side NMV vibrator will be activated."
88950534|NCT05281302|Experimental|left-NMV + anodal-tDCS|"Patient will be equipped with vibratory stimulators and with electrodes for tDCS during conventional occupational therapy sessions.~Only the left-side NMV vibrator will be activated."
89206269|NCT03998956|Active Comparator|Circumferential PV isolation|Circumferential PV isolation only
89477324|NCT04008615||Prospective observational cohort|"Every patient referred to pulmonary rehabilitation program will be eligible. They will perform cardiopulmonary exercise testing prior to join rehabilitation program.~During the first session of pulmonary rehabilitation, they will perform 2 6-minute stepper test with a rest of 20 minutes minimum between each test.~For the purpose of this study, patients will be offered to participate in an additional exercise session in which they will repeat the same procedure (two 6-minute stepper test) but but monitoring cardiopulmonary parameters and gaz exchanges using a face mask, a pneumotachograph and a gaz analyser (indirect calorimetry)."
89477325|NCT02054299|Experimental|Drug application|6 treatment periods. On each period one of the following interventions
89477326|NCT05232591||1|GCF samples will be taken from the teeth diagnosed with chronic apical periodontitis
89477327|NCT05232591||2|GCF samples will be taken from the collateral teeth (healthy teeth) of the teeth diagnosed with chronic apical periodontitis.
89477328|NCT02054377|Experimental|Group A (face to face tai chi)|"8 x 1 hour taught individual classes of Tai Chi over 3 months provided by a Tai Chi instructor at the participant's home/convenient location. These focus on 8 core postures. This is in addition to participant's usual routine care. A DVD and booklet to aid home practise will be provided.~Daily home Tai Chi practise for 6 months (home practice encouraged for 5 to 10mins 5 times a week).~At the end of the 9 months, local Tai Chi classes can be recommended if requested."
89477329|NCT02054377|Active Comparator|Group 2 (online tai chi)|"3 months usual routine care.~8 x 1 hour taught individual classes of Tai Chi over 3 months provided over the internet by a Tai Chi instructor. A DVD and booklet to aid home practise will be provided.~Daily Tai Chi home practise for 6 months (home practice encouraged for 5 to 10mins 5 times a week).~At the end of the 9 months, local Tai Chi classes can be recommended if requested."
89477330|NCT03311061|Experimental|DREAMS|"The experimental group will be exposed to the DREAMS curriculum including the supplemental technology based application.It is composed of 10 modules: Introduction; Self Exploration; Healthy Relationships; Adolescent Sexuality; Attitudes and Adolescent Sexual Activity; Consequences of Sex - HIV/STI; Consequences of Sex - Pregnancy; Managing Pressure to Engage in Sexual Activity through the Lens of Social Media; Financial Literacy; Careers; Post secondary Education; Wrap up and Close Out.~The technology app will include curriculum support and additional resources.~Students will have access to the mobile app after the in school programming ends. The intent is for students to have access to portions of the app that deal with self developed goals and progress monitoring for goals, and resource material. This is similar to a student having continued access to a textbook/other class materials."
89537529|NCT03065361||Group B|Group composed of 21 children and adolescents matching age and gender for the Group A participants. The individuals were recruited in schools of Belo Horizonte.
88950535|NCT05262010|Experimental|experiment group|According to the 0, 2, and 6 months immunization program, intramuscular injection of the upper arm deltoid muscle, 3 doses of the experiment vaccine
88950536|NCT05262010|Placebo Comparator|placebo|According to the 0, 2, and 6 months immunization program, intramuscular injection of the upper arm deltoid muscle, 3 doses of the placebo
88950537|NCT05189340|No Intervention|Standard of Care|Patients in the Standard of Care arm will receive pharmacist discharge education via fully in-person education as is currently being done.
88950538|NCT05189340|Experimental|Intervention|Patients in the Intervention arm will have access to pre-recorded educational videos covering key educational points. Patients will also have in-person interaction with pharmacists to address additional questions not covered in the videos.
88950539|NCT05155527|Experimental|Favipiravir plus Ivermectin|Ivermectin 600 mcg/kg once daily for 5 days in combination with Favipiravir for 5-10 days (1,800 mg twice a day in day 1 then 800 mg twice a day for the other days. For BW > 90 kg: 2,400 mg twice a day in day 1 then 1,000 mg twice a day for the other days).
88950540|NCT05155527|Placebo Comparator|Favipiravir plus Placebo|Matching placebo once daily for 5 days in combination with Favipiravir for 5-10 days (1,800 mg twice a day in day 1 then 800 mg twice a day for the other days. For BW > 90 kg: 2,400 mg twice a day in day 1 then 1,000 mg twice a day for the other days).
88950541|NCT05151146|Experimental|ANJ900 in the fasted state|Single dose (1800 mg) of ANJ900
88950542|NCT05151146|Experimental|ANJ900 in the fed state|Single dose (1800 mg) of ANJ900
88950543|NCT05151146|Active Comparator|Metformin IR in the fasted state|Single dose (1000 mg) of metformin IR
88950544|NCT05068063|Experimental|Femoral Triangle + IPACK block|Patients randomized to receive a combination of femoral triangle block and active IPACK block
88950545|NCT05068063|Active Comparator|Femoral Triangle block|Patients randomized to receive a combination of femoral triangle block and sham IPACK block
88950546|NCT05046509||COVID_Patients|"Patients have been confirmed diagnosed with Covid-19 disease by PCR~Patients aged 18 years and above"
88950547|NCT05002452||Locally Advanced HCC Patients|Patients which are diagnosed with locally advanced hepatocellular carcinoma (HCC) will receive standard HAIC treatment.
88950548|NCT04967378|Experimental|HEPPI program|
88950549|NCT04967378|No Intervention|Waiting-list control group|Receives access to HEPPI program at the end of the study.
88950550|NCT04948996|Experimental|El Buen Consejo Móvil- Group (EBCM-G)|Participants in the group condition will be placed in groups of five participants within the app. Their version of EBCM will have the functionality to connect individuals to one another via a facilitator-guided chat room (EBCM-G), where they can respond to suggested strategies within the app and communicate with each other or their facilitator guide using voice or text.
88950551|NCT04948996|Active Comparator|El Buen Consejo Móvil- Individual (EBCM-I)|Participants randomized to EBCM-I will receive the same program contents without the group functionality.
88950552|NCT04935437|Active Comparator|Intervention|The patients in this arm will be enrolled in a 2 months supervised rehabilitation program. Evaluation will take place at recruitment time and at the end of the program (2 months).
88950553|NCT04935437|No Intervention|Control|The patients in this arm will not be enrolled in a supervised rehabilitation program. Evaluation will take place at recruitment and at 2 months.
88950554|NCT04908657|Experimental|Treatment group|treatment group will administrate oral sildenafil 20 mg three times per day for 3 years
88950555|NCT04908657|No Intervention|Control group|the control group will not receive any specific therapy for decreasing the pulmonary vascular resistance
89206270|NCT03998956|Experimental|Circumferential PV and BOX isolation|Circumferential PV and BOX isolation
89020393|NCT04783155|Experimental|12-weeks pulmonary rehabilitation training plus inspiratory muscle training|To assess maximum inspiratory pressure, you will be asked to breathe through a device called POWERBreathe Plus®. This device is commercially available and will be provided to you by the study. You will be asked to use this device twice per day, 5 days per week, for 12 weeks. Each session will require you to breathe into the device 30 times. You can use the device at home.
89020394|NCT04783155|Placebo Comparator|12-weeks pulmonary rehabilitation plus placebo (inactive) inspiratory muscle|To assess maximum inspiratory pressure with placebo, you will be asked to breathe through a device called POWERBreathe Plus®. This device is commercially available and will be provided to you by the study. You will be asked to use this device twice per day, 5 days per week, for 12 weeks. Each session will require you to breathe into the device 30 times. You can use the device at home. The resistance will be set to about 5% throughout the study.
89020395|NCT04782752|Experimental|Experimental: Radiation|"Patients will be differentiated into 4 groups:~Patients with end-stage interstitial lung disease (ILD) and suspected stage I (up to 4 cm) primary lung cancer~Patients with end-stage lung disease other than ILD (e.g. emphysema/COPD, cystic fibrosis and pulmonary hypertension) and suspected stage I (up to 4 cm) primary lung cancer~Patients with multifocal primary lung cancer (e.g. multifocal adenocarcinoma) in the absence of nodal metastasis and distant metastasis.~Patients with isolated pulmonary metastasis in the absence of other sites of malignancy (primary and metastatic).~For this study, different doses will be used for each different group depending on their tumour size. The first 3 patients will start with a dose of 4 Gy, for the ILD group, or 8 Gy, for the non ILD group. The doses are then increased incrementally until the dose limiting toxicity is reached."
89020396|NCT04780568|Experimental|Treatment (osimertinib, tegavivint)|Patients receive osimertinib PO QD on days 1-28 and tegavivint IV on day 1. Treatment repeats every 28 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive osimertinib PO QD on days 1-28. Treatment repeats every 28 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
89020397|NCT04773873|Active Comparator|Arm 1: Porcelain fused to metal (PFM)|Implant screw-retained PFM crown fabricated by a laboratory using a gold coping cast-on synOcta gold abutment (Ceramicor) for wide (WN) or regular (RN) neck
89020398|NCT04773873|Experimental|Arm 2: Hybrid abutment Lithium disilicate (e.max CAD)|Hybrid crown abutment: chairside-made perforated CAD-CAM Lithium disilicate crown (IPS e.max CAD LT A16) adhesively cemented to a TiBase and screw-retained to a Straumann titanium implant (regular and wide neck)
89020399|NCT04773873|Experimental|Arm 3:Hybrid abutment ceramic polymer infiltrated (Enamic)|Hybrid crown abutment: chairside-made perforated CAD-CAM ceramic-polymer infiltrated crown (Enamic) adhesively cemented to a TiBase and screw-retained to a Straumann titanium implant (regular and wide neck)
89020400|NCT04771156|Experimental|Experimental group (Ketorolac)|
89020401|NCT04771156|Placebo Comparator|Control Group|
89020402|NCT04767854|Experimental|OA school + Virtual Training mobile health application|"After a clinical examination by the physiotherapist, all patients will receive a 1-2-hour group session of patient education according to guidelines.~The intervention group will receive an individually tailored exercise program through the Virtual Training mobile health application. After each exercise the patient score his/her execution of the exercise on a Likert-scale of 1 to 5, judging their effort from very poor to very good. After the session, patients rate their pain on a Numeric Rating Scale from 0 to 10. The patients in the intervention group will be instructed to exercise 3 times per week for 6 weeks. If the patients want to exercise more than 3 times per week, the exercise program will be available in the app once every day."
89020403|NCT04767854|Active Comparator|OA school + usual care|"After a clinical examination by the physiotherapist, all patients will receive a 1-2-hour group session of patient education according to guidelines.~The control group will receive individually tailored supervised exercise therapy by a physiotherapist individually or in a group setting, twice a week for 6 weeks. Additionally, the patients will be motivated to perform one session of home exercise a week, a total of 3 sessions per week"
89020404|NCT04754906||young neurotypical subjects|people from 18 to 40 years old
89020405|NCT04754906||elderly neurotypical subjects|people over 55 years of age
89020406|NCT04754906||Elderly subjects with mild cognitive impairment|people over 55 years of age, with a diagnosis of mild cognitive impairment
89020407|NCT04739943|Experimental|Mobile Monitoring|Participants will be asked to use a smartphone or tablet application for remote monitoring or respiratory health. They will be followed over time with surveys as well as chart review to assess effects of adding these mobile monitoring elements to their standard care.
89020408|NCT04738162|Experimental|5-Aminolevulinic Acid (5-ALA)|Application of 5-ALA oral solution followed by fluorescence-guided brain tumor resection
89020409|NCT04717934|Experimental|GAL1906|Experimental product for correction of wrinkles
89020410|NCT04717934|No Intervention|Control|No treatment control
89020411|NCT04666636|Placebo Comparator|Placebo|Participants in the group will receive placebo.
89206271|NCT03998956|Experimental|circumferential PV and BOX isolation with substrate ablation|Atrial substrate ablation apart from circumferential PV and BOX isolation
89020412|NCT04666636|Experimental|Mirabegron|Participants in this group will receive Mirabegron for 16 weeks.
89020413|NCT04636775||Immunotherapy naïve NSCLC patients|Microbiome in immunotherapy naïve NSCLC patients receiving PD-1/L1 blockade
89020414|NCT04629339|Experimental|INCB086550|INCB086550 will be administered orally twice a day.
89020415|NCT04618913||VTE and history of cancer|VTE and history of cancer
89477331|NCT03311061|Active Comparator|Non DREAMS|The control group experience will include health curriculum already adopted by the school district. Continued services as usual. The control group schools, for the most part, lack any formal pregnancy prevention services. All schools claim that lessons developed by the teachers meet the Texas Essential Knowledge Standards (TEKS). No outside services are provided to students and school based services are limited. The services offered at the schools is predominately abstinence based. Students attending the schools would need to initiate any services that are available within the community. The control group will not have access to the DREAMS curriculum or the technology-based application to enhance the DREAMS curriculum. The technology-based application will be a closed, password protected, system during the research trial.
89477332|NCT02038231|Experimental|Parenting Mindfully Program|Mindfulness program for parents of adolescents provided for 2 hours once per week for 8 weeks.
89477333|NCT02038231|Active Comparator|Parent Education Program|Group for parents of adolescents providing handouts and brief education to parents on topics of adolescence, family relations, and risk behaviors. Group meets 3 times over the course of 8 weeks for about 15 minutes per meeting.
89477334|NCT02058823|Placebo Comparator|Arm 1: Real hypoxia and ¨Placebo|This arm last 4 weeks with 2 periods of 2 weeks separated by a 6 weeks wash-out. The subjects of this arm receive the real hypoxia and the placebo during the first two weeks and, after the wash-out, receive the treatment of the arm 2.
89477335|NCT02058823|Placebo Comparator|Arm 2: Hypoxia placebo and Placebo|This arm last 4 weeks with 2 periods of 2 weeks separated by a 6 weeks wash-out. The subjects of this arm receive the hypoxia placebo and the placebo during the first two weeks and, after the wash-out, receive the treatment of the arm 1.
89477336|NCT02058823|Active Comparator|Arm 3: Hypoxia and Valsartan|This arm last 4 weeks with 2 periods of 2 weeks separated by a 6 weeks wash-out. The subjects of this arm receive the real hypoxia and the Valsartan during the first two weeks and, after the wash-out, receive the treatment of the arm 4.
89477337|NCT02058823|Active Comparator|Arm 4: Hypoxia and Amlodipine|This arm last 4 weeks with 2 periods of 2 weeks separated by a 6 weeks wash-out. The subjects of this arm receive the real hypoxia and the amlodipine during the first two weeks and, after the wash-out, receive the treatment of the arm 3.
89477338|NCT00704535||Subjects with hypercholesterolemia|Subjects with hypercholesterolemia that are using Ezetimibe either alone or in combination with a statin
89477339|NCT02290119|Sham Comparator|Control - Without the use of Verasense|Total Knee Replacement without the use of intraoperative sensors
89477340|NCT02290119|Active Comparator|Sensor-assisted TKR (Verasense)|Total Knee Replacement with the use of intraoperative sensors
89477341|NCT03964467|Experimental|Experimental|Transcranial Direct Current Stimulation.1) Scalp measurements of the scalp will be taken using the 10-20 EEG measurement system to determine anode and cathode placement. 2) One 1x1 Bicarbon electrode with wires attached will be placed in the center of each 5 cm x 7 cm sponge electrode dampened with 8 ml of saline. 3) One sponge electrode will be placed over the ipsilesional PMd (F3) and the other sponge electrode over the contralesional supraorbital region(Fp2). 4) Each sponge electrode will be secured under the plastic EZ strap 5) The current from the Actividose II will be turned up to 2 MA. The current will ramp up/down in 15 seconds. We will observe for adverse effects and hit the pause button, then turn the machine off, if a participant does not tolerate the stimulation. Individuals in this arm will have the stimulation stay in current until the full dose is delivered. Each participant will then engage in the UE TRT as outlined below.
89537530|NCT03064191|Active Comparator|calcium hydroxide chlorhexidine|intervention: calcium hydroxide chlorhexidine combination an intra-canal medication composed of calcium hydroxide powder and chlorhexidine solution as a combination to be administered as intra-canal paste for decreasing postoperative symptoms
89206272|NCT00622908|Experimental|ISV-403|ISV-403 0.6%
89537531|NCT03064191|Active Comparator|calcium hydroxide|intervention: calcium hydroxide an intra-canal medicament composed of calcium hydroxide paste for decreasing postoperative symptoms and signs .
89020416|NCT04618913||VTE and active cancer|VTE and active cancer
89020417|NCT04618770|Other|Triathlon PSR Tibial Insert|Cases receiving a Triathlon Total Knee with the Triathlon PSR Tibial Insert
89020418|NCT04612738|Active Comparator|Group 1:Advance care planning conversation game, 'Hello'|"The 'Hello' game is a commercially available serious game that consists of 32 questions prompting players to share their values, goals, and beliefs about end-of-life issues. The game is played with 4 - 5 players, with each receiving a game booklet and chips. A play reads the first question in the book. Then each player writes down their answers individually and takes turns sharing their answers with the group. Players control what they share, how long they share and when to move to the next questions. During the conversation, plays can acknowledge others for a thoughtful, poignant or even funny comments by giving them a chip. A pre-game coin flip determines whether the player with the most chips wins the game (heads) or player with the least chips win (tails) the game.~Other names; previously name My Gift of Grace"
89020419|NCT04612738|Active Comparator|Group 2: The Conversation Project (CP) Starter Kit|The 'CP Starter Kit' (available for free online) is an 11-page workbook with open- ended prompts to consider one's values and preferences for end-of-life care, who to talk with about one's wishes, and suggestions on how to do so.
89020420|NCT04612738|Placebo Comparator|Group 3: Control Arm (Placebo control game, 'Table Topics')|A placebo/attention control l conversation game called 'Table Topics' will be used. Table Topics is a general conversation starter game that is unrelated to advance care planning. It involves answering open-ended questions in a group setting about a variety of topics.
89020421|NCT04608552|Active Comparator|Active Myofunctional Therapy|Active Myofunctional Therapy is comprised of five 30-minute weekly sessions for 4 weeks.
89020422|NCT04608552|Sham Comparator|Inactive Myofunctional Therapy|Sham MT will be comprised of recommendations for five 30-minute nasal breathing exercises each week, use of nasal lavage with application of 10ml of saline in each nostril two times per day.
89206273|NCT00622908|Placebo Comparator|Vehicle|Vehicle of ISV-403
89206274|NCT00997828|Experimental|everolimus-eluting stent|everolimus-eluting stent
89477342|NCT03964467|Sham Comparator|Control|Individuals in this arm will have the stimulation cycled off after 2-3 minutes. All will be part of the Circuit-Based, UE Task Related Training. Each participant will engage in the training program for 1.5 hours; rotating through 5 stations at about 15 minute intervals, participating in standing as tolerated, but stations can be adapted to sitting. The goal is for each participant perform > 225 movements with the affected arm per session, at the highest functional level. Rest breaks given as needed. Examples of stations are: Reach-to-grasp tasks to objects of various weight, texture and dimension at different distances and table heights. Practice opening simulated locks and containers. Shoulder wheel involving grasping plastic plates with varied grip patterns and sliding them up and over the wheel from the unaffected to the affected side encouraging shoulder abduction, external rotation and supination. Bimanual/unimanual ball toss: catching, releasing.
88950556|NCT04887389|Experimental|Group of • Nano Silver Fluoride varnish ( NSF)|"Selected children will be divided randomly into three groups:~Group 1: Children receiving Nano Silver Fluoride varnish (NSF) (n =50)."
88950557|NCT04887389|Experimental|group of Nano hydroxyapatite varnish (n-HAP)|Group 2 Children receiving Nano-hydroxyapatite varnish (n = 50)
88950558|NCT04887389|Experimental|group of Sodium Fluoride Varnish (NaF)|Group 3: Children receiving Sodium Fluoride Varnish (n = 50)
89477343|NCT02058901|Experimental|Sunitinib high dose, weekly schedule|Initial dose of sunitinib is set at 200 mg once weekly. Three patients are treated at the current dose level. If at least 2 patients are observed to have Dose Limiting Toxicity (DLT), the prior dose level is defined as the Maximum Tolerated Dose (MTD) (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 patients are observed to have DLT, the dose level is escalated one step for the next cohort of 3 patients. If exactly 1 of the 3 patients treated show DLT, 3 additional patients are treated at the current dose level. If none of these show DLT, the dose level is escalated for the next cohort of 3 patients; otherwise, the prior dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). A tentative MTD becomes final when a total of 6 patients are treated with less than 2 showing DLT
89477344|NCT02058901|Experimental|Sunitinib high dose, biweekly schedule|When the final MTD is reached for the cohort of patients treated once weekly and depending on the toxicities developed and defining MTD, enrollment of patients in the once every 2 weeks escalation cohort will begin, with the initial dose set at the MTD dose of the once weekly schedule, escalating again at 100 mg increments per dose level.
89477345|NCT02057731||Ia carriers|Carriers of GSD type Ia will have their blood and urine tested to measure markers of GSD. Their saliva will be tested to determine their specific mutation. A questionnaire will also be filled out.
89477346|NCT02057731||Ib carriers|Carriers of GSD type Ib will have their blood and urine tested to measure markers of GSD. Their saliva will be tested to determine their specific mutation. A questionnaire will also be filled out.
89477347|NCT02057731||III carriers|Carriers of GSD type III will have their blood and urine tested to measure markers of GSD. Their saliva will be tested to determine their specific mutation. A questionnaire will also be filled out.
89477348|NCT02057731||0, VI, IX carriers|Carriers of GSD types 0, VI, and IX will have their blood and urine tested to measure markers of GSD. Their saliva will be tested to determine their specific mutation. A questionnaire will also be filled out.
89477349|NCT02057731||Noncarriers|Noncarriers of any type of GSD will have their blood and urine tested to measure markers of GSD. Their saliva will be tested to ensure their noncarrier status. A questionnaire will also be filled out.
89477350|NCT02038465|Other|patient|Complete questionary remembering the day
89477351|NCT02038465|Other|healthy volunteers|- Complete questionary, remembering the day
88950559|NCT04836325|Experimental|Experimental: transcranial static magnetic field stimulation (tSMS)|The intervention group will receive a treatment of Transcranial Static Magnetic Field Stimulation (tSMS) in the primary motor cortex with a duration of 30 minutes, 5 times a week, during 4 weeks, for a total of 20 sessions.
88950560|NCT04836325|Sham Comparator|Sham transcranial static magnetic field stimulation|The placebo group will receive a dummy treatment with a duration of 30 minutes, 5 times a week, during 4 weeks, for a total of 20 sessions.
88950561|NCT04816734|Experimental|Parents|Parents of children in need of home parenteral nutrition and participating in initial therapeutic education program of Necker-Enfants Malades hospital.
89206275|NCT00997828|Active Comparator|coronary artery bypass graft surgery|coronary artery bypass graft surgery
88950563|NCT04747808|Experimental|LL-BMT1|Group 4 extended-wear contact lens printed with bimatoprost
88950564|NCT04724655|Other|control group|gastric lavage with saline and bicarbonate and standard treatment :inotropes as levophid, fluids and electrolytes , endotracheal intubation, mechanical ventilation and antiarrhythmic agents as Magnesium sulfate
88950565|NCT04724655|Active Comparator|paraffin group|gastric lavage with paraffin oil and bicarbonate and standard treatment :inotropes as levophid, fluids and electrolytes , endotracheal intubation, mechanical ventilation and antiarrhythmic agents as Magnesium sulfate
88950566|NCT04724655|Active Comparator|coconut group|gastric lavage with coconut oil and bicarbonate and standard treatment :inotropes as levophid, fluids and electrolytes , endotracheal intubation, mechanical ventilation and antiarrhythmic agents as Magnesium sulfate
88950567|NCT04722835||Normal RV/TLC Group:|Plethysmographic RV/TLC equal or less than lower limit of normal.
89477352|NCT02058979|Active Comparator|BOLUS INFUSION|Bolus infusion of antibiotics
88950568|NCT04722835||Abnormal RV/TLC Group:|Plethysmographic RV/TLC higher than lower limit of normal.
88950569|NCT04669743|Experimental|Study Population|Subjects will be recruited and consented following screening. Subjects will be characterized into cohorts based on presence of COPD and smoking status. All subjects enrolled will be undergoing the same interventions: 1st Bronchoscopy (3 wks pre-exposure), Ozone Exposure, 2nd Bronchoscopy (1 day post-exposure), 3rd Bronchoscopy (5 days post-exposure). Ozone exposure will take place in an exposure chamber.
88950570|NCT04655625|Experimental|Group A (AG-0302-COVID19)|
88950571|NCT04655625|Placebo Comparator|Group A (Placebo)|
88950572|NCT04655625|Experimental|Group B (AG-0302-COVID19)|
88950573|NCT04655625|Placebo Comparator|Group B (Placebo)|
89477353|NCT02058979|Experimental|CONTINUOUS INFUSION|Continuous infusion of antibiotics by way of infusion pump
89477354|NCT02057809||Parent-child dyad|Children with Developmental Disabilities and their parents
89477355|NCT02057809||Therapits|Therapists experienced in serving children with developmental disabilities
89477356|NCT01915797||Patient having a cancer and abnormal development|Patient having developed a cancerous pathology and presenting one or several anomalies of the development.
89477357|NCT02059369|Active Comparator|CFAE ablation|Intervention: Complex fractionated atrial electrograms (CFAE) Ablation
89477358|NCT02059369|Active Comparator|CFAE + Lines|CFAE Ablation followed by linear lesions (anterior and Roof line)
88950574|NCT04647734|Experimental|High intensity interval training|The experimental group will on top of standard care undergo a 12 weeks supervised exercise high intensity interval exercise training on an ergometer bike three times a week for 38 minutes. The specific intervals will be determined from our ongoing pilot study (NCT04549337)
88950575|NCT04647734|Active Comparator|Control group|This group will be allocated to standard care and therefore no supervised exercise regimen.
89477359|NCT03310827|Experimental|Personalized Nutrition|Participant receives gene test results with diet plan (personalized nutrition)
89020423|NCT04599296|Active Comparator|Hip Brace|This group will be assigned to wear a hip brace post surgery.
89477360|NCT03310827|Placebo Comparator|Gene Test Report Only|Participant receives standard diet plan
89020424|NCT04599296|No Intervention|No Intervention|This group will not be assigned a hip brace after surgery.
89206276|NCT02548338|Other|electric scalpel (ES)|Breast surgery is performed using regular electric scalpel
89477361|NCT02057887|Experimental|Cohort1|HM10660A SC once weekly
89020425|NCT04588792|Experimental|Inhaled Furosemide|40 mg furosemide per dose, given by nebulization (4 mL of 10 mg/mL furosemide in 0.9% saline solution) over 30 mins four times daily (Q6H) for up to 28 days
89020426|NCT04588792|Placebo Comparator|Nebulized Saline|Placebo, given by nebulization (4 mL of 0.9% saline solution) over 30 mins four times daily (Q.I.D.) for up to 28 days
89020427|NCT04576377|Experimental|Influenza vaccination|
89020428|NCT04576377|Placebo Comparator|Placebo|
89020429|NCT04568603|Experimental|Methadone + ISL|Methadone-maintained participants (20 to 200 mg [locally-provided] once daily [QD] from Day -14 to Day -1 and Day 10 to Day 15) receive methadone 20 to 200 mg QD on Day 1 to Day 9; ISL 60 mg is co-administered with methadone on Day 2.
89477362|NCT02057887|Experimental|Cohort2|HM10660A SC once every 2 weeks
89477363|NCT02057887|Experimental|Cohort3|HM10660A SC once every 4 weeks
89477364|NCT02057887|Active Comparator|Cohort4|180 mcg Pegasys SC once weekly
89477365|NCT03108417|Experimental|cNEP|continuous negative external pressure will be used nightly by all participants
89477366|NCT03561337|Experimental|PROTEIN-CARBOHYDRATE|Intervention group receiving protein and carbohydrate supplement
89477367|NCT03561337|Placebo Comparator|CARBOHYDRATE|Intervention groups receiving carbohydrate supplement
89477368|NCT01740687||Essure+NovaSure|The group of women relying on Essure micro-inserts for permanent birth control when NovaSure is performed following a successful Essure Confirmation Test
89477369|NCT03893955|Experimental|Dose Escalation Arm A: ABBV-927 + ABBV-368 Solid Tumors|Participants with Solid Tumors will receive various doses of ABBV-927 by intravenous (IV) infusion plus ABBV-368. This will determine the recommended phase two dose (RP2D) of ABBV-927.
89477370|NCT03893955|Experimental|Dose Escalation Arm B: ABBV-927 + ABBV-368 + ABBV-181 NSCLC|Participants with non-small-cell-lung-cancer (NSCLC) will receive ABBV-927 IV at various dose levels + ABBV-368 + ABBV-181. This will determine the recommended phase two dose (RP2D) of ABBV-927 + ABBV-368 + ABBV-181.
89477371|NCT03893955|Experimental|Dose Expansion Arm 1: ABBV-927 + Carboplatin + ABBV-368 TNBC|Participants with Triple Negative Breast Cancer (TNBC) will receive ABBV-927 (at the RP2D established in Arm A) + Carboplatin + ABBV-368 by IV.
89477372|NCT03893955|Experimental|Dose Expansion Arm 2: ABBV-927 + Carboplatin + ABBV-181 TNBC|Participants with TNBC will receive ABBV-927 (at the RP2D established in Arm A) + Carboplatin + ABBV-181 by IV.
89477373|NCT03893955|Experimental|Dose Expansion Arm 3: ABBV-927 + Carboplatin TNBC|Participants with TNBC will receive ABBV-927 (at the RP2D established in Arm A) + Carboplatin by IV.
89477374|NCT03893955|Experimental|Dose Expansion Arm 4: ABBV-927+ Nab-paclitaxel + ABBV-368 TNBC|Participants with TNBC will receive ABBV-927 (at the RP2D established in Arm A) + Nab-paclitaxel + ABBV-368 by IV.
89477375|NCT03893955|Experimental|Dose Expansion Arm 5: ABBV-927 + ABBV-368 + ABBV-181 NSCLC|Participants with NSCLC will receive ABBV-927 (at the RP2D established in Arm B) + ABBV-368 + ABBV-181 by IV.
89477376|NCT02648204|Experimental|Semaglutide 0.5 mg/Week|
89477377|NCT02648204|Experimental|Semaglutide 1.0 mg/Week|
89477378|NCT02648204|Active Comparator|Dulaglutide 0.75 mg/Week|
89477379|NCT02648204|Active Comparator|Dulaglutide 1.5 mg/Week|
89477380|NCT05232513|Experimental|Hand massage group|The group that received hand massage for 10 minutes before cataract surgery
89477381|NCT05232513|No Intervention|Control group|standard care group
89477382|NCT03310749|Other|Treatment sequence A|Gemigliptin 50 mg q.d. during 7 days, metformin 1000 mg twice a day during 7 days and gemigliptin 50 mg q.d + metformin 1000 mg twice a day during 7 days.
89477383|NCT03310749|Other|Treatment sequence B|Gemigliptin 50 mg q.d + metformin 1000 mg twice a day during 7 days, gemigliptin 50 mg q.d. during 7 days, metformin 1000 mg twice a day during 7 days
89477384|NCT03310749|Other|Treatment sequence C|Metformin 1000 mg twice a day during 7 days, gemigliptin 50 mg q.d + metformin 1000 mg twice a day during 7 days, gemigliptin 50 mg q.d. during 7 days
89477385|NCT03310671||CASES|"Cases:~Age ≥ 65 years at the time of cardiac ultrasound~Genetically diagnosed HFH or in a first-degree relative~History of hypercholesterolemia with LDLc levels> 220 mg / dL without lipid-lowering treatment"
89477386|NCT03310671||Controls|"Genetically Similar~Siblings of the normocholesterolemic case, defined by LDLc <190 mg / dl without lipid-lowering treatment.~In the absence of available siblings, first cousins may be included.~In the presence of several siblings available, the same sex will be included,~Environmentally similar~Stable partner of the case with cohabitation> 25 years"
89477387|NCT02470221||Goal-directed fluid therapy|The fluid in group Goal-directed fluid therapy will be administered based upon real-time monitoring stroke volume variation and cardiac output achieved by the Flo-Trac monitoring system.
89477388|NCT02470221||Conventional fluid therapy|The fluid in group Conventional fluid therapy will be administered based on the principle crystalloid solution: colloid solution =2-3:1. The total volume of fluid will be adjusted in accordance with blood pressure, heart rate and urine output of each patient.
89537532|NCT03957915|Experimental|INA03|INA03 administration
89537533|NCT05291871|Experimental|IM Bivalent HPV vaccine|One-fifth fractional dose (0.1 ml) of bivalent HPV vaccine administered intramuscularly
89537534|NCT05291871|Experimental|ID Bivalent HPV vaccine|One-fifth fractional dose (0.1 ml) of bivalent HPV vaccine administered subcutaneously
89537535|NCT05291871|Experimental|IM Nonavalent HPV vaccine|One-fifth fractional dose (0.1 ml) of nonavalent HPV vaccine administered intramuscularly
89537536|NCT05291871|Experimental|ID Nonavalent HPV vaccine|One-fifth fractional dose (0.1 ml) of nonavalent HPV vaccine administered subcutaneously
89020430|NCT04561544|Experimental|Intervention in Fall 2020|Participants will receive the intervention in Fall 2020
89020431|NCT04561544|Other|Intervention in Spring 2021|Control in Fall 2020
89206277|NCT02548338|Other|argon plasma coagulation (APC)|Breast surgery is performed using argon plasma coagulation scalpel
89206278|NCT00827424|Experimental|1|This arm will receive Lifestyle counseling by applying a modified PACE protocol
89206279|NCT00827424|No Intervention|2|Subject in this arm will be recruited but will receive no intervention
89020432|NCT04554940|Experimental|Vosoritide + Standard of Care|Standard of Care treatment for cervicomedullary compression and once daily subcutaneous injection of recommended dose of vosoritide based on weight-band dosing.
89477389|NCT02799745|Active Comparator|Enzalutamide|Participants received 160-milligrams (mg) enzalutamide administered as four 40-mg capsules, orally once daily for 1 year of treatment period. Following the 1-year treatment period, all participants were followed for 1 additional year. Post the 1-year follow-up period, participants then started the continued follow-up period, in which, participants were followed up every 3 months for these 2 years, after which follow-up was either every 6 months up to 36 months or until the end of study (total duration of follow up in the study was approximately up to 35.9 months).
89020433|NCT04554940|No Intervention|Standard of Care Alone|Institutional standard of care monitoring and treatment for cervicomedullary compression
89020434|NCT04554147|Experimental|FAITH! App-enhanced Hypertension Intervention|"FAITH! HTN App: The program promotes HTN self-management through a 10-week education module series on HTN. Participants will follow each module weekly and use a wireless home BP monitor for self-tracking which syncs to the app. The app includes module quizzes, a BP tracking dashboard and a moderated sharing board to foster discussion on HTN management.~Patient-Provider-CHW ICM. The patient-provider-CHW triad works together for personalized, collaborative goal setting. The patient will complete app modules, self-monitor BP, and engage with a sharing board integrating HTN topics. At weekly virtual visits (telephone or video), the CHW will record patient BPs, assist with addressing social determinants of health (SDOH) identified by the patient (eg, local community resources), and review HTN modules. The CHW will upload clinical/SDOH data to the patient electronic medical record (EMR) for FQHC care providers to review. This cycle will be completed weekly over the 10-week intervention."
89477390|NCT02799745|Other|Active Surveillance (AS)|Participants did not receive any study treatment in this arm but were on continued active surveillance (AS) for 1 year of treatment period. Following the 1-year treatment period, all participants were followed for 1 additional year. Post the 1-year follow up, participants then started the continued follow-up period, in which, participants were followed up every 3 months for these 2 years, after which follow-up was either every 6 months up to 36 months or until the end of study (total duration of follow up in the study was approximately up to 35.9 months).
89477391|NCT00949221|Other|Group 1|monitor Paradigm 754 VEO, MINILINK Real Time, Medtronic, CE: Continuous glucose monitoring for 3 months, then conventional blood glucose self-monitoring for 9 months
89020435|NCT04553549||Transradial approach|"The procedure will be done using standard criteria as per operator preference. All interventional cases at our institution undergo a radial first approach, meaning that the access site of choice is the radial artery. The investigators will measure the radial artery size to ensure that the artery is greater than 2.4 mm in order to use the Infinity catheter (8Fr)."
89020436|NCT04552873|Experimental|EXPERIMENTAL GROUP|the experimental group will be treated during 5 days by urea dose per administration : 1g / kg / 24 hours in 2 or 3 doses morning, noon and evening (dose adjustment of urea according to weight)
89020437|NCT04552873|Placebo Comparator|CONTROL GROUP|the control group will be treated during 5 days by ergytonyl dose per administration : 5mL
89020438|NCT04544709|Other|Discogenic Low Back Pain|Patient with Refractory Discogenic Low back pain who will be scheduled for platelet rich plasma injection as standard of care.
89020439|NCT04535921||Prostatectomy|FCR7 questionnaire pre and postoperative
89020440|NCT04535921||Cystectomy|FCR7 questionnaire pre and postoperative, 6 months follow
89477392|NCT00949221|Other|Group 2|monitor Paradigm 754 VEO, MINILINK Real Time, Medtronic, CE: Intensive strategy using continuous glucose monitoring for 12 months
89477393|NCT00949221|Other|Group 3|monitor Paradigm 754 VEO, MINILINK Real Time, Medtronic, CE: Intermediate strategy using continuous glucose monitoring for 3 months, then discontinuous use of the device for 9 months (approximately 40% of the time, alternating with conventional blood glucose self-monitoring).
89477394|NCT00658671|Experimental|1|Dose-escalation
89477395|NCT00658671|Experimental|2|Advanced cancer, excluding patients with colorectal or ovarian cancers
89020441|NCT04535921||Nephrectomy|FCR7 questionnaire pre and postoperative
89020442|NCT04535921||Orchidectomy|FCR7 questionnaire pre and postoperative
89020443|NCT04532515|Experimental|Seal G / Seal-G MIST|"Seal-G Surgical Sealant [Seal-G]- will be applied on colonic anastomosis created by extra-corporal approach.~Seal-G MIST System [Seal-G MIST]- will be applied on colonic anastomosis created by intra-corporal approach."
89020444|NCT04528732|No Intervention|Usual Care|Usual care consists of the traditional clinic intervention that focuses on testing services, ART treatment, and information about disease management.
89020445|NCT04528732|Experimental|Group-Cognitive Behavioral Therapy (G-CBT)|G-CBT consists of 10-session for HIV/AIDS-associated stigma, utilizing core components of CBT, including psychoeducation, cognitive restructuring, and skill-building to increase adaptive coping mechanisms.
89206280|NCT04095065|Experimental|itMatters|Participants will have access to content focused on general knowledge and injunctive and descriptive norms for a period up to 3 weeks.
89477396|NCT00658671|Experimental|3|Recurrent or resistant epithelial ovarian cancer
89477397|NCT00658671|Experimental|4|Colorectal cancer patients who have progressed and/or failed on irinotecan- and oxaliplatin-based regimens
89477398|NCT02057965|Active Comparator|Mesenchymal Stromal Cells + Everolimus|"Intervention: two doses of autologous bone marrow (BM) derived Mesenchymal Stromal Cells IV, 7 days apart, 6 and 7 weeks after transplantation in combination with Certican® (1.5mg/day). Doses of MSCs will be 1-2x10^6 million MSCs per/kg body weight.~At the time of the second MSC infusion tacrolimus will be withdrawn in 2 weeks (after 1 week dose of tacrolimus wil be halved, after 2 weeks stopped)"
89477399|NCT02057965|No Intervention|Everolimus + Tacrolimus|Patients in the control group will receive Certican® (1.5 mg b.i.d.) and standard dose tacrolimus (through levels 6-8 ng/ml after 6 weeks).
89020446|NCT04528732|Experimental|Multiple Family Group (MFG)|MFG consists of 10-sessions that strengthen family relationships intended to address HIV/AIDS-associated stigma at the individual level and within families. The core components of MFG are known as 4Rs and 2S's: rules, responsibility, relationships, respectful communication, stress and social support.
89020447|NCT04523207|Experimental|Apalutamide + Androgen Deprivation Therapy (ADT)|In the main study, participants will receive apalutamide 240 milligram (mg) once daily orally along with ADT for 12 cycles (Each cycle is of 28 days). Participants who enrolled in the sub-study will receive apalutamide 240 mg once daily along with relugolix (a type of ADT) 120 mg once daily following a loading dose of 360 mg relugolix orally. Sub-study participants will be receiving relugolix up to Day 28 after which they will be transitioned into the main study from Cycle 2 Day 1 and will continue to receive conventional or oral ADT.
89477400|NCT05304884|Active Comparator|single dose ozone|Group 1 received a single dose ozone injection (n:36)
89477401|NCT05304884|Active Comparator|three doses of ozone|Group 2 (n:36) received three doses of ozone injection (n :36).
89477402|NCT05304884|Active Comparator|corticosteroid|Group 3 (n:36) was treated with a corticosteroid injection
89477403|NCT03310593|Experimental|Cannabidiol|Cannabidiol 150-300mg per day for 12 weeks.
89477404|NCT03310593|Placebo Comparator|Placebo|Cannabidiol comparator for 12 weeks.
89477405|NCT02054455|Placebo Comparator|PPI and placebo|Patients will receive PPI and placebo for 3 days/week for 6 months
89477406|NCT02054455|Active Comparator|PPI and Lactobacillus paracasei F19|Patients will receive Lactobacillus paracasei F19 in a dose of 25x10E9 live bacterial cells for 3 days/week for 6 months
89477407|NCT02054455|Active Comparator|PPI and Lactobacillus paracasei F19 cross-over 1|Patients will receive placebo 3 days/week for the first three months and Lactobacillus paracasei F19 in a dose of 25x10E9 live bacterial cells for 3 days/week for the following three months
89477408|NCT02054455|Active Comparator|PPI and Lactobacillus paracasei F19 cross-over 2|Patients will receive Lactobacillus paracasei F19 in a dose of 25x10E9 live bacterial cells for 3 days/week for the first three months and placebo 3 days/week for the following three months
89477409|NCT04878536|Placebo Comparator|Placebo drink|
89477410|NCT04878536|Experimental|Collagen drink|
89477411|NCT03310515||HIV-1 uninfected high risk subjects|The study will involve HIV-1 uninfected high risk MSM and TGW subjects. They will receive comprehensive prevention package including HIV and safe sex counseling, provision of condoms and water-based lubricant, and STI screening and referral for treatment. Visits will include Baseline screening for HIV followed by screenings at Day 1, Weeks 5, 9, and 8 week intervals thereafter until study conclusion. Screening for other STIs will occur at Baseline, Week 9, and every 16 weeks thereafter.
89477412|NCT02054533||IBD patients|patients with IBD undergoing intra-abdominal surgery
89477413|NCT02054611|Active Comparator|Educational Module First|Respondents will complete the online educational module first, followed by the evaluation
89477414|NCT02054611|Placebo Comparator|Evaluation First|Respondents will complete the the evaluation first, followed by the online educational module
89477415|NCT03310437||Primary PCI|In primary PCI we use arterial sheath , wires ,heparin ,intracoronary stents
89477416|NCT03310437||Thrombolytic|In patients recieving thrombolytics they continue on LWMH for 72h ,plus aspirin , clopedogril , BB, statins
89477417|NCT05304650|Other|iTEAR100 Therapy|Treatment Arm. Assessment of usability of generation 2 connected devices
89477418|NCT02260141|Experimental|Treatment with d-ribose|Treatment with ribose 5 gm TID
89477419|NCT05304338|Active Comparator|Chlorhexidine|
89020448|NCT04505540|Experimental|Bridge Clinic|Medication assisted treatment supervised by addiction bridge clinic until stabilized in treatment.
89020449|NCT04497870|Active Comparator|540 mg|Peppermint oil at a dose of 180 mg thrice daily orally
89020450|NCT04497870|Experimental|900 mg|Peppermint oil at a dose of 180 mg five times daily orally
89020451|NCT04482582|Experimental|Image-guided percutaneous ICN (pICN): Group A|Patients who were admitted after a traumatic injury, with rib fractures identified, who are >= 65 years of age will be randomized to percutaneous image-guided cryoneurolysis (pICN) group within 72 hours of presentation.
89020452|NCT04482582|Active Comparator|Standard-of Care : Group B|Patients who were admitted after a traumatic injury, with rib fractures identified, who are >= 65 years of age will be randomized to standard-of-care group within 72 hours of presentation.
89020453|NCT04467437|Active Comparator|Intensive Training Only|Physical and gait training that targets rehabilitation of walking function.
89020454|NCT04467437|Active Comparator|Intensive Training Combined with Spinal Stimulation|Transcutaneous spinal stimulation combined with physical and gait training that targets rehabilitation of walking function.
89477420|NCT05304338|Experimental|Coconut Oil|
89477421|NCT05304338|Experimental|Black Cumin Oil|
89477422|NCT05304338|Experimental|Terebinth Oil|
89477423|NCT05304338|Placebo Comparator|Distilled Water|
89477424|NCT02059447|Experimental|Mindfulness Based Cognitive Therapy|An 8 week course of Mindfulness Based Cognitive therapy
89477425|NCT02059447|Active Comparator|Relaxation Therapy|An 8 week course of Relaxation Therapy.
89477426|NCT03314103|Experimental|Vaccine|live attenuated varicella-zoster virus vaccine (with live virus >=4.3 LgPFU per dose)
89477427|NCT03314103|Placebo Comparator|Placebo|Placebo with no live virus
89477428|NCT02058121|Experimental|Acceptance and Commitment Therapy|
89477429|NCT02058121|Active Comparator|Treatment as usual|
89477430|NCT02058199|Experimental|normal subjects|A single dose of 10 mg of rivaroxaban will be administered
89477431|NCT02058199|Experimental|Obese non bypassed|A single dose of rivaroxaban will be administered
89477432|NCT02058199|Experimental|obese bypassed|A single dose of rivaroxaban will be administered
89020455|NCT04458272|Experimental|DS-1001b|
89020456|NCT04455815|Experimental|Camostat|Patient to receive treatment with camostat tablets, 200mg four times daily (qds) for 14 days.
89020457|NCT04455815|No Intervention|Control arm|Patient to receive best supportive care.
89477433|NCT02058199|Experimental|pre and post bypassed subject|A single dose of rivaroxaban will be administered prior to gastric bypass. Subjects will be restudied 12 to 24 weeks following bypass
89477434|NCT05304026||Population|The group includes all patients undergoing EVAR, each patient is considered as both case and control of himself as the two CO2 injection techniques, through the 5F pigtail and through the 5F introducer, are both used during the procedure.
89477435|NCT02468973|Other|Life style counseling|Students will meet chronic patients and will counsel for life style
89477436|NCT02058277|Other|Healthy volunteers|Healthy volunteers taking a single dose of bosutinib and a single dose of bosutinib plus aprepitant in random order
89477437|NCT04813562|Experimental|Middle-dose vaccine (18-59 years)|Three doses of middle-dose experimental vaccine at the schedule of day 0, 28, 56
89477438|NCT04813562|Experimental|High-dose vaccine (18-59 years)|Two doses of High-dose vaccine at the schedule of day 0, 28, 56
89477439|NCT04813562|Experimental|Middle-dose vaccine (60-85 years)|Three doses of middle-dose experimental vaccine at the schedule of day 0, 28, 56
89477440|NCT04813562|Experimental|High-dose vaccine (60-85 years)|Two doses of High-dose experimental vaccine at the schedule of day 0, 28, 56
89477441|NCT04813562|Placebo Comparator|Middle-dose placebo (18-59 years)|Three doses of middle-dose placebo at the schedule of day 0, 28, 56
89477442|NCT04813562|Placebo Comparator|High-dose placebo (18-59 years)|Two doses of High-dose placebo at the schedule of day 0, 28, 56
89020458|NCT04415268|Experimental|Multitreatment|"Pharmacological treatment per standard of care (whole study length, starting on week 1).~Supervised exercise protocol (phase 1, 8 weeks starting on week 9). Unsupervised exercise protocol (phase 2, 8 weeks starting on week 17)."
89020459|NCT04404192|Experimental|PH94B|Intranasal spray 3.2 micrograms four times a day for 28 days
89020460|NCT04404192|Experimental|Placebo|Intranasal spray four times a day for 28 days
89020461|NCT04402073|Other|standard arms|"Criteria: Adult SHH (p53wt) M0-1, adult WNT M0-1, adult Group 4 M0-1.~Radiotherapy to the cranio-spinal axis of 35.2 Gy in 22 daily fractions of 1.6 Gy, followed by an additional boost to the tumour site of 19.8 Gy in 11 daily fractions of 1.8 Gy, summing up to a total dose of 55.0 Gy in 33 daily fractions of 1.6/1.8 Gy.~Criteria: Post pubertal < 18 y SHH (p53wt) M0.~Radiotherapy to the cranio-spinal axis of 23.4 Gy in 13 daily fractions of 1.8 Gy, followed by an additional boost to the tumour site of 30.6 Gy in 17 daily fractions of 1.8 Gy, summing up to a total dose of 54.0 Gy in 30 daily fractions of 1.8 Gy."
89020462|NCT04402073|Experimental|experimental arms|"Radiotherapy Criteria: Adult and post-pubertal SHH (p53wt) M0; adult WNT M0, adult Group 4 M0.~Radiotherapy to the cranio-spinal axis of 23.4 Gy in 13 daily fractions of 1.8 Gy, followed by an additional boost to the tumour site of 30.6 Gy in 17 daily fractions of 1.8 Gy, summing up to a total dose of 54.0 Gy in 30 daily fractions of 1.8 Gy.~SMO-inhibitor Criteria: Adult and post-pubertal SHH (p53wt) M0.~Sonidegib 200 mg/day (daily) from first day of radio-chemotherapy until end of maintenance chemotherapy, including 6w chemotherapy break."
89020463|NCT04400500||Suspected NSTEACS|Patients urgently admitted to the CCU with suspected NSTEACS
89477443|NCT04813562|Placebo Comparator|Middle-dose placebo (60-85 years)|Three doses of middle-dose placebo at the schedule of day 0, 28, 56
89477444|NCT04813562|Placebo Comparator|High-dose placebo (60-85 years)|Two doses of High-dose placebo at the schedule of day 0, 28, 56
89477445|NCT02470143||Bike application arm|The bike application arm contains cardiac patients that will be instructed to use the cycling application during a one month period.
89477446|NCT02058355|Experimental|Personalized Normative Feedback|This group receive the complete Personalized Normative Feedback (with normative information and a list of consequences)
89477447|NCT02058355|Experimental|Normative Feedback|This group receive a feedback only with normative informations (without a list of consequences)
89477448|NCT02058355|Experimental|Consequences List Feedback|This group receive a list of consequences without normative informations
89477449|NCT03310359|Active Comparator|Astaxanthin (12 mg)|Subjects will be given capsules containing a set oral dose of astaxanthin (12 mg) and instructed to take two capsules each morning after (up to 1 hr) the morning meal for a total of up to 24 weeks (168 days on study drug).
89477450|NCT03310359|Placebo Comparator|Placebo|Subjects will be given capsules containing placebo and instructed to take two capsules each morning after (up to 1 hr) the morning meal for a total of up to 24 weeks (168 days on study drug).
89477451|NCT02054767|Experimental|lidocaine|injections of 3.6 mL of 2% lidocaine with 1:100,000 epinephrine Intervention: inferior alveolar nerve block injection
89477452|NCT02054767|Experimental|mepivacaine|injections of 3.6 mL of 2% mepivacaine with 1:100,000 epinephrine Intervention: inferior alveolar nerve block injection
89477453|NCT02054767|Experimental|articaine|injections of 3.6 mL of 4% articaine with 1:100,000 epinephrine Intervention: inferior alveolar nerve block injection
89477454|NCT03310281|Active Comparator|ALK-T03|AKL-T03 is a digital intervention that requires the subject to navigate a character through a game-like space, while collecting objects, in a fixed period of time.
89477455|NCT03310281|Active Comparator|AKL-T09|AKL-T09 is a digital intervention that requires the subject to spell as many words as possible, by connecting letters in a game-like grid, in a fixed period of time.
89477456|NCT02054845|Experimental|Body awareness therapy|The experimental treatment: BEWARE
89020464|NCT04384770||Group I (CT-SBRT)|Patients undergo 5 fractions of CT-guided SBRT over 14 days in the absence of disease progression or unacceptable toxicity.
89020465|NCT04384770||Group II (MRI-SBRT)|Patients undergo 5 fractions of MRI-guided SBRT over 14 days in the absence of disease progression or unacceptable toxicity.
89020466|NCT04347330|Experimental|Intensive BP Control|Participants randomized into the Intensive BP Control arm will have a goal of home SBP <120mmHg. For most participants in the Intensive Group, a two- or three-drug regimen should be initiated at randomization. Following the randomization visit, addition of another drug or medication dose titration is indicated if home SBP is ≥120 mmHg. Monthly visits will continue in the Intensive Group until home SBP <120 mmHg or no more titration planned. If the home SBP is not <120 mmHg at the every 6-month visit, then an antihypertensive drug from a class different from what is being taken should be added, rather than up-titration the dosage of previous drugs, unless there are compelling reasons against this practice.
89477457|NCT02054845|Active Comparator|Treatment as Usual|The new treatment is compared to this arm: Physical therapy
89477458|NCT05303948|Experimental|Direct laryngoscopy in the ice-pick position|"In this arm, participants are assigned to intubations attempts in weightlessness on a manikin.~The insertion of a 7.0 mm cuffed oro-tracheal tube was performed by using a direct laryngoscope with a Macintosh non-angulated size 3 blade, in a face-to-face or ice-pick position."
89477459|NCT05303948|Experimental|Video-laryngoscopy in free-floating position|"In this arm, participants are assigned to intubations attempts in weightlessness on a manikin.~The insertion of a 7.0 mm cuffed oro-tracheal tube was performed by using a video laryngoscopy in a semi-free-floating position (McGrath model, Covidien™, Medtronic™)."
89477460|NCT04489082|Experimental|Near Infrared Laser Therapy|"On the days of each near-infrared therapy session, patients will undergo 10 minutes of transcranial infrared laser stimulation.~The laser dose for all conditions will be a 3.4 W continuous laser wave, at a 1064 wavelength, with irradiance (power density) at 250 milli-Watts/cm2. All groups will have treatment once a week (10 minutes per session) for 5-6 weeks. For Alzheimer's, the site targeted will be the right prefrontal cortex. Parkinson's patients will have laser delivered to the brain stem, bilateral temporal lobes. TBI/CTE patients will have the laser stimulation site dependent on location of injury. Patients with depression/anxiety will have laser stimulation applied to the prefrontal area of the head."
89477461|NCT03314025|Experimental|Tamsulosin|The patients in the Experimental group will receive Tamsulosin Hydrochloride 0.4 MG (milligrams) once a day for 5 days before the surgery, one capsule on the day of the surgery and one on the day after. The intervention will consist of a total of 7 capsules
89477462|NCT03314025|Placebo Comparator|Placebo|The patients in the Placebo group will receive a placebo oral capsule (sugar) once a day for 5 days before the surgery, one capsule on the day of the surgery and one on the day after. The intervention will consist of a total of 7 capsules
89477463|NCT02054923|Experimental|Routine video recording group|Intervention: Procedure: Implementation of routine videorecording of colonoscopy withdrawal
89477464|NCT02054923|Active Comparator|Control group|Intervention: Behavioral: No routine videorecording (on demand videorecording possible)
89477465|NCT03313947|Other|Difficult Airway|Ultrasound to measure hyo-mental distance, neutral (Frankfort) position, maximal extended neck position to calculate ratio, width of the tongue between the lingual arteries, and tonsillar size (bilateral).
89477466|NCT03313947|Other|Obstructive Sleep Apnea|Ultrasound to measure hyo-mental distance, neutral (Frankfort) position, maximal extended neck position to calculate ratio, width of the tongue between the lingual arteries, and tonsillar size (bilateral).
89477467|NCT03313947|Other|Predictive Obstructive Sleep Apnea|"The following 6 questions will be asked during the preoperative visit:~While sleeping, does your child snore more than half the time?~While sleeping, does your child always snore?~Have you ever seen your child stop breathing during the night?~Does your child occasionally wet the bed?~Did your child stop growing at a normal rate at any time since birth?~Is your child overweight"
89477468|NCT02055079|Experimental|Sirolimus|Fixed oral dose of 3 mg Sirolimus (blinded) once weekly for 24 months.
89477469|NCT02055079|Placebo Comparator|Placebo|Fixed oral dose of placebo (blinded) once weekly for 24 months.
89477470|NCT02470065|Experimental|Neo adjuvant afatinib|once daily afatinib at a dose of 40 mg for 8 weeks followed by surgery with curative intent (anatomical resection and systematic lymph node dissection).
89477471|NCT02470065|Active Comparator|Immediate surgery|immediate surgery with curative intent (anatomical resection and systematic lymph node dissection).
89477472|NCT03313869|Experimental|Control|"Intervention: Reduction in daily steps up to 2000-3000 steps per day and no structured physical activity + High dose ingestion of fructose (3g/kg/day) glucose (0,5g/kg/day)in the last 10 days of the protocol No cocktail during the protocol~Healthy male volunteers in the active range of population (10000 to 15000 steps per day) aged 20-45 years, 22 BMI 27 158 cm height 190 cm, Certified as healthy by a comprehensive clinical assessment."
89477473|NCT03313869|Experimental|Cocktail intervention|"Intervention: Reduction in daily steps up to 2000-3000 steps per day and no structured physical activity + High dose ingestion of fructose (3g/kg/day) glucose (0,5g/kg/day)in the last 10 days of the protocol + Micronutrient cocktail supplementation with 560,7 mg/ day of polyphenols (3 pills/day), 2,1 g/day of omega-3 fatty-acids (3 pills/day), 168 mg/day of vitamin E and 80µg/day of selenium (1 pill/day)~Healthy male volunteers in the active range of population (10000 to 15000 steps per day) aged 20-45 years, 22 BMI 27 158 cm height 190 cm, Certified as healthy by a comprehensive clinical assessment."
89477474|NCT02055391|Active Comparator|Behavioral Weight Loss|State of the art behavioral weight loss treatment
89477475|NCT02055391|Experimental|Enhanced Behavioral Weight Loss|Combines behavioral weight loss skills with skills specifically targeting emotional eating.
89477476|NCT00705159|Experimental|Loteprednol etabonate and tobramycin|Drug: Zylet (loteprednol etabonate and tobramycin)
89477477|NCT00705159|Active Comparator|Loteprednol etabonate|Drug: Lotemax (loteprednol etabonate)
89477478|NCT00705159|Active Comparator|Tobramycin|Drug: Tobramycin
89477479|NCT00705159|Placebo Comparator|Vehicle|Vehicle of Zylet
89477480|NCT01673984|Experimental|Decapeptyl® SR 22.5mg (Triptorelin)|
89477481|NCT01673984|Active Comparator|Current 3-monthly LHRH agonist|One of the following: Decapeptyl® SR 11.25mg (Triptorelin), Prostap® 3 DCS 11.25mg, Zoladex® LA 10.8mg
89477482|NCT03313791|Experimental|Whey protein concentrate|portion size that contains 25 g of protein, oral, single administration
89477483|NCT03313791|Experimental|Yoghurt|portion size that contains 25 g of protein, oral, single administration
89477484|NCT03313791|Experimental|50%whey-50% casein (Standard)|portion size that contains 25 g of protein, oral, single administration
89477485|NCT03313791|Experimental|50%whey-50% casein (Alternative)|portion size that contains 25 g of protein, oral, single administration
89477486|NCT03313791|Experimental|Micellar Casein Isolate- WPH|portion size that contains 25 g of protein, oral, single administration
89477487|NCT03313791|Experimental|Micellar Casein Isolate - Na-caseinate|portion size that contains 25 g of protein, oral, single administration
89477488|NCT03313791|Experimental|Micellar Casein Isolate|portion size that contains 25 g of protein, oral, single administration
89477489|NCT03313791|Experimental|UHT milk|portion size that contains 25 g of protein, oral, single administration
89477490|NCT03313791|Experimental|Recombined milk|portion size that contains 25 g of protein, oral, single administration
89477491|NCT03313791|Experimental|Recombined 50% whey milk|portion size that contains 25 g of protein, oral, single administration
89477492|NCT03313791|Experimental|Ca-caseinate|portion size that contains 25 g of protein, oral, single administration
89477493|NCT03313791|Experimental|Milk protein isolate|portion size that contains 25 g of protein, oral, single administration
89477494|NCT03313713|Active Comparator|Beta-glucans|Beta-glucans, 3 g per day, per 8 weeks, at breakfast
89477495|NCT03313713|Placebo Comparator|Placebo|Placebo, 3 g per day, per 8 weeks, at breakfast
89477496|NCT03310203|Experimental|Obese women: central obesity|OGTT with iron
89477497|NCT03310203|Experimental|Obese women: peripheral obesity|OGTT with iron
89477498|NCT03310203|Experimental|Lean women|OGTT with iron
89477499|NCT03310047|Experimental|Right-low, left-high|"The right-side perineural catheter will be subject to intervention drug Infusion, Lidocaine, 0.5%, 5 mL Lidocaine and the left side perineural catheter will be subject to intervention Infusion, Lidocaine, 0.5%, 10 mL.~This will be repeated after 24 hours."
89477500|NCT03310047|Experimental|Right-high, left-low|"The right-side perineural catheter will be subject to intervention drug Infusion, Lidocaine, 0.5%, 10 mL Lidocaine and the left side perineural catheter will be subject to intervention Infusion, Lidocaine, 0.5%, 5 mL.~This will be repeated after 24 hours."
89477501|NCT03313635||Men presenting with low-T|Men presenting with low-t will undergo a blood draw for evaluation of prealbumin levels.
89477502|NCT03313557|Experimental|Wee-1 kinase inhibitor AZD1775|To assess the safety of AZD1775 following oral dosing of the capsule formulation in patients with advanced solid tumours in patients who have previously completed 1 of the AZD1775 clinical pharmacology studies and not have met any requirements to permanently discontinue treatment with AZD1775.
89477503|NCT03313479||Group 1|GA and Dexmedetomidine
89477504|NCT03313479||group 2|GA and peribulbar
89477505|NCT03313479||group3|GA and xylocaine gel
89477506|NCT02813252||JCAR015-treated|Patients who received previous treatment with JCAR015
89477507|NCT03304899|Experimental|Case group|"Severe isolated Traumatic Brain injury patients with serum fibrinogen level under 200 mg/dl that receive Fibrinogen concentrate after common emergency resuscitation. Instruction:~Airway control & breathing.~Circulation (Serum therapy, Epinephrine,Packed cell, FFP and ...).~Fibrinogen Concentrate(IV injection): Each vial contains 1gr fibrinogen concentrate. Fibrinogen concentrate will be given until serum fibrinogen level riches to 200 mg/dl.~Dose (mg/kg body weight) = ([Target level (mg/dL) - measured level (mg/dL)])/(1.7 (mg/dL per mg/kg body weight))"
89477508|NCT03304899|Active Comparator|Control group|"Severe isolated Traumatic Brain injury patients with serum fibrinogen level under 200 mg/dl that receive common emergency resuscitation. Instruction:~Airway control & breathing.~Circulation (Serum therapy, Epinephrine,Packed cell, FFP and ...)."
89477509|NCT05303012||Overweight and obese patient cohort|"Age: 18 years and older~BMI ≥ 25kg/m²"
89477510|NCT05303012||Overweight and obese patient cohort with bariatric surgery|"Age: 18 years and older~BMI ≥ 25kg/m²~Status post sleeve or gastric bypass surgery"
89477511|NCT03304743||Post-menopausal women|A cohort of 124 consecutive post-menopausal women that performed a DXA scan within the previous 12 months
89477512|NCT05302622|Other|Group 1|Have surgical experience both laparoscopy and laparotomy and senior resident
89477513|NCT05302622|Other|Group 2|Have surgical skills only laparotomic gynecologic procedures and in the middle of his/her residency
89477514|NCT05302622|Other|Group 3|Have no surgical experience on gynecologic procedures and newbie residents
89477515|NCT03309891|Experimental|Cohort 1|GX-H9 subcutaneous injections (weekly)
89477516|NCT03309891|Experimental|Cohort 2|GX-H9 subcutaneous injections (weekly)
89020467|NCT04347330|Active Comparator|Standard BP Control|Participants randomized into the Standard BP Control arm will have a goal of home SBP <135mmHg. The Standard BP protocol is designed to achieve a home SBP of 130-134 mmHg in as many participants as possible. Following the randomization visit, medication dose titration or addition of another drug is indicated if home SBP ≥135 mmHg. Monthly visits will continue in the Standard Group when home SBP ≥155 mmHg. Down titration (a reduction of the dose or number of antihypertensive drugs) should be carried out if the home SBP is <125 mmHg.
89020468|NCT04322136|Other|IPC (with talc pleurodesis if suitable)|"The patients will undertake daily drainage to day 14 post insertion. The drainage will either be performed by the participant's carer or nurses in the community. A bottle or bag will be attached to the drain to allow for removal of accumulated pleural fluid. Once completed the drain will be reattached to the pleural catheter.~Participants will be taught how to perform pleural drainage by the main study doctor at the hospital or a specialist nurse. They will drain their own IPCs at home with the either the help of a family member or friend or have access to community nursing support systems."
89020469|NCT04322136|Other|Pleurodesis via VATS|Participants will undergo VATS within two weeks of randomisation. VATS is usually performed in an operating theatre, using either general anaesthesia or local anaesthesia with sedation. The pleural fluid will be removed and adhesions can be divided (adhesiolysis). Assessment of lung re-expansion will be performed intra-operatively. If lung re-expansion is adequate (as judged by the operating surgeon), a variety of techniques may be employed to induce a pleurodesis, including, but not limited to, talc poudrage and mechanical abrasion. Decortication may be performed if deemed appropriate and feasible by the operating surgeon. A chest drain will be left in situ after the surgery. Post-operative care will be administered as per local practice.
89020470|NCT04290897|Experimental|Supportive care (anhydrous enol-oxaloacetate)|Patients receive anhydrous enol-oxaloacetate PO BID for 8 weeks in the absence of worsening symptoms or unacceptable toxicity.
89020471|NCT04288063||Early onset T1D children|25 young, prepubertal and very early pubertal (Tanner stages 1 and 2) children (13 females and 12 males) with early onset T1D
89020472|NCT04276779|Experimental|Alcohol and Negative Mood|
89020473|NCT04276779|Placebo Comparator|Placebo and Negative Mood|
89020474|NCT04276779|Active Comparator|Alcohol and Positive Mood|
89477517|NCT03309891|Experimental|Cohort 3|GX-H9 subcutaneous injections (twice-monthly)
89020475|NCT04276779|Placebo Comparator|Placebo and Positive Mood|
89020476|NCT04236167|No Intervention|Control half of scar|one half of the scar will receive standard scar treatment with topical products and pressure garments, but no ablative fractional CO2 laser
89020477|NCT04236167|Experimental|Laser treatment half of scar|The other half of the scar will receive standard scar treatment with topical products and pressure garments and, in addition, will receive ablative fractional CO2 laser treatment
89020478|NCT04234971|Experimental|Intervention group (DBM/BMP)|Patient undergoes Alveolar bone graft with DBM/BMP
89020479|NCT04234971|Active Comparator|Control group(autologous ICBG)|Patient undergoes Alveolar Bone Graft with Iliac Crest Bone graft.
89020480|NCT04220411|Experimental|AR100DP1 (1.25%)_Phase I|Subjects topically apply AR100DP1 twice per day with at least 4 hour interval. The daily dosage of 1.25% AR100DP1 topical administration is 31.25 mg/day (1.25% × 1,250 × 2 = 31.25).
89020481|NCT04220411|Experimental|AR100DP1 (2.5%)_Phase I|Subjects topically apply AR100DP1 twice per day with at least 4 hour interval. The daily dosage of 2.5% AR100DP1 topical administration is 62.5 mg/day (2.5% × 1,250 × 2 = 62.5).
89020482|NCT04220411|Experimental|AR100DP1 (5%)_Phase I|Subjects topically apply AR100DP1 twice per day with at least 4 hour interval. The daily dosage of 5% AR100DP1 topical administration is 125 mg/day (5% × 1,250 × 2 = 125).
89020483|NCT04220411|Experimental|AR100DP1 (5%)_Phase IIa|Subjects topically apply AR100DP1 twice per day with at least 4 hour interval. The daily dosage of 5% AR100DP1 topical administration is 125 mg/day (5% × 1,250 × 2 = 125).
89020484|NCT04209543|Experimental|Estetrol 15 mg -Efficacy Part|Estetrol (E4) 15 mg will be administered orally once daily for a minimum of 12 weeks and not longer than 13 weeks
89020485|NCT04209543|Experimental|Estetrol 20 mg -Efficacy Part|Estetrol (E4) 20 mg will be administered orally once daily for a minimum of 12 weeks and not longer than 13 weeks
89020486|NCT04209543|Placebo Comparator|Placebo - Efficacy Part|Placebo will be administered orally once daily for a minimum of 12 weeks and not longer than 13 weeks
89020487|NCT04209543|Experimental|Estetrol 20 mg + P4 100 mg - Safety Part|Estetrol (E4) 20 mg and Progesterone (P4) 100 mg will be administered once daily for up to 53 weeks
89020488|NCT04194489|Experimental|FMF Connect Intervention|
89477518|NCT03309891|Active Comparator|Cohort 4|Genotropin subcutaneous injections (daily)
89477519|NCT05431868||the short AL group|Eyes with AL less than 22.50 mm were devided into the short AL group.
89020489|NCT04194450|Experimental|Ketone monoester|Acute dose of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate (0.3 g/kg body weight)
89020490|NCT04194450|Placebo Comparator|Placebo|Acute dose of flavour-matched placebo.
89020491|NCT04190303||Baseline (pre-intervention)|Current routine care
89020492|NCT04190303||Post-intervention|Care following development and delivery of the system-level intervention
89020493|NCT04188834|Experimental|Sensory Flicker Stimulation|"Participants will be exposed for about 10 to 60 minutes at a time, to a sequence of sensory flicker trials each lasting a few seconds to 5 minutes, while their eyes are open or closed. Each trial may include the following modalities and frequencies of flicker:~Modalities: auditory only, visual only, or audiovisual combined.~Frequencies: random, or anywhere from 3Hz to 200Hz.~Additionally, subjects may be exposed to individual pulses of light and/or sound, i.e. around or less than 1 pulse /second, for up to 20 minutes at a time."
89477520|NCT05431868||the control group|Eyes with AL between 22.50 to 25.50 mm were devided into the control group.
89477521|NCT05431868||the long AL group|Eyes with AL more than 25.50 mm were devided into the long AL group.
89537537|NCT02629965|Experimental|tiotropium + olodaterol|inhalation two puffs from the RESPIMAT inhaler, once a day, in the morning
89020494|NCT04188834|Active Comparator|Electrical Flicker Stimulation|"Participants will be exposed to direct electrical brain stimulation with low-amplitude current, at given flicker frequencies. Participants will be exposed to frequencies ranging from 5-100Hz, for up to 10 seconds at a time. Initially, frequencies of 5.5Hz and 40Hz will be tested.~During brain stimulation sessions, bipolar electrical stimulation will be applied to one or more areas of the brain at a time either with or without associated memory tasks. Stimulation in the absence of any memory task will be applied to assess the subject's neurophysiological response to stimulation and to identify the optimal stimulation parameters for use during memory tasks. Stimulation during behavioral tasks will be applied in an attempt to affect the subject's memory."
89020495|NCT04158739|Experimental|Treatment (flotetuzumab, cytarabine)|Patients receive flotetuzumab IV continuously for 28 days. Treatment repeats every 29 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive cytarabine IT on days -6 to 0 prior to cycle 1. Patients may receive additional doses of cytarabine on day 1 of subsequent cycles per physician discretion.
89020496|NCT04147325||Prospective Cohort|Participants newly diagnosed with Human Immunodeficiency Virus (HIV)-1, will receive Antiretroviral Therapy (ART) in accordance with clinical practice and will be included in a Test and Treat model of care at the outpatient clinic of the center.
89020497|NCT04147325||Historical Cohort|Naive HIV-1 infected participants who had their first care visit at the outpatient clinic of the center through 2017 will be included in this cohort.
89020498|NCT04142697|Active Comparator|Healthy subjects|
89206281|NCT04095065|Experimental|itMatters and itMatters Sexual Violence Prevention|Participants will have access to content focused on general knowledge and injunctive and descriptive norms related to alcohol use and sex. Additionally, participants will have access to content focused on sexual violence including basic information and bystander intervention. This content will be available for a period up to 3 weeks.
89477522|NCT05431790|Experimental|Absorbable screw (Natong Biotechnology (Beijing) Co., Ltd.)|Anterior cruciate ligament reconstruction uses absorbable interface screws manufactured by Natong Biotechnology.
89477523|NCT05431790|Active Comparator|Absorbable screw (Inion Oy, INION, Finland)|Anterior cruciate ligament reconstruction uses absorbable interface screws manufactured by INION.
89477524|NCT03304509|No Intervention|Face-to-face follow-up|Face-to-face follow-up after hospital discharge
89477525|NCT03304509|Experimental|Telematic follow-up|Telematic follow-up after hospital discharge
89477526|NCT03313323|Experimental|Zirconium-ipilimumab|Zirconium-ipilimumab is an experimental tracer and is administered at start of ipilimumab treatment and after second infusion 3 weeks later
89477527|NCT05302232|Experimental|Lidocaine plus steroid|
89477528|NCT05302232|Placebo Comparator|Steroid only|
89477529|NCT02468661|Experimental|INC280 200mg BID + ERL 150mg QD|Subjects who took INC280 200mg twice a day (BID) in combination with erlotinib (ERL) 150mg one a day (QD)
89477530|NCT02468661|Experimental|INC280 400mg BID + ERL 150mg QD|Subjects who took INC280 400mg twice a day (BID) in combination with erlotinib (ERL) 150mg one a day (QD)
89477531|NCT03304431|No Intervention|Control group(Group C)|After pre-oxygenation, anesthesia induction will be performed with intravenous administration of 2 μg / kg fentanyl, 2 mg/kg propofol, 0.6 mg/kg rocuronium bromide (Esmeron 5 mg vial, Organon Oss Holanda).
89477532|NCT03304431|Other|Group L|The induction of group L will be performed 5 minutes after administration of 10% topical lidocaine (Lidocaine pump spray 10% 50 ml) 160 mg (16 puffs) application
89477533|NCT03309969||observation group|Subjects with suspicious iliac vein compression syndrome were included in the observation group.
89477534|NCT04741334||patients not in therapy with anticoagulants or antiplatelets drugs|Patients presenting in ED with mild head trauma and not in therapy with antiplatelets and/or anticoagulants
89477535|NCT04741334||patients in therapy with direct anticoagulant|Patients presenting in ED with mild head trauma and in therapy with direct anticoagulants
89477536|NCT04741334||patients in therapy with oral anticoagulant (dicumarolics)|Patients presenting in ED with mild head trauma and in therapy with oral anticoagulants (dicumarols)
89477537|NCT04741334||patients in therapy with antiplatelet drugs|Patients presenting in ED with mild head trauma and in therapy with antiplatelets
89477538|NCT03309735||1|Utrogestan, 200 mg orally thrice a day until acute symptoms of the threat of termination of pregnancy (scarlet discharge from the genital tract, pain in the abdomen) and then Utrogestan vaginally 200 mg twice a day and 200 mg orally once a day before bed
89477539|NCT03309735||2|Utrogestan vaginally 200 mg twice a day and 200 mg orally once a day before bed
89477540|NCT03309735||3|Duphaston, orally 40 mg once, then 10 mg every 8 hours until the symptoms disappear
89477541|NCT05302076|Experimental|electric current|Electric current will be applied in this group of patients using removable device.
89477542|NCT05302076|Active Comparator|Traditional treatment|No acceleration method will be performed in this group.
89477543|NCT02469363|Active Comparator|Macintosh laryngoscope|Endotracheal intubation with classic (Macintosh) laryngoscope
89477544|NCT02469363|Active Comparator|Mc-Coy laryngoscope|Endotracheal intubation with Mc-Coy laryngoscope
89477545|NCT02469363|Active Comparator|C-Mac videolaryngoscope|Endotracheal intubation with C-Mac videolaryngoscope
89477546|NCT02469363|Active Comparator|McGrath videolaryngoscope|Endotracheal intubation with McGrath videolaryngoscope
89477547|NCT02469207||Deceased organ donors|Patients with consent for organ donation towards transplantation and research. Organs not used for transplantation will be used for this study if determined appropriate and necessary.
89202815|NCT00801216|Experimental|High-dose sequential chemoimmunotherapy|Two courses of methotrexate 3.5 g/mq day 1 and cytarabine 2 g/mq twice a day, for two days, Rituximab 375 mg/mq days 3 & 11 and Intrathecal liposomal cytarabine 50 mg day 6(Phase I) followed in case of response by cyclophosphamide 7 g/mq plus Rituximab 375 mg/mq and Intrathecal liposomal cytarabine 50 mg Leukapheresis A and cryopreservation (Phase II), Cytarabine 2 g/mq twice a day for 4 days, Rituximab 375 mg/m2 and Reinfusion of stem cells (Phase III), etoposide 2 g/mq, Intrathecal liposomal cytarabine 50 mg (Phase IV) and high-dose Thiotepa-BCNU supported by autologous stem cell transplant (Phase V), and whole-brain radiotherapy in patients who do not achieve a complete remission after chemotherapy (Phase VI)
89202816|NCT00756782|Experimental|A|Patients will receive TAC-101 20 mg (2 x 10-mg formulated tablets) administered orally every day with approximately 8 oz. water within 1 hour following a morning meal for 14 days followed by a 7-day recovery period, repeated every 21 days
89202817|NCT00756782|Placebo Comparator|B|Patients will receive placebo (two matching tablets) at same frequency and duration of active treatment
89202818|NCT00748358|Experimental|drug|drug
88950576|NCT04624581|Experimental|Patient with fibromyalgia syndrome|250 patients with fibromyalgia syndrome (according to American College of Rheumatology 2016) will realize explorations to characterize central sensitization: reflex nociceptive flexion threshold by electrophysiological measure and blood sampling for evaluate the distribution of gene polymorphism.
88950577|NCT04624581|Sham Comparator|Healthy subjects|50 healthy matched volunteers (age, sex and menopausal status for women) will realize explorations to characterize central sensitization: reflex nociceptive flexion threshold by electrophysiological measure and blood sampling for evaluate distribution of gene polymorphism
88950578|NCT04520516|Experimental|tVNS active device|VAGUSTIM device from Schwa-Medico Length of use : 12 weeks
88950579|NCT04520516|Sham Comparator|Sham tVNS device|Sham VAGUSTIM device from Schwa-Medico Length of use : 12 weeks
88950580|NCT04487990|No Intervention|Control group|Patients on continuous hemodialysis (blood flow 150 ml / min, dose of 30 ml / kg / h) receiving anticoagulation with sodium citrate at 4 mmol / l.
88950581|NCT04487990|Experimental|Intervention group|Patients on continuous hemodialysis (blood flow 150 ml / min, dose of 30 ml / kg / h) receiving anticoagulation with sodium citrate at 4 mmol / l associated with unfractionated heparin at 10U / Kg / h.
88950582|NCT04476979|Active Comparator|Dexamethasone|Dexamethasone : 10 mg once daily for the first five days (day 1 to day 5) then 5 mg per day for up to 5 days, 2.5mg per day for up to 4 days (or until oxygen supply independency if sooner)
88950583|NCT04476979|Experimental|Dexamethasone + Tocilizumab|"Dexamethasone : 10 mg once daily for the first five days (day 1 to day 5) then 5 mg per day for up to 5 days, 2.5mg per day for up to 4 days (or until oxygen supply independency if sooner)~+Tocilizumab 8mg/kg D1 and if no response (No decrease of oxygen requirement) a second fixed dose of 400mg wil be administered at D3"
88950584|NCT04411953|Active Comparator|Reference Product (Treatment A)|"Subjects received Haloperidol Tablets 2 mg Reference Product (Mylan Pharmaceuticals Inc.). Subjects also received as pre-medication Benztropine Mesylate Tablets, USP (1 mg every 10 to 12 hours), beginning 4 to 6 hours before dosing with IMP and continued for a total of 4 doses.~A high-fat, high-calorie breakfast was served 30 minute before administration of the IMP."
89020499|NCT04142697|Active Comparator|Vestibular Disease patients|
89202819|NCT00751088|Active Comparator|1|Patients treated with Ajust positioning
89202820|NCT00751088|Active Comparator|2|Patients treated with MiniArc positioning
89202821|NCT00751088|Active Comparator|3|Patients treated with TVT secur system
89477548|NCT02469441||Arm A|Arm A (treatment arm: coffee): patients after colorectal surgery receive coffee in addition to the regular infusion therapy and/or alimentation
89477549|NCT02469441||Arm B|Arm B (control arm: water / tea): patients after colorectal surgery receive water or tea (excluding black tea) and no coffee until the first bowel movement in addition to the regular infusion therapy and/or alimentation
89477550|NCT05430776|Active Comparator|Local photobiomodulation|photobiomodulation with red and infrared laser with local application on pain points and
89477551|NCT05430776|Experimental|Systemic photobiomodulation|photobiomodulation with red laser with transcutaneous application in the radial artery.
89477552|NCT03304353|Experimental|Self-managed protocol|
89477553|NCT03304353|Active Comparator|Predetermined protocol|
89477554|NCT03313167||Atrial Fibrillation-potential Patients|individuals 65 years of age or older with moderate-to-high risk of stroke
89477555|NCT03304275|Experimental|Emergency Department vaccination group|Pertussis (Tdap) vaccine offered/administered in the Emergency Department
89477556|NCT03304275|Experimental|Public Health referral group|Public Health referral for Pertussis (Tdap) vaccine administration offered
89477557|NCT03304197|Experimental|Dehydrated|90 minutes cycling, without the ingestion of any fluids, followed by a 15 minute cycling time trial test
89477558|NCT03304197|Experimental|Hypotonic|90 minutes cycling, with the ingestion of six 250 ml carbohydrate (6g sucrose, 3g glucose) drinks, followed by a 15 minute cycling time trial test
89477559|NCT03304197|Experimental|Isotonic|90 minutes cycling, with the ingestion of six 250 ml carbohydrate (6g glucose, 3g fructose) drinks, followed by a 15 minute cycling time trial test
89477560|NCT03304197|Experimental|Placebo|90 minutes cycling, with the ingestion of six 250 ml taste-matched water drinks, followed by a 15 minute cycling time trial test
89202822|NCT00751088|Active Comparator|4|Patients treated with tension free vaginal tape
89202823|NCT00748436|Placebo Comparator|A|Matching placebo twice a day
89202824|NCT00748436|Experimental|B|Betahistine 24 mg twice a day (48 mg/day total)
89477561|NCT04072874|Active Comparator|Régimen 1|"Regimen 1: Curaleish lotion applied three times a day in combination with Curaleish cream applied two times a day for 4 weeks.~For both treatments, the patient applies Curaleish lotion in the morning, afternoon, and evening, that is to say, three times a day. And Curaleish cream in the morning and afternoon, that is, twice a day."
89537538|NCT02629965|Active Comparator|tiotropium|inhalation two puffs from the RESPIMAT inhaler, once a day, in the morning
89477562|NCT04072874|Active Comparator|Régimen 2|"Regimen 2: Curaleish lotion applied three times a day in combination with Curaleish cream applied two times a day for 6 weeks.~For both treatments, the patient applies Curaleish lotion in the morning, afternoon, and evening, that is to say, three times a day. And Curaleish cream in the morning and afternoon, that is, twice a day."
89477563|NCT05184387||Prospective epidemiological cohort|Urban and suburban population of healthy subjects aged 18-55 years, not vaccinated against influenza
89477564|NCT02926586|Experimental|Fludarabine|The patients in experimental arm should receive the consolidation chemotherapy regimen with fludarabine and cytarabine. The dosage of fludarabine is 30mg/m2/d for 5 days intravenously and cytarabine is 1500mg/m2/d for 5 days intravenously.
89477565|NCT02926586|Active Comparator|high-dose cytarabine|The patients in control arm should receive the consolidation chemotherapy regimen with high-dose cytarabine. The dosage of cytarabine is 2000mg/m2/12h for 3 days (1,3,5) intravenously.
89477566|NCT03313089||PSAN + MNP|"PSAN (Papas más nutritivas project) + MNP (micronutrients powders):~Children of the families beneficiaries of Community Schools of Family Agriculture of the municipalities of Cumbal, Carlosama Guachucal and Túquerres, who are part of the project Papas más nutritivas and exposed to project activities in which they work on topics related to food and nutritional security, equity and gender, production and entrepreneurship, Additionally, the home fortification with MNP that is 12 months in total approximately, will be made 2 deliveries of 60 doses (specified in the MNP only group). After the delivery of MNP, advising, measurements of weight and height, clarification of doubts regarding fortification with MNP, nutrition education, and accompaniment by the project staff will take place."
89477567|NCT03313089||MNP only|"Cohort of exposed to MNP (micronutrients powders):~Children who will receive MNP delivered through the hospital or institutional health service providers of the municipalities of Guachucal and Carlosama, following the protocol for the home fortification with MNP that is 12 months in total approximately, will be made 2 deliveries of 60 doses: the first period consists of the taking of MNP for 2 months, followed by a rest period of 4 months and continues again by another MNP intake for 2 months and rest for 4 months, and exposed to dissemination of basic information with regard to MNP and monitoring by growth and development that is routinely performed by health staff."
89477568|NCT04233008|Experimental|6 hour foley|The participant will have a cook catheter inserted digitally or by direct visualization with a speculum with the uterine component of the balloon inflated to maximum 60mL. The catheter will be taped to the inner thigh with gentle traction. Participants will be started on hospital-based oxytocin protocol. The cook catheter will then be removed at 6 hours, determined by randomization. At that point health care providers will manage active labor.
89477569|NCT04233008|No Intervention|12 hour foley|The participant will have a cook catheter inserted digitally or by direct visualization with a speculum with the uterine component of the balloon inflated to maximum 60mL. The catheter will be taped to the inner thigh with gentle traction. Participants will be started on hospital-based oxytocin protocol. The cook catheter will then be removed at 12 hours, determined by randomization. At that point health care providers will manage active labor.
89477570|NCT04490967|Experimental|Silymarin and salicylic acid|There will be one group of patients, that will use salicylic acid peeling on the right side of the face and topical Silymarin cream on the left side
89477571|NCT03312855|Experimental|Revacept 80 mg|single dose, intravenous
89477572|NCT03312855|Experimental|Revacept 160 mg|single dose, intravenous
89477573|NCT03312855|Placebo Comparator|Placebo|single dose, intravenous
89477574|NCT03304041|Experimental|low-FODMAPs diet|"The low-FODMAPs diet(LFD) aims to keep oligosaccharides, fructose in excess of glucose, and polyol content at less than 0.5 g each per serving based on previously published data.~low-FODMAPs diet therapy for 3 weeks"
89477575|NCT03304041|Placebo Comparator|Traditional dietary advice|"Traditional dietary advice (TDA) will focus more on how and when to eat rather than on what foods to ingest . Patients will be instructed to regularly eat, never too much or too little, never to be hungry or too full; to eat in peace and to chew thoroughly; reduce intake of fatty, spicy food, fiber, coffee and alcohol during the intervention period~Traditional dietary advice for 3 weeks"
89477576|NCT05430620|Experimental|I-HMPO2|intermittent surface oxygenation during hypothermic machine perfusion (surface oxygenation interrupted during organ transport)
89477577|NCT05430620|Active Comparator|C-HMPO2|continuous surface oxygenation during HMP (surface oxygenation during the whole machine preservation period included organ transport)
89477578|NCT03312777|Experimental|Omnitram|Oral Omnitram 20 mg (overencapsulated 10 mg tablets) administered every 6 hours for nine doses, coadministered with paroxetine.
89477579|NCT03312777|Active Comparator|Tramadol|Oral tramadol 50 mg (overencapsulated 50 mg tablet) administered every 6 hours for nine doses, coadministered with paroxetine.
89477580|NCT03312777|Placebo Comparator|Placebo|Oral placebo (overencapsulated microcrystalline) administered every 6 hours for nine doses, coadministered with paroxetine.
89477581|NCT02332928|Active Comparator|20 mg Melatonin|RT (as clinically indicated) + melatonin (Subjects will receive 20-mg oral melatonin the night before their first RT treatment, each night throughout the course of RT treatment, and for 2 weeks following the completion of RT).
89477582|NCT02332928|Placebo Comparator|Placebo|RT (as clinically indicated) + placebo (Subjects will receive 20-mg oral placebo the night before their first RT treatment, each night throughout the course of RT treatment, and for 2 weeks following the completion of RT).
89477583|NCT04490733|Experimental|Experimental group|Participants in the experimental group will receive 3 times interventions during 10th to 12th course of chemotherapy and 12 weekly phone-call to assess effect and barriers of dual-task walking.
89477584|NCT04490733|No Intervention|Control group|Participants in control group will receive usual care.
89477585|NCT03312621|Experimental|Intervention|The intervention group received all aspects of enhanced usual care but was also assigned a healthcare transition nurse who coordinated the delivery of specific intervention services. These services included 1) a face-to-face systematic review of the readiness assessment with the participant/caregiver 2) a status assessment of ongoing healthcare transition planning and preparation; 3) monthly phone calls with the participant/caregiver to update and fill gaps in the healthcare transition action plan.
89537539|NCT03062787|Experimental|Cingal®|Single 4 ml intra-articular injection of Hyaluronic Acid plus Triamcinolone Hexacetonide
89537540|NCT03062787|Active Comparator|Monovisc®|Single 4 ml intra-articular injection of Sodium Hyaluronate
89020500|NCT04123093|Experimental|Healthy Volunteers|The initial phase of the study is designed to determine the safety of the study device, the Noxsano Bandage, in healthy volunteers without wounds.
89020501|NCT04123093|Experimental|Wound care|The second phase of the study is designed to determine the effectiveness of the study device in wound healing in subjects with active wounds.
89477586|NCT03312621|No Intervention|Control|The control group received enhanced usual care which provides standardized healthcare transition-specific written information including a written transition policy, as well as insurance and guardianship information. Participants were also provided with a transition readiness assessment and entered into a healthcare transition registry to facilitate tracking and communication.
89477587|NCT03856424|Other|Modality 1 - Washout - Modality 2 - Washout - Modality 3|Three different 30-minute modalities of deventilation will be performed in a randomized order in each patient. Washout periods of 30 minutes will occur between tested modalities.
89477588|NCT03856424|Other|Modality 1 - Washout - Modality 3 - Washout - Modality 2|Three different 30-minute modalities of deventilation will be performed in a randomized order in each patient. Washout periods of 30 minutes will occur between tested modalities.
89477589|NCT03856424|Other|Modality 2 - Washout - Modality 1 - Washout - Modality 3|Three different 30-minute modalities of deventilation will be performed in a randomized order in each patient. Washout periods of 30 minutes will occur between tested modalities.
89477590|NCT03856424|Other|Modality 2 - Washout - Modality 3 - Washout - Modality 1|Three different 30-minute modalities of deventilation will be performed in a randomized order in each patient. Washout periods of 30 minutes will occur between tested modalities.
89477591|NCT03856424|Other|Modality 3 - Washout - Modality 2 - Washout - Modality 1|Three different 30-minute modalities of deventilation will be performed in a randomized order in each patient. Washout periods of 30 minutes will occur between tested modalities.
89477592|NCT03856424|Other|Modality 3 - Washout - Modality 1 - Washout - Modality 2|Three different 30-minute modalities of deventilation will be performed in a randomized order in each patient. Washout periods of 30 minutes will occur between tested modalities.
89477593|NCT03309501|Experimental|Tong-Luo-Qu-Tong Plaster group|Intervention: Tong-Luo-Qu-Tong Plaster, daily 1 time, conventional treatment lasted for 14 days as two courses
89477594|NCT03309501|Active Comparator|Qi-Zheng-Xiao-Tong Plaster group|Intervention: Qi-Zheng-Xiao-Tong Plaster, daily 1 time, conventional treatment lasted for 14 days as two courses
89477595|NCT03309423||Respiratory disease|Patients with acute respiratory insufficiency admitted to the ICU and with pH <7,35 or >7,45
89477596|NCT03309423||Metabolic disease|Patients with acute metabolic disease admitted to the ICU and with pH <7,35 or >7,45
89477597|NCT03309423||Sepsis|Patients with acute sepsis admitted to the ICU and with pH <7,35 or >7,45
89477598|NCT03154671|Experimental|Intervention group|At study enrollment participants allocated to the intervention arm will complete a comprehensive geriatric assessment with the study intervention team (nurse and physician). Based on these findings a care plan tailored to the needs of the older adult with cancer will be developed and implemented. The study intervention nurse will call the participant at least monthly to follow up and evaluate the care (e.g. whether adjustments are required) and more if needed. All participants will receive a monthly healthy aging newsletter.
89477599|NCT03154671|No Intervention|Control group|The participant will receive usual care from their treating oncology team. All participants will receive a monthly healthy aging newsletter.
89477600|NCT01070342||Chidren ages 6 to 18|Children ages 6 to 18 years will be available for participation in this multicenter study. Subjects will be enrolled from community based general pediatric clinics and other well-child care areas within participating hospitals and clinics of the four participating sites. Enrollment will continue until a total of 85 subjects from each age category (6-<12 years and ≥12- <18 years) successfully complete the study.
89477601|NCT04441827|No Intervention|Control|Usual care
89477602|NCT04441827|Experimental|Pranayama|Pranayama breathing exercise
89477603|NCT04441827|Experimental|Deep breathing exercise|Deep breathing exercise
89477604|NCT04699682|Experimental|Control|During follow-up visits, as part of this research, additional stool samples are taken every month (M1 to M12).
89477605|NCT04699682|Experimental|BHR Case|"During follow-up visits, compared to the usual management of patients with BHRe (monthly sampling for 6 consecutive months), additional samples are taken as described below:~- stool samples taken at different times:~every 7 days during the first month (M1)~every 14 days for the following months until the end of the patient's participation (M2 to M12)."
89477606|NCT02647658|Experimental|GBC+PIPT|Guideline Based Care plus Psychologically Informed Physical Therapy (GBC+PIPT)
89477607|NCT02647658|Active Comparator|GBC|Guideline Based Care (GBC)
89477608|NCT00703677|Other|1|All participants will receive lithium. The dosage will be titrated over a 5-week period. Participants will then be followed prospectively for 6 months. Participants will be evaluated at the screening visit, baseline visit, and weeks 2 and 5 during the titration phase. Clinic study visits will then occur on alternate months through week 28. Telephone visits will occur between clinic study visits.
89477609|NCT03303807|Other|Extracorporeal CO2 removal|Extracorporeal CO2 removal (ECCO2-R) (PrismaLung®, Prismaflex ® Baxter)
89020502|NCT04119440|Experimental|Low Dose|Vaccination with 2x10^7 PFU MVA-MERS-S_DF1. Vaccinations will be administered at days 0, 28 or 56, and 336.
89020503|NCT04119440|Experimental|High Dose|Vaccination with 2x10^8 PFU MVA-MERS-S_DF1. Vaccinations will be administered at days 0, 28 or 56, and 336.
89020504|NCT04119440|Placebo Comparator|Placebo|Injection with placebo. Injections will be administered at days 0, 28 or 56, and 336.
89477610|NCT00888680|Experimental|BGC20-1531 200 mg|
89477611|NCT00888680|Experimental|BGC20-1531 400mg|
89477612|NCT00888680|Placebo Comparator|Lactose|
89477613|NCT02468505|Experimental|STEPS|structured psychosocial transition support that includes individual counseling, and education/training for parent and school personnel
89477614|NCT02468505|No Intervention|TAU|typical transition services and supports
89477615|NCT01506986|Active Comparator|H. pylori eradication treatment|Active treatment will consist of seven days of lansoprazole 30mg twice daily, clarithromycin 500mg twice daily and metronidazole 400mg twice daily.
89477616|NCT01506986|Placebo Comparator|Placebo H. pylori eradication treatment|Placebos to seven days of lansoprazole 30mg twice daily, clarithromycin 500mg twice daily and metronidazole 400mg twice daily.
89202825|NCT00748436|Experimental|C|Betahistine 48 mg twice a day (96 mg/day total)
89477617|NCT03309345||Case group, PKU group|Children and adults (10 - 45 years old) with PKU attending the metabolic medicine clinics in the area of National Health Services (NHS) Greater Glasgow and Clyde (GGC) will be approached for recruitment. Participants will be free from history of acute and chronic illness (other than PKU) requiring regular appointments to the doctor and/or chronic use of medication or major gastrointestinal surgery where major part of the gut has been resected as these conditions are known to impact on energy expenditure and dietary intake. Pregnant or lactating women will also be excluded from participation. People with learning or mobility difficulties or those with incapacity to provide informed consent will be excluded too. The clinical treatment team will evaluate patients' capacity to consent before considering them to participate in the study.
89477618|NCT03309345||Control group, healthy control|Gender, BMI and age matched healthy people will be recruited as a control group. Pregnant or lactating women will be excluded from participation. Those with any chronic illnesses or bone injuries will also be excluded.
88950585|NCT04411953|Experimental|Test Product (Treatment B)|"Subjects received Haloperidol Tablets 2 mg Test Product (Cycle Pharmaceuticals Ltd). Subjects also received as pre-medication Benztropine Mesylate Tablets, USP (1 mg every 10 to 12 hours), beginning 4 to 6 hours before dosing with IMP and continued for a total of 4 doses.~A high-fat, high-calorie breakfast was served 30 minute before administration of the IMP."
88950586|NCT04411940|Active Comparator|Reference Product (Treatment A)|Subjects received Haloperidol Tablets 2 mg Reference Product (Mylan Pharmaceuticals Inc.). Subjects also received as pre-medication Benztropine Mesylate Tablets, USP (1 mg every 10 to 12 hours), beginning 4 to 6 hours before dosing with IMP and continued for a total of 4 doses.
88950587|NCT04411940|Experimental|Test Product (Treatment B)|Subjects received Haloperidol Tablets 2 mg Test Product (Cycle Pharmaceuticals Ltd). Subjects also received as pre-medication Benztropine Mesylate Tablets, USP (1 mg every 10 to 12 hours), beginning 4 to 6 hours before dosing with IMP and continued for a total of 4 doses.
88950588|NCT04309734|Experimental|Part A - 60 mg AT-777 single dose|
88950589|NCT04309734|Experimental|Part A - 120 mg AT-777 single dose|
88950590|NCT04309734|Placebo Comparator|Part A - Placebo single dose|
88950591|NCT04309734|Experimental|Part B - 60 mg AT-777 + 550 mg AT-527 once daily for 8 weeks|
88950592|NCT04264767||Cases Group|Peripheral blood collection via routine venipuncture
88950593|NCT04264767||Control Group|Peripheral blood collection via routine venipuncture
88950594|NCT04264182|Experimental|Ultra-conservative ICD programming|Single VF zone programming strategy with maximal detection extension to avoid ICD shock delivery with monitoring-only VT detection zones
88950595|NCT04264182|No Intervention|Standard programming (physician discretion)|Usual care ICD programming, which is historically unchanged from ICD programming pre-LVAD
88950596|NCT04225962||Women with cystic fibrosis|Women with cystic fibrosis
88950597|NCT04202185||G1a|infants under 3 years deaf severe to deep
88950598|NCT04202185||G1b|children under 16 years of age with audiologically proven auditory neuropathy
88950599|NCT04202185||G2|patients <25 years old with one or two Otoferlin mutations
88950600|NCT04186377|Active Comparator|Standard-of-care managed group|This group will receive the optimal standard-of-care for neuropathic/neuroischemic diabetic foot ulcers
88950601|NCT04186377|Experimental|S26E|This group will receive the optimal standard-of-care for neuropathic/neuroischemic diabetic foot ulcers plus daily S26E application
88950602|NCT04068792|Other|Part 1-Observational Phase|Participants will not receive any intervention in the observation phase. All infants will be closely monitored for early signs and symptoms of Respiratory Syncytial Virus (RSV) disease using a mobile RSV application on the parent/caregiver's mobile phone, upon an alert, the RSV will be tested, if RSV negative participants (RSV [-] diagnosed at site) will return to the pre-diagnostic phase and RSV positive participants (RSV [+] diagnosed at site) can be enrolled in the interventional stage of the study after obtaining informed consent for the interventional stage at that time. RSV (+) participants whose parent(s)/caregiver(s) do not consent for enrollment in the interventional stage and participants who are screening failures in the interventional stage will enter the post-diagnostic phase of the observational stage (hospitalized or outpatients).
88950603|NCT04068792|Experimental|Part 2-Interventional Phase|Participants will be randomized to receive either JNJ-53718678 (for Age Group 1 (greater than or equal to [>=] 28 days and less than [<] 3 months): 2.5 milligram per kilogram [mg/kg]; for Age Group 2 (>=3 and <6 months): 3 mg/kg and for Age Group 3 (>=6 months): 4.5 mg/kg) or placebo (Age Group 1, 2 and 3) twice daily for 7 days.
88950604|NCT04060134||SimpliDerm HADM|Patients who had SimpliDerm human acellular dermal matrix used in their breast reconstruction procedure.
88950605|NCT04060134||AlloDerm HADM|Patients who had AlloDerm human acellular dermal matrix used in their breast reconstruction procedure.
89202826|NCT00751244|Active Comparator|1|12 weekly sessions of one-to-one TARGET (psychotherapy)
89202827|NCT00751244|Active Comparator|2|12 weekly sessions of one-to-one PCT (psychotherapy)
89202828|NCT00751244|Other|3|90-day wait-list group
89202829|NCT00751322|Active Comparator|1|RBC transfusion of 5 days or less storage age
89202830|NCT00751322|Active Comparator|2|RBC transfusion of conventional storage age
89202831|NCT00756860|Active Comparator|2|30 subjects will be randomized on Day -1
89202832|NCT00756860|Experimental|1|30 subjects will be randomized on Day -1
89477619|NCT03312387|Experimental|Essential Amino Acid and Exercise|Participants will be provided with essential amino acids during exercise training.
89477620|NCT03312387|Placebo Comparator|Placebo and Exercise|Participants will be provided with placebo supplement during exercise training.
89477621|NCT02469051|Other|Breathhold SPECT-MPI vs. standard freebreathing SPECT-MPI|
89477622|NCT03993938|Experimental|Patients for TMVR|Patients with severe mitral regurgitation scheduled for TMVR procedure at Henry Ford Hospital - main campus.
89477623|NCT04491513||Overall cohort|Pateints that underwent both CTA and CAG in the work-up for TAVI
89477624|NCT02714894||Clozapine Responders (Non-URS)|"Definition of non-URS~(1) ≥30% decrease in the PANSS positive subscale score, CGI-severity ≤3 and CGI-Improvement ≤2 after 12 weeks of treatment."
88950606|NCT04060134||AlloMax HADM|Patients who had AlloMax human acellular dermal matrix used in their breast reconstruction procedure.
88950607|NCT04060134||FlexHD HADM|Patients who had FlexHD human acellular dermal matrix used in their breast reconstruction procedure.
88950608|NCT04060134||DermACELL HADM|Patients who had DermACELL human acellular dermal matrix used in their breast reconstruction procedure.
88950609|NCT04035109|Other|Anakinra (Period 1) then Placebo (Period 2)|Subjects randomized to this arm will receive a single injection of anakinra 1 mg/kg (max dose of 100 mg) administered subcutaneously after their first allergen challenge (Period 1), followed by the matching saline placebo after their second allergen challenge (Period 2).
88950610|NCT04035109|Other|Placebo (Period 1) then Anakinra (Period 2)|Subjects randomized to this arm will receive a single injection of saline placebo administered subcutaneously after their first allergen challenge (Period 1), followed by anakinra 1 mg/kg (max dose of 100 mg) administered subcutaneously after their second allergen challenge (Period 2).
88950611|NCT04030429|Experimental|Crizotinib arm|Crizotinib 250 mg bid orally
88950612|NCT04014595||Rotational atherectomy + Cutting Balloon|Rotational atherectomy in combination with cutting balloon in severely calcified coronary lesions
88950613|NCT03970694|Experimental|Neoadjuvant chemoradiotherapy group|Neoadjuvant chemoradiotherapy（XELOX * 4 + radiotherapy）→ Surgery (if possible) → post-surgery chemotherapy.
88950614|NCT03970694|Other|Neoadjuvant chemotherapy group|Arm Type: control. Neoadjuvant chemotherapy（XELOX * 4）→ Surgery (if possible) → post-surgery chemotherapy.
88950615|NCT03951077|Placebo Comparator|Placebo|Placebo taken orally twice a day (BID)
88950616|NCT03951077|Experimental|Elagolix 25 mg BID|Elagolix 25 mg taken orally BID plus placebo
88950617|NCT03951077|Experimental|Elagolix 50 mg Once Daily (QD)|Elagolix 50 mg taken orally QD plus placebo
88950618|NCT03951077|Experimental|Elagolix 75 mg BID|Elagolix 75 mg taken orally BID plus placebo
89477625|NCT02714894||Clozapine Non-Responders (URS)|"Definition of URS~Taking clozapine for ≥ 12 weeks, attaining a plasma clozapine level ≥350 ng/ml.~CGI-Severity score of ≥4 and score of ≥4 on 2 PANSS positivesymptom items."
89477626|NCT02714894||Healthy Controls|Healthy controls will be matched as closely as possible on age and gender with participants in the patient groups.
89477627|NCT03303729|Experimental|Meat hydrolysate & Cluster Dextrin|Meat hydrolysate containing 25g of protein given together with 75 grams of Cluster Dextrin.
88950619|NCT03951077|Experimental|Elagolix 150 mg QD|Elagolix 150 mg taken orally QD plus placebo
88950620|NCT03951077|Experimental|Elagolix 300 mg QD|Elagolix 300 mg taken orally QD plus placebo
88950621|NCT03941132|Experimental|Ustekinumab|"Week 0: Loading dose of 6mg/kg Ustekinumab Intravenously.~Weeks 8, 16, 24, 32, 40, and 48 (6 visits): 90mg Ustekinumab subcutaneously.~Weeks 28, 52, 78: Non-dosing visits where a Mixed Meal Tolerance Test will be administered.~Total of 11 visits"
88950622|NCT03941132|Placebo Comparator|Saline Solution - Placebo|"Patients allocated to receive placebo will receive respective amounts of a saline-placebo at the same intervals.~Week 0: Loading dose of 6mg/kg saline intravenously.~Weeks 8, 16, 24, 32, 40, and 48 (6 visits): 90mg saline subcutaneously.~Weeks 28, 52, 78: Non-dosing visits where a Mixed Meal Tolerance Test will be administered.~Total of 11 visits"
88950623|NCT03873246|Active Comparator|OC-01 0.1%, 0.6 mg/ml|OC-01 (varenicline) nasal spray, 0.6 mg/mL
88950624|NCT03873246|Active Comparator|OC-01 0.2%, 1.2 mg/ml|OC-01 (varenicline) nasal spray, 1.2 mg/mL
88950625|NCT03873246|Placebo Comparator|Placebo|vehicle control
88950626|NCT03849417||Late-life Depression|Patients aged over 60 years old with severe depression
88950627|NCT03849417||Late-life Depression (ECT)|Patients aged over 60 years old with severe depression who are referred for treatment with electroconvulsive therapy
88950628|NCT03849417||Healthy Controls|Healthy volunteers over 60 years old who will form a comparison group
88950629|NCT03769649|Experimental|Treatment arm|Subjects receive CelluTite treatment followed by Morpheus8 treatment
88950630|NCT03734406|Experimental|Video group|"All subjects enrolled in the study group will be showed during the discharge process the video related to patient's condition (DVT vs AF), using it as a graphic support to doctor's verbal explanation of the diagnosed pathology and its possible complications.~For the purposes of the study we have selected two 3D videoclips, available on various internet sites and not covered by any copyright restrictions; these have been modified and shortened to make them suitable to use in our study setting.~The images contained show the pathophysiological process underlying the two diseases under study, namely deep vein thrombosis and atrial fibrillation.~The SIs will show the videos to patients on the institutional computer or, alternatively, on their personal smartphone / tablet. The videos were purposely left without audio content."
89020505|NCT04091347|Experimental|Intervention Arm|The intervention group will receive the intervention for 12 weeks. The wait list control group will have outcomes measured but will not receive the intervention at this time.
89477628|NCT03303729|Active Comparator|Meat hydrolysate & placebo|Meat hydrolysate containing 25g of protein given together with 75 grams of Glucose.
89477629|NCT03390140|Experimental|Group|ReInventing Yourself after SCI structured group CBT and ReInventing Yourself after SCI study-specific workbook
89477630|NCT03390140|Active Comparator|Indiv|ReInventing Yourself after SCI study-specific workbook and ReInventing Yourself after SCI YouTube videos
89477631|NCT03390140|No Intervention|Control|No group sessions, no YouTube videos, no workbook
89537541|NCT05249517|Experimental|Pain Neuroscience Education (PNE)|Telerehabilitation based pain neuroscience education
89477632|NCT03303651|Experimental|PPI (Pain Pupillary Index)|Opioid administration guided by Pain Pupillary Index (PPI) derived from Videopupillometry performed with the device AlgiScan manufactured by IDMed, Marseille, France. The device measures the degree of pupillary reflex dilation (PRD) following an electric nociceptive stimulation. It automatically increases the intensity of the electric stimulation from 10 to 60 milliampere depending on the degree of PRD and afterwards displays the PPI. The numerical index ranges from 0 to 10. A low PPI score indicates a deep analgesia, a high PPI score indicates an insufficient or light analgesia. A PPI score of 2 or 3 is supposed to represent an optimal level of analgesia according to the manufacturer. 5 µg sufentanil will be administered every 5 minutes if PPI score is calculated more than 3.
89477633|NCT03303651|Experimental|SPI (Surgical Pleth Index)|Opioid administration (sufentanil) guided by by Surgical Pleth Index (SPI) derived from photoplethysmography performed by the device CARESCAPE B650 Patient Monitor from the manufacturer GE (General Electrics) Healthcare, Helsinki, Finland. Included in the monitoring system is a software that continuously calculates the SPI from normalized heart rate and pulse wave amplitude derived from finger plethysmography. The numerical index ranges between 0 (low sympathetic tone) and 100 (high sympathetic tone). A SPI score between 20 and 50 has been proposed as the target range to guide analgesics (15 - 17). 5 µg Sufentanil will be administered every 5 minutes if SPI score is calculated more than 50.
89477634|NCT03303651|Experimental|NOL (Nociception Level)|Opioid administration (sufentanil) guided by Nociception Level (NOL) derived from finger photoplethysmography performed with the analgesia monitoring device PMD200 manufactured by Medasense, Ramat Gan, Israel. The device continuously calculates the NOL with a multi-parametric approach from pulse rate, pulse rate variability, pulse wave amplitude, skin conductance level, skin conductance fluctuations, skin temperature and finger motion. The composite algorithm of the device analyses the data and the numerical index NOL is presented on a scale from 0 (no pain) to 100 (extreme pain) (18). A NOL score between 10 and 25 has been proposed as the target range to guide analgesics. 5 µg Sufentanil will be administered every 5 minutes if NOL score is calculated more than 25.
89477635|NCT03303651|Active Comparator|Control|Opioid administration (sufentanil) guided according to standard clinical practice of the attending anesthesiologist based upon changes of heart rate, blood pressure, lacrimation and sweating of the patient.
89477636|NCT03312153|Experimental|Neem (Azadirachta indica)|Neem (Azadirachta indica) (alcoholic solution) used as an anti inflammatory , antibacterial irrigant
89477637|NCT03312153|Active Comparator|2.5%sodium hypochlorite|2.5% sodium hypochlorite, anti-bacterial root canal irrigant solution
89477638|NCT03309267||Intercostal block|Anesthesia induction was performed to all patients .At the end of the operation some patients were performed with intercostal block by the chest surgeon. For 24 hours postoperatively, tramadol was administered with patient-controlled analgesia (PCA) All patients were extubated after the operation and transferred to ICU.
89477639|NCT03309267||Serratus anterior plane block|Anesthesia induction was performed to all patients. At the end of the operation some patients were performed SAPB under Ultrasound guidance by the same anesthetist.For 24 hours postoperatively, tramadol was administered with patient-controlled analgesia (PCA) All patients were extubated after the operation and transferred to ICU.
89477640|NCT03303573||recombinant human erythropoietin group|cerebral palsy patients who had received erythropoietin from January 2013 to November 2016
89477641|NCT03312075||cystic fibrosis patients|Sputum and blood samples
89477642|NCT03303495|Experimental|FOLFIRI +/- Bevacizumab|Bevacizumab 5 mg/kg IV 90-30 min Day 1; CPT-11 180 mg/m2 IV 90 min Day 1; l-LV (dl-LV) 200 mg/m2 (400 mg/m2) IV 120 min Day 1; 5-FU - bolus 400 mg/m2 IV bolus Day 1; 5-FU - infusional 2400 mg/m2 IV continuous (46 hours) Day 1 - 3
89477643|NCT03303495|Experimental|CPT-11 +/- Bevacizumab|Bevacizumab 5 mg/kg IV 90-30 min Day 1; CPT-11 180 mg/m2 IV 90 min Day 1
88950631|NCT03734406|No Intervention|Control group|"Patients of the control group will receive discharge explanations without the aid of any video.~The communication strategy in these cases won't be standardized, in order to leave the treating doctors free to express themselves in the way they are used to in their clinical practice, which is based solely on doctor's verbal and non-verbal communication skills."
88950632|NCT03715439||Leucocyte- and Platelet-rich Fibrin|Dental implant placed into post-extraction sites preserved with leucocyte- and platelet-rich fibrin
88950633|NCT03715439||Control|Dental implant placed into non-preserved post-extraction sites
88950634|NCT03714880|Experimental|Mifepristone|Participants ingest mifepristone 200 mg oral medication once 18-24 hours prior to dilator placement
88950635|NCT03714880|Placebo Comparator|Placebo|Participants ingest placebo oral medication once 18-24 hours prior to dilator placement
88950636|NCT03645941|No Intervention|Quitline/Treatment Referral|Description of tobacco treatment services, phone numbers and web links sent via postal mail (printed materials) and email. Treatment options provide free, professional assistance based on U.S. clinical practice guidelines: (1)AK quitline, (2)regional tribal tobacco cessation programs, and (3)smokefree.gov resources (e.g., free texting program and smartphone application, quit guide)
88950637|NCT03645941|Experimental|Facebook+Quitline/Treatment Referral|"Participants join a secret/private, culturally relevant Facebook group moderated by an AN tobacco research counselor for 3 months~Once daily moderator postings for 30 days, repeated each month for 3 months; plus 3-4 daily check-ins/postings to respond to participant generated content and encourage sharing of personal stories/experiences relevant to all stages of the quitting process and treatment engagement~Description of tobacco treatment services, phone numbers and web links sent via postal mail (printed materials) and email. Treatment options provide free, professional assistance based on U.S. clinical practice guidelines: (1)AK quitline, (2)regional tribal tobacco cessation programs, and (3)smokefree.gov resources (e.g., free texting program and smartphone application, quit guide)"
88950638|NCT03619850|Experimental|Ferumoxytol|
88950639|NCT03619850|Active Comparator|Iron sucrose|
88950640|NCT03530358|Experimental|Technology-aided rehabilitation|The technology-aided upper limb rehabilitation include reinforced feedback in virtual environment (RFVE), or robotic therapy.
89477644|NCT03309111|Experimental|ISB 1342|Part 1: Cohorts of multiple ISB 1342 dose levels; Part 2: One dose regimen until disease progression or other discontinuation criterion is met
89477645|NCT03308955|Active Comparator|Grup B|Ultrasound guided Quadratus Lumborum block type II with 0.3 ml/kg % 0.25 bupivakain+ 400 mg tramadol, IV 4 mg/ mL tramadol solution into 100 mL normal saline; PCA settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.
89477646|NCT03308955|Sham Comparator|Grup S|Ultrasound guided Quadratus Lumborum block type II with 0.3 ml/kg saline % 0,9+ 400 mg tramadol, IV 4 mg/ mL tramadol solution into 100 mL normal saline; PCA settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.
89477647|NCT03311685|Experimental|Laparoscopic POP repair|"Patients undergoing laparoscopic surgery for the repair of pelvic organ prolapse.~vaginal tactile imager"
89477648|NCT03311685|Experimental|Vaginal POP repair|Patients undergoing vaginal surgery for the repair of pelvic organ prolapse. vaginal tactile imager
89477649|NCT03303183|Active Comparator|Direct Ear Scanner|Digitale impression via direct ear scanner
89477650|NCT03303183|Active Comparator|Silicone Ear impression|Impression via silicone
89477651|NCT03311607|Other|Cohort treated with AmBisome 15 mg/kg|280 patients, receiving AmBisome
89477652|NCT03303027|Experimental|6-0 fast absorbing gut suture|6-0 fast absorbing gut used to suture wound
89477653|NCT03303027|Experimental|5-0 fast absorbing gut suture|5-0 fast absorbing gut used to suture wound
89477654|NCT03311529|Experimental|Applied Relaxation|
89477655|NCT03311529|No Intervention|usual care|
89477656|NCT04490889||Patients with PGT indication|Patients undergo in vitro fertilization with PGT-A or for PGT-SR indication
89477657|NCT05232435|Experimental|pilate group|will receive pilate exercise(1- bridging 2- shoulder bridge 3- front support 4- spine stretch forward 5- spine twist) and standard treatment (stretch hamstring , stretch lower back , strength abdominal muscles and electrical heat pad) for 12 sessions(3 sessions/week) over a period of four weeks.
89477658|NCT05232435|Experimental|MET|will receiveMET treatment for hamstring and erector spinae and standard treatment(stretch hamstring , stretch lower back , strength abdominal muscles and electrical heat pad) for 12 sessions (3 sessions/week)over a period of four weeks.
89477659|NCT05232435|Active Comparator|control group|will receive standard treatment(stretch hamstring , stretch lower back , strength abdominal muscles and electrical heat pad) only for 12 sessions (3 sessions/week) over a period of four weeks.
89477660|NCT03308643|Experimental|Oxytocin infusion|Patients will receive intravenous oxytocin infusion just before the surgery after the induction of general anesthesia.
88950641|NCT03530358|Active Comparator|Conventional rehabilitation|The conventional upper limb rehabilitation program will be based on traditional rehabilitation techniques aimed at restoring upper limb motor functions.
88950642|NCT03439774||Adults 18 years old or older|
88950643|NCT03426878|Active Comparator|Traditional genetic counseling|This will be typical genetic counseling that a patient would receive in a traditional genetic counseling setting.
88950644|NCT03426878|Experimental|Modified genetic counseling|This will be genetic counseling that is modified for a lower literacy patient and will include fewer technical terms and less complicated genetic information.
88950645|NCT03412578|No Intervention|Control|Infants in this group will receive ordinary supportive care and will not receive Massage Therapy
88950646|NCT03412578|Active Comparator|Massage group|"Infants in this group will receive Massage Therapy Massage therapy was started at corrected gestational age of 35 weeks and continued for 5 consecutive days. The protocol of massage therapy was performed as been described by Tiffany Field (Field, Schanberg et al. 1986). Three consecutive, 15 minutes, sessions were performed daily after the noon feeding. Each treatment session was divided into 5 minutes of tactile stimulation, followed by 5 minutes of kinaesthetic stimulation, and then another 5 minutes of tactile stimulation (Field, Diego et al. 2006).~During massage therapy, infant's behavioural reaction was observed for signs of distress (e.g., yawning, finger splaying, crying)."
88950647|NCT03337802|No Intervention|Pregnant women at standard diet|obstetrical and gynecological follow-up
88950648|NCT03337802|Experimental|Pregnant women at mediterranean diet|obstetrical and gynecological follow-up + nutritional counseling
88950649|NCT03333005|Experimental|APX001 with Standard of Care Anti-fungal agent|
88950650|NCT03330496||Preterm infants|preterm neonates (34-37 weeks gestational age, n=15)
88950651|NCT03330496||Term infants|term newborns (37-42 weeks gestation, n=15)
88950652|NCT03330496||Small infants|1-3 month-old infants (n=15)
88950653|NCT03330496||Older infants|3-6 month-old infants (n=15)
88950654|NCT03284268|Experimental|Dose escalation of VCN-01|Dose lower : 2E+9 viral particules/eye Dose medium: 2E+10 viral particules/eye Dose high: 2E+11 viral particules/eye
88950655|NCT03231995|Experimental|Respiratory microbiome biomarkers|
88950656|NCT03166813|Experimental|Intervention RIPC|The intervention RIPC protocol will be induced by three cycles of inflation of a blood pressure cuff placed over the upper or lower limb, where deemed to cause minimal discomfort to patient, to 15 mmHg above the systolic blood pressure for five minutes followed by five minutes of cuff deflation to 0 mmHg.
89477661|NCT03308643|Placebo Comparator|Placebo|Patients will receive pure normal saline infusion at the same rate and volume just before the surgery after the induction of general anesthesia.
89477662|NCT03302871|Experimental|İntensive Therapy Group|Children who received Botulinum toxin type A to plegic upper limb would be treated by transcranial direct current stimulation and a hybrid training model of CIMT and BIT
89477663|NCT03302871|Active Comparator|Control Group|Children who received Botulinum toxin type A to plegic upper limb would continue their usual care
89537542|NCT05249517|Active Comparator|Exercise + PNE|Telerehabilitation based progressive submaximal exercise program and PNE
88950657|NCT03166813|Placebo Comparator|Control|The control protocol involves only placement of blood pressure cuff but without inflation for 30 minutes.
88950658|NCT03148366|Experimental|Levofloxacin based sequential therapy|"Levofloxacin based sequential therapy~: sequential therapy containing levofloxacin for 14 days D1-D7: (esomeprazole 40mg bid + amoxicillin 1gm bid) for 7 days D8-D14: (esomeprazole 40mg bid + levofloxacin 250mg bid + metronidazole 500mg bid) for another 7 days"
89477664|NCT03311295|Experimental|ARTO System|
88950659|NCT03148366|Active Comparator|bismuth quadruple therapy (BQ)|bismuth quadruple therapy for 10 days (BQ) D1-D10: (esomeprazole 40mg bid + Dibismuth trioxide 120mg qid + metronidazole 500mg tid + tetracycline 500mg qid) for 10 days
88950660|NCT03122496|Experimental|durvalumab (MEDI4736) & tremelimumab with SBRT|Patients will receive durvalumab (MEDI4736) and tremelimumab together every 4 weeks. SBRT delivered to one metastatic site per standard of care using a standard 9Gy x 3 fractions will be given within 2 weeks after the completion of the first cycle of durvalumab (MEDI4736) and tremelimumab. After 4 cycles of durvalumab (MEDI4736) and tremelimumab, patients will then continue with single agent durvalumab (MEDI4736) every 4 weeks until disease progression or unacceptable toxicity or a total of 12 months from date of initial treatment.
88950661|NCT03107104||Medical need for FA imaging|Subjects deemed to have a medical need for FA imaging will be imaged on the Topcon DRI OCT Triton (plus) and TRC-50DX retinal camera
88950662|NCT03073694|Active Comparator|Mitomycin C Group|Mitomycin-C initial dose of 15 mg/m2 (milligrams per meter squared) 45 minutes into the perfusion, a maintenance dose of 5 mg/m2 will be administered.
88950663|NCT03073694|Experimental|Melphalan Group|Melphalan 60 mg/m2 (milligrams per meter squared) 45 minutes into the perfusion.
88950664|NCT03069703|Active Comparator|Prime-boost strategy|a single dose of 13-valent pneumococcal conjugate vaccine (Prevenar, PCV13) at Day 0 (lying within a window of ± 2 days of the first infusion of rituximab), followed by a single dose of 23-valent unconjugated vaccine (Pneumovax, PPV23) at month 5 (M5)
88950665|NCT03069703|Experimental|Innovative vaccine strategy 1|2 doses of PCV13 at Day 0 and 2 doses of PCV13 at Day 7, followed by a single dose of PPV23 at M5
88950666|NCT03069703|Experimental|Innovative vaccine strategy 2|4 doses of PCV13 at Day 0, followed by a single dose of PPV23 at M5
88950667|NCT03067675||Subjects Presenting With Normal Eyes|Subjects with no known ocular diseases will be scanned on the Topcon DRI OCT Triton (plus) device
88950668|NCT02982174||Normal Eyes|Subjects with no known ocular diseases will be imaged on the 3D OCT-1 Maestro and DRI OCT Triton
88950669|NCT02963415|Experimental|Virtual Reality Cognitive Training|Exergame to stimulate cognition
88950670|NCT02862548|Experimental|TAF|TAF 25 mg once daily for 48 weeks
88950671|NCT02862548|Active Comparator|TDF-Containing Regimens|TDF alone or in combination with other approved antivirals per local practice for 48 weeks
88950672|NCT02862548|Experimental|Optional Treatment Extension Phase|After Week 48, participants will be eligible to receive TAF 25 mg once daily for an additional 144 weeks.
88950673|NCT02851277|Experimental|Low dose ASP0892 Intradermal|Participants will receive study drug once every 2 weeks for a total of 4 doses. After participants complete the Low dose arms, the Dose Escalation Committee (DEC) will determine if the study can progress to the parallel higher dose arms.
88950674|NCT02851277|Experimental|High dose ASP0892 Intradermal|Participants will receive study drug once every 2 weeks for a total of 4 doses.
88950675|NCT02851277|Placebo Comparator|Placebo Intradermal|Participants will receive comparable Placebo once every 2 weeks for a total of 4 doses.
88950676|NCT02851277|Experimental|High dose ASP0892 Intramuscular|Participants will receive study drug once every 2 weeks for a total of 4 doses.
88950677|NCT02851277|Placebo Comparator|Placebo Intramuscular|Participants will receive comparable Placebo once every 2 weeks for a total of 4 doses.
88950678|NCT02851147||Any Willing and Able Person for Ocular Imaging|Any Willing and Able Person for Ocular Imaging
88950679|NCT02818738|Experimental|Levamisole Hydrochloride|Dosage : 5, 10, 25 et 50mg. Dosage form : oral tablets, coated and non dividable for taste-masking Posology : 2.5 mg/kg on alternate days maximum 150mg. Treatment duration : 6 months
88950680|NCT02818738|Placebo Comparator|Placebo|matching verum
88950681|NCT02782442|Experimental|Structured Cognitive Training & PRIME|Structured cognitive training consists of social cognition and auditory exercises.
88950682|NCT02782442|Active Comparator|Computer Games Control & PRIME|Computer games control condition comes in the official PositScience wrapper.
88950683|NCT02742090|Experimental|TGR-1202|Oral daily dose of TGR-1202
88950684|NCT02723747||Healthy volunteers|Healthy subjects with normal 12-lead electrocardiogram at rest.
88950685|NCT02710682|Active Comparator|Mini-open surgery|Surgery
88950686|NCT02710682|Experimental|Ultrasound-guided Tendon fenestration|Tendon fenestration
88950687|NCT02432898||Normal Healthy Eyes|Normal healthy eyes with no known ocular diseases
88950688|NCT02427256||Non-Pathologic Adults age 18-28 yrs|
88950689|NCT02427256||Non-Pathologic Adults age 29-80 yrs|
88950690|NCT02427256||Pathologic Adults age 29-80 yrs|
88950691|NCT02426671|Experimental|MuteButton sensory stimulation device|"Participants will be asked to use the Mutebutton, neuro-modulation device every day for 60 minutes for 12 weeks. Use of the device involves placing a 'lollipop' type sensor on the tongue and wearing earphones. The participant will hear pink noise through the earphones and will receive neuro-stimulation through the sensor. The participant will not feel any discomfort whilst using the MuteButton device."
88950692|NCT02377089|Sham Comparator|Sham|The stimulators are the same device for the active and sham treatment conditions.
88950693|NCT02377089|Active Comparator|Active|The stimulators are the same device for the active and sham treatment conditions.
88950694|NCT02376868||Normal Eyes|Subjects with no known ocular diseases will be scanned with the iVue and Maestro device
88950695|NCT02376868||Glaucomatous Eyes|Subjects presenting with different stages of glaucoma will be scanned with the iVue and Maestro device
88950696|NCT02376868||Eyes with Retinal Diseases|Subjects presenting with Retinal pathological eyes will be scanned on the iVue and Maestro device
88950697|NCT02335099|Active Comparator|ticagrelor|90 mg of ticagrelor to be given orally twice a day for 6 months
88950698|NCT02335099|Placebo Comparator|Placebo|Placebo drug to be given twice a day for 6 months
89202833|NCT00757016|Placebo Comparator|B|0.99 ml saline solution 9mg/ml and 0.01 ml fat emulsion will be given once to the sacrospinous ligament insertion.
89477665|NCT03311217|Experimental|Intervention group|Healthy retail strategies will be implemented in tribally owned convenience stores in these communities. Specific strategies include pricing discounts, promotional signage, incorporation of new product, and placement of healthier items on shelves.
89477666|NCT03311217|No Intervention|Control group|No intervention will be implemented in the stores in the control communities.
89477667|NCT00703911||activated recombinant human factor VII|Male patients above 2 years of age with haemophilia A or B who have developed inhibitors and have been prescribed on-demand treatment of activated recombinant human factor VII at any dose for treatment of mild to moderate spontaneous bleeds
89477668|NCT03302715|Experimental|Mucosal biopsies|Only blood samples and mucosal biopsies
89477669|NCT03311139||AF and ACS patients: No PCI|Patients with Atrial Fibrillation and Acute Coronary Syndrom who did not undergo a Percutaneous Coronary Intervention
89477670|NCT03311139||AF and ACS patients: PCI without stent|Patients with Atrial Fibrillation and Acute Coronary Syndrom who underwent PCI without stent implantation (NOMESCO code FNG00-96 except FNG05)
89477671|NCT03311139||AF and ACS patients: PCI with stent|Patients with Atrial Fibrillation and Acute Coronary Syndrom who underwent PCI with stent implantation (NOMESCO code FNG05)
89477672|NCT03308487|Active Comparator|vitamin D3 (1000 IU)|group 1
89477673|NCT03308487|Active Comparator|vitamin D3 (2000 IU)|group 2
89477674|NCT03302637||Cases|subjects with histology-confirmed incident pancreatic cancer, with no prior history of cancer (except non-melanoma skin cancer), a valid consent, and pre-diagnostic oral wash samples.
89477675|NCT03302637||Control|selected by incidence density sampling63 among cohort members who had no cancer prior to selection, provided a valid consent and an oral wash. Controls were frequency matched to cases by cohort, age at cohort entry (5 year), sex, race, and calendar year of cohort entry.
89477676|NCT03308331|Experimental|HIV-1 smokers|
89477677|NCT03308331|No Intervention|HIV-1 nonsmokers|
89477678|NCT03308331|Active Comparator|Healthy control smokers|
89477679|NCT03308331|No Intervention|Healthy control nonsmokers|
89477680|NCT03308331|Active Comparator|HIV-1 nonsmokers using nicotine patch|
89477681|NCT03308331|No Intervention|HIV-1 nonsmokers using placebo patch|
89477682|NCT03308331|Active Comparator|Healthy control nonsmokers using nicotine patch|
89477683|NCT03308331|No Intervention|Healthy control nonsmokers using placebo patch|
89477684|NCT02055547|Experimental|Part 1 - Panel A - MK-8521 100μg > PBO|Healthy male participants of 18 to 45 years of age received a single dose of MK-8521 100μg in the first treatment period, and matching placebo (PBO) in the second treatment period. There was a minimum of a 7-day washout period between treatment periods.
89477685|NCT02055547|Experimental|Part 1 - Panel A - PBO > MK-8521 300μg|Healthy male participants of 18 to 45 years of age received a single dose of PBO in the first treatment period, and MK-8521 300μg in the second treatment period. There was a minimum of a 7-day washout period between treatment periods.
89477686|NCT02055547|Experimental|Part 1 - Panel A - MK-8521 100μg > MK-8521 300μg|Healthy male participants of 18 to 45 years of age received a single dose of MK-8521 100μg in the first treatment period, and MK-8521 300μg in the second treatment period. There was a minimum of a 7-day washout period between treatment periods.
89477687|NCT02055547|Experimental|Part 1 - Panel B - MK-8521 150μg > PBO > MK-8521 175μg|Healthy male participants of 18 to 45 years of age received a single dose of MK-8521 150μg in the first treatment period, PBO in the second treatment period, and MK-8521 175μg in the third treatment period. There was a minimum of a 7-day washout period between treatment periods.
89477688|NCT02055547|Experimental|Part 1- Panel B- MK-8521 150μg > MK-8521 200μg > MK-8521 175μg|Healthy male participants of 18 to 45 years of age received a single dose of MK-8521 150μg in the first treatment period, MK-8521 200μg in the second treatment period, and MK-8521 175μg in the third treatment period. There was a minimum of a 7-day washout period between treatment periods.
89477689|NCT02055547|Experimental|Part 1 - Panel B - MK-8521 150μg > MK-8521 200μg > PBO|Healthy male participants of 18 to 45 years of age received a single dose of MK-8521 150μg in the first treatment period, MK-8521 200μg in the second treatment period, and PBO in the third treatment period. There was a minimum of a 7-day washout period between treatment periods.
89477690|NCT02055547|Experimental|Part 1 - Panel B - PBO > MK-8521 200μg > MK-8521 175μg|Healthy male participants of 18 to 45 years of age received PBO in the first treatment period, MK-8521 200μg in the second treatment period, and MK-8521 175μg in the third treatment period. There was a minimum of a 7-day washout period between treatment periods.
89477691|NCT02055547|Experimental|Part 2 - Panel C - MK-8521 50μg > MK-8521 72μg|Healthy male participants of 18 to 45 years of age received a single dose of MK-8521 50μg Days 1 to 5 and MK-8521 72μg Days 6 to 10 in a single treatment period.
89477692|NCT02055547|Experimental|Part 2 - Panel D - MK-8521 100μg > MK-8521 150μg|Healthy male participants of 18 to 45 years of age received a single dose of MK-8521 100μg Days 1 to 5 and MK-8521 150μg Days 6 to 10 in a single treatment period.
89020506|NCT04091347|Active Comparator|Wait List Control Arm|Once the intervention group has completed the intervention the wait list control group will complete the intervention.
89020507|NCT04082767|Active Comparator|Dexmedetomidine|
89477693|NCT02055547|Experimental|Part 2 - Panel E - MK-8521 125μg > MK-8521 150μg|Healthy male participants of 18 to 45 years of age received a single dose of MK-8521 125μg Days 1 to 5 and MK-8521 150μg Days 6 to 10 in a single treatment period.
89477694|NCT02055547|Experimental|Part 2 - Panel F - MK-8521 72μg > MK-8521 125μg|Obese male participants of 45 to 65 years of age received a single dose of MK-8521 72μg Days 1 to 7 and MK-8521 125μg Days 8 to 14 in a single treatment period.
89477695|NCT02055547|Placebo Comparator|Part 2 - Panels C+D+E - Pooled Placebo|Healthy male participants of 18 to 45 years of age received PBO once daily for 10 days.
89477696|NCT02055547|Placebo Comparator|Part 2 - Panel F - Placebo|Obese male participants of 45 to 65 years of age received a single dose of PBO Days 1 to 14.
89477697|NCT02055547|Experimental|Part 3 - Panel H - MK-8521 125μg > MK-8521 35μg > PBO|Healthy male participants of 18 to 45 years of age received a single dose of MK-8521 125μg (high dose) in the first treatment period, MK-8521 35μg (low dose) in the second treatment period, and PBO in the third treatment period. There was a minimum of a 7-day washout period between treatment periods.
89477698|NCT02055547|Experimental|Part 3 - Panel H - MK-8521 35μg > PBO > MK-8521 125μg|Healthy male participants of 18 to 45 years of age received a single dose of MK-8521 35μg (low dose) in the first treatment period, PBO MK-8521 in the second treatment period, and 125μg (high dose) in the third treatment period. There was a minimum of a 7-day washout period between treatment periods.
89477699|NCT02055547|Experimental|Part 3 - Panel H - PBO > MK- 8521 125μg > MK-8521 35μg|Healthy male participants of 18 to 45 years of age received a single dose of PBO in the first treatment period, MK- 8521 125μg (high dose) in the second treatment period, and MK-8521 35μg (low dose) in the third treatment period. There was a minimum of a 7-day washout period between treatment periods.
89477700|NCT02055547|Experimental|Part 3 - Panel H - PBO > MK- 8521 35μg > MK-8521 125μg|Healthy male participants of 18 to 45 years of age received a single dose of PBO in the first treatment period, MK- 8521 35μg (low dose) in the second treatment period, and MK-8521 125μg (high dose) in the third treatment period. There was a minimum of a 7-day washout period between treatment periods.
89477701|NCT02055547|Experimental|Part 3 - Panel H - MK-8521 125μg > PBO > MK-8521 35μg|Healthy male participants of 18 to 45 years of age received a single dose of MK-8521 125μg (high dose) in the first treatment period, PBO in the second treatment period, and MK-8521 35μg (low dose) in the third treatment period. There was a minimum of a 7-day washout period between treatment periods.
89477702|NCT02055547|Experimental|Part 3 - Panel H - MK-8521 35μg > MK-8521 125μg > PBO|Healthy male participants of 18 to 45 years of age received a single dose of MK-8521 35μg (low dose) in the first treatment period, MK-8521 125μg (high dose) in the second treatment period, and PBO in the third treatment period. There was a minimum of a 7-day washout period between treatment periods.
89477703|NCT02468817|Active Comparator|Treadmill Exercise|2 (two) 1-hour of vigorous exercise bouts under different thermal conditions, one at 16 degrees C and one at 26 degrees C.
89020508|NCT04082767|Active Comparator|Midazolam|
89020509|NCT04077320|Experimental|Memory Self-Efficacy Training|Memory self-efficacy group training classes.
89477704|NCT02468817|Experimental|Magnitude of Ca loss during Exercise at 26 degrees Celcius|Blood samples at 15-min intervals starting 15 min before exercise and ending 60 min after exercise.
89477705|NCT04442451|Experimental|Control Exercise|Low-load knee extension resistance training (20% of 1-RM) without blood flow restriction. A 10-cm wide inflatable cuff will be placed around the upper portion of the thigh but not inflated.
89020510|NCT04077320|Active Comparator|General Education Group|General education group classes (e.g., exercise, diet, sustainability, tc.)
89477706|NCT04442451|Experimental|Blood Flow Restriction Exercise|Low-load knee extension resistance training (20% of 1-RM) with blood flow restriction using a 10-cm wide inflatable cuff placed around the most proximal part of the exercising thigh. Blood flow will be restricted in the BFR leg at above the limb occlusion pressure of the and this will be determined prior to the exercise while the participant is seated in the knee extensor machine. The cuff pressure during the BFR protocol will be 10 mmHg above limb occlusion pressure.
89477707|NCT05031585|Experimental|Intervention Group|Nasal lubricant spray
89477708|NCT05031585|Placebo Comparator|Placebo|Placebo spray
89477709|NCT02414854|Placebo Comparator|Placebo (for Dupilumab 200 mg) q2w|2 subcutaneous injections of matched Placebo (for Dupilumab 200 mg) as a loading dose on Day 1 (Week 0), followed by a single injection every 2 weeks (q2w) from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines. Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication.
89202834|NCT00757016|Active Comparator|A|1 ml triamcinolone 20mg/ml (Lederspan), Meda AB, Solna, Sweden) and 1 ml lidocaine hydrochloride 10mg/ml (Xylocain), Astra Zeneca, Södertälje, Sweden)
89202835|NCT00687362|Experimental|Infliximab 5 mg/kg|Infliximab 5 mg/kg of body weight given as an infusion at Weeks 0, 2, 6, 14, and 22.
89202836|NCT00757094||I|Patients planning to observe fasting while receiving chemotherapy during the month of Ramadan
89202837|NCT00757250|Experimental|1|Dose Cohort 1: 50 mcg/kg/day of TXA127
89202838|NCT00757250|Experimental|2|Drug Cohort 2: 100 mcg/kg/day TXA127
89202839|NCT00757250|Experimental|3|Drug Cohort 3: 200 mcg/kg/day TXA127
89202840|NCT00757250|Experimental|4|Drug Cohort 4: 300 mcg/kg/day TXA127
89202841|NCT00757250|Experimental|5|Extended dosing cohort at 300mcg/kg TXA127 for 2 x 28-day treatment cycles, with an extended follow-up period to week 34.
89202842|NCT00751478|Experimental|A|2 Placebo capsules (whole) + ALO-01 2 x 60 mg capsules (crushed) in apple juice + apple juice (MSIR placebo)
89202843|NCT00751478|Experimental|B|2 x 60 mg ALO-01 (whole) + 2 x placebo capsules (crushed) in apple juice + apple juice (MSIR placebo)
89477710|NCT02414854|Experimental|Dupilumab 200 mg q2w|2 subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1 (Week 0), followed by a single 200 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines. Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication.
89477711|NCT02414854|Placebo Comparator|Placebo (for Dupilumab 300 mg) q2w|2 subcutaneous injections of matched Placebo (for Dupilumab 300 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines. Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication.
89477712|NCT02414854|Experimental|Dupilumab 300 mg q2w|2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1 (Week 0), followed by a single 300 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines . Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication.
89477713|NCT04442139||Mini-Gastric Bypass|Patients reported completing survey following Mini-Gastric Bypass
89477714|NCT03308253|Other|Standard of Care|Patients will receive the standard of care for vascular procedures as it is provided at Hamilton General Hospital
89477715|NCT03308253|Experimental|Antibiotic Impregnated Beads|Patients will have their wound packed with calcium sulfate beads prior to closing. The beads will be infused with the antibiotics vancomycin and tobramycin.
89477716|NCT02055625|Experimental|Mesenchymal stromal cell treatment|Biological: Mesenchymal stromal cells
89477717|NCT02467023|Experimental|effective muscle stimulation group|Subjects in this arm will be in the study for up to 28 days or until discharge from the ICU. They will receive lower extremity muscle stimulation with Niveus medical stimulator, multiple measurement of maximal isometric twitch strength, muscle biopsy with muscle biopsy medication fentanyl, muscle biopsy medication versed, muscle biopsy medication lidocaine, and blood and urine sampling.
89020511|NCT04071990|Active Comparator|Family-based cognitive behavioral group therapy (FB-CBGT)|One family member of each patient will be involved during all 12 CBGT sessions. The CBGT program that will be employed in the present study is a protocoled therapy consisting of psychoeducation, ERP techniques, cognitive tools to change dysfunctional thoughts and beliefs, strategies to prevent relapses, discussion on the family involvement (e.g. FA, burden, …) and homework exercises after each session.
89477718|NCT02467023|Active Comparator|ineffective muscle stimulation group|Subjects assigned to this arm will be studied for up to 28 days or until discharge and will receive a sham muscle stimulation with Niveus medical stimulator, multiple measurement of maximal isometric twitch strength blood and urine samples, and a muscle biopsy sample with muscle biopsy medication fentanyl, muscle biopsy medication versed, and muscle biopsy medication lidocaine.
89477719|NCT02055703|Experimental|E2609|Experimental drug for Parts A, B, and C
89477720|NCT02055703|Active Comparator|itraconazole|Comparator drug for Part A1
89477721|NCT02055703|Active Comparator|rifampin|Comparator drug for Part A2
89477722|NCT02055703|Active Comparator|digoxin|Comparator drug for Part B
89477723|NCT02055703|Active Comparator|donepezil|Comparator drug for Part C
89477724|NCT03302481|Experimental|Experimental Group|the biopsies will be performed under laparoscopy and taken in the lower part of the right hepatic lobe
89477725|NCT02058433|Experimental|pharmacokinetics group|Based on pharmacokinetics. Observe safety and efficacy. In first cycle a fixed Paclitaxel dose depends on BSA. In subsequent cycles the dosage of Paclitaxel will be adjusted depending on pharmacokinetics follow up .
89477726|NCT02058433|Active Comparator|Body surface area(BSA) group|Based on body surface area. The dosage of Paclitaxel is based on the BSA of the patient. Paclitaxel/carboplatin up to 4 cycles or disease progression or intolerable toxicity.
89477727|NCT03561181|Experimental|High dose Group|Received Vaccine: S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine,10μg/dose
89477728|NCT03561181|Experimental|low dose Group|Received Vaccine: S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine,5μg/dose
89477729|NCT03308175|Experimental|flat fixed anterior bite plane|"Bands selection will be done for upper 6s. Alginate impressions taken and molar bands are fitted in place into the impressions. Impressions for upper and lower arches are poured with stone plaster. Mounting on simple hinge articulator will be done.~Lingual arches (diameter 1 mm) with anterior acrylic bite plates with thickness enough to separate posterior teeth 4mm .~The acrylic bite planes were in occlusion with the lower anterior teeth and extended sagittally 2-3mm beyond edges of lower incisors.~Finishing ,polishing and cementation into patient's mouth with glass ionomer cement."
89477730|NCT03308175|Experimental|modified inclined fixed anterior bite plane|"In modified inclined fixed anterior bite plane,the modification is that some indentations will be done in the acrylic part where the lower anteriors will fit such that mandible will be held in a more forward position. These indentations will be relieved lingually to overcome it's flaring effect on mandibular incisors .The inclined plane will be 60 degrees to occlusal plane.~Functional bite will be taken to position the mandible in the proper position forward.~Bite taken edge-to-edge for appliance construction. Mounting upper and lower casts on simple hinge articulator for construction of modified flat fixed anterior bite plane"
89477731|NCT02060149|Sham Comparator|no nebulization|Antibiotics protocol is C/S plus minocycline. That is Cefoperazone/ sulbactam 3.0g（intravenous infusion, q8h or q6h) combined with minocycline doxycycline 100mg (oral,q12h).No nebulization will given to these patients.
89477732|NCT02060149|Active Comparator|nebulization with pH 7.4 solution|Patients will received the same antibiotics protocol with C/S plus minocycline and nebulization with pH 7.4 solution(Each time the volume of aerosol solution is 5ml, q8h).
89477733|NCT02060149|Experimental|nebulization with pH 7.8 solution|Patients will received the same antibiotics protocol with C/S plus minocycline and nebulization with pH 7.8 solution(Each time the volume of aerosol solution is 5ml, q8h).
89477734|NCT03302403|Experimental|CAR T cell|"In this study, autologous T cells transduced with a chimeric antigen receptor are used to treat patients with malignant tumors:~CAR-CD19 T cell is for the treatment of B-cell Leukaemia/Lymphoma; CAR-BCMA T cell is for the treatment of Myeloma; CAR-GPC3 T cell is for the treatment of Hepatocellular Carcinoma; CAR-CLD18 T cell is for the treatment of Pancreatic Carcinoma and Adenocarcinoma of Esophagogastric Junction.~Route of administration: Intravenous injection.~Lymphodepletion conditioning:~Lymphodepletion will be conducted several days prior to CAR T cell infusion, which may improve in vivo cell count and survival of T cells.~A combination of fludarabine and cyclophosphamide will be used for lymphodepletion."
89477735|NCT02038621|Experimental|A|Capecitabine: 1000mg/m^2 bid, days 1-14, every 3 weeks until progression/intolerance.
89477736|NCT02038621|Placebo Comparator|B|Observation until progression
89477737|NCT04902651|Experimental|HM242-Gel|
89477738|NCT04902651|Active Comparator|Intrasite Gel|
89477739|NCT02055859|Other|single session radiosurgery|single session radiosurgery (gold standard)
89477740|NCT02055859|Experimental|multisession radiosurgery|multisession radiosurgery (3 fraction)
89202844|NCT00751478|Active Comparator|C|2 x placebo capsules (whole) + 2 X placebo capsules (crushed) in apple juice + 120 mg MSIR in apple juice
89202845|NCT00751478|Placebo Comparator|D|2 x placebo capsules (whole) + 2 X placebo capsules (crushed) in apple juice + apple juice (MSIR placebo)
89202846|NCT00751556|Experimental|Arm 1|
89202847|NCT00751556|Active Comparator|Arm 2|
89477741|NCT04891341|Experimental|Technology Supported Task-Oriented Circuit Therapy Group|Ten workstations, which are frequently used in the literature and determined according to the clinical experience of the research team, have been created. Each workstation will be applied for a total of 1 hour, in the form of 5 minutes of training and 1 minute of rest.
89477742|NCT04891341|Active Comparator|Home-based Telerehabilitation Group|To the telerehabilitation group; A home program consisting of strengthening, balance and coordination exercises determined according to the needs of volunteers with MS will be given. A session will be applied in the home program under the guidance of a physiotherapist. The exercise will take 1 hour. The exercise participation status of the patient will be monitored with a mobile (smartphone) application. Exercises will be constantly updated according to the needs of the patient, the updated exercises will be sent to the mobile application via video, and the patient will be able to communicate with the physiotherapist via video conference whenever he / she wishes. Progress and complication of the treatment program will be achieved by increasing the weights used, changing the ground characteristics and support surface during balance exercises and increasing the complexity of coordination exercises.
89477743|NCT02467959||Ultrasound|Ultrasound evaluation
89477744|NCT03332498|Experimental|Pembrolizumab and Ibrutinib|"Pembrolizumab intravenously (IV): 200 mg every 3 weeks (Q3W).~Ibrutinib by mouth (PO): Phase I Dose Escalation at doses of 420 mg daily (cohort 0) and 560 mg daily (cohort 1);. Phase II treatment at Recommended Phase II dose."
89477745|NCT01334125|Experimental|Metformin|Metformin 1000 mg once daily by mouth for 9 months
89477746|NCT01334125|Placebo Comparator|Placebo|2 capsules once daily by mouth for 9 months
89477747|NCT03302325||Stage IV solid tumors|adult patients with stage IV cancer that are starting a new line of treatment
89477748|NCT02414152|Experimental|anakinra|100mg of Anakinra administered as a daily subcutaneous injection
89477749|NCT03308019|Experimental|Adjunctive photodynamic therapy|This arm will be given scaling and root planing (SRP) with adjunctive photodynamic therapy (aPDT)
89477750|NCT03308019|Active Comparator|Dental scaling|This arm will be given scaling and root planing (SRP) only
89477751|NCT02413996|Experimental|VRRS rehabilitation|exercise therapy through a virtual reality rehabilitation system (VRRS) in addition to a knee continuous passive motion device ( Kinetec® continuous passive motion ( CPM )) and functional activities (e.g.,stairs, walking)
89477752|NCT02413996|Active Comparator|traditional rehabilitation|exercise therapy through a traditional rehabilitation training in addition to a knee continuous passive motion device ( Kinetec® continuous passive motion ( CPM )) and functional activities (e.g.,stairs, walking)
89477753|NCT03302169|Experimental|Posterior Rhabdosphincter Reconstruction|Patients in who posterior rhabdosphincter reconstruction is performed
89477754|NCT03302169|Active Comparator|Standard Technique|Patients in who posterior rhabdosphincter reconstruction is NOT performed, Standard technique.
89477755|NCT05727813|Experimental|cryoablation|"We will enroll women with a biopsy-proven diagnosis of early-stage breast cancer (T1 N0), not eligible for neo-adjuvant therapy, scheduled to breast surgery (mastectomy or nodulectomy), who have given the informed consent for the study.~We will recruit 20 women who will undergo cryoablation."
89477756|NCT05727813|No Intervention|no cryoablation|The results will be compared with those obtained from a control group of 20 women, who will follow the same therapeutic pathway for the treatment of breast cancer without performing cryoablation.
89477757|NCT02467725|Experimental|Dynamic Culture Platform|Embryos randomized to the dynamic arm will be placed on the NSSB-300 microvibration platform within the designated incubator. The platform will vibrate at a strength setting of 4 for 5 seconds every 60 minutes. The embryos will be placed on the platform at the two pronucleur stage of development and remain on the platform until the blastocyst stage of development at which time the embryos will be biopsied for preimplantation genetic screening and frozen.
89477758|NCT02467725|No Intervention|Static Culture|The embryos randomized to the static or control arm of the study will be placed directly into the incubator and will not have any additional vibration, per routine care. The embryos will be placed in the incubator at the two pronucleur stage of development and remain in the incubator until the blastocyst stage of development at which time the embryos will be biopsied for preimplantation genetic screening and frozen.
89477759|NCT01333501|Experimental|Fingolimod|0.5 mg in capsules for oral administration once daily
89477760|NCT01333501|Active Comparator|Interferon beta 1b|250 μg injected s.c. every other day
89477761|NCT01362140|Experimental|Darbepoetin alfa|Participants received darbepoetin alfa 500 µg every three weeks (Q3W) for 24 weeks in the double-blind treatment period, and continued to receive darbepoetin alfa 500 µg Q3W during the active treatment period for an additional 48 weeks.
89477762|NCT01362140|Placebo Comparator|Placebo|Participants received placebo subcutaneous injection every 3 weeks (Q3W) for 24 weeks during the double-blind treatment period. From week 25 participants received darbepoetin alfa 500 µg Q3W during the active treatment period for 48 weeks.
89477763|NCT03307941|Other|Single arm (classic 3+3 design)|
89477764|NCT03307863|Experimental|Carbamazepine-Implant|Women with epilepsy using carbamazepine for at least 3 months will have an etonogestrel-releasing implant inserted
89477765|NCT03307863|Experimental|Topiramate-Implant|Women with epilepsy using topiramate for at least 3 months will have an etonogestrel-releasing implant inserted
89477766|NCT03307863|Active Comparator|Implant|Women without epilepsy and not using an anti-epileptic drug will have an etonogestrel-releasing implant inserted
89477767|NCT02467803|Active Comparator|Intervention|We applied scapula mobilization with shoulder ROM exercises
89477768|NCT02467803|Other|Control|We applied only shoulder ROM exercises
89477769|NCT03302013|Experimental|Vanguard XP Knee Replacement Surgery|Participants randomised in this group will receive the Vanguard XP Bi-cruciate Retaining Knee Replacement System. This total knee replacement device (Vanguard XP) and surgical procedure retain the anterior cruciate ligament in the knee.
89477770|NCT03302013|Active Comparator|Vanguard CR Knee Replacement Surgery|Participants randomised to this group will receive the Vanguard CR Single Cruciate Retaining Knee Replacement Surgery. This total knee replacement device (Vanguard CR) and surgical procedure sacrifice the anterior cruciate ligament and replaces it with artificial support. This is currently the standard practice for knee replacement surgery in the NHS.
89477771|NCT01333189|Experimental|RELOAD: Weight-bearing biofeedback exercise|RELOAD participants participated in two 30-minute training sessions/week with a physical therapist for a total of 6 weeks, focusing on promoting WB symmetry using a progressive series of activities adapted to video games. These biofeedback training sessions were provided in addition to the standard of care rehabilitation that the CONTROL group received. Total dose of exercise across groups was matched.
89477772|NCT01333189|Active Comparator|CONTROL: Standard of care exercise|CONTROL participants were provided two weeks of home rehabilitation (6 visits) by a physical therapist. Patients then progressed to outpatient rehabilitation, consisting of 4 weeks of treatment for a total of 6 weeks of standard of care rehabilitation. Total dose of exercise across groups was matched.
89477773|NCT04662008|Active Comparator|High resource tailored intervention|Tele-coaching arm
89202848|NCT00748592|Placebo Comparator|Placebo|
89477774|NCT04662008|Active Comparator|Low-resource web-only intervention|Website arm
89477775|NCT04656470|Experimental|Dexmedetomidine|During the study visit, patients will be delivered dexmedetomidine anesthesia. 0.5mcg/kg of dexmedetomidine solution will be infused over 10 minutes, and then up to 0.5mcg/kg/hr will be maintained for an additional 20-30 minutes.
89477776|NCT03301701|Experimental|Arm 1|Radical prostatectomy
89477777|NCT03301701|Active Comparator|Arm 2|Radiotherapy
89477778|NCT05391074|Experimental|patients with GA secondary to AMD, myopia or angioid streaks|postbiotics (IGENH35.3A) with vitamins (AREDS formulation and recommended daily dose)
88956500|NCT05047731|Experimental|Deprescribing group|The facility pharmacist will actively deprescribe antihypertensive medication of residents in this group.
89202849|NCT00748592|Experimental|PD 0200390, 5 mg|
89477779|NCT05311358|Experimental|Normal children|Normal children aged 10-15 years play the game and comment on the satisfaction form
89477780|NCT03301545|Active Comparator|Fast-Track to Bariatric Surgery|Patients will undergo standard of care for bariatric surgery patients in Manitoba and receive preoperative evaluation by the Centre for Metabolic and Bariatric Surgery (CMBS) team of nurses, dietitians, psychologist, and kinesiologist. Patients must attend the standard appointments and achieve the personalized program goals to be approved for laparoscopic Roux-En-Y gastric bypass surgery. Once approved, one of four surgeons performs surgery (within 12 months of randomization). Patients are followed post-operatively (by surgeon) at 6 weeks, and at 6 and 12 months. Pharmacologic glycemic control will be determined by an endocrinologist as per a standardized post-operative protocol. Post-procedural multidisciplinary follow-up occurs based on established CMBS guidelines (phone call 1 week post-operatively and an appointment at 3 and 12 months). Patients receive surgery within the current publically funded bariatric surgery program; no additional direct costs incurred by the patients.
89202850|NCT00748592|Experimental|PD 0200390, 15 mg|
89202851|NCT00748592|Experimental|PD 0200390, 30 mg|
88956501|NCT05047731|No Intervention|Usual care group|The facility pharmacist and the attending physician will provide usual care to residents in this group, and this includes quarterly medication reviews.
89477781|NCT03301545|No Intervention|Best Diabetic Care Group|Patients will receive the best available medical practice for the treatment, education, and follow-up T2DM based on Manitoba Diabetes Care Recommendations and Diabetes Canada's clinical practice guidelines. Patients will have access to a general physician, endocrinologist, and a diabetes education nurse. An Endocrinologist will deliver the program to patients. Diabetes care, education and self-management support services will be provided by the Victoria General Hospital (VGH) Diabetes Education Centre; led by a registered nurse and dietitian. Patients will undergo individual diabetes management instruction which may include counseling on topics such as diet, exercise, smoking cessation, medications, diabetic complications, and blood sugar testing. Medical therapies, including pharmaceutical agents, will be determined on an individual basis as per standard protocol. There will be no direct patient-related medication costs (publicly funded).
89477782|NCT03301545|No Intervention|Retrospective Cohort|A retrospective cohort of non-Indigenous bariatric surgery patients from the Centre for Metabolic and Bariatric Surgery Program will allow comparison with the intervention group. The cohort will be age and gender matched.
89477783|NCT02467647|Experimental|A|Arm A: HLJDT 150ml three times per day for 6 months and Thalidomide 100mg once per day for 6 months
89477784|NCT02467647|Active Comparator|B|Arm B: Thalidomide 100mg oral once per day for 6 months
89477785|NCT04614116|Other|Biopsy without cold induction|Participants will undergo a fat biopsy after the first scan, without cooling
89477786|NCT04614116|Other|Biopsy with cold induction|Participants will undergo a fat biopsy after the second scan, with cooling
89477787|NCT01333111|Experimental|Prophylaxis, high dose (trial duration 52 weeks)|
89477788|NCT01333111|Experimental|Prophylaxis, low dose (trial duration 52 weeks)|
89477789|NCT01333111|Experimental|On-demand (trial duration 28 weeks)|
89477790|NCT04613570|Experimental|Yearly endoscopy|Upper gastrointestinal endoscopy every year (12-16 months)
89477791|NCT04613570|Other|Endoscopy every 3 years|Upper gastrointestinal endoscopy every three years (32-40 months)
89477792|NCT03307707||Heart Failure (HF)|subjects with a Left Ventricular Ejection Fraction (LVEF) <50% or LVEF >50% and E/e'>10.
89477793|NCT03307707||No Heart Failure (NHF)|subjects with LVEF>50%
89477794|NCT04612322||Patients undergoing coronary microvascular function assessment|
89477795|NCT03301389||Control group|
89477796|NCT03301389||Pretreatment group|Patients in pretreatment state
89477797|NCT03301389||Anthracycline-based chemotherapy (3 months)|Patients who received anthracycline-based chemotherapy 3 months ago
89477798|NCT03301389||Anthracycline-based chemotherapy (6 months)|Patients who received anthracycline-based chemotherapy 6 months ago
89477799|NCT03301389||Anthracycline-based chemotherapy (more than 1 year ago)|Patients who received anthracycline-based chemotherapy more than 1 year ago
88956503|NCT05036278|Experimental|Damoctocog alfa-pegol prophylaxis regimens|Prophylaxis regimens: All participants will begin with prophylaxis 2x/week (40 IU/kg/dose (recommended maximum dose 6,000 IU)) Participants with a high risk score (> 4) continue on prophylaxis 2x/week (40 IU/kg/dose). Participants with a medium risk score (2 to 4) will switch after 4 weeks to prophylaxis Q5D (50 IU/kg/dose). Participants with a low risk score (< 2) will switch after 4 weeks to prophylaxis Q5D (50 IU/kg/dose) and then after 4 weeks to a less frequent (e.g. Q7D) regimen (60 IU/kg/dose).
89477800|NCT03301389||Other therapy group|Patients who have been treated with other therapies (other chemo-therapies, combined radiation therapy, target agent therapy, hormone therapy)
89477801|NCT02059525||syphilis infected|all patients with a new diagnosis of syphilis, receiving treatment at the Institute of Tropical Medicine
89477802|NCT03263936|Other|Other|decitabine, vorinostat, fludarabine, high dose cytarabine, filgrastim (G-CSF)
89477803|NCT03307629|Experimental|NOX66 + Radiation treatment (combined) in cohorts 1-3|"NOX66 administered on Days 1-16 and radiation treatment given on Day 2 to 9 of 2-week cycle.~NOX66 treatment given to 3 cohorts of 4 patients as 1 of 3 doses, 400mg, 800mg and 1200 mg.~Radiation treatment of 20Gy given over 5 daily fractions to selected target lesion/s for all cohorts."
89477804|NCT03307629|Experimental|NOX66 + Radiation treatment (combined) in cohort 4|"NOX66 administered on Days 1-16 and radiation treatment given on Day 2 to 9 of 2-week cycle.~NOX66 dose will be either one of 3 doses 400mg, 800mg and 1200 mg based on interim analyses of safety data and tumour response at WEEK 6 of 3 dose cohorts of 12 total patients. The Safety Steering Committee will inform on dose for cohort expansion.~Radiation treatment of 20Gy given over 5 daily fractions to selected target lesion/s for all cohorts."
89477805|NCT02055937|Experimental|immediate implant breast reconstruction|immediate implant breast reconstruction
89477806|NCT03307551|Active Comparator|CLADS group|Anaesthesia will be induced and maintained with Propofol administered by CLADS. Its administration rate will be controlled by a feedback loop facilitated by BIS monitoring. A BIS value of 50 will be used as the target point for induction and maintenance of anaesthesia.
89477807|NCT03307551|Active Comparator|Manual group|Anaesthesia will be induced and maintained with propofol administration by an intravenous infusion pump. Its administration rate will be controlled manually to maintain a target BIS of 50 during induction and maintenance of anaesthesia.
89477808|NCT05212376|Experimental|Foot massage|Foot massage (reflexology) is an application that allows the individual to relax, reduce stress, and thus restore the balance of the body by stimulating the nerve cells in the legs.It is stated that reflexology is an effective complementary treatment method that can help the body relax, reduce the symptoms of menopause by affecting the nervous and endocrine system, and thus create a smooth transition to the menopausal period.
89477809|NCT05212376|No Intervention|Control group|No intervention will be applied to the control group.
89477810|NCT02059603|Experimental|Electroacupuncture|Bilateral acupoints relevant to the treatment of abdominal pain, abdominal distension, and constipation, including Zusanli (stomach meridian ST-36), Sanyinjiao (spleen meridian SP-6), Hegu (large intestine meridian LI-4), and Zhigou (triple energizer meridian TE-6), will be used. Electric stimulation at a frequency of 50 Hz will be employed to the acupuncture needles.
89477811|NCT02059603|Active Comparator|Fast-track program|The design of this program is based on the consensus between our surgeons, anesthetists, physiotherapists, dietitians, and nurses, who have reviewed the relevant literature and made appropriate adjustments to suit the local situation.
88950699|NCT02330562|Experimental|Phase 1: MRZ + BEV; Phase 2: MRZ alone|"Part1-Phase1: MRZ 10 minute IV infusion on Days 1, 8, and 15 plus BEV IV infusion on Days 1 and 15 of each 28-day cycle.~Part2-Phase2: MRZ 10 minute IV infusion administered on Days 1, 8, and 15 of each 28-day cycle.~Part3-Phase2: All subjects will receive IV MRZ infusion and IV BEV infusion. MRZ will be administered as a 10-minute, IV infusion on Days 1, 8, and 15 of every 28-day cycle using intra-patient dose escalation. Starting dose will be 0.8 mg/m2.~Part4- Phase1: All subjects will receive MRZ enterally by NG tube as a bolus on Days 1, 8 and 15 of the first 28-day cycle and BEV IV infusion on Day 15 of the first 28-day cycle. For subsequent 28-day treatment cycles, MRZ will be administered as an IV at the recommended dose and schedule determined in Part 1, with BEV IV on Days 1 and 15.~Part5-Phase1: All subjects will receive IV MRZ infusion and IV BEV infusion. MRZ will be administered as a 10-minute, IV infusion at 0.8 mg/m2 on Days 1, 8, and 15 of every 28-day cycle 0.8 mg/m2"
88950700|NCT02293174||Normal Healthy Eyes|Willing and able subjects with normal and healthy eyes
88950701|NCT02138279||Male and female adults 18+ years of age|
88950702|NCT02138266||Non-Pathologic Adults age 18-28 yrs|Non-Pathologic Adults age 18-28 yrs
88950703|NCT02138266||Non-Pathologic Adults age 29-80 yrs|Non-Pathologic Adults age 29-80 yrs
88950704|NCT02138266||Pathologic Adults age 29-80 yrs|Pathologic Adults age 29-80 yrs
88950705|NCT02053363|Experimental|High Dose/Study Group|Tranexamic Acid (Cyklokapron) Loading Dose 50mg/kg given over 15 minutes, followed by 5mg/kg/hr via continuous infusion. The loading dose will be given to coincide with incision. The continuous infusion will be stopped at the conclusion of fascial layer closure.
88950706|NCT02053363|Active Comparator|Standard of Care/Control|Tranexamic Acid (Cyklokapron) Loading Dose 10mg/kg given over 15 minutes, followed by 1mg/kg/hr via continuous infusion. The loading dose will be given to coincide with incision. The continuous infusion will be stopped at the conclusion of fascial layer closure.
88950707|NCT02045823||Normal|Normal results from clinical exam and free of ocular pathology
88950708|NCT02045823||Glaucoma|Clinical exam with results consistent with glaucoma and visual field defects consistent with glaucoma
88950709|NCT02045823||Retina|clinical exam with results consistent with retina pathology
89477812|NCT03307473||e-bike|During 3 months in a the geographic area of Clermont-Ferrand (France), new e-bike buyers and renters are invited to take part in VELONAPS study before starting to use their e-bike
89477813|NCT05189132||Test Group|Adult patients diagnosed with Alzheimer's disease
89477814|NCT05189132||Control Group|The control group will consist of patients who attend consultations at the Faculty of Dentistry of the University of Lisbon, matched for age, gender and other confounding factors, such as smoking and systemic diseases (diabetes).
89477815|NCT02060305|Experimental|Bevacizumab|Bevacizumab intra-articular injection; dose 20mg~40mg every 28 days for 4 times
89477816|NCT03307395|Experimental|Middle Meningeal Artery Embolization|
89477817|NCT03307239|Experimental|cold application (experimental group)|subjects in the experimental group (n = 30) received cold application of 600 g ice packs 15 minutes before CTR
89477818|NCT03307239|Sham Comparator|tap water packs application (sham group)|subjects in the sham group (n = 30) received tap water packs.
89477819|NCT03561025|Active Comparator|18F-FDG-PET/MRI|
89477820|NCT03561025|Experimental|18F-GE180-PET/MRI|
89477821|NCT03307161|Active Comparator|Parkinsons fwd posture manual treatment|Subject will receive the intervention, osteopathic manual treatment protocol.
89477822|NCT03307161|No Intervention|Parkinsons forward posture|Subjects will receive counseling.
89477823|NCT03307161|No Intervention|Parkinsons without forward posture|Subjects will receive counseling.
89477824|NCT02059759|Placebo Comparator|Placebo|"Patients in this arm will receive sub-cutaneous injections of placebo (same vehicle as for experimental arms, and same volume) for 5 consecutive days at the beginning of three consecutive months (a total of 15 injections, 5 per month for 3 months).~Intervention: Placebo"
89477825|NCT02059759|Experimental|1.0 IL-2|"Patients in this arm will receive sub-cutaneous injections corresponding to 1.0 MIU of IL-2 per injection for 5 consecutive days at the beginning of three consecutive months (a total of 15 injections, 5 per month for 3 months).~Intervention: 1.0 MIU IL-2 per day"
89477826|NCT02059759|Experimental|2.0 IL-2|"Patients in this arm will receive sub-cutaneous injections corresponding to 2.0 MIU of IL-2 per injection for 5 consecutive days at the beginning of three consecutive months (a total of 15 injections, 5 per month for 3 months).~Intervention: 2.0 MIU IL-2 per day"
89477827|NCT03378362|Experimental|Partial denervation of the wrist joint|Patients will be operated with a partial denervation of the wrist through a single dorsal approach.
89477828|NCT03103022|Experimental|Interventional Group|Preterm infants who met the eligibility criteria will receive both oral acetaminophen and ibuprofen. Oral acetaminophen [160 mg/5ml concentration] will be administered every 6 hours with dose of 15 mg/kg/dose for a total of twelve doses and oral ibuprofen [100 mg/5 ml] at 10 mg/kg/dose on first day followed by 5 mg/kg/dose at 24 and 48 hours for a total of three doses
89477829|NCT02929082|Experimental|Group 1 : volunteer patient|Group 1 will be constituted of 20 volunteer patients coming for abdominal MRI with no known hepatic disease, in order to determine the feasibility of FRM . A 5-minute- additional sequence to measure FRM will be done for the volunteers.
89477830|NCT02929082|Experimental|Group 2 : patient with resectable HCC|"Group 2 will be constituted of 60 patients with resectable HCC eligible for surgery. This group will enable to evaluate the gold standard.~A 5-minute- additional sequence to measure FRM will be done while MRI sequence."
88950710|NCT04176250|Experimental|TBA-7371 100 mg QD|
88950711|NCT04176250|Experimental|TBA-7371 100 mg BID|
88950712|NCT04176250|Experimental|TBA-7371 200 mg QD|
88950713|NCT04176250|Experimental|TBA-7371 100 mg TID|
89477831|NCT02929082|Experimental|Group 3 : patient with HCC eligible for TACE|"Group 3 will be constituted of 50 patients with HCC eligible for transplant with transcatheter arterial chemoembolization (TACE) treatment as pending treatment before transplant. This groups will enable to evaluate the efficiency of TACE through the necrosis percentage in treated HCC.~A 5-minute- additional sequence to measure FRM will be done while MRI sequence"
89477832|NCT00702507|Active Comparator|Miconazole Nitrate|
88950714|NCT04176250|Experimental|TBA-7371 400 mg QD|
89477833|NCT05727033|Active Comparator|Intervention Group|"The intervention of training-participatory activity will last between 45 and 60 minutes, divided into theoretical training of 15-30 minutes followed by discussion training of 30 minutes. Based on the projection of the posters, photographs and the short film, the pupils will be asked to participate and work on the problem of STIs as well as possible solutions. The group techniques of photo-talk and presentation with a discussion using the short film will be used. Finally, the training includes Kahoot®, a tool for learning and reviewing concepts in a fun, quiz-like way. Four multiple-choice questions have been included. They will learn in a participatory way about STIs, risk practices, barrier methods and health resources to consult or go to in case of suspicion of contracting an STI.~For the activity, a sequence of drawings and signs has been designed to put STIs, their causes and how to prevent infection into context."
89477834|NCT05727033|Sham Comparator|Control Group|"Following the indications of the Department of Education and the Health and School Programme, non specific training intervention will be carried out in the control group out during the study period."
89477835|NCT03301233|Active Comparator|estradiol valerate|oral estradiol valerate (Cyclo-Progynova ® 2mg, white tablets, BAYER Schering Pharma). One tablet every 12 hour from 2nd day of the cycle till the day of trigger of ovulation).
89477836|NCT03301233|Experimental|estradiol valerate and sildenafil|oral estradiol valerate (Cyclo-Progynova ® 2mg, white tablets, BAYER Schering Pharma), one tablet every 12 hour from 2nd day of the cycle + sildenafil (silden® 25 mg, E.I.P.I.CO.) every 8 hour from 2nd day of the cycle till the day of trigger of ovulation).
89477837|NCT05726955|No Intervention|Control|Control
89477838|NCT05726955|Experimental|Exercise|Group 2 (n=28) were included in an exercise training program applied with conservative treatment and a stretching platform (ETSP)
89477839|NCT03301077||General population|recruited from schools and other institutions like job-centers or child and adolescent psychiatries
89477840|NCT02581748|Experimental|safety|Assessment of safety of HLX02 at different doses
89477841|NCT02581748|Active Comparator|PK comparative|Randomised, double-blind, parallel group Phase I study to compare PK profiles and to assess the safety and immunogenicity between HLX02 and Herceptin®(U.S. and German)
89477842|NCT05726877|Experimental|Experimental arm|All patients will be enrolled in the same arm.
89477843|NCT02466633|Experimental|Change in in-hospital cardiac monitoring method|Pre- and post-intervention, where the intervention is a change in in-hospital cardiac monitoring method
89477844|NCT05726799||Cryoenergy|
89477845|NCT05726799||Classic Myectomy|
89477846|NCT05726643|Active Comparator|resistive training group|consists of 20 patients who will receive resistive training for 2times per week for 12 weeks
89477847|NCT05726643|Experimental|kinesotaping group|consists of 20 patients who will receive resistive training program augmented by kinesotaping, 2 times /week for 12 weeks.
89477848|NCT01626404||Patients enrolled|All patients enrolled in the study
89477849|NCT03306771||Metabolic syndrome risk factors|Candidates for bariatric surgery who have metabolic syndrome risk factors will be evaluated by Ultrasound duplex before the bariatric surgery and 6,12 and 24 months post surgery for Intimal-Media Thickness and Carotid artery velocity
89477850|NCT03306771||No metabolic Syndrome risk factors|Candidates for bariatric surgery who lack metabolic syndrome risk factors will be evaluated by Ultrasound duplex before the bariatric surgery and 6,12 and 24 months post surgery for Intimal-Media Thickness and Carotid artery velocity
89477851|NCT03306693|Experimental|Emotional skills|3 group sessions where patients are going to learn how to identify, express and regulate their emotions
89477852|NCT03306693|Sham Comparator|Relaxation and talking group|3 group sessions where patients are going to follow relaxation instructions and after a non directive talking group about cancer
89477853|NCT03113942|Experimental|Pomalidomide group|Open label - all participants will receive pomalidomide 2mg orally once a day for 6 cycles (21 days on treatment and a 7 day rest period constitutes a cycle).
89477854|NCT03300999|Experimental|Ginger Tea|"End of the second menstruation cycle - Start of the third menstruation cycle: Subjects will take ginger tea daily, avoid home remedies, refrain from taking pain medications and supplements, and keep track of ginger tea intake by placing a check mark each day in the daily log checklist.~Start of the third menstruation cycle - End of the third menstruation cycle: Subjects will drink ginger tea daily. Subjects will rate discomfort using the visual analog pain scales and the symptom checklist at the end of each day during menstruation.~After the third menstruation cycle ends: Subjects will meet with student investigators at a location convenient to the subject to turn in daily logs, visual analog pain scales, and symptom checklists."
89477855|NCT03300999|No Intervention|No Ginger Tea|"End of the first menstruation cycle - Start of the second menstruation cycle: Subjects will not take ginger tea, avoid home remedies, and refrain from taking pain medications or supplements.~Start of the second menstruation cycle - End of the second menstruation cycle: Subjects will rate discomfort using the visual analog pain scales and symptom checklist during menstruation. Subjects will meet with student investigators at a convenient location to the subject and will complete surveys and questionnaires. Subjects will be given daily logs, visual analog pain scales, symptom checklists, and supplies for the ginger tea."
89477856|NCT04490577|Experimental|Pilates training group|"In the Pilates group, the exercises were performed with Reformer® for eight weeks, twice in a week, one hour per day."
89477857|NCT04490577|Experimental|Whole-body vibration (WBV) group|"In the WBV group, the training was given Power Plate® for eight weeks, twice in a week, and 30 minutes in a day."
89477858|NCT04490577|No Intervention|Control group|The control group did not receive any training.
88950715|NCT04176250|Active Comparator|HRZE|
88950716|NCT02044276|Experimental|lipegfilgrastim.|subcutaneous (SC) injection of 6 mg lipegfilgrastim
88950717|NCT02044276|Active Comparator|pegfilgrastim|SC injection of 6 mg pegfilgrastim
89202852|NCT00757328||1|Ambulatory bipolar I and II patients, clinically stabilized for at least the two months prior to recruitment and who had at least one acute episode (depressive, manic, hypomanic or mixed) within the year prior to recruitment.
89202853|NCT00757406||1|Test group - Lymphedema sufferers
89202854|NCT00757406||2|Control group - healthy volunteers
89202855|NCT00748670|Experimental|A|
89202856|NCT00757640|No Intervention|B|no cholecystectomy
89202857|NCT00757640|Experimental|A|cholecystectomy
89202858|NCT00325195|Experimental|q2 wks|8 mg pegloticase every 2 weeks
89202859|NCT00325195|Experimental|q4 wks|8 mg pegloticase every 4 weeks (alternating with placebo every 4 weeks)
89202860|NCT00325195|Placebo Comparator|placebo|placebo every 2 weeks
89202861|NCT02562560|Experimental|TGA|
89202862|NCT02562560|Experimental|Controls|
89202863|NCT03976401|Experimental|EFX Dose 1|Main Study
89202864|NCT03976401|Experimental|EFX Dose 2|Main Study
89202865|NCT03976401|Experimental|EFX Dose 3|Main Study
89202866|NCT03976401|Placebo Comparator|Placebo|Main Study
89202867|NCT03976401|Experimental|EFX Dose (Cohort C)|
89202868|NCT03976401|Placebo Comparator|Placebo (Cohort C)|
89202869|NCT00757718|Active Comparator|CPAP treatment|Subjects will have repeat polysomnography on the second night, while wearing a continuous positive airway pressure (CPAP) device. Morning bloodwork will be drawn for inflammatory mediators.
89202870|NCT00757718|Experimental|Oral appliance|Subjects will have repeat polysomnography on the second night, while wearing an oral appliance, as well as a Breathe-Right nasal strip. Morning bloodwork will be drawn for inflammatory mediators.
89202871|NCT00748748|Experimental|1|Lactobacillus rhamnosus GG capsule three times per day while taking their antibiotic(s) and for 7 days following completion of the antibiotic.
89202872|NCT02532907||Patients who will have their second Liver biopsy at week 4|The 4 week time point is performed in lieu of the 12 week and the purpose of this time point is to evaluate earlier responses and transcriptional changes that might predict viral clearance or treatment failure in a subset of patients.
89202873|NCT02532907||Patients who will have their second Liver biopsy at week 12|Liver biopsies will be obtained at week 12 when most DAA treatments end in order to compare the hepatic responses induced or reduced by clearance of HCV
89202874|NCT00751712||Back of skull cerebral oximeter sensor|All patients enrolled will receive non-invasive oxygen perfusion monitoring on the back of the skull during their standard of care congenital heart surgery
89202875|NCT02562638|No Intervention|Group 1 Fasting|Group 1(control group) Fasting for both solids and fluids for up to 4 hours pre-procedure
89477859|NCT03104270|Experimental|Elo Pom Car and Dex|"Drug dosing and administration:~All drugs are administered on a 28-day cycle.~Elotuzumab: 10 mg/kg IV on Days 1,8,15 and 22 Cycles 1 and 2. 20 mg/kg on Day 1 of Cycles 3 and beyond.~Pomalidomide: 3 mg PO on days 1-21~Carfilzomib: 20 mg/m2 IV on days 1 of cycle 1. 56 mg/m2 IV on days 8 and 15 of cycle 1 and Days 1, 8 and 15 of the remaining seven cycles.~Dexamethasone: On days 1,8,15,22 of Cycle 1-2 and day 1 of Cycle 3 and every day 1 thereafter, pre-treatment with 28 mg PO 3-24 hours prior to the start of ELO. On days 8,15,22 of Cycle 3 and beyond, 40mg of DEX PO or IV. On Day 8 and 15 of Cycle 3 and beyond, pre-treatment with DEX 40mg PO or IV at least 30 min and no more than 4 hours prior to the start of CFZ."
89202876|NCT02562638|Experimental|Group 2 Non-fasting|Group 2 (intervention arm) Clear fluids up to 1 hour before the procedure and fasting for solids up to 4 hours pre-procedure
89202877|NCT04013607|Experimental|Fiber drink|A drink high in fructo- and galacto-oligosaccharides.
89202878|NCT04875156|Other|normal volunteers|normal volunteers between 18 and 40 years old, men and women. Measurement of the range of motion of the metacarpophalangeal joint with a goniometer and pinch strength of the thumb with a dynamometer
89202879|NCT00685334|Experimental|1|Participants will take olanzapine
89202880|NCT00685334|Active Comparator|2|Participants will take aripiprazole
88950718|NCT01986478||Normal|Normal results from clinical exam and free of ocular pathology
88950719|NCT01975571|Experimental|Adult|"Population 1: 15 Adults who have a severe sensorineural hearing loss with a pure-tone average (PTA) between 60-90 dB HL between 125-1500 Hz and profound loss at higher frequencies.~Intervention: These patients will receive a Hybrid L24 cochlear implant."
89202881|NCT00325039|Active Comparator|1|retropubic mid-urethral sling (TVT) The specific TVT used was the Tension-free Vaginal Tape (Gynecare)
89202882|NCT00325039|Active Comparator|2|"transobturator mid-urethral sling (TVT-O and the Monarc) Two transobturator slings were used: the Tension-free Vaginal Tape Obturator (Gynecare), which is placed starting inside the vagina and coming out through the obturator foramen (in-to-out) or the Monarc (American Medical System), which is placed starting in the groin area, passing through the obturator foramen, and then into the vagina (out-to-in)."
89202883|NCT04013919||Type 1 Diabetes|
89202884|NCT04013919||Type 2 Diabetes|
89202885|NCT00938925|Experimental|Nail lacquer plus aggressive debridement|Nail lacquer plus aggressive debridement: Will be applied abrasion ungual aggressive, this abrasion will be applied in the beginning of the study, week 0 (baseline), the week 12 and the week 24 and he will follow standard treatment with nail lacquer (Odenil 5%) with 2 weekly applications during 36 weeks.
89202886|NCT00938925|Experimental|nail lacqer alone|Nail lacquer alone: Will be applied exclusively standard treatment with nail lacquer during 36 weeks, according to the usual care
89202887|NCT04864548|Experimental|Group 1A: Low dose challenge|"Intranasal viral challenge with 1 x 10^1 TCID_50 in previously infected volunteers~N= 6-8 participants"
89202888|NCT04864548|Experimental|Group 1B: Medium dose #1 challenge|"Intranasal viral challenge with 1 x 10^2 TCID_50 in previously infected volunteers~N= 6-8 participants"
89202889|NCT04864548|Experimental|Group 1C: Medium dose #2 challenge|"Intranasal viral challenge with 1 x 10^3 TCID_50 in previously infected volunteers~N= 6-8 participants"
89202890|NCT04864548|Experimental|Group 1D: Medium dose #3 challenge|"Intranasal viral challenge with 1 x 10^4 TCID_50 in previously infected volunteers~N= 4-8 participants"
89202891|NCT04864548|Experimental|Group 1E: High dose challenge|"Intranasal viral challenge with 1 x 10^5 TCID_50 in previously infected volunteers~N= 4-8 participants"
89477860|NCT03300765|Experimental|Apatinib with IMRT|Participants will receive apatinib (0.5g, daily) for two cycles followed by intensity modulated radiation therapy (Primary site and lymph nodes: 66 Gy/33F, metastatic site: 40-60Gy/20-30F)
89477861|NCT03306459||1/PCOS|The authors will select 30 PCOS patients who met the more strict and conservative Rotterdam diagnostic criteria (Rotterdam phenotype A) which include the presence of oligo-anovulation (cycles lasting >35 days or amenorrhea) and hyperandrogenemia /hyperandrogenism (hirsutism or obvious acne or pronounced alopecia). All patients should have bilateral polycystic ovaries morphology on ultrasound. Additionally, the authors have decided to enroll PCOS patients that are all without pregnancy desire at the moment they fill out the questionnaires, in order to control for the potential confounding role of infertility on psychological outcomes. Different pituitary, adrenal, ovarian, thyroid or metabolic diseases will be excluded
89477862|NCT03306459||2/CONTROL|The authors will enroll a control group of 30 women, age- matched with the PCOS women, from consecutive women controlled in the same outpatient clinic who met the following inclusion criteria: history of irregular menstrual cycle in absence of severe gynecologic and non-gynecologic diseases. This PCOS sample will be entirely constituted by women with no pregnancy desire; therefore, with the aim to limit the potential effect of the unfulfilled wish to conceive in the final results; additionally, infertile women will not admitted into the control group.
89477863|NCT04064918|Other|Netarsudil 0.02% QD|4 weeks of Netarsudil 0.02% QD, then a 4 Week washout, followed by 4 weeks of Timolol maleate 0.5% BID
89477864|NCT04064918|Other|Timolol maleate 0.5% BID|4 weeks of Timolol maleate 0.5% BID, then a 4 Week washout, followed by 4 weeks of Netarsudil 0.02% QD
89477865|NCT03306381|Experimental|Dietary intervention subject group|n=130. Participants on low FODMAP-similar diet during 4-week study period.
89477866|NCT03306381|No Intervention|Control group|n=20. Participants on traditional IBS diet during 4-week study period.
89477867|NCT02467946|Experimental|Adcetris-Levact (BV-Be) Association|Adcetris® (BV) : 1.2 mg/kg intravenously every 3 weeks Levact® (Be): 90 mg/m2/day intravenously for 2 days every 3 weeks. Up to 6 cycles
89477868|NCT02468349|Experimental|Telemedicine|The telehealth group will be remotely monitored and managed on medication adherence, dosage titration, and management of drug side effects, through a combination of feed-forward blood pressure monitoring, app-based education and medication reminders, and remote consultations.
89477869|NCT02468349|No Intervention|Standard care|The standard care group will receive face-to-face consultations at one month, 6 months and 12 months.
89477870|NCT04714424||Participants undergoing vision exams|
89477871|NCT04057976|Experimental|Patients having pre-operative DTT prior to surgery|All patients in this study will undergo DTT as part of a pre-operative MRI.
89477872|NCT04688294|Experimental|Sacubitril/valsartan|Group 30 patients will undergo treatment with sacubitril/valsartan combination according to guideline-directed medical therapy.
89477873|NCT04688294|Active Comparator|Valsartan|Group 30 patients will undergo treatment with valsartan according to guideline-directed medical therapy.
89477874|NCT03102944||healthy volunteers|no intervention, extra blood tube taken with blood donation at bloodbank and blood is tested on IVD away from patient.
89477875|NCT04042298||5-FU Chemotherapy (Experimental)|Comprised of newly diagnosed cancer patients 21 years or older who have received 5-FU chemotherapy within the past 30 days or are scheduled to receive 5-FU chemotherapy.
89477876|NCT04042298||Non-5-FU Chemotherapy (Sub-Control)|Comprised of newly diagnosed cancer patients 21 years or older who have received chemotherapy other than 5-FU within the past 30 days or are scheduled to receive chemotherapy other than 5-FU.
89477877|NCT04042298||Age/Sex matched Control (Control)|Age, biological sex, and prior health history (excluding cancer diagnosis) matched control for cancer patients
89477878|NCT04042298||5-FU Chemotherapy Cancer Survivor (Survivor)|Cancer survivors who have not received cancer therapy during the past year but previously received 5-Fluorouracil chemotherapy.
89477879|NCT03300687|Active Comparator|Active|Subjects will receive FX-322 as an intratympanic injection
88950720|NCT01975571|Experimental|Children and adolescents (L24)|"Children (ages 5-12 years) and adolescents (ages 13-15 years) who have a sensorineural hearing loss with a pure-tone average (PTA) between 70-90 dB HL between 125-1500 Hz, a hearing threshold >90 dB HL at 1500 Hz and profound loss at higher frequencies.~Intervention: These patients will receive a Hybrid L24 cochlear implant."
88950721|NCT01975571|Experimental|Children and adolescents S12|"Children (ages 5-12 years) and adolescents (ages 13-15 years) who have a sensorineural hearing loss with a pure-tone average (PTA) between 70-90 dB HL between 125-1500 Hz, a hearing threshold hearing threshold between 70-90 dB HL at 1500 Hz and profound loss at higher frequencies.~Intervention: These patients will receive a Hybrid S12 cochlear implant."
88950722|NCT01196845|Other|obese + cPAP|Patients with sleep apnea syndrome will be first randomised in 2 arms according to their obesity. They will be secondly randomised in 2 arms receiving either cPAP treatment or Sham cPAP.
89477880|NCT03300687|Placebo Comparator|Placebo|Subjects will receive Placebo as an intratympanic injection
89477881|NCT03300609|Experimental|Arm I (panitumumab, leucovorin calcium, fluorouracil)|"INDUCTION Patients receive panitumumab IV over 30-60 minutes, oxaliplatin IV over 2 hours, leucovorin calcium IV, and fluorouracil over 46-48 hours on day 1. Treatment repeats every 14 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE:~Patients receive panitumumab IV over 30 minutes, leucovorin calcium IV, and fluorouracil over 46-48 hours on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity."
89477882|NCT03300609|Active Comparator|Arm II (capecitabine)|"INDUCTION Patients receive panitumumab IV over 30-60 minutes, oxaliplatin IV over 2 hours, leucovorin calcium IV, and fluorouracil over 46-48 hours on day 1. Treatment repeats every 14 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE:~Patients receive capecitabine PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity."
88950723|NCT01196845|Other|obese + Sham cPAP|Patients with sleep apnea syndrome will be first randomised in 2 arms according to their obesity. They will be secondly randomised in 2 arms receiving either cPAP treatment or Sham cPAP.
88950724|NCT01196845|Other|non-obese + cPAP|Patients with sleep apnea syndrome will be first randomised in 2 arms according to their obesity. They will be secondly randomised in 2 arms receiving either cPAP treatment or Sham cPAP.
89202892|NCT04864548|Experimental|Group 2: Safety & Dose confirmation Group|"Intranasal viral challenge with the dose identified from Group 1a-e (1x10^1, 1x10^2, 1x10^3, 1x10^4, or 1x10^5 TCID_50)~N=10-30 participants"
89202893|NCT04864548|Experimental|Group 3a: Medium dose #1 challenge|"Intranasal viral challenge with 1 x 10^2 TCID_50 in previously uninfected, vaccinated volunteers~N=6-8 participants"
89477883|NCT03007940|Experimental|NIATx Strategy|"The implementation intervention, NIATx, will be deployed by the first cohort of programs in a 1-year active implementation phase. Each program is assigned an expert quality improvement coach. The coach will help the staff identify ways to improve and integrate services for individuals with co-occurring substance use and mental health disorders. Supports include an in-person coach site visit, coaching including monthly coaching calls and peer to peer coaching calls and learning sessions which promote peer-to-peer sharing about specific goals and objectives and to receive guidance on how to implement organizational level changes to improve integrated treatment services. A walk-through will allow the provider to understand the co-occurring treatment process from a customer perspective."
89477884|NCT03007940|Placebo Comparator|Wait List Control|The wait-list control group will receive the NIATx strategy at the end of the twelve month implementation period for the initial cohort. During the first year of the study, they will follow a business as usual approach to the integration of co-occurring substance use and mental health services.
89477885|NCT00583778|Active Comparator|Levalbuterol|levalbuterol 1.25 mg every 20 minutes for 3 doses plus placebo (saline)
89477886|NCT00583778|Experimental|Levalbuterol plus ipratropium|ipratropium 0.5 mg nebulized every 20 minutes for 3 doses added to levalbuterol 1.25 mg every 20 minutes for 3 doses
89477887|NCT04491435|Experimental|Interventional|4 weeks use of mucin-based saliva substitute
89477888|NCT04491435|Placebo Comparator|Control|4 weeks use of xylitol-based mouthwash
89477889|NCT04398758|Experimental|Treatment group|"Children of the treatment group receive the cream SanaCutan Basiscreme. The cream's main ingredients are white soft paraffin and liquid paraffin and it is already approved for the treatment of several skin diseases due to its skin care effect."
89477890|NCT04398758|No Intervention|Control group|Children of the control group should avoid regular skincare applications. Skincare is not prohibited, however, it is recommended to use products only in urgent cases.
89477891|NCT03300531|Experimental|P-PRP|Blood will be drawn and pure platelet-rich plasma will be injected into the tendon.
89477892|NCT03300531|Experimental|PRP|Blood will be drawn and platelet-rich plasma will be injected into the tendon.
89477893|NCT03300531|Active Comparator|Compound betamethasone|1ml dexamethasone mixed with 0.5-2ml of saline to achieve the same injection volume (which contains betamethasone dipropionate 5mg and betamethasone sodium phosphate 2mg) )
89477894|NCT04817163|Experimental|Stepped care CBT-I|
89477895|NCT03300453|Experimental|rAAV2/5-hNAGLU|Each patient will receive 960 µL of vector suspension. The vector suspension will be deposited simultaneously at 16 sites, each deposit containing 2.4x 1011 vg (4x1012 vg in total).
89477896|NCT05057390|Experimental|New Human Milk Fortifier|From the Baseline (start of intervention) each patient will receive the case study product for at least 4 weeks (28 days), with at least 1-week administration in the community.
89477897|NCT02467335|Active Comparator|Healthy Subjects|Healthy subjects will receive a single, oral dose of BMS-663068 on Day 1.
89477898|NCT02467335|Active Comparator|Hepatic Impaired Subjects - Mild Rating|Mildly impaired subjects will receive a single, oral dose of BMS-663068 on Day 1.
89477899|NCT02467335|Active Comparator|Hepatic Impaired Subjects - Moderate Rating|Moderately impaired subjects will receive a single, oral dose of BMS-663068 on Day 1.
89477900|NCT02467335|Active Comparator|Hepatic Impaired Subjects - Severe Rating|Severly impaired subjects will receive a single, oral dose of BMS-663068 on Day 1.
89477901|NCT05722275||Peking University Cancer Hospital & Institute|Peking University Cancer Hospital & Institute collects clinical information, preoperative CT images, and the golden standard for peritoneal metastasis status for each patient. Clinical information includes gender, age, gastric disease background, tumor markers, gastric cancer stage, gastric cancer type, treatment program, smoking history, alcohol history, etc. All patients undergo diagnostic laparoscopy. Any suspicious lesion discovered during laparoscopy is biopsied and pathologically examined to determine peritoneal metastasis status.
89477902|NCT05722275||Zhenjiang First People's Hospital|Zhenjiang First People's Hospital collects clinical information, preoperative CT images, and the golden standard for peritoneal metastasis status for each patient. Clinical information includes gender, age, gastric disease background, tumor markers, gastric cancer stage, gastric cancer type, treatment program, smoking history, alcohol history, etc. All patients undergo diagnostic laparoscopy. Any suspicious lesion discovered during laparoscopy is biopsied and pathologically examined to determine peritoneal metastasis status.
88950725|NCT01196845|Other|non-obese + Sham cPAP|Patients with sleep apnea syndrome will be first randomised in 2 arms according to their obesity. They will be secondly randomised in 2 arms receiving either cPAP treatment or Sham cPAP.
88950726|NCT01157091|Experimental|Arm I|Patients receive oral pazopanib hydrochloride once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88950727|NCT01100775|Experimental|Galantamine, then Placebo|Participants took lead-in 3 days of 4mg/ twice a day of galantamine followed by 8 mg on the 4th day, the day of testing. Then, after a period of at least one month, participants took lead-in 3 days of 4mg/ twice a day of placebo followed by 8 mg on the 4th day, the day of testing.
88956504|NCT05031780|Experimental|Phase 2: Mitapivat 50 mg BID|Double-blind Period: Mitapivat 50 milligrams (mg) twice daily (BID) for 12 weeks.
88956505|NCT05031780|Experimental|Phase 2: Mitapivat 100 mg BID|Double-blind Period: Mitapivat 100 mg BID for 12 weeks.
89477903|NCT05722275||The First Affiliated Hospital of Zhengzhou University|The First Affiliated Hospital of Zhengzhou University collects clinical information, preoperative CT images, and the golden standard for peritoneal metastasis status for each patient. Clinical information includes gender, age, gastric disease background, tumor markers, gastric cancer stage, gastric cancer type, treatment program, smoking history, alcohol history, etc. All patients undergo diagnostic laparoscopy. Any suspicious lesion discovered during laparoscopy is biopsied and pathologically examined to determine peritoneal metastasis status.
89477904|NCT05722275||Nanfang Hospital of Southern Medical University|Nanfang Hospital of Southern Medical University collects clinical information, preoperative CT images, and the golden standard for peritoneal metastasis status for each patient. Clinical information includes gender, age, gastric disease background, tumor markers, gastric cancer stage, gastric cancer type, treatment program, smoking history, alcohol history, etc. All patients undergo diagnostic laparoscopy. Any suspicious lesion discovered during laparoscopy is biopsied and pathologically examined to determine peritoneal metastasis status.
88956506|NCT05031780|Placebo Comparator|Phase 2: Placebo|Double-blind Period: Mitapivat-matching placebo for 12 weeks.
89477905|NCT05722275||Guizhou Provincial People's Hospital|Guizhou Provincial People's Hospital collects clinical information, preoperative CT images, and the golden standard for peritoneal metastasis status for each patient. Clinical information includes gender, age, gastric disease background, tumor markers, gastric cancer stage, gastric cancer type, treatment program, smoking history, alcohol history, etc. All patients undergo diagnostic laparoscopy. Any suspicious lesion discovered during laparoscopy is biopsied and pathologically examined to determine peritoneal metastasis status.
89477906|NCT05722275||Henan Cancer Hospital|Henan Cancer Hospital collects clinical information, preoperative CT images, and the golden standard for peritoneal metastasis status for each patient. Clinical information includes gender, age, gastric disease background, tumor markers, gastric cancer stage, gastric cancer type, treatment program, smoking history, alcohol history, etc. All patients undergo diagnostic laparoscopy. Any suspicious lesion discovered during laparoscopy is biopsied and pathologically examined to determine peritoneal metastasis status.
89477907|NCT05722275||Yunnan Cancer Hospital|Yunnan Cancer Hospital collects clinical information, preoperative CT images, and the golden standard for peritoneal metastasis status for each patient. Clinical information includes gender, age, gastric disease background, tumor markers, gastric cancer stage, gastric cancer type, treatment program, smoking history, alcohol history, etc. All patients undergo diagnostic laparoscopy. Any suspicious lesion discovered during laparoscopy is biopsied and pathologically examined to determine peritoneal metastasis status.
89477908|NCT05722275||Guangdong Provincial People's Hospital|Guangdong Provincial People's Hospital collects clinical information, preoperative CT images, and the golden standard for peritoneal metastasis status for each patient. Clinical information includes gender, age, gastric disease background, tumor markers, gastric cancer stage, gastric cancer type, treatment program, smoking history, alcohol history, etc. All patients undergo diagnostic laparoscopy. Any suspicious lesion discovered during laparoscopy is biopsied and pathologically examined to determine peritoneal metastasis status.
88956507|NCT05031780|Experimental|Phase 2: Open-Label Extension Period|"Participants who received mitapivat 50mg BID in the double-blind period may choose to receive mitapivat 50mg BID for 216 weeks after.~Participants who received mitapivat 100mg BID in the double-blind period may choose to receive mitapivat 100 mg BID for 216 weeks after.~Participants who received mitapivat-matching placebo in the double-blind period, may be randomized to receive either mitapivat 50 mg or 100 mg BID for 216 weeks after."
88956508|NCT05031780|Experimental|Phase 3: Mitapivat 100 mg BID|Double-blind Period: Mitapivat 100 mg BID for 52 weeks.
88956509|NCT05031780|Placebo Comparator|Phase 3: Placebo|Double-blind Period: Mitapivat-matching placebo for 52 weeks.
89477909|NCT05722275||Guangzhou Medical University|Affiliated Cancer Hospital and Institute of Guangzhou Medical University collects clinical information, preoperative CT images, and the golden standard for peritoneal metastasis status for each patient. Clinical information includes gender, age, gastric disease background, tumor markers, gastric cancer stage, gastric cancer type, treatment program, smoking history, alcohol history, etc. All patients undergo diagnostic laparoscopy. Any suspicious lesion discovered during laparoscopy is biopsied and pathologically examined to determine peritoneal metastasis status.
89477910|NCT05722275||Fujian Medical University Union Hospital|Fujian Medical University Union Hospital collects clinical information, preoperative CT images, and the golden standard for peritoneal metastasis status for each patient. Clinical information includes gender, age, gastric disease background, tumor markers, gastric cancer stage, gastric cancer type, treatment program, smoking history, alcohol history, etc. All patients undergo diagnostic laparoscopy. Any suspicious lesion discovered during laparoscopy is biopsied and pathologically examined to determine peritoneal metastasis status.
89477911|NCT05722275||Shanxi Province Cancer Hospital|Shanxi Province Cancer Hospital collects clinical information, preoperative CT images, and the golden standard for peritoneal metastasis status for each patient. Clinical information includes gender, age, gastric disease background, tumor markers, gastric cancer stage, gastric cancer type, treatment program, smoking history, alcohol history, etc. All patients undergo diagnostic laparoscopy. Any suspicious lesion discovered during laparoscopy is biopsied and pathologically examined to determine peritoneal metastasis status.
89477912|NCT05722275||Sun Yat-sen University|Sun Yat-sen University collects clinical information, preoperative CT images, and the golden standard for peritoneal metastasis status for each patient. Clinical information includes gender, age, gastric disease background, tumor markers, gastric cancer stage, gastric cancer type, treatment program, smoking history, alcohol history, etc. All patients undergo diagnostic laparoscopy. Any suspicious lesion discovered during laparoscopy is biopsied and pathologically examined to determine peritoneal metastasis status.
89477913|NCT05722275||Scientific Institute San Raffaele|Scientific Institute San Raffaele collects clinical information, preoperative CT images, and the golden standard for peritoneal metastasis status for each patient. Clinical information includes gender, age, gastric disease background, tumor markers, gastric cancer stage, gastric cancer type, treatment program, smoking history, alcohol history, etc. All patients undergo diagnostic laparoscopy. Any suspicious lesion discovered during laparoscopy is biopsied and pathologically examined to determine peritoneal metastasis status.
89477914|NCT03104660|Experimental|CE certified mitral valve repair systems|CE certified transcatheter mitral valve repair systems
89477915|NCT02809820|Active Comparator|Carvedilol|Patients who have documented ACS, who are on dual antiplatelet therapy and are randomized to assume carvedilol.
89477916|NCT02809820|Active Comparator|Metoprolol|Patients who have documented ACS, who are on dual antiplatelet therapy and are randomized to assume metoprolol.
89477917|NCT04491357|Experimental|Intervention arm|Intervention arm will receive 1 ampoule of intravenous calcium gluconate within 4 hours of skin closure post total thyroidectomy
89477918|NCT04491357|Placebo Comparator|Placebo arm|Placebo arm will receive 100ml of normal saline within 4 hours of skin closure post total thyroidectomy
89477919|NCT03102788|Active Comparator|Control|Patients in the control group will receive their first consultation in specialist health care by a rheumatologist. Rheumatologist-led care comprises confirmation of diagnosis, information about hand osteoarthritis and symptom modifying medication, and, for some patients, Intra-articular injection of long-acting Corticosteroid. The rheumatologist may also refer participants to occupational therapy if needed.
89477920|NCT03102788|Experimental|Intervention|Patients in the intervention group will receive their first consultation in specialist health care by an occupational therapy specialist. Occupational therapist-led care comprises confirmation of diagnosis, information about hand osteoarthritis and symptom modifying medication, teaching of hand exercises and ergonomic working methods, and, for some patients, provision assistive devices and orthoses/splints. The occupational therapist will refer patients to a short rheumatologist consultation if confirmation of diagnosis or intra-articular injections of long-acting Corticosteroid are needed.
89477921|NCT03306303||Quartile 1 of plasma melatonin|Quartile 1 of plasma melatonin
89020512|NCT04071990|Placebo Comparator|Cognitive-behavioral group therapy (CBGT) without family|Each patient will be involved during all 12 CBGT sessions. The CBGT program that will be employed in the present study is a protocoled therapy consisting of psychoeducation, ERP techniques, cognitive tools to change dysfunctional thoughts and beliefs, strategies to prevent relapses, discussion on the family involvement (e.g. FA, burden, …) and homework exercises after each session., without the involvement of family members.
89477922|NCT03306303||Quartile 2 of plasma melatonin|Quartile 2 of plasma melatonin
89477923|NCT03306303||Quartile 3 of plasma melatonin|Quartile 3 of plasma melatonin
89477924|NCT03306303||Quartile 4 of plasma melatonin|Quartile 4 of plasma melatonin
89477925|NCT05052554|Experimental|30 µg cohort|Open label single dose cohort: Dose level 1
89477926|NCT05052554|Experimental|60 µg cohort|Open label single dose cohort: Dose level 2
89477927|NCT03306147|Experimental|Chronic pain or long-acting opioid use|Education of pain and promotion of adjunct and non-pharmacologic alternative therapies will be completed to engage patients in assessing their pain and seeing the effectiveness of their treatment. Patients will receive 3 follow-up interventions: 2 phone calls with a pharmacist or student pharmacist at weeks 2 and 6, and a follow-up visit with a pain or primary care physician.
89477928|NCT03300375|Active Comparator|Home-Based Resistance Exercise Intervention Group|Participants in the HBRX group will be coached through six phases of the intervention with two weeks per phase. Exercise will use body weight and resistance exercise bands. A set of commercial elastic resistive bands and a stability pad (TheraBand, Inc.) will be provided to each participant to keep for personal use after their participation in the study. The use of elastic bands for resistance training can induce similar results in neuromuscular adaptations as well as strength to those achieved by weight machines and free-weights.
89477929|NCT03300375|Experimental|Wait-List Control Condition Group|Participants who are assigned to the CON group will wait to participate in the resistance training after a three month wait period. Participants will follow all instructions provided to them by their physician and care team, but will be asked to refrain from starting any new strengthening exercise protocols or begin any new physical therapies during this time. The participants will be contacted by phone on a monthly basis during the study period to determine if any changes in LBP symptoms have occurred. At month three, these participants will also receive the elastic resistive bands and a stability pad.
89477930|NCT01673594|Experimental|Naltrexone|Arm 1: Naltrexone + SODAS MPH
89477931|NCT01673594|Placebo Comparator|Placebo|Arm 2: Placebo + SODAS MPH
89477932|NCT03306069|Experimental|Control|Nutritional therapy / no exercise
89477933|NCT03306069|Experimental|HIIT|High-intensity interval training (HIIT) at 90% heart rate maximum (HRmax) combined with Nutritional therapy
89477934|NCT03306069|Experimental|MIIT-HR|Heart rate based moderate-intensity interval training (MIIT-HR) at 70% heart rate maximum (HRmax) combined with Nutritional therapy
89477935|NCT03306069|Experimental|MIIT-LT|Lactate threshold based moderate-intensity interval training (MIIT-LT) at 105% of lactate threshold (corresponding ~70-75% HRmax) combined with Nutritional therapy
89020513|NCT04068831|Experimental|Talazoparib and Avelumab (VHL-deficiency) (Closed to Accrual)|All patients will receive combination treatment at the previously established recommended phase II dose, 800 mg avelumab every 2 weeks with 1 mg talazoparib daily, in 28-day cycles.
89477936|NCT02721147|Experimental|Intimacy Enhancing Intervention|Participants attend 4 intimacy enhancement intervention sessions over 75 minutes every other week for 4 weeks. The intimacy enhancement intervention comprises 4 main sessions: understanding impact of breast cancer on sex and intimacy, communication about sex/intimacy, problem-solving and changing thoughts, and planning ahead and preparing for challenges. Participants are encouraged to participate in written and behavioral activities at home.
89477937|NCT02721147|Active Comparator|Living Healthy Together|Participants receive educational information and support about breast cancer every other week for 4 weeks. The educational information and support comprises topics about breast cancer, its treatments, sleep, energy, stress, stress management, nutrition, and diet. Participants are encouraged to read educational materials.
89477938|NCT04696094||Healthy volunteers|"Health volunteers' inclusion criteria:~Age between 4-60; Male or female;~Exclusion criteria:~Exclude the volunteers with history of cerebrovascular disease."
89477939|NCT04696094||Moyamoya disease patients|"Moyamoya disease patients' inclusion Criteria:~1.written informed consent had been obtained; 2. more than 4 years old and less than 60 years old; 3. cerebral digital subtraction contrast angiography (DSA) revealed severe stenosis or occlusion of the distal internal carotid or proximal middle and anterior cerebral arteries with prominent lenticulostriate 'moyamoya collaterals'; 4. received surgical revascularization;~Exclusion Criteria:~1. There are other vascular diseases, including systemic vasculitis, neurofibroma, meningitis, sickle cell disease, down's syndrome, and previous basilar radiotherapy; 2. Patients with cardiogenic embolism, including a history of atrial fibrillation, valvular disease or cardiac valve replacement; 3. Physical or subjective failure to cooperate with the examination or serious comorbid diseases."
89477940|NCT04690478|Experimental|Remote blood pressure management group|Remote blood pressure management group through remote blood pressure management the platform realizes functions such as automatic upload of patient measurement data, intelligent analysis, and early warning reminders
89477941|NCT04690478|Other|Non-remote blood pressure management group|Non-remote blood pressure management group is distributed a set of ordinary household electronic sphygmomanometer, and the blood pressure is recorded by themselves at home following routine community office follow-up
89477942|NCT04690478|Other|Routine blood pressure management group|Routine blood pressure management group follows routine community office follow-up and uses office electronic sphygmomanometer to measure blood pressure
89477943|NCT02720757||Spiolto Respimat|COPD patients requiring a fixed combination therapy of two long-acting bronchodilators (LAMA + LABA) according to approved Summary of Product Characteristics (SmPC) and Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines
89477944|NCT02786498|Experimental|High Loading Dose|150,000 IU loading dose vitamin D3 at enrolment and 6 weeks, plus daily dose placebo for 3 months.
89477945|NCT02786498|Experimental|High Daily Dose|Loading dose placebo at enrolment and 6 weeks, plus 4,000 IU vitamin D3 per day for 3 months.
89477946|NCT02786498|Experimental|Low Daily Dose|Loading dose placebo at enrolment and 6 weeks, plus 600 IU vitamin D3 per day for 3 months.
89477947|NCT02786498|Placebo Comparator|Control Group|Loading dose placebo at enrolment and 6 weeks, plus daily dose placebo for 3 months.
89477948|NCT03300297|Active Comparator|Cervical Spine Thrust Joint Manipulation|Thrust Manipulation delivered to C0/1 and C2/3 on both the right and left side
88950728|NCT01100775|Experimental|Placebo, then Galantamine|Participants took lead-in 3 days of 4mg/ twice a day of placebo followed by 8 mg on the 4th day, the day of testing. Then, after a period of at least one month, participants took lead-in 3 days of 4mg/ twice a day of galantamine followed by 8 mg on the 4th day, the day of testing.
88950729|NCT00578123|Other|1 Questionnaire|Quality of Life Questionnaires
89477949|NCT03300297|Sham Comparator|Cervical Spine Sham Manipulation|Sham Manipulation delivered to C0/1 and C2/3 on both the right and left side
89477950|NCT03891914|Experimental|Symptomatic Multiple Myeloma on first-line treatment|
89477951|NCT02742506|Experimental|Brain-damaged patients|Electroencephalography (EEG) will be performed in patients in coma, in a vegetative state or in a minimally conscious state to assess the P300 response after different auditive stimulations
89477952|NCT02742506|Active Comparator|Healthy volunteers|Electroencephalography (EEG) will be performed in healthy participants to assess the P300 response and medial prefrontal cortex activity after different auditive stimulations
89477953|NCT02721134|Other|additional blood tubes|
89477954|NCT03300219|Experimental|telerehabilitation|Telerehabilitation refers to the use of technologies to provide rehabilitation services to people in their homes. The intervention will be performed by real-time video-conferencing using an iPad® and Skype™, a software program that allows video calls over the Internet
89477955|NCT02683616|Experimental|OSA + T2DM|CPAP treatment
89477956|NCT02683616|Experimental|OSA no T2DM|CPAP treatment
89477957|NCT02683616|No Intervention|T2DM no OSA|Standard care
89477958|NCT02683616|No Intervention|Healthy controls no ÓSA|no intervention
88950730|NCT00504712|Experimental|Active|Testosterone 200 mg intramuscular every 2 weeks
88950731|NCT00504712|Placebo Comparator|Placebo|Saline
88950732|NCT05413226|Experimental|Amount of Celastrol Administered|Increasing doses of Celastrol to each of five male subjects
89477959|NCT02597660|Active Comparator|Drug: Somatropin|Under ultrasound guidance, patients will receive an injection of somatropin (0.1mg in a volume of 0.2mL of bacteriostatic saline) into the area of tendinopathic lesion. A series of three injections will be delivered one week apart. Vials will be blinded.
88950733|NCT05413213|Experimental|Experimental Group|Ambulatory rehabilitation program based on mobilization and muscular solicitation
88950734|NCT05413213|Active Comparator|Control Group|Ambulatory rehabilitation program using ultrasound physiotherapy
88950735|NCT05413200||Patients|Patients diagnosed with moderate and severe AV accompanied by atrophic acne scars
89202894|NCT04864548|Experimental|Group 3b: Medium dose #2 challenge|"Intranasal viral challenge with 1 x 10^3 TCID_50 in previously uninfected, vaccinated volunteers~N=4-8 participants"
89477960|NCT02597660|Placebo Comparator|Drug: Placebo|Under ultrasound guidance, patients will receive an injection of 0.2mL of bacteriostatic saline (which is an equivalent volume of diluent used in the active comparator arm) into the area of tendinopathic lesion. A series of three injections will be delivered one week apart. Vials will be blinded.
89477961|NCT03101852|Experimental|Nutritional therapy|Children included in the study with severe acute malnutrition receive Plumpy Nut: WHO recommends a Plumpy Nut® prescription of 75 to 100 kcal/kg/d in children aged 5 to 10 years and 60 to 90 kcal/kg/d above that age. The lowest value was used and maximum energy intake provided by RUF was limited to 2,000 kcal/d i.e. 4 sachets in order to preserve habitual diet and prevent appetite saturation
89477962|NCT03101852|Experimental|Nutritional supplementation|Children included in the study with moderate acute malnutrition receive Plumpy Sup: 60kcal/kg/day, limited to 4 doses/day.
89477963|NCT03848858|Experimental|EMDR plus TAU|20 individual weekly sessions of 60 minutes each of Eye Movement Desensitization and Reprocessing Therapy (EMDR), plus Treatment as Usual (TAU), applying first the standard EMDR protocol (Shapiro, 2005), and then a specific protocol for the sequelae of somatic illness and medical trauma (Hase, 2018).
89477964|NCT03848858|No Intervention|TAU only|The patients in this condition are newly diagnosed and will be introduced to the study in their first appointment with the Infectious Diseases Unit, in which analyses of HIV-related biological markers are taken. In a follow up appointment between 1 and 2 weeks later, antiretroviral treatment is initiated. There is a further check-up 1-2 months after initiating antiretroviral treatment, and then 6-monthly check-ups. In these checkups, measures of CD4 and the CD4/CD8 ratio are taken and treatment adherence is reviewed. The patients receiving EMDR therapy will also participate in these activities.
89477965|NCT04368260|Active Comparator|Control swab|FDA cleared swab
89477966|NCT04368260|Experimental|Prototype swab|Injection molded polypropylene flocked nylon NP swab
89477967|NCT04435262||ILR Group followed with RM|Patients with unexplained syncope underwent ILR monitoring and followed with RM
89477968|NCT04435262||ILR Group followed with in-hospital visits|Patients with unexplained syncope underwent ILR monitoring and followed with in-hospital visits
89202895|NCT04864548|Experimental|Group 3c: Medium dose #3 challenge|"Intranasal viral challenge with 1 x 10^4 TCID_50 in previously uninfected, vaccinated volunteers~N=4-8 participants"
89477969|NCT02523248|Active Comparator|Tonsillectomy|Tonsillectomy with cold steel
89477970|NCT02523248|Active Comparator|Uvulopalatopharyngoplasty|Tonsillectomy and uvulopalatoplasty; using cold steel and single sutures of the palate and tonsillar pillars including palatopharyngeal muscle
89477971|NCT02419664|Experimental|Ga-68 DOTATOC PET in pituitary adenomas|"To give Ga-68 DOTATOC in pituitary patients doing PET/CT~They are compared with Ga-68 DOTATOC PET performed in another study on patients with no pituitary disease."
89477972|NCT02646566|Experimental|APD421 standard|Single (standard) dose IV APD421
89477973|NCT02646566|Experimental|APD421 high|Single (high) dose IV APD421
89477974|NCT02646566|Placebo Comparator|Placebo|Single IV placebo
89477975|NCT04351880|Active Comparator|Meals - 2 weeks|Receive meal delivery for 2 weeks (1 meal per day for a total of 14 days). The medically tailored meal ordered for each participant will depend on their medical conditions.
89477976|NCT04351880|Active Comparator|Meals - 4 weeks|Receive meal delivery for 4 weeks (1 meal per day for a total of 28 days). The medically tailored meal ordered for each participant will depend on their medical conditions.
89477977|NCT03102476|Other|Patients with Type 1 Diabetes|Using euglycaemic clamp, the effect of different temperatures and humidity levels will be assessed on the pharmacokinetic and pharmacodynamic profiles of short-acting insulin Humalog.
89477978|NCT04482530|Experimental|Original recipe|Normal fruit paste
89477979|NCT04482530|Experimental|maltodextrin recipe|fruit pastes in which some of the simple sugars in the recipe will be replaced by maltodextrin with a low glycemic index (DE12).
89477980|NCT04482530|Experimental|fructose recipe|fruit pastes in which some of the simple sugars in the recipe (25% min) will be replaced by fructose
89477981|NCT04482530|Experimental|isomaltulose recipe|fruit pastes with some of the sugars will be replaced (25% min) by isomaltulose
89477982|NCT04482530|Experimental|mixed recipe|fruit pastes with some of the sugars will be replaced (25% min) by fructose / isomaltulose
89477983|NCT03104582|Experimental|Biliary drainage 1|Patients with advanced hilar cholangiocarcinoma need biliary drainage performed Endoscopic Retrograde Cholangiopancreatography (ERCP) drainage
89477984|NCT03104582|Active Comparator|Biliary drainage 2|Patients with advanced hilar cholangiocarcinoma need biliary drainage performed percutaneous transhepatic biliary drainage(PTBD) drainage
89477985|NCT04435574|Experimental|Group A|group A is lactoferrin group, receiving 100mg sachet of lactoferrin once daily.
89477986|NCT04435574|Active Comparator|Group b|group B is the ferrous sulfate group, receiving 6mg/kg/ day single dose of ferrous sulfate.
89477987|NCT03102164||cardiac rehabilitation|patients undergoing cardiologic rehabilitation according to the protocol used routinely at the Military Hospital in Wroclaw.The protocol of rehabilitation, adjusted to clinical status, individual needs and physical capability of the patient, includes gradually increasing level of physical exercise. Upon achieving relative stabilization of clinical status and excluding absolute contraindications to physical exercise, usually on the 2nd or 3rd day of hospitalization, the cardiologic rehabilitation is ordered by a physician in charge. The rehabilitation protocol comprises respiratory, assisted, active dynamic,and relaxation exercises, as well as short-term isometric exercises and general strength exercises of very low intensity, short duration and properly adjusted recovery phase;they are conducted in a lying, sitting, or standing position.
89477988|NCT03102164||Controls|patients treated using standard pharmacotherapy within Center for Heart Disease, Military Clinical Hospital in Wroclaw.
89477989|NCT03104426|Active Comparator|Darbepoetin alfa group|Group treated with darbepoetin alfa (Aranesp) 10microg/kg once a week for a period of 8 weeks.
89477990|NCT03104426|No Intervention|Control group|"Standard care which involves close monitoring of hemoglobin levels and if necessary, top-up red cell transfusion."
89477991|NCT04435106||Opaganib + Standard of Care|Study participants received opaganib 2 x 250 mg capsules (500 mg) every 12 hours in addition to Standard of Care
89477992|NCT04435106||Standard of Care|Study participants received Standard of Care
89477993|NCT04015856|Experimental|Full TP intervention including emphasized social norms change|Participants in this study arm will receive the full TP intervention, including emphasized social norms change, for 18 months.
89477994|NCT04015856|Active Comparator|Light TP intervention without emphasized social norms change|Participants in this study arm will receive the light TP intervention, without emphasized social norms change, for 18 months
89477995|NCT04015856|No Intervention|Control|The control group will not have any study interventions.
89477996|NCT03104348|Other|COPD screening|
89477997|NCT03104894|Experimental|Study Group|The study group will receive meibomian glands massage and artificial drops PRN
89477998|NCT03104894|Sham Comparator|Control Group|The control group will receive sham meibomian glands massage and artificial drops PRN.
89477999|NCT02229344||Newly Diagnosed Moderate to Severe Ulcerative Colitis|Participants with newly diagnosed moderate to severe ulcerative colitis in a tertiary referral hospital within 4 weeks before prior to enrollment will be observed.
89478000|NCT03824756|Experimental|NGO supported GMP program|Intervention: NGO supported GMP program Site: Community clinic Duration: 12 months Study participants: 6-12 months aged children living within community clinic catchment area
88950736|NCT05413187|Active Comparator|Medical Grade Cannabis oil 30% CBD ,1.5% Δ9-THC|during phase 1; subjects will receive cannabis oil. They will receive treatment for twelve weeks, following a four-week washout period without any treatment. In the second phase, a crossover of trial arms will take place and patients who received cannabis oil will then receive placebo and vice versa. Clinical evaluation will take place after completing each phase.
89202896|NCT04864548|Experimental|Group 3d: High dose challenge|"Intranasal viral challenge with 1 x 10^5 TCID_50 in previously uninfected, vaccinated volunteers~N=4-8 participants"
88956510|NCT05031780|Experimental|Phase 3: Open-Label Extension Period|"Participants may choose to receive mitapivat 100 mg BID for 216 weeks after the Double-blind Period.~Participants who received mitapivat-matching placebo in the double-blind period, may choose to receive mitapivat 100 mg BID for 216 weeks after the Double-blind Period."
89478001|NCT03824756|Active Comparator|Non-supported GMP program|Comparison: Non-supported GMP program Site: Community clinic Duration: 12 months Study participants: 6-12 months aged children living within community clinic catchment area
89478002|NCT02163356|Experimental|Primary therapy|Fenretinide/LXS oral powder 1500 mg/m2/day for 7 days plus ketoconazole 6 mg/kg/day for 7 days plus single dose vincristine (dose escalating) given on day 3. Starting dose of vincristine is 0.75 mg/m2/dose. Followed by 14 days of rest.
89478003|NCT02004080||TBI admitted to ICU|Intensive Care treatment
89478004|NCT04412564|Experimental|TQ-B3101 capsules|TQ-B3101 capsules 300mg bid administered orally in 28-day cycle.
89478005|NCT04412642|Other|methoxyflurane|methoxyflurane
89478006|NCT04412720|Experimental|Aerobic and Breathing Exercises|The experimental intervention will be aerobic and breathing exercises.
89478007|NCT04412720|Active Comparator|Aerobic and Stretching Exercises|The active comparative intervention will be aerobic and stretching exercises.
89478008|NCT03101618||Allergic LAR|Laboratory animal researchers who experienced allergic symptom during exposure to laboratory or pet animals
89478009|NCT03101618||Non-allergic LAR|Laboratory animal researchers who did not experience allergic symptom during exposure to laboratory or pet animals
89478010|NCT03101618||Allergic PO|Pet owners who experienced allergic symptom during exposure to pet animals
89478011|NCT03101618||Non-allergic PO|Pet owners who did not experience allergic symptom during exposure to pet animals
89478012|NCT03101618||Allergic PIW|Allergic pet-related industry workers who experienced allergic symptom during exposure to pet animals
89478013|NCT03101618||Non-allergic PIW|Allergic pet-related industry workers who did not experience allergic symptom during exposure to pet animals
89478014|NCT03101384||Patient with a diagnostic error|"Defined by one of :~Absence of prescribed test included in an accepted pulmonary diagnosis algorithm in the next 48h00 after the firts contact with a physician~Absence of prescribed test included in an accepted pulmonary diagnosis algorithm by the first contacted physician but the diagnostic is done before 48h00 because the patient went at the emergency room on his own initiative.~More than one doctor consulted before the diagnostic of pulmonary embolism (excluding the emergency physician if the patient was referred by the 1st contact doctor)"
89478015|NCT03101384||Patient without a diagnostic error|Any patient that did not meet the criteria to define the diagnostic error
89478016|NCT03104114|Placebo Comparator|Historical Control|Pharmacy care was standard, high-touch model where an institutional specialty pharmacy contact patients via telephone. Standard adherence and counseling was offered over the phone to patients.
89202897|NCT04864548|Experimental|Group 4: Safety & Dose confirmation Group|"Intranasal viral challenge with the dose identified from Group 3a-d (1x10^2, 1x10^3, 1x10^4 or 1x10^5 TCID_50)~N=10-30 participants"
89202898|NCT03743181||intervention|will be supplied by pharmaceutical care services provided by the clinical pharmacist plus standard care by physician in attendance.
89202899|NCT03743181||control|will received standard care by physician in attendance
89202900|NCT00344461|Experimental|Nevirapine, FTC, Tenofovir|Open Label Drugs- Nevirapine 200 mg twice a day, FTC 200 mg once a day and Tenofovir 300 mg once a day for 96 weeks.
89478017|NCT03104114|Experimental|Pharmacist-intervention|In-person counseling with a clinical pharmacist prior and during treatment with an oral oncology medication. Patients meet with a clinical pharmacist prior, at month 3 and month 6 during the study.
89478018|NCT03867110|Placebo Comparator|Placebo|Placebo is to be taken orally once a day (QD) in the morning for 12 consecutive weeks.
89478019|NCT03867110|Active Comparator|Ezetimibe 10 mg|Ezetimibe 10 mg (MK-0653, SCH 58235) is to be taken orally QD in the morning for 12 consecutive weeks.
89478020|NCT03867110|Active Comparator|Atorvastatin 10 mg|Atorvastatin 10 mg is to be taken orally QD in the morning for 12 consecutive weeks.
89478021|NCT03867110|Experimental|Ezetimibe 10 mg + Atorvastatin 10 mg|Ezetimibe 10 mg (MK-0653, SCH 58235) + Atorvastatin 10 mg is to be taken orally QD in the morning for 12 consecutive weeks.
89478022|NCT03867110|Active Comparator|Atorvastatin 20 mg|Atorvastatin 20 mg is to be taken orally QD in the morning for 12 consecutive weeks.
89478023|NCT03867110|Experimental|Ezetimibe 10 mg + Atorvastatin 20 mg|Ezetimibe 10 mg (MK-0653, SCH 58235) + Atorvastatin 20 mg is to be taken orally QD in the morning for 12 consecutive weeks.
89478024|NCT03867110|Active Comparator|Atorvastatin 40 mg|Atorvastatin 40 mg is to be taken orally QD in the morning for 12 consecutive weeks.
89478025|NCT03867110|Experimental|Ezetimibe 10 mg + Atorvastatin 40 mg|Ezetimibe 10 mg (MK-0653, SCH 58235) + Atorvastatin 40 mg is to be taken orally QD in the morning for 12 consecutive weeks.
89478026|NCT03867110|Active Comparator|Atorvastatin 80 mg|Atorvastatin 80 mg is to be taken orally QD in the morning for 12 consecutive weeks.
89478027|NCT03867110|Experimental|Ezetimibe 10 mg + Atorvastatin 80 mg|Ezetimibe 10 mg (MK-0653, SCH 58235) + Atorvastatin 80 mg is to be taken orally QD in the morning for 12 consecutive weeks.
89478028|NCT03865082|Experimental|IO Naive Subjects MSS CRC|8mg Tilsotolimod by intratumoral injection plus 3mg/kg Nivolumab (every three weeks for four doses followed by 480mg dose every four weeks) and 1mg/kg Ipilimumab every three weeks for four doses intravenous
89478029|NCT03102398|Experimental|Single-arm and Open-label Study|
89478030|NCT03103802|Experimental|Intra-oral scanning|
89478031|NCT03103802|Experimental|extra-oral scanning of the plaster model obtained via alginate|
89478032|NCT03103802|Experimental|extra-oral scanning of plaster model obtained via rubber base|
89478033|NCT03103802|Experimental|extra-oral scanning of the rubber base impression|
89478034|NCT03103802|Experimental|extra-oral scanning of the alginate impression|
89478035|NCT03701360||Aspirin alone group|- Aspirin: 75~100mg once per day, initial loading dose of 300~500mg/d is allowed
89478036|NCT03701360||Aspirin + Clopidogrel resinate group|"Aspirin: 75~100mg once per day, initial loading dose of 300~500mg/d is allowed~Clopidogrel resinate: 75mg once per day, initial loading dose of 300mg/d is allowed"
89478037|NCT03103958|Active Comparator|probiotic|Probiotic consists of Lactobacillus acidophilus NCFM, Lactobacillus rhamnosus HN001, Lactobacillus paracasei LPC-37 and Bifidobacterium lactis HN019 (Probiatop), Subjects will take two sachets per day after diluting them in 100 ml of water for 28 days.
89478038|NCT03103958|Placebo Comparator|Placebo|Placebo consists of maltodextrin. Subjects will take two sachets per day after diluting them in 100 ml of water for 28 days.
89478039|NCT01187810|Experimental|Combination of Fenretinide, Cytarabine, and Methotrexate|IV for 7 days for each 21 day cycle
89478040|NCT03104036|Active Comparator|Mesalazine enema|Will be treated with 4 g mesalazine enema 1x daily for 2 weeks, then every other day until the end of the 6th week.
89478041|NCT03104036|Experimental|Faecal bacterial transplantation enema|Will be applied enema prepared from 50 g of stool of examined donor dissolved in 150 ml of normal saline, the 1st week 5 times, than one time a week until the end of the 6th week.
89478042|NCT01124942|Experimental|MGuard|MGuard net protective stent, investigational device
89478043|NCT01124942|Active Comparator|BMS plus thrombectomy|Bare-metal stent plus manual thrombectomy device
89478044|NCT03101306|Experimental|MR scans|As part of the study patients will undergo 3 additional MR scans during radiotherapy treatment. These will take place in the 1st, 2nd and 5th weeks of treatment.
89478045|NCT03449888||St. Louis VA Healthcare System stress testing referrals|St. Louis VA Healthcare System cardiac stress testing laboratory referrals who are eligible and willing to complete an arm exercise ECG stress test, a treadmill ECG stress test if able, a regadenoson myocardial perfusion imaging stress test, and a coronary artery calcium score and cardiac computed tomographic angiography evaluation within 60 days if not referred for invasive coronary arteriography.
89478046|NCT03308396|Experimental|Single Arm|"This is a non-randomized, single arm, open label Phase Ib/II study.~Phase Ib:~Days 1-5~Guadecitabine:~Dose 0: 60 mg/m^2~Dose -1: 45 mg/m^2~Phase II:~Days 1-5 Guadecitabine (at Ph II dose)~Day 8 Durvalumab (1500 mg IV) Day 8 Durvalumab (1500 mg IV)"
89478047|NCT01072682|Experimental|SCD|Selective Cytopheretic Device
89478048|NCT03102008|No Intervention|2 Week Waitlist|Participants assessed weekly (via self- and parent-report questionnaires administered on the internet) for symptom change during waitlist (baseline) period. At the end of waitlist and prior to treatment phase, symptom/disorder change assessed via clinical interview conducted by independent evaluator.
89478049|NCT03102008|No Intervention|3 Week Waitlist|Participants assessed weekly (via self- and parent-report questionnaires administered on the internet) for symptom change during waitlist (baseline) period. At the end of waitlist and prior to treatment phase, symptom/disorder change assessed via clinical interview conducted by independent evaluator.
89478050|NCT03102008|No Intervention|4 Week Waitlist|Participants assessed weekly (via self- and parent-report questionnaires administered on the internet) for symptom change during waitlist (baseline) period. At the end of waitlist and prior to treatment phase, symptom/disorder change assessed via clinical interview conducted by independent evaluator.
89478051|NCT03102008|Experimental|16 Sessions of Therapeutic Intervention|Participants receive 50 minute sessions weekly of therapeutic intervention (Unified Protocol for the Treatment of Emotional Disorders in Adolescents). Symptom change assessed weekly on the internet or before each session (via self- and parent-report questionnaires). At the end of treatment phase, symptom/disorder change assessed via clinical interview conducted by independent evaluator.
89478052|NCT00985400|Experimental|Exercise Program|Arm I (exercise program): Oncologist advice; Resistance bands & pedometer with written/DVD instructions for resistance exercise twice a week for 16 weeks. Brief moderate-intensity walks multiple times a day for a total of 30 minutes increasing steps weekly by 10% to reach a minimum of 10,000 steps a day. Monthly newsletters; Telephone counseling weekly for 4 weeks then monthly for 12 weeks; and tailored message telephone prompts once every 2 weeks during last 12 weeks of the study intervention.
89478053|NCT00985400|Experimental|Relaxation Intervention|Arm II (relaxation program): Oncologist advice; Written/CD audio instructions on diaphragmatic breathing and guided imagery. Practice relaxation techniques for 15 minutes/day, 5-7 days/week, for 16 weeks. Monthly newsletters, telephone counseling, and tailored-message telephone prompts as in arm I.
89478054|NCT02720523|Experimental|Placebo / Upadacitinib 7.5 mg|"Period 1: Participants will receive placebo once daily for 12 weeks.~Period 2: Participants will receive Upadacitinib 7.5 mg once daily for 248 weeks."
89478055|NCT02720523|Experimental|Placebo / Upadacitinib 15 mg|"Period 1: Participants will receive placebo once daily for 12 weeks.~Period 2: Participants will receive upadacitinib 15 mg once daily for 248 weeks."
88950737|NCT05413187|Placebo Comparator|Olive oil and Chlorophyl|during phase 1; subjects will receive placebo. They will receive treatment for twelve weeks, following a four-week washout period without any treatment. In the second phase, a crossover of trial arms will take place and patients who received cannabis oil will then receive placebo and vice versa. Clinical evaluation will take place after completing each phase.
88950738|NCT05413109|Experimental|Coronary-CT|Patients with PAH, asymptomatic for angina, with a PA trunk diameter ≥ 4 cm that undergo a coronary-CT scan examination
88950739|NCT05413044||Abatacept Group|Participants with established RA or PsA and receiving abatacept.
89478056|NCT02720523|Experimental|Placebo / Upadacitinib 30 mg|"Period 1: Participants will receive placebo once daily for 12 weeks.~Period 2: Participants will receive upadacitinib 30 mg once daily until regulatory approval of RA indication in Japan at which point they will switch to receive upadacitinib 15 mg once daily. Participants will receive upadacitinib for 248 weeks."
89478057|NCT02720523|Experimental|Upadacitinib 7.5 mg / Upadacitinib 7.5 mg|"Period 1: Participants will receive upadacitinib 7.5 mg once daily for 12 weeks.~Period 2: Participants will receive upadacitinib 7.5 mg once daily for 248 weeks."
89478058|NCT02720523|Experimental|Upadacitinib 15 mg / Upadacitinib 15 mg|"Period 1: Participants will receive upadacitinib 15 mg once daily for 12 weeks.~Period 2: Participants will receive upadacitinib 15 mg once daily for 248 weeks."
89478059|NCT02720523|Experimental|Upadacitinib 30 mg / Upadacitinib 30 mg|"Period 1: Participants will receive upadacitinib 30 mg once daily for 12 weeks.~Period 2: Participants will receive upadacitinib 30 mg once daily until regulatory approval of RA indication in Japan at which point they will switch to receive upadacitinib 15 mg once daily. Participants will receive upadacitinib for 248 weeks."
89478060|NCT00779168|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive white button mushroom extract PO twice daily on days 1-28. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.
89478061|NCT02646332|Experimental|(dexlan+amox+clar+metr)+(dexlan+amox)|a 7-day quadruple regimen with dexlansoprazole MR 60 mg once daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily, followed by a 7-day dual regimen with dexlansoprazole MR 60 mg once daily and amoxicillin 1 g twice daily
89478062|NCT02646332|Active Comparator|dexlan+clarith+amox+metro|dexlansoprazole MR 60 mg once daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily for 14 days
89478063|NCT02471716|Experimental|Phase 1 FPA008 Dose Escalation|IV infusion; safety data will be reviewed prior to dose escalation decision. Dose escalation will complete when recommended dose (RD) is determined. RD will be the maximum tolerated dose or lower dose that provide adequate PK exposure and biologic activity with tolerability.
88950740|NCT05413044||Non-targeted Disease Modifying Anti-rheumatic Drug (DMARD) Group|Participants with established RA or PsA and not previously treated with any targeted DMARDs and who start treatment with a non-targeted DMARD.
88950741|NCT05413044||Targeted DMARD Group|Participants with established RA or PsA and previously treated without abatacept who start treatment with targeted DMARDs.
88950742|NCT05412940||Primary total knee replacement patients|
88950743|NCT05412797|Experimental|Cycling|Used a DeskCycle during the workday/the intervention increased the amount of time spent being physically active.
88950744|NCT05412797|Active Comparator|Control|Regular activities
88950745|NCT05412771|Experimental|Main cohort|This is a single-arm study. Samples are collected from consenting donors undergoing surgery for medical purposes.
89478064|NCT02471716|Experimental|Phase 2 FPA008 Dose Expansion|IV infusion; once MTD and/or RD has been determined in Phase 1, expansion cohorts of approximately 30 patients (each cohort) with PVNS or dt-TGCT will be enrolled to characterize clinical activity and safety profile of the RD. Treatment is planned to continue for up to 24 weeks or 56 weeks.
89478065|NCT01370863|Experimental|SPD557|
89478066|NCT01370863|Placebo Comparator|Placebo|
89478067|NCT03103724|Experimental|Enzalutamide|All subjects will receive open label enzalutamide 160 mg (4 x 40 mg capsules), orally once daily.
89478068|NCT03560947|Experimental|Manual Therapy and Exercise|
89478069|NCT03560947|Active Comparator|Usual Care|
89478070|NCT03305913|Experimental|Dose Level 1|TAS-102 25 mg/m2 BID (days 1-5 and 8-12) Regorafenib 120 mg daily (3 weeks on, 1 week off)
89478071|NCT03305913|Experimental|Dose Level 2|TAS-102 35 mg/m2 BID (days 1-5 and 8-12), Regorafenib 120 mg daily (3 weeks on, 1 week off)
89478072|NCT03305913|Experimental|Dose Level 3|TAS-102 35 mg/m2 BID, (days 1-5 and 8-12) Regorafenib 160 mg daily (3 weeks on, 1 week off)
89478073|NCT03305913|Experimental|Dose Level -1a|TAS-102 25 mg/m2 BID, (days 1-5 and 8-12) Regorafenib 80 mg daily (3 weeks on, 1 week off)
89478074|NCT03305913|Experimental|Dose Level -1b|TAS-102 35 mg/m2 BID, (days 1-5 and 8-12) Regorafenib 80 mg daily (3 weeks on, 1 week off)
89478075|NCT03305913|Experimental|Dose Level -2a|TAS-102 30 mg/m2 BID (or 35 mg/m2 a.m. and 25 mg/m2 p.m.), (days 1-5 and 8-12) Regorafenib 120 mg daily (3 weeks on, 1 week off)
89478076|NCT02444182|Experimental|Probiotics|participants will receive a lozenge containing mixture of probiotic bacteria BB-12 and LGG
89478077|NCT02444182|Placebo Comparator|Control - No probiotics|Participants will receive a control lozenge containing no probiotics. all lozenges are sugar-free; sweetened by xylitol (0.5 g xylitol per piece)
89478078|NCT03103412|Experimental|TD-3504 Low-Dose|6 healthy subjects and 6 ulcerative colitis subjects will be randomized to receive low-dose TD-3504 and low-dose of 15N2-tofacitinib orally single dose.
89478079|NCT03103412|Experimental|TD-3504 Mid-Dose|6 healthy subjects will be randomized to receive mid-dose TD-3504 and low-dose of 15N2-tofacitinib orally single dose.
88950746|NCT05412732||group A low risk of infection|
88950747|NCT05412732||group B high risk of infection|
88950748|NCT05412719|Experimental|control group|". Before the procedure, the baby's pulse, blood pressure, SpO2, respiratory rate were checked by an observing nurse and recorded on the Baby Monitoring Form.~An observer nurse will assist the doctor at the beginning of the procedure, and then the baby's upper legs are kept stable in order to maintain the stability of the baby and ensure that the doctor can see the urethral opening. The other observer nurse evaluated the respiratory rate of the baby during the procedure and recorded it in the Infant Follow-up Form after the procedure was completed.~During the procedure, the baby was evaluated by both observer nurses according to the FLAAC pain scale.~No pharmacological or non-pharmacological interventions were made for the baby's pain during the procedure."
89020514|NCT04068831|Experimental|Talazoparib and Avelumab (FH- or SDH-deficiency)|All patients will receive combination treatment at the previously established recommended phase II dose, 800 mg avelumab every 2 weeks with 1 mg talazoparib daily, in 28-day cycles.
89020515|NCT04012138|Experimental|Salbutamol|Patients in this experimental group will receive : 10 mg of salbutamol nebulized in 30 minutes (with oxygen 8 liters per minute or with air);
89478080|NCT03103412|Experimental|TD-3504 High-Dose|6 healthy subjects will be randomized to receive high-dose TD-3504 and low-dose of 15N2-tofacitinib orally single dose.
89478081|NCT03103412|Placebo Comparator|Placebo|6 healthy subjects and 2 ulcerative colitis subjects to receive placebo orally single dose.
88950749|NCT05412719|Experimental|intervention group|Before the procedure, the baby's heart rate, blood pressure, spo2, respiratory rate, FLACC were recorded, 5 minutes before the procedure, the finger puppet was started to be played by singing the red fish song, the baby's pulse, spo2, respiratory rate and FLACC scale were recorded during the procedure, 5 minutes after the procedure Playing more finger puppetry Evaluation of the baby's pulse, blood pressure, spo2, respiratory rate and FLAAC immediately after the procedure and five minutes later
88950750|NCT05412680|Active Comparator|TOETVA|Patients submitted to transoral endoscopic thyroidectomy by vestibular approach
88950751|NCT05412680|Active Comparator|CONVENTIONAL THYROIDECTOMY|Patients submitted to conventional open thyroidectomy by cervical approach
89478082|NCT02061007|Experimental|Scans, Surgery and Follow-up|Pre-surgery scans, surgical resection and post-surgery follow-up. All patients will receive a fluorodeoxyglucose (FDG)-PET scan as part of standard of care. This scan must be completed within 28 days of surgery for the patient to be eligible. All patients will be offered the opportunity to receive an additional 18F-FMISO-PET scan, until 18 such scans are administered. Prior to surgery, patients will be administered a single dose of 0.5 g/m^2 (approximately 13 mg/kg) of oral Hypoxyprobe™-1 (pimonidazole, HCl).
89478083|NCT03305757|Active Comparator|conventional wound closure|The skin flaps will not undergo further treatment in this group.
89478084|NCT03305757|Experimental|flap fixation with vicryl sutures|The skin flaps will be sutured on to the pectoral muscle after having performed the mastectomy.
89478085|NCT03305757|Experimental|Artiss tissue glue|ARTISS tissue glue will be applied to the skin flaps after mastectomy
89478086|NCT02059837||Pterygium,recurrent|Consecutively recorded photographs of recurrent pterygium excision and following grafting were analyzed.
89478087|NCT02086604|Experimental|Starting Dose (brentuximab vedotin & lenalidomide)|"Brentuximab vedotin 1.2 mg/kg intravenously (IV) on Day 1 of every 21 day cycle.~Lenalidomide 20 mg orally on Days 1-21 of every 21 day cycle."
89478088|NCT02086604|Experimental|Dose Level 1 (brentuximab vedotin & lenalidomide)|"Brentuximab Vedotin 1.2 mg/kg intravenously (IV) on Day 1 of every 21 day cycle.~Lenalidomide 20 mg orally on Days 1-21 of every 21 day cycle."
89478089|NCT02086604|Experimental|Dose Level 2 (brentuximab vedotin & lenalidomide)|"Brentuximab Vedotin 1.2 mg/kg intravenously (IV) on Day 1 of every 21 day cycle.~Lenalidomide 20 mg orally on Days 1-21 of every 21 day cycle."
89478090|NCT02467101|Experimental|Corticosteroid/Saline|"Corticosteroid/Saline~Patients with diagnosis of frontal fibrosing alopecia are included in the study. The diagnosis is based on the clinical findings of frontal and temporoparietal hairline recession with loss of follicular ostia.~In the same patient, intralesional triamcinolone acetone will be injected to half-head (in the active border of hairline) and in the other half-head the patient will be injected with saline solution (placebo).~The intralesional triamcinolone acetone (40 mg/ml)l) of 0,1 mL/1cm, is given along the frontal and frontoparietal hairline every 4 weeks (3 sessions).~This study includes 4 visits: 3 visits of treatment (with 1-month interval) and 1 visit of follow-up (month 6)."
89478091|NCT03799471||IBD with MSK pain|IBD patients with self-reported MSK pain. No intervention. Participants will be assessed once regarding: somatosensory functioning, psychological features, MSK pain features, co-morbidity, and IBD features
89478092|NCT03799471||IBD without MSK pain|IBD patients without self-reported MSK pain. No intervention. Participants will be assessed once regarding: somatosensory functioning, psychological features, co-morbidity, and IBD features
89478093|NCT03799471||Healthy Controls|Healthy controls. No intervention. Participants will be assessed once regarding: somatosensory functioning, psychological features, and co-morbidity.
89478094|NCT02055560||PK-Guided Cohort|CRC patients who were treated with 5-FU containing therapy regimen where 5-FU dosing was monitored and optimized using PK-guided dose adjustment.
89478095|NCT02055560||BSA Cohort|CRC patients who were treated with 5-FU containing therapy regimen where 5-FU dosing was done according to body surface area (BSA) and no PK monitoring was performed.
89478096|NCT05100225|Experimental|PTP-001 200 mg|A single intra-articular injection in the target knee of PTP-001 200 mg.
89478097|NCT05100225|Experimental|PTP-001 100 mg|A single intra-articular injection in the target knee of PTP-001 100 mg.
89478098|NCT05100225|Placebo Comparator|Placebo/saline|A single intra-articular injection in the target knee of 4mL of placebo control - physiological saline (0.9% sodium chloride injection, USP).
89478099|NCT03101540|Experimental|Supplementation|Subjects received Omega-3 PUFA supplementation
89478100|NCT02061085|Experimental|monotherapy treatment with Eribulin|Eribulin Dosage: 1.4 mg/m2 Route of administration: IV bolus Schedule of cycle: D1 and D8 every 21 days
89478101|NCT03300063|No Intervention|control|Standard Medical care
89478102|NCT03300063|Active Comparator|Low Flow Nocturnal Oxygen|This group will receive standard medical care as well as low flow oxygen during sleep.
89478103|NCT03103568|Experimental|Arm A - CYP substrates|"In Arm A of the clinical study the potential effect of multiple doses of nitisinone on the blood concentration of the active substances tolbutamide, metoprolol and chlorzoxazone will be investigated. These substances are metabolized by CYP2C9, CYP2D6 and CYP2E, respectively.~A cocktail of the substances tolbutamide, metoprolol and chlorzoxazone will be given as a single dose at the beginning of the study and PK will be investigated. The participants will then administer nitisinone for two weeks until therapeutic serum concentrations level is reached. Serum and urine concentrations of nitisinone will then be investigated for 24 hours, followed by giving the substances tolbutamide, metoprolol and chlorzoxazone as a single dose together with nitisinone to investigate the PK during interaction."
89478104|NCT03103568|Experimental|Arm B - OAT substrates|"In Arm B of the clinical study the potential effect of multiple doses of nitisinone on the blood concentration of the active substances furosemide in the blood, which is transported by the transporter proteins OAT 1 and OAT 3, will be investigated.~Furosemide will be given intravenously as a single dose at the beginning of the study and PK will be investigated. The participants will then administer nitisinone for two weeks until therapeutic dose is reached. Furosemide will then be given as a single dose together with nitisinone to investigate the PK during interaction."
89478105|NCT03299985|Experimental|Diaphragmatic myofascial release|Subjects in this arm will receive different myofascial release techniques aimed to normalize the myofascial tension of the diaphragmatic muscle
89478106|NCT03299985|Sham Comparator|Sham myofascial release|Subjects in this arm will receive the same manual techniques of the diaphragmatic myofascial release group, but without the myofascial stimulus
88950752|NCT05412641|Other|Intervention - Responsible Fatherhood Programming|Participants receive educational programming to include: 24/7 Dad, Couples Communication I, and a comprehensive program targeting financial literacy/money management. The study features only one group. Participants will receive the intervention described. There is no control group.
88950753|NCT05412589|Experimental|intravenous mFOLFOX7 combined with Camrelizumab and apatinib|"Drug: Leucovorin 200mg/m2 administered IV on Days 1 of a 21 day cycle Drug: Oxaliplatin 85 mg/m2 IV on Days 1 of a 21 day cycle. Drug: Fluorouracil 5-FU continuous infusion: 400mg/m2 on D1 and then 2400mg/m2 for 46h of each 21 day cycle.~Drug: Camrelizumab 200mg infusion on D1 for every 21 days Drug: Apatinib 250mg，po，qd for every 21 days"
88950754|NCT05412537|Active Comparator|CAU|"A sickness funds provides a physician or paramedic's consultation with people on work disability 3 to 6 months after the onset of the sickness period. The goal of this conversation is (1) to gather information on the reason of work disability, (2) gather information of the treatment plan and (3) to encourage people to RTW.~CAU stands for consult as usual"
89020516|NCT04012138|Active Comparator|Insuline + dextrose|Patients in the experimental group will receive : 10 units of regular insulin (rapid-acting, insuline asparte, intravenous injection) as an intravenous bolus with 500 ml of 10% dextrose in water administered over a 30-minute period
89478107|NCT03101072|Active Comparator|"Fixed long antibiotic course"|"Patients randomized to this group will receive a fixed long antibiotic course of 14 days."
89478108|NCT03101072|Experimental|"Fixed short antibiotic course"|"Patients randomized to this group will receive a fixed short antibiotic course of 7 days."
89478109|NCT03101072|Experimental|"Individualized antibiotic course"|"Individualized antibiotic course: starting on day 5, therapy will be discontinued after the patient has been afebrile for 48 hours and the CRP level has decreased from its peak by at least 75%"
88950755|NCT05412537|Experimental|Motivational Interviewing|Motivational Interviewing involves a conversation about behavioral change in terms of recovery or RTW. The role of the MI practitioner is to evoke change talk. By change talk, the patient expresses a desire, a reason, an ability or a need for change. It is of importance that patients themselves generate the motivation for change, and it is the practitioner's task to assist them in making informed and contemplated choices to act. The core idea is that people have to become motivated themselves to change such that the new behavior is something that they want instead of something that someone else wants. There are 4 processes: engaging, focusing, evoking and planning. Training in MI for health care professionals typically is provided in 1- to 3-day workshops. This is consistent with the 2-day training in the current research. MI was planned 3 to 6 months after the onset of work disability.
89202901|NCT00939081|Active Comparator|10,000 step/day recommendation|Participants will receive a standard 10,000 step/day recommendation and 3 education sessions: at baseline, at 3 months and at 6 months.
89478110|NCT02061163|Experimental|Subjects with Crohn's disease|Contrast Enhanced Ultrasound Optison
88950756|NCT05412485|Experimental|Treatment group|"Lokomat Certified physiotherapists will perform robotic assisted gait trainings. It will be performed 4 times per a week with a duration of 30 minutes on the lokomat with a treatment of 6 weeks phase.~Initially the Physical therapist will adjust the body -weight support at 70 % which will be gradually reduced until obtain flexion of the knees during stance phases. The lokomat certified physiotherapist will monitor the condition of the knees and adjust the body weight support during the training.~The Gait speed will be set at 0.7 km/hour and will gradually increase according to the comfortable speed selected by the child. The gait speed, Body weight support and the guidance force of the Lokomat will be adjusted and modified individually according to the ability of the child.~Virtual reality games will be used to motivate the participants and verbal encouragement will be used to increase their adherence to the intervention."
89478111|NCT03103646|Experimental|Lu AF35700|Day 1: Single dose of Lu AF35700. Extensive metabolisers (EMs): 10mg. Poor metabolisers (PMs): 5 mg
89478112|NCT03103646|Experimental|Lu AF35700 AND itraconazole|Days 29 to 31: once-daily dosage of 200 mg itraconazole. Day 32: Single dose of Lu AF35700 (EMs: 10 mg, PMs: 5 mg) and 300 mg itraconazole Days 33 to 42: once-daily dosage of 200 mg itraconazole
88950757|NCT05412485|Active Comparator|Control group|The same procedures will be given twice a week frequency.
88950758|NCT05412472|Experimental|1) Healthy subjects with normal renal function|
88950759|NCT05412472|Experimental|2) Mild renal impairment|
89478113|NCT02061241||Patients|All included patients, having CRT implant procedure Will have both Pacing in vein at site of latest mechanical activation and Pacing in other suitable vein.
89478114|NCT03709238||Alzheimers diseased patients|Behavioral: Different thermal stimulation. Recording of facial expression during thermal stimulation.
89478115|NCT03709238||Healthy participants|Behavioral: Different thermal stimulation. Recording of facial expression during thermal stimulation.
89478116|NCT03305679|Experimental|Direct provisional technique|Patients here will be subjected to the direct provisional technique
89478117|NCT03305679|Active Comparator|Indirect Provisional technique|Patients here will be subjected to the indirect provisional technique
89478118|NCT01554410|Experimental|IMRT/Cisplatin/Gemcitabine|All patients get IMRT with concurrent cisplatin & gemcitabine, with the dose of gemcitabine varying according to cohort
89478119|NCT03299907||COPD|Subject with FEV1/FVC post BD < 0.7 or LLN
89478120|NCT03299907||Non COPD|Subject with FEV1/FVC post BD >= 0.7 or LLN
89478121|NCT04968158|Experimental|Group A: Etoricoxib/Tramadol|Administered orally, one packet of etoricoxib / tramadol granules diluted in 100 ml of water, every 24 hours for 7 days.
89478122|NCT04968158|Active Comparator|Group B: Acetaminophen / Tramadol|Administered orally, one tablet, every 8 hours, for 7 days.
89478123|NCT02059915|Experimental|Treatment A|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
89478124|NCT02059915|Experimental|Treatment B|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
89478125|NCT02059915|Experimental|Treatment C|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
89478126|NCT02059915|Experimental|Treatment D|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
89478127|NCT03305523|Experimental|Thermocautery|Circumcision with thermocautery technique was applied all participants
89478128|NCT05607823|Experimental|CST Group|The core stabilization group. Participants in this group will be received core stabilization training, orofacial manuel therapy and conventional physiotherapy (Home exercise program and patient education) as treatment. The number of participants is planned to be 15.
89478129|NCT05607823|Experimental|OMT Group|The orofacial manuel therapy group. Participants in this group will be received orofacial manuel therapy and conventional physiotherapy (Home exercise program and patient education) as treatment. The number of participants is planned to be 15.
89478130|NCT05607823|Experimental|Control Group|Participants in this group will be received only conventional physiotherapy (Home exercise program and patient education) as treatment. The number of participants is planned to be 15.
89478131|NCT02468037|Experimental|Phlebotomy|All subjects receive counseling to follow a healthy diet and regular exercise. Phlebotomy occurs at the rate of 500 ml (one Unit) of blood per month over the period of 3-6 months. At two-month intervals, serum ferritin and complete blood counts are determined. When serum ferritin reaches the lowest quartile of normal (<50 ng/mL for females and <70 ng/mL for males, but no sooner than 3 months or later than 6 months after beginning phlebotomy, subjects will be retested for glucose tolerance as described
89478132|NCT02468037|No Intervention|Control|Subjects receive counseling to follow a healthy diet and regular exercise.
89202902|NCT00939081|Experimental|Adaptive recommendation|The adaptive recommendation will update the participant's recommended step count attainment from 7,000 to 8,000, then 10,000 steps/day. The SMS-based self-monitoring system will collect three data points each day from participants in this group: 1) total number of steps/d recorded by the pedometer during the previous day (steps/d); 2) performance on 2nd weight loss goal; and 3) performance on 3rd weight loss goal.
89202903|NCT00685178|Experimental|1 topiramate + CR|topiramate and contingency reinforcement for urine sample confirming cocaine abstinence
89202904|NCT00685178|Experimental|2 topiramate + NonCR|Topiramate and random reinforcement irrespective of cocaine use
89202905|NCT00685178|Placebo Comparator|4 Placebo + NonCR|
89202906|NCT00685178|Active Comparator|3 Placebo + CR|Placebo and contingency reinforcement for urine sample confirming cocaine abstinence
89478133|NCT04803812|Experimental|Receive weekly SMS containing wellness stories shared by other Ontario physicians|
89478134|NCT04803812|Experimental|Receive weekly SMS containing aim wellness resources/strategies.|
89478135|NCT04803812|Experimental|Receive weekly SMS combining wellness stories & resources/strategies|
89478136|NCT02467257|Experimental|Intrevention arm|Patients received Gum Arabic as intervention
89478137|NCT02060617|Experimental|Impairment-Based Group|The impairment-based intervention will be a multi-modal treatment approach utilizing manual therapy of the thoracolumbosacral spine and hips as well as motor control exercises. Patient education will also be provided.
89478138|NCT02060617|Active Comparator|Classification-Based Group|Patients in this group will be categorized into subgroups according to the Treatment-Based Classification (TBC) Algorithm and treated accordingly. Patient education will also be provided.
89478139|NCT03623594|Experimental|Surgical repair of the diastasis|Repair of the diastasis with a double row plication using absorbable Quill suture
89478140|NCT04491279|Experimental|Neuropilates class.|"Will attend a once-weekly 60-minute neuropilates exercise class over 6 weeks facilitated by the principle investigator (chartered physiotherapist and pilates instructor).~Pitched at a beginner level focused on the core elements of neuropilates and progressing week on week as appropriate.~Includes a warm up, cool down and neuropilates exercises in line with the teaching of APPI (the Australian Physiotherapy and Pilates Institute). Exercises may be completed on mats, chairs, gym balls, plinths and in standing, depending upon the ability level of the participant.~Two classes running with 8 participants in each based on their initial assessment into the higher and lower functionally independent participants.~Participants will be given a home exercise programme weekly based on exercises from the class and will be asked to complete these independently at home twice more during the week and to keep a training diary."
89478141|NCT04491279|Active Comparator|Generalised exercise class.|"Will attend a once weekly, 60-minute generalized exercise class which will be designed by a chartered physiotherapist to address strength, cardiorespiratory fitness and mobility.~Exercises will be more functional and generic than in the pilates classes and will be conducted in a circuit style, including mobility practice, sit to stand practice, cycling with the motomed, and general upper and lower limb strengthening. Warm up and cool downs will also be a feature of this class.~Participants will be also be given a home exercise programme based on exercises completed in the class and will be asked to complete these exercises twice more during the week and to keep a training diary."
89478142|NCT02471404|Active Comparator|Dapagliflozin+metformin|Dapagliflozin + saxagliptin placebo + glimepiride placebo + metformin
89478143|NCT02471404|Active Comparator|Dapagliflozin+saxagliptin+metformin|Dapagliflozin + saxagliptin + glimepiride placebo+ metformin
89478144|NCT02471404|Active Comparator|Glimepiride+metformin|Glimepiride + dapagliflozin placebo + saxagliptin placebo + metformin
89478145|NCT00835094|Experimental|Morning|
89478146|NCT00835094|Experimental|Evening|
89478147|NCT02061475|Active Comparator|Lidocaine Patches|
89478148|NCT02061475|Placebo Comparator|Placebo Patches|
89478149|NCT02468115|Experimental|VIS410|Single intravenous fixed dose of VIS410
89478150|NCT02468115|Placebo Comparator|Placebo|Single intravenous infusion of placebo
89478151|NCT03100994|No Intervention|Group A|without nerve block
89478152|NCT03100994|Active Comparator|Group B|Ultrasound guided transmuscular quadratus lumborum block with 0.125% bupivacaine 30ml
89478153|NCT03100994|Active Comparator|Group C|Ultrasound guided quadratus lumborum type 2 block with 0.125% bupivacaine 30ml
89478154|NCT02060071|Other|Aortic setnsosi|blood test
89478155|NCT02060071|Other|controls|blood test
89478156|NCT03101228|Experimental|Reduced sitting|Objectively measured daily inactive time will be reduced by one hour compared to the baseline.
89478157|NCT03101228|No Intervention|Control|Subjects will be guided to maintain their normal sedentary behaviour and physical activity habits.
89478158|NCT03100916|Experimental|Dose Ranging Arm|
88950760|NCT05412472|Experimental|3) Moderate renal impairment|
88950761|NCT05412472|Experimental|4) Severe renal impairment|
89478159|NCT03100916|Experimental|Food Effect arm|
89478160|NCT04160936|Active Comparator|study group :infiltration with 0.25% bupivacaine post-op|At the end of the procedure ( surgery), In the patients of the study group, the 23-gauge, 90mm spinal needle will inserted up to the renal capsule under fluoroscopic guidance along the nephrostomy tube at 6 and 12 o'clock positions (cranial and caudal); then 20 ml of 0.25% bupivacaine will infiltrated into the nephrostomy tract, while gradually withdrawing the needle from renal capsule to the skin thereby infiltrating the renal capsule, perinephric fat, muscles, subcutaneous tissue and skin
89478161|NCT04160936|No Intervention|control group , no anesthesia infiltration post-op|control group: no anesthesia infiltration had been given post opertatively
89478162|NCT03103334|Experimental|Experimental A|Zeneo® - Methotrexate thigh to Methotrexate Biodim® thigh
89478163|NCT03103334|Experimental|Experimental B|Methotrexate Biodim® thigh to Zeneo® - Methotrexate thigh
89478164|NCT03103334|Experimental|Experimental C|Zeneo® - Methotrexate abdomen to Methotrexate Biodim® abdomen
89478165|NCT03103334|Experimental|Experimental D|Methotrexate Biodim® abdomen to Zeneo® - Methotrexate abdomen
89478166|NCT03305367|No Intervention|Screening/Baseline|A standard OGTT with no supplementation/intervention
89478167|NCT03305367|Experimental|Hydrolyzed pine nut oil low dose|Standard OGTT supplemented with 3 g of hydrolyzed pine nut oil
88950762|NCT05412303||With ECMO-VA|postcardiotomy cardiogenic shosck supported by ECMO-VA
89478168|NCT03305367|Experimental|Hydrolyzed pine nut oil high dose|Standard OGTT supplemented with 6 g of hydrolyzed pine nut oil
89478169|NCT02471014||Obese Individuals|Participants in this group will receive one 0.5mL Pneumovax23 intramuscular vaccine at baseline, four questionnaires administered at baseline, and one 50mL blood draw at baseline and one 50mL blood draw up to 6 weeks later.
89478170|NCT02471014||Normal Individuals|Participants in this group will receive one 0.5mL Pneumovax23 intramuscular vaccine at baseline, four questionnaires administered at baseline, and one 50mL blood draw at baseline and one 50mL blood draw up to 6 weeks later.
89478171|NCT00795158|Experimental|Arm 1|
88950763|NCT05412303||Without ECMO-VA|Post cardiotomy cardiogenic shock medically treated (inotrope and vasopressor)
89478172|NCT02063269|Experimental|Rivastigmine|Rivastigmine
89478173|NCT03305289|Active Comparator|pulsed radiofrequency|sensory stimulation will be carried out at 50 Hz. The definitive position of the electrode will be verified by inducing paresthesia with sensory stimulation between 0.1-0.3 V in the affected painful area, then pulsed radiofrequency will be applied for 10 patients for 10 mins
89478174|NCT03305289|Active Comparator|thermal Radiofrequency|sensory stimulation will be carried out at 50 Hz. The definitive position of the electrode will be verified by inducing paresthesia with sensory stimulation between 0.1-0.3 V in the affected painful area, then Thermal lesion will be applied for 10 patients for 2 cycles of 90 seconds
89478175|NCT00794846|Experimental|Clarinex followed by Zyrtec|Clarinex 5 mg by mouth daily for 7 days followed by Zyrtec 10 mg by mouth daily for 7 days, with 5-28 days washout between treatments.
88950764|NCT05412238|Experimental|Pregnant women receiving fortification sachets|pregnant women receive daily fortified sachets containing micro-and macronutrients for 6-9 months
88950765|NCT05412238|Experimental|6-24 months old children receiving fortification sachets|6-24 months old children receiv daily fortified sachets containing micro-and macronutrients for 6-9 months
88950766|NCT05412238|Experimental|2-5 years old children receiving fortification sachets|2-5 years old children receive daily fortified sachets containing micro-and macronutrients for 6-9 months
89478176|NCT00794846|Experimental|Zyrtec followed by Clarinex|Zyrtec 10 mg by mouth daily for 7 days followed by Clarinex 5 mg by mouth daily for 7 days, with 5-28 days washout between treatments.
89478177|NCT03560713|Experimental|FES + combined exercise|The Functional Electrical Stimulation (FES) + combined exercise group will receive 12 weeks of FES (Neurodyn High Volt, IBRAMED, São Paulo/SP, Brasil), three times a week, frequency 25Hz, pulse rate of 200μs, ON:OFF 5:5, individual maximum tolerated intensity; minimum at strong but comfortable visible muscle contraction (without causing undue pain or discomfort to the participant) and receive aerobic exercise training and resistance exercises for upper limbs and lower limbs.
89478178|NCT03560713|Sham Comparator|FES sham|The Functional Electrical Stimulation (FES) sham + combined exercise group will receive 12 weeks of FES (Neurodyn High Volt, IBRAMED, São Paulo/SP, Brasil), three times a week, frequency 5Hz, pulse rate of 200μs, ON:OFF 5:5, without muscle contraction during 30 minutes and receive aerobic exercise training and resistance exercises for upper limbs and lower limbs.
89478179|NCT00794768|Experimental|Clarinex followed by Allegra|Clarinex 5 mg by mouth daily for 7 days followed by Allegra 180 mg by mouth daily for 7 days, with 5-28 days washout between treatments.
89478180|NCT00794768|Experimental|Allegra followed by Clarinex|Allegra 180 mg by mouth daily for 7 days followed by Clarinex 5 mg by mouth daily for 7 days, with 5-28 days washout between treatments.
89478181|NCT02060851|Experimental|Vifor and EPO|intravenous iron and EPO
89478182|NCT02060851|Placebo Comparator|control|no intravenous iron or EPO
89478183|NCT02060851|Experimental|Vifor|intravenous iton but no EPO
89478184|NCT00779636|Experimental|Desloratadine 10 mg|
89478185|NCT00779636|Placebo Comparator|Placebo|
89478186|NCT05624073||Air-QTM Blocker|GA (n=35): Air-Q Blocker TM will be used as a conduit for blind endotracheal intubation.
89478187|NCT05624073||LarySealTM Pro Laryngeal Mask|GL (n=35): Laryseal TM Pro will be used as a conduit for blind endotracheal intubation.
89478188|NCT02060929|Experimental|Sequence 1|Participants will self administer 1 spray of esketamine solution to each nostril using a intranasal (through nose) device with a nasal guide on Day 1 of period 1 as treatment regimen A at time 0 and repeated twice every 5 minutes (total dose: 84 mg). There will be a washout period of 5-10 days between the treatment regimens. On Day 1 of period 2, participants will self administer 1 spray of esketamine solution to each nostril using a intranasal device without a nasal guide as treatment regimen B at time 0 and repeated twice every 5 minutes (total dose: 84 mg).
89478189|NCT02060929|Experimental|Sequence 2|Participants will self administer 1 spray of esketamine solution to each nostril using a intranasal device without a nasal guide on Day 1 of period 1 as treatment regimen B at time 0 and repeated twice every 5 minutes (total dose: 84 mg). There will be a washout period of 5-10 days between the treatment regimens. On Day 1 of period 2, participants will self administer 1 spray of esketamine solution to each nostril using a intranasal device with a nasal guide as treatment regimen A at time 0 and repeated twice every 5 minutes (total dose: 84 mg).
89478190|NCT00757562|Experimental|DL|Desloratadine syrup once daily
89478191|NCT00757562|Placebo Comparator|Placebo|placebo syrup once daily
89478192|NCT03299517|Experimental|lidocaine|"Initial dose: antiarrythmic drugs Lidocaine (1.5 mg / kg EV in 30 minutes).~Adittional dose: Lidocaine (0.75 mg / kg EV in 30 minutes)."
88950767|NCT05412147|Active Comparator|Control group|The control group takes the multi-vitamins (Elevit, Bayer S.A.) with the dosage of one tablet per day on the 1st to 5th day of menstruation, then perform ovulation induction on the second menstrual cycle, and continue to take multi-vitamins until the day of oocyte retrieval.
89478193|NCT03299517|Experimental|amiodarone|"Initial dose: antiarrythmic drugs Amiodarone (5 mg / kg EV in 30 minutes)~Adittional dose: Amiodarone (3 mg / kg EV in 30 minutes)"
89478194|NCT00651404|Experimental|Ezetimibe|
89478195|NCT00651404|Placebo Comparator|Placebo|
88950768|NCT05412147|Experimental|Treatment group|The treatment group begins to take Reco-18 on the 1st to 5th day of menstruation with a dosage of 4 pills per day for the whole menstrual cycle, then perform ovulation induction on the second menstrual cycle, and continue to take Reco-18 until the day of oocyte retrieval.
89478196|NCT02413372|Experimental|Treatment Group A: BMS-986036|Administered as specified on specified days
89478197|NCT02413372|Experimental|Treatment Group B: BMS-986036|Administered as specified on specified days
89478198|NCT02413372|Placebo Comparator|Treatment Group C: Placebo|Administered as specified on specified days
89478199|NCT00651014|Experimental|Ezetimibe|
89478200|NCT00651014|Placebo Comparator|Placebo|
89478201|NCT03305211|Other|Biological sample|biological sampling will be performed on patients requiring renal biopsy and well-phenotyped patients (diagnosis of renal disease)
89478202|NCT04601558|No Intervention|Control group|The first group of participants was control group. The number of participant was 70, and the participants in this group after recruitment received letter with their own cardiovascular risk factors and count of their 10-year risk of cardiovascular disease.
88950769|NCT05412043|Experimental|Persons with MS - Dance group|12 pwMS in the Dance Therapy intervention
88950770|NCT05412043|Active Comparator|persons with MS - excercise group|12 pwMS in the exercise (placebo) group
88950771|NCT05412043|Placebo Comparator|Healthy controls|
88950772|NCT05411952|Experimental|education-mother and child dyad|Mother and child dyad have received dietary intervention for 6 months
88950773|NCT05411952|Experimental|education-only child|Children have received dietary intervention for 6 months. But their mothers didn't receive any dietary intervention
89478203|NCT04601558|Sham Comparator|Passive-intervention group|The second group of participant was passive-intervention group. There were 70 participants. This group of women after recruitment received letter with their own cardiovascular risk factors and count of their 10-year risk of cardiovascular disease. After this letter, every two months, they were receiving remainder on their own cardiovascular risk factors and count of their 10-year risk of cardiovascular disease.
89478204|NCT04601558|Active Comparator|Active-intervention group|The third group of participant was active-intervention group. There were also 70 participants. This group of women after recruitment received letter with their own cardiovascular risk factors and count of their 10-year risk of cardiovascular disease. After this letter, every two months, active-intervention group were receiving Cochrane abstracts in the form of blog-shots.
89478205|NCT02413294|Experimental|Bright Light Intervention|Before the bright light intervention is initiated (and during the intervention), participants will wear two wrist bands which measure sleep quality and activity levels- the Fitbit and actigraphy watches. These will be worn for two weeks to assess individuals' baseline levels of sleep quality and will continue to be worn during the intervention. Following the baseline period, the re-timer glasses will be introduced and worn for a period of 30 to 50 minutes a day for two weeks.
89478206|NCT03560479|Experimental|alpha1H, 7.4 mg/mL|alpha1H (7.4 mg/mL), solution for instillation, 30 mL
89478207|NCT03560479|Placebo Comparator|placebo|Placebo, 0.9% NaCl (sodium chloride), 30 mL
89478208|NCT03560479|Experimental|alpha1H, 37 mg/mL|alpha1H (37 mg/mL), solution for instillation, 30 mL
89478209|NCT03560479|Experimental|alpha1H, 74 mg/mL|alpha1H (74 mg/mL), solution for instillation, 30 mL
89478210|NCT05588349|Experimental|Dry needling + stretching exercise|"After locating the MTrPs, hand hygiene of the physiotherapist will be done and the needling site will be disinfected with alcohol swab. 0.30 x 50 mm disposable stainless-steel needles (DongBang Acupuncture Inc., Boryeong, Korea) will be used. The needle will be inserted into the muscle and pistoned in an up-and-down fashion using the fast in and fast out technique in order to provoke the local twitch response (LTR). This will be repeated until either the LTRs are exhausted, or the participant's tolerance threshold is met. If the participant is sensitive to the needle stimulation, the manipulation will be reduced. The needle will be left in situ for five minutes (Cotchett et al., 2011). Participants will receive dry needling once per week for three weeks. Plantar fascia and calf stretching exercise will be taught"
89478211|NCT05588349|Active Comparator|Stretching exercise|"Plantar fascia stretching exercise:~Participants will be instructed to sit with the affected foot placed on the contralateral thigh with the toes being grasped and pulled into extension until a stretch is felt in the plantar fascia.~Calf stretching exercise:~To focus on stretching the gastrocnemius, participants will be taught to stand with both hands holding onto the wall and keep the affected leg back with knee straightened and heel in contact with the floor. Slowly lean forward to the wall until a stretch is felt in the calf. To focus on stretching the soleus, the same procedures will be taught except with the affected knee being bent."
89478212|NCT02062255|Active Comparator|Aspirin|Twenty eight enteric coated 81mg Aspirin tablets will be dispensed for daily oral dosing, to be taken with a meal at the same time of day.
89478213|NCT02062255|Active Comparator|Omega-3 Free Fatty Acids|Three hundred thirty-six gelatin coated 450 mg capsules containing approximately 180 mg of EPA and 135 mg of DHA will be dispensed. Patients are to take 12 capsules daily with meals, either once daily (12 capsules with one meal) or divided twice daily (e.g., six with breakfast and six with dinner).
89478214|NCT02062255|Active Comparator|Aspirin & Omega-3 FFAs|Aspirin (81 mg po daily) to be taken simultaneously with Omega-3 Free Fatty Acids (1500mg of docosahexaoic acid (DHA) and 2500mg eicosapentanoic acid (EPA) given daily.
89478215|NCT03299283||Respiratory/Pharyngitis|Subject presents with signs/symptoms of respiratory infection including but not limited to fever, cough, sore throat (pharyngitis), runny nose, myalgia, headache, chills, or fatigue
89202907|NCT00537394|Experimental|A|Regimen with higher predicted activity assigned by the study plus at least 2 NRTIs (personalized choice from expert recommendation) for 96 weeks. A 3-4 drug regimen was selected from the drugs listed to the right.
89478216|NCT03299283||Gastrointestinal|Subject presents with suspected gastroenteritis (e.g. diarrhea, vomiting, nausea, etc.) with duration of symptoms less than or equal to 7 days
89478217|NCT02739542|Active Comparator|Tecfidera|Tecfidera (120mg by mouth twice daily for 7 days with dose escalation to 240mg by mouth twice daily)
89478218|NCT02739542|Placebo Comparator|Placebo|Placebo by mouth twice daily.
89478219|NCT02466477|Experimental|GeneSight Psychotropic (GEN)|The GeneSight Psychotropic (GEN) product is a pharmacogenomic decision support tool that helps clinicians to make informed, evidence-based decisions about proper drug selection. More specifically, patients are tested for clinically important genetic variants of multiple pharmacokinetic and pharmacodynamic genes that affect a patient's ability to metabolize, tolerate or respond to medications.
89478220|NCT02466477|Experimental|Enhanced-GeneSight Psychotropic (E-GEN)|The current GEN test lacks predictive genes for antipsychotic-induced weight gain (AIWG), a major complication of antipsychotic drug use. Therefore, the Enhanced-GeneSight Psychotropic (E-GEN), which is an enhanced version of the GEN test, was developed by incorporating 6 new genes (represented by 7 SNPs) that are predictive for AIWG, to those used in the GEN algorithm. An increasing risk level associated with AIWG is estimated by an increasing number of risk genotypes that a given patient possesses among the 7 SNPs.
88950774|NCT05411952|Experimental|control|Control group did't receive any dietary intervention during the study
88950775|NCT05411926||The group that receiving PD-1 / PD-L1 inhibitor before liver transplantation|
89202908|NCT00537394|Experimental|B|Regimen with higher predicted activity assigned by the study without NRTIs for 96 weeks. A 3-4 drug regimen was selected from the drugs listed to the right.
88950776|NCT05411926||The group without receiving PD-1 / PD-L1 inhibitor before liver transplantation|
88950777|NCT05411900|Experimental|Experimental group: BoNT-A arms|Subjects randomized in experimental group will receive intradermal injections of BoNT-A into the wrist and skin area of the hand where the pain is located.
89202909|NCT00537394|Other|C|Regimen with lower predicted activity assigned plus at least 2 NRTIs (personalized choice from expert recommendation) for 96 weeks. A 3-4 drug regimen was selected from the drugs listed to the right.
89202910|NCT00793494|Experimental|Probaclac|Administration of Bifidobacterium bifidum R0071, Bifidobacterium longum R0175, Lactobacillus helveticus R0052, Lactobacillus Delb. SSP bulgaricus R9001, Lactobacillus rhamnosus R0011, Lactococcus Lactis SSP. lactis R1058 et Streptococcus thermophilus (Probaclac™) b.i.d.
89478221|NCT02466477|Active Comparator|Treatment as Usual (TAU)|"The comparator chosen for this study provides a real world comparison of standard of care for patients who receive no pharmacogenomics guidance.~Patients randomized to the TAU arm will also have their DNA collected and a pharmacogenomic-based interpretive report will be generated using GEN testing. However, this report will not be shared with the treating clinicians until completion at 12 months of the study. Therefore, patients in this arm will receive clinical treatment as usual, without the use or knowledge of genotyping results by their treating clinicians."
89478222|NCT02466945|Other|V063B-DP3003|all patients will received the study product (V063B-DP3003)
89478223|NCT05547243|Experimental|Low dose|Two doses were administered by intramuscular injection, 28 days apart
89478224|NCT05547243|Experimental|High dose|Two doses were administered by intramuscular injection, 28 days apart
89478225|NCT05547243|Placebo Comparator|Placebo|Two doses were administered by intramuscular injection, 28 days apart
89478226|NCT03100604|Experimental|sevoflurane 2%, 1 MAC|Maintenance of anesthesia was provided with 2% sevoflurane in S Group, and 6-9% desflurane in D Group, with 50% air /oxygen mixture and fresh gas flow at 4 l/min in both groups.
89478227|NCT03100604|Experimental|Desfluran 6-9% 1MAC|Maintenance of anesthesia was provided with 2% sevoflurane in S Group, and 6-9% desflurane in D Group, with 50% air /oxygen mixture and fresh gas flow at 4 l/min in both groups.
89478228|NCT02719353|Experimental|comfilcon A Extended Range test lens|Subjects will be randomized to wear either the test or control pair of lens, then cross over to the alternate pair.
89478229|NCT02719353|Active Comparator|comfilcon A control lens|Subjects will be randomized to wear either the test or control pair of lens, then cross over to the alternate pair.
89478230|NCT05244824||Rheumatoid Arthritis|To translate the EDAQ, which determines the difficulties experienced by individuals with rheumatoid arthritis in daily life, into Turkish.
89478231|NCT03101774|Experimental|threshold-IMT group|Using inspiratory muscle training using threshold load device for 8 weeks
89478232|NCT03101774|Experimental|resisive-IMT group|Using inspiratory muscle training using resistive device for 8 weeks
89478233|NCT03101774|Sham Comparator|control group|not conduct inspiratory muscle training for 8 weeks
89478234|NCT05449509||High-SYNTAX score patients|
89478235|NCT05449509||Intermediate/low-SYNTAX score patients|
89478236|NCT03517592|Experimental|EMDR Therapy|EMDR: 20 individual sessions 60 minutes each for 6 months
89478237|NCT03517592|Other|Treatment as Usual|The TAU condition includes follow-up visits with the psychiatry, psychology and with the nursing service. Visits with the psychiatrist consist to evaluate clinical status and readjust the pharmacological treatment if necessary while visits with the psychologist consist to assess and detect risk situations and to prevent relapses using a cognitive behavioral approach. Finally, the nursing service will provide health and care habits and will carry out the abstinence controls.
89478238|NCT04823403|Experimental|Patients with hepatocellular carcinoma|"Intravenous Nivolumab (1mg/kg) will be given every 6 weeks for a maximal period of 6 months within the study.~Ipilimumab, single intra-arterial (IA) injection per patient, at 3 dose-levels*.~(D1) Starting dose : 50 mg; n=3 to 6~(D2) 2nd dose-level : 100 mg; n=3 to 6~(D3) Maximal tested dose : 150mg; n=3 to 6 (if no limiting toxicities) *Dose level (D-1) : 25 mg will be tested if de-escalation is needed at D1 (>1/3 DLT at D1)"
89478239|NCT03497390|Active Comparator|EMERALD|Patients will have 1-year multicomponent program (EMERALD) intervention including a total of 6 interactive workshops focusing on empowerment skills, healthy eating and exercise. Please refer to the protocol for further details.
89478240|NCT03497390|Placebo Comparator|Usual care|Usual management without any workshop or program
89478241|NCT03493646|Active Comparator|Azacitidine|6 cycles of azacitidine (28 day cycle)
88950778|NCT05411900|Placebo Comparator|Control group: Placebo arms|Subjects randomized in control group will receive intradermal injections of placebo.
88950779|NCT05411874|Experimental|Chidamide plus HD-DXM|"Chidamide (orally at 5 mg biw for 24 weeks)~HD-DXM (orally at 40 mg daily for 4 days)"
88950780|NCT05411874|Active Comparator|HD-DXM|HD-DXM (orally at 40 mg daily for 4 days )
88950781|NCT05411809|No Intervention|Arm1|The ctDNA is positive after SBRT and no adjuvant therapy is used after SBRT.
88950782|NCT05411809|Experimental|Arm 2|The ctDNA is positive after SBRT and adjuvant therapy is used after SBRT.
89202911|NCT00793494|Placebo Comparator|Placebo|
89478242|NCT03493646|Experimental|CC 486|6 cycles CC 486 (28 day cycle)
89478243|NCT05519865|Experimental|Tucidinostat Combined with Tislelizumab|Subjects receive Tucidinostat 30mg orally biw and Tislelizumab 200 mg intravenously (IV) Q3W.
89478244|NCT05519865|Active Comparator|Tislelizumab|Subjects receive Tislelizumab 200 mg intravenously (IV) Q3W.
89478245|NCT03100526|Experimental|Intervention--PACT Intensive Management|The intervention is the PACT Intensive Management Program (PIM) which provides intensive interdisciplinary care planning, care coordination, patient self-management support, and tailored goal setting based on patient needs and preferences, and additional care management services.
89478246|NCT03100526|No Intervention|Usual care|High-Risk patients receiving care in PACT.
88950783|NCT05411809|No Intervention|Arm 3|The ctDNA is negative after SBRT and no adjuvant therapy is used after SBRT.
89478247|NCT05244356|Experimental|Descriptive Norm (70%)|"Intervention in the form of a message likened to a social media post. Composed of 3 parts:~Opening tag line highlighting the main concern that Malaysians have about the COVID-19 vaccine (safety and side effects)~Message content describing that about 70% of Malaysians have expressed acceptance for the COVID-19 vaccine.~Rally slogan: It's safe and effective!"
89478248|NCT05244356|Experimental|Descriptive Norm|"Intervention in the form of a message likened to a social media post. Composed of 3 parts:~Opening tag line highlighting the main concern that Malaysians have about the COVID-19 vaccine (safety and side effects)~Message content describing that the COVID-19 vaccine has been widely tested including with the elderly and people with existing health conditions, while subsequently highlighting that the vaccine was already received by millions worldwide.~Rally slogan: It's safe and effective!"
89478249|NCT05244356|Experimental|Healthcare worker (HCW) recommendation|"Intervention in the form of a message likened to a social media post. Composed of 3 parts:~Opening tag line highlighting the main concern that Malaysians have about the COVID-19 vaccine (safety and side effects)~Message content highlights recommendation from Malaysian healthcare workers to get the vaccine, since majority of them has already received it, including the Malaysian Health Director General~Rally slogan: It's safe and effective!"
89478250|NCT05244356|Experimental|Negative attribute framing|"Intervention in the form of a message likened to a social media post. Composed of 3 parts:~Opening tag line highlighting the main concern that Malaysians have about the COVID-19 vaccine (safety and side effects)~Message content describing the rate of side effects occurring with COVID-19 vaccination in a negative frame.~Rally slogan: It's safe and effective!"
89478251|NCT05244356|Experimental|Positive attribute framing|"Intervention in the form of a message likened to a social media post. Composed of 3 parts:~Opening tag line highlighting the main concern that Malaysians have about the COVID-19 vaccine (safety and side effects)~Message content describing the rate of side effects occurring with COVID-19 vaccination in a positive frame.~Rally slogan: It's safe and effective!"
89478252|NCT05244356|Experimental|Risky choice framing (Safety)|"Intervention in the form of a message likened to a social media post. Composed of 3 parts:~Opening tag line highlighting the main concern that Malaysians have about the COVID-19 vaccine (safety and side effects)~Message content describing a risky choice frame which compares the death rates occurring with COVID-19 vaccination versus contracting the virus itself.~Rally slogan: It's safe and effective!"
89478253|NCT05244356|Experimental|Risky choice framing (Side effects)|"Intervention in the form of a message likened to a social media post. Composed of 3 parts:~Opening tag line highlighting the main concern that Malaysians have about the COVID-19 vaccine (safety and side effects)~Message content describing a risky choice frame that compares the incidence rates of blood clots occurring with COVID-19 vaccination versus contracting COVID-19.~Rally slogan: It's safe and effective!"
89478254|NCT05244356|Experimental|Control message|"Control message containing only rally slogan: It's safe and effective!"
89478255|NCT05244356|Experimental|Combination message: Descriptive Norm (70%) + Descriptive Norm|Participants received 2 messages which were exposed one at a time. Sequence of message appearing randomly rotated.
89478256|NCT05244356|Experimental|Combination message: Descriptive Norm (70%) + HCW recommendation|Participants received 2 messages which were exposed one at a time. Sequence of message appearing randomly rotated.
89478257|NCT05244356|Experimental|Combination message: Descriptive Norm (70%) + Negative attribute framing|Participants received 2 messages which were exposed one at a time. Sequence of message appearing randomly rotated.
89478258|NCT05244356|Experimental|Combination message: Descriptive Norm (70%) + Positive attribute framing|Participants received 2 messages which were exposed one at a time. Sequence of message appearing randomly rotated.
89478259|NCT05244356|Experimental|Combination message: Descriptive Norm (70%) + Risky choice framing (Safety)|Participants received 2 messages which were exposed one at a time. Sequence of message appearing randomly rotated.
89478260|NCT05244356|Experimental|Combination message: Descriptive Norm (70%) + Risky choice framing (Side effects)|Participants received 2 messages which were exposed one at a time. Sequence of message appearing randomly rotated.
89478261|NCT05244200|No Intervention|Non-Intervention Group|Patients in the non-intervention group will be followed for the therapeutic outcomes and detection of DTPs without tempting to resolve them
89478262|NCT05244200|Experimental|Intervention Group|A strict protocol developed by IDC for insulin prescription is going to be implement and patients will be assessed for the therapeutic outcomes along with the detection and resolution of drug therapy problems throughout the course
89478263|NCT03100448|Other|On1 Concept|On1 Concept & NobelActive implants
89478264|NCT05032352||Treatment Arm|"Treatment Arm 1: 4 cycles of adjuvant treatment with a standard NSCLC cisplatin-based doublet regimen or carboplatin-based regimen of physician choice.~Treatment 1A: other adjuvant therapy or combination of adjuvant therapies (targeted therapy, immunotherapy, or other)"
88950784|NCT05411796|Experimental|Tampax menstrual cup (regular flow), then Other menstrual cup (size 1)|
88950785|NCT05411796|Experimental|Other menstrual cup (size 1), then Tampax menstrual cup (regular flow)|
89478265|NCT05032352||Observation only|All patients will be observed for progression free survival and overall survival to the end of study or death, whichever occurs first.
89478266|NCT03103256|Experimental|YHP1701|PO, Once daily (QD), 8 weeks
89478267|NCT03103256|Active Comparator|YHR1703|PO, Once daily (QD), 8 weeks
89478268|NCT03103256|Active Comparator|YHR1704|PO, Once daily (QD), 8 weeks
89478269|NCT01362062||RA Cohort|Participants with active RA who had an inadequate clinical response to current non-biologic disease modifying anti-rheumatoid drug (DMARD) and/or anti-tumor necrosis factor (anti-TNF) therapy being treated with tocilizumab according to the routine clinical practice and in line with prescribing information will be observed for a total duration of 12 months.
88950786|NCT05411783|No Intervention|High tie of IMV|The IMV will be tie under the pancreas as the usual procedure in left hemicolectomy and ARR
88950787|NCT05411783|Experimental|Low tie of IMV|The IMV will be tie under the left colic vein
88950788|NCT05411757|Experimental|IBR900 cell injection|IBR900 Cell Injection Combined With Lenvatinib or Bevacizumab
88950789|NCT05411666|Other|Arm 1|Saline solution maintenance of the Central venous catheter (CVC)
88950790|NCT05411666|Experimental|Arm 2|No maintenance of the Central venous catheter (CVC)
88950791|NCT05411640|Experimental|Aerobics with Blood flow restriction|This group will perform Aerobic exercises with Blood Flow Restriction training, patient education and dietary modifications will be given for pre diabetes
88950792|NCT05411640|Active Comparator|Aerobics without Blood flow restriction|This group will perform Aerobic exercises without Blood Flow Restriction training, patient education and dietary modifications will be given for pre diabetes.
88950793|NCT05411640|Other|Education and Dietary modifications|This group will only receive education and dietary modifications for Pre-diabetes.
88950794|NCT05411601||C1|Subjects with socket-type attachment of their prostheses
88950795|NCT05411601||C2|Subjects with direct skeletal attachment
89478270|NCT02114450|Experimental|Robot-assisted Rehabilitation|Participants will receive Robot-assisted training with the H2 lower limb powered exoskeleton. They will perform walking and other lower limb exercises (as applicable) while wearing the H2 lower limb powered exoskeleton. Training will involve 3 sessions per week for 4 weeks, each lasting about 1.5 hours.
89478271|NCT02114450|Active Comparator|Supervised motor practice|Participants in this group will perform walking and other lower limb exercises (as applicable) under the supervision of a research physical therapist. Training will be for 3 sessions per week for 4 weeks, each session lasting about 1.5 hours.
89478272|NCT05243576||incomplete SCI|"1) Be motor incomplete; 2) Be AIS classified as C or D; 3) have a neurological level of injury from C6 - T6; 4) Have LEMS score > 10; 5) Have Modified Ashworth Scale ≤ 3 for spasticity.~Additional - 1) Be able to tolerate electrical stimulation; 2) Be able and willing to comply with study requirements, procedures and verbal instructions; 3) Have been diagnosed with a spinal cord injury by a physician."
88950796|NCT05411510|Experimental|Densah bur|According to the protocol for densah burs. The direction was reversed and the cutting speed was raised to 1200 rpm after the initial perforation close to the sinus floor. After that, two densifying burs were used in succession to elevate the sinus membrane by 2 mm and prepare the implant hole to the desired implant size.
88950797|NCT05411510|Active Comparator|Ostetome|Flat end osteotome of appropriate size will be introduced through the osteotomy to infracture the floor of the sinus by light malleting.
88950798|NCT05411328|Experimental|traditional physical therapy group|received traditional physical therapy protocol
88950799|NCT05411328|Experimental|virtual reality group|received the same traditional physical therapy in addition to virtual reality games
88950800|NCT05411276||Group 1|HER2 rare mutation advanced/metastatic non-small lung cancer (IV)
88950801|NCT05411224|Experimental|Morton Nuroma|In patients with Morton Neuroma, stride length, stance phase percentage, swing phase percentage, cadence and speed parameters, and fore, mid and hind foot pressure distribution will be recorded with the Zebris FDM-THM-S treadmill system in the analysis of barefoot walking after the physical examination evaluation of the cases.
89478273|NCT05243576||complete SCI|"1) Be chronic (≥ 1-year post injury); 2) AIS classified as A or B motor-complete;~Additional - 1) Be able to tolerate electrical stimulation; 2) Be able and willing to comply with study requirements, procedures and verbal instructions; 3) Have been diagnosed with a spinal cord injury by a physician."
89478274|NCT05243576||Able-bodied|1) Be able and willing to tolerate electrical stimulation; 2) Be able and willing to comply with study requirements, procedures and verbal instructions.
89478275|NCT05243498||no acute GVH, no chronic GVH|
89478276|NCT05243498||acute GVH without chronic GVH|
89478277|NCT05243498||chronic GVH without acute GVH|
89478278|NCT05243498||acute and chronic GVH|
89478279|NCT05073770|Experimental|N64|"Based on the penis girth measurements, eligible participants will be assigned to two groups:~Group 1: The couples who will test the 64 mm plain condom (n=25).~The test condom has the following specifications throughout the study:~The plain 64mm condom (i.e., N64): Length 223 ±5mm, width 64±1mm, thickness (single wall) 0.070± 0.005mm, and beading thickness 1.25±0.05mm."
89478280|NCT05073770|Experimental|N69|"Based on the penis girth measurements, eligible participants will be assigned to two groups:~Group 2: The couples who will test the 69 mm plain condom (n=25).~The test condom has the following specifications throughout the study:~The plain 69mm condom (i.e., N69): Length 223 ±5mm, Width 69±1mm, Thickness (single wall) 0.070± 0.005mm, Beading thickness 1.25±0.05mm."
89478281|NCT04034420|Experimental|Online training|To receive self-paced online training and learning materials
89478282|NCT01361594|Active Comparator|Intensive insulin treatment|Intensive insulin treatment (BG target: 100-140 mg/dL)
89478283|NCT01361594|Active Comparator|Conventional insulin treatment|Conventional insulin treatment (BG target: 141-180 mg/dl)
89478284|NCT04435028||control group|55 patients received their standard therapy (anthracycline-containing chemotherapy without ketotifen)
89478285|NCT04435028||ketotifen group|Ketotifen Group: 56 patients received anthracycline-containing chemotherapy plus ketotifen as a cardioprotective agent. Ketotifen will be given orally as one tablet (1 mg/tablet) 3 times daily, before and during the chemotherapeutic cycle for 6 cycles of treatment
89478286|NCT02642432|Experimental|ABT-493/ABT-530|ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 12 weeks.
88950802|NCT05407259|No Intervention|Control condition|During the control condition, participants will be asked to read a book related to exercise for approximately 40 minutes.
89478287|NCT05072834||Cohort A|children with chronic malnutrition who do not respond to adequate supplemental feeding will undergo Upper Gastrointestinal Endoscopy
89478288|NCT05072834||Cohort B|Children 6 months to 24 months old who are undergoing Upper Gastrointestinal endoscopy for any appropriate indication
89478289|NCT04434950|Experimental|Intervention|Intervention group
89478290|NCT03782168||Placental Abruption|Mother-infant dyads with suspected or confirmed diagnosis of placental abruption
89478291|NCT03782168||Phenotypically-matched controlled group|Healthy mother-infant dyads admitted for delivery
89478292|NCT05060198|Active Comparator|Artemether-lumefantrine (AL)|Participants will be randomized to receive a standard weight-based regimen of artemether-lumefantrine (Coartem®, Novartis Pharmaceuticals Corporation, Missouri, USA). Children in the AL arm received two daily doses (morning and evening) orally, over 3 days (6 doses total at 0, 8, 24, 36, 48, and 60 hours post initial dose, administered with food or milk at the clinic and at home). To promote and evaluate adherence, study staff called parents in the evening to remind them to give the AL dose to the child and to bring the blister pack to the clinic the next day for confirmation.
89478293|NCT05060198|Active Comparator|Dihydroartemisinin-piperaquine (DP)|Participants will be randomized to receive a standard weight-based regimen of dihydroartemisinin-piperaquine (DuoCotexin®; Holley-Cotec Pharmaceuticals, Beijing, China). DP was administered once a day for three days (at 0, 24, and 48 hours, orally).
89478294|NCT05060120||confirmed ovarian torsion|immediately before laparoscopy and 1 day post- operation and four weeks after laparoscopy a panel of serum biomarkers will be tested
89478295|NCT05060120||confirmed non ovarian torsion|immediately before laparoscopy
89478296|NCT05060120||control group|match control Compare healthy controls with patients with or without ovarian torsion as confirmed by laparoscopy
89478297|NCT05059574|Experimental|Experimental group|Mothers in this group will begin their baby's first breastfeeding by crawling to the breast.
89478298|NCT05059574|No Intervention|Control group|Mothers in this group will begin their baby's first breastfeeding with biological breastfeeding.
89478299|NCT02640482|Experimental|Arm A DB Active Drug|ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 12 weeks (double-blind [DB] treatment period)
89478300|NCT02640482|Experimental|Arm B DB Placebo|Placebo for ABT-493/ABT-530 QD for 12 weeks (DB treatment period)
89202912|NCT03187977|Active Comparator|Cognitive Training|Participants will participate in computer-based cognitive training at the end of therapy.
89478301|NCT02640482|Experimental|Arm B OL Active Drug|ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 12 weeks (open-label [OL] treatment period)
89478302|NCT04478084|Experimental|Group 1: pediatric participants; VRVg-2|VRVg-2 8 injections: 2 at Day 0, 2 at Day 3, 2 at Day 7, and 2 at Day 28
89478303|NCT04478084|Active Comparator|Group 2: pediatric participants; Verorab|Verorab 8 injections: 2 at Day 0, 2 at Day 3, 2 at Day 7, and 2 at Day 28
89478304|NCT04478084|Experimental|Group 3: adult participants; VRVG-2 + ERIG|"VRVg-2 8 injections: 2 at Day 0, 2 at Day 3 and 2 at Day 7~+ ERIG at D0"
89478305|NCT04478084|Active Comparator|Group 4: adult participants; Verorab + ERIG|"Verorab 8 injections: 2 at Day 0, 2 at Day 3 and 2 at Day 7~+ ERIG at D0"
89478306|NCT04478084|Experimental|Group 5: adult participants; VRVG-2 + HRIG|"VRVg-2 8 injections: 2 at Day 0, 2 at Day 3, 2 at Day 7, and 2 at Day 28~+ HRIG at D0"
89478307|NCT04478084|Active Comparator|Group 6: adult participants; Verorab + HRIG|"Verorab 8 injections: 2 at Day 0, 2 at Day 3, 2 at Day 7, and 2 at Day 28~+ HRIG at D0"
89478308|NCT05072756||Gynecologists|Brazilian gynecologists who agreed to participate and answered the questionnaire
89478309|NCT05072522|Experimental|SKLB1028|"Dose-escalation stage: Patients will receive SKLB1028 capsules orally once daily (QD) in continuous 28-day cycles, in three doses beginning at 200 mg and rising to 400 mg.~Cohort-expansion stage: Patients will receive SKLB1028 capsules orally once daily (QD) in continuous 28-day cycles at selected dose as per the results of dose-escalation stage."
89478310|NCT03098810|Placebo Comparator|Normal children|Placebo
89478311|NCT03098810|Experimental|Malnourished children|Oral zinc sulphate syrup
89478312|NCT03098732|Experimental|Magnetically Enhanced Diffusion (MED)|The Experimental Treatment will receive the complete MED System Procedure consisting of MED MicroBeads and the MED Workstation magnet procedure for 60 minutes in addition to IV tissue plasminogen activator (tPA or Alteplase).
89478313|NCT03098732|Sham Comparator|MED Workstation Magnet Sham Control|The MED Workstation Magnet Sham Comparator will not receive MED MicroBeads while the MED Workstation Magnet will be activated as a Sham control for 60 minutes in addition to IV tissue plasminogen activator (tPA or Alteplase).
89478314|NCT03702842|Experimental|Immediate effects|All participants will complete 2 sessions of walking with tsDCS separated by at least 72 hours. The only difference between sessions will be the dosage of stimulation (higher or lower dosage tsDCS using the Soterix Medical tsDCS stimulator). During each session, participants will be asked to walk for up to 30 minutes on a treadmill while the stimulation is delivered. Assessments will be completed before and after the bout of treadmill walking.
89202913|NCT03187977|No Intervention|Standard-of-Care|At the end of therapy, participants will participate in the current standard-of-care which does not include computer-based cognitive training.
89202914|NCT03986359|Experimental|1|30 subjects receive ESWT (LM-IASO, Litemed Co., Taiwan) for 6 courses in 3 weeks (0.05mJ/mm2, 3000 pulses). Thereafter, the two groups are cross over.
89478315|NCT03702842|Experimental|Interventional effects: Higher dosage|After completing the 2 sessions of the first part of the study, the participants will be randomized to two groups for the second part of the study. Those in the higher dosage group will receive 16 sessions of locomotor training with tsDCS stimulation applied at the higher dosage for up to 30 minutes using the Soterix Medical tsDCS stimulator. The training sessions will be scheduled 4 days per week for 4 weeks. All training will be overseen by a physical therapist with experience in SCI walking rehabilitation and will involve the use of an overhead support harness.
89478316|NCT03702842|Active Comparator|Interventional effects: Lower dosage|After completing the 2 sessions of the first part of the study, the participants will be randomized to two groups for the second part of the study. Those in the lower dosage group will receive 16 sessions of locomotor training with tsDCS stimulation applied at the lower dosage for up to 30 minutes using the Soterix Medical tsDCS stimulator. The training sessions will be scheduled 4 days per week for 4 weeks. All training will be overseen by a physical therapist with experience in SCI walking rehabilitation and will involve the use of an overhead support harness.
89478317|NCT02719743|Active Comparator|H5N1 Formulation 1 Group|Subjects received 2 primary doses (adjuvanted) at Days 0 and 21 of H5N1 vaccine Formulation 1 and a booster dose (unadjuvanted) at Day 385 of H5N1 vaccine (GSK1557484A). All doses were administered intramuscularly (IM) in anterolateral thigh.
89478318|NCT02719743|Experimental|H5N1 Formulation 2 Group|Subjects received 2 primary doses (adjuvanted) at Days 0 and 21 of H5N1 vaccine Formulation 2 and a booster dose (unadjuvanted) at Day 385 of H5N1 vaccine (GSK1557484A). All doses were administered IM in anterolateral thigh.
89478319|NCT02719743|Experimental|H5N1 Formulation 3 Group|Subjects received 2 primary doses (adjuvanted) at Days 0 and 21 of H5N1 vaccine Formulation 3 and a booster dose (unadjuvanted) at Day 385 of H5N1 vaccine (GSK1557484A). All doses were administered IM in anterolateral thigh.
89478320|NCT02719743|Experimental|H5N1 Formulation 4 Group|Subjects received 2 primary doses (adjuvanted) at Days 0 and 21 of H5N1 vaccine Formulation 4 and a booster dose (unadjuvanted) at Day 385 of H5N1 vaccine (GSK1557484A). All doses were administered IM in anterolateral thigh.
89478321|NCT02719743|Experimental|H5N1 Formulation 5 Group|Subjects received 2 primary doses (adjuvanted) at Days 0 and 21 of H5N1 vaccine Formulation 5 and a booster dose (unadjuvanted) at Day 385 of H5N1 vaccine (GSK1557484A). All doses were administered IM in anterolateral thigh.
89478322|NCT02464761|Experimental|Dose escalating PDT|
89478323|NCT04790019|Experimental|Low energy availability|Intervention involves three of dietary energy restriction providing 15 kilo-calories per kilogram of fat-free mass per day.
89478324|NCT04790019|Experimental|Low energy availability and high impact jumping|Intervention involves three days of dietary energy restriction providing 15 kilo-calories per kilogram of fat-free mass per day and brief high impact jumping exercise performed daily in the morning and in the evening.
89478325|NCT04490187|Experimental|Active tDCS stimulation|tDCS will be applied over the left motor cortex at 1 mA for 30 min. The current will be ramped up to 1 mA over 45-60 s, held for 30 min, and ramped down to 0 mA over 45-60 s.
89478326|NCT04490187|Sham Comparator|Sham tDCS stimulation|tDCS will be ramped up and held for only 60 s before it is slowly ramped down. This procedure, called the Fade-in-Short Stimulation-Fade out, has shown its reliability as an effective sham technique through making the same tolerability and transient scalp sensation as active stimulation in both adults (Ambrus 2012) and children (Ciechanski 2017).
89478327|NCT02466711|Active Comparator|Relamorelin|
89478328|NCT02466711|Placebo Comparator|Placebo|
89478329|NCT02462889|Experimental|Intravitreal aflibercept injection|Subjects will be randomized to receive intravitreal aflibercept injection every three months for 24 months.
88950803|NCT05407259|Experimental|Low-intensity barbell resistance exercise|Exercise: Barbell squat, barbell press, and barbell deadlift Number of sets: 3 Number of repetitions: 5 Intensity: 65% 1RM Training method: Circuit training (Squat set 1 ➔ Press set 1 ➔ Deadlift set 1 ➔ Squat set 2 ➔ Press set 2 ➔ Deadlift set 2 ➔ Squat set 3 ➔ Press set 3 ➔ Deadlift set 3) Rest interval between exercises and sets: ~3 minutes (Warm-up: 1 set of 5 repetitions for each exercise at 50% 1RM)
89202915|NCT03986359|Sham Comparator|2|30 subjects receive Sham therapy for 3 weeks (the machine turning on but the energy is zero). Thereafter, the two groups are cross over.
89478330|NCT02462889|Placebo Comparator|Placebo|Subjects will be randomized to receive sham injection every three months for 24 months.
89478331|NCT04489407|Experimental|rPPG Vital Sign Monitor Readings|Oxygen saturation, heart rate and respiratory rate obtained with the rPPG app.
89478332|NCT04489407|Other|Conventional Vital Sign Monitor Readings|Oxygen saturation, heart rate and respiratory rate obtained with conventional vital sign monitors and manual respiratory rate counts.
89478333|NCT02462733|Active Comparator|Tools of the Mind (TOM)|These 10 classrooms will be exposed to the TOM program.
89478334|NCT02462733|Active Comparator|Playing to Learn (PTL)|These 10 classrooms will be exposed to the PTL program.
89478335|NCT04783311|Experimental|Phase 1 - EuCorVac-19 Low dose group|Healthy adults received two intramuscular doses (0.5mL per dose) with 3-week interval
89478336|NCT04783311|Experimental|Phase 1 - EuCorVac-19 High dose group|Healthy adults received two intramuscular doses (0.5mL per dose) with 3-week interval
89478337|NCT04783311|Experimental|Phase 2 - EuCorVac-19 Low dose group|Healthy adults received two intramuscular doses (0.5mL per dose) with 3-week interval
88950804|NCT05407259|Experimental|Moderate-intensity barbell resistance exercise|Exercise: Barbell squat, barbell press, and barbell deadlift Number of sets: 3 Number of repetitions: 5 Intensity: 72% 1RM Training method: Circuit training (Squat set 1 ➔ Press set 1 ➔ Deadlift set 1 ➔ Squat set 2 ➔ Press set 2 ➔ Deadlift set 2 ➔ Squat set 3 ➔ Press set 3 ➔ Deadlift set 3) Rest interval between exercises and sets: ~3 minutes (Warm-up: 1 set of 5 repetitions for each exercise at 50% 1RM)
89478338|NCT04783311|Experimental|Phase 2 - EuCorVac-19 High dose group|Healthy adults received two intramuscular doses (0.5mL per dose) with 3-week interval
89478339|NCT04783311|Active Comparator|Phase 2 - Placebo comparator group|Healthy adults received two intramuscular doses (0.5mL per dose) with 3-week interval
89478340|NCT04768725|Active Comparator|Dietary intervention|Participants will consume a self-selected diet with 25-75% of estimated baseline energy requirements for 2 days/week (fast day) along with ad libitum for 5 days/week (feed day).
89478341|NCT04768725|Active Comparator|Physical-cognitive intervention|Participants will perform home-based physical-cognitive training for 60 minutes per session, 3 session a week.
89478342|NCT04768725|Experimental|Physical-cognitive with dietary intervention|Participants will receive both dietary intervention and physical-cognitive training same as those in the dietary and physical-cognitive intervention groups.
89478343|NCT04768725|No Intervention|Control|Participants in the control group will be encouraged to continue their activities and calorie intakes as they usually would.
89478344|NCT02462655|Experimental|Pre-lipid apheresis|Blood samples will be taken just before the start of the lipid apheresis treatment.
89478345|NCT02462655|Experimental|Post-lipid apheresis|Blood samples will be taken following the lipid apheresis treatment.
89478346|NCT02462577|Active Comparator|local instillation of morphine 5 mg|5 ml plain bupivacaine 0.5% and 5 mg morphine .Study drugs will be diluted by saline 0.9% to 20 ml volume and irrigated onto the surgical field before skin closure and suction drain will be closed for 30 min after skin closure.
89478347|NCT02462577|Active Comparator|local instillation of morphine 10 mg|5 ml plain bupivacaine 0.5% and 10 mg morphine .Study drugs will be diluted by saline 0.9% to 20 ml volume and irrigated onto the surgical field before skin closure and suction drain will be closed for 30 min after skin closure.
89478348|NCT02462577|Active Comparator|local instillation of morphine 15 mg|5 ml plain bupivacaine 0.5% and 15 mg morphine .Study drugs will be diluted by saline 0.9% to 20 ml volume and irrigated onto the surgical field before skin closure and suction drain will be closed for 30 min after skin closure.
89478349|NCT02462577|Placebo Comparator|local instillation of local anesthetics|5 ml plain bupivacaine 0.5% .Study drugs will be diluted by saline 0.9% to 20 ml volume and irrigated onto the surgical field before skin closure and suction drain will be closed for 30 min after skin closure.
89478350|NCT02462499|Experimental|Treatment|Treatment: Eplerenone (Inspra) All patients will receive 25mg eplerenone once a day for a week, followed by 50mg once a day, for a total of 4-12 weeks.
89478351|NCT02464839||Hallux valgus patients|All of participants will perform a potassium hydroxide (KOH) examination and fungal culture to prove a fungal nail and feet fungal infection
89478352|NCT02462343|Other|2 minute walk test|
88950805|NCT05407259|Experimental|High-intensity barbell resistance exercise|Exercise: Barbell squat, barbell press, and barbell deadlift Number of sets: 3 Number of repetitions: 5 Intensity: 78% 1RM Training method: Circuit training (Squat set 1 ➔ Press set 1 ➔ Deadlift set 1 ➔ Squat set 2 ➔ Press set 2 ➔ Deadlift set 2 ➔ Squat set 3 ➔ Press set 3 ➔ Deadlift set 3) Rest interval between exercises and sets: ~3 minutes (Warm-up: 1 set of 5 repetitions for each exercise at 50% 1RM)
89478353|NCT02462343|Other|6 minute walk test|
89478354|NCT02464683|Placebo Comparator|Placebo|The patient will take a single tablet of placebo daily for 60 days. Each patient will go to the hospital in order to take the blood sample.
89478355|NCT02464683|Experimental|VitaminD|The patient will take a single tablet of Vitamin D (200 International Units) daily for 60 days. Each patient will go to the hospital in order to take the blood sample.
89478356|NCT02464605|Experimental|SEL-037 (pegsiticase)|Pegylated uricase
89478357|NCT02641730|Experimental|Group 1|Participants will receive guselkumab 200 milligram (mg) at Week 0, 4, 12 and every 8 weeks thereafter through Week 60, and two syringes of placebo at Week 16 to maintain the blind.
89478358|NCT02641730|Experimental|Group 2|Participants will receive a syringe of guselkumab 100 mg and a syringe of placebo for guselkumab at Week 0, 4, 12 and every 8 weeks thereafter through Week 60, two syringes of placebo at Week 16 to maintain the blind.
89478359|NCT02641730|Experimental|Group 3|Participants will receive two syringes of placebo at Week 0, 4 and 12. At Week 16, placebo participants will be randomized in a 1:1 ratio to guselkumab mg arm (Group 3a) or 100 mg arm (Group 3b). Group 3a participants will receive guselkumab 200 mg at Week 16, 20 and every 8 weeks thereafter through Week 60. Group 3b participants will receive guselkumab 100 mg and a syringe of placebo at Week 16, 20 and every 8 weeks thereafter through Week 60.
89478360|NCT03100136|Experimental|[11C]PF-06809247|A dose intravenous injection of [11C]PF-06809247 followed by PET scanning.
88950806|NCT05406843||Preoperative cognitive status of participants undergoing open heart surgery|"Detection of postoperative cognitive impairment is difficult and it starts with testing in the preoperative period.~In this study, it was aimed to determine postoperative cognitive impairment by comparing cognitive functions by using Minimental status test in the preoperative period in participants scheduled for open heart surgery for one year. It was planned to compare the obtained data in terms of participants undergoing valve and coronary bypass surgery, age, gender, diabetes, kidney disease, chronic obstructive pulmonary disease (COPD), surgical characteristics, bypass time, and crossclamping time."
89478361|NCT02061631|Experimental|Docetaxel, Cisplatin|"Induction:One-hour intravenous infusion of docetaxel at 75 mg/m2 followed by a 30 minute intravenous infusion of cisplatin at 75 mg/m2. All patients to be pre-medicated with oral dexamethasone at 8 mg twice daily for 3 days, commencing one day before docetaxel infusion. All patients will be premedicated with intravenous dexamethasone 20 mg to be administered before cisplatin infusion. Docetaxel and cisplatin treatments to be repeated every 21 days for three cycles.~Chemoradiotherapy (CRT): Cisplatin to be administered by 30 minutes intravenous infusion at a dose of 30 mg/m2 weekly starting concomitantly with conventional radiotherapy for a period of 6 weeks. Intravenous cisplatin to be continued for four weeks.~Radiotherapy: Gross disease dose will be 60 Gy/30 fractions and sub clinical dose 45-50 Gy/30 fractions."
89478362|NCT03100292|Experimental|bariatric surgery|"This trial is a single-arm study and the enrolled patients are going to undergo sleeve gastrectomy (SG) or Roux-en-Y gastric bypass (RYGB).~If the patient has Barrett's esophagus on the preoperative endoscopy, SG is not permitted. Inflammatory bowel disease and Helicobacter pylori infection on a rapid urease test are contraindications of RYGB."
89478363|NCT02061709|Experimental|Ragweed-SPIRE 1|Ragweed SPIRE regimen 1 given 2 weeks apart
89478364|NCT02061709|Experimental|Ragweed-SPIRE 2|Ragweed-SPIRE regimen 2 given 2 weeks apart
89478365|NCT02061709|Experimental|Ragweed-SPIRE 3|Ragweed-SPIRE regimen 3 given 2 weeks apart
88950807|NCT05406843||Postoperative cognitive status of participants undergoing open heart surgery|Detection of postoperative cognitive impairment is difficult and it starts with testing in the preoperative period. In this study, it was aimed to determine the postoperative cognitive impairment by comparing it with the cognitive functions in the preoperative period using the Minimental status test in the postoperative period in participants scheduled for open heart surgery for a year. It was planned to compare the obtained data in terms of participants undergoing valve and coronary bypass surgery, age, gender, diabetes, kidney disease, chronic obstructive pulmonary disease (COPD), surgical characteristics, bypass time, and crossclamping time.
88950808|NCT05405699|No Intervention|Control|
88950809|NCT05405699|Experimental|Intervention|
88950810|NCT05398939||Acne cohort|Adults with acne vulgaris who are going to receive the third dose of COVID-19 vaccine.
88950811|NCT05397366|Experimental|Task Specific Training|Using Task Specific Training
88950812|NCT05397366|Experimental|Neurodevelopmental Training|Using Neurodevelopmental Training
88950813|NCT05396781|Experimental|Augmented Reality High Resolution Microendoscope (HRME) imaging|All study subjects will receive White Light Imaging and Lugol's Chromoendoscopy (LCE) which is the current standard of care procedure. The investigators will record any LCE abnormal areas and record the clinician's plan of action. Following LCE, all subjects will receive Mobile, Augmented Reality High Resolution Microendoscope (marHRME) imaging with the study contrast agent (Proflavine) of any LCE-identified abnormal areas as well as LCE normal areas. The investigators will record the subjective clinician read and confidence level in the investigators' diagnosis, and plan of action. Then the investigators will image the same abnormal and normal areas with the marHRME and record the software read, clinician confidence level, and plan of action. Finally, the imaged areas will be biopsied or resected and evaluated by a pathologist. All subjects will receive both standard of care and marHRME imaging.
88950814|NCT05386420|Experimental|Experimental group|Conventional treatment combined with Hymecromone tablets, 0.4g , tid ac, 7 days.
88950815|NCT05386420|Placebo Comparator|Control group|Conventional treatment combined with placebo.
88950816|NCT05335512||Patients underwent TURBT|Patients undergoing complete TURBT for evaluation of a newly diagnosed bladder lesion in TMH and found to have NMIBC (either low risk or high risk)
88950817|NCT05303038|Experimental|cryoablation combined with tirelizumab + Bevacizumab|
88956511|NCT05030272|Experimental|"Quit on the Go (formerly Learn to Quit)"|A smartphone app developed by the research team designed for people with serious mental illness, that provides Acceptance and Commitment Therapy skills to address (a) smoking cessation and (b) mental health symptoms. This app intervention is combined with an 8-week course of nicotine replacement therapy (NRT) patches and a 5-10 week course of NRT gum (or Nicotine Lozenges if unable to use gum). Participants also receive technical smartphone coaching for the first 4 weeks of the study.
89478366|NCT02061709|Placebo Comparator|Placebo|Placebo given 2 weeks apart
89478367|NCT03100214|Active Comparator|Control|Patients randomized to the control group will continue to receive the physiotherapeutic follow-up performed by the physiotherapist of the Program for Adults with CF during the hospitalization period. Supervision includes respiratory physiotherapy involving inhalation therapy and techniques for removal of secretions.
89478368|NCT03100214|Experimental|Exercise|Patients randomized to the intervention group, in addition to routine physical therapy follow-up, will receive an early rehabilitation program, which will begin within the first 48 hours after admission. The patient will perform physical training (aerobic and anaerobic) 5 times a week during the hospitalization period, with sessions about an hour. The professional who supervises the training will be blinded to the results of the measurements.
89478369|NCT03098342|Experimental|MB-PDT for Onychomycosis|
89478370|NCT03098342|Active Comparator|Amorolfine for Onychomycosis|
89478371|NCT02797951|Experimental|Galcanezumab|Participants received 300 milligram (mg) Galcanezumab administered subcutaneously (SC) up to once a month.
89478372|NCT05070962||Clinical population|having experienced repeated and prolonged traumatic exposure
89478373|NCT05070962||General population|Student volunteers from the University of Lille
89478374|NCT05059496|Experimental|Hamstring stretching with Pressure Biofeedback Unit|Hot pack, Hamstring stretching with Biofeedback unit, TENS
89478375|NCT05059496|Active Comparator|Hamstring stretching with out Pressure Biofeedback Unit|Hot pack, Hamstring stretching without Biofeedback unit, TENS
89478376|NCT05059730|Active Comparator|Men|Men will belong to one arm
89202916|NCT02554110|Experimental|Stimulator Active Device|Intervention: This intervention arm will use a Stimulator Active Device peripheral nerve stimulation. Participants will receive a cutaneous stimuli in response to oxygen desaturations in postoperative surgical patients.
89202917|NCT02554110|Sham Comparator|Stimulator Sham Device|No intervention: This arm will use a Stimulator Sham Device peripheral nerve stimulation.Participants will not receive a cutaneous stimuli in response to oxygen desaturations in postoperative surgical patients.
89202918|NCT00933309|Experimental|Group 1|Exemestane alone
89202919|NCT00933309|Experimental|Group 2|Exemestane plus Avandamet
89202920|NCT00352885|Experimental|Escitalopram|Participants will receive escitalopram and IL-2 treatment
89202921|NCT00352885|Placebo Comparator|Placebo|Participants will receive placebo and IL-2 treatment
89202922|NCT00933387|Experimental|open label|an open-labelled, single-arm
89202923|NCT00660660|Experimental|Nexium 20mg|Nexium 20 mg administered once daily as 22.3 mg of esomeprazole magnesium hydrate
89202924|NCT00660660|Placebo Comparator|Placebo|
89202925|NCT02560766|Experimental|HORIZANT 300 mg|HORIZANT 300 mg once daily
89202926|NCT02560766|Experimental|HORIZANT 600 mg|HORIZANT 600 mg once daily
89202927|NCT02560766|Placebo Comparator|Placebo|Placebo once daily
89202928|NCT00933465|Experimental|tablets first followed by syrup|first 6 weeks of study using tablets, then followed by assessment, and then the next 6 weeks using syrup, followed by assessment
89202929|NCT00933465|Experimental|Syrup first followed by tablets|first 6 weeks of study using syrup, then followed by assessment, and then the next 6 weeks using tablets, followed by assessment
89202930|NCT00757874|Experimental|Tacrolimus cream|
89202931|NCT00757874|Active Comparator|Clobetasol cream|
89202932|NCT00933621|Experimental|Autologous Bone Marrow infusion|Percutaneous intracoronary autologous bone marrow infusion
89202933|NCT04050254|Experimental|Real tDCS + exercise|Transcranial direct current stimulation combined with therapeutic exercise
89202934|NCT04050254|Sham Comparator|Sham tDCS + exercise|Sham transcranial direct current stimulation combined with therapeutic exercise
89202935|NCT04050254|No Intervention|Control|No treatment.
89202936|NCT00933699|Experimental|Dermacyd PH_DESILSTY_FL (Lactic Acid)|Treatment duration: 21 consecutive days
89202937|NCT00344305|Experimental|Cohort 1: Participants Between 6 to < 24 Months Age|Participants received a single, intranasal dose of 0.2 millilitre (mL) (approximately 0.1 mL in each nostril) FluMist trivalent influenza virus vaccine live on Day 0 of the study. Each dose of FluMist vaccine contained 10^7 fluorescent focus units (FFU) of three influenza virus strains namely, A/New Caledonia/20/99 (H1N1), A/Wyoming/03/2003 (H3N2) (A/Fujian/411/2002-like) and B/Jilin/20/2003 (B/Shanghai/361/2002-like).
89202938|NCT00344305|Experimental|Cohort 2: Participants Between 24 to < 60 Months Age|Participants received a single, intranasal dose of 0.2 mL (approximately 0.1 mL in each nostril) FluMist trivalent influenza virus vaccine live on Day 0 of the study. Each dose of FluMist vaccine contained 10^7 FFU of three influenza virus strains namely, A/New Caledonia/20/99 (H1N1), A/Wyoming/03/2003 (H3N2) (A/Fujian/411/2002-like) and B/Jilin/20/2003 (B/Shanghai/361/2002-like).
89202939|NCT00933777|Experimental|Therapy with everolimus and sorafenib|Dose finding: Treatment with defined dose of sorafenib of 2x400 mg with increasing dose of everolimus (2.5 mg, 5 mg, 7.5 mg, 10 mg) Extension: Treatment with defined dose of sorafenib of 2x400 mg with everolimus 7.5 mg
89202940|NCT01564030|Other|Empty stomach|Patients have fasted for 8 hours.
89478377|NCT05059730|Active Comparator|Women (follicular phase)|Women will be allocated in this group during the follicular phase of their menstrual cycle.
89478378|NCT05059730|Active Comparator|women (luteal phase)|Women will be allocated in this group during the luteal phase of their menstrual cycle.
89478379|NCT02063347||Coronary artery disease|With coronary artery disease
89478380|NCT02063347||No coronary artery disease|Without coronary artery disease
89478381|NCT02061865|Experimental|Cohorts 1 - 4|Participants in cohort 1 will receive REGN2176-3 dosing regimen 1. Participants in cohort 2 will receive REGN2176-3 dosing regimen 2. Participants in cohort 3 will receive REGN2176-3 dosing regimen 3. Participants in cohort 4 will receive REGN2176-3 dosing regimen 4.
89478382|NCT05059418|Active Comparator|Clonazepam|Topical treatment of oral mucosa with a 3-min lozenge tablet with clonazepam (0.5 mg), three times a day.
89202941|NCT01564030|Other|Fluid|Patients have fasted for 8 hours, followed by the consumption of 250mL of apple juice.
89202942|NCT01564030|Other|Solid|Patients have fasted for 8 hours, followed by the consumption of their breakfast.
89202943|NCT00801450|Experimental|Intravitreal (IVI)|
89202944|NCT00801450|Experimental|SubTenon´s (STI)|
89202945|NCT05434988||Laparoscopic appendectomy|The laparoscopic appendectomy group is the group that includes patients who underwent appendectomy using the laparoscopic approach
89202946|NCT05434988||Open appendectomy|The open appendectomy group is the group that includes patients who underwent appendectomy using laparoscopic approach
89202947|NCT00989326|Active Comparator|CONTROL group|The patients receive standard of care for 18 months. The CONTROL group patients will be equipped with Home Monitoring. However, the Home Monitoring data will not be used for patient surveillance; i. e. the patient will be followed in the conventional manner.
89202948|NCT00989326|Experimental|ACTIVE group|The patients are followed by Home monitoring only. Every patient must be seen by his physician 18 months after enrolment for regular follow-up. Within this period, the additional Pace Maker follow-up or therapeutic intervention will be primarily triggered on cardio-reports reception or patient/physician call
89478383|NCT05059418|Active Comparator|Capsaicin|Topical treatment of oral mucosa with capsaicin rinsing solution (XXXX IE) for three min three times a day.
89478384|NCT05059418|Placebo Comparator|Placebo|Topical treatment of oral mucosa with rinsing solution without capsaicin for three min three times a day.
89478385|NCT02062333|Active Comparator|dexmedetomidine|0,4-0,8 µg./kg./h dexmedetomidine
89478386|NCT02062333|Active Comparator|esmolol|100- 300 µg./kg./min esmolol
89478387|NCT02062411|Experimental|CBT with booster sessions|Participants will receive 12 cognitive-behavioral therapy sessions weekly and 3 booster sessions monthly following our protocol.
89478388|NCT02062411|Active Comparator|CBT only|Participants will only receive 12 cognitive-behavioral therapy sessions weekly.
89478389|NCT02062411|No Intervention|waiting|Participations will not be treated with CBT and keep waiting for 12 weeks for comparison.
89478390|NCT02063425|Active Comparator|Fluoxetine|
89478391|NCT02063425|Placebo Comparator|Placebo|
89478392|NCT05071118|Active Comparator|pregabalin group|Two hours before surgery, the pregabalin patients (group P) received capsules containing 150mg of pregabalin in the ward then transferred to OR to receive spinal anesthesia before surgery.
89020517|NCT04012138|Experimental|Insuline + Dextrose + Salbutamol|"Patients in the experimental group will receive either:~10 mg of salbutamol nebulized in 30 minutes (with oxygen 8 liters per minute or with air); OR~10 units of regular insulin (rapid-acting, insuline asparte, intravenous injection) as an intravenous bolus with 500 ml of 10% dextrose in water administered over a 30-minute period plus 10 mg of salbutamol nebulized in 30 minutes (with oxygen 8 liters per minute or with air). The nurse will start by giving the 10 units of insulin and the dextrose, and then, immediately, she will start the nebulization of salbutamol."
89478393|NCT05071118|Active Comparator|placebo group|The patients received placebo capsules in the ward Then transferred to OR to receive spinal anesthesia before surgery .
89478394|NCT00701805|Experimental|Paricalcitol 2 µg ± 1 µg|Study drug was administered 3 times per week (no more frequently than every other day) intravenously immediately before the completion of hemodialysis. The initial dosage was administered for 2 weeks, with subsequent dosage adjustment based on the subject's iPTH, calcium (adjusted), and phosphorus levels every 2 weeks. Total duration of treatment was 48 weeks in this study, combined with 12 weeks in the previous study, M10-309 (NCT00667576), for a total of 52 weeks of treatment.
89478395|NCT00701805|Experimental|Paricalcitol 2 µg ± 2 µg|Study drug was administered 3 times per week (no more frequently than every other day) intravenously immediately before the completion of hemodialysis. The initial dosage was administered for 2 weeks, with subsequent dosage adjustment based on the subject's iPTH, calcium (adjusted), and phosphorus levels every 2 weeks. Total duration of treatment was 48 weeks in this study, combined with 12 weeks in the previous study, M10-309 (NCT00667576), for a total of 52 weeks of treatment.
89478396|NCT00701805|Experimental|Paricalcitol 4 µg ± 1 µg|Study drug was administered 3 times per week (no more frequently than every other day) intravenously immediately before the completion of hemodialysis. The initial dosage was administered for 2 weeks, with subsequent dosage adjustment based on the subject's iPTH, calcium (adjusted), and phosphorus levels every 2 weeks. Total duration of treatment was 48 weeks in this study, combined with 12 weeks in the previous study, M10-309 (NCT00667576), for a total of 52 weeks of treatment.
89478397|NCT00701805|Experimental|Paricalcitol 4 µg ± 2 µg|Study drug was administered 3 times per week (no more frequently than every other day) intravenously immediately before the completion of hemodialysis. The initial dosage was administered for 2 weeks, with subsequent dosage adjustment based on the subject's iPTH, calcium (adjusted), and phosphorus levels every 2 weeks. Total duration of treatment was 48 weeks in this study, combined with 12 weeks in the previous study, M10-309 (NCT00667576), for a total of 52 weeks of treatment.
89478398|NCT02063503|Experimental|Motor control therapy|physiotherapy
89478399|NCT02063503|Experimental|Isometric training therapy|physiotherapy
89478400|NCT02063503|Experimental|Combination therapy|physiotherapy
89478401|NCT02062567||Acute Achilles tendon rupture|
89478402|NCT05059106|Experimental|Group 1|Half dose of ChAdOx1 nCoV-19 (AZD1222) ) in a 2-dose schedule with an interval of 8 weeks.
89478403|NCT05059106|Active Comparator|Group 2|Standad dose of ChAdOx1 nCoV-19 (AZD1222) in a 2-dose schedule with an interval of 8 weeks.
89478404|NCT05070416|Experimental|Crowns self-adhesively cemented|Group 1 receives crowns with an occlusal thickness of 1.5 mm and luted with a self-adhesive, self-curing resin cement (SpeedCem Plus, Ivoclar Vivadent AG).
89478405|NCT05070416|Experimental|Crowns adhesively luted|Group 2 receives crowns with an occlusal thickness of 1.2 mm delivered with a dual-curing resin cement (Variolink Esthetic (DC),Ivoclar Vivadent AG).
89478406|NCT04412408|Experimental|Sintilimab|"Sintilimab is administered every 21 days until the disease progresses or treatment is terminated due to unacceptable toxicity. For patients with clinical and radiologic benefits, treatment can last up to 2 years.~Dose: 2 mg / kg intravenously for 60 min (± 10 min window)"
89478407|NCT05070182||Patients with brain damage|"ICU patients with brain damage (due to cardiac arrest, intracranial hemorrhage or traumatic brain injury). and GCS upon entry <=8.~All patients will be examined with a transcranial doppler (TCD) and a metabolic computer (for the measurements of REE) After the final diagnosis the patients' characteristics will be compared according to if they were brain dead or not"
89478408|NCT02731508|Experimental|True stimulation|True repetitive bihemispheric transcranial direct current stimulation, anodal at ipsilesional M1 while cathodal at contralesional M1, daily 20 minutes for 20 sessions
89478409|NCT02731508|Sham Comparator|Sham stimulation|Repetitive bihemispheric transcranial direct current stimulation, as the experimental stimulation condition but only for 120 seconds
89478410|NCT02705924|Experimental|Psychoeducational intervention|group participating to the first psychoeducational intervention: it consists in a week-end session in a SPA center including several conferences about HBOC familial risk, cancer prevention, prophylactic possibilities (surgery), recommendations about nutrition and physical activity a risk modulators, assisted medical procreation and embryo selection, social support...). Besides conferences, Moreno role games and group sharing are organized under the supervision of a psychotherapist.
89478411|NCT02705924|Other|Waiting list|delayed intervention: group participating to the second psychoeducational intervention (6 months later). Intervention is same as in the intervention arm but it is delayed. Because questionnaires are completed before this second intervention in both arms and allocation to arms are randomized, it represents an adequate control group.
89478412|NCT03270189|Experimental|orthoptic treatment|Patients with cervical dystonia occuring only during handwriting.
89478413|NCT03270189|No Intervention|Controls|Patients without cervical dystonia.
89478414|NCT05069870|Experimental|The DDI of SKLB1028 and Itraconazole|Eligible subjects received a single dose of SKLB1028 100 mg on Day 1, then took Itraconazole 200 mg twice-daily on Day 8 and 200 mg once-daily on Day 9 through Day 18, and took a single dose of SKLB1028 100 mg on Day 11.
89478415|NCT05069870|Experimental|The DDI of SKLB1028 and Gemfibrozil|Eligible subjects received a single dose of SKLB1028 100 mg on Day 1, then took Gemfibrozil 600 mg twice-daily on Day 8 through Day 19, and took a single dose of SKLB1028 100 mg on Day 12.
89478416|NCT05069870|Experimental|The DDI of SKLB1028 and Rifampicin|Eligible subjects received a single dose of SKLB1028 150 mg on Day 1, then took Rifampicin 600 mg once-daily on Day 8 through Day22, and took a single dose of SKLB1028 150 mg on Day 15.
89478417|NCT02715765|Sham Comparator|Sham|The sham procedure involves only 40 sec direct current stimulation at 2mA and then drops to 0mA with 15msec pulses every 550msec.
89478418|NCT02715765|Experimental|Active tDCS|Current (2mA) is initiated in a ramp-like fashion over 10s from 0mA to 2mA using (SPONSTIM-25 25cm2 electrodes). The current is held constant for 20 min. Then the current is decreased in a ramp-like fashion over 10s from 2mA to 0mA.
89478419|NCT02715765|Experimental|Active tRNS|Current (2mA) is initiated in a ramp-like fashion over 10s from 0mA to 2mA using (SPONSTIM-25 25cm2 electrodes). Once at 2mA, an alternating current of 2mA with a 0mA offset is applied at random frequencies over a range of 0.1 to 100 Hz. This is performed for 20 minutes. Then the current is decreased in a ramp-like fashion over 10s from 2mA to 0mA.
89478420|NCT05315037|Other|Resistance Training|Bench press, Deadlift, Seated overhead press machine
89478421|NCT04626843|Experimental|Intermittent fasting|
89478422|NCT04605939|Experimental|68Ga-DOTA-FAPI PET/MR|Investigators select subjects from patients with suspected or diagnosed or treated lievr fibrosis for 68Ga-DOTA-FAPI PET/MR imaging.
89478423|NCT04619121|Experimental|Treatment with real NIR-tPBM on top of standing pharmacotherapy|NIR t-PBM to the dorsolateral prefrontal cortex, bilaterally and simultaneously, from 20 minutes to 80 minutes a day, for 8 consecutive weeks.
89478424|NCT04619121|Sham Comparator|Sham device on top of standing pharmacotherapy|Sham device with neglectable energy to the dorsolateral prefrontal cortex, bilaterally and simultaneously, from 20 minutes to 80 minutes a day, for 8 consecutive weeks.
89478425|NCT05291715|Experimental|group 1, test group|This group will receive ozone therapy after harvesting of the free gingival graft from the palatal donor site.
89478426|NCT05291715|No Intervention|group 2, control group|Following harvesting of the free gingival graft, the palatal donor site ozone application will be simulated without starting of the ozone generator and the covered ( protected) by a periodontal pack.
89478427|NCT05275491||Mild to moderate COVID 19 patients|"According to COVID 19 treatment guidelines of National Institutes of Health (NIH):~Mild illness that show symptoms like fever, cough, nausea, vomiting, sore throat, loss of taste & smell but don't show dyspnea or abnormal chest imaging.~Moderate illness that show clinical or radiological lower respiratory disease with SpO2 > 94% on room air."
89478428|NCT05275491||Severe to critical COVID 19 patients|"According to COVID 19 treatment guidelines of National Institutes of Health (NIH):~Severe illness that show SpO2 < 94% on room air, (PaO2/FiO2) <300 mm Hg & lung infiltration > 50% with respiratory rate > 30 breath/min.~Critical illness that show respiratory failure, septic shock or multiorgan failure."
89478429|NCT05275491||Normal male subjects (Control)|
89478430|NCT02976753||Elocta|Elocta will be prescribed and administered for prophylactic treatment of patients with haemophilia A according to usual clinical practice
89020518|NCT04011410|Experimental|Hydroxychloroquine|"Hydroxychloroquine (HCQ)~DOSAGE FORM: 200 mg tablet, oral route~DOSAGE: 200 mg BID by mouth, for a total daily dose of 400 mg~FREQUENCY: HCQ is taken twice daily (morning and night) with food.~DURACTION OF HCQ: 90-days"
89478431|NCT02976753||Conventional factor VIII product|Conventional factor VIII products will be prescribed and administered for prophylactic treatment of patients with haemophilia A according to usual clinical practice
89478432|NCT04603053|Experimental|CBot-A Group|Participants randomly assigned to this arm will receive access to CBot-A app.
89478433|NCT04603053|No Intervention|Wait List Group|Participants randomly assigned to this arm will be offered the intervention after the completion of the trial.
89478434|NCT04490421|Experimental|Experimental|Experimental:Camrelizumab combined with Apatinib, Etoposide and Cisplatin
89478435|NCT02462031|Experimental|KD101|
89478436|NCT02462031|Placebo Comparator|KD101 placebo|
89478437|NCT04542291|Experimental|Dapagliflozin|"Dapagliflozin is an oral drug which will be administered on an outpatient basis. Dosing will start at 5 mg daily and will increase to 10 mg daily after 2 weeks (after consulation with a study endrocrinologist) if the patient is tolerating the 5 mg dose. Dapagliflozin will be given for a total of 8 weeks (2 weeks at 5 mg and 6 weeks at 10 mg)~Treatment with dapagliflozin will be initiated on Cycle 1 Day 1 of standard of care chemotherapy.~Participants will use the BIOSENSE meter once daily"
89478438|NCT02462109|Experimental|Lorazepam|"Children with confirmed Nodding syndrome that had 2 or more of the symptoms on the 10-item Kampala Catatonia Panel (KCP) scale were recruited to undergo the catatonia test using oral Lorazepam EG® (n.v. Eurogenerics s.a. Brussels, Belgium) using the 1 mg formulation tablets. The amount of Lorazepam (LZP) drug given orally was based on the weight of the child. The lower dose (0.5 mg) was used as starting dose for patients with <30 kg body weight, while the higher dose (1 mg) as the starting dose for patients with >30 kg body weight.~A positive response to a catatonia test consisted of a reduction in catatonic symptoms, 60 minutes later, by at least 50% assessed by the KCP (using all 10 items). If no response to the initial dose of LZP, was observed after one hour, a second administration of the same medication at double the dose was given. Catatonia was again assessed at 60 minutes thereafter. If no response was observed, the test was considered negative."
89478439|NCT02464527|Experimental|Stimulus-stimulus pairing (SSP)|Minimally verbal children between 2.0 and 3.9 years with autism spectrum disorder (ASD) and who do not emit vocalizations, will be randomly assigned to the treatment group and will begin the stimulus-stimulus pairing (SSP) procedure. Subjects will be recorded by a vocal recorder at home by the parent/guardian at home or in the community setting.
89478440|NCT02464527|Active Comparator|Waitlist Control (Delayed Treatment)|Minimally verbal children between 2.0 and 3.9 years with autism spectrum disorder (ASD) and who do not emit vocalizations will be randomly assigned to the Waitlist Control group. During the waitlist control subject's assigned session block of six weeks, s/he will not receive any treatment. The subjects will receive the stimulus-stimulus pairing procedure (delayed procedure) after the completion of the assigned 6-week block as a waitlist control participant. Subjects will be recorded by a vocal recorder at home by the parent/guardian at home or in the community setting.
89478441|NCT02466165|Experimental|MS patients intervention group|the feasibilty and influence of high intense interval exercise on the cardiometabolic risk state in MS patients will be investigated in a pilot trial.
89478442|NCT02466165|No Intervention|healthy controls|To identify whether MS patients have a higher cardiometabolic risk state than healthy controls, this project discovers the prevalence of cardiometabolic risk factors (dyslipidemia, hypertension, body fat, glucose tolerance/IR, inflammation and heart function), in MS and referent subjects.
89478443|NCT02466165|No Intervention|larger group of MS patients|To identify whether MS patients have a higher cardiometabolic risk state than healthy controls, this project discovers the prevalence of cardiometabolic risk factors (dyslipidemia, hypertension, body fat, glucose tolerance/IR, inflammation and heart function), in MS and referent subjects.
89478444|NCT02795767|Experimental|Cohort A: 1.5 mg/kg Emicizumab QW|Participants will receive emicizumab at a loading dose of 3 milligrams per kilogram (mg/kg) QW SC for the first 4 weeks followed by a maintenance dose of 1.5 mg/kg QW SC for a minimum of 52 weeks, or until unacceptable toxicity, discontinuation from the study due to any cause, or other criteria set forth in the protocol, whichever occurs first.
89478445|NCT02795767|Experimental|Cohort B: 3 mg/kg Emicizumab Q2W|Participants will receive emicizumab at a loading dose of 3 mg/kg QW SC for the first 4 weeks followed by a maintenance dose of 3 mg/kg every 2 weeks (Q2W) SC for a minimum of 52 weeks, or until unacceptable toxicity, discontinuation from the study due to any cause, or other criteria set forth in the protocol, whichever occurs first.
89478446|NCT02795767|Experimental|Cohort C: 6 mg/kg Emicizumab Q4W|Participants will receive emicizumab at a loading dose of 3 mg/kg QW SC for the first 4 weeks followed by a maintenance dose of 6 mg/kg every 4 weeks (Q4W) SC for a minimum of 52 weeks, or until unacceptable toxicity, discontinuation from the study due to any cause, or other criteria set forth in the protocol, whichever occurs first.
89478447|NCT02597439|Active Comparator|Omega-3 fatty acids|Subjects will be treated daily with 1.2 gram omega-3 polyunsaturated fatty acids (720 mg eicosapentaenoic acid (EPA) and 480 mg Docosahexaenoic acid(DHA)) for six months.
89478448|NCT02597439|Placebo Comparator|Placebo|Subjects will be treated daily with placebo for six months. Placebo capsules will contain a 1:1 combination of coconut oil and medium chain triglycerides because these do not contain polyunsaturated fatty acids and have no impact on omega-3 fatty acid metabolism. Placebo capsules also contain the same amount of vitamin E as the omega-3 capsules and 1% fish oil to mimic flavour and taste.
89478449|NCT02576925||Eligible patients|Adults having had a transient diplopia during the last 8 days.
89478450|NCT02062723||pts addicted to heroin in MMT|patients addicted to heroin who have undertaken methadone maintenance treatment
89537543|NCT04618809|Experimental|Provider Didactic Intervention|"Phase 1 - Providers complete a needs assessment questionnaire, which evaluates the approach to older mGC patients at each site.~Phase 2 - Providers participate in an hour-long didactic session and begin enrolling eligible metastatic gastric cancer (mGC) patients. Enrolled mGC patients complete a comprehensive geriatric assessment (CGA). Providers complete the treatment plan and review of geriatric assessment questionnaires, which also includes an evaluation of their overall view of the utility of the geriatric assessment.~Phase 3 - Follow-up chart reviews (2-3 months post intervention) are completed to assess for actual implementation of recommended interventions identified by the geriatric assessment."
89537544|NCT04601883|Experimental|Colchicine|Tablet colchicine 0.5 mg administered two times daily
89537545|NCT04601883|Placebo Comparator|Placebo|Tablet placebo administered two times daily
89020519|NCT03992469|Experimental|E-B-FAHF-2|Low dose EBFAHF-2 (29 mg/kg/d divided two times a day) for 2 weeks followed by a full dose (71mg/kg/d divided two times a day) for 6 weeks
89020520|NCT03992469|Placebo Comparator|Placebo|capsules are identical in appearance to EBFAHF-2 capsules
89478451|NCT03560401|Experimental|Brace group|After spinal surgery, patients in the brace group were instructed to wear a rigid brace (Knight-Taylor [chairback] brace) full-time for 12 weeks, except when bathing or lying in bed.
89478452|NCT03560401|No Intervention|No brace group|After spinal surgery, patients in the no brace group were instructed to wear a soft corset for 2 weeks, after which it was weaned off.
89478453|NCT04397211|Active Comparator|Angiography-derived FFR-guided PCI group|Percutaneous coronary intervention using drug-eluting stent(s) will be performed by Angiography-derived FFR-guided strategy
89478454|NCT04397211|Active Comparator|IVUS-guided PCI group|Percutaneous coronary intervention using drug-eluting stent(s) will be performed by IVUS-guided strategy
89478455|NCT03443635|Experimental|Treatment|Subjects receiving hands-on cooking and nutrition education classes
89478456|NCT03443635|No Intervention|Control|Subjects not receiving any additional nutrition education aside from that contained in their curricula (for trainees) or medical care (for patients)
89478457|NCT04490265|Experimental|Problem-Solving Treatment|Our PST is 12-weeks and teaches patients strategies to address real-life problems.20 Sessions are once a week for one hour except for the first session, which is two hours. The treatment has four main goals: 1. Safety planning; 2. Problem-orientation-addressing how patients approach problems; 3. Planful problem-solving or a logical approach to address problems; 4. Behavioral activation of daily activities. Patients are provided weekly worksheets on problem-solving and receive weekly assessment of emotional state and suicidal ideation monitoring.
89478458|NCT04490265|Placebo Comparator|Supportive Psychotherapy|"Our control will be supportive psychotherapy which will focus on discussing weekly stressors in a supportive, non-directive way. Session content is patient-driven, and sessions focus on emphasizing the patients' strengths, following patients' emotional affect, and building a therapeutic alliance. Participants will be asked to generate the topic they would like to discuss for the session and will complete a worksheet between sessions noting emotional events throughout their week (A time when I felt stressed was … ) in order to help identify experiences for discussion in session. Participants will be informed that the control condition is supportive and non-directive, and that providers will not engage in problem-solving. Providers will be taught to use reflective listening, clarification, empathy, and validation. The control consists of 12 weekly sessions delivered via telephone or video."
89478459|NCT02063581|Experimental|Sequence 1: Tablet followed by Capsule|
89478460|NCT02063581|Experimental|Sequence 2: Capsule followed by Tablet|
89478461|NCT02063815|Active Comparator|glass ionomer based fissure sealant|fissure sealant application
89478462|NCT02063815|Active Comparator|resin based fissure sealant|fissure sealant application
89478463|NCT02056899|Experimental|Gabapentin|
89478464|NCT02063893||non-vaccine|
89478465|NCT02063893||giving low vaccine|
89478466|NCT02063893||giving middle vaccine|
89020521|NCT03989999|Experimental|TCD Group|Transcranial Doppler within 8 hours of traumatic injury
89020522|NCT03989999|No Intervention|CONTROL Group|Mild TBI management with SFMU recommandations
89478467|NCT02063893||giving high vaccine|
89478468|NCT02462265|Experimental|'Oshadi D & Oshadi R; salvage therapy'|Oshadi D (180mg/tid) & Oshadi R (180mg/tid) will be administrated orally; Salvage therapy - HAM: Hi dose cytosar (5 or 6 days) and mitoxantrone (2 or 3 days) will be administrated
89478469|NCT02461953|Experimental|low flux hemodialysis|low flux hemodialysis alone, 3 times a week, 4 hours per session
89478470|NCT02461953|Experimental|high flux hemodialysis|high flux hemodialysis alone, 3 times a week, 4 hours per session
89478471|NCT02461953|Experimental|low flux hemodialysis + hemoperfusion|low flux hemodialysis 2times a week and the HD+HP once a week
89478472|NCT02461953|Experimental|high flux hemodialysis + hemoperfusion|high flux hemodialysis 2times a week and the HD+HP once a week
89478473|NCT02461797|Other|healthy controls|biopsy of nasal mucosa healthy controls
89478474|NCT02461797|Other|AR patients with use of nasal corticoid spray|biopsy of nasal mucosa allergic rhinitis to house dust mite with nasal corticosteroid spray
89478475|NCT02461797|Other|AR patients without medication|biopsy of nasal mucosa allergic rhinitis to house dust mite without any use of medication for symptom control
89478476|NCT02464215|Active Comparator|open surgery|Conventional procedure,Open surgery
89478477|NCT02464215|Experimental|laparoscopic surgery|Minimum invasive procedure，Laparoscopic surgery
89537546|NCT05223075|Experimental|articaine group|
89478478|NCT02461875|Active Comparator|Cabergoline group|Cabergoline is administered starting on the day of HCG administration.
89478479|NCT02461875|Experimental|GnRH antagonist rescue & cabergoline group|Converting a long GnRH agonist cycle to an GnRH antagonist cycle (GnRH antagonist rescue) and Cabergoline is administered starting on the day of HCG administration.
89478480|NCT02461719|Experimental|CYPORIN N EYE DROPS 0.05%(TJCS eye drop)|CYPORIN N EYE DROPS 0.05%(TJCS eye drop) 1 drop twice/day for 12 weeks to both eyes
89478481|NCT02461719|Active Comparator|Restasis eye drop|Restasis eye drop(Cyclosporine ophthalmic solution 0.05%) 1 drop twice/day for 12 weeks to both eyes
89020523|NCT03989947|Experimental|Active BMN 111|Once daily subcutaneous injections of recommended dose of BMN 111 based on weight-band dosing.
89478482|NCT04489953|Active Comparator|Clinical and Immunologic criteria|In the clinical and immunologic monitoring criteria was based on the 2010 WHO guidelines. Whereby children were monitored using clinical presentation and CD4 count to define treatment failure.
89478483|NCT04489953|Active Comparator|Clinical, Immunologic and Virologic criteria|In the Clinical, Immunologic and Virologic criteria was based on a confirmed viral load of > 1000 HIV RNA copies/ml; as well as clinical and immunologic criteria
89478484|NCT05174247|Experimental|The intervention group (FFRct group)|The people in this group receive an FFRct analysis, which will be included in the treatment plan. If the FFRct analysis shows that there are there is no significant narrowing in your case, then in principle no invasive examination (heart catheterization) performed. If the analysis indicates a significant narrowing, then an invasive cardiac catheterization will usually be required are carried out. The final treatment plan will always be reviewed by your doctor tailored to your individual situation
89478485|NCT05174247|No Intervention|Standard treatment not using result of FFRct analyses|The people in this group receive the regular treatment. This is usually an invasive cardiac catheterization. The additional FFRct analysis is also included in this group, but it is not included in the treatment plan.
89478486|NCT04345497|Experimental|Diabetes-Specific Formula|Diabetes-specific formula 1-2 servings a day and Standard of Care
89478487|NCT04345497|Other|Standard of Care|Standard of Care
89478488|NCT02464293|Experimental|mindfulness-based cognitive therapy|
89478489|NCT02796391|Experimental|Study 1: Immediate Reduction|"Participants will receive cigarettes with the lowest nicotine dose (.03 mb nicotine yield). They will receive a targeted intervention workbook (Count down: Preparing to Quit Smoking with Low-Nicotine Cigarettes) and will be provided with one-on-one counseling."
89478490|NCT02796391|Experimental|Study 1: Gradual Reduction|"Participants will receive VLNC (very low nicotine cigarettes) containing nicotine yields of .7 mg for week 1, .26 mg for week 2, .12 for week 3, and .03 for week 4.They will receive a targeted intervention workbook (Count down: Preparing to Quit Smoking with Low-Nicotine Cigarettes) and will be provided with one-on-one counseling."
89478491|NCT02796391|Experimental|Study 2: Targeted/Immediate Reduction|"Participants will receive VLNC (very low nicotine cigarettes) containing nicotine yields of .7 mg for week 1, .26 mg for week 2, .12 for week 3, and .03 for week 4.They will receive a targeted intervention workbook (Count down: Preparing to Quit Smoking with Low-Nicotine Cigarettes) and will be provided with one-on-one counseling."
89478492|NCT02796391|Experimental|Study 2: Targeted/Gradual Reduction|"Participants will receive VLNC (very low nicotine cigarettes) containing nicotine yields of .7 mg for week 1, .26 mg for week 2, .12 for week 3, and .03 for week 4. Participants will also receive targeted materials (booklet series entitled (Count down: Preparing to Quit Smoking with low-Nicotine Cigarettes) as well as one-on-one counseling."
89537547|NCT05223075|Experimental|lidocaine group|
89478493|NCT02796391|Experimental|Study 2: Generic/Immediate Reduction|"Participants will receive VLNC (very low nicotine cigarettes) with the lowest nicotine dose (.03 mb nicotine yield). Participants will also receive the generic (Clearing the Air) materials, as well as one-on-one counseling."
89478494|NCT02796391|Experimental|Study 2: Generic/Gradual Reduction|"Participants will receive VLNC (very low nicotine cigarettes) containing nicotine yields of .7 mg for week 1, .26 mg for week 2, .12 for week 3, and .03 for week 4. Participants will also receive the generic (Clearing the Air) materials, as well as one-on-one counseling."
89478495|NCT02063971|Experimental|Skin aging|Anti-age product will be applied once a day, in the evening, on half face and neck for an uninterrupted period of 12 weeks and the placebo cream in the morning with the same modalities. On the contralateral face side (right or left side according to a previous randomisation list), the volunteers will apply the placebo cream twice a day
89478496|NCT02064049|Experimental|Hepatitis C treatment|All prisoners (in participating correctional centres) with hepatitis c, as identified during the hepatitis C surveillance phase of the study will be offered treatment for hepatitis C. The treatment course is sofosbuvir/velpatasvir 400/100mg for 12 weeks (1 tablet once daily).
89478497|NCT02064127||Patients with abdominal pain|Adult patients admitted to the Emergency Department with a main complaint of abdominal pain
89478498|NCT03560089|Active Comparator|Rehabilitation with active serious game|25 patients will perform motor rehabilitation programme using the serious game
89478499|NCT03560089|Placebo Comparator|No active serious game|25 patients will not perform motor rehabilitation programme using the serious game
89478500|NCT05576233|Active Comparator|1.The culture taken after disinfection with providing/iodine|1.Blood cultures routinely performed with alcohol/povidine-iodine
89478501|NCT05576233|Active Comparator|2.The culture taken after disinfection with chlorhexidine/alcohol|2. Blood cultures routinely performed with chlorhexidine/alcohol
89478502|NCT03790579||Women with gestational diabetes|We randomly selected the 40 pregnant women diagnosed GDM by two-step procedure based on Carpenter-Coustan criteria at this hospital. The diagnosis of GDM was confirmed if at least 2 of 4 glucose levels exceed based on Carpenter-Coustan criteria: fasting ≥ 95 mg/dL (5.3 mmol/L), 1 hour ≥ 180 mg/dL ( 10.0 mmol/L), 2 hour ≥ 155 mg/dL (8.6 mmol/L), and 3 hour ≥ 140 mg/dL (7.8 mmol/L).
89478503|NCT03790579||Healthy women|We also randomly selected 40 healthy pregnant with normal serum glucose levels ≤129 mg/dL (7.2 mmol/L) after GCT.
89478504|NCT03788473||Control.|Healthy Pregnant
89478505|NCT03788473||Case.|Pregnant with Periodontal Disease
89478506|NCT02063191||Atrial Fibrillation|Patients with atrial fibrillation during the EP study
89478507|NCT02063191||Bundle Branch Block|Patient with bundle branch block during the course of the EP study
89478508|NCT02064283|Experimental|Diffusion MRI Assessment|Men with newly diagnosed metastatic disease initiating therapy with androgen deprivation, or men with hormone refractory prostate cancer initiating treatment with chemotherapy, will be assessed by diffusion MRI (Magnetic Resonance Imaging) at baseline, 2 weeks and again at 9-12 weeks.
89478509|NCT02064751|Experimental|MultiPoint Pacing|CRT with MultiPoint Pacing
89478510|NCT02064829|Active Comparator|Reference Drug - Nab-paclitaxel|260 mg/m2 administered intravenously over 30 minutes on Day 1
89478511|NCT02064829|Experimental|Test Drug - IG-001|260 mg/m2 administered intravenously over 30 minutes on Day 1
89478512|NCT02064361|Experimental|High intensity exercise|A dive to 18 meters sea water for a duration of 41 minutes preceded by high intensity cycling
89478513|NCT02064517|Placebo Comparator|Conventional technique|Apical MTA barrier
89478514|NCT02064517|Experimental|Revascularisation pulpaire|hydroxide of calcium
89478515|NCT01370317|Experimental|MK-1029|
89478516|NCT01370317|Placebo Comparator|Placebo|
89478517|NCT02064595|Other|Intramedullary nail|Fractures treated with intramedullary reamed nail
89478518|NCT02064595|Active Comparator|External fixator|Tibial fractures treated with biplanar external fixation
89478519|NCT02260219|Active Comparator|S2|Surgically Implant an Ahmed Glaucoma Drainage Device Model S2 in Neovascular Glaucoma Patients and evaluate the IOP evolution, complications and need for medication to control IOP
89478520|NCT02260219|Active Comparator|M4|Surgically Implant an Ahmed Glaucoma Drainage Device Model M4 in Neovascular Glaucoma Patients and evaluate the IOP evolution, complications and need for medication to control IOP
89478521|NCT02067871|Experimental|Electrical stimulation|"18-32 min of pulsed current.~stimulation frequency of 80Hz (hertz).~pulse duration of 200μs (microseconds).~stimulation intensity fixed near to maximal tolerated."
89478522|NCT02067871|Experimental|Laser Therapy|"λ = 810 nm (nanometers)~continuous wave~200 mW (milliwatts) output power~low-level laser therapy dose of 4-6J (Joules) per point~six points at the knee joint"
89478523|NCT02067871|Experimental|Combined Treatment|"Electrical Stimulation:~18-32 min of pulsed current,~stimulation frequency of 80Hz (hertz).~pulse duration of 200μs (microseconds).~stimulation intensity fixed near to maximal tolerated.~and~Laser Therapy:~λ = 810 nm (nanometers)~continuous wave~200 mW (milliwatts) output power~low-level laser therapy dose of 4-6J (Joules) per point.~six points at the knee joint."
89478524|NCT02065531|Experimental|Myofascial Soft Tissue Release|Protocol: Transverse Plane-Level Clavicular Release. Diaphragmatic Transverse Plane Release. Square the Lumbar Fascia Release. Gluteal Fascia Release. Hint Of Pubic Region Release. Fascia Psoas Release. Lumbo-sacral Decompression. Pelvic Floor Release.
89478525|NCT02065531|Active Comparator|Mobilization with impulse technique|Subject in lateral decubitus with extension and lower limb traction contact the couch with contralateral lower limb was performed triple flexion and left trunk rotation. This technique reduces the slack (tension joints) of the ventral pelvis, head and into the contralateral side of the sacrum support (base) with the forearm.
89478526|NCT02067949|No Intervention|broad spectrum AB +fluids|Control group :50 patients will be treated according to SURVIVING SEPSIS CAMPAIGN BUNDLES
89478527|NCT02067949|Active Comparator|simvastatin|50 patients will be treated according SSCG plus simvastatin as single oral tablet 40 mg / day begin with inclusion in the study and continue until hospital discharge .If the patient is able to swallow; the tablet will be given orally. Otherwise, it will be crushed, suspended in water and administered via any existing enteral feeding or gastric drainage tube. (White R, Bradnam V, 2013)
89478528|NCT02068105|Experimental|ALKS 5461-A|
89478529|NCT02068105|Experimental|ALKS 5461-B|
89478530|NCT02068105|Experimental|ALKS 5461 Dose 1|
89478531|NCT02068105|Experimental|ALKS 5461 Dose 2|
89478532|NCT02068105|Experimental|ALKS 5461 Dose 3|
89478533|NCT02068105|Placebo Comparator|Placebo|
89478534|NCT02068183||World Trade Center exposed group|After informed consent, anthropometric and blood pressure/brachial artery distensibility assessments; physical examination and environmental and respiratory history questionnaire completion; heart rate variability measurement; and spirometry/IOS will be performed on the World Trade Center exposed group. A research assistant well trained in pediatric phlebotomy will collect 23 mL of fasting blood. Spirometry and IOS, diet diary collection, lung volumes by plethysmography, and arterial wall stiffness.
89478535|NCT02068183||Unexposed comparison group|After informed consent, anthropometric and blood pressure/brachial artery distensibility assessments; physical examination and environmental and respiratory history questionnaire completion; heart rate variability measurement; and spirometry/IOS will be performed on the unexposed comparison group. A research assistant well trained in pediatric phlebotomy will collect 23 mL of fasting blood. Spirometry and IOS, diet diary collection, lung volumes by plethysmography, and arterial wall stiffness.
89478536|NCT02068261|Experimental|Cogmed working memory training|30-40 minutes of Cogmed computerized working memory training 3-5 days a week for 5-8 weeks. Every training session consists of a set of visual- and verbal working memory tasks that are trained on during the session.
89478537|NCT02068261|Active Comparator|Treatment as usual|Treatment as usual can consist of medication, psychotherapy, counseling, and psychological assessment. After a 8 week period participants in this arm well be offered Cogmed working memory training.
89478538|NCT02068339|Placebo Comparator|Placebo|Placebo Comparator / Tid (total 0mg)
89478539|NCT02068339|Experimental|Oltipraz 1|Total 90mg, by mouth, tid
89478540|NCT02068339|Experimental|Oltipraz 2|Total 120mg, by mouth, tid
89478541|NCT02068417|Active Comparator|Shock wave treatment|Shock waves are applied extracorporeally with 0.1 millijoule per square millimeter (mJ/mm2)
89478542|NCT02068417|Placebo Comparator|Placebo Shock wave treatment|Shock waves are prohibited to enter the body by placebo stand-off.
89478543|NCT02065843|Active Comparator|Mulungu|500 mg Mulungu Matusa® (Erytrina mulungu, 2 capsules of 250 mg) to be administered v.o., one hour before the surgical procedure.
89478544|NCT02065843|Placebo Comparator|placebo|500 mg of starch (2 capsules of 250 mg) to be administered v.o., one hour before the surgical procedure.
89478545|NCT02065843|Active Comparator|Passiflora incarnata|100 mg Passiflora incarnata (2 capsules of 50 mg) to be administered v.o., one hour before the surgical procedure.
89478546|NCT02065843|Active Comparator|midazolam|15 mg midazolam (2 capsules of 7.5 mg) to be administered v.o., one hour before the surgical procedure.
89478547|NCT02068573|Active Comparator|Ventilation|Increased ventilation in the childs bedroom to at least 2-3 air changes pr hour.
89478548|NCT02068573|Placebo Comparator|Placebo ventilation|Ventilation system that recirculates the air in the childs bedroom
89478549|NCT02068651|Experimental|Advance care planning programme|Participants in the experimental group will receive a structured advance care planning programme, namely Let Me Talk, delivered by a trained nurse facilitator. The programme will be conducted on individual basis through three one-hour home visits, once weekly. Family carers of the participants will be invited to all sessions.
89478550|NCT02068651|No Intervention|Usual care|Participants in the control group will receive three weekly home visits with basic health assessment and education provided by the trained nurse facilitator. If they request advance care planning information or assistance, an advance directive form, which is available on the Internet for public access, will be provided to them for their information.
89478551|NCT02066077|Experimental|Bilateral temporal and propofol|During the MECT treatment, electrodes are placed at bilateral temporal, with propofol 2mg/kg to Induce anesthesia.
89478552|NCT02066077|Experimental|Bilateral temporal and etomidate|During the MECT treatment, electrodes are placed at bilateral temporal, with etomidate 0.3mg/kg to Induce anesthesia.
89478553|NCT02066077|Experimental|The right temporal and propofol|During the MECT treatment, electrodes are placed at the right temporal, with propofol 2mg/kg to Induce anesthesia.
89478554|NCT02066077|Experimental|The right temporal and etomidate|During the MECT treatment, electrodes are placed at the right temporal, with etomidate 0.3mg/kg to Induce anesthesia.
89478555|NCT02066077|Experimental|Bilateral frontal and propofol|During the MECT treatment, electrodes are placed at bilateral frontal, with propofol 2mg/kg to Induce anesthesia.
89478556|NCT02066077|Experimental|Bilateral frontal and etomidate|During the MECT treatment, electrodes are placed at bilateral frontal, with etomidate 0.3mg/kg to Induce anesthesia.
89478557|NCT02066077|Active Comparator|Standard-therapy Group|During the MECT treatment, electrodes are placed at bilateral temporal, with etomidate 0.3mg/kg to Induce anesthesia.
89478558|NCT02068807|Active Comparator|Lutein drops|oral administration of 0.28 mg of lutein in two doses: within 6 hours (hrs) after birth and at 36 hrs of life
89478559|NCT02068807|Placebo Comparator|Glucose drops|oral administration of 0.28 mg of vehicle (0.5 mL of 5% glucose solution) in two doses: within 6 hours (hrs) after birth and at 36 hrs of life
89478560|NCT02066155|Experimental|Parish nurse|On-going support provided by parish nurse
89478561|NCT02066155|Experimental|Peer support|On-going support provided by a person with diabetes
89478562|NCT02066155|No Intervention|Control group|No on-going support provided
89478563|NCT01370083|Experimental|Stroke: TPPT|Adults with dysphagia post stroke (within 4-16 weeks of onset) who have radiographically confirmed difficulties with thin liquid bolus control. Individuals will complete 24 sessions of tongue-pressure-profile training over 8-12 weeks.
89478564|NCT01370083|Active Comparator|Stroke: TPSAT Control|Individuals with dysphagia (within 4-16 weeks post stroke) who demonstrate difficulties with thin liquid control on videofluoroscopy. Individuals will complete 24 sessions of tongue-pressure strength-and-accuracy training over 8-12 weeks.
89478565|NCT02068963||Study Population|
89478566|NCT03350815|Active Comparator|Responders|Patients who achieved an Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease (total score <1.3) at both Week 12 and Week 16.
89478567|NCT03350815|Active Comparator|Inadequate responders|Patients who have active disease, defined as an Ankylosing Spondylitis Disease Activity Score (ASDAS) total score of >1.3 at both Week 12 and Week 16, and who achieved a decrease (improvement) from baseline in total ASDAS score at both Week 12 and Week 16.
89478568|NCT03350815|Active Comparator|Non-responders|"Patients who exhibit no change or an increase (worsening) from baseline in total Ankylosing Spondylitis Disease Activity Score (ASDAS) score at either Week 12 or Week 16.~Non-responders were not entered Treatment Period 2. Non-responders were discontinued from the study at Week 16."
89478569|NCT02065063|Experimental|Part 1|Part 1 is a dose finding phase in which subjects will be initially administered 75 milligram (mg) of palbociclib (21 days on/7 days off) and 1.5 mg of trametinib (once daily continuous dosing) in each 28-day cycle. Dose escalations will continue based on predefined parameters until the RCR is identified. The RCR will not exceed the maximum tolerated dose (MTD).
89478570|NCT02065063|Experimental|Part 2|Once the MTD and schedule have been determined, two expansion cohorts of up to 20 subjects each will be enrolled. The cohorts will enroll subjects with BRAF-WT (wild type) cutaneous melanoma that are either NRAS-WT or NRAS-MUT (mutated). Subjects will be dosed at or below the RCR to determine the inhibition of selected tumor biomarkers at each dose level.
89478571|NCT02065063|Experimental|Part 3|Part 3 will be a randomized Phase II study in which subjects will be administered the RCR as previously identified. Part 3 will be initiated only if an RCR is identified, and sufficient anticancer activity is observed in Parts 1 and 2.
89020524|NCT03981835||Post -PCI Patients scheduled for Cardiac Surgery|Post -PCI Patients (PCI within the last 2 years) who are currently on Dual- Antiplatelet (DAPT) Medication or have a current indication for DAPT, who will be undergoing Cardiac Surgery. No intervention will be administered.
89020525|NCT03981835||Post -PCI Patients scheduled for Non- Cardiac Surgery|Post -PCI Patients (PCI within the last 2 years) who are currently on Dual- Antiplatelet (DAPT) Medication or have a current indication for DAPT, who will be undergoing Non-Cardiac Surgery. No intervention will be administered.
89478572|NCT02069197|Active Comparator|Ketogenic diet, lifestyle counseling|ketogenic diet consisted of 3:1[fat]:[protein+carbohydrate] weight ratio with 1600kcal restriction.
89478573|NCT02069197|Active Comparator|Orlistat, Lifestyle counseling|Orlistat 120 mg TID, standardized diet and lifestyle-modification counseling based on the LEARN (Life, Exercise, Attitudes, Relationships,and Nutrition) program with recommended caloric goal of 1600 kcal/day.
89478574|NCT02069197|Active Comparator|Standartized diet, Lifestyle counseling|Standardized diet and lifestyle-modification counseling based on the LEARN (Lifestyle, Exercise, Attitudes, Relationship, Nutrition) program with recommended caloric goal of 1600kcal/day.
89478575|NCT02069275|Experimental|Immediate mobilization|Immediate mobilization after coronary angiography or percutaneous coronary intervention
89478576|NCT02069275|Active Comparator|Two hours bedrest|Bedrest two hours after coronary angiography or percutaneous coronary intervention
89478577|NCT00854295|Experimental|Post-Approval Study Group (Group 2)|Subjects enrolled in a short-term study (5 years) consisted of cases eligible to receive the LPS-Flex Mobile Bearing Knee implanted by orthopedic surgeons experienced in primary total knee replacement. All Group 2 subjects, both unilateral and bilateral subjects, are in the same arm of the study. As part of the PAS study, these subjects were followed from Pre-operative to 5 years.
89478578|NCT00854295|Experimental|Investigational Device Exemption Group (Group 1)|Subjects who were implanted with either the LPS Flex Fixed Bearing Knee (control population) or the LPS Flex Mobile Bearing Knee device during the previous Investigational Device Exemption study. As part of the PAS study, these subjects were followed from 4 years to 10 years.
89478579|NCT02792959|Experimental|Functional imaging|A pilot study to evaluate the response to neoadjuvant chemotherapy for advanced ovarian cancer by multimodal functional imaging (Fusion MRI and FDG-PET-CT)
89478580|NCT02464371||ICU acquired muscle weakness (IAMW) group +|"The Medical Research Council score (MRC score) is lower than 48, defining an ICU acquired muscle weakness (IAMW).~Kinetic of microRNAs is measured"
89478581|NCT02464371||ICU acquired muscle weakness (IAMW) group -|The Medical Research Council score (MRC score) is higher than 48. Kinetic of microRNAs is measured
89478582|NCT02069431|Experimental|Intranasal Oxytocin spray|Intranasal OT (24 IUs) self-administration will take place twice a day over a 28-day period.
89478583|NCT02069431|Placebo Comparator|Intranasal Placebo spray|placebo (containing all of the inert ingredients except for the oxytocin) self-administration will take place twice a day over a 28-day period.
89478584|NCT01652872|Active Comparator|Hb-Based Titration Group|Participants received darbepoetin alfa as a subcutaneous (SC) injection once every 4 weeks (Q4W) for up to 96 weeks. The dose of darbepoetin alfa was titrated based on the Hb concentration on the date of the visit, the corresponding Hb rate of rise (ROR), and the previously assigned dose. Doses were reduced if Hb exceeded 10.5 g/dL or Hb ROR exceeded 1.0 g/dL/4W. When darbepoetin alfa therapy was withheld per the dosing algorithm, placebo was administered. The starting dose of darbepoetin alfa was 0.45 micrograms/kilogram (mcg/kg) and the protocol specified doses ranged from 10 to 300 mcg.
89478585|NCT01652872|Experimental|Fixed Dose Group|Participants received darbepoetin alfa as a SC injection Q4W at the same dose as assigned at the time of randomization for the duration of the 96 week treatment period. There was 1 exception to the fixed dose strategy: if the Hb was > 12.0 g/dL, darbepoetin alfa therapy was withheld and placebo administered. Once the Hb fell to < 10.0 g/dL, darbepoetin alfa therapy resumed at the same dose. The starting dose of darbepoetin alfa was 0.45 mcg/kg and the protocol specified doses ranged from 10 to 300 mcg.
89478586|NCT02065219|Experimental|Bupivacaine|injection, 25 mg, once, 5 min
89478587|NCT02065219|Placebo Comparator|Placebo|injection, 10 ml 0.9% sodium chloride, once, 5 min
89478588|NCT02065297||Horton's disease|
89478589|NCT02065297||Infectious disease|
89478590|NCT02065297||Neoplasia|
89478591|NCT02065297||Control|
89478592|NCT03299127|Experimental|imagery rescripting|bibliotherapy, intervention is provided by pdf-manual (either short or long version, i.e. 2 active arms, each 1/3 of sample receives either short or long version)
89478593|NCT03299127|No Intervention|wait-list control|wait-list control, participants receive intervention manual upon completion of post-assessment (1/3 of sample)
89478594|NCT03298971||Survivors of Childhood Osteosarcoma|Survivors of Childhood Osteosarcoma were invited to fill in a set of questionnaires.
89478595|NCT03298971||Healthy Subjects|Healthy Subjects were invited to fill in a set of questionnaires.
89478596|NCT02069587|Experimental|Pomegranate|The women in this group will drink pomegranate juice
89478597|NCT03560011|No Intervention|Rituximab (375 mg/m²)|Single infusion of rituximab (375 mg/m²)
89478598|NCT03560011|Experimental|Rituximab followed by 5 injections of immunoglobulin IV|Rituximab (375 mg/m²) followed by 5 injections of immunoglobulin IV once a month during 5 months (2g/kg at M1, 1.5g/kg at M2 to M5, maximal dose 100g). Treatment duration : 6 months
89478599|NCT02464137|Experimental|Radiation|Patients in each dose cohort will all be treated as a single group. The starting dose will be 8.5 Gy per fraction for 5 fractions (total dose = 42.5 Gy). Subsequent cohorts of patients will receive an additional 0.5 Gy per fraction.
89478600|NCT04251273|Experimental|This is Quitting|"Participants will be enrolled to receive messages from This is Quitting.~Users receive one age-appropriate message per day tailored to their enrollment date or quit date, which can be set and reset via text message. Those not ready to quit receive 4 weeks of messages focused on building skills and confidence. Users who set a quit date receive messages for a week preceding it and 8 weeks afterward that include encouragement and support, skill- and self-efficacy building exercises, coping strategies, and information about the risks of vaping, benefits of quitting, and cutting down to quit. Keywords COPE, STRESS, SLIP, and MORE provide on-demand support."
89478601|NCT04251273|Other|Assessment only Control|After an initial enrollment message, participants will be contacted periodically to assess e-cigarette use. At the end of the intervention period, they will receive information on how to sign up for This is Quitting if they are interested in the program
89478602|NCT02069665|Experimental|Injection, medications and application|"Intravenous injection: Xiyanping injection, produced by Jiangxi Qing Feng Pharmaceutical Co., Ltd;~Medications: according to TCM syndrome differentiations;~Wind-heat blocking lungs pattern (feng re bi fei zheng): Xiaoer Qingfei Heji (mixture), and Zhi Ke San (herbal powder to relieve cough)~Phlegm-heat blocking lungs pattern (tan re bi fei zheng): Xiaoer Qingfei Heji (mixture), and Hua Tan San (herbal powder to remove phlegm)~External application: Fuxiong San"
89478603|NCT02069665|Active Comparator|Injection and medications|"Intravenous injection: Ribavirin Injection;~Medications: symptomatic therapies~Guaifenesin Syrup, for removing phlegm, relieving gasp-cough;~Ibuprofen Suspension, and salbutamol in case of different symptoms"
89478604|NCT04938856|Experimental|Test Group|Oral administration of Lamnet (100mg) Tablet after at least 10 hours fast together with 240 mL of ambient temperature water at their scheduled dosing time-point.
89478605|NCT04938856|Active Comparator|Reference Group|Oral administration of Lamictal (100mg) Tablet after at least 10 hours fast together with 240 mL of ambient temperature water at their scheduled dosing time-point.
89478606|NCT02461641|Other|Standard of Care|Wounds will be treated with Standard of Care treatment which for the purpose of this study is defined as, extensive debridement of nonviable tissue, saline-moistened non-occlusive dressing and off-loading to decrease press on the extremity using a DARCO shoe.
89478607|NCT02461641|Experimental|NuShield|Wounds will be treated with Standard of Care treatment which for the purpose of this study is defined as, extensive debridement of nonviable tissue, saline-moistened non-occlusive dressing and off-loading to decrease press on the extremity using a DARCO shoe. In addition, wounds will be treated with a dehydrated amnion-chorion membrane, NuShield, for up to 4 weeks.
89020526|NCT03977571|Experimental|Deferred nephrectomy|Surgery after induction therapy with IO/IO or a TKI/IO-combination, followed by maintenance therapy with nivolumab or a TKI/IO-combination.
89478608|NCT02461641|Experimental|Affinity|Wounds will be treated with Standard of Care treatment which for the purpose of this study is defined as, extensive debridement of nonviable tissue, saline-moistened non-occlusive dressing and off-loading to decrease press on the extremity using a DARCO shoe. In addition, wounds will be treated with a fresh hypothermically stored amniotic membrane, Affinity, for up to 4 weeks.
89478609|NCT02069821|Experimental|Group A|single administration : amlodipine/valsartan 10/160mg, qd, 10days(oral)
89478610|NCT02069821|Experimental|Group B|single administration : atorvastatin 40mg, qd, 7days(oral)
89478611|NCT04938778|Experimental|Intervention Arm|8 week 14 hour prolonged nightly fasting intervention.
89478612|NCT03785977||Air-Q 5-9kg|Participants weighing 5-9kg may be chosen to wear the Air-Q device.
89478613|NCT03785977||Air-Q 10-14kg|Participants weighing 10-14kg may be chosen to wear the Air-Q device.
89478614|NCT03785977||Air-Q 15-20kg|Participants weighing 15-20kg may be chosen to wear the Air-Q device.
89478615|NCT03785977||ETT 5-9kg|Participants weighing 5-9kg may be chosen to wear the ETT device.
89478616|NCT03785977||ETT 10-14kg|Participants weighing 10-14kg may be chosen to wear the ETT device.
89020527|NCT03977571|Active Comparator|No surgery|Induction therapy wih IO/IO or a TKI/IO-combination, followed by maintenance therapy with nivolumab or a TKI/IO-combination.
89478617|NCT03785977||ETT 15-20kg|Participants weighing 15-20kg may be chosen to wear the ETT device.
89478618|NCT02461329|Experimental|Gelatine solution|"Gelofusine will be administrated like fluid challenge - 250ml of solution will be infused within 5 minutes in case of hypotension ( mean arterial pressure - MAP below 65 mmHg or below 70mmHg in patient with chronic hypertension disease).~The blood pressure and heart rate before and after fluid challenge will be recorded."
89478619|NCT02461329|Experimental|Balanced Crystaloid solution|"Ringerfundin will be administrated like fluid challenge - 250ml of solution will be infused within 5 minutes in case of hypotension ( mean arterial pressure - MAP below 65 mmHg or below 70mmHg in patient with chronic hypertension disease).~The blood pressure and heart rate before and after fluid challenge will be recorded."
89478620|NCT03655990||Treatment with the JUVORA™ Dental Disc|Subjects receive the device as per normal standard practice, there are no other treatment arms for this prospective study.
89478621|NCT02463825|Experimental|Group 1 Pimozide (2mg per day)|Pimozide will be initiated at 1 mg twice daily and maintained on 2mg/day for 50 days. End of study dose reduction will begin following the Final Outcome Measure Visit (Day 65). Pimozide will then be stopped.
89478622|NCT02463825|Experimental|Group 2 Pimozide (4mg per day)|Pimozide will be initiated at 1 mg twice daily then increased by 1mg twice daily every five days to 4 mg/day) for 45 days. End of study dose reduction will begin following the Final Outcome Measure Visit (Day 65). Pimozide will be titrated by reducing the dose by 1 mg twice daily every day to full discontinuation (over 2 days).
89478623|NCT02463825|Placebo Comparator|Group 3 Placebo (Lactose tablet)|Placebo tablets will be utilized and administered in an identical manner for subjects in Group 3
89478624|NCT04936828|Experimental|Intervention group|Receive iCBT based EMI with message content, delivery frequency and timing personalised to participants' preferences.
89478625|NCT04936828|No Intervention|Control group|Receive general mental health information through instant message.
89478626|NCT02069977|Experimental|Aripiprazole|"Dose level: 2, 5, 10, 15 mg/day~Starting dose: 2 mg/day~Dose increment: The dose should be gradually increased according to the investigator's judgment of subject's response.~Target dose: 5-15 mg/day~Maximum dose: 15 mg/day~Flexibly dosed (2 to 15 mg/day) aripiprazole (oral tablet or solution) is taken once in a day at the same time without regarding to meals"
89478627|NCT02066701||Endoscopy Barrett's|Patients undergoing clinically indicated upper endoscopy will be invited to participate. Patients who are known to have Barrett's Esophagus as well as patient who do not will be approached for enrollment
89478628|NCT02066701||Endoscopy control|Patients undergoing clinically indicated upper endoscopy will be invited to participate. Patients who are known to have Barrett's Esophagus as well as patient who do not will be approached for enrollment
89478629|NCT04490031|No Intervention|Midazolam group|Standard sedation for ERCP in UKMMC
89478630|NCT04490031|Experimental|Ketamine group|
89478631|NCT02066935||kidney transplant patient|Kidney transplanted patients for at least one year
89478632|NCT05108961|Experimental|Acupuncture arm|One session of acupuncture with precise acupuncture points
89478633|NCT05108961|Sham Comparator|Sham acupuncture arm|One session of sham acupunture (needles inserted 1 mm, outside the acupuncture points)
89478634|NCT05108961|Placebo Comparator|Control arm|One session where no needles are inserted, the subject lies down under the same conditions as group 1 and 2
89478635|NCT02443402|Experimental|Sitagliptin|Subjects undergoing cardiac surgery with no history of diabetes and with normal blood glucose (BG) will be randomized to take sitagliptin. Subjects with stress hyperglycemia (defined as a BG >180 mg/dL) in the intensive care unit (ICU) will continue to receive sitagliptin and will be started on continuous intravenous insulin (Regular Human Insulin) adjusted to achieve and maintain a BG target between 110 - 180 mg/dL following standard hospital protocol. Additionally, once moved to the regular floors and out of ICU, the subjects can receive insulin glargine, insulin lispro, and/or insulin aspart depending on the blood glucose level.
89478636|NCT02443402|Placebo Comparator|Placebo|Subjects undergoing cardiac surgery with no history of diabetes and with normal blood glucose (BG) will be randomized to take a placebo. Subjects with stress hyperglycemia (defined as a BG >180 mg/dL) in the intensive care unit (ICU) will continue to receive a placebo and will be started on continuous intravenous insulin (Regular Human Insulin) adjusted to achieve and maintain a BG target between 110 - 180 mg/dL following standard hospital protocol. Additionally, once moved to the regular floors and out of ICU, the subjects can receive insulin glargine, insulin lispro, and/or insulin aspart depending on the blood glucose level.
89478637|NCT02067013|Active Comparator|Ranibizumab|Subjects undergoing surgery for neovascular glaucoma, diabetic retinopathy, or tractional Retinal Detachment due to AMD will receive one intravitreal injection of ranibizumab within 2 weeks of their surgery. Vitreous and aqueous humor samples will be collected during the surgery. Serum samples may be collected before, during, or after surgery.
89478638|NCT02067013|Placebo Comparator|Control|Subjects undergoing surgery for ERM or macular hole will NOT receive an injection of ranibizumab, but will have vitreous, and aqueous humor samples collected during surgery (no serum collection).
89478639|NCT02461407|Experimental|Anlotinib|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
89478640|NCT02461407|Placebo Comparator|Placebo|Placebo QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
89478641|NCT02067091|Active Comparator|BVS|Implantation of bioresorbable vascular scaffold in coronary artery by direct stenting after thrombus aspiration by percutaneous coronary intervention
89478642|NCT02067091|Active Comparator|DES|Implantation of drug eluting stent in coronary artery by direct stenting after thrombus aspiration by percutaneous coronary intervention
89478643|NCT03298581|Experimental|Halobetasol propionate spray 0.05%|Patients will instructed o apply halobetasol spray twice daily for 14 days and not to rub over the affected area after application of spray.
89478644|NCT01370005|Experimental|BI 10773 low dose|BI 10773 low dose once daily
89478645|NCT01370005|Experimental|BI 10773 high dose|BI 10773 high dose once daily
89478646|NCT01370005|Placebo Comparator|Placebo|Placebo tablets matching BI 10773
89478647|NCT02070055||No treatment|No treatment
89478648|NCT02070133|Experimental|Simvastatin|Patients with COPD will receive simvastatin 40 mg once a day for 12 weeks
89478649|NCT02070133|Placebo Comparator|Placebo|Patients with COPD will receive placebo once a day during 12 weeks
89478650|NCT02067169||CMV infection|allograft recipient with active CMV infection
89478651|NCT02070211|Experimental|omega-3 PUFAs in add on to standard care|omega-3 PUFA supplementation as an adjunct to non-neuroleptic, standard therapy in individuals with 22q11DS and UHR criteria for psychosis
89478652|NCT02070211|Placebo Comparator|Placebo in add on to standard care|Placebo made by paraffin oil (not absorbed by the gastrointestinal tract) as an adjunct to non-neuroleptic, standard therapy in individuals with 22q11DS and UHR criteria for psychosis
89478653|NCT02067247|Experimental|SOS forearm test|BeamMed Speed-of-Sound bone strength test at forearm
89478654|NCT02070289|Experimental|Group 1: Cohort 1|
89478655|NCT02070289|Experimental|Group 1: Cohort 2|
89478656|NCT02070289|Experimental|Group 1: Cohort 3|
89478657|NCT02070289|Experimental|Group 2: Cohort 4|
89478658|NCT02070289|Experimental|Group 1 or 2: Cohort 5|
89478659|NCT02070289|Experimental|Group 1 or 2: Cohort 6|
89478660|NCT02067325|Experimental|Thai massage|The participants will receive thirty minutes session of Thai massage onto the trapezius muscle for 1 sessions
89478661|NCT02067325|Sham Comparator|Sham Microwave diathermy|The participants will receive thirty minutes session of Sham Microwave diathermy onto the trapezius muscle for 1 sessions
89478662|NCT02070367|Experimental|Somatosensory rehabilitation|Weekly sessions with a certified (RSDC) somatosensory therapist using distal vibro-tactile counter-stimulation to anatomically related territories of the area of allodynia. Participants will also be provided with a structured home exercise program.
89202949|NCT00933855||communication training workshop|"The patient intervention is a 1 hour communication workshop entitled: Getting the Most out of your Doctor's Visit. The workshops will be offered to both patients and family members, but data will be collected only for patients. The workshops will be held on location at Queens Cancer Center."
89202950|NCT02554578|Experimental|Pharmaceutical care programme supported by mHealth|
89478663|NCT02070367|Active Comparator|Usual treatment|Treatment as usual for condition Physiotherapy sessions
89478664|NCT02071927|Experimental|CB-839|CB-839 administered as oral capsules two (BID) or three times daily (TID) in 21-day cycles until disease progression or unacceptable toxicity
89478665|NCT02071927|Experimental|CB-Aza|CB-839 administered as oral capsules twice daily (BID) in combination with azacitidine in 28-day cycles until disease progression or unacceptable toxicity
89478666|NCT02070445||Patients undergoing CABG|Patients will have no ventilation during CABG. There will be non-invasive assessments of the lung using ultrasound at different times during the perioperative period.The first assessment will be conducted before anesthesia induction (i.e. patients will be awake). A second assessment will be conducted after anesthesiology induction, but before the beginning of surgery. A third assessment will be conducted at the end of the surgery in the operating room. And two subsequent assessments will be conducted in ICU before and after extubation.
89478667|NCT02070523|Experimental|PLD-contained VDCLD regimen|PLD 36 mg/m2 ivdrip over 60 minutes( d1、15),VCR 1.4mg/m iv(d1，8，15，22), CTX 800 mg/m2 ivdrip( d1), L-asp 6000u/m2 ivdrip(d19～28),Dex10mg ivdrip (d1～28).
89478668|NCT02070523|Active Comparator|DNR-contained VDCLD regimen|DNR 45 mg/m2 ivdrip over 60 minutes(d1～3),VCR 1.4mg/m2 iv(d1，d8，d15，d22), CTX 800 mg/m2 ivdrip(d1), L-asp 6000u/m2 ivdrip(d19～28),Dex10mg ivdrip(d1～28).
89478669|NCT02072005||Regular cigarette smokers|
89478670|NCT02072083|Active Comparator|dexmedetomidine|intranasal 1mcg/kg
89478671|NCT02072083|Active Comparator|ketamine|intranasal 7,5 mg/kg ketamine and 0,1 mg/kg midazolam
89478672|NCT02442778|Placebo Comparator|Placebo|Participants were administered AVP-786 matching placebo capsules, orally, twice daily (BID) for up to 12 weeks.
89478673|NCT02442778|Experimental|AVP-786-28|Participants were administered AVP-786-18 capsule, orally, once daily (QD) along with AVP-786 matching placebo capsule, orally, QD during Week 1 followed by AVP-786-18 capsules, orally, BID during Weeks 2, 3 and AVP-786-28 capsules, orally, BID during Weeks 4 to 12.
89478674|NCT02442778|Experimental|AVP-786-42.63|Participants were administered AVP-786-28 capsules, orally, QD along with AVP-786 matching placebo capsule, orally, QD during Week 1 followed by AVP-786-28 capsules, orally, BID during Weeks 2, 3, and AVP-786-42.63 capsules, orally, BID during Weeks 4 to 12.
89478675|NCT02067403|Experimental|Eadi optimized pressure-support|
89478676|NCT02070679|Placebo Comparator|Placebo|
89202951|NCT02554578|No Intervention|Routine healthcare by the transplant team|
89202952|NCT03988777||Prospective Magseed|This cohort includes patients with an impalpable breast lesion that are scheduled for breast conserving surgery with Magseed localisation after September 2018. Their data will be prospectively collected and analysed.
89478677|NCT02070679|Active Comparator|Vit-E|600 IU on 12 hours before angiography and 400 IU on 2 hours before angiography
89478678|NCT02067481|Experimental|Single-arm weight loss intervention|This single-arm pre-post study, that involved one-hourly weekly diet sessions delivered by a dietician and 75-minute bi-weekly Physical Activity (AP) sessions of moderate-to-high intensity led by PA monitors, was offered to overweight and obese BC survivors shortly after treatment.
89537548|NCT04433247|Experimental|Peer Led Group Intervention|In the virtual peer-led group Intervention, participants voluntarily engage in verbal, written, and behavioral exercises in which they critique and discuss the costs of pursuing the thin-ideal ideal. The intervention is 4 sessions long (1-hr each) and is administered by trained peer facilitators who use an intervention script. Participants will be asked to complete weekly home exercises throughout the course of the intervention.
88950818|NCT05290818|Active Comparator|Manual Total Knee Arthroplasty|"This group will receive a conventional manual Triathlon (Stryker) TKA with a cruciate retaining polyethylene insert. The surgeon will then make bone cuts using a manual jig and a hand held saw to prepare the bone surfaces for the implant. A measured resection technique will be employed with a three degree tibial slope. The surgeon will use a conventional jig alignment technique for intramedullary referencing for the femur and extra medullary referencing for the tibia. Once the implant is in position the knee is then balanced by the feel though a range of movement and soft tissue releases will be performed as required to balance the knee in flexion and extension."
89478679|NCT02067559|Experimental|ICU Diaries|A bound empty journal will be stored at the patient's bedside near the nurse charting area. All family members and ICU staff are invited to write in the ICU diary at any time. Instructions will be provided to the patient's family at the time of randomization and will be available at the bedside for reference. Staff instructions will be posted at charting area for staff. During the patient's stay in ICU, the diary will never leave the unit. Under no circumstances will any part of an ICU diary be duplicated. Research staff will take a photograph of the patient after consent is obtained and the photograph will be mounted on the first page of the diary. Photographs will be taken with a Polaroid camera; therefore there will be no other record of the photograph.
89478680|NCT02067559|Experimental|Psychoeducation|The research nurse will provide a psychoeducational brochure to study participants at ICU discharge (if cognitive capacity is established) or 30 days after ICU discharge. If participants are not well enough 30 days post-discharge, they will be assessed every two weeks by research staff until the brochure is given to them. The brochure will describe procedures in the ICU (sedation, ventilation), and the delirium, hallucinations, and trauma that may result; as well as symptoms of PTSD post-ICU. It will provide instructions for follow-up, information, and emergency care. The brochure will instruct participants to contact their follow-up healthcare provider if they have any questions. The document will also be mailed to the participant's follow-up physician.
88950819|NCT05290818|Experimental|Robotic Assisted Unicompartmental Knee Arthroplasty|This group will receive the cemented Restoris MCK (Mako, Stryker) with a highly crossed linked (X3) polyethylene insert through a less invasive to the knee joint. Instead of using a manual jig and a hand held burr will be used to prepare the bone surfaces for the implant, the MAKO robotic arm will be used by the surgeon to cut the bone at the required alignment. The information from the CT scan will be used to create a 3D model of the patient's bony anatomy and will used to plan the positioning of the implant. Once the trackers are in place registration of the knee joint surface is performed. The specified bone cuts are then performed using the robotic arm, aiming to gap balance the knee through a full range of movement.
89478681|NCT02067559|Experimental|ICU Diary plus Psychoeducation|Participants will receive both ICU diary and psychoeducation interventions, with both documents provided at ICU-discharge, or 30 days post-discharge as above.
89478682|NCT02067559|No Intervention|Treatment as Usual|No additional intervention to usual ICU care will be given.
89478683|NCT02067637||Exposed|Individuals with one of the following cancer diagnoses: breast, leukemia, lymphoma, and/or any gynecologic cancer.
89478684|NCT02067637||Unexposed|Healthy controls
89478685|NCT02412436|Experimental|Arm A: Depot medroxyprogesterone acetate|At study entry/week 0, participants received depot medroxyprogesterone acetate (DMPA) 150 mg administered intramuscularly as a single dose and co-administered with rifampicin (RIF) and efavirenz (EFV).
89478686|NCT02067715|Experimental|Sealed bleaching Protocol|The 35% hydrogen peroxide gel will be mixed and applied over the buccal surfaces of teeth. The bleaching agent will remain for 45-min application without replacement of peroxide. However, a customized tray will be placed over the bleaching agent during entire permanence of peroxide (45 minutes).
89478687|NCT02067715|Active Comparator|Conventional Bleaching Protocol|The 35% hydrogen peroxide gel will be mixed and applied over the buccal surfaces of teeth. The bleaching agent will remain for 45-min application without replacement of peroxide.
89478688|NCT02072239|Experimental|Device Applied|All participants will be treated with the Angioshield
89478689|NCT02072317|Experimental|Paclitaxel plus raltitrexed|taxol 135 mg/m2, raltitrexed 3 mg/m2 ivgtt d1, every three weeks for a cycle
89478690|NCT02072317|Active Comparator|taxol|taxol 135 mg/m2, every three weeks for a cycle
89478691|NCT02072395|Experimental|Band/Plication|Treatment -- band/plication
89478692|NCT02072473||Unsuccessful right-sided AVNRT ablation|Patients with unsuccessful right-sided slow pathway ablation attempt, will be candidates for Coronary sinus / left-sided slow pathway ablation.
89478693|NCT02072551||Adult with neonatal diabetes|Adult with neonatal diabetes (before 1 year ) and need for insulin
89478694|NCT02072551||non diabetic adults with a relative with neonatal diabetes|
89478695|NCT01651000|Active Comparator|CTAP101 30 μg capsules|1 CTAP101 30 μg capsule daily at bedtime for 12 weeks, with a possible increase to 2 CTAP101 30 μg capsules daily at bedtime for study duration, if needed (26 weeks total). Subjects not requiring a dose increase after 12 weeks would receive 1 CTAP101 30 μg capsule and one sugar pill (to CTAP101 30 μg capsule) for weeks 13-26.
89478696|NCT01651000|Placebo Comparator|Sugar pill to CTAP101 30 μg capsule|1 sugar pill to CTAP101 30 μg capsule daily at bedtime for 12 weeks, with an increase to 2 sugar pills to CTAP101 30 μg capsules daily at bedtime for weeks 13-26.
89478697|NCT03780439||infection group and non-infection group|patients were divided into 2 sub-groups according to the presence of infection or not after radical gastrectomy for gastric cancer.
89478698|NCT02072629|Experimental|Training of VHVs in iCCM|In these villages VHVs will be provided with iCCM training and equipped to support iCCM in their villages
89478699|NCT02469610|Experimental|study|In the study group the surgeon will perform an intercostal Bupivacaine block of 100ml over five intercostal spaces which include the operation cuts. The block will be done in the beginning of the surgery right after the insertion of the video camera to the pleural space.
89478700|NCT02469610|Other|control|In the control group the surgeon will perform the same intercostal block at the end of the surgery just before closing the operation cuts. this approach is used today in our department.
89478701|NCT02076295||Parkinson's disease subjects|
89478702|NCT02076295||Normal control subjects|
89537549|NCT04433247|No Intervention|Wait-List Control|Participants will be placed on a wait list for four weeks, an equal span of time of participants in the peer led group intervention. At four weeks, participants will complete their post-test assessment, then receive the intervention.
89537550|NCT01671111|Experimental|SSP-004814AQ|
89478703|NCT02071069|Experimental|maintenance therapy|"Initially, all subjects received 8 cycles of Cetuximab (400mg/m2 d1,250mg/m2 every week or 500mg/m2 every 2 weeks)plus FOLFIRI (irinotecan 180 mg/m2 IV on day 1 , leucovorin 400mg/m2 on day 1 , fluorouracil 400mg/m2 on day 1 and fluorouracil 2400mg/m2 civ46h every 2 weeks) .~After 8 cycles or severe toxicity, patients received maintenance therapy comprising Cetuximab (250mg/m2 every week or 500mg/m2 every 2 weeks) and either irinotecan( 180 mg/m2 IV every 2 weeks) or fluorouracil arm( leucovorin 400mg/m2 on day 1 , fluorouracil 400mg/m2 on day 1 and fluorouracil 2400mg/m2 civ46h every 2 weeks ). In cases of unacceptable toxicity, only the related medication was stopped"
89478704|NCT02076373|Experimental|recombinant human Erythropoietin (Epo)|"Epo 2000 U in normal saline per ml/kg of body weight 5 times intravenously, total dosage 10000 U per 5ml/kg.~In detail: For loading 3 times beginning at day 5 of life (± 2 days), followed at 24 hours and 48 hours later. For maintenance 2 times, at day 10 and day 17 after the first study medication."
89478705|NCT02076373|Placebo Comparator|Control|"Placebo 1 ml normal saline/kg of body weight 5 times intravenously, total dosage 5 ml/kg.~In detail: For loading 3 times beginning at day 5 of life (± 2 days), followed at 24 hours and 48 hours later. For maintenance 2 times, at day 10 and day 17 after the first study medication."
89020528|NCT03972891|Experimental|12-weeks intervention break|The intervention break starts as soon as 70 - 80 % of the target phoneme / target consonant cluster can be pronounced correctly in spontaneous speech situations during therapy. The intervention break will last for 12 weeks.
89020529|NCT03972891|No Intervention|traditional therapy|After 70 - 80 % of the target phoneme / target consonant cluster can be pronounced correctly in spontaneous speech situations during therapy, the children will maintain their traditional therapy until more than 90% of the target phoneme / target consonant cluster can be pronounced correctly in spontaneous speech situations (max. 12 weeks).
89020530|NCT03969082|Experimental|Bibliotherapy|"Students will read to patients receiving active treatment using the read aloud method. This will be performed in a 1: 1 relationship for half an hour for 8-10 times during a period of six months."
89020531|NCT03964051|Experimental|Omalizumab 300 mg for s.c.injection|Omalizumab 300 mg steril solution in prefilled syringes are administrated every 2. week for 12 weeks
89020532|NCT03951467|Experimental|Interventional arm|
89020533|NCT03951467|No Intervention|Controlled arm|Patients within this arm will be follow as usual care of the cardiologic unit
89020534|NCT03945032|Experimental|8 parents of a childhood cancer survivor|Parent moves the cursor by analogy on their mobile phone (as a visual anagogic scale) four times per year (baseline; month 4; month 8 and month 12).
89020535|NCT03912194|Experimental|Early Withdrawal Exposure plus NAW Regulation Training|The development, application, modification, and repeated practice of individualized withdrawal regulation strategies (e.g., behavioral and cognitive strategies for allaying withdrawal symptoms) across the first 4 hours of abstinence over 4 separate sessions.
89020536|NCT03912194|Active Comparator|Early Withdrawal Exposure plus Relaxation Control Training|The development, application, modification, and repeated practice of relaxation strategies across the first 4 hours of abstinence over 4 separate sessions.
89020537|NCT03912194|Active Comparator|NAW Regulation Training Only|The development, application, modification, and repeated practice of individualized withdrawal regulation strategies (e.g., behavioral and cognitive strategies for allaying withdrawal symptoms) over 4 separate sessions involving smoking as usual.
89478706|NCT02072707|Active Comparator|Epicardial VT ablation|Patients will underwent combined epicardial and endocardial mapping and ablation
89478707|NCT02072707|Active Comparator|Endocardial VT Ablation|Patients will underwent endocardial only VT mapping and ablation
89478708|NCT02072785|Experimental|Vincristine Sulfate Liposome|"Vincristine Sulfate For Injection simulation agent 1.4mg/m2,(2mg, maximum dose), iv, d1, d8, d15, d22. Vincristine Sulfate Liposome For Injection: 1.4mg/m2, (2mg, maximum dose), iv, d1, d8, d15, d22.~Duration between these two agents should be more than 2.5h, and saline should be avoided for flushing before Vincristine Sulfate Liposome For Injection."
89020538|NCT03912194|Active Comparator|Relaxation Control Training Only|The development, application, modification, and repeated practice of relaxation strategies over 4 separate sessions involving smoking as usual.
89537551|NCT05211219|Experimental|Probiotics|The probiotics group was advised to consume a chewable tablet once a day in 14 days.
89020539|NCT03905330|Experimental|Maralixibat|Participants will receive Maralixibat oral solution (up to 600 microgram per kilogram [mcg/kg]) orally twice daily for 26 weeks.
89537552|NCT05211219|Experimental|Kefir|The kefir group was advised to consume kefir as a liquid once a day in 14 days.
89020540|NCT03905330|Placebo Comparator|Placebo|Participants will receive placebo matched to maralixibat oral solution twice daily for 26 weeks.
89478709|NCT02072785|Active Comparator|Vincristine Sulfate|"Vincristine Sulfate For Injection 1.4mg/m2,(2mg, maximum dose), iv, d1, d8, d15, d22. Vincristine Sulfate Liposome For Injection simulation agent: 1.4mg/m2,(2mg, maximum dose), iv, d1, 8, 15, 22.~Duration between these two agents should be more than 2.5h, and saline should not be used for flushing before Vincristine Sulfate Liposome For Injection simulation agent."
89478710|NCT02071147|Other|Standard clinical intervention|Patients reviewed at 6 weeks (+/- 1 week) as is our normal practice and recalled for a further evaluation if deemed appropriate. Patients will be instructed to visit their optometrist once their eye has fully recovered from the operation for provision of glasses.
89478711|NCT02071147|Other|No Clinical Follow up|No routine follow-up appointment is made. Patients will be instructed to visit their optometrist between 6-8 weeks post-operative for review of the patient's glasses.
89478712|NCT02469298|Experimental|Danirixin + Oseltamivir matching placebo|Subjects will receive 75 mg oral Danirixin twice daily with Oseltamivir matching placebo twice daily for a total of ten doses over five days
89478713|NCT02469298|Placebo Comparator|Danirixin matching placebo + Oseltamivir matching placebo|Subjects will receive Danirixin matching placebo twice daily with Oseltamivir matching placebo twice daily for a total of ten doses over five days
89478714|NCT02469298|Experimental|Danirixin + Oseltamivir|Subjects will receive 75 mg oral Danirixin twice daily with 75 mg Oseltamivir twice daily for a total of ten doses over five days
89478715|NCT02469298|Active Comparator|Danirixin matching placebo + Oseltamivir|Subjects will receive Danirixin matching placebo twice daily with 75 mg Oseltamivir twice daily for a total of ten doses over five days
89478716|NCT02076451|Experimental|2 mg/kg DS-8273a|2 mg/kg, 8 mg/kg, 16 mg/kg, and 24 mg/kg of DS-8273a; DS-8273a will be administered as an intravenous (IV) solution. Subjects will receive DS-8273a on Day 1 of a 21 day cycle (once every 3 weeks).
89478717|NCT02076451|Experimental|8 mg/kg DS-8273a|2 mg/kg, 8 mg/kg, 16 mg/kg, and 24 mg/kg of DS-8273a; DS-8273a will be administered as an intravenous (IV) solution. Subjects will receive DS-8273a on Day 1 of a 21 day cycle (once every 3 weeks).
89478718|NCT02076451|Experimental|16 mg/kg of DS-8273a|2 mg/kg, 8 mg/kg, 16 mg/kg, and 24 mg/kg of DS-8273a; DS-8273a will be administered as an intravenous (IV) solution. Subjects will receive DS-8273a on Day 1 of a 21 day cycle (once every 3 weeks).
89478719|NCT02076451|Experimental|24 mg/kg of DS-8273a|2 mg/kg, 8 mg/kg, 16 mg/kg, and 24 mg/kg of DS-8273a; DS-8273a will be administered as an intravenous (IV) solution. Subjects will receive DS-8273a on Day 1 of a 21 day cycle (once every 3 weeks).
89478720|NCT02071303|Active Comparator|Tramadol|Women will receive Tramadol 100mg 1 hour before the procedure.
89478721|NCT02071303|Active Comparator|Celecoxib|Women will receive Celecoxib 200mg 1 hour before the procedure.
89478722|NCT02071303|Placebo Comparator|Placebo|Women will receive a placebo 1 hour before the procedure.
89478723|NCT02260453|Active Comparator|A - Coronary angiography|All the patients receive preoperative coronary angiography followed, if needed, by percutaneous intervention (PCI) or bypass (CABG)
89478724|NCT02260453|Active Comparator|B - standard cardiac workup|Standard cardiac workup
89202953|NCT03988777||Retrospective hooked-wire|This cohort includes patients with an impalpable breast lesion that were scheduled for breast conserving surgery with hooked-wire before September 2018. Their data will be retrospectively collected and analysed.
89478725|NCT02076529|Experimental|Ramosetron 0.6mg|Ramosetron 0.6mg intravenous injection 30min before chemotherapy
89478726|NCT02076529|Experimental|Ramosetron 0.45mg|Ramosetron 0.45mg intravenous injection 30min before chemotherapy
89478727|NCT02076529|Active Comparator|Ramosetron 0.3mg|Ramosetron 0.3mg intravenous injection 30 min before chemotherapy
89478728|NCT04163991|Experimental|VIB4920 1500 mg 4 Times|Participants receive intravenous (IV) infusion of VIB4920 1500 mg on Days 1, 15, 29, and 57
89478729|NCT04163991|Experimental|VIB4920 1500 mg Twice|Participants receive IV infusion of VIB4920 1500 mg on Days 1 and 57, placebo on Days 15 and 29.
89478730|NCT04163991|Experimental|VIB4920 3000 mg Twice|Participants receive IV infusion of VIB4920 3000 mg on Days 1 and 57, placebo on Days 15 and 29.
89478731|NCT04163991|Experimental|VIB4920 3000 mg Once|Participants receive IV infusion of VIB4920 3000 mg on Day 1 and placebo on Days 15, 29, and 57.
89478732|NCT04163991|Placebo Comparator|Placebo|Participants receive IV infusion of placebo matched to VIB4920 on Days 1, 15, 29, and 57.
89478733|NCT02073019|Experimental|Cohort A|Each subject will receive a BL-8040 or Placebo on in a randomized double-blind fashion
89478734|NCT02073019|Experimental|Cohort B|Each subject will receive a BL-8040 or Placebo on in a randomized double-blind fashion
89478735|NCT02073019|Experimental|Cohort C|Each subject will receive a BL-8040 or Placebo on in a randomized double-blind fashion
89478736|NCT02442622|Active Comparator|Occupational therapy|Traditional therapy for de Quervain's Tenosynovitis
89478737|NCT02442622|Experimental|Occupational therapy with ASTYM|Traditional therapy for de Quervain's Tenosynovitis plus ASTYM
89478738|NCT02071381|Experimental|A|only DW330SR 45mg
89478739|NCT02071381|Experimental|B|only DW1030 75mg
88950820|NCT05280925|Experimental|Episodic Future Thinking|Participants will generate vivid, episodic events and be prompted via a guided smartphone app to engage in EFT in their daily lives. EFT will be paired with diet and physical activity support.
88950821|NCT05280925|Active Comparator|Healthy Information Thinking|Participants will be prompted via a guided smartphone app to thinking about their written responses to informational health vignettes during their daily lives. The HIT condition will be paired with diet and physical activity support.
88950822|NCT05275504|Experimental|Dose Escalation for TT-01488|TT-01488 tablets will be administered once daily in a 28-day cycle in increasing strength in order to determine the recommended dose for dose expansion.
89478740|NCT02071381|Experimental|C|DW330SR 45mg and DW1030 75mg
88950823|NCT05275504|Experimental|Dose Expansion for TT-01488|TT-01488 tablets will be administered once daily in 28-day cycles to verify the safety and preliminary efficacy as observed in the dose escalation cohorts.
89478741|NCT02073175|Experimental|Postpartum with crying spells-Full dose|"Healthy women who are within the first 18 months postpartum and have crying spells but do not have major depression. The effect of the dietary supplement in reducing sadness in this group will be assessed.~Intervention: Full dose dietary supplement Motherwell"
89478742|NCT02073175|Experimental|Day-5 postpartum - Full dose|"Healthy women on day-5 postpartum. This group is recruited during pregnancy but the main study day, involving the dietary supplement consumption is being done after delivery and during postpartum.~Intervention: Full dose dietary supplement Motherwell"
89478743|NCT02073175|Experimental|Day-5 postpartum - Half dose|"Healthy women on day-5 postpartum. This group is recruited during pregnancy but the main study day, involving the proposed dietary supplement consumption, is being done after delivery and during postpartum.~Intervention: Half dose dietary supplement Motherwell"
89478744|NCT02073175|Experimental|Day-5 postpartum - Quarter dose|"Healthy women on day-5 postpartum. This group is recruited during pregnancy but the main study day, involving the proposed dietary supplement consumption, is being done after delivery and during postpartum.~Intervention: Quarter dose dietary supplement Motherwell"
89478745|NCT02073175|Other|Day-5 postpartum - Control|"Healthy women on day-5 postpartum. This group is recruited during pregnancy but the main study day, involving a control supplement consumption, is being done after delivery and during postpartum.~Intervention: Control protein to compare with Motherwell"
89478746|NCT02073253|No Intervention|Without performing any operation (Phase Control)|
89478747|NCT02073253|Experimental|With ventilatory support through NIV (NIV Phase)|
89478748|NCT02411578|Experimental|G-Pen Mini™ (glucagon injection)|"Participants are to check blood glucose (BG) with study meter once their continuous glucose monitor (CGM) reads <70 mg/dl or they experience symptoms. Participants will be instructed to treat using mini-dose glucagon for certain phases/periods when BG is 40 to 69 mg/dl (considered a non-severe hypoglycemic event).~For every event, participant will check BG with meter 3 times and treat according to protocol instructions based on BG measurement."
89478749|NCT02411578|Active Comparator|Glucose Tabs|"Participants are to check their blood glucose (BG) with study meter once their continuous glucose meter reads <70 mg/dl or they experience symptoms. Participants will be instructed to treat using oral glucose tablets for certain phases/periods when BG is 40 to 69 mg/dl (considered a non-severe hypoglycemic event).~For every event, participant will check BG with meter 3 times and treat according to protocol instructions based on BG measurement."
89478750|NCT02076607||Conservative Treatment|Eleven patients underwent conservative treatment with Brace.
89478751|NCT02076607||Surgical Treatment|Fourteen patients who underwent surgical treatment (arthrodesis).
89478752|NCT03298503|Active Comparator|early stage or non-freezers PD|"early stage defined as modified Hoehn and Yahr scale 1, 1.5 and 2, means that symptoms involved unilateral or bilateral without impairment of balance.~non-freezers defined as without freezing of gait, means that patients without transient inability to generate effective stepping."
89537553|NCT05211219|Other|Control|the control group was advised without additional food supplements.
89537554|NCT01671345|Active Comparator|Intervention|Patients randomized to the intervention will view the intervention video
89202954|NCT00660816|Active Comparator|Arm I|Patients receive pemetrexed disodium IV over 10 minutes OR docetaxel IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Patients may continue to receive standard chemotherapy with or without erlotinib hydrochloride in the absence of disease progression or unacceptable toxicity.
89478753|NCT03298503|Experimental|moderate stage or freezers PD|"moderate stage defined as modified Hoehn and Yahr scale 2.5 and 3, means that symptoms involved unilateral or bilateral without impairment of balance.~freezers defined as with freezing of gait, means that patients have transient inability to generate effective stepping."
89478754|NCT02076685|Experimental|isoniazid rechalleng|When patients encountered hepatotoxicity during the anti-TB treatment, genotyping and pk study of INH would be performed and dose adjustment accordingly.
89478755|NCT05077917|Experimental|Cromolyn|2mL of 1% cromolyn sodium solution delivered via nebulizer 4 times a day for 4 days followed by 4% cromolyn solution administered intranasally 4 times per day for 14 days
89478756|NCT05077917|Placebo Comparator|Placebo|2-3mL of normal saline delivered via nebulizer 4 times a day for 4 days followed by intranasal administration of normal saline 4 times per day for 14 days
89478757|NCT02071459|Experimental|L-Threo DOPS|patients with Multiple System Atrophy (MSA) after 12 weeks to continued therapy with L-Threo DOPS
89478758|NCT02071459|Placebo Comparator|placebo|patients with Multiple System Atrophy (MSA) after 12 weeks to continued therapy with placebo
89478759|NCT02463747|Experimental|Prolonged Infusion of antibiotics|"Prolonged (4 hours) Infusion of antibiotics.~Intervention:~Primary care would be one of three options:~Piperacillin/tazobactam : 4.5gr, TID, I.V.~Or~Fortum (Ceftazidim): 2.0gr, TID, I.V. - for penicillin-sensitive patients.~Or~Meropenem: 1.0gr, TID, I.V.~Supplementation of Vancomycin will be at the discretion of the treating physician."
89478760|NCT02463747|Active Comparator|Fixed time infusion of antibiotics|"Fixed time (half and hour) infusion of antibiotics.~Intervention:~Primary care would be one of three options:~Piperacillin/tazobactam : 4.5gr, TID, I.V.~Or~Fortum (Ceftazidim): 2.0gr, TID, I.V. - for penicillin-sensitive patients.~Or~Meropenem: 1.0gr, TID, I.V.~Supplementation of Vancomycin will be at the discretion of the treating physician/"
89478761|NCT02076763||Acute intermittent porphyria|Patient diagnosed of AIP (by clinical, biochemical data and genetic confirmation of porphobilinogen deaminase (PBGD) gene mutation). The patient must have a severe AIP condition, with at least two hospitalizations during the previous year due to acute attacks (clinical manifestations of acute porphyria), or at least four hospitalizations during the previous year due to the requirement of hospital treatment administration (including day-hospital and home hospital program).
89478762|NCT02465775|Experimental|UltraShape treatment in all subjects|UltraShape treatment for fat reduction to unilateral flank for all subjects with untreated flank as control.
89478763|NCT02071537|Experimental|Chloroquine with Carboplatin/Gemcitabine|Chloroquine administered orally daily to start one week prior to Carboplatin (AUC5)/Gemcitabine (1250mg/m2). Chloroquine dose is escalating.
89478764|NCT03298425|Active Comparator|Treatment NMES|Patients allocated to the NMES group will be given an information booklet on NMES machines. The Cefar Compex three electrical stimulator will be used. Participants are expected to use the NMES machine for half an hour and complete bed exercises twice daily. Patients should relax during the NMES as completing both does not demonstrate better results, due to unsynchronised activation of the NMES (Gregory & Bickel, 2005). Using the machine once daily will allow for the recovery of the muscle. A voluntary contraction would normally be 20-30Hz but due to the high intensities of the NMES (35-75Hz) it can cause muscle fatigue (Maffiuletti, 2011).
89478765|NCT03298425|Placebo Comparator|Placebo NMES|The placebo group will act as the control group. They will be expected to complete the same regime as previously described above, however these machines will be on TENS setting (80-100Hz) as even low Hz can trigger motor stimulation (Paillard 2008). This setting is designed as a sensory stimulus therefore will have no effects on muscle strength however the patient will feel a small twitch sensation. This setting is not painful and will have no effect on muscle fatigue. The patient will not be expected to complete the bed exercises and the TENS session together.
89478766|NCT02076841||interferon beta-1a|30 μg intramuscularly once a week using an injection device (Avonex Pen).
89478767|NCT02442310|Experimental|Delayed release, fed conditions|A single 1200 mg dose of deferiprone delayed release tablet formulation administered following a high-fat breakfast
88950824|NCT05273840|Placebo Comparator|life intervention group|On the basis of the patient's original eating habits, basic dietary and lifestyle guidance is given to the patients until the end of the visit.
88950825|NCT05273840|Experimental|nutritional supplement intervention group|On the basis of the patient's original eating habits, basic dietary and lifestyle guidance is given, and at the same time, nutritional supplements(Ivital Control) are given to instead a meal per day. 2 bags once a day until the end of the visit.
88950826|NCT05263960|Experimental|Part A, Dose escalation|There are 10 dose groups in dose escalation part.
89478768|NCT02442310|Experimental|Delayed release, fasting conditions|A single 1200 mg dose of deferiprone delayed release tablet formulation, administered following a 10-hour fast
89478769|NCT02442310|Experimental|Delayed release half-tablets|A single 1200 mg dose of deferiprone delayed release tablet formulation, following a high-fat breakfast
88950827|NCT05263960|Experimental|Part B, Dose expansion|Based on the data of part A, one (MTD or the dose of one level less than MTD) or two (MTD and the dose of one level less than MTD) dose levels will be discussed for further evaluation in part B.
88950828|NCT05260398|Experimental|Mightier Now|8 weeks of use ad-libitum. Parents will be encouraged to have their children play Mightier games at least 3 times a week (totalling 45 minutes or more of play each week) for the 8-week duration.
89478770|NCT02442310|Active Comparator|Oral solution, fasting conditions|A single 1200 mg dose of deferiprone oral solution, administered following a 10-hour fast
89478771|NCT02077075|Active Comparator|Web-based weight loss program|Subjects will have access to a web-based weight loss program for an 8-week period.
89478772|NCT02077075|Experimental|On-line health coaching in addition to web-based program|Subjects will have access to the web-based wellness program and will also receive weekly personalized health coaching emails.
89478773|NCT02073721|Experimental|electrostimulation with exercises MAPs|this group will make the electrostimulation with exercises of the pelvic floor muscles with a focus on strengthening the pelvic floor muscles.
89478774|NCT02073721|Active Comparator|exercises MAPs|This group will focus exercises of the pelvic floor muscles with strengthening the muscles of the pelvic floor
89020541|NCT03871816||Participants with Metastatic Prostate Cancer|Participants with metastatic prostate Cancer (PC) will be evaluated for the prevalence of DNA-repair gene defects (DRDs) and will be assessed for biomarker eligibility status for niraparib interventional studies. Participants will be consented to saliva, blood, and/or archival tumor tissue testing for the presence or absence of DNA-repair gene defects.
89478775|NCT02071615|Experimental|Methylphenidate and placebo|Placebo or Methylphenidate 20 mg tablet given once by mouth
89478776|NCT02071615|Experimental|modafinil and placebo|placebo or modafinil 200mg tablet given once by mouth
89478777|NCT02071615|Experimental|caffein and placebo|placebo or caffein 200mg tablet given once by mouth
89478778|NCT02073799||Photoselective vaporization of the prostate|Patients who underwent photoselective vaporization of the prostate for prostatic hyperplasia and in whom 12-months follow-up data were available
89478779|NCT02073799||Holmium laser enucleation of the prostate|Patients who underwent holmium laser enucleation of the prostate for prostatic hyperplasia and in whom 12-months follow-up data were available
88950829|NCT05260398|No Intervention|Mightier Later|8 weeks of wait list. Families in the Mightier Later condition will receive their Mightier shipment and will be encouraged to play Mightier after follow-up questionnaires have been completed 8 weeks after parents and teachers complete baseline questionnaires.
89020542|NCT03839758|Active Comparator|TSA Standard|This group will include patients schedule for a total shoulder arthroplasty. Glenoid preparation will be done following surgeon evaluation of the 2D CT scan with the institution software. Generic guides included in the regular instrumentation set will be used
89478780|NCT02073877||Controls - Holgers 0 & 1|
89478781|NCT02073877||Cases - Holgers >1 (active peri-implant dermatitis)|
89478782|NCT02073955||Pakistani adults|"Men and women aged 40 and above, residing in Ibrahim Hyderi (periurban Pakistani community)~Consenting to Interview about stroke symptoms"
89478783|NCT02411110|Experimental|LiRIS® (Treatment Period 1)/LiRIS® (Treatment Period 2)|Treatment Period 1: continuous release of lidocaine inserted into the bladder by cystoscopy on Day 0 and removed on Day 14 of Period 1. Treatment Period 2: optional continuous release of lidocaine inserted into the bladder by cystoscopy on Day 0 and removed on Day 14 of Period 2.
89478784|NCT02411110|Other|LiRIS Placebo (Treatment Period 1)/LiRIS® (Treatment Period 2)|Treatment period 1: Matching placebo device to LiRIS inserted into the bladder by cystoscopy on Day 0 and removed on Day 14 of Period 1. Treatment Period 2: optional continuous release of lidocaine inserted into the bladder by cystoscopy on Day 0 and removed on Day 14 of Period 2.
89478785|NCT02074033||antibiotics for pneumonia|We will be examined whether the antibiotic prescribed following the orientation of literature, considering the dose, interval between doses, dose adjustment for renal failure infusion time, treatment time and conduct after the culture results (deescalation, escalation or maintenance of antimicrobial initially prescribed )
89478786|NCT02077153|Experimental|Group Reminescence|In the experimental condition, everything begins ensuring the participants that all the memories shared will not be spread out of the group. Every session will deal with a theme, recalling specific autobiographic experiences; they will be suggested following a chronological order. Participants are encouraged to bring photos or objects related to past themes: at the end of each meeting the theme of the following is revealed. The researchers can also bring materials as cues for reminiscence.
89478787|NCT02077153|Active Comparator|Group discussion|In the control condition, every meeting will offer topics for discussion taken from newspaper and newscasts: personal opinions are promoted, and links with the daily life of participants are welcome (everyday activities, personal preferences). The main goal is to stimulate the social interaction and the communication, without dealing with personal events from the past nor private memories.
89478788|NCT02077231|Experimental|vitamin A palmitate eye gel|0.1% vitamin A palmitate; Sinqi, Shenyang, China
89478789|NCT02077231|Experimental|carbomer eye gel|0.2% Carbomer 940; Bausch & Lomb, Aschheim, Germany
89478790|NCT02077309|Active Comparator|Linagliptin|Patients will receive 5 mg linagliptin once daily for a period of 6 months.
89478791|NCT02077309|Placebo Comparator|Placebo|Patients will take placebo tablets once daily for a period of 6 months.
88950830|NCT05227157||1: intensity of perception of metallic taste|"For this study, there is only one arm: swab with iron sulfate solution at a concentration of 10g/l.~Each subject complete visual scale"
88950831|NCT05218291|Experimental|Technology-Supported Yoga Applied Group|"The yoga initiative to be applied to the intervention group; Yoga, which is mind-breath-body work; It includes meditation, pranayama (breath work), and asanas (yoga poses).~The content of the yoga practice consists of the following poses:~-Tadasana (Mountain pose), -Urdhvahastasana, -Uttanasana, -Ardha Uttanasana, -Plank, -Ashtang Pranam, -Bhujangasana (Mini cobra), -Adho Mukha Svanasana (Downward facing dog), -Vrksasana (Tree Pose), - Utthita Trikonasana (Triangle Pose), -Virabhadrasana I (Warrior I), -Virabhadrasana II (Warrior II), -Virabhadrasana I with Anjali Mudra (Hands Reverse Namaste), -Utkatasana (Chair Pose), -Salabhasana, -Paschimottanasana , -Dandasana, -Salamba Sarvangasana (Shoulder pose), -Ardha Urdhva Dhanurasana (Half Wheel Pose), -Reverse Warrior, -Child's pose, -Ananda Balasana (Happy baby), -Wipers, -Corpse Pose"
88950832|NCT05218291|Active Comparator|Control Group|No intervention was made in caregivers.
88950833|NCT05213052|Experimental|Topical cream, 1 - 2 times daily|Application of a pea-sized amount of cream applied to skin over the area with chronic pain
89478792|NCT01369849|Experimental|Treatment (Akt inhibitor MK2206, bendamustine, rituximab)|Patients receive Akt inhibitor MK2206 PO on days 1, 8, 15, and 22 (days 1, 8, 15, 22, and 29 of course 1); rituximab IV on day 1 (day 8 of course 1); and bendamustine hydrochloride IV over 30-60 minutes on days 1-2 (days 8-9 of course 1). Treatment repeats every 28 days (35 days for course 1 and 84 days for course 6) for 6 courses in the absence of disease progression or unacceptable toxicity.
89478793|NCT02077387|Experimental|CHild Inhibitory Control Play (CHIC) Play|CHIC Play paradigm: Children will exposed to several play paradigms that enhance inhibitory control around snack foods. Children will receive the intervention in the preschool setting over a 3 week period.
89478794|NCT02077387|Active Comparator|Attention control|Children will receive information regarding other healthy behaviors: brushing teeth, sunscreen use, being physically active
89478795|NCT02079883||ocriplasmin|
89478796|NCT02077543|Experimental|ProTool|Device: Brain Tissue Imprint - Medical Device (ProTool)
89478797|NCT02716779|Experimental|Pegylated Interferon (PEG-IFN) alfa-2a|Participants with chronic hepatitis C, genotype 1, received pegylated interferon (PEG-IFN) alfa-2a monotherapy for 6 weeks. Thereafter, all participants received combination therapy with PEG-IFN alfa-2a plus ribavirin for 12 weeks.
89478798|NCT02716779|Placebo Comparator|Placebo|Participants with chronic hepatitis C, genotype 1, received ribavirin matching placebo for 6 weeks. Thereafter, all participants received combination therapy with PEG-IFN alfa-2a plus ribavirin for 12 weeks.
89478799|NCT02716779|Experimental|Ribavirin|Participants with chronic hepatitis C, genotype 1, received ribavirin monotherapy for 6 weeks. Thereafter, all participants received combination therapy with PEG-IFN alfa-2a plus ribavirin for 12 weeks.
89478800|NCT02074111||Intracranial atherosclerotic stroke|
89478801|NCT02074111||Moyamoya disease|
89478802|NCT02074111||Healthy controls|
89478803|NCT02074189|Active Comparator|Adjuvant Chemotherapy|Adjuvant Chemotherapy(Gemcitabine, Cisplatin):Gemcitabine 1000 mg/m2 iv,D1,D8,D15;cisplatin 70 mg/m2 iv,D2.With 4 cycles. Treatment begins between 1-5 weeks after radical operation (within 42 days is recommended)
89478804|NCT02074189|No Intervention|Control|No immediate post-surgery treatment. Patients undergo observation followed by cisplatin and gemcitabine as in arm I at local relapse, or receive intravenously chemotherapy with cisplatin and gemcitabine at multiple metastases
89478805|NCT02463591|Experimental|Beriplex 50 IU/Kg|Cross over design: After therapy with Dabigatran Etexilate 300mg BID for 2.5 days, subjects will receive a single dose of Beriplex 50 IU/Kg. After a 10 day minimum wash-out period subjects will receive the alternative treatment (Placebo).
89478806|NCT02463591|Placebo Comparator|Placebo|Cross over design: After therapy with Dabigatran Etexilate 300mg BID for 2.5 days, subjects will receive a single dose of Placebo identically in appearance to Beriplex 50 IU/Kg. After a 10 day minimum wash-out period subjects will receive the alternative treatment (Beriplex).
89478807|NCT02079961|Experimental|Micronutrient-fortified yoghurt|"Micronutrient-fortified yoghurt + BCC~All eligible children within the intervention arm will receive one fortified yoghurt per day, every day of the week, if the household satisfied to the contract of reliability in milk supply during the previous week, during the one year duration of the intervention."
88950834|NCT05197218|Experimental|Healthy subjects|Prebiotic administration
88950835|NCT05195255|Experimental|Healthy subjects|Prebiotic administration
88956512|NCT05030272|Other|Brief Advice (Standard of Care)|Brief Advice and Combined Nicotine Replacement Therapy (patches and gum or lozenges) has been recommended by the US Clinical Practice Guidelines for patients with psychiatric illness. Brief Advice will consist of 20 minutes of guidance about the use of nicotine replacement therapy, and strategies to initiate and maintain a quit attempt. The intervention is combined with an 8-week course of nicotine replacement therapy (NRT) patches and a 5-10 week course of NRT gum (or Nicotine Lozenges if unable to use gum).
88956513|NCT05025319||Taditional Grid|Patients imaged with traditional grid
89202955|NCT00660816|Experimental|Arm II|Patients receive pemetrexed disodium IV over 10 minutes OR docetaxel IV over 60 minutes on day 1 and erlotinib hydrochloride PO once daily on days 2-19. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Patients may continue to receive standard chemotherapy with or without erlotinib hydrochloride in the absence of disease progression or unacceptable toxicity.
89202956|NCT00991666|Experimental|1|AMD Patients
88956514|NCT05025319||Virtual Grid|Patients imaged with virtual grid
88956515|NCT05021120|Experimental|Intervention/treatment|Experimental
89202957|NCT00991666|Active Comparator|2|healthy controls
89202958|NCT00801528|Active Comparator|Ropivacaine|Continuous wound instillation of ropivacaine 0.2 % at a rate set of 10 mL/hr
89202959|NCT00801528|Active Comparator|Diclofenac|Continuous wound instillation of diclofenac (300 mg/240 ml water for injection) at a rate set of 10 mL/hr
89478808|NCT02079961|Active Comparator|Control|"BCC~Children will not receive fortified yoghurt during the duration of the intervention"
89478809|NCT02463903|Experimental|Coping effectiveness Training (CET)|The intervention consists of Coping Effectiveness Training (CET), a manual-based group intervention based on a cognitive transactional theory of stress and coping. The purpose of CET is to improve skills to appraise stress, teach a number of techniques to cope with stress, and to give an opportunity to interact with other people with similar experiences of living with CHF. The CET program will, in this study, be modified for patients with CHF. The intervention consists of seven, 90-minute weekly sessions led by a nurse with a Masters degree in nursing science and extensive experience in heart failure care in collaboration with a professional psychologist. Each group consisted of 8 to 12 patients.
89478810|NCT02463903|No Intervention|Control|The control group will receive standard health care and will not take part of the intervention.
89478811|NCT02080039|Experimental|Electrical Stimulation|
89478812|NCT03298347|Experimental|80mg/kg of caffeine|80mg/kg of caffeine is given to treat AOP.
89478813|NCT03298347|Active Comparator|20mg/kg of caffeine|20mg/kg of caffeine is given to treat AOP.
89478814|NCT02074423|Experimental|MealShape cinnamon extract|Intake of 2 capsules of 500 mg MealShape 30 minutes before consumption of a standard meal (white bread)
88950836|NCT05191108|Experimental|The Effect of mİNDFULNESS Stress Reduction Program on Premenstrual Symptoms|In order to prevent bias in the study groups, the Introductory Information Form and PMSS scale will be applied via online Google forms. Participants who meet the criteria will be randomly assigned to the mindfulness stress reduction group (Group 1) and control group (Group 2) in the number determined by power analysis and a simple random number generator program (www.random.org). These experimental and control groups will be recorded by the researchers as a list. Participants participating in the study will be informed about the mindfulness stress reduction application, but they will not be informed about what the mindfulness stress reduction application does (single-blind method). These participants will be asked to sign the consent form by expressing that they can withdraw from the study at any time.
88950837|NCT05191108|No Intervention|Control group|not routinely do anything to reduce premenstrual symptoms
88950838|NCT05176678|Active Comparator|Escalating dose of natural protein hydrolysate - sequence A|Participants will consume escalating doses of natural protein hydrolysate: Week 1-2: 1 gram/day, Week 3-4: 2 gram/day, Week 5-6: 4 gram/day.
88950839|NCT05176678|Active Comparator|Escalating dose of natural protein hydrolysate - sequence B|Participants will consume escalating doses of natural protein hydrolysate: Week 1-2: 1 gram/day, Week 3-4: 2 gram/day, Week 5-6: 8 gram/day.
88950840|NCT05161039|Other|Serranator|
88950841|NCT05161039|Other|POBA|
88956516|NCT05020314|Experimental|Clinically Based: Healthy Weight Clinic|
89478815|NCT02074423|Placebo Comparator|Placebo|Intake of 2 capsules of 500 mg placebo, composed of 20% microcrystalline cellulose and 80% dicalcium phosphate, 30 minutes before consumption of a standard meal (white bread)
89478816|NCT02461485|Experimental|1=BOW_01|1= Fermented Milk Product containing Probiotics
89478817|NCT02461485|Experimental|2=BOW_01 + fiber C|2= Fermented Milk Product containing Probiotics + Fibers C
89478818|NCT02461485|Experimental|3 =BOW_01 + fiber W|3= Fermented Milk Product containing Probiotics + Fibers W
89478819|NCT02461485|Placebo Comparator|4 = Control|4= Non fermented Milk Product with same color, texture and organoleptic properties as investigational products 1 to 3.
89478820|NCT02074501|Other|training capacity in caregivers|"The participants of the InCARE programme (intervention group) will receive, additionally, intervention based on: (i) empowering caregivers to put hands on caring, which will be the key-point of the pilot programme; (ii) training handling techniques: mobility, bathing, (un)dressing, transferring, positioning, eating and drinking using technical aids, after 1 week, 1 month and 3 months, post hospital discharge; (iii) using telephone support, counselling caregivers on 3rd, 6th, 8th and 10th weeks post discharge. It aims at facilitating the caregivers 'adjustment to stroke demands, increasing knowledge and practical skills to support their decision-making."
88950842|NCT05097157|Experimental|Treatment with Device|Subjects received up to 5 treatments with the device, spaced 4 weeks apart.
88950843|NCT05082103|Active Comparator|Enzyme lozenge 1|The lozenge contains three plaque extracellular matrix degrading enzymes
88950844|NCT05082103|Active Comparator|Enzyme lozenge 2|"The concentration of the three enzymes in the Enzyme lozenge 2 is threefold the enzyme concentration than in the Enzyme lozenge 1"
88950845|NCT05082103|Placebo Comparator|Placebo lozenge|The placebo lozenge contains the same ingredients except for the enzymes and has an identical taste, color and texture
89478821|NCT02465697|Experimental|BPD Emotion Regulation Training|Guided practice in reappraisal
89478822|NCT02465697|No Intervention|BPD Control|no training in reappraisal
89478823|NCT02465697|Experimental|APD Emotion Regulation Training|Guided practice in reappraisal
89478824|NCT02465697|No Intervention|APD Controls|no training in reappraisal
89478825|NCT02465697|Experimental|Healthy Controls Emotion Regulation Training|Guided practice in reappraisal
89478826|NCT02465697|No Intervention|Healthy Controls|no training in reappraisal
89478827|NCT02077699|Experimental|1|Treatment with Lactobacillus casei DG (24 billion of live cells per pill) 2 pills b.i.d. for 4 weeks
89478828|NCT02465619||Severe acute hepatitis|Severe acute hepatitis without ascites.
89478829|NCT02465619||Non-cirrhotic|
89478830|NCT02465619||Cirrhotic patients with ascites|
89478831|NCT02465619||decompensated cirrhosis|
89478832|NCT02077777|Experimental|5-ASA|Mesalazine 800 mg orally t.i.d for 3 months
89478833|NCT02077777|No Intervention|No treatment|no treatment
89478834|NCT02463201||Obese children and adolescents|Attending a weightloss programme, that consist of lifestyle counseling, dietary restriction and exercise. The prevalence of obstructive sleep apnea (OSA) will be investigated in group. Children diagnosed with OSA will be followed to investigate if weight loss changes the condition.
89478835|NCT02077855||Toddlers fractures|
89478836|NCT05036421|Experimental|Study Group|Empagliflozin
89202960|NCT00801528|Placebo Comparator|Water for injection|Continuous wound instillation of water for injection at a rate set of 10 mL/hr
89020543|NCT03839758|Active Comparator|RTSA standard|This group will include patients schedule for a reverse total shoulder arthroplasty. Glenoid preparation will be done following surgeon evaluation of the 2D CT scan with the institution software. Generic guides included in the regular instrumentation set will be used
89478837|NCT03094819|No Intervention|Group 1|Participants randomized to Group 1 will be the control group. They will be observed while they receive usual eye care without any study intervention.
89478838|NCT03094819|Experimental|Financial Incentive|Participants randomized to the Financial Incentive group will be offered a financial incentive in conjunction with their usual eye care. They will receive usual care and a $25 payment if they obtain a confirmed eye examination.
89478839|NCT03094819|Experimental|Retinal Care DR|Participants randomized to the Retinal Care DR Service group will receive: (1) point of care risk assessment for vision-threatening diabetic retinopathy, (2) retinal specialist interpretation of their risk assessment data, and (3) care coordination designed to improve the eye examination rate for patients with diabetes at increased risk for vision-threatening diabetic retinopathy.
89478840|NCT03298191|Experimental|Magnesium sulphate|
89478841|NCT03298191|Experimental|Ritodrine|
89478842|NCT03298191|Experimental|Calcium channel blocker|
89478843|NCT02080117||patients who underwent kidney transplantation|patients who underwent living or deceased donor kidney transplantation between 2008 and 2013
89478844|NCT02074657|Experimental|Activated natural killer cells|
89478845|NCT01369615|Experimental|Oxycodone HCl controlled-release|Oxycodone hydrochloride controlled-release tablets
89478846|NCT02080351|Experimental|Simple cognitive task|"A memory reactivation cue followed by playing the computer game Tetris"
89478847|NCT02080351|No Intervention|Usual care|Usual care in the emergency department
89478848|NCT02074813|No Intervention|Standard|conventional pulmonary rehabilitation
89478849|NCT02074813|Experimental|Inspiratory muscle training|Inspiratory muscle training associated with a conventional pulmonary rehabilitation
89478850|NCT02260375|Experimental|Mesenchymal Stromal Cells (MSC)|A single intravenous infusion (1-2 millions of MSCs per kilogram body weight) of ex-vivo expanded third-party MSC (from healthy donors) will be performed in patients assigned to the MSC procedure in addition to the liver transplantation.
89478851|NCT02260375|No Intervention|No treatment.|
89478852|NCT02077933|Experimental|alpelisib and everolimus|alpelisib and everolimus administered once a day
89478853|NCT02077933|Experimental|alpelisib, everolimus and exemestane|alpelisib, everolimus and exemestane administered once a day
89478854|NCT02077933|Experimental|alpelisib and exemestane|alpelisib and exemestane administered once a day
89202961|NCT04003402|Experimental|Sequence 1: Participants receiving treatment sequence A,B,C,D|"Eligible participants will received treatment sequence A, B, C, D. Each participant will receive a single oral dose and each treatment period has a minimum of a 14 day washout period between investigational product administration.~A= ASP8062 with Alcohol; B= ASP8062 with Placebo Alcohol; C= Placebo ASP8062 with Alcohol; D = Placebo ASP8062 with Placebo Alcohol"
89202962|NCT04003402|Experimental|Sequence 2: Participants receiving treatment sequence B,D,A,C|"Eligible participants will received treatment sequence B, D, A, C. Each participant will receive a single oral dose and each treatment period has a minimum of a 14 day washout period between investigational product administration.~B= ASP8062 with Placebo Alcohol; D = Placebo ASP8062 with Placebo Alcohol; A= ASP8062 with Alcohol; C= Placebo ASP8062 with Alcohol"
89478855|NCT02078011|Experimental|HIFU treatment|The high intensity focused ultrasound (HIFU) will be administered to the targeted site to create heat and cause the cells to die
89478856|NCT02080429|Active Comparator|Immediate Pushing|Patient's will begin to push when they are determined to be completely dilated.
89478857|NCT02080429|Experimental|Passive Descent|Patient's will wait 90 minutes prior to begin pushing
89478858|NCT02078089|Other|Oxcarbazepine and Morphine|"Patients must be on stable or increasing doses of greater than or equal to 180 mg of morphine sulfate per day. Morphine is taken orally for 42 days.~In addition to Morphine, patients will also receive oral Oxcarbazepine 150 mg, every 12 hours, for 2 weeks, then increase the dose to 300 mg, every 12 hours, for 2 weeks and then increase the dose to 450 mg, every 12 hours, for the final 2 weeks. Patients will take oral tablets of oxcarbazepine for a total of 42 days."
89478859|NCT02074891||Persons prescribed PrEP|adults prescribed daily oral antiretroviral preexposure prophylaxis (PrEP) with the coformulated TDF/FTC to reduce HIV acquisition.
89478860|NCT02080585|No Intervention|Control group without advice|Control group receives no intervention or physical activity advice.
89478861|NCT02080585|Experimental|Computer-tailored physical activity advice|Subjects receive computer-tailored physical activity advice.
89478862|NCT02074969|Active Comparator|Gamma Nail 3|Gamma Nail 3 Stryker.
89478863|NCT02074969|Active Comparator|PFNA|PFNA Antirotation Synthes
89478864|NCT02080663||Proximal row carpectomy|Proximal row carpectomy
88950846|NCT05080647|Active Comparator|Mightier Child Play|8 weeks of use ad-libitum. Parents will be encouraged to have their children play Mightier games at least 3 times a week (totalling 45 minutes or more play each week) for the 8-week duration. Parents in the Child Play condition will be advised specifically to not play Mightier for the 8-week duration of the study.
88950847|NCT05080647|Experimental|Mightier Child and Parent Play|8 weeks of use ad-libitum. Parents will be encouraged to have their children play Mightier games at least 3 times a week (totalling 45 minutes or more of play each week) for the 8-week duration. Additionally, parents in the Child and Parent Play condition will be encouraged to play Mightier games at least once a week (totalling 15 minutes or more of play each week) for the 8-week duration.
88950848|NCT05042674|Other|Placebo, Ergothioneine 25mg, Ergothioneine 25mg for 1 week daily|Participants will consume placebo on first study day, consume 25mg of ergothioneine on second study day, then consume 25mg of ergothioneine daily for 1 week
89478865|NCT02078323|Active Comparator|Linaclotide|Linaclotide 290micrograms q day 30 min before meal for a 10 week period
89478866|NCT02078323|Placebo Comparator|placebo|Placebo q day 30 min before meal for a 10 week period
89478867|NCT02078401||Neurofibromatosis type 1 children|
89478868|NCT02075359||Preschoolers|Preschoolers, ages 3 to 5
88950849|NCT05015062|Experimental|Mobile-based intervention with standardized incentive|Participants will receive biweekly messages containing HIV-related educational modules from village doctors who will receive standardized compensation for performing the work.
89478869|NCT02075437|Experimental|Functional Abdominal Pain (FAP)|To access (FAP) subjects will participate in: 10 therapy sessions; and the following treatments: 1) identify strategies with unique patterns of neural circuit maturation associated with early visceral pain on the gut-brain axis: 2) adapt acceptance-based behavioral strategies used to address psychopathology in older children to younger children; and 3) incorporate caregivers as role models and facilitators based on attachment research.
89478870|NCT02075749|Active Comparator|triamcinolone acetonide mucoadhesive|30 patients received triamcinolone acetonide mucoadhesive films
89478871|NCT02075749|Experimental|Licorice|30 patients received licorice mucoadhesive films
89478872|NCT02075749|Placebo Comparator|Mucoadhesive film|30 patients received mucoadhesive films without any drug ingredients
89478873|NCT05527327|Experimental|Prospective arm|All prospective participants will be consented to use of the intervention, a pannus retractor at time of detailed obstetric ultrasound.
89478874|NCT02080897||Palliative Surgery Group|Patients who present to clinic with soft tissue sarcoma with metastatic lung disease who opt to proceed with palliative surgical treatment
89478875|NCT02080897||Non-surgical Group|Patients who present to clinic with soft tissue sarcoma with metastatic lung disease who opt not to pursue palliative surgery
89478876|NCT02075827|Active Comparator|Problem-solving video game|Playing the video game 'Little Big Planet'
89478877|NCT02075827|Experimental|Competitive video game|Playing the video game 'Call of Duty'
89478878|NCT02075905||Barrett's Esophagus-Low Grade Dysplasia|Subjects enrolled who have Barrett's Esophagus with low grade dysplasia. No research intervention is administered.
89478879|NCT02075905||Barrett's Esophagus-no dysplasia|Subjects enrolled with Barrett's Esophagus and no dysplasia. No research intervention is administered.
89478880|NCT02080975|Experimental|Data Collection During Atrial Flutter Ablation|
89478881|NCT02075983|Experimental|Group 3 (IM+EP)|Group 3 will receive 12.0mg of vaccine over 12 weeks administered with EP using the Trigid Ichor device. We expect to see the greatest proportion of individuals making T cell and antigen specific antibody responses responses in this group. Depending on the magnitude of the effects, the differences between group 3 and the other groups may be statistically significant.
89537555|NCT01671345|Placebo Comparator|Control|Patients randomized to control will view an informative video about nutrition and exercise of similar length
89478882|NCT02075983|Experimental|Group 2 (IM+TC)|Group 2 will also receive 13.2mg of vaccine over 12 weeks, with 12.0mg given IM and 1.2mg TC. We are interested in the impact of TC relative to ID vaccination on the ratio between HIV-specific T-cell responses, and whether or not CD8+ Tcells are favoured by this route.
89478883|NCT02075983|Active Comparator|Group 1 (IM+ID)|"Group 1 will serve as the reference arm and this group will receive a total dose of 13.2mg vaccine over 12 weeks with 12.0mg given IM and 1.2mg ID. This is 7.2mg more than has been given previously to healthy individuals and 6.2 mg more than given to those HIV-infected but similar doses of HIV DNA vaccines have been given in other trials with no serious consequences."
89478884|NCT02078479|Active Comparator|Real rTMS|The active group received Real rTMS over the hand area of motor cortex (20 Hz, 10 second, 10 trains with inter-train interval 30 second with total pulses 2000, intensity 80% of motor threshold) every day for ten consecutive days (5 days/week).
89478885|NCT02078479|Sham Comparator|Sham rTMS|Sham-rTMS was applied using the same parameters but with the coil elevated and angled away from the head to reproduce the same of subjective sensation of rTMS
89478886|NCT02081053|Other|RF Ablation and Vertebral Augmentation|
89478887|NCT02078635|Experimental|Portfolio Plus Diet|Participants will be advised to follow a low glycemic index dietary portfolio. Specifically, the advice will be to limit saturated fat (to <7% of total calories and cholesterol to <200 mg/d) plus inclusion of viscous fibres, soy protein, plant sterols and nuts, 5% extra monounsaturated fat and selection of low glycemic index foods; emphasizing current recommendations for fruit and vegetable intakes (5-10 servings/d)
89478888|NCT02078635|Active Comparator|DASH-like (high fibre) diet|The DASH-like dietary advice will emphasize a diet of whole grains, low-fat dairy and current recommendations for fruit and vegetables (5-10 servings/day)
89478889|NCT02081131|Active Comparator|Laparoscopic Surgery|patients will be randomized to laparoscopic pancreatoduodenectomy group
89478890|NCT02081131|Active Comparator|Open Surgery|Patients will be randomized to Open pancreatoduodenectomy
89478891|NCT02081209|Experimental|Fat Reduction|
89478892|NCT02081287|Active Comparator|Lamotrigine|As adjunct to lithium therapy
89478893|NCT02081287|Experimental|IP6|As adjunct to lithium therapy
89478894|NCT02078791|Experimental|Botox infiltration|Botox infiltration in cervical region
89478895|NCT02078791|Experimental|Psychology therapy|Problem solving group therapy
89478896|NCT02078791|Experimental|Botox infiltration & psychology therapy|Botox infiltration in cervical region and problem solving group therapy.
89478897|NCT02076139|Experimental|Nyaditum resae® 10e4|The subjects will receive 1 drinkable vial (4mL) per day during 14 days. Each vial contains 10e4 Colony-forming units (CFUs) of Nyaditum resae®.
89478898|NCT02076139|Experimental|Nyaditum resae® 10e5|The subjects will receive 1 drinkable vial (4mL) per day during 14 days. Each vial contains 10e5 CFUs of Nyaditum resae®.
89478899|NCT02076139|Placebo Comparator|Placebo|The subjects will receive 1 drinkable vial (4mL) of distilled water per day during 14 days.
89478900|NCT02811913|Other|High frequency rTMS|Each subject is provided with three different brain stimulation interventions in a single arm, single session crossover design study. One of the sessions was 5 Hz rTMS
89478901|NCT02811913|Other|Low frequency rTMS|Each subject is provided with three different brain stimulation interventions in a single arm, single session crossover design study. One of the sessions was 1 Hz rTMS
89478902|NCT02811913|Other|Sham rTMS|Each subject is provided with three different brain stimulation interventions in a single arm, single session crossover design study. One of the sessions was sham rTMS
89478903|NCT02083237|Active Comparator|Behavioural Intervention Program|People with MCI and their close family member (80% spouses) participate jointly in the first hour, which provides education about MCI, lifestyle influences on cognitive health, and community resources. During the second hour, family members participate in a separate psychosocial group intervention, while the individuals with MCI participate in memory training. The first 6 of the 8 sessions occur weekly, the 7th occurs as a 1-month follow-up session and the 8th as a 3-month follow-up session. These follow-up sessions provide support to sustain positive outcomes and provide further assistance with resolving continued challenges.
89478904|NCT02083237|No Intervention|Waitlist Control|Due to the heavy demand for this clinical program, there is a naturally-occurring waitlist of approximately 3 months. Control participants are assessed during this period.
89478905|NCT02468674|Other|Follow-up (arm 1)|Patients in Population I received 6 doses of bimagrumab 70 mg, 210 mg, 700 mg or placebo - one approximately every four weeks - over a 20-week period providing drug exposure for a total of 24 weeks.
89478906|NCT02468674|No Intervention|Follow-up (arm 2)|Patients in Population II received either bimagrumab 700 mg or placebo in the core study and did not receive any investigational treatment in the extension study.
88950850|NCT05015062|Experimental|Mobile-based intervention with performance-based incentive|Participants will receive biweekly messages containing HIV-related educational modules from village doctors who will receive performance-based compensation for performing the work.
89478907|NCT03558763|Active Comparator|Normal Care|During normal care the subjects will get the possibility to call the COPD-center via telephone on their own initiative e g with worsening symptoms as usual.
89478908|NCT03558763|Active Comparator|Telemonitoring|"Twice a week subject will perform additional vital functions:~Blood pressure and heart rate will be measured using the Electronic Sphygmomanometers Track.~Weight will be taken using the Scale lite Oxygen saturation will be measured using Pulse Oximeter Air And~Complete two PRO´s (integrated in the application):~CAT MRC All this is estimated to take approximately 20-30 min each time.~For the first 4 weeks there will be weekly video calls with a COPD-center nurse discussing health condition and vital parameters.~Thereafter there will be monthly video calls with a COPD-center nurse for the remaining 5 months, i.e. 4 further calls. The video calls will take approximately 15 min."
88950851|NCT05015062|No Intervention|Control without intervention|Participants will not receive the mobile-based intervention
89478909|NCT04918069|Experimental|Capsaicin|2g of 0.075% topical capsaicin ointment applied four times daily (preferably to the abdomen) for the first five days of chemotherapy
89478910|NCT04918069|Placebo Comparator|Placebo|2g of topical placebo ointment applied four times daily (preferably to the abdomen) for the first five days of chemotherapy
89478911|NCT02081521|Experimental|Community behaviour change campaign|Participants will be exposed to the community behaviour change intervention.
89478912|NCT02081521|No Intervention|No community behaviour change campaign|No community intervention will take place in the control arm, although exposure to some intervention messaging (radio adverts) may take place.
89478913|NCT02467192|Experimental|Low dose CT|All patients will have Thoracic CT scan
89478914|NCT02083315|Experimental|TRV130 1.5 mg|TRV130 1.5 mg IV x 1 dose
88950852|NCT05013021|Other|Sedentary participants|"Series of measures placed throughout the time-course (before, after the 1st , the 2nd and the 3rd block of SIT).~These measurements consist of physiological measurements (VO2max), neuromuscular capacities (force-speed profile), autonomic nervous system responses (heart rate variability) and blood markers (lactate, CK, cytokinases, µRNA)."
89202963|NCT04003402|Experimental|Sequence 3: Participants receiving treatment sequence C,A,D,B|"Eligible participants will received treatment sequence C, A, D, B. Each participant will receive a single oral dose and each treatment period has a minimum of a 14 day washout period between investigational product administration.~C= Placebo ASP8062 with Alcohol; A= ASP8062 with Alcohol; D = Placebo ASP8062 with Placebo Alcohol; B= ASP8062 with Placebo Alcohol"
89478915|NCT02083315|Experimental|TRV130 3 mg|TRV130 3 mg IV x 1 dose
89478916|NCT02083315|Experimental|TRV130 4.5 mg|TRV130 4.5 mg IV x 1 dose
89478917|NCT02083315|Active Comparator|Morphine|Morphine 10 mg IV x 1 dose
89478918|NCT02083315|Placebo Comparator|Placebo|Dextrose 5% in water IV x 1 dose
89478919|NCT04922242|Experimental|Population 1: NICU Study Staff|Interdisciplinary Professional Clinical Staff who are employed to work as a nurse, therapist, social worker or physician in the NICU.
89478920|NCT04922242|Experimental|Population 2: Mother-infant dyads in NICU|Parent and infant dyads admitted to a NICU for over 72 hours.
89478921|NCT03559387|Experimental|ANF-RHO™|Subjects will receive the ANF-RHO™ dose with a volume equivalent to 10 µg/kg, 20 µg/kg and 30 µg/kg as a subcutaneous injection.
89478922|NCT03559387|Active Comparator|Neulasta®|Neulasta® will be administered to the subjects at a dose of 6.0 mg in 0.6 ml as a subcutaneous injection.
89478923|NCT03558685|Experimental|Diet|Nutritional recommendation consisted of moderate caloric restriction, set at 25% to 30% less than calories needed for resting metabolic rate. We applied a high protein Mediterranean diet with the following food group distribution: 30% as protein (> 0.8 g/kg/d); 40% as carbohydrates with medium/low glycemic index; 30% as fat (≥10%monounsaturated fatty acid, ≤7% saturated fatty acid, no trans fats, and 1.6 g omega-3 for men and 1.1 g omega-3 for women). Diet was rich in olive oil, fish, chicken, nuts, white milk products, fruits, and vegetables but low in artificial sugars, commercial sweets, pastries, butter, margarine, and red meat. Dietary fiber content ≥25 g/day
89478924|NCT02410954|Experimental|tDCS electrode configuration|Three rounds of tDCS using NeuroConn Direct Current stimulator Multiple Channel -4, Rogue Resolutions treatment optimization where each round includes identifying a promising electrode configuration based on electric field modeling using a realistic head model and capitalizing on the experience with the prior round (for rounds 2 and 3) and testing that electrode placement by administering a series of electrical doses of tDCS with that tDCS electrode configuration (carrying out a dose titration) in a cohort of 10 healthy control subjects to see if we can find an electrical dose which is well-tolerated, safe, suppresses the AOT pupil response and is below recommended current density safety limits (the safety limit in terms of Amperage varies depending on the electrode configuration)
89478925|NCT02410954|Placebo Comparator|Using tDCS to reduce acute fear|Administration of 7.5% CO2 to see if this elicits symptoms of Acute Fear and activates LC and whether tDCS safely inhibits the LC response to 7.5% CO2 compared with sham in a pilot cross-over trial (N=10). A 3-year double-blind, randomized, controlled trial where clinical symptoms of Acute Fear, the primary outcome are elicited with 7.5% CO2 in healthy volunteers is the final study component.
89478926|NCT03558607|Experimental|Experimental arm|
89478927|NCT02083393||Patients with acute lung injury|Patients with sepsis induced acute lung injury
89478928|NCT02083393||Postsurgery patients|Postsurgery patients without acute lung injury and sepsis
89478929|NCT02083471|Active Comparator|SOTI|Specific Oral Tolerance Induction with Egg or Cow's milk
89478930|NCT02083471|No Intervention|Food Allergy follow-up|
89478931|NCT03559777|Active Comparator|closed sinus lifting by Osteotome|"Local anesthesia will be injected intra-orally~A full thickness flap will be elevated~A pilot drill will be used to start the osteotomy preparation, which should be ended 1mm short of sinus floor.~The widening drills can be sequentially used to widen the osteotomy site to the same level~An osteotome of diameter a little less than the planned implant body, will be inserted in the prepared osteotomy site and gently tapped to reach the same level.~The osteotome will be tapped gently to fracture up the sinus floor.~Xenograft will be added to the osteotomy as the grafting material.~Once the desired height of sinus elevation will be gained and grafted, the implant fixture will be inserted.~Smart peg will be placed on implant and Ostell will be used to record ISQ.~Healing collar will be placed on implant.~Suturing the flab around healing collar."
89478932|NCT03559777|Experimental|closed sinus lifting by Densah bur|"Local anesthesia will be injected intra-orally~A full thickness flap will be elevated~A pilot drill will be used to start the osteotomy , which should be ended 1mm short of sinus floor.~Change the drill motor to reverse- densifying Mode~Begin with the densah bur (2.5mm) until 1 mm short of the sinus floor.~Use the next wider Densah Bur (3.0) in densifying-mode until feeling the haptic feedback of the bur reaching the dense sinus floor, modulate pressure with a gentle pumping motion to advance past the sinus floor in 1 mm increments.~densah burs (3.5mm) advance in the osteotomy.~Xenograft will be added to the osteotomy .~Once the desired height of sinus elevation will be gained and grafted, the implant fixture will be inserted.~Smart peg will be placed on implant and Ostell will be used to record ISQ.~Healing collar will be placed on implant.~Suturing the flab around healing collar."
89478933|NCT02079103|Experimental|Virtual reality|Virtual reality training using the YouGrabber® for patients with impaired arm motor function after stroke. The YouGrabber exercises focus on intensity, repetitions and motivating tasks and are adapted to the patient's motor abilities.
89478934|NCT02079103|Active Comparator|Conventional arm training|The patients receive supervised self-training exercises with focus on functional tasks adapted to their motor abilities.
89478935|NCT02081833||Reminder group|the reminder group receives every 2 weeks a reminder to fill out the symptom diary (postcard or SMS)
89478936|NCT03559309|Other|Alirocumab|Medical Treatment (Clinical Routine)
89537556|NCT03063957||Microscopic Colitis|Patients with confirmed microscopic colitis
89020544|NCT03839758|Experimental|TSA blueprint|This group will include patients schedule for a total shoulder arthroplasty. Glenoid preparation will be done using the personalized guide provided by Wright-Tornier. This guide will be ordered after CT-scan measurement, using Blueprint software prior to surgery.
89020545|NCT03839758|Experimental|RTSA blueprint|This group will include patients schedule for a reverse total shoulder arthroplasty. Glenoid preparation will be done using the personalized guide provided by Wright-Tornier. This guide will be ordered after CT-scan measurement, using Blueprint software prior to surgery.
89020546|NCT03835520|Experimental|MOLECULAR TARGETED THERAPIES|Immunotherapy will be administered according to standard of care and reimbursement modalities in Belgium. Targeted agents will be administered according to manufacturer's instructions.
89020547|NCT03835520|Experimental|IMMUNOTHERAPY|Immunotherapy will be administered according to standard of care and reimbursement modalities in Belgium.
89202964|NCT04003402|Experimental|Sequence 4: Participants receiving treatment sequence D,C,B,A|"Eligible participants will received treatment sequence D, C, B, A. Each participant will receive a single oral dose and each treatment period has a minimum of a 14 day washout period between investigational product administration.~D = Placebo ASP8062 with Placebo Alcohol; C= Placebo ASP8062 with Alcohol; B= ASP8062 with Placebo Alcohol; A= ASP8062 with Alcohol"
89202965|NCT04045860|Experimental|CDT for head and neck lymphedema|Complete Decongestive Therapy
89202966|NCT04045860|Other|Standard of Care for head and neck lymphedema|Observation
88950853|NCT04961320|Experimental|Supportive care (OT, questionnaires)|Patients participate in OT sessions weekly for 3 weeks over 30 minutes each. Patients also complete questionnaires to assess anxiety, depression, fatigue and pain at baseline, 5 and 12 weeks.
88950854|NCT04934397|Experimental|Study Infant Formula|Feed ad libitum during study period
88950855|NCT04927585|Experimental|Group 1 (Treatment): DNA Vaccine + Protein Vaccine/GLA-SE|Participants will receive 2 mg of env (A,B,C,A/E)/gag (C) DNA vaccine and 400 mcg of gp120 (A,B,C,A/E) protein vaccine admixed with GLA-SE adjuvant at Day 0, and Months 3, 6, and 12.
88950856|NCT04927585|Placebo Comparator|Group 1 (Control)|"Participants will receive placebo at Day 0, Months 3, 6, and 12.~Interventions:"
89478937|NCT02079337|Active Comparator|Deep NMB|Videorecordings and subjective ratings of intraabdominal surgical conditions during deep neuromuscular blockade and without neuromuscular blockade
89478938|NCT02079337|Placebo Comparator|No NMB|Videorecordings and subjective ratings of intraabdominal surgical conditions during no neuromuscular blockade and during deep neuromuscular blockade.
89478939|NCT02083549||Trauma 1 massively transfused|Trauma 1 massively transfused patients are identified as a Trauma level one patient by triage through guidelines from the Kessler Regional Trauma Center Trauma Triage Guidelines.
89478940|NCT02083627|Experimental|1:Single rosuvastatin,multiple fidaxomicin,single rosuvastatin|
89478941|NCT02083627|Experimental|2:Multiple fidaxomicin,single rosuvastatin,single rosuvastatin|
89478942|NCT02083705|Experimental|SI+CC|"Chest compression will be superimposed by sustained inflations during CPR:~CC+SI group Infants randomized in the SI group requiring CC, would receive CC at a rate of 90/min during an SI with a duration of 20sec (CC+SI). After 20 sec the SI will be interrupted for 1 sec and the next SI will be started for another 20sec13. Throughout this time CC is continued until ROSC. Every 45 sec (approximately 2 SIs) the clinical team would assess for changes in heart rate. CC+SI was continued until ROSC."
89478943|NCT02083705|Active Comparator|3:1 CPR|"CPR using 3:1 C:V ratio:~3:1 C:V group Infants randomized into the 3:1 group requiring CC, would received CC using the current 3:1 C:V ratio recommend in the neonatal resuscitation guidelines16. Every 45 sec the clinical team would assess heart rate. 3:1 C:V CPR was continued until ROSC."
89478944|NCT02083939||Antibiotic Prophylaxis|This cohort will receive antibiotic prophylaxis prior to the hernia repair
89478945|NCT02083939||No Antibiotic Prophylaxis|This cohort will not receive antibiotic prophylaxis prior to the surgery
89478946|NCT02084017|Active Comparator|Current Standard|Standard Tegaderm (3M Healthcare, St. Paul, MN) adhesive dressing applied under sterile conditions in the operating room following skin closure. Dressing changed post-operative day two and daily thereafter with daily inspection for infection by a physician.
89478947|NCT02084017|Experimental|Negative Pressure Wound Therapy|A negative pressure therapy (Kinetic Concepts, Inc, San Antionio, Tex) device will be applied under sterile conditions post-operatively and placed on suction (125-150 cm H2O). The device will be removed on post-operative day 4-7 depending on day of discharge.
89478948|NCT02079493||Total Knee Arthroplasty patients|TKA patients
89478949|NCT02079571|Experimental|water+ Coconut water|forty subjects
89478950|NCT02079571|Experimental|ginger tea +water|
89478951|NCT02079727|Experimental|Condrosulf (Chondroitin 4&6 sulfate)|1 tablet of Condrosulf 800 mg and 1 capsule of placebo of Celebrex once a day for 182 days
89478952|NCT02079727|Placebo Comparator|Placebo (PBO) 800 mg tablet and Placebo (PBO) 200 mg capsule|1 tablet of PBO of Condrosulf and 1 capsule of PBO of Celebrex, once a day for 182 days
89478953|NCT02079727|Active Comparator|Celebrex 200 mg capsule|1 capsule of 200 mg of Celebrex and 1 tablet of 800 mg placebo of Condrosulf once a day for 182 days
89478954|NCT02081989|Experimental|Denervation|Renal denervation
89478955|NCT02081989|No Intervention|No intervention|Control group - no intervention
89478956|NCT02084173|Other|MET|Motivational Enhancement Therapy (MET)
89202967|NCT00576056|Experimental|Tace and Sorafenib|Patients with unresectable HCC will be treated with TACE in combination with oral sorafenib administration. TACE will be accomplished with gelatin microspheres (Embospheres) following delivery of 125 mg/m2 of cisplatin. Oral sorafenib (400 mg BID) will start the next day after the first TACE treatment.
89202968|NCT00798798|Experimental|Implantable Tissue Expansion Device|Will apply externally implantable tissue expansion device for 2 days
88950857|NCT04927585|Experimental|Group 2 (Treatment): Admixture of DNA Vaccine and Protein Vaccine|Participants will receive admixture of 2 mg of env (A,B,C,A/E)/gag (C) DNA vaccine and 400 mcg of gp120 (A,B,C,A/E) protein vaccine (no adjuvant) at Day 0, and Months 1, 3, 6, and 8.
88950858|NCT04927585|Placebo Comparator|Group 2 (Control)|"Participants will receive placebo at Day 0, and Months 1, 3, 6, and 8.~Interventions:"
89478957|NCT02084173|Other|MET + CRA|Motivational Enhancement Therapy (MET) with subsequent add-on The Community Reinforcement Approach (CRA)
89478958|NCT02082067|Experimental|Adductor canal|All patients in the arm will receive continuous adductor canal block under ultrasound guidance. 10ml of Ropivacaine 0,75%, BBraun, Germany, will be injected to dilate adductor canal. After catheter insertion 10ml of Ropivacaine 0,75% will be injected.
89478959|NCT02082067|Active Comparator|Femoral|All patients in the arm will receive continuous femoral nerve block under ultrasound guidance. Correct position of catheter will be check with injection of 20ml Ropivacaine 0,75% BBraun, Germany medial to femoral nerve.
89478960|NCT02082067|Placebo Comparator|Controls|No patients of this arm receive continuous nerve block. Intravenous opioids analgesia will be administered.
89478961|NCT02084251|Experimental|Exenatide analogue, Injection|PB-119 will be administered once weekly subcutaneously at dosage of 2μg、5μg、10μg、25μg、50μg、100μg、200μg or 400μg.
89478962|NCT06131918|Active Comparator|Resveratrol+ Alpha lipoic acid +Superoxide dismutase|This group will receive Resveratrol 1500 mg BD Tab Alpha lipoic acid 600 mg BD Tab Superoxide dismutase 250 mg BD
88950859|NCT04922411|Experimental|Post-Surgical Group|STN DBS: Subjects with PD and DBS STN implanted will be scanned and tested with DBS ON and OFF
88950860|NCT04912557||Patients|Open major abdominal surgery patient (predicted operative time ≥ 2 hours) with Peridural Analgesia accepted
89478963|NCT06131918|Active Comparator|Resveratrol|This group will receive Tab Resveratrol 1500 mg BD
89478964|NCT06131918|Active Comparator|Alpha lipoic Acid|This group will receive Tab Alpha lipoic acid 600mg BD
89020548|NCT03824769|Active Comparator|Behavioral Weight Loss Maintenance + Healthy Thinking|Contingent upon participants losing 5% of body weight or more in Phase I (weight loss) of this trial, participants will receive a 4-month behavioral weight maintenance intervention consisting of 7 sessions that focus on evidence-based weight management strategies focused on diet, exercise, and behavioral skills. In this treatment, participants will be asked to read short passages related to nutrition and a healthy lifestyle through our study website twice a day for the duration of treatment.
89020549|NCT03824769|Experimental|Behavioral Weight Loss Maintenance Treatment + Future Thinking|Contingent upon participants losing 5% of body weight or more in Phase I (weight loss) of this trial, participants will receive a 4-month behavioral weight maintenance intervention consisting of 7 sessions that focus on evidence-based weight management strategies focused on diet, exercise, and behavioral skills. In this treatment, participants will create descriptions of upcoming positive events and will be asked to read short passages through our study website at least twice a day for the duration of treatment.
89020550|NCT03821233|Experimental|ZW49|
89020551|NCT03793478|Experimental|All Participants|All participants will receive re-induction therapy that includes fludarabine and cytarabine in combination with experimental drug quizartinib. For prophylaxis, IT chemotherapy with cytarabine, methotrexate and prednisolone/hydrocortisone will be given prior to or between re-induction cycles. After completing re-induction therapy, eligible participants may also receive optional consolidation chemotherapy which includes cytarabine, etoposide and quizartinib, if HSCT is not available immediately. After completing re-induction or HSCT successfully, eligible participants can go on to receive continuation therapy with quizartinib.
89020552|NCT03757299|Experimental|Self HPV|
89020553|NCT03736213|Experimental|Visual-acoustic biofeedback|Visual-acoustic biofeedback treatment targeting /r/ distortions.
89020554|NCT03736213|Experimental|Ultrasound biofeedback|Ultrasound biofeedback treatment targeting /r/ distortions.
89020555|NCT03725332|Experimental|Telemedicine Education|This is a stratified cluster randomized controlled trial with randomization of participating clusters into a 'telemedicine' or 'group care' arm. Sites will be stratified into 'high volume' (>500 deliveries/year) and 'low volume' (<500 deliveries per year). Randomization will be within each strata. Patients attending sites randomized to telemedicine will be recruited by research staff.
89020556|NCT03725332|Active Comparator|Group Care Education|This is a stratified cluster randomized controlled trial with randomization of participating clusters into a 'telemedicine' or 'group care' arm. Sites will be stratified into 'high volume' (>500 deliveries/year) and 'low volume' (<500 deliveries per year). Randomization will be within each strata. Patients attending sites randomized to group care will be recruited by research staff.
89020557|NCT03693521|Experimental|Intervention group|Standard care at yearly check-up by diabetes-nurse in primary care. Handgrip strength measurement bilaterally. Measurement of physical activity level.
89020558|NCT03693521|Active Comparator|Control group|Standard care at yearly check-up by diabetes-nurse in primary care. Measurement of physical activity level.
89020559|NCT03684564|Experimental|Rivaroxaban (Treatment Arm)|
89020560|NCT03684564|Active Comparator|Warfarin (Control Arm)|
89020561|NCT03672825|Experimental|RECLAIM|Treating cartilage defects with autologous (your own) cartilage cells mixed with allogeneic (from someone else) adipose-derived mesenchymal stem cells (AMSCs).
89020562|NCT03643939|Experimental|High Flow Nasal Catheter|The HFNC (AIRVO2 Fisher & Paykel, Auckland, New Zealand) consists of an apparatus that allows adjustable FiO2 from 21 to 100% and delivers flow up to 60 L/ min.
89020563|NCT03643939|Active Comparator|Non-invasive positive pressure ventilation|NIPPV will be performed using the devices available on centers. Both a dedicated NIPPV device or invasive mechanical ventilator with NIPPV mode are accepted. The interface should be a oronasal or full face mask.
89020564|NCT03617692||Oral Cannabis|This is an observational study of individuals who have already decided to try cannabis for their cancer treatment-related symptoms. A research assistant will provide information on the range of edible cannabis products and basic information about their various cannabinoid profiles, approximate prices, and nearby locations where participants may choose to purchase their product. Participants will then initiate use of an orally administered product they have selected and obtained. Participants will take the product as they see fit, without any frequency or dosing instructions from study staff, for two weeks.
89020565|NCT03609853|Placebo Comparator|Placebo|Placebo (5mL distilled water)
89020566|NCT03609853|Experimental|Vaporized low THC|15mg of pure THC
89020567|NCT03609853|Experimental|Vaporized high THC|30mg of pure THC
89020568|NCT03609853|Experimental|Vaporized low d-limonene|1mg of d-limonene
89020569|NCT03609853|Experimental|Vaporized high d-limonene|5mg of d-limonene
89020570|NCT03609853|Experimental|Low THC and low d-limonene|15mg of THC paired with 1mg of d-limonene
89020571|NCT03609853|Experimental|High THC and low d-limonene|30mg of THC paired with 1mg of d-limonene
89020572|NCT03609853|Experimental|Low THC and high d-limonene|15mg of THC paired with 5mg of d-limonene
89020573|NCT03609853|Experimental|High THC and high d-limonene|30mg of THC paired with 5mg of d-limonene
89478965|NCT06131918|Active Comparator|Superoxide dismutase|This group will receive Tab Superoxide dismutase 250mg BD
89478966|NCT06131879|Experimental|Laser acupuncture|Laser acupuncture biostimulation for temporalis and masseter muscles
89478967|NCT06131879|Experimental|Modified physical therapy|Muscle relaxation and biofeedback for temporalis and masseter muscles
89537557|NCT03063957||Control|Patients that are not diagnosed with microscopic colitis
89020574|NCT03609853|Experimental|High THC and 15mg d-limonene|30mg of THC paired with 15mg of d-limonene
89478968|NCT06131814|Experimental|Group 1|:- The INT program will involve a standard warm-up and cool down. The INT program involve exercises aimed at improving core stability, power, and strength. These exercises will progressed to more demanding exercises over the 8-week training program. The intensity increased by adding more repetitions, resistance, and through exercise modifications. Integrated resisted exercises include opposite arm and leg lift, bridging, side lying lift, ball back extension, push up 5 times repetition twice a week in first 4 week and then progress to 10 times repetition twice a week from 5-8th week of session
89478969|NCT06131814|Experimental|Group 2|The ISO program involved participants first performing a series of standardized warm up and cool down exercises before and after the training program, respectively. Specifically, the participants rode a stationary bike for 10 minutes followed by static stretching of the calves, hip flexor, and low back. The ISO program began with 5 time repetition and lower body resistance exercises for the first 4 weeks and progressed to 10 exercises for the last 4 weeks. The exercise resistance used in the ISO program also progressed over the 8 weeks. The static stretches were repeated as part of the cool down after completing the ISO program. Isolated exercises include leg press, bench press, Ab crunch, barbell curl and back squat
89478970|NCT06131749||Pregnant women|No intervention. Followed during pregnancy at baseline and 30-34 weeks. Followed after delivery at 3-6 days.
89478971|NCT06131736|Experimental|Tabata Training|HIIT training programs follow Tabata protocol. This protocol was created with the aim of improving the aerobic and anaerobic characteristics beyond the threshold (anaerobic). It consists of performing seven or eight repetitions at maximum intensity, alternating with ten seconds of passive recovery. The series lasts approximately four minutes (240 sec). Given the intensity of the Tabata protocol, it is necessary to finish the workout with a cool down of at least 10-15 minutes. It includes exercises like push-ups, split squats, box jumps, burpees, jumping rope, jumping jacks and more. This training program, lasting about 20 minutes, was repeated three times a week for a total of 6 weeks. The duration of this type of work is not accidental. In fact, it has been scientifically established that only after this period it is possible to find significant improvements in speed, strength and functional activity
88950861|NCT04911478||Subjects from Adicet Bio allogeneic γδ CAR T cell interventional studies.|"This is a rollover protocol designed to provide long-term follow-up to all subjects previously enrolled in Adicet Bio allogeneic γδ CAR T cell study.~Patients will be followed for up to 15 years post treatment of Adicet Bio allogeneic γδ CAR T cell investigational products."
88950862|NCT04898478|Experimental|Treatment Seeking Intervention for Pacific Islanders with Opioid Use Disorders|This arm will consist of a behavioral intervention to increase treatment seeking among Pacific Islanders with opioid use disorders.
88950863|NCT04885946|Experimental|Vancomycin 125 x 4 for 10 days + 2 Fecal Microbota Transplantation|Patients are required to undergo full treatment with vancomycin and are randomized following completion to, in this arm, FMT.
88950864|NCT04885946|Placebo Comparator|Vancomycin 125 x 4 for 10 days + 2 Placebo|Patients are required to undergo full treatment with vancomycin and are randomized following completion to, in this arm, placebo.
88950865|NCT04885946|Other|Open-label for screened, but not randomized patients with fulminant CDI|This arm exists for patients with fulminant CDI and for randomization to placebo may be considered unethical.
88950866|NCT04787315|Active Comparator|Intensive rehabilitation without workstation|
88950867|NCT04787315|Experimental|Intensive rehabilitation with workstations|
89478972|NCT06131736|Experimental|Cluster Traning|The cluster training consist squat, leg extension, leg curl, heel raise, French curl, barbell curl, Bench press, Incline bench press, behind the neck press with barbell, Overhead press with barbell. The movements were performed in 3 sets, each set containing 9 repetitions with 60-90 seconds of rest between each two sets. Each training session consisted of three steps: Warm up Basic training and Cool-down. Both groups performed the first and the third stage in 10 minutes
89478973|NCT06131697|Experimental|McKenzie Exercises without Mulligan Mobilization|McKenzie Exercises including retraction with neck flexion, extension, lateral flexion and rotation exercises.
89478974|NCT06131697|Experimental|McKenzie Exercises with Mulligan Mobilization|McKenzie Exercises including retraction with neck flexion, extension, lateral flexion and rotation exercises and Sustained Natural Apophyseal glide.
89478975|NCT06131684|Active Comparator|Intrauterine pressure catheter (IUPC) present|An IUPC is placed through the standard of care.
89478976|NCT06131684|Active Comparator|Intrauterine pressure catheter (IUPC) absent|No IUPC is required
89478977|NCT06131606|Experimental|experimental group|During the angiography, the researcher asked the patient to squeeze the stress ball once for every count of three. The angiography procedure lasted approximately 25-30 minutes.
89478978|NCT06131606|No Intervention|control group|No intervention other than the clinic protocol was applied to this group.
89478979|NCT06131580|Other|Participant Group/Arm|"Other: osilodrostat~open label, with patients receiving same dose as provided in the parent study"
89478980|NCT06131489||EBV-HLH patients with intestinal involvement|Epstein-Barr virus associated hemophagocytic lymphohistiocytosis patients with imaging confirmed intestinal involvement
89478981|NCT06131476|Experimental|Test/Control|Eligible subjects who are habitual soft contact lens wearers will be randomized into the Test/Control sequence, to receive the TEST lubricating eye drops, with a washout period of 90 minutes between instillations. After the wash-out period, the CONTROL lubricating eye drops will be instilled.
89478982|NCT06131476|Experimental|Control/Test|Eligible subjects who are habitual soft contact lens wearers will be randomized into the Test/Control sequence, to receive the CONTROL lubricating eye drops, with a washout period of 90 minutes between instillations. After the wash-out period, the TEST lubricating eye drops will be instilled.
89478983|NCT06131411|Experimental|Intervention|Health promotion intervention
89478984|NCT06131411|Placebo Comparator|Control|Usual care
88950868|NCT04766476|Experimental|Active Treatment (BMS-963272) Dosing Regimen 1|
88950869|NCT04766476|Experimental|Active Treatment (BMS-963272) Dosing Regimen 2|
89478985|NCT06131359||Younger adults|age 18-35 years
89478986|NCT06131359||Older adults|age over 55 years
89478987|NCT06131346||Patients with anti-IgLON5 antibodies|Adults patients who tested positive for anti-IgLON5 antibodies in the French Reference centre of Autoimmune Encephalitis
89478988|NCT06131333||Complex PCI|All consecutive patients with complex coronary artery disease (CAD) were treated with percutaneous coronary intervention (PCI). The complexity of CAD was defined as having at least one of the following characteristics: chronic total occlusion (CTO), lesion length >40 mm, severe calcification assessed by angiography or intravascular imaging examination, multivessel PCI during the same intervention, or true bifurcation defined as any lesion involving both the main vessel (MV), proximal or distal and the ostium of the side branch (SB) (Medina 1,1,1; 1,0,1; or 0,1,1).
88950870|NCT04766476|Placebo Comparator|Placebo|
89202969|NCT05360602|Experimental|Control group|30 STEMI patients undergoing PCI who will receive standard of care for 1 week that will include the required antiplatelet (Dual Antiplatelet Therapy; DAPT), anticoagulants, and anti-ischemic measures (high-intensity statin, ACEI, or aldosterone) as per latest guidelines recommendations.
89202970|NCT05360602|Experimental|Test group|30 STEMI patients undergoing PCI who will receive the standard of care in addition to IV Alpha Lipoic Acid 600 mg before PCI then 600 mg orally for 1 week after PCI
89478989|NCT06131320||CP child|
89478990|NCT06131320||CP child with a PVSE test and a cerebral MRI performed during his/her follow-up|
88950871|NCT04725864|No Intervention|No progesterone|Patients will have FET in natural cycles with no extra intervention.
88950872|NCT04725864|Experimental|Progesterone for 3 weeks|At day LH+3 patients will start treatment with vaginal progesterone tablet at 100mg three times daily for three weeks.
88950873|NCT04725864|Experimental|Progesterone for 7 weeks|At day LH+3 patients will start treatment with vaginal progesterone tablet at 100mg three times daily for seven weeks.
89202971|NCT00793728|Active Comparator|Antrectomy|
89478991|NCT06131294|Experimental|Expermental Fluoride Application|The two-step system, consisting of Component A (ammonium fluoride solution) and Component B (calcium fluoride application), will be applied once on the white spot lesions one.
89478992|NCT06131294|Active Comparator|Fluor Protector S|The ammonium fluoride gel will be applied once on the white spot lesions.
88950874|NCT04721821||Patients with Rheumatoid Arthritis (RA)|
88950875|NCT04700059|Experimental|Intervention|10 perinatal home visits
89478993|NCT06131268|Experimental|Patients with Major Depression (Group 1)|They will be evaluated at baseline (T0) and at 4 weeks from the setting of drug treatment with venlafaxine (T1)
89478994|NCT06131268|No Intervention|Bipolar disorder patients (Group 2)|Venlafaxine will not be administered. They will be valuated both at T0 and after 4 weeks (T1).
89478995|NCT06131268|No Intervention|Healthy controls (Group 3)|Venlafaxine will not be administered. They will be evaluated only at baseline (T0).
89478996|NCT06131255||Women with Post-Partum Depression|15 women with PPD referred to the S.C. Psychiatry of IRCCS Ca' Granda Ospedale Maggiore Policlinico Foundation and referred to the S.C. Neonatology and Neonatal Intensive Care Unit of the same institution for enrollment.
88950876|NCT04700059|No Intervention|Usual care|Routine medical care for mother and infant. Access to online resources.
88950877|NCT04688333|Experimental|Supportive care (iConquerFear program, questionnaires)|Patients complete 5 sessions of iConquerFear program online over 5 weeks. Patients also complete questionnaires at baseline, after the intervention, and 2 months later.
88950878|NCT04655391|Experimental|Chapter 1 (glasdegib, decitabine, venetoclax)|"MOLECULAR DIAGNOSIS SEGMENT: Patients receive glasdegib PO QD for at least 14 days until their AML TAC recommendation is made and they are either consented to a treatment arm in the Treatment Segment or go off study.~TREATMENT SEGMENT: Patients receive glasdegib PO QD on days 1-28,decitabine IV over 1 hour on days 1-5, and venetoclax PO QD on days 1-14. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity."
89478997|NCT06131229|Experimental|Structured emotional education program (PEE)|A tutorial action focused on a structured program of emotional education with 20 activities divided into 5 blocks with specific objectives. The program involves 34 hours of group work, one per week in the tutoring hour, throughout the 23-24 school year.
88950879|NCT04655391|Experimental|Chapter 2 (glasdegib, gilteritinib)|"MOLECULAR DIAGNOSIS SEGMENT: Patients receive glasdegib PO QD for at least 14 days until their AML TAC recommendation is made and they are either consented to a treatment arm in the Treatment Segment or go off study.~TREATMENT SEGMENT: Patients receive glasdegib PO QD and gilteritinib PO QD on days 1-28. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity."
88950880|NCT04655391|Experimental|Chapter 3 (glasdegib, bosutinib)|"MOLECULAR DIAGNOSIS SEGMENT: Patients receive glasdegib PO QD for at least 14 days until their AML TAC recommendation is made and they are either consented to a treatment arm in the Treatment Segment or go off study.~TREATMENT SEGMENT: Patients receive glasdegib PO QD and bosutinib PO QD on days 1-28. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity."
88950881|NCT04655391|Experimental|Chapter 4 (glasdegib, ivosidenib)|"MOLECULAR DIAGNOSIS SEGMENT: Patients receive glasdegib PO QD for at least 14 days until their AML TAC recommendation is made and they are either consented to a treatment arm in the Treatment Segment or go off study.~TREATMENT SEGMENT: Patients receive glasdegib PO QD and ivosidenib PO QD on days 1-28. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity."
88950882|NCT04655391|Experimental|Chapter 5 (glasdegib, enasidenib)|"MOLECULAR DIAGNOSIS SEGMENT: Patients receive glasdegib PO QD for at least 14 days until their AML TAC recommendation is made and they are either consented to a treatment arm in the Treatment Segment or go off study.~TREATMENT SEGMENT: Patients receive glasdegib PO QD and enasidenib PO QD on days 1-28 .Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity."
88950883|NCT04647994||Covid-19 HC patients|Pregnant women hospitalized with symptoms and diagnosis of SARS-CoV-2 at HC-FMUSP.
88950884|NCT04647994||Delivery patients|Asymptomatic pregnant women that tested SARS-CoV-2 serology (positive or negative serology) at the delivery time at Universitarian Hospital HU-USP and HC-FMUSP.
89202972|NCT00793728|Active Comparator|Without antrectomy|
89478998|NCT06131229|Active Comparator|Incidental tutorial action based on the school's regular curriculum (PCO)|An incidental tutorial action focused on the ordinary school curriculum for the 23-24 school year.
89478999|NCT06131216|Experimental|SHR-2022 Injection|
89479000|NCT06131190|Experimental|study group|ADHD child who exposed to mindfulness training
89479001|NCT06131190|No Intervention|control group|ADHD child take only pharmocological intervention
89479002|NCT06131177|Experimental|Treatment|Patients are treated with supplementary protein drink
89479003|NCT06131177|No Intervention|SOC (standard of Care)|Patient are provided normal hospital diet or meal
89479004|NCT06131151|Experimental|External Oblique Intercostal Block|27 patients will receive External Oblique Intercostal Block. A volume of 20 ml of LA (20 ml of bupivacaine 0.375% plus 5 ug/ml adrenaline ) will be injected.
89479005|NCT06131151|Experimental|Erector Spinae Plane Block|27 patients will receive Erector Spinae Plane Block. A volume of 20 ml of LA (20 ml of bupivacaine 0.375% plus 5 ug/ml adrenaline ) will be injected.
89479006|NCT06131138|Experimental|Aquatic exercises|Group A will perform aquatic exercises that includes abdominal hollowing, vertical downward press, lateral downard press, straight leg raising, trading water and deep water running. Three sessions per week for 6 weeks.
89479007|NCT06131138|Experimental|Core strengthening|Group B will perform core strengthening exercises that includes abdominal hollowing, side bridge, spine extension bridge, straight leg raise from prone, alternate arm and leg raise from quadruped and prone bridge. Three sessions per week for 6 weeks
89479008|NCT06131125|Experimental|Plyometric Training|Group A will perform plyometric training that includes squats, burpees, box jumps, tuck jumps, skaters hop, single-leg deadlift to jump. 10 reps of 3 sets with three sessions per week for 6 weeks.
89479009|NCT06131125|Experimental|Explosive Strength Training|Group B will perform explosive strength training that includes dumbbell push presses, sprint running, sled pushes, shuttle runs. 10 reps of 3 sets with three sessions per week for 6 weeks.
89479010|NCT06131086|Experimental|stabilization exercises|"Scapular stabilization exercise~Scapular Retraction Exercise:~2. Scapular Wall Slide: Stand with your back against a wall and your feet shoulder-width apart.Raise your arms to shoulder height with your elbows bent at a 90-degree angle, so that your hands are pointing up~Slide your arms up the wall as high as you can, while keeping your shoulder blades pinched together and down~Hold the position for 5-10 seconds, then slowly lower your arms back down to the starting position~Repeat for 10-15 repetitions"
89479011|NCT06131086|Experimental|stabilization exercises along with pectoralis minor stretching|"pectoralis minor stretch: Stand facing a wall or a doorway. Raise your right arm to shoulder height and place your right forearm against the wall or doorway, with your elbow bent at a 90-degree angle.~Step forward with your right foot until you feel a stretch in your chest and shoulder.~Slowly lean forward, keeping your arm against the wall or doorway, until you feel a deeper stretch in your chest and shoulder.~Hold the stretch for 10-15 seconds, then release and repeat on the other side. Repeat the stretch 2-3 times on each side."
89479012|NCT06131073|Experimental|speed endurance production (SEP) training along with conventional training.|"Group A along with conventional regime will be given SEP. It will be given 3 days/week.~The SEP protocol consisted of 6-8 reps of 20-s all-out bouts interspersed with 120 seconds of passive recovery between repetitions. During each 20-s bout, players carried out single shuttle runs of approximately 140-150 m (70-75 + 70-75 m, depending on the group) at their full maximal effort. SEP protocol will be given 3 times/ week for 8th weeks"
89479013|NCT06131073|Experimental|conventional exercise|"A standardized 10-minute warm-up consisting of jogging .~Multidirectional dynamic stretching of lower extremity muscles (Hamstring, Quadriceps Calf), for 30 seconds each~Jumping (submaximal ankle and squat jumps) will be used for all soccer players before regime starts~Exercises including squats; Nordic hamstrings; core rotations and barbell rowing, lunges , hamstrings kicks, side way lunges, standing chest press, crunches (90s rest); core rotations; bounding jumps and fast shifting lunges Each exercise will consists of 3*10, after each exercise 90 seconds rest will be given. These exercises will be given to 3 times a week for 8 weeks"
89479014|NCT06131060|Experimental|Progressive eccentric exercises|"Group A will perform progressive eccentric exercises that includes eccentric squats, Nordic hamstring curls and reverse Nordic hamstring curls.~Three sessions per week for 6 weeks."
89479015|NCT06131060|Experimental|Bodyweight exercises|"Group B will perform bodyweight exercises that includes Bulgarian split squat, Glut-Ham bridge, sliding leg curl.~Three sessions per week for 6 weeks."
89479016|NCT06131047|Experimental|High Intensity Traditional Resistance Training Group|Group A will undergo Traditional Resistance training without blood flow Restriction. A 30-minute progressive, weight training program will be initiated 8 weeks after the ACL-reconstruction and will be conducted subsequent to the individual based program. The resistance (training loads) will be increased when the individual could do more repetitions than the number specified in the weight training protocol. The exercises will be performed at a slow speed to ensure full control of the movement.
89479017|NCT06131047|Experimental|High Intensity Traditional Resistance Training with Blood Flow Restriction Group|Group B will perform low-load blood flow restriction (LL-BFR) training using external loads of 20-40% 1RM has been suggested as an alternative to traditional strength rehabilitation. Minimum of 2 -3 sets and maximum total 5 sets,20-30 repetitions of each exercise with 30 to 60 seconds rest period and 2-3 times per weekly for 4-6 weeks to During LL-BFR training, a pressurized cuff is applied to the proximal thigh that oc¬cludes venous outflow while maintaining arterial in¬flow. The combination of venous occlusion and resis¬tance training is believed to induce muscle hypertrophy secondary to elevated systematic hormone production, cell swelling, production of reactive oxygen species, intramus¬cular anabolic signaling and fast-twitch fiber recruit¬ment.(
89479018|NCT06131034|Experimental|Music group|
89479019|NCT06131034|No Intervention|Control group|
89479020|NCT06131021|Experimental|Test Arm|Patient participants in this arm will receive a combination of Amoxicillin 500mg & Metronidazole 500mg orally (AMXM) as adjuncts along with their scheduled non-surgical periodontal treatment as the study intervention. A loading dose of 1g of Amoxicillin and 1g of Metronidazole will be given 30-60 minutes prior to periodontal treatment. After the loading dose, each patient participant will be instructed to take Amoxicillin 500mg & Metronidazole 500mg every 8 hours for 10 days.
89479021|NCT06131021|Placebo Comparator|Control Arm|Patient participants in this arm will receive a placebo capsules identical to the study drug capsules along with their scheduled non-surgical periodontal treatment as the placebo comparator in an identical frequency and duration fashion as the active drug group.
89479022|NCT06131008|Experimental|Diastology-Guided Management|Participants in this arm will undergo a focused echocardiogram every 24 hours. The degree of diastolic dysfunction will be reported to the healthcare team. If the degree of diastolic dysfunction is greater than or equal to grade 2, the research team will recommend escalating the diuretic regimen if either (1) urine output is less than 4,000 mL over 24 hours or (2) weight loss is less than 2 kg over 24 hours. If the degree of diastolic dysfunction is grade 1, the research team will recommend transitioning to or discontinuing oral diuresis.
89479023|NCT06131008|Active Comparator|Usual Care|Participants in this arm will also undergo a focused echocardiogram every 24 hours. However, the results of these echocardiograms will not be available for clinical decision-making. Instead, participants will receive usual care by the healthcare team without daily hemodynamic parameters from a study echocardiogram.
88950885|NCT04647994||Prenatal patients|Pregnant women that performs prenatal care in Universitarian Hospital HU-USP or HC-FMUSP with diagnosis of SARS-CoV-2.
89479024|NCT06130982|Experimental|EG1:Health Qigong·Yijinjing|HQ·Yijinjing includes the following 10 movements:Wei Tuo Presenting the Stick1-3,Picking the star and Embracing the Moon,Hauling Nine Cattle's Tails Inversely,Pushing out the Palms Like Birds Extending the wings,Nine Ghosts Pulling Horse Blade Technique,Three Trays Falling Down,Black Dragon Streching out the Claws,Crouched Tiger,Pouncing on Its Prey,Bowing Posture,Hips Hanging.
89479025|NCT06130982|Experimental|EG2:Health Qigong·Wuqinxi|HQ·Wuqinxi includes the following 10 movements:Tiger Lifting,Tiger Pouncing,Deer Wrestling,Deer Dashing,Bear Lumbering,Bear Swaying,Monkey Hooking,Monkey Picking,Crane Stretching,Crane Flying.
89479026|NCT06130982|Experimental|EG3:Health Qigong·Baduanjin|HQ·Baduanjin includes the following 8 movements:Supperting the Palms to the Sky to Regulate Qi of Sanjiao,Forward Lunge on the Right and Left Like Shooting an Eagle,Lifting One Arm to Regulate the Functions of Spleen and Stomach,Looking Backward to Treat Strain and Impairments,Swaying the Head and the Bottoms to Clear the Heat of Heart,Hands Grabbing Toes to Strengthen the Kidney and the Waist,Clenching Fists with Wild Eyes Glowering to Increase Strength,Raising and Lowering the Heels 7times to Alleviate Diseases.
89479027|NCT06130982|Other|CG:Walking|The control group underwent walking exercise, with a walking speed of 1.0 ± 0.2m/s based on age characteristics and human dynamic stability.
89479028|NCT06130956|Experimental|Vegan group|Subjects in the vegan group will receive a vegan diet during the 2-week preoperative period.
89479029|NCT06130956|Active Comparator|Omnivorous group|Subjects in the omnivorous group will receive an omnivorous diet during the 2-week preoperative period.
89479030|NCT06130904|Experimental|Academic detailing intervention|
89479031|NCT06130904|No Intervention|Control group|Control dentists will receive no intervention at all. Only dentist's prescribing data will be analyzed.
89479032|NCT06130852|Experimental|Behavioral Parent Training|"This program includes 10 thematic sessions aimed at changing the parent's view of their child by encouraging them to focus on appropriate behaviors. The sessions focus on specific themes such as positive attention, the principle of reinforcement, or even homework management.~This program combines knowledge about ADHD with behavioral and cognitive techniques."
89479033|NCT06130852|No Intervention|control group|no behavioral parent training
88950886|NCT04647994||Negative serology patients|Pregnant women that performs prenatal care with symptoms and tested serology/swab negative for SARS-CoV-2.
88950887|NCT04644861|Other|Elders aged 70|Program of adapted physical activity
88950888|NCT04635878||Sepsis group|patients suffering from sepsis hospitalized in intensive care unit
89479034|NCT06130839|Experimental|perturbation based training|"Stretching of the erector spinae,~latissimus dorsi, gluteus Medius, gluteus minimums, and gluteus maximus (knee to chest) Pelvic Bridging Exercises~Strengthening Exercises of latissimus dorsi muscle~Pelvic Bridging Exercises include the gluteus maximus and quadriceps~Rocker board:~Trunk control exercises on Rocker Board in standing position first in medio-lateral direction for 10 min and then in anterio-posterior direction for 10 min with breaks in between."
88950889|NCT04635878||Control group|patients without infection hospitalized in intensive care unit
88950890|NCT04609098|Active Comparator|Dihydroartemisinin-Piperaquine (DP)|Subjects will receive Dihydroartemisinin-Piperaquine (DP) once daily for 3 days, and a low dose of 1.66mg/kg, 0.83mg/kg, or 0.415mg/kg. Tafenoquine (TQ) on the first date of DP treatment.
88950891|NCT04609098|Experimental|DP with 0.415mg/kg Tafenoquine (TQ)|Subjects will receive Dihydroartemisinin-Piperaquine (DP) once daily for 3 days, and a single dose of 0.415mg/kg Tafenoquine (TQ) on the first date of DP treatment.
88950892|NCT04609098|Experimental|DP with 0.83 mg/kg TQ|Subjects will receive Dihydroartemisinin-Piperaquine (DP) once daily for 3 days, and a single dose of 0.83mg/kg Tafenoquine (TQ) on the first date of DP treatment.
88950893|NCT04609098|Experimental|DP with 1.66mg/kg TQ|Subjects will receive Dihydroartemisinin-Piperaquine (DP) once daily for 3 days, and single dose of 1.66mg/kg Tafenoquine (TQ) on the first date of DP treatment.
89479035|NCT06130839|Experimental|bobath based training|"Stretching of the latissimus dorsi muscle~Functional use and strengthening of the latissimus dorsi.~Functional strengthening of abdominal and oblique abdominal muscles~Placing exercises to facilitate trunk extension~Rotations and counter-rotations (right and left) of the hips with the trunk extended Training of lumbar spine stabilizers~Functional reach of shoulder, anterior, right, and left sides."
89479036|NCT06130800||Wheelchair|"The inclusion criteria to participate in the study are being in a wheelchair, preserved cognitive status and having sufficient ability to Oral occlusion for carrying out respiratory tests. The exclusion criteria are following: presence of respiratory diseases or in treatment of respiratory diseases, serious orthopedic diseases that interfere with measurements and those with a diagnosis of dementia. In addition, those who present any contraindication for carrying out the procedure will be excluded.~of the respiratory pressure measurement tests, as established in the SEPAR guidelines. The objectives of the study and the methodology to be used will be explained to all participants.~An information sheet will be provided and the informed consent sheet will be given to them."
88950894|NCT04605614|Experimental|Treatment (pembrolizumab, 64Cu-DOTA-pembrolizumab, PET)|Patients receive pembrolizumab IV over 30 minutes, and within 6 hours also receive 64Cu-DOTA-pembrolizumab via slow IV push over > 1 minute on day 0. Patients then undergo PET over 60 minutes on day 1.
88950895|NCT04560439|Experimental|Treatment (METFIT program)|Patients undergo METFIT program for 16 sessions over 6 months.
89479037|NCT06130800||wanderers|"The inclusion criteria to participate in the study are to have functional ambulation, preserved cognitive status and have sufficient ability to Oral occlusion for carrying out respiratory tests. The exclusion criteria are following: presence of respiratory diseases or in treatment of respiratory diseases, serious orthopedic diseases that interfere with measurements and those with a diagnosis of dementia. In addition, those who present any contraindication for carrying out the procedure will be excluded.~of the respiratory pressure measurement tests, as established in the SEPAR guidelines. The objectives of the study and the methodology to be used will be explained to all participants.~An information sheet will be provided and the informed consent sheet will be given to them."
88950896|NCT04475016|Experimental|Neoadjuvant Therapy|TIP (Paclitaxel + Ifosfamide + Cisplatin) & Nimotuzumab & Triprilimab
88950897|NCT04409743|Active Comparator|Immediate Treatment|The sleep treatment is Cognitive Behavioral Therapy for Insomnia (CBT-I). Participants randomized to this arm will begin treatment immediately after randomization.
88950898|NCT04409743|Other|Waitlist|The subjects assigned to the Waitlist condition will receive the same CBT-I treatment 7 months after randomization.
88950899|NCT04392180||Caregivers|"Caregivers who care for a child that is both under 3 years of age and has experienced acute pain.~This cohort will participate in a qualitative interview about pain assessment, treatment, and response to treatment in their child."
88950900|NCT04372680|Experimental|CTUS strategy group|CTUS examination will be performed until the day of patient extubation. CTUS examination will consist on a fully bedside ultrasonographic assessment of lung, cardiac and diaphragm functions
88950901|NCT04372680|No Intervention|standard strategy group|from the day of patient's inclusion and beyond every day, the clinical team in charge of patients will decide to perform or not an SBT following current recommendations2. These criteria are mainly based on clinical data and do not include any specific ultrasound assessment.
88950902|NCT04359056|No Intervention|control|patients for the observational phase. This corresponds to usual cares where no clinical pharmacy activities will be performed
88950903|NCT04359056|Experimental|Interventional|patients for the interventional phase where clinical pharmacy activities will be performed at each step of the care pathway: from hospitalization to home care.
88950904|NCT04352309||Participants Treated With Glecaprevir/Pibrentasvir (GLE/PIB)|Participants will receive GLE/PIB over 8 weeks of therapy as prescribed by their physicians.
88950905|NCT04331795|Experimental|Group A|Hospitalized, non-critically ill patients with COVID-19 pneumonitis with risk factors for decompensation
88950906|NCT04331795|Experimental|Group B|Hospitalized, non-critically ill patients with COVID-19 pneumonitis without risk factors for decompensation
88950907|NCT04321551|Experimental|Provocative Hormonal Testing|TGN subjects will undergo baseline endocrine and menstrual cycle evaluation, followed by intramuscular (i.m.) administration of testosterone cypionate (TC) 50 mg (standard dose) every 7 d for 32 wks (Fig. 8). After 24 wks, an aromatase inhibitor, letrozole (LET, 2.5 mg/d oral), will be co-administered with TC for 8 wks to block estrogen synthesis and examine whether T's effects are independent of E2 signaling.
88950908|NCT04295824||Mild AD|"20 subjects with mild local AD on their volar forearm (At least 10 with lesions on the face | At least 10 which are globally mild)."
88950909|NCT04295824||Moderate AD|"20 subjects with moderate local AD on their volar forearm (At least 10 with lesions on the face | At least 10 which are globally moderate)."
88950910|NCT04295824||Severe AD|"20 subjects with severe local AD on their volar forearm (At least 10 with lesions on the face | At least 10 which are globally severe)."
88950911|NCT04295824||Healthy|20 healthy volunteers
88950912|NCT04293679|Experimental|Cohort A: STP705 10 μg dose|Cohort A: STP705 10 μg dose, intradermal injection, given once a week for up to 6 weeks
88950913|NCT04293679|Experimental|Cohort B: STP705 20 μg dose|Cohort B: STP705 20 μg dose, intradermal injection, given once a week for up to 6 weeks
88950914|NCT04293679|Experimental|Cohort C: STP705 30 μg dose|Cohort C: STP705 30 μg dose, intradermal injection, given once a week for up to 6 weeks
88950915|NCT04293679|Experimental|Cohort D: STP705 60 μg dose|Cohort D: STP705 60 μg dose, intradermal injection, given once a week for up to 6 weeks
88950916|NCT04293679|Experimental|Cohort E: STP705 120 μg dose|Cohort E: STP705 120 μg dose, intradermal injection, given once a week for up to 6 weeks
89479038|NCT06130761|Experimental|PENG block (P group)|PENG BLOCK : 0.5 ml/kg of 0.25% bupivacaine is deposited between the psoas tendon anteriorly and pubic ramus posteriorly lifting it , and to perform the LFCN block 0.1 ml/kg of 0.25% bupivacaine is injected in lateral to femoral artery below anterior superior iliac spine .
88950917|NCT04252560||Colorectal|30 patients operated for colorectal cancer
88950918|NCT04252560||HIPEC|15 patients operated with CRS+HIPEC for peritoneal carcinomatosis
88950919|NCT04247269||Enteral formula standard|Children fed an intact protein formula
88950920|NCT04247269||Enteral formula semi-elemental|Children fed a semi-elemental protein formula
88950921|NCT04224792|Experimental|Center-based exercise group|Subjects will be enrolled into a center-based exercise program.
88950922|NCT04224792|Experimental|Home-based exercise group|Subjects will be enrolled into a home-based exercise program.
88950923|NCT04175730|Other|MRI and Ultrasound|men with elevated PSA or abnormal DRE for which prostate biopsy is indicated and mpMRI positive for suspected prostate cancer followed by MRI/ultrasound fusion directed prostate needle biopsies
88950924|NCT04175730|Other|Ultrasound|men with elevated PSA or abnormal DRE for which prostate biopsy is indicated and mpMRI negative for suspected prostate cancer followed by standard ultrasound guided prostate needle biospies
88950925|NCT04174781|Experimental|DEB-TACE+Sintilimab|Participants with BCLC Stage A/B Hepatocellular Carcinoma Beyond the Milan Criteria
88950926|NCT04156516|Experimental|HEART|sexual health intervention that focuses on communication skills
88950927|NCT04156516|Active Comparator|HealthyMinds|Attention-matched control: Growth mindset intervention
89479039|NCT06130761|Experimental|TQL block (Q group)|QL is usually identified medial to the aponeurosis of transversus abdominis muscle vertically attached above the iliac crest. A 22-gauge 50 mm needle will be inserted in the plane from the posterior edge of the convex probe through the QL in an anteromedial direction. The needle tip will be placed between the PM muscle and the QL muscle and the local anesthetic will be injected into the fascial plane after aspiration test is negative. A volume 0.5 ml/kg of 0.25% bupivacaine is injected with maximum dose 2.5mg per kg of bupivacaine
88950928|NCT04109963|Active Comparator|RIC once per day|RIC performed once a day on one arm. Each RIC session will consist of 4 cycles of unilateral or simultaneous bilateral upper arm ischemia for 5 minutes followed by reperfusion for another 5 minutes. The procedure will be performed by using an electric auto-control device with cuffs that inflate to a pressure of 200 mmHg during the ischemic period.
89479040|NCT06130748|Experimental|Hybrid Hyrax|"Device: Hybrid hyrax these patents will be treated using Two mini-screws supported hybrid hyrax~Other Names:~• MARPE(miniscrews-assisted rapid palatal expander)"
89479041|NCT06130748|No Intervention|Untreated control group|Ethically ,these patents will be treated at the end of the study using the same appliance used for the experimental group
89479042|NCT06130735|Experimental|Computerized Cognitive Training|See section of intervention/treatment for additional information.
89479043|NCT06130722|Experimental|A Single Arm|
89479044|NCT06130696|Experimental|Clamshell exercise|Clamshell exercise
89479045|NCT06130696|Active Comparator|strengthening exercises with clamshell exercise|Isometric and muscle strengthening exercises with clamshell exercise.
89479046|NCT06130657|Active Comparator|Group 1: Lateral Maxillary Sinus Floor Elevation using surgical guide|
89479047|NCT06130657|Active Comparator|Group 2: Lateral Maxillary Sinus Floor Elevation without surgical guide|
89479048|NCT06130644||Patients with lymph node metastasis|T1/2N+ patients
89479049|NCT06130644||Patients without lymph node metastasis|T1/2N- patients
89479050|NCT06130618|Active Comparator|Ozone injection|After localizing the piriformis muscle with ultrasound guidance, 5 ml - 20 μg/mL ozone will be injected.
89479051|NCT06130618|Active Comparator|Lidocaine injection|After localizing the piriformis muscle with ultrasound guidance, 5 ml - 2% lidocaine will be injected.
89479052|NCT06130605||people over the age of 18|people over the age of 18.
89479053|NCT06130592|Active Comparator|high risk of Arthrogryposis AMC|Patient with a diagnosis during the 1st, 2nd, or 3rd trimester ultrasound, of an abnormality of position / deformation of one or more joints, and / or an abnormality of fetal movements at screening ultrasound or interrogation
89479054|NCT06130592|Active Comparator|low risk of Arthrogryposis AMC|Patient coming for screening ultrasound
89479055|NCT06130488|Experimental|KMC implementation|KMC phases implemented as per the protocol
89479056|NCT06130475|Experimental|Oral Rehydration Solution|Oral rehydration solution with carbohydrate
89479057|NCT06130475|Experimental|Water|Water with flavor
89479058|NCT06130462|Active Comparator|LPT aluminium|Investigation of participants with aluminium allergy versus healthy controls. Aluminium in different concentrations are added to the blood samples to elicit a response
89479059|NCT06130462|Placebo Comparator|LPT control|Tetanus toxoid was added to blood samples as control substance.
89479060|NCT06130449|Placebo Comparator|Placebo|Participant-blinded (Ayr Saline Gel)
89479061|NCT06130449|Active Comparator|Intranasal TRT|Participant-blinded (11 mg of Natesto)
89479062|NCT06130436|Sham Comparator|Sham-Remote Ischemic Conditioning|Sham remote ischemic conditioning (Sham-RIC) is applied in the perioperative using an automated Sham-RIC device.
89479063|NCT06130436|Active Comparator|Remote Ischemic Conditioning Once Daily|Remote ischemic conditioning (RIC) is applied in the perioperative using an automated RIC device once daily.
89479064|NCT06130436|Active Comparator|Remote Ischemic Conditioning Twice Daily|Remote ischemic conditioning (RIC) is applied in the perioperative using an automated RIC device twice daily.
89479065|NCT06130397||Readers/participants|"Reader Selection: 18 readers will be selected from the following five clinical specialty groups (3 readers each):~Emergency Medicine~Trauma and Orthopaedic Surgery~Emergency Nurse Practitioners~Physiotherapy~General Radiology~Radiographers~And from the following level of seniority/experience:~Consultant/Senior/Equivalent - >10yrs experience~Middle Grade/Registrar/Equivalent - 5-10yrs experience~Junior Grade/Senior House Officer/Equivalent - <5yrs experience~Each specialty reader group will include 1 reader at each level of experience.~Readers will be recruited from across 5 NHS organisations which comprise the Thames Valley Emergency Medicine Research Network (www.TaVERNresearch.org):~Oxford University Hospitals NHS Foundation Trust~Royal Berkshire NHS Foundation Trust~Buckinghamshire Healthcare NHS Trust~Frimley Health NHS Foundation Trust~Milton Keynes University Hospital NHS Foundation Trust"
89479066|NCT06130397||Ground truthers|Two consultant musculoskeletal radiologists. A third senior musculoskeletal radiologist's opinion (>20 years experience) will undertake arbitration.
89479067|NCT06130345||Cohort 1: Influenza Vaccinated Concurrent Comparator|Participants who receive an elasomeran/davesomeran or an andusomeran vaccine in routine clinical practice are compared to participants who receive an influenza vaccine to observe differences in the rate of adverse events of special interest during an etiologically relevant window.
89479068|NCT06130345||Cohort 2: Medically Attended COVID-19 Concurrent Comparator|Participants who receive an elasomeran/davesomeran or an andusomeran vaccine in routine clinical practice are compared to participants who diagnosed with COVID-19 to observe differences in in the rate of adverse events of special interest during an etiologically relevant window.
89479069|NCT06130332|Experimental|PD-1 with chemotherapy|"Tirellizumab, Carboplatin,albumin-bound paclitaxel Patients receive Tirellizumab IV on day 1, albumin-bound paclitaxel IV on day 1 and carboplatin IV on day 1 . Treatment repeats every 21 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Then surgery.~Intervention: Drug: Tirellizumab, Carboplatin, albumin-bound paclitaxel:2 cycles~Surgery：Enlarged local excision，excision with the safe margin 1.0-1.5cm away from the original tumor"
89479070|NCT06130332|Other|upright surgery|"Surgery：Primary resection，excision with the safe margin 1.0-1.5cm away from the original tumor~selective neck dissection:I II III region neck dissection"
89479071|NCT06130306||Electrical Pudendal Nerve Stimulation Group|Electrical Pudendal Nerve Stimulation
89479072|NCT06130306||Pelvic Floor Muscle Training Group|Pelvic Floor Muscle Training Plus Transanal Electrical Stimulation
89020575|NCT03587272|Experimental|SUN regimen|"Alemtuzumab, low dose total body irradiation, Sirolimus~HLA-identical sibling donor transplantation using alemtuzumab, low dose total-body irradiation, and sirolimus (Sickle transplant Using a Nonmyeloablative approach, SUN) can decrease the toxicity of transplant while achieving a high cure rate for children with sickle cell disease (SCD)."
89479073|NCT06130293|Experimental|VR training|Using VR training. 40 minutes per session, one session per week, and a total 8 weeks.
89479074|NCT06130293|No Intervention|Waiting list group|
89479075|NCT06130267|Placebo Comparator|control condition|same paradigm without the active agent
89479076|NCT06130267|Experimental|Virtual Reality condition|calming VR environment
89479077|NCT06130241|Other|female with breast cancer and positive axillary lymphnodes|female patients with breast cancer with initially positive axillary lymphnodes who underwent neoadjuvant chemotherapy
89479078|NCT06130228|Experimental|Multi-ingredient supplement (PDT-MIS)|Multi-ingredient supplementation (PDT-MIS) consists of daily intake of high-quality proteins, creatine, vitamin D, calcium, plant extracts (green coffee bean, green tea, beet root, and forskolin), and Omega-3 fatty acids. Concurrent with supplementation, patients will do mixed rehabilitative exercise (cardio and strength) and respiratory muscle training four days a week.
89479079|NCT06130228|Placebo Comparator|Placebo (PLA)|Placebo (PLA) consists of daily intake of collagen, safflower, and microcrystalline cellulose. Concurrent with supplementation, patients will do mixed rehabilitative exercise (cardio and strength) and respiratory muscle training four days a week.
89479080|NCT06130202||NAFLD|
89479081|NCT06130176|Experimental|Single-step Functional Sinus Endoscopy and Transoral Surgery|The patients who will be included in this study will be treated by functional sinus endoscopy and transoral surgery to remove the dental cause in the same visit to treat odontogenic sinusitis. The functional sinus endoscopy will be performed by the otolaryngologist, while the transoral surgery will be performed by oral and maxillofacial surgeon.
89479082|NCT06130176|Active Comparator|Functional sinus endoscopy|The patients who will be included in this study will be treated by functional sinus endoscopy to treat odontogenic sinusitis, and it will be performed by the otolaryngologist.
89479083|NCT06130176|Active Comparator|Trans oral Surgery|The patients who will be included in this study will be treated by transoral surgery to treat odontogenic sinusitis, and it will be performed by by oral and maxillofacial surgeon
89479084|NCT06130163||Intraoperative ERCP|Patients with cholecystocholedocholithiasis getting intraoperative ERCP
89479085|NCT06130163||Splitting|Patients with cholecystocholedocholithiasis getting therapeutic splitting
89479086|NCT06130150||High-risk|This group includes pregnant women with the risk factors determined in the study
89479087|NCT06130150||Normal|This group includes pregnant women with no risk
89479088|NCT06130137||HIV|Patients with HIV infection
89479089|NCT06130137||HBV|Patients with HBV infection
89479090|NCT06129032|Active Comparator|Group Wound infiltration + Intraperitoneal local anaesthetic instillation|the surgeon will be given a solution containing 20 ml of 0.5% bupivacaine, 20 ml of 2% lidocaine and 1:200,000 epinephrine with a total volume of 40 ml. A volume of 10 millilitres of the solution will be administered through the drip technique into each of the four quadrants of the uterus prior to the subsequent closure of the parietal peritoneum or fascia. A total volume of 10 ml of the solution will be administered through infiltration at the edges of the rectus aponeurosis, while the remaining 20 ml will be infiltrated subcutaneously into the incision. Patients will receive 800mg of ibuprofen and 1g of paracetamol 30 minutes prior to the end of the procedure. Following the surgical procedure, each patient will get a dosage of 15 mg/kg paracetamol every 6 hours and 800 mg of ibuprofen every 8 hours for 24 hours.
89479091|NCT06129032|Active Comparator|Group QUADRATUS LUMBORUM BLOCK|In the QLB group, quadratus lumborum type 1 block will be applied bilaterally on both sides with a total of 40 ml of solution containing 20 ml of 0.5% bupivacaine + 20 ml of 2% lidocaine + 1:200.000 epinephrine, under ultrasound guidance. Patients will receive 800mg of ibuprofen and 1g of paracetamol 30 minutes prior to the end of the procedure. Following the surgical procedure, each patient will get a dosage of 15 mg/kg paracetamol every 6 hours and 800 mg of ibuprofen every 8 hours for 24 hours.
89479092|NCT06128928|Experimental|REDES: Motivational interviewing training|Participants in this arm will receive training on motivational interviewing (MI) to promote vaccine acceptance and uptake with their networks. The training will be led by community health workers on how to use MI to address vaccine hesitancy using a guiding approach, open-ended questions, affirmations, reflections, and summaries.
89202973|NCT00991744|Experimental|Liposomal cytarabine|Intrathecal liposomal cytarabine (25 - 50 mg) combined with intrathecal prednisolone sodium succinate and oral dexamethasone 6 times during maintenance treatment for high-risk ALL
89202974|NCT00991744|Active Comparator|Intrathecal triple|Intrathecal methotrexate, cytarabine and prednisolone
89479093|NCT06128928|Active Comparator|Control: COVID-19 vaccine information|Participants in the control condition will receive a brief community health worker-led training about the safety and efficacy of the vaccine. Participants will have the opportunity to ask clarifying questions from the community health workers during the training.
89479094|NCT06128317||MIR (Myocardial Infarction Registry)|All patients presenting to the Emergency Department with suspected acute coronary syndrome
89479095|NCT06127992|Experimental|Typical ColdU|39 patients had typical ColdU confirmed by positive ICT and TempTest® CSTs.
89479096|NCT06127992|Experimental|Atypical ColdU|24 patients had atypical ColdU with negative ICT and TempTest® CSTs.
89479097|NCT06127992|Other|Control group|15 healthy controls (HCs) who had no history of pathological reactions associated with cold exposure, and all of them had negative CSTs
89479098|NCT06127966|Experimental|Erector Spinae Plane Block group(EA group + EB group)|Conventional anesthesia induction, followed by ultrasound-guided erector spinae plane (ESPB) block with 0.5% ropivacaine (20 ml) after anesthesia induction.
89020576|NCT03580629|Experimental|Liver Live Donor Champion|The Liver Live Donor Champion program (LLDC) is the sole educational intervention for this trial. LLDC consists of 2 or 3 monthly sessions (depending on cohort) of approximately 2 or 3 hours each. Each LLDC session is led by a transplant physician or clinical coordinator. The sessions incorporate formal didactics, active-participant learning, personal stories, moderated group discussions, role-playing, and other skill-building exercises. LLDC session topics are as follows: 1) education about End-Stage Liver Disease (ESLD), liver transplantation, and living donation 2) communication skills building 3) Exploring social networks 4) sharing successful donor and recipient stories 5) surgeon and hepatologist panel 6) Program Recap.
89020577|NCT03579446|Experimental|Supportive care (levorphanol, opioid regimen)|Patients receive levorphanol PO every 8 or 12 hours for 30 days. Patients may receive opioid regimen including hydrocodone, morphine, hydromorphone, oxycodone, and oxymorphone for breakthrough pain. Patients may continue levorphanol for an additional 6-8 months if it is determined by the Principal Investigator the patient can continue.
89020578|NCT03538301|Experimental|Dose Level 1|ND-L02-s0201 45mg
89479099|NCT06127966|Sham Comparator|Control group（CA group + CB group)|Conventional anesthesia induction, followed by ultrasound-guided injection of 0.9% saline (20 ml) into the erector spinae plane (ESPB) after anesthesia induction.
89479100|NCT06127953|Other|Unilateral Cleft Lip Patients|Study is intermediate cleft rhinoplasty that will be performed in the patients with nasal deformities after repair of unilateral cleft lip congenital anomaly
89479101|NCT06127940|Experimental|Radiotherapy + sotorasib|Sotorasib is administered as an 8-week-introduction treatment and if response on a CT-scan is observed (stable disease or partial response), the patient is treated with stereotactic radiation therapy (SBRT) to 1-3 of the remaining lesions.
89479102|NCT06127927|Experimental|Impella|
89479103|NCT06127914|Experimental|LEIFc Intervention|There is only 1 arm of this study. All participants will receive the LEIFc intervention.
89479104|NCT06127901||Single arm|Patients over 18 years of age undergoing urgent and scheduled surgery requiring hospital admission, under any type of anaesthesia.
89479105|NCT06127784|Experimental|MI Counselling|An individualized treatment summary and survivorship care plan (TSSP) will be prepared within a one-hour motivational interviewing (MI) counseling session with a clinical nurse specialist. Participants will be asked to identify their top three symptom/survivorship concerns. The intervention will address symptoms/survivorship care specifically tailored to the needs of head and neck cancer patients based on the best available evidence and consultation with patients and a multidisciplinary team of head and neck cancer specialists. Patient participants will engage in role play to empower them to follow-up with their healthcare provider regarding their survivorship care needs.
89479106|NCT06127758|Experimental|VRG|
89479107|NCT06127758|Active Comparator|control group|
89479108|NCT06127745|Experimental|Discure System|All participants enrolled in the study will be treated with the Discure system
89479109|NCT06127693||Mild childhood adversity (control)|Score of 25-36 on the Childhood Trauma Questionnaire-short form.
89479110|NCT06127693||Moderate childhood adversity|Score of 37-67 on the Childhood Trauma Questionnaire-short form.
89479111|NCT06127693||Severe childhood adversity|Score of >67 on the Childhood Trauma Questionnaire-short form.
89479112|NCT06127654|Experimental|Intervention|Lung sparing treatment plan
89020579|NCT03538301|Experimental|Dose Level 2|ND-L02-s0201 90mg
89020580|NCT03538301|Placebo Comparator|Placebo|Control Arm
89479113|NCT06127654|No Intervention|Control|Standard treatment plan
89479114|NCT06127641|Active Comparator|Control|Participants will receive standard care (SC)
89479115|NCT06127641|Experimental|Intervention|Participants will receive the standard care (SC) plus pulmonary rehabilitation (PR)
89020581|NCT03537508|Experimental|Group 1a|MenACYW conjugate vaccine and routine vaccines at 2, 4, 6, and 12 to 15 months of age
89020582|NCT03537508|Experimental|Group 1b|MenACYW conjugate vaccine at 2, 4, 6, and 15 to 18 months of age and routine vaccines at 2, 4, 6, 12 to 15 months of age, and 15 to 18 months of age
89020583|NCT03537508|Active Comparator|Group 2a|MENVEO® at 2, 4, 6, and 12 months of age and routine vaccines at 2, 4, 6, 12, and 15 to 18 months of age
89020584|NCT03537508|Active Comparator|Group 2b|MENVEO® at 2, 4, 6, and 12 months of age and routine vaccines at 2, 4, 6, 12, and 15 to 18 months of age
89479116|NCT06127628|Experimental|Ultrasound-guided scalp with ropivacaine 0.375%|Ultrasound-guided scalp block performed for supraorbital nerve, supratrochlear nerve, zygomaticotemporal nerve, auriculotemporal nerve, superficial cervical plexus, greater occipital nerve and third occipital nerve. The local anaesthetic used will be ropivacaine 0.375%.
89020585|NCT03509558|Active Comparator|Transcutaneous spinal stimulation & Physical therapy|Transcutaneous electrical stimulation combined with physical therapy that targets rehabilitation of walking and standing functions
89020586|NCT03509558|Active Comparator|Physical therapy only|Physical therapy that targets rehabilitation of walking and standing functions
89479117|NCT06127628|Placebo Comparator|Ultrasound-guided scalp with placebo|Ultrasound-guided scalp block performed for supraorbital nerve, supratrochlear nerve, zygomaticotemporal nerve, auriculotemporal nerve, superficial cervical plexus, greater occipital nerve and third occipital nerve. Normal saline will be used as placebo.
89479118|NCT06127615|Experimental|ClearFit Longeviti Implant|Patients with chronic subdural hematomas that qualify for study and agree to participate will receive the ClearFit implant to cover the craniectomy site and have ultrasound imaging for their post-operative follow-up rather than CT/MRI, with exception of first initial post-op CT scan, and crossover to CT/MRI if clinically indicated or required for diagnostic purposes/patient safety
89479119|NCT06127602|Experimental|REACT-NMES: Intervention condition|"The REACT-NMES group will undergo 6 weeks of reactive balance training with NMES involving 12 one-hour sessions (twice a week). Each session will begin with NMES parameter setup where the current amplitude will be customized to individual maximal tolerable levels for a strong yet comfortable experience. NMES settings will include moderate to high intensity (30-50mA) and low frequency (20-45Hz) to target motor nerve thresholds. The REACT-NMES group will wear a footswitch on their paretic shoe for triggering the slips during walking and for NMES synchronization. NMES will be delivered to the paretic limb quadriceps muscles for 500 milliseconds after slip onset."
89020587|NCT03496675|Other|Standard care|Participants receive standard care as locally available. The components of standard care are recorded.
89020588|NCT03496675|Experimental|Group Music Therapy (GMT)|"GMT is provided twice weekly for the first three months, followed by weekly sessions for the next three months, with possible extension after that period as desired and feasible. Sessions are 45 minutes each.~In line with usual practice, and as appropriate in local contexts, residents of a unit allocated to GMT may be divided into smaller groups (e.g. around 5 participants)."
89020589|NCT03496675|Experimental|Recreational Choir Singing (RCS)|"RCS is provided twice weekly for the first three months, followed by weekly sessions for the next three months, with possible extension after that period as desired and feasible. Sessions are 45 minutes each.~RCS may be conducted in larger groups (e.g. with all residents of the unit in one group)."
89020590|NCT03496675|Experimental|GMT + RCS|Group Music Therapy and Recreational Choir Singing are both provided twice weekly for the first three months, followed by weekly sessions for the next three months, with possible extension after that period as desired and feasible. Sessions are 45 minutes each.
89020591|NCT03485157|Experimental|Micronized dHACM|Injection of micronized dHACM
89479120|NCT06127602|Active Comparator|REACT: Control condition|The REACT group will undergo 6 weeks involving 12 one-hour sessions (twice a week) of reactive balance training with ShamNMES. To prevent psychological bias and unblinding, sub-sensory stimulation will be used. ShamNMES will employ low intensity (0-10mA) and high frequency (50-100Hz), staying 20% below the sensory nerve threshold without inducing muscle contraction. The REACT group will wear a footswitch on their paretic shoe for triggering the slips during walking and for ShamNMES synchronization. ShamNMES (control) will be delivered after compensatory step touchdown to avoid interference with balance recovery.
89479121|NCT06127589|Experimental|Brief cessation advice + Nicotine replacement Therapy + Instant Messaging + Financial Incentives|Participants will receive a special designed evidence-based intervention using health advice, behavioral and pharmacological support, mobile health technologies, and awareness building (highlight harms) based on the biofeedback results of SHS exposure in the child. A selected sample of 50 families will receive environmental assessment-derived intervention, including results interpretation and health advice, which will be provided via phone calls for the 50 families within 1 week after the data collection.
89479122|NCT06127589|Active Comparator|Brief cessation advice (AWARD) + Waitlist for same intervention|"Participants in the control group will receive the same AWARD brief advice model, self-help booklet at baseline, and financial incentives for validated abstinence at 3- and 6-month follow-up. After the 6-month follow-up, participants who continued to smoke will receive the remaining intervention components: 1-week sampling of NRT and 3 months instant messaging chat-based personalized psychosocial and behavioural counselling for quitting. Participants who validated abstinence at the 12 months or actively engaged in mobile Health counselling will also receive the financial incentives of HK$ 500 and HK$ 200, respectively (waitlist control).~Similar to the Intervention group, environmental assessment derived intervention, including results interpretation and health advice, will be provided via phone calls for the 50 families within 1 week after the data collection."
89479123|NCT06127537|No Intervention|Control Group|Health Education Programme in cardiac rehabilitation without a Therapeutic Intervention Group
89479124|NCT06127537|Experimental|Experimental Group|Health Education Programme in cardiac rehabilitation with a Therapeutic Intervention Group
89479125|NCT06127511|Experimental|Peanuty group|Families allocated in the intervention group will receive the whole skin roasted peanuts packed in daily doses (25 g per day, 750 g per month), starting the day that we will visit the participants for the first time. They will consume 25 g of whole skin roasted peanuts as a daily snack to be incorporated into their diet for six months.
89479126|NCT06127511|No Intervention|Control group|Usual care
89479127|NCT06127498|Experimental|A8G6 SARS-CoV-2 Neutralization Antibody combination nasal spray|Specifications: 5 mg/mL, 6 mL/ bottle; Provided by Chongqing Mingdao Haoyue Biotechnology Co., LTD
89479128|NCT06127498|Placebo Comparator|A8G6 SARS-CoV-2 Neutralization Antibody nasal excipient|Specification: 0 mg/mL, 6 mL/ bottle; Provided by Chongqing Mingdao Haoyue Biotechnology Co., LTD
89479129|NCT06127485|Active Comparator|Control group|The treatment received is a combination of physiotherapy and conventional occupational therapy sessions two days a week, with a duration of 60 minutes divided into 30 minutes of physiotherapy and 30 minutes of occupational therapy.
89479130|NCT06127485|Experimental|Experimental Group|The experimental group received 60 minutes of conventional rehabilitation combined with the Pilates Method, divided into 20 minutes of physiotherapy, 20 minutes of occupational therapy and 20 minutes of Pilates Method.
89479131|NCT06127433|Experimental|intervention group|Intervention：insulin pump intensive therapy
89479132|NCT06127433|Active Comparator|control group|basal insulin and oral antidiabetic drugs
89020592|NCT03485157|Placebo Comparator|Saline|Injection of 0.9% Sodium Chloride Injection, USP
89020593|NCT03424018|Experimental|BMN 111|
89020594|NCT03405155|Experimental|Treatment (nivolumab)|Patients receive nivolumab IV over at least 30 minutes on day 1. Treatment repeats every 4 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.
89020595|NCT03383692|Experimental|Cohort 1: DS-8201a + Ritonavir|DS-8201a will be administered as an intravenous (IV) solution once every 3 weeks (Q3W) + Ritonavir twice daily (BID) on Day 17 of Cycle 2 until Day 21 of Cycle 3
89020596|NCT03383692|Experimental|Cohort 2: DS-8201a + Itraconazole|DS-8201a will be administered as an intravenous (IV) solution once every 3 weeks (Q3W) + Itraconazole BID on Day 17 of Cycle 2 followed by 200 mg daily (QD) until Day 21 of Cycle 3
89020597|NCT03342196|Experimental|Thiotepa + Fludarabine + Melphalan|Melphalan 100 mg/m2 on day -8 Thiotepa 10 mg/kg on day -7 Fludarabine 160 mg/m2 in divided doses given on days -6, -5, -4 and -3.
89020598|NCT03330132|Active Comparator|Standard vaccine|Once-annual administration of standard vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
88950929|NCT04109963|Active Comparator|RIC twice per day|RIC performed twice a day on one arm, approximately 12 hours apart. Each RIC session will consist of 4 cycles of unilateral or simultaneous bilateral upper arm ischemia for 5 minutes followed by reperfusion for another 5 minutes. The procedure will be performed by using an electric auto-control device with cuffs that inflate to a pressure of 200 mmHg during the ischemic period.
89479133|NCT06127407|Experimental|Ivosidenib|Taken continuously until BICR-confirmed disease progression, unacceptable toxicity, confirmed pregnancy, death, withdrawal of consent, lost to follow-up, or the Sponsor ends the study (estimated average treatment duration of two years).
88950930|NCT04094779|Active Comparator|Usual relational care|Isolate the patient from the group of other patients in order to propose to him a a relationship dual with the caregiver to the aim to calm the agitation
88950931|NCT04094779|Experimental|"Flash activity breath of fresh air"|Isolate the patient from the group of other patients in order to propose to him in a relationship dual with the caregiver a physical activity outside the service that promotes relaxation by focusing his attention to the environment during 15 minutes
88950932|NCT04083690|Active Comparator|Standard CRT Programming, then ECG CRT Optimization|The control arm patients will have standard CRT programming for the first 6 months, and then will be reprogrammed based on the ECG CRT optimization information for the following 6 months
88950933|NCT04083690|Experimental|ECG CRT Optimization|The experimental arm patients will have CRT device reprogrammed based on the ECG CRT optimization information for 12 months.
89479134|NCT06127407|Placebo Comparator|Placebo|Taken continuously until BICR-confirmed disease progression, unacceptable toxicity, confirmed pregnancy, death, withdrawal of consent, lost to follow-up, or the Sponsor ends the study (estimated average treatment duration of two years). Participants randomized to the placebo arm who experience BICR-confirmed disease progression and meet the crossover eligibility criteria will be given the opportunity to cross over and receive ivosidenib.
88950934|NCT04074460|Active Comparator|Propofol (TIVA)|Propofol-based total intravenous anaesthesia
88950935|NCT04074460|Active Comparator|Volatile|Volatile-based (isoflurane, sevoflurane or desflurane) general anaesthesia
88950936|NCT04069000|Active Comparator|Regular grade 3 classrooms|Students in this condition will participate in the regular grade 3 program. Educators will use their usual teaching methods to meet educational outcomes, including standards for social-emotional learning.
88950937|NCT04069000|Experimental|First time MindUP participants|Students in this condition will participate in MindUP for the first time. Their classroom teachers will receive training and implement the program during the school year.
88950938|NCT04069000|Experimental|Repeat MindUP participants|Students in this condition are in schools where MindUP has been implemented since they were in kindergarten (although some students may not have participated in those first three years, depending on when they moved to the school). Their classroom teachers will receive training and implement the program during the school year.
88950939|NCT04041063|Experimental|Nerve transfer + robotic training|Participants will receive nerve transfer surgery at Massachusetts General Hospital in Boston, MA. One year after the surgery, participants will receive six weeks of upper limb robotic training at the Burke Neurological Institute in White Plains, NY.
88950940|NCT04041063|Active Comparator|Nerve transfer + delayed robotic training|Participants will receive nerve transfer surgery at Massachusetts General Hospital in Boston, MA. One year + six weeks after the surgery, participants will receive six weeks of upper limb robotic training at the Burke Neurological Institute in White Plains, NY.
88950941|NCT04033406|Experimental|VIR-2482|VIR-2482
88950942|NCT04033406|Placebo Comparator|Placebo|Placebo
88950943|NCT03936452|Experimental|Treatment arm|Sintilimab 200mg ivdrip D1 Peg-aspargase 2500U/m2 im D1 Anlotinib 12 mg po D1-14 repeat every three weeks When patients obtained an CR or PR after the second dose of the combined regimen, they woud undergo radiotherapy after the third dose of the combined regimen. Subsequently, another three cycles of the combined regimen would be administered to these patients.
88950944|NCT03884231||Infinity DBS System with MR Conditional labelling (Leads-only configuration)|The Infinity DBS system with MR Conditional labelling includes a primary cell implantable pulse generator designed to deliver low-intensity electrical pulses to targeted structures in the brain. The leads-only configuration consists of at least one implanted lead protected with a lead protection boot, as well as an optional cranial burr hole cover. Any leads must be completely implanted with the surgical incision closed.
88950945|NCT03884231||Infinity DBS System with MR Conditional labelling (Full system configuration)|The Infinity DBS system with MR Conditional labelling includes a primary cell implantable pulse generator designed to deliver low-intensity electrical pulses to targeted structures in the brain. The full system configuration consists of at least one IPG, one lead, one extension, and an optional cranial burr hole cover. All devices must be completely implanted with the surgical incision closed.
88950946|NCT03881579|Other|Usual care|one random half of patients will receive usual care
88950947|NCT03881579|Experimental|intervention arm|one random half of patients will receive enhanced usual care (usual care plus nurse-led supportive care intervention)
88950948|NCT03817125|Placebo Comparator|SER-401 Matching Placebo/ Nivolumab|Participants will undergo a 4-day lead-in pretreatment with antibiotic placebo, then matching placebo for SER-401 and nivolumab (480 mg) treatment.
88950949|NCT03817125|Experimental|SER-401/ Nivolumab|Participants will undergo a 4-day lead-in pretreatment with antibiotic (vancomycin) to prime the gut microbiome for engraftment of the oral microbiome study intervention, then SER-401 and nivolumab treatment.
88950950|NCT03703102|Placebo Comparator|Arm A|Subcutaneous administration of placebo
88950951|NCT03703102|Experimental|Arm B|Subcutaneous administration of KHK4083 (dose level 1, dosing regimen 2)
88950952|NCT03703102|Experimental|Arm C|Subcutaneous administration of KHK4083 (dose level 2, dosing regimen 1)
88950953|NCT03703102|Experimental|Arm D|Subcutaneous administration of KHK4083 (dose level 3, dosing regimen 1)
88950954|NCT03703102|Experimental|Arm E|Subcutaneous administration of KHK4083 (dose level 3, dosing regimen 2)
88950955|NCT03699397|Experimental|Dry electrode cap EEG|In this diagnostic accuracy study, all patients that are included in the study will undergo a dry electrode electroencephalography (EEG).
89202975|NCT00575510|Experimental|Intervention|Culturally targeted behavioral and normative beliefs + knowledge/skills + salience + environmental constraints/barriers counseling
89479135|NCT06127381|Experimental|1/4 therapeutic dose (TGKP)|"First 5 (five) healthy volunteers will receive (a single intravenous administration) 1/4 therapeutic dose.~Before administration the study drug will be dosed and diluted in 200 ml of isotonic solution of 0.9% sodium chloride, and then will be administered once intravenously via infusion."
89479136|NCT06127381|Experimental|1/2 therapeutic dose (TGKP)|"Next 5 (five) healthy volunteers will receive (a single intravenous administration) 1/2 therapeutic dose.~Before administration the study drug will be dosed and diluted in 200 ml of isotonic solution of 0.9% sodium chloride, and then will be administered once intravenously via infusion."
89479137|NCT06127381|Experimental|Full therapeutic dose (TGKP)|"Next 15 (fifteen) healthy volunteers will receive (a single intravenous administration) the full therapeutic dose.~Before administration the study drug will be dosed and diluted in 200 ml of isotonic solution of 0.9% sodium chloride, and then will be administered once intravenously via infusion."
89479138|NCT06127355|Experimental|Ursodeoxycholic Acid|500 mg of ursodeoxycholic acid (UDCA)
89479139|NCT06127355|Placebo Comparator|Control|500 mg of Placebo
89479140|NCT06127329|Experimental|BAI combine with DEB-BACE|"Procedure: BAI combine with DEB-BACE: bronchial infusion chemotherapy combined with drug-loaded microsphere embolization of EqualSpheres~First treatment. Only infusion chemotherapy (THP + Platinum + Letitrexed), THP 20 ~30mg/m2, Nedaplatin 40mg/m2, Letitrexed 3mg/m2.~Second treatment. After infusionchemotherapy, EqualSpheres microsphere used for embolization: EqualSpheres microspheres (400 μm) 1tube was loaded and adsorbed THP (40 ~ 60mg/m2). End point of embolization: stagnation of blood flow in tumor feeding artery."
89479141|NCT06127303|Experimental|Toripalimab Combined with Cryoablation|Patients with oligometastatic driver-negative advanced NSCLC after first-line immunotherapy progress would be treated with Toripalimab Combined with Cryoablation.
89479142|NCT06127290||HIV-1 patients naive to therapies|HIV-1 patients naive to therapies with sub subtype A6 treated in first line with INSTI
89479143|NCT06127277|Experimental|Next4You|Next4You is a web-based, self-paced program featuring 6 content modules, each containing 8-10 microlessons intended to reduce rates of unintended pregnancy and sexually transmitted infections (STI) and increase essential knowledge, attitudes, and skills among young people aged 16-19 currently in foster care in California. Each microlesson is 2-4 minutes with diverse content formats. Youth in the intervention condition will have unlimited access to the platform for an intensive 4-week period. During this period, engagement activities will be deployed twice weekly to draw users back into the platform for further engagement with the microlessons. Content will also be released on a schedule to encourage continued engagement. Following the intensive 4-week period, youth will retain unlimited access to the platform but will not receive reminders to engage with the content. Participants complete online surveys at baseline, as well as 3 months and 9 months after the intervention ends.
89479144|NCT06127277|Active Comparator|General Health Mobile Website|Youth randomized to the attention control condition will have access to a mobile-responsive website that contains digital resources focusing on nutrition, sleep, stress/anxiety, and exercise. Like the intervention group, participants in the attention control group will have unlimited access to the general health digital resources for an intensive 4-week period. Each topic area will have between 1-4 digital pamphlets (for a total of 12 pamphlets) that are downloadable and take between 2-4 minutes to read. Participants complete online surveys related to attitudes, knowledge, and behavior around romantic relationships and sexual behavior at baseline, as well as 3 months and 9 months after the intervention ends.
89479145|NCT06127264|No Intervention|NoCDO|Participants will complete study activities without wearing a CDO
89479146|NCT06127264|Experimental|SSCT|Participants will complete study activities while wearing a CDO fastened to their self-selected proximal cuff tightness
89479147|NCT06127264|Experimental|Loose|Participants will complete study activities while wearing a CDO fastened to a loose proximal cuff tightness
89479148|NCT06127264|Experimental|Moderate|Participants will complete study activities while wearing a CDO fastened to a moderate proximal cuff tightness
89479149|NCT06127264|Experimental|Tight|Participants will complete study activities while wearing a CDO fastened to a tight proximal cuff tightness
89479150|NCT06127238|Experimental|ST-1898 Phase Ib|Dose Escalation:participants will be administered orally at 100mg,140mg,160mg,180mg, 220mg,QD during the study, until disease progression or intolerable toxicity.
88950956|NCT03661294|Other|GE Healthcare Metabolic Oxygenator|The actual and predicted energy expenditure of tetraplegic (ventilated/non-vent) and paraplegic patients will be measured at three time points during the patient's rehabilitation in hospital.
88950957|NCT03647085||Group 1 Wearable Cardiac Monitor|Patients diagnosed with, and currently in, persistent atrial fibrillation at the time of enrollment and are scheduled for an ablation or cardioversion.
89479151|NCT06127238|Experimental|ST-1898 Phase II|Dose Expansion: participants with advanced renal cell carcinoma will be dministered orally at recommended phase II dose from phase Ib once daily during the study, until disease progression or intolerable toxicity.
89479152|NCT06127225|Experimental|Treatment 1|1 caplet of Proliverenol 500 mg twice daily
89479153|NCT06127225|Experimental|Treatment 2|2 caplets of Proliverenol 500 mg once daily
89479154|NCT06127225|Experimental|Treatment 3|2 caplets of Proliverenol 500 mg twice daily
89479155|NCT06127225|Placebo Comparator|Treatment 4|2 caplets of Placebo daily
89479156|NCT06127212|Experimental|Test Dapagliflozin Dexa Medica|Dapagliflozon 10 mg Film-Coated tablet, produced by PT Dexa Medica, Indonesia.
89479157|NCT06127212|Active Comparator|Reference Forxiga AstraZeneca|Forxiga® 10 mg Film-Coated Tablet, manufactured by AstraZeneca Pharmaceuticals LP, USA for AstraZeneca Pharmaceuticals Co. Ltd., China imported by PT AstraZeneca Indonesia, Indonesia.
89479158|NCT06127160|Active Comparator|Standard Duration Treatment|
89479159|NCT06127160|Experimental|Patient-directed antimicrobial duration (PDAD)|
89479160|NCT06127134|Active Comparator|Straight-line flow (Group A)|treating less diseased arteries which is in line with distal run off the foot
89479161|NCT06127134|Sham Comparator|Angiosome-targeted (Group B)|treating specific angiosome through a targeted vessel which mainly supplies this angiosome
89202976|NCT00575510|Active Comparator|Active Control|nontargeted behavioral and normative beliefs + knowledge/skills + salience + environmental constraints/barriers counseling
89479162|NCT06127121||Digital Art Activity|"Visit 1, Participants will be asked to complete a symptom questionnaire and then you will interact with the digital art tool. Participants will first complete a short breathing exercise, and then Participants will interact with the digital art tool. The digital tool combines a digital canvas with a collage activity. Participants will be asked to choose a background and then answer questions about your general well-being and your physical and emotional symptoms as they relate to cancer and cancer treatment.~Visit 2, Participants will be asked to fill out the symptom questionnaire, complete another activity such as listening to meditative music for 10 minutes, and then fill out the symptom questionnaire again.~Visit 3, Participants will fill out the symptom questionnaire and engage in the digital art activity again. Participants will then be asked to fill out 3 other questionnaires about your feelings of distress."
89479163|NCT06127056|Active Comparator|real stimulation|The central electrode was placed over F3, with return electrodes at Fp1, Fz, F7 and C3. Fourteen 2-mA sessions (ramp-up and ramp-down periods of 15 and 15 seconds, respectively) were applied for 20 minutes per session, twice daily over 7 consecutive days, and the stimulus frequency was set as IAF.
89479164|NCT06127056|Sham Comparator|sham stimulation|In the sham condition, tACS was delivered only during the ramp-up and ramp-down periods (15 and 15 s); no current was delivered during the 20-minute intervention. Participants will receive sham tACS twice daily for two weeks.
89479165|NCT06126978|Experimental|Vibration Therapy|Vibration Therapy uses vibration as a physical tool during the treatment. It can be applied with different devices that transmit mechanical vibration throughout the whole or a part of the body. Focal Muscle Vibration (FMV) is a safe, well-tolerated and non-invasive technique, which may be an efficient intervention in reducing the upper extremity spasticity, whereas Whole Body Vibration (WBV) can provide proper somatosensory stimulation, and improve muscle strength and postural control in stroke patients (Oliveira et al., 2018).
89479166|NCT06126978|Experimental|Mirror Therapy|Mirror Therapy is a structured, inexpensive, simple and patient-directed treatment. The principle of Mirror Therapy is the use of a mirror to create a reflective illusion of an affected limb, in order to trick the brain into thinking the movement has occurred without pain. It has shown to improve movements of the affected upper limb and the ability to carry out daily activities, in addition to reducing pain (Dhami et al., 2019).
89479167|NCT06126965|Experimental|KX-826-0.5% BID|treatment dose group of 0.5% BID(0.5%)
89479168|NCT06126965|Placebo Comparator|Placebo|Placebo
88950958|NCT03647085||Group 2 Wearable Cardiac Monitor|Patients diagnosed with, and currently in, paroxysmal atrial fibrillation at the time of enrollment and are scheduled for an ablation or cardioversion.
88950959|NCT03647085||Group 3 Wearable Cardiac Monitor|Patients diagnosed with, and currently in, atrial flutter at the time of enrollment and are scheduled for an ablation or cardioversion.
88950960|NCT03581370|Active Comparator|1 hour infusion|"The first group corresponds to 1-hour infusion : First administration of ceftolozane-tazobactam with 2000 mg by infusion for 60 minutes every 8 hours.~24h after this first administration, 7 blood samples will be collected at Hour 24, Hour 25, Hour 26, Hour 28, Hour 30, Hour 32 and Hour 48."
88950961|NCT03581370|Experimental|4 hours infusion|"The second group corresponds to 4-hours infusion: First administration of ceftolozane-tazobactam with 2000 mg by infusion for 4 hours every 8 hours. 24h after this first administration, 7 blood samples will be collected at Hour 24, Hour 25, Hour 26, Hour 28, Hour 30, Hour 32 and Hour 48.~."
88950962|NCT03568604|Experimental|Prasterone|6.5 mg vaginal inserts of prasterone will be used daily once the patient meets inclusion and exclusion for 20 weeks.
89202977|NCT00575510|No Intervention|Standard Care Only|Clinical standard of care at time of study
89202978|NCT00798876|Placebo Comparator|Standard Western Diet|Subjects will be asked to consume a standard Western Diet for 4 weeks. For the 4-week period, subjects will be provided with all food and beverages. Subjects will also undergo a medical examination, dietary interview, blood draw, and radical prostatectomy(as part of standard of care).
89202979|NCT00798876|Experimental|Low-Fat Diet|Subjects will be asked to consume a low fat diet with fish oil and vitamin E supplements for 4 weeks. For the 4-week period, subjects will be provided with all food and beverages. Subjects will also undergo a medical examination, dietary interview, blood draw, and radical prostatectomy(as part of standard of care).
89202980|NCT00989404|Experimental|Period|10 mg BID Zanamivir or placebo for 5 days
89479169|NCT06126913|No Intervention|Standard of Care|At sites randomized to standard care, participants newly diagnosed will receive facility-based care per Uganda Ministry of Health (MoH) protocols
89479170|NCT06126913|Experimental|Community Antiretroviral Therapy|Newly diagnosed individuals (diagnosed in the prior 6 months) at intervention sites will be offered community ART delivery on a rolling basis during the enrollment window, initiating individuals into groups as close to their date of diagnosis as possible. Newly enrolled individuals will join existing community ART delivery groups, or when a new group is needed based on group size or geographic location, a new group will be formed.
89479171|NCT06126848|Other|Observation Cohort|
89479172|NCT06126835||Ozanimod exposed|
89479173|NCT06126835||Conventional therapy exposed|
89479174|NCT06126835||Advanced therapy exposed|
89479175|NCT06126822|Experimental|Zabdeno/Mvabea® vaccinated - Zabdeno® booster|Participants previously vaccinated with the Zabdeno/Mvabea® vaccination schedule, will receive a single intramuscular Zabdeno® booster vaccine (0,5 ml) = homologous vaccination scheme.
89479176|NCT06126822|Experimental|Zabdeno/Mvabea® vaccinated - Ervebo® booster|Participants previously vaccinated with the Zabdeno/Mvabea® vaccination schedule, will receive a single intramuscular Ervebo® booster vaccine (1 ml) = heterologous vaccination scheme.
89479177|NCT06126822|Experimental|Ervebo® vaccinated - Ervebo® booster|Participants previously vaccinated with Ervebo®, will receive a single intramuscular Ervebo® booster vaccine (1 ml) = homologous vaccination scheme.
89479178|NCT06126822|Experimental|Ervebo® vaccinated - Zabdeno® booster|Participants previously vaccinated with Ervebo®, will receive a single intramuscular Zabdeno® booster vaccine (0,5 ml) = heterologous vaccination scheme.
89479179|NCT06126731|Experimental|mCRPC patients dose with a combination of enzalutamide and antibiotics|"Phase I:~The evaluation of the safety and tolerability of the combinations of amoxicillin plus metronidazole, and ciprofloxacin plus vancomycin with enzalutamide.~Phase II:~Determination of the anti-tumour activity of the combinations of amoxicillin plus metronidazole, and ciprofloxacin plus vancomycin with enzalutamide."
89479180|NCT06126718|Experimental|BR201|
89479181|NCT06126718|Active Comparator|Cosentyx (Secukinumab)|
88950963|NCT03566381||Healthy adults|Healthy adults without a history of medical or surgical problems
89479182|NCT06126705|Experimental|Group A|Patients who are surgically resectable or borderline surgically resectable plan to undergo primary lesion resection and peripheral lymph node dissection, and suspect the presence of peripheral lymph nodes or distant metastasis; Pathological results of postoperative primary lesion and lymph node dissection can be obtained
88950964|NCT03539055|Experimental|Treatment arm|"Dabigatran 75 or 150mg BID x 90 days plus ASA 81mg daily.~Single arm, prospective unblinded study on post Watchman LAA closure device implant anti-coagulation management at a primary center (Vanderbilt Medical Center) and up to 5 additional high volume LAA implant centers. This trial will be designed to evaluate the use of dabigatran for 90 days post implantation of an LAA closure device (Watchman LAA Closure Device, Boston Scientific Inc.)"
89479183|NCT06126705|Experimental|Group B|For patients diagnosed or suspected of postoperative recurrence or late metastasis through routine imaging examination, there is at least one measurable lesion (with a short diameter of ≥ 1.5cm for lymph node lesions and ≥ 1cm for non lymph node lesions); Patients who can undergo imaging follow-up for 3-6 months or undergo pathological biopsy and puncture.
89479184|NCT06126692||Severe asthma anti-IL5/IL-5R starters (including Benralizumab cohort)|Patients with High dose ICS (corresponding to minimum 1600 micrograms Budesonide per day) + either LABA, LTRA, or LAMA OR Fixed Prednisolone treatment (OCS) minimum 50% of the time. Minimum 2 exacerbations in the last year or fixed Prednisolone treatment (OCS) minimum 50% of the time OR ACQ>1.5 AND Fulfils national criteria for specific biologic treatment.
89479185|NCT06126692||Severe asthma anti-IL4R starters|Patients with High dose ICS (corresponding to minimum 1600 micrograms Budesonide per day) + either LABA, LTRA, or LAMA OR Fixed Prednisolone treatment (OCS) minimum 50% of the time. Minimum 2 exacerbations in the last year or fixed Prednisolone treatment (OCS) minimum 50% of the time OR ACQ>1.5 AND Fulfils national criteria for specific biologic treatment.
89479186|NCT06126692||Severe asthma anti-TLSP starters|Patients with High dose ICS (corresponding to minimum 1600 micrograms Budesonide per day) + either LABA, LTRA, or LAMA OR Fixed Prednisolone treatment (OCS) minimum 50% of the time. Minimum 2 exacerbations in the last year or fixed Prednisolone treatment (OCS) minimum 50% of the time OR ACQ>1.5 AND Fulfils national criteria for specific biologic treatment.
89479187|NCT06126692||Severe asthma anti-IgE starters|Patients with High dose ICS (corresponding to minimum 1600 micrograms Budesonide per day) + either LABA, LTRA, or LAMA OR Fixed Prednisolone treatment (OCS) minimum 50% of the time. Minimum 2 exacerbations in the last year or fixed Prednisolone treatment (OCS) minimum 50% of the time OR ACQ>1.5 AND Fulfils national criteria for specific biologic treatment.
89479188|NCT06126692||Mild/moderate controlled asthma|Low/Medium dose of ICS/LABA +/- LTRA. ACQ < 1.5. No exacerbations in the last year or need of Prednisolone treatment (OCS). Markers of T2 inflammation (B-eos ≥ 0.15 actual or ≥ 0.30 the last year or Sputum eos ≥ 3%, FeNO ≥ 25 ppb, allergens positivity). Not direct candidate for treatments with monoclonal antibodies.
89479189|NCT06126692||Healthy controls|No history of respiratory diseases. No history of asthma or respiratory symptoms, normal lung function, no history of allergies. No lower or upper respiratory infections in the past 4 weeks.
89479190|NCT06126679|Experimental|intervention group|"The 1-year lifestyle intervention includes intensive, family-based diet and physical activity counselling. The multidisciplinary team consists of one pediatrician, one specialist nurse and a clinical nutritionist. Children with their parents meet the pediatrician two times, the specialist nurse five times and the clinical nutritionist three times during the 1-year intervention. One of the meetings with the clinical nutritionist is only for parents and the child is with the nurse at the same time.~The treatment is based on educational and behavioural counselling and motivating the participants to change their lifestyle and to support the parents in managing their children´s behaviour. The aim of counselling is to increase awareness of healthy dietary and physical activity habits; to achieve a suitable energy balance, to create a positive attitude to physical activity, to promote optimal sleep duration and to improve the children´s body image and body control."
89479191|NCT06126679|No Intervention|control group|Participants in the control group continue with the standard care in primary care and do not receive any special lifestyle intervention during the study.
89479192|NCT06126640|Experimental|SHR-A1811|
89479193|NCT06126640|Active Comparator|Trastuzumab Emtansine (T-DM1)|
89479194|NCT06126627|Experimental|Teachers/student teachers with vocal fatigue|Teachers/student teachers with vocal fatigue based on Vocal Fatigue Index (VFI, German). Pre-Screening and Screening. Experiment 1: MRI with MRI-compatible surface electrodes on the neck and audio recordings during MRI with and without stress induction. Prior to MRI, questionnaires on voice, personality, and stress and practice oft the tasks. During experiment, collection of saliva samples (before, during, and after MRI). During MRI, multiple subjective ratings of emotional state by the participants. Experiment 2 (approximately 2 weeks later): Speech tasks with surface electromyographic sensors applied to the neck with concurrent audio recordings. Prior to the experiment questionnaires on voice and practice of tasks. Subjective ratings of vocal and cognitive effort during the experiment by the participants.
89479195|NCT06126627|Active Comparator|Control group|Control participants without vocal fatigue based on Vocal Fatigue Index (VFI, German). Same experimental procedures as in arm 1.
89479196|NCT06126588|Experimental|Patient treat with everolimus|The product Everolimus is an oral drug.The dosage is 7.5 mg.
89479197|NCT06126575|Experimental|Subjects with normal hepatic function|
89479198|NCT06126575|Experimental|Subjects with severe hepatic impaired function|
89479199|NCT06126510|Experimental|Experimental: Single Arm|VG161:1.0 × 10 ^ 8 PFU daily for 3 consecutive days on Days 1-3 of each cycle (D1-D3)
89479200|NCT06126497|Experimental|Ropanicant 45 mg qd|The participant will take 1 tablet/day in the morning (for qd dosing)
89479201|NCT06126497|Experimental|Ropanicant 30 mg bid|The participant will take 2 tablets/day (~12 hours apart for bid dosing).
89479202|NCT06126497|Experimental|Ropanicant 45 mg bid|The participant will take 2 tablets/day (~12 hours apart for bid dosing).
89479203|NCT06126484|Other|Neonates with congenital heart disease|Neonates with critical congenital heart diseases that require early catheter intervention
89479204|NCT06126458||Good shooting performance|archery athletes who had 589 and more
89479205|NCT06126458||Bad shooting performance|archery athletes who had 588 and less
89479206|NCT06126432|Experimental|To evaluate the effects of probiotics consumption|Subjects consumed 2 bottles of probiotics-containing yogurt per day for 1 month
89479207|NCT06126380|Experimental|AT-1501|AT-1501 20 mg/kg administered every 3 weeks IV + MMF 1000 mg per os (orally) (PO) twice daily (BID) or MPS 720 mg PO BID + Corticosteroids 5 mg of prednisone PO once daily (QD) or equivalent
89479208|NCT06126380|Active Comparator|Tacrolimus|Tacrolimus dosed PO BID with the dose titrated to maintain a trough concentration of 6-8 ng/mL+ MMF 1000 mg PO BID or MPS 720 mg PO BID + Corticosteroids 5 mg of prednisone PO QD or equivalent
88950965|NCT03485534|Experimental|Tenofovir Disoproxil|Tenofovir Disoproxil 245mg, a daily dose for 48 weeks
88950966|NCT03485534|Placebo Comparator|Tenofovir Disoproxil Fumarate|Tenofovir Disoproxil Fumarate 300mg, a daily dose for 48 weeks
88950967|NCT03466255||Cardiac outpatients|Subjects referred for outpatient coronary angiography.
88950968|NCT03461549||Healthy adults|Evaluate sensor performance on both lower limbs of healthy adult subjects for pressure sensing and skin temperature sensing.
88950969|NCT03461549||Venous Leg Ulcer Adults|Evaluate sensor performance on both lower limbs of adult subjects with an active venous leg ulcer or history of a venous leg ulcer for pressure sensing and skin temperature sensing.
88950970|NCT03395704|Active Comparator|LJPC-401|LJPC-401 solution for subcutaneous injection only, 5mg/1 mL (5mg/mL) or 10mg/1mL (10mg/mL) single use vial
88950971|NCT03395704|Placebo Comparator|Placebo|0.9% Sodium Chloride Injection, USP, or equivalent
88950972|NCT03335813|Experimental|brachytherapy with multichannel balloon applicator|6 channel balloon re-positioning, multichannel brachytherapy applicator used to deliver localized radiation therapy to esophageal tumors
88950973|NCT03311152|Experimental|HCC-free cirrhotic patients (Controls)|"Cirrhotic patients enrolled in an HCC screening program by abdominal ultrasound and AFP every six months and followed at the Department of Hepatology of the University Hospital of Nancy. Each patient included will undergo a diagnostic test called Epi proColon 2.0 CE from Epigenomics, Inc (Berlin, Germany) also known as Plasma mSEPT9 test."
88950974|NCT03311152|Experimental|HCC-positive cirrhotic patients (Cases)|"Cirrhotic patients followed at the Department of Hepatology of the University Hospital of Nancy who presents an HCC according to the AASLD guidelines. Each patient included will undergo a diagnostic test called Epi proColon 2.0 CE from Epigenomics, Inc (Berlin, Germany) also known as Plasma mSEPT9 test."
88950975|NCT03296007|Experimental|Mindfulness Meditation App|Participants randomized to this arm will use a smartphone app to practice mindfulness meditation for 12 minutes.
89479209|NCT06126367||Patients identified as eligible for treatment with either a PCSK9i or inclisiran|
89479210|NCT06126367||Patients with moderate or severe aortic calcification identified by non-enhanced cardiac CT scan|
89479211|NCT06126354|Active Comparator|Maintenance hyperinsulinemia (MH) protocol|The basal insulin infusion rate (IIR) necessary to maintain participants' mean basal fasting plasma glucose (mbFPG) will be determined during the basal titration period. Then, during the intervention period, the IIR will remain at 100% of basal for the full duration (225 min). The IIR and resulting insulin levels are expected to be relatively high (cf. hyperinsulinemia) because of dexamethasone-induced insulin resistance.
89479212|NCT06126354|Experimental|Reduction toward euinsulinemia (RE) protocol|The basal insulin infusion rate (IIR) necessary to maintain participants' mean basal fasting plasma glucose (mbFPG) will be determined during the basal titration period. Then, during the intervention period, the IIR will be reduced progressively, at 75-min intervals, to 90%, 75%, and 60% of basal IIR. Thus, the basal hyperinsulinemia expected due to underlying insulin resistance will be reduced toward euinsulinemia.
89479213|NCT06126302||Before 1930|the patients were divided into ten groups according to the decade of their birth: before 1930
89479214|NCT06126302||1930-1939|the patients were divided into ten groups according to the decade of their birth: 1930-1939
89479215|NCT06126302||1940-1949|the patients were divided into ten groups according to the decade of their birth: 1940-1949
89479216|NCT06126302||1950-1959|the patients were divided into ten groups according to the decade of their birth: 1950-1959
89479217|NCT06126302||1960-1969|the patients were divided into ten groups according to the decade of their birth: 1960-1969
89479218|NCT06126302||1970-1979|the patients were divided into ten groups according to the decade of their birth: 1970-1979
89479219|NCT06126302||1980-1989|the patients were divided into ten groups according to the decade of their birth: 1980-1989
89479220|NCT06126302||1990-1999|the patients were divided into ten groups according to the decade of their birth: 1990-1999
89479221|NCT06126302||2000-2009|the patients were divided into ten groups according to the decade of their birth: 2000-2009
89479222|NCT06126302||after 2009|the patients were divided into ten groups according to the decade of their birth: after 2009
89479223|NCT06126289||Pain-free control subjects|According to the 11th Revision of International Classification of Diseases (ICD-11) of International Association for the Study of Pain(IASP) in 2019, diagnose whether patients have CPSP . Patients with no postoperative chronic pain after open reduction and internal fixation of lower limb fractures.
89479224|NCT06126289||Patients with chronic postsurgical pain|According to the 11th Revision of International Classification of Diseases (ICD-11) of International Association for the Study of Pain(IASP) in 2019, diagnose whether patients have CPSP . Patients with postsurgical chronic pain after open reduction and internal fixation of lower limb fractures.
89479225|NCT06126250|Experimental|U-shaped power toothbrush|Device: U-shaped Power Toothbrush with fluoride toothpaste
89479226|NCT06126250|Placebo Comparator|Manual Toothbrush|Device: Soft Manual Toothbrush with fluoride toothpaste
89479227|NCT06126237|Experimental|CM313|CM313 injection, subcutaneous
89479228|NCT06126237|Experimental|CM313 + concomitant medication|CM313 injection, subcutaneous
89479229|NCT06126198|Experimental|Active treatment|Active treatment with Repetitive Transcranial Magnetic Stimulation (rTMS) according to clinical protocol.
89479230|NCT06126172|Experimental|Multiparametric magnetic resonance imaging|Detecting and localizing prostate cancers. The radiomics provide comprehensive quantitative information of all tumor data which could be used for risk stratification and prognosis prediction.
89479231|NCT06126159|Experimental|multiparametric and fat-detection magnetic resonance imaging (MRI)|detecting the small amount of fat with the use of fat-detecting pulse sequences on MRI
89479232|NCT06126133|Experimental|Near İnfrared Spektroskopi (NIRS)|Peripheral oxygen saturation to be measured with NIRS device
89479233|NCT06126107|Active Comparator|Loss-framed Messaging|"Daily text messages on the consequences of hazardous drinking (e.g., Think of all you have lost as a result of drinking too much. Make today a day that sets the stage for change.)"
89479234|NCT06126107|Active Comparator|Gain-framed Messaging|"Daily text messages on the benefits of reducing drinking to safe guidelines (e.g., Think of all you can achieve if you can control your drinking. Make today a day that sets the stage for change.)"
89479235|NCT06126107|Active Comparator|Gain-framed and Loss-framed Messaging|"Daily text messages that alternate between loss-framed (e.g., Think of all you have lost as a result of drinking too much. Make today a day that sets the stage for change.) and gain-framed messaging (e.g., Think of all you can achieve if you can control your drinking. Make today a day that sets the stage for change.)"
89479236|NCT06126094|Experimental|Probiotic|"Participants will consume 800 mg of probiotic Myrkl before consuming alcohol in the form of one capsule. (Myrkl, De Fair Medical, Stockholm, Sweden). This formulation contains AB001™, and one capsule (800mg) consists of:~560 mg of naturally fermented rice bran~Bacillus subtilis~B. coagulans~L-cysteine~dextrin~36 mg of excipients: magnesium stearate salts, calcium phosphate, potassium phosphate"
88950976|NCT03296007|Active Comparator|Mindfulness Meditation No App|Participants randomized to this arm will not use a smartphone app, but will receive instructions to practice mindfulness meditation for 12 minutes.
89479237|NCT06126094|Experimental|Placebo|The subject who consumed 800 mg of placebo- dextrin (maltodextrin) in the form of two capsules before consuming alcohol.
89479238|NCT06126081|Experimental|LBBP+GDMT group|Patients in the LBBP+GDMT group will receive LBBP using dual-chamber device as priority and guideline-directed medical therapy. The pacing lead will be implanted at the left bundle branch and whether LBB is captured will be judged during the procedure. For patients who LBBP is failed, CRTP using triple-chamber device or LVSP by using dual-chamber device will be an alternative option according to the co-determination after consultation between doctors and patients .
89479239|NCT06126081|Active Comparator|GDMT group|Patients in the GDMT group will receive guideline-directed medical therapy according to their complications, heart rate, blood pressure and so on. During follow-up of 6 months, patients may transfer to LBBP group if the LVEF decreased to <35% and patients accepted the device implantation.
89479240|NCT06126042|Experimental|DRL_AB|Drug: Abatacept Prefilled Syringe Each pre-filled syringe contains 125 mg of abatacept in 1 mL Other Name: Dr. Reddy's Abatacept
89479241|NCT06126042|Active Comparator|RP|Drug: Abatacept Prefilled Syringe Each pre-filled syringe contains 125 mg of abatacept in 1 mL Other Names: Orencia
89479242|NCT06126042|Active Comparator|RMP|Drug: Abatacept Prefilled Syringe Each pre-filled syringe contains 125 mg of abatacept in 1 mL Other Names: Orencia
89479243|NCT06126029|Experimental|Metformin group|This group will receive metformin 500mg extended release oral tablet daily along with standard of care for 8 weeks.
89479244|NCT06126029|Placebo Comparator|Placebo group|This group will receive placebo oral tablet daily along with standard of care for 8 weeks.
89479245|NCT06125990|Experimental|Study Group (SGr)|In addition to institutional conventional rehabilitation, this group included breathing exercises to increase lung volumes and a 21-minute breathing exercise with video-based biofeedback.
89479246|NCT06125990|Sham Comparator|Control Group (CGr)|This group was given only institutional conventional rehabilitation.
89479247|NCT06125964|Experimental|Intensity|Participants receive intensity-based goals for two weeks. No enhancements are added to the standard mHealth intervention.
89479248|NCT06125964|Experimental|Affect|Participants receive affect-based goals for two weeks. No enhancements are added to the standard mHealth intervention.
89479249|NCT06125964|Active Comparator|Affect + TYPE/CONTEXT|Participants receive affect-based goals for two weeks. In addition to the standard mHealth intervention, participants engage in the TYPE/CONTEXT enhancement to augment the treatment effects of the affect-based goals condition.
89479250|NCT06125964|Active Comparator|Affect + SAVOR|Participants receive affect-based goals for two weeks. In addition to the standard mHealth intervention, participants engage in the SAVOR enhancement to augment the treatment effects of the affect-based goals condition.
89479251|NCT06125665|Experimental|Aminophylline-Dexmedetomidine Group|10 minutes after endotracheal intubation, patients will receive IV bolus of dexmedetomidine 0.5 microgm/kg Lean body weight (LBW) over 15 min, followed immediately by intravenous infusion at 0.2 microgm /kg LBW/h and IV bolus of aminophylline of 5 mg/kg based on the ideal body weight (IBW) over 30 min, followed immediately by intravenous infusion at 0.6 mg/kg IBW/h. The study solutions will be diluted in 50 ml normal saline.
89479252|NCT06125665|Active Comparator|Dexmedetomidine|10 minutes after endotracheal intubation, patients will receive IV bolus of dexmedetomidine 0.5 microgm/kg LBW over 15 min, followed immediately by intravenous infusion at 0.2 microgm /kg LBW/h. The study solutions will be diluted in 50 ml normal saline.
89479253|NCT06125626|Experimental|Probiotics|This arm will receive a daily sachet of Lacticaseibacillus rhamnosus LR04 + Streptococcus thermophilus FP4 + Bifidobacterium breve BR03
89479254|NCT06125626|Placebo Comparator|Placebo|This arm will receive a dose of placebo
89479255|NCT06125574|Experimental|Treatment|
88950977|NCT03253354|Active Comparator|Pharyngeal stimulation|Pharyngeal stimulation given at 5Hz for 10 minutes
88950978|NCT03253354|Active Comparator|repetitive magnetic stimulation (1Hz)|repetitive transcranial magnetic stimulation at 1Hz applied for 600 pulses
88950979|NCT03253354|Active Comparator|repetitive magnetic stimulation (5Hz)|repetitive transcranial magnetic stimulation at 5Hz applied for 600 pulses
88950980|NCT03253354|Sham Comparator|Sham treatment|Sham repetitive transcranial magnetic stimulation using the coil tilt technique
89479256|NCT06125574|No Intervention|Control|
89479257|NCT06125236||Acute ischemic stroke with large- or medium-vessel occlusion|Acute ischemic stroke patients with large- or medium-vessel occlusion including all treatments.
89479258|NCT06124703|Active Comparator|dose-tapering regimen|The dose selection of oral prednisone is the maximum daily dose for 4 days, followed by a taper every 2 days
89479259|NCT06124703|Experimental|no taper regimen|The dose selection of oral prednisone is the maximum daily dose, applied for 5 consecutive days
89479260|NCT06124183|Experimental|Experimental|A 12-session psychological program The intervention program consisted of 12 sessions of 80 minutes with a weekly frequency. The first session was diagnostic, and the following nine correspond to the following topics: perception (2), facilitation (2), labeling and understanding (2), emotional regulation, and management (3). The last session was evaluative. The intervention included practical tasks in context and supervision by clinical psychologist.
89479261|NCT06124183|Placebo Comparator|Control Group|Does not receive intervention
89479262|NCT06124066|Active Comparator|Mirabegron|The participants were given mirabegron 50 mirabegron/day started 3 days before DJ stent insertion and until 6 weeks after the DJ stent insertion and filled in USSQ every week until 6 weeks after the DJ stent insertion(filled in directly when the patient arrived or by telephone)
89479263|NCT06124066|Active Comparator|Tamsulosin|The participants were given tamsulosin 0.4 mg that was started 3 days before DJ stent insertion and until 6 weeks after the DJ stent insertion and filled in USSQ every week until 6 weeks after the DJ stent insertion(filled in directly when the patient arrived or by telephone)
89479264|NCT06124066|Placebo Comparator|Placebo|The participants were given a placebo that was started 3 days before DJ stent insertion and until 6 weeks after the DJ stent insertion and filled in USSQ every week until 6 weeks after the DJ stent insertion(filled in directly when the patient arrives or by telephone)
89479265|NCT06123936|Experimental|Experimental group|"GPs selected at random in the intervention arm Recall will recall their patients to be vaccinated via the recall module integrated into their Eo medical software"
89479266|NCT06123936|No Intervention|No intervention group|"GPs in the usual care or control arm will not recall their patients to be vaccinated. GPs with their medical software.~They will worked as usual."
89479267|NCT06123871||Type 2 diabetes group|The group was based on the clinically confirmed diagnosis of type 2 diabetes
89479268|NCT06123871||Diabetic nephropathy group|The group was based on the clinically confirmed diagnosis of type 2 diabetes.The group was based on the clinically confirmed diagnosis of type 2 diabetes.Patients were re-screened strictly according to the following admission criteria: persistent albuminuria and/or decreased eGFR,while other causes of chronic kidney disease (CKD) were excluded. When diabetes mellitus is identified as the cause of kidney damage and other primary and secondary glomerular diseases and systemic diseases are excluded, at least one of the following conditions can be diagnosed as DKD: (1) Urinary Albumin/Creatinine Ratio(UACR)≥30 mg/g or Urinary albumin excretion rate (UAER)≥30 mg/24 h, The UACR or UAER was checked again within 3 to 6 months, and 2 out of 3 times reached or exceeded the critical value; Eliminate other interfering factors such as infection; (2) eGFR&lt; 60 ml·min-1.(1.73 m2) -1 for more than 3 months;(3) Renal biopsy was consistent with DKD pathological changes.
89479269|NCT06123442|Experimental|three one-arm trials (N = 4-6/trial)|This research protocol entails three one-arm trials and a pilot RCT with 58 participants. Its primary aim is to develop the Cognitive Resilience Intervention (CRI) and assess its feasibility and acceptability. Student feedback and data on feasibility and acceptability will be collected before and after each trial to fine-tune the intervention using empirical guidance. CRI aims to help participants lead more meaningful lives, emphasizing purpose, autonomy, and the pursuit of goals while avoiding suicidal ideation. In contrast, the comparator RCT's control group will undergo General Psychoeducation (GPE), a structured program focusing on enhancing mental health awareness through psychology psycho-education sessions.
89479270|NCT06123416||Control Caregivers|Control participants will write about their daily and future tasks three times.
89479271|NCT06123416||Expressive Writing Caregivers|Experimental participants will write about their thoughts and feelings about an emotionally difficult event three times.
89479272|NCT06122974|Other|Study Device|Subjects randomized to the Drug Eluting Temporary Spur Stent System
89479273|NCT06122974|Other|Control|Subjects randomized to the PTA
89479274|NCT06122623|Other|A single-arm pre-post approach will be employed in this study;|There will be no control group. All participants will receive the same treatment. The intervention to be used will be a gaming education program conducted once with each participant.
89479275|NCT06122506|Experimental|Intervention|Laparoscopic cerclage
89479276|NCT06122506|Experimental|Control|Vaginal cerclage
89479277|NCT06122415||Patients in secondary care with cognitive symptoms|
89479278|NCT06122155|Experimental|Posterior parietal cortex (PPC)|In the motor adaptation phase, a 20-minute, 2 mA anodal tDCS was delivered through two 5cm x 7cm electrodes using the DC-STIMULATOR MR (neuroConn, Germany). The electrical current gradually ramps up and down in 20 seconds. In the PPC group, the anodal electrode was placed over the P3 or P4 areas on the skull, covering the PPC area on the opposite side of the testing foot (according to the international 10-20 EEG system), and the reference electrode was placed over the supraorbital region on the same side of the testing foot.
89479279|NCT06122155|Experimental|Cerebellum|In the motor adaptation phase, a 20-minute, 2 mA anodal tDCS was delivered through two 5cm x 7cm electrodes using the DC-STIMULATOR MR (neuroConn, Germany). The electrical current gradually ramps up and down in 20 seconds. In the cerebellum group, the anodal electrode was placed 1~2 cm under and 3~4 cm lateral to the inion on the same side of the testing foot, with the reference electrode placed on the buccinator on the same side of the testing foot.
89479280|NCT06122155|Sham Comparator|Sham|In the motor adaptation phase, a 20-minute, 0 mA anodal tDCS was delivered through two 5cm x 7cm electrodes using the DC-STIMULATOR MR (neuroConn, Germany) for the sham group. Participants were informed that they might experience itchiness, burning, or mild discomfort during the tDCS period regardless of which group they were assigned to, so they would not use their sensation as a basis for determining whether they received actual stimulation or not.
89479281|NCT06121752|Experimental|Device assisted endoscopic full thickness resection (EFTR)|The steps of EFTR are as follows. Initially, the lesion will be marked circumferentially using the FTRD probe available with the device (Forced Coag, E1, 20W). Subsequently, wire guided balloon dilatation of the pyloric channel will be performed. The device will be mounted over a therapeutic channel gastroscope and negotiated across the cricopharynx over the guidewire with or without assistance of dilating balloon available with the device. After reaching the target site, the lesion will be pulled withing the FTRD cap with the help of grasping forceps and gentle suctioning. The clip will be fired after ensuring the entry of the lesion inside the cap, the premounted snare closed and electrocautery activated to cut the grasped tissue (HighCut 200W, Effect 4).
89479282|NCT06121752|Active Comparator|Endoscopic submucosal dissection (ESD)|ESD will be performed using the standard technique under general anaesthesia. The steps of the procedure are as follows: a) marking of the lesion using closed tip of DualKnife J in soft coagulation mode (Effect 4, 80W), b) submucosal lifting injection using saline mixed with indigocarmine dye, c) circumferential mucosal incision (Dry Cut, Effect 2, 30W), d) submucosal dissection (SwiftCoag, Effect 2, 30W), removal of the lesion using suction or a polypectomy snare, f) closure of the defect using endoclips or loop and endoclips.
89479283|NCT06121544||Cognitively unimpaired individuals with preclinical Alzheimer's disease|75% of the recruited population will be cognitively unimpaired individuals with preclinical Alzheimer's disease.
89479284|NCT06121544||Cognitively unimpaired individuals without preclinical Alzheimer's disease.|25% of the recruited population will be cognitively unimpaired individuals without preclinical Alzheimer's disease.
89479285|NCT06121414|Experimental|Laserpuncture|Laserpuncture using continous wave, 2 Joule in on condition
89479286|NCT06121414|Sham Comparator|Sham Laserpuncture|Sham laser using laserpuncture in off condition
89479287|NCT06121388||health control group|Health control women with similar age, BMI, working environment, education level and regular menstrual cycle in our hospital, and conduct endocrine examination for health examination.
89479288|NCT06121388||premature ovarian failure group|Patients are diagnosed with premature ovarian failure.
89479289|NCT06121206|Experimental|Altitude-like hypoxia (12%) combined with cognitive training|Participants breathe 12% ambient oxygen in an altitude-training room, 3.5 hours daily, 5-6 days per week for 3 weeks. On iPads, they perform cognitive training, which is interleaved by short breaks.
89479290|NCT06121206|Active Comparator|Altitude-like hypoxia (12%) with no training|Participants breathe 12% ambient oxygen in an altitude-training room, 3.5 hours daily, 6 days per week for 3 weeks. On iPads, they perform matched control games without cognitive benefits, which is interleaved by short breaks.
89479291|NCT06121206|Active Comparator|Normoxia (20%) combined with cognitive training|Participants breathe 20% ambient oxygen in an altitude-training room, 3.5 hours daily, 6 days per week for 3 weeks. On iPads, they perform cognitive training, which is interleaved by short breaks.
89479292|NCT06121206|Sham Comparator|Normoxia (20%) combined with no training|Participants breathe 20% ambient oxygen in an altitude-training room, 3.5 hours daily, 6 days per week for 3 weeks. On iPads, they perform matched control games without cognitive benefits, which is interleaved by short breaks.
89479293|NCT06121206|No Intervention|Treatment as usual|Participants receive no additional care or intervention between baseline and end-of-treatment assessment points.
89479294|NCT06121102|Experimental|Group A (supervoltage pulsed radiofrequency glossopharyngeal nerve block)|Patients will receive supervoltage pulsed radiofrequency glossopharyngeal nerve block.
89479295|NCT06121102|Active Comparator|Group B (standard voltage pulsed radiofrequency glossopharyngeal nerve block)|Patients will receive standard voltage pulsed radiofrequency glossopharyngeal nerve block.
89479296|NCT06120842|Experimental|Bimatoprost Implant System (High Dose) / IOL Combination|
89479297|NCT06120842|Experimental|Bimatoprost Implant System (Low Dose) / IOL Combination|
89202981|NCT02636439|Active Comparator|dietary, and aerobic exercise|"Intervention for diet-A hypocaloric diet will be developed to achieve a 2800 kcal/week deficit, which should produce about 0.4 kg (1 lb.) weight loss per week.~Intervention for aerobic exercise-Based on initial evaluations and the stress testing results, (HR, VO2, RPE) an individual exercise prescription will be developed for aerobic training."
89479298|NCT06120842|Active Comparator|Timolol Maleate Ophthalmic Solution 0.5%|
89202982|NCT02636439|Active Comparator|dietary, aerobic and resistance training|"Intervention for diet-A hypocaloric diet will be developed to achieve a 2800 kcal/week deficit, which should produce about 0.4 kg (1 lb.) weight loss per week.~Intervention for aerobic exercise-Based on initial evaluations and the stress testing results, (HR, VO2, RPE) an individual exercise prescription will be developed for aerobic training.~Intervention for resistance training- Additional weight resistant exercise will be added to this arm."
89202983|NCT00343915|Experimental|2-Dose Engerix|subjects received 2 doses of adult (thiomersal-free) HBV formulation, one at 0 and 6 months, respectively and placebo (physiological saline) at 1 month.
89479299|NCT06120361||Patients in primary care with cognitive symptoms|
89479300|NCT06120348|Experimental|Experimental Group|Charge-Balanced, Symmetric Nerve Stimulation device 30 mins once a day for 4weeks(28days) and twice a week from the 5weeks to the 12 weeks.
89479301|NCT06120348|Sham Comparator|Control Group|Sham device 30 mins once a day for 4weeks(28days) and twice a week from the 5weeks to the 12 weeks.
89479302|NCT06120244||Healthy Volunteers|Healthy volunteers aged 18 years and older
89479303|NCT06118957|Experimental|Enoxaparin|Participants will receive weight-based dosing of enoxaparin at 0.5 mg/kg rounded to the nearest 10 mg every 12 hours based on delivery admission weight. Participants will receive therapy for 14 days.
89479304|NCT06118957|No Intervention|No treatment|Participants will receive no enoxaparin treatment.
89479305|NCT06118606|Experimental|Interventional arm|Intervention arm
89479306|NCT06117904|Experimental|MEBO ointment + symptomatic therapy|This group included twenty-five patients given Mebo ointment in combination with the symptomatic therapy 3 times daily for 7 weeks.
89479307|NCT06117904|Active Comparator|symptomatic therapy|"This group included twenty-five patients given symptomatic therapy 3 times daily for 7 weeks.~These therapies included anti-fungal agents (Miconaz oral gel), topical anesthetics and anti-inflammatory drugs (BBC oral spray), topical analgesic gel (Oracure gel), sodium bicarbonate mouthwash (Alkamisr sachets)."
89479308|NCT06115382|Experimental|Self cueing|Self-cueing training using singing, one hour sessions twice weekly for 12 weeks.
89479309|NCT06115382|Experimental|External cueing|External cueing using music, one hour sessions twice weekly for 12 weeks.
89479310|NCT06114914||ISLAND cohort|About 1,000 participants completed hand motor and speech tests online and 150 will attend the research centre for usablity assessments
89479311|NCT06114914||Clinical|The new app will be tested in about 100 patients at each of the ISLAND Cognitive Clinic or the Royal Hobart Hospital
89479312|NCT06114498||Patient with HFpEF with decompensation|"120 patients hospitalized with a clinical picture of acute decompensation of heart failure (shortness of breath, orthopnea, clinical signs of cardiac asthma and/or pulmonary edema) in the city clinical hospital named after. V.V. Veresaeva, Moscow. Patients with a confirmed diagnosis in accordance with instrumental and/or laboratory criteria"
89479313|NCT06114498||Control group|40 particularly healthy people without heart failure and acute cardiovascular diseases
89479314|NCT06113497|No Intervention|Group 1|The group that received normal saline 40ml injection into the deep fascia and muscular layer during wound closure.
89479315|NCT06113497|Experimental|Group 2|The group that received cocktail therapy injection into the deep fascia and muscular layer during wound closure.
89479316|NCT06108570|Other|Study methodology|This is an intra-individual comparison study.
89479317|NCT06108388||Type 2 Diabetes|Participants living with type 2 diabetes for less than 10 years will be recruited.
89479318|NCT06108388||No Diabetes|Participants not living with diabetes will be recruited.
89479319|NCT06107361|Active Comparator|Arm 1 (6.35cm 20 gauge ultralong intravenous catheter)|Arm 1 Device: B. Braun 6.35cm 20 gauge ultralong intravenous catheter
89479320|NCT06107361|Experimental|Arm 2 (5.71 cm 20 gauge Accucath)|Arm 2 Device: BD 5.71 cm 20 gauge Accucath, ultralong intravenous catheter with guide wire
89479321|NCT06105749|Experimental|contrast-enhanced mammography|Enrolled participants will receive a baseline contrast-enhanced mammography exam for breast cancer screening, along with their scheduled 3D mammography exam, then they will receive another CEM exam for breast cancer screening at 24 months after their baseline CEM exam, and then again at 48 months. All the while, participants will still receive their annual 3D mammography exam as per their usual routine care.
89479322|NCT06105476|Experimental|Alcohol|
89479323|NCT06105476|Experimental|Alcohol+protein|
89479324|NCT06105476|Experimental|Alcohol+retinol|
89479325|NCT06105476|Experimental|Retinol|
89479326|NCT06104332||ProRhinel Naturel spray nasal/ Allergic Rhinitis|
89479327|NCT06104332||ProRhinel Naturel spray nasal/ URTI|
89202984|NCT00343915|Active Comparator|3-Dose Engerix|subjects received 3 doses of paediatric (preservative-free) HBV formulation one at 0, 1 and 6 months, respectively.
89479328|NCT06104332||ProRhinel EXTRA Eucalyptus spray nasal/ URTI|
89479329|NCT06104332||RESPIMER Enfant/ URTI|
89479330|NCT06104332||Phytosun Aroms spray nasal MAX/ URTI|
89479331|NCT06104332||PHYSIOMER RHUME TRIPLE ACTION/ URTI|
89479332|NCT06104332||Phytosun Aroms spray nasal decongestionnant/ URTI|
89479333|NCT06104176|Active Comparator|CBT group|
89479334|NCT06104176|Experimental|VRET group|
89479335|NCT06102122|Other|Patients well established on tube feeds will act as their own control|Patients will switch from current to new tube feed.
89479336|NCT06101667|Active Comparator|Best medical management|Patients randomly assigned to the control group should receive the best medical management according to the guidelines.
89479337|NCT06101667|Experimental|Endovascular treatment|Stent retrievers, thromboaspiration, balloon angioplasty, stent deployment, intra-arterial thrombolysis (Recombinant tissue plasminogen activator (rt-PA) or urokinase), or the various combinations of these approaches.
89479338|NCT06100991||Generalized Pustular Psoriasis (GPP)|Pts presenting to enrolling sites across the North America are invited to enroll if eligible
88950981|NCT03246503|Experimental|Newborns|"Newborns will be enrolled in the study in 2 different ways. At Staged Enrollment sites, newborns will be enrolled when they are < 48 hours old. These newborns will have a study visit when they are 48 - 167 hours old. At the study visit, a BCB will be determined and blood will be drawn for study purposes for a TSB level. At Simultaneous Enrollment sites, newborns will be enrolled and have a study visit at the time of a blood draw (+/- 2 hours) for a TSB level that is being obtained for clinical purposes. Newborns will be 0-191 hours old."
88950982|NCT03228602|Active Comparator|healthy subjects|
88950983|NCT03228602|Experimental|obese|
88950984|NCT03228602|Experimental|obese diabetic|
89479339|NCT06100276|Experimental|Part 1 (Open-Label Single Ascending Dose)|Part 1 will be open-label with an initial plan to explore 3 dose levels of AMT-162 in approximately 6 to 12 subjects (2 to 4 per dose level). Each subject in Part 1 will receive a single treatment delivered via an intrathecal (IT) infusion. All subjects in Part 1 will receive active immunosuppression (IS).
89479340|NCT06100276|Placebo Comparator|Part 2 (Randomized, Double-blind, Placebo-controlled)|"Approximately 30 subjects will be randomly assigned in a 1:1 ratio to treatment Arm A or Arm B:~Arm A (Treatment): Active treatment with AMT-162 and active IS~Arm B (Control): Placebo treatment via control procedure and placebo IS~In addition, if preliminary signs of efficacy were observed in Part 1, subjects from the Part 2 control group (Arm B) will be offered AMT-162 treatment.~Blinded adverse event (AE) raters and blinded efficacy assessors will be used in Part 2, and the blind will be maintained for each subject until they complete Month 6 in Part 2."
88950985|NCT03228602|Experimental|obese diabetic who are going to be operated on|25 of a sleeve gastrectomy and 25 of a Y gastric bypass
89479341|NCT06100276|No Intervention|Part 3 (Extended Follow-up)|Upon completing Part 1 or Part 2, subjects will enter Part 3 to be followed for up to 5 years after AMT-162/placebo administration.
88950986|NCT03195868|Experimental|Photobiomodulation|All patients will be treated similarly in this study
88950987|NCT03170908||Phase I Patients|Patients with depression receiving community-based services will receive Interpersonal Psychotherapy
88950988|NCT03170908||Phase II Patients|Patients with depression receiving community-based services will receive Interpersonal Psychotherapy
88950989|NCT03091881|Active Comparator|Granisetron group|patients in this group will receive intravenous Granisetron 0.1 MG/ML 10 minutes before spinal anesthesia
88950990|NCT03091881|Placebo Comparator|Placebo group|Patients in this group will receive 10 ml normal saline as placebos considering the same timing and color of solution
88950991|NCT03053765|Active Comparator|Individual Supervision in IPT|Bi-weekly individual case supervision in IPT
88950992|NCT03053765|Experimental|Group Supervision in IPT|Bi-weekly group supervision in IPT in groups of 4-6 therapists
89479342|NCT06099041|Other|ND-YAG Laser for iris depigmentation|ND-YAG Laser for iris depigmentation
89202985|NCT00751868|Experimental|ARM 1|FEC e Ixabepilone. A goal of 48 patients will be enrolled in this study by 16 Italian centres of the GIM (Gruppo Italiano Mammella) Group. Subjects must meet all of the inclusion criteria and none of the exclusion criteria to be enrolled in the study
89479343|NCT06098521|Experimental|CONSENT and Follow-up|The therapy in the CONSENT program will be delivered twice a week (total time 12 ± 2 weeks), with measurement after 16±2 weeks. Participants in this arm will have a follow-up period of 16±2 weeks.
89479344|NCT06098521|Experimental|Waiting list and CONSENT|Participants will be on waiting list for 16±2 weeks. After waiting list participants are offered the CONSENT program including therapy delivered twice a week (total time 12 ± 2 weeks), with measurement after for 16±2 weeks.
89479345|NCT06093529||Respondents to second-line therapy|Immune markers in ITPpatients Respondant to second line therapy
89479346|NCT06093529||Non-Respondents to second-line therapy|Immune markers in ITPpatients nonrespondant to second line therapy
89479347|NCT06093022||BCLM-surg|BCLM underwent liver resection
89479348|NCT06093022||BCLM-med|BCLM underwent medical treatment alone
89479349|NCT06091956|Experimental|Deucravacitinib Treatment for Lichen Planopilaris|Subjects diagnosed with Lichen Planopilaris (LP) will receive Deucravacitinib for 24 weeks.
89479350|NCT06088485||low bone mineral density|bone mineral density according to t and z score.
89479351|NCT06088485||normal bone mineral density|bone mineral density according to t and z score.
89479352|NCT06088212|No Intervention|Usual care|Usual care patients will continue with the hospital follow-up plan and routine preventive care after hospital discharge.
89479353|NCT06088212|Experimental|Intervention|Intervention patients will receive a disease management program in addition to the usual care.
88950993|NCT03053765|Experimental|Internet-Based Training in IPT|Access to internet-based training in IPT to review information learned in initial 2-day training
88950994|NCT03053765|No Intervention|Autodidactic Training in IPT|Clinicians allowed access to training materials and can engage in self-study
88950995|NCT02864368|Experimental|5-day TMZ: Components A and B|All patients receive Tetanus-Diphtheria booster vaccine at time of enrollment. Cycles of standard TMZ (150-200 mg/m^2/day on days 1-5 of each 28 day cycle) with PEP-CMV vaccination on Day 23 (-1 day, + 2 days) of each TMZ cycle and tetanus pre-conditioning the day before the first vaccine.
88950996|NCT02864368|Experimental|21-day TMZ: Components A and B|All patients receive Tetanus-Diphtheria booster vaccine at time of enrollment. Cycles of dose-intensified TMZ (75-100 mg/m^2/day on days 1-21 of each 28 day cycle) with PEP-CMV vaccination on day 23 (-1 day, + 2 days) of each TMZ cycle and tetanus pre-conditioning the day before the first vaccine.
89479354|NCT06088147|Active Comparator|Group 1= Methotrexate|After microneedling, we will apply methotrexate topically (25 mg/ml) on half of the scalp at a dose of 0.02ml/cm2 with a maximum of 0.1-0.2 ml (2,5-5 mg) and rub it gently. The patient will take a session every 2 weeks for 12 weeks, on the same patient on the other patch or half of the scalp according to the pattern.
89479355|NCT06088147|Experimental|Group2=Triamcinilone|we will use Triamcinolone acetonide 40 mg/1ml after microneedking at dose 5mg/ml concentration;1/8/ 1:7 dilution session every 3 weeks for 12 weeks. then after 12 weeks of treatment we will follow up our patients after discontinuing therapy for other 12 weeks and evaluate.
89479356|NCT06081114|Placebo Comparator|MNs - Placebo|Placebo powder, daily in the form of a powdered flavored drink. Plus, a daily fortified balanced energy and protein food supplement containing 400 kcals and 14 g of protein and 1 recommended daily allowance (RDA) of 18 micronutrients will be given daily including 90 ug of vitamin K, 400 ug of folic acid, 1 mg of copper and 500 mg of calcium
89479357|NCT06081114|Active Comparator|MNs - Level 1|"Dose 1 of micronutrients (MNs) listed provided daily in the form of a powdered drink.~Micronutrients:~Vitamin A -0.355 mg Vitamin D - 0.02 mg Vitamin E - 34 mg Vitamin B1 - 1.4 mg Vitamin B2 - 1.4 mg Vitamin B3 - 17 mg Vitamin B6 - 2.1 mg Vitamin B12 - 0.0034 mg Vitamin C - 20 mg Selenium - 0.035 mg Choline - 550 mg Pantothenic acid - 7mg Biotin - 0.035 mg Potassium - 1000 mg Manganese - 2.6 mg Magnesium - 145 mg Plus, a daily fortified balanced energy and protein supplement containing 400 kcals and 14 g of protein and 1 RDA of 18 micronutrients will be given simultaneously including 90 ug of vitamin K, 400 ug of folic acid, 1 mg of Copper and 500 mg of calcium"
89479358|NCT06081114|Active Comparator|MNs - Level 2|"Dose 2 of micronutrients listed below provided daily in the form of a powdered flavored drink.~Micronutrients:~Vitamin A -0.93 mg Vitamin D - 0.04 mg Vitamin E - 109 mg Vitamin B1 - 2.8 mg Vitamin B2 - 2.8 mg Vitamin B3 - 47 mg Vitamin B6 - 4.1 mg Vitamin B12 - 0.0094 mg Vitamin C - 20 mg Iron - 10 mg Zinc - 5 mg Selenium - 0.135 mg Choline - 750 mg Pantothenic acid - 7mg Biotin - 0.035 mg Potassium - 1000 mg Manganese - 2.6 mg Magnesium - 145 mg Plus, a daily fortified balanced energy and protein food supplement containing 400 kcals and 14 g of protein and 1 RDA of 18 micronutrients will be given daily including 90 ug of vitamin K, 400 ug of folic acid, 1 mg of copper and 500 mg of calcium"
89479359|NCT06081114|Active Comparator|MNs - Level 3|"Dose 3 of micronutrients listed below provided daily in the form of a powdered drink.~Micronutrients:~Vitamin A - 1.48 mg Vitamin D - 0.06 mg Vitamin E - 184 mg Vitamin B1 - 4.2 mg Vitamin B2 - 4.2 mg Vitamin B3 - 82 mg Vitamin B6 - 8.1 mg Vitamin B12 - 0.0154 mg Vitamin C - 20 mg Iron - 10 mg Zinc - 5 mg Selenium - 0.235 mg Choline - 900 mg Pantothenic acid - 7mg Biotin - 0.035 mg Potassium - 1000 mg Manganese - 2.6 mg Magnesium - 145 mg Plus, a daily fortified balanced energy and protein food supplement containing 400 kcals and 14 g of protein and 1 RDA of 18 micronutrients will be given daily including 90 ug of vitamin K, 400 ug of folic acid, 1 mg of copper and 500 mg of calcium"
89479360|NCT06077253|Other|Arm 1|One eye iridotomy, contralateral eye no intervention
89479361|NCT06069414||Inhalatory induction|Patients who will be induced via mask with inhalators anesthetic gases
89479362|NCT06069414||Intravenous induction|Patients who will be induced with intravenous anesthetics
89479363|NCT06067399||1|Diabetics
89479364|NCT06067399||2|Healthy control
89479365|NCT06063850|Experimental|Cohort 1: AMT-260 starting dose|N# of treated - 6
89479366|NCT06063850|Experimental|Cohort 2: AMT-260 adapted dose|"N# of treated - 6~Dose is dependent on the DSMB recommendation."
89479367|NCT06058962|Experimental|Suramin 10 mg/kg|50 mg test dose of suramin (upon first administration), then suramin 10 mg/kg (minus 50 mg suramin test dose) in 50 mL of saline administered by IV infusion over 30 minutes was given at Visits 2, 4, and 5.
89479368|NCT06058962|Experimental|Suramin 20 mg/kg|50 mg test dose of suramin (upon first administration), then suramin 20 mg/kg (minus 50 mg suramin test dose) in 50 mL of saline administered by IV infusion over 30 minutes was given at Visits 2, 4, and 5.
89479369|NCT06058962|Placebo Comparator|Placebo|Test dose of saline placebo, then saline placebo infusion of 50 mL administered over 30 minutes was given at Visits 2, 4, and 5.
89479370|NCT06058533|No Intervention|Control Group|No intervention will be given to this group. Each treatment visit will move forward as routine.
89479371|NCT06058533|Experimental|Previsit Imagery Group|This group will be given previsit imagery (picture book) before treatment visit.
89020599|NCT03330132|Experimental|Alternating standard vaccine & adjuvanted vaccine|Alternating once-annual administration of standard inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of MF59 adjuvanted inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
89479372|NCT06056310|Experimental|Xevinapant + Cisplatin + IMRT|Participants will receive xevinapant once daily from Day 1 to Day 14, per 3-week cycle (Each cycle is of 3 weeks). The first three cycles are given in combination with weekly cisplatin and radiotherapy, followed by 3 cycles of monotherapy xevinapant.
89479373|NCT06056219|Active Comparator|Mirror therapy using a mirror box|30 minutes' exercise of mirror therapy followed by 20 minutes' task-oriented training
89020600|NCT03330132|Experimental|Alternating adjuvanted vaccine & standard vaccine|Alternating once-annual administration of MF59 adjuvanted inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of standard inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
89202986|NCT00991822|Active Comparator|1|Patients with open angle glaucoma
89479374|NCT06056219|Experimental|Virtual reality-based mirror therapy with rhythmic skill training|30 minutes' activity of virtual reality-based mirror therapy with rhythmic skill training followed by 20 minutes' task-oriented training
89202987|NCT00991822|Active Comparator|2|Patients with open angle glaucoma
89202988|NCT00798954|Active Comparator|TAXUS|
89202989|NCT00798954|Active Comparator|Cypher|
89479375|NCT06054620|Active Comparator|Collagen and Vitamin C|
89479376|NCT06054620|Placebo Comparator|Carbohydrate Placebo|
89479377|NCT06053476|Active Comparator|Chest tube duration at least 3 days plus TEA|
89479378|NCT06053476|Experimental|Chest tube duration at least 3 days plus single-shot PVB|
89479379|NCT06053476|Experimental|Early chest tube removal plus TEA|
89479380|NCT06053476|Experimental|Early chest tube removal plus single-shot PVB|
89479381|NCT06052137|Active Comparator|Active TBS-DLPFC|The active group will receive theta-burst TMS DLPFC stimulation.
89479382|NCT06052137|Active Comparator|Active TBS-DMPFC|The active group will receive theta-burst TMS DMPFC stimulation.
89479383|NCT06049953||Antipsychotic medication|Pregnant women with severe mental illness (diagnosis of bipolar disorder, primary psychotic disorder, or any history of psychiatric hospitalization) who are treated with any of the following medications during pregnancy: Quetiapine, olanzapine, risperidone, aripiprazole, ziprasidone, lurasidone, haloperidol, or any other medication in the first- or second-generation antipsychotic class. All orally administered, with dosages titrated to clinical effect by the participant's primary psychiatrist.
89479384|NCT06049953||Non-antipsychotic medication|Pregnant women with severe mental illness (diagnosis of bipolar disorder, primary psychotic disorder, or any history of psychiatric hospitalization) who are treated with any psychotropic medications during pregnancy other than those listed.
89479385|NCT06049953||No medication|Pregnant women with severe mental illness (diagnosis of bipolar disorder, primary psychotic disorder, or any history of psychiatric hospitalization) who are not treated with any psychotropic medications during pregnancy.
89479386|NCT06048146|Experimental|FOLFOXIRI and Lateral lymph node dissection|"Participants will~receive three cycles of chemotherapy with FOLFOXIRI regimen, and the specific dose was: irinotecan 150mg/m2, d1, Oxaliplatin 85mg/m2, d1, 5-Fu, 2400mg/m2, continuously pumped for 46 hours, repeated for 14 days.~After 3 cycles of chemotherapy, rectal MRI reexamination was performed, and the efficacy was evaluated using the RECIST method.~For cCR or cPR, another 2 cycles of chemotherapy will be performed, and CT and rectal MRI evaluations will be performed again after treatment. Radical rectal cancer surgery and LLND were performed 4-6 weeks after the last administration (unilateral or bilateral LLND was determined based on the metastasis of LLN before treatment)."
89479387|NCT06048146|Active Comparator|Preoperative long-term concurrent chemoradiotherapy and Lateral lymph node dissection|All patients received preoperative long-term concurrent chemoradiotherapy: radiotherapy for five weeks, five days a week (pelvic 2 Gy/ time, GT50 Gy), during which capecitabine (1650mg/m2/ day, orally divided twice). Intensity modulated radiotherapy was used. CT and rectal MRI were evaluated again 8-12 weeks after radiotherapy, followed by radical resection of rectal cancer plus LLND (unilateral or bilateral LLND was performed according to LLN metastasis before treatment).
89479388|NCT06046742|Experimental|M1-c6v1 intravenous injection|M1-c6v1 will be administered through IV drip
89479389|NCT06044948|Experimental|DAILIES TOTAL1|Delefilcon A contact lenses worn in both eyes for the typical number of hours the subject wears his/her habitual contact lenses. The lenses will be worn in a daily disposable manner.
89479390|NCT06041971|Experimental|Group A|Two-week control period before the use of the AIDANET system.
89479391|NCT06041971|Experimental|Group B|Two-week control period after the use of the AIDANET system.
89479392|NCT06039449|Experimental|Cohort A VYD222|
89202990|NCT02560064||laparotomy and small bowel length|measurement of small bowel length in laparotomies
88950997|NCT02864368|Experimental|5-day TMZ: Safety Cohort|All patients receive Tetanus-Diphtheria booster vaccine at time of enrollment. Cycles of standard TMZ (150-200 mg/m^2/day on days 1-5 of each 28 day cycle) with PEP-CMV vaccination on Day 23 (-1 day, + 2 days) of each TMZ cycle and tetanus pre-conditioning the day before the first vaccine. Vaccine components A and B were administered separately, with a delay between them, to determine if it was an individual component or a combination of the components that resulted in adverse reactions.
89479393|NCT06039449|Experimental|Cohort B VYD222|
88950998|NCT02864368|Experimental|5-day TMZ: Component A Alone|All patients receive Tetanus-Diphtheria booster vaccine at time of enrollment. Cycles of standard TMZ (150-200 mg/m^2/day on days 1-5 of each 28 day cycle) with PEP-CMV vaccination on Day 23 (-1 day, + 2 days) of each TMZ cycle and tetanus pre-conditioning the day before the first vaccine.
88950999|NCT02864368|Experimental|21-day TMZ: Component A Alone|All patients receive Tetanus-Diphtheria booster vaccine at time of enrollment. Cycles of dose-intensified TMZ (75-100 mg/m^2/day on days 1-21 of each 28 day cycle) with PEP-CMV vaccination on day 23 (-1 day, + 2 days) of each TMZ cycle and tetanus pre-conditioning the day before the first vaccine.
88951000|NCT02856698|Experimental|midazolam|The dose of midazolam intravenously will be of 1 mg which may be repeated until a total dose of 3 mg.
88951001|NCT02856698|Active Comparator|morphine|The dose of morphine intravenously is of 2-4 mg which may be repeated until a total dose of 8 mg if the patient continue suffering from severe anxiety or distress caused by APE
88951002|NCT02812225||BrainPulse|BrainPulse recordings will be obtained from patients when they come in to the ED after a trauma event. BrainPulse recordings will be also obtained from those subjects who also consent for follow-up.
88951003|NCT02660164||Cohort A: High-Risk of Concussion|Middle school, high school and college athletes of either gender participating in sports where high-risk of concussion is anticipated: football, soccer, lacrosse, hockey, basketball, ice hockey, field hockey, rugby, cheerleading, boxing, and gymnastics.
88951004|NCT02660164||Cohort B: Low-Risk of Concussion|Middle school, high school and college athletes of either gender participating in sports where low-risk of concussion is anticipated: swimming, track, volleyball, baseball, softball and golf.
88951005|NCT02625610|Experimental|Chemotherapy + Best Supportive Care (BSC)|In Maintenance Phase, participants continued the same regimen of oxaliplatin-fluoropyrimidine doublet chemotherapy (oxaliplatin + 5FU/LV or oxaliplatin + capecitabine) as they received during the Induction Phase until disease progression, significant clinical deterioration, unacceptable toxicity, or discontinuation. Participants who were not deemed eligible to receive chemotherapy at the dose and schedule specified above received BSC alone once every 3 weeks. BSC was defined as treatment administered with the intent to maximize quality of life without a specific antineoplastic regimen and was based on Investigator's discretion.
88951006|NCT02625610|Experimental|Avelumab|In Maintenance phase, participants received avelumab as a 1-hour intravenous (IV) infusion at 10 milligrams per kilogram (mg/kg) once every 2-week treatment cycle until progressive disease or unacceptable toxicity or discontinuation.
89202991|NCT00989482|Experimental|Computer Kiosk Eduction|
89479394|NCT06039449|Placebo Comparator|Cohort B Placebo|
89479395|NCT06037798||Bruxism|subjects with known bruxism, no TMD, primary headache or neck pain
89479396|NCT06037798||healthy|non-bruxism, no primary headache, TMD or neck pain
89479397|NCT06036173||developed lymphedema after breast cancer surgery|
89479398|NCT06036173||did not develop lymphedema after breast cancer surgery|
89479399|NCT06036173||without a history of any cancer surgery|
89479400|NCT06032975||Cohort 1:|Patients undergoing their first medical treatment for OC (including adjuvant and neo-adjuvant chemotherapy and first-line treatment for advanced in patients not previously treated with adjuvant chemotherapy)
89479401|NCT06032975||Cohort 2|Patients undergoing their second medical treatment for OC (including the second-line treatment for advanced disease and the first-line treatment for advanced disease in patients previously treated with adjuvant CT)
89479402|NCT06032975||Cohort 3|Patients undergoing their third medical treatment for OC (including the third-line treatment for advanced disease and the second-line treatment for advanced disease in patients previously treated with adjuvant CT)
88951007|NCT02548689||Non-scarring hair loss|Patients seen at Northwestern Memorial Hospital or Northwestern Medical Faculty Foundation physician offices that have undergone evaluation for hair loss and have a diagnosis of androgenetic alopecia, telogen effluvium or alopecia areata.
88951008|NCT02548689||Control|Age-matched controls who do not have a history of hair loss and have normal scalp skin without evidence of hair loss.
88951009|NCT02545660|Experimental|QLF Image|At each of the three visits tooth brushing advice will be given. The participants in the QLF group will be shown the QLFD images.Standardized oral hygiene reinforcement shall be given based on the images. The oral hygiene instruction will focus on the areas of the teeth which require greater emphasis, as shown by the images. Thus the patients should benefit from this detailed instruction.
88951010|NCT02545660|Experimental|White light Image|At each of the three visits tooth brushing advice will be given. The participants in the white light image group will be shown the White light images.Standardized oral hygiene reinforcement shall be given based on the White light images. The oral hygiene instruction will focus on the areas of the teeth which require greater emphasis, as shown by the images. Thus the patients should benefit from this detailed instruction.
88951011|NCT02514447|Experimental|Placebo + Topotecan 1.5 mg/m² - Parts 2a and 2b|"Patients in Parts 2a and 2b were randomized 1:2 to placebo. Patients received placebo administered IV once daily on Days 1 to 5 of each 21-day topotecan chemotherapy cycle.~Following administration of placebo on Days 1 to 5, patients received IV topotecan (1.5 mg/m²)."
88951012|NCT02514447|Experimental|Trilaciclib (G1T28) 240 mg/m² + Topotecan 0.75 mg/m² - Part 2a|"Patients in Part 2a were randomized 2:1 to trilaciclib. Patients received trilaciclib (240 mg/m²) administered IV once daily on Days 1 to 5 of each 21-day topotecan chemotherapy cycle.~Following administration of trilaciclib on Days 1 to 5, patients received IV topotecan (0.75 mg/m²)."
88951013|NCT02514447|Experimental|Trilaciclib (G1T28) 240 mg/m² + Topotecan 1.5 mg/m² - Part 2b|"Patients in Part 2b were randomized 2:1 to trilaciclib. Patients received trilaciclib (240 mg/m²) administered IV once daily on Days 1 to 5 of each 21-day topotecan chemotherapy cycle.~Following administration of trilaciclib on Days 1 to 5, patients received IV topotecan (1.5 mg/m²)."
88951014|NCT02514447|Experimental|Trilaciclib (G1T28) 200 mg/m² + Topotecan 1.5 mg/m² - Cohort 1- Part 1|"Patients received trilaciclib (200 mg/m²) administered intravenously (IV) once daily on Days 1 to 5 of each 21-day topotecan chemotherapy cycle.~Following administration of trilaciclib on Days 1 to 5, patients received IV topotecan (1.50 mg/m²)."
88951015|NCT02514447|Experimental|Trilaciclib (G1T28) 200 mg/m² + Topotecan 1.25 mg/m² - Cohort 2- Part 1|"Patients received trilaciclib (200 mg/m²) administered intravenously (IV) once daily on Days 1 to 5 of each 21-day topotecan chemotherapy cycle.~Following administration of trilaciclib on Days 1 to 5, patients received IV topotecan (1.25 mg/m²)."
88951016|NCT02514447|Experimental|Trilaciclib (G1T28) 200 mg/m² + Topotecan 0.75 mg/m² - Cohort 3- Part 1|"Patients received trilaciclib (200 mg/m²) administered intravenously (IV) once daily on Days 1 to 5 of each 21-day topotecan chemotherapy cycle.~Following administration of trilaciclib on Days 1 to 5, patients received IV topotecan (0.75 mg/m²)."
88951017|NCT02514447|Experimental|Trilaciclib (G1T28) 240 mg/m² + Topotecan 0.75 mg/m² - Cohorts 4 and 6- Part 1|"Patients received trilaciclib (240 mg/m²) administered intravenously (IV) once daily on Days 1 to 5 of each 21-day topotecan chemotherapy cycle.~Following administration of trilaciclib on Days 1 to 5, patients received IV topotecan (0.75 mg/m²)."
88951018|NCT02514447|Experimental|Trilaciclib (G1T28) 280 mg/m² + Topotecan 0.75 mg/m² - Cohort 5- Part 1|"Patients received trilaciclib (280 mg/m²) administered intravenously (IV) once daily on Days 1 to 5 of each 21-day topotecan chemotherapy cycle.~Following administration of trilaciclib on Days 1 to 5, patients received IV topotecan (0.75 mg/m²)."
89202992|NCT04348981|Experimental|Wearable|All patients eligible to enroll in the Enhanced Recovery after Cardiac Surgery pathway will be offered a wearable fitness tracking device.
89202993|NCT00934011|Experimental|Group 1 - C-reactive protein (CRP) guided ab therapy|Intervention on antibiotic therapy will be based on circulating CRP levels
89479403|NCT06032975||Cohort 4|Patients undergoing their fourth medical treatment for OC (including the fourth- treatment for advanced disease and the third-line treatment for advanced disease in patients previously treated with adjuvant CT)
89479404|NCT06022757|Experimental|Dose escalation and Safety of XNW5004 in combination with KEYTRUDA® (pembrolizumab) (Phase Ib)|Dose escalation and safety with repeated administrations of XNW5004 in combination with infusions of KEYTRUDA® (pembrolizumab) in patients with advanced solid tumors.
88951019|NCT02514447|Experimental|Trilaciclib (G1T28) 240 mg/m² + Topotecan 1.0 mg/m² - Cohort 7- Part 1|"Patients received trilaciclib (240 mg/m²) administered intravenously (IV) once daily on Days 1 to 5 of each 21-day topotecan chemotherapy cycle.~Following administration of trilaciclib on Days 1 to 5, patients received IV topotecan (1.0 mg/m²)."
89202994|NCT00934011|Active Comparator|Group 2 - procalcitonin (PCT) guided ab therapy|Intervention on antibiotic therapy will be based on circulating PCT levels
89202995|NCT02554032|Active Comparator|Axillary artery cannulation|Axillary artery cannulation for antegrade cerebral perfusion
89202996|NCT02554032|Active Comparator|Innominate artery cannulation|Innominate artery cannulation for antegrade cerebral perfusion
88951020|NCT02322762||One single cohort.|One single cohort of patients with type 2 diabetes mellitus initiating their second line anti-diabetic therapy after first line anti-diabetic therapy.
89479405|NCT06022757|Experimental|HNSCC：XNW5004 in combination with KEYTRUDA® (pembrolizumab) (Phase II - cohort 1)|Repeated administrations of XNW5004 in combination with infusions of KEYTRUDA® (pembrolizumab) in patients with head and neck squamous cell carcinoma (including nasopharyngeal carcinoma), urothelial carcinoma, metastatic castration-resistant prostate adenocarcinoma, small cell lung cancer, non-small cell lung cancer, other solid tumor (including cervical cancer)
89479406|NCT06022757|Experimental|Urothelial carcinoma：XNW5004 in combination with KEYTRUDA® (pembrolizumab) (Phase II - cohort 2)|Repeated administrations of XNW5004 in combination with infusions of KEYTRUDA® (pembrolizumab) in patients with urothelial carcinoma
88951021|NCT02257346|Active Comparator|Lidocaine|Intravenous lidocaine 1.5 mg/Kg bolus dose and 2mg/Kg/hr infusion
88951022|NCT02257346|Placebo Comparator|Normal Saline|Intravenous normal saline infusion
88951023|NCT02167477|Active Comparator|Laryngoscopy sequence 1|Macintosh laryngoscopy Storz C-MAC, standard blade Storz C-MAC, D-BLADE
88951024|NCT02167477|Active Comparator|Laryngoscopy sequence 2|Macintosh Storz C-MAC, D-BLADE Storz C-MAC, standard blade
88951025|NCT02096393|Experimental|Patient specific instrumentation|The patient will undergo using patient specific instrumentation
88951026|NCT02096393|Active Comparator|Standard instrumentation|The patient will undergo surgery using standard instrumentation
88951027|NCT02031978||WIC Program Participants|The cohort is made up of infants. Pregnant women enrolling in WIC for the first time for that pregnancy and mothers/caregivers of infants younger than 2.5 months of age enrolling in WIC for the first time are recruited to participate.
88951028|NCT01861184||LRTI group|Non-pneumonic LRTI (no radiological consolidation but the presence of clinical signs) or community acquired pneumonia (radiological consolidation) Able to give fully informed consent (mental capacity assessed using trust guidelines) Age>18yrs old Fluent English speaker
88951029|NCT01861184||Control group|Able to give fully informed consent (mental capacity assessed using trust guidelines) Age>18yrs old Fluent English speaker
88951030|NCT01785563|Experimental|Nasal NIV-NAVA|Infants will be transitioned from their current mode of ventilation to nasal NIV-NAVA. If patients are currently on nasal NIV-NAVA an increase in the NAVA level will be utilized for the intervention.
88951031|NCT01595802||Subjects without Vasospasm|Transcranial Doppler (TCD) will be used to evaluate if subject has a vasospasm. Intervention with Nautilus NeuroWave recording to obtain baseline status.
88951032|NCT01595802||Subjects with Vasospasm|"Transcranial Doppler (TCD) will be used to evaluate if subject has a vasospasm. If confirmed by TCD, the degree of vasospasm will also be evaluated and classified as mild, moderate and severe Vasospasm.~Intervention with Nautilus NeuroWave recording to obtain recordings with mild, moderate and severe Vasospasm."
88951033|NCT01480401|Experimental|low-sodium diet|(1500 mg daily)
89202997|NCT04040504|Experimental|Pentax ED-34i10T2 Duodenoscope with Disposable Cap (DEC)|Pentax ED-34i10T2 Duodenoscope with Disposable Cap (DEC)
89479407|NCT06022757|Experimental|mCRPC：XNW5004 in combination with KEYTRUDA® (pembrolizumab) (Phase II - cohort 3)|Repeated administrations of XNW5004 in combination with infusions of KEYTRUDA® (pembrolizumab) in patients with metastatic castration-resistant prostate adenocarcinoma
89479408|NCT06022757|Experimental|Small cell lung cancer：XNW5004 in combination with KEYTRUDA® (pembrolizumab) (Phase II - cohort 4)|Repeated administrations of XNW5004 in combination with infusions of KEYTRUDA® (pembrolizumab) in patients with small cell lung cancer
89479409|NCT06022757|Experimental|non-small cell lung cancer:XNW5004 in combination with KEYTRUDA®(pembrolizumab)(PhaseII-cohort5)|Repeated administrations of XNW5004 in combination with infusions of KEYTRUDA®(pembrolizumab) in patients with non-small cell long cancer
89479410|NCT06022757|Experimental|：XNW5004 in combination with KEYTRUDA® (pembrolizumab) (Phase II - cohort 6)|Repeated administrations of XNW5004 in combination with infusions of KEYTRUDA® (pembrolizumab) in patients with other solid tumor (including cervical cancer)
88951034|NCT01480401|No Intervention|moderate-sodium diet|sodium (100 mmol or 2300 mg daily; Usual Care)
88951035|NCT01434290|Experimental|5 Fractions|36.25 Gy IMRT in 5 fractions over two and a half weeks
88951036|NCT01434290|Experimental|12 Fractions|51.6 Gy IMRT in 12 fractions over two and a half weeks
88951037|NCT01210313||no treatment|
88951038|NCT00951769||Control,|Control
88951039|NCT00951769||DAS: Difficult Airway Society, UK|DAS difficult airway algorithm
89202998|NCT04040504|Active Comparator|Pentax ED-34i10T Duodenoscope|Pentax ED-34i10T Duodenoscope
88951040|NCT00951769||Australian|Australian difficult airway algorithm
88951041|NCT00788502|Experimental|Healing Touch|Healing Touch (HT) is a gentle form of energy balancing work that promotes relaxation. Subjects in this arm will receive three one-hour sessions of Healing Touch during the first two weeks of their IVF cycle.
88951042|NCT00788502|Experimental|Desensitization Therapy|Desensitization Therapy is a quasi-desensitization procedure where subjects meet with a therapist and generate a list of stressful thoughts and a list of neutral thoughts. Subjects in this arm will receive three one-hour sessions of Desensitization Therapy during the first two weeks of their IVF cycle.
88951043|NCT00788502|No Intervention|Standard Care|Subjects in this arm will receive no therapeutic intervention.
88951044|NCT00765791|Active Comparator|Group 1 (Not 2B)|Selective neck dissection is performed on the dominant arm. Level 2B is not dissected.
88951045|NCT00765791|Active Comparator|Group 2 (2B)|Selective neck dissection is performed on the dominant arm. Level 2B is dissected.
88951046|NCT00750269|Experimental|Level 1: 8.0 Gy/FX|SBRT 40.0 Gy
88951047|NCT00750269|Experimental|Level 2: 8.5 Gy/FX|SBRT 42.5 Gy
88951048|NCT00750269|Experimental|Level 3: 9.0 Gy/FX|SBRT 45.0 Gy
88951049|NCT00750269|Experimental|Level 4: 9.5 Gy/FX|SBRT 47.5 Gy
88951050|NCT00750269|Experimental|Level 5: 10.0 Gy/FX|SBRT 50.0 Gy
88951051|NCT00750269|Experimental|Level 6: 10.5 Gy/FX|SBRT 52.5 Gy
88951052|NCT00750269|Experimental|Level 7: 11.0 Gy/FX|SBRT 55.0 Gy
88951053|NCT00750269|Experimental|Level 8: 11.5 Gy/FX|SBRT 57.5 Gy
89202999|NCT01055119|Active Comparator|Omega-3 fatty acids|
89479411|NCT06016452|Experimental|Stratum A (Symptomatic)|Response rates at 1 month with a combination of steroids and CHL in this study is expected to be 65% as compared to the standard 50% response with the use of dexamethasone alone. For the study with an α of 0.1 and power of 80%,50 pts will be needed to achieve the desired output. In the first stage, 22 patients will be needed for assessment and continued to stage 2 if >10 responses are seen.The stage 2 of the study will be considered successful if >29 responses are achieved using the pre-specified response assessment criteria.Considering an attrition rate of 10% from lack of follow-up and another 10% for disease progression, an estimated 60 patients will be accrued in stratum A with the purpose of achieving 50 patients with endpoints available for analysis.
89479412|NCT06016452|Experimental|Stratum B (Asymptomatic)|"This stratum includes pts without neurological worsening during imaging diagnosis of RN (asymptomatic RN).Approx 30% of patients continue to be neurologically/ radiologically stable or regression of imaging findings without need for further interventions (including corticosteroids).In the proposed study with the use of CHL, 45% patients are assumed to remain clinically and neurologically stable. With an α of 0.1 and power of 80%, 48 patients will be needed to achieve the desired outcome. In the first stage, 23 patients will be needed for assessment and continue to stage 2 if >6 responses are seen.~The phase 2 study will be considered successful if >18 responses are achieved using the pre-specified response assessment criteria. Further considering an attrition rate of 10% from lack of follow-up and another 10% for disease progression, an estimated 58 patients will be accrued in stratum B with the purpose of achieving 48 patients with endpoints available for analysis."
88951054|NCT00750269|Experimental|Level 9: 12.0 Gy/FX|SBRT 60.0 Gy
89479413|NCT06015178|Experimental|Intelligent Language Model Group|Subjects must use the intelligent language model to complete the retrieval and protocol design execution of an interdisciplinary task, in addition to Google search, literature search and book query.
89479414|NCT06015178|Placebo Comparator|Control Group|Subjects can only use Google search, literature retrieval and book query, and cannot use any AI-driven conversational natural language processing tools to complete the retrieval and protocol design execution of an interdisciplinary task.
89479415|NCT06012812|Experimental|SHR-1819 injection|
89479416|NCT06011889|Experimental|Etanercept|treatment with etanercept in addition to NSAID treatment and/or classic Disease Modifying Antirheumatic Drugs
88951055|NCT00712322|Experimental|Cohort 1 (Darifenacin 0.030 mg/kg/day)|Following a 7-day washout period, participants received darifenacin liquid oral suspension, 0.030 milligrams/kilogram/day (mg/kg/day) dispensed per twice a day (BID) dosing, for 14 days.
88951056|NCT00712322|Experimental|Cohort 2 (Darifenacin 0.0625 mg/kg/day)|Following a 7-day washout period, participants received darifenacin liquid oral suspension, 0.0625 mg/kg/day dispensed per BID dosing, for 14 days.
88951057|NCT00712322|Experimental|Cohort 3 (Darifenacin 0.125 mg/kg/day)|Following a 7-day washout period, participants received darifenacin liquid oral suspension, 0.125 mg/kg/day dispensed per BID dosing, for 14 days.
88951058|NCT00370604|Experimental|1|19g needle, 23g catheter
89203000|NCT01055119|Placebo Comparator|Olive oil|
88951059|NCT00370604|Active Comparator|2|traditional =>18g needle
88951060|NCT00323856|Experimental|Coagulation factor VIII (Human)|Anti-Hemophilic coagulation factor VIII (Human) Alphanate SD/HT
89479417|NCT06011889|Placebo Comparator|Placebo|treatment with placeboin addition to NSAID treatment and/or classic Disease Modifying Antirheumatic Drugs
89479418|NCT06010017|Experimental|STEPP|"Participants will be randomized in 1:1 fashion, stratified by transplant type (autologous vs. allogeneic), and will complete study procedures as follows:~Baseline self-reported assessment (in-person or remotely).~Virtual, STEPP intervention sessions 1x weekly for five weeks with peer mentor.~HSCT and hospitalization per standard of care.~Day +60 (+/- 10 days) and Day +100 (+/- 10 days) self-reported assessments.~Optional exit interview with study staff (10-20 participants)."
88951061|NCT05415150|Experimental|Measurement of Platelet function|Patients with ischemic stroke may be given alteplase or other thrombolytic. Additionally, patients may be given IV platelet inhibitors and subjected to thrombectomy. Platelet functions are measured after intervention.
88951062|NCT05414942|No Intervention|Treatment As Usual (TAU)|No intervention will be administered.
88951063|NCT05414942|Experimental|Opioid Reduction Program|Participants will engage in a brief, educational intervention pre-surgery and a brief booster session 2 weeks post-surgery.
88951064|NCT05414929|Experimental|HPV self-sampling group|
88951065|NCT05414890||Cell Based Assay (CBA)|The sera samples from patients and control subjects, upon clinic visits, as well as during follow up, will be randomly numbered. All samples will be blindly tested with CBA by different operators.
88951066|NCT05414890||CBA-TSA Assay|The sera samples from patients and control subjects, upon clinic visits, as well as during follow up, will be randomly numbered. All samples will be blindly tested with CBA-TSA by different operators.
88951067|NCT05414799|Other|Control Group|in control group,33 participants (17=male, 16=female) performed figure eight vision exercise for 30 seconds once a day for 4 to 5 days per week for total duration of 4 week.
88951068|NCT05414799|Experimental|Experimental Group|in experimental group, 33 participants (17=male, 16=female) performed figure eight vision exercise for 30 seconds followed by chin nodding for 20 second and followed by self neck stretching for 20 seconds. All the exercises are performed once a day for 4 to 5 days per week for total duration of 4 week.
88951069|NCT05414721|Active Comparator|Low flow desflurane anesthesia (Group D)|All patients were preoxygenated for three minutes. Midazolam 0.03 mg/kg, fentanyl 1.5 mcg/kg , propofol 2 mg/kg and rocuronium 0.6 mg/kg were administered iv for induction of anesthesia. After intubation all patients were mechanically ventilated with 50% O2+50% air + 6-7% desflurane in a 4 L/min fresh gas flow until the MAC value reached 1. When the MAC value of desflurane was 1, fresh gas flow was decreased to 0.5 L/min (60% O2+40% air) in Group D. Hemodynamic parameters, SpO2 and BIS values were recorded after induction, at the beginning of low flow/normal flow anesthesia and every 5 minutes during surgery. The patients were observed in terms of side effects and complications during the operation and in the postoperative period. To research the liver and the kidney functions, blood samples were taken pre-induction, post-surgery, and at the postoperative 24th hour by venous route.
89203001|NCT00934167|Experimental|Test|Hipolabor
89203002|NCT00934167|Active Comparator|Comparator|5.000 USP/mL - APP
89203003|NCT00801606|Experimental|Study drug containing zinc alone|Zinc 20 mg daily
89479419|NCT06010017|No Intervention|Usual Care|"Participants will be randomized in 1:1 fashion, stratified by transplant type (autologous vs. allogeneic), and will complete study procedures as follows:~Baseline self-reported assessment.~HSCT and hospitalization per standard of care.~Day +60 (+/- 10 days) and Day +100 (+/- 10 days) self-reported assessments."
89479420|NCT06006026|Experimental|ropivacaine|Patients will receive a TAP block using 1.5 mg/kg, 2.0 mg/kg or 2.5 mg/kg of ropivacaine. If there is no LAST (local anesthetic systemic toxicity) in the three subjects of 1.5 mg/kg group, the next three patients will receive 2.0 mg/kg of ropivacaine. Another three patients will receive 2.5 mg/kg of ropivacaine if there is no LAST in the three subjects of 2.0 mg/kg group. All subjects will be administered an i.v. bolus of lidocaine 2.0 mg/kg (given as an infusion for 10 min) after anaesthesia induction, then continuous infusion at 2 mg/kg/h until the end of surgery.
89479421|NCT06004271|Active Comparator|control group|In the control group, only the exercise program was applied and the first and last measurements will be compared.
89479422|NCT06004271|Experimental|experimental group|In the experimental group, kinesiology taping will be applied twice a week for 8 weeks together with exercise. Kinesiology taping was first applied by closing the malleoli from the upper part of the foot, and stretching it to the anterior capsule of the foot using the ligament technique. For the second tape, it covered the plantar area under the malleolus and was attached in the form of stirrups. During the application, the tape will be applied with full tension on the malleolus and 50-75% tension will be applied on the other parts.
89479423|NCT06004271|Placebo Comparator|placebo group|Tape application will be applied in the placebo group as it was in the experimental group. Kinesiology taping will be attached horizontally without tension along the Tensor Facie Late line. The application to the ankle will be attached horizontally without tension slightly above the lateral malleolus.
89479424|NCT06002152|Experimental|Bupivacaine|Participants randomized to this arm will receive 10ml of 0.25% bupivacaine on each side of the bilateral block. This will be done after induction of general anesthesia and prior to start of surgery.
89479425|NCT06002152|Placebo Comparator|Placebo|Participants randomized to this arm will receive 10ml of saline on each side of the bilateral block. This will be done after induction of general anesthesia and prior to start of surgery.
89479426|NCT06001515|Active Comparator|Dual scan protocol|Two CBCT scans will be made.One while the patient wearing the radiographic stent and another CBCT for the radiographic stent alone.
89479427|NCT06001515|Experimental|Dual scan protocol +3D facial scan record|3D face scan record will be made plus Two CBCT scans. One while the patient wearing the radiographic stent and another CBCT for the radiographic stent alone.
89479428|NCT06000397|Experimental|Enhanced reminders|
89479429|NCT06000397|Active Comparator|Standard notifications|
89479430|NCT05999981|Active Comparator|Transversalis Fascia Plane Block (TFPB) Group|At TFPB group, the block will be performed by ultrasound guidance after completion of surgery. TFPB will be performed under ultrasonography guidance using a linear 6 to 13 megahertz ultrasound probe by the anesthesiologist. In TFPB group patients will receive 40 ml %0.25 bupivacaine divided into 2 equal doses between transversus abdominis muscle and transversalis fascia bilaterally.
89479431|NCT05999981|Active Comparator|Transversus Abdominis Plane (TAP) Block Group|At TAP block group, the block will be performed by ultrasound guidance after completion of surgery. TAP blocks will be performed under ultrasonography guidance using a linear 6 to 13 megahertz ultrasound probe by the anesthesiologist. In TAP block group patients will receive 40 ml %0.25 bupivacaine divided into 2 equal doses in the fascial plane between internal oblique muscle and transversus abdominis muscle bilaterally.
89479432|NCT05996523|Experimental|Arm 1|PRGN 5x10^11 Viral Particles (VP) SC plus pembrolizumab 200mg IV as induction/ neoadjuvant therapy
89479433|NCT05996497|Other|Auditory Rhythmic at 30 Hz then GraphoGame|Training 1 with Auditory Rhythmic at 30 Hz (6 weeks) then Training 2 with GraphoGame (6 weeks)
89479434|NCT05996497|Other|GraphoGame then Rhythmic Auditory at 30 Hz|Training 1 with GraphoGame (6 weeks) then Training 2 with Auditory Rhythmic at 30 Hz (6 weeks)
89479435|NCT05996497|Other|Auditory Rhythmic at low frequencies then GraphoGame|Training 1 with Auditory Rhythmic at low frequencies (6 weeks) then Training 2 with GraphoGame (6 weeks)
89479436|NCT05996497|Other|GraphoGame then Auditory Low Frequency Rhythmic|Training 1 with GraphoGame (6 weeks) then Training 2 with Auditory Rhythmic at Low Frequency Rhythmic (6 weeks)
89479437|NCT05994937|Experimental|Active Portable Air Cleaner (PAC) Filtration|High Efficiency Particulate Air (HEPA) filter will be left intact in the PAC for 4 weeks.
88951070|NCT05414721|No Intervention|Normal flow desflurane anesthesia (Group N)|All patients were preoxygenated for three minutes. Midazolam 0.03 mg/kg, fentanyl 1.5 mcg/kg , propofol 2 mg/kg and rocuronium 0.6 mg/kg were administered iv for induction of anesthesia. After intubation all patients were mechanically ventilated with 50% O2+50% air + 6-7% desflurane in a 4 L/min fresh gas flow until the MAC value reached 1. When the MAC value of desflurane was 1, fresh gas flow was decreased to 2 L/min (40% O2+60% air) in Group N. Hemodynamic parameters, SpO2 and BIS values were recorded after induction, at the beginning of low flow/normal flow anesthesia and every 5 minutes during surgery. The patients were observed in terms of side effects and complications during the operation and in the postoperative period. To research the liver and the kidney functions, blood samples were taken pre-induction, post-surgery, and at the postoperative 24th hour by venous route.
88951071|NCT05414695|Experimental|Real acupuncture|The patient receives five sessions (weekly) of real acupuncture treatment in the acupuncture points LI4, S6, S7 and SI18. Each session lasts 30 minutes.
88951072|NCT05414695|Placebo Comparator|Placebo acupuncture|The patient receives five sessions (weekly) of placebo acupuncture in the same acupuncture points LI4, S6, S7 and SI18. Each session lasts 30 minutes. The placebo and real acupuncture devices have the same visual features but in the placebo device the needle does not even touch the skin.
88951073|NCT05414669|Experimental|Interventional group|Allopurinol 300 mg was administered orally for a total of 3 days, starting from the day before ESWL
88951074|NCT05414669|Placebo Comparator|Control Group|Placebo was administered orally for a total of 3 days, starting from the day before ESWL
88951075|NCT05414656|Experimental|Group A : Saddle contoured metal matrix|The prepared teeth received the Saddle contoured metal matrix. The saddle clip of matrix connect the band and secured around prepared cavity wall. The anatomical wedge placed into the gingival embrasure to maintain the height of gingival floor and ensure the optimal adaptation of the matrix band in the cervical region.
89479438|NCT05994937|Sham Comparator|Sham Portable Air Cleaner (PAC) Filtration|High Efficiency Particulate Air (HEPA) filter will be removed from the PAC for 4 weeks.
89479439|NCT05991791|Other|Children with autism spectrum disorders|
88951076|NCT05414656|Active Comparator|Group B:pre-contoured self-adhesive matrix|Teeth received the Pre-contoured self adhesive matrix with anatomical wedges. The adhesive end of band closed around the prepared cavity.
88951077|NCT05414643||At- risk group (SCAI stages A, B)|Patients who had a SCAI stage A or B at any point during their stay at the New Brunswick Heart Centre, Saint John Regional Hospital. This group was compared with the cardiogenic shock group only for preliminary analysis.
88951078|NCT05414643||Cardiogenic shock group (SCAI stages C-E)|Patients who had a SCAI (Society for Cardiovascular Angiography and Interventions) stage C-E at any point during their stay at the New Brunswick Heart Centre, Saint John Regional Hospital. This group was used for all subsequent analyses.
88951079|NCT05414630|Experimental|Envafolimab|Envafolimab: subcutaneous injection, 300mg, Q3W
88951080|NCT05414539|Experimental|Intervention group|"OptiCogs Online is a 6-week telehealth intervention consisting of cognitive, physical activity and educational components. Cognitive component of the intervention: Throughout the six-week intervention period, there will be three individualised one-to-one cognitive sessions (occurring on week one, week three and week five), delivered by an occupational therapist. Physical activity: The physical activity component will be delivered via telehealth by a physiotherapist.~Aerobic: Progressions from Week 1-Week 6 will result in individual achieving 60 mins moderate intensity aerobic activity @ frequency of 3 times per week as tolerated.~Muscular strengthening: Progressions from Week 1-Week 6 will result in the person post-stroke achieving 10 strengthening exercises x 10 reps x 3 sets @ frequency of 3 times per week as tolerated. Cognitive education: The cognitive education component is underpinned by the Bridges stroke self-management package and based on self-efficacy principles."
88951081|NCT05414279|Other|Capillary and venous sodium|From each patient a capillary and venous blood sample will be taken in order to determine the sodium level
88951082|NCT05414266|Experimental|4 months Placebo, then 8 months SADBE 5%|
88951083|NCT05414266|Experimental|12 months SADBE 5%|
89203004|NCT00801606|Experimental|Study drug Micronutrient without zinc|micronutrients (vitamin A, thiamine, riboflavin, vitamins B-6 and B-12, folic acid, niacin, vitamins C, E, and D, selenium, and copper) without zinc.
89203005|NCT00801606|Experimental|Study drug Micronutrient with zinc|micronutrients in combination with zinc (vitamin A, thiamine, riboflavin, vitamin B-6 and B-12, folic acid, niacin, vitamins C, E, and D, selenium, copper, and 20 mg elemental zinc).
88951084|NCT05414253|Experimental|Test group 1|"Surgery will be performed following a standardized protocol by a single operator. The procedure consists in the performance of a primary full-thickness flap incision, and of a secondary releasing vertical incision of maximum 3 mm limited to keratinized gingiva. At the end of the surgical procedure, soft tissues will be repositioned by means of a suture involving only the primary incision, while it will not be performed on the releasing incision.~Device: 0.2% chlorhexidine + anti-discoloration system + hyaluronic acid mouth rinse The mouth rinse protocol assigned to each study participant included a 10 ml-rinse for 60 seconds twice-a-day (every 12 hours) for 14 days."
88951085|NCT05414253|Experimental|Test group 2|"Surgery will be performed following a standardized protocol by a single operator. The procedure consists in the performance of a primary full-thickness flap incision, and of a secondary releasing vertical incision of maximum 3 mm limited to keratinized gingiva. At the end of the surgical procedure, soft tissues will be repositioned by means of a suture involving only the primary incision, while it will not be performed on the releasing incision.~Device: 0.2% chlorhexidine + anti-discoloration system mouth rinse The mouth rinse protocol assigned to each study participant included a 10 ml-rinse for 60 seconds twice-a-day (every 12 hours) for 14 days."
88951086|NCT05414253|Placebo Comparator|Control Group|"Surgery will be performed following a standardized protocol by a single operator. The procedure consists in the performance of a primary full-thickness flap incision, and of a secondary releasing vertical incision of maximum 3 mm limited to keratinized gingiva. At the end of the surgical procedure, soft tissues will be repositioned by means of a suture involving only the primary incision, while it will not be performed on the releasing incision.~Device: placebo mouth rinse The mouth rinse protocol assigned to each study participant included a 10 ml-rinse for 60 seconds twice-a-day (every 12 hours) for 14 days."
89203006|NCT00801606|Placebo Comparator|Placebo|Placebo only
89479440|NCT05991076||Activate Bailando Dance Program|The Activate Bailando program is a 6-week dance-focused exercise program that focuses on balance and social connectedness for community-dwelling Spanish-speaking older adults.
89203007|NCT05408806||Virtual Reality Games Group with Nintendo Wii Balance Platform|In addition to neurodevelopmental treatment, the cases are treated with virtual reality (VR) games on nintendo wii balance board for 8 weeks, 2 sessions a week. The VR games are performed twice in the first four weeks at the beginner level. During the following four weeks, advanced levels of the same games are selected and virtual reality therapy is performed with 2 repetitions.
89479441|NCT05987306|Experimental|Intervention|a standard weight loss and internalized weight bias intervention with self-compassion exercises
89479442|NCT05987202||Preterm infants born between January 1st, 2018 and December 31st, 2022|All infants born alive before 37 weeks between January 1st, 2018 and December 31st, 2022 with PDA
89479443|NCT05985642||Observational PIC Destination Cohort|"Step 1: Continued analytical treatment interruption (ATI) - During Step 1, PICs will be monitored for safety (including liver function, creatinine, pregnancy, and STI testing), viral, immune, neuropsychological, and socio-behavioral outcomes for up to 96 weeks of continued ATI.~Step 2: ART Restart - Participants will begin Step 2 if they meet ART restart criteria or reach week 96. Participants will be monitored for safety (including liver function, creatinine, and pregnancy), immune, viral, neuropsychological, and socio-behavioral outcomes through 48 weeks after ART restart."
89479444|NCT05983341||Children (<18 years old) with Berlin Heart EXCOR assisting device.|
89479445|NCT05981963|Experimental|[14C]-BMS-986196|
89479446|NCT05981144||Experimental|Patients with heart failure without significant stenosis of the major epicardial coronary artery and reduced left ventricular ejection fraction below 40%
88951087|NCT05414188|Active Comparator|Pulmonary rehabilitation group|Patients will receive the radiation therapy according to the existing schedule. Additionally, patients in pulmonary rehabilitation group will participate pulmonary rehabilitation program more than two times per week.
88951088|NCT05414188|No Intervention|Control group|Patients will receive the radiation therapy according to the existing schedule. There will be no additional treatment
88951089|NCT05414149|Active Comparator|IVR group|Patients that received intravitreal ranibizumab injections (IVR) (0.5mg/0.05ml) before vitreous surgery were assigned to IVR group 3-5 days before three-port transconjunctival 25-G pars plana vitrectomy (PPV). All patients underwent 25-gauge transconjunctival sutureless vitrectomy using the 25-gauge Constellation system (Alcon, Fort Worth, TX, USA) system under local or anesthesia. A speed of 5000 cuts per minute was used for vitrectomy.
88951090|NCT05414149|Experimental|IVC group|Patients that received intravitreal conbercept injection (IVC) (0.5mg/0.05ml) before vitreous surgery were assigned to IVC group 3-5 days before three-port transconjunctival 25-G pars plana vitrectomy (PPV). All patients underwent 25-gauge transconjunctival sutureless vitrectomy using the 25-gauge Constellation system (Alcon, Fort Worth, TX, USA) system under local or anesthesia. A speed of 5000 cuts per minute was used for vitrectomy.
89479447|NCT05978206|Experimental|Nandrolone|
88951091|NCT05413993|Active Comparator|intra and extraoral application|The laser was applied for 60 seconds, in 2 intraoral points and 2 extraoral points.
88951092|NCT05413993|Experimental|extraoral application|The laser was applied only extraoral points
88951093|NCT05413967|Experimental|Mills manipulation in addition to myofasical release therapy|mills manipulation
88951094|NCT05413967|Experimental|Nirschl exercises in addition to myofascial release therapy|Nirschel exercises
89479448|NCT05978206|Placebo Comparator|Placebo|
89479449|NCT05977595||Deep hand burns|Adult subjects, who were hospitalized at the Pierre Colson Burn Center with a hand burn that required releasing incisions.
89479450|NCT05976867|Experimental|PAT + Smart Parents|Participants in this arm will receive the additional Smart Parents module, added to Parents as Teachers (PAT) in which they are already enrolled. This is the experimental condition.
89479451|NCT05976867|Active Comparator|PAT as usual|Participants in this arm will continue to receive Parents as Teachers (PAT) as usual. This is the treatment as usual condition (comparison).
89479452|NCT05973006|Experimental|Group-A NVX-CoV2601|The Monovalent NVX-CoV2601 of 5 μg of antigen with 50 μg of Matrix-M adjuvant
89479453|NCT05973006|Active Comparator|Group-B Bivalent NVX CoV2373 + NVX CoV2601|The Bivalent NVX CoV2373 + NVX CoV2601 of 5 μg of each antigen with a total of 50 μg of Matrix-M adjuvant
89479454|NCT05971641|Active Comparator|intervention group|The experimental group is the one in which progressive relaxation exercises will be taught, and we will monitor the results in patients.
89479455|NCT05971641|No Intervention|control group|The control group is the one in which the service routine is implemented, and progressive relaxation exercises are not taught but monitored.
89479456|NCT05970354|Active Comparator|EMLA Cream|5 grams will be applied to patient's cervix 7 minutes before gynecological procedure
89479457|NCT05970354|Placebo Comparator|VersaPro Cream|5 grams will be applied to patient's cervix 7 minutes before gynecological procedure
89479458|NCT05967052|Experimental|Pregabalin|
89479459|NCT05967052|Experimental|Pregabalin + Rehabilitation|
89479460|NCT05967052|Experimental|Rehabilitation + Placebo|
89479461|NCT05967052|Placebo Comparator|Placebo|
89479462|NCT05966090|Experimental|RSV+ HZ/su Co-administration Group|Participants will be administered first dose of HZ/su vaccine and the RSVPreF3 OA investigational vaccine together on Day 1. A second dose of the HZ/su vaccine will be administered at Day 61.
89479463|NCT05966090|Active Comparator|RSV+HZ/su Control Group|Participants will be administered first dose HZ/su vaccine on Day 1, followed by the RSVPreF3 OA investigational vaccine on Day 31, and then second dose of HZ/su vaccine on Day 61.
89479464|NCT05964920|Placebo Comparator|Placebo|"The placebo group will complete 10-week treatment period where they continue with their regular habitual daily physical activity and receive two placebo (saline) injections (at baseline and week 3). They will then undergo a 12-week period with no treatment and no training, where they just do their regular habitual daily physical activity. Before they undertake a period of structured, progressive resistance training for 10-weeks.~Questionnaires, physiological and psychological measures, skeletal muscle biopsies and blood samples will be taken at time points of:~Baseline (week 0)~Treatment period (week 10)~Detraining and placebo abstinence (week 22)~Retraining (week 32)"
88951095|NCT05413954|Placebo Comparator|Control|Control snack
89479465|NCT05964920|Experimental|Testosterone Undecanoate|"The testosterone group will complete 10-week treatment period where they continue with their regular habitual daily physical activity and receive two testosterone undecanoate (Nebido) injections (1000 mg/4 ml at baseline and 500 mg/2 ml week 3). They will then undergo a 12-week period with no treatment and no training, where they just do their regular habitual daily physical activity. Before they undertake a period of structured, progressive resistance training for 10-weeks.~Questionnaires, physiological and psychological measures, skeletal muscle biopsies and blood samples will be taken at time points of:~Baseline (week 0)~Treatment period (week 10)~Detraining and testosterone abstinence (week 22)~Retraining (week 32)"
88951096|NCT05413954|Experimental|Test|Test snack
88951097|NCT05414227||PSD|Depressed as assessed by the Hamilton Depression Scale 3 months after stroke
88951098|NCT05414227||Non PSD|Nondepressed as assessed by the Hamilton Depression Scale 3 months after stroke
88951099|NCT05413902|Experimental|MMA Protocol Group|"Preoperative Medications~Orphenadrine 100mg PO once preop~Gabapentin 800mg PO once preop~Toradol 60mg IV once preop~Acetaminophen 1,000mg PO once preop~Intraoperative Paraspinal Infusion~Bupivacaine 30cc~Epinephrine 1cc~Xylocaine-MPF Intramuscular Inj 0.5% (30cc of Saline Solution)~Postoperative Medications~Orphenadrine 100mg PO BID~Gabapentin 300mg PO Q6~Toradol 30mg IV Q6hrs*~Methylprednisolone 125mg Q8hrs"
88951100|NCT05413902|Active Comparator|Control (opioids) Group|"Postoperative Medication~1-Morphine 4mg Q4hrs"
89203008|NCT05408806||Hippotherapy Simulator Group|In addition to neurodevelopmental treatment, the cases are treated on a hippotherapy simulator for 8 weeks, 2 sessions a week. In the first 4 weeks, the warm-up and 1 speed intensities of the hippotherapy simulator are applied. During the next 4 weeks, cases are treated warm-up, 1, 2, 3, speed intensities, respectively.
89479466|NCT05964920|Placebo Comparator|Resistance exercise training + Placebo|"The resistance exercise training + placebo group will complete 10-week treatment period where they undergo a period of structured, progressive resistance training and receive two placebo (saline) injections (at baseline and week 3). They will then undergo a 12-week period with no treatment and no training, where they return to their regular habitual daily physical activity. Before they undertake a second period of structured, progressive resistance training for 10-weeks.~Questionnaires, physiological and psychological measures, skeletal muscle biopsies and blood samples will be taken at time points of:~Baseline (week 0)~Treatment period (week 10)~Detraining and placebo abstinence (week 22)~Retraining (week 32)"
89479467|NCT05964920|Experimental|Resistance exercise training + Testosterone Undecanoate|"The resistance exercise training + testosterone group will complete 10-week treatment period where they undergo a period of structured, progressive resistance training and receive two testosterone undecanoate (Nebido) injections (1000 mg/4 ml at baseline and 500 mg/2 ml week 3). They will then undergo a 12-week period with no treatment and no training, where they return to their regular habitual daily physical activity. Before they undertake a second period of structured, progressive resistance training for 10-weeks.~Questionnaires, physiological and psychological measures, skeletal muscle biopsies and blood samples will be taken at time points of:~Baseline (week 0)~Treatment period (week 10)~Detraining and testosterone abstinence (week 22)~Retraining (week 32)"
89203009|NCT00934245|Active Comparator|Inactivated Polio Vaccine (IPV)|Inactivated trivalent poliovirus vaccine (IPV) age Dose # doses/year 1 # doses year 2 and 3 6 mo -8y 0.5 ml 2 1 9-10 y 0.5 ml 1 1
89203010|NCT00934245|Experimental|Inactivated Trivalent Influenza Vaccine|Inactivated split virion trivalent influenza vaccine (TIV) age Dose # doses year 1 # doses year 2 and 3 6-35 mo 0.25 ml 2 1 3-8 y 0.5 ml 2 1 9-10 y 0.5 ml 1 1
89479468|NCT05953974||NMDAr patients|"Patients > or = 18 years old presenting with auto-immune encephalitis, defined according to the Graus criteria, with neuronal antibodies :~- Anti NMDAr"
89479469|NCT05953974||LGI1 patients|"Patients > or = 18 years old presenting with auto-immune encephalitis, defined according to the Graus criteria, with neuronal antibodies :~- Anti LGI1"
89479470|NCT05953974||CASPR2 patients|"Patients > or = 18 years old presenting with auto-immune encephalitis, defined according to the Graus criteria, with neuronal antibodies :~- Anti CASPR2"
89479471|NCT05953974||GABAb patients|"Patients > or = 18 years old presenting with auto-immune encephalitis, defined according to the Graus criteria, with neuronal antibodies :~- Anti GABAb"
89479472|NCT05953974||GAD patients|"Patients > or = 18 years old presenting with auto-immune encephalitis, defined according to the Graus criteria, with neuronal antibodies :~- Anti GAD"
89479473|NCT05953961|Active Comparator|Therasphere Transarterial Radioembolization|Two-phase treatment including mapping angiogram with personalized dosimetry followed by complete treatment of the tumor angiosome with 90-Yittrium glass microsphere infusion.
89479474|NCT05953961|Active Comparator|Microwave Ablation|Ablation performed with a high powered, gas cooled multi-antenna system targeting an ablative margin > 5mm.
89479475|NCT05952323|No Intervention|Control group|"After obtaining the necessary legal and ethical permissions for data collection, the research will commence. During this stage of the study, participants who agree to take part in the research will be asked to fill out the informed consent form. To obtain the pre-test data for the research, all forms will be filled out.~Students receiving standard care and continuing practice will be provided with information about the research. Pre-test, post-test, and follow-up test data from the control group will be obtained concurrently with the study groups."
89479476|NCT05952323|Experimental|Teach-back group|To obtain the pre-test data for the research, all forms will be filled out. According to the prepared educational materials for medical devices, students will be trained using the teach-back method. After the training, students will be asked to demonstrate their skills in using medical devices on the 7th day. The researcher will use the Medical Device Usage Competency Observer Evaluation Form to assess the student's competency in using medical devices and Medical Device Usage Competency Knowledge Test and the Medical Device Usage Competency Self-Assessment Form for post-test data. After 30 days, all forms will be filled again for the study of the sustainability of training data.
89479477|NCT05952323|Experimental|Video-assisted teaching group|After obtaining the pre-test data, students will be sent educational videos related to medical devices and asked to watch them. On the 7th day after sending the videos, students will be requested to demonstrate their skills in using medical devices. The researcher will assess the students' medical device usage competencies using the Medical Device Usage Competency Observer Evaluation Form. After completing the demonstrations regarding the use of medical devices, students will fill out the Medical Device Usage Competency Knowledge Test and the Medical Device Usage Competency Self-Assessment Form for post-test data. If there are any deficiencies in the students' safe use of devices (if applicable), the researcher will inform them and ask them to re-watch the videos. After 30 days, all forms will be filled again for the study of the sustainability of training data.
88951101|NCT05413694|Experimental|telephone interview 24 months after hospitalization for Covid-19|telephone interview 24 months after hospitalization for Covid-19
88951102|NCT05413512|Experimental|Acute psychological stress|Participants will undergo an acute psychological stress task that has been shown to elicit neural, cardiovascular, and psychological (feelings of stressfulness) responses.
88951103|NCT05413382|Active Comparator|Investigational lozenge|Lozenge containing the enzyme polyphenol oxidase and green coffee extract
89479478|NCT05952141|Experimental|Stage 1 Clinic Outreach + Stage 2 Low Touch|All participants receive direct clinic outreach to communicate readiness of results (stage 1). Participants who do not attend the clinic by 30 days (non-responders) will receive asynchronous text message reminders using framed messaging (stage 2).
89479479|NCT05952141|Experimental|Stage 1 Clinic Outreach + Stage 2 High Touch|All participants receive direct clinic outreach to communicate readiness of results (stage 1). Participants who do not attend the clinic by 30 days (non-responders) will receive asynchronous text message reminders using framed messaging in combination with synchronous patient navigation (stage 2).
89203011|NCT00934245|No Intervention|Surveillance arm|Those ineligible for vaccination will be enrolled for febrile acute respiratory illness (FARI) surveillance to assess indirect effects of vaccination in household members.
89479480|NCT05952141|Experimental|Stage 1 Enhanced Outreach + Stage 2 Low-Touch|All participants receive direct clinic outreach plus enhanced outreach to communicate readiness of results (stage 1). Participants who do not attend the clinic by 30 days (non-responders) will receive asynchronous text message reminders using framed messaging (stage 2).
89479481|NCT05952141|Experimental|Stage 1 Enhanced Outreach + Stage 2 High-Touch|All participants receive direct clinic outreach plus enhanced outreach to communicate readiness of results (stage 1). Participants who do not attend the clinic by 30 days (non-responders) will receive asynchronous text message reminders using framed messaging in combination with synchronous patient navigation.
89479482|NCT05950724|Experimental|Etanercept|Participants receive one dose (25mg) Etanercept via subcutaneous injection just prior to lung transplant. Following transplant, participants receive standard lung transplant care.
89479483|NCT05950724|No Intervention|Control|Participants receive standard lung transplant care.
89479484|NCT05949853||Patients|Patients hospitalized at the Center for Sleep and Respiratory Diseases, between 09/2022 and 11/2022 for suspected OSA All these patients underwent a full night polysomnography
89479485|NCT05949268||Patients with gastrointestinal bleeding undetected in gastroscopy and colonoscopy|Gastrointestinal bleeding in the small bowel.
89479486|NCT05948904|Experimental|Ex Vivo Cryo|Multiple procedures will be performed to each model in order to accomplish the objectives of the study. Tissue samples will be taken from the models and images will be performed. This will allow us to determine which configuration is the optimal for obtaining the more effective and stable models that could offer the best quality specimens as well.
89479487|NCT05944835||Patient who has been treated for an aortoiliac aneurysm|Any patient who has been treated for an aortoiliac aneurysm with a standard Medtronic Endurant aortic stent, standard Gore Excluder or conformable Gore Excluder
89479488|NCT05944822||Essure|patient who underwent removal of the Essure® contraceptive implant
89479489|NCT05944822||Control with no endometriosis/adenomyosis|patient who underwent benign laparoscopic gynecological surgery and with no diagnosis of endometriosis or adenomyosis
89479490|NCT05944822||Control with endometriosis/adenomyosis|patient who underwent benign laparoscopic gynecological surgery and with diagnosis of endometriosis or adenomyosis
89479491|NCT05942885|Experimental|Anxiety scores|
89479492|NCT05942677||Colorectal lesion diagnostic|Every patient referred to our center for colorectal endoscopy for investigation and/or resection of colorectal lesion can join the cohort of this study and will benefit from diagnosis and treatment by experienced endoscopists.
88951104|NCT05413382|Placebo Comparator|Placebo lozenge|Lozenge equal to active comparator but without active ingredients
89203012|NCT05394532|Experimental|Steno Diabetes Dialogue Cards|
89479493|NCT05942066||Healthy donors|Participants who are in good health and willing to provide a blood sample
88951105|NCT05411042|Experimental|Intervention group|The experimental group intervened a dance somatosensory game (DSG), DANZ BASE developed by International Games System Company, at the Xinzhuang health center, which is a local bureau with outpatient clinic. The participants in experimental group played twice a week, each time requiring at least lasting 30 minutes, for half of a year.
89479494|NCT05941702|Experimental|Intervention|Full session plan of the 8 sessions is uploaded to documents. This arm will consist of weekly 1 hour 1:1 sessions with Trainee Clinical Psychologist doing exercises aimed at improving interoception. Exercises will include tuning into the body under different circumstances e.g., while having a drink, looking at pictures to induce a positive mood state.
89479495|NCT05939453|Sham Comparator|Sham Light|
89479496|NCT05939453|Experimental|Light Therapy|
89479497|NCT05937399|Experimental|Intervention Arm|This arm includes patients who view the integrated health video that provides information about both smoking and environmental risk.
88951106|NCT05411042|No Intervention|Control group|The control group only performed routine data collection; the research assistant asked the subjects about their usual activities by telephone every month to understand their physical activity in this half of the year.
88951107|NCT05410899||Pelvic Floor Health Education|Education will compose presentation about women health, urinary incontinence, teaching anatomy of the pelvic floor and bladder training
88951108|NCT05410899||Pelvic Floor Health Education and Exercise Program|pelvic floor health education and exercise of pelvic floor muscles for 12 weeks
89479498|NCT05937399|Experimental|Control Video Arm|This arm includes patients who view the integrated health video that provides information ONLY about smoking risk.
89479499|NCT05935371||Case group - women with obstetric anal sphincter injuries|"Adult women who have had a vaginal delivery~≥ 18 years~Capacity to consent~English-speaking~Primiparous/multi-parous"
89479500|NCT05935371||Control group - women without perineal tears|"Adult women who have had a vaginal delivery~≥ 18 years~Capacity to consent~English-speaking~Primiparous/multi-parous"
89479501|NCT05935111|Active Comparator|Physical Activity Self-efficacy (PAS) group|Participants assigned to the PAS group will proceed through the weight management program provided by the center and will be given 4 weeks of 24-hour access to the PAS intervention during data collection for this study. The login credential for PAS participants will provide access to both the PAS intervention and to a secure website to complete data collection at W1, W2, and W3.
89479502|NCT05935111|No Intervention|Usual Care (UC) group|Participants assigned to the UC group will proceed through the weight management program provided by the center. The login credential for UC participants will provide access to a secure website to complete data collection (i.e., a survey battery, physical activity monitoring) at W1, W2, and W3.
89479503|NCT05932537||subcutaneous contraceptive implants|patients who have benefited from explantation of a subcutaneous contraceptive implant in the gynecology operating room
89479504|NCT05929716|Experimental|magrolimab, rituximab, and radiation, CAR T leukapheresis|"Participants may receive radiation therapy at any time during the study.~Participants will be given Magrolimab by vein once weekly for 4 doses by vein on an outpatient basis over about 180 minutes starting on Day 1 of Cycle 1.~Participants will be given Rituximab by vein once weekly for 4 doses over about 3-4 hours starting on Day 1 of Cycle 1. You will be given rituximab about 30 minutes (no more than 90 minutes) after magrolimab therapy finishes.~Participants will receive 1 dose of magrolimab and rituximab by vein one week before your CAR T leukapheresis and then 3 weekly doses of each drug starting 1 day after leukapheresis that will complete 1 week before lymphodepleting chemotherapy for CAR T"
89479505|NCT05920629|No Intervention|Moderate alcohol consumption|1 standard unit a day for 12 months
89479506|NCT05920629|Other|Abstinence|No alcohol beverages for 12 months
89479507|NCT05914194|Experimental|NLS-2|Participants will receive a single NLS-2 tablet orally once daily from Day 1 to Day 56 (until the end of Week 8).
89479508|NCT05914194|Placebo Comparator|Placebo|Participants will receive a single NLS-2 placebo matching tablet orally once daily from Day 1 to Day 56 (until the end of Week 8).
89479509|NCT05913687||Parkinson's disease|Clinically diagnosed Parkinson's disease
88951109|NCT05410899||Control|This goup will continue routine treatment such as medication usage
89020601|NCT03330132|Experimental|Alternating standard vaccine and high-dose vaccine|Alternating once-annual administration of standard inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of high-dose inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
89020602|NCT03330132|Experimental|Alternating high-dose vaccine and standard vaccine|Alternating once-annual administration of high-dose inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of standard inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
89020603|NCT03330132|Experimental|Alternating adjuvanted vaccine and high-dose vaccine|Alternating once-annual administration of MF59 adjuvanted inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of high-dose inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
89479510|NCT05913687||Multiple System Atrophy, Parkinsonian variant|Clinically diagnosed Multiple System Atrophy, Parkinsonian variant
89479511|NCT05913687||Progressive Supranuclear Palsy|Clinically diagnosed Progressive Supranuclear Palsy
89479512|NCT05912101|Experimental|Group 1 (PENG)|A convex USG Probe (1-5 mHz) is placed transversely on the SIAS (Spina Iliaca Anterior Superior). The probe is then rotated 45 degrees and aligned with the pubic ramus. In this position, the iliopubic eminence, ilipsoas muscle-tendon, femoral artery and pectineus muscle are observed. A 100 mm 21G block needle (Stimuplex A®:B. Braun Melsungen AG, Japan) is inserted in-plane from lateral to medial to the musculofascial plane with the psoas tendon in front and the pubic ramus behind and the injection is performed.
89479513|NCT05912101|Experimental|Group 2 (S-FICB)|A linear USG probe (7-13 mHz) is placed parasagittal to obtain an image of the SIAS. The probe is then shifted medially to identify the fascia iliaca, iliac muscle, internal oblique muscle and deep circumflex iliac artery. A 50 mm 21G block needle (Stimuplex A®:B. Braun Melsungen AG, Japan) is advanced in-plane from caudal to cephalic and injected between the fascia iliaca and iliac muscle.
88951110|NCT05406258|Experimental|Patients performing intermittent catheterization|
88951111|NCT05404074|Experimental|Cobitolimod 500mg|2-3 single doses of rectal cobitolimod (500mg/50ml) over 3-6 weeks
88951112|NCT05397587|Experimental|Experimental Group aged 6~23 months|Up to 146 subjects aged 6~23 months and have received EV71 vaccine developed by Sinovac Biotech Co., Ltd will be collected blood samples at 36 months after full immunization and at the age of 72 months.
88951113|NCT05397587|Experimental|Experimental Group aged 24~35 months|Up to 128 subjects aged 24~35 months and have received EV71 vaccine developed by Sinovac Biotech Co., Ltd will be collected blood samples at 36 months after full immunization .
88951114|NCT05397587|Experimental|Experimental Group aged 36~71 months|100 subjects aged 36~71 months and have received EV71 vaccine developed by Sinovac Biotech Co., Ltd will be collected blood samples at 36 months after full immunization .
89020604|NCT03330132|Experimental|Alternating high-dose vaccine and adjuvanted vaccine|Alternating once-annual administration of high-dose inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of MF59 adjuvanted inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
89479514|NCT05912101|Experimental|Group 3 (3-1)|A linear USG probe (7-13 mHz) is placed at the level of the femoral fold and the femoral vein-arterial-nerve is visualized. The femoral nerve is located below the fascia iliaca. At this point, a 50 mm 21G block needle (Stimuplex A®:B. Braun Melsungen AG, Japan) is inserted in-plane from lateral to medial and injected lateral to the femoral nerve. After injection, pressure is applied distal to the needle entry site to spread the local anesthetic proximally in the nerve sheath.
89479515|NCT05909150|Active Comparator|Hypertonic Saline Solution 3,5% (HSS)|
89479516|NCT05909150|Placebo Comparator|Normal Saline Solution (NS)|
89479517|NCT05908526|Experimental|Treatment|Participants will start on 10mg suvorexant, po, qhs, including instructions on dosage, expectations, and potential side effects, for two nights. Following this low-dose run-in period, individuals in the treatment condition will be increased to 20mg for a 14-day active treatment period (i.e.,16 nights taking a pill). Other assessments include self-report research questionnaires and cognitive testing (completed at baseline and post-treatment), as well as EMA surveys, daily sleep diaries, and actigraphy.
89479518|NCT05908526|Placebo Comparator|Placebo|Participants in the control condition will take placebo (no drug) pill form, po, qhs, including instructions on dosage, expectations, and potential side effects for (16 nights taking a pill). Other assessments include self-report research questionnaires and cognitive testing, daily sleep diaries, and actigraphy.
89479519|NCT05904691|Experimental|Cohort A - Dose 1|
89479520|NCT05904691|Experimental|Cohort A - Dose 2|
89479521|NCT05904691|Experimental|Cohort A - Dose 3|
89479522|NCT05904691|Experimental|Cohort B - Dose TBD|
89479523|NCT05900284|Experimental|Metformin 500 mg|One 500mg tablet will be administered twice a day for the first (5) days of study treatment.
89479524|NCT05900284|Placebo Comparator|Placebo|One inactive tablet will be administered twice a day for the first (5) days of study treatment.
89479525|NCT05900284|Experimental|Metformin 1,000 mg|One 1,000mg tablet will be administered twice a day for the first (5) days of study treatment.
89479526|NCT05900258|Experimental|Treatment|
89479527|NCT05893030|Experimental|Intervention Group|
89479528|NCT05893030|Placebo Comparator|Control Group|
89479529|NCT05893004|Experimental|Test-Retest|sample of convenience headache suffereres will be tested twice
89479530|NCT05891977|Experimental|Group AB (intervention / control)|After a 1-week washout period avoiding consumption of tomato, tomato-based products and other food sources of lycopene (watermelon, papaya, grapefruit and lycopene supplements), participants will consume a daily amount of 0.5 g of tomato paste / kg of body weight following the regular diet plus consumption of low to moderate tomato or tomato-based products and lycopene containing foods during 3 months (intervention). Then they will return to their regular dietary pattern during 3 weeks. At the beginning of the first 4 month, participants will be encouraged to move into the second phase (control), before a 1-week washout period. The second phase or control consists in following their regular diet plus consumption of low to moderate tomato or tomato-based products and lycopene containing foods during the next 3 months.
89479531|NCT05891977|Experimental|Group BA (control / intervention)|After a 1-week washout period avoiding consumption of tomato, tomato-based products and other food sources of lycopene (watermelon, papaya, grapefruit, and lycopene supplements), participants will start the control intervention which consists of following their regular diet plus consumption of low to moderate tomato or tomato-based products and lycopene containing foods during 3 months (control). Then they will return to their regular diet during 3 weeks. At the beginning of the first 4 month, participants will be encouraged to move into the second phase (intervention), before a 1-week washout period. The intervention consist in consuming a daily amount of 0.5 g of tomato paste / kg of body weight diet plus consumption of low to moderate tomato or tomato-based products and lycopene containing foods during the next 3 months.
89479532|NCT05881798||Patients indicated for the placement of a Celect Platinum Vena Cava Filter|Patients indicated for the placement of a Celect Platinum Vena Cava Filter
89479533|NCT05872958|Experimental|AZD3152 Dose X (IM)|Participants will receive dose X of AZD3152 on Day 1 as a single IM injection.
89479534|NCT05872958|Experimental|AZD3152 Dose X (IV)|Participants will receive dose X of AZD3152 on Day 1 as an IV infusion.
89479535|NCT05872958|Experimental|AZD3152 Dose Y (IM)|Participants will receive dose Y of AZD3152 on Day 1 as 2 sequential IM injections.
89479536|NCT05872958|Experimental|AZD3152 Dose Y (IV)|Participants will receive dose Y of AZD3152 on Day 1 as an IV infusion.
89479537|NCT05872958|Experimental|AZD3152 Dose Z (IV)|Participants will receive dose Z of AZD3152 on Day 1 as an IV infusion.
89479538|NCT05872958|Placebo Comparator|Pooled placebo|Participant will receive placebo on Day 1 either via IM injection or IV infusion.
89479539|NCT05871892|Other|18F-FDGal PET/CT or PET/MRI|Diagnostic scan.
89020605|NCT03330132|Experimental|High-dose vaccine|Once-annual administration of high-dose inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
89479540|NCT05871814|Experimental|Colon preparation guided by an artificial intelligence device|Regular oral and written information will be provided to this group. In addition, participants will take a picture of the last rectal effluent with the smart phone that have to upload to a server. A convolutional neural network will assess whether the bowel preparation is correct or not (clean or not). The system will issue specific recommendations based on the quality of cleansing.
89479541|NCT05871814|Active Comparator|Control group|Regular oral and written information will be provided to this group
89479542|NCT05871255||Genitourinary syndrome of menopause (GSM) patients|Patients will apply the vaginal gel (ZG) for a total of 150 days of treatment. The application was daily for the first 12 days, then every 48 hours until the end of the study. Patients will be examined at baseline (T0), after 12 (T1), 57 (T2) and 150 (T3) days of treatment. Examination will include (1) Filling of a Female Sexual Distress Scale (FSDS) questionnaire and (2) Gynecology examination with colposcopy and pH test to evaluate vaginal elasticity, vaginal secretions, pH, mucosal epithelium, and vaginal hydration to calculate the Vaginal Health Index (VHI).
88951115|NCT05397587|Active Comparator|Control Group aged 36~71 months|100 subjects aged 36~71 months and have received EV71 vaccine developed by Institute of Medical Biology,Chinese Academy of Medical Sciences will be collected blood samples at 36 months after full immunization .
88951116|NCT05387785|Experimental|500 mg QD|500 mg QD of ANG-3070 will be taken once a day for 10 days.
89479543|NCT05871242|Experimental|Treatment arm|Treatment with Lactobacillus crispatus M247
89479544|NCT05871242|No Intervention|Control arm|No Probiotic treatment
89479545|NCT05870891|Experimental|Peanut Butter Cereal|Consumption of Peanut Butter Cereal
89479546|NCT05870891|Experimental|Cinnamon Almond Cereal|Consumption of Cinnamon Almond Cereal
89479547|NCT05870891|Experimental|Sriracha Crisps|Consumption of Sriracha Crisps
89479548|NCT05870891|Experimental|Cheddar Crisps|Consumption of Cheddar Crisps
89479549|NCT05870891|Experimental|Almond Blueberry Butter Bar|Consumption of Almond Blueberry Butter Bar
89479550|NCT05870891|Experimental|Peanut Butter and Dark Chocolate Bar|Consumption of Peanut Butter and Dark Chocolate Bar
89479551|NCT05870891|Experimental|Almond Dark Chocolate Bar|Consumption of Almond Dark Chocolate Bar
89479552|NCT05870891|Experimental|White Bread 5 g available carbohydrate|Consumption of white bread containing 5 g available carbohydrate
89479553|NCT05870891|Active Comparator|White Bread 20 g available carbohydrate|Consumption of white bread containing 20 g available carbohydrate
89479554|NCT05869734|Experimental|Intervention group A|The intervention group A receives conservative management with sleep hygiene related adjustments, pelvic floor muscle training, and urologic health promotion.
89479555|NCT05869734|Experimental|Intervention group B|The intervention group B receives conservative management with brief behavioral treatment for insomnia (BBTI), pelvic floor muscle training, and urologic health promotion.
89479556|NCT05869734|Sham Comparator|Comparison group|The comparison group receives information related to pelvic floor muscle training and urologic health promotion.
89479557|NCT05862649|Experimental|PD patients|Men and women with idiopathic PD (Hoehn & Yahr scale 1-2) aged 40-85 years
89479558|NCT05861427|Experimental|Atogepant Dose A|Participants will receive atogepant dose A once daily (QD) for 24 weeks.
89479559|NCT05861427|Experimental|Atogepant Dose B|Participants will receive atogepant dose B QD for 24 weeks.
89479560|NCT05861427|Experimental|Atogepant Dose C|Participants will receive atogepant dose C QD for 24 weeks.
89479561|NCT05861427|Experimental|Placebo|Participants will receive placebo QD for 12 weeks. Participants will be re-randomized at week 12 to receive atogepant dose A, dose B or dose C QD for 12 weeks.
89479562|NCT05849194|Experimental|POCUS group|Group that will undergo POCUS examination
89479563|NCT05849194|No Intervention|Control group|The group that will not undergo POCUS examination
88951117|NCT05387785|Experimental|300 mg BID|300 mg BID of ANG-3070 will be taken twice a day for 10 days.
88951118|NCT05387785|Placebo Comparator|Placebo-to-match 500 mg QD|Placebo-to-match 500 mg QD of ANG-3070 will be taken once a day for 10 days.
88951119|NCT05387785|Placebo Comparator|Placebo-to-match 300 mg BID|Placebo-to-match 300 mg BID of ANG-3070 will be taken twice a day for 10 days.
88951120|NCT05379244|Experimental|CBT-i|Cognitive Behavioral Therapy for insomnia adjusted for patients with mixed psychiatric disorders
89479564|NCT05841784|Active Comparator|MBCT-T (Reference)|Participants will receive Mindfulness-Based Cognitive Therapy delivered via Telephone (MBCT-T).
88951121|NCT05371795|Active Comparator|Lancets|
88951122|NCT05371795|Experimental|Comfort Marker 2.0|
89479565|NCT05841784|Experimental|MBCT-T + Booster Mindfulness Sessions|Participants will receive Mindfulness-Based Cognitive Therapy delivered via Telephone (MBCT-T), in addition to booster mindfulness sessions.
89479566|NCT05841784|Experimental|MBCT-T + Website Support|Participants will receive Mindfulness-Based Cognitive Therapy delivered via Telephone (MBCT-T), in addition to website support.
89479567|NCT05841784|Experimental|MBCT-T + Website Support + Booster Mindfulness Sessions|Participants will receive Mindfulness-Based Cognitive Therapy delivered via Telephone (MBCT-T), in addition to both booster sessions and website support.
89479568|NCT05840432||Cardiac Surgery Postoperative Patients|Cardiac Surgery Postoperative Patients who are admitted to the intensive care unit after the surgery, from the surgical room
89479569|NCT05839717||PV and ET patients|The cohort will be composed of PV and ET patients, some with a history of thrombosis and some without any history of thrombosis. A comparison will also be performed between patients with different MPN (PV or ET) and the type of thrombosis (venous, arterial, splanchnic)
89479570|NCT05837637||Parkinson's disease patients|Parkinson's disease patients attend the Parkinson and Movement disorder clinic at Ho Chi Minh University Medical Center
89479571|NCT05837637||healthy control|The participants including hospital staffs and relatives of patients that matched age and gender
89479572|NCT05835466|Experimental|Reparixin|Eligible patients will receive oral reparixin three times daily on a 4-week cycle for a core study period of 6 cycles (24 weeks). After cycle 6, patients may continue receiving reparixin once daily on a 4-week cycle if at least stable disease (SD) is met by IWG-MRT criteria until loss of response, disease progression, unacceptable toxicity, patient/physician withdrawal, or termination of study by sponsor.
89479573|NCT05833867|Experimental|SG + Adaptive radiotherapy|Sacituzumab Govitecan, IV, 8 mg/kg, 21-day cycles for 1 loading cycle prior to radiation and two subsequent cycles with concurrent adaptive radiotherapy
89479574|NCT05830877|Experimental|the acupuncture group|the patients included in this arm will recept the Tiaoshen acupuncture.
89479575|NCT05830877|Active Comparator|the placebo acupuncture group|Subjects in the placebo acupuncture group will receive non-insertive acupuncture using the sham needle supported by the Park device, and the selected acupoints is the same as the acupuncture group.
88951123|NCT05352178|Active Comparator|MDT alone|Metastasis-directed therapy alone
89479576|NCT05827432|Experimental|NAFLD|Participants with different degree of steatohepatitis and NAFLD will undergo one FCI scan.
88951124|NCT05352178|Experimental|MDT + 1 month of ADT|Metastasis-directed therapy plus one month of androgen deprivation therapy (gosereline 3.6 mg sc, leuproreline 7.5 mg sc, triptoreline 3.75 mg im)
89203013|NCT02560688|Experimental|Period 1 - DS-1040b|Single 12-hour intravenous infusion of DS-1040b (20 mg)
89479577|NCT05826314|Experimental|Experimental group 1 (adapted boxing)|Experimental boxing - The general structure of adapted boxing will include a 10-minute warm-up consisting of walking at a slow, self-selected speed, and at the same time joint rotation exercises; followed by 25-30 minutes of adapted boxing (consisting of non-contact activities, distributed in coordination and balance/footwork, shadow boxing-choreography (sequence of arm and leg movements that simulate an imaginary fight and punching bag), to end the session there will be a content fixation exercise, relaxation with gentle movements and breathing for 5 -10 minutes.
89479578|NCT05826314|Active Comparator|Experimental group 2 (multi-component training)|Sessions will be divided in 10 minutes warm-up (including slow walk, postural and mobility exercises for general activation, and stretching exercises), specific training (25-30 minutes, including balance/coordination training, strength, and aerobic exercises) and cool down 5 - 10 minutes (breathing and stretching exercises for the main worked joints and muscles) following the main guidelines recommended by the American College of Sports Medicine (4) and the WHO (3).
89479579|NCT05826314|No Intervention|Control group|Participants from the control group will participate in assessments (initial and final) and will be asked to maintain their usual activities. At the end of the intervention period, the control group will be invited to participate in a physical activity program that takes place at the University.
89479580|NCT05824338|Active Comparator|General anesthesia with endotracheal tube|Currently the standard at our centre. Participants in this group will undergo lower lumbar surgery with general anesthesia with endotracheal intubation.
89479581|NCT05824338|Active Comparator|Spinal anesthesia with bupivacaine|Participants in this group will undergo lower lumbar surgery under spinal anesthesia with bupivacaine 0.5% 10-15 mg with fentanyl 10-15 mcg.
89479582|NCT05824338|Experimental|Spinal anesthesia with ropivacaine|Participants in this group will undergo lower lumbar surgery under spinal anesthesia with ropivacaine 0.5% 10-20 mg with fentanyl 10-15 mcg.
89479583|NCT05821309|Experimental|PEG 3350|Patients will receive PEG 3350 (miralax or generic equivalent) for their MACE flushes.
89479584|NCT05821309|Experimental|PEG 3350 with electrolytes|Patients will receive PEG 3350 with electrolytes (Go-Lytely or generic equivalent) for their MACE flushes.
89479585|NCT05815680|Experimental|warfarin+atorvastatin+IBI362|
89479586|NCT05815680|Experimental|metformin+digoxin+IBI362|
89479587|NCT05803551|Experimental|Ketamine Group|Adult patients who have been in the Mayo Clinic Florida ICU for one week with moderate or severe depression will receive intravenous (IV) ketamine
89479588|NCT05803551|Placebo Comparator|Placebo Group|Adult patients who have been in the Mayo Clinic Florida ICU for one week with moderate or severe depression will receive intravenous (IV) placebo
89479589|NCT05800860|Experimental|GH001 - Part 1|GH001 is administered via inhalation, as an IDR consisting of up to 3 increasing doses of GH001 (6 mg, 12 mg, and 18 mg), on a single day. The second and third doses are only administered if the patient did not achieve intense psychoactive effects (a peak experience [PE]) at the previously administered dose.
89479590|NCT05800860|Placebo Comparator|Placebo - Part 1|Placebo is administered via inhalation, as an IDR consisting of up to 3 doses of Placebo, on a single day. The second and third doses are only administered if the patient did not achieve intense psychoactive effects (a PE) at the previously administered dose.
89479591|NCT05800860|Other|Open-Label Extension (OLE) - Part 2|Patients can receive up to five GH001 IDRs as needed during the OLE based on the patient's clinical response.
89479592|NCT05799157|Experimental|Treatment Group A (Low Dose)|Low does patch will be applied adjacent to the target wart and remain in place for 5 minutes then removed. There may be up to 6 treatments (approximately 1 per month).
89479593|NCT05799157|Experimental|Treatment Group B (High Dose)|High does patch will be applied adjacent to the target wart and remain in place for 5 minutes then removed. There may be up to 6 treatments (approximately 1 per month).
88951125|NCT05352178|Experimental|MDT + 6 months of ADT + anzalutamide|Metastasis-directed therapy plus 6 months of androgen deprivation therapy (gosereline 3.6 mg sc 1x/month or gosereline 10.8 mg sc or leuproreline 7.5 mg sc 1x/month or leuproreline 45 mg sc or triptoreline 3.75 mg im 1x/month or triptoreline 11.5 mg im 1x/3months or triptoreline 22.5 mg im) and enzalutamide (4 x 40 mg each day during 6 months )
88951126|NCT05328141|Experimental|Bread and butter|A toast bread with butter meal without insect biomass with FeSO4 (isotopic iron 54)
88951127|NCT05328141|Experimental|X.gideon|Intrinsically labelled (57Fe) or non labelled X.gideon flour mixed with butter and sugar meal with FeSO4 (extrinsic label, isotopic iron 58)
88951128|NCT05328141|Experimental|X.gideon with ascorbic acid|Intrinsically labelled (57Fe) or non labelled X.gideon flour mixed with butter and sugar meal with FeSO4 (extrinsic label, isotopic iron 58) and ascorbic acid
88951129|NCT05310916|Experimental|Test group|(n=30): type 2 diabetes mellitus patients who will receive an oral antidiabetic along with dapagliflozin at a dose of 10 mg daily for 12 weeks.
88951130|NCT05310916|Active Comparator|Control group|(n=30): type 2 diabetes mellitus patients who will receive two oral antidiabetic agents for 12 weeks
88951131|NCT05278481|Active Comparator|Reward Message with standard introduction|
88951132|NCT05278481|Active Comparator|Reward Message with culturally tailored introduction|
88951133|NCT05278481|Active Comparator|Threat/Self-efficacy with standard introduction|
88951134|NCT05278481|Active Comparator|Threat/Self-efficacy with culturally tailored introduction|
88951135|NCT05278481|Active Comparator|Social norms message with standard introduction|
88951136|NCT05278481|Active Comparator|Social norms message with culturally tailored introduction|
88951137|NCT05272475|Experimental|Chamomile Tea|Subjects will consume a single serving of chamomile tea on the visit day. The tea serving will be prepared using 3 grams of chamomile tea steeped in hot water according to the study protocol.
89537558|NCT03064971|Experimental|Standard care + PTF DVD|The intervention will include the standard care, with the addition of the PTF DVD. Participants randomized to this condition will receive Pathways to Freedom: Leading the Way to a Smoke-Free Community© (PTF). The content of the intervention parallels the types of education, advice, and cessation/relapse prevention strategies that are delivered in clinic and quitline contexts, except for the focus on the specific needs of the Black community. The 60- minute DVD consists of 7 sections. The cultural adaptations (e.g., focus on menthol, focus on religion/spirituality, Black images and music) were infused throughout the DVD. The PTF DVD is useable at varying levels along the readiness to quit smoking continuum, as viewers are empowered to view sections that match their interests and goals. Quit Coaches will be trained to refer participants to appropriate sections for additional help.
89537559|NCT03064971|Active Comparator|Standard care + standard smoking cessation DVD|"This arm includes standard care, plus a standard smoking cessation DVD. The evidence-based How to Quit DVD contains 60 minutes of smoking cessation information and strategies. Narrated by a physician, it describes the process of quitting and strategies for increasing physical activity and healthy nutrition. It includes testimonials from former smokers and dialogue among smokers in a group counseling setting. The information is presented in a standard format, intended for the general population of smokers."
89537560|NCT03064971|Active Comparator|Standard care only|Following the first counseling session, participants may receive up to 3 additional proactive counseling calls. Follow-up calls focus on challenges that may have occurred on the quit date or with the use of medication. Quit Coaches® review and modify the person's quit plan, and provide support as appropriate. Participants also receive standard self-help materials by mail, which is often referred to by Quit Coaches. For individuals who have successfully quit, the Coach will focus on relapse prevention strategies. Quit Coaches provide medication education to all participants eligible and interested in using cessation medications. This study will provide starter NRT kits (2 weeks supply) to all participants. Coaches provide decision support using a database-supported algorithm based on current scientific evidence and the product manufacturer use instructions for each drug.
89537561|NCT05176899||Prospective cohort|Patients who are at least 50 years of age during their primary care exam will undergo SENSORA™ screening if they provide consent.
89537562|NCT05176899||Retrospective cohort|Patients who saw participating providers in the 6 months prior to study start date, and who were referred to echocardiogram and/or cardiology, will be included as provider self-control for patient outcomes and referral rates.
89537563|NCT04433325||Patients transferred|Patients transferred from Paris's Intensive Care Units
89537564|NCT04433325||Patients not transferred|Patients admitted in Intensive Care Units with no transfer from Paris
89020606|NCT03330132|Experimental|Adjuvanted vaccine|Once-annual administration of MF59 adjuvanted inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
89020607|NCT03330132|Experimental|Recombinant vaccine|Once-annual administration of recombinant hemagglutinin inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
89020608|NCT03330132|Experimental|Alternating recombinant vaccine and adjuvanted vaccine|Alternating once-annual administration of recombinant hemagglutinin inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of MF59 adjuvanted inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
89020609|NCT03329274||Patients with Erdheim-Chester Disease and Other Histiocytoses|
89020610|NCT03309007|Experimental|Metformin|Metformin started at 500 mg po twice daily (BID), and then titrated up to 1000 mg po q morning (AM) and 500 po q evening (PM) over the course of 1 month, as tolerated.
89479594|NCT05799157|Placebo Comparator|Treatment Group C (Vehicle)|Vehicle patch will be applied adjacent to the target wart and remain in place for 5 minutes then removed. There may be up to 6 treatments (approximately 1 per month).
89479595|NCT05794204|Experimental|Patients randomized to dose 1 study drug|Approximately 25 patients randomized to dose 1 of RMP-A03
89479596|NCT05794204|Experimental|Patients randomized to dose 2 of study drug|Approximately 25 patients randomized to dose 2 of RMP-A03
89479597|NCT05794204|Placebo Comparator|Patients randomized to placebo|Approximately 25 patients randomized to placebo.
89479598|NCT05792670|Active Comparator|Standard Ventilatation Mode|SV mode is defined according to the mechanical ventilator parameters (patients' age and weight) Standard ventilation mode is defined as 8-10 mL/kg tidal volume and 10-15 respirations/min. No changes were made in the inspiratory expiratory ratio (1:2), FiO2, and positive end-expiratory pressure (PEEP) parameters
89479599|NCT05792670|Active Comparator|High Ventilatation Mode|Hv mode is defined as the tidal volume decreased to 6-8 mL/kg and the frequency is increased to 15-18 respirations/min. No changes were made in the inspiratory expiratory ratio (1:2), FiO2, and positive end-expiratory pressure (PEEP) parameters
89020611|NCT03309007|Placebo Comparator|Placebo Oral Tablet|Near-identical CaCO3 as a Placebo Oral Tablet will be started at 648 mg po BID, and then titrated up to 1296 mg po q AM and 648 mg po q PM over the course of 1 month, as tolerated.
89479600|NCT05792228|Experimental|The intervention group|The intervention group will receive evidence-based, nurse-led standardized management of CINV, including nurse-led risk assessment, education on prevention and control of CINV, antiemetics following guidelines, dietary strategies, relaxation therapy, and follow up.
89479601|NCT05792228|No Intervention|The control group|The control group will receive the routine CINV management. Patients are given drugs to prevent and control emesis according to the physicians' individual prescriptions. Nurses provide related education about nausea and vomiting control and recommend patients to drink more water and eat light food. Patients will be given Metoclopramide when they are vomiting.
89479602|NCT05790824|Experimental|Spa therapy|Protocol of spa therapy in rheumatology for 3 weeks
89479603|NCT05789342|Experimental|The DDI of GP681 and Rosuvastatin Calcium Tablets|Subjects will receive a single dose of Rosuvastatin Calcium 10 mg on Day 1, then take a single doses of 40mg GP681, 10mg Rosuvastatin Calcium on Day 8.
89479604|NCT05789342|Experimental|The DDI of GP681 and Digoxin Tablets|Subjects will receive a single dose of Digoxin 0.25 mg on Day 1, then take a single doses of 40mg GP681, 0.25mg Digoxin on Day 15.
89479605|NCT05789342|Experimental|The DDI of GP681 and Itraconazole Capsules|Subjects will receive a single dose of GP681 20mg on Day 1, then take Itraconazole 200 mg twice-daily on Day 22 and 200 mg once-daily on Day 23 through Day 36, and took a single dose of GP681 20 mg on Day 26.
89479606|NCT05789342|Experimental|The DDI of GP681 and Oseltamivir Capsules|Subjects will receive all three treatments in a crossover fashion according to the randomized sequence. The treatments were as follows: single oral administration of GP681 at 40 mg on day 1 in the fasted state; single oral administration of oseltamivir at 75 mg on day 1 and day 5in the fasted state, followed by repeated twice-daily administration of oseltamivir at 75 mg until day 5 after each meal; co-administration of GP681 at 40 mg and oseltamivir at 75 mg simultaneously on day 1 in the fasted state, followed by repeated twice-daily administration of oseltamivir at 75 mg until day5 after each meal. There was an at least 21-day washout interval between each treatment.
88951138|NCT05272475|Experimental|Chamomile Extract Capsule|Subjects will consume a single chamomile capsule on the visit day. Each capsule consists of 500 milligrams of a chamomile extract that has been standardized to 1.2% apigenin content.
89479607|NCT05784129|Active Comparator|Group 1: Guselkumab|Participants will receive Guselkumab Dose 1 subcutaneously (SC) followed by Dose 2 SC thereafter through Week 144. Participants with disease recurrence will receive guselkumab SC treatment.
88951139|NCT05263466|Experimental|Brain tumour patients|Patients will be those undergoing routine care of primary brain tumours. Study group patients will undergo additional PET-MRI examination and biopsies in addition to the standard of care.
88951140|NCT05233709|Other|OTf + FeSO4|OTf + FeSO4 - This is the experimental arm where Ferrous sulfate will be given to the participants along with apo-Ovotransferrin, a potential iron absorption enhancer. They will be given as solutions that will be spread on bread with butter and honey, a breakfast meal.
89479608|NCT05784129|Placebo Comparator|Group 2: Placebo|Participants will receive matching placebo injections subcutaneously. Participants with disease recurrence will receive guselkumab SC treatment.
89479609|NCT05783765|Experimental|Heightened Drive to Eat|"Eating rate~Eating in the absence of hunger~Relative reinforcing value of food"
88951141|NCT05233709|Other|Lf+ FeSO4|Lf + FeSO4 - This is the experimental arm where Ferrous sulfate will be given to the participants along with lactoferrin, a potential iron absorption enhancer. They will be given as solutions that will be spread on bread with butter and honey, a breakfast meal.
89479610|NCT05783180|Experimental|Treatment|Sesderma LACTYFERRIN™ Forte (64mg/20ml, TID) and Sesderma ZINC Defense™ (20mg/20ml QD) + SOC (N=20).
89479611|NCT05783180|Placebo Comparator|Control|Placebo +SOC (N=20)
89479612|NCT05777512|Experimental|Group A: Gastric Followed by Jejunal Feeds|Participants randomized into this group will begin with one ten-day block of nasogastric (NG) feeds followed by one ten-day block of nasojejunal (NJ, postpyloric) feeds.
89479613|NCT05777512|Experimental|Group B: Jejunal Followed by Gastric Feeds|Participants randomized into this group will begin with one ten-day block of nasojejunal (NJ, postpyloric) feeds followed by one ten-day block of nasogastric (NG) feeds.
89479614|NCT05775991||Medical Oncologists|Individuals practicing as medical oncologists or with expertise in medical oncology
89479615|NCT05775991||Clinicians with expertise in cognitive impairment and dementia|Clinicians with expertise in cognitive impairment and dementia
89479616|NCT05775991||Older patients with cancer|Older patients with cancer or older survivors of patients with cancer
89479617|NCT05775991||Caregivers of patients with dementia or cognitive impairment|Caregivers of patients with dementia or cognitive impairment
89479618|NCT05764005|Experimental|Intervention website|
88951142|NCT05233709|Other|FeSO4|FeSO4 - This is the control arm where Ferrous sulfate will be given in the form of a solution that will be spread on bread with butter and honey, as a breakfast meal
89479619|NCT05764005|Active Comparator|Control MUSIC website|This is usual care and all urologists are encouraged to refer their patients to the patient educational materials on the MUSIC website (http://www.musicurology.com/patientmaterials/).
89479620|NCT05749588|Experimental|IM/HER2-low|If patients were triple-negative breast cancer with IM subtype and HER2-low-positive
89479621|NCT05749588|Experimental|IM/HER2-0|If patients were triple-negative breast cancer with IM subtype and HER2-zero
89479622|NCT05749588|Experimental|BLIS / HER2-low|If patients were triple-negative breast cancer with BLIS subtype and HER2-low-positive
89479623|NCT05749588|Experimental|BLIS /HER2-0|If patients were triple-negative breast cancer with BLIS subtype and HER2-zero
89479624|NCT05749588|Experimental|LAR / HER2-low|If patients were triple-negative breast cancer with LAR subtype and HER2-low-positive
89479625|NCT05749588|Experimental|LAR /HER2-0|If patients were triple-negative breast cancer with LAR subtype and HER2-zero
89479626|NCT05749588|Experimental|MES/ HER2-low|If patients were triple-negative breast cancer with MES subtype and HER2-low-positive
89479627|NCT05749588|Experimental|MES /HER2-0|If patients were triple-negative breast cancer with MES subtype and HER2-zero
89479628|NCT05747079|Experimental|Conservative treatment|Rehabilitation and optional delayed ACL reconstruction
89479629|NCT05747079|Experimental|Immediate ACL reconstruction|Immediate ACL reconstruction + rehabilitation
89479630|NCT05742568|Experimental|High-dose dual therapy|Esomeprazole Enteric Tablets 40mg, 3 times/day; Amoxicillin Capsules 1000mg, 3 times/day.The course of all drugs is two weeks.
89479631|NCT05742568|Active Comparator|Bismuth Quadruple Therapy|Esomeprazole Enteric Tablets 40mg, 2 times/day; Amoxicillin Capsules 1000mg, 2 times/day; Clarithromycin Tablets 500mg, 2 times/day; Colloidal Bismuth Tartrate Capsules 220mg, 2 times/day.The course of all drugs is two weeks.
89479632|NCT05742386|Experimental|HPV vaccine communication training|Staff in clinics randomized to this arm will receive an intervention called Announcement Approach Training (AAT). This training is designed to improve communication about HPV vaccination.
89203014|NCT02560688|Other|Period 2 - Clopidogrel|Clopidogrel (Plavix) administered orally over 5 days (300 mg loading dose on Day 1 followed by 75 mg daily on Days 2-5)
89203015|NCT02560688|Experimental|Period 2 - DS-1040b and Clopidogrel|Concomitant administration of DS-1040b (20 mg single 12-hour intravenous infusion) and clopidogrel (single 75 mg oral dose)
89479633|NCT05742386|Experimental|HPV vaccine communication training and standing orders optimization|Staff in clinics randomized to this arm will receive the AAT and conduct a set of activities to optimize use of HPV vaccine standing orders.
89479634|NCT05742139||Patient group|Have been hospitalized or consulted for neuroborreliosis between 2010 and 2021; Have a diagnosis of probable neuroborreliosis (compatible clinical signs + lumbar puncture with positive intrathecal synthesis of immunoglobulins) or certain (compatible clinical signs + lumbar puncture with pleocytosis and positive intrathecal synthesis of immunoglobulins); Have received adequate treatment according to the recommendations (1st intention DOXYCYCLINE 100mgx2/day or 2nd intention CEFTRIAXONE IV 2g/day for 14 to 21
89479635|NCT05742139||Control group|Be part of the entourage of the cases; Do not have ATCD of Lyme borreliosis (especially erythema migrans); Not having been bitten by a tick in the last 5 years;
89479636|NCT05729594|Experimental|T4032|
89479637|NCT05729594|Active Comparator|Lumigan|
89479638|NCT05727527|Active Comparator|Study group|Will initially receive the infiltration injection after applying a candy flavor first, followed by sterile water in the next visit
89479639|NCT05727527|Active Comparator|Control group|Will initially receive the infiltration injection after applying sterile water first, followed by candy flavor in the next visit
89479640|NCT05727475|Active Comparator|Study group|In this group, a composite facing will be placed on the anterior incisors to mask the opacity. Minimal invasive treatment will be done without drilling or removal of enamel. They will be asked to fill in the Child Oral Health Impact Profile-Short Form (C-OHIP-SF19) questionnaire pre and 1 month post treatment.
89479641|NCT05727475|Active Comparator|Control group|"In this group, fluoride gel application will be done for all teeth using 1.23% APF gel delivered through a foam tray. They will be asked to fill in the Child Oral Health Impact Profile-Short Form (C-OHIP-SF19) questionnaire pre and 1 month post treatment.~After filling the C-OHIP-SF19 questionnaire 1 month post treatment, if the child is not happy with the appearance after fluoride gel application, a composite facing will be offered."
89479642|NCT05722782|Active Comparator|NSAI|Piroxicam: 20 mg per pill; one pill per day for five days
89479643|NCT05722782|Active Comparator|Acetaminophen|Paracetamol: 1000 mg per day for five days
89479644|NCT05722782|Placebo Comparator|Placebo|Placebo: one pill per day for five days
89479645|NCT05722327|Experimental|Stage 1 ( MRTX849 and Irinotecan)|Participants assigned to Stage 1, participants dose levels of MRTX849 and irinotecan will depend on when the participants joined the study. This study will also test 2 different dosing schedules: concurrent dosing or staggered dosing
88951143|NCT05414461|Experimental|Combination treatment|PD-1 inhibitor-based combination treatment
88951144|NCT05173701|Experimental|Probiotics|Administration of a mixture of probiotics once daily for three months
88951145|NCT05173701|Placebo Comparator|Placebo|Administration of a placebo (maltodextrin) once daily for three months
88951146|NCT05165537|Experimental|NIMM_MRS|testing of new MRS methods
88951147|NCT05150951|Experimental|Experimental group|Novel exploration is used before extinction in an attempt to strengthen the extinction consolidation.
88951148|NCT05150951|Experimental|Control group|Participants perform a control task (visual attention) instead of the novel exploration.
88951149|NCT05121896|Active Comparator|Patients with facial synkinesis|Functional MRI scan of the primary and secondary somatosensory cortexes, the primary motor cortex, the supplementary motor cortex, and the ventral lateral premotor cortex while the participant performs motor and sensory tasks.
88951150|NCT05121896|Active Comparator|Control participants|Functional MRI scan of the primary and secondary somatosensory cortexes, the primary motor cortex, the supplementary motor cortex, and the ventral lateral premotor cortex while the participant performs motor and sensory tasks.
88951151|NCT05111821|Experimental|Deferiprone|Patients receiving Deferiprone during 6 months. Oral deferiprone for 6 months at a dose of 30 mg/kg/d
88951152|NCT05111821|Active Comparator|Treatment As usual|Patients followed during 6 months according to standard care
88951153|NCT05105282|Active Comparator|Deep Serratus Anterior Plane Block|Following the visualization of the anatomical structures, the nerve block needle will be advanced via the in-plane technique beneath the serratus anterior muscles until the interfascial space was reached. After hydrodissection with 2 ml normal saline, 20 ml 0.25% bupivacaine will be injected into the area.
88951154|NCT05105282|Active Comparator|Superficial Serratus Anterior Plane Block|Following the visualization of the anatomical structures, the nerve block needle will be advanced via the in-plane technique above the serratus anterior muscles until the interfascial space was reached. After hydrodissection with 2 ml normal saline, 20 ml 0.25% bupivacaine will be injected into the area.
88951155|NCT05086835|Experimental|Working Memory App (Active Intervention)|A visual-spatial app-based working memory intervention.
88951156|NCT05086835|Active Comparator|Visual Search App (Control Condition)|An app-based visual search task to be used as a control condition.
88951157|NCT05066815|Experimental|Hybrid superstructure|screw retained hybrid ceramic crowns
88951158|NCT05066815|Active Comparator|Ceramic superstructure|screw retained lithium disilicate based ceramic crowns
88951159|NCT05036772|No Intervention|Standard Practice|The control arm is supported according to the usual practice. The experimental arm will have the possibility to use a distracting virutel environment for the duration of hysterosalpingography
88951160|NCT05036772|Experimental|Interventionnal|The experimental arm will have the possibility to use a distracting virutel environment for the duration of hysterosalpingography.
88951161|NCT05005455|Active Comparator|bevacizumab with old manufacturing process.|
89479646|NCT05722327|Experimental|Stage 2 ( MRTX849 and Irinotecan)|Participants assigned to Stage 2 will receive MRTX849 and irinotecan at the dose level that was recommended during Stage 1. This study will also test 2 different dosing schedules: concurrent dosing or staggered dosing
88951162|NCT05005455|Experimental|bevacizumab with new manufacturing process.|
88951163|NCT05003622|Experimental|encorafenib|Encorafenib hard capsule will be orally self-administered. A fixed-flat dose of 300 mg (4 x 75 mg) Per Oral (PO) encorafenib will be administered once-daily (QD).
88951164|NCT04983017|Active Comparator|Dietary supplements|Dietary supplements are either (1) designated as Generally Recognized As Safe (GRAS) by the Food and Drug Administration or (2) compounds at similar concentrations to those found in foods.
88951165|NCT04983017|Placebo Comparator|Placebo|Placebo-matched formulations
88951166|NCT04969406|Experimental|Imaging by BOSS System|Imaging by the BOSS System
88951167|NCT04959149|Experimental|face-to-face intubation|intubation approach from front of the patient
88951168|NCT04959149|Active Comparator|standard position intubation|intubation approach from behind the head of the patient
88951169|NCT04904107|Experimental|Intervention group|"Chest pain patients in the intervention group will be assessed by EMT personnel by performing the modified HEART score (including POC high sensitive troponin-I measurement (POC HS cTnI)) and the referral policy depends on the result.~In case of a low modified HEART score (modified HEART 0-3) patients will not be referred to the cardiac ED.~Patients with a modified HEART score >3 are directly referred to the cardiac ED after evaluation. These patients will receive standard care."
88951170|NCT04904107|Active Comparator|Control group|Chest pain patients in the control group will receive standard triage and standard care according to the local (EMT) protocol.
88951171|NCT04890977|Experimental|Talking Story|Talking Story is a modular behavioral intervention intended to increase mental health treatment-seeking among Pacific Islanders through the use of narrative films and other culturally syntonic approaches.
88951172|NCT04890977|Placebo Comparator|Wait-list control|The wait-list control will be administered as a control arm to the active Talking Story arm.
88951173|NCT04880486|Sham Comparator|Control group|usually care with extra health education on upper limb exercise
88951174|NCT04880486|Experimental|Exercise group|usually care with extra supervision upper limb exercise with VR
88951175|NCT04870632|Sham Comparator|Control group|Patients in control group received the education booklet with words and pictures.
89203016|NCT00939549|Experimental|High-dose cyclohosphamide|
89203017|NCT00799032|Other|Stent|Catania Stent
89479647|NCT05721053||Older Adults in Radiation Therapy|Older Adults who are receiving Radiation Therapy.
89479648|NCT05716490|Active Comparator|Standard|Control group which will cover surgical wound with conventional wound dressing
89479649|NCT05716490|Experimental|PICO|Group that will use Pico® device for wound dressing
89479650|NCT05716490|Experimental|PREVENA|Group that will use Prevena® device for wound dressing
89479651|NCT05710978|Experimental|Work Heat Stress|Each participant will complete three consecutive days of heavy intensity aerobic work in a hot environment.
88951176|NCT04870632|Experimental|Video group|Patients in intervention group watched YOUTUBE videos to rehab and recorded the intensity after the exercise by RPE scores. During the intervention, a physical therapist would have weekly telephone calls or LINE calls for 6 times to monitor and modify the intensity of exercise.
88951177|NCT04870632|Experimental|Booklet group|Patients in intervention group read education booklet with words and pictures to rehab and recorded the intensity after the exercise by RPE scores. During the intervention, a physical therapist would have weekly telephone calls or LINE calls for 6 times to monitor and modify the intensity of exercise.
88951178|NCT04858399||Mild Severity OSAS|Mild sleep apnea: An Apnea-Hypopnea Index (AHI) of five to 14 events per hour.
88951179|NCT04858399||Moderate Severity OSAS|Moderate sleep apnea: An Apnea-Hypopnea Index (AHI) of 15 to 29 events per hour.
88951180|NCT04858399||High Severity OSAS|Severe sleep apnea: An Apnea-Hypopnea Index (AHI) of 30 or more events per hour
88951181|NCT04857541||Health adult|
88951182|NCT04798144|Experimental|Cryotherapy group|Final canal irrigation will be done for 5 minutes with 20 mL of distilled water kept at 2.5°C in the refrigerator using EndoVac negative pressure irrigation system.
88951183|NCT04798144|Placebo Comparator|Control group|Final canal irrigation will be done for 5 minutes with 20 mL of distilled water kept at room temperature in the refrigerator using EndoVac negative pressure irrigation system.
88951184|NCT04759872|Experimental|Metabolic Study Visit|Participants will complete a study visit for metabolic phenotyping and determination of the impact of hyperinsulinemia on outcomes of interest.
88951185|NCT04751825|Experimental|I-EAET|Internet administrated Emotional and Awareness and Expression Therapy (I-EAET). 10 weeks. Self-help treatment with therapist contact via text messages at least once a week.
88951186|NCT04751825|No Intervention|WL|Wait-list.
88951187|NCT04742322|Placebo Comparator|Placebo|1x capsule/day - maltodextrin, period of 10 to 14 days
88951188|NCT04742322|Experimental|B Lactis|1x capsule/day - 9x10x10 UFC, period of 10 to 14 days
88951189|NCT04742010|Experimental|Zoledronic Acid|Active treatment
88951190|NCT04742010|Placebo Comparator|Placebo|Placebo
88951191|NCT04733911|Experimental|Eccentric 75|Participants in this arm will perform an eccentric exercise protocol consisted of 75 eccentric repetetions on an isokinetic dynamometer.
88951192|NCT04733911|Experimental|Eccentric 150|Participants in this arm will perform an eccentric exercise protocol consisted of 150 eccentric repetetions on an isokinetic dynamometer.
88951193|NCT04733911|Experimental|Eccentric 300|Participants in this arm will perform an eccentric exercise protocol consisted of 300 eccentric repetetions on an isokinetic dynamometer.
88951194|NCT04733911|No Intervention|Control|Participants in this arm will receive no intervention.
88951195|NCT04646681|Experimental|Group 1|
88951196|NCT04646681|No Intervention|Group 2|
88951197|NCT04641234||Cohort 1|Adult Belgian patients diagnosed with neovascular age-related macular degeneration (nAMD) with treatment-naïve study eye.
88951198|NCT04636034|Experimental|Ropivacaine-Lidocaine|
89479652|NCT05708755|Experimental|Lung Transplant Recipients|Lung transplant recipients with pre-transplant serological immunity to CMV. CMV-TCIP will be measured every 3 months post-transplant with antiviral prophylaxis discontinued when threshold is exceeded.
88951199|NCT04636034|Placebo Comparator|Placebo|
88951200|NCT04636034|Sham Comparator|"Sham-block with Placebo"|
88951201|NCT04594941|Experimental|Treatment Sequence: SPE-SPE|"Participants received 2 intravenous (IV) boluses of Flurpiridaz (18F) Injection manufactured by SPE process at Visit 1 and 2.~The targeted dose to the body of Flurpiridaz (18F) Injection was to be in the range of 1.7 to 2.5 millicurie (mCi) (63 to 93 megabecquerel [MBq]) for each administration and not exceed a total of 6 mCi (222 MBq) for an individual participant."
88951202|NCT04594941|Experimental|Treatment Sequence: HPLC-HPLC|"Participants received 2 IV boluses of Flurpiridaz (18F) Injection manufactured by HPLC process at Visit 1 and 2.~The targeted dose to the body of Flurpiridaz (18F) Injection was to be in the range of 1.7 to 2.5 mCi (63 to 93 MBq) for each administration and not exceed a total of 6 mCi (222 MBq) for an individual participant."
88951203|NCT04594941|Experimental|Treatment Sequence: SPE-HPLC|"Participants received 2 IV boluses of Flurpiridaz (18F) Injection manufactured by 2 different processes (1 dose manufactured by SPE followed by 1 dose manufactured by HPLC) at Visit 1 and 2.~The targeted dose to the body of Flurpiridaz (18F) Injection was to be in the range of 1.7 to 2.5 mCi (63 to 93 MBq) for each administration and not exceed a total of 6 mCi (222 MBq) for an individual participant."
88951204|NCT04594941|Experimental|Treatment Sequence: HPLC-SPE|"Participants received 2 IV boluses of Flurpiridaz (18F) Injection manufactured by 2 different processes (1 dose manufactured by HPLC followed by 1 dose manufactured by SPE) at Visit 1 and 2.~The targeted dose to the body of Flurpiridaz (18F) Injection was to be in the range of 1.7 to 2.5 mCi (63 to 93 MBq) for each administration and not exceed a total of 6 mCi (222 MBq) for an individual participant."
88951205|NCT04524663|Experimental|Camostat mesilate|Patients will receive camostat mesilate for 10 days in addition to standard of care treatment.
88951206|NCT04524663|Placebo Comparator|Placebo|Study participants will receive placebo to match camostat mesilate for 10 days in addition to standard of care treatment.
88951207|NCT04462198|Experimental|PIPE-505|
88951208|NCT04462198|Placebo Comparator|Placebo|
89531457|NCT06066112|Experimental|Fasting state|The subjects fasted overnight for at least 10 hours, and an indwelling needle was buried before administration. On the morning of administration, one test formulation (T) or one control formulation (R) was administered on an empty stomach, and the start time of administration was recorded. After administration, the oral cavity and medication container should be checked to ensure the correct use of the medication. Do not drink water from 1 hour before medication to 1 hour after medication (except for 20ml of water moistened with the test formulation and 240 mL of water from the control formulation). Control drinking water from 1 hour to 4 hours after medication, and drink freely at other times. Fasting within 4 hours after medication. After medication, keep the upper body upright for 4 hours. The meal time on the day of the two cycles of medication is roughly the same.
89020612|NCT03261544||Proximal Femur Replacement|The proximal femur is a common site for primary bone sarcomas and metastatic disease. The purpose of this study is to assess the functional outcomes in patients undergoing proximal femur resection and reconstruction with an endoprosthesis, based on the abductor muscle repair technique.
89020613|NCT03206671|Experimental|R1/R2 stage I+II|Rituximab window + standard chemotherapy without anthracyclines (Vincristine not in R1)
89020614|NCT03206671|Experimental|R2 stage III experimental arm|Rituximab window + Standard chemotherapy
89479653|NCT05704101||Asthma patients (n=20) out of them 10 with mild, controlled and 10 with severe, uncontrolled asthma|"Assessments of the SNA-axis. For this, HRV and dBPV will be analyzed using a 3-lead ECG and a continuous non-invasive arterial blood pressure signal. HRV and dBPV will be computed and presented as the high frequency , low frequency , their relative ratio (LF/HF), and the very low frequency component for both.~MSNA will be recorded via a tungsten microelectrode placed in the peroneal nerve.~NHFT at a flow rate of 20/30/40 liters/minute for 30 minutes respectively, with breaks of 15 minutes for all physiological variables to return to baseline.~OSA severity: defined as apnoea-hypopnoea index [AHI] >15/h and obstructive apnoea index [OAI] >5/h~Determination of PH and right HF severity (TAPSE ≤14 mm) and pulmonary arterial pressure (PAsys) using TTE.~Comprehensive lung function and inspiratory muscle strength and function testing as described previously by our group.~Assessment of systemic inflammation in blood samples."
89479654|NCT05704101||Controls (n=10) (and in a group of healthy controls [2:1] matched for age, sex and BMI).|"Assessments of the SNA-axis. For this, HRV and dBPV will be analyzed using a 3-lead ECG and a continuous non-invasive arterial blood pressure signal. HRV and dBPV will be computed and presented as the high frequency , low frequency , their relative ratio (LF/HF), and the very low frequency component for both.~MSNA will be recorded via a tungsten microelectrode placed in the peroneal nerve.~NHFT at a flow rate of 20/30/40 liters/minute for 30 minutes respectively, with breaks of 15 minutes for all physiological variables to return to baseline.~OSA severity: defined as apnoea-hypopnoea index [AHI] >15/h and obstructive apnoea index [OAI] >5/h~Determination of PH and right HF severity (TAPSE ≤14 mm) and pulmonary arterial pressure (PAsys) using TTE.~Comprehensive lung function and inspiratory muscle strength and function testing as described previously by our group.~Assessment of systemic inflammation in blood samples."
89479655|NCT05685394|Experimental|Dapagliflozin|Dapagliflozin 10mg P.O. daily for 6 months add-on to standard treatment
89479656|NCT05685394|No Intervention|Control|No intervention. Patients will be followed for 6 months on their standard treatment.
89479657|NCT05677633|Experimental|Leukine Treatment|48 week regimen of Leukine administered as a weight-based dose at 3 µg/kg/day for 5 days (week), followed by a 2-day holiday (weekend)
89479658|NCT05676476|Experimental|Intervention|Antihypertensive treatment for a BP goal of less than 140/90 mmHg
89479659|NCT05676476|No Intervention|Usual Care|Antihypertensive treatment only if BP ≥ 160/110 mmHg
89479660|NCT05669703||1|Community cohort of families
89479661|NCT05667727|Experimental|epinephrine group|this arm will include the participant who will receive back to back nebulization (standard of care) plus epinephrine nebulization.
89479662|NCT05667727|Active Comparator|control group|in this arm, participant will receive the standard of care treatment (salbutamol and ipratropium, back to back) plus salbutamol as 4th nebulization.
89479663|NCT05667181|Experimental|robotic group|Robot linear cutting stapler
89479664|NCT05667181|Active Comparator|laparocaopic group|laparoscopic linear cutting stapler
89479665|NCT05651737|Active Comparator|Sui App+ (peer guided)|"The active phase of the study is eight weeks per participant with a follow-up online assessment after another eight weeks.~One of the active study groups, the Sui App+ condition, receives the Sui app plus a peer who will guide them online. They receive weekly individual messages from their peer within the chat of the app."
89479666|NCT05651737|Active Comparator|Sui App (unguided)|"The active phase of the study is eight weeks per participant with a follow-up online assessment after another eight weeks.~The second active study group receives the app as a standalone intervention. They use whatever content they are interested in and receive weekly push-notifications in case they were not active."
89020615|NCT03206671|Other|R2 stage III standard arm|Standard chemotherapy
89020616|NCT03206671|Experimental|R3/R4 rituximab plus arm|Rituximab window + standard chemotherapy plus six additional doses of rituximab
89020617|NCT03206671|Experimental|R3/R4 standard arm|Rituximab window + standard chemotherapy
89020618|NCT03184792|Active Comparator|Transcutaneous spinal stimulation & Physical therapy|Transcutaneous cervical electrical stimulation combined with physical therapy that targets rehabilitation of upper extremity functions
89479667|NCT05651737|No Intervention|Waitlist control group|The control arm is a waitlist control group that receives access to the app after eight weeks.
89479668|NCT05637567|Experimental|Treatment Arm|100 mg acetylsalicylic acid per os once daily, starting 1-4 weeks before surgery until 6 months after surgery
89479669|NCT05637567|Placebo Comparator|Control Arm|Identically looking placebo pill, starting 1-4 weeks before surgery until 6 months after surgery
89479670|NCT05630638|Experimental|Delstrigo|doravirine/lamivudine/tenofovir disoproxil 100 mg/ 300 mg/ 245 mg film coated tablets, dosed 1 tablet once daily for the duration of the study
89479671|NCT05630638|Active Comparator|Standard of care|dolutegravir/lamivudine/tenofovir disoproxil 50 mg/300 mg/245 mg film coated tablets, dosed 1 tablet once daily for the duration of the study
89479672|NCT05627323|Experimental|Treatment (CAR T cell therapy) 1|"Arm 1 participants will undergo resection of their tumor. Participants receive half the CHM-1101 dose via Rickham catheters into the tumor cavity and half into the lateral ventricle.~Cycle 1 (28 days) CHM 1101 total dose will be divided across 3 once-weekly administrations.~After Cycle 1, additional cycles may be initiated in the absence of disease progression or unacceptable toxicity provided that the principal investigator and participant agree to continue and if adequate autologous CAR-T doses remain."
89020619|NCT03184792|Active Comparator|Physical therapy only|Physical therapy that targets rehabilitation of upper extremity functions
89479673|NCT05627323|Experimental|Treatment (CAR T cell therapy) 2|"Arm 2 participants will undergo resection of their tumor. Participants receive half the CHM-1101 dose via Rickham catheters into the tumor cavity and half into the lateral ventricle.~Cycle 1 (28 days) CHM 1101 total dose will be divided across 3 once-weekly administrations.~After Cycle 1, additional cycles may be initiated in the absence of disease progression or unacceptable toxicity provided that the principal investigator and participant agree to continue and if adequate autologous CAR-T doses remain."
89479674|NCT05627206|No Intervention|Usual care|
89479675|NCT05627206|Experimental|Intervention|
89479676|NCT05625789|Experimental|Postural control (weight shifting) training followed by steady state gait training.|"For postural control training, participants will be provided visual biofeedback to increase weight shift prior to the first step. The feedback program cues participants to reach a target amount of weight shift. Once the target is reached, participants are cued to initiate walking. Participants will complete a total of 30 minutes of training, ensuring at least 45 repetitions.~To create larger amplitude movements during steady state gait, participants will walk on a treadmill set to their comfortable gait speed while attempting to match their steps to a metronome beeping at 85% of their comfortable cadence. Participants will complete a total of 10 minutes of treadmill walking with rest breaks as needed. Next, participants will walk overground to a metronome beeping at 115% of their comfortable cadence with a goal of 10 total minutes of training.~Each training will be three times per week for two weeks. There is a one week break between the two trainings."
89479677|NCT05625789|Experimental|Steady state gait training followed by postural control (weight shifting) training.|"To create larger amplitude movements during steady state gait, participants will walk on a treadmill set to their comfortable gait speed while attempting to match their steps to a metronome beeping at 85% of their comfortable cadence. Participants will complete a total of 10 minutes of treadmill walking with rest breaks as needed. Next, participants will walk overground to a metronome beeping at 115% of their comfortable cadence with a goal of 10 total minutes of training.~For postural control training, participants will be provided visual biofeedback to increase weight shift prior to the first step. The feedback program cues participants to reach a target amount of weight shift. Once the target is reached, participants are cued to initiate walking. Participants will complete a total of 30 minutes of training, ensuring at least 45 repetitions.~Each training will be three times per week for two weeks. There is a one week break between the two trainings."
89479678|NCT05624346|Experimental|Experimental Group|After the operation, breathing exercises will be applied to the patients.
89479679|NCT05624346|No Intervention|Control Group|There will be no intervention other than routine nursing care practices in the hospital.
89479680|NCT05623748||Cancer for CTC culture|participants are cancer patients with transitional cell carcinoma
89479681|NCT05623748||Healthy for CTC culture|enroll participants without cancer
89479682|NCT05615649|Experimental|Study procedure|This single-arm, repeated-measures study includes study visits at baseline, surgery, device activation, and at 1, 3, 6, and 12 months post-activation.
89479683|NCT05604976|Experimental|SC-PCI|Primary PCI is initiated with a universal guiding catheter (Ikari left). The guiding catheter is used to contrast the left and right coronary arteries and PCI is started directly. This method does not require a catheter exchange. It is Single Catheter PCI (SC-PCI) method.
89479684|NCT05604976|Active Comparator|Conventional|Primary PCI is initiated with a diagnostic catheter. The catheter is used to contrast one of the coronary arteries. Then, the catheter is replaced with a contralateral side diagnostic catheter. Then, the catheter is replaced with a guiding catheter and PCI is started.
89479685|NCT05604820|Experimental|experimental|Progressive Muscle Relaxation Exercise
89479686|NCT05604820|No Intervention|no ıntervention|
89479687|NCT05587244|Experimental|Total Hip Arthroplasty Treatment Group|This study will enroll (implant) up to 202 hips in total according to the IFU and surgical technique. Of these, up to 135 will be revision hips and up to 67 will be primary hips. This is a dual cohort study (primary and revision); each subject will receive the G7 Acetabular System with the Freedom Constrained Vivacit-E bearing. To minimize potential bias and to maximize our ability to assess inter-site differences, each study site will target up to 27 primary hip arthroplasties and up to 54 revision hip arthroplasties (not exceed 81 implanted hips or 40% of total study population). Each site is encouraged to enroll (implant) both primary and revision subjects.
89479688|NCT05585034|Experimental|Dose Escalation and Expansion XmAb®808 administered in combination with pembrolizumab|XmAb®808 in combination with pembrolizumab
89479689|NCT05579769|Active Comparator|ArmA- Lymphoid|Total Body Irradiation and cyclophosphamide (TBI/Cy)
89479690|NCT05579769|Active Comparator|ArmB-Myeloid|TBF with comparable NRM in comparison to busulfan and cyclophosphamide (BuCy)
89479691|NCT05575869|Experimental|Experimental group: Access to online PRONEtect educational material|A website with educational material (simulation video, protocol, checklist).
89479692|NCT05575869|Active Comparator|Control group: Classic one-hour lecture|Didactive presentation by the usual nursing school lecturer.
89479693|NCT05574764|Active Comparator|Teachers|This cohort includes K-12 teachers. Schools will offer all teachers the professional development program called Cultivating Awareness and Resilience in Education (CARE) . CARE will be presented in three in-person training sessions over two to three months during the school year. Tools include mindful awareness practices and caring and emotion skills training. Each intervention workshop includes 30 to 35 participants and a facilitator, who is part of the CARE team. The workshops will be held at a location selected by the school, likely on their campus.
89479694|NCT05574764|Active Comparator|Staff, Non-Administrative|This cohort includes non-administrative staff. Schools will offer all non-administrative staff the professional development program called Cultivating Awareness and Resilience in Education (CARE) . CARE will be presented in three in-person training sessions over two to three months during the school year. Tools include mindful awareness practices and caring and emotion skills training. Each intervention workshop includes 30 to 35 participants and a facilitator, who is part of the CARE team. The workshops will be held at a location selected by the school, likely on their campus.
89537565|NCT03065127|Experimental|Cognitive Training|"Participants will independently complete cognitive exercises on the Smartbrain Pro computer software. These exercises aim to train different aspects of executive function. The difficulty level of each exercise will increase relative to each participant's progress. Sessions will last for one hour, occurring twice weekly for a period of 4 weeks."
89020620|NCT03178617|Active Comparator|Arm I (standard of care LIP)|Parents or caregivers attend standard of care LIP consisting of a meeting to review results of a neurocognitive evaluation and to discuss recommendations for optimal learning and school performance for 1 session.
89479695|NCT05574764|Active Comparator|Staff, Administrative|This cohort includes non-administrative staff. Schools will offer all non-administrative staff the professional development program called Cultivating Awareness and Resilience in Education (CARE) . CARE will be presented in three in-person training sessions over two to three months during the school year. Tools include mindful awareness practices and caring and emotion skills training. Each intervention workshop includes 30 to 35 participants and a facilitator, who is part of the CARE team. The workshops will be held at a location selected by the school, likely on their campus.
89479696|NCT05562999|Experimental|Deep neuromuscular blockade|Participant will receive deep neuromuscular blockade (PTC 1-2)
89479697|NCT05562999|Active Comparator|Moderate neuromuscular blockade|Participant will receive moderate neuromuscular blockade (TOF 1-2)
89479698|NCT05558293|Placebo Comparator|Periodontitis quadrant Scaling root planing|Patients undergo non surgical quadrant scaling and root planing performed per quadrant
89479699|NCT05558293|Active Comparator|Periodontitis full mouth scaling root planing|Patients undergo non surgical full mouth scaling and root planing
89479700|NCT05558267|Experimental|Standard Table Salt, then Salt Substitute|"The two intervention periods will last 16 days with a 19-day washout period in between.~During the first 16-day treatment period, participants will receive the Standard Table Salt to use for cooking and as an additive at the table. Participants will then undergo a 19-day washout period. The second 16-day treatment period will immediately follow the washout period. During the second 16-day treatment period, participants will receive the Salt Substitute to use for cooking and as an additive at the table.~Participants will be encouraged to replace their use of regular salt with the Standard Table Salt and Salt Substitute. They will be encouraged to reduce their overall intake of salt throughout the study period. There are no restrictions or further instructions regarding timing or dosing.~In addition, participants will undergo standard of care hemodialysis (typically 3x/week) and have their blood chemistries measured according to the usual standard of care during the study."
89479701|NCT05558267|Experimental|Salt Substitute, then Standard Table Salt|"The two intervention periods will last 16 days with a 19-day washout period in between.~During the first 16-day treatment period, participants will receive the Salt Substitute to use for cooking and as an additive at the table. Participants will then undergo a 19-day washout period. The second 16-day treatment period will immediately follow the washout period. During the second 16-day treatment period, participants will receive the Standard Table Salt to use for cooking and as an additive at the table.~Participants will be encouraged to replace their use of regular salt with the Standard Table Salt and Salt Substitute. They will be encouraged to reduce their overall intake of salt throughout the study period. There are no restrictions or further instructions regarding timing or dosing.~In addition, participants will undergo standard of care hemodialysis (typically 3x/week) and have their blood chemistries measured according to the usual standard of care during the study."
89479702|NCT05556174|Experimental|Intensive intraoperative lung-protective ventilation|intraoperative lung-protective ventilation with periodic lung recruitment maneuvers
89479703|NCT05556174|No Intervention|Moderate intraoperative lung-protective ventilation|intraoperative lung-protective ventilation without periodic lung recruitment maneuvers
89479704|NCT05554861|Experimental|Low Frequency rTMS Protocol|It was planned to apply 1 Hz low-frequency inhibition protocol to the primary motor cortex foot area in the non-lesional hemisphere, 5 days a week for 2 weeks, for a total of 10 sessions.
89479705|NCT05554861|Active Comparator|Intermittent Theta Burst Stimulation (iTBS) Protocol|It was planned to apply 50 Hz high-frequency stimulation protocol to the primary motor cortex foot area in the ipsilesional hemisphere, 5 days a week for 2 weeks, for a total of 10 sessions.
89479706|NCT05554861|Placebo Comparator|Sham rTMS Protocol|It was planned to apply daily sham rTMS to the motor extremity area of the primary motor cortex along a 10 cm thick wood for 10 sessions.
89479707|NCT05554653|Active Comparator|Leucine enriched essential amino acids|Leucine enriched essential amino acids (4g total, of which 1.6g are leucine). 20g carbohydrate, 2g of protein free drink powder, and 5g of Splenda to mask taste.
89479708|NCT05554653|Placebo Comparator|Carbohdyrate Placebo|Iso-caloric placebo (4g maltodextrin to replace LEAA). 20g carbohydrate, 2g of protein free drink powder, and 5g of Splenda to mask taste.
89479709|NCT05551117|Experimental|MGC018 2.0 mg (Arm A)|MGC018 2.0 mg/kg every 4 weeks
89479710|NCT05551117|Experimental|MGC018 2.7 mg (Arm B)|MGC018 2.7 mg/kg every 4 weeks
89479711|NCT05547607||definite or high suspicion endocarditis|All consecutive patients referred for an echocardiography (transthoracic or transesophageal approach) with a high suspicion of endocarditis and those with a confirmed diagnosis of endocarditis independently by the request will be eligible for the study.
89479712|NCT05547607||negative examination with low suspicion of endocarditis|For patients with no evidence of endocarditis on their echocardiogram, data on the following will be collected: i) risk factors for endocarditis; i) size, type and position of valve prosthesis or other devices if present; iii) Duke criteria verification.
89479713|NCT05547373|Experimental|Intervention|The investigators will select HCWs from the selected departments at the national hospitals, provincial hospitals, and district referral hospitals to participate in the pilot intervention. The participants will also include representatives from the Communicable Disease Control Department and the Department of Hospital Services of the Ministry of Health, the provincial hospitals, and the district referral hospitals in Cambodia and Lao PDR.
89479714|NCT05547165|Active Comparator|Primary Comparator|Interventional groups that subject will be randomly assigned to include Percutaneous Patent Ductus Arteriosus Closure (PPC) or Responsive Management. Those assigned to PPC will undergo active intervention to close a hemodynamically significant patent ductus arteriosus (HSPDA) whereas those assigned to Responsive Management will be treated to manage the symptoms of the HSPDA and permit natural closure over time.
89479715|NCT05547165|Other|Secondary Intervention|Sub-group of patients initially randomized to Responsive Management who may suffer a decline in health status that can be attributed to the presence of a hemodynamically significant patent ductus arteriosus (HSPDA). These patients, upon meeting pre-specified clinical criteria, will undergo active treatment via Percutaneous Patent Ductus Arteriosus Closure (PPC) as in the active comparator arm.
89479716|NCT05541887|Active Comparator|Intervention-Placebo|Participants in this arm will consume muscadine wine polyphenol for six weeks and then placebo for another six weeks. The two phases are separated by a 21-day washout period
89479717|NCT05541887|Active Comparator|Placebo-Intervention|Participants in this arm will first consume placebo for six weeks and then muscadine wine polyphenol for another six weeks. The two phases are separated by a 21-day washout period
89479718|NCT05540899|Experimental|Hypofractionated Postoperative Radiotherapy (H-PORT)|H-PORT of 50 Gy given over 4 weeks.
89479719|NCT05535114|Experimental|Yoga-resistance exercise (YRE) group|"The YRE group will perform breathing exercises, flexibility, resistance exercises and relaxation. It will be carried out for about 30 to 45 minutes in the first two hours of each hemodialysis session, three times weekly for 12 weeks. The intensity of resistance exercise will be adjusted individually at week 3, week 7, and week 11 to the rate of perceived exertion of somewhat hard (on the Borg scale 6-20). The intensity of resistance exercise will be increased gradually by changing the different colors of elastic bands."
89479720|NCT05535114|No Intervention|Control group|Participants in the control group will receive only usual care. They will be able to receive the YRE protocol after completing the study.
89479721|NCT05533138|Active Comparator|Assessment form allocated by chance & guided ICBT for antenatal depression|Patients are randomized to assessment modality (telephone, video or face-to-face visit) of a perinatal psychiatric semi-structured assessment & and are randomised to treatment with internet-CBT for antenatal depression without extra-support (10 weeks)
89479722|NCT05533138|Active Comparator|Assessment form allocated by choice & guided ICBT for antenatal depression|Patients choose assessment modality (telephone, video or face-to-face visit) of a perinatal psychiatric semi-structured assessment & are randomised to treatment with internet-CBT for antenatal depression without extra-support (10 weeks)
89479723|NCT05533138|Experimental|Assessment form allocated by chance & guided ICBT for antenatal depression with extra support|Patients are randomized to assessment modality (telephone, video or face-to-face visit) of a perinatal psychiatric semi-structured assessment & and are randomised to treatment with internet-CBT for antenatal depression with extra-support
89479724|NCT05533138|Experimental|Assessment form allocated by choice & guided ICBT for antenatal depression with extra support|Patients choose assessment modality (telephone, video or face-to-face visit) of a perinatal psychiatric semi-structured assessment & are randomised to treatment with internet-CBT for antenatal depression with extra-support (10 weeks)
89479725|NCT05525949|Experimental|VIVID Brain|VIVID Brain, 5 times a week for 12 weeks
89479726|NCT05525949|Other|No-treatment Control|No-treatment is administered during control period.
89020621|NCT03178617|Experimental|Arm II (HIP)|Parents or caregivers attend HIP consisting of individual parental skill training sessions with a bilingual therapist over 60-90 minutes every 2 weeks for a total of 8 sessions.
89020622|NCT03161431|Experimental|Monotherapy: SX-682 dose escalation|Escalating oral doses of SX-682 (study drug) of 25, 50, 100, 200 and 400 mg twice-daily (i.e., 50, 100, 200, 400 and 800 mg total each day.
89020623|NCT03161431|Experimental|Combination therapy: SX-682 dose escalation with pembrolizumab|SX-682 will be administrated at the same dose the participant was administered in monotherapy and will be administered in a 6 week cycle that includes 2 i.v. infusions of pembrolizumab on days 1 and 22 of each cycle, for a total of up to 17 cycles. Once the highest safe dose of SX-682 in combination therapy with pembrolizumab is determined, participants will be enrolled in an expansion phase at that SX-682 dose with pembrolizumab combination therapy.
89479727|NCT05523843||Treatment seeking individuals|Individuals seeking treatment in the Laureate Psychiatric Clinic and Hospital (LPCH).
89479728|NCT05523843||Healthcare professionals|Healthcare professionals (HCPS) include nurses, psychologists, therapists, medical doctors, dieticians, etc who work at LPCH and are engaged in direct patient care.
89020624|NCT03129126|Experimental|LP-10 2mg|LP-10 (intravesical tacrolimus), 2mg reconstituted in sterile water for injection, intravesical instillations, up to two instillations, instillations will occur greater than 3 days but less than 7 days apart as needed.
89020625|NCT03129126|Experimental|LP-10 4mg|LP-10 (intravesical tacrolimus), 4mg reconstituted in sterile water for injection, intravesical instillations, up to two instillations, instillations will occur greater than 3 days but less than 7 days apart as needed.
89020626|NCT03129126|Experimental|LP-10 8mg|LP-10 (intravesical tacrolimus), 8mg reconstituted in sterile water for injection, intravesical instillations, up to two instillations, instillations will occur greater than 3 days but less than 7 days apart as needed.
89020627|NCT03066960|Active Comparator|Radiofrequency neurotomy group|Unilateral radiofrequency neurotomy of medial branches to the dorsal ramus at one or two cervical levels
88951209|NCT04458155||Chest pain patients|"Patients are eligible for participation if they are admitted to:~The cardiac emergency department (ED) because of chest pain for ruling out acute coronary syndrome by troponin analysis~The Coronary Care Unit (CCU) with a NSTEMI or post-percutaneous coronary intervention (PCI) STEMI.~Troponin analysis will be performed according to standard protocol. From every included patient two capillary blood samples and an extra venous blood sample will be drawn during regularly ordered blood work to evaluate HS cTnI levels obtained with the POC instrument."
89479729|NCT05520086|Experimental|Single dose Allogenic Adiposse derived mesenchimal stem cells|Allogenic Adiposse derived mesenchimal stem cells (MSC) Dose: 12,5 million cells
89479730|NCT05520086|Experimental|Double dose Allogenic Adiposse derived mesenchimal stem cells|Allogenic Adiposse derived mesenchimal stem cells (MSC) Dose: 12,5 million cells at day 0 and 12,5 million cells at day 14
89479731|NCT05515874|No Intervention|Arm 1 - MRI Brain with CO2 inhalation|"A research MRI exam that uses CO2 inhalation and gadavist contrast injections. This examination will last for about 45 minutes and will be performed at Northwestern.~A mask will be placed over the nose and mouth during the MRI exam.~Air mixed with CO2, and odorless, colorless gas will be delivered to the mask for breathing.~After the images are collected (approximately 5 minutes) normal air will be delivered to the mask~This scan with CO2 will last approximately 10 minutes, however the total duration of the scan will be 45 minutes as it also involves injection of gadavist."
89479732|NCT05515874|No Intervention|Arm 2 - MRI Brain with Tc-99m-HMPAO tracer|This type of MRI shows the flow of blood in different areas of the brain and will be performed at University of Chicago. This is done with a tracer called Tc-99m-HMPAO, injected through a vein in the arm. HMPAO is Technetium-99m hexamethyl propylenamine oxime and used clinically to assess blood supply in the brain. This MRI will be performed one hour after the injection of this tracer at University of Chicago and will last up to one hour. A tracer is a specially designed drug that is bound to a radioactive material. Tracers are designed to act like natural products in the body allowing imaging to look at how the body is working. Tracers are designed to look at very specific organ functions and, in this case, brain.
89479733|NCT05515874|Experimental|Arm 3 - Feumoxytol infusion and MRI Brain|An intravenous ferumoxytol infusion (before the patient leaves Northwestern or University of Chicago after stroke care or at another visit) and an MRI exam 72 hours later. This MRI examination will last approximately 30 minutes and will not involve gadavist. All arm 3 procedures will be performed either at Northwestern or University of Chicago.
89479734|NCT05513703|Experimental|Telisotuzumab Vedotin|Participants will receive telisotuzumab vedotin every 2 weeks until meeting study drug discontinuation criteria.
89479735|NCT05510700|Experimental|Acupuncture group|"Participants will be given sleep hygiene instructions. Participants will receive acupuncture treatment at Nei Guan (PC 6), Shen Men (HT 7), Shen Ting (GV 24), Yin Tang (GV 29), Zhong Wan (CV 12), San Yin Jiao (SP 6), Zhao Hai (KI 6), and Shen Mai (BL 62). Among the above acupoints, Nei Guan (PC 6), Shen Men (HT 7), San Yin Jiao (SP 6), Zhao Hai (KI 6), and Shen Mai (BL 62) are all taken from both sides.~Participants will receive three treatments per week (every other day), each lasting 30 minutes, for a total of 12 sessions over the course of four weeks. The follow-up observation will be recorded on week 8 and 16."
89479736|NCT05510700|Sham Comparator|Sham acupuncture group|"Participants will be given sleep hygiene instructions. To match the true acupuncture points, sham treatment at sham Nei Guan (PC 6), Shen Men (HT 7), Shen Ting (GV 24), Yin Tang (GV 29), Zhong Wan (CV 12), San Yin Jiao (SP 6), Zhao Hai (KI 6), and Shen Mai (BL 62) will be used.~Participants will have the same needle retention time, treatment time, and follow-up time as the acupuncture group."
89479737|NCT05509231|Experimental|ASD High-intensity Exercise (Group 1a - ASD)|The high-intensity group (Group 1a - ASD). Subjects will be asked to meet 2-3 times a week for exercise training for 60-90 minutes a session. Subjects will be asked to take part in tests that measure motor skills and thinking abilities.
89479738|NCT05509231|Experimental|Neurotypical Group (Group 1b - Neurotpical)|The high-intensity group (Group 1b - Neurotypical). Subjects will be asked to meet 2-3 times a week for exercise training for 60-90 minutes a session. Subjects will be asked to take part in tests that measure motor skills and thinking abilities.
89479739|NCT05509231|Experimental|ASD Wearable Technology (Group 2a - ASD)|ASD Wearable Technology (Group 2a- ASD). Subjects wear a glove and arm sleeve with sensors that will measure arm and hand performance. Subjects will be training 2 times a week for 20-30 minutes. The Subjects will be asked to copy a series of hand and arm gestures. Subjects will perform a series of hand exercises with the glove. The glove will record the movement data that will provide the investigators and subjects feedback on hand performance and fine motor capabilities.
89479740|NCT05509231|Experimental|ASD Wearable Technology (Group 2b - Neurotypical)|ASD Wearable Technology (Group 2b - Neurotypical). Subjects wear a glove and arm sleeve with sensors that will measure arm and hand performance. Subjects will be training 2 times a week for 20-30 minutes. The Subjects will be asked to copy a series of hand and arm gestures. Subjects will perform a series of hand exercises with the glove. The glove will record the movement data that will provide the investigators and subjects feedback on hand performance and fine motor capabilities.
89479741|NCT05509231|No Intervention|Control (Group 3)|The wait-list control group will not receive the experimental intervention but will be put on a waiting list to receive the intervention after the active intervention group completes the study.
89479742|NCT05496543|Experimental|Acupuncture group|"Participants will receive acupuncture treatment at Zhao Hai(KI 6), Da Zhong(KI 4), Tai Xi(KI 3), Tian Shu(ST 25), and Shang Ju Xu(ST 37) bilaterally.~Each treatment will last 30 minutes and participants will receive the treatment 3 times per week (every other day) for 8 weeks, 24 sessions in total. Follow-up time is week 4 and week 12 after treatment (ie, week 12 and week 20)."
89479743|NCT05496543|Placebo Comparator|Sham acupuncture group|"Participants will receive sham acupuncture treatment on bilateral sham Zhao Hai(KI 6), Da Zhong(KI 4), Tai Xi(KI 3), Tian Shu(ST 25), and Shang Ju Xu(ST 37) that match real acupuncture points.~The duration of needle retention, treatment period, and follow-up in the control group is the same as that in the intervention group."
89479744|NCT05488665|Experimental|Crush technique group|Two stenting with the Crush technique
88951210|NCT04438668|Active Comparator|Standard Care|Standard care (SC) for screening for FGR is a healthcare provider auscultating the foetal heart rate with a standard stethoscope, palpation of foetal size by hand, and measuring the size of the woman's uterus with a tape measure, and comparing the measurement to the expected measurement for the gestational age of the foetus.
89479745|NCT05488665|Active Comparator|Culotte technique group|Two stenting with the Culotte technique
89020628|NCT03066960|Sham Comparator|Sham group|Unilateral sham treatment of medial branches to the dorsal ramus at one or two cervical levels
89479746|NCT05488535|Experimental|Non-significant risk study of a cochlear implant headpiece|This arm aims to evaluate a cochlear implant headpiece.
89479747|NCT05479994|Experimental|Treatment Arm|Participants will receive BGB-11417 orally until disease progression, intolerable toxicity, or other scenarios specified in the protocol
89479748|NCT05478720|Experimental|Dose escalation in healthy Malawian adults - 0.1 mg/kg IV DON|The first 10 healthy adult participants enrolled will receive a single 0.1 mg/kg intravenous (IV) DON. If this dose is proven safe, in each subsequent group of 10, the dose will be increased to 1.0 mg/kg IV DON and then 5.0 mg/kg IV DON the final group will receive 10.0 mg/kg IV DON.
89479749|NCT05478720|Experimental|Dose escalation in healthy Malawian adults - 1.0 mg/kg IV DON|The first 10 healthy adult participants enrolled will receive a single 0.1 mg/kg intravenous (IV) DON. If this dose is proven safe, in each subsequent group of 10, the dose will be increased to 1.0 mg/kg IV DON and then 5.0 mg/kg IV DON the final group will receive 10.0 mg/kg IV DON.
89479750|NCT05478720|Experimental|Dose escalation in healthy Malawian adults - 5.0 mg/kg IV DON|The first 10 healthy adult participants enrolled will receive a single 0.1 mg/kg intravenous (IV) DON. If this dose is proven safe, in each subsequent group of 10, the dose will be increased to 1.0 mg/kg IV DON and then 5.0 mg/kg IV DON the final group will receive 10.0 mg/kg IV DON.
89479751|NCT05478720|Experimental|Dose escalation in healthy Malawian adults - 10.0 mg/kg IV DON|The first 10 healthy adult participants enrolled will receive a single 0.1 mg/kg intravenous (IV) DON. If this dose is proven safe, in each subsequent group of 10, the dose will be increased to 1.0 mg/kg IV DON and then 5.0 mg/kg IV DON the final group will receive 10.0 mg/kg IV DON.
89479752|NCT05478720|Experimental|Dose escalation in Malawian adults with uncomplicated malaria - 0.1 mg/kg IV DON|The first 10 adults with uncomplicated malaria participants enrolled will receive a single 0.1 mg/kg intravenous (IV) DON. If this dose is proven safe, in each subsequent group of 10, the dose will be increased to 1.0 mg/kg IV DON and then 5.0 mg/kg IV DON, and then the final group will receive 10.0 mg/kg IV DON.
89479753|NCT05478720|Experimental|Dose escalation in Malawian adults with uncomplicated malaria - 1.0 mg/kg IV DON|The first 10 adults with uncomplicated malaria participants enrolled will receive a single 0.1 mg/kg intravenous (IV) DON. If this dose is proven safe, in each subsequent group of 10, the dose will be increased to 1.0 mg/kg IV DON and then 5.0 mg/kg IV DON, and then the final group will receive 10.0 mg/kg IV DON.
89479754|NCT05478720|Experimental|Dose escalation in Malawian adults with uncomplicated malaria - 5.0 mg/kg IV DON|The first 10 adults with uncomplicated malaria participants enrolled will receive a single 0.1 mg/kg intravenous (IV) DON. If this dose is proven safe, in each subsequent group of 10, the dose will be increased to 1.0 mg/kg IV DON and then 5.0 mg/kg IV DON, and then the final group will receive 10.0 mg/kg IV DON.
89479755|NCT05478720|Experimental|Dose escalation in Malawian adults with uncomplicated malaria - 10.0 mg/kg IV DON|The first 10 adults with uncomplicated malaria participants enrolled will receive a single 0.1 mg/kg intravenous (IV) DON. If this dose is proven safe, in each subsequent group of 10, the dose will be increased to 1.0 mg/kg IV DON and then 5.0 mg/kg IV DON, and then the final group will receive 10.0 mg/kg IV DON.
89479756|NCT05478720|Experimental|Dose escalation in Malawian children with cerebral malaria - 0.1 mg/kg IV DON - Cohort 1|After adult doses are shown to be safe. The first 6 children with cerebral malaria enrolled will receive 0.1 mg/kg IV DON, and 2 will receive placebo.
89479757|NCT05478720|Experimental|Dose escalation in Malawian children with cerebral malaria - 0.1 mg/kg IV DON - Cohort 2|10 participants will receive 0.1 mg/kg IV DON, and 2 will receive placebo.
89479758|NCT05478720|Experimental|Dose escalation in Malawian children with cerebral malaria - 1.0 mg/kg IV DON - Cohort 3|14 participants will receive 0.1 mg/kg IV DON, and 4 will receive placebo.
89479759|NCT05478720|Experimental|Dose escalation in Malawian children with cerebral malaria - 1.0 mg/kg IV DON - Cohort 4|28 participants will receive 0.1 mg/kg IV DON or1.0 mg/kg IV DON (n=TBD), and 8 will receive placebo.
89479760|NCT05478720|Placebo Comparator|Dose escalation in Malawian children with cerebral malaria - placebo|Cohort 1 will dose 2 participants to receive placebo Cohort 2 will dose 2 participants to receive placebo Cohort 3 will dose 4 participants to receive placebo Cohort 4 will dose 8 participants to receive placebo
89479761|NCT05474755|Experimental|GP681 40mg|Patients in the GP681 40mg group will receive a single oral dose of GP681 tablet 40mg with 240mL water.
89479762|NCT05474755|Placebo Comparator|placebo group|Patients in the Placebo group will receive a single oral dose of GP681 Simulant 40mg with 240mL water.
89479763|NCT05474430||Cystic Fibrosis Carrier Group|Participants have been identified as Cystic Fibrosis Carriers via previous genetic testing.
89479764|NCT05474430||Control Group|Participants have been identified as not being Cystic Fibrosis Carriers via previous genetic testing.
89479765|NCT05472792|Active Comparator|Endocrine Therapy|Endocrine therapy will be chosen by the treating medical oncologist with an aim of 5 years duration, as tolerated by the patient.
89479766|NCT05472792|Experimental|Accelerated Partial Breast Irradiation (APBI)|APBI will consist of 5 fractions of radiation therapy delivered every other day to the lumpectomy cavity.
89479767|NCT05472714|No Intervention|Without Video|In year 1, we will recruit families of patients receiving the current standard-of-care approach to tumor-normal genetic testing with provider based education.
89479768|NCT05472714|Experimental|With Video|In year 2, we will recruit families of patients receiving the updated standard-of-care approach to tumor-normal genetic testing with provider based education and an educational video.
89020629|NCT03048019||Tirofiban Therapy|patients randomized to tirofiban therapy
89020630|NCT03048019||Cangrelor Therapy|patients randomized to cangrelor therapy
89479769|NCT05465161|Experimental|StingMark Fiducial Marker|Device insertion will occur with the designated needles and through the appropriate organ-specific route and imaging guidance. Multiple STING-MARK fiducials will be inserted. Plain film x-rays in 3 planes of the organs with the marker inserted will be taken and recorded.
89479770|NCT05463783|Experimental|Biktarvy|15 subjects will get Biktarvy (single-tablet regimen of bictegravir/emtricitabine/tenofovir alafenamide) once daily.
89479771|NCT05463783|Experimental|Symtuza|15 subjects will get Symtuza (single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide) once daily.
89479772|NCT05463224|Experimental|Lazertinib group|Lazertinib 240mg daily (1 cycle of 21 days)
89479773|NCT05457244|Experimental|Participant arm|
89479774|NCT05456308|Experimental|Pressure (30 centimeters), Duration (1 minute), Number of times done (1)|
89479775|NCT05456308|Experimental|Pressure (30 centimeters), Duration (2 minute), Number of times done (1)|
89479776|NCT05456308|Experimental|Pressure (30 centimeters), Duration (1 minute), Number of times done (2)|
89479777|NCT05456308|Experimental|Pressure (80 centimeters), Duration (1 minute), Number of times done (1)|
89479778|NCT05456308|Experimental|Pressure (80 centimeters), Duration (2 minute), Number of times done (1)|
89479779|NCT05456308|Experimental|Pressure (80 centimeters), Duration (1 minute), Number of times done (2)|
89479780|NCT05456308|Experimental|Pressure (30 centimeters), Duration (2 minute), Number of times done (2)|
89479781|NCT05456308|Experimental|Pressure (80 centimeters), Duration (2 minute), Number of times done (2)|
89479782|NCT05454605||group 1, ex vivo|"Assessment of the degree of cartilage damage according to the International Cartilage Regeneration & Joint Preservation Society (ICRS) classification.~Optical spectroscopy of patient tissue samples.~Study of the mechanical properties of intra-articular tissues and cartilage thickness with an indenter.~Histological assessment of tissues according to the Osteoarthritis Research Society International (OARSI) classification."
89479783|NCT05454605||group 2, in vivo|"Assessment of the degree of cartilage damage according to the ICRS classification.~Optical spectroscopy during arthroscopy/arthroplasty.~Magnetic resonance imaging (MRI)."
89479784|NCT05453604|Experimental|Sample collection|This is a prospective study in which urine samples will be collected from healthy volunteers, urine samples and a blood sample from pregnant women and cancer patients with solid tumors with emphasis on breast- and prostate cancer. The participants will be asked to provide a urine sample collected with the Colli-Pee® device and fill out an online questionnaire to collect usability data.
89479785|NCT05446194|Experimental|Investigational Treatment 1|Investigational treatment stimulation pattern 1
89479786|NCT05446194|Experimental|Investigational Treatment 2|Investigational treatment stimulation pattern 2
89479787|NCT05441345||SBS patients|
89479788|NCT05432999|Experimental|Intervention|This group will receive a focused extracorporeal shockwave therapy treatment (three applications over three weeks), applied to the spastic medial gastrocnemius.
89479789|NCT05432999|Sham Comparator|Control|This group will go through the same procedures as the intervention group, but the shockwave device will not touch their skin and thus they will receive no therapeutic effect.
89479790|NCT05427981|Experimental|Buprenorphine|Buccal Films
89479791|NCT05427981|Placebo Comparator|Placebo|Buccal Films
88951211|NCT04438668|Experimental|Standard Care and Centaflow|Centaflow uses sound-derived maternal intra-arterial turbulence as a marker of foetal growth restriction (FGR) and provides information on the foetal heart rate. Indication for use is as a screening device for FGR in women beyond 27 weeks of pregnancy with a singleton pregnancy.
88951212|NCT04435795|Active Comparator|Ciclesonide inhaled and nasal|Intranasal ciclesonide BID 50mcg BID to each nostril and inhaled ciclesonide 600mcg BID x 14 days
88951213|NCT04435795|Placebo Comparator|Placebo|Normal Saline intranasal BID and Placebo 3 puff MDI inhaled BID
88951214|NCT04356248|Experimental|High-intensity interval training + energy management education|"High-intensity interval training (HIIT): physiologically defined heart rate-controlled cycling with 80-100 rounds per minute (rpm) at 95-100% of maximum heart rate (HRmax). Participants will perform 5 × 1.5-min high-intensive exercise bouts at 95-100% of their HRmax followed by active breaks of unloaded pedalling over 2 min with the aim to achieve 60% of HRmax.~Energy management education (IEME): face-to-face education sessions of 6.5 h in duration over a 3-week period, all conducted by a trained occupational therapist. Participants acquire knowledge and understanding about factors that influence energy and the consequences of fatigue on their habits and lifestyle. Six weeks after returning home, the participants will receive a reinforcement letter in the form of information material to remember the content of the IEME and to reinforce the implementation of the behaviour change in managing energy."
89020631|NCT03035604||Nutritional geriatric assessment|Participants undergo nutritional geriatric assessment over 15 minutes in person or on the phone every 3 months for 12 months.
89020632|NCT03030079|Experimental|Experimental Electrical stimulation Regimen|Explore the efficacy of an electrical stimulus regimen on the treatment of chronic phantom limb pain using a standard-of-care electrical stimulation system
89020633|NCT03019133|No Intervention|Usual Care|Usual care will be provided.
89479792|NCT05424718|Experimental|Immediate Intervention|Study participants randomized to the intervention arm will have access to the MyPEEPS Mobile application for the first three months of the trial and then the intervention is removed at the 3 month follow-up visit.
89479793|NCT05424718|Experimental|Delayed Intervention|Participants randomized to the delayed intervention arm will not have access to MyPEEPS Mobile for the first 3 months of the study and will receive access to the MyPEEPS Mobile App at the 3 month follow-up visit.
89479794|NCT05424146|Placebo Comparator|Placebo Non-Prebiotic Bar Group|This group of participants will be consuming non-prebiotic bars for the duration of the trial.
89479795|NCT05424146|Active Comparator|Prebiotic Bar Group|Participants will be asked to consume prebiotic bars for the duration of the trial.
89479796|NCT05420740|Experimental|COPD patients with Small Airway Disease|Subjects will be given Aerobika OPEP and IOS, CAT score, Spirometry, 6MWT and Exacerbation were assessed at Week 0, Week 12 and Week 24
89479797|NCT05419466|Experimental|melatonin and zinc bioavailability|dietary supplement, 1 tablet containing delayed release melatonin, zinc and lemon balm
89479798|NCT05418101|Experimental|Part A Cohort 1: Dose level 1|Participants will be randomized to SAD dose of VIS171 (or placebo).
89479799|NCT05418101|Experimental|Part A Cohort 2: Dose level 2|Participants will be randomized to SAD dose of VIS171 (or placebo).
89479800|NCT05418101|Experimental|Part A Cohort 3: Dose level 3|Participants will be randomized to SAD dose of VIS171 (or placebo).
89479801|NCT05418101|Experimental|Part A Cohort 4: Dose level 4|Participants will be randomized to SAD dose of VIS171 (or placebo).
89479802|NCT05418101|Experimental|Part A Cohort 5: Dose level 5|Participants will be randomized to SAD dose of VIS171 (or placebo).
89479803|NCT05418101|Experimental|Part B Cohort 1: Dose level to be determined from SAD Cohort(s) data|Participants will be randomized to MAD dose of VIS171.
89479804|NCT05418101|Experimental|Part B Cohort 2: Dose level to be determined from SAD Cohort(s) data|Participants will be randomized to MAD dose of VIS171.
89203018|NCT00758186|Experimental|Colonic-stenting|Colonic-stenting and elective surgery: Emergency endoscopic colonic stenting followed by elective surgery at a later date for acute left-sided malignant colonic obstruction.
89203019|NCT00758186|Active Comparator|Emergency surgery|Emergency surgery: Patients underwent emergency surgery for acute left-sided malignant colonic obstruction.
89479805|NCT05418101|Experimental|Part B Cohort 3: Dose level and regimen to be determined from prior MAD and SAD Cohort(s)|Participants will be randomized to MAD dose of VIS171.
89479806|NCT05412121|Experimental|Acupressure|The self-acupressure intervention will be delivered using the modified MeTime Acupressure mobile application (App) in addition to in-person or virtual instruction via study staff.
89479807|NCT05410145|Experimental|D3S-001|"Dose Escalation, D3S-001 administered orally.~Dose Expansion, D3S-001 administered orally in selected cancer type patients."
89479808|NCT05409274||Pregnant women|Pregnant women enrolled across 5 country study sites at any point during pregnancy, up to and including the day of delivery.
89479809|NCT05400915|Experimental|Variltinib, Paclitaxel|
88951215|NCT04356248|Active Comparator|Low-intensity training + progressive muscle relaxation|"Low-intensity training (ST): participants will exercise for 24 min continuously at 65% of participants' HRmax (60-70 rpm).~Progressive muscle relaxation (PMR): The aim of PMR is to achieve enhanced mental relaxation by reducing muscle tension. Participants will attend six 1-h group sessions over the 3-week intervention period, instructed by a trained physical therapist. Six weeks after returning home, the participants will receive a reinforcement letter with information material for remembering the content of the PMR techniques and to reinforce the implementation of the exercises at home."
88951216|NCT04350593|Active Comparator|Dapagliflozin 10mg|Dapagliflozin 10 mg daily
88951217|NCT04350593|Placebo Comparator|Placebo|Dapagliflozin matching placebo 10 mg daily
88951218|NCT04342754|Experimental|Deep Brain Stimulation ON (DBS ON)|The device will be turned ON
88951219|NCT04342754|Sham Comparator|Deep Brain Stimulation OFF (DBS OFF)|The device will be turned OFF
88951220|NCT04320836||Cervical epidural steroid injection|This group will receive an interlaminar cervical ESI at C6-7 or C7-T1 with 1 mL steroid (depo-methylprednisolone 40 mg at Johns Hopkins and the DC VA Hospital or dexamethasone 10 mg at Seoul National University) and 2 mL normal saline.
88951221|NCT04298112||relapse after radical treatment for prostate cancer|prostate cancer patients with biochemical relapse following radical treatment, or patients with persistently elevated PSA levels after radical prostatectomy, that have been (or will be) referred to PSMA PET/CT and PSMA PET/MRI at one of the participating hospitals.
89020634|NCT03019133|Active Comparator|Sound reduction|Use of noise reduction headphones. Pro For Sho safety ear muffs with a noise reduction rate of 34dB will be used.
89203020|NCT00989560|Active Comparator|Active arm|
89203021|NCT00989560|No Intervention|Standard care arm|
89203022|NCT00934323|Experimental|TR sequential group|Amaryl M SR 1/500 mg in period 1 and Amaryl M SR 2/500 mg in period 2
89203023|NCT00934323|Active Comparator|RT sequential group|Amaryl M SR 2/500 mg in period 1 and Amaryl M SR 1/500 mg in period 2
89203024|NCT00793962|Experimental|hypofractionation radiotherapy|breast cancer women with mastectomy high-risk: T3-4 and/or 4 or more axillary nodes involvement postmastectomy hypofractionation radiotherapy of 43.5Gy/15f/3w to the chest wall and supraclavicular nodal region
89479810|NCT05391230|Experimental|Intervention Arm : Arm that received permethrin-treated lesu|Intervention Arm is the group that receives permethrin-treated lesu for use. The lesus of participants in the intervention group will be treated and subsequently retreated each month with 0.5% permethrin (Sawyer Products, Safety Harbor, FL).
89479811|NCT05391230|Sham Comparator|Control Arm: Arm that received none permethrin-treated lesu|The lesus of participants in the control group will undergo sham treatment and re-treatment in which the cloth is soaked in water for a period of time similar to that of the intervention group. Participants and clinical staff (but not administrative staff) will be blinded to group assignments.
89479812|NCT05386706|Experimental|Digital Intervention|A mini program-based digital intervention.
89020635|NCT03019133|Active Comparator|Sound masking|Use of headphones and relaxing music. Sennheiser HD 280 pro headphones will be used for sound masking.
89479813|NCT05386706|Active Comparator|Metformin|Traditional metformin monotherapy.
89479814|NCT05383469|Active Comparator|Compression Group|Routine compression therapy will be administered.
89479815|NCT05383469|Experimental|Active Group|Exercise training will be administered.
89479816|NCT05383469|Experimental|Passive Group|Massageand neuromuscular electrical stimulation will be administered.
89479817|NCT05380531|Experimental|Mother undergoing planned Cesarean section|Mother subject will have genotyping blood draw performed at the time of controlled delivery (CD). Blood samples and breast milk samples will also be taken during the oxycodone dosing schedule.
89479818|NCT05380531|Experimental|Infant|Infant subject will have genotyping blood draw performed only at the time of controlled delivery (CD)
89479819|NCT05377554|Experimental|ALM-488-002a WLR only|Patients with a preoperative diagnosis of malignancy will be assigned to study ALM-488-002a. All patients will receive ALM-488 infusion. Intraoperative nerve visualization will be performed using WLR only.
89479820|NCT05377554|Experimental|ALM-488-002a WLR with FL Overlay|Patients with a preoperative diagnosis of malignancy will be assigned to study ALM-488-002a. All patients will receive ALM-488 infusion. Intraoperative nerve visualization will be performed using WLR with FL Overlay.
89479821|NCT05377554|Experimental|ALM-488-002b WLR only|Patients without a preoperative diagnosis of malignancy will be assigned to study ALM-488-002b. All patients will receive ALM-488 infusion. Intraoperative nerve visualization will be performed using WLR only.
89479822|NCT05377554|Experimental|ALM-488-002b WLR with FL Overlay|Patients without a preoperative diagnosis of malignancy will be assigned to study ALM-488-002b. All patients will receive ALM-488 infusion. Intraoperative nerve visualization will be performed using WLR with FL Overlay.
89479823|NCT05377281|Experimental|Implantation of peripheral nerve tissue|Bilateral deployment of peripheral nerve tissue to the substantia nigra.
89479824|NCT05376319|Experimental|Intravenous dose of obinutuzumab|Subjects who have clinical diagnoses of either granulomatosis with polyangiitis or microscopic polyangiitis will receive two intravenous doses of obinutuzumab
89479825|NCT05376319|Active Comparator|Intravenous dose of rituximab|Subjects who have clinical diagnoses of either granulomatosis with polyangiitis or microscopic polyangiitis will receive two intravenous doses of rituximab
89479826|NCT05371834|Experimental|Microwave Treatment (Swift System)|5-10 Watts of microwave energy applied locally on each wart for a 2-3 second burst with 3-5 repetitions per lesion.
89479827|NCT05371834|Active Comparator|Cryotherapy Treatment|For each wart, two cycles of cryotherapy treatment is administered.
89479828|NCT05369585|Experimental|TOTUM-63|Experimental active are supplemented with TOTUM-63, taken 3 times per day.
89479829|NCT05367609|Other|Children undergoing Spine Fusion Surgery|"This arm will include approximately 300 children undergoing spine fusion surgery~Pharmacokinetic (PK): collection of 10-13 serial blood samples to determine serum levels of methadone/oxycodone and its metabolites~Pharmacogenetic (PG): Preoperative CYP2D6 genotyping (for preferential recruitment of CYP2D6 PMs and UMs). This will be collected in the pre-operative clinic via blood if there are clinical labs needed for standard of care. If no blood is needed in the pre-op clinic, the investigators will collect this via saliva.~Postoperative Analgesia Dose and PK Sampling Schedule:~Clinical care providers are blinded to CYP2D6/CYP2B6 when prescribing oxycodone/methadone; and genetic analysis of proposed targeted genes. Results of these samples will be used to determine personalized analgesia plan."
89479830|NCT05367271|Experimental|Botulinum Toxin A (BTX-A)|20 units of Onabotulinum A in 200 µL of saline
89479831|NCT05367271|Active Comparator|Corticosteroid|1 mL of 4 mg/mL dexamethasone with 2 mL of 1% lidocaine OR 1 mL of 4 mg/mL dexamethasone, 1 mL of 2% lidocaine and 1 mL saline
89479832|NCT05365594|Active Comparator|Self Selected Pace|Tennis shoes, CAM Boot, CAM Boot plus EvenUp Lift
89479833|NCT05365594|Active Comparator|Speed Walking Pace|Tennis shoes, CAM Boot, CAM Boot plus EvenUp Lift
88951222|NCT04233645|Experimental|Study Group|The group will be given a standard scripted verbal and identical written instructions plus the study group will be shown a 5-minute educational video (available at https://youtu.be/rvYfDc-Yfus ) which depicts key components of entering data on the diary. Patients in this group will also have online access to the video when they are filling out their diaries.
88951223|NCT04233645|Active Comparator|Usual Care Group|The group will be given a standard scripted verbal and identical written instructions as per usual care.
88951224|NCT04222283|Experimental|open label, multicentric, non randomized|one arm study to evaluate the safety and efficacy of switching from ritonavir- or cobicistat- booster containing regimens to a fixed-dose combination (FDC) of tenofovir alafenamide (TAF), emtricitabine (FTC) and bictegravir (BIC) in over 65 years old HIV-1-infected patients with virological suppression. Polymedications and drug-drug interactions will be analysed.
88951225|NCT04153006||Chest pain patients|"Patients who are admitted to the cardiac ED because of chest pain for ruling out acute coronary syndrome by troponin analysis are eligible for participation.~Troponin analysis will be performed according to standard protocol (0-1h protocol). From every included patient capillary blood samples and an extra venous blood sample will be drawn to evaluate HS cTnI levels obtained with the POC instrument and central laboratory (CL)."
88951226|NCT04137367|Experimental|Active Affective Bias Modification|Computer based Affective Bias Modification
88951227|NCT04137367|Sham Comparator|Sham Affective Bias Modification|Computer based sham Affective Bias Modification
88951228|NCT04074486||Injured and Matched Control Subjects|Head Injured subjects are defined as those who sustained a closed head injury and meet specified protocol inclusion/exclusion criteria. Matched Control subjects are enrolled based on matching criteria (for e.g. age, gender, and same population i.e. sports vs non-sports) to the head injured subjects. For all head injured and matched control group subjects, the full battery of tests will be performed. The injured pool will begin test procedures when a subject sustains a concussion injury. The matched control pool will follow the same time point/date interval as their matched injured subject. The matched control will be assigned by site to an injured subject and matched by age, gender, and sport (if applicable) or from the same population (if non-sport).
88951229|NCT04074486||Healthy Volunteer Subjects|Healthy Volunteer subjects are defined as those who are normal subjects i.e. not head-injured meeting specified protocol inclusion/exclusion criteria.This group of subjects are recruited only for the purpose of collecting data for norming the electronic near point convergence measurement (eNPC). These subjects will only perform a limited battery of BrainScope tests at a single visit and will include data collection regarding their demographics, concussion history, signs and symptoms, sports information, etc. These subjects will not undergo EEG or neurocognitive assessment.
89479834|NCT05364606||50 Subjects|50 Subjects Receiving the Patient Specific Talus Spacer.
89479835|NCT05364554|Experimental|Group 1: JNJ-77242113 Dose 1 Once Daily (QD)|Participants originally randomized to JNJ-77242113 Dose 1 QD in originating study 77242113PSO2001 will continue to receive JNJ-77242113 Dose 1 QD from Week 0 through Week 36 in this study.
89479836|NCT05364554|Experimental|Group 2: JNJ-77242113 Dose 2 QD|Participants originally randomized to JNJ-77242113 Dose 2 QD in originating study 77242113PSO2001 will continue to receive JNJ-77242113 Dose 2 QD from Week 0 through Week 36 in this study.
89479837|NCT05364554|Experimental|Group 3: JNJ-77242113 Dose 3 QD|Participants originally randomized to JNJ-77242113 Dose 3 QD in originating study 77242113PSO2001 will continue to receive JNJ-77242113 Dose 3 QD from Week 0 through Week 36 in this study.
89479838|NCT05364554|Experimental|Group 4: JNJ-77242113 Dose 1 Twice Daily (BID)|Participants originally randomized to JNJ-77242113 Dose 1 BID in originating study 77242113PSO2001 will continue to receive JNJ-77242113 Dose 1 BID from Week 0 through Week 36 in this study.
89479839|NCT05364554|Experimental|Group 5: JNJ-77242113 Dose 3 BID|Participants originally randomized to JNJ-77242113 Dose 3 BID in originating study 77242113PSO2001 will continue to receive JNJ-77242113 Dose 3 BID from Week 0 through Week 36 in this study.
89479840|NCT05364554|Experimental|Group 6: JNJ-77242113 Dose 3 QD|Participants originally randomized to placebo in originating Study 77242113PSO2001 will receive JNJ-77242113 Dose 3 QD from Week 0 through Week 36 in this study.
89479841|NCT05357222|Experimental|Straw Phonation|Participants will undergo one session of voice habilitation via a straw phonation exercise protocol. This protocol has been extensively studied and validated in the largest randomized clinical trial in voice therapy by our team.
89479842|NCT05354830|Experimental|Foot Massage|Patients undergoing TPF surgery and foot massage
89479843|NCT05354830|No Intervention|Control|Those who underwent TPF surgery and did not receive foot massage
89479844|NCT05345587|Experimental|Prolife group|scheduled consultation with the hospital clinical pharmacist, therapeutic follow-up and collection of clinical information by the patient via the THESS monitoring system
89479845|NCT05345587|No Intervention|Standard care|
89479846|NCT05322473|Experimental|sonelokimab dose 1|Subjects randomized to this arm will receive assigned sonelokimab dosage regimen and placebo to maintain the blinding with adalimumab and placebo arms during the Treatment Period.
89479847|NCT05322473|Experimental|sonelokimab dose 2|Subjects randomized to this arm will receive assigned sonelokimab dosage regimen and placebo to maintain the blinding with adalimumab and placebo arms during the Treatment Period.
89479848|NCT05322473|Placebo Comparator|Placebo|Subjects randomized to this arm will receive placebo during the Double-Blind Treatment Period and will be re-randomized to receive a sonelokimab dosage regimen during Part B.
89479849|NCT05322473|Active Comparator|adalimumab|Subjects randomized to this arm will receive adalimumab during the Double-Blind Treatment Period and will be reallocated to receive sonelokimab dosage regimen during Part B.
89479850|NCT05317637||Adults with OI|"18 participants will be enrolled through in this pilot study. Interested males with OI will be preferred over females to compensate for our highly female original cohort and determine if sexual dimorphism exists for cardiopulmonary outcomes in people with OI.~This study is cross-sectional. At the participant's one study visit, data will be obtained at a single point in time and reflect the patients' current condition. All efforts will be made to complete all data collection and testing on the same day. However, procedures completed within ±12 months will be accepted. Evaluations will include family and medical history, self-report questionnaires, physical evaluation, diagnostic studies, and radiographic studies. Participants will be enrolled regardless of OI type since BWT, a finding we are attempting to validate, was observed in all types of OI. Smokers will not be excluded."
89479851|NCT05316220|Experimental|Mesalamine Dose A|Participants will receive mesalamine Dose A twice daily for 26 weeks.
89479852|NCT05316220|Experimental|Mesalamine Dose B|Participants will receive mesalamine Dose B twice daily for 26 weeks.
89479853|NCT05312814||Twin pregnancies undergoing non-invasive prenatal screening|"Women carrying a twin pregnancy undergoing non-invasive prenatal screening for zygosity and aneuploidy syndromes.~No drug/device will be administered; clinical data will be collected for research analysis."
89479854|NCT05311878|Experimental|EEG based perceptual training|Subjects complete a perceptual learning task in which EEG-based visual feedback is provided
89479855|NCT05311878|Active Comparator|Behavior based perceptual training|Subjects complete a perceptual learning task in which ground truth visual feedback is provided
89479856|NCT05311085|Active Comparator|Monotherapy (Cytisine only)|12 weeks of cytisine: Participants allocated cytisine will be instructed to follow the manufacturer's 25-day dosing regimen, then follow a maintenance dose of cytisine from day 26 to week 12. Participants will also receive six months of text-based smoking cessation support.
89479857|NCT05311085|Active Comparator|Monotherapy (Nicotine e-cigarette only)|12 weeks of a nicotine e-cigarette. Participants will also receive six months of text-based smoking cessation support.
89479858|NCT05311085|Active Comparator|Combination therapy (Cytisine plus a nicotine e-cigarette)|12 weeks of cytisine (as above) and 12 weeks of a nicotine e-cigarette. Participants will also receive six months of text-based smoking cessation support.
89479859|NCT05310435||Pregnant women with lower leg edema|Pregnant women with clinical lower leg edema measured two times with Edema Stocking device, two times with water displacement volumetry and two with tape measure each day for three days.
89479860|NCT05304390|Experimental|Health services research (patient navigation intervention)|Participants receive a patient navigation intervention consisting of a series of points of contact (mostly via telephone) between the PN/TTS and includes: 1) An introduction and enrollment in LCS, 2) facilitation of a SDM visit with the LCS-dedicated nurse practitioner, 3) individual assessment of barriers and facilitators to in-person low-dose CT screening, 4) explanation of results and needed follow-up, and 5) follow-up reminders. Participants also undergo carbon monoxide measurement by exhaling into a disposable monitor for 10 seconds at the initial visit and the post-intervention visit. The PN may also provide an intervention for smoking cessation.
89479861|NCT05303519|Experimental|safusidenib 125mg bid|safusidenib 125mg bid administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment with safusidenib until disease progression or development of other unacceptable toxicity.
89479862|NCT05303519|Experimental|safusidenib 250mg bid|safusidenib 250mg bid administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment with safusidenib until disease progression or development of other unacceptable toxicity.
89479863|NCT05303519|Experimental|safusidenib 500mg qd|safusidenib 500mg qd administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment with safusidenib until disease progression or development of other unacceptable toxicity.
89479864|NCT05303519|Experimental|safusidenib 375mg bid|safusidenib 375mg bid administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment with safusidenib until disease progression or development of other unacceptable toxicity.
89479865|NCT05303519|Experimental|safusidenib 500mg bid|safusidenib 500mg bid administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment with safusidenib until disease progression or development of other unacceptable toxicity.
89479866|NCT05300737||Symptomatic carotid stenosis with low risk features|50-99% symptomatic carotid stenosis with low clinical or radiologic risk features (see inclusion criteria) Patients will receive intensive medical therapy, including dual antiplatelet therapy, high potency statins, BP control, and lifestyle modification
89479867|NCT05298384|Experimental|Study Group|Individuals with nocturia as a result of idiopathic edema and autonomic failure will be assigned to wearing knee high then thigh high compression stockings to assess the effect on weight gain during the day and the number of nocturia events.
89479868|NCT05296421|Experimental|Basic science (uniformly-labeled [13C]glucose)|Patients receive uniformly-labeled [13C]glucose IV over 10 minutes and then over up to 120 minutes until time of biopsy. Patients then undergo surgery and biopsy per standard of care.
89479869|NCT05294731|Experimental|Part 1a Monotherapy Dose Escalation|BGB-16673 will be orally administered
89479870|NCT05294731|Experimental|Part 1b Monotherapy Safety Expansion|BGB-16673 will be orally administered
89479871|NCT05294731|Experimental|Part 2 Monotherapy Dose Expansion|BGB-16673 will be administered at the recommended Phase 2 dose (RP2D) that was identified in Part 1
89479872|NCT05291676|Active Comparator|21-30 standard dose Fluad|Participants age 21-30 years will receive the standard dose Fluad
89479873|NCT05291676|Active Comparator|21-30 high dose Fluzone|Participants age 21-30 years will receive the high dose Fluzone
89479874|NCT05291676|Experimental|≥65 years standard dose Fluad|Participants age ≥65 years will receive standard dose Fluad
89479875|NCT05291676|Experimental|≥65 years high dose Fluzone|Participants age ≥65 years will receive high dose Fluzone
89479876|NCT05289908|Experimental|Phase I study|Pemetrexed (Alimta, Eli Lilly and Company) is administrated by intrathecal injection, plus dexamethasone 5 mg, twice per week for 2 weeks, followed by once per week for 4 weeks. The initial dose of intrathecal pemetrexed is 15 mg, escalated to 20 mg, and then 25 mg.... A minimum of three patients and a maximum of six are enrolled in each cohort. Folic acid 200-400 μg is administered orally once daily, prior to the first intrathecal pemetrexed, until 21 days after the last intrathecal pemetrexed. A single dose of vitamin B12 1000 μg is administered by intramuscular injection before the first intrathecal pemetrexed, once per 3 weeks.
89479877|NCT05289908|Experimental|Phase II study|Pemetrexed (Alimta, Eli Lilly and Company) is administrated by intrathecal injection, plus dexamethasone 5 mg, twice per week for 2 weeks, followed by once per week for 4 weeks. The maximum-tolerated dose determined in phase I study is chosen as the treatment dose in phase II study.
89479878|NCT05285345||Pre-Guideline Implementation|Participants in this group will be recruited during the first 3 months of the study and the time will be used for baseline data collection with existing standards of care around discharge practices of infants with BPD
89479879|NCT05285345||Post-Guideline Implementation|After 3 months, the discharge bundle developed from consensus from the Delphi process will be introduced to both NICUs using Quality Improvement principles. Participants will be recruited after the introduction of the discharge bundle.
89479880|NCT05285137|Experimental|Cohort 1A (sentinel)|Low dose level: 2 subjects randomized at a ratio of 1:1 to receive a single dose of 50 mg CD388 or placebo, administered by IM injection
89479881|NCT05285137|Experimental|Cohort 1A (main)|Low dose level: 9 subjects randomized at a ratio of 7:2 to receive a single dose of 50 mg CD388 or placebo, administered by IM injection
89479882|NCT05285137|Experimental|Cohort 1B (sentinel)|Low dose level: 2 subjects randomized at a ratio of 1:1 to receive a single dose of 50 mg CD388 or placebo, administered by SQ injection
89479883|NCT05285137|Experimental|Cohort 1B (main)|Low dose level: 9 subjects randomized at a ratio of 7:2 to receive a single dose of 50 mg CD388 or placebo, administered by SQ injection
89479884|NCT05285137|Experimental|Cohort 2A (sentinel)|Mid dose level: 2 subjects randomized at a ratio of 1:1 to receive a single dose of 150 mg CD388 or placebo, administered by IM injection, followed by another single dose of the same treatment (CD388 or placebo) administered by the same route after washout of 5 effective half-lives after the first dose
89479885|NCT05285137|Experimental|Cohort 2A (main)|Mid dose level: 9 subjects randomized at a ratio of 7:2 to receive a single dose of 150 mg CD388 or placebo, administered by IM injection, followed by another single dose of the same treatment (CD388 or placebo) administered by the same route after washout of 5 effective half-lives after the first dose
89479886|NCT05285137|Experimental|Cohort 2B (sentinel)|Mid dose level: 2 subjects randomized at a ratio of 1:1 to receive a single dose of 150 mg CD388 or placebo, administered by SQ injection, followed by another single dose of the same treatment (CD388 or placebo) administered by the same route after washout of 5 effective half-lives after the first dose
89479887|NCT05285137|Experimental|Cohort 2B (main)|Mid dose level: 9 subjects randomized at a ratio of 7:2 to receive a single dose of 150 mg CD388 or placebo, administered by SQ injection, followed by another single dose of the same treatment (CD388 or placebo) administered by the same route after washout of 5 effective half-lives after the first dose
89479888|NCT05285137|Experimental|Cohort 3A (sentinel)|High dose level: 2 subjects randomized at a ratio of 1:1 to receive a single dose of 450 mg CD388 or placebo, administered by IM injection, followed by another single dose of the same treatment (CD388 or placebo) administered by the same route after washout of 5 effective half-lives after the first dose
89537566|NCT03065127|Experimental|Cognitive Behavioural Therapy|Participants will undergo one-on-one sessions of cognitive-behavioural therapy (CBT) working with a therapist to establish an individualized CBT plan which will focus on symptoms of anxiety. Participants will complete a total of eight one-hour sessions over 4 weeks.
88951230|NCT04074486||Non-Concussed Head Injured Subjects|A secondary group of non-concussed head-injured controls shall be also recruited who were observed to have a head impact/injury but were not restricted from play within the same game or deemed non-concussed following on-field/sideline evaluation by the standard of care at each site. They will perform the entire BrainScope battery of tests within 5 days after the incident and defined as Day 0 and a follow-up assessment at 15 Days following Day0
88951231|NCT04070352||clostridium difficile infection (CDI)|This is a pilot project. Data from electronic medical records will be collected on all patients diagnosed with clostridium difficile infection and who are receiving fidaxomicin as part of their treatment. A total of 50 patients will be enrolled
89537567|NCT03065127|Experimental|Proprioceptive Training|Participants will complete one-on-one sessions a target matching proprioceptive training protocol using their upper and lower limbs. For the upper limb target-reaching task, participants will be seated in front of a surface marked with ten targets. They will first visualize a specified target, then blindfolded and asked to reach towards that target with the blindfold on. The blindfold will then be removed allowing participants to view their performance relative to the target. This task will be repeated for the remaining targets on both sides and for both upper and lower limbs. Participants will complete a total of eight one-hour sessions over 4 weeks.
89537568|NCT03719313|Experimental|Group 1|Lonafarnib 50 mg BID + Ritonavir 100 mg BID
89537569|NCT03719313|Experimental|Group 2|Lonafarnib 50 mg BID + Ritonavir 100 mg BID + PEG IFN alfa-2a 180 mcg QW
88951232|NCT04065152|Experimental|oncolytic immunotherapy|Talimogene laherparepvec Dose: 10^6 pfu/ml at week 1 then 10^8/ml at week 4 and every 2 weeks (up to 4ml for each injection) Route: intralesional injection Duration of treatment: 6 months (12 cycles)
88951233|NCT03962998|Active Comparator|Lactulose/Rhamnose|1000 mg of lactulose and 200 mg of rhamnose administered orally as a 10 mL solution
88951234|NCT03962998|Experimental|MB-102|4 μmol of MB-102/kg body weight administered orally as a solution
88951235|NCT03947450|Experimental|Autologous skin fibroblasts|"For whole stump participants: The investigators will be comparing whole stump injection sites that receive autologous skin fibroblasts to vehicle (placebo) injections. This subject receives autologous skin fibroblast whole stump injections.~For localized injection participants: The investigators are comparing two injection sites in the same individual. This site receives autologous skin fibroblasts."
88951236|NCT03947450|Placebo Comparator|Control|"For whole stump participants: The investigators will be comparing whole stump injection sites that receive autologous skin fibroblasts to vehicle (placebo) injections. This subject receives vehicle (placebo) whole stump injections.~For localized injection participants: The investigators are comparing two injection sites in the same individual. This site receives a placebo."
88951237|NCT03917667||Geriatric patients|Patients aged 70 years and older who are admitted to the acute care geriatric units.
88951238|NCT03859635|Active Comparator|Ultrasound guided Liposomal Bupivacaine Erector Spinae Block|All the erector spinae plane blocks will be placed preoperatively using Liposomal Buvicaine. All procedures will be placed under the supervision of the attending anesthesiologist on the acute pain service or the attending anesthesiologist in the operating room.
88951239|NCT03859635|Active Comparator|Ultrasound guided Standard Bupivacaine Erector Spinae Block|All the erector spinae plane blocks will be placed preoperatively using Liposomal Buvicaine. All procedures will be placed under the supervision of the attending anesthesiologist on the acute pain service or the attending anesthesiologist in the operating room.
88951240|NCT03859635|Active Comparator|Surgeon Infiltration|At the end of the surgery, the surgeon will infiltrate liposomal bupivacaine under thoracoscopic guidance along the intercostal nerves from T4-T8.
88951241|NCT03847090|Experimental|Reloxaliase|Reloxaliase (ALLN-177) 142 mg of oxalate decarboxylase (equivalent to 3,750 units of enzyme activity) per capsule
88951242|NCT03847090|Placebo Comparator|placebo|placebo capsule
88951243|NCT03796026|Experimental|Seltorexant Followed by Placebo|Participants will receive seltorexant (40 milligram [mg] capsules) once daily for 4 consecutive days, and after a washout period of 7 to 10 days, participants will receive matching placebo orally once daily for 4 consecutive days.
88951244|NCT03796026|Experimental|Placebo Followed by Seltorexant|Participants will receive placebo once daily for 4 consecutive days, and after a washout period of 7 to 10 days, participants will receive seltorexant (40 mg capsules) orally once daily for 4 consecutive days.
88951245|NCT03783013|Other|No Soy and Low Lycopene Juice|Participants will consume two cans daily of a low lycopene tomato juice in addition to a diet low in lycopene and isoflavones.
88951246|NCT03783013|Other|Soy and Lycopene Juice|Participants will consume two cans daily of a high lycopene tomato juice with added soy germ extract in addition to a diet low in lycopene and isoflavones.
88951247|NCT03738423|Experimental|Treatment 1|
88951248|NCT03738423|Experimental|Treatment 2|
88951249|NCT03738423|Experimental|Treatment 3|
88951250|NCT03738423|Experimental|Treatment 4|
88951251|NCT03738423|Experimental|Treatment 5|Matching placebo
88951252|NCT03726229||Fontan patient|Cholate assay will be administered once to Fontan patients and blood specimens will be collected to analyze cholate clearance.
89537570|NCT03719313|Active Comparator|Group 3|placebo Lonafarnib + placebo Ritonavir + PEG IFN-alfa-2a 180 mcg QW
88951253|NCT03712228|Placebo Comparator|Placebo|Subjects with C1-INH HAE receiving buffer only
88951254|NCT03712228|Active Comparator|CSL312 (low)|Subjects with C1-INH HAE receiving low dose CSL312
89537571|NCT03719313|Placebo Comparator|Group 4|placebo Lonafarnib + placebo Ritonavir
88951255|NCT03712228|Active Comparator|CSL312 (med)|Subjects with C1-INH HAE receiving medium dose CSL312
88951256|NCT03712228|Active Comparator|CSL312 (high)|Subjects with C1-INH HAE receiving high dose CSL312
88951257|NCT03712228|Active Comparator|CSL312 (med/high)|Subjects with C1-INH HAE receiving medium/high dose CSL312
88951258|NCT03626922|Experimental|Cohort 1|"Pembrolizumab + Pemetrexed every 21 days. Folic Acid 5 days prior to first dose of pemetrexed and daily including 21 days after last dose of pemetrexed.~Dexamethasone twice daily on the day before, the day of, and the day after each dose of pemetrexed.~Vitamin B-12 7 days prior to first dose of pemetrexed, every 9 weeks, continue until 3 weeks after last dose of pemetrexed."
89537572|NCT03063801||Cardiac surgery|All adult patients having undergone surgery between January 2006 and December 2016 within the CHU Brugmann hospital.
89537573|NCT03063645|Experimental|Group ABC|AC-1202, AC-SD-01 (50g), AC-SD-01 (75g)
89537574|NCT03063645|Experimental|Group BCA|AC-SD-01 (50g), AC-SD-01 (75g), AC-1202
89020636|NCT03006705|Experimental|Nivolumab group|"Nivolumab: 360 mg solution intravenously for 30 min in every 3 weeks (maximum 1 year).~Chemotherapy: S-1 Therapy or CapeOX Therapy is determined by the investigator.~S-1 therapy(maximum 1 year):~Tegafur-gimeracil-oteracil potassium combination drug 40 - 60 mg bid orally in 28 days, followed by 14 days off~CapeOX Therapy(maximum 6 months):~Oxaliplatin 130 mg/m2 (body surface area) solution intravenously for 2 hours once-daily, followed by 20 days off.~Capecitabine 1000 mg2 (body surface area) bid orally in 14 days, followed by 7 days off."
89203025|NCT00793962|Active Comparator|conventional fractionation radiotherapy|breast cancer women with mastectomy high-risk with T3-4 and/or 4 or more axillary nodes postmastectomy conventional fractionation radiotherapy of 50Gy/25f/5w to the chest wall and supraclavicular nodal region
89203026|NCT00575666|Experimental|A|Intranasal Insulin Treatment
89479889|NCT05285137|Experimental|Cohort 3A (main)|High dose level: 9 subjects randomized at a ratio of 7:2 to receive a single dose of 450 mg CD388 or placebo, administered by IM injection, followed by another single dose of the same treatment (CD388 or placebo) administered by the same route after washout of 5 effective half-lives after the first dose
89479890|NCT05285137|Experimental|Cohort 3B (sentinel)|High dose level: 2 subjects randomized at a ratio of 1:1 to receive a single dose of 450 mg CD388 or placebo, administered by SQ injection, followed by another single dose of the same treatment (CD388 or placebo) administered by the same route after washout of 5 effective half-lives after the first dose
89479891|NCT05285137|Experimental|Cohort 3B (main)|High dose level: 9 subjects randomized at a ratio of 7:2 to receive a single dose of 450 mg CD388 or placebo, administered by SQ injection, followed by another single dose of the same treatment (CD388 or placebo) administered by the same route after washout of 5 effective half-lives after the first dose
89479892|NCT05285137|Experimental|Cohort 4B (sentinel)|Highest dose level: 2 subjects randomized at a ratio of 1:1 to receive a single dose of 900 mg CD388 or placebo, administered by SQ injection
89479893|NCT05285137|Experimental|Cohort 4B (main)|Highest dose level: 9 subjects randomized at a ratio of 7:2 to receive a single dose of 900 mg CD388 or placebo, administered by SQ injection
89479894|NCT05277207|Experimental|MESH|Participants assigned to this group will receive a treatment that includes personalized smoking cessation facilitation meetings with cognitive-behavioral therapy, personalized smoking cessation pharmacotherapy, and personalized text messaging.
89479895|NCT05277207|Active Comparator|Best Practice Telehealth Group|Participants assigned to this group will be referred to Quit Vet (VA's quitline for stopping tobacco) and SmokefreeVET (a free text messaging program to help you quit), and will receive information about getting quit medications.
89479896|NCT05274074|No Intervention|Aim 1|
89479897|NCT05274074|Experimental|Aim 2|We will be utilizing the Life Enhancing Activities or Caregivers (LEAF) intervention to display that social networks' can be used as a means of reinforcing the positive life skills of the intervention; and that these same skills will enhance social networks, increase mutual satisfaction in social interactions, and boost motivation to reach out to others, thus combatting social isolation.
89479898|NCT05269160|Experimental|Dermaprazole 1% (Arm A:Head and neck)|Dermaprazole cream at a concentration of 1% will be applied to the skin twice daily starting from CT simulation throughout the radiation treatment period.
89479899|NCT05269160|Experimental|Dermaprazole 1% (ArmB: Breast)|Dermaprazole cream at a concentration of 1% will be applied to the skin twice daily starting from CT simulation throughout the radiation treatment period.
89479900|NCT05269160|Experimental|Dermaprazole 2% (Arm A: Head and neck)|Dermaprazole cream at a concentration of 2% will be applied to the skin twice daily starting from CT simulation throughout the radiation treatment period.
89479901|NCT05269160|Experimental|Dermaprazole 2% (Arm B: Breast)|Dermaprazole cream at a concentration of 2% will be applied to the skin twice daily starting from CT simulation throughout the radiation treatment period.
89479902|NCT05267054|Experimental|Cohort 1 (participants with PD-L1 positive on the surface of tumor cells)|participants will receive ociperlimab in combination with tislelizumab
89479903|NCT05267054|Experimental|Cohort 2 (participants with PD-L1 negative on the surface of tumor cells|participants will receive ociperlimab in combination with rituximab
89479904|NCT05265208|Experimental|Capecitabine combined with SIRT|Patients in the experimental arm will be treated with capecitabine combined with Selective Internal Radiotherapy (SIRT) before surgery.
89479905|NCT05265208|Other|Surgery only|Patients in the control group will receive surgery only.
89479906|NCT05264025|Active Comparator|Fexo group|
89479907|NCT05264025|Placebo Comparator|Placepo|
89479908|NCT05260567|Experimental|Exercise and Lifestyle Change|Exercise training and lifestyle change
89479909|NCT05260567|Other|Standard Care|Patients will also receive specific advice to perform an unsupervised walking exercise according to NICE guideline.
89479910|NCT05258058|Experimental|MAAT-G Intervention|MAAT-G Workshops & participant workbook use (8 workshops)
89479911|NCT05241444|Experimental|Cohort A (≥12 years)|"The first participant in Dose Level 1 will be administered 1.0 x 10^6 CD4^LVFOXP3 /kg (± 20%).~If there is no toxicity observed in the first participant, the following participants in Dose Level 1 will be administered the same dose of 1.0 x 10^6 CD4^LVFOXP3 /kg (± 20%).~If there is no toxicity observed in any participants in Dose Level 1, participants will be enrolled into Dose Level 2 and administered 3 x 10^6 CD4^LVFOXP3 /kg (± 20%).~If there is no toxicity observed in any participants in Dose Level 2, participants will be enrolled into Dose Level 3 and administered 10 x 10^6 CD4^LVFOXP3 /kg (± 20%).~If in any dose level 1 of 2 participants show toxicity, that dose level will be expanded to 6 participants."
89479912|NCT05241444|Experimental|Cohort B (<12 years)|"Participants in Cohort B will always follow treatment of participants in Cohort A for the same dose level.~Cohort B will start at Dose Level 2 and be administered 3 x 10^6 CD4^LVFOXP3 /kg (± 20%).~If there is no toxicity observed in any participants in Dose Level 2, participants will be enrolled into Dose Level 3 and administered 10 x 10^6 CD4^LVFOXP3 /kg (± 20%).~If in any dose level 1 of 2 participants show toxicity, that dose level will be expanded to 6 participants."
89479913|NCT05234866||Phase I (Feasibility Study)|
89479914|NCT05234866||Phase II (Prospective Study)|
89479915|NCT05223127|Experimental|Experimental group|Aloe vera
89479916|NCT05223127|No Intervention|Control group|routine care (dressing with dry gauze)
89479917|NCT05219877|Experimental|Pre-urodynamic Levofloxacin|Levofloxacin 500 mg single dosage 1 hour before the urodynamic examination
89479918|NCT05219877|Active Comparator|Post-urodynamic Levofloxacin|Levofloxacin 500 mg will be given for 3 days, once daily, post-urodynamic examination
89479919|NCT05217979|Active Comparator|Transcutaneous pulsed radiofrequency|After signing informed consent, patients assigned to the intervention group by randomization will receive a single treatment with transcutaneous pulsed radiofrequency.
88951259|NCT03626922|Experimental|Cohort 2|"Pembrolizumab + Pemetrexed + Oxaliplatin every 21 days. Folic Acid 5 days prior to first dose of pemetrexed and daily including 21 days after last dose of pemetrexed.~Dexamethasone twice daily on the day before, the day of, and the day after each dose of pemetrexed.~Vitamin B-12 7 days prior to first dose of pemetrexed, every 9 weeks, continue until 3 weeks after last dose of pemetrexed."
89479920|NCT05217979|Sham Comparator|Sham|After signing informed consent, patients assigned to the sham group by randomization will receive a single treatment with sham, which is indistinguishable from the active treatment. This is achieved by putting the device in demo mode, which gives all the same audiovisual signals as the active mode, but no treatment. Given that the treatment is not felt by patients, this ensures blinding.
89479921|NCT05217797|Experimental|Glasses|Participants in the experimental arm are asked to wear glasses (sunglasses or other glasses) when outside their home and close to others (e.g. on public transport, in shopping centres etc.).
89479922|NCT05217797|No Intervention|Not glasses|Participants in no interventions arm are asked to not wear glasses (sunglasses or other glasses) when outside their home and close to others (e.g. on public transport, in shopping centres etc.).
89479923|NCT05216978|Experimental|PATH Intervention|"Participants in the PATH Intervention arm will receive psychosocial support phone calls during week 1 through 9 following enrollment.~After consent procedures, participants will begin an 9-week positive-psychology program involving weekly calls with an interventionist and exercises (i.e. writing a letter of gratitude, identifying personal strengths, planning meaningful and enjoyable activities).~Self-assessment questionnaires to measure positive affect, health behaviors, and overall function before and after completing the Positive Psychology Intervention."
89479924|NCT05199051|Experimental|Gemtuzumab ozogamicine - Cytarabine - Gilteritinib|"For Gemtuzumab ozogamicine administrated during the induction phase at D1, D4 and D7, 3mg/m2/day (5mg max), IV, 2h of infusion.~For Cytarabine during induction and consolidation phase at D1 to D5, 1000 mg/m2, IV, 2h of infusion.~For Gilteritinib during induction phase from D10 for 14 consecutive days, per os, two doses level study with dose level 1 (80mg/d) in part 1 or dose level 2 (80 or 120mg/d depending of the result of part 1) in part 2.~During consolidation (2 cycles max) from D8 for 14 consecutive days, per os, 120mg/d or reduced dose of 80 mg/kg is planned to be used in patients receiving concomitantly CYP3A4 inhibitors.~During the maintenance (24 months max) dose level 2 (120mg/d), per os."
89479925|NCT05198024|Placebo Comparator|Usual care|"Where patients access to two exercise classes per week and all facilities as part of their cardiac rehabilitation. In addition to this, patients in this group took part in the 'Biggest loser' program in which the patients attended weekly sessions outside of their usual exercise class times. Each session follows a specific theme based on British Heart Foundation healthy eating guidelines.~Participants will undergo this approach for 6-weeks and then switch to usual care for 6-weeks."
89479926|NCT05198024|Experimental|Usual care plus biggest loser|"Where patients access to two exercise classes per week and all facilities as part of their cardiac rehabilitation. In addition to this, patients in this group took part in the 'Biggest loser' program in which the patients attended weekly sessions outside of their usual exercise class times. Each session follows a specific theme based on British Heart Foundation healthy eating guidelines.~Participants will undergo this approach for 6-weeks and then switch to usual care for 6-weeks."
89479927|NCT05198024|Experimental|Usual care plus new education programme|"Where patients access to two exercise classes per week and all facilities as part of their cardiac rehabilitation. In addition to this, patients in this group too part in a new education programme (anecdotally referred to as Healthy Heart Happy You) in which the same weekly topics as the biggest loser are covered yet with bespoke information regarding portion sizes and recipes provided each week and patients given a challenge each week in relation to the topic being covered e.g. include more vegetables.~Participants will undergo this approach for 6-weeks and then switch to usual care for 6-weeks."
89479928|NCT05192642||Larotrectinib clinical trial cohort|
89479929|NCT05192642||RW external comparator cohort|
89479930|NCT05192122|Other|Bone marrow MRD-negative VGPR or CR|Discontinue maintenance therapy after at least three years
89479931|NCT05192122|Other|Bone marrow MRD-positive VGPR or CR|Continue maintenance therapy as per SOC
89479932|NCT05192109|Active Comparator|Addressed|Children participate via video in an interaction with an experimenter who uses the word to be learned.
89479933|NCT05192109|Experimental|Overheard|Children watch via video while an experimenter uses the word to be learned in an interaction with another experimenter.
89479934|NCT05188053|Experimental|HTX-011 Treatment Group|Subjects undergoing a total knee arthroplasty will receive HTX-011 (Zynrelef) for perioperative analgesia
89537575|NCT03063645|Experimental|Group CAB|AC-SD-01 (75g), AC-1202, AC-SD-01 (50g)
88951260|NCT03600818|Placebo Comparator|Placebo+52 Week Taper|Participants received sarilumab-matching placebo as subcutaneous (SC) injection every 2 weeks (q2w) up to 52 weeks along with the combination of prednisone and/or prednisone-matching placebo according to the protocol-defined schedule. Participants received prednisone/prednisone-matching placebo tapering oral daily doses for 52 weeks.
88951261|NCT03600818|Experimental|Sarilumab 200mg q2w+14 Week Taper|Participants received sarilumab 200 milligrams (mg) as SC injection q2w up to 52 weeks along with the combination of prednisone and/or prednisone-matching placebo according to the protocol-defined schedule. Participants received prednisone tapering oral daily doses during the first 14 weeks and prednisone-matching placebo from Week 14 up to Week 52.
88951262|NCT03578276|Active Comparator|LessDrops|Compounded eye drop containing Gatifloxacin (antibiotic), bromfenac (non-steroidal anti-inflammatory), and prednisolone acetate 1% used three times a day (TID) starting 1 day prior to surgery and continuing after surgery for 2 weeks then twice a day for a week and once a day for another week.
88951263|NCT03578276|Active Comparator|Standard of Care|"Gatifloxacin 0.5%, 1 drop, QID for 3 days prior to surgery and will continue for 2 weeks after surgery and then discontinue.~Bromfenac 0.07%: 1 drop QD starting 3 days before surgery, continue QD for 4 weeks after surgery and then discontinue.~Prednisolone acetate 1% will be started after surgery QID for 2 weeks, tapered to BID for 2 weeks, and then discontinue."
89479935|NCT05188053|Active Comparator|Standard Block Control Group|Subjects undergoing a total knee arthroplasty will receive standard of care arthroplasty block for perioperative analgesia
89479936|NCT05177536|Experimental|Iberdomide|Iberdomide will be dosed at 1.0 mg PO daily for days 1-21 of a 28-day cycle
89479937|NCT05177302||Individuals with hip and/ or groin pain|The young to middle-aged physically active individuals with hip and/ or groin pain, which symptoms lasting for 2 to 6 month.
89479938|NCT05177042|Experimental|Oral tablet(s) in combination with abiraterone and a corticosteroid.|ARV-110 oral tablets in combination with abiraterone and a corticosteroid administered daily in 28 day cycles.
89479939|NCT05176392|Active Comparator|Active rTMS with telehealth headache management therapy|Participants receive both active rTMS treatment at the left dorsolateral prefrontal cortex and therapy for headache management
89479940|NCT05176392|Other|Active rTMS with telehealth headache education control|Participants receive active rTMS treatment at the left dorsolateral prefrontal cortex and headache education
89479941|NCT05176392|Other|Sham rTMS with telehealth headache management therapy|Participants receive sham rTMS treatment at the left dorsolateral prefrontal cortex and therapy for headache management
89479942|NCT05176392|Sham Comparator|Sham rTMS with telehealth headache education control|Participants receive sham rTMS treatment at the left dorsolateral prefrontal cortex and headache education
89479943|NCT05173454|Experimental|Breastfeeding Education and Support|The intervention arm will receive antenatal and postnatal breastfeeding education and support intervention for six months starting in their third trimester pregnancy period. The intervention package is comprised of four components: Antenatal breastfeeding education, providing specific take-home print materials, Telephone call counseling and Individual home visit.
89479944|NCT05173454|No Intervention|Usual or routine care|The routine care will be continued in the control group.
89479945|NCT05173155|Experimental|Direct anterior approach for hemiarthroplasty|Patients in this arm will receive a hemiarthroplasty using the direct anterior approach (DAA)
89479946|NCT05173155|Experimental|Lateral approach for hemiarthroplasty|Patients in this arm will receive a hemiarthroplasty using the lateral approach
89479947|NCT05169411|Active Comparator|angiotensin converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB) categories|The first anti-hypertensive prescribed will be categorized as ACEi, ARB, thiazide diuretic, loop diuretic, beta-blocker, calcium channel blocker, other, and none.
89479948|NCT05169411|Active Comparator|Combined renin-angiotensin-aldosterone system (RAAS) blocker category|Secondary analyses will combine ACEi and ARB into a single RAAS blocker category.
89479949|NCT05169411|Active Comparator|Urine protein dichotomous indicator|We will determine whether urine protein is evaluated at each encounter and create a dichotomous indicator.
89479950|NCT05167526|Placebo Comparator|Part 1: ASP8731 Placebo|Participants receive a single dose of matching placebo under fasting conditions.
89479951|NCT05167526|Experimental|Part 1: ASP8731 3mg|Participants receive a single dose of ASP8731 3mg under fasting conditions.
89479952|NCT05167526|Experimental|Part 1: ASP8731 12mg|Participants receive a single dose of ASP8731 12 mg under fasting conditions.
89479953|NCT05167526|Placebo Comparator|Part 2: Placebo|Participants receive a multiple matching dose of placebo twice daily for 14 days under fasting conditions.
89479954|NCT05167526|Experimental|Part 2: ASP8731 6mg|Participants receive ASP8731 6mg twice daily for 14 days under fasting conditions.
89479955|NCT05167526|Experimental|Part 1: ASP8731 6mg|Participants receive a single dose of ASP8731 6 mg of under fasting conditions.
89479956|NCT05160766|Active Comparator|Comirnaty-Comirnaty-Comirnaty|Participants are already fully vaccinated with 3x Comirnaty (BNT162b2) when entering the trial, only the 4th dose will be administered in the study. Treatment will be given as a single shot of either Comirnaty (BTN162b2) or Spikevax (mRNA-1273) using the approved dose and mode of administration of each vaccine included in this trial.
89479957|NCT05160766|Active Comparator|Spikevax-Spikevax-Spikevax|Participants are already fully vaccinated with 3x Spikevax (mRNA-1273) when entering the trial, only the 4th dose will be administered in the study. Treatment will be given as a single shot of either Comirnaty (BTN162b2) or Spikevax (mRNA-1273) using the approved dose and mode of administration of each vaccine included in this trial.
89479958|NCT05160766|Active Comparator|Vaxzevria-Vaxzevria-Spikevax|Participants are already fully vaccinated with 2x Vaxzevria (ChAdOx-1-S) and 1x Spikevax (mRNA-1273) when entering the trial, only the 4th dose will be administered in the study. Treatment will be given as a single shot of either Comirnaty (BTN162b2) or Spikevax (mRNA-1273) using the approved dose and mode of administration of each vaccine included in this trial.
89479959|NCT05160766|Active Comparator|Vaxzevria-Vaxzevria-Comirnaty|Participants are already fully vaccinated with 2x Vaxzevria (ChAdOx-1-S) and 1x Comirnaty (BNT162b2) when entering the trial, only the 4th dose will be administered in the study. Treatment will be given as a single shot of either Comirnaty (BTN162b2) or Spikevax (mRNA-1273) using the approved dose and mode of administration of each vaccine included in this trial.
89479960|NCT05160766|Active Comparator|Spikevax-Spikevax-Comirnaty|Participants are already fully vaccinated with 2x Spikevax (mRNA-1273) and 1x Comirnaty (BNT162b2) when entering the trial, only the 4th dose will be administered in the study. Treatment will be given as a single shot of either Comirnaty (BTN162b2) or Spikevax (mRNA-1273) using the approved dose and mode of administration of each vaccine included in this trial.
89537576|NCT03063879|Experimental|Sovodak|Sofosbuvir 400 mg and daclatasvir 60 mg
88951264|NCT03514784|Active Comparator|BB-12 with LGG (Lower Dose)|BB-12 with LGG (Multistrain probiotic; lower dose): 1 billion CFUs
89537577|NCT03063567|Other|one month trial of Nasal Mask|All patients in study underwent crossover prospective trial of the same 3 types of CPAP interfaces in randomized order. Trial was 1 month duration for each interface.
88951265|NCT03514784|Placebo Comparator|Placebo|Maltodextrin
88951266|NCT03514784|Active Comparator|BB-12 with LGG (Higher Dose)|BB-12 with LGG (Multistrain probiotic: higher dose): 10 billion CFUs
88951267|NCT03506893|Experimental|Alphapump|Alfapump® device implantation under general anesthesia (30-45 minutes)
88951268|NCT03506893|Active Comparator|Ascites puncture|Iterative paracentesis compensated for by albumin infusions in ambulatory care.
88951269|NCT03491267|Experimental|Subjects with alopecia-- area treated|One area will be treated
88951270|NCT03491267|Experimental|Subjects with alopecia-- area un-treated|One area will be un-treated
89479961|NCT05160766|Active Comparator|Comirnaty-Comirnaty-Spikevax|Participants are already fully vaccinated with 2x Comirnaty (BNT162b2) and 1x Spikevax (mRNA-1273) entering the trial, only the 4th dose will be administered in the study. Treatment will be given as a single shot of either Comirnaty (BTN162b2) or Spikevax (mRNA-1273) using the approved dose and mode of administration of each vaccine included in this trial.
88951271|NCT03439982|Experimental|FMT|Open label FMT administered at week 0 by colonoscopy and weeks 1-4 by enema
88951272|NCT03384602|Active Comparator|Dalcroze Eurhythmics program|music-based multi-task exercise intervention
88951273|NCT03384602|Active Comparator|home exercise strength program|simple strength training program to perform individually at home
88951274|NCT03384602|No Intervention|Control group|no change in the daily activities, no exercise intervention
89479962|NCT05157568|Active Comparator|Control (C)|Participants will receive a exercise prescription and a home exercise plan. It will specify how many days per week they should exercise and will indicate how hard they should be working using their heart rate and rating of perceived exertion (RPE) as a guide. They will attend 8 onsite rehabilitation classes at the University of Ottawa Heart Institute (1 class per week for 8 weeks). These classes will be led by a specially trained instructor who will teach and encourage self-monitoring of heart rate and RPE. The class will include a warm-up, 30 minutes of aerobic exercise and a 15 min cool-down, including strength exercises and stretches. Following each class there will be a short mini-education session highlighting a variety of topics on how to manage risk factors. Patients will have access to onsite classes for nutrition and stress management. Participants will receive access to 8 additional educational videos that highlight topics such as exercise safety, goal setting and nutrition.
89479963|NCT05157568|Active Comparator|Exercise Streaming (ES)|"Participants will complete 1 live virtual class per week for 8-weeks. Classes will be led by a specially trained instructor and will include a warm-up, 30 minutes of aerobic exercise, 10 minutes of strength exercises, and a cooldown and stretching segment. During each live class, the instructor will play the corresponding video and supervise the participants through the Zoom for Healthcare platform. Heart rates and RPE data will be collected from each participant. Participants will have access to other pre-recorded exercise videos that they can stream on demand at any time. They will be encouraged to access them on demand throughout the week. In addition participants will have access to the same 8 pre-recorded educational videos that the control group will receive. Topics include; exercise safety, goal setting, nutrition, stress management, medication information, risk factor awareness and transition planning."
89479964|NCT05157568|Active Comparator|Exercise Streaming + Equipment (ES+E)|"Participants will receive an indoor bicycle and an exercise band (delivered and set up in their home). Participants will complete 1 live class per week for 8 weeks. Their exercise prescription will be based on a stress test. Classes will be led by a specially trained instructor and will include a warm-up, 30 minutes of aerobic exercise, 10 minutes of strength exercises, and a cooldown and stretching segment. During each live class, the exercise supervisor will play the corresponding video and supervise the participants through the Zoom for Healthcare platform. Heart rate and RPE data will be collected from each participant. Participants will have access to other pre-recorded exercise videos that they can stream on demand at any time. Participants will be encouraged to access them throughout the week. Participants will have access to the same 8 pre-recorded educational videos that the control and exercise streaming groups will receive."
89479965|NCT05154591|Experimental|Bilateral Treatment|Intra-arterial injection of SVF cells into the kidneys.
89479966|NCT05154084||Audit only|This group of sites will participate in the audit. No performance feedback will be provided during the period under study. Feedback will be provided at the end of the study period.
88951275|NCT03365063|Experimental|Active Knowledge Translation Group|Primary care clinics receiving the active knowledge translation intervention.
89479967|NCT05154084||Audit with feedback|This group of sites will participate in the audit, and receive a feedback intervention about their practice based on retrospective data about surgery performed before the start of the study period.
89479968|NCT05153499|Active Comparator|CP101|
89479969|NCT05153499|Placebo Comparator|Placebo|
88951276|NCT03365063|No Intervention|Control Group|Primary care clinics receiving the current standard of care. Information on personalized risk and risk-based referral will not be provided.
88951277|NCT03338504||Suspected type 2 myocardial infarction|The investigators will identify consecutive patients with acute myocardial injury (defined as a rise and or fall in cardiac troponin concentration on serial testing, with at least one value >99th centile) where the likely mechanism of injury is thought to be myocardial oxygen supply and demand imbalance (e.g secondary to hypoxia, hypotension, tachycardia or anaemia). Patients will be identified through screening of cardiac troponin measurements. Patients who meet both the inclusion and exclusion criteria, will be approached and those who provide consent will comprise the study population. All patients will have a Cardiac MRI scan, with invasive coronary angiography or CT coronary angiography dependent on baseline fitness. The investigators will record demographic and clinical information from the electronic patient record for patients who meet inclusion criteria but have one or more exclusion criteria.
88951278|NCT03196206|Experimental|Group A|Normal Renal Function
88951279|NCT03196206|Experimental|Group B|Moderate Renal Impairment
88951280|NCT03196206|Experimental|Group C|Severe Renal Impairment
89203027|NCT00575666|Placebo Comparator|B|Drug: Placebo
89203028|NCT05378230|Experimental|Probiotic mixture|Arm that received Lactobacillus plantarum mixture (CECT 7527, CECT 7528 and CECT 7529)
89479970|NCT05152290|Experimental|Treatment Group (AlloRx)|intravenous infusion and intrathecal injection (total of 100 million cells)
89479971|NCT05147987|Experimental|Intervention Group|Will be provided a discreet, hands-free, wearable breast pump with an associated App
89479972|NCT05147987|No Intervention|Standard care group|Will be provided a standard mechanical breast pump with no associated App.
89479973|NCT05147766|Experimental|Treatment Group (AlloRx)|Single intravenous infusion of 100 million cells
89479974|NCT05147311|Experimental|PATH Intervention|"Participants in the PATH Intervention arm will receive psychosocial support phone calls during week 1 through 9 following enrollment.~At approximately 100-days post-HSCT, participants will begin an 9-week positive-psychology program involving weekly calls with an interventionist and exercises (i.e. writing a letter of gratitude, identifying personal strengths, planning meaningful and enjoyable activities).~-Self-assessment questionnaires to measure positive affect, health behaviors, and overall function before and after completing the Positive Psychology Intervention."
89479975|NCT05147311|No Intervention|Usual Care Control|Participants in the Usual Care Control arm will receive regular social work assessments as part of HSCT recovery and work does not focus on PPWB skill building or cognitive strategies.
89479976|NCT05141357|Experimental|HBI-8000 in combination with pembrolizumab|
89479977|NCT05141149|Experimental|Cohort 1M|1 mg/kg of PBP1510 as monotherapy will be administered
89479978|NCT05141149|Experimental|Cohort 1C|1 mg/kg of PBP1510 and 1000 mg/m^2 of gemcitabine as combination therapy will be administered
89479979|NCT05141149|Experimental|Cohort 2M|3 mg/kg of PBP1510 as monotherapy will be administered
89479980|NCT05141149|Experimental|Cohort 2C|3 mg/kg of PBP1510 and 1000 mg/m^2 of gemcitabine as combination therapy will be administered
89479981|NCT05141149|Experimental|Cohort 3M|6 mg/kg of PBP1510 as monotherapy will be administered
89479982|NCT05141149|Experimental|Cohort 3C|6 mg/kg of PBP1510 and 1000 mg/m^2 of gemcitabine as combination therapy will be administered
89479983|NCT05141149|Experimental|Cohort 4M|10 mg/kg of PBP1510 as monotherapy will be administered
89479984|NCT05141149|Experimental|Cohort 4C|10 mg/kg of PBP1510 and 1000 mg/m^2 of gemcitabine as combination therapy will be administered
89479985|NCT05141149|Experimental|Cohort 5M|15 mg/kg of PBP1510 as monotherapy will be administered
89479986|NCT05141149|Experimental|Cohort 5C|15 mg/kg of PBP1510 and 1000 mg/m^2 of gemcitabine as combination therapy will be administered
89479987|NCT05137184|Experimental|Methoxyflurane|3 ml inhalation Can be repeated once (3 ml) Maximum total dose of 6 ml
89479988|NCT05137184|Experimental|Fentanyl IN|100 µg IntraNasal, Patients >70 years: 50 µg IN Can be repeated Maximum total dose 500 µg IN
89479989|NCT05137184|Active Comparator|Morphine IV|0.1 mg/kg Intravenous (IV) Patients ≥ 70 years or fragile: 0.05 mg/kg IV Can be repeated Maximum total dose 0.5 mg/kg IV
89479990|NCT05136092|Experimental|Cohort 1: HFCS (fructose-fed)|"On the day of Surgery, between two and three hours before surgery.~Subjects will prepare the sugar solutions (Fructose-containing solution: 250 mL of water containing 41.25 g of D-Fructose and 33.75 g of D-Glucose) by adding 250 ml water to the sugar powder provided by the study team and drink it between two and three hours before surgery. Subjects will be reminded the day before the surgery to drink the solution."
89479991|NCT05136092|Experimental|Cohort 2: D-Xylose (xylose-fed)|"On the day of Surgery, between two and three hours before surgery.~Subjects will prepare the sugar solutions (Xylose-containing solution: 250 mL of water containing 41.25 g of D-Xylose and 33.75g of D-Glucose) by adding 250 ml water to the sugar powder provided by the study team and drink it betweentwo and three hours before surgery. Subjects will be reminded the day before the surgery to drink the solution."
89479992|NCT05129865|Experimental|LYT-300 in healthy volunteers LYT-300, Doses TBD|Subjects will crossover across 3 dosing periods in which they will receive placebo and two experimental dose levels
89479993|NCT05129865|Experimental|LYT-300 in healthy volunteers LYT-300|LYT-300, Dose TBD with and without food, separated by 7-day washout
89479994|NCT05129865|Experimental|LYT-300, Dose TBD QAM every 24 h for 7 days|
89479995|NCT05129865|Placebo Comparator|Placebo QAM every 24 h for 7 days|
89479996|NCT05129865|Placebo Comparator|Placebo QHS every 24 h for 7 days|
89479997|NCT05129865|Experimental|LYT-300 in healthy volunteers LYT-300, Dose TBD QHS every 24 h for 7 days|
89479998|NCT05129865|Experimental|LYT-300|
89479999|NCT05129865|Placebo Comparator|Placebo|
89480000|NCT05109091|Experimental|ATH434 Arm 1|
89480001|NCT05109091|Experimental|ATH434 Arm 2|
89480002|NCT05109091|Placebo Comparator|Placebo|
89480003|NCT05108181|Active Comparator|Slow muscle typology group|The participants receive the same exercise training intervention, but they are divided in two groups: a slow typology group and a fast typology group based on their inherent physiological characteristics: their muscle fiber type.
89480004|NCT05108181|Active Comparator|Fast muscle typology group|The participants receive the same exercise training intervention, but they are divided in two groups: a slow typology group and a fast typology group based on their inherent physiological characteristics: their muscle fiber type.
89480005|NCT05100043||Cases|Patients having multiple recurrent and recalcitrant cutaneous and genital warts
89480006|NCT05100043||Controls|Healthy volunteers matched for age and sex
89480007|NCT05096351||Patients with venous allograft|
89480008|NCT05092490|Experimental|Combined serratus anterior plane block and transversus thoracis plane block|The study group will receive a combined plane block by a dedicated anesthesia team prior to their procedure. 20 mL of local anesthetic (0.25% bupivacaine) will be injected for the Serratus anterior plane block and another 20 mL of local anesthetic (0.25% bupivacaine) will be injected in transversus thoracis plane block
89480009|NCT05092490|Active Comparator|Stand local anesthetic infiltration|Local anesthetic infiltration of the incision sites will be performed by the cardiologist prior to, and as, necessary during the procedure. The amount of local anesthetic used will be determined intraoperatively by the cardiologist according to the patients' requirements.
89537578|NCT03063567|Other|One month trial of Oronasal mask|All patients in study underwent crossover prospective trial of the same 3 types of CPAP interfaces in randomized order. Trial was 1 month duration for each interface.
89537579|NCT03063567|Other|One month trial of Nasal pillows|All patients in study underwent crossover prospective trial of the same 3 types of CPAP interfaces in randomized order. Trial was 1 month duration for each interface.
89480010|NCT05086419|Experimental|Exercise group|The exercise group will in addition to treatment as usual, receive sub-symptom threshold aerobic exercise for approx. 30 minutes 3-5x / week for 12 weeks. Sub-symptom threshold aerobic exercise is based on the individual patient's symptom threshold and will be between 80-90% of the maximum heart rate achieved during testing/BCTT. To ensure proper exercise dosage and progression, participants will be retested every 3 weeks. An experienced doctor and / or physiotherapist will carry out the testing and guide the participants in the content and dosage (duration, intensity, and frequency) of the sub-symptom threshold aerobic exercise/intervention.
89480011|NCT05086419|No Intervention|Treatment as usual group|"The treatment as usual group will receive assessment and treatment provided by a multidisciplinary outpatient rehabilitation team. Patients will undergo a medical examination and assessment of physical, cognitive and mental health and functioning, followed by individually adapted rehabilitation. The interdisciplinary team consists of a specialist in physical medicine and rehabilitation, neuropsychologist, occupational therapist, physiotherapist, and social worker. The main focus is on stabilizing the level of function in everyday life and gradual return to work and education.~Participants receive general advice on physical activity based on recommendations from the Norwegian Directorate of Health, but not specific guidance in sub-symptom threshold aerobic exercise and help with exercise dosage (frequency, duration and intensity)."
89480012|NCT05085288|Active Comparator|Intermittent electrical stimulation system (IES) treatment Group|Charged pulses will be administered to bilateral gluteus maximus through surface electrodes. Stimulation occurs at 30 Hz for 10 seconds every 10 minutes.
89480013|NCT05085288|Active Comparator|Standard of care Group|Standard inpatient nursing practice for wound care, wound care prevention, and any other wound care or plastic surgery treatments deemed appropriate as per usual care.
89480014|NCT05083364|Experimental|ARO-C3 (Healthy Volunteers)|1 or 2 doses of ARO-C3 by subcutaneous (sc) injection
89480015|NCT05083364|Placebo Comparator|Placebo (Healthy Volunteers)|placebo calculated volume to match active treatment by sc injection
89480016|NCT05083364|Experimental|ARO-C3 (Adult Patients with C3G or IgAN)|3 doses of ARO-C3 by sc injection
89480017|NCT05082038|Other|Group IF|Two Tapered IF implants will be installed in one side of the mandible
89480018|NCT05082038|Other|Group CF|Two Tapered IF implants will be installed in the other side of the mandible
89480019|NCT05073133|Experimental|OAV101|A single IV infusion at 1.1e14 vg/kg over approximately 60 minutes
89480020|NCT05068830|Experimental|Exercised plasma (ExPlas)|Dosage: 200 mL at every time point Dosage form: Solution for intravenous infusion Frequency of administration: 12 ExPlas transfusions during the time span of one year (weekly transfusions in 3 four-week periods)
89480021|NCT05068830|Active Comparator|Octaplasma|Dosage: 200 mL at every time point Dosage form: Solution for intravenous infusion Frequency of administration: 12 Octaplasma transfusions during the time span of one year (weekly transfusions in 3 four-week periods)
89480022|NCT05068830|Placebo Comparator|Saline|Dosage: 200 mL at every time point Dosage form: Solution for intravenous infusion Frequency of administration: 12 saline infusions during the time span of one year (weekly transfusions in 3 four-week periods)
89480023|NCT05062161|Experimental|Sleep Hygiene/Extension Intervention|Participants with short sleep duration will receive a 60-minute educational session on sleep hygiene/extension. Over an 8-week period, participants will receive weekly phone or Zoom video calls from the Educational Research Coordinator to review additional materials including handouts and/or complete questionnaires about sleep. Participants will undergo sleep tracking/monitoring during the 8-week period, and repeat BP/heart rate monitoring for 24 hours after the 8-week period.
89480024|NCT05062161|Active Comparator|Control Condition|Participants with short sleep duration will receive a 60-minute educational session on sleep physiology. Over an 8-week period, participants will receive weekly phone or Zoom video calls from the Educational Research Coordinator to review additional materials including handouts. Participants will undergo sleep tracking/monitoring during the 8-week period, and repeat BP/heart rate monitoring for 24 hours after the 8-week period.
89480025|NCT05052827|Active Comparator|Children|Participants underwent 3 metabolic trials in a randomized crossover fashion, where they were provided with an isonitrogenous quantities of either milk protein concentrate, soy protein isolate, and rice protein isolate following a standardized bout of variable intensity exercise.
89480026|NCT05052827|Active Comparator|Adolescent Females|Participants underwent 3 metabolic trials in a randomized crossover fashion, where they were provided with an isonitrogenous quantities of either milk protein concentrate, soy protein isolate, and rice protein isolate following a standardized bout of variable intensity exercise.
89480027|NCT05052827|Active Comparator|Adolescent Males|Participants underwent 3 metabolic trials in a randomized crossover fashion, where they were provided with an isonitrogenous quantities of either milk protein concentrate, soy protein isolate, and rice protein isolate following a standardized bout of variable intensity exercise.
89480028|NCT05047770|Active Comparator|HZ/suSeq Group|Participants randomized to HZ/suSeq Group received one mRNA-1273 booster dose administered at Day 1, followed by the first dose of HZ/su vaccine administered at Week 2 and the second dose of HZ/su vaccine administered at Week 10.
89480029|NCT05047770|Experimental|HZ/suCoAd Group|Participants randomized to HZ/suCoAd Group received one mRNA-1273 booster dose co-administered with the first dose of HZ/su vaccine at Day 1, followed by the second dose of HZ/su vaccine administered at Week 8.
89480030|NCT05047770|Active Comparator|FluD-QIVSeq Group|Participants randomized to FluD-QIVSeq Group received one mRNA-1273 booster dose at Day 1, followed by one dose of Flu D-QIV vaccine at Week 2.
89480031|NCT05047770|Experimental|FluD-QIVCoAd Group|Participants randomized to FluD-QIVCoAd Group received one mRNA-1273 booster dose co-administered with one dose of Flu D-QIV vaccine at Day 1.
89480032|NCT05046886|Other|Usual Care Control (UCC)|Baseline advice about the Mediterranean-style diet and attention control.
89480033|NCT05046886|Active Comparator|Standardized|One-size-fits-all dietary counseling to follow a Mediterranean-style diet
89480034|NCT05046886|Active Comparator|Personalized|Dietary counseling to follow a Mediterranean-style diet personalized to reduce postprandial glycemic response
89480035|NCT05042349||Elite athletes|Pregnant female elite athletes
89480036|NCT05042349||Controls|Moderately physical active pregnant females
89480037|NCT05042349||Sponsors|Sponsors of the athletes
89480038|NCT05042349||Coaches/tema leaders|Coaches or team leaders of the atheltes
89480039|NCT05041218||Patients undergoing coronary artery angiography and/or percutaneous coronary intervention|Consecutive patients with indication to perform coronary artery angiography and/or percutaneous coronary intervention at Ferrara University Hospital
89480040|NCT05039424|Active Comparator|Endoscopic per-oral pyloromyotomy (POP)|Participants will undergo Endoscopic per-oral pyloromyotomy (POP).
89480041|NCT05039424|Sham Comparator|Sham / Control Arm|Participants will undergo a diagnostic esophagogastroduodenoscopy (EGD) without pyloric disruption. Following the 12-week blinded trial period, these participants will be unblinded and offered Endoscopic per-oral pyloromyotomy (POP) if they remain symptomatic.
89480042|NCT05034627|Experimental|Treatment (calaspargase pegol-mknl, cobimetinib)|Patients receive calaspargase pegol-mknl IV over 1 hour on day 1 and cobimetinib PO QD on days 1-14. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
89480043|NCT05033067|No Intervention|Usual Care|
89480044|NCT05033067|Experimental|Intervention (P3-BC) Usual Care|intervention + usual care group. In addition to receiving usual care, patients will have access to the aid and related materials before consultation with the physician about cystectomy and urinary diversion.
89480045|NCT05032196|Experimental|WVE-003 (Dose A) or placebo|
89480046|NCT05032196|Experimental|WVE-003 (Dose B) or placebo|
89480047|NCT05032196|Experimental|WVE-003 (Dose C) or placebo|
89480048|NCT05029895||Participants Receiving Upadacitinib|Participants receiving upadacitinib for atopic dermatitis.
89480049|NCT05018455|Experimental|Fall prevention intervention program conducted through telehealth|The training program is based on the principles of the Otago program, designed specifically to prevent falls. It consists set of leg muscle strengthening and balance retraining exercises progressing in difficulty, and a walking plan. The training will be delivered to a group of 10 participants. Each participant will practice from home, using a zoom system. The duration of each training will be one hour, the frequency of training will be twice a week for three months.
89480050|NCT05018455|Active Comparator|Similar fall prevention intervention program conducted through face to face group training|The training program is based on the principles of the Otago program, designed specifically to prevent falls. It consists set of leg muscle strengthening and balance retraining exercises progressing in difficulty, and a walking plan. The training will be delivered to a group of 10 participants. The training sessions will be delivered at the local community center, twice a week for one hour for three months.
89480051|NCT05003960|Experimental|Treatment Group|One intravenous infusion of 100 million cells
89480052|NCT04993066|Experimental|Treatment Arm|All study subjects are to receive treatment with GentleMax Pro Plus device. Subjects will be scheduled to receive as little as one (1) and up to eight (8) treatments with the GentleMax Pro Plus™ Laser System. Up to 2 follow-ups will occur.
89480053|NCT04977700|Experimental|Intervention Group|Participants will be enrolled on a rolling basis and participate in SS for 4 weeks in the intervention condition. After pretesting, participants will receive sun protection messages from SS through emails/comments based on results from their activity data. All participants will complete posttest survey 4 weeks from randomization.
89480054|NCT04977700|No Intervention|Control Group|A small control group will be included to see if a no-treatment control condition is acceptable to users and estimate follow-up rates for planning a randomized trial. Participants will be enrolled on a rolling basis and will complete a pretest at randomization. All participants will complete a posttest survey 4 weeks from randomization.
89480055|NCT04976920||Treatment Group|"Patients will undergo a routine IVF cycle. This will include ovarian stimulation, egg retrieval and fertilization of oocytes through intracytoplasmic sperm injection (ICSI). All fertilized oocytes will be cultured up to blastocyst for five to six days.~Spent media will be collected on day 5-6 for all embryos reaching blastocyst on day 5, and on day 6 for those reaching blastocyst on day 6. The spent culture media will be sent to a lab for metabolomic analysis.~For the embryo transfer, the best morphology blastocyst will be selected for transfer by the New Hope embryologist. The embryo transfer outcome will be compared to the metabolomics result to determine the NPV and PPV of metabolomics vs implantation."
89480056|NCT04976816|Experimental|A1 peri-levator betamethasone injection|patients with isolated thyroid-related upper lid retraction who will be given the Peri-levator injection of betamethasone suspension
89537580|NCT03063723||CHC patients|15 treatment-naive CHC patients treated by Ledipasvir-Sofosbuvir orDaclatasvir-Sofosbuvir.
89203029|NCT00934479|No Intervention|Healthy Subjects|Healthy subjects completed a baseline 1-week diary of stool and defecatory characteristics, fasting breath for hydrogen and methane and a stool sample for pyrosequencing. Otherwise, the healthy subjects received no intervention.
89480057|NCT04976816|Experimental|A2 Peri-levator triamcinolone acetate injection|patients with isolated thyroid-related upper lid retraction who will be given Peri-levator injection of triamcinolone acetate
89480058|NCT04976816|Experimental|B1 Peri-levator and retrobulbar betamethasone injection|patients with thyroid-related upper lid retraction and proptosis who will be given Peri-levator and retrobulbar injection of betamethasone suspension
89480059|NCT04976816|Experimental|B2 Peri-levator and retrobulbar triamcinolone acetate injection|patients with thyroid-related upper lid retraction and proptosis who will be given Peri-levator and retrobulbar injection of triamcinolone acetate
89480060|NCT04971356|Experimental|Experimental arm|1-month of Aspirin + Ticagrelor, followed by 5-month of Ticagrelor monotherapy; Afterward, Aspirin monotherapy for 6 months
89480061|NCT04971356|Active Comparator|Reference arm|12-month Aspirin plus Ticagrelor
89480062|NCT04970888|Experimental|Combined|Combined physical exercise and cognitive training. The combined intervention will include a cognitive training with aerobic and resistance exercises training, three sessions per week for 6 months. Participants will be allowed to perform cognitive and exercise training sessions either home-based or centre-based.
89480063|NCT04970888|Experimental|Exercise|The physical exercises intervention will include aerobic and resistance exercises training, three sessions per week for 6 months. Participants will be allowed to perform exercise training sessions either home-based or centre-based.
89480064|NCT04970888|Active Comparator|Usual care|Usual medical care with no interventions
89480065|NCT04969081|Active Comparator|treatment as usual|usual substance use treatment
89480066|NCT04969081|Experimental|treatment as usual plus referral to work focused program|usual substance use treatment plus referral to a competitive or non-competitive work-focused program
89480067|NCT04965701||Untreated EGFR-mutant advanced non-small-cell lung cancer patients|
89480068|NCT04962646|Experimental|Intervention|Once the thoracic cavity os opened during surgery, carbon dioxide flooding using a diffusor will be instigated with a flow of 5L/min. The flooding will be terminated once the aorta and the heart have no open contact with surrounding air.
89480069|NCT04962646|No Intervention|Control|No intervention. No sham will be used as the staff performing the surgery would have been able to detect the lack of carbon dioxide in the surgical wound.
89480070|NCT04961593||Treatment group|Children treated with caspofungin in the pediatric intensive care unit
89480071|NCT04961580||Ceftazidime avitbatan sodiumt group|Children treated with ceftazidime avitbatan sodium in the pediatric intensive care unit will be enrolled in this group. Blood sample will be retained at various time intervals for pharmacokinetics.
89480072|NCT04961190|Active Comparator|Prolonged Exposure Therapy|8-14 sessions of psychotherapy, each lasting 60-90 minutes, focused on imaginal exposure to trauma memories and in vivo exposure to trauma reminders
89480073|NCT04961190|Active Comparator|Pharmacotherapy|20-60mg of paroxetine daily, or 75-300mg of venlafaxine XR daily
89480074|NCT04961190|Active Comparator|Combined treatment (Prolonged Exposure and Pharmacotherapy)|8-14 sessions of psychotherapy, each lasting 60-90 minutes, focused on imaginal exposure to trauma memories and in vivo exposure to trauma reminders AND 20-60mg of paroxetine daily, or 75-300mg of venlafaxine XR daily
89480075|NCT04959890||Subjects Previously Treated with Strimvelis (or GSK2696273) Gene Therapy|It is expected that this study will include approximately 70 eligible samples from approximately 15 subjects previously treated with gamma retroviral gene therapy (gRV-GT).
89480076|NCT04952597|Experimental|Arm A: Ociperlimab + Tislelizumab|Ociperlimab + tislelizumab + cCRT for 4 cycles followed by ociperlimab + tislelizumab
89480077|NCT04952597|Experimental|Arm B: Tislelizumab|Tislelizumab + cCRT for 4 cycles followed by tislelizumab alone
89480078|NCT04952597|Experimental|Arm C: Concurrent Chemoradiotherapy (cCRT)|cCRT for 4 cycles
89480079|NCT04952129|Experimental|Selenomethionine|50 micrograms of selenium as Selenomethionine per oral capsule. Dosage: One capsule a day for 6 weeks, followed by two capsules per day for 6 weeks.
89480080|NCT04952129|Experimental|Methylselenocysteine|50 micrograms of selenium as Methylselenocysteine per oral capsule. Dosage: One capsule a day for 6 weeks, followed by two capsules per day for 6 weeks.
89480081|NCT04950816|Experimental|tailored MBI (.b)|
89480082|NCT04950816|Active Comparator|attention control condition|
89480083|NCT04948944|Experimental|active transcranial direct current stimulation|The investigators use Soterix mini-CT Stimulator to deliver 30 minutes 2mAmp tDCS to the bilateral DLPFC (optimized lateral electrode placement montage), with the the anode on the left hemisphere and the cathode on the right hemisphere. The electrodes are rubber and are placed in an MRI compatible holder and affixed with conductive paste. The investigators will use a bespoke headstrap to place the electrodes, which are held in place by the conductive paste.
88951281|NCT03174184|Experimental|Rifampin resistant A|Participants with the presence of rifampin resistance-conferring rpoB mutations in M. tuberculosis who will receive RIFAMPIN 20mg/kg once daily (QD), MEROPENEM 2 grams (G) thrice daily (TID) intravenously, Amoxicillin/Clavulanate Potassium 500 milligrams (MG)-125 MG Oral Tablet once daily for 14 days
88951282|NCT03174184|Experimental|Rifampin resistant B|Participants with the presence of rifampin resistance-conferring rpoB mutations in M. tuberculosis who will receive MEROPENEM 2 grams TID (thrice daily) intravenously, Amoxicillin/Clavulanate Potassium 500 MG-125 MG Oral Tablet once daily for 14 days
89206282|NCT04095065|Experimental|itMatters Well-being and itMatters Sexual Violence Prevention|Participants will have access to content focused on basic information related to sleep wellness and time management. In Addition, participants will have access to content focused on sexual violence including basic information and bystander intervention. This content will be available for a period up to 3 weeks.
89480084|NCT04948944|Sham Comparator|sham transcranial direct current stimulation|In the sham stimulation mode, the device shows pseudorandom numbers on the screen that look like real stimulation is being delivered. The device gives a low level of stimulation at the very beginning and at the very end of the stimulation session (30 seconds ramp up and 30 seconds ramp down) in order to recreate the feeling of tingling that subjects perceive at the beginning and end of real stimulation.
89480085|NCT04946253|Active Comparator|DOCC with standard implementation (No TEAM or LEAD)|Practices in this arm will receive DOCC materials/training and technical support, but will not receive care team coaching/consultation (TEAM) or practice leadership facilitation (LEAD) after the training phase.
89480086|NCT04946253|Experimental|DOCC with TEAM implementation|Practices in this arm will receive DOCC training and materials and one type of implementation support after the training: coaching/consultation for the provider care team (TEAM).
89206283|NCT04095065|Experimental|itMatters Well-being|Participants will have access to content focused on basic information related to sleep wellness and time management. This content will be available for a period up to 3 weeks.
89480087|NCT04946253|Experimental|DOCC with LEAD implementation|Practices in this arm will receive DOCC training and materials and only one type of implementation support after the training: facilitation for practice leadership (LEAD).
89480088|NCT04946253|Experimental|DOCC with TEAM + LEAD implementation|Practices in this arm will receive DOCC training and materials and both types of implementation support after the training: coaching/consultation for the provider care team (TEAM) and facilitation for practice leadership (LEAD).
89480089|NCT04941703|Experimental|Magnesium Citrate plus a Probiotic Arm:|Participants assigned to the magnesium citrate plus a probiotic arm will receive 1 bottle of magnesium citrate 296 mL PO once to be taken within a 4-hour period, (about 10 oz.). Because magnesium citrate remains within the intestinal lumen, a second bottle can be provided if there is limited bowel movement. Patients will be asked to take 2 capsules of probiotics twice daily for six days or until discharge, whichever is earlier.
89480090|NCT04941703|Placebo Comparator|Placebo|Participants randomized to the placebo arm will receive matching placebo 296 mL PO once to be taken within a 4-hour period, (about 10 oz.) and 2 cellulose capsules twice daily for six days or until discharge, whichever is earlier. The placebo will be flavored to match the taste of the interventional arm.
89480091|NCT04926597|Experimental|Intervention group: individualized nutritional support|Intervention group patients will receive individualized nutritional support to reach energy and protein goals with the support of an experienced, unblinded dietician and with use of oral nutritional supplements (ONS) as needed
89480092|NCT04926597|Other|Control group: general information on healthy food habits|Control group patients will receive nutritional counselling (general information on healthy food habits) at discharge, but no nutritional support strategy will be used during follow-up
89480093|NCT04923633||Phase I Instrument-Assisted Soft Tissue Manipulation (IASTM) Stroke Pattern Analysis|Fifteen (n=15) experienced clinicians, each with 8 or more years experiences in instrument-assisted soft tissue manipulation (IASTM), will participate in an observational studying analyzing their application of basic stroke patterns (linear, curved) to a consistent research assistant/model. IASTM is a type of massage that uses rigid devices. A Quantifiable Soft Tissue Manipulation (QSTM) device system will be used for determining objective metrics of stroke parameters (e.g. stroke force, rate, angle) and results will be compared between participants to determine characteristic stroke profile patterns for use in training and research.
89480094|NCT04923633||Phase II Consistency of IASTM Force Application|"The reproducibility of applying a targeted STM stroke force will be determined within and between therapists, both with and without visual monitoring of the QSTM metrics and graphic display. Two novice and two experienced therapists will be trained using QSTM. A novice is defined as a clinician with <1 year and an experienced with >8 years of practice. Fifty (n=50) healthy, non-obese subjects will be enrolled that meet the inclusion/exclusion criteria. First, the clinicians will apply a self-perceived moderate force for 15sec (non-therapeutic dose), within subject tolerance, without using QSTM feedback. Then, the clinician will apply a targeted force of 10N with visual monitoring of QSTM feedback. This process will be repeated 5-7 days later to determine repeatability. After testing, subjects will participate in simple back and/or leg stretches and an ice pack applied."
89480095|NCT04923633||Phase III Reliability of Dynamic Pressure Pain Threshold Assessment|"The reliability of dynamic pressure pain threshold (DPPT) assessment over a specified area will be determined. Two novice and two experienced clinicians will be trained using QSTM. Subjects (n=50) will be recruited that meet the inclusion/exclusion criteria of healthy, non-obese, younger (≥18 but ≤30yo) and older individuals (≥50 but ≤75yo) (males and females). The clinicians will apply force to standardized areas of the back and thigh regions for 1 min, using the Quantifiable Soft Tissue Manipulation (QSTM) device system. The force applied will be applied up to but below the threshold of when a subject says to stop when they feel the pressure change into any sort of irritating discomfort/pain. Secondary clinical outcomes will be assessed before and after testing since testing could have effects on the soft tissue, pain, and physical performance measures. After testing, the subject will be instructed in simple back and/or leg stretches and an ice pack applied."
89480096|NCT04916535|Experimental|diagnostic flow|all patients with MAD as assessed during routine transthoracic echocardiography will undergo to the following further exams: i) 12-lead electrocardiogram (ECG), ii) 24-hour ECG monitoring, iii) cardiac magnetic resonance imaging (CMR), iv) cardiological visit
89480097|NCT04914975|Experimental|NMES Group|Participants will receive neuromuscular electrical stimulation of the abdominal wall before defaecation for 30 minutes over the course of 16 weeks.
89480098|NCT04903002|Other|Crossover sequence 1: Oxytocin first|Patients receive 2-weeks courses of 24-IU oxytocin, placebo, 48-IU oxytocin.
89480099|NCT04903002|Other|Crossover sequence 2: placebo first|Patients receive 2-weeks courses of placebo, 24-IU oxytocin, 48-IU oxytocin.
89480100|NCT04898764|No Intervention|Healthy Volunteers|This study arm will only participate in part A of the study (Characterisation study) and thus will not receive the study drug. A maximum of 35 healthy volunteers will be included in this study arm.
89480101|NCT04898764|Experimental|Patients with long-term use of nasal decongestants|"A maximum of 100 patients with long-term use of nasal decongestants will be included in this study arm, for part A of the study (Characterisation study).~The investigators will consecutively recruit patients from part A (Characterisation study) into part B of the study (Intervention study) until a total of 35 patients completed all study-related visits of part B. During the intervention study, patients with long-term use of nasal decongestants will administer Mometasone furoate intranasally, two doses (50µg/actuation) in each nostril, twice daily (total daily dose of 400µg) during a 12 week period."
89537581|NCT03063723||Healthy controls|10 Healthy controls without any treatment
89537582|NCT04350567|Experimental|Intervention|
89206284|NCT00825084|Experimental|single dose cohort-Japanese group|Japanese healthy subjects
89537583|NCT04438005|Experimental|ICP-022|
89537584|NCT00859677||1|HIV-positive and MRSA negative
89537585|NCT00859677||2|HIV-positive and MRSA infected (skin/soft tissue)
89537586|NCT00859677||3|HIV-positive and MRSA colonized
89480102|NCT04878991||Treatment Group|"Patients will undergo a routine IVF cycle. This will include ovarian stimulation, egg retrieval and fertilization of oocytes through intracytoplasmic sperm injection (ICSI). All fertilized oocytes will be cultured up to blastocyst for five to six days.~Spent media will be collected on day 5-6 for all embryos reaching blastocyst on day 5, and on day 6 for those reaching blastocyst on day 6. The spent culture media will be sent to a lab for metabolomic analysis.~For the embryo transfer, the best morphology blastocyst will be selected for transfer by the study embryologist. The embryo transfer outcome will be compared to the Metabolomics result to determine the NPV and PPV of Metabolomics vs implantation."
89480103|NCT04872452|Experimental|Gastrointestinal dysmotility participants|
89480104|NCT04872452|Other|Healthy participants|
89480105|NCT04870853||Observational (medical record review)|Patients' medical records are reviewed retrospectively.
89480106|NCT04868032|Experimental|Positive Psychology-Motivational Interviewing Intervention|Participants will receive a written treatment manual with detailed information about each topic. The intervention consists of 10 weekly phone sessions (30 minutes each). Each session includes a new psychological skill designed to increase positive emotions experienced during physical activity, a motivational skill designed to boost physical activity, and setting a physical activity goal for the next week using information from the Fitbit. A motivational interviewing approach will be used for all topics.
89480107|NCT04868032|Active Comparator|Physical Activity Education Control|Participants randomized to this condition will be provided with a Fitbit, and will be mailed educational materials about physical activity at 4 time points throughout the intervention period. They will not receive a manual or phone calls with an interventionist.
89480108|NCT04861350|Experimental|motor imagery with action observation|The subjects will perform the exercises mentally for 3 sets with video, 10 reps for 1 set.
89480109|NCT04861350|Experimental|physical training|The subjects will perform the exercise physically for 3 sets with supervision of investigator, 10 reps for 1 set.
89480110|NCT04861350|Experimental|combine physical training and motor imagery with action observation|The subjects will perform the exercise mentally with video for 1 set and physically with supervision of investigator for 2 sets, 3 sets totally, 10 reps for 1 set.
89480111|NCT04850222|Experimental|Subjects randomized to get Fluoxetine therapy|Subjects will be randomized to take Fluoxetine (10mg by mouth per day). The randomized drug will be prescribed by the orthopedic team on the day randomization so that the patient may be monitored for side effects during the remainder of their hospitalization. The patient will be prescribed the randomized medication on the day of discharge and a 90 day supply will be provided by the inpatient research pharmacy.
89480112|NCT04850222|Active Comparator|Subjects randomized to get Calcium Supplmentation|Subjects will be randomized to take Calcium supplementation (1000mg by mouth per day). The randomized drug will be prescribed by the orthopedic team on the day randomization so that the patient may be monitored for side effects during the remainder of their hospitalization. The patient will be prescribed the randomized medication on the day of discharge and a 90 day supply will be provided by the inpatient research pharmacy.
89480113|NCT04849390|Experimental|ESO-101|Oral use of 1 hard gelatin capsule (800 μg)
89480114|NCT04849390|Placebo Comparator|Placebo|Oral use of 1 hard gelatin capsule
89480115|NCT04838457|Experimental|ACME-TM|Participants will obtain 4 sessions of telehealth cognitive behavioral therapy (CBT) focused on reducing alcohol misuse. Participants will receive a 5th telehealth coaching call to develop a plan for ensuing treatment regarding their elevated cardiovascular risk factors. Participants will then receive daily texts for one month aimed at helping them decrease these cardiovascular risk factors.
89480116|NCT04837378|Experimental|Abdominal Massage Group|Abdominal massage process stage; After the preliminary test data were obtained, the hands were warmed and creamed with vaseline, abdominal massage was applied to the patient in the supine position for 15 minutes. After 24 hours, gastrointestinal complications and comfort parameters were recorded.
89480117|NCT04837378|Experimental|In-bed Exercise Group|In-bed exercise process phase; After the pre-test data were obtained, the patient was applied passive in-bed exercises for approximately 15 minutes in all extremities in the supine position. After 24 hours, gastrointestinal complications and comfort parameters were recorded.
89480118|NCT04837378|No Intervention|Control Group|Control group stage; Gastrointestinal complications and comfort parameters were recorded in this group at the same time as the experimental groups without any intervention.
89480119|NCT04818242|Active Comparator|POC testing with Blinded CGM (Standard of Care)|Patients in the standard of care study arm will wear a blinded CGM and receive POC testing before meals and bedtime, with providers adjusting oral agents or insulin dose based on POC results.
89480120|NCT04818242|Experimental|Dexcom CGM with Glucose Telemetry System (CGM-GTS)|Patients in the intervention CGM study arm will have a single daily fasting POC testing and will wear a real-time Dexcom G6 with GTS, and providers will adjust oral or insulin therapy based on CGM-GTS profile information.
88951283|NCT03174184|Experimental|Rifampin susceptible C|Participants without the presence of rifampin resistance-conferring rpoB mutations in M. tuberculosis who will receive RIFAMPIN 20mg/kg once daily, MEROPENEM 2 grams TID (thrice daily) intravenously, Amx/Clv orally at a dose of 500 mg/125 mg thrice daily for 14 days
88951284|NCT03174184|Experimental|Rifampin susceptible D|Participants without the presence of rifampin resistance-conferring rpoB mutations in M. tuberculosis who will receive MEROPENEM 2 grams TID intravenously, Amoxicillin/Clavulanate Potassium 500 MG-125 MG Oral Tablet once daily for 14 days
88951285|NCT03174184|Experimental|Rifampin susceptible E|Participants without the presence of rifampin resistance-conferring rpoB mutations in M. tuberculosis who will receive MEROPENEM 1 gram TID intravenously, Amoxicillin/Clavulanate Potassium 500 MG-125 MG Oral Tablet once daily for 14 days
89020637|NCT03006705|Placebo Comparator|Placebo group|"Placebo: Placebo solution intravenously for 30 min in every 3 weeks (maximum 1 year).~Chemotherapy: S-1 Therapy or CapeOX Therapy is determined by the investigator.~S-1 therapy(maximum 1 year):~Tegafur-gimeracil-oteracil potassium combination drug 40 - 60 mg bid orally in 28 days, followed by 14 days off~CapeOX Therapy(maximum 6 months):~Oxaliplatin 130 mg/m2 (body surface area) solution intravenously for 2 hours once-daily, followed by 20 days off.~Capecitabine 1000 mg2 (body surface area) bid orally in 14 days, followed by 7 days off."
89206285|NCT00825084|Experimental|single dose cohort-Western group|Western healthy subjects
89206286|NCT00825084|Experimental|multiple dose cohort-Japanese group|Japanese healthy subjects
89480121|NCT04815005||HoFH|Patients diagnosed with HoFH by their physicians, either based on clinical or genetic criteria.
89480122|NCT04812925|Experimental|efgartigimod PH20 SC|Patients receiving efgartigimod PH20 SC treatment
89480123|NCT04811027|Experimental|(CPS ≥1): Pembro + Efti|"Eftilagimod alpha: 30 mg every 2 weeks for the first 4 cycles;thereafter every 3 weeks for up to 18 cycles(1 cycle = 6 weeks).~Pembrolizumab: 400 mg every 6 weeks for up to 18 cycles (1 cycle = 6 weeks)."
89480124|NCT04811027|Active Comparator|(CPS ≥1): Pembro|Pembrolizumab: 400 mg every 6 weeks for up to 18 cycles (1 cycle = 6 weeks).
89480125|NCT04811027|Experimental|(CPS <1): Pembro + Efti|"Eftilagimod alpha: 30 mg every 2 weeks for the first 4 cycles;thereafter every 3 weeks for up to 18 cycles(1 cycle = 6 weeks).~Pembrolizumab: 400 mg every 6 weeks for up to 18 cycles (1 cycle = 6 weeks)."
89480126|NCT04796597|Experimental|Single-arm|Implantation of subcutaneous leads and connection to an external EEG amplifier
89480127|NCT04795934|Active Comparator|Laparoscopic Nissen Fundoplication (LNF)|Control
89480128|NCT04795934|Active Comparator|Combo Transoral Incisionless Fundoplication (CTIF)|Treatment
89480129|NCT04793737|Experimental|Precision Radiation (SBRT)|Precision radiation of melanoma metastases
89480130|NCT04767464|Other|Compass Course|Virtual Compass Course
89480131|NCT04762888|Experimental|Diagnostic (68Ga-PSMA PET/MRI or PET/CT)|Patients receive 68Ga-PSMA IV over 90 minutes. Patients then undergo PET/MRI over 60 minutes or PET/CT over 30 minutes.
89480132|NCT04761107||GU participants with active or past infection of SARS-Co-V-2|GU patients from medical records with active or past infection of SARS-Co-V-2
89206287|NCT00825084|Experimental|multiple dose cohort-Western group|Western healthy subjects
89480133|NCT04740307|Experimental|Pembrolizumab/Quavonlimab + Lenvatinib|Participants receive pembrolizumab/quavonlimab via intravenous (IV) infusion every 6 weeks (Q6W) for up to 2 years, plus lenvatinib orally (based on actual body weight at screening) until progressive disease or unacceptable toxicity for up to 5 years. In the event of discontinuation of pembrolizumab/quavonlimab due to intolerable toxicity, re-initiation of treatment with pembrolizumab may be considered.
89480134|NCT04739969|Active Comparator|Active TBS-DLPFC|The active group will receive theta-burst TMS stimulation.
89480135|NCT04739969|Sham Comparator|Sham TBS-DLPFC|The sham group will receive sham theta-burst TMS stimulation.
89480136|NCT04728230|Experimental|Treatment (chemo-immunotherapy, radiation therapy)|See detailed description.
89480137|NCT04727424|Active Comparator|Fluvoxamine Maleate + Budesonide Inhalation powder|"Fluvoxamine 100 mg oral tablets:~One tablet after randomization (Day 0) followed by 100 mg BID for the following 09 days PLUS~Budesonide Inhalation powder 400 mcg capsule:~One 400 mcg capsule (inhalation) after randomization (Day 0) followed by 400 mcg BID for the following 09 days"
89480138|NCT04727424|Active Comparator|Fluvoxamine Maleate|"Fluvoxamine 100 mg oral tablets:~One tablet after randomization (Day 0) followed by 100 mg BID for the following 09 days"
89480139|NCT04727424|Placebo Comparator|Placebo (mild disease)|"Placebo SC normal saline syringe (single day schedule):~Matching syringes containing 0,5 ml normal saline administered by SC route after randomization Day 0 (single dose SC).~OR~Placebo oral tablets (10-day schedule):~Matching tablets started after randomization using the dosing regimen of 01 tablet every 12 hs starting at Randomization Day (Day 0) until end of Day 09 (total of 10 day schedule) PLUS~Placebo Inhalation Therapy:~One dosing (inhalation) right after randomization (Day 0) followed by one dose BID for the following 09 days~OR~Paracetamol (07-day schedule - active comparator):~Paracetamol 500 mg tablets started after randomization using the dosing regimen of 01 tablet BID starting at Rand. Day (Day 0) until end of Day 06 (total of 07 days schedule)~OR~Placebo oral tablets (10-day schedule for patients with SPO2 < 94%):~One tablet after randomization (Day 0) followed by 01 tablet BID for the following 09 days (total of 10 days schedule)"
89480140|NCT04727424|Active Comparator|Peginterferon Lambda|"Peginterferon Lambda 180 mcg syringe:~One syringe of Peginterferon Lambda will be administered by SC route just after randomization (Day 0 - single dose SC administration)."
89480141|NCT04727424|Active Comparator|Fluxetine + Budesonide Inhalation powder|"Fluoxetine 20 mg oral tablets:~Two tablets right after randomization (Day 0) followed by 40 mg MID for the following 06 days PLUS~Budesonide Inhalation powder 400 mcg capsule:~One 400 mcg capsule (inhalation) right after randomization (Day 0) followed by 400 mcg BID for the following 06 days"
89480142|NCT04719390|Experimental|TMI Component On|Randomized at daily time point to ON, text messaging intervention gets sent to participant at that time
89480143|NCT04719390|No Intervention|TMI Component Off|Randomized at daily time point to OFF, text messaging intervention does not get sent to participant at that time
89480144|NCT04697602|Experimental|Dose titration group|Stepwise dose titration of febuxostat and low-dose colchicine
89480145|NCT04697602|Active Comparator|Standard treatment group|Fixed dose febuxostat and low-dose colchicine
89480146|NCT04688151|Experimental|Dose level 1,Dose level 2|Dose level 1 Rituximab 375mg/m2 infusion once every 4 weeks for 8 cycles Acalabrutinib 100mg PO once every day Durvalumab 1500mg infusion once every 4 weeks Dose level 2 Rituximab 375mg/m2 infusion once every 4 weeks for 8 cycles Acalabrutinib 100mg PO twice every day Durvalumab 1500mg infusion once every 4 weeks
89480147|NCT04687072|Experimental|Efgartigimod PH20 SC|Patients receiving efgartigimod PH20 SC treatment
89480148|NCT04687072|Placebo Comparator|Placebo PH20 SC|Patients receiving placebo PH20 SC treatment
89480149|NCT04683835||Patients|Patients who are assessed by the clinical staff using Mini-Mental State Exam (MMSE)
89480150|NCT04677153|Experimental|Test and Treat plus Peer Mentors Intervention Arm|Participants offered 8 weeks of glecaprevir/pibrentasvir (GLE/PIB) at OTP plus peer support.
89480151|NCT04677153|Active Comparator|Standard of Care Referral Arm|Participants referred to offsite (non-OTP) location for HCV treatment.
89480152|NCT04669301|Active Comparator|Supportive therapy (time and attention control)|"Supportive Therapy (ST) is a behavioral placebo and controls for non-specific psychotherapeutic factors of the clinician-subject relationship, such as empathy and support, but does not provide active cognitive training. ST utilizes reflective listening to help deepen awareness of participants' emotional experience. Timing and duration of ST sessions will mirror the intervention, and will consist of 10 weekly sessions, 30 to 45 minutes each, delivered by trained psychologists via video-conferencing."
89537587|NCT00859677||4|HIV-negative and MRSA negative
89537588|NCT00859677||5|HIV-negative and MRSA infected (skin/soft tissue)
89480153|NCT04669301|Experimental|MAAT-G intervention|The MAAT-G intervention will be delivered by a trained psychology fellow at the University of Rochester Medical Center. The intervention will be delivered through televideoconferencing and participants will be provided a tablet equipped with a HIPPA compliant televideoconferencing application to use for the MAAT-G workshop sessions. We will use the University of Rochester Zoom application which is HIPPA compliant. A tablet instruction manual will be given to patients to help guide them through how to use a tablet and how to navigate the Zoom application. A unique meeting ID number will be given to each patient to log in to the Zoom application. If participants do not have access to wireless internet, the tablet will be equipped with a data package for participant use for the purposes of this study
89480154|NCT04668885|Experimental|Primary refractory/relapsed AML|Lower dose CPX-351 in participants with primary refractory/relapsed AML. Participants will receive an induction and maintenance phase of CPX-351
89480155|NCT04668885|Experimental|MDS after HMA failure|Lower dose CPX-351 in participants with MDS after HMA failure. Participants will receive an induction and maintenance phase of CPX-351
89480156|NCT04667689|Other|CAMPFIRE Assessment|NIH Toolbox Cognitive Assessment and PROMIS Surveys
89480157|NCT04656496|Experimental|NOURISH-T+|NOURISH-T+ targets parents as agents of change by providing intensive parent skills training emphasizing role modeling of positive health behaviors to foster the development of healthy eating and physical activity in pediatric cancer survivors. The NOURISH-T+ group will have 6 weekly, 1-1.5 hour, manualized sessions delivered using video-conferencing. There will be 2 additional brief sessions where the child will participate along with their parent to promote child engagement. Additionally, there will be one session with a pediatric oncology dietician based out of Nicklaus Children's Hospital who will discuss personalized nutritional strategies. Brief booster sessions at 2-, 4-, 8-, and 10- months will maximize retention and follow-up participation. NOURISH-T+ content is theory-based, manualized, and builds upon strengths of our prior work with NOURISH-T (our pilot) and NOURISH (our work with otherwise healthy overweight and obese children).
89480158|NCT04656496|Active Comparator|EUC - Brief NOURISH-T+|The EUC condition (Brief NOURISH-T+) engages parents in one information session moderated by a USF-based interventionist using videoconferencing. Session content is taken from the publicly available We Can! Manual. Parents in this group will receive nationally available web-based brochures on pediatric overweight/obesity on two occasions during the 6 weeks that NOURISH-T+ families participate in the study. Check-ins will take place at 2-, 4-, 8-, and 10- months post-intervention.
89480159|NCT04647240|Active Comparator|Dermacyte® Liquid (human amniotic fluid)|Dermacyte® Liquid (human amniotic fluid) solution 1.0mL to 2.0mL weekly
89480160|NCT04647240|Placebo Comparator|Placebo (0.9% saline)|Matching placebo solution 1.0mL to 2.0mL weekly
89480161|NCT04636203||General population|A sample of 3,000 men and women, residents in the territories of ASST Sette Laghi (Lombardia) and of Molise Region will be randomly selected from the municipal registries, and will be invited to participate.
89480162|NCT04636203||Healthcare workers (HCWs)|All HCWs from the occupational registries of ASST Ospedale di Circolo Varese (Lombardia) and IRCCS Neuromed Pozzilli (Molise) will be invited to participate, up to reach 500 recruited subjects.
89480163|NCT04635462|Experimental|Multidomain intervention|The multidomain intervention will combine a remote monitoring of home-based cognitive training with physical exercise training for 6-month.
89480164|NCT04635462|Experimental|Physical exercise intervention|The physical exercises intervention will include the remote monitoring of physical exercise training for 6-month.
89480165|NCT04633460|Experimental|Ketone ester|(R)-3-hydroxybutyl (R)-3-hydroxybutyrate, a ketone ester
89480166|NCT04633460|Placebo Comparator|Placebo|KE-free solution
89480167|NCT04632056||Beovu|Brolucizumab (Genetical Recombination) 6 mg (0.05 mL) was administered by intravitreal injection every 4 weeks for the first three doses(loading phase). In the following maintenance phase, Brolucizumab was basically administered every 12 weeks. The interval between treatments was adjusted as appropriate according to the symptoms. The interval between two doses was not to be shorter than 8 weeks
89480168|NCT04631302|Experimental|Mindfulness|
89480169|NCT04631302|Active Comparator|Light Physical Exercise|
89480170|NCT04630990||Participants Treated With Elagolix|Participants will receive Elagolix according to the local label.
89480171|NCT04627571||Patient Population|Patients diagnosed with neurotrophic keratopathy.
89480172|NCT04624672|Placebo Comparator|Control Arm|Once weekly injection of placebo 4-6 months at prescribed dose
89480173|NCT04624672|Active Comparator|Test Arm|Once weekly injection of 1.0mg Semaglutide 4-6 months at prescribed dose
89480174|NCT04590404|Experimental|MIST (Metabolism-Informed Smoking Treatment)|At hospital discharge, participants randomized to the MIST precision care arm will receive a prescription for medication (either varenicline or NRT). Post discharge, participants will receive automated phone calls via TelASK to promote continued engagement. Medication prescriptions will be informed by nicotine metabolism (i.e., NMR result) such that faster metabolizers are prescribed varenicline and slower metabolizers are prescribed NRT.
89480175|NCT04590404|Active Comparator|Usual Care|At hospital discharge, participants randomized to the Usual Care arm will receive a prescription for medication (either varenicline or NRT). Post discharge, participants will receive automated phone calls via TelASK to promote continued engagement. Medication prescription will not be informed by nicotine metabolism.
89480176|NCT04589039||Participants with Ovarian Cancer|Participants diagnosed with ovarian cancer (including fallopian tube or primary peritoneal cancer) who have been prescribed with niraparib for the first time in a real-world setting, and who are in a complete or partial response to first-line platinum-based chemotherapy or who had complete or partial response to 2 or more line of platinum-based chemotherapy or who have been treated with 3 or more prior chemotherapy regimens with either breast cancer susceptibility gene (BRCA) mutation (irrespective of platinum sensitivity) or platinum-sensitive homologous recombination deficiency (HRD) positive will be observed prospectively over 24-month period, or until treatment discontinuation, or until end of study, which occurs first.
89480177|NCT04573660||Coronary and peripheral stents|Participants in the Coronary and peripheral stents arm will receive Coronary and peripheral stents
89480178|NCT04573660||Pacing catheters|Participants in the Pacing catheters arm will receive Pacing catheters
89480179|NCT04573660||Vascular plugs|Participants in the Vascular plugs arm will receive Vascular plugs
89480180|NCT04573660||Measurement and imaging (FFR and OCT)|Participants in the Measurement and imaging (FFR and OCT) arm will receive Measurement and imaging (FFR and OCT)
89480181|NCT04573660||Peripheral dilatation catheters|Participants in the Peripheral dilatation catheters arm will receive Peripheral dilatation catheters
89480182|NCT04573660||Coronary dilatation catheters|Participants in the Coronary dilatation catheters arm will receive Coronary dilatation catheters
89480183|NCT04573660||Coronary and peripheral guidewires|Participants in the Coronary and peripheral guidewires arm will receive Coronary and peripheral guidewires
89480184|NCT04573660||Vessel closure/compression devices|Participants in the Vessel closure/compression devices arm will receive Vessel closure/compression devices
89480185|NCT04573660||Vascular access introducers|Participants in the Vascular access introducers devices arm will receive Vascular access introducers
89480186|NCT04565327|Experimental|Cohort A: Single Dose/Image|Patients receive hyperpolarized carbon C 13 pyruvate intravenously (IV) over less than one minute then undergo MRI over 5 minutes at baseline
89480187|NCT04565327|Experimental|Cohort B: Multiple Dose/Images|Patients receive hyperpolarized carbon C 13 pyruvate IV over less than one minute then undergo MRI over 5 minutes at baseline and 4 weeks after beginning treatment
89480188|NCT04561986|Active Comparator|Arm A: Standard of care (SOC) + tocilizumab (TCZ)|SOC, as below + TCZ (162 mg every week, subcuataneous administration)
89480189|NCT04561986|No Intervention|Arm B: SOC|Tacrolimus (target concentration 6 ±1 µg/L) + MPA (1.5-2 g/day as tolerated) + prednisolone (not less than 5 mg/day), all oral administration
89480190|NCT04561492|Experimental|[68Ga]Ga-PentixaFor|
89480191|NCT04561362|Experimental|Part A-1 -BT8009 Monotherapy Dose Escalation|Participants will receive escalating doses of BT8009 via IV.
89480192|NCT04561362|Experimental|Part A-2 -BT8009 in Combination with Pembrolizumab Dose De-Escalation|Participants will receive BT8009 and a standard dose of pembrolizumab.
89480193|NCT04561362|Experimental|Cohort B-1 - BT8009 Monotherapy Dose Expansion|Participants will receive a selected dose of BT8009.
89480194|NCT04561362|Experimental|Cohort B-2- BT8009 Monotherapy Dose Expansion|Participants will receive a selected dose of BT8009.
89480195|NCT04561362|Experimental|Cohort B-3- BT8009 Monotherapy Dose Expansion|Participants will receive a selected dose of BT8009. .
89480196|NCT04561362|Experimental|Cohort B-4- BT8009 Monotherapy Dose Expansion|Participants will receive a selected dose of BT8009.
89480197|NCT04561362|Experimental|Cohort B-5- BT8009 Monotherapy Dose Expansion|Participants will receive a selected dose of BT8009.
89480198|NCT04561362|Experimental|Cohort B-6- BT8009 Monotherapy Dose Expansion|Participants will receive a selected dose of BT8009.
89480199|NCT04561362|Experimental|Cohort B-7- BT8009 in Combination with Pembrolizumab Dose Expansion|Participants will receive a selected dose of BT8009 and standard dose of pembrolizumab.
89480200|NCT04561362|Experimental|Part C - Renal Insufficiency BT8009 Monotherapy Dose Expansion|Participants will receive a selected dose of BT8009.
89480201|NCT04561362|Experimental|Part D - BT8009 Monotherapy Supplementary PK|Participants will receive a selected dose of BT8009.
89480202|NCT04547686|Experimental|Smoke-Free Homes Intervention|Participants in the intervention condition will receive the expanded Smoke-Free Homes intervention coupled with a connection to the quitline. Follow-up will be at six and twelve months, including saliva cotinine validation for reported 7-day cessation.
89480203|NCT04547686|Active Comparator|Control|The usual care/control arm will receive mailed information on the quitline and a connection to the quitline at their request. Follow-up will be at six and twelve months, including saliva cotinine validation for reported 7-day cessation.
89480204|NCT04545957|Experimental|Phase I MRI Simulation|"This research study involves a screening period to determine eligibility.~- Radiation mapping to define the target for radiation.acquiring MR data at the specified timepoint in a patient's care plan and ability to identify the radiation target and develop a radiation therapy plan on the MR data."
89480205|NCT04545957|Experimental|Phase II MR Simulation Protocol: Track A|MR-only Radiation Therapy Simulation MRI-simulation and synthetic CT to plan treatment
89480206|NCT04545957|Experimental|Phase II MR Simulation Protocol: Track B|Adjusted Margin or / Dose Painted RT Based on Imaging of MR Simulator (e.g. biological imaging or higher resolution imaging)
89480207|NCT04544683|Other|Cervical Pain for 6 months or less and scheduled for TFESI|Participants who meet inclusion and exclusion criteria will be enrolled into the study after consenting to and before receiving a first cervical TFESI. The baseline examination and all baseline questionnaires will be completed within 2 weeks before the first cervical TFESI. Participants will be given a daily pain diary chart to record NRS and percentage improvement during the 1st month post-injection. Participants will be contacted in the 1st week post-injection with a standardized questionnaire about their symptoms and a reminder about the 4 week (+/- 1 week) post-injection follow up. Routine scheduled follow-up by clinic visit or telephone call will occur at 4 weeks (+/- 1 week), 8 weeks (+/- 2 weeks), 3 months (+/- 2 weeks), 6 months (+/- 1 month), and 12 months (+/- 1 month), at which times all follow-up measures will be obtained.
89480208|NCT04529421||Students, Higher Education Institution 1|All first, second, and third year students at Higher Education Institution 1 who agree to take part in study.
89480209|NCT04529421||Students, Higher Education Institution 2|All first, second, and third year students at Higher Education Institution 2 who agree to take part in study.
89480210|NCT04529421||Students, Higher Education Institution 3|All first, second, and third year students at Higher Education Institution 3 who agree to take part in study.
89480211|NCT04529421||Students, Higher Education Institution 4|All first, second, and third year students at Higher Education Institution 4 who agree to take part in study.
89480212|NCT04529421||Students, Higher Education Institution 5|All first, second, and third year students atHigher Education Institution 5 who agree to take part in study.
89480213|NCT04529421||Students, Higher Education Institution 6|All first, second, and third year students at Higher Education Institution 6 who agree to take part in study.
89480214|NCT04529421||Students, Higher Education Institution 7|All first, second, and third year students at Higher Education Institution 7 who agree to take part in study.
89537589|NCT00859677||6|HIV-negative and MRSA colonized
89480215|NCT04529421||Students, Higher Education Institution 8|All first, second, and third year students at Higher Education Institution 8 who agree to take part in study.
89480216|NCT04529421||Students, Higher Education Institution 9|All first, second, and third year students at Higher Education Institution 9 who agree to take part in study.
89480217|NCT04529421||Students, Higher Education Institution 10|All first, second, and third year students at Higher Education Institution 10 who agree to take part in study.
89480218|NCT04529421||Students, Higher Education Institution 11|All first, second, and third year students at Higher Education Institution 11 who agree to take part in study.
89480219|NCT04529421||Students, Higher Education Institution 12|All first, second, and third year students at Higher Education Institution 12 who agree to take part in study.
89480220|NCT04529421||Students, Higher Education Institution 13|All first, second, and third year students at Higher Education Institution 13 who agree to take part in study.
89480221|NCT04529421||Students, Higher Education Institution 14|All first, second, and third year students at Higer Education Institution 14 who agree to take part in the study.
89480222|NCT04521205|Experimental|Standardized FMT|The patients will receive standardized FMT. The FMT was given by capsule. It was given three times a week.
89480223|NCT04521205|Placebo Comparator|Without FMT|The patients will receive FMT with blank capsule.
89480224|NCT04519164|Experimental|Eplerenone|Participants will receive eplerenone, ranging from 25-100mg daily for one year.
89480225|NCT04519164|Active Comparator|Chlorthalidone with potassium chloride|Participants will receive chlorthalidone (6.25-25mg daily for one year) along with potassium chloride (up to 20 mEq daily for one year)
89480226|NCT04516499||f-FTLD mutation carriers|All participants must be from a family with f-FTLD mutations. The f-FTLD mutation carrier group members will have their genetic status tested and included in this group if a f-FTLD mutation is observed. Participants do not need to know or be told their genetic status.
89480227|NCT04516499||Non-mutation carriers from families with f-FTLD mutations|All participants must be from a family with f-FTLD mutations. The non-mutation carrier group members will have their genetic status tested and included in this group if they do not have a f-FTLD mutation. Participants do not need to know or be told their genetic status.
89480228|NCT04509674|Experimental|Empagliflozin|
89480229|NCT04509674|Placebo Comparator|Placebo|
89480230|NCT04496115|Experimental|Mindfulness Intervention|Mindfulness training
89480231|NCT04496115|No Intervention|Control|Standard of Care
89480232|NCT04491955|Experimental|1/Arm 1|CEA/ MUC1 Vaccines + M7824 + N-803 (Triple Therapy).
89480233|NCT04491955|Experimental|2/Arm 2A|CEA/ MUC1 Vaccines + M7824 + N-803 + NHSIL12 (Quadruple Therapy); dose escalation of NHS-IL12.
89480234|NCT04491955|Experimental|3/Arm 2B|CEA/ MUC1 Vaccines + M7824 + N-803 + NHSIL12 (Quadruple Therapy); fixed dose of NHS-IL12.
89480235|NCT04476108|Experimental|750 Mg-500 mg LY3016859|Participants received LY3016859 every 2 weeks with 750 mg as starting dose followed by 500 mg intravenous (IV) infusion for a total of 4 doses.
89480236|NCT04476108|Placebo Comparator|Placebo|Participants received LY3016859 every 2 weeks with 750 mg as starting dose followed by 500 mg IV infusion for a total of 4 doses.
89480237|NCT04474912||Control group|Healthy volunteers with no symptoms or signs of rheumatoid arthritis or osteoarthritis
89480238|NCT04474912||Rheumatoid arthritis group|Rheumatoid arthritis (RA) patients fulfilled 2010 American college of rheumatology (ACR) classification criteria. A patient is considered having definite RA if he/she scores at least 6 points in the established classification system
88951286|NCT03174184|Experimental|Rifampin susceptible F|Participants without the presence of rifampin resistance-conferring rpoB mutations in M. tuberculosis who will receive MEROPENEM 3 grams QD intravenously, Amoxicillin/Clavulanate Potassium 875 MG-125 MG Oral Tablet once daily for 14 days
88951287|NCT03052933|Experimental|Copanlisib/gemcitabine|
88951288|NCT02959697|Experimental|Subcut. + Subconj. Injection|Patients will undergo standard blepharoptosis repair using an anterior approach, with an added injection of local anesthetic (Xylocaine) beneath the conjunctiva of the lid being operated on. They will still receive the standard subcutaneous local anesthetic given during blepharoptosis repair.
89480239|NCT04474912||Osteoarthritis group|Osteoarthritis (OA) patients fulfilled 1990 ACR criteria for the classification and reporting of osteoarthritis of the hand. A patient is considered having hand OA if he /she Hand pain, aching, or stiffness plus 3 or 4 of hard tissue enlargement of 2 or more of 10 selected joints or hard tissue enlargement of 2 or more DIP joints or fewer than 3 swollen MCP joints, or deformity of at least 1 of 10 selected joints which are are the second and third distal interphalangeal (DIP), the second and third proximal interphalangeal, and the first carpometacarpal joints of both hands
89480240|NCT04456686|Experimental|750 Mg-500 mg LY3016859|Participants received LY3016859 every 2 weeks with 750 milligram (mg) as starting dose followed by 500 mg intravenous (IV) infusion for a total of 4 doses.
89480241|NCT04456686|Placebo Comparator|Placebo|Participants received placebo every 2 weeks by IV infusion for a total of 4 doses.
89480242|NCT04447352|Active Comparator|Arm A - FLOT|"Patients randomized to treatment Arm A already received 3-6 cycles of FLOT in 2-week treatment cycles prior to undergoing surgery. Following surgery, patients will receive four further 2-week cycles FLOT. FLOT can be deescalated to FLO, FLT or FL in case of chemorelated toxicity at any time and at the discretion of investigator.~FLOT = Docetaxel 50 mg/m², Oxaliplatin 85 mg/m², Leucovorin 200 mg/m², 5-FU 2600 mg/m²."
88951289|NCT02959697|Sham Comparator|Subcut. + Sham Subconj. Injection|Patients will undergo standard blepharoptosis repair using an anterior approach, however they will not receive the additional subconjunctival Xylocaine injection. Instead, they will receive a sham injection of Normal Saline to prevent them from knowing which eye received the additional anesthetic.
89020638|NCT02998645|Experimental|Eltrombopag + cyclosporine|Participants received eltrombopag (orally, 150 mg once daily for non-Asian participants / 100 mg once daily for participants of Asian ancestry) in combination with cyclosporine (orally, 10.0 mg/kg/day in divided doses every 12 hours) for up to 6 months. Thereafter, responders at Month 6 were treated with cyclosporine until Month 24
89020639|NCT02953899|Experimental|Contingency Management|This is a treatment where participants earn points for treatment attendance and for providing evidence of gambling abstinence. These points are added to study accounts that can be redeemed for goods and services available at a variety of on-line businesses (e.g., Amazon, Walmart, etc.). Submission of evidence of gambling behaviour or non-attendance at an on-line counselling session re-sets subsequent points to the starting level. The CM procedure is implemented as part of the CBT counselling session.
89206288|NCT02598635|Experimental|Cholecalciferol|A capsule of pulverized cholecalciferol 4800 U will be administered once a day for 16 weeks. At serum calcium levels > 10.5 mg/dL (2.65 mmol/l) and/or at serum phosphorus levels > 7 mg/dL (2.26 mmol/L) capsule administration will be discontinued and restarted one month after when serum calcium levels or phosphorus levels declined to < 10.6 mg/dL and/or <7.1 mg/dL respectively.
89480243|NCT04447352|Experimental|Arm B - FLOT/HIPEC|"Patients randomized to treatment Arm B already received 3-6 cycles of FLOT in 2-week treatment cycles prior to undergoing surgery including Intraoperative Hyperthermic IntraPEritoneal Chemoperfusion (HIPEC) during gastric-/ esophagogastric resection using Cisplatin 75mg/m². Following surgery, patients will receive four further 2-week cycles FLOT. FLOT can be deescalated to FLO, FLT or FL in case of chemorelated toxicity at any time and at the discretion of investigator.~FLOT = Docetaxel 50 mg/m², Oxaliplatin 85 mg/m², Leucovorin 200 mg/m², 5-FU 2600 mg/m²."
89480244|NCT04428398||No renal involvement|Patients with ANCA-vasculitis and no ANCA-associated renal involvement in disease history
89480245|NCT04428398||Renal remission|Patient with ANCA-vasculitis in renal remission
89480246|NCT04420650|Active Comparator|Anodal tDCS|Anodal tDCS of the hypothalamus-cognitive network
89480247|NCT04420650|Active Comparator|Cathodal tDCS|Cathodal tDCS of the hypothalamus-cognitive network
89480248|NCT04420650|Sham Comparator|Sham Stimulation|Double blind sham stimulation (ramp-up ramp-down stimulation will be applied in order to simulate the active condition without any further continuous administration of current)
89480249|NCT04420351|Experimental|Urokinase thrombolysis|The patients of intervention group will receive 1 millions units urokinase dissolved by 100 saline through intravenous infusion within 30 minutes.
89480250|NCT04420351|Other|Antiplatelet treatment|The control group will receive antiplatelet agents as decided by the physicians according to Chinese guideline for diagnosis and treatment of acute ischemic stroke 2018
89480251|NCT04409418|Experimental|Experimental Group|If the patient is randomized to the experimental group (lower arm), the research staff will direct the insert to place the catheter into the forearm at least 10 cm away from the antecubital fossa.
89480252|NCT04409418|Active Comparator|Control Group|Control group (upper arm). If the patient is in the control group the research staff will direct the inserter to place the catheter into the upper arm vein at least 2 cm above the antecubital fossa.
89480253|NCT04406454||Heathy volunteers|Patients has healthy skin at 5 anatomical locations including face, back, dorsal forearm, volar forearm, calf and at least a nevus without superficial scales and crusting.
89480254|NCT04400318|Experimental|Dupilumab|2 x loading dose on Day 1, followed by 1 x maintenance dose every 2 weeks (Q2W) during 24 weeks.
89480255|NCT04400318|Placebo Comparator|Placebo|2 x placebo injections on Day 1, then 1 placebo injection Q2W during 24 weeks.
89480256|NCT04396496|Experimental|Daratumumab Injection|"Up to 12 four-week cycles of Daratumumab (DARA), in combination with the immunomodulatory drug (IMiD) lenalidomide.~DARA is injected. Dosage calculated by weight.On Cycles 1 and 2, DARA is given on Days 1, 8,15 and 22. On Cycles 3-6,DARA is given on Days 1 and 15. On Cycles 7-12, DARA is given on Day 1.~Lenalidomide is taken by mouth. 15 mg on Days 1-21 of each cycle."
89480257|NCT04379050|Experimental|ABBV-951|Participants will receive ABBV-951 solution by continuous subcutaneous infusion (CSCI), at the discretion of the investigator, for up to 96 weeks.
89480258|NCT04375267|Experimental|177Lu-DOTA-TATE and olaparib|
89480259|NCT04371315||Positive COVID-19|"Baseline and Day 28: Respiratory and Whole blood Samples Collected, Days 7 and 14: Respiratory Samples Collected~Monthly follow-up until Covid-19 is negative: Respiratory and Whole Blood Samples Collected"
89480260|NCT04371315||Negative COVID-19|Baseline and Day 28: Respiratory and Whole blood Samples Collected, Days 7 and 14: Respiratory Samples Collected
89480261|NCT04370522||Cohort A: hormone-sensitive disease|"Patients who initiate ET in first line of advanced disease, they could be patients de novo with no previous ET or patients who received adjuvant ET and experience disease recurrence more than one year after its completion.~Patients will be divided in two subgroups according to having or not received previous ET."
89480262|NCT04370522||Cohort B: hormone-resistant disease|"Patients in progression who are starting a first or second line of ET for advanced Breast Cancer (BC) and showing one of following the hormone-resistance criteria to any ET:~For first line:~Primary hormone-resistance: disease recurrence occurs within the first two years of adjuvant ET.~Secondary hormone-resistance: disease recurrence occurs after the first two years of adjuvant ET or during the first year after its completion.~For second line:~Primary hormone-resistance: disease progression occurs within the first 6 months of ET for advanced disease.~Secondary hormone-resistance: disease progression occurs after the first 6 months of ET for advanced disease.~Patients will be divided in two subgroups according to having primary or secondary hormone-resistance."
89480263|NCT04365660|Experimental|18-F-FTC 146 PET/CT|For PET scans, subjects will receive intravenous injection of 10 mCi 18-F -FTC 146 administered twice with 18-F-FTC 146, once at baseline (pre chemotherapy) and once at final study visit (post chemotherapy).
89480264|NCT04362670|Experimental|OTX-CSI-Cohort 1|Formulation 2A-.36 mg
89480265|NCT04362670|Experimental|OTX-CSI-Cohort 2|Formulation 1- .36 mg
89480266|NCT04362670|Placebo Comparator|HV|"Cohort 2:~Formulation 2B"
89480267|NCT04362670|Experimental|OTX-CSI- Cohort 2|Formulation 2A- .36 mg
89480268|NCT04362670|Placebo Comparator|HV-2|"Cohort 2:~Formulation 3"
89480269|NCT04353258|Experimental|Behavioral Economics intervention (BE mHealth)|Participants will receive a 12-month behavioral weight loss intervention delivered primarily via mobile phone (mHealth) that includes behavioral economics components.
88951290|NCT02953652|Experimental|HBI-8000|Four 10 mg tablets or less twice weekly orally approximately 30 minutes after any regular meal. The treatment will be continuous, with 3-4 days between dosing. Treatment will continue until disease progression in the absence of unacceptable toxicity.
88951291|NCT02924935|Experimental|Treatment|L-Histidine in 500mg capsules taken at a dose of 50mg/kg to maintain high-normal serum histidine levels
88951292|NCT02900560|Active Comparator|Cohort 1|CC-486 100 mg once a day, 21 days on, 7 days off combined with Pembrolizumab 200 mg IV every 21 days
89480270|NCT04353258|Active Comparator|Standard mHealth intervention (mHealth)|Participants will receive a 12-month behavioral weight loss intervention delivered primarily via mobile phone (mHealth).
89480271|NCT04347161|Experimental|Intervention Arm|Participants in the intervention arm will be tracked and able to engage with the intervention (conversational agent) on their mobile telephone for 12 weeks.
89480272|NCT04347161|Active Comparator|Control Arm|Patients in the control arm will receive usual care, which includes clinician-driven education on medication management and self-monitoring of symptoms.
89480273|NCT04345757|No Intervention|Standard instructions|Standard instructions: activity restrictions, including no strenuous exercise, sexual intercourse, or lifting objects greater than 25 pounds for 6 weeks or until evaluation at the 6 week postpartum visit
89480274|NCT04345757|Experimental|Study Group|Study group: Structured 10 week exercise protocol
89480275|NCT04345536||Patients hospitalized with confirmed Covid-19|All patients hospitalized with confirmed Covid-19
89480276|NCT04343053|Other|SARS-Cov-2 infection|Single study group of patients with respiratory failure due to SARS-Cov-2 infection. Three blood samples will be collected at different stages of disease: early, defined as first 96 hours, mid, defined as time from 96 hours and 14 days, late. defined as >14 days
89480277|NCT04329806|Experimental|Moxonidine|Moxonidine to be administered at a dose to produce a decrease in BP of at least 20% of baseline for 9 weeks
89480278|NCT04329806|Active Comparator|Amlodipine|Amlodipine to be administered at a dose to produce a decrease in BP of at least 20% of baseline for 9 weeks
89480279|NCT04325217||Patients newly initiating Ofev®/Nintedanib Capsules|
89480280|NCT04324840|Experimental|Part A|
89480281|NCT04324840|Experimental|Part B - CC-90010 + Temozolomide (TMZ) + Radiotherapy (RT)|
89480282|NCT04324840|Other|Part B - Standard TMZ + RT|Control
89480283|NCT04321759|Experimental|Cognitive Enhancement Therapy|CET is a comprehensive manualized cognitive remediation program designed to maximize gains in social functioning by integrating computer-based training to enhance neurocognition with group-based exercises to improve social cognition.
89480284|NCT04321759|Active Comparator|Social Skills Training|The HOPES social rehabilitation program uses the principles of SST (modeling, role playing, positive and corrective feedback, homework assignments, in vivo skills practice), designed to improve both psychosocial functioning and preventive health..
88951293|NCT02900560|Active Comparator|Cohort 2|CC-486 100 mg twice a day, 21 days on, 7 days off combined with Pembrolizumab 200 mg IV every 21 days
88951294|NCT02900560|Active Comparator|Cohort 3|CC-486 300 mg once a day, 14 days on and 14 days off combined with Pembrolizumab 200 mg IV every 21 days
88951295|NCT02900560|Active Comparator|Cohort 4|CC-486 300 mg once a day, 21 days on, 7 days off combined with Pembrolizumab 200 mg IV every 21 days
89480285|NCT04320069|Experimental|Omnipod Horizon™ Automated Glucose Control System|All subjects using the Omnipod Horizon™ Automated Glucose Control System in Manual Mode without a connected CGM for 7 days and with a connected CGM for 7 days.
89480286|NCT04314895|Experimental|NanoPac|Intratumoral injection of NanoPac 15 mg/mL at a volume of up to 20% of the total calculated tumor and lymph node volume (not to exceed 40 mL) on up to three occasions 4 weeks apart.
89480287|NCT04310176|Active Comparator|Standard|"Chemotherapy (mFOLFOX-6/mOXELL) + Bevacizumab for 12 cycles (24 weeks)~Maintenance treatment (Standard): Fluoropyrimidines (5-Fluorouracil/Capecitabine) + Bevacizumab until disease progression or unacceptable toxicity"
89480288|NCT04310176|Experimental|Experimental|"Chemotherapy (mFOLFOX-6/mOXELL) + Bevacizumab + Valproic Acid administered oral daily from day -14 increasing doses and an intra-patient titration for a target serum level of 50-100µg/ml for 12 cycles (24 weeks)~Maintenance treatment (Experimental): Fluoropyrimidines (5-Fluorouracil/Capecitabine) + Bevacizumab + Valproic Acid until disease progression or unacceptable toxicity"
89480289|NCT04296175|Active Comparator|conventional group|epirubincin 90mg/m2 d1 and CTX 600mg/m2 d1, every 2 or 3 weeks followed by paclitaxel 80mg/m2 d1,d8,d15, every 3 weeks.
89480290|NCT04296175|Experimental|carboplatin group|epirubincin 90mg/m2 d1 and CTX 600mg/m2 d1, every 2 weeks followed by paclitaxel 80mg/m2 and carboplatin AUC=2 d1,d8,d15, every 4 weeks.
89480291|NCT04291001|Active Comparator|ENG Implant alone|Women will receive a contraceptive implant in the setting of a dominant follicle to assess ovulation incidence and timing following insertion.
89480292|NCT04291001|Active Comparator|ENG Implant plus oral UPA|Women will receive a contraceptive implant and oral UPA the same day in the setting of a dominant follicle to assess ovulation incidence and timing following insertion.
89480293|NCT04286282|Active Comparator|Standard of Care|The first 100 participants with HIV and depression will receive standard of care including SSRI therapy.
88951296|NCT02877550|Experimental|Part A - dose escalation and part B - dose expansion|"Part A: dose escalation:~Combination therapy N= 4-18 pts Cycle 1-6 (1 cycle = 28 days) Obinutuzumab: 1000 mg, i.v. infusion; d1, 8, 15 C1 and d1 C2-6 Venetoclax: p.o. once daily according to dose level (DL)~Part B - dose expansion:~Combination therapy N= up to 25 pts Cycle 1-6 (1 cycle = 28 days) Obinutuzumab: 1000 mg, i.v. infusion d1, 8, 15 C1 and d1 C2-6 Venetoclax: p.o. once daily according to MTD~Part A and part B are followed (in case of no PD) by an obinutuzumab maintenance therapy for 2 years"
88951297|NCT02877251||Deep venous thrombosis|To identify clinical characteristics, treatment trends, in-hospital and 3, 6, and 12 months follow-up outcome through major adverse cardiovascular events (MACE) of patients diagnosed with deep venous thrombosis
89020640|NCT02953899|Active Comparator|Cognitive Behavioural Therapy|"CBT is currently considered best practice for the treatment of problem gambling, as noted in the National Health and Medical Research Council (Australia) endorsed Clinical Guidelines for problem and pathological gambling treatment (Problem Gambling Research and Treatment Centre, 2011). CBT is typically a semi-structured approach for delivering cognitive behavioural therapy addressing the participant's experiences, thoughts, and emotions relating to their gambling and substance use. Techniques include psychoeducation, behavioural interventions, and cognitive strategies. Participants are expected to attend on-line counselling sessions three times a week for approximately 12 weeks. All participants will receive individual counselling from an experienced counsellor/therapist."
89480294|NCT04286282|Experimental|Standard of Care + Group Support Psychotherapy|The second 100 participants with HIV and depression will receive standard of care, including SSRI therapy, and group support psychotherapy.
89480295|NCT04286282|Active Comparator|Standard of Care (Non-Depressed)|100 participants with HIV and without depression will receive standard of care therapy for HIV and no depression treatment.
89480296|NCT04284540|Experimental|Adjuvant Hypofractionated Radiation Treatment|Short course radiation therapy for patients who have undergone surgery
89480297|NCT04284540|Experimental|Definitive Hypofractionated Radiation Treatment|Short course radiation therapy for patients who have not had surgery
89480298|NCT04283539||CPI with ircAE|Participants on check point inhibitors with immune related cutaneous adverse event
89480299|NCT04283539||no ircAE|Participants who do not have a cutaneous adverse event
89480300|NCT04279730||Inpatient pulmonary rehabilitation|Multidisciplinary inpatient pulmonary rehabilitation program lasting 4 weeks (40 sessions, 2 sessions per day, 5 days per week).
89480301|NCT04275232|Experimental|Allogenic Plasma Aliquots|Allogenic Plasma Aliquots to be used as eye drops in the treatment of recurrences of ligneous conjunctivitis. Two drops will be administered to the affected eye, every 1 to 4 hours, depending on severity of the recurrence.
89480302|NCT04269889|Experimental|Refractory Diamond-Blackfan Anemia in Eltrombopag|"Participants with Refractory Diamond-Blackfan Anemia will be administered Eltrombopag. Participants 12 years of age an above will receive the adult dose of 150 mg by mouth daily. Participants between ages of 6 and 11 years old will start at 75 mg by mouth daily, and children 2 and 5 years of age will start at 2.5 mg/kg, not to exceed 75 mg by mouth daily.~To adjust for the higher expected exposure in participants of East Asian and South East Asian ancestry, the starting dose for East Asian and South East Asian participants 12 years of age and above will be 75 mg by mouth once daily. For East Asian and South East Asian participants between 6 and 11 years of age, the starting dose will be 37.5 mg once daily by mouth, and for children between 2 and 5, the starting dose will be 1.25 mg/kg by mouth."
89480303|NCT04263597|Experimental|2'-fucosyllactose for ages 0-5 years|Dose for ages 0-5 years: 2.5 g/day;
89480304|NCT04263597|Experimental|2'-fucosyllactose for ages 5.1-10 years|Dose for ages 5.1-10 years: 5 g/day;
89480305|NCT04263597|Experimental|2'-fucosyllactose for ages >10 years|Dose for ages >10 years: 10 g/day;
89480306|NCT04253483|Experimental|Arm I (HDR)|Patients undergo HDR.
89480307|NCT04253483|Experimental|Arm II (SABR)|Patients undergo SABR every other day for 5 treatments.
89480308|NCT04243798|Experimental|Active TBS-DLPFC|The active group will receive theta-burst TMS stimulation.
89480309|NCT04243798|Sham Comparator|Sham TBS-DLPFC|The sham group will receive sham theta-burst TMS stimulation.
89480310|NCT04243226|Experimental|this study is to develop exercise prescription of TBI patients|The aim of this study is to develop exercise prescription of TBI patients and then to evaluate the effectiveness of programmed aerobic exercise to improve psysical-psycho-social health such as cognitive status, 6 minutes walk test, depression relief, motivation, symptom, resilience and quality of life. This will be a randomized-controlled clinical trial, by using a mixed method to explore the feasibility and validity of such a safety exercise prescription. In the next stage, a randomized clinical control trial will be applied in TBI patients to evaluate the effectiveness of programmed aerobic exercise to promote psysical-psycho-social health such as cognitive status, 6 minutes walk test, depression relief, motivation, symptom, resilience and quality of life.
89480311|NCT04243226|No Intervention|No exercise prescription in TBI patients|Routine Care of TBI Patients
89480312|NCT04240444|Experimental|SeQuent® SCB|patients will receive sirolimus (rapamycin)-coated balloon (SeQuent® SCB)
89480313|NCT04240444|Active Comparator|SeQuent® Please Neo|patients will receive SeQuent® Please Neo balloon
89480314|NCT04233606|Placebo Comparator|Control|Participants will be infused with normal (0.9% NaCL) saline for a 120 minute period.
89480315|NCT04233606|Experimental|Hypertonic Saline|Participants will be infused with hypertonic (3% NaCL) saline for a 120 minute period.
89480316|NCT04230941|Experimental|MAAT-G Intervention|MAAT-G Workshops & participant workbook use (8 workshops)
89480317|NCT04226508|No Intervention|Control|
89480318|NCT04226508|Experimental|Physical exercise|
89480319|NCT04226248|Active Comparator|Active (Rivastigmine)|Rivastigmine Transdermal Patches
89480320|NCT04226248|Placebo Comparator|Placebo|Placebo Matched Transdermal Patches
89480321|NCT04219787|Experimental|Long Biliopancreatic Limb LRYGB|LRYGB with an 180 cm biliopancreatic limb (BPL) and an alimentary limb (AL) of 80 cm.
89480322|NCT04219787|Active Comparator|Short Biliopancreatic Limb LRYGB|Standard LRYGB with a 80 cm BPL and a 180 cm long AL.
89480323|NCT04208347|Experimental|Apatinib and Camrelizumab and S-1 and Oxaliplatin|
89480324|NCT04208347|Experimental|Apatinib and S-1 and Oxaliplatin|
89480325|NCT04208347|Active Comparator|S-1 and Oxaliplatin|
89480326|NCT04198454|Active Comparator|Compression bandages|Class I (20-30 mmHg) compression bandages or stocking. This is considered a standard measure in the recovery of lower extremity wounds and often recommended.
89480327|NCT04198454|Other|Standard wound dressings|Wound dressings alone consisting of gauze and skin tape to cover the wound.
89480328|NCT04198454|Experimental|Compression bandages with FACL|Class I compression (20-30 mmHg) bandage or stocking with FACL.
89480329|NCT04186169|Placebo Comparator|Arm 1: Paroxysmal AF - PVI arm|The subjects with paroxysmal AF undergo pulmonary vein isolation (PVI).
89480330|NCT04186169|Placebo Comparator|Arm 2: Persistent AF - PVI arm|The subjects with persistent AF undergo pulmonary vein isolation (PVI).
89480331|NCT04186169|Experimental|Arm 3: Persistent AF - PVI + Fat-targeted ablation|The subjects with persistent AF undergo pulmonary vein isolation (PVI) and additional ablation to target the inflammatory fat tissue
88951298|NCT02877251||Deep venous thrombosis and Pulmonary embolism|To identify clinical characteristics, treatment trends, in-hospital and 3, 6, and 12 months follow-up outcome through major adverse cardiovascular events (MACE) of patients diagnosed with deep venous thrombosis and pulmonary embolism
89480332|NCT04179019|Experimental|Amlodipine|Amlodipine (dose 10 mg, once daily)
89480333|NCT04176731|Experimental|Treatment|All subjects wearing the Omnipod Horizon™ Automated Glucose Control System using the closed-loop algorithm
89480334|NCT04166591|Active Comparator|Addressed|Children participate in an interaction with an experimenter who uses the word to be learned.
89480335|NCT04166591|Experimental|Overheard|Children are present in the room while an experimenter uses the word to be learned in an interaction with another experimenter.
89480336|NCT04162990|Experimental|Lifestyle remodeling|
89480337|NCT04162990|Active Comparator|Does Comparator: regular treatment|
88951299|NCT02877251||Pulmonary embolism|To identify clinical characteristics, treatment trends, in-hospital and 3, 6, and 12 months follow-up outcome through major adverse cardiovascular events (MACE) of patients diagnosed with pulmonary embolism
88951300|NCT02775812|Experimental|Treatment (cisplatin, pembrolizumab, IMRT)|Patients receive cisplatin IV over 1-2 hours once weekly for weeks 1-6 and pembrolizumab IV over 30 minutes every 3 weeks in weeks 9, 12, 15, 18, and 21. Patients also undergo IMRT in weeks 1-6. Patients may also receive pembrolizumab IV over 30 minutes in weeks 3, 6, 24, and 27.
88951301|NCT02679170||Routine clinical practice group (NSCLC ALK+, ROS1)|Patients diagnosed and treated following routine clinical practice, for their NSCLC ALK+ or ROS1
88951302|NCT02518009||Men with gender dysphoria|Genetic men treated with estrogen
88951303|NCT02518009||Women with gender dysphoria|Genetic women treated with androgen
88951304|NCT02505022||Treatment seeking patients|Patients between 18 and 26 who arrive seeing treatment for new-onset mental health symptoms. They will receive treatment as usual, while being assessed overt he course of one year for changes in role functioning.
88951305|NCT02357082||MRI Scan|Patients with a previously implanted Cardiac Implantable Electronic Device who are undergoing an MRI Scan for clinically indicated, diagnostic purposes.
88951306|NCT02238496|Other|Surgical Cohort - cytoreductive surgery|Cytoreductive surgery planned (surgical cohort). After post-operative standard evaluations, patients will resume therapy. After anti-emetic prophylaxis, patients will receive the first divided dose of the perifosine loading dose after recovery from surgery. Patients will be observed for at least 30 minutes to ensure there has been adequate anti-emetic prophylaxis, and then patients will receive temsirolimus administered over 30-60 minutes IV. The remaining divided doses of the perifosine loading dose will then be administered. Patients will then return weekly for infusion of temsirolimus over 30-60 minutes IV. Dosing will be continuous although for the purposes of evaluation, a cycle will be defined as 4 weeks (28 days).
89480338|NCT04159779||Venetoclax Participants|Participants for whom the treating physician has decided to treat with venetoclax before enrollment in this study.
89480339|NCT04159311|Active Comparator|Treated group|"The treated group will have 3 sessions of osteopathy testing followed by osteopathy treatment (M0, M1, M2) and a final testing session at M3."
89480340|NCT04159311|Sham Comparator|Untreated group|"The untreated group will have 4 sessions of only testing osteopathy (M0, M1, M2, M3)."
89480341|NCT04153136|Experimental|Sacubitril/Valsartan|Sacubitril/Valsartan 49-51mg twice daily along with lifestyle modification (counseling regarding diet and healthy activity) for 6 months
89480342|NCT04153136|Placebo Comparator|Placebo|Placebo twice daily along with lifestyle modification (counseling regarding diet and healthy activity) for 6 months
89480343|NCT04141605||SherpaPak CTS Patients|Patients whose donor heart was transported with the SherpaPak CTS
89480344|NCT04141605||Standard Transport Patients|Patients whose donor heart was transported with a method other than SherpaPak CTS in the past two years
89480345|NCT04134104||Bowel, Bladder, and Sexual Dysfunction group|Out of 38 patients included for surgery 12 were excluded due to poor follow up and those patients who underwent upfront surgery. Only 26 patients were included in the study. There were 20 (76.9%) males and 6 (23.1%) females respectively. The mean age of the patient was 43.577yrs (26-75) and mean BMI was 20.78. The number of patients that underwent LAR was 24 (92.30%) and those who underwent APR were 2( 7.6%) after neoadjuvant chemoradiotherapy respectively.
89480346|NCT04127409|Placebo Comparator|Control Chicken-meat & Control Eggs|Participants will be provided with control chicken-meat and control eggs, and will be requested to eat at least three portions/week of the control chicken-meat, and to eat at least three control eggs/week, for 6 months.
89480347|NCT04127409|Experimental|Control Chicken-meat & Omega-3 Eggs|Participants will be provided with control chicken-meat and omega-3-PUFA enriched eggs, and will be requested to eat at least three portions/week of the control chicken-meat, and to eat at least three omega-3-enriched eggs/week, for 6 months.
89480348|NCT04127409|Experimental|Omega-3 Chicken-meat & Control Eggs|Participants will be provided with omega-3-PUFA enriched chicken-meat and control eggs, and will be requested to eat at least three portions/week of the omega-3-PUFA enriched chicken-meat, and to eat at least three control eggs/week, for 6 months.
89480349|NCT04127409|Experimental|Omega-3 Chicken-meat & Omega-3 Eggs|Participants will be provided with omega-3-PUFA enriched chicken-meat and omega-3-PUFA enriched eggs, and will be requested to eat at least three portions/week of the omega-3-PUFA enriched chicken-meat, and to eat at least three omega-3-PUFA enriched eggs/week, for 6 months.
89480350|NCT04105855||Older Infants|Infants age 6-12 months presenting for routine healthy visits
89480351|NCT04105855||Pregnant Women|Women 18 years and older (and emancipated minors) presenting for routine antenatal visits
88951307|NCT02238496|Other|Medical Cohort - no cytoreductive surgery|No-Cytoreductive surgery planned (medical cohort). After anti-emetic prophylaxis, patients will receive the first divided dose of the perifosine loading dose. Patients will be observed for at least 30 minutes to ensure there has been adequate anti-emetic prophylaxis, and then patients will receive temsirolimus administered over 30-60 minutes IV. The remaining divided doses of the perifosine loading dose will then be administered. Patients will then return weekly for infusion of temsirolimus over 30-60 minutes IV. Dosing will be continuous although for the purposes of evaluation, a cycle will be defined as 4 weeks (28 days).
89480352|NCT04103489|Experimental|HELLP Syndrome at less than 30 weeks gestation|Women diagnosed with HELLP syndrome at 23-30 weeks gestation will receive eculizumab.
89203030|NCT00934479|Experimental|Constipated Subjects|"Subjects with constipation included those with chronic constipation (CC) and those with constipation predominant irritable bowel syndrome (C-IBS). They completed a baseline 1-week diary of stool and defecatory characteristics, fasting breath for hydrogen and methane and a stool sample for pyrosequencing.~Following baseline test and because of differences in the FDA-approved dosing for the 2 subtypes of chronic constipation, the CC subjects received open-label lubiprostone 24 mcg orally twice daily for 4 weeks; while the C-IBS subjects received open-label lubiprostone 8 mcg orally twice daily for 4 weeks.~Following the 4-weeks treatment with lubiprostone, they completed another stool diary, fasting breath test, and stool sample for pyrosequencing."
89203031|NCT00658632|Experimental|1|
89203032|NCT00658632|Active Comparator|2|
89203033|NCT05408650|Experimental|Aromatherapy massage group|The massage will be applied to the patient's hands and feet while the patient in semi-fowler's position.
89203034|NCT05408650|No Intervention|control group|The patients will receive the routine care of the ICU (such as decreased movements of the staff and soft light in the area at night).
89480353|NCT04099355|Experimental|dronabinol|active group
89480354|NCT04099355|Placebo Comparator|control|control group
89480355|NCT04099251|Experimental|Nivolumab|
89480356|NCT04099251|Placebo Comparator|Placebo|
89480357|NCT04097860|Experimental|Intervention group|Will be sent one message that includes general information pertinent to all mothers expressing BM for their infants and one personalized real-time biomarker based message which will include the sodium level contained in the BM since the previous message, the number of times pumped on those days and will either congratulate the participant on how well the is pumping BM for the infant or how many more times per day the participant needs to pump to decrease the BM sodium level and increase BM production
89480358|NCT04097860|No Intervention|Control group|Will only be sent text messages that include the same general lactation information sent to the treatment group
89480359|NCT04088708|Experimental|Aerobic Exercise Training|Progressive aerobic exercise training sessions supervised by exercise specialists who have experience training cancer survivors.
88951308|NCT02234531|Experimental|EVER TEACHER|"In EVER TEACHER group a specific feedback called virtual teacher will be displayed. The virtual teacher perform the correct movement to emulate, that is supposed to stimulate the motor adaptation exploiting a supervised learning mechanism. This feedback will give an on-line information on motor performance quality, allowing a real time visual comparison between patient's own execution and teacher one. During the experiment, patients will receive 1 hour of virtual reality-based therapy and the treatment will last 1 hour a day, five days weekly for four weeks."
88951309|NCT02234531|Other|NEVER TEACHER|In NEVER TEACHER group the subjects will be asked to perform the same exercises with the upper limb without the virtual teacher assistance. The treatment will last four weeks with daily sessions of 60 minutes, five times per week.
88951310|NCT02205424||Ischaemic stroke patients|Patients who have suffered an ischaemic stroke, as determined clinically and verified with imaging (CT brain; MRI).
88951311|NCT02205424||Healthy control participants|People who have never suffered a stroke, and are matched to the ischaemic stroke patient group according to age, education, and vascular risk factors.
88951312|NCT02034110|Experimental|Dabrafenib + Trametinib|Subjects received Dabrafenib 150 mg twice daily orally plus Trametinib 2 mg once daily orally on a continuous basis. Dabrafenib was administered under fasted conditions, either 1 hour (hr) before or 2 hours (hrs) after a meal with approximately 200 mL of water with an interval of 12 hours. Trametinib was administered under fasted conditions, either 1 hr before or 2 hrs after a meal with approximately 200 mL of water. Subjects took their dose of Trametinib concurrently with the morning dose of Dabrafenib. A treatment cycle was 28 days in duration. Subjects continued treatment until an unacceptable toxicity, disease progression, or death occurs.
88951313|NCT01968213|Experimental|Rucaparib|Oral tablets administered twice daily with 8 oz (240 mL) of water on an empty stomach or with food; 28-day cycles of treatment. Doses should be taken as close to 12 hours apart as possible, preferably at the same times every day. Tablets should be swallowed whole.
88951314|NCT01968213|Placebo Comparator|Placebo|Oral tablets administered twice daily with 8 oz (240 mL) of water on an empty stomach or with food; 28-day cycles of treatment. Doses should be taken as close to 12 hours apart as possible, preferably at the same times every day. Tablets should be swallowed whole.
88951315|NCT01809704||Normal|Normal results from clinical exam and free of ocular pathology.
88951316|NCT01809704||Glaucoma|Clinical exam results consistent with glaucoma and visual field defects consistent with glaucoma.
89480360|NCT04088708|Active Comparator|Attention Control|The non-aerobic exercise attention control condition will control for the effects of attention with flexibility/toning activities.
89480361|NCT04070976|Active Comparator|Standard treatment|Cisplatin 40mg/m2 weekly and concomitant pelvic radiotherapy (45 Gray/25 fractions) followed by brachytherapy 28Gray at point A.
89480362|NCT04070976|Experimental|Experimental treatment|Cisplatin 40mg/m2 weekly and hypofractionated concomitant external radiotherapy (37,50 Gray/15 fractions) followed by brachytherapy 28 Gray at point A.
89480363|NCT04070573|Active Comparator|81mg ASA|Patients in Arm 1, will be instructed to take one tablet of 81mg aspirin per day.
89480364|NCT04070573|Active Comparator|162mg ASA|Patients in Arm 2, will be instructed to take two tablets simultaneously orally once per day.
89480365|NCT04067882||Cervix cancer|Women older than 18 years with histopathological diagnosis of cervical cancer clinical stage I2-IVA, candidates to receive standard treatment with chemotherapy followed by brachytherapy.
89480366|NCT04066491|Experimental|Safety Run-In Part: M7824 + Gemcitabine + Cisplatin|
89480367|NCT04066491|Experimental|Double-blinded Part: M7824 + Gemcitabine + Cisplatin|
89480368|NCT04066491|Placebo Comparator|Double-blinded Part: Placebo + Gemcitabine + Cisplatin|
89480369|NCT04066309|Experimental|Abutment removal|At the time of surgery, customizable healing abutments will be placed on implants. These will be replaced by Pro PEEK Abutments 21 days later to placement of temporary prostheses (loading). The final abutments (Titanium Bases) and final prostheses will be inserted 2 months after loading.
89480370|NCT04066309|Experimental|Final abutment|The final abutments (Titanium Bases) will be placed at the time of the implant placement surgery and will stay at mouth during all period of the study. Temporary and final prosthesis will be placed on Titanium Bases.
89480371|NCT04066049|Active Comparator|Treatment|Participants in the Treatment group will receive a hybrid therapist-implemented and caregiver-implemented intervention be compared to a BAU control group. Caregivers and children will be assessed at baseline, after the intervention, 6 months after intervention, and 12 months after intervention, and will receive a $50 gift card for participating in each assessment time point, $75 for completing all four assessments, and books and play/activity materials with target word lists in Spanish.
89480372|NCT04066049|No Intervention|Control|Participants in the BAU group will be offered 10 caregiver support sessions after completing the 12-month follow-up. These home-based sessions will emphasize shared book reading, modeling vocabulary for school readiness in play and routines, and include general information for families about options for public school language related services. Each session will last about 30 minutes and be conducted by a trained staff member. Caregivers and children will be assessed at baseline, after the intervention, 6 months after intervention, and 12 months after intervention, and will receive a $50 gift card for participating in each assessment time point, $75 for completing all four assessments, and books and play/activity materials with target word lists in Spanish.
89480373|NCT04064827|Experimental|Participants Receiving Paricalcitol|Participants will be administered paricalcitol three times a week (TIW) but no more frequently than every other day for 24 weeks
89480374|NCT04064008||Primary Total Hip Arthroplasty|Single study group from a single site previously implanted with the PROFEMUR® Z Revision Femoral Stem
89480375|NCT04062266|Experimental|Treatment (azacytidine, venetoclax)|Patients receive azacitidine SC or IV over 1 hour daily on days 1-5, and venetoclax PO daily on days 1-14. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
89480376|NCT04045665|Active Comparator|Antiplatelet Therapy|Antiplatelet-only strategy
89480377|NCT04045665|Active Comparator|Oral Anticoagulant|OAC-based strategy
89480378|NCT04044365||1/Project 1 Child/caregiver-proxy|Children age 5-7 with cGVHD and their caregiver, n=20 child/parent dyads
89480379|NCT04044365||2/Project 1 Child/caregiver-proxy|Children age 8-12 with cGVHD and their caregiver, n=35 child/parent pairs
89480380|NCT04044365||3/Project 1 Child/caregiver-proxy|Children age 13-17 with cGVHD and their caregiver, n=35 child/parent pairs
89480381|NCT04044365||4/Project 2 Child/caregiver-proxy|Children age 5-7 with cGVHD and their caregiver, n=40 child/parent pairs
89480382|NCT04044365||5/Project 2 Child/caregiver-proxy|Children age 8-12 with cGVHD and their caregiver, n=40 child/parent pairs
89480383|NCT04044365||6/Project 2 Child/caregiver-proxy|Children age 13-17 with cGVHD and their caregiver, n=40 child/parent pairs
89480384|NCT04034459|Active Comparator|FOLFOXIRI plus bevacizumab|"One cycle (cycle duration 14 days) consists of:~Irinotecan 150 mg/m² iv, 30 - 90 min. day 1~Folinic acid (racemic) 400 mg/m² iv, 120 min. day 1~Oxaliplatin 85mg/m² day 1~5-FU 3000 mg/m² iv over 48 h days 1-2~Bevacizumab 5 mg/kg BW iv over 30 to 90* min day 1 *1st administration 90 min.; in case of good tolerability, second administration 60 min.; further administrations 30 min.~Repeat administration every 2 weeks for a maximum of 12 cycles~Dose adaptation at the treating physician's discretion.~Switch to the recommended maintenance treatment with fluoropyrimidine and bevacizumab after the 8th cycle (following 2nd staging after baseline) is possible at the treating physician's discretion if response according to RECIST 1.1 (CR or PR) has been achieved."
89480385|NCT04034459|Experimental|FOLFOXIRI plus cetuximab|"One cycle (cycle duration 14 days) consists of:~Irinotecan 150 mg/m² iv, 30 - 90 min. day 1~Folinic acid (racemic) 400 mg/m² iv, 120 min. day 1~Oxaliplatin 85mg/m² day 1~5-FU 3000 mg/m² iv over 48 h days 1-2~Cetuximab initially 400 mg/m² with infusion rate of ≤5 mg/min., subsequently 250 mg/m² iv with infusion rate of ≤10 mg/min. days 1+8~Repeat administration every two weeks up to a maximum of 12 cycles.~Dose adaptation at the treating physician's discretion.~Switch to the recommended maintenance treatment with 5-FU and cetuximab or irinotecan and cetuximab after the 8th cycle (following 2nd staging after baseline) is possible at the treating physician's discretion if response according to RECIST 1.1 (CR or PR) has been achieved."
89480386|NCT04028401|Experimental|5 % benzoyl peroxide topical treatment|Application of 5% benzoyl peroxide
89480387|NCT04028401|No Intervention|No topical treatment|No intervention
89480388|NCT04023552|Experimental|TQJ230|TQJ230 80 mg injected monthly administered subcutaneously
89480389|NCT04023552|Placebo Comparator|Placebo|Monthly subcutaneous injections.
89480390|NCT04023227|Experimental|Sacubitril/valsartan|"Sacubitril/valsartan 200 mg b.i.d.~Following randomization, patients will receive sacubitril/valsartan in titrated doses from level 1 up to level 3 (50, 100 and 200 mg twice daily).~Participants taking ACEIs who are randomized to sacubitril/valsartan will do a 36-hour ACEI washout before they start taking the study drug~Sacubitril/valsartan in dose levels of 50 mg, 100 mg, and 200 mg are equivalent to sacubitril/valsartan 24/26 mg, 49/51 mg and 97/103 mg, respectively"
89480391|NCT04023227|Active Comparator|Enalapril|"Enalapril 10 mg b.i.d.~Following randomization, patients will receive the enalapril in titrated doses from level 1 up to level 3 (2.5, 5 and 10 mg twice daily)."
89480392|NCT04011800|Active Comparator|Catheter ablation|Patients will undergo catheter ablation of atrial fibrillation.
89480393|NCT04011800|Experimental|Risk factor modification|Patiemt will undergo risk factor intervention and antiarrhythmic drugs
89203035|NCT04014465||patients with radiotherapy|The patients of lung cancer or esophagueal cancer, who received definitvie RT, should included in this Cohort.
89480394|NCT04007692||Simple interrupted suture group|Participants will have a simple interrupted suturing pattern, determined by care provider, at the time of esophageal stent placement for esophageal stent fixation as part of standard care and will have an endoscopy at 3-4 weeks after the stent placement as part of a routine follow-up.
89480395|NCT04007692||Triangular suture group|Participants will have a triangular suturing pattern, determined by care provider, at the time of esophageal stent placement for esophageal stent fixation as part of standard care and will have an endoscopy at 3-4 weeks after the stent placement as part of a routine follow-up.
89480396|NCT03999749|Experimental|Induction Phase, Maintenance Phase|"Induction Phase: 2 induction treatment cycles of 42 days (6 weeks) each, of which the first cycle of 6 weeks is the DLT period.~Maintenance Phase: Consists of treatment cycles of 84 days (12 weeks) each, and may extend up to 1 year."
89480397|NCT03988543|No Intervention|Usual Care|Patients will receive current standard care of EHR-integrated symptom monitoring.
89480398|NCT03988543|Experimental|Enhanced Care|Patient will receive current standard care of EHR-integrated symptom monitoring, plus patient self-management intervention.
89480399|NCT03987399|Experimental|Tailored educational intervention|The intervention will be based on previous research and results from baseline (T1). The intervention will be a one-day educational day and includes lectures and workshops with main focus on the lowest competence in pediatric postoperative pain management. Healthcare providers at the included surgical wards will be invited to participate on this educational day. As a supplement, there will be provided clinical supervision in pediatric postoperative pain management and reminders (such as lectures and posters) over a period of six months after educational day.
89480400|NCT03985852|Active Comparator|Patient Directed Standard of Care|Patients receive pre-test genetic counseling and, if relevant, post-test counseling for a negative result from an automated genetics education assistant.
89480401|NCT03985852|No Intervention|Enhanced Standard of Care|Patients receive standard counseling from a genetic counselor.
89480402|NCT03982394||Participants treated with Risankizumab|Treatment decision independently made of study enrollment
89480403|NCT03982394||Participants treated with other approved biological therapies|Treatment decision independently made of study enrollment
89480404|NCT03981185|Experimental|Accelerated theta burst treatment|All participants will receive theta-burst TMS.
89480405|NCT03978637|Experimental|Itacitinib 300 mg|Phase 1: Itacitinib 300 mg twice daily. There can be required dose adjustments in the protocol for concurrent CYP3A administration.
89480406|NCT03978637|Experimental|Itacitinib 400 mg|Phase 1: Itacitinib 400 mg once daily. There can be required dose adjustments in the protocol for concurrent CYP3A administration.
88951317|NCT01809704||Retina|Clinical exam results consistent with retina pathology
89480407|NCT03978637|Experimental|Itacitinib 600 mg|Phase 1: Itacitinib 600 mg once daily. There can be required dose adjustments in the protocol for concurrent CYP3A administration
89480408|NCT03978637|Experimental|Itacitinib|Phase 2: Itacitinib administered orally at the recommended dose from Phase 1.
89480409|NCT03956043||Patients with suspected sepsis in Emergency Department|Patients with suspected sepsis treated by the sepsis emergency team or the medical emergency team in the Emergency Department of Oslo University Hospital Oslo are included prospectively.
89480410|NCT03945513|Experimental|LPRI424|Dienogest 2 mg / ethinyl estradiol 0.02 mg tablet orally once daily for 24 days followed by 4 placebo tablets for a 28 day cycle, for 13 cycles
89480411|NCT03941262|Experimental|Cohort 1 - Low dose SNK01|SNK01 (low dose) administered once a week for five weeks.
89480412|NCT03941262|Experimental|Cohort 2 - Medium dose SNK01|SNK01 (medium dose) administered once a week for five weeks.
89480413|NCT03941262|Experimental|Cohort 3 - High dose SNK01|SNK01 (high dose) administered once a week for five weeks.
89480414|NCT03941262|Experimental|Cohort 4 - SNK01 with avelumab|SNK01 (high dose) administered in combination with avelumab once every two weeks (14-day cycle) for five cycles.
89480415|NCT03941262|Experimental|Cohort 4 - SNK01 with pembrolizumab|SNK01 (high dose) administered in combination with pembrolizumab once every three weeks (21-day cycle) for five cycles.
89480416|NCT03941080||GIMICC|Adult patients with newly diagnosed metastasized or irresectable CRC with an indication for standard palliative systemic anti-tumor treatment.
89480417|NCT03932643|Experimental|ONC201 treatment|A 3+3 dose escalation design will be followed. Given the safety profile in prior trials, A dose of 250 mg weekly will be the starting dose. The first 12-15 patients are expected to receive escalating doses of ONC 201, the remaining patients will go on the expansion cohort.
88951318|NCT01711333|Experimental|Pletaal SR capsule|
89203036|NCT00677534|Experimental|1|Cholecalciferol (Vitamin D)
89203037|NCT00940173|Other|Group 1|Dose Group 1 (Receiving a dose of 10,000 IEQ/kg of DIABECELL(R))
89480418|NCT03927053||HIV infected youth who use marijuana only|
89480419|NCT03927053||HIV infected youth who use tobacco only|
89480420|NCT03927053||HIV infected youth who use tobacco and marijuana|
89480421|NCT03927053||HIV infected youth with no substance use|
89480422|NCT03926091|Experimental|4 cycles of TC adjuvant chemotherapy|4 cycles of TC (Docetaxel 75 mg/m^2 ivgtt d1+Cyclophosphamide 600 mg/m^2 iv d1, 21 days per cycle).
89480423|NCT03926091|Active Comparator|6 cycles of TC adjuvant chemotherapy|6 cycles of TC (Docetaxel 75 mg/m^2 ivgtt d1+Cyclophosphamide 600 mg/m^2 iv d1, 21 days per cycle).
89480424|NCT03918421||Immunogloblin M-anti myelin-associated-glycoprotein neuropathy|Patient group (25 subjects) presenting with an Immunogloblin M-anti myelin-associated-glycoprotein peripheral neuropathy
89480425|NCT03913559|Experimental|Inotuzumab ozogamicin|"Experimental:Inotuzumab Ozogamicin (InO) Patients with B cell acute lymphoblastic leukemia (B-ALL) that is showing early signs of relapsing (coming back) or is not responding to treatment (refractory).~Interventions:methotrexate, hydrocortisone and cytarabine into the central nervous system (called triple intrathecal chemotherapy or IT chemotherapy) during this study.~Premedication: diphenhydramine, acetaminophen and methylprednisolone"
88951319|NCT01656486|Experimental|Stereotactic Radiation|Treatment of pancreas with 30 Gy of radiation given in 5 fractions of 6 Gy each with stereotactic radiosurgery.
88951320|NCT01631318|Experimental|Diagnostic (3D contrast-enhanced ultrasound imaging)|Patients undergo 3D dynamic contrast-enhanced ultrasound imaging before initiation of chemotherapy and at 2 weeks.
88951321|NCT01498458|Experimental|pazopanib plus capecitabine|
89480426|NCT03910218|Experimental|NCM4HIV|Participant will receive NCM4HIV intervention which includes Personalized HIV prevention education, behavior goal-setting,behavioral self-monitoring,Pre exposure prophylaxis (PrEP) eligibility screening,PrEP/non occupational post exposure prophylaxis(nPEP)services (labs, medication), healthcare planning/coordination, Motivational Interviewing (MI) counseling approach, assisting with cognitive appraisals (clarifying misconceptions),promoting health seeking and coping behaviors that incorporate the situational, personal, social, and resource needs affecting health
89480427|NCT03910218|Placebo Comparator|Usual care|Participants will receive the usual care which includes Housing, food, and clothing needs,health assessment, basic healthcare, limited anticipatory guidance, mental health counseling,substance use treatment referrals,PrEP/nPEP referrals
89480428|NCT03909035|Experimental|Medication therapy management|Medication therapy management by the community pharmacist in collaboration with the General Practitioners to the Optimizations of Prescriptions
89203038|NCT00940173|Other|Group 2|Dose Group 2 (Receiving a dose of 15,000 IEQ/kg of DIABECELL(R))
89480429|NCT03909035|No Intervention|Usual pharmaceutical care|Usual pharmaceutical care provided by the community pharmacist (first level pharmaceutical analysis of the prescriptions)
89480430|NCT03900897|Experimental|Prospective|Detailed interventions and outcome measures refer to the prospective, experimental study arm. The prospective arm is active but not enrolling.
88951322|NCT01427712||LipaCreon|"In general, pancrelipase 600 mg/dose was orally administered immediately after a meal, 3 times a day.~Also, the dose was adjusted appropriately according to the patient's condition."
89203039|NCT00940173|Other|Group 3|Dose Group 3 (Receiving a dose of 20,000 IEQ/kg of DIABECELL(R))
89203040|NCT00940173|Other|Group 4|Dose Group 4 (Receiving a dose of 5,000 IEQ/kg of DIABECELL(R))
89203041|NCT02559284|Experimental|A - Experimental|Treatment Arm: 100 patients using Respimer® NetiFlow® solution as standard treatment for healing of nasal surgery wounds following an endoscopic ethmoidectomy as a postoperative care after ethmoid sinus surgery
89480431|NCT03900897|Other|Retrospective|Study identification, sponsor/collaborators, oversight, purpose, indications, and primary endpoints for the retrospective, observational study arm align with the prospective study arm. The retrospective arm will be enrolling by invitation for chart review of subjects implanted with a MED-EL cochlear implant under 6 years of age between January 2005 and October 2020. The specific devices and outcome measures will vary slightly for retrospective subjects, based on what was clinically available and used at the time of implantation.
89480432|NCT03899376|Active Comparator|Conventional radiotherapy|patients with gynecological cancer treated with adjuvant conventional radiotherapy
89480433|NCT03899376|Experimental|Volumetric modulated arc therapy|Patients with gynecological cancer treated with adjuvant VMAT radiotherapy
89480434|NCT03892187|Experimental|Intervention Group|Participants are prescribed a walking prescription based on their baseline daily step count. During the interim between the day of consultation until the day of surgery, a study staff member will make weekly calls to each participant. Participants will also log all of their physical activities including the date, activity type, and number of minutes.
89480435|NCT03892187|No Intervention|Control Group|Participants receive usual care prior to surgery. Participants will also log all of their physical activities including the date, activity type, and number of minutes.
89480436|NCT03892187|No Intervention|Observation Group|Participants who are not frail will receive usual care prior to surgery and charts will be reviewed for outcomes following surgery.
89480437|NCT03883828|Experimental|Treatment Arm|The purpose of this study is to determine whether bacterial decolonization of the nares and skin prior to treatment with radiotherapy (RT) for patients with cancers of the head and neck or breast, can prevent high-grade radiation dermatitis (RD) and improve quality of life. This study is being conducted because prior studies from this research group have found bacterial colonization in the nose prior to initiation of RT to be associated with an increased risk of high-grade RD. Patients in the treatment arm will receive pretreatment with mupirocin ointment to the nares and chlorhexidine wash to the body while patients in the control arm will receive standard of care treatment. Bacterial cultures will be taken from the nares and skin, and participants will also complete a quality of life questionnaire before and after RT.
89480438|NCT03883828|No Intervention|Control|Patients in the control arm will be treated according to standard of care without any radiation dermatitis prophylaxis.
89480439|NCT03860272|Experimental|3-Week Monotherapy|3+3 Dose escalation: botensilimab, every 3 weeks, starting at dose level 0.1 milligrams/kilogram (mg/kg) up to 4 mg/kg, administered intravenously (IV) for up to 2 years.
89480440|NCT03860272|Experimental|6-Week Monotherapy|3+3 Dose escalation: botensilimab, every 6 weeks, starting at dose level 1 mg/kg up to 4 mg/kg, administered IV for up to 2 years.
89480441|NCT03860272|Experimental|6-Week Combination Therapy|3+3 Dose escalation: balstilimab, every 2 weeks, at dose level 3 mg/kg in combination with botensilimab, every 6 weeks, starting at dose level 0.1 mg/kg up to 4 mg/kg, administered IV for up to 2 years. Participants enrolled at sites in the United Kingdom (UK) may have the option for extended treatment. An additional cohort will investigate balstilimab, every 3 weeks, at 450 mg in combination with botensilimab every 6 weeks, at 150 mg, administered IV for up to 2 years.
89480442|NCT03844269|Experimental|AKL-T01|
89480443|NCT03835819|Experimental|IMGN853 + Pembrolizumab|"Pembrolizumab is administered intravenously once every 3 weeks~IMGN853 is administered intravenously once every 3 weeks"
89480444|NCT03832361|Experimental|IMGN853|IMGN853 administered 6 mg/kg adjusted ideal body weight (AIBW) once every three weeks (Q3W)
89480445|NCT03828292|Experimental|Part 1: Belantamab mafodotin Monotherapy|
89480446|NCT03828292|Experimental|Part 2: Arm A: Belantamab mafodotin+Bortezomib/Dexamethasone|
89480447|NCT03828292|Experimental|Part 2: Arm B: Belantamab mafodotin+Pomalidomide/Dexamethasone|
89480448|NCT03825250|No Intervention|Group A: Control|Standard of care
89480449|NCT03825250|Experimental|Group B: Sodium Valproate Treatment|15 mg/kg for 1-2 weeks
89480450|NCT03825250|Experimental|Group C: Sodium Valproate Treatment|15 mg/kg for 4-6 weeks
89480451|NCT03825250|Experimental|Group D: Sodium Valproate Treatment|25 mg/kg for 4-6 weeks
89480452|NCT03805100|Experimental|Xlucane|Xlucane (0.05 mL of 10 mg/mL ranibizumab) in the study eye monthly for 52 weeks.
89480453|NCT03805100|Active Comparator|Lucentis|Lucentis (0.05 mL of 10 mg/mL ranibizumab) in the study eye monthly for 52 weeks.
89480454|NCT03804619|Experimental|Left DLPFC aiTBS stimulation|Participants will receive aiTBS (intermittent theta burst stimulation) to a brain area called the left dorsolateral prefrontal cortex (L-DLPFC). Stimulation intensity will be individualized according to the individual's resting motor threshold.
89480455|NCT03804619|Experimental|ACC aiTBS stimulation|Participants will receive aiTBS (intermittent theta burst stimulation) to a brain area called the anterior cingulate cortex (ACC). Stimulation intensity will be individualized according to the individual's resting motor threshold.
89480456|NCT03803683|Experimental|mLab App Intervention|Youth randomized to the intervention arm (arm 1) will be provided with the mLab App, 2 OraQuick tests (including the package insert), and a box of condoms to take home at baseline. They will receive 2 more OraQuick tests at their 6 month visit. At their baseline appointment, youth will also be sent an email or text with links to mobile-optimized online prevention information, including PrEP and HIV testing information that is found on the CDC website. They will also receive a study information card listing the Columbia University School of Nursing / Lurie Children's study teams' contact information.
89480457|NCT03803683|Active Comparator|Standard of Care HIV Information Control Arm|Youth randomized to the Standard of Care HIV information control arm (arm 2) will receive standard-of-care HIV/STI testing-related risk reduction counseling, a box of condoms, PrEP assessment, and referral information for clinics that provide PrEP during their first visit. Youth randomized to the standard of care will be sent an email with links to mobile-optimized online prevention information, including pre-exposure prophylaxis (PrEP) and HIV testing information that is found on the CDC website.They will also receive a study information card listing the Columbia University School of Nursing / Lurie Children's study teams' contact information.
89537590|NCT00695253|Other|Talent Endoluminal Spring Graft System|Single Arm study of the endoluminal treatment of Abdominal Aortic Aneurysms using the Talent Endoluminal Spring Graft System
89537591|NCT04225923|Experimental|NPC-21 Low dose|NPC-21 (Low dose) will be administered
89537592|NCT04225923|Experimental|NPC-21 High dose|NPC-21 (High dose) will be administered
89480458|NCT03803683|Active Comparator|HIV Home Tests|Youth randomized to the HIV home testing arm (arm 3) will be provided with the 2 OraQuick tests (including the package insert), and a box of condoms to take home at baseline. They will receive 2 more OraQuick tests at the 6 month visit. At their baseline appointment, youth will also be sent an email or text with links to mobile-optimized online prevention information, including PrEP and HIV testing information that is found on the CDC website. They will also receive a study information card listing the Columbia University School of Nursing / Lurie Children's study teams' contact information.
89480459|NCT03799562|Experimental|Pregnenolone|Placebo lead in 14 DAYS, followed by Pregnenolone 50 mg BID x 14 DAYS, followed by Pregnenolone 150 mg BID x 14 DAYS, followed by Pregnenolone 250 mg BID x thereafter for the remainder of the 8-week trial
88951323|NCT01369147|Experimental|Parenteral nutrition energy dose at 0.6 x measured REE|Participants in this study arm will be provided a total daily calorie (kcal) intake at 0.6 x REE for up to 28 days. The dose of parenteral nutrition (PN) will be adjusted taking into account any calories from propofol, clevidipine, dextrose-containing IV fluids surpassing 500 mL/day, and any enteral feedings, to obtain the energy dose that the participant was randomized to receive.
89480460|NCT03799562|Placebo Comparator|Placebo|Same as pregnenolone (active study medication), except placebo dispensed.
89480461|NCT03794999||Benralizumab-exposed group|Pregnant women with asthma exposed to benralizumab anytime during pregnancy or within 8 weeks prior to last menstrual period
89480462|NCT03794999||Asthmatic comparison group|Pregnant women currently treated for asthma not exposed to benralizumab during pregnancy or within 8 weeks prior to last menstrual period
89480463|NCT03794999||Non-asthmatic comparison group|Pregnant women who are not diagnosed with asthma, have not had exposure to a known human teratogen, and have not taken benralizumab during pregnancy.
89480464|NCT03777917|Experimental|Belotero Balance®|
89480465|NCT03777917|No Intervention|No treatment|
89480466|NCT03750539|Active Comparator|Standard Treatment|External Beam pelvic radiation therapy daily dose of 1.8-2 Gray (Gy) per session for 25 sessions to accomplish 45 Gy Chemotherapy ( cisplatin 40mg/m2), intravenous administration of chemotherapy once a week in an hour infusion Type II or type III open radical hysterectomy after 4-6 weeks after completion of external beam radiation
89480467|NCT03750539|Experimental|hypofractionated treatment|External Beam pelvic radiation therapy daily dose of 1.8-2gy per session for 15 sessions to accomplish 37.5 Gy Chemotherapy ( cisplatin 40mg/m2), intravenous administration of chemotherapy once a week in an hour infusion Type II or type III open radical hysterectomy after 4-6 weeks after completion of external beam radiation
89480468|NCT03750487|Experimental|e-screening & brief intervention (e-SBI)|A two-session (20 minutes each) computer-delivered screening and brief motivational intervention targeting alcohol and drug use. Computerized screening is conducted using the ASSIST. Session 1 of the BI includes personalized feedback, readiness to change interventions, and goal setting around substance use. Session 2 will contain motivational content reinforcing engagement in home visiting and information around other challenges mothers may experience including tobacco use, postpartum depression, and intimate partner violence.
89480469|NCT03750487|Sham Comparator|Control|The control group will receive a similar 2-session brief motivational intervention. Session 1 focuses on nutrition and healthy eating, session 2 focuses on exercising while pregnant or in the postpartum period.
89480470|NCT03745118|Other|Monitoring Device|Subjects will be asked to wear up to 4 different noninvasive seizure detection devices including EpiTel EpiLog, Byte Flies Sensor Dots, Empatica E4, Biovotion Everion, GeneActiv
89480471|NCT03735199|Experimental|PCL-TCP scaffold|During the surgery, the PCL-TCP scaffold will be shaped by cutting and shaving with a scalpel so as to fit the extraction socket snugly at the crestal half to two-thirds aspect. A Geistlich Bio-Gide collagen membrane will be placed over the scaffold at the crestal aspect of the socket. The periosteum of the buccal flap will then be incised to allow a tension-free primary closure with 4/0 Vicryl® suture.
89480472|NCT03735199|Active Comparator|Geistlich Bio-Gide collagen membrane|"No space filler will be inserted in the extraction socket but similar to the test group, a Geistlich Bio-Gide collagen membrane will be placed over the crestal aspect of the socket and the periosteum of the buccal flap will be incised to allow a tension-free primary closure with 4/0 Vicryl® suture.~denture overlying the extraction site will be completely relieved."
89537593|NCT04225923|Placebo Comparator|NPC-21 Placebo|Placebo (normal saline) will be administered
88951324|NCT01369147|Active Comparator|Parenteral nutrition energy dose at 1.0 x measured REE|Participants in this study arm will be provided a total daily calorie (kcal) intake at 1.0 x REE for up to 28 days. The dose of PN will be adjusted taking into account any calories from propofol, clevidipine, dextrose-containing IV fluids surpassing 500 mL/day, and any enteral feedings, to obtain the energy dose that the participant was randomized to receive.
88951325|NCT01369147|Experimental|Parenteral nutrition energy dose at 1.3 x measured REE|Participants in this study arm will be provided a total daily calorie (kcal) intake at 1.3 x REE for up to 28 days. The dose of PN will be adjusted taking into account any calories from propofol, clevidipine, dextrose-containing IV fluids surpassing 500 mL/day, and any enteral feedings, to obtain the energy dose that the participant was randomized to receive.
88951326|NCT01197066|Other|Certolizumab Pegol|Single Arm
88951327|NCT01945827||DeltaMaxx treated Patients|
88951328|NCT01945840|Active Comparator|Roux en Y Gastric Bypass|Participants will be those already scheduled to undergo Roux en Y Gastric Bypass Surgery
88951329|NCT01945840|Experimental|Gut hormone infusion|"Infusion of three gut hormones (GLP-1, PYY and oxyntomodulin) subcutaneously for 4 weeks as below:~Combination of GLP-1/OXM/PYY (GOP)~Single GLP-1~Single OXM~Single PYY~Combination of GLP-1 and OXM~Combination of GLP-1 and PYY~Combination of OXM and PYY"
88951330|NCT01945840|Placebo Comparator|Placebo infusion|Saline infusion given subcutaneously for 4 weeks.
88951331|NCT01945840|Active Comparator|Very low calorie diet|Participants will be asked to follow a very low calorie diet for 4 weeks.
88951332|NCT01945853|Experimental|7 Tesla MRI|7T MRI will be done on ALS patients at baseline and at 6 month intervals.
88951333|NCT01945879|Experimental|GFFC + LMWH|gemcitabine/ 5-flourouracil/folinic acid/ cisplatin as chemotherapeutic treatment plus enoxaparine as experimental addition
89023581|NCT05118932|Experimental|Mindful Movement Intervention|"The Mindful Movement Intervention (MMI) targets improved attentional, behavioral and emotional regulation through engagement of the motor system and mindful practice in school-age children. For this project, children will participate in the MMI twice a week for 45 minutes a session for the duration of the academic year. The intervention will be held during school hours to make it more accessible to all students and require fewer additional resources.~Briefly, there are five components that make-up the Mindful Movement Intervention: Biomechanical Warm-ups, Yoga postures, a modified Tai Chi sequence, Imaginative Play, and Reflection.~One goal of this intervention is to help children to develop the skills needed to cope with naturally occurring changes and to adapt to their environment in a mindful, non-reactive manner. In this context, students are learning to control and manage their attention, behavior and emotion through implicit procedural learning."
89480473|NCT03731585|Experimental|Group I (psychological intervention)|Patients participate in 5 psychological sessions and complete training on mindfulness, compassion, emotional processing, social support, generating positive emotions, and proactive coping strategies once a week for up to 5 weeks. Patients also complete questionnaires over 35 minutes and participate in video-based group sessions weekly for 5 weeks.
89480474|NCT03731585|Experimental|Group II (educational intervention)|Patients participate in 5 information sessions and receive education on lung cancer, symptom management, communication, and practicing self-care once a week for up to 5 weeks. Patients also complete questionnaires and participate in group sessions as in group I.
89480475|NCT03715504|Experimental|Single Arm TP-3654|TP-3654 by oral administration
89480476|NCT03709784||Cohort 1|This is a prospective, longitudinal, multi-center, observational study designed to evaluate the safety, tolerability, and effectiveness of SPINRAZA® (nusinersen) in ambulatory and non-ambulatory adult patients with SMA. Subjects with SMA II/III that are 18 years to 70 years of age who are planning to initiate treatment with SPINRAZA® (nusinersen) as part of their clinical care plan will be enrolled in this study. This study does not provide SPINRAZA® (nusinersen) or cover costs associated with standard clinical care.These patients will be treated by their respective physicians according to standard clinical practice. Study visits, some of which including standardized assessments of strength and function, will occur at baseline, day 15 after treatment initiation, day 30, day 60, and then 4-month intervals through month 30.
89480477|NCT03709784||Cohort 2|The cohort 2 is a one time survey to gain a better understanding of this adult population and their treatment preferences.
89480478|NCT03706495|Experimental|The Group I|The Group I Postural exercise will receive postural exercise for 60 min/day 2 times/week for 8 weeks.
89480479|NCT03706495|Experimental|The Group II|The Schroth method three-dimensional exercise therapy program consists of individual exercise programs combined with correction patterns. It is based on sensorimotor and kinesthetic principles. Goals of this exercise are to facilitate the correction of the asymmetric posture and to maintain the correct posture in the daily activities of the patient. The Group II receive Schroth method based on three-dimensional exercise therapy program for 60 min/day 2 times/week for 8 weeks.
89480480|NCT03698851|Experimental|Test Group|Guidor® and Guidor easy-graft® CRYSTAL Regeneration of the lesion will be performed with a synthetic membrane (Guidor®) with either Guidor easy-graft® CRYSTAL (Test).
89480481|NCT03698851|Active Comparator|Control Group (C)|Guidor® and Guidor easy-graft® CLASSIC Regeneration of the lesion will be performed with a synthetic membrane (Guidor®) with either Guidor easy-graft® CLASSIC (Test).
89480482|NCT03697850|Experimental|atezolizumab|Anti-PD-L1 immunotherapy: atezolizumab (1200 mg) administered IV over 1 h every 3 weeks for 12 months (18 injections). Beginning 30 days (±5 days) after chemo-radiotherapy.
89480483|NCT03696888|Experimental|Telecoach|A skills-training web-app teaching skills for reducing problematic alcohol use.
89480484|NCT03696888|Active Comparator|TeleCoach control|A web-app giving information on health-related consequences of alcohol consumption.
89480485|NCT03696043|Active Comparator|EVD placement|Catheter placement is most commonly performed via a freehand approach using external anatomical landmarks to help identify the location of the lateral ventricle within the brain without the aid of imaging. Proper identification of the ventricles on pre-procedure imaging, surgeon skill, and estimation of pathologic perturbations to the normal location of the ventricles all factor into the success of catheter placement. Multiple passes are often required. The accuracy rate from the freehand technique has been reported to range from 40 to 98 percent.
89480486|NCT03696043|Experimental|Axium Stealth Image Guidance|The novelty of this study is to investigate whether using image guidance technology can improve EVD catheter placement. Image guidance is used very commonly for EVD and shunt placement in the operating room with excellent accuracy and precision. We hypothesize that using this same workflow at the bedside will improve accuracy; decrease the number of passes needed for a successful placement, decrease the number of post-placement hemorrhagic events, and help improve the effectiveness of the catheter as well as patient outcomes.
89480487|NCT03693014|Experimental|Stereotactic Body Radiotherapy|Image Guided, Stereotactic Body Radiotherapy (27 Gy over 3 fractions) to 1-3 lesions. Treatment with the checkpoint inhibitor will continue until progression at the discretion of the treating physician or unacceptable toxicity.
89480488|NCT03643991|Experimental|Weighted Blanket Cohort|Subjects will receive weighted blanket for three nights with monitoring by nurse. Weight of blanket is determined by weight of the patient (10% of patients body weight).
89480489|NCT03643991|No Intervention|Control Cohort|Subjects will receive treatment as usual while inpatient, no blanket.
89480490|NCT03614793|Active Comparator|Cooled Radiofrequency Ablation Procedure|
89480491|NCT03614793|Active Comparator|Facet Joint Inject Procedure|
89480492|NCT03602235|Experimental|Low dose melphalan + high dose ascorbate acid (HDAA)|"Patients will receive a test dose of 15g of HDAA prior to starting treatment dose. This will be mainly to rule out allergic reactions.~HDAA + Melphalan:~HDAA on day 1 and day 4 in combination with melphalan 12.5 mg/m2, followed by 2 additional doses of HDAA on day 2 and day 5.~A 3 + 3 cohort method will be used for this study. After successfully completing the test dose, subjects will receive 50gms, 75gms and 100gms of ascorbate per infusion in 3 different cohorts. Dose modifications are not made for weight or body surface area."
89480493|NCT03598530||Tibial Shaft Fracture|Patients sustaining a tibial shaft fracture (AO/OTA type 42) that requires surgery
89480494|NCT03594123|Experimental|Prior Brexpiprazole|Participants who received brexpiprazole in a previous double-blind phase 3 study (Trial 331-14-213 {NCT03548584}), received the same dose of brexpiprazole [2 or 3 milligrams (mg)], once daily (QD), orally, as they received during the previous study, for up to 12 weeks with dose adjustment.
89480495|NCT03594123|Experimental|Prior Placebo|Participants who received placebo in a previous double-blind phase 3 study (Trial 331-14-213 {NCT03548584}), received brexpiprazole following a titration schedule, to gradually increase their dose from 0.5 mg QD, in the starting to 2 or 3 mg QD, orally, for up to 12 weeks with dose adjustment.
89480496|NCT03583359|Experimental|Treatment with Radiesse (+)|
89480497|NCT03583359|Other|Control/Delayed Treatment with Radiesse (+)|
89480498|NCT03575013|Experimental|Avelumab and Docetaxel|"Induction phase:~Avelumab (10 mg/kg) + Docetaxel (75 mg/m2) every 3 weeks for 6 cycles~Maintenance phase:~Avelumab (10 mg/kg) every 2 weeks until disease progression or toxicity"
89480499|NCT03554356|Experimental|Cryoballoon Focal Ablation System (CbFAS) Treatment|Subjects undergoing CbFAS treatment as part of their clinical care for their condition.
89480500|NCT03548428|Experimental|A|SBRT + Atezolizumab
89480501|NCT03548428|Active Comparator|B|SBRT
89480502|NCT03537651|Experimental|TEZ/IVA|TEZ 50 mg once daily (qd)/IVA 75 mg every 12 hours (q12h) or TEZ 100 mg qd/IVA 150 mg q12h based on body weight for participants aged 6 through 11 years at enrollment and TEZ 100 mg qd/IVA 150 mg q12h for participants aged >=12 years at enrollment. Doses were adjusted upward for changes in body weight and/or age.
89480503|NCT03506438|Experimental|ICU physician mobile app group|Clinicians and family members will receive access to versions of the needs-focused mobile app that differ in content.
89480504|NCT03506438|Placebo Comparator|ICU physician usual care group|Usual ICU care in an ICU as per the standards of the ICU attending
89480505|NCT03503786|Active Comparator|Chemotherapy|Carboplatin AUC 5+Paclitaxel 175 mg/m2 q 21days for 6-8 cycles and Avelumab
89480506|NCT03503786|Experimental|Chemotherapy and avelumab|Carboplatin AUC 5+ Paclitaxel 175 mg/ m2+Avelumab 10 mg/kg q 21days for 6 -8 cycles + Avelumab 10 mg/kg every 14 days until disease progression or unacceptable toxicity
89480507|NCT03493542|Experimental|Chinese Girls Aged 9 to 19 Years|Participants will receive V501 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6
89480508|NCT03493542|Active Comparator|Chinese Young Women Aged 20 to 26 Years|Participants will receive V501 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6
89480509|NCT03484130||High-Risk Normotensives|These high-risk normotensives are considered to be enriched for subclinical autonomous aldosterone secretion and have a high risk for developing incident hypertension
89480510|NCT03473015|Experimental|PICSO arm|STEMI patients with elevated pre-stenting index of microcirculatory resistance (IMR) greater than 40 units treated with pressure-controlled intermittent coronary sinus occlusion (PICSO)
89480511|NCT03473015|No Intervention|Control|Matched historical cohort of STEMI patients with elevated IMR greater than 40, not treated with PICSO
89480512|NCT03472807|Other|Cancer patient|"Collection of blood sample or saliva~Collection of a tumor sample taken before the participation of the patient in study~Collection of blood sample if tumor sample is not available"
89480513|NCT03472807|Other|Parent of cancer patient|-Collection of blood sample or saliva
89480514|NCT03459625|Experimental|Mindfulness-Based Stress Reduction (MSBR)|MSBR (Kabat-Zinn, 1990), 8-week group-based intervention where participants learn mindfulness skills to help alleviate parenting stress among parents of young children with Autism Spectrum Disorder.
89480515|NCT03459625|Active Comparator|Psychoeducational Support Group (PE)|PE is a 8-week group-based intervention to provide psychosocial support and resources for parents of young children with Autism Spectrum Disorder.
89480516|NCT03431064||Surgical patients less than 18 years old|Patients less than 18 years old having surgery with general anesthesia at Boston Children's Hospital
89480517|NCT03429218|Experimental|Single Arm TP-0184|Weekly dose of TP-0184 by oral administration
89480518|NCT03426683|Experimental|Standardized IMT|The patients will receive Standardized Intestinal Microbiota Transplantation(Standardized IMT). The IMT was given to mid-gut by nose-jejunum nutrition tube or capsules. It was given three times a week.
89480519|NCT03426683|No Intervention|traditional drugs|The patients will receive traditional medicine treatment as usual.
89480520|NCT03425643|Experimental|NAC + Neoadjuvant/Adjuvant Pembrolizumab|"Neoadjuvant: Prior to surgery, participants receive up to 4 cycles (cycle length: 3 weeks) of pembrolizumab [200 mg, intravenous (IV); given on cycle day 1] in combination with platinum doublet neoadjuvant chemotherapy (NAC), consisting of cisplatin [75 mg/m^2, IV; given on cycle day 1] and either Gemcitabine [1000 mg/m^2, IV; given on cycle days 1 and 8] or Pemetrexed [500 mg/m^2, IV; given on cycle day 1].~Adjuvant: 4-12 weeks following surgery, participants receive 13 cycles (cycle length: 3 weeks) of pembrolizumab [200 mg, IV; given on cycle day 1]."
88951334|NCT01945892||Irvine Gass Syndrome|"Patients older than 18 years who develop macula edema secondary to cataract surgery.~Group may receive intravitreal Ozurdex medication in case of persistent macular edema."
89480521|NCT03425643|Placebo Comparator|NAC + Neoadjuvant/Adjuvant Placebo|"Neoadjuvant: Prior to surgery, participants receive up to 4 cycles (cycle length: 3 weeks) of placebo [normal saline, IV; given on cycle day 1] in combination with platinum doublet NAC, consisting of cisplatin [75 mg/m^2, IV; given on cycle day 1] and either Gemcitabine [1000 mg/m^2, IV; given on cycle days 1 and 8] or Pemetrexed [500 mg/m^2, IV; given on cycle day 1].~Adjuvant: 4-12 weeks following surgery, participants receive 13 cycles (cycle length: 3 weeks) of placebo [normal saline, IV; given on cycle day 1]."
89480522|NCT03416816|Experimental|DSP-0337|In Part 1 - Up to six dose levels will be investigated in dose-escalating cohorts to identify a maximum tolerated dose (MTD). An additional subset of patients will be treated to assess the effect of food intake on the PK of DSP-0337 administration at the MTD level. Once the recommended Phase 2 dose (RP2D) has been established, patients will be treated with the RP2D to explore preliminary antitumor activity and safety profile.
89480523|NCT03400176|Experimental|Dose Escalation|Increasing doses of VAY736 in combination with a fixed dose of ibrutinib.
89480524|NCT03400176|Experimental|Dose expansion|Evaluation of the MTD/RD of the combination of VAY736 and ibrutinib that was identified in dose escalation.
89480525|NCT03365453|Experimental|frailty evaluation|all consecutive patients admitted to hospital for valvular disorders more than 69 years will be evaluated with several frailty and comorbidities scores.
89480526|NCT03354390|Experimental|1|This is a single-arm, phase 1 trial of HERV-E TCR transduced CD8+/CD34+ T cells in HLA-A*11:01 positive patients with metastatic ccRCC. The study is planned based on a Phase 1 3+3 dose escalation design. The maximum tolerated dose (MTD) is defined as the highest dose at which 0 or 1 patient in six has experienced a dose limiting toxicity (DLT).
89480527|NCT03350906|Experimental|n3-PUFA|Participants will be instructed to swallow 2 Docosahexaenoic acid (DHA)/EPA soft gels twice per day with meals (morning and evening) for a total of 4 soft gels per day.
89480528|NCT03350906|Placebo Comparator|Placebo|Participants will be instructed to swallow 2 placebo soft gels twice per day with meals (morning and evening) for a total of 4 soft gels per day.
89480529|NCT03342079|Experimental|Group 1|local anesthetic + placebo
89480530|NCT03342079|Experimental|Group 2|local anesthetic + nitrous oxide
89480531|NCT03342079|Placebo Comparator|Group 3|Placebo + nitrous oxide
89480532|NCT03333356|Experimental|Experimental Arm|adjuvant pelvic radiotherapy consisting of 28 x 1.8 Gy fractions (total dose of 50.4 Gy), 5 days per week, 1 fraction / day (duration of RT is 38 days).
89480533|NCT03333356|No Intervention|Standard Arm|Surveillance
89480534|NCT03332017|Experimental|Arm A|Approximately 140 subjects to receive BGB-3111 and obinutuzumab
89480535|NCT03332017|Experimental|Arm B|Approximately 70 subjects to receive obinutuzumab
89480536|NCT03327961||scaffold|Patients receiving during PCI the implantation of at least one scaffold
89480537|NCT03319628|Experimental|Dose Escalation|"XMT-1536 (upifitamab rilsodotin) treatment is administered in groups of patients who will receive doses that increase over time.~This cohort is closed to enrollment."
89480538|NCT03319628|Experimental|Dose Expansion - Ovarian Cancer|"Once the maximum tolerated dose or recommended Phase 2 dose is achieved in dose escalation, new groups of patients will receive XMT-1536 (upifitamab rilsodotin) at this fixed-dose.~This cohort is closed to enrollment."
89480539|NCT03319628|Experimental|Dose Expansion - NSCLC adenocarcinoma|"Once the maximum tolerated dose or recommended Phase 2 dose is achieved in dose escalation, new groups of patients will receive XMT-1536 (upifitamab rilsodotin) at this fixed-dose.~This cohort is closed to enrollment."
89480540|NCT03319628|Experimental|Pivotal Cohort (UPLIFT)|"Patients with platinum-resistant ovarian cancer will receive XMT-1536 (upifitamab rilsodotin) to further confirm the efficacy.~This cohort is closed to enrollment."
89023582|NCT05118932|Experimental|Mindful Movement Intervention Family Based Component|In this additional component, participants and their families will have access to monthly Mindful Movement activities intended to reinforce concepts discussed in Mindful Movement class and foster familial relationships. The family-based component will include access to lesson plans and accompanying resources (e.g., videos, worksheets, audio tracks) once a month from October through May, that offer strategies to improve awareness of thoughts, emotions, and body. Families will also be expected to track their adherence to the lesson plans and provide feedback via a survey.
89023583|NCT05118932|Experimental|Mindful Movement Intervention Peer to Peer Mentorship Component|In this additional component, participants will have the opportunity to become student instructors and lead younger students in modified instructional classes.
89480541|NCT03319628|Experimental|QTc Sub-Study|"For sites participating in the sub-study, patients with platinum -resistant ovarian cancer will have the option to enroll in this sub-study to evaluate potential changes in the QTc interval following administration of XMT-1536.~This cohort is closed to enrollment."
89480542|NCT03311074|Experimental|Strimvelis treatment receivers|Approximately 15 subjects with ADA-SCID who were previously received Strimvelis will be included in the analysis and a total of 5 blood samples will be collected from each subject at approximately annual interval.
89480543|NCT03277170|Experimental|High-dose Montelukast Oral Granules|30 mg (high-dose) oral montelukast granules mixed in apple sauce will be administered orally immediately after informed consent and assent are obtained.
89480544|NCT03277170|Placebo Comparator|Placebo|Identical placebo mixed in apple sauce will be administered orally immediately after informed consent and assent are obtained.
89480545|NCT03269578||1|Patients with cancer or benign tumors being treated on NCI/DTC studies
89480546|NCT03253744|Experimental|Cohort 1, Level 1, Arm 1: Tumor Irradiation|"Arm 1: Tumor irradiation.~Cohort 1, Level 1, Arm 1 - 40 gray (Gy) to Tumor planning target volume (PTV)~Stereotactic body radiation therapy (SBRT) will be delivered to areas of recurrent prostate cancer identified on imaging and biopsy.~External beam radiation therapy (EBRT): Participants with locally recurrent prostate cancer after treatment with EBRT. These participants cannot have had permanent brachytherapy as part of their treatment."
89480547|NCT03253744|Experimental|Cohort 1, Level 2, Arm 1 - Tumor Irradiation|"Arm 1: Tumor irradiation.~Cohort 1, Level 2, Arm 1 - 42.5 gray (Gy) to Tumor planning target volume (PTV)~Stereotactic body radiation therapy (SBRT) will be delivered to areas of recurrent prostate cancer identified on imaging and biopsy; and a reduced dose will be delivered to the entire prostate.~External beam radiation therapy (EBRT): Participants with locally recurrent prostate cancer after treatment with EBRT. These participants cannot have had permanent brachytherapy as part of their treatment."
89480548|NCT03253744|Experimental|Cohort 2, Level 1, Arm 2 - Prostate and Tumor Irradiation|"Arm 2: Prostate and tumor irradiation~Cohort 2, Level 1, Arm 2 - 30 gray (Gy) PTV to Prostate and 40 Gy to Tumor planning target volume (PTV)~Stereotactic body radiation therapy (SBRT) will be delivered to areas of recurrent prostate cancer identified on imaging and biopsy; and a reduced dose will be delivered to the entire prostate.~Brachytherapy: Participants with locally recurrent prostate cancer after treatment with brachytherapy +/- external beam radiation therapy (EBRT). These participants must have had brachytherapy as part of their treatment."
89480549|NCT03253744|Experimental|Cohort 2, Level 2, Arm 2 - Prostate and Tumor Irradiation|"Arm 2: Prostate and tumor irradiation~Arm 2 - 30 gray (Gy) planning target volume (PTV) to Prostate and 42.5 Gy to Tumor PTV~Stereotactic body radiation therapy (SBRT) will be delivered to areas of recurrent prostate cancer identified on imaging and biopsy; and a reduced dose will be delivered to the entire prostate.~Brachytherapy: Participants with locally recurrent prostate cancer after treatment with brachytherapy +/- external beam radiation therapy (EBRT). These participants must have had brachytherapy as part of their treatment."
89480550|NCT03232736||Healthy Control|Individuals free of cardiovascular disease and not on any medications to treat a cardiovascular-related condition
89480551|NCT03232736||LVAD Group|Individuals with history of advanced heart failure who are supported by left ventricular assist devices
89480552|NCT03232203||Health care providers|A HCP survey instrument of approximately 20 questions will be provided. Survey questions will be based on the STRIMVELIS summary of product characteristics and educational materials
89480553|NCT03232203||Parent/carer|A parent/carer survey instrument of approximately 20 questions will be provided. Survey questions will be based on the STRIMVELIS Patient Information Leaflet and educational materials
89480554|NCT03214601|Experimental|Relay Branch System|Subjects who receive the Relay Branch System for repair which includes those with aneurysmal disease, penetrating atherosclerotic ulcer (PAU), and chronic uncomplicated Type B aortic dissection.
89480555|NCT03200834|Active Comparator|D2 lymph node dissection for right colon cancer|Hemicolectomy for right colon cancer with D2 lymph node dissection
89480556|NCT03200834|Experimental|D3 lymph node dissection for right colon cancer|Hemicolectomy for right colon cancer with D3 lymph node dissection
89480557|NCT03199300||Anthracylines-treated with toxicity|Patients with toxicity during/after treatment with anthracylines.
89480558|NCT03199300||Anthracyclines-treated without toxicity|Patients without toxicity during/after treatment with anthracylines.
89480559|NCT03199300||Trastuzumab-treated with toxicity|Patients with toxicity during/after treatment with trastuzumab.
89480560|NCT03199300||Trastuzumab-treated without toxicity|Patients without toxicity during/after treatment with trastuzumab.
89480561|NCT03199300||Cisplatin-treated with toxicity|Patients with toxicity during/after treatment with cisplatin.
89480562|NCT03199300||Cisplatin-treated without toxicity|Patients without toxicity during/after treatment with cisplatin.
89480563|NCT03199300||Bleomycin-treated with toxicity|Patients with toxicity during/after treatment with bleomycin.
89480564|NCT03199300||Bleomycin-treated without toxicity|Patients without toxicity during/after treatment with bleomycin.
89480565|NCT03180086|Experimental|Breast cancer risk report|An individualized report will inform women of their 5-year breast cancer risk using BCRAT or Tice (when breast density is available from a past mammogram), whichever is higher, and the average 5-year risk for women their age. The report will present 5-year risk as a frequency and in a pictograph and it will describe what experts recommend in terms of mammography screening, breast cancer prevention medications, breast MRIs, and BRCA testing, for women in their 40s based on their risk.
89480566|NCT03171844|Experimental|Skin to skin|Implement of skin to skin
89480567|NCT03134027||Subjects from which PDXs have been generated.|Subjects will be identified from which PDXs have been generated from an already approved IRB protocol.
89480568|NCT03134027||Subjects without an existing PDX|Subjects with prostate cancer amenable to a tumor biopsy.
89023584|NCT05118932|Experimental|Mindful Movement Intervention Community Education Component|In this additional component, participants will have the option to assist with the development of an instructional video that showcases students in the Mindful Movement program demonstrating mindful movement practices such as breathing techniques, yoga poses, and T'ai Chi movements.
89023585|NCT05112627||Observational (biospecimen collection)|Patients undergo blood sample collection at baseline prior to SBRT or PCA, then at 14 days, 3 and 6 months after SBRT or PCA.
89023586|NCT05104723|Experimental|XELJANZ (tofacitinib)|Tofacitinib is self-administered orally at 5 mg twice per day or 11 mg once per day for 3 months.
89480569|NCT03121456|Experimental|18F-FDG PET SCAN|"REALIZATION OF INITIAL 18F-FDG PET SCAN (PRE THERAPEUTIC), THEN BETWEEN CYCLE 2 DAY 10 AND CYCLE 3 DAY 1~MRI DIFFUSION REALIZATION OF INITIAL MRI DIFFUSION WITHIN 7 DAYS AFTER INITIAL 18F-FDG PET SCAN, THEN WITHIN 7 DAYS AFTER 18F-FDG PET SCAN 1."
89480570|NCT03104400|Experimental|Upadacitinib 15 mg|"Period 1: Participants receive upadacitinib 15 mg orally once a day (QD) and matching placebo to adalimumab by subcutaneous injection every other week (EOW) for 56 weeks.~Period 2: Participants will continue to receive upadacitinib 15 mg once daily."
89480571|NCT03104400|Experimental|Upadacitinib 30 mg|"Period 1: Participants receive upadacitinib 30 mg orally once a day and matching placebo to adalimumab by subcutaneous injection every other week for 56 weeks.~Period 2: Participants will continue to receive upadacitinib 30 mg once daily."
89480572|NCT03104400|Active Comparator|Adalimumab|"Period 1: Participants receive adalimumab 40 mg by subcutaneous injection every other week and matching placebo to upadacitinib orally QD for 56 weeks.~Period 2: Participants continue to receive adalimumab 40 mg every other week."
89480573|NCT03104400|Placebo Comparator|Placebo / Upadacitinib 15 mg|"Period 1: Participants receive matching placebo to upadacitinib orally once a day for 24 weeks then upadacitinib 15 mg once daily for 32 weeks, and matching placebo to adalimumab by subcutaneous injection EOW for the entire 56 weeks.~Period 2: Participants will continue to receive upadacitinib 15 mg once daily."
89480574|NCT03104400|Placebo Comparator|Placebo / Upadacitinib 30 mg|"Period 1: Participants receive matching placebo to upadacitinib orally once a day for 24 weeks then upadacitinib 30 mg once daily for 32 weeks, and matching placebo to adalimumab by subcutaneous injection EOW for the entire 56 weeks.~Period 2: Participants will continue to receive upadacitinib 30 mg once daily."
89480575|NCT03092674|Active Comparator|Arm A (azacitidine)|Patients receive azacitidine SC or IV daily on days 1-7 or on an interrupted schedule which ensures that all 7 days of therapy are received within a 12 day period. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89480576|NCT03092674|Experimental|Arm B (azacitidine, nivolumab)|Patients receive azacitidine as in Arm A and nivolumab IV over 30-60 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89480577|NCT03092674|Experimental|Arm C (azacitidine, midostaurin)|Patients receive azacitidine as in Arm A and midostaurin orally (PO) twice daily (BID) on days 8-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89480578|NCT03092674|Experimental|Arm D (decitabine, cytarabine)|"INDUCTION: Patients receive decitabine IV over 2 hours on days 1-5 and cytarabine IV continuously on days 6-11. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients deemed stable at the discretion of the treating physician receive decitabine as in Induction. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
89480579|NCT03053453|Active Comparator|Standard of Care Spinal Surgery|Patients will be given spinal anesthesia with 2.6 mL of 0.5% isobaric bupivacaine.
89480580|NCT03053453|Experimental|Sensor Guided Spinal Surgery|The Verasense Knee System device (OrthoSensor inc., Dania Beach, Florida) is a sterile sensor system that replaces the tibial insert trials used during surgery. The sensor contains a microprocessor and integrated nanosensor system, which wirelessly transmits real-time data to a portable graphic display unit used for read-out of the data. The sensor measures and localizes peak load at the medial and lateral tibiofemoral joint interfaces. Loading data is thereby captured intra-operatively through the full range of movement (ROM) using the sensor system.
89480581|NCT02999360|Experimental|Treatment 1|
89480582|NCT02999360|Active Comparator|Treatment 2|
89480583|NCT02974998|Experimental|Young Women's Health CoOp (YWHC)/ HTC|Participants received an enhanced gender-focused HTC intervention.
89480584|NCT02974998|Active Comparator|Standard HTC|Participants received the standard HTC available in South Africa for this population.
89480585|NCT02974725|Experimental|LXH254+LTT462|
89480586|NCT02974725|Experimental|LXH254+Trametinib|
89480587|NCT02974725|Experimental|LXH254+Ribociclib|
89480588|NCT02938416|Experimental|Isokinetic training|Ten times, three sets of isokinetic strengthening exercise using 30 degree/sec and 120 degree/sec
89480589|NCT02938416|Active Comparator|Isotonic training|Ten times, three sets of isotonic strengthening exercise using consistent resistance of 60% of 1-repetition maximum of hip or knee
88951335|NCT01945905|Experimental|Extramural|Extramural medication delivery and supervision
89480590|NCT02938416|Placebo Comparator|isometric training|home exercise education on isometric quadriceps strengthening on the day of out-patient appointment
89480591|NCT02932618|Experimental|On-demand Treatment|Participants will receive recombinant von Willebrand factor (rVWF) treatment for non-surgical bleeding episodes over a 12 to 18-month period.
88951336|NCT01945905|Active Comparator|Intramural|Intramural medication delivery and supervision
88951337|NCT01945918|Active Comparator|Self-management support education|Project staff will meet onsite with practice clinicians for a two-hour session to discuss what self-management support (SMS) is, why it is important, how primary care plays a role in this process, how others have approached it, and how it can be time and cost efficient for them to engage in SMS as part of standard diabetes care. Practices will have access to a website displaying general and local SMS resources. Discussion of the implementation of these resources into the practice will be facilitated. Two additional academic detailing visits will be made to check on progress on SMS adoption, provide additional information as needed, and answer questions. No input will be provided regarding how unique practice characteristics might be utilized for more effective implementation of SMS, and CTH will not be introduced.
89023587|NCT05102370|Experimental|Participants with CCUS with mutations in IDH2|Participants will have CCUS with mutations in IDH2
89023588|NCT05092035|Other|COPD patients|COPD patients
89023589|NCT05092035|Other|ILD patients|ILD patients
89023590|NCT05092035|Other|non-smoker controls|non-smoker controls
89023591|NCT05092035|Other|smoker controls|smoker controls
89480592|NCT02932618|Experimental|Elective Surgery|12-24 hours prior to surgery and within 3 hours of surgery. Minor surgery: infuse every 12-24 hours for at least 48 hours based on post-operative dosing. Oral Surgery: infuse at least once within first 8-12 hours post-surgery based on post-operative dosing. Major Surgery: infuse every 12-24 hours for at least first 96 hours post-surgery based on post-operative dosing.
89480593|NCT02932618|Experimental|Emergency Surgery|Within 3 hours prior to surgery. Minor surgery: infuse every 12-24 hours for at least 48 hours based on post-operative dosing. Oral Surgery: infuse at least once within first 8-12 hours post-surgery based on post-operative dosing. Major Surgery: infuse every 12-24 hours for at least first 96 hours post-surgery based on post-operative dosing.
89480594|NCT02922764|Experimental|Recurrent NSCLC (2nd/3rd Line Lung Cancer). Expansion|"RGX-104 in combination docetaxel~RGX104 120 mg BID (5day on/2days off)"
89480595|NCT02922764|Experimental|Newly dignosed NSCLC Cohort Expansion|"RGX104 + pembrolizumab + carboplatin/pemetrexed~RGX104 120 mg BID (5day on/2days off)"
89480596|NCT02922764|Experimental|Recurrent/Relapsed Small Cell Lung Cancer (SCLC) Expansion|"RGX-104 + docetaxel~RGX104 120 mg BID (5day on/2days off)"
89480597|NCT02922764|Experimental|Recurrent/Relapsed Endometrial Cancer Expansion|"RGX-104 combined with ipilimumab~RGX104 120 mg BID (5day on/2days off)"
89480598|NCT02919956||Group I: CBF-I Single Ventricles|The 1st group (cohort group) will be patients who were enrolled in the original NIH CBF grant. These patients will undergo a 60-90 minute Magnetic Resonance Imaging scan of the brain and heart. They will also have Neurodevelopmental Testing.
89480599|NCT02919956||Group II: Prospective Single Ventricles|The 2nd group (cross sectional group) will be prospectively recruited from SV patients after Fontan operation but were not participants in the original study and will be age matched to Group I to enrich the patient population. These patients will undergo a 60-90 minute Magnetic Resonance Imaging scan of the brain and heart. They will also have Neurodevelopmental Testing.
89480600|NCT02919956||Group III: CBF-I Normal Controls|The 3rd group (cohort group) will be normal controls who were enrolled in the original CBF grant. These patients will have Neurodevelopmental Testing. The data from these patients' MRI from CBF-I (original CBF grant) will be used.
89480601|NCT02919956||Group IV: Prospective Normal Controls|The 4th group (cross sectional group) will be prospectively recruited from patients who come to Children's Hospital of Philadelphia (CHOP) for clinically indicated MRIs and found to have structurally normal cardiac and brain anatomy. These patients will have an abbreviated research MRI, lasting 15-20 minutes, added onto their clinically-indicated MRI at CHOP. They will also have Neurodevelopmental Testing.
89480602|NCT02919956||Volunteer Group|There will also be a volunteer group of one to five volunteers that will be enrolled prior to enrollment in the other four study groups. These volunteers will be prospectively recruited from patients who come to Children's Hospital of Philadelphia (CHOP) for a clinically-indicated MRI and consent to have an additional 15-20 minutes of research MRI scanning. The purpose will be to ensure that the brain MRI sequences run correctly and produce useful information before the patient and normal control enrollment begins. The volunteers will not undergo neurodevelopmental testing.
89480603|NCT02903290|Other|cerebellar ataxia|Evaluation ataxia according SARAs; measuring the quality of life through SF36 Questionnaire; quantifying the severity of fatigue perceived by FSS questionnaire quantifying the severity of physical tiredness by VAS before and after physical activity; quantified analysis of walking on walking track GAITRite® (with score calculation FAP and GVI) before and after physical activity; physical activity like walking on a treadmill (with measurement of maximal voluntary quadriceps by manual dynamometer before and after physical activity to ensure the induction of fatigue). Patients will be provided with a portable device for analyzing gas exchange FitMateMED® (COSMED, Rome, Italy) during walking analyzes GAITRite®
89480604|NCT02878798|Placebo Comparator|Placebo|An overencapsulated placebo of identical color, shape and packaging to topiramate will be used.
89480605|NCT02878798|Experimental|Topiramate|Oral topiramate
89480606|NCT02854501||Uncomplicated pregnancies|women who did not develop any of the complications
89480607|NCT02854501||Preeclampsia|pregnant women who developed preeclampsia
89480608|NCT02854501||Isolated IUGR|participants were those who had IUGR
89480609|NCT02854501||Any complication|participants who developed other complications (abruptio placentae, stillbirth, or preterm labor).
89480610|NCT02854436|Experimental|Niraparib|Participants will receive 300 milligram (mg) niraparib (3 capsules*100 mg) orally once daily.
89480611|NCT02845323|Experimental|Nivolumab in combination with Urelumab|"Nivolumab and Urelumab combination:~Nivolumab 240 mg will be administered by 1 hour intravenous infusion on day 1 and day 15 for two cycles~Urelumab 8mg will be administered by 1 hour intravenous infusion on day 1 for two cycles"
89480612|NCT02845323|Active Comparator|Nivolumab monotherapy|Nivolumab 240 mg will be administered by 1 hour intravenous infusion on day 1 and day 15 for two cycles
89480613|NCT02826434|Experimental|PVX-410 and Durvalumab|"Each patient will receive 6 PVX-410 vaccine injections and 2 infusions of Durvalumab.~The injection of PVX-410 will be co-administered with Hiltonol every 2 weeks for 6 injections.~The infusion of Durvalumab will be given on the day of the 4th and 6th PVX-410 injection, for a total of 2 infusions."
89480614|NCT02824731|Active Comparator|supratentorial, grade III/IV, photon|Radiation with photons normofractionated 54-60 Gy. Not pre-irradiated patients.
89480615|NCT02824731|Experimental|supratentorial, grade III/IV, proton|Radiation with protons normofractionated 54-60 Gy(RBE). Not pre-irradiated patients.
89480616|NCT02824731|Active Comparator|supratentorial, grade I/II, photon|Radiation with photons normofractionated 54-60 Gy. Not pre-irradiated patients, bening tumors.
89480617|NCT02824731|Experimental|supratentorial, grade I/II, proton|Radiation with protons normofractionated 54-60 Gy(RBE). Not pre-irradiated patients, bening tumors.
89480618|NCT02824731|Active Comparator|infratentorial, photon|Radiation with photons normofractionated 54-60 Gy. Not pre-irradiated patients.
89023592|NCT05090475|Experimental|Experimental group in Koprivnica Križevci County|Hospital A-team provided academic detailing intervention to primary care physicians in Koprivnica Križevci county who agree to participate
89480619|NCT02824731|Experimental|infratentorial, proton|Radiation with protons normofractionated 54-60 Gy(RBE). Not pre-irradiated patients.
89480620|NCT02824731|Active Comparator|pre-radiation, photon|> 40Gy in the region of recurrence. Radiation with photons normofractionated 54-60 Gy(RBE) or 5 Gy(RBE)/fraction until 30 Gy(RBE) or normofractionated 36 Gy(RBE).
89480621|NCT02824731|Experimental|pre-radiation, proton|> 40Gy in the region of recurrence. Radiation with protons normofractionated 54-60 Gy(RBE) or 5 Gy(RBE)/fraction until 30 Gy(RBE) or normofractionated 36 Gy(RBE).
89023593|NCT05090475|No Intervention|Control group in Koprivnica Križevci county|Primary care physicians in Koprivnica Križevci county who did not agree to participate in academic detailing intervention
89023594|NCT05090475|No Intervention|Control group in Bjelovar Bilogora county|Primary care physicians in Bjelovar Bilogora county without the academic detailing intervention
89480622|NCT02819141|No Intervention|Control|These patient will get usual care - sedation administered by ICU Nurses as deemed necessary by primary care team
89480623|NCT02819141|Experimental|Dexmedetomidine|These patients will receive a basal intravenous infusion of medication (Dexmedetomidine) and have access to self-administered sedation medication (Dexmedetomidine) for anxiety.
89480624|NCT02741193|Experimental|nTMS|Patients will receive a single-pulse TMS mapping of the motor area for the following reasons to determine the motor threshold, measure concurrent EMG, and mapping of the upper extremity.
89480625|NCT02733003|Experimental|Women's Health CoOp (WHC)|This is an adapted behavioral intervention for women in South Africa, who use alcohol and other drugs and are living with HIV or at risk of acquiring HIV.
89480626|NCT02729298|Experimental|Advanced Solid Tumors|"Phase 1a Single daily dose of TP-0903 by oral administration on Days 1-21 of a 28 day cycle~AND~Phase 1b - Upon confirmation of MTD, will receive single oral daily doses of a flat dose of TP-0903 based on the average of the dose administered in the MTD expansion safety cohort on Days 1-21 of each 28 day cycle."
89480627|NCT02729298|Experimental|EGFR+ NSCLC|Phase 1b - Upon confirmation of MTD, will receive single oral daily doses of a flat dose of TP-0903 based on the average of the dose administered in the MTD expansion safety cohort on Days 1-21 of each 28 day cycle.
89480628|NCT02729298|Experimental|BRAF-, KRAS-, or NRAS-Mutated CRC|Phase 1b - Upon confirmation of MTD, will receive single oral daily doses of a flat dose of TP-0903 based on the average of the dose administered in the MTD expansion safety cohort on Days 1-21 of each 28 day cycle.
89203042|NCT02559284|Active Comparator|B - Comparator|Control Arm: 100 patients using saline solution (0.9% NaCl) as standard treatment for healing of nasal surgery wounds following an endoscopic ethmoidectomy as a postoperative care after ethmoid sinus surgery
89480629|NCT02729298|Experimental|Persistent/Recurrent Ovarian Cancer|Phase 1b - Upon confirmation of MTD, will receive single oral daily doses of a flat dose of TP-0903 based on the average of the dose administered in the MTD expansion safety cohort on Days 1-21 of each 28 day cycle.
89480630|NCT02729298|Experimental|BRAF-Mutated Melanoma|Phase 1b - Upon confirmation of MTD, will receive single oral daily doses of a flat dose of TP-0903 based on the average of the dose administered in the MTD expansion safety cohort on Days 1-21 of each 28 day cycle.
89480631|NCT02726750||Observational (biospecimen collection)|Patients undergo collection of blood samples every 6 months for 3 years. Patients may also undergo a biopsy, x-rays, PET/CT scans, and/or MRI scans to check the status of disease at the discretion of the treating physician.
89480632|NCT02725177|Experimental|H.P. Achtar Gel 80 U|H.P. Acthar Gel (repository corticotropin) Injection, 80 U daily for 10 days, then 80 U twice weekly for up to a total of 24 weeks on therapy.
89480633|NCT02624596|Experimental|Ketamine|OCD patients in this arm will receive 0.5mg/kg of ketamine - one single infusion
89480634|NCT02624596|Active Comparator|Midazolam|OCD patients in this arm will receive 0.045mg/kg of midazolam - one single infusion
89480635|NCT02624128|Experimental|valproic acid plus cisplatin and cetuximab|
89480636|NCT02621151|Experimental|Pembrolizumab, Gemcitabine, and RT|"Lead-in single dose Pembrolizumab 200 mg, intravenously (IV)~Transurethral Resection of Bladder Tumor (TURBT) at pre-RT (maximal) and completion of therapy (diagnostic)~External Beam Radiation Therapy (EBRT) - 52 Gy in 20 fractions over 4 weeks (1 fraction = 2.6 Gy)~Gemcitabine 27 mg/m^2 IV twice weekly for 4 weeks concurrent with EBRT~Pembrolizumab 200 mg IV every 3 weeks for total 3 doses starting day 1 of EBRT"
89480637|NCT02579083|Experimental|Segment A: Single MB66 Administration|10 mg of HSV8-N and 10 mg of VRC01-N monoclonal antibodies per MB66 film
89480638|NCT02579083|Placebo Comparator|Segment B: Repeated Administrations Placebo Film|The placebo film is composed of the identical excipients as MB66 without the monoclonal antibodies.
89480639|NCT02579083|Experimental|Segment B: Repeated Administrations MB66|10 mg of HSV8-N and 10 mg of VRC01-N monoclonal antibodies per MB66 film
89480640|NCT02578368|Experimental|Arm A: FLOT chemotherapy + surgery (OP)|"4 cycles (8 weeks) FLOT pre-OP - surgery - 4-8 cycles FLOT (8-16 weeks) post-OP~Docetaxel (50 mg/m2) in 250 ml sodium chloride (NaCl) 0.9% i.v. for 1 h, d1; Oxaliplatin (85 mg/m2) in 500 ml G5% (glucose 5%) i.v. for 2 h, d1; Leucovorin (Ca-folinate) (200 mg/m2) in 250 ml NaCl 0.9% i.v. for 1 h, d1*; 5-FU (2600 mg/m2) continuous infusion for 24 h, d1; Repeated every two weeks (qd15).~* Leucovorin can be replaced by sodium folinate. Dose adjustment necessary if levo-leucovorin is used instead of racemic leucovorin mixture.~For HER-2 positive disease, trastuzumab should be added:~Trastuzumab 4 mg/kg body weight (6 mg loading dose at 1st administration), i.v. for 1 h, d1~For PD-L1 positive disease (CPS ≥ 5), nivolumab can be added according to SmPC:~Nivolumab 240 mg i.v. for 30 min, d1, repeated every two weeks (q15d)"
89531458|NCT06066112|Experimental|Fed state|Before administration, subjects were placed with an indwelling needle and fasted overnight for at least 10 hours before consuming a high-fat meal. They started eating a high-fat meal 30 minutes before taking the medication on the morning of the day of administration. Control drinking water from 1 hour to 4 hours after taking the medication, and drink freely at other times. Fasting within 4 hours after taking the medication. After medication, keep the upper body upright for 4 hours. The meal time on the day of the two cycles of medication is roughly the same.
89203043|NCT00989638||Women at high risk for breast cancer|
89203044|NCT00989716|Active Comparator|Glyceryl trinitrate transdermal patch|
89203045|NCT00989716|Experimental|Continue or stop pre-stroke antihypertensives|
89203046|NCT00660348|Active Comparator|morphine|morphine given traditionally (IV, pill, patch). This is standard of care dosing.
89203047|NCT00660348|Active Comparator|Intrathecal pump|Pump internal used to deliver morphine. This is a newer method for delivery of morphine. Morphine is FDA approved for intrathecal use. The intrathecal pump will be titrated gradually to effect by the interventional pain medicine team. These are the maximum doses and concentrations in keeping with the Polyanalgesic Consensus Conference guidelines: Dose (mg/day):15 ; Conc (mg/cc): 20
89480641|NCT02578368|Active Comparator|Arm B: FLOT chemotherapy alone|"4 cycles (8 weeks) FLOT followed by further 4-8 cycles FLOT (8-16 weeks)~Docetaxel (50 mg/m2) in 250 ml sodium chloride (NaCl) 0.9% i.v. for 1 h, d1; Oxaliplatin (85 mg/m2) in 500 ml G5% (glucose 5%) i.v. for 2 h, d1; Leucovorin (Ca-folinate) (200 mg/m2) in 250 ml NaCl 0.9% i.v. for 1 h, d1*; 5-FU (2600 mg/m2) continuous infusion for 24 h, d1; Repeated every two weeks (qd15).~* Leucovorin can be replaced by sodium folinate. Dose adjustment necessary if levo-leucovorin is used instead of racemic leucovorin mixture.~For HER-2 positive disease, trastuzumab should be added:~Trastuzumab 4 mg/kg body weight (6 mg loading dose at 1st administration), i.v. for 1 h, d1~For PD-L1 positive disease (CPS ≥ 5), nivolumab can be added according to SmPC:~Nivolumab 240 mg i.v. for 30 min, d1, repeated every two weeks (q15d)"
89480642|NCT02570542|Active Comparator|3-4 x 10^6 CD34+ stem cells/kg|Patients will receive standard supportive measures (including: growth factor support post-HDT/ASCT, antimicrobial prophylaxis, red blood cell and platelet transfusion and treatment for neutropenic fever) as per institutional guideline practices.
89480643|NCT02570542|Experimental|6-8 x10^6 CD34+ stem cells/kg|Patients will receive standard supportive measures (including: growth factor support post-HDT/ASCT, antimicrobial prophylaxis, red blood cell and platelet transfusion and treatment for neutropenic fever) as per institutional guideline practices.
89480644|NCT02557464|Experimental|Alzheimer's disease group|24 patients with an Alzheimer's disease or related disorders
89480645|NCT02557464|Active Comparator|control group|24 age matched controls participants
89480646|NCT02531087||Individuals with OI|Individuals with OI with confirmed specific genetic mutations
89480647|NCT02531087||Controls/Unaffected|Individuals who do not have OI and who are not related to an individual with OI
89480648|NCT02518243|Experimental|Alzheimer's Disease|
89480649|NCT02498665|Experimental|Dosing Escalation Cohort|Patients will be administered escalating doses of DSP-7888 Dosing Emulsion intradermally or subcutaneously. Dose-escalation will proceed according to the Criteria for Dose Escalation and Criteria for Determination of Dose-Limiting Toxicity (DLT) as indicated below. Dose Level I: 3.5 mg, Dose Level II: 10.5 mg, Dose Level III: 17.5 mg
89480650|NCT02498665|Experimental|MDS Cohort 1|Patients will be intradermally administered of DSP-7888 at 10.5 mg every week for 4 weeks, every 2 weeks until Week 24, and then every 4 weeks.
89480651|NCT02498665|Experimental|MDS Cohort 2|Patients will be intradermally administered of DSP-7888 at 10.5 mg every 2 weeks until Week 24, and then every 4 weeks.
89480652|NCT02488759|Experimental|Neoadjuvant Cohort|"Nivolumab intravenous infusion as specified~**Not participating: Japan, Korea, and Taiwan"
89480653|NCT02488759|Experimental|Metastatic Monotherapy Cohort|Nivolumab intravenous infusion as specified
89480654|NCT02488759|Experimental|Nivolumab plus Ipilimumab Cohort|"Nivolumab intravenous infusion as specified with Ipilimumab intravenous infusion as specified~**Not participating: Belgium, France and Germany~Cohort expansion participating countries: Spain, US, UK, Netherlands, Japan and Mexico~**Not participating in cohort expansion: France, Germany, Korea and Taiwan"
89480655|NCT02488759|Experimental|Nivolumab plus Relatlimab Cohort|"Nivolumab intravenous infusion as specified with Relatlimab intravenous infusion as specified~** Not Participating: Belgium, Germany, France, Japan, Korea, Taiwan, UK, and Netherlands~Enrollment is closed for this cohort"
89480656|NCT02488759|Experimental|Nivolumab plus Daratumumab Cohort|"Nivolumab intravenous infusion as specified with Daratumumab intravenous infusion as specified~**Not Participating: Belgium, Germany, France, Japan, Korea, Taiwan, UK, and Netherlands~Enrollment is closed for this cohort"
89480657|NCT02483247|Experimental|Combo with Capecitabine|
89480658|NCT02483247|Experimental|Combo with Doxorubicin|
89480659|NCT02483247|Experimental|Combo with Nivolumab (US only)|
89480660|NCT02483247|Experimental|Combo with Pembrolizumab|
89480661|NCT02483247|Experimental|Combo with Paclitaxel|
89480662|NCT02483247|Experimental|Combo with Sunitinib|
89480663|NCT02471378||Pregnant Women 15-25 years old|Malaria-infected pregnant Women
89480664|NCT02471287||Affected Participants|Participants with eye disease
89480665|NCT02471287||Healthy volunteers|Unaffected first degree relatives of participants with a known or suspected inherited eye disease.
89480666|NCT02467361|Experimental|Combo with Ipilimumab|
89480667|NCT02467361|Experimental|Combo with Nivolumab|
89480668|NCT02467361|Experimental|Combo with Pembrolizumab|
89480669|NCT02466685|Experimental|JNJ-18038683|Subjects will be randomized to receive JNJ-18038683 or placebo after the completion of the baseline assessments. Subjects randomized to JNJ-18038683 will receive 10 mg for one week, then titrate to 20 mg for the duration of the trial, with the provision for a single, downward dose adjustment for intolerance, based upon investigator judgment.
89480670|NCT02466685|Placebo Comparator|Placebo|Placebo treatment for 8 weeks.
89480671|NCT02461459||Tuberous Sclerosis Complex|Tuberous Sclerosis Complex
89480672|NCT02461446||PTEN ASD|PTEN participants with Autism Spectrum Disorder group
89480673|NCT02461446||PTEN no ASD|PTEN participants without Autism Spectrum Disorder group
89480674|NCT02461446||Controls|Healthy control group
89480675|NCT02461420||Phelan-McDermid Syndrome|Phelan-McDermid Syndrome
89480676|NCT02438085||ACS patients|prospective collection of data and follow-up
89480677|NCT02369003|Experimental|Peripheral Nerve Graft|The intervention includes the surgical implantation of autologous peripheral nerve graft into the substantia nigra, basal forebrain, putamen, and/or STN of participants with Parkinson's Disease that are undergoing Deep Brain Stimulation (DBS).
89480678|NCT02352558|Experimental|Arm 1|Patients with multiple myeloma treated with BBI608
89480679|NCT02352558|Experimental|Arm 2|Patients with lymphoma treated with BBI608
89480680|NCT02352558|Experimental|Arm 3|Patients with acute myeloid leukemia or myelo-dysplastic syndrome treated with BBI608
89480681|NCT02352558|Experimental|Arm 4|Patients with chronic myeloid leukemia treated with BBI608
89480682|NCT02352558|Experimental|Arm 5|Patients with multiple myeloma treated with BBI608 and dexamethasone
89480683|NCT02352558|Experimental|Arm 6|Patients with multiple myeloma treated with BBI608 and bortezomib
89480684|NCT02352558|Experimental|Arm 7|Patients with chronic myeloid leukemia treated with BBI608 and imatinib
89480685|NCT02352558|Experimental|Arm 8|Patients with chronic lymphocytic leukemia treated with BBI608
89480686|NCT02352558|Experimental|Arm 9|Patients with chronic lymphocytic leukemia treated with BBI608 and ibrutinib
89480687|NCT02344485|Experimental|OMM treatment|Subject will receive osteopathic manipulative treatment protocol for constipation in Parkinson's disease once a week for 4 weeks, in addition to continuing with their routine care
89480688|NCT02344485|No Intervention|Control|Subjects will continue with their routine care. No OMM will be performed during this study period
89480689|NCT02312206|Experimental|NEOD001|24 mg/kg (maximum dose of 2500 mg) of NEOD001 administered once every 28 days.
89480690|NCT02312206|Placebo Comparator|Placebo|Placebo will be administered as a 250 mL bag of normal saline once every 28 days.
89480691|NCT02284581||Retrospective cohort|All consecutive metastatic breast cancers patients treated in the participating site with a first-line therapy (chemotherapy or hormonal therapy with or without biological therapy) from last contact with patient or death which ever event comes first retrospectively back until 1st of January 2000.
89480692|NCT02284581||Prospective cohort|All new consecutive metastatic breast cancers patients will be treated in the participating site with a first-line therapy (chemotherapy or hormonal therapy with or without biological therapy) from site activation to June 2023.
89480693|NCT02276430||Cases|Patients who developed cardiovascular disease after testicular cancer treatment
89480694|NCT02276430||Subcohort members|A random selection out of the total cohort of testicular cancer patients per participating hospital
89480695|NCT02264665||Sunitinib|
89480696|NCT02264665||Afinitor|
89480697|NCT02264665||other treatment (chémotherapy, SSA..)|
89480698|NCT02234557|Experimental|Tai Chi|Tai Chi instruction, 1 hour, twice per week Home Tai Chi practice with video, requesting 15-30 minutes, 3 times per week, monitored by practice log
89480699|NCT02232646|Experimental|BBI503|
89480700|NCT02232633|Experimental|BBI503|BBI503 will be administered orally, daily, in continuous 28-day cycles at a dose of 300 mg once daily
89480701|NCT02232620|Experimental|BBI503|
89480702|NCT02231840||Not treatment-seeking participants|Individuals who meet current or past DSM 5 criteria for AUD but are not seeking treatment. Healthy volunteers and other volunteers.
89480703|NCT02231840||Treatment-seeking Patients|Individuals who meet current DSM 5 criteria for AUD and are seeking treatment for it.
89480704|NCT02221427|Active Comparator|Static labour progression curve (F)|Guideline with the following expected labour progression: if the cervix dilates at least 1 centimetre per hour assessed after 4 hours. Labour dystocia is diagnosed if progression proceeds slower than this definition throughout the active phase of the first stage of labour. Labour dystocia in the second stage of labour is diagnosed if lasting longer than two hours, three hours for women with epidurals or if the expulsion phase lasts longer than 60 minutes.
89480705|NCT02221427|Experimental|Dynamic progression curve (Z)|Guideline which takes into account the dilatation of the cervix on admission and calculates the expected progression during the active phase of the first stage of labour based on this finding. Labour dystocia in the second stage of labour is diagnosed if lasting longer than two hours and 45 minutes, three hours and 30 minutes for women with epidurals or if the expulsion phase lasts longer than 60 minutes.
89480706|NCT02207062|Experimental|Treatment (ibrutinib)|Patients receive ibrutinib PO QD in the absence of disease progression or unacceptable toxicity.
89480707|NCT02198690|Experimental|Mammography Decision Aid|Development and pilot testing of the decision aid (DA) has been described previously. In brief, the DA is written at a 6th grade reading level and includes information on 1) breast cancer risk factors for women >75 years; 2) health/life expectancy; 3) likely outcomes if screened and not screened with mammography; 4) competing mortality risks; 5) breast cancer treatments; and 6) a values clarification exercise. The last page asks users their intentions of being screened on a 15-point validated scale and invites users to share this information with their clinician. PCPs whose patients are randomized to receive the DA will be sent a copy of the DA via email and a link to an optional training on using the DA (5 informational slides and a 3-minute video).
89480708|NCT02198690|Placebo Comparator|Home safety pamphlet|To reduce response bias and to compensate for the time and attention required by the intervention group to read the DA, patients in the control arm will be provided a two page pamphlet on home safety for older adults developed by the American Geriatrics Society (AGS) Foundation for Health in Aging. PCPs whose patients are randomized to the receive the home safety pamphlet, will be sent an email informing them that their patient will be coming in early to read health educational materials for older adults as part of a study. We otherwise do not plan any intervention for control group PCPs because we do not want to change their usual behavior. However, if PCPs in the control arm request a copy of the educational materials then we will email them a copy of the home safety pamphlet.
89480709|NCT02155712|Active Comparator|Triathlon Tritanium Knee|Cases are enrolled in the Cohort 1 (cementless) until a total of 356 cases receive the Triathlon Tritanium Tibial Baseplate, Triathlon Tritanium Patella, Triathlon CR or PS Beaded Femur with PA and the Triathlon Tibial Insert. All components in this cohort must used in a cementless application.
89480710|NCT02155712|Active Comparator|Triathlon Knee|Enrollment in Cohort 2 (cemented) will begin upon completion of enrollment into the Cohort 1 (cementless), and will continue until a total of 144 cases receive the Triathlon Tibial Tray, Triathlon Patella, Triathlon CR or PS Femur and Triathlon Tibial Insert. All components in this cohort must be used in a cemented application.
89480711|NCT02151032||Colorectal Cancer Screening Booklet + Audio CD|Participants read the booklet about colorectal cancer screening tests, and listen to an audio CD that will narrate the booklet. Questionnaire completion before and after viewing the program.
89480712|NCT02151032||Video with Non-Moving Images on iPad|Participants watch a video with non-moving images about colorectal cancer screening tests on an iPad. Questionnaire completion before and after viewing the program.
89480713|NCT02151032||Video with Animated Images on iPad|Participants watch a video with animated images about colorectal cancer screening tests on an iPad. Questionnaire completion before and after viewing the program.
89480714|NCT02052882|Experimental|Romiplostim|"All patients will begin weekly romiplostim at 2 mcg/kg, subcutaneously. The romiplostim dose will be titrated on weekly CBC/platelet counts. For titration purposes, the target platelet count is 150,000-200,000/mcL. Treatment can be held up to 16 days if a patient develops an intercurrent medical illness or symptom that is unrelated to study drug therapy.~Treatment may be held up to 20 days if the patient unavailable for non- medical reasons, such as vacation or travel."
89480715|NCT02047474|Experimental|Treatment (mFOLFIRINOX)|"NEOADJUVANT THERAPY: Patients receive mFOLFIRINOX comprising oxaliplatin IV over 2 hours, levoleucovorin calcium IV over 2 hours, irinotecan hydrochloride IV over 90 minutes, and fluorouracil IV continuously for 46 hours on day 1. Treatment repeats every 2 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.~SURGERY: Beginning 3-8 weeks after completion of neoadjuvant therapy patients undergo surgical resection.~ADJUVANT THERARPY: Beginning within 12 weeks after surgery, patients receive mFOLFIRINOX as in neoadjuvant therapy. Treatment repeats every 2 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity."
89480716|NCT02039557||NiCord®/CordIn™ (omidubicel) transplanted|Anyone who signed the consent for this study received a NiCord®/CordIn™ (omidubicel) infusion as part of a GC clinical interventional study, and completed the interventional study Day 365 status assessment.
89480717|NCT02008045||Neonates at Risk for Brian Injury|Magnetic Resonance Imaging Neurodevelopmental Testing - 18 Month
89480718|NCT02008045||Term Neonates|Magnetic Resonance Imaging Neurodevelopmental Testing - 18 Month
89480719|NCT01972217|Active Comparator|Olaparib|200 mg or 300 mg bid
89480720|NCT01972217|Placebo Comparator|Placebo|placebo to match olaparib bid
89480721|NCT01970735|Experimental|FSHD patient|
89480722|NCT01934452||Complete Remission|Complete remission arm in mRCC patients treated with sunitinib.
89480723|NCT01934452||Non Complete Remission|Non complete remission arm in mRCC patients treated with sunitinib.
89480724|NCT01918007|Active Comparator|AT (adenotonsillectomy) Group|AT (adenotonsillectomy) immediately after the baseline study evaluation
89480725|NCT01918007|No Intervention|Control Group|No AT (adenotonsillectomy) for 3 months after the baseline study evaluation
89480726|NCT01893554|Experimental|Group 1: RSV vaccine|Healthy RSV-seropositive children ages 12 to 59 months will receive one dose of the RSV ΔNS2 Δ1313 I1314L vaccine administered as nose drops at study entry.
89480727|NCT01893554|Placebo Comparator|Group 1: Placebo|Healthy RSV-seropositive children ages 12 to 59 months will receive one dose of the placebo administered as nose drops at study entry.
89480728|NCT01893554|Experimental|Group 2: RSV vaccine|Healthy RSV-seronegative infants and children ages 6 to 24 months will receive one dose of the RSV ΔNS2 Δ1313 I1314L vaccine administered as nose drops at study entry.
89480729|NCT01893554|Placebo Comparator|Group 2: Placebo|Healthy RSV-seronegative infants and children ages 6 to 24 months will receive one dose of the placebo administered as nose drops at study entry.
89480730|NCT01893554|Experimental|Group 3: RSV vaccine|Healthy RSV-seronegative infants and children ages 6 to 24 months will receive one dose of the RSV ΔNS2 Δ1313 I1314L vaccine administered as nose drops at study entry.
89480731|NCT01893554|Placebo Comparator|Group 3: Placebo|Healthy RSV-seronegative infants and children ages 6 to 24 months will receive one dose of the placebo administered as nose drops at study entry.
89480732|NCT01893554|Experimental|Group 4: RSV vaccine|Healthy infants between the ages 4 to 6 months who have not been screened for RSV serostatus will receive one dose of the RSV ΔNS2 Δ1313 I1314L vaccine administered as nose drops at study entry.
89480733|NCT01893554|Placebo Comparator|Group 4: Placebo|Healthy infants between the ages 4 to 6 months who have not been screened for RSV serostatus will receive one dose of the placebo administered as nose drops at study entry.
89480734|NCT01870960|Other|right control|the patient is his own control The right side will be treated as normal while the left side will also receive the emdogaim
89480735|NCT01870960|Other|left control|the patient is his own control The left side will be treated as normal while the right side will also receive the emdogaim
89203048|NCT05408416|Active Comparator|preoperative group|PDR patients who received ranibizumab injection (0.5mg/0.05ml) 3-5 days before vitrectomy were assigned to preoperative group
89203049|NCT05408416|Experimental|intraoperative group|PDR patients who received ranibizumab injection (0.5mg/0.05ml) at the end of vitrectomy were assigned to intraoperative group
89203050|NCT00940251|Placebo Comparator|CORN STARCH|
89203051|NCT00940251|Active Comparator|Mersina, Diet and exercise|
89203052|NCT04013373||BIS home-based monitoring|
89480736|NCT01864109|Experimental|Patients with localized disease|"Patients with localized disease will receive six cycles of the combination as maintenance therapy following standard chemotherapy.~Cycles 4-6 will include:~Ifosfamide 2,800 mg/m2/day on days 1-5~Etoposide 100 mg/m2/day on days 1-5~Cycle 7 will include :~Cyclophosphamide will be given on days 1 and 2 at a dose of 2,100 mg/m2/day, or for patients < 10 years of age at a dose of 70 mg/kg/day~Doxorubicin will be given on days 1 and 2 at a dose of 37.5 mg/m2/day~Vincristine will be given on day 1 at a dose of 2 mg/m2 or 0.067 mg/kg (whichever is lower, to a max dose of 2 mg)~Cycles 8-13 will include:~Irinotecan will be given on 10 days over weeks 1 and 2 of a cycle at a dose of 20 mg/m2/day intravenously~Temozolomide will be given daily on the first 5 days of irinotecan administration at a dose of 100 mg/m2/day orally or intravenously"
89480737|NCT01864109|Experimental|Patients with metastatic disease|"Patients will get 10 cycles of the combination intercalated between the final 4 cycles of standard chemotherapy.~Cycles 4, 5, 7, 8, 10, 11, 13, 14, 16, and 17 will include:~Irinotecan will be given on 10 days over weeks 1 and 2 of a cycle at a dose of 20 mg/m2/day intravenously~Temozolomide will be given daily on the first 5 days of irinotecan administration at a dose of 100 mg/m2/day orally or intravenously~Cycles 6, 9, and 12 will include:~Ifosfamide 2,800 mg/m2/day on days 1-5~Etoposide 100 mg/m2/day on days 1-5~Cycle 15 will include:~Cyclophosphamide will be given on days 1 and 2 at a dose of 2,100 mg/m2/day, or for patients < 10 years of age at a dose of 70 mg/kg/day~Doxorubicin will be given on days 1 and 2 at a dose of 37.5 mg/m2/day~Vincristine will be given on day 1 at a dose of 2 mg/m2 or 0.067 mg/kg (whichever is lower, to a max dose of 2 mg)"
89480738|NCT01863446|Experimental|Lighting1|Ocular light exposure of a red wavelength light for one night
88951338|NCT01945918|Active Comparator|Connection to Health Interactive Behavior Change Technology|Connection to Health (CTH) Arm: The number and length of staff visits to these practices will be the same as for the SMS Education Arm, but the content of the visits will center on the implementation and use of the CTH program as a way to implement SMS. Clinicians and selected staff members will be given hands-on experience using the system and will be provided with scenarios that will highlight the effective use of CTH as a tool for diabetes SMS. The practices will then implement CTH, using protocols selected from several suggested by the research team. Additional technical assistance with implementing CTH will also be provided as needed.
89480739|NCT01863446|Experimental|Lighting2|Ocular light exposure of a blue-green wavelength light for one night
89480740|NCT01863446|Experimental|Lighting3|Ocular light exposure to a red wavelength light on night 1 and to a red wavelength light on night 2
89480741|NCT01863446|Experimental|Lighting4|Ocular light exposure to a red wavelength light on night 1 and to a blue-green wavelength light on night 2
89480742|NCT01815788|Experimental|Teo first|"Mild and moderate presbycusis (20 to 50 dB average hearing loss at 500, 1000, 2000 Hz and 4000 Hz)~Patient 60 years of age and older,~No previous hearing aid"
89480743|NCT01809691|Experimental|ADT + TAK-700|"LHRH agonist - given as approved for androgen deprivation at a dose necessary to maintain castrate levels and equivalent to 22.5 mg of Leuprolide IM every 3 months.~TAK-700, 300 mg, PO, twice daily"
89480744|NCT01809691|Active Comparator|ADT + Bicalutamide|"LHRH agonist - given as approved for androgen deprivation at a dose necessary to maintain castrate levels and equivalent to 22.5 mg of Leuprolide IM every 3 months.~Bicalutamide, 50 mg, PO, q daily"
89480745|NCT01805349|Other|X-Rays|patients with digital arthrosis and hip/knee arthrosis will practice hand X-rays
89480746|NCT01786265|Active Comparator|Arm A (finite androgen ablation)|Participants receive either leuprolide acetate via injection every month or every 4 months, goserelin acetate via injection every month, or degarelix via injection every month for 8 months. Patients also receive bicalutamide PO QD, flutamide PO TID, or nilutamide PO QD. Patients may crossover to Arm B with disease progression after 8 months.
88951339|NCT01945918|Experimental|Connection to Health plus Coaching|"Connection to Health plus Coaching (CTH+C) Arm: This arm adds practice coaching as described above to CTH. The active coaching phase focuses on meetings of the practice improvement team, scheduled every other week for approximately 40 minutes each. The improvement team will consist of 6 - 10 diverse representatives of the practice (e.g., front office, medical assistants, physicians). The coach will assist the team in developing a CTH adoption plan and then help them break it down into small bites for rapid cycle change using the Plan-Do-Study-Act quality improvement (QI) model. Active coaching will last for 3 months, followed by monthly calls by the coach to review data regarding the practice's use of CTH and brief booster coaching to deal with problems."
88951340|NCT01945931|Experimental|Safe Delivery Smartphone Application|The safe delivery smartphone application is designed to train midwives and other birth attendants in developing countries in management of normal and complicated deliveries. The safe delivery smartphone application will be introduced to health workers in the intervention clusters.
88951341|NCT01945931|No Intervention|Control|Health workers in the control clusters will not have access to the Safe Delivery App
89480747|NCT01786265|Experimental|Arm B (finite androgen ablation, abiraterone, prednisone)|Participants receive leuprolide acetate, goserelin acetate, degarelix, bicalutamide, flutamide, or nilutamide as in Arm A. Patients also receive abiraterone acetate PO daily for 8 months and prednisone daily. Patients may crossover to Arm A with disease progression after 8 months.
89480748|NCT01781455|Experimental|BBI503|
89480749|NCT01775423|Experimental|BBI608|
89203053|NCT03734198|Experimental|Ibrutinib + daratumumab|"Prephase (D-27 to D0): ibrutinib 420 mg/day~Cycle 1 (4 weeks): ibrutinib 420 mg/day from D1 to D28 + daratumumab 8 mg/kg D1 and D2, then 16 mg/kg at D8, D15, D22.~Cycle 2 (4 weeks): ibrutinib 420 mg/day D1 to D28 + daratumumab 16 mg/kg at D1, D8, D15 and D22.~Cycles 3 to 6 (4 weeks) : ibrutinib 420 mg/day D1 to D28 + daratumumab 16 mg/kg at D1 and D15.~Cycles ≥ 7 (4 weeks) : ibrutinib 420 mg/day D1 to D28 + daratumumab 16 mg/kg at D1."
89480750|NCT01775072||Pts with solid tumors|Patients must have solid or hematologic cancer. for treatment on a . Patients must have undergone pathologic confirmation of their tumor at MSKCC and have either: 1) archival tissue available for analysis, 2) have fresh tissue collection planned as routine standard of care biopsy or part of a research biopsy under another clinical trial(or peripheral blood / bone marrow collection in the case of hematologic cancers) outside of the context of this protocol, or 3)archival tissue .available at an outside facility. For prospective genotyping tissue specimens from the primary site, a metastasis or recurrence will be used based upon the availability and quality of tissue.
89480751|NCT01765777|No Intervention|Control Group|Subjects in this arm continue with standard medical care
89480752|NCT01765777|Experimental|Osteopathic Manipulative Medicine Group|Subjects in this arm will receive an OMM intervention.
89480753|NCT01765777|Experimental|Phototherapy Group|Subjects in this arm will receive a phototherapy intervention.
89480754|NCT01765777|Experimental|OMM and Phototherapy Group|Subjects in this arm will receive both the OMM and phototherapy interventions.
89480755|NCT01661491||Cystic Fibrosis|Infants and toddlers with Cystic Fibrosis
89480756|NCT01661491||Non-cystic fibrosis controls|Infants and toddlers without Cystic Fibrosis
89480757|NCT01619176|Experimental|Acupuncture|Acupuncture plus conventional treatment (methotrexate+leflunomide+non-steroid anti-inflammatory drugs)
89480758|NCT01619176|Active Comparator|Control|Conventional treatment (methotrexate+leflunomide+non-steroid anti-inflammatory drugs)
89480759|NCT01585844||Women with sleep apnea|
89480760|NCT01585844||Women without sleep apnea|
89480761|NCT01532388|Experimental|eScreen|Web based self-monitoring of problematic alcohol and drug use.
89480762|NCT01532388|No Intervention|Control group|Untreated control group
89480763|NCT01481974|Experimental|Treprostinil|This is a single center, open-label, dose-escalation Phase I/II study of Treprostinil.
89480764|NCT01413516|Placebo Comparator|Placebo Control|Smoking cessation counseling with placebo comparator
89480765|NCT01413516|Active Comparator|Experimental: Varenicline|Smoking cessation counseling with varenicline
89480766|NCT01374997|Other|patients with Fabry disease|detection of this disease in end-stage renal failure patients, transplant or hemodialysis
89480767|NCT01371383|Experimental|n-3 fatty acids|EPA 1680 mg/d + DHA 880 mg/d
89480768|NCT01371383|Placebo Comparator|Placebo|Soybean oil
89480769|NCT01266915||Control group|Normal disease free (non lupus) subjects
89480770|NCT01266915||Diseased Control|
89480771|NCT01266915||Diseased group 1|Those subjects with systemic lupus erythematosus.
89480772|NCT01266915||Diseased group 2|Subjects diagnosed with cutaneous lupus.
89480773|NCT01246765||Atypical Antipsychotic Cohort|"Pregnant women who have taken at least one type of atypical antipsychotic at some point during pregnancy.~Medications of Special Interest:~Abilify (aripiprazole)~Aristada (aripiprazole lauroxil)~Aristada Initio (aripiprazole lauroxil)~Clozaril (clozapine)~Lybalvi (olanzapine and samidorphan)~Rexulti (brexpiprazole)~Risperdal (risperidone)~Seroquel (quetiapine)~Symbax (olanzapine-fluoxetine HCL)~Zyprexa (olanzapine)"
89480774|NCT01246765||Antidepressant Medications|"Pregnant women who have taken at least one type of antidepressant medication at some point during pregnancy.~Medications of Special Interest:~Spravato (esketamine)~Zulresso (brexanolone)"
89480775|NCT01246765||ADHD Medications|"Pregnant women who have taken at least one type of ADHD medication at some point during pregnancy.~Medications of Special Interest:~• Qelbree (viloxazine)"
89480776|NCT01246765||Sedative Hypnotic Medications|"Pregnant women who have taken at least one type of sedative hypnotic medication at some point during pregnancy.~Medications of Special Interest:~• Dayvigo (lemborexant)"
89480777|NCT01246765||Other Psychiatric Medications|Pregnant women who have taken other psychiatric medications (other than atypical antipsychotics, ADHD medications, antidepressants, or sedative hypnotics) at some point during pregnancy.
89480778|NCT01246596|Active Comparator|chronic periodontitis|
89480779|NCT01246596|Active Comparator|aggressive periodontitis|
89480780|NCT01246596|Active Comparator|healthy patient (orthodontics extraction)|
89480781|NCT01141023|Experimental|Datscan SPECT Imaging|Subjects will b injected with 3-5 mCi of dopamine transporter. Within a 4 hour (+/- 30 minutes) window following the injection, subjects will undergo SPECT imaging on the camera.
89480782|NCT01129544|Experimental|Gene Transfer|open label single arm study
89480783|NCT01106534|Placebo Comparator|12 month DAPT arm|placebo + aspirin
89480784|NCT01106534|Active Comparator|30 month DAPT arm|clopidogrel + aspirin OR prasugrel + aspirin
89480785|NCT01098955|Experimental|ACT Group 1|Acceptance and Commitment Therapy (ACT). Varenicline 2 mg daily for 12 weeks.
89480786|NCT01098955|Experimental|MBC Group 2|Motivational and Behavioral Counseling (MBC). Varenicline 2 mg daily for 12 weeks.
89480787|NCT01047735|Experimental|Roux-en-Y Gastric Bypass Surgery|Roux-en-Y Gastric Bypass Surgery
89480788|NCT01047735|Experimental|Laparoscopic Adjustable Gastric Banding|Laparoscopic Adjustable Gastric Banding
89480789|NCT01047735|Experimental|Lifestyle/Behavioral Weight Loss|Lifestyle Weight Loss Intervention
89480790|NCT01009788|Experimental|TMZ/ABT888|Combination therapy with temozolomide and veliparib
89480791|NCT00997009|Experimental|Arm A|chemotherapy plus cetuximab
89480792|NCT00997009|Active Comparator|Arm B|chemotherapy
89480793|NCT00979238|Other|Group 1|"All participants who meet the eligibility requirements.~Intervention: Gene Transfer and drug (scAAV2/8-LP1-hFIXco)."
89480794|NCT00961064|Experimental|Eltrombopag in Low to Int-2 Risk Myelodysplastic Syndrome (MDS)|Eltrombopag will be initiated at 50 mg/day (Asians 25 mg/day) and dose adjusted up to 150mg/day based response and safety in participants with Low to Int-2 Risk Myelodysplastic Syndrome (MDS)
89480795|NCT00894257||HCV/HIV infected pregnant women|
89480796|NCT00667030|Experimental|Lifestyle Modification|Combined hypocaloric diet and aerobic exercise training
89480797|NCT00657878|Experimental|non platinum based chemotherapy|a non platinum based therapy (corresponding to stealth liposomal doxorubicin, or topotecan, or gemcitabine,or any other drug approved in clinical practice for the treatment of patients with ovarian cancer after previous platinum-based chemotherapy) followed by a platinum based chemotherapy at disease progression
89480798|NCT00657878|Active Comparator|platinum based chemotherapy|platinum based chemotherapy (corresponding to the combination of carboplatin + paclitaxel, or carboplatin + gemcitabine for patients with significant but lower than grade 3 neuropathy at baseline) followed by a non platinum based chemotherapy at disease progression
89480799|NCT00611585|Other|Hip Resurfacing|Birmingham Hip Resurfacing
89480800|NCT00513526|Experimental|Gardasil|Quadrivalent HPV Vaccine (types 6, 11, 16, 18) for intramuscular injection at study entry, week 8, week 24, and week 128.
89480801|NCT00412594|Experimental|Treatment (cladribine and rituximab)|Patients receive cladribine IV over 2 hours QD on days 1-5 and rituximab IV once weekly for 8 weeks beginning on day 28 in the absence of disease progression or unacceptable toxicity.
89480802|NCT00321555|Experimental|LMB-2 to Treat Hairy Cell Leukemia|LMB-2 Infusion: 40 micro-g/Kg will be infused in 50 ml of 0.9% Sodium chloride (NaCl) and 0.2% albumin via over 30 minutes every other day for 3 doses. Patients may receive up to six treatment cycles every 4 weeks.
89480803|NCT00184119|Experimental|Psychiatric Intensive Care Unit|
89480804|NCT00184119|Active Comparator|Whole acute unit|
89480805|NCT00143923|Active Comparator|1|Intervention: 6 months of individualized advice regarding Nutrition, Exercise, Stress Management Counseling for participants who are at intermediate or high Framingham risk for CVD and are randomized to Arm 1
88951342|NCT01945957|Experimental|OT (24 IU)|Phase I Aim 1a. (fMRI) Will determine the effect of oxytocin dose (24 IU) on neural activation and connectivity compared to placebo. Aim 1 b (eye-tracking) will occur on a separate visit from fMRI scanning and will also assess response to oxytocin in an eye-tracking task (social vs. non-social image).
88951343|NCT01945957|Experimental|OT (8 IU and 40IU)|Each phase will require a separate subject consent. Phase II Aim 2a. (fMRI) Will determine the effect of oxytocin dose (8 or 40 IU) on neural activation and connectivity. Aim 1 b (eye-tracking) will occur on a separate visit from fMRI scanning and will also assess response to oxytocin (8 or 40 IU) in an eye-tracking task (social vs. non-social image).
89480806|NCT00143923|Placebo Comparator|2|Intervenition: 6 months of Usual care for participants who are at intermediate or high Framingham risk for CVD and are randomized to Arm 2. No active Nutrition, Exercise, Stress Management Counseling
89480807|NCT00143923|No Intervention|3|No intervention for all participants who are at low Framingham risk for CVD or have preexisting CVD prior to study entry/ No active Nutrition, Exercise, Stress Management Counseling
89480808|NCT00131885|Placebo Comparator|Levonorgestrel 1.5 with Placebo Herb|This group had baseline pharmacokinetic studies after an oral dose of levonorgestrel (LNG) 1.5 mg, then took a placebo herb daily for 4-6 weeks, during which time pharmacokinetic studies were repeated after an oral dose of LNG 1.5 mg
89480809|NCT00131885|Active Comparator|Levonorgestrel 1.5 with SJW 900 mg|This group had baseline pharmacokinetic studies after an oral dose of levonorgestrel (LNG) 1.5 mg, then took St. John's Wort (SJW) 900 mg a Day orally for 4-6 weeks, during which time pharmacokinetic studies were repeated after an oral dose of LNG 1.5 mg
89480810|NCT00131885|Active Comparator|Levonorgestrel 2.25 with SJW 900 mg|This group had baseline pharmacokinetic studies after an oral dose of levonorgestrel (LNG) 1.5 mg, then took a St. Johns's Wort 300 mg capsules three times daily for 4-6 weeks, during which time pharmacokinetic studies were repeated after an oral dose of LNG 2.25 mg
89480811|NCT00131885|Active Comparator|Levonorgestrel 1.5 with SJW 1500 mg|This group had baseline pharmacokinetic studies after an oral dose of levonorgestrel (LNG) 1.5 mg, then took a St. Johns's Wort 300 mg capsules five times daily for 4-6 weeks, during which time pharmacokinetic studies were repeated after an oral dose of LNG 1.5 mg
89480812|NCT00047060|Experimental|Stem Cell Transplant Therapy With Campath-1H|Recipients received a nonmyeloablative preparative regimen of alemtuzumab 30mg iv three times a week for two weeks followed by fludarabine 25mg/m2/day for five days followed by a PBPC graft targeted to deliver ≥ 5x106 CD34+ cells/kg. Cyclosporine A (CSA) for GVHD prophylaxis used initially with target CSA levels in the therapeutic range (200 -400 ng/ml).
89480813|NCT02084329|Experimental|Weighted Compression Vest|Weighted Compression Vest
89480814|NCT02084329|No Intervention|Control|
89480815|NCT02087917|Placebo Comparator|Placebo|
89480816|NCT02087917|Active Comparator|HS-25 5 MG|
89480817|NCT02087917|Active Comparator|HS-25 10 MG|
89480818|NCT02087917|Active Comparator|HS-25 20 MG|
89480819|NCT02087917|Active Comparator|HS-25 30 MG|
89531459|NCT06066086|Experimental|Hinge Flap group|Patients who will be included in this study will be treated by using hinge flap and buccal advancement flap to close their oroantral fistula. A circular incision will be performed at the oral side of the oroantral fistula. The tissues will be reflected and sutured by purse sutures. Then the tissues will be pushed up to close sinus membrane. A pyramidal flap will be reflected at the buccal tissues, then horizontal incisions will be performed at the base of the flap to allow advancement of the flap over the fistula and a tension-free suturing to the palatal tissues.
88951344|NCT01945983|Active Comparator|Early norepinephrine|Norepinephrine 4 mg in 5% dextrose water 250 ml Intravenous infusion rate range from 8 to 15 ml/hour, adjusted according to patient's body weight to achieve norepinephrine 0.05microgram/kg/min Continuous drip for 48 hours.
89480820|NCT02082223|Experimental|Preoperative Rehabilitation|"Patient & caregiver input regarding 'single biggest concern right now' (modified BEACON buttons) will be elicited. Information gathered by the study team which includes a trained nursing coach and the patient/caregiver will together develop an individualized 'toolbox' of possible interventions to improve preoperative quality of life.~Candidate interventions include, but not limited to: Participation in SMART program, caregiver participation in Caregivers study protocol MC1295 (IRB 13-002943), nutritional recommendations (deficiencies, immuno-nutrition), low impact resistance training/tai chi, referral to financial or counseling services, establishment of information sources & plans for concerns not frequently covered in clinical practice such as sleeplessness, spiritual assistance."
89480821|NCT02084407|Active Comparator|DM1 subject with cardiopathy|Clinical examination, Skin biopsy, Blood and urine sampling
89480822|NCT02084407|Active Comparator|DM1 subject without cardiopathy|Clinical examination, Skin biopsy, Blood and urine sampling
89480823|NCT02084407|Active Comparator|Not DM1subject|Clinical examination, Skin biopsy, Blood and urine sampling
89480824|NCT02082301||Gestational diabetes|Primary cohort is women with diagnosis of gestational diabetes without evidence of overt diabetes
89480825|NCT02084485|Experimental|Arm A|
89480826|NCT02084485|Placebo Comparator|Arm B|
89480827|NCT03559231|Experimental|dFTRD|Endoscopic full-thickness resection of the duodenal adenoma with the 'duodenal Full-Thickness resection device' (dFTRD).
89480828|NCT03559231|Active Comparator|EMR|Endoscopic Mucosal Resection (EMR) of the duodenal adenoma (=standard therapy).
89480829|NCT02084563|Other|AML-Intensive Chemotherapy|"Patients with Acute Myeloid Leukemia fit for intensive chemotherapy Patients will receive Induction Chemotherapy, and CR will be evaluated after 28 days.~Patients who achieve CR post-induction chemotherapy will receive post-remission therapy according to risk:~Low risk patients: Consolidation chemotherapy or Autologous stem cell transplantation~Intermediate and high-risk patients: Allogeneic stem cell transplantation Patients who do not achieve CR may receive one second induction cycle, and if CR is achieved may proceed to post-remission therapy as per above. Patients who do not achieve CR after two cycles of induction will be deemed refractory and removed from the study."
89480830|NCT02084563|Other|AML-Non-intensive chemotherapy|"Patients with acute myeloid leukemia not fit for intensive chemotherapy Patients will receive induction chemotherapy with either low dose cytarabine or decitabine. Assignment to each drug will depend on drug availability and physician discretion. No randomization will be done between the drugs.~Cycles will be repeated every 28 days. Patients who achieve CR will continue to post-consolidation therapy with either cytarabine or decitabine, based on the induction therapy received. Patients will receive a maximum of 4 cycles until achieving CR, if no response is seen after 4 cycles patients will be deemed refractory."
89480831|NCT02084563|No Intervention|Chronic Myeloid Disorders|"Patients with Chronic Myeloid Disorders:~Myeloproliferative Neoplasms~Myelodysplastic Syndromes~Myeloproliferative/Myelodysplastic Neoplasms"
89480832|NCT03559153|No Intervention|Control group|All workers will receive ergonomics instructions. Instruction for rest break.
89480833|NCT03559153|Experimental|Passive rest break - Shiatsu massage|"All workers will receive ergonomics instructions. The workers will be receive quick massage using shiatsu techniques."
89480834|NCT03559153|Active Comparator|Active rest break - Physical Exercise Program|All workers will receive ergonomics instructions. The workers will be receive exercises during the rest break.
89480835|NCT02084641|Experimental|Insulin resistant|Both groups will be given the same intervention and then outcomes compared between groups
89480836|NCT02084641|Experimental|Insulin Sensitive|Both groups will be given the same intervention and then outcomes compared between groups
89480837|NCT02084719|Experimental|Group A|Patients will be tests with both the standard algorithm and the Oraquick HCV Rapid Antibody Test
89480838|NCT02084719|Active Comparator|Group B|Patients will be tested only with the standard algorithm
89480839|NCT02088307|No Intervention|Control|Subjects in the control arm will not receive an intervention.
89480840|NCT02088307|Experimental|CardioLife|The main ingredients in the CardioLife supplements are as follows: garlic, co-enzyme Q10, arjuna, hawthorn, guggul, red yeast rice, policosanol, nattokinase, tumeric/curcumin, ashwangandha, L-carnitine, grape seed extract and vitamin B12.
89480841|NCT02082379|Active Comparator|Term newborns 1-6 week old|A Hudson nebulizer will be loaded with 3 mls of normal saline and operated at 7 L/min of wall air for 3 minutes with each scenario with a 5-minute interval between interfaces. The interfaces that will be used are: tight mask, the angled PediNeb, the B&B adapter, mask placed at 2 cm from the face, the PediNeb T-piece, and a capped corrugated tubing placed 2 cm away from the face.
89480842|NCT02082379|Active Comparator|Infants 6-8 month old|A Hudson nebulizer will be loaded with 3 mls of normal saline and operated at 7 L/min of wall air for 3 minutes with each scenario with a 5-minute interval between interfaces. The interfaces that will be used are: tight mask, the angled PediNeb, the B&B adapter, mask placed at 2 cm from the face, the PediNeb T-piece, and a capped corrugated tubing placed 2 cm away from the face.
89480843|NCT02084875|Experimental|tofacitinib MR 11 mg Fed|tofacitinib modified release (MR) 11 mg tablet administered with food.
89480844|NCT02084875|Experimental|tofacitinib MR 11 mg Fasting|tofacitinib modified release (MR) 11 mg tablet administered without food.
89480845|NCT02689453|Experimental|1A-Interleukin 15 (IL-15) Followed by Alemtuzumab|IL-15 for 10 doses over two weeks followed by alemtuzumab for 4 weeks per dosing schema to determine the maximum tolerated dose (MTD)
89480846|NCT02689453|Experimental|1B - Interleukin-15 (IL-15) Followed by Alemtuzumab at the Maximum Tolerated Dose|IL-15 for 10 doses over two weeks followed by alemtuzumab for 4 weeks at the maximum tolerated dose (MTD)
88951345|NCT01945983|Placebo Comparator|Placebo|5% dextrose water 250 ml Intravenous infusion rate range from 8 to 15 ml/hour. Adjust rate of infusion according to patient's body weight to achieve dosage of norepinephrine comparable to 0.05 microgram/kg/min Continuous drip for 48 hours.
88951346|NCT01946009|Experimental|Cidofovir 1%|Cidofovir 1% cream's basis, 2gr, three times per week, during 4 weeks.
88951347|NCT01946022|Active Comparator|GnRH Agonist|GnRH long agonist protocol of invitro fertilization
88951348|NCT01946022|Active Comparator|GnRH Antagonist|GnRH fixed antagonist protocol of in vitro fertilization
88951349|NCT01946035|Placebo Comparator|Placebo|Participants will take 1 capsule placebo each evening
88951350|NCT01946035|Experimental|Doxazosin XL|Participants will take 1 capsule Doxazosin 4mg XL each evening
88951351|NCT01946048|Experimental|mesenchymal stem cells|Stem cells implantation Patients with severe coronary artery disease with ischemic cardiomyopathy managed with intramyocardial administration of allogeneic mesenchymal stem cells.
88951352|NCT01946061|Experimental|Treatment group|
88951353|NCT01946087|Experimental|RIPC group|
88951354|NCT01946087|Placebo Comparator|Control group|
88951355|NCT01946113||Retrospektive Cohort|Patients requiring renal replacement therapy from 2011 to 2012 on intensive care unit
88951356|NCT01946113||Prospektive Cohort|Patients requiring renal replacement on intensive care unit in 2013 and 2014
88951357|NCT01946217||Observational (questionnaire administration)|Participants complete the IMPACTS survey comprising questions about socio-demographic information and clinical trial participation.
89480847|NCT02082457|Placebo Comparator|Placebo|Two tablets of YKP10811 placebo are administered orally once a day for 12 weeks.
89480848|NCT02082457|Experimental|YKP10811 10mg|Two tablets of YKP10811 5mg are administered orally once a day for 12 weeks.
89480849|NCT02082457|Experimental|YKP10811 20mg|One tablet of YKP10811 20mg and one tablet of placebo are administered orally once a day for 12 weeks.
89480850|NCT02082457|Experimental|YKP10811 40mg|Two tablets of YKP10811 20mg are administered orally once a day for 12 weeks.
89480851|NCT02084953|Experimental|ARM A: BMS-791325|BMS-791325 600 mg tablet orally on 1st and 2nd day, then 900 mg on the 3rd day once a day for 3 days
89480852|NCT02084953|Active Comparator|ARM B: Moxifloxacin|Moxifloxacin 400mg tablet orally once on third day
89480853|NCT02084953|Placebo Comparator|ARM C: Placebo matching BMS-791325|Placebo matching BMS-791325 0 mg tablet orally once daily for 3 days
88951358|NCT01946256|Active Comparator|Amoxicillin|Amoxicillin 500mg three times in a day for 1 week
88951359|NCT01946256|Placebo Comparator|Erythromycin|Erythromycin 500mg four times in a day for 1 week
88951360|NCT01946269|Active Comparator|Standard group|
88951361|NCT01946269|Active Comparator|Goal-directed therapy (GDT) protocol|
88951362|NCT01946295|Experimental|Famotidine|Famotidine 100mg x 2 orally
88951363|NCT01946295|Placebo Comparator|Placebo|Placebo control
88951364|NCT01946308|Experimental|conformational positioner & mattress|conformational positioner & mattress, five hours on each
88951365|NCT01946321|Other|Post-amputation functional rehab|Patients will continue with their rehabilitation programme, as specified by their clinical team, following amputation. A series of functional outcome measures will be carried out at 3 or 4 time points during the first 3 months following delivery of their artificial limb.
88951366|NCT01946334|Experimental|patients|
88951367|NCT01946347|Experimental|Patients with type 2 diabetes|30 individuals with type 2 diabetes Intervention: mixed meal, acute in vivo induced hyperinsulinemia
88951368|NCT01946347|Active Comparator|Healthy subjects|30 healthy men and women with no metabolic syndrome Intervention: mixed meal, acute in vivo induced hyperinsulinemia
89480854|NCT02082613|Experimental|Lord´s procedure|Lord´s procedure for testicular hydrocele, under local anesthesia in a conventional operation room, under sterile conditions
89480855|NCT02082613|Active Comparator|Sclerotherapy|Sclerotherapy with 4 ml of polidocanol 30mg/ml after complete emptying of the hydrocele. With or without local anesthesia, not performed in an operation room.
89480856|NCT02085031|Experimental|Intracorporeal Roux-en-Y esophagojejunostomy|During totally laparoscopic total gastrectomy, Roux-en-Y esophagojejunostomy intracorporeally using a transorally inserted anvil (OrVil™) will be performed for the patients assigned to this arm.
89480857|NCT02085031|Active Comparator|Extracorporeal Roux-en-Y esophagojejunostomy|During laparoscopic total gastrectomy, Roux-en-Y esophagojejunostomy extracorporeally using a transabdominally inserted anvil will be performed for the patients assigned to this arm.
89480858|NCT02085109|Experimental|High fat meal|A high fat milkshake containing 60.6 grams of fat
89480859|NCT02085109|Placebo Comparator|Low fat meal|A Low fat milkshake containing 10.5 gram of fat
89480860|NCT02085109|Experimental|A Low fat meal containing theobromine|A low fat milkshake containing 10.5 grams of fat supplemented with 850 mg of theobromine
89480861|NCT02088463|Experimental|Mobilization (manual therapy)|Mobilization (manual therapy) posterior- anterior at the L3 for 2 minutes in addition to the traditional treatment in the form of infra-red and ultrasound. The treatment duration for the three groups was 3 times/week for 4 weeks.
88951369|NCT01946360|No Intervention|ACLF and Acute Liver Failure (ALF)..|Methacetin Breath Test will be done on Day 0,7,14,28 in Acute on Chronic Liver Failure (ACLF)and on day 0,1,3,7 in Acute Liver failure (ALF).
88951370|NCT01946386|Experimental|LEO 90100|
89480862|NCT02088463|Placebo Comparator|placebo mobilization|placebo mobilization applied without force application. The treatment duration for the three groups was 3 times/week for 4 weeks
89480863|NCT02088463|Other|Ultrasound and infrared therapy|ultrasound and infrared are a traditional treatment for low back painThe treatment duration for the three groups was 3 times/week for 4 weeks.
89480864|NCT02085187|Experimental|Telemedicine training and counselling|
89480865|NCT02547727|Experimental|Four-site intradermal vaccination|0.1 ml of rabies vaccine is distributed to 4 sites over both arms and thigh intradermally on day 0. Blood would be drawn for rabies neutralizing antibody, OX-40 assay and cytokines assessment on day 0,7,14.
89480866|NCT02547727|Active Comparator|Intramuscular vaccination|0.5 ml of rabies vaccine is injected to one arm on day 0 and 3.Blood would be drawn for rabies neutralizing antibody, OX-40 assay and cytokines assessment on day 0,7,14.
89480867|NCT02310919|Experimental|Low dose hCG plus FSH co-trigger|On the day of ovulation trigger the patient will receive hCG 1,500 IU SQ plus FSH 450 IU SQ
89480868|NCT02310919|Active Comparator|Standard dose of hCG alone|On the day of ovulation trigger the patient will receive standard dose of hCG (10,000 or 5,000 IU SQ)
89480869|NCT02082925|Experimental|COPD patient|
89480870|NCT03557983|Experimental|fenofibrate|Fenofibrate should be topically spread three times per day at the irradiated areas, with a concentration of 400 μg/mL for week.
88951371|NCT01946399|Other|Ozurdex implant|Intravitreal injection of Ozurdex implant
88951372|NCT01946451||Idiophatic ERMs|
88951373|NCT01946451||Secondary ERMs|
88951374|NCT01946464||undergoing surgery with general anesthesia|pts: edentulous, bearded, obstructive sleep apnea, Mallampati Class III or IV
88951375|NCT01946464||Mallampati I and II|Control group Mallampati I visualization of tonsils, uvula and soft palate Mallampati II visualization of hard and soft palate, and upper portion of tonsils and uvula.
88951376|NCT01946490||Radiotherapy in 2001|
88951377|NCT01946490||Radiotherapy in 2004|
88951378|NCT01946490||Radiotherapy in 2006|
88951379|NCT01946490||Radiotherapy in 2010|
89480871|NCT03557983|Placebo Comparator|Saline|Saline is topically spread three times per day for one week.
89480872|NCT02085343|Experimental|EXP + SBF + AA|Exposure therapy (EXP) with safety behavior fading (SBF) and anti-phobic action (AA)
89480873|NCT02085343|Active Comparator|EXP + SBF|Exposure therapy (EXP) with safety behavior fading (SBF)
89480874|NCT02085343|Active Comparator|EXP|Standard therapist-guided in vivo exposure therapy (EXP)
89480875|NCT02085343|No Intervention|Wait-list control|Subjects assigned to this arm will undergo assessments at Weeks 0, Week 1, and Week 5, but will not receive any interventions.
89480876|NCT03558919|Experimental|Mirabegron|Mirabegron 25mg will give daily at night for 12 weeks
89480877|NCT03558919|Active Comparator|Solifenacin|Solifenacin Succinate 5mg will give daily at night for 12 weeks
89480878|NCT02083003|Experimental|Polyamine low-diet|Polyamines depleted diet during the week before surgery : 2 cans per day of Polydol (oral alimentation without polyamines), associated to predefined menus low in polyamines
89480879|NCT02083003|Active Comparator|Liberal alimentation|No specific alimentary diet
89480880|NCT02083159||Patients with NAFLD|
89531460|NCT06066086|Active Comparator|Palatal Flap group|Patients who will be included in this study will be treated by using he anteriorly based palatal rotational flap to close the oroantral fistula. Two paralleling incisions will be performed on the palatal side of the fistula. The distance between the two incisions will be 2 to 3 mm greater than the width of the fistula. Then the two incisions will be connected together via a circular incision at the bony end of the hard palate. The flap reflection will be performed, and the greater palatine vessels will be legated and cauterized to allow lateral repositioning of the flap over the fistula. The flap will be sutured to the buccal tissues.
89480881|NCT02085577|Experimental|Ketamine|"(S)-(+)-Ketamine Hydrochloride Solution 25 mg/ml bolus 0.5 mg/kg administered immediately after induction of anesthesia, followed by infusion ketamine 0,25 mg/kg/h terminated at last suture to the skin.~Morphine. Morphine Sulphate 1 mg/ml, bolus 0.4 mg/kg administered 45 min before expected awakening.~Escape sufentanil. Sufentanil 5 microgram/ml, bolus 5 micrograms administered by the anaesthetic nurse in the operating room if the patient is in pain upon awakening.~Morphine. PCA-morphine, bolus 2.5 mg, lock-out-time 5 min. Concentration : Morphine sulphate 1 mg/ml.~Escape morphine. Morphine Sulphate 1 mg/ml, bolus 2.5 mg administered by the PACU nurse on request of the patient for the first hour postoperatively.~Ondansetron 2 mg/ml, 4 mg iv in case of moderate to severe nausea, supplemented by 1 mg iv if needed~Paracetamol 1 g orally 1 h preoperatively and every 6 h after extubation time during the first 24 h.~The patients usual daily opioids"
88951380|NCT01946555||Worst pain, Average pain|"It is necessary that patients are treated for their baseline pain with opioid medications 3rd step (WHO guidelines), having seven different provisions molecules (morphine, methadone, fentanyl, buprenorphine, oxycodone, hydromorphone and tapentadol), and that they receive opioid rescue medication, based on free choice among the options available on the market (in the form of transmucosal fentanyl: OTFC - lollipop, buccal buccal tablets, sublingual tablets, nasal spray in aqueous solution, with pectin nasal spray, morphine or other opioid oral immediate release or intravenously)."
89480882|NCT02085577|Placebo Comparator|Placebo|"Isotonic sodium chloride 0.9 percent 0.02 ml/kg administered immediately after induction of anesthesia, followed by infusion isotonic sodium chloride 0.01 ml/kg/h terminated at last suture to the skin.~Morphine. Morphine Sulphate 1 mg/ml, bolus 0.4 mg/kg administered 45 min before expected awakening.~Escape sufentanil. Sufentanil 5 microgram/ml, bolus 5 micrograms administered by the anaesthetic nurse in the operating room if the patient is in pain upon awakening.~Morphine. PCA-morphine, bolus 2.5 mg, lock-out-time 5 min. Concentration : Morphine sulphate 1 mg/ml.~Escape morphine. Morphine Sulphate 1 mg/ml, bolus 2.5 mg administered by the PACU nurse on request of the patient for the first hour postoperatively.~Ondansetron 2 mg/ml, 4 mg iv in case of moderate to severe nausea, supplemented by 1 mg iv if needed~Paracetamol 1 g orally 1 h preoperatively and every 6 h after extubation time during the first 24 h.~The patients usual daily opioids"
89480883|NCT03557827|Sham Comparator|control|Mechanical debridement by periodontal curets alone
89480884|NCT03557827|Active Comparator|Photodynamic Therapy|Mechanical debridement by periodontal curets and supplement with photodynamic appliance
89480885|NCT02088619|Experimental|Quality of Life Therapy (QOLT)|Positive emotion-focused cognitive behavioral psychotherapy
89480886|NCT02088619|Active Comparator|Heart Healthy Education (HHE)|Heart healthy education program
89480887|NCT03558841|Experimental|Intervention Group|Gait training with the THERA-Trainer Lyra (3x/week) in addition to conventional geriatric rehabilitation physical therapy (6x/week) during inpatient period. After discharge home, continuation of Lyra gait training (3x/week), discontinuation of physical therapy.
89480888|NCT03558841|Active Comparator|Control Group|Conventional geriatric rehabilitation physical therapy (6x/week) during inpatient period. After discharge home, discontinuation of physical therapy.
89480889|NCT02090803||Graft of autologous hematopoietic stem cells|
89480890|NCT02088853|Experimental|high fat diet|
89480891|NCT02088853|Active Comparator|high carb diet|
89480892|NCT02085655|Experimental|PEG-ASP+Gemox regimen group|PEG-ASP 2000U/m2 im d1 Gemcitabine 800mg/m2 ivdrip 30min d1，8 Oxaliplatin 100mg/m2 ivdrip d1 Thalidomide 150-200mg po qn d8-21
89480893|NCT02085655|Active Comparator|AspaMetDex regimen group|Pegaspargase 2000U/m2 im， d1 methotrexate 3000m g/m2 civ 6-hour，d1, Calcium folinate 30mg iv q6h x6 Dexamethasone 40 mg ivdrip QD
89480894|NCT02085733||Possible Septic Arhtritis Patients|
89480895|NCT02085811||Patients|
89480896|NCT02090881|Experimental|ultrasound scan in ages 2-16 years|Children aged 2-16 years of age with Sickle Cell Disease and under the care of consultant haematologist as part of the NHS screening programme.
89480897|NCT02085889||food intolerance|lactose intolerance fructose intolerance neither intolerance
89480898|NCT02085967|Experimental|E2006 Part A|E2006 10-mg tablets alone and in combination with rifampin 600 mg or itraconazole 200 mg
89480899|NCT02085967|Experimental|E2006 Part B|E2006 10-mg tablets alone and in combination with midazolam 2 mg plus bupropion 75 mg
89480900|NCT02089009|Other|Group 1 Standard Population|Retinal Imaging, vessel measurements, vessel changes of a population of a female health hospital
89480901|NCT02089009|Other|Group 2 Pregnant Population|Change in vessel diameter at perinatal visits with retinal imaging (Retinal Imaging, vessel measurements, vessel changes)
89480902|NCT02089087|Experimental|CFZ533 in healthy volunteers|CFZ533 single dose in healthy volunteers
89480903|NCT02089087|Experimental|CFZ533 in rheumatoid arthritis patients|CFZ533 single dose in rheumatoid arthritis patients
89480904|NCT02089087|Placebo Comparator|Placebo|Placebo single dose
88951381|NCT01946568|Experimental|Single dose Dalbavancin|
88951382|NCT01946581||Cataract Surgery|
88951383|NCT01946594|Active Comparator|Acetaminophen Arm|"Acetaminophen Suspension 160 mg / 5 mL:~Oral dose immediately following IIV and every 4-6 hours up to 24 hours (Maximum 5 oral doses)"
88951384|NCT01946594|Placebo Comparator|Placebo Arm|"Placebo Suspension:~Oral dose immediately following IIV and every 4-6 hours up to 24 hours (Maximum 5 oral doses)"
89480905|NCT02091115|Placebo Comparator|Dairy drink|Patients received dairy drink for 60 days and were instructed to consume a glass of 150 mL daily.
88951385|NCT01946607|Active Comparator|Citalopram|20 mg citalopram capsule, 1/ day, after breakfast (approximately 8am), for 7 days
88951386|NCT01946607|Placebo Comparator|Placebo|Placebo capsule 1/ day, after breakfast (approximately 8am), for 7 days
89480906|NCT02091115|Active Comparator|Dairy drink with probiotic culture|Patients received dairy drink with probiotic culture for 60 days and were instructed to consume a glass of 150 mL daily.
89480907|NCT02091193||Placebo to Krill Oil|Group 2 receives supplement B for four weeks, undergoes a two week washout period, and then receives supplement A for another four weeks. Measurements are taken at baseline, after supplement B completion and after supplement A completion. Participants are informed which supplement was krill oil and which was placebo following completion of this phase of the study. Group 2 participants are given an option to also take an additional 17 weeks of Krill Oil and return for a follow up evaluating the long term use of krill oil.
89480908|NCT02091193||Krill Oil to Placebo|Group 1 receives supplement A for four weeks, undergoes a two week washout period, and then receives supplement B for another four weeks. Measurements are taken at baseline, after supplement A completion and after supplement B completion. Participants are informed which supplement was krill oil and which was placebo following completion of this phase of the study. Group 1 participants are given an option to also take an additional 17 weeks of Krill Oil and return for a follow up evaluating the long term use of krill oil.
89480909|NCT02091349|Placebo Comparator|Group A- placebo|control- snack bar or muffin containing no fiber
89480910|NCT02091349|Experimental|Group B- polydextrose|polydextrose- randomly bonded polysaccharide of glucose which is poorly digested in small intestine
89480911|NCT02091349|Experimental|Group C- soluble corn fiber|Soluble corn fiber made from corn starch and contains oligosaccharides with random glyucosyl bonds and may contain minor amounts of monosaccharides
89480912|NCT02086123|Active Comparator|Epidural Analgesia|Subjects randomized to this arm will receive Bupivacaine + Fentanyl Epidural Analgesia. Subjects on this group could be allowed to receive Toradol Intravenously (IV) + Acetaminophen Orally (PO) if needed.
89480913|NCT02086123|Active Comparator|Parenteral Analgesia (Intravenous)|Subjects randomized to this arm will receive Analgesia with Dilaudid 0.2 -0.4 mg Intravenously (IV) every 3 hours. Subjects on this group could be allowed to receive Toradol Intravenously (IV) + Acetaminophen Orally (PO) if needed.
89480914|NCT02091505|Experimental|Intravitreal injection of Ranibizumab|
89480915|NCT02086201|Active Comparator|Problem Solving Therapy|Problem solving therapy is an evidence based psychotherapy for depression, with 30 years of research supporting its efficacy. PST focuses on the patients themselves and helps them develop skills in identifying, prioritizing, and solving problems, and thereby creates a sense of empowerment.
89480916|NCT02086201|Experimental|Engage|"Engage utilizes reward exposure consisting of the reintroduction of activities that patients once found rewarding and enjoyed, but have abandoned after they developed depression. Engage uses basic problem solving through which patients learn how to form action plans for pursuing rewarding activities of their choice."
89480917|NCT02089165|Experimental|Krill oil|The interventions are administered in the randomized order.
89480918|NCT02089165|Experimental|Krill meal|The interventions are administered in the randomized order.
89480919|NCT02089165|Active Comparator|Fish oil|The interventions are administered in the randomized order.
89480920|NCT02091661|Active Comparator|Radical retropubic prostatectomy|The surgery arm underwent radical retropubic prostatectomy, performed by a technique described by Walsh.surgery started with dissection of the pelvic lymph nodes. If there were no signs of metastasis in frozen sections, the operation was continued with retropubic radical prostatectomy. The prostatectomy is performed in retrograde way, preserving the neurovascular bundles if feasible. The degree to which the surgeon preserve the nerves is categorized as non-nerve-sparing, unilateral nerve-sparing, or bilateral nerve-sparing.The operative time is about 2 to 3 hours and required hospital stay. The patient has a urinary catheter placed for 6 to 9 days to facilitate bladder emptying.
89480921|NCT02091661|Active Comparator|External beam radiotherapy|External beam radiotherapy is carried out with intensity-modulated radiation technique. The treatment is designed to maximize the radiation dose to the prostate and seminal vesicles and minimize exposure to surrounding structures, including the bladder and rectum. Radiation to the prostate was delivered in fractionated doses divided over multiple treatments (180 to 200 centigray (cGy) daily fractions, 5 days per week) for a total dose to the prostate of 68 to 77 gray (Gy), prescribed at 90% to 100% of the isodose line.
89480922|NCT02089243|Experimental|Vagus nerve stimulation therapy|Surgical follow-up typically occurred 2 weeks postoperatively and, subsequently, on a variable schedule as indicated. The adjustments in device parameters were performed, individually, and solely at the discretion of the primary epileptologist with a formal protocol guiding changes. Retrospective chart review was performed to collect follow-up and outcome data. At the time of last available clinical follow-up, the following data were collected: mean weekly seizure frequency (from seizure logs kept by caretakers or patient or caretaker report averaged of the last 3 months prior to ﬁnal follow-up), complications of VNS therapy, duration of VNS therapy, timing and all subsequent surgical procedures.
88951387|NCT01946620|Experimental|Flutiform 250/10 micrograms|Flutiform 250/10 µg (2 puffs twice daily)
88951388|NCT01946620|Experimental|Flutiform 125/5 micrograms|Flutiform 125/5 µg (2 puffs twice daily)
88951389|NCT01946620|Active Comparator|Formoterol 12 micrograms|Formoterol 12 µg 1 puff twice daily
88951390|NCT01946633|Experimental|Esophagogastroduodenoscopy（ECG）|n=15
88951391|NCT01946646|Experimental|S-1-CCRT|There are five dose levels and one arm only. Level 1: S-1, 25 mg/m2, bid, Day 1-14; RT 25 Gy/10 fx, Day 1-5, 8-12 Level 2: S-1, 25 mg/m2, bid, Day 1-14; RT 30 Gy/10 fx, Day 1-5, 8-12 Level 3: S-1, 30 mg/m2, bid, Day 1-14; RT 30 Gy/10 fx, Day 1-5, 8-12 Level 4: S-1, 30 mg/m2, bid, Day 1-16; RT 36 Gy/12 fx, Day 1-5, 8-12, 15-16 Level 5: S-1, 35 mg/m2, bid, Day 1-16; RT 36 Gy/12 fx, Day 1-5, 8-12, 15-16 All dose levels are followed by Gemcitabine/S-1 (G 1000 mg/m2, iv, D1 and 15 plus S-1 60/80/100 mg/day based on BSA, po, D1-7, D15-21, q4w) after the CCRT
88951392|NCT01946659|Experimental|Adherence to Sleep Apnea Treatment|The intervention arm of the study receives tailored education regarding Sleep Apnea by the study health educator via telephone.
88951393|NCT01946659|Other|Standard Care Group|The standard care group gets the standard print communications about sleep apnea produced by NLHBI and American Academy of Sleep Medicine.
89203054|NCT00660192|Placebo Comparator|Placebo|Subjects are randomized to receive Placebo which is inactive saline (sterile salt water solution). The Subjects are injected with a comparable amount of placebo solution (2cc-3cc) as received by those randomized to receive active study drug. The randomization will be done in a double blinded manner where the investigator nor the subject knows which substance (Placebo vs. Botox) is being injected.
89480923|NCT02089243|Experimental|Resective surgery|The type of surgery performed consisted of standard anterior temporal lobectomy, electrocorticography tailored temporal lobectomy, anteromedial temporal lobectomy, transcortical or transsylvian or subtemporal selective amygdalohippocampectomy, temporal lobe disconnection and hippocampal transection.
89480924|NCT02091817|Other|Control group|Control group will be administered oxytocin and placebo, in a double-blind randomized order.
89480925|NCT02091817|Experimental|congenital prosopagnosia|Congenital prosopagnosics will be administered oxytocin and placebo in a double-blind randomized order.
89480926|NCT03557671|Experimental|TRHF - Placebo|Each subjects will receive both TRHF and placebo formula during the 1st part of the study
89480927|NCT03557671|Placebo Comparator|Placebo - TRHF|Each subjects will receive both TRHF and placebo formula during the 1st part of the study
89480928|NCT02089321||Patients with Low Back Pain|"n= 19~Inclusion Criteria:~Between the ages of 18 and 70 years Currently seeking, but not yet initiated, treatment from a health care professional (PT, MD, DO, DC) for a chief complaint of pain between the level of the twelfth thoracic vertebrae and the coccyx Able to transition between standing, sitting, supine, prone and sidelying independently~Exclusion Criteria:~Signs of neurological impairment including diminished myotatic reflex, sensory impairment or strength deficits in a myotomal pattern No previous spine or hip surgery Serious spinal or systemic pathology Pregnancy within previous 12 months Inability to understand and follow verbal instructions in English"
89480929|NCT02089321||Healthy Controls|"n= 19~Inclusion Criteria:~Between the ages of 18 and 70 years No LBP episodes requiring clinical care by a health professional and/or greater than 3 days absence from work/school/recreation within the previous 5 years Able to transition between standing, sitting, supine, prone and sidelying independently~Exclusion Criteria:~No previous spine or hip surgery Serious spinal or systemic pathology Pregnancy within previous 12 months Inability to understand and follow verbal instructions in English"
89480930|NCT02086279|No Intervention|GnRH analogue|"Patients with uterine myoma, endometriosis, fibromatous uterus, chronic pelvic pain in list for surgery are usually pharmacologically treated by administration of GnRHa, 11.25 mg at 21° day of the menstrual cycle and repeated after 3 months to reduce pain symptoms, menstrual blood loss, uterine or fibroids vascularization and size, during the months spent on surgery waiting list.~Patients enrolled will be subjected to valuation of ovarian reserve: specifically, serum levels of AMH and antral follicle count (AFC) between 1 and 4 days of the menstrual cycle will be measured at study entry and at 1, 3 and 6 months after the administration of the first vial of GnRH-a"
89480931|NCT02086357||SWUE|
89480932|NCT02086435|Experimental|Extracorporeal morcellation|"Extracorporeal morcellation in which patients are treated with protected removal by endobag and extracorporeal myoma morcellation with cold scissors and scalpel blade or with power morcellator used inside the bag itself"
89480933|NCT02086435|Active Comparator|Intracorporeal morcellation|Intracorporeal morcellation patients treated with standard intracorporeal morcellation, using reusable electronic device
89480934|NCT02091895|Experimental|endo group|colon polyp, early colon cancer, colorectal submucosal tumor, ileocecal ulcers
89480935|NCT02081911|Experimental|High volume Adductor canal block|Adductor canal block performed in the distal thigh (1/3 of the total distance between the superior border of the patella and the femoral crease, cephalad to the patella) utilizing an injectate volume of 30 mL 0.25% bupivacaine/ epinephrine
89480936|NCT02081911|Experimental|Low volume Adductor Canal Block|Adductor canal block performed in the distal thigh (1/3 of the total distance between the superior border of the patella and the femoral crease, cephalad to the patella) utilizing an injectate volume of of 10 mL 0.75% bupivacaine/ epinephrine
89480937|NCT02081911|Experimental|Femoral nerve block|Femoral nerve block with 10 mL 0.75 % bupivacaine/epinephrine
89480938|NCT02091973|Experimental|Everolimus|everolimus dosing to tough level 6-10 ng/ml
89480939|NCT02091973|Experimental|Tacrolimus|Tacrolimus dosing to target tough level 5-10 ng/ml
89480940|NCT02092051|Experimental|Continuous glucose monitoring|Continuous glucose monitoring with DexCom G4 platina during 6 months
89480941|NCT02092051|No Intervention|Conventional therapy|Conventional therapy during 6 months using only SMBG for glucose monitoring
89480942|NCT02086513|Experimental|LDE225|LDE225 will be administered orally, on a continuous once daily dosing schedule at a dose of 200 mg, 400 mg, 600 mg, or 800 mg depending on the specific cohort. Starting dose 200 mg daily for a 28 day cycle. The DLT period will be for the first 2 cycles of therapy. Each cycle is 28 days in length, making the DLT period of minimum of 56 days.
89480943|NCT02086669|Experimental|Pneumatic dilatation|Repetitive pneumatic dilatation as the initial treatment followed by repetitive dilatation in case of dysphagia recurrence.
89480944|NCT02086669|Active Comparator|Surgical myotomy|Laparoscopic myotomy and subsequent follow up.
89480945|NCT02089399|Experimental|Treatment AB|S->S+C
89480946|NCT02089399|Experimental|Treatment C|C
89480947|NCT02089477|Experimental|Support|"The participants in the intervention group receives the intervention and support consisting of:~Individual Goal Setting: 2-3 functional goals related to everyday life evaluated every 4th week.~SMS send every Sunday with 5 possible responses. depending on the answer of the participant it will cause a telephone call from a project about motivation and barriers for interval walking."
89480948|NCT02089477|No Intervention|Control group|Patient's in the control group receives the intervention with interval Walking and no other support.
89480949|NCT02089555||African Americans|This group consists of African American (AA) individuals aged 65-80 who are part of the Emory Alzheimer's Disease Research Center (ADRC) (a multi-racial cohort of subjects with normal cognition, Mild Cognitive Impairment (MCI) or mild Alzheimer's Disease (AD)) or the Registry for Remembrance (RfR) (a community of AA individuals who are interested in studies of memory and aging). AA and Non-Hispanic White (NHW) participants will be frequency-matched for age, gender, and education within each cognitive category (35 with normal cognition, 30 with MCI, and 10 with mild AD for each race).
88951394|NCT01946698||Fertility patients|Women with endometriosis compared to women without endometriosis. Different samples will be collected (blood, follicular fluid, cells from the uterus)
88951395|NCT01946737|Active Comparator|Invasive coronary angiography (ICA)|Routine diagnostic ICA
89480950|NCT02089555||Non-Hispanic Whites|This group consists of Non-Hispanic White (NHW) individuals aged 65-80 who are part of the Emory Alzheimer's Disease Research Center (ADRC) (a multi-racial cohort of subjects with normal cognition, Mild Cognitive Impairment (MCI) or mild Alzheimer's Disease (AD)). African American (AA) and Non-Hispanic White (NHW) participants will be frequency-matched for age, gender, and education within each cognitive category (35 with normal cognition, 30 with MCI, and 10 with mild AD for each race).
89480951|NCT03557515|Experimental|CBT Telephonic Sessions|All participants will receive four stress management sessions. Then, the participant is randomly assigned to receive 4 weekly additional CBT telephonic sessions. Participants will be given weekly assignments to practice the skills learned in the sessions. Sessions will last 45 minutes to 1 hour. Optional grief and loss telephonic session will be offered.
89480952|NCT03557515|Experimental|Metta-Meditation Telephonic Sessions|All participants will receive four stress management sessions. Then, the participant is randomly assigned to receive 4 weekly additional Metta-meditation sessions. Participants will be given weekly assignments to practice the skills learned in the sessions. Sessions will last 45 minutes to 1 hour. Optional grief and loss telephonic session will be offered.
89480953|NCT03557437|Active Comparator|Triple Therapy|Esomeprazole 20mg bid, Amoxicillin 1.0g tid and Metronidazole 0.4g tid for 14 days
89480954|NCT03557437|Experimental|Bismuth Plus Triple Therapy|Esomeprazole 20mg bid, Bismuth Potassium Citrate 600mg bid, Amoxicillin 1.0g tid and Metronidazole 0.4g tid for 14 days
89480955|NCT02089633|Experimental|PACOX|Pegylated human arginase (PA) in combination with Capecitabine (C) and Oxaliplatin (OX)
89480956|NCT02086747|Active Comparator|Acetaminophen|Postoperative 72 hours acetaminophen 1 g iv 4 times a day for 72 hours iv
89480957|NCT02086747|Placebo Comparator|isotonic|1 g intravenous %0.9 NaCl four times Daily for 72 hours
89480958|NCT02086825|Experimental|Rifaximin|
89480959|NCT02086825|Experimental|Lactulose|
89480960|NCT02086903|Experimental|Ticagrelor 90 mg|The subjects administer Ticagrelor 90 mg as loading dose (LD) follow by 90 mg/day as maintenance dose (MD) for 5 days, following a 2-week washout period, to receive the alternate thienopyridine (Clopidogrel 600 mg as LD follow by 75 mg/day as MD for 5 days).
88951396|NCT01946737|Experimental|HD-CTCA with ASIR|HD-CTCA with Adaptive statistical iterative reconstruction (ASIR)within 4 weeks of routine diagnostic ICA
88951397|NCT01946750|Experimental|Case|Hospitalized patient with clinical signs of Clostridium Difficile Infection and specific detection in stools of Clostridium Difficile toxins
88951398|NCT01946750|Other|Non-diarrheal control|Hospitalized patient and asymptomatic carrier of Clostridium Difficile
88951399|NCT01946763|No Intervention|safety of Anesthesia|No pre operative education
88951400|NCT01946763|Experimental|Behavioral : pre operative education|Behavioral pre operative education
89480961|NCT02086903|Experimental|Clopidogrel 600 mg|The subjects administer Clopidogrel 600 as loading dose (LD) follow by 75 mg/day as maintenance dose (MD) for 5 days, following a 2-week washout period, to receive the alternate thienopyridine (Ticagrelor 90 mg/day as LD, follow by 90 mg/day as MD for 5 days).
89480962|NCT05502055||LGBTQ+_PD|Individuals who identify as LGBTQ+ and are diagnosed with PD
89480963|NCT05502055||Non-LGBTQ_PD|Individuals who identify as non-LGBTQ+ and are diagnosed with PD
89480964|NCT05502055||Care Partner|Individuals who are Care Partners of individuals with PD
89203055|NCT00660192|Active Comparator|Botox|Subjects are randomized to receive Active study drug Botox (onobotulinumtoxinA). The Botox is prepare by diluting 100units of toxin /1cc Saline. The Subjects are injected with 200-300units of units of Botox which is 2cc-3cc of solution. The randomization will be done in a double blinded manner where the investigator nor the subject knows which substance (Placebo vs. Botox) is being injected.
89203056|NCT01564108|Experimental|Ranibizumab|Series of intravitreal injections of Ranibizumab
89203057|NCT02559128||HF+T2D+|40 patients with chronic HF and type 2 diabetes or prediabetes without previous pharmacological treatment
89203058|NCT02559128||HF+T2D-|20 subjects with HF without T2D or prediabetes
89203059|NCT02559128||HF-T2D+|20 subjects with T2D or prediabetes alone
89203060|NCT02559128||HF-T2D-|20 healthy control volunteers
89480965|NCT05502055||Health Care Provider|Health Care Providers who provide service to people with PD
89480966|NCT02087137|Active Comparator|Memory and Aging Program|The Memory and Aging Program intervention consists of five 2-hour sessions conducted over five consecutive weeks. The content of the program includes: (a) the provision of factual information (i.e., about memory, age-related memory changes, lifestyle factors affecting memory, and memory strategies) in an informal lecture format; and (b) memory intervention (i.e., practice and application of several evidence-based memory strategies) in a hands-on interactive format.
89480967|NCT02087137|No Intervention|Wait-list Control|Participants randomized to the wait-list control group will receive no intervention following randomization. They will be offered the intervention immediately following completion of the week 14 outcome testing session.
89480968|NCT02087215|Active Comparator|boron gel|diabetic foot ulcer care with formulation gel: addition of borate as sodium penta boric acid pentahydrate 3% (w/v) and two different copolymer as pluronic block namely F68 2% (w/v) and f127 2% (w/v).
89480969|NCT02087215|Placebo Comparator|control gel|placebo gel containing polymer of carbopol ultrex (1%)
89480970|NCT02087293|Experimental|Intervention group, IVR call, RPh counseling|Group receives interactive voice response automated call asking about side effects of newly prescribed medications; has opportunity to speak with study pharmacist via phone about medication
89480971|NCT02087293|No Intervention|Control|Intervention patients are matched with control patients; control patients have only chart review completed.
89480972|NCT02087371||Included patients|Patients with end-stage liver failure and registered on transplantation list.
89480973|NCT02087527|Experimental|CORTICOSTEROID|In addition to standard care for cellulitis, subject will receive intravenous Dexamethasone (8mg/2ml) 0.15 mg/kg/dose every 6 hours for the first 48 hours
89480974|NCT02087527|Placebo Comparator|NORMAL SALINE|In addition to standard care for cellulitis, subject will receive normal saline solution administered intravenously using the same volume as the active drug group every 6 hours for the first 48 hours
89480975|NCT02092129||Acromegaly|Patients with acromegaly who have received surgical treatment
89480976|NCT02089711||Japanese healthy subjects|subjects with healthy eyes
89480977|NCT02249611|Experimental|MT and life counseling|To improve physical activity, body composition, physiological parameters and quality of life by using MT (mobile physical activity promotion tool) and lifestyle counseling in diet control, increased physical activity, less smoking and drinking, deal with pressure, and regular health examination will be conducted for 3 months in intervention periods.
89480978|NCT02249611|Active Comparator|Standard care|Lifestyle counseling in diet control, increased physical activity, less smoking and drinking, deal with pressure, and regular health examination based on the booklet of metabolic syndrome prevention which is edited by Health Promotion Administration, Ministry of Health and Welfare in Taiwan only once in this period (3 months).
89480979|NCT02092207|Experimental|KL7016 900mg|
89480980|NCT02092207|Placebo Comparator|Placebo|
89480981|NCT02092207|Experimental|KL7016 600mg|
89480982|NCT02087683|Other|Vitamin D Supplementation|Participants in this group will receive vitamin D supplements of 5 000 International units per day for 12 months.
89480983|NCT02087683|Placebo Comparator|Control Group (Placebo)|Participants in this group will receive a placebo containing gelatin and corn oil per day for 12 months
89480984|NCT02092363|Experimental|Drug: OMP-54F28, Paclitaxel and Carboplatin|
89480985|NCT03558139|Experimental|Magrolimab + Avelumab (Part 1, Safety Run-in)|"Dose Level 1: Participants with solid tumors will be given a starting priming dose of 1 mg/kg magrolimab in Week 1, followed by 30 mg/kg weekly for 4 doses (Cycle 1). Starting in Cycle 2, magrolimab 30 mg/kg will be given every 2 weeks. The magrolimab dose will be combined with avelumab 800 mg given once every 2 weeks.~Based on Dose Limiting Toxicities (DLTs) assessment in Dose Level 1 Cycle 1; additional participants will be enrolled and administered Dose Level 2.~Dose Level 2: Participants with solid tumors will be given a starting priming dose of 1 mg/kg magrolimab in Week 1, followed by 45 mg/kg on Days 8,11,15, 22 and 29 for Cycle 1, continuing weekly in Cycle 2 on Days 1, 8, 15 and 22. Starting in Cycle 3, magrolimab 45 mg/kg will be given every 2 weeks. The magrolimab dose will be combined with avelumab 800 mg given once every 2 weeks.~Additional lower or higher dose levels may be explored after reviewing all available clinical data."
89480986|NCT03558139|Experimental|Magrolimab + Avelumab (Part 2, Ovarian Cancer Expansion)|After Part 1 Safety Run-in has completed and the recommended expansion dose(s) for magrolimab is determined, participants with ovarian cancer will be administered the recommended magrolimab dose(s) combined with avelumab 800 mg given once every 2 weeks.
89203061|NCT00801918|Other|DD Alone|Patients will get Denileukin Diftitox for 5 days every 3 weeks for a total of 4 cycles.
89203062|NCT00801918|Experimental|DD with ICE Chemotherapy|For patients who show a response to DD alone after 4 cycles or for patients who show progressive disease after 2 cycles, DD will be given with ICE chemotherapy for 2 cycles.
89203063|NCT05590858||non-diabetes|patients without diabetes
89480987|NCT02089867|Experimental|Ezetimibe|The ezetimibe group will receive 10 mg/day ezetimibe for 6 weeks.
89480988|NCT02089867|Experimental|Plant sterols|The plant sterol group will receive spread enriched with 2g daily of plant sterols for 6 weeks
89480989|NCT02089867|No Intervention|Control group|No additional therapy, statin maintenance
89480990|NCT02089867|Experimental|Ezetimibe + plant sterols|The ezetimibe + plant sterols group will receive ezetimibe 10 mg/day + spread enriched with 2g daily of plant sterols for 6 weeks
89203064|NCT05590858||well-regulated diabetes|patients with diabetes and HbA1c ≤ 7%
89203065|NCT05590858||poorly regulated diabetes|patients with diabetes and HbA1c > 7%
89480991|NCT02092519|Active Comparator|Needle without sideport (NA-220H-8022)|EUSFNA using needle without sideport (NA-220H-8022)
89480992|NCT02092519|Active Comparator|Needle with sideport (NA-230H-8020)|EUSFNA using needle with sideport (NA-230H-8020)
89480993|NCT02092597|Active Comparator|GLP-1 agonist|Exenatide 5 ug s.c. bid for the 1st month, 10 ug s.c. bid for the next 2 months
89480994|NCT02092597|Active Comparator|DPP-4 inhibitor|Linagliptin 5 mg tbl qd for 3 months
89203066|NCT00799188|No Intervention|1|reduction of immunosuppression
89203067|NCT00799188|Experimental|2|switch to Everolimus : 50% reduction of calcineurin inhibitors (ciclosporine or tacrolimus)
89480995|NCT02092597|Active Comparator|Sulfonylurea derivate|Gliclazid 30 mg tbl qd for 3 months
88951401|NCT01946776|Other|Reveal XT|People with drug-resistant epilepsy whose heart rhythm will be monitored continuously for 2 years using Reveal XT, an implantable heart rate monitor.
89480996|NCT02092675||COPD patients - frequent exacerbator|COPD patients with 2 and more exacerbation in one year
89480997|NCT02092675||COPD patients - non frequent exacerbator|COPD patients with less than 2 exacerbation during one year
89480998|NCT02092675||control group - healthy smokers|healthy smokers, they do not have COPD
89480999|NCT02092753|Placebo Comparator|Standard diet|Standard diet (SD): Nutrition following the standard recommendations of the German society for nutrition
89481000|NCT02092753|Experimental|Ketogenic diet|"Nutritional intervention: Ketogenic diet (KD).~Intervention: Nutritional support (hospital) + self support (outpatient phase) with KD"
89481001|NCT02092753|Experimental|Logi diet|"Nutritional intervention: low glycämic and insulinemic diet (LOGI)~Intervention: Nutritional support (hospital) + self support (outpatient phase) with LOGI"
89481002|NCT02089945||transcatheter aortic valve implantation|This study recruits individuals that are undergoing transcatheter aortic valve implantation.
89481003|NCT02092831|Experimental|Crossover sequence 1|
89481004|NCT02092831|Experimental|Crossover sequence 2|
89481005|NCT02092831|Experimental|Crossover sequence 3|
89481006|NCT02092831|Experimental|Crossover sequence 4|
89481007|NCT02090023||NHIRD obstructive sleep apnea|Secondary database from community-based National Health Insurance Research Database
89481008|NCT02090023||NTUH obstructive sleep apnea cohort|Primary database from enrollment of retrospective NTUH hospital-based cohort
89481009|NCT02250313||Case|All patients will have the tissue from their previous negative biopsy tested with the assay. Cases are defined as those subjects who receive the ConfirmMDx assay results.
89481010|NCT02250313||Control|All patients will have the tissue from their previous negative biopsy tested with the assay. Controls are defined as subjects who will be blinded to the ConfirmMDx assay results.
89481011|NCT02250391|Experimental|NPB-06|1,500 unit, 5 days continuous-infusion
89481012|NCT02250391|Placebo Comparator|Placebo|0 unit, 5 days continuous-infusion
89481013|NCT02093143|Experimental|Remifentanil|"The general anesthesia during the diagnostic panendoscopy of the upper airway will associate the target controlled infusion of propofol (pharmacologic model of Schnider et al.) and of remifentanil (pharmacologic model of Minto et al.) in the remifentanil group.~The arm will be randomized prior to the beginning of the surgical procedure and blinded to the investigator and to the practitioner in charge of the patient.~Two milligrams of remifentanil will be diluted in 40 cc of sodium chloride 0,9% in a 50 ml syringe."
88951402|NCT01946789|Experimental|ALT-803|
89481014|NCT02093143|Placebo Comparator|Placebo|"The general anesthesia during the diagnostic panendoscopy of the upper airway will consist in the target controlled infusion of propofol alone (pharmacologic model of Schnider et al.) in the placebo group.~The placebo is a 40 ml sodium chloride 0,9% solution in a 50 ml syringe. No one can distinguish the syringe of placebo from the syringe of remifentanil."
89481015|NCT02090179||MPS IIIB|Those with a definitive diagnosis of MPS IIIB (Sanfilippo B Syndrome).
89481016|NCT02095795|Experimental|Technological Rehabilitation|Patients in the experimental group received a multimodal treatment intervention consisting of 60 minutes of conventional treatment according to the Bobath approach (Bobath B. Adult hemiplegia: evaluation and treatment. Oxford: Butterworth-Heineman, 1990) followed by 30 minutes of robotic gait training on the Lokomat robotic system with the supervision of an expert rehabilitator. Patients started the first session with 50% weight unload and 1.5 Km/h gait speed, performances increments are allowed only in the following sessions. Each patient received 20 sessions over a period of 4 weeks (5 sessions per week).
89481017|NCT02095795|Active Comparator|Control Rehabilitation|Patients in the control group received the same number of treatment sessions of a similar duration as those in the experimental group but they received activities of overground walking exercises targeted to improve walking in substitution of the robotic gait trainer.
89481018|NCT00701103|Experimental|Dalotuzumab 1.25 mg/kg Q1W (10 mg/mL)|Participants received dalotuzumab 1.25 mg/kg (10 mg/mL) intravenous (IV) infusion 1 time every 1 week (Q1W).
88951403|NCT01946828|Experimental|FIM|safety and efficacy of the FIM when exposed to a large and varied population of patients and users and operated according to its instructions for use
88951404|NCT01946841|Experimental|RealDiet®Renal enteral nutrition|
88951405|NCT01946893|Experimental|Mindfulness Meditation|One session per week for 6 weeks online through study iPAD. The intervention is a standardized and structured program. The objectives are to: 1) help participants understand their personal reactions to stress, 2) teach them skills to modify their stress reactions, and 3) promote their desire for self-care and feelings of competence and mastery.
89481019|NCT00701103|Experimental|Dalotuzumab 2.5 mg/kg Q1W (10 mg/mL)|Participants received dalotuzumab 2.5 mg/kg (10 mg/mL) IV infusion Q1W.
89481020|NCT00701103|Experimental|Dalotuzumab 5 mg/kg Q1W (10 mg/mL)|Participants received dalotuzumab 5 mg/kg (10 mg/mL) IV infusion Q1W.
89481021|NCT00701103|Experimental|Dalotuzumab 10 mg/kg Q1W (10 mg/mL)|Participants received dalotuzumab 10 mg/kg (10 mg/mL) IV infusion Q1W.
89481022|NCT00701103|Experimental|Dalotuzumab 10 mg/kg Q1W (20 mg/mL)|Participants received dalotuzumab 10 mg/kg (20 mg/mL) IV infusion Q1W.
89481023|NCT00701103|Experimental|Dalotuzumab 15 mg/kg Q1W (10 mg/mL)|Participants received dalotuzumab 15 mg/kg (10 mg/mL) IV infusion Q1W.
89481024|NCT00701103|Experimental|Dalotuzumab 15 mg/kg Q1W (20 mg/mL)|Participants received dalotuzumab 15 mg/kg (20 mg/ mL) IV infusion Q1W.
89481025|NCT00701103|Experimental|Dalotuzumab 20 mg/kg Q1W (10 mg/mL)|Participants received dalotuzumab 20 mg/kg (10 mg/mL) IV infusion Q1W.
89481026|NCT00701103|Experimental|Dalotuzumab 20 mg/kg Q1W (20 mg/mL)|Participants received dalotuzumab 20.0 mg/kg (20 mg/mL) IV infusion Q1W.
88951406|NCT01946893|Active Comparator|Education|Education sessions- 1 session per week for 6 weeks on study iPAD.
88951407|NCT01946906|No Intervention|No treatment|patient receive no active treatment
89203068|NCT00799344||Stent|Catania Stent
89481027|NCT00701103|Experimental|Dalotuzumab 20 mg/kg Q2W (20 mg/mL)|Participants received dalotuzumab 20 mg/kg (20 mg/mL) IV infusion 1 time every 2 weeks (Q2W).
89481028|NCT00701103|Experimental|Dalotuzumab 30 mg/kg Q3W (20 mg/mL)|Participants received dalotuzumab 30 mg/kg (20 mg/mL) IV infusion1 time every 3 weeks (Q3W).
89481029|NCT02093299||Stroke|clopidogrel 75 mg
89481030|NCT01907295||Patients|Patients diagnosed with idiopathic, anorexigen-induced, heritable PAH and PVOD/PCH
89203069|NCT00571688|Experimental|Risperdal Consta|Risperdal Consta injection in conjunction with existing treatment
89203070|NCT00571688|Active Comparator|Treatment As Usual|Clinician and patient decide upon treatment, as in a non-research clinical setting. The only treatment exclusion is any form of risperidone.
88951408|NCT01946906|Experimental|Rifaximin|Patient takes Rifaximin 550mg twice daily for 14 days
88951409|NCT01946945|No Intervention|Control - Standard ART treatment|
89203071|NCT00989794|Experimental|GelrinC|GelrinC one step implantation to the femoral condyle lesion
89203072|NCT00794274|Experimental|Open label drug|"Drug: CC-100004~After the screening period, subjects will receive CC-10004 20mg by mouth BID for 84 days. The 84-day duration of treatment is expected to provide adequate time to assess the short-term efficacy and safety of CC-10004 in a population of subjects with chronic cutaneous sarcoidosis"
89481031|NCT01907295||Relatives and controls|Relative has a family member diagnosed with idiopathic, anorexigen-induced, heritable PAH and PVOD/PCH Self declared healthy individuals
89203073|NCT02560610|Active Comparator|OC000459|Once daily dose of 50mg OC000459 tablets orally for 12/24 weeks
89203074|NCT02560610|Placebo Comparator|Placebo|Once daily dose of placebo tablets orally for 12/24 weeks
89481032|NCT02093377|No Intervention|Control|optimal medical therapy for the management of myocardial infarction according to the current guidelines of the European Society of Cardiology alone
89481033|NCT02093377|Active Comparator|Adaptive servo-ventilation|optimal medical therapy for the management of myocardial infarction according to the current guidelines of the European Society of Cardiology plus treatment of sleep apnea with adaptive servo-ventilation (ASV, most recent technology of AutoSetCS device, ResMed, Sydney, Australia). Dose: The optimal ASV settings will be determined during 1-2 nights monitored by polygraphy within 5 days after PCI.
89481034|NCT02093533|Experimental|Eculizumab|Patient Body weight ≥40 kg: initial phase 900 mg weekly x 4 and maintenance phase 1200 mg at week 5; then 1200 mg every 2 weeks Patient Body weight 30 - <40 kg : initial phase 600 mg weekly x 2 and maintenance phase 900 mg at week 3; then 900 mg every 2 weeks
89481035|NCT02461251|Experimental|Rotational thromboelastometry (ROTEM)|"Rotational thromboelastometry results are used to guide the treatment of major obstetric hemorrhage, eg. administration of prothrombin complex concentrate, fresh-frozen plasma, fibrinogen concentrate or platelets. In case of massive hemorrhage, shock packs of blood products in 1:1:1 ratio are administered."
89481036|NCT02461251|No Intervention|Standard care|"Patients are treated according to clinical decision making and conventional coagulation tests, and in case of massive hemorrhage, shock packs are administered."
88951410|NCT01946945|Experimental|Test - PGS|All embryos will be hatched on day 3. Patients will have hatching blastocysts (*) biopsied on day 5,/6. Embryos will be vitrified. Patients will have a single hatching euploid blastocyst (*) replaced on a thawed cycle.
89203075|NCT00799500|Experimental|Weekly screening|Screening and treatment of bacterial vaginosis during pregnancy through self-administered weekly vaginal pH determination.
89203076|NCT00799500|No Intervention|Observation|Usual care
89203077|NCT05590546||Obese|No intervention, only performing cross-sectional analysis of pooled data collected in previous studies
89203078|NCT05590546||Control|No intervention, only performing cross-sectional analysis of pooled data collected in previous studies
89481037|NCT02090257|Experimental|TRANSIT, behavioral|The intervention group will receive more guidance during their transition from a pediatric center to the adult center
89481038|NCT02090257|No Intervention|Usual Care Group|The usual care group will receive a standard transfer of care from a pediatric center to an adult center.
89531461|NCT06066073|Experimental|Lavender group|Patients who were included in this group were subjected to vapors of the lavender oil in waiting rooms, during dental therapy, and on day after dental procedures
89531462|NCT06066073|Placebo Comparator|Control group|Patients who were included in this group were subjected to vapors of distal water in waiting rooms and during dental therapy
88951411|NCT01946958|Experimental|Trained in Primary Care (PC) Triple P|This group received standardized training in Primary Care (PC) Triple P.
89481039|NCT03297957|Experimental|Arm 1: Goggle Imaging|-Patient will then be taken to the operating room for this surgical procedure. Prior to starting the operation, the patient will undergo injection of ICG around the tumor per standard techniques while in the operating room. Those undergoing intraoperative visualization of parathyroid glands will not have any administration of ICG as these glands autofluoresce. Patients will then undergo the standard SLN biopsy procedure (those undergoing parathyroid visualization will not undergo this). The surgeon will put on the goggle system to attempt to identify the SLN using fluorescence guidance or parathryroid visualization. After this is performed, the goggle system will be removed and the procedure will be completed per normal.
89481040|NCT02093611|Placebo Comparator|Placebo|This arm will serve as the placebo supplementation.
89481041|NCT02093611|Active Comparator|ATP|This arm will serve as the treatment intervention, ATP
89481042|NCT03297879|Experimental|exenatide group|The drug-naïve, overweight or obese patients with newly diagnosed T2D
89481043|NCT03297879|Active Comparator|metformin group|The drug-naïve, overweight or obese patients with newly diagnosed T2D
89481044|NCT02090335|Experimental|In SHAPE|In SHAPE is a health promotion intervention consisting of a fitness club membership and a health promotion coach with basic certification as a fitness trainer, instruction on principles of healthy eating and nutrition, and training in tailoring individual wellness plans to the needs of persons with serious mental illness.
89481045|NCT02090335|Active Comparator|Fitness Club Membership|Fitness club membership with education in using the exercise equipment.
89481046|NCT03297801||Fish oil group|Women who chose to supplement with fish oil, rich in omega-3 polyunsaturated fatty acids, during gestation or lactation.
89481047|NCT03297801||No fish oil group|Women who chose not to supplement with fish oil during gestation or lactation.
89481048|NCT02250001||Treatment with DCV/ASV|Patients who are beginning to receive the treatment with DCV/ASV under the approved indications, dosage, and administration will be included in this study
89481049|NCT03297723||Experimental arm|The experimental group will be constituted after the medical staff was trained to TPE. Cancer patients will benefit from a PEP aiming at learning how to better manage their pain.
89481050|NCT03297723||Controle arm|The control group will be constituted before the training of the medical staff to TPE. Patients' pain will be managed conventionally.
89481051|NCT02096185|Experimental|3 dimensional tomosynthesis imaging|Breast specimen to be x-rayed using both conditions 3 dimensional tomosynthesis imaging 2 dimensional conventional digital imaging
89481052|NCT02096185|Experimental|2 dimensional digital imaging|Breast specimens to be x-rayed under both conditions 3 dimensional tomosynthesis imaging 2 dimensional digital imaging
89481053|NCT02093767|Active Comparator|7.5g dose Synergy1|7.5 g/day dose of Synergy1 (oligofructose enriched inulin 1:1) for 9 weeks. The daily dose is dispersed in two sachets of 3.75 g each which are consumed at breakfast and dinner
89481054|NCT02093767|Active Comparator|15g Synergy1|15 g/day dose of Synergy1 (oligofructose enriched inulin 1:1) for 9 weeks. The daily dose is dispersed in two sachets of 7.5 g each which are consumed at breakfast and dinner
89481055|NCT05011461|Experimental|Almond Oil|Almond Oil Pressed Cold
89481056|NCT05011461|Active Comparator|Topical Retinol|Retinol Lotion 0.5%
89481057|NCT02093845|Active Comparator|SYNERGY|Coronary implantatation of the SYNERGY everolimus-eluting stent
88951412|NCT01946958|Experimental|Care as Usal|This group provided care as usual. This group was not trained in PC Triple P interventions.
88951413|NCT01946971|Experimental|PL|Placebo once a day orally for 7 days, then lansoprazole 1mg/kg once a day orally for 7 days
89481058|NCT02093845|Active Comparator|Biomatrix Neoflex|Coronary implantation of the biolimus-eluting Biomatrix NeoFlex stent
89481059|NCT04489797|Experimental|Arm A|Participants will receive single oral dose of acalabrutinib capsule with 100 mL of water.
89481060|NCT04489797|Experimental|Arm B|Participants will receive single oral dose of acalabrutinib capsule taken with 100 mL of COCA-COLA along with 20 mg rabeprazole.
89481061|NCT02094001|Experimental|Riociguat therapy|After an overnight fast, patients will undergo a 20 minute dynamic PET scan with injection of 3 MBq/kg of N-13 ammonia (NH3) to measure myocardial perfusion. Followed by a 60 min dynamic PET scan with injection of 3MBq/kg of F-18-FDG to measure glucose uptake.
89481062|NCT02090569|Experimental|Functional micro-Doppler sonography|
89481063|NCT02250079|Experimental|Polyethilene body bag group|The intervention group infants were provided the same care as control infants, but were dressed with the polyethylene body bag immediately after birth. The bag had an upper opening for the head and a seal at the bottom. The intervention group infants remained in the plastic bag for the first 10 minutes after birth. The same process was done in surgery room in case of cesarean. Umbilical prophylaxis, vitamin K1 application, initial physical examination and ocular prophylaxis are performed. The infants were swaddled in blankets provided by the mother, the head was covered with a hat, and the infants were placed either in an open crib or under a radiant warmer as necessary and available. The same process were done in surgery room in case of cesarean
89481064|NCT02250079|Active Comparator|Conventional group|): Infants randomized to the control group received standard hospital care newborn. This included immediate drying, skin-to-skin contact, early and exclusive breast feeding, postponed bathing, bundling, and radiant warmer. While waiting for criteria cord clamping, the environment humidity and temperature and segment and rectal temperature of the newborn were measure. It was repeated at 1-5- 10-60 and 120 minutes. After clamping, the newborn were positioned in a radiant warmer, and completed the drying process. Umbilical prophylaxis, vitamin K1 application, initial physical examination and ocular prophylaxis are performed. The infants were swaddled in blankets provided by the mother, the head was covered with a hat, and the infants were placed either in an open crib or under a radiant warmer as necessary and available. The same process was done in surgery room in case of cesarean.
89481065|NCT02094079||L-T4 treated hypothyroid pregnant women|L-T4 treated pregnant women
89481066|NCT02090647|Active Comparator|titanium 1|titanium abutment type 1
89481067|NCT02090647|Active Comparator|titanium 2|titanium abutment type 2
89481068|NCT02090647|Active Comparator|zirconia 1|zirconia abutment type 1
89481069|NCT02090647|Active Comparator|zirconia 2|zirconia abutment type 2
89481070|NCT02090647|Active Comparator|titanium nitrate|titanium nitrate abutment
89481071|NCT02096341|Experimental|RRx-001|RRx-001 will be administered as subcutaneous injections twice weekly for at least 8 weeks. At least three subjects must complete 2 weeks of treatment with RRx-001 at each dose level, before escalation to the next higher RRx-001 dose level; 2 doses-16 and 27 mg/m2- will be tested.
89481072|NCT02096419|No Intervention|control group|Patients in this group will receive standard clopidogrel dose
89481073|NCT02096419|Experimental|interventional group|"Patients in the interventional arm will receive clopidogrel dose adjustment to maintain optimal platelet reactivity determined by Multiplate function analyzer (19-46U).~They will undergo platelet function testing on day 1,2,3,7,30 and month 2,3,6,9 and 12.~On first two measurements patients will receive up to 2 additional clopidogrel loading doses (600 mg) and put on 150 mg and 75 mg a day if platelet reactivity >18U and <18U, respectively. Maintenance dose will be determined on following measurements - increased by 75 mg if >46U; not changed if 19-46U; decreased by 75 mg if <19U. Minimal dose - 75 mg; maximal dose 300 mg (for patients >70 years 150 mg)"
88951414|NCT01946971|Experimental|LP|Lansoprazole 1mg/kg orally once a day for 7 days, then placebo orally once a day for 7 days
88951415|NCT01946984|Active Comparator|Diclofenac,75 mg, 3 ml,|patients were given Diclofenac IM before ERCP.
88951416|NCT01946984|Placebo Comparator|Normal Saline, 3ml, IM|patients were given normal saline 3 ml before ERCP
88951417|NCT01946997||Group 1: Non Diabetic|Normal retina
88951418|NCT01946997||Group 2: Diabetes with no retinopathy|Diabetic patients without diabetic retinopathy
88951419|NCT01947010|Active Comparator|Crohn's patients treated with Azathioprine|Vaccination with PPV23 or Vaccination with PCV 13
88951420|NCT01947010|Active Comparator|Crohn's patients treated with Azathioprine and TNFa inhibitors|Vaccination with PPV23 or Vaccination with PCV 13
88951421|NCT01947010|Active Comparator|Crohn's disease patients without treatment|Vaccination with PPV23 or Vaccination with PCV 13
88951422|NCT01947036||Healthy Subjects|Healthy adult controls (no auto-immune disease)
89481074|NCT02096497||Vascular pattern 1|
89481075|NCT02096497||Vascular pattern 2|
89481076|NCT02096497||Vascular pattern 3|
89481077|NCT02096497||Vascular pattern 4|
89481078|NCT02096497||Vascular pattern 5|
89481079|NCT02096497||Vascular pattern 6|
89481080|NCT02096497||Vascular pattern 7|
89481081|NCT02096497||Vascular pattern 8|
89481082|NCT02096497||Vascular pattern 9|
89481083|NCT02096497||Vascular pattern 10|
89481084|NCT02096497||Vascular pattern 11|
89481085|NCT02094157|Active Comparator|Bridged regimen|Bridged regimen Warfarin therapy is stopped for 5 days before surgery and restarted in the evening of surgery at double the usual dose for two days. Bridging with low-molecular-weight heparin at therapeutic dose is given for 2½ days before surgery.
89481086|NCT02094157|Experimental|Tapered warfarin regimen|Tapered warfarin regimen Warfarin is given at half the usual maintenance dose for 3-6 days before surgery depending on the INR at the baseline visit. A double dose is given in the evening of surgery. No bridging with LMWH is used.
89481087|NCT03059329||Fycompa-treated epilepsy participants|Adult epilepsy participants with partial-onset seizures (with or without secondary generalized seizures) or primary generalized Tonic-clonic seizures who receive long-term treatment with Fycompa
89481088|NCT01369225|Experimental|0.5 mg/kg AAB-003|
89481089|NCT01369225|Experimental|1 mg/kg AAB-003|
89481090|NCT01369225|Experimental|2 mg/kg AAB-003|
89481091|NCT01369225|Experimental|4 mg/kg AAB-003|
89481092|NCT01369225|Experimental|8 mg/kg AAB-003|
89481093|NCT03556813||Group Vik|women over the age of 18 with breast cancer or remission
89481094|NCT03556813||Group physicians|women over the age of 18 with breast cancer or remission
89481095|NCT03556267|Other|spinal needle 27 gauqge|It is a device used to penetrate the dura to take CSF sample before injecting the drugs used for spinal anesthesia for cesarean section.
89481096|NCT03556267|Other|spinal needle 25 gauage|It is a device used to penetrate the dura to take CSF sample before injecting the drugs used for spinal anesthesia for cesarean section.
89481097|NCT03556735|Other|PEMF treatment|No sham group (placebo) was chosen. Treatment consisted of one active group in a multicenter study.
89481098|NCT02094235|Experimental|1|E6005 0.2% ointment applied twice a day to eczema areas
89481099|NCT02094235|Experimental|2|E6005 0.05% ointment applied twice a day to eczema areas
89481100|NCT02094235|Placebo Comparator|3|Placebo ointment applied twice a day to eczema areas
89481101|NCT02094313|Experimental|atovastatin|
89481102|NCT02098759|Experimental|epilepsy early diagnosis|Infants that have epileptiform discharges on vEEG and no clinical seizures, if their parents/caregivers give consent, will enter the randomized part of the study. Those children will be randomized into two groups: group A will be diagnosed as having epilepsy after subclinical (electroencephalographic) epileptiform discharges, and the patients in group B will be diagnosed as epileptic after clinical seizures appear. All infants diagnosed with epilepsy will receive standard therapy with recommended first line antiepileptic drug starting from the day of diagnosis.
89481103|NCT02098759|Experimental|standard epilepsy diagnosis|Infants that have epileptiform discharges on vEEG and no clinical seizures, if their parents/caregivers give consent, will enter the randomized part of the study. Those children will be randomized into two groups: group A will be diagnosed as having epilepsy after subclinical (electroencephalographic) epileptiform discharges, and the patients in group B will be diagnosed as epileptic after clinical seizures appear. All infants diagnosed with epilepsy will receive standard therapy with recommended first line antiepileptic drug starting from the day of diagnosis.
89481104|NCT02250235|Experimental|Self-affirmation|In the self-affirmation arm, the patients completed a 10 item questionnaire about their past acts of kindness (self-affirmation) prior to reading the health risk information.
89481105|NCT02250235|No Intervention|Control|Control patients completed 10 matched control questions with no self-affirming properties, prior to reading the health risk information.
89481106|NCT02094391|Experimental|Ipilimumab|
89481107|NCT02094391|No Intervention|No Ipilimumab|
89481108|NCT03556189|Experimental|Experimental|case management consists adjusting AV delay of pacemaker to achieve best cardiac output measured by trans-thoracic echocardiogram
89481109|NCT03556189|No Intervention|Control: Usual care|Usual care is provided with routine pacemaker interrogation.
89481110|NCT02094469|Other|Cilostazol|Cilostazol 50mg and 100mg
89481111|NCT02094547|Experimental|New infant formula|New infant formula with key ingredients.
89481112|NCT02094547|Active Comparator|Standard infant formula|Standard infant formula
89481113|NCT02094547|Other|Breastfeeding|Control
89481114|NCT02094703|Experimental|levofloxacin and solifenacin succinate|Levofloxacin 500 mg tablet and solifenacin succinate 5 mg tablet by mouth once daily for 3 days
89481115|NCT02094703|Active Comparator|levofloxacin and placebo|Levofloxacin 500 mg tablet and placebo (for solifenacin succinate) by mouth once daily for 3 days
89481116|NCT03556111|Experimental|anterior knife-edge maxilla graft (Without Xenograft Usage)|"The intervention will be a Sticky bone augmentation of defect. It is prepared using particulate autologous graft only along with fibrin glue and growth factors obtained from the patients' blood.~The sample is withdrawn and placed in plastic tubes which are spun twice in a centrifuge at a certain speed and time. The first spin to obtain the fibrin glue and the second to obtain the growth factors. The mixture is added to the harvested autogenous bone to form a semi-solid bone graft that is easily manipulated in the recipient site."
89481117|NCT03556111|Experimental|anterior knife edge maxilla graft (With Xenograft Usage)|"The intervention will be the sticky bone augmentation of the defect using both particulate autogenous and xenograft bovine bone.~The bone will be harvested from the donor, coupled with the bovine bone, the growth factors and the fibrin glue that is obtained from the patient's own blood sample.~The venous blood sample is placed in plastic tubes to be centrifuged at a certain speed and time to obtain the fibrin glue and growth factors.~The mixture is prepared until the bone is sticky and ready to be placed in the recipient defective maxilla"
89481118|NCT02098837|Active Comparator|Immediate switch|Patients will be randomised to switch from a boosted PI to dolutegravir at baseline.
89481119|NCT02098837|Active Comparator|Deferred switch|Patients will be randomised to switch from a boosted PI to dolutegravir after 48 weeks.
89481120|NCT02094781|Experimental|Whey protein and creatine supplement|Each sachet contained 30g whey protein powder and 5g creatine powder, administered twice a day. The first serving was consumed with breakfast and the second serving was consumed within 60 minutes of completing training or in the evening on non-training days. Participants also drank at least 2 litres of water per day
89481121|NCT02094781|Active Comparator|Whey protein only supplement|Each sachet contained 30g of whey protein powder and 5g of bulking agent powder, administered twice a day. The first serving was consumed with breakfast and the second serving was consumed within 60 minutes of completing training or in the evening on non-training days. Participants also drank at least 2 litres of water per day
89481122|NCT02094781|Placebo Comparator|Placebo|Each sachet contained 30g of isocaloric carbohydrate powder and 5g of bulking agent powder, administered twice a day. The first serving was consumed with breakfast and the second serving was consumed within 60 minutes of completing training or in the evening on non-training days. Participants also drank at least 2 litres of water per day
89481123|NCT02098915|Experimental|intravenous metoclopramide|the experimental arm will receive intravenous metoclopramide
89481124|NCT02098915|Placebo Comparator|control arm|the control arm will receive placebo
89481125|NCT02094859||GlucoClear System|
88951423|NCT01947036||Subjects with Crohn's Disease|Diagnosed with or suspected of having Crohn's disease (CD)
88951424|NCT01947036||Subjects with Rheumatoid Arthritis|Diagnosed with or suspected of having rheumatoid arthritis (RA)
88951425|NCT01947036||Subjects with Type 1 diabetes|Diagnosed with or suspected of having type 1 diabetes mellitus (T1D, T1DM)
88951426|NCT01947036||Subjects with Multiple Sclerosis (MS)|Diagnosed with or suspected of having MS
88951427|NCT01947036||Subjects with Psoriasis|Diagnosed with or suspected of having psoriasis (Ps)
88951428|NCT01947049|No Intervention|Control Arm|Participants in this arm will receive usual care (influenza testing and treatment)
88951429|NCT01947049|Experimental|Rapid Testing|Participants in this arm will receive rapid influenza testing with Xpert Flu.
88951430|NCT01947062|Active Comparator|Standard intravenous chemotherapy|Patients will receive standard intravenous chemotherapy based on cisplatin and etoposide.
89481126|NCT03556033|Active Comparator|Dapagliflozin|Dapagliflozin 10 mg capsule once daily for 8 weeks
89481127|NCT03556033|Placebo Comparator|Placebo oral capsule|Placebo matched to dapagliflozin 10 mg capsule once daily for 8 weeks
89481128|NCT02096653|Experimental|X-ray guided intra-articular injection|Injection of 40 mg depomethylprednisolone and 2 ml 0.5% bupivacaine into the SI (sacroiliac joint) cavity under fluoroscopic guidance
89481129|NCT02096653|Active Comparator|Landmark-guided SI joint injection|Injection of 40 mg depomethylprednisolone and 2 ml 0.5% bupivacaine at the point of maximal tenderness (3 ml)
89481130|NCT03556657|Experimental|Music Therapy Group|Patient receives 6 sessions of music therapy with a board-certified music therapist. Patient will learn various music interventions for pain management that he/she will utilize at home.
89481131|NCT03556657|No Intervention|Wait-List Control Group|Patient receives standard care alone. Patient will receive music therapy sessions following completion of the post-test.
89481132|NCT02095015||Analysis population|All subjects enrolled in the study who meet the eligibility criteria
89481133|NCT02099071|Experimental|Group 1|Six subjects will receive a single oral dose of ACT-389949 1 mg and two subjects will receive a single oral dose of placebo. Treatment will be administered in the morning on an empty stomach.
89481134|NCT02099071|Experimental|Group 2|Six subjects will receive a single oral dose of ACT-389949 5 mg and two subjects will receive a single oral dose of placebo. Treatment will be administered in the morning on an empty stomach.
89481135|NCT02099071|Experimental|Group 3|Six subjects will receive a single oral dose of ACT-389949 20 mg and two subjects will receive a single oral dose of placebo. Treatment will be administered in the morning on an empty stomach.
89481136|NCT02099071|Experimental|Group 4|"Subjects will participate in two different treatment periods separated by a washout of 7-10 days between the study drug administrations.~In the first treatment period six subjects will receive a single oral dose of ACT-389949 50 mg and two subjects will receive a single oral dose of placebo. Treatment will be administered in the morning on an empty stomach.~In the second treatment period, subjects randomized to ACT-389949 will receive a single oral dose of ACT-389949 50 mg in fed condition, 30 minutes after the start of a high fat and high calorie breakfast."
89481137|NCT02099071|Experimental|Group 5|Six subjects will receive a single oral dose of ACT-389949 100 mg and two subjects will receive a single oral dose of placebo. Treatment will be administered in the morning on an empty stomach.
89481138|NCT02099071|Experimental|Group 6|Six subjects will receive a single oral dose of ACT-389949 200 mg and two subjects will receive a single oral dose of placebo. Treatment will be administered in the morning on an empty stomach.
89481139|NCT02099071|Experimental|Group 7|Six subjects will receive a single oral dose of ACT-389949 500 mg and two subjects will receive a single oral dose of placebo. Treatment will be administered in the morning on an empty stomach.
89481140|NCT02099071|Experimental|Group 8|Six subjects will receive a single oral dose of ACT-389949 1000 mg and two subjects will receive a single oral dose of placebo. Treatment will be administered in the morning on an empty stomach.
89481141|NCT02639546|Experimental|Phase I (Tablet) Cobimetinib (0.6 mg/kg)|Dose-Escalation: Participants received 0.6 milligrams per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.
89481142|NCT02639546|Experimental|Phase I (Tablet) Cobimetinib (0.8 mg/kg)|Dose-Escalation: Participants received 0.8 milligrams per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.
89481143|NCT02639546|Experimental|Phase I (Tablet) Cobimetinib (1 mg/kg)|Dose-Escalation: Participants received 1 milligram per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.
88951431|NCT01947062|Experimental|Intravenous with metronomic chemotherapy|Patients will receive both intravenous (cisplatin and etoposide based) and metronomic chemotherapy (with oral cyclophosphamide).
88951432|NCT01947075||Adults with fever|Every adult with fever will be screened for different infectious diseases and for nasopharyngeal respiratory viruses and bacteria
88951433|NCT01947075||Healthy volonteers|For every adult with fever included with a diagnosis of pneumonia, a healthy volunteer will be included. These healthy volunteers will be screened for nasopharyngeal respiratory viruses and bacteria.
88951434|NCT01947088|Experimental|Music Therapy Arm|Music therapy evaluation prior to surgery (Baseline 1). These evaluations will also be given within 3 days of epilepsy surgery (Baseline 2), 8 weeks after surgery (Baseline 3), and 9-12 months after surgery (Baseline 4.) Pre-study and post-study scores from the neuropsychological assessments will be compared to determine if music therapy has a significant effect on the child's cognitive recovery. Will consist of meeting with the music therapists, Certified Child Life Specialists (CCLS), or Child Life Assistants (CLA) for music therapy (treatment group) for about 45 minutes, twice per week, for Weeks 1-8. CThe Music Therapy group will partake in interventions such as singing and playing musical instruments.
88951435|NCT01947088|Active Comparator|Unstructured Play Arm|Child life programs provide children with opportunities to engage in normal play and recreational activities that promote growth, development and feelings of success and fulfillment.All brain surgery candidates receive a neuropsychological assessment before and after surgery (9-12 months after surgery). This is the standard of care for all brain surgery patients. The results of this assessment and will be used in this research study. In addition, patients who agree to participate in the study will receive cognitive screening and a music therapy evaluation prior to surgery (Baseline 1). These evaluations will also be given within 3 days of epilepsy surgery (Baseline 2), 8 weeks after surgery (Baseline 3), and 9-12 months after surgery (Baseline 4.)
88951436|NCT01947101|Experimental|Ulcerative Colitis|Fecal Microbiota Transplant
89481144|NCT02639546|Experimental|Phase I (Suspension) Cobimetinib (0.6 mg/kg)|Dose-Escalation: Participants received 0.6 milligrams per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.
89481145|NCT02639546|Experimental|Phase I (Suspension) Cobimetinib (0.8 mg/kg)|Dose-Escalation: Participants received 0.8 milligrams per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.
89481146|NCT02639546|Experimental|Phase I (Suspension) Cobimetinib (1 mg/kg)|Dose-Escalation: Participants received 1 milligram per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.
89481147|NCT02639546|Experimental|Phase I (Suspension) Cobimetinib (1.33 mg/kg)|Dose-Escalation: Participants received 1.33 milligrams per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.
89481148|NCT02639546|Experimental|Phase II (Suspension) Cobimetinib (1 mg/kg)|Dose-Expansion: Participants received 1 milligram per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.
89481149|NCT02095093|Experimental|Intellijoint HIP|Patient's will have their leg length and hip offset determined intraoperatively using Intellijoint HIP.
89481150|NCT02095093|Active Comparator|Outrigger|Control patients will have their leg length and hip offset determined intra-operatively using the standard at Mount Sinai Hospital, which is a pin and outrigger system.
89481151|NCT02099149||Controls|Infants born to GBS colonized mother who do not develop GBS disease
89481152|NCT02099149||Cases|Infants with culture confirmed GBS disease
89481153|NCT02096809|Experimental|One week loading of Bone Anchored Hearing Aid (BAHA)|Bone Anchored Hearing Aid (BAHA) loading after one week
89481154|NCT02096887|Other|Patient Education|Patient Education
89481155|NCT02095171|Experimental|PRX002|
89481156|NCT02095171|Placebo Comparator|Placebo|
89481157|NCT02099227||Ultrasound|those who received point-of-care ultrasound as part of their emergency department evaluation/ treatment for suspected soft tissue infections
89481158|NCT02099227||No Ultrasound|those who did not receive point-of-care ultrasound as part of their emergency department evaluation/ treatment for suspected soft tissue infections
89481159|NCT05069480|Active Comparator|Control Group|"Participants who participated in the control group received a traditional physical therapy program for two hours. It included two parts, each of them was one hour and few minutes rest in between. The first part included: reflex inhibiting patterns, strengthening activities, stretching exercises, and postural reactions exercises. The second part included: arm-reaching tasks, arm-hand tasks, hand manipulative tasks for the more affected upper limb through performing functional tasks of daily living activities.~The traditional intervention was carried out three sessions per week for twelve successive weeks."
89481160|NCT05069480|Experimental|Experimental Group|"Participants of the experimental group have received two hours treatment program that included three parts, the first and the second parts were similar to that applied for participants in the control group for one hour followed by few minutes rest, then the third part was applied for one hour. The third part included a virtual reality intervention program by using virtual reality equipment to simulate a range of upper limb tasks related to arm-hand activities and hand manipulative tasks through using different games and soft-wares.~The treatment program for the experimental group was carried out three sessions per week for twelve successive weeks."
89481161|NCT05046626|Experimental|nutritional counseling|Arm with intervention
89481162|NCT02099305|Experimental|Intervention|Receive Adolescent Depression Awareness Program (ADAP) intervention
89481163|NCT02099305|No Intervention|Wait list control|no intervention
89481164|NCT02095405|Active Comparator|Caffeine arm|"SVT group: Caffeine tablets, 5 mg/kg.~AF group: Caffeinated substances and Dark Chocolate"
89481165|NCT02095405|Placebo Comparator|Placebo arm|"SVT group: Placebo~AF group: Decaffeinated substances and White Chocolate"
89481166|NCT03099980|Experimental|Secukinumab|All participants will be assigned to receive secukinumab 300 mg (2 x 150 mg PFS subcutaneous injections) administered at Baseline, Weeks 1, 2, 3, 4, and then Q4W for 24 more weeks.
89481167|NCT02099383|Active Comparator|normal saline, bolus|Patients of study group will receive intravenous normal saline 20cc per kilogram of body weight, one third of which will be given as a bolus followed by delivery of the remaining two third as a constant infusion over a period of 8 hours.
89481168|NCT02099383|No Intervention|normal saline, control|Patients of control group will receive intravenous normal saline 60 cc per hour.
88951437|NCT01947114|Active Comparator|Group Propofol|
88951438|NCT01947114|Active Comparator|Group Ketamine|
88951439|NCT01947179|No Intervention|Physical Health Training|The Physical Health Training condition will include information on the importance and benefits of a healthy lifestyle. Additionally, the program will discuss guidelines for a healthy lifestyle including information on diet, water consumption, exercise, and sleep.
88951440|NCT01947179|Experimental|Anxiety Risk Reduction|The anxiety risk reduction intervention will include psychoeducation focused on the nature of stress and its effect on the body. Interoceptive exposure exercises that were designed to correct the conditioned fear of bodily sensations will be explained and practiced.
88951441|NCT01947192|Experimental|Chlorhexidine|Dentin pre-treatment with a experimental solution (chlorhexidine), after the dentin acid etching
89203079|NCT02560532|Experimental|Clazosentan|Diluted solution administered as a continuous intravenous infusion at a rate of 15 mg/h for up to a cumulative maximum of 10 days
89203080|NCT00799656|Experimental|1|First period: Ataciguat - Second period: Placebo
88951442|NCT01947192|Placebo Comparator|Water|Application of water (placebo) after dentin acid etching.
88951443|NCT01947205|Active Comparator|paracetamol|Duration
88951444|NCT01947205|Active Comparator|without drug|Control group
88951445|NCT01947205|Active Comparator|dexketoprofen trometamol|Study group
88951446|NCT01947205|Active Comparator|two puff xylocain administration on cervical surface|Study group
88951447|NCT01947205|Active Comparator|paracervical block with ultracaine|study group
88951448|NCT01947231|Experimental|Global Postural Re-education|Global Postural Re-education is delivered in a single treatment session each week for nine weeks.
88951449|NCT01947231|Active Comparator|Standard manual physical therapy|Standard manual physical therapy is delivered in a single treatment session each week for 9 weeks.
88951450|NCT01947244|Experimental|Doula Home Visiting|Participants assigned to the intervention group receive prenatal and short-term postpartum home visitation from doulas, and support from doulas at the hospital during labor, delivery, and with early breastfeeding. Additionally, these participants receive longer-term home visiting services from family support workers during pregnancy and after the birth.
89203081|NCT00799656|Experimental|2|First period: Placebo - Second period: Ataciguat
89481169|NCT02095639||ECT and Treatment Resistant Depression|Subjects will be those with diagnosis of major depressive disorder that have not responded to many different treatments and who are planning to take electroconvulsive therapy (ECT). This group will receive two [18F]FEPPA PET scans, one baseline and one after an average of 2.5 weeks of ECT treatments.
89481170|NCT03771859||Participants who initiate adjuvant treatment with nivolumab|
89481171|NCT05057156|Experimental|"application supervised by a psychologist via teleconsultations"|patient have app, and teleconsultation with psychologist
89481172|NCT05057156|Placebo Comparator|"application in total autonomy"|patients have app, they play when they want
89481173|NCT05057156|No Intervention|"control group without using the application"|patients haven't app
89481174|NCT05045924||Intervention group|20 patients with decompensated liver cirrhosis monitored using a wrist-watch wearable device, with associated smart weighing scales and blood pressure cuff, along with a smartphone application (including economic smartphone in those patients if not available), to facilitate home monitoring.
89481175|NCT05045924||Control group|20 patients with decompensated liver cirrhosis receiving standard quality of care.
89481176|NCT02096965|Experimental|Tolvaptan first, then Placebo|Tolvaptan twice daily in first intervention period and placebo twice daily in second intervention period. (after washout period)
89481177|NCT02096965|Experimental|Placebo first, then Tolvaptan|Placebo twice daily in first intervention period and Tolvaptan twice daily in second intervention period. (after washout period)
89481178|NCT03099902||Cases|Children with asthma/wheezing whose mothers were active smokers during pregnancy
89481179|NCT03099902||Controls|Children without asthma/wheezing whose mothers were active smokers during pregnancy
89203082|NCT04050020|Active Comparator|Group A|
89481180|NCT02097043|Experimental|[Group 1] DA-7218|200mg, By mouth or orally (PO) & intravenous(IV) administration
89481181|NCT02097043|Placebo Comparator|[Group 1] Placebo|Placebo, By mouth or orally (PO) & intravenous(IV) administration
89481182|NCT02097043|Experimental|[Group 2] DA-7218|400mg, By mouth or orally (PO) administration
89481183|NCT02097043|Placebo Comparator|[Group 2] Placebo|Placebo, By mouth or orally (PO) administration
89481184|NCT02097043|Experimental|[Group 3] DA-7218|600mg, By mouth or orally (PO) administration
89481185|NCT02097043|Placebo Comparator|[Group 3] Placebo|Placebo, By mouth or orally (PO) administration
89481186|NCT05069246|Experimental|Group 1 / Nigella Sativa oil / NS|"Group 1- Nigella Sativa (NS) N. sativa oil (Al-Hussan Food Products Factory, Riyadh, Kingdom of Saudi Arabia), which was brought from the local market in Riyadh.~Each participant was given a 3 weeks supply of oil, and a sterile plastic 15ml graduated measuring cap. They were asked to measure 5ml of oil into the cap and add 5ml of normal drinking water to this and rinse their mouth for 3mins with this solution and spit it out at the end. This was done morning and evening for 14 days.~Group 1: Maintained adequate plaque control levels using mechanical methods + N.sativa oil (5ml oil + 5ml water) pulling for 3 mins twice daily in the morning and at night (after brushing/breakfast in the morning, and after brushing and before sleeping at night).~Unified oral hygiene instructions and instructions for each intervention were provided to all participants."
89531463|NCT06066060|Experimental|JMKX000623/Metformin/ JMKX000623+Metformin|D1-D8, JMKX000623; D14-D19, Metformin; D20-D27, JMKX000623+Metformin
89531464|NCT06066034||Normal group|With the informed consent of the patient, venous blood was extracted on an empty stomach in the morning, and follicular fluid from multiple follicles was extracted during the 5-9 day menstrual cycle
89203083|NCT04050020|Placebo Comparator|Group B|
89203084|NCT05408104||tolvaptan (TLV)|LVAD recipients with post-operative hyponatremia (Na < 135 mEq/L). Eligible patients took tolvaptan 15 mg daily as part of a routine care treatment plan.
89203085|NCT05408104||no tolvapton (no-TLV)|LVAD recipients with post-operative hyponatremia (Na < 135 mEq/L). Eligible patients did not take tolvaptan as part of routine care.
88951451|NCT01947244|Active Comparator|Case Management|Mothers in the comparison group receive low intensity case management services during pregnancy and following the birth.
89203086|NCT00801996||1. Prostate Cancer|"Inclusion Criteria:~All study subjects should be able to provide informed consent~Males ages 40 years or older~Individuals from the Qatari Peninsula whose ancestors up to three generations back were natives of Qatar.~Individuals undergoing Trans Rectal Ultrasound (TRUS) biopsy as dictated by their standard clinical care~Ultrasound OR digital rectal examination consistent with prostate disease OR A level of PSA (Prostatic Specific Antigen) greater than 3.0~Exclusion Criteria:~• Patient refuses consent"
89206289|NCT02598635|Placebo Comparator|Placebo|An oral placebo capsule matching Cholecalciferol in terms of appearance, smell and taste will be administered once a day for 16 weeks. At serum calcium levels > 10.5 mg/dL (2.65 mmol/l) and/or at serum phosphorus levels > 7 mg/dL (2.26 mmol/L) capsule administration will be discontinued and restarted one month after when serum calcium levels or phosphorus levels declined to < 10.6 mg/dL and/or <7.1 mg/dL respectively.
89531465|NCT06066034||Insulin resistance group|With the informed consent of the patient, venous blood was extracted on an empty stomach in the morning, and follicular fluid from multiple follicles was extracted during the 5-9 day menstrual cycle
89203087|NCT00801996||2. Normal Healthy Controls|"Inclusion Criteria:~All study subjects should be able to provide informed consent~Males or females ages 40 years or older (see section A8 for the rationale for the inclusion of females)~Individuals of Arab descent from Qatari peninsula without any personal or family history of prostate cancer~Exclusion Criteria:~Individuals with family history of prostate cancer~Individuals not deemed in good overall health by the investigator will not be accepted into the study"
89203088|NCT00802152|Experimental|Home Monitoring|100 eligible subjects identified as (HbA1c >= 8% OR SBP > 130 mm Hg)
89203089|NCT00802152|No Intervention|Usual Care|100 eligible subjects identified as (HbA1c >= 8% OR SBP > 130 mm Hg)
89203090|NCT00343291|Active Comparator|Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/6)|"Cycles 1-6:~Cetuximab 400 mg/m² initial dose on day 1 and then 250 mg/m² given every week~Bevacizumab 15 mg/kg given on day 8 of every 3 week cycle~Paclitaxel 200 mg/m² on day 1 of every 3 week cycle~Carboplatin area under curve (AUC=6 min*mg/mL) on day 1 of every 3 week cycle~Patients who demonstrate a response or stable disease after six cycles of therapy may continue on weekly cetuximab monotherapy until disease progression, unacceptable toxicity, or another withdrawal criterion is met"
89481187|NCT05069246|Active Comparator|Group 2 / Chlorohexidine / CHX|"Group 2- Chlorohexidine (CHX).~Chlorohexidine (Middle East Pharmaceutical Industries Ltd, Riyadh, Kingdom of Saudi Arabia).~Each participant was given a 3 week supply of chlorohexidine. They were asked to use 10ml of CHX morning and evening, rinsing their mouth for 3 mins and then spit it out at the end. This was done morning and evening for 14 days.~Group2: maintained adequate plaque control levels using mechanical methods + chlorohexidine rinse twice daily 10ml in the morning and at the night (after brushing/breakfast in the morning, and after brushing and before sleeping at night).~Unified oral hygiene instructions and instructions for each intervention were provided to all participants."
89481188|NCT02095717|Experimental|Curcumin|curcumine capsule
89481189|NCT02095717|Placebo Comparator|Placebo|placebo capsule
89481190|NCT05044988|Experimental|HS-10342|Each subject will receive repeat doses (C1, C2…) for 28-day cycles. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criteria is met.
89481191|NCT02102425||Chronic kidney disease, PD|Patients with or without bandage over exit site
89481192|NCT02097199||Sports group|The cohort will consist of about 55 female and 55 male individuals aged 30-65 years with mostly sedentary work (>6 hours/day) doing no or less physical activity (<30 minutes quick walking/day) who want to engage more in physical activity (at least 150 minutes of at least moderate intensity per week). The gain in workload will be objectified and quantified by performing a bicycle stress test at the beginning of the study and after 8 months of physical engagement.
89481193|NCT05055674|Experimental|Motherly App|Participants in this arm will have access to Motherly, a smartphone app that is designed to promote life habits that have been shown to improve depression and mental health in mothers.
89481194|NCT05055674|Active Comparator|COMVC App|Participants in this arm will have access to COMVC, a smartphone app designed to deliver only psychoeducational content and mental health monitoring.
89481195|NCT02097355|Experimental|TriVox Active|Provider using TriVox for clinical care
89481196|NCT02097355|No Intervention|TriVox Delayed-start|Providers not using TriVox for clinical care
89481197|NCT03099824|Experimental|GC4419 IV + GC4711 Oral G-101 (82mg)|
89481198|NCT03099824|Experimental|GC4419 IV + GC4711 Oral G-101 (164mg)|
89481199|NCT03099824|Experimental|GC4419 IV + GC4711 Oral G-101 (246mg)|
89481200|NCT03099824|Experimental|GC4419 IV + GC4711 Oral G-111 (175mg)|
89481201|NCT03099824|Experimental|GC4419 IV + GC4711 Oral G-112 (145mg)|
89481202|NCT03099824|Experimental|GC4711 IV + GC4711 Oral G-119 (233mg)|
89481203|NCT03099824|Experimental|GC4711 IV + GC4711 Oral G-125 (233mg)|
89481204|NCT02639390|Experimental|Robotic|The experimental group will receive 1-hour robotic training sessions, 3 times per week for a total of 12 sessions supervised by a research assistant. Immediately following this robot training, these subjects will receive the same dosage and schedule (1-hour sessions, 3 times/week, 12 total sessions) of conventional one-on-one therapy from an occupational therapist.
89481205|NCT02639390|Active Comparator|Conventional|Subjects will receive 24 hours of one-on-one treatment from an occupational therapist. The treatment schedule will parallel that given to the experimental group (1-hour sessions, 3 times/week).
89481206|NCT05055518|Experimental|A Phase I, open-labeled multicenter study|APL-102 Capsules
89481207|NCT05067608|Active Comparator|Control arm|"Subjects in the control arm will receive normal pooled platelets for all of their transfusion within a single thrombocytopenic period. If subjects participate in the study for more than one thrombocytopenic period, they will automatically be enrolled in the opposing arm for their second thrombocytopenic period."
89481208|NCT05067608|Experimental|Treatment arm|"Subjects in the treatment arm will receive thawed cryopreserved pooled platelets for all of their transfusions (except for unplanned or urgent platelet transfusions outside stipulated periods when thawed cryopreserved platelets are unavailable) within a single thrombocytopenic period. If subjects participate in the study for more than one thrombocytopenic period, they will automatically be enrolled in the opposing arm for their second thrombocytopenic period."
89481209|NCT05055284|Experimental|Experimental group|Experimental: Participants in this group will receive electromyography biofeedback (EMG-BF) guided strength training along with patellar taping
89481210|NCT05055284|Sham Comparator|Control group|No Intervention: Control: Participants in this group will receive Sham EMG-BF guided strength training without patellar taping
89481211|NCT05044754||SCAP|Patients with recurrent prostate cancer undergoing SCAP
89481212|NCT05044754||HIFU|Patients with recurrent prostate cancer undergoing HIFU
88821621|NCT03268421|Experimental|Fibromyalgia Integrative Training for Teens|Fibromyalgia Integrative Training for Teens (FIT Teens) is a combined coping skills training and physical exercise program. Pain coping skills training, also called cognitive behavioral therapy (CBT) teaches a number of behavioral skills (e.g. breathing, relaxation, activity pacing, distraction, and calming statements). Participants also receive a specialized type of neuromuscular exercise training which focuses on core strength, gait and balance.
89481213|NCT03097640|Experimental|CHAMP|Participants enrolled in CHAMP are followed by a team of a social worker and physician across the care continuum. CHAMP team members visit patients in the ED and on inpatient floors. Along with the patient's input, the team develops an Individualized Care Plan outlining the patient's medical and social history and providing recommendations to other providers on specific aspects of their care. Care plans are reviewed with patients on an individual basis and reviewed periodically by the CHAMP providers. CHAMP-enrolled participants are scheduled for physician and social worker follow-up appointments at the CHAMP clinic; this time is used to provide intensive case management, medical care, and psychosocial support.
89481214|NCT03097640|No Intervention|Standard Care|Individuals in the standard care arm will receive care as they do normally when hospitalized, including medical and inpatient social work services, as well as outpatient care from their providers.
89481215|NCT02718417|Active Comparator|Arm A|Chemotherapy followed by observation
89481216|NCT02718417|Experimental|Arm B|Chemotherapy followed by avelumab in maintenance
89481217|NCT02718417|Experimental|Arm C|Chemotherapy in combination with avelumab followed by avelumab in maintenance
89481218|NCT03097718||Non-specific low back pain|Individuals with recurrent non-specific low back pain
89481219|NCT03097718||Healthy control subjects|Healthy individuals without low back pain
89481220|NCT05067530|Experimental|CDK4/6 inhibitor alone: Palbociclib (IMP)|Palbociclib alone (125 mg orally (PO) per day, days 1-14)
89481221|NCT05067530|Active Comparator|Chemotherapy alone: Paclitaxel|Paclitaxel alone (80 mg/m^2 intravenously (IV), day 1, 8, 15 and 22)
89481222|NCT05067530|Experimental|CDK4/6 inhibitor + chemotherapy: Paclitaxel + Palbociclib|Paclitaxel (80 mg/m^2 IV, day 1, 8, 15 and 22) + Palbociclib (125 mg PO per day, days 1-21)
89481223|NCT05067530|Active Comparator|Chemotherapy alone: Carboplatin|Carboplatin alone (area under the curve (AUC) 2 IV, day 1, 8, 15 and 22)
89481224|NCT05067530|Experimental|CDK4/6 inhibitor + chemotherapy: Carboplatin + Palbociclib|Carboplatin (AUC 2 IV, day 1, 8, 15 and 22) + Palbociclib (125 mg PO per day, days 1-21)
89481225|NCT05067218|Active Comparator|buzzy device (intervention)|The wings of buzzy device will be kept frozen and once the child is ready, the frozen wing will be attached to the device and Buzzy will be placed extra-orally above the area/cheek where local anesthetic is to be delivered.
88951452|NCT01947257|Other|ventilated patients|
89481226|NCT05067218|Experimental|Conventinal anasthesia ( control )|"The site of injection will be dried then topical anesthetic gel of 20% benzocaine (Dharma Ophal-S) will be applied. The duration of application of gel will be 1 minute.~Local anesthetic solution will be delivered using a standard aspirating syringe with 27-gauge, 21 mm short needles."
89531466|NCT06066034||PCOS group|With the informed consent of the patient, venous blood was extracted on an empty stomach in the morning, and follicular fluid from multiple follicles was extracted during the 5-9 day menstrual cycle
89531467|NCT06066034||PCOS with insulin resistance group|With the informed consent of the patient, venous blood was extracted on an empty stomach in the morning, and follicular fluid from multiple follicles was extracted during the 5-9 day menstrual cycle
89531468|NCT06065995|Experimental|Intervention|Access to the mobile application
89481227|NCT03097562|Experimental|CT1|"FLACS- Initial Wound parameters (CT1)~Sample size calculation based on woundleak incidence estimated from preliminary results:~For CT1 vs MT, we will only need 10 per group to have 80% power assuming a 1:1 ratio of CT to MT and 5% type 1 error.~For CT1 vs CT2, we will need 22 per group to have 80% power (assuming 60% wound leakage in CT1 and 20% wound leakage in CT2, a 1:1 ratio, and a 5% type 1 error rate)~A total of 253 patients are eligible for this study, 101 with FLACS and 152 with Manual Cataract Surgery. We thus expect that our study population will allow adequate analysis of the main outcome parameters proposed herein."
89481228|NCT03097562|Experimental|CT2|"The revised profile CT2, consists of a wider anterior side cut angle (beveled corneal undercut) and a narrower posterior side cut angle compared to the initial CT1 profile. This new corneal incision profile is constructed to ensure a tigher wound closure and a better corneal wound reapposition.~The traditional manual wound performed with a standard keratome wil be used as a reference."
89481229|NCT03097562|Active Comparator|MT control group|Standard manual technique (MT)
89481230|NCT02640404|Experimental|Menactra® Vaccine (9 to 23 Months)|Participants (infants and toddlers) received 2-dose series of study vaccine with 3-month interval (first dose at Day 0 and second dose 3 months after dose 1).
88951453|NCT01947270||Control group|Patients of this group are hospitalized in a time frame where the multidisciplinary intervention program is not implemented in the medical department. Drug prescriptions are conducted under usual care in the department.
89481231|NCT02640404|Experimental|Menactra® Vaccine (2 to 55 Years)|Participants (children, adolescents and adults) received 1 dose of study vaccine at Day 0.
89481232|NCT05054972||A|Group of patients in whom the left renal vein was divided for exposure of the aorta.
89481233|NCT05054972||A+|Subgroup of group A in whom a communicating vein to the left ascending lumbar vein was present.
89481234|NCT05054972||A-|Subgroup of group A in whom a communicating vein to the left ascending lumbar vein was not present.
89481235|NCT05054972||B|Group of patients in whom the left renal vein was mobilized but not divided for exposure of the aorta.
89481236|NCT05067296||Cesarean section niche and patients with abnormal uterine bleeding|Observation by Tvs
89481237|NCT05067296||Abnormal uterine bleeding in patients without Cesarean section niche|Observation by Tvs
89481238|NCT03297567|Experimental|verbal guidance and booklet|verbal guidance and a booklet on the importance and benefits of movement during hospital stay, as well as what the patients should do to increase the level of physical activity.
89481239|NCT03297567|No Intervention|No Intervention|The control group will not receive any type of intervention
89481240|NCT03097406||Osteoarthritis group|Patients with osteoarthritis (2017-2019) at Herlev Hospital treated with Global Unite total shoulder arthroplasty
89481241|NCT03097406||Osteoarthritis control group|Patients with osteoarthritis (2013-2016) at Herlev Hospital treated with a Global Advantage
89481242|NCT03097406||Fracture group|Patients with a fracture of the proximal humerus (2017-2019) at Køge and Herlev Hospital treated with Global Unite hemiarthroplasty
89481243|NCT03097406||Fracture control group|Patients with a fracture of the proximal humerus (2013-2016) at Køge and Herlev Hospital treated with Global FX hemiarthroplasty
89481244|NCT02461095|Active Comparator|Impairment based approach|The intervention will address the patients impairments found during evaluation. Treatment will based on the Physical therapist evaluation and will be individualized to each patient.
89481245|NCT02461095|Experimental|PFPS algorithm|The Patellofemoral Syndrome algorithm is designed to determine what deficits a patient may have and addressing these sequentially. This subgrouping first assesses a patient fear avoidance beliefs, flexibility, body mechanics, and then strength and functional ability. The reason for sequential treatment is that there is evidence that without adequate flexibility a patient will be unable to perform exercises with proper body mechanics, and without proper mechanics strengthening and functional activity can cause increased stress on the patellofemoral joint. Progression through each specific subgroup is based on objective goals. Once the patient has met these goals they are progressed to the next treatment subgroup until discharge.
89481246|NCT03099590|Experimental|Active Treatment, Alkontrol-herbal|Alkontrol-herbal, a kudzu extract which contains 19% puerarin, 4% daidzin and 2% daidzein, so each capsule contains a total of 25% active isoflavones or 125 mg.
89481247|NCT03099590|Placebo Comparator|Placebo Control|Matched dextran containing capsules will serve as placebo.
89481248|NCT05067062|Active Comparator|new zealand blackcurrant extract|Capsules will be take daily or every other day.
89481249|NCT05067062|Placebo Comparator|control|no capsules will be provided.
89481250|NCT03297489|Experimental|Diagnostic (intravital microscopy)|Patients receive fluorescein sodium injection IV. Patients also undergo observation of primary and metastatic tumors via microscopy over 15-20 minutes during the course of standard of care surgery.
89481251|NCT03097250||PKU Subjects|Subjects with PKU will be asked to undergo an MRI and blood draw on Day 1 and Day 2 of the study. They will also receive neuropsychological testing on Day 1 of the study
89481252|NCT03097250||Controls|Controls will undergo only one MRI and blood draw on Day 1 of the study. They will also receive neuropsychological testing on Day 1 of the study.
89481253|NCT03297411|Active Comparator|Brief Temporoparietal ECT|Brief Pulse Temporoparietal ECT
89481254|NCT03297411|Active Comparator|Ultrabrief Temporoparietal ECT|Ultrabrief Pulse Temporoparietal ECT
89481255|NCT03297411|Active Comparator|Brief Frontoparietal ECT|Brief Pulse Frontoparietal ECT
89481256|NCT03297411|Active Comparator|Ultrabrief Frontoparietal ECT|Ultrabrief Pulse Frontoparietal ECT
88951454|NCT01947270||Intervention group|Patients of this group are hospitalized in a time frame where the multidisciplinary intervention program is implemented in the medical department.
88951455|NCT01947296||"Group  coordinated care"|"Patient living in place covered by cancer network participating to the study is in the group coordinated care"
88951456|NCT01947296||"Group  usual care "|"Patient living in place covered by cancer network non participating to the study or without cancer network is in the group usual care"
88951457|NCT01947309||Multiple Myeloma Patients Treated with Revlimid (lenalidomide)|Single Cohort of Multiple Myeloma Patients Treated with Revlimid
88951458|NCT01947322|Experimental|Allogenic NK cells infusion|
88951459|NCT01947348|Experimental|treatment with A3 SVF|These patients that have been treated. The control patients that have not been treated.
89481257|NCT03098498|Experimental|Two-Stage Subgingival Debridement|Initially soft subgingival bacterial biofilms are removed from periodontal lesions by an airpolishing device and erythritol cleaning powder. 6 weeks later subgingival calculus is mechanically removed in a second step by mechanical scaling and root planing
89481258|NCT03098498|Active Comparator|One-Stage Subgingival Debridement|Soft subgingival bacterial biofilms, as well as subgingival calculus are concomitantly removed from periodontal lesions by mechanical scaling and root planing
89481259|NCT02461017||Endotracheal Leak|Assess for Audible Endotracheal Leak; Assess for Endotracheal Leak with direct visualization under rigid bronchoscope
88951460|NCT01947374|Experimental|Chondrocyte implantation|From a previous biopsy, articular cartilage matrix is digested and chondrocytes are cultured in 2 passages until implants with at least 6,000,000 cells are constructed. These constructus of 8 mm in diameter are implanted arthroscopically by means of biodegradable anchor (MINILOK QUICKANCHOR TM from DePuy-Mitek ) located at the defect and tied securely.
89481260|NCT03297333|Experimental|Resistance training group|Resistance training will consist of a supervised circuit training 3 sessions/week for approximately 45-50 min/session. The circuit will include 7 strength exercises engaging the major muscle groups (leg press, rows, back squats, weighted crunches, deadlifts, bench press, and squat jumps with weights). The participants will perform 3 sets of 10 repetitions with resting periods of 30 seconds between exercises, and 2 minutes between sets. The overall OMNI-Resistance Exercise Scale per set will range between 8-10. Heart rate and exercise energy expenditure during the workout will be monitored. The load will be changed depending on the participants' perception when needed. In addition, the intensity will be monitored assessing Lactate concentrations at baseline and at the end of each session. Circuit will be repeated until meeting the targeted exercise energy expenditure of 450-500 kcal/session.
88951461|NCT01947374|Experimental|Microfractures|Subchondral bone perforations that allow a clot to be formed, and subsequent scar at the cartilage defect area.
89481261|NCT03297333|Experimental|Aerobic interval training group|Aerobic interval will consist of a supervised aerobic interval training sessions 3 times/week. Duration will range between 45-50 min/session depending on the exercise energy expenditure. Each interval will have a total duration of 5 min, and it will be divided into 2 periods. The first period will consist of 3 minutes of high-intensity activity, and the second period the intensity will be reduced for 2 minutes. The speed/incline will be changed depending on the participants' heart rate and perception using the Borg's rating of perceived exertion as needed. Heart rate and exercise energy expenditure during the workout will be monitored. Intensity will be monitored assessing Lactate concentrations at the end of each session. Intervals will be repeated until meeting the targeted exercise energy expenditure (450-500 kcal/session).
89481262|NCT03297333|No Intervention|Control group|Participants in the control group will not participate in the training programs.
89481263|NCT05066906|Experimental|Use of Identifor and Companion+referral to employment agencies|This group will use the Identifor tool and Companion app for a period of 6 months. They will also receive standard referral to employment agencies.
89481264|NCT05066906|Active Comparator|Referral to employment agencies|This group will not use the Identifor tool and Companion app. They will only receive standard referral to employment agencies.
89481265|NCT04477460||Infants with BRUE receiving thickened feeds|
89481266|NCT04477460||Infants with BRUE not receiving thickened feeds|
89481267|NCT05044442|No Intervention|Control|Participants will continue with their habitual lifestyle but perform no exercise for 2 weeks
89481268|NCT05044442|Active Comparator|Moderate intensity continous training|Participants will complete moderate intensity continous training during a 2 week intervention period
89481269|NCT05044442|Experimental|high intensity interval training|Participants will complete high intensity interval training during a 2 week intervention period
89481270|NCT05054426|Experimental|intravenous MTX|intravenous methotrexate at a dose of 1g/m2 for 4 courses
89481271|NCT05054426|Experimental|intrathecal MTX|intrathecal methotrexate 10mg at a time for 4 courses
89481272|NCT04475900||Healthy|Healthy eyes without any signs of ocular diseases
89481273|NCT04475900||Ectasia|ectasia suspects early, moderate and advanced keratoconus
89481274|NCT04475900||Glaucoma|Normal Tension glaucoma Primary Open-Angle Glaucoma
89481275|NCT00701727|Experimental|1|ezetimibe (10mg/day)for 7 weeks
89481276|NCT00701727|Placebo Comparator|2|Placebo control
89481277|NCT05054660|Experimental|caring chatbot|The investigators will enroll participants aged over 55 in the psychiatric outpatient department. The participants will get a one-month caring chatbot and can interact with the chatbot freely.
89481278|NCT03099512|Experimental|Ex+SFE Group|Individuals in this group who will perform exercises for knee and also short foot exercise
88951462|NCT01947387||Integra|
88951463|NCT01947387||Integra + NPWT (short-inpatient use only)|
88951464|NCT01947387||Integra + NPWT (long-all other durations)|
88951465|NCT01947387||Integra + STSG|
88951466|NCT01947387||Integra + Dermoinductive Agent|
88951467|NCT01947387||Free Flap|
88951468|NCT01947387||Local Tissue Flap|
88951469|NCT01947387||NPWT|
88951470|NCT01947387||NPWT then Integra (on same admission)|
88951471|NCT01947400||Hospitalists|AIDET Training
88951472|NCT01947413|Experimental|iTBS group|In intermittent theta burst stimulation (iTBS group), they received iTBS (80% of active motor threshold) on affected hemisphere.
88951473|NCT01947413|Experimental|cTBS group|In continuous theta burst stimulation (cTBS group), they received cTBS (80% of active motor threshold) on unaffected hemisphere.
89481279|NCT03099512|Active Comparator|Ex Group|Individuals in this group who will perform exercises for knee only
89481280|NCT02463513|Placebo Comparator|Treatment 1|
89481281|NCT02463513|Active Comparator|Treatment 2|
89481282|NCT02463513|Active Comparator|Treatment 3|
89481283|NCT04155008|Active Comparator|Patients with fair to good appetite|"The patients with fair-good appetite (score on CNAQ more than 24) will not receive any pharmacological agents and will receive nutrition intervention alone.~CNAQ = Council on Nutrition Appetite Questionnaire"
89481284|NCT04155008|Experimental|Patients with poor to fair appetite|"The patients with poor-fair appetite (score on CNAQ less than 24) will be provided nutrition intervention by the Registered Dietitian and then put into one of three pharmacological groups.~CNAQ = Council on Nutrition Appetite Questionnaire"
88951474|NCT01947413|Sham Comparator|sham TBS group|In sham theta burst stimulation (sham TBS group), they received sham TBS stimulation.
88951475|NCT01947426|Experimental|DHA supplementation|mother consuming 400 mg/day of DHA and tehir neonates
89481285|NCT05044364|Experimental|China clevidipine butyrate injection|Yangtze River Pharmaceutical Group Co., Ltd.
89481286|NCT05044364|Active Comparator|Original research clevidipine butyrate injection|Fresenius Kabi Austria Gmb H (Austria)
89481287|NCT03096860|Experimental|Alcohol consumption and hookah|
89481288|NCT03096860|Placebo Comparator|Placebo consumption and hookah|
89481289|NCT02461173|Active Comparator|Stimulated IUI|On the 3rd day of menstruation women in group 1 will have a vaginal ultrasound and will receive daily intramuscular 150 IU of human menopausal gonadotropins starting from the 3nd day of menstruation. On day 8 the ultrasound will be repeated and serum E2 will be measured, hMG dose will be adjusted and continued and the frequency of ultrasound scans will be individualized. HMG will be stopped when at least 2 follicles measuring 18 mm are associated with serum E2 of 500-3000 Pg/mL, this was followed by the administration of 10000 IU of human chorionic gonadotropin
89481290|NCT02461173|Active Comparator|Unstimulated IUI|Women in group 2 will be asked to test their morning urine specimen for luteinizing hormone daily starting 4 days before the expected day of ovulation. This will be done using a qualitative kit. IUI will be performed on the day after the surge in urinary excretion of luteinizing hormone.
89481291|NCT02461173|Active Comparator|Control group|Women will be asked to test their urine for luteinizing hormone by the same method as group 2. They will be asked to have an intercourse on the day after the surge in urinary excretion of luteinizing hormone and this will be repeated for 12 months.
89481292|NCT04434716|Other|Feasibility of Wearing a Readiband|"Participants will wear the Fatigue Science Readiband for 42 consecutive day. On day one, every seventh day and at the end of the study each participant will complete the Dyspnea-Characteristic scale, BRICS NINR PROMIS Fatigue Short Form6a scale , Modified Pulmonary Functional Status, Dyspnea Questionnaire and the BRICS NINR PROMIS SF v1.0-Sleep Disturbance 6a scale.The Minnesota Living with Heart Failure Questionnaire and Self-Care of Heart Failure Index will be completed on day one and day 60. The purpose of this intervention is to assess the Feasibility of Wearing a Readiband.~Semi-structured Interview will be conducted at the end of 42 days to assess patient comfort and challenges with wearing the Readiband."
89481293|NCT04489329|Experimental|Single Arm|Participant swallows and retrieves capsule in stool before and after ingestion of a probiotic. Capsule and stool samples are analyzed for presence of probiotic strain and compared to baseline.
89481294|NCT02463279|Experimental|SinuSys Dilation System|Opening of previously constrained frontal recess and/or sphenoid sinus ostia via dilation procedure (sinuplasty)
89481295|NCT03097172||Group 1|"Stable elective patients Stenotic coronary artery 10 x LAD 10 x RCA 10 x Cx~30 patients total"
89481296|NCT03097172||Group 2|"Stable elective patients Chronic total occlusion of one artery~10 x LAD 10 x RCA~20 patients total"
89481297|NCT03096938|Placebo Comparator|Normal screening group|patients receive the routine screening examination
89481298|NCT03096938|Experimental|methylation markers screening group|patients receive the methylation markers screening
89481299|NCT02463435|Active Comparator|Nutritional intervention|Patients under only nutritional intervention for weight loss
89481300|NCT02463435|Experimental|Nutritional intervention plus olive oil|Patients under conventional treatment (nutritional intervention) plus extra virgin olive oil supplementation
89481301|NCT02463435|Experimental|Olive oil|Patient under habitual food consumption plus extra virgin olive oil supplementation
89481302|NCT04152668|Active Comparator|Titanium curette and ultrasonic.|Control implants will be debrided with titanium curette and ultrasonic device without time limit.
89481303|NCT04152668|Experimental|Titanium curette, ultrasonic and air-polishing.|Test implants will be treated with titanium curette, ultrasonic device and a specially designed nozzle mounted on a hand piece (Perio-Flow) connected to an airflow unit also without time limit.
89481304|NCT03297177|Experimental|Microcannula Harvest Adipose|Acquisition AD-tSVF Via Closed Syringe Microcannula
89481305|NCT03297177|Experimental|Centricyte 1000|Autologous Adipose-Derived Tissue Stromal Vascular Fraction (tSVF) via enzymatic digestive isolation & concentration in Centricyte 1000 closed system to create AD-cSVF
88951476|NCT01947426|Placebo Comparator|Control (milk without DHA)|Mothers comsuming placebo and their neonates
88951477|NCT01947439|Experimental|Biolimus A9 eluting stent|biolimus A9 stent( Biomatrix or Biomatrix Flex) will be placed in under Percutaneous Coronary Intervention.
88951478|NCT01947439|Active Comparator|Zotarolimus-eluting stent|zotarolimus eluting stent (Resolute Integrity) will be placed in under Percutaneous Coronary Intervention.
88951479|NCT01947452|Experimental|Jobs Only|Youth will be offered a 5-hour per day, 5-day per week employment opportunity over 7 weeks. They will be paid the Illinois minimum wage of $8.25 per hour.
89481306|NCT03297177|Experimental|Sterile Normal Saline Infusion|Sterile Normal Saline to Re-Suspend Autologous cSVF pellet for delivery via intravascular (IV) route
89481307|NCT03099668|Experimental|OSAC|Single visit to a multidisciplinary clinic (the One Stop Arthritis Clinic, OSAC), followed by routine care
89481308|NCT03099668|No Intervention|Routine care|Routine care
89481309|NCT03297099|Experimental|Robot-assisted Laparoscopic operation|Da Vinci surgical robot can overcome limitations of conventional laparoscopic surgery in terms of vision and instrumentation flexibility, making the minimally invasive treatment of complex hepatolithiasis possible.
89481310|NCT03297099|Active Comparator|Open surgery|The indication of laparoscopic surgery is mainly for early regional type hepatolithiasis. Open surgery is the traditional treatment method for heptolithiasis.
89481311|NCT05066828|Active Comparator|conventional obturator|Participants received conventional obturator one piece
89481312|NCT05066828|Experimental|sectional obturator|two pieces obturators connected by magnet attachments
89481313|NCT05054114|Experimental|Drug: Interferon Gamma|IFN-G administered for 2 10-day courses with a 1-week pause between the courses.
89481314|NCT05054114|No Intervention|Control: No intervention|Any preventive method including a variety of pharmacologic therapies against COVID-19, alongside the use of antiviral and immunomodulating agents, with the exception of drugs prescribed off-label or for research purposes, and IFN-G as well.
89481315|NCT02463045|Experimental|TOP1288 1mg (or placebo)|TOP1288 1mg single dose or placebo
89481316|NCT02463045|Experimental|TOP1288 10mg (or placebo)|TOP1288 10mg single dose or placebo
89481317|NCT02463045|Experimental|TOP1288 100mg (or placebo)|TOP1288 100mg single dose or placebo
89481318|NCT02463045|Experimental|TOP1288 200mg single dose or placebo|TOP1288 200mg single dose or placebo
89481319|NCT02463045|Experimental|TOP1288 400mg dose or placebo|TOP1288 400mg (200mg bid) dose or placebo
89481320|NCT02463045|Experimental|TOP1288 A mg or placebo|TOP1288 A mg daily for 4 days
89481321|NCT02463045|Experimental|TOP1288 B mg or placebo|TOP1288 B mg daily for 4 days
89481322|NCT02463045|Experimental|TOP1288 C mg or placebo|TOP1288 C mg daily for 4 days
89481323|NCT02463045|Experimental|TOP1288 D mg or placebo|TOP1288 D mg bid for 4 days
89481324|NCT02463045|Experimental|TOP1288 Xmg or placebo|TOP1288 X mg od or bid for 4 days
89481325|NCT05053802|Experimental|Microwave ablation plus Camrelizumab|Microwave ablation plus Camrelizumab (no more than 16 cycles)
89481326|NCT05053802|Other|Microwave ablation|Microwave ablation
89481327|NCT04665531|Experimental|Group A - Erector Spinae Catheter group|"Patients in the experimental group will receive the erector spinae catheter prior the surgery and will be administered local anesthetics for 48 hours post-operatively.~Anesthetic regimen: initial bolus of 20ml 0.5% levobupivacaine before the end of surgery. Then continually ropivacaine 0,2% 5ml/h with intermittent boluses 15ml ropivacaine 0,2% every 4h.~Both groups will receive multimodal analgetic treatment consisting of a patient-controlled (PCA) pump with opioid analgetics and a peripherally acting analgetic metamizol on a regular basis. The PCA pump will be set to intermittent boluses of 3mg piritramide with a lock-out time 15 min and a maximal number of 6 boluses /3 hours. Patients will receive metamizol 2,5g/12hours i.v. on the day of surgery and 500-1000mg / 6 hours orally on the first and second post-operative day."
89481328|NCT04665531|Active Comparator|Group B - Intercostal block|"Patients will receive standard treatment, i.e. the multi-level intercostal block administered at the end of the surgery by the surgeon. They will receive 20ml 0,5% levobupivacaine on 6 levels of the thoracic wall according to the operative wound level.~Both groups will receive multimodal analgetic treatment consisting of a patient-controlled (PCA) pump with opioid analgetics and a peripherally acting analgetic metamizol on a regular basis. The PCA pump will be set to intermittent boluses of 3mg piritramide with a lock-out time 15 min and a maximal number of 6 boluses /3 hours. Patients will receive metamizol 2,5g/12hours i.v. on the day of surgery and 500-1000mg / 6 hours orally on the first and second post-operative day."
89481329|NCT05053568|Experimental|Intervention group|Live visualised, fluoroscopy-fused, image-guided, left ventricular lead placement on the basis of avoiding scar and targeting late mechanically activated segments.
89481330|NCT05053568|No Intervention|Control group|Empirical standard-of-care left ventricular lead placement, in line with current CRT implantation guidelines with electrical guiding on the basis of Q-LV sense.
89481331|NCT04943289|Experimental|DUOC-01|Intrathecal Infusion of DUOC-01 and hydrocortisone. Cohort 1: 10 million cells Cohort 2: greater than 10 to 25 million cells Cohort 3: greater than 25 to 50 million cells
89481332|NCT05053724|Experimental|Start to move group|In the Start to move group, physical therapy was included according to the Gosselink protocol, which establishes 6 levels of care divided according to system stability and state of consciousness. At level 0, no physical mobilization therapy was applied due to systemic lability. From level 1 to 5, passive mobilizations, use of muscle electrostimulation, active mobilizations and exercises against resistance, application of conventional cycloergometer, up to walking with assistance if the subject is able to perform it.
89481333|NCT05053724|Active Comparator|Conventional treatment group|In the conventional treatment group, passive mobilization, active-assisted mobilization and exercises against resistance, facilitation of high functional positions such as sedentary, bipedal and walking were applied, according to conventional treatment protocol.
89481334|NCT01369069|Experimental|IV insulin drip with target glucose 80 mg/dL - 130 mg/dL|The intervention arm will have a targeted glucose concentration of 80-130 mg/dL. IV insulin drip will be titrated to keep glucose concentration in this range.
89481335|NCT01369069|Active Comparator|Sub Q insulin to keep glucose less than 180 mg/dL|This standard care arm will get sub q insulin sliding scale to keep glucose concentration less than 180 mg/dL
89481336|NCT04489563|Other|Aged persons|A feasibility test of 20-30 minutes in aged persons with an adapted Kinect-based system, i.e. i-ACT.
89481337|NCT05053178|Experimental|Intervention group|Mindfulness-based mandala activity was applied to the intervention group via the zoom online program. Students will be divided into groups of 6-10 and mandala activities will be carried out. 3 weeks of mandala activity, breathing exercises, affirmations, etc. a therapeutic application program was created and implemented.
88951480|NCT01947452|Experimental|Jobs plus Social-Emotional Learning|Youth will be offered a 3-hour per day, 5-day per week employment opportunity over 7 weeks. They will also be offered 2-hour per day, 5-day per week social-emotional learning programming, for which they will be paid the same hourly wage as their job ($8.25/hour).
88951481|NCT01947465||Healthy controls|If a vaccination is indicated according to the recommendations by the Swiss Federal Office of Public Health: 319 healthy controls will be enrolled and will receive hepatitis A and/or tetanus vaccination
88951482|NCT01947465||Patients with rheumatoid arthritis|If a vaccination is indicated according to the recommendations by the Swiss Federal Office of Public Health: 142 patients with rheumatoid arthritis will be enrolled and will receive hepatitis A and/or tetanus vaccination.
89206290|NCT00831246|Experimental|1|Patients are given standard post-op care with clear liquid diet as tolerated plus chewing gum q8 for 30minute chewing intervals.
89481338|NCT05053178|No Intervention|Control group|For the students in the control group, the standard support program given by the school administration and course instructors will be applied for clinical problems. At the end of the study, it is planned to apply mandala activities among the students in the control group
89481339|NCT04489641|Experimental|Brief group psychotherapy|"Group brief psychological intervention by adaptation of the Guide NICE Common Mental Health Disorders (ISBN 978-1-84936-585-7) and the unified protocol for the trasndiagnostic treatment of the emotional disorders of Barlow (Boisseau et al., 2010). This intervention is provided by clinical psychologist in primary care."
89481340|NCT04489641|Active Comparator|Treatment as usual (TAU)|Medication provided by a general practitioner.
89481341|NCT02441218|Experimental|Ivabradine|
89481342|NCT02441218|Placebo Comparator|Placebo|
88951483|NCT01947465||Patients with axial spondylarthritis|If a vaccination is indicated according to the recommendations by the Swiss Federal Office of Public Health: 142 patients with axial spondylarthritis will be enrolled and will receive hepatitis A and/or tetanus vaccination.
88951484|NCT01947465||Patients with vasculitis|If a vaccination is indicated according to the recommendations by the Swiss Federal Office of Public Health: 142 patients with vasculitis will be enrolled and will receive hepatitis A and/or tetanus vaccination.
88951485|NCT01947478|Experimental|MDT-2113 Drug-Eluting Balloon|Paclitaxel drug-eluting angioplasty balloon
88951486|NCT01947478|Active Comparator|Standard angioplasty balloon|Standard PTA balloon without Paclitaxel drug-elution
88951487|NCT01947504|Experimental|education and support intervention|education and support intervention
88951488|NCT01947504|No Intervention|waiting list|waiting list and regular medical follow-up
88951489|NCT01947530|Active Comparator|Navigational Bronch/Standard Bronch|Patient will have first the Navigational Bronchoscopy then the standard bronchoscopy completed.
88951490|NCT01947530|Active Comparator|Standard Bronch/Navigational Bronch|Patient will first have a standard bronchoscopy then a navigational bronchoscopy completed.
89481343|NCT03098264|Experimental|Simultaneous surgery|to perform surgery both on biliary stone and portal hypertension
88951491|NCT01947543||Ventricular tachycardia|Patients with ventricular tachycardia of unknown origin treated with an ICD.
88951492|NCT01947543||Family members|Family members (parents, siblings and children) for patients with results showing mutations in the calmodulin genes.
88951493|NCT01947556|Other|insujet is tested first|first procedure: experiment with the investigational product (Insujet pen)containing insulin aspart; second procedure: control device (conventional Novopen III insulin pen) contains insulin aspart.
88951494|NCT01947556|Other|insujet is tested second|first procedure: experiment with the conventional Novopen III insulin pen containing insulin aspart; second procedure: investigational device (Insujet) contains insulin aspart.
88951495|NCT01947569|Experimental|iDC recipients|iDC cells modified by in vitro engineering.
88821622|NCT03268421|Active Comparator|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) is a psychological coping skills training using education on gate control theory of pain, behavioral strategies such as muscle relaxation and activity pacing, and cognitive strategies including distraction, problem-solving, and using calming self-statements.
88951496|NCT01947569|Active Comparator|Control DC recipients|DC cells which have not been modified.
88951497|NCT01947569|Placebo Comparator|Placebo recipients|Saline injections.
88951498|NCT01947595|Active Comparator|high risk non-responder, intensified lifestyle intervention|"high risk non-responder:~A) reduced Insulin secretion (disposition index: (IGI * ISI-Matsuda)< 760)~B) insulin resistance (ISI-Matsuda < 9,2)~C) elevated liver fat ( MRT > 5,56%)~A+B or A+C or B+C or A+B+C"
88821623|NCT03268421|Active Comparator|Graded Aerobic Exercise|Graded aerobic exercise (GAE) utilizes a circuit-training approach with short intervals of exercise interspersed with brief rest breaks.
88821624|NCT03247413|Experimental|Dexamethasone|Lesions where dexamethasone 4 milligram is administered post-radiofrequency ablation
88951499|NCT01947595|Active Comparator|hight risk non responder, normal lifestyle intervention|"high risk non-responder:~A) reduced Insulin secretion (disposition index: (IGI * ISI-Matsuda)< 760)~B) insulin resistance (ISI-Matsuda < 9,2)~C) elevated liver fat ( MRT > 5,56%)~A+B or A+C or B+C or A+B+C"
88951500|NCT01947595|Active Comparator|Responder, normal lifestyle intervention|"Responder:~A) reduced Insulin secretion (disposition index: (IGI * ISI-Matsuda)< 760)~B) insulin resistance (ISI-Matsuda < 9,2)~C) elevated liver fat ( MRT > 5,56%)~No A, only B or C"
88951501|NCT01947595|Active Comparator|Responder, single lifestyle advice (control group)|"Responder:~A) reduced Insulin secretion (disposition index: (IGI * ISI-Matsuda)< 760)~B) insulin resistance (ISI-Matsuda < 9,2)~C) elevated liver fat ( MRT > 5,56%)~No A, only B or C"
88951502|NCT01947634|Experimental|ResMed Apnea Link plus|Overnight respiratory polygraphy is performed in Fabry patients
88951503|NCT01947660|Experimental|Continuous regional anesthesia|
88951504|NCT01947660|Active Comparator|Systemic analgesia|
88951505|NCT01947673|Experimental|Modified Mindfulness Based Stress Reduction (MBSR) Program|After individual instruction, participants in this arm will perform meditation by following a series of mindfulness meditation (MM) recordings during hemodialysis for the next 4 to 8 weeks.The MM instructor will also meet with the participants weekly to provide continued instruction. Participants will also be encouraged to perform MM using a digital audio (MP3) player at home on non-dialysis days, and asked to keep a log of these sessions.
88951506|NCT01947673|Placebo Comparator|Health Education|Participants randomized to the control condition will undergo a 4 to 8 week health education series, with a parallel protocol as the MBSR intervention. Monitoring of adherence will be same as above.
88951507|NCT01947686||Patellofemoral Knee Arthroplasty|Patient who have received a robotically guided isolated patellofemoral implant.
88951508|NCT01947699|Experimental|Glyburide once daily|Timing of glyburide dosing will be changed, glucose will be monitored using continuous a glucose monitor.
88951509|NCT01947699|Experimental|Glyburide twice daily|Dose interval and timing of glyburide dose will be changed, glucose will be monitored using continuous a glucose monitor.
89481344|NCT03098264|Active Comparator|Staged surgery|to perform surgery on biliary stone and portal hypertension by staged surgery
89481345|NCT03296943|Experimental|Essential oil|Essential oil is prepared from the product of Thailada with manufacture standard ID 1087/2548 by Thailand Ministry of Industry. Essential oil is extracted by a cold compressed method from the lavandula angustifolia (lavender) grown in Australia.
89481346|NCT03296943|Sham Comparator|Perfume|Perfume is the synthetic perfume of lavender flavor without essential oil.
88821625|NCT03247413|Placebo Comparator|Placebo|Lesions where 1 milliliter of normal saline is administered post-radiofrequency ablation
88821626|NCT03222531|Experimental|HCV seropositive non-viremic (HCV Ab+/NAT-) donor|"HCV seropositive non-viremic (HCV Ab+/NAT-) donor hearts to HCV seronegative recipients.~Heart recipients will be monitored for HCV for one year following transplant. When HCV RNA is detected, the transmission-triggered treatment phase will be initiated.~Recipients will be treated with 12-week oral course of sofosbuvir/velpatasvir (Epclusa®), a fixed-dose combination of a nucleotide analogue HCV NS5B polymerase inhibitor (sofosbuvir - 400mg) and a NS5A inhibitor (velpatasvir - 100mg).~Intervention: Drug: sofosbuvir/velpatasvir"
88951510|NCT01947699|Experimental|Mixed meal tolerance test.|Subjects will be admitted to the Clinical Translational Research Center, receive a Mixed meal tolerance test and have timed blood draws to assess the effect of glyburide on glucose and insulin metabolism.
88951511|NCT01947712|Placebo Comparator|milk chocolate|dosage form: orally given dosage:40 g milk chocolate (≤35% cocoa) frequency and duration: 40 g/day for one month
88951512|NCT01947712|Active Comparator|dark chocolate|dosage form: orally given dosage:40 g dark chocolate (≥85% cocoa) frequency and duration: 40 g/day for one month
88951513|NCT01947738|Experimental|VBY-891|VBY-891
88951514|NCT01947738|Placebo Comparator|Placebo|Capsules containing excipient but no active drug
88951515|NCT01947751|Active Comparator|CVC exchange|The CVC will be removed immediately.
88951516|NCT01947751|Experimental|CVC maintenance|The CVC will be maintained, and exchanged only if confirmed catheter-related infection or worsening of sepsis
88951517|NCT01947764|No Intervention|Usual Care|"The Usual Care components for the control clinics will include the following:~All clinicians (pediatricians, medical officers, clinical officers, and nurses) caring for children undergo the existing 3-day disclosure training~Chart materials to guide and document disclosure counseling and visits~The presence of the AMPATH SOP mandating disclosure to children ages 10 and older.~In Usual Care clinics, no specific personnel will be dedicated to disclosure."
88951518|NCT01947764|Experimental|HADITHI Intervention|"In addition to the Usual Care components, the HADITHI Intervention clinics will include:~Modified materials to guide disclosure sessions~Videotaped narratives for parental counseling~Dedicated disclosure counselors to initiate and conduct the disclosure process~Post-disclosure support groups for children~The disclosure counselors will avail themselves for conducting disclosure with any families referred to them by the AMPATH clinicians. They will post fliers that describe their services for parents and caregivers so that families can self-refer for disclosure counseling. Similarly, the post-disclosure support groups for children will be available for anyone enrolled in the clinic and families will be able to self-refer or to be referred by the clinicians."
88951519|NCT01947790|Experimental|Pioglitazone group|Pioglitazone 15 mg/day will be given in this group for 9 months
88951520|NCT01947790|Active Comparator|Metformin group|Metformin 0.85 twice daily will be given in this group for 9 months as control.
88951521|NCT01947803|Experimental|Paliperidone Palmitate|
88951522|NCT01947829||Chronic Hemodialysis|
88951523|NCT01947881||Patients with DME|Patients with DME who need treatment with anti-VEGF injections of Lucentis.
88951524|NCT01947920|Experimental|1: Tramadol HCl 200 mg daily or placebo|Participants will receive one capsule of Tramadol hydrochloride (HCl) every 6 hours. Participants assigned to placebo will receive matching placebo capsules. A total of 9 doses will be administered.
88951525|NCT01947920|Experimental|2: Tramadol HCl 400 mg daily or placebo|Participants will recieve two capsules of Tramadol HCl every 6 hours. Participants assigned to placebo will receive matching placebo capsules. A total of 9 doses will be administered.
88951526|NCT01947920|Experimental|3: Tramadol HCl 600 mg daily or placebo|Participants will receive three capsules of Tramadol HCl every 6 hours. Participants assigned to placebo will receive matching placebo capsules. A total of 9 doses will be administered.
88951527|NCT01947933|Placebo Comparator|Placebo IV|Participants with psoriasis will receive a single dose of placebo matching mirikizumab intravenously (IV)
89481347|NCT05052788||Case group|40 patients according to inclusion criteria .
89481348|NCT05052788||Control group|20 normal people with no history of previous brain insult and with free neurological examination .
89481349|NCT02097433|Experimental|Dacomitinib|
89481350|NCT03296865|No Intervention|Without taping|Evaluations without taping
88951528|NCT01947933|Experimental|Mirikizumab IV|Participants with psoriasis will receive a single escalating dose of 5 milligram (mg), 20 mg, 60 mg, 120 mg, 200 mg, 350 mg, or 600 mg mirikizumab, IV
88951529|NCT01947933|Experimental|Mirikizumab SC|Healthy participants will receive a single dose of 120 mg mirikizumab subcutaneously (SC).
88951530|NCT01947959||Rivaroxaban|Patients who have been prescribed Rivaroxaban for the first time
88951531|NCT01947959||Standard of care|Patients who have been prescribed Standard of care for the first time
88951532|NCT01947972|Other|protein intake of 4g/kg/d|Tailored protein fortification and nutritional status of preterm neonate. 4.5g protein per kg for preterms with body weight less than 1000g and 4g protein per kg for preterms with body weight more than 1000g, after human milk analysis. Intervention regards protein supplementation to fulfil the exact protein needs of preterms
88951533|NCT01947985||Rivaroxoban|Patients who have been prescribed Rivaroxaban for the first time
89481351|NCT03296865|Experimental|Kinesio taping|Kinesio taping was apllied only one time. It was removed after intervention.
89481352|NCT03296865|Placebo Comparator|Placebo|Placebo was apllied only one time. It was removed after intervention.
89481353|NCT05043818||IBD patients with depression|IBD patients with depression
89481354|NCT05043818||IBD patients without depression|IBD patients without depression
89481355|NCT02097511|Experimental|Sarpogrelate pretreatment and Metoprolol|Sarpogrelate hydrochloride 100 mg pretreatment three times a day for three days and Metoprolol Tartrate 100 mg once a day with Sarpogrelate hydrochloride 100 mg three times a day
89481356|NCT02097511|Active Comparator|Sarpogrelate and Metoprolol|Metoprolol Tartrate 100 mg once a day with Sarpogrelate hydrochloride 100 mg three times a day
89481357|NCT02097511|Active Comparator|Metoprolol only|Metoprolol Tartrate 100 mg once a day
89481358|NCT03957681|Experimental|KHK4827|
89481359|NCT03957681|Placebo Comparator|Placebo|
89481360|NCT05043740|No Intervention|Control|Standard of care: management as recommended in ESC/EAS 2019 guidelines, within reimbursement criteria
88951534|NCT01947985||Standard of care|Patients who have been prescribed standard of care for the first time
88951535|NCT01947998||Rivaroxaban / Cohort 1|Patients who have been prescribed Rivaroxaban for the first time
88951536|NCT01947998||Standard of care / Cohort 2|Patients who have been prescribed Standard of care for the first time
88951537|NCT01948011|Experimental|Racecadotril 10mg suspension|single oral dose
88951538|NCT01948011|Experimental|Racecadotril 30mg suspension|single oral dose
88951539|NCT01948011|Experimental|Racecadotril 60mg suspension|single oral dose
88951540|NCT01948011|Active Comparator|Racecadotril 60mg granules|single oral dose
88951541|NCT01946932|Active Comparator|Cardiac Arrest 33°|survivors with temperature treatment 33°
88951542|NCT01946932|Active Comparator|Cardiac Arrest survivors 36°|survivors with temperature treatment 36°
88951543|NCT01948024|Active Comparator|Reference Arm - SAPHRIS|10 mg BID sublingual tablet
89481361|NCT05043740|Experimental|treatment|On top of Standard of care, Evolocumab (Repatha®) 140 mg or Alirocumab(Praluent) 75mg every two weeks: first subcutaneous injection at the time of randomization, followings during 12 months.
89481362|NCT02099539|Experimental|ALT-803|
89481363|NCT03928275|Experimental|Intralesional IL-2 Treatment|CMM patients will received 4 treatments of intralesional Interleukin-2 two weeks apart over an eight week period.
89481364|NCT03928275|Experimental|Combination therapy: Intralesional IL-2 and BCG Treatment|CMM patients will receive 4 treatments of combination therapy intralesional Interleukin-2 and Bacillus Calmette Guerin two weeks apart over an eight week period.
89481365|NCT05043896|Experimental|Combination therapy|Li-ESWT + tadalafil
89481366|NCT05043896|Sham Comparator|Single Therapy|tadalafil only
89481367|NCT02410252|Experimental|iThermonitor|Participants are asked to use the iThermonitor device for two weeks to monitor their temperature. Participants are asked to wear the device for as many hours as they can but at a minimum to wear while sleeping.
89481368|NCT03097016|Experimental|Single oral dose of 3 mg CC-122|All subjects will receive one 3 mg CC-122 capsule the morning of Day 1 which will be administered in the fasted state.
89481369|NCT03096704||slow transit time constipation|
89481370|NCT04933929|Experimental|"Coronavirus disease Positive group Covid (+)"|Positive PCR test.
89481371|NCT04933929|Active Comparator|"Coronavirus disease Negative group Covid (-)"|Negative PCR test.
89481372|NCT02099695|Active Comparator|Oxybutynin Chloride|"Tablet~Dose 5,0 or 10 mg/ day"
89481373|NCT02099695|Placebo Comparator|Placebo|- Tablet
89481374|NCT02099773||support workers & AAC users|Support workers who use KeyWordSigning in the communication with their client who has an intellectual disability
89481375|NCT02099773||support workers & KWS users|Support workers who use aided AAC in the communication with their client who has an intellectual disability
89531469|NCT06065995|No Intervention|Control group|Standard care, without access to the application
89531470|NCT06065969|Active Comparator|Local photobiomodulation|Delivering an energy of 6J per point (60 seconds) at 2 points in the masseter muscle region, 1 point in the temporal muscle, and 1 point in the trapezius muscle in the cervical region. The total application will take 4 minutes per session
88951544|NCT01948024|Experimental|Test Arm - Asenapine|10 mg BID sublingual tablet
88951545|NCT01948037|Active Comparator|hydrotherapy|
88951546|NCT01948037|Other|hot spring|30-minutes/per day;4weeks
88951547|NCT01948089|Experimental|Variable Structured Cognitive Exercise|This training group will consist of 10 randomly assigned participants who will begin the adaptive working memory training task immediately after baseline assessment. Each participant will receive 30 minutes of cognitive exercise per day, 3 days a week for 10 weeks.
88951548|NCT01948089|Experimental|Constant Structured Cognitive Exercise|This training group will consist of 10 randomly assigned participants who will begin the adaptive working memory training task immediately after baseline assessment. Each participant will receive 30 minutes of cognitive exercise per day, 3 days a week for 10 weeks.
88951549|NCT01948115|Placebo Comparator|Medical air|
88951550|NCT01948115|Experimental|equimolar mixture of oxygen and nitrous oxide|
88951551|NCT01948128|Experimental|Vitamin D3|Vitamin D3 40,000 iu per day by mouth
88951552|NCT01948128|Placebo Comparator|Placebo|Placebo taken daily by mouth
88951553|NCT01948154||children with CP|Cerebral palsy (CP) encompass a group of non-progressive, non-contagious motor conditions that cause physical disability in human development. 2-12 years old (n=60-80)
88951554|NCT01948154||normal child|normal child 2-12 years old (50 subjects)
88951555|NCT01948167|Experimental|Interpersonal Psychotherapy- Adolescent Skills Training|Interpersonal Psychotherapy- Adolescent Skills Training
88951556|NCT01948167|Experimental|Coping with Stress|Coping with Stress
88951557|NCT01948180|Experimental|baltaleucel-T|"Treatment consists of 2 infusions of 2x10E7 cells/m2 given on Days 1 and 15 intravenously via a peripheral or central line over a 1 to 10 minute period.~Subjects who tolerate the study treatment well and who do not require treatment with an alternative chemotherapeutic agent will be eligible for up to 3 additional infusions of 2x10E7 cells/m2 administered at week 8, month 3 and month 6."
88951558|NCT01948206||Prolonged paced QRS group|Patients with implantable cardioverter-defibrillators with Prolonged Paced(>=150ms) QRS duration
88951559|NCT01948206||Narrow paced QRS group|Patients with Implantable Cardioverter-Defibrillators with Narrow Paced(<150ms) QRS duration
88951560|NCT01948219|Experimental|ENTegral Artificial Larynx implant|ENTegral Artificial Larynx implantation
88951561|NCT01948232|Experimental|Perindopril|
88951562|NCT01948271|Experimental|TSO 7500|Subjects in this arm will receive doses of 7500 trichuris suis ova every two weeks, starting at the baseline visit, for a total of 8 doses.
88951563|NCT01948284|Active Comparator|maximal suction pressure|The pressure level of the suction unit (DF 601, Hanlien, Taipei, Taiwan) will be set at the maximal (-70 cm Hg).
88951564|NCT01948284|Active Comparator|half-maximal pressure|The pressure level of the suction unit will be set at the half-maximal (-35 cm Hg).
88951565|NCT01948297|Experimental|Part A|Adaptive doses of Debio1347 (CH5183284) - (10 mg to 210 mg/day) until the recommended dose (RD) is determined.
88951566|NCT01948297|Experimental|Part B|Participants with various tumours receive Debio1347 (CH5183284) orally at the recommended dose established during Part A.
88951567|NCT01948323|Other|.HEDUAfrica IT package+ std care info|"The HEDUAfrica IT package website aims to target disadvantaged gravid women representing the core aspect of the intervention. The website is available on a touch screen panel at the two intervention clinics, (Cape Town and Soweto, SA). A healthcare worker will assist women with the touchscreen tablet at the follow up sessions. The website content includes a number of short videos and health messages related to a pregnancy-specific-disease outcomes. Patients participating in the IT package also receive std car info~Participants are also asked to complete 2 questionnaires (24 hour dietary recall assessment and short messaging service technology driven) in conjunction to engaging with the HEDUAfrica website. The intervention is standardized across all participants in the intervention group."
88951568|NCT01948323|No Intervention|Health awareness brochure + std care|Participants in the non-intervention group at another clinic in Soweto, will receive an enhanced form of standard care. This will include, in conjunction with the normal form of care at each clinic,a health awareness brochure that will focus specifically on health information relating to obesity, diabetes, diet, exercise and breastfeeding at each follow-up sessions. These participants will also be asked to fill out the 24 hour dietary recall assessment and short messaging service technology questionnaire (exactly the same as the intervention group) with help from a healthcare worker.
88951569|NCT01948336|Placebo Comparator|Control|The patients in group C (control) (n=30) were bolused with 1 mg kg-1 ketamine (Ketalar®, Eczacibasi, Luleburgaz, Turkey) (IV) and 1 mg kg-1 propofol (Propofol 1% Fresenius, Fresenius Kabi Deutschland, Bad Homburg, Germany) (IV) followed by 1 mg kg-1 hour-1 ketamine (IV) and 50 µg kg-1 min-1 propofol (IV) infusion. Additionally a loading dose of 1 ml kg-1 D5 0.3% NaCl IV given over 10 minutes, followed by 0.5 ml kg-1 hour-1 IV D5 0.3% NaCl infusion were administered.
88951570|NCT01948336|Active Comparator|Dexmedetomidine|The patients in group D (dexmedetomidine) (n=30) were bolused with 1mg kg-1 ketamine (IV), 1mg kg-1 propofol (IV) followed by 1 mg kg-1 hour-1 ketamine (IV) and 50 µg kg-1 min-1 propofol (IV) infusion. Additionally a loading dose of 1 µg kg-1 dexmedetomidine (Precedex Abbott Labs, North Chicago, IL) IV given over 10 minutes, followed by 0.5 µg kg-1 hour-1 IV dexmedetomidine infusion were administered. Dexmedetomidine was prepared as a 1 µg ml-1 solution using D5 0.3% NaCl solution.
88951571|NCT01948349|No Intervention|Non-tongue scraping and twin brackets|Patients in this subgroup will be instructed to follow standard at-home oral hygiene protocols. They will be instructed by the study coordinators to utilize the traditional Bass brushing technique [31], brushing twice daily (morning and night) for 2 minutes each time. Patients will all be given the same toothbrush and toothpaste to use during the study. They will also be instructed on the method of flossing and be shown how to use interdental brushes to clean around the orthodontic appliances.
89203091|NCT00343291|Active Comparator|Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/3)|"Cycles 1-6:~Cetuximab 400 mg/m² initial dose on day 1 and then 250 mg/m² given every week~Bevacizumab 15 mg/kg given on day 8 of every 3 week cycle~Cycles 1-3:~Paclitaxel 200 mg/m² on day 1 of each 3 week cycle for the first 3 cycles~Carboplatin AUC=6 min*mg/mL on day 1 of each 3 week cycle for the first 3 cycles~Patients who demonstrate a response or stable disease after six cycles of therapy may continue on weekly cetuximab monotherapy until disease progression, unacceptable toxicity, or another withdrawal criterion is met"
89206291|NCT00831246|Sham Comparator|2|Patients are given standard post-op care with clear liquid diet as tolerated .
89481376|NCT02440594|Experimental|Enhanced Care High-Symptom AD/AX|Patients newly prescribed an antidepressant or anxiolytic who report significant baseline symptoms receive Enhanced BHL Program Services, which include the: 1) Standard Clinical Monitoring Module - evidence-based care consisting of up to 4 brief (5-10 minutes), structured assessments following the Core/baseline assessment. Interviews are conducted over the telephone by the Health Technician/BHP and take place during the initial 12 weeks of pharmaceutical treatment (e.g., 2, 6, 9, and 12 weeks), and monitor adherence, side effects, and treatment response. A progress report is provided to the prescribing clinician after each interview to help in treatment planning and to alert the clinician of special issues, and 2) Enhanced Care Management Module - Care Management services with a BHP.
89481377|NCT02440594|Active Comparator|Standard Care High-Symptom AD/AX|Patients newly prescribed an antidepressant or anxiolytic who report significant baseline symptoms receive Standard BHL Program Services, which include the Standard Clinical Monitoring Module - evidence-based care consisting of up to 4 brief (5-10 minutes), structured assessments following the Core/baseline assessment. Interviews are conducted over the telephone by the Health Technician/BHP and take place during the initial 12 weeks of pharmaceutical treatment (e.g., 2, 6, 9, and 12 weeks), and monitor adherence, side effects, and treatment response. A progress report is provided to the prescribing clinician after each interview to help in treatment planning and to alert the clinician of special issues.
89481378|NCT02440594|Experimental|Enhanced Monitoring Low-Symptom AD/AX/AP|Patients newly prescribed an antidepressant, anxiolytic, or antipsychotic who report low baseline symptoms receive Enhanced BHL Program Services, which for this group include the: 1) Standard Clinical Monitoring Module - evidence-based care consisting of up to 4 brief (5-10 minutes), structured assessments following the Core/baseline assessment. Interviews are conducted over the telephone by the Health Technician/BHP and take place during the initial 12 weeks of pharmaceutical treatment (e.g., 2, 6, 9, and 12 weeks), and monitor adherence, side effects, and treatment response. A progress report is provided to the prescribing clinician after each interview to help in treatment planning and to alert the clinician of special issues, and 2) Enhanced Monitoring via a one-time BHP follow-up call with the enrollee after 6 weeks to discuss continuing versus discontinuing the medication.
89481379|NCT02440594|Active Comparator|Standard Monitoring Low-Symptom AD/AX/AP|Patients newly prescribed an antidepressant, anxiolytic, or antipsychotic who report low baseline symptoms receive Standard BHL Program Services, which include the Standard Clinical Monitoring Module - evidence-based care consisting of up to 4 brief (5-10 minutes), structured assessments following the Core/baseline assessment. Interviews are conducted over the telephone by the Health Technician/BHP and take place during the initial 12 weeks of pharmaceutical treatment (e.g., 2, 6, 9, and 12 weeks), and monitor adherence, side effects, and treatment response. A progress report is provided to the prescribing clinician after each interview to help in treatment planning and to alert the clinician of special issues.
89531471|NCT06065969|Experimental|Vascular photobiomodulation|660 nm and 100 mW, directing the light beam towards the radial artery region, for 10 minutes per session. The participant will be seated in a comfortable chair with side support for resting their arms during the application
88951572|NCT01948349|Experimental|Tongue scraping with standard twin brackets|Patients allocated to this group will receive the same oral hygiene protocol as the non-tongue scraping subjects. However, they will also be in instructed and asked to use the tongue-scraping method of cleaning the tongue as part of their oral hygiene regimen. Patients will be instructed to scrape the tongue once during their nighttime oral hygiene session of brushing and flossing. All patients in this subgroup will be given the same tongue scraper.
88951573|NCT01948349|Experimental|No tongue scraping with self-ligating brackets|Patients in this group are treated with passive self-ligating Carrier brackets (Ortho Organizer). They will be instructed to use the traditional Bass brushing technique, brushing twice daily (morning and night) for 2 minutes each time. Patients will all be given the same toothbrush and toothpaste to use during the study. They will also be instructed on the method of flossing and be shown how to use interdental brushes to clean around the orthodontic appliances.
88951574|NCT01948349|Experimental|Tongue scraping with SLB|Patients in this group are treated with passive self-ligating Carrier brackets (Ortho Organizer). Patients allocated to this group will receive the same oral hygiene protocol as non-tongue scraping subjects. However, they will also be in instructed and asked to use the tongue-scraping method of cleaning the tongue as part of their oral hygiene regimen. Patients will be instructed to scrape the tongue once during their nighttime oral hygiene session of brushing and flossing. All patients in this subgroup will be given the same tongue scraper.
88951575|NCT01948362|Active Comparator|Sulforadex|Active compound
88951576|NCT01948362|Experimental|alpha Cyclodextrin|Placebo control arm
88951577|NCT01948401|Experimental|Controlled asthma|
89203092|NCT00799734|Active Comparator|alternative medicine|Intake of prepacked Chinese herbal medicine (EXD), one sachet of granules (15g extracted granules) twice a day
89481380|NCT02440594|Experimental|Enhanced Care High-Symptom AP|Patients newly prescribed an antipsychotic who report significant baseline symptoms receive Enhanced BHL Program Services, which include the: 1) Standard Clinical Monitoring Module - evidence-based care consisting of up to 4 brief (5-10 minutes), structured assessments following the Core/baseline assessment. Interviews are conducted over the telephone by the Health Technician/BHP and take place during the initial 12 weeks of pharmaceutical treatment (e.g., 2, 6, 9, and 12 weeks), and monitor adherence, side effects, and treatment response. A progress report is provided to the prescribing clinician after each interview to help in treatment planning and to alert the clinician of special issues, and 2) Enhanced Care Management Module - Care Management services with a BHP.
89481381|NCT02440594|Active Comparator|Standard Care High-Symptom AP|Patients newly prescribed an antipsychotic who report significant baseline symptoms receive Standard BHL Program Services, which include the Standard Clinical Monitoring Module - evidence-based care consisting of up to 4 brief (5-10 minutes), structured assessments following the Core/baseline assessment. Interviews are conducted over the telephone by the Health Technician/BHP and take place during the initial 12 weeks of pharmaceutical treatment (e.g., 2, 6, 9, and 12 weeks), and monitor adherence, side effects, and treatment response. A progress report is provided to the prescribing clinician after each interview to help in treatment planning and to alert the clinician of special issues.
89481382|NCT02440594|Experimental|Caregiver TEP Intervention|Caregivers of patients newly prescribed an antidepressant, anxiolytic, or antipsychotic who cannot participate due to cognitive impairment and meet criteria for dementia receive Enhanced BHL Program Services which include: 1) a baseline clinical assessment of caregiver and care recipient factors (e.g., level of disability, burden, safety concerns) and contact information for local community services, and 2) the Telehealth Education Program (TEP) - BHPs provide manual and workbook-guided psychoeducation, support, and skills training.
89481383|NCT02440594|Active Comparator|Caregiver Control|Caregivers of patients newly prescribed an antidepressant, anxiolytic, or antipsychotic who cannot participate due to cognitive impairment and meet criteria for dementia receive Standard BHL Program Services, which include a baseline clinical assessment of caregiver and care recipient factors (e.g., level of disability, burden, safety concerns) and contact information for local community services
89481384|NCT05043662||Urothelial carcinoma group|The extracted DNA from morning urine will be analyzed by UroCAD to determine the level of CNV. CTU and cytology will be performed according to the routine of clinical practice (N=80).
89481385|NCT05043662||Control group|Patients need to undergo CTU examination and being treated for benign diseases with ureteroscopy, but without any tumor will provide a negative control to provide data for determining the sensitivity and specificity of UroCAD, CTU and cytology assay (N=30).
89481386|NCT02099851|Experimental|Carotid body ablation|Patients undergoing the unilateral endovascular ablation of the right or left carotid body.
89481387|NCT02102503|Experimental|MI and Medication review|The intervention starts three months post-discharge after the standard treatment at the out-patients clinic. A medication review focused on cardiovascular drugs, and a counselling session with a clinical pharmacist using Motivational Interviewing (MI)-approach, and a follow-up phone call two weeks later. For patients with negative beliefs about medicines, three additional MI-sessions in clinic or by phone are planned together with the patient. Irrespective of beliefs the intervention ends with a second medication review and counselling session, which is coordinated with the 12-months post-discharge follow-up in primary care.
89481388|NCT02102503|Active Comparator|Standard treatment|Standard treatment at the cardiology out-patient clinic. Follow-up by nurse after two weeks and by physician after two months.
89481389|NCT04935580|Experimental|GC012F treatment|GC012F will be infused at a dose of1- 3 x 10^5 CAR+ T cells/kg after receiving lymphodepleting chemotherapy. Lenalidomide maintenance therapy will be given post month 6 at physicians' choice.
89203093|NCT00799734|Placebo Comparator|placebo|placebo therapy of 15g granules with similar colour and taste.
89203094|NCT05407870|Active Comparator|Propofol|induction - 0.5mg/kg Propofol maintenance - 0.25mg/kg Propofol
89203095|NCT05407870|Experimental|Etomidate|induction - 0.25mg/kg Propofol + 0.05mg/kg Etomidate maintenance - 0.05mg/kg Etomidate
89203096|NCT03988231|Active Comparator|Enoxaparin 40mg once daily|All patients will have enoxaparin prophylaxis or placebo initiated at 8 hours after surgery. Prophylaxis or placebo will be provided every 24 hours and will be continued for the duration of inpatient stay.
89481390|NCT05066516|Experimental|Period 1: Individual components (ICs), period 2: FCDP|Period 1: Individual components (ICs), period 2: FCDP
89481391|NCT05066516|Experimental|Period 1: FCDP, period 2: ICs|Period 1: FCDP, period 2: ICs
89481392|NCT02097589|Experimental|Pneumovax-Atorvastatin|10-person arm receiving treatment for 28 days: 40 mg atorvastatin, taken orally, once daily, for 28 days. Pneumovax 23 injected once, intramuscularly at Day 7.
89481393|NCT02097589|Placebo Comparator|Pneumovax-Placebo|10-person arm receiving treatment for 28 days: Placebo (lactose pill), taken orally, once daily for 28 days. Pneumovax 23 injected once, intramuscularly at Day 7.
89481394|NCT05066594||Transoral incisionless fundoplication with EsophyX device (EndoGastric Solutions)|Patients treated by transoral incisionless fundoplication (TIF) using the EsophyX device (EndoGastric Solutions) for gastro-esophageal reflux disease will be enrolled in the registry and clinically followed-up for 5 years from the date of TIF procedure.
89481395|NCT02102581||short time tourniquet|60 patients were randomly divided into 2 groups (30 cases/group): group A using the tourniquet throughout the operation, and group B using the tourniquet starting from the implantation of prosthesis to the completion of the operation(short time).
89481396|NCT05066438||Antenatal hand expression - intention to exclusively breastfeed|Eligible participants in this group intend to exclusively breastfeed AND must have received standardized counselling on and practiced antenatal hand expression for a minimum of 10 days beginning no earlier than 36 weeks gestational age.
89481397|NCT05066438||No antenatal hand expression - intention to exclusively breastfeed|Eligible participants in this group intend to exclusively breastfeed but have NOT received any standardized counselling on antenatal hand expression and have not practiced antenatal hand expression OR have practiced antenatal hand expression but for less than 10 days.
89481398|NCT02099929|Experimental|Coffee with Sugar|300mL of Coffee with 30g of Sugar
89481399|NCT02099929|Experimental|Coffee without Sugar|300mL of Coffee without Sugar
89481400|NCT02099929|Experimental|Decaffeinated Coffee without Sugar|300mL of Decaffeinated Coffee without Sugar
88951578|NCT01948401|Experimental|Uncontrolled asthma with additional OCS|
88951579|NCT01948401|Experimental|Uncontrolled asthma without additional OCS|
89481401|NCT02099929|Sham Comparator|Water with Sugar|300mL of Water with 30g of Sugar
89481402|NCT02099929|Sham Comparator|Water without Sugar|300mL of Water without Sugar
89481403|NCT05052164|Experimental|Gluten-free nutrition plan + exercise group|Celiac women who perform a physical exercise program 3/4 times per week and a gluten-free isocaloric dietary plan.
89481404|NCT05052164|Experimental|Gluten-free nutrition plan group|Women with celiac disease following a gluten-free isocaloric dietary plan.
89481405|NCT05052164|Active Comparator|Celiac controls group|Women with celiac disease in whom all variables are measured but no intervention is performed.
89481406|NCT05052164|No Intervention|Non-celiac controls group|Non celiac menopausal or post-menopausal in whom all the tests were measured but they did not perform an intervention program with physical exercise or special follow-up of an adapted dietary-nutritional program
89481407|NCT02102659|Experimental|Upper Limit Nutrition Support Therapy|"Upper limit nutrition support therapy will be used in patens assigned to this group based on the patient's curve of apoptosis of oral mucosal epithelium."
89481408|NCT02102659|Active Comparator|Formula Nutrition Support Therapy|"Formula nutrition support therapy will be used in patens assigned in this group based on Harris Bendiest Formula."
89481409|NCT03836001|Placebo Comparator|Placebo Oral Tablet|Participants will undergo two months of dosing with a placebo (inactive drug or sugar pill), followed by one month of washout. After the washout period, all participants were invited to participate in an open-label extension study with serlopitant 5 mg daily. The duration of the open-label extension study was either 12 months (for those who enrolled before May 2020) or 3 months (for those who registered after May 2020) due to drug availability.
89481410|NCT03836001|Active Comparator|Serlopitant Tablet|Participants will undergo two months of Serlopitant 5mg daily per oral, followed by one month of washout. After the washout period, all participants were invited to participate in an open-label extension study with serlopitant 5 mg daily. The duration of the open-label extension study was either 12 months (for those who enrolled before May 2020) or 3 months (for those who registered after May 2020) due to drug availability.
89481411|NCT05052242||one group compared two measurement methods|one group compared two measurement methods
89481412|NCT02100085||Observational group|Subjects in the period less than 48 weeks after the final administration of GX-188E
89481413|NCT02465866|Experimental|Treatment A: CL-108 (Fasted)|CL-108 single dose tablet (7.5 mg/325 mg/12.5 mg) by mouth under fasted condition
89481414|NCT02465866|Experimental|Treatment B: CL-108 (Fed)|CL-108 single dose tablet (7.5 mg/325 mg/12.5 mg) by mouth under fed condition
89481415|NCT02465866|Active Comparator|Treatment C: Vicoprofen, Ultracet and Phenergan (Fasted)|Vicoprofen 7.5 mg/200 mg + Ultracet 37.5 mg/325 mg + Phenergan 12.5 mg single dose tablets by mouth under fasted condition
89481416|NCT02465866|Active Comparator|Treatment D: Vicoprofen, Ultracet and Phenergan (Fed)|Vicoprofen 7.5 mg/200 mg + Ultracet 37.5 mg/325 mg + Phenergan 12.5 mg single dose tablets by mouth under fed condition
89481417|NCT02100163|Experimental|Virtual Reality Hypnosis|The patient receives VRH daily.
89481418|NCT02100163|Experimental|Audio Hypnosis|The patient receives Audio Hypnosis daily.
89481419|NCT02100163|Experimental|Standard Treatment|The patient receives the standard treatment. This is a control group and there are no interventions.
89481420|NCT03555955|Experimental|Cohort 1|Normal renal function
89481421|NCT03555955|Experimental|Cohort 2|Moderate renal impairment
89481422|NCT03555955|Experimental|Cohort 3|Severe renal impairment
89481423|NCT05066360|Other|participants with epilepsy|healthy, menstruating females between 12-18 ages
89481424|NCT05066360|Other|healthy participants|epileptic, menstruating females between 12-18 ages
88951580|NCT01948414|Other|obese women with eating disorders|Obese women with eating disorders : women with BMI higher or equal 35 and disinhibition score to TFEQ strictly higher to 8
88951581|NCT01948414|Other|Obese women without eating desorders|Obese women without eating disorders : women with BMI higher or equal to 35 and disinhibition score to TFEQ lower or equal to 8
89481425|NCT03296631||children|"Enrollment of 15 to 20 children (< 9 months old) at the early beginning of their entry in nursery (crèche) between August and November 2017.~This cohort will be followed during a maximum period of 36 months . Diapers with fresh stools will be collected once a week per child and then frozen.~Spontaneous personal day care informations given by the parents to the nurses and recorded in each child's daily logbook will be collected for the research. No specific interviews will be conducted."
89481426|NCT02439970|Active Comparator|Treatment 1|100 mg brincidofovir (BCV; 1 tablet) administered orally twice weekly, plus valganciclovir (vGCV) placebo (2 tablets) administered orally once daily.
89481427|NCT02439970|Active Comparator|Treatment 2|900 mg valganciclovir (vGCV; two 450 mg tablets) administered orally once daily, plus brincidofovir (BCV) placebo (1 tablet) administered orally twice weekly.
89481428|NCT02097901|Experimental|Microfracture|Rotator Cuff Repair AND Microfracture at rotatorcuff footprint
89481429|NCT02097901|Active Comparator|NO microfracture|Rotator cuff reinsertion without microfracture
89481430|NCT05065814|Other|Systemic lupus erythematosus group|Demographic information of systemic lupus erythematosus patients who accepted to participate in the study will be obtained, and respiratory and peripheral muscle strength and exercise capacity of the patients will be evaluated with a 6-minute walking test. Patients will be asked to complete the International Physical Activity Questionnaire, the numerical pain questionnaire, the Short Form-36, and the Hospital Anxiety and Depression Questionnaire. In addition, Modified Medical Research Council Dyspnea Scale will be applied by the interviewer.
88951582|NCT01948414|Other|Lean women|Lean women : women with BMI from 18.5 to 24.5 and disinhibition score to Three-Factor Eating Questionnaire (TFEQ)lower or equal to 8
89020641|NCT02917720|Experimental|TKI-stop, pre-treatment with nilotinib|"Treatment after unsuccessful 1st or 2nd discontinuation at least two year with nilotinib (300 mg/bid). In total, retreatment with TKI for at least 3 years before entering screening for stopping phase is warranted. Clinical monitoring every 3 months during this 2 years.~Patients who re-achieved and maintained MR4 for at least 12 months and MR4.5 for at least 6 months can enter screening phase for TFR .If MR4.5 is confirmed by an validated laboratory, patient may enter stopping phase of the study. Patient not fulfilling these criteria can be screened again every 3 months until month 48. After TKI-stop hematological monitoring and quantitative PCR of BCR/ABL1 (month 1-6 after stopping: monthly; month 7-12 after stopping: every 1.5 months, thereafter once every three months, for 3 years in total.~Relapse is defined as BCR-ABL1 > 0.1% on IS at a single time point (loss of MMR) In case of relapse restart of TKI. In general, the same TKI (nilotinib) as before second stop is recommended"
89020642|NCT02805855|Experimental|S50|Subjects in the S50 cohort will receive one injection of 50 million AMSCs.
89020643|NCT02805855|Experimental|S100|Subjects in the S100 cohort will receive one injection of 100 million AMSCs.
89020644|NCT02805855|Experimental|M50|Subjects in the M50 cohort will receive three injections of 50 million AMSCs at one-month intervals.
89020645|NCT02805855|Experimental|M100|Subjects in the M100 cohort will receive three injections of 100 million AMSCs at one-month intervals.
89020646|NCT02724228|Experimental|BMN 111 - Subcutaneous Injection|111-205 is an open-label, extension study. Subjects receive the same stable dose of BMN 111 received upon completion of the 111-202 study, initially up to 30 μg/kg. BMN 111 will be administered by weight-band dosing regimen.
89020647|NCT02719327|Experimental|icosapent ethyl (IPE)|Participants will be randomized in a 1:1 ratio to receive icosapent ethyl 4 g daily vs. matching gel cap placebo
89020648|NCT02719327|Placebo Comparator|placebo|Participants will be randomized in a 1:1 ratio to receive icosapent ethyl 4 g daily vs. matching gel cap placebo
89020649|NCT02711709||Intra-abdominal sepsis|Frailty measurements. Modified Minnesota Leisure Time Activities. Computed tomography morphometrics. Mobility Monitors.
89020650|NCT02710734|Experimental|CRT|Trimodality of Maximal TURBT#1 Followed by AMVAC and TURBT#2 and then chemoradiation followed by TURBT#3
89020651|NCT02710734|Experimental|Surveillance|Trimodality of Maximal TURBT#1 Followed by AMVAC and TURBT#2 and then active surveillance
89020652|NCT02710734|Experimental|Intravesicle therapy|Trimodality of Maximal TURBT#1 Followed by AMVAC and TURBT#2 and then intravesicle therapy followed by TURBT#3
89020653|NCT02710734|Experimental|Radical Cystectomy|Trimodality of Maximal TURBT#1 Followed by AMVAC and TURBT#2 and then cystectomy
89020654|NCT02669225|Experimental|Rested Wakefulness|RW PET/MR Scanning Sessions
89203097|NCT03988231|Placebo Comparator|Placebo|All patients will have enoxaparin prophylaxis or placebo initiated at 8 hours after surgery. Prophylaxis or placebo will be provided every 24 hours and will be continued for the duration of inpatient stay.
89203098|NCT00794742||Burn Wounds|Patients with burn wounds
89020655|NCT02669225|Experimental|Sleep Deprivation|SD PET/MR Scanning Sessions
89203099|NCT03988465||Cardiac Surgery Patients|Patients undergoing cardiopulmonary bypass surgery, including placement of a ventricular access device.
88951583|NCT01948440|Experimental|ASI-MV Solutions|The Experimental group will complete the ASI-MV and use the ASI-MV Solutions program for eight 30-minute sessions, followed by monthly booster sessions. The Experimental group will undergo a baseline assessment and one-month post-baseline, two-month post-baseline, and six-month post-intervention.
89481431|NCT05065814|Other|Systemic sclerosis group|Demographic information of systemic sclerosis who accepted to participate in the study will be obtained, and respiratory and peripheral muscle strength and exercise capacity of the patients will be evaluated with a 6-minute walking test. Patients will be asked to complete the International Physical Activity Questionnaire, the numerical pain questionnaire, the Short Form-36, and the Hospital Anxiety and Depression Questionnaire. In addition, Modified Medical Research Council Dyspnea Scale will be applied by the interviewer.
89481432|NCT05065814|Other|Healthy control group|Healthy individuals with no chronic diseases who agreed to participate in the study and gave their consent will be included in the study.
89481433|NCT03290859||Training intervention|Train anesthesia providers who deliver propofol sedation for GI endoscopy procedures to follow a uniform propofol monotherapy administration guideline to titrate propofol monotherapy infusion to effect according to a standardized protocol.
89481434|NCT03290859||Effectiveness of training intervention|Compare the effectiveness of training intervention and standardized titration to effect through aggregate data for metrics of recovery times.
89203100|NCT03742219|Experimental|Lifestyle Intervention|Impoverished communities in Lima, Peru will be offered free medical clinics. Four communities have been chosen initially for focus over the following 10 years. These communities will be made aware of their risk for chronic lifestyle related diseases. In conjunction with the communities, specific interventions focused on a plant-based diet, physical activity, stress management and control of unhealthy habits will be devised.
89203101|NCT00658788|Active Comparator|Study Treatment|"clobetasol propionate spray 0.05%~Other Names:~Clobex® Spray 0.05% clobetasol propionate spray, 0.05%, applied topically twice daily~calcitriol ointment~Other Names:~Calcitriol Ointment calcitriol ointment, 3 µg/g, applied topically, not to exceed 30 g daily"
89481435|NCT03555799||Labor analgesia patients|Patients with clinical indication of labor epidural will have IVC diameter measurement with ultrasound before and after the epidural placement
89481436|NCT02437864|No Intervention|Baseline Group|Airway management (intubation) undertaken immediately after anesthetic induction, without simultaneous supplemental oxygen via nasal cannula.
89481437|NCT02437864|Experimental|With-Cannula Group|Airway management (intubation) undertaken immediately after anesthetic induction, with simultaneous supplemental oxygen via nasal cannula.
89481438|NCT03098186|Active Comparator|Intervention SMS|"SMS aimed to improved adherence to medications used in secondary prevention of cardiovascular disease.~Control SMS: SMS to thanks for participation in the trial and reminders of trial appointments."
89481439|NCT03098186|Placebo Comparator|Control SMS|SMS to thanks for participation in the trial and reminders of trial appointments.
89481440|NCT03296475|Experimental|Midline Ventral Hernia|"Main inclusion criteria:~Patients with midline hernia defects.~Patients with either a maximal ventral hernia axial width of greater than 5cm or a loss of domain of greater then 20%.~Patients aged ≥ 18 years old.~Midline hernias closed in the midline with primary fascial closure with or without mesh augmentation.~Midline ventral hernias of VHWG grade 2 or 3."
88951584|NCT01948440|No Intervention|Treatment as Usual|The Control group participants will complete the ASI-MV and receive their normal course of treatment. The Control group will undergo a baseline assessment and one-month post-baseline, two-month post-baseline, and six-month post-intervention.
89481441|NCT02102737|Experimental|6-DIG and clamp|injection of 6-DIG and hyperinsulinemic euglycemic clamp
89481442|NCT03296397|Active Comparator|HPV Quadrivalent vaccine (QHV)|Gardasil
89481443|NCT03296397|Placebo Comparator|Placebo|Normal Saline
88951585|NCT01948453|Active Comparator|Garlic|daily consumption of two odor controlled garlic tablets
88951586|NCT01948453|Placebo Comparator|Placebo|daily consumption of placebo
88951587|NCT01948466|Experimental|Commercials|Schools Administered Commercials
88951588|NCT01948466|No Intervention|Control|Schools not Administered Commercials
88951589|NCT01948479|Experimental|Insole optimised with inshoe analysis|
89481444|NCT02102815|Experimental|Dexamethasone|Preoperative dexamethasone 0.15mg/Kg mixed with NSS to 50 mL IV slowly push over 5 minutes
89481445|NCT02102815|Placebo Comparator|Placebo|Preoperative intravenous normal saline 50 mL slowly push over 5 minutes
88951590|NCT01948479|Active Comparator|Routine insole provision|
88951591|NCT01948492|Experimental|protein|varying protein intake in random order from deficient to excess
88951592|NCT01948531|Experimental|Gynomunal® gel|The study will be conducted on 33 healthy volunteers of female sex aged between 35 and 65 years old; each subject will apply a fixed quantity of the Gynomunal gel on the face (including the submental area) twice a day, in the morning and in the evening (preferentially always at the same hour), with a mild massage.
88951593|NCT01948544||chronic obstructive pulmonary disease|"More than 12 million adults are diagnosed with COPD~COPD is the 4th leading cause of death in the U.S.~Breathing difficulty is the major reason patients seek medical attention~COPD patients requiring hospitalization were associated with higher costs~Oximetry is an important tool for assessing need for Long-term oxygen therapy~LTOT has been proven to improve survival and quality of life~Patients will be provided a lightweight portable oxygen concentrator to:~support increased activity~improve quality of life~increase functional capacity"
88951594|NCT01948557|Other|Infant feeding counselling and support|All mothers provided with counselling. Subsequent support interventions depended on mothers' selection of feeding practice
89481446|NCT04935112|Experimental|Group 1 Treatment A (sitravatinib only)|Period 1: A single oral dose of 100 mg sitravatinib on Day 1
89481447|NCT04935112|Experimental|Group 1 Treatment B (sitravatinib and pantoprazole)|Period 2: Oral pantoprazole once daily for 7 days (Days 1 to 7) and a single oral dose of 100 mg sitravatinib on Day 7
89481448|NCT04935112|Experimental|Group 2 Treatment C (sitravatinib only)|Period 1: A single oral dose of 100 mg sitravatinib on Day 1
89481449|NCT04935112|Experimental|Group 2 Treatment D (sitravatinib and famotidine)|Period 2: A single oral dose of 100 mg sitravatinib followed by a single oral dose of famotidine 40 mg approximately 2 hours after sitravatinib dose on Day 1
89481450|NCT05065112|Active Comparator|PVI only|Patients in this arm will undergo only standard pulmonary veins isolation with radiofrequency (RF) energy to treat their AF.
89481451|NCT05065112|Experimental|PVI + IM|Patients in this arm will undergo standard wide area circumferential pulmonary veins isolation along with radiofrequency energy and additional RF ablation guided by individualised mapping with Cartofinder to treat their AF.
89481452|NCT03296319|Active Comparator|echocardiography guided fluid resuscitation|
89203102|NCT05407402|Experimental|laughter yoga|laughter yoga
89481453|NCT03296319|Experimental|clinically guided fluid resuscitation|
89481454|NCT02102971||Hepatocellular carcinoma|Participants undergoing a liver resection/liver transplantation surgery. During the liver surgery a small piece of tissue will be removed to undergo additional laboratory testing.
89481455|NCT03296241|Experimental|Laser|One session of non-ablative Er:YAG laser (2940 nm) treatment of the vaginal wall, introitus and vestibule.
89481456|NCT03296241|Sham Comparator|Sham control|The sham control group was treated with the same procedure but with zero intensity settings - without receiving therapeutic irradiation (placebo).
89481457|NCT04909996|Experimental|Group A: Sentinox treatment performed 3 times/day for 5 days (as add-on to the standard therapy)|
89481458|NCT04909996|Experimental|Group B: Sentinox treatment performed 5 times/day for 5 days (as add-on to the standard therapy)|
89481459|NCT04909996|No Intervention|Group C: no Sentinox treatment; only the standard therapy will be performed|
89481460|NCT04908033||myocardial pacing group|patients with the pacing lead placed into the right ventricle to obtain myocardial capture
89481461|NCT04908033||physiological pacing group|patients with the pacing lead placed into the His bundle or left bundle branch area
89481462|NCT03555487|Experimental|18F-choline PET|PET/CT
89481463|NCT05043194|Experimental|ursodeoxycholic acid arm|Premature infants who meet the inclusion criteria take preventive oral ursodeoxycholic acid on the 7th day after birth. ursodeoxycholic acid capsules (Ursofalk, 250 mg/capsules), starting with oral administration of pharmacologic doses of 20-25mg/kg/d, twice daily, until they were discharged .
89481464|NCT05043194|Sham Comparator|the control arm|The control group was treated with UDCA after the occurrence of cholestasis.ursodeoxycholic acid capsules (Ursofalk, 250 mg/capsules), starting with oral administration of pharmacologic doses of 20-25mg/kg/d, twice daily, until they were discharged .
89481465|NCT04909606|Experimental|Nurse-led prevention program|Patients will receive a general summary sheet of preventive measures associated with long term corticosteroids therapy (no individual assessment) in addition to the usual care provided by their physician
89481466|NCT04909606|Active Comparator|Standard of care|Subjects randomized to the nurse-led prevention program group will be evaluated by the dedicated nurse within 2 weeks following randomization (individual assessment)
89481467|NCT02103049|Other|Ezetimibe, dyslipidemia, kidney transplant|
89481468|NCT03099278|Experimental|Ezetimibe|
89481469|NCT04909528|Experimental|Experimental Group|Low-level tragus stimulation
89481470|NCT04909528|Sham Comparator|Control Group|Sham stimulation
89481471|NCT02097979|Experimental|Glaucoma Educational Intervention|
89481472|NCT02097979|No Intervention|Delayed Intervention|
89481473|NCT05043272||Overweight population with basic diseases|Basic diseases include diabetes, hypertension.
89481474|NCT05043272||Overweight population with chronic liver diseases|Chronic liver diseases include chronic hepatitis ,liver cirrhosis, primary hepatocellular carcinoma.
89481475|NCT05043272||Healthy population|Control group
89481476|NCT02103205|Active Comparator|Low iron, with lactoferrin|Low iron, with lactoferrin
89481477|NCT02103205|Active Comparator|Low iron, no lactoferrin|Low iron, no lactoferrin
89481478|NCT02103205|Placebo Comparator|Normal iron, no lactoferrin|Normal iron, no lactoferrin
89481479|NCT03290703|Experimental|Part 1: GDC-0853 (Effect of Formulation)|Participants will receive five single oral doses of test formulations of GDC-0853 co-administered with rabeprazole in the fasted state.
89481480|NCT03290703|Experimental|Part 2: GDC-0853 (Effect of Food and Rabeprazole)|Participants will receive three single oral doses of one GDC-0853 formulations selected from Part 1 of this study. One dose will be administered in the fasted state, one dose will be administered in the fed state, and one dose will be co-administered with rabeprazole in the fed or fasted state, depending on randomization.
89481481|NCT03290703|Experimental|Part 3: GDC-0853 Optimized (Effect of Food and Rabeprazole)|Participants will receive three single oral doses of an optimized tablet formulations of GDC-0853. One dose will be administered in the fasted state, one dose will be administered in the fed state, and one dose will be co-administered with rabeprazole in the fed or fasted state, depending on randomization.
89481482|NCT02098057|Placebo Comparator|Placebo|A total of 24 patients with NCGS and 12 healthy controls will be recruited for this study. The 24 patients with NCGS will be randomized to receive one of two diets (GFD or GCD) in a 1:1 ratio
89481483|NCT02098057|Active Comparator|Gluten|A total of 24 patients with NCGS and 12 healthy controls will be recruited for this study. The 24 patients with NCGS will be randomized to receive one of two diets (GFD or GCD) in a 1:1 ratio
88951595|NCT01948570||not in therapy (GROUP 1)|A fixed quantity of the medical device will be applied on the face twice a day, in the morning and in the evening (always at the same hour), with a mild massage according to the instructions received by the investigator during the baseline visit (T0).
88951596|NCT01948570||in therapy (GROUP 2)|A fixed quantity of the medical device will be applied on the face twice a day, in the morning and in the evening (always at the same hour), with a mild massage according to the instructions received by the investigator during the baseline visit (T0). Group 2 will continue also the standardised treatment with topical or systemic retinoids, benzoyl peroxide, clindamycin or AHA until the end of the study
88951597|NCT01948583|Active Comparator|Arm I: vaginal gel new formulation|"Application once a day at evening during the first study week of the vaginal gel new formulation (hyaluronic acid).~One week of wash-out (second week). Application once a day at evening during the third study week of the vaginal gel on the market (hyaluronic acid)."
88951598|NCT01948583|Active Comparator|Arm II: vaginal gel on the market|"Application once a day at evening during the first study week of the vaginal gel on the market (hyaluronic acid).~One week of wash-out (second week). Application once a day at evening during the third study week of the vaginal new formulation (hyluronic acid)."
88951599|NCT01948596|Experimental|Omega-3 polyunsaturated fatty acids|1200mg eicosapentaenoic acid (EPA) and 600mg docosahexaenoic acid (DHA) daily
88951600|NCT01948622|Active Comparator|Mulungu|500 mg Mulungu Matusa® (Erytrina mulungu, 2 capsules of 250 mg) administered v.o., one hour before the surgical procedure.
88951601|NCT01948622|Placebo Comparator|placebo|500 mg of starch (2 capsules of 250 mg) administered v.o., one hour before the surgical procedure.
88951602|NCT01948635|Experimental|tapered PVC-cuffed tracheal tubes|Patients in this arm will be intubated with tapered PVC-tracheal tubes
88951603|NCT01948635|Active Comparator|Standard PVC-cuffed tracheal tube|Patients in this arm will be intubated with standard (barrel-shape cuffed) PVC tracheal tubes
88951604|NCT01948648|Active Comparator|Colesevelam|3.75g/day for 6 weeks
88951605|NCT01948648|Active Comparator|Fish Oil|1g/day for 6 weeks
88951606|NCT01948648|Active Comparator|Combination of Fish Oil and Colesevelam|3.75g/day of colesevelam and 1g/day of fish oil for 6 weeks
88951607|NCT01948661|Experimental|Anthocyanins+Phospholipidic Curcumin|Mirtoselect ® 500 mg tablet, 1000 mg (two oral tablets) per day and Meriva ®, 500 mg tablet, 1000 mg (two oral tablets) per day for 28 days
88951608|NCT01948661|Placebo Comparator|placeboA + placeboB|placeboA + placeboB per day for four weeks
88951609|NCT01948674|Experimental|computerized tasks- adaptive|
88951610|NCT01948674|Active Comparator|computerized tasks - nonadaptive|
88951611|NCT01948687||1. the control group|healthy adult volunteers
88951612|NCT01948687||2. patients with chronic hepatitis|patients with chronic hepatitis B or C (defined by the presence of serum anti hepatitis C antibody or serum hepatitis B surface antigen)
88951613|NCT01948687||3. liver cirrhosis type B or C|patients with liver cirrhosis type B or C
89203103|NCT05407402|Experimental|funny videos,|funny videos,
88951614|NCT01948713|Experimental|Group 1|Strengthening of pelvic floor muscles.
89203104|NCT05407402|No Intervention|control|control group. routine nursing care will be applied.
88951615|NCT01948713|Experimental|Group 2|Strengthening of pelvic floor muscles associated with strengthening of hip muscles.
88951616|NCT01948726|Experimental|Hypofractionation with SIB|
88951617|NCT01948752|No Intervention|Menu - no nutrition information (control)|"Participants were randomized to receive one of four menus that each contained different type of nutrition information. This condition included a normal menu with no nutrition information."
88951618|NCT01948752|Experimental|Calorie labels|Participants were randomized to receive one of four menus that each contained different type of nutrition information. This condition included menus with the calorie amounts displayed.
88951619|NCT01948752|Experimental|Calorie Traffic Light|"Participants were randomized to receive one of four menus that each contained different type of nutrition information. This condition included menus with calorie amounts in green/amber/red traffic lights to signify low/medium/high amounts."
88951620|NCT01948752|Experimental|Multi-Traffic Light|"Participants were randomized to receive one of four menus that each contained different type of nutrition information. This condition included menus with calorie amounts as well as sodium, fat, and sugar amounts in green/amber/red traffic lights to signify low/medium/high amounts."
88951621|NCT01948765|Active Comparator|Xenon and propofol|
88951622|NCT01948765|Placebo Comparator|propofol|
88951623|NCT01948778|Experimental|oXiris™ filter|oXiris™ filter
88951624|NCT01948778|Experimental|Toraymyxin Filter|Toraymyxin Filter
88951625|NCT01948778|Other|Standard of Care|Standard of Care CRRT if necessary
88951626|NCT01948804|Experimental|IVF patients|patients that has applied to Yeditepe University Hospital assisted reproduction center
88951627|NCT01948817|Experimental|Deferasirox|Deferasirox 20mg/kg taken BID
89203105|NCT01060969|Active Comparator|Acetazolamide|acetazolamide 125 mg BID
89203106|NCT01060969|Experimental|Acetazolamide and Tadalafil|Intervention arm
89203107|NCT05407246|Active Comparator|Hemay005 75mg BID group|75mg BID of Hemay005; daily oral administrtion for 16 weeks
89203108|NCT05407246|Active Comparator|Hemay005 60mg BID group|60mg BID of Hemay005; daily oral administrtion for 16 weeks
89203109|NCT05407246|Placebo Comparator|placebo group|Placebo of Hemay005; daily oral administrtion for 16 weeks
89481484|NCT02408068|Active Comparator|Chronocort : fed|Volunteers will be admitted, take dexamethasone at 22.00hrs, fast overnight, and receive a high fat, high calorie breakfast on the morning of Day 1. Thirty minutes after the start of the breakfast they will receive 20mg of modified release hydrocortisone with 200 millilitres of water, and no further food for 4 hours, water will be allowed from 1 hour after the food. Further dexamethasone doses will be given at 06:00, 12:00, 18:00 and 22:00 hours on Day 1. One baseline pharmacokinetics (PK) sample will be taken starting prior to the dose and then over 24 hours (29 samples).
88951628|NCT01948843|Experimental|ADI-PEG 20|arginine deiminase formulated with polyethylene glycol
88951629|NCT01948856|Experimental|J022X ST|
88951630|NCT01948856|Placebo Comparator|Placebo|
88951631|NCT01948869|Experimental|Phoenix II|Application over 29 days twice daily
88951632|NCT01948869|Active Comparator|Phoenix I|Application over 29 days twice daily
88951633|NCT01948869|No Intervention|Untreated skin|Untreated skin areas of subjects will be observed over 29 days
88951634|NCT01948895|Experimental|Single-arm study|Desvenlafaxine 50mg/day Desvenlafaxine 100mg/day
88951635|NCT01948921|Placebo Comparator|placebo|1 ml normal saline will be given 5 minutes before EGD
88951636|NCT01948921|Active Comparator|meperidine|25 mg intramuscular meperidine will be given 5 minutes before EGD
88951637|NCT01948934|Experimental|amniotic membrane in big wounds|The wound will be washed with saline and debrided if necessary. Control microbiological cultures will be taken and applied amniotic membrane fragments sufficient to cover the wound, putting in contact the basement membrane of the AM with granulation tissue
88951638|NCT01948960|No Intervention|standard care|everolimus dose is continued independently of everolimus AUC
88951639|NCT01948960|Active Comparator|everolimus dose escalation|patients with an AUC below mean will have dose escalation of everolimus based on their AUC
88951640|NCT01948973|Active Comparator|OFF, subsensory, suprasensory|Here the stimulator is turned OFF for the first 2 weeks, then set subsensory (90% of sensory threshold) for the next 2 weeks and finally set suprasensory for the last 2 weeks.
88951641|NCT01948973|Active Comparator|Subsensory, OFF, suprasensory|Here the stimulator is set subsensory (90% of sensory threshold), then turned OFF for the next 2 weeks and finally set suprasensory in the last 2 weeks.
88951642|NCT01948999|Active Comparator|ECT|Electroconvulsive Therapy Anesthesia and concomitant muscular paralysis
88951643|NCT01948999|Sham Comparator|SHAM ECT|Anesthesia and concomitant muscular paralysis
88951644|NCT01949012|No Intervention|Control|Standard monitoring
88951645|NCT01949012|Experimental|Capnography|Standard monitoring and capnography
88951646|NCT01949025|Experimental|ALARM intervention|The training of nursing and medical staff about the observation, detection, assessment and communication of deteriorating and critically ill patients and the introduction of a standardized observation and communication protocol on medical and surgical wards.
88951647|NCT01949025|No Intervention|Control group|
88951648|NCT01949038|Placebo Comparator|Oral placebo|Patients receive one oral dose of placebo least 30 minutes before the procedure.
88951649|NCT01949038|Placebo Comparator|Sublingual placebo|Patients receive one oral dose of placebo at least 30 minutes before the procedure.
88951650|NCT01949038|Active Comparator|Sublingual alprazolam|Patients receive one oral dose of alprazolam 0.5 mg at least 30 minutes before the procedure.
88951651|NCT01949038|Active Comparator|Oral alprazolam|Patients receive one oral dose of alprazolam 0.5 mg at least 30 minutes before the procedure.
88951652|NCT01949064|Active Comparator|Michigan-type occlusal splint|Occlusal splint, Michigan-type
88951653|NCT01949064|Active Comparator|Grindcare|Biofeedback device
88951654|NCT01949103|Experimental|TD-1607 or placebo (Dose1)|TD-1607 or placebo administered intravenously
88951655|NCT01949103|Experimental|TD-1607 or placebo (Dose 2)|TD-1607 or placebo administered intravenously
88951656|NCT01949103|Experimental|TD-1607 or placebo (Dose 3)|TD-1607 or placebo administered intravenously
88951657|NCT01949103|Experimental|TD-1607 or placebo (Dose 4)|TD-1607 or placebo administered intravenously
88951658|NCT01949103|Experimental|TD-1607 or placebo (Dose 5) [Optional]|TD-1607 or placebo administered intravenously
88951659|NCT01949103|Experimental|TD-1607 or placebo (Dose 6) [Optional]|TD-1607 or placebo administered intravenously
88951660|NCT01949168|Active Comparator|Boceprevir triple therapy with 5-day lead in|Victrelis® (boceprevir) 800mg by mouth, TID (200 mg tablets) for 5 days, followed by boceprevir plus • Peg-Intron® (peginterferon-α-2b), 1.5ug/kg sc injection plus • Rebetol® (ribavirin), 1000/1200mg, by mouth daily for 24 weeks. In patients who achieve an undetectable plasma HCV RNA level at week 4 of triple therapy (week 5 from baseline), and maintain an undetectable plasma HCV RNA at week 20 of triple therapy (week 21 from baseline), treatment will stop at week 25. Patients who have a detectable plasma HCV RNA at week 4 of triple therapy, but an undetectable plasma HCV RNA at week 20, will continue a with follow-on peginterferon-α-2b plus ribavirin for a further 23 weeks (stopping at week 48).
88951661|NCT01949168|Active Comparator|Boceprevir triple therapy|Victrelis® (boceprevir) 800mg by mouth, TID (200 mg tablets) plus Peg-Intron® (peginterferon-α-2b), 1.5ug/kg sc injection and Rebetol® (ribavirin), 1000/1200mg, by mouth daily for 24 weeks. In patients who achieve an undetectable plasma HCV RNA level at week 4 of triple therapy, and maintain an undetectable plasma HCV RNA at week 20 of triple therapy, treatment will stop at week 24. Patients who have a detectable plasma HCV RNA at week 4 of triple therapy, but an undetectable plasma HCV RNA at week 20, will continue a with follow-on peginterferon-α-2b plus ribavirin for a further 24 weeks (stopping at week 48).
88951662|NCT01949168|Active Comparator|Standard of Care|48 weeks of Peg-Intron® (peginterferon-α-2b), 1.5ug/kg sc injection and Rebetol® (ribavirin), 1000/1200mg by mouth daily (200mg tablets)
88951663|NCT01949181|Experimental|Pulmonary cancer|
88951664|NCT01949194|Experimental|Regorafenib|Single-agent regorafenib
88951665|NCT01949207|Experimental|EVLA, phlebectomies & Trlop closure of incompetent perforators|endovenous laser ablation (EVLA) of great saphenous vein (GSV) plus phlebectomies plus TRansluminal Occlusion of Perforators (TRLOP) closure of incompetent perforators.
89481485|NCT02408068|Active Comparator|Immediate release hydrocortisone: fasted|Volunteers will be admitted, take dexamethasone at 22.00hrs, fast overnight, and take 20mg immediate release hydrocortisone with 200 millilitres of water on the morning of Day 1. Water will be allowed 1hr after the study drug, but no food for at least 4hrs post dose. Further dexamethasone doses will be given at 06:00, 12:00 and 18:00 hours on Day 1. One baseline pharmacokinetics (PK) sample will be taken prior to the dose, and then afterwards for over a 12 hour period (16 samples)
89481486|NCT02408068|Active Comparator|Chronocort: fasted|Volunteers will be admitted, take dexamethasone at 22.00hrs, fast overnight, and take 20mg modified release hydrocortisone with 200millilitres of water on the morning of Day 1. Water will be allowed 1hr after the dose, but no food for at least 4hrs post dose. Further dexamethasone doses will be given at 06:00, 12:00, 18:00 and 22:00 hours on Day 1. One baseline pharmacokinetics (PK) sample will be taken prior to the dose, and then afterwards for over a 12 hour period (16 samples)
88951666|NCT01949207|Experimental|EVLA & phlebectomies|endovenous laser ablation (EVLA) of great saphenous vein (GSV) + phlebectomies.
89481487|NCT02465853|Placebo Comparator|Placebo group|Injection 0.9% Physiological saline solution<2.5 ml and physical therapy and occupational therapy
89481488|NCT02465853|Experimental|Hyaluronic Acid|injection Hyaluronic Acid 2.5ml and physical therapy and occupational therapy
88951667|NCT01949220||Von Willebrand factor deficient patient|Inherited von Willebrand disease
88951668|NCT01949233|Experimental|Irbesartan 150-300mg (and doxycycline placebo)|Irbesartan 150-300mg capsules daily for 6 months Doxycycline placebo capsules daily for 6 months
88951669|NCT01949233|Experimental|Doxycycline 100-200mg (and irbesartan placebo)|Doxycycline 100-200mg capsules daily for 6 months Irbesartan placebo capsules daily for 6 months
88951670|NCT01949233|Experimental|Irbesartan 150-300mg and doxycycline 100-200mg|Irbesartan 150-300mg capsules daily for 6 months Doxycycline 100-200mg capsules daily for 6 months
88951671|NCT01949233|Placebo Comparator|irbesartan and doxycycline placebo|Irbesartan placebo capsules daily for 6 months Doxycycline placebo capsules daily for 6 months
88951672|NCT01949259||Retrospective collection|Retrospective collection of data from included lung cancer patients.
88951673|NCT01949272||ARDS|ARDS patients achieving stades II and III of Berlin 2011 Classification
88951674|NCT01949285|Sham Comparator|Grp#1: sham stimulation|"Group #1: Baseline clinical assessment; followed by two weeks training with no stimulation; then four weeks training + sham Transcutaneous Electrical Spinal Cord Stimulation; followed by repeat clinical assessment; then four weeks training + effective non-sham Transcutaneous Spinal Cord Stimulation; repeat clinical assessment.~Secondary outcome measurements: assess ability to stand with and without stimulation using a stance frame support; assess trunk function (core stability) with and without stimulation"
88951675|NCT01949285|Active Comparator|Grp#2: Control|"Group #2: Baseline clinical assessment; followed by two weeks training with no Transcutaneous Electrical Spinal Cord Stimulation; then four weeks training + effective Transcutaneous Electrical Spinal Cord Stimulation; followed by repeat clinical assessment.~Secondary outcome measurements: assess ability to stand with and without stimulation using a stance frame support; assess trunk function (core stability) with and without stimulation"
88951676|NCT01949298|Experimental|Immediate implant loading|The test group had implant immediately loaded by means of a implant supported mandibular denture connected with locator abutment.
88951677|NCT01949298|Active Comparator|Delayed implant loading group|The control group had implant loaded after 3 months of submerged healing by means of a implant supported mandibular denture connected with locator abutment.
88951678|NCT01949350|Active Comparator|Carbohydrate|CHO loaded test:
88951679|NCT01949350|Active Comparator|Carbohydrate protein|CHO-P loaded test:
88951680|NCT01949350|Active Comparator|Water|Starved as for surgery
88951681|NCT01949363|Experimental|Stage 2 (Cohorts C and D)|Cohort C will first be given 1200mg cefixime orally once; Cohort D will be given 800mg cefixime orally three times (every 8 hours); 6 subjects in each cohort
88951682|NCT01949363|Experimental|Stage 1 (Cohorts A and B)|Cohort A will be given 400mg of cefixime orally once; Cohort B will be given 800mg of cefixime given orally once; 6 subjects in each cohort
88951683|NCT01949376||HT Patients|any stage of breast cancer without brain metastasis, will undergo hormonal therapy without chemotherapy
89203110|NCT00799890|Experimental|Sunphenon|
89481489|NCT03098108|Experimental|CCPT|
89481490|NCT02103283|Experimental|Teprotumumab|Teprotumumab 20mg/kg administered by intravenous infusion every 3 weeks for 3 infusions
88951684|NCT01949376||CT and HT Patients|any stage of breast cancer without brain metastasis, will undergo chemotherapy and hormonal therapy
88951685|NCT01949376||CT Patients|any stage of breast cancer without brain metastasis, has undergone surgery prior to screening, will undergo chemotherapy without hormonal therapy
88951686|NCT01949376||RT or NT Patients|any stage of breast cancer without brain metastasis, will not undergo chemotherapy or hormonal therapy; may undergo radiation therapy or have no therapy
88951687|NCT01949376||Controls|healthy, cognitively normal subjects
88951688|NCT01949402||Haemodialysis|Patients with end-stage renal failure (ESRF) requiring long-term regular haemodialysis.
89203111|NCT00799890|Placebo Comparator|Placebo|
89481491|NCT02100241|Experimental|Active stretching with currents|Active stretching performed while currents are applied on hamstring muscles.
89481492|NCT02100241|Experimental|Active stretching|Active stretching are performed.
89481493|NCT02100241|No Intervention|Control group|Routine clinical practice
89481494|NCT02465385|Experimental|Intervention|Linaclotide 290mcg
89481495|NCT05050604|Experimental|Choline Alfoscerate|
89481496|NCT05050604|Placebo Comparator|Placebo of Choline Alfoscerate|
89481497|NCT03290625|Experimental|DexKet|Intranasal DEXMEDETOMIDINE (2.0 mcg/kg, maximum 100 mcg) + KETAMINE (1.0 mg/kg, maximum 100 mg)
89481498|NCT03290625|Active Comparator|Dex|DEXMEDETOMIDINE (2.5 mcg/kg, maximum 100 mcg)
89481499|NCT02250781|Experimental|Treatment (Oral ONC201)|Patients receive Oral ONC201 PO on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89481500|NCT03099122|Experimental|Thymoglobuline|"A cumulative dose of Thymoglobuline will be given intravenously, with a variable interval dose. Methylprednisolone will be given as induction therapy, according to institutional practice.~Tacrolimus, mycophenolate, and prednisone will be given as maintenance therapies."
89481501|NCT03099044|Active Comparator|Single Active Dose|Subjects are assigned to receive a single Active beverage and a single placebo beverage.
89481502|NCT03099044|Active Comparator|Double Active Dose|Subjects are assigned to receive 2 doses of Active beverage.
89020656|NCT02580994|Experimental|Pembrolizumab + chemotherapy|Pembrolizumab, in combination with cis/carboplatin and etoposide for 4 cycles intravenous 200mg on day 1 (every 3 weeks), pembrolizumab continued alone as continuation maintenance until progressive disease
89020657|NCT02580994|Active Comparator|Chemotherapy|4 cycles of cis/carboplatin and etoposide
89020658|NCT02543567|Experimental|Group 1|Ad26.ZEBOV 5*10^10 viral particles (vp) single dose intramuscular (IM) injection on Day 1; MVA-BN-Filo 1*10^8 Infectious Unit [Inf. U.] single dose IM injection on Day 57
89020659|NCT02543567|Experimental|Group 2|Ad26.ZEBOV 2*10^10 vp single dose intramuscular (IM) injection on Day 1; MVA-BN-Filo 5*10^7 Inf. U single dose IM injection on Day 57
89203112|NCT01057771|Experimental|Meditation|Eight weeks of training in mindfulless meditation. Weekly group sessions of 2.5 hours, with 45 minutes/day of practice.
89481503|NCT03099044|Placebo Comparator|Placebo comparator|Subjects are assigned to receive 2 doses of a placebo beverage.
89481504|NCT04335201|Experimental|Arm Label|with the experimental drug: Defibrotide 25 mg/kg body weight total dose in 2 hours duration infusion each, every 6 hours (Defibrotide 6.25 mg/kg body weight each dose) Treatment duration = 7 days
89481505|NCT02098135|Experimental|ArmeoSenso|The ArmeoSenso system is an easy to set up and use upper limb rehabilitation system for the home environment. It consists of a motion capture system based on wearable sensors in combination with a personal computer as well as a therapy software that provides an ergonomic user interface, therapy games and automated assessments.
89203113|NCT01057771|Experimental|Exercise|Eight weeks of training in moderately strenuous exercise. Weekly group sessions of 2.5 hours, with 45 minutes/day of practice.
89481506|NCT05050370|Experimental|Lifestyle-integrated exercise and care support|The experimental group will receive a face-to-face group session and a package of instant messages related to lifestyle-integrated exercise and cancer-related information with personalized support.
89481507|NCT03555175|Other|Group one|This participants group must do eccentric exercise for 12 weeks
89481508|NCT03555175|Other|Group two|This participants group must do proprioception exercise for 12 weeks
89481509|NCT03555175|Other|Group 3|This participants group mustn't do exercise extra
89481510|NCT03099200||Cohort 1|Participants with early breast cancer currently undergoing treatment (either chemotherapy and targeted HER2 therapy OR targeted HER2 therapy alone) will be observed.
89481511|NCT03099200||Cohort 2|Participants with early breast cancer who have completed treatment and are in disease-free survival (i.e. no longer receiving loco-regional treatment, chemotherapy or targeted HER2 therapy; participants may still be receiving hormone therapy) will be observed.
89481512|NCT03099200||Cohort 3|Participants receiving treatment for metastatic breast cancer will be observed.
89481513|NCT03295851|Experimental|IV Ferric Carboxymaltose|Patients in the intervention group will receive preoperative IV ferric carboxymaltose, given as a single dose (15 mg/kg body weight, to a maximum dose of 1000 mg) over 30 minutes.
89481514|NCT03295851|Active Comparator|Oral Ferrous Fumarate|Patients will be given oral iron as per current clinical protocol, which is Ferrous fumarate 200mg twice daily
88951689|NCT01949402||Chronic Obstructive Pulmonary Disease|Patients with a confirmed diagnosis of COPD based on clinical history, obstructive spirometry (FEV1/VC ratio <70%) and radiology (e.g. hyperexpansion on plain chest radiograph; evidence of small airways disease or emphysema on cross-sectional imaging).
89481515|NCT02098213|Active Comparator|Immediate Spa treatment|Three week course of spa treatment soon after randomization
89481516|NCT02098213|Sham Comparator|Late Spa treatment|Three week course of spa treatment soon after 4,5 months visit
89481517|NCT03096470||anesthesia|The children were treated with closed reduction with anesthesia after prolonged traction
89481518|NCT03096470||No anesthesia|The children were treated with closed reduction with no anesthesia after prolonged traction
89481519|NCT04484649|Experimental|Intervention|Sleeping Healthy/Living Healthy
89481520|NCT04484649|Active Comparator|Control|Attention Control
89481521|NCT02103517|Experimental|Omega-3 fatty acid capsules|Omega-3 fatty acid capsules, 4 g/day, requiring intake 2 capsules (1g each one) in the morning and two at night for 3 months.
89481522|NCT02103517|Placebo Comparator|corn oil|Corn oil in similar presentation as omega-3 fatty acid capsules, requiring intake 2 capsules in the morning and two at night for 3 months.
89481523|NCT04489875|Experimental|Chewing gum|the patients in this arm will receive the post-operative oral feeding along with chewing gum which they'll be required to chew for at least 15 minutes before their meal 3 times a day
89481524|NCT04489875|No Intervention|No chewing gum|The patients in this arm will only receive the post-operative oral feeding
89481525|NCT02098291|Experimental|G17DT|
89481526|NCT05042570|Experimental|Instrument Assisted Soft Tissue Mobilization|Group 1 (n=13): Each session will consist of 40 minutes. An additional 10 minutes of IASTM will be performed to the 30-minute NDT program.
89481527|NCT05042570|Experimental|Stretching Exercises|Group 2 (n=13): Each session will consist of 40 minutes. In addition to the NDT program applied for 30 minutes, 10 minutes of Stretching Exercises will be performed.
89481528|NCT05042570|Active Comparator|Control|Group 3 (n=13): Each session will consist of 40 minutes. There will be no additional application to the NDT program, which is applied for 40 minutes, and it will be included as a control group in the study.
89481529|NCT02098447|Experimental|auricular vagal nerve stimulation|"Study participants (healthy and diabetics) are treated with auricular vagal nerve stimulation using four needle electrodes connected to an electrical stimulation device (PrimeStim). After an acclimatization phase the stimulation is turned on for 20 minutes followed by 20 minutes of paused stimulation, 20 minutes of stimulation, and another 10 minutes paused stimulation. This intervention is repeated on four consecutive days. Needle electrodes stay fixed over the whole study period.~Two different stimulation schemes are tested, each being assessed twice in random order. Stimulation amplitudes are adjusted with respect to a distinct but comfortable sensation at the auricle.~During the described protocol various biosignals are continuously recorded, including ECG, respiration, blood perfusion, oxygen saturation, transcutaneous oxygen tension, blood pressure and skin temperature."
89481530|NCT02103595|Other|Accu-Chek FlexLink Plus cross over to Accu-Chek FlexLink|
89481531|NCT02103595|Other|Accu-Chek FlexLink cross over to Accu-Chek FlexLink Plus|
89481532|NCT05064566||caries diagnosis|diagnostic accuracy of clinical visual examination (ICDAS II), digital intraoral radiography, near infrared light transillumination (NIR-LT), and laser fluorescence (LF), by examining third molar teeth in comparison to gold standard micro-CT images.
88951690|NCT01949402||Interstitial Lung Disease|Patients with a confirmed diagnosis of ILD based on clinical history and radiology (evidence of ILD on cross-sectional imaging).
88951691|NCT01949402||Control|Age-matched healthy volunteers with no history of cardiac, respiratory or renal disease.
89203114|NCT01057771|No Intervention|Waiting list control|Waiting list control subjects will be treated exactly like those in active intervention groups, but will not receive interventions.
89203115|NCT00799968|Active Comparator|Group 1|UK-12h group
88951692|NCT01949428||HDM-Induced Rhinoconjunctivitis Subjects|
88951693|NCT01949441|Experimental|ToleroMune HDM|
89481533|NCT02098525||HIV associated CM patients|The study population is all adult HIV positive patients with CM at Ramathibodi Hospital.
89481534|NCT05392465|Experimental|Group A|baseline physical therapy treatment along with facial mobilization
89481535|NCT05392465|Other|Group B|baseline (Conventional) physical therapy treatment
89481536|NCT05049668||RACE 1 patients|After exiting the RACE trial (NCT02099747) patient will be invited to participate in this study
88951694|NCT01949441|Placebo Comparator|Placebo|
88951695|NCT01949454|Experimental|Fluorometholone 0.1% 1 gtt bid x4weeks|Fluorometholone 0.1% 1 drop two times daily for four weeks
88951696|NCT01949454|Placebo Comparator|Artificial Tears 1 gtt bid x4 weeks|
88951697|NCT01949454|Experimental|Fluorometholone 0.1% 1 gtt qid x 4 weeks|Fluorometholone 0.1% 1 drop four times daily for four weeks
88951698|NCT01949454|Placebo Comparator|Artificial Tears 1 gtt qid x4 weeks|
89481537|NCT04445103||History of malaria|Individuals with a history of malaria infection
89481538|NCT04445103||Controls|Individuals without a history of malaria infection
89481539|NCT04445103||Symptomatic malaria|Patients with symptomatic malaria infection (complicated and uncomplicated)
89481540|NCT02100553|Other|Non-Obese|BMI <30 kg/m^2
89481541|NCT02100553|Other|Obese|BMI >= 30 kg/m^2
89481542|NCT03290469|Experimental|15 day cWGS and Standard of Care|Enrolled cohorts receive the results of the clinical whole genome sequencing (cWGS) after 15 days of the sample receipt while still undergoing standard of care (SOC).
89481543|NCT03290469|No Intervention|Standard of Care|Enrolled cohorts receive the results of the clinical whole genome sequencing (cWGS) after 60 days of the sample receipt while still undergoing standard of care (SOC).
89481544|NCT04444245|Experimental|ARM 1 Platelet Rich Plasma|Blood draw, processing of PRP, white blood cell poor, high platelet multiple >/= 4, e.g. (Emcyte II Pure PRP) Endovaginal ultrasound guided intra-ovarian placement into ovarian parenchyma, preferably both if accessible.
88951699|NCT01949454|Experimental|Fluorometholone 0.1% 1 gtt qid x 8 weeks|Fluorometholone 0.1% 1 drop four times daily for eight weeks
88951700|NCT01949454|Placebo Comparator|Artificial Tears 1 gtt qid x8 weeks|
89481545|NCT04444245|Experimental|ARM 2 emulsified tSVF and PRP|"Blood draw, processing of PRP, white blood cell poor, high platelet multiple >/= 4, e.g. Emcyte PRP Lipoaspiration utilizing closed microcannula harvesting of small volume (Tulip tumescent fluid infiltrator and Tulip Harvester). Decanting of free lipid. Emulsification of adipose tissue into tSVF (Tulip Nanofat device). Blending of Nanofat with PRP at a 3:1 ratio.~Endovaginal ultrasound guided intra-ovarian placement into ovary, preferably both if accessible."
89481546|NCT04444245|Experimental|ARM 3 emulsified tSVF and PRP, enriched with cSVF|"Blood draw, processing of PRP, white blood cell poor, high platelet multiple >/= 4, e.g. Emcyte PRP tSVF preparation: Lipoaspiration utilizing closed microcannula harvesting of small volume (Tulip tumescent fluid infiltrator and Tulip Harvester). Decanting of free lipid. Emulsification of adipose tissue (Tulip Nanofat device).~cSVF preparation: lipoaspiration as above. Isolation and Concentration of cellular stromal vascular fraction (cSVF) using a Healeon Medical CentriCyte 1000 centrifuge, incubator and shaker plate with sterile Liberase enzyme (Roche Medical) per manufacturer protocol. Quantification of viable nucleated cell count with flow cytometry. Addition of pellet of viable nucleated cells to tSVF.~Blending of tSVF/cSVF emulsion with PRP at a 3:1 ratio. Endovaginal ultrasound guided intra-ovarian placement into ovary, preferably both if accessible.~Intervention:"
89481547|NCT04444245|Experimental|ARM 4 Intra-ovarian guided placement|Specifically designed 23 gauge modified oocyte harvester needle for ultrasound guided placement
89481548|NCT01361126|Experimental|On-demand|The routine prophylactic therapy interval is targeted at every 7 days.
89481549|NCT01361126|Experimental|Prophylactic|On-demand subjects will receive rIX-FP only for the treatment of a bleeding episode.
89481550|NCT02100709|No Intervention|Control Arm|This arm will perform the pulmonary rehabilitation as specified with no respiratory assistance.
89481551|NCT02100709|Active Comparator|Intervention Arm|This arm will conduct the pulmonary rehabilitation program with BiLevel Noninvasive Ventilation assistance from a ResMed ventilator.
89481552|NCT04434872|Active Comparator|FMT from a healthy donor|"Patients will undergo FMT 4 times during the study:~first time, through a colonoscopy (sample volume: 250ml), and 3 more times (each sample volume: 100ml) during the following three days through:~A Naso-jejunal feeding tube (that will be inserted through a gastroscopy) for patients suffering from colitis that involves more than 40 cm of the colon.~Enemas, for patients suffering from colitis that involves the left colon up to 40 cm from the rectum."
89481553|NCT04434872|Placebo Comparator|FMT from a self donated stool sample|"Patients will undergo FMT 4 times during the study:~first time, through a colonoscopy (sample volume: 250ml), and 3 more times (each sample volume: 100ml) during the following three days through:~A Naso-jejunal feeding tube (that will be inserted through a gastroscopy) for patients suffering from colitis that involves more than 40 cm of the colon.~Enemas, for patients suffering from colitis that involves the left colon up to 40 cm from the rectum."
88951701|NCT01949467|Other|TDHS|20 Patients with Treated Dysmetabolic Hepatosiderosis (TDHS)
88951702|NCT01949467|Other|UDHS|20 patients with untreated Dysmetabolic Hepatosiderosis (UDHS)
88951703|NCT01949467|Other|TFPD|20 patients with treated Ferroportin Disease (TFPD)
88951704|NCT01949467|Other|UFPD|20 patients with untreated Ferroportin Disease (UFPD)
88951705|NCT01949467|Other|HV|20 Healthy volunteers (HV) patients
89481554|NCT03290313|Experimental|shu gan yi yang capsule|4 capsules / time, 3 times / day, taking 8 weeks
89481555|NCT03290313|Placebo Comparator|shu gan yi yang capsule capsule simulation agent|4 capsules / time, 3 times / day, taking 8 weeks
89481556|NCT02100787|Experimental|TheraTears lubricating drops|TheraTears lubricating eye drops to be used 1 drop in both eyes four times a day (QID)
89481557|NCT03295695|Experimental|Cardiac Imaging - All Participants|Study agent: 2-deoxy-2-[18F]fluoro-D-glucose (FDG). Fluoro-D-glucose-positron Emission Tomography: Participants will undergo a PET-CT scan with Fluoro-D-glucose-labeled (FDG-labeled) red blood cells (RBCs) within 2 weeks of obtaining an echocardiogram prior to start of chemotherapy. A repeat FDG-RBC PET-CT scan will be completed within two weeks of obtaining their follow-up echocardiogram to determine post-therapy cardiac ejection fraction. If the participant has an echocardiogram obtained prior to completion of chemotherapy, an attempt will be made to obtain a FDG-RBC PET-CT scan within two weeks of the echocardiogram.
89481558|NCT02100865|Experimental|Solar powered oxygen|Solar panels used to drive an oxygen concentrator to deliver at stream of oxygen at approximately 90% FiO2 and a rate of 1-5L/min.
89481559|NCT02100865|Active Comparator|Oxygen from cylinders|Conventional oxygen delivery from compressed gas cylinders
89481560|NCT04718805|Experimental|Treatment A|Participants will receive Treatment A (a single dose of darunavir [DRV]/cobicistat [COBI] as one fixed dose combination [FDC] tablet under fed condition on Day 1) as per assigned treatment sequence (Treatment sequence AB or BA). A washout period of at least 7 days will be maintained between each treatment period.
88951706|NCT01949493|Other|Care as usual|The patient will receive the usual care provided by the neurologists at VieCuri Medical Center. This may include an expectant strategy, a wrist splint, corticosteroid injection or carpal tunnel release surgery.
88951707|NCT01949493|Experimental|Mechanical traction|Twelve treatments with mechanical traction using the Phystrac traction apparatus.
88951708|NCT01949519|Experimental|Docetaxel and Lycopene|
88951709|NCT01949558|No Intervention|Control group|The control group receives a brochure on healthy dietary habits according to regular care.
88951710|NCT01949558|Experimental|Dietary intervention|12 week individual intervention based on a cognitive behavioral approach. It includes dietary restriction under guidance by a dietitian. Thereafter monthly follow-up takes place via email during the following 9 mo.
89203116|NCT00799968|Experimental|Group 2|UK-2h group
88951711|NCT01949571|Experimental|Mirtazapine|During the first and second phase of the study, subjects assigned to the control group received one tablet of placebo under daily basis, whereas the mirtazapine group received 30 mg of mirtazapine daily. During the third phase, placebo group received same tablet under daily basis, whereas the mirtazapine group received 15 mg of mirtazapine.
88951712|NCT01949597||Patients with symptomatic endometriosis|
88951713|NCT01949610|Experimental|14C-JNJ26489112|
88951714|NCT01949623||RP patients|Retinitis Pigmentosa patients
89481561|NCT04718805|Active Comparator|Treatment B|Participants will receive Treatment B (a single dose of DRV/COBI as separate tablets under fed condition on Day 1) as per assigned treatment sequence (Treatment sequence BA or AB). A washout period of at least 7 days will be maintained between each treatment period.
89481562|NCT02098603|No Intervention|Testing Only|
89481563|NCT02098603|Experimental|Testing & Intervention|
89481564|NCT02100943||OSA in Pregnancy|Pregnant women between 32 0/7 prior to 35 6/7 weeks gestation
89481565|NCT03290235|Experimental|PEG-somatropin-1|Dosage 0.2mg/kg/w
89481566|NCT03290235|Experimental|PEG-somatropin-2|Dosage 0.1-0.2mg/kg/w
88951715|NCT01949623||Controls|Patients who will be undergoing surgery for macular hole, epiretinal membrane, or vitreomacular traction, patients who have a retinal detachment , patients with neovascular age related macular degeneration and patients with diabetic retinopathy.
88951716|NCT01949636||lean adolescents|
89481567|NCT05063708|Sham Comparator|Traditional dysphagia therapy plus sham Neuromuscular electrostimulation|"Traditional dysphagia therapy (TDT) involved orofacial, lingual, and laryngeal motor exercises and compensatory swallowing strategies included various modifications of head, neck, and body postures and adjustment of food/liquid temperature, viscosity, and volume. The choice of specific strategies was based on the FEES findings and the clinical swallowing examination. The rehabilitative treatment will be administered in the 8 centers taking part to the study. The electrodes in this sham group will be placed in the same positions as the active treatment, with a current between 3 and 5 mA (average of 3.5 mA) current unable to perform muscle contraction. Every MS patient will be received 16 sessions of TDT according to their degree of dysphagia, contemporary associated with Sham neuromuscular electrostimulation two 30-min treatment a day, separated by a rest period of at least 45 minutes for four consecutive days per week, within a period of 4 weeks"
89481568|NCT05063708|Experimental|traditional dysphagia therapy plus Neuromuscular electrostimulation|Every MS patient will be treated with traditional dysphagia therapy, associated with an active neuromuscular electrostimulation. The amplitude will be increased until the subject will feel a 'grabbing sensation' which corresponded to muscular contraction. This will be the amplitude used for the therapy. This process will be repeated for the second channel of the stimulator. The typical electrical stimulus is at 80 Hz and at 300 microsec, and it will be adapted to avoid annoying stimulus to the patients. During therapy, both channels will be active. Every MS patient will be received 16 sessions of traditional dysphagia therapy according to their degree of dysphagia, contemporary associated with neuromuscular electrostimulation , according to our previous experiences, two 30-min treatment a day, separated by a rest period of at least 45 minutes for four consecutive days per week, within a period of 4 weeks.
89481569|NCT03555019|Experimental|Formulaid|The intervention group will receive enteral supplementation with Formulaid containing ARA and DHA at a ratio of 2:1, from birth until 36 weeks PMA
89481570|NCT03555019|Active Comparator|MCT-oil|The control group will receive enteral supplementation with MCT oil containing coconut and/or palm kern oil, from birth until 36 weeks PMA
89481571|NCT04857255|Active Comparator|Technology Assisted Language Intervention (TALI)|Augmentative and alternative communication software incorporated into active speech-language therapy
89481572|NCT04857255|Active Comparator|Treatment as Usual|Speech language therapy child is typically receiving (no change to current care)
89481573|NCT05042336|Experimental|camrelizumab/lenvatinib combined with TACE|"Phase Ib trial： Ib-A group [camrelizumab q3w group]: TACE d1, camrelizumab 200mg, d1, 22, 43; Lenvatinib d7-43; Surgery d50; Group Ib-B [camrelizumab q2w group]: TACE d1, camrelizumab 200mg, d1, 15, 29; Lenvatinib d7-43; Surgery d50.~Phase II trial： The enrolled patients received camrelizumab/lenvatinib combined with TACE treatment (a relatively safer treatment plan based on phase Ib), and the first imaging efficacy evaluation was performed at 6-8 weeks to evaluate surgical resection"
89481574|NCT02103673|Experimental|DAOIB|Drug: DAOIB 250-1500 mg/day by mouth for 6 weeks
89481575|NCT02103673|Placebo Comparator|Placebo|Placebo by mouth per day for 6 weeks
88951717|NCT01949649|Active Comparator|Peer-Led Group Intervention|In the Peer-Led Group Intervention, participants voluntarily engage in verbal, written, and behavioral exercises in which they critique the thin-ideal ideal during 4 1-hr sessions and in homework activities which are led by peer leaders.
88951718|NCT01949649|Active Comparator|Clinician-Led Group Intervention|In the Clinician-Led Group Intervention, participants voluntarily engage in verbal, written, and behavioral exercises in which they critique the thin-ideal ideal during 4 1-hr sessions and in homework activities which are led by University clinicians.
88951719|NCT01949649|Active Comparator|Internet-Based Intervention|The Internet-Based Intervention consists of 6 40-min modules involving user-driven self-education activities and games (e.g., role-plays), writing/video contests, and off-line exercises designed to induce dissonance regarding pursuit of the thin-ideal, mirroring activities from the group Body Project.
88951720|NCT01949649|Active Comparator|Education Video|The Education Video describes eating disorders, their adverse effects, and the need for treatment, which is key information to provide to young women at elevated risk for eating disorders due to body dissatisfaction.
88951721|NCT01949675|Experimental|Study Group 1|Participants aged 1 through 4 years at enrollment
88951722|NCT01949675|Experimental|Study Group 2|Participants aged 5 through 14 years at enrollment
89481576|NCT03295617||spinal thoracic herniation|
89481577|NCT03096392|Experimental|HDV insulin lispro 100 UNT/mL|insulin lispro with 0.8 ml HDV added to a 10 ml vial of insulin lispro, injected subcutaneous before meals as needed. Study duration of 7 weeks (6 weeks of treatment)
89481578|NCT03096392|Active Comparator|insulin lispro 100 UNT/ML|insulin lispro with 0.8 ml sterile water for injection added to a 10 ml vial of insulin lispro, injected subcutaneous before meals as needed. Study duration of 7 weeks (6 weeks of treatment)
89481579|NCT04428645|Experimental|DailyDose Decision Support|Subjects will use DailyDose decision support for 8 weeks at home.
89481580|NCT05049434|Experimental|Medicurtain®|Treat GUARDIX-SG 5ml prefilled syringe after surgery
89481581|NCT05049434|Active Comparator|GUARDIX-SG®|Treat Medicurtain® 5ml prefilled syringe after surgery
89481582|NCT02103829|Active Comparator|Condition #1|Condition #1 will consist of Brief Intervention #1, a brief online suggestion that takes less than 1 minute to complete.
89481583|NCT02103829|Experimental|Condition #2|Condition #2 will consist of Brief Intervention #1 and Brief Intervention #2 that together take less than a minute to complete.
89481584|NCT02103829|Experimental|Condition #3|Condition #3 will consist of Brief Intervention #1 and Brief Intervention #3, which, together, will take less than 8 minutes to complete.
89481585|NCT02103829|Experimental|Condition #4|Condition #4 will consist of Brief Intervention #1, Brief Intervention #2, and Brief Intervention #3, which, together, will take less than 8 minutes to complete.
89481586|NCT03290157|No Intervention|Control group|Regular colonoscopy preparation paper based information provided
89481587|NCT03290157|Other|ColoprAPP group|Regular colonoscopy preparation paper based information provided plus usage of a downloaded SPA (ColoprAPP) as a reminder system for colonoscopy preparation
89481588|NCT02103907|No Intervention|Wait list|Wait list control group. Participants will be placed on the wait list and asked to maintain their current routine and level of activity during the 10 week period. Control group participants will receive the dynamic balance training program in a single training session after the followup (second testing session at 10 weeks).
89481589|NCT02103907|Experimental|Treatment (balance training)|Targeted dynamic balance training. Dynamic balance training will consist of progressive exercise training over three phases, with exercises emphasising dynamic balance control, muscle strength and proprioception. Exercises will be performed four times per week for ten weeks. Exercises will be taught and supervised by a trained kinesiologist. Difficulty of exercises will be increased progressively over time by increasing resistance, time of timed exercises, and distance of walking exercises. Exercises will be progressed to different exercises in each new phase (total 3 phases). Participants will complete six treatment sessions at the university (during weeks 1, 2, 3, 5, 7, and 9) that will be included in the total number of sessions per week. All other sessions will be performed at home.
89481590|NCT05042024|Active Comparator|the SRP Group|Patients received conventional periodontal therapy including scaling and root planing as a full-mouth procedure, n=25.
89020660|NCT02543567|Experimental|Group 3|Ad26.ZEBOV 0.8*10^10 vp single dose intramuscular (IM) injection on Day 1; MVA-BN-Filo 5*10^7 Inf. U. single dose IM injection on Day 57
89020661|NCT02543567|Experimental|Group 4|Participants will receive intramuscular (IM) injection of Placebo (0.9% saline) once on Day 1 and Day 57
89203117|NCT01061125||Unblinded|Transtelephonic (TTM) monitoring weekly for 5 months Holter monitor recording at 4 months and at 12 months Implantable Loop Recorder (ILR) weekly reports
89481591|NCT05042024|Experimental|the Arg Group|Patients received oral L-arginine aspartate (Yuria-Pharm, Ukraine) at a dose of 1 g t.i.d. for 10 days after conventional periodontal therapy, n=25.
89481592|NCT05042024|Experimental|the Orn Group|Patients received oral L-ornithine aspartate (Farmak, Ukraine) at a dose of 3 g t.i.d. for 15 days after conventional periodontal therapy, n=25.
89481593|NCT02460393|Placebo Comparator|Placebo group|The arm is as a control group to study the tolerance, safety and pharmacokinetic characteristics of Subcutaneous injection of different doses of humanized TNFα monoclonal antibody.
89481594|NCT02460393|Experimental|experimental group|The arm is as an experimental group to study the tolerance, safety and pharmacokinetic characteristics of Subcutaneous injection of different doses of humanized TNFα monoclonal antibody.
89481595|NCT03554941|Experimental|noise stimulation|noise stimulation
89481596|NCT02106169|Experimental|Therapeutic education group|"At first, all patients will be invited to participate in a study of troop having for objective to estimate their quality of life. Then, the doctors offer patients randomized to therapeutic education to have a therapeutic education before the 4th month.~The sessions will be led by a multidisciplinary equip. Each child and his family will have a therapeutic session (2 times 2 hours)."
89481597|NCT02106169|No Intervention|Control group|At first, all patients will be invited to participate in a study of troop having for objective to estimate their quality of life. Then, the patients randomized in this group will have the habitual medical care.
89481598|NCT02464995|Experimental|Thermoplasty group|Procedure: Bronchial thermoplasty with the Alair System and conventional therapy
89481599|NCT02464995|No Intervention|Control group|Conventional therapy
89481600|NCT05063630|Experimental|Medical treatment plus intracranial stenting (MT plus IS)|This group will be both given medical treatment (aspirin 100 mg and clopidogrel 75 mg per day for 90 consecutive days and clopidogrel 75 mg per day thereafter) and performed with intracranial stenting.
89481601|NCT05063630|Active Comparator|Medical treatment alone (MT)|This group will be given medical treatment including aspirin 100 mg and clopidogrel 75 mg per day for 90 consecutive days and clopidogrel 75 mg per day thereafter.
89481602|NCT02103985|Experimental|Treatment A|Participants will receive 100 mg JNJ-39823277 under fed (after a high fat) condition.
89481603|NCT02103985|Experimental|Treatment B|Participants will receive 100 mg JNJ-39823277 under fasted condition.
89481604|NCT03289845|Other|BHX implant|All patients implanted with BHX implant
89481605|NCT05063864|Experimental|Nursing Support Program|the group that applied the nursing support program
89481606|NCT05063864|No Intervention|No Nursing Support Program|the group that did not receive a nursing support program
89481607|NCT03295539|Other|Acute or Chronic clot|If chronic clot, no intervention given via Indigo
89481608|NCT02250859|Experimental|FMX101 Minocycline 4% foam|FMX101, 4% applied to the face, upper chest, upper back and shoulders for sixsteen consecutive days in subjects either with acne or with normal skin
89481609|NCT02465229|Experimental|Diagnostic methods of indeterminate biliary stricture|
89203118|NCT01061125||Blinded|TTM and Holter Monitor conventional follow up Implantable Loop Recorder (ILR) unblinded at 5 months
89203119|NCT01055275||Cook Iliac Branch Graft|Patients implanted with a Cook Iliac Branch Graft
89481610|NCT02101099||Patients undergoing colonoscopy|Patients who are undergoing outpatient colonoscopy for colorectal cancer screening or for symptoms suggestive of colonic diseases.
89481611|NCT03295461|Active Comparator|test group|SRP+ 10% Emblica officinalis irrigation
89481612|NCT03295461|Active Comparator|positive control group|SRP + 0.2% Chlorhexidine irrigation
89481613|NCT03295461|Active Comparator|negative control group|SRP + 0.9% Saline irrigation
89481614|NCT03295461|Active Comparator|test gropup|SRP +10% E. officinalis gel application
89481615|NCT03295461|Placebo Comparator|control group|received SRP+ placebo gel application.
89481616|NCT05063474||PAD: Peripheral Artery Disease|People with Peripheral Artery Disease (PAD). No intervention given, observation and assessment only
89481617|NCT05063474||PLL+PAD: People with Limb Loss and Peripheral Artery Disease|People with Lower-Limb Loss (PLL) and Peripheral Artery Disease (PAD) No intervention given, observation and assessment only
89481618|NCT03289767|Experimental|Curved-tube|Giving additional curve to the endotracheal tube by simple preparation.
89481619|NCT03289767|No Intervention|Control|No other manipulation of the endotracheal tube is done.
89481620|NCT02104063||MRI-PET|Participants will have an MRI-PET scan (the Index test) in addition to the procedures they would normally receive as their standard of care (Reference tests). The accuracy of MRI-PET in detecting or ruling out metastatic penile cancer will be compared to the reference tests.
89481621|NCT05048420|Experimental|Ramp lesion repair|
89481622|NCT05048420|Experimental|Anterior cruriciate ligament reconstruction|
89481623|NCT03295383|Experimental|Rituximab treatment|"Rituximab at a dose of 1000 mg (or matching placebo) will be administered by IV infusion on Day 1 and Day 15 whatever the patient's weight, with repeat maintenance rituximab (or matching placebo) administration on Day 182 and Day 197~cyclophosphamide placebo will be administered orally once daily"
89481624|NCT03295383|Active Comparator|Cyclophosphamide treatment|"cyclophosphamide will be administered orally once daily at the following initial doses:~patients younger than 75 years: 1.5 mg/kg/day, orally. patients older than 75 years: 1 mg/kg/day, orally.~Rituximab placebo (NaCl 0.9 %) will be administered by IV infusion on Day 1 and Day 15 whatever the patient's weight, with repeat maintenance rituximab (or matching placebo) administration on Day 182 and Day 197"
89481625|NCT02101177||Patients under Dual therapy|- 1500 patients who started treatment between April 1st 2013 and March 31st 2014 and will be seen for their week 60 visit between July 1st 2014 and June 30th 2015 (Cohort A).
89481626|NCT02101177||Early Defaulters|- 1000 patients recruited between July 1st 2014 and estimated March 31st 2015, of which 200 are expected to be early defaulters and will be contacted by the study team (Cohort B).
89481627|NCT02101255|Experimental|Curodont Repair|Application on Day 0 and Day 360
89481628|NCT02101255|Active Comparator|Fluoride|Application on Day 0, Day 180, Day 360, Day 540
89481629|NCT05063318|Active Comparator|Sequence TR|"Sequence 1 (TR)~Cycle 1: Itraconazole + lurbinectedin 0.8 mg/m²~Cycle 2: Lurbinectedin alone 3.2 mg/m²~Cycle 3: Lurbinectedin alone 3.2 mg/m² (optional)~PART A The dose of lurbinectedin when given in combination with itraconazole for the initial three patients in Part A will be 0.8 mg/m². In Part A, all patients will receive itraconazole plus lurbinectedin in Cycle 1 and lurbinectedin alone in Cycles 2 and 3 (this last cycle being optional).~PART B Randomization will apply for study Part B only. In Part B is susceptible to be adjusted properly if deemed necessary based on exposure and safety experience in Part A. In Part B, patients will be randomly assigned to the corresponding sequences."
89481630|NCT05063318|Active Comparator|Sequence RT|"Sequence 2 (RT):~Cycle 1: Lurbinectedin alone 3.2 mg/m²~Cycle 2: Itraconazole + lurbinectedin 0.8 mg/m²~Cycle 3: Lurbinectedin alone 3.2 mg/m² (optional)"
89481631|NCT02106247|Experimental|1 BI 1181181 low dose|tablet
89481632|NCT02106247|Experimental|BI 1181181 high dose|tablet
89481633|NCT02106247|Experimental|Placebo|tablet
89481634|NCT02465151|Experimental|No Protein|
89481635|NCT02465151|Experimental|Low Protein|
89481636|NCT02465151|Experimental|Medium Protein|
89481637|NCT02465151|Experimental|High Protein|
89481638|NCT03096002||Lifestyle change (one-treatment group)|The lifestyle change program is a 3-week program that will introduce participants to a regular healthy lifestyle that includes exercising at least three times per week and the program will highlight simple dietary strategies. There is no randomization to this program - all individuals enrolled will partake in the same program and will be followed up for 12 months after the program has concluded.
89481639|NCT03289689|Experimental|Whole body vibration|"The subjects in the WBV group performed one series of five consecutive repetitions of 60 sec unsynchronised multidimensional WBV (Zeptoring, Scisen GmbH, Germany; 4 Hz, amplitude 3mm) with a 1-min pause between administrations, three times a week. The construction of this device is designed to perform a nonharmonious generation of oscillating movements in vertical and horizontal planes in order to prevent occurrences of resonance and habituation of receptors.~During the intervention, subjects wore thin-soled gymnastic-type shoes, carrying out in a squatting standing position, with slight flexion at the hips, knees and ankle joint, on the vibration platform."
89481640|NCT03289689|No Intervention|Control|The controls did not receive any training.
89481641|NCT02104297|Active Comparator|Deksmedetomidine infusion|To prevent agitation deksmedetomidine infused during operation and at the end of surgery agitation scor measured by Riker sedation agitation scale.
89481642|NCT02104297|Experimental|Remifentanil infusion|To prevent agitation remifentanil infused during operation at the end of surgery agitation scor measured by Riker sedation agitation scale.
88951723|NCT01949675|Experimental|Study Group 3|Participants aged 15 years and above at enrollment
88951724|NCT01949688|Experimental|HLA-A*2402 restricted peptides|HLA-A*2402 restricted peptides with adjuvant
88951725|NCT01949688|Experimental|HLA-A*0201 restricted peptides|HLA-A*0201 restricted peptides with adjuvant
88951726|NCT01949701|Experimental|Vaccine|HLA-A*0201restricted URLC10 peptides
88951727|NCT01949727||AIM 1/AIM 2: AECOPD Admitted Patients|"AIM 1:All patients admitted to the hospital (either to Pulmonary or General Medicine) will be recruited to enroll in this observational study. No specific intervention is planned for this group.~AIM 2: All patients admitted to the pulmonary ward for an AECOPD, including those who have completed Aim 1, will be offered participation into this arm of the study. Pulmonary rehabilitation will be conducted through the Breathe Easy Program at the Centre for Lung Health."
88951728|NCT01949740||Observational (patient preferences)|Patients participate in a 45-minute interview comprising assessment of priorities and quality of life at baseline, 1, 6, and 12 months.
89481643|NCT02104297|Placebo Comparator|Saline infusion|Saline infused during operation and at the end of surgery agitation scor measured by Riker sedation agitation scale.
89481644|NCT03096158|Experimental|Ventilatory Muscle Training (TREMVEN)|The enrolled participants will perform inspiratory muscle training (IMT) for 20 minutes during the period of hospitalization, using the Power Breathe device (POWERbreathe International LTD). During training, subjects will be instructed to maintain diaphragmatic breathing at a rate at 15 to 20 breaths/min. The inspiratory load will be set at 30% of maximal static inspiratory pressure (PImax). It will be occur once per day until the hospital exit.
89481645|NCT03096158|Experimental|Aerobic Training (AERO)|It will consist of supervised walking, lasting 20 minutes a day, during the period of hospitalization of the participants. Heart rate (HR) will be constantly monitored through a cardiac monitor (Polar), with the objective of maintaining between 50 and 60% of the maximum HR predicted by age; Similar to 40 to 50% of VO2max. Blood pressure, oxygen saturation (SpO2) and level of dyspnea (Borg's effort perception scale) will also be monitored constantly. It will be occur once per day until the hospital exit.
89481646|NCT03096158|Experimental|Isometric Handgrip Training (ISO)|Study participants will perform 5 x 2 min alternating bilateral contractions of the hand flexor muscles at 30% maximum voluntary contraction with one minute rest between contractions, in a total of 20 minutes training during the period of hospitalization. It will be occur once per day until the hospital exit.
88951729|NCT01949753|Experimental|Nutritional supplement Pregnenolone|Exposure therapy, exposure with response prevention and pharmacological facilitation (nutritional supplement pregnenolone), orally two hours before exposure therapy.
88951730|NCT01949753|Placebo Comparator|Placebo|Exposure therapy, exposure with response prevention without pharmacological facilitation (Placebo), orally two hours before exposure therapy.
89481647|NCT03295305|Experimental|Action Based Cognitive Remediation|
88951731|NCT01949792|Active Comparator|270 microg/kg rFVIIa|Each subject will receive one single injection of 270 microg/kg and three injections of 90 microg/kg rFVIIa (one injection every 3 hours) in a randomised order. The two administration days will be separated by a wash-out period of at least 48 hours
88951732|NCT01949792|Active Comparator|3x90 microg/kg rFVIIa|Each subject will receive one single injection of 270 microg/kg and three injections of 90 microg/kg rFVIIa (one injection every 3 hours) in a randomised order. The two administration days will be separated by a wash-out period of at least 48 hours
88951733|NCT01948245|Active Comparator|TaurolockTMHep100|"2-4 ml of TaurolockTMHep100 will be instilled into the central venous access device (CVAD)after each infusion of parenteral nutrition/intravenous fluids. The instillation varying between twice per week to once daily depending on the patients individual HPN programme. The catheter lock solution is kept in situ in the lumen to the next infusion.~The duration of TaurolockTMHep100 administration will be maximum 24 month or until occurence of primary outcome(CRBSI)."
88951734|NCT01948245|Placebo Comparator|Heparin 100 IE/ml|"2-4 ml of Heparin 100 IE/mk will be instilled into the central venous access device (CVAD)after each infusion of parenteral nutrition/intravenous fluids. The instillation varying between twice per week to once daily depending on the patients individual HPN programme. The catheter lock solution is kept in situ in the lumen to the next infusion.~The duration of Heparin 100 IE/ml administration will be maximum 24 month or until occurence of primary outcome(CRBSI)."
88951735|NCT01949805|Active Comparator|Hydroxyurea|Hydroxyurea capsules (500 mg each). Daily intake of doses from 500 mg Q2D to 3000 mg QD
89481648|NCT03295305|Active Comparator|Unstructured support group|
89481649|NCT02106481|Active Comparator|Femoral Nerve Catheters|Patients will receive a Single Shot Femoral Nerve Block along with a conventional continuous femoral nerve catheter
89481650|NCT02106481|Active Comparator|Single Shot Femoral Nerve Blocks|Patients will receive a Single Shot Femoral Nerve Block and a sham catheter post op.
89481651|NCT05048186||Decision Aid Arm|Participants in this arm will review educational material from the ADHD Decision Aid developed by the Cincinnati Children's Hospital Medical Center.
89481652|NCT05048186||Control Arm|Participants in this group will not receive any educational materials.
89481653|NCT03289611|No Intervention|Control|Usual management
89481654|NCT03289611|Experimental|Experimental|Ambulatory management if sFlt-1 / PlGF ratio is below 38 Usual management if sFlt-1/PlGF is between 38 and 85. If the ratio is > 85, monitoring will be intensified and patient hospitalization will be continued
89481655|NCT02106559|Experimental|Treatment (surgery, porfimer sodium, PDT)|Patients receive porfimer sodium IV over 3-5 minutes. Beginning 24 hours later, patients undergo tumor resection and/or radical pleurectomy followed by intraoperative photodynamic therapy to the pleural space.
89481656|NCT03289377|Experimental|RDAD training to APNs|Half-day workshop to provide APNs with all skills necessary to conduct RDAD in their clinical settings. A subset of the trained APNs will implement RDAD as part of their ongoing care of persons with ADRD.
89481657|NCT05047874||short-term (3 days) high-dose (1000 mg) systemic methylprednisolone|retrospectively, the 15-day continuous hemodynamic, laboratory and clinical course of COVID 19 patients to whom we administered short-term (3 days) high-dose (1000 mg) systemic methylprednisolone
89481658|NCT05047874||low-dose long-term (2x 40 mg) systemic methylprednisolone|retrospectively, the 15-day continuous hemodynamic, laboratory and clinical course of COVID 19 patients to whom low-dose long-term (2x 40 mg) systemic methylprednisolone
89481659|NCT02101333|Experimental|TOCILIZUMAB MONTHLY DURING 6|intravenous injection, 8 mg/kg, monthly during 6 months
89481660|NCT04434794|Experimental|mesenchymal stem cells|standard treatment according to clinical protocols plus mesenchymal stem cells
89481661|NCT04434794|Active Comparator|control|standard treatment according to clinical protocols
89481662|NCT01368835|Experimental|Ulthera treatment|
89481663|NCT04488705|Experimental|Single ascending dose|
89481664|NCT04488705|Experimental|Repeat dose - 7 days|
89481665|NCT04488705|Experimental|Repeat dose - 14 days|
89481666|NCT04488705|Experimental|Repeat dose - 7 days with SABA|
89481667|NCT03295071||Single-group study|This study is a multi-country retrospective and cross-sectional observational study of affected LHON subjects, based on retrospective subjects' medical chart abstractions and cross-sectional administration of patient-reported outcomes (PROs).
89481668|NCT02104375|Experimental|L-citrulline|L-citrulline (6 g/day for 2 weeks)
89481669|NCT02104375|Placebo Comparator|Maltodextrin|6g/day of placebo (maltodextrin)
89020662|NCT02530489|Experimental|Treatment (atezolizumab, nab-paclitaxel)|"NEOADJUVANT: Patients receive atezolizumab IV over 60 minutes on day 1 and nab-paclitaxel IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.~SURGERY: Patients undergo definitive breast surgery within 6 weeks of the completion of treatment.~ADJUVANT: Within 4 weeks after surgery, patients receive atezolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity."
89020663|NCT02519985|Experimental|Repeatability and Reproducibility of ArcScan Insight 100|"For repeatability and reproducibility in normal eyes (n=20):~Firstly, 5 consecutive repeated ArcScan Insight 100 scans of the cornea and anterior segment will be performed by the first operator.~After a break of about 30 minutes, 5 consecutive repeated ArcScan Insight 100 scans of the cornea and anterior segment will be performed by the second operator.~For repeatability and reproducibility in eyes after laser refractive surgery (n=20):~Firstly, 5 consecutive repeated ArcScan Insight 100 scans of the cornea will be performed by the first operator.~After a break of about 30 minutes, 5 consecutive repeated ArcScan Insight 100 scans of the cornea will be performed by the second operator."
89020664|NCT02431780|No Intervention|non ANSeR Software System|Routine clinical EEG monitoring
89020665|NCT02431780|Experimental|ANSeR Software System|The intended use of the ANSeR Software System is to provide a real time decision support tool to assist in the diagnosis of seizures in neonates (between 36 weeks and 44 weeks corrected age) and to provide a review tool for EEG and seizure analysis. ANSeR is intended to provide a reliable, effective, objective and intuitive means of identifying seizures
89020666|NCT02363205|No Intervention|control|Weekly check-up
89020667|NCT02363205|Experimental|internet-delivered CBT|Tailored Internet-administrated CBT-Treatment
89020668|NCT02253238|Other|Standard of Care Group|Surveys administered in person or by telephone interview and are audio-recorded.
89020669|NCT02253238|Experimental|CYCORE Group + Standard of Care|"Home use of CYCORE devices (blood pressure monitor, weight scale, electronic tablet, palm-sized plug-in computer).~Surveys administered in person or by telephone interview and are audio-recorded."
89020670|NCT02239341|Active Comparator|Music Intervention (M)|The M intervention will be 30 minutes (same amount of time as E group), but the participants will simply be listening to the same music in bed with no exercise component. They will be wearing the heart rate monitor as in the E group. The M group will act as a control group for the E group.
89020671|NCT02239341|Experimental|Muscle Conditioning Intervention (E)|E (exercise) is 30 minutes in length and will consist of 5 minutes of warm-up, 20 minutes of light strengthening exercises using a theraband, and 5 minutes of cool-down. All exercises will be completed in bed. Each participant will be listening to the same music (as the M group) during exercise. A heart rate monitor will be worn throughout each session. The first session for each participant will be used to complete baseline measurements and to assess initial muscle strength. Difficulty level will be adjusted by using different strength therabands.
89020672|NCT02227719|Experimental|Test: CTI|CTI is titanium mesh
89020673|NCT02227719|Active Comparator|Control: Collagen membrane|Collagen membrane is used for ridge augmentation
89020674|NCT02223377|Active Comparator|Morphine|"Analgesia with equipotent doses of Morphine and Hydromorphone will be administered in titrated doses. Doses are 1ml=1mg of morphine or 0.2 mg of hydromorphone. Potency ratio of 1:5 (M: HM).~0.05mg/kg morphine units (rounding off to the nearest 1 ml or 0.5 ml)"
89020675|NCT02223377|Active Comparator|Hydromorphone|"Analgesia with equipotent doses of Morphine and Hydromorphone will be administered in titrated doses. Doses are 1ml=1mg of morphine or 0.2 mg of hydromorphone. Potency ratio of 1:5 (M: HM).~0.05mg/kg morphine units (rounding off to the nearest 1 ml or 0.5 ml)"
89020676|NCT02146508|Experimental|Endoscopic treatment|Participants undergo upper GI endoscopy with endoscopic mucosal resection (EMR) and/or radiofrequency ablation (RFA) of esophageal squamous dysplasia (ESD). After initial therapy participants undergo repeat endoscopy every 3 months for a year, with re-biopsy and re-treatment of residual ESD as appropriate.
89020677|NCT02139020||No treatment|"Patients with squamous cell carcinoma of the head and neck, targeted therapies, plasma samples:~Group 1 = patients treated with radiation therapy and cetuximab according to Bonner et al [11]~Group 2 = patients treated with cetuximab in combination with chemotherapy according to Vermorken et al. [10]~Group 3 = patients treated with a molecular targeted agent as a part of a clinical study"
89020678|NCT02094261|Experimental|AZD9291|Once daily tablet 80 mg
89020679|NCT02077192|Experimental|Fostamatinib Disodium|Fostamatinib Disodium tablet 100 mg or 150 mg by mouth twice a day
89020680|NCT02074553|Experimental|Ro542-4802/F03;Ro542-4802/F07;Ro542-4802/F14;Ro542-4802/F08|Participants will receive Ro542-4802/F03 (containing 50% SLS) capsules orally on Day 1 of first intervention period; then Ro542-4802/F07 (containing 25% SLS) capsules orally on Day 1 of second intervention period; then Ro542-4802/F14 (containing 12.5% SLS) capsules orally on Day 1 of third intervention period; followed by Ro542-4802/F08 (containing 3% SLS) capsules orally on Day 1 of fourth intervention period during both fasted (Part 1) and fed (Part 2) conditions. A washout period of at least 10 days will be maintained between each period.
89020681|NCT02074553|Experimental|Ro542-4802/F07;Ro542-4802/F08;Ro542-4802/F03;Ro542-4802/F14|Participants will receive Ro542-4802/F07 (containing 25% SLS) capsules orally on Day 1 of first intervention period; then Ro542-4802/F08 (containing 3% SLS capsules orally on Day 1 in second intervention period; then Ro542-4802/F03 (containing 50% SLS) (containing 12.5% SLS) capsules orally on Day 1 of third intervention period; followed by Ro542-4802/F14 (containing 12.5% SLS) capsules orally on Day 1 of the fourth intervention period during both fasted (Part 1) and fed (Part 2) conditions. A washout period of at least 10 days will be maintained between each period.
89020682|NCT02074553|Experimental|Ro542-4802/F08;Ro542-4802/F14;Ro542-4802/F07;Ro542-4802/F03|Participants will receive Ro542-4802/F08 (containing 3% SLS) capsules orally on Day 1 of first intervention period; then Ro542-4802/F14 (containing 12.5% SLS) capsules orally on Day 1 in second intervention period; then Ro542-4802/F07 (containing 25% SLS) capsules orally on Day 1 of third intervention period; followed by Ro542-4802/F03 (containing 50% SLS) capsules orally on Day 1 of the fourth intervention period during both fasted (Part 1) and fed (Part 2) conditions. A washout period of at least 10 days will be maintained between each period.
89531472|NCT06065969|Sham Comparator|sham local photobiomodulation|The same procedures described for local photobiomodulation will be followed; however, the equipment will emit only the sound signal, exactly like the equipment used in local photobiomodulation group, without emitting laser light.
89481670|NCT03289221|Experimental|Experimental Group|Thirty (30) consecutive patients indicated for treatment of prostate cancer with HIFU (FocalOneR, Edap TMS, France) will be selected to the manometry study before the treatment together with the application of specific questionnaires (Cleveland Clinic Incontinence Score-CCIS, Fecal Incontinence Quality of Life Score-FIQLS, and Rome IV for functional constipation. This evaluaton will be conducted again after the treatment.
89481671|NCT02106637|Active Comparator|study groups|study groups will receive Varenicline
88951736|NCT01949805|Experimental|Peg-P-IFN-alpha-2b (AOP2014)|Peg-P-IFN-alpha-2b at 50mcg to max 500 mcg, given every other week as one subcutanous injection
88951737|NCT01949818|Experimental|Yangzhengxiaoji Capsule combined with CHOP regimen|Yangzhengxiaoji Capsule combined with CHOP(Cyclophosphamide,Vincristine,Doxorubicin,Prednisone) regimen
88951738|NCT01949818|Experimental|CHOP regimen|CHOP(Cyclophosphamide,Vincristine,Doxorubicin,Prednisone) regimen
88951739|NCT01949831|No Intervention|Control|Usual care
88951740|NCT01949831|Experimental|Functional assessment|Assessment of functional ability in combination with follow-up at home
88951741|NCT01949896|Other|Intervention: NPO|"Infants in this group will be made NPO approximately 4 hours prior to receiving a blood transfusion and will remain NPO until approximately 24 hours after the blood transfusion.~Pro-inflammatory cytokine response will be monitored at 3 times points."
89481672|NCT02106637|Placebo Comparator|control group|Participants allocated to the control group will receive placebo
89481673|NCT02104453|Experimental|E-C clamp mask holding technique|"the airway maneuver that press the mask against the patient's face (using the C of our thumb and forefinger) while pulling the jaw forward (using the E of our other fingers behind the mandible), and leaves one hand free to squeeze the bag."
89481674|NCT02104453|Experimental|two-handed ventilation with jaw thrust|the airway maneuver performed with thumbs point toward feet, palms press down and other fingers perform jaw thrust
89481675|NCT02104453|Experimental|triple airway maneuver|the airway maneuver performed with two-handed mask ventilation, jaw thrust and head-tilt chin-lift technique
89481676|NCT03288909||Early onset Parkinson's disease|Idiopathic Parkinson's disease within 1 year of symptom onset
89481677|NCT03288909||Idiopathic REM Sleep Behavior Disorder|Idiopathic REM Sleep Behavior Disorder
89481678|NCT03288909||Age-matched healthy controls|Age-matched healthy controls
89481679|NCT02104531||Shoulder Pain|No intervention. Subjects will have a standard static MRI taken of their shoulder, and also complete a series of shoulder motions using video fluoroscopy.
89481680|NCT02104531||Healthy Subjects|No intervention. Subjects will receive a standard shoulder MRI and perform shoulder motions while being measured with video fluoroscopy.
89481681|NCT05047484|Experimental|Cohort 1: 40 mg ALXN2050/Placebo|Participants randomized to receive ALXN2050 or placebo twice daily (BID) on Day 1 through Day 14 in a fasted state.
89481682|NCT05047484|Experimental|Cohort 2: 80 mg ALXN2050/Placebo|Participants randomized to receive ALXN2050 or placebo BID on Day 1 through Day 14 in a fasted state.
89481683|NCT05047484|Experimental|Cohort 3: 120 mg ALXN2050/Placebo|Participants randomized to receive ALXN2050 or placebo BID on Day 1 through Day 14 in a fasted state.
89481684|NCT05047484|Experimental|Cohort 4: 200 mg ALXN2050/Placebo|Participants randomized to receive ALXN2050 or placebo BID on Day 1 through Day 14 in a fasted state.
89481685|NCT05047484|Experimental|Cohort 5: 120 mg ALXN2050/Placebo|Participants randomized to receive a single dose of ALXN2050 or placebo on Day 1 in a fed state.
89481686|NCT05047484|Experimental|Cohort 6: 240 mg ALXN2050/Placebo|Participants randomized to receive a single dose of ALXN2050 or placebo on Day 1 in a fasted state.
89481687|NCT02460861|Active Comparator|PCA Magdeburg|Prostate cancer conducted for RPVE with curative Intention, biopsies of the prostatic fossa in Magdeburg
89481688|NCT02460861|Active Comparator|Non-prostate cancer Magdeburg/Gronau|Conducted for CE in Male with bladder cancer or other indication for cystectomy but without prostate cancer in Magdeburg or Gronau, biopsies of the prostatic fossa in Gronau
89481689|NCT02460861|Active Comparator|PCA Gronau|Prostate cancer conducted for ETRARP with curative Intention, biopsies of the prostatic fossa
88951742|NCT01949896|Other|Control: Continue feedings|"Infants in this group will be allowed to continue feedings during the transfusion at the discretion of the medical team.~Pro-inflammatory cytokine response will be monitored at 3 times points."
88951743|NCT01949909|Experimental|Alhydrogel CH-Alum50|intramuscular administration to Swiss volunteers of Alhydrogel and P27A antigen (50 microg)
89481690|NCT02104609||Normal weight women|Levonorgestrel 1.5mg by mouth once
89481691|NCT02104609||Obese women|Levonorgestrel 1.5mg by mouth once
89481692|NCT02104609||Extremely obese women|Levonorgestrel 1.5mg by mouth once
89481693|NCT05047562|Active Comparator|Pilates Group|Participants will undergo 16 sessions, twice a week on alternate days through the following Pilates Method exercises: Pelvic Curl, Leg lift Supine, One leg circle modified and Hundred modified. There will be 4 sets of 5 repetitions in the first week, 6 repetitions in the second week, 7 repetitions in the third week, 8 repetitions in the fourth week, 9 repetitions in the fifth week, 10 repetitions in the sixth to eighth week.
89481694|NCT05047562|Active Comparator|Segmental Stabilization Group|Participants will undergo 16 consultations, twice a week on alternate days through the following Segmental Stabilization exercises: multifidus in prone position, transverse abdomen in four supports, transverse abdomen in dorsal decubitus and transverse abdomen associated with multifidus in position orthostatic. There will be 4 sets of 10 repetitions of 10 seconds in all appointments.
88951744|NCT01949909|Experimental|CH-GLA2.5/50|intramuscular administration to Swiss volunteers of GLA-SE (2.5microg) together with the P27A antigen (50 microg)
88951745|NCT01949909|Placebo Comparator|Control rabies vaccine Verorub TM TZ Ver|intramuscular administration of Rabies vaccine Verorub TM to in Phase IIb only to 8 Tanzanian volunteers in three injections
88951746|NCT01949909|Experimental|Alhydrogel TZ Alum 50|intramuscular administration to Tanzanian volunteers of Alhydrogel and P27A antigen (50 microg)
89481695|NCT03294915|Active Comparator|Resistant Starch|Green banana flour
88951747|NCT01949909|Experimental|GLA-SE TZ GLA 2.5/10|intramuscular administration to Tanzanian volunteers of GLA-SE (2.5 microg ) together with the P27A antigen (10 microg)
89481696|NCT03294915|Placebo Comparator|Placebo|Maltodextrin, cellulose and guar gum
89481697|NCT02106715|Active Comparator|Training|Two exercises for training of core stability and mobility.
89481698|NCT02106715|No Intervention|Control|Control group without training
89481699|NCT02104687|Active Comparator|Flow|The Flow therapeutic algorithm will be responsible for adjustment of intraoperative interventions - volumotherapy and administration of vasoactive drugs, with the aim to maintain the CI value >2.5 l/m/m2 (FTc - flow time <330 ms was chosen as variable defining preload; PV, peak velocity <70 ms-1 will be used as a variable defining contractility; SVR, total systemic vascular resistance between 1000-1800 cdyn.s/cm5m2 will be used as variable defining after load). After the desired values of CI have been obtained, no further increase of therapeutic intervention (fluids, vasoactive drugs) will be performed.
89481700|NCT02104687|Active Comparator|Press|The Press therapeutic algorithm will be responsible for adjustment of intraoperative interventions based upon standard pressure parameters and will include volumotherapy and administration of vasoactive drugs, with the aim to maintain the desired values of MAP of 65-105 mmHg and CVP 8-12 mmHg. After the desired values of MAP and CVP have been obtained, no further increase of therapeutic intervention (fluids, vasoactive drugs) will be performed.
89481701|NCT04488627||Critically ill patients|Critically ill patients hospitalised in the intensive care unit indicated to echocardiographic examination.
89481702|NCT02106793|Experimental|Mitomicin C|Mitomicin C (0.4 mg/ml) will be provided in a sterile vial and prepared by pharmacist at the Faculty of Medicine Ramathibodi Hospital.The treatment solution will be drawn and soaked ono two one inch neurosurgical cotton pledgets. Each pledget will be placed on each side of the nose for 5 minutes. The nurse will set the alarm for removal of the cotton pledgets, then normal saline will be used to irrigate both sides of the nose, using 100 ml on each side.
89481703|NCT02106793|Placebo Comparator|Placebo|Identical placebo solution
89481704|NCT05041556||Case-control study of clinical outcomes|These are children who live in RTS,S implementation areas aged less than 5 years and who were eligible to have received RTS,S based on their date or birth and age, will be eligible to be recruited into the study. Cases will be recruited in sentinel hospitals of the ongoing malaria Vaccine Pilot Evaluation (MVPE). Control for a case will be a child who lives outside a 100-metre radius from the case, matched on date of birth (+/- 1 month of date of birth of the case)
89481705|NCT05041556||Case-control study of mortality outcome|These will be children who died of any cause excluding accidents or trauma, who are eligible to have received the RTS,S vaccine based on their date of birth and age. Cases will be recruited from the community-based mortality surveillance of MVPE. Control for a mortality case will be a live child who lives outside a 100 metre radius from the case with date of birth +/- 1 month of the date of birth of the case who are eligible to have received the RTS,S vaccine.
89481706|NCT02104843|Experimental|Arm 1: DCV/ASV/BMS-791325 FDC + BMS-791325 + Rosuvastatin|"Treatment A: Rosuvastatin tablet orally on specified days~Treatment B: Daclatasvir, Asunaprevir and BMS-791325 Fixed dose combination (FDC) + BMS-791325 tablet orally on specified days~Treatment C: Daclatasvir, Asunaprevir and BMS-791325 FDC + BMS-791325 + Rosuvastatin tablet orally on specified days"
89481707|NCT03283293|Experimental|Target volume delineation after NACT|
89481708|NCT05041634|Experimental|Single Group Pilot study pre/post|One group of 8 participants receiving 14 week intervention
89481709|NCT02460315|Active Comparator|early cholecystectomy|group (A) will be managed by early laparoscopic cholecystectomy after clearness ERCP
89481710|NCT02460315|Active Comparator|late cholecystectomy|group (B) will be managed by late LC one month after ERCP.
89481711|NCT02104999|Other|Point-of-care test for CRP|Device: C Reactive Protein (CRP) measurement on capillary blood using a point-of-care test to determine the CRP level in the blood
89481712|NCT05041790|Experimental|Choline Alfoscerate|
89481713|NCT05041790|Placebo Comparator|Placebo|
89481714|NCT02101489|Active Comparator|Intraop Foley catheter measurement|20 women will have intraoperative Foley catheter measurement of the urethral length
89481715|NCT02101489|No Intervention|Without intraop Foley cath measurement|20 women without intraoperative Foley catheter measurement of the urethral length
89481716|NCT02105077||Xenon|Patients undergoing surgery with xenon-based general anesthesia
89481717|NCT03288831|Active Comparator|Normal Subjects, Gluten Drink|Normal subjects will drink a solution containing 6 grams of gluten one time.
89481718|NCT03288831|Placebo Comparator|Normal Subjects, Placebo Drink|Normal subjects will drink a solution without gluten one time.
89481719|NCT03288831|Active Comparator|Celiac Subjects, Gluten Drink|Subjects with celiac disease will drink a solution containing 6 grams of gluten one time.
89481720|NCT03288831|Placebo Comparator|Celiac Subjects, Placebo Drink|Subjects with celiac disease will drink a solution without gluten one time.
89481721|NCT03288831|Active Comparator|Gluten Sensitivity, Gluten Drink|Subjects with non-celiac gluten sensitivity will drink a solution containing 6 grams of gluten one time.
89481722|NCT03288831|Placebo Comparator|Gluten Sensitivity, Placebo Drink|Subjects with non-celiac gluten sensitivity will drink a solution without gluten one time.
89481723|NCT03095924|Active Comparator|News with Spin|News items reporting results of RCTs with spin
89481724|NCT03095924|Experimental|News without spin|News items reporting results of RCTs without spin
89481725|NCT02101567|Active Comparator|Pabal ( carbetocin)|Pabal (carbetocin which is a long acting oxytocin ) given as 100 mcg slow i.v. injection over 1 minute ( Draxis/Multiph). It will be given to the patients included in the study after delivery of the fetal head.
89481726|NCT02101567|Active Comparator|Oxytocin and Methergine (methyl ergometrine)|The second group of patients included in the study will be given Oxytocin 5 IU ampoule by intravenous infusion and Methergine 0.2 mg IV after delivery of fetal head.
89481727|NCT05061914|Active Comparator|pericardiocentesis|vitally unstable patients with tamponading pericardial effusion undergone percutaneous gradual drainage by a central venous catheter
89481728|NCT05061914|Active Comparator|subxiphoiodal drainage|drainage of the pericardial effusion through a subxiphoidal midline incision
89481729|NCT05061914|Active Comparator|thoracotomy|encysted and undiagnosed pericardial effusion drainage through anterior thoracotomy performing a pericardiopleural window and take a pericardial biopsy
89481730|NCT05061914|Active Comparator|VATS drainage|encysted and undiagnosed pericardial effusion drainage through VATS that permits performing a pericardiopleural window and take a pericardial biopsy with minimal incisions
88951748|NCT01949909|Experimental|GLA-SE TZ GLA5/50|intramuscular administration to Tanzanian volunteers of GLA-SE (5 microg) together with the P27A antigen (50 microg)
88951749|NCT01949909|Experimental|GLA-SE TZ GLA2.5/50|intramuscular administration to Tanzanian volunteers of GLA-SE (2.5microg) together with the P27A antigen (50 microg)
89481731|NCT02101645|Experimental|LIDC treatment and bioimpedance monitoring of venous ulcers.|Lower extremity venous ulcers will be treated using periodical LIDC stimulation. Wound healing and edema reduction efforts will be monitored using bioimpedance based monitoring.
88951750|NCT01949922|Experimental|Injection of autologous muscle fibers in the anal sphincter|All patients, that still have relevant symptoms after completion of three months with individualized pelvic floor muscle training and dietary intervention to control defecatory function, will be offered injection of autologous muscle fiber fragments in the anal sphincter. A myscle biopsy will be taken from the leg, cut into small pieces in a saline solution and injected in the anal sphincter.
88951751|NCT01949935|Placebo Comparator|Control|Placebo made from Glaxal base Applied once 1 day preoperatively and bid for 3 days postoperatively.
88951752|NCT01949935|Experimental|Mupirocin|Mupirocin ointment applied to nares once 1 day preoperatively and bid for 3 days postoperatively.
88951753|NCT01949948|Active Comparator|Tenecteplase|0.4 mg/kg single bolus intravenously
88951754|NCT01949948|Active Comparator|Alteplase|0.9 mg/kg as 10% bolus + 90% infusion/60 minutes intravenously
88951755|NCT01949961|Active Comparator|Ultrasound|Patients eligible (NOR-SASS A/B) and ineligible (NOR-SASS C) for intravenous thrombolysis all receive intravenous ultrasound contrast (microbubbles). The groups are separately randomised to 2 megahertz (MHz) transcranial ultrasound treatment for one hour.
88951756|NCT01949961|Placebo Comparator|Sham ultrasound|Patients eligible (NOR-SASS A/B) and ineligible (NOR-SASS C) for intravenous thrombolysis all receive intravenous ultrasound contrast (microbubbles). The two groups are separately randomised to sham ultrasound treatment for one hour.
88951757|NCT01949974|Experimental|Integral Attention Program (PAI)|"The key points of the PAI are:~To assess and manage pain and other symptoms resulting from disease progression.~To evaluate the information needs that may arise and to address them.~To encourage patient and family adaptation to the situation of advanced disease and in the terminal phase of it.~To provide guidance in decision-making while respecting patient autonomy.~To establish a plan of care and treatment, adapted to the evolution and needs of the patient.~To promote continuity of care."
88951758|NCT01949974|Active Comparator|Standard Palliative Chemotherapy and PAI|Standard palliative chemotherapy will be administered, depending on type of cancer, as well as PAI as been defined above.
88951759|NCT01949987|Active Comparator|2 hours after surgery|the investigators permit the patients to resume oral intake two hours after surgery and observe child's behavior and score; cry, facial expression, verbal expression, torso, legs, activity, and consolability
88951760|NCT01949987|Experimental|1 hour after surgery|the investigators permit the patients to resume oral intake one hour after surgery and observe child's behavior and score; cry, facial expression, verbal expression, torso, legs, activity, and consolability
88951761|NCT01950000|Placebo Comparator|Placebo|Placebo Treatment: A sterile sodium chloride injection 0.9% 10 ml
88951762|NCT01950000|Experimental|Fentanest|"For this study Fentanest doses were adjusted based on published guidelines from the values recommended media to a whole number and differentiating two groups of patients (multiple trauma / surgical or medical) The maximum dose is 100 mcg Fentanest. The multiple trauma patients / surgical 1.5 mcg / kg and in medical patients 1.0 mcg / kg were given a single bolus Fentanest / Placebo by type of patient (surgical / multiple trauma or physician) 5 'before turning mobilization with personal hygiene.~The bolus is given slowly (30'') intravenously, to be preferred by a peripheral without vasoactive drugs (only with fluid therapy).~Pharmaceutical form:~Sterile solution for injection. Each mL of injectable solution contains the equivalent of 0.05 mg of Fentanest; Excipients: sodium chloride and water for injection."
88951763|NCT01950026|Experimental|white|cryotherapy application
88951764|NCT01950026|Experimental|black|cryotherapy application
88951765|NCT01950026|Experimental|Brown|cryotherapy application
88951766|NCT01950026|Experimental|asian|cryotherapy application
88951767|NCT01950052|No Intervention|Control group|No special diet, patients will continue with a normal diet
88951768|NCT01950052|Experimental|Diet group|Pre-operative liver shrinking diet of 800 Kcal diet is administered for 4 weeks
88951769|NCT01950091|Experimental|FitBack on-line intervention|On-line Fitback intervention: Self care for on-going pain; behaviors to lessen the chance of reoccurrence
88951770|NCT01950091|Active Comparator|Alternative website control|Intervention is a Menu of links to 4 popular Websites offering back pain education
88951771|NCT01950091|No Intervention|Usual care control group|No contact; Control group
88951772|NCT01950104|Active Comparator|Day 3 embryo biopsy|Embryo biopsy is applied at day 3 of the embryo development
88951773|NCT01950104|Experimental|Blastocyst biopsy|Embryo biopsy is applied at the blastocyst stage of the embryo development (day 5 or 6)
88951774|NCT01950117|Active Comparator|Conventional polypectomy|Colorectal polyps from 10 mm to 25 mm was found. Submucosal injection of saline solution before removal was not performed for polypectomy. The snare used for polypectomy was a dual loop wire snare with a loop size of 33/16 mm (SN-3316LX, Medico's Hirata Inc., Osaka, Japan). An ERBE ICC200 (Amco, Tokyo, Japan) was used in the Endocut mode with the effect 3 current set at output limit 120W and forced coagulation current set at output limit 35W for conventional polypectomy. Prophylactic clipping after polyp removal was routinely performed.
89203120|NCT00800046|Experimental|AccuCinch® Ventriculoplasty System|Patients meeting the enrollment criteria will be treated with the AccuCinch® Ventriculoplasty System.
89481732|NCT03108105|Experimental|AOS-C2001-B|A new 2-piece appliance composed with 2 parts: a base plate and an ostomy collection special pouch (1 base plate for 2 or 3 days and 1 to 4 collection special pouch per day)
89481733|NCT05036954||no arm|
89481734|NCT03294603|Experimental|[14C]-CC-220 solution|A single oral dose of 1 mg [14C]-CC-220 solution, containing approximately 1.4 μCi of radioactivity, will be administered on Day 1 under fasted conditions.
89481735|NCT02101723|Active Comparator|Micronutrient Powder (MNP) + Zn/Fe|Micronutrient Powder with 5 mg Zn and 12 mg Fe
89481736|NCT02101723|Active Comparator|MNP + Zn|Micronutrient Powder with 5 mg Zn
89481737|NCT02101723|Placebo Comparator|Control|Placebo sachets without micronutrients
89481738|NCT05061836|Experimental|Dextrose0|Acetate Ringer's solution
89481739|NCT05061836|Experimental|Dextrose1|1.25%dextrose equivalence
89481740|NCT05061836|Experimental|Dextrose2|2.5%dextrose equivalence
89481741|NCT05061836|Active Comparator|Dextrose5|5%dextrose
89481742|NCT02106871|Placebo Comparator|Placebo|Placebo daily for 4 weeks
89481743|NCT02106871|Active Comparator|Sildenafil|50mg sildenafil daily for 4 weeks
89481744|NCT04488783|Experimental|Glioblastoma patients|newly diagnosed GB who underwent at least partial resection of the tumor surgically
88951775|NCT01950117|Experimental|Endoscopic mucosal resection|Colorectal polyp from 10 mm to 25 mm was found. Submucosal injection of saline solution before removal was performed for EMR. The snare used for EMR was a dual loop wire snare with a loop size of 33/16 mm (SN-3316LX, Medico's Hirata Inc., Osaka, Japan). An ERBE ICC200 (Amco, Tokyo, Japan) was used in the Endocut mode with the effect 3 current set at output limit 120W and forced coagulation current set at output limit 35W for EMR. Prophylactic clipping after polyp removal was routinely performed.
88951776|NCT01950143|Active Comparator|Standard broccoli soup|26 volunteers
88951777|NCT01950143|Experimental|Beneforte broccoli soup|26 volunteers
88951778|NCT01950143|Experimental|Beneforte extra broccoli soup|26 volunteers
88951779|NCT01950156|Experimental|Vaccine|HLA-A*2402restricted URLC10, CDCA1, and KIF20A peptides with adjuvant
88951780|NCT01950182|Active Comparator|Palliative chemotherapy|Chemotherapy combined with trastuzumab. Chemotherapy could use the following drugs such as capecitabine , Vinorelbine, or Gemcitabine.
88951781|NCT01950182|Experimental|Palliative endocrine therapy|Endocrine therapy combined with trastuzumab. Endocrine therapy could use tamoxifen or aromatase inhibitors including anastrozole, letrozole, or exemestane.
89203121|NCT04002544|Active Comparator|NTG group|In this group, nitroglycerin patch will be applied near the radial artery pulsation covered with a gauze.
89203122|NCT04002544|Placebo Comparator|Control group|In this group, no patch as applied to the patient. However, a gauze will be applied to confirm blinding
89203123|NCT04829214|Experimental|OTO-313|
89203124|NCT04829214|Placebo Comparator|Placebo|
89481745|NCT05036564|Experimental|Study population - PCNSL|"Patients (pts) with clinical and radiological suspicion of PCNSL or with confirmed diagnosis of PCNSL will be enrolled to the protocol. They will represent the Study population"
89481746|NCT05036564|Other|Control|"Pts with suspicion of secondary CNS lymphoma, that includes subjects with DLBCL and involvement of the CNS at presentation in association with systemic disease, or subjects with systemic DLBCL and CNS relapse during or after primary therapy.~Pts with histological diagnosis of systemic DLBCL at high risk of CNS relapse according to Institutional guidelines and patients with histological diagnosis of systemic high grade B cell lymphoma, according to 2017 WHO classification;~pts affected by neurological disorders that are usually differential diagnosis of PCNSL (i.e. neurodegenerative and neuroinflammatory disorders, toxic or infective encephalitis, other primary CNS tumors)."
89481747|NCT02251015|Active Comparator|therapeutic exercises|13 as control group - The control group got only orientation related to therapeutic exercises.The orientation for therapeutic exercises seek to correctly position the jaw in the resting position. Maxillary teeth approximately 2mm away from the mandibular teeth and the tip of the tongue accommodated on top of the incisive papilla on the hard palate, beyond an exercise that consisted of repeated opening and closing movements paying close attention to the position of the tongue, the point of which being accommodated on the incisive papilla during the exercises. The patient was instructed to perform 15 repetitions 3 times a day.
89481748|NCT02251015|Experimental|occlusal plate group|36 getting occlusal splints - the splinted group was subjects that used occlusal plate under the occlusal stability criteria. The patients also received therapeutic exercises too. The plate group arm, the patients used the occlusal splints for all night plus 4 hours during the day and they made therapeutic exercises 15 repetitions 3 times a day.
89481749|NCT04371471||Patient with COVID-19|Patient with clinical signs of CoV-2-SARS infection and signs of severity
89481750|NCT05041244|Experimental|Interventional arm|NPWT will be delivered through devices (ActiVac and InfoVac) according to FDA protocol in conjunction with the polyurethane foams. Dressing changed will be on a weekly basis.
89481751|NCT05041244|Other|Control|Standard of care Participants will be given the standard care provided in specialist foot care clinics or in-patients.
89481752|NCT02251093|Experimental|Lcr Regenerans|
89481753|NCT02251093|Placebo Comparator|Placebo|
89481754|NCT03288597||A: advanced and metastatic neuroendocrine tumors|Advanced and metastatic neuroendocrine tumors receive syestematic treatment
89481755|NCT03288597||A: advanced and metastatic neuroendocrine carcinomas|Advanced and metastatic neuroendocrine carcinomas receive syestematic treatment
89481756|NCT05040854||Healthy Subjects|Blood donors
89481757|NCT05040854||IBD patients - under biological therapy|Patients with IBD followed up in consultation on biological therapy with anti-TNF, anti-integrin α₄β₇ or anti-interleukin 12-23.
89481758|NCT05040854||IBD patients - naive|Patients newly diagnosed with IBD and need for biological therapy with anti-TNF, anti-integrin α₄β₇ or anti-interleukin 12-23,
89481759|NCT02407990|Experimental|BGB-A317 Phase 1A|
89481760|NCT02407990|Experimental|BGB-A317 Phase 1B|
89481761|NCT02105155|Experimental|Conversion at day 7 ± 3|Conversion from Prograf to Advagraf at D7 ± 3
89481762|NCT02105155|Active Comparator|Conversion at day 90±5|Conversion from Prograf to Advagraf at 90±5
89481763|NCT03294525||Escitalopram-for MDD|Eligible patients were assigned to escitalopram treatment based on investigators' clinical practice.
89481764|NCT03294525||Duloxetine-for MDD|Eligible patients were assigned to duloxetine treatment based on investigators' clinical practice.
89481765|NCT03294525||Mirtazepine-for MDD|Eligible patients were assigned to mirtazepine treatment based on investigators' clinical practice.
89481766|NCT03294525||other antidepressant-for MDD|Eligible patients were assigned to other antidepressant treatment (including sertraline, paroxetine, fluoxetine, venlafaxine, etc) based on investigators' clinical practice.
89481767|NCT05040620|No Intervention|Placebo|controlling group who will receive traditional orthodontic treatment.
89481768|NCT05040620|Experimental|Olive Oil|experimental group who will receive the local application of Olive Oil five times daily after teeth brushing
89481769|NCT02106949|Experimental|SMS|The patients of the test group receive a first SMS 48 hours after their discharge from the hospital then a total of 10 messages distributed over six months: 48 hours, S1, S2, M1, M2, M3, M4, M5, M6 and M13.
89481770|NCT02106949|No Intervention|Without SMS|The patients of the group benefit from the usual care.
89481771|NCT03294447|Experimental|Fall Prevention Intervention by OT|Fall prevention interventions implemented by an OT in a geriatric primary care setting for a client immediately following the provider visit within the office.
89481772|NCT05036174|Experimental|Diphenhydramine|Topical 5% diphenhydramine ointment applied at knee joint at a dose of 2 g three times a day for 7 days
89481773|NCT05036174|Placebo Comparator|Placebo|Vehicle (placebo) ointment applied at knee joint at a dose of 2 g three times a day for 7 days
89481774|NCT02107027|Active Comparator|nMARQ catheter (circular catheter)|Group treated with the circular ablation catheter for atrial fibrillation ablation
89481775|NCT02107027|Active Comparator|Navistar catheter (conventional catheter)|Group treated with the conventional ablation catheter for atrial fibrillation ablation
89481776|NCT05235087|Experimental|Bovine Atelocollagen Skin Sensitization Test|Volunteer cohort tested for hypersensitivity towards intradermal injection of bovine atelocollagen.
89481777|NCT04469426|Experimental|Informational online app group|Participants will have access to an interactive online peer support app developed by the research team.
89481778|NCT04469426|No Intervention|Booklet only|Participants will only have access to the educational booklet on LARS developed by the colorectal research team.
89481779|NCT02101801|Other|freshwater|receives vegetables from freshwater farms
88951782|NCT01950195|Experimental|Brain|"A cohort of six (6) patients will be treated at Dosing Schedule 1. If the observed dose limiting toxicity (DLT) rate is less ≤33%, the dose cohort will be expended to a total of 15 patients. Brain and spine metastases will be evaluated as two separate cohorts.~If the first schedule produces DLTs in >33% of patients, the Second Dosing schedule will be implemented. If the second dosing schedule produces DLTs in >33% of patients, the Third Dosing schedule will be implemented.~After 6 patients were enrolled in a cohort, their safety and toxicity will be continuously monitored till 12 weeks (3 months) after the initial dose of Ipilimumab is given for evaluating dose-limiting toxicities."
88951783|NCT01950195|Experimental|Spine|"A cohort of six (6) patients will be treated at Dosing Schedule 1. If the observed dose limiting toxicity (DLT) rate is less ≤33%, the dose cohort will be expended to a total of 15 patients. Brain and spine metastases will be evaluated as two separate cohorts.~If the first schedule produces DLTs in >33% of patients, the Second Dosing schedule will be implemented. If the second dosing schedule produces DLTs in >33% of patients, the Third Dosing schedule will be implemented.~After 6 patients were enrolled in a cohort, their safety and toxicity will be continuously monitored till 12 weeks (3 months) after the initial dose of Ipilimumab is given for evaluating dose-limiting toxicities."
88951784|NCT01950208||knee pain|patients suffering from knee injury
88951785|NCT01950221|Experimental|POMx|POMx is a 1,000 milligram capsule of natural pomegranate polyphenol extract.
88951786|NCT01950221|Placebo Comparator|Placebo|Composition of the Drug Placebo Component/Function/Weight/Percentage of Fill Weight = Cellulose/Bulk agent/658 mg/64.5% Caramel/Colorant/79mg/7.8% Beet root/Flavor Ingredient/263mg/25.8% Magnesium stearate/USP Lubricant/10mg/1.0% Silica Dioxide/FCC Glidant/10mg/1.0% Total = 1020 mg/100% The method of manufacture of the placebo is identical to that of the drug product, except cellulose, caramel, and beet root are added in place of the active ingredient.
89481780|NCT02101801|Active Comparator|recycled wastewater|receives vegetables from farms using recycled wastewater irrigation
89481781|NCT03283059|Experimental|Octohydroaminoacridine Succinate Tablet|Octohydroaminoacridine Succinate Tablet 4mg P.O. tid
89481782|NCT03283059|Active Comparator|Aricept|Aricept 5mg/day P.O.
89481783|NCT03283059|Placebo Comparator|Placebo|Placebo P.O. tid
88951787|NCT01950247|Experimental|Injectafer|2 doses at 15 mg/kg for a maximum single dose of 750 mg given 7 days apart for a total of up to 1500 mg.
89481784|NCT02101879||Breast cancer Her2 positive|Trastuzumab & Pertuzumab & Taxanes
89481785|NCT05060900|Experimental|Hand and Wrist Ligament Reconstruction with Allograft Ligament|Participants will undergo surgery for hand and wrist ligament reconstruction using allograft ligament.
89481786|NCT02105233|Experimental|BMG|brain mimicking fluid
89481787|NCT03288441||antiplatelet only|"Patients receiving antiplatelet medication, but not anticoagulation. Antiplatelet drugs include any class, dose or duration of any platelet aggregation inhibitor.~This refers to the antithrombotic regimen when the current thrombocytopenia, or risk thereof (i.e. predicted), was first identified (even if the treatment is subsequently stopped)"
89481788|NCT03288441||anticoagulant-based|"Patients receiving only anticoagulants or both anticoagulant and antiplatelet medication combined. This includes any class, dose or duration of any antiplatelet or anticoagulant drug.~This refers to the antithrombotic regimen when the current thrombocytopenia, or risk thereof (i.e. predicted), was first identified (even if the treatment is subsequently stopped)"
89481789|NCT05060588|Experimental|Sacubitril/Valsartan|Sacubitril/Valsartan 24/26 mg once every 12 hours for 6 months
89481790|NCT05060588|Active Comparator|Valsartan|1 tablet of Valsartan every 24 hours for 6 months
89481791|NCT03554863|Active Comparator|Facial mask|
89481792|NCT03554863|Experimental|Optiflow anesthesia|
89481793|NCT02101957|Experimental|RP103|RP103 capsule, 16 capsules per day
88951788|NCT01950247|Active Comparator|IV Iron Standard of Care (SOC)|At a dose and administration regimen as determined by the study site investigator
88951789|NCT01950312|Experimental|gevokizumab|Solution for subcutaneous injection
89481794|NCT02101957|Placebo Comparator|placebo|placebo capsule, 16 capsules per day
89481795|NCT03282903||Crohn's disease patients|1550 Crohn's disease patients who are symptomatically controlled.
89481796|NCT03282903||Ulcerative Colitis patients|1550 Ulcerative Colitis patients who are symptomatically controlled.
89481797|NCT02107183|Experimental|Nasal high-flow oxygen therapy|High-flow, fully humidified oxygen delivered through nasal cannula (Optiflow, Fisher & Paykel Healthcare) after extubation up to ICU discharge
89481798|NCT02107183|Active Comparator|Venturi mask oxygen therapy|Oxygen delivered through standard Venturi mask after extubation up to ICU discharge
89481799|NCT03294369||Cohort of the study|A sample from the general population aged 18 years or older, randomly selected from a database of sanitary cards stratified by age and gender.
89481800|NCT02105311|Experimental|Selective laser trabeculoplasty|Treating with the selective laser trabeculoplasty
89481801|NCT02105311|Active Comparator|Travoprost|Using eye drop: travoprost
89481802|NCT03294291|Active Comparator|Quadratus Lumborum block group|After preoxygenation for three minutes, anesthesia would be induced with 8% sevoflurane inhalation in 50% oxygen and % 50 air ; 1ug/kg fentanyl and 3 mg/kg propofol is administered intravenously. Then laryngeal mask is inserted when conditions are satisfactory. Under ultrasound guidance a 22 Gauge, Pajunk Sonoplex(medical Germany) needle will be used for both techniques. Under ultrasound 0.7 ml/kg bupivacaine 0.25 % injected unilaterally at the posterior border of the quadratus lumborum muscle.
89481803|NCT03294291|Active Comparator|Caudal block|After preoxygenation for three minutes, anesthesia would be induced with 8% sevoflurane inhalation in 50% oxygen and % 50 air ; 1ug/kg fentanyl and 3 mg/kg propofol is administered intravenously. Then laryngeal mask is inserted when conditions are satisfactory caudal block wil performe with bupivacaine 0.7 ml/kg as 0.25%.
89481804|NCT05040074|Experimental|SQ-Kyrin TMVr Feasibility Study|Experimental group is allocated to use the transcatheter edge-to-edge valve repair system of Shanghai Shenqi Medical Technology Co., Ltd.
89481805|NCT05039762|Active Comparator|Extracorporeal anastomosis|Laparoscopic right hemicolectomy with Extracorporeal anastomosis in patients with colon cancer.
88951790|NCT01950325|Experimental|Group 1|1mg/kg IV
88951791|NCT01950325|Experimental|Group 2 or Group 3|5 mg/kg IV (Group 2) or 5 mg/kg SC (Group 3)[only portion of the study that is randomized]
88951792|NCT01950325|Experimental|Group 4|20 mg/kg IV
88951793|NCT01950325|Experimental|Group 5|40 mg/kg IV
88951794|NCT01950338|Experimental|Dry needling group|The experimental group will receive a single session of DDN with disposable stainless steel needles (0.3mm x 50mm) that will be inserted into the skin over taut bands of the gastrocnemius and tibialis anterior muscles.
88951795|NCT01950338|No Intervention|Control group|The control group will not receive any intervention.
88951796|NCT01950416|Experimental|Ticagrelor|Ticagrelor 180mg loading dose (LD), followed by a 90mg x2 maintenance dose (MD) starting 12±6 hours post LD, until discharge.
88951797|NCT01950416|Active Comparator|Clopidogrel|Clopidogrel 600mg loading dose (LD), followed by a 150mg once daily maintenance dose (MD) starting 12±6 hours post LD, until discharge.
89481806|NCT05039762|Experimental|Intracorporeal anastomosis|Laparoscopic right hemicolectomy with Intracorporeal anastomosis in patients with colon cancer.
89481807|NCT02102035|Other|Dorsal digital island flap|The flap is used to cover the soft-tissue defects of the fingers.
89481808|NCT03294057|Experimental|ICT programs + Tele-coaching programs|ICT programs that include health information learning by disease and self-management based on Smart Management Strategy for Health (SMASH) are provided. And a trained nurse provides tele-coaching programs to subjects. After that, subjects will conduct self-management health care and tele-coaching programs for 12 weeks. After 3 months, they finish self-management ICT + coaching programs, and then they fill out the questionnaire.
88951798|NCT01950455|Experimental|NAV5001|
88951799|NCT01950468|Experimental|NAV5001|
89203125|NCT00802308|Experimental|Treatment A|Single dose administration of Egalet® morphine with alcohol
89203126|NCT00802308|Experimental|Treatment B|Single dose administration of Egalet® morphine with alcohol
88951800|NCT01950468|Active Comparator|DaTscan|
88951801|NCT01950481|Experimental|Normal Hepatic Function|Subjects with normal hepatic function
89203127|NCT00802308|Experimental|Treatment C|Single dose administration of Egalet® morphine with alcohol
89203128|NCT00802308|Placebo Comparator|Treatment D|Single dose administration of Egalet® morphine with water
89203129|NCT00562965|Experimental|A|Subjects will receive rituximab intravenously at a dose level of 375 mg/m² on day 1 of each cycle followed by inotuzumab ozogamicin administered intravenously at a dose level of 1.8 mg/m2 on day 2. The sequence will be repeated every 28 days.
89203130|NCT00562965|Active Comparator|B|Subjects will receive the investigator's choice from the following rituximab-containing regimens: R-CVP or R-FND. The investigator's choice of therapy will be administered every 21 days. Dosing for R-CVP will be intravenous rituximab at a dose of 375 mg/m2 on day 1, intravenous cyclophosphamide at a dose of 750 mg/m2 on day 1, intravenous vincristine at a dose of 1.4 mg/m2 (not to exceed 2 mg) on day 1, and oral prednisone/prednisolone at a dose of 40 mg/m2 on days 1 through 5. Dosing for R-FND will be as follows: rituximab 375 mg/m2 intravenous on day 1, mitoxantrone 10 mg/m2 intravenous on day 2, fludarabine 25 mg/m2 intravenous on days 2 through 4 and oral dexamethasone 20 mg/day on days 1-5.
89203131|NCT05358496||NAFLD cohort|
89203132|NCT05358496||Validation cohort|
89203133|NCT00802542||1|Adult patients with mild or moderate essential hypertension who do not tolerate ACE inhibitors because of cough, already treated with Atacand 8mg for 2-4 weeks, who have not reached the blood pressure treatment goal and the doctor has decided to increase the Atacand dose to 16mg as per SmPC.
89203134|NCT05407090|Experimental|Probiotic|Patients will take 4 capsules of a multi-strain probiotic preparation daily. Product characteristics: 1 capsule of the preparation contains ≥2.5 x 10^9 CFU / g of live bacteria (Bifidobacterium lactis W52, Lactobacillus brevis W63, Lactobacillus casei W56, Lactococcus lactis W19, Lactococcus lactis W58, Lactobacillus acidophilus W37, Bifidobacterium bifidillum W23)
89203135|NCT05407090|Placebo Comparator|Placebo|Patients will take 4 capsules of a placebo preparation daily.
89203136|NCT05406934||healthy group|the healthy group, not diagnosed IBD
89203137|NCT05406934||IBD patients controlled by conventional treatment|controlled by conventional treatment and divided to UC group and Crohns group
89481809|NCT03294057|Experimental|ICT programs|ICT programs that include health information learning by disease and self-management based on Smart Management Strategy for Health (SMASH) are provided. After that, subjects will conduct self-management health care for 12 weeks. After 3 months, they finish self-management ICT programs, and then they fill out the questionnaire.
88951802|NCT01950481|Experimental|Mild Hepatic Impairment|Subjects with mild hepatic impairment
89203138|NCT05406934||uncontrolled IBD patients on biological's treatment|divided to uc received biological and Crohns received biolgical
89203139|NCT00800124|No Intervention|1|Cemented hemiprosthesis
89481810|NCT03294057|Active Comparator|A book about chronic disease|Subjects in the group get a book about chronic disease for patients. After 3 months, they finish reading the materials, they fill out the questionnaire.
89481811|NCT02105389|Experimental|Individualized Yoga Intervention|Individualized Yoga Intervention sessions will be administered by a trained yoga instructor three times weekly (or up to a maximum of five times per week) for three consecutive weeks. There will be a common structure for all sessions that will include relaxation and breathing exercises as well as a series of poses focused on strengthening, flexibility, and balance. There will be low, moderate and high intensity regimens prescribed depending on the wishes and abilities of the child and parent and the judgment of the yoga instructor.
88951803|NCT01950481|Experimental|Moderate Hepatic Impairment|Subjects with moderate hepatic impairment
88951804|NCT01950481|Experimental|Severe Hepatic Impairment|Subjects with severe hepatic impairment
88951805|NCT01950494|Experimental|fiteBac Hand Sanitizer|Blinded fitBac Hand sanitizer
88951806|NCT01950494|Placebo Comparator|Blinded emollient therapy|Blinded emollient therapy
89203140|NCT00800124|Active Comparator|2|Non-cemented hemiprosthesis
89203141|NCT00940329|Active Comparator|Treatment A|
89203142|NCT00940329|Active Comparator|Treatment B|
89203143|NCT00794898|Experimental|Arm 1|Remicade in the treatment of patients with active RA despite treatment with MTX.
89203144|NCT00934557|Experimental|Good prognosis/mismatched donor/BM|
89203145|NCT00934557|Experimental|Good prognosis/mismatched donor/PB|
89203146|NCT00934557|Experimental|Poor prognosis/matched donor/BM|
89203147|NCT00934557|Experimental|Poor prognosis/matched donor/PB|
89203148|NCT00934557|Experimental|Poor prognosis/mismatched donor/BM|
89203149|NCT00934557|Experimental|Poor prognosis/mismatched donor/PB|
89203150|NCT00934557|Experimental|Good prognosis/matched donor/BM|
89203151|NCT00934557|Experimental|Good prognosis/matched donor/PB|
89203152|NCT05357092|Experimental|Intervention group|"Patients treated with clear aligners to bring cleft segments closer previous to primary lip surgery.~An average of 15 aligners will be needed although it depends on the cleft."
89203153|NCT05357092|No Intervention|Gold Standard|The reference therapeutic action (no pre-surgical orthopedic intervention previous to primary lip surgery)
89203154|NCT00800280|Experimental|Single dose PD 0332334|
89203155|NCT00800280|Experimental|Single dose PD 0332334 with steady-state cimetidine|
89203156|NCT04014153||Group 1 (5-year prognosis)|
89203157|NCT04014153||Group 2 (1-year prognosis)|
89203158|NCT04996576|Active Comparator|intranasal injection approach sphinopalatine ganglion block|Then in one nasal side (intranasal injection group) will be chosen randomly (right or left) by closed envelopes method 2 ml Lidocaine with Epinephrine 1/200000 will be injected posterior to meatus of middle concha to block terminal nerve branches of sphinopalatine ganglia and 2 ml saline will be injected in the same place in the other nasal side (to prevent surgeon expectation of intra nasal group by seeing injection site in one side only) by surgeon assistant who will be blind for the injection content.
89203159|NCT04996576|Active Comparator|infrazygomatic approach sphinopalatine ganglion block|"In the side saline only given by the intranasal injection A lateral fluoroscopic view of the face will be obtained with the C-arm by superimposing the mandibular rami on top of each other spinal needle with a slightly bent tip is inserted with lateral fluoroscopic guidance. superiorly and medially toward the sphinopalatine fossa.~(AP) view intermittently obtained to check the depth 0.2 mL of contrast material will be injected to rule out intravascular spread and confirm spread of the dye within the sphinopalatine fossa .Local anesthetic, such as 2 mL of 1% lidocaine will be slowly injected"
89203160|NCT00800358|Experimental|1|Oral Paricalcitol in varying doses
89203161|NCT00800358|Active Comparator|2|Calcitriol
89203162|NCT00934713|Active Comparator|montelukast|montelukast 4 mg once per day for 8 weeks
89203163|NCT00934869||Metacarpal Shaft Fractures|
89203164|NCT00802698|Experimental|Group 1|
89203165|NCT00935025|Experimental|1, AZD1305|
89203166|NCT00935025|Placebo Comparator|2, Placebo|
89203167|NCT00802776|Active Comparator|FLAK|Femtosecond laser assisted keratoplasty
89203168|NCT00802776|Active Comparator|PKP|Penetrating Keratoplasty
89203169|NCT00939861|Experimental|1|laparoscopy
89203170|NCT00939861|Experimental|2|laparotomy
89203171|NCT00802932||Partial Breast Radiation|1. Patients receiving Partial breast radiation
89203172|NCT00802932||Whole Breast Radiation|2. Patients receiving whole breast radiation
89203173|NCT01057849|Experimental|Risperidone, Intensive|risperidone and intensive psychosocial intervention
89203174|NCT01057849|Active Comparator|risperidone, basic|risperidone and basic psychosocial support
89203175|NCT01057849|Experimental|olanzapine, intensive|olanzapine and intensive psychosocial intervention
89203176|NCT01057849|Active Comparator|olanzapine, basic|olanzapine and basic psychosocial support
89203177|NCT01057849|Experimental|aripiprazole, intensive|aripiprazole and intensive psychosocial intervention
89203178|NCT01057849|Active Comparator|aripiprazole, basiv|aripiprazole and basic psychosocial support
89203179|NCT00794976|Experimental|1|Dexamethasone Iontophoretic Patch (low dose)
89203180|NCT00794976|Experimental|2|Dexamethasone Iontophoretic Patch (high dose)
89203181|NCT00794976|Experimental|3|Dexamethasone Passive Patch
89203182|NCT00794976|Placebo Comparator|4|Placebo Patch
89203183|NCT00939939|Experimental|sitagliptin|
89203184|NCT00939939|Active Comparator|glimepirid|
89203185|NCT00537082|Experimental|FTY720 0.5 mg|FTY720
89481812|NCT02459925|Active Comparator|CBT- Mental Health Program|Cognitive Behavioral Therapy. Manualized Stress Management class; brief individual behavioral counseling.
89203186|NCT00537082|Experimental|FTY720 1.25 mg|FTY720
89203187|NCT00537082|Placebo Comparator|Placebo|
89203188|NCT03828487|Experimental|Neonatal Test group|Subjects will receive a Masimo O3 Neonatal sensors as well as a 510(k) cleared sensor.
89203189|NCT00795054||allogeneic stem cell recipients|Pediatric and adult allogeneic stem cell transplant recipients and their care givers.
89203190|NCT04012983||diabetic patients with periodontitis|
89203191|NCT04012983||periodontitis patients|
89481813|NCT02459925|Active Comparator|MOMS GROW|MOMS GROW (Generating Real Opportunities for Work) Teaching, coaching, and supportive services for participants as they navigate their journeys to sustainable employment that pays a family-supporting wage.
89203192|NCT04012983||healthy control|
89531473|NCT06065969|Sham Comparator|Sham Vascular photobiomodulation|The same procedures described for vascular photobiomodulation will be followed; however, the equipment will emit only the sound signal, exactly like the equipment used in vascular photobiomodulation group, without emitting laser light
89203193|NCT00805662|Experimental|Oxytocin|Intranasal oxytocin during IUI
89203194|NCT03988153|Experimental|Probiotic Milk Formula (PMF)|Twenty subjects should drink 200 mL of PMF (30 gm mixed with 200 mL of water) before breakfast and dinner (2 times/day) for 10 weeks
89203195|NCT03988153|Placebo Comparator|Skimmed Milk Formula|Twenty subjects should drink 200 mL of skimmed milk drink (30 gm mixed with 200 mL of water) before breakfast and dinner (2 times/day) for 10 weeks
89203196|NCT04014309|Experimental|Supportive and survivorship care program|Routine distress screening will be conducted using the Distress Thermometer (DT) and an accompanying problem list. Participants will complete the screening tool before their consults with oncologists and the results will be stored in their medical records. During the consult, oncologists will review the DT scores and problem list with each participant to provide the corresponding educational materials, advice or referrals. Highly distressed participants may be referred by oncologists to the supportive care nurses (SCN) for further triage and review.
89203197|NCT04014309|Placebo Comparator|Usual care|No routine distress screening will be performed.
89203198|NCT04978012|Experimental|Combination of Fluzoparib and Camrelizumab|Fluzoparib,150mg bid po, d1-21, q3w Camrelizumab 200mg iv, d1, q3w
89203199|NCT00803088|Experimental|1|Treatment of airways with the Alair System
89203200|NCT01061203|Active Comparator|Grazax|Grazax tablet 75.000 SQ-T. One tablet per day for administration under the tongue.
89203201|NCT01061203|Placebo Comparator|Tablet with no active grass|Tablet with no active grass component. One tablet per day administered under the tongue.
89203202|NCT00803166||Cohort Group 1|Subjects number 1 to 30
89203203|NCT00803166||Cohort Group 2|Subjects number 31 to 60
89203204|NCT00935181|Experimental|exercise training program|The exercise training program consisted of three 90-minute sessions per week for eight weeks. Each session consisted of a stretching exercise, resistance that patients started at 70% of the initial one-repetition maximum (1RM: the maximum load which can be moved only once over the full range of motion without compensatory movements) in the first week (3x8 repetitions). Every week the load was increased by 5% of the 1RM, and endurance training (treadmill walking speed was set at 60% of the average speed obtained from the 6MWT (6MWTpeak) for 10 mins in the first week and was increased to 20 mins in week 8
89203205|NCT00324961|Experimental|Single arm open label adefovir dipivoxil|adefovir dipivoxil once daily 10 mg orally
89203206|NCT04002232|Experimental|CPP-ACP-NaF|Dental varnish that contains calcium phosphoprotein stabilized amorphous calcium phosphate and sodium fluoride (CPP-ACP-NaF) is applied to the teeth with orthodontic brackets on one side of the mouth immediately after the teeth have received the bracket.
89481814|NCT03095534|Experimental|3-Step Workout for Life|Participants will exercise at the moderate intensity three times a week for 10 weeks. The total of 30 workout sessions will consist of 18 sessions of group single-joint resistance exercise, 6 sessions of one-on-one multiple-joint resistance exercise, and 6 sessions of one-on-one activities of daily living exercise. During the resistance exercise sessions, participants will use resistance tubing to strengthen major muscle groups of the upper extremity and lower extremity. During the activities of daily living exercise, participants will practice daily tasks around the home. The community fitness staff will modify the task demand to increase the physical challenge of the task to each participant, for example, increasing travel distance.
89481815|NCT03554395|Experimental|Cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
89481816|NCT03554395|Active Comparator|Cryotherapy & Activated CIK and bispecific antibody|the maximum tumor length≥2cm, use cryotherapy. the maximum tumor length<2 cm,Biological/Vaccine:Activated CIK and bispecific antibody CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
89481817|NCT03554395|No Intervention|Conventional therapy|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
89481818|NCT03282825|Experimental|Decitabine|"A standard 3+3 trial design will be used for Decitabine dose escalation cohorts.~The number of cohorts is three. The subjects will be administered Decitabine on every seven days in a 28day cycle and Decitabine is sequential administered with Paclitaxel.~Cohort 1: Decitabine 15mg/m2, Cohort 2: Decitabine 20mg/m2, Cohort 3: Decitabine 25mg/m2"
89481819|NCT02105623|Active Comparator|Standard Therapy|Risk factor control Diet Exercise
89481820|NCT02105623|Experimental|Rosuvastatin therapy|Risk factor control Rosuvastatin
89481821|NCT05026190|Other|azoospermic patients|
89481822|NCT02107417|Experimental|Experimental Group (EG) - TENS active|Experimental Group (EG) - TENS active: who will receive the application of active TENS. The participants of these group will receive TENS active within the following parameters: VF mode TENS with a variable frequency between 7 Hz and 65 Hz. It has a pulse width of 200 µs, this is the highest tolerable intensity while still remaining comfortable for the patient. It has an application time of 60 minutes with the highest tolerable intensity, while still remaining comfortable for the patient.
89481823|NCT02107417|Sham Comparator|Control Group (CG)- Placebo TENS|Control Group (CG) who will be administering the placebo TENS.The participants of these group will receive TENS within the following parameters: VF mode TENS with a variable frequency between 7 Hz and 65 Hz. It has a pulse width of 200 µs, . It has an application time of 60 minutes The TENS-placebo will be applied where no current will be emitted.
89481824|NCT05039918|Experimental|Intervention|"Following randomisation, infants will receive CT-optimal stimulation (gentle stroking) at a velocity of 3cm/s over the area which the infant will be stroked (10cm) for a duration of 10s applied proximally to the pain site prior to the heel prick. Location of the heel prick will be based on clinical judgement. There will be an inter-stimulus interval of approximately 1 second between the end of the touch and heel prick, and touch stimulation will be applied to the lower leg ipsilateral to the heel receiving the noxious stimuli. All infants will have cardio-respiratory monitoring during the intervention. All other environmental factors will be as standard care (e.g., temperature, lighting and sounds).~The heel prick will be performed by a member of the infants designated clinical team who have performed the procedures in a standardised manner according to the institutional and unit policy."
89481825|NCT05039918|No Intervention|Control|Infants who are randomised to the control group will receive standard care consistent with neonatal policy. The infant will undergo a heel prick in the incubator or crib in an identical fashion to the infants in the intervention group.
89481826|NCT05039606|Experimental|the treatment group|Nedplatin combined with intensive radiotherapy group
89481827|NCT05039606|Active Comparator|the control group|Cisplatin was combined with the IMRT group
89531474|NCT06065956|Experimental|Morphine group|Half of participants will be comprising of morphine group
89531475|NCT06065956|Experimental|Esmolol group|Half of participants will be comprising of esmolol group
89531476|NCT06065930||Obese insulin-sensitive subjects (Ob-IS)|Obese Insulin Sensitive subjects (BMI > 30 kg/m2, fasting insulin < 9.0 mU/l and fasting plasma glucose < 6.1 mmol/l) undergoing subcutaneous microdialysis, needle biopsy, glucose clamp and MRI.
89481828|NCT03288129|Experimental|Perampanel|Perampanel will be administered orally once daily (QD) at bedtime. At the beginning of the Titration Period, oral perampanel will start at a dose of 2 milligrams (mg) QD. Doses of perampanel will then be up titrated in increments of 2 mg at no less than 2-week intervals according to the investigator's judgment. At the 4 mg dose, the investigator will confirm whether further dose escalation is needed based on participant response and tolerability. The investigator may adjust dosing further or leave the participant at 4 mg. The maximum dose is 12 mg. During the 39-week Maintenance Period, participants will continue to receive the perampanel dose level that was administered at the end of the Titration Period.
89481829|NCT05039372|Experimental|training and consultancy|"Patient Description Form, Bristol Rheumatoid Arthritis Fatigue Multidimensional Questionnaire, McGill Pain Scale Short Form, Stanford Health Assessment Questionnaire will be administered to the patients in this group at the first interview. Individual training will be given to the patient in line with the training guide prepared for the rheumatoid arthritis patient, and the guide will be shared after the training. In line with the theory of planned behavior in patients with rheumatoid arthritis, counseling service will be provided by the researcher to the extent of the training plan prepared for symptom management. At the end of the 3rd month, the patients will be interviewed face to face and the Bristol Rheumatoid Arthritis Fatigue Multidimensional Questionnaire, McGill Pain Scale Short Form, Stanford Health Assessment Questionnaire will be administered again."
89481830|NCT05039372|No Intervention|control|"After obtaining written consent from the patients who agreed to participate in the study, the patients included in the control group were asked to continue their rheumatologist follow-up and their normal lives (hospital routine, daily life). Patients in this group will fill out the Patient Description Form, Bristol Rheumatoid Arthritis Fatigue Multidimensional Questionnaire, McGill Pain Scale Short Form, Stanford Health Evaluation Questionnaire at the first interview. After 3 months, data collection tools other than the Patient Identification Form will be applied to the patients and the training guide to be prepared for rheumatoid arthritis patients will be given."
89481831|NCT02107495||CHF-confirmed subjects|Subjects 21 years of age or greater with clinically confirmed heart failure or have presented to the clinical site with signs, symptoms and/or risk factors suggestive of heart failure.
89203207|NCT04002232|Placebo Comparator|Placebo|Dental varnish base that does not contain calcium phosphoprotein stabilized amorphous calcium phosphate and sodium fluoride (CPP-ACP-NaF) is applied to the teeth with orthodontic brackets on one side of the mouth immediately after the teeth have received the bracket.
88951807|NCT01950507|Experimental|Cohort 1|subjects may be on fluconazole or micafungin at study entry or be on no antifungal prophylaxis.
88951808|NCT01950507|Experimental|Cohort 2|subjects are on voriconazole at study entry. Voriconazole will continue throughout days O to 7.
88951809|NCT01950507|Experimental|Cohort 3|subjects are on fluconazole at study entry. Fluconazole will continue throughout days O to 7.
88951810|NCT01950533||Peanut allergic|Subjects allergic to peanuts by oral food challenge
88951811|NCT01950533||Milk allergic|Subjects allergic to milk by oral food challenge
88951812|NCT01950533||Egg allergic|Subjects allergic to egg by oral food challenge
89481832|NCT02107495||Subjects with potentially co-morbidities|non-CHF subjects 21 years or greater, with potentially confounding comorbidities such as diabetes, renal insufficiency, hypertension and chronic obstructive pulmonary disease (COPD).
89481833|NCT02107495||Apparently healthy subjects|Apparently healthy subjects (meeting inclusion criteria) greater than 45 years of age, with no prior history of myocardial infarction (MI), acute coronary syndrome (ACS) congestive heart failure (CHF) or any other cardiac-related disease.
89481834|NCT05039294|Experimental|intervention|provided the educational programs with all contents, and follow up after one month
89481835|NCT05039294|No Intervention|control|received no intervention, but assessed pre-post
89481836|NCT03555253|Experimental|PwMS and their Support Partner|Support Partners will participate in six resilience coaching Program Sessions conducted weekly by a study resilience coach. PwMS will participate in the initial and final coaching Program Sessions with their Support Partners.
89481837|NCT03288051|Active Comparator|Crystalloid group|
89481838|NCT03288051|Active Comparator|Colloid group|
89481839|NCT05035472|Active Comparator|Phenylephrine group|Prophylactic phenylephrine bolus simultaneous with spinal anesthesia
89481840|NCT05035472|Experimental|Norepinephrine group|Prophylactic norepinephrine bolus simultaneous with spinal anesthesia
89481841|NCT02105779|Experimental|Targeted Cognitive Training|40 hours of BFP auditory training
89481842|NCT02105779|Experimental|Social Cognitive Training|40 hours of auditory training and 10 hours social exercises
89481843|NCT02460471|Experimental|palliative radiation therapy|25 Gy in 5 daily fractions
89481844|NCT05035238|Active Comparator|Arm 1|3 μg / 0.5 mL
89481845|NCT05035238|Active Comparator|Arm 2|4,5 μg / 0.5 mL
88951813|NCT01950546|Experimental|Nanosilver fluoride|This product is a solution composed of: 390 mg / ml 9nm silver nanoparticles ;21 mg / ml chitosan ; 22 mg / ml NaF.The cariostatic agent, nanosilver fluoride, was formulated in a similar way to silver diamine fluoride, so that this new formulation contained 5% nanosilver fluoride, while commercial diamine silver fluoride contains 30% silver fluoride. It will be applied once with a microbrush on tooth surfaces to check if it prevents the growth of S. mutans biofilms on dental surfaces.
88951814|NCT01950559||Subjects who are allergic to Soy|Subject allergy to soy is determined by an oral food challenge or history of positive soy food challenge.
88951815|NCT01950598|Active Comparator|Fresh carrier graft for KPro|KPro implanted using fresh cornea, preserved in optisol GS
88951816|NCT01950598|Experimental|Frozen carrier graft for KPro|KPro implanted using frozen cornea, which was supplied as a whole globe cryopreserved at -80°C in gramicidin 0.025 mg/mL and polymyxin B sulfate 10 000 U/mL ophthalmic solution.
88951817|NCT01950611|Experimental|Bortezomib in treatment|
88951818|NCT01950637||Patients with type 2 diabetes mellitus (T2DM)|
88951819|NCT01950637||Healthcare professionals (HCPs)|
88951820|NCT01950650||Patients with diabetes|
88951821|NCT01950650||Physicians|
88951822|NCT01950676|No Intervention|Control|Individuals in the control group will not use the smart phone application
88951823|NCT01950676|Experimental|Intervention|Individuals in the intervention group will use the smart phone application in insulin titration
88951824|NCT01950689|Placebo Comparator|Placebo|Placebo given in parallel with radiotherapy for 6 weeks.
88951825|NCT01950689|Experimental|Nimorazole|Nimorazole given in parallel with radiotherapy for 6 weeks
88951826|NCT01950702|Active Comparator|Lightwand intubation|"After standard total intravenous anesthesia using propofol and remifentanil continuous infusion, traditional lightwand intubation was done by pre-specified anesthesiologist who experienced more than 100 times of lightwand intubation.~Patient's head were fixed at neutral position during all intubation period."
89481846|NCT02105857|No Intervention|Standard care|Patients receiving the standard rehabilitation protocol
89481847|NCT02105857|Experimental|grade A+ knee mobilization|Patients receiving the standard rehabilitation protocol plus grade A+ knee mobilization
89481848|NCT03287973|Active Comparator|Lifestyle modification program group|Patients with apnea-hypopnea index (AHI) ≥ 15/hr on home sleep study will participate in a dietitian-led lifestyle modification program (LMP) for 6 months. Patients will attend dietary consultation weekly in the first 4 months, and then monthly in the following two months.
88951827|NCT01950702|Experimental|Laryngoscope assisted lightwand intubation|After standard total intravenous anesthesia using propofol and remifentanil continuous infusion, lightwand intubation using specific device(Macintosh laryngosope, female:3/Male:4) was done by pre-specified anesthesiologist who experienced more than 100 times of laryngoscope assisted lightwand intubation.
89481849|NCT03287973|Other|CPAP group|Patients randomized into the continuous positive airway pressure (CPAP) group in each arm will be interviewed by the physician on duty and invited to start autoCPAP treatment for 6 months. They will be offered a CPAP education package. Patients will then commence autoCPAP treatment for 6 months at home.
89481850|NCT05026892||moderate to severe|patients with known inflammatory rheumatism, auto-immune or auto-inflammatory diseases (as define in the inclusion criteria) with moderate to severe or severe form of covid-19
89481851|NCT05026892||begining to moderate|Patients with known inflammatory rheumatism, auto-immune or auto-inflammatory diseases (as define in the inclusion criteria) with begnin to moderate or moderate form of covid-19
89481852|NCT02107651||NOAC|Patients admitted for GI bleeding while in treatment with NOAC
89481853|NCT04488939|Experimental|Bilateral treatment|
89481854|NCT05034380|Active Comparator|Lean|males aged 18-30 years with BMI < 25
89481855|NCT05034380|Experimental|Overweight/Obese|males aged 18-30 years with BMI >= 25
89481856|NCT02102191|Active Comparator|cigarette|common cigarette sold in the stores
89481857|NCT02102191|Active Comparator|e-cigarette|e-cigarette (Ovale Elips)
89481858|NCT03287895|Experimental|Intervention - Decision Support|In addition to the regular conversation about CPR that a patient's physician may have with them, participants will be given a two-part intervention. First, the participant will receive a values clarification tool which helps them rate and understand which relevant values are most important to them. There are two forms of this tool, a full and simplified version. All participants in this arm will receive both, in randomized order. The second aspect of the intervention is an educational video about the potential risks and benefits of CPR, which all participants in this arm will receive.
89481859|NCT03287895|No Intervention|Control|Participants in this arm will receive usual care, the regular conversation about CPR that their physician may have with them.
89481860|NCT02105935||Normative study|male and female athletes, ages 8-14.
89481861|NCT02105935||Baseline|male and female athletes, ages 8-18.
89481862|NCT03287739||Single-group study|Assessment of behavioral biometric impairments
89481863|NCT05033834||Group A|People received any registered COVID-19 vaccination
89481864|NCT05033834||Group B|People developed COVID-19 infection after partial or full vaccination with any registered COVID-19 vaccine
89481865|NCT03554239|Other|Voriconazole treatment|Patients who start voriconazole treatment and receive benefits of genotyping
89481866|NCT03095690|Other|Idiopathic Parkinson's Disease patients|High resolution peripheral scanner (HRpQCT).
89481867|NCT02460627|Experimental|Lidocaine adhesive tape|
89481868|NCT02460627|Placebo Comparator|Adhesive tape|
89481869|NCT02107729|Experimental|Needle gauge small|injection needle 23 G
89481870|NCT02107729|Experimental|Needle gauge normal|injection needle 25 G
89481871|NCT02107729|Experimental|Needle gauge large|injection needle 27 G
89481872|NCT05038748||ASD group|80 youths with the clinical diagnosis of ASD according to the DSM-5 diagnostic criteria
89481873|NCT05038748||Sibling group|30 unaffected siblings of ASD youths
89481874|NCT05038748||TD group|40 healthy typical developing(TD) control from cohort established at Department of Psychiatry, National Taiwan University Hospital (NTUH) starting from 2007
89481875|NCT03287661|Experimental|Treatment Condition|An Online 8-week Acceptance-based Behavioural Therapy for chronic pain.
89481876|NCT03287661|No Intervention|Wait-list Control Condition|Wait-list Control group (8-weeks)
89481877|NCT02106013||Low HDL-C|Study participants with HDL-C levels below the 10th percentile (HDL-C ≤32 mg/dL)
89481878|NCT02106013||Intermediate HDL-C|Study participants with HDL-C levels between 40th and 60th percentiles (40≤HDL-C≤67 mg/dL)
89481879|NCT02106013||High HDL-C|Study participants with HDL-C levels above the 90th percentile (HDL-C ≥78mg/dL)
88821627|NCT03222531|Experimental|HCV seropositive viremic (HCV Ab+/NAT+) donor|"HCV seropositive viremic (HCV Ab+/NAT+) donor hearts to HCV seronegative recipients.~Starting post-operative day 1, heart recipients will be treated with 12-week oral course of sofosbuvir/velpatasvir (Epclusa®), a fixed-dose combination of a nucleotide analogue HCV NS5B polymerase inhibitor (sofosbuvir - 400mg) and a NS5A inhibitor (velpatasvir - 100mg).~Intervention: Drug: sofosbuvir/velpatasvir"
88821628|NCT03208868|Active Comparator|Leucine enriched essential amino acid|Patients with cirrhosis that are given a leucine enriched essential amino acid (EEA/LEU) supplement.
89481880|NCT05038670|Active Comparator|PERSONA|Patients undergoing total knee replacement for treatment of primary knee ostearthritis with use of Zimmer Biomet PERSONA system
89481881|NCT05038670|Active Comparator|Journey II|Patients undergoing total knee replacement for treatment of primary knee ostearthritis with use of Smith&Nephew Journey II system
89481882|NCT03293823|Experimental|vision-based speed of processing (VSOP) cognitive training|use the INSIGHT online program (Posit Science), which includes five training paradigms (Eye for detail, Peripheral challenge, Visual sweep, Double decision, Target tracker) that practice processing speed and attention. All exercises share visual components and focus on accuracy and fast reaction times. Participants respond either by identifying what object they see or where they see it on the screen. The training will automatically adjust the difficulty of each task based on the participant's performance, ensuring that the participants always operate near their optimal capacity. The training programs will automatically record the percentage of completion of each game and scores.
89481883|NCT03293823|Active Comparator|active control|The standardized computerized leisure activities program - MLA, including crossword puzzle, Sudoku, etc. will be used
89481884|NCT02102347|Experimental|exercise group|An exercise program will be performed to increase range of motion, improve motor learning and strengthen the muscles of the lower limb. The program will include exercises 2 times a week for four weeks. The first week the exercises will be performed with 2 sets of 15 repetitions and the remaining weeks 3 sets of 15 repetitions for each exercise. To exercise will be performed with the resistance of cinnamon, It will be recommended weight by 70% of one repetition maximum painless assigned individually per patient.
89481885|NCT02102347|Experimental|phototherapy group|And, Phototherapy will be administered with a portable nine-diode cluster. The portable nine-diode cluster will be used overlapping three quadrants of the knee in random sequence: medial quadrant, lateral quadrant and posterior quadrant.with one 905-nm diode (mean power: 1 milliwatt ; peak power: 10 megawatt; spot size: 0.44 cm2), four 875-nm diodes (mean power of each diode: 17.5 milliwatt; spot size: 1 cm2) and four 670-nm diodes (mean power of each diode: 15 mW; spot size: 1 cm2); frequency: 1000 Hz; 300-second irradiation time in each quadrant; total energy: 39.3 Joules per quadrant. Phototherapy will be included in the exercises group.
89481886|NCT02102347|Placebo Comparator|Phototherapy placebo|Phototherapy will be administered with a portable nine-diode cluster. The portable nine-diode cluster will be used overlapping three quadrants of the knee in random sequence: medial quadrant, lateral quadrant and posterior quadrant), with one 905-nm diode (mean power: 0 milliwatt; peak power: 0 watt; spot size: 0.44 cm2), four 875-nm diodes (mean power of each diode: 0 milliwatt; spot size: 1 cm2) and four 670-nm diodes (mean power of each diode: 0 milliwatt; spot size: 1 cm2); frequency: 0 Hz; 300-second irradiation time in each quadrant; total energy: 0 Joules per quadrant. Phototherapy will be included in the exercises group.
89481887|NCT05039060|Active Comparator|Group 1|Group 1: Modified MAC diet (first 3-weeks) followed by conventional diet (second 3-weeks)
89481888|NCT05039060|Placebo Comparator|Group 2|Group 2: Conventional diet (first 3-weeks) followed by modified MAC diet (second 3-weeks)
89481889|NCT03282513|Experimental|Cohort 1A: Mild Hepatic Impairment|"Drug: AG-120 (Ivosidenib)~A single 500 mg oral dose of AG-120 (Ivosidenib) in subjects with mild hepatic impairment(Child-Pugh Score A.)"
89481890|NCT03282513|Active Comparator|Cohort 1B: Healthy Volunteers|"Drug: AG-120 (Ivosidenib)~A single 500 mg oral dose of AG-120 (Ivosidenib) in subjects with normal hepatic function."
89481891|NCT03282513|Experimental|Cohort 2A: Moderate Hepatic Impairment|"Drug: AG-120 (Ivosidenib)~A single 500 mg oral dose of AG-120 (Ivosidenib) in subjects with moderate hepatic impairment (Child-Pugh Score B.)"
89481892|NCT03282513|Active Comparator|Cohort 2B: Healthy Volunteers|"Drug: AG-120 (Ivosidenib)~A single 500 mg oral dose of AG-120 (Ivosidenib) in subjects with normal hepatic function."
89481893|NCT02106091|Experimental|AFM11|IV (intravenous) infusion, dose escalation
89481894|NCT02107807|Experimental|Arm 1: aH5N1 adult|aH5N1 healthy and non-healthy adults
89481895|NCT02107807|Experimental|Arm 2: aH5N1 elderly|aH5N1 healthy and non-healthy elderly
89481896|NCT02107807|Active Comparator|Arm 4: aTIV elderly|aTIV healthy and non-healthy elderly
89481897|NCT02107807|Active Comparator|Arm 3: aTIV adult|aTIV healthy and non-healthy adults
89481898|NCT01673282||Vimpat + Na Channel Blocking AED|Patients prescribed adjunctive lacosamide (LCM) added to one or more baseline Anti-Epileptic Drugs (AEDs) to include at least 1 sodium channel blocking AED.
89481899|NCT01673282||Vimpat + Non-Na Channel Blocking AED|Patients prescribed adjunctive lacosamide (LCM) added to one or more baseline Anti-Epileptic Drugs (AEDs), none of which is a sodium channel blocking AED.
89481900|NCT03554161|Experimental|Tocilizumab for refractory BDU|This study is a self-control study and all the participants will be enrolled in the interventional arm.
89481901|NCT05025254||PD patients|This is an observational study. The PD patient group will consist of participants who self-report that they have a diagnosis of Parkinson's disease
88821629|NCT03208868|Active Comparator|Balanced amino acid supplement|Patients with cirrhosis that are given a balanced amino acid (BAA) supplement.
88951828|NCT01950715|Other|sacral nerve stimulation|A single armed study to evaluate the on the gastro-colic response in IBS patients treated with sacral nerve stimulation
89481902|NCT05025254||Healthy controls|This is an observational study. The healthy control group will consist of participants who self-report that they do not have a diagnosis of Parkinson's disease
89481903|NCT02113735|Experimental|Group 1|H.P. Acthar® Gel , 64 U, 0.8 mL daily
89481904|NCT02113735|Placebo Comparator|Group 2|Placebo, 0.8 mL, daily
89481905|NCT02113735|Experimental|Group 3|H.P. Acthar® Gel , 32 U, 0.4 mL, 2x daily
89481906|NCT02113735|Placebo Comparator|Group 4|Placebo, 0.4 mL, 2x daily
89481907|NCT02113735|Experimental|Group 5|H.P. Acthar® Gel , 16 U, 0.2 mL, 2x daily
89481908|NCT02113735|Placebo Comparator|Group 6|Placebo, 0.2 mL, 2x daily
89481909|NCT02113813|Experimental|ASP8273 Dose Escalation cohort (part 1)|oral
89481910|NCT02113813|Experimental|ASP8273 Response Expansion cohort (part 1)|oral
89481911|NCT02113813|Experimental|ASP8273 and Midazolam RP2D Expansion cohort (part 2)|oral
89481912|NCT02113813|Experimental|Food Effect Fasted cohort (part 2)|oral
89481913|NCT02113813|Experimental|Food Effect Fed cohort (part 2)|oral
89481914|NCT02113813|Experimental|Exon 20 Cohort (part 2)|oral
89481915|NCT03095144||Spinal anesthesia|Lumbar puncture was performed with a midline approach through either the fourth or fifth lumbar space using a 22 or 25 -gauge 4 cm disposable styletted needle. Spinal isobaric Bupivacaine 0.5%, 0.8-1 mg.kg-1 without epinephrine was injected using a 1ml tuberculin syringe.
89481916|NCT03095144||General anesthesia|The General anesthesia is preformed by intravenous Propofol (2-4 mg.kg-1) and Fentanyl (1-2 µg.kg-1) and Rocuronium bromide (0.5mg.kg-1) administration to facilitate endotracheal intubation, assisted by Sellick manoeuvre. Anaesthesia maintenance with Sevoflurane (2-3%) in an air/oxygen mixture, intravenous Fentanyl as required.
89481917|NCT02109991|Experimental|CG-100 device|
89481918|NCT03095222|Active Comparator|Group 1: Daily|Daily ketamine infusions of 5 hours in length. Duration of participation will last 4 days.
89481919|NCT03095222|Active Comparator|Group 2: Continuous|Continuous ketamine infusions (24 hours/day). Duration of participation will last 4 days.
89481920|NCT02113891|Experimental|Eculizumab|Eculizumab will be given in addition to standard immunosuppression regimen (tacrolimus, mycophenalte mofeti, prednisone)
89481921|NCT03095378|Active Comparator|Control|Root treatment with scaling and root planing.
89481922|NCT03095378|Experimental|Citric acid plus tetracycline|Root treatment with 50% citric acid plus 10% tetracycline, pH1, passive application for 90s.
89481923|NCT03095378|Experimental|Antimicrobial photodynamic therapy|Antimicrobial photodynamic therapy with toluidine blue O (100ug/ml - 60s pre-irradiation - pH4) and red laser (660nm, 30 milliwatts, 45 joules per square centimeter, sweeping mode, 90s)
89481924|NCT02107885|Experimental|DS-1971|single ascending dose of 5mg, 10mg, 30mg, 90mg, 250mg, 500mg, 1000mg, 1500mg.
89481925|NCT02107885|Placebo Comparator|placebo|placebo matching each of the DS-1971 dosages.
89481926|NCT05025566||Psychotic disorders|
89481927|NCT05025566||Depressive disorders|
89481928|NCT05025566||Bipolar disorders|
89481929|NCT05025566||Anxiety disorders|
89481930|NCT05025566||Autism spectrum disorders|
89481931|NCT05025566||Eating disorders|
89481932|NCT05025566||Healthy volunteers|
89481933|NCT02113969|Experimental|Vaginal Pessary|Pessary users for at least 12 months
89481934|NCT03003247|Experimental|IDP-120 Gel|IDP-120 Gel is a combination treatment
89481935|NCT03003247|Active Comparator|IDP-120 Component A Gel|IDP-120 Monad Gel of Component A
89481936|NCT03003247|Active Comparator|IDP-120 Component B Gel|IDP-120 Monad Gel of Component B
89481937|NCT03003247|Placebo Comparator|IDP-120 Vehicle Gel|IDP-120 Vehicle Gel
89481938|NCT05038046|Experimental|TCM daycare model|15 patients will be assigned to this arm. The assignment depends on the patients' own will. After diagnosis by nephrology physician, these patients will be distributed to control group by their wills. The intervention is Traditional Chinese Medicine (TCM) daycare model, which provides multiple approaches of traditional Chinese medical treatment, including 5 tones of Chinese music, massage on meridians and collaterals, acupuncture, and patient education. The treatment course is one time a week, for 12 weeks (12 treatments in total). And the model will be provided by a team work clinical care system organized by doctors, nurses, pharmacists and case managers, also provide a comprehensive TCM care system for every visit.
89481939|NCT05038046|No Intervention|Control group|15 patients will be assigned to this arm. The assignment depends on the patients' own will. After diagnosis by nephrology physician, these patients will be distributed to control group by their wills. The control group will only receive assessment and follow-up without intervention.
89481940|NCT05025098|Active Comparator|Standard therapy|"This study is a randomization between treatment principles, not treatments, i.e., standard therapy vs precision therapy (tumor board determined).~Standard treatment for AML patients is Azacitidine + Venetoclax.*~*Only if venetoclax is available to the study at the time-point of study start. If venetoclax is not available AML patients will receive Azacitidine alone similar to MDS patients.~Standard treatment for MDS is Azacitidine."
89481941|NCT05025098|Experimental|Precision therapy|This study is a randomization between treatment principles, not treatments, i.e., standard therapy vs precision therapy (tumor board determined). The precision therapy arm will receive standard therapy + tumor board decided precision therapy. The tumor board decided precision therapy can in principle be any therapy with marketing authorization in Norway.
89203208|NCT04013451|Experimental|Intervention Group|Participants allocated to the intervention group will participate in the intervention (acts of kindness).
89203209|NCT04013451|No Intervention|Control Group|Participants allocated to the control group will not participate in the intervention and will act as the comparison condition.
89481942|NCT02114125|No Intervention|Usual Care Group:|Usual care consists of standard institutionalized services provided by physicians, nurses, and support staff (e.g., nurse assistants, social workers) in long-term care facilities.
89481943|NCT02114125|Experimental|High-intensity physical activity (5PA)|The intervention conducts the group-based physical activity, 5 days per- week for 8 weeks.
89481944|NCT02114125|Experimental|Low-intensity PA and CT(3PA+2CT)|The intervention conducts 3 days per-week physical activity and 2 days per-week cognitive training for 8 weeks.
89481945|NCT02114125|Experimental|High-intensity PA and CT (5PA+5CT)|The intervention conducts the individual-based, multi-domains cognitive training, 5days per- week and group-based physical activity, 5 days per- week and for 8 weeks.
89481946|NCT02114125|Experimental|Low-intensity cognitive training (2CT)|The intervention conducts the individual-based, multi-domains cognitive training, 2 days per- week for 8 weeks.
89481947|NCT02114125|Experimental|High-intensity cognitive training (5CT)|The intervention conducts the individual-based, multi-domains cognitive training, 5 days per- week for 8 weeks.
89481948|NCT05024786||control group|
89481949|NCT05024786||CQI group|
89481950|NCT02114281|Experimental|Care|Patient with dental care
89481951|NCT02114281|Active Comparator|Not care|Patient with not dental care
89481952|NCT02114359|Experimental|Platinum/fluoropyrimidine combination chemotherapy|
89481953|NCT02114359|Active Comparator|Fluoropyrimidine monochemotherapy|
89481954|NCT05024942||Severe aortic stenosis patients undergoing TAVR|Severe aortic stenosis patients undergoing TAVR will be stratified according to LUS evaluated pulmonary congestion before and after TAVR
89481955|NCT02110303|Experimental|18F-F Positive - Ticagrelor|Ticagrelor oral tablets, one (90mg) tablet, twice daily, 12 month duration
89481956|NCT02110303|Placebo Comparator|18F-F Positive - Placebo|Identical placebo, one tablet, twice daily, 12 month duration
88951829|NCT01950728|No Intervention|Control group|This group will not receive electrical stimulation. Volunteers will rest during 30 minutes.
88951830|NCT01950728|Active Comparator|Interferential current group|Interferential current will be applied during 30 minutes to volunteer's forearm. Intensity will be increase until volunteers fell a strong but comfortable paresthesia.
89481957|NCT02110303|Experimental|18F-F Negative - Ticagrelor|Ticagrelor oral tablets, one (90mg) tablet, twice daily, 12 month duration
89481958|NCT02110303|Placebo Comparator|18F-F Negative - Placebo|Identical placebo, one tablet, twice daily, 12 month duration
89481959|NCT03095846|Experimental|Winter Swimmers|Individualized cooling protocol
89481960|NCT03095846|Experimental|Not-winter Swimmers|Individualized cooling protocol
89481961|NCT05037890|Active Comparator|Plant sterol enriched margarine|20 grams plant sterol enriched margarine on a daily basis for a period of 6 months.
89481962|NCT05037890|Active Comparator|Plant stanol enriched margarine|20 grams plant stanol enriched margarine on a daily basis for a period of 6 months.
89481963|NCT05037890|Placebo Comparator|Control margarine|20 grams control margarine on a daily basis for a period of 6 months.
89481964|NCT02108119|Active Comparator|Probiotics|
89481965|NCT02108119|Placebo Comparator|Control placebo|
89481966|NCT02108197|Experimental|CPAP Intervention|Continuous positive airway pressure (S9, ResMed)
89481967|NCT02108197|No Intervention|Wait-list|Wait list controls
89481968|NCT05024630|Experimental|RDN+PVI group|The experimental group received renal artery cryoablation and pulmonary vein cryoablation. Pulmonary vein cryoablation was first followed by renal artery cryoablation.
89481969|NCT05024630|Sham Comparator|PVI only group|The control group received pulmonary vein cryoablation alone. To ensure single blindness, the control group received femoral artery puncture and renal arteriography after cryoablation.
89481970|NCT02114437|Experimental|Closed-loop TCI|the controller in the current study measures and calculates the error(NI error),which is the difference between the set point(NI=36)and the measured NI.If the NI error is different from 0,the controller determines a new propoflo and/or remifentanil concentration.
89203210|NCT04846140|Experimental|tDCS group|This group is defined as the participants who will receive tDCS at the first session. Participants in this group will receive 4 stimulation types (active a-tDCS, tACS, tRNS, and sham) in random order with at least a 48-hour separation between visits.
89203211|NCT04846140|Experimental|tACS group|This group is defined as the participants who will receive tACS at the first session. Participants in this group will receive 4 stimulation types (active a-tDCS, tACS, tRNS, and sham) in random order with at least a 48-hour separation between visits.
89481971|NCT02114437|Placebo Comparator|Opened-loop TCI|the investigator modified the effect-site target concentrations of both drugs without minimum or maximum concentration limits to maintain NI at approximately 36 within a range of 26 to 46 to the extent possible.
89481972|NCT02114593|Experimental|Parent support program|Parent support program
89481973|NCT02114593|No Intervention|Standard activities|Standard activities
89481974|NCT03093740|Experimental|HCV treatment - no viral resistance|Based on the genotype and negative viral resistance testing of the donor, (determined within the first week) we will initiate a genotype specific regimen of Zepatier
89481975|NCT03093740|Experimental|HCV treatment - viral resistance|Based on the genotype and positive viral resistance testing of the donor, (determined within the first week) we will initiate a genotype specific regimen of Zepatier plus Sofosbuvir
89481976|NCT02108353|Active Comparator|Melatonin 2mg|The study medication will be compared to placebo control.
89481977|NCT02108353|Placebo Comparator|Placebo|The study medication will be compared to placebo control.
89481978|NCT04157751|Experimental|Empagliflozin|
89481979|NCT04157751|Placebo Comparator|Placebo|
89481980|NCT05033444|Experimental|PRV-002|"A single dose of PRV-002 will be administered to each study participant in this arm on study Day 1 at the following dose levels:~Cohort 1: 9.66 mg~Cohort 2: 19.38 mg~Cohort 3: 38.7 mg."
89481981|NCT05033444|Placebo Comparator|Placebo comparator|A single dose of placebo comparator will be administered to each study participant in this arm on study Day 1. Placebo used is hydroxypropyl beta cyclodextrin (HPβCD)
89481982|NCT02114671|Experimental|Faldaprevir QD high dose|capsules, oral administration with 240 ml water, fed conditions
89481983|NCT02114671|Experimental|Faldaprevir QD low dose|tablets/capsules, oral administration with 240 ml water, fed conditions
89481984|NCT02114671|Placebo Comparator|Placebo|capsules, oral administration with 240 ml water, fed conditions
89481985|NCT02114671|Active Comparator|Ciprofloxacin|tablets, oral administration with 240 ml water, fed conditions
89481986|NCT03093506|Active Comparator|Low-dose rhEpo|RhEpo 60IU/kg/week
89481987|NCT03093506|Active Comparator|Micro-dose rhEpo|RhEpo 20IU/kg/week
89481988|NCT03093506|Placebo Comparator|Placebo Control|Saline
89481989|NCT02110459|Experimental|Mild renal impairment|3h IV POL7080 infusion
89481990|NCT02110459|Experimental|Moderate renal impairment|3h IV POL7080 infusion
89481991|NCT02110459|Experimental|Severe renal impairment|3h IV POL7080 infusion
89481992|NCT02110459|Experimental|End stage renal disease arm 1|3h IV POL7080 infusion
89481993|NCT02110459|Experimental|End stage renal disease arm 2|3h IV POL7080 infusion
89481994|NCT02110459|Experimental|Normal Renal function|3h IV POL7080 infusion
89481995|NCT03094988|Other|Control|The active attention control group will receive a binder with information about personal health including sleep hygiene, nutritional changes, and stress reduction. In addition, they will participate in a control version of the cognitive training program. They will receive weekly phone calls by cognitive and physical therapy teams to address issues with any aspects of the program.
89481996|NCT03094988|Experimental|Cognitive and physical prehabilitation|The intervention group will receive the prehabilitation program consisting of a guided progressive program of home-based aerobic and resistance training exercise, which will be adapted based on kinesiologist recommendation for each individual and the individual's perceived exertion. In addition, they will have access to the full cognitive training program. They will receive weekly phone calls by cognitive and physical therapy teams to address issues with any aspects of the program.
89481997|NCT02114749|Experimental|volunteers in daily life activities|a set of wearable respiration and cardiac monitoring devices
89481998|NCT02108431|Experimental|balloon catheter for transurethral bladder-drainage|intraoperatively placement of transurethral catheter after robot-assisted radical prostatectomy
89481999|NCT02108431|Active Comparator|balloon catheter for suprapubic bladder-drainage|intraoperatively placement of suprapubic catheter after robot-assisted radical prostatectomy
89482000|NCT03287505|Experimental|Abilify IM Depot 300mg by once|300 mg dose group: single-administration of Aripiprazole IM Depot (300 mg) in 12 subjects;
89482001|NCT03287505|Experimental|Abilify IM Depot 400mg by once|400 mg dose group: single-administration of Aripiprazole IM Depot (400 mg) in 12 subjects.
89482002|NCT03553381||obese without MS|BMI 25- 35 Kg/mq without metabolic syndrome (MS) submitted to hypocaloric balanced diet
89482003|NCT03553381||obese with MS|BMI 25- 35 Kg/mq with metabolic syndrome submitted to hypocaloric balanced diet
89482004|NCT02459691|Active Comparator|Usual Care Only|Patients assigned to this group will continue medical care as usual.
89482005|NCT02459691|Experimental|Vida Sana|Patients assigned to this group will continue medical care as usual and in addition will receive the culturally adapted intervention.
89482006|NCT05032586|No Intervention|control groups: without wearing virtual reality headsets|"Before dressing, the child was given paracetamol, which is routinely used to prevent pain. The child was reminded that they would be with their family during the procedure, and either the mother or father was taken to the dressing room during dressing. After the standard burn dressing was applied to the patient by the healthcare personnel in the burn center treatment room, oxygen saturation and heart rate measurements were made again after the procedure and recorded in the Application Registration Form. Before and after the procedure, the patients were asked about the pain and anxiety levels felt during dressing and marked on the Wong Baker Scale, State-Trait Anxiety Inventory for Children and Children's Fear Scale."
89482007|NCT05032586|Experimental|experimental groups|"When the patient adapted to the headset and started to play games, he was taken to the dressing room with the VR headset and the application continued until the process was completed. Before starting the study, a pilot study was conducted to determine the time to wear headsets in ten children. It was observed that the children who were taken to the dressing room without wearing VR headsets refused to wear it. In order to prevent the child from experiencing anxiety in the dressing room, the child was put on VR headset in the patient room and then taken to the dressing room. After the procedure was completed, the VR headset was removed and the patient's oxygen saturation and heart rate were recorded on the Application Registration Form. The patients were asked regarding the pain and anxiety levels felt during dressing before and after the procedure and marked on the Wong Baker Scale, State-Trait Anxiety Inventory for Children and Children's Fear Scale."
89482008|NCT03090698|Active Comparator|Hylan|Intra-articular (knee) 6ml Hylan GF20 administration (single shot)
89482009|NCT03090698|Active Comparator|Hylan + Corticosteroid|Intra-articular (knee) 6ml Hylan GF20 and 1ml Triamcinolone 20mg/ml administration (single shot)
89482010|NCT03090698|Active Comparator|Corticosteroid|Intra-articular (knee) 1ml Triamcinolone administration (single shot)
89482011|NCT02460549|Experimental|therapeutic education program|patients attend three sessions of therapeutic education
89482012|NCT02114827|Experimental|Video|"Patients will view the 23-minute Guide to Stem Cell Transplantation video depicting the HSCT experience"
89482013|NCT02114827|Active Comparator|FAQ Sheet|Patients will receive HSCT FAQ sheet developed by the NCI at the NIH
89482014|NCT05018468|Experimental|ventilation with an anatomical facial mask|Intervention group 1: Patients in this group undergo ventilation with an anatomical facial mask and 100% oxygen for three minutes. Intervention group 2: Patients in this group undergo ventilation with a nasal mask and 100% oxygen for three minutes. In both groups, ventilation will be performed with the controlled mode of the anesthesia machine with a volume of 8 cc/kg and a speed of 12-20/min.
89482015|NCT05018468|Experimental|ventilation with a nasal mask|Intervention group 2: Patients in this group undergo ventilation with a nasal mask and 100% oxygen for three minutes. Ventilation will be performed with the controlled mode of the anesthesia machine with a volume of 8 cc/kg and a speed of 12-20/min.
89482016|NCT03287115|Experimental|Broccoli|Subjects will consume a dose of broccoli on day 11
89482017|NCT02108587|Experimental|optical coherence tomography for diagnosis|Patients undergo optical coherence tomography over 10-15 minutes.
89482018|NCT03090542|No Intervention|Control|
89482019|NCT03090542|Active Comparator|Product|
89482020|NCT03293589||OR|patients treated with open revascularization
89482021|NCT03293589||EVT|patients treated with endovascular revascularization
89482022|NCT02108665|Other|Radiographic hysterosalpingography|Realisation in first: radiographic hysterosalpingographyresonance then imaging hysterosalpingography
89482023|NCT02108665|Other|Magnetic resonance imaging hysterosalpingography|Realisation in first : magnetic resonance imaging hysterosalpingography then a radiographic hysterosalpingography
88821630|NCT03206203|Experimental|Arm 1 (atezolizumab, carboplatin)|Patients receive atezolizumab IV over 30-60 minutes and carboplatin IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
88821631|NCT03206203|Experimental|Arm 2 (atezolizumab, carboplatin)|Patients receive carboplatin as in Arm 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients may cross-over to Arm 1 upon disease progression.
89482024|NCT04954274|Experimental|Fertiline group|Treated by supplementation of the culture medium with the molecule.
89482025|NCT04954274|No Intervention|Control group|No supplementation
89482026|NCT03293511|Experimental|Order of administration: oxytocin - placebo|Participants first receive oxytocin (24 IU). After a washout period of 2 weeks, they receive placebo nasal spray
89482027|NCT03293511|Experimental|Order of administration: placebo - oxytocin|Participants first received placebo nasal spray. After a washout period of 2 weeks, they then receive oxytocin (24 IU).
89482028|NCT02251171|Experimental|TPV/RTV - Rifabutin|"Day 1: single dose Rifabutin~Days 8-20: morning and evening doses of Tipranavir/Ritonavir~Day 15: single dose Rifabutin"
89482029|NCT03093194|Active Comparator|Women going CS without vaginal preparation before surgery|Women going CS without vaginal preparation before surgery. No vaginal preparation before CS with Septal soap and septol.
89482030|NCT03093194|Placebo Comparator|Women going CS with vaginal preparation before surgery|Women going CS with vaginal preparation before surgery. vaginal preparation before CS with Septal soap and septol.
89482031|NCT03553927|Other|Low Energy Diet|Commercially available diet products
89482032|NCT03553927|Other|NHS advice on healthy eating|Dietary / lifestyle advice programme
88821632|NCT03188796|Placebo Comparator|Placebo|oral/enteral loading dose of 37.5 ml MCT followed by 10 drops daily for 90 days
89482033|NCT03293433||Patient with lung cancer|Patient with pulmonary nodule showed in scanner (defined as a rounded picture higher than 5 mm and less than 30 mm in the lung parenchyma) presenting at one of the 3 participant services and meeting the inclusion criteria and exclusion. A blood punction will be performed in order to extract micro RNA.
89482034|NCT03293355|No Intervention|Control|Standard of care
89482035|NCT03293355|Experimental|Intervention|"The VPN intervention has 2 in-person sessions:~1) Providing training on service integration and team building for CHW and tools for them to network more effectively with OPC and MMT treatment providers as well as reach out to their patients; and 2) Learning to use effective communication tools such as motivational ruler and decision balance sheet to work more effectively with their patients and use Facebook group to facilitate collaboration among providers and e-chat for patient engagements. Sessions will occur once a week for two weeks, with each session featuring a different set of themes and relevant activities."
89482036|NCT02110537|Experimental|Active Acupuncture + flecainide|The participants in this group receive verum acupuncture treatment once a week for 10 weeks and flecainide 75 mg twice daily.
89482037|NCT02110537|Sham Comparator|Sham acupuncture + flecainide|The participants in this group receive sham acupuncture treatment once a week for 10 weeks and flecainide 75 mg twice daily.
89482038|NCT03293277|Experimental|A1|20µg Dexmedetomidine or Placebo is administered intranasally on Day 1, and 20µg Dexmedetomidine or Placebo is administered intravenousally on Day 8
89482039|NCT03293277|Experimental|A2|20µg Dexmedetomidine or Placebo is administered intravenousally on Day 1, and 20µg Dexmedetomidine or Placebo is administered intranasally on Day 8
89482040|NCT03293277|Experimental|B1|40µg Dexmedetomidine or Placebo is administered intranasally on Day 1, and 40µg Dexmedetomidine or Placebo is administered intravenousally on Day 8
89482041|NCT03293277|Experimental|B2|40µg Dexmedetomidine or Placebo is administered intravenousally on Day 1, and 40µg Dexmedetomidine or Placebo is administered intranasally on Day 8
89482042|NCT03293277|Experimental|C|80µg Dexmedetomidine or Placebo is administered intranasally on Day 1
89531477|NCT06065930||Obese insulin-resistant subjects (Ob-IR)|Obese Insulin Resistant subjects (BMI > 30 kg/m2, fasting insulin > 9.0 mU/l and fasting plasma glucose < 6.1 mmol/l) undergoing subcutaneous microdialysis, needle biopsy, glucose clamp and MRI.
89020683|NCT02074553|Experimental|Ro542-4802/F14;Ro542-4802/F03;Ro542-4802/F08;Ro542-4802/F07|Participants will receive Ro542-4802/F14 (containing 12.5% SLS) capsules orally on Day 1 of first intervention period; then Ro542-4802/F03 (containing 50% SLS) capsules orally on Day 1 in second intervention period; then Ro542-4802/F08 (containing 3% SLS) capsules orally on Day 1 of third intervention period; followed by Ro542-4802/F07 (containing 25% SLS) capsules orally on Day 1 of the fourth intervention period during both fasted (Part 1) and fed (Part 2) conditions. A washout period of at least 10 days will be maintained between each period.
89020684|NCT01904851||Stent|The patient received one or more stents to the superficial femoral, popliteal, peroneal, anterior tibial, or posterior tibial arteries in AT LEAST one of the lesions treated during the course of the procedure.
89482043|NCT02110615|Experimental|Primary Care Practice Changes|The clinical intervention components included (1) advanced training on clinical quality improvement and obesity prevention, assessment, management; (2) computerized, point-of-care decision support tools for clinicians; (3) implementation of multi-disciplinary weight management programs within the community health centers, e.g. Healthy Weight Clinics (HWC); (4) integrating community health workers into the primary care and HWC teams; and (5) health center environmental changes to support behavior change modification.
89482044|NCT03093584|Active Comparator|Auricular stimulation|Auricular acupuncture with indwelling fixed auricular acupuncture needles
89482045|NCT03093584|Experimental|Expressive writing|Expressive writing - sharing the emotional expectations in front of forthcoming exam
89482046|NCT03093584|No Intervention|No intervention|No intervention, just observation and monitoring of outcome measures
89482047|NCT02114905|Experimental|OTs Trained and Deliver CBIT|CBIT certified clinicians will train OTs in delivering CBIT to affected youth. OTs will be supervised in the practice of CBIT with youth in the New York City and Birmingham areas. Pre- and post-treatment assessment measures will be collected from 16 families (8 from each site) to evaluate intervention acceptability, feasibility, and fidelity. Patient and parent satisfaction of CBIT-OT will also be documented.
89482048|NCT03293199|Active Comparator|Chest tube drainage|This group will undergo chest tube drainage as an intervention for spontaneous pneumothorax treatment.
89482049|NCT03293199|Active Comparator|Needle aspiration|This group will undergo repetitive needle aspiration as an intervention for spontaneous pneumothorax treatment.
89482050|NCT02114983||first episode of suspected DVT of the lower limbs|patients with first suspected episode of DVT of the lower limbs
89482051|NCT03293121|Experimental|Strength and Coordination Training|The strength and coordination group will perform a progression of exercises utilizing body weight and resistance bands as resistance. Exercises include squats, lunges, jumps etc. typical of a normal strength training program.
89482052|NCT03293121|Active Comparator|Walking|The walking group will be instructed to walk 3x/week, progressing from 30 to 45 min over 8 weeks.
89482053|NCT05031728|Experimental|CPT Group|Cognitive Processing Therapy (CPT) is employed. Each patient will attend 12 individual sessions with the therapist. The sessions will be on the weekly basis. The standard manual of CPT (Resick et al., 2016) is going to be employed.
89482054|NCT02108743|Active Comparator|Albuterol|2.5 mg of albuterol inhaled via jet nebulizer 15 minutes prior to symptom-limited maximal CPET.
89482055|NCT02108743|Placebo Comparator|Placebo|Normal saline placebo inhaled via jet nebulizer 15 minutes prior to symptom-limited maximal CPET.
89482056|NCT03293043|Experimental|Experimental Group|After initial screening, appropriately obtained informed consent and confirmation of eligibility at time of transplant, those recipients (a total of 12 subjects) who agree to continue as participants will receive reconditioned marginal lungs should the lungs on the device meet acceptable criteria to proceed with clinical transplantation.
89482057|NCT01673126|Active Comparator|Anodal tDCS|Patients received anodal tDCS (on DLPF cortex) during 20 minutes preceded and followed by a clinical assessment (Coma Recovery Scale-Revised)
89482058|NCT01673126|Sham Comparator|sham tDCS|Patient received a sham tDCS (5sec of stimulation). The device runs during 20minutes and the anode was placed over the DLPF cortex. A behavioral assessment preceded and followed the stimulation.
89482059|NCT02115061|Active Comparator|Cyanoacrylate|"This group owned fourteen patients who met all the inclusion criteria. These will be treated with cyanoacrylate.~Treatment: cyanoacrylate"
89482060|NCT02115061|Sham Comparator|Coil + cyanocrylate|"This group had fourteen patients who met all inclusion criteria. These will be treated with coil + cyanoacrylate.~Treatment: coil + cyanoacrylate"
89482061|NCT03292965|Active Comparator|Neostigmine|"At the end of surgery, administrating neostigmine to participants according to the protocol below:~when train-of-four (TOF) 2-3, administrating neostigmine 50mcg/kg when TOF 4 with fade, administrating neostigmine 40mcg/kg when TOF 4 without fade, administrating neostigmine 20mcg/kg"
89482062|NCT03292965|Active Comparator|Sugammadex|"At the end of surgery, administrating sugammadex to participants according to the protocol below:~when TOF=0 and post-tetanic count (PTC)=1 or more, administrating sugammadex 4mg/kg when TOF=1 or more, administrating sugammadex 2mg/kg when TOF 4 without fade, administrating neostigmine 20mcg/kg"
89531478|NCT06065930||Lean healthy controls (Lean)|Lean healthy controls (BMI < 25 kg/m2, fasting insulin < 9.0 mU/l and fasting plasma glucose < 6.1 mmol/l) undergoing subcutaneous microdialysis, needle biopsy, glucose clamp and MRI.
89482063|NCT02109055|Experimental|Pilates|Regarding upper limb exercises the limit of flexion and abduction less than 90°, with the exercises involving only the movement of flexion and extension of elbow shoulder will be respected. Along with patient data will be an exercise protocol based on the Pilates method that will be performed by a trained team of physiotherapists. Before and after the exercises the data of heart rate, blood pressure, oxygen saturation and subjective feeling of perceived exertion using the Modified Borg scale will be listed.
89482064|NCT02109055|Active Comparator|Convencional Physiotherapy|The conventional physiotherapy group will continue with the routine hospital consisting of respiratory physiotherapy.
89482065|NCT03094910|Other|123I-MIBG|Only the group of participants with primary Raynaud's phenomenon (Raynaud's disease) is also scheduled for this intervention, the 123I-MIBG.
88951831|NCT01950728|Active Comparator|TENS Group|TENS will be applied during 30 minutes to volunteer's forearm. Intensity will be increase until volunteers fell a strong but comfortable paresthesia.
88951832|NCT01950728|Active Comparator|Aussie current group|Aussie current will be applied during 30 minutes to volunteer's forearm. Intensity will be increase until volunteers fell a strong but comfortable paresthesia.
88951833|NCT01950793|Active Comparator|steroid|"used ultrasound-guided inject 1c.c triamcinolone acetonide 10mg/mL (Shincort®, YSP, Taiwan)into the sheath of the flexor tendons, penetrated to the A1 pulley.~One injection only"
88951834|NCT01950793|Experimental|Hyaluronic acid|"used ultrasound-guided inject 1c.c Hyaluronic acid (Artz®, Seikagaku, Japan)into the sheath of the flexor tendons, penetrated to the A1 pulley.~One injection only"
89482066|NCT03094910|Other|All participants|Examination of vibration perception threshold in fingertips, thermography, Ewing's test, tilt table test, blood samples.
89482067|NCT02460705|Experimental|IBD patients receiving FMT|IBD patients receiving biologically active human fecal material sourced from OpenBiome. The physician will administer 250 mL of the fecal suspension in aliquots of 50-60 mL, through the endoscope. The material will be delivered to the most proximal point of insertion.
89482068|NCT03282435|Experimental|CIK cells with PD-1 blocking|CIK cellular therapy with PD-1 blocking combined with standard lung cancer treatment
89482069|NCT03282435|Active Comparator|CIK cells without PD-1 blocking|CIK cellular therapy without PD-1 blocking combined with the same standard lung cancer treatment as the experimental group patients receive
89482070|NCT03092882|Experimental|Intervention|Diabetes Self-Management Program
89482071|NCT03092882|No Intervention|Control|
89482072|NCT02109211|Other|Standard care - Magill forceps|Patients will be intubated, as per standard care, with Magill forceps.
89482073|NCT02109211|Experimental|Altered Magill forceps|Patients will be intubated with modified Magill forceps.
89482074|NCT02110771|Experimental|GAÏA - facial affect recognition targeted|"GAÏA:20hours individual cognitive remediation with therapist, 10 tasks at home, 10 week-treatment cognitive remediation targeted on facial affects recognition. exercises were designed by Gaudelus and Franck (2012) and tutoractiv'company. It includes photos, computer and role games exercises.Computer based exercises have 5 difficulty levels.~2 sessions of one hour per week with therapist.~Tasks at home are given once a week and targeting functional outcomes associated with facial affects recognition impairment."
88951835|NCT01950806|Active Comparator|Pecan-containing diet|Test diet containing 1.5 oz pecans/2000 kcal/day for 28 days
88951836|NCT01950806|Placebo Comparator|Nut-free diet|Placebo diet containing no nuts or nut products, and identical in total fat and fiber as the test diet, for 28 days
88951837|NCT01950832||polycystic ovary syndrome (PCOS) group|Patients who were diagnosed as PCOS according to 2003 Rotterdam Criteria.
88951838|NCT01950832||Control|60 healthy volunteers
88951839|NCT01950845|Experimental|Automated fluid management system (Closed-loop system)|cardiac output Vigileo® (Edwards Lifesciences) monitoring is connected to the closed loop system that will automatically provide per operative fluid bolus to optimize cardiac output by automated detection of fluid responsiveness state.
88951840|NCT01950845|Sham Comparator|Current practice manual fluid management|cardiac output Vigileo® (Edwards Lifesciences) monitoring will be used to help the anesthesiologist team to detect fluid responsiveness state for the manual fluid management optimization
88951841|NCT01950858|Experimental|Biological|6 weeks of HBO treatment as well as non weight bearing
88951842|NCT01950858|Active Comparator|Control|non weight bearing
88951843|NCT01950871|Other|single arm study|Prostate HistoScanning (HS) analysis with HS-guided biopsy will be used to sample two cores per suspicious area (displayed as red on an imaging monitor), up to a maximum of 3 suspicious areas per subject. Depending on the number of suspicious areas identified by prostate HS, the number of cores will be zero (if no suspicious area is identified) up to a maximum of 6 cores.
89482075|NCT02110771|Active Comparator|RECOS - attentional process targeted|"RECOS (Cognitive REmediation for Schizophrenia): 20 hours individual cognitive remediation with therapist, 10 tasks at home, 10 week-treatment.~RECOS is a validated cognitive remediation program, developed by P. Vianin and SBT company. It includes paper and pen and computer based exercises. The original program proposes 5 modules targeting 5 cognitive functions, each patient participated in the module corresponding to his/her most altered cognitive function. In this study, all patients randomized in this arm are allocated in the attentional module.Every computer exercises have 10 difficulty levels.~2 sessions of one hour per week with therapist.~Tasks at home are given once a week and targeting functional outcome"
89482076|NCT03282279||TVOR population|The data have been collected from the Humanitas Fertility Center' Department database (ART.it) from all transvaginal oocyte retrieval procedures performed between 1996 and October 2016.
89482077|NCT03282201||Transfused|Patients in whom blood transfusion is used
89482078|NCT03282201||Nontransfused|Patients in whom blood transfusion is not used
89482079|NCT05031884||MGIR3-US group|using MGIR3-US to do ultrasonic examinations.
89482080|NCT05031884||control group|using conventional B-mode ultrasound to do ultrasonic examinations.
89482081|NCT02110849||Prostate Cancer Patients|Prostate cancer patients who received proton radiation therapy
89482082|NCT03282045|Experimental|Lysobact Complete Sprey|"Lysobact Complete Sprey~Route of administration: Oromucosal spray, sprayed directly toward the affected area with the applicator while the mouth is wide open~Dose regimen: Sprayed 3 to 6 doses a day. For a single dose, spraying pump should be pressed 5 times and one press of the spray pump release 0.20 mL of the solution containing 4 mg lysozyme, 0.3 mg cetylpyridine and 0.1 mg lidocaine hydrochloride."
89203212|NCT04846140|Experimental|tRNS group|This group is defined as the participants who will receive tRNS at the first session. Participants in this group will receive 4 stimulation types (active a-tDCS, tACS, tRNS, and sham) in random order with at least a 48-hour separation between visits.
88951844|NCT01950884|Experimental|Ezetimibe|Ezetimibe tablets plus lifestyle
88951845|NCT01950884|Active Comparator|lifestyle|lifestyle
88951846|NCT01950923|Experimental|Arm I (sildenafil citrate)|Patients receive sildenafil citrate PO before the initiation of standard robotic partial nephrectomy.
88951847|NCT01950923|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO before the initiation of standard robotic partial nephrectomy.
88951848|NCT01950936|Experimental|Procalcitonin-guidance|Discontinuation of Antibiotics. Procalcitonin is measured on day 1/2, day 3, day 5 and day 7 (all days where the patient is still admitted to hospital and antibiotics are discontinued, whenever Procalcitonin is <0.15 ng/ml and dis-encouraged whenever Procalcitonin is <0.25 ng/ml
89203213|NCT04846140|Experimental|sham group|This group is defined as the participants who will receive sham stimulation at the first session. Participants in this group will receive 4 stimulation types (active a-tDCS, tACS, tRNS, and sham) in random order with at least a 48-hour separation between visits.
89203214|NCT00935337|Experimental|Mind-Body Bridging Program|Mind Body Bridging subjects will be accessed with questionnaires and medical history evaluations for the impact of MBBP over the past 6 months since undertaking the program.
89482083|NCT03282045|Active Comparator|Tantum Verde® Spray|"Tantum Verde® Spray~Route of administration: Oromucosal spray, sprayed directly toward the affected area with the applicator while the mouth is wide open.~Dose regimen: Sprayed 4 to 8 doses, 2 to 6 times a day. One press means one dose."
89482084|NCT03282045|Active Comparator|Pharyngal® Oromucosal Spray|"Pharyngal® Oromucosal Spray~Route of administration: Oromucosal spray, sprayed directly toward the affected area with the applicator while the mouth is wide open.~Dose regimen: Sprayed 2 to 4 doses, repeated 6 to 10 times per day. One press of the pump (one dose) releases 0.14 ml of the solution with 0.28 mg chlorhexidine digluconate and 0.07 mg of lidocaine hydrochloride."
88951849|NCT01950936|No Intervention|Control - Standard of Care|Antibiotics are administered according to current guidelines
88951850|NCT01950949|Experimental|change respiratory parameters, volume expanding|
88951851|NCT01950962|Other|slight periodontal disease|
88951852|NCT01950962|Other|moderate periodontal disease|
88951853|NCT01950962|Other|severe periodontal disease|
88951854|NCT01951001|Active Comparator|group 1|Fixed-dose Prasugrel of 10 mg/d
88951855|NCT01951001|Active Comparator|group 2|Fixed-dose Prasugrel of 5 mg/d
88951856|NCT01951001|Active Comparator|group 3|"Phenotype-based prasugrel dose~If patients show PRU < 85, prasugrel dose will be reduced by 5 mg/d.~If patients show PRU ≥ 85, prasugrel dose will continue 10 mg/d."
88951857|NCT01951014|Experimental|Teen Social Media Education|See description under intervention description
88951858|NCT01951014|No Intervention|Healthcare Provider Insights|Healthcare providers providing care to pregnant adolescents will serve as key informants to provide an additional perspective for adolescent health beliefs and behaviors.
88951859|NCT01951027|Experimental|Cohort 1|GX-G3 12.5 μg/kg or Placebo
88951860|NCT01951027|Experimental|Cohort 2|GX-G3 25 μg/kg or Placebo
88951861|NCT01951027|Experimental|Cohort 3|GX-G3 50 μg/kg or Placebo
88951862|NCT01951027|Experimental|Cohort 4|GX-G3 100 μg/kg or Placebo
88951863|NCT01951040||Oxytocin|Oxytocin was administered during labor
89203215|NCT00935337|Active Comparator|Sleep Hygiene|Sleep Hygiene subjects will be accessed with questionnaires and medical history evaluations for the impact of SH over the past 6 months since undertaking the program.
88951864|NCT01951040||No Oxytocin|Oxytocine was not administered during labor
88951865|NCT01951053|Experimental|Sequence 1|Participants will receive the study medications in the sequence of placebo, citalopram, and JNJ-40411813, in 3 treatment periods. Each treatment period has 3 days and subsequent treatment period will be separated by 7 days.
88951866|NCT01951053|Experimental|Sequence 2|Participants will receive the study medications in the sequence of placebo, JNJ-40411813, and citalopram, in 3 treatment periods. Each treatment period has 3 days and subsequent treatment period will be separated by 7 days.
88951867|NCT01951053|Experimental|Sequence 3|Participants will receive the study medications in the sequence of citalopram, placebo, and JNJ-40411813, in 3 treatment periods. Each treatment period has 3 days and subsequent treatment period will be separated by 7 days.
88951868|NCT01951053|Experimental|Sequence 4|Participants will receive the study medications in the sequence of citalopram, JNJ-40411813, and placebo, in 3 treatment periods. Each treatment period has 3 days and subsequent treatment period will be separated by 7 days.
88951869|NCT01951053|Experimental|Sequence 5|Participants will receive the study medications in the sequence of JNJ-40411813, placebo, and citalopram, in 3 treatment periods. Each treatment period has 3 days and subsequent treatment period will be separated by 7 days.
88951870|NCT01951053|Experimental|Sequence 6|Participants will receive the study medications in the sequence of JNJ-40411813, citalopram, and placebo, in 3 treatment periods. Each treatment period has 3 days and subsequent treatment period will be separated by 7 days.
88951871|NCT01951079|Experimental|second trimester abortion , feticide|all patients admitting to second trimester abortion above 22 weeks will be injected intra-amniotic DIGOXIN for feticide .
88951872|NCT01951144|Experimental|Cohort 1:|Single ascending doses of PF-06372865 or placebo to investigate the safety/tolerability PK and PD of PF-06372865.
89203216|NCT02553174||Ketorolac|Patients who receive ketorolac perioperatively
89203217|NCT02553174||Caldolor|Patients who receive Caldolor perioperatively
89482085|NCT03282045|Placebo Comparator|Placebo|"Route of administration: Sprayed directly toward the affected area with the applicator while the mouth is wide open.~Dose regimen: Sprayed 3 to 6 doses a day. For a single dose, spraying pump should be pressed 5 times."
89203218|NCT02553174||No NSAIDS|Patients who do not receive NSAIDS perioperatively
89482086|NCT02407054|Experimental|Part A: 200 mg LY3023414 BID + 160 mg of Enzalutamide QD|Participants received 200 milligrams (mg) LY3023414 orally twice daily (BID) during the initial week to assess pharmacokinetics (PK). Thereafter, participants received 200 mg of LY3023414 BID in combination with 160 mg of enzalutamide QD beginning Cycle 1 Day 1. A treatment cycle was defined as 28 days.
89482087|NCT02407054|Experimental|Part B: 200 mg LY3023414 BID + 160 mg Enzalutamide QD|Participants received 200 mg LY3023414 orally BID in combination with 160 mg enzalutamide orally once daily (QD).
89482088|NCT02407054|Active Comparator|Part B: Placebo + 160 mg Enzalutamide QD|Participants received placebo in combination with 160 mg enzalutamide QD.
89482089|NCT03090464||Standard of Care (SOC)|Participants have standard of care with no access to digital disease management tool
89482090|NCT03090464||SOC + digital disease management|Participants have access to the digital disease management tool in addition to standard of care
89482091|NCT02115217|Experimental|Leukotape K, basketball training|Use of Leukotape K to ensure stability of the ankle in basketball players
89482092|NCT02115217|Placebo Comparator|Sham, basketball training|Use of sham tape
89482093|NCT03281967|Other|Minimally Invasive Ponto Surgery|Surgical method for installation of a bone anchored hearing system for hearing rehabilitation
89482094|NCT02110927|Experimental|Transcutaneous microcurrent|This group performed aerobic exercise just after microcurrent in the abdominal region with four transcutaneous electrodes in a parallel position, intensity below the sensitivity threshold and a maximum of 1 milliampere (mA). Every 20 minutes changed from 25 hertz (Hz) to 10 Hz
89482095|NCT02110927|Placebo Comparator|Control group|Control group performed aerobic exercise just after microcurrent in the abdominal region with four transcutaneous electrodes in a parallel position, but microcurrent device was switched off.
89482096|NCT03287037|Experimental|tDCS over DLPFC|Direct current (DC) generated by a DC stimulator (Eldith DC stimulator: www. neuroconn.de/dc-stimulator_plus_en/) was bilaterally delivered through a pair of saline-soaked surface sponge electrodes (35 cm2). The anodal electrode was placed over the left dorsolateral prefrontal cortex (F3, International EEG System 10-20) and cathode electrode over F4. Stimulation was applied at an intensity of 2 mA for 20 min, twice-daily on 5 consecutive weekdays. The twice daily sessions were separated by at least 3 hours.
89482097|NCT05024084|Active Comparator|Group Sevoflurane|The patients in this arm will be given Sevoflurane (2-3%) as volatile anesthetic throughout the duration of anesthesia.
89482098|NCT05024084|Active Comparator|Group Desflurane|The patients in this arm will be given Desflurane (7-8%) as volatile anesthetic throughout the duration of anesthesia.
89482099|NCT02109289|Experimental|Methotrexate and Etanercept|Patients already taking Methotrexate prior to the study will continue taking 15 mg weekly and start Etanercept 50 mg every week for 16 weeks
89482100|NCT04908670|Active Comparator|PNE group|5 minute video :Understanding Pain in less than 5 minutes, and what to do about it! https://www.youtube.com/watch?v=C_3phB93rvI.
89482101|NCT04908670|Active Comparator|Manipulation group|PA grade I-II oscillation on C7, T4 and L4
89482102|NCT03553303|Experimental|Intervention|Increasing doses of Sacubitril/Valsartan
89482103|NCT03286959|Active Comparator|PCR WITH CALCIUM HYDROXIDE|PCR WITH CALCIUM HYDROXIDE : A layer of dycal (dentsply) was placed adjacent to pulpal or axial wall after mixing as per manufacturer recommendations followed by etching and restoration with composite using incremental technique.
89482104|NCT03286959|Active Comparator|PCR WITH RMGIC|PCR WITH RMGIC: A layer of resin modified liner ( GC Fuji II ) was placed adjacent to pulpal or axial wall and light cured for 40 sec. afterwards the cavity was restored with composite as in other groups.
89482105|NCT03286959|Active Comparator|PCR WITH DIRECT COMPOSITE|PCR WITH DIRECT COMPOSITE: After partial caries excavation , etching and bonding was done directly without using any liner and cavity was restored with composite as in other groups
89482106|NCT03090074|Active Comparator|Moderate carbohydrate restriction and traditional support|Moderate carbohydrate restriction and traditional support with group meetings
89482107|NCT03090074|Active Comparator|Extreme low carbohydrate diet and traditional support|Extreme carbohydrate restriction and traditional support with group meetings
89482108|NCT03090074|Active Comparator|Moderate carbohydrate restriction and ACT support|Moderate carbohydrate restriction and psychological support based on acceptance and commitment therapy
89482109|NCT03090074|Active Comparator|Extreme carbohydrate restriction and ACT support|Extreme carbohydrate restriction and psychological support based on acceptance and commitment therapy
89482110|NCT02115451||Surgical treatment|Patients who undergo rehabilitation and anterior cruciate ligament reconstruction, other surgical interventions may be performed
89482111|NCT02115451||Nonsurgical treatment|Patients who undergo rehabilitation without anterior cruciate ligament reconstruction, other surgical interventions may be performed
89482112|NCT03292575||Stroke related to CAAF|
89482113|NCT05023928|Experimental|Tumor antigen-sensitized DC vaccine|"Tumor antigen-sensitized vaccine is administrated, 1-week interval, totally 2 times.~2-week later, Neo-antigen DC vaccine is administrated, 2-week interval, totally 5 times."
89482114|NCT03286881|Experimental|Group 1|
89482115|NCT03286881|Experimental|Group 2|
89203219|NCT00809250|Experimental|GM-K562/leukemia cell vaccine|Biological/Vaccine: GM-K562/leukemia cell vaccine Cultured cell line genetically changed to secrete GM-CSF mixed with irradiated leukemia cells obtained from the participant. A total of 6 vaccine will be given. Vaccines 1-3 will be given once a week. Vaccines 4-6 will be given every other week.
89482116|NCT03286881|Experimental|Group 3|
89482117|NCT03286881|Experimental|Group 4|
89482118|NCT03286881|Active Comparator|Group 5|
89482119|NCT02115529|Active Comparator|Cesamet (nabilone)|0.5 mg capsule containing Cesamet (single dose) given preoperatively
89482120|NCT02115529|Placebo Comparator|Placebo|identical capsule containing placebo (single dose) given preoperatively
89482121|NCT03092804||normal pressure hydrocephalus|"Included will be subjects with a probable diagnosis of NPH. The diagnosis will be based primarily on presence of gait impairment plus at least one other impairment in urinary symptoms, cognition impairment or both~The NPH patients will undergo the CSF tap test and then receive the ventriculo-peritoneal shunting surgery. They will have the examination of brain constructure neuroimaging and functional MRI prior to and posterior to the shunting."
89482122|NCT03092804||normal control|Healthy volunteers will undergo the examination of brain constructure and functional MRI.
89482123|NCT01652716|Experimental|Exenatide once weekly suspension|Exenatide suspension 2 mg weekly subcutaneous injection
89482124|NCT01652716|Active Comparator|Exenatide twice daily (BID)|Exenatide 5 mcg BID for 4 weeks followed by 10 mcg BID for 24 weeks
89482125|NCT03292341|Experimental|Patients|"Patients diagnosed with larynx cancer and ex-larynx cancer patients:~Interviews with patients to define their decisional needs and to determine the barriers and facilitators to the implementation of shared decision making and the decision aid.~Navigating through the Treatmentchoice Decisional Tool and think aloud while running the tool~Questionnaires"
89482126|NCT03292341|Experimental|Clinicians|"2.Clinicians Radiotherapy-oncologists, ENT(Ear-Nose-Throat)-specialists, General practitioners, Nurses~Interviews with patients to define their decisional needs and to determine the barriers and facilitators to the implementation of shared decision making and the decision aid.~Navigating through the Treatmentchoice Decisional Tool and think aloud while running the tool~Questionnaires"
89482127|NCT03292341|Experimental|Other involved organizations|Patient Organizations and insurance companies Interviews with stakeholders (patients, clinicians, nurses, GP's, patient organizations, insurance companies) to determine the barriers and facilitators to the implementation of shared decision making and the decision aid
89482128|NCT02109601|Active Comparator|Control|Control patients receive iPad tablets during their hospital stay with only LIMITED bedside training from a research assistant on how to access and effectively use their patient portal.
89482129|NCT02109601|Experimental|Intervention|Intervention patient receive iPad tablets during their hospital stay with EXTENSIVE bedside training from a research assistant on how to access and effectively use their patient portal.
89482130|NCT05024240|Experimental|Patient group|20 patients with cerebellum disorders, who suffer from stability disorders and with specific 3 Hz tremor
88951873|NCT01951144|Experimental|Cohort 2:|Single ascending doses of PF-06372865 or placebo to investigate the safety/tolerability PK and PD of PF-06372865.
89482131|NCT05024240|Active Comparator|Control group|20 healthy age-matching probands without any neurological disorders and stability issues
89482132|NCT02459613|Experimental|Imaging|99mTc Annexin V-128 SPECT
89482133|NCT02251249|Experimental|STEMI Group|
89482134|NCT02251249|Other|Stable patient Group|Patient referred for angioplasty for angina or non-ST-segment elevation myocardial infarction (NSTEMI)
89482135|NCT02115685|No Intervention|One day testing|Aim 1 will be to measure bloodflow during exercise of the legs (below the injury). This aim will examine the control of bloodflow and muscle contractions and how it changes after spinal cord injury.
89482136|NCT02115685|Experimental|Effects of long term training|Aim 3 will then look at changes in bloodflow during exercise after training. Three different eight week exercise training programs will be tested including 1) treadmill training at high intensity as defined by 70-80% of HRR or 15-17 RPE 2) treadmill training at low intensity as defined by 30-40% of HRR or <13 RPE
89482137|NCT03281889|Experimental|Proton Radiotherapy|"Patients will be treated with Proton Beam once daily 5 days per week.~Doses will be prescribed such that maximum possible coverage is achieved"
89482138|NCT03292263|Experimental|Mel+Nivo|Autologous Stem Cell Transplant Drug: Melphalan 140-200 mg/m^2, Nivolumab100 mg iv days -3, +17
89482139|NCT02111005||Smoking Aggressive Periodontitis group|This group comprises 20 patients who are smokers and aged < 35 years and diagnosed with rapid attachment loss with periodontal pocket depth (PD) > 4 mm around at least three teeth other than the first molars and incisors. Rapid bone destruction (>50%bone loss at diseased sites). Weak relationship between dental plaque and the severity of gingival inflammation.
89482140|NCT02111005||Smoking Chronic Periodontitis group|This group comprises 20 patients who are smokers and aged > 45 years and have presence of ≥2 non-adjacent sites per quadrant that were not first molars or incisors, with probing depth (PD) ≥5 mm, which bleed on gentle probing. The demonstrated radiographic bone loss ≥30% of the root length, patient with poor oral hygiene, the amount of accumulated plaque commensurate with the amount of clinical attachment level (CAL)
89482141|NCT02111005||Non-smoking Aggressive Periodontitis grp|This group comprises 20 patients who are age- and sex- matched to the 'Smoking Aggressive Periodontitis group' and are non-smokers suffering from aggressive periodontitis.
89482142|NCT02111005||Non-smoking Chronic periodontitis grp|This group comprises 20 patients who are age- and sex-matched to the 'Smoking Chronic Periodontitis group' and are non-smokers suffering from chronic periodontitis.
89482143|NCT05017844|Placebo Comparator|KSR-001-04|KSR-001-04 eyedrops recieved one drop to both eyes four times a day for 12 weeks.
89482144|NCT05017844|Experimental|KSR-001-02|KSR-001-02 eyedrops recieved one drop to both eyes four times a day for 12 weeks.
89482145|NCT05017844|Experimental|KSR-001-03|KSR-001-03 eyedrops recieved one drop to both eyes four times a day for 12 weeks.
89482146|NCT02115763|Experimental|Caffeine|There is only one arm, it receives both caffeine and placebo.
89482147|NCT03286803|Experimental|Arm A|Inactivated Poliovirus vaccine
89482148|NCT03286803|Active Comparator|Arm B|fractional dose inactivated poliovirus vaccine
89482149|NCT03286803|Experimental|Arm C|inactivated poliovirus vaccine
89482150|NCT03286803|Active Comparator|Arm D|fractional dose inactivated poliovirus vaccine
89020685|NCT01904851||Non-Stent|The patient did not receive a stent to the superficial femoral, popliteal, peroneal, anterior tibial, or posterior tibial arteries in ANY of the lesions treated during the course of the procedure.
89482151|NCT03553693|Experimental|Intervention Clinics|RAPID-VL study intervention testing and counseling package, which includes near point-of-care viral load (VL) testing at local testing hubs, structured VL counseling, forms to track VL ordering and testing, with feedback and performance evaluations at regular intervals.
89482152|NCT03553693|No Intervention|Control Clinics|Standard of care VL testing and counseling procedures consistent with country guidelines.
89482153|NCT03292185|Experimental|IDeglira-IDeg-Liraglutide|Treatment sequence first Insulin Degludec/Liraglutide, then Insulin Degludec, then Liraglutide
89482154|NCT03292185|Experimental|IDeglira-Liraglutide-IDeg|Treatment sequence first Insulin Degludec/Liraglutide, then Liraglutide, then Insulin Degludec
89482155|NCT03292185|Experimental|IDeg-Liraglutide-IDeglira|Treatment sequence first Isulin Degludec, then Liraglutide, then Insulin Degludec/Liraglutide
89482156|NCT03292185|Experimental|IDeg-IDeglira-Liraglutide|Treatment sequence first Insulin Degludec, then Insulin Degludec/Liraglutide, then Liraglutide
89482157|NCT03292185|Experimental|Liraglutide-IDeg-IDeglira|Treatment sequence first Liraglutide, then Insulin Degludec, then Insulin Degludec/Liraglutide
89482158|NCT03292185|Experimental|Liraglutide-IDeglira-IDeg|Treatment sequence first Liraglutide, then Insulin Degludec/Liraglutide, then Insulin Degludec
89482159|NCT05031260|No Intervention|Control group|The individuals in the control group will be asked to brush their teeth (2x per day) at home throughout the 4 weeks of study period. They will be asked not to use the supplementary oral hygiene products including mouth rinse, dental floss and chewing gum.
89482160|NCT05031260|Experimental|Experimental group|The individuals in this group will be asked to brush their teeth (2x per day) at home throughout the 4 weeks of study period. They will be asked not to use the supplementary oral hygiene products including mouth rinse, dental floss and chewing gum. Instead, they will be asked to come to the clinic to use COMORAL® three times a day, every day except Saturday and Sunday.
89482161|NCT02115841|Experimental|E1|Experiment 1 will measure the cortical excitability change after TENS intervention.
89482162|NCT02115841|Experimental|E2|Experiment 2 will measures implicit sequential motor task performance and cortical hemodynamic response using near infrared spectroscopy (NIRS) during motor execution. Cortical excitability will also be measured contemporary
89482163|NCT05031104|Active Comparator|Control group|Patients in this group undergone a standard exercise program.
89482164|NCT05031104|Experimental|LLT group|Patients in this group undergone a standard exercise program as the control group in addition to the LLT.
89482165|NCT02115919|Experimental|Cohort A|Cohort A participants will undergo perilesional Multikine injections (200IU) once daily, Monday through Friday, for 14 days, off for 14 days, then again once daily, Monday through Friday for 14 days.
89482166|NCT02115919|Experimental|Cohort B|Cohort B participants will undergo perilesional Multikine injections 400IU once daily, Monday through Friday, for 14 days, off for 14 days, then again once daily, Monday through Friday for 14 days.
89482167|NCT02109679|Experimental|Treatment A|multiple doses BI 187004
89482168|NCT02109679|Experimental|Treatment B|multiple doses BI 187004 + multiple doses metformin
89020686|NCT01751360|Experimental|SYR-472 100mg|SYR-472 100mg
89203220|NCT00935415|Active Comparator|Montelukast|capsules prepared in blindness
89482169|NCT02109679|Experimental|Treatment C|multiple doses metformin
89482170|NCT05030636|Experimental|EX starts at 9:30 am|A warm-up, 30 min at 70% VO2 max and a cool-down performed at 9:30 am.
89482171|NCT05030636|Experimental|EX starts at 11:00 am|A warm-up, 30 min at 70% VO2 max and a cool-down performed at 11:00 am.
89482172|NCT05030636|No Intervention|No EX|Control condition. A choice of 30 minutes sedentary activities.
89482173|NCT03553849|Experimental|Very Low Calorie Diet|If they are randomized into the treatment arm, they will be prescribed with a 2-week VLCD that will begin 2 weeks prior to the scheduled elective surgery. Patients will be required to pay for the meal replacements.
89482174|NCT03553849|No Intervention|Standard Preop Diet|The control group will continue a regular diet until the day before surgery.
89203221|NCT00935415|Placebo Comparator|Placebo|matched placebo
89203222|NCT00935571||Group I, Group II|"Group I: anesthetized with TIVA (Propofol + Remifentanil)~Group II: anesthetized with inhalation (sevoflurane)"
89203223|NCT00324649|Experimental|Truvada|Truvada + NNRTI or PI.
89482175|NCT02460237|Experimental|Arm I (intervention)|Participants receive a study kit that includes culturally appropriate instructions for using and returning the HPV self-test device and a photo story information sheet about HPV and HPV self-testing. Participants are asked to complete the HPV self-test and return the test for HPV testing.
89482176|NCT02460237|Active Comparator|Arm II (control)|Participants receive a study kit that includes standard instructions for using and returning the HPV self-test device and a standard information sheet about HPV and cervical cancer. Participants are asked to complete the HPV self-test and return the test for HPV testing.
89482177|NCT02109757|Experimental|Software intervention and education|This group will receive software intervention and education before and after receiving one-on-one education, thus showing if benefit or effect occurs simply due to having the software input before receiving education.
89482178|NCT02109757|Active Comparator|Education only|This group will not receive software intervention prior to and after one-on-one education, only afterwards.
89482179|NCT05023694||Newborn reanimated video recordings|Newborns, requiring stabilization at birth in Delivery Room, prior authorization by verbal and written informed consent
89482180|NCT02116075|Experimental|Epidural Steroid|80mg depo-medrol 9mL 1% lidocaine
89482181|NCT02116075|Active Comparator|Epidural Prolotherapy|10ml of 5% generic dextrose
89482182|NCT05023304|Experimental|Group A Dextenza|
89482183|NCT05023304|Active Comparator|Group B Topical Prednisolone|
89482184|NCT02109835||Asymptomatic type 2 diabetes|Patients without previous history of coronary artery disease
89482185|NCT05017376||group A|small optical zone
89203224|NCT00324649|Active Comparator|Zidovudine/lamivudine|Zidovudine/lamivudine + NNRTI or PI.
88821633|NCT03188796|Experimental|High Dose Vitamin D3|"oral/enteral pharmacological dose of cholecalciferol (vitamin D3) - total dose 900,000~loading dose of 540,0000 (dissolved in 37.5 ml of medium chain triglycerides - MCT)~followed by 4000 IU daily (10 drops) for the entire active study period (90 days)"
89203225|NCT00803322||1|communities where tuberculosis patients followed the conventional health facility based tuberculosis case finding and treatment
89203226|NCT00803322||2|community where suspects of pulmonary tuberculosis were identified by community health workers and received treatment in the community
89203227|NCT03743259|Experimental|LuminoMark inj. 0.1mL|Injection LuminoMark inj. 0.1mL once in this study.
89203228|NCT03743259|Experimental|LuminoMark inj. 0.2mL|Injection LuminoMark inj. 0.2mL once in this study.
89203229|NCT03743259|Active Comparator|Charcotrace Inj.|Charcotrace Inj. about 0.3~1mL
89482186|NCT05017376||group B|large optical zone
89482187|NCT03281655|Experimental|Vulvovaginal atrophy|Postmenopausal sexually active women affected by vulvovaginal atrophy undergoing treatment (15 days, 1 application per day) with a vaginal cream containing visnadine, prenylflavonoids and bovine colostrum.
89482188|NCT05030168|No Intervention|Placebo|Twice weekly hemodialysis program plus regular protein diet (1.0 g/kg/day) every day
89482189|NCT05030168|Experimental|Ketosteril|Incremental hemodialysis program, starting from once weekly hemodialysis/hemodialysis filtration(HDF) plus low protein diet (0.6 g/kg/day) and ketoanologues 0.12g/kg/day supplementation on non-dialysis days and regular protein diet (1.0-1.2 g/kg/day) on dialysis day
89482190|NCT03286647|Experimental|NORMALGRIEF|Oral hygiene instruction
89482191|NCT03286647|Experimental|COMPLICATEDGRIEF|Oral hygiene instruction
89482192|NCT03286647|Active Comparator|CONTROLS|Oral hygiene instruction
89482193|NCT03092648|Experimental|Bronchial basal cells|
89482194|NCT03092648|No Intervention|Control|
89482195|NCT02109913|Other|Everolimus plus exemestane|Biomarker study in patients receiving standard treatment
89482196|NCT05030246|Experimental|Surufatinib 250mg/Toripalimab 240mg|Surufatinib at a dose of 250mg Qd, with humanized anti-PD-1 monoclonal antibody（Toripalimab） injected intravenously 240mg per 3 weeks until disease progresses or unacceptable tolerability occurs.
89482197|NCT03291873|Active Comparator|topography guided PRK in one eye|Topography-guided (placido disk- based) using T-CAT Contoura treatment.
89482198|NCT03291873|Active Comparator|Q-value adjusted ( custom Q) PRK in the other eye|The target Q will be estimated according to a nomogram considering the patient's age
89482199|NCT02116231|Experimental|Concurrent chemoradiotherapy|Concurrent chemoradiotherapy: IMRT was given to the patients with regimen of 66Gy-76Gy to the gross target volume of nasopharynx,66-70Gy to the gross target volume of positive nodes, 60-62Gy the high risk clinical target volume, 50-56Gy to the low risk clinical target volume. Concurrent chemotherapy is administrated with cisplatin 100mg/m2 at d1, d22, d43 during radiotherapy.
88821634|NCT03188354|Experimental|CNS lymphoma patients|Patients included in the study will be examined with both 18F-FDG and 18F-Fluciclovine as well as standard MRI in the PET/MRI scanner on two consecutive days, both in primary staging and for therapy assessment
88821635|NCT03186508|Active Comparator|Optimize Sleep (OS)|Optimize Sleep will focus exclusively on enhancing sleep by using effective behavioral strategies. Specific strategies to be used include: goal setting and self-monitoring, positive bedtime routines, stimulus control/sleep hygiene strategies, problem-solving regarding challenges, and review of effective strategies for relapse prevention.
89203230|NCT04045782|Other|single arm|Adult patients (≥ 18 years of age) with Ulcerative Colitis or Crohn's Disease on maintenance therapy with Humira® for at least 8 weeks prior to switch to Imraldi®.
89203231|NCT02553720|Experimental|Aquatic Group|Conventional management plus aquatic exercise At least 15 minutes of walking 3 times/week for 3 months
89203232|NCT02553720|Other|Control Group|Conventional management without aquatic exercise
89203233|NCT00935727|Other|1|normally functioning transplanted kidneys
89203234|NCT00935727|Other|2|transplanted kidney undergoing known rejection or other known abnormality
89203235|NCT00935727|Other|3|transplanted kidney with unknown diagnosis
89482200|NCT02116231|Active Comparator|IMRT alone|IMRT is given to the patients with regimen of 66Gy-76Gy to the gross target volume of nasopharynx,66-70Gy to the gross target volume of positive nodes, 60-62Gy the high risk clinical target volume, 50-56Gy to the low risk clinical target volume.
89482201|NCT03291795|Experimental|Exercise Intervention|
89482202|NCT05030480||Chronic kidney disease|eGFR values of less than 60 mL/min/1.73 m2
89482203|NCT05030480||Non-Chronic kidney disease|eGFR values more than 60 mL/min/1.73 m2
89482204|NCT02111161|Active Comparator|IVIG (Privigen)|Intravenous polyspecific immunoglobulin G (Privigen). Dosage: 25 g/day (250 ml) for three consecutive days
89482205|NCT02111161|Placebo Comparator|Saline 0.9%|0.9% saline for Intravenous administration. Dosage: 250 ml for three consecutive days.
89482206|NCT03291717|Experimental|Bridging Community Gaps Photovoice (BCGP)|The BCGP program is a 6-month photovoice-based intervention to help individuals with psychiatric disabilities enhance their community participation.
89482207|NCT03291717|No Intervention|Services as Usual|Individuals in this group continue with their regular mental health services with no additional intervention.
89482208|NCT05017220|Experimental|Nature-based stimulation program|Participants will receive a single intervention with a duration of 30 minutes based on a multisensorial nature-based stimulation
89482209|NCT05017220|Other|Control intervention|Participants will be involved in a placebo task for 30 minutes
89482210|NCT03286569|Active Comparator|Active upper Wilson appliance|Active upper arch Wilson quadhelex appliance
89482211|NCT03286569|Placebo Comparator|Non active upper expansion appliance|Non-Active upper arch Wilson quadhelex appliance
89482212|NCT02111239|No Intervention|No imaging|No preoperative imaging is performed for this group
89482213|NCT02111239|Experimental|CTA|Patients randomized to this group will undergo a preoperative CTA scan.
89482214|NCT02111239|Experimental|MRA|Patients randomized to this group will undergo a preoperative MRA scan.
89482215|NCT02116387|Active Comparator|Routine Physical Therapy|"Patients randomized to this arm will follow a classic, routine, physical therapy program.~Intervention: Routine Physical Therapy"
89482216|NCT02116387|Experimental|I-Moove Physical Therapy|"Patients randomized to this arm will follow a physical therapy program using the I-Moove device.~Intervention: I-Moove Physical Therapy"
89482217|NCT05016830|Sham Comparator|Sham bilateral transcranial direct current stimulation|Sham bilateral transcranial direct current stimulation consisted of 2 milliamperes (mA) of current from the anodal electrode in the amblyopic primary visual cortex to the cathodal electrode located in the fellow primary visual cortex, but the stimulation was turned off after 30 seconds. On Sham Stimulation onset, the participant's fellow eye was occluded and the participant performed a reading task for 20 minutes.
89482218|NCT05016830|Experimental|Bilateral transcranial direct current stimulation|Bilateral transcranial direct current stimulation consisted of 2 mA of current from the anodal electrode in the amblyopic primary visual cortex to the cathodal electrode located in the fellow primary visual cortex and the stimulation was on for 20 minutes. On stimulation onset, the participant's fellow eye was occluded and the participant performed a reading task for 20 minutes.
89482219|NCT03092570|Experimental|tDCS Post-CVA|The participants will get a 20min stimulation at a maximal intensity of 2mA
89482220|NCT03092570|Sham Comparator|Sham Post-CVA|The tDCS will be placed as for the Experimental group and will last 30 seconds at the beginning of task
89482221|NCT03092570|Experimental|tDCS Young Healthy|The participants will get a 20min stimulation at a maximal intensity of 2mA
89482222|NCT03092570|Sham Comparator|Sham Young Healthy|The tDCS will be placed as for the Experimental group and will last 30 seconds at the beginning of task
89482223|NCT03092570|Experimental|tDCS Older Healthy|The participants will get a 20min stimulation at a maximal intensity of 2mA
89482224|NCT03092570|Sham Comparator|Sham Older Healthy|The tDCS will be placed as for the Experimental group and will last 30 seconds at the beginning of task
89482225|NCT02790073|Other|SNF472|SNF472 for calciphylaxis
89482226|NCT02116465|Active Comparator|Levodopa Carbidopa 100/25 tablets Test 1|single oral dose of levodopa carbidopa immediate release tablets
89482227|NCT02116465|Active Comparator|Levodopa Carbidopa 100/25 tablets Ref. 1|single oral dose of levodopa carbidopa immediate release tablets
89482228|NCT02116465|Active Comparator|Levodopa Carbidopa 100/25 tablets Test 2|single oral dose of levodopa carbidopa immediate release tablets
89482229|NCT02116465|Active Comparator|Levodopa Carbidopa 100/25 tablets Ref. 2|single oral dose of levodopa carbidopa immediate release tablets
89203236|NCT00803478|Active Comparator|Hinge position|superior vs. temporal
89203237|NCT00803478|Active Comparator|Hinge width|45 vs 90 degrees
89203238|NCT00803478|Active Comparator|Flap Thickness|110 vs 130 microns
89203239|NCT03983239|Experimental|Fedratinib plus Rifampin|A single dose of fedratinib on Day 1. On Days 9 through 18, once-daily (QD) doses of rifampin. On Day 17, a single dose of fedratinib will be concomitantly administered with rifampin.
89203240|NCT03983239|Experimental|Fedratinib plus Efavirenz|A single dose of fedratinib on Day 1. On Days 9 through 18, once-daily (QD) doses of efavirenz. On Day 17, a single dose of fedratinib will be concomitantly administered with efavirenz.
89203241|NCT00935805||Treatment|124 patients attending the primary care unit included after formal consent.
89203242|NCT03986125|Experimental|Emotional Awareness & Expression Therapy|Participants will attend three individual sessions focused on becoming aware of and expressing avoided or conflicted emotions.
89203243|NCT03986125|Experimental|Mindfulness Meditation Training|Participants will attend three individual sessions focused on increasing equanimity and compassion and reducing self-judgement.
89203244|NCT03986125|No Intervention|Wait-List Control|Participants will receive the intervention of their choice following assessment at four and eight weeks after randomization.
89482230|NCT03552679||LVAD recipients|Consecutive patients accepted for elective LVAD implantation in the context of routine care, will undergo routinely scheduled echocardiography before, within 1 week, 1 month, 3 months and 1 year after LVAD implantation. Echocardiography will be performed using ultrasound machines that are capable of acquisition of two-, three-dimensional and Multiplane Echocardiography of the right ventricle. Invasive hemodynamic data will be collected in the perioperative period.
89482231|NCT03094676|No Intervention|Control|Only the HRV will be followed for two hours without intervention.
89482232|NCT03094676|Experimental|Only Massage|Only the massage, and will have the monitoring of the HRV on the techniques and accompanied for two hours.
89482233|NCT03094676|Experimental|Only Exercise|Only the exercise, and will have the monitoring of the HRV on the techniques and accompanied for two hours.
89482234|NCT03094676|Experimental|Exercise and Massage immediately|Performing the exercise and massage immediately after, will be accompanied by the HRV during the techniques and two hours after.
89482235|NCT03094676|Experimental|Exercise and Massage after recovery|Performing the exercise and massage will be applicated after recovery of HRV, will be accompanied by the HRV during the techniques and two hours afte
89482236|NCT02118883|Other|Essentia Water|Essentia Water, electrolyzed high-pH water
89482237|NCT02118883|Other|Bottled Water|Purified bottle water
89482238|NCT03094598|No Intervention|Control|No intervention
89482239|NCT03094598|Experimental|Leaflet|The leaflet is based on information and journalism theories, paying attention primarily to reader appeal and readability.
89482240|NCT03094598|Experimental|Brochure|The brochure is based on practical communication experience, focusing primarily on logical composition and presentation of condensed information.
89482241|NCT03094598|Experimental|Booklet|The booklet is also based on practical communication experience, but give more elaborate explanations.
89482242|NCT02116543|Experimental|TD-6450|TD-6450 capsules
89482243|NCT02116543|Placebo Comparator|Placebo|Placebo capsules
89482244|NCT03553225|Placebo Comparator|Placebo|Formulation containing inert artificially colored maltodextrin, once daily, in a 2-hard capsules regimen (1g)
89482245|NCT03553225|Active Comparator|Concord Grape Extract 1|1 g Concord Grape Extract in 2 capsules
89482246|NCT03553225|Active Comparator|Concord Grape Extract 2|500 mg Concord Grape Extract in 2 capsules
89482247|NCT02119039|Experimental|RGTA OTR 4120 (CACICOL20)|
89482248|NCT02119039|Active Comparator|Genteal HA|
89482249|NCT02119117|Placebo Comparator|sugar pill|Group 2 will receive a placebo of CoQ10
89482250|NCT02119117|Experimental|CoQ10|Patients will be divided into 2 groups. Group 1 will be treated with an oral supplement, 125 mg/twice daily of CoQ10 (NeoQ10, Theralogix, Rockville, Maryland, USA) for 3 months prior to IVF. This dosage will equate to a Cmax of 6.89 ug/ml (Liu and Artmann, 2009).
89482251|NCT05029700|Experimental|Combined exercise group|Combined training consists of trunk stabilization training and aerobic training.
89482252|NCT05029700|Active Comparator|Control group|Aerobic training was given to the control group.
89482253|NCT02119195|No Intervention|No treatment|The composite resin restorations had marginal defects, but were clinically acceptable, did not receive treatment
89482254|NCT02119195|No Intervention|Positive control|Composite resins with alpha value in marginal adaptation criteria
89482255|NCT02119195|Experimental|Intervention|For this group, defective areas were acid etched with 35% phosphoric acid for 15 seconds. A resin-based sealant (Clinpro Sealant, 3M ESPE) was applied over the defective area. The sealant was polymerized with a photocuring unit (Curing Light 2500, 3M ESPE) for 40 seconds. Rubber dam isolation was used for this procedure
89482256|NCT05016128|Experimental|S-ketamine|a 0.25 mg/kg bolus and 0.125 mg/kg/h via intravenous infusion during surgery
89482257|NCT05016128|Placebo Comparator|Saline|a 0.25 mg/kg bolus and 0.125 mg/kg/h via intravenous infusion during surgery
89482258|NCT02111317|Experimental|ASP015K and verapamil|Single dose of ASP015K, then repeat dose of verapamil, then a second single dose of ASP015K while continuing verapamil
89482259|NCT03092414|Experimental|Group A|Patients with indications for gastroduodenoscopy will be evaluated with WLE and then LCI.
89482260|NCT03092414|Experimental|Group B|Patients with indications for gastroduodenoscopy will be evaluated with LCI and then WLE.
89482261|NCT03553615|Experimental|Oral treatment|12mg oral ivermectin treatment taken once a week for four weeks
89482262|NCT05016206|Experimental|Treatment Arm (ABC)|"Treatment Sequence ABC - Participants received all 3 doses of danicopan in ascending fashion over 3 periods:~Treatment A (Period 1): Danicopan 400 milligrams (mg) and moxifloxacin-matching placebo.~Treatment B (Period 2): Danicopan 800 mg and moxifloxacin-matching placebo.~Treatment C (Period 3): Danicopan 1200 mg and moxifloxacin-matching placebo."
89482263|NCT05016206|Placebo Comparator|Control Arm (EFG and IJK)|"Participants received 1 of 2 treatment sequences (Treatment Sequence EFG or Treatment Sequence IJK) over 3 periods:~Treatment E (Period 1): Danicopan-matching placebo (400 mg) and moxifloxacin-matching placebo.~Treatment F (Period 2): Danicopan-matching placebo (800 mg) and moxifloxacin 400 mg.~Treatment G (Period 3): Danicopan-matching placebo (1200 mg) and moxifloxacin-matching placebo.~Treatment I (Period 1): Danicopan-matching placebo (400 mg) and moxifloxacin 400 mg.~Treatment J (Period 2): Danicopan-matching placebo (800 mg) and moxifloxacin-matching placebo.~Treatment K (Period 3): Danicopan-matching placebo (1200 mg) and moxifloxacin 400 mg."
89482264|NCT02116855|Experimental|tertiary prophylaxis prophy on Hemophilia A patiets|A multi centre 2 year long term tertiary prophylaxis study designed with a three step escalating dose protocol adjusted by individual joint bleeding patterns/frequencies to study the effect and cost saving of 3 low dose /cost prophylaxis regimens in boys with severe hemophilia A and arthropathy in China. Each patient will start treatment with a low dose regimen in step I and be assessed every 3 months according to the escalating criteria.
89482265|NCT02111473|Other|testosterone|testosterone 250 mg injection per 3-4 weeks for 6 months
89482266|NCT02111551|Experimental|DMXB-A 75 mg|DMXB-A 75 mg dose followed by a second dose of 37.5 mg at 2 hours to maintain the blood level
89482267|NCT02111551|Experimental|DMXB-A 150 mg|DMXB-A 150 mg followed by a second dose of 75 mg at 2 hours to maintain the blood level
89482268|NCT02111551|Placebo Comparator|Sugar Pill|placebo comparator dose followed by a second placebo dose at 2 hours to maintain blind
89203245|NCT00935961|Experimental|RAD001 + docetaxel + cisplatin|In this phase I trial, the primary endpoint will be considered to be reached when we have described a phase II recommended dose of RAD001 given with docetaxel + cisplatin as induction chemotherapy for head and neck cancer. Up to 3 dose levels of daily RAD001 will be studied. A standard 3 + 3 phase I dose escalation design will be used. The phase II recommended dose will be determined according to the dose escalation plan.
89203246|NCT00656370|Experimental|NS Infusion Group|Normal Saline (NS) and Hylenex
89482269|NCT05029544|Active Comparator|intervention group 1|dynamic taping and standard rehabilitation program
89482270|NCT05029544|Active Comparator|intervention group 2|Kinesio taping and standard rehabilitation program
89482271|NCT05029544|Other|Control group|No taping on shoulder, only standard rehabilitation program
89482272|NCT02119273|Experimental|Steroid|The steroid arm will take prednisone 10mg tabs starting 7 days prior to surgery with a taper (4 tabs/day for 3 days, 3 tabs/day for 3 days, 2 tabs/day for 3 days, 1 tab/day for 3 days).
89482273|NCT02119273|Placebo Comparator|Placebo|The placebo arm will receive placebo pills identical in appearance to prednisone 10mg pills. They will start taking them 7 days prior to surgery with a taper (4 tabs/day for 3 days, 3 tabs/day for 3 days, 2 tabs/day for 3 days, 1 tab/day for 3 days).
89482274|NCT05022914||1|Patients affected by biochemical relapse after radical prostatectomy undergoing staging PSMA-PET/CT and baseline blood sample for miRNA panel assessment.
89482275|NCT02119351|Active Comparator|ViaValve™ Safety IV Catheter|Insertion of the ViaValve™ Safety IV Catheter
89482276|NCT02119351|Active Comparator|ProtectIV® Plus Safety IV Catheter|Insertion of the ProtectIV® Plus Safety IV Catheter
89482277|NCT05029778|Experimental|Experimental L-arginine 3 g and L-citruline 2 g|Drug: L-arginine 3g and L-citruline 2g, Food supplement, PO , for 24 h, until birth
89482278|NCT05029778|Experimental|placebo|Placebo 3g ( starch ) PO for 24 h. until birth
89482279|NCT02119429|Placebo Comparator|Wheat Germ Oil|Participants will be instructed to consume 2 wheat germ oil capsules ,2g, per day for 12 weeks.
89482280|NCT02119429|Experimental|Pumpkin Seed Oil|Participants will be instructed to consume 2 pumpkin seed oil capsules ,2g, per day for 12 weeks
89482281|NCT05029076|Experimental|Liraglutide injection + Victoza|Subjects receive liraglutide injection in the first cycle and Victoza in the second cycle.
89482282|NCT05029076|Experimental|Victoza +Liraglutide injection|Subjects receive Victoza in the first cycle and liraglutide injection in the second cycle.
89482283|NCT02119507|Experimental|Curodont Repair|Single application on Day 0.
89482284|NCT02119507|Other|No treatment - control|"No treatment as control - wait and see."
89482285|NCT05016440|Active Comparator|Lisinopril|10mg Lisinopril tablets
89482286|NCT05016440|Placebo Comparator|Sugar pill|sugar pill
89482287|NCT02116933|Active Comparator|Level I|A small, level I study will compare autologous fat grafting alone to stromal vascular fraction SVF enriched autologous fat grafting int he same patient. One breast will be treated with AFG alone and act as the control, and the other breast will be treated with SVF enriched AFG adn act as the experimental side exploring the efficacy of adipose derived stem cells.
89482288|NCT02116933|Active Comparator|Level II|A larger, level II study comparing Autologous Fat Grafting to SVF enriched AFG in different patients. In this study, patients can choose to have AFG in both breasts or SVF enriched AFG in both breasts. The two patient groups will be compared. Here the group with the AFG in both breasts will be the control and the SVF enriched AFG in both breasts will be the experimental group exploring the efficacy of adipose derived stem cells.
89482289|NCT05016362||Group A|blepharoplasty with repositioning of the nasal fat pad to the central arcus marginalis of the superior orbital rim during surgery.
89482290|NCT05016362||Group B|blepharoplasty with repositioning of the nasal fat pad to orbitoglabellar groove during surgery.
89482291|NCT02251639|Experimental|Oral Imaging and Cytology|Participant completes a short questionnaire regarding their awareness of oral cancer and risk factors. Oral cavity inspected using a standard white light headlamp. Oral cavity then examined with one or more of the widefield imaging devices, such as the VELscope and/or PS2 device. Exfoliative cells for cytology from an abnormal area (if present) and from a contralateral normal appearing area obtained using a brush.
89203247|NCT00656370|Experimental|LR Infusion Group|Lactated Ringer's (LR) and Hylenex
89203248|NCT01055431|Placebo Comparator|Control|Control bread
89203249|NCT01055431|Active Comparator|Teff bread|Teff bread
89482292|NCT05029388|Experimental|Aerobic Exercise|This experimental group will receive aerobic exericse. This group will be led by a certified personal trainer with at least three years of experience in guiding adolescents in group exercises. The aerobic exercise training will be conducted in the fitness room of a local sports center that is hosted by the Leisure and Cultural Services Department in Hong Kong.
89482293|NCT05029388|Experimental|High Intensity Interval Training|This experimental group will receive high intensity interval training. This group will be led by a certified personal trainer with at least three years of experience in guiding adolescents in group exercises. The HIIT training will be conducted in the fitness room of a local sports center that is hosted by the Leisure and Cultural Services Department in Hong Kong.
89482294|NCT05029388|No Intervention|Control Group|This group will not take part in aerobic exercise and HIIT training programme. Participants will be given an exercise diary or logbook to keep track of their exercise habits (i.e., record the type of exercise/activity, hours, and intensity of exercise/activity every day) throughout the intervention periods.
89482295|NCT03553147|Experimental|Group/Cohort 1|all patient SARC-F score, handgrip test and impedancemetry
88951874|NCT01951144|Experimental|Cohort 3:|Single ascending doses of PF-06372865 or placebo to investigate the safety/tolerability PK and PD of PF-06372865.
88951875|NCT01951144|Experimental|Cohort 4 (optional cohort):|Two single doses of PF-06372865 or placebo or lorazepam to further investigate the pharmacodynamics of PF-06372865.
88951876|NCT01951183|Placebo Comparator|Placebo|
88951877|NCT01951183|Experimental|RO6811135|
89020687|NCT01697527|Experimental|Treatment (gene and vaccine therapy)|"CONDITIONING: Patients receive cyclophosphamide IV over 1 hour on days -5 to -4 and fludarabine phosphate IV over 30 minutes on days -4 to -1.~TRANSPLANT: Patients receive NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL IV on day 0. Patients also receive NY-ESO-1 (157-165) peptide pulsed dendritic cell vaccine therapy ID on days 1, 14, and 30 and aldesleukin SC BID on days 1-14. Patients may receive 3 additional doses of NY-ESO-1 (157-165) peptide pulsed dendritic cell vaccine therapy after day 90."
89020688|NCT01664598|Experimental|Tocilizumab|
89020689|NCT01632007|Experimental|SYR-472 100 mg|
89020690|NCT01632007|Active Comparator|Alogliptin 25 mg|
89020691|NCT01632007|Placebo Comparator|Placebo|
89020692|NCT01524926|Experimental|Crizotinib in Anaplastic large cell lymphoma|
89020693|NCT01524926|Experimental|Crizotinib in Inflammatory myofibroblastic tumor|
89020694|NCT01524926|Experimental|Crizotinib in Papillary renal cell carcinoma type 1|
89020695|NCT01524926|Experimental|Crizotinib in Clear cell sarcoma|
89020696|NCT01524926|Experimental|Crizotinib in Alveolar soft part sarcoma|
89020697|NCT01524926|Experimental|Crizotinib in Alveolar rhabdomyosarcoma|
89020698|NCT01402271|Experimental|pazopanib in combination with paclitaxel and carboplatin|Phase I: Dose-escalation study of pazopanib in combination with paclitaxel and carboplatin given weekly in a group of patients with platinum-refractory or -resistant ovarian, fallopian tube or peritoneal carcinoma Phase II: Paclitaxel 30 mg/m² and Carboplatin 2.0 AUC weekly for 18 courses PLUS Pazopanib 400 mg daily
89020699|NCT01402271|Active Comparator|Paclitaxel and carboplatin only|Carboplatin AUC 2.7 and paclitaxel 60mg/m² weekly for 18 courses.
89020700|NCT01387295|Experimental|chemotherapy|
89020701|NCT01288378|Active Comparator|Empirical|Empirical approach (fever driven) for starting antifungal therapy
89020702|NCT01288378|Experimental|Pre-emptive|Pre-emptive approach (diagnostic driven) for starting antifungal therapy
89020703|NCT01280682|Experimental|rituximab|patients who had newly diagnosed type 1 diabetes are assigned to receive infusions of rituximab of 125mg/m^2 day1 day8 day15 day22 repeat after six months (only day1 and day8) besides insulin
89020704|NCT01280682|No Intervention|parallel control|patients who had newly diagnosed type 1 diabetes only use insulin
89020705|NCT01209936|Experimental|deuterium oxide and BC3|Testing of total body water on the BC3 compared to total body water measured by deuterium oxide.
89020706|NCT01072825||transgender people starting hormone treatment|
89020707|NCT01050218|Other|DVS SR Open Label|Daily dose of 100mg or 200mg at the investigators discretion. Subjects already randomized at a dose of 400mg may continue at that dose level.
89020708|NCT00679029|Experimental|Chemotherapy with Bevacizumab|"Doxorubicin 60 mg /M2 followed by cyclophosphamide 600 mg/M2 (AC) will be given every 2 weeks for cycles 1-4.~Paclitaxel 175 mg/M2 followed by gemcitabine 1500 mg/M2 (TG) will be given every 2 weeks for cycles 5-8.~Beginning cycle 5, B1= Avastin 10 mg/kg will be given as a single IV dose following each TG treatment every 2 weeks for cycles 5-7."
89020709|NCT00548730||White Light Bronchoscopy|Patients with known or suspected malignancies of the lung and with a medical indication for a bronchoscopy will have images taken with white light bronchoscopy
89203250|NCT00936039|Experimental|unloading|2 weeks of unloading
89203251|NCT00803556|Experimental|Arm 1|"Patients whose last dose is > 21 days prior to first dose of Trastuzumab on study. First infusion: 90 mins for 4 mg/kg loading dose of trastuzumab followed by 60 min infusion of alvespimycin. Subsequent infusions weekly 30 mins for 2 mg/kg trastuzumab followed by 60 min infusion of alvespimycin~Patients whose last dose is < 21 days prior to first dose of Trastuzumab on study. All infusions: 30 mins for 2 mg/kg trastuzumab followed by 60 min infusion of alvespimycin"
89020710|NCT00548730||Autofluorescence Bronchoscopy|Patients with known or suspected malignancies of the lung and with a medical indication for a bronchoscopy will have images taken with autofluorescence bronchoscopy
89020711|NCT00548730||Narrow Band Imaged Bronchoscopy|Patients with known or suspected malignancies of the lung and with a medical indication for a bronchoscopy will have images taken with narrow band imaged bronchoscopy
89020712|NCT00338689|Experimental|Lower protein formula|"Intervention: Infant formula with relatively low protein content (1.25 g/ 100 ml) during the first year of life; described as Lower protein formula"
89020713|NCT00338689|Placebo Comparator|Higher protein formula|"Intervention: Infant formula with a relatively high protein content (2.05 g/ 100 ml) during the first year of life; described as Higher protein formula"
89020714|NCT00338689|No Intervention|Breastfed reference group|Non-randomized breastfed group of infants at least 3 months exclusively breastfed
89020715|NCT00195429|Experimental|Sirolimus + Tacrolimus|
89482296|NCT03094364|Active Comparator|Immediate Treatment|"Patients will receive an in-home consultation with an occupational/physical therapist in which they are educated about the intervention, the system is set up, and they are guided through use of the system. After initial contact, therapist support will be available via telephone to address specific difficulties with operating the system, as well as three additional home visits throughout the 3 week intervention.~The rehabilitation program requires use of the rehabilitation gaming system for 1.5 hours daily for 21 consecutive days (equivalent dosage to standard CI therapy), limb activation device worn for 90% of waking hours, and completion of the automated transfer package to facilitate real-world arm use (e.g., problem-solving modules, daily monitoring of arm use). After completing the intervention, the patient will receive additional consultation with the therapist to formulate goals for follow-up. Follow-up assessments will be conducted to assess long-term retention of motor gains."
89482297|NCT03094364|Active Comparator|Delayed Treatment|"Patients will receive an in-home consultation with an occupational/physical therapist in which they are educated about the intervention, the system is set up, and they are guided through use of the system. After initial contact, therapist support will be available via telephone to address specific difficulties with operating the system, as well as three additional home visits throughout the 3 week intervention.~The rehabilitation program requires use of the rehabilitation gaming system for 1.5 hours daily for 21 consecutive days (equivalent dosage to standard CI therapy), limb activation device worn for 90% of waking hours, and completion of the automated transfer package to facilitate real-world arm use (e.g., problem-solving modules, daily monitoring of arm use). After completing the intervention, the patient will receive additional consultation with the therapist to formulate goals for follow-up. Follow-up assessments will be conducted to assess long-term retention of motor gains."
89482298|NCT05022992|Experimental|Resistance Training Session|Resistance training. Heavy resistance training. 10 reps x 3 set of upper- and lower-body resistance exercises
89482299|NCT05022992|No Intervention|Control|Control activity. None-exercising. 30 min of rest
89482300|NCT05029232|Active Comparator|ambulant patient with DMD|patient that walk alone or with minor assist
88951878|NCT01951196||Chronic kidney disease, CKD III+IV|150 patients with Chronic kidney disease, CKD stage III+IV.
88951879|NCT01951196||Healthy subjects|75 healthy subjects.
88951880|NCT01951209|Experimental|Rifaximin/Placebo|Rifaximin 550mg po bid for 12 weeks followed by crossover to matched placebo po bid x 12 weeks
88951881|NCT01951209|Experimental|Placebo/Rifaximin SSD|Matched placebo po bid for 12 weeks followed by crossover to Rifaximin 550mg po bid x 12 weeks
88951882|NCT01951222|Experimental|V0162 dose1|
88951883|NCT01951222|Experimental|V0162 dose2|
88951884|NCT01951222|Placebo Comparator|placebo|Placebo
88951885|NCT01951248|Experimental|CPAP treatment|Patients with chronic kidney disease and moderate to severe obstructive sleep apnea is treated 3 months with CPAP treatment
88951886|NCT01951287|Experimental|Acute beverage (Water) consumption|Acute beverage (Water)consumption with breakfast measuring blood glucose and insulin levels at specific time points. consumption with breakfast measuring blood glucose and insulin levels at specific time points.
88951887|NCT01951287|Experimental|Acute beverage (Black Coffee) consumption|Acute beverage (Black Coffee)consumption with breakfast measuring blood glucose and insulin levels at specific time points. consumption with breakfast measuring blood glucose and insulin levels at specific time points
88951888|NCT01951287|Experimental|Acute beverage (Orange Juice) consumption|Acute beverage (Orange Juice)consumption with breakfast measuring blood glucose and insulin levels at specific time points. consumption with breakfast measuring blood glucose and insulin levels at specific time points
88951889|NCT01951287|Experimental|Acute beverage (Whole Milk) consumption|Acute beverage (Whole Milk) consumption with breakfast measuring blood glucose and insulin levels at specific time points. consumption with breakfast measuring blood glucose and insulin levels at specific time points
88951890|NCT01951287|Experimental|Acute beverage (2% Milk) consumption|Acute beverage (2% Milk) consumption with breakfast measuring blood glucose and insulin levels at specific time points. consumption with breakfast measuring blood glucose and insulin levels at specific time points
89020716|NCT00195429|Active Comparator|Sirolimus + Prednisone|
89482301|NCT05029232|Active Comparator|non ambulant patient with DMD|patient need wheel chair
89482302|NCT05015582|Experimental|Treatment|"Preop: Use of full body forced air warming pre-operative at ambient (32˚C) for at least 30 minutes and fluids from warmed cabinet set at 45˚C~Intraop: Use of upper body and lower forced air warming intra-operative at 32 and 42˚C respectively and IV fluids with hotline fluid warmer set at 42˚C"
89482303|NCT05015582|Active Comparator|Control Group|"Preop: Use of full body forced air warming pre-operative at ambient (32˚C) for at least 30 minutes and fluids from warmed cabinet set at 45˚C~Intraop: Use of upper body forced air warming intra-operative at ambient (32˚C) and IV fluids at room temperature"
89531479|NCT06065917|Experimental|Artificial intelligence training cohort and validation cohort|Three high-volume Italian centers will enroll 195 obese patients who are candidates for metabolic surgery for obesity. Part of them will be established a training cohort (total = 105 patients), used to set up the AI-based method of TSBL measurement. The other 90 patients (30 for each center) will represent the validation cohort.
89531480|NCT06065904|Experimental|CP with recommended diet|CP children that will follow a recommended menu
89203252|NCT00803556|Experimental|Arm 2|"Patients whose last dose is > 21 days prior to first dose of Trastuzumab on study. First infusion: 90 mins for 4 mg/kg loading dose of trastuzumab followed by 60 min infusion of paclitaxel and 60 min of infusion of alvespimycin. Subsequent infusions weekly 30 mins for 2 mg/kg trastuzumab followed by 60 min infusion of paclitaxel and 60 min infusion of alvespimycin~Patients whose last dose is < 21 days prior to first dose of Trastuzumab on study. All infusions: 30 mins for 2 mg/kg trastuzumab followed by 60 min infusion of paclitaxel and 60 min infusion of alvespimycin. Subsequent infusions weekly 30 mins for 2 mg/kg trastuzumab followed by 60 min infusion of paclitaxel and 60 min infusion of alvespimycin"
89203253|NCT00936195|Active Comparator|Atripla (R)|
89203254|NCT00936195|Active Comparator|Combivir (R) + Kaletra (R) or Aluvia (R)|
89203255|NCT00809484||1: Low risk|Anastrozole 1mg/d, Vit D 400 IU and 500mg Calcium daily
89203256|NCT00809484||2:Moderate risk|Anastrozole 1mg/d, Vit D 400 IU and 500mg Calcium daily, +/- Risedronate 35mg orally once a week
89203257|NCT00809484||3:High risk|Anastrozole 1mg/d, Vit D 400 IU and 500mg Calcium daily, Risedronate 35mg orally once a week
89203258|NCT00936273||Suspected sleep apnea syndrome|Outpatients with suspected sleep apnea syndrome, age > 18 year
89203259|NCT02552550||Ability to swallow, speak and quality of life|This will just be an evaluation, before any treatment, his ability to swallow, speak and quality of life then, as in normal practice, after 3, 6 and 12 months after treatment.
89482304|NCT05015738|Other|Traditional diabetes education|"The subjects and activities were applied to the control group, who received traditional diabetes education, between 8:00 and 10:00 with the classical method, which lasted 2 hours, for 10 weeks. The training was completed by the researcher with the verbal narration method. Diabetes Achievement Assessment Test with question and answer method was administered to the students at the beginning and end of the application. These questions were the same questions asked to the experimental group. Interaction of groups with each other was limited. Students were informed about this and their consent was taken.At the end of the course, students' opinions were taken through the form developed by the researchers. Instructional Materials Motivation Survey (IMMS) was used to measure to student' motivation levels."
89482305|NCT05015738|Experimental|Diabetes Education supported by digital tools|The subjects included in the course content were given between 10:00-12:00 with the animation supported method, which lasted for 2 hours. The animations were created by the researchers to reflect all guidelines for diabetes. The scenario of the animation video was prepared in line with the training content. Storyboards in videos and animations were created with the collaboration of researchers and experts in their fields (software specialists, computer programmers). The animation video was voiced in Turkish by a professional actor. Animations are 2 minutes each and a total of 18 minutes long. The 'Kahoot' application, a Web 2.0 tool, was used to apply Diabetes Achievement Evaluation Test. At the end of the course, students' opinions were taken through the form developed by the researchers. Instructional Materials Motivation Survey (IMMS) was used to measure to student' motivation levels.
89482306|NCT03094520|Experimental|Anodal tDCS + semantic, motor, attentional tasks|Combination of gestural (subjects have to indicate if the gesture is related to the word), attentional and motor tasks with anodal stimulation
89482307|NCT03094520|Sham Comparator|Sham tDCS + semantic, motor, attentional tasks|Combination of gestural (subjects have to indicate if the gesture is related to the word), attentional and motor tasks with sham stimulation
89482308|NCT05028686||Hospitalized heart failure cohort|Patients hospitalized with heart failure
89482309|NCT05028842||Non Cirrhotic|Non Cirrhotic
89482310|NCT05028842||Compensated Cirrhotics|Compensated Cirrhotics
89482311|NCT05028842||Decompensated Cirrhotics|Decompensated Cirrhotics
89020717|NCT02959931|Experimental|High potassium meal|In this arm individuals will be provided with a breakfast meal that provides ~2400 mg of dietary potassium.
89020718|NCT02959931|Active Comparator|Low potassium meal|In this arm individuals will be provided with a breakfast meal that provides ~540 mg of dietary potassium.
89020719|NCT00349362|Experimental|Testosterone|Testosterone injections- 200mg- every 2 weeks
89020720|NCT00349362|Placebo Comparator|Placebo|Normal saline injections- every two weeks
89020721|NCT00316316|Active Comparator|1|Participants will receive motivational interviewing plus exposure and response prevention
89020722|NCT00316316|Active Comparator|2|Participants will receive exposure and response prevention only
89020723|NCT00349440|Active Comparator|1|
89203260|NCT00680186|Experimental|Dabigatran etexilate (150mg bid)|Patients will receive 1 capsule containing 150 mg dabigatran etexilate/matching placebo twice daily
89020724|NCT00349440|Placebo Comparator|2|
89203261|NCT00680186|Active Comparator|Warfarin (INR 2.0-3.0)|Patients will receive tablets PRN warfarin/matching placebo to maintain a target INR of 2.0-3.0
89020725|NCT00349479|Active Comparator|Intervention|
89020726|NCT00349479|No Intervention|Control|
89020727|NCT00349596|Experimental|Decitabine|Decitabine administered intravenously (IV) over 1 hour at 10 mg/m2 daily x 5 days every other week.
89020728|NCT00316745|Active Comparator|1|mFOLFOX6 （ → IRIS ( Irinotecan and S-1) ）
89020729|NCT00316745|Experimental|2|IRIS ( Irinotecan and S-1 ) → mFOLFOX6
89020730|NCT00349791|Placebo Comparator|1|placebo patch replaced twice a week for two years
89020731|NCT00349791|Experimental|2|testosterone patch replaced twice a week for two years
89020732|NCT00317018|Other|Arm 1|Implementation Group
89020733|NCT00317018|No Intervention|Arm 2|Control Group
89203262|NCT00936429|Experimental|10 µg DEN1-80E + 3.5 mg Alhydrogel|Administration of 10 µg DEN1-80E vaccine at Weeks 0, 4, and 8.
89203263|NCT00936429|Experimental|50 µg DEN1-80E + 3.5 mg Alhydrogel|Administration of 50 µg DEN1-80E vaccine at Weeks 0, 4, and 8.
89482312|NCT03094208|Experimental|study group|muscle strengthening, weight transfer, dual task balance exercises, dual task gait exercises.
89203264|NCT00936429|Placebo Comparator|Placebo|Administration of placebo vaccine at Weeks 0, 4, and 8.
89482313|NCT03094208|Active Comparator|control group|muscle strengthening, weight transfer, balance exercises, gait exercises.
89482314|NCT03089060|Experimental|Silicone Finger Cap|Patients randomized to this arm will be treated with the novel silicone finger cap for the first two weeks of treatment.
89482315|NCT03089060|Active Comparator|Film dressing|Patients randomized to this arm will be treated with conventional film dressings for the first two weeks of treatment.
89482316|NCT02119585||Patients undergoing OLT|insertion of nasogastric tube for measurements of chest wall mechanics
89482317|NCT02111629|Experimental|Fluconazole and Secnidazole|
89482318|NCT05015348|Experimental|O3A arm|participants of this arm will be provided with omega-3 PUFA
89482319|NCT05015348|Placebo Comparator|placebo arm|participants of this arm will be provided with same amount of palm oil as placebo
89482320|NCT02119741||Affected Interdental Papillae Group|This is the only group in which the material will be used
89482321|NCT05028218|Experimental|TQB3824 tablets|TQB3824 tablets orally administrated orally on Days 1-21 of each 21-day treatment cycle. Dose escalation of TQB3824 will be based on evaluation of clinical safety and tolerability and guided by accumulating PK data
89482322|NCT02117011|Other|Physical activity|An 8-week structured, moderate-intensity aerobic training exercise regimen concurrent with their radiation therapy (N=15),
89482323|NCT02117011|No Intervention|Control|Patients will continue with usual care, which includes radiation treatment.
89482324|NCT02111707|Active Comparator|Rectal Indomethacin pre-ERCP|Patients will receive rectal indomethacin 100mg 30 minutes before procedure (ERCP).
89482325|NCT02111707|Active Comparator|Rectal Indomethacin post-ERCP|Patients will receive rectal indomethacin 100mg immediately after procedure (ERCP)
89482326|NCT05015036||Minimally invasive surgery of the lumbar spine with ERAS|Minimally invasive surgery of the lumbar spine with Enhanced Recovery After Surgery (ERAS)
89482327|NCT05015036||Minimally invasive surgery of the lumbar spine|Minimally invasive surgery of the lumbar spine
89482328|NCT05015192|Experimental|NH102 3mg|NH102 3mg, tablet, orally, once on Day 1 or NH102 placebo-matching tablet, orally, once on Day 1. NH102 or placebo will be administered after an overnight fast of approximately at least 10 hours.
89482329|NCT05015192|Experimental|NH102 9mg|NH102 9mg, tablet, orally, once on Day 1 or NH102 placebo-matching tablet, orally, once on Day 1. NH102 or placebo will be administered after an overnight fast of approximately at least 10 hours.
89203265|NCT00656292|Placebo Comparator|Simvastatin|Subjects randomized to this arm will receive statin therapy (simvastatin 40 mg) two days before surgery -- allowing three doses of simvastatin before incision -- and these will be continued until patients are either discharged from the hospital or have completed a 3-day postoperative course (6 days of simvastatin therapy), whichever occurs earlier. If patients are unable to take oral medications, the enteral route via nasogastric tube (at our institution, nasogastric tubes are routinely placed for both lumbar and thoracic instrumentation) will be used to deliver either placebo or the statin, as no parenteral form of this drug is currently available.
89482330|NCT05015192|Experimental|NH102 20mg|NH102 20mg, tablet, orally, once on Day 1 or NH102 placebo-matching tablet, orally, once on Day 1. NH102 or placebo will be administered after an overnight fast of approximately at least 10 hours.
89482331|NCT05015192|Experimental|NH102 40mg|NH102 40mg, tablet, orally, once on Day 1 or NH102 placebo-matching tablet, orally, once on Day 1. NH102 or placebo will be administered after an overnight fast of approximately at least 10 hours.
89482332|NCT05015192|Experimental|NH102 60mg|NH102 60mg, tablet, orally, once on Day 1 or NH102 placebo-matching tablet, orally, once on Day 1. NH102 or placebo will be administered after an overnight fast of approximately at least 10 hours.
89482333|NCT05015192|Experimental|NH102 80mg|NH102 80mg, tablet, orally, once on Day 1 or NH102 placebo-matching tablet, orally, once on Day 1. NH102 or placebo will be administered after an overnight fast of approximately at least 10 hours.
89482334|NCT02119897|Experimental|Low Level Light Therapy (LLLT)|"LLLT: The LLLT device will be positioned next to the face and neck for a total of 6 exposures: Right face, Midline face, Left face, Left neck, Midline neck, Right neck~Dose per anatomic site 50mW/cm2, 60 sec = 3.0J/cm2~Route: Extraoral~Total Treatment Time (all sites): 6 min~Schedule: Participants will be treated daily (including weekends and holidays) beginning on the first day of HCT conditioning and continuing through day +20 or hospital discharge if prior to day +20.~Evaluation: Participants will undergo formal mucositis and toxicity assessments at baseline and daily from day -1 through day +20, with a final assessment on the last day of treatment."
89482335|NCT03552601|Other|traditional speed|The target amount of every day's net negative fluid balance for the first three days is 1000mL.
89482336|NCT03552601|Other|faster speed|The target amount of every day's net negative fluid balance for the first three days is 1500mL.
89482337|NCT05021588|Experimental|Group A:dexamethasone|
89482338|NCT05021588|Experimental|Group B: prednisolone or methyl prednisolone according to D-dimer levels.|
89482339|NCT05021588|Experimental|Group C: prednisolone or methylprednisolone and anticoagulants according to the flexible protocol.|
89482340|NCT03087890|Active Comparator|Cotrimoxazole|Patients in the Cotrimoxazole study arm will receive 2 tablets daily of Cotrimoxazole (trimethoprim 80mg + sulfamethoxazole 400mg), these tablets are purchased locally in Tanzania, and are the same as used for pneumocystis preventive therapy under the National AIDS control programme.
89482341|NCT03087890|Placebo Comparator|Placebo|Participants in the Placebo arm will receive 2 placebo tablets daily. These tablets have been manufactured by Kragero Tablettproduksjon AS, Norway, and care has been taken to make them look as similar as possible to the locally purchased cotrimoxazole tablets from Tanzania. Neither study participants, care providers, investigators or outcome assessors will know which patients receive cotrimoxazole or placebo
89482342|NCT02112019|Experimental|Sialoendoscopy with saline|By performing a sialoendoscopy, the ducts of the salivary glands are rinsed with saline and possible strictures are dilated
89482343|NCT02112019|Active Comparator|Sialoendoscopy: saline and hydrocortisone|By performing a sialoendoscopy, the ducts of the salivary glands are rinsed with saline and hydrocortisone and possible strictures are dilated
89482344|NCT02112019|No Intervention|Control: no treatment|
89482345|NCT04434638|Experimental|Transitions of Care Coordinator Group|We developed the Transition of Care Coordinator (TOCC) program to aid in the completion of the diagnostic evaluations as well as in the transition out of the acute care hospital setting. In the TOCC intervention, the stroke nurse navigator completed eight specific tasks: (1) met the patient and family within 48 hours of admission, (2) identified patient home location and insurance status, (3) coordinated communication between treating providers (neurologists, cardiologists, etc.) regarding pending diagnostic tests, (4) followed up physical, occupational, and speech therapy teams' recommendations for rehabilitation, (5) attended daily multi-disciplinary rounds, (6) facilitated referrals to acute and subacute rehabilitation facilities with case managers, (7) assisted beside nurses in providing tailored stroke education and discharge instructions to patients and families, and (8) arranged stroke clinic follow-up appointments.
89482346|NCT04434638|Active Comparator|Usual Care Group|Patients in the usual care group, which served as the control, received the current, ongoing method of care coordination by members of the multi-disciplinary stroke team. The current practice is that members of this multi-disciplinary team meet with each other every weekday morning to discuss the discharge plan of care for each stroke patient on the inpatient stroke service. Physicians, nurses, rehabilitation therapists and case managers are then individually responsible for talking to patients and their families/caregivers about the different aspects of the plan of care.
89482347|NCT02117401|Experimental|group 1|age: 2 to 12 months induction dosage of mivacurium chloride: 0.15 mg/kg administration: intravenous injection for 20 s
88951891|NCT01951287|Experimental|Acute beverage (Skim Milk) consumption|Acute beverage (Skim Milk)consumption with breakfast measuring blood glucose and insulin levels at specific time points. consumption with breakfast measuring blood glucose and insulin levels at specific time points
89482348|NCT02117401|Experimental|group 2|age: 2 to 12 months induction dosage of mivacurium chloride: 0.15 mg/kg administration: intravenous injection for 40 s
89482349|NCT02117401|Experimental|group 3|age: 2 to 12 months induction dosage of mivacurium chloride: 0.20 mg/kg administration: intravenous injection for 20 s
89482350|NCT02117401|Experimental|group 4|age: 2 to 12 months induction dosage of mivacurium chloride: 0.20 mg/kg administration: intravenous injection for 40 s
89482351|NCT02117401|Experimental|group 5|age: 13 to 35 months induction dosage of mivacurium chloride: 0.20 mg/kg administration: intravenous injection for 20 s
89482352|NCT02117401|Experimental|group 6|age: 13 to 35 months induction dosage of mivacurium chloride: 0.20 mg/kg administration: intravenous injection for 40 s
89482353|NCT02117401|Experimental|group 7|age: 13 to 35 months induction dosage of mivacurium chloride: 0.25 mg/kg administration: intravenous injection for 20 s
89482354|NCT02117401|Experimental|group 8|age: 13 to 35 months induction dosage of mivacurium chloride: 0.25 mg/kg administration: intravenous injection for 40 s
89482355|NCT02117401|Experimental|group 9|age: 3 to 6 years induction dosage of mivacurium chloride: 0.20 mg/kg administration: intravenous injection for 20 s
89482356|NCT02117401|Experimental|group 10|age: 3 to 6 years induction dosage of mivacurium chloride: 0.20 mg/kg administration: intravenous injection for 40 s
89482357|NCT02117401|Experimental|group 11|age: 3 to 6 years induction dosage of mivacurium chloride: 0.25 mg/kg administration: intravenous injection for 20 s
88951892|NCT01951300|Other|Gallium-68 citrate|Intravenous bolus injection of 200 MBq of Gallium-68 citrate
88951893|NCT01951313|Experimental|Egg consumption|No egg 75g of scrambled eggs 150g of scrambled eggs
88951894|NCT01951365||Growing schwannoma|Overall volumetric growth rate more over than 10%
88951895|NCT01951365||Stable schwannoma|Overall volumetric growth rate less than 10%
88951896|NCT01951404|Active Comparator|Allopurinol|Participants in this arm will be given allopurinol with the dose gradually increasing weekly as tolerated up to the dose determined in the first phase of the study. The drug dose will be given orally 3 times weekly after dialysis for 1 year.
89482358|NCT02117401|Experimental|group 12|age: 3 to 6 years induction dosage of mivacurium chloride: 0.25 mg/kg administration: intravenous injection for 40 s
88951897|NCT01951404|Placebo Comparator|Placebo|Participants in this arm will be given placebo with the dose appearing to gradually increase weekly as tolerated up to the dose determined in the first phase of the study. The drug dose will be given orally 3 times weekly after dialysis for 1 year.
88951898|NCT01951430||Myelodysplastic syndrome patients|Patients affected by myelodysplastic syndrome enrolled in the observational study
88951899|NCT01951443|Experimental|Ginseng|Encapsulated 400mg Rg3-KRG extract
88951900|NCT01951443|Placebo Comparator|Wheat Bran|400mg Wheat Bran capsule
89206292|NCT04093271|Experimental|Randomized to consume Rest-ZZZ, comparator, then placebo|Each study product will be consumed as 2 capsules daily for 7 days. Randomized to consume the Rest-ZZZ dietary supplement in Study Period 1, Comparator (Diphenhydramine HCl) in Study Period 2, and Placebo in Study Period 3.
89482359|NCT02117401|Experimental|group 13|age: 7 to 14 years induction dosage of mivacurium chloride: 0.20 mg/kg administration: intravenous injection for 20 s
89482360|NCT02117401|Experimental|group 14|age: 7 to 14 years induction dosage of mivacurium chloride: 0.20 mg/kg administration: intravenous injection for 40 s
89482361|NCT02117401|Experimental|group 15|age: 7 to 14 years induction dosage of mivacurium chloride: 0.25 mg/kg administration: intravenous injection for 20 s
89482362|NCT02117401|Experimental|group 16|age: 7 to 14 years induction dosage of mivacurium chloride: 0.25 mg/kg administration: intravenous injection for 40 s
89482363|NCT04434404|Placebo Comparator|control group|33, patients in the control group received anthracycline-containing chemotherapy in a dose of 50 mg/m2 without cardioprotective agents
89482364|NCT04434404|Active Comparator|L-carnitine group|25 patients received anthracycline-containing chemotherapy in a dose of 50 mg/m2 plus L-carnitine
89482365|NCT04434404|Active Comparator|Silymarin group|25 patients received anthracycline-containing chemotherapy in a dose of 50 mg/m2 plus Silymarin140 mg
89482366|NCT03092336|Experimental|Electrical Stimulation|"The training with electrostimulation will be performed with the following intensity:~Medium frequency current: 2.500Hz Modulation frequency: up to 50Hz Time on / off: 1: 2 Average session time 10 to 15 min Being applied in the same muscle groups that will be trained in the group that will perform strength training."
89482367|NCT03092336|Experimental|Strength training|There will be 10 exercises: upper limbs: Supine with dumbbells; High pulley pull; Alternating thread with dumbbells; Triceps dumbbell test; Lower limbs: knee extensor, squatting with body weight, plantar flexion, knee flexion and plantar dorsiflexion. The session time will be from 45 minutes to one hour 2 times weekly totaling at the end of the 12 weeks, 24 strength training sessions.
89482368|NCT02117557|Experimental|Single incision laparoscopic surgery|Transumbilical single incision laparoscopic surgery will be performed for patients in this group.And addition of only one trocar through the stoma for drainage tube is allowed.
89482369|NCT02117557|Active Comparator|Conventional laparoscopic surgery|Conventional laparoscopic surgery for colorectal cancer will be performed for patients in this group.
89482370|NCT02119975|Placebo Comparator|Placebo working memory training|
89482371|NCT02119975|Experimental|Working memory training|
89482372|NCT02120053|Experimental|Bone substitute material group|Immediate denture placement following extractions and alveolar sockets filling with bone substitute material
89482373|NCT02120053|Active Comparator|Conventional protocol|Immediate denture placement following the conventional protocol
89482374|NCT03552445|Active Comparator|Tetanus-diphtheria (Td) and PCV13|
89482375|NCT03552445|Active Comparator|PCV13 alone|
89482376|NCT03552445|Active Comparator|Td alone|
89482377|NCT02117635|Experimental|allogeneic human neural stem cell|"CTX DP~human neural stem cell product, single dose once only injection"
89482378|NCT02251483|Other|SBI|Group 1: SBI (N=30) - one packet daily
89482379|NCT02251483|Placebo Comparator|Placebo|Group 2: Placebo (N=30) - one packet daily
89482380|NCT02120131||test envelope|envelope flap
89482381|NCT02120131||control, trapezodal|standard incision
89482382|NCT02117869|Experimental|Low furanocoumarin hybrid grapefruit juice|3 consecutive daily doses of 200ml low furanocoumarin hybrid grapefruit juice plus midazolam 5mg orally on the third day.
89482383|NCT02117869|Active Comparator|Regular grapefruit juice|3 consecutive daily doses of 200ml regular grapefruit juice plus midazolam 5mg orally on the third day.
89482384|NCT02117869|Other|water (control)|3 consecutive daily doses of 200ml water plus midazolam 5mg orally on the third day.
89482385|NCT02120521||Sepsis group|Sixty patients are critically ill with evidence of sepsis during ICU stay (sepsis group) and sixty patients are critically ill without evidence of infectious organism (SIRS group). At admission, Patients data include clinical status; SOFA score; central venous pressure; laboratory analysis and arterial blood gas analysis are measured. Routine cultures will be obtained. The attending physician will evaluate the patients for sepsis, severe sepsis, or septic shock as long as their stay in ICU. A serum level of sTREM-1 and MNDA will be monitored.
89482386|NCT02120521||SIRS group|Sixty patients are critically ill without evidence of infectious organism (SIRS group). At admission, Patients data include clinical status; SOFA score; central venous pressure; laboratory analysis and arterial blood gas analysis are measured. Routine cultures will be obtained. The attending physician will evaluate the patients for sepsis, severe sepsis, or septic shock as long as their stay in ICU. A serum level of sTREM-1 and MNDA will be monitored.
89482387|NCT02120599|Active Comparator|corn-soy-blend|This is the control group for the study, which will receive the Malawi standard of care. The treatment provided to women randomized to this arm of the study includes daily iron (60 mg) and folic acid (400 mcg) supplementation, along with 4 kg/2 weeks corn-soy blend (~357 gm/d CSB).
89482388|NCT02120599|Experimental|corn-soy-blend + multiple micronutrients|The treatment provided to women randomized to this arm of the study includes 200gm/d CSB along with a standard maternal multiple micronutrient tablet, which together provide a comparable amount of energy, protein and micronutrients to the ready-to-use supplemental food. The micronutrient supplement known as the United Nations Children's Emergency Fund (UNICEF) / World Health Organization (WHO) / United Nations University (UNU) international multiple micronutrient preparation (UNIMMAP) is widely available and has been used in many settings worldwide in pregnant women.
89482389|NCT02120599|Experimental|ready-to-use supplementary food|RUSF-P (ready-to-use supplementary food) provides 750 kcal/d, 20 g protein/d, and 200% of RDA/d for most micronutrients during pregnancy (except for vitamins A, B3, folic acid, minerals iodine, magnesium, and calcium which will remain near 100%)
89482390|NCT01672970||Cohort|
89482391|NCT02112097|Experimental|For Left Upper Arm|"For Left Upper Arm Total Persistent % subdermally, For Left Upper Arm Total Persistent % subcutaneously, and For Left Upper Arm Relative Prolongation Ability Score.~Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9cc normal saline subcutaneously for 30 patients, and subdermally with ASIS Device for 30 patients."
89531481|NCT06065904|No Intervention|CP with a standard of care nutritional menu|Children with CP that will not be advised on a specific menu
88951901|NCT01951456|Experimental|Resistance training|Participants will attend two, 45-60-minute progressive, moderate intensity resistance training sessions per week for 12 weeks. The program will maintain a format of a 5-minute warm-up, 35-50 minutes of resistance training and a 5-minute cool-down with flexibility and abdominal exercises.
89482392|NCT02112097|Experimental|For Right Upper Arm|"For Right Upper Arm Total Persistent % subdermally, For Left Upper Arm Total Persistent % subcutaneously, and For Left Upper Arm Relative Prolongation Ability Score.~Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9cc normal saline subcutaneously for 30 patients, and subdermally with ASIS Device for 30 patients."
89482393|NCT02112097|Experimental|sPGA 50 n(%)|"sPGA 50 n(%) as Efficacy of Enbrel subcutaneously at Week 12, Efficacy of Enbrel subcutaneously at Week 24, and Efficacy of Enbrel subcutaneously at Week 36 vs. Efficacy of Enbrel subdermally at Week 12, Efficacy of Enbrel subdermally at Week 24, and Efficacy of Enbrel subdermally at Week 36. sPGA 50 n(%) clear or minimal is the % of patients who achieve a score of clear or minimal by the Static Physician Global Assessment (sPGA) and % of patients with a reduction of PASI of at least 50% from baseline."
89482394|NCT02112097|Experimental|PASI 75 n(%)|"PASI 75 n(%)~Response to treatment defined as the proportion of patients who achieved a reduction in score of at least 75% from baseline by the PASI, as PASI 75 n(%) subcutaneously at Week 12, PASI 75 n(%) subcutaneously at Week 24, and PASI 75 n(%) subcutaneously at Week 36 vs. PASI 75 n(%) subdermally at Week 12, PASI 75 n(%) subdermally at Week 24, and PASI 75 n(%) subdermally at Week 36."
89482395|NCT02112097|Experimental|Adverse Injection site reactions|Injection site reactions as Adverse Reactions of Enbrel subcutaneously vs. Adverse Reactions of Enbrel subdermally at Week 36.
89482396|NCT02112097|Experimental|Adverse Reactions with Heart failure|Heart failure as Adverse Reactions of Enbrel subcutaneously vs. Adverse Reactions of Enbrel subdermally at Week 36.
89482397|NCT02112097|Experimental|Adverse Reactions Allergic Reactions|Allergic Reactions as Adverse Reactions of Enbrel subcutaneously vs. Adverse Reactions of Enbrel subdermally at Week 36.
89482398|NCT02112097|Experimental|Adverse Reactions Blood/low blood counts|Blood problems/low blood counts as Adverse Reactions of Enbrel subcutaneously vs. Adverse Reactions of Enbrel subdermally at Week 36.
89482399|NCT02112097|Experimental|Adverse Reactions with Nervous system|Nervous system problems, such as multiple sclerosis, seizures, or inflammation of the nerves of the eyes, as Adverse Reactions of Enbrel subcutaneously vs. Adverse Reactions of Enbrel subdermally at Week 36.
89482400|NCT02112097|Experimental|Adverse Reactions with Infections|Infections (upper respiratory infection, pyelonephritis, bronchitis, septic osteomyelitis, wound infection, pneumonia, foot abscess, leg ulcer), as Adverse Reactions of Enbrel subcutaneously vs. Adverse Reactions of Enbrel subdermally at Week 36.
89482401|NCT02112097|Experimental|Adverse Reactions with Malignancies|Malignancies (lymphoma, basal & squamous skin cancer, non-cutaneous solid tumor, & Wegener's granulomatosis), as Adverse Reactions of Enbrel subcutaneously vs. Adverse Reactions of Enbrel subdermally at Week 36.
89482402|NCT02112097|Experimental|Adverse Reactions with Immunogenicity|Immunogenicity as Adverse Reactions of Enbrel subcutaneously vs. Adverse Reactions of Enbrel subdermally at Week 36.
89482403|NCT02112097|Experimental|Adverse Reactions with Autoantibodies|Autoantibodies, Lupus-like syndrome, autoimmune hepatitis, as Adverse Reactions of Enbrel subcutaneously vs. Adverse Reactions of Enbrel subdermally at Week 36.
89482404|NCT02112175|Experimental|Lenalidomide|Treatment Arm A: lenalidomide 10 mg/day orally from Days 1 to 21; given in 28-day cycles for up to disease progression.
89482405|NCT05027984|Experimental|Intermediate lesion OCT-based management|"At OCT analysis, lesion features prompting intervention instead of conservative approach will be the following:~FCT <75 µm, plus at least 2 of 3 other OCT criteria of plaque vulnerability (i.e., MLA <3.5 mm2, lipid arc with circumferential extension >180°, and the presence of macrophages).~The presence of intracoronary thrombus at a non-culprit site, irrespective of the presence of other vulnerability criteria, may prompt treatment with DES, at the operator's discretion.~All lesions fulfilling these interventional criteria will be treated with an OCT guided DES implantation in order to achieve an optimal stent implantation.~In presence of a MLA <2.0 mm2, best cut-off showing correlation with fractional-flow reserve positive functional (FFR) assessment, clinical decision whether to treat the lesion will be based on FFR assessment irrespective of the presence of other criteria of vulnerability. Alternatively authors will have the option to treat the lesion with a DES."
89482406|NCT05027984|Active Comparator|Intermediate lesion physiology-based management|The iFR/FFR/RFR measurements will be obtained using a coronary-pressure guidewire. For FFR, hyperemia will be induced with the administration of intravenous adenosine, in accordance with the clinical practice at each participating center. Lesion features prompting intervention instead of conservative medical approach will be the following: iFR ≤0.89, or FFR ≤0.80.(32) All lesions fulfilling these interventional criteria will be treated with an FFR guided DES implantation. PCI will be performed with the aim of achieving a post-stenting FFR ≥0.90 (i.e. optimal FFR result). If post-stenting FFR was <0.90 a further post-dilation of the stent could be performed and if FFR remained at <0.90, a pullback of the wire to identify another possible pressure drop and/or a subsequent stent implantation at least 5 mm from the stent will be performed according to physician's preference.
89482407|NCT03553537|Experimental|Decitabine + CHOP regimen|decitabine plus CHOP (D-CHOP) administered in 4 week cycles for 6 cycles
89482408|NCT03553537|Active Comparator|CHOP regimen|cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) administered in 3 week cycles for 6 cycles
89482409|NCT05027828||patients using olaparib only|
89482410|NCT05027828||patients using olaparib combined with bevacizumab|
89482411|NCT02117947|Experimental|Behavioral Counseling|Behavioral counseling used evidence-based smoking cessation intervention components as well as a theoretically-framed focus on behavioral shaping to promote the adoption of smoke-free homes and cars. Sessions included two, 1-hour in-home counseling and seven, 5-15 minute telephone follow-up sessions over 16 weeks. Content included health ed around the benefits of eliminating children's exposure to secondhand smoke; skills training around adoption and maintenance of smoke-free environments; goal setting, problem solving, and positive reinforcement for progress toward goals; coping skills training for smoking urge and mood management; and home support for maternal smoking behavior change achieve through family contracts and home detailing promoting pro-smoke-free home norms.
89531482|NCT06065904|Experimental|ASD with recommended diet|Children with ASD that will not be advised on a specific menu
89203266|NCT00656292|Experimental|Placebo|Subjects randomized to this arm will receive placebo two days before surgery -- allowing three doses of placebo before incision -- and these will be continued until patients are either discharged from the hospital or have completed a 3-day postoperative course (6 days of placebo), whichever occurs earlier. If patients are unable to take oral medications, the enteral route via nasogastric tube (at our institution, nasogastric tubes are routinely placed for both lumbar and thoracic instrumentation) will be used to deliver either placebo or the statin, as no parenteral form of this drug is currently available.
89482412|NCT02117947|Active Comparator|Self-help control|The self-help control group received a comprehensive self-help manual that outlined all of the goals and strategies covered in counseling, however, counseling was not provided to this group.
89482413|NCT05027672|Active Comparator|Gam-COVID-Vac (rAd26) / Gam-COVID-Vac (rAd5)|At the time of randomisation, patients in this arm receive a second dose of Sputnik V (rAd5) vaccine component two.
89482414|NCT05027672|Experimental|Gam-COVID-Vac / ChAdOx1 nCoV-19|At the time of randomisation, patients in this arm receive Astra Zeneca's vaccine (ChAdOx1 nCoV-19) as a second dose.
89482415|NCT05027672|Experimental|Gam-COVID-Vac / Gam-COVID-Vac (rAd26)|At the time of randomisation, patients in this arm receive a second dose of a repeat of the first component of the Sputnik V vaccine (rAd26) as a second dose.
89482416|NCT05027672|Experimental|Gam-COVID-Vac / mARN-1273|At the time of randomisation, patients in this arm receive as a second dose the vaccine produced by Moderna (mRNA-1273).
89482417|NCT02118025||Off-pump coronary artery bypass graft|Patients operated on with off-pump coronary artery bypass graft, beating heart surgery.
89482418|NCT02118025||Mini extracorporeal circulation bypass|Patients operated on with mini extracorporeal circulation bypass. A modified extracorporeal system.
89482419|NCT02118103|Experimental|Spinal Manipulation|bilateral lumbar spine manipulation
89482420|NCT02118103|No Intervention|No Intervention - control|no intervention
89482421|NCT03086174|Experimental|humanized anti-PD-1monoclonal antibody|humanized anti-PD-1 monoclonal antibody is to be injected intravenously 1mg/kg or 3mg/kg Q2w PLUS axitinib 5 mg orally Q2w until disease progresses or unacceptable tolerability occurs
89482422|NCT02112253|Experimental|Deep brain stimulator ventral electrode up to 2 mA|The ventral contact within the anterior globus pallidus interna near the ansa lenticularis is activated. Stimulator settings are 90 microseconds pulse width and stimulation frequency of 130 Hertz. Amplitude of stimulation is raised from zero until side effects occur or 2 mA amplitude is reached; whichever comes first.
89482423|NCT02112253|Experimental|Deep brain stimulator ventral electrode up to 3 mA|The ventral contact within the anterior globus pallidus interna near the ansa lenticularis is activated. Stimulator settings are 90 microseconds pulse width and stimulation frequency of 130 Hertz. Amplitude of stimulation is raised from zero until side effects occur or 3 mA amplitude is reached; whichever comes first.
89482424|NCT02112253|Experimental|Deep brain stimulator dorsal electrode up to 2 mA|The dorsal contact within the superior half of the anterior globus pallidus interna is activated. Stimulator settings are 90 microseconds pulse width and stimulation frequency of 130 Hertz. Amplitude of stimulation is raised from zero until side effects occur or 2 mA amplitude is reached; whichever comes first.
89482425|NCT02112253|Experimental|Deep brain stimulator dorsal electrode up to 3 mA|The dorsal contact within the superior half of the anterior globus pallidus interna is activated. Stimulator settings are 90 microseconds pulse width and stimulation frequency of 130 Hertz. Amplitude of stimulation is raised from zero until side effects occur or 3 mA amplitude is reached; whichever comes first.
89482426|NCT02112253|Active Comparator|Deep brain stimulator empirical programming|Any of the four electrode contacts on each of the two deep brain stimulation leads can be activated in any combination with any amplitude, frequency or pulse width settings to achieve optimized clinical control of motor tics whilst minimizing side effects. Both programmer and patient may be unblinded. The assessors are blinded to stimulation settings.
89482427|NCT04131764||Optic neuritis diagnosis only|Patients who have a diagnosis of optic neuritis, without a diagnosis of MS or NMOSD.
89482428|NCT04131764||ON and multiple sclerosis|Patients who have a diagnosis of optic neuritis AND multiple sclerosis.
89482429|NCT04131764||ON and NMOSD|Patients who have a diagnosis of optic neuritis and neuromyelitis optica spectrum disorder.
89482430|NCT03085862||Lung ultrasound and EVLW|This prospective study involved 60 patients without known cardiac or pulmonary diseases admitted to the intensive care unit at our hospital after elective abdominal or vascular surgery. The inferior vena cava collapsibility index (IVCcl), PaO2/FiO2 ratio, and appearance of B-lines ≤7 mm were determined upon admission to the intensive care unit and at 6, 12, and 24 h later. Fluid overload was defined as IVCcl ≤ 40% and the presence of B-lines ≤7 mm. Tissue oxygenation impairment was defined as a PaO2/FiO2 ratio < 200.
89482431|NCT03085784|Experimental|Loading Dose|"20 Patients will receive 4, 2 mg IVT Aflibercept (IAI) a month apart, screening/baseline, weeks 4, 8, & 12. At week 12, patient will be followed & treated per treat & extend protocol.~Treat & Extend Protocol entails patients being extended as long as:~Absence of retinal fluid (resolution of intraretinal & subretinal fluid on SD-OCT; Small intraretinal cysts that don't distort foveal contour on SD-OCT are acceptable & can be considered dry.) AND~< 5 ETDRS letter loss from previous visit, due to new or persistent retinal edema.~Each extension will be 2 weeks in duration beyond the initial 4-week interval. If the extension criteria are not met on a follow-up visit, treatment interval will be reduced by 2 weeks. Follow up interval will continue to be reduced by 2 weeks until the extension criteria are met or a 4-week interval is reached."
89482432|NCT03085784|Experimental|Treat and Extend|"20 Patients will receive 2 mg IVT Aflibercept (IAI) at screening/baseline followed by a visit at week 4. At week 4, patient will be treated & followed per the treat & extend protocol.~Treat & Extend Protocol entails patients being extended as long as:~Absence of retinal fluid (resolution of intraretinal & subretinal fluid on SD-OCT; Small intraretinal cysts that don't distort foveal contour on SD-OCT are acceptable & can be considered dry.) AND~< 5 ETDRS letter loss from previous visit, due to new or persistent retinal edema.~Each extension will be 2 weeks in duration beyond the initial 4-week interval. If the extension criteria are not met on a follow-up visit, treatment interval will be reduced by 2 weeks. Follow up interval will continue to be reduced by 2 weeks until the extension criteria are met or a 4-week interval is reached."
89482433|NCT02788747|Experimental|4 mg elamipretide|4 mg elamipretide once daily for 28 consecutive days
89482434|NCT02788747|Experimental|40 mg elamipretide|40 mg elamipretide once daily for 28 consecutive days
89203267|NCT00936507|Experimental|Low-ED, small portion|
89203268|NCT00936507|Experimental|Low-ED, large portion|
88951902|NCT01951456|Active Comparator|Health and Wellness|Participants in this group will be required to attend the exact same number of sessions as those in the Resistance Training group. Each session will last approximately 45-60 minutes. Sessions will include a practical component/demonstration, an informational video, and a handout on a pertinent healthy lifestyle topic for adults.
88951903|NCT01951482|Experimental|Bevacizumab and Pemetrexed/cisplatin|Bevacizumab 7.5mg/kg d1+Pemetrexed/cisplatin q21d
89203269|NCT00936507|Experimental|High-ED, small portion|
89203270|NCT00936507|Experimental|High-ED, large portion|
89203271|NCT00352417|Experimental|VIA-2291|
89203272|NCT00352417|Placebo Comparator|Placebo|Matching Placebo
89203273|NCT00809640|Active Comparator|1|The intervention group will receive prevention of low back pain education through a Back Comic-Book, and their beliefs/knowledge will be tested twice after intervention.
89203274|NCT00809640|No Intervention|2|The control group will receive no intervention, and their beliefs/knowledge on low back pain will be tested twice after the first assessment.
89203275|NCT01055509|Experimental|Cognitive Adaptation Training|Cognitive adaptation training and treatment as usual
89203276|NCT01055509|No Intervention|Treatment as ususal|Pharmacological treatment, weekly contact to professionals (often in patient's homes), psychoeducation, social skill training in groups and psychosocial intervention with relatives.
89203277|NCT00944619|Experimental|Closed loop (algorithm)|Subcutaneous delivery of Novorapid insulin, dose calculated by computer-driven control algorithm, based on continuous glucose sensor readings
89203278|NCT00944619|Placebo Comparator|Open loop|Subcutaneous delivery of Novorapid insulin according to usual pump regime
89203279|NCT00805896|Experimental|1|Songyou Granule
89203280|NCT00805896|Placebo Comparator|2|
89203281|NCT00323869|Experimental|Bevacizumab + carboplatin + gemcitabine|"Bevacizumab in combination with carboplatin and gemcitabine:~•Carboplatin, administered IV at area under the curve (AUC) of 5, every 3 weeks on day 1 of each 3-week cycle (once per cycle) for up to 6 cycles.~Carboplatin was administered before the gemcitabine infusion:~•Gemcitabine, administered 1000 mg/m² IV on days 1 and 8 of each 3-week cycle (twice per cycle) for up to 6 cycles~Bevacizumab was administered 1 hour after end of all chemotherapy infusions:~•Bevacizumab was administered 15 mg/kg IV on day 1 of each 3-week cycle (once per cycle) for up to 6 cycles in combination with chemotherapy, then continuing until evidence of progressive disease or significant treatment-related toxicity"
89203282|NCT05434832|Experimental|Virtual Reality Group|watching the cartoon by wearing virtual reality glass to the child during the intramuscular injection
89203283|NCT05434832|Experimental|Local cold-vibration Group|The local cold-vibration device is placed 5 cm above the area to be injected
89203284|NCT05434832|No Intervention|Control Group|standart care
89203285|NCT01057927|Experimental|OC000459|
89203286|NCT01057927|Placebo Comparator|Placebo|
89203287|NCT01058083|Experimental|BMS-770767 (Treatment A)|
89203288|NCT01058083|Experimental|BMS-770767 (Treatment B)|
89203289|NCT01058083|Experimental|BMS-770767 (Treatment C)|
89203290|NCT01058083|Experimental|BMS-770767 (Treatment D)|
89203291|NCT01058083|Placebo Comparator|Placebo (Treatment E)|
89203292|NCT05434676|Experimental|IVL group|Shockwave Medical Peripheral Intravascular Lithotripsy (IVL) System M5 or S4
89203293|NCT00323557|Experimental|Pneumococcal Vaccine + GM-CSF|Vaccine subcutaneously + GM-CSF (3 Doses of 250 mg subcutaneously) given either Pre Vaccine at Day -7, Day -1 and Day 0 (day of pneumococcal vaccine) or Post Vaccine given at Day 0, Day +3 and Day +7.
89203294|NCT00323557|Experimental|Pneumococcal Vaccine Alone|First vaccine dose subcutaneously, Day 0.
89203295|NCT00558363|Experimental|Avodart|Patients will receive a 3-month supply of study drug or placebo. Patients will be instructed to take one capsule by mouth once daily. Study medication will be supplied at 3-month intervals during scheduled clinic visits for a total of 24 months.
89203296|NCT00558363|Placebo Comparator|Placebo Arm|Patients will receive a 3-month supply of study drug or placebo. Patients will be instructed to take one capsule by mouth once daily. Study medication will be supplied at 3-month intervals during scheduled clinic visits for a total of 24 months.
89203297|NCT00352105|Experimental|Concurrent Chemotherapy and ZD1839|
89203298|NCT00944775|Experimental|exercise training|10-month exercise training program
89203299|NCT00944775|No Intervention|controls|usual care sedentary lifestyle
89203300|NCT03988075|Active Comparator|Acetaminophen and hydrocodone based pain control|Patients receive acetaminophen 650mg every 4 for pain level 1-3, hydrocodone/acetaminophen 5/325mg every 4 for pain level 4-6, or hydrocodone/acetaminophen 10/650mg every 4 for pain level 7-10 on as needed basis.
89203301|NCT03988075|Experimental|Acetaminophen and ibuprofen based pain control|Patients receive standing dose of acetaminophen 650mg every 8 hours and ibuprofen 800mg every 8 hours with alternating ibuprofen and acetaminophen every 4 hours.
89203302|NCT00944853|Experimental|Zinc syrup|Liquid Zinc Syrup (ZnSO4) solution provided daily
89482435|NCT02788747|Placebo Comparator|Placebo|Placebo once daily for 28 consecutive days
89482436|NCT05021276|Experimental|ruxolitinib+basiliximab|Patients with grade 3-4 steroid-refractory aGVHD receive combined therapy of basiliximab and ruxolitinib.
89531483|NCT06065904|No Intervention|ASD with a standard of care nutritional menu|Children with ASD that will not be advised on a specific menu
89531484|NCT06065891|Other|Resection of Paraartic lymph nodes|Single arm
89203303|NCT00944853|Experimental|Zinc tablet|Dispersible zinc tablets provided daily
89482437|NCT01796054|Experimental|Stress Free Now with group support|Randomized participants have access to online stress reduction program, Stress Free Now. Participants will log in to online program, read daily lessons and practice therapeutic exercises. They will also attend weekly group support session during 6-week program
89482438|NCT01796054|Experimental|Stress Free Now|Randomized participants have access to online stress reduction program, Stress Free Now, for 6 weeks. Participants will log into online program, read daily lessons and practice therapeutic exercises.
88951904|NCT01951482|Active Comparator|Pemetrexed/cisplatin|Pemetrexed/cisplatin q21d
88951905|NCT01951508|Other|Methylphenidate, Modafinil, MDMA, Placebo|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but four treatment conditions in the same subject.
88951906|NCT01951521|Experimental|Boost|Boost radiation consists of 5 fractions of 3 Gy (total 15 Gy) delivered to the tumor (Gross Tumor Volume) additional to standard chemoradiation of 50 Gy with Capecitabine.
88951907|NCT01951521|No Intervention|Standard chemoradiation|Standard chemoradiation consisting of 25 x 2 Gy (total 50 Gy) with Capecitabine.
88951908|NCT01951534|Experimental|Breast Reconstruction Decisional Aid (BRDA)|In the BRDA arm, participants will be provided with a website address for using the Breast Reconstruction Decisional Aid, a secure password, and instructions for using the website for the decisional aid.
88951909|NCT01951534|Other|Usual Care (UC)|In the UC Condition, the participant will not be given the web-based decisional aid but will be given the Cancer Support Community pamphlet. This 56-page pamphlet contains information about the types of Breast Reconstruction, lists reasons why women choose reconstruction, key factors to considering when deciding, how to plan for surgery, possible risks, and a glossary of terms. The pamphlet is primarily informational. It is not customized, not interactive.
88951910|NCT01951547|Experimental|Nonsurgical periodontal therapy|Nonsurgical periodontal therapy given at baseline
88951911|NCT01951547|Active Comparator|Oral hygiene instructions|Oral hygiene instructions given at baseline
88951912|NCT01951560|Experimental|valproic acid (Depacon)|Valproic acid by IV infusion over one hour
88951913|NCT01951560|Placebo Comparator|Isotonic saline solution|The placebo administered by IV infusion over 1 hour
88951914|NCT01951599|Experimental|AZD9291 20mg (oral capsule fasted)|Volunteers will receive AZD9291 20mg administered by mouth, as a capsule, in the fasted state.
88951915|NCT01951599|Experimental|AZD9291 20mg (oral solution fasted)|Volunteers will receive AZD9291 20mg administered by mouth, as a solution, in the fasted state.
88951916|NCT01951599|Experimental|AZD9291 20mg (oral tablet fasted)|Volunteers will receive AZD9291 20mg administered by mouth, as a tablet, in the fasted state.
88951917|NCT01951599|Experimental|AZD9291 20mg (oral fasted)|Volunteers will receive AZD9291 20mg administered by mouth, as a capsule or tablet in the fasted state.
88951918|NCT01951599|Experimental|AZD9291 20mg (oral fed)|Volunteers will receive AZD9291 20mg administered by mouth, as a capsule or tablet in the fed state.
88951919|NCT01951612|Experimental|Executive Function Training Program|Participants in this group will receive the novel intervention training.
88951920|NCT01951612|Active Comparator|Psychoeducational Training Program|Participants in this group will receive the control intervention training.
88951921|NCT01951664|Experimental|Modified Yoga Program for HNC Survivors|Following the completion of baseline study measures, participants will be randomized to either do go directly into a Yoga program or to an 8 week wait-list control group. Those in the yoga program will undergo an initial Yoga Evaluation. Patients will receive customized yoga guided practice program, a home practice plan with ongoing modifications. Instructors will assess compliance. A satisfaction assessment is conducted at study-end.
88951922|NCT01951664|Active Comparator|Wait list control|Those in the wait list group will have the same assessments as those in the yoga program over the same period of time.
88951923|NCT01951677|Active Comparator|HBsAg + alum adjuvant|HBsAg + standard alum adjuvant
88951924|NCT01951677|Experimental|HBsAg + Advax-1(TM)|HBsAg + Advax-1
88951925|NCT01951677|Experimental|HBsAg + Advax-2(TM)|HBsAg + Advax-2
88951926|NCT01951677|Experimental|HBsAg + Advax-3(TM)|HBsAg + Advax-3
89203304|NCT00944853|Placebo Comparator|Placebo|Liquid placebo supplement provided daily
89203305|NCT03987997|Active Comparator|Association electrical muscle stimulation with cyclo-ergometer|Randomized leg with receive electrical muscle stimulation of the quadriceps in addition to early mobilization of lower limbs with cyclo-ergometer.
88951927|NCT01951677|Active Comparator|preS HBsAg + alum adjuvant|preS HBsAg + alum adjuvant
88951928|NCT01951677|Experimental|preS HBsAg + Advax-1(TM)|preS HBsAg + Advax-1
88951929|NCT01951677|Experimental|preS HBsAg + Advax-2(TM)|preS HBsAg + Advax-2
88951930|NCT01951677|Experimental|preS HBsAg + Advax-3(TM)|preS HBsAg + Advax-3
88951931|NCT01951677|Active Comparator|high dose preS HBsAg + alum adjuvant|high dose preS HBsAg + alum adjuvant
88951932|NCT01951677|Experimental|high dose preS HBsAg + Advax-1(TM)|high dose preS HBsAg + Advax-1
88951933|NCT01951677|Experimental|high dose preS HBsAg + Advax-2(TM)|high dose preS HBsAg + Advax-2(TM)
88951934|NCT01951677|Experimental|high dose preS HBsAg + Advax-3(TM)|high dose preS HBsAg + Advax-3
88951935|NCT01951716|Experimental|Truncal Vagotomy|Healthy participants without diabetes who have undergone a complete truncal vagotomy
88951936|NCT01951716|Experimental|No Vagotomy|Healthy participants without diabetes who have not had a complete truncal vagotomy
88951937|NCT01951729|Experimental|Pre-diabetes|Otherwise healthy individuals exhibiting hemoglobin A1c levels between 6.0% - 7.0%
88951938|NCT01951781|Other|NEOCD64|NEOCD64 : dosage of CD64 blood marker in preterm newborn who are suspected of nosocomial infection (blood sample)
89203306|NCT03987997|Other|Cyclo-ergometer only|This control group correspond to the leg which don't receive electrical muscle stimulation (as usually supported)
89482439|NCT01796054|No Intervention|Control|Randomized participants do not have access to online stress reduction program, Stress Free Now, nor do they attend weekly group support sessions.
89482440|NCT03552367|Experimental|Personalized structured exercise|"This group will be enrolled in a multicomponent program for obese children (8-12 years old) that includes intervention workshops concerning nutrition, emotional factors, cognitive therapy and personalized structured exercise prescription that will be offered on-site and online and monitored through the use of heart rate monitoring devices. The type of exercise offered to patients in this arm is precisely designed for obese patients according to age and physical fitness parameters.~Intervention: Non-personalized non-structured exercise"
89482441|NCT03552367|Active Comparator|Non-personalized non-structured exercise|This group will be enrolled in a multicomponent program for obese children (8-12 years old) that includes intervention workshops concerning nutrition, emotional factors, cognitive therapy and non-personalized non-structured exercise prescription Intervention: Non-personalized non-structured exercise
89482442|NCT05014490|Experimental|Exib (Test)|A single oral dose of the test product Exib 120 mg etoricoxib film-coated tablets.
89482443|NCT05014490|Active Comparator|Arcoxia® (Reference)|A single oral dose of the reference product Arcoxia® 120 mg etoricoxib film-coated tablets.
89482444|NCT03552991|Other|Agio arm|It is a pilot study based on the proof-of-concept that dietary fiber helps glucose control in patients with type 2 diabetes. As a single-arm study, 'Agiocur Pregranules' (dietary fiber) is administered for 28 days and stopped for next 28 days, in patients with type 2 diabetes.
89482445|NCT05020964|Experimental|Experimental Arm|Trastuzumab and Pyrotinib
89482446|NCT05021042||Acute mastitis (MA)|Lactating women with confirmed acute mastitis
89482447|NCT05021042||Subacute mastitis (SAM)|Lactating women with confirmed subacute mastitis
89482448|NCT05021042||Control (CT)|Lactating women with the absence of acute or subacute mastitis symptomatology.
89482449|NCT03552913||2015 Total knee arthroplasty, hysterectomy or left colectomy|Group of patients having a total knee arthroplasty, hysterectomy or left colectomy in 2015
89482450|NCT03552913||2017 Total knee arthroplasty, hysterectomy or left colectomy|Group of patients having a total knee arthroplasty, hysterectomy or left colectomy in 2017
89482451|NCT03552913||2015 Total hip prosthesis, ovariectomy or gastrectomy|Group of patients having total hip prosthesis, ovariectomy or gastrectomy in 2015
89482452|NCT03552913||2017 Total hip prosthesis, ovariectomy or gastrectomy|Group of patients having total hip prosthesis, ovariectomy or gastrectomy in 2017
89482453|NCT05020886||Healthy|
89482454|NCT05020886||Stroke|
89482455|NCT02118181|No Intervention|Control|
89482456|NCT02118181|Experimental|HMB|Group taking oral supplementation with Beta-hydroxy-beta-methylbutyrate
89482457|NCT02112409|Experimental|cell salvage and hemodilution technique|cell salvage technique throughout scoliosis corrective surgery; Acute normovolemic hemodilution technique commenced after induction of anaesthesia and prior the starting of surgery.
89482458|NCT02112409|Active Comparator|cell salvage|cell salvage technique throughout scoliosis corrective surgery
88951939|NCT01951807|Experimental|Coping & Communication Skills|The CCI intervention focuses on bolstering stress management and problem solving abilities, identifying and expressing support needs constructively, facilitating the ability to cope with unchangeable issues, cognitive restructuring, and dealing effectively with body image and sexuality issues over seven weekly 60 minute sessions.
88951940|NCT01951807|Experimental|Supportive Counseling (SC)|The SC intervention incorporates a supportive, non-directive counseling approach in seven weekly 60 minute sessions
88951941|NCT01951807|No Intervention|Usual Care (UC)|Patients receive standard psychological and emotional care (usual care [UC]) (i.e., social work consultations and referral to a psychiatrist or psychologist, if requested or deemed necessary by the attending physician).
88951942|NCT01951833||Cystic fibrosis (Ecomedics vs NDD)|No treatment, observational
88951943|NCT01951833||Healthy (Ecomedics vs NDD)|"Free of respiratory symptoms for at least two weeks and will not have any chronic or recurrent chest problem.~No treatment, observational"
88951944|NCT01951846|Experimental|BIBF 1120|
88951945|NCT01951859|Experimental|Topical Neuropathy/Ulcer Cream|an anti-inflammatory topical cream that contains homeopathic ingredients
88951946|NCT01951859|Placebo Comparator|Placebo Cream|
89482459|NCT03084614||Controls|non exposed controls
89482460|NCT03084614||donors with naturally enriched antimicrobial blood samples and|Donors with naturally enriched antimicrobial blood samples an breast milk, Comparisons will be made with non exposed controls.
88951947|NCT01951872|Experimental|Immediate treatment|Immediate manual-based treatment for caffeine dependence: administered within approximately one week following intake.
89482461|NCT02118259|Other|The study population|"See inclusion and exclusion criteria.~Intervention: Before-after study"
89482462|NCT05014100|Experimental|The treatment group|Orelabrutinib 150mg once daily in a 28-day cycle. Lenalidomide 25mg once daily for 21 days and rituximab 375mg/m2 for 7 days
89482463|NCT02251327||Case detection group|Suspected or confirmed new pulmonary tuberculosis cases who have received anti-tuberculosis drugs for less than 3 (three) days and provide up to two expectorated sputum specimens. One investigational Xpert DST test and one Xpert MTB/RIF test were performed directly on the same sputum specimen; in addition, one smear microscopy test, one mycobacterial liquid culture, and one solid culture were performed after digestion and decontamination of sputum.
89531485|NCT06065878|No Intervention|IPACK block|In the IPACK block group, a 20 mL solution containing 50 mg of 0.25% bupivacaine (Buvicaine®, Polifarma, Tekirdağ, Turkey) and 8 mg of dexamethasone (Dekort®, Deva, Istanbul, Turkey) was infiltrated between the popliteal artery and femur, starting 2 cm distal to the popliteal artery and being withdrawn while infiltrating proximally.
88951948|NCT01951872|Experimental|Delayed treatment|Delayed manual-based treatment for caffeine dependence: administered within approximately six weeks following intake.
88951949|NCT01951898|Active Comparator|Montelukast|
88951950|NCT01951898|Sham Comparator|Vitamin B6|
88951951|NCT01951911|Active Comparator|Ketamine|Ketamine 1 mg per kg per 24 hours as subcutaneous infusion via syringe driver for 48 hours.
88951952|NCT01951911|Placebo Comparator|Placebo|Sodium chloride 0.9% administered as a subcutaneous infusion via syringe driver for 48 hours.
89482464|NCT02251327||Drug resistance risk group|Confirmed pulmonary tuberculosis cases with documented rifampin resistance, who have received anti-tuberculosis drugs for 31 days or less and/or history of prior tuberculosis PLUS ongoing signs and/or cases with symptoms of pulmonary tuberculosis PLUS suspected drug resistance and provide up to two expectorated sputum specimens. One investigational Xpert DST test and one Xpert MTB/RIF test were performed directly on the same sputum specimen; in addition, one smear microscopy test, one mycobacterial liquid culture, and one solid culture were performed after digestion and decontamination of sputum.
89482465|NCT03083912||Fortimel Complete|All of the residents included receive ONS
89482466|NCT03552835|Experimental|no caries removal|mandibular occlusal caries were treated with placement of stainless steel crown with no caries removal
89482467|NCT03552835|Experimental|partial caries removal upto soft dentin|mandibular occlusal caries were treated by partial caries removal upto soft dentin
89482468|NCT03552835|Experimental|partial caries removal upto firm dentin|mandibular occlusal caries were treated by partial caries removal upto firm dentin
89482469|NCT02251405|Placebo Comparator|One big bag, no stainless container|No stainless container
89482470|NCT02251405|Active Comparator|One big bag with two stainless containers|Two stainless containers
89482471|NCT05027126|Active Comparator|Group A: Dexketoprofen (Stadium®)|Reference Drug Pharmaceutical Form: Tablets Dosage: 25 mg Administration way: oral
89482472|NCT05027126|Experimental|Group B: Fixed dose Dexketoprofen-Vitamin B Complex|Fixed dose combination: Pharmaceutical Form: capsule Dosage: 25 mg of Dexketoprofen + Cyanocobalamin, Thiamine,and Pyridoxine. Administration way: oral
88951953|NCT01951924|Experimental|Group A: I10E then Kiovig®|1 g/kg for 1-3 days up to 2 g/kg for 2-5 days every 4 to 8 weeks (±7 days)
88951954|NCT01951924|Experimental|Group B : Kiovig® then I10E|1 g/kg for 1-3 days up to 2 g/kg for 2-5 days every 4 to 8 weeks (±7 days)
88951955|NCT01951976|Experimental|Intervention Condition|"Questionnaires and yoga classes.~Group will attend a series of 90-minute yoga classes twice a week for 12 weeks."
88951956|NCT01951989|Experimental|Imiglucerase|"Primary purpose: to evaluate the pharmacokinetics of Imiglucerase activity into target cellular compartment depending on dose and frequency of infusions.~Secondary purposes : 1) to establish a possible relationship between the intra-monocytic activity of glucocerebrosidase and the clinical and biological activity of Gaucher disease and to define a possible threshold value of enzyme activity; 2) to establish a better correlation with known biomarkers of disease (routine markers and markers recently identified), which would better predict and / or monitor response to treatment ; 3) to compare the residual and natural rate of activity enzyme intra-monocytic for untreated patients (low severity disease)."
88951957|NCT01952002||IMT - Inspiratory Muscle Training|21 (16 males/5 femalesen) with a mean age of 73 ± 7.4 years were studied. Among the 21 study participants, the most prevalent clinical condition was coronary artery disease (11 cases); four individuals showing a diagnosis of chronic obstructive pulmonary disease and/or asthma, two presented congestive heart failure and the last four had other diseases
88951958|NCT01952093||Usual care program|VLBW preterm infants who received usual medical care during hospitalization after birth.(in the previous study)
88951959|NCT01952093||Clinic-based intervention program|VLBW preterm infants who received specific early intervention program delivered at clinic before 1 year of corrected age (in the previous study)
88951960|NCT01952093||Home-based intervention program|VLBW preterm infants who received specific early intervention program delivered at home before 1 year of corrected age (in the previous study)
88951961|NCT01952093||Term control group|Healthy term infants
88951962|NCT01950065|Experimental|Immediate Treatment with iovera|Immediate treatment with iovera
88951963|NCT01950065|Active Comparator|Delayed Treatment with iovera|Delayed Treatment with iovera
88951964|NCT01952106|Experimental|distraction|use the computer game to distract children's pain and anxiety during venepuncture
88951965|NCT01952119|No Intervention|Routine Care|Routine care, no intervention
88951966|NCT01952119|Active Comparator|Secure message reminder|Will receive a secure message reminder asking subjects to schedule an appointment with their provider or make a nurse visit to follow-up on their blood pressure
88951967|NCT01952184|Active Comparator|closed vitrification with closed storage|Half of the oocytes of every donor will be vitrified with the Cryo Bio Systems High Security vitrification (CBSvit HS) device; the standard device in our lab.
88951968|NCT01952184|Experimental|open vitrification with closed storage|Half of the oocytes of every donor will be vitrified with the Cryotop closed system (Cryotop SC).
88951969|NCT01952197|Experimental|Passive Leg Raise|The intervention is made on all adult patients receiving CPR by the ambulance crew. The leg raise is performed during the first minutes of CPR (limit 5 min) and will continue as long as the patients receive chest compression. In Spain the patient is immediate randomized by envelope. If the patient is randomized to PLR, the ambulance crews use a special folding stool that allows the legs to be raised about 20 degrees.
88951970|NCT01952210|Experimental|nutrition consultation and exercise program|individual nutritional consultation and exercise
88951971|NCT01952210|Active Comparator|usual care|pre-CCRT education included self-care during CCRT and body weight maintenance
88951972|NCT01952236|Experimental|Web+Mobile|A best-practices Web-based smoking cessation program integrated with a tailored treatment program delivered using a smartphone application.
88951973|NCT01952236|Active Comparator|Web Only|A best-practices Web-based smoking cessation program.
89482473|NCT02120677|Experimental|Itraconazole ointment|Patients with histologically proven BCC will be eligible for study enrollment. 50% itraconazole compounded in petrolatum jelly will be applied under occlusion for up to 3 to 7 days.
89482474|NCT03091946|Placebo Comparator|Cooked cream of rice|Cream of rice with additional dried fruits, nuts and seeds cooked just prior to its consumption and served with skim milk as a beverage
89482475|NCT03091946|Experimental|Overnight oats|Oats with additional dried fruits, nuts and seeds soaked overnight in skim milk
89482476|NCT02118415|Experimental|Interventional|Interventional group: activated autologous NK cell treatment
89482477|NCT02118415|No Intervention|Control group|Control group: BSC
88951974|NCT01952249|Experimental|Demcizumab|Demcizumab will be administered prior to paclitaxel by intravenous (IV) infusion.
89482478|NCT05026970|Active Comparator|Biofeedback+Electrostimulation+Kegel|Biofeedback (3 sessions) Electrostimulation (12 weeks daily treatment) Kegel exercises (twice daily)
89482479|NCT05026970|Active Comparator|Biofeedback+Tibial Neuromodulation+Kegel|Biofeedback (3 sessions) Transcutaneous Neuromodulation (12 weeks daily treatment) Kegel exercises (twice daily)
89482480|NCT05026970|Active Comparator|Biofeedback+Kegel|Biofeedback (6 sessions) Kegel exercises (twice daily)
89482481|NCT02120755|Active Comparator|AmnioClear™|AmnioClear™ Human Allograft Amniotic Membrane
89482482|NCT02120755|No Intervention|Standard of Care|Standard moist wound dressing (saline wet-to-moist or a hydrogel dressing)
89482483|NCT03092102|Experimental|A single dose HEC585（A1）|"Drug: HEC585 Capsule~Drug: HEC585-matching placebo Capsule"
89482484|NCT03092102|Experimental|A single dose HEC585（A2）|"Drug: HEC585 Capsule~Drug: HEC585-matching placebo Capsule"
89482485|NCT03092102|Experimental|A single dose HEC585/FE（A3）|"Drug: HEC585 Capsule~Drug: HEC585-matching placebo Capsule~Treatment Period 1：No food prior to dosing；Treatment Period 2：High-fat meal prior to dosing"
89482486|NCT03092102|Experimental|A single dose HEC585（A4）|"Drug: HEC585 Capsule~Drug: HEC585-matching placebo Capsule"
89482487|NCT03092102|Experimental|A single dose HEC585（A5）|"Drug: HEC585 Capsule~Drug: HEC585-matching placebo Capsule"
89482488|NCT03092102|Experimental|A single dose HEC585（A6）|"Drug: HEC585 Capsule~Drug: HEC585-matching placebo Capsule"
89482489|NCT03092102|Experimental|A single dose HEC585（A7）|"Drug: HEC585 Capsule~Drug: HEC585-matching placebo Capsule"
89482490|NCT03092102|Experimental|A single dose HEC585（A8）|"Drug: HEC585 Capsule~Drug: HEC585-matching placebo Capsule"
89482491|NCT03092102|Experimental|Multiple doses HEC585（B1）|"Drug: HEC585 Capsule~Drug: HEC585-matching placebo Capsule"
89482492|NCT03092102|Experimental|Multiple doses HEC585（B2）|"Drug: HEC585 Capsule~Drug: HEC585-matching placebo Capsule"
89482493|NCT03092102|Experimental|Multiple doses HEC585（B3）|"Drug: HEC585 Capsule~Drug: HEC585-matching placebo Capsule"
89482494|NCT03092102|Experimental|Multiple doses HEC585（B4）|"Drug: HEC585 Capsule~Drug: HEC585-matching placebo Capsule"
89482495|NCT03092102|Experimental|Multiple doses HEC585（B5）|"Drug: HEC585 Capsule~Drug: HEC585-matching placebo Capsule"
89482496|NCT03092102|Experimental|Multiple doses HEC585（B6）|"Drug: HEC585 Capsule~Drug: HEC585-matching placebo Capsule"
89482497|NCT02120911|Experimental|Pertuzumab, trastuzumab|Pertuzumab, trastuzumab
89482498|NCT05013866|Active Comparator|Repair of resin Z350|Repair with Z350 on resin composite proximal
89482499|NCT05013866|Experimental|Repair of Tetric Evo Ceram Bulkfill|Repair with Tetric Evo Ceram on resin composite proximal
89482500|NCT02121145|Experimental|Vivotif + Typherix primary immunization|Vivotif + Typherix primary immunization
89482501|NCT02121145|Experimental|Vivotif booster|Volunteers previously immunized with Vivotif, now receiving a Vivotif secondary immunization
88951975|NCT01952249|Experimental|Taxol|demcizumab combined with weekly paclitaxel
88951976|NCT01952314|Placebo Comparator|Control groups with only analgesics|Control groups will receive only analgesics.
88951977|NCT01952314|Active Comparator|Naftopidil|This interventional group will receive analgesics and naftopidil 75mg po qd.
88951978|NCT01952327|Other|plueurapump|Implantation of pleurapump system
89482502|NCT02121145|Experimental|Typherix booster|Volunteers previously immunized with Typherix, now receiving a Typherix secondary immunization
89482503|NCT02121145|Experimental|Vivotif + Typherix booster|Volunteers previously immunized with Vivotif and Typherix, now receiving Vivotif and Typherix as secondary immunization
89482504|NCT05020262||Test Group|Using PI/PC reconstruct raw data
89482505|NCT05020262||Control Group|Using Idose4/Cardiac Image reconstruct raw data
89482506|NCT02112487|Experimental|Macitentan|10 mg once daily
89482507|NCT03094442|Active Comparator|Dexamethasone|"Dexamethasone is a potent corticosteroid that has been widely used for chemotherapy induced nausea and vomiting. The mechanism of action is not completely understood. It has been proposed that a single dose may hinder the production and release of anti-inflammatory mediators. Dexamethasone also has a central antiemetic effect by inhibition of prostaglandin and/or release of endogenous opioids. A recent metanalysis concluded that Dexamethasone administration at induction is safe.~We will be using a 8mg dose of Dexamethasone, that is equivalent to 2ml of injectable drug."
89482508|NCT03094442|Placebo Comparator|Saline|Normal saline contains 0.9% weight/ volume of sodium chloride. It is used routinely for intravenous resuscitation and fluid maintenance. Patients in the placebo arm will receive 2 ml of normal saline in the blinded syringe provided by the pharmacy.
89482509|NCT02406742|Experimental|CC-122 Single Agent|An intrasubject dose escalation design was selected to determine the safety of single agent CC-122 (Arm A) in order to reach an optimal, clinically active dose and to mitigate the risk of early tumor flare reactions, based on earlier experience with lenalidomide monotherapy in CLL.
89482510|NCT02406742|Experimental|CC-122 in combination with ibrutinib|Ascending fixed dose cohorts evaluated in a 3 + 3 dose-finding design will be used to determine the safety and tolerability of the combination of CC-122 and ibrutinib to determine the NTD, MTD, and Recommended Phase 2 Dose (RP2D). An intrasubject dose escalation cohort may also be evaluated at the discretion of the Safety Review Committee. The RP2D of the combination may be evaluated in ibrutinib-naïve and high-risk CLL patients in the dose expansion phase to continue to evalute safety and efficacy.
89482511|NCT02406742|Experimental|CC-122 in combination with obinutuzumab|Ascending fixed dose cohorts evaluated in a 3 + 3 dose-finding design will be used to determine the safety and tolerability of the combination of CC-122 and obinutuzumab to determine the , MTD, and Recommended Phase 2 Dose (RP2D). An intrasubject dose escalation cohort may also be evaluated at the discretion of the Safety Review Committee.. The RP2D of the combination may be evaluated in CLL patients who failed a B-cell receptor pathway inhibitor or venetoclax in the dose expansion phase to continue to evalute safety and efficacy.
89482512|NCT05020340|Experimental|Intervention|External cephalic version
89482513|NCT05020340|No Intervention|Control|ECV will not be performed.
89482514|NCT02112643|Active Comparator|Selenium|100 micrograms of sodium selenate will be taken orally twice daily (total 200 micrograms daily) for 6 months.
89482515|NCT02112643|Placebo Comparator|Sugar pill|A placebo pill will be taken orally twice daily for 6 months.
89482516|NCT03094130|Active Comparator|News with Spin|News items reporting results of phase I/II (non-randomized) trials with spin
89482517|NCT03094130|Experimental|News without spin|News items reporting results of phase I/II (non-randomized) trials without spin
89482518|NCT02118493|Experimental|Benign Biliary Stenosis, Laser|Subjects that undergo the experimental intervention, that being single use of a laser excision catheter.
89482519|NCT02121223|Active Comparator|Control|Patients in control group will receive current standard therapy for STEMI: manual thrombus aspiration + Promus Element stent implantation ( with a pressure less than 12 atm), but not post-dilatation
89482520|NCT02121223|Experimental|Post-dilatation|Patients in this group will receive high pressure post-dilatation with a Quantum Maverick balloon after manual thrombus aspiration + Promus Element stent implantation
89482521|NCT02714595|Experimental|Cefiderocol|Participants will receive cefiderocol 2 g administered intravenously over 3 hours, every 8 hours for 7-14 days. Treatment could be extended to 21 days at the discretion of the investigator.
89482522|NCT02714595|Active Comparator|Best Available Therapy (BAT)|Best available therapy (BAT) will be chosen by the investigator and may include up to three antibacterial agents for carbapenem resistant Gram-negative bacteria, intravenously administered per country-specific guidelines for 7-14 days. Treatment could be extended to 21 days at the discretion of the investigator.
89482523|NCT02112721|Experimental|Vitamin D Group|Each participant will be given an initial stat dose of 2500 μg (100,000 IU) of Ostelin (Reckitt Benckiser). Thereafter, participants will take 100 μg/day (4,000 IU, 4 tablets) Ostelin daily for a period of 16 weeks.
88951979|NCT01952353|Experimental|Preoperation TACE arm|In the preoperative TACE arm (Arm 2), patients underwent TACE followed by surgical resection. Preoperative TACE sessions were repeated once at 4-week intervals unless patients showed either PD or PVTT PD. Then, the patients were prepared for surgical resection, with the exception of those with unresectable disease after TACE For patients who had unresectable disease after TACE, plans for surgical resection were abandoned and the subsequent treatment course was determined by his/her attending oncologist
88951980|NCT01952353|Active Comparator|Resection arm|Liver resection Plus Thrombectomy
88951981|NCT01952379||Melasma|Women affected by symmetric facial malar melasma.
88951982|NCT01952392||Control group|Patients aged 18 years or more with an acute coronary syndrome, agreed to participate and able to answer an interview in French and/or providing the details of an alternative replier (proxy) if necessary
88951983|NCT01952392||Case group|Patients aged 18 years or more with a history of acute coronary syndrome (i.e. a recurrent MI after myocardial history or unstable angina), agreed to participate and able to answer an interview in French and/or providing the details of an alternative replier (proxy) if necessary
88951984|NCT01952405|Experimental|Dialectical behavior therapy|Dialectical behavior therapy (DBT), developed by Marsha Linehan, has gained widespread popularity as a treatment for BPD, and its efficacy has been demonstrated in several trials.
88951985|NCT01952405|Placebo Comparator|alternative psychotherapy|The therapists of the alternative psychotherapy in the comparison group are asked to provide the type and dose of therapy that they believed is most suited to the patient, with a minimum of 1 scheduled individual session per week. Ancillary treatment could be prescribed as needed. Case management strategies are also available in the comparison group (alternative psychotherapy group). No restrictions are placed on ancillary pharmacotherapy in either condition.
88951986|NCT01952431|Experimental|PulmOne MiniBox PFT|Total Lung Capacity (TLC) testing with PulmOne MiniBoxPFT
88951987|NCT01952431|Active Comparator|ZAN500|Total Lung Capacity (TLC) testing with ZAN500.
88951988|NCT01952457|Experimental|Zilver PTX|Patients in the Zilver PTX arm have to be treated by placement of the Zilver PTX drug-eluting stent (Cook), according to standard procedures based on the Instructions for Use. The only pre-treatment allowed prior to placement of the Zilver PTX drug-eluting stent (Cook) is standard PTA. Diameter measurements must be performed of the healthy vessel proximal and distal to the previously stented area. Diameter selection of the Zilver PTX drug-eluting stent (Cook) should result in minimal oversizing. The target lesion needs to be completely covered by using as few stents possible. Post-dilatation can be performed according to the Instructions of Use.
88951989|NCT01952457|Active Comparator|prosthetic bypass|Patients in the bypass arm have to be treated with a prosthetic bypass graft according to the institution's standard of care and the Instructions for Use of the prosthetic bypass graft.
88951990|NCT01952483||vitamin D deficient,|Vitamin D deficiency (serum level <20ng/ml)
89203307|NCT03985891|Experimental|JS001 in combination with Folfox|Patients who meet the enrollment criteria will receive Folfox(Oxaliplatin 85mg/m2 iv Day1; Leucovorin 400mg/m2 iv Day1; 5-FU 400mg/m2 iv bolus on Day1, then1200mg/m2/d x 2days(total 2400mg/m2 over 46-48 hours) iv continuous infusion repeat every 2 weeks) in combination with JS001 (3mg/kg, Q2W). Patients will receive 6 cycles treatment in pre-operation and same cycles after operation.
89482524|NCT02112721|Placebo Comparator|Placebo group|Each participant will be given an equivalent number of placebo tablets
89482525|NCT02112799|Experimental|NVR 3-778|NVR 3-778 in varying doses of capsules by mouth for 1 day, 14 days, or 28 days
89482526|NCT02112799|Placebo Comparator|Placebo for NVR 3-778|Placebo for NVR 3-778 in varying doses of capsules by mouth for 1 day, 14 days, or 28 days
89482527|NCT02112799|Experimental|NVR 3-778 and Pegasys|NVR 3-778 and Pegasys in combination in a yet to be determined dose by mouth and subcutaneous injection for 28 days
89482528|NCT02112799|Active Comparator|Pegasys|Pegasys alone in a yet to be determined dose by subcutaneous injection for 28 days
89482529|NCT03093896|Placebo Comparator|snack mix|snack mix, 3 ounces: dried coconut, meat jerky, butter, cereal party mix
89482530|NCT03093896|Active Comparator|almonds, 1.5 ounces|almonds, 1.5 ounces/day
89482531|NCT03093896|Active Comparator|almonds, 3 ounces|almonds, 3 ounces/day
89482532|NCT02122939|Experimental|Escitalopram|
89482533|NCT04434014||males from 20 to above 65 y|will be sub divided into 4 groups according to age sub group I from 20 - 35 sub group II from 36- 45 sub group III from 46- 65 sub group IV more than 65
89482534|NCT04434014||female from 20 to above 65 y|will be sub divided into 4 groups according to age will be sub divided into 4 groups according to age sub group I from 20 - 35 sub group II from 36- 45 sub group III from 46- 65 sub group IV more than 65
89482535|NCT02121379|No Intervention|control|stretching exercise
89482536|NCT02121379|Experimental|pulmonary rehablitation|warming up exercise strengthening exercise aerobic exercise cool down
89482537|NCT04434248|Experimental|Favipiravir, lower dose (pilot stage)|1600mg BID on the 1st day followed by 600mg BID for 13 days
89482538|NCT04434248|Experimental|Favipiravir, higher dose (pilot stage)|1800mg BID on the 1st day followed by 800mg BID for 13 days
89482539|NCT04434248|Active Comparator|Standard of care (pilot stage)|Based on approved clinical recommendations for treatment of COVID-19 in the Russian Federation (but not Favipiravir). Might include hydroxychloroquine, chloroquine, lopinavir/ritonavir or other recommended schemes.
89482540|NCT04434248|Experimental|Favipiravir, selected dose (pivotal stage)|The dose will be selected based on pilot study results.
89482541|NCT04434248|Active Comparator|Standard of care (pivotal stage)|Based on approved clinical recommendations for treatment of COVID-19 in the Russian Federation (but not Favipiravir). Might include hydroxychloroquine, chloroquine, lopinavir/ritonavir or other recommended schemes.
89482542|NCT04433936||Thyroid Gland Dysfunction|Patients with a recent diagnosis of TGD (the study group) were recruited from endocrinology outpatient clinic of Specialized Medical Hospital, Mansoura University. Diagnosis of TGD was based on précised history, clinical examination and laboratory investigations. In order to avoid bias, patients with history of intake of any thyroid-related medications (antithyroid medications or thyroxine replacement), radioactive iodine or thyroidectomy were excluded from the study.
88951991|NCT01952483||Vitamin D normal|Serum level >35 ng/ml
88951992|NCT01952496|Other|Force-measuring platform|"A force-measure platform will be placed under each foot of the subject to record the time course of load borne by each of the lower extremities during weight-bearing training in an assisted standing device.~Intervention: Assisted Standing Treatment Program. Assisted standing treatment program will include at least 2 hours a day, 5 days a week (a total of at least 10 hours a week) for a period of ~9 months."
88951993|NCT01952509||Cohort|
88951994|NCT01952535|Experimental|HMS5552 dose 1|A single dose of HMS5552 tablets (5~50mg) taken orally.
88951995|NCT01952535|Experimental|HMS5552 dose 2|A single dose of HMS5552 tablets (5~50mg) taken orally.
88951996|NCT01952535|Experimental|HMS5552 dose 3|A single dose of HMS5552 tablets (5~50mg) taken orally.
88951997|NCT01952535|Experimental|HMS5552 dose 4|A single dose of HMS5552 tablets (5~50mg) taken orally.
88951998|NCT01952535|Experimental|HMS5552 dose 5|A single dose of HMS5552 tablets (5~50mg) taken orally.
88951999|NCT01952535|Experimental|HMS5552 dose 6|A single dose of HMS5552 tablets (5~50mg) taken orally.
88952000|NCT01952548|Experimental|Dose 1 Active|
88952001|NCT01952548|Experimental|Dose 2 Active|
88952002|NCT01952548|Experimental|Dose 3 Active|
88952003|NCT01952548|Experimental|Dose 4 Active|
88952004|NCT01952548|Experimental|Dose 5 Active|
88952005|NCT01952548|Experimental|Dose 6 Active|
88952006|NCT01952548|Experimental|Dose 7 Active|
88952007|NCT01952548|Placebo Comparator|Dose 1 Placebo|
88952008|NCT01952548|Placebo Comparator|Dose 2 Placebo|
88952009|NCT01952548|Placebo Comparator|Dose 3 Placebo|
88952010|NCT01952548|Placebo Comparator|Dose 4 Placebo|
88952011|NCT01952548|Placebo Comparator|Dose 5 Placebo|
88952012|NCT01952548|Placebo Comparator|Dose 6 Placebo|
88952013|NCT01952548|Placebo Comparator|Dose 7 Placebo|
88952014|NCT01952561|Experimental|2 weeks|
88952015|NCT01952561|Experimental|1 week|
88952016|NCT01952561|Experimental|4 weeks|
88952017|NCT01952561|Experimental|8 weeks|
88952018|NCT01952561|Experimental|12 weeks|
88952019|NCT01952587|Other|HIV-infected women|A peripheral blood sample will be collected from HIV-infected women to measure TLR-7 SNP frequency by PCR. IFN-alpha production from pDCs after HIV-1 RNA sensing by TLR7 will also be assessed.
88952020|NCT01952587|Other|Healthy control women|A peripheral blood sample will be collected from healthy women to measure TLR-7 SNP frequency by PCR. IFN-alpha production from pDCs after HIV-1 RNA sensing by TLR7 will also be assessed
88952021|NCT01952613|Experimental|Stroke - FES|Stroke population currently prescribed a FES orthotic device (< week)
88952022|NCT01952626|Active Comparator|ondansetron|Intravenous administration of ondansetron 4mg 15 minutes before spinal anesthesia
88952023|NCT01952626|Experimental|palonosetron|Intravenous administration of palonosetron 0.075mg 15 minutes before spinal anesthesia
88952024|NCT01952639|Experimental|30 g of wheat protein|Subjects will consume 30 g of wheat protein protein type and amount
88952025|NCT01952639|Experimental|30 g of wheat protein hydrolysate|Subjects will consume 30 g of wheat protein hydrolysate protein type and amount
88952026|NCT01952639|Active Comparator|30 g of whey protein|Subjects will consume 30 g of whey protein protein type and amount
88952027|NCT01952639|Active Comparator|30 g of casein|Subjects will consume 30 g of casein protein type and amount
88952028|NCT01952639|Experimental|60 g of wheat protein hydrolysate|Subjects will consume 60 g of wheat protein hydrolysate protein type and amount
88952029|NCT01952652|Active Comparator|Group Naproxen sodium (Group N)|Group N received naproxen sodium 550 mg 60 minutes before surgery.
88952030|NCT01952652|Active Comparator|Group Naproxen sodium codeine phosphate (Group NC)|Group NC received naproxen sodium 550 mg+30 mg codeine 60 minutes before surgery.
89482543|NCT04433936||Control|fifty age and gender matched healthy subjects without known personal or family history of thyroid disease or any autoimmune diseases were recruited from candidates of refractive surgery referred to the outpatient clinic of Mansoura Ophthalmology Center for pentacam assessment and who were proved to have normal corneal pentacam parameters. They were further examined by the endocrinologist to exclude thyroid dysfunction; this was supported by normal thyroid function profile (serum TSH and free T4) and negative anti-TPO and antithyroglobulin antibodies.
88952031|NCT01952704|Experimental|Aerobic exercise|30 minutes x 3 times/week x 12 weeks of stationery cycling
89482544|NCT02121457|No Intervention|Control Group|This group did not receive any intervention.
89482545|NCT02121457|Experimental|Treatment Group|This group took one Brazil nut daily during 6 months.
88952032|NCT01952704|Placebo Comparator|Non-aerobic exercise|30 minutes x 3 times/week x 12 weeks of gentle non-aerobic stretching
88952033|NCT01952743|Active Comparator|AF Ablation alone|Clinical AF ablation performed as deemed appropriate by operator
88952034|NCT01952743|Experimental|AF ablation with Renal Denervation|Renal denervation performed using the same ablation catheter after clinical AF ablation
88952035|NCT01952756|Active Comparator|Cilostazol|One tablet (100 mg) twice per day for 12 weeks
88952036|NCT01952756|Placebo Comparator|Dummy Placebo|One tablet twice per day for 12 weeks
88952037|NCT01952769|Experimental|treatment of DIPG with MDV9300|treatment of diffuse pontine glioma with MDV9300 with the combination of radiation and low dose cyclophosphamide
88952038|NCT05876819||Iranians|Disabled Middle and Older Adults
88952039|NCT05876819||Lebanese|Disabled Middle and Older Adults
89203308|NCT03985891|Active Comparator|Folfox|Patients who meet the enrollment criteria will receive Folfox(Oxaliplatin 85mg/m2 iv Day1; Leucovorin 400mg/m2 iv Day1; 5-FU 400mg/m2 iv bolus on Day1, then1200mg/m2/d x 2days(total 2400mg/m2 over 46-48 hours) iv continuous infusion repeat every 2 weeks). Patients need to receive 6 cycles treatment in pre-operation and same cycles after operation.
89203309|NCT00350779|Experimental|1|Sitagliptin
89203310|NCT00350779|Placebo Comparator|2|Placebo
89482546|NCT03281421|Experimental|Group from posterior to anterior (GPA)|Participants in group GPA will receive a manual therapy intervention, through the technique of mobilization with movement in the ankle joint, with a slip sense from posterior to anterior. The physiotherapist will be positioned in front the participant's ankle, and a belt will be posicioned above the participant's malleolus and around physiotherapist's pelvis. The therapist applies with belt a anterior slip sustained in the tibia of the participant, while the talus are secured with the space between the thumb and the second finger of the hand of both hands on the physiotherapist´s. The participant will be instructed to perform a slow dorsiflexion movement at its maximum amplitude and hold five seconds in that position, returning to the initial position at the end of the five seconds.
89482547|NCT03281421|Active Comparator|Group from anterior to posterior (GAP)|Participants in group GAP will receive a manual therapy intervention, through the technique of mobilization with movement in the ankle joint, with a slip sense from anterior to posterior. The physiotherapist will be positioned behind the participant's ankle. An belt will be posicioned above the participant's malleolus and around physiotherapist's trunk. The therapist applies with belt a posterior slip sustained in the tibia of the participant, while the heel and rearfoot are secured with the space between the thumb and the second finger of the hand of both hands on the physiotherapist´s. The participant will be instructed to perform a slow dorsiflexion movement at its maximum amplitude and hold five seconds in that position, returning to the initial position at the end of the five seconds.
89482548|NCT03281421|Active Comparator|Group GPA-AP|Participants in group GAP will receive a manual therapy intervention, through the technique of mobilization with movement in the ankle joint, with a slip sense both from posterior to anterior and anterior to posterior. In the group GPA-AP, will be apllied both the procedure described for the group GPA as for the group GAP. To standardized the sequence of mobilization, the first two sets will be performed with slip sense from posterior to anterior, and the last two sets will be performede with slip sense from anterior to posterior.
89482549|NCT02123173||non-intubated|VATS, non-intubated
89482550|NCT02123173||intubated|VATS, intubated
89482551|NCT03286491||Patients presenting with acute coronary syndrome|Patients presenting to emergency department with acute coronary syndrome
89482552|NCT03091790|Active Comparator|Synthetic Mesh|Synthetic mesh (mid-density polypropylene (generic) Bard soft mesh) will be used in open ventral hernia repair
89482553|NCT03091790|Active Comparator|Biologic Mesh|Biologic mesh (non cross linked porcine acellular dermal matrix: Strattice) will be used in open ventral hernia repair
89482554|NCT02251795|Experimental|Tipranavir/Ritonavir|500 mg Tipranavir / 200 mg Ritonavir 10 days BID
89482555|NCT02251795|Active Comparator|Darunavir/Ritonavir|600 mg Darunavir /100 mg Ritonavir 10 days BID
89482556|NCT02251795|Active Comparator|Ritonavir|100 mg Ritonavir 10 days BID
89482557|NCT05026658|Experimental|Visibly Digital Acuity Product|
89482558|NCT05026658|Experimental|ETDRS Visual Acuity Lane Test|
89482559|NCT03286413|Experimental|microwave ablation|Microwave ablation（MWA）refers to all electromagnetic methods of inducing tumor destruction by using devices with frequencies greater than or equal to 900MHz. The rotation of dipole molecules accounts for most of the heat generated during MWA. Water molecules as dipoles attempt to continuously reorient at the same rate in microwave's oscillating electric field. As a result of microwave transmission, the water molecules flip back and forth billions of times a second. The vigorous movement of water molecules produce friction and heat, thus inducing cellular death via coagulation necrosis. The microwave unit (KY-2000, Kangyou Medical, Nanjing, China) is capable of producing 100 Watts of power at 2450 MHz.The needle antenna has a diameter of 1.6 mm (16G) and a length of 10 cm. The active tip length is 3mm and 5mm.
89482560|NCT03286413|Active Comparator|cryoablation|Clinically, cryosurgery is accomplished by placing a cryoprobe(up to 3.5 mm) through a stab incision into the tumor under ultrasound guidance.Liquid nitrogen is utilized under low operating pressure as cryogen which is controlled by the computer modulated cryogen regulator. The cryoprobe achieves rapid freezing by means of an active freeze zone at its distal tip.
89482561|NCT02112955|Experimental|Stroke self-management program|The program is aimed at enhancing community-dwelling stroke survivors' post-stroke recovery.
88821636|NCT03186508|Active Comparator|Optimize Sleep-Plus (OS-Plus)|OS-Plus will focus on enhancing sleep and targeted eating (decreasing sugar-sweetened beverages and sweet and salty snack foods) and activity (increasing physical activity and decreasing TV viewing) behaviors. Specific strategies to be used include: goal setting and self-monitoring, positive bedtime routines, stimulus control/sleep hygiene strategies, problem-solving regarding challenges, and review of effective strategies for relapse prevention.
89203311|NCT00350623|Experimental|MRKAd5 HIV-1 gag/pol/nef 4 x 10^9 Ad5 vg/dose|MRKAd5 HIV-1 gag/pol/nef 4 x 10^9 Ad5 vg/dose, 3 doses administered at Day 1, Week 4, and Week 26.
89203312|NCT00350623|Experimental|MRKAd5 HIV-1 gag/pol/nef 8 x 10^9 Ad5 vg/dose|MRKAd5 HIV-1 gag/pol/nef 8 x 10^9 Ad5 vg/dose, 3 doses administered at Day 1, Week 4, and Week 26.
89482562|NCT02112955|Active Comparator|Usual care|Usual care provided to stroke survivors discharged to their home.
89203313|NCT00350623|Experimental|MRKAd5 HIV-1 gag/pol/nef 1.5 x 10^10 Ad5 vg/dose|MRKAd5 HIV-1 gag/pol/nef 1.5 x 10^10 Ad5 vg/dose, 3 doses administered at Day 1, Week 4, and Week 26.
89482563|NCT05013398|Experimental|The Together Webinar Programme (TTP-Webinar)|Participants receive the six weekly session TTP-Webinar intervention.
89482564|NCT05013398|No Intervention|Waitlist condition|Participants do not receive any intervention as part of waitlist condition. Note: Following the collection of measures at the follow-up time point, participants assigned to the waitlist condition were offered four TTP-Webinar groups to sign up to.
89482565|NCT02113033|Experimental|Treated with Equilia system|Implantation and activation of the Vagus Nerve Stimulator, nerve electrode and cardiac lead
89482566|NCT05013164|Experimental|Folinic Acid + Behavioral Therapy|Children receiving folinic acid and behavioral therapy. Folinic Acid was given at the dose of 2mg/kg per day in two divide doses( maximum 50 mg per day) given for 12 weeks.
89482567|NCT05013164|No Intervention|Behavioral Therapy|Children received only behavioral therapy for 12 weeks.
89482568|NCT03291561|Experimental|Electroacupuncture group|Electroacupuncture Acupuncture at Baihui, Nei guan, bilateral Zu sanli and bilateral Tian shu.
89482569|NCT03291561|Placebo Comparator|Sham electroacupuncture group|Sham acupuncture at Baihui, Nei guan, bilateral Zu, sanli and bilateral Tian shu.
89482570|NCT02251951|Experimental|nab-Paclitaxel|Abraxane
89482571|NCT03091868|Experimental|Group 1 (BIA 6-512 25 mg + Placebo)|"Single-doses were prepared as follows:~BIA 6-512 25 mg dose = 1 capsule of 25 mg plus 1 capsule of placebo In all groups, placebo recipients received 2 capsules of placebo. BIA 6-512/Placebo capsules and Sinemet® 100/25 and Comtan® tablets were administered simultaneously, by oral route, in fasting conditions."
89482572|NCT03091868|Experimental|Group 2 (BIA 6-512 50 mg + Placebo)|"Single-doses were prepared as follows:~BIA 6-512 50 mg dose = 2 capsules of 25 mg In all groups, placebo recipients received 2 capsules of placebo. BIA 6-512/Placebo capsules and Sinemet® 100/25 and Comtan® tablets were administered simultaneously, by oral route, in fasting conditions."
89482573|NCT03091868|Experimental|Group 3 (BIA 6-512 100 mg + Placebo)|"Single-doses were prepared as follows:~BIA 6-512 100 mg dose = 1 capsule of 100 mg plus 1 capsule of placebo In all groups, placebo recipients received 2 capsules of placebo. BIA 6-512/Placebo capsules and Sinemet® 100/25 and Comtan® tablets were administered simultaneously, by oral route, in fasting conditions."
89482574|NCT03091868|Experimental|Group 4 (BIA 6-512 200 mg + Placebo)|"Single-doses were prepared as follows:~BIA 6-512 200 mg dose = 2 capsules of 100 mg In all groups, placebo recipients received 2 capsules of placebo. BIA 6-512/Placebo capsules and Sinemet® 100/25 and Comtan® tablets were administered simultaneously, by oral route, in fasting conditions."
89482575|NCT03291483|Experimental|whole body vibration group|basketball players had done exercises on whole body vibration platform.
89482576|NCT03291483|Sham Comparator|plyometric training|Basketball players had done same plyometric exercises
89482577|NCT02121613|Experimental|Permixon® 160 mg & Placebo|
89482578|NCT02121613|Placebo Comparator|Placebo|
89482579|NCT02121613|Other|Tamsulosine LP & Placebo|Active control arm
89482580|NCT05026268|Experimental|Intracorporeal anastomosis|A laparoscopic right colectomy will be performed according to the surgeons standard practice with the intracorporeal anastomosis performing.
89482581|NCT05026268|No Intervention|extracorporeal anastomosis|A laparoscopic right colectomy will be performed according to the surgeons standard practice.
88821637|NCT03167905|Experimental|Epidural group|Patients are assigned to receive epidural delivery system (fentanyl and ropivacaine) for labour as pain relief option.
88821638|NCT03167905|Active Comparator|Non-epidural group|Patients are assigned to receive entonox (laughing gas), meperidine (pethidine) or remifentanil (Ultiva) for labour as pain relief option.
88821639|NCT03161028|Experimental|Arm 1: Lipoic Acid|59 subjects receive oral lipoic acid 1200mg daily
88821640|NCT03161028|Placebo Comparator|Arm 2: Placebo|59 subjects receive placebo daily
88821641|NCT03132129||Type 2 diabetics|Participants will be aged (≥18 and ≤75 years) with T2D and no prior history of cardiovascular disease.
88821642|NCT03132129||Healthy controls|Cases will be compared with age-, gender- and ethnicity-matched healthy controls.
88821643|NCT03128021|Active Comparator|Escitalopram Pill|Participants in this arm will receive an initial dose of 5 mg. Further titrations will be decided based on clinical response and tolerability (maximum dose of 20 mg). The medication will be taken by mouth in pill form, once daily.
88821644|NCT03128021|Placebo Comparator|Placebo|"Participants will be given a sugar pill (placebo) to be taken by mouth once daily for the 6 week duration of Phase I. As this arm is also double-blinded, participants will receive an initial dose of 5 mg and further titrations (maximum dose of 20 mg) will be decided based on clinical response and tolerability.~Note: This arm no longer applies as of 5/16/18. Participants are now randomly assigned to Lexapro or Fetzima."
88821645|NCT03128021|Other|Escitalopram Pill (Phase II)|"Participants who were in the placebo arm for Phase I who do not show signs of response to treatment by week 6 (defined as either a MADRS score of greater than 12 or less than a 30% reduction in MADRS score to be deemed a non-responder) will be given the option to have an open-label trial of escitalopram in Phase II.~Participants in this arm will receive an initial dose of 5 mg. Further titrations throughout the 6 week duration of Phase 2 (maximum dose of 20 mg) will be decided based on clinical response and tolerability. The medication will be taken by mouth in pill form, once daily.~Note: This arm no longer applies as of 5/16/18. Participants are now randomly assigned to Lexapro or Fetzima and the assignment does not change throughout the study."
88821646|NCT03128021|Active Comparator|Levomilnacipran Pill|Participants will receive an initial dose of 20 mg blinded levomilnacipran. At day 7, the doses will be titrated to 40 mg of levomilnacipran. Further titrations (maximum dose of 120 mg of levomilnacipran) will be decided based on clinical response and tolerability. The medication will be taken by mouth in pill form, once daily.
88821647|NCT03126214|Experimental|Active Pharmacist Arm|OAC therapy will be initiated/adjusted by the community pharmacist in accordance to the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation.
89203314|NCT00656136|Placebo Comparator|Placebo|Patients receive placebo once daily
89203315|NCT00656136|Experimental|BIBW 2992|Patients receive BIBW 2992 tablets once daily
89203316|NCT00676520||1|Single-arm study
89020734|NCT00317096|Active Comparator|FCM|"All patients underwent a central randomization procedure. Randomization was done by a Computer program stratified for histology, Response to the preceding chemotherapy, and the number of previous chemotherapies using the method of permutuated blocks.~The FCM combination comprised:~25 mg/m2 fludarabine per day iv over 30 minutes, days 1 to 3 200 mg/m2 cyclophosphamide per day as a 4-hour-infusion, days 1 to 3 8 mg/m2 mitoxantrone per day iv over 30 minutes, day 1 4 treatment Cycles á 4 weeks per cycle In patients with peripheral lymphocyte Counts more than 20.000/mm3 and/or a large Tumor mass (ie, bulky disease more than 10 cm) a cytoreductive pre-phase could be performed, comprising cyclophosphamide at a dose of 200 mg/m2 as a 1-hour-infusion over 3 to 5 days."
89020735|NCT00317096|Experimental|R-FCM|"All patients underwent a central randomization procedure. Randomization was done by a Computer program stratified for histology, Response to the preceding chemotherapy, and the number of previous chemotherapies using the method of permutuated blocks.~The R-FCM combination comprised:~375 mg/m2 rituximab on the day before the respective FCM course. 25 mg/m2 fludarabine per day iv over 30 minutes, days 1 to 3 200 mg/m2 cyclophosphamide per day as a 4-hour-infusion, days 1 to 3 8 mg/m2 mitoxantrone per day iv over 30 minutes, day 1 4 treatment Cycles á 4 weeks per cycle In patients with peripheral lymphocyte Counts more than 20.000/mm3 and/or a large Tumor mass (ie, bulky disease more than 10 cm) a cytoreductive pre-phase could be performed, comprising cyclophosphamide at a dose of 200 mg/m2 as a 1-hour-infusion over 3 to 5 days."
89020736|NCT00317096|Other|Observation only|"Patients achieving a complete or partial remission after FCM or R-FCM underwent a subsequent randomization for 2 courses of rituximab to be given 3 and 6 months after completion of salvage therapy versus observation only.~This second randomization was stratified for the type of salvage therapy with FCM or R-FCM, the Response to this Treatment (CR or PR), and histology."
89020737|NCT00317096|Other|rituximab maintenance|"Patients achieving a complete or partial remission after FCM or R-FCM underwent a subsequent randomization for 2 courses of rituximab to be given 3 and 6 months after completion of salvage therapy versus observation only.~Courses of rituximab consisted of 4 doses of 375 mg/m2 per day given at 4 consecutive weeks.~This second randomization was stratified for the type of salvage therapy with FCM or R-FCM, the Response to this Treatment (CR or PR), and histology."
89020738|NCT00349947|Active Comparator|1|Participants will take part in an exercise program.
89020739|NCT00349947|No Intervention|2|Participants will take part in a usual activity group.
89020740|NCT00317135|Experimental|Hib-MenAC Lot 1 Group|Healthy male or female subjects aged 56 to 83 days of age at the time of the first study vaccine dose, with previous hepatitis B vaccine at birth, received Tritanrix-HepB combined vaccine mixed extemporaneously with Meningitec conjugate vaccine Lot 1 at 2, 4 and 6 months of age as an intramuscular injections in the anterolateral part of the left thigh.
89020741|NCT00317135|Experimental|Hib-MenAC Lot 2 Group|Healthy male or female subjects aged 56 to 83 days of age at the time of the first study vaccine dose, with previous hepatitis B vaccine at birth, received Tritanrix-HepB combined vaccine mixed extemporaneously with Meningitec conjugate vaccine Lot 2 at 2, 4 and 6 months of age as an intramuscular injections in the anterolateral part of the left thigh.
89020742|NCT00317135|Experimental|Hib-MenAC Lot 3 Group|Healthy male or female subjects aged 56 to 83 days of age at the time of the first study vaccine dose, with previous hepatitis B vaccine at birth, received Tritanrix-HepB combined vaccine mixed extemporaneously with Meningitec conjugate vaccine Lot 3 at 2, 4 and 6 months of age as an intramuscular injections in the anterolateral part of the left thigh.
89020743|NCT00317135|Active Comparator|Hiberix Group|Healthy male or female subjects aged 56 to 83 days of age at the time of the first study vaccine dose, with previous hepatitis B vaccine at birth, received Tritanrix-HepB vaccine mixed extemporaneously with conjugate vaccine Hiberix at 2, 4 and 6 months of age as intramuscular injection in the anterolateral part of the thigh.
89020744|NCT00317252|Experimental|Hold ACEI or ARB|Angiotensin converting enzyme inhibitor or angiotensin receptor blocker held >= 24 hours pre-cardiac catheterization and restarted post-catheterization after creatinine measurement (48-96 hours post)
89020745|NCT00317252|Other|Continue ACE1 or ARB|Randomized to continue on prescribed ACE1 or ARB
89020746|NCT04714788|Experimental|Intervention group RECAP_MyLife mobile app|Participants in the intervention group will be instructed to use the mobile app daily for four weeks.
89020747|NCT04714788|Active Comparator|Control group|Comparator will be the usual data collection method applied by the cohorts.
89020748|NCT00317291|Experimental|Acupuncture/Moxibustion|Acupuncture/Moxibustion for Peripheral Neuropathy in HIV
89020749|NCT00317291|Sham Comparator|Sham acupuncture/Placebo moxibustion|Sham acupuncture/Placebo moxibustion for Peripheral Neuropathy in HIV
89020750|NCT00345189|Other|Dosing Schedule 1|Starting dose of 25 mg, with dosing twice a week for 3 weeks out of a 4-week course (Schedule 1). Dosing for schedule 1 is currently closed.
89020751|NCT00345189|Other|Dosing Schedule 2|Starting dose of 600 mg, with dosing twice a week for 4 weeks out of a 4-week course (without drug holidays; Schedule 2).
89020752|NCT02959554|Experimental|Nivolumab (A)|Nivolumab: 240 mg i.v. on D1 of every cycle (Q2W) for 16 weeks. After 16 weeks 480 mg i.v. on D1 of every cycle (Q4W) until disease progress, intolerable toxicity, withdrawal of consent or end of study.
89482582|NCT02460081|Experimental|PDA-002 -3x10^6 cells|Subjects will be treated with Investigational Product (IP) administered intramuscular (IM) on Study Days 1, 29 and 57.
89482583|NCT02460081|Experimental|PDA-002 - 30X10^6 cells|Subjects will be treated with IP administered IM on Study Days 1, 29 and 57.
88952040|NCT05876793|Experimental|remimazolam tosylate|The fixed dose of propofol in this study was 0.5mg/kg, with an injection time of 30 seconds. Subsequently, remimazolam was administered at an initial dose of 0.1mg/kg. After 1 minute of administration, sedation was evaluated using MOAA/S. When the MOAA/S score was ≤ 1, endoscopic examination could begin. If the patient did not show physical activity or coughing, sedation was considered successful, and the next patient's medication dose was reduced by 0.02mg/kg; On the contrary, if sedation fails, the next patient will receive an additional 0.02mg/kg of medication.
88952041|NCT05876741||Participants|patient presented with hematemesis , coffee ground vomiting , melena and haematoectasia to gastroenterology department will be included.
88952042|NCT05876728||cases group|50 patient of histologically confirmed breast cancer
88952043|NCT05876728||control group|50 healthy volunteers with no clinical evidence of any neoplastic disorder
88952044|NCT05876585|Experimental|Ondansetron 8 mg ampoule|A clear, colorless, sterile solution for injection or infusion. Each 1 ml of the solution contains 2 mg of ondansetron as hydrochloride dihydrate.
88952045|NCT05876585|Active Comparator|Metoclopramide 10 mg ampoule|Metoclopramide 10 mg/ 2 ml solution for injection in ampoules. Each 2 ml of the solution contains 10 mg of metoclopramide hydrochloride equivalent to 10 mg of anhydrous metoclopramide
88952046|NCT05876559|Experimental|active intervention group|Participants will receive immediate access to Joyuus selfcare mobile app
88952047|NCT05876559|Active Comparator|standard care control group|Participants will receive standard care, and will not have access to Joyuus selfcare mobile app until study completion.
88952048|NCT05876520|Other|Total pulpotomy with I-PRF only|Total pulpotomy is done in mature permanent molars followed by I-prf application. Topped with BC putty for coronal seal, RMGI and restored with composite as final restoration
88952049|NCT05876507|Experimental|exercise|Participants will receive a training about progressive relaxation exercises on the first day, then given an audio-record containing instructions about exercises. They will perform exercises at home for 4 week and revisited by the principal investigator at the 2nd and 4th week.
88952050|NCT05876507|No Intervention|Control|Participants will receive routine care.
88952051|NCT05876481|Experimental|Psilocybin-assisted Psychotherapy|All participants will receive 25mg psilocybin (capsule, hard, oral administration) in two 8-hour psilocybin dosing sessions, followed by Cognitive Processing Therapy.
88952052|NCT05876468|Experimental|A description of each arm of the clinical trial that indicates its role in the clinical trial|"Arm 1 Description:~The study will consitent of recording the measurments of ventilatory settings, respiratory mechanics, flow and pressure curves, gaz exchange, haemodynamics and ventilation distribution in 5 consecutive conditions in adult patients with moderate to severe ARDS :~After 16 hours of prone position~In supine position 1 hour after the prone position~15mn after CACC with a pressure equal to the one observed in the prone position~15mn after CACC with a pressure set at 60 - 80 cmH20~15mn after taking of the CACC"
88952053|NCT05876455|Active Comparator|Control group|On the conventional non-surgical periodontal therapy side, a power-driven piezo-electric ultrasonic scaling device with scaling tips will be used the majority of the time to debride subgingival biofilm and calculus, and manual standard Gracey curette instruments (Gracey curettes Hu-Friedy, Chicago, IL, USA) will be used to remove residual deposits from the root surface.
88952054|NCT05876455|Active Comparator|Test Group|Experimental sites designated to receive minimally invasive non-surgical periodontal therapy will undergo careful scaling and root planing under magnification (use of 3.5 X magnification loupes) with mini curettes and using an ultrasonic device with specific thin and delicate tips. These instruments will be carefully inserted through the periodontal pocket of the affected tooth to reach the root surface for debridement. Caution will be taken to preserve the stability of soft tissues.
88952055|NCT05876429|Active Comparator|Pre-Intervention: Current Transfer Process|Control: Transfer patients are admitted per usual based on existing processes for GMS, Cardiology, and Oncology services. Data collection assesses clinician reported feedback on the logistics for each patient transfer, and issues along the transfer supply chain.
88952056|NCT05876429|Experimental|Post-Intervention: Implementing Standardized Accept Note|Intervention Arm: After engaging stakeholders and finalizing a standardized accept note for transfer patients, appropriate staff will be trained on the use of the note and the note will be implemented in the transfer patient admission process. Data collection will assess clinician reported feedback on the logistics for each patient transfer, and issues along the transfer supply chain, post-intervention.
88952057|NCT05876364|Experimental|Cohort 1|Injection in the muscle at 0day , 28 day
88952058|NCT05876364|Experimental|Cohort 2|Injection in the muscle at 0day , 28 day
88952059|NCT05876364|Experimental|Cohort 3|Injection in the muscle at 0day , 28 day
88952060|NCT05876325|Experimental|Financial Navigation and Insurance Assistance (FINassist) Patient Only|Patients only participated in FINassist program
88952061|NCT05876325|Experimental|Financial Navigation and Insurance Assistance (FINassist) Patient Caregiver|Caregivers of minor patients only participated in FINassist program
88952062|NCT05876208|Experimental|Group 1|Group 1 will be using the BAND CVCP both in the clinic and at home to supplement the treatment protocols used in the clinic today.
88952063|NCT05876208|Placebo Comparator|Group 2|Group 2 will receive standard-of-care physical therapy without the use of the BAND CVCP.
88952064|NCT05876195|Placebo Comparator|Group 1: Saline 0.9% (placebo) primary dose|IM saline 0.9% (placebo) day 0, followed by multi-dose ID subunit KLH (0 mcg (saline), 1 mcg, 3 mcg, 10mcg, 30mcg, 100mcg) day 28
88952065|NCT05876195|Active Comparator|Group 2: subunit KLH 1000mcg primary dose|IM dose subunit KLH 1000 mcg day 0, followed by multi-dose ID subunit KLH (0 mcg (saline), 1 mcg, 3 mcg, 10mcg, 30mcg, 100mcg) day 28
88952066|NCT05876195|Active Comparator|Group 3: subunit KLH 1000mcg plus aluminium hydroxide adjuvant 900mcg primary dose|IM dose subunit KLH 1000 mcg plus aluminium hydroxide 900mcg day 0, followed by multi-dose ID subunit KLH (0 mcg (saline), 1 mcg, 3 mcg, 10mcg, 30mcg, 100mcg) day 28
88952067|NCT05876195|Active Comparator|Group 4: subunit KLH 1000mcg plus Montanide ISA-51 primary dose|IM dose subunit KLH 1000 mcg plus Montanide ISA-51 day 0, followed by multi-dose ID subunit KLH (0 mcg (saline), 1 mcg, 3 mcg, 10mcg, 30mcg, 100mcg) day 28
88952068|NCT05876195|Active Comparator|Group 5: subunit KLH 10mcg primary dose|IM dose subunit KLH 10 mcg day 0, followed by multi-dose ID subunit KLH (0 mcg (saline), 1 mcg, 3 mcg, 10mcg, 30mcg, 100mcg) day 28
88952069|NCT05876195|Active Comparator|Group 6: subunit KLH 10mcg plus aluminium hydroxide adjuvant 900mcg primary dose|IM dose subunit KLH 10 mcg plus aluminium hydroxide 900mcg day 0, followed by multi-dose ID subunit KLH (0 mcg (saline), 1 mcg, 3 mcg, 10mcg, 30mcg, 100mcg) day 28
88952070|NCT05876195|Active Comparator|Group 7: subunit KLH 10mcg plus Montanide ISA-51 primary dose|IM dose subunit KLH 10 mcg plus Montanide ISA-51 day 0, followed by multi-dose ID subunit KLH (0 mcg (saline), 1 mcg, 3 mcg, 10mcg, 30mcg, 100mcg) day 28
88952071|NCT05876195|No Intervention|Group 8: Blood-sample only group (non-randomised)|No challenge agent, blood sampling only.
88952072|NCT05876169|Other|Prospective longitudinal study design|Patients that will undergo orthognatic surgery will be given opportunity to participate in jaw and neck motor function analysis.
88952073|NCT05876143||Fixed cementless UKP|Patient implanted with a fixed cementless Unicompartmental prosthesis
88952074|NCT05876143||Fixed cemented UKP|Patient implanted with a fixed cemented Unicompartmental prosthesis
88952075|NCT05876143||Mobile Cementless UKP|Patient implanted with a mobile cementless Unicompartmental prosthesis
88952076|NCT05876143||Mobile Cemented UKP|Patient implanted with a mobile cemented Unicompartmental prosthesis
88952077|NCT05876143||Fixed Cementless UKP (TIT coating)|"Patient implanted with a fixed cementless Unicompartmental prosthesis coating with TIT"
88952078|NCT05876130|Experimental|POHIM_EM|adjuvant hypofractionated IMRT for endometrial cancer
89203317|NCT00652938|Active Comparator|Cervarix & Engerix Group|Subjects received 3 doses of Cervarix™ (Human Papillomavirus [HPV] vaccine) co-administered with Engerix™ (Hepatitis B [HBV] vaccine) according to a 0, 1, 6-month schedule.
89203318|NCT00652938|Experimental|Cervarix Group|Subjects received 3 doses of Cervarix™ (Human Papillomavirus [HPV] vaccine) according to a 0, 1, 6-month schedule.
89203319|NCT00652938|Active Comparator|Engerix Group|Subjects received 3 doses of Engerix™ (Hepatitis B [HBV] vaccine) according to a 0, 1, 6-month schedule.
89203320|NCT05434520||Preoperative biliary drainage|Patients who had undergone preoperative biliary drainage (ERC og PTC) prior to pancreatoduodenectomy
88952079|NCT05876052|Experimental|Hypothermic oxygenated Perfusion - HOPE|"Belzer machine perfusion solution at 4°C-10°C in sterile conditions and continuous oxygenation (partial pressure of oxygen=500-600 mmHg) will be used for perfusion, 3000 ml for livers, 1-3 hours.~Liver perfusion will be performed through the portal vein at a 5 mmHg pressure. Flow, pressure and temperature will be monitored and registered on REDCap software during organ perfusion. Gas analysis of the effluent perfusate (partial pressure O2 and CO2, pH, lactate and glutamate production) will be accomplished every 15 minutes."
88952080|NCT05876052|No Intervention|Static Cold Storage - SCS|Livers undergoing SCS will be stored in sterile organ bags with Belzer or Celsior solution and cooled in ice until transplant.
88952081|NCT05876039|Experimental|Group remifentanil of 1.0 ng/mL|Initial remifentanil effect-site concentration of 1.0 ng/mL
88952082|NCT05876039|Active Comparator|Group remifentanil 2.0 ng/mL|Initial remifentanil effect-site concentration of 2.0 ng/mL
88952083|NCT05876013||BPTB group|Bone-patellar tendon- bone graft used for ACL reconstruction.
88952084|NCT05876013||Hamstring group|Double-looped semitendinosus and gracilis graft used for ACL reconstruction
88952085|NCT05875935|Experimental|Subject with a non-recurrent glial lesion requiring surgery in vigilance|
89020753|NCT02959554|Active Comparator|TKI (B)|Sunitinib: According to Standard of Care (SOC). Recommended dose is 50 mg p.o. once daily for 4 consecutive weeks followed by a 2-week rest period (schedule 4/2) to comprise a complete cycle of 6 weeks (until disease progress, intolerable toxicity, withdrawal of consent or end of study) or Pazopanib: According to Standard of Care (SOC). Recommended dose is 800 mg p.o. daily continuously (until disease progress, intolerable toxicity, withdrawal of consent or end of study)
89203321|NCT05434520||No preoperative biliary drainage|Patients who had not undergone preoperative biliary drainage (ERC og PTC) prior to pancreatoduodenectomy
89203322|NCT02559908|Experimental|Treatment Group_VYC-25L|VYC-25L injection into the chin and/or jaw areas on Day 1, volume determined by the investigator (up to 4.0 mLs) and repeat treatment if applicable
88952086|NCT05875909|Experimental|corneal flap transplantation|Patients with macular holes underwent a 25-gauge, 3-port pars plana vitrectomy . Fluid-air exchange was performed in patients with pathologic myopia suffering from macular holes with retinal detachment. We used a flute needle to drain the subretinal fluid. A corneal flap was obtained by small incision lenticule extraction (SMILE). Stripping pliers were applied to spread corneal flap over the macular hole. A drop of fresh autologous whole blood was dripped over the corneal flap to immobilise it. The vitreous cavity was filled with 14% perfluoropropane (C3F8) for macular holes with retinal detachment . The surgical incision was self-closed or sutured with a 6-0 polyglactin 910 suture . The patients were instructed to maintain a prone position for 2 weeks postoperatively.
88952087|NCT05875844|Other|Wrist Splint|
88952088|NCT05875844|Experimental|Occupational Therapy|
88952089|NCT05875831|Other|Coughing|
88952090|NCT05875831|Experimental|Active Cycle of Breathing|
89203323|NCT02559908|Other|Control Group_No treatment then VYC-25L|No treatment for 3 months followed by VYC-25L injection into the chin and/or jaw areas, volume determined by the investigator (up to 4.0 mLs) and repeat treatment if applicable.
89203324|NCT00322621|Experimental|Duloxetine|All subjects receive 30 mg once daily (QD), by mouth (per os - PO) for 1 week followed by duloxetine 60 mg QD, PO for 7 weeks, then maintenance at 60 mg QD, PO for responders to 6 months and rescue at 120 mg QD, PO for non-responders to 6 months. Patients beginning maintenance at the 60 mg QD dose could be increased to the 120 mg QD level if they did not maintain appropriate level of response throughout the maintenance period.
89203325|NCT02558972|Placebo Comparator|Northera-single dose|Study #1 -Does single large dose (600mg) of Northera improve upright hemodynamics and orthostatic intolerance in POTS and VVS
89203326|NCT02558972|Placebo Comparator|Northera- chronic administration|Study #2 -Patients will randomized to receive Northera or placebo for two weeks after which they will return for instrumented tilt studies as in Study 1. Doses of Northera will be titrated upwards by 100mg/dose every 48 hours from a starting dose of 100mg three times a day to a maximum of 600mg three times a day.
89203327|NCT00809718|Other|raltegravir and rifapentine|Concomitant administration of raltegravir and rifapentine in healthy volunteers
89203328|NCT05427266|Other|Study Group - Tap Block|"Study Group: Study group: Laparoscopic Transversus Abdominis Plane in four points: above and below the umbilicus in both right and left sides; dose calculation 2.5mg per body weight.~After the appendicectomy is done and just before withdrawing port and deflating the abdomen, the operating surgeon will advance a needle into the abdominal wall to the level of the preperitoneal space. Once the needle tip is seen, it is withdrawn slowly and gently about 0.5cm above/superficial to the transversus abdominis (TA) muscle. The surgeon then infiltrates the local anaesthetic into the plane, and the right plane is confirmed by visualising a uniform protrusion downwards of the TA muscle fibres (Doyle's bulge). Seeing a preperitoneal or muscle blister laparoscopically indicates that the infiltration is deeper to this plane, and the needle should be withdrawn more superficially."
89203329|NCT05427266|Other|Control Group - Standard port site infiltration|Patients will be randomised after diagnosis either clinically or radiologically of appendicitis (both complicated and uncomplicated) Control Group _ standard port site infiltration using 0.25% plain bupivacaine. The dose is calculated to 2.5mg/per kg body weight. After the appendicectomy is done, after removal of ports and deflating the abdomen, the total calculated dose volume will be infiltrated into the subcutaneous plane at the umbilicus and the other 2 ports sites
89203330|NCT00575042|Experimental|Patients treated with Fenofibrate|Fenofibrate IDD-P (Insoluble Drug Delivery-Micro Particle) 160 mg table per day for 1 year
89203331|NCT01058161|Other|Suspects or affected by rheumatoid polyarthritis|
89203332|NCT01058161|Other|stiffening spondylitis with axial and peripheral infringement|
89203333|NCT01058161|Other|polyarthralgies with or without arthritis|Affected by connectivity with anti-nuclear antibody positive and / or specific antibodies, suffering of polyarthralgias with or without arthritis
89203334|NCT01058161|Other|Healthy control|
89203335|NCT01058161|Other|not inflammatory control|Presenting a degenerative osteoarthritis of the wrist traumatic comment, noticed radiologically, which will serve as not inflammatory control.
89203336|NCT00676208|Experimental|Shared Medical Appointments|Medical students participated in shared medical appointments for patients with diabetes for one month.
89203337|NCT00676208|No Intervention|No shared medical appointments|Medical students in this arm did not participate in shared medical appointments.
89203338|NCT02533297|Experimental|clinical education|the researcher used the checklist to assess the student's mastery level skill l while changing a skill and recorded his score on the learning curve based on a 1 (no mastery) to 100 (complete mastery) scoring scale. This procedure continued until the learning curve reached to a plateau state, i.e. either reaching to the full mastery score (100) or revealing no significant change in three subsequent sessions. All the students achieved mastery (the plateau state) after performing the task for at most ten times.
89203339|NCT00656058|Experimental|Montelukast to Treat Bronchiolitis Obliterans|Montelukast for the treatment of BO following allogeneic or autologous stem cell transplant.
89203340|NCT00537316|Experimental|Infliximab (IFX)|Part 1: IFX 5 mg/kg of body weight intravenous (IV) infusions was to be administered at Weeks 0, 2, and 6 and placebo to AZA was to be taken orally every day for 16 weeks. Responders to IFX at Week 8, were to receive one more IFX infusion at Week 14; non-responders to IFX were to receive placebo IFX infusions at Weeks 8 and 10 and an additional IFX infusion at Week 14. Part 2: Participants in steroid-free remission at Week 16 of Part 1 were to be randomized to either maintenance (every 8 weeks [q8w]) or intermittent (upon relapse) open-label IFX (last IFX infusion administered at Week 86) plus double-blind oral AZA/placebo treatment as allocated in Part 1 (last dose at the final visit, Week 94). Responders at Week 16 who had not achieved steroid-free remission were to continue to receive IFX infusions every 8 weeks.
89482584|NCT02460081|Placebo Comparator|Placebo|Subjects will be treated with Placebo administered IM on Study Days 1, 29 and 57.
88952091|NCT05875818|Other|Tele-rehabilitation|
88952092|NCT05875818|Experimental|In-clinic Rehabilitation|
89537594|NCT04431219|Experimental|Ascending Dose Cohort|"The AD cohort will be first recruited and will include 5 patients: 1 patient per dose, sequentially recruited, the recruitment of the next dose level patient will be assessed by Data Safety Monitoring Board :~Patient 1: 0.6 mg/Kg/day~Patient 2: 1 mg/Kg/day~Patient 3: 3 mg/Kg/day~Patient 4: 6 mg/Kg/day~Patient 5: 8 mg/Kg/day~Once the 5 AD patients complete LIS1 treatment, the sponsor and the DSMB will rule on the LIS1 dose to obtain an optimal CD3+ cells depletion, with a good safety profile and will determine the therapeutic dose."
89206293|NCT04093271|Experimental|Randomized to consume comparator, placebo, then Rest-ZZZ|Each study product will be consumed as 2 capsules daily for 7 days. Randomized to consume the Comparator (Diphenhydramine HCl) in Study Period 1, Placebo in Study Period 2, and the Dietary Supplement, Rest-ZZZ in Study Period 3.
88952093|NCT05875792|Experimental|Intervention|people who have recently had a stroke and need upper limb rehabilitation
88952094|NCT05875766|Experimental|Patient with osteopathy session|Patients after their DIDT surgery have 4 osteopathy sessions in addition to physiotherapy
88952095|NCT05875766|Placebo Comparator|Patient without osteopathy session|Patients after their DIDT surgery have only physiotherapy
88952096|NCT05875753|Experimental|68Ga-FAPI-FS PET/CT|Each patient will receive one dose of 68Ga-FAPI-FS by intravenous route. Dedicated whole-body PET/CT imaging will be performed.
88952097|NCT05875688|Experimental|Group A|Filling the crown with cement up to margins.
88952098|NCT05875688|Experimental|Group B|Applying a cement layer on all fitting surfaces.
88952099|NCT05875688|Experimental|Group C|Applying a cement layer on all fitting surfaces except occlusal surface.
88952100|NCT05875675|Experimental|Drug group|Dietary Supplement: Pioglitazone 30 mg by mouth daily
88952101|NCT05875675|Placebo Comparator|Control group|Dietary Supplement: Placebo
88952102|NCT05875662||Mechanical ventilation patients undergoing fiberoptic bronchoscopy|
88952103|NCT05875610|Experimental|Venlafaxine Arm|Patients receiving Taxanes (Docetaxel or Paclitaxel) or Oxaliplatin containing regimens.
88952104|NCT05875610|Active Comparator|Gabapentin Arm|Patients receiving Taxanes (Docetaxel or Paclitaxel) or Oxaliplatin containing regimens.
88952105|NCT05875597|Experimental|Experimental Group Exercise|Participants will be required to undertake a strength oriented physical therapy exercise programme.
88952106|NCT05875597|No Intervention|Control Group|Participants will not engage in a strength oriented therapeutic physical exercise programme.
88952107|NCT05875558|Experimental|M-TACE|
88952108|NCT05875545|Active Comparator|Breathing Exercise Group|Combined breathing and pelvic floor exercises
88952109|NCT05875545|Active Comparator|Control Group|Pelvic floor exercises
88952110|NCT05875532||Patients with fibrosing interstitial lung disease (ILD)|
88952111|NCT05875519|Experimental|Anaesthesia with vasocontrictor|
88952112|NCT05875519|Active Comparator|Anaesthesia without vasocontrictor|
88952113|NCT05875480|Experimental|synchronized telerehabilitation group|Patients in the synchronized telerehabilitation group had taken real time videoconferencing rehabilitation by physiotherapist 2 times a week, during 4 weeks.
88952114|NCT05875480|Experimental|asynchronized telerehabilitation group|Patients in the asynchronized telerehabilitation group had done the postoperative rehabilitation with exercise videos via application.
88952115|NCT05875480|Active Comparator|supervized conventional rehabilitation group|Patients in the supervised physiotherapy group had taken their rehabilitation sessions in the physiotherapy department of the hospital twice a week, during 4 weeks.
88952116|NCT05875402|Experimental|XKDCT080 treatment for patients with GCC target positivity|"Drug: XKDCT080 (chimeric antigen receptor T cell preparation targeting GCC)~Dosage form: Cell suspension~Dose: 30-50mL/bag~Medication method: intravenous drip~Frequency: Once"
88952117|NCT05875389|Experimental|Virtual assessment|virtual assessment with a stroke neurologist/advanced practice nurse, with interdisciplinary support, to facilitate the care of patients admitted to primary stroke centres using existing tools for remote evaluation and review.
88952118|NCT05875376|Experimental|ASD couple|Either one of the couple has ASD diagnosis, including couples who are married or in romantic relationship.
88952119|NCT05875363||ADHD|ADHD is among the most commonly diagnosed neurodevelopmental disorders, and the worldwide prevalence.
88952120|NCT05875363||ASD|Autistic spectrum disorder (ASD), characterized by overriding obsessions and difficulties in social cognition, might render the affected individuals vulnerable for becoming an offender or a victim of crime.
88952121|NCT05875363||Other disorders in youth: CD or substance use disorder|Conduct disorder (CD), characterized by antisocial and aggressive behavior, affects 2-2.5% of children and adolescents. CD is a risk factor for antisocial personality disorder, and despite the fact that a CD diagnosis completely relies on behavioral symptoms, research has identified neurocognitive impairments.
88952122|NCT05875324|Experimental|VR Group|The patients in the VR group were informed about the disease, the goals of post-surgical rehabilitation, the exercises, and the circumstances to be considered following TKA. On the postoperative first day, activities included sitting on the side of the bed and mobilizing in and out of the room using a walker. Patients were discharged 2.5 days after surgery. Patients were provided an exercise program for at-home practice. In addition to the exercise program, VR glasses were used before the exercises in the VR group. The second examination was performed three days after the completion of treatment.
89203341|NCT00537316|Active Comparator|Azathioprine (AZA)|AZA 2.5 mg/kg of body weight orally every day for 16 weeks. Responders to AZA monotherapy at Week 8 were to continue on AZA therapy and receive one placebo infusion at Week 14; non-responders to AZA at Week 8 would be eligible to receive an IFX infusion at Weeks 8, 10, and 14. Participants in steroid-free remission at Week 16 were to continue on AZA monotherapy and were to be followed up for safety in Part 2. Participants who experienced a relapse of disease after Week 16 were to continue daily AZA monotherapy and receive 3 infusions of IFX (induction therapy at Weeks 0, 2, and 6) followed by infusions every 8 weeks (maintenance therapy).
88952123|NCT05875324|Active Comparator|Exercise Group|Exercise group were informed about the disease, the goals of post-surgical rehabilitation, the exercises, and the circumstances to be considered following TKA. On the postoperative first day, activities included sitting on the side of the bed and mobilizing in and out of the room using a walker. Patients were discharged 2.5 days after surgery. Patients in the exercise group were provided an exercise program for at-home practice. The second examination was performed three days after the completion of treatment.
88952124|NCT05875311|Experimental|telemonitoring|Patients in the intervention group will come to the ambulatory centre 2 times, undergoing mobile application training and the same educational talks as in the control group. Subsequently, they will follow the scheduled physical activities and adherence to the risk factor management according to individualised guidelines in their App, until the end of the study period. All data generated are recorded on the professional website. The degree of compliance with the objectives set is monitored by means of 7 coloured icons, which vary according to the target achievement.
88952125|NCT05875311|Other|control follow-up|Patients in the control group will come to the ambulatory centre only once. The same educational talks as to the intervention group will be given. A conventional outpatient follow-up by primary care and the corresponding specialist will be carried out.
88952126|NCT05875298|Experimental|physical therapy protocol|the patients will receive physical therapy protocol three times a week for four weeks
88952127|NCT05875298|Experimental|physical therapy protocol and medical drugs|the patients will receive physical therapy protocol three times a week for four weeks and medication twice daily for four weeks
88952128|NCT05875298|Active Comparator|medical drugs|the patients will receive medical drugs twice daily for four weeks
88952129|NCT05875285|Experimental|Methotreaxate iontophoresis|Thirty patients of both sexes of primary palmar hyperhidrosis are selected to participate in this group from EL KASR EL- AINI
89482585|NCT03091712|Experimental|Paper Titration Tool and Glooko MIDS|"Glooko mobile insulin dosing system(MIDS), using the STEP WISE degludec titration algorithm.~The eligible subjects will be started on insulin degludec (Tresiba® U-200 FlexTouch®). Subjects will use MIDS for insulin degludec titration management. The clinician will configure MIDS Prescription Instruction Form(PIF) using pre-configured Novo Nordisk, Tresiba Protocol Dosing Treatment Plan which is based on the Novo Tresiba degludec Stepwise Program. The Clinician can alter this as appropriate based on medical judgment. Subjects will be started on MIDS and trained on use of Glooko MIDS mobile app. Subjects will get dose adjustment check up on the app and also alert to contact physician if subject experiences hyperglycemia or hypoglycemia."
89482586|NCT03091712|No Intervention|Paper Titration tool|"Usual care for insulin degludec (Tresiba® U-200 FlexTouch® pens) titration using the STEP WISE degludec titration algorithm.The eligible subjects will be started on insulin degludec(Tresiba® U-200 FlexTouch®).~Subjects in this group will be provided with a one-page description of the pre-configured Novo Nordisk, Tresiba Protocol Dosing Treatment Plan which is based on the Novo Tresiba degludec Stepwise Program and how to follow it. The Clinician can alter this as appropriate based on medical judgment. This document will also include instructions to contact the HCP if the subject experiences hyperglycemia or hypoglycemia."
89482587|NCT03291405||Body Mass Index less than 30|
89482588|NCT03291405||Body Mass Index more than 30|
89482589|NCT02121691|Experimental|Walk by Faith|Intervention arm
89482590|NCT02121691|No Intervention|Comparison|Non-intervention arm
89482591|NCT04488471||high-risk group|IBD patients who were high risk of infection and were shielding
89482592|NCT04488471||low-risk group|IBD patients who were low risk of infection and were following standard quarantine guidance
89482593|NCT04488471||young people from affiliated study|32 IBD patients from an affiliated study
89482594|NCT02123407|Experimental|Carbon Nanoparticles|Carbon Nanoparticles could be used in this arm.The drug is injected into the subserosa of stomach.Injections of 1.0 ml of Carbon Nanoparticles (0.2 ml in each cardinal point adjacent to the lesion) will be performed about 10 minutes before surgery.Then,gastrectomy with D2 dissection will be performed.
89482595|NCT02123407|Active Comparator|Gastrectomy with D2 dissection|Gastrectomy with D2 dissection will be performed in the control arm,no Carbon Nanoparticles or other coloring materials used
89482596|NCT03081650|Experimental|Prospective Open label|"All of the patients that will be Selected to participate in the study will be given an AIRVO humidifier by the study sponsor. Patients will be connected to and instructed in the use of the AIRVO. The total flow will be set at 20-25 L/min, exact flow rate will be dependent on the patient's preference. Optiflow oxygen catheter will be used to ensure against unpleasant sensation due to high flow and to avoid push back in the system.~When acceptable flow rated has been established, it is recorded in the patient's folder. The patients is then instructed to use the AIRVO for a minimum eight (8) hour period, preferably at night. Using the humidifier for a longer period of time is allowed. The total number of hours the humidifier was operational will be recorded at the end of the study"
89482597|NCT03291327|Active Comparator|Investigational product (Lactobacillus A)|"All volunteers considered to be suitable for the study will receive a pre-baseline dental prophylaxis. At baseline (BL) they will be instructed to abstain from all methods of tooth cleaning in mandible for 2 weeks (2W) apart from the fluoride toothpaste provided. A soft gum shield provided will cover the mandibular teeth whilst brushing and will be removed 10 minutes after brushing. Gingival health assessments and gingival crevicular fluid (GCF) and bacterial plaque samples be undertaken at BL and 2W. At 2W, all participants will receive a dental prophylaxis following the collection of samples and will be asked to resume their normal oral hygiene regime.~Lactobacillus (A) in the form of a lozenge to be taken twice daily (in the morning and in the evening). The lactobacilli will be in the form of a lozenge, which should be placed on the tongue and allowed to dissolve. Any undissolved particles may be swallowed by the participant."
89482598|NCT03291327|Active Comparator|Investigational product (Lactobacillus B)|"All volunteers considered to be suitable for the study will receive a pre-baseline dental prophylaxis. At baseline (BL) they will be instructed to abstain from all methods of tooth cleaning in mandible for 2 weeks (2W) apart from the fluoride toothpaste provided. A soft gum shield provided will cover the mandibular teeth whilst brushing and will be removed 10 minutes after brushing. Gingival health assessments and gingival crevicular fluid (GCF) and bacterial plaque samples be undertaken at BL and 2W. At 2W, all participants will receive a dental prophylaxis following the collection of samples and will be asked to resume their normal oral hygiene regime.~Lactobacillus (B) in the form of a lozenge to be taken twice daily (in the morning and in the evening). The lactobacilli will be in the form of a lozenge, which should be placed on the tongue and allowed to dissolve. Any undissolved particles may be swallowed by the participant."
89482599|NCT03291327|Placebo Comparator|Placebo Product (P)|"All volunteers considered to be suitable for the study will receive a pre-baseline dental prophylaxis. At baseline (BL) they will be instructed to abstain from all methods of tooth cleaning in mandible for 2 weeks (2W) apart from the fluoride toothpaste provided. A soft gum shield provided will cover the mandibular teeth whilst brushing and will be removed 10 minutes after brushing. Gingival health assessments and gingival crevicular fluid (GCF) and bacterial plaque samples be undertaken at BL and 2W. At 2W, all participants will receive a dental prophylaxis following the collection of samples and will be asked to resume their normal oral hygiene regime.~Placebo (P) in the form of a lozenge to be taken twice daily (in the morning and in the evening). The placebo will be in the form of a lozenge, which should be placed on the tongue and allowed to dissolve. Any undissolved particles may be swallowed by the participant."
89482600|NCT02460003|Experimental|Physiotherapy program|Physiotherapy program and usual drugs
89482601|NCT02460003|Active Comparator|Home exercise program|Home exercise program and usual drugs
89482602|NCT04960826||Crohn's disease patients|
89482603|NCT04960826||Non IBD patients|
89482604|NCT03552211||Patients treated with biotin|This is a national, academic, observational and retrospective study comparing one group of progressive MS patients with high dose biotin to another group without this treatment using a propensity score, in intention to treat
89482605|NCT03552211||Control patients|This is a national, academic, observational and retrospective study comparing one group of progressive MS patients with high dose biotin to another group without this treatment using a propensity score, in intention to treat
89482606|NCT03091634|Experimental|test group|the patients in this group take 6 xue-fu-zhu-yu capsules once, twice a day, for 7weeks.
89482607|NCT03091634|Placebo Comparator|control group|the patients in this group take 6 xue-fu-zhu-yu capsule simulated agents once, twice a day, for 7weeks..
89482608|NCT05009888||Adult KCL IoPPN Staff|Freely consenting Adult KCL Staff attending King's College London, IoPPN, Denmark Hill site will all have an antibody test on finger prick blood. The antibody test will give a rapid result for the presence of IgG or IgM antibodies to COVID-19
89482609|NCT02113111||Fasting|Patients being admitted to an internal integrative medicine hospital and referred to therapeutic fasting therapy
89482610|NCT05009810|Experimental|astaxanthin 4 mg|The astaxanthin 4 mg will be taken 1 capsule once daily for 2 months.
89482611|NCT05009810|Experimental|astaxanthin 6 mg|The astaxanthin 6 mg will be taken 1 capsule once daily for 2 months.
89482612|NCT05009810|Placebo Comparator|Placebo|The placebo will be taken 1 capsule once daily for 2 months.
89482613|NCT02113267|Experimental|Mometasone furoat|Mometasone furoate monohydrate. 4 spray doses à 50 micrograms by mouth to be swallowed 4 times daily after meals (9) with no eating or drinking allowed 30 minutes after intake. Duration of treatment is 8 weeks.
89482614|NCT02113267|Placebo Comparator|Placebo spray|Placebo. 4 spray doses à 50 micrograms by mouth to be swallowed 4 times daily after meals (9) with no eating or drinking allowed 30 minutes after intake. Duration of treatment is 8 weeks.
89482615|NCT05009576|Active Comparator|vac with silver|wounds of patients will be covered with a vac dressing with single layer of Ag+ hydrocolloid dressings. Such pattern of dressing will be followed in every change of dressing in 48 hours.
89482616|NCT05009576|Active Comparator|simple VAC without silver alginate|wounds of patients will be covered with VAC dressings only. Such pattern of dressing will be followed in every change of dressing in 48 hours.
88952130|NCT05875285|Experimental|Coal tar ointment|Thirty patients of both sexes of primary palmar hyperhidrosis are selected to participate in this group from EL KASR EL- AINI
89482617|NCT03281187|Experimental|Nasotestt 5 mg|Participants randomized to this arm must administer one packet of Nasotestt 5 mg in each nostril (3 times a day - T.I.D) for 60 days.
88952131|NCT05875194|Experimental|active transcranial direct current stimulation (tDCS)|A single application of transcranial direct current stimulation (tDCS), anodal stimulation of the left dlPFC placed (10-20 position F3) and the reference electrode on the arm, intensity 2mA, with retangular electrodes, size 35cm2, current intensity is ramped up to 2mA over a period of 20 seconds, duration 15 minutes
89020754|NCT00350181|Experimental|Regimen Treatment 1|For subjects 18-60 years old with lymphoma: (BCNU+ VP-16 +CY) BCNU 15 mg / kg (maximum dose 550 mg/m² actual body weight) on day -6. VP 60 mg / kg on day 4 and CY 100 mg / kg on day -2. Followed by Sirolimus and MMF as prophylaxis
89482618|NCT03281187|Active Comparator|Androgel 50 mg|Participants randomized to this arm must administer one packet of Androgel 50 mg applied once daily to skin of shoulder for 60 days.
89482619|NCT03281187|Placebo Comparator|Androgel Placebo|Participants must administer one packet of Androgel placebo applied once daily to skin of shoulder in addition to an experimental drug for 60 days.
89482620|NCT03281187|Placebo Comparator|Nasotestt Placebo|Participants must administer one packet of Nasotestt Placebo in each nostril (3 times a day - T.I.D) in addition to an experimental drug for 60 days.
89482621|NCT02113345|Experimental|lifestyle counseling|Metamemory Cognitive Intervention
89482622|NCT03291249|Placebo Comparator|Group A|Group A will receive placebo solution for 30 consecutive days
89482623|NCT03291249|Experimental|Group B|Group B will receive 0.5 mg Foralumab Solution daily for 30 consecutive days
89482624|NCT03291249|Experimental|Group C|Group B will receive 2.5 mg Foralumab Solution daily for 30 consecutive days
89482625|NCT03291249|Experimental|Group D|Group B will receive 5.0 mg Foralumab Solution daily for 30 consecutive days
88952132|NCT05875194|Sham Comparator|sham transcranial direct current stimulation (tDCS)|A single application of transcranial direct sham stimulation (tDCS), with sponge electrodes, placed over left dlPFC (10-20 position F3) and the reference electrode on the arm, with retangular electrodes 35cm2,intensity is ramped up to 2mA over a period of 20 seconds duration and then switched off again at the end of 20 s ramp. To ensure that there are no differences in perception, this is applied in both verum and sham stimulation, duration 15 min
88952133|NCT05875155||Cryopreservation|Participants will have autologous ovarian tissue cryopreserved for fertility preservation.
88952134|NCT05875064|Active Comparator|conventional restoration group (control)|The teeth allocated in the conventional restoration group (control) will receive restorations in resin composed by incremental technique, using opaque resin. For this, 37% phosphoric acid (Condac37, FGM) will be applied for 15 seconds, and then, after washing and relative drying of the surface, application of universal adhesive (Universal Beautibond Adhesive, Shofu) with the aid of microbrush on the entire dental surface, photoactivation of the adhesive and restoration by incremental technique and photoactivation of each layer of resin for 20 seconds. The tooth will receive finishing and polishing through rotating instruments and abrasive discs (Supersnap, Shofu).
89482626|NCT05013320|Active Comparator|Dexmedetomidine only|dexmedetomidine is administered during the surgery
89482627|NCT05013320|Experimental|Combined dexmedetomidine and glycopyrrolate|glycopyrrolate and dexmedetomidine are administered during the surgery
89482628|NCT02437162|Placebo Comparator|Group 1 (Placebo)|Placebo subcutaneous (SC) injection at Weeks 0, 4, and 16. At Week 24 all participants (with the exception of participants who qualified for early escape [EE]) will be re-randomized to receive either ustekinumab 45 or 90 milligram (mg) SC injection at Weeks 24 and 28 followed by every 12 weeks (q12w) dosing, with the last administration of study agent at Week 100. Participants who meet EE criteria (less than [<] 10 percent [%] improvement from baseline in both total back pain and morning stiffness measures at both Week 12 and Week 16) will be administered open-label golimumab 50 mg SC administrations at Week 16 and every 4 weeks (q4w) thereafter through Week 52.
89482629|NCT02437162|Experimental|Group 2 (Ustekinumab 45 mg)|Ustekinumab 45 mg SC injection at Weeks 0 and 4, followed by every 12 week dosing, with the last administration of study agent at Week 100. At Week 24, participants will receive placebo SC injection to maintain the blind. Participants who meet EE criteria (<10% improvement from baseline in both total back pain and morning stiffness measures at both Week 12 and Week 16) will be administered open-label golimumab 50 mg SC administrations at Week 16 and q4w thereafter through Week 52.
89482630|NCT02437162|Experimental|Group 3 (Ustekinumab 90 mg)|Ustekinumab 90 mg SC injection at Weeks 0 and 4, followed by q12w dosing, with the last administration of study agent at Week 100. At Week 24, participants will receive placebo SC injection to maintain the blind. Participants who meet EE criteria (<10% improvement from baseline in both total back pain and morning stiffness measures at both Week 12 and Week 16) will be administered open-label golimumab 50 mg SC administrations at Week 16 and q4w thereafter through Week 52.
89482631|NCT02113423|Experimental|recurrent T1-2 NPC,no treatment|3D-CRT, IMRT, BT, BT combined 3D-CRT or IMRT
89482632|NCT03091556||The individuals taking XLGB Pill|The overall individuals taking XLGB Pill with recommended dosage and achieving the inclusion criteria.
89482633|NCT03553459|Experimental|Trendelenburg Maneuver|Trendelenburg maneuver is performed to predict fluid responsiveness. Responders are defined by an increase in stroke volume over 15% after infusion of 500ml of crystalloid solution.
89482634|NCT03291093|Experimental|18F-Flutemetamol PET/MRI dynamic|"All included patients will be patients with a recent stroke and a significant carotid plaque.~The first 5 patients will undergo a slightly longer scan protocol to determine optimal scan time for the use of 18F-Flutemetamol in atherosclerosis imaging."
89482635|NCT03291093|Experimental|18F-Flutemetamol PET/MRI CEA|10 patients will be selected from patients that will undergo carotid endarterectomy (CEA) and will undergo the the optimized (shorter) scan protocol with 18F-Flutemetamol. The decision for this operation is made by the surgeon and neurologist and based on clinical standards and is thus independent of study participation.
89482636|NCT03291093|Experimental|18F-Flutemetamol PET/MRI|The remaining 10 patients will undergo the optimized (shorter) scan protocol with 18F-Flutemetamol.
89482637|NCT03079466|Active Comparator|Treatment CPAP|A group treated with CPAP
89482638|NCT03079466|Sham Comparator|group without treatment|
89482639|NCT02123563|Experimental|Ultrason Essential oils rinse|Ultrasonic debridement followed by twice daily home use of an essential-oils mouth rinse (20mL, 30 seconds for each rinse) for 3 months
89482640|NCT02123563|Placebo Comparator|Ultrason Placebo rinse|Ultrasonic debridement followed by twice daily home use of a placebo rinse (20mL, 30 seconds for each rinse) for 3 months
89482641|NCT03091322||SR-T group|single chamber pacemaker
89482642|NCT03091322||DR-T group|dual chamber pacemaker
89482643|NCT03091322||HF-T group|triple chamber pacemaker (IS-1 connector)
88956517|NCT05019027|Other|On-Off Sequence|This arm will follow an On-Off sequence. This is the only arm in the study. Subjects will begin in the On phase (Period 1), maintaining their beta-blocker dosage as previously prescribed to the subjects by their physician. Subjects will then continue to the Off phase (Period 2) where they will down-titrate their beta-blocker by 50% each week until they are completely off the drug for a total of two weeks. At the end of Period 2, the subjects will have their End of Intervention visit in which they will determine if they would like to continue or discontinue their beta-blockers for the foreseeable future.
89482644|NCT03091322||HF-T QP group|triple chamber pacemaker (with IS4 connector) and a lead of the Sentus QP lead family
89482645|NCT03291015|Other|radiographic guided treatment|radiographic guided treatment of kienbock disease using plain x ray for determine treatment plan
89482646|NCT03291015|Other|arthroscopic guided treatment|arthroscopic guided treatment of kienbock disease using wrist arthroscopy for determine treatment plan (Wrist arthroscopy)
89482647|NCT02122003|Experimental|sorafenib|Sorafenib 400 mg bid
89482648|NCT03079388|Experimental|Ready-to-use supplementary food + anti-infective bundle|The women randomized to this arm will receive a ready-to-use-supplementary food (RUSF) designed specifically for pregnancy. The RUSF will provide a total of 520 kcal, 18 g protein, and 200% of recommended daily allowance (RDA) for most micronutrients during pregnancy. The supplement is also optimized to provide excellent protein quality and optimal polyunsaturated fatty acid composition. These women will receive 5 anti-infective interventions: 1) insecticide-treated mosquito net, 2) monthly intermittent preventive treatment of malaria during pregnancy (IPTp) 3) azithromycin at the second and third trimester 4) albendazole given in second trimester, and 5) bacterial vaginosis testing and treatment at enrollment and again at weeks 28-34
89482649|NCT03079388|Active Comparator|Corn-soy-blend|The women randomized to this arm will receive the standard of care for Sierra Leone. The treatment provided to women in this group includes 3.5 kg super cereal with 350 g vegetable oil every two weeks. This provides 250 mg portion/day of the super cereal and 25g oil/day for the mother. Women will receive the food for the duration of their pregnancy. These women will receive the current recommendations of the government of Sierra Leone, which includes standard intermittent preventive treatment of malaria during pregnancy (IPTp) of 2 doses of sulfadoxine/ pyrimethamine, iron and folic acid supplement with a goal of 90 pills/pregnancy, an insecticide-treated mosquito net, and albendazole for deworming in the second trimester.
89482650|NCT03286101|Experimental|0.5% Ivermectin Lotion|
89482651|NCT03286101|Placebo Comparator|Vehicle control|
89482652|NCT01368211|Active Comparator|Mirasol first, then Reference|This study arm will receive first a 2-4-day-old Mirasol-treated platelets transfusion and then a reference 2-4-day-old untreated platelets transfusion (Mirasol-Reference sequence).
89482653|NCT01368211|Active Comparator|Reference first, then Mirasol|This study arm will receive first a reference 2-4-day-old untreated platelets transfusion and then a 2-4-day-old Mirasol-treated platelets transfusion (Reference-Mirasol sequence).
89482654|NCT02437084|Other|Individuals without diabetes eligible to receive statin therapy|Eligible participants will receive 40 mg of atorvastatin
89482655|NCT03286023||Stereotactic radiation|Stereotactic radiation for brain metastases
89482656|NCT05009498|Placebo Comparator|Placebo group|Patient will receive a placebo dosing, identical in appearance and at the same intervals as the interventional dose
89482657|NCT05009498|Active Comparator|Vitamin D3 supplementation group|Patient will receive high-dose Vitamin D3 supplementation in capsule form, identical in appearance and at the same intervals as the placebo dose
89482658|NCT02123641|Active Comparator|Heavy resistance training|Heavy resistance training of the lower and upper extremities three times weekly for 52 weeks.
89482659|NCT02123641|Experimental|Moderate intensity training|Home-based moderate intensity training of the lower and upper extremities three times weekly for 52 weeks.
89482660|NCT02123641|Experimental|Control|No training
88821648|NCT03126214|Active Comparator|Enhanced Usual Care Arm|Pharmacist will be refer participants to their physician in regards to OAC therapy for atrial fibrillation. The pharmacist will provide a current medication list to the physician as well as notification of a new diagnosis of atrial fibrillation
88821649|NCT03126019|Experimental|Treatment A: Parsaclisib 20 mg QD for 8 Weeks Followed by 20 mg QW|Participants received parsaclisib 20 mg once daily (QD) for 8 weeks followed by 20 mg once weekly (QW) for up to approximately 52 weeks.
88821650|NCT03126019|Experimental|Treatment B: Parsaclisib 20 mg QD for 8 Weeks Followed by 2.5 mg QD|Participants received parsaclisib 20 mg QD for 8 weeks followed by 2.5 mg QD for up to approximately 52 weeks.
89482661|NCT03079622|Active Comparator|Electric vacuum aspiration|Electric vacuum aspiration will be performed with Synevac® Vacuum Curettage System 10 (Richmond, CA, USA) with a rigid cannula.
89482662|NCT03079622|Active Comparator|Manual vacuum aspiration|Manual vacuum aspiration will be performed using the 60-mL double valve aspirator, manufactured by Ipas (Chapel Hill, NC, USA) with a flexible cannula.
88821651|NCT03112681|Experimental|Saroglitazar magnesium 2 mg|Saroglitazar magnesium 2 mg tablet Once daily for 16 weeks
88821652|NCT03112681|Experimental|Saroglitazar magnesium 4 mg|Saroglitazar magnesium 4 mg tablet Once daily for 16 weeks
88821653|NCT03112681|Placebo Comparator|Placebo|Placebo tablet Once daily for 16 weeks
88821654|NCT03110107|Experimental|Part 1A: Monotherapy (BMS-986218)|
88821655|NCT03110107|Experimental|Part 1B: Combination Therapy (BMS-986218 + Nivolumab)|
88821656|NCT03110107|Experimental|Part 2A: Monotherapy (BMS-986218 OR Ipilimumab)|
88821657|NCT03110107|Experimental|Part 2B: Monotherapy (BMS-986218)|
88821658|NCT03110107|Experimental|Part 2C: Expansion Combination Therapy (BMS-986218 + Nivolumab)|
88821659|NCT03110107|Experimental|Part 2D: Expansion Combination Therapy (BMS-986218 + Nivolumab)|
88821660|NCT03072862||Commercial Nucleus Cochlear Implant Systems|
88821661|NCT03061721|Experimental|Saroglitazar magnesium 1 mg|Saroglitazar magnesium 1 mg tablet orally once daily in the morning before breakfast for 16 weeks.
88821662|NCT03061721|Experimental|Saroglitazar magnesium 2 mg|Saroglitazar magnesium 2 mg tablet orally once daily in the morning before breakfast for 16 weeks.
88821663|NCT03061721|Experimental|Saroglitazar magnesium 4 mg|Saroglitazar magnesium 4 mg tablet orally once daily in the morning before breakfast for 16 weeks.
88821664|NCT03061721|Placebo Comparator|Placebos|Placebo tablet orally once daily in the morning before breakfast for 16 weeks.
88821665|NCT03055221|Experimental|Intravenous Treprostinil|Intravenous treprostinil was supplied as 1 mg/mL.
89203342|NCT00537316|Experimental|IFX/AZA|IFX 5 mg/kg of body weight IV infusions at Weeks 0, 2, and 6 plus AZA 2.5 mg/kg orally every day for 16 weeks. Responders to IFX/AZA at Week 8 were to receive one more IFX infusion at Week 14; non-responders to IFX/AZA were to receive placebo infusions at Weeks 8 and 10 and one additional IFX infusion at Week 14. Part 2: Participants in steroid-free remission at Week 16 of Part 1 were to be randomized to either maintenance (every 8 weeks [q8w]) or intermittent (upon relapse) open-label IFX (last IFX infusion administered at Week 86) plus double-blind oral AZA/placebo treatment as allocated in Part 1 (last dose at the final visit, Week 94). Responders at Week 16 who had not achieved steroid-free remission were to continue to receive IFX infusions every 8 weeks.
89203343|NCT00537316|Experimental|Maintenance IFX/AZA (during Part 2)|Participants randomized to maintenance IFX/AZA in Part 2 of the study were to receive IFX 5 mg/kg of body weight IV infusions every 8 weeks (beginning at Week 22, Week 6 for direct entry) plus AZA 2.5 mg/kg of body weight daily. Four participants were from Part 1 of the study and 1 participant was enrolled directly into Part 2 of the study.
89203344|NCT00537316|Experimental|Maintenance IFX (during Part 2)|Participants randomized to maintenance IFX were to receive IFX 5 mg/kg of body weight IV infusions every 8 weeks (beginning at Week 22, Week 6 for direct entry) in Part 2 of the study. Placebo to AZA therapy was to continue as allocated in Part 1 of the study. All participants were from Part 1 of the study.
89482663|NCT03285945||PET3|Post-therapeutic FDG PET/CT performed after 3 days of steroid treatment
88821666|NCT03043339||Renal transplant recipient|"Participants who are scheduled for a planned renal transplant as the recipient of the kidney.~All participants will complete the following interventions:~Stool Specimen Collection~Anal Swab Sampling~Short Diet Assessment (SDA)~NHANES Dietary Screener Questionnaire (DSQ)"
89482664|NCT03285945||PET10|Post-therapeutic FDG PET/CT performed after 10 days of steroid treatment
89482665|NCT02123719||Patients post liver transplantation|Patients after liver transplantation
89482666|NCT02123719||Control group|Patients with an abdominal incisional hernia without a history of immunosuppresion
89482667|NCT05009654|Experimental|carnitine + leucine|1000 mg L-carnitine with 3000 mg L-leucine per day for 24 weeks
89482668|NCT05009654|Placebo Comparator|leucine|4000 mg L-leucine per day for 24 weeks
89482669|NCT02122159|Experimental|MA09-hRPE Cellular Therapy|MA09-hRPE cells for transplantation will be provided by Ocata Therapeutics as a suspension frozen to the temperature of liquid nitrogen (approximately -196 °C). They will be processed at UCLA under GMPs according to protocol. Following vitrectomy performed under general anesthesia or waking sedation at the surgeon's discretion, hRPE cells will be introduced into a subretinal bleb formed by the injection of balanced salt solution (BSS). Direct viewing will guide the implantation of thawed and washed MA09-hRPE cells, resuspended in BSS, into the created bleb over a period of one minute. To avoid cell reflux, the cannula used to introduce the cells will be held in position for an additional minute. A suspension of either 50,000 MA09-hRPE cells (first cohort), 100,000 MA09-hRPE cells (second cohort), 150,000 MA09-hRPE cells (third cohort) or 200,000 MA09-hRPE cells (fourth cohort) in 150 uL of BSS plus will be implanted over 1 minute in the space created.
89482670|NCT02406586|Experimental|Salsalate|Obese, normotensive, healthy subjects will receive an intravenous (IV) administration of Intralipid 20% for 24 hours, and then one salsalate 750 mg tablet twice daily for two weeks. If the subject has no side effects, the dose will be increased to two salsalate 750 mg tablets twice daily for the remaining four weeks. The subjects will then receive another 24-hour IV administration of Intralipid 20% at the 6-week point.
89482671|NCT02406586|Experimental|Carvedilol|Obese, normotensive, healthy subjects will receive an intravenous (IV) administration of Intralipid 20% for 24 hours, and then one carvedilol 3.125 mg tablet twice daily for two weeks. If the subject has no side effects, the dose will be increased to two carvedilol 3.125 mg tablets twice daily for the remaining four weeks. The subjects will then receive another 24-hour IV administration of Intralipid 20% at the 6-week point.
89482672|NCT02406586|Placebo Comparator|Placebo|Obese, normotensive, healthy subjects will receive an intravenous (IV) administration of Intralipid 20% for 24 hours, and then one placebo tablet twice daily for two weeks. The dose will be increased to two placebo tablets twice daily for the remaining four weeks. The subjects will then receive another 24-hour IV administration of Intralipid 20% at the 6-week point.
89482673|NCT03285867||HCC received TACE|observational study set only one group with HCC received TACE
89020755|NCT00350181|Experimental|Regimen Treatment 2|For subjects 18-50 years old with AML, ALL or CML: (VP-16 +CY+ FBI) Patients aged 18-50 years with AML, ALL or CML: FTBI 1320 cGy delivered in 11 120 cGy fractions over 4 days on days -8 through -5. VP 60 mg / kg on day -4 and CY 60 mg / kg on day -2. Followed by Sirolimus and MMF as prophylaxis
89020756|NCT00350181|Experimental|Regimen Treatment 3|For subjects 51-60 years with MDS, AML or ALL or 18-60 with MDS, secondary AML pr non-CML myeloproliferative disease: (BU+ VP-16 +CY) BU 1 mg/kg every 6 hours X 14 doses on days -9 through -6 with target concentration at steady state of X 800 ng / ml based on first dose pharmacokinetics. VP 60 mg / kg on day -5 and CY 45 mg / kg per day -2 days on day -3 and day -2. Followed by Sirolimus and MMF as prophylaxis
89020757|NCT00345501|Experimental|1|Iloprost
89020758|NCT00345501|Placebo Comparator|2|Placebo
89020759|NCT00317837|Active Comparator|1|Patients treated with a cemented modular hemiarthroplasty, with a unipolar head
89020760|NCT00317837|Active Comparator|2|Patients treated with a modular cemented hemiarthroplasty with a bipolar head.
89020761|NCT00350415|Experimental|1|Asacol 2.4 g/day (400 mg tablet)
89020762|NCT00350415|Active Comparator|2|Asacol 4,8 g/day (800 mg tablet), oral, for 6 weeks
89020763|NCT00318032|Other|Intensive Treatment|Frequent specialised diabetes clinician contact. DESMOND self-management programme
89482674|NCT05012852|Experimental|VagiVitalAC|
89482675|NCT05012852|No Intervention|No treatment|
89482676|NCT04262115|Experimental|AM-EX|Participants in this group will be prescribed morning aerobic exercise.
89482677|NCT04262115|Experimental|PM-EX|Participants in this group will be prescribed evening aerobic exercise.
89482678|NCT05012774|Experimental|Aim 1, Sentence Training: Sentence Feedback|"In Aim 1, which is sentence lipreading training, the intervention compares the provision of three different types of feedback for lipreading.~This arm gives printed whole sentence feedback following an attempt to lipread each sentence.~Participants receive pre- and post-training tests."
89482679|NCT05012774|Experimental|Aim 1, Sentence Training: Word Feedback|"In Aim 1, which is sentence lipreading training, the intervention compares the provision of three different types of feedback for lipreading.~This arm gives printed whole word feedback following an attempt to lipread each sentence. Word feedback is for correct words and words that are perceptually similar but incorrect responses.~Participants receive pre- and post-training tests."
89482680|NCT05012774|Experimental|Aim 1, Sentence Training: Consonant Feedback|"In Aim 1, which is sentence lipreading training, the intervention compares the provision of three different types of feedback for lipreading.~This arm gives printed consonant word feedback following an attempt to lipread each sentence. Word feedback is for correct words, but only the consonants are given as feedback for words that are perceptually similar but incorrect responses.~Participants receive pre- and post-training tests."
89482681|NCT05012774|No Intervention|Aim 1, Sentence Training: No Training Control|Participants receive only the pre- and post-training tests.
89482682|NCT05012774|Experimental|Aim 2, Nonsense Word Training|Participants train to lipread nonsense words that name nonsense pictures. Participants receive pre- and post-training tests.
89020764|NCT00318071|Experimental|Treatment|Treatment arm patients had at least one Merci Retriever deployed
89020765|NCT00318110|Experimental|MUD treatment|NST using MUD for metastatic renal cell carcinoma
89020766|NCT04708236|Experimental|ORTD-1 Low dose|Arm 1: ORTD-1
89482683|NCT05012774|Experimental|Aim 3, Audiovisual Nonsense Word Training|"Participants train to recognize audiovisual spoken nonsense words that name nonsense pictures and are presented in speech-shaped noise. The paradigm is the same as in Aim 2.~Participants receive pre- and post-training tests."
89482684|NCT05012774|Experimental|Aim 3, Audiovisual Sentence Training|"Participants receive the same training paradigm from Aim 1 with the most effective feedback type from Aim 1. But the sentences are audiovisual and in speech-shaped noise.~Participants receive pre- and post-training tests."
89482685|NCT04282551|Experimental|oligosaccharide group 1|
89482686|NCT04282551|Experimental|oligosaccharide group 2|
89482687|NCT04282551|Placebo Comparator|placebo group|
89482688|NCT05012696|Experimental|Sequence A: Non-invasive ventilation - High flow nasal cannula|Once participants are extubated they will receive one hour of Non-invasive ventilation followed by one hour of high-flow nasal cannula.
89482689|NCT05012696|Experimental|Sequence B: High flow nasal cannula - Non-invasive ventilation|Once participants are extubated they will receive one hour of high flow nasal cannula followed by one hour of Non-invasive ventilation
89020767|NCT04708236|Experimental|ORTD-1 Mid Dose|Arm 2: ORTD-1
89482690|NCT04918342|Active Comparator|Individual Exercise Instruction|The participant will receive individual exercise instruction.
89482691|NCT04918342|Experimental|Group Exercise Instruction|The participant will receive the instruction in a group of up to 9 other participants.
89482692|NCT03280875|Experimental|healthy volunteers|
89020768|NCT04708236|Experimental|ORTD-1 High Dose|Arm 3 : ORTD-1
89020769|NCT04708236|Placebo Comparator|Vehicle Control|Arm 4: Vehicle control
89020770|NCT00318188|Experimental|Intervention group|The patients in this group will do a personalized standardized rehabilitation program on the quality of life.
89020771|NCT00318188|No Intervention|Control group|Habitual care
89020772|NCT00350454|Active Comparator|A|Drug eluting stent using biodegradable polymer BP stent
89020773|NCT00350454|Active Comparator|B|polymer-free drug eluting stent PF stent
89020774|NCT00350454|Active Comparator|C|permanent polymer using stents PP stent
89020775|NCT00318227|Active Comparator|Liberal Red cell transfusion arm|Transfusion if Hgb <100g/L
89020776|NCT00318227|Active Comparator|Restrictive Red Cell transfusion|Transfusion if Hgb <70g/L
89020777|NCT00318266||patients with suerficial transitional cell carcinoma|
89020778|NCT02959749|Active Comparator|Docetaxel, bevacizumab|docetaxel, 75mg/m2, intravenous infusion on day 1. VEGF monoclonal antibody bevacizumab, 7.5 mg/m2, intravenous infusion on day 1, every 21days a cycle，until disease progression, intolerable toxicities, or patient death.
89020779|NCT02959749|Experimental|EGFR TKI|osimertinib 80mg oral once daily，until disease progression, intolerable toxicities, or patient death.
89020780|NCT00318383|Experimental|1|200 mcg NicVAX in each of 4 doses
89020781|NCT00318383|Experimental|2|200 mcg NicVAX in each of 5 doses
89206294|NCT04093271|Experimental|Randomized to consume placebo, Rest-ZZZ, then comparator|Each study product will be consumed as 2 capsules daily for 7 days. Randomized to consume Placebo in Study Period 1, Dietary Supplement, Rest-ZZZ in Study Period 2, and Comparator (Diphenhydramine HCl) in Study Period 3.
89482693|NCT02122237|Experimental|Cathodal Cefaly tDCS|Cathodal Cefaly tDCS is delivered over the visual cortex at 2 mA of intensity, for 20 minutes, everyday for 2 months, in 14 patients. The anode is placed over the left DLPFC.
89482694|NCT04420858|Other|Control|The control arm will receive standard education about cell-free DNA screening that would typically be presented during a prenatal visit.
89482695|NCT04420858|Experimental|Experimental|The experimental arm will receive additional education about federal legislation that protects the privacy of genetic information (Genetic Information Nondiscrimination Act, GINA).
89482696|NCT03285633|Other|Cognitive Behavioral Mutli-Symptom management(CBT)|Learn to manage distress, fatigue, and/or pain via Cognitive Behavioral Multi-Symptom Management(CBT). Four sessions will be conducted each session is approximately one hour.
89482697|NCT02122315|Experimental|Physical therapy plus dry needling|Best-evidence physical therapy intervention in addition to a single session of TrP-DN targeted to active TrPs in the neck-shoulder muscles.
89482698|NCT02122315|Active Comparator|Physical therapy|Best-evidence physical therapy intervention
89482699|NCT03091166|Active Comparator|Dexmedetomidine|
89482700|NCT03091166|No Intervention|No Dexmedetomidine|
89482701|NCT02460562|Active Comparator|PMMA resin|A denture base will be made with PMMA resin as a standard material.
89482702|NCT02460562|Experimental|PMMA resin & S-PRG filler|A denture base will be made from PMMA resin & S-PRG filler for subject to wear.
89482703|NCT02122393|Active Comparator|Sertraline|
89482704|NCT02122393|Active Comparator|Cognitive Behavioural Therapy|
89482705|NCT02122393|Active Comparator|Combined Therapy|
89482706|NCT03080870|Experimental|Intervention|"Art groups are held once a week, each with the duration of 60 minutes. They begin with a 45 minute art intervention and conclude with a 15 minute discussion. The art groups include music, dance and visual arts, which is psychologically, socially, and physically activating. Music has the main emphasis in art intervention. The preferences of the subjects are taken into consideration in art intervention. Art intervention is conducted by trained and experienced art pedagogues.~Art intervention aims to revive previously learned art-related skills, to learn and enhance new skills, and to improve and intensify physiological, emotional, social, motoric, and cognitive abilities."
89482707|NCT03080870|No Intervention|Control|Baseline and follow-up measurements.
89482708|NCT03821883|Experimental|Aspirin group|Study patients assigned to Aspirin group will receive enteric coated aspirin (100 mg/day).
88952135|NCT05875064|Experimental|polyvinyl crown - experimental group|The teeth allocated in the experimental group will have the restorations carried out through monochromatic composite resin with chameleon effect in single insertion through polyvinyl crown. For this, 37% phosphoric acid (Condac37, FGM) will be applied for 15 seconds, and then, after washing and relative drying of the surface, application of universal adhesive (Universal Beautibond Adhesive, Shofu) with the aid of microbrush on the entire tooth surface, photoactivation of the adhesive and adaptation of the crown matrix in acetate filled with resin in the tooth. Photoactivation will be done for 20 seconds per dental face, and the acetate matrix is then removed. The tooth will receive finishing and polishing through rotating instruments and abrasive discs (Supersnap, Shofu).
89482709|NCT03821883|Placebo Comparator|Control group|Study patients assigned to control group will receive placebo.
89482710|NCT02113501||HGT1a|HGT1a bladder cancer patients will undergo BCG induction and maintenance followed by conventional follow-up (cystoscopy and cytology at 3months and then every 6months).
89482711|NCT02113501||HGT1b|HGT1b bladder cancer patients will undergo a 2nd TUR after BCG induction. If negative, continue with maintenance BCG followed by conventional follow-up (cystoscopy and cytology every 6months).
89482712|NCT03080636|Experimental|Men|11 men randomly underwent three experimental sessions in early morning prior to their work routine.
89482713|NCT03080636|Experimental|Women|9 women randomly underwent three experimental sessions in early morning prior to their work routine.
89482714|NCT03285243|Sham Comparator|Blue light - non monochromatic|
89482715|NCT03285243|Experimental|Monochromatic blue light|
89482716|NCT03080480|Experimental|Pioglitazone|Treatment for chronic granulomatous disease patients with severe infection.
89482717|NCT02126761|Active Comparator|Group 1|aTIV
89482718|NCT02126761|Experimental|Group 2|aTIV + 1X MF59
88952136|NCT05875051|Experimental|Reduced-exertion high intensity training group|The REHIT part will consist of maximum cycling sprints of all-out exercise at 100% of the HRmax, increasing for up to 10 seconds, 15 seconds on week two and 20 seconds on week three.
88952137|NCT05875051|Active Comparator|Short moderate intensity training group|The SMIT part of the session will consist of 6 minutes of moderate intensity exercise at 60-70% HRmax.
89482719|NCT02126761|Experimental|Group 3|aTIV + TIV
89482720|NCT02126761|Experimental|Group 4|aTIV + aTIV
89206295|NCT00825240||Cancer Survivorship Study|Survey of colorectal cancer patients within one year from treatment end.
89482721|NCT02126761|Active Comparator|Group 5|aTIV (Left deltoid) Saline (Right deltoid)
89482722|NCT02126761|Experimental|Group 6|aTIV+2X MF59 (Left deltoid) Saline (Right deltoid)
89482723|NCT02126761|Experimental|Group 7|aTIV (Left deltoid) aTIV (Right deltoid)
89482724|NCT03605277|Experimental|Normal renal function|healthy volunteers with normal renal function
89482725|NCT03605277|Experimental|Severe renal impairment|subjects with severe renal impairment
89482726|NCT03605277|Experimental|Moderate renal impairment|subject with moderate renal impairment
89482727|NCT03605277|Experimental|Mild renal impairment|subjects with mild renal impairment
89482728|NCT05008952|Active Comparator|Control group|The control group for this study will consist of individuals with normal BMI (18.5 - 24.9 kg/m2), body fat percent < 25% (male) or < 35% (female), and up to 1 other risk factor among the following: blood pressure > 130/85 mmHg, fasting glucose >100 mg/dL, fasting triglycerides >150 mg/dL, and HDL < 40 (male) or < 50 (female).
89482729|NCT05008952|Experimental|Normal-weight obesity|Individuals with normal-weight obesity will be defined as having normal BMI (18.5 - 24.9 kg/m2), body fat percent > 25% (male) or > 35% (female).
89203345|NCT00537316|Experimental|Intermittent IFX/AZA (during Part 2)|Participants randomized to intermittent IFX/AZA were to receive IFX 5 mg/kg of body weight IV infusions only upon relapse of disease (initiated at Weeks 0, 2, and 6 of individual treatment cycle and continued every 8 weeks until remission was regained) plus AZA 2.5 mg/kg of body weight daily in Part 2 of the study. Three participants were from Part 1 of the study and 1 participant was enrolled directly into Part 2 of the study.
88952138|NCT05875038|Experimental|Intelligent Video Monitoring + Tele-alarm|
89482730|NCT05008952|Active Comparator|Metabolic Syndrome|Metabolic syndrome will be defined using the international Diabetes Federation criteria of an obese BMI ( > 30 kg/m2) and 2 or more of the following risk factors: blood pressure > 130/85 mmHg, fasting glucose >100 mg/dL, fasting triglycerides >150 mg/dL, and HDL < 40 (male) or < 50 (female).
89482731|NCT02788357|Experimental|Atomoxetine with motor training|40 mg atomoxetine paired with task-oriented therapy for 10 consecutive weekdays
89482732|NCT02788357|Placebo Comparator|Placebo with motor training|Placebo capsules paired with task-oriented therapy for 10 consecutive weekdays
88952139|NCT05875038|Active Comparator|Tele-alarm only|
88952140|NCT05875012|Active Comparator|Action observation arm|
89482733|NCT05009186|Other|Covid-19 group|We will measure the PSA value during and after Covid-19 infection in the same group via paired simple t test
89482734|NCT02458599|Experimental|Test product|One ready-to-drink beverage of 500 milliliter (mL) volume, containing 20 gram (g) protein will be administered orally, twice daily for four days.
89482735|NCT02458599|Active Comparator|Reference product 1|One ready-to-drink beverage of 500 mL volume, containing 20 g carbohydrate will be administered orally, twice daily for four days.
89482736|NCT02458599|Placebo Comparator|Reference product 2|One ready-to-drink beverage of 500 mL volume, containing 0 g carbohydrate will be administered orally, twice daily for four days.
89482737|NCT03552133|Experimental|Smart CO2|Effects of rebreathe device over two sleep nights on sleep apnea, hypoxemia, sleep state, and blood pressure.
89482738|NCT03552133|No Intervention|No intervention|Effects of control night, i.e. no intervention on sleep apnea, hypoxemia, sleep state, and blood pressure.
89482739|NCT03091088|Active Comparator|Control|walking at an intense pace
89482740|NCT03091088|Experimental|Experimental|osteoporosis specific-oriented training
89482741|NCT03280641||Dabigatran Group|Patiets with atrial fibrillation received dabigatran (110mg, bid).
89482742|NCT03280641||Warfarin Group|Patiets with atrial fibrillation received warfarin (110mg, bid).The target international normalized ratio (INR):1.6-3.0
89482743|NCT02123875|Other|Control arm|Routine hospital based physiotherapy
89482744|NCT02123875|Other|Physiotherapy intervention arm|Caregiver delivered, home based physiotherapy
89482745|NCT05008640||Study group (all subjects)|All subjects belonged to the same study group, regardless of symptoms, disease diagnosis or state. Furthermore, there was no stratification of the population by sex, age, race or disease severity.
89482746|NCT03285165|Active Comparator|DEX I|Trauma Patients without TBI received 0.2-0.7 mcg/kg/h dexmedetomedine infusion.
89482747|NCT03285165|Active Comparator|DEX II|Trauma Patients with TBI received 0.2-0.7 mcg/kg/h dexmedetomedine infusion.
89482748|NCT03285165|Active Comparator|Propofol I|Trauma Patients without TBI received 10-70 mcg/kg/h propofol infusion.
89482749|NCT03285165|Active Comparator|Propofol II|Trauma Patients with TBI received 10-70 mcg/kg/h propofol infusion.
89482750|NCT02123953|Experimental|TAK-438 10 mg|TAK-438 10 mg, tablets, orally, once, daily, Days 1 to 7.
89482751|NCT02123953|Experimental|TAK-438 15 mg|TAK-438 15 mg, tablets, orally, once, daily, Days 1 to 7.
89482752|NCT02123953|Experimental|TAK-438 20 mg|TAK-438 20 mg, tablets, orally, once, daily, Days 1 to 7.
89482753|NCT02123953|Experimental|TAK-438 30 mg|TAK-438 30 mg, tablets, orally, once, daily, Days 1 to 7.
89482754|NCT02123953|Experimental|TAK-438 40 mg|TAK-438 40 mg, tablets, orally, once, daily, Days 1 to 7.
89482755|NCT02123953|Placebo Comparator|Placebo|TAK-438 placebo-matching tablets, orally, once, daily, Days 1 to 7.
89482756|NCT03285087|Experimental|DEX 0.2 μg/kg/h|Patients will receive dexmedetomidine for sedation with initial maintenance dose rate of 0.2 μg/kg/h. The dose will be increased in 0.1 μg/kg/h increments to achieve target Richmond Agitation Sedation Scale (RASS) levels of -2 to zero and with a maximum dose of 1.4 μg/kg/h for 24 hours.
89482757|NCT05008406||Preclinical medical students|
89482758|NCT05008406||Clinical medical students|
89482759|NCT02122627|Experimental|Vitamin D|colecalciferol 16.800 IU per week
89482760|NCT02122627|Placebo Comparator|Placebo|placebo
88952141|NCT05875012|Active Comparator|traditional physical training|
89482761|NCT03516591|Experimental|Dose Escalation (3+3 design)|A 3 + 3 design, with dose-escalation of AMV564, up to a Maximum Tolerated Dose (MTD) level. AMV564 will be tested as a 14-Day CIV regimen (14-Day Continuous Intravenous Infusion Regimen).
89482762|NCT03516591|Experimental|Dose Expansion|Following determination of the MTD of AMV564, the study will expand at the MTD or a dose level lower than the MTD to obtain initial estimates of response rates and additional information on safety.
89482763|NCT03091244||The individuals taking XLGB Capsule|The overall individuals taking XLGB Capsule with recommended dosage and achieving the inclusion criteria.
89482764|NCT02458443|Sham Comparator|IHG 5% Un-medicated|Participants with high blood pressure (greater than 120/80) who are not medicated for blood pressure control will conduct isometric handgrip (IHG) exercise at 5% of their maximum voluntary contraction (MVC). Isometric resistance training will be conducted three times a week for 12 weeks, with participants conducting 4 x 2min IHG exercises at each session.
89482765|NCT02458443|Sham Comparator|IHG 5% BB|Participants with high blood pressure (greater than 120/80) who are currently taking beta blockers for blood pressure control will conduct isometric handgrip exercise at 5% of their maximum voluntary contraction (MVC). Isometric resistance training will be conducted three times a week for 12 weeks, with participants conducting 4 x 2min IHG exercises at each session.
89482766|NCT02458443|Experimental|IHG 30% Un-medicated|Participants with high blood pressure (greater than 120/80) who are not medicated for blood pressure control will conduct isometric handgrip exercise at 30% of their maximum voluntary contraction (MVC). Isometric resistance training will be conducted three times a week for 12 weeks, with participants conducting 4 x 2min IHG exercises at each session.
89203346|NCT00537316|Experimental|Intermittent IFX (during Part 2)|Participants randomized to intermittent IFX were to receive IFX 5 mg/kg of body weight IV infusions only upon relapse of disease (initiated at Weeks 0, 2, and 6 of individual treatment cycle and continued every 8 weeks until remission was regained). Placebo to AZA therapy was to continue as allocated in Part 1 of the study. One participant was from Part 1 of the study and 1 participant was enrolled directly into Part 2 of the study.
89482767|NCT02458443|Experimental|IHG 30% BB|Participants with high blood pressure (greater than 120/80) who are currently taking beta blockers for blood pressure control will conduct isometric handgrip exercise at 30% of their maximum voluntary contraction (MVC). Isometric resistance training will be conducted three times a week for 12 weeks, with participants conducting 4 x 2min IHG exercises at each session.
89482768|NCT05008016||Procalcitonine analysed|The invistagatore had analysed the Procalcitonine of patient that survived and the non Survived frome COVID infection in Intensive care departement
89482769|NCT02122705||VPIA remifentanil|VPIA remifentanil labour analgesia
89482770|NCT03285009|Other|Training intervention|See information elsewhere
89482771|NCT05019248||vaccination prior to first cladribine exposition|
89482772|NCT05019248||vaccination shortly after first cladribine exposition|
89482773|NCT05019248||vaccination prior to second cladribine exposition|
89482774|NCT05019248||vaccination following completion of cladribine treatment|
89482775|NCT05019248||vaccination in patients with RRMS not subjected to cladribine|
89482776|NCT05011916|No Intervention|Control group|Patients in the control group received 0.1% fluorometholone eye drops (0.1% fluorometholone + 0.05% tacrolimus eye drops for patients after corneal transplantation). The patients applied 0.1% fluorometholone eye drops 4 times daily for 10 weeks. Patients were instructed to continue with their usual ophthalmic medication regimens, such as topical antibacterial and antiviral drugs.
89482777|NCT05011916|Experimental|Low-concentration group|Patients in the low-concentration group applied 4mg/ml KDR2-2 suspension eye drops 4 times daily for 6 weeks. The rest of the medication regimen is the same as the control group.
89482778|NCT05011916|Experimental|Medium-concentration group|Patients in the medium-concentration group applied 4mg/ml KDR2-2 suspension eye drops 4 times daily for 6 weeks. The rest of the medication regimen is the same as the control group.
89482779|NCT05011916|Experimental|High-concentration group|Patients in the High-concentration group applied 4mg/ml KDR2-2 suspension eye drops 4 times daily for 6 weeks. The rest of the medication regimen is the same as the control group.
89482780|NCT03466203|Experimental|LLF580|LLF580 every 28 days * 3
89482781|NCT03466203|Placebo Comparator|Placebo|Placebo to LLF580 every 28 days * 3
89482782|NCT05011604|Other|Implant Failure|Early peri-implantitis and failed osseointegration.
89482783|NCT03411837||Dupilumab|Patients with moderated-to-severe atopic dermatitis who are receiving dupilumab as a standard of care
89482784|NCT03079310|Experimental|Spinal cord stimulation|Boston Scientific SCS system
89482785|NCT03384225|Experimental|CBA group|"CBA as HSCT conditioning:~cladribine 5mg/m2 day -6 to day -2 busulfan(iv) 3.2mg/kg day-6 to day -3 cytarabine 2g/m2 day-6 to day -2"
89482786|NCT03384225|Active Comparator|FBA group|"FBA as HSCT conditioning:~fludarabine 30mg/m2 day -6 to day -2 busulfan(iv) 3.2mg/kg day-6 to day -3 cytarabine 2g/m2 day-6 to day -2"
89482787|NCT03091010|Experimental|Fecal Microbiota Transplantation|
89482788|NCT03091010|Active Comparator|Steroid|
89482789|NCT03284697|Active Comparator|DPC with Ca(OH)2|Direct pulp capping with Ca(OH)2.
89482790|NCT03284697|Active Comparator|DPC with MTA|Direct pulp capping with MTA
89482791|NCT03272607|No Intervention|Control|All participants in the control arm will receive medication reconciliation at admission and discharge, and identical follow up, but no prioritized deprescribing list will be generated.
89482792|NCT03272607|Experimental|Intervention|"Participants in the intervention arm will be electronically screened using an electronic software MedSafer which will generate output of PIMs that will be brought to the attention of the CTU team via the unit pharmacist as deprescribing opportunities. (Note that in the case of multiple recommendations, they will be limited and prioritized so as to avoid overwhelming the treating team.) Based on their own expert medical judgement, in collaboration with the patient/caregiver and other relevant clinicians, a decision will be made to deprescribe if appropriate by the patient's in-hospital doctors."
89482793|NCT05008094||Genetic testing cohort (Phase 1)|Group of Croatian Parkinson's disease patients who will be tested with whole-exome sequencing in target Parkinson's genes.
89482794|NCT05008094||Drug-naive Parkinson's disease patients (Phase 2)|Drug-naive Parkinson's disease patients that will be prospectively followed in the two-year period for each patient.
89482795|NCT05008094||Control group (Phase 2)|Control patients who do not have neurodegenerative diseases. The control group will perform the same measurement as the drug-naive Parkinson's disease patients.
89203347|NCT00803868|Experimental|1|Varenicline
89203348|NCT00803868|Placebo Comparator|2|Placebo
89482796|NCT02459535|Active Comparator|Glucose only|oral ingestion of 54 g Glucose in 300 ml water at t=0 in fasted state; blood samples over 120 mins
89482797|NCT02459535|Active Comparator|Glucose + Saccharin|oral ingestion of 54 g Glucose + 0,112 g Saccharin in 300 ml water at t=0 in fasted state; blood samples over 120 mins
89482798|NCT02459535|Active Comparator|Saccharin only|oral ingestion of 0,112 g Saccharin in 300 ml water at t=0 in fasted state; blood samples over 120 mins
89482799|NCT02459535|Active Comparator|Glucose + Aspartame|oral ingestion of 54 g Glucose 0,197 g Aspartame in 300 ml water at t=0 in fasted state; blood samples over 120 mins
89482800|NCT02459535|Active Comparator|Aspartame only|oral ingestion of 0,197 g Aspartame in 300 ml water at t=0 in fasted state; blood samples over 120 mins
89482801|NCT02459535|Active Comparator|Glucose + Sucralose|oral ingestion of 54 g Glucose + 0,088 g Sucralose in 300 ml water at t=0 in fasted state; blood samples over 120 mins
89482802|NCT02459535|Active Comparator|Sucralose only|oral ingestion of 0,088 g Sucralose in 300 ml water at t=0 in fasted state; blood samples over 120 mins
89203349|NCT03827395|Experimental|HEV-239|0.5 mL of HEV-239 administered intramuscularly into the deltoid muscle as a single injection on Days 1, 29, and 180. N=20
88952142|NCT05874934|Experimental|Intervention|Intrahepatic plastic biliary stent with retrieval string
88952143|NCT05874882|Placebo Comparator|control|patients with periodontitis will receive scaling and rootplaning and a placebo mouthwash twice daily for 4 weeks. saliva will be collected at the 1st visit and after one month then biochemical analysis for inflammatory biomarker will be done. periodontal parameters also will be evaluated at the 1st visit and after 1 month
89203350|NCT03827395|Placebo Comparator|Placebo|0.5 mL of HEV-239 placebo administered intramuscularly into the deltoid muscle as a single injection on Days 1, 29, and 180. N=5
89203351|NCT04504708|Experimental|ZX-101A Dose Level 1|Starting dose (SD) of ZX-101A administered orally once daily in a 28-day cycle
89482803|NCT05019326|Experimental|Andrographis extract|Andrographis extract, equivalent to andrographolide 20 mg per capsule, for a total of 180 mg of andrographolide per day, dosing into 3 capsules taking before meal for 3 times per day, for 5 days.
89482804|NCT05019326|Experimental|Boesenbergia extract|Boesenbergia extract, equivalent to pinostrobin 30 mg per capsule, for a total of 180 mg of pinostrobin per day, dosing into 2 capsules taking after meal for 3 times per day for 5 days.
89482805|NCT05019326|Other|Standard supportive treatment|Standard supportive treatment, as recommended by guideline from Ministry of Public Health, Thailand, there will be no antivirus given in this asymptomatic group
89203352|NCT04504708|Experimental|ZX-101A Dose Level 2|2-times the SD of ZX-101A administered orally once daily in a 28-day cycle
89203353|NCT04504708|Experimental|ZX-101A Dose Level 3|3-times the SD of ZX-101A administered orally once daily in a 28-day cycle
89203354|NCT04504708|Experimental|ZX-101A Dose Level 4|4-times the SD of ZX-101A administered orally once daily in a 28-day cycle
89203355|NCT04504708|Experimental|ZX-101A Dose Level 5|5-times the SD of ZX-101A administered orally once daily in a 28-day cycle
89203356|NCT00655980|Experimental|Treatment|Vitamin B12 and folic acid
89203357|NCT00655980|Placebo Comparator|Comparator|Nitrous oxide and placebo
89203358|NCT00655980|Other|Standard of care|standard of care
89203359|NCT00679172|Experimental|M01ZH09 Vaccine Candidate Cohort 1|Dose of 5.0 x 10^9 colony forming units (CFU) S. typhi (Ty2 aroC-ssaV-) ZH9 or placebo, administered as a single, oral dose
89203360|NCT00679172|Experimental|M01ZH09 Vaccine Candidate Cohort 2|Dose of 7.5 x 10^9 CFU S. typhi (Ty2 aroC-ssaV-) ZH9 or placebo, administered as a single, oral dose
89203361|NCT00679172|Experimental|M01ZH09 Vaccine Candidate Cohort 3|Dose of 1.1 x 10^10 CFU S. typhi (Ty2 aroC-ssaV-) ZH9 or placebo, administered as a single, oral dose
89203362|NCT00679172|Experimental|M01ZH09 Vaccine Candidate Cohort 4|Dose of of 1.7 x 10^10 CFU S. typhi (Ty2 aroC-ssaV-) ZH9 or placebo, administered as a single, oral dose
89203363|NCT01063621|Experimental|KW-6500|
89203364|NCT02533141|Experimental|Intervention group|10 healthy subjects receiving at first simvastatin for 4 weeks, then crossover. Measurements will be done with the Dynamic Vessel Analyzer (DVA) and Laser Doppler Velocimetry (LDV).
89203365|NCT02533141|Placebo Comparator|Placebo group|10 healthy subjects receiving at first placebo for 4 weeks, then crossover. Measurements will be done with the Dynamic Vessel Analyzer (DVA) and Laser Doppler Velocimetry (LDV).
89203366|NCT00809796|Experimental|single arm|Use of pentamidine in second and/or third line metastatic colon cancer
89203367|NCT05589454|Experimental|High-dose atorvastatin|atorvastatin calcium tablets 80 mg, quaque nocte, continue to the end of the study
89203368|NCT05589454|Active Comparator|Low-dose atorvastatin|atorvastatin calcium tablets 20 mg, quaque nocte, continue to the end of the study
89203369|NCT01063699|Experimental|Lap Kasai|Patients in this arm had their necessary Kasai procedure in a laparoscopic way.
89203370|NCT00803946|Active Comparator|Test Product|
89203371|NCT00803946|Active Comparator|Reference Product|
89203372|NCT00676130|Active Comparator|Standard therapy|cephalexin plus placebo
89203373|NCT00676130|Experimental|Standard plus anti-CA-MRSA|cephalexin plus trimethoprim-sulfamethoxazole
89203374|NCT04874818||lymphopenia|lymphocyte counts (<1.0 x10e9/L)
89203375|NCT04874818||normal lymphocyte numbers|lymphocyte counts ((1.0 - 3.5 x10e9/L))
89203376|NCT02553408|Other|Neo meter|This is a single arm purely qualitative (interview only) study with no comparator. All participants will use the FreeStyle Precision Neo-Meter for at least 3 months for self-monitoring of their blood glucose.
89203377|NCT03742882|Experimental|Administration of CC-90001|Single oral dose of 200 mg of CC-90001
89203378|NCT00804024||ClearWay™ RX|
89203379|NCT00809874|Active Comparator|Casein|
89482806|NCT05008250|Experimental|study group|Metoprolol tartrate (25 mg twice per day, orally) plus TMYXP (40 pills twice per day, orally). the treatment duration is 8 weeks.
89203380|NCT00809874|Active Comparator|Whey Isolate|
89203381|NCT00809874|Active Comparator|Whey Hydrolysate|
89203382|NCT00809874|Active Comparator|Alphalact-Albumin|
89203383|NCT00809952||Recombinat FSH|
89203384|NCT00676052|Experimental|Arm 1|GSK233705 12.5mcg
89203385|NCT00676052|Experimental|Arm 2|GSK233705 25mcg
89203386|NCT00676052|Experimental|Arm 3|GSK233705 50mcg
89203387|NCT00676052|Experimental|Arm 4|GSK233705 100mcg
89203388|NCT00676052|Experimental|Arm 5|GSK233705 200mcg
89203389|NCT00676052|Placebo Comparator|Arm 6|Placebo
89203390|NCT05436002|Active Comparator|With Cross-linked Hyaluronic Acid|Tunnel Technique in Conjunction With Cross-linked Hyaluronic Acid and Subepithelial Connective Tissue Graft.
89203391|NCT05436002|Placebo Comparator|Whitout Cross-linked Hyaluronic Acid|Tunnel Technique in Conjunction With Subepithelial Connective Tissue Graft.
89203392|NCT02560376|Experimental|68Ga-NOTA-exendin-4 PET/CT|The patients were injected with 55.5-111 MBq of 68Ga-NOTA-exendin-4 PET/CT in one dose intravenously and underwent PET/CT scan 30-60 min later.
89203393|NCT00921752||Patients at high cardiovascular risk|
89203394|NCT05435690|Experimental|Computer-assisted arthroplasty|
89203395|NCT05435690|No Intervention|Conventional arthroplasty|
89203396|NCT00535288|Placebo Comparator|Placebo|Participants receive encapsulated tablets, orally, once daily (QD) for up to 12 weeks.
89203397|NCT00535288|Experimental|Esmirtazapine 2.25 mg|Participants receive esmirtazapine, 2.25 mg, encapsulated tablets, orally QD for up to 12 weeks.
89203398|NCT00535288|Experimental|Esmirtazapine 4.5 mg|Participants receive esmirtazapine, 4.5 mg, encapsulated tablets, orally QD for up to 12 weeks.
88952144|NCT05874882|Active Comparator|chlorohexidine mouthwash|patients with periodontitis will receive scaling and rootplaning and a chlorhexidine mouthwash twice daily for 4 weeks. saliva will be collected at the 1st visit and after one month then biochemical analysis for inflammatory biomarker will be done. periodontal parameters also will be evaluated at the 1st visit and after 1 month
89482807|NCT05008250|Placebo Comparator|control group|Metoprolol tartrate (25 mg twice per day, orally) plus placebo (40 simulated pills twice per day, orally). The treatment is 8 weeks.
89482808|NCT05019014||Neurodegenerative disease|Participants with a diagnosis of Probable Alzheimer's Disease, prodromal Alzheimer's Disease, Frontotemporal Dementia, Mild Cognitive Impairment, Dementia with Lewy Bodies, mild and moderate/severe TBI, and familial or sporadic ALS per El Escorial Criteria or individuals with known gene mutations associated with ALS.
89482809|NCT05019014||Age-matched controls|Healthy participants with no diagnosis.
89482810|NCT02459301|Experimental|IPH2201|"Part 1: 1, 4 or 10mg/kg, IV, 1 hour duration on Day 1 every 2 weeks.~Part 2: Patients will receive single agent IPH2201 as above with the actual dose dependent on the outcome of Part 1"
89482811|NCT05018936|Experimental|treatment group|Hetrombopag would be started with 5mg/day. The dosage would be increased by 2.5mg/day every 2 weeks if the platelet count remains less than 20×10e9/L and reduced if the platelet count reaches over than 150×10e9/L. The maximum dosage is 15mg/day.
89482812|NCT03079076|Active Comparator|thoracolumbar interfascial plane block|Bilateral ultrasound guided thoracolumbar interfascial plane block with 20 ml %0,25 bupivacaine
89482813|NCT03079076|Placebo Comparator|sham block|Bilateral ultrasound guided sham block with 2 ml saline subcutaneously
89482814|NCT03272061|Experimental|Aerobic-based exercise program|
89482815|NCT03272061|No Intervention|Control program|Maintenance of habitual physical activity levels
89482816|NCT03079934||Absorb-BVS|Bioresorbable vascular scaffold implantation
89482817|NCT03271827|Experimental|Apnoeic oxygenation group|Standard airway management + 3 L/min of oxygen by nasal cannula
89482818|NCT03271827|No Intervention|Standard care group|Standard airway management
89482819|NCT03079856|Experimental|Brief Intervention|ED-based computer-guided intervention for substance use and HIV risk reduction utilizing Motivational Interviewing
89482820|NCT03079856|No Intervention|Enhanced Usual Care|Substance use and sexual health services information within a brochure provided to participants
89482821|NCT03271749|No Intervention|Conventional|The participants of this arm will receive the convencional pre operative, anesthesia and postoperative care for lung resections for treatment of lung neoplasms
89482822|NCT03271749|Experimental|PROSM interventional|The participants of this arm will receive the PROSM protocol pre operative, anesthesia and postoperative care for lung resections for treatment of lung neoplasms
89482823|NCT03079778|Active Comparator|TACE alone|Transarterial chemoembolization (TACE)
89482824|NCT03079778|Experimental|TACE plus RT|Combination of transarterial chemoembolization and radiation (TACERT)
89482825|NCT03079154|Experimental|Teacher-led MBCT course|Eight-session mindfulness-based cognitive therapy course, including an initial orientation session, led by a qualified mindfulness teacher working with the Sussex Mindfulness Centre, a part of the NHS Sussex Partnership Mental Health Trust.
89482826|NCT03079154|Active Comparator|Self-guided MBCT course|Mindfulness-based cognitive therapy course, after an initial information session, which is self-guided using the audiobook Mindfulness: A practical guide to finding peace in a frantic world by Mark Williams and Danny Penman (2011). It consists of eight substantive chapters that map on to the eight-session MBCT course taught by teachers to groups of students. Students will be asked to work through one chapter a week, thus matching the pace of the teacher-led intervention.
89482827|NCT03079154|No Intervention|Wait list control|Students in the wait list (control) arm do not receive any intervention for the same length of time as the experimental and active comparator arms of the intervention are taking place. Students are invited to complete the self-guided MBCT course after the end of the research project.
89482828|NCT03284619|Experimental|treatment arm|Single arm study, 5 patient with bone metastasis will be enrolled for palliative treatment with the Magnetic resonance imager linear accelerator (MR-Linac).
89482829|NCT05019092|Experimental|Screening|Ultrasound (US) examination of lower limbs 48 hours after admission and again after 3-5 days (5-7 days after the admission)
89482830|NCT05019092|No Intervention|Control|Ultrasound (US) examination according to the clinical evaluation of risk factors for deep vein thrombosis (DVT) and life-threatening bleeding, based on the standard of care (SOC) of the enrolling institution.
89482831|NCT02458677|Experimental|PRX003|
89482832|NCT02458677|Placebo Comparator|Placebo|
89482833|NCT03078998|Experimental|Juvenile idiopathic Arthritis|
89482834|NCT03078998|Experimental|Obstetric Brachial Plexus Palsy|
89482835|NCT03078998|Experimental|Cerebral Palsy|
89482836|NCT03079232|Experimental|OCTAV Patient|The patients who will have a biopsy of skin suspected to be a melanoma, basal cell carcinoma or squamous cell carcinoma will have a skin imaging with a new Microscopy Optical Coherence (OCTAV)
89482837|NCT03079232|Experimental|OCTAV Control group|Control group (patients without skin cancer) will have a skin imaging with a new Microscopy Optical Coherence (OCTAV)
89482838|NCT03078920|Other|11 unilateral adult cochlear implant users|Speech Reception Threshold (SRT) measured with an adaptive test
89482839|NCT03280407|Active Comparator|A, capecitabine|Radiochemotherapy with 50.4 Gy in 28 fractions concomitantly with chemotherapy
89482840|NCT03280407|Experimental|B, FOLFOX or CAPOX|Neoadjuvant chemotherapy with CAPOX (oxaliplatin/capecitabine) or FOLFOX regimen (oxaliplatin/leucovorin/5FU), according to institutional practice
89482841|NCT02457910|Experimental|Taselisib 2 mg|Patients receive taselisib PO QD on days 1-28 and enzalutamide PO QD on days 9-28 of course 1 and days 1-28 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients experiencing unacceptable toxicity due to enzalutamide may continue to receive taselisib.
89482842|NCT02457910|Active Comparator|Enzalutamide|Patients receive enzalutamide PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Upon disease progression, patients may crossover to receive Enzalutamide + Taselisib
89482843|NCT02457910|Experimental|Taselisib 4 mg|Patients receive taselisib PO QD on days 1-28 and enzalutamide PO QD on days 9-28 of course 1 and days 1-28 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients experiencing unacceptable toxicity due to enzalutamide may continue to receive taselisib.
89482844|NCT02457910|Experimental|Taselisib 6 mg|Patients receive taselisib PO QD on days 1-28 and enzalutamide PO QD on days 9-28 of course 1 and days 1-28 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients experiencing unacceptable toxicity due to enzalutamide may continue to receive taselisib.
89482845|NCT02457910|Experimental|Taselisib 8 mg|Patients receive taselisib PO QD on days 1-28 and enzalutamide PO QD on days 9-28 of course 1 and days 1-28 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients experiencing unacceptable toxicity due to enzalutamide may continue to receive taselisib.
89482846|NCT02457910|Experimental|Enzalutamide + Taselisib|Patients receive enzalutamide PO QD starting on day 1 of cycle 1, and will receive Taselisib PO QD starting on day 1 of cycle 2. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89482847|NCT02457910|Experimental|Cross-Over|Upon progression of disease, patients on the enzalutamide only arm will be allowed to crossover to enzalutamide + taselisib (must begin no later than 21 days after the clinic visit at which disease progression is determined) Enzalutamide and Taselisib will be taken PO QD
89482848|NCT02458521|Experimental|Transcranial Magnetic Stimulation|TMS sessions will consist of both 10Hz left pre-frontal stimulation for 3,500 pulses followed by 1Hz right pre-frontal stimulation for 1,500 pulses per session, for a total stimulation time of approximately one hour per session.
89482849|NCT02458521|Sham Comparator|Sham Transcranial Magnetic Stimulation|Sham TMS treatments will be conducted five times a week for 5 consecutive weeks, followed by a tapering of three sessions during week 6 and two sessions during week 7.
89482850|NCT03078842|Active Comparator|Zinc-20|Zinc tablets, 20 mg per day
89482851|NCT03078842|Experimental|Zinc-10|Zinc tablets, 10 mg per day
88952145|NCT05874882|Experimental|resveratrol mouthwash|patients with periodontitis will receive scaling and rootplaning and a resveratrol mouthwash twice daily for 4 weeks. saliva will be collected at the 1st visit and after one month then biochemical analysis for inflammatory biomarker will be done. periodontal parameters also will be evaluated at the 1st visit and after 1 month
88952146|NCT05874830|Active Comparator|FMT through colonoscopy|Patient gets FMT in ceacum and plasebo in duodenum.
88952147|NCT05874830|Active Comparator|FMT through duodenogastroscopy|Patient gets plasebo in ceacum and FMT in duodenum.
88952148|NCT05874830|Placebo Comparator|Plasebo|Patient gets plasebo in colonoscopy and in gastroscopy.
88952149|NCT05874778|Experimental|Radiation Group|"Paients will be treated with 6-8 cycles (21 days per cycle) of standard R-CHOP chemotherapy.~After completing the standard immunochemotherapy, subjects will be randomly divided into the radiotherapy group or the non-radiotherapy group, and the curative effects will be evaluated every three months after the end of the treatment or after a patient's leaving the group, so as to obtain the relevant data including those for figuring up 2-year PFS and survival of subjects and any treatment-related side effects as well."
89482852|NCT03078842|Experimental|Zinc-05|Zinc tablets, 5 mg per day
89482853|NCT03090854||Alzheimer disease patients|
89482854|NCT03269877||Liver cirrhosis and hypersplenism|Patients proven to have Liver Cirrhosis and Hypersplenism based on clinical examination, Laboratory findings, and abdominal ultrasound examinaton
88952150|NCT05874778|Active Comparator|Non-radiation Group|Paients will be treated with 6-8 cycles (21 days per cycle) of standard R-CHOP chemotherapy, but after this treatment patients will not be further given radiation therapy.
88952151|NCT05874752||nonsignificant coronary artery stenosis group|Exclusion criteria: ≥70% proximal luminal stenosis in at least one major coronary vessel based on coronary angiography
88952152|NCT05874752||significant coronary artery stenosis group|Defined as ≥70% proximal luminal stenosis in at least one major coronary vessel based on coronary angiography
89203399|NCT00535288|Experimental|Esmirtazapine 9 mg|Participants receive esmirtazapine, 9 mg, encapsulated tablets, orally QD for up to 12 weeks.
89482855|NCT05007860||No active therapy|Age ≥18 years and CLL/SLL (WHO criteria). We excluded patients with known HIV or primary immune deficiency disorder, known active progression of CLL/SLL, active therapy, treating physician intent to initiate CLL/SLL therapy within ≤2 months, prior cytotoxic chemotherapy within ≤1 year, CD20 monoclonal Ab within ≤6 months, or any prior bendamustine or fludarabine. We excluded patients who received PCV13 within ≤2 years, or within 2-5 years with nonprotective titers for ≥50% of PCV13-specific S. pneumonia IgG titers.
89482856|NCT05007860||BTK inhibitor therapy (continued)|Age ≥18 years, CLL/SLL (WHO criteria), and active therapy with a BTK inhibitor which is continued through vaccination. We excluded patients with known HIV or primary immune deficiency disorder, known active progression of CLL/SLL, prior cytotoxic chemotherapy within ≤1 year, CD20 monoclonal Ab within ≤6 months, or any prior bendamustine or fludarabine. We excluded patients who received PCV13 within ≤2 years, or within 2-5 years with nonprotective titers for ≥50% of PCV13-specific S. pneumonia IgG titers.
89482857|NCT05007860||BTK inhibitor therapy (interrupted)|Age ≥18 years, CLL/SLL (WHO criteria), and active therapy with a BTK inhibitor which is interrupted at time of vaccination. We excluded patients with known HIV or primary immune deficiency disorder, known active progression of CLL/SLL, prior cytotoxic chemotherapy within ≤1 year, CD20 monoclonal Ab within ≤6 months, or any prior bendamustine or fludarabine. We excluded patients who received PCV13 within ≤2 years, or within 2-5 years with nonprotective titers for ≥50% of PCV13-specific S. pneumonia IgG titers.
89482858|NCT02405962|Placebo Comparator|Control group|Parents of children with asthma will receive one session of asthma educational talk as the usual care, plus three weekly sessions of telephone calls to assess the child's asthma symptoms
89482859|NCT02405962|Experimental|ACT group|Parents of children with asthma will receive four sessions of group-based ACT intervention integrated with asthma education (its content will be the same as that of the Control Group).
89482860|NCT03270033|Active Comparator|Dexamethasone|4 milligrams dexamethasone administered once intravenously with a 30 millilitres 0.5% bupivacaine interscalene brachial plexus block
89482861|NCT03270033|Active Comparator|Dexmedetomidine|50 micrograms dexmedetomidine administered once intravenously with a 30 millilitres 0.5% bupivacaine interscalene brachial plexus block
89482862|NCT03270033|Active Comparator|Dexamethasone and Dexmedetomidine|4 milligrams dexamethasone and 50 micrograms dexmedetomidine administered once intravenously with a 30 millilitres 0.5% bupivacaine interscalene brachial plexus block
89482863|NCT05007626||zero to six Exo|
89482864|NCT03280329|No Intervention|Control|the patients who belong to this group will not be assigned to a regulated music therapy treatment, thus they will listen to the background sounds (alerts, voices) right in the Intensive Care environment; radio use will be allowed according to medical/ nursing judgements
89482865|NCT03280329|Active Comparator|Personalised treatment|A music therapy advice will be performed with each patient (if possible from the neurological point of view) or their caregivers to assess their musical preferences and a list of songs will be generated which will be reproduced for 2 hours per day from admission to discharge with the use of earphones.
89482866|NCT03280329|Active Comparator|Generalized treatment|"Music will be broadcasted in each patient room after the creation of a 'weekly playlist' with the following considerations:~Daily sound reproduction from 7 am to 11 pm, with 10 minutes break about every 50 minutes of music;~Spread through the environment with specifically designated speakers, at a controlled volume (30-50 dB);~Choice of playlist of music both classic and modern, with very easy listening, selected according to the daily hours to restore circadian rhythm and following predictable activities of care provided to patients (hygienic care, retail food, administration other therapies, physiotherapy, visit by relatives, …);~Mixing tracks so that there is continuity and fluidity of listening"
89482867|NCT04959110|Experimental|Acute Liver Failure|Acute liver failure critically ill patients receiving CRRT
89482868|NCT04959110|Experimental|Acute on top Chronic Liver Failure|Acute on top chronic liver failure critically ill patients receiving CRRT
89482869|NCT03280173|Experimental|61 mgA tafamidis free acid soft gelatin capsule fed|fasted
89482870|NCT03280173|Experimental|61 mgA tafamidis free acid soft gelatin capsule fasted|fed
89482871|NCT03280173|Experimental|4 × 20 mg tafamidis meglumine soft gelatin capsules fed|fed
89482872|NCT03280173|Experimental|4 × 20 mg tafamidis meglumine soft gelatin capsules fasted|fasted
89482873|NCT02436304|Experimental|EXE844 for 7 Days + Tubes|EXE844 Sterile Otic Suspension, 0.3%, ototopical, 4 drops, twice daily (BID) in each ear for 7 days after Tympanostomy Tube Insertion
89482874|NCT02436304|Experimental|EXE844 for 3 Days + Tubes|EXE844 Sterile Otic Suspension, 0.3%, ototopical, 4 drops BID in each ear for 3 days after Tympanostomy Tube Insertion
89482875|NCT02436304|Active Comparator|Tubes Only|Bilateral myringotomy and tympanostomy tube insertion
88952153|NCT05874700|Experimental|Sivelestat sodium group|sivelestat sodium
88952154|NCT05874700|Placebo Comparator|Placebo control group|Placebo control
89482876|NCT03076736|Active Comparator|Resource pack|Aphasia resource pack
89482877|NCT03076736|Experimental|Singing group + resource pack|Singing group + Aphasia resource pack
89482878|NCT03284073|Experimental|Uterus Transplantation|Patients undergo transplantation of the uterus from a live donor
89482879|NCT03280095|Experimental|Treatment 1|One capsule of test product (co-codamol 15mg/500mg capsule) containing 15mg codeine phosphate hemihydrate and 500mg paracetamol.
89482880|NCT03280095|Experimental|Treatment 2|Two capsules of test product (co-codamol 15mg/500mg capsule), each containing 15mg codeine phosphate hemihydrate and 500mg paracetamol (i.e. a total dose of 30mg codeine phosphate hemihydrate and 1000mg paracetamol).
89482881|NCT03280095|Active Comparator|Treatment 3|One tablet of reference product (co-codamol 30mg/500mg tablet) containing 30mg codeine phosphate hemihydrate and 500mg paracetamol.
89482882|NCT04463030|Active Comparator|Liposomal vitamin C, 1 gram|Participants will consume 1 gram on study day
89482883|NCT04463030|Active Comparator|Liposomal vitamin C, 2 grams|Participants will consume 2 grams on study day
89482884|NCT04463030|Active Comparator|Liposomal vitamin C, 5 grams|Participants will consume 5 grams on study day
89482885|NCT04463030|Placebo Comparator|Placebo|Participants will consume placebo on study day
89482886|NCT03279627||Hypoglycemia|This group will be those who experience a BG < 70 mg/dl in the 24-48 hour time period preceding hospital discharge. Study procedures are identical for each group. All participants in this group will be asked to complete the Diabetes Management Questionnaire.
89482887|NCT03279627||Hyperglycemia|This group will be those who experience a BG > 250 mg/dl in the 24-48 hour time period preceding hospital discharge. Study procedures are identical for each group. All participants in this group will be asked to complete the Diabetes Management Questionnaire.
89482888|NCT03279627||Glycemic control|This group will be those who maintain BG of 70 to 250 mg /dl in the 24-48 hour time period preceding hospital discharge. Study procedures are identical for each group, but study outcomes including comprehension of discharge instructions and 1 and 3 month readmissions will be analyzed according to group category.All participants in this group will be asked to complete the Diabetes Management Questionnaire.
89020782|NCT00318383|Experimental|3|400 mcg NicVAX in each of 4 doses
89482889|NCT04462640||regurgitation|45 infants aged 0 to 5 months suffering from regurgitation
89482890|NCT04462640||colic|45 infants aged 0 to 5 months suffering from colic
89482891|NCT03269721||Never Smoker|Neuropsychological Assessment, Spirometry, Arterial Blood Gas, Diffusion Capacity of the Lung for Carbon Monoxide, 6 Minute Walk test, Systemic Vascular Measures, Blood Biomarkers, Symptom Questionnaire Measures, Brain MRI
89482892|NCT03269721||Smoker/Past smoker-No Airflow Limitation|Neuropsychological Assessment, Spirometry, Arterial Blood Gas, Diffusion Capacity of the Lung for Carbon Monoxide, 6 Minute Walk test, Systemic Vascular Measures, Blood Biomarkers, Symptom Questionnaire Measures, Brain MRI
89482893|NCT03269721||Smoker/Past smoker-W/Airflow Limitation|Neuropsychological Assessment, Spirometry, Arterial Blood Gas, Diffusion Capacity of the Lung for Carbon Monoxide, 6 Minute Walk test, Systemic Vascular Measures, Blood Biomarkers, Symptom Questionnaire Measures, Brain MRI
89482894|NCT05010356|Experimental|Healthy control subjects|Healthy control subjects undergoing a hyperinsulinemic euglycemic clamp
89482895|NCT05010356|Experimental|Breast cancer survivors|Breast cancer survivors undergoing a hyperinsulinemic euglycemic clamp
89482896|NCT03269955|Experimental|application of TachoSil®|Fibrinogen/thrombin-coated collagen patch (TachoSil®) and fibrin glue are applied to the pancreas anastomosis site in pancreatoduodenectomy
89482897|NCT03269955|No Intervention|control|Only fibrin glue alone is applied to the pancreas anastomosis site in pancreaticoduodenectomy.
89482898|NCT05010278||Latarjet|Patients followed up 6 months after a Latarjet procedure
89482899|NCT03269643|Experimental|Investigational Group|The RHEA device and Patient Monitor Device are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
89020783|NCT00318383|Experimental|4|400 mcg NicVAX in each of 5 doses
89020784|NCT00318383|Placebo Comparator|5|Placebo in 4 or 5 doses
89020785|NCT00318383|Experimental|6|200 mcg NicVAX formulation 2 in each of 5 doses
89482900|NCT03269643|Active Comparator|Reference Group|The reference device and Patient Monitor Device are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
89482901|NCT03076424||1|Obese patients (BMI greater than or equal to 30 kg/m2) with Type 2 Diabetes Mellitus.
89482902|NCT03076424||2|Obese patients (BMI greater than or equal to 30 kg/m2) without Type 2 Diabetes Mellitus.
89482903|NCT03076424||3|Normal weight lean controls without Type 2 Diabetes Mellitus.
89482904|NCT03283995||cardiogenic shock without SCA|
89482905|NCT03283995||cardiogenic shock with SCA|
89482906|NCT03283995||SCA,|
89482907|NCT03283995||acute left heart failure with severe alteration of LVEF|
89482908|NCT03269799|Active Comparator|test group|vitamin C 500 mg oral capsule
89482909|NCT03269799|Placebo Comparator|control group|placebo
89482910|NCT05006846||Cohort 1|Primary care physicians (PCPs) and their patients used the intervention (OARS) for 4 weeks. They completed 2 interviews to obtain their feedback on the acceptability and feasibility of using OARS in a primary care setting. Data for this cohort was collected between February 18, 2020, to May 25, 2020.
89482911|NCT05006846||Cohort 2|Primary care physicians (PCPs) and their patients used the intervention (OARS) for 4 weeks. They completed 2 interviews to obtain their feedback on the acceptability and feasibility of using OARS in a primary care setting. Data for this cohort was collected between July 17, 2020, to August 31, 2020.
89482912|NCT03269487||Healthcare professionals in partner sites|NHS employee or student nurse involved in the delivery of care to patients on partner wards in which the PERFECTED ERP is being implemented.
89482913|NCT03283839|Other|Temporomandibular disorder|
89482914|NCT03283839|Other|Without temporomandibular disorder|
89482915|NCT05010044|Experimental|Participants received MBCT once a week for 8 weeks|Participants received MBCT once a week for 8 weeks. At the same time, the drug therapy for psoriasis was used .
89482916|NCT05010044|Active Comparator|Active comparator|Only the drug therapy for psoriasis was used .
89482917|NCT03269565|Experimental|Arm 1|BCD-100 1 mg/kg Q2W;
89482918|NCT03269565|Experimental|Arm 2|BCD-100 3 mg/kg Q3W.
89482919|NCT05000918|Experimental|OPH group|Participants should eat a pack of OPH once a day for 28 days. The dosage of the OPH is 11.74 g/day.
89482920|NCT02402218|Active Comparator|Usual Care|Participants receive standard of care for Hepatitis C in the clinic.
88952155|NCT05874687||1: hypotension +,|hypotension +: hypotension defined as a decreased SAB greater than 20% of baseline, a decreased MAP below 90 mmHg, or a MAP of 65 mmHg
88952156|NCT05874687||2:hypotension -|hypotension -:none hypotension (hypotension defined as a decreased SAB greater than 20% of baseline, a decreased MAP below 90 mmHg, or a MAP of 65 mmHg)
88952157|NCT05874674|Active Comparator|nafamostat|Patients received dialysis through nafamostat
88952158|NCT05874674|No Intervention|Cnoxane|Patients received dialysis through cnoxan
89482921|NCT02402218|Experimental|Usual care plus peer-mentors|In addition to receiving standard of care for HCV in the clinic, this is an investigational strategy in which participants assigned to this group will be asked to interact with a peer-mentor who is someone who has been cured of their HCV infection.
89482922|NCT02402218|Experimental|Usual care plus incentives|In addition to receiving standard of care for HCV in the clinic, this is an investigational strategy in which participants assigned to this group will be given incentives after completing certain goals during the course of the study.
89482923|NCT05006768|Experimental|T test|Test drug (Barcimiant) 1 tablet contains 4 mg Baricitinib
89482924|NCT05006768|Active Comparator|B reference (first dose)|Reference drug (Olumiant) 1 tablet contains 4 mg Baricitinib
89482925|NCT05006768|Active Comparator|B reference (second dose)|Reference drug (Olumiant) 1 tablet contains 4 mg Baricitinib
89482926|NCT03269331||ARCC EBP Model|CTEP EBP Immersion Course
89482927|NCT03269331||Control Group|No CTEP EBP Immersion Course
89482928|NCT04993508|Experimental|Arm A|Men with PI-RADS 4/5 or PI-RADS 3 in conjunction with PSAD ≥ 0.15 that are randomized into arm A will undergo only targeted MRI/US fusion-guided biopsies. Men with PI-RADS 3 and PSAD > 0.15 with negative biopsy results will receive a follow-up MRI annually and PSA every 6 months for 3 years. In case of upgrade to PI-RADS 4/5, men will be re-biopsied. Men with PI-RADS 4/5 without cancer diagnosis or with clinically insignificant cancer in the subsequent biopsy will be offered an additional MRI inbore biopsy. If MRI inbore biopsy is negative or with clinically insignificant cancer, men will be followed-up with MRI annually and PSA every 6 months for 3 years. In the case of persistent PI-RADS 4/5, men will be re-biopsied.
89482929|NCT04993508|Active Comparator|Arm B|Men with PI-RADS 4/5 or PI-RADS 3 in conjunction with PSAD ≥ 0.15 that are randomized into arm B will undergo targeted MRI/US fusion-guided biopsies and systematic biopsies (standard of care). Men with PI-RADS 3 and PSAD > 0.15 with negative biopsy results will receive a follow-up MRI annually and PSA every 6 months for 3 years. In case of upgrade to PI-RADS 4/5, men will be re-biopsied. Men with PI-RADS 4/5 without cancer diagnosis or with clinically insignificant cancer in the subsequent biopsy will be offered an additional MRI inbore biopsy. If MRI inbore biopsy is negative or with clinically insignificant cancer, men will be followed-up with MRI annually and PSA every 6 months for 3 years. In the case of persistent PI-RADS 4/5, men will be re-biopsied.
89482930|NCT04993508|Other|Arm C|Men with PI-RADS 3 in conjunction with PSAD < 0.15 will not be biopsied, but followed-up with MRI annually and PSA every 6 months for 3 years.
89482931|NCT04993508|Other|Arm D|Men with PI-RADS 1 or 2 will not be biopsied, but followed-up with PSA every 6 months for 3 years. A control MRI will be performed after 3 years. At any time, a follow-up can be performed in case of clinical suspicion of PCa or a relevant PSA increase (> 1.0 ng/ml/a).
89482932|NCT02457520|Experimental|Single treatment arm|ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks.
89482933|NCT04993820|Experimental|Physical Activity (PA)|Combination of aerobic exercise and muscle strengthening exercise.
89482934|NCT04993820|Active Comparator|Education Control (CON)|No exercise group.
89482935|NCT05000684|Experimental|JS004 200 mg in combination with toripalimab 240 mg was administered every 3 weeks as planned|
89482936|NCT04993118|Experimental|Integrated Neuromuscular inhibition technique|Experimental group received Integrated neuromuscular inhibition technique. At first ischemic compression was given using a pincer grip over the active trigger point till the tissue barrier was felt .The process was repeated till the tension reduced for 90 seconds.Ischemic compression was followed by the application of strain counterstrain. M If pain was reproduced the pressure was maintained over the active trigger point as the position of ease was identiﬁed. Once the position of ease was identiﬁed, it was held for 90 seconds and repeated for three to ﬁve repetitions. Muscle energy technique was applied as last part of iINIT.Each isometric contraction was held for 7-10 seconds and was followed by further contralateral side bending, ﬂexion, and ipsilateral rotation to maintain the soft tissue stretch. Each stretch was held for 30 seconds and was repeated three to ﬁve times per treatment session
89482937|NCT04993118|Active Comparator|Ischemic Compression,Hotpack,TENS|Control group received conventional physical therapy. It included HOT Packs ( 20 minutes) , TENS (10 minutes) ,Ischemic compression .Using a pincer grasp, we identified the trigger point. Once the trigger point was identiﬁed we applied ischemic compression by placing the thumb and index ﬁnger over the active TrP. Slow, increasing levels of pressure was applied until the tissue resistance barrier was identiﬁed. Pressure was maintained until a release of the tissue barrier was felt. At that time, pressure was again applied until a new barrier was felt. This process was repeated until tension/tenderness is unable to be identiﬁed
89482938|NCT03269175|Other|Experimental arm 15 years ago|This long term study does not imply current study medication. It looks at the status 15 years after the clinicial trial (BENEFIT)
88952159|NCT05874661|Active Comparator|Internal Focus of Attention Group|"Participants will be given instructions that make them think about their body's movements.~Participants assigned to this condition first will complete the external focus condition second in the cross over."
88952160|NCT05874661|Experimental|Extneral Focus of Attention Group|"Participants will be given instructions that make them think about an outside target or outcome.~Participants assigned to this condition first will complete the internal focus condition second in the cross over."
88952161|NCT05874648||Cancer arm|
88952162|NCT05874648||Non-cancer arm|
88952163|NCT05874609|Experimental|VR group|In the VR group, the participants spent 30 minutes with the VR spine simulator after receiving the didactic teaching session.
88952164|NCT05874609|Active Comparator|Control group|In the control group, the participants received a 30-min traditional didactic teaching session of spine ultrasonography.
88952165|NCT05874583|Active Comparator|Intravenous Group|patients receiving 2 doses of 1 g of tranexamic acid in in intra venous route 3 hours apart
89482939|NCT03269175|Other|Placebo arm, offered treatment at MS diagnosis or at Month 24|This long term study does not imply current study medication. It looks at the status 15 years after the clinicial trial (BENEFIT)
89482940|NCT05006690|Experimental|Telerehabilitation Training Group|"In the telerehabilitation group, an individualized rehabilitation program according to the principles of spinal stabilization exercises will be applied via video conference, 3 days a week, 1 hour, online in real-time, accompanied by a physiotherapist, for 8 weeks.~In the first session, informative training about the disease (pathophysiology of spondyloarthritis, its course, physical structures it covers, etc.), pain management training (information about the relationship between pain, muscle spasm, stress, depression, methods that can be used for coping with pain, etc.), exercise. The importance of exercise training (trunk stabilization, anatomy) and aims will be given within the scope of patient education."
89482941|NCT05006690|Experimental|Face-to-Face Training Group|"In the face-to-face training group, an individualized rehabilitation program according to the principles of spinal stabilization exercises will be applied in the clinic under the supervision of a physiotherapist for 1 hour, 3 days a week, for 8 weeks.~In the first session, informative training about the disease (pathophysiology of spondyloarthritis, its course, physical structures it covers, etc.), pain management training (information about the relationship between pain, muscle spasm, stress, depression, methods that can be used for coping with pain, etc.), exercise. The importance of exercise training (trunk stabilization, anatomy) and aims will be given within the scope of patient education."
89482942|NCT05006690|Experimental|Home-Based Training Group|"In the home exercise group, patients will be asked to perform individualized spinal stabilization exercises at home, 3 days a week, for 8 weeks.~In the first session, informative training about the disease (pathophysiology of spondyloarthritis, its course, physical structures it covers, etc.), pain management training (information about the relationship between pain, muscle spasm, stress, depression, methods that can be used for coping with pain, etc.), exercise. The importance of exercise training (trunk stabilization, anatomy) and aims will be given within the scope of patient education."
89482943|NCT05006222|Active Comparator|ERT group|The participants are enrolled in this group whose get enzyme replacement therapy
89482944|NCT05006222|No Intervention|non-ERT group|The participants are enrolled in this group whose not get enzyme replacement therapy
89482945|NCT03268707|Other|Conventional follow up|Conventional follow up at physician practice
89482946|NCT03268707|Experimental|Telemetric smartphone application|Structured follow up with a telemetric smartphone application
89482947|NCT03078530|Placebo Comparator|Placebo|Placebo (not an active drug/ Inactive component) is given to this group
89482948|NCT03078530|Experimental|Visbiome|Visbiome (probiotic mixture) is given to this group.
89482949|NCT03078530|Experimental|VSL #3|VSL #3 (probiotic mixture) is given to this group
89482950|NCT02457585|Experimental|experimental group|"anti Tumor necrosis factor treatment group : treatment with remicade 5mg/kg as scheduled (0, 2, 6, 14, 22, 30, 38, 46, 54weeks).~evaluation of response at 30weeks by PET CT, acute phase reactants, symptom~No placebo group"
89482951|NCT03078764|Experimental|Patient Arm using mHealth|Patients with uncontrolled type 2 diabetes
89482952|NCT03078764|Experimental|Community nurses|Nurses who receive mHealth report about patients in the patients' arm.
89482953|NCT02457507|Experimental|Vitamin B12|Vitamin B12, 1mg, daily, 27 months
89482954|NCT02457507|Placebo Comparator|Placebo|Placebo comparator
89482955|NCT03265197|Experimental|Intratympanic injection of drugs;|intervention by Intratympanic injection of drugs in two studied groups; group A, injection of combined 2 drugs( lidocaine and dexamethasone) and group B, injection of one drug (dexamethasone only).
89482956|NCT03265197|Active Comparator|Data management of Intratympanic drugs|intervention by Manage data of two study group as blind statistical between group A, injection of combined 2 drugs( lidocaine and dexamethasone) and group B, injection of one drug (dexamethasone only).
89482957|NCT03078374|Other|Reduced Anticoagulation|Reduced anticoagulation
89482958|NCT03269019||HIT-group|The patients with heparin-induced thrombocytopenia.
89482959|NCT03269019||HITTs-group|The patients with heparin-induced thrombocytopenia with thrombosis.
89482960|NCT03269019||Control group|The patients without heparin-induced thrombocytopenia and heparin-induced thrombocytopenia with thrombosis.
89482961|NCT05005598||pediatric population|pediatric population of CHU of Nancy, France.
89482962|NCT02459223|Active Comparator|Test Group|Treated with nutritional biscuits and khichadi. Nutritional biscuits providing 2.5 to 3 gm Protein and 90-100kcal/kg body Weight/day, as well as local food Khichadi (Rice and hulled split green gram cooked together with spices) for the three months period.
89482963|NCT02459223|Active Comparator|Control Group|Treated with only local food Khichadi (Rice and hulled split green gram cooked together with spices) for the three months period.
89482964|NCT03078686|Active Comparator|Control ARM 1|Control: 1) HD-PRP + Matristem Matrix (ACell) (Current Standard of Care); 2) Platelet Rich Plasma Concentrate)
89482965|NCT03078686|Experimental|Emulsification tSVF + PRP ARM 2|HD-PRP + Emulsified AD-tSVF; Intervention: Platelet Rich Plasma Concentrate
89482966|NCT03078686|Experimental|Emulsification tSVF + PRP + cSVF ARM 3|tSVF; PRP; cSVF cell enriched biocellular therapeutic mix
89482967|NCT03078686|Experimental|cSVF in Normal Saline IV ARM 4|cSVF + Normal Saline IV (500 cc) Infusion
89482968|NCT03264729|Experimental|Isometric exercise|
89482969|NCT03264729|Active Comparator|Isotonic exercise|
89482970|NCT03264729|Active Comparator|Walking|
89482971|NCT03276819|Experimental|Cohort A|"Samples collection and Tobacco and alcohol status follow-up for patient with OPML:~Follow-up of the lesions (pictures, biopsies, brushes), malignant transformation oversight, smoking and alcohol status follow-up (questionnaires), blood and saliva samples"
88821667|NCT03043339||Renal transplant donor|"Participants who are scheduled for a planned renal transplant as the donor of the kidney.~All participants will complete the following interventions:~Stool Specimen Collection~Anal Swab Sampling~Short Diet Assessment (SDA)~NHANES Dietary Screener Questionnaire (DSQ)"
88821668|NCT03026101|Experimental|Migraine Intervention|Subjects who will be administered 200 micrograms of nitroglycerin once into branches of their external carotid artery to determine the role of dilation of this artery to cause migraine-like pain
89482972|NCT03276819|Experimental|Cohort B|"Samples collection; Psychological and Sociological evaluation; Intensive and sustained smoking cessation program; Tobacco and alcohol status follow-up for patient with resectable HNSCC requiring postoperative radiotherapy or chemoradiation and which are either current smokers motivated to quit or reformed smokers within 3 months before the diagnosis of a resectable HNSCC.~Randomization 1:1, arm 1 = minimal tobacco cessation intervention, arm 2 = intensive and sustained smoking cessation program.~Smoking and alcohol status follow-up, adhesion to the smoking cessation program, tumoral follow-up, second malignant lesion, tumoral collection, blood biomarkers research"
89482973|NCT03276819|Experimental|Cohort C|Samples collection and Tobacco and alcohol status follow-up for patients with resectable HNSCC wich are not eligible to cohort B Smoking and alcohol status follow-up (questionnaires), tumoral follow-up, second malignant lesion and OPML lesion appearance oversight, tumoral collection, blood biomarkers research
89482974|NCT03276663|Other|Formula fed group|Formula feeding regimen
89482975|NCT03276663|No Intervention|Human milk-fed group|
89482976|NCT02788279|Experimental|Atezolizumab|Participants will receive atezolizumab monotherapy 1200 milligrams (mg) intravenous (IV) on Day 1 in a 21-day cycle until disease progression according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1, unacceptable toxicity, death, participant's or physician decision to withdraw, or pregnancy, whichever occurs first.
89482977|NCT02788279|Experimental|Cobimetinib + Atezolizumab|Participants will receive cobimetinib 60 mg orally on Days 1 to 21 plus atezolizumab 840 mg IV on Day 1 and Day 15 in a 28-day cycle until disease progression according to RECIST Version 1.1, unacceptable toxicity, death, participant's or physician decision to withdraw, or pregnancy, whichever occurs first.
89482978|NCT02788279|Active Comparator|Regorafenib|Participants will receive regorafenib 160 mg orally on Days 1 to 21 in a 28-day cycle until disease progression according to RECIST Version 1.1, unacceptable toxicity, death, participant's or physician decision to withdraw, or pregnancy, whichever occurs first.
89482979|NCT03268785|No Intervention|Control|Previous admitted patients who were given conventional thyroidectomy combined with central neck lymph node dissection, without intra-operative nodes identification were enrolled into control group.
89482980|NCT03268785|Experimental|Experimental group|Newly admitted patients,from august 2016 to august 2018, who were given thyroidectomy combined with central neck lymph node dissection, with intra-operative identification of suspicious lymph nodes or parathyroid glands were regarded as experimental group.Intraoperative identification method includes Diff-quik staining and PTH test assay. 200 participants were planed for enrollment.
89482981|NCT03268863|Experimental|Virtual Reality|Google Cardboard Virtual Reality headset running an interactive game
89482982|NCT03268863|Sham Comparator|Control|Powered down Google Cardboard Virtual Reality headset
89482983|NCT03078608|Experimental|Intervention arm|Participants in the intervention arm will receive access to a mobile app-based/online mindfulness meditation program and asked to practice meditation daily for 8 weeks.
89482984|NCT03078608|Active Comparator|Active control arm|Participants in this arm will receive access to a mobile app-based/online progressive muscle relaxation (PMR) program and asked to practice PMR daily for 8 weeks.
89482985|NCT03078608|Other|Wait list control arm|Participants in the wait list control arm will also receive access to a mobile app-based/online mindfulness meditation program and asked to practice meditation daily for 8 weeks, but they will not receive access to the program until after the intervention group completes the intervention (8 weeks later).
89482986|NCT03264651|Experimental|oral enobosarm and anastrozole|9 mg of oral enbosarm and 1 mg of anastrozole daily
89482987|NCT03073226|Experimental|Barrett's surveillance Olympus Spectrum|Barrett's surveillance with Olympus Spectrum.
89482988|NCT03073226|Experimental|Barrett's Surveillance Olympus Elite|Barrett's surveillance with Olympus ELITE.
89482989|NCT03073226|Experimental|Polyp Surveillance Olympus Spectrum|Colonic polyp surveillance/screening with Olympus Spectrum.
89482990|NCT03073226|Experimental|Polyp Surveillancewith Olympus ELITE.|Colonic polyp surveillance/screening with Olympus ELITE.
89482991|NCT03268317||Patients with chronic hepatitis C treated by DAAs|All subjects will be given the same treatment regimen which includes Sofosbuvir 400 mg orally/24 hours (pre-breakfast) and Daclatasvir 60 mg orally/24 hours after lunch with or without ribavirin for a total period of 12 weeks.
89482992|NCT03275727|Experimental|A - iACT-BC experimental group|
89482993|NCT03275727|Other|B - Waiting list control group|
89482994|NCT05000606|Experimental|A home visit program|A home visit program including five visits over three months were performed.
89482995|NCT05000606|Other|Control|No other intervention was applied to the control group other than the standard education given in the outpatient clinic
89482996|NCT03264885|No Intervention|Usual Care|The usual stand of care (UC) after community eye screening was to provide a GP referral letter and advice to attend a tertiary eye care facility most accessible to them
88952166|NCT05874583|Experimental|Combined Group|receiving the first 1g of tranexamic acid Intra venously and the second topical dose was 1,5g after reduction of the fascia.
89482997|NCT03264885|Other|Incentive Care|In addition to the UC, those assigned to the ICS also received social and financial support to incentivise and improve compliance. All ICS participants were assisted with scheduling their tertiary care appointments, given telephone reminders, provided once-off transportation allowance and subsidy for their first tertiary eye-care consultation - while participants with mobility issues were assisted by volunteers.
89482998|NCT03264963|Active Comparator|Control|
89482999|NCT03264963|Experimental|Intervention|
89483000|NCT03078062|Active Comparator|Dexamethasone|During the performance of spinal anesthesia using isobaric 0.5% bupivacaine 12 mg, an intravenous infusion of dexamethasone 8 mg (2 ml) will be initiated. The study drug will be administered over 5 -10 minutes diluted in a 500 ml bag of Normal Saline for a total volume of 502 ml. The study drug will be prepared by an independent assistant.
89483001|NCT03078062|Placebo Comparator|Normal Saline|During the performance of spinal anesthesia using isobaric 0.5% bupivacaine 12 mg, an intravenous infusion of 502 ml of Normal Saline will be initiated. The infusion will be administered over 5 -10 minutes. The study drug will be prepared by an independent assistant.
89483002|NCT03264807|Active Comparator|D2 lymphadenectomy|Subtotal gastrectomy with D2 lymphadnectomy (lymph node #1, #3, #4sb, #4d, #5, #6, #7, #8a, #9, #11p, #12a) could be performed in this arm
88952167|NCT05874557||treatment group|MHD patients who took compound amino acid capsules regularly(2# tid po) for 9 months
88952168|NCT05874557||control group|MHD patients in the control group are selected by PSM with age, sex, dialysis month, baseline BMI, baseline Kt/V and baseline ultrafiltration volume. And they did not take compound amino acid capsules or similar amino acid nutritional supplement for the same 9 months.
88952169|NCT05874518|Experimental|Experimental group|"Ask the patient to empty the bladder, and take supine position. Take guanyuan, zhongji, bilateral Tianshu, zigong, guilai, sanyinjiao, Taixi, zusanli, hegu points. Select 0.3mm×40mm fine needles. After conventional disinfection, the needle is 0.5-1 inch deep. Then the 1.5 cm moxa cones were inserted into the tail of the needle of the bilateral sanyinjioa and zusnli points for moxibustion. At the same time, electroacupuncture therapy was used. Select the density wave and set the time for 25 minutes.~Generally, the patient feels comfortable as moderate, so that the patient feel acid, distension, heat or local muscles for rhythmic contraction. After treatment, first reduce the power to zero value, turn off the power supply, then remove the electrode clip from the needle handle, and pull out the fine needle stabbed into the tissue. Treatment begins on the 5th day of the menstrual cycle, qd (once a day), usually for 6-8 consecutive days, and continuing to the day of ovulation."
89483003|NCT03264807|Experimental|D2 and #14v lymphadenectomy|Subtotal gastrectomy with D2 (lymph node #1, #3, #4sb, #4d, #5, #6, #7, #8a, #9, #11p, #12a) and lymph node #14v lymphadnectomy could be performed in this arm
89483004|NCT02435992|Experimental|RPC1063 (Ozanimod)|1mg, daily oral administration during Induction and Maintenance periods.
89483005|NCT02435992|Placebo Comparator|Placebo|Daily oral administration during Induction and Maintenance periods.
89483006|NCT05000060|Experimental|1 week restart|Restart of mono or dual antiplatelet therapy one week post injury in TICrH patients
89483007|NCT05000060|Active Comparator|3 week restart|Usual Care for restart of mono or dual antiplatelet therapy after TICrH at clinician's discretion
89483008|NCT03264573|Active Comparator|stem cell, PRP|Adipose derived MSCs, versus Platelet rich plasma
89483009|NCT03264573|Active Comparator|Stem cell, Stem cell and PRP|Adipose derived MSCs alone, other group is injected Adipose derived MSCs, and Platelet rich plasma
89483010|NCT03078140|Active Comparator|Triferdine|Triferdine 1 tablet by mouth daily. Start after 1st trimester until delivery
89483011|NCT03078140|Active Comparator|Triferdine/Ferli-6|Triferdine or ferli-6 1 tablet by mouth daily base on iodine status. The supplement will give after 1st trimester until delivery
89483012|NCT03274557|Active Comparator|Radiofrequency microtenotomy|Treatment of Achilles tendinose with radio-frequency microtenotomy
89483013|NCT03274557|Active Comparator|Phusical therapy|Supervised eccentric training
89483014|NCT03077984|Experimental|the cohort of Chinese medicine treatment|The cohort of Chinese medicine treatment uses its comprehensive program of TCM on the basis of treatment with western medicine, including Chinese Herbs, acupuncture and acupoint application therapies.
89483015|NCT03077984|No Intervention|the cohort of western medicine treatment|The cohort of Western medicine treatment refers to the treatment of cerebrovascular disease prevention and cure guideline of China-related programmes, including anti-platelet aggregation, blood pressure,blood glucose,Blood Lipids lowering therapies.
89483016|NCT02457351|Experimental|Roniciclib + Itraconazole|Pharmacokinetics and safety in patients with advanced solid tumor
89483017|NCT03077906||Existing gastroœsophageal reflux|"Patients who benefited from a sleeve gastrectomy surgery between 2008 and the end of 2015 in the department of digestive surgery of the CHU Brugmann.~Patients who already had a disabling gastroœsophageal reflux resistant to medical treatment in pre-op, and lost it in post-op."
89483018|NCT03077906||De novo gastroœsophageal reflux|"Patients who benefited from a sleeve gastrectomy surgery between 2008 and the end of 2015 in the department of digestive surgery of the CHU Brugmann.~Patients who developped gastroœsophageal reflux de novo."
89483019|NCT02788513|Experimental|BI 425809 dose 1|
89483020|NCT02788513|Experimental|BI 425809 dose 2|
89483021|NCT02788513|Experimental|BI 425809 dose 3|
89483022|NCT02788513|Experimental|BI 425809 dose 4|
89483023|NCT02788513|Placebo Comparator|Placebo|
89483024|NCT03268395|Other|CO2 Measurement|Each subject will received simultaneous arterial blood gas CO2 and transcutaneous CO2 monitor assessments. The correlation of these two measurements will be compared.
89483025|NCT03077750|Experimental|VBP-245|VBP-245 Topical Gel Applied to Affected Area BID
89483026|NCT03077750|Placebo Comparator|Vehicle|Vehicle Gel Applied to Affected Area BID
89483027|NCT03268629|Experimental|Mindfulness-Based Joyful Sleep|The proposed 'Joyful Sleep' program will be conducted weekly, 2 hours per session, 8 sessions, group-based in mindfulness. The content and skills are based upon MBSR, MAPs and Tai Chi. The proposed topics include: 1) mindfulness and insomnia, 2) mindful awareness of stress, 3) mindful working with thoughts, 4) mindful working with emotions, 5) mindful interactions, 6) moving mindfulness meditation: the first taste of Tai Chi, 7) moving mindfulness meditation: the second taste of Tai Chi, 8) dealing with obstacles of mindful practices and wrap-up. Mindfulness practices embedded in the program will include mindfulness breathing meditation, body scan meditation, sitting meditation, standing meditation, walking meditation, Taichi, and daily life meditation.
89483028|NCT03268629|Active Comparator|CBT-I|The CBT-I is a weekly, 2-hour, 8 session, group-based program. CBT-I includes 4 central components: stimulus control, sleep restriction, relaxation training and cognitive therapy. The aim of CBT-I is to reduce sleep-related physiologic and cognitive arousal so that restorative sleep function can be re-established.
89483029|NCT03268239|Other|MRI sequences|"There will be only one arm of patients with central nervous system inflammatory disease.~Each patient will be its own control. The usual and additional MRI sequences will be performed in all patients and the number of lesions obtained in usual sequences and additional sequences will be compared in the same patient."
89483030|NCT04999670|Active Comparator|Single suture, knot above fascia|Fascia sutured with #1 polysorb braided absorbable suture, with the knot being superficial to the fascia, starting at the left angle of the fascial incision and closed in a continuous fashion. The contralateral angle is grasped with a kocher clamp and the suture is then tied behind the angle ensuring adequate closure.
89483031|NCT04999670|Active Comparator|Two sutures, knot above fascia|Fascia sutured using #1 polysorb braided absorbable suture with a superficial knot, starting at the left angle and closed in a continuous fashion until the suture is above the right rectus abdominis muscle belly. A second #1 polysorb braided absorbable suture is tied behind the right angle with a superficial knot and run across in a continuous fashion to meet the opposing suture which are then tied together.
88952170|NCT05874518|Active Comparator|Control group|Treatment was started on day 5 of the menstrual cycle. Letrozole tablets were given at 2.5mg (Jiangsu Hengrui Pharmaceutical Co., Ltd., H19991001, 2.5mg per tablet), po (oral), qd, for 5-7 consecutive days. When the diameter of follicles reaches 18mm, Chorionic gonadotrophin is given at 5000u (Lizhu Group Lizhu Pharmaceutical Factory, Chinese medicine H44020668, 5000u per branch), with intramuscular injection, qd, to promote follicle discharge. Patients were also instructed to have sexual intercourse on the same day and on day 2.
88952171|NCT05874505|Experimental|Adalimumab|Adalimumab 80 mg at Day 0 then 40 mg subcutaneous at week 1, 3, 5, 7, 9, 11, 13 and 15
88952172|NCT05874505|Experimental|Tocilizumab|Tocilizumab 162 mg subcutaneous each week for 15 weeks
88952173|NCT05872412|Experimental|Platinum-based regimen|Patients will be treated with doxorubicin 60 mg/m2 IV on day 1 and cyclophosphamide 600 mg/m2 IV on day 1 every 3 weeks for four cycles, followed by paclitaxel 80 mg/m2 IV weekly for 12 weeks concurrently with carboplatin (area under the curve: 6 mg/ml/min, i.v. every 3 weeks for four cycles).
88952174|NCT05872412|Active Comparator|Non-platinum based regimen|Patients will be treated with doxorubicin 60 mg/m2 IV on day 1 and cyclophosphamide 600 mg/m2 IV on day 1 every 3 weeks for four cycles, followed by paclitaxel 80 mg/m2 IV weekly for 12 weeks.
88952175|NCT05871476|Active Comparator|Intervention district|An information, communication, education and hygiene intervention, developed in collaboration with local health authorities, will aim to improve hygiene and decrease antibiotic use.
88952176|NCT05871476|Active Comparator|cohort care at the hospital|"A laminated note (yellow for suspicious CRE carrier: green for (CRE-) patients and red for (CRE+) patients) should be put on the front of the patients' bed."
88952177|NCT05870826|Sham Comparator|Sham laser therapy|The control group (PL group) is subjected to a laser sham (placebo), employing a device identical to the one under investigation but lacking the laser emission capability, and the same mode of administration in terms of time and place. Both the sham laser and the test device emit visible light of the same color and are not distinguishable in any way.
88952178|NCT05870826|Experimental|Laser therapy|"The MLS group receives MLS synchronized diode laser therapy emitted by the MLS M8 robotic device (ASA, Italy).~MLS M8 (ASA, Arcugnano, Italy), a Class IV (high-power) laser approved by the Food Drug Administration (FDA) and CE certified, characterized by a combined, synchronized two-wavelength (CPW) emission: a continuous emission with a wavelength of 808 nm and a pulsed emission at 905 nm.~The duration of each session is 5 min 45 sec.seconds, delivering a total energy of 1500 J and an energy dose of 5 J/cm2, for an area of 300 cm2.~The robotic device is placed in the lumbar area, oriented on the muscles erector spinae and quadratus lumborum. The target area set on the device is lumbar area. The parameters set on the device are Synchronized Emission of Continuous Pulsed Wave (CPW), intensity of 100%, time of 5 minutes and 45 seconds, and area of 1x300 cm2."
88952179|NCT05870124|Active Comparator|PNS Therapy plus Conventional Medical Management (CMM)|Subjects in this arm will receive a peripheral nerve stimulator and conventional medical management
88952180|NCT05870124|Active Comparator|Conventional Medical Management|Subjects will receive only CMM
88952181|NCT05869006|No Intervention|Control Group|"No attempt was made. Measurement tools were applied simultaneously with the placebo control group and intervention group before, after and during the follow-up.~pretest~final test~Evaluated by follow-up measurements."
88952182|NCT05869006|Placebo Comparator|Placebo Control Group|"A symbolic intervention consisting of six sessions, which was different from the content of the sessions applied to the intervention group, did not have any curative and active content, and was carried out simultaneously with the intervention group as the application time, was applied.~Sessions lasted approximately one hour. It was carried out once a week. It was completed in six weeks. In the sessions, the problems faced by nursing students due to distance education during the Covid-19 pandemic, professional difficulties, experiences, and issues related to their professional goals were discussed.~The effectiveness of the semi-structured sessions;~pretest~symbolic group work~final test~evaluated by follow-up measurements."
89483032|NCT04999670|Active Comparator|Two sutures, buried knots below fascia|Fascia sutured using #1 polysorb braided absorbable suture with a buried knot below the fascia starting at the left angle and closed in a continuous fashion until the suture overlies the right rectus abdominis muscle belly. A second #1 polysorb braided absorbable suture is then tied behind the right angle with a buried knot below the fascia and run across in a continuous fashion to meet the opposing suture which are then tied together.
89483033|NCT03268161||Patients with anti-MAG neuropathy|Mutational analysis of clonal B cells
89483034|NCT03077828|Experimental|Treatment (pembrolizumab, etoposide, carboplatin, ifosfamide)|Patients receive pembrolizumab IV over 30 minutes on day 1, etoposide IV over 60 minutes on days 1-3 of courses 1-2, carboplatin IV over 60 minutes on day 2 of courses 1-2, and ifosfamide IV over 24 hours on day 2 of courses 1-2. Pembrolizumab in combination with ICE chemotherapy repeats every 21 days for 2 courses, patients will then receive pembrolizumab as monotherapy on course 3.
89483035|NCT02122861|Experimental|ID-LV305|Dose escalation and expansion cohort including treatment of melanoma
89483036|NCT04931290|Experimental|supracapsular delivery of plate of valve|ncision of the perilimbal superior temporal conjunctiva with separation of the conjunctiva from the Tenon's capsule till reaching the encapsulated valve plate. Incision of the capsule in a z pattern will be done then the plate is dissected from the tissues and delivered out of the capsule through the opening to the subconjunctival space.The mobility of AGV and its tube will be evaluated and refixation of the plate will be done if needed. The plate will be covered with ologen implant sizing 12mm width and 1 mm thickness. The conjunctiva will be closed by 10/0 nylon sutures.
89483037|NCT02251873|Experimental|TPV + RTV (low dose)+ ddI|
89483038|NCT02251873|Experimental|TPV+ RTV (high dose)+ ddI|
89483039|NCT02126995|Experimental|Metadoxine Immediate/Slow-release|Flexed and fixed-dose Metadoxine Immediate/Slow-release 700 mg and 1400 mg administered orally once daily
89483040|NCT02126995|Placebo Comparator|Placebo|Placebo tablet identical in appearance to study investigational product. Administered orally once daily
89483041|NCT02457429|Other|Routine oesophageal pH monitoring|Routine oesophageal pH investigation involves the trans-nasal placement of a microelectrode into the distal oesophagus as per hospital protocol. Examining the oropharynx and confirming visualisation of the red LED at the catheter tip in the correct position just below the soft palate will confirm its position in the oropharynx. The internal pH value of the oesophagus is then continuously measured and recorded onto a small ambulatory device. The 2 catheters are connected to the ambulatory recording devices and recording commences. The duration of the investigation is 24 hours.
89483042|NCT02401672|Active Comparator|Active TMS|Repetitive TMS pulse stimulation
89483043|NCT02401672|Sham Comparator|Sham TMS|The sham TMS system will be connected to an electrical generator on a 9 V battery and electrodes will be placed over the prefrontal cortex. The regulator is triggered by the TMS machine to allow brief, microsecond, pulses of the electrical current through to the skin on the subjects' forehead. Electrical stimulation will be triggered by the TMS machine to correspond to the sham TMS pulses.
89483044|NCT05257291|No Intervention|Control group|Group of essential hypertensive patients who have received no additional therapies in addition to their established treatment plan (each patient was on specific antihypertensive therapy that has not been changed).
89483045|NCT05257291|Active Comparator|Melatonin treated group|Group of essential hypertensive patients who have received additional therapies consisting in 1 mg/day of melatonin for 1 year, in addition to their established treatment plan.
89483046|NCT03267927|Experimental|Patient with OSA|
89483047|NCT04930900|Experimental|ARS-1 with URTI|ARS-1 with URTI
89483048|NCT04930900|Experimental|ARS-1 without URTI|ARS-1 without URTI
89483049|NCT03264339|Experimental|Smal step|Small Step Program, comprising 3 treatment focus areas (Hand use, Mobility, Communication)
89483050|NCT02124109||Control|Control group
89483051|NCT02124109||rheumatic heart disease|Patients with rheumatic heart disease
89483052|NCT02458209|Active Comparator|Treatment A|150 mg SC dose administered in a prefilled syringe using drug substance manufactured at Pfizer Andover
89020786|NCT00350571|Active Comparator|Standard care follow up|Standard care counselor follow up care phone calls or letters.
89020787|NCT00350571|Experimental|Drop out reengagement motivational intervention|Single session office based or phone based motivational counseling session designed to promote participant re-engagement in standard treatment.
89020788|NCT00345813|Experimental|Arm I|Patients receive oral soy supplementation daily for 4 weeks. Patients undergo radical prostatectomy within 21 days after completion of soy supplementation.
89020789|NCT00345813|Placebo Comparator|Arm II|Patients receive oral placebo supplementation daily for 4 weeks. Patients undergo radical prostatectomy within 21 days after completion of placebo supplementation.
89020790|NCT00350610|Active Comparator|1|Standard treatment as usual (TAU) in a community based clinic consisting of individual and group therapy sessions and regular urine monitoring.
89020791|NCT00350610|Experimental|2|Standard treatment as usual (TAU) plus coping skills computer program. In addition to the individual and group therapy sessions (TAU), individuals will work with a computerized program that teaches skills for stopping cocaine use and increasing coping skills twice weekly for 8 weeks.
89020792|NCT00350649|Experimental|1|manualized delivery of CBT by trained clinicians
89020793|NCT00350649|Active Comparator|2|CBT with Contingency Management reinforcement for attendance and completing homework (CBT+CM/adherence)
89020794|NCT00350649|Experimental|3|Contingency Management for abstinence alone (CM/abstinence)
89020795|NCT00350649|Active Comparator|4|Contingency Management integrated with CBT (CM/abstinence+CBT)
89483053|NCT02458209|Experimental|Treatment B|• Treatment B: 150 mg SC dose administered in a prefilled syringe using drug substance manufactured at Boehringer Ingelheim Pharma
89483054|NCT02458209|Experimental|Treatment C|150 mg SC dose administered in a prefilled pen using drug substance manufactured at Pfizer Andover.
89020796|NCT00350688|Other|Helical tomotherapy IMRT|Helical tomotherapy IMRT
89483055|NCT02127151|Experimental|BMN 673|BMN 673 daily until progression, death, unacceptable toxicity, withdrawal of consent or any other criterion felt by the Investigator to preclude continuation of treatment.
89483056|NCT03077516||Mobi-C|Prior recipient of Mobi-C Disc in IDE/Post Approval Study
89483057|NCT03077516||ACDF|Prior control subject in IDE/Post Approval Study
89483058|NCT03075800|No Intervention|Assertive Community Treatment (ACT) - Only|ACT is a multidisciplinary, team-based approach to providing a range of treatment, rehabilitation, and support services to high-need, high-risk people with severe mental illness who tend not to use clinic-based services; most services are provided on an outreach basis (e.g., in the person's home) and services are available 24 /7(27).
89483059|NCT03075800|Experimental|Assertive Community Treatment+Illness Management and Recovery|IMR follows a manualized curriculum to help clients pursue personal recovery goals and to teach them information, strategies, and skills over 11 modules (e.g., using medications, coping with stress) to manage their psychiatric illness. IMR can be provided in individual or group formats. The integrated ACT+IMR model was developed and manualized prior to the start of this evaluation (27). The model incorporates the following key features: a) ACT staff provide IMR in office-based group and/or individual sessions in office or community settings; b) regular community follow-up by ACT staff to assist clients with practicing IMR skills and achieving their goals; c) regular communication within ACT team (e.g., during daily meetings) on IMR client goals and progress; and d) supervision and consultation on IMR within ACT.
89203400|NCT00535288|Experimental|Esmirtazapine 18 mg|Participants receive esmirtazapine, 18 mg, encapsulated tablets, orally QD for up to 12 weeks.
89203401|NCT00921830|Experimental|Ibuprofen|ibuprofen
89020797|NCT00419198|Experimental|1|Post-conditioning during angioplasty
89020798|NCT00419198|Active Comparator|2|standard angioplasty
89020799|NCT00419237|Active Comparator|Healthy subjects|Subjects with normal liver function test will be administered a single oral inhaled dose of 400 micrograms (mcg) GW685698X in the morning of the study day. Each healthy subject will be matched as closely as possible for age, gender, bodyweight and race to a subject with impaired liver function.
89020800|NCT00419237|Experimental|Subjects with hepatic impairment|Subjects with Child Pugh B hepatic dysfunction will be administered a single oral inhaled dose of 400 mcg GW685698X in the morning of the study day.
89020801|NCT00350766|Experimental|Treated Group|Intracoronary injection in the infarcted-related artery of 100 million bone marrow mononuclear cells resuspended in a 10 ml solution of saline with autologous serum.
89020802|NCT00350766|Placebo Comparator|Control Group|Intracoronary injection in the infarcted-related artery of placebo solution consisting of a saline containing autologous blood serum.
89020803|NCT00318695|Experimental|Probiotics|Bifidobacterium longum [BL999] and Lactobacillus rhamnosus [LPR]
89203402|NCT05435534|Experimental|Multicomponent intervention|Participants randomly assigned to the Multicomponent intervention group will received a multifactorial intervention.
89203403|NCT05435534|Active Comparator|Usual care group|Participants randomly assigned to the usual care group will received normal outpatient care, including physical rehabilitation when needed.
89203404|NCT02560220|Experimental|Intervention arm|Patients receive MIC cell therapy together with standard immunosuppressive therapy
89203405|NCT05435456|Experimental|Experimental Group|Performed strengthening and relaxation exercises 3 times a week for 8 weeks.
89203406|NCT05435456|No Intervention|Control Group|There is no intervention
89483060|NCT02435914|Experimental|AGN-223575 Dose A|1 drop of AGN-223575 Dose A ophthalmic solution administered in each eye twice daily for 14 day followed by either 1 drop of AGN-223575 Dose A ophthalmic solution or 1 drop of vehicle to AGN-223575 in each eye once daily for 7 days.
89483061|NCT02435914|Experimental|AGN-223575 Dose B|1 drop of AGN-223575 Dose B ophthalmic solution administered in each eye twice daily for 14 day followed by either 1 drop of AGN-223575 Dose B ophthalmic solution or 1 drop of vehicle to AGN-223575 in each eye once daily for 7 days.
89483062|NCT02435914|Experimental|AGN-223575 Dose C|1 drop of AGN-223575 Dose C ophthalmic solution administered in each eye twice daily for 14 day followed by either 1 drop of AGN-223575 Dose C ophthalmic solution or 1 drop of vehicle to AGN-223575 in each eye once daily for 7 days.
89020804|NCT00318695|Placebo Comparator|Placebo|Commercially available cow's milk based infant formula without probiotic supplementation
89483063|NCT02435914|Placebo Comparator|AGN-223575 Vehicle|1 drop of Vehicle to AGN-223575 ophthalmic solution administered in each eye twice daily for 14 day followed by 1 drop of vehicle to AGN-223575 ophthalmic solution in each eye once daily for 7 days.
89020805|NCT00346047|Placebo Comparator|0|
89020806|NCT00346047|Experimental|1|
89020807|NCT00421200|Experimental|Hemospan (MP4OX)|4.3 g/dL MalPEG-Hb solution
89020808|NCT00421200|Active Comparator|Control|Voluven (HES 130/0.4)
89483064|NCT03273699|Experimental|Mindfulness|"The study will be a randomized trial where subjects (N=100) will be randomly assigned to receive either 1) an eight week meditation program involving use of an EEG-based biofeedback device, or 2) wait list as per usual. The experimental design is a 2 (treatment condition: Group 1: Mindfulness, Group 2: Control) by 3 (assessment phase: baseline (week 0), mid-treatment (week 4), post-treatment (week 8)) repeated measures factorial design. Group randomization will be completed by the principal investigator, using the GraphPad Quick Calcs online calculator which offers simple random allocation into equal-sized groups"
89483065|NCT03273699|No Intervention|Control|"The study will be a randomized trial where subjects (N=100) will be randomly assigned to receive either 1) an eight week meditation program involving use of an EEG-based biofeedback device, or 2) wait list as per usual. The experimental design is a 2 (treatment condition: Group 1: Mindfulness, Group 2: Control) by 3 (assessment phase: baseline (week 0), mid-treatment (week 4), post-treatment (week 8)) repeated measures factorial design. Group randomization will be completed by the principal investigator, using the GraphPad Quick Calcs online calculator which offers simple random allocation into equal-sized groups"
89483066|NCT02124343|Experimental|Interval Exercise|"Subjects will undertake an interval exercise session (on a harnessed treadmill) (HP Cosmos Mercury 4.0, HP Cosmos Sports and Medical Gmbh, Nussdorf-Traustein,Germany) based on the average speed calculated from the 6 minute walk test (6MWT).~Intervals are based on the work previously done by Mador et al., 2009 who used intervals of 150% (for 1 minute) followed by intervals of 75% (for 2 minutes) based on 80% average speed from the 6 minute walk test.~This study repeated these intervals 7 times with a duration of 23 minutes in total for the exercise intervention with the 75% intervals at the start and at the end of the exercise session. No warm up was undertaken for this method as it was a walking exercise test and the risk of injury was minimised with use of the harnessed treadmill."
89483067|NCT03077282|Experimental|group1|Group1 will take Prasaprohyai 95% ethanolic extract capsules at a dose of 100 mg three times a day before meals (for 6 weeks)
89483068|NCT03077282|Experimental|group2|Group2 will take Prasaprohyai 95% ethanolic extract capsules at a dose of 200 mg three times a day before meals (for 6 weeks)
89483069|NCT02457273|Experimental|Assigned Interventions|TLC 388
89483070|NCT03551275|Experimental|Cohort no. 1, BCD-132, 100 mg, IV|"Cohort no. 1, Group #1 includes 3 (+3) subjects who will receive the single intravenous infusion of BCD-132 at the dose of 100 mg.~Cohort no. 1, Group #2 includes 3 (+3) subjects who will receive the single intravenous infusion of BCD-132 at the dose of 50 mg and second dose of 50 mg IV after 14 days period after first infusion.~If there is no DLT within the first 14 days after infusion then Cohort no.2 is included."
89483071|NCT03551275|Experimental|Cohort no. 2, BCD-132, 250 mg, IV|"Cohort no. 2, Group #3 includes 3 (+3) subjects who will receive the single intravenous infusion of BCD-132 at the dose of 250 mg.~Cohort no. 2, Group #4 includes 3 (+3) subjects who will receive the single intravenous infusion of BCD-132 at the dose of 125 mg and second dose of 125 mg IV after 14 days period after first infusion.~If there is no DLT within the first 14 days after infusion then Cohort no.3 is included."
89483072|NCT03551275|Experimental|Cohort no. 3, BCD-132, 500 mg, IV|"Cohort no. 3, Group #5 includes 3 (+3) subjects who will receive the single intravenous infusion of BCD-132 at the dose of 500 mg.~Cohort no. 3, Group #6 includes 3 (+3) subjects who will receive the single intravenous infusion of BCD-132 at the dose of 250 mg and second dose of 250 mg IV after 14 days period after first infusion.~If there is no DLT within the first 14 days after infusion then Cohort no.4 is included."
89483073|NCT03551275|Experimental|Cohort no. 4, BCD-132, 1000 mg, IV|"Cohort no. 4, Group #7 includes 3 (+3) subjects who will receive the single intravenous infusion of BCD-132 at the dose of 1000 mg.~Cohort no. 4, Group #8 includes 3 (+3) subjects who will receive the single intravenous infusion of BCD-132 at the dose of 500 mg and second dose of 500 mg IV after 14 days period after first infusion."
89483074|NCT03077126|Other|Pre-surgery Ultrasound|Aixplorer® ShearWave Elastography (SWE™) Ultrasound. Participants will undergo ultrasound prep with Fleet Enema and ultrasound procedure at their pre-op visit one to two weeks before their standard of care prostatectomy.
89483075|NCT03264105|Experimental|NovaPro™ Flow|NovaPro™ Flow Flowable Composite, Nanova Biomaterials company, USA
89483076|NCT03264105|Active Comparator|Conventional resin-based flowable composite|Filtek™Supreme Ultra Flowable Restorative, 3M ESPE company, USA
89483077|NCT02127229|No Intervention|Blinded observation of ERCP|Blind observation of disposable accessories use.
89483078|NCT02127229|Experimental|Endoscopist informed of cost per procedure|Endoscopists informed following each ERCP.
89483079|NCT04993040|Experimental|Oraxol|Subjects will receive Oraxol 205 mg/m2 daily x 3 days weekly for up to 16 weeks.
89020809|NCT00350805||Healthy volunteers|
89203407|NCT04836832|Experimental|Treatment (acalabrutinib, duvelisib)|Patients receive acalabrutinib PO BID, and duvelisib PO BID on days 1-28. Treatment repeats every 28 days for up to 18 cycles in the absence of disease progression or unacceptable toxicity. Beginning cycle 19, patients receive acalabrutinib PO BID for up to 60 months in absence of disease progression or unacceptable toxicity.
89020810|NCT00350805||Patients|
89020811|NCT00318851|Experimental|Carotid Artery Stenting|
89020812|NCT00350883|Other|Treatment as Usual|
89020813|NCT00350883|Experimental|Cognitive Therapy|
89020814|NCT00318890|Experimental|Docetaxel + cisplatin followed by radiation|Docetaxel with cisplatin is given for three cycles, followed by concomitant therapy with weekly docetaxel for 4 weeks. Radiation therapy is given 5 days each week on Days 64-106 with a concomitant boost in the last 2 weeks of treatment. Amifostine is given as an injection on a daily basis during radiotherapy.
89020815|NCT00319124||Case|Patients with hip Osteoarthritis
89483080|NCT03072992|Active Comparator|Group A: Paclitaxel & Curcumin|75 patients, treatment with Curcumin (CUC-01, yellow solution), 300mg i.v. plus i.v. Paclitaxel (colorless solution) 80 mg /m2 BS i.e., once weekly for 12 weeks.
88952183|NCT05869006|Experimental|Intervention Group|"A semi-structured group study consisting of six sessions based on interpersonal relations supported by the designed SIA instrument was applied. Sessions lasted approximately one hour. One session per week was administered. It was completed in six weeks. The initiatives applied in the sessions were implemented based on Peplau's theory of Interpersonal Relations. Group work was supported by the SIA instrument and music therapy techniques were used. In addition, positive psychology and psychological well-being literature were examined in the creation of initiatives. The effectiveness of semi-structured sessions;~pretest~group interaction study consisting of six sessions~final test~evaluated by follow-up measurements."
89483081|NCT03072992|Placebo Comparator|Group B: Paclitaxel & Placebo|Group B, 75 patients, treatment with Paclitaxel (colorless solution) 80 mg /m2 BS, i.v. plus placebo i.v. solution (250 ml, yellow solution for masking/blinding), once weekly for 12 weeks.
89483082|NCT03272841||Transplant recipients|Renal, heart, lung, liver, small bowel, pancreas or combined transplant recipients
89483083|NCT04992806||patients accepted hip arthroscopy|patients with hip diseases and accepted hip arthroscopy in Peking University Third Hospital
89483084|NCT03267771|Active Comparator|progesterone suppositories vaginal group|vaginal micronized progesterone suppositories (prontogest®) 400 mg, one vaginal suppository twice daily through 18 weeks of gestation.
89483085|NCT03267771|Experimental|Dydrogesterone oral tablets group|20 mg tablets (Duphaston ®), 2 tablets orally twice daily through 18 weeks of gestation.
89483086|NCT04992962|Experimental|CBD/CBN|Participants will receive a 28-day supply of CBD/CBN sublingual tablets to be taken 3 times a day for 28 days.
89483087|NCT04992962|Experimental|CBD/THC|Participants will receive a 28-day supply of CBD/THC sublingual tablets to be taken 3 times a day for 28 days.
89483088|NCT04992962|Placebo Comparator|Placebo|A placebo sublingual tablet to be taken three times a day for 28 days
89483089|NCT02131051||Azelastine group|Azelastine nasal spray Azelastine eye drops
89483090|NCT02131051||Ectoin group|Ectoin Allergy Nasal Spray Ectoin Allergy Eye Drops
89483091|NCT02131207||Diagnostic (MRI and biopsy)|Participants undergo pelvic magnetic resonance imaging (MRI). Within 1-2 weeks, patients undergo scheduled prostate biopsy.
89483092|NCT03267537|Active Comparator|Conventional office-based CBT-I|CBT-I will be delivered by a licensed clinical psychologist in weekly sessions lasting up to 1 hour. There will be 6 CBT-I sessions over the course of therapy with the option of an additional 2 treatments if deemed necessary by the clinical psychologist.
89483093|NCT03267537|Experimental|Telemedicine based CBT-I|The treatment will be the exact same as the active comparator group, with the same clinical psychologist doing the office-based CBT-I, but will be administered through a telemedicine modality
88952184|NCT05864807|Experimental|Interventional arm|Electrical stimulation to the dorsal genital nerve.
88952185|NCT05860166|Experimental|trial group|The Clinical trial group consists of infants to whom the tests will be applied.
88952186|NCT05856461|Sham Comparator|Pulmonary vein isolation+sham pulmonary artery denervation (group 1)|In group 1, standard pulmonary vein isolation will be performed (with manual or remote robotic 3D navigation using radiofrequency energy) with sham pulmonary artery denervation procedure including 3D reconstruction of the pulmonary artery tree and creation of the false ablation point
88952187|NCT05856461|Active Comparator|Pulmonary vein isolation+pulmonary artery denervation (group 2)|In group 2, standard pulmonary vein isolation will be performed (with manual or remote robotic 3D navigation using radiofrequency energy) combined with pulmonary artery denervation procedure
88952190|NCT05823675|Experimental|Itolizumab Dose Level 1|Itolizumab of 25 mg administered by intravenous infusion every 2 weeks for a total of 5 doses.
89483094|NCT03072836|Experimental|CD alone|
89483095|NCT03072836|Experimental|SPA alone|
89483096|NCT03072836|Experimental|CD + SPA|
89483097|NCT03550651|Experimental|Licorice extract mouthrinse|10ml twice a day for 4 Days.
89483098|NCT03550651|Experimental|Hypertonic salt solution|10ml twice a day for 4 Days.
89483099|NCT03550651|Active Comparator|Essential oil mouthrinse|10ml twice a day for 4 Days.
89483100|NCT03550651|Active Comparator|Chlorhexidine Gluconate mouthrinse|10ml twice a day for 4 Days.
89483101|NCT03550651|Placebo Comparator|Distilled water|10ml twice a day for 4 Days.
89203408|NCT02917928|Active Comparator|Intervention|Each participant will be given a daily oral dose 2 g of carnosine (4 tablets of 500mg each) for 14 weeks
89203409|NCT02917928|Placebo Comparator|Control|Each participant will be given a daily oral dose 2 g of placebo (4 tablets of 500mg each) for 14 weeks
89203410|NCT03904420|Experimental|Group A - New Model|Standardized programming and testing method
89203411|NCT03904420|Active Comparator|Group B - Traditional Model|Traditional clinical model which is not standardized across clinical sites
89203412|NCT05358184|Experimental|High frequency percussive ventilation|High Frequency Percussive Ventilation will be applied for 10 minutes at an oscillation frequency of 10 Hz, superimposed to oxygen therapy at high flow through nasal cannula
89203413|NCT02783300|Experimental|Part 1: Dose Escalation, Food effect and Relative Bioavailability of Capsule formulation to Tablet|Participants will receive escalating doses of GSK3326595 until the maximum tolerated dose level is reached. The recommended phase 2 dose (RP2D) will be determined. Participants will be dosed in a fed (high-fat, high-calorie meal) and fasted state to determine the effect of food on bioavailability of GSK3326595, and will be dosed with tablet and capsule to compare two formulations of GSK3326595 (capsule versus tablet).
89203414|NCT02783300|Experimental|Part 2: Disease-Specific Expansion cohort|Participants with triple-negative breast cancer (TNBC), metastatic transitional cell carcinoma of the urinary system (mTCC), Grade IV anaplastic astrocytoma (glioblastoma multiforme [GBM]), non-Hodgkin's lymphoma (NHL), adenoid cystic carcinoma (ACC), hormone receptor-positive adenocarcinoma of the breast (ER+BC), human papillomavirus (HPV)-positive solid tumors of any histology, and p53-wild type non-small cell lung cancer (NSCLC) will be administered GSK3326595 at the recommended phase 2 dose (RP2D) as determined in Part 1.
88952191|NCT05823675|Experimental|Itolizumab Dose Level 2|Itolizumab of 50 mg administered by intravenous infusion every 2 weeks for a total of 5 doses.
89483102|NCT02456961|Active Comparator|Standard epithelium-off CXL|Removing the central 8-10mm of the epithelium and applying a riboflavin solution (0.1% riboflavin-5-phosphate and 20% dextran T-500) to the corneal surface 30 minutes before irradiation and at 5 minutes intervals during the course of a 30 minute exposure to 370 nm UVA with an irradiance of 3 mWcm-2 (UFalink, Russian Federation)
89483103|NCT02456961|Experimental|Transepithelial CXL via iontophoresis of riboflavin|"impregnation of the cornea with a riboflavin 0.1% hypotonic solution is performed by using an iontophoresis device (galvanizator; Potok-1, Russian Federation). The passive electrode (anode) was applied to the inferior part of the cervical vertebrae. The active electrode (cathode), a bath tube (glass or plastic - 10-12 ml) is applied to the open eye,then r the tube is taped to the skin of the orbital margins and filled with riboflavin 0.1%. The current intensity is initially 0.2 mA and then gradually increased to 1.0 mA at 0.2 mA for 1 minute at 10-second intervals increments to determine individual tolerance. The total time that the riboflavin administration is 10 minutes.~Standard surface UVA irradiation (370 nm, 3 mW/cm2) using UFalink device, (Russian Federation) is then applied at a 5-cm distance for 30 minutes with continuing hypotonic riboflavin drops every 2 minutes"
88952192|NCT05823675|Experimental|Itolizumab Dose Level 3|Itolizumab of 100 mg administered by intravenous infusion every 2 weeks for a total of 5 doses.
89483104|NCT03075956|Experimental|5 mg E4 single-dose|Group A: a single 5 mg E4 dose will be administered under fasted conditions during period 1.
89483105|NCT03075956|Experimental|15 mg E4 single-dose|Group B: a single 15 mg E4 dose will be administered under fasted conditions during period 1.
89483106|NCT03075956|Experimental|45 mg E4 single-dose|Group C: a single 45 mg E4 dose will be administered under fasted conditions during Period 1.
89483107|NCT03075956|Experimental|15 mg E4 multiple-dose|15 mg E4 dose will be administered once daily for 14 consecutive days during Period 2.
89483108|NCT03551197|Experimental|Budesonide and formoterol bid|At baseline,lung function test,blood oxygen saturation and pulse are measured before and after 6-min walk test for each subject.Quality of life is assessed through questionnaires including modified Medical Research Council dyspnoea scale(mMRC),St George's Respiratory Questionnaire(SGRQ),clinical chronic obstructive pulmonary questionnaire(CCQ) and chronic obstructive pulmonary disease assessment test(CAT).And then budesonide(160ug) and formoterol(4.5ug) bid will be given to the subjects for 3 months.The subjects will have a follow-up visit with all the examinations mentioned above after 3 months' treatment.
89483109|NCT03072914|No Intervention|The control group|The control group has a sphygmomanometer wound around the upper arm or lower extremity and applies the same pressure, but a 3-way stopcock is installed in the middle so that no pressure is applied.
89483110|NCT03072914|Active Comparator|RIPC with RIPostC group|The sphygmomanometer is closed to the lower limb and the cuff is inflated and the pressure is increased by 30 mmHg higher than the systolic blood pressure of each patient for 5 minutes. The loss of the distal pulse is confirmed by Doppler in the dorsalis pedis pulse. If there is a pulse, increase the pressure until it disappears. After 5 minutes of ischemia time, the cuff is deflated to confirm that the pulse has returned and has a reperfusion time of 5 minutes. A total of 4 cycles of 5 cycles of ischemic time and 5 minutes of reperfusion time are performed. (Estimated total 40 minutes) When the skull is started to close, RIpc with RIPostC group performs RpostC and the method is the same as the above RIPC method. (Estimated total 40 minutes)
89483111|NCT02456883|Experimental|gilteritinib and 14C-labeled gilteritinib|Gilteritinib will be taken once daily on study days 1 through 14 and days 16 through 47. On day 15, each participant will be given a single dose of 14C-labeled gilteritinib.
88952193|NCT05823675|Experimental|Itolizumab Dose Level 4|Itolizumab of 150 mg administered by intravenous infusion every 2 weeks for a total of 5 doses.
88952194|NCT05874869|Active Comparator|Dihydroartemisinin-piperaquine|Dihydroartemisinin-piperaquine will be administered to the intervention arm
88952195|NCT05874869|No Intervention|Control|Individuals that will get malaria infection and present at the health facility with clinical signs and symptoms will be treated according to the Tanzania National Malaria Treatment guidelines using artemether-lumefantrine.
88952196|NCT05816603|Experimental|Real tDCS stimulation|Subjects randomized to receive real/active electrical stimulation.
88952197|NCT05816603|Sham Comparator|Sham tDCS stimulation|Subjects randomized to receive sham/non-activating electrical stimulation.
88952198|NCT05814757|Experimental|OTX-DED 0.3mg|
88952199|NCT05814757|Experimental|Controlled Insertion utilizing Collagen Punctal Plug|
89537595|NCT04431219|Experimental|Therapeutic Dose Cohort|"The TD cohort will be recruited once the therapeutic dose is defined. This cohort will be divided in 2 subgroups of respectively 2 and 3 patients sequentially recruited.~DSMB will review the safety and efficacy profile of the first 2 patients (Subgroup1) and decide:~To continue at the same dose and recruit the next 3 patients of Subgroup 2~To recruit the next 3 patients with a lower dose, estimated from AD as bringing efficient depletion~To recruit the next patient with a higher dose (+2 mg/kg), if the depletion is not considered satisfactory and if the safety profile is considered acceptable~To end the trial if LIS1 toxicity is too important vs its efficacy in CD3+ depletion.~If the decision to increase the dose after the first two TD patients is made, an additional DSMB review will be planned after patient 8. The DSMB will decide to maintain the dose for the last 2 patients or to get back to the previous dose"
89537596|NCT03063489|Experimental|Loteprednol Etabonate Ophthalmic Gel|Formulated LE into a gel (loteprednol etabonate ophthalmic gel, [Lotemax® gel])
89537597|NCT04430127||Colorectal adenocarcinoma|patients with pathology-proved colorectal tumor (detected by optical colonoscopy) who undergo routine thoraco-abdominal DECT for initial staging
89537598|NCT03368001|Experimental|SENSE Theatre|SENSE Theatre is a peer-mediated, theatre-based intervention targeting social competence in youth with autism spectrum disorder. The 40 hour intervention is comprised of 10 sessions in which trained typically peers are paired with children with autism spectrum disorder (ASD).
89537599|NCT03368001|Active Comparator|Tackling Teenage Together|The Tackling Teenage Together is a psychosocial and sexual education program developed for youth with ASD. It is comprised of 10 sessions.
89537600|NCT03305445|Experimental|Pts with Diffuse Large B Cell Lymphoma|"Patients with DLBCL not eligible for autologous stem cell transplant. All patients will receive dual checkpoint blocking antibody (DCBA) therapy of ipilimumab and nivolumab given at three week intervals, two times before, and two times following immunotransplant in which T cells (in whole PBMCs) are cryopreserved and re-infused (adoptive T cell transfer or ATCT) following lymphodepleting chemotherapy regimen, currently being employed in adoptive T cell therapies."
89537601|NCT01504893|Experimental|Protective|"Two-lung ventilation (TLV): tidal volume = 8 mL / kg PBW, peak airway pressure ≤ 25 cm H2O, I: E = 1:2; after lung re-expansion to the closure of the chest will set a PEEP of 5 cmH2O~OLV (OLV): 4 mL / kg PBW, peak airway pressure ≤ 35 cmH2O, respiratory rate <30, I:E = 1:2 / 1:3.~During OLV in case of desaturation (before increasing the FiO2) and every 60 minutes alveolar recruitment maneuvers followed by the setting of PEEP to 5 cmH2O"
88952200|NCT05814757|Placebo Comparator|Collagen Punctal Plug (Full Insertion)|
88952201|NCT05799820|Experimental|QL1706|
88952202|NCT05799820|Experimental|QL1706 in combination with bevacizumab and XELOX|
88952203|NCT05796882|Experimental|WFPBD Group|The participants in this group follow a Whole Food Plant-Based Diet for 8 weeks
88952204|NCT05796882|Active Comparator|Nutritional Standard Care Group|The participants in this group receive a nutritional consultation every month with dietetic guidance and recommendations about a healthy lifestyle, duration 8 weeks
88952205|NCT05790928||AONDA DW|Lotrafilcon A contact lenses worn in a daily wear (DW) modality (lenses removed nightly for cleaning) for at least 1 year with monthly replacement.
88952206|NCT05790928||AONDA CW|Lotrafilcon A contact lenses worn in a continuous wear (CW) modality (lenses worn continuously including overnight) for at least 1 year with monthly replacement.
88952207|NCT05790161|Experimental|Sleep Restriction|3 nights with 6h sleep opportunity each.
88952208|NCT05790161|Experimental|Sleep Extension|3 nights with 9,5h sleep opportunity each.
88952209|NCT05763368|Active Comparator|Minimally Invasive Lateral Approach|
88952210|NCT05763368|Active Comparator|Anterior Approach|
88952211|NCT05718362|Experimental|Intervention Group|Ayres Sensory Integration Therapy and Home Program
88952212|NCT05718362|Active Comparator|Control Group|Home Program
88952213|NCT05686096|Experimental|MYK-224|
88952214|NCT05677412|Active Comparator|neutral story|Neutral story before the sleep onset
88952215|NCT05677412|Experimental|suggestive story|Suggestive story to find out the effect of relaxation to sleep structures.
88952216|NCT05676801|Experimental|PDT group|PDT with 5% topical methyl aminolevulinate (MAL) before skin antisepsis
88952217|NCT05671315|Experimental|Combined treatment group|Peginterferon alfa-2b Injection combined Nucleos (t) ide Analogue therapy
88952218|NCT05671315|Active Comparator|Monotherapy group|Nucleos (t) ide Analogue monotherapy
88952219|NCT05662215|Experimental|CK-3828136 for SAD Cohort|Subjects will be assigned to one of approximately 8 planned dose cohorts and receive single doses of CK-3828136
88952220|NCT05662215|Placebo Comparator|Placebo for SAD Cohort|Subjects will be assigned to one of approximately 8 planned cohorts and receive single doses of placebo
88952221|NCT05662215|Experimental|CK-3828136 for MAD Cohort|Subjects will be assigned to one of approximately 8 planned dose cohorts and receive multiple doses of CK-3828136
88952222|NCT05662215|Placebo Comparator|Placebo for MAD Cohort|Subjects will be assigned to one of approximately 8 planned cohorts and receive single doses of placebo
89020816|NCT00319124||Control|Healthy controls without hip osteoarthritis
89537602|NCT01504893|No Intervention|Conventional|"Two-lung ventilation (TLV): tidal volume = 8 mL / kg PBW, peak airway pressure ≤ 25 cmH2O; I: E = 1:2; after lung re-expansion to the closure of the chest PEEP set to 5 cmH2O~OLV (OLV): 6 mL / kg PBW, peak airway pressure ≤ 35 cmH2O; I: E = 1:2."
89537603|NCT04982523|Experimental|Online Mental Health Program Group|The online mental health program of 8 sessions is provided. Data collection was collected pre-, post-, and one month after the program.
89537604|NCT04982523|No Intervention|Control Group|"Data collection was collected three times for three months. No intervention was provided during the study.~If they wanted, they were provided the online mental health program same as the experimental group after data collection."
89537605|NCT04982601|Experimental|Yoga Group|Yoga-based exercises were performed by a physiotherapist has Yoga training, by consisting of 10-person groups, 6 weeks, 3 days in a week for a total of 18 sessions. Yoga-based exercises are Hatha yoga-based sessions consisting of breathing exercises, warm-up exercises, relaxation, asanas exercises and lasts about one hour. Especially combined movements with upper extremity and neck movements and breathing exercises were used in breathing exercises. In the warm-up exercises, the muscles were extended by giving exercises especially for stretching the muscles. In this way, asanas were prepared. Asanas Ardra kati cahkrasana, padahastasana, trikosana, sasankasana, varaksana poses have been performed. Asanas were modified and applied according to the patient's condition. Relaxation exercises were used both after breathing exercises and at the end of the exercise program. With relaxation, the patients were allowed to leave their muscles relaxed with the whole body relaxation
89537606|NCT04982601|No Intervention|Control Group|No kind of intervention has been applied to control group they awaited for therapy procedure for 6 week. They have assessed at the end of the 6 weeks.
89537607|NCT04436913|Experimental|preventive regimen using Herbal toothpaste(Himalaya)|"The regimen includes herbal toothpaste containing Neem , Miswak , Babool and Pomegranate (Himalaya Complete Care)."
89537608|NCT04436913|Experimental|preventive regimen using Fluoride based toothpaste (Signal).|Participants will be using fluoride-based toothpaste (Signal), (1450 ppm sodium fluoride)
89537609|NCT04436913|Active Comparator|Fluoride toothpaste and fluoride varnish|Participants will be using fluoride-based toothpaste (Signal), (1450 ppm sodium fluoride) and fluoride varnish
89537610|NCT04436757|Experimental|IPS (Self-image and body-representation program)|"The IPS program (Self-image and body representation) was designed by Dr PLAZAT and coll. for specific use with patients with severe mental disorders suffering of low self- and body-esteem and aiming at  reinsert themselves in the society."
89537611|NCT04436757|Active Comparator|TAU|Treatment As Usual : the usual care proposed by the health service (SUR/CL3R).
89537612|NCT03855137|Placebo Comparator|Placebo|Participants received atogepant-matching placebo tablets, orally, twice daily (BID) for 12 weeks in a double-blind (DB) treatment period.
89537613|NCT03855137|Active Comparator|Atogepant 30 mg BID|Participants received atogepant 30 mg tablet, orally, BID and atogepant-matching placebo tablets orally, BID for up to 12 weeks in a DB treatment period.
88952223|NCT05662215|Experimental|Food Effect|Healthy subjects will be administered CK-3828136 with and without food in a cross-over fashion.
88952224|NCT05654545|Other|Chatbot coaching|Due to the single-group design there will only be one arm. All participants will be exposed to four different chatbot relapse prevention coaching dialogs, which are presented in a random order.
88952225|NCT05641467|Experimental|Video will be watched with virtual reality glasses during episiotomy repair|Views of nature with virtual reality glasses during episiotomy repair.
88952226|NCT05641467|No Intervention|Control|It will be perform routine practice who the women in the control group.
88952227|NCT05576090|Experimental|Mindfulness Meditation|Half of the subjects will be randomly assigned to participate in the Mindfulness Meditation intervention. This class will meet once a week, for two hours, over the course of six weeks.
88952228|NCT05576090|Active Comparator|Sleep Education|Half of the subjects will be randomly assigned to participate in the Sleep Education intervention. This class will meet once a week, for two hours, over the course of six weeks.
88952229|NCT05547724|Experimental|Virtual reality|
88952230|NCT05532657|Active Comparator|Hearing intervention (HI) group|Participants in this group were randomized to the hearing intervention (HI) group at ACHIEVE trial baseline and received a best practices hearing rehabilitation treatment program, consisting of fitting with hearing aids and other hearing assistive technologies along with comprehensive, individualized hearing rehabilitation sessions with a study audiologist spaced over the 2-3 months post-fitting designed to provide all the active components of the intervention. Participants also received semi-annual booster sessions with the study audiologist. These participants will continue to receive hearing healthcare from the study audiologist and complete semi-annual sessions for 3 additional years.
88952231|NCT05532657|Active Comparator|Successful aging/Delayed hearing intervention (SA/DHI) group|Participants in this active control group were randomized to the successful aging (SA) group at ACHIEVE trial baseline and received a successful aging health education program, following the protocol and materials developed for the 10 Keys to Healthy Aging program. The program involved individualized sessions with a study health educator to control for staff-participant time and attention between the two groups. Upon completion of the ACHIEVE trial, these participants are offered the best practices hearing rehabilitative treatment program with comprehensive, individualized sessions post-fitting and will receive semi-annual booster sessions with the study audiologist for 3 years.
88952232|NCT05531721||pediatric patients affected by hemophagocytic lymphohistiocytoses|pediatric patients with HLH
88952233|NCT05527301|Experimental|HEM1036 (Lactobacillus fermentum)|Daily dose of 1 × 10^10 colony-forming units divided in 2 equal doses as a powder for BID oral administration
88952234|NCT05527301|Placebo Comparator|Placebo|2g Powder for BID oral administration
88952235|NCT05523336||Paediatric patients receiving HCTS with infectious complications post HCTS|Paediatric patients receiving allogeneic hematopoietic stem cell transplantation (HCTS) and who present with infectious complications post HSCT or with transplant related complications (acute graft-versus-host disease- GvHD-, sinusoidal obstruction syndrome -SOS-, engraftment-ES- and pre-engraftment syndrome- pre-ES-, graft failure, thrombotic microangiopathy associated with HSCT- TA-TMA or those without complications post HSCT).
89020817|NCT00319202|Experimental|1|
89020818|NCT00319202|Placebo Comparator|2|
89020819|NCT00319280|Experimental|1|Minced Iliac Crest autograft in osteotomysite
89203415|NCT02783300|Experimental|Part 3: GSK3326595 in combination with pembrolizumab|Participants with selected solid tumors will be administered GSK3326595 in combination with pembrolizumab as part of this dose determination study.
89203416|NCT02781272||Women with a pelvic mass|Women diagnosed with a pelvic mass (ovarian, uterine, retroperitoneal, etc.) who are scheduled for an imaging guided biopsy, surgical biopsy or surgical excision for evaluation of their pelvic mass. Must have a pelvic imaging study performed within 60 days prior to surgery and a research blood draw within 30 days prior to surgery.
89483112|NCT02786953|Experimental|Sleep Promotion|Behavioral sleep-promoting intervention, including components such as limiting caffeine, establishing a media curfew, and positive bedtime routines, as well as needs unique to adolescents with T1D, such as fear of hypoglycemia.
89483113|NCT02786953|No Intervention|Usual Care|Usual Care
89483114|NCT02435836|Experimental|Aripiprazole|All subjects began open-label treatment with 30 mg aripiprazole on the first day of participation in the current trial. Once a subject stabilized at the 30 mg per day dose, the investigator could adjust the dose within the range of 10 to 30 mg per day as needed (throughout this long-term trial), to manage AEs.
89483115|NCT05004818|Sham Comparator|sham procedure|Participants with severe motion sickness were sited in the the rotatory chair with the videonystagmography recorder masking their eyes, while two galvanic vestibular stimulation electrodes were connected to the mastoid processes. No active stimulus was given.
89483116|NCT05004818|Experimental|GVS stimulation coupled with inverse phase rotatory chair stimulation|Participants with severe motion sickness were sited in the the rotatory chair with the videonystagmography recorder masking their eyes, while two galvanic vestibular stimulation electrodes were connected to the mastoid processes. The rotatory chair was activated in sinusoidal harmonic acceleration protocol in inverse phase to galvanic vestibular stimulation.
89483117|NCT02127385||IUGR|
89483118|NCT03075488|Active Comparator|Conventional landmark-guided technique|In this arm spinal anesthesia will be performed by using conventional cutaneous landmarks
89483119|NCT03075488|Experimental|Accuro device guided technique|In this arm spinal anesthesia will be performed only after having detected the intralaminar space, the mid-line, the depth and the orientation for spinal needle insertion with pre-procedural scan performed with Accuro device
89483120|NCT02127463|Experimental|MC-1101 active|Topical Drug 1% Ophthalmic Solution Topically, two times per day; morning and bedtime
89483121|NCT02127463|Placebo Comparator|MC-1101 Vehicle Control|"Topical Drug:~Ophthalmic Solution Topically, two times per day; morning and bedtime"
89483122|NCT03075722|Experimental|Saturn nasal mask|Participants to use nasal mask in-home for 7 ± 3 days
89483123|NCT05075265||Methadone Group|adult patients undergoing cardiac surgery with extracorporeal circulation
89483124|NCT02127541|Experimental|Ga -exendin PET/CT, In- exendin SPECT/CT, MRI|This is a cross-over study comparing three imaging methods (68Ga-DOTA-exendin-4 PET/CT, 111In-DOTA-exendin-4 SPECT/CT, MRI) in the same patient.
89483125|NCT05075343|Experimental|Custom foot orthoses (CFO)|Participants with a confirmed diagnosis of PsA and foot pain received and wore custom foot orthoses (CFO).
89483126|NCT03076892|Active Comparator|Conventional PDT|Aktilite® Galderma
89483127|NCT03076892|Experimental|PHOS ISTOS PDT|Light Emitting textile device
89483128|NCT02131285|Experimental|Sensory training|Experimental group received balance rehabilitation aimed at improving motor strategies and sensory strategies. Subjects in this group were treated to improve recovery of sensory impairment and were given exercises in the impaired sensory conditions, inhibiting the reliable sensory systems and forcing the Central Nervous System to use the impaired ones.
89483129|NCT02131285|No Intervention|No sensory strategy|Control group received usual care rehabilitation which did not include training of sensory strategies.
89483130|NCT03263871|Experimental|Intervention|PTM202 and micro-nutrient sprinkles
89483131|NCT03263871|Other|Control|micro-nutrient sprinkles
89483132|NCT02131363|Experimental|Ingrowing Toenail Treatment Kit|"Ingrowing Toenail Treatment Kit consists of 3 components:~Toe nail clip: one clip to be applied each week, for 6 weeks.~Aerosol spray: to be applied up to 5 times a day, no more than one spray per hour.~Nail adhesive: used to attach the clip to the nail."
89483133|NCT03077048|No Intervention|Low protein diet|Low protein diet with 0.6 g protein/kg BW/day (20-30% high biological value) and an energy intake of 30-35 kcal/kg BW/day
89483134|NCT03077048|Experimental|Supplemented low protein diet|Ketosteril® supplemented low protein diet (sLPD), (1 tablet/5 kg BW/day) with 0.6 g protein/kg BW/day (20-30% high biological value) and an energy intake of 30-35 kcal/kg BW/day
89483135|NCT02131441|Other|laparoscopic hepatectomy|laparoscopic hepatectomy
89483136|NCT02131441|Other|open liver resection|open liver resection
89483137|NCT05075499|Active Comparator|MS no immunomodulatory treatment|MS patients receiving no immunomodulatory treatment
89483138|NCT05075499|Active Comparator|MS Teriflunomide treatment|MS patients under treatment with Teriflunomide
89483139|NCT05075499|Active Comparator|MS Alemtuzumab treatment|MS patients under treatment with Alemtuzumab
89020820|NCT00319280|Experimental|2|Injectable calcium phosphate cement in osteotomysite
89020821|NCT00319280|Active Comparator|3|Local autograft in the osteotomysite serves as control
89020822|NCT00351078|Experimental|PTC124 PO|4-, 4-, and 8-mg/kg TID first 14 days of cycle 10-, 10-, and 20-mg/kg TID second 14 days of cycle 28 day study
89020823|NCT00319358|Active Comparator|Antioxidants|Intervention was done with antioxidants
89020824|NCT00319358|Placebo Comparator|Placebo|
89020825|NCT00346437|Experimental|1|Ad5FGF-4
89020826|NCT00346437|Experimental|2|Ad5FGF-4
89020827|NCT00346437|Placebo Comparator|3|Placebo
89020828|NCT00351117|Experimental|1|St. John's wort 300mg PO TID
89020829|NCT00351117|Placebo Comparator|2|Lactose in capsule matching the St. John's wort. 300mg PO TID
89020830|NCT00319826||1|Subjects with Staphylococcus Bacteremia
89020831|NCT00319826||2|Healthy (Non-infected) Control Subjects in the Nasal Carriage Group
89020832|NCT02959593|Experimental|Glaucoma patients|To view commercially available content through the VISIOR video goggles for thirty minutes
89483140|NCT03072758|Experimental|Men's Club Intervention Group|Participants randomized to this group will receive interventions from the study team.
89483141|NCT03072758|No Intervention|Men's Club Control Group|Male participants in the control group will receive only education pamphlets related to breastfeeding during the 3rd trimester of their female partner's pregnancy
89483142|NCT02131519||internal jugular vein catheter|pediatric patients required internal jugular vein catheter
89483143|NCT04992182|Experimental|Inactivated vaccine booster|One standard IM CoronaVac dose (0.5 mL)
89483144|NCT04992182|Experimental|mRNA vaccine booster|One standard IM BNT162b2 dose (0.3 mL)
89483145|NCT04992182|Experimental|Viral vector vaccine booster|One standard IM ChAdOx1 dose (0.5 mL)
89483146|NCT04992182|Placebo Comparator|Placebo|Saline solution IM (0.3 mL)
89483147|NCT05074797||covid not diabetic with AKI|AKI in pt with covid_19 not diabetic
89483148|NCT05074797||AKI in covid_19 in diabetic|AKI in covid_19 in diabetic pt
89483149|NCT05074797||covid_19 in diabetic|covid_19 in diabetic without AKI
89483150|NCT02131675||Boost shake|children that have had type 1 diabetes for more than 1 year
89483151|NCT03072524||Stroke patients|Stroke patients who will undergo the FAST PLUS test within 12 hours from the stroke onset.
89483152|NCT03267069||alcohol liver disease|Patients with alcohol liver disease consenting to participate in the study will be administered an initial survey at inclusion and then follow-up surveys at 3, 6, 9, 12, 15, and 18 month intervals and then 2, 5, and 10 years. There is no intervention cohort, all enrolled will complete the same surveys. Recidivism will be measured by responses to survey questions, clinical interviews documented in the chart, and urine ethnyl glucuronide or blood ethanol testing.
89483153|NCT02131831||cirrhosis|
89483154|NCT04998968||Patients with permanent hypoparathyroidism after total thyroidectomy|Patients with permanent hypoparathyroidism after total thyroidectomy for benign thyroid disease. These patients should be operated between 2005-2015 in Uppsala-Örebro healthcare region. Permanent hypoparathyroidism is defined as treatment with Calcium and/or vitamin D more than 12 months after surgery.
89483155|NCT04998968||Patients without permanent hypoparathyroidism after total thyroidectomy|Patients without permanent hypoparathyroidism after total thyroidectomy for benign thyroid disease. These patients should be operated between 2005-2015 in Uppsala-Örebro healthcare region.
89483156|NCT03266913|Active Comparator|Probiotic|Routine phototherapy plus probiotic oral drops at the dose of 10 drops daily
89483157|NCT03266913|No Intervention|No probiotic|Routine phototherapy
89483158|NCT02124655|Experimental|Essential oils/0.2% chlorhexidine/Sterile water|A) 20 ml rinses for 30 seconds with essential oils/2 times daily (1/0/1). -----14 days----- B) 10 mL rinses for 30 seconds with 0.2% chlorhexidine/2 times daily (1/0/1). -----14 days----- C) 20 mL rinses for 30 seconds with sterile water (1/0/1).
89483159|NCT04911140|Active Comparator|Photobiomodulation twice a week|This group will receive the application of photobiomodulation (PBM) twice a week for 4 weeks.
89483160|NCT04911140|Active Comparator|Photobiomodulation three times a week|This group will receive the application of photobiomodulation (PBM) three times a week for 4 weeks.
89483161|NCT04911140|Placebo Comparator|Simulated Photobiomodulation|This group will receive the application of simulated photobiomodulation (PBM) twice a week for 4 weeks.
89483162|NCT05075031||300 Newborn feeding on Breast Milk or Artificial Milk Formula rom birth to about 2 months of age|The electronic patient record of 300 Newborn feeding on Breast Milk or Artificial Milk Formula from birth to about 2 months of age would be examined and followed between March 2020 and October 2021 and compare their rates of Covid-19 infection, hospitalization and complications with the rates of the Control Groups
89483163|NCT05075031||300 Infant feeding on Breast Milk or Artificial Milk Formula from 2 months to 1 year|The electronic patient record of 300 Infant feeding on Breast Milk or Artificial Milk Formula from 2 months to 1 year would be examined and followed between March 2020 and October 2021 and compare their rates of Covid-19 infection, hospitalization and complications with the rates of the rates of the Control Groups
89483164|NCT05075031||300 child feeding on Breast Milk or Artificial Milk Formula from 1 year to 5 year|The electronic patient record of 300 child feeding on Breast Milk or Artificial Milk Formula from 1 year to 5 year would be examined and followed between March 2020 and October 2021 and compare their rates of Covid-19 infection, hospitalization and complications with the rates of the rates of the Control Groups
89483165|NCT05075031||300 child feeding on Breast Milk or Artificial Milk Formula from 5 year up to 15 year|The electronic patient record of 300 child feeding on Artificial Milk Formula or any source of DHA from 5 year up to 15 year would be examined and followed between March 2020 and October 2021 and compare their rates of Covid-19 infection, hospitalization and complications with the rates of the Control Groups
89483166|NCT05075031||Control Group|"The electronic patient record of 150 infant and child patients who feed on only cow's milk which does not provide a rich source of DHA and did not feed on any Artificial Milk Formula or any source of DHA would be examined and followed between March 2020 and October 2021 and compare their rates of Covid-19 infection, hospitalization and complications with the rates of the cohorts that feed on Breast Milk or Artificial Milk Formula~The electronic patient record of 150 adult patients from 15 years to 25 years who did not feed on any Artificial Milk Formula or any source of DHA would be examined and followed between March 2020 and October 2021"
89483167|NCT03263793|Experimental|Behavioral vocal training|12-week vocal training program will use maximum vocal function exercises targeting vocal deficits specific to Parkinson Disease.
89483168|NCT03075332|Experimental|protocol with physical exercise|Both groups underwent a combined training intervention consisting of aerobic and resisted exercises in the same training session
89483169|NCT03263715|Experimental|Tocilizumab|Tocilizumab-based regimen (Tocilizumab Prefilled Syringe [Actemra] 162 mg s.c. administered weekly) on top of rapidly tapered Glucocorticoid [Glucocorticoids]
89483170|NCT03263715|Placebo Comparator|Placebo|Placebo [Placebos] and rapidly tapered Glucocorticoid [Glucocorticoids] treatment
89483171|NCT02457039|Active Comparator|Comprehensive acupuncture (CAI)|Breast cancer patients receiving Cytoxan-containing chemotherapy regimens (Chemo) will receive Dense cranial electroacupuncture stimulation (DCEAS) and Body acupuncture (BA).
89483172|NCT02457039|Sham Comparator|Least acupuncture stimulation (LAS)|Breast cancer patients receiving Cytoxan-containing chemotherapy regimens (Chemo) will receive Least acupuncture stimulation (LAS)
89020833|NCT02959593|Experimental|Healthy subjects|To view commercially available content through the VISIOR video goggles for thirty minutes.
89020834|NCT00320099|Active Comparator|1|Hydrocortisone and convention glycemic control
89020835|NCT00320099|Experimental|2|Hydrocortisone and fludrocortisone and conventional glucose control
89483173|NCT03076580||cardiomyopathy|Patients are diagnosed as cardiomyopathy by three cardiologists and recruited in Beijing Anzhen Hospital, recording the results of clinical lab and echocardiography.
89483174|NCT03076580||disease control|Patients have similar symptoms with cardiomyopathy patients, and are further excluded by three cardiologists and recruited in Beijing Anzhen Hospital, recording the results of clinical lab and echocardiography.
89483175|NCT03076580||healthy control|Healthy subjects are recruited in Beijing Anzhen Hospital, with negative results of echocardiography and clinical lab examination.
89483176|NCT04998890|Experimental|Adventure-based cognitive behavioral intervention|An adventure-based cognitive behavioral intervention program A 13-session adventure-based cognitive behavioral intervention program, including 6 lectures, 5 workshops and adventure training (one adventure day camp (2 sessions) and adventure activities in the beginning of each workshop). One session per week, 3 hours for each session. A variety of cognitive behavioral skills were taught in lectures and these skills were practiced in two groups (with appropriately 20 students in each group) in workshop to help students to apply these skills to cope with their own daily life stress. Skill briefing, case demonstration and debriefing, group sharing and discussion, in-class exercise and homework were used in the intervention program.
89483177|NCT04998890|No Intervention|Control group|No intervention of the adventure-based cognitive behavioral program
89483178|NCT02459145|Active Comparator|Graduated Exercise Protocol|Intervention involves exercise starting at 50% of maximum age-adjusted heart rate (MHR) for 10 minutes (warm-up and Recovery)_ plus 5 minutes of target heart rate per day 5 days a week for 2 weeks, supervised by the athletic trainer or parent. The protocol increases the intensity of target heart rate by 10% MHR and duration of 50% MHR by 2 minutes every 2 weeks if there is no symptom exacerbation. The exercise protocol includes treadmill speed and track minutes per lap conversion, rate of perceived exertion and talk test for each stage of exercise plus total time to execute for 5 days each week.
89483179|NCT02459145|Other|Rest followed by Protocol|No activity in weeks 1 - 8. In week 9 we will begin their intervention phase as described in graduated exercise protocol
89483180|NCT04991636|Experimental|Protocol|Each patient agreeing to participate in the study will be distributed in the protocol group and will receive an angioscan according to the protocol in pre-operative and at the usual post-operative check-up within 3 months after the operation. The usual procedure, foresees an angioscanner with injection of contrast product and the measurement of the images is performed during a deep breath. In order to obtain a complete respiratory cycle, the study procedure foresees in addition to the usual procedure, an image measurement during a deep exhalation.
89483181|NCT04433624|Active Comparator|Group (B)|will receive The bilateral ESP blocks before surgery
89483182|NCT04433624|Active Comparator|Group B MG|will receive bilateral ESP blocks performed by each side) before surgery
89483183|NCT02788201|Experimental|Treatment Regimen|Treatment regimen selected by CO eXpression ExtrapolatioN (COXEN) model
89483184|NCT05004194|Experimental|Cold water caloric stimulation|50 cc of ice-cold water irrigation into the right ear at 1-2 cc/second, once per participant.
88821669|NCT03022487||ICD Patients with Ischaemic cardiomyopathy|A standard 30-minute electrophysiological (EP) cardiac stimulation protocol will be performed at the end of the ICD implant at baseline. Participants will be followed up for at least 12 months for endpoints.
89020836|NCT00320099|Experimental|3|Hydrocortisone and intensive insulin therapy
89483185|NCT04998656|Active Comparator|Werewolf FLOW 50 Group|The Werewolf FLOW 50 electrocautery device will be used during surgical treatment for patients assigned to this group.
89483186|NCT04998656|Placebo Comparator|Control Group|No electrocautery device will be used during surgical treatment for patients assigned to this group.
89483187|NCT03266679|Other|Patients receiving metacognition-based intervention|Case-Series Design - all participants receive the intervention - metacognition-based therapy (adapted version of Metacognitive Reflection and Insight Therapy developed by Lysaker & Klion) - weekly for a period of 12 months. No control/comparison group.
89483188|NCT02456740|Placebo Comparator|Placebo|Participants received placebo once a month (QM) by subcutaneous injection on day 1 and weeks 4, 8, 12, 16, and 20 in the 24-week double-blind treatment phase. At week 24, participants were re-randomized to receive either erenumab 70 mg or erenumab 140 mg, administered QM at weeks 24, 28, 32, 36, 40, 44, and 48, with actual dose blinded.
89483189|NCT02456740|Experimental|Erenumab 70 mg QM|Participants received erenumab 70 mg QM by subcutaneous injection on day 1 and weeks 4, 8, 12, 16, and 20 in the 24-week double-blind treatment phase. At week 24, participants were re-randomized to receive either erenumab 70 mg or erenumab 140 mg, administered QM at weeks 24, 28, 32, 36, 40, 44, and 48, with actual dose blinded.
89483190|NCT02456740|Experimental|Erenumab 140 mg QM|Participants received erenumab 140 mg QM by subcutaneous injection on day 1 and weeks 4, 8, 12, 16, and 20 in the 24-week double-blind treatment phase. At week 24, participants were re-randomized to receive either erenumab 70 mg or erenumab 140 mg, administered QM at weeks 24, 28, 32, 36, 40, 44, and 48, with actual dose blinded.
89483191|NCT03263403|Experimental|Test Group|"44 participants will be randomly assigned to the test group for receiving the locally produced meningococcal vaccine Ingovax ACWY (Incepta)."
89020837|NCT00320099|Experimental|4|hydrocortisone, fludrocortisone and intensive insulin therapy
89020838|NCT00346671|Placebo Comparator|Supine Rest|30min supine rest listening to soft music
89020839|NCT00346671|Sham Comparator|Sham Reiki|30 min intervention by sham practitioner
89020840|NCT00346671|Experimental|Reiki|30 min session with Reiki practitioner
89020841|NCT00320138|Active Comparator|Acupuncture|
89020842|NCT00320138|No Intervention|Wait List|Usual Care
89483192|NCT03263403|Active Comparator|Comparator Group|44 participants will be randomly assigned to the comparator group for receiving 'Quadri Meningo' (BiO-MeD Private Limited).
89483193|NCT03075098|Experimental|colposcopy of intraepithelial carcinoma|Digital colposcope will be used to detect the swede score of the lesion
89483194|NCT03266835|Other|SoundBite™ Crossing System - Peripheral|This is a multinational, single-arm, pivotal trial assessing the efficacy and safety of the SoundBite™ Crossing System with subjects diagnosed with de novo infrainguinal arterial chronic total occlusion(s).
89483195|NCT03550495|No Intervention|Control|Patients will undergo standard of care including the use of the ABCDEF bundle; psychiatry team will not be involved on daily ICU rounds.
89483196|NCT03550495|Experimental|Intervention|Patients will receive standard ICU care, including the use of the ABCDEF bundle, but will also receive the intervention of psychiatry involvement; the psychiatry team will participate in daily ICU rounds with the ICU team to help identify, prevent, and treat ICU delirium and identify other psychiatric disorders which may be otherwise undetected by the ICU team.
89483197|NCT05003492|Active Comparator|Combination Therapy plus Standard therapy|"Methylene Blue 1 mg/kg water solution. Participants will orally receive Methylene Blue solution of 1 mg/kg concentration one time if any. After 3 hours of Methylene Blue administration irradiation of chest using 650 nm laser source with 18 J/cm^2 energy dose will be performed.~Patients will be administered study medication (Inhaled 100-150 mg phenformin per day; or, if broken into 3 doses/day, 30-50 mg/dose. this dose well be once daily for 5 days, for a maximum of 7 days for those who remain hospitalized.~Patients will receive an Enriched Grape Juice containing 234.5 mmol microcrystalline KCl (a total of 6000 mg of K in 2 EGJ, but split into 2 intakes daily)~Patients received will receive Zinc gluconate capsule 15 mg x 2 per day during 14 days"
89483198|NCT05003492|Sham Comparator|Standard Therapy|Infected patients will receive the standard therapy for COVID-19 for 14 days
89483199|NCT03266601|Experimental|Recombinant Human Interferon α-2b Spray|
89483200|NCT03266601|Active Comparator|Ribavirin|
89020843|NCT00351390|Placebo Comparator|SOC|Standard of care HF therapy without NT-proBNP guidance
89020844|NCT00351390|Active Comparator|NT-proBNP arm|NT-proBNP plus standard HF management
89483201|NCT03266523||Control|The CONTROL (neutral) environment corresponds to the standard environment of the imaging waiting rooms
89483202|NCT03266523||Zen|The ZEN environment will represent a clean, minimalist nature
89537614|NCT03855137|Active Comparator|Atogepant 60 mg QD|Participants received atogepant 60 mg, orally, once daily (QD) along with atogepant-matching placebo 30 mg as morning dose followed by atogepant-matching placebo 30 mg and 60 mg as evening doses for up to 12 weeks in a DB treatment period.
88956523|NCT05000931|Experimental|To demonstrate the safety of the Osia 2 System in a pediatric population aged 5 - 11 years.|
88956524|NCT04998162|Experimental|SVF injection|All patients with ankle osteoarthritis will be treated with a single injection of SVF, obtained from the patient's abdominal adipose tissue. All patients will be examined with a baseline clinical visit and will be followed-up with clinical evaluation at 1, 3, 6, 12 and 24 months.
89020845|NCT00346749|Experimental|Arm 1|
89483203|NCT03266523||Green|The GREEN environment will represent rural landscapes, undergrowth
89483204|NCT03266523||Sea|The SEA environment will represent lakes, ponds, seaside
89483205|NCT03266211||Patients|People older than 65 years in the Auvergne-Rhônes-Alpes region who are consulting their general practitioner.
89483206|NCT03266211||General practitioner|General practitioner of the Auvergne-Rhônes-Alpes region
88956525|NCT04992624|Placebo Comparator|Placebo|
88956526|NCT04992624|Experimental|Cannabidiol (CBD)|Up to 150 mg/day.
89483207|NCT02131987||Dislocation|Patients operated with hip hemiarthroplasty for a femoral neck fracture with a postoperative dislocation of the prosthesis
89483208|NCT02131987||Non-dislocated|Patents without dislocation of a hemiarthroplasty for a femoral neck fracture
89483209|NCT02458755|Experimental|High-dose statin treatment|Atorvastatin (40mg) or Rosuvastatin (20mg)
89483210|NCT03551587|Experimental|Irrigant delivered by the Vibringe|"Experimental group:~The irrigant will be delivered and sonically activated with the Vibringe system."
89020846|NCT00346788|Experimental|MIS|minimally invasive incision
89020847|NCT00346788|Active Comparator|Standard|Standard incision length
89020848|NCT00419276|Experimental|Prolonged infusion|At least 100 hours of femoral perineural ropivacaine infusion.
89483211|NCT03551587|No Intervention|Irrigation by Conventional needle|"Control group:~Irrigation procedures will br performed with a conventional method using conventional gauge 24 needle."
89483212|NCT04462406|Experimental|Arm A (active surveillance)|Patients with a negative FDG-PET/CT scan or a positive FDG-PET/CT scan but with a negative biopsy for viable tumor discontinue the anti-PD-1 therapy and undergo active surveillance.
89483213|NCT04462406|Active Comparator|Arm B (nivolumab, pembrolizumab, ipilimumab)|Patients with a positive FDG-PET/CT scan and positive biopsy for viable tumor or a positive FDG-PET/CT scan and biopsy not performed continue their standard of care anti-PD-1 therapy for 12 months in the absence of disease progression or unacceptable toxicity.
89483214|NCT04462406|Other|Standard of Care (nivolumab, pembrolizumab, ipilimumab)|Patients continue their standard of care anti-PD-1 therapy. Treatment may consist of the following regimens: 1) nivolumab IV over 30 minutes Q2W or Q4W; 2) pembrolizumab IV over 30 minutes Q3W or Q6W; 3) nivolumab IV over 30 minutes and ipilimumab IV Q3W for 4 doses followed by nivolumab IV over 30 minutes Q2W or Q4W; or 4) pembrolizumab IV over 30 minutes and ipilimumab IV Q3W for 4 doses followed by pembrolizumab IV over 30 minutes Q3W or Q6W. Treatment continues until 52 weeks from start of standard of care anti-PD-1 therapy in the absence of disease progression or unacceptable toxicity.
89483215|NCT02400580|Experimental|Intravenous IV acetaminophen|The patients in the treatment arm will receive 1000mg of IV acetaminophen.
89483216|NCT02400580|Placebo Comparator|Normal Saline|The patients in the placebo arm will receive normal saline.
89483217|NCT02132065|No Intervention|Standard pain keller|
89483218|NCT02132065|Experimental|TAP block|Patients will be scheduled to receive routine analgesic and an unilaterally dual TAP block with 2 points injections of 15 ml of 0,375 % Ropivacain( in total 30 ml 0,375% Ropivacain) in the same side of nephrectomy.
89483219|NCT03262857|Experimental|time of start of anesthesia|
89483220|NCT03262857|Experimental|intensity of anesthesia|
89483221|NCT02132143|Experimental|Progression-free survival&Concurrent chemoradiotherapy|"The first day of radiotherapy given pemetrexed(Powder for Injection) 500mg/m2 + cisplatin(Powder for Injection) 75mg/m2, two cycles of chemotherapy given during radiotherapy; then continue to give two cycles of consolidation chemotherapy, 21 days as a cycle.~Intensity-modulated radiation therapy(IMRT),5000cGy～6000cGy/5～6W."
89483222|NCT02132143|Active Comparator|Progression-free survival&sequential chemoradiotherapy|Patients received adjuvant chemotherapy for four cycles,pemetrexed(Powder for Injection) 500mg/m2 + cisplatin(Powder for Injection) 75mg/m2, 21 days as a cycle.Then accept the Intensity-modulated radiation therapy(IMRT),5000cGy～6000cGy/5～6W.
89483223|NCT02260609|Other|Open-Label|Grafix®: Cryopreserved Placental Membrane
89483224|NCT05074329|Active Comparator|Active|Subjects randomized to the Active group, programming parameters will be set, and therapy will be delivered for a minimum of 2-hours per day for the duration of the study.
89483225|NCT05074329|Placebo Comparator|Delayed|The delayed group will begin 2-hour stimulation/day at the 3-Month visit.
89483226|NCT02127697|Experimental|NVA237|Participants will receive NVA237 once daily in addition to their background therapy during the 52- week treatment period. All participants will receive salbutamol/ albuterol as rescue medication.
88952236|NCT05523336||Paediatric patients receiving HCTS without infectious complications post HCTS|Paediatric patients receiving HCTS without infectious complications post HCTS
88952237|NCT05519735|Other|Multimodal imaging|Multimodal imaging approach. This includes a CXCR4 targeted PET/CT ([68Ga]Pentixafor) during the acute hospital stay, and serial CMR and Echo imaging.
88952238|NCT05515653||Case - atherosclerotic cardiovascular disease|Patients with the first atherosclerotic cardiovascular event (Acute Myocardial Infarction, Stroke and Peripheral Artery Thrombotic-Ischemic Events)
88952239|NCT05515653||Control - without atherosclerotic cardiovascular disease ou healthy|Patients who sought medical care at the same site as cases without atherosclerotic cardiovascular event (Acute Myocardial Infarction, Stroke and Peripheral Artery Thrombotic-Ischemic Events) or healthy individuals
88952240|NCT05510063|Experimental|Switched between Humira and SB5|All subjects will receive an initial dose of Humira 80 mg at Week 0, followed by Humira 40 mg every other week starting one week after the initial dose up to Week 11. From Week 13, the subjects will switch between Humira and SB5 up to Week 23.
88952241|NCT05510063|Active Comparator|Continued on Humira|All subjects will receive an initial dose of Humira 80 mg at Week 0, followed by Humira 40 mg every other week starting one week after the initial dose up to Week 23.
88956527|NCT04992624|Experimental|Tetrahydrocannabinol (THC)|Up to 10 mg/day.
88956528|NCT04992624|Experimental|CBD plus THC|Up to 150 mg/day CBD plus up to 10 mg/day THC.
89483227|NCT02127697|Placebo Comparator|Placebo|Participants will receive placebo to NVA237 in addition to their background therapy during the 52-week treatment period. All participants will receive salbutamol/ albuterol as rescue medication.
89483228|NCT05074095||1|Patients with urogenital injuries
89483229|NCT05074095||2|Patients without urogenital injuries
89483230|NCT02127775|Experimental|Sequence B|Day 1: Lesinurad 400 mg (manufactured at Site 2); Day 5: Lesinurad 400 mg (manufactured at Site 1)
89483231|NCT02127775|Experimental|Sequence A|Day 1: Lesinurad 400 mg (manufactured at Site 1); Day 5: Lesinurad 400 mg (manufactured at Site 2)
89483232|NCT03266133|Experimental|Sleep Education Intervention|This is a two-session program designed to educate patients about healthy sleep in respect to timing, regularity, efficiency, and duration in order to promote sleep during pregnancy.
89483233|NCT03266133|No Intervention|Routine Care|Usual care
89483234|NCT02124967|Experimental|Exercise|A one hour exercise session which includes both aerobic activity and resistance training
89537615|NCT02214719|Experimental|Baseline observation for EASI-IDM use|Baseline observation period to gather information on current practice about diabetes care
89537616|NCT03756077||Primary diagnosis and staging|Patients suspected of or diagnosed with prostate cancer who want a differential diagnosis and staging by 68Ga-PSMA-11 and/or 18F-FDG PET/MR, PET/CT before treatment
89020849|NCT00419276|Placebo Comparator|Standard-of-Care|Overnight femoral perineural ropivacaine infusion followed by a femoral perineural normal saline infusion (placebo) until postoperative day 4.
89483235|NCT02252341|Placebo Comparator|placebo|"Dietary Supplement: N-Acetyl-Cysteine Phase 4 Study Type: Interventional Study Design: Treatment, Parallel Assignment, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Randomized, Efficacy Study~Primary Outcome Measure:~Hamilton Depression Rating Scale [Time Frame: baseline, 1, 2, 3 months] [Designated as safety issue: Yes]~Secondary Outcome Measures:~Carbon Oxide exhalation [Time Frame: basal, 1, 2, 3 months] [Designated as safety issue: Yes]~Other Pre-specified Outcome Measures:~Biological outcome measures [Time Frame: baseline and 3 months] [Designated as safety issue: Yes] inflammatory and oxidative stress biomarkers N-Acetyl-cysteine 1800 mg / day will be taken for 12 weeks versus placebo 12 weeks."
89483236|NCT02252341|Placebo Comparator|N-Acetyl-Cysteine|"Study Type: Interventional Study Design: Treatment, Parallel Assignment, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Randomized, Efficacy Study~Official Title: Effects of N-Acetyl-Cysteine on Oxidative Stress Biomarkers in Bipolar Patients With and Without Tobacco Use Disorder~Primary Outcome Measure:~Hamilton Depression Rating Scale [Time Frame: baseline] [Designated as safety issue: Yes]~Secondary Outcome Measures:~Carbon Oxide exhalation [Time Frame: basal, 1, 2, 3 months] [Designated as safety issue: Yes]~Other Pre-specified Outcome Measures:~Biological outcome measures [Time Frame: baseline and 3 months] [Designated as safety issue: Yes] inflammatory and oxidative stress biomarkers~Placebo will be taken for 12 weeks."
89483237|NCT03266367||patients|NGAL and renal functions will be measured two hours after Percutaneous coronary intervention and two days later as a follow up
89483238|NCT03266367||Healthy Group|control group
89483239|NCT02127853|Experimental|Gabapentin|gabapentin pretreatment
89483240|NCT02127853|Placebo Comparator|Placebo|placebo drug pretreatment
89483241|NCT03263013||FMD patients|patients with a diagnosis of clinically definite FMD who have been assessed at the HMCS clinic, and who have completed protocol 07-N-0190.
89483242|NCT03266445|Active Comparator|FULL-BUPRENORPHINE|Participants will be randomly assigned to be maintained on their daily dose of buprenorphine/naloxone
89483243|NCT03266445|No Intervention|LOW-BUPRENORPHINE (control)|Participants will be randomly assigned to have their daily dose of buprenorphine/naloxone reduced to 8mg on the day of surgery
89483244|NCT03550339|Active Comparator|SURG|subjects attending bariatric surgery
89483245|NCT03550339|Active Comparator|DIET|subjects attending dietary weight loss program
89483246|NCT03550339|Active Comparator|HAES|subjects attending Health At Every Size weight management program
89483247|NCT02458833|Experimental|Intervention|Behavioral: Home Plate intervention
89483248|NCT02458833|Experimental|Delayed Entry Control|This Arm will receive the Home Plate intervention 3 months after the Intervention Arm completes the intervention.
89483249|NCT02125045|Experimental|L-GSH|Glutathione 100 mg tablets twice a day
89483250|NCT02125045|Placebo Comparator|Placebo|Matching placebo will be administered for 4 weeks in a double blind fashion.
89483251|NCT02456805|Active Comparator|Infant Formula 1|A standard commercial milk-based infant formula
89020850|NCT00351429|Experimental|1|
89020851|NCT00320567|Experimental|001|norgestimate/ethinyl estradiol
89020852|NCT00320684||1|Women who have had anorexia nervosa but are now maintaining a healthy weight
89020853|NCT00320684||2|Women who have never had anorexia nervosa and are maintaining a healthy weight
89020854|NCT00346944|Experimental|Treatment group|
89020855|NCT00346944|No Intervention|Reference group|
89020856|NCT00346983|Experimental|A|
89020857|NCT00346983|Placebo Comparator|B|
89483252|NCT02456805|Experimental|Infant Formula 2|A standard commercial soy-based infant formula.
89483253|NCT03265977|Experimental|H56:IC31|5 ug H56/500 nmol IC31, 0.5 mL Intramuscular (IM), Days 0 and 56
89483254|NCT03265977|Placebo Comparator|Placebo|Normal saline, 0.5 mL IM, Days 0 and 56
89483255|NCT03550105|Experimental|GJ-Only|Study Subjects with Baseline Glucose of > 150mg/dl, will have Gentle Jogger Only for 7 days
89483256|NCT03550105|Experimental|GJ-OGTT|Study Subjects with Baseline Glucose of < 150mg/dl, will have Oral Glucose Tolerance Test (OGTT) at baseline and after 7 days of Gentle Jogger
89483257|NCT03263169||WE Health Tapestry|Completion of baseline measures then enrolled in a community-based personalized care intervention that consists of four core elements: volunteer support, interprofessional care, technology, social network linkage
89483258|NCT03263169||Usual Care|Completion of baseline measures with six-month delayed community-based personalized care intervention: volunteer support, interprofessional care, technology, social network linkage
89483259|NCT03550027|Experimental|PleurX|Positioning of Pleurx drainage during surgical exploration if lung does not reinflate
89483260|NCT03550027|Experimental|Pleurocath|Positioning of Pleur o cath drainage during surgical exploration if lung does not reinflate
89483261|NCT03265743||Patients with Cystic Fibrosis|Patients with Cystic Fibrosis, followed in a pediatric or mixed Cystic Fibrosis center of the region Auvergne Rhône Alpes (AuRA), aged 11 years or older.
89483262|NCT01367119|Active Comparator|Ketamine|Subjects were dosed with approximately 1.0 mg/kg, using ketamine as anesthetic prior to electroconvulsive therapy (ECT).
89537617|NCT03756077||Evaluation of recurrence|Patients with a history of prostate cancer and elevated PSA level after treatment, who need to determining whether or not there are recurrences/metastatic lesions and its locations by 68Ga-PSMA-11 and/or 18F-FDG PET/MR, PET/CT
89537618|NCT04535063|Other|severe pneumonia arm|patients with severe COVID19 pneumonia defined by: spontaneous breathing patients with respiratory failure requiring O2 nasal cannula more than 3 L/min or reservoir oxygen mask and SaO2 less than 95% or patients with critical pneumonia define by mechanical ventilation with less than 300 mmHg PaO2/FiO2 or shock or multi-organic dysfunction
89537619|NCT03742193|Experimental|Apatinib + GD group|Apatinib + GD regimen. For unilateral metastases,3 cycles before metastasectomy, and 4 cycles after. For bilateral metastases, 3 cycles before first metastasectomy, 1 cycle inbetween, and then second metastasectomy followed by 4 cycles. Apatinib monotherapy is then maintained until 1 year following complete resection.
89537620|NCT02462135|Experimental|Virtual interactive memory training|Training sessions of the VIMT group are divided into initial training and booster training. Each training session is 45 minutes/day, 3 sessions/week, for 12 weeks for both initial training and booster training (36 sessions each).
89537621|NCT02462135|Active Comparator|Passive information activities|The training of active control group is the same as VIMT group (45 min/day, 3 days/week, for 12 weeks, for a total of 36 sessions). The active control group receives only the initial training.
89537622|NCT03108287|Active Comparator|RAK therapy|rabeprazole+amoxicillin+clarithromycin
89537623|NCT03108287|Active Comparator|RBAK therapy|rabeprazole+amoxicillin+clarithromycin+bismuth subcitrate
89537624|NCT03108209|Experimental|single arm|Signle arm study. Every subjects apply Photoderm Max lait SPF50+ and Photoderm stick SPF50+
89537625|NCT02461823|Experimental|Z Crown|A Zirconia crown will be provided to patients.
89537626|NCT02461823|Active Comparator|PFM Crown|A Porcelain metal crown will provided to patients.
89537627|NCT02461979|Other|Hepatocellular carcinoma (HCC)|The VDR genotype in 20 HCV cirrhotic patient with HCC
89537628|NCT02461979|Other|Liver cirrhosis|The VDR genotype in 20 HCV cirrhotic patient without HCC
88952242|NCT05509998|Active Comparator|Screening Method (SM)|In the SM condition all consecutive incoming patients ages 12-30 entering mental health services will complete a self-report screener, the PQ-B on intake. The intake clinician will review the PQ-B and refer all patients who endorse 6 or more items for evaluation with the SIPS to determine whether the patient meets criteria for psychosis, CHR, or neither. Evaluating clinicians will meet with patients to discuss findings and make referrals to specialty care as appropriate. The evaluating clinician will follow-up with patients referred to CSC and CHR programs to determine date of initial engagement. This information will be corroborated with records from CHR and FEP programs.
88952243|NCT05509998|Experimental|Screening and Communication Method (SCM)|In the SCM condition, the same screening and evaluation procedures described above will continue, but clinicians conducting evaluations and making referrals will be trained to discuss findings and provide referrals using the ComPsych model. Following the evaluation, the clinician who conducted the evaluation will schedule a session with the patient, their family, and their treatment team (as applicable) and use the ComPsych model to discuss the findings of the evaluation, provide psychoeducation, and make referrals to specialty FEP or CHR services, as appropriate. The evaluating clinician will follow-up with patients referred to CSC and CHR programs to determine date of initial engagement. This information will be corroborated with records from CHR and FEP programs.
88952244|NCT05508815|Experimental|Modified Zhiwang Decoction Combined with Methotrexate|
88952245|NCT05508815|Active Comparator|Methotrexate|
88952246|NCT05505175||Breast Cancer Patients|Eligible patients including patients with a potential follow-up period of 6 months following the index date
88952247|NCT05501912|Experimental|Monotherapy Dose Escalation and Dose Expansion|In US studies, dose escalation started at a 25 mg BID dose and subsequent dose-escalation groups included: 50 mg BID, 100 mg BID, 150 mg BID, 225 mg BID and 325 mg BID. In this study, the actual dose escalation will be based on a priming dose one level below the highest safe dose or two levels below the MTD that has been tested in US clinical trials when the enrolment of the China study actually initiates, and subsequent escalated doses may be adjusted as appropriate (e.g., the escalated doses following 150 mg BID in the China study may be adjusted to 200 mg BID, 250 mg BID and 300 mg BID. The actual priming dose and subsequent escalated doses for the China study are determined by the SMC) The dose expansion stage in this study will be initiated at the MTD or the optimal dose determined by the SMC as a fixed dose level (MTD or the optimal dose needs to be reviewed by the SMC and subjects are safe and tolerable at that dose level).
88952248|NCT05471726|Experimental|Prospective audit-and-feedback at discharge|When hospitals are in the intervention arm, they will perform the audit-and-feedback process focused on patients receiving antimicrobials who have an anticipated discharge.
88952249|NCT05471726|No Intervention|Standard of care|When hospitals are in the control arm, they will not perform a stewardship process that focuses on hospital discharge.
88952250|NCT05463861|Active Comparator|Lemborexant|Patients receive Lemborexant 5mg for 7 days and may be dose adjusted to 10mg. Patients continue to take Lemborexant 5mg or 10 mg for an additional 7 days.
88952251|NCT05463861|Placebo Comparator|Placebo|Patients receive placebo to match Lemborexant for 14 days.
89020858|NCT00347100|Experimental|1|Administration of Insulin Glargine and Sulfonylurea or Metformin
89020859|NCT00347100|Active Comparator|2|Administration of Sulfonylurea or Metformin + a second Oral Anti Diabetic (OAD) among Glyburide, Glyclazide,Glimiperide,Glipizide or Metformin
89020860|NCT00347139|Experimental|GW642444|
89537629|NCT02461979|Other|Control group|The The VDR genotype in 10 healthy individuals as control
89537630|NCT02461121|Experimental|MST（microtransplantation）|The microtransplantation conditioning regimen included high-dose Ara-C chemotherapy (2.0 to 2.5 g/m2 per 12 hours intravenously on days -4 to -2) followed by an infusion of HLA mismatched stem cell 24 hours (day 0) after the completion of cytarabine.
89537631|NCT02461121|Active Comparator|NST（nonmyeloablative transplantation）|The NST（nonmyeloablative transplantation）conditioning regimen consisted of 30 mg/m2/d fludarabine for days -6 to -2, 1.5-2 mg/kg/d anti-lymphocyte globulin for days -5 to -2, 40 mg/kg/d cyclophosphamide for days -4 and -2 and 2.0-3.0 g/m2/d cytarabine for days -6 to -4，followed by an infusion of HLA matched stem cell after the completion of regimen. The GVHD prophylaxis included cyclosporine A and mycophenolate mofetil
89537632|NCT03297047|Active Comparator|upper arm combi cast|standardized treatment
88952252|NCT05462210|No Intervention|Control group|The first mobilization of patients undergoing surgical treatment for lumbar disc herniation in the clinics where the study will be conducted is routinely performed within the first 24 hours after surgery. When the data collection process of the control group is completed, the data will be integrated with the mobilization protocol assisted with simulated clinical immersion videos created for the research.
89483263|NCT01367119|Active Comparator|Methohexital|Subjects were dosed with approximately 1.0 mg/kg, using methohexital as anesthetic prior to electroconvulsive therapy.
89483264|NCT05068011||Spinal cord stimulation|Patients will receive differential target multiplexed spinal cord stimulation
89483265|NCT05066685||All Participants|All the particpants enrolled in the brolucizumab Patient Support Services (PSS) program
89483266|NCT02252107|Experimental|Decitabine|Single arm study: the addition of 10 days (20 mg/m2) decitabine to the conditioning regimen prior to allogeneic hematopoietic transplantation.
89483267|NCT03262545|Experimental|experimental group|apatinib 500 mg p.o. once daily
89483268|NCT03262545|Placebo Comparator|control group|placebo p.o. once daily
89483269|NCT02128009||osteoporosis,non-osteoporosis|
89483270|NCT02125123|Experimental|Nutritional Supplement and Counseling|Two servings a day; ready-to-feed nutritional supplement plus dietary counseling
89203417|NCT04293484|Experimental|Real tDCS - Real tDCS|10 sessions of anodal bilateral motor cortex and cathodal spinal transcranial direct current stimulation (5 days/week for 2 weeks) followed by an open-label 10 sessions of anodal cerebellar and cathodal spinal transcranial direct current stimulation (5 days/week for 2 weeks)
89203418|NCT04293484|Sham Comparator|Sham tDCS - Real tDCS|10 sessions of sham bilateral motor cortex and sham spinal transcranial direct current stimulation (5 days/week for 2 weeks) followed by an open-label 10 sessions of anodal cerebellar and cathodal spinal transcranial direct current stimulation (5 days/week for 2 weeks)
89483271|NCT02125123|Active Comparator|Counseling|Dietary Counseling
89483272|NCT03262077|Experimental|MB 1 min|Methylene blue 100 μM photosensitizer was deposited in the periodontal pocket of one incisor and 1 min of pre-irradiation time was adopted to allow the drug to stain the bacterial biofilm. Then the laser emitting wavelength of 660 nm, with power of 100 mW, was applied to the mucosa during 1 min.
89483273|NCT03262077|Experimental|MB 3 min|Methylene blue 100 μM photosensitizer was deposited in the periodontal pocket of one incisor and 1 min of pre-irradiation time was adopted to allow the drug to stain the bacterial biofilm. Then the laser emitting wavelength of 660 nm, with power of 100 mW, was applied to the mucosa during 3 min.
89483274|NCT03262077|Experimental|MB 5 min|Methylene blue 100 μM photosensitizer was deposited in the periodontal pocket of one incisor and 1 min of pre-irradiation time was adopted to allow the drug to stain the bacterial biofilm. Then the laser emitting wavelength of 660 nm, with power of 100 mW, was applied to the mucosa during 5 min.
89483275|NCT03262077|Experimental|MBS 1 min|Methylene blue photosensitizer 100 μM + soap was deposited in the periodontal pocket of one incisor and 1 min of pre-irradiation time was adopted to allow the drug to stain the bacterial biofilm. Then the laser emitting wavelength of 660 nm, with power of 100 mW, was applied to the mucosa during 1 min.
89483276|NCT03262077|Experimental|MBS 3 min|Methylene blue photosensitizer 100 μM + soap was deposited in the periodontal pocket of one incisor and 1 min of pre-irradiation time was adopted to allow the drug to stain the bacterial biofilm. Then the laser emitting wavelength of 660 nm, with power of 100 mW, was applied to the mucosa during 3 min.
89483277|NCT03262077|Experimental|MBS 5 min|Methylene blue photosensitizer 100 μM + soap was deposited in the periodontal pocket of one incisor and 1 min of pre-irradiation time was adopted to allow the drug to stain the bacterial biofilm. Then the laser emitting wavelength of 660 nm, with power of 100 mW, was applied to the mucosa during 5 min.
89537633|NCT03297047|Experimental|forearm combi cast|Treatment with a forearm combi cast should be a sufficient immobilization
88952253|NCT05462210|Experimental|Intervention group|Mobilization Protocol Assisted with Simulated Clinical Immersion Videos Simulated clinical immersion videos created for the mobilization protocol for patients in the intervention group will be sent to their smartphones once they are admitted to the clinic. The videos prepared within the scope of the mobilization protocol will be watched by patients in company with the researcher the day before the operation, their questions will be answered, and the correct mobilization techniques will be shown practically. It is expected that patients watch the videos at least four times, as twice with the researcher and twice by themselves.
88952254|NCT05458947|Experimental|pulsed wound irrigation (PWI)|The necrotic wound is irrigated with normal saline (0.9%) with an 8-12 pounds per square inch pressure (PSI) to provide a mechanical force to loosen necrotic tissue for wound healing
88952255|NCT05458947|Experimental|electrical stimulation (ES)|ES works to promote the migration of cells based on natural cell polarity known as galvanotaxis, enhancing and mimicking the natural current of injury. By recreating the natural electrical fields of the skin, ES attracts immune cells vital to healing to wound to facilitate wound closure
89020861|NCT00347139|Active Comparator|Salmeterol|
88952256|NCT05458947|Experimental|electrical stimulation (ES) and pulsed wound irrigation (PWI)|The necrotic wound is irrigated with normal saline (0.9%) with an 8-12 pounds per square inch pressure (PSI) to provide a mechanical force to loosen necrotic tissue for wound healing and ES to promote the migration of cells based on natural cell polarity known as galvanotaxis, enhancing and mimicking the natural current of injury. By recreating the natural electrical fields of the skin, ES attracts immune cells vital to healing to wound to facilitate wound closure
89020862|NCT00321074|Active Comparator|1|
89020863|NCT00321074|Experimental|2|
89203419|NCT05355922|Sham Comparator|Aussie current (placebo) and Exercises|
89203420|NCT05355922|Experimental|Aussie current and Exercises|
89203421|NCT00675506|Experimental|1|Participants will receive treatment with growth hormone releasing hormone 1-44 (TH9507).
89203422|NCT00675506|Placebo Comparator|2|Participants will receive treatment with placebo medication.
89537634|NCT01846091|Experimental|Treatment (MV-NIS)|Patients receive oncolytic measles virus encoding thyroidal sodium iodide symporter IT on day 1.
89483278|NCT03551119|Experimental|Exercise|"Personnel experienced in training people with chronic conditions (exercise specialist) will supervise the exercise training. At each in-center session in phase 1, the patient's exercise will be monitored to assess whether they are achieving target levels. Training intensities will be prescribed based on the most recent exercise test.~Phase 1: an eight-week program of once weekly-supervised facility-based exercise sessions and twice weekly home-based sessions.~Phase 2: a 16-week home-based exercise program overseen by an exercise specialist. During this phase, participants will be progressed through their home-based exercise program from Phase 1 on an individual basis.~i. Frequency. A minimum of three exercise sessions per week. ii. Intensity. A moderate intensity (40-60% heart rate reserve) based on exercise testing.~iii. Time. 150 minutes of exercise per week. iv. Type. We will prescribe aerobic exercise supplemented with isometric resistance exercises."
88952257|NCT05442021|Experimental|Neubie Direct Current Electrical Stimulation|The experimental group subjects follow with 12 sessions of physical therapy over a 6-week period which include: a 30-min foot bath session using the Neubie and 15-min of various physical therapy exercises.
88952258|NCT05442021|Other|Transcutaneous Electrical Nerve Stimulation|The control group subjects follow with 12 sessions of physical therapy over a 6-week period which include: a 30-min footbath with TENS and 15-min of various physical therapy exercises.
89483279|NCT03551119|Other|Enhanced usual care|Participants in the control group will perform accelerometry. This is enhanced usual care because physical activity measurement is not routinely performed in CKD clinics. Control arm participants will only receive their accelerometry data after they have completed the study.
89483280|NCT03265899|Experimental|Oxytocin|40 IU Oxytocin, intranasal application 30 min prior to the experiment
89483281|NCT03265899|Placebo Comparator|Placebo|sodium chloride solution, intranasal application 30 min prior to the experiment
89483282|NCT04460846|Active Comparator|Alkaline water|Participants will consume 1.5 liters per day
89483283|NCT04460846|Placebo Comparator|Reverse osmosis water|Participants will consume 1.5 liters per day
89483284|NCT02132221|Experimental|Cognitive Behavioral Therapy (CBT)|cognitive therapy (10 weekly sessions)
89483285|NCT02132221|No Intervention|no CBT- wait list|no cognitive therapy
89483286|NCT03265587||Orientation 1|Nursing staff allocated to a bed space with orientation 1
89483287|NCT03265587||Orientation 2|Nursing staff allocated to a bed space with orientation 2
89483288|NCT03265587||Floater / Control group|Nursing staff not allocated to a bed space with an orientation.
89483289|NCT04459988||Patients with MS|Patients with MS who have been newly prescribed Ocrevus
89483290|NCT04459988||Healthy Controls|Healthy Controls
89483291|NCT02132299|Experimental|Group 1|Three volunteers will receive 3 ascending doses of PfSPZ Vaccine by IV administration four weeks apart. The three doses are 3x10^4, 1.35x10^5, and 2.7x10^5 PfSPZ. This is the safety group that will be inoculated first before all others for demonstration of safety and will be followed up for assessment of safety after the completion of the three doses. The follow up will be at weeks 1, 2, 4, 8 and 24 after completion of vaccination. Volunteers in Group 1 will not undergo CHMI. Group 1 is unblinded.
89483292|NCT02132299|Experimental|Group 2(A)|Group 2: Two sub groups: 2A and 2B. Grp 2A (n=20) receives 5 vaccinations IV of 1.35x10^5 PfSPZ Vaccine; 4 doses at 4 wk intervals; 5th dose at 8 wks after 4th dose. Grp 2 starts 1 wk after Grp 1 has completed 2nd dose; and received clearance from Safety Monitoring Committee (SMC). Grp 2 starts with 4 volunteers (3 safety + 1 placebo control to maintain blinding) receiving their first doses (at each dosing time point) before the remaining 20 volunteers in Grp 2. The remaining 20 volunteers start inoculations 48 hrs after first 4 safety volunteers at each dosing time point. Three weeks after last immunization, Grp 2 will undergo the first CHMI by IV injection of 3.2x10^3 PfSPZ Challenge (NF54). 24 weeks after the last immunization, volunteers from Grp 2 who underwent the first CHMI and did not become infected will have a second CHMI by IV injection of 3.2x10^3 PfSPZ Challenge (NF54).
89483293|NCT02132299|Placebo Comparator|Group 2(B)|Group 2: Two sub groups: 2A and 2B. Grp 2B (n=4) receives 5 placebo injections of normal saline (NS) by IV administration; 4 doses at 4 wk intervals; 5th dose at 8 wks after 4th dose. Grp 2 starts 1 wk after Grp 1 has completed 2nd dose; and received clearance from Safety Monitoring Committee (SMC). Grp 2 starts with 4 volunteers (3 safety + 1 placebo control to maintain blinding) receiving their first doses (at each dosing time point) before the remaining 20 volunteers in Grp 2. The remaining 20 volunteers start inoculations 48 hrs after first 4 safety volunteers at each dosing time point. Three weeks after last placebo injection, Grp 2 will undergo the first CHMI by IV injection of 3.2x10^3 PfSPZ Challenge (NF54).
89483294|NCT02132299|Experimental|Group 3(A)|Group 3: Two sub groups: 3A and 3B. Grp 3A (n=20) receives 5 vaccinations IV of 2.7x10^5 PfSPZ Vaccine; 4 doses at 4 wk intervals; 5th dose at 8 wks after 4th dose. Grp 3 starts 1 wk after Grp 1 has completed 3rd dose; and received clearance from Safety Monitoring Committee (SMC). Grp 3 starts with 4 volunteers (3 safety + 1 placebo control to maintain blinding) receiving their first doses (at each dosing time point) before the remaining 20 volunteers in Grp 3. The remaining 20 volunteers start inoculations 48 hrs after first 4 safety volunteers at each dosing time point. Three weeks after last immunization, Grp 3 will undergo the first CHMI by IV injection of 3.2x10^3 PfSPZ Challenge (NF54). 24 weeks after the last immunization, volunteers from Grp 3 who underwent the first CHMI and did not become infected will have a second CHMI by IV injection of 3.2x10^3 PfSPZ Challenge (NF54).
88952259|NCT05375032|Experimental|Cycling combined with cognitive tasks|
88952260|NCT05375032|Active Comparator|Cycling|
88952261|NCT05365516|No Intervention|Medical Safety Huddles - Pre-implementation|
88952262|NCT05365516|Experimental|Medical Safety Huddles - Post-implementation|
88952263|NCT05333263|Experimental|Balance assessment on specialized treadmill|Subjects will undergo a balance assessment on a microprocessor-controlled treadmill
88952264|NCT05323708|Experimental|Bmab 1000, A single 60 mg dose of Bmab 1000 administered by subcutaneous injection.|
88952265|NCT05323708|Active Comparator|Prolia®, A single 60 mg dose of Prolia® administered by subcutaneous injection.|
89020864|NCT00321113|Active Comparator|1|oral
89020865|NCT00321113|Experimental|2|oral
89020866|NCT00321152|Experimental|1|Deplin/Deplin = participants will receive 7.5 mg/day of Deplin (6(S)-5-MTHF)for the first 4 weeks, and then 15 mg/day of Deplin for the next 4 weeks.
89020867|NCT00321152|Experimental|2|placebo/Deplin = participants will receive placebo for the first 4 weeks, and then 7.5 mg/day of Deplin (6(S)-5-MTHF) for the next 4 weeks.
89483295|NCT02132299|Placebo Comparator|Group 3(B)|Group 3: Two sub groups: 3A and 3B. Grp 3B (n=4) receives 5 placebo injections of normal saline (NS) by IV administration; 4 doses at 4 wk intervals; 5th dose at 8 wks after 4th dose. Grp 3 starts 1 wk after Grp 1 has completed 3rd dose; and received clearance from Safety Monitoring Committee (SMC). Grp 3 starts with 4 volunteers (3 safety + 1 placebo control to maintain blinding) receiving their first doses (at each dosing time point) before the remaining 20 volunteers in Grp 3. The remaining 20 volunteers start inoculations 48 hrs after first 4 safety volunteers at each dosing time point. Three weeks after last placebo injection, Grp 3 will undergo the first CHMI by IV injection of 3.2x10^3 PfSPZ Challenge (NF54).
89483296|NCT02132299|Experimental|Group 4|The fourth group will include 6 volunteers who will be unblinded and will receive 5 vaccinations of 2.7 x 10^5 PfSPZ Vaccine by IV administration. Four vaccinations at 4 weeks intervals of 2.7x10^5 PfSPZ will be given and the fifth dose will be administered 8 weeks after the 4th. Volunteers from Group 4 will start their vaccinations 48 hours after the four safety volunteers from Group 3 have received their first dose, at each dosing time point. This group will participate in only one CHMI assessment at 24 weeks to assess duration of protection at 24 weeks.
89483297|NCT02132299|Placebo Comparator|Group 5|The 5th group will be divided into 3 sub groups 5A, 5B, 5C, who will be screened and recruited to serve as unblinded controls for the 1st and 2nd CHMI at 3 and 24 weeks. They will participate only in the screening and 4 weeks follow up of the 1st and 2nd CHMI assessments. Group 5A (n=2) will be challenged at the time of the 3-week CHMI of Group 2. Group 5B (n=2) will be challenged at the time of the 3-week CHMI of Group 3. Groups 5A and 5B will supplement the 4 NS- injected volunteers as infectivity controls, totaling 6 altogether. Group 5C (n=6) will be challenged at the time of the 24-week CHMI for Groups 3 and 4.
89483298|NCT03072680|Experimental|BPS PAST + BPS FUT|Participants practice BPS PAST the first week, then they switch fot BPS FUT.
89483299|NCT03072680|Experimental|BPS FUT|Participants practice BPS FUT during the two weeks.
89483300|NCT03072680|Active Comparator|CONTROL|Participants practice DAILY ACTIVITIES for the two weeks.
89483301|NCT02125201|Experimental|intranasal fentanyl|Intranasal Fentanyl 1.5-2 mcg/kg
89483302|NCT02125201|Active Comparator|intravenous fentanyl|Intravenous Fentanyl 1-1.5 mcg/kg
89483303|NCT03072368|Active Comparator|Blue eyes|50 babies born with blue eyes will be photographed and followed-up at baseline; 3 months and 12 months of age
89483304|NCT03072368|Active Comparator|Brown eyes|50 babies born with brown eyes will be photographed and followed-up at baseline; 3 months and 12 months of age
89483305|NCT03072368|Active Comparator|Green eyes|50 babies born with green eyes will be photographed and followed-up at baseline; 3 months and 12 months of age
89483306|NCT03072368|Active Comparator|Hazel eyes|50 babies born with hazel eyes will be photographed and followed-up at baseline; 3 months and 12 months of age
89483307|NCT02125357|Other|A - Abiraterone Acetate|Abiraterone acetate 1000mg PO OD with prednisone 5mg PO BID or 10mg OD as per standard of care, or until PSA progression then cross-over to Arm B.
89483308|NCT02125357|Other|B - Enzalutamide|160mg PO OD as per standard of care, or until PSA progression then cross-over to Arm A.
89483309|NCT03265509|Active Comparator|Glutamine|30 g/day Glutamine supplementation for three months
89483310|NCT03265509|Placebo Comparator|Fantomalt|30 g/day Fantomalt supplementation for three months
89483311|NCT03074942|Experimental|Reslizumab|Reslizumab 3 mg/kg once / every 4 weeks during 24 weeks
89483312|NCT02125435|Experimental|ASP2408 dose escalation cohort|
89483313|NCT02125435|Placebo Comparator|Placebo dose escalation cohort|
89483314|NCT03265353|Other|Moderate Potassium/Low Sodium Diet|Vascular function will be assessed at both the conduit artery and microvascular level after 7 days of the moderate potassium/low sodium diet.
89483315|NCT03265353|Other|Moderate Potassium/High Sodium Diet|Vascular function will be assessed at both the conduit artery and microvascular level after 7 days of the moderate potassium/high sodium diet.
89483316|NCT03265353|Other|High Potassium/High Sodium Diet|Vascular function will be assessed at both the conduit artery and microvascular level after 7 days of the high potassium/high sodium diet.
89483317|NCT03072446|Experimental|Gel-Beads arm|This group will undergo embolization of symptomatic uterine fibroids with Gel-Beads embolic agent
89483318|NCT02128087|No Intervention|Control group|This study arm will receive care as usual.
89483319|NCT02128087|Experimental|Two-way SMS intervention group|"Two-way messages allow the recipient of the SMS message (the patient) to respond to the messages (We hope you are feeling well today. Reply 1 if well, 2 if unwell) to request a follow-up call from the clinic."
89483320|NCT02128087|Experimental|One-way SMS intervention group|"Clients will receive a weekly one-way SMS with the message We hope you are feeling well today. There will be no prompt for response."
88952266|NCT05312515|Experimental|Warm Application to Feet and Follow-up After Cesarean Section|Warm application will be applied to the feet of women who come to the surgical service after cesarean delivery, 3 hours after they are admitted to the service. For hot application, a hot water bag will be used, the temperature of the water to be placed in the hot water bag is max. It will be set by the researcher to be 44°C. Since the temperature of the water (max. 44°C) does not create a risk of burns, no additional precautions were required. A stopwatch clock will be used to track the duration of the application. After the application will be done for 30 minutes, a hot water bag will be taken. Hot application will be done once. During the application, the researcher will be with the women, will check whether any complications have developed, and if complications or discomfort develop, the application will be terminated.
89483321|NCT03075020|Active Comparator|Active carbon monoxide|Inhalation of carbon monoxide up to a carboxyhemoglobin concentration 22%
89483322|NCT03075020|Placebo Comparator|Air|
89483323|NCT03262311|Experimental|Hypoxia marker|Administration of a single dose of the hypoxia marker Pimonidazole
89483324|NCT02128165|Active Comparator|BMI more than 45 BMI|Air filled gastric balloon (Heliosphere) those BMI above 45
89483325|NCT02128165|Active Comparator|BMI less than 45 BMI|Air filled gastric balloon (Heliosphere)those BMI below 45
89483326|NCT02125591|Experimental|Active PoNS CN-NINM|Active CN-NINM PoNS - Active cranial-nerve non-invasive neuromodulation (CN-NINM) using the Portable Neuromodulation Stimulator (PoNS) and balance/gait rehabilitation with physical therapy
88952267|NCT05312515|No Intervention|Control|The control group will be given routine post-operative care without any intervention and data collection tools will be applied at the same time as the intervention group. In addition, the patient and his family will be informed to write it down with the watch if there is gas after the procedure when the researcher is not with them.
89483327|NCT02125591|Sham Comparator|Sham PoNS CN-NINM|Sham CN-NINM PoNS - Sham cranial-nerve non-invasive neuromodulation (CN-NINM) using the Portable Neuromodulation Stimulator (PoNS) and balance/gait rehabilitation with physical therapy
89483328|NCT05002634|Experimental|undenatured collagen type II (UCII) supplement|The undenatured collagen type II (UCII) supplement 40 mg will be taken once daily for 2 months.
89483329|NCT04831437|Experimental|Hypofractionated|EBRT 40Gy/15fr
89483330|NCT04831437|Active Comparator|Control Group|EBRT 45Gy/ 25fr
89483331|NCT02128243|Experimental|Arm A: De-escalation therapy|Patients in Arm A will continue with S-1 de-escalation phase starting at week 13 until disease progression, toxicities requiring discontinuation, withdrawal of consent, pregnancy, death or lost to follow up whichever occurs first. In patients with drug-related severe toxicity S-1 dose will be adjusted or study treatment will be terminated.
89483332|NCT02128243|Experimental|Arm B: Chemotherapy by Investigator's choice|Patients in Arm B will continue to receive the same polychemotherapy as during induction therapy until tumor progression, toxicities requiring discontinuation, withdrawal of consent, pregnancy, death or loss to follow up whichever occurs first.
89483333|NCT03072212||HIV infected with stroke|No intervention will be administered
89483334|NCT03072212||HIV uninfected with stroke|No intervention will be administered
89483335|NCT02132455|Experimental|3 minutes in the right side colon|Colonoscopy, at least 3 minutes in the right side colon from the total withdrawal time
89483336|NCT02132455|Experimental|4 minutes in the right side colon|Colonoscopy, at least 4 minutes in the right side colon from the total withdrawal time
89483337|NCT02132455|No Intervention|6 minutes whole withdrawal time|Colonoscopy, at least 6 minutes whole withdrawal time regardless of time spent in any segment
89483338|NCT02132455|Experimental|8 minutes whole withdrawal time|Colonoscopy, at least 8 minutes whole withdrawal time regardless of time spent in any segment
89483339|NCT04769427|Experimental|PDO Max thread injection to nose|
89483340|NCT02125669|Active Comparator|Laser Treatment|Pulsed dye laser 595nm
89483341|NCT02125669|Sham Comparator|SHAM Treatment|using the pulsed dye laser (PDL) laser without releasing a pulse
89483342|NCT03072056|Experimental|Extensive Metabolizers, 4 mg|subjects will receive 32 mL of MIN-101 as a 0.125 mg/mL oral solution
89483343|NCT03072056|Experimental|Extensive Metabolizers, 8 mg|subjects will receive 32 mL of MIN-101 as a 0.25 mg/mL oral solution
89483344|NCT03072056|Experimental|Extensive Metabolizers, 16 mg|subjects will receive 32 mL of MIN-101 as a 0.5 mg/mL oral solution
88952268|NCT05312502|Experimental|Experimental: Birth Ball|In the second stage, the birth ball application was made and followed. Pregnant women with a vaginal opening of 4 cm admitted to the delivery room were instructed to sit on the delivery ball for a total of 30 minutes. A stopwatch clock was used to determine these 30 minutes. The pregnant woman was not asked to sit on the ball all the time, and she could take a break for rest or other needs. The birth ball, which is suitable for women's use, was preferred in 45 cm dimensions, and the pilates circle was used as a stabilizer. Under the supervision of the researcher, the pregnant women sat upright on the ball and began to rock back and forth. Meanwhile, the researcher held the pregnant woman's hand. In order for the pregnant woman not to lose her balance, the birth ball was placed on a pilates circle and she was supported by the researcher in making the movements.
88952269|NCT05312502|No Intervention|Control|A routine care was performed.
88952270|NCT05310773|Experimental|Community Stigma Reduction Training and HTS/ART/PrEP Only|Participants in the communities/catchment areas randomized to this arm will complete the community stigma assessments and will receive with stigma reduction training through community workshops. Couples will have access to standard HIV testing services (HTS) with antiretroviral therapy (ART)/pre-exposure prophylaxis (PrEP) but not the Couples Health CoOp Plus (CHC+) intervention.
88952271|NCT05310773|Experimental|Community Stigma Reduction Training and HTS/ART/PrEP with CHC+|Participants in the communities/catchment areas randomized to this arm will complete the community stigma assessments with stigma reduction training through community workshops. Couples will have access to the Couples Health CoOp Plus (CHC+) intervention and standard HTS with antiretroviral therapy (ART)/pre-exposure prophylaxis (PrEP).
88952272|NCT05310773|No Intervention|No Community Stigma Reduction Training and HTS/ART/PrEP Only|Participants in the communities/catchment areas randomized to this arm will complete the community stigma assessments but will not receive the stigma reduction training workshops. Couples will have access to standard HIV testing services (HTS) with antiretroviral therapy (ART)/pre-exposure prophylaxis (PrEP) but not the Couples Health CoOp Plus (CHC+) intervention.
88952273|NCT05310773|Experimental|No Community Stigma Reduction Training and HTS/ART/PrEP with CHC+|Participants in the communities/catchment areas randomized to this arm will complete the community assessments but not the stigma reduction training workshops. Couples will have access to the Couples Health CoOp Plus (CHC+) intervention and standard HIV testing services (HTS) with antiretroviral therapy (ART)/pre-exposure prophylaxis (PrEP).
89020868|NCT00321152|Placebo Comparator|3|placebo/placebo = both tablets of study medication will be placebo during both phases of the study.
89020869|NCT00321191|Experimental|N2O|
89483345|NCT03072056|Experimental|Poor Metabolizers, 4 mg|subjects will receive 32 mL of MIN-101 as a 0.125 mg/mL oral solution
89483346|NCT03072056|Experimental|Poor Metabolizers, 8 mg|subjects will receive 32 mL of MIN-101 as a 0.25 mg/mL oral solution
89203423|NCT02558660|Experimental|Double Up Food Bucks|Clinic-based educational intervention about an existing SNAP healthy food incentive program, as well as a $10 voucher to spend on produce at farmers markets
89483347|NCT03072056|Experimental|Poor Metabolizers, 16 mg|subjects will receive 32 mL of MIN-101 as a 0.5 mg/mL oral solution
89483348|NCT02125747|Other|No Respiratory Therapy|Patients with acute exacerbation of chronic obstructive pulmonary disease. Patients received conventional treatment.
89483349|NCT02125747|Experimental|Respiratory therapy|Patients with acute exacerbation of chronic obstructive pulmonary disease. Patients received conventional treatment and Respiratory Therapy
89483350|NCT03072290|Experimental|low dose steroid|ultrasound-guided steroid injection using 1ml of 10 mg (10mg/ml) triamcinolone acetonide (Shincort) mixed with 1 ml of 2% lidocaine hydrochloride (Xylocaine)
89483351|NCT03072290|Active Comparator|comparator|ultrasound-guided steroid injection using 1ml of 40 mg (40mg/ml) triamcinolone acetonide (Shincort) mixed with 1 ml of 2% lidocaine hydrochloride (Xylocaine)
89483352|NCT05002712|Experimental|Heavy resistance training|Group A
89483353|NCT05002712|Experimental|Contrast strength training|Group B
89483354|NCT05002712|Active Comparator|Elastic resistance training|Group C
89483355|NCT02132689|Active Comparator|Actilyse|Thrombolytic therapy: Patients treated with initial thrombolytic therapy (Actilyse) followed with anticoagulant therapy (unfractionated/low-molecular weight heparin).
89483356|NCT02132689|Active Comparator|UHF/LMWH|Anticoagulation therapy: Patients treated with anticoagulation therapy only (unfractionated/low-molecular weight heparin).
89483357|NCT02458053|Experimental|TEAM Enhanced|The enhanced intervention will include group sessions where the participant attends with partner ( including a couples skill training session), weekly tailored feedback, and weekly lessons.
89483358|NCT02458053|Active Comparator|TEAM Traditional|The intervention will include group sessions where the male attends alone, weekly tailored feedback, and weekly lessons.
89203424|NCT04001920|Experimental|Training program|12-week strength and endurance training program
89203425|NCT05435378|Experimental|vitamin B3|Vitamin B-3 capsule consists of Manufacturer: DSM Nutritional products Ltd generic name: nicotine amide Constituent components: 100mg of nicotine amide Route of administration: orally dosing schedule:1capsule/day/ before meal duration: for 30 days
89483359|NCT02128321|Experimental|Isavuconazole + Repaglinide + Caffeine|Isavuconazole three times a day on Days 5 and 6 and once a day on Days 7 through 17, repaglinide on Days 1 and Day 14, caffeine on Days 3 and 16
89483360|NCT02458131|Experimental|TEEN HEED|Adolescent pre-diabetics will receive 8-12 weekly peer-led diabetes prevention educational workshops in community sites. The in-person group workshops will be supplemented by support through mobile health technologies such as text messaging and social media.
89483361|NCT02458131|No Intervention|Wait List Control|Adolescent pre-diabetics in this group will not receive any intervention until collection of all follow up data and will then be offered the same intervention as the participants in the experimental arm.
89483362|NCT02457975|Active Comparator|Intravitreous VEGF-inhibitors|Three intravitreous VEGF inhibitors - aflibercept (Eylea, Regeneron Pharmaceuticals), bevacizumab (Avastin, Genentech), and ranibizumab (Lucentis, Genentech) - are commonly used for the treatment of diabetic macular edema causing vision impairment and have been shown to be beneficial and relatively safe. Study participants in the anti-VEGF group will be treated with intravitreous injections of one of these agents: afibercept (2.0 mg), bevacizumab (1.25 mg) or ranibizumab (0.5 mg) at appropriate intervals as determined by the treating ophthalmologist.
89483363|NCT02457975|Experimental|670nm PBM plus VEGF-inhibitors|Subjects in the 670 nm Photobiomodulation (PBM) intervention arm will be treated (in addition to Anti-VEGF treatment) with 670nm light (WARP10, Quantum, Devices, Inc, Barneveld, WI). The portable, battery-operated 670 nm LED array specifically designed not to generate heat will be held 1 inch from the closed treatment eye. A 90-sec light treatment will be delivered. After 90 sec a timer turns off the light. The dose of light delivered at the surface of the cornea is calculated to be 4.5 J/cm2 (90 sec x 0.05 W/cm2 = 4.5 J/cm2). PBM treatment will be applied for 90 sec once per day, three consecutive days per week for 8 weeks. Previous clinical studies, have shown this treatment regimen and dose to be safe and effective in the treatment of dry AMD and non-center involving DME
89483364|NCT03074864|Experimental|EGFR-mutant IIIA/IIIB NSCLC|Erlotinib Hydrochloride 150mg daily intercalated with radiotherapy
88821670|NCT03019029|Experimental|Peripheral nerve amyloidosis|Patients with pathologically-confirmed peripheral nerve amyloidosis will undergo 18-F Florbetapir PET/MR scan on a GE SIGNA PET/MR scanner.
89020870|NCT00321191|Placebo Comparator|No N2O|
89483365|NCT02125825||Parkinson's disease on levodopa|Individuals with Parkinson's disease who are taking levodopa to treat motor symptoms
89483366|NCT04997720|Other|Training|The course will be theoretical-practical, lasting eight hours, divided into two meetings with a theoretical class and practical exercises in microsurgery of increasing complexity. The course will also have an initial and final evaluation.
89483367|NCT02456571||Group A|men with mCRPC starting sipuleucel-T (Provenge) with or without abiraterone acetate or enzalutamide will have CTC enumeration and immune checkpoint characterization at baseline, 3 months, 4-12 weeks after completion of sipuleucel-T, and at progression.
89483368|NCT02456571||Group B|men with mCRPC with visceral or high risk disease pre-abiraterone/enzalutamide will have CTC enumeration and immune checkpoint characterization at baseline, 3 months, and progression.
89483369|NCT02456571||Group C|men with high volume metastatic castration sensitive prostate cancer (mCSPC) starting hormonal therapy and docetaxel chemotherapy or who decline docetaxel chemotherapy will have CTC enumeration and immune checkpoint characterization at baseline, 3 months, and progression.
89483370|NCT02456571||Group D|men with enzalutamide or abiraterone acetate resistant mCRPC will have CTC enumeration and immune checkpoint characterization at baseline (i.e. progression on enzalutamide or abiraterone acetate) and 4-12 weeks after completion of next therapy (ex. radium-223 or chemotherapy)
89483371|NCT03550963|Other|rice-richen meal|All participants included in the study will be randomized assigned into one of two groups in parallel, the rice-richen meal group and wheaten-richen meal group. The intervention of group one is that participants will be provided with rice-richen meal, meaning most of the calculated carbohydrates are from rice.
89483372|NCT03550963|Other|wheaten-richen meal|All participants included in the study will be randomized assigned into one of two groups in parallel, the rice-richen meal group and wheaten-richen meal group.The intervention of group two is that participants will be provided with wheaten-richen meal, meaning most of the calculated carbohydrates are from wheaten.
89483373|NCT03071978|Experimental|LV-fusion pacing|Left Ventricular pacing (without Right Ventricular pacing)
88952274|NCT05285566|Experimental|Exparel® Injection Group|On the day of clinically indicated nasal surgery the surgical wound on the chest, where the rib cartilage is removed, will be injected with Exparel®
88952275|NCT05285566|Active Comparator|Xylocaine® Injection Group|On the day of clinically indicated nasal surgery the surgical wound on the chest, where the rib cartilage is removed, will be injected with Xylocaine® as part of standard of care.
88952276|NCT05220774||anesthetist-administered sedation (AAS)|Patients undergoing ERCP and receiving AAS
88952277|NCT05220774||endoscopist-directed conscious sedation (EDCS)|Patients undergoing ERCP and receiving EDCS
88952278|NCT05204576|No Intervention|Standard care treatment as usual (TAU)|Individuals will receive buprenorphine or methadone in addition to regular individual or group sessions as offered by the clinic
89483374|NCT03071978|Active Comparator|BV pacing|Bi-Ventricular pacing
89483375|NCT02132845|Active Comparator|Arm A (standard of care therapy)|Patients undergo collection of tissue and blood samples for analysis via next generation sequencing. Patients receive standard of care therapy based on the discretion of the treating physician.
89483376|NCT02132845|Experimental|Arm B (target-directed therapy)|Patients undergo collection of tissue and blood samples for analysis via next generation sequencing. Based on the results of the next generation sequencing, patients receive target-directed therapy.
89483377|NCT03261687|Experimental|Water Exercise + advice|Each group undertook four, once weekly exercise sessions (including a warm up, cool down, relaxation, pelvic control and stability exercise). Both programmes focused on similar exercise and muscle groups, but due to the aquatic medium programmes were unable to be exactly matched.
89483378|NCT03261687|Experimental|Land Exercise + advice|Each group undertook four, once weekly exercise sessions (including a warm up, cool down, relaxation, pelvic control and stability exercise). Both programmes focused on similar exercise and muscle groups, but due to the aquatic medium programmes were unable to be exactly matched.
89483379|NCT03551431|Experimental|Video EEG with verbal suggestion|
89483380|NCT03551431|Experimental|video EEG with verbal suggestion and tuning fork|
89483381|NCT03551431|Experimental|video EEG with verbal suggestion and cotton swab|
88952279|NCT05204576|Experimental|CBT4CBT-Copes|Individuals will receive standard agonist treatment plus access to the CBT4CBT-COPES website plus daily texts with a link to a survey.
88952280|NCT05196698|Experimental|High Flow Oxygen Therapy|
88952281|NCT05196698|Other|Long-Term Oxygen Therapy|Control arm
88952282|NCT05187130|Experimental|Intervention|Mindfulness-based breathing and music therapy
88952283|NCT05187130|No Intervention|Control|No intervention has been made
88952284|NCT05179278|Experimental|Intervention Group: post-surgical face-to-face follow up consultation|
88952285|NCT05179278|Experimental|Control Group: post-surgical telephone follow up consultation|
88952286|NCT05145439|Experimental|VibratoSleeve TUS|In this single arm study, there is only one group/arm, all of whom will be given 3 levels of treatment with the VibratoSleeve TUS device.
88952287|NCT05138172|Placebo Comparator|Sedation without forced air heating temperature management|Sedation without forced air heating temperature management = present standard in sedation during endoscopic retrograde cholangiography (ERC)
89020871|NCT00351624|Active Comparator|DHA|
89483382|NCT04729257|Other|Group A1 (Norms + Validation, 18-49 years) + Group A2 (Validation, 50+ years)|Visit 1: Participants' cognition is measured using digital tests. Visit 2: Participants' cognition is measured using paper-pencil tests.
89483383|NCT04729257|Other|Group B (Validation, 18+)|Visit 1: Participants' cognition is measured using paper-pencil tests. Visit 2: Participants' cognition is measured using digital tests.
89483384|NCT04729257|Other|Group C1 (Norms + Validation, 18-49 years) + Group C2 (Validation, 50+ years)|Visit 1: Participants' cognition is measured using digital tests. Visit 2: Participants' cognition is measured using digital tests.
88952288|NCT05138172|Experimental|Sedation with forced air heating temperature management|Sedation without forced air heating temperature management = proposed new standard in sedation during endoscopic retrograde cholangiography (ERC)
88952289|NCT05133986|Experimental|Onion feeding first, couscous feeding second|Participants will report to the laboratory at 8am in a fasted state (water consumption is permitted) and provide a spot baseline urine sample. Participants will then be served a 120g portion of onions (experimental condition), prepared under standardized conditions. Participants shall remain supervised in the laboratory and will only consume water (100mL per hour) for the subsequent 6 hours, after which participants are free to consume their habitual diet (except alcohol, tea coffee, and FVs). In the 24-hour postprandial test period, participants will obtain urine samples at several time-points. Urine collection vessels will be used to obtain samples at 0-1, 1-2, 2-4, 4-6, 6-12, 12-24 hours. This experimental protocol shall be repeated following a 4-day washout period (habitual diet consumption with no restrictions imposed on participants) with 120g of couscous consumed instead of onions, as a control condition.
89020872|NCT00351624|Placebo Comparator|placebo|
89020873|NCT00351663|Active Comparator|IV by weight|intravenous dose of 0.5 mg/kg enoxaparin once daily
89020874|NCT00351663|Active Comparator|SC fixed dose|subcutaneous fixed dose of 40 mg enoxaparin once daily
89020875|NCT00351663|Active Comparator|SC by weight|subcutaneous dose of 0.5 mg/kg enoxaparin once daily
89020876|NCT00351702|Active Comparator|Isoniazid|Isoniazid (300mg) daily for 36 months
89483385|NCT04729257|Other|Group D (Validation, 18+)|Visit 1: Participants' cognition is measured using paper-pencil tests. Visit 2: Participants' cognition is measured using paper-pencil tests.
89483386|NCT04729257|Other|Group E (Norms, 18-49 years)|Visit 1: Participants' cognition is measured using digital tests. Visit 2: N/A
89483387|NCT04729257|Other|Group F (Norms, 80-95 years)|Visit 1: Participants' cognition is measured using digital tests. Visit 2: N/A
89483388|NCT02132923||Patients with respiratory syncytial virus (RSV) infection|The RSV infection is laboratory confirmed
89483389|NCT04900688|Other|Ureteroscopy (URS) with the LithoVue Elite disposable flexible ureteroscope|Ureteroscopy will be done using the LithoVue Elite disposable flexible ureteroscope instead of the satandard ureteroscope
89483390|NCT04798911||Observational - phase 1|"Determination of Informational Needs (Months 0- 9)~Qualitative interviews with patients with SS~Interview transcriptions and thematic analysis"
89020877|NCT00351975|Experimental|Arm I (chemotherapy)|Patients receive azacitidine SC on days 1-5.
89020878|NCT00351975|Experimental|Arm II (chemotherapy, enzyme inhibitor therapy)|Patients receive azacitidine as in arm I and belinostat at the MTD IV over 30 minutes on days 1-5.
89020879|NCT00321659|Experimental|Aerobic and flexibility exercise|16 weeks of aerobic and flexibility exercise. Three days per week for 1 hour of walking and cycling.
89020880|NCT00321659|Experimental|Strength, aerobic, and flexibility|16 weeks of strength training, aerobic, and flexibility exercise (ST) intervention;
89020881|NCT00321659|Experimental|Fibromyalgia Self-Help Course|7 weeks of FSHC behavior change education
89020882|NCT00321659|Experimental|a Combination of ST and FSHC|16 wks of a combination of ST and FSHC (ST-FSHC) exercise and behavior change education
89020883|NCT00322010|Experimental|Early PT OT|Early PT/OT Therapy assessments to begin on the first day that consent is obtained. Therapy is delivered by a team consisting of a physical and occupational therapist and coordinated with daily sedative interruption.
89020884|NCT00322010|No Intervention|Standard Care|PT/OT delivered as ordered by the primary ICU team
89020885|NCT00322127|Experimental|1|AMD3100 given as a single 240 g/kg dose followed 14-90 days later by a single 320 g/kg dose
89020886|NCT00322127|Experimental|2|AMD3100 given as a single 320 g/kg dose followed 14-90 days later by a single 400 g/kg dose
89020887|NCT00322127|Experimental|3|AMD3100 given as a single 400 g/kg dose followed 14-90 days later by a single 480 g/kg dose.
89020888|NCT00322127|Experimental|4|randomized to either receive 240 g/kg first followed by 480 g/kg after a washout period or 480 g/kg first followed by 240 g/kg after a washout period.
89020889|NCT00352170|Experimental|1|calcium supplementation
89020890|NCT00352170|Experimental|2|calcium and vitamin D3 supplementation
89020891|NCT00352170|Experimental|3|placebo
89020892|NCT00322166|Active Comparator|Group A, Sunlight|Participants in this arm are required to sit in the sun most days of the week for 15 minutes
89020893|NCT00322166|Active Comparator|Group B, sunlight and calcium|Participants in this group receive sunlight and a calcium supplement
89020894|NCT00322166|No Intervention|Group C|Control group
89020895|NCT02959580|Experimental|medical|Hydrocortisone butyrate cream(0.1%) was applied to the breast by the patient twice a day on alternate days until the termination of treatment.
89020896|NCT02959580|Active Comparator|surgical|lesion extended excision
89020897|NCT00352326|Experimental|Children (with dystonia and controls)|"Participants sat in a chair or their own wheelchair in front of a table whose surface height was adjusted at the midpoint between the hip and the Xiphoid process. They placed the hand that was not used for the task on their lap.~An iPad® (Apple Inc, Cupertino, California) was located on the table in portrait mode in front of the participants at a distance that ranged between 40 and 55 cm. An adjustable metal bookstand supported the iPad® to allow the participants a comfortable screen view. The size of the screen was 19.5 × 14.6 cm. Custom software was developed for the experimental task (XCode 3.2 development environment, iOS 4.2 operating system; Apple Inc, Cupertino, California)."
89020898|NCT00322283|Experimental|Oglemilast|
89020899|NCT00322283|Placebo Comparator|Placebo|
89020900|NCT00322322|Experimental|1|L-Carnitine
89020901|NCT00352443|Experimental|everolimus/lapatinib|Part 1, dose finding: everolimus and lapatinib at assigned dose daily Part 2, cohort A: Everolimus MTD from Part I: 5 mg PO 1-28 Daily Lapatinib MTD from Part I: 1,250 mg PO Cycle 1, Daily Days 8-28** Subsequent Cycles, Days 1-28 Part 2, cohort B: Lapatinib MTD from Part I: 1,250 mg PO 1-28 Daily Everolimus MTD from Part I: 5 mg PO Cycle 1, Daily Days 8-28** Subsequent Cycles, Days 1-28
89020902|NCT00322361|Experimental|1|Modified Process Hepatitis B Vaccine
89020903|NCT00322361|Active Comparator|2|Recombivax HB™
89020904|NCT00322400|Experimental|B1|AMG 706 50 mg daily + Docetaxel (100 mg/m2 D1 every 21 days)
89020905|NCT00322400|Experimental|A4|75 mg AMG 706 daily + Paclitaxel (90 mg/m2 on D1, D8 and D15 every 28 days)
89020906|NCT00322400|Experimental|A1|AMG 706 50 mg daily + Paclitaxel (90 mg/m2 D1, D8, D15 every 28 days)
89020907|NCT00322400|Experimental|B4|75 mg AMG 706 daily + Docetaxel (100 mg/m2, D1 every 21 days)
89020908|NCT00322400|Experimental|B5|MTD of AMG 706 + Docetaxel (75mg/m2 D1 every 21 days)
89020909|NCT00322400|Experimental|B3|100 mg AMG 706 daily + Docetaxel (100 mg/m2 on D1 every 21 days)
89020910|NCT00322400|Experimental|B2|AMG 706 125 mg daily + Docetaxel (100 mg/m2 D1 every 21 days)
89020911|NCT00322400|Experimental|A2|AMG 706 125 mg daily + paclitaxel 90 mg/m2 D1, D8, D15 every 28 days
89020912|NCT00322400|Experimental|A3|100 mg AMG 706 daily + Paclitaxel (90 mg/m2 on D1, D8, and D15 every 28 days)
89020913|NCT00352521|Experimental|Bevacizumab and irinotecan|The bevacizumab will be dosed at 10 mg/kg every 14 days (days 1, 15 and 29) and the irinotecan on days 2, 15, and 29 of the first six week schedule. The irinotecan dose will depend on whether the patient is on an enzyme-inducing antiepileptic drug (EIAED). If the patient is on an EIAED, the patient will receive 340 mg/m2 on days 2, 15, and 29 of the first six week schedule. If the patient is not on an EIAED, the dose of irinotecan will be 125 mg/m2 on days 2, 15, and 29 of the first six week schedule. After the first cycle, the irinotecan and bevacizumab will be given on days 1, 15 and 29.
89020914|NCT00322478|Other|GlucoMON-ADMS enabled|Patients who are equipped with the automated technology vs. standard/conventional care
89020915|NCT00352599|Active Comparator|Lovastatin|Lovastatin
89020916|NCT00352599|Placebo Comparator|Placebo pill|Placebo pill
89483391|NCT04798911||Observational - phase 2|"Phase 2 Development of the informational need instrument for SS [SS-INQ] (Months 9-32)~Adaptation of TINQ-BC for use in patients with SS - generation of relevant questions using themes from Phase 1 qualitative study (removal of those solely related to breast cancer from TINQ-BC) by the expert group~Pilot testing of SS-INQ for content and readability will be done via focus groups whilst structural validity will be explored using factor analysis~Testing of SS-INQ for reliability - internal consistency reliability and test-retest reliability"
89483392|NCT02456649|Experimental|MarginProbe|Single arm study - MarginProbe in addition to standard procedure
89483393|NCT02125903|Active Comparator|Continuous Adductor Canal Block (CACB)|"Continuous Adductor Canal block performed with:~loading dose 0,375% Ropivacaine 15ml (56,25mg) start infusion 0,2% Ropivacaine 6ml/h~Procedure: Femoral Nerve Block. Adductor Canal Block Drug: Ropivacaine"
89483394|NCT02125903|Active Comparator|Continuous Femoral Nerve Block (CFNB)|"Continuous Femoral Nerve Block performed with:~loading dose 0,375% Ropivacaine 15ml (56,25mg) start infusion 0,2% Ropivacaine 6ml/h~Procedure: Femoral Nerve Block. Adductor Canal Block Drug: Ropivacaine"
89483395|NCT05002166||Children aged less than 18 years with a confirmed diagnosis of IBD.|"All patients admitted with inflammatory bowel disease will be subjected to:~History: including name, age ,sex ,family history, consanguinity, history of rectal bleeding, mucus or blood in the stool, diarrhea, abdominal pain ,vomiting ,nausea and loss of appetite.~Examination: including general examination, chest, cardiac, abdominal and neurological examination~Investigation:including labortatory such as fecal calprotectin ,CRP,CBC,ESR. Endoscopic examination of the gastrointestinal tract Histological examination of the biopsies retrieved during gastrointestinal endoscope."
89483396|NCT02126059|Experimental|Cognitive stimulation|One cognitive stimulation session per week for a continuous 10 weeks, each session contains 50 minutes, totally 10 session topics related to cognitive stimulation.
89483397|NCT02126059|Experimental|Aroma-massage|One hand and shoulder massage session per week for a continuous 10 weeks, each session contains 30 minutes, totally 10 session massage.
89483398|NCT02126059|Experimental|reminiscence|One reminiscence session per week for a continuous 10 weeks, each session contains 50 minutes, totally 10 session topics related to reminiscence.
89483399|NCT02126059|No Intervention|Control|Control group remain regular activities
89483400|NCT04713501|Experimental|PARTS|The PARTS Program is a 16-week group intervention model, with 8 individual clinical sessions on a biweekly basis, developed to resolve and alleviate trauma and stress for individuals diagnosed with PTSD.
89483401|NCT02133079|Experimental|gp96 group|autologous gp96 vaccination + basal treatment
89483402|NCT04997876||Study Group|Biomarkers from presurgical OCTs are diagnosed
89483403|NCT02133157|Experimental|Sulfatinib capsule|cohort 1: Sulfatinib single oral dosing;after 7days,Sulfatinib continuous oral dosing ( once a day) 28days as a cycle.
89020917|NCT04714632||Children with idiopathic scoliosis|Adolescent between 10-18y with diagnosing idiopathic scoliosis
89020918|NCT04714632||Healthy children|Healthy children between 10-18y without any orthopedics problems
89020919|NCT00322946|Experimental|1|One subcutaneous vaccination with rDEN4delta30-4995 vaccine (10^5 PFU dose) into the deltoid region of either arm.
89020920|NCT00322946|Experimental|2|One subcutaneous vaccination with rDEN4delta30-4995 vaccine (10^3 PFU dose) into the deltoid region of either arm. This arm will enroll after Arm 1.
89020921|NCT00322946|Experimental|3|One subcutaneous vaccination with rDEN4delta30-4995 vaccine (10^1 PFU dose) into the deltoid region of either arm. This arm will enroll after Arms 1 and 2.
89483404|NCT04997564|Experimental|non-cirrhotic patients|patients will be discontinued TAF once daily therapy at the end of week 28 if no HBV reactivation occurs during treatment
89483405|NCT04997564|Other|cirrhotic patients|patients will be received TAF once daily for 64 weeks. In this study, after week 64, and patients will continue NUC treatment but pay by themselves.
89483406|NCT02128399||patients before and after intervetion|
89483407|NCT03842943|Experimental|Combination T-VEC/Pembrolizumab|"Pre-operative talimogene laherparepvec (T-VEC) with Pembrolizumab~T-VEC - intra-lesional injection into palpable lymph nodes every 3 weeks for 6 months, or until complete response of target tumors.~Pembrolizumab - administered intravenously every 3 weeks for 6 months, then every 3 weeks for one year in the adjuvant setting following complete lymph node dissection."
89483408|NCT02126137|Experimental|Ezetimibe|Ezetimibe administered by mouth 10 mg BID for 12 weeks
89483409|NCT04647591|Experimental|ENT Barotrauma incidence and link with risk factors|
89020922|NCT00322946|Placebo Comparator|4|One subcutaneous vaccination with placebo into the deltoid region of either arm.
89020923|NCT00331500|Experimental|Olopatadine Hydrochloride 0.2%|Olopatadine hydrochloride ophthalmic solution, 0.2%, 1 drop in each eye, once-daily in the morning for 6 weeks
89020924|NCT00331500|Placebo Comparator|Vehicle|Olopatadine hydrochloride ophthalmic solution vehicle, 1 drop in each eye, once-daily in the morning for 6 weeks
89020925|NCT00353028|Experimental|F|
89020926|NCT00353028|Placebo Comparator|P|
89020927|NCT00353106||Patients|Patients with chronic GVHD
89020928|NCT00353106||Content Expert Panel|Content expert panel with 5 years experience caring for patients with cGVHD.
89020929|NCT00353106||Caregivers|Caregivers of patients with cGVHD
89020930|NCT00323375|Experimental|AQ-13 (Investigational 4-Aminoquinoline)|Arm: Experimental: AQ-13 AQ-13 capsules with 350 mg AQ-13 base per capsule. Two capsules orally on days 1 and 2, one capsule orally on day 3.
89020931|NCT00323375|Active Comparator|CQ (Chloroquine)|Arm: Active Comparator: CQ CQ Capsules with 300 mg CQ base per capsule per capsule. Two capsules orally on days 1 and 2, one capsule orally on day 3.
89020932|NCT00331695|Experimental|1|17 alpha-hydroxyprogesterones caproate
89020933|NCT00323531|Active Comparator|1|Video assisted thoracoscopic decortication
89020934|NCT00323531|Experimental|2|Fibrinolysis through the chest tube
89020935|NCT00353145|Experimental|Gemcitabine + Oxaliplatin|Gemcitabine 1000 mg/m^2, infused at 10 mg/m^2/min on Day 1 and Oxaliplatin 100 mg/m^2 by vein infused on Day 2 over two hours. Repeated every 14 days (one cycle).
89020936|NCT00323648|Experimental|postoperatively antibiotics|
89020937|NCT02959515|Active Comparator|Capnothorax|Capnothorax is obtained by the insufflation of CO2in the right pleural cavity and maintained at a preset pressure of 10 mmHg .Arterial and central venous blood gasanalyses, hemodynamic and respiratory variables will be recorded.
89020938|NCT02959515|Active Comparator|Capnothorax and CPAP|Capnothorax is obtained by the insufflation of CO2in the right pleural cavity and maintained at a preset pressure of 10 mmHg. CPAP on the non ventilated lung is set at 10 cm H2O and FiO2=1. Arterial and central venous blood gasanalyses, hemodynamic and respiratory variables will be recorded.
89020939|NCT00353223|Experimental|A|Participants will receive combined interpersonal and behavioral psychotherapy aimed at reducing depression in patients with heart failure.
89020940|NCT00353223|Active Comparator|B|Participants will receive the attention control condition.
89020941|NCT00323804|Experimental|Randomised PegIFN alfa 2b + ribavirin (RBV) arm|Combination of ribavirin capsules 200 mg, weight-based daily dose ( <75 kg : 1000 mg ; ≥ 75 kg : 1200 mg), and low-dose PegIFN alfa 2b by subcutaneous injection 0.5 μg / kg / week, from day 0 to M36
89020942|NCT00323804|Placebo Comparator|Randomised PegIFN alfa 2b + ribavirin-placebo arm|Combination of ribavirin-placebo capsules 200 mg, weight-based daily dose ( <75 kg : 1000 mg ; ≥ 75 kg : 1200 mg), and low-dose PegIFN alfa 2b by subcutaneous injection 0.5 μg / kg / week, from day 0 to M36
89020943|NCT00331890|Experimental|Active|Receives active drug
89020944|NCT00331890|Placebo Comparator|Placebo|Receives a placebo
89020945|NCT01059773|Experimental|Immediate Methotrexate Cessation|Patients will receive ustekinumab by SC injection at Weeks 0, 4, 16, 28 and 40. The last dose of methotrexate will be taken anytime in the week prior to baseline (week 0).
89020946|NCT01059773|Active Comparator|Gradual Reduction of Methotrexate|Patients will receive ustekinumab by SC injection at Weeks 0, 4, 16, 28 and 40. Patients will gradually reduce the dose of methotrexate over the 4 week period after week 0.
89020947|NCT00353379|Experimental|guanfacine|Participants will take guanfacine.
89203426|NCT05435378|Experimental|Vitamin B-9|Vitamin B-9 capsule Manufacturer: Hebei Jiheng pharmaceutical Co. Ltd generic name: folic acid. Constituent components: 5 mg of folic acid. Route of administration: orally dosing schedule: 1capsule/day/before meal duration: for 30 days
89483410|NCT02126215||Study group - MRI CO2 and O2 stress test|This is a pilot study to assess feasibility of using MRI CO2 and O2 stress testing to predict POD.
89483411|NCT03261843|Active Comparator|posterior lumbar interbody fusion + platelet rich plasma|the addition of autologous platelet rich plasma to the bone graft
89483412|NCT03261843|Active Comparator|posterior lumbar interbody fusion|bone graft alone
89483413|NCT02133313||Peritoneal Dialysis Patients|Patients on Peritoneal Dialysis
89483414|NCT02126293|Experimental|Zinc deficient patients|If the patient is found to be zinc deficient (serum zinc < 11.5 μmol/L), the family will be contacted by the RA to commence zinc supplement: zinc citrate (Zinc Lozenges, manufactured by Douglas Laboratories Inc, London, ON, Health Canada NPN 80032476) for 3 months. As per the NPN licence the dose is 10 mg (1 lozenge) orally once a day for children age 4-8 years, and 10 mg twice a day for children age 9-18 years. This should give enough time to restore serum zinc to normal in most patients.
89483415|NCT02126293|Active Comparator|Zinc sufficient patients|Zinc sufficient patients will repeat blood and urine tests in 3 month time to compare the changes with intervention arm.
89483416|NCT03261765||Multiple repeat cesarean (four or more)|
89483417|NCT03261765||Fewer repeat cesarean (two-three)|
89483418|NCT02126371|Other|Active|LEO32731
89483419|NCT02133391|Active Comparator|Practice-based reminder/recall or Usual care arm|"Practices participating in state immunization registry invited to reminder/recall (R/R) webinar trainings and provided educational materials to encourage immunization within their practices (child and adolescent trials only)~Patients not randomized to the collaborative centralized R/R arm will receive usual care from their provider, which does not include R/R (adult trials only)"
89483420|NCT02133391|Experimental|Collaborative centralized R/R|Collaborative centralized reminder/recall (R/R) effort will be conducted by state immunization registry in collaboration with accountable care organizations and practices
89483421|NCT03261921|Active Comparator|Dexamethasone group|In this group the patients received 0.5 ml/kg of bupivacaine 0.25% + (0.1 mg/kg dexamethazone) caudally.
89483422|NCT03261921|Active Comparator|Dexmedetomidine group|In this group the Patients received 0.5 ml/kg of bupivacaine 0.25% + dexmedetomidine(1 mu/kg) caudally.
89483423|NCT03261921|Active Comparator|Combination group|In this group the patients received 0.5 ml/kg of bupivacaine 0.25% + dexamethasone(0.1mg/kg) and dexmedetomidine (1 mu/kg) caudally.
89483424|NCT02635724|Experimental|Peramivir|Single dose 600 mg IV injection
89483425|NCT02133469|Experimental|PCV7 (Vaccine)|Randomized group of 1634 subjects to be administered a single dose of PCV7 (Hib vaccine offered at end of study).
89483426|NCT02133469|Active Comparator|Hib vaccine|Randomized group of 1634 subjects to be administered a single dose of Hib Vaccine(PCV7 vaccine offered at end of study).
88952290|NCT05133986|Experimental|Couscous feeding first, onion feeding second|Participants will report to the laboratory at 8am in a fasted state (water consumption is permitted) and provide a spot baseline urine sample. Participants will then be served a 120g portion of couscous (control condition), prepared under standardized conditions. Participants shall remain supervised in the laboratory and will only consume water (100mL per hour) for the subsequent 6 hours, after which participants are free to consume their habitual diet (except alcohol, tea coffee, and FVs). In the 24-hour postprandial test period, participants will obtain urine samples at several time-points. Urine collection vessels will be used to obtain samples at 0-1, 1-2, 2-4, 4-6, 6-12, 12-24 hours. This experimental protocol shall be repeated following a 4-day washout period (habitual diet consumption with no restrictions imposed on participants) with 120g of onions consumed instead of couscous, as an experimental condition.
88952291|NCT05133986|Other|Onion supplementation period|This dose-dependent biomarker validation intervention will include three 4-day supplementation periods separated by two 3-day washout periods. Supplementation periods will provide participants with a daily portion of onions to be consumed with their evening meals. The daily quantity of onion supplementation, low (40g), medium, (80g) and high (160g), will remain constant throughout each 4-day period, and the order will be individually randomised. Participants will be asked to avoid onion intake throughout the supplementation periods, other than the portions provided by researchers. First morning void urine samples will be collected by participants on the morning after the supplementation period and obtained by researchers.
89020948|NCT00353379|Placebo Comparator|placebo|Participants will take placebo.
89483427|NCT03760653|Experimental|Physical Exercise and probiotic group|The subjects will receive 3 weekly sessions of combined exercise supervised by professionals in a specialized gym (60 minutes each one). The exercise will consist of a combination of aerobic and strength exercises involving the main muscle groups. They will take the probiotic supplementation at the established dose, 3 capsules/day before bedtime. Each probiotic capsule contains Lactobacillus rhamnosus, Lactobacillus paracasei, Lactobacillus acidophilus, Bifidobacterium bifidum.
89020949|NCT00331929|Experimental|A|Cohort of school children that evaluated with questionnaire and spirometry with MINATO 500 JAPAN spirometer
89020950|NCT00324194|Experimental|1|MGCD0103 oral dose 2 times per week.
89020951|NCT00324311|Experimental|DGD|
89020952|NCT00324311|Active Comparator|SOC|
89020953|NCT00353613|Other|1|LBJ Hospital
89020954|NCT00353613|Other|2|Ben Taub Hospital
89020955|NCT00332007|Experimental|1|Tonabersat 40 mg daily
89483428|NCT03760653|Experimental|Probiotic group|Participants will follow their usual sedentary lifestyle (i.e to practice less than 3 days a week of physical exercise, as is specified in the inclusion criteria). They will take the probiotic supplementation at the established dose. Each probiotic capsule contains Lactobacillus rhamnosus, Lactobacillus paracasei, Lactobacillus acidophilus, Bifidobacterium bifidum
89483429|NCT03760653|Placebo Comparator|Placebo group|They will follow their sedentary lifestyle. Placebo probiotic will consist of a maltodextrin capsule.
89483430|NCT02635646|Experimental|Family and interdisciplinary approach|Family and interdisciplinary approach: Patients in this group will receive a Family and interdisciplinary approach that includes nutritional, physical activity and psychological counseling + metformin 850mg twice at day for 12 months
89483431|NCT02635646|Active Comparator|individual approach|individual approach: Patients in this group will receive individual approach that includes nutritional and physical activity counseling + metformin 850mg twice at day for 12 months
89483432|NCT02128555|Active Comparator|Arthrodesis|Ankle arthrodesis (fusion)
89483433|NCT02128555|Experimental|Total Ankle Replacement|Total Ankle Replacement
89483434|NCT02456259||Neck cannula group|Patients in this group are indicated for neck cannula insertion due to tzpu of cardiac surgery (MICS)
89483435|NCT02456259||Central venous catheter only group|Patients in this group are indicated for central venous catheter insertion only.
89483436|NCT02126449|Experimental|Fasting mimicking diet|Short term fasting using Fasting mimicking diet around neoadjuvant chemotherapy (AC>T)
89483437|NCT02126449|No Intervention|regular diet|Standard neoadjuvant chemotherapy (AC>T)
89483438|NCT03259659||irritable bowel disease patient|Patients with ulcerative proctitis and proctosigmoiditis who meet the inclusion criteria, they will have ECG recording, inflammatory cytokines, microbiota, ulcerative colitis disease activity index.
89483439|NCT03259659||healthy control|Healthy participates who meet the inclusion criteria, they will have ECG recording, inflammatory cytokines, microbiota, ulcerative colitis disease activity index.
89483440|NCT03724305|Experimental|MBTI|Mindfulness-Based Therapy for Insomnia
89483441|NCT05001542|Experimental|Experimental Arm|VR simulation exercise with a digital follow-up component to help assess the physiological and psychological indicators of moral distress
89483442|NCT02126527|Experimental|Treatment (auranofin and sirolimus)|Patients receive auranofin PO QD and sirolimus PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89483443|NCT04997330|Experimental|Active rTMS|Bilateral high frequency (20Hz) Repetitive Transcranial Magnetic Stimulation (rTMS) over DLPFC
89483444|NCT04997330|Placebo Comparator|Sham rTMS|Sham bilateral high frequency (20Hz) Repetitive Transcranial Magnetic Stimulation (rTMS) over DLPFC
89020956|NCT00332007|Placebo Comparator|2|
89020957|NCT00324428|Experimental|Transcranial Magnetic Stimulation (TMS)|This arm provides active 1Hz repetitive TMS (rTMS) applied to SII
89020958|NCT00324428|Sham Comparator|Transcranial Magnetic Stimulation Sham|This arm provides sham 1Hz repetitive TMS (rTMS) applied to SII
89020959|NCT00324467|Active Comparator|R-CHOP (Negative Mid-Treatment PET Scan)|"All participants will receive 4 cycles of standard dose R-CHOP chemotherapy administered at 3-weekly intervals. Non-progressing participants will undergo a mid-treatment PET scan along with routine restaging investigations after 4 cycles of R-CHOP. Patients with a negative mid-treatment PET scan (no evidence of abnormal 18F-FDG uptake) will complete therapy with two additional cycles of R-CHOP for a total of 6 cycles of chemotherapy. Patients with a mid-treatment PET scan interpreted to be indeterminate or equivocal will be recorded as such, but should be considered negative for the purpose of treatment planning and should not prompt a change in therapy."
89203427|NCT05435378|Placebo Comparator|Placebo capsule|Placebo capsule Manufacturer: Shivangan Foods & Pharma Products Pvt. Ltd Constituent components: inactive fillers Route of administration: orally dosing schedule: 1capsule/day/before meal duration: for 30 days
89203428|NCT04002622|Experimental|TQB2450|TQB2450 1200 milligrams (mg) administered intravenously (IV) on Day 1 of each 21-day cycle.
89203429|NCT04003324|Experimental|Intervention group|Self-monitoring tool (Activator) and general information
89483445|NCT02133625|Experimental|Pioglitazone and Carboplatin|"MTD Determination~Pioglitazone: 45 mg Once Daily by mouth,Cycle 1Days 1-28; Subsequent cycles: Days 1-21~Carboplatin:6 AUC IV 60 minute infusion (or per institutional policy) Cycle 1: Day 8; Subsequent cycles: Day 1"
89483446|NCT02133625|Experimental|MTD Expansion Carboplatin and Pioglitazone|"MTD Expansion:~Carboplatin alone on cycle 1, day 1.~Pioglitazone Over days 15-21 of the cycle pioglitazone will be administered alone.~On cycle 2, day 1, both carboplatin and pioglitazone will be administered. Cycle 2 and onward are 21-day cycles, with pioglitazone administered once daily and carboplatin administered once every 3 weeks"
89483447|NCT02455635|Active Comparator|women with pain|women who felt pain at time of office hystroscopy at time of saline infusion and for 15 minutes after end of procedure
89483448|NCT02455635|Active Comparator|women without pain|women who didn't feel pain at time of office hystroscopy at time of saline infusion and for 15 minutes after end of procedure
89483449|NCT02260687||Group 1|Decision of treatment is made by attending investigator according to the Japanese Package Insert
89483450|NCT05001464||Reflectance Pulse Oximeter|The participants wear reflectance pulse oximeter for continuous monitoring when carrying out PSG . Oxygen desaturation index (ODI), average blood oxygen saturation, minimum blood oxygen saturation, percentage of blood oxygen saturation less than 90% in the whole recording time (TS90%), fastest heart rate, slowest heart rate and average heart rate are recorded by reflectance pulse oximeter.
89483451|NCT03252639||Patients with Renal Artery Stenosis|Patients with renal artery stenosis which may benefit from endovascular treatment will be recruited. Those patients who cannot benefit from this procedure will be excluded.
89483452|NCT02260765|Active Comparator|HCP dTMS|this arm will receive dTMS treatment
89483453|NCT02260765|No Intervention|HCP TAU|this arm will continue with the same drugs that they are using usually, which mean treatment as usual
89483454|NCT03071900|Experimental|SCCHN|squamous cell carcinoma of the head and neck
89483455|NCT03071900|Experimental|Control|health volunteers
89483456|NCT03252483|Active Comparator|HIV Only|Those randomized to the control group were offered only an HIV test.
89483457|NCT03252483|Experimental|Bundled HCV/HIV|Those randomized to the intervention group were offered both HCV and HIV test.s
89483458|NCT02260843|No Intervention|Control|Subjects in this group do not received any intervention.
89483459|NCT02260843|Active Comparator|Tai Chi Intervention|Subjects in this group will receive three tai chi lessons in a week while each session last for 1 hour for 12 weeks
89483460|NCT02260843|Placebo Comparator|Generic Fitness Intervention|Subjects in this group will receive three fitness lessons in a week while each session last for 1 hour for 12 weeks
89483461|NCT03071588|Active Comparator|Control|the conventional protocol in indirect pulp capping include the use of mechanical rotary burs for caries removal in teeth with reversible pulpitis.
89483462|NCT03071588|Experimental|Conservative|the conservative protocol of indirect pulp capping include the use of Carisolv gel for caries removal in teeth with reversible pulpitis.
89483463|NCT03259347|Experimental|Counter-attitudinal therapy|Counter-attitudinal therapy (CAT) is dissonance-based group intervention. CAT consists of behavioral, written, and verbal exercises in which participants discuss the costs of pursuing the thin ideal and behaviors that are used to pursue the thin ideal. The intervention is 8 sessions long (1-hr each) and is administered by a trained facilitator who uses an intervention script. Participants will be asked to complete weekly home exercises throughout the course of the intervention.
89483464|NCT03259347|Active Comparator|Educational-support group|The educational support group intervention that is representative of typical treatment groups offered at universities and community settings. For the current study, the educational support group was designed to match the dissonance group on treatment modality (group-based), duration (8 1-hr sessions), and use of an intervention script administered by a trained facilitator. In the intervention sessions, participants will be provided with a basic education about eating disorders, support for themselves and fellow group members, and learn mindfulness techniques.Participants will be asked to complete weekly homework assignments.
88952292|NCT05129722|Experimental|Patients receiving low dose combination polydiuretic therapy|This patient group will receive a low dose combination polydiuretic therapy treatment consisting of: bumetanide 0.5 mg (loop diuretic), eplerenone 25 mg (mineralocorticoid receptor antagonist) and empagliflozin 10mg (sodium-glucose co-transporter 2 inhibitor) daily on top of their background therapy.
89483465|NCT03071822|Experimental|PIGLETs|Patient will be given this combination of chemotherapy (cisplatin, ifosfamide, gemcitabine, L-asparaginase, etoposide and dexamethasone) for a total of 6 courses
89483466|NCT03551353||Group before Video-assisted feedback|Ten anesthesia residents will be included in this group. Preoperative evaluation in terms of general anesthesia will be completed for a patient before anesthesia induction. After receiving informed consent from the patient resident will complete the preparations by checking the above-mentioned list (anesthesia machine, operating room desk, monitorization methods, aspirator systems, operating room gas systems, waste systems and other anesthesia equipment) then induction will be started. All these steps will be recorded with a camera system. Once the anesthetic application is completed and all stages are recorded, the video records will be evaluated in terms of ASA guideline
89483467|NCT03551353||Group after Video-assisted feedback|Before the second phase of the study, the resident will be informed about the guideline (checkout procedure) by a staff. Then induction of general anesthesia in another patient will be recorded at all stages. Once the anesthesia application is complete, the camera record will be monitored. Differences and developments or possible similar mistakes between the records will be discussed.
89483468|NCT02456493||increased carotid IMT group|Patients who have increased carotid IMT (intima media thickness)
89483469|NCT02456493||normal carotid IMT group|Patients who have normal carotid IMT
89483470|NCT02252653||Familial Amyloidotic Cardiomyopathy (FAC)|
89483471|NCT04930172||Steerable introducers|
89483472|NCT02456415|Experimental|K-MET™ Bioresorbable Bone screw|The K-MET™ Bioresorbable Bone Screw, intended to be used for trauma therapy, consists of Cortex screws, Cannulated headless screws. For Headless screw and Cannulated headless screws, the design is similar to normal headless compression screws but the compression function was achieved by using different lengths for the front and rear pitches. These screws are dynamic and allow therewith the fracture at the Carpal, metacarpal, and small hand bone.
89483473|NCT04991012|Experimental|photodynamic therapy side|On one side, the OLP lesion eligible for treatment was subjected to photodynamic therapy in four sessions every 2 days.Using as photosensitizer Methylen blue for 10min the lesion was irradiated with a 650 nm semiconductor laser at a dose of 120 J / cm2
89483474|NCT04991012|Active Comparator|Triamcinolone (Substance) therapy side|on the other side The OLP on the other side was treated by daily sticking a cut-to-size carrier with 0.05% triamcinolone acetonide for 8 days
89483475|NCT03261219|Experimental|Intrapulmonary Percussive ventilation|
89483476|NCT03261219|Active Comparator|Chest Physiotherapy vest|
89483477|NCT02252731|Experimental|warfarin and FG-4592|Single dose of warfarin and Multiple doses of FG-4592 in combination with a single dose of warfarin
89483478|NCT03259113|Other|Insertable cardiac monitor|All patients will undergo monitoring using an insertable cardiac monitor (single arm)
89483479|NCT02128633|Placebo Comparator|placebo|"Individuals that were randomized for treatment  A  . The product tested were always delivered in a transparent plastic syringe with 10 mls marking identified by the letters  A  . The syringes were given to individuals in an opaque plastic envelope sealed and delivered along with a reminder of the correct way to use the products. Guidance for the use of substances was to make application with a new toothbrush, 1 time a day (at night, before bed, after brushing the teeth) with the product received, for 1 minute and the amount of 0.25 g (0.5 ml) of the product as the demarcation the syringe. It was recommended that after using the products, they were expelled without rinsing the oral cavity with water (Placebo gel)."
89483480|NCT02128633|Experimental|Experimental gel|"Individuals that were randomized for treatment  B  - The product was delivered in a transparent plastic syringe with 10 mls identified by the letter  B . The syringes were given to individuals in an opaque plastic envelope sealed and with a reminder of the correct way to use the products. Guidance for the use of substances was to make application with a new toothbrush, 1 time a day (at night, before bed, after brushing the teeth) with the product received, for 1 minute and the amount of 0.25 g (0.5 ml) of the product as the demarcation the syringe. It was recommended that after using the products, they were expelled without rinsing the oral cavity with water (5% sodium fluoride, potassium oxalate 5%, strontium chloride 10% ) ."
89483481|NCT02128633|Active Comparator|Positive control|"Individuals that were randomized for treatment  C  . The product tested were always delivered in a transparent plastic syringe with 10 mls marking identified by the letters  C  . The syringes were given to individuals in an opaque plastic envelope sealed and delivered along with a reminder of the correct way to use the products. Guidance for the use of substances was to make application with a new toothbrush, 1 time a day (at night, before bed, after brushing the teeth) with the product received, for 1 minute and the amount of 0.25 g (0.5 ml) of the product as the demarcation the syringe. It was recommended that after using the products, they were expelled without rinsing the oral cavity with water (Fluoride neutral NaF gel 2 %)."
89483482|NCT04990856|Experimental|Experimental arm|Blood flow of the tumor experimented
89483483|NCT03259191|Other|completely circumferential ARMS|
89483484|NCT03259191|Other|semi-circumferential ARMS|
89483485|NCT02126683|Experimental|Plaquenil first|Start Plaquenil 200mg BID orally since enrollment Duration: 6 months
89483486|NCT02126683|Experimental|Plaquenil later|Start Plaquenil 200mg BID orally since the 25th week after enrollment Duration: 6 months
89483487|NCT03258957|Experimental|Fresh milk group|In the intervention group, mothers will be asked to provide at least 1 feed of fresh milk (i.e. within 4 hours of milk expression) per day.Other time, feed frozen milk.
89483488|NCT02252185|Experimental|China made spine fusion system|patents in this arm will be implanted with Johnson&Johnson Medical Suzhou made Spine Fusion System.
89483489|NCT02252185|Active Comparator|Imported spine fusion system|patents in this arm will be implanted with Imported EXPEDIUM screws and OPAL cage .
89483490|NCT03252561|Experimental|TAP block|Patients in this arm will receive ultrasound guided TAP bock with Bupivacaine 0.25% 20ml per side or to a maximum 1mg/kg per side and the skin puncture will be covered with a small plaster
89483491|NCT03252561|Active Comparator|Local anaesthetic infiltration|Laparoscopic port sites will be infiltrated with a total of 20 mls 0.5% bupivacaine subcutaneously at the end of the procedure in the control group and plasters will be stuck on either side approximately where a skin puncture for tap block would be made.
89483492|NCT02133859||Chronic Heart Failure patients using ASV|Patients with chronic heart failure who are using or willing to use adaptive servo ventilation (ASV) therapy will be enrolled. Respiratory data will be collected from this group every 3 months over a 12 month period
89483493|NCT02455323|Experimental|Suboccipital inhibitory|Suboccipital inhibitory pressure technique. According to this technique, the suboccipital musculature is palpated until contact is made with the posterior arch of the atlas, and progressive and deep gliding pressure is applied, pushing the atlas anteriorly. The occiput rests on the hands while the atlas is supported by the fingertips. Finger pressure must be maintained for 10 minutes to produce the therapeutic effect of inhibiting the suboccipital soft tissues.
88952293|NCT05129722|Active Comparator|Comparator group receiving monotherapy empagliflozin|This comparator patient group will receive empagliflozin 10mg (sodium-glucose co-transporter 2 inhibitor) daily on top of their background therapy.
88952294|NCT05100745|Experimental|Activated Therapy|Therapy: these subjects will undergo 30 treatments with an activated Vibratosleeve TUS device.
89483494|NCT02455323|Experimental|Spinal Manipulative|Suboccipital inhibitory pressure technique. This technique is performed along an imaginary vertical line passing through the odontoid process of the axis. No flexion or extension and very little lateroflexion are used. Application is bilateral. First, cephalic decompression is performed lightly, followed by small circumductions. Selective tension is applied to take up tissue slack and create a firm joint barrier. Manipulation is then performed with rotation towards the manipulated side in a helicoidal cranial movement. This technique is designed to correct a generalized dysfunction with the aim of restoring occiput, atlas, and axis joint mobility.
89483495|NCT02455323|Experimental|Combined treatment|Consisted in applying the above two techniques using exactly the same sequence: first the SI technique, and then the SM technique.
89483496|NCT02455323|Placebo Comparator|Control group|The subjects received no treatment, but attended the same number of sessions, maintaining the resting position for longer than the experimental groups, and underwent the same evaluations (test for arterial compromise, and the three assessments).
89483497|NCT02252263|Experimental|Arm 1: Elotuzumab + Lirilumab|Elotuzumab weekly for 8 wks and every 2 wks thereafter + Lirilumab every 4 wks Intravenous solution for Up to 2 yrs, depending on response
89483498|NCT02252263|Experimental|Arm 2: Elotuzumab + Urelumab|Elotuzumab weekly for 8 wks and every 2 wks thereafter + Urelumab every 4 wks Intravenous solution for Up to 26 weeks, depending on response
89483499|NCT04996550||Carvedilol group|Treated with Carvedilol
89483500|NCT04996550||Metoprolol succinate group|Treated with Metoprolol succinate
89483501|NCT03252171|Experimental|Experimental: CAR-T cell immunotherapy|Enrolled patients will receive CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at GD2 antigen by infusion.
89483502|NCT03252171|No Intervention|No Intervention|
89483503|NCT04996784||Normal weight|"The patients (n=30) will be stratified into 2 groups based on their body mass Index (BMI).The normal weight group will contain 15 patients with a 18.5 ≤ BMI ≤ 25 kg/m2.~Each group will be divided in two subgroups (female/ male)"
89483504|NCT04996784||Obese|"The patients (n=30) will be stratified into 2 groups based on their body mass Index (BMI). The obese group will contain 15 patients with a BMI ≥ 30 kg/m2.~Each group will be divided in two subgroups (female/ male)"
88952295|NCT05100745|Sham Comparator|Sham Therapy|An inactive (sham) device will be used in these subjects for the first 30 treatments followed by a 30-treatment regimen with an activated VibratoSleeve TUS device after crossover.
88952296|NCT05060510|No Intervention|control phase|Schools will start in the control phase (SARS-CoV-2 diagnostic testing at an assessment center, primary care office or acute care center) and transition to the intervention phase at a randomly assigned time point over the course of the study.
88952297|NCT05060510|Active Comparator|Intervention phase|Schools will have take home saliva kits available at the school to support SARS-CoV-2 diagnostic testing. Schools will transition to the intervention phase at a randomly assigned time (wedge) over a 6-week period with all schools receiving the program by the end of the study.
89483505|NCT02133937|Experimental|High Concentration Liquid Formulation (HCLF)|
89483506|NCT02133937|Active Comparator|Lyophilized formulation|
89483507|NCT03252405|Active Comparator|mask ventilation|induction is made with mask ventilation
89483508|NCT03252405|Experimental|intravenous induction|induction is made with intravenous cannulation
89483509|NCT02135965|Experimental|Albuterol 2mg|2 mg of Albuterol is in a pill form or placebo
89483510|NCT02135965|Experimental|Albuterol 4mg|4mg of Albuterol or placebo is given in pill form
89483511|NCT02135965|Experimental|Caffeine 100mg|100mg of Caffeine or placebo is given in a pill form.
89483512|NCT02135965|Experimental|Caffeine 200mg|200mg of Caffeine or placebo is given in a pill form
89483513|NCT02135965|Experimental|Albuterol 2mg & Caffeine 100mg|100mg of Caffeine in combination with Albuterol 2mg or placebo is given in a pill form.
89483514|NCT02135965|Experimental|Albuterol 2mg and Caffeine 200mg|200mg of Caffeine in combination with Albuterol 2mg or placebo is given in a pill form.
89483515|NCT02135965|Experimental|Albuterol 4mg and Caffeine 100mg|100mg of Caffeine in combination with Albuterol 4mg or placebo is given in a pill form.
89483516|NCT02135965|Experimental|Albuterol 4mg and Caffeine 200mg|200mg of Caffeine in combination with Albuterol 4mg or placebo is given in a pill form.
89483517|NCT03261141||study group sixty three children|"severity and character of dysphonia APA using a modified GRBAS scale which gives scores as regard the degree and severity of dysphonia and its character.~Acoustic Analysis of voice : which is Computerized Speech Laboratory analysis of voice that gives the following measures jitter (%), shimmer (dB), and harmonic to noise ratio (H/N).~the degree of social ,emotional ,functional and physical disturbance ,if present in those children with voice disorders by application of The Arabic Pediatric Voice Related Quality of Life (PV-RQOL)."
89483518|NCT03261141||control group sixty three children|"severity and character of dysphonia (APA using a modified GRBAS scale which gives scores as regard the degree and severity of dysphonia and its character.~Acoustic Analysis of voice : which is Computerized Speech Laboratory analysis of voice that gives the following measures jitter (%), shimmer (dB), and harmonic to noise ratio (H/N).~the degree of social ,emotional ,functional and physical disturbance ,if present in those children with voice disorders by application of The Arabic Pediatric Voice Related Quality of Life (PV-RQOL)."
89483519|NCT03074708|Other|3D visualization and 3D printing|From January 2016 to December 2018,the clinical data of 200 patients with the hepatobiliary and pancreatic diseases will be collected.All the patients received abdominal CT scanning and 3D reconstruction. Then we used the 3D reconstruction model and the 3D printed model based on the 3D reconstruction model in the operation planning and the operation.The clinical data include operative time, intraoperative blood loss,and postoperative complications after surgery.
89483520|NCT02455401|Experimental|high dose remifentanil group|Intervention: high dose remifentanil will be administrated.
89483521|NCT02455401|Experimental|low dose remifentanil group|Intervention: low dose remifentanil will be administrated
88952298|NCT05056376|Experimental|Fully-Automated Digital Diabetes Prevention Program|Participants will receive Sweetch Digital Diabetes Prevention Program consists of a smartphone app and bluetooth-enabled digital body weight scale that syncs with the app.
88952299|NCT05056376|Active Comparator|Human Coach-Based Diabetes Prevention Program|Participants will attend a total of 16 weekly sessions during months 1 to 6 and 6 sessions during months 7 to 12. These group sessions may be delivered in-person at the local program or remotely using video conferencing. During these sessions, participants will receive information about lifestyle change behaviors focusing on weight loss, physical activity, and nutrition from a trained lifestyle coach.
89483522|NCT02455401|Placebo Comparator|No remifentanil group|Intervention: no remifenatnil will be administrated
88952300|NCT05055505|No Intervention|control phase|Schools will start in the control phase (SARS-CoV-2 diagnostic testing at an assessment center, primary care office or acute care center) and transition to the intervention phase at a randomly assigned time point over the course of the study.
89483523|NCT02128789|No Intervention|Control Condition|Subjects receive usual care and support. No study intervention provided
89483524|NCT02128789|Experimental|Elder Tree Condition|Elder Tree website. Subjects receive usual care, support and access to the study intervention website.
89483525|NCT02136043|Experimental|Group 1|Insertion of catheter into nasal cavity carried out by patient. Fixation of catheter during treatment with patient´s hand.
89483526|NCT02136043|Experimental|Group 2|Insertion of catheter into nasal cavity carried out by health professional. Fixation of catheter during treatment with helmet.
89483527|NCT04987268||Current-smoking|exposure: smoking
89483528|NCT04987268||Smoking-cessation|exposure: smoking cessation
89483529|NCT04987268||non-smoking|exposure: none
89483530|NCT03258801||Pirfenidone|Patients who are admitted to the lung transplantation department and fulfill the international criteria for idiopathic pulmonary fibrosis and are treated with Pirfenidone as bridging therapy.
89483531|NCT03258801||Control|Patients who are admitted to the lung transplantation department and fulfill the international criteria for idiopathic pulmonary fibrosis and are not treated with Pirfenidone.
89483532|NCT02136121|Experimental|da Vinci Sp Surgical System|da Vinci Sp Surgical System - Robotic - assisted single-port surgery
89483533|NCT03070262|Experimental|CA group|caffeic acid (300mg, tid, po) continue given until progression of disease or death, or patients are unable to bear the side effects
89483534|NCT03070262|Placebo Comparator|placebo group|the same shape placebo tablets continue given until progression of disease or death, or patients are unable to bear the side effects
89483535|NCT03260829|Active Comparator|vitamin C injection|orthodontic traction with vitamin C injection
89483536|NCT03260829|Placebo Comparator|orthodontic traction|orthodontic traction without vitamin C injection
89483537|NCT03258879|Experimental|Modified CSE|MCSE group: 1 ml of 0.25% bupivacaine will be injected intrathecally
89483538|NCT03258879|Active Comparator|Dural puncture epidural|Dural puncture performed with a spinal needle, but no medication will be injected intrathecally.
89483539|NCT04987190||all cleft patients divided into unilateral and bilateral groups|One group of cleft patients received the alveolar bone graft surgery
89020960|NCT00324467|Active Comparator|R-ICE (Positive Mid-Treatment PET Scan|"All participants will receive 4 cycles of standard dose R-CHOP chemotherapy administered at 3-weekly intervals. Non-progressing participants will undergo a mid-treatment PET scan along with routine restaging investigations after 4 cycles of R-CHOP. Patients with a mid-treatment PET scan (abnormal 18F-FDG uptake) will be switched to R-ICE chemotherapy and receive 4 cycles of R-ICE for a total of 8 cycles of chemotherapy.~Following completion of R-ICE chemotherapy, patients will undergo a post-treatment PET scan along with routine restaging investigations. The post-treatment PET scan will be performed between days 28 and 35 following the final cycle of R-ICE. Patients with a negative post-treatment PET scan will undergo no further therapy. Patients with a positive post-treatment PET scan corresponding to persistent abnormalities on CT scan will be considered for radiation therapy to PET positive sites."
89020961|NCT00324506|Active Comparator|Cellcept and Avonex|
89020962|NCT00332124|Placebo Comparator|1|Participants will take placebo
89483540|NCT03260985|Experimental|Feedback Group|All participants in the study will undergo a comprehensive neuroscience assessment including clinical questionnaires, a structured diagnostic interview, neuropsychological assessment, genetic testing, and structural and functional MRI. Participants randomized to the Feedback Group will have the results of this assessment shared with their psychiatric treatment team before they begin treatment. This data will be used at the full discretion of the treatment team to inform personalized treatment options. All treatment decisions remain up to the treatment providers and patient.
89020963|NCT00332124|Active Comparator|2|Participants will take choline
89020964|NCT00419432|Active Comparator|Group A (standard pre-operative analysis)|
89020965|NCT00419432|Experimental|Group B (additional pre-operative analysis)|
89020966|NCT04714554|Experimental|Part 1: Relugolix/E2/NETA Plus Erythromycin|"Treatment Period 1: Healthy premenopausal women will receive a relugolix/E2/NETA (40 mg/1 mg/0.5 mg) alone on Day 1.~Treatment Period 2: Healthy premenopausal women will receive erythromycin on Day 1 through 12 (500 mg, QID), with co-administration of a single dose of relugolix/E2/NETA (40 mg/1 mg/0.5 mg) with the morning dose of erythromycin on Day 8."
89483541|NCT03260985|No Intervention|Delayed Feedback Group|All participants in the study will undergo a comprehensive neuroscience assessment including clinical questionnaires, a structured diagnostic interview, neuropsychological assessment, genetic testing, and structural and functional MRI. However, participants randomized to the Delayed Feedback Group will not have the results of this assessment shared with their treatment team until the end of their participation in this study (12 weeks).
89483542|NCT04990700|No Intervention|Control Group|Includes patients undergoing routine thoracotomy
89483543|NCT04990700|Experimental|Intervention Group|The group that will undergo 1 cm partial rib resection during thoracotomy.
89483544|NCT03260907|Experimental|Electroacupuncture|The patients in this group received electroacupuncture using the same acupuncture points prescribed by a certified Korean Medicine Doctor with more than 6 years of oriental medicine college education and 1 years of clinical experience.
89483545|NCT03260907|Experimental|Acupuncture|The patients in this group received acupuncture without electric stimulation using the same acupuncture points prescribed by a certified Korean Medicine Doctor with more than 6 years of oriental medicine college education and 1 years of clinical experience.
89020967|NCT04714554|Experimental|Part 2: Relugolix Plus Erythromycin|"Treatment Period 1: Male participants will receive a single 120-mg dose of relugolix alone on Day 1.~Treatment Period 2: Male participants will receive erythromycin on Days 1 through 12 (500 mg, QID), with co-administration of a single 120-mg dose of relugolix with the morning dose of erythromycin on Day 8."
89020968|NCT00419471|Experimental|Escitalopram|
89020969|NCT00419471|Placebo Comparator|Placebo pill|
89483546|NCT02134093|Placebo Comparator|Normal saline|Continuous pump infusion of normal saline with identical volume, compared with the low dose and high dose group,until the end of surgery
89483547|NCT02134093|Experimental|High dose group, dexmedetomidine|Continuous pump infusion dexmedetomidine at 1μg/kg for 15 minutes before anesthesia induction ,then continuous pump infusion dexmedetomidine at 0.4μg/kg/h until the end of surgery
89483548|NCT02134093|Experimental|Low dose group, dexmedetomidine|Continuous pump infusion dexmedetomidine at 0.5μg/kg for 15 minutes before anesthesia induction ,then continuous pump infusion dexmedetomidine at 0.2μg/kg/h until the end of surgery
89483549|NCT03071354|Experimental|HMB Protein Supplementation Group|"Intervention patients will receive 2 x 237mL bottles of the commercially available liquid HMB protein supplement (3g) (Ensure Active™ Muscle Health) throughout the study.~In addition, all patients will be fed according to the Canadian Critical Nutrition Practice Guidelines, and protein/energy requirements will be determined by the local dietitians according to their local practice standards."
89483550|NCT03071354|Active Comparator|Control Group|"Control patients will receive 2 x 237mL bottles of the commercially available nutritional supplement (Ensure® Original) throughout the study.~In addition, all patients will be fed according to the Canadian Critical Nutrition Practice Guidelines, and protein/energy requirements will be determined by the local dietitians according to their local practice standards."
89483551|NCT03252327|No Intervention|routine care|Preterm infants in the control condition will receive only usual neonatal intensive care units (NICU) care
89483552|NCT03252327|Experimental|Multiple Sensory Integrations(1)|The sensory integrations are provided through combining the use of sensory integrations ( olfactory, taste, auditory or tactile).
89483553|NCT03252327|Experimental|Multiple Sensory Integrations(2)|The sensory integrations are provided through combining the use of sensory integrations ( olfactory, taste, auditory or tactile).
89483554|NCT03252327|Experimental|Multiple Sensory Integrations(3)|The sensory integrations are provided through combining the use of sensory integrations ( olfactory, taste, auditory or tactile).
89020970|NCT00426348|Active Comparator|1|In arm 1,Valsartan(80-160mg/day) is given to patients in combination with Placebo
89020971|NCT00426348|Experimental|2|Valsartan(80-160mg/day) + Probucol(750mg/day)
89020972|NCT00353808|Experimental|s, s reboxetine|
89020973|NCT00324623|Experimental|Lymphodepletion, vaccine, IMP321 adjuvant|
89020974|NCT00426426|Active Comparator|Meta-Cognitive Therapy|first Meta-cognitive therapy then Cognitive Behaviour Therapy
89020975|NCT00426426|Active Comparator|Cognitive Behaviour Therapy|first Cognitive Behaviour Therapy then Meta-cognitive therapy
89020976|NCT00426426|Other|Waiting List|Waiting List
89020977|NCT00324974|Experimental|Lansoprazole QD|
89483555|NCT03261063|Experimental|Evera Implanted Group|
89483556|NCT03074786|Experimental|Vaginal Matrix Ring|Dapivirine vaginal ring containing 25 mg of dapivirine to be replaced each month.
89483557|NCT03074786|Experimental|Oral Emtricitanbine/Tenofovir Disoproxil|Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) tablets to be taken orally daily
89483558|NCT04990076||Patients planned for hysterectomy with a myometrial lesion of more than 1 cm.|
89483559|NCT03260751|Experimental|Zingiber officinale Roscoe extract 200 mg|2 cap/day, 800 mg/cap for 12 weeks
89483560|NCT03260751|Placebo Comparator|Placebo|Placebo for 12 weeks
89020978|NCT00324974|Placebo Comparator|Placebo QD|
89020979|NCT00325013|Experimental|II|
89020980|NCT00426504|Experimental|radiotherapy|Helical Tomotherapy Intensity Modulated Radiotherapy (HT-IMRT) with the intend of delivering radical radiotherapy to a dose of 66-70 Gy to involved areas and at least 50 Gy to un-involved sites to be treated prophylactically.
89020981|NCT00325286|Experimental|1|Treatment with lithium and extended release carbamazepine
89020982|NCT00354081|Active Comparator|1|folic acid (0.8 mg) plus vitamin B12 (0.4 mg) and vitamin B6 (40 mg)
89020983|NCT00354081|Active Comparator|2|folic acid (0.8 mg) plus vitamin B12 (0.4 mg)
89020984|NCT00354081|Active Comparator|3|vitamin B6 (40 mg)
89020985|NCT00354081|Placebo Comparator|4|placebo
89020986|NCT00325520||Anorexia nervosa|Individuals with anorexia nervosa receiving inpatient treatment
89020987|NCT00325520||Healthy controls|
89020988|NCT04705311|Experimental|pain neuroscience education plus rotator cuff repair rehabilitation|
89020989|NCT04705311|Active Comparator|rotator cuff repair rehabilitation|
89483561|NCT03074552|Experimental|Probiotics|The probiotic preparation [ LactoLevure] will consist a combination of four probiotics.
89483562|NCT03074552|Placebo Comparator|Placebo|Placebo will consist of identical capsules of powdered glucose polymer, and they will be constructed by the same industry that manufactures the probiotics capsules.
88952301|NCT05055505|Active Comparator|Intervention phase|Schools will have take home saliva kits available at the school to support SARS-CoV-2 diagnostic testing. Schools will transition to the intervention phase at a randomly assigned time (wedge) over a 6-week period with all schools receiving the program by the end of the study.
89020990|NCT00325637|Active Comparator|A,1,III|To compare the effect of cilnidipine (calcium channel blocker) and losartan (angiotension II receptor blocker) on CBF in patients with ischemic stroke
89203430|NCT02560454|Experimental|Cogmed®|"Cogmed® : working memory training (unifactorial) Before beginning the program an appointment of one hour will be organized to present the program.~Participants will train at home during 25 sessions (about 30-45 minutes each) over a maximum of 5-6 weeks.~A coach will call the participant one a week to verify program adherence. The coach will verify participant results on internet before calling."
89203431|NCT02560454|Experimental|Presco®|"Presco® : different cognitive function are trained (multifactorial) Before beginning the program an appointment of one hour will be organized to present the program.~Participants will train at home during 25 sessions (about 30-45 minutes each) over a maximum of 5-6 weeks.~A coach will call the participant one a week to verify program adherence. The coach will verify participant results on internet before calling."
89203432|NCT02560454|No Intervention|Control|Control ( waiting list)
89203433|NCT03895840|Experimental|Intra-articular Zilretta injection|32 mg Zilretta in a 5ml diluent for each knee, per manufacturer guidelines
89203434|NCT00310375|Experimental|Ezogabine: USAN Retigabine (International Nonproprietary Name)|Film-coated tablets - 50mg, 100mg or 300mg
89203435|NCT02532673||Hyperbilirubinemia Cohort|Patients will be included who have evidence of hyperbilirubinemia (laboratory test of grade 2 or greater or > 2 medical claims with an International Classification of Diseases, Ninth Revision, Clinical Modification code of 782.4 or 277.4 in any position) in the first 90 days after initiating Atazanavir therapy.
89203436|NCT02532673||Non-hyperbilirubinemia cohort|Patients will be included who have no evidence of hyperbilirubinemia (no laboratory test of grade 2 or greater or any medical claims with an International Classification of Diseases, Ninth Revision, Clinical Modification of 782.4 or 277.4 in any position) in the 12-month follow-up period.
89203437|NCT01061281|Active Comparator|Tecnis MF IOL|
89203438|NCT01061281|Active Comparator|Crystalens AO IOL|
89203439|NCT02532985|Placebo Comparator|Negative control|No added fiber
89203440|NCT02532985|Active Comparator|Positive fiber control|90g positive control fiber
89203441|NCT02532985|Experimental|Novel fiber 30g|30g novel fiber
89203442|NCT02532985|Experimental|Novel fiber 60g|60g novel fiber
89203443|NCT02532985|Experimental|Novel fiber 90g|90g novel fiber
89203444|NCT00309907|Experimental|Etanercept and corticosteroid therapy|Patients receive etanercept IV (dose 0.4 mg/kg- max 25 mg) over 30 minutes on day 0 and subcutaneously (dose 0.4 mg/kg- max 25 mg) on days 3, 7, 10, 14, 17, 21, and 24. Treatment continues in the absence of an infectious pathogen, disease progression, or unacceptable toxicity. Patients also receive methylprednisolone (or corticosteroid equivalent) IV (dose 2.0 mg/kg/day) on days 0-2 and then orally with a taper beginning day 7. Dose on days 7-20 (1.0 mg/kg/day), days 21-34 (0.5 mg/kg/day), days 35-48 (0.25 mg/kg/day) and days 49-56 (0.25 mg/kg/every other day) discontinuing on day 56.
89203445|NCT01063777|Active Comparator|1|
89203446|NCT01063777|Active Comparator|2|
89203447|NCT00655824|Experimental|Ofatumumab|1000 mL dilution of 35mls ofatumumab in sterile, pyrogen free, 0.9% NaCl
89203448|NCT03985969|Experimental|DDI|Period 1: study of elafibranor's pharmacokinetics Period 2: study of elafibranor's pharmacokinetics under CHRONO-INDOCID® (indomethacin) at steady state
89203449|NCT01061437|Active Comparator|Arm 1|Standard 14 day, 3-drug regimen
89203450|NCT01061437|Experimental|Arm 2|Concomitant Therapy - 5 day, 4-drug regimen
89203451|NCT01061437|Experimental|Arm 3|Sequential Therapy - 10 day, 4-drug regimen
89203452|NCT00575588|Experimental|Saxagliptin|
89203453|NCT00575588|Experimental|Glipizide|
89203454|NCT01058317|Experimental|Children treated with propranolol|
89203455|NCT01058473||Sickle Cell Disease|
89203456|NCT02553096|Experimental|ACCESS|ACCESS is used when participants experience more COPD symptoms.
89203457|NCT02553096|No Intervention|paper plan|Paper exacerbation action plan is used when participants experience more COPD symptoms.
89203458|NCT00810030|Experimental|FERINJECT® (Ferric carboxymaltose)|
89203459|NCT00810030|Active Comparator|VENOFER® (Iron Sucrose)|
89203460|NCT02560142||All Participants|Healthy participants will undergo behavioral assessment and fMRI.
89203461|NCT00804102|Active Comparator|Retinitis pigmentosa|
89203462|NCT00804102|Active Comparator|Macula off|condition after treatment of retinal detachment
89203463|NCT00804102|Active Comparator|Primary open angle Glaucoma|
89203464|NCT00804102|Active Comparator|Hereditary Macular Degeneration|
89203465|NCT00804102|Active Comparator|Treated Retina detachment|
89203466|NCT00804102|Active Comparator|Retinal Artery Occlusion|
89203467|NCT00804102|Active Comparator|Retinal Vein Occlusion|
89203468|NCT00804102|Active Comparator|Non-Arteriitic-Anterior-Ischemic Optic-Neuropathy|
89203469|NCT00804102|Active Comparator|Hereditary autosomal dominant Optic atrophy|
89203470|NCT00804102|Active Comparator|dry Age-related Macular Degeneration|
89203471|NCT00804102|Active Comparator|Ischemic Macula edema|
89203472|NCT00804102|Sham Comparator|Non-stimulated|
89203473|NCT00804180|Other|Coping skills intervention|Self-Injection Anxiety Counseling: Evaluation of a group treatment for injection-related anxiety. The intention of the study is to obtain basic evaluation of a clinical treatment offered in a natural clinic setting, and does not include a control group, or procedure for random assignment of participants.
89203474|NCT00675428|Experimental|Natalizumab 300 mg|Intravenous (IV) infusions of natalizumab 300 mg once every 28 days for 6 months.
89203475|NCT00675428|Experimental|Natalizumab 450 mg|Intravenous (IV) infusions of natalizumab 450 mg once every 28 days for 6 months.
89203476|NCT04049396|Experimental|Berberine|Berberine (6.25 g/day)
89203477|NCT04049396|No Intervention|Control|No intervention
89203478|NCT00760916|Placebo Comparator|Placebo|placebo
89203479|NCT00760916|Active Comparator|UT-15C 0.25 mg|UT-15C 0.25 mg
89020991|NCT04714593|Experimental|Low Dose Group|CD19-CD22 CAR-T cells injection, infused only once,3-6 subjects of low dose group will be intravenously infuse with 0.5×10^6 CAR+T cells/kg.
89203480|NCT00760916|Active Comparator|UT-15C 1 mg|UT-15C 1 mg
89483563|NCT04986878|Active Comparator|Single shot adductor canal block|Following sterile preparation and draping, an ultrasound survey of the medial thigh was performed, halfway between the superior anterior iliac spine and the patella. The superficial femoral artery has been identified beneath the sartorius muscle in a short-axis view, with the vein just inferior and the saphenous nerve just lateral to the artery. A 20 Gauge, 120 mm, non-cuttings tip echogenic needle (SonoPlex STIM, Germany) needle was introduced in-plane, and 2 to 3 mL of LA bolus (0.25 % Bupivacaine) was used to confirm proper needle placement in the adductor canal near the saphenous nerve. Then, a bolus of 20 ml of Bupivacaine 0.25 % was injected through the needle
89483564|NCT04986878|Active Comparator|Continuous adductor canal block|a catheter was secured in place using Tegaderm. The catheters were connected to a pump that infused local anesthetic, 20 mL of 0.25 % bupivacaine, followed by 48 hours of continuous infusion of 0.125 % bupivacaine at 5 mL/h.
89483565|NCT03258333||Stented bioprosthesis|Standard aortic valve replacement with stented bioprosthesis. Surgery is performed through median sternotomy, aortic and right or bicaval venous cannulation, normothermic perfusion, antegrade cardioplegia with use cardioplegic solution Custodiol. A transverse aortotomy was performed 1 to 2 cm above the right coronary artery. The aortic annulus was thoroughly débrided of calcium. Valve sizing was performed with standard manufacturers' sizers, with selection of the size that would comfortably fit within the aortic annulus. A noneverting suture technique was used in all patients with interrupted horizontal mattress 2-0 braided sutures placed around the aortic annulus, with the pledgets on the ventricular aspect.
89483566|NCT03258333||Ozaki procedure|Aortic valve reconstruction using autologus pericardium (Ozaki procedure). The autologous pericardium is harvested after routine median sternotomy. Harvested pericardium is then treated with a 0.6% glutaraldehyde solution for 10 min and then rinsed 3 times with sterilized saline each time for 6 min. After resection of the diseased aortic valve cusps, the distance between each commissure is measured using a self-developed sizing instrument. Glutaraldehyde-treated autologous pericardium is trimmed with a self-developed template corresponding to the measured value. The annular margin of the pericardial leaflet is then running-sutured to each annulus with 3-0 monofilament sutures. Commissural coaptation is secured with additional 4-0 monofilament sutures. The coaptation of the 3 cusps is then checked with negative pressure on the left ventricular vent.
89483567|NCT03260673||the diabetic group|patients with type 2 diabetes scheduled to undergo cataract surgery
89483568|NCT03260673||the control group|patients without diabetes scheduled to undergo cataract surgery
89483569|NCT03070028|Experimental|Phenol|crystallised phenol application
89483570|NCT03070028|Experimental|platelet rich plasma|PRP application
89483571|NCT03260439|Other|G1 (group BT)|The children were randomized to 2 groups (n = 53 in each group) to receive 0.1% BPV non-adrenalinated 0.5% / kg on each side with tramadol 2mg / Kg (G1: GroupBT ). Tramadol
89483572|NCT03260439|Other|G2 (group B or control)|The children were randomized to 2 groups (n = 53 in each group) to receive 0.1% BPV non-adrenalinated 0.5% / kg on each side with saline serum at the same volume (G2: Group B or control). Placebo
89483573|NCT03258411|Active Comparator|Haas group (H)|Rapid Expansion of palatal suture device: tooth-tissue supported expander (Haas (H)).
89483574|NCT03258411|Active Comparator|Hyrax (Hx)|Rapid Expansion of palatal suture device: tooth anchored expander (Hyrax (Hx)).
89483575|NCT03258411|Active Comparator|Miniscrew-supported (MHx)|Rapid Expansion of palatal suture device: bone anchored expander (Temporary anchorage devices(miniscrew)-supported (MHx))
89483576|NCT03260517|Experimental|Treatment arm (Mdt Drug-Coated Balloon)|Medtronic Coronary Drug-Coated Balloon Catheter used for dilatation of the target lesion.
89483577|NCT02634788|Experimental|Buprenorphine 0.5 mg TID|Participants received buprenorphine 0.5 mg sublingual (under the tongue) spray three times daily (TID) for two days.
89483578|NCT02634788|Experimental|Buprenorphine 0.25 mg TID|Participants received buprenorphine 0.25 mg sublingual spray TID for two days.
89483579|NCT02634788|Experimental|Buprenorphine 0.125 mg TID|Participants received buprenorphine 0.125 mg sublingual spray TID for two days.
89020992|NCT04714593|Experimental|Middle Dose Group|CD19-CD22 CAR-T cells injection, infused only once,3-6 subjects of low dose group will be intravenously infuse with 2×10^6 CAR+T cells/kg.
89203481|NCT00760916|Active Comparator|UT-15C 5 mg|UT-15C 5 mg
89203482|NCT05166200|Experimental|Experimental Formula|One 237 ml serving of study product
89203483|NCT05166200|Active Comparator|Test Meal|48 g Instant oatmeal
89203484|NCT00761072||1|The source of data will be from spinal surgery procedures performed at CHOP from 4/1/07 to 3/31/08 using a TIVA anesthetic technique of propofol/remifentanil infusions
89203485|NCT00761228|Active Comparator|Apomorphine|Patients will receive an ascending dosing schedule to reach a maximum infusion rate of up to 6 mg/hour for 12 hours a day.
89203486|NCT00761228|Placebo Comparator|Placebo|Patients will receive a continues subcutaneous infusion of saline solution.
89203487|NCT00758654||1|Patients with suspected or known stable coronary artery disease
89203488|NCT00758654||2|Healthy subjects as a control group
89203489|NCT00921908||epidural catheter|subfascial placement of a triple-orifice epidural catheter
89203490|NCT00921908||multiholed catheter|subfascial placement of a multi-orifice 15 cm catheter
89203491|NCT02558738||Ectoin Ear Spray|treatment according to instruction for use
89203492|NCT02558738||Normison ear spray|treatment according to instruction for use
89203493|NCT00758732|Experimental|1|Docetaxel/carboplatin
89203494|NCT00758732|Experimental|2|Docetaxel/Caelyx
89483580|NCT02634788|Placebo Comparator|Placebo|Participants received placebo-matching buprenorphine sublingual spray TID for two days.
89483581|NCT03258255|Active Comparator|Pudendal block group in circumcision|Nerve stimulated pudendal nerve block performed under general anesthesia
89483582|NCT03258255|Active Comparator|Penil block group in circumcision|Penil block performed by surgeon under general anesthesia
89483583|NCT03071432|Active Comparator|Non-diabetic patients|Study interventions include a medical history and short physical examination as well as autonomic function tests and cerebral autoregulation tests on the day before surgery. In addition we determine CO2 sensitivity of the cerebral vasculature by three minutes hyperventilation and three minutes CO2 rebreathing. Perioperatively, continuous measurement of heart rate, blood pressure, stroke volume and cardiac output is aquired using the ccNexfin monitor, a non-invasive device using a single finger cuff. Continuous monitoring of cerebral perfusion parameters using transcranial Doppler ultrasound (TCD) of the middle cerebral artery (MCA) and cerebral oxygenation using near-infrared-spectroscopy (NIRS) will be obtained. BRS and condition of CA will be determined preoperatively during autonomic function testing (see below) and 30 minutes after induction of anaesthesia.
89483584|NCT03071432|Active Comparator|Diabetic patients with cardiovascular autonomic neuropathy|Study interventions include a medical history and short physical examination as well as autonomic function tests and cerebral autoregulation tests on the day before surgery. In addition we determine CO2 sensitivity of the cerebral vasculature by three minutes hyperventilation and three minutes CO2 rebreathing. Perioperatively, continuous measurement of heart rate, blood pressure, stroke volume and cardiac output is aquired using the ccNexfin monitor, a non-invasive device using a single finger cuff. Continuous monitoring of cerebral perfusion parameters using transcranial Doppler ultrasound (TCD) of the middle cerebral artery (MCA) and cerebral oxygenation using near-infrared-spectroscopy (NIRS) will be obtained. BRS and condition of CA will be determined preoperatively during autonomic function testing (see below) and 30 minutes after induction of anaesthesia.
89483585|NCT03071432|Active Comparator|Diabetic patients without cardiovascular autonomic neuropathy|Study interventions include a medical history and short physical examination as well as autonomic function tests and cerebral autoregulation tests on the day before surgery. In addition we determine CO2 sensitivity of the cerebral vasculature by three minutes hyperventilation and three minutes CO2 rebreathing. Perioperatively, continuous measurement of heart rate, blood pressure, stroke volume and cardiac output is aquired using the ccNexfin monitor, a non-invasive device using a single finger cuff. Continuous monitoring of cerebral perfusion parameters using transcranial Doppler ultrasound (TCD) of the middle cerebral artery (MCA) and cerebral oxygenation using near-infrared-spectroscopy (NIRS) will be obtained. BRS and condition of CA will be determined preoperatively during autonomic function testing (see below) and 30 minutes after induction of anaesthesia.
89483586|NCT03260283|Experimental|Group I|0.4 mgkg-1 of pethidine hydrochloride
89483587|NCT03260283|Experimental|Group II|2ml of ropivacaine (0.75%) with 15 mcg of fentanyl
89483588|NCT03071198|Experimental|Preoperative neoadjuvant CT|Give neoadjuvant chemotherapy for four cycle ,if achieve cCR or cPR after four cycles neoadjuvant chemotherapy , receive Total Mesorectal Excision(TME) ,then received the complete adjuvant therapy
89483589|NCT03071198|Experimental|Preoperative neoadjuvant CT-RCT|Give neoadjuvant chemotherapy for four cycle ,if not achieve cCR or cPR after four cycle neoadjuvant chemotherapy ,give concurrent chemo-radiotherapy,then additional neoadjuvant chemotherapy for 2 cycles ,then receive Total Mesorectal Excision(TME) ,then received the complete adjuvant therapy
89483590|NCT03071198|Active Comparator|Concurrent chemo-radiotherapy|Give concurrent chemo-radiotherapy ,then receive Total Mesorectal Excision(TME) ,then received the complete adjuvant therapy
89020993|NCT04714593|Experimental|High Dose Group|CD19-CD22 CAR-T cells injection, infused only once,3-6 subjects of low dose group will be intravenously infuse with 5×10^6 CAR+T cells/kg.
89020994|NCT04714593|Experimental|Amplification Dose Group|CD19-CD22 CAR-T cells injection, infused only once.After determined maximum tolerated dose,15 subjects of amplification dose group will be intravenously infuse with 0.5-5.0×10^6 CAR+Tcells/kg.
89020995|NCT00426582|Experimental|Patupilone only|Cycle 1 patupilone alone Cycle 2 and onward patupilone and carboplatin
89483591|NCT03258489|Active Comparator|Transcutaneous nervous electric stimulation (TENS)|Autonomic balance, blood pressure, and blood collection (catecholamines) will be evaluated before and after TENS. The autonomic balance will be evaluated by heart rate variability (HRV), systemic arterial pressure (SBP) will be evaluated by an Ambulatory Blood Pressure Monitor (ABPM) and catecholamines of kits.
89020996|NCT00426582|Active Comparator|Carboplatin alone|Cycle 1 Carboplatin alone Cycle 2 and onward patuilone and carboplatin
89203495|NCT00758810||1|Patients without cardiac rehabilitation
89020997|NCT04717583|Experimental|IPL-treated side|For each participant, the two sides of face will be randomized into an IPL-treated side and a control side. In the first 3 visits, the IPL-treated side of the face will be treated with IPL, once every 4 weeks for 3 consecutive times.
89203496|NCT00758810||2|Patients with cardiac rehabilitation
89483592|NCT03258489|Active Comparator|Interferential electrical stimulation (IES)|Autonomic balance, blood pressure, and blood collection (catecholamines) will be evaluated before and after Interferential electrical stimulation (IES). The autonomic balance will be evaluated by heart rate variability (HRV), systemic arterial pressure (SBP) will be evaluated by an Ambulatory Blood Pressure Monitor (ABPM) and catecholamines of kits.
89483593|NCT03258489|Placebo Comparator|TENS and IES Placebo|Autonomic balance, blood pressure, and blood collection (catecholamines) will be evaluated before and after of the TENS and IES placebo. The autonomic balance will be evaluated by heart rate variability (HRV), systemic arterial pressure (SBP) will be evaluated by an Ambulatory Blood Pressure Monitor (ABPM) and catecholamines of kits.
89483594|NCT03074396|Other|before and after use of program|one arm (10 patients and 4 physicians) before and after use of dialysisNet (for doctors) and Avatar Beans (for patients)
89483595|NCT03251469|Active Comparator|Group 1|intravenous tranexamic acid, 15mg/kg, preoperatively, single dose
89483596|NCT03251469|Placebo Comparator|Group 2|Intravenous normal saline, 100mg, preoperatively, single dose
89483597|NCT04986644|Experimental|Test to Moist|1 week of Test DD contact lenses followed by cross over to 1 week of 1-DAY ACUVUE® Moist contact lenses.
89483598|NCT04986644|Active Comparator|Moist to Test|1 week of 1-DAY ACUVUE® Moist contact lenses followed by cross over to 1 week of Test DD contact lenses.
89483599|NCT03251625|Placebo Comparator|To assess the effect of multistrain probiotics on abdominal|To assess the effect of multistrain probiotics on abdominal pain using a validated symptom severity score in IBS patients.
89483600|NCT03251625|Placebo Comparator|To assess the efficacy of a multistrain probiotic supplement|To assess the efficacy of a multistrain probiotic supplement as a treatment option for IBS in a tertiary referral centre
89483601|NCT04920266|Experimental|Smart sweat patch for sweat rate and sweat chloride concentration|Epidermal microfluidic patch that is a flexible 27 cm2 platform with an adhesive backing that collects sweat through a skin-facing inlet port. Custom software uses the smartphone camera to capture and analyze the microfluidic patch.
89483602|NCT04920266|Placebo Comparator|Reference sweat patch for sweat rate and sweat electrolytes|Regional absorbent patch technique for sweat rate (gravimetry) and electrolytes (sodium, potassium, chloride) by ion chromatography
89483603|NCT04920266|Experimental|Smart Cap bottle fluid measurement|Fluid level sensor integrated into the squeeze bottle cap measures the amount of fluid remaining in the bottle via light reflection
89483604|NCT04920266|Other|Reference method bottle fluid measurement|Scale weight of bottle (gravimetry method) for Smart Cap bottles (running and fitness subjects) and non-Smart Cap bottles (cyclists)
89483605|NCT03251547||NovoSeven|Non-hemophiliac patients experienced massive haemorrhage who was treated with recombinant activated factor VII
89483606|NCT03069872|Experimental|Intervention|All GPs in Central Denmark Region, are planned to be enrolled in the study during the one year study period.
89483607|NCT03259893|Active Comparator|Standard of care group 1|Participants randomized to the standard of care group will receive guideline-directed medical therapy according to clinical standard practice at Boston Medical Center. Each participant will receive an AliveCor mobile ECG cardiac monitor which is capable of providing real-time heart telemetry using a smart phone.
89483608|NCT03259893|Experimental|Intervention group 2|The intervention group will receive the AF program which include a bundle of sub-interventions that target specific AF risk factors including hypertension, obesity, physical inactivity, sleep hygiene, and smoking. Each participant will receive an AliveCor mobile ECG cardiac monitor which is capable of providing real-time heart telemetry using a smart phone.
89483609|NCT03069794|Other|Use of stable force platform|Ennrollment of every patient programmed for spinal surgery in orthopaedic service
89483610|NCT02238587|Placebo Comparator|Placebo/Ganoderma|In control group, oral placebos for 6 weeks. Then the patients in control groups are switched, Ganoderma Spores Powder Capsules are given for 6 weeks. The data pertaining to their life quality are collected using Quality of Life Questionnaire after the first 6 weeks and the second 6 weeks. The immunity status is also studied at the same time.
89483611|NCT02238587|Experimental|Ganoderma|In experimental group, Ganoderma Spores Powder Capsules for 12 weeks. The data pertaining to their life quality are collected using Quality of Life Questionnaire after the first 6 weeks and the second 6 weeks. The immunity status is also studied at the same time.
89483612|NCT03251391|Experimental|Cardiac Rehabilitation Group|Participants randomized to this group will undergo cardiac rehabilitation program.
89483613|NCT03251391|Active Comparator|Control Group|Participants randomized to this group will receive care for their condition, conventional therapy, that they would normally receive.
89020998|NCT04717583|No Intervention|Control side|"For each participant, the two sides of face will be randomized into an IPL-treated side and a control side. In the first 3 visits (before Week 12), the control side of face will not be treated by IPL.~Starting from Week 12 (the time point of the primary endpoint), the control side of face will also be treated by IPL if the IPL-treated side shows satisfactory improvement of erythema or telangiectasia by IPL treatment. If the patient was unsatisfied with the improvement in the IPL-treated side at Week 12 visit, no IPL treatment will be given to either side of the face any more."
89020999|NCT00354198|Active Comparator|corticosteroids|[intravenous pulse methylprednisolone (15 mg/kg/day or a maximum of 1 g/day) x 3 days + oral prednisolone (0.5-1.0 mg/kg/day) for 27 days] x 3 courses
89021000|NCT00354198|Experimental|pentoxifylline + corticosteroids|[intravenous pulse methylprednisolone (15 mg/kg/day or a maximum of 1 g/day) x 3 days + oral prednisolone (0.5-1.0 mg/kg/day) for 27 days] x 3 courses + intravenous infusion of pentoxifylline (0.33-0.66 mg/kg/h) x 7 days + oral pentoxifylline (400-800 mg/day) from days 8 to 90
89021001|NCT00325715|Experimental|1|
89021002|NCT00325715|Active Comparator|2|
89021003|NCT00354237|Other|B|No intensive treatment
89021004|NCT00354237|Experimental|A|Intensive insulin treatment
89021005|NCT04717661||76 healthy early pregnant women in the trial group|The pulse sound waves of three parts and five layers of each of the two hands of 76 pregnant women will be collected by Pulse Detection System of Sound Waves.
89021006|NCT04717661||76 relatively healthy non-pregnant women in the control group|The pulse sound waves of three parts and five layers of each of the two hands of 76 relatively healthy non-pregnant women will be collected by Pulse Detection System of Sound Waves.
89021007|NCT00426621|Experimental|1|
89021008|NCT00426621|Placebo Comparator|2|
89021009|NCT04717778|Experimental|pH milk|Group of children who were given the different types of milk and only the pH was measured
89021010|NCT04714242||Patients underwent anti-VEGF therapy|intravitreal Anti-VEGF therapy: Three monthly intravitreal injections
89021011|NCT04714242||Control Group|Healthy eyes without actual and previous ocular diseases
89021012|NCT00354315|Experimental|1|Immediate Continuous medical education (CME)
89021013|NCT00354315|No Intervention|2|control, 6 months delay CME intervention
89021014|NCT00325949|Experimental|arm label (1) hydrocodone/acetaminophen extended release|
89021015|NCT00325949|Experimental|arm label (2) hydrocodone/acetaminophen extended release|
89021016|NCT00325949|Placebo Comparator|Arm label (3) placebo|
89021017|NCT04714476|Experimental|Fit test of made-to-measure garments|Healthy subjects will test made-to-measure compression garments
89021018|NCT00326027|Active Comparator|1|Pantoprazole 20 mg
89021019|NCT00326027|Active Comparator|2|Pantoprazole 40 mg
89021020|NCT01059318|Experimental|Everolimus|"All patients received a starting dose of everolimus 2.5mg/day for 4 weeks, followed by a dose of 5 mg/day for 4 weeks and finally a dose of 10mg/day for 18 weeks.~The 26 week treatment period was followed by an optional extension period wherein patients continued therapy until the last patient had completed 26-weeks of treatment. The longest period a patient participated in the study was 62 weeks."
89483614|NCT02785939|Experimental|Arm I - Palbociclib|"Participants receive palbociclib PO on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Closed to accrual 09/01/2016"
89021021|NCT00326066|Active Comparator|1|
89021022|NCT00326066|Placebo Comparator|2|
89021023|NCT04714515||Hydroxychloroquine and Montelukast|Group 1 was given Standard of care (SOC) + HCQ + Montelukast
89021024|NCT04714515||Montelukast|Group 2 was given Standard of care (SOC) + Montelukast
89021025|NCT04714515||Hydroxychloroquine|Group 3 was given Standard of care (SOC) + HCQ
89021026|NCT04714515||Hydroxychloroquine, Montelukast and Invermectin|Group 4 was given Standard of care (SOC) + Montelukast + HCQ and Ivermectin
89021027|NCT00354354|Experimental|1|Combivent
89483615|NCT02785939|Experimental|Arm II - Docetaxel|"Participants receive docetaxel IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Upon progression, participants may be eligible to re-register to Arm III.~Closed to accrual 12/18/2015"
89021028|NCT00354354|Placebo Comparator|2|Saline Solution (0.9% NaCl)
89021029|NCT01058655|Experimental|Phase I Cohort 1: Everolimus 5 mg + Tivozanib 1 mg|Patients received oral everolimus daily continuously and oral tivozanib daily for 3 of a 4 weeks cycle. Patients are treated until disease progression, unacceptable toxicity or withdrawal of consent.
89021030|NCT01058655|Experimental|Phase I Cohort 2: Everolimus 10 mg + Tivozanib 1 mg|Patients received oral everolimus daily continuously and oral tivozanib daily for 3 of a 4 weeks cycle. Patients are treated until disease progression, unacceptable toxicity or withdrawal of consent.
89021031|NCT01058655|Experimental|Phase I Cohort 3: Everolimus 10 mg + Tivozanib 1.5 mg|Patients received oral everolimus daily continuously and oral tivozanib daily for 3 of a 4 weeks cycle. Patients are treated until disease progression, unacceptable toxicity or withdrawal of consent.
89021032|NCT01058655|Experimental|Phase II: Everolimus 10 mg + Tivozanib 1 mg|Patients received oral everolimus daily continuously and oral tivozanib daily for 3 of a 4 weeks cycle. Patients are treated until disease progression, unacceptable toxicity or withdrawal of consent.
89021033|NCT00326222|Experimental|1|Lifestyle counseling
89021034|NCT00326222|No Intervention|2|Usual care
89021035|NCT00426777|Active Comparator|risedronate|
89021036|NCT00426777|Placebo Comparator|placebo|
89537635|NCT03296969|Active Comparator|rectus muscle approximation|All women underwent Pfnannenstiel incision under general or spinal anaesthesia, with a combination of sharp and blunt dissection to open the abdomen. The rectus muscles are dissected off the fascia, and the muscles are separated in the midline by pulling. Then the uterus is opened followed by fetal and placental extraction. The transverse lower uterine segment incision is closed in two layers of continuous Vicryl number 1 suture. The parietal peritoneum is closed using a continuous absorbable suture. In group (A): rectus muscle re-approximation is done by 3 interrupted sutures, but muscle is not closed in the other group. The rectus sheath is sutured using continuous absorbable sutures. Finally, skin is sutured with subcuticular sutures with Vicryl Rapide
89537636|NCT03296969|Active Comparator|rectus muscle non approximation|All women underwent Pfnannenstiel incision under general or spinal anaesthesia, with a combination of sharp and blunt dissection to open the abdomen. The rectus muscles are dissected off the fascia, and the muscles are separated in the midline by pulling. Then the uterus is opened followed by fetal and placental extraction. The transverse lower uterine segment incision is closed in two layers of continuous Vicryl number 1 suture. The parietal peritoneum is closed using a continuous absorbable suture. In group (A): rectus muscle re-approximation is done by 3 interrupted sutures, but muscle is not closed in the other group. The rectus sheath is sutured using continuous absorbable sutures. Finally, skin is sutured with subcuticular sutures with Vicryl Rapide
89537637|NCT01530659|Experimental|NT-501|Encapsulated cell therapy that delivers ciliary neurotrophic factor to the retina
89537638|NCT01530659|Sham Comparator|Sham|Sham surgery
89021037|NCT00326339|Experimental|1|R788 50 mg PO bid
89021038|NCT00326339|Experimental|2|R788 100 mg PO bid
89537639|NCT00701363|Experimental|Lanreotide Autogel 120 mg|
89537640|NCT01193075||CMT1B|Families/patients with genetically confirmed CMT1B
89537641|NCT01193075||CMT2A|Families/patients with genetically confirmed CMT2A
89537642|NCT01193075||CMT4A|Families/patients with genetically confirmed CMT4A
89021039|NCT00326339|Experimental|3|R788 150 mg PO bid
89021040|NCT00326339|Placebo Comparator|4|Placebo PO bid
89021041|NCT01058421|Experimental|Intensive physical therapy|four week intervention of daily intensive physical therapy
89021042|NCT01058421|Active Comparator|control group|
89021043|NCT00419549|Active Comparator|1|Valdecoxib
89021044|NCT00419549|Active Comparator|2|
89537643|NCT01193075||CMT4C|Families/patients with genetically confirmed CMT4C
89537644|NCT01193075||All other CMT|Families/patients with all other forms of CMT or CMT that has not yet been genetically identified
89021045|NCT00419549|No Intervention|3|
89021046|NCT00419588||1-Healthy Infants|"Group 1: We have recruited 50 healthy infants born >37 weeks gestation, and between 2 and 36 months of age. Infants were excluded for any of the following reasons.~Congenital cardio-respiratory disease~Hospitalization for respiratory illness~Treatment with asthma medications for more than one time~Small for gestational age at birth~More than one respiratory illness~More than one episode of wheezing"
89021047|NCT00419588||3-Premature Infants|"Group 3: We will recruit 115 infants born prematurely, 23-35 weeks gestation. Subjects will be evaluated at the corrected age between 2 and 24 months. The subjects will have no oxygen requirements, and be clinically stable outpatients when evaluated. Infants will be excluded for any of the following reasons.~Congenital cardio-respiratory disease~Severe developmental delay"
89021048|NCT00419588||2-Healthy Infants CT|"Group 2: The investigators recruited 50 infants born at > 37 weeks gestation and they were evaluated between 2 and 36 months of age when scheduled for high resolution computed tomography (HRCT) imaging for non-respiratory medical problems. Subjects were enrolled and HRCT of the chest were obtained. Infants were excluded for the following reasons:~Congenital cardio-respiratory disease~Hospitalization for respiratory illness~Treatment with asthma medications"
89021049|NCT00326378|Active Comparator|CCRT arm without consolidation chemotherapy|Docetaxel 20mg/m2 & Cisplatin 20mg/m2 (D1,8,15,22,29,36) during radiotherapy
89021050|NCT00326378|Experimental|CCRT arm with consolidation chemotherapy|docetaxel 20mg/m2 & cisplatin 20mg/m2 (D1,8,15,22,29,36) during radiotherapy, and followed by consolidation chemotherapy with 3-weekly docetaxel 35mg/m2 & cisplatin 35mg/m2 (D1,8) every 3 weeks (#3).
89021051|NCT00326534||Controls|Patients without sarcoidosis, but requiring a fiberoptic bronchoscopy
89021052|NCT00326534||Sarcoidosis patients|Patients with newly diagnosed sarcoidosis
89021053|NCT04717232|Experimental|The blended learning approach to mentoring education for dental health care professionals|The blended learning approach to mentoring education for dental health care professionals will last five weeks, including four face-to-face seminars, interprofessional group work and self-reflection assignments lasting for two days. The educational content will include mentoring as a process, mentoring as a relationship, challenges of mentoring, and personal mentoring.
89203497|NCT00761384|Experimental|90Y-ibritumomab|90Y-ibritumomab given with stem cells support, based on absorbed dose escalation to the liver. Absorbed dose escalation starts at 12 Gy and is capped at 36 Gy to the liver.
89203498|NCT00758888|Experimental|Treatment|Place the blocks under the pelvis for 2 minutes
89203499|NCT00758888|Active Comparator|Trochanter Belt|Participant is fitted with trochanter belt on the adjusting table and wear it while Investigator checks their flexion and extension strength.
89203500|NCT00758888|Sham Comparator|Sham|Participant lies on adjusting table, blocks are placed in a similar configuration but distant to actual points of leverage.
89203501|NCT02559674|Experimental|Phase Ib/II ALT-803 w/ gemcitabine and nab-paclitaxel|
89203502|NCT00759044||AMD|Patients diagnosed with AMD
89203503|NCT00759044||DME|Patients diagnosed with DME
89203504|NCT00761540|Experimental|A1|
89203505|NCT00761540|Placebo Comparator|A2|
89203506|NCT00761540|Experimental|B1|
89203507|NCT00761540|Placebo Comparator|B2|
89203508|NCT00761540|Experimental|C1|
89203509|NCT00761540|Placebo Comparator|C2|
89203510|NCT04913636|Experimental|Test Group|
89203511|NCT04913636|Sham Comparator|Control Group|
89203512|NCT00761696|Experimental|IPI-926|Oral daily dosing
89203513|NCT00759122|Active Comparator|1|VENLAFAXINE
89203514|NCT00759122|Placebo Comparator|2|
89203515|NCT00759200|Experimental|alb-interferon arm 1|
89203516|NCT00759200|Experimental|alb-interferon arm 2|
89203517|NCT00759200|Experimental|alb-interferon arm 3|
89203518|NCT00759200|Experimental|alb-interferon arm 4|
89203519|NCT00759200|Active Comparator|peg-interferon|
89203520|NCT00557505|Experimental|PF-03732010|Single Arm study
89203521|NCT02558816|Experimental|Ibrutinib - GA101 - GDC_0199|STEP A:C1:Ibrutinib 560mg D2-28;GA101 1000mg day 1/2,8,15;C2-6:Ibrutinib 560mg D 1-28;GA101 1000mg D1 / C7 (Maintenance phase)-C24:Ibrutinib 560mg D1-28 (until progression);GA101 1000mg D1 every 2cycles (from C8) STEP B:C1:Ibrutinib 560mg D2-28;GA101 1000mg D1/2,8,15 / C1bis : Ibrutinib 560mg day 1-28 ; GA101 1000mg D 1 ; GDC-0199 20mg/d at W1, 50mg/d at W2, 100mg at W3, 200 mg/d at W4 / C2-6:Ibrutinib 560mg D1-28;GA101 1000mg D1;GDC-0199:400mg/d W1 and 400, 600 or 800mg/d W2-3-4 + 400, 600 or 800 mg/d C3-C6 (patients 1-12).Patients 13-24:GDC-199 400mg/d / C7(Maintenance phase)-C23:Ibrutinib 560mg D1-28 (until progression);GA101 1000mg D1 every 2 cycles (from C8);GDC:400, 600 or 800 mg D1-28 (patient 1-12).Patients 13-24 : 400mg/d STEP C:C1-C1bis=Step B; C2-6:Ibrutinib 560mg D1-28;GA101 1000mg D1;GDC:400mg/d C7 (Maintenance phase)-C23 : Ibrutinib 560mg D1-28 (-->progression);GA101 1000mg D1/2 cycles (from C8);GDC-0199 400mg/d
89203522|NCT00759278||1|Group of 30 women who are pregnant as subjects that take antihypertensive medication
89203523|NCT00759278||2|Group of 30 women who are pregnant and do not take antihypertensive medications as a control group
89203524|NCT01299753|Placebo Comparator|Control|
89203525|NCT01299753|Experimental|Beta blockade|
89203526|NCT02559440|Active Comparator|mometasone furoate|In the first treatment stage, 120 children were assigned to mometasone furoate (50μg, 1 puff in each nostril every evening) after two week's run-in period.
89203527|NCT02559440|Placebo Comparator|Placebo|In the first treatment stage, 120 children were assigned to control group (normal saline) after two week's run-in period.
89203528|NCT02559440|Active Comparator|Oxymetazoline + Placebo|Stage two is a parallel, randomized, double-blind, double-dummy study. Non-responders underwent 2-week washout period and were randomly assigned to groups receiving Oxymetazoline and placebo.
89203529|NCT02559440|Placebo Comparator|Placebo + placebo|Stage two is a parallel, randomized, double-blind, double-dummy study. Non-responders underwent 2-week washout period and were randomly assigned to groups receiving placebo and placebo.
89203530|NCT02559440|Active Comparator|mometasone furoate + Placebo|Stage two is a parallel, randomized, double-blind, double-dummy study. Non-responders underwent 2-week washout period and were randomly assigned to groups receiving mometasone furoate and placebo.
89203531|NCT02559440|Active Comparator|mometasone furoate + Oxymetazoline|Stage two is a parallel, randomized, double-blind, double-dummy study. Non-responders underwent 2-week washout period and were randomly assigned to groups receiving mometasone furoate and Oxymetazoline.
89483616|NCT02785939|Experimental|Arm III - Palbociclib re-reg|"Participants in Arm II eligible for re-registration receive palbociclib PO on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Closed to accrual 09/01/2016"
89483617|NCT04990154|Experimental|experimental group|The experimental group received a 12-week intradialytic exercise (supine lower-limb ergometer, 30 minutes/session, 3 sessions/week)
89483618|NCT04990154|No Intervention|control group|the control group maintained their usual lifestyles
89483619|NCT03583229|Other|Aspirin - single arm|1 tablet of Aspirin 75 mg administered x 1 daily for 7 days.
89483620|NCT03583229|Experimental|Extracorporeal photopheresis|All patients with HLA antibodies receive 4 ECP-treatments in 2 months.
89483621|NCT03583229|No Intervention|Control group|The control group does not receive ECP-treatments, but blood samples are drawn at the same intervals as treatment group and CAG+OCT are also performed at baseline and 12 months follow up as the treatment group.
89537645|NCT03296891|Active Comparator|PoCUS Guided Resuscitation of Shock|Participants randomized to this arm of the study will undergo PoCUS guided resuscitation of shock.
89483622|NCT02456181|Experimental|JumpMath|"The JUMP method focuses more on the mental activity involved in constructing mathematical knowledge. There is a strong emphasis on symbolic math (numbers, letters, mathematical symbols). Manipulatives are used prescriptively, in lessons carefully scaffolded to help students connect the objects (e.g., three buttons) to what they are intended to stand for (the magnitude 3)."
89483623|NCT04989920|Experimental|CIMT (Constraint-Induced Movement Therapy)|Therapy intervention: This arm will deliver the signature Constraint-induced therapy protocol for 60 hrs of training over a two-week period.
89483624|NCT04989920|No Intervention|Delayed (Control) intervention group|"Subjects randomized to the delayed intervention group will receive the usual and customary services provided by their personal health care system."
89483625|NCT02456337|Experimental|CAF+MC+EMD|Coronally Advanced Flap with Mucograft and Emdogain
89483626|NCT02456337|Active Comparator|CAF+MC|Coronally Advanced Flap with Mucograft
89483627|NCT02456337|Active Comparator|CAF+EMD|Coronally Advanced Flap with Emdogain
89483628|NCT02456337|Active Comparator|CAF|Coronally Advanced Flap alone
89483629|NCT04915742|Experimental|exercises and thetahealing|
89483630|NCT04915742|Active Comparator|exercises|
89483631|NCT02259803|Experimental|Telmisartan/amlodipine fixed-dose combination|
89483632|NCT02259803|Active Comparator|Telmisartan and amlodipine mono-components|
89483633|NCT03260049||1|there was no retinal detachment (RD) at the first visit. The group 1 patients were treated with systemic antiviral medications, as well as with intravitreal antiviral injections
89483634|NCT03260049||2|there was no RD at the first visit. The group 2 patients were treated with systemic antiviral medications and PPV plus silicone oil tamponade and intravitreal injection.
89483635|NCT03260049||3|there was RD at the first visit. The group 3 patients were treated with systemic antiviral medications and PPV plus silicone oil tamponade and intravitreal injection
89483636|NCT03069950|Experimental|HAI FUDR/Dex in addition to Pmab plus FOLFIRI|Panitumumab plus FOLFIRI on Day 1 and Day 15 of each cycle. HAI pump therapy with FUDR and Dex on Day 1 of each cycle. Patients will start protocol therapy approximately 2 weeks after surgery. All patients will receive Panitumumab (6 mg/kg IV over 60 min). The HAI FUDR group will receive FOLFIRI in the following dosing; 5-Fluouracil (5FU) (1000 mg/m2/day continuous infusion over two days), Leucovorin (LV) (400 mg/m2 IV over 30 min to an hour), and Irinotecan (CPT) (150 mg/m2 IV over 30 min to an hour) on Day 1 and Day 15.
89483637|NCT03069950|Experimental|Pmab plus FOLFIRI alone|The dosing of FOLFIRI in the systemic arm will be 5-Fluouracil (5FU) (1200 mg/m2/day continuous infusion over two days), Leucovorin (LV) (400 mg/m2 IV over 30 min to an hour), bolus 5FU 400mg/ m2 and Irinotecan (CPT) (150 mg/m2 IV over 30 min to an hour) on Day 1 and 15.
89483638|NCT03433287|Experimental|18F-NaF-PET/MRI|Eligible patients who give informed consent will be offered a NaF -PET/MRI scan
89483639|NCT03582839|Experimental|PROTECT+|The PROTECT+ intervention group is a self-selected sample, which receives the PROTECT+ group therapy (4 modules in 4 subsequent weeks à 100 min). Participants are assessed at T1 (baseline), T2 (post treatment, 1-month follow-up), T3 (4-months follow-up), and T4 (12-months follow-up).
89483640|NCT04913870|Experimental|Angiotensin Receptor Blockers|Angiotensin Receptor Blockers will be given orally once a day for 2 years.
89483641|NCT04913870|Placebo Comparator|Placebo|Participants will receive a matched placebo orally once a day for 2 years.
89483642|NCT03251001|Active Comparator|Control|Sites receiving a free gingival graft
89483643|NCT03251001|Experimental|Device - Acellular dermal matrix|Sites receiving acellular dermal matrix
89483644|NCT03577691|Experimental|Training for use of web based Decision Aid|Subjects will be provided access to the decision aid website and will receive a log-in identification, user password and url at time of consent and will be guided during a 30 minutes training session to use the website. They will ben be asked to continue to peruse the website at home to learn more about hydroxyurea. Participants in each group will be further randomized to 1) pretest surveys and posttest surveys; and 2)only posttest surveys
89483645|NCT03577691|Placebo Comparator|No training for use of web based Decision Aid|Subjects will receive a log-in identification, user password and url at time of scheduled appointment for web access. They will not receive training but will be instructed to maneuver through the website and access the information pertaining to hydroxyurea and access the videos for the purposes of learning. Participants will be asked to peruse the website for 30 minutes at time of consent then to continue to access the website at home to learn about hydroxyurea treatment. Participants in each group will be further randomized to 1) pretest surveys and posttest surveys; and 2)only posttest surveys
89483646|NCT04989608|Other|patients having suffered to transient ischemic accident|
89483647|NCT04989608|Other|healthy volunteers|
89483648|NCT03251235|Experimental|Treatment Group|Group receives four weekly sessions of CBT prior to experimental testing/ fMRI
89483649|NCT03251235|No Intervention|Waiting Group|Group receives four weekly sessions of CBT after experimental testing/ fMRI
89483650|NCT03577613||Early stage Cervical Cancer- Open Radical Hysterectomy(RH)|Patients who were clinically diagnosed with FIGO stage IA2-IB1-IIA1 cervical cancer and underwent a open RH at our institution as primary treatment were included in the study
89483651|NCT03577613||Early stage Cervical Cancer- Laparoscopic Radical Hysterectomy|Patients who were clinically diagnosed with FIGO stage IA2-IB1-IIA1 cervical cancer and underwent a laparoscopic RH at our institution as primary treatment were included in the study
89483652|NCT03577613||Early stage Cervical Cancer- Robotic radical Hysterectomy(RRH)|Patients who were clinically diagnosed with FIGO stage IA2-IB1-IIA1 cervical cancer and underwent a robotically assisted RH at our institution as primary treatment were included in the study
89483653|NCT04989764||perioperative chemotherapy vs. adjuvant therapy in gastric ca patients|
89483654|NCT04989764||perioperative chemotherapy group vs. adjuvant chemotherapy group|
89483655|NCT03258099||wild genotype|Through next generation sequencing, distinguish wild genotype of capecitabine
89483656|NCT03258099||mutant genotype|Through next generation sequencing, distinguish mutant genotype of capecitabine
89483657|NCT03259971|Placebo Comparator|Placebo (for tic disorder)|The placebo will be dispensed to equal the volume of 1 tablet of Probiotic PS128, which is taken orally in 2 divided doses, 12 hours apart during the study period of 2 months for Tic disorders.
89483658|NCT03259971|Active Comparator|PS128 (tic disorder)|The Probiotic group in tic disorder will take Probiotic-Lactobacillus plantarum PS128, which contain 300mg (3x10^10 CFU) Lactobacillus plantarum PS128 and 100mg of Microcrystalline Cellulose in each tablet. It will be taken orally in 2 divided doses, 12 hours apart during the study period of 2 months for Tic disorders.
89483659|NCT03259971|Placebo Comparator|Placebo (for Rett syndrome)|The placebo will be dispensed to equal the volume of 1 tablet of Probiotic PS128, which is taken orally in 2 divided doses, 12 hours apart during the study period of 4 months for Rett syndrome
89203532|NCT01190943||Ancillary-Correlative (biomarker sampling and analysis)|Archived tumor tissue and peripheral blood DNA specimens are analyzed for DNA copy number profiling, gene expression profiling, DNA methylation profiling, microRNA profiling, and genomic resequencing. Clinical data including demographics; date of diagnosis, surgery, chemotherapy, recurrence, progression, and death; imaging; toxicity; and pathologic data elements associated with the specimens are also collected and analyzed.
89483660|NCT03259971|Active Comparator|PS128 (Rett syndrome)|The Probiotic group will take Probiotic-Lactobacillus plantarum PS128, which contain 300mg (3x10^10 CFU) Lactobacillus plantarum PS128 and 100mg of Microcrystalline Cellulose in each tablet. It will be taken orally in 2 divided doses, 12 hours apart during the study period of 4 months for Rett Syndrome.
89483661|NCT03577535|Experimental|Oncoxin®|Chemo-, radiotherapy or their combination + standard oral mucositis treatment + ONCOXIN
89483662|NCT03577535|No Intervention|No Oncoxin Treatment®|Chemo-, radiotherapy or their combination + standard oral mucositis treatment.
89483663|NCT03258021||GBM with indication for TTFields|newly diagnosed GBM with clinical indication for TTFields
89483664|NCT04989530|Active Comparator|Low energy level of ESWT|
89483665|NCT04989530|Active Comparator|medium energy level of ESWT|
89483666|NCT04989530|Active Comparator|high energy level of ESWT|
89483667|NCT03577457|Experimental|male oxytocin and ATD group|male subjects receiving oxytocin and ATD treatment
89483668|NCT03577457|Experimental|male oxytocin and placebo group|male subjects receiving oxytocin and ATD-placebo treatment
89483669|NCT03577457|Experimental|male placebo and ATD group|male subjects receiving oxytocin placebo and ATD treatment
89483670|NCT03577457|Placebo Comparator|male placebo group|male subjects receiving oxytocin placebo and ATD placebo treatment
89483671|NCT02455245|Active Comparator|Carboplatine and Vincristine|"Induction: 10 weeks of Carboplatin and Vincristine therapy. Carboplatin 175 mg/m2 give an an IV infusion weeks 1, 2, 3, 4, 7, 8, 9, 10. Vincristine 1.5mg/m2 (0.05 mg/kg if child less than 12 kg) (maximum dose 2.0 mg) give as an IV bolus infusion on weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10.~Maintenance: Maintenance consists of 8, 6-week cycles of chemotherapy. It begins week 12 of Induction or when peripheral counts recover with ANC >1,000/µL and platelet count >100,000/µL. Each cycle will consist of 4 weekly doses of carboplatin, three weekly doses of vincristine (given concomitantly with the first 3 weeks of carboplatin), followed by two weeks of rest for a total of 6 weeks. Maintenance will continue for a total of 8 cycles.~Carboplatin 175 mg/m2 as an IV continuous infusion over 60 minutes on Week 1, 2, 3, 4 of each cycle. Vincristine 1.5 mg/m2 (0.05 mg/ kg for children <12 kg) (maximum dose 2.0 mg) IV bolus infusion on Week 1, 2, 3 of each cycle."
89483672|NCT02455245|Experimental|Carboplatin alone|"Carboplatin is given once every four weeks, Each 4-week period is considered a cycle. Regimen B will last for 13 cycles which is equivalent to one year (52 weeks).~Carboplatin 560 mg/m2 (or 19 mg/kg for children weighing less than 12 kg) IV over 1 hour every 4 weeks"
89483673|NCT04989296|Experimental|Level of NF-κB translocation in lymphocyte in children with psoriasis and in comparison group|The analysis of the relative count of cells with NF-κB translocation in the lymphocyte populations the group of patients with psoriasis and in the comparison group.
89483674|NCT04989296|Experimental|Level of NF-κB translocation in lymphocyte in children with psoriasis, based on the type of therapy|Determination of the level of NF-kB translocation in lymphocyte populations in patient groups depending on the type of therapy: Group 1 - patients receiving basic and external therapy; Group 2 - patients receiving methotrexate; and Group 3 - patients receiving therapy with biological drugs.
89483675|NCT04989296|Experimental|Severity of psoriasis based on level of NF-κB translocation in psoriasis who received biologics|Assessment of the level of NF-kB translocation in lymphocyte populations, assessment of PASI and BSA, assessment of the effectiveness of biological drugs in patients with psoriasis. Identification of patients in the stage of regression of the disease and in the progressive stage.
89483676|NCT03577223|Experimental|Whole Eggs|
89203533|NCT02559596||Cases|Adults (aged 16+) with stored serum samples collected for the Health Survey for England (HSE) between 2009 and 2013, who have a record of hospitalisation for stroke, transient ischaemic attack or myocardial infarction occurring after their participation in the HSE.
89203534|NCT02559596||Controls|Adults (aged 16+) with stored serum samples collected for the Health Survey for England (HSE) between 2009 and 2013, who do not have a record of hospitalisation for stroke, transient ischaemic attack or myocardial infarction and are matched to cases on age, gender and year of participation in the HSE.
89483677|NCT03577223|Active Comparator|Egg White-Based Egg Substitute|
89483678|NCT04988984||Suspected TB|Patient suspected of TB undergoing diagnostic testing.
89483679|NCT03537599|Experimental|Treatment (DLI, daratumumab)|Participants receive daratumumab intravenously once a week for 8 weeks and donor lymphocyte infusion in weeks 3 or 4 in the absence of disease progression or unacceptable toxicity.
89483680|NCT04986410||Myocardial Perfusion examination|
89537646|NCT03296891|No Intervention|Usual Care|Participants randomized to the 'usual care' arm of the study will be suggested to have the following guide resuscitation: 1) Pulse pressure variation (PPV), stroke volume variation (SVV) and/or systolic pressure variation (SPV) on their arterial line, 2) central venous pressure (CVP) and oxygen saturation(ScvO2) measurement, 3) Passive leg raise (PLR) maneuver, and/or 4) pulmonary artery catheter
89203535|NCT04861220|Experimental|Pre-habilitation group + neoadjuvant treatment|The patients in the Pre-habilitation group + neoadjuvant treatment (Group A), will undergo neoadjuvant cancer therapy and be instructed to practice physical exercises at home 03 times a week, during neoadjuvant therapy, until the date of surgery. The pre-habilitation program (intervention) will consist of prescription of physical exercises and guidance on its importance, through a booklet and practice practice diary. The intervention group will be accompanied weekly by a call to encourage the performance of the exercises, and in case of doubts, new explanations regarding the performance of these exercises.
89021054|NCT04717232|Experimental|The interprofessional online mentoring education|The intervention group will attend mentoring competence education. The Interprofessional online mentoring educations includes videos of specialist lectures, e-learning materials, along with assignments concerning reflection skills and participant-based evaluation. The education content included the processes and interactions of mentoring, goal-oriented mentoring, along with student-based feedback and student-centered evaluation. The mentoring education can be completed in an online learning environment and participants can complete the education at their own pace within six weeks.
89021055|NCT04717232|Active Comparator|The Control group|The control group are dentists´ and dental hygienists´ who are working at health care centers on the Finnish Dental Association site, participate in student mentoring and have not received any education before.
89483681|NCT02239133|Experimental|ProVATE vaginal pessary|"The ProVATE device is a disposable, single-use, vaginal pessary for the management of Pelvic Organ Prolapse (POP). The ProVATE device is similar to other ring pessaries currently on the market. Its features allow for easy and comfortable insertion and removal by the user herself at her home environment. The ProVATE device is provided in six (6) different sizes and is intended for prescription use only."
89483682|NCT04986254||Benzylpenicillin|ICU patients receiving benzylpenicillin for confirmed/suspected community-acquired pneumonia, ventilator-associated pneumonia, aspiration pneumonia or a clinically-diagnosed lung infection (n = 20)
89021056|NCT01058304|Experimental|Group Physical Therapy for Knee OA|Group Physical Therapy for Knee OA
89021057|NCT01058304|Active Comparator|Individual Physical Therapy for Knee OA|Individual Physical Therapy for Knee OA
89203536|NCT04861220|Experimental|Prehabilitation Program + immediate surgical treatment|The patients in the Pre-habilitation group + immediate surgical treatment (Group B), will be instructed to practice physical exercises at home 03 times a week until the date of surgery. The pre-habilitation program (intervention) will consist of prescription of physical exercises and guidance on its importance, through a booklet and practice practice diary. The intervention group will be accompanied weekly by a call to encourage the performance of the exercises, and in case of doubts, new explanations regarding the performance of these exercises.
89483683|NCT04986254||Ceftriaxone|ICU patients receiving ceftriaxone for confirmed/suspected community-acquired pneumonia, ventilator-associated pneumonia, aspiration pneumonia or a clinically-diagnosed lung infection (n = 20)
89483684|NCT04986254||Meropenem|ICU patients receiving meropenem for confirmed/suspected community-acquired pneumonia, ventilator-associated pneumonia, aspiration pneumonia or a clinically-diagnosed lung infection (n = 20)
89483685|NCT04986254||Piperacillin/tazobactam|ICU patients receiving piperacillin/tazobactam for confirmed/suspected community-acquired pneumonia, ventilator-associated pneumonia, aspiration pneumonia or a clinically-diagnosed lung infection (n = 20)
89483686|NCT03257943|Experimental|Ivermectin Lotion, 0.5%|One 10 minute application, under at-home use conditions
89483687|NCT03257943|Active Comparator|SKLICE (ivermectin) Lotion, 0.5%|One 10 minute application, under at-home use conditions
89483688|NCT03257943|Placebo Comparator|Vehicle of the Test product|One 10 minute application, under at-home use conditions
89483689|NCT02239211|Experimental|BTT1023|BTT1023 8mg/kg IV infusion, total of 7 infusions over 11 weeks. Duration 1-2 hours per infusion.
89483690|NCT04986488||Without delirium|
89483691|NCT04986488||With delirium|
89483692|NCT03577145|Experimental|Tomato, onion & lovage soup with inulin|One dose of tomato (300g), onion (100g) & lovage (20g) with 10g inulin will be given to subjects in the form of a soup
89483693|NCT03577145|Experimental|Tomato, onion & lovage soup|One dose of tomato (300g), onion (100g) & lovage (20g) will be given to subjects in the form of a soup
89483694|NCT03577145|Experimental|Inulin|One dose of 10g inulin will be given to subjects in the form of a drink
89203537|NCT04861220|No Intervention|Usual activities + neoadjuvant treatment|Patients allocated to this group (Group C) will not participate in the pre-habilitation program and will be instructed to continue their usual activities during the neoadjuvant cancer therapy, until the date of surgery.
89483695|NCT03577067||Patients submitted to liver resection|Patients underwent liver resection for primary and secondary disease
89483696|NCT03257709|Active Comparator|Arthroscopic acetabular labral repair|Acetabular labral tear will be identified and reattached using suture anchors until a stable repair is achieved. If evidence of FAI is present ie: a cam or pincer lesion is identified then this will be treated with osteochondroplasty (cam) or acetabular rim recession (pincer).
89483697|NCT03257709|Active Comparator|Arthroscopic acetabular labral resection|The acetabular labral tear will be identified and its' limits defined. The torn portion of labrum will be resected to a stable edge. As with arm 1 there will be treatment of FAI if identified.
89483698|NCT03250533|Experimental|LED 620 nm group (G-LED 620)|The LED device in the red light spectrum, with a wavelength of 620 nm, will be applied over the full extent of the wound.
89483699|NCT03250533|Experimental|LED 940 nm group (G-LED 940)|The LED device in the infrared light spectrum, with a wavelength of 940 nm, will be applied over the full extent of the wound.
89483700|NCT03250533|Experimental|Fixed diphasic current group (G-DF)|The electrical stimulation will be carried out with the fixed diphasic current of the Dualpex 071 equipment, being applied throughout the extension of the wound.
89483701|NCT03250533|No Intervention|Control group (G-C)|Volunteers from this group will not be submitted to treatment and will only be evaluated before, every 30 days, after the 12 week period and 30 days after the last evaluation. It is worth mentioning that, after the end of its participation, if the wound is not fully healed, the treatment will be offered with LED or diphasic current.
89483702|NCT04986020||Parkinson disease|Participants with a clinical diagnosis of Parkinson's disease
89483703|NCT04986020||Control|Controls
89483704|NCT02239367|Experimental|Depression Decision Aid protocol|The Depression Decision Aid protocol, integrated into the Electronic Health Record (EHR), is a streamlined adaptation of an in-person Shared Decision-Making intervention. Shared decision-making, in contrast to traditional medical decision-making, involves a collaborative process where patients discuss personal values and preferences and clinicians provide information to arrive at an agreed upon treatment decision. The focus of the intervention is to empower the elderly depressed primary care patients and help them efficiently arrive at a treatment decision that can be successfully implemented.
89483705|NCT03246321|Experimental|repetitive ePIPAC-OX|
89537647|NCT02461043|Experimental|Arm A|chemotherapy and radiotherapy
89483706|NCT02239445|Active Comparator|chloral hydrate group|chloral hydrate 0.25 mg/kg oral solution diluted with oral syrup to 5 ml and 0.2 mL intranasal placebo (normal saline)
89483707|NCT02239445|Experimental|low dose dexmedetomidine Group|"Group L received intranasal dexmedetomidine at 1mcg/kg and 5 ml oral syrup~Undiluted preservative-free dexmedetomidine (AiBeiNing; Jiang Su Heng Rui Medicine Co. Ltd, Jiangsu Province, China) was prepared in a concentration of 100mcg/ml and dripped into both nostrils using a 1 mL syringe with the child in the Supine position."
89483708|NCT02239445|Experimental|high dose dexmedetomidine group|"Group H received intranasal dexmedetomidine at 2mcg/kg and 5 ml oral syrup~Undiluted preservative-free dexmedetomidine (AiBeiNing; Jiang Su Heng Rui Medicine Co. Ltd, Jiangsu Province, China) was prepared in a concentration of 100mcg/ml and dripped into both nostrils using a 1 mL syringe with the child in the Supine position."
89483709|NCT04985786|Experimental|AUD Intervention|Risk behavior specific intervention, targeting alcohol drinking
89483710|NCT04985786|Active Comparator|AUD Control|Non-risk behavior specific intervention, targeting cognitive exercises
89483711|NCT04985786|Experimental|AUD & SZ Intervention|Risk behavior specific intervention, targeting alcohol drinking
89483712|NCT04985786|Active Comparator|AUD & SZ Control|Non-risk behavior specific intervention, targeting cognitive exercises
89483713|NCT04985786|Experimental|SZ Intervention|Risk behavior specific intervention, targeting medication non-adherence
89483714|NCT04985786|Active Comparator|SZ Control|Non-risk behavior specific intervention, targeting cognitive exercises
89483715|NCT04985786|No Intervention|HC Control|Healthy control subjects will participate in fMRI assessments only
89483716|NCT02238665||Ulcerative colitis|
89483717|NCT02238665||Crohn's disease|
89483718|NCT02454465|Experimental|Intervention group|The first group at the top of the waiting list will receive the Acceptance and Commitment Therapy group intervention, which is 1 hour per week for six weeks.
89483719|NCT02454465|No Intervention|Waiting list group|The outcomes of those on the waiting list will be compared with those in the intervention group. Once the intervention group completes, those on the waiting list will be invited to attend the Acceptance and Commitment Therapy group intervention.
89483720|NCT03071042|Experimental|Apatinib plus Docetaxel|Each subject will receive one dose of Apatinib in the whole cycle (21 days), during which single dose induced DLT and safety monitoring will be performed. If the initial dose is well tolerated, next cycle the subject will receive more Apatinib as respectively. This study will enroll in 4 cohorts of Apatinib; cohort 1 at the dose of 425mg Apatinib, which followed by cohort 2(500mg), cohort 3(675mg) and cohort 4(750mg).
89483721|NCT03582605|Placebo Comparator|Control Group|All participants will be weighed. This group will receive a placebo (glucose) 1 hour prior to insertion of mini-screw implants.
89483722|NCT03582605|Experimental|Experimental Group|All participants will be weighed so that appropriate dosing can be ensured and will receive 2 grams of Amoxicillin 1 hour prior to mini-screw insertion. Patients weighing less than 40 kg will be given 50mg/kg of Amoxicillin.
89483723|NCT03257553|Experimental|intervention arm|do fecal calprotectin, doppler and ultrasound for each patient
89483724|NCT04433546|Experimental|High Dose (100 mg) Group|High: Pemziviptadil (PB1046) 100 mg subcutaneous (SC) weekly for 4 weeks or until hospital discharge
89483725|NCT04433546|Experimental|Middle Dose (40 mg) Group|Middle: Pemziviptadil (PB1046) 40 mg SC weekly for 4 weeks or until hospital discharge
89483726|NCT04433546|Placebo Comparator|Low Dose (10 mg) Control Group|Low Control: Pemziviptadil (PB1046) 10 mg SC weekly for 4 weeks or until hospital discharge
89483727|NCT03251781|Experimental|Pulmonary Rehabilitation|Pulmonary Rehabilitation
89483728|NCT03574883|Experimental|In-phase tACS|6 Hz stimulation (1000 μA) will be applied simultaneously over the left prefrontal dorso-lateral cortex (F3 of the 10-20 international scalp EEG system) and the left parietal cortex (P3) for 20 minutes using an 8-channels stimulator. The phase difference between the two stimulation sites will be 0°.
89483729|NCT03574883|Active Comparator|Anti-phase tACS|6 Hz stimulation (1000 μA) will be applied simultaneously over the left prefrontal dorso-lateral cortex (F3 of the 10-20 international scalp EEG system) and the left parietal cortex (P3) for 20 minutes using an 8-channels stimulator. The phase difference will be 180°,
89483730|NCT03574883|Sham Comparator|Sham tACS|The stimulation (anti-phase) will start with a current intensity of 1000 μA lasting for 30 seconds. Afterwards, the intensity will progressively decrease over 20 seconds until cessation.
89483731|NCT03574883|Experimental|Active tDCS|1000 μA tDCS stimulation will be applied simultaneously over the left prefrontal dorso-lateral cortex (F3 of the 10-20 international scalp EEG system) and the left parietal cortex (P3) for 20 minutes using an 8-channels stimulator
89483732|NCT03574883|Sham Comparator|Sham tDCS|The stimulation will start with a current intensity of 1000 μA lasting for 30 seconds. Afterwards, the intensity will progressively decrease over 20 seconds until cessation.
89483733|NCT03257787|Experimental|Test of a new adhesive strip|A new adhesive strip has been developed and will be tested in this investigation.
89483734|NCT04996082||Systemic sclerosis group|Patients with systemic sclerosis
89483735|NCT04996082||No Systemic sclerosis group|Patients without systemic sclerosis
89483736|NCT03246243||Preterm infants|Group A will consist of preterm infants born < 37 weeks gestational age. Non-nutritive and nutritive sucking will be assessed using an FDA-approved device (Nfant Feeding Solution) to measure sucking activity. Additionally, those infants who have MRI of the brain for any reason during the course of their hospital admission will also be included in the study and allocated to the appropriate group accordingly. If a subject undergoes any clinically ordered EEG, EMG, MEG, and MRI throughout the duration of their study participation before the age of three then that data will be collected from their medical record. Additionally, any neurodevelopmental testing data completed up to the age of three will be collected.
89531486|NCT06065878|Active Comparator|IPACK + Genicular Nerve Block|In the IPACK+GNB group, 12 mL of the same solution was used for the IPACK block infiltration. Then, the patient was positioned supine, and an ultrasound (Logiq e®, GE, Boston, USA) linear probe was placed approximately 2-3 cm above the patella, in the midline of the femur, with a sagittal plane angle of 45 degrees to visualize the femur and genicular artery . The visible needle was advanced in-plane towards the genicular artery, and 4 mL of local anesthetic solution was injected on the surface of the femur. The same procedure was repeated for the superior lateral genicular nerve block, creating a mirror image on the lateral side of the femur.
89483737|NCT03246243||Term infants with HIE or at risk of brain injury|Group B will consist of term infants admitted to the NICU for therapeutic hypothermia who are at risk of HIE; admitted with concern for neonatal stroke; seizures of unknown etiology; and those admitted who are at risk of abnormal neurodevelopment such as those with hypoglycemia or NAS. Non-nutritive and nutritive sucking will be assessed using an FDA-approved device (Nfant Feeding Solution) to measure sucking activity. Additionally, those infants who have MRI of the brain for any reason during the course of their hospital admission will also be included in the study and allocated to the appropriate group accordingly. If a subject undergoes any clinically ordered EEG, EMG, MEG, and MRI throughout the duration of their study participation before the age of three then that data will be collected from their medical record. Additionally, any neurodevelopmental testing data completed up to the age of three will be collected.
89537648|NCT02461043|Active Comparator|Arm B|radiotherapy
89021058|NCT01058265|Experimental|Integrative|Integrative Medical care is defined as a comprehensive medical evaluation that emphasizes wellness and healing of the whole person as major goals above and beyond suppression of a specific somatic disease. The patient is viewed as a whole person with mind and spirit as well as body and these dimensions are incorporated into diagnosis and treatment plans. An integrative medicine evaluation includes four aspects of health: physical, emotional, mental and spiritual health. Maximum improvement in health is achieved by addressing each aspect through an integrated treatment plan. The evaluation generally takes 90-120 minutes.
89021059|NCT01058265|Active Comparator|Standard|Standard general medical evaluation.
89537649|NCT03296735|Experimental|Ipsilateral tilt|Measuring the cross-sectional area of right subclavian vein in the 20 degree left tilting posture.
89021060|NCT04717037|Experimental|Study|The olive oil massage will be applied initially at 72 hrs of life then twice daily with a dose of 4ml/kg till 28 days .
89021061|NCT04717037|No Intervention|Control|Patients who are assigned to the control group will receive standard care as per unit policies.
89021062|NCT04716842||sepsis|In intensive care patients with suspected or proven infection, if the SOFA score ≥2, the patients will be evaluated as sepsis and routine examination, monitoring and treatment will be applied.
89021063|NCT04716842||septic shock|Patients with sepsis who require vasopressor to keep mean arterial pressure above 65 mmHg and lactate> 2 mmol/l will be included in the septic shock group.
89021064|NCT04716842||control|It will be formed from patients who are hospitalized in the intensive care unit for a reason other than sepsis and septic shock, without suspected or proven infection.
89021065|NCT01057251|Experimental|1|
89483738|NCT03246243||Term infants healthy at birth|Group C will consist of healthy term infants from the community and term infants admitted to who had an initial uncomplicated postnatal course that will serve as the control group. Non-nutritive and nutritive sucking will be assessed using an FDA-approved device (Nfant Feeding Solution) to measure sucking activity. Additionally, those infants who have MRI of the brain for any reason during the course of their hospital admission will also be included in the study and allocated to the appropriate group accordingly. If a subject undergoes any clinically ordered EEG, EMG, MEG, and MRI throughout the duration of their study participation before the age of three then that data will be collected from their medical record. Additionally, any neurodevelopmental testing data completed up to the age of three will be collected.
89483739|NCT03471377||standard scheduling process|Scheduling office assigns start time and room for case and places case on schedule. At this point a default case duration is evaluated by the scheduling office, to see if the value is considered excessively short or excessively long.
89021066|NCT01057251|Placebo Comparator|2|
89021067|NCT04708353|Placebo Comparator|control group|the patient will receive one placebo capsule (vitamin c) once one hour before the operation.
89021068|NCT04708353|Active Comparator|Group Pregabalin 150|the patient will receive one capsule of pregabalin 150 mg once one hour before the operation
89021069|NCT04708353|Active Comparator|Group Pregabalin 300|the patient will receive one capsule of pregabalin 300 mg once one hour before the operation
89021070|NCT04708574|Experimental|Intervention|The intervention group attended a supervised exercise program for women only that presented Arabic music and traditional dance steps (the Lebanese Dabka) three times a week in the London Muslim Mosque Gym. The intervention lasted 12 weeks. There was also a nutrition education component that occurred once per week for the duration of the intervention. The lifestyle intervention group was instructed to walk 10,000 steps per day for the 12 weeks of the program. They were given instructions to take a 30-min walk on days when no formal exercise sessions were offered.
89021071|NCT04708574|Placebo Comparator|Control|The control group participants followed their typical work and leisure routines during the weeks of investigation. The women in the control group were offered the same intervention at the end of the 12 weeks.
89021072|NCT00426816|Experimental|Crossover population|All study population receive placebo and doses of SB-649868 at 10mg, 30mg and 60mg in a crossover desing
89021073|NCT00327197|Experimental|Intermittent mild steroid-naïve asthmatic group|Asymptomatic subjects receiving only beta-agonist inhaler with predicted FEV1 >=80% and normal peak expiratory flow between attacks will be included.
89021074|NCT00327197|Experimental|Mild to moderate persistent asthmatic group|Subjects with mild to moderate persistent asthma on low to moderate dose of inhaled corticosteroid (200-500 microgram fluticasone propionate daily or equivalent), an FEV1 >= 80% predicted (post-bronchodilator), and less than 20% variability in peak expiratory flow.
89203538|NCT04861220|No Intervention|Usual activities + immediate surgical treatment|Patients allocated to this group (Group D) will not participate in the pre-habilitation program and will be instructed to continue their usual activities until the date of surgery.
89203539|NCT00202761|Experimental|PIH|Intensified training of children with CP. Functional training (motor, speech, executive function). Coaching of parents by psychologist, individually and in groups.
89203540|NCT04012281||Post PCI state|The study population of this study underwent percutaneous coronary intervention(PCI) with 2nd generation drug-eluting stent (DES) and measured fractional flow reserve after PCI
89203541|NCT00674570|Experimental|Arm 1: Hydrocortisone|Hydrocortisone
89483740|NCT03471377||assigned a planned case duration value from predictive model|Predictive model calculates new duration for case at 3AM the day before surgery, and the predictions are made available on a SecureShare-site.
89483741|NCT04989140|Experimental|IxaPD|Ixazomib 4 mg, capsules, orally, once on Days 1, 8 and 15 of every 28-day cycle , pomalidomide 25mg qd day 1~21 of every 28-day cycle, Dexamethasone 40 mg (20 mg for patients >75 years of age) was given on days 1, 8, 15, and 22 of every 28-day cycle.
89483742|NCT02134171|Experimental|Biological investigations|From day 1 to day 3, specific blood tests will be performed (serum troponin Ic and brain natriuretic peptide [BNP]). A cardiac ultrasonography within the 4 first days and a cerebral MRI within the first 7 days after TMA diagnosis will be performed.
89483743|NCT03246009|Experimental|single injection-1.8mg|rHSA/GCSF,injection,1.8mg,Single subcutaneous injection,Duration 1 day
89483744|NCT03246009|Experimental|single injection-2.1mg|rHSA/GCSF,injection,2.1mg,Single subcutaneous injection,Duration 1 day
89483745|NCT03246009|Experimental|single injection-2.4mg|rHSA/GCSF,injection,2.4mg,Single subcutaneous injection,Duration 1 day
89537650|NCT03296735|No Intervention|Supine|Measuring the cross-sectional area of right subclavian vein in supine position.
89537651|NCT03296735|Active Comparator|Contralateral tilt|Measuring the cross-sectional area of right subclavian vein in the 20 degree left tilting posture.
89537652|NCT03298997|Experimental|Ligation and Hemorrhoidopexy|"The patient will be placed in the Lloyd-Davies position. Provision of a sterile field, using a 10% povidone iodine solution. Rectal dilatation will be performed with a 10% xylocaine gel. Introduction of a proctoscope. Identification of the hemorrhoidal nodules (3rd, 7th, 11th hour). Confirmation of the hemorrhoidal artery location, through palpation. Ligation of the hemorrhoidal nodules using an absorbable polyglycolic acid suture (2-0, 5/8 inch needle).~Placement of a fixative suture in the hemorrhoidal nodule and then performance of hemorrhoidopexy Placement of a hemostatic gauze in the surgical field. Prior to operation, the patients will be submitted to pudendal nerve block. Using an atraumatic 25 Gauge (G) needle, a 20ml lidocaine solution (diluted with saline in a 1:1 rate) will be administered bilaterally, medially to the ischial tuberosity.~10 minutes before the operation, the patient will receive 1-2.5mg midazolam and 0.1-0.2 mg fentanyl."
89537653|NCT03298997|Active Comparator|Ultrasound Guided Ligation of Hemorrhoidal Arteries|"The patient will be placed in the Lloyd-Davies position. Provision of a sterile field, using a 10% povidone iodine solution. Rectal dilatation will be performed with a 10% xylocaine gel. Use of a proctoscope combined with a Doppler sensor. After the hemorrhoidal artery localization, Z ligations will be placed, using an absorbable polyglycolic acid suture (2-0, 5/8 inch needle).~The proper artery ligation will be confirmed by the absence of the Doppler signal.~In the presence of residual hemorrhoidal tissue hemorrhoidopexy will be performed, by applying a continuous suture.~Placement of a hemostatic gauze in the surgical field. Prior to operation, the patients will be submitted to spinal anesthesia. Using an atraumatic 25 Gauge (G) needle, a levobupivacaine 5mg/ml and fentanyl 25mg solution, will be administered at the height of lumbar (L)2-L3 or L3-L4."
89537654|NCT03296657|Experimental|stannous fluoride toothpaste|0.454% stannous fluoride will be used twice a day, brushing for at least 1 minute for 2 weeks
89537655|NCT03298919|Experimental|Exercise Videogames|Exercise videogames 3 times weekly for 12 weeks followed by 6 months of home practice
89537656|NCT03298919|Active Comparator|Standard Exercise|Exercise using aerobic equipment such as stationary bikes and treadmills 3 times weekly for 12 weeks followed by home practice
89537657|NCT03298919|No Intervention|Wellness Control|Weekly mailings on general health and wellness topics for 12 weeks followed by monthly mailings for 6 months.
89537658|NCT03296579|Active Comparator|Conventional asthma therapy.|Bilevel Positive Airway Pressure group(BiPAP). BiPAP settings at 15/5 cm H2O by face mask with background rate 10 to 15/min. Standard steroid dose plus hourly salbutamol and oxygen to keep SaO2 > 92%.
89537659|NCT03296579|Experimental|Non-invasive ventilation (CPAP).|Continuous Positive Airway Pressure group (CPAP). CPAP settings at 8 to 10 cm H2O. Standard steroid dose plus hourly salbutamol and oxygen to keep SaO2 > 92%.
89537660|NCT03296579|Experimental|Non-invasive ventilation (BiPAP)|Standard steroid dose, hourly salbutamol, oxygen as needed, nebulized ipratropium q 6 hrly, magnesium sulfate 50 mg/kg IV (4 doses q 6 hrly), loading dose of aminophylline 6 mg/kg IV if no progress.
89537661|NCT02461901||Fidaxomicin treatment|Patients being treat with fidaxomicin (on the decision of their treating physician)
89537662|NCT02461901||Metronidazole or vancomycin treatment|Patients being treated with metronidazole or vancomycin (on the decision of their treating physician)
89537663|NCT02461199||Fecal microbiota transplantation|Patients with proven gut colonization status with following bacteria: Klebsiella pneumoniae resistant to carbapenems, Pseudomonas aeruginosa resistant to carbapenems, Enterococcus faecalis VRE (vancomycin-resistant enterococcus), Enterococcus faecium VRE, Enterobacter cloacae resistant to carbapenems or other MDR species. Gut colonization proven by conventional microbiological culture and/or molecular methods.
89537664|NCT02461667|Placebo Comparator|placebo|SRP plus placebo SRP was done for all the subjects. Placebo gel was delivered subgingivally into the pocket
89537665|NCT02461667|Active Comparator|Metformin|SRP plus Metformin SRP was done for all the subjects. metformin was delivered in the pocket subgingivally
89537666|NCT02461667|Active Comparator|Alendronate|SRP plus Alendronate SRP was done for all the subjects. Alendronate was delivered in the pocket subgingivally
89021075|NCT00327197|Experimental|Severe asthma group|Subjects with severe persistent asthma. They will be on either: high inhaled corticosteroid (CS >=1000 microgram fluticasone daily or equivalent) or on high dose inhaled CS plus oral CS (no more than 20 milligrams predisolone a day). The subjects should have at least one ( if on oral steroids) or two (if only on inhaled steroids) of the following: 1) FEV1<80% and FEV1/FVC ratio <70% 2) more than 25% variability in peak expiratory flow 3) daily symptoms ± nocturnal symptoms 4) severe exacerbations of >= twice a year in at least one of the last two years.
89021076|NCT00327197|Placebo Comparator|Healthy subjects group|Non-asthmatic and non-smokers with FEV1 > 85% predicted, on no regular medication.
89203542|NCT00674570|Experimental|Arm 2: D-Cycloserine|D-Cycloserine
89537667|NCT03296501|Experimental|Autologous ADRC injection|
89537668|NCT03296423|Placebo Comparator|Placebo|One intradermal injection of 0.1ml of sodium chloride 0.9%
89021077|NCT00425763|Experimental|AQAS|
89021078|NCT00327509||1-HTG|high tension glaucoma highest IOP > 21 mmHg
89021079|NCT00327509||2-NTG|normal tension glaucoma highest measured IOP < 21 mmHg
89021080|NCT00327509||3-PEX|pseudoexfoliation glaucoma PEX material visible
89021081|NCT00327509||4-Juvenile|juvenile glaucoma
89537669|NCT03296423|Active Comparator|Vaccination|One intradermal injection of 0.1ml of BCG (BCG vaccine Bulgaria strain 1331; Intervax)
89537670|NCT04489511|Experimental|Dose 1|STG-001 given orally at Dose 1 once a day for 28 days
89537671|NCT04489511|Experimental|Dose 2|STG-001 given orally at Dose 2 once a day for 28 days
89021082|NCT00327509||5-Control1|healthy subjects (age group 1)
89021083|NCT00327509||6-Control2|healthy subjects (age group 2)
89021084|NCT00425880||Pregnant Asthmatics|
89021085|NCT00425880||Pregnant Smokers|
89021086|NCT00425880||Healthy Pregnant Controls|
89203543|NCT00674570|Placebo Comparator|Arm 3: Placebo|Placebo
89203544|NCT00940563|Experimental|Imatinib|
89203545|NCT00759512|Active Comparator|Arm 1|This arm received the Kreiger/Kunz method of Therapeutic Touch in addition to Standard of Care
89021087|NCT05459168|Other|Calm Meditation Smartphone App Feedback (Aim 1)|Advisory committee members will be asked to use the current Calm meditation app platform for a full week and to keep an informal journal prior to participating in focus groups in which they will provide feedback about the app.
89021088|NCT05459168|Other|Cancer-Specific Meditation App Prototype Design (Aim 2)|Findings from Aim 1 will inform the development of a cancer-specific meditation app prototype to be tested in Aim 3.
89021089|NCT05459168|Other|Cancer-Specific Meditation App Prototype (Aim 3)|Recruited cancer patients/survivors will be asked to beta-test the cancer-specific app prototype for four weeks. The prototype will be developed in Aim 2 and informed by qualitative findings of Aim 1.
89483746|NCT03246009|Experimental|multiple injection-1.8mg|rHSA/GCSF,injection,1.8mg, subcutaneous injection,Duration 4 day,A total of 2 injections, each interval of 3 days.
89483747|NCT03246009|Experimental|multiple injection-2.1mg|rHSA/GCSF,injection,2.1mg, subcutaneous injection,Duration 4 day,A total of 2 injections, each interval of 3 days.
89483748|NCT03246009|Experimental|multiple injection-2.4mg|rHSA/GCSF,injection,2.4mg, subcutaneous injection,Duration 4 day,A total of 2 injections, each interval of 3 days.
89483749|NCT04995770|Experimental|Praise Text Messages|"The text message praise intervention lasted for 6 months. Each week, transplant coordinators, masked from who enrolled in the study or to which condition participants were randomized, prepared a list of all patients in the study age group whose laboratory blood tests indicated that immunosuppressant medications were within the expected range. A researcher reviewed the list to identify whether any of patients were currently assigned to the intervention, and if so, sent text message praise via REDCap's text message function. We rotated through 14 standardized text messages each week. Examples of messages included: Your labs look very good. Super job taking your meds! and Your labs look great! Thanks for putting in the effort to take care of your health!."
89483750|NCT04995770|No Intervention|Usual Care|Participants in the usual care arm did not receive any praise text messages. All participants continued to receive usual care from the multidisciplinary liver transplant team, including phone calls and follow-up care when laboratory blood tests indicated that immunosuppressant medications were outside of the expected range.
89483751|NCT04995302|Active Comparator|Microneedling and Amnion Bilayer|Microneedling is a dermaroller procedure that uses small needles to prick the skin. Amnion bilayer is used as an additional therapy after microneedling therapy.
89483752|NCT04995302|Placebo Comparator|Microneedling|Microneedling is a dermaroller procedure that uses small needles to prick the skin.
89483753|NCT02136199|Other|Active Implementation of Share EBM Toolkit|Investigators led implementation of tailored activities and tactics (Shared EBM Toolkit) designed to promote the use of the decision aids in clinical encounters (i.e. journal clubs, value map streaming).
89483754|NCT02136199|Other|Passive Implementation of Share EBM Toolkit|Locally supported dissemination of Shared EBM Toolkit designed to promote the use of the decision aids in clinical encounters.
89483755|NCT03246399|Experimental|0.03mg SM04690|0.03mg SM04690 per 0.5 mL intradiscal injection (single injection at Day 1)
89483756|NCT03246399|Experimental|0.07mg SM04690|0.07mg SM04690 per 0.5 mL intradiscal injection (single injection at Day 1)
89483757|NCT03246399|Experimental|0.15mg SM04690|0.15mg SM04690 per 0.5 mL intradiscal injection (single injection at Day 1)
89483758|NCT03574805|Active Comparator|PRS-060|PRS-060 or Placebo
89483759|NCT03574805|Placebo Comparator|Placebo|PRS-060 or Placebo
89021090|NCT05458895|Experimental|High concentration free-base nicotine (5%), Tobacco flavor|Participate in vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
89021091|NCT05458895|Experimental|High concentration nicotine salt (5%), Tobacco flavor|Participate in vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
89021092|NCT05458895|Experimental|High concentration free-base nicotine (5%), Menthol flavor|Participate in vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
89483760|NCT02134249|Active Comparator|Group A (Diosmin group)|In group A, (Diosmin group), 2 tab / 8 hs Diosmin ( 500mg) will be given from at day of HCG injection and for 14 days.
89483761|NCT02134249|Active Comparator|Group B(Cabergoline group)|while in group B (Cabergoline group), 1 tab/day Cabergoline(Dostinex)( 0.5 mg) will be given at day of HCG injection and for 8 days .
89483762|NCT03245853|Other|Treatment|Treatment as per protocol, there is no placebo arm.
89483763|NCT04989062||Healthy children|Apparently healthy children at Year 1 to Year 6 in the primary school in Taiwan. Exclusion criteria are children with metal implant or splint, pacemaker implantation, limb defect or injury and pregnant.
89483764|NCT03574649|Experimental|NANT NSCLC Combination Immunotherapy regimen|
89483765|NCT03574649|Active Comparator|Standard of Care|
89483766|NCT02128945|Experimental|FLUDATEP|[18F] - Fludarabine PET/CT
89483767|NCT03250611|Experimental|Occipito-Cervical Instability|Stabilization of the occipito-cervical junction by Occipital Condyle Screw (OCS) as a sole cranial anchor, with posterior bone graft.
89483768|NCT02136277||Colorectal patients|Subjects undergoing colorectal surgery
89483769|NCT03245775|Experimental|iChoose|12 bi-weekly sessions & 24 IVR calls/12 months, 24 physical activity sessions over 6 months; delivers intervention to parents and children only
89483770|NCT03245775|Experimental|Family Connections|2 in-person sessions spaced one week apart & 10 IVR calls/6 months, promotes physical activity but does not include structured exercise sessions; delivers intervention to parents only
89483771|NCT04985474||Pulmonary resection|
89483772|NCT02129023|Experimental|exergame|Participants were asked to use exergame (Xbox 360) half hour for three times per week in the 12-week study period.
89483773|NCT02129023|No Intervention|control|Participants were not asked to use exergames.
89483774|NCT03250455||CTA+CTP|
89483775|NCT03250455||CTA only|
89537672|NCT03296267|Other|gastroduodenoscopy|all participants undergo a gastroduodenoscopy to use the biopsies in an Ussing chamber experiment.
89537673|NCT01670877|Experimental|Part I: Neratinib Only|-Patients will receive neratinib PO daily on Days 1-28. Each cycle is 4 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
89021093|NCT05458895|Experimental|High concentration nicotine salt (5%), Menthol flavor|Participate in vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
89021094|NCT05458895|Experimental|Low concentration free-base nicotine (1%), Tobacco flavor|Participate in vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
89021095|NCT05458895|Experimental|Low concentration nicotine salt (1%), Tobacco flavor|Participate in vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
89021096|NCT05458895|Experimental|Low concentration free-base nicotine (1%), Menthol flavor|Participate in vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
89021097|NCT05458895|Experimental|Low concentration nicotine salt (1%), Menthol flavor|Participate in vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
89021098|NCT00427089|Experimental|1|2L gut cleansing solution
89021099|NCT00427089|Active Comparator|2|
89021100|NCT05458661|Other|recruited patient population|
89021101|NCT05458466|Experimental|Pilates training Group|The Pilates Training program consisted of warm-up, work-out and cool-down sections. For the warm-up section, breathing, standing roll down, and spine twist exercises were selected; for the work-out section, the hundred, shoulder bridge, scissors, swimming, and quadruped exercises, and for cool-down section, torso twist, cat-camel, and standing stretches. The Pilates Training progression was achieved by increasing the number of repetitions of the selected exercises and adding some equipment (balls, foam rollers) to challenge postural stability. In the first five sessions, after each exercise was performed for six to eight repetitions, the number of repetitions was increased to 10-12. Moreover, the environment where the training took place was carefully arranged according to the needs of children with autism.
89203546|NCT00759512|No Intervention|Arm 2|Standard of Care
89203547|NCT00940641|Experimental|1|IV dose of AZD7325
89203548|NCT00940641|Experimental|2|14C oral dose of AZD7325
89203549|NCT00761852|Active Comparator|1|Ruboxistaurin
89203550|NCT00761852|Placebo Comparator|2|Placebo
89203551|NCT00940719|Experimental|Vitamin D3|Patients receive 1dd 500ug vitamin D3 for 3 months
89483776|NCT03073928|Active Comparator|Interscalene Block|"Receives interscalene block with 15mL of ropivacaine 0.5% at the level of C6. A total of 15mL will be injected with repeated aspirations to rule out intravascular placement of the needle tip. Once this is done, the needle tip will be moved to the lateral edge of sternocleidomastoid muscle and additional 3mL of 0.5% ropivacaine will be injected between the deep fascia of the sternocleidomastoid and deep investing fascia of the neck (superficial cervical plexus block SCP).~We will administer injection of saline similar to experimental group to blind the patient"
89483777|NCT03073928|Experimental|Paracoracoid SPB|Receives paracoracoid subscapularis plane block with the ultrasound. Using a 50mm 22G block needle 15ml of 0.5% Ropivacaine will be deposited anterior to the fascia of subscapularis muscle after eliciting a motor response with 0.6mA current delivered through the needle. Following this, superficial cervical plexus block will be done using 3mL of 0.5% ropivacaine similar to group 1.
89483778|NCT03578861|Experimental|Dementia related mobility and counseling|"The DESKK mobility program is based on the already existing day structure of the RC facility with two slots a day for physical activation activities (1 ½ hours forenoon and 1 ½ hours afternoon). The program structures these activities based on specific developed exercises, which are focused on the individual mobility level of every PwD and his/her mobility level.~The DESKK counseling program is an effort to structure and systemize counseling processes focused on the respite care setting by different documents and assessments."
89483779|NCT03257397|Experimental|left iTBS and right cTBS|40 patients will receive intermittent theta-burst stimulation (iTBS) over the left dorsolateral prefrontal cortex (DLPFC) and continuous TBS (cTBS) over the right DLPFC
89483780|NCT03257397|Active Comparator|left and right iTBS|40 patients will receive intermittent theta-burst stimulation (iTBS) over the left and right dorsolateral prefrontal cortex (DLPFC)
89483781|NCT02134405|Experimental|Rebamipide and Esomeprazole|Rebamipide tablets 100mg tid for 8 weeks Esomeprazole tablets 20mg od for 8 weeks
89483782|NCT02134405|Active Comparator|Rebamipide and placebo|Placebo drug with Rebamipide 100mg tid
89483783|NCT03574415|Experimental|Japanese_DWP14012 Amg|DWP14012 Amg, tablets, orally, single and multiple administration
89483784|NCT03574415|Experimental|Japanese_DWP14012 Bmg|DWP14012 Bmg, tablets, orally, single and multiple administration
89483785|NCT03574415|Experimental|Japanese_DWP14012 Cmg|DWP14012 Cmg, tablets, orally, single and multiple administration
89483786|NCT03574415|Experimental|Caucasian_DWP14012 Bmg|DWP14012 Bmg, tablets, orally, single and multiple administration
89203552|NCT00940797|Experimental|DMMET-01|
89483787|NCT03574415|Experimental|Caucasian_DWP14012 Cmg|DWP14012 Cmg, tablets, orally, single and multiple administration
89483788|NCT03574415|Experimental|Korean_DWP14012 Bmg|DWP14012 Bmg, tablets, orally, single and multiple administration
89483789|NCT03574415|Experimental|Korean_DWP14012 Cmg|DWP14012 Cmg, tablets, orally, single and multiple administration
89483790|NCT03574415|Placebo Comparator|Placebo|DWP14012 placebo-matching tablets
89483791|NCT03074006|Experimental|low dose|
89483792|NCT03074006|Experimental|high dose|
89483793|NCT02456025|Active Comparator|Topical tacrolimus|20 eyes with active Vernal Keratoconjunctivitis
89483794|NCT02456025|Placebo Comparator|Placebo|20 eyes with active Vernal Keratoconjunctivitis
89203553|NCT00940797|Placebo Comparator|Control|
89483795|NCT02136433|Experimental|Tablet - self exercise|"Existing tablet Apps that encourage finger movement in a fun manner while playing a game will be used. The apps will be taught to the participants and then they will be requested to exercise alone (or with family) everyday for one hour in addition to their regular rehabilitation sessions (Occupational, Physical Therapy, speech).~The intervention will include 15-20 sessions of 60 minutes of self-training using a tablet."
89483796|NCT02136433|Active Comparator|GRASP self exercise|"GRASP (Graded Repetitive Arm Supplementary Program)(Harris et al., 2009)is an arm and hand exercise program developed for individuals with stroke with upper extremity impairments GRASP provides a method for patients to undertake a self-directed arm and hand exercise program.~The exercises will be taught to the participants and then they will be requested to exercise alone (or with family) everyday for one hour in addition to their regular rehabilitation sessions (Occupational, Physical Therapy, speech).~The intervention will include 15-20 sessions of 60 minutes of self-training"
89483797|NCT04985552|Experimental|ciNPT|
89483798|NCT04985552|Active Comparator|Conventional tape dressings|
89483799|NCT02035631|Experimental|Intervention|Lifestyle intervention combining weight control, diet and physical activity
89483800|NCT02035631|Sham Comparator|Minimal intervention|Minimal diet intervention and minimal physical activity intervention
89483801|NCT02134483|Experimental|Parathyroid allo-transplantation|patients who have permanent hypoparatyroidism
89483802|NCT04985240|Experimental|No Intervention: (control group)|The control group was assigned to crop lettuce without any biofortification but with the same characteristic of bioforticated lettuce(soil, water, harvesting time).
89483803|NCT04985240|Experimental|Experimental: intervention group|The intervention group was assigned to biofortificated Molibdenum crop lettuce.
89483804|NCT02454387|Experimental|Experimental: ONO-4474 Part A1|Single doses of ONO-4474 or placebo, randomized 3 active: 1 placebo
89483805|NCT02454387|Placebo Comparator|Experimental: ONO-4474 Placebo Part A1|Single doses of ONO-4474 or placebo, randomized 3 active: 1 placebo
89483806|NCT02454387|Experimental|Experimental: ONO-4474 Part A2|Single doses (2 periods) of ONO-4474 or placebo, randomized 3 active: 1 placebo
89483807|NCT02454387|Placebo Comparator|Experimental: ONO-4474 Placebo Part A2|Single doses (2 periods) of ONO-4474 or placebo, randomized 3 active: 1 placebo
89483808|NCT02454387|Experimental|Experimental: ONO-4474 Part B|Multiple ascending doses of ONO-4474 or placebo, randomized 3 active: 1 placebo
89483809|NCT02454387|Placebo Comparator|Experimental: ONO-4474 Placebo Part B|Multiple ascending doses of ONO-4474 or placebo, randomized 3 active: 1 placebo
89483810|NCT02454387|Experimental|Experimental: ONO-4474 Part C|NGF hyperalgesia and single or multiple doses of ONO-4474, randomized 1 active: 1 placebo in cross over design
89483811|NCT02454387|Placebo Comparator|Experimental: ONO-4474 Placebo Part C|NGF hyperalgesia and single or multiple doses of ONO-4474, randomized 1 active: 1 placebo in cross over design
89483812|NCT02454387|Experimental|Experimental: ONO-4474 Part D|Single doses of ONO-4474 or placebo, randomized 3 active: 1 placebo
89483813|NCT02454387|Placebo Comparator|Experimental: ONO-4474 Placebo Part D|Single doses of ONO-4474 or placebo, randomized 3 active: 1 placebo
89483814|NCT04433702|Experimental|Experimental Eye|10 mmHg of negative pressure is applied to the periocular microenvironment. This is achieved by programming the Mercury™ Multi-Pressure Dial (MPD) such that only one goggle receives negative pressure.
89483815|NCT04433702|Placebo Comparator|Control Eye|The opposing eye serves as the intrasubject control for each participant. No negative pressure is applied to the periocular microenvironment. This is achieved by programming the Mercury™ Multi-Pressure Dial (MPD) such that the other goggle does not receive negative pressure.
89483816|NCT02134561|Other|All subjects|psychological interview, MRI, neurological tests, cognitive tests
89483817|NCT04985006|Experimental|Moderate intensity aerobic exercise|each subject will undergo running in medium intensity.
89483818|NCT04985006|Active Comparator|High intensity aerobic exercise|each subject will undergo running in high intensity.
89483819|NCT03576833|Experimental|Balloon|
89203554|NCT00759590||1|ALI/ARDS patients
89483820|NCT02136589|Experimental|Dicrofenac|
89483821|NCT02134639||Patient who is suspected of endocrine tumors|According to symptomatology, biology or imaging or pathological context
89483822|NCT04985162|Experimental|Intervention|Intervention group (n=10) received differential learning based physiotherapy program: 3 times a week ordinary physiotherapy, 2 times a week differential learning based on physiotherapy, total 3 weeks
89483823|NCT04985162|Active Comparator|Control|Control group (n=10) received ordinary physiotherapy program 5 times a week, total 3 weeks
89483824|NCT02129101|Experimental|Treatment (azacitidine, sonidegib, decitabine)|"Patients receive azacitidine SC or IV on days 1-7, sonidegib PO QD on days 1-28 or 1-7* or decitabine IV on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~NOTE: Sonidegib PO QD is given on days 1-7 if in combination with azacitidine or on days 1-28 is given if in combination with decitabine."
89483825|NCT03245697||Lactating mothers|Lactating mothers recruited in Galicia (NW Spain)
89483826|NCT03250221||Robotic or laparoscopic myomectomy|Women who received robotic or laparoscopic myomectomy
89483827|NCT02136667||Exposed|Women with a history of preeclampsia 10 years ago
89483828|NCT02136667||Unexposed|Women with a history of uncomplicated pregnancy 10 years ago
89483829|NCT04894916|Experimental|My Diabetes Care Mobile (MDC-m)|Patients have access to a patient web portal embedded with the My Diabetes Care Mobile (MDC-m) intervention.
89203555|NCT04012905|Experimental|Short tapering corticosteroids|Corticosteroid taper over 28 weeks
89203556|NCT04012905|Active Comparator|Long tapering corticosteroids|Corticosteroid taper over 52 weeks
89483830|NCT03250065|Experimental|ETT Study Group|The Sensing ET Tube study Group
89483831|NCT02134717|Experimental|sarcoidosis stage II|All subjects with active stage II sarcoidosis with or without skin disease will receive the drug maraviroc 300mg to be taken orally twice a day for 6 weeks duration.
89483832|NCT03245385|Experimental|Treatment with topical halobetasol spray 0.05%|Patients will instructed o apply halobetasol spray twice daily for 14 days and not to rub over the affected area after application of spray.
89531487|NCT06065852||Alport Syndrome Rare Disease Group|"The evidence base in Alport Syndrome is small, but there is a very important education gap which it is the group's priority.~Our first priorities are to assemble and make available clear information for clinicians caring for patients, as well as for patients themselves including making it clear for Commissioners 'Who should be tested' establish contact details for advice on specific issues make it clear how to approach the group for clinical advice and how to enrol patients in the group.~In time this may lead to specialised regional clinics, made possible by recruiting more interested clinicians as the project develops."
89483833|NCT02136745|Experimental|Relaxation Response Mind-Body Intervention|The Relaxation Response Mind-Body Intervention (RR-MBI) involved a 9-week group program conducted by a nurse practitioner or psychologist skilled in MBI, which included a GI-specific session conducted by a physician. The groups met once weekly for 1.5 hours. The program was multidimensional and included daily elicitation of the RR using a variety of methods (including breath focus, single-pointed focus, imagery, contemplation, yoga, and mindful awareness); cognitive reappraisal skills, health enhancing behaviors, and the promotion of optimism and acceptance. Throughout the course of treatment, participants were asked to elicit the RR at home each day for 15-20 minutes.
89203557|NCT02559518|Experimental|anodal ctDCS|Volunteers will be submitted to non-invasive cerebellar stimulation during serial reaction time task (SRTT).
89483834|NCT03249987|Other|Electronic bladder diary|Participants will be asked to complete the electronic diary for three days before crossing over to the paper diary. Patients will be asked to record the time and volume of voids, any incontinence or urgency episodes and sleep-wake times. Patients will be asked to complete a short questionnaire regarding their opinions
89483835|NCT03249987|Other|Paper bladder diary|Participants will be asked to complete the paper diary for three days before crossing over to the electronic diary. Patients will be asked to record the time and volume of voids, any incontinence or urgency episodes and sleep-wake times. Patients will be asked to complete a short questionnaire regarding their opinions
89483836|NCT04894838|Experimental|Distal gastric bypass type I|Laparoscopic distalisation of RYGB type I. The RYGB is modified by dividing the Roux limb (AL) at the jejuno-jejunal anastomosis and re-anastomosed distally to 200 cm from the ileocecal valve using linear staplers, creating a long biliopancreatic limb (BPL). In cases of initial AL lengths shorter than 100 cm, the CC lengths should be adjusted to create a TALL of at least 300 cm.
89483837|NCT04894838|Experimental|Distal gastric bypass type II|Laparoscopic distalisation of RYGB type II. The RYGB is modified by dividing the BPL at the jejuno-jejunal anastomosis and re-anastomosed distally to 200 cm from the ileocecal valve using linear staplers, creating a long AL.
89483838|NCT02136823|Placebo Comparator|sugar pill|sugar pill, oral administration, placebo capsule
89483839|NCT02136823|Experimental|riluzole|50mg tablet, single oral dose, one day (single dose)
89483840|NCT02136823|Experimental|isradipine|5mg capsule, single oral dose, one day (single dose)
89483841|NCT02136823|Experimental|memantine|5mg tablet, single oral dose, one day (single oral dose)
89483842|NCT02136823|Experimental|therapeutic stretching|Manual therapeutic stretching of tested muscle by licensed clinician
89483843|NCT03250143|Active Comparator|group A|Oral cyclosporine 3mg/kg/day (200mg/day) will be started.If there is no improvement in 1 week then escalating the dose maximum upto 5mg/kg/day.
89483844|NCT03250143|Active Comparator|group B|Oral azathioprine will be started at 1mg/kg/day.If there is no improvement in 1 week then escalating the dose maximum upto 100mg/day
89483845|NCT03073850|Experimental|Antiplatelet therapy|acetylsalicylic acid (ASA) 100mg or clopidogrel 75mg if intolerant to ASA
89483846|NCT03073850|Experimental|Low-dose OAC therapy|Edoxaban of 30mg (Reduced dose of 15mg if body weight < 60kg, CCr< 50 ml/min, concomittant use of P-gp)
89483847|NCT03073850|Active Comparator|Standard-dose OAC therapy|Edoxaban of 60mg (Reduced dose of 30mg if body weight < 60kg, CCr< 50 ml/min, concomittant use of P-gp)
89483848|NCT03549793|Experimental|dance thrapy|4-week Multidisciplinary Rehabilitation Treatment + Dance Therapy Treatment (2 hours par week)
89483849|NCT03549793|Active Comparator|exercises without dance|4-week Multidisciplinary Rehabilitation Treatment + Exercises without music (2 hours par week)
89483850|NCT03257319|Experimental|inhaled morphine + IV placebo|Arm A: inhaled titration of morphine chlorhydrate+ IV placebo
89483851|NCT03257319|Placebo Comparator|IV morphine +inhaled placebo|Arm B:IV titration of morphine chlorhydrate + inhaled placebo
89483852|NCT03070574|Experimental|2400 MG mesalamine (5-ASA) total|2400mg (1200mg mesalamine/1200mg) mesalamine once daily in the morning for the treatment phase of the study (24 months)
89483853|NCT03070574|Experimental|1200 MG mesalamine (5-ASA) total|placebo/1200mg mesalamine once daily in the morning for the treatment phase of the study (24 months)
89483854|NCT03070574|Placebo Comparator|Placebo|placebo/placebo once daily in the morning for the treatment phase of the study (24 months)
89483855|NCT02134795|Experimental|TNM (trade name), a form of brainstem stimulation|ThermoNeuroModulation (TNM) device with a standardized active neuromodulation waveform will be used for all patients. The device will be used twice for ~19 minutes each time. There will be a gap of roughly 1 hour between the two device applications.
89483856|NCT02134873|Active Comparator|0.1ml 24% sucrose concurrent opioids|0.1ml 24% sucrose concurrent opioids
89483857|NCT02134873|Active Comparator|0.5ml 24% sucrose concurrent opioids|0.5ml 24% sucrose concurrent opioids
89483858|NCT02134873|Active Comparator|1.0ml 24% sucrose concurrent opioids|1.0ml 24% sucrose concurrent opioids
89203558|NCT02559518|Experimental|cathodal ctDCS|Volunteers will be submitted to non-invasive cerebellar stimulation during serial reaction time task (SRTT).
89203559|NCT02559518|Sham Comparator|sham ctDCS|Volunteers will be submitted to non-invasive cerebellar stimulation during serial reaction time task (SRTT).
89483859|NCT02134873|Active Comparator|0.1ml 24% sucrose no opioids|0.1ml 24% sucrose no opioids
89483860|NCT02134873|Active Comparator|0.5ml 24% sucrose no opioids|0.5ml 24% sucrose no opioids
89483861|NCT02134873|Active Comparator|1.0ml 24% sucrose no opioids|1.0ml 24% sucrose no opioids
89483862|NCT04984694|Experimental|Computerized virtual reality training programs group (Hot-Plus group)|Participants who are in Hot-Plus group will divide several small groups which will be 4 persons with mild cognitive impairment. Participants will receive computerized virtual reality training program by Hot-Plus as a group activity for one hour, once a week for 12 weeks.
89483863|NCT04984694|Active Comparator|Social interaction group|The participants in the social interaction group will come as a group for social interaction one hour weekly for 12 weeks.
89483864|NCT04984694|No Intervention|Control group|The control group will maintain regular activities.
89021102|NCT05458466|Experimental|Aerobic Training Group|Each training session consisted of a 20-minutes treadmill workout (using the motorized Ultıma Ac 3500 treadmill) followed by 20-minutes bicycle workout (Voit Yellow Collection 112u exercie bike). The intensity of training, which began at 50% to 60% of maximum heart rate (HR), was increased each week so that by week five, the children were at 75% to 80% maximum HR. The maximum HR, as recommended for children, was calculated using the formula 208 - 0.7 x (age) (Mahon et al., 2010). To ensure that the exercise intensity remained in the target HR zone during training, the child's HR was continuously monitored from the used treadmill and exercise bike monitors.
89483865|NCT03257241|Active Comparator|A arm (DA-90)|"Induction I:~DNR 90 mg/m2 D 1-3 in 30-60 min i.v. infusion~Ara-C 100 mg/m2 D 1-7 in 24 h i.v. infusion"
89483866|NCT03257241|Active Comparator|B arm (DAC)|"Induction I:~DNR 60 mg/m2 D 1-3 in 30-60 min i.v. infusion~cladribine 5 mg/m2 D 1-5 in 2 h i.v. infusion prior to Ara-C~Ara-C 200 mg/m2 D 1-7 in 22 h i.v. infusion."
89483867|NCT03257241|Active Comparator|A arm (CLAG-M)|Cladribine 5mg/m2 in 2 h i.v. infusion on days (1-5) Ara-C 2 g/m2 in 4 h i.v. infusion, 2 h after cladribine infusion on days (1-5) Mitoxantrone 10 mg/m2 i.v. 1xd on days (1-3) G-CSF 30MU s.c. 1xd from day 0 to 5 of the treatment (6 doses).
89483868|NCT03257241|Active Comparator|B arm (FLAG-IDA)|Fludarabine 30 mg/m2 in 30-min i.v. infusion on days (1-5) Ara-C 2 g/m2 in 4 h i.v. infusion, 2 h after fludarabine infusion on days (1-5). Idarubicin 8 mg/m2 i.v. 1xd on days (1-3) G-CSF 30MU s.c. 1xd from day 0 to 5 of the treatment (6 doses).
89483869|NCT02129179|Experimental|GLP-1|
89483870|NCT04984460||life-style counseling|"A sample of one or more of the following characteristics. Symptoms: vulva pruritus, burning pain, but also accompanied by pain in urine and sexual pain and other symptoms; Leucorrhea increased.~Physical signs: Vulva flushing, edema, visible scratches or chaps, white membrane attached to the inner side of the labia minora and the vaginal mucosa, more white bean residue like secretions can be seen in the vagina, which can be curd."
89483871|NCT02129257|Experimental|FOLFIRI-AFLIBERCEPT|Aflibercept 4 mg/kg administered over 1 hour on Day 1, followed by FOLFIRI regimen. Treatment will be repeated every 2 weeks. FOLFIRI regimen: Irinotecan 180 mg/m² intravenous (IV) infusion and folinic acid 400 mg/m² IV infusion followed by: 5-fluorouracil (5-FU) 400 mg/m² IV bolus followed by: 5-FU 2400 mg/m² continuous IV infusion over 46 hours. FOLFIRI administration will immediately follow the aflibercept one. In the absence of PD after 6 months of the combination of chemotherapy and aflibercept, the patient will be treated with a maintenance therapy with aflibercept alone until PD or unacceptable toxicities, investigator's decision or patient's refusal of further treatment or death, whichever comes first.
89483872|NCT03256929|Experimental|depression participants - intervention|personalized diet intervention based on microbiota analysis and health status
89483873|NCT03256929|Experimental|depression participants - control|General information on nutrition and health
89483874|NCT03256929|Experimental|pre-depression participants - control|General information on nutrition and health for pre-depression participants
89483875|NCT03256929|Experimental|pre-depression participants - intervention|personalized diet intervention based on microbiota analysis and health status for pre-depression participants
89483876|NCT04995146||Retrospective 3 months cohort (admitted stroke patients)|
89483877|NCT04995146||"Prospective pre-implementation standard of core care quality measures cohort"|
89021103|NCT00427206|Active Comparator|1|acetaminophen 4 g/day
89021104|NCT00427206|Placebo Comparator|2|placebo undistinguishable from active drug
89021105|NCT05458388|Active Comparator|Kimura-Takemoto classification|
89483878|NCT04995146||"Prospective post-implementation standard of core care quality measures cohort"|
89483879|NCT03249441|Experimental|Compassion-focused therapy|Compassion-Focused Therapy (CFT) Participants were taught the main compassion-focused exercises as outlined in 'The Compassion-Mind Guide to Ending Overeating: Using Compassion-Focused Therapy to overcome Bingeing and Disordered Eating' manual (Goss, 2011) over a ten session period (weekly for 2 hours), offered over a 3 month period. Self-criticism and shame were key foci across sessions. Participants in the CFT arm also received Treatment as Usual.
89483880|NCT03249441|No Intervention|Treatment as Usual|Treatment As Usual Treatment as usual was based in the Diabetes, Endocrinology and Metabolism Clinic in Galway University Hospital. The Weight Management Service provides assessment by a multi-disciplinary team of endocrinologists, dieticians, nurse specialists and clinical psychologists. Dietary advice is given by a specialist dietician regarding weight management, assessment by the Consultant Endocrinologist with possible medication for management of diabetes and weight, and participation in a healthy lifestyle education program.
89483881|NCT03550729|Experimental|Training|12-weeks of supervised endurance training program.
89021106|NCT05458388|Active Comparator|EGGIM|
89021107|NCT05458349|Experimental|dermis group|Group will receive standard of care treatment and interventions plus the use of the acellular dermal graft during surgery
89021108|NCT05458349|No Intervention|control group|Group will receive standard of care treatment and interventions but the acellular dermal graft will not be used during surgery
89021109|NCT05458154|Experimental|Experimental group|"Seven of the 22 pain measures demonstrated satisfactory psychometric properties and clinical utility and are thereby recommended for clinical and research use in adults with a diagnosis of cancer.~Participants received Physical therapy program is critical to preserve flexibility, strength, range of motion, and normal neuromuscular recruitment. Patients' efforts to cut back their pain through avoidance behaviors can severely undermine function if mobility, activity of daily living, performance, or vocational capacity are affected. Physical therapy may involve trials of analgesic modalities like desensitization techniques, transcutaneous electrical nerve stimulation (TENS), and topical cold. Modality trials are rapid, relatively harmless, and inexpensive with the additional benefit that patients can self-administer effective treatments The pain management protocol of physiotherapy of PMPS depends mainly on education regarding the subsequent points that are paramount."
89021110|NCT05458115||liver resection group|
89021111|NCT05458076|Experimental|QLS1128 A-Dose 1~5|single dose
89021112|NCT05458076|Experimental|QLS1128 C-Dose 1~3|Twice daily for 7 days
89021113|NCT05458076|Experimental|QLS1128 D-Dose 1|fasting，high fat meal
89021114|NCT05458037|Experimental|Fast tenaculum application|
89021115|NCT05458037|Experimental|Slow tenaculum application|
89021116|NCT05457920|Experimental|Group A (continuous treatment group)|The treatment period is 12 weeks as a treatment unit, starting from the first day of baseline, subcutaneous injection of Peg-IFNα-2b 180μg once a week, the total treatment course does not exceed 96 weeks. During treatment, when any efficacy check point reaches the disappearance of HBsAg with or without the appearance of HBsAb, at least 2 treatment units of consolidation therapy are given and then the drug is discontinued. Observed for 24 weeks after treatment.
89021117|NCT05457920|Experimental|Group B (pulse therapy group)|The treatment period is 12 weeks as a treatment unit. From the first day of baseline, subcutaneous injection of Peg-IFNα-2b 180 μg, every injection for 8 weeks, stop for 4 weeks, periodically, the total treatment course does not exceed 96 weeks. During treatment, when any efficacy check point reaches the disappearance of HBsAg with or without the appearance of HBsAb, at least 2 treatment units of consolidation therapy are given and then the drug is discontinued. Observed for 24 weeks after treatment.
89483882|NCT03070652|Experimental|NBO, Newborn behavioral observation|In the intervention group new parents will receive the NBO delivered in connection with the examination of the newborn in a shared observation with the parents in the homevisit of the health visitor 3 weeks post partum
89483883|NCT03070652|Experimental|Practice as usual|In the comparison group new parents will receive practice as usual due to the examination of their newborn in the homevisit of the health visitor 3 weeks post partum
89483884|NCT03245307|Experimental|Treament|In phase A, subjects receiving a single 30 mg oral dose of Nifedipine controlled-release tablets and wash-out for 2 days,a single 3 mg oral dose of warfarin tablets and wash-out for 12 days, then apatinib 750 mg once daily with a single 30 mg oral dose of Nifedipine controlled-release tablets co-administered on day 6 ,a a single 3 mg oral dose of warfarin tablets co-administered on day 9.
89483885|NCT02136979|Active Comparator|Propofol group|patients with propofol-based anesthesia
89483886|NCT02136979|Active Comparator|Sevoflurane group|patients with sevoflurane-based anesthesia
89483887|NCT03249363|Experimental|Group A - Pulsed PVP-I Irrigation|Group in wich the patients who underwent spinal surgery were treated with 5-10 minutes of low-pressure irrigation with Povidone-Iodine (PVP-I) diluted to a 3% concentration (30g/l) in 2 l of saline performed before applying the bone graft
89483888|NCT03249363|Active Comparator|Group B - Pulsed Saline Irrigation|Group in wich the patients who underwent spinal surgery were treated with 5-10 minutes of low-pressure irrigation with only 2 litres of saline solution (without povidone Iodine) performed before applying the bone graft
89483889|NCT04983758||PHP|
89483890|NCT04983758||Moderate PCP|
89483891|NCT04983758||Severe PCP|
89483892|NCT03257007|No Intervention|Usual Care|Participants assigned to Usual Care will continue to receive standard care from their oncology team, including access to supportive care from oncology social workers. At the end of the study, usual care dyads will receive a packet of informational materials on mindfulness meditation, receive a CD with 5 mindfulness meditation practices, and meet with the study interventionist for guidance on how to use the materials and mindfulness recordings to their advantage in coping with cancer-related challenges.
89483893|NCT03257007|Active Comparator|Mindfulness|The Mindfulness intervention will consist of six 2-hour sessions that will include guided mindfulness practices, didactics, and group discussion. The course curriculum is modeled on the Mindfulness-Based Stress Reduction program which involves intensive experiential training of participants in secular mindfulness meditation practices (i.e., body scan, sitting meditation, gentle hatha yoga with chair adaptations, compassion meditation), with an emphasis on embodying interpersonal mindfulness in dialogue.
89483894|NCT04983992||observation group|People suffered from excessive lateral pressure syndrome with extracapsular release of lateral retinaculum.
89483895|NCT04983992||control group|People suffered from excessive lateral pressure syndrome with conservative treatment
89483896|NCT03245073|Active Comparator|Exercise|Strengthening and stretching exercises for hip and knee muscles, balance and proprioceptive exercises
89483897|NCT03245073|Experimental|Action observation therapy and exercise|Video of normal human movement and Strengthening and stretching exercises for hip and knee muscles
89483898|NCT03257085|Experimental|Low-carbohydrate, high-fat|Participants adhering to low-carbohydrate, high-fat diet for 8 weeks.
89483899|NCT03257085|Experimental|High-carbohydrate, moderate fat|Participants following high-carbohydrate, moderate-fat diet for 8 weeks.
89021118|NCT01056822|Active Comparator|1|Mycophenolate mofetil
89021119|NCT01056822|Experimental|2|Miycophenolate sodium
89021120|NCT05457764|Experimental|Virtual Reality|Participants use Virtual reality headsets as medium of erotica to produce their sperm sample
89483900|NCT04988594|Experimental|Premium probiotic yogurt|Participants receive 300 g/d of yogurt with concentrated and freeze-dried probiotic cultures for 12 weeks. Also, the nutritional recommendations of the American Diabetes Association (ADA).
89483901|NCT04988594|Experimental|Conventional yogurt|Participants receive 300 g/d of conventional yogurt for 12 weeks. Also, the nutritional recommendations of the American Diabetes Association (ADA).
89483902|NCT04988594|Experimental|no fermented dairy|Participants followed the American Diabetes Association (ADA) recommendations without including fermented dairy.
89483903|NCT04988828|Active Comparator|Control|"deep squat~1min*6repetitions"
89483904|NCT04988828|Experimental|Whole body vibration group|"deep squat on a whole body vibration platform with 30Hz and 4mm amplitude~1min*6repetitions"
89483905|NCT03249597||1. Suspected Infection.|Adult (≥18 years), non-trauma patient transported by the ambulance, who according to the EMS suffer from an infection.
89483906|NCT03249597||2. Control|Adult (>18 years of age), non-trauma patient immediately following the included patient with suspected infection, transported in the same ambulance but without infection.
89483907|NCT04994678|Experimental|Virtual Reality Training Group|VR training system will be setup in multidisciplinary lab of Foundation University Institute of Rehabilitation Sciences Foundation University Islamabad. Display will be provided on 55 inch LED TV with audio feedback. Display will be at height of 5 feet from floor and at distance of 6 feet from Subject. The Virtual reality based training group will receive a game based virtual reality training via XBOX 360 or wii fit balance games. Particiapants will be required to physically move to move avatar on screen to rapidly leaning away, squat to avoid overhead obstacles and try small jump to avoid lower obstacles, single leg stance, in addition person will required to do half squatting, side to side jumps and vertical jumps. Treatment will be provided 3 times a week for 6 weeks with each session lasting for 30-50 minutes. Progressively challenge will be increased.
88952302|NCT05055492|No Intervention|Control period|Schools will start in the control phase (SARS-CoV-2 diagnostic testing at an assessment center, primary care office or acute care center) and transition to the intervention phase at a randomly assigned time point over the course of the study.
88952303|NCT05055492|Active Comparator|Intervention phase|Schools will have take home saliva kits available at the school to support SARS-CoV-2 diagnostic testing. Schools will transition to the intervention phase at a randomly assigned time (wedge) over a 6-week period with all schools receiving the program by the end of the study.
89483908|NCT04994678|Active Comparator|Moderate Aerobic Exercise Training Group|Moderate aerobic exercise training will be provided using motorized tread mill and stationary/recombinent cycle. Treatment will be provided for 30-50 minutes 3 times a week for 6 weeks.
89483909|NCT02455011|Experimental|REMD-477 Treatment A|Administered as a single and repeated SC doses in subjects with Type 2 Diabetes
89483910|NCT02455011|Placebo Comparator|Matching placebo|Placebo administered as single and repeated SC doses in subjects with Type 2 Diabetes
89203560|NCT02559518|Experimental|high frequency c-rTMS|Volunteers will be submitted to non-invasive cerebellar stimulation during serial reaction time task (SRTT).
89203561|NCT02559518|Experimental|low frequency c-rTMS|Volunteers will be submitted to non-invasive cerebellar stimulation during serial reaction time task (SRTT).
89483911|NCT02455011|Experimental|REMD-477 Treatment B|Administered as a single and repeated SC doses in subjects with Type 2 Diabetes
88952304|NCT05044962|Experimental|Aim 1a (PK study group 1)|Initiating injectable cabotegravir/rilpivirine (LA ART) and DMPA
88952305|NCT05044962|Experimental|Aim 1a (PK study group 2)|Initiating injectable cabotegravir/rilpivirine (LA ART) and and etonogestrel implant
88952306|NCT05044962|Experimental|Aim 1a (PK study group 3)|Initiating injectable cabotegravir/rilpivirine (LA ART) and levonorgestrel implant.
89203562|NCT02559518|Sham Comparator|sham c-rTMS|Volunteers will be submitted to non-invasive cerebellar stimulation during serial reaction time task (SRTT).
89483912|NCT02455011|Experimental|REMD-477 Treatment C|Administered as a single and repeated SC doses in subjects with Type 2 Diabetes
89483913|NCT02455011|Experimental|REMD-477 Treatment D|Administered as a single and repeated SC doses in subjects with Type 2 Diabetes
89483914|NCT02455011|Experimental|REMD-477 Treatment E|Administered as a single and repeated SC doses in subjects with Type 2 Diabetes
89483915|NCT03249285|Experimental|Peri profile yes|patient with genetic Perindopril profile, receiving Perindopril treatment with 4-8 mg/day oral for 4-8 weeks
89483916|NCT03249285|Experimental|HCTZ profile yes|patient with genetic HCTZ profile, receiving HCTZ treatment with 12,5-25 mg/day oral for 4-8 weeks
89483917|NCT03249285|Active Comparator|Peri no profile|patient with no genetic profile, receiving after randomisation Perindopril treatment with 4-8 mg/day oral for 4-8 weeks
89483918|NCT03249285|Active Comparator|HCTZ no profile|patient with no genetic profile, receiving after randomisation HCTZ treatment with 12,5-25 mg/day oral for 4-8 weeks
88952307|NCT05044962|Active Comparator|Aim 1a (PK study group 4)|Receiving injectable cabotegravir/ rilpivirine (LA ART) and not using any hormonal contraceptive method (e.g. copper IUD)
88952308|NCT05044962|Active Comparator|Aim 1a (PK study group 5)|AGYW without HIV and not exposed to antiretrovirals (e.g., for PrEP) initiating DMPA
89203563|NCT04012515|Experimental|CAVA Electrode Pad Appraisal Trial Arm|All trial participants are within this arm. All participants will wear the same selection of electrode pads and follow the same replacement schedules.
89483919|NCT03070496|Experimental|STEMI cohort|"Patients recruited in the cohort will have 4 additional interventions compared to the usual follow-up :~an additional blood sampling at 6 months~an additional electrocardiogram (ECG) at 6 months~Magnetic Resonance Imaging (MRI)~Quality of life questionnaire"
89483920|NCT03244683|Other|Intervention|Subjects randomized to this arm will receive: An Oral Nutritional Supplementation (Ensure Surgical), home-based resistance training, and dietary counseling
88952309|NCT05044962|Experimental|Aim 2a (Hybrid trial intervention group)|AGYW with viral suppression on their current ART regimen to switch to cabotegravir/ rilpivirine.
88952310|NCT05044962|Active Comparator|Aim 2a (Hybrid trial comparator group)|AGYW with viral suppression to continue their oral ART regimen.
88952311|NCT05027529|Experimental|VA-ECMO and CytoSorb|standard ICU care WITH CytoSorb
88952312|NCT05027529|Placebo Comparator|VA-ECMO only|standard ICU care WITHOUT CytoSorb
88952313|NCT05014568|Experimental|tapinarof cream|tapinarof cream, 1%, applied topically once daily
88952314|NCT05014568|Placebo Comparator|vehicle cream|vehicle cream, applied topically once daily
88952315|NCT04994431|Experimental|Perioperative Tamsulosin Hydrochloride|Participants undergoing thoracic surgery will receive 0.4mgTamsulosin Hydrochloride orally nightly for the two nights immediately prior to surgery and the morning of surgery.
89203564|NCT00759746|Active Comparator|Weight Maintenance Education|Participants assigned to this group will receive the Weight Maintenance Education intervention. They will meet every other week during the maintenance phase of the study for a total of 16 sessions over 8 months. During the visit, participants will participate in a series of interactive workshops within child and parent groups to learn general information about healthy eating and physical activity.
88952316|NCT04994431|No Intervention|Historical Comparator|Participants who underwent thoracic surgery (historical). Information about occurrence of Peri-Operative Urinary Retention in thoracic surgery patients will be obtained via retrospective chart review.
89203565|NCT00759746|Experimental|SFM+ Low Dose|Participants assigned to this group will receive the SFM+ Low Dose.
88952317|NCT04993872|Experimental|BIC/FTC/TAF|Development phase 4: Biktarvy®
89203566|NCT00759746|Experimental|SFM+ High Dose|Participants assigned to this group will receive the SFM+ High Dose.
89203567|NCT00940953|Experimental|Captisol-Enabled Budesonide + Azelastine|
89203568|NCT00940953|Active Comparator|Rhinocort Aqua+Astelin|
89203569|NCT00940953|Placebo Comparator|Placebo|
89203570|NCT00759824|Experimental|1|Chemotherapy regimen (adriamycin, cyclophosphamide, vindesine) plus valproic acid
89203571|NCT04012593||premenopausal women|diary
89203572|NCT00759980||Platelet Number|Infants randomized to this group will be transfused based on a specific set of transfusion guidelines pertaining to the total number of platelets
89203573|NCT00759980||Platelet Mass|Infants randomized to this group will be transfused based on a specific set of transfusion guidelines pertaining to a combination of platelet number and platelet size (mass)
89203574|NCT04049240|Active Comparator|Active Comparator: 18<BMI<30 - LFNO|Low-flow nasal oxygenation (LFNO) O2 flow 5L/min, FiO2 40%
89203575|NCT04049240|Active Comparator|Active Comparator: 30≤BMI<35 kg/m2 - LFNO|Low-flow nasal oxygenation (LFNO) O2 flow 5L/min, FiO2 40%
89483921|NCT03244683|Other|Nutrition Counseling alone|Subjects randomized to this arm will receive: Dietary counseling along with standard of care procedures.
89483922|NCT04988204|Experimental|Treatment Arm|Patients enrolled in 1 year program
88952318|NCT04986787|Experimental|Entrainment with personalized bi-focal fronto-parietal synchronized tACS in HV - within-frequency|double-blind, randomized, sham-controlled, cross-over trials assessing the effects of individualized fronto-parietal tACS on a visual working memory task in aged HV
88952319|NCT04986787|Experimental|Entrainment with personalized bi-focal fronto-parietal synchronized tACS in HV - cross-frequency|double-blind, randomized, sham-controlled, cross-over trials assessing the effects of individualized cross-frequency fronto-parietal tACS stimulation on a visual WM task in aged HV
89203576|NCT04049240|Active Comparator|Active Comparator: BMI≥35 kg/m2 - LFNO|Low-flow nasal oxygenation (LFNO) O2 flow 5L/min, FiO2 40%
89021121|NCT05457764|No Intervention|No Virtual Reality|Participants did not use Virtual reality headsets as medium of erotica to produce their sperm sample. They used a computer screen to display erotica.
89203577|NCT04049240|Active Comparator|Experimental: 18<BMI<30 kg/m2 - HFNO|High Flow nasal oxygenation (HFNO) O2 flow 40L/min, FiO2 40%
89203578|NCT04049240|Active Comparator|Experimental: 30≤BMI<35 kg/m2 - HFNO|High Flow nasal oxygenation (HFNO) O2 flow 40L/min, FiO2 40%
89203579|NCT04049240|Active Comparator|Experimental: BMI≥35 kg/m2 - HFNO|High Flow nasal oxygenation (HFNO) O2 flow 40L/min, FiO2 40%
89203580|NCT00760058|Experimental|1|AcrySof® IQ intraocular lens
89203581|NCT00760058|Active Comparator|2|Tecnis® Aspheric intraocular lens
89203582|NCT00760058|Active Comparator|3|Akreos® MI60 intraocular lens
89203583|NCT00762242||1|Blood sampling and brachial artery ultrasound
89203584|NCT02558426||CVD patients|Patients with CVD at various stages (C2-C6 of CEAP classification of CVD) with varicose veins and eligible to receive Open Venous Surgery.
89203585|NCT00561951|Experimental|Fesoterodine fumarate 4 mg (Double-Blind)|
89203586|NCT00561951|Placebo Comparator|Placebo (Double-Blind)|
89203587|NCT00561951|Experimental|Fesoterodine fumarate 8 mg (Double-Blind)|
89203588|NCT02558348|Experimental|AL3818|"Part 1 (Phase 1b): Cohort 1 will initiate at a dose of 12 mg/day of AL3818, for 21-Day cycles (14 days of AL3818 treatment followed by 7 days of rest). After three subjects have completed the first cycle of therapy without a DLT, additional cohorts may be enrolled sequentially. After the first cohort has completed one full cycle of therapy without a DLT, two additional cohorts will be sequentially enrolled at 16 mg/day and 20 mg/day doses of AL3818 for the same 21-day cycles.~Part 2 (Phase 2a): Each subject will receive a dose of up to 20 mg AL3818 or a maximum of the MTD from Part 1 (Phase 1b) of this study for continuous 21-Day cycles of therapy (14 days of AL3818 treatment followed by 7 days of rest)."
89203589|NCT00762398||Adult patient undergoing a surgery|Adult patient undergoing a surgery in the supine position and require an arterial line for anesthesia/surgery purposes
89483923|NCT03249519|Experimental|Standard Arm|Radiation therapy: 50.4 Gy Brachytherapy: 35-40 Gy Chemotherapy: Cisplatin weekly 40mg/m^2 (6 cycles) Hyperthermia: 10 times
89483924|NCT04983524|Experimental|Propolis|intervention intracanal medicament
89483925|NCT04983524|Active Comparator|Calcium Hudroxide|Gold standard intracanal medicament
89483926|NCT03073772|No Intervention|Continued multimodal rehabilitation|No addition of extra training in this group. Only ordinary continued multimodal rehabilitation.
89537674|NCT01670877|Experimental|Part II: Neratinib Only (ER-)|-Patients will receive neratinib PO daily on Days 1-28. Each cycle is 4 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
89021122|NCT05457530|Active Comparator|Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate|Participants to receive DOR/3TC/TDF tablet once daily for 48 weeks
89021123|NCT05457530|Active Comparator|Doravirine + Emtricitibine/Tenofovir alafenamide Fumerate|Participants to receive DOR + FTC/TAF tablets once daily for 48 weeks
89021124|NCT05457530|Active Comparator|Bictegravir/Emtricitibine/Tenofovir alafenamide|Participants to receive BIC/FTC/TAF tablet once daily for 48 weeks
89021125|NCT04705194||One stage resection|Patients that are selected for a single hepatectomy of 2 segments or more.
89021126|NCT04705194||Two stage resection|Patients that are selected for a two-stage resection, where the first stage consists of either PVE or ALPPS and the second stage is a hepatectomy of 2 or more segments.
89021127|NCT05457452|Experimental|Knee Brace|Use of a Knee Brace after ACL Reconstruction, the patient is put on a knee brace by an orthopedic doctor or orthopedic resident after ACL reconstruction
89021128|NCT05457452|No Intervention|No Knee Brace|
89021129|NCT04705857||test group|"bone reconstructive surgery with the use of Histograft bone substitute (gene-activated matrix based on octacalcium phosphate and plasmid DNA encoding VEGFA gene) mixed with shredded autobone (in a ratio of 50/50) harvested during the surgery"
89021130|NCT04705857||control group|bone reconstructive surgery with the use of shredded bone autograft harvested from iliac crest
89021131|NCT04705506|Experimental|Gemigliptin group|The participants will receive gemigliptin 50 mg daily
89021132|NCT04705506|Placebo Comparator|Control|The control received standard care of diabetes
89021133|NCT05457374|Experimental|Partial hepatectomy+LVD|
89021134|NCT05457374|Experimental|Partial hepatectomy+PVE|
89021135|NCT04704960||Lung metastases from colorectal cancer, local ablative therapy (surgery or radiation)|patients diagnosed with lung metastases from colorectal cancer and undergoing surgery or radiation for lumg metastasis
89021136|NCT05457335||PGT-A group|For patients undergoing PGT-A, trophectoderm biopsy was performed on good quality blastocysts and about five cells were aspirated gently and separated from the blastocyst by applying multiple pulses of a noncontact 1.48- μm diode laser (Saturn 5 ActiveTM, Cooper Surgical, Inc., CT, USA) through a zona pellucida opening created by the laser. The biopsied cells were washed three times in 1 × phosphate buffered saline (PBS) (Life Technologies, NY, USA), transferred to a PCR tube containing 2.5 μl 1× PBS and cryopreserved at -80◦C until analysis. Genetic laboratories analyzed and interpreted biopsies. The genetic screening was performed using the next-generation sequencing (NGS)-based assay VeriSeq PGS following standard protocols and manufacturer recommendations (Illumina Inc., San Diego, USA）. The PGT-A report can be euploid, aneuploidy, mosaic and non-conclusive. Euploid embryos were transferred while aneuploid and mosaic embryos were not replaced.
89021137|NCT05457335||Expectant management group|In the this group, one attempt at conception was defined as one calendar months trying to conceive spontaneously. Either in natural cycles for ovulatory women and in clomiphene/letrozol induced cycles for anovulatory women with or without ultrasound monitoring.
89021138|NCT05455385|Active Comparator|Control group|
89021139|NCT05455385|Experimental|Hydrotherapy group|
89021140|NCT05455385|Experimental|Ground exercise group|
89021141|NCT04705077|Experimental|Single Dose Treatment|"Each subject will be assigned to the fixed period sequence.~Period 1: SR419 suspension in the fasted state;~Period 2: SR419 capsule in the fasted state;~Period 3: SR419 capsule in the fed state (high-fat meal)."
89021142|NCT04705077|Experimental|Repeated Dose Treatment|Each subject will receive 30 mg of SR419 capsule, once every 8 hours (Q8h), for 5 days.
89537675|NCT01670877|Experimental|Part II: Neratinib + Fulvestrant (ER+, fulvestrant-naive)|-Patients will receive neratinib PO daily on Days 1-28 and fulvestrant on Day 1 of each cycle (and C1D15). Each cycle is 4 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
89021143|NCT05453045|Experimental|Albendazole|400 mg po single dose
89021144|NCT05451251|Experimental|Deep brain stimulation|Implantation of deep brain stimulation lead within the pontine demyelinating lesion
89021145|NCT00432432|Placebo Comparator|2|placebo with infliximab
89021146|NCT05421494|Experimental|WET-R|
89021147|NCT05421494|Placebo Comparator|MCC|
88952320|NCT04986787|Experimental|Cerebellar rTMS to modify the effects of cortico-cortical, fronto-parietal tACS in HV|double-blind, randomized, sham-controlled, cross-over trial assessing the effects of cerebellar stimulation on individualized fronto-parietal tACS stimulation during a visual WM task in aged HV
88952321|NCT04986787|Experimental|Neuromodulation protocol in MCI patients (precise protocol to be chosen on results of previous arms)|double-blind, randomized, sham-controlled, cross-over trials assessing the effects of individualized striatal TIS combined with cereberal TMS on a visual working memory task in MCI patients
89483927|NCT03073772|Active Comparator|Computer-based cognitive training|This arm also consisted of continued multimodal rehabilitation.
89483928|NCT03073772|Active Comparator|Physical fitness training|This arm also consisted of continued multimodal rehabilitation.
89483929|NCT03249675||ARM 1|ARM 1: Retrospective Arm: Subjects tested with BNA in the past and have been diagnosed by their physician as having Post Concussive Syndrome. Study staff will contact the subjects and obtain Informed Consent. Study physicians will then review both BNA data and Clinical data. All relevant clinical data and all available BNA data will be shared with ElMindA. Subjects may be invited for an additional BNA follow up as part of the study.
89483930|NCT03249675||ARM 2|"ARM 2: Subjects will be prospectively enrolled in the study at the following time points when available:~Acute: within 2 weeks of injury~PCS: Subjects which sustained a concussion in the past 3 months or more, and are still experiencing symptoms related to the injury"
89483931|NCT03576911|Experimental|Coenzyme Q10|100mg CoQ10 capsule taken orally three times per day for 6 months
89483932|NCT03576911|Placebo Comparator|Placebo|Placebo capsule taken orally three times per day for 6 months
89483933|NCT02454777|Experimental|ARM I (HIT group)|Participants undergo HIT exercises over 30 minutes, thrice weekly for 8 weeks.
89483934|NCT02454777|Active Comparator|Arm II (Delayed group)|Participants maintain their current sedentary activity level (< 60 minutes of total exercise per week) for 8 weeks. Participants document their weekly activity in an exercise log. Following completion of all study visits, participants are given the option to complete the HIT program as in Arm I.
89483935|NCT04983290|Experimental|intervention|The participating subjects belonging to the experimental group, will receive at home a set of foods with modified textures that allow the patient to feed for the observation period of 4 months, will also be followed by the dietary service of the center and by personnel identified within the protocol in order to verify compliance, liability and information regarding the evaluation scales involved in the project.
89483936|NCT04983290|No Intervention|control|The control group will continue with its own feeding for the entire observation period of the experimental group.
89483937|NCT02455089|Experimental|Test group|"250 SLE patients : All SLE patients included in the study. Intervention : Blood analysis including GADD34 RNA level measurement every 3 months up to 1 year.~They will provided a blood sample every 3 months during a year. The result of GADD34 RNA level in mononuclear blood cells will be correlated to the clinical assessment of a SLE flare during the next 3 months.~A flare occurence will the group"
89483938|NCT02634320|Other|Aripiprazole Lauroxil|Intramuscular (IM) injection
89483939|NCT03244761||The standard HFT|The high-flow oxygen was delivered via tracheostomy using a standard HFT.
89483940|NCT03244761||The modified HFT|The high-flow oxygen was delivered via tracheostomy using a modified HFT.
89483941|NCT03256617|Experimental|Provider training|
89483942|NCT04982978|Active Comparator|PMT Threat Appraisal|The PMT present group will include an 8-minute informational video that explains the current research and health risks associated with vaping, within the context of a threat appraisal focus (Perceived Vulnerability and Perceived Severity). During this video intervention, the severity and vulnerability of vaping among young adults, both in the short and long-term health effects will be presented. In addition, the video will explain the negative impact of vaping and focus the attention of the participants on the lack of research and information that currently exists on popular vaping products and the potentially devastating impact it can have on the health of young adult populations.
89021148|NCT02957526|Experimental|App|The web-based app will be used to ask participants about their aromatase inhibitor use in the previous 7 days and ask about treatment-related adverse symptoms, or changes in the severity of symptoms. Participants will receive reminders via text or email to use the app once per week. All participants will be followed for a 6-8 weeks (depending on the data of participants' in-clinic follow-up visit) and will be asked to complete a baseline survey at enrollment and a follow-up survey at their 6-8 week in-clinic follow-up visit.
89021149|NCT02957526|Active Comparator|Usual Care|Participants will have access to the web-based app, but will not receive reminders. All participants will be followed for a 6-8 weeks (depending on the data of participants' in-clinic follow-up visit) and will be asked to complete a baseline survey at enrollment and a follow-up survey at their 6-8 week in-clinic follow-up visit.
89021150|NCT02957448|Experimental|BMS 986141 and Rifampin|
89021151|NCT00432471|Experimental|Optical Imaging|Imaging using the multispectral digital microscope (MDM), a system that shines different colors of light on the skin and takes pictures of fluorescence and reflectance on the skin area.
89021152|NCT04704765|Experimental|The effectiveness of receiving abdominal breathing training|The patients receiving the intervention of abdominal breathing training were in the experimental group. The experimental group received the abdominal breathing training for a total of 8 weeks. During this period, they received the abdominal breathing training at the outpatient clinic (every day 30 minutes, can include every time during the day). When the subjects were at home, they received self-training using the abdominal breathing training video (once every day and 30 minutes every time). The control group without training.
89021153|NCT04704765|No Intervention|The effectiveness of not receiving abdominal breathing training|The control group who did not receive abdominal breathing training. The effectiveness assessment used the Beck anxiety inventory and physiological index (heart beats, breath and blood pressure), required to be completed by the control group.
89021154|NCT00432510|Experimental|Single Dose|1,000 Units (U) of C1INH-nf administered intravenously (IV).
89021155|NCT00432510|Experimental|First Dose Followed by Second Dose|1,000 U of C1INH-nf administered IV, followed by a second 1,000 U dose 60 minutes later.
89537676|NCT01670877|Experimental|Part II: Neratinib + Fulvestrant (ER+. prior fulvestrant-tx)|-Patients will receive neratinib PO daily on Days 1-28 and fulvestrant on Day 1 of each cycle (and C1D15). Each cycle is 4 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
89021156|NCT05354258|Placebo Comparator|Vitamin A + Zinc supplements on Day 0, followed by SMC course on Day 1,2 & 3|
89021157|NCT05354258|Experimental|Praziquantel + Vitamin A on Day 0, followed SMC course on Days 1,2 & 3|
89021158|NCT05354258|Experimental|Albendazole + Praziquantel on Day 0, followed by SMC course on Days 1, 2 & 3|
89021159|NCT05338580|Experimental|TJ271 Injection in Combination with Pembrolizumab|TJ271 Injection: 0.9% sodium chloride solution Pembrolizumab: 0.9% sodium chloride solution or 5% glucose solution
89021160|NCT00427674|Experimental|injection of 5 mCi of 123-I mZINT|
89021161|NCT05306366|Experimental|[11C]-Lu AF90103|Participants will receive [11C]-Lu AF90103 via an intravenous bolus injection on Day 1.
89021162|NCT01588899|Experimental|MR-HIFU Treatment|Patients in this arm will receive MR-HIFU uterine fibroid treatment
89021163|NCT02273466|Active Comparator|Desipramine alone|
89021164|NCT02273466|Experimental|Desipramine with Crobenetine|
89021165|NCT05245643|Other|Patients with severe and resistant Anorexia Nervosa|12 consecutive patients fulfilling the inclusion criteria and consenting to participate in the research, recruted in the three inclusion centers.
89021166|NCT02273505|Experimental|Asasantin (ER)|
89021167|NCT02273505|Active Comparator|Combination of Persantin and ASA|
89021168|NCT05210621|Other|Patients with MS who have completed the CONSONANCE study|
89021169|NCT00427752|Experimental|Whipple|Patients with pancreatic cancer who will proceed to a Whipple procedure.
89537677|NCT01670877|Experimental|Crossover: Neratinib + Trastuzumab|-If a participant experiences disease progression during Part I or Part II following neratinib, trastuzumab (or FDA approved biosimilar) may be added to the treatment regimen. Trastuzumab may be administered intravenously with a loading dose of 6 mg/kg then 4 mg/kg every 2 weeks. A cycle will be defined as 28 days. Patients will continue to receive neratinib PO daily on Days 1-28. Each cycle is 4 weeks.
89021170|NCT05174156|Experimental|biomarker study and treatment study|"All enrolled patients undergo biomarker study and treatment study.~Biomarker study: the baseline tumor tissue will be collected and analyzed via NGS and mIHC~Treatment study: SHR-1210 plus albumin-bound paclitaxel and platinum-based chemotherapy"
89021171|NCT00427947|Experimental|1|Continuous sciatic nerve bloc : ropivacaine infusion
89021172|NCT00427947|Placebo Comparator|2|Continuous sciatic nerve bloc : NaCl Infusion
89021173|NCT00428025|Placebo Comparator|placebo suppository|
89021174|NCT00428025|Active Comparator|diclofenac suppository|
89021175|NCT05011253|Experimental|Intervention|The group which will receive the InBasket message to notify users that a patient has clinically significant microscopic hematuria and makes recommendations for follow-up.
89021176|NCT05011253|No Intervention|Control|The group which will not receive the InBasket message to notify users that a patient has clinically significant microscopic hematuria. (Standard practice)
89021177|NCT00432627|Experimental|Mild hepatic impaired|
89021178|NCT00432627|Experimental|Moderate hepatic impaired|
89021179|NCT00432627|Experimental|Severe hepatic impaired|
89021180|NCT00432627|Experimental|Healthy volunteers|Controlled group
89021181|NCT00419705|Experimental|Transcranial Laser Therapy|
89021182|NCT00419705|Sham Comparator|Sham control procedure|
89021183|NCT00419783|Experimental|1|Bilastine 20 mg
89021184|NCT00419783|Experimental|2|Bilastine 100 mg
89021185|NCT00419783|Active Comparator|3|Bilastine 20 mg + Ketoconazole 400 mg
89021186|NCT00419783|Active Comparator|4|Moxifloxacin 400 mg
89021187|NCT00419783|Placebo Comparator|5|Placebo
89021188|NCT04704492|Experimental|Biological: SM03|Biological: SM03 600 mg or 900 mg intravenous (IV) on week 0 , 2.
89021189|NCT00419822|Active Comparator|Acupuncture|
89021190|NCT00419822|Sham Comparator|Sham Acupuncture|
88952322|NCT04966546|Experimental|Memantine|Subjects will be given memantine 10mg PO/ NG BID for 7 days
88952323|NCT04966546|Placebo Comparator|Placebo|Subjects will be given identical placebo syrup PO/NG BID for 7 days
88952324|NCT04966416|Experimental|Pyrophosphate|Disodium pyrophosphate
88952325|NCT04966416|Placebo Comparator|Placebo|Glucose
88952326|NCT04853446|Placebo Comparator|Placebo|Encapsulated glucosemonohydrate will be used as placebo. Two capsules containing placebo will be administered in the placebo arm.
88952327|NCT04853446|Experimental|Dexamethasone 12 mg|Dexamethasone tablets of 4 mg encapsulated in pairs of three. One capsule containing 12 mg dexamethasone and one capsule containing placebo will be administered in the 12mg dexamethasone arm for a total dose of 12 mg of dexamethasone.
88952328|NCT04853446|Experimental|Dexamethasone 24 mg|Dexamethasone tablets of 4 mg encapsulated in pairs of three. Two capsules containing 12 mg dexamethasone will be administered in the 25mg dexamethasone arm for a total dose of 24 mg of dexamethasone.
88952329|NCT04846231|Active Comparator|Rosuvastatin|5 mg once per day
88952330|NCT04846231|Placebo Comparator|Placebo|comparable to rosuvastatin 5 mg once per day
88952331|NCT04846231|Active Comparator|Fish Oil|Nature Made 2 soft gels per day
88952332|NCT04846231|Active Comparator|Cinnamon|1200mg, 2 capsules per day
88952333|NCT04846231|Active Comparator|Garlique|Manufactured by Focus Consumer Health Marketgate,1 tablet per day
88952334|NCT04846231|Active Comparator|Turmeric|Bio Schwartz Turmeric Curcumin 1500 mg, 3 capsules per day
88952335|NCT04846231|Active Comparator|Plant Sterol|Nature Made CholestOff Plus, 2 soft gels twice a day
88952336|NCT04846231|Active Comparator|Red Yeast Rice|Arazo Nutrition 1200 mg, 2 capsules per day
88952337|NCT04811651|Experimental|Treatment group|intravenous umbilical cord derived mesenchymal stem cells
88952338|NCT04811651|Placebo Comparator|Placebo Comparator|intravenous placebo solution with the same appearance as the treatment group.
88952339|NCT04784689||Prospective - Cancer Patients that have received COVID-19 Vaccination|
88952340|NCT04778189|Placebo Comparator|normal saline group (NS)|patients in group( NS ) will receive 500-mL normal saline IV in 5-10 minutes after spinal anesthesia
88952341|NCT04778189|Active Comparator|dexamethasone group (SD)|patients in group( SD )will receive 8-mg dexamethasone IV in 500-mL normal saline in 5-10 minutes after spinal anesthesia
88952342|NCT04761146|Experimental|DaRT Diffusing Alpha-emitters Radiation Therapy|DaRT Diffusing Alpha-emitters Radiation Therapy using the DaRT applicator and seeds, inserted for 14 days prior to removal.
88952343|NCT04705428|Experimental|Group I: intervention group 1|Professional hygiene will be carried out with the application of fluoride varnish (Duraphat) and the use of fluoride paste according to the age will be recommended for oral hygiene at home.
88952344|NCT04705428|Experimental|Group II: intervention group 2|Professional hygiene will be carried out with the application of fluorine varnish (Tiefenfluoride) and the use of fluoride paste according to the age will be recommended for oral hygiene at home.
88952345|NCT04705428|Experimental|Group III: intervention group 3|Professional hygiene will be carried out with the application of fluorine varnish (Fluor Protector S) and the use of fluoride paste according to the age will be recommended for oral hygiene at home.
88952346|NCT04671225|Experimental|Intervention - Psychoeducation at the referral hospital|Intervention: Manual-structured group psychoeducation.
88952347|NCT04671225|Other|Waiting list - at the referral hospital|Participants in the control group will be assigned to a waiting list and receive group-psychoeducation after the active intervention groups.
88952348|NCT04664933|Experimental|Intra-arterial administration of 3-n-butylphthalide|Intra-arterial administration of 3-n-butylphthalide for 16 to 24 hours during and after the operation at 17.36 to 26.04 ug/min.
88952349|NCT04660760|Experimental|Arm A (TAS-102, ramucirumab)|Patients receive TAS-102 PO BID on days 1-5 and 8-12, and ramucirumab IV over 30-60 minutes on days 1 and 15. Treatment repeats every 28 days for up to 36 cycles in the absence of disease progression or unacceptable toxicity.
88952350|NCT04660760|Active Comparator|Arm B (paclitaxel, ramucirumab)|Patients receive paclitaxel IV over 1-96 hours on days 1, 8, and 15, and ramucirumab IV over 30-60 minutes on days 1 and 15. Treatment repeats every 28 days for up to 36 cycles in the absence of disease progression or unacceptable toxicity.
88952351|NCT04642222|Experimental|APOLO-Teens Intervention Group (APOLO-Teens group)|In addition to the Treatment As Usual for pediatric obesity offered in Portuguese public hospitals, participants in this group receive the APOLO-Teens web-based intervention. It comprises three key components: 1) a manualized psychoeducational intervention implemented via Facebook® private groups, including cognitive-behavioral therapy strategies; 2) A weekly self-monitoring system (the APOLO-Teens web application) with automatic feedback messages assessing hours of physical activity, sedentary time, and consumption of fruits and vegetables; and 3) Monthly chat sessions.
88952352|NCT04642222|Active Comparator|Treatment As Usual (TAU) Control Group (TAU control group)|Treatment As Usual control group receives the standard intervention for pediatric obesity offered in Portuguese public hospitals. It comprises pediatric or/and nutritional appointments, usually a 30-minute appointment every 3 months. These appointments usually include a physical examination (weight, height) and personalized dietary/lifestyle recommendations. The Treatment As Usual intervention is common to the APOLO-Teens group and TAU control groups.
88952353|NCT04633655||Patients who are receiving a neurotoxic chemotherapy|"List of neurotoxic drugs eligible for enrolment~Platinum drugs~Taxanes~Vinca alkaloids~Epothilones~Proteasome inhibitors~Thalidomide~Vedotin-based drugs~checkpoint inhibitors~Any combination of the aforementioned drugs"
88952354|NCT04631211|Experimental|Thrombosomes Low Dose|
88952355|NCT04631211|Experimental|Thrombosomes Medium Dose|
88952356|NCT04631211|Experimental|Thrombosomes High Dose|
88952357|NCT04631211|Active Comparator|Liquid Stored Platelets (Control)|
89483943|NCT04982978|Sham Comparator|Nutrition and Lifestyle Control|"The PMT absent group will feature an 8-minute nutritional information video as an attention control strategy titled, Vaping Health Effects. During this video intervention, the general risks and benefits of nutrition and lifestyle will be presented. The focus of this video will be on how a balanced diet and proper lifestyle choices (i.e., adequate sleep, diet, etc.) can benefit the participants lives in the short-term and long-term."
88952358|NCT04533594|Experimental|NOVELA|Hospice family caregivers will work with the interventionist to use a web-enabled device (computer, smartphone or tablet) to access and view the video (3-6 mins) over the course of 4 hospice telehealth visits.
88952359|NCT04522726|Experimental|Treatment group A|"Treatment group A received Weiyang Yupingfang Granules orally for 1 month on the Sanfu days and on theSanjiudays each year for a total of 2 months a year."
88952360|NCT04522726|Experimental|Treatment group B|Treatment group A received Weiyang Yupingfang Granules orally for 1 month in the first month of each quarter in the four quarters of the year, for a total of 4 months a year.
88952361|NCT04507217|Experimental|Eligible patients|tislelizumab (200mg) in combination with pemetrexed (500mg/m2) and carboplatin (AUC=5) intravenously on day 1 of a 3-week cycle for 4 cycles. Afterwards, patients without disease progression were treated with maintenance treatment with tislelizumab (200mg) plus pemetrexed (500mg/m2) every 3 weeks up to 24 months or until disease progression, unacceptable toxicity, or death.
88952362|NCT04464187||Participants exposed to Elagolix-containing products|Pregnant participants exposed to Elagolix from 14 days after last menstrual period (LMP) or at any point during pregnancy.
88952363|NCT04464187||Participants not exposed to Elagolix-containing products|Pregnant participants with endometriosis, uterine fibroids, or other conditions based on approved indications and prescribing patterns of Elagolix-containing products not exposed to Elagolix from 14 days after LMP or at any point during pregnancy.
88952364|NCT04447846|Experimental|Cannabidiol/ Epidiolex|All subjects will receive the experimental Epidiolex (cannabidiol) oral solution to be taken at home twice a day, and will be treated on an outpatient basis. The drug will be taken for 24 weeks unless the subject chooses to participate in the extension phase of the study, in which case the subject will continue to receive the drug for one additional year or until the drug is approved for clinical use for the treatment of cognitive impairments in patients with Sturge-Weber syndrome.
88952365|NCT04415424|Experimental|Treatment arm A - 4CMenB vaccine|4CMenB vaccine will be administered as an intramuscular injection in 0.5 ml single-dose pre-filled syringe in two doses with 3-month apart (at Baseline and Month 3 visit).
88952366|NCT04415424|Placebo Comparator|Treatment arm B - placebo|Placebo will be administered as an intramuscular injection in 0.5 ml single dose pre-filled syringe in two doses with 3-month apart (at Baseline and Month 3 visit).
88952367|NCT04405245|Experimental|AKB-9778 4% QD + Latanoprost|• AKB-9778 4% daily (AM) and placebo for ophthalmic solution daily (PM) plus latanoprost daily (PM) for 28 days
88952368|NCT04405245|Experimental|AKB-9778 4% BID + Latanoprost|• AKB-9778 4% twice daily (AM & PM) plus latanoprost daily (PM) for 28 days
88952369|NCT04405245|Placebo Comparator|Placebo Twice Daily + Latanoprost|• Placebo for AKB-9778 4% ophthalmic solution twice daily (AM & PM) plus latanoprost daily (PM) for 28 days
88952370|NCT04369599|Experimental|V/Q System|Participants with acute respiratory failure will undergo therapy with the V/Q System.
88952371|NCT04364282||Parent-Child Dyads Taking Part in Weight-Management Programs|Participants in this study will be children and their parents taking part in existing pediatric weight-management programs at participating sites. All participants will be seen at baseline and 6-months for data collection visits.
88952372|NCT04356391|Active Comparator|Connective Tissue Graft harvest from Palate|In each participant, a tooth will be assigned to the Connective Tissue Graft (CTG) technique and another tooth to the Pinhole Technique. The tooth assigned to the CTG technique will receive the graft harvested from the palate.
88952373|NCT04356391|Experimental|collagen resorbable membrane material|In each participant, a tooth will be assigned to the Connective Tissue Graft (CTG) technique and another tooth to the Pinhole Surgical Technique (PST). The tooth assigned to the PST technique will receive the collagen resorbable membrane material.
88952374|NCT04335968|Experimental|Experimental group|melatonin 4mg per os every night, starting the evening before surgery (or 2 hours before emergency surgery) and until day 5 after surgery
88952375|NCT04335968|Placebo Comparator|Control group|placebo of this drug with the same schedule, during the same period of time.
88952376|NCT04332796|Active Comparator|Chorhexidine scrub|Chorhexidine scrub was given to patients for 4 weeks
88952377|NCT04332796|Active Comparator|ZnO-NPs socks|ZnO-NPs socks to patients for 4 weeks
88952378|NCT04332796|Active Comparator|Combination of chorhexidine scrub and ZnO-NPs socks|Chorhexidine scrub and ZnO-NPs socks to patients for 4 weeks
88952379|NCT04328181|Experimental|SPCCT and standard DECT|Comparative intra-patients (each patient will have both types of scanner imaging done), clinical superiority study, evaluating the imaging performances (e.g. image quality and radiation dose) of SPCCT and standard DECT for several body regions/anatomical structures.
88952380|NCT04262024|Active Comparator|Group A|Women with hyperprolactinemia are scheduled for cabergoline therapy cabergoline 1.5-2 mg/week. for one month plus health education.
88952381|NCT04262024|Active Comparator|Group B|Women with hyperprolactinemia are scheduled for cabergoline therapy 1.5-2 mg/week. for one month without health education.
88952382|NCT04255849|Experimental|9-valent HPV vaccine|Participants receive 9-valent HPV vaccine 0.5mL at entry, Month 2 and Month 6
88952383|NCT04255849|Placebo Comparator|Saline Placebo|Participants receive 0.9% NaCl 0.5 mL at entry, Month 2 and Month 6
88952384|NCT04237103|Experimental|methotrexate|Methotrexate once a week orally for 8 months in conjunction with narrow band UVB phototherapy starting 2 months after Methotrexate therapy for 6 months.
88952385|NCT04237103|Placebo Comparator|placebo|Placebo once a week orally for 8 months in conjunction with narrow band UVB phototherapy starting 2 months afterplacebo therapy, for 6 months.
88952386|NCT04212325|Active Comparator|Group C (Continuous sciatic nerve block)|Patients randomized to this group will receive a sciatic nerve block with the catheter tip insertion at the popliteal location 1-3 cm cephalad to the sciatic bifurcation.
88952387|NCT04212325|Active Comparator|Group S (sciatic nerve block)|Patients randomized to this group will receive a sciatic nerve block with the single injection at the popliteal location 1-3 cm cephalad to the sciatic bifurcation.
88952388|NCT04201964|Experimental|Intra-arterial administration of tenecteplase|Intra-arterial administration of tenecteplase (0.2-0.4 mg/min) immediately after thrombectomy device pass for 30-40 minutes.
88952389|NCT04198805|Active Comparator|Vitamin E (1000 mg)|Vitamin E (1000 mg) once daily for 6 months (1 capsule) and matching placebos (2 matched capsules) for 6 months.
89021191|NCT00419822|Placebo Comparator|Standard of Care|
89021192|NCT04703517|Other|Self Controlled|Patients will active as their own comparator
89021193|NCT04959305|Experimental|Experimental 1|HCP1803-3
89021194|NCT04959305|Active Comparator|Active Comparator 1|RLD2003
89021195|NCT04959305|Active Comparator|Active Comparator 2|RLD2004
89021196|NCT04959305|Active Comparator|Active Comparator 3|RLD2005
89021197|NCT04704687|Experimental|tDCS|
89021198|NCT04704687|Active Comparator|Sham|
89021199|NCT04906109|Experimental|Reference-Test|
89021200|NCT04906109|Experimental|Test-Reference|
89021201|NCT04871438|Experimental|FGM|Flash glucose monitoring at weeks 0-2, weeks 6-8 post-discharge
89483944|NCT03244605|Experimental|Rehabilitation training plus TCM|"Rehabilitation training include aerobic exercise training and Liu Zi Jue lung exercises, which will be started in one month after operation.~Prescriptions formulated into granules origin from Professor Xu Ling in Yueyang hospital. Package of granules is made into three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe. Each package contained 20g of water-soluble herbal granules that were manufactured at a Good Manufacture Practice standard facility (Tian Jiang Ltd, Jiangyin, China). Each package was labeled with a serial number. The prescription form comprised the stock list with both the name and serial number.The patient will take TCM granules for 3 months."
89021202|NCT04871438|No Intervention|SMBG|Self-monitoring of blood glucose at least 4 times a day, 3 days a week
89021203|NCT04823897|Experimental|Dose Escalation and Expansion|"Dose escalation phase: CCI-001 will be administered at the starting dose to a cohort of patients with recurrent and/or metastatic solid tumours. The dose will be escalated sequentially in subsequent cohorts to determine the maximum tolerated dose, or recommended dose for the dose expansion cohort.~Dose expansion phase: patients with the following tumour types will be permitted to enroll: transitional cell bladder cancer, pancreaticobiliary adenocarcinomas, gynecologic cancers (ovarian, cervical, endometrial), and lung adenocarcinoma. These patients will be treated at the dose determined during the dose escalation phase."
89021204|NCT00428181|Active Comparator|1 Brief Intervention|The primary purpose of the proposed research is to compare the effectiveness of brief intervention, brief intervention plus a booster and treatment as usual for adult patients with an alcohol related injury.
89021205|NCT00428181|Active Comparator|2) Booster|The primary purpose of the proposed research is to compare the effectiveness of brief intervention, brief intervention plus a booster and treatment as usual for adult patients with an alcohol related injury.
89021206|NCT04703478|Experimental|Single group|Implementation of a mobile application for the rehabilitation of patients with respiratory sequelae of COVID-19
89483945|NCT03244605|Placebo Comparator|Rehabilitation education plus placebo|"Patients who received rehabilitation education will not accept rehabilitation training.~We compromise the raw materials for the placebo including food color and artificial flavors. The placebo and therapeutic packages were stored in different cabinets, and only the dispensing technician knew the contents of the packages.~The patient will take placebo granules for 3 months."
89483946|NCT03244371|Experimental|Co infected HIV and HCV patients|
89483947|NCT04988438||esophageal manometry|"The patients who has previously mentioned symptoms will underwent to manometry monitoring of esophageal and anorectal disorders.~For this investigation we have proven normal and standardized manometric values on previous investigations by other authors, so the control group is not needed. We know the normal manometric values (Chicago 3 score)."
89483948|NCT04988438||anorectal manometry|"The patients who has previously mentioned symptoms will underwent to manometry monitoring of esophageal and anorectal disorders.~For this investigation we have proven normal and standardized manometric values on previous investigations by other authors, so the control group is not needed. We know the normal manometric values (London protocol)."
89483949|NCT03256461|Experimental|Lactate clearance 10% target group|Lactate clearance falls by 10-percent every two hours.
89483950|NCT03256461|Experimental|Lactate clearance 20% target group|Lactate clearance falls by 20-percent every two hours.
89483951|NCT03256461|Placebo Comparator|Standard EGDT group|Refer to the Surviving Sepsis Campaign(SSC) 2012 sepsis guidelines within 6 h liquid resuscitation.
89483952|NCT02435680|Experimental|Arm 1: MCS110+carboplatin+gemcitabine|MCS110+carboplatin+gemcitabine
89483953|NCT02435680|Active Comparator|Arm 2: carboplatin+gemcitabine|carboplatin+gemcitabine
89483954|NCT03249051|Experimental|Indirect Calorimetry|The energy need is being determined by using indirect calorimetry and if necessary, optimized by parenteral, enteral and additive parenteral nutrition.
89483955|NCT03249051|No Intervention|Standard Care|"This group receives nutrition supply according to the hospital routine (standard care)"
89483956|NCT04988126||Patient Group|Patient with Covid 19 Pneumonia
89483957|NCT04988048|Active Comparator|Gam-COVID-Vac C1/ ChAdOx1 nCoV-19|Heterologous: Gam-COVID-Vac C1/ ChAdOx1 nCoV-19
89483958|NCT04988048|Active Comparator|ChAdOx1 nCoV-19 / Gam-COVID-Vac C1|Heterologous: ChAdOx1 nCoV-19 / Gam-COVID-Vac C1
89021207|NCT00432861|Active Comparator|1|Pancrecarb(R) MS-16 Capsules
89021208|NCT00432861|Placebo Comparator|2|
89021209|NCT04768946||Adolescents with Acquired Brain Injury|Adolescents with traumatic brain injury, stroke, and other acquired brain injury ages 12 - 17 will participate in interviews about home safety. They also will have the opportunity to look at and, if desired, try the virtual simulation training system and provide feedback about how to make it more appropriate for adolescents with brain injury, including gamifying it and ensuring appropriate hazards.
89021210|NCT04768946||Caregivers of Adolescents with Acquired Brain Injury|Caregivers of adolescents with traumatic brain injury, stroke, and other acquired brain injury will participate in interviews about home safety. They also will have the opportunity to look at the virtual simulation training system and provide feedback about how to make it more appropriate for adolescents with brain injury, including gamifying it and ensuring appropriate hazards.
89483959|NCT04988048|Active Comparator|Gam-COVID-Vac C1/ BBIBP-CorV|Heterologous: Gam-COVID-Vac C1/ BBIBP-CorV
89483960|NCT04988048|Active Comparator|BBIBP-CorV / Gam-COVID-Vac C1|Heterologous: BBIBP-CorV / Gam-COVID-Vac C1
89483961|NCT04988048|Active Comparator|ChAdOx1 nCoV-19 / BBIBP-CorV|Heterologous: ChAdOx1 nCoV-19 / BBIBP-CorV
89483962|NCT04988048|Active Comparator|BBIBP-CorV / ChAdOx1 nCoV-19|Heterologous: BBIBP-CorV / ChAdOx1 nCoV-19
88952390|NCT04198805|Active Comparator|DHA EE (1.89 g)|DHA EE (1.89 g) once daily for 6 months (2 capsules) and matching placebo for DHA EE (1 matched capsule for 6 months).
88952391|NCT04198805|Active Comparator|DHA EE (1.89 g) and Vitamin E (1000 mg)|DHA EE (1.89 g) once daily for 6 months and Vitamin E (1000 mg) once daily for 6 months.
89203590|NCT04552886|Experimental|Dendritic cell vaccine: Starting dose|This arm will evaluate the safety of administering a total dendritic cell dose of 3.5 x 10^6. A total of 3-6 patients will be enrolled with this dose. If this dose is associated with unacceptable side effects, as detailed in the study protocol, no further patients will be enrolled at this dose.
88952392|NCT04198805|Placebo Comparator|Placebo|Matching soybean oil placebo (3 capsules) of all arms daily for 6 months.
88952393|NCT04179890||Uncommon EGFR mutation cohort|"This arm included patients with Non-Small Cell Lung Cancer (NSCLC) carrying uncommon mutations in the epidermal growth factor receptor (EGFR) who were treated with the following Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR-TKIs) as first or second-line therapy:~Afatinib (Gi(l)otrif®):50mg or 40mg or 30mg or 20mg tablet once daily as indicated in the approved labels of afatinib (Gi(l)otrif®).~Erlotinib (Tarceva®): 25mg or 100mg or 150mg tablet once daily as indicated in the approved labels of erlotinib (Tarceva®).~Gefitinib (IRESSA®): 250mg tablet once daily as indicated in the approved labels of gefitinib (IRESSA®).~Osimertinib (Tagrisso®): 80 mg or 40 mg tablets once daily as indicated in the approved labels of osimertinib).~In the first- or second-line with a threshold of start of treatment of at least 12 months respectively prior to data entry."
88952394|NCT04179890||Sequencing cohort|"This arm included Non-Small Cell Lung Cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutation positive who received the following treatment sequence:~- Afatinib (Gi(l)otrif®): 50mg or 40mg or 30mg or 20mg tablet once daily as indicated in the approved labels of afatinib (Gi(l)otrif®) as first line therapy, in the case the T790M resistance mutation was developed (second line therapy) the patients received osimertinib (Tagrisso®): 80 mg or 40 mg tablets once daily as indicated in the approved labels of osimertinib; the threshold of start of osimertinib at least 10 months prior to data entry."
88952395|NCT04178668|Experimental|20-40 years old|33 patients between 20 and 40 years old
88952396|NCT04178668|Experimental|70-90 years old|33 patients between 70 and 90 years old
88952397|NCT04173663|Experimental|ASSIST intervention group|This group will attend the 12 sessions of the ASSIST training program (one 2-hour session per week for 12 weeks).
88952398|NCT04173663|Other|Control: Written materials only group|"This informational control group will receive the ASSIST binder and all written materials developed for the program on the same schedule as the treatment group but will not attend the group sessions.~After the treatment group is treated and follow up data is collected for comparison between treatment and control, the control group will have the option to take the ASSIST training program."
88952399|NCT04084210|Active Comparator|Juul + Active Patch in Wk 1 and Placebo Patch in Wk 2|Participants will be given Juul e-cigarettes for four weeks; in Switch Week 1, participants also will use active nicotine patches; in Switch Week 2, participants will use placebo patches.
88952400|NCT04084210|Active Comparator|Juul + Placebo Patch in Wk 1 and Active Patch in Wk 2|Participants will be given Juul e-cigarettes for four weeks; in Switch Week 1, participants also will use placebo patches; in Switch Week 2, participants will use active nicotine patches.
89203591|NCT04552886|Experimental|Dendritic cell vaccine dose de-escalation|If unacceptable side effects, as detailed in the study protocol, are identified at a total dose of 3.5 x 10^6, then a cohort of 3-6 enrolled patients will receive a de-escalated total dendritic cell dose of 1.75 X 10^6.
89203592|NCT04552886|Experimental|Dendritic cell vaccine dose escalation one|If no unacceptable side effects, as detailed in the study protocol, are identified at a total dose of 3.5 x 10^6, then a cohort of 3-6 enrolled patients will receive an escalated total dendritic cell dose of 7.0 X 10^6.
89203593|NCT04552886|Experimental|Dendritic cell vaccine dose escalation two|If no unacceptable side effects, as detailed in the study protocol, are identified at a total dose of 7.0 x 10^6, then a cohort of 3-6 enrolled patients will receive an escalated total dendritic cell dose of 1.4 X 10^7.
89203594|NCT00322387|Experimental|Plerixafor PM|"Participants received chemotherapy and G-CSF mobilization for 7 days according to standard procedures at the study center. When participants achieved a target CD34+ count of ≥20 cells/µL, apheresis began. G-CSF was given daily in the morning on the days of apheresis. After the first apheresis, plerixafor (240 µg/kg) was administered each evening (approximately 10pm) followed by apheresis 10 to 11 hours later for up to 4 consecutive days.~Called 'Cohort A' in protocol, study report and publications."
89203595|NCT00322387|Experimental|Plerixafor AM|"Participants received chemotherapy and G-CSF mobilization for 7 days according to standard procedures at the study center. When participants achieved a target CD34+ count of ≥20 cells/µL, apheresis began. G-CSF was given daily in the morning on the days of apheresis. The morning of the second day after the first apheresis, plerixafor (240 µg/kg) was administered followed by apheresis 6 hours later. Plerixafor (240 µg/kg) was administered in the morning followed by apheresis 6 hours later for up to 4 consecutive days.~Called 'Cohort B' in protocol, study report and publications."
89203596|NCT00322387|Experimental|Low CD34+ Count/ Plerixafor PM|"Participants received chemotherapy and G-CSF mobilization for 7 days according to standard procedures at the study center. If participants had a CD34+ count of >=10 cells/µL but <20 cells/µL on 2 consecutive days, plerixafor (240 µg/kg) was given in the evening. G-CSF was administered and apheresis performed in the morning. Plerixafor (240 µg/kg) administered in the evening followed by G-CSF and apheresis 10 to 11 hours later was repeated for up to 4 consecutive days.~Called 'Cohort C' in protocol, study report and publications."
89483963|NCT04988048|Active Comparator|Gam-COVID-Vac C1/ mRNA-1273|Heterologous: Gam-COVID-Vac C1/ mRNA-1273
89483964|NCT04988048|Active Comparator|ChAdOx1 nCoV-19 / mRNA-1273|Heterologous: ChAdOx1 nCoV-19 / mRNA-1273
89483965|NCT04988048|Active Comparator|BBIBP-CorV / mRNA-1273|Heterologous BBIBP-CorV / mRNA-1273
89483966|NCT04988048|Active Comparator|Gam-COVID-Vac C1/ Gam-COVID-Vac C2|Homologous: Gam-COVID-Vac C1/ Gam-COVID-Vac C2
89483967|NCT04988048|Active Comparator|ChAdOx1 nCoV-19 / ChAdOx1 nCoV-19|Homologous: ChAdOx1 nCoV-19 / ChAdOx1 nCoV-19
89483968|NCT04988048|Active Comparator|BBIBP-CorV / BBIBP-CorV|Homologous: BBIBP-CorV / BBIBP-CorV
89483969|NCT04988048|Active Comparator|mRNA-1273 / mRNA-1273|Homologous: mRNA-1273 / mRNA-1273
89483970|NCT04988048|Active Comparator|Gam-COVID-Vac C1/ Gam-COVID-Vac C1|Homologous: Gam-COVID-Vac C1/ Gam-COVID-Vac C1
89483971|NCT03248895|Active Comparator|Immediate (I-med)|Participants allocated to the I-med group will take part in the mobile DOT intervention for the first 6 weeks. Outcomes will be evaluated at the start (week 0) and end of the 6 week intervention period and during clinic visits at weeks 12 and 18 for follow-up
89483972|NCT03248895|Active Comparator|Delayed (D-med)|"Those participants allocated to the D-med group will have the DOT intervention started after a 6 week intervention-free interval with usual Asthma Clinic care. Outcomes in the D-med group will be assessed at baseline (week 0), week 6 (intervention start), week 12 (end of intervention), and at weeks 18 and 24 for follow-up."
89483973|NCT03073616||Lung ultrasound|Every patient will receive a chest RX and lung US
89483974|NCT03244527|Experimental|BCAA group|Participants in the BCAA group take 40g of BCAA supplement before each aerobic exercise session. The interventions include 24 aerobic training sessions. Accordingly, the participants intake 960g of BCAA during a 8-week intervention period.
89483975|NCT03244527|Placebo Comparator|Control group|Participants in the control group take 40g of placebo before each aerobic training session. The placebo has the same caloric as the BCAA supplement but with different constitution (eg, different percentage of protein, fat and carbohydrate)
89483976|NCT04987736||COVID-19 (RT-PCR +ve) patients|
89483977|NCT03256383||Adult|Patients aged 18+ years
89483978|NCT03256383||Children 7 - 17|Patients aged 7 - 17 years
89483979|NCT03256383||Children <7|Patients aged under 7 years
89483980|NCT03244215|Experimental|The study group|"The intervention to be evaluated is the patient response and compliance to best medical treatment and prevention of recognized stroke risk factors and the recurrence of stroke and TIA in the study group and its relation to the incidence of blood biomarkers.~The Nurse practitioners at the stroke ward will withdraw blood and collect urine samples from all the subjects. All the subjects from the study group will have 2 follow up visits (1 month and at 1 year) at HGH and one telephonic follow up at 3 months. The blood samples will be used to monitor blood inflammatory biomarker levels. At the beginning of the study, all subjects will have an MRI scan to assess plaque volume (this MRI scan will be ordered as part of the standard of care as per the policies applied to all stroke patients). MRI scans will be repeated at one year to assess any progression or regression in the plaque volume of the subjects.~No drugs will be administered to the patients for the purpose of our study."
89483981|NCT03244215|Other|Control|The control group will have blood work done to assess their blood inflammatory biomarkers but not the corneal confocal imaging.
89483982|NCT03073460|Other|Ultrasound examination|Participants will undergo an ultrasound examination at 40 weeks gestation to assess the fetal ductus arteriosis.
89483983|NCT03244137||Pulmonary rehabilitation|The whole population will benefit from a comprehensive pulmonary rehabilitation program, including aerobic training, superior and inferior limb strength training, self-management and add-on to pulmonary rehabilitation as needed (i.e : electrical muscle stimulation, inspiratory muscle training, non-invasive ventilation, high flow nasal canula).
89483984|NCT04982900|Experimental|EGFR-TKI Treatment Arm|After randomization, the enrolled patients in this arm should be completely free from the risk of perioperative complications or recovered from the effects of complications, usually no earlier than 4 weeks after surgery but no more than 10 weeks after surgery, before receiving baseline follow-up and starting oral administration of Furmonertinib on the day of baseline follow-up. Patients in the treatment group should take Furmonertinib (80 mg each time) orally on an empty stomach before breakfast once a day. The medicine should be taken about the same time each day, by swallowing the whole tablet with water, without crushing or chewing. Patients should maintain oral administration of Furmonertinib for 6 consecutive months, unless there is disease progression, death, new anti-tumor therapy received or intolerance of investigational drugs.
89537678|NCT01670877|Experimental|Crossover: Neratinib + Fulvestrant + Trastuzumab|-If a participant experiences disease progression during Part I or Part II following neratinib, trastuzumab (or FDA approved biosimilar) may be added to the treatment regimen. Trastuzumab may be administered intravenously with a loading dose of 6 mg/kg then 4 mg/kg every 2 weeks. A cycle will be defined as 28 days. Patients will receive neratinib PO daily on Days 1-28 and fulvestrant on Day 1 of each cycle (and C1D15). Each cycle is 4 weeks.
89021211|NCT04768946||Healthcare Workers|This cohort includes health professionals involved in discharge planning and community re-integration of adolescents with ABI. Healthcare workers will participate in interviews about home safety. They also will have the opportunity to look at the virtual simulation training system and provide feedback about how to make it more appropriate for adolescents with brain injury, including gamifying it and ensuring appropriate hazards.
89021212|NCT00432900|Active Comparator|Healthy Volunteer|Healthy Volunteers
89021213|NCT00432900|Experimental|Patient|Multiple Sclerosis Patients
89021214|NCT04627805|No Intervention|Phase 2: Usual Care|The investigators will enroll 33 women with SUDs to evaluate baseline family planning discussions and referrals to women's health providers in SUD treatment settings. To establish usual care practice patterns, MyPath will not be administered to this group of participants. Participants will be asked to complete a pre-visit survey, including substance use history and current reproductive health goals, as well as questions about reproductive health knowledge, self-efficacy, and decision conflict. The participants will then attend their scheduled therapy visit with the substance use treatment provider. Following the therapy visit, they will complete the post-visit survey, which will include the same knowledge, efficacy, and decision conflict survey questions as the pre-visit survey. Occurrence of reproductive health discussions, prescriptions or referrals, and satisfaction with reproductive health services will be measured following the visit as well.
89021215|NCT04627805|Experimental|Phase 3: MyPath Pilot|Following completion of the usual care arm, the investogators will enroll a second group of 33 women with SUDs to participate in the MyPath intervention arm. Participants will complete the same pre-visit survey as the usual care group. In addition, they will be provided a website link to navigate through the online MyPath tool. Following completion of MyPath, participants will receive a summary page that they will be encouraged to use as a guide when discussing their reproductive health with their substance use treatment provider at their next scheduled therapy visit. After the visit, they will complete the post-visit survey. In addition to satisfaction with reproductive health services, the intervention group will be asked specific questions about their perception of the MyPath tool.
89021216|NCT00428337|Experimental|1|Participants will receive one injection of DNA vaccine EP-1233 or placebo in each shoulder on Days 0 and 28 and one injection of MVA-mBN32 or placebo in each arm on Days 84 and 168
89021217|NCT00428337|Experimental|2|Participants will receive one injection of DNA vaccine EP-1233 or placebo in each shoulder on Days 0, 28, 84, and 168
89206296|NCT04090307|Experimental|TLC Group Prenatal Care|TLC will start in the late first trimester or early second trimester and run for ~6-10 sessions. Groups of 2-10 consented women, with two or more GDM risk factors, will meet under the supervision of an obstetric provider (nurse practitioner or MD) and co-facilitator (health educator, nutritionist, or nurse) for two-hour sessions. A major focus of TLC will be education, and much of each visit will be spent on pregnancy, exercise/nutrition education, and behavioral health.
89021218|NCT00428337|Experimental|3|Participants will receive one injection of MVA-mBN32 or placebo in each arm on Days 0, 28, 84, and 168
89021219|NCT04575233|Experimental|Laparoscopic Transversus Abdominis Plane (L-TAP) group|Patients will undergo the planned laparoscopic colectomy according to the standard of treatment. A solution of 15 ml of Ropivacaine (0.2%) is then injected for postoperative pain under laparoscopic control
89021220|NCT04575233|Active Comparator|Ultrasound Transversus Abdominis Plane (U-TAP) group|Patients will undergo the planned laparoscopic colectomy according to the standard of treatment. A solution of 15 ml of Ropivacaine (0.2%) is then injected for postoperative pain under ultrasound control
89021223|NCT00428454|Experimental|Zotarolimus eluting stent|Zotarolimus eluting stent
89021224|NCT00428454|Active Comparator|Sirolimus eluting stent|Sirolimus eluting stent
89021225|NCT00419861||Group 1|Adults >/= 50 years of age, hospitalized for respiratory illness in Davidson County, TN.
89021226|NCT04476602||COVID-19 (SARS-CoV-2) patients|adults 18 or older, ambulatory , with COVID-19 (SARS-CoV-2)
89021227|NCT00433056|Experimental|1|STI
89483985|NCT04982900|Placebo Comparator|Control Arm|After randomization, the enrolled patients in this arm should be completely free from the risk of perioperative complications or recovered from the effects of complications, usually no earlier than 4 weeks after surgery but no more than 10 weeks after surgery, before receiving baseline follow-up and starting oral administration of placebo on the day of baseline follow-up. Patients in the treatment group should take placebo (80 mg each time) orally on an empty stomach before breakfast once a day. The medicine should be taken about the same time each day, by swallowing the whole tablet with water, without crushing or chewing. Patients should maintain oral administration of placebo for 6 consecutive months, unless there is disease progression, death, new anti-tumor therapy received or intolerance of investigational drugs.
89483986|NCT03256071|Experimental|Decitabine plus Modified BUCY|For high-risk patients with Acute Myeloid Leukemia (AML) undergoing allo-HSCT, The Decitabine plus Modified BuCy regimen consisted of decitabine,semustine,cytarabine, busulfan and cyclophosphamide.
89483987|NCT03256071|Active Comparator|Modified BUCY|For high-risk patients with Acute Myeloid Leukemia (AML) undergoing allo-HSCT, The Modified BuCy regimen consisted of semustine,cytarabine, busulfan and cyclophosphamide.
89483988|NCT03248817|Experimental|single shot|spinal anesthesia will be performed using intrathecal bupivacaine. Then, a single shot phenylephrine (1.5 ug/Kg) will be administered
89483989|NCT03248817|Active Comparator|fixed infusion|spinal anesthesia will be performed using intrathecal bupivacaine. Then, fixed infusion phenylephrine will be administered at a dose of (0.75 mcg/Kg/min). the infusion will stop if reactive hypertension occurred
89483990|NCT03248817|Active Comparator|variable infusion|spinal anesthesia will be performed using intrathecal bupivacaine. Then, variable infusion phenylephrine will be administered at a starting dose of (0.75 mcg/Kg/min). the infusion will be titrated according to blood pressure
89483991|NCT05635994||Single arm|There is only one arm. Initially, a tentative diagnosis would be performed by the clinician, only taking into account patients's clinical information and angiography images. After applying AID strategy, a final diagnosis will be reached and compared with the tentative one.
89483992|NCT03248583|Experimental|Default|
89483993|NCT03248583|Active Comparator|Psychoeducation|
89483994|NCT03248583|Active Comparator|Incentive|
89021228|NCT00433056|Active Comparator|2|stable HAART, Any registered regimen containing NRTIs (AZT or D4T or 3TC or TDF or DDI), NNRTIs (EFV or NVP) or PIs (RTV-boosted ATV; IDV; LPV, fosAPV, SQV; unboosted ATV or NFV)is allowed according to international guidelines
89021229|NCT04460612|Placebo Comparator|Placebo Sock|Placebo Socks will be placed on participants feet either first or second for 60 minutes
89483995|NCT03647774|Experimental|Extended release naltrexone|Extended release naltrexone 380 mg as an intramuscular injection every 4 weeks.
89483996|NCT03647774|No Intervention|Treatment As Usual (TAU)|Daily sublingual buprenorphine in flexibel dose according to the patients need and ART guidelines.
89483997|NCT02832531|Experimental|Rivaroxaban (15 mg)|Rivaroxaban 15 mg od (n ~ 1000)
89483998|NCT02832531|Active Comparator|Aspirin (ASA)|Aspirin 100 mg od (n~1000)
89483999|NCT05635760|Experimental|Group-based Parent-implemented Social Communication Training|
89484000|NCT05635760|Active Comparator|Self-learning-based Parent-implemented Social Communication Training|
89021230|NCT04460612|Active Comparator|Active IR Sock|Active IR socks will be placed on participants feet either first or second
89021231|NCT04401332|Experimental|Intervention|
89021232|NCT04401332|No Intervention|Usual Care|
89484001|NCT03248505|Placebo Comparator|Placebo TENS|TENS unit turned on, but with zero amplitude.
89484002|NCT03248505|Experimental|Conventional TENS|Symmetrical biphasic pulsed current, with frequency of 100 Hz, pulse duration of 100 micro-seconds and sensory-level amplitude.
89484003|NCT03248505|Experimental|Burst TENS|Carrier frequency of 100 Hz burst-modulated at 4Hz, pulse duration of 200 micro-seconds and motor-level amplitude.
89484004|NCT03248505|Experimental|Cryotherapy|1,5 Kg crushed ice pack
89203597|NCT00322387|Experimental|Plerixafor After Chemo|"This investigational cohort evaluated the effect of administering plerixafor before white blood cell recovery.~Participants received mobilizing chemotherapy, followed by 5 consecutive days of G-CSF (10 µg/kg). Starting on the sixth day, participants received G-CSF (10 µg/kg) plus plerixafor (240 µg/kg) daily for up to 3 consecutive days. If CD34+ counts reached >= 20 cells/µL 6 hours after any of the 3 plerixafor doses, apheresis began. If not, G-CSF administration continued until the participant qualified for one of the other treatment arms.~Called 'Investigational Cohort' in protocol, study report and publications."
89484005|NCT03248505|Experimental|Burst TENS + Cryotherapy|Carrier frequency of 100 Hz burst-modulated at 4Hz, pulse duration of 200 micro-seconds and motor-level amplitude plus an ice pack of 1,5 Kg.
89484006|NCT03248505|Experimental|Conventional TENS + Cryotherapy|Symmetrical biphasic pulsed current, with frequency of 100 Hz, pulse duration of 100 micro-seconds and sensory-level amplitude plus an ice pack of 1,5 Kg.
89484007|NCT05635682||Study Group|Individuals in the process of maintenance therapy with opioid use disorder
89484008|NCT05635682||Control Group|Healty people
89484009|NCT03248661|Experimental|Intervention media condition|monthly social media contact will be used to keep people connected to the idea of completing a second screening test 12 months after their last one.
89484010|NCT03248661|No Intervention|control condition|this group will receive only a standard reminder for the annual repeat test, one month before the test due date
89484011|NCT05635526||1|8-12 years old
89484012|NCT05635526||2|13-16 years old
89484013|NCT05635526||3|over 16 years old
89484014|NCT03248427|Experimental|Ribociclib + Letrozol|Ribociclib: 600mg, 3-weeks-on/-week-off treatment Letrozole: 2.5mg daily; Six 28 days cycles
89484015|NCT03248427|Other|Chemotherapy|Chemotherapy treatment will consist of four cycles of AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 every 21 days) followed by weekly paclitaxel during 12 weeks.
89484016|NCT03248349||1|Pharmacokinetics
89484017|NCT03248193|Experimental|Healthy subjects|To assess safety and tolerability of scalp and limb hypothermia, as well as to determine the optimal temperature and pressure to be used. Establishing the occurrence or lack of core hypothermia will be studied.
89484018|NCT03248193|Experimental|Cancer subjects|Once the optimal temperature and pressure of scalp and limb hypothermia is established in healthy patients, a group of cancer patients will undergo concomitant scalp and limb hypothermia over multiple cycles of chemotherapy to establish safety and tolerability of repeated therapy.
89484019|NCT03256305|Experimental|"personalized rTMS+drug treatment"|"Received personalized rTMS treatment 15 times for 15 days;Take paroxetine for 2 weeks"
89484020|NCT03256305|Active Comparator|Traditional rTMS +drug treatment|Received traditional rTMS treatment 15 times for 15 days;Take paroxetine for 2 weeks
89484021|NCT03255837|Experimental|Transcranial direct current stimulation (tDCS) - anodal|Transcranial direct current stimulation - anodal (positive) 1.5 millamps for 15 minutes
89484022|NCT03255837|Experimental|Transcranial direct current stimulation (tDCS) - cathodal|Transcranial direct current stimulation - cathodal (negative) 1.5 millamps for 15 minutes
89484023|NCT03255837|Sham Comparator|Transcranial direct current stimulation (tDCS) - sham|Transcranial direct current stimulation - sham session 15 minutes
89484024|NCT03255681|Experimental|Split face study|Split face study with the left side of the face receiving PRP injections and the right side of the face receiving PRP with 0.1cc of 10% calcium chloride per 1mL of PRP. The volume of PRP will be used upon the discretion of the provider for treatment of the cosmetic facial deformity but will be in equal amounts for each side on every patient participating in the study.
89484025|NCT03255759|Active Comparator|Molecular dx arm|Positive blood cultures are tested using a molecular ID system in addition to the standard of care (biochemical identification)
89484026|NCT03255759|No Intervention|Standard of care arm|Positive blood cultures are treated as per normal lab protocol (biochemical identification)
89484027|NCT03371732|Other|Groupe 1|G1 : Motivational Intervention group
89484028|NCT03371732|Other|Groupe 2|G2 : Educational advises group
89484029|NCT03255603|Experimental|Modified potato starch|Modified potato starch is a resistant starch type IV and will be used as an experimental arm.
89484030|NCT03255603|Experimental|Modified corn starch|Modified corn starch is a resistant starch type IV and will be used as an experimental arm.
89484031|NCT03255603|Experimental|Modified tapioca starch|Modified tapioca starch is a resistant starch type IV and will be used as an experimental arm.
89484032|NCT03255603|Placebo Comparator|Corn starch|Corn starch is digestible and will therefore will be used as a placebo control for the study.
89484033|NCT03255525|Active Comparator|Deep friction massage P50|In this group it was applied a pressure previously found to be the mean pressure applied by physiotherapists during deep friction massage.
89484034|NCT03255525|Experimental|Deep friction massage P25|In this group it was applied the percentile 25, of the pressure previously found to be the mean pressure applied by physiotherapists during deep friction massage.
89484035|NCT03255525|Experimental|Deep friction massage P75|In this group it was applied the percentile 75, of the pressure previously found to be the mean pressure applied by physiotherapists during deep friction massage.
89484036|NCT02454309|Experimental|Cranberry concentrate|Each capsule contains 500 mg of cranberry powder at a concentration ratio of 36:1 (36 grams of cranberries equals 1 gram of concentrate)
89484037|NCT02454309|Placebo Comparator|Placebo|A capsule containing control formulation
89484038|NCT03068546||Participants providing samples|NCI employees agreeing to provide samples for microbiome sample study
89484039|NCT03255369||Child exposed Zika virus proved|child born to mothers with proved zika virus in pregnancy by RT-PCR
89484040|NCT03255369||Child exposed to zika virus suspected|Child born with symptoms similar to babies proved exposed to zika virus but mothers without symptoms or positive RT-PCR
89484041|NCT03255369||Normal Child|Normal child from mothers without Zika (IgG and IgM negative)
89484042|NCT03069560|Experimental|SMS|The patients will receive from the caregiver a first SMS 48 hours after their discharge from the hospital then a total of 4 messages : 48 hours, S1, S2, and S4.
89484043|NCT03255447|Experimental|Immunoadsorption therapy|Peptide GAM immunoadsorption therapy
89484044|NCT03247959|Experimental|Group A|Group A: Videogame distraction during extraction procedure
88952401|NCT04084210|Active Comparator|VLNC + Active Patch in Wk 1 and Placebo Patch in Wk 2|Participants will be given very low nicotine cigarettes (VLNCs) for four weeks; in Switch Week 1, participants also will use active nicotine patches; in Switch Week 2, participants will use placebo patches.
88952402|NCT04084210|Active Comparator|VLNC + Placebo Patch in Wk 1 and Active Patch in Wk 2|Participants will be given very low nicotine cigarettes (VLNCs) for four weeks; in Switch Week 1, participants also will use placebo patches; in Switch Week 2, participants will use active nicotine patches.
88952403|NCT04084210|Other|No Product + Active Patch in Wk 1 and Placebo Patch in Wk 2|Participants will be given no alternative nicotine delivery products but in Switch Week 1, participants will use active nicotine patches; in Switch Week 2, participants will use placebo patches.
89484045|NCT03247959|Experimental|Group B|Group B: Video distraction during extraction procedure
89484046|NCT03247959|Active Comparator|Group C|group C: Verbatim during extraction procedure
89484047|NCT03247881|Other|Nut Free Diet|Participants will consume whatever they like, as much as they like, from a pre-determined buffet with 0 g/d of mixed nuts.
89484048|NCT03247881|Active Comparator|Added Mixed Nuts Diet|Participants will consume whatever they like, as much as they like, from a pre-determined buffet which will include 2 servings (2 ounces) of mixed nuts per day (1 serving just prior to breakfast and 1 serving as an afternoon snack).
89484049|NCT03243903|Experimental|needle-free insulin injector|Using QS-M insulin-free injector as insulin carrier to control blood glucose of T2DM and insulin dose is prescribed.
89484050|NCT03243903|Active Comparator|conventional insulin pen|Using conventional insulin pen as insulin carrier to control blood glucose of T2DM and insulin dose is prescribed.
89484051|NCT03247647|Experimental|Enhanced Intervention|Participants assigned to this arm will complete a personal values task before reviewing their personalized feedback (eCheckUpToGo).
88952404|NCT04084210|Other|No Product + Placebo Patch in Wk 1 and Active Patch in Wk 2|Participants will be given no alternative nicotine delivery products for two weeks but in Switch Week 1 participants will use placebo patches; in Switch Week 2, participants will use active nicotine patches.
88952405|NCT04047264|Experimental|Basic Science (microdialysis)|Patients undergo microdialysis over 30 minutes during standard of care biopsy or resection.
88952406|NCT04046497|Experimental|Smartphone App|artificial intelligence (AI) smartphone app to provide support for medication adherence
88952407|NCT04046497|Active Comparator|Usual Care|Usual care provided at CSC clinic
88952408|NCT04030026|Experimental|NAL ER then placebo|Participants will receive NAL ER 27 mg QD, 27 mg BID, 54 mg BID, 108 mg BID, 162 mg BID over a 3 week period, followed by a 2 week washout. They will then receive Placebo tablet (matching NAL ER BID) for 3 weeks.
88952409|NCT04030026|Experimental|Placebo then NAL ER|Participants will receive Placebo tablet (matching NAL ER BID) for 3 weeks, followed by a 2 week washout. They will then receive NAL ER 27 mg QD, 27 mg BID, 54 mg BID, 108 mg BID, 162 mg BID over a 3 week period .
88952410|NCT03968900|Experimental|Sleep Restriction|4 hours time in bed (1 am to 5 am)
88952411|NCT03968900|Experimental|Sleep Extension|10 hours time in bed (10 pm to 8 am)
88952412|NCT03932097|Experimental|REAL Parenting|REAL Parenting digital intervention emphasizing parent-teen/young adult communication on drinking/risks of drinking/risks of alcohol abuse, with the addition of a communication component on the risks of nicotine and marijuana use, with the goal of reducing alcohol, nicotine and marijuana use in college students.
88952413|NCT03932097|Active Comparator|Active Control Materials|NIAAA materials on underage drinking for parents
88952414|NCT03927274|Experimental|Cleveland Multiport Catheter (CMC) + Topotecan|For predominantly enhanced tumors with volume of 8 cc or less, only 1 Cleveland Multiport Catheter (CMC) will be placed and convection-enhanced delivery (CED) will be performed over a 4-hour period within an MRI scanner, with the goal of complete tumor coverage (as evidenced by tracer distribution on MRI). The initial rate will be 1.20 ml/hour (5.0 microliters/minute/microcatheter) and infusion will be monitored by intermittent MRI imaging. The rate may be adjusted upwards during the infusion, in the event of incomplete tumor coverage, or downwards, if new mass effect is apparent. Following completion of the 4-hour infusion, the CMC will be removed. The initial rate for each subsequent patient may be adjusted upwards in increments of up to 5 microliters/minute/microcatheter based upon the tumor coverage and safety characteristics of the previously treated patients.
88952415|NCT03926585||Responders|Patients in combination therapy due to persistent symptoms on L-thyroxin mono-therapy who experience a longtime effect of triiodothyronine treatment.
88952416|NCT03926585||Non-responders|Patients who have tried combination therapy due to persistent symptoms on L-thyroxin mono-therapy, but did not experience a longtime effect.
88952417|NCT03923699|No Intervention|Standard of care arm|Operating rooms in the standard of care group will be monitored but, the ACT clinicians will not contact the operating room unless it is clinically necessary for patient safety purposes.
88952418|NCT03923699|Experimental|Anesthesia Control Tower monitoring|Clinicians in the Anesthesiology Control Tower will provide extra support for the anesthesiology team in the operating room using AlertWatch and integrating machine-learning forecasting algorithms for adverse outcomes.
89484052|NCT03247647|Placebo Comparator|Standard Intervention|Participants assigned to this arm will complete a writing task about the food they have eaten in the past 48 hours immediately before reviewing their personalized feedback (eCheckUpToGo).
89484053|NCT03247491|Experimental|Experimental|TAU + mindfulness applied face to face 8 sessions of 120 minutes/session Mindfulness and Compassion based intervention applied in groups of 12-15 people in traditional format. Written material and sound recordings will be offered as support elements. The estimated duration of the face to face program is two months.
89484054|NCT03247491|No Intervention|No intervention|Usual medical treatment (TAU) In this group the midwife will apply the usual treatment (childbirth education class in the third trimester of pregnancy).
89484055|NCT02745119|Experimental|Lampalizumab Every 4 Weeks|Participants who received either lampalizumab or sham comparator every 4 weeks in one of the parent studies and completed the Week 96 visit will receive open-label lampalizumab as 10 milligrams (mg) via ITV injection, administered every 4 weeks.
89484056|NCT02745119|Experimental|Lampalizumab Every 6 Weeks|Participants who received either lampalizumab or sham comparator every 6 weeks in one of the parent studies and completed the Week 96 visit will receive open-label lampalizumab as 10 mg via ITV injection, administered every 6 weeks.
88952419|NCT03919344|Other|Central SAS cases|Patients with central apnea
88952420|NCT03919344|Other|Obstructive SAS controls|Patients with moderate to severe obstructive apnea (apnea-hypopnoea index ≥ 15 / h)
89484057|NCT03247725|Active Comparator|Treatment as usual (waiting list)|Patients at this condition will receive the usual medical treatment at the pain unit, but they will not be monitored daily using the app.
89484058|NCT03247725|Experimental|Treatment as usual + app (without alarm)|Participants at this condition will receive the usual medical treatment for their pain but also they will be monitored daily using the Pain Monitor app. Because alarms will not be generated, physicians will not know if an undesired event is occuring despite the app is actually collecting data.
89484059|NCT03247725|Experimental|Treatment as usual + app (with alarm)|Participants at this condition will receive the usual medical treatment for their pain but also they will be monitored daily using the Pain Monitor app. Alarms will be generated in the face of certain preestablished events. Physicians will be asked to call patients and change/stop treatment if an alarm is received.
89484060|NCT03247803|Experimental|Air-Q SP|air-Q Self-Pressurizing intubating Laryngeal Airway, sizes 3.5 and 4.5 (Mecury Medical, Clearwater, FL, USA)
89484061|NCT03247803|Experimental|Williams Intubating Airway|Airway Intubator, Williams, Adult Female, Single Use, Molded Surlyn Plastic, 9 cm or Airway Intubator, Williams, Adult Male, Single Use, Molded Surlyn Plastic, 10 cm
89484062|NCT03243825|Experimental|chemo/brachytherapy|Patients in this arm will receive neoadjuvant chemotherapy (paclitaxel/cisplatinum) and brachytherapy before radical hysterectomy.
89484063|NCT03243825|Active Comparator|chemotherapy|Patients in this arm will receive neoadjuvant chemotherapy (paclitaxel/cisplatinum) before radical hysterectomy.
89484064|NCT03247179|Experimental|PTSD Coach Condition|PTSD Coach App
89484065|NCT03247179|No Intervention|Treatment as Usual Condition|Treatment as Usual
89484066|NCT03578627|No Intervention|Assessment-only|
89484067|NCT03578627|Experimental|Intervention|
89484068|NCT03576677|Active Comparator|Levosimendan|Study participants in this arm will receive a 6 hours infusion of levosimendan 0.2 µg/kg/min.
89484069|NCT03576677|Placebo Comparator|Placebo|Study participants in this arm will receive a 6 hours infusion of placebo (sterile isotonic sodium chloride + 5% dextrose + vitamin B)
89484070|NCT03247257|Active Comparator|Group A: General Anesthesia|35 patients will be randomized to receive general anesthesia during their laparoendoscopic single site incision cholecystectomy.
89484071|NCT03247257|Active Comparator|Group B: Epidural Anesthesia|35 patients will be randomized to receive epidural anesthesia during their laparoendoscopic single site incision cholecystectomy.
89484072|NCT03578471|Active Comparator|Hearing Aid without NR and BF|Hearing Aid without Noise Reduction (NR) or beam forming (BF) enabled serves as reference condition.
89484073|NCT03578471|Experimental|Hearing Aid with NR|Hearing Aid with Noise Reduction (NR) enabled.
89484074|NCT03578471|Experimental|Hearing Aid with BF|Hearing Aid with beam forming (BF) enabled.
89484075|NCT02454699|Experimental|1000mg MBX400|6 subjects receive 1000 mg MBX400 orally once per day for 7 days, 2 subjects receive Placebo orally once per day for 7 days
88952421|NCT03919344|Other|Snorers controls|Snorers controls : Patients with snoring, with or without mild obstructive apneas (index of apnea-hypopneas <15 / h)
89484076|NCT02454699|Experimental|100mg MBX400|6 subjects receive 100 mg MBX400 orally once per day for 7 days, 2 subjects receive Placebo orally once per day for 7 days
89484077|NCT02454699|Experimental|350mg MBX400|6 subjects receive 350 mg MBX400 orally once per day for 7 days, 2 subjects receive Placebo orally once per day for 7 days
89484078|NCT02454699|Experimental|750mg MBX400|6 subjects receive 750 mg MBX400 orally once per day for 7 days, 2 subjects receive Placebo orally once per day for 7 days
89484079|NCT03243123|Experimental|Passive mobilization|Upper limb passive mobilization assisted with robotic device
89484080|NCT03576599|Active Comparator|Zoledronic Acid Injectable Product|Patients randomized to treatment with Zoledronic Acid 5mg infusion, repeated after 3 months
89484081|NCT03576599|Placebo Comparator|Placebo|Patients randomized to Placebo infusion (saline), repeated after 3 months
89484082|NCT03247101|Experimental|Probiotics group|Miyarisan-BM (Clostridium Butyricum Miyairi) 40 mg po tid x 6 months
89484083|NCT03247101|Active Comparator|Urso group|ursodoxycholic acid, 200mg po tid x 6 months
89484084|NCT03247101|Active Comparator|Biotase group|Biotase 1# [Biodiastase 30mg + lipase 65mg + newlase 10mg]/tab po tid x 6 months
89484085|NCT02239757|Experimental|Right radial approach|Primary PCI performed through right radial approach.
89484086|NCT02239757|Experimental|Left radial approach|Primary PCI performed through left radial approach.
89484087|NCT03255213|Experimental|Late Onset Pompe Disease who have tongue weakness|
89484088|NCT02239835|Experimental|TPV low dose + RTV low dose|
89484089|NCT02239835|Experimental|TPV high dose + RTV low dose|
89484090|NCT02239835|Active Comparator|SQV + RTV high dose|
89484091|NCT02239913|Placebo Comparator|Placebo|Subjects will be maintained on oral placebo. Subjects will be maintained on placebo and phentermine during placebo maintenance. Cocaine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.
89484092|NCT02239913|Experimental|Topiramate Dose 1|Subjects will be maintained on the low topiramate dose. Subjects will be maintained on placebo and phentermine during maintenance on the low dose of topiramate. Cocaine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.
89484093|NCT02239913|Experimental|Topiramate Dose 2|Subjects will be maintained on the high topiramate dose. Subjects will be maintained on placebo and phentermine during maintenance on the high dose of topiramate. Cocaine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.
89484094|NCT03243201|Experimental|Colloidal Silver|The colloidal silver arm will administer intranasal colloidal silver, 2 sprays each nostril twice daily, for a total volume of 0.8ml per day (8 mcg of silver per day), for 28 days.
89484095|NCT03243201|Placebo Comparator|Purified Water|The placebo arm will administer intranasal purified water, 2 sprays each nostril twice daily, for a total volume of 0.8ml per day, for 28 days.
89484096|NCT03243435||Native 1,5 Tesla breast MRI group|From all patients a 1,5 Tesla MRI of the breast will be obtained
89484097|NCT02239055||Focus Group 1|Staff Perceptions
89484098|NCT02239055||Focus Group 2|Staff Perceptions
89484099|NCT03070418|Experimental|Abdulhai|One show man technique, it is the same of AO Dynamic Hip Screw (DHS) technique using 4 holes plate or smaller, in this case it is enough to make just a 3 cm skin incision.
89484100|NCT03243357|Experimental|TF Adaptive (First Apical Binding File)|Endodontic treatment(teeth with periapical periodontitis&radiolucence).Local anesthesia (4%Articaine with1:100,000 epinephrine),isolation with rubber dam&standard access cavity preparation.Using 2.5 %sodium hypochlorite,canal negotiation,glide path,coronal flaring with Sx(ProTaper),determining working length&first apical binding file.Intervention: Root canal instrumentation:TF Adaptive system with enlargement of the root canal performed with up to 3 files larger than the diameter of the initial apical file. Irrigation2.5%NaOCl&EDTA (Ethylenediaminetetraacetic acid)under activation with ultrasound. Irrigation with saline solution and placement of medication based on calcium hydroxide. After 14 days, obturation: gutta-percha&epoxy resin sealer.
89484101|NCT03243357|Other|TF Adaptive (Control)|In the control group,endodontic treatment (teeth with periapical periodontitis&radiolucence). Local anesthesia(4% Articaine with 1:100,000 epinephrine), isolation with rubber dam&standard access cavity preparation. Using 2.5 % sodium hypochlorite, canal negotiation, determining working length&glide path. Root canal instrumentation:TF Adaptive system according to the protocol recommended by the manufacturer.Irrigation 2.5% NaOCl & EDTA(Ethylenediaminetetraacetic acid)under activation with ultrasound. Irrigation with saline solution and placement of medication based on calcium hydroxide. After 14 days, the canals will be obturated with gutta-percha and epoxy resin sealer.
89484102|NCT03576521|Experimental|Ocoxin-Viusid®|The CT with Adriamycin 60 mg per m2 of Body Surface (BS) and Cyclophosphamide Infusion intravenous every 21 days, up to a total of 4 to 6 cycles + OV nutritional supplement.
89484103|NCT03576521|Placebo Comparator|Placebo|The QT Adriamycin scheme 60 mg per m2 of Body Surface (SC) and Cyclophosphamide Infusion intravenous every 21 days, up to a total of 4 to 6 cycles + a placebo of the OV nutritional supplement.
89484104|NCT03255135|Experimental|HIFU|Patients with untreated recent diagnosed localized prostate cancer candidates of focal therapy.
89484105|NCT03578315|Experimental|Solar lentigo|25 Patients with Solar lentigo
89484106|NCT03578315|Experimental|Nevus zygomaticus|25 Patients with Nevus zygomaticus
88952422|NCT03883880|Experimental|Epigallocatechin gallate|Epigallocatechin gallate solutions will be provided to participants to rinse with daily for two weeks. A control solution will be provided for two weeks as well. Order will be counterbalanced across participants and groups.
88952423|NCT03883880|Experimental|Linoleic acid|Linoleic acid emulsion will be provided to participants to rinse with daily for two weeks. A control solution will be provided for two weeks as well. Order will be counterbalanced across participants and groups.
88952424|NCT03883880|Experimental|Capsaicin|Capsaicin solutions will be provided to participants to rinse with daily for two weeks. A control solution will be provided for two weeks as well. Order will be counterbalanced across participants and groups.
88952425|NCT03832946|Experimental|A. GB0139 3 mg once a day|Inhalation of GB0139
88952426|NCT03832946|Placebo Comparator|B. Placebo once a day|Inhalation of Placebo
88952427|NCT03764618|Experimental|Fostamatinib|Initial dose is 100 mg by mouth (PO) twice a day (bid). At week 4 dose will be increased to fostamatinib 150 mg PO bid if subjects have adequately tolerated the study drug in the opinion of the Investigator.
88952428|NCT03764618|Placebo Comparator|Placebo|Initial dose is 100 mg by mouth (PO) twice a day (bid). At week 4 dose will be increased to placebo 150 mg PO bid if subjects have adequately tolerated the study drug in the opinion of the Investigator.
88952429|NCT03721016|Experimental|MT10109L Dose 1 + Placebo|MT10109L Dose 1 will be injected into the Glabellar Lines (GL) and Placebo into the Lateral Canthal Lines (LCL): initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period.
88952430|NCT03721016|Experimental|MT10109L Dose 1 + MT10109L Dose 2|MT10109L Dose 1 will be injected into the Glabellar Lines (GL) and MT10109L Dose 2 into the Lateral Canthal Lines (LCL): initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period.
88952431|NCT03721016|Placebo Comparator|Placebo|Placebo will be injected into the Glabellar Lines (GL) and into the Lateral Canthal Lines (LCL): initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period.
88952432|NCT03707340||Breast Cancer Pts with hyposexual desire disorder/HSDD|
88952433|NCT03649659|Experimental|Silver Diamine Fluoride (SDF)|SDF will be applied to the affected teeth twice during the study. Once at screening/baseline and again at the 6-month visit.
88952434|NCT03649659|Placebo Comparator|Placebo|The placebo will be applied to the affected teeth twice during the study. Once at screening/baseline and again at the 6-month visit.
88952435|NCT03620981|Experimental|Brexpiprazole, 1mg/day|Drug: 1mg/day Once daily for 10 weeks
88952436|NCT03620981|Experimental|Brexpiprazole, 2mg/day|Drug: 2mg/day Once daily for 10 weeks
88952437|NCT03620981|Placebo Comparator|Placebo|Drug: Placebo (0mg/day) Once daily for 10 weeks
88952438|NCT03501238|Experimental|BSG|Participant receives bovine milk, then milk substitute, then milk substitute treated with gelatin
88952439|NCT03501238|Experimental|BGS|Participant receives bovine milk, then milk substitute with gelatin, then milk substitute
88952440|NCT03501238|Experimental|SBG|Participant receives milk substitute, then bovine milk, then milk substitute with gelatin.
88952441|NCT03501238|Experimental|SGB|Participant receives milk substitute, then milk substitute with gelatin, then bovine milk
88952442|NCT03501238|Experimental|GSB|Participant receives milk substitute with gelatin, then milk substitute, then bovine milk.
88952443|NCT03501238|Experimental|GBS|Participant receives milk substitute with gelatin, then bovine milk, then milk substitute.
89484107|NCT02455713||Intervention|Alter PEEP and PIP and measure hemodynamic outcomes.
88952444|NCT03486106|Placebo Comparator|Headphones without music|Participants in the control group will receive noise-cancelling wireless headphones that will not play any noise throughout the procedure. They will also receive propofol for sedation as needed.
89484108|NCT03576287|Experimental|apremilast|apremilast standard doses
89484109|NCT02455869|Placebo Comparator|Placebo group|SRP plus placebo SRP was done for all the subjects. Placebo gel was delivered subgingivally into the pocket
89484110|NCT02455869|Active Comparator|Atorvastatin group|SRP plus Atorvastatin SRP was done for all the subjects. Atorvastatin was delivered in the pocket subgingivally
89484111|NCT02455869|Active Comparator|Alendronate Group|Alendronate SRP plus Alendronate SRP was done for all the subjects. Alendronate was delivered in the pocket subgingivally
89484112|NCT03574025||Cardiac Arrest Questionnaire|Children who will survive 3 months after Cardiac Arrest
89484113|NCT03246867|Experimental|Isolytic stretching group|The participants in this group will receive isolytic stretching in modified cross body position.
89484114|NCT03246867|Experimental|Static stretching group|The participants in this group will receive static stretching in modified cross body position.
89484115|NCT03246867|Active Comparator|Control group|The participants in this group will receive no stretching. They will only be evaluated.
89484116|NCT03578159||Arsha Vidya Chhatralaya|Chhatralaya is residential setting for children 8 to 16 years old. It provides residence,food and education opportunities along with regular practice of Yoga, Spiritual sessions and vedic practices to learn and follow.
89484117|NCT03246945|Experimental|Study Arm|Patient-Parent Dyad receiving photography instructions prior to taking photographs of skin conditions
89484118|NCT03246945|No Intervention|Control Arm|Patient-Parent Dyad not receiving photography instructions prior to taking photographs of skin conditions
89484119|NCT03573869|Experimental|Cryoballoon ablation|A 28-mm cryoballoon (Arctic Front Advance™ Cardiac CryoAblation Catheter, Medtronic, Minneapolis, MN) will be employed. The cryoballoon catheter will be introduced into the left atrium, following a single transeptal puncture, through a 12F FlexCath steerable sheath (Medtronic), constantly flushed with heparinized saline. A circular mapping catheter (Achieve, Medtronic) will be advanced through the cryoballoon to the PV orifice and positioned as proximally as possible inside the vessel to record the PV potentials at baseline and monitor the isolation procedure in real time.
89484120|NCT03573869|No Intervention|Standard treatment|Standard treatment, including at least one rhythm control medication, on top of optimized rate control and HF treatment
89484121|NCT03576209|Active Comparator|Intervention Group|12 week intervention
89484122|NCT03576209|No Intervention|Control Group|No walking program
89484123|NCT03242811|Experimental|Examination by MRI|MRI scan of knee, ankle and wrist
89484124|NCT03578003|Experimental|Morning Bright Light Therapy|Subjects who engage in morning bight light therapy
89484125|NCT03578003|No Intervention|Control|Subjects who do not engage in morning bright light therapy
89484126|NCT03246555|Experimental|Fimasartan or Fimasartan/Hydrochlorothiazide|
89484127|NCT03246555|Active Comparator|Perindopril or Perindopril/Indapamide|
89484128|NCT03576053|Experimental|Histamine+cowhage+heat|
89484129|NCT03576053|Experimental|Histamine+cowhage+serotonin+pre-heating|
89484130|NCT03576053|Placebo Comparator|lidocaine and saline+heat|
89484131|NCT03246711||Totally fasting|Fasting each day from sunrise to sunset the whole month
89484132|NCT03246711||Partially fasting|means fasting from sunrise to sunset part of the month
89484133|NCT03246711||Non fasting|women who did not fast at all
89484134|NCT02239991|No Intervention|Historical control|Group of patients that had their coagulopathy secondary to the liver transplant treated based on conventional laboratory tests. Before the implementation of thromboelastometry.
89203598|NCT00561015|Experimental|TVR then Peg-IFN-alfa-2a + RBV (T2 & PR24) - Genotype 2|Participants who are never treated for chronic hepatitis C (inflammation of the liver) genotype 2 will receive telaprevir (TVR) 750 milligram (mg) tablet orally 3 times a day during investigational treatment phase from Day 1 to Day 15. Participants will then be treated with standard treatment regimen of pegylated interferon (Peg-IFN)-alfa-2a and ribavirin (RBV) from Day 15 to Week 26 (standard treatment phase). Each dose of pegylated interferon 180 microgram (mcg) will be administered as a subcutaneous injection once a week. RBV will be taken orally as 400 mg tablets 2 times a day. Total duration of treatment will be 26 weeks.
89484135|NCT02239991|Experimental|Intervention|Group of cirrhotic bleeding patients that are treated with a bed side, point of care protocol based on thromboelastometry to guide transfusion and manage coagulopathy
89484136|NCT03246633|Other|Perceptual Training|Single-Arm study, all participants will receive educational training via online modules and will be assessed after completion of the training.
89484137|NCT03242967|Experimental|Vadadustat|Oral tablet
89484138|NCT03242967|Active Comparator|Darbepoetin alfa|subcutaneous or intravenous
89484139|NCT03573713|Experimental|IPT-G (Treatment arm)|This arm will receive IPT-G for 12 weeks. Following IPT-G, this arm will go on to receive the Care Group intervention parallel to the control arm.
89484140|NCT03573713|Other|Control arm (Treatment as usual - Care Group)|This arm will receive assessment only at the beginning of the study (parallel to the start of IPT-G) and then receive the Care Group intervention after 12 weeks together with the IPT-G arm.
89484141|NCT01367665|Experimental|Vismodegib - Locally Advanced|Participants received vismodegib 150 mg orally once a day until one of the following occurs: Disease progression, intolerable toxicity most probably attributable to vismodegib, consent withdrawal, death, study termination by the Sponsor, or other reason deemed by the Investigator. vismodegib: 150 mg once daily until disease progression or unacceptable toxicity
89484142|NCT01367665|Experimental|Vismodegib - Metastatic|Participants received vismodegib 150 mg orally once a day until one of the following occurs: Disease progression, intolerable toxicity most probably attributable to vismodegib, consent withdrawal, death, study termination by the Sponsor, or other reason deemed by the Investigator. vismodegib: 150 mg once daily until disease progression or unacceptable toxicity
89484143|NCT02576847|Experimental|Treatment|Omiganan gel applied once daily
89484144|NCT02454621|Active Comparator|Control|"Participants read a brief statement designed to encourage them to quit smoking (We want you to plan to quit smoking). Participants are presented with a table with two columns and twenty rows. Twenty critical situations (temptations) are presented in the left hand column and 20 appropriate responses (processes of change) are presented in the right hand column (see Armitage, 2008). Participants are told that identifying situations in which they were tempted to smoke and identifying ways to overcome those temptations had been shown to promote smoking cessation and are asked to tick critical situations/appropriate responses that might be useful to them."
89484145|NCT02454621|Experimental|Volitional help sheet|"Participants read a brief statement designed to encourage them to quit smoking (We want you to plan to quit smoking). Participants are presented with a table with two columns and twenty rows. Twenty critical situations (temptations) are presented in the left hand column and 20 appropriate responses (processes of change) are presented in the right hand column (see Armitage, 2008). Participants are told that identifying situations in which they were tempted to smoke and identifying ways to overcome those temptations had been shown to promote smoking cessation. Implementation intentions are formed by linking critical situations with appropriate responses by drawing lines between critical situations and appropriate responses."
89484146|NCT03107949|Experimental|Lungpacer Diaphragm Pacing Therapy (DPTS)|The LIVE Catheter will be temporarily inserted (LIVE Catheter will be inserted into every patient enrolled and can stay in place for up to 30 days) into the left subclavian vein and connected to the Lungpacer Control Unit in order to perform diaphragm pacing to stimulate the phrenic nerves and activate the diaphragm 3 x a day on all patients until extubated/removed from mechanical ventilation or until day 30 whichever comes first.
89484147|NCT03242733||Hip fracture patients|Fasted elderly patients scheduled for hip fracture surgery except exclusion criteria are enrolled.
89484148|NCT03239379|Placebo Comparator|Placebo|Normal saline
89484149|NCT03239379|Experimental|BNZ132-1-40|PEGylated BNZ-1 for Injection
89484150|NCT03239457||Heberprot P treatment|Patients with diabetic foot ulcers treated with Heberprot P
89484151|NCT04487535|Other|Standard Total Knee Arthroplasty Surgery|Surgery performed by one orthopedic surgeon
89484152|NCT00075803|Active Comparator|Fluconazole|The dose of fluconazole is 400 mg by mouth or intravenous drip.
89484153|NCT00075803|Experimental|Voriconazole|The dose of oral voriconazole is 200 mg twice daily. When voriconazole must be given intravenously, it will be given at a dose of 200 mg every 12 hours for the duration of intravenous therapy.
89484154|NCT03242499|Experimental|Active|Lovastatin 80mg per day for 48 weeks.
89484155|NCT03242499|Placebo Comparator|Placebo|Placebo 80mg per day for 48 weeks.
89484156|NCT03254979|Experimental|Sequential engagement|Inter-professional collaborative practice directed by a local leader and an external facilitator to optimize the integration of a T2D primary prevention recommended clinical intervention. In this group, a sequential engagement of professional categories, initiated in nursing, which finally involves the whole professional groups of the center (eg. physicians, etc), will be followed
89484157|NCT03254979|Active Comparator|Global engagement|Inter-professional collaborative practice directed by a local leader and an external facilitator to optimize the integration of a T2D primary prevention recommended clinical intervention. In this group, a global strategy of engagement with the participation of all professionals from the beginning, will be followed
89484158|NCT03254823||Severe ME/CFS patients|patients with a clinical diagnosis of ME/CFS and are house or bed bound.
89484159|NCT03254823||Household controls|Healthy human participants who are either related/non-related to, living in the same household or in close proximity to, or providing care to the severe ME/CFS patient they are paired with. They are used as an environmental control.
89021233|NCT01051791|Experimental|Everolimus 10 mg daily|"The study of the efficacy of everolimus will proceed in two stages after the method of Simon1. In the first stage 15 patients will be accrued and treated. If 9 or fewer patients show clinical benefit the study will be terminated. If 10 or more patients show clinical benefit the study will proceed to the second stage, accruing an additional 26 patients. If the second stage is complete and a total of 29 or more patients show clinical benefit among the 41 patients treated, the treatment CBR for will be considered high enough to warrant further study. Conversely, if the evaluation of everolimus concludes at the first stage, or if 28 or fewer patients experience a clinical benefit after completing the second stage, the therapy will not be considered for further study.~1"
89021234|NCT01056510|Experimental|A|
89021235|NCT01056510|Experimental|B|
89484160|NCT02523911|Active Comparator|Simethicone Group|Early in the evening prior to colonoscopy, patients will be instructed to consume one 6 ounce bottle of oral sodium sulfate/potassium sulfate/magnesium sulfate (Suprep) solution (containing sodium sulfate 17.5 grams, potassium sulfate 3.13 grams, and magnesium sulfate 1.6 grams) diluted with 16 ounces of water over one hour. Over the next hour, the patient will be instructed to drink an additional 32 ounces of water. On the day of colonoscopy, the same procedure will be repeated. Patients will take 2.4 mL simethicone in a half glass of water immediately after consuming each dose of the Suprep. All of the bowel preparation solution and required water should be consumed at least 2 hours prior to colonoscopy.
89484161|NCT02523911|Placebo Comparator|Placebo Group|Early in the evening prior to colonoscopy, patients will be instructed to consume one 6 ounce bottle of oral sodium sulfate/potassium sulfate/magnesium sulfate (Suprep) solution (containing sodium sulfate 17.5 grams, potassium sulfate 3.13 grams, and magnesium sulfate 1.6 grams) diluted with 16 ounces of water over one hour. Over the next hour, the patient will be instructed to drink an additional 32 ounces of water. On the day of colonoscopy, the same procedure will be repeated. Patients will take 2.4 mL of placebo (identical in appearance to simethicone) in a half glass of water immediately after consuming each dose of the Suprep. All of the bowel preparation solution and required water should be consumed at least 2 hours prior to colonoscopy.
89484162|NCT03239223|Experimental|Dose 1 - Multiple Ascending Dose (MAD)|ABI-1968 or Placebo topical cream applied at Day 1, Day 8, Day 15 and Day 22
89484163|NCT03239223|Experimental|Dose 2 - Multiple Ascending Dose (MAD)|ABI-1968 or Placebo topical cream applied at Day 1, Day 8, Day 15 and Day 22
89484164|NCT03573635|Other|Supratube|Patient with orotracheal intubation and supratube device
89484165|NCT03573479||Pre-implementation cohort|This is the pre-implementation phase where a baseline documentation will take place about usual clinical practice, perceptions and attitudes of PICU staff and clinicians
89484166|NCT03573479||PICU Liber8 bundle|After the implementation of the bundle (the PICU Liber8 components) same measurements will be captured and analyzed comparatively.
89484167|NCT03575741||Patients|After suffering from a concussion patients will be investigated 48 h, 72 h, 120 h, 360 h and 720 h after sustaining the injury. Postural control will be measured using 7 different easy balance tests.
89484168|NCT03575741||Control|Healthy children will be measured in the very same way to collect data of possible matched controls.
89484169|NCT03572231||mirabegron|Participants will commence the OAB treatment with mirabegron that is prescribed by a physician in routine clinical practice.
89484170|NCT03572231||Antimuscarinics|Participants will commence the OAB treatment with one of the following antimuscarinics: solifenacin, darifenacin, imidafenacin, tolterodine, oxybutynin, trospium, fesoterodine or propiverine. The antimuscarinic is prescribed by a physician in routine clinical practice.
89484171|NCT02135029|Experimental|Bococizumab (PF-04950615;RN316)|Bococizumab (PF-04950615;RN316)
89484172|NCT02135029|Active Comparator|Atorvastatin|
89484173|NCT02135029|Placebo Comparator|Placebo|
89484174|NCT03575585|Experimental|Comparator: No Feedback, Standard Counselor|Patient assigned to a Standard Training counselor, completed the BEST assessment, but did NOT receive a feedback report.
89484175|NCT03575585|Experimental|Active1: Feedback, Standard Counselor|Patient assigned to a Standard Training counselor, completed the BEST assessment, and received a personalized feedback report.
89484176|NCT03575585|Experimental|Active2: No feedback, Enhanced Counselor|Patient assigned to a Enhanced Training counselor, completed the BEST assessment, but did NOT receive a feedback report.
89484177|NCT03575585|Experimental|Active3: Feedback, Enhanced Counselor|Patient assigned to a Enhanced Training counselor, completed the BEST assessment, and received a personalized feedback report.
89021236|NCT01051323||1|
89021237|NCT04321811||Participants|"Adult men and women currently in the United States and willing to provide written informed consent and:~who are feeling sick but have not tested positive for COVID-19~who are feeling sick and have tested positive for COVID-19~People who are not feeling sick but want to participate"
89021238|NCT01056276|Experimental|Treatment|Bendamustine, Bortezomib,and Dexamethasone for 8 cycles or 2 cycles beyond a confirmed complete response, assessed by IMWG criteria. Patients with stable disease and no intolerable toxicity may continue maintenance therapy with Bortezomib and Dexamethasone until disease progression or intolerable toxicity.
89021239|NCT01055886|Active Comparator|Nicotine Patch|Nicotine patch given pre-quit attempt at weeks 4 through 6
89021240|NCT01055886|Placebo Comparator|placebo patch|placebo patch given pre-quit from weeks 4 through 6
89021241|NCT01055613|Experimental|Experimental multi-purpose solution|Multi-purpose contact lens care solution.
89484178|NCT03575507|Experimental|Treatment Group|Treatment with the investigational device BTL EMSCULPT.
89484179|NCT03573245||intra-op single dose|intra-operative single dose of tranexamic acid
89484180|NCT03573245||intra-op dose and additional dose|intra-operative dose of tranexamic acid and additional dose 3 hours after
89203599|NCT00561015|Experimental|TVR with Peg-IFN-alfa-2a + RBV (T2/PR24) - Genotype 2|Participants who are never treated for CHC genotype 2 will receive TVR 750 mg tablet orally 3 times a day during investigational treatment phase from Day 1 to Day 15 along with standard treatment regimen of Peg-IFN-alfa-2a and RBV which will be continued in the standard treatment phase from Day 15 to Week 24. Each dose of Peg-IFN-alfa-2a 180 mcg will be administered as a subcutaneous injection once a week. RBV will be taken orally as 400 mg tablets 2 times a day. Total duration of treatment will be 24 weeks.
89203600|NCT00561015|Active Comparator|Pbo with Peg-IFN-alfa-2a + RBV (Pbo/PR24) - Genotype 2|Participants who are never treated for CHC genotype 2 will receive TVR matching placebo (Pbo) tablet orally 3 times a day during investigational treatment phase from Day 1 to Day 15 along with standard treatment regimen of Peg-IFN-alfa-2a and RBV which will be continued in the standard treatment phase from Day 15 to Week 24. Each dose of Peg-IFN-alfa-2a 180 mcg will be administered as a subcutaneous injection once a week. RBV will be taken orally as 400 mg tablets 2 times a day. Total duration of treatment will be 24 weeks.
89203601|NCT00561015|Experimental|TVR then Peg-IFN-alfa-2a + RBV (T2 & PR24) - Genotype 3|Participants who are never treated for CHC genotype 3 will receive TVR 750 mg tablet orally 3 times a day during investigational treatment phase from Day 1 to Day 15. Participants will then be treated with standard treatment regimen of Peg-IFN-alfa-2a and RBV from Day 15 to Week 26 (standard treatment phase). Each dose of Peg-IFN-alfa-2a 180 mcg will be administered as a subcutaneous injection once a week. RBV will be taken orally as 400 mg tablets 2 times a day. Total duration of treatment will be 26 weeks.
89203602|NCT00561015|Experimental|TVR with Peg-IFN-alfa-2a + RBV (T2/PR24) - Genotype 3|Participants who are never treated for CHC genotype 3 received TVR 750 mg tablet orally 3 times a day during investigational treatment phase from Day 1 to Day 15 along with standard treatment regimen of Peg-IFN-alfa-2a and RBV which will be continued in the standard treatment phase from Day 15 to Week 24. Each dose of Peg-IFN-alfa-2a 180 mcg will be administered as a subcutaneous injection once a week. RBV will be taken orally as 400 mg tablets 2 times a day. Total duration of treatment will be 24 weeks.
89203603|NCT00561015|Active Comparator|Pbo with Peg-IFN-alfa-2a + RBV (Pbo/PR24) - Genotype 3|Participants who are never treated for CHC genotype 3 will receive TVR matching Pbo tablet orally 3 times a day during investigational treatment phase from Day 1 to Day 15 along with standard treatment regimen of Peg-IFN-alfa-2a and RBV which will be continued in the standard treatment phase from Day 15 to Week 24. Each dose of Peg-IFN-alfa-2a 180 mcg will be administered as a subcutaneous injection once a week. RBV will be taken orally as 400 mg tablets 2 times a day. Total duration of treatment will be 24 weeks.
89021242|NCT01055613|Active Comparator|ReNu MultiPlus Multi-Purpose Solution|Multi-purpose contact lens care solution.
89021243|NCT04301804|Experimental|Dose level 1|Subjects will be randomised to receive a single dose of SHR6390 at Dose level 1
89203604|NCT00560937|Active Comparator|1|Pregnenolone
89203605|NCT00560937|Placebo Comparator|2|Placebo
89203606|NCT00945165|Experimental|Exercise|
89203607|NCT00945165|Experimental|No exercise|
89203608|NCT04012437|Experimental|Experimental|.The groups completed Sphincter Control Training over 8 weeks. The SCT consists of 8 different exercises into a mobile app and an educational videos. Its objective is to provide patients with greater knowledge, awareness, and control of the external urethral sphincter. The groups use of a masturbation aid device called Myhixel I from the spanish company New Wellness Concept SL.
89203609|NCT04012437|Active Comparator|Control|.The groups completed Sphincter Control Training over 8 weeks. The SCT consists of 8 different exercises into a video tutorial and an educational videos. Its objective is to provide patients with greater knowledge, awareness, and control of the external urethral sphincter.
89203610|NCT00945399|Experimental|Autologous Chondrocytes Implantation|
89203611|NCT00945399|Active Comparator|Microfracture|
89203612|NCT00941187||patients after a first episode of pulmonary embolism|
89203613|NCT04012359||Bullous emphysema|Participants with known bullous emphysema will undergo lung ultrasound according to standard of care clinical practice during a regular follow-up consultation or scheduled hospitalization.
89203614|NCT04012359||Pneumothorax|Participants hospitalized in pulmonary medicine units for the treatment of a pneumothorax will undergo lung ultrasound according to standard of care clinical practice.
89203615|NCT04012047|Active Comparator|Levcromakalim|
89203616|NCT04012047|Placebo Comparator|Saline|
89203617|NCT00941265|Other|levodopa 100 mg and benserazide 25 mg|2 weeks with Daily CAT on list A+ levodopa and benserazide
89203618|NCT00941265|Other|placebo|2 weeks with Daily CAT on list B + placebo.
89203619|NCT00941343|Experimental|1|XATRAL 10mg OD
89484181|NCT03573245||intra-op dose and perfusion|intra-operative dose of tranexamic acid followed by a continuous infusion during 6 hours.
88952445|NCT03486106|Experimental|Headphones with music|Participants in the experimental group will receive the same noise-cancelling wireless headphones but will be permitted to listen to the music of their choice while in the operating room. They will also receive propofol for sedation as needed.
88952446|NCT03434275|Experimental|N1539 30 mg|N1539 (meloxicam injection for IV use) 30 mg every 24 hours
88952447|NCT03434275|Placebo Comparator|IV Placebo|IV Placebo every 24 hours
89484182|NCT02241161|Active Comparator|plantaricin a - rejuvenating cream|single application on an area of 17,5 cm2, on the forearm, after skin stripping, and left absorbing on the skin for at least 15 minutes
89484183|NCT02241161|Active Comparator|plantaricin a - rejuvenating serum|single application on an area of 17,5 cm2, on the forearm, after skin stripping, and left absorbing on the skin for at least 15 minutes
89484184|NCT02241161|Active Comparator|plantaricin a - antioxidant serum|single application on an area of 17,5 cm2, on the forearm, after skin stripping, and left absorbing on the skin for at least 15 minutes
89484185|NCT02241161|Active Comparator|plantaricin a (rejuvenating cream +rejuvenating serum)|single application on an area of 17,5 cm2, on the forearm, after skin stripping, and left absorbing on the skin for at least 15 minutes
89484186|NCT02241161|Active Comparator|plantaricin a (rejuvenating cream + antioxidant serum)|single application on an area of 17,5 cm2, on the forearm, after skin stripping, and left absorbing on the skin for at least 15 minutes
89484187|NCT02135185|Experimental|Rehabilitation effort|custom work endurance combining dietary management adapted to the nutritional status and an APA. Included patients benefit from support for 19 weeks from the start of treatment
89484188|NCT02135185|Active Comparator|Control|Control with dietary management adapted to the nutritional status
89484189|NCT03573167|Active Comparator|In-Person Motivational Interviewing|In-Person Motivational Interviewing (MI) is the standard form of MI treatment delivered in person face to face at the primary care office. MI is a type of brief intervention that uses open-ended questions, affirmations, reflective listening, and summarizing as key tools and has been shown to treat a range of problem behaviors, including alcohol use disorders, by helping participants to identify and address ambivalence towards changing the behavior. MI is delivered in a communicative style that promotes individual autonomy and improves self-efficacy. The investigator provides counseling in-person with the participant for one session of MI lasting approximately 30 minutes.
89484190|NCT03573167|Experimental|Mobile MI|Mobile Motivational Interviewing (MI) is delivered by a counselor over the mobile phone, rather than in-person (face-to-face). MI is a type of brief intervention that uses open-ended questions, affirmations, reflective listening, and summarizing as key tools and has been shown to treat a range of problem behaviors, including alcohol use disorders, by helping the patient to identify and address ambivalence towards changing the behavior. MI is delivered in a communicative style that promotes individual autonomy and improves self-efficacy. The investigator provides counseling over the mobile phone with the participant for one session of mobile MI lasting approximately 30 minutes.
89484191|NCT03573167|No Intervention|Waitlist Control|After consenting to participate in the study, the Waitlist control participants receive no intervention for one (1) month, and then the Waitlist control participants are contacted by the investigators for follow up..
89484192|NCT02137057||control ( patients without diabetes)|patients without diabetes
89484193|NCT02137057||DM ( patients with diabetes)|patients with diabetes
89484194|NCT02240147|Experimental|home-based exercise training|
89484195|NCT02240147|No Intervention|Control group|
89484196|NCT02135263|Experimental|Methylphenidate|
89484197|NCT02135263|Experimental|Enalapril|
89484198|NCT03572075|Experimental|Group A|assessment of symptoms at the first medical examination; standard care protocol; pelvic floor physiotherapy; assessment of symptoms after four months
89484199|NCT03572075|Experimental|Group B|assessment of symptoms at the first medical examination; standard care protocol; assessment of symptoms after four months
89484200|NCT02135341|Experimental|Group A: Botulinum toxin A|BoNT-A 100 units in normal saline 10ml, suburothelial injection at 20 sites of bladder wall in single treatment
89484201|NCT02135341|Experimental|Group B: Botulinum toxin A|BoNT-A 100 units in normal saline 10ml, suburothelial injection 50 U in 10 sites and 50 U urethral injections in 5 sites
89484202|NCT03573011|Experimental|2.0 ± 0.2 MBq/kg [18F]PSMA-11 dosing group|"To define the optimal [18F]PSMA-11 scan protocol, the quality of the PET images from patients that received 2.0 ± 0.2 MBq/kg will be compared to the images from patients that received 4.0 ± 0.4 MBq/kg.~Patients in this study arm will receive 2.0 ± 0.2 MBq/kg for acquiring the [18F]PSMA-11 scan. All other study parameters and procedures are identical to those in the other study arm.~As for the use of radiopharmaceuticals, the ALARA ('as low as reasonably achievable') principle must be applied, this study arm is considered to be the reference."
89484203|NCT03573011|Experimental|4.0 ± 0.4 MBq/kg [18F]PSMA-11 dosing group|Concerning the dose of [18F]PSMA-11, the patients in this study arm will receive 4.0 ± 0.4 MBq/kg for the [18F]PSMA-11 scan. All other study parameters and procedures are identical to those in the other study arm
89484204|NCT03572855|Experimental|Scoliosis Brace|The Peak Scoliosis Brace designed to alleviate pain in adult patients with chronic pain secondary to scoliosis.
88952448|NCT03400371||Patients diagnosed with JME|People who meet the eligibility requirements and have been diagnosed with juvenile myoclonic epilepsy.
88952449|NCT03400371||Controls|People without a lifetime history of seizures.
88952450|NCT03354013|Experimental|AOA, genetic screening, calcium pattern|"Clinical setting: Patients will undergo ICSI-AOA. Furthermore, patients will give a saliva sample to do genetic screening. Genes important during oocyte activation and embryo development will be investigated.~Also, calcium pattern analysis of the patients' spermatozoa will be executed."
88952451|NCT03348423|Experimental|DEX-IN 50 µg|Dexmedetomidine Intranasal Spray
88952452|NCT03348423|Active Comparator|Fentanyl 50 µg|Intravenous Fentanyl
88952453|NCT03348423|Placebo Comparator|Placebo|Placebo
88952454|NCT03299322|Placebo Comparator|Control Group|80 participants will take oral therapy of 9.25 g Jia Wei Yang He granule Placebo twice a day for 28 consecutive days and also standard therapy of inhaled corticosteroid or beta2-agonist.
88952455|NCT03299322|Experimental|High dose Treatment Group|Participants in high Jia Wei Yang He formula group will receive Jia Wei Yang He granule 18.5g twice a day for 28 consecutive days and also standard therapy of inhaled corticosteroid or beta2-agonist.
89484205|NCT03549637|Experimental|Psychiatric population|"At inclusion: Patients will have A Lipid Panel Test, other biological analyzes and a clinical assessment. In case of a low LDL-C level (≤ 0, 50 g/L), genetic analyzes will be performed to screen for genetic forms of hypobetalipoproteinemia (HBL).~At 2- 4 weeks: for patients with HBL (LDL-C ≤ 0,50 g/L with no secondary cause of LDL-C reduction), another Lipid Panel Test will be performed to confirm the maintenance of the low LDL-C level.~At 6 months : Patients with a HBL will perform a full biological examination, and the LDL-C levels and genetic analyzes will be confirmed. A dietary survey will be performed, together with a psychiatric assessment. The same numbers of matched controls will performed a quick telephone interview to collect the psychiatric characteristics."
89484206|NCT02137135|Experimental|follicular phase|Visual anlogue score vas used to evaluate pain. The anxiety/depression scale (HAD) was used to assess anxiety and depression. The SF 12 test (SHORT FORM 12) was used to evaluate quality of life.
89484207|NCT02137135|Active Comparator|luteal phase|Visual anlogue score vas used to evaluate pain. The anxiety/depression scale (HAD) was used to assess anxiety and depression. The SF 12 test (SHORT FORM 12) was used to evaluate quality of life.
89484208|NCT03575273|Experimental|Opioid dependence receiving methadone|Patients with a history of opioid dependence receiving methadone maintenance therapy will be administered Sniffin' Sticks Odor Identification and Hedonic Scale, Sucrose Taste Preference Assessment, Food Preferences Task, Progressive Ratio Task, Clinical Electrophysiology, and Standardized Meal and Hunger and Satiety Ratings
89484209|NCT03575273|Experimental|Opioid dependence not on methadone|Patients with a history of opioid dependence not current receiving methadone maintenance therapy will be administered Sniffin' Sticks Odor Identification and Hedonic Scale, Sucrose Taste Preference Assessment, Food Preferences Task, Progressive Ratio Task, Clinical Electrophysiology, and Standardized Meal and Hunger and Satiety Ratings
89484210|NCT03575273|Active Comparator|Healthy controls|Healthy controls without history of opioid use will be administered Sniffin' Sticks Odor Identification and Hedonic Scale, Sucrose Taste Preference Assessment, Food Preferences Task, Progressive Ratio Task, Clinical Electrophysiology, and Standardized Meal and Hunger and Satiety Ratings
89484211|NCT02129335||stress|patient with glioblastoma diagnosis and partners
89484212|NCT02239523|Active Comparator|Letter Group|Patients will be given discharge letter that includes recommendation to discuss further testing and treatment with their primary care physician.
89484213|NCT02239523|Experimental|Intervention Group|Patients will be given a pamphlet about osteoporosis and importance of treatment, have a bone density test (DEXA) arranged, be given a specific medication recommendation and monthly followup phone calls.
89484214|NCT02253043|Experimental|Deep Brain Stimulation|DBS Implant and stimulation
89484215|NCT03575117|Experimental|NCI HYT--GA + CSM--Be Well|"Participants who view the Common Sense Model (CSM) Be Well text and image communication will be invited to receive two sets of daily text messages: (1) one text message and one image per day and (2) National Cancer Institute (NCI) HealthyYouTXT-Get Active (HYT-GA) program that is delivered 2-5 times daily for 6 weeks. After baseline and at timepoint 2, participants will view a slide presentation with imagery and text related to colorectal cancer risk and sedentary lifestyle. The same messages will be delivered as a drip campaign alongside the NCI HYT-GA text messaging program."
89484216|NCT03575117|Other|NCI HYT--GA + ACS usual messages|Adapted American Cancer Society (ACS) informational messages about colorectal cancer risk and lifestyle will be invited to receive one set of daily text messages, NCI HealthyYouTXT-Get Active (HYT-GA) program that is delivered 2-5 times daily for 6 weeks. After baseline and at timepoint 2, participants will view an informational slide presentation that is based on adapted language from American Cancer Guidelines related to cancer prevention and physical activity (https://www.cancer.org/healthy/eat-healthy-get-active/acs-guidelines-nutrition-physical-activity-cancer-prevention.html).
89484217|NCT02129413|Experimental|Delta system treatment|
89484218|NCT03575039|Experimental|Single arm clinical investigation|Subjects in experimental group will be implanted the VitaFlow II Transcatheter Aortic Valve System.
89484219|NCT02137213|Experimental|Arm A: Naloxone then placebo|Subjects assigned to Arm A will receive methadone with naloxone for one week and then methadone with placebo for one week
89484220|NCT02137213|Experimental|Arm B: Placebo then naloxone|Subjects assigned to Arm B will receive methadone with placebo for one week and then methadone with naloxone for one week
89484221|NCT03574961|Experimental|e-Support Group|Participants in this arm will receive the treatment, 12 weeks of 1-hr weekly moderated e-Support sessions.
89484222|NCT03574961|Placebo Comparator|e-Journaling Placebo|Participants in this arm will complete 12 weeks of 1-hr weekly online journaling activities.
89484223|NCT02129491||Pediatric Stroke and Hemiplegia|Any infant or child with acute stroke or hemiplegia
89484224|NCT03571919|Placebo Comparator|Control|Will receive normal saline bolus and infusion and have sham lab draws every 8 hours.
89484225|NCT03571919|Active Comparator|Lidocaine|Will receive lidocaine bolus and infusion and have lidocaine lab draws every 8 hours.
89484226|NCT02135575|Experimental|Premenopausal women|The Premenopausal women are randomized to exercise by spinning (cycle)
89484227|NCT02135575|Experimental|Postmenopausal women|The Postmenopausal women are randomized to exercise by spinning (cycle)
89484228|NCT03570671|Experimental|Spasm positive|Ergonovine-induced coronary spasm provocation test positive: defined as transient, total, or sub-total occlusion (>90% stenosis) of a coronary artery with symptoms of myocardial ischemia (angina pain and ischemic ECG change).
88952456|NCT03299322|Experimental|Low dose Treatment Group|Participants in high Jia Wei Yang He formula group will receive Jia Wei Yang He granule 9.25g twice a day for 28 consecutive days and also standard therapy of inhaled corticosteroid or beta2-agonist.
88952457|NCT03262142|Active Comparator|Standard antibiotic treatment|Intravenous Piperacillin/tazobactam + oral Ciprofloxacin for 14 days
88952458|NCT03262142|No Intervention|Antibiotic-free treatment|No antibiotic treatment
88952459|NCT03228134|Experimental|Hanxiao treatment group|80 patients belongs to Hanxiao type of asthma will take Ke Chuan Liu Wei Granule oral therapy twice everyday for 28 days and receive background therapy of ICS and beta2-agonist.
88952460|NCT03228134|Sham Comparator|Hanxiao control group|80 patients belongs to Hanxiao type of asthma will take Ke Chuan Liu Wei Granule placebo oral therapy twice everyday for 28 days and receive background therapy of ICS and beta2-agonist.
88952461|NCT03228134|Experimental|Xuxiao treatment group|80 patients of deficiency type of asthma will take Yang He Ping Chuan Granule oral therapy thrice everyday for 28 days and background therapy of ICS and beta2-agonist.
88952462|NCT03228134|Sham Comparator|Xuxiao control group|80 patients of deficiency type of asthma will take Yang He Ping Chuan Granule placebo oral therapy thrice everyday for 28 days and background therapy of ICS and beta2-agonist.
88952463|NCT03150810|Experimental|Arm A (Dose Escalation) TMZ Pulse Dosing|Participants receive continuous BGB-290 and escalating flat doses of 40mg, 80mg, 100mg, 120mg (as 20 mg capsules) daily administered orally up to the maximum tolerated dose (MTD) of TMZ on Days 1 - 7 of a 28-day cycle.
88952464|NCT03150810|Experimental|Arm B (Dose Escalation) TMZ Continuous Dosing|Participants receive continuous BGB-290 and escalating flat doses of 40mg, 80mg, 100mg, 120mg (as 20 mg capsules) daily administered orally up to the maximum tolerated dose (MTD) of TMZ on Days 1 - 28 of a 28-day cycle.
88952465|NCT03150810|Experimental|Dose Expansion, 6 cohorts|Participants receive continuous BGB-290 and TMZ at the recommended phase 2 dose (RP2D) and schedule in 28 day cycles
89484229|NCT03570671|Placebo Comparator|Spasm negative|Suspected vasospastic angina subjects with negative ergonovine provocation test are considered as reference modality.
89484230|NCT02252809|Active Comparator|adalimumab|adalimumab 40 mg by subcutaneous way 7 days before endotoxin inhalation
89484231|NCT02252809|Active Comparator|methylprednisolone|methylprednisolone 20 mg daily , 7 days before endotoxin inhalation
89484232|NCT02252809|No Intervention|control|no intervention, 7 days before endotoxin inhalation
89484233|NCT02137291||Left-sided double-lumen tube|Lung isolation with a left-sided double-lumen tube (BronchoCath, Mallinckrodt Medical, Cornamaddy, Athlone, Westmeath, Ireland)
89484234|NCT02137291||Modified right-sided double-lumen tube|Right-sided double-lumen tube modified in accordance with Bussières et al. in Can J Anesth 2007
89484235|NCT03571685|Experimental|Sustainable Early Episode Clinic Model of Care|The model of care given in the sustainable early episode clinic study, provides early intense intervention, with an ongoing maintenance phase in an outpatient setting.
89484236|NCT03570593|No Intervention|Retrospective Group|
89484237|NCT03570593|Experimental|Prospective Group|
89484238|NCT02137525|Active Comparator|Morphine 6 mg|Placebo Sublingual Spray (PSS) + Intravenous Morphine (IVM 6 mg), every 30 minutes for two hours as needed (or until rescue), maximum exposure morphine 30 mg
89484239|NCT02137525|Experimental|Fentanyl 100 µg|Intravenous Placebo (IVP) + Fentanyl Sublingual Spray (FSS 100 µg), every 30 minutes for two hours as needed (or until rescue), maximum exposure fentanyl 500 µg
89484240|NCT02137525|Experimental|Fentanyl 200 µg|Intravenous Placebo (IVP) + Fentanyl Sublingual Spray (FSS 200 µg), every 30 minutes for two hours as needed (or until rescue), maximum exposure fentanyl 1000 µg
89484241|NCT02137525|Experimental|Fentanyl 400 µg|Intravenous Placebo (IVP) + Fentanyl Sublingual Spray (FSS 400 µg), every 30 minutes for two hours as needed (or until rescue), maximum exposure fentanyl 2000 µg
89484242|NCT02842151|Other|Manifest refraction|Manifest refraction performed by autorefraction (automated) and manual procedures (standard). Subject implanted with ACRYSOF® IQ Monofocal IOL Model SN60WF. Autorefraction performed by Topcon® KR-1W Wave-Front Analyzer.
89484243|NCT02135731|No Intervention|Paper|Usual care -medication review on paper
89484244|NCT02135731|Experimental|Computer|Medication review software with pictures
89484245|NCT02244593|No Intervention|Mammography screening only|"This group will receive their standard of care mammogram only. Participants in this arm will not receive the FAST MRI.~Participants will complete 4 questionnaires at 3 time points: enrollment; 2 weeks after they receive their mammogram; 6 months after their mammogram."
89484246|NCT02244593|Experimental|FAST MRI and mammogram screening|Patients in this group will receive Breast MRI and annual mammography. Participants will complete 4 questionnaires at 3 time points: enrollment; 2 weeks after they receive their mammogram; 6 months after their mammogram. The intervention is the addition of the FAST Breast MRI.
89484247|NCT02135809|Experimental|FCSEMS|Patients will receive the WallFlex Pancreatic Stent.
89484248|NCT02137681|Experimental|2 cycles|2 cycles RTX
89484249|NCT02137681|Active Comparator|standard 4 cycles|standard 4 cycles RTX
89484250|NCT02842073|Experimental|Naltrexone and Buproprion|Investigators will use standard clinical doses of bupropion-XL 300 mg/d (lower seizure risk) and naltrexone 50 mg/d dispensed by the UNC Investigational Drug Services. Bupropion XL will be initiated at 150 mg/d on Days 1-4 and increased to 300 mg/d for Days 5-84. Naltrexone will be initiated at 25 mg/d from Days 7-9 and then go to 50 mg/d for Days 10-84.
89484251|NCT02135887||MB-6+FOLFOX chemotherapy|MB-6, 6 capsules tid be taken with meals plus FOLFOX chemotherapy, will be given for 18 weeks
89484252|NCT02135887||Placebo+FOLFOX chemotherapy|Placebo, 6 capsules tid be taken with meals plus FOLFOX chemotherapy, will be given for 18 weeks
89484253|NCT03572777|Active Comparator|Concomitant therapy|Amoxicillin ('Amoksicilin') 1 g bid, metronidazole ('Medazol')500 mg bid, clarithromycin ('Makcin')500 mg bid and esomeprazole ('Emanera')40 mg bid for 14 days.
89484254|NCT03572777|Active Comparator|Hybrid therapy|Amoxicillin ('Amoksicilin') 1 g bid and esomeprazole ('Emanera') 40 mg bid for 14 days, with metronidazole ('Medazol')500 bid and clarithromycin ('Makcin') 500 mg bid for the last 7 days.
89531886|NCT04975178|Experimental|MTBVAC|"Both MTBVAC and BCG vaccines are administered by intradermal route in the left deltoid region. One 0.05 mL reconstituted dose of MTBVAC will be defined based on the phase IIa results.~MTBVAC is manufactured by Biofabri. MTBVAC is formulated (1.5 - 8.5 x104 CFU/dose, 1.5 - 8.5 x105 CFU/dose or 1.5 - 8.5 x106 CFU/dose (to be selected) and presented as a lyophilised pellet in 20 dose vials (0.05 mL/dose, after reconstitution with sterile water for injection). MTBVAC vaccine will be released and distributed by BIOFABRI, and imported to the sites following approval by the local regulatory authority. MTBVAC vaccine must be stored at +2°C to +8°C. Reconstituted MTBVAC vaccine must be stored at +2ºC to +8ºC and administered as soon as possible, within 4 hours of reconstitution. A single vaccine vial will be used for each participant."
88952466|NCT03133273|No Intervention|Usual care|Patient is followed within the usual care for stage 4 colorectal cancer
88952467|NCT03133273|Experimental|Oncogramme®|For patients in the Oncogramme® group, chemotherapy will be adapted to Oncogramme® results.
88952468|NCT03117998|Experimental|35 mg REMD-477|Administered as a repeated subcutaneous (SC) doses in subjects with Type 1 Diabetes
88952469|NCT03117998|Experimental|70 mg REMD-477|Administered as a repeated SC doses in subjects with Type 1 Diabetes
88952470|NCT03117998|Placebo Comparator|Matching placebo|Administered as a repeated SC doses in subjects with Type 1 Diabetes
88952471|NCT03114865|Experimental|Post-alloHSCT Maintenance|Blinatumomab will be administered as a continuous intravenous (IV) infusion over four weeks followed by a two-week treatment free interval. It is recommended that patients are hospitalized at least during the first three days of the first cycle and the first two days of the second cycles.
88952472|NCT03100370|Experimental|tsDCS-Anodal & robotic arm training (RAT), then tsDCS-Cathodal & RAT, then tsDCS-Sham & RAT|anodal tsDCS over cervical spine, 2.5mA for 20 minutes
88952473|NCT03100370|Experimental|tsDCS-Anodal & robotic arm training (RAT), then tsDCS-Sham & RAT, then tsDCS-Cathodal & RAT|cathodal tsDCS over cervical spine, 2.5mA for 20 minutes
88952474|NCT03100370|Experimental|tsDCS-Cathodal & robotic arm training (RAT), then tsDCS-Anodal & RAT, then tsDCS-Sham & RAT|sham tsDCS over cervical spine, 2.5mA for 20 minutes
88952475|NCT03100370|Experimental|tsDCS-Cathodal & robotic arm training (RAT), then tsDCS-Sham & RAT, then tsDCS-Anodal & RAT|
88952476|NCT03100370|Experimental|tsDCS-Sham & robotic arm training (RAT), then tsDCS-Anodal & RAT, then tsDCS- Cathodal & RAT|
88952477|NCT03100370|Experimental|tsDCS-Sham & robotic arm training (RAT), then tsDCS-Cathodal & RAT, then tsDCS-Anodal & RAT|
89484255|NCT02253277|Experimental|Nilotinib and Ruxolitinib|The study included two strata, which were to be treated in parallel. The first stratum consisted of CML-patients in CP, which had been on nilotinib treatment before entering the study. These patients did not optimally respond to the previous treatment. The second stratum consisted of patients with CML in AP or BC and patients with relapsed/refractory Ph+ ALL and Ph+ ALL patients with MRD, with or without previous nilotinib treatment. Patients were treated with 300mg nilotinib BID during the escalation phase (12 months) with increasing doses of ruxolitinib. The dose expansion phase (12 months) began following the determination of the MTD of the combination and the decision to explore the cohort for confirmation of RPIID. In this phase, safety and tolerability of the MTD and/or potential RPIID was to be further evaluated, with the purpose of establishing that this dose is suitable for use in this patient group.
89484256|NCT02129569|Experimental|Arm I (psychoeducational and behavioral interventions)|Participants meet with a nurse in-person for approximately 30 minutes to receive information about strategies for cognitive self-management of distress and an individualized walking prescription to gradually increase their walking to 30 minutes per day, 5 times per week. Participants wear a pedometer for at least 3 consecutive days during weeks 1, 6, and 12. Participants are also contacted by the nurse via telephone at 1 and 3 weeks for supplemental counseling support.
89484257|NCT02129569|Active Comparator|Arm II (control)|Participants meet with a nurse in-person for approximately 20 minutes to receive NCI educational booklets and a link to the ACS website. Participants are also contacted by the nurse via telephone at 1 and 3 weeks but the calls are primarily social in nature and do not include counseling support.
89484258|NCT02524067|Experimental|Intervention|Intervention: Circadian lighting, systematic information, music, foreclosure of the individual patient
89484259|NCT03571529|Active Comparator|Robotic rehabilitation|"Active Comparator: Robotic rehabilitation~Protocol with EMG-driven hand exoskeleton (Hand of Hope):~Warm-up: 10 min passive mode 2 min resting~Training: According to residual muscle power:~10 min active-assistive, 2 min resting, 10 min Active-assistive or~5 min active, 2 min resting, 15 min active assistive or~10 min active, 2 min resting, 10 min active and~10 min window cleaning game Robotic rehabilitation will be applied 5 times a week; Totally 15 sessions (3 weeks). Conventional physiotherapy also will be performed to the robotic rehabilitation group."
89484260|NCT03571529|Active Comparator|conventional physiotherapy|"Conventional Physiotherapy will be performed to the both group 5 sessions a week and totally 15 sessions (3 weeks).~Conventional physiotherapy will include neurophysiological approaches. Each session will last around 1,5 hours."
89484261|NCT05579353||cancer group|
89484262|NCT05579353||control group|
89484263|NCT02137993|Experimental|A-prexa|A-prexa 5, 10mg
89484264|NCT02137993|Active Comparator|Zyprexa|Zyprexa 5, 10mg
89484265|NCT02253355|Experimental|Deep Brain Stimulation|Stimulation is on
89484266|NCT02253355|Sham Comparator|Placebo|Stimulation is off
89484267|NCT03571295|Experimental|videolaryngoscopy|
89484268|NCT03571295|Experimental|direct laryngoscopy|
89484269|NCT02138071||Individual|Treatment in the 'Individual group therapy' will include physiotherapy protocols usually used by physiotherapist working at Maccabi Healthcare Services (Exercises, Modalities, Maual therapy and Back Care education)
89484270|NCT02138071||group|Participants in group therapy will receive 6-8 group treatments (6-12 pateints per group) which will also include exercises and back-care education. No intervention will be done by the investigator.Therapists will use protocols commonly used in Maccabi Healthcate Services.
89484271|NCT02138149||spinal cord injury|individuals with neurogenic lower urinary tract dysfunction
89484272|NCT02138149||control group|individuals with physiologic bladder function
89484273|NCT03262259|Experimental|GSDG Intervention|Cities receiving a multi-component intervention, including screening and brief intervention, other evidence-based interventions (e.g., enforcement of drink-driving or underage drinking laws), and novel or partially tested interventions that warrant further evaluation.
89484274|NCT03262259|No Intervention|Comparison|Comparison cities receiving no evidence-based interventions.
89484275|NCT03571217||Diabetic retinopathy cohort|
89484276|NCT03571217||Mild visual impairment cohort|
89484277|NCT02245841|Experimental|H.P Acthar Gel|80 U (1 mL) of H.P. Acthar gel via subcutaneous injection twice weekly for 24 weeks
89484278|NCT03571139||Diabetics type 2 with and without diabetic retinopathy|Patients with diabetes mellitus type 2 with and without diabetic retinopathy who needs cataract surgery by phacoemulsification. All patients will undergo OCT angiography examination prior to their cataract surgery and 4 weeks after the cataract surgery.
89021244|NCT04301804|Experimental|Dose level 2|Subjects will be randomised to receive a single dose of SHR6390 at Dose level 2
89021245|NCT04301804|Experimental|Dose level 3|Subjects will be randomised to receive a single dose of SHR6390 at Dose level 3
89484279|NCT02129881|Experimental|Autologous regulatory T Cell Product|"Autologous regulatory T Cell Product (1-10 million cells/kg) infused intravenously 5 days post renal transplantation. Recipients also receive prednisolone, mycophenolate mofetil, and tacrolimus as detailed below:~Prednisolone Day 0: 500 mg IV (250mg pre-op, 250mg intra-op) Day 1: 125 mg IV Day 2 to 14: 20.0 mg/day oral Week 3 to 4: 15.0 mg/day oral Week 5 to 8: 10.0 mg/day oral Week 9 to 12: 5.0 mg/day oral Week 13 to 14: 2.5 mg/day oral Week 15 to End: Cessation Mycophenolate Mofetil (MMF) Day -7 to -2: 500 mg/day oral Day -1 to 14: 2000 mg/day oral Week 3 to 36: 1000 mg/day oral Week 37 to 40: 750 mg/day oral Week 41 to 44: 500 mg/day oral Week 45 to 48: 250 mg/day oral Week 49 to End: Cessation Tacrolimus Day -4 to 14: 3-12 ng/ml oral Week 3 to 12: 3-10 ng/ml oral Week 13 to 36: 3-8 ng/ml oral Week 37 to End: 3-6 ng/ml oral"
89484280|NCT05709041|Active Comparator|Standard lung protective ventilator settings|Ventilator settings will be adjusted to standard lung-protective settings according to the anesthesiologist's clinical judgement for the patient, their comorbodities, and the surgical procedure.
89021246|NCT01055457|Experimental|Experimental Multi-Purpose Solution|contact lens care solution
89484281|NCT05709041|Experimental|Individualized lung protective ventilator settings|Lung-protective ventilator settings will be individualized based on the patient's transpulmonary pressures (TPP), as measured by esophageal manometry.
89484282|NCT02138305|Other|Patients referred for CABG|"Patients who after undergoing standard of care diagnostic coronary angiography will be referred for CABG~ComboMap XT Guidewire~'SPY' NIRF During CABG"
89484283|NCT03254225|Experimental|Resistance training|Resistance training performed three times at week for 16 weeks, in 8 exercises for the main muscles, the protocol of 3 sets of 10 repetitions with intensity of 50% of 1 maximum repetition (MR).
89484284|NCT03254225|No Intervention|Control|in this arm, the group will remain sedentary for the same period of the experimental group, and they will be invited to engage on the raining program after the sedentary period
89484285|NCT02242565|Other|Control: all-sizes of ShangRing|All-sizes of ShangRings will be available.
89484286|NCT02242565|Active Comparator|Reduced-sizes|7 adult sizes of ShangRings will be available
89484287|NCT03570281|Experimental|Edoxaban group|Edoxaban, per oral, 60mg qd (may consider reduced dose to 30mg qd in patients with proper clinical reason by attending physician, estimated creatinine clearance of 30 to 50 ml per minute, a body weight of 60 kg or less, or the concomitant use of verapamil or quinidine), for 90 days.
89484288|NCT03570281|Active Comparator|Enoxaparin group|Enoxaparin, subcutaneous injection, 1mg/kg BID (may consider reduced dose to 1mg/kg qd in patients with proper clinical reason by attending physician, Creatinine clearance <30 mL/min), for 90 days.
89484289|NCT02129959||laparoscopy|laparoscopic cholecystectomy, laparoscopic gastrectomy, laparoscopic colectomy, laparoscopic appendectomy, laparoscopic assisted vaginal hysterectomy, robot-assisted laparoscopic radical prostatectomy
89484290|NCT03570203||Retrospective Cohort|Supratentorial/Suprasellar brain tumor patients with Glasgow Coma Score > 3 at time of admission.
89484291|NCT03570203||Prospective Cohort|Supratentorial/Suprasellar brain tumor patients with Glasgow Coma Score > 3 at time of recruitment.
89484292|NCT02242799|Experimental|Study A Sequence 1|Artemether-lumefantrine combination alone for 3 days with PK sampling at steady state, then 21 day washout period followed by Dolutegravir 50mg od dosing to steady state (7 days) with PK sampling then a further 3 days where Artemether-lumefantrine combination and Dolutegravir 50mg od are given together, with PK sampling at steady state.
89484293|NCT02242799|Experimental|Study A Sequence 2|Dolutegravir 50mg od given for 7 days with PK sampling at steady state, followed immediately by a further 3 days where Artemether-lumefantrine combination and Dolutegravir 50mg od are given together, again with PK sampling at steady state. Following a 21 day washout period, the subject will then receive Artemether-lumefantrine combination alone for 3 days, with PK sampling at steady state.
89021247|NCT01055457|Active Comparator|ReNu MultiPlus Multi-Purpose Solution|contact lens care solution
89021248|NCT04148144||Adolescents with low back pain|Adolescents aged 8-19 with low back pain.
89203620|NCT00561795|Experimental|Arm A|Oral Pazopanib 800 mg once a day+ carboplatin area under the concentration-time curve (AUC) 5 intravenous (IV) over 1 hour every 3 weeks + paclitaxel 175 mg/m^2 IV over three hours day one q 3 weeks for six cycles
89203621|NCT00561795|Experimental|Arm B|Oral Pazopanib 800 mg once a day+ carboplatin AUC 6 IV over 1 hour every 3 weeks + paclitaxel 175 mg/m^2 IV over three hours day one q 3 weeks for six cycles
89203622|NCT00652626|Experimental|Azacitidine 25 mg/m^2|Participants with normal renal function received a single subcutaneous dose of azacitidine 25 mg/m^2 on Day 1. Participants could continue treatment in the extension phase, which allowed up to 6 cycles of treatment with 75 mg/m^2 daily on Days 1-7 of each 28-day cycle.
89203623|NCT00652626|Experimental|Azacitidine 50 mg/m^2|Participants with normal renal function received a single subcutaneous dose of azacitidine 50 mg/m^2 on Day 1. Participants could continue treatment in the extension phase, which allowed up to 6 cycles of treatment with 75 mg/m^2 daily on Days 1-7 of each 28-day cycle.
89203624|NCT00652626|Experimental|Azacitidine 75 mg/m^2|Participants with normal renal function received subcutaneous doses of azacitidine 75 mg/m^2 on Days 1 to 5. Participants could continue treatment in the extension phase, which allowed up to 6 cycles of treatment with 75 mg/m^2 daily on Days 1-7 of each 28-day cycle.
89203625|NCT00652626|Experimental|Azacitidine 100 mg/m^2|Participants with normal renal function received a single subcutaneous dose of azacitidine 100 mg/m^2 on Day 1. Participants could continue treatment in the extension phase, which allowed up to 6 cycles of treatment with 75 mg/m^2 daily on Days 1-7 of each 28-day cycle.
89484294|NCT02242799|Experimental|Study B Sequence 1|Administration of artesunate-amodiaquine for 3 days with PK sampling at steady state
89484295|NCT02242799|Experimental|Study B Sequence 2|Dolutegravir alone for 7 days with PK sampling at steady state, followed immediately by administration of both artesunate-amodiaquine and dolutegravir together for a further 3 days with PK sampling at steady state
89021249|NCT04148144||Parents of included adolescents|Parents recruited for the parallel cohort, are required to be a parent or a legal guardian of the included adolescent. Siblings, grandparents or a similar person are not eligible for inclusion in the parallel cohort.
89203626|NCT00652626|Experimental|Severe RI: azacitidine 75 mg/m^2|Participants with severe renal impairment (RI; defined as creatinine clearance < 30 mL/min/1.73 m^2) received subcutaneous doses of azacitidine 75 mg/m^2 on Days 1 to 5. Participants could continue treatment in the extension phase, which allowed up to 6 cycles of treatment with 75 mg/m^2 daily on Days 1-7 of each 28-day cycle.
89203627|NCT00941421|Other|videocapsul and OGDFE|Each patient have a Fiberoptic endoscopy by videocapsul, followed by one traditional oeso-gastro-duodenal fiberoptic endoscopy
89203628|NCT00560703|Active Comparator|COL-101 (doxycycline, USP) capsules|COL-101
89203629|NCT00560703|Placebo Comparator|Placebo|Sugar capsule
89203630|NCT00308737|Experimental|TI Inhalation Powder|Technosphere® Insulin Inhalation Powder
89484296|NCT03548857||COPD patients|COPD patients on the waiting list for a lung transplantation
89484297|NCT02243423|Experimental|SUPINE group|The surgical table will remain horizontal after intrathecal (spinal) anesthesia injection for cesarean section. Choosing to position the patient supine is the intervention.
89484298|NCT02243423|Active Comparator|TILT group|The surgical table will be turned to 15° of left lateral tilt after patients are laid supine after spinal anesthesia injection. The tilted group is the control group.
89484299|NCT02138383|Experimental|Dose Escalation and Dose Expansion|"Dose Escalation: To find the dose of enzalutamide that can be safely given with gemcitabine and nab-paclitaxel in patients with advanced pancreatic cancer.~Dose Expansion: To find the effect on tumor of the combination of enzalutamide, gemcitabine and nab-paclitaxel."
89484300|NCT02243735|Active Comparator|Ferrous fumarate|Patients randomized to standard care with ferrous fumarate will receive three tablets of 200 mg daily from randomisation until day before surgery
89484301|NCT02243735|Active Comparator|ferric(III)carboxymaltose|Patients randomized to intravenous iron (ferric(III)carboxymaltose) will be dosed according to Summary of Product Characteristics (SPC) depending on body weight and Hb value and administered in one or two infusions with one week in between. A maximum dose of 1000mg or 15mg/kg per week will be administered
89484302|NCT02138539|Active Comparator|4% Hydroquinone|4% hydroquinone applied to one side of the face.
89484303|NCT02138539|Experimental|Herbal depigmenting agent|Herbal depigmenting agent applied on the other side of the face.
89484304|NCT03571061|Active Comparator|whole colon water immersion group|whole colon water immersion group: the air supply was turn off until the cecum was reached. For adequate lumen distention to advance the colonoscope tip, warm water which stored in 1L bottles and maintained 37°C with a water bath, was instilled intermittently into the colon through the auxiliary working channel of colonoscope using a footswitch-controlled flushing pump
89484305|NCT03571061|Experimental|sigmoid water immersion group|sigmoid water immersion group: air pump would be turned off and the procedure would be switched from water immersion method to air insufflation method after successful passage through the descending sigmoid junction.
89484306|NCT03571061|Placebo Comparator|carbon dioxide (CO2) insufflation|carbon dioxide (CO2) insufflation group: carbon dioxide (CO2) was insufflated through out the whole procedure for advancement and inspection when needed.
89484307|NCT02244047|Active Comparator|Bifidobacterium breve|Bifidobacterium breve BR03 and B632 powder containing 10/9 CFU daily dosage in a period of 3 months
89484308|NCT02244047|Active Comparator|Placebo|Placebo in the same powder packages as Bifidobacterium breve
89484309|NCT03570125|Experimental|Dietary intervention arm|"group will follow an ad libitum diet but, every two months, will follow a 5 day of fasting mimicking diet (PROLON). The diet consists of natural ingredients, which are Generally Regarded As Safe (GRAS).~Prolon will be provided for free by L-nutra or in case of unforeseeable budget constraint at one fifth of its commercial value."
89484310|NCT03570125|No Intervention|no intervention|Control/Placebo with multivitamin supplementation
89484311|NCT05578729|Other|Single surgical mask group|Participants wore single surgical masks.
89484312|NCT05578729|Other|Double surgical mask group|Participants wore double surgical masks.
89484313|NCT05578729|Other|N95 mask group|Participants wore N95 masks.
89484314|NCT03569969|Experimental|control group|Step1. Under local anesthesia and sedation , the temporal muscle fascia was removed, Step2. After the preparation on the tympanic membrane embedded , foam gel smeary with Dexamethasone was worn.Step3. Then the wound dressing was done with a gas number and a Surgifix. Step4. Patients were discharge from the operating room with an oral administration of Cephalexin capsules.
89203631|NCT00308737|Other|Usual care|Usual care
88952478|NCT02920008|Experimental|guadecitabine|Guadecitabine will be given SC at a dose of 60 mg/m^2 in 28-day cycles (delayed as necessary to allow blood count recovery).
89203632|NCT00308737|No Intervention|Non-diabetes|Subjects without abnormalities in glucose control (Note: Hypoglycemia and HbA1c were not reported for this group)
89203633|NCT04711902|Active Comparator|Arm 1|Arm 1 - Secukinumab Dose level 1
89203634|NCT04711902|Placebo Comparator|Arm 2|Arm 2 Secukinumab Placebo
89203635|NCT04711902|Active Comparator|Arm 3|Arm 3 Secukinumab Dose level 1 and Placebo
89203636|NCT04711902|Active Comparator|Arm 4|Arm 4 Secukinumab Dose level 2
89203637|NCT00945711||1|Eating Disorder Diabetes Mellitus T1 patients
89203638|NCT00945711||2|Eating Disorder only patients
89203639|NCT00941499|Experimental|Group 1|HAI oxaliplatin in combination with HAI 5-fluorouracil and IV bevacizumab
89203640|NCT00941499|Experimental|Group 2|HAI oxaliplatin in combination with IV 5-fluorouracil, leucovorin, bevacizumab, and cetuximab
89203641|NCT00941499|Experimental|Group 3|HAI oxaliplatin in combination with IV bevacizumab.
89203642|NCT00941499|Experimental|Group 4|HAI oxaliplatin in combination with IV bevacizumab and cetuximab.
89203643|NCT00941577|Experimental|AIR645|AIR645 (an IL-4/IL-13 dual cytokine signaling inhibitor) solution (diluent: physiologic saline solution)
89203644|NCT00941577|Placebo Comparator|Physiologic saline solution|Physiologic saline solution
89203645|NCT00945789|Experimental|EPO HIE Group|Infants with hypoxic ischemic encephalopathy receive human recombinant erythropoietin
89203646|NCT00945789|No Intervention|Control HIE|Infants with hypoxic ischemic encephalopathy who do not receive treatment drug (EPO)
89203647|NCT00945789|Other|Healthy Controls|Healthy newborn without hypoxic ischemic encephalopathy
89203648|NCT04737096|Experimental|tDCS+DAOIB|
89203649|NCT04737096|Placebo Comparator|tDCS+placebo|
89203650|NCT04725006|Experimental|Stimulation in individuals with implanted stimulation systems|During psychophysical stimulation trials, an external stimulator will be connected to the SCS lead, a volley of stimulation will be performed, and the subject will be asked to respond to standard psychophysical questions, as well as to provide any additional comments.
89203651|NCT02553018|Experimental|Auto-injector of methotrexate|"The Auto-injector is a disposable, fixed, single dose, auto-injector to be used for Methotrexate (25mg/ml) therapy.~Dosage form: solution for injection Dosage: 0.3ml contains 7.5mg of Methotrexate, 0.4ml contains the 10.0mg of Methotrexate, 0.6ml contains 15.0 mg of Methotrexate, 0.8ml contains 20.0 mg of Methotrexate, 1.0ml contains 25.0 mg of Methotrexate.~Frequency: one injection per week Duration: until the end of the study"
89203652|NCT02553018|Active Comparator|Pre-filled syringe of methotrexate|"Pre-filled syringes contains a volume of 1 ml with attached injection needle. Dosage form: solution for injection. Dosage: 0.15 ml contains 7.5 mg of methotrexate, 20 ml contains 10 mg of methotrexate, 0.30 ml contains 15 mg of methotrexate, 0.40 ml contains 20 mg of methotrexate, 0.50 ml contains 25 mg of methotrexate disodium.~Frequency: one injection per week Duration: until the end of the study"
89203653|NCT00950079|Experimental|Sodium bicarbonate|sodium bicarbonate
89203654|NCT00950079|Active Comparator|Saline|saline infusion
89203655|NCT00810186||Newborns needing respiratory monitoring|Premature and term newborn infants (male/female)
89203656|NCT00941967|Experimental|Arm I|Patients receive oral sorafenib tosylate as in arm I. Patients also receive gemcitabine hydrochloride IV over 100 minutes on day 1 and oxaliplatin IV over 2 hours on day 2. Treatment with gemcitabine hydrochloride and oxaliplatin repeats every 14 days for 12 courses in the absence of disease progression or unacceptable toxicity.
89203657|NCT00941967|Experimental|Arm II|Patients receive oral sorafenib tosylate twice daily on days 1-14.
89203658|NCT00655746|Experimental|1|
89203659|NCT00338455|Experimental|001|Natrecor (nesiritide)+Standard Care+dobutamine or milrinone 28-day continuous infusion no bolus 3-hour 0.005 mcg/kg/min may be titrated to 0.015 mcg/kg/min
89203660|NCT00338455|Placebo Comparator|002|Placebo+Standard Care+dobutamine or milrinone 28-day continuous infusion no bolus 3-hour 0.005 mcg/kg/min may be titrated to 0.015 mcg/kg/min
89203661|NCT00950157|Experimental|"Directive open question statement"|"Survey describes the surrogate outcome of the drug along with a directive warning (i.e., stating the issue and why it matters) for drugs shown to improve surrogate outcomes.~This directive warning mentions that it is not known whether the drug will help patients feel better, and that readers should ask their doctor if there is an available drug shown to improve patient outcomes."
89203662|NCT00950157|Experimental|Non-directive open question statement|"Survey describes the surrogate outcome of the drug along with a non-directive warning (i.e., stating the issue only) for drugs shown to improve surrogate outcomes.~This non-directive warning mentions only that it is not known whether the drug will help patients feel better."
89203663|NCT00950157|Experimental|No open question statement|Survey only describes the surrogate outcome of the drug.
89203664|NCT00806208|Active Comparator|1|MEDI 507 and Methylprednisolone
89203665|NCT00806208|Active Comparator|2|MEDI-507 and Methylprednisolone
88952479|NCT02920008|Active Comparator|Treatment Choice (TC)|"High intensity~Low intensity~Best supportive care (BSC)."
89021250|NCT00428571|Placebo Comparator|Intensive Medical Management|Medical management of obesity including medication optimization and lifestyle and dietary advice.
89021251|NCT00428571|Active Comparator|Laparoscopic Gastric Bypass|
89021252|NCT00428571|Active Comparator|Laparoscopic Adjustable Gastric Band|
89021253|NCT04100291|Active Comparator|FMT|Faecal microbiota transplantation
89203666|NCT00806208|Active Comparator|3|MEDI-507 and Methylprednisolone
89203667|NCT00806208|Active Comparator|4|MEDI-507 and Methylprednisolone
89203668|NCT00806208|Placebo Comparator|5|Placebo
88952480|NCT02868671|Experimental|real acupuncture|Participants will receive treatment four times a week for two weeks and three times a week for two weeks. Participants will be treated with major points: Yintang, Du20 (Bai Hui), LI4 (He Gu), LR3 (Tai Chong), ST36 (Zusanli) (front treatment) or GB20 (Feng Chi), SP6 (Sanyinjiao), BL15 (Xin Shu), BL18 (Gan Shu), BL23 (Shen Shu) (back treatment). The position of the treatment will alternate between sessions such that the first session will be on the back, with the next session on the front. In addition to the 5 required points, acupuncturist will be allowed to choose 1-3 more points. The supplemental points may be chosen from the following: HT7 (Shenmen), PC6 (Neiguan), SI3 (Hou Xi), RN6 (Qi Hai), KI 3 (Taixi), KI 6 (Zhao Hai), SP10 (Xue Hai), BL14 (Jue Yin Shu), BL17 (Ge Shu), BL20 (Pi Shu).
88952481|NCT02868671|Sham Comparator|sham acupuncture|Participants randomized to sham acupuncture will receive a 'placebo' acupuncture session. For sham acupuncture, Streitberger needles, which acted like stage dagger with the shaft of the needle retracting into the handle, were placed at non-acupuncture points with the same number of acupuncture points in the VA group. The needle guiding tube will be used to create sensations that mimic needle manipulation.
88952482|NCT02868671|No Intervention|No Intervention|All participants in this study will not receive interventions.
88952483|NCT02866747|Active Comparator|Arm A: radiation therapy alone|Hypofractionated stereotactic radiation therapy (hFSRT) 24 Gray (Gy), 8 Gy per fraction preferentially at 80% isodose (60 to 90 % accepted), 3 fractions scheduled on Day 1 of the radiotherapy (RT), Day 3 RT and Day 5 RT.
88952484|NCT02866747|Experimental|Arm B: combined treatment|"hFSRT 24 Gy, 8 Gy per fraction preferentially at 80% isodose (60 to 90 % accepted), 3 fractions scheduled on Day 1 RT, Day 3 RT and Day 5 RT, combined with Durvalumab infusion: first administration of Durvalumab* on Day 5 RT (i.e. the same day after the last fraction of radiation, corresponding to the Day 1 for Durvalumab treatment) and then administration of Durvalumab 1500 milligrams (mg) every four weeks.~* Dosing 750 mg or 1500 mg, according to the recommended combination schema determined in phase I."
88952485|NCT02777528|Other|Zone 0/1 Aortic aneurysm|Zone 0/1 Aortic aneurysm
88952486|NCT02777528|Other|Zone 0/1 Non-aneurysm aortic lesions|Includes dissection and other isolated lesion types
88952487|NCT02766335|Experimental|Arm I (MEDI4736 - closed to accrual 12/2015)|Patients receive durvalumab IV over 60 minutes on day 1. Treatment repeats every 14 days for 12 months in the absence of disease progression or unacceptable toxicity.
88952488|NCT02766335|Active Comparator|Arm II (docetaxel - closed to accrual 4/2015)|Patients receive docetaxel IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. (closed to accrual with Revision #2 4/22/15)
89021254|NCT04100291|Placebo Comparator|Placebo|Placebo mixture
89021255|NCT04703283|Experimental|Lifestyle Medicine Group|Lifestyle intervention with components including exercise, diet, stress management, and sleep management
89484315|NCT03569969|Experimental|Test group|Step1. After sedation and conducting local anesthesia with Lidocaine 2% and inserting the edges of the tympanic membrane and inserting the foam gel into the middle ear, amniotic membranes (produced in Iran tissue product) with a thickness of 100 microns on the tympanic membrane and the foam gel embedded. Step2. Under-layered and short-lived foam gel (manufactured by Ethicon Company) smeary with dexamethasone was covered.
89484316|NCT02130037|Active Comparator|psychotherapy only|
89484317|NCT02130037|Experimental|application|
89484318|NCT02244359|Experimental|Training|Online tutorial, decision aid and interactive workshop
89484319|NCT02244359|Other|Usual care|Usual care
89484320|NCT02252419|Active Comparator|Dexamethasone|Dexamethasone will be administered 30 minutes before the anesthetic induction.
89484321|NCT02252419|Experimental|Dexamethasone+ Paracetamol (DP)|Dexamethasone will be administered 30 minutes before the anesthetic induction. Paracetamol will be administered at the end of the surgery.
89484322|NCT03570905|Experimental|Sugartong Splint|
89484323|NCT03570905|Experimental|Clam Shell Splint|
89484324|NCT02252497|Active Comparator|Tranexamic acid|"1g Intra Venous just before surgery~Then infusion of 1g of Exacyl over eight hours."
89484325|NCT02252497|Placebo Comparator|Physiologic serum|"1g Intra Venous, just before surgery~Then infusion of 1g of physiologic serum over eight hours."
89484326|NCT02138695||Yonsei AF Cohort|Patients with atrial fibrillation who undergoing catheter ablation of atrial fibrillation
89484327|NCT02252575|Experimental|Electromagnetic field|Exposure to the elctromagnetic field of an electric motor
89484328|NCT03548701||Emergency Department|Patients enrolled in the Emergency Department undergoing evaluation for threatened abortion abnormalities.
89484329|NCT03548701||Obstetric Clinic|Patients with normal pregnancies being treated at first obstetric visit in clinic.
89484330|NCT02138773|Experimental|Fed, formulation-A|drug administered at 0.5h after the start of a standard breakfast
89484331|NCT02138773|Experimental|Fed, formulation-B|drug administered at 0.5h after the start of a standard breakfast
89484332|NCT02138773|Experimental|Fasted, formulation-A|drug administered under fasted condition (fasting for at least 10 hours)
89484333|NCT02138773|Experimental|Fasted, formulation-B|drug administered under fasted condition (fasting for at least 10 hours)
89484334|NCT05578573|Experimental|KARAHOC group|A group of patients in which paracentesis will be performed using a KARAHOC device.
89484335|NCT05578573|Active Comparator|conventional group|A group of patients in which paracentesis will be performed using an angiocatheter.
89484336|NCT02138851|Experimental|Ficus Carica|Ficus Carica 300g/day
89484337|NCT02138851|Placebo Comparator|Placebo|Placebo 300g/day
89484338|NCT05578495|Other|Chronic diseases|Cohort Study
89484339|NCT01367275|Experimental|Brivanib + Irinotecan|Brivanib 800 mg orally daily Days 1-14, and Irinotecan intravenously 180 mg/m^2 on Day 1.
89537679|NCT00701129|Experimental|Alglucosidase Alfa|Alglucosidase alfa (Myozyme®) 20 milligrams per kilogram (mg/kg) intravenous (IV) infusion every other week (qow) (or optionally 20 mg/kg IV infusion every week [qw]) beginning from Day 0 to a minimum of 18 months or if the patient was less than (<) 6 months of age at the time of enrollment, until the patient was 2 years of age, along with methotrexate 0.4 mg/kg subcutaneously for 3 consecutive days qow beginning from Day 0 to Week 6 (9 doses) and rituximab 375 milligrams per square meter (mg/m^2) (or 12.5 mg/kg for patients with body surface area less than or equal to 0.5 m^2) IV infusion qw beginning from Day -1 to Week 4 (4 doses) as per local prescribing information. An additional 4-week cycle of rituximab (up to 4 additional doses) and 6-week cycle of methotrexate (up to 9 additional doses) may have been administered within the first 6 months of the study as per local prescribing information.
89537680|NCT03298763|Experimental|Phase 1 - RP2D finding study|Phase I of the trial aims to establish the recommended MSCTRAIL dose when given in combination with cisplatin/pemetrexed chemotherapy in metastatic non-small cell lung cancer (NSCLC) patients
89537681|NCT03298763|Active Comparator|Phase 2 Intervention Arm|"Cisplatin 75mg/m2 and Pemetrexed 500mg/m2 on day 1 followed by MSCTRAIL (at the recommended phase 2 dose) on day 2. This schedule will be repeated after 21 days for 3 cycles.~Patients will then receive a further 1-3 cycles of pemetrexed/ cisplatin alone. They may then be eligible for maintenance pemetrexed according to clinical response as directed by their Oncologist in line with local standard of care."
89203669|NCT05301309|Experimental|Breastfeeding Consultation|"The intervention group would receive integrative early breastfeeding support and intervention programs, including breastfeeding for prematurity brochure, group education class, weekly interview, one-by-one breastfeeding consultation and online peer group support."
89203670|NCT05301309|Active Comparator|routine care|"The control group only receive breastfeeding for prematurity brochure and routine care."
89203671|NCT00651924|No Intervention|Phase 1|Review the materials and provide feedback regarding how understandable, engaging, and informative the materials are
89203672|NCT00651924|Experimental|Phase 2|Piloting the 'IVR-based Cognitive-behavior therapy' using the new materials
89203673|NCT00950313|Active Comparator|Self Assessment|Patients are approached and asked to complete a risk score that will determine their current risk of diabetes and the likelihood of requiring further testing.
89203674|NCT00950313|Active Comparator|Electronic risk score|Patients diabetes riks is determined based on their data held on practice systems. Patients are then invited for further testing based on this score.
89537682|NCT03298763|Placebo Comparator|Phase 2 Control Arm|"cisplatin 75mg/m2 and pemetrexed 500mg/m2 on day 1 and placebo on day 2. This will be repeated after 21 days for up to 3 cycles.~Patients will then receive a further 1-3 cycles of pemetrexed/ cisplatin alone. They may then be eligible for maintenance pemetrexed according to clinical response as directed by their Oncologist in line with local standard of care."
89537683|NCT03298685||CF patient and parents cohort in 3 CF center|All adolescents for whom the transition to the adult center is scheduled within six months and their parent will be interviewed before and after transition.
89537684|NCT03296189|Active Comparator|Local anaesthetic|Post-ureteroscopy intraluminal injection of alkalinised high concentration levo-bupivicaine in the renal pelvis
89537685|NCT03296189|Active Comparator|Local anaesthetic + steroid|Post-ureteroscopy intraluminal injection of 10 mls alkalinised high concentration levo-bupivicaine with l dexamethasone in the renal pelvis
89537686|NCT03296189|Placebo Comparator|Placebo|Post-ureteroscopy intraluminal injection of 10 mls normal saline (placebo) in the renal pelvis
89537687|NCT03298607|Placebo Comparator|Placebo|2 capsules daily for 2 months containing inactive substances
89203675|NCT00678392|Experimental|Axitinib|
89203676|NCT00678392|Active Comparator|Sorafenib|
89203677|NCT00950391|Experimental|Tacrolimus|Treatment with tacrolimus following nerve repair/reconstruction
89203678|NCT00804336|Experimental|Pasireotide and RAD001|RAD001 was administered orally as a once-daily dose. Pasireotide s.c. was self-administered s.c. twice daily for 4 weeks. If pasireotide s.c. was tolerated, patients received pasireotide LAR i.m. at the corresponding dose level. Pasireotide s.c. was continued for an additional 2 weeks after administration of pasireotide LAR until anticipated steady-state levels of pasireotide LAR were achieved. Pasireotide LAR was administered every 28 days. Cycles for everolimus and pasireotide LAR were repeated every 28 days.
89203679|NCT00942201|Active Comparator|Single dose dexamethasone|Single dose dexamethasone 0.6 mg/kg, rounded to nearest 2 mg, max 16 mg administered in ED
89203680|NCT00942201|Active Comparator|Two dose dexamethasone|First dose in ED, a prescription for second dose to be administered on Day 3 after discharge
89203681|NCT00804414|Experimental|1|
89203682|NCT00804414|Placebo Comparator|2|
89203683|NCT00942435|Experimental|YM150 group|
89203684|NCT00942435|Active Comparator|mechanical prophylaxis group|
89484340|NCT02138929|Experimental|Everolimus + LDE 225|"Dose Escalation: Everolimus at a dose of 10 mg by mouth daily with dose escalation of LDE 225 from 200 mg - 800mg by mouth daily. Study cycle is 28 days.~Dose Expansion: Everolimus at a dose of 10 mg by mouth daily. LDE 225 at MTD from Dose Escalation. Study cycle is 28 days."
89484341|NCT05578339|Other|Capsular bag size|"Lens thickness, lens shape, anterior chamber depth, axial eye length and angle-to-angle will be used as explanatory variables (independent variables) and the size of the capsular bag will be used as main outcome parameter (dependent variable).~We will perform a multiple linear regression analysis (that allows determination of the overall fit (variance explained) of the model and the relative contribution of each of the predictors to the total variance explaine) between the independent and the dependent variable."
89484342|NCT02253199|Active Comparator|1-6 months (Group 1)|Subjects stratified into four groups according to age: 1-6 months (Group 1), 7-12 months (Group 2),13-24 months (Group 3), 26-36 months (Group 4).
89484343|NCT02253199|Active Comparator|7-12 months (Group 2)|Subjects stratified into four groups according to age: 1-6 months (Group 1), 7-12 months (Group 2),13-24 months (Group 3), 26-36 months (Group 4).
89484344|NCT02253199|Active Comparator|13-24 months (Group 3)|Subjects stratified into four groups according to age: 1-6 months (Group 1), 7-12 months (Group 2),13-24 months (Group 3), 26-36 months (Group 4).
89484345|NCT02253199|Active Comparator|25-36 months (Group 4)|Subjects stratified into four groups according to age: 1-6 months (Group 1), 7-12 months (Group 2),13-24 months (Group 3), 26-36 months (Group 4).
89484346|NCT02842853|Experimental|MenACYW Conjugate Vaccine Lot 1|Healthy, meningococcal-vaccine naive adolescents aged 10 to 17 years (Group 1a) and adults aged 18 to 55 years (Group 1b) received a single dose of MenACYW conjugate vaccine from lot 1 on Day 0.
89484347|NCT02842853|Experimental|MenACYW Conjugate Vaccine Lot 2|Healthy, meningococcal-vaccine naive adolescents aged 10 to 17 years (Group 2a) and adults aged 18 to 55 years (Group 2b) received a single dose of MenACYW conjugate vaccine from lot 2 on Day 0.
89484348|NCT02842853|Experimental|MenACYW Conjugate Vaccine Lot 3|Healthy, meningococcal-vaccine naive adolescents aged 10 to 17 years (Group 3a) and adults aged 18 to 55 years (Group 3b) received a single dose of MenACYW conjugate vaccine from lot 3 on Day 0.
89484349|NCT02842853|Active Comparator|Menactra®|Healthy, meningococcal-vaccine naive adolescents aged 10 to 17 years (Group 4a) and adults aged 18 to 55 years (Group 4b) received a single dose of Menactra® on Day 0.
89484350|NCT02130271||Healthy|"Healthy subjects with no pain.~Radioactive dye~PET/MRI~Blood draw"
89484351|NCT02130271||Sciatica|"Subjects with sciatica and scheduled for an epidural steroid injection (ESI).~Radioactive dye~PET/MRI~Blood draw"
89484352|NCT02130349||Crohns Disease|IBD patients diagnosed with Crohn's disease
89484353|NCT02130349||Ulcerative colitis|IBD patients diagnosed with ulcerative colitis
89484354|NCT02130349||IBD-Undefined|IBD patients with undefined IBD
89484355|NCT02139085|Active Comparator|GSV Electrocoagulation|GSV Electrocoagulation Source: Electrosurgical Generator(FX-Valley Lab; USA) Energy: 60 Watts x 10 seconds
89484356|NCT02139085|Active Comparator|GSV Radiofrequency|GSV Radiofrequency Source: Closure FAST(Covidien, USA) Energy: 60 Joules / cm
89484357|NCT02130505|Active Comparator|T2DM|Patients with type 2 diabetes mellitus, defined as having met the diagnostic criteria as outlined by the World Health Organization
89484358|NCT02130505|Active Comparator|FCH|Patients with familial combined hyperlipidemia, defined as familial hyperlipidemia with a dominant inheritance pattern, elevated plasma apolipoprotein (apo) B concentrations (>1.2 g/L) and elevated triglyceride (TG) levels (>1.7 mmol/L) at the time of diagnosis
89484359|NCT02130505|Active Comparator|FH|Patients with familial hyperlipidemia, defined as having met the diagnostic criteria as outlined by the world Health Organization
89484360|NCT02130505|Active Comparator|Healthy controls|Healthy controls
89484361|NCT03548545|Experimental|CBT combined with active tDCS|Subjects allocated to this arm will receive cognitive-behavior therapy combined with active tDCS over the dorsolateral prefrontal cortex.
89484362|NCT03548545|Sham Comparator|CBT combined with sham tDCS|Subjects allocated to this arm will receive cognitive-behavior therapy combined with sham tDCS over the dorsolateral prefrontal cortex.
89484363|NCT02246543|Placebo Comparator|Treatment 1 - Control|Water, Toast & Egg (Yolk only) + 0.1g 13C Octanoic Acid
89484364|NCT02246543|Active Comparator|Treatment 2 - HPL|High Protein Smoothie (Liquid): 30% protein; 30% fat and 40% CHO + 0.1g 13C Octanoic Acid
89484365|NCT02246543|Active Comparator|Treatment 3 - LPL|Low Protein Smoothie (Liquid): 15% protein; 30% fat and 55% CHO + 0.1g 13C Octanoic Acid
89484366|NCT02246543|Active Comparator|Treatment 4 - HPS|High Protein Milk Jelly (Solid): 30% protein; 30% fat and 40% CHO + 0.1g 13C Octanoic Acid
89484367|NCT02246543|Active Comparator|Treatment 5 - LPS|Low Protein Milk Jelly (Solid): 15% protein; 30% fat and 55% CHO + 0.1g 13C Octanoic Acid
89484368|NCT02139163||patients with pneumonia|
89484369|NCT03569267|Experimental|OLX10010|OLX10010, an siRNA therapeutic, with four different doses by Groups (dose ascending manner with 1, 4, 10, 20 mg)
89484370|NCT03569267|Placebo Comparator|Placebo|placebo
89484371|NCT02139241|Experimental|Ramosetron|Intravenous administration of ramosetron 0.3 mg before the induction of general anesthesia
89484372|NCT02139241|Placebo Comparator|Control|Intravenous administration of 2ml normal saline before the induction of general anesthesia
89484373|NCT02433340|Experimental|ABT-122 120 mg EOW|All subjects receive open-label ABT-122 120 mg EOW subcutaneously, with the first dose administered at the last visit of Study M12-963 randomized controlled trial.
89484374|NCT05578105||Autoimmune polyendocrine syndrome type II|patients with autoimmune polyendocrine syndrome type II
89484375|NCT03569579|Experimental|Group 1(Treatment A/Treatment B)|"Period 1: Treatment A(Memantine Tab. 10mg)*2T, QD, PO.~Period 2: Treatment B(Memantine Tab. 10mg)*2T + Donepezil Tab. 10mg)*1T, QD, PO.~Each treatment period was separated by a washout period of at least 21 dyas."
89484376|NCT03569579|Experimental|Group 1(Treatment B/Treatment A)|"Period 1: Treatment B(Memantine Tab. 10mg)*2T + Donepezil Tab. 10mg)*1T, QD, PO.~Period 2: Treatment A(Memantine Tab. 10mg)*1T, QD, PO.~Each treatment period was separated by a washout period of at least 21 dyas."
89537688|NCT03298607|Active Comparator|Serelys PMS|2 capsules daily for 2 months containing pollen extract
89203685|NCT00950469||patients with acute coronary syndrome|"94 consecutive patients without ST-segment elevation admitted to the Chest Pain Unit of the University of Heidelberg were enrolled with symptoms suggestive of ACS.~Unstable angina and non-ST-segment elevation myocardial infarction were diagnosed using the joint European Society of Cardiology/American College of Cardiology/American Heart Association/World Heart Federation Task Force redefinition of myocardial infarction guidelines. Patients with ST-segment elevation were excluded."
89203686|NCT05301075|Sham Comparator|control group|patients will receive sham block.
89203687|NCT05301075|Active Comparator|RISS group|will receive Rhomboid Intercostal and Sub-Serratus block under ultrasound guidance
89203688|NCT00950547|Active Comparator|Control|Traditional Chest drains
89203689|NCT00950547|Experimental|CARDIOPAT|CARDIOPAT Cell Saver after Surgery
89203690|NCT00946179|Experimental|Group 1|Participants aged 18 to 60 years at enrollment
89203691|NCT00946179|Experimental|Group 2|Participants aged 61 years or older at enrollment
89203692|NCT00946257|Experimental|Cohort 1|0.3 mg dose
89203693|NCT00946257|Experimental|Cohort 2|0.6 mg dose
89203694|NCT00946257|Experimental|Cohort 3|1.2 mg dose
89203695|NCT00946257|Experimental|Cohort 4|1.8 mg dose
89203696|NCT00946257|Experimental|Cohort 5|2.4 mg dose
89203697|NCT00946257|Experimental|Cohort 6|3.0 mg dose
89021256|NCT04703283|No Intervention|Waitlist Control Group|Participants in the waitlist control group will receive the intervention after the immediate post-treatment assessment
89203698|NCT00950625|Active Comparator|intraperitoneal lignocaine|Intraperitoneal lignocaine will be compared with intraperitoneal bupevacaine for pain control after laparoscopic cholecystectomy
89203699|NCT00950625|Active Comparator|intraperitoneal bupevacaine|intraperitoneal lignocaine will be compared with intraperitoneal bupevacaine after laparoscopic cholecystectomy
89203700|NCT04049318||24 weeks|Subjects who participated in the intervention who have data available at week 24
89203701|NCT04049318||48 weeks|Subjects who participated in the intervention who have data available at week 48
89203702|NCT00760292||1|Type 2 Diabetic Patients
89203703|NCT00760292||2|Non-diabetic individuals
89203704|NCT04049630|Experimental|LEV 1 mg/kg|Tablets of LEV at 1 mg/kg will be administrated to the participant ; in single dose only one time. The number of tablets of LEV of 50 mg or 10 mg will be adapted according to the weight of the participant.
89203705|NCT04049630|Experimental|LEV 1,5 mg/kg|Tablet of LEV at 1,5 mg/kg will be administrated to the participant ; in single dose only one time. The number of tablets of LEV of 50 mg or 10 mg will be adapted according to the weight of the participant.
89203706|NCT04049630|Experimental|LEV 2,5 mg/kg|Tablet of LEV at 2,5 mg/kg will be administrated to the participant ; in single dose only one time. The number of tablets of LEV of 50 mg or 10 mg will be adapted according to the weight of the participant.
89537689|NCT03298529|Experimental|Traditional egg pasta|"Traditional egg pasta. 12 healthy subjects, after a 10 to 12-hour overnight fasting period, will assume fettuccine pasta made with 8 eggs/kg flour. The serving size is calculated to contain 50 g of carbohydrates according to nutritional analysis of the product."
89203707|NCT04049630|Placebo Comparator|Placebo|Tablets of placebo will be administrated to the participant in single dose only one time.
89203708|NCT00942591|Experimental|1|Interferon beta-1b AND atorvastatin
89203709|NCT00942591|Active Comparator|2|Interferon beta-1b
89203710|NCT00950781||Group|Group
89203711|NCT00946335|Experimental|Treatment (veliparib, temozolomide)|"Patients receive oral ABT-888 twice daily and oral temozolomide once daily on days 1-5. Treatment repeats every 28 days for 13-26 courses in the absence of disease progression or unacceptable toxicity.~Blood samples are collected for pharmacokinetics and further laboratory analysis."
89203712|NCT00762944||Biomet TMJ Replacement System|All patients required total reconstruction of the temporomandibular joint (unilateral or billateral)
89203713|NCT00763022|Experimental|TAK-559 16 mg QD|
89203714|NCT00763022|Experimental|TAK-559 32mg QD|
89203715|NCT00763022|Placebo Comparator|Placebo QD|
89203716|NCT04392284|Experimental|Diet Counseling|Delivery of nutrition counseling intervention to improve diet quality.
89203717|NCT04392284|Experimental|Exercise Counseling|Delivery of exercise counseling intervention to increase engagement in physical activity..
89203718|NCT00760604|Active Comparator|A|En bloc esophagectomy is performed through a transthoracic approach by removing the tumor-bearing esophagus, the pericardium anteriorly, both pleural surfaces laterally, as well as the thoracic duct and all other lymphoareolar tissue wedged posteriorly between the esophagus and the spine, and en-bloc resection of all nodal groups in the middle and lower mediastinum as well as the upper abdomen.
89203719|NCT00760604|Active Comparator|B|Transhiatal esophagectomy is performed through an abdominal incision and a neck incision. The stomach is mobilized, and the left gastric vessels are transected at its origin. Celiac lymph nodes are dissected, and the intrathoracic esophagus is dissected bluntly through the hiatus and through the neck. The cervical esophagus is divided at the level of the neck. After the esophagogastrectomy is performed, a gastric tube is created. An esophagogastrostomy is then performed in the neck. If a transthoracic approach is used, dissection will be as described for the transhiatal approach.
89203720|NCT00763100||Breast cancer|Patients in treatment or post-treatment for breast cancer
89203721|NCT00763178|Experimental|PTSD|Duloxetine
89203722|NCT00760682|Experimental|1|30 preoperative HBO sessions, sequestrectomy and 10 postoperative HBO sessions. The duration of each session is 90 minutes. 100 % oxygen is inhaled during decompression to 2.4 ATA.
89203723|NCT00760682|No Intervention|2|Sequestrectomy without HBO treatment
89203724|NCT00308581|Experimental|Active 1|"Q4W regimen~- every 4 weeks: alternatively placebo and 400mg Certolizumab Pegol"
89021257|NCT04046120|No Intervention|Heel included|The bandage is made by including the heel as recommended in routine.
89021258|NCT04046120|Experimental|Heel not included|he bandage is made by leaving the heel uncovered.
89021259|NCT04716647|Experimental|Ayurveda Intervention|Ashwagandha, Giloy and Tulsi were given in tablet form for oral administration.
89021260|NCT00428649|Experimental|1|20 µg selenium as selenomethionine
89021261|NCT00428649|Experimental|2|40 µg selenium as selenomethionine
89021262|NCT00428649|Experimental|3|60 µg selenium as selenomethionine
89203725|NCT00308581|Experimental|Active 2|"Q2W regimen~- every 2 weeks: 400 mg Certolizumab Pegol"
89203726|NCT00678080|Experimental|Metformin|Metformin therapy as prescribed by their health care provider
89203727|NCT00678080|Active Comparator|Insulin|Insulin as prescribed by their health care provider
89203728|NCT00658320|Experimental|Everolimus + Reduced dose of cyclosporine|An initial everolimus dose of 0.75 mg orally twice daily (1.5 mg/day) was administered 24-36 hours from reperfusion after transplantation and dose adjustments based on everolimus trough level (target trough level 3-8 ng/mL). Reduced dose of cyclosporine was initiated either pre-transplantation or within 24 hours after transplantation following the local regimen. Patients were treated with antibody induction therapy using 20 mg basiliximab two hours prior to transplant and 20 mg basiliximab 4 days post transplant or according to local practice. Corticosteroids were administered according to local practice. Patients were treated for 12 months in the core study and 12 months in the extension study. Everolimus was available after 24 months for compassionate use.
89203729|NCT00658320|Active Comparator|Mycophenolate mofetil (MMF) + Standard dose of cyclosporine|Patients were treated with 1 gram twice a day (2 grams/day) of Mycophenolate mofetil (MMF) and standard dose of cyclosporine for 12 months post renal transplant. Patients were treated with antibody induction therapy using 20 mg basiliximab two hours prior to transplant and 20 mg basiliximab 4 days post transplant or according to local practice. Corticosteroids were administered according to local practice. Patients were treated for 12 months in the core study and 12 months in the extension study.
89203730|NCT02558192|Experimental|Probiotics|Vials containing 3 x 10^9 Colony Forming Units of LGG, vitamins ( B and C) and zinc
89203731|NCT02558192|Placebo Comparator|Placebo|Vials containing water, maltodextrin, magnesium stearate, potassium sorbate, sodium benzoate, citric acid, fructose, flavor.
89203732|NCT04137614|Placebo Comparator|Digital substraction angiography|
89203733|NCT04137614|Experimental|Drug-coated balloon|
89203734|NCT02553252|Experimental|Sudarshan Kriya Yoga Trauma Relief Program (SKY)|Participants will receive training in SKY soon after completing baseline assessments.
89203735|NCT02553252|No Intervention|wait list control (WLC)|Participants will receive training in SKY after 12 weeks have passed since the baseline assessment.
89203736|NCT02558270|Active Comparator|patients dapa|Patients will be administered Dapagliflozin 10mg
89203737|NCT02558270|Placebo Comparator|patients placebo|Patients will be administered a placebo
89203738|NCT02558270|Active Comparator|controls dapa|controls will be administered Dapagliflozin 10mg
89203739|NCT02558270|Placebo Comparator|controls placebo|controls will be administered a placebo
89203740|NCT00804492|Experimental|1|To establish an integrated intervention model for prevention of elderly fall
89203741|NCT00804492|Experimental|2|To perform a RCT to investigate the effectiveness of the multicenter, multifaceted intervention program
89203742|NCT00763568|Experimental|Nitazoxanide|One nitazoxanide 500 mg tablet orally twice a day for 4 weeks followed by one nitazoxanide 500 mg tablet orally twice a day plus weekly injections of 180µg peginterferon alfa-2a for 36 weeks.
89203743|NCT04049006|Experimental|complex-treatment benefiting group|Participants in the intervention group will receive the complex treatment and the usual clinical practice.
89203744|NCT04049006|No Intervention|complex-treatment no benefiting group|Participants in the control group will receive the care from the usual clinical practice
89203745|NCT00806754|Active Comparator|1|Ciclesonide nasal spray (50 mcg/spray, one spray per nostril) and placebo azelastine nasal spray ( two sprays per nostril) administered twice daily approximately 1 minute apart, once in the morning and 12 hours later, in the evening.
89203746|NCT00806754|Active Comparator|2|Ciclesonide nasal spray (50 mcg/spray, one spray per nostril) and azelastine nasal spray (137 mcg/spray, two sprays per nostril) administered twice daily approximately 1 minute apart, once in the morning and 12 hours later, in the evening.
89021263|NCT00428649|Experimental|4|80 µg selenium as selenomethionine
89021264|NCT00428649|Experimental|5|100 µg selenium as selenomethionine
89021265|NCT00428649|Experimental|6|120 µg selenium as selenomethionine
89021266|NCT00428649|Placebo Comparator|7|placebo
89021267|NCT03790709|Experimental|High dose ANAVEX2-73|High dose active once daily orally
89021268|NCT03790709|Experimental|Mid dose ANAVEX2-73|Mid dose active once daily orally
89021269|NCT03790709|Placebo Comparator|Placebo oral capsule|Placebo dose once daily orally
89021270|NCT00433173|Placebo Comparator|1|1) Group 1: Placebo
89021271|NCT00433173|Active Comparator|2|2) Group 2: Depot GnRH agonist (Zoladex) + Testosterone + placebo
89021272|NCT00433173|Active Comparator|3|3) Group 3: (Zoladex + Testosterone + aromatase inhibitor (anastrozole)
89021273|NCT01055028|Experimental|Regimen A / Treatment 1|"Participants were to receive paclitaxel 200 mg/m² intravenously over 3 hours every 21 days followed by bevacizumab 15 mg/kg intravenously over (cycle 1: 90 min; cycle 2: 60 min; cycles 3 to 6: 30 min) every 21 days x 6 cycles.~Maintenance bevacizumab (MB), 15 mg/kg once every 21 days intravenously for a maximum of 8 cycles, was initiated after the completion of paclitaxel + bevacizumab combination."
89021274|NCT01055028|Experimental|Regimen B / Treatment 2|"Patients were to receive paclitaxel 90 mg/m² weekly x 3 of a 28-day cycle followed by bevacizumab 15 mg/kg intravenously over (cycle 1: 90 min; cycle 2: 60 min; cycles 3 to 6: 30 min) every 21 days x 6 cycles.~Maintenance bevacizumab (MB), 15 mg/kg once every 21 days intravenously for a maximum of 8 cycles, was initiated after the completion of paclitaxel + bevacizumab combination."
89021275|NCT00433212|Active Comparator|A|Non-invasive respiratory support via nasal intermittent positive pressure ventilation
89021276|NCT00433212|Active Comparator|B|Non-invasive respiratory support via nasal Continuous Positive Airway Pressure
89484377|NCT03548389|Experimental|Mother and newborn skin to skin contact|By assistance of the researcher, intervention infants were placed undressed in a prone position against their mothers' bare chest between breasts immediately after birth and before placental delivery and suturing of tears or episiotomy. The Apgar score was determined, the infant's nose and mouth were suctioned while on the mother's chest, it was well dried, and both mother and infant were covered with a pre-warmed blanket. To prevent heat loss, the infant's head was covered with a dry cap that was replaced when it became damp. Dressing and measuring of the infant were postponed to an hour after the delivery by registered midwife.
89484378|NCT03548389|No Intervention|Conventional care|In the routine care group, the infant was delivered from the mother by a midwife, wrapped in blankets, taken to be routinely cared under a warmer, and then dried quickly. Afterwards, the Apgar score was determined immediately after the umbilical cord was cut. The infants were provided with all routine care by the midwife working in the delivery room. After the infants were weighed, dressed, and measured, they were handed to their mothers who were encouraged to begin breastfeeding.
89484379|NCT03569501|No Intervention|nutritional guidance|routine care (all arms with nutritional guidance per routine care)
88952489|NCT02766335|Experimental|Arm III (MEDI4736 retreatment)|For patients assigned to Arm 1, MEDI4736: Upon evidence of progression following discontinuation of 12 months of treatment, patients may restart treatment with Arm 3, MEDI4736 for up to 12 months with the same treatment guidelines followed during the initial 12-month treatment period. Patients will only be able to restart treatment once; thus a maximum of two 12-month periods will be allowed. Patients receive durvalumab IV over 60 minutes on day 1. Treatment repeats every 14 days for 12 months in the absence of disease progression or unacceptable toxicity.
88952490|NCT02745847|Experimental|Re-irradiation with SBRT|Patients with relapsed pancreatic cancer meeting all inclusion criteria will receive re-irradiation with SBRT.
88952491|NCT02739711|Active Comparator|Glycoprotein IIb/IIIa inhibitor|Glycoprotein IIb/IIIa inhibitor administration
88952492|NCT02739711|No Intervention|Standard therapy|No glycoprotein IIb/IIIa inhibitors
88952493|NCT02680483||AF cohort|AF consecutive patients
88952494|NCT02607423|Experimental|Diagnostic (18F-FDG PET/CT)|"Patients undergo fludeoxyglucose F-18 PET/CT at baseline and after course 1 of chemotherapy. Patients undergo 1 of 3 chemotherapy regimens at the discretion of the investigator.~CHEMOTHERAPY REGIMEN 1: Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, and 8. Patients also receive cisplatin IV over 60 minutes on day 1. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity.~CHEMOTHERAPY REGIMEN 2: Patients receive docetaxel IV over 60 minutes and cisplatin IV over 60 minutes on day 1. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity.~CHEMOTHERAPY REGIMEN 3: Patients receive pemetrexed disodium IV over 10 minutes and cisplatin IV over 60 minutes on day 1. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity."
88952495|NCT02577523|Experimental|ND0612 (Levodopa/Carbidopa solution) Dosing Regimen 1|Dosing Regimen 1 of ND0612 (Levodopa/Carbidopa solution) continuous SC infusion over 24 hours.
88952496|NCT02577523|Experimental|ND0612 (Levodopa/Carbidopa solution) Dosing Regimen 2|Dosing Regimen 2 of ND0612 (Levodopa/Carbidopa solution) continuous SC infusion over 14 hours. Infusion started at wake-up time supplemented with an oral IR LD/CD tablet.
88952497|NCT02344810|Experimental|Arm A (AMG 337, mFOLFOX6)|Patients receive c-Met inhibitor AMG 337 PO QD on days 1-28; and oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and fluorouracil IV over 46-48 hours on days 1 and 15.
89484380|NCT03569501|Active Comparator|oat grains|90 mg oat, per day.
89484381|NCT03569501|Experimental|oat grains and DHA tablets|90 mg oat and 500 mg DHA oral tablets, per day.
89484382|NCT03569501|Active Comparator|DHA tablets|500 mg DHA oral tablets, per day.
89484383|NCT02130661|Experimental|Part A|Subjects will receive 250 mg of rilapladib once daily (QD) for 14 days (Days 1-14)
89484384|NCT02130661|Experimental|Part B|Subjects will receive 25 mg of rilapladib QD for 1 day (Day 1), 200 mg of itraconazole twice daily (BID) for 1 day (Day 8) and QD for 2 days (Days 9-10). Subjects will receive 25 mg of rilapladib + 200 mg of itraconazole for 1 day (Day 11) and 200 mg of itraconazole QD for 6 days (Day 12-17)
89484385|NCT02139475||Colonoscopy|patients undergoing colonoscopy after colorectal cancer surgery
89484386|NCT03569189|Experimental|High Fat Diet|Participants will consume a high-fat, high-calorie diet for 7 days (i.e. westernised diet) following a 3-day weight maintenance diet. Measurements will be made pre- and post-high fat diet intervention.
88952498|NCT02344810|Active Comparator|Arm B (placebo, mFOLFOX6)|Patients receive placebo PO QD on days 1-28; and oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and fluorouracil IV over 46-48 hours on days 1 and 15.
88952499|NCT02333565|Experimental|Combinaison everolimus and octreotide|
88952500|NCT02333110|Experimental|GRID radiation therapy|A single dose of 15-20Gys of spatially fractionated radiation therapy
88952501|NCT02278185|Experimental|Arm I (enzalutamide)|Patients receive enzalutamide PO QD for 12 months in the absence of disease progression or unacceptable toxicity.
88952502|NCT02278185|Active Comparator|Arm II (ADT)|Patients receive standard of care ADT comprising one of the following at the discretion of the treating physician: leuprolide acetate, goserelin acetate, histrelin acetate, triptorelin, or degarelix SC or IM for 12 months in the absence of disease progression or unacceptable toxicity. Patients may also choose to undergo surgical castration as an alternative form of ADT.
88952503|NCT02205060|Experimental|virtual reality exposure therapy (VRET)|
88952504|NCT02205060|Experimental|cognitive and behavioral approaches therapy without VRET|
88952505|NCT02177695|Experimental|Gemcitabine & Cisplatin|Gemcitabine, 1000 mg/m2, IV, Days 1&8, q 21 days x 4 cycles Cisplatin, 70 mg/m2, IV, Day 1, q 21 days x 4 cycles
88952506|NCT02177695|Experimental|Dose Dense MVAC|Methotrexate, 30 mg/m2, IV, Day 1, q 14 days x 4 cycles Vinblastine, 3 mg/m2, IV, Day 1 or 2, q 14 days x 4 cycles Doxorubicin, 30 mg/m2, IV, Day 1 or 2, q 14 days x 4 cycles Cisplatin, 70 mg/m2, IV, Day 1 or 2, q 14 days x 4 cycles Filgrastim, 5 mcg/kg, SubQ/IV, Days 3-7, q 14 days x 4 cycles
88952507|NCT02005172|Other|Alivecor device and event monitor|Both the Alivecor device (experimental) and the standard of care (event monitor) will be provided to all patients for the duration of the study
89484387|NCT02139553|Experimental|Rhythmic rehabilitation|Patients undergo a first evaluation, and a second evaluation one month later to determine their natural evolution. The following month, patients get 12 sessions of rhythmic therapy. A third evaluation is organized straight after this month and a fourth evaluation, 3 months after to assess the after-effects of the therapy.
89484388|NCT03569423|Experimental|Transepithelial PRK|Transepithelial photorefractive keratectomy was done in 100 right eyes of 100 patients included in the study.
89484389|NCT03569423|Active Comparator|Alcohol assisted PRK|Alcohol assisted photorefractive keratectomy was done in 100 left eyes of the same 100 patients included in the study.
89484390|NCT02130739||thoracic epidural anesthesia|thoracic epidural anesthesia following continuous thoracic epidural analgesia for mastectomy
89484391|NCT02248493|Experimental|paracetamol and ketoprofen|"paracetamol 20 mg/kg (1% 2 ml/kg) IV at the end of surgery 6 and 20 hours thereafter.~ketoprofen 1.5 mg/kg IV at the end of surgery 8 and 16 hours thereafter. tramadol 2 mg/kg IV on patient request up til 4 mg/kg or PCA morphine during 24 hours postoperatively."
89484392|NCT02248493|Placebo Comparator|placebo and ketoprofen|"0.9% sodium chloride (2 ml/kg) IV at the end of surgery 6 and 20 hours thereafter.~ketoprofen 1.5 mg/kg IV at the end of surgery 8 and 16 hours thereafter. tramadol 2 mg/kg IV on patient request up til 4 mg/kg or PCA morphine during 24 hours postoperatively."
89484393|NCT05577949|Experimental|Aerobics|This group will perform structured aerobics exercise program in addition to the standard treatment given for women with PCOS.
89484394|NCT05577949|No Intervention|"Management used as Treatment As Usual"|This group will receive the standard management given for women with PCOS
89484395|NCT03569345|Experimental|Arm|Basal cell carcinoma (BCC) patients Patients (>18 pr) with histologically-verified superficial or nodular basal cell carcinoma (<20 mm on face/scalp, <50 mm on trunk/extremities)
89484396|NCT05577871|Active Comparator|dex group|patients medicated with dexmedetomidine.
89484397|NCT05577871|Placebo Comparator|control group|patients took placebo normal saline.
89484398|NCT03166319|Experimental|Suspected CNS Vasculitis|Patients with suspected CNS vasculitis will undergo an MRI, including intracranial vessel wall imaging.
89484399|NCT05577793|Experimental|Mother's Voice|The mothers were asked to sing lullabies, and their voices were recorded in a quiet environment. Which lullaby they would sing was left to the mothers' discretion, and the audio recording process took an average of 2-3 minutes. The voice recordings taken were applied for a total of 15 minutes before, during and after the nasal CPAP application.The NIPS and PICS scores were evaluated and recorded before, during and after the application.
89484400|NCT05577793|Experimental|Therapeutic Touch|Therapeutic touch was started 5 minutes before nasal prongs were placed, and was applied for 5 minutes during the application, and continued for another 5 minutes after the nasal prongs were placed. The method was applied for a total of 15 minutes as 5 minutes of hand resting, 5 minutes of gentle caressing and 5 more minutes of hand resting.The NIPS and PICS scores were evaluated and recorded before, during and after the application.
89484401|NCT05577793|Experimental|Mother's Voice+Therapeutic Touch|Both applications were applied together for 15 minutes.The NIPS and PICS scores were evaluated and recorded before, during and after the application.
89484402|NCT05577793|No Intervention|Control|The premature babies in the control group did not receive any intervention other than the hospital procedure.The NIPS and PICS scores were evaluated and recorded before, during and after the application.
89484403|NCT02247791|Active Comparator|Cemented femoral stem|Patient undergoing total hip arthroplasty surgery
89484404|NCT02247791|Active Comparator|Uncemented femoral stem|Patients undergoing total hip arthroplasty
89484405|NCT02139631|Experimental|Healthy volunteers|The volunteers initially underwent a clinical examination, spirometry and echocardiography to prove the health state. Then, different levels of positive end expiratory pressure (PEEP) is applied by the noninvasive ventilation in all individuals and the hemodynamic repercussions are evaluated by the doppler echocardiography
89484406|NCT02130817|Experimental|Belatacept|"Belatacept (nujolix):~Tacrolimus withdrawal~Standard of care(SOC) treatment:~Plasmapheresis/Intravenous Immunoglobulin G (IVIG) therapy~Thymoglobulin will be administered to a total cumulative dose of 4.5-6 mg/kg starting in the operating room.~Maintenance immunosuppression:~Myfortic: Patients will receive 720mg bid of Myfortic throughout the study, starting day 1 after surgery.~Steroids: Patients will receive Dexamethasone IV on the day of surgery (Day 0) with tapered doses through Day 4 followed by prednisone tapered to 10mg/d by day 30."
89484407|NCT04420390|Experimental|Radiotherapy|
89484408|NCT02139865|Experimental|30%|Training at 30% 1RM
89203747|NCT00760760|Experimental|n-3 PUFA|
89484409|NCT02139865|Experimental|80%|Training at 80% 1RM
89484410|NCT02400346|Experimental|Adjunct brexpiprazole|All patients continue their current antidepressant treatment (ADT) and receive brexpiprazole in addition
88952508|NCT01898390|Experimental|Transplant|Neural Allo-Transplantation with Fetal Ventral Mesencephalic Tissue
88952509|NCT01898390|No Intervention|Control|comparison group of controls, will receive the same observational and scanning assessments but will not receive any surgical procedures
88952510|NCT01840566|Experimental|HIGH DOSE CHEMOTHERAPY AND ASCT|This is a phase 1 dose escalation study designed to determine the maximum tolerated dose (MTD) of CAR modified T cells in patients with relapsed and refractory aggressive B-NHL. Three dose levels (5 x 106 19-28z T cells/kg, 1 x 107 19-28z T cells/kg, and 2 x 107 19-28z T cells/kg) are considered for the MTD.
89203748|NCT00760760|Placebo Comparator|Control|
89203749|NCT00764816|Active Comparator|1 grain (soy) protein diet:|The patient is to eat a grain (soy) protein diet for 7 days. The food is prepared by a registered dietitian.
89484411|NCT02130895|Experimental|Intervention|STOPP Criteria Decision Support Content Intervention arm will receive CDS suggestions based on the STOPP criteria.
89484412|NCT02130895|No Intervention|Control|Control arm will provide care as usual during the intervention period.
89484413|NCT05354843|Experimental|Dose Escalation and Dose Expansion|ET0038 will be administered orally once daily in 21 days treatment cycles.
89484414|NCT02140099|Experimental|Healthy Relationships Education/Skills|The experimental intervention is the group-based, 15-session Healthy Relationships Plus Program (HRPP). In this study, the HRPP will be offered in a condensed 8-day format (July 8-11 and 14-17, 2014). On days 1 to 7, participants will attend the program for 2 hours, and on day 8, participants will attend the program for 1 hour. The program will be facilitated by high school teachers. Eight HRPP groups will run concurrently during the study period.
89484415|NCT02140099|Other|Classroom Activities|The control condition is a group-based, 15-session program focusing on typical Classroom Activities. The primary activity is to create a school welcome packet for incoming Grade 9 students, with other activities including reading and physical exercise. The control condition will be offered on 8 consecutive weekdays (July 8-11 and 14-17, 2014). On days 1 to 7, participants will attend the control program for 2 hours, and on day 8, participants will attend the control program for 1 hour. The control group will be facilitated by bachelor's level research assistants and pre-service teachers. Eight control groups will run concurrently during the study period.
89484416|NCT03568955||Swiss Bereaved|Adults from the Swiss population who have lost a loved one at least 6 months to 10 years prior to testing
89484417|NCT03568955||Japanese Bereaved|Adults from the Japanese population who have lost a loved one at least 6 months to 10 years prior to testing
89484418|NCT03568955||Chinese Bereaved|Adults from the Chinese population who have lost a loved one at least 6 months to 10 years prior to testing
89484419|NCT03567317|No Intervention|CPAP|According to study design, patients will be randomized to remain on CPAP during the initial study visit or withdraw CPAP one week before. If randomized to withdraw CPAP during the initial study visit, patients will resume CPAP use for one week before the second study visit.
89484420|NCT03567317|Experimental|CPAP withdrawal|According to study design, patients will be randomized to remain on CPAP during the initial study visit or withdraw CPAP one week before. If randomized to withdraw CPAP at the second study visit, patients will withdraw CPAP one week before.
89484421|NCT02399254||Pulmonary Rehabilitation|Chronic Obstructive Pulmonary Disease (COPD) patients following pulmonary rehabilitation
89484422|NCT02130973|Active Comparator|Standard Clinical Practice Regimen|Standard Clinical Practice (Daily) Regimen: 18 months of daily subcutaneous Forteo followed by denosumab therapy for 18 months (18 months of Forteo then 3 injections of Prolia at 18, 24 and 30 months).
89484423|NCT02130973|Experimental|Experimental (cyclic) regimen|Experimental (Cyclic) Regimen: three separate 6-month cycles of daily subcutaneous Forteo, each followed by one subcutaneous injection of Prolia (Forteo from 0 to 6 months, and then from 12 to 18 months and then from 24 to 30 months, for a total dose of 18 months; 3 injections of Prolia at 6, 18 and 30 months).
89484424|NCT03567239|Experimental|Using adaptive device|Participants will use a non-commercially available device, designed to meet their needs.
89484425|NCT02456662|Placebo Comparator|Placebo|160 Patients will randomly be assigned, using sealed numbered opaque envelopes to receive placebo tablet 30 minutes prior to taking 200mg PO doxycycline
89484426|NCT02456662|Active Comparator|Ondansetron|160 Patients will randomly be assigned, using sealed numbered opaque envelopes to receive 8mg ondansetron tablet 30 minutes prior to taking 200mg PO doxycycline
89021277|NCT03611816||Group 1a|Patient with atrial fibrillation and without stroke history.
89484427|NCT03567161|Experimental|Cavitron ultrasonic surgical aspirator|"Patients.with periodontitis.~Inclusion criteria:~Having received a diagnosis of chronic periodontitis (Armitage 1999)~Being treated by full mouth debridement, and supportive periodontal treatment (SPT) in the last year (at least three sessions)~Having at least one residual pocket ≥ 5 mm with and intra bony component at least ≥ 2 mm~Exclusion criteria:~Smoking more than ten cigarettes per day~Pregnancy~Irregular compliance during SPT in the last year; and systemic conditions or therapies known to affect the healing potential of periodontal tissues (e.g., uncontrolled diabetes, oncological conditions, immunosuppressant drugs)."
89484428|NCT03567083|Experimental|E-CAU with Problem Management Plus (PM+)|30 participants will be randomly assigned to E-CAU with PM+ group. The PM+ is developed by the World Health Organization (WHO) especially for the communities who are exposed to adversity. PM+ (Dawson et al., 2015) belongs to a set of programs which are low-intensity, shorter, less expensive and trans-diagnostic (i.e., not condition-specific, but targeted at a broader set of symptoms of common mental disorders) programs to reduce common mental health symptoms (including depression, anxiety and stress symptoms) and improve psychosocial functioning.
89203750|NCT00764816|Active Comparator|2 casein (meat) protein diet|The patient is to eat a casein (meat) protein diet for 7 days. The food is prepared by a registered dietitian.
89203751|NCT00810654|Experimental|ANPEP|Aspergillus niger prolyl endoprotease (AN-PEP), a microbial-derived prolyl endoprotease which cleaves gluten
89203752|NCT00810654|Placebo Comparator|Placebo|
89203753|NCT00764894||Foundation Knee|Retrospective data collection on 510(k) approved device
89203754|NCT00804726|Experimental|Akreos MI Five-O|Accommodating intraocular lens
89537690|NCT03298529|Experimental|Pasta with only eight egg whites/kg flour|"Pasta with only eight egg whites/kg flour. 12 healthy subjects, after a 10 to 12-hour overnight fasting period, will assume fettuccine pasta with only eight egg whites/kg flour. The serving size is calculated to contain 50 g of carbohydrates according to nutritional analysis of the product."
89537691|NCT03298529|Experimental|Pasta with four eggs/kg flour|"Pasta with four eggs/kg flour. 12 healthy subjects, after a 10 to 12-hour overnight fasting period, will assume fettuccine pasta with four eggs/kg flour. The serving size is calculated to contain 50 g of carbohydrates according to nutritional analysis of the product."
89537692|NCT03298529|Experimental|Hyperproteic pasta (with added gluten and albumin)|"Hyperproteic pasta (with added gluten and albumin). 12 healthy subjects, after a 10 to 12-hour overnight fasting period, will assume fettuccine pasta with added gluten and albumin. The serving size is calculated to contain 50 g of carbohydrates according to nutritional analysis of the product."
89537693|NCT03298529|Experimental|Pasta with only four egg whites/kg flour|"Pasta with only four egg whites/kg flour. 12 healthy subjects, after a 10 to 12-hour overnight fasting period, will assume fettuccine pasta with only four egg whites/kg flour. The serving size is calculated to contain 50 g of carbohydrates according to nutritional analysis of the product."
89537694|NCT03295955|Active Comparator|Postop antibiotics group|Prescribe Amoxicillin Clavulanate
89537695|NCT03295955|No Intervention|No postop antibiotics|Do not prescribe Amoxicillin Clavulanate
89537696|NCT03298373|Placebo Comparator|Placebo|Placebo capsules that look like the 11β-MNTDC capsules but with no active ingredients.
89537697|NCT03298373|Experimental|11β-MNTDC|11β-MNTDC capsules administered orally (200 mg or 400 mg).
89203755|NCT00804804|Experimental|Y1|young volunteers (20-30 years), morningness chronotype
89537698|NCT01670721|Experimental|Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)|Aflibercept 4 mg/kg intravenous (IV) infusion over 60 minutes followed by Irinotecan 180 mg/m^2 IV infusion over 90 minutes and Leucovorin 400 mg/m^2 IV infusion over 120 minutes at the same time followed by 5-FU 400 mg/m^2 IV bolus over 2-4 minutes followed by 5-FU 2400 mg/m^2 continuous IV infusion over 46 hours on Day 1 of each cycle (1 Cycle = 2 weeks), until DP, unacceptable toxicity, death, Investigator's decision or participant's refusal of further treatment.
89537699|NCT03295877|Experimental|RO7171009: SAD|Patients will receive a single dose of RO7171009, in multiple escalating cohorts.
89537700|NCT03295877|Experimental|RO7171009: MD|Patients will receive RO7171009 at maximum tolerated dose (MTD), identified during the SAD stage for three doses.
89537701|NCT04489043|Experimental|Exercise and healthy life style recommendations|A planned exercise programme to test the impact of this treatment. An Oral Glucose Tolerant Test (OGTT) at intermediate time points in order to increase the frequency and duration of aerobic exercise and eventually to add anaerobic/resistance training.
89537702|NCT03063411|Experimental|Executive function intervention|The intervention comprises four weekly sessions lasting 15-20 minutes. In these sessions, children complete computerised tasks requiring working memory and inhibitory control. These tasks are child friendly and are based on established measures of executive function. The working memory tasks involve maintaining information in mind and processing information (for example, finding items hiding in different locations that move around) and suppressing a dominant but incorrect response (for example, a game where children try to catch fish but not sharks). Children receive feedback on their responses. If children score 75% or more correct in a session the difficulty level increases in the following session.
89537703|NCT03063411|Active Comparator|Visual search and simple decision making|The control task program, like the intervention, comprises four weekly sessions lasting 15-20 minutes. In these sessions, children complete computerised tasks not requiring executive function skills. Instead, they require simple attention and decision making skills and visual search skills. For example, finding an item among distractors (e.g., a spaceship), or deciding which of two animals can fly (out of a bird and a fish). Children receive feedback on their responses.
88952511|NCT01719237|Active Comparator|Ropivacine and Cholroprocaine mixture|20 ml's of 1% ropivacaine + 10 ml's of 3% 2-chloroprocaine + 0.1 ml of 1 mg/ml epinephrine
89203756|NCT00804804|Experimental|Y2|young volunteers (20-30 years), eveningness chronotype
89203757|NCT00804804|Experimental|O1|Aged volunteers (65-75 years), morningness chronotype
89203758|NCT00804804|Experimental|O 2|aged volunteers (65-75 years), eveningness chronotype
89203759|NCT00806832||Medical clowns treatment|Patients scheduled for an elective cataract surgery will receive pre-operative conventional treatment and in addition will be exposed to medical clowns effect
88952512|NCT01719237|Sham Comparator|Ropivacine only|30 ml syringe with either 20 ml's of 1% ropivacaine + 10 ml's of normal saline + 0.1 ml of 1mg/ml epinephrine
89484429|NCT03567083|No Intervention|Enhanced care as usual (E-CAU) only|30 participants will be randomly assigned to E-CAU group. CAU ranges from the free health services government provides to Refugee and Asylum Seekers Assistance and Solidarity Association's (RASASA) mental health services which are provided by the Psychological Support Unit (MHPSS Support Unit) which includes counselling as well. The enhanced care arm (CAU, with the addition of a referral document), is to be used as a benchmark for measuring the effectiveness of STRENGTHS's intervention, which is Problem Management Plus (PM+).
88952513|NCT01352429||Phase 1 Feasibility|
88952514|NCT01352429||Phase 2 Registration|
88952515|NCT01274962|Experimental|A - neoadjuvant chemotherapy|Patients in arm A will receive 6 cycles of FOLFOX chemotherapy prior to radiotherapy and surgery as well as 6 cycles of chemotherapy in adjuvant
89484430|NCT03548311|Placebo Comparator|Placebo|intramuscular injection of saline solution
89484431|NCT03548311|Active Comparator|methylcobalamin|intramuscular injection of methylcobalamin
89484432|NCT01653262|Experimental|Brivaracetam|"The subjects will be treated with Brivaracetam (BRV) tablets 200 mg/day during 12 weeks: four 25 mg tablets, twice daily.~Based on the Investigator's judgement, at any time, the dose can be decreased to BRV 150 mg/day, 100 mg/day, or 50 mg/day. Flexible dosing, can be up- and down-titrated as needed.~At the end of the Treatment Period, the subject will either enter the N01372 long-term follow-up study or down-titrate during 4 weeks."
89484433|NCT03568877|Placebo Comparator|Placebo Control|2 capsules per day, each with 400 mg Cellulose microcrystalline, for 8 weeks
89484434|NCT03568877|Experimental|Dietetic Supplement Group|2 Capsules per day of Metabolaid® (each capsule contains 250 mg Metabolaid®, 150 mg cellulose microcrystalline), for 8 weeks
89484435|NCT05577325|Experimental|PLANNED EDUCATION BASED ON THE HEALTH IMPROVEMENT MODEL|Educational content based on the health promotion model, including nutrition and physical activity, will be created by the researcher by scanning the literature and considering the needs of the students. For the nutrition and physical activity plans included in the training, a diet specialist and a sports specialist will be consulted on the subject. The created training content and the booklet will be submitted to the opinion of at least three experts who are suitable for the subject area. Educational content deemed appropriate will be shared with students for 1 lesson per week for 10 weeks.
89484436|NCT05577325|Experimental|follow without interference|follow up without any education
89484437|NCT03566927|Experimental|FLEX Scoring Catheter plus DCB|This is a single-arm study. All patients will be treated with the FLEX Scoring Catheter, then a standard balloon angioplasty, followed by a Lutonix® drug-coated balloon (DCB).
89484438|NCT03568799|Experimental|4-[18F]Fluoroglutamine|Patients undergo 18F-FDG PET/CT scan first. Within 7 working days, patients receive 4-[18F]Fluoroglutamine IV and 60 minutes after injection, undergo 4-[18F]Fluoroglutamine PET/CT before the start of therapy.
89484439|NCT02455336|Experimental|Fenofibrate|Subjects with adverse TG concentrations (i.e., paraplegia: >/=135 mg/dl; tetraplegia >/=115 mg/dl) will be randomized to receive once daily fenofibrate therapy (i.e., 145 mg) for 4 months
89484440|NCT02455336|Other|No Intervention|Subjects with adverse TG concentrations (i.e., paraplegia: >/=135 mg/dl; tetraplegia >/=115 mg/dl) will be randomized to receive no therapy for 4 months
89484441|NCT05577169|Experimental|Mind-body skills + diabetes education|"Participants randomly assigned to this arm will undergo 20-30 minutes discussing a predetermined diabetes topic followed by 20-30 minutes working on a mind-body skills component. This mind-body skills component will be a combination of deep breathing, self-reflection, and meditation techniques focused on self-awareness to calm the stress-response. Participants will be assigned homework designed to encourage practice of the learned skill."
89484442|NCT05577169|Active Comparator|Diabetes education alone|Participants randomly assigned to this arm will similarly undergo 20-30 minutes discussing the same predetermined diabetes topic as the intervention group.
89484443|NCT00825929||1|Treated with one of the antiretroviral agents under study, PK parameters during pregnancy will be compared with PK parameters after pregnancy (within the same woman)
89484444|NCT02253121|Experimental|Dapagliflozin + sliding scale insulin.|Treatment with dapagliflozin 10mg once daily orally. Treatment will start as soon as possible after initation of glucocorticoid pulse therapy for acute exacerbation COPD and will end when pulse therapy is finished (expected duration 10-14 days). In case of persistent glucose levels > 12 mmol/l, subjects will receive escape treatment with sliding scale insulin.
89484445|NCT02253121|Placebo Comparator|Placebo + sliding scale insulin|Treatment with placebo once daily orally. Treatment will start as soon as possible after initation of glucocorticoid pulse therapy for acute exacerbation COPD and will end when pulse therapy is finished (expected duration 10-14 days). In case of persistent glucose levels > 12 mmol/l, subjects will receive escape treatment with sliding scale insulin.
89484446|NCT03548233|Other|bcg vaccinated|children under five year vaccinated by bcg vaccine
89484447|NCT03568721|Experimental|ibuprofen|ibuprofen (400 mg) immediately after insertion of the initial archwire and 6/6 hs for a week if there is any orthodontic pain.
89484448|NCT03568721|Experimental|acetaminophen|acetaminophen (500 mg) immediately after insertion of the initial archwire and 6/6 hs for a week if there is any orthodontic pain.
89484449|NCT03568721|Experimental|chewing gum|chewing gum (01 tablet) immediately after insertion of the initial archwire and 6/6 hs of chewing gum for a week if there is any orthodontic pain.
89484450|NCT03568721|No Intervention|control|control (no reliever for orthodontic pain)
89537704|NCT03287427|Experimental|TetMYB Vaccine & BGB-A317|
88952516|NCT01274962|Experimental|Arm B - adjuvant chemotherapy|Patients in arm B will receive 12 cycles of FOLFOX after radiotherapy and surgery
88952517|NCT01257594|Experimental|No cytoreductive surgery planned|Patients who are not candidates for surgery as part of their routine care will enroll into the medical arm of the trial. They will initiate pulsatile erlotinib dosing and continue therapy until either disease progression or intolerable toxicity.
88952518|NCT01257594|Experimental|Cytoreductive surgery planned|"Patients scheduled for salvage resection as part of their routine care will be considered for this cohort. They will receive 1 pre-operative dose of 2000 mg erlotinib. Resection will occur ≤ 3 hours after the pre-operative dose. After recovery from surgery, patients will resume pulsatile erlotinib dosing."
89484451|NCT03549325|Experimental|Group 1|"Nasal drops containing Neisseria lactamica are administered at Day 0 by the study doctor.~Eradication therapy with the antibiotic Ciprofloxacin given on Day 4, unless required sooner.~Follow up visits occur on Days 5, 14 and 32."
88952519|NCT01004731|Experimental|Cetuximab in combination with Carboplatin/Gemcitabine|Approximately 30 patients with advanced NSCLC will be enrolled. Patients will receive 3-week cycles of Cetuximab in combination with Carboplatin/Gemcitabine.
88952520|NCT00987753|Experimental|infusion of L-377202|
88952521|NCT00771017|Active Comparator|Arm I|Patients receive oral bicalutamide once daily on days 1-28. Patients also receive luteinizing-hormone releasing-hormone (LHRH) agonist treatment comprising leuprolide acetate or goserelin intramuscularly (IM) on day 8. Treatment with LHRH agonist repeats every 12 weeks for 24 weeks.
88952522|NCT00771017|Experimental|Arm II|Patients receive androgen ablation as in arm I. Patients receive GVAX prostate cancer vaccine (CG1940 and CG8711) intradermally (ID) on day 1. Beginning on day 1 of week 3, patients receive booster doses of CG1940 and CG8711 ID every 2 weeks for 24 weeks.
88952523|NCT00391365||Group 1|Subjects undergoing ankle arthrodesis (fusion) for treatment of ankle arthritis
89484452|NCT03549325|Experimental|Group 2|"Nasal drops containing Neisseria lactamica are administered at Day 0 by the study doctor.~Follow up visits on Day 4 and 7 to check for N. lactamica carriage. Eradication therapy with the antibiotic Ciprofloxacin given on Day 14, unless required sooner.~Follow up visits occur on Days 15, 24 and 42."
89484453|NCT03568565|Experimental|ePREP Program|The ePREP program is based on the in-person Prevention and Relationship Enhancement Program. The ePREP program consists of six sections of material. In each section, new information and skills are presented, videos demonstrate real couples practicing the skills, participants are encouraged to discuss the information in the context of their own relationship, and a multiple choice quiz reiterates and summarizes the section. In addition to the core educational materials, couples are asked to complete six additional online and offline homework assignments (one per week), each lasting approximately one hour. Participants who do not complete activities in a timely manner will be re-randomized to either continue without a coach or to receive a coach.
89484454|NCT03568565|Experimental|ePREP Program plus Coach|The ePREP program is based on the in-person Prevention and Relationship Enhancement Program. The ePREP program consists of six sections of material. In each section, new information and skills are presented, videos demonstrate real couples practicing the skills, participants are encouraged to discuss the information in the context of their own relationship, and a multiple choice quiz reiterates and summarizes the section. In addition to the core educational materials, couples are asked to complete six additional online and offline homework assignments (one per week), each lasting approximately one hour. Couples also have four, brief video or phone calls with a coach throughout the program.
89484455|NCT03568565|Experimental|OurRelationship Program|The OurRelationship program is based on Integrative Behavioral Couple Therapy and encourages couples to select, understand, and solve a relationship problem. Partners complete the majority of the web-based program on their own and come together for three key conversations with their partner.Participants who do not complete activities in a timely manner will be re-randomized to either continue without a coach or to receive a coach.
89484456|NCT03568565|Experimental|OurRelationship Program plus Coach|The OurRelationship program is based on Integrative Behavioral Couple Therapy and encourages couples to select, understand, and solve a relationship problem. Partners complete the majority of the web-based program on their own and come together for three key conversations with their partner. The first conversation between partners centers on discussing possible core relationship issues and jointly deciding on the problem(s) to focus on during the program. During the second conversation, both partners' previous written responses are displayed on the screen and conversation is encouraged. During the final conversation, couples share their strategies to decrease stress, improve patterns of communication, and engage in problem-solving exercises specific to their core issue(s). Couples also have four, brief video or phone calls with a coach throughout the program.
89484457|NCT03568565|No Intervention|Waitlist|Participants are assessed at 1, 2, 4, and 6 months after randomization; however, no active intervention is given during the waitlist period.
89484458|NCT04905940|Experimental|Turmeric mouthwash|Evaluation of cost-effectiveness of turmeric mouthwash in controlling halitosis
89484459|NCT04905940|Active Comparator|Essential oil mouthwash|Evaluation of cost-effectiveness of essential oil mouthwash in controlling halitosis
89484460|NCT04905940|Placebo Comparator|Placebo mouthwash|Evaluation of cost-effectiveness of placebo mouthwash in controlling halitosis
89484461|NCT03566849|Experimental|KC group|It mainly involve all segment in kinetic chain, not only shoulder girdle, include exercise training 3 times a week for a total 4 weeks.
89484462|NCT03566849|Experimental|CT group|It involve shoulder girdle only, include exercise training 3 times a week for a total 4 weeks.
89021278|NCT03611816||Group 1b|Patient with atrial fibrillation with scheduled electrophysiology exploration or ablation.
89484463|NCT02140177||Adult Medical Inpatients|Adult medical inpatients; We will enroll adult patients, ages 18 years and older, admitted to identified inpatient medical units during designated data collections days.
89484464|NCT03568487|Experimental|Intensive scapula-focused approach|
89484465|NCT03568487|Active Comparator|Control therapy|
89484466|NCT05576935|Experimental|Intervention|"The intervention task consists of a 60 minute Stroop task. In this task, four coloured words (rood, blauw, groen and geel) will be presented one at a time on a computer screen. The participants will be required to indicate the colour of the word, ignoring the meaning of the word itself. If, however, the ink colour of the word is red, the button to be pressed will be the button linked to the real meaning of the word. The word presented and its ink colour will be randomly selected by a computer (100% incongruent), with all incongruent word-colour combinations being equally common. Subjects will be instructed to respond as quickly and accurately as possible. To assess performance both ACC and reaction time (RT) will be collected and averaged every block."
89484467|NCT05576935|Active Comparator|Control|In the control task subjects will have to watch a documentary of 60 min.
89484468|NCT05576779||Ofatumumab|all eligible patients with at least 1 claim for ofatumumab observed during the index period were included in the ofatumumab cohort
89484469|NCT05576779||Non-ofatumumab|patients with no evidence of ofatumumab during the index period were included in the non-ofatumumab cohort and included in subgroups based on the index medication: Siponimod, Ocrelizumab, Dimethyl fumarate, Glatiramer acetate
89484470|NCT03566771|Active Comparator|Usual care|Usual care according to regular treatment routines at the clinic during 12 months
89484471|NCT03566771|Active Comparator|CLOSS|Usual care plus using a web-based support system for self-monitoring weight, physical activity and communication with the clinic during 12 months
89484472|NCT01562899|Experimental|Dose escalation|Dose finding group chosen in order to establish a safe and tolerated dose of binimetinib in combination with ganitumab in patients with selected advanced solid tumors.
89484473|NCT01562899|Experimental|KRAS mutated colorectal adenocarcinoma|"Patients with KRAS mutant colorectal cancer.~The starting dose (30 mg bid) of binimetinib chosen for this study was a fraction of the MTD (60 mg bid) and the RP2D (45 mg bid) determined for single agent use. The starting dose for ganitumab was 12 mg/kg q2w which had been shown to be a well-tolerated dose in combination with other anti-cancer agents."
89484474|NCT01562899|Experimental|Metastatic pancreatic adenocarcinoma|"Patients with metastatic pancreatic cancer.~The starting dose (30 mg bid) of binimetinib chosen for this study was a fraction of the MTD (60 mg bid) and the RP2D (45 mg bid) determined for single agent use. The starting dose for ganitumab was 12 mg/kg q2w which had been shown to be a well-tolerated dose in combination with other anti-cancer agents."
89484475|NCT01562899|Experimental|BRAF mutated melanoma|"Patients with mutant BRAF V600 melanoma.~The starting dose (30 mg bid) of binimetinib chosen for this study was a fraction of the MTD (60 mg bid) and the RP2D (45 mg bid) determined for single agent use. The starting dose for ganitumab was 12 mg/kg q2w which had been shown to be a well-tolerated dose in combination with other anti-cancer agents."
89484476|NCT05354375|Experimental|CAR-T cell immunotherapy|The registered patients will receive CAR-T cell immunotherapy for the new specific chimeric antigen receptor of PSMA antigen by infusion.
89484477|NCT03549247||quality of life in periodontal healthy|250 individuals who have teeth pocket depth is at most 3 mm and there is no loss of attachment, no radiological bone loss and no gingival inflammation determeined for their quality of life
89484478|NCT03549247||quality of life in gingivitis|250 individuals who have teeth pocket depth in the mouth is at most 3 mm and there is no loss of attachment, no radiological bone loss and have chronic gingival inflammation with the sign of bleeding determeined for their quality of life
89484479|NCT03549247||quality of life in periodontitis|250 individuals who have more than 30% of teeth in the mouth which have pocket depths equal or more than 4mm and clinical attachment levels equal or more than 5mm and have radiologically detected bone loss determeined for their quality of life
89484480|NCT03566693|Experimental|Continous Glucose Monitor|
89484481|NCT03566693|Active Comparator|Self Monitoring Blood Glucose|
89484482|NCT03568331|Experimental|Tradipitant|
89484483|NCT03568331|Placebo Comparator|Placebo|
89484484|NCT03548077|Experimental|Intervention group|Powerplay, a workplace wellness program designed for male-dominated work sites, is the intervention. The program focuses on physical activity, healthy eating, mental wellness, and smoking cessation as well as promoting changes in workplace environments to support employee health and wellness. Program delivery is supported with a detailed program manual and web-based resources. More information about the intervention is available here: http://www.powerplayatwork.com/
89484485|NCT05468827|Experimental|interventional|lymphatic mapping by indocyanine green
89484486|NCT03566537||Cases|Patients who are going to undergo a thyroid surgery due to symptomatic non-toxic multinodular goiter, uncontrolled thyrotoxicosis or suspicious FNA
89484487|NCT03566537||Controls|Patients with benign thyroid disease, not undergoing thyroidectomy
89484488|NCT03566459||Veterans with opioid use disorder (OUD)|Veterans with opioid use disorder (OUD) in VA Maine Healthcare System catchment area
89484489|NCT03566303|Active Comparator|Rivaroxaban|Rivaroxaban 15mg BID
89484490|NCT03566303|Placebo Comparator|Warfarin|Warfarin dose adjusted
89484491|NCT02140333|Experimental|Erlotinib 100mg|Erlotinib 100mg
89484492|NCT02140333|Active Comparator|Erlotinib 150mg|Erlotinib 150mg
89484493|NCT05936541|Experimental|Probiotic Bifidobacterium Bifidum PRL2010|Participants in this group will receive probiotic Bifidobacterium Bifidum PRL2010 supplementation from the time of discharge to a daily for the 6 months
89484494|NCT05936541|Active Comparator|Control|Participants in this group will not receive probiotic probiotic supplementation
89537705|NCT04491695|Experimental|Tirofiban+Oral antiplatelet therapy|Patients will receive Tirofiban in the first 72 hours and bridge to oral antiplatelet therapy thereafter.
89021279|NCT03611816||Group 1c|Patient with atrial fibrillation and with stroke history.
89021280|NCT03611816||Group 2|Patients aged over 80 years old and without history of atrial fibrillation.
89021281|NCT03611816||Group 3|Patient with cryptogenic stroke history before the age of 50.
88952524|NCT00391365||Group 2|Subjects undergoing ankle arthroplasty (replacement) for treatment of ankle arthritis
88952525|NCT00318903|Experimental|Taxotere/Irinotecan|Taxotere and Irinotecan is given intravenously for 3 consecutive weeks with a one-week break before radiotherapy for 5-6 weeks. A combination of Taxotere and Irinotecan will then be administered simultaneously with the radiotherapy.
88952526|NCT00129090|Experimental|R-CHOEP14 with 12x Rituximab|8 cycles of standard CHOP with etoposide in 14-day intervals. Patients with CD20+ lymphoma receive 12 doses of Rituximab (day 0,1,4,8 of cycle 1, day 1 and 8 of cycle 2, day1 of cycle 3-8 )
88952527|NCT00001850||Children|with reproductive disorders
88952528|NCT00001850||Men|with reproductive disorders
88952529|NCT00001850||Woman|with reproductive disorders
89021282|NCT00428727|Experimental|1|Nitric oxide patches
89021283|NCT00428727|Placebo Comparator|2|Placebo patches
89021284|NCT03440957|Other|Osteopathy treatment|
89021285|NCT04716569|Experimental|intranasal Ivermectin group|Ivermectin group Patients who will receive intranasal ivermectin
89484495|NCT05936515||Post-intervention group (Training course group)|The experimental group will be composed of patients aged 75 and over hospitalised in specialised departments after the establishment of geriatric correspondents trained in the specific care for the elderly.
89484496|NCT05936515||Pre-intervention group (Control group)|The control group will be composed of patients aged 75 years and over hospitalised in specialised departments before the introduction of geriatric correspondents trained in the specific care for the elderly. Their care will be conducted in accordance with usual practices.
89484497|NCT05936450|Experimental|test group|placentrex gel + Open Flap Debridement
89484498|NCT05936450|Active Comparator|control group|Open Flap Debridement alone
89484499|NCT05936424|Active Comparator|Non-Exercise Control (CON)|This condition will serve as a non-exercise control and will not be performing resistance exercise training (RET)
89484500|NCT05936424|Experimental|Follicular Based Training (FOL)|This condition will have high volume of RET (20 weekly sets) during the follicular phase and low volume during the luteal phase of the participant's menstrual cycle.
89484501|NCT05936424|Experimental|Luteal Based Training (LUT)|This condition will have high volume of RET (20 weekly sets) during the luteal phase and low volume during the follicular phase of the participant's menstrual cycle.
89484502|NCT05936424|Experimental|Exercise Control (EX)|This condition will have consistent training volume (12 weekly sets) throughout the duration of the study, regardless of what phase of the menstrual cycle the participant is in.
89484503|NCT05936411|Other|Healthy Subjects|
89484504|NCT05936398|Active Comparator|Voluntary Isocapnic Hyperpnoea (VIH)|Group performing respiratory muscle training with Voluntary Isocapnic Hyperpnoea (VIH) method.
89484505|NCT05936398|Active Comparator|Inspiratory Pressure Threshold Loading (IPTL)|Group performing respiratory muscle training with Inspiratory Pressure Threshold Loading (IPTL) method.
89484506|NCT05936333|Experimental|Patient with chronic histiocytic intervillositis|Patient with CHI, as well as her children and their father. Blood collection from the parents, saliva collection (or blood collection) from the children, placenta collection
89484507|NCT05936333|Active Comparator|patients with anti-phospholipid syndromes (APS)|Patient with antiphospholipid syndrome, as well as her children and their father. Blood collection from the parents, saliva collection (or blood collection) from the children, placenta collection
89484508|NCT05936333|Placebo Comparator|women with a third full-term pregnancy without growth retardation.|Patient with normal pregnancies, as well as her children and their father. Blood collection from the parents, saliva collection (or blood collection) from the children, placenta collection
89484509|NCT05936320|Experimental|Intervention group|Verbal information along with information leaflets containing text with illustrations about hearing aid functions
89484510|NCT05936320|Experimental|Control group|Verbal information along with information leaflets containing text-only about hearing aid functions
89484511|NCT05936294|Other|CRT Optimization|Each patient will have atrial pacing 10% higher than the sinus rate or atrial pacing at a rate of 60 bpm if significant sinus bradycardia is present. Each patient will have six ECGs and echocardiographic sequences performed in the same session. In addition six electrical activation evaluations by the Medtronic ECG belt will be done as well. The first study will always be with no ventricular pacing. One study will be echocardiography-optimized BIV pacing and four studies for echocardiography-optimized (?) adaptive RV-only pacing with different AV intervals. A random-sequence will be performed to determine the order for the rest of the studies.
89484512|NCT05936281|Experimental|Genakumab group|Genakumab 100mg single injection,Genakumab 200mg single injection
89484513|NCT05936281|Active Comparator|Colchicine group|Colchicine 0.5mg qd po.for 12 weeks
89484514|NCT05936125|Experimental|Patients with tricuspid valve regurgitation undergoing open heart surgery|Patients undergoing open heart surgery (for any reason) with concomitant tricuspid valve regurgitation
89484515|NCT05936112|Other|Infants < 4 months old with FGID|Infants < 4 months old presenting one or several Functional GastroIntestinal Disorder(s)
89484516|NCT05936112|Other|Infants < 4 months old free from FGID|Infants < 4 months old without any Functional GastroIntestinal Disorder
89484517|NCT05936060|Experimental|IMUNOCEM|Administration of umbilical cord-derived mesenchymal stromal cells suspension
89484518|NCT05936060|Placebo Comparator|PLASMALYTE|Administration of plasmalyte as vehicle for MSC
89537706|NCT04491695|Active Comparator|Oral antiplatelet therapy|Patients will receive oral antiplatelet therapy alone.
89021286|NCT04716569|Other|Control group|patients who will receive regular protocol drugs
89484519|NCT05935904||MetS_risk|Pregnant women in their first trimester who have one or more of the following risk factors: abdominal obesity defined as waist circumference ≥ 2 standard deviations (SD) for gestational age in the first half of pregnancy or presentational BMI >30 kg/m2; triglycerides concentration >150 mg/dl; HDL cholesterol concentrations <50 mg/dL; fasting glucose > 105 mg/dL; and blood pressure > 130/85 mm Hg.
89484520|NCT05935904||MetS_Free|Pregnant women in their first trimester who are free of any MetS component.
89484521|NCT05935891|Experimental|Violet|Patients receiving CBD-dominant balm
89484522|NCT05935891|Experimental|Red Xs|Patients receiving THC-dominant balm
89484523|NCT05935852|Other|Study group 1|Multispectral Optoacoustic Tomography (MSOT) of the gastric antrum and terminal ileum in patients with T1DM, aged> 18 years, with diabetic neuropathy
89484524|NCT05935852|Other|Study group 2|Multispectral Optoacoustic Tomography (MSOT) of the gastric antrum and terminal ileum in patients with T1DM, aged> 18 years, without diabetic neuropathy
89484525|NCT05935852|Other|Study group 3|Multispectral Optoacoustic Tomography (MSOT) of the gastric antrum and terminal ileum in patients with T1DM, aged < 18 years, disease activity 5 - 10 years, HbA1c > 8,5%
89484526|NCT05935852|Other|Study group 4|Multispectral Optoacoustic Tomography (MSOT) of the gastric antrum and terminal ileum in patients with T1DM, aged < 18 years, disease activity 5 - 10 years, HbA1c < 7,5%
89484527|NCT05935839|Experimental|Adult Patients with diabetes mellitus type 1|"Laboratory-confirmed diagnosis of diabetes mellitus type 1~Age 18-99 years~Duration of disease at least 5, preferably 10 years with inadequate medication control (HbA1c value > 8.5 mmol/mol)"
89484528|NCT05935839|Experimental|Pediatric Patients with diabetes mellitus type 1|"Laboratory-confirmed diagnosis of diabetes mellitus type 1~Age 6-17 years~Duration of disease at least 5, preferably 10 years with inadequate medication control (HbA1c value > 8.5 mmol/mol)"
89484529|NCT05935839|Experimental|Healthy volunteers|- Age 18-99 years
89484530|NCT05935813||1996 birth year|Followed cohort for 6 years (2008-2014) to study time trends in caries experience
89484531|NCT05935813||1997 birth year|Followed cohort for 6 years (2009-2015) to study time trends in caries experience
89484532|NCT05935813||1998 birth year|Followed cohort for 6 years (2010-2016) to study time trends in caries experience
89484533|NCT05935813||1999 birth year|Followed cohort for 6 years (2011-2017) to study time trends in caries experience
89484534|NCT05935813||2000 birth year|Followed cohort for 6 years (2012-2018) to study time trends in caries experience
89484535|NCT05935813||2001 birth year|Followed cohort for 6 years (2013-2019) to study time trends in caries experience
89484536|NCT05935813||2002 birth year|Followed cohort for 6 years (2014-2020) to study time trends in caries experience
89537707|NCT04974021||Participants|HFrEF patients undergoing iron therapy with intravenous carboxymaltose (FCM). FCM administered dosage as per clinical routine. FCM administration is repeated no sooner than 3 months than last therapy, based on repeat ferritin and transferrin saturation levels.
89203760|NCT00806832||Conventional treatment only|Patients scheduled for elective cataract surgery will receive only conventional pre-operative treatment
88952530|NCT01952795|Active Comparator|Diet and exercise|Total caloric intake aimed at maintaining a diet with> 50% of the caloric content in the form of carbohydrates, less than 10% in the form of saturated fats and 20% from monounsaturated / polyunsaturated (if applicable, up to 25% fat monounsaturated), less than 300 mg / day of dietary cholesterol and about 1.0 g of protein / kg ideal body weight / day. 3 sessions per week on a bicycle ergometer or on a treadmill (according to body fat distribution and other parameters) modifications carried out weekly, with a gradual increase as to exercise until maximal oxygen consumption 60 - 70% would always preceded by heating 5 minutes.
88952531|NCT01952795|No Intervention|No intervention|Usual diet and exercise
88952532|NCT01952808|Experimental|Intervention Group|Participants randomly assigned to this group will receive the intervention immediately.
88952533|NCT01952808|No Intervention|Control Group|Participants randomly assigned to this group will not receive the intervention until one year after enrollment.
88952534|NCT01952821||Test Group|This group will receive all listed outcome measures on 2 testing visits.
89484537|NCT05935761|Active Comparator|Pregnenolone|Pregnenolone dosing will begin at 500mg/day x 7 days, and will increase by 500mg each following week as tolerated (to a potential maximum dose 2000mg/day).
89484538|NCT05935761|Active Comparator|DHEA|DHEA dosing will begin at 100mg/day x 7 days, and will increase by 100mg each following week as tolerated (to a potential maximum dose 400mg/day).
89484539|NCT05935761|Placebo Comparator|Placebo|Same as active comparator arms, except placebo dispensed
89484540|NCT05935722|Experimental|Parenting Young Children|Home based parenting programme for supporting parent with IDDs. 3-6 months of structured coaching sessions.
89484541|NCT05935722|Active Comparator|Treatment as Usual|Variety of interventions as usually provided by the social services.
89484542|NCT05935696||Tuberculous Pleural Effusion|"Tuberculous pleural effusion (TBE)~if any of the following criteria is presence:~Histological evidence of caseating granuloma from pleural biopsy~Microbiological evidence (positive growth of Mycobacterium tuberculosis culture, positive TB-PCR, positive Xpert MTB/RIF) from pleural fluid or pleural biopsy specimen~In patients with positive sputum smear for acid fast bacilli, sputum positive for mycobacterium tuberculosis culture, sputum positive for Xpert MTB/RIF or TB-PCR with no apparent cause of an exudative pleural effusion~Patient without histological or microbiological evidence who demonstrated therapeutic response to anti-tuberculosis drugs will not be accepted as TBE in current study."
89484543|NCT05935696||Malignant Pleural Effusion (Control)|"Malignant pleural effusion (MPE)~if any of the following criteria is presence:~• Histological or cytological evidence of specific histopathological diagnosis of malignancy from pleural biopsy Patient without histological or cytological evidence or malignancy (para-malignant) will not be considered as MPE in the context of this study."
89484544|NCT05935670|Experimental|Ischemic Conditioning - High|During each testing session, the investigators will be measuring how one treatment of ischemic conditioning effects leg blood flow and muscle function. One day participants will receive a high cuff inflation pressure on the leg, called ischemic conditioning - high (225 mmHg).
89484545|NCT05935670|Experimental|Ischemic Conditioning - Low|During each testing session, the investigators will be measuring how one treatment of ischemic conditioning effects leg blood flow and muscle function. One day participants will receive a low cuff inflation pressure on the leg, called ischemic conditioning - low (25 mmHg).
89484546|NCT05935592|Experimental|Experimental Group|The experimental group will receive access to Intervention INC, a theory-guided interactive, family-centered web-based tool promoting healthy dietary behaviors.
89484547|NCT05935592|Active Comparator|Comparison Group|The comparison group will receive access to web-based newsletters focused on promoting healthy dietary behaviors.
89484548|NCT05935501|Experimental|Formaderm Young|Formaderm Young was randomly administered to subjects. The injection volume was limited to 2c.c.
89484549|NCT05935501|Active Comparator|Restylane|Restylane was randomly administered to subjects. The injection volume was limited to 2c.c.
89484550|NCT05935449|Experimental|Formaderm Lidocaine|Formaderm Lidocaine was randomly administered either side of subjects' facial areas once.The injection volume was limited to 2c.c.
89484551|NCT05935449|Active Comparator|Formaderm Dermal Filler Injection|Formaderm Dermal Filler Injection was randomly administered either side of subjects' facial areas once.The injection volume was limited to 2c.c.
89484552|NCT05935423|Experimental|UC-MSC|Patients assigned in UC-MSC intervention group will get Umbilical Cord Mesenchymal Stem Cell transplantation
89484553|NCT05935423|No Intervention|Control|Patient assigned in control group doesn't get Umbilical Cord Mesenchymal Stem Cell transplantation. However, they will be fully treated based on European Society of Cardiology (ESC) guidelines
89484554|NCT05935397||patients with CAD undergoing PCI|patients with CAD undergoing PCI with second generation DES
89484555|NCT05935345|Experimental|Addressing NSSI in schools|During the four months of active experimental condition, adolescents receive five sessions of the youth aware of mental health program in the class room, and one additional session on NSSI. Parents and school staff receive an online psychoeducation on NSSI. School health care personnel receive a 2-day workshop on NSSI and suicidality.
89484556|NCT05935345|Other|Control condition|Participating adolescents, parents, teachers and school health care personnel receive no intervention during four months
88952535|NCT01952860|Experimental|Hatha Yoga|Participants receive 18 sessions of Hatha yoga over the course of radiation therapy. Each 45 to 60 minute session guided by an instructor. Participant should attend each session together with their caregiving partner. Some sessions videotaped. At first session, participant given a CD and instructions for practicing Hatha yoga at home. Questionnaire completion at baseline, during radiation therapy, and at completion of radiation therapy.
88952536|NCT01952886|Experimental|Granisetron patch|Granisetron transdermal delivery system (supplied as a 52 cm^2 patch containing 34.3 mg of granisetron - 3.1 mg/day) is applied once per week.
89484557|NCT05935319|Experimental|experimental group|Vivifrail
88952537|NCT01952886|Active Comparator|Ondansetron tablet|Ondansetron 8 mg oral tablet is prescribed for once a day.
88952538|NCT01952899||Albert Schweitzer Hospital|
88952539|NCT01952899||Erasmus MC Academic Hospital|
88952540|NCT01952899||Ikazia Hospital|
88952541|NCT01952899||IJsselland Hospital|
88952542|NCT01952899||Maasstad Hospital|
88952543|NCT01952899||Sint Franciscus Gasthuis Hospital|
88952544|NCT01952912|Active Comparator|PkEP|
88952545|NCT01952912|Active Comparator|OP|
88952546|NCT01952925|Experimental|Combined afib ablation and RA denervation|Patients with atrial fibrillation and resistant hypertension will be enrolled and undergo a single procedure consisting of pulmonary vein isolation and renal artery denervation.
88952547|NCT01952938||LINK SL|Patients
89484558|NCT05935319|No Intervention|control group|Traditional Sports Health Leaflet
89484559|NCT05935293|Experimental|Dexmedetomidine|"Patients in the dexmedetomidine group will receive intraoperative dexmedetomidine initiated in the operating room, before anesthetic induction.~Bolus of 0.6/mcg/Kg 15 mins before induction, followed by a continuous infusion of 0.4 mcg/kg/h during the per-operative period until transfer to intensive care and then 0.1 mcg/kg/h continued for additional 24 hours."
89484560|NCT05935293|Placebo Comparator|Control|"Patients in the control group will receive intraoperative sodium chloride 0.9% initiated in the operating room, before anesthetic induction.~IV administration rate will be weight adapted and similar to that of Dexmedetomidine group in volume (mL) and time (minutes) Bolus of 0.6/mcg/Kg 15 mins before induction, followed by a continuous infusion of 0.4 mcg/kg/h during the per-operative period until transfer to intensive care and then 0.1 mcg/kg/h continued for additional 24 hours."
89484561|NCT05935254|Experimental|ADHD-Electric Toothbrush Group|Children aged 8-10 years who were diagnosed with Attention Deficit Hyperactivity Disorder (ADHD) according to DSM-5 criteria, who applied to Aydın Adnan Menderes University Faculty of Medicine Child Psychiatry Clinic, were randomly assigned to the electric toothbrush group.
89484562|NCT05935254|Experimental|ADHD-Manual Toothbrush Group|Children aged 8-10 years who were diagnosed with Attention Deficit Hyperactivity Disorder (ADHD) according to DSM-5 criteria, who applied to Aydın Adnan Menderes University Faculty of Medicine Child Psychiatry Clinic, were randomly assigned to the manual toothbrush group.
89484563|NCT05935254|Active Comparator|Healthy- Electric Toothbrush Group|Among the physically and psychologically healthy children aged 8-10 who applied to the Pediatric Dentistry Clinic of ADU Faculty of Dentistry, those assigned to the electric toothbrush group as a result of randomization
89484564|NCT05935254|Active Comparator|Healthy- Manual Toothbrush Group|Among the physically and psychologically healthy children aged 8-10 who applied to the Pediatric Dentistry Clinic of ADU Faculty of Dentistry, those assigned to the manual toothbrush group as a result of randomization
88952548|NCT01952938||EnduRo|Patients
88952549|NCT01952951|Experimental|chemoradiation followed by CapOx|preoperative chemoradiation 50.4Gy with capecitabine or 5-fluorouracil/leucovorin (pelvic radiation capecitabine 5-fluorouracil) followed by 2 cycles of chemotherapy (Capecitabine Oxaliplatin - CapOx) and surgery (total mesorectal excision)
88952550|NCT01952951|Active Comparator|chemoradiation|preoperative chemoradiation 50.4Gy with capecitabine or 5-fluorouracil/leucovorin (pelvic radiation capecitabine 5-fluorouracil) followed by rest for 8 weeks and surgery (total mesorectal excision)
88952551|NCT01952964|Experimental|JUC spray dressing|
88952552|NCT01952977|Active Comparator|MCT|MCT oil (20 g) was included in the test breakfast
88952553|NCT01952977|Placebo Comparator|LCT|Corn oil (20 g) was included in the test breakfast
88952554|NCT01953029||non obstructive coronary disease|non obstructive coronary disease
88952555|NCT01953042|No Intervention|Waitlist as Per Usual|Wait list as per usual with no additional information sessions
88952556|NCT01953042|Active Comparator|Waitlist and Psychoeducation|Patients remain on waitlist but also receive 4 additional educational sessions (8 hours each)
88952557|NCT01953055|Experimental|Stereotactic ablative radiotherapy|40 Gy in 5 fractions over 4 weeks to prostate; 25 Gy in 5 fractions over 4 weeks to pelvic lymph nodes given simulataneously.
88952558|NCT01953094|Other|Anal Screening Pap Smear - Negative|Anal Pap Smear with no High Resolution Anoscopy
88952559|NCT01953094|Other|Anal Pap Smear - Positive Result - High Resolution Anoscopy|Patient who have a positive anal pap smear will go on to have a high resolution anoscopy.
88952560|NCT01953107|Experimental|Ferrous Fumarate 300 mg + Vitamin C|300 mg once a day of Oral Ferrous Fumarate
89484565|NCT05935163|Experimental|Group A (Coventional treatment with Bowen Therapy)|Group A will be treated with Bowen Technique in addition to conventional treatment. One session, 45 minutes for technique along with conventional treatment will be given. Technique will be performed for 10 minutes on each limb. The data will be collected at baseline and at 4th week. Follow up will be performed for 4 weeks and 3 sessions will be given each week.
89484566|NCT05935163|Active Comparator|Group B (Conventional treatment with DSTM)|Group B will be treated with Dynamic Soft Tissue Mobilizations (DSTM) in addition to conventional treatment. One session, 45 minutes for technique along with conventional treatment will be given. Technique will be performed for 10 minutes on each limb. The data will be collected at baseline and at 4th week. Follow up will be performed for 4 weeks and 3 sessions will be given each week.
89484567|NCT05935137||Pregnant women|It is a group of pregnant women after finished 37th week of gestation. We will take blood sample for a coagulation test on the device ClotPro.There is no more intervention.
89484568|NCT05935137||Non-pregnant women|It is a control group - non-pregnant women. We will take blood samples for blood count and coagulation status and a coagulation test on the device ClotPro.There is no more intervention.
89484569|NCT05935124|Other|First withdrawal - White light endoscopy|white light (WLE) high definition colonoscope (Olympus 190 series) first and then B-NBI
89484570|NCT05935124|Other|First withdrawal - Bright Narrow Band Imagin|B-NBI first and then WLE with the same colonoscope.
89484571|NCT05935046|Experimental|Premenopausal Status|
89484572|NCT05935046|Experimental|Peri Menopausal status|
89484573|NCT05935046|Experimental|Menopausal status|
89484574|NCT05934968|Experimental|Mad Dog cooking class intervention group|This 6-week series consists of a once-weekly cooking class and educational session where a group of individuals with neuromuscular disability can come together to learn about the health benefits of an anti-inflammatory diet, receive instruction on how to cook selected anti-inflammatory recipes, and experiment with various pieces of accessible kitchen equipment that may increase their meal preparation skills. This series will also allow participants to share a meal together once per week.
89484575|NCT05934968|No Intervention|Control group|The control group will be given the Mad Dog recipes but will not take part in the Mad Dog cooking class series.
89484576|NCT05934929|Experimental|circulating tumor DNA detection on operating bed|biological assessment on operating bed to detect residual circulating tumor DNA
89484577|NCT05934916|Experimental|Continuous Positive Airway Pressure (CPAP) group in (Coronavirus disease 2019) patients|receive medical treatment plus oxygen therapy according to recommendation of protocol of the Egyptian Ministry of Health 2020 and using Continuous Positive Airway Pressure (CPAP)
89484578|NCT05934916|Experimental|Non-CPAP group|Non-CPAP group will receive medical treatment plus oxygen therapy according to recommendation of protocol of the Egyptian Ministry of Health 2020
89484579|NCT05934864||Gene mutation profile of PTCL|84-gene penal was targeted sequenced in 1000 PTCL patients to investigate their mutation profile and molecular subtypes.
89484580|NCT05934825|Experimental|Injectable suspension of allogeneic adult mesenchymal stem cells|Patients will receive an injectable suspension of allogeneic adult mesenchymal stem cells from adipose tissue intralesionally.
89484581|NCT05934825|Placebo Comparator|Placebo|Patients will receive the cell-free suspension vehicle: 49% DMEM without phenol red, 1% L-Alanine LGlutamine and 50% hyaluronic acid
89484582|NCT05934812|Experimental|Oxytocin|24IU oxytocin liquid delivered with a pump-actuated nasal spray device, administered twice-daily
89484583|NCT05934812|Placebo Comparator|Placebo|Placebo delivered with a pump-actuated nasal spray device, administered twice-daily
89484584|NCT05934799|Other|Sequence TR|30 subjects assigned to the sequence TR will receive a single 75 mg dose of the test product Clopidogrel (1 x 75 mg film-coated tablet), marked as T in the sequence, in Period 1 and Period 3, and a single 75 mg dose of the reference product Plavix® (1 x 75 mg film-coated tablet), marked as R in the sequence, in period 2 and Period 4. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
89484585|NCT05934799|Other|Sequence RT|30 subjects assigned to the sequence RT will receive a single 75 mg dose of the reference product Plavix® (1 x 75 mg tablet), marked as R in the sequence, in Period 1 and Period 3 and a single 75 mg dose of the test product Clopidogrel (1 x 75 mg tablet), marked as T in the sequence, in period 2 and Period 4. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
89484586|NCT05934786|Active Comparator|Early intervention group|The intervention is planned to consist of six individual one-hour therapy sessions with certified psychologists followed by two group sessions (a total of two months (8 weeks) per patient).
89484587|NCT05934786|Active Comparator|late intervention group|For 8 weeks this group will receive the usual treatment, then, after repeated cognitive evaluation, will receive the same intervention: six individual one-hour therapy sessions with certified psychologists followed by two group sessions (a total of two months per patient).
89537708|NCT05155371|Experimental|Optimal Positive End-expiratory Pressure obtained with Titration of Fraction of Inspiratory Oxygen|Obtained Optimal Positive End-expiratory Pressure obtained with Titration of Fraction of Inspiratory Oxygen and sustained the PEEP intraoperatively
88952561|NCT01953107|Placebo Comparator|Placebo + Vitamin C|300 mg of Placebo
89021287|NCT03190577|Experimental|patients with neuropathy of unknown aetiology|from a blood sample performed at inclusion, a genetic analysis will be performed to research transthyretin mutation
88952562|NCT01953133|No Intervention|Control|"Couples do not receive intervention (counseling sessions) during study period. They do undergo one group-based session.~Upon completion of 9 month follow-up, participants in this arm can undergo a condensed, 2 session version of the intervention."
88952563|NCT01953133|Experimental|Couples' Counseling Sessions|4 couples' counseling sessions focusing on problem solving and communication skills for the couple. Based upon the Prevention and Relationship Enhancement Program (PREP.)
88952564|NCT01953146||PCOS criteria|nfertile patients undergoing assisted reproduction were consecutively recruited at the Fertility Clinic, Arhus University Hospital from February 2011 to May 2013. Women aged < 38 years without endometriosis where more than > 8 oocytes were retrieved were eligible. Patients were categorized in PCOS and non-PCOS according to the Rotterdam criteria for PCOS, defined by the presence of anovulation and polycystic ovaries.
88952565|NCT01953172|Placebo Comparator|Placebo capsules|Placebo capsules
88952566|NCT01953172|Experimental|AMP-886 (alpha-tocotrienol) in capsules|AMP-886 (alpha-tocotrienol) in capsules
88952567|NCT01953185|Experimental|Manual diaphragm release technique|
88952568|NCT01953185|Sham Comparator|Control group|
88952569|NCT01953198||All study participants|A total of 44 healthy and trained volunteers, age between 18 and 70 years. Subjects must have basic mountaineering experience.
88952570|NCT01953250||Infiltrating endometriosis|272 patients that underwent laparoscopic sigmoid and/or rectum resection with the indication of deep infiltrating endometriosis, in the department of Abdominal Surgery, University Hospital Leuven, between the year 1997 and September 2011.
88952571|NCT01953289||Appendicitis|Free fluid in perforated or non-perforated appendicitis
89484588|NCT05934760|Experimental|High intensity interval training (HIIT)|"Older participants (over 60) will be randomized to perform home-based unsupervised exercise, the HIIT group will perform the HIIT intervention 3 times a week, at home, unsupervised for 4 weeks. This will be supported by regular contact from a member of the research team to provide support and to encourage adherance.~Our research group has conducted many similar exercise regimes of this intensity to subjects in the anticipated age-range without incident. Participants will be adviced to terminate exercise training immediately if experiencing:~Chest pain or tightness~Faintness~Sudden pallor~Loss of co-ordination~Confusion~Dizziness~Palpitations~Sudden breathlessness~Should any participant experience these effects during any session, they will be advised to seek urgent medical attention and will be withdrawn from the exercise arm of the study for safety purposes."
89484589|NCT05934760|Experimental|Resistance exercise training (RET)|"Older participants (over 60) will be randomized to perform home-based unsupervised exercise, the RET group will perform the RET intervention at home, 3 times a week unsupervised for 4 weeks.This will be supported by regular contact from a member of the research team to provide support and to encourage adherance.~Our research group has conducted many similar exercise regimes of this intensity to subjects in the anticipated age-range without incident. Participants will be adviced to terminate exercise training immediately if experiencing:~Chest pain or tightness~Faintness~Sudden pallor~Loss of co-ordination~Confusion~Dizziness~Palpitations~Sudden breathlessness~Should any participant experience these effects during any session, they will be advised to seek urgent medical attention and will be withdrawn from the exercise arm of the study for safety purposes."
89484590|NCT05934734||Cohort 1 (Mild)|Participants with mild self-reported thoracic outlet syndrome symptoms (visual analog scale score 1-3).
89484591|NCT05934734||Cohort 2 (Moderate)|Participants with moderate self-reported thoracic outlet syndrome symptoms (visual analog scale score 4-6). No intervention will be provided.
89484592|NCT05934734||Cohort 3 (Severe)|participants with severe self-reported thoracic outlet syndrome symptoms (visual analog scale score 7-9). No intervention will be provided
89484593|NCT05934734||Cohort 4 (Very Severe)|Participants with very severe self-reported thoracic outlet syndrome symptoms (visual analog scale score 10). No intervention will be provided.
89484594|NCT05934721||RA patients aged 70-90 years|Patients meeting inclusion/exclusion criteria will be recruited from rheumatology clinics and community sources.
89484595|NCT05934565|Experimental|Mindful Steps|Multi-modal web intervention including: pedometer with individualized step-count goals, motivational and educational content, online community forum, mind-body videos (short themed clips that support walking, plus library of mind-body exercises), online group mind-body exercise classes, star incentive system; educational booklet
89484596|NCT05934565|No Intervention|Usual Care|Pragmatic usual care (standard care through participant's healthcare provider including pharmacological treatment and general advice for physical activity); educational booklet
89484597|NCT05934539|Experimental|ALG.APV-527|"Part 1 Dose Escalation using ALG.APV-527 doses with a starting dose of 0.1 mg/kg and projected 6 dose cohorts will be explored to determine the MTD and/or the RP2D. Part 1 consists of a 3 + 3 dose-escalation examination of ALG.APV-527 single agent therapy in adult patients with RECIST Version1.1-measurable advanced solid tumors.~Part 2 Dose Expansion with ALG.APV-527 based on RP2D determined during Dose Escalation."
89484598|NCT05934513|Experimental|GFH009|all patients will be administrated with GFH009
89484599|NCT05934461||an open-label, multiinstitutional, single-arm retrospective study|Three-dimensional conformal radiotherapy (3DCRT) or intensity-modulated conformal radiotherapy (IMRT) at a prescribed dose of 54-66 Gy/27-33 f. The combined TKI includes gefitinib, erlotinib, erlotinib, oseltinib, and ametinib. The specific uses are: gefitinib 250 mg orally once daily; erlotinib 125 mg orally three times daily; erlotinib 150 mg orally once daily; oseltinib 80 mg orally once daily; ametinib 110 mg orally once daily. TKI is taken until disease progression or intolerability.
89484600|NCT05934461||RT+C|Three-dimensional conformal radiotherapy (3DCRT) or intensity-modulated conformal radiotherapy (IMRT) at a prescribed dose of 54-66 Gy/27-33 f. The combined TKI includes gefitinib, erlotinib, erlotinib, oseltinib, and ametinib. The specific uses are: gefitinib 250 mg orally once daily; erlotinib 125 mg orally three times daily; erlotinib 150 mg orally once daily; oseltinib 80 mg orally once daily; ametinib 110 mg orally once daily. TKI is taken until disease progression or intolerability.
89484601|NCT05934422|Experimental|Prior Intervention - enhanced micronutrients, probiotics, myo-inositol in preconception & pregnancy|NiPPeR Study intervention drink containing a mix of micronutrients, probiotics and myo-inositol given to the mother during preconception & pregnancy
89484602|NCT05934422|Active Comparator|Prior Control - standard micronutrients in preconception & pregnancy|NiPPeR Study control nutritional drink containing a mix of micronutrients given to the mother during preconception & pregnancy
88952572|NCT01953302|Experimental|"modified open mesh technique"|"We performed an open intraperitoneal mesh technique in all patients: we placed surgical mesh of appropriate size intraperitoneally with transfascial fixation and drainage."
89484603|NCT05934396|Active Comparator|Enhanced Control|Cognitive Behavioral Therapy (CBT) Worksheets
89484604|NCT05934396|Active Comparator|Affect Regulation|Cognitive Behavioral Therapy (CBT) Worksheets; Safety Planning; Virtual Reality (VR) Enhanced Affect Regulation
89484605|NCT05934396|Active Comparator|Problem Solving|Cognitive Behavioral Therapy (CBT) Worksheets; Safety Planning; Virtual Reality (VR) Enhanced Problem Solving
89484606|NCT05934396|Active Comparator|Affect Regulation + Problem Solving|Cognitive Behavioral Therapy (CBT) Worksheets; Safety Planning; Virtual Reality (VR) Enhanced Affect Regulation; VR Enhanced Problem Solving
89484607|NCT05934396|Active Comparator|Cognitive Restructuring|Cognitive Behavioral Therapy (CBT) Worksheets; Safety Planning; Virtual Reality (VR) Enhanced Cognitive Restructuring
89484608|NCT05934396|Active Comparator|Affect Regulation + Cognitive Restructuring|Cognitive Behavioral Therapy (CBT) Worksheets; Safety Planning; Virtual Reality (VR) Enhanced Affect Regulation; VR Enhanced Cognitive Restructuring
89484609|NCT05934396|Active Comparator|Cognitive Restructuring + Problem Solving|Cognitive Behavioral Therapy (CBT) Worksheets; Safety Planning; Virtual Reality (VR) Enhanced Cognitive Restructuring; VR Enhanced Problem Solving
89484610|NCT05934396|Active Comparator|Affect Regulation + Cognitive Restructuring + Problem Solving|Cognitive Behavioral Therapy (CBT) Worksheets; Safety Planning; Virtual Reality (VR) Enhanced Affect Regulation; VR Enhanced Cognitive Restructuring; VR Enhanced Problem Solving
89484611|NCT05934383|Experimental|Renal sympathetic denervation|
89484612|NCT05933538|Experimental|Cariprazine monotherapy|
89484613|NCT05933538|Active Comparator|Treatment as usual|
89484614|NCT05933408||Patients with serious infectious complications|Complications were graded according to the five grade Clavien-Dindo classification (CD 1-5). Complications have been divided into mild (CD 1-2) and severe (CD 3-5).
89484615|NCT05933408||Patients without complications|Patients with infectious complications who formed group 1, were matched 1:1 with patients without complications (group 2). Case-matched analysis was performed by selecting patients for the control group from the group of patients paired by age, ASA scale, stage of cancer and type of surgery.
89484616|NCT05932160|Active Comparator|Experimental group|Patients in the experimental group were infused intravenously with 5% dextrose (400 ml/h) in the PACU. The study outcomes were collected at three assessment periods, 0-0.5 h, 0.5-6 h, 6-24 h, after anesthesia by an independent investigator.
89484617|NCT05932160|Active Comparator|Control group|Patients in the control group were infused intravenously with ringer lactate solution (400 ml/h) in the PACU. The study outcomes were collected at three assessment periods, 0-0.5 h, 0.5-6 h, 6-24 h, after anesthesia by an independent investigator.
89484618|NCT05930509|Experimental|Treatment|tDCS stimulation
89484619|NCT05925452|Experimental|GenaKumab|15 subjects: GenaKumab 0.5mg/kg dose group and 4.0 mg/kg dose group, Subcutaneous injection, Q4w
89484620|NCT05916053|No Intervention|Control|Nutritional education about food sources of vitamin D
89484621|NCT05916053|Experimental|VItamin D supplemented|Vitamin D supplementation of 50.000 IU weekly for 3 months.
89484622|NCT05915078||Tula Tympanostomy|Patients undergoing in-office tympanostomy using the Tula® System
89484623|NCT05912556|Other|Cohort A|Remote-Only subjects
89484624|NCT05912556|Other|Cohort B|Remote + Imaging subjects
89484625|NCT05901558|Experimental|STAR intervention group|The intervention strategies in STAR model are designed under the Naturalistic Developmental Behavioral Intervention (NDBI) framework which are implemented in natural settings targeting at improving social and communicational capabilities. The structure of the STAR model is with 2 modules and 16 sessions. Module I derives from our previous offline parent-tutoring courses with 8 intervention strategy topics combining academic instruction and real child demonstration but modified into on-line version. Module II is designed specifically for long-term consolidation of parents' intervention skills containing 8 biweekly sessions of distance coaching with parents practicing intervention with their children in real time at home.
89484626|NCT05901558|Other|community intervention group|This group will have community interventions parents can choose.
89484627|NCT05899881|Experimental|Yoga intervention|10 week yoga intervention; one yoga session per week, 60 minutes in length
89484628|NCT05899881|No Intervention|Control|Waitlist control asked not to make any lifestyle changes over the 10 week intervention period, and not engage in yoga
89484629|NCT05894902|Active Comparator|Open label Phase I safety & dose finding study: low dose group|4 study participants will receive a low oral dose (0.5 mL/Kg) of SM-001
89484630|NCT05894902|Active Comparator|Open label Phase I safety & dose finding study: medium dose group|4 study participants will receive a medium oral dose (1.0 mL/Kg) of SM-001
89203761|NCT00322153|Placebo Comparator|Placebo|Oral administration, once daily.
89203762|NCT00322153|Active Comparator|Memantine ER|28mg, once daily. Oral administration for 24 weeks.
89203763|NCT00806910|Active Comparator|Treatment|Subjects will be treated with Intravenous Vaprisol along with Nesiritide infusion and intravenous Furosemide (either continuous infusion or bolus injections - total dose of Furosemide received will be calculated at the end of the study).
89484631|NCT05894902|Active Comparator|Open label Phase I safety & dose finding study: high dose group|4 study participants will receive a high oral dose (2.0 mL/Kg) of SM-001
89484632|NCT05892393|Experimental|Cohort A ([89Zr]DFO-YS5, single scan|Participants receive [89Zr]DFO-YS5 IV and undergo a single PET/CT or PET/MRI scan 5-7 days post-injection. Participants also receive fludeoxyglucose F-18 IV and undergo PET/CT or PET/MRI scan within 28 days prior to day 1
89484633|NCT05892393|Experimental|Cohort B ([89Zr]DFO-YS5, multiple scans|Participants receive [89Zr]DFO-YS5 IV and undergo four PET/CT or PET/MRI scans on days 1, 2, 3-4, and 5-7 post-injection. Participants also receive fludeoxyglucose F-18 IV and undergo PET/CT or PET/MRI scan within 28 days prior to day 1
89484634|NCT05889702||KATR Clients|participants in the early stages of recovery and in substance use disorder (SUD) treatment; or those that have completed within the past year SUD treatment for opioid use disorder or stimulant use disorder or have a history of overdose from opioid use.
89484635|NCT05879419|Active Comparator|Subproject A: Patients with ARDs who received the vaccine at study entry (P1)|Patients with ARDs who received the vaccine at study entry (P1) (n = 590). ARD patients will be randomly assigned in a 1:1 ratio, with the use of an automated Web and telephone system, to one of two subgroups: P1, patients allocated to receive vaccine right after randomization (at D0 and D42), and P2, patients allocated to receive placebo at D0 and D42. Subsequently, blindness will be broken at D84 and P2 patients will receive vaccine doses at the D84 and D126.
89484636|NCT05879419|Placebo Comparator|Subproject A: Patients with ARDs who received the placebo at study entry (P2)|"Subproject A: Patients with ARDs who received the placebo at study entry (P2) (n = 590).~ARD patients will be randomly assigned in a 1:1 ratio, with the use of an automated Web and telephone system, to one of two subgroups: P1, patients allocated to receive vaccine right after randomization (at D0 and D42), and P2, patients allocated to receive placebo at D0 and D42. Subsequently, blindness will be broken at D84 and P2 patients will receive vaccine doses at the D84 and D126."
89484637|NCT05879419|Active Comparator|Subproject A: Control group of non-immunosuppressed individuals (CG)|Subproject A: Control group of non-immunosuppressed individuals (CG) (n = 393). The control group of non-immunosuppressed individuals (CG) (≥50 years old) will be invited to receive the vaccine at study entry (3 patients:1 control).
89484638|NCT05879419|Active Comparator|Subproject B: MTX-withhold|Subproject B: MTX-withhold (n = 101). Patients using MTX at a stable dose for at least 12 weeks, prednisone maximum dose of 5 mg/day, in association or not with other drugs except rituximab, to be randomized into two arms: one that will withhold MTX for 2 weeks after each vaccine dose (MTX-withhold) and other that will maintain stable therapy (MTX-maintain).
89484639|NCT05879419|Active Comparator|Subproject B: MTX-maintain|Subproject B: MTX-maintain (n = 101). Patients using MTX at a stable dose for at least 12 weeks, prednisone maximum dose of 5 mg/day, in association or not with other drugs except rituximab, to be randomized into two arms: one that will withhold MTX for 2 weeks after each vaccine dose (MTX-withhold) and other that will maintain stable therapy (MTX-maintain).
89484640|NCT05879419|Active Comparator|Subproject B: MMF-withhold|Subproject B: MMF-withhold (n = 115). Patients with ARDs using MMF at a stable dose for at least 12 weeks, prednisone maximum dose of 7.5 mg/day, not associated with other immunosuppressive therapy, will be consecutively evaluated at outpatient clinics regarding disease activity. Those considered to be at stable disease (at remission or low disease activity according to specific standardized disease activity indexes) will be randomized (1:1) into two arms: one that will withhold MMF for one week after each vaccine dose (MMF-withhold) and other that will maintain stable therapy (MMF-maintain).
89203764|NCT00806910|Placebo Comparator|Placebo|Subjects will be given Placebo (at the same rate of Vaprisol given in the treatment arm) along with Nesiritide infusion and intravenous Furosemide (either continuous infusion or bolus injections - total dose of Furosemide received will be calculated at the end of the study).
88952573|NCT01953341|Experimental|AMG 333|Subjects will receive a single oral dose of AMG 333 .
88952574|NCT01953341|Placebo Comparator|Placebo|Subjects will receive a single oral dose of placebo.
88952575|NCT01953367|Experimental|Vantobra; Treatment A|Vantobra, 170 mg tobramycin/1.7 mL nebulizer solution
88952576|NCT01953367|Active Comparator|TOBI; Treatment B|TOBI, 300 mg tobramycin/5 mL nebulizer solution
88952577|NCT01953380|Active Comparator|extended information|Extended information on specific allergy
89203765|NCT00804882||1|Mexican Americans with heart failure and metabolic syndrome
89203766|NCT00804882||2|Mexican Americans with heart failure without metabolic syndrome
89203767|NCT00804882||3|Non-Hispanic White Americans with heart failure and metabolic syndrome
89203768|NCT00804882||4|Non-Hispanic White Americans with heart failure without metabolic syndrome
89203769|NCT00807066|Experimental|A|Gefitinib
89203770|NCT00807066|Active Comparator|B|Platinum based chemotherapy
89203771|NCT01058551|Experimental|Reveal XT ILR|Implantable Loop Recorder Insertion
89021288|NCT03114059||standalone CyPass implantation|patients who have undergone a standalone cypass implantation without cataract surgery more than 3 years ago
89021289|NCT04703127|Active Comparator|Patients with lifelong premature ejaculation and non-responding to dapoxetine alone|Group 1 was given on-demand 30 mg dapoxetine and 10 mg tadalafil 1 h before intercourse.
89021290|NCT04703127|Active Comparator|Patients with Lifelong Premature Ejaculation and Non-responding to Dapoxetine Alone.|Group 2 was given on-demand 30 mg dapoxetine 1 h before intercourse and apply lidocaine 5% spray on the glans penis 10 minutes the wash before intercourse.
89021291|NCT03082391|Active Comparator|Heavy weight Mesh|Intervention: Patients will undergo ventral hernia repair with implantation of a heavy weight mesh.
89021292|NCT03082391|Active Comparator|Medium weight Mesh|Intervention: Patients will undergo ventral hernia repair with implantation of a medium weight mesh.
89021293|NCT04702971|Experimental|patients with migraine|patient with migraine will be prescribed with flunarizine or routine clinical care per clinician's decision based on the condition of each individual patient
89021294|NCT04702971|Other|healthy control|healthy control
89021295|NCT02841644||Traumatic Arthrotomy- Treated Nonoperatively|Patient diagnosed with traumatic arthrotomy treated nonoperatively.
89021296|NCT02841644||Traumatic Arthrotomy- Treated Operatively|Patient diagnosed with traumatic arthrotomy treated operatively.
89021297|NCT00433407|Experimental|trastuzumab|blood sample collected on different days from patients receiving trastuzumab
89021298|NCT02676791|Experimental|A (Povidone-Iodine)|Esophageal washout will be performed via a nasogastric tube with approx. 50ml of a 11% povidone-iodine solution (Betaisodona®, Mundipharma) during esophageal resection.
89021299|NCT02676791|No Intervention|B (Control)|Esophageal resection will be performed without esophageal washout.
89021300|NCT01600079||Vaccinated Cohort|Participants vaccinated with at least one dose of ZOSTAVAX™
89021301|NCT01600079||Unvaccinated Comparison Cohort|Participants who are not yet vaccinated with any zoster vaccine
89021302|NCT01370486|Active Comparator|melatonin|
89021303|NCT01370486|Placebo Comparator|placebo|
89021304|NCT00429117||Survey|Physician members of the International Gynecologic Oncologists Society or the Society of Gynecologic Oncologists.
89021305|NCT00491309|Active Comparator|exercise training group|exercise and respiratory therapy with specific program for pulmonary hypertension (respiratory therapy, dumbbell training, ergometer training, mental training)
89021306|NCT00491309|No Intervention|Control group without exercise training|continuation of sedentary lifestyle without advice for specific exercise training
89021307|NCT00429156|Active Comparator|1|Home non-invasive ventilation
89021308|NCT00429156|Sham Comparator|2|Home sham non-invasive ventilation with CPAP 5 cm H2O
89021309|NCT00327665|Experimental|Group A|
89021310|NCT00327665|Experimental|Group B|
89021311|NCT00327665|Experimental|Group C|
89021312|NCT00327665|Active Comparator|Group D|
89021313|NCT00327665|Active Comparator|Group E|
89021314|NCT00433641|Placebo Comparator|1|placebo tablet
89021315|NCT00433641|Experimental|2|sibutramine
89021316|NCT00433641|Experimental|3|sibutramine
89021317|NCT00327704|Active Comparator|Albumin|
89021318|NCT00327704|Placebo Comparator|Saline|
89021319|NCT01050816|Experimental|Chondron implantation|ankle cartilage defect patients who had CHONDRON transplantation
89021320|NCT00429234|Experimental|Dasatinib + Gemcitabine|Dasatinib starting dose 70 mg by mouth daily for Week 1. Cycle is 28 days, except Cycle 1 which is 8 weeks. Gemcitabine starting dose of 800 mg/m^2 by vein once weekly over 30 minutes beginning Cycle 1 Day 1. All other cycles once weekly for 7 weeks on Days 8, 15, 22, 29, 36, and 43. Cycle is 28 days, except Cycle 1 which is 8 weeks.
89021321|NCT00433719|Experimental|1|Combivir, efavirenz for 12 months
89021322|NCT00433719|Placebo Comparator|2|Placebo for 2 months followed by Combivir and efavirenz for 10 months
89021323|NCT04704297|Active Comparator|Standard Therapy (ST)|ST will consist of 975mg of Acetaminophen PO and either 30mg of Ketorolac IM or 15 mg IV. Upon discharge ST will consist of prescriptions for acetaminophen 650mg every 4 hours by mouth, Ibuprofen 400mg every 4 hours by mouth, and 10 mg of cyclobenzaprine nightly by mouth. Additionally, participants will be provided a handout going over these medications and the use of heat for low back pain and instructions on the performance of McKenzie stretching exercises for low back pain.4
89203772|NCT00804960|Experimental|Letrozole|1) Letrozole/ Recombinant FSH
89203773|NCT00804960|Active Comparator|Standard IVF|luteal phase GnRHa suppression/gonadotropin
89021324|NCT04704297|Active Comparator|ST plus Trigger Point Injections (TPI) with 8 mL of 0.5 percent Bupivacaine|ST plus TPI with 8 mL of 0.5 percent Bupivacaine
89021325|NCT04704297|Active Comparator|ST plus TPI with 8 mL of Normal Saline (NS)|ST plus TPI with 8 mL of Normal Saline
89021326|NCT04704414|Experimental|Validation of smartphone face scanner|Validation of smartphone face scanner in comparison to Hertel Exophthalmometer and high-definition face scanner.
89021327|NCT00328211|Experimental|Bile Acid|To assess the role of bile acid pool size changes on cholesterol absorption, synthesis and intralumenal cholesterol solubilization.
89021328|NCT00328211|Experimental|Cholesterol Absorption|To determine whether cholesterol absorption, synthesis and solubilization will be significantly altered by changes in phospholipid content, specifically sphingolipids and phosphatidylcholine in the intestinal lumen.
89021329|NCT00328211|Experimental|Intralumenal|To assess intralumenal solubilization and absorption of biliary and dietary cholesterol.
89021330|NCT04704180|Experimental|Experimental Group: Facilitation Tuchking Group|The experimental group neonates received facilitated tucking under the radiant heater after birth of the NICU as well as the routine interventions.
89021331|NCT04704180|No Intervention|Control Group|The control group underwent the routine interventions of the observation unit of the NICU. The group did not receive any other intervention
89021332|NCT00419939||1|ab 10 patientsr with acquired severe brain injury (GCS 3 - 9), >18 år, PTA phase at the end (GOAT scoring), RLAS score at minimum 4 and informed consent in writing
89021333|NCT01054560|Experimental|SOLITAIRE™ Device|The SOLITAIRE™ Device (investigational device) is the experimental arm
89203774|NCT00805116|Experimental|1|Whale blubber oil
89021334|NCT01054560|Active Comparator|MERCI® Device|The MERCI® Device (control device) is commercially available.
89021335|NCT00328250|Experimental|1|Participants will receive the online CBT intervention immediately and will use the online program for 8 weeks
89021336|NCT00328250|Active Comparator|2|Participants will receive the online CBT intervention after a 4-month waiting period
89021337|NCT00433797|Experimental|1|Tomato
89021338|NCT00433797|Experimental|2|Multi-diet
89021339|NCT00433797|Active Comparator|3|Control
89021340|NCT00328367|Experimental|A|clozapine plus aripiprazole
89021341|NCT00328367|Placebo Comparator|B|clozapine plus placebo
89021342|NCT04703088|Experimental|INTERVENTION GROUP - ONDANSETRON|2 mL of a solution of Ondansetron containing 2mg/ml in a 3 ml syringe will be given intravenously to a patient five minutes before positioning for induction of spinal anesthesia
89021343|NCT04703088|Placebo Comparator|CONTROL GROUP - NORMAL SALINE|2 mL of 0.9% Saline in a 3 ml syringe will be given intravenously to a patient five minutes before positioning for induction of spinal anesthesia
89021344|NCT00328445|No Intervention|Control|Business as usual
89021345|NCT00328445|Experimental|Treatment|Positive Action
89021346|NCT00328484|Experimental|1|Eleven month lifestyle activity program
89021347|NCT00328484|Active Comparator|2|Three month exercise program
89021348|NCT00429312|Experimental|Single Arm|Intratumoral injection(s) of Recombinant Vaccinia GM-CSF, JX-594
89021349|NCT04702932||Patient with Monoclonal gammopathies of inflammatory significance|This group of patient will present a monoclonal gammopathy associated with inflammatory symptoms without known origin.
89021350|NCT04702932||Control group|The Control group will be healthy subject and patients with monoclonal gammopathies without inflammatory symptoms.
89021351|NCT00328679|Experimental|A|
89021352|NCT01054443|Placebo Comparator|Placebo|Participants received placebo tablets orally once a day for 42 days.
89021353|NCT01054443|Experimental|Lusutrombopag 0.5 mg|Participants received 0.5 mg lusutrombopag orally once a day for 42 days.
89021354|NCT01054443|Experimental|Lusutrombopag 0.75 mg|Participants received 0.75 mg lusutrombopag orally once a day for 42 days.
89021355|NCT01054443|Experimental|Lusutrombopag 1.0 mg|Participants received 1.0 mg lusutrombopag orally once a day for 42 days.
89021356|NCT01580319|No Intervention|Control|Participants do not receive a physical exercise plan. Participants receive a simple orientations about lifestyle activities.
89021357|NCT01580319|Experimental|Exercise|Participants receive a physical exercise plan to play at home
89021358|NCT00420173||Patients with CLE|
89021359|NCT04702698|Experimental|Part 1: Peposertib: Treatment Sequence A-B-C|Participants will receive single oral dose of peposertib tablet (Treatment A) on Day 1 under fasted condition in period 1, followed by single oral dose of peposertib tablet (Treatment B) on Day 8 under fed condition in period 2, followed by oral suspension dose of peposertib (Treatment C) on Day 15 under fasted condition in period 3. There will be washout period of 7 days between each treatment period.
89021360|NCT04702698|Experimental|Part 1: Peposertib Treatment Sequence A-C-B|Participants will receive single oral dose of peposertib tablet (Treatment A) on Day 1 under fasted condition in period 1, followed by oral suspension dose of peposertib (Treatment C) on Day 8 under fasted condition in period 2, followed by single oral dose of peposertib tablet (Treatment B) on Day 15 under fed condition in period 3. There will be washout period of 7 days between each treatment period.
89021361|NCT04702698|Experimental|Part 1: Peposertib Treatment Sequence B-A-C|Participants will receive single oral dose of peposertib tablet (Treatment B) on Day 1 under fed condition in period 1, followed by single oral dose of peposertib tablet (Treatment A) on Day 8 under fasted condition in period 2, followed by oral suspension dose of peposertib (Treatment C) on Day 15 under fasted condition in period 3. There will be washout period of 7 days between each treatment period.
89021362|NCT04702698|Experimental|Part 1: Peposertib Treatment Sequence B-C-A|Participants will receive single oral dose of peposertib tablet (Treatment B) on Day 1 under fed condition in period 1, followed by oral suspension dose of peposertib (Treatment C) on Day 8 under fasted condition in period 2, followed by single oral dose of peposertib tablet (Treatment A) on Day 15 under fasted condition in period 3. There will be washout period of 7 days between each treatment period.
89021363|NCT04702698|Experimental|Part 1: Peposertib: Treatment Sequence C-A-B|Participants will receive oral suspension dose of peposertib (Treatment C) on Day 1 under fasted condition in period 1, followed by single oral dose of peposertib tablet (Treatment A) on Day 8 under fasted condition in period 2, followed by single oral dose of peposertib tablet (Treatment B) on Day 15 under fed condition in period 3. There will be washout period of 7 days between each treatment period.
89021364|NCT04702698|Experimental|Part 1: Peposertib Treatment Sequence C-B-A|Participants will receive oral suspension dose of peposertib (Treatment C) on Day 1 under fasted condition in period 1, followed by single oral dose of peposertib tablet (Treatment B) on Day 8 under fed condition in period 2, followed by single oral dose of peposertib tablet (Treatment A) on Day 15 under fasted condition in period 3. There will be washout period of 7 days between each treatment period.
89021365|NCT04702698|Experimental|Part 2: Peposertib Treatment Sequence A-B|Participants will receive single oral dose of peposertib tablet (Treatment A) on Day 1 under fasted condition in period 1, followed by single oral dose of peposertib tablet (Treatment B) on Day 8 under fed condition in period 2. There will be washout period of 7 days between each treatment period.
89021366|NCT04702698|Experimental|Part 2: Peposertib: Treatment Sequence B-A|Participants will receive single oral dose of peposertib tablet (Treatment B) on Day 1 under fed condition in period 1, followed by single oral dose of peposertib tablet (Treatment A) on Day 8 under fasted condition in period 2. There will be washout period of 7 days between each treatment period.
89021367|NCT00328874|Placebo Comparator|Placebo|
89021368|NCT00328874|Active Comparator|Coenzyme Q10|
89021369|NCT00429546|Experimental|Intervention|Participants will receive a cognitive-behavioral intervention designed to improve mother-child communication and parenting skills and prepare caregiver for disclosure of HIV serostatus to child
89021370|NCT00429546|Active Comparator|Control|Participants will receive treatment as usual
89021371|NCT02957643|Placebo Comparator|pregnant women|iron dosage 1 per day for 3 months
89021372|NCT02957643|Experimental|pregnant women with anemia|iron dosage 1 per day for 6 months
88952578|NCT01953380|No Intervention|Information according to clin. routine|Information according to clinical routine
88952579|NCT01953406|Experimental|The 5-fluorouracil/mitomycin group|Systemic chemotherapy with 5-fluorouracil/mitomycin 5-fluorouracin 15mg/kg/day D1-6 civ + Mitomycin 4mg/day iv push D1,4 till progression, every 4 weeks
89484641|NCT05879419|Active Comparator|Subproject B: MMF-maintain|Subproject B: MMF-maintain (n = 115). Patients with ARDs using MMF at a stable dose for at least 12 weeks, prednisone maximum dose of 7.5 mg/day, not associated with other immunosuppressive therapy, will be consecutively evaluated at outpatient clinics regarding disease activity. Those considered to be at stable disease (at remission or low disease activity according to specific standardized disease activity indexes) will be randomized (1:1) into two arms: one that will withhold MMF for one week after each vaccine dose (MMF-withhold) and other that will maintain stable therapy (MMF-maintain).
89484642|NCT05875467|Experimental|Single Arm, Intervention with SE3 Game|This is a single arm study. This arm will receive the intervention. This intervention is a prototype of online game, about 50 minutes in duration. The online game provides gameplay that allows the user, with a gameplay narrative, to identify and remove sources of environmental hazards in the home environment. Participants play the prototype game for about 50 minutes at which time the intervention is complete.
89484643|NCT05845697|Experimental|Actual dry needling group|Will receive actual dry needling of the lumbar multifidus with a 50-60mm filiform needle
89484644|NCT05845697|Sham Comparator|Sham dry needling group|Will receive needling from a sham needle that is blunted so it does not pierce the skin but has been shown to be valid for being indistinguishable from receiving an actual needle.
89484645|NCT05845658|Active Comparator|Active VeNS|The active device utilizes a technology termed vestibular nerve stimulation (VeNS). The device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 30 minutes per day.
89484646|NCT05845658|Sham Comparator|Sham VeNS|The sham device looks identical to the active device and interacts with the app in a similar manner to the active device. It will apply some stimulation to a user for a limited period of time (30 seconds), before tapering down to zero over a further 20 seconds, thus creating the impression of an active device. The device will be placed on the head in a manner analogous to headphones with hydrogel electrodes placed over the mastoid processes. Participants will be advised to use the device at home for 30 minutes per day.
89484647|NCT05843669|Experimental|N/A. Only one arm.|Single arm. During the 12-week period of receiving treatment, patient participants will take Mucinex® 12h, 2 x 600 mg (1200 mg total) twice daily and complete weekly bespoke surveys and the CASA-Q instrument.
89484648|NCT05842356|No Intervention|Communication Technique 1|A standard communication technique will be used in this group.
89484649|NCT05842356|Experimental|Communication Technique 2|A new communication technique will be used in this group.
89484650|NCT05820594|Experimental|Intradermal injection with BCG SSI|Intradermal injection with BCG (bacillus calmette-guerin) vaccine at day 0.
89484651|NCT05819879|Active Comparator|PENG group|
89484652|NCT05819879|Active Comparator|scaitico femoral block group|
89484653|NCT05804812|No Intervention|control group|"At the beginning of the study, data collection tools Personal Information Form and Psychological Well-Being Scale will be applied to the control group.~No intervention will be made in the control group. Measurement tools will be applied for the post-test."
89484654|NCT05804812|Experimental|experimental group|Inclusion criteria for the research: Faculty of Health Sciences, to study in the 2022-2023 academic spring semester, to have been diagnosed with migraine, to be young and to volunteer to participate in the research. Exclusion criteria from the study; Not studying at the Faculty of Health Sciences and not volunteering to participate in the research. The application and control group will be determined on random.org among the group that constitutes the sample of the study. Laughter therapy sessions will be applied online for 25-30 minutes once a week for 2 months by the researcher who has the Laughter therapy certificate to the application group. At the end of two months, the Personal Information Form and Psychological Well-Being Scale will be administered again to both the application group and the control group.
89484655|NCT05802680|Sham Comparator|Sham-tPBM, non-ADHD|Participants with no medical diagnosis of ADHD will be exposed to the same conditions as treated participants, with the exception that the infrared light will be turned off (sham condition).
89484656|NCT05802680|Sham Comparator|Sham-tPBM, ADHD|Participants with a medical diagnosis of ADHD will be exposed to the same conditions as treated participants, with the exception that the infrared light will be turned off (sham condition).
89484657|NCT05802680|Experimental|tPBM, non-ADHD|Participants with no medical diagnosis of ADHD will be exposed to the same conditions as sham participants, with the exception that the infrared light will be turned on (treated condition).
89484658|NCT05802680|Experimental|tPBM, ADHD|Participants with a medical diagnosis of ADHD will be exposed to the same conditions as sham participants, with the exception that the infrared light will be turned on (treated condition).
88952580|NCT01953419|Experimental|Treatment group|received Pemetrexed disodium 500mg/m2 every 21 days until the presence of progressive disease or unacceptable toxicity
88952581|NCT01953445|Experimental|Treatment (PI3K inhibitor BKM120, paclitaxel)|Patients receive PI3K inhibitor BKM120 PO QD on days 1-28 and paclitaxel IV over 60 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity.
88952582|NCT01953471||Allergic rhinitis|
89537709|NCT05155371|Experimental|Optimal Positive End-expiratory Pressure obtained with electrical impedance tomography|Obtained Optimal Positive End-expiratory Pressure obtained with EIT and sustained the PEEP intraoperatively
89537710|NCT04489277||Patients with Silent Brain Infarction|treated with an aortic endoprosthesis deployed in Ishimaru zone 0 to 3 and brain diffusion-weighted magnetic resonance imaging (DW-MRI) within 7 days after the procedure with silent brain infarction
89537711|NCT04489277||Patients without Silent Brain Infarction|treated with an aortic endoprosthesis deployed in Ishimaru zone 0 to 3 and brain diffusion-weighted magnetic resonance imaging (DW-MRI) within 7 days after the procedure without silent brain infarction
89537712|NCT03062397|Experimental|Low-dose group|JPI-289 Low dose or placebo
89021373|NCT02957604||Specific Evolocumab-Exposed Cohort|Women diagnosed with Atherosclerotic Cardiovascular Disease (ASCVD), or hypercholesterolemia associated with Familial Hypercholesterolemia (FH), who were exposed to Evolocumab (Repatha) during pregnancy
89203775|NCT00805116|Active Comparator|2|Cod liver oil
89203776|NCT03985735||Group good sleepers|"Duration of sleep was defined as the duration of all Bispectral Index data below 80 in the 12 hours of monitoring (from 20:00pm to 06:00am).~Sleeping time are more than six hours."
89203777|NCT03985735||Group poor sleepers|"Duration of sleep was defined as the duration of all Bispectral Index data below 80 in the 12 hours of monitoring (from 20:00pm to 06:00am).~Sleeping time are less than two hours."
89203778|NCT00807222|Active Comparator|lisdexamfetamine dimesylate|30, 50, or 70 mg
89203779|NCT00807222|Placebo Comparator|placebo|
89203780|NCT00657618|Experimental|Treatment only|All consented subjects who meet all inclusion and no exclusion criteria will enter this open label protocol and be treated with Sodium Stibogluconate (SSG).
89203781|NCT02553564|Experimental|Intervention group|"Checklist driven clinical encounter after hospital discharge~- Participant will receive standard medical care with the addition of a checklist driven clinical encounter upon return to the dialysis unit after hospital discharge.~* participants in both group will be receiving standard post discharge care which includes nursing assessment, social work intervention as needed and new dialysis orders."
89203782|NCT02553564|No Intervention|Usual care group|"Participant will receive standard medical care upon return to the dialysis unit after hospital discharge.~* participants in both group will be receiving standard post discharge care which includes nursing assessment, social work intervention as needed and new dialysis orders."
89203783|NCT00657540|Experimental|Analatro|Antivenin Latrodectus (Black Widow) Equine Immune F(ab)2
89203784|NCT00657540|Placebo Comparator|Normal Saline Placebo|Normal Saline
89203785|NCT00672620|Experimental|Vortioxetine 2.5 mg|Vortioxetine 2.5 mg, encapsulated tablets, orally, once daily for up to 8 weeks, then placebo-matching capsules, orally, once daily, for 1 week following the treatment period.
89203786|NCT00672620|Experimental|Vortioxetine 5 mg|Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up to 8 weeks, then placebo-matching capsules, orally, once daily, for 1 week following the treatment period.
89203787|NCT00672620|Active Comparator|Duloxetine 60 mg|Duloxetine 60 mg, capsules, orally, once daily for up to 8 weeks, then duloxetine 30 mg capsules, orally, once daily for 1 week after the treatment period.
89203788|NCT00672620|Placebo Comparator|Placebo|Placebo-matching capsules, orally, once daily for up to 9 weeks.
89203789|NCT00805272|Experimental|1|
89203790|NCT00764972|Experimental|Sorafenib and Vinorelbine|
89203791|NCT00765050|Experimental|CD133+ cells|CD133+ cells, obtained from peripheral blood in the treatment of diabetic patients with critic ischemia in lower limbs.
89203792|NCT00673790|Active Comparator|Nebivolol|Nebivolol with concomitant losartan or lisinopril
89203793|NCT00673790|Active Comparator|Hydrochlorothiazide (HCTZ)|HCTZ with concomitant losartan or lisinopril
89203794|NCT00673790|Placebo Comparator|Placebo|Placebo with concomitant losartan or lisinopril
89203795|NCT00770276||Bariatric surgery|Bariatric surgery
89203796|NCT00770276||conservative Therapie|diet and exercise
89203797|NCT00763724||1|Duloxetine
89203798|NCT00763724||2|Venlafaxine
89203799|NCT00763724||3|SSRI
89203800|NCT00763724||4|TCA
89203801|NCT00763724||5|Multiple Antidepressants
89203802|NCT00763724||6|Depressed (not antidepressant treated)
89203803|NCT00763724||7|General population
89203804|NCT00763802||MNPDR|Type 2 diabetic patients with Mild non-prolipherative retinopathy.
89203805|NCT00763880|Experimental|Lidocaine|Subjects randomly assigned to this arm will receive 2% lidocaine by injection into their fracture site in the form of a hematoma block.
89203806|NCT00763880|Placebo Comparator|Normal Saline|Subjects randomly assigned to this arm will receive normal saline by injection into their fracture site
89537713|NCT03062397|Experimental|High-dose group|JPI-289 High dose or placebo
89537714|NCT03062397|Placebo Comparator|Placebo group|Same dosage of JPI-289 low and high dose
89537715|NCT03298139|Experimental|parabolic flights|parabolic flights in normogravity (1g), hypergravity (1.8g) and microgravity (0g).
89537716|NCT04982055|Experimental|Intravenous group|
89537717|NCT04982055|Active Comparator|Subcutaneous group|
89537718|NCT02461277|Active Comparator|Fast-track protocol|Before surgery, patients are informed about the surgical procedure, anesthesia and rehabilitation protocol. The surgery occurs in accordance with the principles of the Fast-track: minimal invasive surgery, epidural anesthetic management, avoiding the need opioid in postoperatory analgesia and use of an standardized postoperatory management protocol to an early oral intake and early mobilization.
89537719|NCT02461277|No Intervention|Conventional care|Usual care routine postoperative
89537720|NCT03297983|Experimental|First M7583 Tablet:Fasted, Then PiC:Fasted, Then Tablet:Fed|
89537721|NCT03297983|Experimental|First M7583 PiC:Fasted, Then Tablet:Fasted, Then Tablet:Fed|
89537722|NCT04981743|No Intervention|group 1|Twenty five patients will be administered only the standard treatment regimen according to Ministry Of Health, and Population management protocol for COVID-19 patients (November 2020).
89537723|NCT04981743|Active Comparator|group 2|Twenty five patients will be administered a single dose (900mg) of Nigella Sativa capsule twice daily plus standard therapy
89537724|NCT04981743|Active Comparator|group 3|Twenty five patients will be administered a single dose (2000 IU) of vitamin D3 tablet once daily plus standard therapy
89537725|NCT04981743|Active Comparator|group 4|Twenty five patients will be administered a single dose (900 mg) of Nigella Sativa capsule twice daily, and single dose of vitamin D3 tablet (2000 IU) once daily plus standard therapy.
89537726|NCT04441853|Experimental|YouTube video group|The intervention group attended five sessions of weekly-based tutorial, by watching YouTube videos on older people's and their caregivers' lived experience. On each session, they would joined post-video group discussion.
89537727|NCT04441853|Active Comparator|No YouTube video group|The control group were offered for five sessions of tutorial with same content without YouTube or other audio-visual tools. They also needed to join for group discussion in each tutorial.
89537728|NCT04974255|Experimental|Operated Patients|Measurement of fibrosis degree and Anti-tTG levels
89203807|NCT00765284||Treatment|Ten subjects will be low HDL-C male volunteers who will receive aspirin and Niaspan
89203808|NCT00765284||Placebo|Five subjects will be low HDL-C male volunteers who will receive only aspirin.
89203809|NCT00765440|Placebo Comparator|Arm I|Patients receive standard oral or enteral nutrition (IMPACT® placebo) over 7 days prior to surgery and over 7 days after surgery.
89537729|NCT03062709|Experimental|All Participants|Breathe Easy Coalition written materials provided to parent/guardian, plus Maine Tobacco Helpline referral provided to smoking adult in the home, plus testing of the child's urine cotinine and results reported to parent/guardian
89537730|NCT03297671||Pregnant Women|2000 pregnant women from the communities in the catchment area of THQ Johi and DHQ Dadu. Rh negative women will receive two RhIg prophylaxis injections.
89537731|NCT03297671||Lady Health Visitors (LHVs)|3-5 LHVs who are full time employees at THQ Johi and DHQ Dadu. LHVs will perform ELDONCARD test and provide RhIg prophylaxis injections.
89537732|NCT03295409|Experimental|Experimental: Standard self-affirmation|"Participants are asked to form a self-affirming implementation intention at the end of a questionnaire:~The beginning to a sentence appears below. Below it are 4 different ways of completing the sentence. On the lines below, please write out the beginning of the sentence and then complete it with 1 of the 4 options we have given you.~If I feel threatened or anxious, then I will…~think about the things I value about myself~remember things that I have succeeded in~think about what I stand for~think about things that are important to me~If…___________________________________________________________________"
89537733|NCT03295409|Experimental|Experimental: Familial self-affirmation|"Participants are asked to form a self-affirming implementation intention at the end of a questionnaire:~The beginning to a sentence appears below. Below it are 4 different ways of completing the sentence. On the lines below, please write out the beginning of the sentence and then complete it with 1 of the 4 options we have given you.~If I feel threatened or anxious, then I will…~think about the things my family and I value about ourselves~remember things that my family and I have succeeded in~think about what my family and I stand for~think about things that are important to my family and me~If…__________________________________________________________________"
89537734|NCT03295409|No Intervention|Control|Participants are asked to complete a questionnaire.
89537735|NCT03295331||GINA-defined clinical diagnosis of Asthma|All patients with GINA-defined clinical diagnosis of Asthma seen at respiratory clinic from January to August 2016 with age 18 and above
89537736|NCT02460965||Patients with schizophrenia|
89537737|NCT02460965||Patients with borderline personality disorder|
89537738|NCT02460965||Patients with hearing impairment|
89537739|NCT02460965||Patients with visual loss|
89537740|NCT02460965||Patients with Parkinson's Disease|
88952583|NCT01953484|Experimental|Acute Respiratory Distress Syndrome|Acute hypoxemia, bilateral pulmonary infiltrates and no evidence of primary left atrial hypertension
88952584|NCT01953484|Experimental|Chronic Obstructive Pulmonary Disease|Acute-on-Chronic Respiratory Insufficiency (patients with Chronic Obstructive Pulmonary Disease)
89203810|NCT00765440|Experimental|Arm II|Patients receive oral or enteral neoadjuvant IMPACT® nutrition over 7 days prior to surgery and enteral adjuvant standard nutrition (IMPACT® placebo) over 7 days after surgery.
89537741|NCT02460965||Patients with Alzheimer's Disease|
89537742|NCT02460965||Patients with dementia with Lewy Bodies|
89537743|NCT02460965||Healthy participants|
89537744|NCT04489121|Experimental|omalizumab preseasonal treatment|For patients in the Omalizumab group, subcutaneous injections of Omalizumab based on the specific participant's weight and serum total IgE was performed 2 weeks prior the anticipated pollen season. Rescue medication could be used during pollen seasons.
89537745|NCT04489121|No Intervention|control|No preseasonal treatment was performed. Rescue medication could be used during pollen seasons.
89537746|NCT04858113|Placebo Comparator|Baby Shampoo|Conventional Baby shampoo
89537747|NCT04858113|No Intervention|No intervention|Baseline condition without intervention
89537748|NCT04858113|Experimental|Blephaclean|Intervention
89537749|NCT03295253|Experimental|Female patients with Stress Incontinence|Female patients who will undergo autologous adipose tissue harvesting/grafting using Lipogems and grafting in urethra/bladder neck
89537750|NCT04981353|Active Comparator|group 1|:(group 1) will be putted in sitting position and disinfecting her back. A real-time high-frequency linear ultrasound will be used to do the thoracic (ESP) at the level of T11 by visualizing the transverse process of T11 thoracic vertebrae and erector spinae muscle and injecting a 20 ml of bupivacaine 0.25% bilaterally using an in-plane technique, a 20-gauge, 70-mm needle (Tuoren, Henan, China) will be advanced into the plane below (ESM) after injecting lidocaine 1% 2ml at the site of injection, Needle will be advanced with a cranial to caudal direction
89537751|NCT04981353|Active Comparator|group 2|(group 2) patients will receive pethidine 25mg doses if NRS >4.
89484659|NCT05790499|Experimental|Atorvastatin|
89021374|NCT02957604||Comparison Group I|Women diagnosed with Atherosclerotic Cardiovascular Disease (ASCVD), or hypercholesterolemia associated with Familial Hypercholesterolemia (FH) who were not exposed to Evolocumab during pregnancy
89484660|NCT05787327|Experimental|Active treatment (Yinqiaosan-Maxingganshitang )|Chinese Medicine granules
89484661|NCT05787327|Placebo Comparator|Placebo|Placebo granules
89021375|NCT02957604||Comparison Group II|A general comparison group of pregnant women who have not been diagnosed with Atherosclerotic Cardiovascular Disease (ASCVD), or hypercholesterolemia associated with Familial Hypercholesterolemia (FH), and who were not exposed to Evolocumab during pregnancy.
89021376|NCT02957604||General Evolocumab-Exposed Case Series|Women who were exposed to Evolocumab (Repatha) but do not fulfill eligibility criteria for the Specific Evolocumab-Exposed Cohort
89021377|NCT04702503|Experimental|10% WP1220 ointment|10% WP1220 ointment topically applied 2x day for 84 days
89484662|NCT05781503|Experimental|Portable Rent Subsidies + Identity Capital Intervention|Young people randomized to the intervention group will receive 12 months of: portable rent subsidies, engage in a co-designed leadership guide, and be assigned a coach (one coach/10 youth).
89484663|NCT05781503|Active Comparator|Portable Rent Subsidies Only|The control group will be offered 12 months of portable rent subsidies.
89484664|NCT05771974|Experimental|Compression therapy using surgical gloves|Study participants wear two-layer of normal-sized surgical gloves on both hands during chemotherapy infusion
89484665|NCT05771974|No Intervention|Control|No intervention is provided on both hands.
89484666|NCT05768919|Experimental|Tolerability, Safety, and Efficacy of LC in Combination with RT and TMZ|Define the MTD/recommended Phase 2 dose (RP2D) of LC, administered IV weekly in combination with standard CRT (60 Gy in 30-33 fractions M-F, and daily oral TMZ 75 mg/m2), in patients with high grade malignant gliomas. This study seeks the MTD/RP2D of LC when added to TMZ during concurrent RT and adjuvant TMZ after RT. The study will evaluate escalating doses of LC delivered by IV infusion weekly as a gravity infusion (without infusion pump). Within each cohort, the dose will remain the same. In the first cohort, dosing will begin at Level 1 (300 mg/m2). The infusion of LC will begin at the start of CRT. Patients will be evaluable for the cohort if they have completed 80% of the planned doses of LC, 80% of RT and 60% of TMZ within the first 10 weeks of treatment. Patients who experience a dose-limiting toxicity (DLT) will be evaluable for the cohort if they have received at least 1 dose of LC.
89484667|NCT05768399||Asthma group|Children with asthma diagnosed by a respiratory physician
89484668|NCT05768399||Control group|Children without respiratory disease or inflammatory diseases
89484669|NCT05766917|No Intervention|control group|this group will receive the routine hospital care provided in burn center
89484670|NCT05766917|Experimental|peer education group|this group will receive the routine hospital care, in addition to the proposed peer education by trained peer.
89484671|NCT05757180|Experimental|Intervention group|Classes that will follow Positive Events Training.
89484672|NCT05757180|Active Comparator|Control group|Classes that will follow Bogus Control Training.
89484673|NCT05723211|Experimental|Vinyasa yoga group|The vinyasa yoga practice will be 60 minutes in duration and includes standing, seated, and supine postures in the following sequences in order: integration, sun salutations, crescent lunge series, balancing, standing, back bending, and restorative series. Participants will be instructed to follow the cues provided in the video and to take any necessary modifications to make each yoga pose more accessible. Vinyasa yoga intervention level 1 will be performed for week 1, level 2 will be performed for week 2, and level 3 will be performed for weeks 3 and 4 of the intervention.
89484674|NCT05723211|Other|Non-active control group|The participants in the non-active control condition will serve as a control group. They will be asked to maintain their current lifestyle habits and refrain from starting a new exercise and/or yoga program. A staff member will contact each participant weekly to check in and review any changes to their medical history or activity levels.
89484675|NCT05701800|Experimental|mRNA-1468: Dose 1|Participants will receive placebo by intramuscular (IM) injection on Day 1 followed with mRNA-1468 by IM injection on Day 57.
89484676|NCT05701800|Experimental|mRNA-1468: Dose 2|Participants will receive mRNA-1468 by IM injection on Day 1 and Day 57.
89484677|NCT05701800|Experimental|mRNA-1468: Dose 3|Participants will receive mRNA-1468 by IM injection on Day 1 and Day 57.
89484678|NCT05701800|Experimental|mRNA-1468: Dose 4|Participants will receive mRNA-1468 by IM injection on Day 1 and Day 57.
89021378|NCT01050543|Experimental|Sugammadex|
89021379|NCT01050543|Active Comparator|Neostigmine|
89021380|NCT00329342|Experimental|1|
89484679|NCT05701800|Active Comparator|Shingrix|Participants will receive Shingrix by IM injection on Day 1 and Day 57.
89484680|NCT05700786|No Intervention|Control Group|"The control group is made up of participants who are eligible but not assigned to the treatment. For ethical reasons they will be able to access the intervention once the experimental group has concluded the study. During the waiting-list phase, participants can access a mental health intervention, but in this case they are excluded from the study. Participants are told that there is only one possible active group and therefore a waiting-list is created. This explanation is given to reduce a worsening symptom bias for feeling excluded from treatment."
89537752|NCT04973787||axSpA|Patients with clinical diagnosis of axialSpondyloarthritis according to ASAS criteria, with indication for bDMARD (Portuguese Rheumatology Society Guidelines)
89537753|NCT04973787||RA|Patients with clinical diagnosis of Rheumatoid arthritis according to 2010 ACR/EULAR classification criteria, with indication for bDMARD (Portuguese Rheumatology Society Guidelines)
89021381|NCT00329342|No Intervention|2|
89021382|NCT00329381|Placebo Comparator|1|Placebo will be compared to Xolair 150-375 mg SQ every 2 or 4 weeks based on body weight and pre treatment IgE level.
89021383|NCT00329381|Experimental|2|Xolair 150-375 mg SQ every 2 or 4 weeks based on body weight and pre treatment IgE level.
89021384|NCT00429780|No Intervention|Alum-ALM + BCG|Alum-ALM + BCG
89021385|NCT00429780|No Intervention|Placebo|BCG diluent
89021386|NCT00329459|Experimental|arm 1|Treximet (sumatriptan/naproxen sodium)
89021387|NCT00329459|Placebo Comparator|arm 2|placebo to match
89021388|NCT00329537|Experimental|Arm 1|
89021389|NCT00329537|Placebo Comparator|Arm 2|
89484681|NCT05700786|Active Comparator|Experimental Group 1 - Online Format|The experimental intervention is an integrative mindful compassion group therapy as manualized by Cheli, Cavalletti, Flett & Hewitt (2020). The structure was outlined on the base of standard mindfulness-based interventions, comprising eight 2-hour online group sessions and one day of silence lasting 4 hours. The contents and the phases of the intervention were rooted in two different frameworks. On the one hand, the sequence of and the types of practices were defined in accordance with the mindful compassion protocol (Gilbert & Choden, 2014). On the other hand, the shared conceptualization of perfectionism and its role in triggering, maintaining, and inducing relapses in personality disoders was proposed through the relational model by Hewitt and colleagues (2017). The hybrid format (online weekly sessions plus an in presence half-day of silence) has been developed in accordance with existing COViD-19 emergency and rules.
89484682|NCT05700786|Active Comparator|Experimental Group 2 - Online Format|The experimental intervention is an integrative mindful compassion group therapy as manualized by Cheli, Cavalletti, Flett & Hewitt (2020). The structure was outlined on the base of standard mindfulness-based interventions, comprising eight 2-hour in presence group sessions and one day of silence lasting 4 hours in presence. The contents and the phases of the intervention were rooted in two different frameworks. On the one hand, the sequence of and the types of practices were defined in accordance with the mindful compassion protocol (Gilbert & Choden, 2014). On the other hand, the shared conceptualization of perfectionism and its role in triggering, maintaining, and inducing relapses in personality disoders was proposed through the relational model by Hewitt and colleagues (2017).
89484683|NCT05643170|Experimental|KarXT|
89484684|NCT05641441||Stereotactic radiosurgery group|Patients with unilateral Vestibular Schwannoma treated with stereotactic radiosurgery, as proposed by the institution's skull base tumor board independently of the study.
89484685|NCT05641441||Wait and scan group|Patients with unilateral Vestibular Schwannoma followed with an MRI-based observation strategy, as proposed by the institution's skull base tumor board independently of the study.
89484686|NCT05635916|Experimental|Liposomal Bupivacaine|Adductor canal block using liposomal bupivacaine and conventional bupivacaine
89484687|NCT05635916|Active Comparator|Standard of Care|Adductor canal block using conventional bupivacaine
89484688|NCT05633771||Hyrimoz|Patients prescribed with Hyrimoz
89484689|NCT05613062|Experimental|Active treatment (Modified Huang-Lian-Jie-Du Decoction (MHLJDD))|Chinese medicine
89484690|NCT05613062|Placebo Comparator|Placebo|Placebo
89484691|NCT05604417|Experimental|PHASE 1: ZANDELISIB + TAZEMETOSTAT|"Phase 1 study (3+3 design), followed by a phase 2 expansion component~For phase 1 portion, which follows the same dosing schedule as Arm A, there will not be any randomization.~Zandelisib, oral, daily on predetermined days each cycle for a total of 14 cycles~Tazemetostat oral, twice daily on predetermined days (Cycles 1) and predetermined days (Cycles 2-14) for a total of 14 cycles. There will be 2 dose levels of tazemetostat."
89484692|NCT05604417|Experimental|Arm A: COMBINATION ZANDELISIB + TAZEMETOSTAT|"Participants randomized into Arm A of the phase 2 component will receive~Zandelisib, oral, daily on predetermined days each cycle for a total of 14 cycles~Tazemetostat oral, twice daily on predetermined days (Cycles 1) and predetermined days (Cycles 2-14) for a total of 14 cycles"
89537754|NCT04973787||Control|Healthy participants, e.g. with no clinical diagnosis of rheumatic inflammatory disease, crossed by age, gender and diet profile
89537755|NCT03297515|Experimental|Omega 3 fatty acids|Omega 3 fatty acids
88952585|NCT01953484|Experimental|Bridge to Lung Transplant|Acute-on-Chronic Respiratory Insufficiency (patients awaiting lung transplant)
88952586|NCT01953497|Placebo Comparator|Placebo|Placebo
88952587|NCT01953497|Active Comparator|URC102|URC102
88952588|NCT01953523|Experimental|Deployment of stromal vascular fraction|Administration of autologous adipose derived SVF
88952589|NCT01953536|Experimental|Vintafolide|Participants receive intravenous (IV) vintafolide 2.5 mg on Days 1, 3, 5, 15, 17, and 19 of a 28-day cycle.
88952590|NCT01953536|Experimental|Vintafolide + Paclitaxel|Participants receive IV vintafolide 2.5 mg on Days 1, 3, 5, 15, 17, and 19 of one 28-day cycle and receive IV paclitaxel on Days 1, 8, 15, and 22 of a 28-day cycle.
88952591|NCT01953536|Active Comparator|Paclitaxel|Participants receive IV paclitaxel on Days 1, 8, 15, and 22 of a 28-day cycle.
88952592|NCT01953549|Experimental|physical fitness training|aerobic physical fitness training
88952593|NCT01953549|Active Comparator|relaxation|non-aerobic training
88952594|NCT01953562||Intubated infants|
88952595|NCT01953614|Sham Comparator|Placebo group|Ten people. Participants will receive what appears to be a chiropractic adjustment but which actually is not. This is the sham adjustment. Participants will also fill out Achenbach questionnaire. There will be a follow up in 7 days.
88952596|NCT01953614|Active Comparator|Chiropractic adjustment|Ten people. Group will be getting chiropractic adjustments. Participants will be filling out Achenbach questionnaire. There will be a follow up in 7 days.
88952597|NCT01953614|No Intervention|Control group|Ten people. This group will simply have their EEG recorded at baseline and after 7 days. There will be an Achenbach questionnaire like the two other groups.
88952598|NCT01953627|Experimental|Surgical procedure with the system Kymerax|
88952599|NCT01953653|Other|A: Begin with Interactive Voice Response (IVR) System|Group A participants are randomized the IVR system as Modality #1. After 33 days of diary completion using IVR, they switch to the interactive web response system (IWR)as Modality #2.
88952600|NCT01953653|Other|B: Begin with Interactive Web Response (IWR) System|Group B participants are randomized to the IWR system as Modality #1. After 33 days of diary completion using IWR, they switch to the interactive voice response (IVR)system as Modality #2.
88952601|NCT01953666|Experimental|Rehabilitation Group|People with spinal cord injury who have a rehabilitation program on a word prediction software with an occupational therapist.
88952602|NCT01953666|Active Comparator|Self Training at Home Group|People with spinal cord injury who don't have a rehabilitation program with an occupational therapist but who have instructions for learning at home on a word prediction software
88952603|NCT01953666|No Intervention|No treatment Group|People with spinal cord injury who don't have instructions, rehabilitation programm on word prediction software. They have no treatment.
89484693|NCT05604417|Experimental|Arm B: Zandelisib and Tazemetostat|"Participants randomized into Arm B of the phase 2 component will receive~Zandelisib oral, daily on predetermined days (Cycles 1-2) and predetermined days of cycle 3 and onwards up to 14 cycles.~Tazemetostat, oral, twice daily on predetermined days of each cycle. This will begin on cycle 3 and will continue for up to 12 cycles."
89484694|NCT05538481||Focus Group|A total of 16 participants, including patients and caregivers, will be enrolled for 2 focus groups (group of 8 patients with cancer and group of 8 caregivers).
89484695|NCT05538481||Cognitive Interviews Group|A total of up to 30 participants will be enrolled in this cohort, and up to 3 rounds of cognitive interviews will be conducted. This cohort of participants will be enrolled after survey development based on the themes identified from the focus group analyses.
89484696|NCT05537675||20 patients with meningioma|20 meningioma patients will be included in this study, 10 of whom will have been treated with Lutathera®.
89484697|NCT05537675||10 patients will have been treated with Lutathera®.|10 patients of the 20 will have been treated with Lutathera®.
89203811|NCT00765440|Experimental|Arm III|Patients receive oral or enteral IMPACT® nutrition over 7 days prior to surgery and enteral adjuvant IMPACT® nutrition over 7 days after surgery.
89484698|NCT05536336|Experimental|Okamoto Lubricated Synthetic Polyurethane Male Condom|The test device name is Okamoto 001 Lubricated Polyurethane Male Condom. The condom is made in Japan and conforms to ASTM D6324-11 (2017) Standard Test Methods for Male Condoms Made from Polyurethane.
89484699|NCT05536336|Active Comparator|Latex condom|Commercially available latex lubricated condom.
89484700|NCT05535296|Experimental|Intervention group|Standard health examination and related feedback. Functional examination. Risk profile and related advice.
89203812|NCT00657150|Experimental|Dabigatran etexilate|220 mg once daily
89203813|NCT00657150|Active Comparator|Enoxaparin|40 mg once daily
89203814|NCT00770354|Experimental|1|AS1402 plus letrozole
88952604|NCT01953679|Active Comparator|5mg UPA|Continuous regimen of oral daily 5 mg of ulipristal acetate (UPA) versus a cyclic regimen of 5 mg UPA for 24 days followed by a 4 day hormone free interval.
88952605|NCT01953679|Active Comparator|10mg UPA|Continuous regimen of oral daily 10 mg of ulipristal acetate (UPA) versus a cyclic regimen of 5 mg UPA for 24 days followed by a 4 day hormone free interval.
88952606|NCT01953705|Experimental|omega 3 polyunsaturated fatty acids|1.65 grams of EPA+DHA taken daily over 3 years
88952607|NCT01953705|Placebo Comparator|Soybean oil|1.65 grams of soybean oil taken daily over 3 years
88952608|NCT01953731|Experimental|Single-Arm Fixed-Sequence|Subjects will receive two different interventions in fixed-sequence two-period study. In the first period the subjects will receive a single-dose of palbociclib. In the second period, subjects will receive 12 days of rifampin and a single dose of palbociclib on day 8. In both periods, subjects will undergo pharmacokinetic sampling at prespecified time points up to 120 hours post palbociclib dose.
89203815|NCT00770354|Active Comparator|2|Letrozole
89203816|NCT00805428||2|control group
89203817|NCT00805428||patients with UC|patients with UC, without corticosteroid or immunosuppressive therapy
89203818|NCT00805506||Diabetes Insulin Treated|People with type 1 or type 2 diabetes on insulin.
89203819|NCT02553486||Internationally adopted children|All internationally adopted children, who arrived in France between 2008 and 2013, living in four French districts
89203820|NCT00670748|Experimental|#1 Anti-NY-ESO-1 TCR PBL+HD IL-2 Mel/RCC|Patients with melanoma or renal cell cancer (RCC) will receive non-myeloablative lymphodepleting regimen of cyclophosphamide and fludarabine followed by anti-NY ESO-1 T-cell receptor (TCR) peripheral blood lymphocytes (PBL) and high dose aldesleukin.
89203821|NCT00670748|Experimental|#2 Anti-NY-ESO-1 TCR PBL+HD IL-2 OtherCa|Patients with cancers other than melanoma or RCC will receive non-myeloablative lymphodepleting regimen of cyclophosphamide and fludarabine followed by anti-NY ESO-1 TCR PBL and high dose (HD) aldesleukin
89484701|NCT05535296|No Intervention|Control group|Standard health examination and related feedback. Functional examination.
89484702|NCT05529823|Experimental|Experimental group|The women in this group will have a warm shower during the labor process.
88952609|NCT01953744|Experimental|Fluconazole|Fluconazole will be administered by oral route at 6-8mg/kg/day during 28 days.
88952610|NCT01953744|Active Comparator|Meglumine Antimoniate|Meglumine Antimoniate will be administered by intravenous route at 20mg/kg/day during 20 days.
89203822|NCT00670748|Experimental|#3ESO1 TCR PBL+ALVAC ESO1+HD IL2 Mel/RCC|Patients with melanoma or RCC will receive non-myeloablative lymphodepleting regimen of cyclophosphamide and fludarabine followed by replication-defective recombinant canarypox virus (ALVAC) NY-ESO-1 vaccine, anti-NY ESO-1 TCR PBL and high dose aldesleukin
89203823|NCT00670748|Experimental|#4ESO1 TCR PBL+ALVAC ESO1+HD IL2 OtherCa|Patients with cancers other than melanoma or RCC will receive non-myeloablative lymphodepleting regimen of cyclophosphamide and fludarabine followed by ALVAC NY-ESO-1 vaccine, anti-NY ESO-1 TCR PBL and high dose aldesleukin
89203824|NCT00646776|Active Comparator|A|
89203825|NCT00646776|Active Comparator|B|
89203826|NCT00765596||1 RYGB|Subjects undergoing RYGB with gastric tube placement
89484703|NCT05529823|No Intervention|Control group|Women in the control group will not be interfered with and will be followed in line with the routine follow-up protocol of the clinic.
89484704|NCT05528562|Experimental|PrEP Rapid Access|Participants who are at risk of HIV and being seen at the Victory Program's Mobile Prevention Services Van.
89484705|NCT05509829|Experimental|NPWT group|Patients who receive NPWT after surgery.
89484706|NCT05509829|No Intervention|Control group|Retrospective cohort who did not receive NPWT.
89203827|NCT00765596||2 Matched controls|Subjects matched by BMI, age, gender to RYGB group
89203828|NCT04048928|Experimental|Strength group|Receives maximal strength training
89203829|NCT04048928|No Intervention|Control group|receives no active treatment
89484707|NCT05509712||Focus Groups to Refine MobileMen App Content|Focus groups are conducted virtually to refine content in the mobile app for African American men. African American men are recruited in Louisiana and Washington, DC and surrounding areas, using via listservs, ResearchMatch, social media, community events, local networking, and word of mouth.
89537756|NCT03297515|Placebo Comparator|Placebo|Placebo (sunflower oil)
89484708|NCT05509712||Beta testing of MobileMen App Prototype|The prototype MobileMen app is evaluated for feasibility, acceptability, and usability in semi-structured interviews with African American men recruited in Louisiana who meet eligibility criteria similar to those used for the focus groups
89484709|NCT05451407|Experimental|TQB2618 injection combined with Toripalimab injection|TQB2618 injection combined with Toripalimab injection，21 days as a treatment cycle.
89484710|NCT05428696|Experimental|SAD - Cohort 1|Eight participants will receive a single dose of Dose Amount 1 of ALXN2080, and 2 participants will receive placebo.
89484711|NCT05428696|Experimental|SAD - Cohort 2|Eight participants will receive a single dose of Dose Amount 2 of ALXN2080, and 2 participants will receive placebo.
89021390|NCT00429936|Active Comparator|100 mg fenretinide softgel capsules|Three (3) 100-mg fenretinide softgel capsules
89021391|NCT00429936|Active Comparator|Fenretinide and placebo softgel capsules|One (1) 100-mg fenretinide softgel capsule and two (2) placebo softgel capsules
89021392|NCT00429936|Placebo Comparator|Placebo softgel capsules|Three (3) placebo softgel capsules
89021393|NCT00430014|Experimental|Atiprimod|
89021394|NCT00329654|Experimental|Embar® light therapy or sham irradiation|Phototherapy with the Embar® light therapy or sham irradiation.
89021395|NCT01056393|Experimental|ibalizumab 800mg Q2Weeks|Subject will receive 800mg of ibalizumab every 2 weeks administered by intravenous infusion. All patients also will receive optimized background regimen
89021396|NCT01056393|Experimental|ibalizumab 2000mg Q4Weeks|Subject will receive 2000mg of ibalizumab every 4 weeks administered by intravenous infusion. All patients also will receive optimized background regimen
89021397|NCT04716491|Experimental|Intervention group|Intervention to decrease disruptive sleep in patients undergoing percutaneous intervention to treat cardiac disorders admitted to the ICU: ear protector and eye mask.
89021398|NCT04716491|No Intervention|Control group|Participants will not use the devices at any time of admission to the intensive care unit
89021399|NCT01055106|Active Comparator|1D|
89021400|NCT01055106|Active Comparator|3D|
89021401|NCT01055106|Active Comparator|5D|
89021402|NCT01055106|Active Comparator|Metronidazole|
89021403|NCT00329693|Placebo Comparator|1|Daily Tablets Dosing
89021404|NCT00329693|Experimental|2|Daily Tablets Dose
89021405|NCT00329693|Experimental|3|Daily Tablets Dosing
89484712|NCT05428696|Experimental|SAD - Cohort 3|Eight participants will receive a single dose of Dose Amount 3 of ALXN2080, and 2 participants will receive placebo.
89484713|NCT05428696|Experimental|SAD - Cohort 4|Eight participants will receive a single dose of Dose Amount 4 of ALXN2080, and 2 participants will receive placebo.
89484714|NCT05428696|Experimental|SAD - Cohort 5|Eight participants will receive a single dose of Dose Amount 5 of ALXN2080, and 2 participants will receive placebo.
89021406|NCT00329693|Experimental|4|Daily Tablets Dosing
89484715|NCT05428696|Experimental|SAD - Cohort 6|Eight participants will receive a single dose of Dose Amount 6 of ALXN2080, and 2 participants will receive placebo.
89484716|NCT05428696|Experimental|MAD - Cohort 1|Eight participants will receive multiple doses of Dose Amount A of ALXN2080 at a Dosing Frequency 1, and 2 participants will receive placebo for 14 days.
89484717|NCT05428696|Experimental|MAD - Cohort 2|Eight participants will receive multiple doses of Dose Amount B of ALXN2080 at a Dosing Frequency 1, and 2 participants will receive placebo for 14 days.
89021407|NCT00329810|Experimental|Switch|
89021408|NCT00430170|Active Comparator|1|dipyridamol during 7 days and before ischemic exercise caffeine 4mg/kg
89021409|NCT00430170|Placebo Comparator|2|dipyridamol during 7 days and before ischemic exercise placebo
89021410|NCT00430287||1: Primary open angle glaucoma|Patients with a form of primary open angle glaucoma
89021411|NCT00430287||2: No known eye disease (controls)|Patients with no known eye disease (controls)
89021412|NCT04716530||born before 2000|No patient treatment is associated with the study.
89021413|NCT04716530||born between 2000-2010|No patient treatment is associated with the study.
89484718|NCT05428696|Experimental|MAD - Cohort 3|Eight participants will receive multiple doses of Dose Amount C of ALXN2080 at a Dosing Frequency 1 or Frequency 2, and 2 participants will receive placebo for 14 days.
89484719|NCT05428696|Experimental|MAD - Cohort 4|Eight participants will receive multiple doses of Dose Amount D of ALXN2080 at a Dosing Frequency 1 or Frequency 2, and 2 participants will receive placebo for 14 days.
89484720|NCT05427487|Experimental|IVX037|IVX037 administered intratumorally, 1, 2 or 3 doses q2wks, Day 1, 15 and 29 of Cycle 1.
89021414|NCT04716530||born after 2010|No patient treatment is associated with the study.
89021415|NCT00330044|Experimental|Drug|Carboplatin and Pemetrexed
89484721|NCT05426616|Active Comparator|Control group: Collagen membrane|(Xenoprotect, Nobel Biocare, Göteborg, Sweden)
89484722|NCT05426616|Experimental|Test group: titanium reinforced d-PTFE membrane|(Creos Syntoprotect,Nobel Biocare AB, Göteborg, Sweden)
89484723|NCT05424679|Experimental|Intervention group|Individuals randomized to the intervention group will receive an evidence-based tool (coping plan + two additional check-in calls or visits), up to three COVID-19 safety messages, information on and facilitated referrals to community support services (e.g., tribal behavioral health), and up to seven culturally responsive caring messages (i.e. Caring Contacts) from the research team over a period of three months.
89021416|NCT00430365|Placebo Comparator|placebo group|Administration of oral placebo
89021417|NCT00430365|Experimental|lenalidomide group|Administration of lenalidomide
89484724|NCT05424679|Active Comparator|Control group|Individuals randomized to the control group will receive an evidence-based tool (coping plan + two additional check-in calls or visits), up to three COVID-19 safety messages, and information on and facilitated referrals to community support services (e.g., tribal behavioral health) from the research team over a period of three months.
89484725|NCT05405218|Experimental|Carpal Tunnel Release with Ultrasound Guidance (CTR-US)|
89484726|NCT05405218|Active Comparator|Mini Open Carpel Tunnel Release (mOCTR)|
89484727|NCT05402475|Experimental|Experimental|Online cognitive behavioural therapy with the added components of mindfulness meditation
89484728|NCT05402475|Active Comparator|Active comparator|Online cognitive behavioural therapy alone
89021418|NCT01051557|Experimental|Treatment (temsirolimus and perifosine)|"PHASE I: Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22 and perifosine PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~PHASE II: Patients receive temsirolimus and perifosine as in phase I. Some patients may also undergo cytoreductive surgery."
89021419|NCT00430404|No Intervention|Usual care (controlled group)|Usual care for management of depression
89021420|NCT00430404|Experimental|collaborative care (Intervention)|Collaborative care for management of depression for intervention group. We provided multidisciplinary groups of care from psychiatrist, psychologist, social counselor, general practitioners and case managers for intervention group.
89484729|NCT05381857||Individual from the initial Milieu Intérieur study|Individual who provided samples for the initial Milieu Intérieur study
89021421|NCT00330317|Experimental|Letrozole|
89021422|NCT03270384|Experimental|Treatment|Up to 15 subjects will be enrolled and treated with the Urotronic drug coated balloon (DCB)
89021423|NCT00330434|Other|Trial Withdrawn 2|Trial Withdrawn 2
89021424|NCT00330434|Other|Trial Withdrawn 1|Trial Withdrawn 1
89021425|NCT00430560|Active Comparator|1|work therapy
89203830|NCT00765752||1 Primary Insomnia|Individuals with insomnia not related to another identified cause.
89021426|NCT00430560|Experimental|2|work therapy plus cognitive remediation
89021427|NCT01054170|Experimental|AZD9668|
89021428|NCT01054170|Placebo Comparator|Placebo|
89021429|NCT00330629|Active Comparator|Standard Behavioral Treatment|"Goal setting: daily/weekly goals for calorie and fat consumption, exercise time, and behavior change.~Self-monitoring: systematically observing and recording one's behavior,45,46 which will be reviewed by the therapists, and written feedback will be provided to reinforce positive behaviors.~Feedback: therapists monitor the recorded behavior changes and provide feedback/encouragement."
89021430|NCT00330629|Active Comparator|SBT+LOV Group|In addition to SBT, participants will aim to eliminate all meat, poultry, and fish from their diet over the first 6 weeks, and will be taught how to select appropriate substitutes for these foods, such as low- or no-fat dairy products (cheeses, milk), and protein-containing vegetable sources (soy products, legumes). .
89021431|NCT00434460||1|Patients receiving invasive mechanical ventilation > 48 hours.
89021432|NCT00330746|Experimental|A|cetuximab and gemcitabine combination
89203831|NCT00765752||3 Healthy comparison subjects|Healthy subjects with no history of insomnia
89203832|NCT02558114|Other|Group A|Patients will receive ribavirin during 12 weeks
89203833|NCT02558114|Other|Group B|"Patients will receive:~ribavirin during 12 weeks if RNA (Ribonucleic acid) Hepatitis E virus (HEV) is undetectable at week 4 after treatment start (adjust to renal function)~- ribavirin during 24 weeks if RNA (Ribonucleic acid) Hepatitis E virus (HEV) is detectable at week 4 after treatment start (adjust to renal function)"
89203834|NCT00770666|Experimental|1|Nicotine patch, nicotine inhaler, bupropion
89203835|NCT00770666|Active Comparator|2|Nicotine patch
89203836|NCT00811044||Entry|This group is just entering the study and will need to be genotyped.
89203837|NCT00811044||Affected|This group has been genotyped and has the gene undergoing study at that time.
89203838|NCT00811044||Control|This group has been genotyped and does not have the gene currently under study.
89203839|NCT00764036|Experimental|experimental arm only|add-on therapy with 100, 150 or 200 mg oral artesunate once daily
89203840|NCT00764114|Active Comparator|1|- group A : during 6 weeks after the inclusion
89203841|NCT00764114|Active Comparator|2|-group B : during 12 weeks after the inclusion
89203842|NCT00811200|Active Comparator|1: Lucentis|
89203843|NCT00811200|Active Comparator|2: Kenalog|
89203844|NCT00811200|Sham Comparator|3: No treatment|
89484730|NCT05373017|Experimental|EGS Delirium Model|The delivery of the model will occur in five phases that correspond to the known stages of recovery after surgery. During the acute stage (0 - 1 month after surgery), participants will undergo the initial case review and two initial virtual visits, and the development of the recovery care plan. During the recovery (2 - 6 months after surgery) and maintenance (7-12 months after surgery) stages, the participants will undergo the interaction phase of the EGS Delirium Recovery Model.
89484731|NCT05373017|Other|Usual Care|Participants will receive the usual rehabilitation and post-operative care.
89484732|NCT05369299|Experimental|Two-piece zirconia implants|Immediate dental implant placement will be performed by using the new two-piece zirconia implant Straumann® Pure Ceramic Two Piece Implant
89484733|NCT05369299|Active Comparator|Two-piece titanium implants|Immediate dental implant placement will be performed by using the conventional two-piece titanium implant Neoss® ProActive Tapered Implant
89484734|NCT05362734||First fresh embryo transfer (group A)|The two groups analysed were defined according to the modality of first embryo transfer: cycles in which a fresh ET was performed at first, after a dual triggering or a rescue protocol (Group A) and cycles where a frozen-thawed ET was performed at first, after being chosen a freeze-all strategy (Group B).
88952611|NCT01953757|Experimental|Vegan diet and vitamin B12 supplement|The diet/supplement group will be asked to follow a low-fat, vegan diet for 20 weeks, and take a vitamin B12 supplement daily.
89484735|NCT05362734||First cryopreserved embryo transfer (group B)|The two groups analysed were defined according to the modality of first embryo transfer: cycles in which a fresh ET was performed at first, after a dual triggering or a rescue protocol (Group A) and cycles where a frozen-thawed ET was performed at first, after being chosen a freeze-all strategy (Group B).
89484736|NCT05350215|Placebo Comparator|Placebo oral capsules|Placebo (2 pills) before sleep for a week
89484737|NCT05350215|Active Comparator|Atomoxetine and DAW2020 oral capsules|DAW2020 34 mg 4 h before sleep, single night administration for a week. Simultaneous administration of atomoxetine 40 mg for 3 days 30 min before sleep, 80 mg for the following 4 days, 30 min before sleep
89484738|NCT05349643|Experimental|AMB-05X|Subjects will receive an injection of AMB-05X once every 4 weeks for 24 weeks (for 6 treatments total). Based on ongoing review of the available safety, PK, PD, and efficacy data, the Sponsor may either increase or decrease the dose.
89484739|NCT05340686|Experimental|Braining high intensity|Moderate to vigorous physical exercise, supervised by psychiatric staff 3 times per week
89484740|NCT05340686|Active Comparator|Braining relaxing exercise|Relaxation, light yoga or stretching exercise, supervised by psychiatric staff 3 times per week
89484741|NCT05340686|Active Comparator|Information about physical exercise|Written and oral information about health benefits from physical exercise, provided by researcher on one occasion.
89484742|NCT05324488||Type 1 Diabetes|Patients with diagnosed type 1 diabetes mellitus
89484743|NCT05324488||Type 2 Diabetes|Patients with diagnosed type 2 diabetes mellitus
89484744|NCT05324488||Adipositas|Obese patients with a BMI > 30kg/m2
89484745|NCT05324488||Lipid metabolism disorder|Patients with disorder of lipid metabolism
89484746|NCT05324488||Type 3 Diabetes Mellitus|Patients with diagnosed type 3 diabetes mellitus
89484747|NCT05324488||Maturity onset diabetes of the young (MODY)|Patients with diagnosed MODY
89484748|NCT05324488||Late onset diabetes of the adult (LADA)|Patients with diagnosed LADA
89484749|NCT05301881|Other|Surgery, radiotherapy or radiofrequent ablation|The oligoprogresive lesion(s) will be treated with Surgery, radiotherapy or radiofrequent ablation depending on the location of the lesion. treatment will be standard of care and will be decided by the treating team of the patient.
89484750|NCT05299515|Experimental|"Peer-Delivered Behavioral Activation (Peer Activate)"|Participants in the Peer Activate intervention will receive a PRS-delivered behavioral activation intervention to address barriers to retention in methadone treatment and increase substance-free, positive reinforcement to support retention.
88952612|NCT01953757|Active Comparator|Vitamin B12 supplement|The supplement group will be asked to take a daily vitamin B12 supplement, and to make no changes to their current diet.
88952613|NCT01953770|Active Comparator|Cranial irradiation|Consolidation therapy with cranial irradiation in intermediate risk group patients
88952614|NCT01953770|Experimental|Additional TIT|Consolidation therapy with additional triple intrathecal therapy (N6) and without cranial irradiation in intermediate risk group patients
88952615|NCT01953770|Experimental|MTX 2,000 mg/m2|Consolidation therapy with High-dose Methotrexate 2,000 mg/m2/24 h i.v. biweekly in intermediate risk group patients
88952616|NCT01953770|Active Comparator|MTX 30 mg/m2|Consolidation therapy with Low-dose Methotrexate 30 mg/m2 i.m. weekly in intermediate risk group patients
89484751|NCT05299515|No Intervention|Treatment As Usual|Participants in the TAU group will receive treatment as usual (weekly group and individual counseling with an addiction counselor in addition to referral to other available services in the community through study contact).
88952617|NCT01953770|Experimental|PEG-asp 1,000 U/m2|Consolidation therapy with PEG-L-asparaginase cons 1,000 U/m2 biweekly in standard risk group patients
88952618|NCT01953770|Active Comparator|L-asp 5,000 U/m2|Consolidation therapy with E.coli L-asparaginase 5,000 U/m2 weekly in standard risk group patients
88952619|NCT01953770|Active Comparator|PEG-DNR+|Induction therapy without PEG-L-asparaginase and with Daunorubicin 45 mg/m2 in standard and intermediate risk group patients
89484752|NCT05295979|Experimental|Inflammatory skin disease formula (ISDF)|Subjects will receive ISDF granules (10.85g twice daily) for 12 weeks.
89484753|NCT05295979|Placebo Comparator|Placebo|Subjects will receive placebo granules (10.85g twice daily) for 12 weeks.
89484754|NCT05288634|Experimental|Experimental|Routine maintenance and Progressive relaxation exercise practice
89484755|NCT05288634|No Intervention|Control|Routine maintenance
89484756|NCT05266976|Experimental|Resistance Exercise|Participants will perform total body resistance training 3x per week for 10 weeks. Each exercise session will last approximately 1 hour.
88952620|NCT01953770|Experimental|PEG+DNR+|Induction therapy with PEG-L-asparaginase ind (1,000 U/m2 on day 3 of therapy)and daunorubicin 45 mg/m2 in standard and intermediate risk group patients
89203845|NCT00811278||step1|asthma patients on step 1 therapy
89484757|NCT05266976|Experimental|Endurance Exercise|Participants will complete 60 minutes of stationary cycling 3x per week at 70-80% of maximal heart rate for 10 weeks.
89484758|NCT05258747|Experimental|Olaparib tablets, 150 mg|participants will receive 2 x 150 mg Olaparib tablets twice daily for 16 days in a crossover design
89484759|NCT05258747|Active Comparator|Lynparza® (olaparib) tablets 150 mg|participants will receive 2 x 150 mg Olaparib tablets twice daily for 16 days in a crossover design
89484760|NCT05254067||Device recipient|
89484761|NCT05240534|Placebo Comparator|Control group (ET-Text)|Participants will receive ElderTree on a laptop.
89484762|NCT05240534|Experimental|Experimental group (ET-Voice)|Participants will receive ElderTree on a smart system.
89484763|NCT05238779||End Stage Liver Disease (ESLD)|Patients with ESLD
89484764|NCT05229549|Active Comparator|A. One day treatment with 3 self-administrations of GOLIKE PLUS 3-16|
89484765|NCT05229549|Active Comparator|B. One day treatment with 2 self-administrations of GOLIKE PLUS 3-16|
89484766|NCT05229549|Placebo Comparator|C. One day treatment with 3 self-administrations of free AAs|
89484767|NCT05229549|Placebo Comparator|D. One day treatment with 2 self-administrations of free AAs|
89484768|NCT05225220|Experimental|Transcutaneous Vagus Nerve Stimulation (t-VNS)|Participants will receive 60 minutes of t-VNS stimulation every day for 10 consecutive days while wearing a fitness tracker.
89484769|NCT05219474|Experimental|Cochlear implant subjects|Participates in 7 visits over a six-month duration. Subjects will be given several tests that require them to listen to sounds presented to their cochlear implant and answer questions about those sounds.
89484770|NCT05219474|No Intervention|Normal hearing subjects|Participates in 1 visit lasting 3 hours. Will be given several tests that require you to listen to sounds and answer questions about those sounds. The sounds will be distorted in ways that approximate how a cochlear implant sounds.
89484771|NCT05181449|Experimental|Twin Precision Treatment (TPT)|Twin Precision Treatment (combination of AI and lifestyle coaching)
89484772|NCT05181449|No Intervention|Usual Care (UC)|Usual care prescribed by Cleveland Clinic diabetes specialists and primary care physicians
89484773|NCT05127200|Experimental|Anodal tsDCS (cervical active, lumbar sham)|"Participants will receive:~20 minutes of 2.5 milliampere (mA) anodal tsDCS at the cervical level.~sham tsDCS at the lumbar level."
89484774|NCT05127200|Active Comparator|Anodal tsDCS (cervical sham, lumbar active)|"Participants will receive:~20 minutes of 2.5 milliampere (mA) anodal tsDCS at the lumbar level.~sham tsDCS at the cervical level."
88952621|NCT01953770|Experimental|PEG+DNR-|Induction therapy with PEG-L-asparaginase ind (1,000 U/m2 on day 3 of therapy) without daunorubicin on day 8 in standard risk group patients
89484775|NCT05122975|Experimental|S48168 (ARM210) once daily for 28 days|Oral dose of S48168 (ARM210) once daily on top of standard of care regimen for 28 days.
89484776|NCT05122975|Placebo Comparator|Matching Placebo once daily for 28 days|Oral dose of placebo once daily on top of standard of care regimen for 28 days.
89484777|NCT05118204|Experimental|BUP microdose induction|Participants in this arm will receive a novel BUP microdose induction protocol.
89484778|NCT05118204|Active Comparator|Treatment As Usual (TAU)|Participants in this arm will receive standard BUP induction protocol.
89484779|NCT05093400||Normal Saliva|"saliva from normal healthy adults."
89484780|NCT05082935|Experimental|Partner-optimized venue placement strategy|The Phase II intervention involves outreach from community partners to attend testing at existing events organized by community partners, such as the Mexican Consulate. At the event, it includes the on-site Promotores de Salud psychoeducation related to SARS-CoV-2 health related behaviors.
89484781|NCT05082935|Experimental|Active Comparator, Residential density-located venue placement strategy|This is the Phase I intervention (Clinical Trial ID: NCT04793464). It includes the Phase I Promotores de Salud intervention, which consists of outreach to promote testing and vaccination at re-occurring testing events that have been selected for sites that have a high residential density of Latinx persons. At the testing events, it includes the on-site Promotores de Salud psychoeducation related to SARS-CoV-2 health related behaviors.
88952622|NCT01953796|Experimental|Study of Stair-step Clomiphene Protocol|50 mg clomiphene given for 5 days beginning on day 2 of the cycle. Tv USS done at days 11-14. When there is no response (no follicle >10 mm), 100 mg clomiphene is initiated immediately for 5 days, and U/S is repeated 1 week after the first tvUSS at day 21. If there is no response, another 150 mg clomiphene is initiated immediately for 5 days and U/S is performed 1week after the second U/S (day28). Ovulation for the stair-step cycles was confirmed by folliculometry (follicle tracing) by tvUSS.
89484782|NCT05082870|Experimental|Supportive-expressive group therapy|The SEGT approach fosters mutual support, promotes openness and emotional expression. SEGT will be delivered and co-facilitated by a psychiatrist and an allied healthcare professional. It is a 6-module program held over a 3-week period (approximately 2 hour sessions X 2 week) that is framed within social cognitive theory, whereby resilience to adversity (limb loss in this instance) relies on personal enablement.
88952623|NCT01953796|Active Comparator|Traditional Protocol.|Clomiphene medication was initiated at day two of the cycle. The starting dose was 50 mg/day for 5 consecutive days. In case of absent response, the patient was treated with 10 mg medroxyprogesterone acetate (MPA) for10 days. Daily doses of clomiphene citrate were increased by 50 mg in the next cycle up to 3 treatment cycle. In each cycle monitoring of follicular growth was done by tvUSS at day 11-14 of each cycle. First ovulation was used as the endpoint and the duration of follow-up was three treatment cycles (up to 150mg). Ovulation was assessed by tvUSS monitoring of follicle growth.
88952624|NCT01953809|Experimental|Run-in Period|All subjects will receive EE/NE for first 21 days and EE/NE matching placebo for next 7 days before start of treatment phase
89484783|NCT05082870|No Intervention|Treatment as usual|The treatment as usual group will receive standard care only (which may include an individual psychiatric consultation).
89484784|NCT05064930|Active Comparator|Bifidobacterium lactis|Probiotic formula contains 5x109 Bifidobacterium lactis Nordbiotic™ BI040 colony forming units (CFU)/capsule
89484785|NCT05064930|Active Comparator|Bacillus coagulans|Probiotic formula contains 2x109 Bacillus coagulans Nordbiotic™BC300 colony forming units (CFU)/capsule
89484786|NCT05064930|Placebo Comparator|Maltodextrin|Maltodextrin (starch hydrolisate) as a compound presents in probiotic formula.
89484787|NCT05036369|Experimental|Active capsule|The Vibrant non-biodegradable capsule administrated twice a week
89484788|NCT05036369|Placebo Comparator|Placebo|The placebo capsule is a softgel biodegradable capsule which is visually similar to the Vibrant active capsule and administrated twice a week
89484789|NCT05031663|Experimental|Almonds|The almond group will receive 15% of their daily energy intake in the form of almonds
89484790|NCT05031663|Placebo Comparator|Pretzel|The placebo group will receive an isocaloric carbohydrate based pretzel snack
89484791|NCT05027685||Renal Denervation Treatment|Patients candidate for treatment or already treated within 6 months prior to consent, as per the sites normal practice with the commercially available Paradise Ultrasound Renal Denervation System, will be enrolled in this single arm registry.
89484792|NCT05022342||HR-positive HER2-negative ABC/MBC|Hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC)/ metastatic breast cancer (MBC) patients
89484793|NCT05022342||PIK3CA mutation positive|Patients with Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha (PIK3CA) gene mutation positive
89484794|NCT05008549|Experimental|First Product Order: order not stated to protect study blinding|Participants will receive each of the 6 study products sequentially in a cross-over design, consuming one study product for 7 days, followed by a 7 day wash-out period before beginning the next product in the sequence.
89484795|NCT05008549|Experimental|Second Product Order: order not stated to protect study blinding|Participants will receive each of the 6 study products sequentially in a cross-over design, consuming one study product for 7 days, followed by a 7 day wash-out period before beginning the next product in the sequence
89484796|NCT05008549|Experimental|Third Product Order: order not stated to protect study blinding|Participants will receive each of the 6 study products sequentially in a cross-over design, consuming one study product for 7 days, followed by a 7 day wash-out period before beginning the next product in the sequence
89484797|NCT05008549|Experimental|Fourth Product Order: order not stated to protect study blinding|Participants will receive each of the 6 study products sequentially in a cross-over design, consuming one study product for 7 days, followed by a 7 day wash-out period before beginning the next product in the sequence
89484798|NCT05008549|Experimental|Fifth Product Order: order not stated to protect study blinding|Participants will receive each of the 6 study products sequentially in a cross-over design, consuming one study product for 7 days, followed by a 7 day wash-out period before beginning the next product in the sequence
89484799|NCT05008549|Experimental|Sixth Product Order: order not stated to protect study blinding|Participants will receive each of the 6 study products sequentially in a cross-over design, consuming one study product for 7 days, followed by a 7 day wash-out period before beginning the next product in the sequence
89484800|NCT04981106|Experimental|Elastic Band Exercise|"All the participants were subjected to walking training and a standard postoperative care and exercise protocol until discharged from the hospital. During discharging, all the participants in both groups were provided with explanation and illustration about how to perform the exercises. In order to prevent any problem, the participants in both groups were recommended to start the at-home rehabilitation programs, which incorporate knee movement exercises, to be ready 2 weeks (14 days) after the surgery and they were asked to continue their current exercise programs thus far.~The patients in intervention group were recommended to do, in addition to the at-home exercise program given to the patients in control group, elastic band exercises and researchers showed them how to use the elastic bands by making use of instructions."
89484801|NCT04981106|No Intervention|Exercise|The patients in control group were recommended to maintain only an at-home exercise program incorporating knee flexion and extension exercises.
89484802|NCT04968574|Experimental|ENV-101|taladegib, 200 mg tablet, once daily for 12 weeks
89484803|NCT04968574|Placebo Comparator|placebo|placebo, tablet, once daily for 12 weeks
89484804|NCT04958694|Experimental|CEDARS|Using an adapted stress-reduction intervention called the CEDARS, we will pilot the intervention in adolescents (N=50) to determine the feasibility and acceptability of CEDARS implementation and to investigate adolescent stress reduction.
89484805|NCT04950270||Group|Critically ill adult patients meeting all eligibility criteria with MRI-based PRES diagnosis within the last 48 hours
89484806|NCT04893447|Experimental|SPI+: Safety Planning Intervention plus structured phone-based follow-up|The Safety Planning Intervention (SPI+) includes safety planning (moderate or high risk for suicide) or connection & support planning (low risk for suicide) at the clinic or ED, plus a structured telephone-based intervention from a suicide prevention hotline
89484807|NCT04893447|Experimental|Caring Contacts: Safety Planning Intervention plus Caring Contacts (SP+CC)|SP+CC will include safety planning (moderate or high risk for suicide) or connection & support planning (low risk for suicide) at the clinic or ED, plus caring text messages or emails from a suicide prevention hotline.
89484808|NCT04878731|Experimental|single arm|PF-06741086 300mg subcutaneous(SC)
89484809|NCT04855253|Experimental|Dose level 1 : E7777 at 5 mcg/kg|Single dose of E7777 given on Day -7 two days prior to the start of lymphodepleting chemotherapy
89484810|NCT04855253|Experimental|Dose level 1 : E7777 at 7 mcg/kg|Single dose of E7777 given on Day -7 two days prior to the start of lymphodepleting chemotherapy
89484811|NCT04855253|Experimental|Dose level 1 : E7777 at 9 mcg/kg|Single dose of E7777 given on Day -7 two days prior to the start of lymphodepleting chemotherapy
89484812|NCT04855253|Experimental|MTD from phase 1|Single dose of E7777 (Maximum tolerated dose level identified in phase 1) given on Day -7 two days prior to the start of lymphodepleting chemotherapy
89484813|NCT04854850|Experimental|Apollo|Participants will all receive Apollo devices.
89484814|NCT04829279|Experimental|Case|Emergency patient transferred by CONNECT AI system
89484815|NCT04829279|No Intervention|Control|Emergency patient transferred by conventional EMS
89484816|NCT04826809|Experimental|Health care workers|Health care workers will complete a fit test while wearing the Nordell Single E-100 layer + (cotton layer) mask, Nordell Double E-100 layer mask and an N95 mask
89484817|NCT04809064|Experimental|Arthroscopic Bankart repair with remplissage of Hill-Sachs lesion/rehabilitation|Arthroscopic Bankart repair surgery with remplissage of Hill-Sachs lesion and post-operative rehabilitation.
89484818|NCT04809064|Experimental|Open Bankart/rehabilitation|Open Bankart surgery and post-operative rehabilitation.
89484819|NCT04809064|Experimental|Latarjet/rehabilitation|Latarjet surgical procedure and post-operative rehabilitation.
89484820|NCT04802876|Experimental|Spartalizumab (PDR001) (Cohort-1 PD1-high)|400mg/intravenous every 28 days
89484821|NCT04802876|Experimental|Spartalizumab (PDR001) (Cohort-2 PD1-low)|400mg/intravenous every 28 days
89484822|NCT04802876|Experimental|Tislelizumab (Cohort-3 PD1-high)|300mg/intravenous every 28 days
89484823|NCT04802291|Experimental|Healthy HomeStyles|Online educational intervention addressing salient factors affecting school-age children's health and nutritional status: inadequate intake of fruits and vegetables, infrequent family meals, excessive consumption of sugar-sweetened beverages, large portion sizes, irregular breakfast consumption, limited physical activity, and inadequate sleep as well as children's limited food preparation skills.
88952625|NCT01953809|Experimental|Group 1|Subjects upon completion of 28 days of run-in period will receive GSK1322322/Placebo + EE/NE in period 1 and only EE/NE in period 2 and 3 of treatment phase. Each period will be of 7 days
88952626|NCT01953809|Experimental|Group 2|Subjects upon completion of 28 days of run-in period will receive only EE/NE in period 1, GSK1322322/Placebo + EE/NE in period 2 and again EE/NE only in period 3 of treatment phase. Each period will be of 7 days
88952627|NCT01953809|Experimental|Group 3|Subjects upon completion of 28 days of run-in period will receive only OC in period 1 and 2, and GSK1322322/Placebo + EE/NE in period 3 of treatment phase. Each period will be of 7 days
88952628|NCT01953822||Cervarix vaccinated (exposed) female cohort|Female subjects vaccinated with at least one dose of Cervarix® between the ages of 9 to 25 years.
88952629|NCT01953822||Unexposed historical female cohort|Unexposed female subjects identified from historical data, will be frequency matched for age and practice region identifier to the subjects included in the vaccinated (exposed) cohort.
88952630|NCT01953822||Unexposed concurrent male cohort|Male population is composed of 9- to 25-year-old male subjects not vaccinated with Cervarix®.
88952631|NCT01953822||Unexposed historical male cohort|Male population is composed of 9- to 25-year-old male subjects not vaccinated with Cervarix®. Comparison of the unexposed concurrent male cohort with the unexposed historical male cohort will be used as an internal control for changes over time in Clinical Practice Research Datalink (CPRD) GOLD in reporting New Onset of Autoimmune Diseases (NOAD). The male subjects will be frequency matched for age and practice region identifier to the subjects included in the vaccinated (exposed) cohort.
88952632|NCT01953835|Experimental|Cohort A|Cohort A is a single-sequence, open-label study in which each subject will receive Simvastatin 10 mg single dose oral tablet on Days 1 and 10, Rosuvastatin 10 mg single dose oral tablet on Days 3 and 12 and GSK2586184 standard formulation 400 mg twice daily oral tablet from Day 6 to Day 14 immediately after food. At Day 10 GSK2586184 and Simvastatin and at Day 12, GSK2586184 and Rosuvastatin will be co-administered.
88952633|NCT01953835|Experimental|Cohort B|Cohort B is a three-way crossover study in which each subject will receive a single dose of GSK2586184 standard formulation 400 mg oral tablet with food and two doses of a new formulation of GSK2586184 400 mg oral tablet, once with food and once in a fasted state, on Day 1, 4 and 7 according to their treatment sequence, with a 3-day wash out between doses.
88952634|NCT01953848|Experimental|1: Low dose EC905|
88952635|NCT01953848|Experimental|2: High dose EC905|
88952636|NCT01953861|Experimental|1: fasted|EC905 + fasted
88952637|NCT01953861|Experimental|2: low-fat breakfast|EC905 + low-fat breakfast
88952638|NCT01953861|Experimental|3: high-fat breakfast|EC905 + high-fat breakfast
88952639|NCT01953887|Experimental|1 combination tablet EC905|
88952640|NCT01953887|Experimental|2: solifenacin|
88952641|NCT01953887|Experimental|3: tamsulosin|
88952642|NCT01953939|Experimental|Prosthetic Limb Users|Single lower limb amputees who are wearing their artificial limb all day and are using them outdoors for the majority of the time will be enrolled into this reliability study.
89021433|NCT00330746|Experimental|B|gemcitabine followed by cetuximab (sequential)
89021434|NCT01053741|Experimental|Seminal Fluid then Normosol|2.5 mL radiolabeled autologous seminal fluid administered rectally x1. Two week pause between interventions. Then 2.5 mL radiolabeled Normosol-R administered rectally X1.
89484824|NCT04802291|Active Comparator|Safe HomeStyles|Online educational intervention addressing aspects of home safety issues, such as indoor air quality, mold & moisture, hazardous household products, carbon monoxide, home safety, foodborne illness, and refrigerator temperatures.
89484825|NCT04793464|Experimental|Promotores|The Promotores de Salud intervention involves specified outreach and psychoeducation on SARS-CoV-2 health related behaviors.
89484826|NCT04793464|Active Comparator|Control|Services as usual includes outreach as usual strategies and pamphlets on site at events.
88952643|NCT01953952|Experimental|Arm I (surgery, risk-based adjuvant therapy)|Patients undergo eHNS. Depending on post-operative pathology findings, patients may undergo IMRT QD five days a week for 6 weeks, beginning within 6 weeks after surgery. High-risk patients also receive cisplatin IV on days 1, 8, 15, 22, 29, and 36 during radiation therapy.
89484827|NCT04789928|Experimental|Patients with uncomplicated LTIVC-related BSI and eligible|Patients included in this study will receive daily injection of genta-EDTA-Na2 lock associated with systemic antibiotics.
89484828|NCT04774536|Experimental|CRISPR_SCD001 Drug Product|CRISPR_SCD001 Drug Product (autologous CD34+ cell-enriched population that contains cells modified by the CRISPR-Cas9 ribonucleoprotein) dose will be ≥3.0×106 CD34+ cells/kg recipient weight for each subject and the upper limit cell dose is 20 ×106 CD34+ cells/kg.
89484829|NCT04763083|Experimental|Group A: Haematological malignancies|
89484830|NCT04763083|Experimental|Group B: Solid tumours|
89484831|NCT04762992|Experimental|Intervention group, enoxaparin|Enoxaparin subcutaneous injections
89484832|NCT04762992|Placebo Comparator|Placebo, normal saline|Normal saline subcutaneous injections
89484833|NCT04745325|Experimental|Smartphone app - full access|"A smartphone app containing 5 modules: 1) personalized feedback on alcohol use (containing normative feedback by age and sex for those located in the Canada), 2) self-monitoring and goal setting tool, 3) tool to choose a designated driver, 4) blood alcohol content (BAC) calculator, and 5) educational information on alcohol use and its consequences (i.e. fact sheets)."
89484834|NCT04745325|Active Comparator|Smartphone App - education only|"A version of the Smartphone app containing only the module with the educational information on alcohol use and its consequences (i.e. fact sheets)."
89484835|NCT04738123|Experimental|KarXT|
89484836|NCT04738123|Placebo Comparator|Placebo|
89484837|NCT04711369|Active Comparator|Intervention group (laser therapy)|Participants allocated to the laser-therapy group will receive 2 laser treatments over a period of 3 months. Laser therapy will be performed according to a standardized protocol.
89484838|NCT04711369|Sham Comparator|Control group (sham laser therapy)|Participants allocated to the control group will receive 2 sham laser treatments over a period of 3 months. Laser therapy will be performed according to a standardized protocol.
89484839|NCT04704453|Experimental|Experimental arm (A): capsaicin patch|
89484840|NCT04704453|Other|Standard arm (B): amitriptyline|
89484841|NCT04697563|Active Comparator|Laser|"Before treatment the vulva will be carefully inspected to rule out signs of infection or recent trauma. A local anesthetic cream (Emla cream 5%) will be applied to the entire introitus vulvae and all areas intended for local laser treatment. Before laser treatment another cotton swab test will be performed to ensure sufficient local anesthesia.~Vulvovaginal laser therapies will be performed with the non-ablative 2940 nm Er:YAG laser (Smooth XS, Fotona, Slovenia) in the Renova mode according to the manufacturer's guidelines and recommendations. The spot size (diameter of the laser beam) is 7 mm, with a pulse at a frequency of 1.6 Hz, and a fluence (laser energy delivered per unit area) of 5.0 to 10.0 J/cm2. The vulva will be treated using 1-3 repetitions."
89484842|NCT04697563|Placebo Comparator|Placebo Laser|"Clinical examination and preparations will be identical to the intervention group. Sham laser treatments will be performed with the same laser and the same device. However, a specially designed placebo probe, which blocks the emission of radiation, will be used. Women will therefore receive no therapeutic laser treatment. Before treatment, a study assistant, who is aware of the study allocation, will prepare the laser with the placebo probe, which looks identically to the normal probe. The treating physician will not be aware of the study allocation and the type of probe in use."
89484843|NCT04695847|Experimental|Part 1: M1231|Participants with solid tumors for whom no effective standard therapy exists will be included in this Part. Dose escalation of M1231 will be administered as single agent.
89484844|NCT04695847|Experimental|Part 2: Cohort A M1231: Metastatic NSCLC|Participants with metastatic Non-small Cell Lung Cancer (NSCLC) expressing Epidermal Growth Factor Receptor (EGFR) and Mucin 1 (MUC1) on archival tumor tissue will receive M1231 at the dose determined as recommended dose for expansion (RDE) in Part 1.
89484845|NCT04695847|Experimental|Part 2: Cohort B M1231: Metastatic Esophageal Squamous Cell Carcinoma|Participants with metastatic esophageal squamous cell carcinoma will receive M1231 at the dose determined as recommended dose for expansion (RDE) in Part 1.
89484846|NCT04676360|Experimental|(BELANTAMAB MAFODOTIN|"Belantamab mafodotin will be administered intravenously on day 1 of a 21-day cycle.~Treatment is intended to be administered on an outpatient basis."
89484847|NCT04665050|Experimental|V116|Participants receive a single 1.0 mL intramuscular (IM) injection of V116 on Day 1.
88952644|NCT01953952|Active Comparator|Arm II (chemoradiotherapy)|Patients undergo IMRT QD five days a week for 7 weeks. Patients also receive cisplatin IV on days 1, 8, 15, 22, 29, and 36 during radiation therapy.
88952645|NCT01953978|Active Comparator|Dexamethasone|"Intravenous administration of dexamethasone 16 mg (concentration 4 mg/ml, volume 4 ml) immediately after endotracheal intubation~Morphine. Patient controlled intravenous morphine (PCA-pump), bolus 2.5 mg, lock-out-time 10 minutes. Concentration : Morphin 1 mg/ml.~Zofran 4 mg iv in case of moderate to severe nausea, supplemented by Zofran 1 mg iv if needed~Tablet Paracetamol 1 g orally and tablet Ibuprofen 400 mg orally. Both 1 hour preoperatively and every 6 hours after extubation time during the first 48 hours."
88952646|NCT01953978|Placebo Comparator|Placebo|"Intravenous administration of isotonic sodium chloride (concentration 9 mg/ml, volume 4 ml) immediately after endotracheal intubation~Morphine. Patient controlled intravenous morphine (PCA-pump), bolus 2.5 mg, lock-out-time 10 minutes. Concentration : Morphin 1 mg/ml.~Zofran 4 mg iv in case of moderate to severe nausea, supplemented by Zofran 1 mg iv if needed~Tablet Paracetamol 1 g orally and tablet Ibuprofen 400 mg orally. Both 1 hour preoperatively and every 6 hours after extubation time during the first 48 hours."
88952647|NCT01953991|Active Comparator|Cobalt chrome dentures|Cobalt chrome dentures are used as part of standard care for patients
89484848|NCT04665050|Active Comparator|PNEUMOVAX™23|Participants receive a single 0.5 mL IM injection of PNEUMOVAX™23 on Day 1.
89484849|NCT04644159||Housolds|Pupils, teachers and non-teaching staff who attended schools of the city during the 2019-2020 school year and members of their households
88952648|NCT01953991|Active Comparator|PEEK dentures|PEEK dentures will be used as a comparator denture for patients
88952649|NCT01954030|Experimental|CTO and Bevacizumab (Phase 1)|The combination of CTO with the standard dosing of bevacizumab of 10 mg/kg every 2 weeks among patients with recurrent malignant glioma (World Health Organization (WHO) grade III or IV) that have previously failed bevacizumab
89484850|NCT04644159||Subjects hospitalized or residing in health care facilities|Residents and patients from retirement homes and long-term care units
89484851|NCT04644159||Staff of health care institutions|Staff of health care institutions
89484852|NCT04637009|Experimental|Part 1 (dose escalation)|Oral administration of TAS1553 once daily at specific time points.
88952650|NCT01954030|Experimental|Phase 2: CTO alone (Phase 2)|The first 25 patients will be treated with CTO alone at the maximum tolerated dose (MTD) established in the Phase 1 portion of the study.
88952651|NCT01954030|Experimental|CTO and Bevacizumab (Phase 2)|The second group of 25 patients will be treated with the combination of CTO at the MTD established in the Phase 1 portion of this study and standard dosing of bevacizumab.
88952652|NCT01954043|Experimental|Arm A|Subjects will administer Dabrafenib from Day 1 to Day 15, Dabrafenib and Rabeprazole from Day 16 to Day 19, Dabrafenib and Rifampin from Day 20 to Day 29. The serial PK samples will be collected for 12 hours following dosing on Day 15 (Dabrafenib alone), Day 19 (Dabrafenib and Rabeprazole), and Day 29 (Dabrafenib and Rifampin).
88952653|NCT01954069|Other|Semi-quantitative pregnancy test|Semi-quantitative urine pregnancy test (SQPT) (dBest One Step hCG Panel Test Kit)
88952654|NCT01954095||Group 1: No prior preterm birth & normal cervix length|Pregnant women at 16 0/7 - 23 6/7 weeks gestation who have had one or more term births (no prior preterm births) and have a normal cervical length (> 25 mm). These women will serve as gestational age controls for all groups.
88952655|NCT01954095||Group 2: No prior preterm birth & short cervix length|Pregnant women at 16 0/7 - 23 6/7 weeks gestation who have no prior preterm births and have a short cervical length (20mm or less). These women may receive treatment (e.g. vaginal progesterone, cerclage, pessary, NSAIDs, or a combination thereof) or no treatment.
88952656|NCT01954095||Group 3: Prior preterm birth, normal cervix length, 17-OHPC|Pregnant women at 16 0/7 - 23 6/7 weeks gestation who have had prior preterm birth, have a normal cervical length and will receive 17-OHPC treatment.
88952657|NCT01954095||Group 4: Prior preterm birth, normal cervix length, no treat|Pregnant women at 16 0/7 - 23 6/7 weeks gestation who have had prior preterm birth, have a normal cervical length, and will not receive any treatment. These women will serve as controls for Group 3.
88952658|NCT01954108|Other|ESWT (Extracorporal Shock Wave Therapy)|Three applications in weekly interval.
88952659|NCT01954108|Active Comparator|hyaluronic acid sodium salt|Two injections of 2% (40 milligrams (mg) / 2 millilitres (ml)) hyaluronan in weekly interval.
88952660|NCT01954134||thyroid cancer, healty|Thyroid cancer group: patients with differentiated or dedifferentiated thyroid cancer Healty: control group
88952661|NCT01954147|Experimental|SC-GLP-1|Umbilical Cord Mesenchymal Stem Cell Infusion Combined With Liraglutide
88952662|NCT01954147|Experimental|SC|Umbilical Cord Mesenchymal Stem Cell Infusion
88952663|NCT01954147|Experimental|GLP-1|Liraglutide
89484853|NCT04637009|Experimental|Part 2 (dose expansion)|Oral administration of TAS1553 once daily at specific time points.
89484854|NCT04628468|Experimental|Possibility to use the mobile application without a predefined number of physiotherapy sessions|Rehabilitation after hip or knee arthroplasty with the option to use a mobile application and no predefined traditional physiotherapy.
88952664|NCT01954147|Active Comparator|Control|Standard Medical Treatment
89484855|NCT04628468|Experimental|Possibility to use the mobile application with a predefined number of physiotherapy sessions|Rehabilitation after hip or knee arthroplasty with the option to use a mobile application and a predefined number of traditional physiotherapy sessions
89484856|NCT04628468|No Intervention|Usual care|Rehabilitation after hip or knee arthroplasty without the use of a mobile application.
89484857|NCT04601038|Other|MCI|Individuals with mild cognitive impairment due to Alzheimer's disease
89484858|NCT04601038|Other|Cognitively Normal|Individuals who are cognitively normal but who are at risk for Alzheimer's disease
88952665|NCT01954186|Experimental|intravenous & intramuscular oxytocin|intravenous or intramuscular 10 iu oxytocin
88952666|NCT01954186|Active Comparator|after delivery & when anterior shoulder seen|oxytocin 10 iu after the delivery of the fetus or when the anterior shoulder was seen after the fetal head was delivered
88952667|NCT01954199|Experimental|Neurodynamic group|Patients allocated to this group will receive three different neurodynamic techniques: a lumbar foramen dynamic opener; a side-lying slider and a slider in the slump position. Patients will be asked to perform home exercises (a slider and a tensioner technique). Treatment will receive four treatments during two weeks (two sessions/week).
89484859|NCT04581395|Other|Not pretreated|Succinylcholine administration with no Rocuronium pre-treatment
89484860|NCT04581395|Active Comparator|Pre-treated 1 minute before succinylcholine administration|Succinylcholine administration 1 minute following Rocuronium pre-treatment
89484861|NCT04581395|Active Comparator|Pre-treated 2 minutes before succinylcholine administratjion|Succinylcholine administratjion 2 minutes following Rocuronium pre-treatment
89484862|NCT04580368|Experimental|CFTR modulator or other therapies|CFTR modulator or active therapy
89484863|NCT04572100|Experimental|Group A - Low Risk|Participants who have low-risk cancer and significant reduction (greater than 50%) in tumor size following induction therapy will be assigned to this group.
89484864|NCT04572100|Experimental|Group B - Intermediate Risk|Participants who have low-risk cancer and intermediate reduction (30-50%) in tumor size or high-risk cancer with significant reduction (greater than or equal to 50%) in tumor size following induction therapy will be assigned to this group.
89484865|NCT04572100|Experimental|Group C - High-Risk|Participants who have high-risk cancer and less than a 50% reduction in their tumor size following induction therapy will be assigned to this group.
89484866|NCT04572100|Experimental|Induction Therapy (Carboplatin and Paclitaxel)|All study participants will be assigned to this group to first receive induction therapy using a combination of carboplatin and paclitaxel. Participant response to this phase of therapy will determine which group (low-risk, intermediate risk or high-risk) the participant will be in.
89484867|NCT04564625||Fracture and Vitamin D assessment|All patients between 18 and 25 years treated for fractures at Methodist Dallas Medical Center (MDMC) with an index admission vitamin D assessment will be enrolled. This study will consider any patients with an index admission occurring between February 2016 and February 2020. No changes to care or intervention will occur and this study will be conducted completely via chart review. The aim is to identify 100 subjects with a one-year follow-up appointment for their injury to determine the rate of nonunion and vitamin D levels. As patients receive vitamin D supplementation as standard of care if index values are low, impact will be assessed through relative deficiency and clinical outcomes. Data collected from subjects without need for supplementation may be used to generate a threshold.
89484868|NCT04564599||alcohol- and drug-related motor vehicle collisions|Number of alcohol- and drug-related motor vehicle collisions
89484869|NCT04564599||auto-ped alcohol- and drug-related collisions|Number of auto-ped alcohol- and drug-related collisions
89484870|NCT04560322|Experimental|Venetoclax-Obinutuzumab +/- Acalabrutinib|"A treatment cycle is defined as 28 consecutive days. Participants with undetectable MRD (uMRD) at 1 year will complete an additional 1 year of VO then stop therapy.~Participants with high detectable MRD at 1 year will complete an additional 1 year of VO plus acalabrutinib then stop therapy.~Participants with low detectable MRD at 1 year will complete an additional 1 year of VO alone. If this eradicates MRD, they will stop therapy. If there is still residual MRD, they will complete an additional 1 year of IVO then stop therapy.~If progression occurs on VO, I will be added and IV will be administered indefinitely. After 2 years, V may be stopped and I continued as monotherapy at investigator discretion.~Infused Study Drug: Obinutuzumab on Days 1, 2, 8, and 15 of Cycle 1 and then on Day 1 of Cycles 1-6~Oral Study Drugs: Venetoclax daily starting on Cycle 1 Day 22~Oral Drug: acalabrutinib daily for Days 1-28 (if applicable)"
89484871|NCT04538755|Placebo Comparator|Placebo|Placebo capsule 4 hours before sleep
89484872|NCT04538755|Active Comparator|DAW2020|DAW2020 capsule 4 hours before sleep
89484873|NCT04528303|Experimental|Whole genome sequencing|
89484874|NCT04528303|Active Comparator|Whole exome sequencing|
89484875|NCT04525703|Experimental|Pathways for Parents|
89484876|NCT04509076|Experimental|PrEP iT! (plus usual PrEP care)|The PrEP iT! intervention is a mobile-optimized website with components tailored for young men who have sex with men on PrEP.
89484877|NCT04509076|Placebo Comparator|Usual PrEP care only|Clinic visits every 3 months in the initial period following PrEP initiation, including HIV/STI screening and laboratory toxicity testing
89484878|NCT04504734|Active Comparator|Bucillamine low dose|Bucillamine 100 mg 3 times a day (TID)
89484879|NCT04504734|Active Comparator|Bucillamine high dose|Bucillamine 200 mg 3 times a day (TID)
89484880|NCT04504734|Placebo Comparator|Placebo|Placebo, 3 times a day (TID)
89484881|NCT04499079|No Intervention|Probation Referral Practice as Usual|Data are collected regarding standard probation practice and outcomes before implementation of the Learning Health System.
89484882|NCT04499079|Experimental|Learning Health System|Participating counties receive a system-level intervention, a Learning Health System, designed to improve youth connection to substance use treatment.
89484883|NCT04445532||hepatobiliary tumor patients|benign or malignant hepatobiliary tumors patients
89484884|NCT04445532||Benign Hepatobiliary Disease|chronic hepatitis, cirrhosis, and healthy control
89484885|NCT04388774|Experimental|Ketamine|Total dose administration or 0.5 mg/kg of ketamine
89484886|NCT04380454|Experimental|Fast treadmill walking with functional electrical stimulation (FastFES)|Participants with post-stroke hemiparesis who are randomized to receive 12 sessions of FastFES. FastFES is a targeted intervention that provides motor level stimulation-induced cues to improve ankle propulsion. FES is delivered only to the paretic ankle muscles, enhancing afferent ascending as well as descending corticomotor drive. Increased corticomotor drive in lesioned corticomotor circuits in turn promotes improved timing and intensity of muscle activation in the paretic plantar- and dorsi-flexor muscles, increasing plantarflexor moment and propulsion from the paretic ankle.
89484887|NCT04380454|Active Comparator|Fast treadmill walking (Fast)|Participants with post-stroke hemiparesis who are randomized to receive 12 sessions of Fast. Fast is a non-targeted intervention that provides similar structure, dose, and intensity of stepping practice as FastFES, but does not include FES, and no specific instructions are provided to target practice to the paretic leg or specific ankle deficits
89484888|NCT04377932|Experimental|AGAR T cells|GPC3-CAR and the IL15 (AGAR T cells) will be administered to patients with GPC3-positive solid tumors.
89484889|NCT04376736|No Intervention|Control arm|Patients are reminded about their appointments
89484890|NCT04376736|Experimental|Intervention arm|Patients are offered a one-time home visit by providers in lieu of their upcoming in-person visit
89484891|NCT04343209||Individuals with confirmed or suspected cardiovascular disease|Individuals in this group will undergo myocardial perfusion imaging, utilizing Ammonia N-13 PET imaging agent. Each individual will receive two intravenous injections of Ammonia N-13 in accordance with site imaging protocol.
89484892|NCT04332172|Placebo Comparator|General information|Control
89484893|NCT04332172|Experimental|General information + SMS|SMS refers to tailored text messaging.
89484894|NCT04332172|Experimental|Baseline brief intervention|Brief technology-delivered intervention for alcohol use during pregnancy
89484895|NCT04332172|Experimental|Baseline brief intervention + SMS|Brief technology-delivered intervention for alcohol use during pregnancy, plus tailored text messaging
89484896|NCT04332172|Experimental|Baseline brief intervention + 2 booster sessions|Brief technology-delivered intervention for alcohol use during pregnancy, plus two very brief (<5 minutes) online boosters using the participants' own mobile device.
89203846|NCT00811278||step 2|asthma patients on step 2 therapy
89021435|NCT01053741|Experimental|Normosol then Seminal Fluid|2.5 mL radiolabeled Normosol-R administered rectally x1. Two week pause between interventions. Then 2.5 mL radiolabeled autologous seminal fluid administered rectally X1.
89203847|NCT00811278||healthy|non-asthmatics
89537757|NCT04973865||Disease Population|50 Patients who have chronic diseases, such as cardiovascular, will consider as high risk, those who have more than two number of CAD risk factor will categorize as mild and patients have less than two risk factor of CAD will consider as low risk factor. (ACSM risk stratification guide lines)
89537758|NCT04973865||Healthy|30 Healthy individual with no cardiac diseased.
89537759|NCT03295097|Other|Clinical Decision Support System|The Clinical Decision Support System is composed of pharmacogenomic results and a pharmacist evaluated drug to drug interaction review. This system provides clinicians with patient-specific genetic information on opioid responsiveness and multi-drug interactions.
89537760|NCT04982211|Experimental|Propranolol and standard trauma memory reactivation group|Oral propranolol will be administered 60 minutes prior to writing (Treatment 1) or reading aloud a trauma narrative.
89537761|NCT04982211|Placebo Comparator|Placebo and standard trauma memory reactivation group|Oral placebo will be administered 60 minutes prior to writing (Treatment 1) or reading aloud a trauma narrative.
89537762|NCT04982211|Active Comparator|Propranolol and mismatch trauma memory reactivation group|Oral propranolol will be administered 60 minutes prior to a memory reactivation procedure involving variations in the contexts where the trauma memory reactivations occur.
89484897|NCT04332172|Experimental|Baseline brief intervention + 2 booster sessions + SMS|Brief technology-delivered intervention for alcohol use during pregnancy, plus two very brief (<5 minutes) online boosters using the participants' own mobile device, plus tailored SMS.
89484898|NCT04325646||CORSER-1a|Subjects who had been to China in the weeks before the outbreak began
89484899|NCT04325646||CORSER-1b|Subject who had a clinical profile compatible with an SARS-CoV-2 infection between August 1, 2019 and February 29, 2020
89484900|NCT04325646||CORSER-2a|Subjects with suspected CoV-2-SARS infection with negative results from RT-PCR testing of respiratory specimens
89484901|NCT04325646||CORSER-2b|Contacts or co-exposures of confirmed CoV-2-SARS infection cases, or who have worked or stayed in a hospital where confirmed CoV-2-SARS infection has been managed
89484902|NCT04325646||CORSER-2c|"Subjects who have been exposed to a risk of infection with SARS-CoV-2 in a geographical area of SARS-CoV-2 circulation.~study among pupils, their parents and siblings, as well as teachers and non-teaching staff of a high-school located in Oise~study among pupils from 5 to 12 and their parents in elementary schools located in Oise~study among choir members"
89484903|NCT04325646||CORSER-2d|Staff of health care institutions
89484904|NCT04325646||CORSER-2e|Subjects in care, hospitalized or residing in health care facilities
89484905|NCT04325646||CORSER-3|Subjects returning from a humanitarian mission that started before 31/01/2020
89484906|NCT04325646||CORSER-2f|Subjects with two symptomatic episodes of SARS-CoV-2 infection
89484907|NCT04325646||CORSER-4|Subjects being vaccinated against COVID-19
89484908|NCT04325646||CORSER-5|Subjects with acute SARS-CoV-2 infection and uninfected controls
89484909|NCT04306939||Case/Chronic complex disorders|Chronic complex disorders are composed of multiple population sub classifications - many of which have not been fully defined. Thus, all eligible patients should be included to maximize study power. Sufficient numbers of controls, those individuals in the general population, who may or may not have complex disorders are needed to match future comparison studies for a subset of questions, and so should also be included.
89484910|NCT04306939||Control|The number of controls that are anticipated for this study is less than patient numbers since they will not be needed for calculating the minor allele frequency of the majority of genetic polymorphism of interest in genetic association studies. This data is already available in public and research databases. Controls will be useful for evaluating case report form questions, providing assessment of the local genetic pool, and for possibly participating in future studies as provided by the consent.
89484911|NCT04305340|Experimental|SKIIN Textile Device in children with healthy hearts|The Myant SKIIN Device will be worn by study participants while they lay down, sit, stand, exercise and cool-down.
89484912|NCT04305340|Experimental|SKIIN Textile Device in children with heart failure|The Myant SKIIN Device will be worn by study participants while they lay down, sit, stand, exercise and cool-down
89484913|NCT04267614||Patients with Rheumatoid Arthritis (RA)|Patients receiving etanercept from Baghdad teaching hospital registry(Rheumatology center) from 2012 till 2017. Patients were identified as receiving early versus delayed etanercept treatment.
89484914|NCT04264442|Experimental|Losmapimod|FSHD1 patients with genetic confirmation will receive Losmapimod 15 mg by mouth twice daily for a total of 30 mg daily until 90 days after commercial drug is available post regulatory approval or until the study is discontinued by the Sponsor.
89484915|NCT04225663|Active Comparator|Intervention group|The Intervention group will receive 30-minute sessions of guided meditation. During meditation, they will lie down with their backs and torsos elevated by a mat/soft blocks. They will undergo guided breath work.
89484916|NCT04225663|No Intervention|Control group|The Control group will not have intervention. They will have quiet, independent study for 30-minute sessions.
89484917|NCT04171999|Experimental|Usual Care + Intervention (Case)|Cases will receive the CommunityRx Intervention.
89484918|NCT04171999|No Intervention|Usual Care (Control)|Controls will receive the usual standard care, which consists of information about hospital food resources and access to Feed1st hospital food pantries prior to discharge.
89484919|NCT04170309||With medical condition of interest|"Participants treated with ceftobiprole with at least one of the following conditions:~Renal Insufficiency~Hepatic Insufficiency~Immunosuppression"
89484920|NCT04170309||Without medical condition of interest|"Patients treated with ceftobiprole without any of the following conditions:~Renal Insufficiency~Hepatic Insufficiency~Immunosuppression"
89484921|NCT04164212|Other|open label|FLUMIST QUADRIVALENT 0.2 mL dose supplied in a single-dose pre-filled intranasal sprayer
89484922|NCT04112199|Experimental|BIV201 plus Standard of Care|BIV201 continuous infusion - treatment for two 28 day cycles.
89484923|NCT04112199|No Intervention|Standard of care|Per AASLD guidelines: diuretics and therapeutic paracentesis
88952668|NCT01954199|No Intervention|Control Group|"Patients allocated to Control Group (CG) will receive no intervention and will be advised according to the best evidence available; i.e, advice to remain active and to resume activities of daily living~Upon trial completion, treatment will be offered."
89021436|NCT04702230||post-TAE|
89484924|NCT04089904|Experimental|ARM 1|
89484925|NCT04076735|Experimental|Distal femoral replacement (DFR)|"Distal femoral replacement will be performed by excising the distal portion of the femur (up to two thirds) and replacing with a prosthesis incorporating a hinged total knee replacement.~Surgical approach and implant selection will be at the discretion of the treating surgeon and within the standard of care. Surgeons performing this procedure will be qualified by training and experience in arthroplasty."
89484926|NCT04076735|Active Comparator|Surgical Fixation (ORIF)|Surgical fixation of the distal femoral fracture will be performed with the goals of obtaining and maintaining anatomic reduction and stable fixation of the distal portion of the femur. Surgical approach and implant selection for the surgical fixation (ORIF) will be at the discretion of the treating surgeon and within the standard of care. Surgeons performing this procedure will be qualified by training and experience in trauma of the knee.
89484927|NCT04055428|Experimental|Sacubitril/Valsartan|We will enroll 100 adult Black individuals. Each participant will take the assigned dose of medication twice daily for 12 weeks. We evaluate insulin sensitivity and energy expenditure at baseline and after 12 weeks of intervention.
89537763|NCT04982211|Placebo Comparator|Placebo and mismatch trauma memory reactivation group|Oral placebo will be administered 60 minutes prior to a memory reactivation procedure involving variations in the contexts where the trauma memory reactivations occur.
89203848|NCT00764192|Experimental|1|14 HD patients are studied before and after a single HD using a polysulphone dialyser.
89203849|NCT00811356|Experimental|Single Dose, Repeat Dose, Drug-Drug Interaction|"GSK932121 or placebo will be administered as a single dose with or without food in a dose escalation manner. Once the results from the single dose is obtained and reviewed, GSK932121 or placebo will be administered as a repeat dose. The results from each repeat dose level will be reviewed prior to determining the next repeat dose level.~To better understand the effect of GSK932121 on rosiglitazone and rosuvastatin, a drug-drug interaction arm will also be investigated in this study. Rosiglitazone and rosuvastatin will be administered alone, then GSK932121 will be given as a repeat dose. Rosiglitazone and rosuvastatin will then be administered in combination with GSK932121."
89484928|NCT04055428|Active Comparator|Valsartan|We will enroll 100 adult Black individuals. Each participant will take the assigned dose of medication twice daily for 12 weeks. We evaluate insulin sensitivity and energy expenditure at baseline and after 12 weeks of intervention.
89484929|NCT04049383|Experimental|5 x 10^5 CAR-20/19-T cells/kg|The study will utilize a 3+3 dose escalation design in ALL followed by a six-patient expansion cohort.
89484930|NCT04049383|Experimental|1 x10^6 CAR-20/19-T cells/kg|The study will utilize a 3+3 dose escalation design in ALL followed by a six-patient expansion cohort.
89484931|NCT04049383|Experimental|2.5 x10^6 CAR-20/19-T cells/kg|The study will utilize a 3+3 dose escalation design in ALL followed by a six-patient expansion cohort.
89484932|NCT04049383|Experimental|Dose Expansion Phase|The study will utilize a 3+3 dose escalation design in ALL followed by a six-patient expansion cohort. Subjects will receive one of three dose levels. The dose expansion arm will be updated with the appropriate dose in the future based on the escalation results.
89484933|NCT04049019|Experimental|Urine collection, children with nocturnal enuresis|"The child ́s weight and height will be registered. The children's urine will be tested for infection with a dipstick urinalysis.~The child will be asked to perform home recordings for seven days consisting of measurements of diaper weight and first morning voided volume and a two-day frequency-volume chart."
89484934|NCT04049019|Active Comparator|Urine collection, healthy children|The child ́s weight and height will be registered. The children's urine will be tested for infection with a dipstick urinalysis.
89484935|NCT04035590|Active Comparator|With drain|Patients undergo mastectomy with flap fixation and low vacuum drainage.
89484936|NCT04035590|Experimental|No drain|Patients undergo mastectomy with flap fixation and low vacuum drainage is omitted.
89484937|NCT04026425|Experimental|ME/CFS|Adults with ME/CFS
89484938|NCT04026425|Active Comparator|Healthy controls|Healthy, low-active adults
89484939|NCT04004000|Experimental|Treatment|FSHD1 subjects with genetic confirmation with receive 15 mg of losmapimod twice daily given by mouth; for a total of 30 mg daily until 90 days after commercial drug is available post regulatory approval or study termination.
89484940|NCT03998488|Experimental|Investigational FMT|"Participants will be blindly randomized to receive a single dose of investigational FMT during the week 0 colonoscopy.~Additionally, participants will blindly receive a single dose of placebo FMT during the week 8 by flexible sigmoidoscopy."
89484941|NCT03998488|Active Comparator|Investigational FMT + psyllium fiber|"Participants will be blindly randomized to receive a single dose of investigational FMT during the week 0 colonoscopy. They will also receive fiber supplementation of 1 teaspoon 2x/day for 8 weeks.~Additionally, participants will blindly receive a single dose of placebo FMT during the week 8 by flexible sigmoidoscopy."
89484942|NCT03998488|Placebo Comparator|Placebo FMT +/- psyllium fiber|"Participants will be blindly randomized to receive a single dose of placebo FMT during the week 0 colonoscopy. They may or may not also receive fiber supplementation of 1 teaspoon 2x/day for 8 weeks.~Additionally, participants will blindly receive a single dose of investigational FMT during the week 8 by flexible sigmoidoscopy."
89484943|NCT03959904|Active Comparator|Small Stitch|Small stitch for wound closure
89021437|NCT04702230||post-TARE|
89203850|NCT00765908|Experimental|A|Patients undergoing elective PCI will be randomised to 90 second balloon inflations rather than the standard less than 30 second inflations in order to induce peri-ischaemic conditioning.
89203851|NCT00765908|Active Comparator|B|Control group. These patients will have a standard procedure with balloon inflations of 30 seconds or less as per standard.
89203852|NCT00765986||1|Patients with inoperable NSCLC undergoing RT or Chemo-RT
89203853|NCT00766064|Experimental|Paliperidone Dosing|Paliperidone Dosing up to 6 weeks, with a maximum dosage of 6mg
89484944|NCT03959904|Active Comparator|Large Stitch|Large Stitch for wound closure
89203854|NCT00770744|Experimental|Zicronapine|
89484945|NCT03953417|Experimental|Accelerated intermittent theta burst treatment|All participants will receive accelerated intermittent theta-burst stimulation.
89484946|NCT03946228|Experimental|Behavioral Intervention|The intervention will use behavioral strategies (self-monitoring, goal setting, problem solving, social support, stimulus control), environment modification (sit-stand attachment), and proximal (activity prompter) and distal (text messages) external prompts to target a 2-4 hour/day reduction in sedentary behavior.
89484947|NCT03946228|No Intervention|Control Condition|Participants randomized to the control condition will receive no intervention during the study. After the 3-month assessment, control participants will be provided with a wrist-worn activity monitor and will be offered the 3-month delayed intervention if desired to aid in retention and recruitment.
89484948|NCT03912246|Experimental|Healthy volunteers|"Human biological samples:~whole blood (serum or plasma, PBMCs, red blood cells), urine, feces, saliva, tears, mouth and skin swabs.~Bio-clinical data :~adjusted to the purpose of the searches will be collected"
89484949|NCT03912246|Experimental|Patients with neuro-meningeal infection|"Human biological samples:~Whole blood (serum or plasma, PBMCs, red blood cells), urine, feces, saliva, tears, mouth and skin swabs.~Extended collection of CSF~Bio-clinical data :~adjusted to the purpose of the searches will be collected"
89484950|NCT03896776|Experimental|Community Based Organization (CBO) Delivery|"CBOs will be selected through a Request for Proposal (RFP) process. The RFP will describe research and KIU! delivery activities to be conducted as part of the study and allowable budget to carry out the activities. The RFP will ask CBOs to describe past experience providing HIV services for YMSM. Selected CBOs will recruit participants into the intervention and encourage participants to complete each session of intervention content at baseline, 6 Week Follow-up, and 12 Week Follow-up.~Participants in the CBO delivery arm will receive baseline HIV and STI testing at a CBO. Participants will receive an at-home STI test kit at 12 Week Follow-up if testing is not provided at their CBO site."
89484951|NCT03896776|Experimental|Direct to Consumer (DTC) Delivery|"In the DTC arm, participants will be recruited online via paid social media advertising (e.g., Facebook, Instagram). Advertisements will target placements by age, gender, sexual orientation, racial background, likes that are relevant to YMSM (e.g., local LGBT organizations, out celebrities), and location (i.e., target county). Dating/sex-seeking apps (e.g., Grindr) will also be used to recruit YMSM, using a similar advertising approach as social media. These online recruitment strategies will be supplemented by referrals from local organizations and participant registries, and snowball recruitment. Study staff at Northwestern University will manage this recruitment process and encourage participants to complete each session of intervention content at baseline, 6 Week Follow-up, and 12 Week Follow-up.~Participants in the DTC delivery arm will receive at-home HIV and STI test kits at baseline. Participants will receive an at-home STI test kit at 12 Week Follow-up."
89484952|NCT03809351|Experimental|[F-18]AV-1451-PET/MRI|All participants in this study will undergo a tau-PET imaging using the tracer [F-18]AV-1451 with a simultaneous PET/MRI system. The [F-18]AV-1451 dosage is 740MBq (10 mCi) given intravenously, and the PET/MRI imaging will occur 75-105 min after tracer injection.
89484953|NCT03735680|Experimental|Patients receiving ONM-100|All patients in this arm will receive ONM-100 for injection and undergo intraoperative imaging.
89484954|NCT03726658|Experimental|AGN-241751 3mg|AGN-241751, oral administration, once per day in Part A. Twice per day (BID) in Part B
89484955|NCT03726658|Experimental|AGN-241751 10mg|AGN-241751, oral administration, once per day
89484956|NCT03726658|Experimental|AGN-241751 25mg|AGN-241751, oral administration, once per day in Part A. Twice per day (BID) in Part B
89484957|NCT03726658|Placebo Comparator|Placebo|Placebo, oral administration, once per day in part A. Twice per day (BID) in Part B
89484958|NCT03719885|Experimental|Intervention|
89484959|NCT03718091|Experimental|Cohort T1: ATRX-mutant Leiomyosarcoma|M6620 will administered intravenously on days 1,4, 8, 11, 15, 18, 22, 25 on a 28-day cycle.
89484960|NCT03718091|Experimental|Cohort T2: Truncating ATM Mutation|M6620 will administered intravenously on days 1,4, 8, 11, 15, 18, 22, 25 on a 28-day cycle.
89484961|NCT03718091|Experimental|Cohort T3: Other HR Gene Mutations|M6620 will administered intravenously on days 1,4, 8, 11, 15, 18, 22, 25 on a 28-day cycle.
88952669|NCT01954212|Experimental|Enhanced complex oral health care intervention|The complex oral health care (OHC) intervention (SOCLE intervention) includes patient, staff and service level interventions.
89203855|NCT00770744|Active Comparator|Olanzapine|
89203856|NCT00770822|Experimental|Device, HIFU|High Intensity Focused Ultrasound
89203857|NCT00770822|Active Comparator|Device, brachytherapy|Brachytherapy
89484962|NCT03718091|Experimental|Cohort 1A: Osteosarcoma|M6620 will administered intravenously on days 1,4, 8, 11, 15, 18, 22, 25 on a 28-day cycle.
89484963|NCT03718091|Experimental|Cohort 1B: Leiomyosarcoma|M6620 will administered intravenously on days 1,4, 8, 11, 15, 18, 22, 25 on a 28-day cycle.
89484964|NCT03718091|Experimental|Cohort 2: Truncating ATM mutation|M6620 will administered intravenously on days 1,4, 8, 11, 15, 18, 22, 25 on a 28-day cycle.
89484965|NCT03718091|Experimental|Cohort 3A: Germline BRCA mutation|M6620 will administered intravenously on days 1,4, 8, 11, 15, 18, 22, 25 on a 28-day cycle.
89484966|NCT03718091|Experimental|Cohort 3B: Other HR Alteration|M6620 will administered intravenously on days 1,4, 8, 11, 15, 18, 22, 25 on a 28-day cycle.
89484967|NCT03718091|Experimental|Cohort 4A: MYC amplification, FBXW7 mutation|M6620 will administered intravenously on days 1,4, 8, 11, 15, 18, 22, 25 on a 28-day cycle.
89484968|NCT03718091|Experimental|Cohort 4B: Cyclin E amplification|M6620 will administered intravenously on days 1,4, 8, 11, 15, 18, 22, 25 on a 28-day cycle.
89484969|NCT03718091|Experimental|Cohort 5: ARID1A mutation|M6620 will administered intravenously on days 1,4, 8, 11, 15, 18, 22, 25 on a 28-day cycle.
89484970|NCT03718091|Experimental|Cohort T4: SDH-Mutant GIST|M6620 will administered intravenously on days 1,4, 8, 11, 15, 18, 22, 25 on a 28-day cycle.
89484971|NCT03662607|No Intervention|Control|Standard pre-procedural education for cardiac catheterization.
89484972|NCT03662607|Experimental|Treatment|Standard pre-procedural education plus virtual reality experience for cardiac catheterization.
89484973|NCT03654664|Experimental|inactivated hepatitis A vaccine|A 0.5ml dose is administered twice in total at an interval of 6 months to healthy children aged 12-23 months.
89484974|NCT03654664|Active Comparator|Havrix Inj|A 0.5ml dose is administered twice in total at an interval of 6 months to healthy children aged 12-23 months.
89484975|NCT03653338|Experimental|Hematopoietic Stem Cell Transplantation|"All patients will receive a CD3+/CD19+ depleted stem cell transplant. In this study, the investigators will use HLA mismatched unrelated or haploidentical related donor peripheral blood stem cells. Prior to transplantation, the marrow (90-95%) will be negatively selected for CD3/CD19 using the ClinicMACs® depletion device. The remaining (5-10%) will undergo CD45+RA+ depletion and be frozen for future use as an immune boost.~Subjects will undergo hematopoietic stem cell transplant utilizing CD3+/CD19+ depleted cells following conditioning therapy."
89484976|NCT03628703|Experimental|Repetitive TMS|Repetitive Intermittent Theta-Burst Transcranial Magnetic Stimulation
89484977|NCT03576755|Experimental|spironolactone|spironolactone, 100 mg capsule administered orally once daily for 6 or 12 months
89484978|NCT03576755|Placebo Comparator|placebo|matching placebo capsule administered orally once daily for 6 or 12 months
89484979|NCT03572049|Experimental|SUBA itraconazole|"Stage 1: Day 1-3 two 65 mg capsules three times daily with food. Days 4-42 two 65 mg capsules twice daily with food.~Stage 2 : Days 43-180 two 65 mg capsules twice daily with food"
89484980|NCT03572049|Active Comparator|Conventional itraconazole|"Stage 1: Day 1-3 two 100 mg capsules three times daily with food. Days 4-42 two 100 mg capsules twice daily with food.~Stage 2 : Days 43-180 two 100 mg capsules twice daily with food"
89484981|NCT03555877|Experimental|Anti-hormonal treatment + ribociclib|In the experimental arm ribociclib will be dosed on a flat scale of 600mg/day (corresponding to three 200mg tablets once daily, 3 week on, one week off). Anti-hormonal/endocrine treatment of choice of investigator: anastrozole, exemestane, letrozole, fulvestrant.
89484982|NCT03555877|Active Comparator|Anti-hormonal treatment|In the control arm patients will receive endocrine treatment only (of choise of investigator). Anti-hormonal/endocrine treatment of choice of investigator: anastrozole, exemestane, letrozole, fulvestrant.
89484983|NCT03481972|Experimental|Doxy/TUDCA|"doxycicline (100 mg / BID)~tauroursodeoxycholic acid (250 mg / TID)"
89484984|NCT03481972|Active Comparator|Standard of care|Standard of care therapies.
89484985|NCT03476876|Experimental|Dermacell|Subject will receive treatment for one non-healing deep diabetic foot ulcer using one Dermacell acellular matrix. Subject will be followed up to 16 weeks post treatment, or until wound has closed, whichever comes first.
89484986|NCT03476876|Active Comparator|Integra|Subject will receive treatment for one non-healing deep diabetic foot ulcer using one Integra bilayer cross-linked matrix. Subject will be followed up to 16 weeks post treatment, or until wound has closed, whichever comes first.
89484987|NCT03472560|Experimental|Avelumab in combination with axitinib|Avelumab administered at 800 mg IV every two weeks in combination with axitinib, 5 mg PO BID.
89484988|NCT03421184|Experimental|Patient with Systemic Lupus Erythematosus|30 women with SLE
89484989|NCT03421184|Active Comparator|Patients with other autoimmune diseases|20 patients with rheumatoid arthritis, 20 patients with autoimmune thrombocytopenia
89484990|NCT03421184|Active Comparator|Healthy control|30 healthy control women
89484991|NCT03371602|Experimental|control group|non-septic mesocolic programmed abdominal or thoracic surgery: gastrectomy, esophagectomy, pancreatectomy, hepatectomy
89484992|NCT03371602|Experimental|sepsis group|Abdominal or thoracic surgery in a septic context (peritonitis, mediastinitis, pleural abscess)
89484993|NCT03371602|Experimental|mechanical ventilation group|Patient in brain death for whom a multi-organ sampling is planned
89484994|NCT03371602|Experimental|mechanical ventilation - sepsis group|Patient under controlled mechanical ventilation to undergo abdominal or thoracic surgery in a septic context (peritonitis, mediastinitis, pleural abscess)
89203858|NCT00764348||no treatment|
89484995|NCT03336216|Active Comparator|Arm A|"Investigator choice of chemotherapy:~Gemcitabine/Nab-Paclitaxel (Abraxane®) or 5-Fluorouracil/Leucovorin/Irinotecan Liposome (ONIVYDE)"
89484996|NCT03336216|Experimental|Arm B|Cabiralizumab Q2W + Nivolumab Q4W
89484997|NCT03336216|Experimental|Arm C|Cabiralizumab Q2W + Nivolumab Q4W and Gemcitabine + Nab-Paclitaxel (Abraxane®) D1, 8 and 15 Q4W
89484998|NCT03336216|Experimental|Arm D|Cabiralizumab Q2W + Nivolumab Q4W and Oxaliplatin/5-Flurouracil/Leucovorin (FOLFOX) Q2W
89484999|NCT03298815|Active Comparator|Amniotic Fluid Eye Drops (AFED) - All participants, One eye|
89485000|NCT03298815|Placebo Comparator|Saline Solution - All participants, One eye|
89485001|NCT03269994|Active Comparator|Cefoxitin|
89485002|NCT03269994|Experimental|Piperacillin-tazobactam|
89485003|NCT03220646|Experimental|A:recurrent IDH wildtype RB1 intact grade II and III gliomas|The main study cohort will consist of patients with recurrent IDH wildtype, RB1 wildtype, WHO grade II and III gliomas that have failed previous therapy. This arm is currently on hold.
89021438|NCT00330824|Experimental|antibiotic steroid (single vial)|efficacy of antibiotic steroid combination compared with individual administration in prevention of postoperative inflammation in patients having LASIK surgery
89021439|NCT00330824|Active Comparator|antibiotic / steroid (2 vials)|efficacy of antibiotic steroid combination compared with individual administration in prevention of postoperative inflammation in patients having LASIK surgery
89021440|NCT00330902|Active Comparator|1|Sulfadoxine pyrimethamine plus three daily doses of artesunate
89021441|NCT00330902|Experimental|2|Sulfadoxine pyrimethamine plus artesunate plus primaquine
89021442|NCT00434616|Placebo Comparator|1|saline injections
89021443|NCT00434616|Active Comparator|2|autologous bone marrow transplantation into the ischemic leg
89021444|NCT00330980|Experimental|1|Participants will receive 20 mg of simvastatin for 6 months.
89021445|NCT00330980|Experimental|2|Participants will receive 40 mg of pravastatin for 6 months.
89021446|NCT00330980|Placebo Comparator|3|Participants will receive placebo for 6 months.
89021447|NCT00434655|Active Comparator|1 LAP BAND|
89203859|NCT00655668|Experimental|Lenalidomide|Open-label, oral lenalidomide monotherapy
89203860|NCT00770900|Experimental|Montelukast|Asthmatic children and teenagers took montelukast daily.
89203861|NCT00770900|Placebo Comparator|Placebo|Placebo to montelukast tablet daily.
89021448|NCT00434655|Experimental|2 Sleeve gastrectomy|
89203862|NCT00766220|Active Comparator|SIR-Spheres + Therapy|SIR-Spheres with Cetuximab + Irinotecan Therapy
89203863|NCT00766220|Active Comparator|Therapy Only|Cetuximab + Irinotecan Therapy
89203864|NCT00807300|Active Comparator|brachytherapy|
89203865|NCT00807300|Other|TACE|transarterial chemoembolization
89203866|NCT00813540|Experimental|1|Exercise
89203867|NCT00813540|Other|2|Usual Care, no intervention
89203868|NCT00770978|Experimental|Ceftobiprole q12h|Ceftobiprole, 1G q12h as 4 hour infusions, on Day 1 and Ceftobiprole, 1G as single 4 hour infusion on Day 2
89203869|NCT00770978|Experimental|Ceftobiprole q8h|Ceftobiprole, 1G q8h as 4 hour infusions, on Day 1 and Ceftobiprole, 1G as single 4 hour infusion on Day 2
89203870|NCT02557724||liver transplant patients|5 blood samples at time points as described in protocol
89203871|NCT02557724||Liver resection patients|3 blood samples at time points described in protocol
89203872|NCT00766298|Experimental|1|Weight Loss
89203873|NCT00766298|Experimental|2|Exercise
89203874|NCT00766298|Experimental|3|Exercise and Weight Loss
89203875|NCT00569166|Active Comparator|Paced breathing (15 min once daily, 6 breaths/min)|Patients practice paced breathing for 15 minutes once daily, 6 breaths/min, 5-7 days weekly, following an instructional CD, for 8 weeks.
89203876|NCT00569166|Active Comparator|Paced breathing (15 min twice daily, 6 breaths/min)|Patients practice paced breathing for 15 minutes twice daily, 6 breaths/min, 5-7 days weekly, following an instructional CD, for 8 weeks.
89203877|NCT00569166|Placebo Comparator|Paced breathing (10 min once daily, 14 breaths/min)|Patients practice paced breathing for 10 minutes once daily, 14 breaths /min, 5-7 days weekly, following an instructional CD, for 8 weeks.
89021449|NCT00331058|Other|healthy volunteers|control group not receiving prednisolone
89021450|NCT00331058|Other|asthmatic volunteers|receive prednisolone for 14-16 days
89021451|NCT00430872||MDASI-Spine Tumor Module Survey|M. D. Anderson Symptom Inventory-Spine (survey) of patients with a tumor on the spine or spinal cord.
89021452|NCT00331097|Active Comparator|A|Standard chemotherapy with CMF
89021453|NCT00331097|Experimental|B|Weekly docetaxel
89021454|NCT00331214|Sham Comparator|Placebo|placebo patch for 6 months
89021455|NCT00331214|Experimental|Testosterone|Testosterone patch
89021456|NCT04702074|Experimental|Traditional Chinese medicine granules|The experimental group will be given Bu Fei Jian Pi Hua Tan granule or Yi Qi Yang Yin Qing Fei granule based on TCM syndrome differentiation.
89021457|NCT04702074|Placebo Comparator|Traditional Chinese medicine granules placebo|The control group will be given Bu Fei Jian Pi Hua Tan granule placebo or Yi Qi Yang Yin Qing Fei granule placebo based on TCM syndrome differentiation.
89021458|NCT04703907|Experimental|Intervention group|This group is constituted from patients who will receive the intervention first within 15 weeks
89021459|NCT04703907|No Intervention|Waiting list|This group is constituted from patients who will receive the intervention after 15 weeks
89021460|NCT00434889||1|Memory problems
89021461|NCT00434889||2|No memory problems
89021462|NCT00431028|No Intervention|colirio|prednisolone 1% eye drops + ciprofloxacin 0,3% eye drops
89021463|NCT00431106|Active Comparator|1|Vinorelbine/Gemcitabine (VG)
89021464|NCT00431106|Active Comparator|2|Capecitabine (Cap)
89021465|NCT00331487|Experimental|Pioglitazone QD|
89203878|NCT00764426|Active Comparator|non-alcoholic beverages|dealcoholised red wine, de-alcoholised beer, water
89203879|NCT00764426|Active Comparator|alcoholic beverages|red wine, beer, ethanol
89203880|NCT02558036|Active Comparator|C-Mac D-Blade Neutral Position|C-Mac D-Blade videolaryngoscope with patients head and neck in neutral position.
89203881|NCT02558036|Active Comparator|C-Mac D-Blade Sniffing Position|C-Mac D-Blade videolaryngoscope with patients head and neck in sniffing position.
89203882|NCT02558036|Active Comparator|King Vision Neutral Position|King Vision videolaryngoscope with patients head and neck in neutral position.
89203883|NCT02558036|Active Comparator|King Vision Sniffing Position|King Vision videolaryngoscope with patients head and neck in sniffing position.
89203884|NCT00807378||1|AIDS PATIENTS
89203885|NCT00807378||2|NON-AIDS PATIENTS
89203886|NCT02552160||Patients on Duaklir® Genuair®|Patients on fixed-dose combination Duaklir® Genuair® (Aclidinium/Formoterol)
89203887|NCT02552160||Patients on Ultibro® Breezhaler®|Patients on fixed-dose combination Ultibro® Breezhaler® (Glycopyrronium/Indacaterol)
89203888|NCT02552160||Patients on Anoro®|Patients on fixed-dose combination Anoro® (Umeclidinium/Vilanterol)
89203889|NCT04048772|Experimental|Intervention|Standard of care in vitro fertilization patients randomized to the psychoeducational group intervention.
89203890|NCT04048772|Other|Control|Standard of care in vitro fertilization patients at our institution.
89203891|NCT00764582|Experimental|1|
89021466|NCT00331487|Active Comparator|Rosiglitazone QD|
89021467|NCT00431223|Active Comparator|Active Group|7 patients were assigned to Cognitive Remediation Therapy..
89021468|NCT00431223|No Intervention|Control Group|4 patients were assigned to Control group or no cognitive remediation therapy.
89021469|NCT00435084|Experimental|Single-arm mono therapy|APO866 will be administered by civ infusion at 0.126 mg/m2/hr for 4 consecutive days (96 hours). This constitutes 1 cycle.
89021470|NCT00331565|Experimental|Surgery|Bariatric surgery
89021471|NCT00331604|Experimental|A|
89021472|NCT00331604|Active Comparator|B|
89021473|NCT00331604|Active Comparator|C|
89021474|NCT00435123|Active Comparator|A|Patients are randomly assigned to receive either Active Comparator (ProStat 64) or placebo for the first 3 months. At the end of this, all patients receive open label ProStat64.
89021475|NCT00435123|Placebo Comparator|B|Patients are randomly assigned to Placebo Comparator or Active Comparator (ProStat 64). At the end of 3 months, all patients receive active ProStat 64
89021476|NCT04716764||Case Group|The study will include female individuals aged 19-64 years who applied to Necmettin Erbakan University Meram Medical Faculty General Surgery and Medical Oncology Departments and were diagnosed with breast cancer for the first time and volunteering to participate in the study. Patients with breast cancer will be followed up before surgery, before chemotherapy, and in the sixth and twelfth months after starting chemotherapy.
89021477|NCT04716764||Healthy (Control) participants|The control group consists of healthy adult women who applied to the Internal Diseases (Internal Medicine) outpatient clinic of Necmettin Erbakan University Meram Medical Faculty Hospital, who are at the same age as the case group, and who have not been diagnosed with any disease by the doctor, and who are willing to participate in the study. Healthy individuals will be interviewed once. The obtained data will be compared with the preoperative data of breast cancer patients.
89021478|NCT00431301||Case|PSP Cases
89021479|NCT00431301||Control|Healthy Controls
89021480|NCT00331643|Experimental|Treatment (ixabepilone)|Patients receive ixabepilone IV over 1 hour on days 1-5. Courses repeat every 21 days in the absence of unacceptable toxicity or disease progression.
89021481|NCT00331721|Active Comparator|1|Enecadin
89021482|NCT00331721|Placebo Comparator|2|Placebo
89485004|NCT03220646|Experimental|B:Recurrent glioma any grade|Ten patients who require standard of care cytoreductive surgery for recurrent astrocytoma, oligodendroglioma, or glioblastoma, will be offered pre-surgical abemaciclib and then resume the drug following recovery from surgery, continuing until disease progression or unacceptable toxicity analogous to the non-surgical patients in cohort A and C. This arm is closed to accrual.
89485005|NCT03220646|Experimental|C:All other recurrent brain tumors|This is an exploratory cohort including patients with recurrent IDH mutant glioma, meningioma, recurrent ependymoma, and recurrent PCNSL,and other primary brain tumors.
89485006|NCT03219827|Experimental|Patients allergic to wasp venom|"Patient with major allergic reaction to wasp venom.~Blood samples collection at visit 1, at visit 2 (4 weeks after visit 1), at visit 3 (one year after treatment onset)~After visit 1, an allergen-specific immunotherapy will be conducted as part of the classical patient care program."
89485007|NCT03219827|Experimental|Patients allergic to penicillin|"Patient with major allergic reaction to penicillin.~- Blood samples collection at visit 1 and at visit 2 (4 weeks after visit 1= end of study, none treatment will be evaluated in this arm)"
89485008|NCT03217006|Experimental|Single Arterial Group|Patients in this group will receive a single arterial graft which will be the left internal thoracic artery. Additional grafts used in this group will all be venous grafts.
89485009|NCT03217006|Experimental|Multiple Arterial Group|Patients in the group will receive multiple arterial grafts. All patients will receive at least two arterial grafts, the left internal thoracic artery with the addition of either the right internal thoracic artery or the radial artery as the second conduit. Some patients may receive additional arterial grafts consisting of the radial artery, the right internal thoracic artery, or the right gastroepiploic artery.
89485010|NCT03062358|Experimental|pembrolizumab + BSC|Participants receive pembrolizumab by intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 cycles of treatment plus BSC.
89485011|NCT03062358|Placebo Comparator|placebo + BSC|Participants receive placebo by intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 cycles of treatment plus BSC.
89021483|NCT00331838|Experimental|Semuloparin 5 mg|Semuloparin sodium 5 mg + Placebo (for Enoxaparin sodium) once daily for 4-10 days with an initial dose given 12 hours before or 8 hours after surgery depending on the willingness of the investigator
89203892|NCT00764582|Active Comparator|2|
89485012|NCT02936700|Other|Control group|Add on relaxation group
89485013|NCT02936700|Experimental|Therapy ACT|Add on ACT group
89485014|NCT02903537|Experimental|5 * 10 ^6 tolDC-VitD3|5 million autologous VitD3 tolerogenic monocyte-derived dendritic cells loaded with a pool of myelin peptides (tolDC-VitD3)
89485015|NCT02903537|Experimental|10 * 10 ^6 tolDC-VitD3|10 million autologous VitD3 tolerogenic monocyte-derived dendritic cells loaded with a pool of myelin peptides (tolDC-VitD3).
89485016|NCT02903537|Experimental|15 * 10 ^6 tolDC-VitD3|15 million autologous VitD3 tolerogenic monocyte-derived dendritic cells loaded with a pool of myelin peptides (tolDC-VitD3).
89485017|NCT02903537|Experimental|Interferon-beta|Additional group (patients treated with beta-interferon) will receive the selected dose of those 3 previously cohorts studied
89485018|NCT02878915|Active Comparator|Ultrasound guided femoral puncture|
89203893|NCT00813618|Experimental|1|MEDI-507
89203894|NCT00813618|Experimental|2|MEDI-507
89203895|NCT00813618|Experimental|3|MEDI-507
89203896|NCT00771212||001|
89203897|NCT02557802|Experimental|Group A|Nasal spray at day 0, intramuscular injection at day 28
89485019|NCT02878915|No Intervention|palpation guided femoral puncture|
89021484|NCT00331838|Experimental|Semuloparin 10 mg|Semuloparin sodium 10 mg + Placebo (for Enoxaparin sodium) once daily for 4-10 days with an initial dose given 12 hours before or 8 hours after surgery depending on the willingness of the investigator
89021485|NCT00331838|Experimental|Semuloparin 20 mg|Semuloparin sodium 20 mg + Placebo (for Enoxaparin sodium) once daily for 4-10 days with an initial dose given 12 hours before or 8 hours after surgery depending on the willingness of the investigator
89021486|NCT00331838|Experimental|Semuloparin 40 mg|Semuloparin sodium 40 mg + Placebo (for Enoxaparin sodium) once daily for 4-10 days with an initial dose given 12 hours before or 8 hours after surgery depending on the willingness of the investigator
89021487|NCT00331838|Experimental|Semuloparin 60 mg|Semuloparin sodium 60 mg + Placebo (for Enoxaparin sodium) once daily for 4-10 days with an initial dose given 12 hours before or 8 hours after surgery depending on the willingness of the investigator
89021488|NCT00331838|Active Comparator|Enoxaparin 40 mg|Enoxaparin sodium 40 mg + Placebo (for Semuloparin sodium) once daily for 4-10 days with an initial dose given 12 hours before or 8 hours after surgery depending on the willingness of the investigator
89021489|NCT00331838|Experimental|Placebo pre-op / Semuloparin 20 mg|"Placebo (for Semuloparin sodium) + Placebo (for Enoxaparin sodium) 12 hours before surgery then,~Semuloparin sodium 20 mg + Placebo (for Enoxaparin sodium) once daily for 4-10 days with an initial dose given 8 hours after surgery"
89021490|NCT00331838|Experimental|Placebo pre-op / Semuloparin 40 mg|"Placebo (for Semuloparin sodium) + Placebo (for Enoxaparin sodium) 12 hours before surgery then,~Semuloparin sodium 40 mg + Placebo (for Enoxaparin sodium) once daily for 4-10 days with an initial dose given 8 hours after surgery"
89021491|NCT00431418|Active Comparator|1|Sildenafil oral solution.
89021492|NCT00431418|Placebo Comparator|2|Placebo oral solution.
89021493|NCT00331955|Experimental|Treatment (vorinostat, doxorubicin hydrochloride)|Patients receive oral vorinostat twice daily for 5 doses on days 1-3, 8-10, and 15-17 and doxorubicin hydrochloride IV on days 3, 10, and 17. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with responding or stable disease after 6 courses of treatment may continue to receive vorinostat alone in the absence of disease progression.
89021494|NCT00331994|Experimental|1|
89021495|NCT00331994|Active Comparator|2|
89021496|NCT00435279|Experimental|Eszopiclone|
89021497|NCT00435279|Experimental|Placebo|
89021498|NCT00431613|Experimental|1|DG -> RT
89021499|NCT00431613|Experimental|2|DG -> RT -> DCarbo
89021500|NCT00332228|Active Comparator|CE plus oral +depot naltrexone|Compliance enhancement (CE), simulating standard treatment with oral naltrexone plus two depot naltrexone;
89021501|NCT00332228|Placebo Comparator|CE plus oral naltrexone+ placebo|CE with oral naltrexone plus two placebo injections
89021502|NCT00332228|Experimental|BNT plus Depot naltrexone|BNT plus two doses of depot naltrexone prior to hospital discharge
89021503|NCT00332228|Placebo Comparator|BNT plus PBO injection|BNT plus two placebo injections
89021504|NCT00431691|Active Comparator|1|
89021505|NCT00431691|Placebo Comparator|2|
89021506|NCT00435357|Experimental|mobile-bearing TKA|
89021507|NCT00435357|Active Comparator|fixed- bearing TKA|
89021508|NCT00332306|Experimental|2|Didanosine + Lamivudine + Nevirapine
89021509|NCT00332306|Active Comparator|1|Didanosine + Lamivudine + Efavirenz
89021510|NCT00435396|Experimental|Group A|
89021511|NCT00420485|Experimental|Daily times five schedule|
89485020|NCT02849002||Interventional Device|"The BrainPulse is used on a patient's head to non-invasively detect, amplify and capture the brain motion caused by pulsatile blood flow from the cardiac cycle.~The BrainPulse consists of a reusable headset that contains the accelerometers used to measure motion caused by pulsatile blood flow. The system is powered by rechargeable battery pack. The headset is placed on the subject's head and outputs data to a data collector that forwards the data to the computer. Each accelerometer has an attached tip that makes contact with the subject's head through hair. The headset also includes a photoplethysmograph (PPG) that simultaneously captures the subject's heart-rate information. There is no energy delivered to the brain or subject by these highly sensitive sensors."
89021512|NCT00420485|Experimental|Continuous schedule, twice daily|
89021513|NCT00435474|Active Comparator|1|Silver product
89021514|NCT00435474|Experimental|2|Honey product
89021515|NCT00435513||Transsexual group|Female-to-male and male-to-female transsexuals
89021516|NCT00435513||Controls|Healthy blood donors
89021517|NCT04704102|Experimental|Muscle energy technique group|Use one of the muscle energy technique methods -- postisometric relaxation technique(PIR) as the intervention method.
89021518|NCT04704102|Experimental|Strain-counterstrain group|Use the Strain-counterstrain technique as the intervention method.
89021519|NCT04704102|Sham Comparator|Control group|Use the modified Strain-counterstrain technique as the intervention method.
89021520|NCT00332774|Experimental|Nevanac|
89021521|NCT00332774|Active Comparator|Acular|
89021522|NCT00332774|Placebo Comparator|Vehicle|
89021523|NCT00431769|Experimental|Bortezomib|
89021524|NCT00435630|Other|1|Completing simulator training sessions
89021525|NCT00332852|Experimental|Letrozole|
89021526|NCT00435708|No Intervention|1|
89021527|NCT00435708|Experimental|2|5 portions fruit and vegetables/day
89021528|NCT00431808|Experimental|I, AMA1 vaccine|20 volunteers will receive 3 doses of the vaccine
89021529|NCT00332969|Experimental|Sandostatin|
89021530|NCT00333125|Experimental|Travoprost/Timolol|
89021531|NCT00333125|Active Comparator|Dorzolamide/Timolol|
89021532|NCT00333203|Experimental|NGOIS|
89021533|NCT00333203|Active Comparator|BSS Plus|
89021534|NCT01052493|Experimental|2mg PP 1420|PP 1420 single dose, subcutaneous
89021535|NCT01052493|Experimental|4mg PP 420|PP 1420 single dose, subcutaneous
89021536|NCT01052493|Experimental|8mg PP 1420|PP 1420 single dose, subcutaneous
89021537|NCT01052493|Placebo Comparator|Placebo|0.9% saline
89203898|NCT02557802|Experimental|Group B|Intramuscular injection at day 0, nasal spray at day 28
89203899|NCT03868332||inflammatory bowel diease patients|
89203900|NCT03868332||normal indivuals|
89021538|NCT04703634|Experimental|erector spinae group|All blocks will be done under general anesthesia. Using a 6-10 MHz linear ultrasound (Esaote my-lab 6, Italy). With the ultrasonography device of our clinic, the side of the nephrectomy surgery will be performed with the position of the nephrectomy, and the position (lateral decubitus) is given to the patient. The thoracic 10th vertebra will be found under ultrasound guidance. After the T12 transverse protrusion is seen by sliding 3 cm laterally from the midline, 30 ml of 0.25% Bupivacaine will be injected under the erector spinae muscle above it.
89021539|NCT04703634|Placebo Comparator|placebo group|No block transaction will be applied to this group. Only postoperative analgesia methods will be used for this group as specified in the protocol.
89485021|NCT02845401|Experimental|HBeAg-CHB patients who stop NA Therapy|"Patients with early antigen negative form of disease (HBeAg-CHB) who are already taking standard oral HBV antiviral therapy for at least 192 weeks that stop treatment.~Intervention: Cases will stop antiviral therapy"
89021540|NCT00435864|Other|allogeneic donor from a file|
89485022|NCT02845401|No Intervention|HBeAg-CHB patients continue NA Therapy|"Patients with early antigen negative form of disease (HBeAg-CHB) who are already taking standard oral HBV antiviral therapy for at least 192 weeks that continue to stay on treatment.~Intervention: None. Controls will continue antiviral therapy."
89485023|NCT02792322|Other|Trans Oral Robotic Surgery (TORS)|Patient's are having TORS surgery in a seated position
89485024|NCT02706873|Active Comparator|Methotrexate|"Period 1: Participants will receive placebo to upadacitinib once daily and methotrexate once weekly for 48 weeks.~Period 2: Participants will continue on placebo to upadacitinib once daily and methotrexate once weekly until the study is unblinded, after which participants will receive open-label methotrexate up to Week 260."
89485025|NCT02706873|Experimental|Upadacitinib 7.5 mg (Japan-only)|"Period 1: Participants will receive upadacitinib 7.5 mg once daily and placebo to methotrexate once weekly for 48 weeks.~Period 2: Participants will continue on upadacitinib 7.5 mg once daily and placebo to methotrexate once weekly until the study is unblinded, after which participants will receive open-label upadacitinib 7.5 mg up to Week 260."
89021541|NCT00435864|Other|Registry geno-identical donor family|
89021542|NCT00435864|Other|transplantation of HSCs derived from placental blood|
89485026|NCT02706873|Experimental|Upadacitinib 15 mg|"Period 1: Participants will receive upadacitinib 15 mg once daily and placebo to methotrexate once weekly for 48 weeks.~Period 2: Participants will continue on upadacitinib 15 mg once daily and placebo to methotrexate once weekly until the study is unblinded, after which participants will receive open-label upadacitinib 15 mg up to Week 260."
89485027|NCT02706873|Experimental|Upadacitinib 30 mg|"Period 1: Participants will receive upadacitinib 30 mg once daily and placebo to methotrexate once weekly for 48 weeks.~Period 2: Participants will continue on upadacitinib 30 mg once daily and placebo to methotrexate once weekly until the study is unblinded, after which participants will receive open-label upadacitinib 30 mg once daily. After implementation of Protocol Amendment 6 participants will receive upadacitinib 15 mg once daily up to Week 260."
89485028|NCT02677038|Experimental|Treatment (olaparib)|Patients receive olaparib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89485029|NCT02584634|Experimental|Group A|ALK negative Non-Small Cell Lung Cancer
89485030|NCT02584634|Experimental|Group B|ALK positive Non-Small Cell Lung Cancer
89485031|NCT02584049|Active Comparator|Osteopathy|3 sessions of Osteopathic treatment in addition to the usual follow
89485032|NCT02584049|Sham Comparator|Sham osteopathy|3 sessions of Sham osteopathy treatment in addition to the usual follow
89485033|NCT02573753|Experimental|sleep restriction|Sleep restriction
89485034|NCT02573753|No Intervention|normal sleep|Normal sleep
89021543|NCT00333320|Placebo Comparator|- Control|
89021544|NCT00333320|Experimental|-postconditioning group|
89021545|NCT00333398|Experimental|1|250 subjects-Lot #1 multiple-dose vial (thimerosal-containing).
89021546|NCT00333398|Experimental|2|250 subjects-Lot #2 multiple-dose vial (thimerosal-containing).
89021547|NCT00333398|Experimental|3|250 subjects-Lot #3 multiple-dose vial (thimerosal-containing).
89021548|NCT00333398|Placebo Comparator|4|250 subjects-multiple-dose vial placebo (thimerosal-containing).
89021549|NCT00333398|Experimental|5|250 subjects-Prefilled Lot #1, #2, or #3 (TBD) (thimerosal-free).
89021550|NCT01052103|Experimental|LY2140023|40 mg/day, given orally twice daily (BID) as a 20-mg tablet. LY2140023 dosage was adjustable from 10 mg to 40 mg BID.
89021551|NCT01052103|Placebo Comparator|Placebo|Placebo tablets to match LY2140023 tablets
89485035|NCT02573753|Experimental|weight gain|Weight gain
89485036|NCT02409316|Experimental|FES PET/CT|All subjects will receive an [18F]FES PET/CT scan.
89485037|NCT02391909||Group A|Vivotif 6.9-10.0 x109 CFU/capsule
89485038|NCT02391909||Group B|Vivotif 4.0-6.8 x109 CFU/capsule
89485039|NCT02365441|Active Comparator|Arm A|imatinib 400mg orally daily continuously
89485040|NCT02365441|Experimental|Arm B|alternating 28-day periods of imatinib 400mg orally daily for 21 to 25 days followed by a washout (drug free) period of 3 to 7 days, then regorafenib 160mg orally daily for 3 weeks followed by a 7 day washout (drug free) period.
89485041|NCT02256137||Childhood Cancer Survivors|This study will evaluate 1493 members of the St. Jude Lifetime Cohort Study (SJLIFE) who have completed a baseline functional assessment six or less years ago when 18-45 years of age.
89485042|NCT02124941|Experimental|1H MRS|All subjects will undergo three magnetic resonance spectroscopy (1H-MRS) scans, including before and after two-weeks of placebo and NAC administration.
89485043|NCT02124941|Experimental|[18F]-FDG PET scan|All subjects will undergo [18F]FDG PET to establish previously demonstrated reductions in glucose utilization in PFC and assess VS/nucleus accumbent metabolism at baseline.
89485044|NCT02124941|Experimental|[11C]APP311 PET scan|All subjects will undergo [11C]APP311 PET imaging to investigate whether there are differences in synaptic integrity / neuronal plasticity in the brains of individuals abstinent from cocaine compared to healthy controls at baseline.
89485045|NCT02124941|Active Comparator|Medication (NAC & placebo) administration|Upon completion of baseline (abstinence) 1H-MRS scanning at 7T, CU and HC subjects will participate in two additional 1H-MRS scans, including after 2 weeks of placebo and 2 weeks of NAC administration (3600 mg/day) given in double-blind, randomized, counterbalanced order.
89021552|NCT00333515|Experimental|1|Administration of one of 3 doses (dose escalation) of the active drug (HuBChE). (Dose-escalation proceeds only after safety evaluation and after the previous dosage has been found to be acceptable by an independent Data Safety Monitoring Board.)
89021553|NCT00333515|Placebo Comparator|2|Administration of placebo
89485046|NCT01967849|Other|Obese/overweight chldren/adolescents|Obese or overweight children and adolescents between ages 7-21 that are at risk for developing type 2 diabetes will undergo an Oral Glucose Tolerance test (OGTT) to asses glucose status.
89485047|NCT01967849|Other|Lean children/adolescents|Lean children/adolescents between the ages of 7-21. This cohort should have family members that have type 2 diabetes or was the result of a gestational diabetes pregnancy. They will undergo an Oral Glucose Tolerance Test to assess glucose status.
89485048|NCT01892566|No Intervention|Usual care for COPD|Usual care for AECOPD in the JHHCC consists of patient-initiated contact with the clinic for change in respiratory symptoms. Participants will be asked to complete a weekly symptom diary assessment which will be returned to the study staff at every 3-month visits. Participants contacting research staff with a worsening in respiratory symptoms will be referred to their assigned clinical providers.
89485049|NCT01892566|Experimental|mHealth Intervention|For the mHealth intervention, investigators will use of the eResearch Technology, Inc system (ERT®; Philadelphia, PA) for home-based monitoring of spirometry and respiratory symptoms. In conjunction, wireless sensor-based inhalers will monitor the frequency of rescue inhaler use (Asthmapolis®; Madison, WI). As well, on a daily basis, participants in the early identification group will complete eight respiratory symptom questions from the COPD Assessment Test (CAT). Participants' short acting beta-agonist inhaler use will be monitored by an Asthmapolis Spiroscout Inhaler Tracker. Based on participant responses, flags or electronic notifications can be generated. Based on severity of symptoms and guidelines for recommended care, participants will be instructed to self-manage by optimizing inhaler use (if symptoms are mild) or present for an acute care visit at JHHCC if necessary.
89485050|NCT01868451|Experimental|Cohort 1 (completed accrual)|Patients received 4 cycles of brentuximab vedotin & AVD chemotherapy. Brentuximab vedotin, 1.2 mg/kg, will be administered on days 1 and 15 of each 28 day cycle. Doxorubicin 25 mg/m2, Vinblastine 6 mg/m2, & Dacarbazine 375 mg/m2 will be administered on days 1 and 15 of each 28 day cycle. This may be followed by 30 Gy involved site radiotherapy. Involved site radiotherapy should be initiated from 12 days to 42 days after completion of chemotherapy. It is mandatory to administer prophylactic growth factor support starting with cycle 1. Choice of growth factor and dosing can be determined at the discretion of the treating physican.
89485051|NCT01868451|Experimental|Cohort 2|Patients with early stage, unfavorable risk Hodgkin lymphoma. The definition of disease bulk, one of the unfavorable risk features, has been updated, and is defined as the presence of any lymph node mass with transverse maximal diameter > 7.0 cm OR coronal maximal diameter > 7.0 cm. Patients will receive 4 cycles of brentuximab vedotin & AVD chemotherapy. Brentuximab vedotin, 1.2 mg/kg, will be administered on days 1 and 15 of each 28 day cycle. Doxorubicin 25 mg/m2, Vinblastine 6 mg/m2, and Dacarbazine 375 mg/m2 will be administered on days 1 & 15 of each 28 day cycle. This may be followed by 20 Gy involved site radiotherapy.
89485052|NCT01868451|Experimental|Cohort 3|Patients will have early stage, unfavorable risk classical Hodgkin lymphoma with disease bulk defined as the presence of any lymph node mass with transverse maximal diameter > 7.0 cm or coronal maximal diameter > 7.0 cm. Patients will receive 4 cycles of brentuximab vedotin and AVD chemotherapy. Brentuximab vedotin, 1.2 mg/kg, will be administered on days 1 and 15 of each 28 day cycle. Doxorubicin 25 mg/m2, Vinblastine 6 mg/m2, and Dacarbazine 375 mg/m2 will be administered on days 1 and 15 of each 28 day cycle. This may be followed by 30.6 Gy CVRT.
89485053|NCT01868451|Experimental|Cohort 4|Patients will have early stage, unfavorable risk classical Hodgkin lymphoma with disease bulk defined as the presence of any lymph node mass with transverse maximal diameter > 7.0 cm or coronal maximal diameter > 7.0 cm. In this cohort. Pts will receive 4 cycles of brentuximab vedotin & AVD chemo. Brentuximab vedotin, 1.2 mg/kg, will be administered on days 1 & 15 of each 28 day cycle. Doxorubicin 25 mg/m2, Vinblastine 6 mg/m2, & Dacarbazine 375 mg/m2 will be administered on days 1 & 15 of each 28 day cycle. Pts whose PET scan is negative after 4 cycles of brentuximab vedotin & AVD chemotherapy will not receive RT. Pts whose PET scan is positive after 4 cycles of brentuximab vedotin & AVD chemo, but subsequent biopsy is neg, will also receive no RT. Upon MSK PI approval, if the simulation can't be covered by the institution or the pts insurance, a diagnostic IV contrast CT neck & diagnostic IV contrast CT CAP scan will be done in addition to the FDG-PET done after 4 cycles of chemo.
89485054|NCT01835964|Experimental|Glucose Variability Observation|The study procedures will start after CGM device training & practice using the blinded CGM for 2 days and will continue over the course of ~33 days. The study team will collect data about diabetes management including blood glucose data from fingerstick and CGM values along with insulin pump records throughout the 4 week observation period. Insulin sensitivity will be evaluated at home with predetermined meals' carbohydrate count. At the mid-study point glucose variability will be simulated in clinic with a metabolic challenge (liquid mixed meal) followed 4 hours later by the induction of hypoglycemia with an intravenous insulin injection. Insulin sensitivity, as well as glucagon and epinephrine counterregulatory responses will be evaluated to be related to overall Glucose Variability.
89485055|NCT01678547|Experimental|Robot G-EO|Each subject will be asked to perform 15 sessions (3 to 5 days a week for 4 up to 5 weeks) consisting of a treatment cycle using the GE-O system device, according to individually tailored exercise scheduling.
89485056|NCT01678547|Active Comparator|Treadmill Training|Each subject will be asked to perform 15 sessions (3 to 5 days a week for 4 up to 5 weeks) consisting of a treatment cycle using the treadmill system device, according to individually tailored exercise scheduling.
89021554|NCT00333554|Experimental|DHA Treatment Group|DHA study treatment given on daily basis to nursing mother (breast milk) or baby as either formula, or capsules (removing content and mixing with food)depending on age of child.
89021555|NCT00333554|Placebo Comparator|Control Group|Placebo for DHA given to nursing mother (breast milk), study formula, or capsules (removing content and mixing with food)depending on age of child.
89021556|NCT00436020|Active Comparator|1|Active
89021557|NCT00436020|Placebo Comparator|2|Sham TMS
89021558|NCT00420524|Experimental|Arm A (Normal liver function)|
89021559|NCT00420524|Experimental|Arm B (Mild liver dysfunction)|
89021560|NCT00420524|Experimental|Arm C (Moderate liver dysfunction)|
89021561|NCT00432120|Active Comparator|A|"nonselective - clopidogrel 600 mg >6 hours before coronary angiography;"
89021562|NCT00432120|Active Comparator|B|"selective - clopidogrel 600 mg in the cath-lab after coronary angiography, only in case of percutaneous coronary intervention"
89021563|NCT00436098|Experimental|1|physical training
89485057|NCT01678547|Active Comparator|Ground treatment|Ground Control Group (cCG): Each subject will be asked to perform 15 sessions (3 to 5 days a week for 4 up to 5 weeks) of traditional lower limb physiotherapy treatment.
89485058|NCT01668407|Experimental|Robot-Assisted Gait Training (RAGT)|Robot-Assisted Gait Training (RAGT): Subjects (at least 40) will undergo inpatient rehabilitation consisting of a treatment cycle using the GE-O system device, according to individually tailored exercise scheduling. The practice will include robot-assisted walking at variable speeds for 45 min with a partial body weight support (BWS). All participants started with 30-40% BWS and an initial treadmill speed of 1.5 km/h speed will be increased to a range of 2.2 to 2.5 km/h before BWS will be decreased.
89485059|NCT01668407|Active Comparator|Treadmill Gait Training (TT)|Treadmill Gait Training (TT): Subjects (at least 40) will undergo inpatient rehabilitation consisting of a treatment cycle using the treadmill device, according to individually tailored exercise scheduling. The practice included treadmill walking at variable speed for 45 minutes. All participants will start at an initial treadmill speed of 1.5 km/h speed will be increased to a range of 2.2 to 2.5 km/h.
89485060|NCT01536522|Active Comparator|Nutritional Approach for Asthma|individuals will be provide a pre measured dose of medium chain triglyceride to consume along with their meals. They will be instructed to add the MCT to their meal 3 times per day
89485061|NCT01536522|Placebo Comparator|Standard American Diet|patients will consume their usual diet with a pre measured dose of canola oil in place of the medium chain triglyceride as a control group. They will be instructed to add the placebo dose to their meal 3 times a day
89485062|NCT01536522|Active Comparator|Alternate Day Diet|"patients will consume a regular Standard American Diet for 4 weeks and then provided a regulated dosed quantity of low caloric value shakes. they will consume this on alternating days"
89021564|NCT00436098|No Intervention|2|
89021565|NCT00432198|Experimental|1|Oral
89021566|NCT00432198|Experimental|2|Oral
89021567|NCT00432198|Placebo Comparator|3|Oral
89021568|NCT01051986|Active Comparator|SVG group|"patients who underwent off-pump coronary artery bypass using saphenous vein composite grafting based on the left internal thoracic artery~use saphenous vein as a composite graft connected to the left internal thoracic artery"
89021569|NCT01051986|Active Comparator|RITA group|"patient who underwent off-pump coronary artery bypass using right internal thoracic artery composite grafting based on the left internal thoracic artery~use right internal thoracic artery as a composite graft connected to the left internal thoracic artery"
89485063|NCT01536522|Active Comparator|Whole Lung Allergen Challenge|patients with or without asthma will be given controlled doses of specified allergens
89485064|NCT01275729|Experimental|Lasix|Pt to get dose of furosemide after meeting entry criteria - dose dependent on previous exposure to diuretics
89485065|NCT01107626|Experimental|Arm A (Induction then Maintenance with Bevacizumab)|"Induction Therapy:~Patients receive paclitaxel IV over 3 hours, carboplatin IV over 15-30 minutes, and bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.~Maintenance Therapy:~Patients achieving complete response, partial response or stable disease following induction therapy are randomized to 1 of 3 treatment arms. Patients in arm A receive bevacizumab IV over 30-90 minutes on day 1 of every cycle until progression or unacceptable toxicity."
89485066|NCT01107626|Experimental|Arm B (Induction then Maintenance with Pemetrexed)|"Induction Therapy:~Patients receive paclitaxel IV over 3 hours, carboplatin IV over 15-30 minutes, and bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.~Maintenance Therapy:~Patients achieving complete response, partial response or stable disease following induction therapy are randomized to 1 of 3 treatment arms. Patients in arm B receive pemetrexed IV over 10 minutes on day 1 of every cycle until progression or unacceptable toxicity."
89485067|NCT01107626|Experimental|Arm C (Induction then Maintenance with Bevacizumab & Pemetrexed)|"Induction Therapy:~Patients receive paclitaxel IV over 3 hours, carboplatin IV over 15-30 minutes, and bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.~Maintenance Therapy:~Patients achieving complete response, partial response or stable disease following induction therapy are randomized to 1 of 3 treatment arms. Patients in arm C receive bevacizumab as in arm A and pemetrexed as in arm B."
89485068|NCT01082224|Experimental|Waitlisted with HCC-Exception Points|Participants undergo CT and MRI every 90 days for the trial with iodinated contrast dye and motexafin gadolinium, during liver transplant wait listing. Possible Eovist-enhanced MRI substudy participation
89021570|NCT00420563|Experimental|CYCLOPHOSPHAMIDE|
89021571|NCT00420563|Active Comparator|MEGESTROL|
89021572|NCT00432315|Experimental|1|Resectable NSCLC
89021573|NCT00432315|Experimental|2|Unresectable NSCSC
89021574|NCT00333749|Experimental|1|55 children < 5 years with acute oral ulcer disease.
89021575|NCT00333749|Placebo Comparator|2|55 Children < 5 years with acute oral ulcer disease.
89021576|NCT00333827|Active Comparator|Optimal Therapy|Optimal therapy for cardiac failure
89021577|NCT00333827|Experimental|cell therapy|stem cell
89021578|NCT03278184|Sham Comparator|tDCS sham motor cortex|25 participants will have sham stimulation for 20 minutes using transcranial direct current stimulation device.
89021579|NCT03278184|Active Comparator|Active motor cortex stimulation|25 participants will have active stimulation targeting the left motor cortex for 20 minutes using transcranial direct current stimulation device.
89021580|NCT03278184|Active Comparator|active prefrontal cortex stimulation|25 participants will have active stimulation targeting the left dorsolateral prefrontal cortex for 20 minutes using transcranial direct current stimulation device.
89021581|NCT00436137|Experimental|1|Patients will receive a mailing recommending colonoscopy, followed by a telephone outreach
88952670|NCT01954212|No Intervention|Usual oral health care|"Oral health care (OHC) will be provided in the standard manner, with no change to usual care.~Provision of this standard OHC will be sampled monthly. Surveys suggest that standard oral health care (OHC) in stroke care settings comprise poorly supported OHC interventions delivered by staff that lacked access to specialist training, products, equipment, assessments, protocols and dental services."
89485069|NCT00828009|Experimental|Tecemotide/bevacizumab after chemoradiation|"Concomitant Chemoradiotherapy: Patients (pts) receive paclitaxel intravenously (IV) over 1 hour and carboplatin IV over 15-30 minutes weekly for 6 weeks. Pts also receive radiotherapy 5 days a week for 6½ weeks. Pts with CR, PR, or SD proceed to consolidation chemotherapy.~Consolidation chemotherapy: Pts receive paclitaxel IV over 3 hours and carboplatin IV over 15-30 minutes on day 1. Treatment repeats every 21 days for 2 courses in the absence of disease progression (PD) or unacceptable toxicity. Pts with CR, PR, or SD proceed to maintenance therapy.~Maintenance therapy: Pts receive a single dose of cyclophosphamide IV over 15-30 minutes 3 days before the first dose of bevacizumab and tecemotide. Pts then receive bevacizumab IV over 30-90 minutes on day 1 and tecemotide subcutaneously on days 1, 8, and 15 of courses 1 and 2 and on day 1 of every other course beginning in course 4. Treatment repeats every 21 days for up to 34 courses in the absence of PD or unacceptable toxicity."
89485070|NCT00578721|Experimental|325 mg Aspirin|325 mg aspirin po qd with arginine-restricted diet
89485071|NCT00357890|Experimental|Pump therapy (CSII)|Use of pump therapy
89485072|NCT00357890|Active Comparator|Multiple daily injections (MDI)|Use of MDI (basal bolus therapy with glargine)
89485073|NCT00068393|Experimental|Doxorubicin/Gemcitabine|Doxorubicin was given at 50 mg/m² by IV slow push, followed by gemcitabine 1500 mg/m² IV infusion over 30 minutes on day 1. Patients will receive G-CSF at a subcutaneous dose of 5mcg/kg/day on days 2 or 3 to 10 or neulasta at a dose of 6mg on day 2. Growth factor must be administered as close as possible to 24 hours after the completion of chemotherapy. It is recommended that neulasta be administered only on day 2 due to its prolonged half-life. Cycles were repeated every 2 weeks.
89485074|NCT00062010|Experimental|IFN-alpha, 13-CRA, paclitaxel|Interferon alpha: 6 million U/m2 on days 1 and 2 of each week for 6 weeks of an 8-week cycle 13-cis-retinoic acid: 1 mg/kg on days 1 and 2 of each week for 6 weeks of an 8-week cycle Paclitaxel: 75 mg/m2 on day 2 of each week for 6 weeks of an 8-week cycle
89485075|NCT00061568|Experimental|Participants with Severe Beta-globin Disorders in Allogeneic Peripheral Blood Stem Cell Transplants|Nonmyeloablative transplant regiment, consisting of alemtuzumab (1 mg/kg in divided doses), total-body irradiation (300 cGy), sirolimus, and infusion of unmanipulated filgrastim mobilized peripheral blood stem cells from human leukocyte antigen-matched siblings.
89485076|NCT00061568|Experimental|Human Leukocyte Antigens (HLA) Matched Related Stem Cell Donor|Participants received Filgrastim to mobilize peripheral blood stem cells for apheresis collection. Collected stem cells of donor will then be infused to HLA matched sibling.
89485077|NCT00047008|Other|Standard fractionation RT + cisplatin|Standard fractionation radiation therapy with concurrent cisplatin followed by conventional surgery for select patients.
89485078|NCT00047008|Experimental|Accelerated fractionation RT + cisplatin|Accelerated fractionation radiation therapy by concomitant boost with concurrent cisplatin followed by conventional surgery for select patients.
89485079|NCT03547921||operative|operative
89485080|NCT03547921||non operative|non operative
89485081|NCT03568253|Active Comparator|Bulk fil composite|
89485082|NCT03568253|Active Comparator|High viscosity glass ionomer|
89485083|NCT03567941|Placebo Comparator|Placebo|Single dose
89485084|NCT03567941|Experimental|Hydrocodon bitartrate-acetaminophen arm 1|Single dose
89485085|NCT03567941|Experimental|Hydrocodon bitartrate-acetaminophen arm 2|Single dose
89485086|NCT03567941|Active Comparator|Reference|Single dose
88952671|NCT01954225|Other|Udumbara sutra|The Udumbara Sutra is a standard medicated thread smeared with latex of Udumbara (Ficus Glomerata) which has cutting and healing property.
89485087|NCT02140489|Experimental|Sequence 1|amosartan → rosuvastatin → amosartan and rosuvastatin
89485088|NCT02140489|Experimental|Sequence 2|rosuvastatin → amosartan and rosuvastatin → amosartan
89485089|NCT02140489|Experimental|Sequence 3|amosartan and rosuvastatin → amosartan → rosuvastatin
89485090|NCT03566225|Active Comparator|Group A|Pioglitazone in adose 30 mg tablet will be administered dialy+ clomiphene citrate as ovulation induction
89485091|NCT03566225|Placebo Comparator|Group B|Metformin in adose 1500 mg dialy will be administered + clomiphene citrate
89485092|NCT05462353|Experimental|Cohort 1 Low Dose|1 tablet of ASC41 (2 mg) for 52 weeks
89485093|NCT05462353|Experimental|Cohort 2 High Dose|2 tablet of ASC41 (4 mg) for 52 weeks
89485094|NCT05462353|Placebo Comparator|Placebo tablet|Placebo tablet for 52 weeks
89485095|NCT03566147|Experimental|low dose group|300,000 HuRPE cells
89485096|NCT03566147|Experimental|middle dose group|500,000 HuRPE cells
89485097|NCT03566147|Experimental|high dose group|1,000,000 HuRPE cells
89485098|NCT02397694|Experimental|BIC + F/TAF|"Participants will receive BIC + F/TAF FDC + DTG placebo for 48 weeks.~Following Week 48, participants will continue to take their blinded treatment and attend visits every 12 weeks until treatment assignments have been unblinded. Participants will return for an unblinding visit and be given the option to participate in an open-label rollover extension and receive bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) until it becomes commercially available, or until Gilead Sciences elects to terminate the development of BIC/F/TAF."
89485099|NCT02397694|Active Comparator|DTG + F/TAF|"Participants will receive DTG + F/TAF FDC + BIC placebo for 48 weeks.~Following Week 48, participants will continue to take their blinded treatment and attend visits every 12 weeks until treatment assignments have been unblinded. Participants will return for an unblinding visit and be given the option to participate in an open-label rollover extension and receive B/F/TAF until it becomes commercially available, or until Gilead Sciences elects to terminate the development of BIC/F/TAF."
89485100|NCT02397694|Experimental|Open Label Extension Phase|After Week 48 participants continued to take their randomized study drug and attended visits every 12 weeks until treatment assignments were unblinded, at which point all participants returned for an unblinding visit and were given the option to participate in an open-label rollover extension to receive an FDC containing B/F/TAF.
89485101|NCT05452369|Experimental|rhomboid intercostal plane block|as in intervention description
89485102|NCT05452369|Experimental|Erector spinae plane block|As in intervention description
89485103|NCT03567863|Active Comparator|Group A|"The two punctures performed successively with the 20-GAUGE PROCORE® (COOK) and the 22-GAUGE ACQUIRE® (BOSTON SCIENTIFIC)~20-GAUGE PROCORE® first, then 22-GAUGE ACQUIRE®"
89485104|NCT03567863|Active Comparator|Group B|"The two punctures performed successively with the 22-GAUGE ACQUIRE® (BOSTON SCIENTIFIC) and the 20-GAUGE PROCORE® (COOK)~22-GAUGE ACQUIRE® first, then 20-GAUGE PROCORE®"
89485105|NCT03549169|Experimental|TOMAS|Intervention centered on taking decisions for management of symptoms in adults with Heart Failure. Includes 3 doses (self-care maintenance, symptom perception and symptom management) and 4 strategies are developed: knowledge of the situation, experience and abilities in decision taking and compatibility with personal values.
89485106|NCT03549169|Other|Standard or regular attention|Regular attention is centered on education for therapeutic adherence
89485107|NCT03566069|Experimental|Experimental Group|After a double-blind rabdomization, patients allocated to the experimental group will be followed for four weeks beginning at the start of their hospitalization, after signing a consent form. After completing baseline self-report measurements, they will be assessed for the severity of their symptoms; their working alliance with their therapist; and their treatment outcome after each session. Psychotherapy will be delivered twice a week. Intranasal OT will be administered twice a day (at 08:00 a.m. and at 17:00 p.m.). The experimental group will receive - 32IU (16IU*2) of OT, Sorbitol, Benzyl, alcohol glycerol, distilled water. OT will be inhaled in two sprays, one in each nostril.The substance for both study groups will be prepared in the hospital pharmacy, (in identical bottles), after randomization that will be conducted by the pharmacist. A month post intervention, patients will complete self-report measurements as part of a follow-up evaluation.
89485108|NCT03566069|Placebo Comparator|Placebo Group|After a double-blind rabdomization, patients allocated to the placebo group will be followed for four weeks beginning at the start of their hospitalization, after signing a consent form. After completing baseline self-report measurements, they will be assessed for the severity of their symptoms; their working alliance with their therapist; and their treatment outcome after each session. Psychotherapy will be delivered twice a week. Intranasal Placebo will be administered twice a day (at 08:00 a.m. and at 17:00 p.m.). The placebo group will receive - 32IU (16IU*2) of Sorbitol, Benzyl, alcohol glycerol, distilled water, meaning all ingredients except for the OT and will be inhaled in two sprays, one in each nostril.The substance for both study groups will be prepared in the hospital pharmacy, (in identical bottles), after randomization that will be conducted by the pharmacist. A month post intervention, patients will complete self-report measurements as part of a follow-up evaluation.
89485109|NCT03565757|Experimental|SMART intervention|90-minute SMART small group session
89485110|NCT03565601||CTD patients with anti-Ro52 antibodies|Connective tissue disease patients with anti-Ro52 antibodies at diagnosis
89485111|NCT03565601||CTD patients without anti-Ro52 antibodies|Connective tissue disease patients without anti-Ro52 antibodies at diagnosis
89485112|NCT03567629|Experimental|Irinotecan-based chemotherapy|
89485113|NCT03567629|Active Comparator|Oxaliplatin-based chemotherapy|
89485114|NCT02783599|Experimental|Olaratumab + Doxorubicin|"Cycle 1: Olaratumab 20 milligram per kilogram (mg/kg) given intravenously (IV) on Day 1 and Day 8 (21 day cycle).~Cycle 2: Olaratumab 20 mg/kg given IV on Day 1 and Day 8 plus doxorubicin 75 mg/m2 given IV on Day 1 (21 day cycle).~Cycle 3 through Cycle 7: Olaratumab 15 mg/kg given IV on Day 1 and Day 8 plus doxorubicin 75 mg/m2 given IV on Day 1 (21 day cycles)."
89485115|NCT02783599|Experimental|Olaratumab + Radiotherapy Addendum|"Olaratumab given IV on Day 1 and Day 8 (21 day cycle) concurrently with radiotherapy.~Radiotherapy addendum was not implemented."
89485116|NCT03565523|Experimental|Test Beet shot|Containing 385 mg nitrate
89485117|NCT03565523|Placebo Comparator|Placebo beverage|<0.1 mmol nitrate in sucrose solution with beet coloring
89485118|NCT03567395|Active Comparator|Melatonin|Melatonin (5 mg sublingual tablet)
89485119|NCT03567395|Experimental|Honey|raw honey (1.5 tablespoons)
89203901|NCT04048226|Placebo Comparator|Control group|The patients in this group will be connected to the syringe pump that contain normal saline with starting infusion at a rate of 0.1 ml/kg/hr till the end of the surgery.
89485120|NCT03565289||All patients|All
89485121|NCT03565133|Experimental|Oral quinine, gastric placebo|Oral sham feeding of quinine and a gastric capsule containing placebo (cellulose)
89485122|NCT03565133|Experimental|Oral placebo, gastric quinine|Oral sham feeding of placebo (tap water) and a gastric capsule containing quinine
89485123|NCT03565133|Experimental|Oral quinine, gastric quinine|Oral sham feeding of quinine and a gastric capsule containing quinine
89485124|NCT03565133|Placebo Comparator|Oral placebo, gastric placebo|Oral sham feeding of placebo (tap water) and a gastric capsule containing placebo (cellulose)
89485125|NCT05353673|Experimental|Sitagliptin and Danazol|Sitagliptin is given at a dose of 100 mg/m2 qd for 12 weeks. Danazol is given at 200mg bid for 12 weeks.
89485126|NCT05353673|Active Comparator|Danazol|Danazol is given at 200mg bid for 12 weeks.
89485127|NCT03565055|Experimental|IPCST|Intervention = Patients that participate in IPCST programme
89485128|NCT03565055|Active Comparator|E.A.S.Y|Treatment as usual = Patients of E.A.S.Y Programme in HK Kwai Chung Hospital
89485129|NCT05708495|Active Comparator|Group 1|
89485130|NCT05708495|Experimental|Group 2|
89485131|NCT03564899|No Intervention|control|Receive no physical activity intervention (maintain baseline physical activity participation)
89021582|NCT04716374||Patients with epithelial ovarian cancer|Patients with epithelial ovarian adenocarcinoma with archival tumor tissue available for analysis were identified through the Hellenic Cooperative Oncology Group (HeCOG)'s tumor repository. Patients had received treatment at HeCOG-affiliated institutions following standard international guidelines.
89021583|NCT00438009|Experimental|CAVATAK|
89021584|NCT00334022|Placebo Comparator|Did not receive enfuvirtide|patients were randomized to either receive enfuviratide or not receive it
89021585|NCT00334022|Active Comparator|enfuvirtide|enfuvirtide 1ml BID
89021586|NCT04701528|Experimental|Voclosporin (VCS)|"Prior to or at study entry, subjects are reduced in their standard immunosuppressive therapy to dual therapy with prednisone and tacrolimus according to current local guidelines.~In the experimental arm tacrolimus is switched to voclosporin 6 capsules (of 7.9 mg each) BID for a treatment period of minimal 56 days with a possible extension up to 1 year.~Safety drug monitoring will take place during the study to ensure that VCS trough levels are maintained between 30-60 ng/mL. If trough levels are not within these levels, dose adjustments will take place."
89021587|NCT04701528|Active Comparator|Tacrolimus (TAC)|"Prior to or at study entry, subjects are reduced in their standard immunosuppressive therapy to dual therapy with prednisone and tacrolimus according to current local guidelines.~In the Active comparator arm tacrolimus dosage is maintained.~Safety drug monitoring will take place during the study to ensure that TAC trough levels are maintained between 3-7 ng/ml. If trough levels are not within these levels, dose adjustments will take place."
89021588|NCT00334100|Other|Arm 1|
89021589|NCT04701294|Experimental|Giomer Beautifil flow plusF03 Shofu-Japan|Giomer beautifil flow plusF03 shofu-Japan an application of flowable resin with sprg as a sealant for pits and fissures on the occlusal surface of permanent first molars until the end of the experiment.
89021590|NCT04701294|Active Comparator|Tetric N flow ivoclar vivadent-Germany|Tetric N flow ivoclar vivadent-Germany an application of flowable resin a sealant for pits and fissures on the occlusal surface of permanent first molars until the end of the comparator.
89021591|NCT00334139|Experimental|zoledronic acid|
89021592|NCT03279978|Experimental|BI 730357 25 mg fast|Subjects were orally administered BI 730357 25 mg, film-coated tablet once daily over 14 days after a fasting period of at least 6 hours
89021593|NCT03279978|Placebo Comparator|Placebo fast|Subjects were orally administered matching Placebo to BI 730357, film-coated tablet after a fasting period of at least 6 hours.
89021594|NCT03279978|Placebo Comparator|Placebo fed|Subjects were orally administered matching Placebo to BI 730357, film-coated tablet after the intake of a standard continental breakfast.
89021595|NCT03279978|Experimental|BI 730357 50 mg fast|Subjects were orally administered BI 730357 50 mg, film-coated tablet once daily over 14 days after a fasting period of at least 6 hours.
89021596|NCT03279978|Experimental|BI 730357 50mg/Placebo|Subject was orally administered mixed treatment of BI 730357 50 mg and placebo, film-coated tablet once daily over 14 days after a fasting period of at least 6 hours
89021597|NCT03279978|Experimental|BI 730357 50 mg fed|Subjects were orally administered BI 730357 50 mg, film-coated tablet once daily over 14 days after the intake of a standard continental breakfast.
89021598|NCT03279978|Experimental|BI 730357 100 mg fast|Subjects were orally administered BI 730357 100 mg, film-coated tablet once daily over 14 days after a fasting period of at least 6 hours
89021599|NCT03279978|Experimental|BI 730357 200 mg fast|Subjects were orally administered BI 730357 200 mg, film-coated tablet once daily over 28 days after a fasting period of at least 6 hours
89021600|NCT03279978|Experimental|BI 730357 200 mg fed|Subjects were orally administered a microdose of midazolam 75 microgram (75 μg) solution for injection, orally on Day -1, and prior receiving BI 730357 on Days 3, and 14. Subjects were orally administered BI 730357 200 mg, film-coated tablet once daily over 28 days after the intake of a standard continental breakfast.
89021601|NCT03279978|Experimental|BI 730357 400 mg fed|Subjects were orally administered a microdose of midazolam 75 microgram (75 μg) solution for injection, orally on Day -1, and prior receiving BI 730357 on Days 3, and 14. Subjects were orally administered BI 730357 400 mg, film-coated tablet once daily over 28 days after the intake of a standard continental breakfast.
89021602|NCT00334217|Experimental|1|PSS CogRehab exercises
89021603|NCT00334217|No Intervention|2|On-line computer games
89021604|NCT00438048|Active Comparator|a,b|Compare Pilocarpine and Artificial saliva
89021605|NCT00438087|Placebo Comparator|2|placebo versus methylprednisolone
89485132|NCT03564899|Experimental|Lighter intensity physical activity|Receive an intervention of 300 minutes/week of physical activity at an intensity of 40-60% of heart rate reserve for 12 weeks.
89485133|NCT03564899|Active Comparator|Higher intensity physical activity|Receive an intervention of 150 minutes/week of physical activity at an intensity of 60-80% of heart rate reserve for 12 weeks.
89485134|NCT05353205|Experimental|Flumatinib (400mg)|Flumatinib 400mg QD
89485135|NCT05353205|Experimental|Flumatinib (600mg)|Flumatinib 600mg QD
89485136|NCT03564665|Experimental|400mg Magnesium Glycinate BID Arm|Prescription for an 8 week supply (+/- 4 days) of Magnesium Glycinate will be sent to the pharmacy for patient pick up. Study Coordinator will then dispense study diaries (Supplementation Diary and Hot Flash Diary) with instructions on how to complete for the eight week study duration. Study Coordinator will discuss upcoming phone calls on Weeks 2-8 to complete the MDASI by phone and the best times to do so with the patient. Coordinator will schedule a return visit with the Patient approximately 9 weeks after the start of the study for follow-up. At follow-up, Coordinator will retrieve Patient Diaries (Hot Flash Diary and Medication Diary), perform supplement reconciliation, and exit Patient from the study.
89021606|NCT00438087|Experimental|1|placebo versus methylprednisolone
89021607|NCT00334373|Experimental|Post conditioning|Balloon inflations-deflations
89021608|NCT00334373|Placebo Comparator|Standard care|No balloon inflations
89021609|NCT03279939|Experimental|Subjects with Normal Eyes|OCT Angiography, Color Fundus Photography, and Fluorescein Angiography as per protocol in subjects without ophthalmic pathology.
89021610|NCT03279939|Experimental|Subjects with Pathology|OCT Angiography, Color Fundus Photography, Fluorescein Angiography, and when clinically indicated, Indocyaine Green Angiography as per protocol in subjects with retinal vascular pathology.
89021611|NCT00438165|No Intervention|1|Control group
89021612|NCT00438165|Experimental|2|Nurse home visits
89021613|NCT04701879|Active Comparator|Spine decompression with core stability exercises|Interventions in experimental group includes Hot pack, Spinal decompression therapy and core stability exercises
89021614|NCT04701879|Experimental|Spine decompression|Intervention includesHot pack and spinal decompression therapy ..
89021615|NCT00334490|Active Comparator|1|Oral Sildenafil 12.5 mg
89021616|NCT00334490|Placebo Comparator|2|Placebo in 5 mls distilled water
89021617|NCT00436176|Experimental|1|Intervention clinicians receive monthly performance reports, cultural competency training, and health navigation training
89021618|NCT00436176|No Intervention|2|Control clinicians function within the context of the generic chronic care model.
89021619|NCT04716218|Placebo Comparator|neutral position|The initial percentage of glottic opening (POGO) by laryngoscopy was recorded in the ramped position. Thereafter, a second POGO (laryngeal view) was scored in the neutral position and then intubation was performed.
89021620|NCT04716218|Experimental|back up head elevated position|The initial POGO was recorded in the neutral position. The second POGO was scored in the ramped position and then the trachea was intubated.
89021621|NCT03271281|Experimental|Experimental: Angiogenesis PET/CT|One injection of the radioligand 68Ga-NODAGA-E[c(RGDyK)]2 followed by PET/CT
89021622|NCT00334568|Experimental|Rosi XR|Rosi XR
89021623|NCT00334568|Placebo Comparator|Placebo|Placebo (matched)
89021624|NCT03272451|Experimental|culprit vessel intervention|culprit vessel PCI prior to contralateral angiography using a single transradial guiding catheter
89021625|NCT03272451|Active Comparator|traditional approach|complete coronary angiography followed by guiding catheter selection for culprit vessel PCI
89021626|NCT02273544|Experimental|Asasantin ER (new formulation - low)|
89021627|NCT02273544|Experimental|Asasantin ER (new formulation - medium)|
89021628|NCT02273544|Experimental|Asasantin ER (new formulation- high)|
89485137|NCT03564665|Placebo Comparator|Control Arm|Prescription for an 8 week supply (+/- 4 days) of placebo will be sent to the pharmacy for patient pick up. Study Coordinator will then dispense study diaries (Supplementation Diary and Hot Flash Diary) with instructions on how to complete for the eight week study duration. Study Coordinator will discuss upcoming phone calls on Weeks 2-8 to complete the MDASI by phone and the best times to do so with the patient. Coordinator will schedule a return visit with the Patient approximately 9 weeks after the start of the study for follow-up. At follow-up, Coordinator will retrieve Patient Diaries (Hot Flash Diary and Medication Diary), perform supplement reconciliation, and exit Patient from the study.
89485138|NCT05353049|Experimental|Bathing technique based on Basale Stimulation|
89485139|NCT05353049|No Intervention|Traditional bathing technique|
89021629|NCT02273544|Active Comparator|Asasantin ER - commercial formulation|
89021630|NCT00436293|Experimental|1|Neo-adjuvant Taxotere followed by cisplatin and radiotherapy
89021631|NCT00436293|Active Comparator|2|Cisplatin and radiotherapy alone without neo-adjuvant chemotherapy
89021632|NCT00334646|Experimental|Arm A|cyclophosphamide + dexamethasone + ondansetron
89021633|NCT00334646|Experimental|Arm B|cyclophosphamide + dexamethasone + ondansetron + GW679769
89021634|NCT04701606|Experimental|Artecom® (pyronaridine-artesunate)|Artecom® is treated orally once a day for 3 consecutive days.
89021635|NCT04701606|Placebo Comparator|Placebo|Placebo is treated orally once a day for 3 consecutive days.
89021636|NCT00334685|Experimental|[S,S]-Reboxetine + Pregabalin|
89021637|NCT00334685|Active Comparator|Pregabalin|
89021638|NCT00436371|Experimental|1|Amisulpride 400-800mg per day on a twice-a-day regimen
89021639|NCT00334724|Active Comparator|1|Home blood pressure group
89021640|NCT00334724|Active Comparator|2|Office blood pressure group
89021641|NCT04716062||subjects who underwent open-air surgery|Fifty-one (37%) out of 138 subjects underwent open-air surgery.
89021642|NCT04716062||subjects underwent laparoscopic-assisted surgery|A total of 87 (63%) out of 138 subjects underwent laparoscopic-assisted surgery.
89021643|NCT00436800|Experimental|1|Gemcitabine on Day 1 followed by Oxaliplatin on Day 2. The regimen is given every 2 weeks to a maximum of 12 cycles.
89021644|NCT00436839|Experimental|1|Docetaxel 75mg/m² intravenously (day 1) every 21 days, plus prednisone 10mg orally given daily, minimal for 6 cycles and up to 10 cycle
89021645|NCT00436839|Active Comparator|2|Mitoxantrone 12mg/m² intravenously every 21 days, plus prednisone 10mg orally given daily, minimal for 6 cycles and up to 10 cycle
89021646|NCT00335036|Active Comparator|Thin leads|Thin (less than or equal to 7 French introducer) isodiametric ICD leads
89021647|NCT00335036|Active Comparator|Gore PTFE-coated|ICD lead with PTFE-coated coils
89021648|NCT00436878|Experimental|Portion Size|Each experiment manipulated food portion size of beverages, entrees, and side dishes
89021649|NCT00335075|Experimental|Temodal group|Subjects treated with temozolomide.
89021650|NCT00335075|Active Comparator|Semustine group|Subjects treated with semustine.
89021651|NCT00436995|Other|Single|
89021652|NCT00437190|Active Comparator|Anterior Cervical Discectomy Fusion|
89021653|NCT00437190|Experimental|BRYAN Cervical Disc Prosthesis|BRYAN Cervical Disc Prosthesis is a cervical intervertebral disc prosthesis designed to provide for motion like the normal cervical functional spinal unit.
89021654|NCT04716179|Experimental|Patients with COVID-19|Patients with confirmed COVID-19 infection
89021655|NCT04716179|Other|Healthy participants|The controlled group with healthy participants without COVID-19 infection.
89203902|NCT04048226|Experimental|Dexmedetomidine-Ketamine group|The patients in this group will be connected to the syringe pump that contain mixture of dexmedetomidine and ketamine with starting infusion at a rate of 0.1 ml/kg/hr till the end of the surgery. The solution will contain 2 ug dexmedetomidine/ml and 1 mg ketamine/ml.
89485140|NCT02838017|Experimental|Tissue Adhesive|Tissue Adhesive will be placed over subcuticular suture closure.
89485141|NCT02838017|Active Comparator|Steri-Strips|Sterile strips will be placed over subcuticular suture closure.
89485142|NCT03564431||controls|
89485143|NCT03564431||T2DM patients|
89485144|NCT03564431||depression patients|
89485145|NCT03564431||T2DM with depression patients|
89485146|NCT02870465||CRIF in operating room|Patients who present with a hand fracture amendable to closed reduction internal fixation (CRIF) who are managed in the operating room.
89485147|NCT02870465||CRIF outside of operating room|Patients who present with a hand fracture amendable to closed reduction internal fixation (CRIF) who are managed outside of the operating room (i.e.: in clinical setting, the emergency department or minor procedures area).
89203903|NCT00811746|Experimental|1|Rozerem (Ramelteon) 8 mg taken orally 30 minutes before a split-night PSG
89485148|NCT03188666|Experimental|REGN2477|
89485149|NCT03188666|Experimental|Placebo|
89485150|NCT03564977|Experimental|CD19-targeted CAR-T cells|
89485151|NCT02770703|Experimental|Open inguinal hernia repair (Lichtenstein)|Open inguinal hernia repair using a DynaMesh visible mesh
89485152|NCT02770703|Experimental|Total extraperitoneal inguinal hernia repair (TEP)|Total extraperitoneal inguinal hernia repair using a DynaMesh visible mesh
89485153|NCT02770703|Experimental|Trans abdominal preperitoneal hernia repair (TAPP)|Trans abdominal preperitoneal hernia repair using a DynaMesh visible mesh
89485154|NCT02836769|Experimental|Rehabilitation Consult (RC)|Pilot testing: single group pre-post design
89485155|NCT03069092|Experimental|Aerobic exercise (AE)|AE training will consist of 60 min of treadmill, elliptical, or bike exercise at a moderate to vigorous intensity (50-80% of heart rate reserve). Intensity of the exercise sessions will be built up gradually. Sessions will occur 3 times per week for the duration of the 1 year trial.
89485156|NCT03069092|Experimental|Resistance exercise (RE)|RE will consist of 3 sets of 8-15 repetitions at 50-80% of 1 rep-max of each exercise for 12 exercises (chest press, shoulder press, pull-down, back extension, abdominal crunch, torso rotation, biceps curl, triceps extension, leg press, leg extension, leg curl, and calf raise). Weight loads will be increased gradually. With one minute of rest between sets, this plan is estimated to take approximately 60 minutes per session. Sessions will occur 3 times per week for the duration of the 1 year trial.
89485157|NCT03069092|Experimental|Combined Resistance and Aerobic Exercise|Participants will perform exactly the same AE and RE exercises as listed previously; however, the time of AE and RE will each be reduced to 30 min (for 60 min/session total). For the RE aspect, participants will perform 2 sets of 8-15 repetitions of 9 exercises (excluding biceps curl, triceps extension, and calf raise, as these are minor muscle groups). Exercise intensity and resistance will be increased gradually. Combined AE and RE sessions will take place 3 times per week for the duration of the trial.
89485158|NCT03069092|No Intervention|No training control|Participants in this group will be asked to maintain their current level of activity during the 1 year study period. After 1 year, they will be offered the training program of their choice (AE, RE, or combined).
89485159|NCT04451642||Peripheral nerve block Group|Every patient scheduled during 2011-2019 for the surgery needed a peripheral nerve block were enrolled.
89485160|NCT02836613|Active Comparator|Galcanezumab Reference|Single dose of 240 milligrams (mg) galcanezumab (LY2951742) administered subcutaneously (SC) by manual prefilled syringe (PFS).
89485161|NCT02836613|Experimental|Galcanezumab Test|Single dose of 240 mg galcanezumab (LY2951742) administered SC by autoinjector.
89485162|NCT03068234|Experimental|Pirfenidone group|The subjects will receive pirfenidone from 200mg three times a day, oral administrated, with low dose steroids.
89485163|NCT03068234|Placebo Comparator|Control group|The subjects will receive placebo within first 24-week, and pirfenidone 200mg three times a day for the second 24-week, with low dose steroids.
89485164|NCT02397460|Experimental|Gefapixant 50 mg|Gefapixant 50 mg (1 tablet) administered as a single dose
89485165|NCT02397460|Experimental|Gefapixant 300 mg|Gefapixant 300 mg (6 tablets) administered as a single dose
89485166|NCT02397460|Placebo Comparator|Placebo|Placebo-matching tablets administered as a single dose
89485167|NCT05344079|Active Comparator|Epidural|Patients in this group were entered the epidural space from the midline using the loss of resistance method with an 18-Gauge Touhy (Egemen®, Combifix Standard Spinal Epidural Combined Set, İzmir, Turkey) needle from the L4-L5 or L5-S1 vertebral space.
89485168|NCT05344079|Active Comparator|local infiltrative analgesia|At the end of the operation, a 20-gauge infiltrative analgesia catheter connected to an ON-Q elastomeric pump that provides 5 mL/hour infusion prepared with 60 mL of 0.9% NaCl + 60 mL of 0.5% Bupivacaine (Bustesin®, 0.5% Spinal Heavy Vem Pharmaceuticals, Turkey) was placed on the fascia by the surgeon in such a way that all the holes of the catheter were under the skin and parallel to the incision line.
89021656|NCT00437229|Experimental|Subjects in Part A|In PART A, subjects received Regimen A: oral casopitant alone (150 mg once daily [QD] Day 1, 50 mg QD Days 2 and 3); Regimen B: oral dexamethasone (20 mg QD Day 1 and 8 mg twice daily [BID] Days 2 and 3) and intravenous (IV) ondansetron (32 mg single-dose Day 1); and Regimen C: oral casopitant as in Regimen A, IV ondansetron as in Regimen B and a lower dose oral dexamethasone than in Regimen B (12 mg QD Day 1, 8 mg QD Days 2 and 3).
89203904|NCT00811746|Active Comparator|2|Lunesta (Eszopiclone) 3 mg taken 30 minutes before the start of split-night PSG
89203905|NCT00811746|Other|3|Historical controls (chart review) matched for demographics and comorbidities of the study drug groups.
88952672|NCT01954238|Active Comparator|Rivaroxaban|Orally active direct factor Xa inhibitor for use in the prevention and treatment of venous thromboembolic disease
88952673|NCT01954238|Placebo Comparator|Placebo|GCC-4401C matching placebo capsule
88952674|NCT01954238|Experimental|GCC-4401C|Orally active direct factor Xa inhibitor for use in the prevention and treatment of venous thromboembolic disease. It is a novel molecule with a structural similarity to Rivaroxaban.
88952675|NCT01954277|Experimental|Electroacupuncture|All patients will receive 10 electroacupuncture sessions.
88952676|NCT01954277|Sham Comparator|Placebo Sham|All patients will receive 10 placebo sham sessions.
89203906|NCT00766766|Experimental|1|Experimental Intervention Group
89485169|NCT05347862|Other|Control group|Usual standard advice to practice physical activity as an important measure to promote health benefits.
89485170|NCT05347862|Experimental|Physical Activity Promotion|The intervention will consist of telephone calls and text messages to promote the practice of 150 minutes/week of physical activity in the daily life of participants.
89485171|NCT03069170|Experimental|Stem Cells|Intravenous administration of purified autologous bone marrow-derived stem cells.
89485172|NCT03069170|Experimental|Stem Cell Transplantation|Intrathecal administration of purified autolgous bone-marrow derived stem cells.
89485173|NCT05339399||4 cm cervical os dilatation|Low risk women with cervical os dilatation of 4 cm at amniotomy and whether they need oxytocin augmentation and analgesia.
89485174|NCT05339399||6 cm cervical os dilatation|Low risk women with cervical os dilatation of 6 cm at amniotomy and whether they need oxytocin augmentation and analgesia.
89485175|NCT02834819|Experimental|Hypertonic Saline|Patients randomized to the hypertonic saline group will be administered one nebulized treatment of 3% hypertonic saline. They will also receive what is considered standard of care, which includes suctioning and supportive care as needed.
89485176|NCT02834819|No Intervention|No treatment|"Patients in the No treatment arm will receive no additional treatment other than standard of care, which includes suctioning and supportive care as needed."
89485177|NCT05634824|Experimental|IVIg plus low dose rhTPO|Patients were randomized into experimental and control groups. For the experimental patients, the initial combination therapy consisted rhTPO at an initial does of 150U/kg once daily subcutaneously for 28 days and IVIg 400mg/kg per day for 5 days. If the platelet count was in the range of 30 to 50 × 10^9/L, the combination therapy was repeated. To reduce the risk for thrombocytosis, patients received maintenance therapy consisting rhTPO at a dose of 150U/kg per day if the platelet count rose above 50 × 10^9/L, and treatment discontinued when platelet counts exceeded 100 × 10^9/L. After delivery, the treatment consisted rhTPO 150U/kg per day, and maintained the dose if the platelet count exceeded 30 × 10^9/L. In addition, IVIg 400mg/kg per day for 5 days was added if the platelet count could not maintain above 30 × 10^9/L. If patients did not achieve 30 × 10^9/L within 4 weeks treatment was also discontinued.
89485178|NCT05634824|Active Comparator|IvIg treatment|Patients would be treated with IVIg 400mg/kg per day for 5 days monthly. And treatment discontinued when platelet counts exceeded 100 × 10^9/L.
89485179|NCT02454478|Experimental|Lenvatinib plus Everolimus|
89485180|NCT01341587|No Intervention|Control|Provider-driven care, based in office, no special diabetes management; Patient self-monitoring of blood glucose (SMBG)
89485181|NCT01341587|Active Comparator|Intervention|"Home diabetes monitoring by patient using cellular enabled glucometer to communicate information and receive feedback.~Care provider can access raw and analyzed patient data; Physician receives report summary."
89485182|NCT02361515|Active Comparator|Moderate Hypofractionated radiotherapy (62Gy)|20 fractions of 3.1Gy
89485183|NCT02361515|Experimental|Stereotactic radiotherapy (37.5Gy)|5 fractions of 7.5Gy)
89485184|NCT05730452|No Intervention|Phase 1: Observational, children 0-59 months of age|Phase 1: Observational only
89485185|NCT05730452|Experimental|Phase 2: Interventional, children 0-59 months of age|Phase 2: Intervention
89485186|NCT02359097|Experimental|Diagnostic (DSC/DCE-CBV, SS-CBV mapping)|Patients receive 2 doses (2nd dose optional) of gadoteridol IV and undergo MRI including DSC or DCE-CBV mapping over approximately 45-60 minutes on day 1. Within 3 days, patients receive 3 doses of ferumoxytol non-stoichiometric magnetite IV and undergo MRI including DSC and SS-CBV mapping after each dose over approximately 90 minutes. Patients undergo MRI without contrast 24 hours after ferumoxytol non-stoichiometric magnetite over approximately 30 minutes. This 3 day series of imaging repeats at different stages of disease and may be performed up to 5 times: prior to surgery, prior to chemoradiation therapy, 4-6 weeks post-chemoradiation therapy, at time of progression on gadolinium MRI per RANO criteria, and again at time of progression (if the previous time of progression showed pseudoprogression).
89485187|NCT05634590|Experimental|Fruquintinib plus FOLFIRI/FOLFOX|Patients will receive fruquintinib plus FOLFIRI/FOLFOX. Oxaliplatin-based or irinotecan-based chemotherapy depending on previous chemotherapy (chemotherapy switch).
89485188|NCT05708339|Active Comparator|conventionally fabricated ear prosthesis|
88956529|NCT04982835|Experimental|M6-C Artificial Cervical Disc|The M6-C is an investigational device composed of two outer and inner endplates made of titanium with a polycarbonate urethane nucleus (plastic center) and a polyethylene fiber annulus (strong thread-like binding). Around the polyethylene annulus is a polyurethane sheath (plastic cover). The outer endplates have keels to anchor the disc to bone. The outer endplates and keels are both coated with a titanium plasma spray. The M6-C is provided in two heights (6mm and 7mm) and four footprints (Medium, Medium Long, Large, Large Long).
89203907|NCT00766766|No Intervention|2|Standard Care Control
89485189|NCT05708339|Experimental|virtually fabricated ear prosthesis|
89485190|NCT01358825|Experimental|Infanrix hexa Group|Subjects aged 5 years previously vaccinated at 3, 5 and 11 months of age with 3 doses of Infanrix hexa™ (DTPa-HBV-IPV/Hib) administered intramuscularly in study NCT00307034.
89485191|NCT01358825|Experimental|Infanrix-IPV/Hib Group|Subjects aged 5 years previously vaccinated at 3, 5 and 11 months of age with 3 doses of Infanrix-IPV/Hib™ (DTPa-IPV/Hib) administered intramuscularly in study NCT00307034.
89485192|NCT03563963|Active Comparator|Lidocaine 2% in Endotracheal Tube cuff|Lidocaine 2% will used to inflate the endotracheal tube cuff using the stethoscope guided inflation technique described by Kumar and Hirsch (2). The anesthesiologist will documented the volume in millilitres instilled into the cuff to create a seal. Once a seal was created the anesthesiologist will documented the ETT cuff pressure. If an endotracheal cuff leak occurred during the surgical procedure, the randomized solution was used to inflate the cuff.
89485193|NCT03563963|Experimental|Ropivacaine 0.5% Endotracheal Tube cuff|Ropivacaine 0.5% will used to inflate the endotracheal tube cuff using the stethoscope guided inflation technique described by Kumar and Hirsch (2). The anesthesiologist will documented the volume in millilitres instilled into the cuff to create a seal. Once a seal was created the anesthesiologist will documented the ETT cuff pressure. If an endotracheal cuff leak occurred during the surgical procedure, the randomized solution was used to inflate the cuff.
89485194|NCT03563963|Active Comparator|Air in the Endotracheal Tube cuff|Air will used to inflate the endotracheal tube cuff using the stethoscope guided inflation technique described by Kumar and Hirsch (2). The anesthesiologist will documented the volume in millilitres instilled into the cuff to create a seal. Once a seal was created the anesthesiologist will documented the ETT cuff pressure. If an endotracheal cuff leak occurred during the surgical procedure, the randomized solution was used to inflate the cuff.
89485195|NCT03066518|Placebo Comparator|Melatonin|Melatonin 5 mg, daily, eight weeks
89485196|NCT03066518|Placebo Comparator|placebo|Placebo, daily, eight weeks
89485197|NCT05252156|Experimental|Therapy Dose-A|Neuromuscular electrical stimulation; two 20-minute sessions per day.
89485198|NCT05252156|Experimental|Therapy Dose-B|Neuromuscular electrical stimulation; one 30-minute session per day.
89485199|NCT05252156|No Intervention|No Therapy|Under the care of the referring physician, with no therapy applied
89485200|NCT03069014|Active Comparator|400mg LM11A-31-BHS|400mg LM11A-31-BHS and 400mg Placebo per day
89485201|NCT03069014|Active Comparator|800mg LM11A-31-BHS|800mg LM11A-31-BHS
89485202|NCT03069014|Placebo Comparator|Placebos|800mg (microcrystalline cellulose with 0.5 - 1% magnesium stearate) per day
89485203|NCT03069248|Experimental|treatment arm|"Salvage treatment with CHOP or DHAP followed by high dose therapy and stem cell support prior to consolidative immunotherapy with Rituximab and Alpha interferon.~."
89485204|NCT05730296|Experimental|group 1|rTMS active + training
89485205|NCT05730296|Experimental|group 2|rTMS active
89485206|NCT05730296|Sham Comparator|sham coil|rTMS sham
88952677|NCT01954290|Active Comparator|Hypertonic Saline (3%) and/or Mannitol arm|"The subjects in this arm will be given hypertonic saline and/or Mannitol.~For hypertonic saline,various concentrations are used clinically,up to 30-mL boluses of 23.4% saline.Rapid increases in sodium in this context do not appear to cause other neurologic complications observed with rapid correction of hyponatremia.Sodium levels up to 160 mmol/L may be acceptable,beyond which it may lead to worsening delirium,seizures,and overall poor outcome.~For Mannitol,every 4 hours serum osmolarity,serum glucose,urea,sodium and potassium will be measured till the therapy is given.Major complications include hypovolemia and hypotension.Strict fluid goals and volume replacement are essential.Impaired mannitol clearance may manifest as nephrotoxicity.Common practice includes repeating measurements of serum osmolarity and withholding repeat doses of mannitol when osmolarity exceeds 320 milliosmol(mOsm).Monitoring the osmole gap may be a more sensitive method for discerning mannitol clearance."
88952678|NCT01954290|Experimental|Conivaptan arm|The subjects in this arm will be given infusion of Conivaptan.
88952679|NCT01954303||Troponin status|"Patients are divided into troponin positive (if hsTnT on first presentation is <14 ng/L) and troponin negative (if hsTnT on first presentation is >=14 ng/l)."
88952680|NCT01954303||Progress of CHD|
89203908|NCT04048070|Experimental|ERAS with postoperative intravenous Flubiprofen Axetil|The patients was given extended perioperative counseling, shorter fasting food for 6 to 8 hours and carbohydrate water for 2 hours before surgery. Early ambulation and oral intake 2 hours after patient recovery from anesthesia. Once a day 100mg Flubiprofen Axetil in this group for postoperative pain management.
88952681|NCT01954329||Patients suspected of TIA by the GP|
89485207|NCT05634434||control group|Same patient, stone free kidney
89485208|NCT05634434||Study group|uric acid stone former, diseased kidney (stone harboring)
89485209|NCT05730140||patients undergoing general anesthesia|patients undergoing general anesthesia
89485210|NCT05730062|Experimental|SSRI 1 week following initiation oxycodone|Patients will be included day 4-10 following initiation of treatment with either Paroxetine, Sertraline, Escitalopram or Citalopram and will be administered oxycodone 10 mg IR
89485211|NCT05730062|Placebo Comparator|SSRI 1 week following initiation placebo|Patients will be included day 25-45 following initiation of treatment with either Paroxetine, Sertraline, Escitalopram or Citalopram and and will be administered placebo comparator
89485212|NCT05730062|Experimental|SSRI 1 month following initiation oxycodone|Patients will be included day 25-45 following initiation of treatment with either Paroxetine, Sertraline, Escitalopram or Citalopram and and will be administered oxycodone 10 mg IR.
89485213|NCT05730062|Placebo Comparator|SSRI 1 month following initiation placebo|Patients will be included day 25-45 following initiation of treatment with either Paroxetine, Sertraline, Escitalopram or Citalopram and and will be administered placebo comparator.
89485214|NCT02453386|Experimental|Tozadenant 60 mg BID|"During Part A, patients took two (2) tablets, one 60 mg tozadenant and one placebo, by mouth BID for a total of four (4) tablets per day.~Upon completion of Part A, all patients will begin dosing with open label tozadenant in Part B."
89485215|NCT02453386|Experimental|Tozadenant 120 mg BID|"During Part A, patients took two (2) tablets of 60 mg tozadenant, by mouth BID for a total of four (4) tablets per day.~Upon completion of Part A, all patients will begin dosing with open label tozadenant in Part B."
88952682|NCT01954355|Experimental|LDE225 & Paclitaxel|"Phase I, Part A: LDE225: dose escalation in cohorts of 3-6 patients (days 1-28) and Paclitaxel 80 mg/m2 (days 1, 8, 15)~Phase I, Part B and C: LDE225: RP2D established in Part A (days 1-28) and Paclitaxel 80 mg/m2 (days 1, 8, 15)"
88952683|NCT01954368|Placebo Comparator|Intranasal placebo|Patients receiving intranasal placebo at ED admission
89485216|NCT02453386|Placebo Comparator|Placebo BID|"During Part A, patients took two (2) tablets of placebo, by mouth BID for a total of four (4) tablets per day.~Upon completion of Part A, all patients will begin dosing with open label tozadenant in Part B."
89485217|NCT03068936|Experimental|IMRT group|Intensity modulated radiotherapy once a day, 5 times a week, continuous treatment for about 6 weeks (DT 70Gy)
89485218|NCT03068936|Other|IMRT plus cisplatin group|Intensity modulated radiotherapy once a day, 5 times a week, continuous treatment for about 6 weeks (DT 70Gy),plus synchronous cisplatin (100mg / m2 / times) chemotherapy, once every 3 weeks, a total of 2 times
89485219|NCT05017610|Experimental|Treatment (methimazole, lomustine, liothyronine)|See Outline in Detailed Description.
89485220|NCT03068078|No Intervention|Control-group|The control group will be eating a regular diabetes diet according to the Danish National Recommendations
89485221|NCT03068078|Experimental|Intervention-group|Intervention-group will be eating a low carbohydrate diet, high in monounsaturated fats
89485222|NCT02431468|Experimental|Bryostatin 1 20ug|Bryostatin 20 micrograms administered IV over 45 minutes every other week after 2 initial loading doses of 24 micrograms administered weekly. A total of 7 doses administered over 12 weeks.
89485223|NCT02431468|Experimental|Bryostatin 1 40ug|Bryostatin 40 micrograms administered IV over 45 minutes every other week after 2 initial loading doses of 48 micrograms administered weekly. A total of 7 doses administered over 12 weeks.
89485224|NCT02431468|Placebo Comparator|Placebo|Placebo administered IV over 45 minutes every other week after 2 initial doses administered weekly. A total of 7 doses administered over 12 weeks.
89485225|NCT02452762|Experimental|Enteral Loading Arm|Vitamin D3 (cholecalciferol) - Single dose at enrolment of 10000 IU/kg of cholecalciferol (max 400000 IU)
89485226|NCT02452762|Placebo Comparator|Placebo Arm|Patients will receive a placebo solution equivalent in volume to the dose of cholecalciferol administered to patients in the enteral loading arm.
89485227|NCT05729828||Observation group|Neonates with PMA 33 weeks, 0 days or more, present in NICU. No intervention was done.
89485228|NCT03068858|Experimental|SYNTAX score category feedback group|A real-time SYNTAX score category feedback from angiographic core lab will be given to the cardiologists rightafter the angiographies.
89485229|NCT03068858|No Intervention|Controlled group|Cardiologists' subjective SYNTAX score category judgement will be recorded during the angiography.
89485230|NCT05729750|Experimental|Lable litter A (Study group)|The sealed opaque brown envelope contains a case record form and the letter A paper for listening to the music before and during the BPP assessment (study group), which cannot be visible from the outside.
89485231|NCT05729750|Placebo Comparator|Lable litter B (control group)|The sealed opaque brown envelope contains a case record form and the letter B for not listening to the music before and during the BPP assessment (control group), which cannot be visible from the outside.
89485232|NCT04915118||Patients with HFrEF|Patients with HFrEF (Heart failure with reduced ejection fraction) who had a previous decompensation event.
89485233|NCT03068702||African Canadians|African Canadians with sickle cell disease maculopathy diagnosed by OCTA.
89485234|NCT04886414|Experimental|Phone-based monitoring without blood oxygenation monitoring with ABHS|Study staff will perform daily phone-based assessments using standardized electronic study tools (tablets). Clinical features will be documented on a phone-based patient monitoring form. Subjects will received a home-based care kit that contains alcohol-based hand sanitizer (ABHS).
89485235|NCT04886414|Experimental|Phone-based monitoring without blood oxygenation monitoring without ABHS|Study staff will perform daily phone-based assessments using standardized electronic study tools (tablets). Clinical features will be documented on a phone-based patient monitoring form. Subjects will received a home-based care kit that does not contain alcohol-based hand sanitizer.
89485236|NCT04886414|Experimental|Phone-based monitoring with blood oxygenation monitoring with ABHS|Study staff will perform daily phone-based assessments using standardized electronic study tools (tablets). Clinical features and oxygen saturation levels will be documented on a phone-based patient monitoring form. Oxygen saturation level will be assessed four times per day (morning, midday, evening, plus during the phone-based assessment) by the patient and/or family member and the lowest stable (i.e. without substantial fluctuations) level recorded during a monitoring period of one minute will be recorded and registered. Patient's will be provided monitoring sheets to record the times and dates of the oxygen saturation levels. Subjects will received a home-based care kit that contains alcohol-based hand sanitizer.
88952684|NCT01954368|Experimental|Intranasal sufentanil|Patients receiving intranasal sufentanil at ED admission
89485237|NCT04886414|Experimental|Phone-based monitoring with blood oxygenation monitoring without ABHS|Study staff will perform daily phone-based assessments using standardized electronic study tools (tablets). Clinical features and oxygen saturation levels will be documented on a phone-based patient monitoring form. Oxygen saturation level will be assessed four times per day (morning, midday, evening, plus during the phone-based assessment) by the patient and/or family member and the lowest stable (i.e. without substantial fluctuations) level recorded during a monitoring period of one minute will be recorded and registered. Patient's will be provided monitoring sheets to record the times and dates of the oxygen saturation levels. Subjects will received a home-based care kit that does not contain alcohol-based hand sanitizer.
89485238|NCT04411004||Women who underwent shaving for rectal endometriosis|
89485239|NCT04886492||NMO|Pts presenting to enrolling sites across the northern America are invited to enroll if eligible
89485240|NCT05729672|Experimental|The experimental group|The experimental group will participate in the SPOC- based education program, consisting of five online teaching and learning modules over the span of 3 months and two hours of offline classroom.
89485241|NCT05729672|No Intervention|The control group|The control group will not receive any education. Data will be collected at baseline, 1 month and 3 months after intervention.
89485242|NCT05633420|Experimental|Pyramax|pyronaridine-artesunate (180/160 mg)
89485243|NCT05633030|Active Comparator|operated using UAS during flexible ureteroscopy|
89537764|NCT03295019|Experimental|Test Oral Spray|Subjects will be instructed to mouth spray with 0.3 ml ( 2 sprays to the mouth) of their assigned mouth spray, 2 times daily (morning and evening), using only the assigned mouth spray provided for the 4 week duration of the study.
89537765|NCT03295019|Placebo Comparator|Placebo Oral Spray|Subjects will be instructed to mouth spray with 0.3 ml ( 2 sprays to the mouth) of their placebo mouth spray, 2 times daily (morning and evening), for the 4 week duration of the study.
89537766|NCT03242889|Experimental|DARA SC|Participants will receive DARA SC (daratumumab 1800 milligram [mg] with Recombinant Human Hyaluronidase [rHuPH20] 30,000 units [U] that is 2000 U/milliliter [U/mL]) subcutaneous (SC) injection once weekly for the first 8 weeks in Cycles 1 and 2 (Days 1, 8, 15, and 22 of each week), every 2 weeks in Cycles 3 to 6 (Days 1 and 15) for the following 16 weeks and then every 4 weeks (from Cycle 7 [Day 1]) in subsequent cycles until disease progression, unacceptable toxicity, or any other reason for discontinuation. Each cycle is 28 days in duration.
89537767|NCT04488731||NW/MCC|Normal body mass index (BMI) / with moderate coffee consumption
89537768|NCT04488731||NW/HCC|Normal body mass index (BMI) / with heavy coffee consumption
89537769|NCT04488731||OW/MCC|Overweight / with moderate coffee consumption
89537770|NCT04488731||OW/HCC|Overweight / with heavy coffee consumption
89537771|NCT03290963|Active Comparator|Ketamine plus Lithium|Lithium will be used in conjunction to Ketamine infusions for the treatment of major depression disorder or bipolar disorder type I or II. Before the first ketamine infusion, subjects will be randomized to 2 weeks of lithium treatment. All subjects will receive three IV ketamine infusions (0.5 mg/kg, over 100 min.) over 7 days. Those who achieve positive response (>50% decrease in MADRS total score from baseline) will be given 4 additional once-weekly ketamine infusions (same dose and infusion rate) and lithium treatment .
89537772|NCT03290963|Placebo Comparator|Ketamine plus Placebo|Placebo tablets will be used in conjunction to Ketamine infusions for the treatment of major depression disorder or bipolar disorder type I or II. Before the first ketamine infusion, subjects will be randomized to 2 weeks of placebo treatment. All subjects will receive three IV ketamine infusions (0.5 mg/kg, over 100 min.) over 7 days. Those who achieve positive response (>50% decrease in MADRS total score from baseline) will be given 4 additional once-weekly ketamine infusions (same dose and infusion rate) and placebo treatment.
89537773|NCT03062553|Experimental|MCT + Neuromodulation (MCT-N)|"Participants (n=50) randomly assigned to the MCT-N condition will undergo transcranial alternating current stimulation (tACS) prior to participation in MCT.~Neuromodulation involving tACS will target increasing the power of the alpha band at dorsomedial prefrontal regions, and this is expected to also decrease the power of the beta band in ventro-medial regions. This will be confirmed by EEG recordings and source estimation during a task.~The Metacognitive Training (MCT) group intervention will consist of an 8-module cycle occurring twice a week for 4 weeks, for a total of 8 sessions. Each module will include a 45 to 60 minute instructor-led group session using PowerPoint slides and homework assignments to facilitate learning. Groups will consist of 4-10 subjects."
89537774|NCT03062553|Experimental|Sham/MCT group (MCT- S)|"Participants (n=50) randomly assigned to the Sham/MCT (MCT-S) condition will undergo the application of random patterns of low-grade currents to the same brain region as the neuromodulation condition prior to participation in MCT.~MCT is a four week program with eight one-hour sessions. MCT can be obtained online at no cost (www.uke.de/mkt). This experimental intervention will consist of an 8-module cycles occurring twice a week for 4 weeks, for a total of 8 sessions. Each module will include a 45 to 60 minute instructor-led group session using PowerPoint slides and homework assignments to facilitate learning. Groups will consist of 4-10 subjects."
89537775|NCT03062553|Experimental|Neuromodulation/Treatment as Usual TAU-N|"Participants (n=50) randomly assigned to the Neuromodulation/TAU (TAU - N) condition will undergo transcranial alternating current stimulation (tACS) prior to being placed on the TAU waitlist.~Neuromodulation involving tACS will target increasing the power of the alpha band at dorsomedial prefrontal regions, and this is expected to also decrease the power of the beta band in ventro-medial regions. This will be confirmed by EEG recordings and source estimation during a task.~TAU is a four week waitlist control group."
89537776|NCT03294785|Experimental|Chuna manual therapy|The Chuna manual therapy group will receive Chuna manual therapy alone. Chuna manual therapy will employ a semi-standardized treatment plan of Chuna manual therapy through Chuna technique selection based on physician judgement of techniques from Chuna Medicine (Korean Society of Chuna Manual Medicine for Spine & Nerves: Chuna Medicine: Seoul: Korean Society of Chuna Manual Medicine for Spine & Nerves; 2017) and osteopathic manipulative medicine. The Chuna techniques employed in this study are divided into cervical, thoracic and rib cage, lumbar, pelvic, sacral, pubic, and hip joint area techniques. Chuna manual therapy sessions will be administered 2 sessions/week over a period of 5 weeks (total 10 sessions). The time duration of 1 Chuna manual therapy session will consist of approximately 10-20 minutes of diagnosis and approximately 10 minutes of treatment.
89537777|NCT03294785|Active Comparator|Usual care|The usual care group will receive usual care alone. Usual care will be limited to physical therapy and conventional medication in this study. Usual care will be provided with reference to a list of most frequently used treatments in neck pain-related patients from Korean Health Insurance Review and Assessment (HIRA) 2014 statistics. Frequency and types of physical therapy used will be recorded in a separate electronic case report form for outcome assessor blinding purposes.
89537778|NCT03290885|Experimental|Combined use of contact aspiration and stent retriever|Combined use of contact aspiration and stent retriever mechanical thrombectomy for recanalization
88952685|NCT01954381|Other|control|
88952686|NCT01954381|Experimental|patient|
88952687|NCT01954407|No Intervention|Control: No Smoking-Related Messages|Respondents will answer questions about smoking-related beliefs and intentions to smoke before receiving the treatment smoking-related messages (they will still receive them at the end to make the groups comparable and still expose them to anti-smoking messages).
88952688|NCT01954407|Experimental|Promising Smoking-Related Messages|Respondents will receive one of the possible sets of promising smoking-related messages and these should affect smoking-related intentions to a greater extent (make respondents less likely to smoke) than less-promising smoking-related messages.
88952689|NCT01954407|Experimental|Less-Promising Smoking-Related Messages|Respondents will receive one of the possible sets of less-promising smoking-related messages and these should affect their intentions to a lesser extent than the promising smoking-related messages.
89485244|NCT05633030|Active Comparator|operated using PCN during flexible ureteroscopy|
89485245|NCT05632094|No Intervention|Conventional Group|"This group will comprise 20 patients who will receive conventional supportive care for the treatment of acute clozapine toxicity that include the following:~Airway: maintaining clear patent airways.~Breathing: oxygen inhalation, respiratory support whenever required (mechanical ventilation).~Circulation: intravenous fluids, and symptomatic treatment according to ECG abnormalities.~Decontamination: administration of activated charcoal (1 gm/kg)."
89485246|NCT05632094|Experimental|L-Carnitine Group|This group will comprise 20 patients who will receive conventional supportive care (same as group 1), in addition to IV L-carnitine
89485247|NCT04768322|Experimental|Early Left Ventricular Assist Device and Guideline Directed Medical Therapy|The intervention group will receive an early left ventricular assist device implantation (bridge to transplantation, bridge to candidacy or destination therapy) in addition to guideline directed medical therapy within 21 days of randomization.
88952690|NCT01954420|Other|Attention Control|"Standard care + cancer education~Participants receive a single session with a research nurse to discuss the importance of understanding cancer and cancer treatment strategies, and to introduce educational recordings available on an MP3 player. The educational recordings provide a selection of publicly available American Cancer Society patient information materials addressing topics related to cancer and cancer treatment strategies. Participants are asked to listen to at least one recording per day, or more frequently as desired."
89485248|NCT04768322|Other|Guideline Directed Medical Therapy|Patients randomized in the control group will continue their guideline directed medical therapy which comprises the following stable combination at the maximal tolerated dose of betablockers, Angiotensin-Converting-Enzyme-inhibitors or Angiotensin II Receptor Blockers or Angiotensin receptor Neprilysin inhibitor and Mineralocorticoid Receptor Antagonists and Sodium-GLucose co-Transporter-2 (SGLT2) inhibitors if tolerated.
89485249|NCT03068156|Experimental|excimer laser|
89485250|NCT03068156|No Intervention|Control|
89485251|NCT05575466||Patients|Will have thromboembolic incidence rate evaluated and will have a battery of hemostatic markers analyzed
89485252|NCT05575466||Controls|Will have thromboembolic incidence rate evaluated and will have a battery of hemostatic markers analyzed
89485253|NCT05729360|Experimental|Patients with a verified diagnosis of COVID-19|
89485254|NCT04699058||Health care workers|questionnaire and COVID antibody test
89485255|NCT04699058||Household members|questionnaire and COVID antibody test
89485256|NCT05729126||active arm|participants responding to the questionnaire emailed.
89485257|NCT05518760||Case|A COVID-19 confirmed case is a patient with an acute respiratory illness and RT-PCR confirmation of SARS-CoV-2 infection (i.e. any positive RT-PCR results obtained prior to admission or after enrolment in the study). In case the patient has any inconsistent RT-PCR results (e.g. a positive followed by a negative or a negative followed by a positive result), he/s he/she will be considered as a COVID-19 confirmed case if he/she has at least one positive result during his/her illness under consideration.
89485258|NCT05518760||Test-negative control|A COVID-19 negative case is a patient with an acute respiratory illness, in whom all RT-PCR tests are negative for SARS-CoV-2
89485259|NCT05487092|Experimental|Letrozole|They will be given letrozole 2.5mg daily on top of combined oral contraceptive (COC) pills (Microgynon 30, which contains 30mcg ethinyloestradiol and 150 mcg levonorgestrel) orally for 6 months after laparoscopic ovarian cystectomy, followed by COC pills alone subsequently as routine
89485260|NCT05487092|Placebo Comparator|Standard treatment|They will be given placebo tablets (which will be identical to letrozole) on top of COC pills (Microgynon 30, which contains 30mcg ethinyloestradiol and 150 mcg levonorgestrel) orally for 6 months after laparoscopic ovarian cystectomy, followed by COC pills alone subsequently
89485261|NCT04568954|Experimental|TB testing using the Truenat platform/TB assays|TB testing using the Truenat platform/TB assays placed at primary health care clinics combined with rapid communication of results and same day TB treatment initiation
89485262|NCT04568954|No Intervention|Standard of care Arm|Standard of care for TB testing using a combination of smear microscopy and laboratory (off-site) Xpert testing, may vary by clinic depending on availability of transport and stock of Xpert MTB/RIF or Xpert MTB/RIF Ultra cartridges (Xpert).
89485263|NCT04554056|Experimental|MW05 300μg/kg|Subjects will receive MW05(300 μg/kg s.c.) on day 3 of each cycle (6~10 a.m.)
89485264|NCT04554056|Experimental|MW05 500μg/kg|Subjects will receive MW05(500 μg/kg s.c.) on day 3 of each cycle (6~10 a.m.)
89485265|NCT04554056|Active Comparator|PEG-rhG-CSF|Subjects will receive PEG-rhG-CSF(100 μg/kg s.c.) on day 3 of each cycle (6~10 a.m.)
89485266|NCT03067766|Experimental|Workshop A (10 weeks - comic art creation workshop)|Patients and a family member, caretaker, or friend participate in an artist-led comic art therapy workshop over 2 hours once a week for 10 weeks. Patients and participants receive a range of assignments that focus on creative art and experimentation with materials and storytelling in order to make a series of small handmade books that relate directly or indirectly to their experience with cancer. Patients undergo a qualitative interview over approximately 45 minutes and complete validated questionnaires within 4 weeks prior to the workshop and midway through the workshop.
89485267|NCT03067766|Experimental|Workshop B and C (5 weeks - comic art creation workshop)|Patients participate in an artist-led comic art therapy workshop over 3 hours once a week for 5 weeks. Patients receive a range of assignments that focus on creative art and experimentation with materials and storytelling in order to make a series of small handmade books that relate directly or indirectly to their experience with cancer. Patients undergo a qualitative interview over approximately 45 minutes and complete validated questionnaires within 4 weeks prior to the workshop.
89485268|NCT03067688|Experimental|"Combination drug:Temisartan+Amlodipine+Rosuvastatin"|"60 subjects will be assigned and the subjects will be administered Temisartan+Amlodipine+Rosuvastatin for 8 weeks."
89485269|NCT03067688|Active Comparator|Temisartan+Amlodipine|"60 subjects will be assigned and the subjects will be administered Twynsta Tab.(Temisartan+Amlodipine) for 8 weeks."
89485270|NCT03067688|Active Comparator|Temisartan+Rosuvastatin|"60 subjects will be assigned and the subjects will be administered Micardis Tab. and Crestor Tab.(Temisartan+Rosuvastatin) for 8 weeks."
89485271|NCT03067532|Experimental|A|
89485272|NCT03067532|Active Comparator|B|
89485273|NCT03067454|Other|conservative group|Treatment with early mobilisation
88956530|NCT04982835|Active Comparator|Anterior Cervical Discectomy & Fusion (ACDF)|"ACDF will be performed using one of four FDA-approved anterior cervical plate systems and corticocancellous allograft bone. The four plating systems used in this study are:~Orthofix CETRA Anterior Cervical Plate System~Medtronic Sofamor/Danek Venture Anterior Cervical Plate System~DePuy Synthes: SKYLINE Anterior Cervical Plate System~Stryker Aviator Anterior Cervical Plating System"
89485274|NCT03067454|Other|operative group|Treatment with operation
89485275|NCT03067142||Cohort 1 (Phase 1): PH1|Cross-Sectional/Observational
89485276|NCT03067142||Cohort 2 (Phase 1): Controls|Cross-Sectional/Observational
89485277|NCT03067142||Cohort 3 (Phase 2): PH1|Longitudinal/Observational
89485278|NCT03067220|Other|Standard outpatient clinic appointment|Patients will be sent an appointment letter to return to a scheduled outpatient clinic for review approximately 6 weeks after their discharge from hospital
89485279|NCT03067220|Experimental|Virtual out patient clinic appointment|Patients will be sent an appointment letter stating a specific day approximately 6 weeks after their discharge from hospital in which they will be contacted by telephone for a review by a junior doctor from the discharging team.
89485280|NCT03065972|Active Comparator|Surgical fistula creation from patient's anatomy|Patients randomized to surgical arteriovenous fistula will have a fistula surgically created from their anatomy to be used for hemodialysis access.
89485281|NCT03065972|Active Comparator|Surgical graft implant|Patients randomized to surgical graft, will have a commercially available graft surgically implanted to be used for hemodialysis access.
89485282|NCT03065894|Experimental|Stratified Care|"In three Participating Sites from Family Medicine sites, the Keele STarT Back Screening Tool will be administered to patients with acute and chronic low back pain and based on patients' responses, patients will be stratified into one of three risk groups: low, medium or high-risk. Patients in the medium- and high-risk groups will be referred to physical therapy for a matched physical therapy (PT) intervention based on the risk strata. Patients in the low-risk group will be managed in Family Medicine with an intervention that includes advice, reassurance, patient education, and NSAIDs (with no referral for imaging or specialist care)."
89485283|NCT03065894|Active Comparator|Current Care|"In three Comparator Sites from Family Medicine, providers will give the current care at The University of Vermont Medical Center for patients with acute and chronic low back pain."
89485284|NCT05555030|Experimental|At least 30 children between 2 and 13 years of age|Participants 2-13 years of age will have a nasopharyngeal swab sample collected by trained study site personnel for testing on a high sensitivity EUA SARS-CoV-2 RT-PCR assay to compare the result to the result of the iCura SARS-CoV-2 Antigen Rapid Home Test. The parent or legal guardian of the child will collect an anterior nasal swab sample from the child and perform the iCura SARS-CoV-2 Antigen Rapid Home Test.
89485285|NCT05555030|Experimental|Subject 14-65+ years of age|Participants will have a nasopharyngeal swab sample collected by trained study site personnel for testing on a high sensitivity EUA SARS-CoV-2 RT-PCR assay to compare the result to the result of the iCura SARS-CoV-2 Antigen Rapid Home Test. The participant will then self-collect or, if both are over 18, collect from another study participant an anterior nasal swab sample and test using the iCura SARS-CoV-2 Antigen Rapid Home Test.
89485286|NCT03066128|Experimental|Intervention|Participants in the Intervention Group will receive chronic ART management from a Professional Nurse and/or Enrolled Nurse every 2 months, and if stable after 6 months, community pharmacy ART collection through CCMDD. Viral load monitoring will be by a point-of-care viral load testing.
89485287|NCT03066128|Experimental|Standard of Care|Participants in the Standard-of-Care control arm will receive the standard-of-care for the clinic consisting of visits with a professional clinician (Physician or Professional Nurse) and once stable, community pharmacy ART collection through CCMDD.Viral load monitoring will be by lab-based viral load testing
89485288|NCT02633306|Experimental|Transcranial Magnetic Stimulation|transcranial magnetic stimulation
89485289|NCT02396758|Experimental|APT/2 Hours-r-tPA/2 mg/hr/Catheter|A total of 4 or 8 mg r-tPA (as 2 mg/hour [hr]/catheter) will be delivered through Ekosonic® Endovascular Device (EKOS) ultrasonic infusion catheter for 2 hrs.
89485290|NCT02396758|Experimental|APT/4 Hours-r-tPA/1 mg/hr/Catheter|A total of 4 or 8 mg r-tPA (as 1 mg/hr/catheter) will be delivered through EKOS ultrasonic infusion catheter for 4 hrs.
89485291|NCT02396758|Experimental|APT/6 Hours-r-tPA/1 mg/hr/Catheter|A total of 6 or 12 mg r-tPA (as 1 mg/hr/catheter) will be delivered through EKOS ultrasonic infusion catheter for 6 hrs.
89485292|NCT02396758|Experimental|APT/6 Hours-r-tPA/2 mg/hr/Catheter|A total of 12 or 24 mg r-tPA (as 2 mg/hr/catheter) will be delivered through EKOS ultrasonic infusion catheter for 6 hrs.
89485293|NCT05728424|Active Comparator|2 weeks vonoprazan containing triple regimen|"For two weeks:~Vonaprazan: 20 mg twice daily Amoxicillin: 1gm twice daily Levofloxacin: 500 mg once daily"
89485294|NCT05728424|Placebo Comparator|1 week vonoprazan containing triple regimen|"For One week:~Vonaprazan: 20 mg twice daily Amoxicillin: 1gm twice daily Levofloxacin: 500 mg once daily~For the second week:~Placebo"
89485295|NCT03065738|Experimental|osteoarthritis knee ,severe varus deformity|reduction osteotomy in total knee replacement
89485296|NCT03067376|Experimental|[14C]-CORT125134|Two capsules each containing 125 milligrams (mg) [14C]-CORT125134 administered to each participant on 1 occasion
89485297|NCT04407260||Intervention|Patients on oxygen hoods who have fail conventional high-flow oxygen delivery systems.
89485298|NCT04407260||Control|Patients maintained on conventional high-flow oxygen delivery systems (such as non-rebreather masks, high-flow nasal cannula, BiPAP, CPAP) or who have failed on these conventional symptoms and were subsequently mechanically ventilated.
88952691|NCT01954420|Experimental|Cognitive-Behavioral Intervention|"Standard care + Patient-Controlled Cognitive Behavioral Intervention~Participants will receive a single training session with a research nurse including: 1) Information about the causes of cancer-related pain, fatigue, and sleep disturbance. 2) An explanation of how cognitive-behavioral interventions may affect symptoms. 3) Review of the specific cognitive-behavioral strategies provided on the MP3 player. 4) Individualized recommendations for using the cognitive-behavioral strategies. The nurse interventionist and patient will develop a written plan for practicing the strategies with recommendations to use a strategy at least once a day, or more frequently as needed."
88952692|NCT01954433||Operated TSA Patients|Patients with glenohumeral arthritis and/or rotator cuff tear arthropathy who were operated and received a total shoulder prosthesis
88952693|NCT01954433||Non-operated TSA Patients|TSA-patients, indicated for treatment with a total shoulder prosthesis, who decided not to operate
88952694|NCT01954433||Operated RCR Patients|Patients with rotator cuff tear who were operated and received a rotator cuff reconstruction by arthroscopy
88952695|NCT01954433||Non-operated RCR Patients|RCR-patients, indicated for rotator cuff reconstruction by arthroscopy, who decided not to operate
89485299|NCT05728268|Experimental|dose-dense arm|
89485300|NCT02632838|Experimental|the mHealth Group|The mHealth group will ask to use iHealth BP7-Wireless Blood Pressure Wrist Monitor on a daily basis at HOME and also will be asked to visit community health center once a week to receive the regular hypertension care for the 6-month period as usual.
89485301|NCT02632838|No Intervention|the Standard Follow-up Group|The standard follow-up group will receive regular hypertension care as usual which consists: nursing assessment, medication management, patient education, follow up and continuing care in the community health center
89485302|NCT05728190|Experimental|Lavender essential oil|In the intervention group, five days, seven drops of lavender essential oil were dripped onto a 5x5 gauze pad in the morning and evening, for 20 minutes, 10 cm away from the nose, and sniffed.
89485303|NCT05728190|Placebo Comparator|Steril/Salin water|Five days seven drops of saline/sterile water were dripped onto a 5x5 gauze pad in the morning and evening, and they were put to sniff for 20 minutes, 10 cm away from the nose.
89485304|NCT02396212|Experimental|Canakinumab|All patients received canakinumab (ACZ885) as open-label study medication. Patients were administered canakinumab 4 mg/kg every 4 weeks. The maximal total single dose of canakinumab allowed was 300 mg.
89485305|NCT04449458|Experimental|Positively Me|Positively Me is a 12-session (8 [1.5] hour main sessions plus four booster sessions) intervention guided by Social Cognitive Theory to promote smoking cessation in people with certain health conditions.
89485306|NCT04449458|Sham Comparator|Positively Living|Positively Living is a modified updated version of a healthy living intervention based on Social Cognitive Theory that is designed for people with certain health conditions and attention-matched to the experimental condition (8 [1.5] hour main sessions plus four booster sessions).
89485307|NCT05490914||Experimental Group|COVID-19 case
89485308|NCT05490914||Control Group|Healthy population without COVID-19
89485309|NCT04883762|Experimental|Fecal Microbiota Transplantation (FMT)|Study subjects will undergo standard bowel preparation and diagnostic colonoscopy with routine biopsies for pathologic assessment. FMT will be performed at the proximal extent of the colon reached, according to the same protocol used in prior randomized studies. FMT will use healthy donor stool provided by OpenBiome, a nonprofit 501(c)(3) organization that provides clinicians and hospitals with screened, filtered and frozen stool to be used for FMT. Routine clinical and research biopsies will be collected during the FMT colonoscopy procedure.
89485310|NCT04882358|Experimental|GROUP 1 DIRECT SODIUM REMOVAL + SGLT-2 INHIBITOR|SUBJECTS TREATED WITH DSR + STANDARD DOSE OF APPROVED SGLT-2 INHIBITOR
89485311|NCT04882358|Experimental|GROUP 2 DIRECT SODIUM REMOVAL|SUBJECTS TREATED WITH DSR
89485312|NCT02395822|Experimental|Preparative Regimen and SubQ rHuIL-15|"Preparative Regimen of Fludarabine and Cyclophosphamide~IL-15 Activation of Donor NK Cells:~IL-15 to Facilitate NK Cell Survival and Expansion"
89485313|NCT05726942|Experimental|Healthi|
89485314|NCT05726942|No Intervention|Control|
89485315|NCT04926844|Experimental|Study group|Children receiving levetiracetam + midazolam
89485316|NCT04926844|Placebo Comparator|Control group|Children receiving placebo + midazolam
89485317|NCT05482256|Experimental|Toothpaste detergents with Eosinophilic Esophagitis Testing|Subjects will complete an esophageal string test prior to and after completing a high resolution esophageal manometry then brushing their teeth using Colgate toothpaste.
89485318|NCT01651936|Experimental|Base Study: MK-8457|Participants received MK-8457 100 mg dosed twice daily (BID) orally with MTX at the stable dose received upon study enrollment. The Base Study lasted up to 24 weeks.
89485319|NCT01651936|Placebo Comparator|Base Study: Placebo|Participants received placebo BID orally with MTX at the stable dose received upon study enrollment. The Base Study lasted up to 24 weeks.
89485320|NCT01651936|Experimental|Safety Extension: MK-8457|Participants received MK-8457 100 mg dosed twice daily (BID) orally with MTX at the stable dose received upon study enrollment. The Safety Extension was to last up to 76 weeks.
89485321|NCT04217174|Experimental|Avatar intervention app|The intervention is a mobile phone app that features a realistic talking human avatar who promotes adherence to ART and retention in care, motivates, and provides information and opportunities for HIV care-related behavioral skills.
89537779|NCT03290885|Active Comparator|Stent retriever mechanical thrombectomy alone|Stent retriever mechanical thrombectomy alone for recanalisation
89485322|NCT04217174|Other|Control app|The control app is a mobile phone app that features a realistic talking human avatar who primarily promotes food safety and also offers knowledge of sugar content in food. This app is expected to have no effect on ART adherence and retention in care, however, it has never been tested to determine if it may have any effect so it has been categorized as Other (arm type) rather than as placebo.
89485323|NCT04199078|Experimental|A - papilocare alternative days treatment|Arm A: scheme A (21 days / 1 cannula per day + 7 days rest) x 1 month + alternate days up to 6 months (except for menstruation days)
89485324|NCT04199078|Experimental|B - papilocare semiintensive treatment|Arm B: scheme B (21 days / 1 cannula per day + 7 days rest) x 3 months + alternate days up to 6 months (except menstruation days)
89485325|NCT04199078|Experimental|C - papilocare intensive treatment|Arm C: scheme C (21 days / 1 cannula per day + 7 days rest) x 6 months
89485326|NCT04199078|No Intervention|D - standard of care|Arm D: usual clinical practice - no treatment
89485327|NCT05634512||Collect blood from patients with MPS-IH) undergoing laronidase therapy and stem cell transplant.|The primary aim is to characterize the PK of IV laronidase in individuals with MPS IH and identify patient specific covariates that impact drug exposure. The secondary aim is to identify key differences pre-and post-HCT leading to variability in PK parameters for patients receiving IV laronidase therapy for the treatment of MPS-IH.
89485328|NCT04042844|Experimental|Active Treatment- BRTX-100|BRTX-100 consists of a population of hypoxic-cultured bone marrow mononuclear cells highly enriched in mesenchymal stem cells from autologous bone marrow with autologous platelet lysate.
89485329|NCT04042844|Placebo Comparator|Saline|Isotonic saline will be used as a control in this study. Drug: saline (0.9% sodium chloride).
88952696|NCT01954433||Operated TMC OA Patients|Patients with trapeziometacarpal (TMC) osteoarthritis who were operated and received a resection interposition suspension arthroplasty of the TMC joint
89485330|NCT03065504|Active Comparator|Turmeric group|"2,000 mg turmeric per day - supplied by Banyan® Botanicals )~o Each tablet contains 500 mg of Turmeric (Curcuma longa). Subjects will take 2 tablets twice per day, with a total daily dose of 2,000 mg."
88952697|NCT01954433||Non-operated TMC OA Patients|TMC OA-patients, indicated for surgical treatment (resection interposition suspension arthroplasty), who decided not to operate
88952698|NCT01954446|Experimental|ContiPress vs. 3M|ContiPress vs. 3M passive and during exercise
88952699|NCT01954446|Experimental|ContiPress vs. Mobil-O-Graph|ContiPress vs. Mobil-O-Graph passive, then oscillometric passive, then oscillometric for 24 hrs every 15 mins.
88952700|NCT01954459|Active Comparator|Sensor alone|Glucose sensor site will not have Insupatch
88952701|NCT01954459|Experimental|Sensor with Insupatch|Glucose sensor site with Insupatch
88952702|NCT01954472|Experimental|Enhanced Portfolio plus structured exercise|Diet: The dietary portfolio advice: to limit saturated fat to <7% of total calories and cholesterol to <200 mg/d) plus inclusion of viscous fibres, soy protein, plant sterols and nuts, 5% extra monounsaturated fat, and selection of low glycemic index foods and will emphasize current recommendations for fruit and vegetable intakes (5-10 servings/d).
88952703|NCT01954472|Active Comparator|High fiber diet plus routine exercise|A diet of whole grain foods (brown rice, whole wheat breads, muffins and breakfast cereals); reduced meat consumption; lower fat dairy foods and a control margarine
88952704|NCT01954485|Experimental|LaserLok abutment|Laser microtexturing dental implant abutment
88952705|NCT01954485|Active Comparator|3inOne abutment|Standard dental implant abutment
88952706|NCT01954498|Experimental|Walnuts|2 ounces whole-shelled walnuts per day for 12 weeks
89485331|NCT03065504|Active Comparator|Turmeric-containing combination tablets|"• 2,000 mg Healthy Skin™ Tablets, contains:~Turmeric (Curcuma longa) - 50 mg/tablet~Hemidesmus Indicus root (Anantamul)~Indian Madder root~Neem leaf~Gotu Kola leaf~Indian TInospora stem~Amla fruit~Licorice root~Phyllanthus Amarus herb Each tablet contains 500mg total of the above herbs. There is 50 mg of Turmeric in each Healthy Skin ™ tablet. Subjects will take 2 tablets twice per day, which will be a total daily dose of 200 mg of Turmeric. This is comparable to the daily amount of Turmeric in many commercially-available Turmeric supplements; therefore, it is valuable to compare this formulation to the turmeric-only tablets."
88952707|NCT01954498|Active Comparator|OTC (over-the-counter) multivitamin|OTC multivitamin tablet 2 per day for 12 weeks
88952708|NCT01954511|No Intervention|Manual therapy|Upper cervical flexion mobilization, C5 central posterior-anterior mobilization, Pressure biofeedback device
88952709|NCT01954537||Professional football players|Offensive and defensive professional football players ranging in age from 22 to 30 years old.
88952710|NCT01954537||Collegiate Football Players|Division III collegiate football players ranging in age from 20 to 23 years old.
88952711|NCT01954537||High School Football Players|High school football players ranging in age from 16 to 18 years old.
88952712|NCT01954563|Experimental|Group 1|Receive 5x10^7 MVA85A by aerosol at day 0, followed by boost intradermal vaccination of 5x10^7 MVA85A at day 28.
89485332|NCT03065504|Placebo Comparator|Placebo tablets group|"Supplement appearing similar to those in the turmeric and curcumin groups, supplied by Banyan® Botanicals~Ingredients (all organic): Placebo ingredients: Rice hulls concentrate, Maltodextrin, Micro Crystalline Cellulose, Beet Root Powder, Dutch coco powder~Dose: subjects in this group will take 2 tablets twice per day"
89485333|NCT02395042|Placebo Comparator|LiRIS Placebo, LiRIS Placebo (Tx 1)/LiRIS® (Tx 2)|Treatment 1 Period (Tx 1): Matching placebo device to the LiRIS inserted into the bladder by cystoscopy on Day 10 and then removed and a second matching placebo device to the LiRIS inserted into the bladder by cystoscopy on Day 14 and removed on Day 28. Treatment 2 Period (Tx 2): optional LiRIS® (continuous release of lidocaine) 400 mg inserted into the bladder by cystoscopy on Day 0 and removed on Day 14.
89485334|NCT02395042|Experimental|LiRIS®, LiRIS® (Tx 1)/LiRIS® (Tx 2)|Treatment 1 Period: LiRIS® (continuous release of lidocaine) 400 mg inserted into the bladder by cystoscopy on Day 0 then removed and a second LiRIS® 400 mg inserted into the bladder on Day 14 and removed on Day 28. Treatment 2 Period: optional LiRIS® (continuous release of lidocaine) 400 mg inserted into the bladder by cystoscopy on Day 0 and then removed on Day 14.
89485335|NCT02395042|Experimental|LiRIS Placebo, LiRIS® (Tx 1)/ LiRIS® (Tx 2)|Treatment 1 Period: Matching placebo device to the LiRIS inserted into the bladder by cystoscopy on Day 0 and then removed and LiRIS® (continuous release of lidocaine) 400 mg inserted into the bladder by cystoscopy on Day 14 then removed on Day 28. Treatment 2 Period: optional LiRIS® 400 mg inserted into the bladder by cystoscopy on Day 0 then removed on Day 14.
89485336|NCT02394808|Experimental|Test Lens 1|senofilcon A (Approved contact lens material)
89485337|NCT02394808|Active Comparator|Test Lens 2|lotrafilcon B (Approved contact lens material)
89485338|NCT02630966|Experimental|Group 1: Vedolizumab IV 300 mg + Placebo|Vedolizumab 300 mg, IV infusion, once, at Weeks 0, 2, 6, 14, and 22, and vedolizumab placebo-matching, IV infusion once, at Week 10 to maintain the blind.
89485339|NCT02630966|Experimental|Group 2: Vedolizumab 300 mg|Vedolizumab 300 mg, IV infusion, once, at Weeks 0, 2, 6, 10, 14, and 22.
89485340|NCT05453942|Experimental|SAR441566|Repeated dose of SAR441566 administered twice a day (BID) for 4 weeks under fed conditions
89485341|NCT05453942|Placebo Comparator|Placebo|Repeated dose of matching placebo administered twice a day (BID) for 4 weeks under fed condition
88952713|NCT01954563|Experimental|Group 2|Receive 5x10^7 MVA85A by intradermal injection at day 0, followed by boost aerosol vaccination of 5x10^7 MVA85A at day 28.
89485342|NCT05446220|Experimental|Diet + physical activity|Dietary advise and advise on physical activity monitored by pedometer
89485343|NCT05446220|Experimental|Physical activity|Advise on physical activity monitored by pedometer
89485344|NCT05446220|No Intervention|Control|No intervention
89485345|NCT05724992|Other|Saliva testing swab|Subjects with familiarity with pancreatic cancer enrolled into the IRFARPC registry (NCT04095195) will be submitted to buccal swab for saliva-based genetic testing
89485346|NCT05724212||Control Group (healthy subject)|
89485347|NCT05724212||Subject with Pulmonary Tuberculosis (PTB)|
89485348|NCT01651780|Experimental|Bivalirudin|Bivalirudin administered as a bolus and intravenous (IV) infusion during TAVR. It was recommended that the bolus (0.75 milligrams per kilogram [mg/kg]) be directly administered through the valve delivery sheath immediately following its successful delivery via percutaneous femoral access. Systemic IV administration of the bolus dose was also acceptable. The bivalirudin IV infusion was initiated immediately after the bolus administration. All wires, catheters, and sheaths were to be flushed with heparinized saline.
88952714|NCT01954563|Experimental|Group 3|Receive 5x10^7 MVA85A by intradermal injection at day 0, followed by boost intradermal vaccination of 5x10^7 MVA85A at day 28.
88952715|NCT01954589|Experimental|ACT-462206 5 mg/Placebo|6 subjects received a single, 5 mg, oral dose of ACT-462206 and 2 subjects received a single, oral dose of placebo
88952716|NCT01954589|Experimental|ACT-462206 25 mg/Placebo|6 subjects received a single, 25 mg, oral dose of ACT-462206 and 2 subjects received a single, oral dose of placebo
88952717|NCT01954589|Experimental|ACT-462206 100mg/Placebo|6 subjects received a single, 100 mg, oral dose of ACT-462206 and 2 subjects received a single, oral dose of placebo
89485349|NCT01651780|Active Comparator|Unfractionated heparin (UFH)|The dose of UFH adhered to the standard institutional practice. An activated clotting time (ACT) target ≥250 seconds was recommended. All wires, catheters, and sheaths were to be flushed with heparinized saline.
89485350|NCT03065426||Roux-en-Y Gastric Bypass|Patients planning to undergo Roux-en-Y Gastric Bypass will be invited to participate in this study.
89485351|NCT03065426||Sleeve Gastrectomy|Patients planning to undergo Sleeve Gastrectomy will be invited to participate in this study.
89485352|NCT05723354|Active Comparator|5ml axillary block group|interfascial plane axillary block group using 5 ml local anesthetics
89485353|NCT05723354|Active Comparator|10ml axillary block group|interfascial plane axillary block group using 10 ml local anesthetics
89485354|NCT02394730|Experimental|vorapaxar|2.5mg of vorapaxar po qd
89485355|NCT02394730|Placebo Comparator|Placebo|sugar pill po qd
89485356|NCT04926610|Experimental|proactive clinical ethics consultation group|
89485357|NCT04926610|No Intervention|routine care group|
89485358|NCT02430532|Experimental|Dimethyl fumarate|BG00012 120 mg (1 BG00012 120 mg capsule + 1 matching placebo capsule) orally twice daily (BID) for 1 week, followed by BG00012 240 mg orally BID thereafter.
89485359|NCT02430532|Experimental|Placebo|BG00012 120 mg capsule orally once a day supplemented with matching placebo capsules for the first 4 weeks of treatment, as an additional blinding measure. Matched placebo capsules only thereafter.
89485360|NCT02394340|Experimental|Luliconazole Cream 1%|Participants will receive 1 oral capsule of omeprazole 40 milligrams (mg) on Day 1 and Day 8. Participants will also receive luliconazole cream 1% to cover the entire affected surface areas and adjacent areas once daily in the morning on Day 2 (24 hours after initial omeprazole dosing) through Day 8.
89485361|NCT01672736|Experimental|ASP7487, Velcade, Dexamethasone|ASP7487 administered orally 75, 100 and 150 mg) BID continuously for each cycle. Bortezomib administered at 1.3 mg/m2 twice weekly for the first 8 21 day cycles and once weekly beyond cycle 9 for 35 day cycles. Dexamethasone is administered on bortezomib administration days at 20 mg
89485362|NCT05337410|Experimental|YES-ERACE|Students participate in the YES-ERACE program.
89485363|NCT05337410|No Intervention|Control|Students participate in the regular after-school programming.
89021657|NCT00437229|Experimental|Subjects in Part B|In PART B, subjects received Regimen D: oral casopitant alone (150 mg QD Day 1, 50 mg QD Days 2 and 3); Regimen E: IV dexamethasone (8 mg single-dose Day 1 only) and oral ondansetron (8 mg BID Days 1 to 3); and Regimen F: oral casopitant regimen as in Regimen D, and IV dexamethasone and oral ondansetron as in Regimen E.
89485364|NCT05686850|Active Comparator|High-Flow Oxygen|Patients assigned to the control group will be continuously treated by high-flow nasal oxygen during the 48 hours following randomization
89485365|NCT05686850|Experimental|NIV alternating with High-Flow Oxygen|Patients assigned to the intervention group will be treated with curative NIV alternating with high-flow nasal oxygen during the 48 hours following randomization
89485366|NCT03065660|Active Comparator|Mifepristone|A single dose of oral mifepristone 200mg, followed by a single dose of vaginal, oral or sublingual misoprostol 800mcg 2 days later
89485367|NCT03065660|Placebo Comparator|Placebo|Oral placebo tablet followed by a single dose of vaginal, oral or sublingual misoprostol 800mcg 2 days later.
89485368|NCT03065348|Experimental|Intervention|"Around 2 to 4 weeks before surgery:~Fried frailty score~CARE score assessment~NRS Kondrup assessment~Plasma albumin and CRP values~Start with daily oral whey protein administration until evening before surgery45~Around 5-7 days before surgery:~- Start with immunonutrition~Evening before surgery:~CARE score assessment~NRS Kondrup~CERAD cognition test assessment~Plasma albumin and CRP values, urine specific gravity~Carbohydrate loading~If urine specific gravity is >1.020 then additional tap water drinking will be encouraged~Day of surgery:~Carbohydrate loading~Start anesthesia with spinal anesthesia (continuous)~POD 7:~CARE assessment~CERAD assessment~Plasma albumin and CRP values~POD14:~CARE assessment~Plasma albumin and CRP value~POD 30:~CARE assessment~NRS Kondrup~CERAD assessment~Plasma albumin and CRP values~POD 90:~CARE assessment~NRS Kondrup~CERAD assessment"
89485369|NCT03065270|Experimental|A group|
89485370|NCT03065270|Experimental|B group|
89485371|NCT03893630|Active Comparator|Control Group|Patients will receive standard of care.
89485372|NCT03893630|Experimental|Acetylsalicylic Acid 81mg|Patients will receive low dose (81mg) acetylsalicylic acid (Aspirin).
89485373|NCT03893630|Experimental|Acetylsalicylic Acid 162mg|Patients will receive low dose (162mg) acetylsalicylic acid (Aspirin).
89485374|NCT03066752||7 pediatric-onset multiple sclerosis|
89485375|NCT03066752||7 non-patient healthy volunteers|
89485376|NCT04879238|Experimental|Yoga-Mindfulness Intervention|Completing single session of yoga blended with mindfulness.
89485377|NCT03066986|Experimental|25mcg JJA venom|Subjects will receive semi-rush JJA VIT (without delta-inulin) aiming to achieve a maintenance dose of JJA venom of 25mcg (dose finding comparison).
89485378|NCT03066986|Experimental|25mcg JJA venom + 5mg delta-inulin|Subjects will receive semi-rush JJA VIT with delta-inulin (at a fixed dose of 5 mg with each dose of venom) aiming to achieve a maintenance dose of JJA venom of 25mcg (dose finding comparison, adjuvant comparison).
89485379|NCT03066986|Active Comparator|50mcg JJA venom|Subjects will receive semi-rush JJA VIT (without delta-inulin) aiming to achieve a maintenance dose of JJA venom of 50mcg, ie. the current standard of care.
89485380|NCT03066986|Experimental|50mcg JJA venom + 5mg delta-inulin|Subjects will receive semi-rush JJA VIT with delta-inulin (at a fixed dose of 5 mg with each dose of venom) aiming to achieve a maintenance dose of JJA venom of 50mcg (adjuvant comparison).
89485381|NCT03065816|Experimental|Sequence 1 (Z0063 to Gaviscon)|The subjects will be given Z0063 single dose and then will crossover to Gaviscon single dose
89485382|NCT03065816|Experimental|Sequence 2 (Gaviscon to Z0063)|The subjects will be given Gaviscon single dose and then will crossover to Z0063 single dose
89485383|NCT05619848|Experimental|Mild fat infiltration|Fat infiltration rate is less than 30%
89485384|NCT05619848|Experimental|Moderate fat infiltration|Fat infiltration rate is 30%~50%
89485385|NCT05619848|Experimental|Server fat infiltration|Fat infiltration rate is greater than 50%
89485386|NCT03066674|Experimental|McKenzie group|This group will receive Hand-on technique on the lumbar spine.
89021658|NCT00335192|Experimental|1|"Phase I: 3TC + TDF + NVP or LPV/rtv~Phase II: patients on treatment with LPV/rtv, stop TDF during 4 weeks: 3TC + LPV/rtv"
89021659|NCT00335192|Experimental|2|"Phase I: ABV + TDF + NVP or LPV/rtv~Phase II: patients on treatment with LPV/rtv, stop TDF during 4 weeks: ABV + LPV/rtv"
89021660|NCT00335192|Experimental|3|"Phase I: 3TC + ABV + TDF + NVP or LPV/rtv~Phase II: patients on treatment with LPV/rtv, stop TDF during 4 weeks: 3TC + ABV + LPV/rtv"
89021661|NCT00437307|Active Comparator|1|Topotecan: 0,75 mg/m²/d, Tage 1-3 und Carboplatin: AUC 5 (after Cockroft and Gault formula) am Tag 3 nach Topotecan, q 21d.
89485387|NCT03066674|Experimental|Control group|The Group will not receive Hand-on technique on the lumbar spine.
89021662|NCT00437307|No Intervention|2|Paclitaxel 175 mg/m2/d, day 1 and Carboplatin: AUC 5 (after Cockroft and Gault formula), day 1, q21d OR gemcitabine 1000 mg/m2/d, day 1 and 8 and Carboplatin AUC 4 (after Cockroft and Gault formula), day 1, q 21d.
89021663|NCT00335231|Experimental|gatifloxacin|one group will receive topical application of gatifloxacin prior to surgery,
89021664|NCT00335231|No Intervention|no eye drops|this group will receive no eye drops.
89021665|NCT00437346|Active Comparator|Group A|Patients is given thorough information based on the tests taken plus medical treatment.
89021666|NCT00437346|Active Comparator|Group B|Patients receive simple written information based on the tests taken plus medical treatment.
89485388|NCT03066362|Experimental|Echocardiography-Doppler|Ultrasonographic recordings, systemic arterial pressure, heart rate, and respiratory rate are recorded immediately before and after volume expansion (VE), performed as a 30-minute infusion of 500 mL of 4% gelatin. Inferior Vena Cava diameters are measured during spontaneous and standardized respiratory cycles. Stroke volume is measured during spontaneous respiratory cycles.
89485389|NCT01560637|Experimental|UT-15C|Open label access
89485390|NCT05268380||Household contact study|Investigation of Covid-19 index cases' households for TB infection and disease, HIV seropositivity, Covid-19 active infection and previous infection.
89485391|NCT05268380||Primary healthcare facility study|Investigation of primary healthcare facility attendees for TB infection and disease, HIV seropositivity, Covid-19 active infection and previous infection.
89485392|NCT02260999||healthy|> 18 years old sufficient language knowledge
89485393|NCT02260999||chronic pain patients|
88952718|NCT01954589|Experimental|ACT-462206 200mg/Almorexant 400mg/Placebo|"Subjects were assigned to one of two possible treatment sequences: A/B or B/A with a washout period of 14 days between treatment periods.~Treatment A: Single oral dose of ACT-462206 200 mg or placebo. Treatment B: Single oral dose of almorexant 400 mg or placebo. In each sequence 6 subjects received ACT-462206 or almorexant & 2 subjects received placebo"
89203909|NCT04048070|Experimental|ERAS with analgesia pump|The patients was given extended perioperative counseling, shorter fasting food for 6 to 8 hours and carbohydrate water for 2 hours before surgery. Early ambulation and oral intake 2 hours after patient recovery from anesthesia. An electronic analgesic pump containing opioids drug and Flubiprofen Axetil in this group for postoperative pain management.
89485394|NCT02260999||patients with injury at the upper etxremity|
89485395|NCT05416567|Experimental|Endovascular embolization|
88952719|NCT01954589|Experimental|Experimental: ACT-462206 400mg/Placebo|6 subjects received a single, 400 mg, oral dose of ACT-462206 and 2 subjects received a single, oral dose of placebo
89485396|NCT04157036|Experimental|800mg Ibuprofen|Subject will take 800mg of Ibuprofen 45 minutes prior to anesthetic delivery.
89485397|NCT04157036|Experimental|40mg Methylprednisolone|Subject will take 40mg of Methylprednisolone 45 minutes prior to anesthetic delivery.
89485398|NCT03547375|Experimental|treatment group|Apatinib 500mg/d po,28 days as one cycle
89485399|NCT01353911|Experimental|Grazoprevir 100 mg|TN non-cirrhotic (NC) participants receive Grazoprevir 100 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.
89485400|NCT01353911|Experimental|Grazoprevir 200 mg|TN NC participants receive Grazoprevir 200 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.
89485401|NCT01353911|Experimental|Grazoprevir 400 mg|TN NC participants receive Grazoprevir 400 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.
89485402|NCT01353911|Experimental|Grazoprevir 800 mg|TN NC participants receive Grazoprevir 800 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.
89485403|NCT01353911|Active Comparator|Boceprevir 800 mg|TN NC participants start a 4 week lead-in with Peg-IFN + RBV, then receive Boceprevir 800 mg + Peg-IFN + RBV for 24 weeks followed by 0 or 20 weeks of Peg-IFN + RBV, based on response guided therapy.
89485404|NCT01353911|Experimental|Grazoprevir 400 mg/100 mg|As the result of an interim analysis, TN NC participants assigned to the 400 mg grazoprevir group were unblinded and transitioned to 100 mg grazoprevir once daily + Peg-IFN + RBV and will remain in the study.
89485405|NCT01353911|Experimental|Grazoprevir 800 mg/100 mg|As the result of an interim analysis, TN NC participants assigned to the 800 mg grazoprevir group were unblinded and transitioned to 100 mg grazoprevir once daily + Peg-IFN + RBV and will remain in the study.
89485406|NCT01353911|Experimental|OL Grazoprevir 100 mg|TN cirrhotic participants receive open-label Grazoprevir 100 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.
88952720|NCT01954589|Experimental|ACT-462206 1000 mg|6 subjects received a single, 1000 mg, oral dose of ACT-462206 and 2 subjects received a single, oral dose of placebo
88952721|NCT01954589|Experimental|ACT-462206 1500mg/Placebo|6 subjects received a single, 1500 mg, oral dose of ACT-462206 and 2 subjects received a single, oral dose of placebo
89485407|NCT05575297|Experimental|Methotrexate|
89485408|NCT05575297|Experimental|Methotrexate + Rifampicin|Methotrexate + Rifampicin
89485409|NCT05575297|Experimental|Methotrexate + Febuxostat|Methotrexate + Febuxostat
89485410|NCT05575297|Experimental|Methotrexate + Rifampicin + Febuxostat|Methotrexate + Rifampicin + Febuxostat
89485411|NCT05575141|Active Comparator|Robotic-assisted repair of wide ventral incisional hernia|Robotic
89485412|NCT05575141|Active Comparator|Open repair of wide ventral incisional hernia|Open
89485413|NCT01671488|Experimental|Treatment|"The first dose will be given 10-14 days prior to the initiation of chemoradiation.~Patient will then receive 5-FU: 1 gm/m2/day x 96 hours beginning on day 1-4 and day 29-32 + 7 days and Mitomycin: 10 mg/m2, day 1 and 29 with IMRT radiation: 54 Gy in 30 fractions at 1.8 Gy per fraction.~The 2-4th dosages of ADXS11-001 will not be until after completion of all chemoradiation. The second dosage of ADXS11-001 will not be administered until a minimum of 10 days after completion of chemoradiation. The subsequent third and fourth treatment with of ADXS11 will be administered at 28 day intervals."
89485414|NCT05574829||Patients under pressure support ventilation|Patients under assisted mechanical ventilation monitored with esophageal manometry and electrical activity of the diaphragm
89485415|NCT02783911|Experimental|Mineral Trioxide Aggregate|Subject with pulpotomy treated with MTA MTA paste (< 1gm) will be placed on pulp orifice once for the life of the primary teeth
89485416|NCT02783911|Experimental|Ferric Sulfate|Subject with pulpotomy treated with FS FS paste (<1gm) will placed on pulp orifice once for 15 secs and removed on primary teeth
89485417|NCT05400889|Experimental|tofacitinib or baricitinib|Tofacitinib 5mg was taken orally once or twice a day and baricitinib 2mg or 4mg was taken orally once a day for 6 months.
89485418|NCT01561807|Experimental|787 low dose|VX-787 low dose capsule, taken orally for 5 days
89485419|NCT01561807|Experimental|787 high dose|VX-787 high dose capsule, taken orally for 5 days
89485420|NCT01561807|Experimental|Placebo low dose|Matching placebo low dose capsule, taken orally for 5 days
89203910|NCT04048070|Experimental|Traditional care with Flubiprofen Axetil|Conventional perioperative counseling and regular fasting food for 12 hours and water for 6 hours before surgery. Lie down and oral intake at least 4 hours after recovery. Once a day 100mg Flubiprofen Axetil in this group for postoperative pain management.
89485421|NCT01561807|Experimental|Placebo high dose|Matching placebo high dose capsule, taken orally for 5 days
88952722|NCT01954602|Active Comparator|Touch group|Sphincterotome assisted guide-wire cannulation
89485422|NCT04870177|Experimental|Advanced gynecological neoplasms|
89485423|NCT05325229|Experimental|Docetaxel combined with Bevacizumab|Docetaxel for Injection (Albumin-bound) will be administrated once every 3 weeks at a dose of 75 mg/m^2 or 100 mg/m^2; Bevacizumab will be administrated once every 3 weeks at a dose of 15mg/kg.
89485424|NCT05573581|Experimental|Botox injection group|Botox injection in anterior belly of digastric before mandibular advancement orthognathic surgery
89485425|NCT05573581|No Intervention|placebo group|no injection before surgery
89485426|NCT01358357|Experimental|Lurasidone 20-80 mg flexible dose|
89485427|NCT01358357|Placebo Comparator|Placebo|
89485428|NCT05573425|Active Comparator|Group on Treatment:Tazarotene Gel|"In group A, patients were instructed to apply a thin film of tazarotene gel 0.1% over the affected area once daily in the evening by placing a pea-sized amount of gel in the palm of the hand and using tip of a finger to cover the entire half of the face. Patients who experienced facial dryness were allowed to use a moisturizing cream during the day on entire face but use of any other medication on the face was prohibited.~Intervention - Tazarotene gel 0.1%"
89485429|NCT05573425|Active Comparator|Group on Treatment:Microneedling|"In group B, microneedling was performed with a standard dermaroller (192 needles of length 1.5 mm) by the same investigator, once per month for 6 months. A topical anesthetic mixture of lignocaine and prilocaine was applied over the face in a thick layer under occlusion 1 hour before the procedure.~Microneedling was performed by rolling the dermaroller with uniform and firm pressure in 4 different directions (i.e, perpendicular and diagonal to each other) with to-and-fro motion up to 8 times (a total of 32 passes) or until the end point of uniform pinpoint bleeding was achieved. After treatment, the area was wetted with saline pads. The participants were instructed to follow strict photoprotective measures including the application of a broad-spectrum sunscreen with sun protection factor 30 over the entire face.~Intervention - Microneedling via dermarolller"
89485430|NCT02253901|Experimental|TRUVADA with BILR 355 BS and ritonavir|
89485431|NCT02253901|Active Comparator|BILR 355 BS in combination with ritonavir|
89485432|NCT03563885|Experimental|RYGB or SG|Baseline testing followed by subject's already scheduled RYGB or SG surgery, and then post-testing.
89485433|NCT03563885|No Intervention|Lean|Lean control subjects doing baseline testing only.
89485434|NCT03546283|Placebo Comparator|Control|The patients with hypertensive intracerebral hemorrhage will be randomized into giving placebo group, the other treatments in this group follow the guidelines on the treatment of hypertensive intracerebral hemorrhage.
89485435|NCT03546283|Experimental|CEGI treatment|The patients with hypertensive intracerebral hemorrhage will be randomized into giving drug CEGI, the other treatments in this group follow the guidelines on the treatment of hypertensive intracerebral hemorrhage.
89485436|NCT03065114||PGSno.|blastocysts from patients underwent preimplantational genetic screen (PGS) prtocols. only euploid embryos were selected to transfer.
89485437|NCT02831387|Experimental|0.017% P-321 Ophthalmic Solution|0.017% P-321 Ophthalmic Solution TID for 28 days.
89485438|NCT02831387|Placebo Comparator|Placebo|P-321 Ophthalmic Solution Placebo TID for 28 days.
89485439|NCT02253511|Experimental|Cidan capsule|Patients who undergone operation and TACE were administered 1.35 g cidan capsules (Weida Pharmaceutical Co., Ltd., Beijing, China) three times a day for 3 months.
89485440|NCT02253511|No Intervention|Control group|Patients were only accepted operation and TACE.
89021667|NCT00437385|Active Comparator|1|Continuation-Medication with Antidepressants (after WBS Guidelines)
89021668|NCT00437385|Experimental|2|Continuation-ECT with Antidepressants
89485441|NCT04948736|Experimental|Combined exercise nutrition intervention group|Customized exercise and nutrition intervention by underlying disease and functional state for 12 weeks during intervention period.
89485442|NCT04948736|Active Comparator|Conventional medial care group|Conventional medical care service for 12weeks during intervention period.
89485443|NCT02253589|No Intervention|Waiting list|Participants will assessment only during study, same intervention after posttest
89485444|NCT02253589|Experimental|Intervention|Participants assigned to this arm will receive the modified ASSIST-linked Brief Intervention
89485445|NCT03563573|Active Comparator|Lidocaine-effective ADHD: Intervention|Single-dose potassium gluconate oral capsule intervention for ADHD subjects for whom lidocaine is effective
89485446|NCT03563573|Placebo Comparator|Lidocaine-effective ADHD: Placebo|Single-dose placebo oral capsule intervention for ADHD subjects for whom lidocaine is effective
89485447|NCT03563573|Active Comparator|Lidocaine-ineffective ADHD: Intervention|Single-dose potassium gluconate oral capsule intervention for ADHD subjects for whom lidocaine is ineffective
89485448|NCT03563573|Placebo Comparator|Lidocaine-ineffective ADHD: placebo|Single-dose placebo oral capsule intervention for ADHD subjects for whom lidocaine is ineffective
89485449|NCT05555719|Experimental|Mandibular Protraction Appliance|the first group that received Mandibular Protraction Appliance
89485450|NCT05555719|Experimental|PowerScope Appliances|the first group that received PowerScope Appliances
89485451|NCT02259881|Experimental|Low dose of BIBT 986 CL|
89021669|NCT00437385|Experimental|3|"Continuation-Psychotherapy (Cognitive Behavioral Group Psychotherapy including the Situational Analysis of CBASP)"
89021670|NCT00335309|Experimental|1|The Investigational arm is treated with sinus irrigation with normal saline 0.9% and intravenous antibiotics of Augmentin 1 gram 3 times a day for 4 days, and then per os (PO) Augmentin 875mg twice a day (BID) for another 10 days. The treatment is done while the patient is admitted to the otolaryngology - head and neck surgery department.
89021671|NCT00335309|Active Comparator|2|The control arm is treated with the same intravenous antibiotics of Augmentin 1 gram 3 times a day for 4 days, and then per os (PO) Augmentin 875mg twice a day (BID) for another 10 days. There is no sinus irrigation with normal saline for this arm. The treatment is done while the patient is admitted to the otolaryngology - head and neck surgery department.
89021672|NCT00437424|Experimental|1|
89485452|NCT02259881|Experimental|Medium dose of BIBT 986 CL|
89485453|NCT02259881|Experimental|High dose of BIBT 986 CL|
89021673|NCT00335348|Experimental|Bortezomib and Dexamethasone|
89021674|NCT00437463|Experimental|1|Ramipril
89021675|NCT00437463|No Intervention|2|
89021676|NCT00420602|Other|Single Arm, Open Label|Single Arm, Open Label
89021677|NCT00437502|Experimental|tumor peptide vaccine|2 cohorts: High and low dose tumor peptide vaccine
89021678|NCT00420680|Experimental|Arm 1|Sugammadex 2.0 mg/kg
89021679|NCT00420680|Experimental|Arm 2|Sugammadex 4.0 mg/kg
89021680|NCT00420680|Placebo Comparator|Arm 3|Placebo
89485454|NCT02259881|Placebo Comparator|Placebo|
89537780|NCT03062475|Experimental|lifestyle intervention group|Pregnant women allocated to this group receive lifestyle intervention. With the dietary intervention we aimed to promote a healthy pattern of eating but not necessarily to restrict energy intake. With respect to advice on physical activity, we focused on incremental increases in walking from a pedometer assessed or encourage them to do moderate cycling.
89537781|NCT03062475|No Intervention|control group|Pregnant women allocated to this group receive standard prenatal care.
89537782|NCT04980963|Experimental|Full Treatment|Steps of the Intervention Condition. Following an in-person session in which a pretest assessment is completed, each member of the intervention group will participate in three face-to-face sessions with the interventionist at the student's campus or at the interventionist's office to complete the CST component of the intervention. Taking into consideration available psychoeducational assessment data, functional assessments from other agencies, and the participant's self-report regarding the functional difficulties that result from his or her ASD-related cognitive impairments, Scherer's (2012) Matching Person and Technology (MPT) protocol will guide the CST assessment. For purposes of the CST component of this intervention, the technological platform for cognitive accommodations will be an iPad II that is provided to each intervention-group participant at no charge (including wireless access if needed). The interventionist will provide training in the use of the iPad if necessary.
89537783|NCT04980963|Active Comparator|Abbreviated Treatment|Steps of the Control Condition. Following an in-person session in which the pretest assessment is completed, each member of the control group will participate in two telephone or Skype sessions with the interventionist to discuss her or his needs for electronic cognitive supports. An abbreviated version of Scherer's (2012) MPT assessment will be administered via telephone or Skype in the first of these virtually-administered sessions. In the second telephone or Skype session, the interventionist will summarize the results of the abbreviated MPT assessment, suggest a variety of cognitive enhancement apps for tablet computers or smart phones that the control group participant can consider.
89537784|NCT03290729|Experimental|narrow ridge|edentulous site with crestal bone width comprised between 3,5 and 5 millimeters wedge shape implants insertion
89537785|NCT04980729|Experimental|the template-guided group|In the template-guided group (n = 10), a navigation template was designed and applied to assist acetabular reconstruction using a modular hemipelvic prosthesis.
89537786|NCT04980729|Active Comparator|the traditional operation group|In the traditional operation group (n = 14), acetabulum was manually reconstructed using a modular hemipelvic prosthesis by the surgeon's experience.
89537787|NCT04980729|Sham Comparator|the validation group|In the validation group (n = 12), patients undergoing periacetabular puncture or curettage without acetabulum reconstruction.
89537788|NCT03294707|Experimental|AG10 single oral dose|AG10 oral tablet, administered by mouth, once
89537789|NCT03294707|Placebo Comparator|Placebo single oral dose|Placebo Oral Tablet, administered by mouth, once
89537790|NCT04973475|Experimental|Experimental: Indocyanine Green Tracer|Indocyanine Green Tracer will be used in laparoscopic distal gastrectomy with lymph node dissection for gastric adenocarcinoma.
89537791|NCT04371809||control subjects|
89537792|NCT04371809||subjects with Atrial Fibrillation|
89537793|NCT04371809||subjects with Acute Coronary Syndrome|
89537794|NCT04371809||subjects with Acute Coronary Syndrome and Atrial Fibrillation|
89537795|NCT03062319|Active Comparator|Dual-therapy group|Dual-therapy group: single anticoagulant drug and single antiplatelet drug. The dosage is determined according to each drug's package insert in Japan. In patients treated with warfarin, the target international normalized ratio (INR) range of 2.0-3.0 for those <70 years and 1.6-2.6 for those =>70 years is recommended according to the Japanese guidelines.
89537796|NCT03062319|Active Comparator|Single-therapy group|Single-therapy group: single anticoagulant drug. The dosage is determined according to each drug's package insert in Japan. In patients treated with warfarin, the target international normalized ratio (INR) range of 2.0-3.0 for those <70 years and 1.6-2.6 for those =>70 years is recommended according to the Japanese guidelines.
88952723|NCT01954602|Experimental|No touch group|Guide-wire cannulation
89021681|NCT04701567||Liver disease|
89021682|NCT04701567||Pancreatic disease|
89021683|NCT00420758|No Intervention|Control|
89021684|NCT00420758|Experimental|LNS|Lipid-based nutrient supplement
89485455|NCT05543239|Active Comparator|TaVNS|Patients will receive TaVNS stimulation for 30 minutes, twice a day (between 9:00 to 10:00 and 15:00 to 16:00), for 7 consecutive days. Stimulation pulses (30 Hz frequency, 300 μs pulse width) were generated by a commercial transcutaneous auricular vagus nerve stimulation unit (tVNS 501，Jiangsu, China), and the amplitude was increased to the maximum amount tolerated by the subject without pain, then stimulate for 30 min. All subjects were told that they may or may not feel any sensation from the stimulation, and the unit is packed in an opaque bag throughout the treatment.
89485456|NCT05543239|Sham Comparator|Sham TaVNS|Patients will receive sham TaVNS stimulation for 30 minutes, twice a day (between 9:00 to 10:00 and 15:00 to 16:00), for 7 consecutive days. Stimulation unit was active for the first 30s, stimulation pulses (30 Hz frequency, 300 μs pulse width) were generated by a commercial transcutaneous auricular vagus nerve stimulation unit (tVNS 501，Jiangsu, China).Then dropped to zero stimulation during 15s and shut down. All subjects were told that they may or may not feel any sensation from the stimulation, and the unit is packed in an opaque bag throughout the treatment.
89485457|NCT05708261|Experimental|MR Intervention|Grounded in Social Cognitive Theory, the intervention delivers five 2-hour sessions with 3 post-session group check-in's to develop skills in partnership communication, HIV disclosure and prevention. The intervention utilizes self-assessments on skills learned and then action plan for these developed and then finalized in the last session.
89485458|NCT05708261|Other|Be Well|Attention match control arm. Participants will receive standard of care for HIV treatment and one-way SMS with video content about general health. This will occur once per week during the first 5 weeks after enrollment.
89485459|NCT04132778|Experimental|Intervention - Asthmatuner|Asthmatuner (Medituner AB, Stockholm, Sweden) is a CE-marked cloud-computing-based system with a healthcare interface and a downloadable patient app (Android or iOS).The intended use of Asthmatuner is to automate asthma self-management by letting patients register symptoms and measure forced expiratory volume in one second (FEV1) with a Bluetooth spirometer (MIR, SmartOne). The patient then receives immediate feedback on the status of symptom control (controlled, partly controlled or uncontrolled), and a treatment recommendation, with an image of the correct inhaler or other type of medication and the dose. Symptom control is quantified based on lung function; litre to percentage of personalised best FEV1, using a cut-off ≤80% and symptoms during the last week based on four questions: 1) need for rescue medication more than twice due to asthma symptoms, 2) any daytime symptoms, 3) nocturnal symptoms/awakenings, and 4) limitation in physical activities.
89485460|NCT04132778|No Intervention|Control group - Traditional asthma management|Traditional self-management is defined as all other types of non-digital asthma management. This could be treatment plan written on paper or by oral communication to patient/caregiver on asthma treatment.
89485461|NCT03563807|Experimental|Golf|Group golf lessons will be led by professional golf instructors.
89485462|NCT03563807|Active Comparator|Tai Chi|Group Tai Chi classes led by a certified Tai Chi instructor.
89485463|NCT03547219|Experimental|Escitalopram|Participants with depression were treated with escitalopram(ranging from 5mg to 30mg) for 8 weeks. Escitalopram was initiated at 5mg for 1 week, followed by an increase to 10mg at week 2. After week 2, doses of escitalopram were titrated according to symptoms and adverse effects. Specific, indicated psychotherapy for depression was not allowed during the study.
89485464|NCT05269069||Patients with rheumatoid arthritis|
89485465|NCT05269069||Control group|
89485466|NCT05265091|Experimental|KL590586|Multiple doses of KL590586 capsule
89485467|NCT03064880|Active Comparator|SV maximization|Dynamic fluid responsiveness parameters, such as stroke volume (SV) response to fluid therapy, are precise fluid indicators that specifically determine patient volume status and are helpful for clinicians to determine the appropriate time for fluid bolus. For SV maximization, the investigators maximize SV after anesthetic induction by fluid therapy up to achieve maximized SV maintained.
89485468|NCT03064880|No Intervention|SV normalization|NO active fluid therapy.
89485469|NCT05518201|Experimental|The 9vHPV Recombinant Vaccine among 18-45yrs|Subjects received 3 doses of 9-valent HPV vaccine according to a 0, 2, 6-month schedule (0.5mL/each dose).
89485470|NCT05518201|Experimental|The 9vHPV Recombinant Vaccine among 9-17 yrs|Subjects received 3 doses of 9-valent HPV vaccine according to a 0, 2, 6-month schedule (0.5mL/each dose).
89485471|NCT03064802||BioBurst Fluid, Burst Allograft|Spinal Fusion with BioBurst Fluid or Burst Allograft
89485472|NCT02253667|Experimental|HFONC|Patient will use HFONC with FiO2 enough to achieve SpO2>90%. If needed, morphine is titrated to reduce a patient's dyspnoea score by at least one point on the Borg scale and to achieve at least level 5 or less. Initial dose: 10 mg, repeated every 4h until the desired reduction in dyspnoea is obtained. In the case of refractory dyspnoea, the dose is increased by 50%.
89485473|NCT02253667|Other|Conventional oxygen|Patient will use venturi or reservoir mask with FiO2 enough to achieve SpO2>90%. If needed, morphine is titrated to reduce a patient's dyspnoea score by at least one point on the Borg scale and to achieve at least level 5 or less. Initial dose: 10 mg, repeated every 4h until the desired reduction in dyspnoea is obtained. In the case of refractory dyspnoea, the dose is increased by 50%.
88952724|NCT01954615|Experimental|Group A 5 mg ACT-281959 prodrug formulation I/placebo|6 subjects to receive a single, oral dose of 5 mg ACT-281959 prodrug formulation I and 2 subjects to receive a single, oral dose of matching placebo. Medication to be administered in the fasted state.
89485474|NCT03065036|Experimental|Hydrus Aqueous Implant|Hydrus implanted into Schlemm's Canal.
89485475|NCT03065036|Other|IOL placement and Hydrus implant|Cataract Extraction with IOL placement and Hydrus implant into Schlemm's canal
89485476|NCT04069819|Placebo Comparator|Control group|Escitalopram 20 mg tablet once daily for 6 week plus placebo tablet twice daily for 6 weeks
89485477|NCT04069819|Experimental|Cilostazol group|Escitalopram 20 mg tablet once daily for 6 week plus Cilostazol 50mg tablet twice daily for 6 weeks
89485478|NCT03064646|Experimental|Organ Preservation|The experimental strategy is the omission of radical surgery if complete or almost complete response after neoadjuvant treatment for locally advanced rectal cancer
89485479|NCT03545815|Experimental|anti-mesothelin CAR-T cells|"Patients receive mesothelin-directed CAR-T cells infusion with dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de- escalation.~Patients receive anti-mesothelin-CAR T cells on day 0."
89485480|NCT03064724|Experimental|Smoking Cessation Group|Patients received the interactive mobile doctor (iMD) intervention.
89485481|NCT04102514|Other|Real-time Group Video|
89485482|NCT04102514|Other|Enhanced Usual Care|
89485483|NCT02831855|Experimental|CP-690,550 and methotrexate|Open-label tofacitinib tablet and blinded methotrexate capsule
89485484|NCT02831855|Placebo Comparator|CP-690,550 and placebo|open-label tofacitinib tablet and blinded matching placebo for methotrexate capsule
89485485|NCT05167448|Experimental|Cohort 1 Phase 1|
89485486|NCT05167448|Experimental|Cohort 2 Phase 1|
89485487|NCT05167448|Experimental|RP2D Phase 2|
89485488|NCT02628938|Experimental|Miswak extract mouth wash|50% mouthwash aqueous solution 5ml twice a day for 7 days
89485489|NCT02628938|Experimental|Miswak sticks|Sticks twice a day for 7 days
89485490|NCT02628938|Active Comparator|Chlorohexidine gluconate mouth wash|0.2% mouth wash aqueous solution (Oraxine ®) 5 ml twice a day for 7 days
89485491|NCT04904510||Sample Collection|People routinely testing for COVID-19 would have an extra sample collected to assess the diagnostic device.
89485492|NCT01356407|Experimental|PICOPREP|"Split Dose method and consists of two separate doses: the first dose during the evening before the colonoscopy and the second dose the next day before the colonoscopy."
88952725|NCT01954615|Experimental|Group B 20 mg ACT-281959 prodrug formulation I/placebo|6 subjects to receive a single, oral dose of 20 mg ACT-281959 prodrug formulation I and 2 subjects to receive a single, oral dose of matching placebo. Medication to be administered in the fasted state.
88952726|NCT01954615|Experimental|Group C ACT-281959 prodrug formulation I/placebo|Group C: 6 subjects to receive a single, oral dose of ACT-281959 prodrug formulation I and 2 subjects to receive a single, oral dose of matching placebo. Medication to be administered in the fasted state. Dose selection will be based on pharmacokinetic data derived from Groups A-B.
88952727|NCT01954615|Experimental|Group D ACT-281959 prodrug formulation I/placebo|6 subjects to receive a single, oral dose of ACT-281959 prodrug formulation I and 2 subjects to receive a single, oral dose of matching placebo. Medication to be administered in the fasted state. Dose selection will be based on pharmacokinetic data derived from Groups A-C.
88952728|NCT01954615|Experimental|Group E ACT-281959 prodrug formulation I/placebo|6 subjects to receive a single, oral dose of ACT-281959 prodrug formulation I and 2 subjects to receive a single, oral dose of matching placebo. Medication to be administered in the fasted state. Dose selection will be based on pharmacokinetic data derived from Groups A-D.
88952729|NCT01954615|Experimental|Group F ACT-281959 prodrug formulation I/placebo|Food effect dose group: 6 subjects to receive a single, oral dose ACT-281959 prodrug formulation I and 2 subjects to receive a single, oral dose of matching placebo. Medication to be administered in the fasted state. Following a 7-10 day washout period, subjects will receive the identical treatments administered in the first period. Medication to be administered in the fed state. Dose selection will be based on pharmacokinetic data derived from Groups A-E.
89021685|NCT00420758|Experimental|CSB|Corn-soy blend supplement
89021686|NCT00437619|Experimental|1|
89021687|NCT00437736|Experimental|Single arm dose escalation|
89021688|NCT00437892|Experimental|Atorvastatin and lipid lowering diet|
89021689|NCT00437892|Active Comparator|lipid lowering diet|
89021690|NCT00437931||A|patients with subclinical hypothyroidism
89485493|NCT01356407|Active Comparator|PEG-ELS|PEG-ELS was used according to the approved labeled dosage and administration instructions. Only received one dose of 2 boxes (6 packets), administrated on the day of colonoscopy examination.
89485494|NCT05708027|Experimental|AtriCure|Group of patients to whom was applied AtriCure device during thoracoscopic ablation.
89485495|NCT05708027|Active Comparator|Medtronic|Group of patients to whom was applied Medtronic device during thoracoscopic ablation.
89485496|NCT05228717||COVID+|"Patients with confirmed COVID-19 pneumonia as the primary diagnosis, or COVID-associated acute hypoxemic respiratory failure or hypoxia (minimum O2 requirement 3L), that are being admitted from the emergency department, who either have waiver of consent, give verbal consent to participate, or have NOK (next of kin) provide consent.~Exclusion criteria: age <18 years old, pregnant patients, or patients that verbally refuse participation Intervention/observation: q48-72h POCUS of the lungs, heart, and IVC"
89485497|NCT03563495|Active Comparator|tissue engineered group|autogenous bone marrow derived and cultured stem cells loaded on collagen matrix was implanted in the alveolar cleft in the study group (1st arm)
89485498|NCT03563495|Active Comparator|autogenous bone graft group|autogenous cortico-cancellous bone graft harvested from the anterior iliac crest was implanted in the alveolar cleft of the control group (2nd arm)
89485499|NCT00109837|Experimental|Induc x2, Consol, Maint|Induc 1: Allopurinol; Daunorubicin; Vincristine; Prednisone; asparaginase; Bactrim Induc 2: Allopurinol; cytarabine; Dexamethasone; filgrastim; mitoxantrone; Methotrexate; leucovorin Consol: Cyclophosphamide; cytarabine; 6-mercaptopurine; Methotrexate; filgrastim Maint:Course 1: 6-mercaptopurine; Methotrexate Course 2: Vincristine; doxorubicin; Dexamethasone Course 3: Cyclophosphamidee; thioguanine; cytarabine Course 4: 6-mercaptopurine; methotrexate
89485500|NCT03547141|Experimental|botulinum toxin 1U|
89485501|NCT03547141|Experimental|botulinum toxin 5U|
89485502|NCT03547141|Experimental|botulinum toxin 15U|
89485503|NCT03547141|Experimental|botulinum toxin 30U|
89485504|NCT02253979|Placebo Comparator|standard double lumen tube|Intervention: Standard double lumen tube
89485505|NCT02253979|Experimental|VivaSight double lumen tube|Intervention: VivaSight double lumen tube
89485506|NCT05229445|Experimental|CGM insulin bolus calculator arm|All participants will receive the CGM insulin bolus calculator
89485507|NCT02828111|Experimental|Patidegib gel 2% - Cohort 1|Patidegib gel 2%, applied topically, once daily for 12 weeks (Cohort 1)
89485508|NCT02828111|Experimental|Patidegib gel 4% - Cohort 2|Patidegib gel 4%, applied topically, once daily for 12 weeks (Cohort 2)
88952730|NCT01954615|Experimental|Group G ACT-281959 prodrug formulation I & II/ACT-246475|9 subjects to receive a single, oral dose of ACT-281959 prodrug formulation I (Treatment A), a single, oral dose of ACT-281959 prodrug formulation II (Treatment B), and a single, oral dose of ACT-246475 (Treatment C). Subjects will be equally randomized to one of 3 treatment sequences: ABC, BCA, and CAB. Treatments will be separated by 7-10 day washout periods. Medication to be administered in the fasted state. Data from Groups A-E will be used for pharmacometric modeling to guide the selection of doses to be used in Group G.
89485509|NCT02828111|Placebo Comparator|Vehicle gel - Cohort 1|Vehicle gel, applied topically, once daily for 12 weeks (Cohort 1)
89485510|NCT02828111|Experimental|Patidegib gel 2% - Cohort 3|Patidegib gel 2%, applied topically, twice daily for 12 weeks (Cohort 3)
89485511|NCT02828111|Experimental|Patidegib gel 4% - Cohort 4|Patidegib gel 4%, applied topically, twice daily for 12 weeks (Cohort 4)
89485512|NCT02828111|Placebo Comparator|Vehicle gel - Cohort 2|Vehicle gel, applied topically, once daily for 12 weeks (Cohort 2)
89485513|NCT02828111|Placebo Comparator|Vehicle gel - Cohort 3|Vehicle gel, applied topically, twice daily for 12 weeks (Cohort 3)
89485514|NCT02828111|Placebo Comparator|Vehicle gel - Cohort 4|Vehicle gel, applied topically, twice daily for 12 weeks (Cohort 4)
89485515|NCT03825653||one group|"This study will be carried out on three hundred postmenopausal.They will be selected from gynecological outpatient clinic of (Oum El Masryn Hospital).~their age will range from 60-70 years.Their BMI will not exceed 30 kg/m2. They are complaining from stress urinary incontinence."
89485516|NCT04013945|Active Comparator|Superba Boost capsules|1000 mg krill oil concentrate per capsule
89485517|NCT04013945|Placebo Comparator|Placebo capsules|1000 mg capsule composed of mixed vegetable oil.
89485518|NCT01671332|Active Comparator|Docetaxel|
89485519|NCT01671332|Experimental|Docetaxel plus Suramin|
89485520|NCT04432766|Experimental|Low dose|
89485521|NCT04432766|Experimental|Medium dose|
89485522|NCT04432766|Experimental|High dose|
89485523|NCT04856930|Experimental|ANB019 Biological Humanized Monoclonal Antibody Low Dose|
88952731|NCT01954641|Experimental|ACCURE Navigator|For those patients assigned to the ACCURE Navigator, the ACCURE Real-Time Registry is programmed to automatically alert the Navigator when a patient misses a scheduled treatment appointment and to require the Navigator to include details as to how she addressed and resolved that missed appointment, ensuring the ACCURE Navigator's proactive approach to addressing such issues. In addition, a warning message will be produced if no follow-up appointments or procedures are scheduled within 21 days of the index visit.
88952732|NCT01954641|Active Comparator|Usual Care by Cancer Center Care Team|A list of registry warnings about all patients enrolled in the study will be delivered securely to a designated representative at the clinic.
88952733|NCT01954654|Experimental|Accelerated treatment|
88952734|NCT01954654|Active Comparator|Standard treatment|
89485524|NCT04856930|Experimental|ANB019 Biological Humanized Monoclonal Antibody High Dose|
89485525|NCT04856930|Placebo Comparator|Placebo Solution|
89485526|NCT05093270|Experimental|Part A Dose Escalation (Single Ascending Dose)|Up to 5 dose levels of BGB-23339 or Placebo
89485527|NCT05093270|Experimental|Part B Dose Escalation (Multiple Ascending Dose)|Up to 4 dose levels of BGB-23339 or placebo based on data collected in Part A
89485528|NCT05093270|Experimental|Part C Dose Escalation (Multiple Ascending Dose in Chinese Subjects Sub-study)|Up to 2 dose levels of BGB-23339 or placebo based on data collected in Part A and B (conducted in China only)
89485529|NCT05093270|Experimental|Part D (Food-Effect Study)|Three single dose levels of BGB-23339 under different feeding conditions
89485530|NCT03063242|Experimental|Project I: Healthy participants|5 healthy participants will be used to optimize the dosage and timing of sargramostim administration with regard to the primary and secondary outcomes. Blood samples will be drawn and analyzed for mDC levels.
89485531|NCT03063242|Experimental|Project II: Patients with CKD stage IV/V|5 Patients with CKD stage IV/V who are cytomegalovirus (CMV) seropositive with mean blood mDC levels <1.0x104/mL will receive sargramostim treatment once all 5 healthy participants have completed treatment and the data have been analyzed to guide subsequent dosing. Blood samples will be drawn and analyzed for mDC levels.
89485532|NCT03063242|Experimental|Project III: kidney transplant patients|5 Kidney transplant recipients who are CMV seropositive with neutropenia (defined as absolute neutrophil count <1.0 x103/mm3) and/or CMV viremia will receive sargramostim treatment once all 5 Project I participants have completed treatment and the data have been analyzed to guide subsequent dosing. Blood samples will be drawn and analyzed for mDC levels.
89485533|NCT03062852|Experimental|Medication safety vest|During administration rounds, nurses will wear the medication safety vest.
89485534|NCT03062852|No Intervention|Control|During administration rounds, nurses will be dressed as usual without a safety vest.
89485535|NCT03063008|Other|Lumbar fusion with PEEK cage|Control arm
89485536|NCT03063008|Other|Lumbar fusion with TiPEEK cage|Study arm
89485537|NCT03897062|Active Comparator|Treatment group|Patients (n=64): 20mg tablets of suvorexant nocte daily for six months
89485538|NCT03897062|Placebo Comparator|Placebo group|Placebo control group: Patients (n=64): 1 placebo tablet nocte daily for six months in addition to treatment as usual
89485539|NCT01355627|Experimental|TachoSil®|
89485540|NCT01355627|Active Comparator|Current practice group|
89485541|NCT04740710|Active Comparator|Standard Breathing and Attention Training|The standard breathing and attention training (BAT) includes guided instructions on deep breathing and relaxation. Participants will practice standard BAT once a day for 15 minutes for 5 days in a row.
89485542|NCT04740710|Experimental|Focused Breathing and Attention Training|The focused BAT is similar to the standard BAT in most ways but includes extra instructions to help focus and alter breathing patterns. Participants will practice focused BAT once a day for 15 minutes for 5 days in a row.
89485543|NCT03563105|Experimental|Desaturation|Vascular Occlusion Test
89485544|NCT05085041|Experimental|Intervention Group|"The participants in this group will receive 8 sessions of a multi-component online education intervention. The education curriculum will be focused on addressing evidence-based healthy habits that are related to preventing childhood obesity: more vegetables and fruits, less screen time, and more physical activity. Topics may include age-appropriate nutrition and eating, picky eating, positive parental feeding practices, active playtime, and screen time. Strategies for eating healthy on a budget will be also provided to the participants.~The intervention will incorporate multi-component as follow: instructional YouTube videos, online cooking activities, reminder text messages with key information, and telephone consultation. Each session will include a lifestyle component regarding eating, feeding, and physical activity, aimed at equipping parents with knowledge and skills to improve fruit and vegetable intake and physical activity levels of young children."
89485545|NCT05085041|No Intervention|Control Group|The participants in the control group will receive no intervention. However, the investigators will provide the control group with a copy of the booklet that includes 2020 USDA dietary guidelines for a healthy diet for young children. This will enable the investigators to see if the multi-component education intervention (stated above) is more effective on behavior changes than the written booklet in the control group.
89485546|NCT05006183|Experimental|iFR-guided|One-stage, virtually planned, iFR-guided and optimized PCI.
89485547|NCT05006183|Active Comparator|Angiography-guided|Standard practice staged angiography-guided PCI
89485548|NCT03836768|Experimental|Experimental Treatment|DTRMWXHS-12, oral capsule, daily, 28 days as a cycle
89485549|NCT03830255||Renal Transplant patients treated with cyclosporine|Detecting the genetic polymorphism affecting cyclosporine level
89485550|NCT03830255||Renal Transplant patients treated with tacrolimus|Detecting the genetic polymorphism affecting tacrolimus level
89485551|NCT04954547|Experimental|Subsidy Arm|Participants in the arm will receive $$50 if they reach the PBF goal and will be subsidized on approved health-improving expenses.
89485552|NCT04954547|Experimental|Cash Arm|Participants in the arm will receive S$350 if they reach the PBF goal.
89485553|NCT04954547|No Intervention|Control|Other than the participation fees, no additional incentives will be provided.
89485554|NCT02673749|Experimental|RP-G28 Dose 1|
89485555|NCT02673749|Experimental|RP-G28 Dose 2|
89485556|NCT02673749|Placebo Comparator|Placebo|
89485557|NCT00100802|Experimental|Treatment (lomustine, temozolomide, radiation therapy)|Patients receive oral temozolomide once daily on days 1-42. Patients also undergo concurrent radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, 29-33 and 36-40. Patients who did not undergo prior gross total resection also undergo boost radiotherapy once daily on days 43-47. Four weeks after completion of chemoradiotherapy, patients receive oral temozolomide once daily on days 1-5 and oral lomustine on day 1. Treatment repeats every 42 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
89485558|NCT01355159|Experimental|Folic Acid 4 mg|Folic Acid 1.0 mg x 4 tablets will be taken daily by oral administration. The majority of women in the study will routinely take 1.0 mg folic acid in a prenatal vitamin supplement, as recommended by their primary obstetrical provider; the study requirements do not require that participants change their practice. Therefore the actual total daily dose may be up to 5.1 mg of folic acid
89485559|NCT01355159|Placebo Comparator|Placebo|Women will be randomised in a 1:1 ratio to folic acid 4.0 mg or placebo
89485560|NCT03064334||one medium of focus groups|"The present study aims to understand patient experiences and outcomes post- Total Knee Arthroplasty(TKA). Therefore, a qualitative approach will be most appropriate to facilitate the collection of in-depth experiences and perceptions of patients post-TKA.~The medium of focus groups (with 8-10 patients) is preferred to allow a group of patients to share their perceptions and experiences post-surgery, with sufficient quantity and diversity of views while balancing the facilitator's ability to manage all patients' participation for 90-120 minutes (Bloor, 2006)."
89485561|NCT03747380|Experimental|inspiratory muscle program|Inspiratory muscle training preoperative with standard of care
89485562|NCT03747380|Other|no inspiratory muscle program|standard of care: postoperative spirometry with enhanced recovery program in thoracic surgery
89485563|NCT04763837|Experimental|Intraureteral stent group|Patients assigned to this group will undergo placement of an intraureteral stent, a tube that drains urine from the kidney to the bladder and has a loop of tube in only in the kidney and NOT in the bladder. This group will be the experimental group.
89485564|NCT04763837|Active Comparator|Conventional Double-J stent|Patients assigned to this group will undergo placement of a double-J ureteral stent, a tube that drains urine from the kidney to the bladder and has a loop of tube in both the kidney and the bladder. This group will serve as the control.
89485565|NCT04661852|Experimental|CABOZANTINIB WITH TOPOTECAN-CYCLOPHOSPHAMIDE|"Participants will be accrued to dose levels in cohorts of 3 using the 3 + 3 design with a combination of cabozantinib, topotecan and cyclophosphamide.~Each study treatment cycle lasts 21 days.~Participants may receive up to 17 cycles.~Participants will be assigned a specific dose and schedule of the study drugs determined when enrolled in the study."
89485566|NCT03562949|Experimental|Test Product|Test Product, 40 mcg, 2 x daily
89485567|NCT03562949|Active Comparator|Reference Product|Reference Product, 40 mcg, 2 x daily
89485568|NCT03562949|Placebo Comparator|Placebo|Placebo Product 2 x daily
89485569|NCT02630186|Experimental|Single Arm Rociletinib and MPDL3280A|Specific doses of rociletinib, taken continuously BID, will be administered in combination with a fixed dose of MPDL3280A, given intravenously on Day 1 of each 21-day cycle.
89485570|NCT01669928|Active Comparator|Evening medication|Anti hypertensive medication in the evening (between 18.00 and 23.00)
89485571|NCT01669928|Active Comparator|Morning medication|Antihypertensive medication in the morning(between 06.00 and 11.00)
89485572|NCT00510848|Experimental|1|Reconstruction with an autograft tendon (hamstrings)
89485573|NCT00510848|Experimental|2|Reconstruction with an allograft tendon (tibialis posterior)
89485574|NCT01355081|Experimental|Vortioxetine 5 mg|Vortioxetine 5 mg, tablets, orally, once daily for up to 8 weeks.
88952735|NCT01954667||obese and overweight|Group1 (n=30): overweight and obese (BMI ≥25 and/ or WHtR≥0.5)
89485575|NCT01355081|Experimental|Vortioxetine 10 mg|Vortioxetine 10 mg, tablets, orally, once daily for up to 8 weeks.
89485576|NCT01355081|Placebo Comparator|Placebo|Vortioxetine placebo-matching tablets, orally, once daily for up to 8 weeks.
89485577|NCT04606823|Other|Single-arm|In this single-arm study the patients will be undergoing a minimally invasive surgery after which they will re-visit the clinic at five occasions for follow-up visits (1-3 extra compared to routine clinical practice at the hospitals) and complete a quality of life-questinnaire three months after surgery.
89485578|NCT02259959|Experimental|BI 1744 CL in combination with Tiotropium|
89485579|NCT02259959|Placebo Comparator|Placebo|
89485580|NCT01354223|Experimental|stenfilcon A contact lens|Randomized to stenfilcon A contact lens worn in a daily wear, daily disposable mode
89485581|NCT01354223|Active Comparator|ocufilcon B contact lens|Randomized to ocufilcon B contact lens worn in a daily wear, daily disposable mode
89485582|NCT03062462|Active Comparator|clopidogrel|To observe double standard-dose clopidogrel on platelet aggregation in clopidogrel resistance's patients with coronary heart disease
89485583|NCT03062462|Experimental|ticagrelor|To observe low-dose of ticagrelor on platelet aggregation in clopidogrel resistance's patients with coronary heart disease
89485584|NCT03562715||Control group|Blood samples were collected from 100 control with normal pregnancies. Thirty fresh umbilical cord samples of women with healthy pregnancies (n=15) were retrieved during caesarean deliveries and umibilical cord mesenchymal stem cells (UCMSCs) were isolated from Wharton jelly.
89485585|NCT03562715||Preeclampsia group|Blood samples were collected from 100 patients with PE. Thirty fresh umbilical cord samples of PE patients (n=15) were retrieved during caesarean deliveries and UCMSCs were isolated from Wharton jelly.
89485586|NCT04542239||Infants with GER|Infants (N=25) meeting inclusion/exclusion criteria
89485587|NCT04542239||Controls without GER|Infants (N=10) meeting inclusion/exclusion criteria, but no GER
89485588|NCT04433078|Experimental|Doxycycline|Participants receive 100 MG BID for 21 days
89485589|NCT04433078|Placebo Comparator|Placebo|Participants receive Placebo BID for 21 days
89485590|NCT04591730||Type I maternity|Fathers who experienced a first childbirth in a type I maternity in Lorraine.
89021691|NCT00437931||B|patients with subclinical hyperthyroidism
89485591|NCT04591730||Type II maternity|Fathers who experienced a first childbirth in a type II maternity in Lorraine.
88952736|NCT01954667||average body weight|Group2 (n=30): normal weight (BMI ≥ 18 to < 25 and/or WHtR ≥0.4 to <0.5)
88952737|NCT01954667||Control group|Control Group (n= 20): healthy subjects, matched for age and gender, were included in this study. All included controls had average weight (BMI ≥ 18 to < 25 and/ or WHtR ≥0.4 to <0.5)
89021692|NCT00437931||C|patient with normal thyroid function.
89021693|NCT00437970|Active Comparator|A|Arm A- Metformin
89485592|NCT04591730||Type III maternity|Fathers who experienced a first childbirth in a type III maternity in Lorraine.
89485593|NCT03062930|Active Comparator|Track 1|Training of non-paretic arm for 3 weeks consisting of occupational therapy and kinematic tasks followed by sham condition (playing board games/computer games) for 3 weeks
89485594|NCT03062930|Sham Comparator|Track 2|Sham condition (playing board games/computer games) for 3 weeks followed by training of the non-paretic arm for 3 weeks consisting of occupational therapy and kinematic tasks
89485595|NCT04458311|Experimental|Phase I|Increasing doses of tildrakizumab in combination with a fixed dose of abiraterone to establish the recommended phase II dose in patients with metastatic castration resistant prostate cancer..
89485596|NCT04458311|Experimental|Phase II|The Phase II part of the study will evaluate the recommended phase II dose identified in Phase I of the study in patients with metastatic castration resistant prostate cancer.
89485597|NCT04982432|Experimental|Orismilast|Orismilast tablet, oral administration, multiple titrated doses twice daily, 10 mg up to 40 mg, morning and evening, 16 weeks treatment.
89485598|NCT04382183|Experimental|Ketogenic weight loss maintenance diet|The ketogenic weight loss maintenance group will undergo in a ketogenic diet (50 g CHO/day) plant-based for 1 year.
89485599|NCT04382183|Experimental|Isocaloric balanced weight loss maintenance diet|The isocaloric balanced weight loss maintenance group will undergo in a diet following the standard Norwegian Health Directorate recommendations for 1 year.
89485600|NCT03062774|Experimental|PB-119|intervention: PB-119 injection
89485601|NCT03064100||Specimens that meet inclusion criteria|
89021694|NCT00437970|Active Comparator|B|Arm B- Pioglitazone
89485602|NCT04368533|Experimental|Livionex Dental Gel|Children assigned to this arm will brush/clean teeth with Livionex Dental Gel twice a day for up to 12 months.They will undergo a dental exam by a trained dentist including caries assessment (at baseline, 1, 3, 6, 9 or 12 months), dental plaque photograph, (at baseline, 1, 3, 6 and 9 or 12 months), and swab samples for dental plaque and saliva will be collected at all study visits. A questionnaire will be given to address dentifrice and brushing experience. Data on compliance and side-effects of toothpastes will be collected at each of the calls.
89485603|NCT04368533|Active Comparator|A standard children's toothpaste containing 1500 ppm fluoride|Children assigned to this arm will brush/clean teeth with a standard children's toothpaste containing 1500 ppm fluoride twice a day for up to 12 months. They will undergo a dental exam by a trained dentist including caries assessment (at baseline, 1, 3, 6, 9 or 12 months), dental plaque photograph, (at baseline, 1, 3, 6, 9 or 12 months), and swab samples for dental plaque and saliva will be collected at all study visits. A questionnaire will be given to address dentifrice and brushing experience at each study visit. A monthly phone call will be made to assess compliance with the study protocol, and to answer any questions or concerns. Data on compliance and side-effects of toothpastes will be collected at each of the calls.
89485604|NCT03062696|Experimental|Intervention (CBT-RD)|There is only one arm in this study - all participants will be in the same arm, as all participants will receive CBT-RD. There is no control group.
89485605|NCT03820349||Cystic Fibrosis|Subjects with cystic fibrosis
89485606|NCT03820349||controls|matched healthy controls
89485607|NCT04043455|Experimental|Olorinab low dose (Main Study)|
89485608|NCT04043455|Experimental|Olorinab medium dose (Main Study)|
89485609|NCT04043455|Experimental|Olorinab high dose (Main Study)|
89485610|NCT04043455|Placebo Comparator|Placebo (Main Study)|
89485611|NCT04043455|Experimental|Olorinab (Long-Term Extension)|Participants will receive olorinab based on their treatment assignment in the Main Study.
89485612|NCT04365959||covid-19 pneumonia related patients|This study will be conducted on all patients admitted to the Infectious Diseases and UTIR units of the S. Gerardo Hospital in Monza with the diagnosis of related COVID pneumonia requiring oxygen support or CPAP.
89485613|NCT03064256|Experimental|Physical training program|"Intervention participants are submitted to supervised aerobic physical training at the predetermined intensity, which is composed of three weekly sessions, lasting one hour, over a period of 12 weeks.~All sessions were started with stretches for lower and upper limbs lasting 10 minutes for warm-up, and after trekking on treadmill using the predetermined critical velocity (Vcrit). The exercises were completed with cooling of the muscle groups for one minute still on the treadmill, plus 10 minutes of relaxation exercises on the mat at the end of aerobic exercise."
89485614|NCT03064256|No Intervention|Control Group|Control participants receive routine outpatient care for a 12-week period.
89485615|NCT03064022||Size < the 3rd or 10th percentiles|Infant size smaller than the 3rd or 10th percentiles relative to the Fenton growth chart for weight or head circumference at discharge from neonatal intensive care
89485616|NCT03064022||Rapid early growth|Rapid early growth will be defined as exceeding birthweight in the first week of life
89485617|NCT03064022||Growth velocity calculation methods|We will compare a variety of growth velocity calculation methods used in clinical care and research to compare and assess growth velocity calculation methods
89485618|NCT03064022||Size for gestational age|Small size for gestational age
89485619|NCT05126407||Olynth Nasal Saline Drops/Spray and Olynth Ectomed Nasal Spray|Participants who have personally used or administered the Olynth Nasal Saline Drops/Spray and Olynth Ectomed Nasal Spray to a child at least once within the past 6 months will provide feedback via electronic survey on the prior use of the Drop/Spray.
89485620|NCT02627144||Advanced and/or Metastatic RCC participants|Participants with mRCC who are being treated with bevacizumab at the recommended dose of 10 milligram per kilogram (mg/kg) of body weight once every 2 weeks as an intravenous infusion, in combination with interferon alpha-2a at the recommended starting dose of 9 million international units (MIU) 3 times a week until disease progression will be observed. No diagnostic or therapeutic interventions will be given other than used in normal daily routine.
89485621|NCT03062384|Experimental|AT-001|Yeast-selenium supplement
89485622|NCT03062384|Placebo Comparator|Placebo|Yeast supplement devoid of selenium
89485623|NCT04981886|Experimental|Group 1: Normal tension glaucoma subjects with thin corneas|NTG subjects with CCT ≤ 540 nm will be randomized to receive either netarsudil or bimatoprost.
89485624|NCT04981886|Experimental|Group 2: Normal tension glaucoma subjects with thick corneas|NTG subjects with CCT > 540 nm will be randomized to receive either netarsudil or bimatoprost.
89485625|NCT03873727|Experimental|Prevenar13/ Pneumovax|Prime-boost strategy combining a single dose of 13-valent pneumococcal conjugate vaccine (Prevenar 13, PCV13) at month 0 (M0) followed by a single dose of 23-valent unconjugated vaccine (Pneumovax, PPS23) at month 12 (M12).
89485626|NCT03873727|Placebo Comparator|Placebo / Pneumovax|Standard strategy combining a single dose of placebo vaccine (Prevenar 13 placebo) at month 0 (M0) followed by a single dose of 23-valent unconjugated vaccine (Pneumovax, PPS23) at month 12 (M12)
89485627|NCT04982276|Experimental|AK104 and AK109|AK104 IV every 2 weeks (q4w) AK109 IV every 2 weeks (q4w)
89485628|NCT04982276|Experimental|AK104 and AK109 combined with chemotherapy|AK104 IV every 2 weeks (q4w) AK109 IV every 2 weeks (q4w) PTX iV 85mg/m2 day1 day8 day15(q4w)
89021695|NCT03279003|Experimental|Light-emitting diode therapy|Exposure to LED light
89485629|NCT03870295|Experimental|Patients suffering from polyneuropathies|Type C fibre conduction velocity determination in patients suffering from polyneuropathy
89485630|NCT03870295|Active Comparator|Control patients|Type C fibre conduction velocity determination in control patients
89485631|NCT02254057|Experimental|BIBT 986 BS - single rising dose|
89485632|NCT02254057|Placebo Comparator|Placebo|
89485633|NCT04548440|Experimental|Preoperative Sintilimab plus Nab-paclitaxel and Cisplatin|"Patients receive the following regimen every 3 weeks:~Sintilimab 200mg IV on Day 1; Albumin-bound paclitaxel 125 mg/m2 IV on Day 1 and Day 8; Cisplatin 75mg/m2 IV on Day 1; Standard hydration regimen on Day 0-3~After 2-4 cycles, radiological evaluation and multidisciplinary assessment will be performed. If radical resection is possible, surgery is to be performed 3-6 weeks after the last chemotherapy session. In the case of a R0 resection, the investigator will decide whether to perform adjuvant therapy depending on the patient's condition; in the case of R1 or R2 resection, concurrent chemoradiotherapy is recommended. If the multidisciplinary assessment considers that radical resection is not possible, radical concurrent chemoradiotherapy is performed."
89485634|NCT04982120|Experimental|Repris Needle|Reprise sheath and needle
89485635|NCT04981652|Experimental|Whole Milk|Participants randomly assigned to the whole milk condition will undergo three sequential study phases, each lasting three days in length. During phase 1, these participants will participate in habitual physical activity and consume a standardized diet, delivering 0.8 g/kg/body mass per day of protein. During the second phase, participants in this group will continue to perform habitual activity, but will have two whole milk experimental beverages (250 mL each serving, 3% milk fat) added to their standardized diet each day for the three day period. Finally, during the last three days of the study, participants will continue to consume the their intervention diet, but their physical activity levels (monitored via daily step count) will be increased to ~150% of their habitual levels.
89485636|NCT04981652|Experimental|Skim Milk|Participants randomly assigned to the skim milk condition will undergo three sequential study phases, each lasting three days in length. During phase 1, these participants will participate in habitual physical activity and consume a standardized diet, delivering 0.8 g/kg/body mass per day of protein. During the second phase, participants in this group will continue to perform habitual activity, but will have two skim milk experimental beverages (250 mL each serving, 0% milk fat) added to their standardized diet each day for the three day period. Finally, during the last three days of the study, participants will continue to consume the their intervention diet, but their physical activity levels (monitored via daily step count) will be increased to ~150% of their habitual levels.
89485637|NCT04981652|Experimental|Almond Beverage|Participants randomly assigned to the almond beverage condition will undergo three sequential study phases, each lasting three days in length. During phase 1, these participants will participate in habitual physical activity and consume a standardized diet, delivering 0.8 g/kg/body mass per day of protein. During the second phase, participants in this group will continue to perform habitual activity, but will have two almond experimental beverages (250 mL each serving) added to their standardized diet each day for the three day period. Finally, during the last three days of the study, participants will continue to consume the their intervention diet, but their physical activity levels (monitored via daily step count) will be increased to ~150% of their habitual levels.
89485638|NCT04982042|Experimental|Post COVID-19 Outpatient Pulmonary Rehabilitation Program|The outpatient Pulmonary Rehabilitation Program will be carried out at the Pulmonary Rehabilitation Laboratory, consisting of a combination of aerobic and strengthening exercises, lasting 12 weeks, with a frequency of 3 times a week, always in the morning. Each session consists of active warm-up exercises, upper and lower limb strengthening, aerobic conditioning and stretching exercises. The warm-up phase consists of intercalated calisthenic exercises for different muscle groups, according to each patient's tolerance.
89485639|NCT04982042|Active Comparator|Post COVID-19 Home Pulmonary Rehabilitation Program|The Home Pulmonary Rehabilitation Program will be carried out at the patients' homes, consisting of the same combination of aerobic and strengthening exercises, lasting 12 weeks, 3 times a week, always in the morning. Each session consists of active warm-up exercises, upper and lower limb strengthening, aerobic conditioning and stretching exercises. The warm-up phase consists of intercalated calisthenic exercises for different muscle groups, according to each patient's tolerance. Patients will be monitored weekly via whatsapp.
89537797|NCT04488965|Experimental|Autologous neural cell ecosystems - ANCE|The patient will undergo first surgery under general anesthesia for the collection of the cortical biopsy (5x5x5 mm biopsy of non-dominant frontal cortex). After the production of ANCE from the cortical biopsy, which last 8 to 12 weeks, the patient will undergo a second neurosurgery, for the stereotaxic reimplantation of ANCE under general anesthesia.
89021696|NCT04716140|No Intervention|MTP1 joint with no cartillage laesion or grade I|Patients in whom no treatment of the cartilage lesions is performed: these patients have no cartilage lesion or a grade I cartilage lesion at the MTP I joint that has been found peroperatively. The degree of the cartilage lesions will be determined on the basis of the ICRS scale and an MS Hololens.
89485640|NCT04981340|Experimental|Standard urotherapy + Diaphragmatic breathing exercises+ pelvic floor exercises|Diaphragmatic breathing exercises will be demonstrated by a qualified physiotherapist. Exercises will be done in lying and sitting positions respectively. In supine, with the lower extremities supported over a pillow and hands positioned on the abdominal muscles, children will be asked to inhale the air through the nose, bulge the abdomen outwards as much as possible, hold their breath for a few seconds, and then exhale slowly through pursed lips. The same exercise will be then performed in both side-lying positions and in a sitting position in front of the mirror. Children will be instructed to watch the anterior abdominal wall movement during inspiration and to repeat the same action while seated on the toilet to initiate voiding. They will be asked to perform the diaphragmatic breathing exercises daily at home.
89485641|NCT04981340|Active Comparator|Standard urotherapy|Standard urotherapy will start with the education of the children and their parents about the normal function of the bladder and external urinary sphincter and the nature of their voiding disorder. The importance of regular fluid intake (200 ml 5-6 times per day) and regular voiding will be explained. Special voiding and defecation diaries that a child has to fill out at home will be provided. An optimal voiding posture will be demonstrated in front of a mirror: a sitting position, with feet supported, hips abducted and abdominal muscles relaxed.
88952738|NCT01954680|Experimental|COGFLEX-skill building levels|In the R33, children will be randomized to receive either COGFLEX with skill-building levels or just baseline/non-probabilistic trials. All children will play COGFLEX twice per week for 8-weeks.
88952739|NCT01954680|Experimental|COGFLEX-control condition|In the R33, children will be randomized to receive either COGFLEX with skill-building levels or the control condition--which is just baseline/non-probabilistic trials. All children will play COGFLEX twice per week for 8-weeks.
89021697|NCT04716140|No Intervention|MTP1 joint with cartillage laesion > grade I - non treatment|Patients in whom a cartilage lesion> grade 1 is found during surgery randomised in the no treatment group
89203911|NCT04048070|Experimental|Traditional care with analgesia pump|Conventional perioperative counseling and regular fasting food for 12 hours and water for 6 hours before surgery. Lie down and oral intake at least 4 hours after recovery. An electronic analgesic pump containing opioids drug and Flubiprofen Axetil in this group for postoperative pain management.
89485642|NCT03688867|Experimental|At-home prehabilitation regimen|"Grip strength: Squeeze a stress ball in your hand, holding it squeezed for 5 seconds. Perform this at least thirty times with each hand over the course of a day.~Lower body strength: Perform at least one hundred chair sit-stands in a day.~Endurance: Walking at least 7,500 steps in a day."
89485643|NCT02626520|Experimental|Resectable, Low Risk|Systemic chemotherapy followed by definitive surgery without pre-operative or post-operative radiotherapy.
89485644|NCT02626520|Experimental|Locally Advanced|Systemic chemotherapy followed by chemoradiation, followed by definitive surgery
89485645|NCT04498754|Experimental|Cognitive Behavior Therapy for Insomnia (CBT-I)|Participants assigned to this arm will receive eight sessions of a well-established, evidence-based therapy called cognitive behavior therapy for insomnia (CBT-I).
89485646|NCT04498754|Other|Minimal Contact Control Condition|Participants assigned to this condition will be contacted every week for eight weeks and monitored regarding their insomnia symptoms.
89485647|NCT03547063||Sleeve Gastrectomy (SG)|25 participants, male and female, aged 18-50 years, body mass index (BMI) 35-50 kg/m2, due to undergo primary SG
89485648|NCT03547063||Lifestyle Intervention|25 participants, male and female, aged 18-50 years, BMI 35-50 kg/m2
89485649|NCT03547063||Normal Weight|25 participants, aged 18-50 years BMI 18.5-24.9 kg/m2, age and gender matched to group with severe obesity
89485650|NCT03546985|Experimental|Group A|
89485651|NCT03546985|Active Comparator|Group B|
89485652|NCT03546127||STS|Patients with advanced/metastatic soft-tissue sarcoma
89485653|NCT03546127||CCR|Patients with metastatic colorectal carcinoma
89485654|NCT05084521|Experimental|Famotidine|Suspension of famotidine, 0.5 mg/kg/12h (with a maximum dose of 80 mg/day, regardless of the patient's weight) during 29 days.
89485655|NCT03610789||REDAPT Revision Femoral System|REDAPT Revision Femoral System Monolithic Sleeveless Stems, monolithic sleeved stems and/or Acetabular Components or modular shells and/or augments
89485656|NCT03574987|Active Comparator|CONTROL|Diet consisting of 50% carbohydrate (20% sugar), 15% protein, 35% fat
89485657|NCT03574987|Experimental|LOW SUG|Diet consisting of 50% carbohydrate (<5% sugar), 15% protein, 35% fat
88952740|NCT01954693|Experimental|Everolimus (RAD001)|2x2.5mg daily
88952741|NCT01954693|Placebo Comparator|Placebo|2x2.5mg daily
88952742|NCT01954706|Experimental|Structured Exercise|Structured and supervised aerobic and resistance training 2 times per week
88952743|NCT01954706|Active Comparator|Usual Care|Subjects will be counseled on American Cancer Society and American College of Sports Medicine physical activity and nutritional guidelines at the initiation of the study. Study participants will be contacted by a physician or nurse on weeks 2, 6, 10, and 14 to provide support and encouragement to patients.
88952744|NCT01954719|Experimental|cervix dilated after surgery|Digital cervical dilatation performed by surgeon
88952745|NCT01954719|No Intervention|control group|cervix not dilated after surgery
88952746|NCT01954732|No Intervention|Group I (observation)|Patients undergo observation.
88952747|NCT01954732|Experimental|Group II (metformin hydrochloride)|Patients receive metformin hydrochloride PO BID for at least 7 days in the absence of disease progression or unacceptable toxicity.
88952748|NCT01954732|Experimental|Group III (metformin hydrochloride)|Patients receive metformin hydrochloride as in Group II.
89485658|NCT03574987|Experimental|LOW CHO|Diet consisting of <8% carbohydrate (<5% sugar), 15% protein, >77% fat
89485659|NCT05063851|Experimental|Memantine hydrochloride|
89485660|NCT05063851|Placebo Comparator|Placebo|
89485661|NCT04522141|Experimental|Self-control treatment group|The self-control treatment group will wear a Fitbit step counter across 8 weeks. In addition, they will use the MindHike smartphone application across 8 weeks. Each day, the app sends the a reminder to wear the Fitbit as well as a short interventional input targeting self-control.
89485662|NCT04522141|Active Comparator|Control group|The control group will wear a Fitbit step counter across 8 weeks. In addition, they will use the MindHike smartphone application across 8 weeks. Each day, the app sends the a reminder to wear the Fitbit.
89485663|NCT05046379||Patients with Fabry disease|Adult men and women with well characterized Fabry disease
89485664|NCT05046379||Healthy controls (with no Fabry disease)|Adult men and women from the endocrinology and nephrology in- or out-patient clinic
89485665|NCT03545581|Other|Experimental diet Fru rich diet|Enriched fructose diet from day 1 to day 7.
89485666|NCT03545581|Other|Experimental low Fru diet|Low fructose diet from day 1 to day 7.
89485667|NCT03481543|Experimental|In-line nebulization through NIV mask|Bronchodilator nebulization is given through NIV circuit.
89485668|NCT03481543|Active Comparator|Off-NIV nebulization|Bronchodilator nebulization is given during which NIV mask is taken off for a short time and reapplied when nebulization is finished.
89485669|NCT03433339|Experimental|Active Treatment|Thoracic anodal transcutaneous spinal direct current stimulation 2.5mA for 20 min/ three times per week for 8 weeks.
89485670|NCT03433339|Sham Comparator|Sham Treatment|Thoracic anodal transcutaneous spinal direct current sham stimulation session of 20min/ three times per week for 8 weeks.
89485671|NCT03359161|Experimental|In-Home Subcutaneous Furosemide Treatment ARm|Prospective, open-label arm to evaluate the clinical effectiveness of a novel formulation of furosemide delivered by subcutaneous administration.
89203912|NCT04048070|Placebo Comparator|traditional care without postoperative intravenous analgesia.|Conventional perioperative counseling and regular fasting food for 12 hours and water for 6 hours before surgery. Lie down and oral intake at least 4 hours after recovery. Intravenous saline with necessary oral analgesic for postoperative pain management.
89485672|NCT03297775||RA with Sub-clinical ILD|"Subjects will be followed annually until study closure.~Assessments are as follows:~Clinical (Annual): Demographics, health-related behaviors, co-morbidities, medications, respiratory symptoms, rheumatologic assessment, quality of life~Physiologic (3-5 yrs FU): Lung function on Pulmonary Function Test (PFT)~Radiologic (3-5 yrs FU): HRCT scan of chest~Genetic (3-5 yrs FU): Blood sample collection for RNA~Biologic (3-5 yrs FU): Blood sample collection for other blood markers"
89485673|NCT03297775||RA with No-ILD|"Subjects will be followed annually until study closure.~Assessments are as follows:~Clinical (Annual): Demographics, health-related behaviors, co-morbidities, medications, respiratory symptoms, rheumatologic assessment, quality of life~Physiologic (3-5 yrs FU): Lung function on Pulmonary Function Test (PFT)~Radiologic (3-5 yrs FU): HRCT scan of chest~Genetic (3-5 yrs FU): Blood sample collection for RNA~Biologic (3-5 yrs FU): Blood sample collection for other blood markers~Note: Certain follow-up procedures may not occur for every subject and will be determined by the research team."
89485674|NCT05031871|Experimental|Treatment group A|HR17031 injection dose+INS068 injection dose+SHR20004 injection dose+(INS068+SHR20004) injection dose
89485675|NCT05031871|Experimental|Treatment group B|INS068 injection dose+(INS068+SHR20004)injection dose+ HR17031 injection dose +SHR20004 injection dose
89485676|NCT05031871|Experimental|Treatment group C|SHR20004 injection dose+ HR17031 injection dose +(INS 068+SHR20004) injection dose+ INS068 injection dose
89485677|NCT05031871|Experimental|Treatment group D|(INS 068+SHR20004) injection dose+ SHR20004 injection dose+ INS068 injection dose+ HR17031 injection dose
89485678|NCT05016583|Experimental|Paula Method|
89485679|NCT05015725||Treated hypothyroidism|Patients with treated hypothyroidism
89485680|NCT02253823|Experimental|TPV+RTV - low dose|
89485681|NCT02253823|Experimental|TPV+RTV - high dose|
89485682|NCT04308967|Experimental|Balance exercises and information|Balance exercises six weeks and three days in a week and information about central sensitisation.
89485683|NCT04308967|No Intervention|Information|Information about central sensitisation.
89021698|NCT04716140|Experimental|MTP1 joint with cartillage laesion > grade I - treatment|Patients in whom a cartilage lesion> grade 1 is found during surgery randomised in the treatment group. They will be treated through debridement of the lesion and microfracture.
89485684|NCT03277339|Experimental|Paroxetine|Paroxetine (Deroxat®) Posology : 20 mg per day for 3 weeks. After 2 weeks of treatments, if indicated, physicians will prescribe until 50 mg.
89485685|NCT03277339|Other|Thermal cure|This study is controlled with a comparator which is the Thermal cure. Thermal cure is realized for 3 weeks.
89485686|NCT03232801|Experimental|mindfulness group|A multicomponent group-based intervention rooted in mindfulness, administered in 3 sessions over 6 weeks
89485687|NCT03232801|Active Comparator|educational group|A general midlife health and aging educational group, administered in 3 sessions over 6 weeks
89485688|NCT03145675|Experimental|Enoxaparin (Staged-dose PCI Group)|Enoxaparin 0.5 mg/kg at the beginning of coronary angiography (i.e., insertion of angiographic catheter) and additional enoxaparin 0.25 mg/kg at the beginning of PCI (i.e., insertion of guiding catheter).
89485689|NCT03145675|Active Comparator|Enoxaparin (Single-dose PCI Group)|Enoxaparin 0.75 mg/kg at the beginning of coronary angiography (i.e., insertion of angiographic catheter) and NO additional enoxaparin at the beginning of PCI (i.e., insertion of guiding catheter).
89485690|NCT03145675|Experimental|Enoxaparin (High-dose Group)|Enoxaparin 0.75 mg/kg at the beginning of coronary angiography (i.e., insertion of angiographic catheter).
89485691|NCT03145675|Active Comparator|Enoxaparin (Standard-dose Group)|Enoxaparin 0.5 mg/kg at the beginning of coronary angiography (i.e., insertion of angiographic catheter).
89203913|NCT00655356|Experimental|Active|
89485692|NCT01329029|Active Comparator|Roflumilast|concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid
89485693|NCT01329029|Placebo Comparator|Placebo|concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid
89537798|NCT04980261|Active Comparator|Control Group (ORIF + autograft)|The patients will receive the current gold standard to treat long bone defects.
89537799|NCT04980261|Experimental|Treatment Group (ORIF + FD BHA/Secretome composite)|The patients will receive a novel bone substitute following the ORIF procedure.
89021699|NCT03270111|Experimental|A2: Breast Cancer Survivor|Participants will include breast cancer survivors who take part in a weight loss intervention program. The intervention is the same for all participants.
89485694|NCT03111277|Experimental|Experimental: ExAblate Transcranial treatment|The ExAblate Transcranial system will be used to destroy a small cluster of cells that may be causing the study participant's pain . The ExAblate uses ultrasound to heat a small spot in the brain. Ultrasound passes through the skin and skull and into the brain to focus on a spot the study investigator wants to treat.
89485695|NCT02254135|Experimental|BEA 2180 BR solution - rising dose|
89485696|NCT02254135|Placebo Comparator|Placebo|
89485697|NCT04300673|Experimental|All patients|Intervention: radio guided surgery
89485698|NCT03545425||Idiopathic Parkinson's Disease patients|Up to 30 Parkinson's Disease patients will be enrolled.
89485699|NCT03545425||Healthy Controls|Up to 30 Healthy Controls will be enrolled.
89485700|NCT03545425||LRRK2 G2019S - Manifesting|Up to 30 LRRK2 G2019S Manifesting carriers will be enrolled.
89485701|NCT03545425||LRRK2 G2019S - Non-Manifesting|Up to 30 LRRK2 G2019s Non-Manifesting carriers will be enrolled.
89485702|NCT01372085|Experimental|Part A: 25 mg RF|A single 25 mg dose of LY2584702 RF
89485703|NCT01372085|Placebo Comparator|Part A: Placebo|Placebo taken orally
89485704|NCT01372085|Experimental|Part B: Sequence 1|A single 10 mg dose of LY2584702 TF during the first intervention period, followed by placebo in the second intervention period, followed by a single dose of 50 mg TF in the third intervention period, followed by either an open-label single dose of 50 mg TF after a high fat breakfast (Period 4a) OR placebo or escalated dose of TF in the fasted state (Period 4b). There will be a washout period of at least 3 days between periods.
89485705|NCT01372085|Experimental|Part B: Sequence 2|Placebo during the first intervention period, followed by a single dose of 50 mg RF in the second intervention period, followed by a single dose of 50 mg TF in the third intervention period, followed by either an open-label single dose of 50 mg TF after a high fat breakfast (Period 4a) OR placebo or escalated dose of TF in the fasted state (Period 4b). There will be a washout period of at least 3 days between periods.
89485706|NCT01372085|Experimental|Part B: Sequence 3|A single 10 mg dose of LY2584702 TF during the first intervention period, followed by a single dose of 50 mg RF in the second intervention period, followed by a single dose of 50 mg TF in the third intervention period, followed by either an open-label single dose of 50 mg TF after a high fat breakfast (Period 4a) OR placebo or escalated dose of TF in the fasted state (Period 4b). There will be a washout period of at least 3 days between periods.
89485707|NCT01372085|Experimental|Part B: Sequence 4|A single 10 mg dose of LY2584702 TF during the first intervention period, followed by a single dose of 50 mg RF in the second intervention period, followed by placebo in the third intervention period, followed by either an open-label single dose of 50 mg TF after a high fat breakfast (Period 4a) OR placebo or escalated dose of TF in the fasted state (Period 4b). There will be a washout period of at least 3 days between periods.
89485708|NCT04042727|Experimental|Dexmedetomidine plus Standard of Care|Dexmedetomidine hydrochloride infusion will be prepared by the investigational pharmacy and administered intravenously at a rate of 1mcg/kg/hr for a duration of 8 hrs to patients in rapid Afib in addition to the usual standard of care as deemed necessary by patient's ICU team.
89485709|NCT04042727|Placebo Comparator|Placebo plus Standard of Care|Normal Saline solution will be prepared by investigational pharmacy and administered intravenously at a rate of 1mcg/kg/hr for a duration of 8 hrs to patients in rapid Afib in addition to the usual standard of care as deemed necessary by patient's ICU team.
89485710|NCT04012853|Experimental|treatment arm|tDCS treatment group
89485711|NCT04012853|No Intervention|control arm|Sham tDCS
89485712|NCT02035865||Participants from former study 1|Surviving participants from a former study called 'Psykosomale faktorer hos pasienter med hjertesvikt og hos hjertetransplanterte'
89485713|NCT02035865||Participants from former study 2|Surviving participants, included at the Norwegian centre, from a study called 'Scandinavian Heart Transplant Everolimus De Novo Study with Early Calcineurin Inhibitor Avoidance (SCHEDULE)' (NCT01266148)
89485714|NCT02035943|Active Comparator|Insulin separated|Seprated infusion of insulin
89485715|NCT02035943|Active Comparator|Insulin added to parenteral nutrition|Insulin added to parenteral nutrition
89485716|NCT05707637||VA group|Consecutive patients with VA originating from the base of the heart undergoing unipolar ablation
89485717|NCT02941549|Placebo Comparator|Placebo|2 x placebo 500 mg capsules orally administered twice a day (4 capsules daily) for 16 weeks
89485718|NCT02941549|Experimental|1000 mg Epeleuton|1 x Epeleuton 500 mg capsule and 1 x placebo 500 mg capsule orally administered twice a day (4 capsules daily) for 16 weeks
89485719|NCT02941549|Experimental|2000 mg Epeleuton|2 x Epeleuton 500 mg capsules orally administered twice a day (4 capsules daily) for 16 weeks
89485720|NCT03819959||Intensive Care Patients|Polytrauma patients who have been admitted to intensive care
89203914|NCT00655356|Placebo Comparator|Placebo|
89203915|NCT00571064|Experimental|1|
89537800|NCT03290573|Active Comparator|Dorsum of hand group|short peripheral venous catheter place in the dorsum of the hand
89537801|NCT03290573|Experimental|Forearm group|short peripheral venous catheter place in the forearm
89485721|NCT02394028|Experimental|Induction Phase - Cohort 1 (Exploratory): Etrolizumab 210 mg|Cohort 1 enrolled participants first before Cohorts 2 and 3 in order to conduct an exploratory analysis on induction data. Participants randomized to this arm will receive one subcutaneous (SC) injection of etrolizumab (210 mg) at Weeks 0, 2, 4, 8, and 12 during the 14-week Induction Phase. In order to preserve the masking, participants will also receive one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12.
89485722|NCT02394028|Experimental|Induction Phase - Cohort 1 (Exploratory): Etrolizumab 105 mg|Cohort 1 enrolled participants first before Cohorts 2 and 3 in order to conduct an exploratory analysis on induction data. Participants randomized to this arm will receive one SC injection of etrolizumab (105 mg) at Weeks 0, 4, 8, 12 and one SC injection of etrolizumab-matching placebo at Week 2 during the 14-week Induction Phase. In order to preserve the masking, participants will also receive one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12.
89485723|NCT02394028|Placebo Comparator|Induction Phase - Cohort 1 (Exploratory): Placebo|Cohort 1 enrolled participants first before Cohorts 2 and 3 in order to conduct an exploratory analysis on induction data. Participants randomized to this arm will receive two SC injections of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12 (and one SC injection of etrolizumab-matching placebo at Week 2) during the 14-week Induction Phase, in order to preserve the masking.
89485724|NCT02394028|Experimental|Induction Phase - Cohort 2 (Open-Label): Etrolizumab 210 mg|"Cohort 2 is enrolling participants after Cohort 1 and is considered a feeder cohort to help achieve the necessary sample size for the Maintenance Phase. Participants randomized to this arm will receive one SC injection of open-label etrolizumab (210 mg) at Weeks 0, 2, 4, 8, and 12 during the 14-week Induction Phase. In order to preserve the masking for the dose of etrolizumab, participants will also receive one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12."
89485725|NCT02394028|Experimental|Induction Phase - Cohort 2 (Open-Label): Etrolizumab 105 mg|"Cohort 2 is enrolling participants after Cohort 1 and is considered a feeder cohort to help achieve the necessary sample size for the Maintenance Phase. Participants randomized to this arm will receive one SC injection of open-label etrolizumab (105 mg) at Weeks 0, 4, 8, 12 and one SC injection of etrolizumab-matching placebo at Week 2 during the 14-week Induction Phase. In order to preserve the masking of the dose of etrolizumab, participants will also receive one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12."
89485726|NCT02394028|Experimental|Induction Phase - Cohort 3 (Pivotal): Etrolizumab 210 mg|Cohort 3 is the last to enroll participants (after Cohort 2) and will be the pivotal cohort for the Induction Phase. Participants randomized to this arm will receive one SC injection of etrolizumab (210 mg) at Weeks 0, 2, 4, 8, and 12 during the 14-week Induction Phase. In order to preserve the masking, participants will also receive one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12.
89485727|NCT02394028|Experimental|Induction Phase - Cohort 3 (Pivotal): Etrolizumab 105 mg|Cohort 3 is the last to enroll participants (after Cohort 2) and will be the pivotal cohort for the Induction Phase. Participants randomized to this arm will receive one SC injection of etrolizumab (105 mg) at Weeks 0, 4, 8, 12 and one SC injection of etrolizumab-matching placebo at Week 2 during the 14-week Induction Phase. In order to preserve the masking, participants will also receive one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12.
89485728|NCT02394028|Placebo Comparator|Induction Phase - Cohort 3 (Pivotal): Placebo|Cohort 3 is the last to enroll participants (after Cohort 2) and will be the pivotal cohort for the Induction Phase. Participants randomized to this arm will receive two SC injections of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12 (and one SC injection of etrolizumab-matching placebo at Week 2) during the 14-week Induction Phase, in order to preserve the masking.
89485729|NCT02394028|Placebo Comparator|Maintenance Phase - Placebo Responders: Placebo|Participants who received placebo during the Induction Phase (from Cohorts 1 and 3) and achieved a CDAI-70 response at Week 14 will undergo a sham randomization into the Maintenance Phase. Placebo responders from induction will receive blinded maintenance treatment with an SC injection of placebo once every 4 weeks (q4w) from Week 16 to Week 64.
89485730|NCT02394028|Placebo Comparator|Maintenance Phase - Etrolizumab Responders: Placebo|Participants who received etrolizumab during the Induction Phase (from Cohorts 1-3) and achieved a CDAI-70 response at Week 14 without the use of rescue therapy will be re-randomized into the Maintenance Phase. Etrolizumab responders from induction who are re-randomized to this arm will receive blinded maintenance treatment with an SC injection of placebo q4w from Week 16 to Week 64.
89485731|NCT02394028|Experimental|Maintenance Phase - Etrolizumab Responders: Etrolizumab 105 mg|Participants who received etrolizumab during the Induction Phase (from Cohorts 1-3) and achieved a CDAI-70 response at Week 14 without the use of rescue therapy will be re-randomized into the Maintenance Phase. Etrolizumab responders from induction who are re-randomized to this arm will receive blinded maintenance treatment with an SC injection of etrolizumab (105 mg) q4w from Week 16 to Week 64.
89485732|NCT03546751|Experimental|CPAP|This arm will consist of patients with obstructive sleep apnea who will be asked to use CPAP nightly to treat their OSA for six months
89485733|NCT03546751|Active Comparator|Diet and Exercise|This arm will consist of patients with obstructive sleep apnea who will be asked to engage in dietary management and regular exercise for six months.
89485734|NCT04005677||lung cancer|
89485735|NCT04005677||benign lung nodule|
89485736|NCT04005677||lung nodule|
89485737|NCT04073069|Experimental|The DR group|Participates received peri-incisional scalp infiltration with 15ml ropivacaine 1% wt/vol, 0.5ml diprospan, plus 14.5ml saline;
89485738|NCT04073069|Active Comparator|The R group|Participates received peri-incisional scalp infiltration with 15ml ropivacaine 1% wt/vol, plus 15ml saline;
89485739|NCT01371539|Other|Lotrafilcon B / Comfilcon A|Lotrafilcon B contact lenses worn first, with comfilcon A contact lenses worn second. Both products worn bilaterally on a daily wear basis for one week each.
89485740|NCT01371539|Other|Comfilcon A / Lotrafilcon B|Comfilcon A contact lenses worn first, with lotrafilcon B contact lenses worn second. Both products worn bilaterally on a daily wear basis for one week each.
89485741|NCT02819297|Experimental|BLI400 Laxative|BLI400 Laxative
89485742|NCT02819297|Placebo Comparator|Placebo|BLI400 placebo
89485743|NCT02036021||PRE/non-PRE|children who develop or did not perioperative respiratory events between November 2012 and December 2013
89485744|NCT03546673|No Intervention|Control Condition|Participants in the control group were asked to write for three weeks about facts regarding their cancer and its treatment for three sessions.
89485745|NCT03546673|Experimental|Self-regulation Condition|For the self-regulation condition, each weekly writing assignment covers a different task. During session one, participants will be asked to write about their deepest feelings and thoughts regarding their experience with breast cancer as well as its impact on their lives; in session two, participants will be asked to write about their coping strategies to deal with stressors associated with the cancer diagnosis and treatment, as well as future plans for coping with cancer-related stressors; and in session three, participants will be asked to write about positive thoughts and feelings regarding their experience with breast cancer.
89485746|NCT03546673|Experimental|Emotional Disclosure condition|For the emotional disclosure condition, participants were asked to write about their deepest thoughts and feelings about their cancer experience for three weeks.
89485747|NCT04980950|Experimental|gastric cancer patients (immunonutrition)|Experimental gastric cancer group will receive Impact Oral Nestlé Health Science/ Cubitan® Nutricia for 10 days.
89485748|NCT04980950|Active Comparator|gastric cancer patients (standard nutrition)|These patients will receive Nutridrink® Nutricia/ Resource 2.0 Nestlé Health Science for 10 days.
89485749|NCT04980950|Experimental|colorectal cancer patients (immunonutrition)|Experimental colorectal cancer group will receive Impact Oral Nestlé Health Science/ Cubitan® Nutricia for 10 days.
89485750|NCT04980950|Active Comparator|colorectal cancer patients (standard nutrition)|These patients will receive Nutridrink® Nutricia/ Resource 2.0 Nestlé Health Science for 10 days.
89485751|NCT03546595|Experimental|Auricular acupoints acupressure|
89485752|NCT03546595|Sham Comparator|Sham auricular acupoints acupressure|
89485753|NCT04981028||Patients with acute episode of thrombotic thrombocytopenic purpura (TTP)|Any adult patients with a suspected diagnosis of TTP (defined by low platelets and anaemia with evidence of red cell breakdown) and confirmed by a low ADAMTS13 enzyme level <10%
89485754|NCT04981028||Healthy volunteers|Non-blood relative / friend / carer
89485755|NCT04981028||Patients with known diagnosis of TTP|Any adult patients with a previously confirmed diagnosis of TTP (more than 12 months ago) based on an ADAMTS13 enzyme level <10% at initial diagnosis
89485756|NCT02429830|Other|Single arm study|Previous LSG patient will be treated with the LINX device and serve as their own control
89485757|NCT03063788|Experimental|HIV uninfected|A single intravenous infusion of 3mg/kg 3BNC117 combined with Copper-64 to 2 HIV uninfected individuals
89485758|NCT03063788|Experimental|HIV infected viremic|A single intravenous infusion of 3mg/kg 3BNC117 combined with Copper-64 to 4 HIV infected individuals with viremia who are not receiving antiretroviral therapy
89485759|NCT03063788|Experimental|HIV infected aviremic|A single intravenous infusion of 3mg/kg 3BNC117 combined with Copper-64 to 4 HIV infected individuals with undetectable HIV viral load who are receiving antiretroviral therapy
89485760|NCT02821715|Active Comparator|Modafinil + placebo|3 tablets modafinil 100 mg per day and 3 capsules flecainide placebo per day for 2 weeks
89485761|NCT02821715|Experimental|THN102 300/3|3 tablets modafinil 100 mg per day and 3 capsules flecainide 1 mg per day (THN102 as 300 + 3 mg) for 2 weeks
89485762|NCT02821715|Experimental|THN102 300/27|3 tablets modafinil 100 mg per day and 3 capsules flecainide 9 mg per day(THN102 as 300 + 27 mg) for 2 weeks
89485763|NCT02877823|Experimental|Treatment|"Home delivery of bottled water supplying 48 oz. /day for the child and 24 oz. /day per other household members (up to 6 family members).~Child pedometer use and activity tracking to encourage child physical activity/goal setting and engage parents in monitoring their child's health behavior.~Family Navigator Services by telephone with the parent to help engage and empower parents in child healthy lifestyle changes. They will also be able to assist with resource needs for the household (food/housing services).~Healthy Lifestyle Education based on the American Academy of Pediatrics Institute for the Healthiest Childhood Weight daily guidelines which are 5 fruit and vegetable servings, two hours or less screen time, one hour or more physical activity, no sugary drinks daily and limit fruit juice to one hundred percent real fruit juice."
89021700|NCT03270111|Experimental|B: High Risk Women|Participants will include women at high risk of breast cancer who take part in a weight loss intervention program. The intervention is the same for all participants.
89485764|NCT02877823|Active Comparator|Control|Healthy Lifestyle Education based on the American Academy of Pediatrics Institute for the Healthiest Childhood Weight daily guidelines which are 5 fruit and vegetable servings, two hours or less screen time, one hour or more physical activity, no sugary drinks and limit fruit juice to one hundred percent real fruit juice.
89485765|NCT02036177|Experimental|SCu300A IUB|
89485766|NCT02036177|Active Comparator|T380A copper IUD|
89485767|NCT02036099|Experimental|Intervention|Participants in this arm will assess patients using the Driving in Mild Dementia Decision Tool.
88952749|NCT01954758|Experimental|Personalized embryo transfer (pET)|Patients will undergo a cycle of endometrial preparation following hormone replacement therapy (HRT) and an endometrial biopsy in a substituted cycle after 5 days (around 120 hours) of progesterone administration. The ERA test will determine the window of implantation (WOI) for each patient and will recommend the best time for embryo transfer thereby increasing the chances of a successful outcome. In some specific cases (≤ 10%) a second biopsy will be required to help the bioinformatic predictor to ensure the most appropriated moment for the embryo transfer. In a different cycle, patients will undergo a cycle of controlled ovarian stimulation (COS) to obtain oocytes which will be fertilized by IVF/ICSI and vitrified. In a subsequent cycle, following the ERA result, a personalized embryo transfer (pET) will be carried out following the same conditions in which the ERA test was obtained, using 1 or 2 viable blastocysts previously obtained (day 5 or 6 stage)
89485768|NCT02036099|No Intervention|Control|Participants in this arm will assess patients using their usual care strategies.
89485769|NCT04855838|Experimental|Intervention group|Intensive training with oral neuromuscular device (intervention group) and traditional compensatory swallowing training under 8 weeks with start 4 (±1) weeks post-operation.
89485770|NCT04855838|No Intervention|Control group|Traditional compensatory swallowing training under 8 weeks with start 4 (±1) weeks post-operation.
89485771|NCT02036333||Concussion Group|
88952750|NCT01954758|Active Comparator|Frozen embryo transfer (FET)|Patients will undergo a cycle of controlled ovarian stimulation (COS) to obtain oocytes which will be fertilized by IVF/ICSI. In a subsequent cycle, following hormone replacement therapy (HRT), a frozen embryo transfer (FET) will be performed using 1 or 2 viable blastocysts previously obtained (day 5 or 6 stage).
89485772|NCT02036333||Control Group|
89485773|NCT04436276|Experimental|Cohort 1a|Participants (healthy adults aged greater than or equal to (>=)18 to less than or equal to (<=) 55 years) will receive Ad26.COV2.S at 2 dose levels, as a single dose or 2 dose schedule with an 8-week interval or matching Placebo on Day 1 and Day 57. At unblinding visit, post Emergency Use Authorization (EUA), conditional licensure, or approval for the single dose regimen of Ad26.COV2.S vaccine, participants initially receiving placebo will be offered to receive a single dose of Ad26.COV2.S. If they choose not to receive Ad26.COV2.S they will be asked to continue to be followed in this study. All eligible participants who have previously received coronavirus disease-2019 (COVID-19) vaccination (as primary regimen or additional dose) if the last vaccination was >=6 months ago, will be offered to receive a single ad hoc booster dose of Ad26.COV2.S. If they choose not to receive ad-hoc booster dose they will be asked to continue to be followed in this study.
88952751|NCT01954758|Active Comparator|Fresh embryo transfer (ET)|Patients will undergo a controlled ovarian stimulation cycle (COS) to obtain oocytes which will be fertilized by IVF/ICSI. In the same cycle, a fresh embryo transfer will be performed using 1 or 2 viable blastocysts previously obtained (day 5 or 6 stage).
88952752|NCT01954784|Experimental|Treatment (nonmyeloablative alloHSCT, lenalidomide)|"PREPARATIVE REGIMEN: Patients receive fludarabine phosphate on days -5 to -3 and undergo TBI on day -1.~TRANSPLANT: Patients undergo allogeneic hematopoietic SCT on day 0.~GVHD PROPHYLAXIS: Patients receive standard GVHD prophylaxis comprising cyclosporine PO BID beginning on day -1 with taper beginning on day 100, mycophenolate mofetil PO BID on days 1-56, and bortezomib SC weekly from day 1 to day 91.~MAINTENANCE THERAPY: Beginning on day 100, patients receive lenalidomide PO daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
88952753|NCT01954797||Physical Fitness|Patients from this group underwent 4 weeks of aerobic fitness training additional to normal supportive care, 5 times a week, for 50 minutes
88952754|NCT01954797||Relaxation|Patients of this group received 4-weeks of relaxation sessions additional to normal supportive care, 5 times a week, for 50 minutes.
88952755|NCT01954810|No Intervention|Japanese encephaltis chimerix vaccine|This is a single-arm study. Japanese encephalitis chimeric vaccine (JECV) will be administered to all subjects and check for antibody response 4 weeks after vaccination.
88952756|NCT01954823|Experimental|e-diary|The study group will have assess to an e-diary developed for people with MS, through the Internet and/or smart-phones. In addition, participants will continue to receive regular care at the MS clinic
88952757|NCT01954823|No Intervention|no use of e-diary|Participants of the control group will receive regular care at the MS clinic and will and no use of the e-diary
88952758|NCT01954836|Experimental|Initial fasting|Fasting during chemotherapy of the first half of chemotherapy cycles (1 and 2 of four or 1 to 3 of six cycles)
88952759|NCT01954836|Active Comparator|Secondary fasting|Fasting during the second half of chemotherapy cycles (3 and 4 of four cycles or 4 to 6 of six cycles)
88952760|NCT01954849|Experimental|Probiotic formulation|Probiotic dissolving lozenge, at least 1 billion total CFU, taken at a certain prescribed regimen for 28 days.
88952761|NCT01954849|Placebo Comparator|Placebo|Placebo dissolving lozenge, with the exact same appearance as the treatment lozenge (including flavour, colour, shape and texture), and formulated with all the same ingredients except for the live bacteria, taken for 28 days at the same prescribed regimen as the probiotic lozenge.
88952762|NCT01954862|Active Comparator|Air insufflation method.|Colonoscopy performed in the standard fashion, with the minimal air insufflation required to aid insertion and allowing for washing as needed. Considered to be standard procedure.
88952763|NCT01954862|Experimental|CO2 insufflation|Colonoscopy performed with CO2 insufflation using the insufflation unit, allowing for washing as needed.
88952764|NCT01954862|Experimental|Water Immersion/CO2|Infusion of water during the insertion phase of colonoscopy mainly to open the colonic lumen and progress to the cecum immersed in the water environment thus created, without attempting to clear the colon contents. Residual air in the colon will not be removed. Infused water and residual feces will be suctioned back predominantly during withdrawal. Insufflation not used until the cecum is reached. It will be allowed only 3 times and no more than 10 seconds each time (ITT failure if >3) if the lumen cannot be seen. Withdrawal phase done using CO2 insufflation.
88952765|NCT01954862|Experimental|Water Exchange/CO2|Insufflation not used until the cecum is reached. Infusion of a sufficient amount of water to render the lumen of the colon a slit to progress with the colonoscope. Part of the infused water will be constantly suctioned back exchanging clean for dirty or hazy water. Air pockets will be always aspirated to collapse the lumen. After cecal intubation as much residual water as possible will be aspirated before beginning the withdrawal phase. During withdrawal residual water and feces will be suctioned. Withdrawal phase done using CO2 insufflation.
89021701|NCT00336245|Experimental|Copper T Intrauterine Contraceptive Device|
89021702|NCT00336245|Active Comparator|Hormonal Contraception|
89485774|NCT04436276|Experimental|Cohort 1b|Participants (healthy adults aged >=18 to <= 55 years) will receive Ad26.COV2.S as a single vaccination in the primary regimen or matching Placebo on Day 1 and Day 57. At unblinding visit, post EUA, conditional licensure, or approval for the single dose regimen of Ad26.COV2.S vaccine, participants initially receiving placebo will be offered to receive a single dose of Ad26.COV2.S. If they choose not to receive Ad26.COV2.S they will be asked to continue to be followed in this study. All eligible participants who have previously received any COVID-19 vaccination (as primary regimen or additional dose) if the last vaccination was >=6 months ago will be offered to receive a single ad hoc booster dose of Ad26.COV2.S. If they choose not to receive ad-hoc booster dose they will be asked to continue to be followed in this study.
89021703|NCT00336362|Active Comparator|1|Participants will receive hydroxyurea pretreatment.
88952766|NCT01954862|Experimental|Water Immersion/AI|Infusion of water during the insertion phase of colonoscopy mainly to open the colonic lumen and progress to the cecum immersed in the water environment thus created, without attempting to clear the colon contents. Residual air in the colon will not be removed. Infused water and residual feces will be suctioned back predominantly during withdrawal. Insufflation not used until the cecum is reached. It will be allowed only 3 times and no more than 10 seconds each time (ITT failure if >3) if the lumen cannot be seen. Withdrawal phase done using room air insufflation.
89485775|NCT04436276|Experimental|Cohort 2a|Participants (healthy adults aged >=18 to <=55 years) will receive Ad26.COV2.S as single vaccination in the primary regimen or matching Placebo on Day 1, followed by booster vaccination at 6 or 12 months with same dose or matching Placebo. At unblinding visit, post EUA, conditional licensure, or approval for the single dose regimen of Ad26.COV2.S vaccine, participants initially receiving placebo will be offered to receive a single dose of Ad26.COV2.S vaccine and who are not willing to receive single dose of Ad26.COV2.S vaccine will continue to receive booster vaccination. All eligible participants who have previously received any COVID-19 vaccination (as primary regimen or additional dose) if the last vaccination was >= 6 months ago, will be offered to receive a single ad hoc booster dose of Ad26.COV2.S and who are not willing to receive single ad hoc booster dose of Ad26.COV2.S or are not eligible to receive the ad hoc booster dose will continue to receive booster vaccination.
89485776|NCT04436276|Experimental|Cohort 2b|Participants(healthy adults aged >=18 to <=55 years)will receive Ad26.COV2.S in primary regimen or matching Placebo on Day 1 and 57,followed by booster vaccination at 8 or 14 months (that is, 6 or 12 months after completion of primary regimen)with same dose or matching Placebo.At unblinding visit,post EUA,conditional licensure,or approval for single dose regimen of Ad26.COV2.S vaccine,participants initially receiving placebo will be offered to receive single dose of Ad26.COV2.S vaccine and who are not willing to receive single dose of Ad26.COV2.S vaccine will continue to receive booster vaccination.All eligible participants who have previously received any COVID-19 vaccination(as primary regimen or additional dose)if last vaccination was >= 6 months ago,will be offered to receive single ad hoc booster dose of Ad26.COV2.S and who are not willing to receive single ad hoc booster dose of Ad26.COV2.S or are not eligible for ad hoc booster dose will continue to receive booster vaccination.
89485777|NCT04436276|Experimental|Cohort 3|Participants (good or stable health adults aged >=65 years) will receive Ad26.COV2.S at 2 dose levels, as a single dose or 2 dose schedule with an 8-week interval or matching Placebo on Day 1 and Day 57. At unblinding visit, post EUA, conditional licensure, or approval for the single dose regimen of Ad26.COV2.S vaccine, participants initially receiving placebo will be offered to receive a single dose of Ad26.COV2.S. If they choose not to receive Ad26.COV2.S they will be asked to continue to be followed in this study. All eligible participants who have previously received any COVID-19 vaccination (as primary regimen or additional dose) if the last vaccination was >=6 months ago will be offered to receive a single ad hoc booster dose of Ad26.COV2.S. If they choose not to receive ad-hoc booster dose or if they are not eligible for ad-hoc booster dose, then they will be asked to continue to be followed in this study.
89485778|NCT03546517|Experimental|Intervention with DNHS technique|Dry needling of biceps brachii, brachialis, flexor digitorum superficialis and flexor digitorum profundus, triceps brachialis, extensor digitorum and adductor pollicis
89485779|NCT03546517|Sham Comparator|Sham Dry Needling|Sham Dry needling of biceps brachii, brachialis, flexor digitorum superficialis and flexor digitorum profundus, triceps brachialis, extensor digitorum and adductor pollicis
89485780|NCT02813681|Active Comparator|US-epidural SVD|US-epidural SVD group - participants who received US examination prior to epidural placement. The purpose of this group is to determine if US derived landmarks reduce pressure sensitivity
89485781|NCT02813681|Sham Comparator|(US sham- epidural SVD)|US sham- epidural SVD group- participants who received US examination process but with the monitor turned off.
89485782|NCT02813681|Placebo Comparator|SVD without an Epidural|Spontaneous vaginal delivery without an Epidural group The purpose of the control group is to serve as a baseline.
89485783|NCT04900363|Experimental|AK112|Subjects receive AK112 monotherapy intravenously (IV) until no more benefits from treatment.
88952767|NCT01954862|Experimental|Water Exchange/AI|Insufflation not used until the cecum is reached. Infusion of a sufficient amount of water to render the lumen of the colon a slit to progress with the colonoscope. Part of the infused water will be constantly suctioned back exchanging clean for dirty or hazy water. Air pockets will be always aspirated to collapse the lumen. After cecal intubation as much residual water as possible will be aspirated before beginning the withdrawal phase. During withdrawal residual water and feces will be suctioned. Withdrawal phase done using room air insufflation.
88952768|NCT01954888|Active Comparator|Blind technique|Stellate ganglion block using the anterior paratracheal approach using surface landmarks.
88952769|NCT01954888|Active Comparator|Ultrasound-guided technique|Stellate ganglion block using the ultrasound-guided lateral approach at the sixth cervical vertebral level.
88952770|NCT01954901|Experimental|Standard treatment plus Hyperbaric Oxygen|The study treatment group will be compressed on air in the hyperbaric chamber to 2.0 atmospheres absolute (ATA), then placed on 100% oxygen by a head tent for 90 minutes.
89485784|NCT03545347|Experimental|Nandrolone Decanoate|Physical therapy with strength training, protein-rich nutritional supplement plus Nandrolone decanoate.
89485785|NCT03545347|Placebo Comparator|Placebo (Sodium Chloride)|Physical therapy with strength training, protein-rich nutritional supplement plus placebo.
89485786|NCT02393950|Experimental|Drug: ODM-106|Oral capsules dosage 2-800mg once daily for one day
88952771|NCT01954901|Placebo Comparator|Standard treatment with Hyperbaric Room Air|The study control group will be compressed to 2.0 ATA on air, then breath 21% oxygen and 79% nitrogen through the hood for 90 minutes.
89485787|NCT02393950|Placebo Comparator|Drug: Placebo|Oral capsules given once daily for one day
89485788|NCT02815397|Experimental|Single arm, open label|Metformin added to standard of care treatment for all patients
89485789|NCT03562403|Experimental|DBS on patients with abnormal movement disorders|16 patients with intractable abnormal movement disorders (Parkinson's disease, Essential tremors and Dystonia)
89485790|NCT02427958|Experimental|Leuprorelin|Participants with body weight greater than or equal to (>=) 20 kilogram (kg) will receive the recommended dose of leuprorelin 3.75 milligram (mg), injection, subcutaneously, once every 4 weeks for 96 weeks. Participants with body weight less than (<) 20 kg will receive leuprorelin 1.88 mg, injection, subcutaneously, once every 4 weeks for 96 weeks.
89485791|NCT03715127|Placebo Comparator|Placebo|one oral dose of 100% mannitol (placebo)
89485792|NCT03715127|Active Comparator|Psilocybin|one oral dose of 0.215mg/kg psilocybin (verum)
88952772|NCT01954914|Experimental|Plerixafor, Mozobil|Administration of a single dose of Plerixafor 240 µg/kg body weight of the donor SC in the evening at 10 PM after frustraneous stem cell apheresis on day 1.
88952773|NCT01954940|Experimental|Whole Body Vibration Therapy|Group will receive daily whole body vibration therapy for up to 9 minutes maximum at a maximum of 18 Hz.
88952774|NCT01954940|No Intervention|Control group|Group will not receive whole body vibration therapy. This group will conduct all other tests and outcomes except whole body vibration therapy.
88952775|NCT01954953||no intervention|
88952776|NCT01955018|Experimental|VeoTM|A new algorithm called VeoTM (General Electric Healthcare, Milwaukee, MI, USA) decreases the image noise up to 70% compared with the gold standard FBP model. Moreover, Veo improves spatial resolution with excellent detection of low and high contrast objects from a CT Dose Index (CTDIvol) equal to 0.3 mGy
88952777|NCT01955018|Other|gold standard FBP model|The objective of the present study is to compare Veo with the gold standard FBP for detecting pulmonary asbestos-related conditions among workers previously exposed to asbestos. Comparisons included radiation delivered and image quality
88952778|NCT01955031|Experimental|Telemonitoring|Patient with type 2 diabetes randomized in telemonitoring group have a telemonitoring device with educational Tools at their home
88952779|NCT01955031|Sham Comparator|Usual care|patient randomized in this group have a usual care
88952780|NCT01955057||Smokers with lung cancer|
88952781|NCT01955070|Experimental|Implementation|Multimedia Presentation for Ketamine sedation
88952782|NCT01955070|Experimental|Intervention|Multimedia Presentation for Ketamine sedation
88952783|NCT01955070|No Intervention|Control|Patients that received the standard consent with signed consent form
89485793|NCT03562325|Other|ACT|Acceptance & Commitment Therapy (ACT)
89485794|NCT02260037|Experimental|Epinastine nasal|single rising doses
89485795|NCT02260037|Placebo Comparator|Placebo|
88952784|NCT01955096|Experimental|fast-track surgery|The included patients will be randomly divided to two groups :30 that will undergo LAG with FTS rehabilitation programme and 31 that also will undergo LAG but receive conventional postoperative care.Laparoscopy-assisted gastrectomy will be carried out in this approach.There will be no difference in the surgical procedures of both groups.The criteria for discharge are: tolerance of solid diet, return of bowel habits and ability to walk on their own.
88952785|NCT01955096|Other|conventional postoperative care|The included patients will be randomly divided to two groups :30 that will undergo LAG with FTS rehabilitation programme and 31 that also will undergo LAG but receive conventional postoperative care.Laparoscopy-assisted gastrectomy will be carried out in this approach.There will be no difference in the surgical procedures of both groups.The criteria for discharge are: tolerance of solid diet, return of bowel habits and ability to walk on their own.
88952786|NCT01955135|Active Comparator|sedation|The sedation group (Group S, n=30), received 1 mg/kg ketamine and 1 mg/kg propofol as a bolus for induction. The patients then received an infusion of 100-150 mcg/kg/min propofol and 0.25mg/kg/h of ketamine for maintenance.
88952787|NCT01955135|Active Comparator|general anesthesia|In the general anesthesia group (Group G, n=30), anesthesia was induced using 8% sevoflurane by inhalation with 50% nitrous oxide in oxygen; endotracheal intubation was facilitated without use of a neuromuscular blocker agent. Anesthesia was maintained with sevoflurane (2%) and 50% nitrous oxide in oxygen.
88952788|NCT01955148||Prior sPTB or PROM|Women who have had a previous delivery of a live born singleton between 20 weeks, 0 days and 36 weeks, 6 days due to spontaneous preterm premature labor or preterm rupture of fetal membranes
88952789|NCT01955148||Short cervical length|Short cervical length (≤25 mm) determined by transvaginal ultrasound
88952790|NCT01955148||Twin Pregnancy|Current twin pregnancy
88952791|NCT01955148||Prior cervicdal surgeries|Cervical cerclage in a prior pregnancy or prior cone biopsy or prior LEEP
88952792|NCT01955174|Experimental|Botulinum toxin injection|Esophageal endoscopic injection of botulinum toxin
88952793|NCT01955174|Sham Comparator|No injection|No injection of botulinum toxin
88952794|NCT01955187|Experimental|Sequential therapy: Tacrolimus-Rituximab|Tacrolimus: Initial dose of 0.05 mg/Kg/day PO, adjusted to blood levels (5- 7 ng/ml) for six months. Starting at the end of month 6, tacrolimus will be reduced by 25% per month, resulting in a complete withdrawal at the end of month 9.
88952795|NCT01955187|Active Comparator|Cyclical therapy: Corticosteroids and Cyclophosphamide|Month 1, 3 and 5: 1g IV methylprednisolone daily for three doses, oral methylprednisolone (0.5mg/kg/day) Month 2, 4 and 6: Oral Cyclophosphamide (2.0 mg/kg/day)
88952796|NCT01955200|Experimental|CLOP-150|clopidogrel 150mg once daily
88952797|NCT01955200|Experimental|CLOP+CILOST|clopidogrel 75mg once daily plus cilostazol 100mg twice daily
88952798|NCT01955200|Experimental|TICAG|ticagrelor 90mg twice daily
88952799|NCT01955200|Active Comparator|CON(conventional DAPT)|clopidogrel 75mg once daily
88952800|NCT01955200|Active Comparator|Non-HOPR|clopidogrel 75mg once daily
88952801|NCT01955213||Morphine Sulphate|Patient groups are defined by the type of opioid used, being either morphine sulphate, fentanyl or oxycodone.Patients will be treated with methylnaltrexone in a standard dosing regimen for their weight: 38-62kg:8 mg, 62-114kg:12 mg, >114 kg: 0.15 mg/kg) Methylnaltrexone will be administered subcutaneously every other day for up to 7 doses.
89485796|NCT02036489|Experimental|Induction and consolidation treatment|
89485797|NCT02392624|Experimental|Omalizumab|Participants will receive open-label omalizumab treatment at 300 mg SC Q4W for 24 weeks. After 24 weeks open-label treatment, eligible participants will be randomized to receive omalizumab treatment at 300 mg SC Q4W for next 24 weeks (up to Week 48). Participants randomized to omalizumab may, at the discretion of the investigator, be transitioned from blinded study drug to open-label omalizumab at 300 mg SC Q4W if they experience clinically significant worsening in their CIU (as judged by the investigator). Participants who are transitioned to open-label omalizumab will continue to receive open-label omalizumab as study drug until Week 48.
88952802|NCT01955213||Fentanyl|Patient groups are defined by the type of opioid used, being either morphine sulphate, fentanyl or oxycodone.Patients will be treated with methylnaltrexone in a standard dosing regimen for their weight: 38-62kg:8 mg, 62-114kg:12 mg, >114 kg: 0.15 mg/kg) Methylnaltrexone will be administered subcutaneously every other day for up to 7 doses.
89485798|NCT02392624|Placebo Comparator|Placebo|Participants will receive open-label omalizumab treatment at 300 mg SC Q4W for 24 weeks. After 24 weeks open-label treatment, eligible participants will be randomized to receive placebo SC Q4W for next 24 weeks (up to Week 48). Participants randomized to placebo may, at the discretion of the investigator, be transitioned from blinded study drug to open-label omalizumab at 300 mg SC Q4W if they experience clinically significant worsening in their CIU (as judged by the investigator). Participants who are transitioned to open-label omalizumab will continue to receive open-label omalizumab as study drug until Week 48.
89485799|NCT02036567||surgical patients|no interventions, observational study
89485800|NCT02036567||laboring women|no interventions, observational study
88952803|NCT01955213||Oxycodone|Patient groups are defined by the type of opioid used, being either morphine sulphate, fentanyl or oxycodone.Patients will be treated with methylnaltrexone in a standard dosing regimen for their weight: 38-62kg:8 mg, 62-114kg:12 mg, >114 kg: 0.15 mg/kg) Methylnaltrexone will be administered subcutaneously every other day for up to 7 doses.
88952804|NCT01955226|Experimental|Tegaderm CHG clear dressing|Patients randomized to receive Tegaderm CHG clear dressing. All central line care will remain uniform between the two groups as dictated by the central line maintenance bundle currently directing central line care in our children's hospital.
88952805|NCT01955226|Active Comparator|Standard clear Tegaderm dressing|Patients randomized to receive standard clear Tegaderm dressing. All central line care will remain uniform between the two groups as dictated by the central line maintenance bundle currently directing central line care in our children's hospital.
88952806|NCT01955239|Active Comparator|Standard IMRT|Standard IMRT in which the mean dose to both whole parotid glands is minimized.
89485801|NCT02036567||volunteers|pain induction by noxious heat stimulation, measurement of pain by device and documentation of pain reported by subjects
89485802|NCT02047565|Experimental|Part 1 - 60mg edoxaban|Treatment A: single oral dose of 60 mg edoxaban (1 × 60 mg tablet)
89485803|NCT02047565|Experimental|Part 1 - 180mg edoxaban|Treatment B: single oral dose of 180 mg edoxaban (3 × 60 mg tablet)
89485804|NCT02047565|Experimental|Part 2 - 60mg edoxaban and 50 IU/kg Beriplex P/N|Dose cohort 1: 60 mg edoxaban + 50 IU/kg Beriplex P/N in 1 period and placebo (0.9% Sodium Chloride Injection, USP), in the other period
89485805|NCT02047565|Experimental|Part 2 - 60mg edoxaban and 20 IU/kg Beriplex P/N|Dose cohort 2: 60 mg edoxaban + 25 IU/kg Beriplex P/N in 1 period and placebo (0.9% Sodium Chloride Injection, USP), in the other period
89485806|NCT02047565|Experimental|Part 2 - 60mg edoxaban and 10 IU/kg Beriplex P/N|Dose cohort 3: 60 mg edoxaban + 10 IU/kg Beriplex P/N in 1 period and placebo (0.9% Sodium Chloride Injection, USP), in the other period
89485807|NCT03156686|No Intervention|Control|Patients will be randomly assigned to conventional hospital care
89485808|NCT03156686|Experimental|Home care treatment|Patients will be randomly assigned to the HOME-based hospitalization and treated with intravenous diuretics. Following discharge within 48 hours from the hospital, patients in the HC group will be treated at home.
89485809|NCT03063866|Active Comparator|M group|Midazolam 3 mg i.v added to fentanyl 0.5 ug/kg
89485810|NCT03063866|Active Comparator|P Group|Propofol 1 mg/kg i.v added to fentanyl 0.5 ug/kg i.v
89485811|NCT02037191|Placebo Comparator|ARM A : METHOTREXATE|"Arm A: methotrexate 20 to 25 mg / week for 6 months. Patients who will experience at least a 25% hair regrowth after the month 5 evaluation will continue methotrexate or placebo from month 6 to the end of the study (month 12).~Non responder patients in both arms A and B will be re-randomized to receive from month 6 to the end of the study (month 12):~methotrexate alone or~methotrexate associated with prednisone 0.3 mg/Kg/day"
88952807|NCT01955239|Experimental|Stem-cell Sparing IMRT|Stem-cell Sparing IMRT in which the mean dose to the stem cell containing region of the parotid gland is minimized
88952808|NCT01955252|Experimental|Azithromycin|"All participants older than 2 months (population 18,000) will be offered a single oral dose of oral azithromycin (tablets) 30 mg per Kg up to a maximum dose of 2g.~Women who tell the investigators they are pregnant and people with known allergy to macrolides will be offered benzathine benzylpenicillin.~This will be a single arm study. Study participants who met the inclusion criteria and agree to sign the consent form will be managed with proposed drug and systematically observed to measure outcomes of interest."
89485812|NCT02037191|Placebo Comparator|ARM B : PLACEBO|"Arm B placebo Patients who will experience at least a 25% hair regrowth after the month 5 evaluation will continue methotrexate or placebo from month 6 to the end of the study (month 12).~Non responder patients in both arms A and B will be re-randomized to receive from month 6 to the end of the study (month 12):~methotrexate alone or~methotrexate associated with prednisone 0.3 mg/Kg/day"
89485813|NCT04980170|Experimental|clindamycin group|Patients who take Clindamycin after Dental implants
89485814|NCT04980170|Experimental|Amoxicillin With Clavulanic Acid group|Patients who take Amoxicillin With Clavulanic Acid after Dental implants
89485815|NCT02047721|Experimental|Physical Intervention|A supervised exercise program
89485816|NCT02047721|Experimental|Nutritional Intervention|A supervised diet program
89485817|NCT02387164|Experimental|Alum-GAD, Vitamin D3|Two doses à 20 microgram of subcutaneous alum-GAD (Diamyd), 30 Days apart. Vitamin D 2000 U/Daily with start 30 days before the first injection of Diamyd. Vitamin D treatment will continue throughout the whole study period of 5 years.
89485818|NCT02387164|Placebo Comparator|Placebo, Vitamin D3|Two doses of subcutaneous placebo, 30 Days apart. Vitamin D 2000 U/Daily with start 30 days before the first injection of Diamyd. Vitamin D treatment will continue throughout the whole study period of 5 years
89485819|NCT02047799|Active Comparator|Calcitriol|A daily dose of 1000 IU of cholecalciferol (administered as 1 capsule of 25 μg each)
89485820|NCT02047799|Placebo Comparator|Control|A daily dose of placebo (administered as 1 capsule )
89485821|NCT02047877||Respiratory Illness|Previously healthy patients admitted with acute respiratory illness who are then intubated requiring mechanical ventilator support. Endotracheally intubated patients of age 37 weeks gestation through 17 years with an acute respiratory illness in the absence of existing cardiopulmonary disease, tracheostomy, or immunocompromised condition. Tracheal aspirates (TA), bronchial fluid (nb-BALF), and blood are collected within 48-hours following endotracheal intubation. All three samples are collected again at two additional time points following intubation: between days 3-4 and between days 5-7, so long as the patient remains endotracheally intubated.
89485822|NCT02048033|Active Comparator|Arm with Apollo Endosurgery OverStitch technical|
89485823|NCT02048033|Placebo Comparator|Arm without Apollo Endosurgery OverStitch technical|
88952809|NCT01955265|Experimental|Sports mentorship programme|1.5-hour sports mentorship session once a week, 18 weeks total.
89485824|NCT02048111|Experimental|IB1001|
89485825|NCT02048267||Alcoholic|
89485826|NCT02048267||Non alcoholic|
89485827|NCT03813719||All patients attending Rapid access Gynaecology Clinic|All patients attending Rapid access Gynaecology Clinic for the first time.
89485828|NCT02392234|Experimental|VX-661/Ivacaftor combination|
89485829|NCT02392234|Experimental|Ivacaftor monotherapy|
89485830|NCT02392234|Placebo Comparator|Placebo|
89485831|NCT03816605||control|Cells were cultured in the basic medium containing 2× penicillin and streptomycin antibody.
89485832|NCT03816605||Recombinant FGF19|Cells were cultured in the basic medium with recombinant FGF19 at concentration of 100ng/ml.
88952810|NCT01955265|Active Comparator|Health promotion|The access to a health promotion website any time during the intervention period. The website contains general health information including those related to physical activity.
88952811|NCT01955278|Experimental|Creation of defitinive end colostomy|Patients undergoing elective laparoscopy assisted colorectal surgery, with the creation of a permanent end colostomy
88952812|NCT01955291|Experimental|Reinforced Feedback in Virtual Environment|During the experiment, patients in the RFVE training group (Reinforced Feedback in Virtual Environment) will receive 1 hour of virtual reality-based therapy by means of RFVE and 1 hour of TNR treatment (Traditional Neuromotor Rehabilitation). Both treatments will last 1 hour a day, five days weekly for four weeks. The treatment is focused on motor function impairment of the upper extremity.
88952813|NCT01955291|Other|Traditional Neromotor Rehabilitation|The TNR training group (Traditional Neuromotor Rehabilitation) patients will be treated totally for two hours daily by means of a TNR programme. The treatment will last 4 weeks.
88952814|NCT01955304|Experimental|A-fasted dosing followed by fed dosing|Experimental: Fasted dosing of fruquintinib followed by fed dosing; Dosing in the fasted state followed by fed dosing
88952815|NCT01955304|Experimental|B-fed dosing followed by fasted dosing|Experimental: Fed dosing of fruquintinib followed by fasted dosing; Dosing in the fed state followed by fasted dosing
88952816|NCT01955317|Experimental|chlorhexidine intervention|The intervention arm will also receive hand hygiene counselling with chlorhexidine and a pump bottle with chlorhexidine lotion along with mothers and neonatal health counseling.
89485833|NCT03816605||High-glucose|Cells were cultured in the high-glucose medium at concentration of 25mM.
89485834|NCT03816605||FGF19 and HG|Cells were cultured in the medium with both recombinant FGF19 and high-glucose.
89485835|NCT02036723|Experimental|BCD-021|"BCD-021 is a product code for bevacizumab biosimilar manufactured by CJSC BIOCAD, Russia.~In this arm 72 patients will receive BCD-021 at a dose 1.25 mg (in 0.05 ml of solution) as an intravitreal injection on day 1 and then every 28 days during 12 months."
89485836|NCT02036723|Active Comparator|Lucentis®|Lucentis® is ranibizumab drug produced by Novartis Pharmaceuticals Canada Inc. In this arm 36 patients will receive Lucentis® at a dose 0.50 mg (in 0.05 ml of solution) as an intravitreal injection on day 1 and then every 28 days during 12 months.
89485837|NCT02036801||ARDS|Patients with ARDS (according to the Berlin Definition criteria) in mechanical ventilation
89485838|NCT02036801||Healthy control|Patients with healthy lung supported with mechanical ventilation for clinical purposes
89485839|NCT02036879|No Intervention|Main study|"The main study is an observational study.~All women will be followed for one menstrual cycle (or approximately one month) observationally off of any hormone supplementation. They will have 3 study visits corresponding to their menstrual cycle phases (menses, ovulation, and luteal).~Women participating in the main study may participate in the optional interventional sub-study.~Men participating in this study will be followed for 1 month observationally. They will have 3 study visits that correlate with the female arm of this study."
88952817|NCT01955317|Active Comparator|Control|This arm will receive maternal and neonatal health counselling which includes discussion and education about antenatal care, safe and clean delivery, recognition of danger signs for the mother and neonate, immediate new born care, and essential new born care. Each mother will receive a clean delivery kit and pictoral cue cards for danger sign recognition.
88952818|NCT01955330||Hybrid robotic cabg patients|Postoperative (5-7 years)Hybrid CABG robotically assisted surgical revascularization patients
89021704|NCT00336362|No Intervention|2|Participants will not receive hydroxyurea pretreatment.
89485840|NCT02036879|Experimental|Loestrin Optional Substudy|Women participating in the main study may participate in the optional sub-study. Following a negative urine pregnancy test, women will be started on once daily oral Loestrin (1.5 mg norethindrone + 0.03 mg ethyl estradiol). They will be followed for two months on this agent and have 2 additional study visits.
89485841|NCT02036957|Experimental|BALM ARM|The product will be applied throughout the body in abundant quantity to achieve that the skin be perfectly hydrated. Will be applied twice a day (after showering and at night), massaging the area until completely absorption.
89485842|NCT02036957|Placebo Comparator|PLACEBO ARM|It be applicated in like manner that balm arm
89485843|NCT02049983|Experimental|Use of Levita Magnetics Grasper|
89485844|NCT02050061|Experimental|compression stocking|compression stocking (SIGVARISTM), daily for 3 months
89485845|NCT02050061|No Intervention|standard medical therapy|Usual care
89485846|NCT02050139|Experimental|L-cysteine (Biocysan®)|Study subjects will take one tablet of L-cysteine or placebo every morning four times a week and two tablets of L-cysteine or placebo three times a week during the whole study period
89485847|NCT02050139|Placebo Comparator|Placebo|Study subjects will take one tablet of L-cysteine or placebo every morning four times a week and two tablets of L-cysteine or placebo three times a week during the whole study period
88952819|NCT01955343||Lung cancer|Newly diagnosed and untreated non small cell lung cancer patients who underwent surgical resection for NSCLC (pathological stage I-III)
89485848|NCT02050217|Experimental|Noninvasive ventilation|Neurally Adjusted Ventilatory Assist versus Pressure Support flow triggered delivered by helmet
88952820|NCT01955343||Control|Subjects who will have surgery due to recurrent spontaneous pneumothorax Patients without lung cancer or other malignancies
88952821|NCT01955395|Active Comparator|Immediate Group|If the participant is assigned to the Immediate Group, the participant will immediately receive the Relaxation Response Resiliency Program (3RP) intervention (3 months), followed by 3 months of continuing to practice what the participant learned during the intervention.
88952822|NCT01955395|Active Comparator|Waitlist Group|If the participant is assigned to the Waitlist Group, the participant will wait for 3 months and then receive the full Relaxation Response Resiliency Program (3RP) intervention (3 months).
88952823|NCT01955408||Overactive bladder after Synergo|
88952824|NCT01955421|Experimental|Erlotinib100|Patients will be randomized to buy and receive erlotinib 100mg qd.
88952825|NCT01955421|Experimental|Gefitinib250|Patients will be randomized to buy and receive gefitinib 250mg qd.
88952826|NCT01955447|Placebo Comparator|Reference|no added plant-based ingredients
88952827|NCT01955447|Active Comparator|Low level plant-based ingredients|Low level addition of plant-based ingredients
88952828|NCT01955447|Active Comparator|Medium level plant-based ingredients|Medium level addition of plant-based ingredients
88952829|NCT01955447|Active Comparator|High level plant-based ingredients|High level addition of plant-based ingredients
88952830|NCT01955486|Experimental|flight simulation|flight simulation in pressure chamber
88952831|NCT01955525||Acute coronary patients|Patients aged 18 and above who have been hospitalised with an ACS during the period of 2011 to 2013.
88952832|NCT01955538|Active Comparator|Control|Psychiatric treatment as usual for 6 months according to best clinical practice: 10 consultations with a medical doctor (medication and psycho-education) as well as 16 consultations with a psychologist.
88952833|NCT01955538|Experimental|Basic Body Awareness Therapy|Standard psychiatric treatment + Basic Body Awareness Therapy for 20 weeks, 1 hour/week.
88952834|NCT01955538|Experimental|Mixed physical activity|Standard psychiatric treatment + Mixed physical activity for 20 weeks, 1 hour/week.
88952835|NCT01955551|Experimental|Motiv. Interviewing|In the MI (motivational interviewing) study arm, participants will receive MI phone calls designed to evoke change talk and to prompt the participant to identify goals in regards to child behavior or parenting. The caller will engage in problem solving with the participants.
88952836|NCT01955551|Active Comparator|Anticipatory Guidance|In the Anticipatory Guidance on Child Development study arm, the participants will receive two phone calls with no MI content. The content of these phone calls is derived from an alignment of the Teaching Strategies GOLD® standards with the Head Start Development and Early Learning Framework. , This content is entirely scripted and pre-specified.
88952837|NCT01955577|Experimental|Vitamin D3 cholecalciferol|1000IU x3 daily in a period of 14 days. After 14 days 1000IU x 1 daily.
88952838|NCT01955577|Placebo Comparator|Placebo orally everyday|One placebo pill x3 daily in a period of 14 days. After 14 days x1 placebo pill daily.
88952839|NCT01955590|Experimental|Metacognitive therapy|The focus of metacognitive therapy (MCT) is on metacognitive beliefs thought to underlie the development and maintenance of posttraumatic symptomatology.
88952840|NCT01955590|Active Comparator|EMDR|Eye movement desensitization reprocessing (EMDR): participant is asked to focus on trauma-related imagery, negative cognitions and body sensations while simultaneously focusing attention to a bilateral physical stimulation.
88952841|NCT01955590|Active Comparator|Treatment as usual|A group of 30 patients matched for age, gender and personality disorders receiving treatment as usual (TaU) in an outpatient setting will be included as a non-randomized comparative control condition.
88952842|NCT01955603|Experimental|Dose level 1|
88952843|NCT01955603|Experimental|Dose level 2|
88952844|NCT01955603|Experimental|Dose level 3|
89485849|NCT02048345|Experimental|Suspension, fasted state|Suspension Noxafil will be administered in the fasted state to the volunteers.
88952845|NCT01955642||AVC|Patients with non-cardioembolic AIC requiring initiation of treatment with clopidogrel as usual indications
88952846|NCT01955655|Active Comparator|Baclofen|The starting dose was 0.75 mg/kg in four divided doses daily and was cautiously increased at three-day intervals until crying subsided or symptoms of over dosage or side effects appeared. The usual maximum dose was two mg/kg in four divided doses daily.
88952847|NCT01955655|Placebo Comparator|placebo|Placebo contained fructose powder in equal quantity in packets mimicking those of Baclofen.
88952848|NCT01955668|Experimental|AZD6738|Patients will receive a single dose on day 1 followed by ongoing multiple dosing until MTD or MFD is reached.
89485850|NCT02048345|Experimental|Suspension, with sugar (delay gastric emptying)|Suspension will be co-administered with glucose to delay the gastric emptying time
89485851|NCT02048345|Experimental|Solution, fasted state|A solution (by acidifying the suspension in water to pH 1.2) will be administered to healthy volunteers in a fasted state.
89485852|NCT02048345|Experimental|Solution, with sugar (delaying gastric emptying)|A solution of posaconazol (by acidifying the suspension in water to pH 1.2) will be administered together with sugar to delay the gastric emptying.
89485853|NCT02963090|Active Comparator|Topotecan|Topotecan IV at 1265mg/m^2 Days 1-5 of every 21 day cycle
89485854|NCT02963090|Experimental|Pembrolizumab|Pembrolizumab IV 200mg infusion Day 1 of every 21 day cycle
89485855|NCT02048423|Experimental|Ketamine|Drug
89485856|NCT02037035|Experimental|Healthy|Healthy participants will receive ketamine in the scan
89485857|NCT02037035|Experimental|Depressed|Depressed participants will receive ketamine in the scan
89485858|NCT02048501|Other|Weight Regain|The weight regain group will include 20 subjects who underwent Roux-en-Y gastric bypass (RYGB) with a follow up of at least 2 years and have experienced excess weight loss (EWL) of at least 50% at 12 (+ 2) months post-operatively and regained at least 15% of the post-operative nadir weight.
89485859|NCT02048501|Other|Sustained Weight Loss (SWL)|The sustained weight loss group will include 20 subjects who underwent Roux-en-Y gastric bypass (RYGB) with a follow up of at least 2 years and have experienced excess weight loss (EWL) of at least 50% at 12 (+ 2) months post-operatively and have regained less than 15% of the post-operative nadir weight.
89485860|NCT04979936|Active Comparator|early laparoscopic cholecystectomy|early laparoscopic cholecystectomy
89485861|NCT04979936|Active Comparator|percutaneous cholecystostomy|percutaneous cholecystostomy first followed by delayed laparoscopic cholecystectomy
89485862|NCT04979468|Other|ARM A|Participants in Arm A will be randomized to switch to DTG/3TC 50/300 mg QD until week 48 (early switch).
88952849|NCT01955694|Experimental|BAY94-8862 (2.5 mg)|2.5 mg BAY94-8862 tablet and placebo capsule once daily in the morning, with possible up-titration to 5 mg once daily at Visit 6 (Day 30), and sham up-titration at Visit 8 (Day 60), based on the value of blood potassium
88952850|NCT01955694|Experimental|BAY94-8862 (5 mg)|5 mg BAY94-8862 tablet and placebo capsule once daily in the morning, with possible up-titration to 10 mg once daily at Visit 6 (Day 30), and sham up-titration at Visit 8 (Day 60), based on the value of blood potassium
88952851|NCT01955694|Active Comparator|Eplerenone|25 mg eplerenone every other day, i.e. one 25 mg eplerenone capsule on Day 1, Day 3, Day 5, etc. in the morning, 1 placebo capsule on Day 2, Day 4, Day 6, etc. in the morning, and 1 placebo tablet once daily in the morning, with possible up-titration to 25 mg eplerenone once daily at Visit 6 (Day 30), i.e. one 25 mg eplerenone capsule once daily in the morning and 1 placebo tablet once daily in the morning, and a possible up-titration to 25 mg once daily [if not performed at Visit 6 (Day 30)] or to 50 mg once daily [if up-titrated to 25 mg once daily at Visit 6 (Day 30)] at Visit 8 (Day 60), based on the value of blood potassium
89485863|NCT04979468|Other|ARM B|Participants in Arm B will continue the INSTI-based ART regimen until week 48, and then will be switched to DTG/3TC through week 96 (delayed switch).
89485864|NCT02048579|No Intervention|Treatment as Usual|
89485865|NCT02048579|Experimental|Behavior Therap + Motivational Interviewing|Supporting Teens' Academic Needs Daily Therapy program delivered to parents and teens
89485866|NCT03562169|Active Comparator|Conventional Autologous Stem Cell Transplant (ASCT)|Melphalan 200mg/m2 IV infusion on Day -1, followed by ASCT on Day 0
89485867|NCT03562169|Experimental|Augmented Autologous Stem Cell Transplant (ASCT)|Melphalan 100mg/m2 IV infusion on Day -3 and -2 plus ixazomib 4mg capsules on Day -4 and -1. ASCT will then be given on Day 0.
89485868|NCT03063554|Active Comparator|Endoscopic Ultrasound Guided Biliary Drainage|Endoscopic Ultrasound Guided biliary drainage with stent placement. EUS via either stomach or duodenum.
89485869|NCT03063554|Placebo Comparator|ERCP|Endoscopic Retrograde Cholangiopancreatography with transpapillary biliary stent placement only.
88952852|NCT01955694|Experimental|BAY94-8862 (7.5 mg)|7.5 mg BAY94-8862 tablet and placebo capsule once daily in the morning, with possible up-titration to 15 mg once daily at Visit 6 (Day 30), and sham up-titration at Visit 8 (Day 60), based on the value of blood potassium Note: This treatment group may be introduced into the study or not after safety and tolerability of these doses has been assessed by an independent Data Monitoring Committee (DMC) (1st dose recommendation DMC meeting).
89485870|NCT02427802|Experimental|Gentamicin sponge group|Topical Gentamicin Collagen Sponge: Up to four collagen sponges each containing 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base) administered daily, with systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.
89485871|NCT02427802|Placebo Comparator|Placebo sponge group|Matching placebo collagen sponge administered daily, with systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.
88952853|NCT01955694|Experimental|BAY94-8862 (10 mg)|10 mg BAY94-8862 tablet and placebo capsule once daily in the morning, with possible up-titration to 20 mg once daily at Visit 6 (Day 30), and sham up-titration at Visit 8 (Day 60), based on the value of blood potassium Note: Only in case the above mentioned additional treatment arm (BAY94-8862, 7.5 mg) has been added, a second dose decision meeting of the DMC will take place, Again safety and tolerability of all doses will be assessed by an independent DMC (2nd dose recommendation DMC meeting). Based on this data, none or up to two treatment groups (BAY94-8862, 10 mg and BAY94-8862,15 mg) may be introduced into the study.
88952854|NCT01955694|Experimental|BAY94-8862 (15 mg)|15 mg BAY94-8862 tablet and placebo capsule once daily in the morning, with possible up-titration to 20 mg once daily at Visit 6 (Day 30), and sham up-titration at Visit 8 (Day 60), based on the value of blood potassium Note: Only in case the above mentioned additional treatment arm (BAY94-8862, 7.5 mg) has been added, a second dose decision meeting of the DMC will take place, Again safety and tolerability of all doses will be assessed by an independent DMC (2nd dose recommendation DMC meeting). Based on this data, none or up to two treatment groups (BAY94-8862, 10 mg and BAY94-8862,15 mg) may be introduced into the study.
88952855|NCT01955746||Type 1 DM|
88952856|NCT01955759|Experimental|beta blocker and amiodarone|The inteventin will be that patients will receive beta blocker Bisoprolol in adjusted dose + Amiodarone per os starting 7 days before coronary by-pass surgery, 200 mg. x 3 tab, followed by 200 mg x 2 tab per os starting on the second postoperative day untill discharge
88952857|NCT01955759|Experimental|beta blocker and statin|The intervention will be that patients will receive beta blocker (Bisoprolol tab in adjusted dose)+ Rosuvastatin 20 mg. x 1 starting 7 days before coronary by-pass surgry untill discharge.
88952858|NCT01955759|Placebo Comparator|beta blocker|Patients will receive beta blocker (Bisoprolol tab in adjusted dose).
89021705|NCT00336557||Regularly Scheduled NAb Testing Arm|Subjects will be scheduled for 5 study visits over the course of 12 months and any NAbs test results will be available to the investigator during the study.
89485872|NCT02427802|No Intervention|No sponge group|Systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.
89485873|NCT02050295|Experimental|Nerve block washout|Patients will receive a washout infusion of saline through their perineural catheter to reverse their motor block while maintaining the sensory block.
89485874|NCT02050295|Sham Comparator|Sham washout|Patients will receive an infusion of saline run just enough to maintain catheter patency.
89485875|NCT02050451|Experimental|Nutrition Intervention|Ensure Plus®, consumed orally twice daily for 2 weeks before and 4 weeks after surgery
89485876|NCT02050451|Active Comparator|Control|Over the counter daily multivitamin for 2 weeks before and 4 weeks after surgery
89485877|NCT02050529|Experimental|Labetalol|This group (Group A; Labetalol) receiveD intravenous(IV) labetalol manufactured by Zafa pharmaceutical, 50mg/10 ml ampoule) bolus doses administered over 2 minutes, at 10 minutes interval. Initially dose of 20 mg wAS administered, and if required repeated in increments of 40 mg,80 mg,80 mg,80 mg every 10 minutes till SBP became <160 and DBP <110 mm Hg, upto a maximum cululative dose of 300mg(total 5 bolus doses).During this time pulse and blood pressure were checked every 10 minutes.
89485878|NCT02050529|Active Comparator|Hydralazine|This group (Hydralazine;Group B) received intravenous Hydralazine and served control. Bolus doses of 5 mg administered over 2 minutes, at 20 minutes interval. Pulse and blood pressure were checked every 10 minutes interval. If SBP threshold of 160 mm Hg or DBP 110 mm Hg was still reached after 20 minutes, then second bolus was repeated. Similarly if after 20 minutes SBP was still ≥160 or DBP ≥110 mm Hg, then third dose was given. If SBP or DBP thresholds were still exceeded after 20 minutes then similarly 4th and 5th dose of 5 mg were given. Failure to reduce SBP<160 or DBP<110 after consecutive maximum 5 boluses(total 25 mg) was labeled as severe persistent hypertension.
89485879|NCT02050607|No Intervention|Control group|Control group
89485880|NCT02050607|Experimental|Fecal microbiota transplantation|Fecal microbiota transplantation from healthy lean donors
89485881|NCT02427646|Experimental|ET BoNT-A treatment|ET participants treated with kinematic-guided BoNT-A injections over 6 injection cycles
89485882|NCT02427646|Experimental|PD tremor BoNT-A treatment|PD participants treated with kinematic-guided BoNT-A injections over 6 injection cycles
89485883|NCT02048657|Experimental|Foley group|The Foley Airway Stylet Tool was used to guide ProSeal LMA insertion
89485884|NCT02048657|Experimental|I-Tool group|the ProSeal LMA was inserted with a standard introducer-tool
89485885|NCT02392000|Experimental|WatchPAT and CBT-i Coach mobile app|Individuals use the WatchPAT sleep monitor and the CBT-i Coach app to self-manage insomnia
89485886|NCT02051465|Experimental|LumenR Retractor|Endoscopic removal of polyp using modified overtube LumenR Retractor
89485887|NCT02051465|Active Comparator|Removal without overtube|Endoscopic removal of polyp without overtube
89485888|NCT02048969|Experimental|Flumazenil|A priming dose bolus of 0.4 mg of flumazenil will be administered intravenously (Minute 0). At this time the 1H-MRS scan will begin. Over the next 6 minutes, a drip infusion of flumazenil will be administered to the patient at a rate of 0.1 mg flumazenil per minute for a total of 7 doses during the scan. Total dose will be 1.0 mg.
89485889|NCT02048969|Placebo Comparator|Saline|A priming dose bolus of 0.4 mg of placebo will be administered intravenously (Minute 0). At this time the 1H-MRS scan will begin. Over the next 6 minutes, a drip infusion of placebo mixed with saline will be administered to the patient at a rate of 0.1 mg per minute for a total of 7 doses during the scan. Total dose will be 1.0 mg.
89485890|NCT02050685||All patients for PSG at SLBO|All patients incoming in the sleep study centre for a PSG. At the arrival the screening score will be recorder. AHI will be recorded next morning after analysis of the PSG.
89485891|NCT03561935|Experimental|Propafenone group|Prescribtion of propafenone for the management of premature ventricular complex
89485892|NCT03561935|Active Comparator|Indenol group|Prescribtion of indenol for the management of premature ventricular complex
89485893|NCT02385526||Group A|Vagus Nerve Stimulation Therapy Standard Titration
89485894|NCT02385526||Group B|Vagus Nerve Stimulation Therapy Alternate Titration 1
89485895|NCT02385526||Group C|Vagus Nerve Stimulation Therapy Alternate Titration 2
89485896|NCT03061994||Cardiomyopathy|"Children(older than 18 years old) are diagnosed as cardiomyopathy by three cardiologists and recruited in pediatric heart center,Beijing Anzhen Hospital, recording the results of clinical lab and echocardiography.~Adults are diagnosed as cardiomyopathy by three cardiologists and recruited in the department of cardiology ,Beijing Anzhen Hospital."
89485897|NCT03061994||Control|Healthy children and adults are recruited in Beijing Anzhen Hospital, with negative results of echocardiography and clinical lab examination.
89485898|NCT02808143|Experimental|Treatment (pembrolizumab, BCG solution)|"PRE-INDUCTION PHASE: Patients receive pembrolizumab intravesically once on day -14.~INDUCTION PHASE: Patients receive BCG solution intravesically once weekly for 6 weeks at weeks 0-5 and pembrolizumab intravesically every 2 weeks at weeks 0, 2, and 4.~MAINTENANCE PHASE: Beginning 2 weeks after the last dose of BCG solution, patients receive pembrolizumab intravesically every 2 weeks for 12 weeks at weeks 7, 9, 11, 13, 15, and 17 for a total of 6 doses. Patients then receive pembrolizumab intravesically every 4 weeks at weeks 21, 25, 29, 33, 37, 41, 45, and 49 for a total of 8 doses."
89485899|NCT02427100|No Intervention|Control Group|Control participants will be paid for assessments. They will receive study newsletters and a pedometer with advice after the final follow-up visit.
89485900|NCT02427100|Active Comparator|Intervention Group|Intervention participants will receive 4 weekly newsletters, a pedometer with walking advice, and twice daily fruit/vegetable snacks during weekdays.
89485901|NCT02050763|Experimental|Intervention arm|Intervention arm clusters (n=4) received an IPV prevention intervention (the Safe Homes and Respect for Everyone (SHARE) Project), enhanced HIV testing and treatment and routine HIV services.
89485902|NCT02050763|No Intervention|Control arm|Control arm clusters (n=7) received standard of care HIV services alone.
89485903|NCT02629796||CIDP treated (IVIG)|patients with a diagnosis of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) according to European criteria, treated with IVIG (intravenous immunoglobulin as a first line of treatment) as a usual treatment
88952859|NCT01955772|Experimental|EN (Enteral Nutrition)|"NE group: According to the HAS and SFNEP recommendations and the good practice rules, a polyurethane or silicone NGT, 8 to 10 French units, will be inserted and its positioning will be controlled by radiography before the EN beginning. Polyurethane and silicone are very well tolerated by nasal and oesophagus mucosa and have a long life duration allowing keeping the same tube during 2 to 3 months.~PN group: PN will be administrated by a central venous catheter, which is usually inserted in allo-HSCT patients to allow the administration of chemotherapy and of the different parenteral treatments."
89485904|NCT02629796||control|healthy subjects
89485905|NCT04979390|Experimental|Treatment group|
89485906|NCT02806973|Experimental|Nasal Glucagon (NG) - Treatment 1|One dose of 3 milligram (mg) NG administered in one of four study periods.
89485907|NCT02806973|Experimental|NG - Treatment 2|Two NG doses, 3 mg each dose, administered 15 minutes apart, in the same nostril, in one of four study periods.
89021706|NCT00336557||Usual Care Arm|Subjects will be scheduled for 2 study visits over the course of 12 months and any NAbs test results will be unknown by the investigator until the conclusion of the subject's study participation.
89485908|NCT02806973|Experimental|NG - Treatment 3|Two NG doses, 3 mg each dose, administered 15 minutes apart, in opposite nostrils, in one of four study periods.
89485909|NCT02806973|Experimental|NG - Treatment 4|Two NG doses, 3 mg each dose, administered one immediately after the other, in opposite nostrils, in one of four study periods.
89485910|NCT03561857|Experimental|Confocal Laser Endomicroscopy|All included patients will undergo probe-based Confocal Laser Endomicroscopy during Robotic-Assisted Radical Prostatectomy (RARP) or Laparoscopic Radical Prostatectomy (LRP)
89485911|NCT02049125||No AKI|Patients with cirrhosis admitted to hospital with bacterial infection with initial serum creatinine below 1.5mg/dL.
89485912|NCT02049125||AKI and Infection|Patients with cirrhosis admitted to hospital with bacterial infection and initial serum creatinine above 1.5mg/dL.
89485913|NCT02049125||AKI with No Infection|Patients with cirrhosis admitted to hospital with initial serum creatinine above 1.5mg/dL without bacterial infection.
89485914|NCT02049203|Placebo Comparator|Placebo|Placebo gel capsule, dosage matches number of Ataciguat capsules for each respective dose, capsules taken once daily with breakfast for 14 consecutive days.
89485915|NCT02049203|Active Comparator|Ataciguat|Ataciguat, orally administered gel capsule, 50, 100, or 200 mg, once per day with breakfast for 14 consecutive days
89485916|NCT02037737||RA patients on Abatacept IV|Rheumatoid Arthritis (RA) patients with inadequate response to one or more conventional DMARDs including Methotrexate and treated with Abatacept IV according to routine clinical practice in France
89485917|NCT02051543|Experimental|Brief Behavioral Treatment of Insomnia-Military Version|
89485918|NCT02049281|Experimental|Vintafolide|Participants receive vintafolide intravenous (IV) bolus, starting dose 1.4 mg, on Days 1, 3, 5, 15, 17, and 19 of each 28-day cycle for up to 6 cycles.
89485919|NCT02037503|Placebo Comparator|Placebo for drug resistant depression|Patients will be treated for 21 days with daily oral placebo
89203916|NCT00811824|Active Comparator|1|Immediate physical activity and dietary change intervention
89203917|NCT00811824|Other|2|Delayed physical activity and dietary change intervention
89485920|NCT02037503|Experimental|Ketamine for suicidal ideation|Patients will be treated for 21 days with daily oral Ketamine
89485921|NCT02037503|Experimental|Ketamine for drug resistant depression|Patients will be treated for 21 days with daily oral Ketamine
89485922|NCT02037503|Placebo Comparator|Placebo in suicidal ideation|Patients will be treated for 21 days with daily oral placebo
89485923|NCT02037503|Experimental|Healthy Participants|Healthy participants that underwent a romantic relationship breakup will attend in tow experimental sessions, one with placebo and one with ketamine. Sessions will be separated within the range of 1 to 6 weeks
89485924|NCT02049671||Growth Hormone Therapy|
89485925|NCT02049671||Control Group|
89485926|NCT03561779|Experimental|YYD302|YYD302 (2ml)
89485927|NCT03561779|Active Comparator|Synovian Inj.|Synovian Inj. (3ml)
89485928|NCT02037815|Experimental|Mannitol|20% mannitol solution, 125 ml, IV infusion in 15 min
89485929|NCT02037815|Experimental|Hypertonic saline|3.1% sodium chloride solution, 125 ml, IV infusion in 15 min
89485930|NCT02037581|Experimental|Early detection and Integrated Care|"The intervention condition consisted of measures to improve early detection and treatment quality (Integrated Care).~Interventions for the improvement of early detection. The measures for improved early detection aiming at reducing the duration of untreated psychosis included 4-year measures to improve mental health literacy, reduce stigma and improve service utilization.~Measures to improve treatment quality should be achieved through extending the Hamburg model to a cross-age and interdisciplinary Integrated Care model for adolescent and young adult patients with psychotic disorders aged 12-29 years."
89485931|NCT02037581|Other|Standard Care|Historical control group with standard care parallelized regarding age, diagnosis and illness stage, which was treated in the period before the implementation of the intervention conditions. The control group consisted of n=105 patients with early psychosis between the ages of 12 and 29, who had been treated between January 2005 and December 2008. The central differences in comparison with the intervention conditions lie in the lack of measures for the improvement of early detection, the absence of the TACT team, as well as the regular referral to an established psychiatrist with in most cases regular contact frequency.
89485932|NCT02051621|Active Comparator|Cavo-tricuspid-isthmus-ablation|Ablation of atrial flutter
88952860|NCT01955772|Other|PN (Parenteral Nutrition)|"NE group: According to the HAS and SFNEP recommendations and the good practice rules, a polyurethane or silicone NGT, 8 to 10 French units, will be inserted and its positioning will be controlled by radiography before the EN beginning. Polyurethane and silicone are very well tolerated by nasal and oesophagus mucosa and have a long life duration allowing keeping the same tube during 2 to 3 months.~PN group: PN will be administrated by a central venous catheter, which is usually inserted in allo-HSCT patients to allow the administration of chemotherapy and of the different parenteral treatments."
88952861|NCT01955785|Active Comparator|PC ventilation|Intervention with pressure controlled ventilator
88952862|NCT01955785|Active Comparator|PRVC ventilation|Intervention with Pressure Regulated Volume Controlled Ventilator
88952863|NCT01955798|Experimental|Trocar|Pyramidal tip reusable 11mm trocar
88952864|NCT01955798|Active Comparator|Veress needle|Veress needle
88952865|NCT01955811|Other|Platelet concentrate transfusion and Human Fibrinogen|Blood samples will be collected directly before the start of transfusion and 1 hour after the end of transfusion. These samples will be spiked with Human Fibrinogen and clotting tests will be performed. After 24 h after end of transfusion a clotting test will be performed again.
88952866|NCT01955824|Experimental|1% lignocaine|"Each patient included in study will be nebulized prior to flexible bronchoscopy with 2.5 ml of 4% lignocaine. This will be followed by spray of 2 puffs of 10% lignocaine over the posterior pharynx and vocal cords. Lignocaine jelly (2%) will be applied in the nasal cavity. Lignocaine (1%) 8ml will be administered as spray as you go technique through the bronchoscope over the vocal cords, carina, right and left main bronchus as aliquots of 2 ml each. Additional requirement of lignocaine will also be recorded for all the patients."
89021707|NCT03277872|Active Comparator|GlideScope (GVL) Blade|Patients in this arm will have the first laryngoscopy performed with the GlideScope (GVL) blade and the second one with the MacIntosh blade. The tool used for the third laryngoscopy, followed by intubation, (either GlideScope or MAC blade) will be decided according to a second randomization, necessary to one of our secondary objectives.
89485933|NCT02051621|Active Comparator|Pulmonary vein isolation|pulmonary vein isolation
89485934|NCT02051621|Active Comparator|Antiarrhythmic drug|"Medical treatment of atrial flutter with either class I antiarrhythmics (flecainide (Tambocor ®) 100 mg twice daily or propafenone (Rytmonorm ®) up to 150 mg 3 times daily) or amiodarone (Cordarex®) 200 mg daily~cardioversion as needed"
89485935|NCT02051699||One-leg standing view|
89485936|NCT02051699||both-leg standing view|
89485937|NCT02806505|Experimental|Peginterferon alfa-2a 135 microgram (mcg)|Chronic Hepatitis C participants with end-stage renal disease undergoing hemodialysis will receive Peginterferon alfa-2a 135 mcg subcutaneously (SC) once weekly up to Week 48.
89485938|NCT02806505|Experimental|Peginterferon alfa-2a 90 mcg|Chronic Hepatitis C participants with end-stage renal disease undergoing hemodialysis will receive Peginterferon alfa-2a 90 mcg SC once weekly up to Week 48.
89485939|NCT02051777|Other|ONS 1 and DA|Oral Nutritional Supplement 1 and Dietary Advice
89485940|NCT02051777|Other|ONS 2 and DA|Oral Nutritional Supplement 2 and Dietary Advice
89485941|NCT02051777|Other|DA Alone|Dietary Advice Alone
89485942|NCT02053337|Experimental|Self adhesive foam dressing|Sponsor manufactured self adhesive foam dressing. Use of CE marked dressing according to instructions for use and study protocol.
89485943|NCT02053337|Active Comparator|Comparator self adhesive foam dressing|Non Sponsor manufactured self adhesive foam dressing. Use of CE marked dressing according to instructions for use and study protocol.
89485944|NCT02037971|Experimental|Aerobic Exercise|Subjects will follow one defined exercise process, according their cardiopulmonary exercise test, during 16 weeks, two times per a week.
89485945|NCT02037971|Experimental|Control Group|A non-exercise group will receive regular educational information relating to their condition.
89485946|NCT02053415|Experimental|Krill oil low dose|3 capsules krill oil per day, for 28 days
89485947|NCT02053415|Experimental|Krill oil high dose|9 capsules krill oil per day, for 28 days
89485948|NCT02053571|Experimental|TIPS with 3D overlay|
89485949|NCT02053649|Active Comparator|Usual Care|Usual Care will consist of medication administered by a perinatal psychiatrist and/or psychotherapy
89485950|NCT02053649|Experimental|Triple Chronotherapy + Usual Care|triple chronotherapy (TC) will consist of bright light therapy, sleep phase advance, and sleep deprivation/restriction
88952867|NCT01955824|Active Comparator|2% lignocaine|"Each patient included in study will be nebulized prior to flexible bronchoscopy with 2.5 ml of 4% lignocaine. This will be followed by spray of 2 puffs of 10% lignocaine over the posterior pharynx and vocal cords. Lignocaine jelly (2%) will be applied in the nasal cavity. Lignocaine (2%) 8ml will be administered as spray as you go technique through the bronchoscope over the vocal cords, carina, right and left main bronchus as aliquots of 2 ml each. Additional requirement of lignocaine will also be recorded for all the patients."
88952868|NCT01955850|Experimental|Internet-delivered CBT for insomnia|Online Cognitive behavioral treatment for insomnia
88952869|NCT01955850|Experimental|Face-to-face CBT for insomnia|Face-to-face Cognitive behavioral treatment for insomnia
88952870|NCT01955850|No Intervention|Waiting-list|Waiting-list
88952871|NCT01955863|Active Comparator|patient discharge on postoperative day 2|The patient was discharge on postoperative day 2 (as was done routinely)
88952872|NCT01955863|Experimental|patient discharge on postoperative day 1|The patient was discharge on postoperative day 1
88952873|NCT01955863|Experimental|patient discharge in the day of surgery|The patient was discharge in the evening of the same day of surgery (average 12 hours of hospitalization)
88952874|NCT01955876||Group 1|
89485951|NCT02053727|Active Comparator|Abatacept Arm|This arm of study subjects will receive 125 mg subcutaneous abatacept during the 24 week double blind period.
89485952|NCT02053727|Placebo Comparator|Placebo Arm|This arm of study patients will receive matching placebo injections during the 24 week double blind period.
89485953|NCT02053805|Other|screening tests|The screening will include: DRE, PSA , a multiparametric prostate MRI and a trans-rectal ultra-sound guided prostate biopsy/ MRI-US fusion , IPSS questionnaire, trans-rectal US assessment of prostate size, urine flow and residual.
89485954|NCT02051075|Active Comparator|PXN only|Sperm activation with PXN before ICSI
89485955|NCT02051075|Experimental|PXN activation and oocyte activation|Sperm activation with PXN and oocyte activation
89485956|NCT02051153|Experimental|Placebo|"Placebo: study participants received, in a double blind fashion, either a single dose (100 mg) of modafinil or a placebo pill identical to the drug.~Other Names: Placebo."
89485957|NCT02051153|Experimental|Modafinil|"Study participants received, in a double blind fashion, either a single dose (200 mg) of modafinil or a placebo pill identical to the drug.~Other Names:~Provigil"
89485958|NCT02807363|Experimental|Treatment A: Leuprolide Oral Tablet, 4 mg QD|Leuprolide Oral Tablet QD: 4 mg for 28 consecutive days.
89485959|NCT02807363|Experimental|Treatment B: Leuprolide Oral Tablet, 4 mg BID|Leuprolide Oral Tablet BID: 4 mg, 12 hours apart for 28 consecutive days.
89485960|NCT02807363|Active Comparator|Treatment C: Leuprolide 1 month depot|Leuprolide Depot : intramuscular (IM) 3.75 mg depot injection administered for one month of therapy
89485961|NCT02807363|Experimental|Treatment D: Leuprolide Oral Tablet, 10 mg BID|Leuprolide Oral Tablet BID: 10 mg, 12 hours apart for 28 consecutive days
89485962|NCT02052089|Active Comparator|Physiotherapy|patients were educated to do stretching and eccentric strengthening exercise of wrist extensor muscles
89485963|NCT02052089|Experimental|extracorporeal shockwave therapy|patients were treated with 3 sessions of high-energy shock wave therapy ESWT (Evotron, Switech medical, Kreuzlingen, CH) in 2 weeks interval. Total energy flux density ranged from 0.1 to 0.14 mJ/mm2 (1500 impulses). Shockwave was targeted over lateral epicondyle where maximum tenderness was located.
89485964|NCT02052089|Experimental|Prolotherapy|injection of 20% dextrose (3cc mixed with 0.3cc of lidocaine) to ECRB tendon was done under ultrasound guidance
89485965|NCT02052089|Experimental|Platelet-rich plasma|3 cc of PRP (Harvest SmartPReP 2 APC 30 Process Kit, Harvest Technologies, Plymouth, MA) was injected into ECRB tendon under ultrasound guidance
89485966|NCT02051231|No Intervention|Control|A control sample from each patient (no oxytocin applied) will be measured concurrently with samples treated with oxytocin.
89485967|NCT02051231|Experimental|Oxytocin|Samples from each patient will be exposed to oxytocin and then allowed to rest for 30, 60 or 90 minutes.
89485968|NCT03561623||Patients with Post Polio Syndrome|Post Polio syndrome diagnosed according to March of Dimes Criteria; 'magnetic resonance (MR) Imaging' will be performed including a 'quantitative muscle force assessment'
89485969|NCT03561623||Healthy controls|subjects age- and sex-matched; 'magnetic resonance (MR) Imaging' will be performed including a 'quantitative muscle force assessment'
89485970|NCT02051387|Active Comparator|Cannabidiol|Cannabidiol capsule, 200 mg single dose
89485971|NCT02051387|Experimental|Cannabidiol CR|Cannabidiol tablet, various dosages
89485972|NCT02051387|Experimental|Amisulpride and Cannabidiol CR|Interaction between Amisulpride and Cannabidiol CR
89485973|NCT02051387|Experimental|Olanzapine and Cannabidiol CR|Interaction between Olanzapine and Cannabidiol CR
88952875|NCT01955889|Experimental|Mobile Health Technology|Stretching and strengthening exercises provided via video using mobile health technology; walk daily using a pedometer; interact with a physical therapist remotely through an exercise application on a tablet device over 12 month period
89485974|NCT02051387|Experimental|Quetiapine and Cannabidiol CR|Interaction between Quetiapine and Cannabidiol CR
89485975|NCT02051387|Experimental|Risperidone and Cannabidiol CR|Interaction between Risperidone and Cannabidiol CR
89485976|NCT02051387|Placebo Comparator|Cannabidiol CR and Placebo|Cannabidiol CR levels without interaction with antipsychotics
89485977|NCT02053883|Placebo Comparator|Placebo|Fibrin sealant only.
89485978|NCT02053883|Experimental|Cethrin (BA-210) - Low Dose|Low dose of Cethrin in a fibrin sealant.
89485979|NCT02053883|Experimental|Cethrin (BA-210) - High Dose|High dose of Cethrin in a fibrin sealant.
89485980|NCT02053961|Active Comparator|1Hz dTMS Real|This group will receive dTMS real treatment of 1Hz
89485981|NCT02053961|Sham Comparator|1HZ dTMS SHAM|This group will receive 1HZ dTMS SHAM treatment
89485982|NCT02052167|Experimental|Methotrexate|
89485983|NCT02054039|Experimental|Incentive spirometry (IS)|Group I
89485984|NCT02054039|Active Comparator|Breath stacking (BS)|Group II
89485985|NCT03561545|Experimental|Functional capillary density|Functional capillary density during weightlessness
89485986|NCT02054117||Intracerebral Hemorrhage|Spontaneous intracranial or intraparenchymal hemorrhage that occurred in a supratentorial location.
89485987|NCT02054195|Experimental|IUD new technique|Training
89485988|NCT02054195|Experimental|No Training|No Training
89485989|NCT02052245||Subject delivering preterm baby|
89485990|NCT02052245||Subject delivering term baby|
89485991|NCT03524417|Experimental|RIG injection|RIG injection on day 7
89485992|NCT02052323|Experimental|artesunate/mefloquine (AS/MQ)|The antimalarial drug regimen being evaluated is: artesunate (AS) 4mg/kg by mouth once daily at 0, 24 and 48 hours; plus mefloquine (MQ) 15mg/kg by mouth once at 72 hours, and 10mg/kg once by mouth at 84-96 hours; plus primaquine (PQ) 0.5mg/kg single dose by mouth at 84-96 hours
89485993|NCT02056067|Experimental|Exercise|The exercise intervention group will receive social, behavioral support and research staff contact time to encourage them to increase their activity level to include twice weekly strength-training sessions and 150 min of walking/week (e.g., three 50-min walking sessions or five 30-min walking sessions) over 12 months.
89485994|NCT02056067|Active Comparator|Attention Control (Health Education)|The Attention Control Group will be provided written information that emphasizes the importance of a healthy lifestyle. Participants will be encouraged to follow the NCI and ACS physical activity guidelines. This procedure was followed in our exercise trials, with no increase in physical activity levels observed at follow-up among women in the usual care group. Attention Control participants will also receive frequent contacts throughout the 12 month intervention. Each month, women randomized to attention control will be contacted by phone to discuss a health education topic of interest
89485995|NCT02056145|Placebo Comparator|Group 1|Group 1 consented subjects who will receive for their hip surgery procedures general anesthesia (sevoflurane) with single shot femoral and lateral femoral cutaneous nerve blocks under ultrasound guidance, with 20 cc of 0.9% saline solution for the femoral block and 10 cc of 0.9% saline solution for lateral femoral cutaneous block, for a total of 30 ml saline solution 0.9%.
89485996|NCT02056145|Active Comparator|Group 2|Group 2 consented subjects who will receive for their hip surgery procedures general anesthesia (sevoflurane) with single shot femoral and lateral femoral cutaneous nerve blocks under ultrasound guidance, with 20 cc of 0.25% bupivacaine solution for the femoral block and 10 cc of 0.9% saline solution for lateral femoral cutaneous block, for a total of 20 cc 0.25% bupivacaine solution en 10 cc saline solution 0.9%.
89485997|NCT02056145|Active Comparator|Group 3|Group 3 consented subjects who will receive for their hip surgery procedures general anesthesia (sevoflurane) with single shot femoral and lateral femoral cutaneous nerve blocks under ultrasound guidance, with 20 cc of 0.25% bupivacaine solution for the femoral block and 10 cc of 0.25% bupivacaine solution for lateral femoral cutaneous block, for a total of 30 cc of 0.25% bupivacaine solution.
89485998|NCT02056223|Experimental|paracetamol|Boluses of intravenous paracetamol at 15 mg/Kg four time a day for three consecutive days.
89485999|NCT02056223|Active Comparator|Intravenous ibuprofen|Standard boluses of ibuprofen at 10-5-5-mg/Kg/dose once a day for three consecutive days.
89486000|NCT02056379|Active Comparator|Budesonide|2 mg of nebulized budesonide at 12/12 hours and 8 cc of intravenous normal saline.
89486001|NCT02056379|Active Comparator|Dexamethasone|This group will receive 0,15 mg/kg/dose of intravenous dexamethasone at 6/6 hours and 8 cc of nebulized normal saline at 12/12 hours.
89486002|NCT02056457|Experimental|Responsible fatherhood or healthy marriage|
89486003|NCT02056457|Experimental|Control|
89486004|NCT03804593||Group 1|Diagnosis of cirrhosis and no HCC confirmed by medical imaging including MRI or CT performed within 6 months of study enrollment. If lesions are present, a Liver Imaging Reporting and Data System (LI-RADS) score of LR-1 or LR-2.
89486005|NCT03804593||Group 2|Diagnosis of HCC confirmed by medical imaging (MRI or CT performed within 6 months of study enrollment with LI-RADS score of LR-5) and/or biopsy with histopathology.
89486006|NCT02056535|No Intervention|Screened Only|Screened only and met criteria for eligibility for study
88952876|NCT01955889|Active Comparator|Control|Stretching and strengthening exercises provided using printed photographs; walk daily using a pedometer; interact with a physical therapist at the beginning of the 12 month study; no use of mobile technology
89486007|NCT02056535|No Intervention|Screened and Assessed|Screened as eligible for the study and received baseline assessment
89486008|NCT02056535|Active Comparator|Intervention|Screened eligible, received baseline assessment and intervention
89486009|NCT02056691|Experimental|Exercise programme|Exercise programme Muscle biopsies
89486010|NCT02038283||Low-risk Colorectal Polyps|≤2 adenomas or 3-4 adenomas all of which are <1cm
89486011|NCT02038283||High-risk Colorectal Polyps|≥5 adenomas or ≥3 adenomas at least one of which is ≥1cm
89486012|NCT02038283||Stage I CRC|at least six months since diagnosis of Stage I CRC
89486013|NCT02038283||Stage II CRC|at least six months since diagnosis of Stage II CRC
89486014|NCT02038283||Stage III CRC|at least six months since diagnosis of Stage III CRC
89486015|NCT02038283||Stage IV CRC|at least six months since diagnosis of Stage IV CRC
89486016|NCT02054507|No Intervention|Former premature infants|Cognitive and executive evaluation by Wechsler IV tests
89486017|NCT02383966|Experimental|Cetuximab + Cisplatin/Carboplatin + 5-Fluorouracil|
89486018|NCT02383966|Active Comparator|Cisplatin/Carboplatin + 5-Flurouracil|
88952877|NCT01955902||Opioid addicts|Opioid addicts undergoing bup/nal maintenance therapy
88952878|NCT01955928|Experimental|Online Cognitive behavioral treatment for insomnia|Online Cognitive behavioral treatment for insomnia
89486019|NCT02054585|Active Comparator|NaCl %0.9|"Children will be included in each group in a randomized way using SAS (Statistical Analysis System) program.~Intervention: In this arm children will receive 20 ml/kg bolus of IV NaCl 0.9% The bags will be identical and the content will be 1 liter. This way if a second bolus is administrated before hospitalization or discharge is decided, the child will still receive the same fluid."
89486020|NCT02054585|Experimental|NaCl 0.9% +5% dextrose|"Children will be included in each group in a randomized way using SAS program.~Intervention: In this arm children will receive 20 ml/kg bolus of IV NaCl 0.9% + 5% glucose. The bags will be identical and the content will be 1 liter. This way if a second bolus is administrated before hospitalization or discharge is decided, the child will still receive the same fluid."
89486021|NCT02054663|Experimental|Bolus|Patients randomized to this arm will receive a 600mg bolus dose of clopidogrel at the time of switching from ticagrelor to clopidogrel, followed by 75mg daily.
89486022|NCT02054663|Experimental|no bolus|Individuals randomized to this arm will receive 75mg of clopidogrel at the time of the transition followed by a daily dose of 75mg orally.
89486023|NCT02054819|Other|Single arm study|"Induction chemotherapy and concurrent radiation to primary tumor Cycle 1: irinotecan 65mg/m2 and cisplatin 30 mg/m2 on Day 1 and 8 Q 21 days Cycles 2-4: irinotecan 65 mg/m2, and cisplatin 30 mg/m2 Day 1 and 8 Q 21 days PLUS radiation therapy 66 Gy/7weeks/33 daily fractions~Consolidation Radiation: therapy to metastatic sites At least 60 Gy total (taking into account a possible 3 Gy x 4 pre-treatment or equivalent) to all metastatic sites."
89486024|NCT02383576||Bevacizumab|Participants who received bevacizumab in IMELDA (MO22223) P-trial and were in maintenance phase were observed.
89486025|NCT02383576||Bevacizumab and Capecitabine|Participants who received bevacizumab and capecitabine in IMELDA (MO22223) P-trial and were in maintenance phase were observed.
89486026|NCT02748317|Experimental|Adults with Spinal Cord Injury|Lactobacillus rhamnosus GG
89486027|NCT02054975|Experimental|vitamin D2 + vitamin D3|Vitamin D2 50,000 IU each week x 4 + vitamin D3 4,000 IU each day for 3 months
89486028|NCT02054975|Active Comparator|Vitamin D lower dose|800 IU vitamin D3 by mouth each day for 3 months
89486029|NCT02052401|Experimental|Occupational Therapy Intervention|Post Discharge Domiciliary Intervention by Occupational Therapy (OT)
89486030|NCT02052401|No Intervention|Usual follow-up|Usual follow-up of post discharge elderly patients, including pharmacological, and non-pharmacological care.
89486031|NCT02055131|Placebo Comparator|aspirn fixed dose|patients of this arm will receive 100 mg of aspirin daily.over the period of follow up we will detect all thromboembolic events.
89486032|NCT02055131|Placebo Comparator|aspirin dose titrated with PFA-100|patients of this arm will receive 100 mg of aspirin daily.this dose will be multiplied whenever the PFA-100 is not suitable.once the time of occlusion is correct ,we will keep the same dose of aspirin and continue monitoring the PFA-100 durin the follow up period.
89486033|NCT02055131|No Intervention|placebo arm|in this group of patients we will just supervise thromboembolic events of the vascular access.
89486034|NCT02056847|Active Comparator|Pitavastatin calcium 4mg|Pitavastatin calcium (LIVALO®) 4mg, once a day
89486035|NCT02056847|Active Comparator|Pitavastatin calcium 2mg|Pitavastatin calcium (LIVALO®) 2mg, once a day
89486036|NCT02052479|Other|Polycystic Ovary Synrome, PCOS, Caucasian, No treatment|Frequently Sampled Intravenous Glucose Tolerance Test with minimal model analysis (MINMOD FSIVGTT)
89486037|NCT02052479|Other|Polycystic Ovary Synrome, PCOS, African-American, No treatment|Frequently Sampled Intravenous Glucose Tolerance Test with minimal model analysis (MINMOD FSIVGTT)
89486038|NCT02056925|Experimental|Experimental|
89486039|NCT02055287|Experimental|LY03004- 12.5|LY03004 dosage strength at 12.5mg
89486040|NCT02055287|Experimental|LY03004 - 25|LY03004 Dose Strength 25mg
89486041|NCT02055287|Experimental|LY03004- 37.5|LY03004 Dose Strength 37.5mg
89486042|NCT02055287|Experimental|LY03004 - 50|LY03004 Dose Strength 50mg
89486043|NCT02052713|Experimental|Sequence AB|Subjects will receive Treatment A (commercially available combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg) in period 1 and Treatment B (combination of second generation dutasteride 0.5 mg and tamsulosin HCl 0.4 mg combination) in period 2 orally once daily under fasted condition.
89486044|NCT02052713|Experimental|Sequence BA|Subjects will be randomized to receive Treatment B (combination of second generation dutasteride 0.5 mg and tamsulosin HCl 0.4 mg combination) in period 1 and Treatment A (commercially available combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg) in period 2 orally once daily under fasted condition.[dutasteride 0.5 mg and tamsulosin HCl 0.4 mg) in period 2 orally once daily under fasted condition.
89486045|NCT02055443||Holter monitor group|12-lead holter monitor application
89486046|NCT02052791|Experimental|nusinersen|
89486047|NCT02057003||DAA-based therapy against HCV|HIV/HCV-coinfected patients who start therapy against HCV including one or more DAA
89486048|NCT02426086|Experimental|Imetelstat 4.7 mg/kg|
89486049|NCT02426086|Experimental|Imetelstat 9.4 mg/kg|
89486050|NCT02057159|Experimental|NeuroVax|NeuroVax
89486051|NCT02057159|Placebo Comparator|IFA Placebo|IFA Placebo
89486052|NCT02052869|Other|esophagus intubation|all patients will be intubated in the trachea first, with subsequent intubation in the esophagus. measurements will be performed on both tubes in a blinded manner.
89486053|NCT02052947|Other|SPEC-DaTscan|SPEC-DaTscan
89486054|NCT02055833|Experimental|Intensive nutritional counseling|Nutritional counseling (follow-up visits once a week for 6 weeks [during radiotherapy] and at 1 month and at 3 months since the end of radiotherapy) + n-3 polyunsaturated fatty acids-enriched oral nutritional supplements (1-2 bottles/day)
89486055|NCT02055833|Active Comparator|Nutritional counseling|Nutritional counseling (follow-up visits once a week for 6 weeks [during radiotherapy] and at 1 month and at 3 months since the end of radiotherapy)
89486056|NCT02055911|Experimental|Ranibizumab|monthly ranibizumab (0,5 mg injected intravitreally in a standard fashion) until maximum visual acuity (VA) is achieved and remains stable for three consecutive months (for a minimum of 3 initial injections).
89486057|NCT02422264|Experimental|dTpa Group|This group will consist of infants born to mothers belonging to the dTpa Group in study 116945 [DTPA (BOOSTRIX)-047] i.e. who received a single dose of BoostrixTM during pregnancy and a dose of placebo immediately post-delivery. All infants in this group will receive Infanrix hexaTM co-administered with Prevenar 13®.
88952879|NCT01955928|No Intervention|Waiting-list|Waiting-list
88952880|NCT01955967|Other|Lidocaine|
88952881|NCT01955993||Fentanyl use for surgical pain|Adolescent patient having surgery
88952882|NCT01956006|Experimental|MIlrinone|ER milrinone
88952883|NCT01956019|Experimental|MRI scanning|patients undergo special MRI techniques (DWI-MRI and DCE-MRI) after their routine MRI examinations while undergoing routine radiotherapy. 3 lots of scans in total. They will also have a blood test.
88952884|NCT01956045||Decision making|
88952885|NCT01956058|Experimental|brachytherapy remedial|
88952886|NCT01956136|Experimental|Arm 1|The patients receive 10 weeks of Music-based Neurological Rehabilitation (MBNR) and Standard Care (SC) followed by 10 weeks of SC only.
88952887|NCT01956136|Experimental|Arm 2|The patients receive 10 weeks of Standard Care (SC) only followed by 10 weeks of Music-based Neurological Rehabilitation (MBNR) and SC.
88952888|NCT01956149|Experimental|Cabazitaxel|Cabazitaxel 20 mg/m2 over 1 hour i.v., repeated on day 22
88952889|NCT01956162|Experimental|"Group Orthèse Diabète"|"Using Orthèse Diabète, a new customized removable device with rocker sole for plantar off-loading"
88952890|NCT01956162|Active Comparator|Control Group|"Using Conventional devices, removable off-loading systems among the devices available in France"
88952891|NCT01956175|Experimental|Electrical pharyngeal stimulation|Electrical pharyngeal stimulation once daily for 10 minutes on three consecutive days.
88952892|NCT01956175|Sham Comparator|Sham stimulation|Sham stimulation once daily for 10 minutes on three consecutive days. If the subject cannot be decannulated after three days of sham stimulation, another three days of real electrical pharyngeal stimulation will be delivered.
89486058|NCT02422264|Active Comparator|Control Group|This group will consist of infants born to mothers belonging to the Control group in study 116945 [DTPA (BOOSTRIX)-047], i.e. who received a single dose of placebo during pregnancy and a dose of BoostrixTM immediately post-delivery. All infants in this group will receive Infanrix hexaTM co-administered with Prevenar 13®.
89486059|NCT02390362|Experimental|Rituximab|Rituximab 375 mg/m2 will be administered intravenously on Study weeks 1 & 3.
89486060|NCT02390362|Active Comparator|Mycophenolate Mofetil (MMF)|Mycophenolate Mofetil will be continued in the patients in the MMF arm at a standard oral dose of 600 mg/m2 PO, BID starting on Study week 1 and continuing for 12 months
89486061|NCT02389894|Active Comparator|Embol-X Embolic Protection Device|The surgeon may use either the EMBOL-X® Access Device/Aortic Cannula or a standard cannula with the EMBOL-X® filter deployed through a separate introducer sheath.
89486062|NCT02389894|Active Comparator|CardioGard Cannula|The Cardiogard embolic protection device is a curved tip 24-French aortic perfusion cannula.
89486063|NCT02389894|No Intervention|Standard Cannula|Patients in this arm will receive the standard of care surgical procedure using a cannula of the surgeon's choosing.
89486064|NCT02389816|Placebo Comparator|Placebo|Placebo tablets, orally, once daily for up to Week 8
89486065|NCT02389816|Experimental|Vortioxetine 10 mg|Vortioxetine 10 mg tablets, orally, once daily for up to Week 8
89486066|NCT02389816|Experimental|Vortioxetine 20 mg|Vortioxetine 10 mg tablets, orally, once daily for up to Week 1 followed by vortioxetine 20 mg tablets, orally, once daily for up to Week 8
89486067|NCT02388724|Experimental|Vonoprazan 20 mg|Vonoprazan 20 mg, tablet, orally, once daily and lansoprazole placebo-matching capsule, orally, once daily for up to 8 weeks.
89486068|NCT02388724|Active Comparator|Lansoprazole 30 mg|Lansoprazole 30 mg, capsule, orally, once daily and vonoprazan placebo-matching tablet, orally, once daily for up to 8 weeks.
89486069|NCT02382796|Experimental|Dacomitinib|3 dose strengths (45 mg, 30 mg, and 15 mg), continuous oral daily dosing
89486070|NCT04901260||Quality Initiative|Each participant will be asked to complete the symptoms log daily for up to 6 months. Additional surveys will be completed throughout the study by participants and GAA clinical staff.
89486071|NCT02382640|Experimental|Sequence 1: ABDC|Experimental: Sequence 1: ABDC Febuxostat 80 mg extended-release (XR) capsule, orally, once, after a 10-hour fast, and 20 mL Maalox Advance Regular Strength liquid containing Aluminum Hydroxide 200 mg, Magnesium Hydroxide 200 mg, and Simethicone 20 mg/5 mL (hereafter referred as Maalox) or equivalent, orally, once, after a 10-hour fast, on Day 1 of Period 1 (A), followed by a 7-day washout period, followed by Maalox or equivalent, orally, once, after a 9-hour fast, and febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast (1 hour after Maalox or equivalent), on Day 1 of Period 2 (B), followed by a 7-day washout period, followed by febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast, on Day 1 of Period 3 (D), followed by a 7-day washout period, followed by febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast, and Maalox or equivalent, orally, once, after an 11-hour fast (1 hour after febuxostat), on Day 1 of Period 4 (C).
89531887|NCT04975178|Active Comparator|BCG|"BCG is a live attenuated M. bovis strain developed 100 years ago and is used as a preventive vaccine against tuberculosis. It is administered at birth.~One 0.05 mL reconstituted dose of BCG contains 2.5 x 105 CFU. The control vaccine will be the BCG vaccine available and recommended in South Africa at time of the trial.~BCG vaccine produced by AJ Biologics (formerly Staten Serum Institute) is the only BCG vaccine (Danish strain) currently licensed for routine use in South Africa. The recommended BCG injection volume for newborn infants (0.05 mL, after reconstitution with BCG diluent) contains approximately 2.5 x 105 CFU (range 1-4 x 105 CFU). BCG vaccine vials should be stored in the site pharmacy at 2-8ºC."
88952893|NCT01956188|Experimental|EPA and DHA supplementation|EPA (1800mg/d) and DHA (1200mg/d) supplementation
88952894|NCT01956188|Placebo Comparator|Placebo|Soy oil (3000 mg/d)
89203918|NCT04045626|Active Comparator|Transepithelial accelerated cross-linking|"Paracel is instilled 1 drop every 1.5 minutes for 4.5 minutes then vibex-xtra is instilled 4 drops at 5.5 minutes followed by 1 drop at 6.5 minutes for a total soak time of 11 minutes followed by ultraviolet-A UVA irradiation with intended irradiance of 45mW/cm2 for 2.4 minutes"
89486072|NCT02382640|Experimental|Sequence 2: DACB|Experimental: Sequence 2: DACB Febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast, on Day 1 of Period 1, followed by a 7-day washout period, followed by febuxostat 80 mg extended-release (XR) capsule, orally, once, after a 10-hour fast, and Maalox or equivalent, orally, once, after a 10-hour fast, on Day 1 of Period 2, followed by a 7-day washout period, followed by febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast, and Maalox or equivalent, orally, once, after an 11-hour fast (1 hour after febuxostat), on Day 1 of Period 3, followed by a 7-day washout period, followed by Maalox or equivalent, orally, once, after a 9-hour fast, and febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast (1 hour after Maalox or equivalent), on Day 1 of Period 4.
89486073|NCT02382640|Experimental|Sequence 3: CDBA|Febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast, and Maalox or equivalent, orally, once, after an 11-hour fast (1 hour after febuxostat), on Day 1 of Period 1, followed by a 7-day washout period, followed by febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast, on Day 1 of Period 2, followed by a 7-day washout period, followed by Maalox or equivalent, orally, once, after a 9-hour fast, and febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast (1 hour after Maalox or equivalent), on Day 1 of Period 3, followed by a 7-day washout period, followed by Febuxostat 80 mg extended-release (XR) capsule, orally, once, after a 10-hour fast, and Maalox or equivalent, orally, once, after a 10-hour fast, on Day 1 of Period 4.
89486074|NCT02382640|Experimental|Sequence 4: BCAD|Maalox or equivalent, orally, once, after a 9-hour fast, and febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast (1 hour after Maalox), on Day 1 of Period 1, followed by a 7-day washout period, followed by febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast, and Maalox or equivalent, orally, once, after an 11-hour fast (1 hour after febuxostat), on Day 1 of Period 2, followed by a 7-day washout period, followed by febuxostat 80 mg extended-release (XR) capsule, orally, once, after a 10-hour fast, and Maalox or equivalent, orally, once, after a 10-hour fast, on Day 1 of Period 3, followed by a 7-day washout period, followed by febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast, on Day 1 of Period 4.
89486075|NCT02801669|Experimental|DU-176b 15 mg group|DU-176b orally administered at a dose of 15 mg once daily.
89486076|NCT02801669|Placebo Comparator|Placebo group|Placebo orally administered once daily.
89486077|NCT02057471|Experimental|Intravenous Ferric Carboxymaltose|All recruited patients will be allocated to this treatment. 1 gram of Ferric carboxymaltose (FERINJECT) to be given at recruitment
89486078|NCT02057627|Experimental|Perinatal Dyadic Psychotherapy|The Perinatal Dyadic Psychotherapy intervention consists of 8 home-based, nurse-delivered mother-infant sessions consisting of (a) a supportive, relationship-based, mother-infant psychotherapeutic component, and (b) a developmentally based infant-oriented component focused on promoting positive mother-infant interactions. The 8 sessions take place over three months with weekly 4 sessions (weeks 1 through 4) followed by 4 every other week sessions (weeks 5 through 8)
89486079|NCT02057627|Placebo Comparator|Standard care plus depression monitoring|Standard care plus depression monitoring by phone on a schedule comparable to the intervention groups' home visits. Eight phone calls will take place over three months with weekly 4 calls (weeks 1 through 4) followed by 4 every other week calls (weeks 5 through 8). Phone monitoring will include administration of the Edinburgh Postnatal Depression Scale.
89486080|NCT02804399|Experimental|all subjects|subjects will receive a 100 mg single oral dose of PF-06463922 followed by a 100 mg single dose of PF-06463922 combined with 600 mg QD dose of rifampin with at least 10 days of washout period between two PF-06463922 doses.
89486081|NCT02053025|Active Comparator|mycoprotein|3 levels of mycoprotein will be consumed
89486082|NCT02053025|Active Comparator|control protein|3 levels of a control protein will be consumed
89486083|NCT02038439|Experimental|Interventions: A + B + C|"See Interventions Description. In this arm, clinicians will be offered all 3 online interventions combined:~Intervention A - Online Clinical Questions Recorder~Intervention B - Online Evidence Retrieval Coach~Intervention C - Online Audit and Feedback"
89486084|NCT02038439|Experimental|Interventions A + B|"See Interventions Description. In this arm, clinicians will be offered the 2 following interventions combined:~Intervention A - Online Clinical Questions Recorder~Intervention B - Online Evidence Retrieval Coach"
88952895|NCT01956201|Experimental|Atorvastatin 20mg, Fenofibrate 160mg|Atorvastatin 20mg, Fenofibrate 160mg: po, q.d.
88952896|NCT01956201|Active Comparator|Atorvastatin 20mg, Placebo|Atorvastatin 20mg, Placebo for Fenofibrate 160mg po, q.d.
88952897|NCT01956214|Experimental|FES exercise|Participants will receive FES
88952898|NCT01956214|Sham Comparator|Mock FES exercise|participant will receive Mock FES
88952899|NCT01956227|Experimental|Home-based Exercise|Participants will be taught a series of exercises targeting balance and lower limb strength in four instructional sessions. They will be asked to complete exercises 3 times a week for 12 weeks. Exercise compliance will be recorded with a diary.
88952900|NCT01956227|Experimental|Education|Participants will attend 4 education sessions focusing on interaction of beliefs, behaviors and symptoms on falls. They will be taught self-management principles to modify their fall risk.
89203919|NCT04045626|Active Comparator|Epithelium-off accelerated cross-linking|"Vibex-rapid is instilled every 2 minutes for 10 minutes followed by ultraviolet-A UVA irradiation of 30 mW/cm2 for 4 minutes"
89486085|NCT02038439|Experimental|Interventions A + C|"See Interventions Description. In this arm, clinicians will be offered the 2 following online interventions combined:~Intervention A - Online Clinical Questions Recorder~Intervention C - Online Audit and Feedback"
88952901|NCT01956227|Experimental|Exercise plus education|Participants will attend 2 instructional exercise sessions as well as 2 education sessions. Participants will be asked to complete exercises at home 3 times per week and engage in behavior to minimize fall risk.
88952902|NCT01956227|No Intervention|Control|Participants will not receive any treatment.
88952903|NCT01956266|Experimental|Emotional prosodic treatment|The experimental treatment is consistent with the standard treatment in that it targets impairments in pitch/stress, loudness variability and control of speech rate, the core characteristics of prosodic insufficiency in PD (Darley, Aronson & Brown, 1969). However, the experimental treatment provides an innovative and targeted emphasis on the emotional component of the disorder. The production of emotional intonation in an utterance requires varying combinations of pitch/stress, loudness, and rate.
89486086|NCT02038439|Experimental|Interventions B + C|"See Interventions Description. In this arm, clinicians will be offered the 2 following online interventions combined:~Intervention B - Online Evidence Retrieval Coach~Intervention C - Online Audit and Feedback"
88952904|NCT01956292||Intraparenchimal cerebral haemorrhage|
89486087|NCT02038439|Experimental|Intervention A alone|"See Interventions Description. In this arm, clinicians will be offered only the following intervention:~* Intervention A - Online Clinical Questions Recorder"
89486088|NCT02038439|Experimental|Intervention B alone|"See Interventions Description. In this arm, clinicians will be offered only the following intervention:~* Intervention B - Online Evidence Retrieval Coach"
89486089|NCT02038439|Experimental|Intervention C alone|"See Interventions Description. In this arm, clinicians will be offered only the following intervention:~* Intervention C - Online Audit and Feedback"
89486090|NCT02038439|No Intervention|No intervention|In this arm, clinicians will be offered non of the 3 online interventions, but will just be using the usual features of the search engine available to all users.
88952905|NCT01956305|Experimental|Cohort A 10mg DS-7309|DS-7309 10 mg twice daily
89486091|NCT02055989|Experimental|Dose-escalated radiotherapy level 1|
89486092|NCT02055989|Experimental|Sequential dose-escalated radiotherapy level 2|
89486093|NCT03804827||Heart Failure With Sleep Disordered Breathing|AHI3% >/= 5 events per hour of sleep.
89486094|NCT03804827||Heart Failure without Sleep Disordered Breathing|AHI3% < 5 events per hour of sleep.
89486095|NCT02053181|Experimental|Cadazolid|Single oral dose of 3000 mg.
89486096|NCT05614037|Experimental|Felodipine Controlled Release Tablets|Test preparation (T) :Felodipine Controlled Release Tablets Specification: 5 mg Batch number: 22090301 Content: 100.8% Valid until: September 2024 Storage conditions: sealed, room temperature (10~30℃) Manufacturer: Overseas Pharmaceuticals, Ltd. Supplier: Overseas Pharmaceuticals, Ltd. Usage: Oral, 1 tablet at a time, once a day. Take it before bed and swallow it with water. Do not break, press or chew the pill.
89486097|NCT05614037|Active Comparator|Felodipine Modified-release Tablets (trade name:plendil ®)|Reference preparation (R) : Felodipine Modified-release Tablets (trade name:plendil ®) Specification: 5 mg Batch number: 2204 a11 Content: 99.1% Valid until March 2025 Storage conditions: below 25℃ Manufacturer:AstraZeneca AB Supplier: Overseas Pharmaceuticals, Ltd. Usage: Oral, 1 tablet at a time, once a day. Take it before bed and swallow it with water. Do not break, press or chew the pill.
89486098|NCT02058719||Cohort A1|HIV positive smokers
88952906|NCT01956305|Experimental|Cohort B 20mg DS-7309|DS-7309 20 mg twice daily
88952907|NCT01956305|Experimental|Cohort C DS-7309 40 mg|DS-7309 40 mg twice daily
89486099|NCT02058719||Cohort A2|HIV positive non-smokers
89486100|NCT02058719||Cohort A3|HIV negative smokers
89486101|NCT02058719||Cohort A4|HIV negative non-smokers
89486102|NCT02058719||Cohort B1|HIV positive with COPD
88952908|NCT01956305|Experimental|Cohort D DS-7309 75 mg|DS-7309 75 mg twice daily
88952909|NCT01956305|Experimental|Cohort E DS-7309 150 mg|DS-7309 150 mg twice daily
88952910|NCT01956305|Experimental|Cohort F DS-7309 150 mg with escalating metformin doses|DS-7309 150 mg twice daily with escalating metformin doses
89486103|NCT02058719||Cohort B2|HIV positive without COPD (non-COPD)
89486104|NCT02058719||Cohort B3|HIV negative with COPD
89486105|NCT02058797|Experimental|Coherence Therapy|Individual treatment with Coherence Therapy: three one-hour sessions + one booster session.
89486106|NCT02058797|Active Comparator|Cognitive Behavioral Therapy|Individual treatment with Cognitive Behavioral Therapy: three one-hour sessions + one booster session.
89486107|NCT02058875|Experimental|Treatment Group|Maximization of mycophenolicacid (MPA) derivative (to a total daily dosage of 1440mg of Myfortic®) and reduction of cyclosporine dosage (as defined by C2 monitoring) in 50 stable renal transplant patients previously on immunosuppressive therapy with cyclosporine, an MPA derivative and prednisone.
89486108|NCT02058875|Active Comparator|Control Group|25 patients continued on an mycophenolicacid (MPA) derivative, cyclosporine and prednisone.
89486109|NCT02058875|No Intervention|Observation Group|25 patients continued on an mycophenolic acid (MPA) derivative, tacrolimus, and prednisone will be followed during the same recruitment period as an additional comparison, as this is the other Calcineurin Inhibitor (CNI), which is used in kidney transplantation.
88952911|NCT01956305|Placebo Comparator|Placebo|placebo to match DS-7309
88952912|NCT01956318|Experimental|Crenobalneotherapy|18 days of balneotherapy session in 3 weeks. Patients are also delivered a booklet with advice on lifestyle.
88952913|NCT01956318|No Intervention|control group|patients are allowed to continue their usual drugs, compression therapy and are delivered a booklet with advice on lifestyle.
89486110|NCT02058953||Craniotomy scheduled|"Patients who have scheduled craniotomy with melanoma brain metastases will have the following specimens collected:~CNS tumor specimens, specifically the remaining portion from the resected melanoma CNS metastasis~the remaining portion from the adjacent normal CNS tissue. No additional normal brain tissue will be collected for research purposes only, however the routinely collect peritumoral tissue will be retained.~melanoma specimens from other extracranial, clinically palpable metastatic sites.~CSF taken at around the time of the craniotomy procedure~peripheral blood prior to craniotomy."
89486111|NCT02058953||Collection for non-craniotomy|"For those eligible patients who are not having a craniotomy:~collection of CSF will be performed by lumbar puncture or from the patient's Ommaya reservoir, if present.~collection of peripheral blood.~NOTE: Only patients who have no absolute contraindications or up to two relative contraindications will be considered for lumbar puncture"
89486112|NCT03561155|Experimental|Robot assisted treatment|The experimental group (EG) will undergo a robot-assisted arm training using Amadeo® (Tyromotion-Austria).
89486113|NCT03561155|Active Comparator|Conventional treatment|The conventional group (CG) will undergo robot unassisted treatment (Conventional treatment).
89486114|NCT02038595|Experimental|Healthy subjects|Healthy subjects (male, female)
89486115|NCT02059031|Experimental|Part A|In Part A, subjects will be randomized to receive two new formulations of GSK1265744 30 mg (New formulation 1 -micronized [B], New formulation 2un-micronized [C]) and the sodium salt reference formulation 30 mg (Reference formulation [A]) in one of six sequences; ABC, BCA, CAB, BAC, ACB, CBA in three treatment periods under fasting condition.
89486116|NCT02059031|Experimental|Part B|Fifteen eligible subjects completing the Part A of the study will enter in to Part B where they will receive either formulation B or C. The selected drug (B or C) will be administered under fed (moderate fat meal) condition in the fourth treatment period.
89486117|NCT02059109|Experimental|Single|Staff will work alone to assemble the Belmont Rapid Infuser
89486118|NCT02059109|Experimental|Pair|Staff will work in pairs to assemble the Belmont Rapid Infuser
89486119|NCT02059343||age less than or equal to 2 years|
89486120|NCT03561077|Experimental|Mindfulness program|To study the feasibility in France of a mindfulness program with mindfulness-based interventions (MBI's) dedicated for adolescents with chronic pain.
89486121|NCT02059421|Experimental|Johrei Therapy|"3 sessions per week lasting 30 minutes.~Daily report of bedtime and wake time.~Baseline:~Polysomnography~Actigraphy~Questionnaires~Blood draw~Urine collection~2 weeks:~Questionnaires~Actigraphy download~Sleep log reconciliation~6 weeks:~Polysomnography~Actigraphy download~sleep log reconciliation~Questionnaires~Blood draw~Urine collection"
89486122|NCT02059421|Active Comparator|Cognitive Behavioral Therapy for Insomnia (CBT-I)|"1 session per week for a total of 6 weeks with the option of 2 additional sessions.~Daily report of bedtime and wake time.~Baseline:~Polysomnography~Actigraphy~Questionnaires~Blood draw~Urine collection~2 weeks:~Questionnaires~Actigraphy download~Sleep log reconciliation~6 weeks:~Polysomnography~Actigraphy download~sleep log reconciliation~Questionnaires~Blood draw~Urine collection"
89486123|NCT01333943|Experimental|Experimental|Saphenous (Adductor Canal) Nerve Block
89486124|NCT01333943|Active Comparator|Control|Femoral Nerve Block
89486125|NCT01333865|Experimental|Memantine (Namenda) Treatment|
89486126|NCT01333475|Experimental|TAC1:MK-2206 & AZD6244 in Pts with Colorectal Ca|Cycle = 28 days:MK-2206:90 mg PO days 1, 8, 15, and 22 AZD6244 Hydrogen sulfate: 75 mg PO QD (every day) MK-2206 + AZD6244: MK-2206 and AZD6244 hydrogen sulfate are selective inhibitors of human AKT and MEK, respectively, with preclinical and clinical anti-tumor activity as single agents and in combination with a variety of drugs. Combination treatment in mouse cancer models harboring mutations in both the PI3K and RAS pathways was more potent compared to either agent used alone, and resulted in substantial tumor inhibition, including tumor regression.
89486127|NCT01333475|Experimental|TAC1A:MK-2206 & AZD6244 in Pts with Colorectal Ca|"Cycle = 28 days:MK-2206:135 mg PO days 1, 8, 15, and 22 AZD6244 Hydrogen sulfate: 100 mg PO QD~MK-2206 + AZD6244: MK-2206 and AZD6244 hydrogen sulfate are selective inhibitors of human AKT and MEK, respectively, with preclinical and clinical anti-tumor activity as single agents and in combination with a variety of drugs. Combination treatment in mouse cancer models harboring mutations in both the PI3K and RAS pathways was more potent compared to either agent used alone, and resulted in substantial tumor inhibition, including tumor regression."
89486128|NCT04978922|Experimental|TelEPOC with Machine Learning (ML)|"Hospital with an active telemonitoring programme of readmitted COPD patients (TelEPOC) after application of an artificial intelligence system (Machine Learning: ML).~* TelEPOC: The program consisted of: 1) Educational program about COPD. This educational program was carried-out by a respiratory nurse in two 30-minute speeches to the patient and career, once at their inclusion in the program and again 1 year later. 2) Training in using the device (smart phone) that supported the telemonitoring. 3) Daily phone calls to make self-confident the patient during the first week. Afterwards the phone calls were established according to the capacity of the patient to manage on their own."
89486129|NCT04978922|No Intervention|TelEPOC without ML|Hospitals with an active telemonitoring programme of readmitted COPD patients (TelEPOC) without the application of an artificial intelligence system (Machine Learning: ML).
89486130|NCT04978688|Experimental|Relugolix|Participants received relugolix 40 milligrams (mg) alone for 6 weeks.
89486131|NCT04978688|Experimental|Relugolix + E2/NETA|Participants received relugolix 40 mg and E2/NETA at 1 mg/ 0.5 mg for 6 weeks.
89486132|NCT04876820|Experimental|Pharmacist-led intervention|
89486133|NCT04876820|Sham Comparator|Standard of care|
89486134|NCT04434326|Experimental|[14C]CM082|To investigate the absorption properties, as well as to evaluate the mass balance and elucidate the pathways of biotransformation after a single oral dose (200mg, 100µCi) of [14C]CM082 to healthy Chinese male subjects
89486135|NCT01333397|Experimental|Dysport RU 20 U|
89486136|NCT01333397|Experimental|Dysport RU 50 U|
89486137|NCT01333397|Experimental|Dysport RU 75 U|
89486138|NCT01333397|Active Comparator|Dysport (Azzalure) 50 U|
89486139|NCT01333397|Placebo Comparator|Placebo|
89486140|NCT04974320||MINOCA|All patients diagnosed with MINOCA in precision cohort (NCT04044066) will be included.
89486141|NCT04974320||acute myocardial infarction (AMI）|All patients diagnosed with acute myocardial infarction（AMI）in precision cohort (NCT04044066) will be included.
89203920|NCT04045392|Experimental|Mediterranean diet group|Mediterranean diet with calorie restriction below 1,500 kcal per day.
89203921|NCT04045392|No Intervention|Conventional diet group|Conventional diet with calorie restriction below 1,500 kcal per day.
89203922|NCT00811980||Heathy Subjects|
89486142|NCT04974320||unstable angina (UA)|The patients diagnosed with unstable angina（UA) in precision cohort (NCT04044066) will be selected according to the matching method.
89486143|NCT04974320||MINOCA （multi-center）|The patients diagnosed with MINOCA in multi-center cohort will be included.
89486144|NCT02172872|Active Comparator|standard combination chemotherapy|
89486145|NCT02172872|Experimental|decitabine|
89486146|NCT02059577|Experimental|Treatment Group|This group received a combination of nutritional treatments, added sequentially, including vitamins/minerals, essential fatty acids, Epsom salt baths, carnitine, digestive enzymes, and healthy, gluten-free, casein-free diets.
89486147|NCT02059577|No Intervention|Non-Treatment Group|This group did not have any significant changes in their treatments for 12 months
89486148|NCT04974242|Experimental|Physiotherapist-led exercise|Structured and progressive physiotherapist-led exercise programme. Reflective of current guidance for exercise programmes for people with rotator cuff disorders, an individualised programme developed in relation to the participant's specific goals will be prescribed by the physiotherapist and supported over approximately six contact sessions across a 12-week period.
89486149|NCT04974242|No Intervention|Waiting-list control|Continue on the waiting list for rotator cuff repair surgery, as per usual care.
89486150|NCT02059655|Placebo Comparator|Eye drop solution|Patients will receive 1 dose daily over 3 month period followed by 2 months washout period. Subsequently patient will cross over to the opposite treatment and continue further treatment for 3 month period.
89486151|NCT02059655|Active Comparator|Bimatoprost|1 drop daily of Bimatoprost 0.03%. Patients will receive 1 dose daily over 3 month period followed by 2 months washout period. Subsequently patient will cross over to the opposite treatment and continue further treatment for 3 month period.
89486152|NCT03061448|Experimental|Inhibitory learning based treatment|The experimental group will go through Internet-based treatment. The exposure treatment is 8 weeks long and based on the principles of inhibitory learning, i.e. the participant is instructed to stay in the frightening situation until his/her expectancy has been maximally violated.
89486153|NCT03061448|Active Comparator|Habituation based treatment|The active comparator group will also go through Internet-based treatment. The exposure treatment is 8 weeks long and based on the principles of emotional processing theory, i.e. the participant is instructed to stay in the frightening situation until anxiety has declined (habituated).
89486154|NCT02059733|Experimental|18F-DTBZ for Parkinson's Disease and parkinsonism|"This study will compare the brain uptake of 18F- DTBZ in 20 patients with PD, 20 patients with MSA, 20 patients with PSP, 20 patients with CBS, and 20 patients with VaP, 20 patients with ET, and 10 patients with DT.~Each evaluable subject involved in this study must fulfill all the inclusion and exclusion criteria according the subject grouping, each subject will have 3 visits in this study. Safety measurement will be evaluated by medical history, vital signs, physical examinations, laboratory examinations and collecting of adverse events."
89486155|NCT03062618|Experimental|Part A: Single Dose|Two escalating sequences of single oral doses of PRCL-02, in 3 periods, starting at 4 milligrams (mg)
89486156|NCT03062618|Placebo Comparator|Part A: Single Dose (Placebo)|Two escalating sequences of matching placebo oral tablets, in 3 periods
89486157|NCT03062618|Experimental|Part B: Multiple Dose|Multiple oral doses of PRCL-02 for 28 days, at up to 3 dose levels
89486158|NCT03062618|Placebo Comparator|Part B: Multiple Dose (Placebo)|Multiple oral doses of placebo for 28 days, at matching dose levels
89486159|NCT03062618|Experimental|Part C: Multiple Dose|Multiple oral doses of PRCL-02 for 28 days, at up to 3 dose levels
89486160|NCT03062618|Placebo Comparator|Part C: Multiple Dose (Placebo)|Multiple oral doses of placebo for 28 days, at matching dose levels
89486161|NCT02057783|Experimental|Physical activity|Obstructive sleep apnea and resistant hypertension controlled + physical activity
89486162|NCT02057783|No Intervention|Control Group|Obstructive sleep apnea and resistant hypertension controlled
89486163|NCT02057861||non-diabetic|non-diabetic group; 2 mg/kg sugammadex iv, postoperatively Extubation times were recorded.
89486164|NCT02057861||diabetic|Diabetic group; 2 mg/kg sugammadex iv, postoperatively Extubation times were recorded
88952914|NCT01956344|Experimental|Immediate Treatment|Cognitive-behavioral therapy
88952915|NCT01956344|No Intervention|Delayed Treatment|This group will receive the cognitive-behavioral therapy after a 16 week delay
88952916|NCT01956344|No Intervention|Healthy Control|This group is matched to the immediate treatment group on age and gender. They do not receive an active treatment and will be used a a healthy comparator group.
88952917|NCT01956357|Experimental|Aquatic exercise|"The aquatic aerobic training had a duration of 12 weeks and adopted the interval-training method, with intensities ranging between 85 and 100% of second ventilatory threshold (VT2) and total duration of 45 minute per session.~The sessions consisted of warm up, main part and calm down. The warm-up consisted of a walk in deep water at low intensity for three minutes. The main part was intended to aerobic training in deep water, in which subjects walked and / or ran, depending on your fitness level found in pre-training test. The calm down consisted of walking in deep water at low intensity for two minutes and stretching standardized, emphasizing the muscles worked in the main part of the session, with a total duration of approximately five minutes."
88952918|NCT01956357|Experimental|Land exercise|"The land aerobic training had a duration of 12 weeks and adopted the interval-training method, with intensities ranging between 85 and 100% of second ventilatory threshold (VT2) and total duration of 45 minute per session.~The sessions consisted of warm up, main part and calm down. The warm-up consisted of a walk in athletic track at low intensity for three minutes. The main part was intended to aerobic training in athletic track, in which subjects walked and / or ran, depending on your fitness level found in pre-training test. The calm down consisted of walking in athletic track at low intensity for two minutes and stretching standardized, emphasizing the muscles worked in the main part of the session, with a total duration of approximately five minutes."
88952919|NCT01956370|Experimental|PrePex™ device|Intervention 'PrePex™ device for adult male circumcision
88952920|NCT01956370|Active Comparator|Surgical|Adult male surgical circumcision
89486165|NCT02260115|Experimental|LABS™|hydrogel sprayed laparoscopically over all pelvic areas of surgical trauma
89486166|NCT02260115|Sham Comparator|Surgical Control|Laproscopic Surgery Only
89486167|NCT03561311|Experimental|Remote ischemic conditioning group|
89486168|NCT03561311|Sham Comparator|Sham remote ischemic conditioning group|
89486169|NCT02058017|Experimental|Part I & Part II|"Part I - This is a lead-in dose-finding, open-label, non-randomised arm of the study: Using a starting dose of 10mg per week, an accelerated dose titration escalation followed by a 3+3 design will be employed until MTD and recommended weekly dose are determined.~Part II - This is a single-centre, open-label non-randomised phase II study evaluating OPB-51602 in stage III-IVB NPC conducted in the window period prior to definitive chemoradiotherapy. Eligible patients will receive OPB-51602 on a weekly basis (Day 1, 8, 15) at the recommended dose determined in part I for a total of 15 days prior to definitive chemoradiotherapy."
89486170|NCT05636501|Active Comparator|Treat-to-target Prednisolone Taper|"Patients randomized to the Treat-to-target group is prescribed with a systematic prednisolone taper according to a specific scheme. The starting dose can be increased if remission is not reached initially or in case of relapse, folloved by taper according to the specific scheme. A nurse will make a minimum of 5 phone consultations the first year, and hereafter minimum every 3 months."
89486171|NCT05636501|Placebo Comparator|Usual Care|"Patients randomized to usual care are dismissed from the hospital after the diagnosis and the prednisolone taper are subsequently performed by discretion of the patient's general practitioner."
89486172|NCT02058173|Experimental|chloroquine|150 mg chloroquine and lacebo , one tablet daily for 2 month
89486173|NCT02058173|Experimental|placebo|150 mg chloroquine and lacebo , one tablet daily for 2 month
89486174|NCT02058329|No Intervention|No intervention|Standard of care with no home visit
89486175|NCT02058329|Experimental|Home Visit|After the post hip-fracture patient is discharged to home, there will be home visits by a geriatric fellow assess overall function and response to treatment/s by depression screen, FIM scores, and environmental risk assessment
89486176|NCT02060201|Other|Treatment A: Saxagliptin 2.5mg+Dapagliflozin 5mg; Fasting|Saxagliptin 2.5 mg tablet and Dapagliflozin 5 mg tablet single dose orally on Day 1 in one of 3 periods
89486177|NCT02060201|Other|Treatment B: Saxagliptin 2.5mg/Dapagliflozin 5mg FDC; Fasting|Saxagliptin 2.5 mg/Dapagliflozin 5 mg fixed dose combination tablet single dose orally on Day 1 in one of 3 periods
89486178|NCT02060201|Other|Treatment C: Saxagliptin 2.5mg/Dapagliflozin 5mg FDC; Fed|Saxagliptin 2.5 mg/Dapagliflozin 5 mg fixed dose combination tablet single dose orally on Day 1 in one of 3 periods
89486179|NCT02060201|Other|Treatment D: Saxagliptin 5mg+Dapagliflozin 10mg; Fasting|Saxagliptin 5 mg tablet and Dapagliflozin 10 mg tablet single dose orally for on Day 1 in one of 3 periods
89486180|NCT02060201|Other|Treatment E: Saxagliptin 5mg/Dapagliflozin 10mg FDC; Fasting|Saxagliptin 5 mg/Dapagliflozin 10 mg fixed dose combination tablet single dose orally on Day 1 in one of 3 periods
89486181|NCT02060201|Other|Treatment F: Saxagliptin 5mg/Dapagliflozin 10mg FDC; Fed|Saxagliptin 5 mg/Dapagliflozin 10 mg fixed dose combination tablet single dose orally on Day 1 in one of 3 periods
88952921|NCT01956383|Experimental|PrePex™ device|Adult male circumcision by the PrePex™ device
89486182|NCT03561233|Experimental|proton pump inhibitor|omeprazole 20 mg twice daily
89531888|NCT04966741|Experimental|Setmelanotide|Investigational product: Setmelanotide,10 mg/mL in a sterile solution for Subcutaneous (SC) injection
88952922|NCT01956396|Experimental|Experimental: PrePex™ device|Adult male circumcision by the PrePex™ device
88952923|NCT01956409|Experimental|diagnostic accuracy of PET and MR spectroscopy|To investigate the diagnostic accuracy of 18F-Fluorocholine PET and proton MR spectroscopy of breast lesions, using pathology as gold standard.
88952924|NCT01956422|Experimental|Continuous Positive Airway Pressure(CPAP)|In the first 24 hours after laparoscopic prostatectomy patients undergo 3 CPAP cycles (PEEP 7.5, FIO2 40% delivered with Helmet)lasting 2 hours.
88952925|NCT01956422|Active Comparator|Venturi Mask FiO2 40%|In the first 24 hours after laparoscopic prostatectomy patients breathe Oxygen 40% delivered with Venturi Mask
88952926|NCT01956448|Experimental|Drug eluting stent (BioMatrix Flex)|Device: Percutaneous coronary intervention with implantation of drug eluting stent (BioMatrix Flex)
88952927|NCT01956448|Experimental|Drug eluting stent (Resolute Integrity)|Device: Percutaneous intervention with implantation of drug eluting coronary stent (Resolute Integrity)
88952928|NCT01956474|Other|Theralight crosslinking and Riboflavin|ultraviolet-A (UVA)-induced cross-linking of corneal collagen (CXL) using UVA light and the photo- mediator riboflavin
88952929|NCT01956487|Other|Propafenone|Open label comparison of 2 formulations
88952930|NCT01956500|Experimental|Instaflex|Instaflex Joint Support supplement (3 capsules per day for 8 weeks)
88952931|NCT01956500|Placebo Comparator|Placebo|Placebo (3 capsules per day for 8 weeks)
88952932|NCT01956526|Experimental|CORolla™ TAA Stand Alone|Single arm study design including with patients with isolated HFpEF, in NYHA f. Cl. III-IV. These patients will receive the CORolla™ TAA device. For assessments of results, intra-patient comparisons of pre-procedure and follow-up data will be performed;
88952933|NCT01956526|Experimental|AVR and CORolla™ TAA Add On group|patients who require aortic valve replacement (AVR) due to aortic stenosis and have diastolic dysfunction will receive the CORolla™ TAA device.
88952934|NCT01956526|No Intervention|AVR and CORolla ADD On - Control|patients who require only the aortic valve replacement (AVR) due to aortic stenosis and have diastolic dysfunction.
89021708|NCT03277872|Active Comparator|MacIntosh (MAC) Blade|Patients in this arm will have the first laryngoscopy performed with the MacIntosh (MAC) blade and the second one with the GlideScope blade. The tool used for the third laryngoscopy, followed by intubation, (either GlideScope or MAC blade) will be decided according to a second randomization, necessary to one of our secondary objectives.
89203923|NCT00766844|Experimental|Active|Spinal cord stimulation
88952935|NCT01956565|Experimental|Inspiratory muscle training|Participants will perform 8 weeks of IMT strength training using the Powerbreathe Kinetic device (Powerbreathe). Training will progress to 60% maximum inspiratory pressure (PiMax) with 30 breaths at high velocity (paced initially over a period of 15 minutes), twice a day, 5 days per week. Tidal breathing without inspiratory resistance is acceptable for recovery between each high velocity breath. Training will be titrated and supervised weekly for the first 8 weeks by a physiotherapist. After 8 weeks training the participants are advised to continue training unsupervised, twice a day, 3 times per week for a further 18 weeks.
89486183|NCT02058407|Experimental|Cohort 1- Part A|This cohort will follow an interlocking design with Cohort 2 - Part A. Out of the 9 healthy subjects in this cohort, 3 subjects will receive placebo and 6 subjects will receive GSK2793660 according to randomization schedule in three single-dose study periods. Drug administration will be staggered over 2 days in each period. On Day 1, only 1 subject will receive GSK2793660 and 1 subject will receive placebo. The remaining subjects will be dosed on Day 2 of each treatment period assuming adequate safety from Day 1. Placebo administration and an escalation of GSK2793660 from 0.5 mg, to 3 mg, and 20 mg in the subsequent periods, will be done with a minimum washout period of 13 days between doses. If the target clinical dose is determined as being one of the doses administered to this cohort, they will have an additional study period for the administration of target clinical dose GSK2793660 following the standard Food and drug administration (FDA) high fat/high calorie meal.
89486184|NCT02058407|Experimental|Cohort 2- Part A|This cohort will follow an interlocking design with Cohort 1 - Part A. Out of the 9 healthy subjects in this cohort, 3 subjects will receive placebo and 6 subjects will receive GSK2793660 according to randomization schedule in three single-dose study periods. Drug administration will be staggered over 2 days in each period. On Day 1, only 1 subject will receive GSK2793660 and 1 subject will receive placebo. The remaining subjects will be dosed on Day 2 of each treatment period assuming adequate safety from Day 1. Placebo administration and an escalation of GSK2793660 from 1 mg, to 10 mg, and 50 mg in the subsequent periods, will be done with a minimum washout period of 13 days between doses. If the target clinical dose is determined as being one of the doses administered to this cohort, they will have an additional study period for the administration of target clinical dose GSK2793660 following the standard FDA high fat/high calorie meal.
89486185|NCT02058407|Experimental|Cohort 3- Part B|It is planned that up to two doses evaluated in Part A will be taken through to Part B. In this cohort, the lower dose (which will be the likely clinically efficacious dose) will be given for 14 days. The dosing frequency (once a day or twice daily) will be based on a review of the safety, tolerability, PK and PD data from Part A. It is planned that 10 subjects will receive GSK2793660 and 5 subjects will receive placebo. Subjects will be dosed on Day 1 and then on Days 3-15 (assuming once-daily dosing). If dosing is twice-daily, doses will be administered in the morning and evening from Day 1-14.
89486186|NCT02058407|Experimental|Cohort 4- Part B|It is planned that up to two doses evaluated in Part A will be taken through to Part B. In this cohort, the higher dose (maximum tolerated or safe dose) will be given for 14 days. The dosing frequency (once a day or twice daily) will be based on a review of the safety, tolerability, PK and PD data from Part A. It is planned that 10 subjects will receive GSK2793660 and 5 subjects will receive placebo. Subjects will be dosed on Day 1 and then on Days 3-15 (assuming once-daily dosing). If dosing is twice-daily, doses will be administered in the morning and evening from Day 1-14. Cohort 4 will commence only after Cohort 3 is completed and data is reviewed. Also there will be no Cohort 4, if only one dose is to be evaluated in Part B.
89486187|NCT03803813||sepsis group|Patients have developed sepsis at ICU admission or during their ICU stay.
89486188|NCT03803813||non-sepsis group|Patients do not develope sepsis at ICU admission or during their ICU stay.
88952936|NCT01956565|No Intervention|Declining Inspiratory muscle training|No intervention. Interview and baseline assessment only.
88952937|NCT01956578|Experimental|Breathing Exercise Cohort|All patients enrolled will be asked to wear an external respiration band while performing a series of breathing exercises.
88952938|NCT01956591||Axillary hyperhidrosis|Patients whose major complaint is excessive sweating in the axillary region (i.e, sweating in the armpit). Patients that also have hyperhidrosis - but that are less bothersome on other sites (e.g., palmar hyperhidrosis) are not excluded, but are accounted for accordingly to their main complaint.
88952939|NCT01956591||Palmar hyperhidrosis|Patients whose major complaint is excessive sweating in the palmar region (i.e, sweating in the hands). Patients that also have hyperhidrosis - but that are less bothersome on other sites (e.g., axillary hyperhidrosis) are not excluded, but are accounted for accordingly to their main complaint.
88952940|NCT01956591||Plantar hyperhidrosis|Patients whose major complaint is excessive sweating in the plantar region (i.e, sweating in the feet). Patients that also have hyperhidrosis - but that are less bothersome on other sites (e.g., axillary hyperhidrosis) are not excluded, but are accounted for accordingly to their main complaint.
88952941|NCT01956591||Cranio-facial hyperhidrosis|Patients whose major complaint is excessive sweating in the cranio-facial region (i.e, sweating in the face). Patients that also have hyperhidrosis - but that are less bothersome on other sites (e.g., axillary hyperhidrosis) are not excluded, but are accounted for accordingly to their main complaint.
88952942|NCT01956591||Other sites hyperhidrosis|Patients whose major complaint is excessive sweating in other sites of the body (e.g., on the chest, on the abdomen). Patients that also have hyperhidrosis - but that are less bothersome on other sites previously grouped (e.g., axillary hyperhidrosis) are not excluded, but are accounted for accordingly to their main complaint.
88952943|NCT01956604|Experimental|Clonidine|"Clonidine administered orally:~Day 1/loading doses: 75µg every 3rd hour until maximum 4 doses. Day 2-7/maintenance doses: 75µg BID. Duration of treatment is maximum 7 days."
88952944|NCT01956604|Placebo Comparator|Placebo (sugar pill)|"Placebo administered orally (identical capsula as for expirimental drug):~Day 1/loading doases: 75µg every 3rd hour until maximum 4 doses. Day 2-7/maintenance doses: 75µg BID. Duration of treatment is maximum 7 days."
88952945|NCT01956617|Other|injection volume|block success or failure determines a 5 ml decrease or increase for the subsequent patient, respectively
88952946|NCT01956630|Experimental|Genetically modified DCs plus CIK cells|Patients received four subcutaneous injections of 2-5×10e7 cells of DCs at the groin, axilla, and neck respectively on days 7, 9, 11, and 13 and i.v. infusions of 2-15×10e9 CIK on days 11 and 13 per cycle. The cycle was repeated until Wilms' tumor 1(WT1) turned negative by polymerase chain reaction(PCR) or graft-versus-host disease(GVHD) appeared.
88952947|NCT01956630|Active Comparator|Donor leukocyte infusions (DLI)|Patients received DLI at a dose of 2×10e7/kg, 5×10e7/kg and 1×10e8/kg cluster of differentiation 3(CD3)+ cells at months 1, 2 and 3 respectively unless GVHD appeared.
89203924|NCT03895372|Experimental|PF-06826647 Drug Dose Level 1|Delivered orally for 16 weeks during the Investigational Treatment Period
89486189|NCT02058485|Active Comparator|Group HD|Dexmedetomidine was administered 0.5 µg.kg-1 in hypertensive patient
89486190|NCT02058485|Sham Comparator|Group ND|Dexmedetomidine was administered 0.5 µg.kg-1 in normotensive patient
89203925|NCT03895372|Experimental|PF-06826647 Placebo|Delivered orally for 16 weeks during the Investigational Treatment Period
89486191|NCT02058485|Active Comparator|Group HM|Midazolam was administered 0.025 mg. kg-1 in hypertensive patient.
89486192|NCT02058485|Sham Comparator|Group NM|Midazolam was administered 0.025 mg. kg-1 in normotensive patient.
89486193|NCT02060279|Experimental|Lifestyle intervention and carotenoid supplement|
89486194|NCT02060279|Experimental|Lifestyle intervention and placebo|
89486195|NCT02058641|Experimental|Part A|Part A will consist of 2 sessions. In Session 1, 3 blisters will be induced by a challenging agent (cantharidin solution 0.2 %, with 5 microliter administered topically) in T2DM subjects on Day 1. Blisters will be harvested 48 (+/-2) hour (hr) post induction. In Session 2, the same subjects will be administered darapladib EC tablet 160 mg orally, once daily for 11 days. On Day 10, 3 blisters will be induced by cantharidin. Blisters will be harvested 48 (+/-2) hr post induction.
89486196|NCT02058641|Experimental|Part B|In Part B, healthy subjects will be enrolled and will follow the same dosing procedure as in Part A. The decision to initiate Part B will be made by the GSK study team based on an evaluation of data from Part A.
89486197|NCT03560921||Stored blood transfusion|measurement of urinary NGAL
89486198|NCT03560921||Fresh blood transfusion|measurement of urinary NGAL
89486199|NCT03560843|Experimental|MBSR treatment|MBSR will be administered over 8 week period.
89486200|NCT03560843|No Intervention|Control group|Usual care will continue for this group.
89486201|NCT02060357|Active Comparator|Resolute Integrity Stent|Patients will be randomised in a 1:1 ratio to receive two different types of DES
89486202|NCT02060357|Active Comparator|Promus Stent|Patients will be randomised in a 1:1 ratio to receive two different types of DES
89486203|NCT02060435||EBER+ AMC|EBV+DLBCL patients in Asan Medical Center
89486204|NCT02060435||EBER+ SMC|EBV+DLBCL patients in Samsung Medical Center
89486205|NCT02060435||EBER- SMC|EBV-DLBCL patients in Samsung Medical Center
89486206|NCT02059811|Experimental|DASH Diet|"All participants will be provided a control diet for a 7-day run-in period followed by the DASH dietary intervention for a 14-day intervention period. Participants will consume the largest meal of the day in a supervised setting at the study center and all other meals and snacks will be provided in to-go packages. Weight will be held constant by measuring participant weight daily and adjusting caloric content of meals. Adherence will be monitor by review of daily food diaries."
89486207|NCT02060981|Active Comparator|Interview only|Patients will be asked to participate in an interview regarding their views on hypertension and taking medications to treat hypertension.
89486208|NCT02060981|Placebo Comparator|Control|Control group patients will then be mailed an American Heart Association brochure regarding hypertension and a brief, 5-question, paper-based survey. These patients will be asked to review the brochure, complete the survey, and mail it back to the research team using a self-addressed stamped envelope.
89486209|NCT02060981|Experimental|Interview plus decision support tool|Patients will be asked to participate in an interview regarding their views on hypertension and taking medications to treat hypertension, and to provide feedback regarding a new tool for helping patients learn more about their medications. Interview plus patients' index date for follow-up is the date of the scheduled interview.
89203926|NCT03895372|Experimental|PF-06826647 Drug Dose Level 2|Delivered orally for 16 weeks during the Investigational Treatment Period
89203927|NCT03895372|Experimental|PF-06826647 Drug Dose Level 3|Delivered orally for 16 weeks during the Investigational Treatment Period then 24 weeks in Extension Period.
89203928|NCT03895372|Experimental|PF-06826647 Drug Dose Level 4|Delivered orally for 16 weeks then for 24 weeks in Extension Period.
89203929|NCT02551926|Experimental|mobile text messaging|Patients will receive some SMS in a regular interval.
89203930|NCT02551926|Experimental|virtual communities|Patients will receive some messages by a virtual community in a regular interval.
89203931|NCT02551926|Experimental|brochures|Patients will receive some messages by as a printed media
89486210|NCT03560687|Experimental|CardioSIDERAL|Adminsitration of 2 pills per day of CArdiosideral from 30 days before operation to time of operation
89486211|NCT03560687|No Intervention|Control|
89486212|NCT02061059|Other|group 1|"group is assigned to block 1: shoemaker 1 produces shoes according to standard methods, shoemaker 2 uses plantar pressure measurements.~group is assigned to standard: wears shoes produced with standard procedure"
89486213|NCT02061059|Other|group 2|"group is assigned to block 1: shoemaker 1 produces shoes according to standard methods, shoemaker 2 uses plantar pressure measurements~group is assigned to with measurements: wears shoes produced with plantar pressure measurements"
89486214|NCT02061059|Other|group 3|"group is assigned to block 2: shoemaker 2 produces shoes according to standard methods, shoemaker 1 uses plantar pressure measurements~group is assigned to standard: wears shoes produced with standard procedure"
89486215|NCT02061059|Other|group 4|"group assigned to block 2: shoemaker 2 produces shoes according to standard methods, shoemaker 1 uses plantar pressure measurements~group is assigned to with measurements: wears shoes produced with plantar pressure measurements"
89486216|NCT02059889|Experimental|Diagnostic (diffusion-weighted MRI, 4D CT, FDG-PET)|Patients undergo 15 imaging studies: 5 chest CT scans, 5 chest MRI scans, 5 PET scans. Each scan will be obtained before treatment begins, weeks 2 and 4 during radiation therapy, 3 months and 1 year following radiation therapy. THe chest CT obtained pre-treatment, at 3 months post treatment and 1 year post treatment are considered routine and would be obtained regardless of study participation. The pre-treatment PET scan is also considered routine. All other scans are being done for the purposes of this research.
89486217|NCT02798861||CAP assessment|Controlled Attenuation Parameter with Fibroscan 402/530 before liver procurement and after liver transplantation to assess steatosis, and its association with clinical outcomes
89486218|NCT02059967|Experimental|Treatment (IGART using ABC, SIVAB, paclitaxel, carboplatin)|Patients undergo IGART using ABC 5 days a week for 7 weeks, for a total of 33 fractions with SIVAB during fractions 26-33. Patients also receive paclitaxel IV over 1 hour and carboplatin IV over 30 minutes once a week for 6 weeks.
89486219|NCT02061137|Experimental|Rett syndrome, fingolimod (FTY720)|0.5 or 0.25mg Fingolimod daily
89486220|NCT02061215||recipients aged 20-40|CMV viral load
89486221|NCT02061215||recipients older than 60|CMV viral load
89486222|NCT02061371|Experimental|virtual therapy|Group 1 (G1) included 20 patients who will carry out the virtual therapy.
89486223|NCT02061371|Experimental|conventional physiotherapy|Group 2 (G2) included 20 patients who hold conventional physiotherapy.
89486224|NCT02061449|Experimental|Initiating therapy with Romidepsin (Arm A)|Patients who are starting therapy with Romidepsin (intravenously on days 1, 8, and 15 of every 21-day cycle or alternate schedule per treating physician) also receive focal lesional radiation on days 1,3, and 5 without (level 1) or with (level 2) Poly ICLC (subcutaneously on days 1, 3, and 5) on the first cycle.
89486225|NCT02061449|Experimental|treatment with Romidepsin with SD or PR (Arm B)|Patients with stable disease on the treatment with Romidepsin (intravenously on days 1, 8, and 15 of every 21-day cycle or alternate schedule per treating physician) also receive focal lesional radiation on days 1,3, and 5 without (level 1) or with (level 2) Poly ICLC (subcutaneously on days 1, 3, and 5) on the first cycle.
89486226|NCT03799055||easy intubation|Cormack _Lehane : 1&2
89486227|NCT03799055||difficult intubation|Cormack _Lehane : 3&4
89486228|NCT02060591|Active Comparator|Exparel|
89486229|NCT02060591|Active Comparator|Marcaine|
89486230|NCT02060045|Experimental|bundle implementation|The measures were a specific training program, aspiration of subglottic secretions (ASS), introduction of an inclinometer to improve the semirecumbent position, and reinforcement of oral care with chlorhexidine.
89486231|NCT05604911||Kidney transplant patients|
89486232|NCT02060669|Experimental|Arm 1|xeloda maintaenance
89486233|NCT02060669|No Intervention|Arm 2|best supprotive care
89486234|NCT02060123|Experimental|Qigong training|"a total of 103 hours over a period of 5.5 months, consisting of:~Group learning and practice: a 2-hour qigong exercise training session will be provided by a qigong master twice a week for six consecutive weeks (24 hours),~Weekly group follow-up: a 1-hour qigong exercise will be conducted with reinforcement of learning and remedial teaching by a qigong master once a week for four consecutive months (16 hours) after the group learning and practice, and~Self-practice: participant will engage in qigong exercise for 30 minutes every day for the whole intervention period lasting 5.5 months (63 hours)."
89486235|NCT02060123|Other|Wait-list control- Health talks|Monthly health education talks unrelated to qigong will be provided starting from the point when the intervention group starts the qigong weekly follow-up.Once the intervention group has completed the qigong intervention program, the wait-list control group will receive the qigong exercise training.
89486236|NCT05654441|Experimental|Influenza Vaccine|Experimental group given influenza vaccine (Flulaval)
89486237|NCT05654441|Placebo Comparator|Sham Vaccine|The control group given a placebo (saline injection)
89486238|NCT04428008|Experimental|Active arm|1.6 mg thymalfasin in 1 mL subcutaneous injection twice weekly after dialysis for 8 weeks
89486239|NCT04428008|No Intervention|Control arm|Standard care
89486240|NCT02061527|Experimental|Breast reconstruction with ADM|Implant based Breast Reconstruction with ADM. Both arms will undergo skin or nipple sparing mastectomy and immediate breast reconstruction with implants. Patients in group B with ADM and partial submuscular coverage.
88952948|NCT01956643|Experimental|gum chewing|"Gum type was standardized with all subjects receiving sugar-free xylitol gum.~The patients in the chewing gum group, gum chewing began the morning of postoperative day 1. Patients chewed gum (two tablets) 3 times daily in the morning, afternoon, and evening for 15 min. The administration of the therapy was implemented by ICU nurses and recorded in the clinical report form file. All gum-chewing patients completed their course of gum chewing until gas out."
88952949|NCT01956643|Placebo Comparator|Control|Routine care during NPO
88952950|NCT01956656|Placebo Comparator|lotus leaf mouthwash|10 ml mouthwash to be used for 4days twice daily
88952951|NCT01956656|Placebo Comparator|placebo mouthwash|10 ml mouthwash to be used for 4 days twice daily
88952952|NCT01956669|Experimental|Pazopanib|All subjects were treated with pazopanib GW786034 tablets at a dose of 450 mg/m^2/dose or as a powder in suspension at a dose of 225 mg/m^2/dose. The maximum daily dose administered was to be 800 mg for the tablet and 400 mg for suspension. If 225 mg/m^2/dose was not tolerated (>=2 DLTs in 6 evaluable subjects), the dose for subjects who required suspension was reduced to 160 mg/m^2/dose. A cycle was defined as 28 days with no rest periods between cycles.
89486241|NCT02061527|Active Comparator|Breast reconstruction without ADM|Breast reconstruction without ADM. Both arms will undergo skin or nipple sparing mastectomy and immediate breast reconstruction with implant. Patients in group B will be reconstructed with implant and total submuscular coverage.
89531889|NCT04955964||All Participants|Participants with diagnosis of HAE who have received at least one dose of lanadelumab according to currently approved indications in routine clinical practice settings in Argentina will be observed in this study.
88952953|NCT01956682|Active Comparator|Infant formula|HA formula + starch + L. reuteri
88952954|NCT01956682|Placebo Comparator|Standard Formula|Standard Infant Formula
89486242|NCT02046590|Active Comparator|Deep Sedation|"Remifentanil 1ng/ml throughout the procedure. Propofol administration starts at an initial (estimated plasma) target concentration of 1,5 microg/ml.~Propofol administration is adjusted to level 1 or 2 on the modified observer's assessment of alertness/sedation scale. The propofol infusion will be increased stepwise by 0,5 microg/ml every 1 minute until loss of consciousness. Propofol is continued while maintaining spontaneous ventilation without assistance and systolic blood pressure ≥ 60 % of baseline systolic blood pressure."
89486243|NCT02046590|Active Comparator|General Anaesthesia|"General anesthesia will be induced with target controlled infusion (TCI) of propofol and remifentanil as in the group deep sedation.~Suxamethonium (succinylcholine) will be used to facilitate intubation. Endotracheal tube balloon pressure will be controlled during the procedure. Ventilation will be assisted using 40% oxygen in air mixture and mechanically controlled using an anaesthetic ventilator."
89486244|NCT02060747|Experimental|Coordinator-based post fracture program|The intervention arm deals with the intervention of a nurse trained in the management of osteoporosis fractures assisted by a clinical research technician who will manage the logistics and reglementary aspects of the study (patient enrollment, quality and study proceedings).
89486245|NCT02060747|No Intervention|standard care|
89486246|NCT02798315||Participants With Hepatitis C Virus (HCV) Genotype 1 or 4|"Participants with HCV genotype 1 or 4 receiving paritaprevir/r - ombitasvir with or without dasabuvir (ABBVIE REGIMEN) ± RBV.~The prescription of a treatment regimen is at the discretion of the physician in accordance with local clinical practice and label, is made independently from this observational study and precedes the decision to offer the patient the opportunity to participate in this study."
89486247|NCT02062073|Active Comparator|Abametapir Lotion 0.74%|0.2 mL applied topically to the infrascapular area of the back under occlusive patch conditions 3 times weekly for 3 weeks, following with rest period and a challenge.
89486248|NCT02062073|Placebo Comparator|Vehicle Lotion|0.2 mL applied topically to the infrascapular area of the back under occlusive patch conditions 3 times weekly for 3 weeks, following with rest period and a challenge.
89486249|NCT02062073|Other|0.1% sodium lauryl sulfate|Concurrent control 0.2 mL applied topically to the infrascapular area of the back under occlusive patch conditions 3 times weekly for 3 weeks, following with rest period and a challenge.
89486250|NCT02062073|Other|Saline 0.9%|Concurrent control 0.2 mL applied topically to the infrascapular area of the back under occlusive patch conditions 3 times weekly for 3 weeks, following with rest period and a challenge.
89486251|NCT02062229||Halthy controls|Subjects not affected by any disease and with normal seminal fluid characteristics
89486252|NCT02062229||Oligospermia|Infertile subjects with oligospermia
89486253|NCT02062229||Varicocele|Infertile subjects with varicocele
89486254|NCT02062229||Asthenospermia|Infertile subjects with asthenospermia
89486255|NCT03796949||threatened preterm birth|Women with either preterm labor or preterm prelabor rupture of the membranes. Blood samples taken at time of inclusion in the study.
89486256|NCT03796949||Controls|Women with normal pregnancies. Blood samples taken at time of inclusion in the study, either prelabor (during pregnancy) or during active phase of labor.
89486257|NCT02060825||Regional saturation monitor|Patients undergoing surgical repair of hypoplastic left heart syndrome.
89486258|NCT02063243|Other|keloid or hypertrophic scars|All patient including all skin types with keloid or hypertrophic disease receiving Intralesional Cryotherapy
89486259|NCT02062307||control patients|BMI and age matched healthy male subjects
89486260|NCT02062307||hypogonadism patients|unconfounded group of patients with hypogonadism
89486261|NCT02796755|Experimental|Riluzole Arm|Participants will take a daily oral dose of 100 mg of riluzole (50 mg two times per day). Participants will be instructed to take the study medication on an empty stomach (1 hour before or 2 hours after meals).
89486262|NCT02796755|Placebo Comparator|Placebo Arm|Participants will take a daily oral dose of 100 mg of a placebo that appears identical to riluzole (50 mg two times per day). Participants will be instructed to take the study medication on an empty stomach (1 hour before or 2 hours after meals).
89486263|NCT02062541|Experimental|Funct. assessment+fast rehabilitation|Funct. assessment+fast rehabilitation
89486264|NCT02062541|Experimental|Funct. assessment+usual rehabilitation|Funct. assessment+usual rehabilitation
89486265|NCT02062541|Experimental|usual assessment+fast rehabilitation|usual assessment+fast rehabilitation
89486266|NCT02062541|No Intervention|usual assessment+usual rehabilitation|usual assessment+usual rehabilitation
89486267|NCT02062619|Experimental|Real tDCS|"Transcranial direct current stimulation (tDCS) administered concurrently with computer-based behavioural word reading therapy.~2mA anodal direct current stimulation applied to the left inferior frontal gyrus (IFG) for first 20 minutes of therapy."
89486268|NCT02062619|Sham Comparator|Sham tDCS|"Transcranial direct current stimulation (tDCS) administered concurrently with computer-based behavioural word reading therapy.~Sham tDCS (periodical fade-in and fade-out stimulation routine) applied to the left inferior frontal gyrus (IFG) for first 20 minutes of therapy."
88952955|NCT01956695|Experimental|Lenalidomide & Rituximab|"Induction treatment : Lenalidomide 20 mg capsule on days 1 to 21 days of a 28 days cycle for the first cycle followed by 25 mg on daily on days 1 to 21 of a 28 days cycle for cycles 2 to 8 (in the absence of hematologic toxicity. Rituximab at day 1 of each induction course 375 mg/m² intravenous.~Maintenance : Lenalidomide 10 mg capsule on days 1 to 21 days of a 28 days cycle for 1 year or until progression or intolerance."
89203932|NCT02551926|Active Comparator|Control|control group will be included without any intervention
89203933|NCT00775034|Experimental|1|Study group (Tisseel®)
89203934|NCT00775034|Other|2|Control group
89203935|NCT00813696|Experimental|A|cisplatin + gemcitabine
89203936|NCT00813696|Active Comparator|B|gemcitabine
89486269|NCT02062697|Other|Ovarian Epithelial Cancer|"Lavage of the Cavum uteri and proximal fallopian tubes~Liquid-PAP (Papanicolaou) smear"
89486270|NCT02061839|Experimental|Teinted sunscream|UVA, UVB and visible light protection (exactly the same UVA and UVB protection as the comparator)
89486271|NCT02061839|Active Comparator|Regular sunscream|UVA and UVB protection
88952956|NCT01956708|Active Comparator|Remote ischemic preconditioning|"Remote ischemic preconditioning (RIPC) protocol before coronary artery bypass surgery (CABG):~after induction of anesthesia and before surgery: 3 cycles of 5 minutes left upper arm ischemia by inflation of a blood pressure cuff to 200mmHg and 5 minutes of reperfusion Anesthesia is with isoflurane (0.7-0.8% end-tidal) +sufentanil"
88952957|NCT01956708|Placebo Comparator|Placebo|"No Remote ischemic preconditioning (RIPC) protocol before coronary artery bypass surgery (CABG):~after induction of anesthesia and before surgery: the cuff is left uninflated"
89486272|NCT02061917|Experimental|Tobacco-Heating Cigarette|A group of 44 subjects who smoke and are switched to a tobacco-heating cigarette
89486273|NCT02061917|Experimental|Snus (Smokeless Tobacco)|A group of 43 subjects who smoke and are switched to snus (smokeless tobacco)
88952958|NCT01956721|Experimental|Patients with heart failure (FEVG ≥ 50%)|Patients with heart failure (FEVG ≥ 50%)
88952959|NCT01956721|Experimental|Patients with heart failure (FEVG ≤ 35%),|Patients with heart failure (FEVG ≤ 35%),
88952960|NCT01956721|Other|Healthy Volunteers|Healthy Volunteers with no heart failure
89203937|NCT02557880|Experimental|Sleep Application Diary|A sleep application diary which will automatically report results back to sleep doctor is used in addition to standard sleep hygiene counseling.
89203938|NCT02557880|Active Comparator|Treatment as Usual|Sleep hygiene counseling
89203939|NCT00813774|Active Comparator|Reference|Lyophilized formulation (reference)
89203940|NCT00813774|Experimental|Liquid|Liquid Formulation (test)
89203941|NCT00813774|Experimental|Pre-filled Syringe|Pre-filled syringe (test)
89486274|NCT02061917|Experimental|Tobacco-Burning Cigarette|A group of 44 subjects who smoke and are switched to a tobacco-burning ultra-low machine yield cigarette
89486275|NCT02061995|Experimental|PREOB® Intravenous Infusion|
89486276|NCT02062775|Active Comparator|Self-Fixating Hernia Mesh|Self-fixating polyester mesh will be used for laparoscopic inguinal hernia repair.
89486277|NCT02062775|Placebo Comparator|Non-Fixating Hernia Mesh|Non-fixating polyester mesh will be used for laparoscopic hernia repair.
89486278|NCT05654285|Placebo Comparator|Carbonated water|355ml of an orally ingested carbonated water
89486279|NCT05654285|Experimental|Cola beverage with aspartame and acesulfame K|355ml of an orally ingested carbonated cola drink, sweetened with 142mg of aspartame and acesulfame k, combined (soft drink in its commercial presentation)
89486280|NCT05654285|Experimental|Cola beverage with sucrose and stevia|355ml of an orally ingested carbonated cola drink, sweetened with 16g of sucrose and 15.62mg of stevia (soft drink in its commercial presentation)
89486281|NCT05654285|Active Comparator|Cola beverage with sucrose|355ml of an orally ingested carbonated cola drink, sweetened with 37g of sucrose
89486282|NCT03560375|Experimental|Circuit resistance training (CRT)|2-3 circuits * 10 exercises * 3 times per week
89486283|NCT03560375|Experimental|Empagliflozin 10 MG|10 mg once daily
89486284|NCT03560375|Experimental|Vegeterranean diet (V-Med diet)|The modified V-Med diet will be considered as ad-libitum (using fat sources), aimed for sufficient protein from animal and mainly plant-based sources with carbohydrates limitation.
89486285|NCT02063477|Placebo Comparator|Product one|150 mg (maltodextrin)/day (75 mg maltodextrin included in 280 mg/gelule; 2 times/day: morning and evening) of Placebo plus Dietary Approaches to Stop Hypertension (DASH)
89486286|NCT02063477|Active Comparator|Product two|150 mg Oligopin/day (75mg Oligopin included in 280mg/gelule; 2 times/day: morning and evening) of Oligopin® plus Dietary Approaches to Stop Hypertension (DASH)
89486287|NCT02382016|Experimental|Investigational treatment|Macitentan film-coated tablet 10 mg once daily.
89486288|NCT02382016|Placebo Comparator|Placebo|Matching placebo tablet once daily.
89486289|NCT04899700|Placebo Comparator|WLE-LCI|First endoscopist will perform an optical diagnosis of recurrence of post-polypectomy scar with WLE. Then a second diagnosis will be performed by the same endoscopist with blue light imaging (BLI)
89486290|NCT04899700|Active Comparator|LCI-WLE|First endoscopist will perform an optical diagnosis of recurrence of post-polypectomy scar with Linked Color Imaging (LCI). Then a second diagnosis will be performed by the same endoscopist with blue light imaging (BLI)
89486291|NCT02422186|Experimental|Intranasal Esketamine plus Oral Antidepressant|Participants will self-administer esketamine intranasally twice per week for 4 weeks as a flexible dose regimen in the Double-Blind Induction Phase. All participants will start with first dose (Day 1 as 28 milligram [mg]); second dose (Day 4) is either 28 or 56 mg. All subsequent doses may be 28, 56 or 84 mg. After the first dose, all dosing decisions are determined by the investigator based on efficacy and tolerability. In addition participants will simultaneously initiate a new, open-label oral antidepressant (Duloxetine, Escitalopram, Sertraline, or Venlafaxine extended release [XR]) on Day 1 that will be continued for the duration of Double-Blind Induction Phase.
89486292|NCT02422186|Active Comparator|Placebo plus Oral Antidepressant|Participants will self-administer matching placebo, intranasally, twice per week for 4 weeks as a flexible dose regimen in Double-Blind Induction Phase using the same titration as Esketamine. In addition participants will simultaneously initiate a new, open-label oral antidepressant (Duloxetine, Escitalopram, Sertraline, or Venlafaxine XR) on Day 1 that will be continued for the duration of Double-Blind Induction Phase.
89486293|NCT02421952||Single Cohort|All subjects will be asked to assess their pain and nausea using the visual analogue scales (VAS), the modified faces scale and the BARF scale as described below in the preoperative and postoperative areas.
89486294|NCT02796677|Experimental|AB/FF 400/12 μg BID|Participants were administered AB/FF 400/12 μg via Pressair®/Genuair® inhaler twice daily for 24 weeks of treatment.
89486295|NCT02796677|Experimental|AB 400 μg BID|Participants were administered AB 400 μg via Pressair®/Genuair® inhaler twice daily for 24 weeks of treatment.
89486296|NCT02796677|Experimental|FF 12 μg BID|Participants were administered FF 12 μg via Pressair®/Genuair® inhaler twice daily for 24 weeks of treatment.
89486297|NCT02796677|Experimental|TIO 18 μg QD|Participants were administered TIO 18 μg via Handihaler® inhale once daily for 24 weeks of treatment.
89486298|NCT05585099|Experimental|Experimental|Participants will walk in retro walking exercise on lower body positive pressure treadmill.
89486299|NCT05585099|Other|Control|Participants will walk in forward walking exercise on lower body positive pressure treadmill.
89486300|NCT02062853|Experimental|Video Group|Subjects view educational video on the use of cream medication for the treatment of actinic keratoses.
89486301|NCT02062853|Active Comparator|Verbal Group|Subjects are given verbal instructions on the use of cream medication for the treatment of actinic keratoses.
89486302|NCT02063555|Experimental|DAR-901|"Intradermal administration at 0, 2 and 4 months~Three dose groups in dose escalation: 0.1 mg, 0.3 mg and 1.0 mg, all constituted in 0.1 mL"
89486303|NCT02063555|Active Comparator|BCG|Intradermal injection of 0.1 mL saline at 0 mos, 2 mos, intradermal injection of 0.1 mL BCG at 4 mos
89486304|NCT02063555|Placebo Comparator|Sterile saline|Intradermal injection of 0.1 mL sterile saline at 0, 2 and 4 mos
89486305|NCT04978532|Experimental|Guided Imagery Group|One minute before venipuncture and during venipuncture, the children in the guided imagery group listened to a voice recording prepared in a studio. This voice recording named 'Stroll in the Forest' helped the children to imagine that they are strolling in a forest and guided them.
89486306|NCT04978532|Other|Control Group|No intervention was performed to reduce pain in the control group.
89486307|NCT03789305||Critically ill patients|Critically ill patients admitted to intensive care for more than 48 hours
89486308|NCT01947842|Experimental|Smartphone App|The pharmacist will download and configure the Dosecast smartphone application to remind the patient to take their medication in addition to pharmacist counseling on the importance of adherence.
89486309|NCT01947842|No Intervention|Counseling Alone|This arm will receive only counseling from the pharmacist with no other intervention.
89486310|NCT04973462|Active Comparator|Triazavirin group|Patients will take the standard treatment COVID-19 + Triazavirin 250mg three times daily for 7 days]
89486311|NCT04973462|Active Comparator|Oseltamivir group|Patients will take the standard treatment COVID-19 + Oseltamivir 75 mg twice daily for 7 days]
89486312|NCT02421172|Experimental|Period 1: CJM112 High Dose|Period 1: CJM112 High Dose subcutaneously (s.c.) weekly for 5 doses followed by bi-weekly for 5 doses for a total of 10 doses
89486313|NCT02421172|Placebo Comparator|Period 1: Placebo|Period 1: Placebo subcutaneously (s.c.) weekly for 5 doses followed by bi-weekly for 5 doses for a total of 10 doses
89486314|NCT02421172|Placebo Comparator|Period 2: CJM112 High Dose (Period 1) / Placebo (Period 2)|Period 2: Placebo subcutaneously (s.c.) weekly for 5 doses then bi-weekly for 5 doses for a total of 10 doses this group.This group was on CJM112 High Dose in Period 1
89486315|NCT02421172|Experimental|Period 2: Placebo (Period 1)/CJM112 Low Dose (Period 2)|Period 2: CJM112 Low Dose subcutaneously (s.c.) weekly for 5 doses then bi-weekly for 5 doses for a total of 10 doses this group.This group was on Placebo in Period 1
89486316|NCT02421172|Experimental|Period 2: Placebo (Period 1)/CJM112 High Dose (Period 2)|Period 2: CJM112 High Dose subcutaneously (s.c.) weekly for 5 doses then bi-weekly for 5 doses for a total of 10 doses this group.This group was on Placebo in Period 1
89486317|NCT02379052|Experimental|Dupilumab 300 mg QW|Participants received SC dupilumab 300 mg during the 12-week double-blind treatment phase. Participants received 2 injections (300-mg initial dose, followed by a 300-mg loading dose) on day 1, followed by weekly injections.
89486318|NCT02379052|Experimental|Placebo|Participants received matching placebo once weekly (qw) during the 12-week double-blind treatment phase. Participants received 2 injections on day 1, followed by weekly injections.
89486319|NCT02378662|Experimental|Group A|MDGN201 TARGTEPO secreting EPO (18-25 IU/Kg/day)
89486320|NCT02378662|Experimental|Group B|MDGN201 TARGTEPO secreting EPO (35-45 IU/Kg/day)
89486321|NCT02378506|Experimental|ETN 50mg QW|
89486322|NCT02347774|Experimental|SUN-101 50 mcg BID eFlow (CS) nebulizer|SUN-101 50 mcg Twice Daily (BID) via e-Flow (R) Closed System (CS) nebulizer
89486323|NCT02347774|Experimental|SUN-101 25 mcg BID e-Flow (CS) nebulizer|SUN-101 25 mcg (BID) via e-Flow (R) Closed System (CS) nebulizer
89486324|NCT02347774|Placebo Comparator|Placebo BID Eflow (CS) nebulizer|Placebo (BID) via e-Flow (R) Closed System (CS) nebulizer
89486325|NCT02794883|Active Comparator|Treatment (durvalumab)|Patients receive durvalumab IV over 1 hour on days 1 and 15. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.
89486326|NCT02794883|Active Comparator|Treatment (tremelimumab and durvalumab)|Patients receive tremelimumab IV over 1 hour on day 1 then durvalumab IV over 1 hour on days 1 and 15. Courses repeat every 4 weeks for up to 7 courses. Patients then receive both tremelimumab and durvalumab IV over 1 hour every 12 weeks in the absence of disease progression or unacceptable toxicity.
89486327|NCT02794883|Experimental|Treatment (tremelimumab)|Patients receive tremelimumab IV over 1 hour on day 1. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
89486328|NCT03796325||Depression|patients characterize with morbid obesity or obesity type 2 with co-morbidities and depression
89486329|NCT03796325||No-depression|patients characterize with morbid obesity or obesity type 2 with co-morbidities without depression
89486330|NCT02062931|Experimental|Stem Cell Preparation and Injection|"Stem Cell Preparation and Injection:~Stem Cells 60 ml of bone marrow will aspirated and used for stem cells isolation. Then stem cells will cultured using autologous serum, characterized and prepared and suspended in platelets rich plasma (PRP) using GMP rules and finally injected into ovarian tissues and ligaments .~Stem Cell Dose: 3-5 Million Autologous MSCs Injected into Ovarian tissue."
89486331|NCT02063711|Experimental|Yoga Intervention|A 1-hour yoga session will take place with guided instruction provided by a registered yoga instructor. The class includes a warm up period of 5 minutes, which includes sitting with the eyes closed and slowly breathing through the nose. After which the participant will perform a series of yoga postures in coordination with her breathing for approximately 45 minutes. The last 10 minutes of class will encompass a semi-recumbent relaxation period. This is a one time intervention.
89486332|NCT02063711|No Intervention|Control group|In order to control for 1 hour worth of time, the participants in the control group will be given a 1 hour Power Point presentation on the benefits of exercise and yoga during pregnancy.
89486333|NCT03796247||multiple sclerosis|
89486334|NCT03796247||healthy control|
89486335|NCT02063789|Experimental|Human immunoglobulin intravenous|Human immunoglobulin intravenous; GC5107A (IV-Globulin SN Inj. 10%); Day 1: GC5107A, 1g/kg, intravenous Day 2: GC5107A, 1g/kg, intravenous; Starting infusion rate: 0.01mg/kg/min (1mg/kg/min) for first 15 minutes, and then 2-fold increase every 30 minutes by maximum 0.08ml/kg/min (8mg/kg/min). Dosing modification is allowed due to tolerance.
89486336|NCT02063945|Active Comparator|Methylphenidate|"Participants in this arm will be given either Concerta - a long acting (12 hours) Methylphenidate pill - once daily, in the morning (starting dose 1 mg/kg, max dose 2 mg/kg), or Ritalin LA - a long acting (10 hours) Methylphenidate pill - once daily, in the morning (starting dose 0.6 mg/kg, max dose 1.5 mg/kg) for children who can not swallow pills."
89486337|NCT02063945|Active Comparator|Risperidone|Participants in this arm will be given a low dose of Risperidone. Starting dose will be 0.5 mg/d, max dose will be 2 mg/d.
89486338|NCT02064647|Experimental|Trend Arrow Adjustment Tool|The Trend Arrow Adjustment Tool, uses a formula based on the patients Insulin Sensitivity Factor (ISF) to allow adjustments to meal time insulin boluses, based on CGM trend arrows.
89486339|NCT02064647|Active Comparator|10/20% bolus adjustment|10-20% increase/decrease of the total original recommended bolus dose (10% for one arrow up or down, and 20% for two arrows up or down), with the original bolus dose calculated by the pump calculator (i.e. Bolus Wizard).
89486340|NCT02064647|No Intervention|No adjustment/ignore trend arrows|Subjects will ignore the CGM trend arrows, meal time bolus insulin as per Bolus Wizard
89486341|NCT02064023|Experimental|insulin pump|subjects will use an insulin pump for the duration of the pregnancy. The intervention is that they will control their diabetes using an insulin pump
89486342|NCT02064023|Active Comparator|Multiple Daily Insulin injections|subjects will continue their usual insulin treatment with multiple daily injections of sc insulin
89486343|NCT05573477|Experimental|ATB-1011 + ATB-1012|Participants will receive 1 tablet/day of each drug for 12 weeks
89486344|NCT05573477|Experimental|ATB-1012 + ATB-1013|Participants will receive 1 tablet/day of each drug for 12 weeks
89486345|NCT05573477|Active Comparator|ATB-1011|Participants will receive 1 tablet/day of each drug for 12 weeks
89486346|NCT05573477|Active Comparator|ATB-1012|Participants will receive 1 tablet/day of each drug for 12 weeks
89486347|NCT02064101||Adolescent idiopathic scoliosis|Patients with adolescent idiopathic scoliosis undergoing spinal fusion
89486348|NCT02064725|Experimental|Sodium cridanimod|Sodium cridanimod in combination with megestrol acetate or medroxyprogesterone acetate. Treatment period is 12 months; patients will be followed for another 12 month period or to disease progression whichever occurs first.
89486349|NCT01370603|Active Comparator|Ezetimibe and atorvastatin|Medication will be administered in a double dummy fashion as 3 tablets orally on a daily basis, including 10 mg ezetimibe, 40 mg atorvastatin, and placebo to ezetimibe/atorvastatin.
89486350|NCT01370603|Experimental|Ezetimibe/atorvastatin combination|Medication will be administered in a double dummy fashion as 3 tablets orally on a daily basis, including ezetimibe/atorvastatin 10 mg/40 mg, placebo to ezetimibe, and placebo to atorvastatin.
88952961|NCT01956734|Experimental|DNX2401 and Temozolomide|"DNX2401: Virus injection in the brain parenchyma. Total dose will be 3x1010 vp suspended in 1 ml for all cases.~Temozolomide: 14 (window 14-28 days) days after the virus injection, patients will begin therapy with temozolomide in a dose of 150mg/m2 in days 1-7 and 15 -21 of a 28 days cycle, (dose dense scheme 7 days on, 7 days off), until a maximum of 2 x 28 days cycles in absence of toxicity."
89486351|NCT02063009||patients scheduled for oncologic high-risk surgery|
89486352|NCT02659397|Experimental|ETC-1002 + Atorvastatin|ETC-1002 180 mg treatment, oral once daily added-on to Atorvastatin 80 mg once daily
89486353|NCT02659397|Placebo Comparator|Placebo + Atorvastatin|Placebo treatment, oral once daily added-on to Atorvastatin 80 mg once daily
89486354|NCT02064257|Experimental|Intervention group|Participants will be included in all pre-intervention and post-assessment measures. Participants will receive the Listening Project Protocol intervention. The duration of the intervention is approximately 45 minutes per day, for 5 consecutive days.
89486355|NCT02064257|No Intervention|Assessment-only group|The assessment-only group will participate in all pre- and post-intervention assessments, but will not receive the Listening Project Protocol.
89486356|NCT04973618|Experimental|APVO436|CD123 and CD3 epsilon bispecific antibody
89486357|NCT02065427|Experimental|Social support|"Social support intervention~Intervention is performed by the health professionals working at the primary health care team responsible for the patient, and consisits of the following components:~a) PHCT professionals: standardized training to implement caregivers intervention. b) Caregivers: 1 individualized counselling session, 1 family session, and 4 educational group sessions conducted by participating PHCT professionals; in addition to usual home health care visits, periodic telephone follow-up contact and unlimited telephone support."
89486358|NCT02065427|No Intervention|Usual home health care|Caregivers and dependent patients: usual home health care, consisting of bimonthly scheduled visits, follow-up as needed, and additional attention upon request
89486359|NCT02064335|Experimental|Intervention group|"Physical activity coaching: Participants will be coached by a professional physical activity coach through individual and group sessions.~Intake: This talk (1 hour) is the start of the coaching. A physical activity plan will be set up, according to the needs and possibilities of the participant. Activities in leisure time and daily physical activity will be included.~Group sessions: During 5 weeks and one time a week, the subjects will take part in the exercise lessons. About 5 subjects will be in one group and all sessions are supervised by a professional physical activity coach. Activities are walking, Nordic walking and conditional fitness.~Evaluation: After the 5 weeks of group sessions, an evaluation moment will take place between each participant and the physical activity coach. The physical activity plan will be refined."
89486360|NCT02064335|No Intervention|Control group|The control group will operate as a waiting group. It means that in the first 6 months of the project, the subjects of the control group will only be measured and will not receive any intervention.
89486361|NCT04977596||Group PNETs|The investigators retrospectively analyzed data for patients who underwent contrast-enhanced MDCT for the evaluation of G3 PNETs at the Second Affiliated Hospital of Zhejiang University School of Medicine (n = 12) between January 2011 and May 2019, patients with G3 PNET who underwent MDCT at the First Affiliated Hospital of Zhejiang University School of Medicine (n = 4) and the Military Medical University of Air Force (The Fourth Military Medical University) (n = 4) between January 2013 and October 2018
89486362|NCT04977596||Group PDAC|Patients with PDAC who underwent MDCT at the Second Affiliated Hospital of Zhejiang University School of Medicine (n = 58) from February 2014 to August 2015.
89486363|NCT02347072|Experimental|GFF MDI (PT003)|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI)
89486364|NCT02347072|Placebo Comparator|Placebo MDI|Placebo Metered Dose Inhaler (MDI) for Glycopyrronium and Formoterol Fumarate Inhalation Aerosol
89486365|NCT02347072|Active Comparator|Spiriva® Respimat® (Tiotropium Bromide)|Tiotropium Bromide Inhalation Solution; Spiriva® Respimat® (Spiriva)
89486366|NCT02064413|Experimental|ESS310|All subjects that sign the informed consent and meet the eligibility criteria will be scheduled for an implant procedure.
89486367|NCT02064491|Experimental|Erlotinib and Chemotherapy|Intercalated erlotinib in combination with chemotherapy for four to six cycles followed by continuous erlotinib maintenance
89486368|NCT02064491|Active Comparator|Chemotherapy|Chemotherapy for four to six cycles
89486369|NCT02064569|Experimental|GS010|
89486370|NCT02065505|Experimental|Pilates Group Solo|participate in this group 30 individuals who will be treated with the Pilates Method performing the exercises on the ground, using the Swiss ball and elastic bands. The exercises will aim to lengthen the musculature that are shortened due to the characteristic postural pattern of pathology (major and minor pectoral, shoulder adductors, biceps, wrist flexors, trunk side chain); strengthen the musculature that provide postural support (abdominal, middle trapezius, rhomboids, gluteus maximus, erector spinae and latissimus dorsi) and the upper limb musculature important for activities of daily living (triceps, biceps, internal rotators, external rotators and abductors of the shoulder).
89486371|NCT02065505|Experimental|Water Pilates Group|participate in this group 30 individuals who will be treated with the Pilates method, but doing the exercises in the therapy pool, with the aid of floats and weights. The protocol of stretches and exercises will work the same muscle groups than the G1, keeping the same decubitus whenever possible. The adaptations to the exercises are justified by the physical principles of water, which at one point may act for or against the activity being performed.
89486372|NCT02064881|Experimental|metformin glycinate|"620mg tablets of metformin glycinate: 1 tablet by mouth at night for 3 days, 1 tablet in the morning and evening for 3 days, 1 tablet in the morning and 2 tablets in the evening for 3 days and 2 tablets in the evening and 2 tablets in the morning until the end of the study.~Total study dose: 1240mg every 12 hours."
89486373|NCT02064881|Active Comparator|metformin hydrochloride|"500mg tablets of metformin hydrochloride:1 tablet by mouth at night for 3 days, 1 tablet in the morning and evening for 3 days, 1 tablet in the morning and 2 tablets in the evening for 3 days and 2 tablets in the evening and 2 tablets in the morning until the end of the study.~Total study dose: 1000mg every 12 hours."
89486374|NCT02067845|Other|Pre-post test design|
89486375|NCT02794103|Experimental|Virtual Reality Distraction|The child will visualize and interact with the virtual environment throughout the hydrotherapy session.
89486376|NCT02065037|Experimental|Warmed Carbon Dioxide Insufflation|warmed carbon dioxide insufflation used in colonoscopy
89486377|NCT02065037|Active Comparator|Room Temperature Air Insufflation|room temperature air insufflation used in colonoscopy
88952962|NCT01956747||standard anticancer treatment|Patients older than 70 years of age with advanced malignancies of colorectum, breast or prostate, who will start with full standard anticancer treatment as decided by their oncologist.
89486378|NCT02065583||GI abdominal surgery patients|Patients recovering from gastrointestinal abdominal surgery.
89486379|NCT02346370|Experimental|PEGPH20 + Docetaxel|PEGylated recombinant human hyaluronidase PH20 (PEGPH20) (1.6, 3.0, or 2.2 micrograms per kilogram (ug/kg)) was administered on Day 1 of each 21-day cycle (every 3 weeks) as an intravenous (IV)-infusion over 10 minutes, approximately 1 milliliter/minute (mL/min) (a window of +2 minutes allowed, i.e., infusion could be 10 to 12 minutes). Docetaxel (75 milligrams/meter squared (mg/m^2)) was administered on Day 2 of each 21-day cycle.
89486380|NCT02065739|Experimental|Period 1|Participants will receive a single 30-mg dose of JNJ-42165279 on Day 1.
89486381|NCT02065739|Experimental|Period 2|Participants will receive itraconazole 200 mg once a day from Day 4 to Day 10. A single oral 30-mg dose of JNJ-42165279 will be administered on Day 8 along with the dose of 200 mg itraconazole.
89486382|NCT02067923||Anti-CD3 mAb Plus Diabetes Standard of Care Group|This group of individuals received treatment in the original AbATE study.
89486383|NCT02067923||Diabetes Standard of Care Group|During the original AbATE study these individuals received standard care.
89486384|NCT02068001||RYGB|Food preference assessment in 100 patients at different timepoints, in a subset of 30 participants, also brain reward response to food cues will be assessed.
89486385|NCT02068079|Other|Vemurafenib and Trientine|
89486386|NCT02346136|Experimental|Tai Chi|This arm will receive a 6-month Tai Chi training intervention. Tai Chi training will include gentle dynamic stretching and strengthening, slow integrated movements, efficient posture, heightened body awareness and inner focus, active relaxation of body and mind, mindful diaphragmatic breathing, and healing imagery and intention. Participants will be asked to complete two formal group classes each week for at least 6 months, led by senior Tai Chi instructors. Additionally, participants will be given practice Digital Versatile Disc (DVD), DVD players if necessary, and instructions for daily home practice a minimum of 20 minutes on 3 non-class days each week.
89486387|NCT02346136|Active Comparator|Educational Control|This arm will receive a 6-month educational control intervention. Participants will attend monthly educational group sessions within a common area of each housing facility. Sessions will be led by research personnel and include material from Patient Education Forms (PEFs) produced by the American Geriatric Society. Sessions will be semi-structured and contain approximately 30 minutes of lecture and 30 minutes of group discussion.
89486388|NCT02793947|Experimental|Peri-incisional injection|A 100 cc multimodal analgesic cocktail will be injected into the superficial and deep peri-incisional tissues after the completion of femur fracture fixation/instrumentation while the patient remains under general anesthesia and prior to wound closure. This cocktail includes 400 mg of 0.75% ropivacaine (53.33 mL), 0.6 mg of 1 mg/mL epinephrine (0.6 mL), 5 mg of 0.5 mg/mL morphine sulfate (10 mL), and 36.07 mL 0.9% sodium chloride solution. All infiltrations will be completed with a blunt trochar to minimize the risk of intravascular injection.
89486389|NCT02793947|No Intervention|Control (no injection)|Femur fracture fixation/instrumentation will be completed per the standard of care. No peri-incisional injection will be completed.
89486390|NCT02065817|Experimental|Tracer|
89486391|NCT02065115|Experimental|Cryotherapy|Cryotherapy: 12 ounces of crushed ice place in a plastic bag applied to the radial artery puncture area for 3 minutes
89486392|NCT02065115|No Intervention|Control|Cryotherapy is not applied to the radial artery puncture area
89486393|NCT02345512|Other|Falls|Wearing of Lycra splinting garment
89486394|NCT03560063|Experimental|Corin OPS arm|Total hip replacement with use of Corin Optimised Positioning System to guide implant positioning
88952963|NCT01956760|Experimental|Acupuncture|Acupuncture and intradermal acupuncture The acupuncture was applied at 5 acupoints(HT7 Shenmen, PC6 Neiguan, SP6 Sanyinjiao, KI6 Zhaohai, BL62 Shenmai) 3 times in a week. It was performed by a certified practitioner with sterile needles (0.25*40.0mm). The needles were inserted at least 10.0mm deep through the skin and maintained for 20 minutes The intradermal acupuncture was applied at the same acupoints, immediately after the acupuncture needles were removed. It was performed by the same practitioner with sterile needles (0.20*8.0mm).attached to skin tape (10.0*10.0mm). The needles were inserted 3.0~5.0mm deep and maintained for 48~72 hours
88952964|NCT01956760|Placebo Comparator|Placebo Acupuncture|Placebo acupuncture and placebo intradermal acupuncture The acupuncture was applied 3 times in a week at 2 sham points on the wrist and 3 sham points on the ankle, approximately 1cm lateral to the acupoints. It was performed by a certified practitioner with sterile needles (0.25*40.0mm). The needles were inserted at least 10.0mm deep through the skin and maintained for 20 minutes The intradermal acupuncture was applied at the same sham points, immediately after the acupuncture needles were removed. It was performed by the same practitioner with sterile needles (0.20*8.0mm).attached to skin tape (10.0*10.0mm). The needles were inserted 3.0~5.0mm deep and maintained for 48~72 hours
88952965|NCT01956786|Active Comparator|Amlodipine|5mg amlodipine,once daily for 8 weeks
88952966|NCT01956786|Experimental|Amlodipine-FA tablet,low dose group|5mg amlodipine combined with 0.4mg of folic acid (FA),once daily for 8 weeks.
88952967|NCT01956786|Experimental|Amlodipine-FA tablet,high dose group|5mg amlodipine combined with 0.8mg of folic acid (FA),once daily for 8 weeks.
88952968|NCT01956825|Placebo Comparator|water|just water
88952969|NCT01956825|Experimental|"L-CARNITINE AND MAGNESIUM (slim water product)"|"The experimental arm will receive a product slim water, which contains 150 mg magnesium lactate and 2000 mg L-carnitine. The purpose is to follow the patients and examine several metabolic parameters over time (liver function test, lipid profile, liver fat content, etc.) and by that to show and prove the positive effect of the experimental treatment over placebo."
88952970|NCT01956838|Experimental|Umami|intraduodenal infusion of umami
88952971|NCT01956838|Experimental|sweet|intraduodenal infusion of sweet tastant
88952972|NCT01956838|Experimental|bitter|intraduodenal infusion of bitter tastant
88952973|NCT01956838|Experimental|combination|intraduodenal infusion of a combination of tastants (umami, bitter and sweet)
89486395|NCT03560063|Active Comparator|Standard care arm|Total hip replacement with standard templating to guide implant positioning
89486396|NCT02345434|No Intervention|No informative letter|This is the control arm and it involves no contact with the prescriber
89486397|NCT02345434|Experimental|Informative letter|This is the treatment arm; prescribers in this arm receive an informative letter (called a comparative billing report or peer activity report)
89486398|NCT02065973|Active Comparator|Cohort 1 (Low Dose)|The group will receive the lowest dose of the vaccine
88952974|NCT01956838|Placebo Comparator|placebo|intraduodenal infusion of placebo (tap water)
88952975|NCT01956851||Normal Healthy|Normal Healthy: includes healthy patients eligible for enrolment,
89203942|NCT02557490|Experimental|Oxaliplatin by TACE|Oxaliplatin for the therapy of Colorectal Cancer With Liver Metastases by TACE.No interventions was raltitrexed for the therapy of Colorectal Cancer With Liver Metastases by TACE.
89203943|NCT02557490|No Intervention|Raltitrexed by TACE|Raltitrexed for the therapy of Colorectal Cancer With Liver Metastases by TACE.
89486399|NCT02065973|Active Comparator|Cohort 2 (Mid Dose)|The Group will receive the middle dose of the vaccine
89486400|NCT02065973|Active Comparator|Cohort 3 (High Dose)|The Group will receive the highest dose of vaccine to be tested
89203944|NCT00775112|Experimental|1|with pillow
89486401|NCT02065193||Beijing group|
89486402|NCT02065193||Guangdong group|
89486403|NCT02065193||Shenzhen group|
89486404|NCT02065193||Shanxi group|
89486405|NCT02065193||Liaoning group|
89486406|NCT02065193||Jilin group|
89486407|NCT02065193||Heilongjiang group|
89486408|NCT02065193||Jiangsu group|
89486409|NCT02065193||Zhejiang group|
89486410|NCT02065193||Fujian group|
89486411|NCT02065193||Henan group|
89486412|NCT02065193||Hubei group|
89486413|NCT02065193||Hunan group|
89486414|NCT02065193||'Shanxi group|
89486415|NCT02068235|Experimental|Pilot Phase|Subjects will receive a single intravenous (i.v.) dose of 5 mg ponesimod dissolved in 50 mL sterile 0.9% sodium chloride (NaCl) solution as a 3-hour infusion in the fasted state in the morning (infusion rate: 0.028 mg/min).
89486416|NCT02068235|Experimental|Treatment A/Treatment B|"Subjects will receive Treatment A followed by Treatment B.~Treatment A: a single i.v. dose of ponesimod administered in the fasted state in the morning.~Treatment B: a single oral dose of ponesimod (10 mg) administered as 1 tablet in the fasted state in the morning.~There will be a washout period between doses of 12-15 days."
89486417|NCT02068235|Experimental|Treatment B/Treatment A|"Subjects will receive Treatment B followed by Treatment A.~Treatment A: a single i.v. dose of ponesimod administered in the fasted state in the morning.~Treatment B: a single oral dose of ponesimod (10 mg) administered as 1 tablet in the fasted state in the morning.~There will be a washout period between doses of 12-15 days."
89486418|NCT01370213|Experimental|CD34 Schema - High-Risk Acute Myeloid Disease|Patients with high risk acute myeloid disease treated with preparative regimen including Fludara, Cytoxan and total body irradiation followed by haploidentical donor NK cells, Interleukin-2, rabbit anti-thymocyte globulin, and filgrastim mobilized CD34+ selected peripheral blood stem cell graft from the same donor.
89486419|NCT01370213|Experimental|TCRα/β Schema - High-Risk Acute Myeloid Disease|Patients with high risk acute myeloid disease treated with preparative regimen including Fludara, Cytoxan and total body irradiation followed by haploidentical donor NK cells, Interleukin-2, rabbit anti-thymocyte globulin, and same donor TCR α/β-depleted cells infusion.
89486420|NCT02068313||Single cohort|
89486421|NCT02066207|Experimental|Fenofibrate|Subjects received Fenofibrate
89486422|NCT02066207|Experimental|Atorvastatin|Subjects received Atorvastatin
89486423|NCT02066207|Experimental|Fenofibrate and Atorvastatin|Subjects received Fenofibrate and Atorvastatin
89486424|NCT02065271|Experimental|herbal supplements|500mg, 3 per day, 4weeks
89486425|NCT02065271|Placebo Comparator|placebo|500mg, 3 per day, 4 weeks
89203945|NCT00775112|No Intervention|2|without pillow
89486426|NCT02068391|Experimental|Exercise|This group will perform the 'Exercise Program' for months 0 to 6, and will be unsupervised for months 7 to 12.
89486427|NCT02068391|Active Comparator|Stretching|This group will perform the 'Stretching Program' for months 0 to 6, and the 'Exercise Program' for months 7 to 12.
89486428|NCT01370525|Experimental|Esomeprazole 20 mg|
89486429|NCT01370525|Placebo Comparator|Placebo|
89486430|NCT02065349|Placebo Comparator|Placebo|oral
89486431|NCT02065349|Active Comparator|ASP8477|oral
89486432|NCT02068625|Experimental|Treatment|Patients getting perioperative oral treatment with rasagiline (1mg daily) for 7 days
88952976|NCT01956851||Diabetics on Oral Hypoglycemic Agents|Diabetics on Oral Hypoglycemic Agents: includes diabetic patients on oral diabetic drug therapy with all eligibility criterion fulfilled,
88952977|NCT01956851||Diabetics on Insulin Therapy|Diabetics on Insulin Therapy: includes diabetic patients on insulin therapy with all eligibility criterion fulfilled
88952978|NCT01956864|Experimental|Dose VD 1|Vitamin D
88952979|NCT01956864|Experimental|Dose VD 2|Vitamin D
88952980|NCT01956864|Experimental|Dose VD 3|Vitamin D
88952981|NCT01956864|Experimental|Dose VD 4|Vitamin D
88952982|NCT01956864|Experimental|Dose VD 5|Vitamin D
88952983|NCT01956864|Experimental|VD 6 Month Treatment|Vitamin D
88952984|NCT01956877||Healthy volunteers|
88952985|NCT01956890|Other|diagnostic accuracy|diagnostic accuracy of PET and MRI for breast cancer diagnosis.
88952986|NCT01956903|Experimental|Allogenic Mesenchymal Stem Cell|Sequential Infusion of Expanded in-Vitro Allogenic Mesenchymal Stem Cell (MSC). Dosage 0,7 x 10e6 MSC/Kg/dose (cumulative minimum dose: 2,8 x 10e6 CSM/Kg.
88952987|NCT01956916|Experimental|Probiotics|Capsules containing lyophilized 6x10^9 Colony Forming Units (CFU)/die of Lactobacillus rhamnosus GG (LGG)
89203946|NCT00813852|Experimental|2|exercise training, CPAP, and inspiratory muscle strengthening program
89486433|NCT02068625|Placebo Comparator|Control|Patients getting perioperative oral treatment with placebo for 7 days
89486434|NCT02068703|Active Comparator|Intervention|Subjects will receive a 10 minute presentation, aimed at educating on the value of sleep PLUS a demonstration of tools (face mask, ear plugs and white noise machine) to improve sleep.
89486435|NCT02068703|Placebo Comparator|Inert Control|Same 10 min time exposure and tool delivery to subjects in this arm WITHOUT demonstration.
89486436|NCT02068781|Active Comparator|Start with low-sodium diet|One week of low-sodium diet, followed by a two-week wash-out period and subsequently, another week of high-sodium diet
89486437|NCT02068781|Active Comparator|Start with high-sodium diet|One week of high-sodium diet, followed by a two-week wash-out period and subsequently, another week of low-sodium diet
88952988|NCT01956916|Placebo Comparator|Placebo|Capsules containing maltodextrin
88952989|NCT01956929|Experimental|Metformin|2 weeks of Metformin use. First week 1000mg/day, Second week Max dose of 2000 mg/day.
88952990|NCT01956929|Placebo Comparator|Placebo|2 weeks of Placebo (lactulose pills)
88952991|NCT01956955|Active Comparator|enoxaparin and alteplase|After alteplase therapy , 4-6 hour later, activated partial thromboplastin time (APTT) was checked. According to initial SC LMWH use time, fixed dose SC LMWH, enoxaparin, was administered subcutaneous every 12 hours.
88952992|NCT01956955|Active Comparator|Unfractionated heparin and alteplase|After thrombolytic treatment, a bolus of 10 mg of alteplase followed by 90 mg over 2-h infusion, patients either administered a constant heparin infusion (18 U/Kg per hour) adjusted to maintain an activated partial thromboplastin time of 46-70 s.
89486438|NCT02068859|Experimental|Diclofenac Cream 8%|Diclofenac Cream 8% applied 3-4 times daily for 6 weeks.
89486439|NCT02068859|Active Comparator|Control|Diclofenac Gel 1% applied 3-4 times daily fr 6 weeks
89486440|NCT02068937|Active Comparator|Control Group|In the control group, patients just diuretic adjusted (Furosemide 40 milligrams) by the doctor on the baseline. The patients do not receive phone calls neither advising on non-pharmacological treatment; The medication is adjusted by the doctor during the initial evaluation of study baseline.
89486441|NCT02068937|Experimental|Furosemide and Phone contact|The intervention group is conducted by a nurse in a systematic way during one time per week. If signs and symptoms of congestion, the dose of diuretic ( furosemide ) is revised , nonpharmacological guidelines are provided. According to the algorithm 1KG weight changes are indicative of modifying the diuretic dose , with the addition or reduction 1 tablet a day.
89486442|NCT02066363|Active Comparator|Best nutritional Care|Best supportive nutritional care and dietician advise
89486443|NCT02066363|Experimental|Parenteral nutrition|Supplemental Parenteral Nutrition and dietician advise. Supplemental parenteral Nutrition 30% of estimated needs. Parenteral nutrition given at home, administered by a nurse. The patient will be seen at the Outpatient Clinic every 6th week, talk to dietician and a doctor.
89486444|NCT02066441|Experimental|Bio-D-Mulsion Forte®|Bio-D-Mulsion Forte® at a dosage level of 2 drops (4,000 IU) once daily for the 6-month treatment period.
89486445|NCT02066441|Placebo Comparator|Placebo|Placebo a dosage level of 2 drops once daily for the 6-month treatment period.
89486446|NCT02069171||early ovarian cancer group|
89486447|NCT02069171||locally advanced cervical cancer group|
89486448|NCT02069171||primary endometrial cancer group|
89486449|NCT02066519|Experimental|Physical exercise arm|Arm with physical exercise on rowing machine between M3 and M6
89486450|NCT02066519|No Intervention|Control arm|Arm with standard medical care without additional physical exercise
89486451|NCT02792777||Interviews|Interview participants will be recruited from 3 different care settings: an acute care visit (in the emergency department), a post-acute care visit (within 1 week of a hospital discharge), and a routine primary care visit. Target sample size within each healthcare setting is 30 patients, which is the anticipated number needed for thematic saturation. The total recruitment goal for this cohort is 90-120 participants.
89486452|NCT02792777||Concept Mapping|Concept mapping participants will be recruited from existing clinical and research databases for 3 separate concept mapping groups, each with a target of 20 patients. The total recruitment goal for this cohort is 60 people.
89486453|NCT02066597|Experimental|Intervention|
89486454|NCT02069249|Experimental|Healthy Nutrition Intervention|Healthy Nutrition Intervention (HNI)
89486455|NCT02069249|Experimental|Healthy Sleep Intervention|Healthy Sleep Intervention (HSI)
89486456|NCT02069249|No Intervention|Waiting list control|Waiting list control group
89486457|NCT03559907|Experimental|Cooking Matters for Parents|Trained instructors with a background in nutrition or culinary arts will lead six weekly, two-hour sessions to groups of 10 parent participants at local Family Support Centers.
89486458|NCT03559907|Experimental|Mealtime PREP|Trained group leaders with experience in pediatric occupational therapy will lead six weekly, two-hour, Mealtime PREP sessions to groups of 10 parent participants at local Family Support Centers.
89486459|NCT03559907|Experimental|Cooking Matters + Mealtime PREP|Parents will receive both programs in succession. They will attend Cooking Matters for Parents followed by Mealtime PREP. In total, this will equal 12 weekly, two-hour sessions delivered to groups of 10 parent participants at a local Family Support Center.
89486460|NCT02069405|Experimental|Music Group plus normal standard of care|Patients will listen to music prior and during the scan
89486461|NCT02069405|No Intervention|Control Group - Normal standard of care|
89486462|NCT02066675|Experimental|Trabectedin|Trabectedin administered at the dose of 1.5 mg/mq-1.3 mg/mq a 24-hour continuous infusion via a central venous access, every 3 weeks
88952993|NCT01956981|Placebo Comparator|Magnesium|40 mg kg-1 IV magnesium sulfate (OSEL ilaç San. Ve Tic. A.Ş., Beykoz, Istanbul, Turkey) in 100 ml saline solution was applied to patients in Group M as a loading dose 10 minutes before the induction and continued during the surgery at the dose of 10-15 mg kg-1hour-1.
88952994|NCT01956981|Active Comparator|Dexmedetomidine|1 µg kg-1 IV dexmedetomidine (Precedex Abbott Labs, North Chicago, IL) in 100 ml saline solution was applied to patients in group D 10 minutes before the surgery and continued during the surgery at the dose of 0.5-1 µg kg-1.
88952995|NCT01956994|Experimental|Whey protein supplement|Subjects will be instructed to consume 40 g whey protein each day for 12 weeks.
89486463|NCT02069483|Active Comparator|Motivational Interviewing|Subjects will engage in motivational interviewing and come up with messages to motivate quitting during the activity.
89486464|NCT02069483|Active Comparator|Tailored Feedback|Subjects will use reasons for quitting that they provided during the phone baseline for the text messages and audio recordings.
89486465|NCT02066753|Active Comparator|24 hours mild therapeutic hypothermia|The patient will be treated with mild therapeutic hypothermia for 24 hours after reaching the target temperature between 32-34°C.
89486466|NCT02066753|Experimental|48 hours mild therapeutic hypothermia|The patient will be treated with mild therapeutic hypothermia for 48 hours after reaching the target temperature between 32-34°C.
89021709|NCT00336674|Active Comparator|DV001|Recombinant human intranasal insulin formulation in a buffered solution of benzalkonium chloride and glycerol presented in multi-dose nasal spray devices with actuators (Pfeiffer) designed to deliver 100ul spray doses to nasal mucosa. The product is formulated at a dose strength of 1100 IU / mL (40mg/mL) manufacturing formulation. The product will be self administered by eligible participants as two 100 microlitre spray doses per nostril. Treatment will be administered daily for 7 consecutive days then on one day each week for 12 months. Participants will be followed until they develop diabetes or until 5 years after the last participant has been randomised (maximum period of follow up is expected to be 10 years.
89486467|NCT02066831|Experimental|Telemedical Coaching|Patients will receive telemedical devices i.e. for the measurement of blood glucose, weight and physical activity. These devices will transfer the data to a data collector with a SIM card which sends the data to a data portal, which can be monitored by the participant and the coach. Health coaches which will have close phone contact to patients, supporting them to reduce weight and increase physical activity. In the first 12 weeks, patients will follow a formula diet (Almased) to achieve an initial weight reduction.
89486468|NCT02066831|Active Comparator|Telemedicine|Patients will receive telemedical devices i.e. for the measurement of blood glucose, weight and physical activity. These devices will transfer the data to a data collector with a SIM card which sends the data to a data portal which can be monitored by the participant.
89486469|NCT02069561|Experimental|Eicosapentaenoic Acid|Subjects with long-standing ulcerative colitis and meeting the inclusion criteria will receive 2 g/day of Eicosapentaenoic Acid as a supplement for 90 days
89486470|NCT02069561|No Intervention|Normal controls|Five patients undergoing screening colonoscopy and polypectomy using biopsy forceps. Six biopsies of healthy mucosa will be collected at the time of colonoscopy. Faeces, urine and blood samples will be collected prior to performing colonoscopy. The samples will serve as healthy reference for the basic studies.
89486471|NCT02066909|Experimental|Cohort 1|Dosing in healthy Western subjects.
89486472|NCT02066909|Experimental|Cohort 2|Dosing in healthy Western subjects.
89486473|NCT02066909|Experimental|Cohort 3|Dosing in healthy Western subjects.
89486474|NCT02066909|Experimental|Cohort 4|Dosing in healthy Western subjects.
89486475|NCT02066909|Experimental|Cohort 5|Dosing in healthy Western subjects.
89486476|NCT02066909|Experimental|Cohort 6|Dosing in healthy Western subjects.
89486477|NCT02066909|Experimental|Cohort 7|Dosing in healthy Western subjects.
89486478|NCT02066909|Experimental|Optional Cohort 8|Dosing in healthy Western subjects. Cohort may not be conducted.
89486479|NCT02066909|Experimental|Cohort 9|Dosing in healthy Japanese subjects.
89486480|NCT02066987|Experimental|Implementation intention|"It may be helpful for you to plan when and where you will brush your teeth each day over the next month. Please write below when, where, and after what activity you will brush your teeth (e.g., at 8.00 a.m. and 9.00 p.m. in the bathroom after eating breakfast/dinner). Because you should brush your teeth twice a day, please make two plans.~If it is _____ (WHEN) at or in _______ (WHERE) before/after ______ (ACTIVITY), then I will brush my teeth! If it is _____ (WHEN) at or in _______ (WHERE) before/after ______ (ACTIVITY), then I will brush my teeth!"
89486481|NCT02066987|Experimental|Action planning|"It may be helpful for you to plan when and where you will brush your teeth each day over the next month. Please write below when, where, and after what activity you will brush your teeth (e.g., at 8.00 a.m. and 9.00 p.m. in the bathroom after eating breakfast/dinner). Because you should brush your teeth twice a day, please make two plans.~I will brush my teeth at ___(WHEN) at or in ____(WHERE) before/after ___ (ACTIVITY).~I will brush my teeth at ___(WHEN) at or in ____(WHERE) before/after ___ (ACTIVITY)."
89486482|NCT02066987|Active Comparator|active control group|Participants in the active control group will receive an educational pamphlet containing what it is dental brushing, why it is done, and how it is done.
89486483|NCT02071979|Experimental|Autologous PRP Gel|The method of application for PRP treatment will be decided by the clinician in accordance with the appearance of the wound bed. The application of topical PRP gel may be used in chronic wounds possessing an open, moist wound bed according to following treatment schedule: Baseline/Week 0, Week 1, Week 2, Week 3, Week 7, and Week 11. The Arteriocyte Magellan® System (510(k) cleared) will be used to prepare the autologous PRP gel. For data analysis, the data from these patients will be classified as PRP Treatment Group (Topical application) data.
89486484|NCT02071979|Experimental|Autologous PRP Injections|The method of application for PRP treatment will be decided by the clinician in accordance with the appearance of the wound bed. Autologous PRP Injections may be used where chronic wounds possess a raised, hyperproliferative wound margin and/or plaque, according to following treatment schedule: Baseline/Week 0, Week 1, Week 2, Week 3, Week 7, and Week 11. The Arteriocyte Magellan® System (510(k) cleared) will be used to prepare Autologous PRP for injections. For data analysis, the data from these patients will be classified as PRP Treatment Group (Direct Injection) data.
89486485|NCT02071979|Experimental|Autologous PRP Gel plus PRP Injections|The method of application for PRP treatment will be decided by the clinician in accordance with the appearance of the wound bed. Some wounds may be suitable for both Autologous PRP Gel plus PRP Injections. Autologous PRP injections into, or to the periphery of, a moist wound bed in which no scarification or raised wound margin is apparent (where autologous PRP Gel can also be used) may further augment wound healing by addressing wound healing in multiple areas, following the treatment schedule: Baseline/Week 0, Week 1, Week 2, Week 3, Week 7, and Week 11. The Arteriocyte Magellan® System (510(k) cleared) will be used to prepare the autologous PRP gel. For data analysis, the data from these patients will be classified as PRP Treatment Group (Topical and Direct) data.
89486486|NCT02071979|No Intervention|Standard Wound Care|Subjects in the control group will receive Standard Wound Care treatment for chronic wounds according to accepted medical practices. For data analysis, the data from these patients will be classified as Control (Standard of Care) Group data
89486487|NCT02072057|Experimental|Ruxolitinib|Interventional arm
89486488|NCT03292523||Hyperventilation syndrome|
89486489|NCT02069639||no treatment|
89486490|NCT02072135|Experimental|Exparel|Exparel 266mg
89486491|NCT02067065|Experimental|Non-anesthesiologist propofol sedation|Bolus propofol sedation by non-anesthesiologist
89486492|NCT02067065|Active Comparator|Anesthesiologist administered propofol|Propofol sedation administered by an anesthesiologist
89486493|NCT02067143|Experimental|Study population|In this phase II multicentric trial, eligible patients with Ph- ALL/LL will receive homogeneous supportive care and chemotherapy and will be homogeneously analyzed for response at prefixed timepoints from induction day 1. For risk-/MRD-oriented therapy, CR patients will be stratified by risk class according to diagnostic characteristics, MRD study and CT/PET (LL only) results during early consolidation.
88952996|NCT01956994|Active Comparator|Carbohydrate supplement|Subjects will be instructed to consume a carbohydrate supplement (iso-caloric to the whey supplement) each day for 12 weeks.
88952997|NCT01957007|Experimental|Docetaxel|Drug: Docetaxel - administered intravenously
88952998|NCT01957007|Experimental|vantictumab|Drug: vantictumab - administered intravenously
89486494|NCT02072213|Experimental|GL2702 GLARS-NF1 , fasted|Tamsulsoin 0.4mg
89486495|NCT02072213|Active Comparator|Omix Ocas® , fasted|Tamsulsoin 0.4mg
89486496|NCT02072213|Experimental|GL2702 GLARS-NF1, after meal|Tamsulsoin 0.4mg
89486497|NCT02072213|Active Comparator|Omix Ocas®, after meal|Tamsulsoin 0.4mg
89486498|NCT03330743|No Intervention|Usual care|
89486499|NCT03330743|Placebo Comparator|Parent Mentor|
89486500|NCT03330743|Active Comparator|Parent Mentor with Positive Deviance|
89486501|NCT02072291|Experimental|Nifedipine|Nifedipine 5mg single dose
89486502|NCT02072291|Placebo Comparator|Placebo|
89486503|NCT02069717||Not applicable-observational study|Not applicable-observational study
89486504|NCT02072369|Experimental|VAEDA Glove|Voice And EMG-Driven Actuated glove used during hand occupational therapy training
89486505|NCT02072369|Active Comparator|No-glove|hand occupational therapy sessions without assistive device
89486506|NCT02067221|Active Comparator|RIRS (retrograde intrarenal surgery)|Use of flexible ureteroscopy to access and remove renal stones without percutaneous nephrostomy tract
89486507|NCT02067221|Experimental|MPCNL (mini-perc)|"A new technique that reduced the size of percutaneous tract to make renal stone into small pieces.~Patients will be randomized and assigned to each group at the ratio 1:1"
89486508|NCT04977440||standard protein|
89486509|NCT04977440||high protein|
89486510|NCT02069795|Experimental|Voice recording|Subjects voices were recorded as they spoke specific words
89486511|NCT04154462|No Intervention|No intervention|The VAMC sites randomized to the comparison arm will not have medical scribes introduced into emergency departments or specialty clinics.
89486512|NCT04154462|Experimental|Treatment|The VAMC sites randomized to the treatment arm are each expected to have four medical scribes, with two being VA employees and two being contractors, introduced into emergency departments or specialty clinics to assist providers during patient encounters.
89486513|NCT02069873|Experimental|16-Week Group Treatment|The 16-week treatment group will contain 3 blocks of treatment (exposure, cognitive, skills) with order randomized within the treatment. The first and last group session are considered inactive treatment sessions. The group treatment will be provided weekly.
89486514|NCT02069873|No Intervention|Wait List Control|The Wait List Control group will receive minimal attention, as they will meet bi-monthly for supportive sessions with the study psychologist. The study psychologist will not introduce any active treatment in the individual sessions.
89486515|NCT04977518||Patients diagnosed during 2008-2011|Patients diagnosed with definite and probable infective endocarditis defined according to the modified Duke clinical criteria during 2008-2011
89486516|NCT04977518||Patients diagnosed during 2012-2015|Patients diagnosed with definite and probable infective endocarditis defined according to the modified Duke clinical criteria during 2012-2015
89486517|NCT02067299|Experimental|Cohort A|5 participants will be included in this cohort. Participants will receive the study medications in the sequence of placebo (Period 1), JNJ-42847922 10 mg (Period 2), JNJ-42847922 20 mg (Period 3), and JNJ-42847922 40 mg (Period 4). Each treatment period and each subsequent treatment period will be separated by 1 week.
89486518|NCT02067299|Experimental|Cohort B|5 participants will be included in this cohort. Participants will receive the study medications in the sequence of JNJ-42847922 10 mg (Period 1), JNJ-42847922 40 mg (Period 2), placebo (Period 3), and JNJ-42847922 20 mg (Period 4). Each subsequent treatment period will be separated by 1 week.
89486519|NCT02067299|Experimental|Cohort C|5 participants will be included in this cohort. Participants will receive the study medications in the sequence of JNJ-42847922 20 mg (Period 1), placebo (Period 2), JNJ-42847922 40 mg (Period 3), and JNJ-42847922 10 mg (Period 4). Each subsequent treatment period will be separated by 1 week.
89486520|NCT02067299|Experimental|Cohort D|5 participants will be included in this cohort. Participants will receive the study medications in the sequence of JNJ-42847922 40 mg (Period 1), JNJ-42847922 20 mg (Period 2), JNJ-42847922 10 mg (Period 3), and placebo (Period 4). Each subsequent treatment period will be separated by 1 week.
89486521|NCT04977284|Experimental|TCSCS|
89486522|NCT02072447|Experimental|Microdose|
88952999|NCT01957033|Experimental|Duration 6 weeks, frequency 3/week|Exercise and education 3 times/week for 6 weeks Manual therapy 3 times/week for 6 weeks
88953000|NCT01957033|Experimental|Duration 6 weeks, Frequency twice/week|Exercise and education twice/week for 6 weeks Manual therapy twice/week for 6 weeks
89486523|NCT03060122|No Intervention|Standard Care|Patient's randomized to this arm will receive standard post operative/post immobilization physical therapy or occupational therapy rehabilitation care without the use of NIN or CES.
89531890|NCT04916652||S-26 GOLD/ULTIMA GUM-fed group:|"Parent(s) to continue feeding their child S-26 GOLD or ULTIMA GUM during the course of the study.~We will collect information from parents on the S-26 GOLD/ ULTIMA GUM for a maximum of 2 months prior to the study start and during the course of the study."
89531891|NCT04916652||Cow's milk-fed group:|"Parent(s) to continue feeding their child cow's milk during the course of the study.~We will collect information from parents on the cow's milk consumed for a maximum of 2 months prior to the study start and during the course of the study."
88953001|NCT01957033|Experimental|Duration 6 weeks, Frequency once/week|Exercise and education once/week for 6 weeks Manual therapy once/week for first 6 weeks
88953002|NCT01957033|Experimental|Duration 3 weeks, Frequency 3 times/week|Exercise and education 3 times/week for 6 weeks Manual therapy 3 times/week for first 3 weeks
88953003|NCT01957033|Experimental|Duration 3 weeks, Frequency twice/week|Exercise and education twice/week for 6 weeks Manual therapy twice/week for first 3 weeks
89486524|NCT03060122|Experimental|NIN (InterX) and CES (Alpha-Stim)|"The Alpha-Stim Cranial Electrical Stimulation device applies a micro-current trans-cranially via electrodes attached to the ear.The electrical current is controlled through a handheld device. Standard treatment sessions lasting approximately 20-60 minutes.~InterX Therapy (non-invasive) has been developed specifically for the treatment of acute and chronic pain. It is delivered on the skin of the involved area. The device will be applied by a trained therapist along the course of the dermatomes in the affected area. Electrical current is controlled through a handheld device. Standard treatment sessions last approx 20-45 min.~The treatment will be delivered in conjunction with the rehab visit (physical or occupational therapy)"
89486525|NCT03060122|Active Comparator|NIN (InterX) and sham CES|"The Alpha-Stim Cranial Electrical Stimulation device intensity will be preset and locked by the manufacturer at its lowest therapeutic dose at 100 mA, a sub-sensory level that serves as a sham treatment.~InterX Therapy (non-invasive) has been developed specifically for the treatment of acute and chronic pain. It is delivered on the skin of the involved area. The device will be applied by a trained therapist along the course of the dermatomes in the affected area.Electrical current is controlled through a handheld device. Standard treatment sessions last approx 20-45 min.~The treatment will be delivered in conjunction with the rehab visit (physical or occupational therapy)"
89486526|NCT02072525|Experimental|Mtdap1 Group|Subjects will receive concomitant doses of Menveo and Boostrix.
89486527|NCT02072525|Experimental|Mtdap2 Group|Subjects will receive concomitant doses of Menveo and Boostrix.
89486528|NCT02072525|Experimental|Mtdap3 Group|Subjects will receive concomitant doses of Menveo and Boostrix.
89486529|NCT02072525|Experimental|Pneum1 Group|Subjects will receive a dose of Pneumovax 23.
89486530|NCT02072525|Experimental|Pneum2 Group|Subjects will receive a dose of Pneumovax 23.
89486531|NCT02072525|Experimental|Pneum 3 Group|Subjects will receive a dose of Pneumovax 23.
89486532|NCT02072525|Experimental|Prev1 Group|Subjects will receive a dose of Prevnar 13.
89486533|NCT02072525|Experimental|Prev2 Group|Subjects will receive a dose of Prevnar 13.
89486534|NCT02072525|Experimental|Prev3 Group|Subjects will receive a dose of Prevnar 13.
89486535|NCT04977128|Experimental|Experimental：89Zr-KN035 injection|Patients will receive a tracer (10 mg, IV) dose of Zr-89 (2-3mCi) labelled KN035 (89Zr- KN035)
89486536|NCT03059888|Experimental|Abatacept|125mg abatacept in 1ml solution administered once per week by subcutaneous injection
89486537|NCT02069951|Experimental|Practice two procedures on a simulator|"All participants start by practicing a series of six basic skills modules until they reach a predefined proficiency level for each module. For all of the basic skills exercises proficiency is reached when the participants have passed the proficiency level for all exercises.~Participants randomised to the intervention group will practice two procedures on a simulator. First a procedural module A (a laparoscopic appendectomy) to a predefined proficiency level. Upon reaching proficiency for procedural module A the participants will practice procedural module B (a laparoscopic salpingectomy) to a predefined proficiency level."
89486538|NCT02069951|No Intervention|Practice one procedure on a simulator|"All participants start by practicing a series of six basic skills modules until they reach a predefined proficiency level for each module. For all of the basic skills exercises proficiency is reached when the participants have passed the proficiency level for all exercises. Each exercise has to be passed twice within five consecutive attempts.~Participants randomised to the control group will practice procedural module B (a laparoscopic salpingectomy) to a predefined proficiency level."
89486539|NCT03061292|Experimental|Pectoral Nerve Block|Patients undergoing cardiac implantable electronic device implantation with local anaesthesia and sedation with pectoral nerve block
89486540|NCT03061292|Sham Comparator|Without Pectoral Nerve Block|Patients undergoing cardiac implantable electronic device implantation with local anaesthesia and sedation without pectoral nerve block
89486541|NCT02070029|Experimental|Acupuncture|"Acupuncture Therapy~- twice weekly sessions for 5 weeks: 1st session 60 minutes with remaining 9 session approximately 45 minutes each. Physical exam at 1st session includes evaluation of peripheral pulses, head, neck, throat/tongue. No pelvic exam required."
89486542|NCT03059966|Experimental|Enamel Matrix Derivative|Microsurgery for root coverage associated with Enamel Matrix Derivative
89486543|NCT03059966|Placebo Comparator|Placebo|Microsurgery for root coverage associated with a Placebo comparator
89486544|NCT02260349|Experimental|patient with Indocyanine green infusion|Infusion of Indocyanine Green 0,25 mg/Kg 24h before prostatic surgery
89486545|NCT02072603|Experimental|Intervention Hospitals|HITSystem implementation at hospital and its affiliated laboratory
89486546|NCT02072603|Active Comparator|Control Hospitals|Existing standard of EID care
89486547|NCT02072681||Mild and Rapidly Improving Ischemic Stroke|"Patients 18 years or older with mild or rapidly improving acute ischemic stroke defined clinically. .Absence of non-ischemic conditions neuro-imaging (i.e. absence of hemorrhage or a mass on brain imaging that arrived to the hospital within 4.5 hours after the onset of stroke symptoms.~All participants will have two follow up telephone calls: One at approximately 30 days after the stroke and one at approximately 90 days after the stroke to ask questions about how well participant can carry out usual duties after the stroke, how much assistance do he/she needs to perform your daily activities and how good or bad would he/she considers current health to be."
89486548|NCT04964648||Inflammatory pancreatic lesions|older than 18 years with a diagnosis of acute or chronic pancreatitis
88953004|NCT01957033|Experimental|Duration 3 weeks, frequency once/week|Exercise and education once/week for 6 weeks Manual therapy once/week for first 3 weeks
88953005|NCT01957033|Experimental|Duration 0 weeks, Frequency 3 times/week|Exercise and education 3 times/week for 6 weeks No manual therapy
88953006|NCT01957033|Experimental|Duration 0 weeks, Frequency twice/week|Exercise and education twice/week for 6 weeks. No manual therapy
88953007|NCT01957033|Experimental|Duration 0 weeks, Frequency once/week|Exercise and education once/week for 6 weeks No manual therapy
88953008|NCT01957046|Other|Oral Laxative|
89486549|NCT04964648||Malignant pancreatic lesions|older than 18 years with a diagnosis of pancreatic neoplasm
89486550|NCT04964648||Control group|Healthy adult subjects
89486551|NCT03061838|Active Comparator|MabThera®|2 intravenous infusions on Week 0 and Week 2 (14-day interval).
89486552|NCT03061838|Experimental|Ritumax®|2 intravenous infusions on Week 0 and Week 2 (14-day interval).
89486553|NCT02070107|Other|no arms|no arms, sponsor withdrew
89486554|NCT04972994|Active Comparator|laparoscopic intracorporeal anastomosis for right and left hemicolectomies|Surgical outcomes after laparoscopic intracorporeal versus for right and left hemicolectomies in management of colonic cancers
89486555|NCT04972994|Active Comparator|laparoscopic extracorporeal anastomosis for right and left hemicolectomies|Surgical outcomes after laparoscopic extracorporeal anastomosis for right and left hemicolectomies in management of colonic cancers
89486556|NCT04964180|Active Comparator|indomethacin group|group indomethacin (40 patients) recived two 100 mg indomethacin rectal suppositories 2 hours prior to surgery
89486557|NCT04964180|Active Comparator|intraperitoneal lidocaine|200 ml saline containing 200 mg 2%lidocaine immediately after abdominal cO2 insufflation( pneumoperitoneum) the surgeon sprayed the total solution on the upper surface of the liver under the right subdiaphragmatic space, left subdiaphragmatic space and around the cholecystectomy site , all patients were maintained in trendelenberg position
89486558|NCT02067377|Placebo Comparator|inactive powder substance|inactive powder substance by mouth twice a day for 6 months
89486559|NCT02067377|Experimental|serum bovine immunoglobulin (SBI) medical food|SBI medical food 5 gr powder substance by mouth twice a day for 6 months
89486560|NCT02067377|Experimental|serum bovine immunoglobulin (SBI) medicalfood|SBI medical food 10 gr powder substance by mouth twice a day for 6 months
89486561|NCT02070185|Experimental|2 exposures|During the conditioning period, the children of this group was exposed only twice to the beverages
88953009|NCT01957059|Experimental|Dose escalation phase|In the dose-escalation phase, following screening assessment, two cohorts of three subjects each receive two single doses of BMN 053 in two study periods (i.e., four single doses in total per subject). In each study period they will receive BMN 053 by IV infusion and by SC injection (separated by one week). The proposed doses are 1 mg/kg (Cohort 1, study period 1), 3 mg/kg (Cohort 2, study period 1), 6 mg/kg (Cohort 1, study period 2) and 9 mg/kg (Cohort 2, study period 2). The actual doses may be amended or repeated based on emerging data from previous doses.
88953010|NCT01957059|Experimental|Regimen selection|After completion of the dose-escalation period of Cohort 1, the safety data of the subjects will be reviewed by a DSMB and if no safety concerns these subjects will continue to receive 6 mg/kg BMN053 weekly by SC injection for 48 weeks. 3 more treatment-naïve subjects will be entered into this Group. These 6 subjects will form Group 1 of the Regimen Selection phase who received 6 mg/kg SC. At the time of this amendment (4) this part of the study has been completed. Following completion of the dose-escalation study period of Cohort 2 (9 mg/kg), the planned review of the preliminary plasma PK data from the dose-escalation phase showed a relative bioavailability of 50% for BMN053 with SC dosing (50% lower plasma AUC after SC dosing compared to IV dosing). Taking into consideration the risk of injection site reactions noted with similar compounds when administered SC over longer term, the planned 9 mg/kg BMN053 weekly by SC injection will be discontinued to be replaced by an IV regimen.
89486562|NCT02070185|Experimental|7 exposures|During the conditioning period, children of this group were exposed exposed 7 times to the beverages
89486563|NCT04976504||Oxygen reserve index|Male and female patients aged 18 to 80 years with ASA physical status I to III scheduled for elective surgery with planned arterial catheter placement before induction of general anesthesia and did not match the exclusion criteria.
89486564|NCT04964102|Experimental|Workshop|Workshop of Enhancing Interpersonal Effectiveness, Emotional Regulation and Clinical Communication Skills
89486565|NCT02072759|Experimental|Carnitine supplement|Carnitine supplement
89486566|NCT02072759|Placebo Comparator|Placebo|Placebo supplement
89486567|NCT02072759|No Intervention|Healthy control|Healthy control group
89486568|NCT02067455|Other|LVAD patients|
89486569|NCT02072915|Experimental|Suction|Suction will be applied to patients undergoing EUS-FNA
89486570|NCT02072915|No Intervention|Without suction|No suction will be applied to patients undergoing EUS-FNA
89486571|NCT02070341|Experimental|Split dose PEG|Patients randomized to the Polyethylene Glycol (PEG) group will be instructed to ingest 2L of bowel preparation the night before their colonoscopy (starting at 7PM), as well as 1.5-2L of carbohydrate-electrolyte rehydration solution. The following day they will be instructed to ingest the remaining 2L of bowel preparation and must finish ingesting the entire preparation at least 4 hours prior to the scheduled colonoscopy.
89486572|NCT02070341|Experimental|Split dose Picosalax|Patients randomized to the Picosalax (P/MC) group will be instructed to mix one sachet in 150mL of water and ingest the entire mixture at 7PM the night before their colonoscopy. In addition, they will be instructed to ingest 1.5-2L of carbohydrate-electrolyte rehydration solution after they consume the P/MC sachet. The following day they will mix the second sachet in 150mL of water and must finish ingesting the entire preparation at least 4 hours prior to the scheduled colonoscopy. They will also be instructed to drink additional carbohydrate-electrolyte rehydration solution after they ingest the P/MC sachet.
89486573|NCT02072993|Experimental|AZD1979|Single ascending doses of oral solution AZD1979
89486574|NCT02072993|Placebo Comparator|Placebo|Placebo to match single ascending doses of oral solution AZD1979
89486575|NCT02070419|Active Comparator|Arm I (TACE)|Patients undergo (transarterial chemoembolization) TACE according to institutional standard with doxorubicin-eluting beads.
89486576|NCT02070419|Experimental|Arm II (TACE+SBRT)|Patients undergo transarterial chemoembolization (TACE) as in Arm I and 3 or 5 fractions of stereotactic radiosurgery (SBRT) given at least 48 hours apart over 14 days.
89486577|NCT02073071||Preterm/low birth weight infants|Preterm infant formula per standard of care
89486578|NCT02073149|Active Comparator|Low-dose iron as NaFeEDTA|Daily point-of-care fortification of (complementary) foods with 3 mg iron as NaFeEDTA.
89486579|NCT02073149|Active Comparator|Conventional dose iron as ferrous salt|Daily point-of-care fortification of (complementary) foods with 12.5 mg iron as encapsulated ferrous fumarate.
89486580|NCT02073149|Placebo Comparator|Placebo|Daily point-of-care fortification of (complementary) foods with placebo.
89486581|NCT02625974|Experimental|Nifurtimox 60 days / Arm 1|Nifurtimox tablets administered three times daily for 60 days (Days 1 - 60, active nifurtimox treatment)
89486582|NCT02625974|Other|Nifurtimox 30 days / Arm 2|Nifurtimox tablets administered three times daily for 30 days, followed by placebo administered three times daily for 30 days (Days 1 - 30, active nifurtimox treatment; Days 31 - 60, placebo)
89486583|NCT02067689|Experimental|Hemisphere Stimulation|Participants will receive 1mA vs. 2mA transcranial direct current stimulation of a) right and b) left brain structures (1x1 stimulation), and sham/placebo stimulation. A subset of participants will undergo right and left brain stimulation, but all will undergo sham stimulation.
89486584|NCT02067689|Experimental|Temporal Lobe Stimulation|A group of participants will undergo 1x1 transcranial direct current stimulation of the temporal lobes at 1 mA vs. 2 mA vs. sham stimulation. A second group of participants will undergo 1mA or 2mA stimulation, and sham, in right vs. left structures using 4x1 stimulation (e.g., 1mA left temporal, 1mA right temporal, sham; 2mA left temporal, 2mA right temporal, sham).
89486585|NCT02067689|Experimental|Frontal Lobe Stimulation|A group of participants will undergo 1x1 transcranial direct current stimulation of the frontal lobes at 1 mA vs. 2 mA vs. sham stimulation. A second group of participants will undergo 1mA or 2mA stimulation, and sham, in right vs. left frontal structures using 4x1 stimulation (e.g., 1mA left frontal, 1mA right frontal, sham; 2mA left frontal, 2mA right frontal, sham).
89486586|NCT02067689|Experimental|Parietal Lobe Stimulation|A group of participants will undergo 1x1 transcranial direct current stimulation of the parietal lobes at 1 mA vs. 2 mA vs. sham stimulation. A second group of participants will undergo 1mA or 2mA stimulation, and sham, in right vs. left parietal lobes using 4x1 stimulation (e.g., 1mA left parietal lobes, 1mA right parietal lobes, sham; 2mA parietal lobes, 2mA right parietal lobes, sham).
89486587|NCT02067689|Experimental|Supplementary Motor Stimulation|A group of participants will undergo 1x1 transcranial direct current stimulation of the Supplementary Motor Area at 1mA vs. 2mA vs. sham stimulation. A second group of participants will undergo 1mA or 2mA stimulation, and sham, in right vs. left Supplementary Motor Area using 4x1 stimulation (e.g., 1mA left Supplementary Motor Area, 1mA right Supplementary Motor Area, sham; 2mA left Supplementary Motor Area, 2mA right Supplementary Motor Area, sham).
89486588|NCT02067689|Experimental|Brain Structure Interactions Group|This cohort will evaluate the interaction between frontal, parietal, temporal, and SMA regions in cognitive function. To accomplish this goal will require evaluation of change in cognitive and neurocognitive performance following transcranial direct current stimulation of different brain regions within the same subjects. For example, we will evaluate the contribution of frontal, SMA, and parietal regions by asking participants to undergo stimulation sessions at each of these sites, in addition to a sham session.
89486589|NCT02070497|Experimental|case management_new|The patients with new-diagnosed lung cancer and accepting case management
89486590|NCT02070497|Experimental|case management_old|the patients with non-new-diagnosed lung cancer and with accepting case management
89486591|NCT02070497|No Intervention|control group|The patients with new-diagnosed lung cancer in the period of one year ago and without accepting case management
89486592|NCT02067767|Experimental|Abacavir/Lamivudine/Dolutegravir|Patients switched from their ongoing treatment of ABC/3TC + NVP to ABC/3TC/DTG.
89486593|NCT02073227|Experimental|Treatment A|Each participant will receive a single dose of 1 tablet of canagliflozin (CANA), 300 mg, and 4 tablets of metformin extended release (MET XR), 500 mg each, administered together under fed conditions.
89486594|NCT02073227|Experimental|Treatment B|Each participant will receive a single dose of 2 tablets of CANA/MET XR FDC, formulation 1, under fed conditions.
89486595|NCT02073227|Experimental|Treatment C|Each participant will receive a single dose of 2 tablets of CANA/MET XR FDC, formulation 2, under fed conditions.
89486596|NCT04976582|Experimental|interventional group|experimental group in which dry needling with conventional physical therapy treatment modalities including transcutaneous electrical nerve stimulation (TENS); electrical muscle stimulation (EMS); and interferential current (IFC). Physical agents including ultrasound, hot packs, and cold packs. Exercise including McKenzie exercises) will be administered.
89486597|NCT04976582|No Intervention|control group|control group in which kinesiotaping with conventional physical therapy treatment (modalities including transcutaneous electrical nerve stimulation (TENS); electrical muscle stimulation (EMS); and interferential current (IFC). Physical agents including ultrasound, hot packs, and cold packs. Exercise including McKenzie exercises) will be administered.
89486598|NCT02073305||No sleep apnea|Subjects with no or light sleep apnea (AHI < 15/h)
89486599|NCT02073305||Sleep Apnea - untreated|"Subjects with moderate to severe sleep apnea (AHI ≥15/h) and no specific treatment.~Decision to treat or not sleep apnea is left to the treating physician, independently of the study protocol."
88953011|NCT01957059|Experimental|48-week Treatment Phase|"Thirty additional treatment-naïve subjects will be recruited for the primary evaluation and will receive treatment at the recommended regimen for a total of 48 weeks. Subjects dosed initially in the dose escalation phase and/or the regimen selection phase of the study will not be included in the primary analysis.~Following completion of the 2nd study period for Cohort 2, the safety data will be reviewed by the DSMB and in the absence of safety concerns the subjects may enter the 48 week treatment phase and receive 9 mg/kg PRO053 once weekly by SC injection. Three new subjects will enter cohort 2 (i.e. 6 subjects in total at this dose level).~After the initial 12 subjects have completed 12 weeks of dosing the dose for the Treatment group (30 new subjects) will be selected based on the totality of the 12-week data from those initial 12 subjects. The initial 12 subjects will also be dosed on the selected dose (i.e. continue on their dose or [down-]titrate)."
89486600|NCT02073305||Sleep Apnea - treated|Subjects with treated moderate to severe sleep apnea (AHI ≥15/h). Decision to treat or not sleep apnea is left to the treating physician, independently of the study protocol.
89486601|NCT04972838|Experimental|UNITED|UNITED is premised on the idea that successful implementation in organizations like schools and early intervention systems requires a team-based approach, in which the team is thoughtfully assembled, develops a plan for implementation, assigns roles and responsibilities, and carefully tracks and supports implementation and sustainment in all its stages within a few meetings and ongoing coaching from the research staff.
89486602|NCT04972838|Active Comparator|Implementation as Usual (IAU)|The organizations will implement RR as usual. The research team will be available to provide support on the RR intervention as needed.
89486603|NCT02073383|Experimental|Around Artery|"Intervention Name: Axillary brachial plexus block~Group A: 30 ml of 0.375% bupivacaine will be injected around the artery . If this were a clock, would deposit 7,5 ml of anesthetic in positions 0, 3, 6 and 9 ."
89486604|NCT02073383|Experimental|Two injections|Group 2: 30 ml of bupivacaine 0.375 % below the artery will be injected in the 6 o'clock position .
89486605|NCT02073383|Active Comparator|Perineural|Group Perineural : 10 ml of bupivacaine 0.375 % will be injected around the median, ulnar and radial nerves .
89486606|NCT03060044|Experimental|Salmeterol/fluticasone Easyhaler|single dose of Salmeterol/fluticasone Easyhaler
89486607|NCT03060044|Experimental|Salmeterol/fluticasone Easyhaler with charcoal|Single dose of Salmeterol/fluticasone Easyhaler with concomitant charcoal administration
89486608|NCT03060044|Active Comparator|Seretide Diskus|Single dose of Seretide Diskus
89486609|NCT03060044|Active Comparator|Seretide Diskus with charcoal|Single dose of Seretide Diskus with concomitant charcoal administration
89486610|NCT02073539|Experimental|chest compression with 5cm feedback|We will feedback by one accelerometer (U-cpr). U-cpr is android based smartphone application.
89486611|NCT02073539|Experimental|chest compression with 6cm feedback|We will feedback by one accelerometer(U-cpr). U-cpr is android based smartphone application.
89486612|NCT02073539|Experimental|chest compression with 7cm feedback|We will feedback by one accelerometer(U-cpr). U-cpr is android based smartphone application.
89486613|NCT04972370||Patients with Unilateral Cleft Lip with or without Cleft Palate|
89486614|NCT02070653|Active Comparator|Ticagrelor|Ticagrelor 90 mg tablets twice daily for 12 months.
89486615|NCT02070653|Placebo Comparator|Placebo|Ticagrelor-placebo tablets twice daily for 12 months.
89486616|NCT04972448||Group1|Chemotherapy+endocrine therapy+radiotherapy
89486617|NCT04972448||Group2|Chemotherapy+endocrine therapy
89486618|NCT04972448||Group3|endocrine therapy+radiotherapy
89486619|NCT04972448||Group4|endocrine therapy
89486620|NCT02073617|Experimental|Real-time 3-dimensional DynaCT|Patients will undergo the standard CTA protocol and invasive coronary angiography performed as part of the pre-operative assessment for TAVR. Patients in this study will also undergo DynaCT during coronary angiography, utilizing 1 acquisition sweep and 20 to 35cc more of contrast media. Measurements of the major aortic annulus diameter, orthogonal minor aortic annulus diameter, aortic annulus perimeter, maximum ascending aorta diameter at 40mm above the annulus, sinus of Valsalva diameters, sinus of Valsalva heights, and aortic root angulation will be made using both the CTA and DynaCT protocols by a radiologist blinded to patient identity. Based on these measurements, a trained interventional cardiologist will select the appropriate TAVR size for the patient.
89486621|NCT03059732||Thailand|Thai patients who diagnosed gastric cancer
89486622|NCT03059732||Japan|Japanese patients who diagnosed gastric cancer
89486623|NCT04976114|No Intervention|Control group|Standard of care
89486624|NCT04976114|Experimental|story book|Parents read a book with the chid previous to surgery.
89486625|NCT04976114|Experimental|video|Parents watch a video with the chid previous to surgery.
89486626|NCT04976114|Experimental|both instrument|Parents read a book and watch a video with the chid previous to surgery.
89486627|NCT02076269|Other|Arm 1|Subjects will receive no treatment in this study. Each subject will attend the clinic on 2 occasions, initially for a screening visit and then for further assessments (Visit 1). Subjects will remain in the study for maximum 33 days from the screening visit to follow up.
89486628|NCT04831892|Experimental|Moisturizer Containing Isosorbide Diesters and Colloidal Oatmeal|Topical lotion containing isosorbide diesters and colloidal oatmeal to be applied to the entire body once daily.
89486629|NCT04831892|Active Comparator|Moisturizer containing colloidal oatmeal|Topical moisturizer with colloidal oatmeal to be applied to the entire body once daily
89486630|NCT02070731|No Intervention|unprotected TAVI|standard unprotected Transcatheter Aortic Valve Implantation
89486631|NCT02070731|Experimental|TAVI with the TriGuard HDH|TAVI with the TriGuard HDH embolic deflection device
89486632|NCT04831112|Experimental|Honey|Topical honey to be used for dressing 4ml per square inch.
89486633|NCT04831112|Active Comparator|EUSOL|EUSOL soaked gauze to be placed over the wound as dressing.
89486634|NCT02073695|Other|Neutral Rotation Brace|Neutral Rotation Brace
89486635|NCT02073695|Other|Standard polysling (Current practice)|Standard polysling (Current practice)
89486636|NCT04972214||Very Preterm Infants|preterm infants were born at gestational age of less than 32 weeks
89486637|NCT02073773|Experimental|Virtual Reality based therapy, levodopa|"The VR therapy session consists of the subject interacting with a computer-based program in which they guide an avatar to gather items by using flexion and extension gestures of the affected upper limb. VR therapy sessions will last for 15-30 minutes depending on the subject's tolerance and participation. For patients who are unable to overcome gravity fully, they can still participate in this therapy by resting their arm on a table.~Patients will receive a single dose of 100mg levodopa in combination with benserazide 2-3 hours before each additional Occupational therapy session or VR therapy session depending on the assigned group."
89486638|NCT02073773|Active Comparator|occupational therapy, levodopa|"The control group will receive and additional half an hour per working day of standard occupational therapy.~Patients will receive a single dose of 100mg levodopa in combination with benserazide 2-3 hours before each additional Occupational therapy session or VR therapy session depending on the assigned group."
89486639|NCT04830800|Experimental|COVIVAC 1mcg|1mcg IVAC COVIVAC vaccine for intramuscular injection administered as two doses (0.5mL each) 28 days apart.
89486640|NCT04830800|Experimental|COVIVAC 3mcg|3mcg IVAC COVIVAC vaccine for intramuscular injection administered as two doses (0.5mL each) 28 days apart.
89486641|NCT04830800|Experimental|COVIVAC 10mcg|10mcg IVAC COVIVAC vaccine for intramuscular injection administered as two doses (0.5mL each) 28 days apart.
89486642|NCT04830800|Experimental|COVIVAC 1mcg + CpG1018 1.5mg|1mcg + CpG1018 IVAC COVIVAC vaccine for intramuscular injection administered as two doses (0.5mL each) 28 days apart.
89486643|NCT04830800|Placebo Comparator|Placebo|Phosphate buffered saline (pH 7.2) for intramuscular injection administered as two doses (0.5mL each) 28 days apart.
89486644|NCT04964336||Multiple sclerosis|Patients with relapsing-remitting multiple sclerosis
89486645|NCT02073851|Experimental|TriGuard™HDH|Patients undergoing TAVR will be treated wIth experimental device TriGuard™HDH
89486646|NCT04963868|Experimental|The novel strategy group|The stents were removed during the last necrosectomy when the endpoint of necrosectomy was achieved
89486647|NCT04963868|Active Comparator|The conventional strategy group|The stent was removed after the last necrosectomy when clinical symptoms were relieved and fluid was nearly completely resolved confirmed by CT image
89486648|NCT02076347|Experimental|Office visit-based intervention|
89486649|NCT02076347|Experimental|Electronic message-based intervention|
89486650|NCT03061760||1. OAB (-) BOO (-)|Patients diagnosed with prostate cancer, undergoing radical prostatectomy, with no overactive bladder (OAB) symptoms and without bladder outlet obstruction (BOO). 'Initial evaluation' before the surgery and follow up - 'Evaluation after 1,3,6,9,12 months'.
89486651|NCT03061760||2. OAB (-) BOO (+)|Patients diagnosed with prostate cancer, undergoing radical prostatectomy, with no overactive bladder (OAB) symptoms and with bladder outlet obstruction (BOO). 'Initial evaluation' before the surgery and follow up - 'Evaluation after 1,3,6,9,12 months'.
89486652|NCT03061760||3. OAB (+) BOO (+)|Patients diagnosed with prostate cancer, undergoing radical prostatectomy, with overactive bladder (OAB) symptoms and with bladder outlet obstruction (BOO). 'Initial evaluation' before the surgery and follow up - 'Evaluation after 1,3,6,9,12 months'.
89486653|NCT03061760||4.OAB (+) BOO (-)|Patients diagnosed with prostate cancer, undergoing radical prostatectomy, with overactive bladder (OAB) symptoms and without bladder outlet obstruction (BOO). 'Initial evaluation' before the surgery and follow up - 'Evaluation after 1,3,6,9,12 months'.
89486654|NCT03061760||5.Control group|Healthy volunteer individuals aged 20-40. 'Initial evaluation' made only once.
89486655|NCT02070887||Entacapone|
89486656|NCT02070887||No Entacapone|
89486657|NCT03062150|Placebo Comparator|Placebo+Placebo|Placebo: pill, 8mm, single dose, Lichtenstein, Winthrop Arzneimittel GmbH.
89486658|NCT03062150|Active Comparator|Fludrocortisone+Placebo|"Fludrocortisone: pill, Astonin H 0,1gm, single dose, Merck Serono GmbH~Placebo: pill, 8mm, single dose, Lichtenstein, Winthrop Arzneimittel GmbH."
89486659|NCT03062150|Active Comparator|Placebo+D-Cycloserine|"Placebo: pill, 8mm, single dose, Lichtenstein, Winthrop Arzneimittel GmbH.~D-Cycloserine: capsule, Cycloserine 250mg, single dose, King Pharmaceuticals Ltd"
89486660|NCT03062150|Active Comparator|Fludrocortison+D-Cycloserine|"Fludrocortisone: pill, Astonin H 0,1gm, single dose, Merck Serono GmbH~D-Cycloserine: capsule, Cycloserine 250mg, single dose, King Pharmaceuticals Ltd"
89486661|NCT02076503|Experimental|PET-MR 18F-FACBC|
89486662|NCT02076581||Stroke|Ten individuals with chronic stroke and limb spasticity will be recruited.
89486663|NCT02076581||Dystonia|Ten individuals with dystonic limbs and no spasticity will be recruited.
89486664|NCT02076581||Cerebral Palsy|Ten individuals with Cerebral palsy with the potential for a mix of dystonic and spastic abnormal tone in their affected limbs will be recruited.
89486665|NCT02076581||Neurologically normal|Thirty individuals without neurological injury that are age matched to the rest of the study population will be recruited.
89486666|NCT03061916|Experimental|Cinnamon|20% cinnamon will be given after collection of saliva (baseline) and samples will be taken after 30 minutes , one hour and two hours of giving cinnamon 20%
89486667|NCT03061916|Experimental|Ginger|20% ginger will be given after collection of saliva (baseline) and samples will be taken after 30 minutes , one hour and two hours of giving ginger 20%
89486668|NCT03061916|Active Comparator|Chlorhexidine|Chlorhexidine gluconate 0.2%,will be given after collection of saliva (baseline) and samples will be taken after 30 minutes , one hour and two hours of giving chlorhexidine.
89486669|NCT02076659|Experimental|F8IL10 + MTX|"Ten cohorts of 3-6 RA patients will be treated at increasing doses per cohort of F8IL10 plus fixed doses of MTX and folic acid.~An additional 12 patients will be randomized (6+6) in a double blind, placebo controlled cohort with F8IL10 given at RD and placebo. In both arms, MTX will be administered as concomitant medication.~In all coohorts a stable dose of folic acid (5 mg) will be administered on Day 2."
89486670|NCT04963556|Experimental|Red Bull|Drinking of 355 ml Red Bull
89486671|NCT04963556|Placebo Comparator|Placebo|Drinking of 355 ml sweetened water
89486672|NCT04963244||AECOPD|
89486673|NCT04963244||Stable COPD|
89486674|NCT04963244||Control|
89486675|NCT02076815|Experimental|Anagrelide retard|Anagrelide Retard prolonged-release formulation
89486676|NCT02076815|Active Comparator|Thromboreductin|Anagrelide immediate release formulation
89486677|NCT04975490||SAPIENT = Sepsis ACLF patients|
89486678|NCT04975490||PROACT = Portal mediators as ACLF Targets|
89486679|NCT04975490||ELITE = prEdictors of beneficial LIver Tx in ACFL patiEnts|
89486680|NCT04971434|Experimental|laser|In fatty liver patients (30 patients), a daily application of 4-minute laser (for one month, except Fridays) on acupoint number 25,40,36 of stomach meridian, acupoint number 3 of liver meridian, acupoint number 6 of spleen meridian,acupoint number 9.12,4 of conception vessel meridian, acupoint number 14 of governor vessel meridian, acupoint number 4, 11 of large intestine meridian, acupoint number 34 of gall bladder meridian
89486681|NCT04971434|Experimental|cupping with scarification|In fatty liver patients (30 patients),every-two-week applied cupping (with scarification) session within one month on back of upper thorax
89486682|NCT02071043|Experimental|XELOX|"XELOX: Schedule of Oxaliplatin plus capecitabine (XELOX) will be as follow:~Capecitabine 1000 mg/m2 ，orally taken 30 minutes after meal, bid ， d 1~14 every 3 weeks(treatment for 2 weeks and rest 1 week) Oxaliplatin：130mg/m2， iv infusion over 2h，d1,every 3 weeks"
89486683|NCT02076893|Active Comparator|Tramadol/gabapentin/ibuprofen|(A) Scheduled tramadol 1mg/kg Q6h [max. 50mg] for 5 days; plus tramadol 1mg/kg Q6h PRN [max. 50mg] for 5 days (B) Scheduled gabapentin 3 mg/kg [max 150 mg] Q6h for 5 days (C) PRN ibuprofen 10 mg/kg [max. 500 mg] Q6h PRN
89486684|NCT02076893|Placebo Comparator|Tramadol/placebo/ibuprofen|(A) Scheduled tramadol 1mg/kg Q6h [max. 50mg] for 5 days; plus tramadol 1mg/kg Q6h PRN [max. 50mg] for 5 days (B) Scheduled placebo of same volume Q6h for 5 days (C) PRN ibuprofen 10 mg/kg [max. 500 mg] Q6h PRN
89486685|NCT02074163|Experimental|Glabella|"Glabella~Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
89486686|NCT02074163|Experimental|Frontal|"Frontal~Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
89486687|NCT02074163|Experimental|Temporal|"Temporal~Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
89486688|NCT02074163|Experimental|Occipital|"Occipital~Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
89486689|NCT02074163|Experimental|Paraspinal|"Paraspinal~Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
89486690|NCT02074163|Experimental|Trapezius|"Trapezius~Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
89486691|NCT02074163|Experimental|Change in frequency of headache days|Change in frequency of headache days as Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12, Efficacy of Botox intramuscularly at Week 18, Efficacy of Botox intramuscularly at Week 24, and Efficacy of Botox intramuscularly at Week 30 vs.Efficacy of Botox subdermally at Week 6, Efficacy of Botox subdermally at Week 12, Efficacy of Botox subdermally at Week 18, Efficacy of Botox subdermally at Week 24, and Efficacy of Botox subdermally at Week 30.
89486692|NCT02074163|Experimental|Change in hrs of HA on HA days|Change in hrs of HA on HA days as Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12, Efficacy of Botox intramuscularly at Week 18, Efficacy of Botox intramuscularly at Week 24, and Efficacy of Botox intramuscularly at Week 30 vs.Efficacy of Botox subdermally at Week 6, Efficacy of Botox subdermally at Week 12, Efficacy of Botox subdermally at Week 18, Efficacy of Botox subdermally at Week 24, and Efficacy of Botox subdermally at Week 30.
89486693|NCT02074163|Experimental|Adverse Reactions with Facial paresis|Facial paresis as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
89486694|NCT02074163|Experimental|Adverse Reactions with Eyelid ptosis|Eyelid ptosis as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
89486695|NCT02074163|Experimental|Adverse Reactions with Bronchitis|Bronchitis as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
89486696|NCT02074163|Experimental|Adverse Reactions with Neck pain|Neck pain as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
89486697|NCT02074163|Experimental|Adverse Reactions with Muscle stiffness|Musculoskeletal stiffness as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
89486698|NCT02074163|Experimental|Adverse Reactions with Muscular weakness|Muscular weakness as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
89486699|NCT02074163|Experimental|Adverse Reactions with Myalgia|Myalgia as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
89486700|NCT02074163|Experimental|Adverse Reactions with Muscle pain|Musculoskeletal pain as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
89486701|NCT02074163|Experimental|Adverse Reactions with Muscle spasms|Muscle spasms as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
89486702|NCT02074163|Experimental|Adverse Reactions Injection site pain|Injection site pain as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
89486703|NCT02074163|Experimental|Adverse Reactions with Hypertension|Hypertension as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
89486704|NCT04963088|Experimental|TISLELIZUMAB、Anlotinib plus XELOX|
89486705|NCT04970732|Experimental|Experimental group|The patients in the experimental group returned to the ward for general anesthesia, started to wake up for 2 hours, chewed xylitol gum, and the professional nurses distributed it on time every 2 hours on the operation day, then 3 times / day, 15-20 minutes / time, 2 tablets / time. Body position: lateral position. The first anal exhaust stop chewing, normal sleep at night (8 p.m.), do not chew gum. Gum waste must be identified
89486706|NCT04970732|No Intervention|Control group|The control group received routine nursing after surgery.
89486707|NCT02074241||Positive Expression|Expression analysis:Positive expression of DNA repair-related genes(XPC, XPF, Brca1, Rad51,SNF5, etc) in bladder cancer specimens.
89486708|NCT02074241||Negative Expression|Expression analysis:Negative expression of DNA repair-related genes(XPC, XPF, Brca1, Rad51, SNF5,etc) in bladder cancer specimens.
89486709|NCT02074319|Placebo Comparator|Placebo|Matching placebo for methotrexate
89486710|NCT02074319|Experimental|Methotrexate|Methotrexate 10 mg once a week orally
89486711|NCT04975022|Experimental|T group|
89486712|NCT04975022|Active Comparator|R group|
89486713|NCT04975412||acne vulgaris group (cases)|Filipino patients, aged 18-25 years old with diagnosis of Acne Vulgaris
89486714|NCT04975412||control group|healthy Filipino patients, aged 18-25 years old
89486715|NCT02071121|Placebo Comparator|Placebo|Fasted participants will receive a single oral dose of placebo to BIIB061.
89486716|NCT02071121|Experimental|BIIB061 3 mg|Fasted participants will receive a single oral dose of BIIB061 3 mg.
89486717|NCT02071121|Experimental|BIIB061 10 mg|Fasted participants will receive a single oral dose of BIIB061 10 mg followed by a tracer amount of 14C-BIIB061 (at ≤ 500 nCi/participant; approximately 4 μg of BIIB061), administered by manual slow intravenous push injection at 4 hours postdose.
89486718|NCT02071121|Experimental|BIIB061 30 mg|Fasted participants will receive a single oral dose of BIIB061 30 mg. Following a washout period, participants will receive the same dose of BIIB061 after a high-fat, high-calorie meal (fed state).
89486719|NCT02071121|Experimental|BIIB061 60 mg|Fasted participants will receive a single oral dose of BIIB061 60 mg.
89486720|NCT02071121|Experimental|BIIB061 100 mg|Fasted participants will receive a single oral dose of BIIB061 100 mg.
89486721|NCT03284879||Patients with PsV and PsA treated with OTEZLA Tablets|Patients with psoriasis vulgaris and patients with psoriatic arthritis who are treated with OTEZLA Tablets
89486722|NCT03061604|Experimental|Hemospray|"All subjects will be treated by medical treatment in the terms of combination of vasoactive medication, blood transfusion and Ceftriaxone PLUS Hemospray treatment within 2 hours of admission.~The medical treatment will be continued till 12 hours after admission and then second endoscopy will be performed (12-24 hours after admission)."
89486723|NCT03061604|Active Comparator|Non Hemospray|"All subjects will be treated by medical treatment in the terms of combination of Octreotide, blood transfusion and Ceftriaxone.~The medical treatment will be continued till 12 hours after admission and then second endoscopy will be performed (12-24 hours after admission)."
89486724|NCT02077049|Experimental|serious games self-training program|Serious games are played, using Kinect® and Fit Bit®. This program is performed during the 10 days of the intervention on a self-training basis and 2 specific time-slot (2x30 min) per day are allocated for this program.
89486725|NCT02077049|Active Comparator|Conventional self-training program|conventional physical exercises are performed during the 10 days of the intervention, on a self-training basis and 2 specific time-slot (2x30 min) per day are allocated for this program.
89486726|NCT04962854||Monoblock Cup|53 patients received a monoblock cup (RM Pressfit vitamys®)
89486727|NCT04962854||Modular Cup|64 patients received a modular cup (ANA.NOVA® Implantec)
89486728|NCT04974944|Experimental|Camrelizumab + Apatinib|On Day 1 and Day 15 of each 28-day cycle, participants receive an intravenous (IV) infusion of camrelizumab 200 mg Plus an oral apatinib 250 mg once daily. Apatinib will be administered 250 mg once every other day when completing twice tumor assessement. All treatments are administered until disease progression or unacceptable toxicity.
89486729|NCT04974944|Active Comparator|Paclitaxel + Cisplatin/Carboplatin + Bevacizumab|On Day 1 of each 21-day cycle, participants receive an intravenous (IV) infusion of paclitaxel 175 mg/m^2 PLUS cisplatin 50 mg/m^2 WITH bevacizumab 15 mg/kg OR paclitaxel 175 mg/m^2 PLUS carboplatin Area Under the Curve (AUC) 5, WITH bevacizumab 15 mg/kg). All treatments are administered until disease progression or unacceptable toxicity.
89486730|NCT02071199|Experimental|Low dose 0.3X ACCS|20 microliters of 0.3X ACCS per tooth is applied directly excluding third molars by dental professional daily Monday through Friday for two weeks
89486731|NCT02071199|Experimental|High dose 1X ACCS|20 microliters of 1X ACCS per tooth is applied directly excluding third molars by dental professional daily Monday through Friday for two weeks
89486732|NCT02071199|Placebo Comparator|Normal saline|20 microliters of saline placebo per tooth is applied directly excluding third molars by dental professional daily Monday through Friday for two weeks
89486733|NCT04974632|Other|localization|small, deep or ground-glass opacity (GGO) lung tumor, Mobile 3D C-arm CT assisted pre-operative localization, video-assisted thoracic surgery(VATS)
89486734|NCT02071277|Experimental|Pressure targeted modes|
89486735|NCT04970498||acute myelosuppression group|WBC <4.0×10^9 14 days after radiotherapy
89486736|NCT04970498||chronic myelosuppression group|WBC <4.0×10^9 90 days after radiotherapy
89486737|NCT04970498||no myelosuppression group|WBC >4.0×10^9 during radiotherapy
89486738|NCT02077205|Experimental|Manualised Cognitive Behavioral Therapy|Manualised Cognitive Behavioral Therapy in a Routine Care Setting
89486739|NCT02074397|Experimental|Distant extrafascial injection|Injection away from the brachial plexus with the needle tip positioned in the middle scalene muscle
89486740|NCT02074397|Active Comparator|Subfascial injection|Injection within the brachial plexus, with the needle tip positioned between C5 and C6
89486741|NCT04970420|Experimental|HeRFAPIW|Health Responsibility and Family Planning ın Immigrant Women (Ahıska Turks).
89486742|NCT04970420|Active Comparator|Control group|
89486743|NCT02074475||Control group|The control group of three sites for larger Adequacy of Anaesthesia study. Total 150 patients
89486744|NCT04962386||Perimenopausal women who did not undergo HRT|Perimenopausal women who did not undergo HRT at baseline. And they did not receive any other drugs
89486745|NCT04962386||Perimenopausal women who did undergo HRT|Perimenopausal women who did undergo HRT received estrogen-progesterone combination therapy packaged with estradiol tablets/estradiol and dynamic progesterone (Abbott Health Products BV. Weesp, The Netherlands).Take this medicine once a day. A course of treatment was defined as 28 days of continuous treatment.
89486746|NCT02071355|Experimental|Group 1|Participants will receive 100 mg TMC435 once daily for 7 days.
89486747|NCT02071355|Experimental|Group 2|Participants will receive 150 mg TMC435 once daily for 7 days.
89486748|NCT03061682|Experimental|Add on lens|
89486749|NCT02077283||Healthy people|This group contains healthy people only whose liver function and B ultrasound are normal.
88953012|NCT01957059|Experimental|Dosing extension|All subjects who have completed the dose escalation and regimen selection phase of the study (N=15), and subjects who have complete the treatment phase of the study who have tolerated the treatment will be offered to continue dosing in the dosing extension with ongoing assessment of efficacy, safety, and tolerability of BMN 053. Safety, efficacy, PK/PD and biomarker assessments will be performed at scheduled visits; adverse events (AEs) and concomitant medications and therapies will be continuously monitored. The dose extension phase will provide BMN 053 treatment for 48 weeks.
89486750|NCT02077283||"group of liver depression and spleen deficiency pattern"|"In this group, patients are considered to be the pattern of liver depression and spleen deficiency. They mainly have the symptoms of loose stool, depression, fat tongue with white coating and teeth marks and soft or string pulse."
89486751|NCT02077283||"group of damp-heat in the interior pattern."|In this group ,NAFLD patients have symptoms with dry mouth, bitter mouth, heavy feeling in legs, yellow urine, reddish tongue with thick yellowish coating and slippery pulse.
89486752|NCT04962464|Experimental|Fasting Mimicking Diet + Supplement / Usual Routine|Participants in will be asked to begin the Peak Human Labs calorie mimetic supplement. They will also begin on day 1 the 5 day Fasting Mimicking Diet Program. Participants will continue the supplementation for the 90 days and repeat the 5 day Fasting Mimicking Diet Program on days 1, 29 and 57. Starting at day 91, they will return to their usual daily routine.
89486753|NCT04962464|Experimental|Supplement / Usual Routine|Participants will be asked to begin the Peak Human Labs calorie mimetic supplement. Participants will continue the supplementation for 90 days. Starting at day 91, they will return to their usual daily routine.
89486754|NCT04962464|Experimental|Usual Routine / Fasting Mimicking Diet + Supplement|Participants will have no intervention for the first 90 days, during which they will be asked not to start a new fasting program supplement. At day 91, they will begin the 5-day Fasting Mimicking Diet Program and start the Peak Human Labs calorie mimetic supplement. Participants will continue the supplementation for 90 days and repeat the 5-day Fasting Mimicking Diet Program on days 91, 120, and 148.
89486755|NCT04962464|Experimental|Usual Routine / Supplement|Participants will have no intervention for the first 90 days, during which they will be asked not to start a new fasting program supplement. At day 91,start the Peak Human Labs calorie mimetic supplement. Participants will continue the supplementation for 90 days.
89486756|NCT02071433|Experimental|Saphenous nerve blockade|Experimental treatment 15 mL of levobupivacaine 0.5%
89486757|NCT02071433|Active Comparator|Femoral nerve blockade|Standard treatment 15 mL of levobupivacaine 0.5%
89486758|NCT04962308|Experimental|Experimental Group|200 subjects in group A1 will receive one dose of booster immunization 3 months after the completion of the second dose of primary immunization of the SARS-CoV-2 Inactivated vaccine.
89486759|NCT04962308|Experimental|Control Group|200 subjects in group A2 will receive one dose of booster immunization 5 months after the completion of the second dose of primary immunization of the SARS-CoV-2 Inactivated vaccine.
89486760|NCT04962308|Experimental|Safety group|1000 subjects in group B will be enrolled and receive 1 dose of booster immunization more than 3 months after the completion of the second dose of primary immunization of the SARS-CoV-2 Inactivated vaccine
89486761|NCT02071589|Experimental|Nifedipine oral solution|Nifedipine 5 mg/mL oral solution, 6 mL (30 mg of Nifedipine) at single dose
89486762|NCT02071589|Active Comparator|Nifedipine soft gelatine capsules|Nifedipine soft gelatine capsules x3 (total 30 mg Nifedipine) at a single dose
89486763|NCT04962620||Longidaze|75 patients receiving combination therapy: Longidaze + dienogest
89486764|NCT04962620||Control|74 patients receiving only Dienogest.
89486765|NCT02077439|Experimental|Hand Robotic Training|Hand Robotic Training
89486766|NCT02077439|Experimental|Hand and Arm Robotic Training|Hand and Arm Robotic Training
89486767|NCT02077439|Active Comparator|Conventional therapy|Conventional therapy
88953013|NCT01957072|Experimental|Behaviour change intervention|Intensive behaviour change intervention for 3 months, followed by a maintenance phase for 3 months
88953014|NCT01957072|Other|Wait-list Control|Usual care for 3 months, followed by intensive behaviour change intervention for 3 months
88953015|NCT01957098|Placebo Comparator|0% pentose|Pure sucrose without pentoses added.
88953016|NCT01957098|Active Comparator|4% D-xylose|Sucrose drink supplemented with 4% D-xylose
88953017|NCT01957098|Active Comparator|8% D-xylose|Sucrose drink supplemented with 8% D-xylose
89203947|NCT02551848|Experimental|Essential tremor treatment|"A serotype of botulinum toxin type A (BoNT-A) that has specificity for cleavage of SYNAPTOSOMAL-ASSOCIATED PROTEIN 25 (SNAP-25). BoNT-A's pharmacological action is to inhibit the release of acetylcholine from the neuromuscular junction.~Participants will be treated by BoNT-A injections every 12 weeks over 72 weeks. BoNT-A parameters will be determined solely by biomechanical analysis of tremulous movements in both upper extremity BoNT-A dose will range from 50-300 U per arm"
89486768|NCT03059654|Active Comparator|Ultrasound PCT|Ultrasound guide Percutaneous tracheostomy
89486769|NCT03059654|Active Comparator|Surgical tracheostomy|Surgical tracheostomy
89486770|NCT02077517|Active Comparator|hand sewn anastomosis|Patients with hand sewn anastomosis during Roux en Y Gastric bypass performing
89486771|NCT02077517|Active Comparator|stapled anastomosis|Patients with stapled anastomosis during Roux en Y Gastric Bypass performing
88953018|NCT01957098|Active Comparator|8% L-arabinose|Sucrose drink supplemented with 8% L-arabinose
88953019|NCT01957124|Experimental|PRF application|
88953020|NCT01957189|Experimental|Dutasteride with/ without Tamsulosin|All subjects will be assigned to the same treatment group
88953021|NCT01957228|Experimental|bone biopsies|
88953022|NCT01957241||Hepatocellular Carcinoma and Esophageal Cancer|
88953023|NCT01957254||Severe Sepsis|Patient with severe sepsis
89203948|NCT00807534|Active Comparator|ipratropium bromide|acute bronchodilation: ipratropium bromide
89203949|NCT00807534|Placebo Comparator|placebo|placebo nebulization
89203950|NCT00812058|Experimental|RG2417|Oral RG2417 taken twice daily for 8 weeks
89486772|NCT02077595|Active Comparator|120Hz alternating current stimulation group|
89486773|NCT02077595|Active Comparator|5Hz alternating current stimulation group|
89486774|NCT02077595|Sham Comparator|sham alternating current stimulation group|
89486775|NCT02077673||open surgery|25 patients undergoing open gastroesophageal resection
89486776|NCT02077673||robotic-assissted surgery|25 patients under-going robotic-assisted gastroesophageal surgery
89486777|NCT02076737|Experimental|VEO|
89486778|NCT04970030|Active Comparator|mechanical intracanal (ML) lithotripsy|TTS mechanical lithotripter
89486779|NCT04970030|Experimental|electrohydraulic intracolangioscopic (EHL) lithotripsy|electrohydraulic lithotripsy with Autolith probe
89486780|NCT02077751|Experimental|Biotin labelled RBCs|Subjects receive biotin labelled autologous red blood cells.
89486781|NCT04847960|Experimental|L.reuterii probiotic lozenges from BioGaia|Subjects were willing to provide 2 samples of saliva, dental plaque and gingival fluid (gum fluid), on the first day (before consuming lozenges) and on the 14th day after the subject consumed lozenges containing L. reuteri probiotic. Probiotics are taken once a day for two weeks after breakfast and brushing their teeth.
89486782|NCT02077829|Other|IMR therapists, IMR patients|"30 voluntary therapists from 9 mental health services will be trained and coached in IMR.~40 patients from the 9 mental health services will receive Illness Management and Recovery from the therapists in training."
89486783|NCT02071667||Subjects who require sinus surgery|
89486784|NCT02077907|Active Comparator|Super Cereal Plus (SC+)|"800 kcal/d, 215 g/d~Current protocol for treating MAM is supplemental food distribution, often providing a fortified blended food (FBF) that requires cooking. In Sierra Leone, their FBF standard is Super Cereal Plus."
89486785|NCT02077907|Experimental|Super Cereal (SC) and oil and sugar|"200 g SC and 20 g fortified oil and 15 g sugar, per day~Fortified blended food (FBF) Fortified Oil with Vitamins A & D"
89486786|NCT02077907|Experimental|Corn Soy Blend 14 (CSB14) and fortified oil|"978 kcal/day - 150 g CSB14 and 45 g oil, per day~Fortified blended food (FBF) Fortified Oil with Vitamins A & D"
89486787|NCT02077907|Experimental|Plumpy'Sup|"500 kcal/d, 92 g/d~Ready-to-Use Supplementary Food (RUSF)"
89486788|NCT04954508||P|patients suffering form shoulder pain and/or weakness or dislication
89486789|NCT02074865||newborns|
89486790|NCT02074787||Adult burn injuries|Adult patients with burns injuries attending the regional burns unit at Chelsea & Westminster hospital between 48 and 72 hours post burn will be invited to take part in the study at the time of presentation to the unit.
89486791|NCT02071745||Navigation|
89486792|NCT04961684|Experimental|Solver Pen|
89486793|NCT04961684|Active Comparator|Loceryl 5%|
89486794|NCT02074943|Experimental|PRP/Saline|Same patient will be injected with PRP and normal saline. Each one will be inject on half head.
89486795|NCT03061058|Experimental|Individualized Group|"mRNA levels of BRCA1, topoisomerase I (TOPO1), and thymidylate synthase (TS) were assessed in tumor tissue. Chemotherapeutic agents were selected based on the mRNA levels.~Patients with high level BRCA1 will receive intraperitoneal docetaxel (15mg/m^2, d1, d15, q4w), intravenous docetaxel (30mg/m^2, d1, d15, q4w), and oral S-1 (40mg/m^2, d1-14, q4w).~Patients with low level BRCA1 will receive intraperitoneal cisplatin (25mg/m^2, d1, d15, q4w), intravenous oxaliplatin (75mg/m^2, d1, d15, q4w), and oral S-1 (40mg/m^2, d1-14, q4w).~Patients with middle level BRCA1 and high level TOPO1 will receive intraperitoneal irinotecan (45mg/m^2, d1, d15, q4w), intravenous docetaxel (90mg/m^2, d1, d15, q4w), and oral S-1 (40mg/m^2, d1-14, q4w).~Patients with middle level BRCA1, low or middle level TOPO1, and low level TS will receive intraperitoneal pemetrexed (150mg/m^2, d1, q3w), and intravenous pemetrexed (350mg/m^2, d1, q3w)."
89486796|NCT03061058|Active Comparator|Control Group|"mRNA levels of BRCA1, TOPO1, and TS were assessed in tumor tissue for every enrolled patients.~Patients in control group will receive intravenous docetaxel (45mg/m^2, d1, d15, q4w), and oral S-1 (40mg/m^2, d1-14, q4w)."
89486797|NCT04954118|Active Comparator|Group P|The clinicians performed an internal jugular vein cannulation using only personal protective equipment.
89486798|NCT04954118|Active Comparator|Group P&A|The clinicians performed an internal jugular vein cannulation using personal protective equipment and aerosol box.
89486799|NCT04954430||fatigue|After enrollments, subjects were assigned to perform mental fatigue-inducing experiment-a 90 min of monotonous simulated driving task. They underwent repeated measurements of quantitative pupillary light reflex (PLR) using an automated quantitative pupillometer at baseline and at an interval of 30 min during the task. Subjective ratings, heart rate variability (HRV), and electroencephalography (EEG) were performed simultaneously.
89486800|NCT04962074|Experimental|Density gradient method|Sperm prepared by density gradient method
89486801|NCT04962074|Experimental|Microfluidic chip|Sperm prepared by microfluidic chip method
89486802|NCT04969484|Experimental|ImPAcTT intervention|Within 48-72 hours of enrollment in the study, the primary participant and family will receive an ImPAcTT Telehealth visit with the PC provider. The provider will conduct a comprehensive PC assessment aligned with the National Consensus Project for Quality Palliative Care guidelines. Visits, which may include remote physical assessment using a digital stethoscope, dermatoscope, etc., will be documented and transmitted to the NH. Advanced Care Planning (ACP) and goals of care discussions will be facilitated by the ability to virtually share and edit documents, such as the Physician Orders for Life Sustaining Treatment (POLST), in real time with primary participants and/or family. The PC provider will conduct follow-up visits 1 week following the initial visit, then on a case-by-case basis.
89486803|NCT04969484|No Intervention|Usual care|Participants will receive the standard of care established at the NH.
89486804|NCT04961918|Experimental|Treatment Group|Hepatic Arterial Infusion Chemotherapy (HAIC) Combine Lenvatinib and Durvalumab (HILL)
89486805|NCT04961294|Experimental|Electro-Acupuncture group|The patients in this group will be treated with electro-acupuncture for 30 minutes twice a week in a month. We conduct Nei Guan (PC6), Shen Men (HT7), ZuSanli (ST36), SanYinjiao (SP6) as the major points. Each time treating, according to other symptoms, we will give no more than 2 additional points.
89486806|NCT04961294|No Intervention|Wait-list group|We give no intervention to the patients this group during the whole experiment. When finishing, the same ways of treatment will be given to these patients.
89486807|NCT04969172|Active Comparator|1010 Exosome|103 patients will receive either 1010 exosome particles.
89486808|NCT04969172|Placebo Comparator|Placebo|52 patients will receive placebo- saline.
89203951|NCT00812058|Placebo Comparator|Placebo|Oral placebo taken twice daily for 8 weeks
89203952|NCT05589142|Experimental|eTRE with BCAA|participants allocated to this group will only consume calories during 0800h and 1600h daily. Prior to sleep, participants will consume a single bolus of 5.6g of BCAA.
89203953|NCT05589142|Active Comparator|eTRE|participants allocated to this group will only consume calories during 0800h and 1600h daily.
89203954|NCT05589064|Experimental|Dietary intervention and nutritional supplements (group A)|Patients in group A will receive four consultations with a dietitian over eight weeks, in addition to conventional physiotherapy treatments. These patients will receive nutritional counselling and omega-3 (2500mg/day), vitamin D (2000 IU/day) and creatine monohydrate (10mg/day) supplements prescribed by their doctor.
89203955|NCT05589064|Active Comparator|Nutritional supplements (group B)|Patients in group B will be prescribed omega-3 (2500mg/day), vitamin D (2000 IU/day) and creatine monohydrate (10mg/day) supplements and receive physiotherapy treatments over eight weeks.
89203956|NCT05589064|Other|Physiotherapy treatment (control group)|Patients in the control group will receive physiotherapy treatments over eight weeks.
89203957|NCT00813930|Experimental|INTERxVENT Program|Participants in INTERxVENT will complete a 'Baseline Assessment' and 'Follow-up' questionnaire, and will have a health professional visit his/her home for an initial assessment (BP,height,weight,waist measurement) and blood collection (blood glucose and cholesterol levels). As part of the program, each participant will also complete a self-reported 'Health History Questionnaire' (HHQ); a follow-up HHQ will be completed about 12 weeks into the program to monitor progress. Each participant randomized to INTERxVENT receives educational articles which address diabetes management issues. A structured, individualized program, consisting of educational materials and 12 live mentoring/coaching telephone calls will take place over 6 months. The mentors consist of allied health professionals. The sequence by which educational content is administered will be both self-directed and guided by the mentors using an algorithmic approach according to the participant's readiness-to-change scores.
89203958|NCT00813930|No Intervention|Usual medical care|Each participant randomized to this group will not receive any formal intervention but will receive the same care over the 6-month period as he/she usually receives from his/her health care team. Participants in this group will undergo the same baseline and outcome assessment as those in the intervention group, including blood pressure (BP) measurement, physical assessment (height, weight, waist measurement) and blood collection (blood glucose and cholesterol levels), as well as completion of the 'Baseline Assessment' and 'Follow-up' questionnaires.
89203959|NCT05355844|Sham Comparator|Patients without Benzoyl peroxide|
89203960|NCT05355844|Experimental|Patients with Benzoyl peroxide|
89203961|NCT00814086|Experimental|Treatment (paclitaxel, cisplatin)|Patients receive paclitaxel IV over 3 hours and cisplatin intraperitoneally (IP) on day 1 and paclitaxel IP on day 8. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
89203962|NCT04114786|Experimental|3D-printed mask|Patients will undergo the standard CT SIM, and MR SIM necessary for radiation therapy, creating the masks from the MRIs. Prior to the start of their treatment, patients will have an additional CT scan with the 3D printed mask to confirm safety and treatment accuracy. Patients will then proceed with their standard radiation therapy, immobilized with the mask.The group will complete a mask tolerability questionnaire throughout the course of their treatment to capture the level of discomfort patients may feel with either masks.
89203963|NCT04114786|Active Comparator|Control group|Control group that will be treated with the standard thermoplastic mask, as a comparison measure. The group will complete a mask tolerability questionnaire throughout the course of their treatment to capture the level of discomfort patients may feel with either masks.
89203964|NCT00669110|Experimental|A|
89203965|NCT04604860|Experimental|EL-FIT|Patients using the EL-FIT app
89203966|NCT00654732|Experimental|Arm A (rituximab, combination chemotherapy)|Participants receive rituximab intravenously IV over 7 hours on days 1, 8, 15, and 22 of course 1 and on days 1 and 8 of course 2. Participants also receive doxorubicin hydrochloride, bleomycin, vinblastine, and dacarbazine IV over 1 hour on days 1 and 15. Treatment with ABVD repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
89203967|NCT00654732|Active Comparator|Arm B (combination chemotherapy)|Participants receive doxorubicin hydrochloride, bleomycin, vinblastine, and dacarbazine as in Arm A.
89203968|NCT00771368|Experimental|Nitric Oxide|gaseous nitric oxide delivered topically for 30 minutes
89203969|NCT00767156|Active Comparator|SBA24 capsule plus Omega7 cream|the subjects took SBA24 sea buckthorn oil capsule and apply Omega7 cream
89203970|NCT00767156|Active Comparator|SBA24 capsule plus base cream|the subjects took SBA24 sea buckthorn oil capsule and apply a base cream
89203971|NCT00767156|Active Comparator|Omega7 Cream|The subjects Omega 7 Sea Buckthorn Oil Cream, twice per day
89203972|NCT00767156|Placebo Comparator|Base cream|The subjects use base cream on the face, twice per day
89203973|NCT05358028|Experimental|Hand arm Bimanual intensive Technique including Lower extremity (HABIT-IL)|Hand arm Bimanual activities involving Lower extremity
89203974|NCT05358028|Active Comparator|Hand Arm bimanual intensive Technique (HABIT)|Hand arm Bimanual activities without involvement of lower extremity
89203975|NCT00771524|Experimental|Ceftobiprole|Ceftobiprole, 500 mg single 2 hour infusion prior to hip replacement surgery
89486809|NCT04954040|Experimental|Hydroxychloroquine + Azithromycin|"Hydroxychloroquine. 1st day 200mg 2-0-2; 2nd to 5th day 200mg 1-0-1 Azithromycin. 1st day 500m 0-1-0, 2nd to 5th day 250mg 0-1-0~Oral intake in all cases. Pills will be taken simultaneously."
89203976|NCT00771524|No Intervention|Control|Standard of care antibiotics prior to hip replacement surgery
89203977|NCT00649428|Experimental|Active|
89203978|NCT00649428|Placebo Comparator|Control|
89203979|NCT00767390||ACL Patch|
89203980|NCT02552082||Scorpio NRG|
89203981|NCT04000438|Experimental|Experimental DF01 high dose|The subject receives sc injections once daily for up to 7 days until labor induction or spontaneous onset of labor.
89203982|NCT04000438|Experimental|Experimental: DF01 medium dose|The subject receives sc injections once daily for up to 7 days until labor induction or spontaneous onset of labor.
89203983|NCT04000438|Experimental|Experimental: DF01 low dose|The subject receives sc injections once daily for up to 7 days until labor induction or spontaneous onset of labor.
89021710|NCT00336674|Placebo Comparator|Placebo|Placebo insulin carrier solution of benzalkonium chloride and glycerol presented in multi-dose nasal spray devices with actuators (Pfeiffer) designed to deliver 100ul spray doses to nasal mucosa. The product will be self administered by participants as two 100 microlitre spray doses per nostril. Treatment will be administered daily for 7 consecutive days then on one day each week for 12 months. Participants will be followed until they develop diabetes or until 5 years after the last participant has been randomised (maximum period of follow up is expected to be 10 years.
89021711|NCT00336752|Active Comparator|1|Non operative treatment of Weber B ankle fracture. Use of cast, with no surgical intervention
89021712|NCT00336752|Active Comparator|2|Operative treatment of Weber B ankle fracture. Open reduction and internal fixation to repair a broken bones.
89021713|NCT00336791|Experimental|Paclitaxel + Additional FAC/FEC|"12 weekly Paclitaxel treatments 80 mg/m^2 by vein (IVPB) over 1 hour + 4 additional FAC or FEC combination chemotherapy treatments; FAC or FEC treatments given once every 3 weeks.~FAC Chemotherapy: 5-Fluorouracil 500 mg/m^2 intravenous (IV) day 1 & 4 + Doxorubicin 50 mg/m^2 IV day 1 over 72 hour continuous infusion or IV bolus + Cyclophosphamide 500 mg/m^2 IV day 1.~FEC Chemotherapy: 5-Fluorouracil 500 mg/m^2 IV day 1 + Epirubicin 100 mg/m^2 IV day 1 + Cyclophosphamide 500 mg/m^2 IV day 1."
89021714|NCT00336791|Active Comparator|FAC/FEC|"6 courses FAC or FEC Combination Chemotherapy~FAC Chemotherapy: 5-Fluorouracil 500 mg/m^2 intravenous (IV) day 1 & 4 + Doxorubicin 50 mg/m^2 IV day 1 over 72 hour continuous infusion or IV bolus + Cyclophosphamide 500 mg/m^2 IV day 1.~FEC Chemotherapy: 5-Fluorouracil 500 mg/m^2 IV day 1 + Epirubicin 100 mg/m^2 IV day 1 + Cyclophosphamide 500 mg/m^2 IV day 1."
89021715|NCT00336830|Active Comparator|Usual Care|Comparator without MD endorsement of Cardiac Rehabilitation
89021716|NCT00336830|Experimental|MD Endorsment of CR|Provided with MD endorsement of participation in Cardiac Rehabilitation
89486810|NCT04954040|Active Comparator|SOC (Standard of Care)|"SOC for symptoms treatment~Acetaminophen or Metamizole, 1-1-1 Antitussives if needed"
89486811|NCT04968704||patients undergoing facial reconstructive surgery|Patients with facial cancer or disfigurement who require reconstructive surgery will be offered participation in this study.
89486812|NCT04424654|Experimental|Bipolar Androgen Therapy (BAT)|Testosterone cypionate 400 mg IM every 28 days for 3 cycles
89486813|NCT04968626|Experimental|IS GROUP|Patients who received an operation to treat their isthmic spondylolisthesis (IS, Meyerding grade I-II)
89486814|NCT04968626|No Intervention|AS GROUP|The asymptomatic adults had no history of severe back pain or spinal trauma
89486815|NCT04969016|Experimental|LSA (liquid skin adhesive)|surgical wound closure with liquid skin adhesive (LiquiBand®)
89486816|NCT04969016|Active Comparator|Stapler|surgical wound closure with stapler
89486817|NCT04953572|Experimental|test group|Patients in the test group received autologous peripheral blood mesenchymal stem cell therapy
89486818|NCT04953572|Active Comparator|control group 1|Patients in the control group 1 received microfracture surgical treatment
89486819|NCT04953572|Active Comparator|control group 2|Patients in the control group 2 received microfracture combined with surgical treatment of collagen membrane
89203984|NCT04000438|Placebo Comparator|Placebo comparator: PL1|The subject receives sc injections once daily for up to 7 days until labor induction or spontaneous onset of labor.
89486820|NCT04953572|Active Comparator|control group 3|Patients in the control group 3 received autologous osteochondral transplantation
89486821|NCT04953416|Experimental|Scalp treatment with ResurFX|
89486822|NCT04953494||Amyotrophic lateral sclerosis patients group|
89486823|NCT04424576||Regular Menstrual Cycles|22 adolescents with regular menstrual cycles (i.e., once every 4-6 weeks) will be enrolled within 11 months of menarche.
89203985|NCT00771680||A|
89486824|NCT04424576||Irregular Menstrual Cycles|26 adolescents with irregular menstrual cycles (i.e., < 4 weeks or > 6 weeks between periods) will be enrolled within 11 months of menarche.
89486825|NCT04424186|Experimental|'Rehabilitation for Life'|Vital sign measurement and rehabilitation
89486826|NCT04424186|Active Comparator|Usual care and rehabilitation|Usual care and rehabilitation provided in primary and secondary sectors
89486827|NCT04961606||patients with coronary artery disease|
89486828|NCT04961606||medical professionals|
89486829|NCT04953260|No Intervention|GTR group|only conventional GTR technique was used to treat periodontal bone defect,
89486830|NCT04953260|Active Comparator|APRF+GTR group|GTR technique combined with APRF was used to treat periodontal bone defect
89486831|NCT04953260|Active Comparator|CGF+GTR group|GTR technique combined with CGF was used to treat periodontal bone defect
89486832|NCT04968392|Experimental|L group|20 mL of 0.25% levobupivacaine plus 1 mL normal saline
89486833|NCT04968392|Experimental|LD group|20 mL of 0.25% levobupivacaine plus 0.5 µg/kg dexmedetomidine
89486834|NCT04953026||Normal control group-Grade 0|Arthroscopic examination of the labrum was normal, and the labrum was intact without injury or tear.
89486835|NCT04953026||Ligament injury -Grade 1|Arthroscopic examination of the shoulder showed labrum degeneration or injury, but no local or complete tear.
89486836|NCT04953026||Ligament tear-Grade 2|Arthroscopy of the shoulder revealed partial or complete loss of labrum.
89203986|NCT02552784|Experimental|patients and their parents with inherited metabolic diseases|The population is a dynamic/open cohort consists of all patients MHMRS diagnosed and supported in one of the six Centers of Reference for Metabolical disease or one of the three Centers of Competence for Hereditary Metabolic Diseases or in the Center of Réference for Hereditary liver Metabolism Diseases since 2000. For each patient, the date of entry into the cohort is the diagnostic date of MHMRS. The study includes all prevalent and incident cases .
89203987|NCT04003558||Sun Yat-Sen Memorial Hospital of Sun Yat-sen University|The cohort of Sun Yat-Sen Memorial Hospital of Sun Yat-sen University is a training cohort.
89203988|NCT04003558||Sun Yat-sen University Cancer Center|The cohort of Sun Yat-sen University Cancer Center is a validation cohort.
89486837|NCT04961450||Patients|"Inclusion Criteria:~Patients aged 18-80 years who visit Peking University Third Hospital, Beijing, China from December 2020.~Patients who diagnosis MND/FTD spectrum disease (including ALS, FAS, FLS, PLS, PBP, PMA, FTD, MND-FTD) by an experienced neurologist strictly according to a list of diagnosis criteria and clinical guidelines~Informed consent signed~Exclusion Criteria~Patients who receive alternative diagnoses during the follow-up.~Patients who refuse to sign informed consent."
89486838|NCT04961450||Control|"Control group consists of individuals matched for gender and age with the patients who are mainly the caregivers of the patients, including but not limited to the patients' spouses and their long-term nurses.~Exclusion criteria:~Suffering from neurological disease, including but not limited to motor neuron disease/frontotemporal dementia spectrum disease, dementia, Alzheimer's disease, Parkinson's disease, multiple sclerosis, neuromyelitis and so on.~Individuals who refuse to sign informed consent."
89486839|NCT02792699|Experimental|ABP 798 / ABP 798|Participants received ABP 798 on days 1 and 15 (dose 1) and a second dose of ABP 798 at weeks 24 and 26 (dose 2). Each dose consisted of two 1000 mg intravenous infusions 2 weeks apart.
89486840|NCT02792699|Active Comparator|Rituximab (US) / ABP 798|Participants received rituximab (United States [US] formulation) on days 1 and 15 (dose 1) and transitioned to receive ABP 798 at weeks 24 and 26 (dose 2). Each dose consisted of two 1000 mg intravenous infusions 2 weeks apart.
89486841|NCT02792699|Active Comparator|Rituximab (EU) / Rituximab (EU)|Participants received rituximab (European Union [EU] formulation) on days 1 and 15 (dose 1) and a second dose of rituximab (EU formulation) at weeks 24 and 26 (dose 2). Each dose consisted of two 1000 mg intravenous infusions 2 weeks apart.
89486842|NCT04968002|Experimental|Preoperative neoadjuvant therapy for patients with stage IIa-IIIa non-small cell lung cancer.|No EGFR mutation or ALK gene translocation was found in the untreated patients with NSCLC stage IIa-IIIb diagnosed by imaging, histopathology or cytology. After informed consent is signed by the patients. The patients were treated according to the protocols.
89486843|NCT04961216|Experimental|OPTIMISE intervention|"After a baseline week of self-monitoring their meat consumption, participants will receive health and environmental feedback on their consumption and will be prompted to think about how they could reduce their intake. They will be asked to pre-select strategies from a list of meat consumption reduction actions and set themselves a meat reduction goal.~During the following four weeks (weeks 2-5), participants will be asked every morning to log their meat consumption of the previous day, plan one of their chosen actions and formulate an if-then plan. Participants will receive weekly feedback on their achieved meat reduction in comparison to week 1.~After the completion of the fifth week (follow-up 1), participants will be asked to continue performing the actions they found useful for the next four weeks (weeks 6-9). During the ninth week (follow-up 2) participants will be invited back to log their meat intake."
89486844|NCT04961216|No Intervention|Control|After a baseline week of self-monitoring their meat consumption participants will be asked to try and reduce their meat consumption over the next eight weeks, with no further guidance. They will be invited back to complete log their meat consumption of the previous day during weeks five and nine (follow-up 1 and 2).
89486845|NCT04961138|Experimental|Neoadjuvant group|
89486846|NCT04961138|Active Comparator|Surgery group|
89486847|NCT03061136|Placebo Comparator|Placebo|Placebo administered orally
89486848|NCT03061136|Experimental|Clonazepam 0.1mg|0.1mg clonazepam administered orally
89486849|NCT03061136|Experimental|Clonazepam 0.2mg|0.2mg clonazepam administered orally
89486850|NCT03061136|Experimental|Clonazepam 0.3mg|0.3mg clonazepam administered orally
89486851|NCT04953182||Around the clock analgetic treatment|Patients that underwent hemorrhoidectomy and pain killers are prescribed every specific hour independent of pain degree, if necessary drugs can be administered on demand.
89486852|NCT04953182||On demand analgetic treatment|A pain killers list is prescribed by the physician and the nurse decides which drug to administer depending on a protocol of treatment based on the visual analog scale.
89486853|NCT04952948|Experimental|PILATES Method Training Group|The PILATES program at moderate intensity lasted 12 weeks, at a frequency of 3 times a week, and with duration of 60 minutes for each exercise session.
89486854|NCT04952948|Sham Comparator|CONTROL Group|While the PILATES Group participated in the intervention with physical exercises, the CONTROL group only participated in the functional capacity and blood pressure assessments. However, at the end of the intervention in the PILATES Group, the CONTROL Group was invited to participate in a similar training program.
89486855|NCT04960982||PCOS-RM|PCOS women with history of RM
89486856|NCT04960982||Non PCOS RM|Non PCOS women with history of RM
89486857|NCT04960982||Control|women with no history of RM
89486858|NCT02079857|Experimental|Standard|Fixed protocol
89486859|NCT02079857|Experimental|Individualized|Individualized protocol
89486860|NCT02079857|Sham Comparator|Control|Sham acupuncture/Placebo moxa
89203989|NCT04003558||Tungwah Hospital of Sun Yat-Sen University|The cohort of Tungwah Hospital of Sun Yat-Sen University is a validation cohort.
89486861|NCT03058874|Placebo Comparator|Control arm|Standard protocol of fluid management in hemodialysis
89537802|NCT03061383|Active Comparator|8% Arginine based toothpaste|The procedure will be performed after scaling in group D1 using 8% arginine based toothpaste (Colgate Pro-relief) . Treatment will be done at baseline then patients will use the toothpaste at home twice per day by using soft bristled tooth brush and the given dentifrice using modified stillmans method as explained by examiner
89537803|NCT03061383|Active Comparator|8% Strontium acetate based toothpaste|The procedure will be performed after scaling in group D2 using 8% strontium acetate based toothpaste (Sensodyne Rapid Action) . Treatment will be done at baseline then patients will use the toothpaste at home twice per day by using soft bristled tooth brush and the given dentifrice using modified stillmans method as explained by examiner
89537804|NCT03061383|Placebo Comparator|tooth past without active ingredient|The procedure will be performed after scaling in group D3 control group using placebo . Treatment will be done at baseline then patients will use the toothpaste at home twice per day by using soft bristled tooth brush and the given dentifrice using modified stillmans method as explained by examiner
89537805|NCT03290495|Active Comparator|isonly|This arm will receive spinal anesthesia. then this arm will receive saline during isoflurane anesthesia. this arm will serve as a control group.
89537806|NCT03290495|Active Comparator|isoket|this arm will receive spinal anesthesia. then will receive isoflurane inhalation. during isoflurane inhalation, this arm will receive single injection of ketamine. at end of anesthesia, effect of ketamine on recovery will be monitored.
89537807|NCT04429893|Experimental|Group BM|The patients will receive 20 ml of 0.5% bupivacaine plus 150 mg magnesium sulphate in 0.9% normal saline with a total volume of 25 ml.
89537808|NCT04429893|Active Comparator|Group B|The patients will receive 20 ml of 0.5% bupivacaine plus 5 ml 0.9% normal saline with total volume 25 ml
89537809|NCT03290417|No Intervention|Unmodified Diet|Patients are under active surveillance with no modification to their diet, as is standard of care for low risk prostate cancer
89537810|NCT03290417|Experimental|Diet modification|Patients receive Vitamin D, Omega-3 and turmeric curcumin as dietary supplements
89537811|NCT04429347|Experimental|Tizanidine 2mg|Friday night: 1 capsule Saturday night: 2 capsules Sunday night: Subject chooses 1-2 capsules
89537812|NCT04429347|Experimental|Gabapentin 300mg|Friday night: 1 capsule Saturday night: 2 capsules Sunday night: Subject chooses 1-2 capsules
89537813|NCT04429347|Placebo Comparator|Placebo|Friday night: 1 capsule Saturday night: 2 capsules Sunday night: Subject chooses 1-2 capsules
89537814|NCT03294551|No Intervention|Standard of Care Control|Usual source of care
89537815|NCT03294551|Experimental|HPV Vaccine Reminder Recall - Autodialer|HPV Vaccine Reminder Recall - Autodialer: Receive up to 4 reminders via telephone (live call or voicemail) - includes brief educational message + providers name + providers telephone number
89021717|NCT00444561|Active Comparator|Pramlintide acetate (AC137)|Pramlintide acetate (AC137) injection is a clear, colorless, sterile solution for SC administration. It consists of pramlintide in sodium acetate buffer, pH 4.0, containing 43 mg/mL mannitol as an osmolality modifier and 2.25 mg/mL metacresol as a preservative. The concentration of pramlintide injection to be used in this study is 0.6 mg/mL.
89021718|NCT00444639|Experimental|1|triptorelin 11.25mg given 12 weekly by subcutaneous formulation
89021719|NCT00444639|Active Comparator|2|triptorelin 11.25mg given 12 weekly by intramuscular injection
89021720|NCT00347646|Experimental|Plasmin|Human-derived plasmin reconstituted with sterile sodium chloride for intravitreal injection.
89021721|NCT00421239||A|
89021722|NCT00421239||B|
89021723|NCT00421278|Experimental|1|Arm 1: Drug
89021724|NCT00337259|Experimental|Gemcitabine|"histologically confirmed marginal zone lymphoma~gemcitabine 1,250 mg/m2 on days 1 and 8 of each cycle, repeated every 3 weeks and continued for 6 cycles, until disease progression, withdrawal due to toxicity, or withdrawal of consent."
89021725|NCT04699734|Active Comparator|Xylocaine|Nerve block
89021726|NCT04699734|Placebo Comparator|Isotonic saline|Nerve block
89021727|NCT00337298|Experimental|1|Crossover design. Arm is same all the way
89021728|NCT04699851|Experimental|Intervention|The intervention arm are participants who will receive tailored recommendations about health prevention in a pandemic based on their answers in the survey.
89203990|NCT04003558||Shunde hospital of southern medical university|The cohort of Shunde hospital of southern medical university is a validation cohort.
89203991|NCT00767468|Experimental|Bilirubin Normal to 3x Upper Limit of Normal|
89537816|NCT03294551|Experimental|HPV Vaccine Reminder Recall - Texting|HPV Vaccine Reminder Recall - Texting: Receive up to 4 reminders via text message - includes brief educational message + providers name + providers telephone number
89537817|NCT04156581|Active Comparator|ESPB with Bupivacaine and Dexamethasone|23 complex spine surgery patients will be randomized to receive intraoperative ultrasound-guided bilateral ESPB with 0.375% bupivacaine plus 2 mg preservative free dexamethasone, 25-30 mL total per side according to patient weight.
89537818|NCT04156581|Placebo Comparator|ESPB with saline placebo|23 complex spine surgery patients will be randomized to receive intraoperative ultrasound-guided bilateral ESPB with saline placebo, 25-30 mL total per side according to patient weight.
89203992|NCT00767468|Experimental|Bilirubin >3x to 6x Upper Limit of Normal|
89537819|NCT03294473|Experimental|Autodial R/R|R/R Autodialers:Participants in this group will receive up to 3 influenza vaccination reminders via telephone call - with a brief educational message + practice name + practice phone number
89537820|NCT03294473|Experimental|Text Message R/R|R/R Texting: Participants in this group will receive up to 3 influenza vaccination reminders via text message - with a brief educational message + practice name + practice phone number
89537821|NCT03294473|Experimental|Postcard R/R|R/R Mailed Postcard:Participants in this group will receive up to 3 influenza vaccination reminders via postcard - with a brief educational message + practice name + practice phone number
88953024|NCT01957280|Experimental|Process 2 patritumab|Process 2 patritumab 18 mg/kg (loading dose) on Day 1 of Cycle 1 followed by Process 2 patritumab 9 mg/kg (maintenance dose) once every 21 days starting on Day 1 of Cycle 2 through Cycle 5.
88953025|NCT01957293|Experimental|Salbutamol|
89203993|NCT05074914|Experimental|Adenocarcinoma of the oesophagus|curative oesophagectomy
89537822|NCT03294473|No Intervention|Standard of Care Control|Participants in this group will not receive any influenza vaccination reminders
89537823|NCT02983071|Experimental|Once-Daily G1T38 Dosing|G1T38 (lerociclib) orally (once daily) in combination with fulvestrant.
88953026|NCT01957293|Placebo Comparator|Sugar Syrup|
88953027|NCT01957306|Experimental|Dr. Tagliaferri's Menoapause Formula|Administered as 2 grams PO BID.
88953028|NCT01957319|Active Comparator|Silybin - vitamin E - phospholipids complex|Silybin 94 mg + vitamin E 90 mg + phospholipids 194 mg in one pill for 12 months.
88953029|NCT01957319|Placebo Comparator|placebo|sugar pill
88953030|NCT01957345|Other|bleeding disorder|"Blood punction at patients with bleeding disorder definitely other than of platelet origin (e.g. low von Willebrand)"
88953031|NCT01957345|Other|constitutional platelet disorder|Blood punction at patients with constitutional platelet disorder (e.g. Glanzmann thrombasthenia)
88953032|NCT01957345|Other|defect of platelet function|Blood punction at patients with defect of platelet function of unknown origin, potentially defective in signalling pathway.
88953033|NCT01957358|Experimental|Lifestyle counselling using the Grief Recovery Method|Volunteers will participate in a series of weekly and twice-weekly sessions with a counselor who has obtained special training in the Grief Recovery Method.
88953034|NCT01957371|Experimental|Mindful Yoga Therapy|12 sessions of Mindful Yoga Therapy delivered two times per week for 75 minutes each.
88953035|NCT01957423|Experimental|Whey protein|Whey protein was provided as sachets with 15g. Patients were advised to consume two sachets per day (amounting to 22.4g of protein) mixed with food or a cold beverage, for 16 weeks. All patients remained on an unrestricted diet and did not receive nutritional advice.
88953036|NCT01957423|Active Comparator|Soy protein|Soy protein was provided as sachets with 15g. Patients were advised to consume two sachets per day (amounting to 22.4g of protein) mixed with food or a cold beverage, for 16 weeks. All patients remained on an unrestricted diet and did not receive nutritional advice.
88953037|NCT01957449|Active Comparator|Propranolol|Propranolol by mouth given daily throughout hospitalization for up to 12 months
88953038|NCT01957449|Placebo Comparator|Sugar Pill|Placebo by mouth given daily throughout hospitalization for up to 12 months
88953039|NCT01957501||Major Depressive Disorder Participants|
88953040|NCT01957501||Bipolar Disorder Participants:|
88953041|NCT01957501||Healthy Control Participants|
88953042|NCT01957514||Ancillary-Correlative (sample collection)|Patients undergo collection of tissue biopsy, blood, buccal swab, saliva, and urine at baseline.
88953043|NCT01957527||Ticagrelor discontinuation|
88953044|NCT01957540|Experimental|Ticagrelor|Ticagrelor 90mg bid for 15 days
88953045|NCT01957540|Active Comparator|Prasugrel|Prasugrel 10mg od for 15 days
88953046|NCT01957566|Experimental|APS|
88953047|NCT01957592||Subjects with diabetes mellitus (type 2)|
88953048|NCT01957605||prone position|Patient scheduled for surgery in the prone position
88953049|NCT01957618||Treatment group|liver cirrhosis group who received indefinite anti-viral treatment
88953050|NCT01957618||Historical control group|Liver cirrhotic patients who were enrolled before 2004 and did not receive treatment during the follow-up
88953051|NCT01957631|Active Comparator|Corticosteroid injection|Corticosteroid injection
88953052|NCT01957631|Experimental|Platelet rich plasma injection|Platelet rich plasma injection
88953053|NCT01957670|Experimental|Treatment with Lacrima medical device|
88953054|NCT01957683|Experimental|Single Arm|
89203994|NCT05074914|No Intervention|Barrett's oesophagus|Weight stable patient under survelliance with Barrett's oespophagus
89537824|NCT02983071|Experimental|Twice-Daily G1T38 Dosing|G1T38 (lerociclib) orally (twice daily) in combination with fulvestrant.
89537825|NCT03294395|Active Comparator|Ceftriaxone im|Current standard treatment. Ceftriaxone 500mg (single intramuscular dose) + placebo (single oral dose)
89537826|NCT03294395|Experimental|Ertapenem im|Ertapenem 1000mg (single intramuscular dose) + placebo (single oral dose)
89537827|NCT03294395|Experimental|Fosfomycin po|Fosfomycin oral suspension 6g (single oral dose) + placebo (single intramuscular dose)
89537828|NCT03294395|Experimental|Gentamicin im|Gentamicin sulfate, injectable 5mg/kg (single intramuscular dose) + placebo (single oral dose)
89537829|NCT03061461|Active Comparator|rESWT|"Treatment of chronic wounds with the Swiss DolorClast (Electro Medical Systems S.A., Nyon, Switzerland) and the EvoBlue handpiece as follows:~Use of the 15-mm applicator or the 36-mm applicator of the Swiss DolorClast according to the individual wound size.~Six treatment sessions, two treatment sessions per week.~1000 radial shock waves per cm^2 wound and treatment session.~Energy flux density 0.07 mJ/mm^2 (i.e., setting of the air pressure of the Swiss DolorClast at 2 bar when using the 15-mm applicator, and at 4 bar when using the 36-mm applicator).~Frequency of the radial shock waves set at 15 Hz."
89537830|NCT03061461|Sham Comparator|Sham rESWT|"Treatment of chronic wounds with the Swiss DolorClast (Electro Medical Systems S.A., Nyon, Switzerland) and the placebo EvoBlue handpiece of the Swiss DolorClast (that looks and sounds like the EvoBlue handpiece of the Swiss DolorClast, but does not generate radial shock waves) as follows:~Use of the 15-mm applicator or the 36-mm applicator of the Swiss DolorClast according to the individual wound size.~Six treatment sessions, two treatment sessions per week.~1000 sham radial shock waves per cm^2 wound and treatment session.~Energy flux density 0.00 mJ/mm^2 (setting of the air pressure of the Swiss DolorClast at 2 bar when using the 15-mm applicator, and at 4 bar when using the 36-mm applicator).~Frequency of the sham radial shock waves set at 15 Hz."
89537831|NCT03061617|Other|volume controlled ventilation (VCV)|VCV mode, tide volume 6ml/kg, f 12-14, set fixed tide volume for each breath
89537832|NCT03061617|Experimental|pressure controlled ventilation (PCV)|PCV mode, pressure is adjusted to achieve tide volume 6ml/kg, f 12-14
89537833|NCT04488887||Diabetic retinopathy Group|Patients with non-proliferative and proliferative diabetic retinopathy with clear media will be recruited.
89537834|NCT04488887||Myopia Group|Patients with different grades of myopia, with accurate segmentation will be recruited
89537835|NCT04488887||Choroidal neovascularization group|Patients with active choroidal vascularization without scarring will be recruited
89537836|NCT04488887||Healthy controls|Healthy individuals without retinal disorders will be included for comaprison
89537837|NCT04980183|Experimental|Arthroscopic surgical robot assisted navigation and positioning for cruciate ligament reconstruction|Patient undergoes cruciate ligament reconstruction with robot-assisted navigation and positioning under arthroscopic surgery
89537838|NCT04980183|Active Comparator|Conventional arthroscopic cruciate ligament reconstruction|The patient undergoes conventional arthroscopic cruciate ligament reconstruction
89537839|NCT03294239|Experimental|Group A (Transurethal group)|Patients will have trans urethral approach for management of their bladder stones. Either pneumatic or Holmium:YAG laser will be used for stone disintegration. Stone basket and/or Elics current evacuation will be used to retrieve stone fragments. Urethral catheter will be applied for 48 hours.
89537840|NCT03294239|Experimental|Group B (Percutaneous group)|Patients will have per cutaneous approach for management of their bladder stones. After initial cystoscopy a Foley's urethral catheter will be fixed for continuous irrigation. Then, the bladder will be filled to capacity with normal saline. Access to the distended bladder will be obtained by 10-gauge needle in the mid line 1-2 cm above the pubic bone. Once suitable placement is confirmed with return of fluid, a guide wire will be passed through the needle into the bladder. Dilatation will be done using 8-10 Fr coaxial dilators then single fascial dilator with placement of 16 Fr Amplatz sheath as a working tract. No ultrasonic or fluoroscopic guidance will be used. Stone basket will be used to extract the stone. If the stones were larger than the used sheath, disintegration will be performed with a pneumatic lithotrite. Primary skin closure of the suprapubic stab wound by one stitch will be done and the urethral catheter will remain for 48 hours.
89537841|NCT03290183||Intrathoracic malignancy|Patients with (strong suspicion of) intrathoracic malignancy and an indication for tissue collection by CT-guided, transthoracic or thoracoscopic approach undergo additional imaging with confocal laser endomicroscopy (CLE).
89537842|NCT04980105|Experimental|Platelet-rich plasma arm|
89537843|NCT04980105|Active Comparator|Hyaluronic acid arm|
88953055|NCT01957696||Pancreas-Tx recipients; single cohort|This is a prospective, single cohort observational study, aimed at using a historical control group as comparison. It will be conducted at our single, national centre for organ transplantation in Oslo. All pancreas recipients > 18 years of age, who fulfill the inclusion criteria, will prior to transplantation be asked for inclusion.
88953056|NCT01957735|Experimental|BP31510 monotherapy|"Starting dose level of BPM31510 will be 66 mg/kg administered by IV infusion over 48 hours 2 times per week of each 28-day cycle.The 2 doses will be administered over 4 consecutive days.The study drug will be administered undiluted via a central venous access device and the infusion rate will be controlled by a programmable ambulatory infusion pump.~first dose of each week of the cycle a loading dose will be infused over 1 hour with the remainder of the dose volume infused over 47 hours.At each dose level of Arm 1 and Arm 2, patients will be treated for either 8 hours at minimum of outpatient monitoring or inpatient monitoring for the first 24-hrs of the first infusion of Cycle 1.~second dose of each week of the cycle, the total dose volume given over 48 hours with no loading dose."
89021729|NCT04699851|Active Comparator|Control|The control group will receive general recommendations about health prevention in a pandemic.
89021730|NCT00337376|Experimental|1|
89021731|NCT03275688||Stage 1 Lung Cancer (Case)|These are the participants with identified stage 1 lung cancer.
89021732|NCT03275688||Type 1 Control|These are participants who have similar clinical characteristics as our cases, but do not have any history of cancer.
89021733|NCT03275688||Type 2 Control|These are housemates of the participants with stage 1 lung cancer (cases).
89021734|NCT00337493|Experimental|1|
89021735|NCT00337493|Experimental|2|
89021736|NCT00337493|Experimental|3|
89203995|NCT00669032|Experimental|hyaluronic acid|Cycles of 5 injections of hyaluronic acid at specified intervals
89203996|NCT00669032|Placebo Comparator|Placebo|Cycles of 5 injections of saline at specified intervals
89203997|NCT04001998|Experimental|Tablet vs Capsule Formulation|Single oral dose of BLD-2660 capsule or tablet formulation
89203998|NCT04001998|Experimental|Dose Proportionality|Single oral dose of BLD-2660 tablet formulation
89486862|NCT03058874|Experimental|Active arm|Extra-vascular lung water measurements by ultrasound (LW-US)
89486863|NCT02075099|Experimental|Isotonic drink|"Predonation hydratation with 500 ml of isotonic drink, to drinking in immediate predonation.~(The half of included donors will do tensing exercises during the blood whole donation and the other half will do no tensing exercises)"
89486864|NCT02075099|Experimental|mineral water|"Predonation hydratation with 500 ml of mineral water to drinking in immediate predonation whole blood.~(The half of included donors will do tensing exercises during the blood whole donation and the other half will do no tensing exercises)"
89486865|NCT02075099|Active Comparator|Advices|"Advices of drinking water or fruit juice glass(es) in immediate predonation whole blood.~(The half of included donors will do tensing exercises during the blood whole donation and the other half will do no tensing exercises)"
89486866|NCT03058718|Experimental|Procalcitonin-guided antibiotic treatment group|"Patients were divided into 2 subgroups:~No infection group (including patients with procalcitonin<0.1 ng/ml at enrollment, and patients with 0.1 ng/ml ≤procalcitonin ≤0.25 ng/ml at enrollment who are with stable respiratory and hemodynamics, and without serious complications) : the group is not given the application of antibiotics.~Infection group (including patients with procalcitonin>0.25 ng/ml at the time of enrollment, and patients with 0.1 ng/ml ≤ procalcitonin≤0.25 ng/ml at enrollment who have severe disease, unstable hemodynamics, and severe complications or intensive care unit treatment): the group is given the application of antibiotics. According to the guidelines for severe sepsis / septic shock treatment, the standard for discontinuation of antimicrobial agents: If the procalcitonin level falls below <0.1 ng/ml or more than 80%, compared with the baseline before enrollment, it is recommended to discontinue the antimicrobial agent."
89486867|NCT03058718|Active Comparator|Standard antibiotic therapy group|The application of antibiotics is given to patiens according to the doctor's experience.
89486868|NCT04967924|Experimental|Sports specific training|Treatments will be provided in 30 mins per week for 3 consecutive weeks. Weight programs include closed chain exercises (squats, pushups) and open chain exercises (leg press, chest fly using dumbbell) Stretch shortening cycle (enhances performance through storage of elastic energy during eccentric phase and activation of stretch reflex).
89486869|NCT04967924|Active Comparator|neuromuscular training|Treatments will be provided in 30 mins per week for 3 consecutive weeks Proprioceptive Neuromuscular Facilitation (PNF)
89486870|NCT04968080||Full Analysis Set|Participants will have their temperature collected by infrared thermal camera (IRT), oral, forehead, and ear thermometers.
89486871|NCT03010319|Experimental|PriMatrix|Arm will receive PriMatrix Dermal Repair Scaffold plus secondary dressings to maintain a moist wound healing environment and an appropriate off-loading device.
89486872|NCT03010319|Active Comparator|Standard of Care|Arm will receive moist wound therapy consisting of 0.9% Sodium Chloride gel plus secondary dressings and an appropriate off-loading device.
89486873|NCT03058640|Experimental|Karate Intervention|Participants will be enrolled into PKSA karate classes which includes at least two, standardized 1-hour classes per week for 12 weeks. Participants must attend at LEAST 20/24 classes. Attendance sheets will be signed by parents at each site. Practice at home will also be encouraged. Log sheets will be provided to participants to log their practice
89486874|NCT03058640|No Intervention|Standard Care|Participants will have no initial intervention. Investigators will request that participants do not enroll in a structured martial arts class during the one-year period. Participants will, however, be given the option of receiving the structured karate program at 6 months, once measurements are completed
89486875|NCT04961060||Eosinophilic exacerbation|COPD exacerbation associated with eosinophilia.
89486876|NCT04961060||Viral exacerbation|COPD exacerbation associated with viral infection.
89486877|NCT04961060||Bacterial exacerbation|COPD exacerbation associated bacterial infection.
89486878|NCT04961060||Pauci-inflammatory exacerbation|Pauci-inflammatory COPD exacerbation
89486879|NCT02079935|Experimental|Cognitive Behaviour Therapy|Treatment with small groups following a modified protocol first described by Fairburn 2008
89486880|NCT02079935|Experimental|Physical activity and dietary therapy|Treatment with guided physical activity and dietary therapy in small groups
89486881|NCT02080013|Sham Comparator|ClosureFast group|Radiofrequency Ablation for the Treatment of Great Saphenous Vein Reflux
89486882|NCT02080013|Sham Comparator|group 1|EVL group Endovenous Laser Ablation for the Treatment of Great Saphenous Vein Reflux
89486883|NCT02075333|Active Comparator|Sucrose (50g)|A 381g blackcurrant drink (cordial and water) providing 50g of sucrose
89486884|NCT02075333|Placebo Comparator|Sucralose (0.92 g sugars)|A 381g blackcurrant drink (cordial and water) providing 0.92g of natural sugars
89486885|NCT04952558||Cross sectional observational study|"Cross sectional observational study will be conducted among 700 patients of Egyptian inflammatory bowel diseased patients for different regions~Detailed history will be taken from all included patients focus on~age ,sex , special habit ,residence .~education level -socioeconomic status~type of the inflammatory bowel disease~lag time for reaching the proper diagnosis of inflammatory bowel disease which definite as time from the first symptoms presentation to reaching definite diagnosis~symptoms that causing patients seeking medical advice~number of Inflammatory bowel diseased patients referred for first time from surgeons~number of patients have perianal symptoms~number of patients have previous history of appendicectomy"
89486886|NCT02075489|Experimental|Acupressure|This group of patients will serve as the experimental group and receive acupressure treatment in addition to routine clinical care. Acupressure will be provided 40 mins/day, 2 days/week for 6 weeks (total of 12 sessions).
89537844|NCT04980105|Active Comparator|Methylprednisolone acetate arm|
89486887|NCT02075489|Active Comparator|Reiki|This group of participants will serve as control group and receive Reiki treatment in addition to routine clinical care. Reiki will be provided 40 mins/day, 2 days/week for 6 weeks (total of 12 sessions).
89486888|NCT03060824||CABG with the aid of CPB.|Cardiac surgical patients subjected to coronary artery bypass grafting with the aid of Cardiopulmonary Bypass. Perioperative measurements of osmolality in plasma.
89486889|NCT02075567|Experimental|Therapy adaption T1DM|
89486890|NCT04960436|Experimental|Meniscus Allograft Transplantation|The patient underwent Meniscus Allograft Transplantation
89486891|NCT04960436|Active Comparator|Meniscectomy|The patient underwent Meniscectomy
89486892|NCT02075645|Other|team training|"Intervention: team training course. A 1-day simulation-based team-training course. There will be 4 simulated resuscitation events. Simulation #1 will be the pre-course team performance and simulation #4 will be the post-course performance."
89486893|NCT02075723|Experimental|Overfeeding + sleep restriction|overfeeding condition (130 % of energy requirements ) + 6 days of sleep restriction (4 hours per night)
89486894|NCT02075723|Experimental|Overfeeding + normal sleep duration|overfeeding condition (130 % of energy requirements ) + 6 days of normal sleep duration (8 hours per night)
88953057|NCT01957735|Active Comparator|BP31510 in combination with chemotherapy|"standard 3+3 design will be used for Arm 2 of the study. BPM31510 will be started at one dose level below the dose that has been studied and determined to be safe in the monotherapy portion of the trial. Arm 2 patients will be enrolled onto one of 3 chemotherapies, gemcitabine, 5-FU, or docetaxel according to the dose levels below:~Gemcitabine IV once weekly at a starting dose of 600 mg/m2 ;~5-Fluorouracil (5-FU) IV once weekly at a starting dose of 350 mg/m2 with leucovorin (LV) 100 mg/m2; OR~Docetaxel IV once weekly at a starting dose of 20 mg/m2.~Note:Both BPM31510 and the chemotherapy agent can escalate simultaneously in Cohorts 3 and 4 only if there are no DLTs observed in the previous cohorts. If one or more DLTs are observed, then intermediate dose levels will be added where one agent is escalated."
88953058|NCT01957774|Experimental|THR-18|
88953059|NCT01957774|Placebo Comparator|Placebo|matching placebo; look-alike with no active ingredients
88953060|NCT01957800|Experimental|Website|Group will be asked to complete a daily plan online for specific situations that tempt people to overeat. The website can be accessed online using a computer or smart phone and will allow participants to view others' plans. Participants will also be asked to enter their weight online every week.
88953061|NCT01957800|Active Comparator|Usual Care|Group will be given access to the online intervention after the 3-month study ends.
89203999|NCT04045236||Non metastatic rectal cancer|Patients receiving the diagnosis of non metastatic rectal cancer and the indication for a curative treatment will be enrolled in the registry. The study population will consist of all the patients enrolled in the participating centres from the start of the rectal cancer registry on.
89486895|NCT04967456|Active Comparator|Measurement of pulpal blood flow of traumatised tooth|In the split-mouth design, the traumatised maxillary incisor will be investigated using Laser Doppler flowmetry.
89486896|NCT04967456|Other|Measurement of pulpal blood flow of non-traumatised tooth|In the split-mouth design, this arm - the non-traumatised maxillary incisor, contralateral tooth, will be investigated using Laser Doppler flowmetry as a control tooth.
89486897|NCT02075801||Defective amalgam restorations|"Treatment Groups:~A. Sealing of amalgam margin defects: Defective areas were acid etched with 35% phosphoric acid for 15 seconds. A resin-based sealant (Sealant, 3MESPE)was applied over the defective area. The sealant was polymerized with a photo curing unit (Curing-Light 2500, 3MESPE) for 40 seconds. Rubber dam isolation was used for this procedure. All treatments were applied by the same clinician.~B. Replacement Group: The clinician totally removed and replaces the defective restoration with a new amalgam (Tytin, Kerr, Orange, USA). Rubber dam isolation was used for this procedure. All treatments were applied by the same clinician.~C. Control Group: The defective restorations did not receive any treatment."
89486898|NCT04967300||First Visit|Children who visit dentist at first time
89486899|NCT04967300||Second Visit|Children who visit dentist at second time
89486900|NCT04952246||multiple sclerosis group|
89486901|NCT04952246||non-prognosis group|
89486902|NCT02077985|No Intervention|Regular Dental Environment|There are two dental environments - the regular dental environment and the sensory dental environment; each child will be randomized to which is first. In the Regular dental environment no sensory characteristics of the dental environment are altered, the cleaning is conducted as per usual.
89486903|NCT02077985|Experimental|Sensory Adapted Dental Environment|There are two dental environments - the regular dental environment and the sensory dental environment; each child will be randomized to which is first. In the Sensory Adapted Dental Environment the sensory characteristics of the dental environment are altered (visual, auditory, tactile adaptations).
89486904|NCT02080169|Experimental|midazolam|Initiative dosage of midazolam is 0.05 mg/kg given intravenously, the maintenance dosage is 0.01-0.05 mg/kg/h, drug dosage is adjusted by target sedation level.
89486905|NCT02080169|Experimental|Dexmedetomidine|The loading dose of dexmedetomidine is 0.5-0.8 μg/kg given intravenously more than 10 min, the maintenance dosage is 0.2-0.7 μg/kg/h,the drug dosage is adjusted by target sedation level.
89486906|NCT02080169|Experimental|midazolam & dexmedetomidine|"Initiative dosage of midazolam is 0.05 mg/kg given intravenously, The loading dose of dexmedetomidine is 0.5-0.8 μg/kg given intravenously more than 10 min(given or not according to patients' condition),.~The maintenance dosage of midazolam is 0.01-0.05 mg/kg/h, the maintenance dosage of dexmedetomidine is 0.2-0.7 μg/kg/h,the drug dosage is adjusted by target sedation level."
89486907|NCT04960670||Dyads|Mother/infant pairs will be evaluated for anthropometric parameters, prenatal (dietary/lifestyle maternal factors)/postnatal determinants (type of feeding, sleep patterns, speed of growth) before discharge and after different follow-up after birth. Infant urinary and stool samples will be collected and stored. The infant adiposity rebound will be monitored.
89486908|NCT02078063|Experimental|Mepivacaine|10 ml of Mepivacaine for injection (Carbocain®) 10 mg/ml instilled into the uterus through a hydrosonography catheter
89486909|NCT02078063|Placebo Comparator|NaCL|10 ml NaCl 9mg/ml instilled into the uterus through a hydrosonography catheter
89486910|NCT04960358||Chronic LBP|Will be applied Surface Electromyography
89486911|NCT02075879|Experimental|Nurse-led interviewing|Participants in experimental arm received the in-center exercise training (20 minutes) before hemodialysis sessions weekly for 6 weeks and were instructed to perform exercise at home. They were additionally instructed to start walking or brisk walking at low duration and gradually progress to a maximum of 30 minutes daily per week. To facilitate exercise progression, the nurse case managers discussed exercise benefits, explored exercise barriers and developed mutual goals with patients. The nurse motivated them and checked the exercise behaviors to ensure adherence to the recommended exercise regime. The nurse case managers interviewed the patients weekly for six weeks and biweekly for another six weeks.
89486912|NCT02075879|Active Comparator|Brief group exercise|Participants received the in-center exercise training (20 minutes) before hemodialysis sessions weekly for 6 weeks and were instructed to perform exercise at home. The in-center training was conducted by the researcher with a group of four-to six participants focusing on flexibility and strengthening exercise only.
89486913|NCT04952168|Experimental|Almonertinib group|All patients were treated with Almonertinib 110 mg once a day for 3 months. Patients evaluated as CR, PR and SD were given concurrent chemoradiotherapy. The dose of radiotherapy was 60-66Gy/30-33F, After the end of concurrent chemoradiotherapy, the patients were treated with 110 mg of ametinib once a day until the disease progressed or the side effects were intolerable.
89486914|NCT04951856|Experimental|Evolocumab + SOC|Investigational Product is open label Evolocumab (Repatha®) 140 mg every two weeks: first subcutaneous injection at the time of randomization, before PCI, followings during 12 months.
89486915|NCT04951856|Active Comparator|Standard of care (SOC)|management as recommended in ESC/EAS 2019 guidelines, within reimbursement criteria
89486916|NCT02260427|Experimental|the i-gel group|After induction of general anesthesia, the i-gel will be inserted according to randomly allocated group.
89486917|NCT02260427|Active Comparator|the Air-Q sp group|After induction of general anesthesia, the air-Q sp will be inserted according to randomly allocated group.
89486918|NCT04952012||ATA-positive|
88953062|NCT01957813|Other|Standard Health Services|Service currently being provided to FSW in Naivasha include peer education and health services delivered through a drop-in center (DIC) staff by a counselor and a nurse. For peer education, there are six modules that the peer educators walk all peers through with sessions being held once a week.
89204000|NCT04045314|Experimental|Before-and-after|54 Healthy adults 18 years of age or older at the visit or will receive the first application and will be evaluated according to the objectives defined in the study (short-term data) and to evaluate the long-term effects, two other visits will be made at intervals of 2 weeks to evaluate the impact of topical skin application according to the parameters defined in the study.
89486919|NCT04952012||ATA-negative|
89486920|NCT04966988||CAV 0(Not significant)|No detectable angiographic lesion
89486921|NCT04966988||CAV 1 (Mild)|Angiographic left main (LM) <50%, or primary vessel with maximum lesion of <70%, or any branch stenosis <70% (including diffuse narrowing) without allograft dysfunction
89486922|NCT04966988||CAV 2 (Moderate)|Angiographic LM <50%; a single primary vessel≥70%, or isolated branch stenosis ≥70% in branches
89486923|NCT04966988||CAV 3 (Severe)|Angiographic LM≥50%, or two or more primary vessels ≥70% stenosis, or isolated branch stenosis≥70%in all 3 systems; or CAV1 or CAV2 with allograft dysfunction (defined as LVEF≤45% usually in the presence of regional wall motion abnormalities) or evidence of significant restrictive physiology
89486924|NCT04966832|Experimental|XW10508|XW10508 capsules or tablets
89204001|NCT00775424|Experimental|PENNVAX-B alone|PENNVAX-B alone
89486925|NCT04966832|Placebo Comparator|Placebo|Placebo capsules or tablets
89486926|NCT04966286|Placebo Comparator|conventional education service program|received only standard enterostomy care brochure
89486927|NCT04966286|Experimental|multimedia education service program|received multimedia education service program introduction
89486928|NCT04966442|Experimental|GrandAides|Patients randomized to this arm of the trial received access to a specially trained GrandAide to work as a credible messenger community health worker. This GrandAide received 6 weeks of education around congestive heart failure to support the patient in the outpatient setting.
89486929|NCT04966442|No Intervention|Standard of Care|This arm served as the control and included standard of care outpatient support for patients with heart failure.This support was done telephonically.
89486930|NCT04966208|Active Comparator|root coverage surgeries using autologous connective tissue for treatment of gingival recession|root coverage surgeries using tunneling technique of autologous connective tissue as a treatment of Miller class two gingival recession
88953063|NCT01957813|Experimental|LifeStyle Counseling|A package of enhancements to the current package of services delivered to FSW will be implemented and evaluated.
88953064|NCT01957826|Placebo Comparator|placebo comparator|transendocardial injection of placebo solution
88953065|NCT01957826|Experimental|bone marrow-derived MSCs injection|transendocardial injection of 30-40 million bone marrow-derived MSCs with the NOGA XPTM platform. 15 injections in the anterior wall of the left ventricle.
89486931|NCT04966208|Experimental|root coverage surgeries using xenogenic collagen matrix for treatment of gingival recession|root coverage surgeries using tunneling technique of mucodrm membrane ; xenogeneic collagen matrix as a treatment of Miller class two gingival recession
89486932|NCT03058484|No Intervention|Control|Standard of care, i.e. regular clinic services are provided prior to the study.
89486933|NCT03058484|Experimental|Community Health Worker Intervention|This arm is a four-part behavioral intervention that includes: 1) formal linkage of CHWs to health facilities; 2) CHW-led antiretroviral therapy (ART) adherence counseling; 3) loss to follow-up tracing by CHWs; and 4) distribution of Action Birth Cards (ABCs), a birth planning tool.
89486934|NCT03058406||Eribulin mesylate|
89486935|NCT04959656||X-ray|This study completed the manual labeling of preoperative multi-modal images of cervical spine structures and tumor lesions. On the normal cervical spine, six target areas were labeled: cervical spinal cord (MRI), cervical spine alignment (MRI), cervical intervertebral discs ( MRI), cervical spinal canal area (MRI), cervical cobb angle (X-ray) and cervical posterior longitudinal ligament ossification (CT). For cervical tumor lesions, complete MR and CT as well as orthopedic, axial and coronal positions. The label on the lateral X-ray image.
89486936|NCT04959656||CT|This study completed the manual labeling of preoperative multi-modal images of cervical spine structures and tumor lesions. On the normal cervical spine, six target areas were labeled: cervical spinal cord (MRI), cervical spine alignment (MRI), cervical intervertebral discs ( MRI), cervical spinal canal area (MRI), cervical cobb angle (X-ray) and cervical posterior longitudinal ligament ossification (CT). For cervical tumor lesions, complete MR and CT as well as orthopedic, axial and coronal positions. The label on the lateral X-ray image.
89486937|NCT04959656||MRI|This study completed the manual labeling of preoperative multi-modal images of cervical spine structures and tumor lesions. On the normal cervical spine, six target areas were labeled: cervical spinal cord (MRI), cervical spine alignment (MRI), cervical intervertebral discs ( MRI), cervical spinal canal area (MRI), cervical cobb angle (X-ray) and cervical posterior longitudinal ligament ossification (CT). For cervical tumor lesions, complete MR and CT as well as orthopedic, axial and coronal positions. The label on the lateral X-ray image.
89486938|NCT04951232|Experimental|Test group (cinnarizide maleate injection group)|
88953066|NCT01957839|No Intervention|pretreatment group|doppler evaluation at pretreatment period
88953067|NCT01957839|Experimental|posttreatment group|doppler evaluatıon in normoprolactinemia women who given cabergoline treatment
88953068|NCT01957852||FloSeal +|Routine use of Floseal during cytoreductive and HIPEC surgery
89486939|NCT04951232|Placebo Comparator|control group (placebo group)|
89486940|NCT04959578|Active Comparator|Erythropoietin|Recombinant Human Erythropoietin
89486941|NCT04959578|Experimental|Darbepoetin alfa|Darbepoetin Alpha
89486942|NCT04950140|Experimental|Robot Assisted Laparoscopic|Robot Assisted Laparoscopic Surgery for the Treatment of Parastomal Hernia of the Oncology Patient
89486943|NCT04950140|Active Comparator|Conventional Laparoscopic Surgery|Conventional Laparoscopic Surgery for the Treatment of Parastomal Hernia of the Oncology Patient
89486944|NCT03059186|Experimental|Intervention|Online daily gratitude journal.
89486945|NCT03059186|No Intervention|Control|
89486946|NCT04959500|Experimental|Experimental group|Experimental: Radiation therapy, Temozolomide and anlotinib Patients will receive standard radiation therapy plus temozolomide (Stupp regimen). Anlotinib hydrochloride will be given with a daily dose of 10 mg for 14 days of a 21-day cycle up to 2 cycles, initiated on the first day of radiation therapy and followed by adjuvant treatment with the same dosing schedule until patients have disease progression or intolerable toxicities.
89486947|NCT04959500|Placebo Comparator|control group|Experimental: Radiation therapy, Temozolomide and Placebo Patients will receive standard radiation therapy plus temozolomide (Stupp regimen). Placebo will be given with a daily dose of 0 mg for 14 days of a 21-day cycle up to 2 cycles, initiated on the first day of radiation therapy and followed by adjuvant treatment with the same dosing schedule until patients have disease progression or intolerable toxicities.
89486948|NCT04950452|Experimental|CLL-EX|Subjects will undergo supervised exercise training 3 x per week for 12 weeks. Three/sessions per week will consist of intervals of high-intensity (~85% of maximal capacity) will be 5 to 10 bouts of 30 seconds at this intensity with rest periods in between intervals that range from 30 seconds to 2 minutes. Following this, on 2 occasions/week subjects will complete muscular endurance resistance training on machine weights.
89486949|NCT04950452|No Intervention|CLL-CON|Subjects will not receive supervised exercise training and will be asked to maintain their daily lifestyle behaviors.
89486950|NCT04958564|Active Comparator|group interlock|Intra medullary device used to treat tibial shaft fractures
89486951|NCT04958564|Active Comparator|group DCP (dynamic compression plate)|dynamic compression plate used to treat tibial shaft fractures
89486952|NCT01369511|Placebo Comparator|Placebo|Administered subcutaneously every 4 weeks for 12 weeks (administered 4 times)
89486953|NCT01369511|Experimental|35 mg LY2495655|LY2495655: 35 milligrams (mg) administered subcutaneously every 4 weeks for 12 weeks (administered 4 times)
89486954|NCT01369511|Experimental|105 mg LY2495655|LY2495655: 105 mg administered subcutaneously every 4 weeks for 12 weeks (administered 4 times)
89486955|NCT01369511|Experimental|315 mg LY2495655|LY2495655: 315 mg administered subcutaneously every 4 weeks for 12 weeks (administered 4 times)
89486956|NCT04949984|Experimental|Bright light therapy|The devices used for the intervention were bright white light lamps providing an intensity of 10,000 lux. Four users participated in each session, placing two users per lamp, seated in a comfortable chair with armrests 70 cm from the lamp. The sessions were 30 minutes/day in the time slot between 10:30 and 12:00 in the morning, 5 days a week (Monday to Friday) for 4 weeks (total 20 sessions). Two groups of participants per day were established, the first shift being from 10:30 to 11:00, and the second from 11:15 to 11:45 a.m., which means the stimulation of 8 people per day (month). During the sessions, while exposed to light, participants were watching documentaries on neutral topics (nature, Spanish and Galician culture, etc.).
89486957|NCT04949984|No Intervention|Control group|Participants were evaluated before and after the experimental group finishes the intervention program (pre- vs. postintervention) to facilitate an examination of the changes in the outcome measures.
89486958|NCT04950218||Psoriasis patients|Eligible psoriasis patients will be identified from the daily outpatient program, at the Department of Dermato-Allergology, that is the department will provide the patient's contact information to the project group. As most outpatient clinic psoriasis is classified as moderate to severe, in order to approximate a random sample as accurate as possible including patients with mild psoriasis, all people with a diagnosis of psoriasis will a general invitation to participate in the study through appropriate channels such as the Danish Psoriasis Foundation's newsletter.
89486959|NCT04950218||Control group|The control group will consist of a retrospective random sample of around 1.000 patients from the general population examined in the 4th and 5th Copenhagen City Heart Study, 2001-2003 and 2011-2014 (ClinicalTrials.gov identifier NCT02993172, I-Suite no. 03741, National Committee on Health Research Ethics approval HEH-2015-045). Existing data from the Copenhagen City Heart Study will be transferred to the current study and will include personal identification number from the Central Office of Civil Registration, echocardiographic assessments, electrocardiograms as well as health related data (health conditions including symptoms, risk factors for cardiovascular disease, medication, prior clinical and/or paraclinical assessments including blood test results and procedures relevant to psoriasis and potential heart disease).
89486960|NCT04950374|Experimental|Moisturizer Body Lotion and Lip Moisturizer Regimen|All participants will receive and use both products.
89486961|NCT02076191|Experimental|Myeloproliferative neoplasms|In phase I, increasing doses of ruxolitinib in combination with decitabine at a dose of 20 mg/m2 daily intravenously over 5 days. An initial dose of ruxolitinib of 10 mg orally twice daily is anticipated with planned, dose escalations of 15 mg orally twice daily, 25 mg orally twice daily and 50 mg orally twice daily. The dose can also be de-escalated to 5mg orally twice daily if dose limiting toxicities (DLTs) are observed at the initial 10mg dose. Patients will receive ruxolitinib as a single agent for the first 7 days followed by the administration of decitabine on day 8 for a total of 5 consecutive days. Patients will continue ruxolitinib at the assigned dose through the first cycle and may reduce the dose for specified toxicity beginning with the second cycle. Patients in Phase II will start at the recommended phase II dose (RPTD) of ruxolitinib in combination with decitabine at a dose of 20 mg/m2 daily intravenously over 5 days.
88953069|NCT01957852||FloSeal -|FloSeal not used during CRS and HIPEC procedure
89204002|NCT00775424|Experimental|PENNVAX-B+IL12|PENNVAX-B+IL12
89204003|NCT00775424|Experimental|PENNVAX-B+IL15|PENNVAX-B+IL15
89204004|NCT00775424|Placebo Comparator|PLACEBO|PLACEBO
88953070|NCT01957878|Experimental|HPV therapeutic vaccine|ProCervix consists of two recombinant adenylate cyclase (CyaA) proteins, CyaA-HPV 16E7 (C16-1) and CyaA-HPV 18E7 (C18-1) in a 50/50 ratio (C16C18-2 Ag mixture). ProCervix is adjuvanted by Aldara™, a cream containing 5% of imiquimod
88953071|NCT01957878|Placebo Comparator|Placebo matching ProCervix|Placebo matching ProCervix and adjuvanted by Aldara™, a cream containing 5% of imiquimod
88953072|NCT01957904|Other|ArterX Surgical Sealant|
88953073|NCT01957917|Experimental|NAC + Food Assistance|Arm 1 participants will receive NAC (nutritional assessment and counseling), plus a food ration once a month for 6 months if they continue their regular HIV care.
88953074|NCT01957917|Experimental|NAC + Cash Transfer|Arm 2 participants will receive NAC (nutritional assessment and counseling), plus a cash transfer equivalent in value to the food transfer once a month for 6 months if they continue their regular HIV care.
88953075|NCT01957917|Active Comparator|NAC Only|Arm 3 participants will receive NAC (nutrition assessment and counseling) only, which is the standard of care at the selected health facilities.
89486962|NCT04949906||The experimental group|The application of raising serum brain granules
89486963|NCT04949906||The control group|No nourishing serum brain granules are used
88953076|NCT01957943|Placebo Comparator|Control|38 patients Will receive standard oral diet 3 days before the operation will receive similar volume of 10% glucose solution Will receive same solution for 5 days postoperatively
88953077|NCT01957943|Active Comparator|OMEGA_PRE|38 patients Will receive standard oral diet 3 days before the operation will receive lipid supplementation 2 days before the operation with omega 3 enriched lipid emulsion (SMOFlipid) Will receive omega 3 enriched lipid emulsion (SMOFlipid) supplementation for 5 days postoperatively
88953078|NCT01957943|Active Comparator|OMEGA_POST|38 patients Will receive standard oral diet 3 days before the operation will receive glucose 10% solution 2 days before the operation Will receive omega 3 enriched lipid emulsion (SMOFlipid 20%) supplementation for 5 days postoperatively
89486964|NCT02080247|Active Comparator|Intervention: Skin care regimen with Calmoseptine ointment|In this arm the patients with IAD will receive treatment with Calmoseptine Ointment for 6 days as a part of a structured skin regimen
89486965|NCT02080247|Active Comparator|Control: Skin care regimen with Destin ointment|In this arm , patient will receive treatment with Destin Maximum Strength 40% Zinc Oxide. Diaper Rash Paste (Destin) for 6 days as part of a structured skin care regimen.
89486966|NCT04950062|Experimental|High intensity interval training|Group A included 30 subjects who will participate in high intensity interval training on a treadmill for 12 weeks, 3 times/week.
89486967|NCT04950062|Active Comparator|Intermittent fasting|Group B that included 30 subjects will participate in intermittent fasting for 12 weeks, 3 times/week.
89486968|NCT02078297||Scalp psoriasis|Patients have at least one psoriatic lesion on trunk or and psoriasis that is more resistant to treat such as scalp psoriasis, pustular palmo-plantar psoriasis, non-pustular palmo-plantar psoriasis, elbow psoriasis and lower leg psoriasis.
89486969|NCT02078297||pustular palmo-plantar psoriasis|Patients have at least one psoriatic lesion on trunk or and psoriasis that is more resistant to treat such as scalp psoriasis, pustular palmo-plantar psoriasis, non-pustular palmo-plantar psoriasis, elbow psoriasis and lower leg psoriasis.
89486970|NCT02078297||non-pustular palmo-plantar psoriasis|Patients have at least one psoriatic lesion on trunk or and psoriasis that is more resistant to treat such as scalp psoriasis, pustular palmo-plantar psoriasis, non-pustular palmo-plantar psoriasis, elbow psoriasis and lower leg psoriasis.
89486971|NCT02078297||elbow psoriasis|Patients have at least one psoriatic lesion on trunk or and psoriasis that is more resistant to treat such as scalp psoriasis, pustular palmo-plantar psoriasis, non-pustular palmo-plantar psoriasis, elbow psoriasis and lower leg psoriasis.
89486972|NCT02078297||leg psoriasis|Patients have at least one psoriatic lesion on trunk or and psoriasis that is more resistant to treat such as scalp psoriasis, pustular palmo-plantar psoriasis, non-pustular palmo-plantar psoriasis, elbow psoriasis and lower leg psoriasis.
89486973|NCT02078297||Healthy subjects|
89486974|NCT04949672||Open TME|Total Mesorectal Excision (TME) is the gold standard surgical treatment of rectal cancer. According to the technique first described by Bill Heald, TME entails the resection of the rectum including the whole mesorectal fat and an intact mesorectal fascia. Open TME is accomplished through a midline xifo-umbilical laparotomy and requires a complete mobilization of the left colon and central ligature of inferior mesenteric artery and vein.
89486975|NCT04949672||Laparoscopic TME|Laparoscopic TME mirrors the procedure performed through laparotomy with the same operative steps and performing rectal resection including the excision of the surrounding mesorectal fat and fascia.
89486976|NCT04949672||Robotic TME|Robotic TME mirrors the procedure described by Bill Heald for open surgery but the operation is performed by the master-slave DaVinci System under 3D laparoscopic guidance. The rectal resection is performed including mesorectal fat and fascia.
89486977|NCT04949672||TransAnal TME|TaTME has first described by Antonio Lacy in 2012. This procedure has two steps: abdominal and perineal. The abdominal step is performed through a laparoscopic approach as described for laparoscopic TME but the caudal dissection is stopped right below the level of the peritoneal rectal reflection (Douglas pouch). The perineal step is accomplished transanally inserting a specially designed platform into the anal canal and performing the total mesorectal excision under endoscopic guidance.
89486978|NCT02078375|Placebo Comparator|Carbohydrate supplement|Participants will be enrolled in a twice weekly resistance exercise program. They will receive a carbohydrate supplement to take twice daily (once after exercise).
89486979|NCT02078375|Experimental|Protein Supplementation|Participants will be enrolled in a twice weekly resistance exercise program. They will receive a twice daily protein supplement (once after exercise).
89486980|NCT02080325|Other|High Protein-Weight loss-Meat/High Protein-Weight loss Soy|After 3 Days - Normal Protein Maintenance diet (NP- MTD, 3 days), there is the first arm of the study, Days 14 days- randomised to High Protein-Weight loss-Meat with High Protein-Weight loss-Soy
89486981|NCT02080325|Other|High Protein-Weight loss-Soya/High Protein Weight loss-meat|After 3 Days - Normal Protein Maintenance diet (NP- MTD, 3 days), there is the first arm of the study, Days 14 days- randomised to High Protein-Weight loss-Soy with High Protein-Weight loss-Meat
88953079|NCT01957969||Principal Population|Patients who undergo a definitive neuro-stimulator implantation.
89486982|NCT04965974|Experimental|1 blue light blocking filter group|digital blue light blocking filter is installed laptops and mobile phones of 80 individual using digital devices more than 4 hours. asked them to use the filter continuously while using digital devices.
89486983|NCT04965974|Experimental|2 non filter users|Effect of time duration of digital screen on the dry eyes is checked.
89486984|NCT02080559|Experimental|4CMenB - Test group|Administered at 2, 4 and 12 months of age
89204005|NCT04652622|Experimental|Intervention arm|Participants will receive 4 hours of exposure to the Mindful Garden digital therapeutic platform in addition to standard care
89204006|NCT04652622|No Intervention|Control Arm|Participants will be monitored over a 4 hour period of standard care interventions
89486985|NCT02080559|Active Comparator|4CMenB - control group|Given at 5, 7 and 13 months of age
89486986|NCT04966052||COPD combined with TB group|COPD combined with pulmonary TB infection
89486987|NCT04966052||COPD non-TB control group|COPD combined without pulmonary TB infection
89486988|NCT04966052||TB non-COPD control group|pulmonary TB infection without COPD
89486989|NCT04966052||Non-smoking non-TB control group|Non-smoking without pulmonary TB infection
89486990|NCT02078453|Active Comparator|Visual inspection|Dental treatment performed according to the caries diagnosis obtained with visual inspection performed alone
89486991|NCT02078453|Experimental|Radiographic examination|Dental treatment performed according to the caries diagnosis obtained with visual inspection and additional radiographic method.
89486992|NCT04965896|Placebo Comparator|Control meal|Participants will receive plain white rice (75g of available carbohydrate) alongside a snack with crackers and cheese. The meal is similar in energy and macronutrients to the test meal.
89486993|NCT04965896|Experimental|Nut meal|Participants will receive plain white rice (75g of available carbohydrate) alongside a portion of 30g of nuts. The meal is similar in energy and macronutrients to the control meal.
89486994|NCT03558659|Experimental|Positional Therapy Belt|Use of positional therapy belt (SlumberBUMP) during sleep.
89486995|NCT03558659|No Intervention|Standard Care|No positional therapy belt provided for use during sleep.
89486996|NCT04422236||Obese patients eligible for laparoscopic bariatric surgery|
89486997|NCT03558581|No Intervention|Control|Patients have not received any special intervention, the follow up care was the standard care for the specific clinic
89486998|NCT03558581|Experimental|Intervention|After initial allocation the select patient received six educational interventions selected from Nursing Intervention Classification (NIC)
89486999|NCT02080715|Experimental|Tolcapone|Tasmar
89487000|NCT02083367||Hepatic Encephalopathy Group|Disease Group
89487001|NCT02083367||Control Group|Healthy Group
89487002|NCT04965584||Active Crohn's disease group|Patients diagnosed with Crohn's disease after comprehensive evaluation of clinical symptoms, endoscopic features, radiological manifestations and histological features were recruited, and patients with CDAI score ≥ 150 were included in this group.
89487003|NCT04965584||Crohn's disease remission group|Patients diagnosed with Crohn's disease after comprehensive evaluation of clinical symptoms, endoscopic features, radiological features and histological features were recruited, and patients with CDAI score < 150 were included in this group.
89487004|NCT04965584||Healthy control group|Normal healthy people were randomly recruited as the control group
89487005|NCT04965662|Experimental|Arm A: Home PEPSE (Immediate)|Patients randomised to the immediate arm (ARM A) will receive a 5 day PEPSE 'Home pack' containing Truvada® (tenofovir disoproxil -as fumarate- 245 mg, emtricitabine 200 mg), ONE tablet OD and Maraviroc 300 mg, TWO tablets OD.
89487006|NCT04965662|No Intervention|Arm B: Standard of Care (Deferred)|Standard of care antiretroviral therapy for PEPSE as per the British Association for Sexual Health and HIV (BASHH) guidelines.
89487007|NCT02083445|Placebo Comparator|Control group|Once a week there will be an attendance cognitive session (specific sessions designed to work on aspects related to body perception, movement, space) and the extraction of blood samples will be carried out to determine the progenitor cells on the same day of the active groups.
89487008|NCT02083445|Active Comparator|Exercise group|Patients with past history of TBI will perform exercise sessions two hours three days a week during 12 weeks. The sessions will consist of aerobic, strength, flexibility, proprioception and balance activities and muscle electro-stimulation sessions or cycling sessions.
89487009|NCT02083445|Active Comparator|Muscle electro-stimulation and IHH|Patients with past history of TBI will perform a 12 weeks program: intermittent hypobaric hypoxia (IHH) 2 hours at a simulated altitude of 4500 meters 3 days/week. Muscle electro-stimulation for two periods of 20 minutes during the stay in the hypobaric chamber.
89487010|NCT02083523|Active Comparator|Motivational Interview|The Motivational Interview, or MI, (15-30 minutes) was provided after initial substance use disorder assessments but prior to treatment admission. I twas facilitated by a computer generated report and included: an orientation to the session, discussion of the participants' strengths, an agenda setting procedure, a review of concerns, and a session summary. Therapists conveyed empathy, used reflective listening, tried to elicit and reinforce change talk elements, and elicited action steps from the participants.
89487011|NCT02083523|Active Comparator|MI with Normative Feedback|The Motivational Interview with Normative Feedback, or MI + NF, condition/intervention included all procedures described for the MI condition. Additionally, in the MI + NF condition/intervention, the participants' days of marijuana and alcohol use were compared to two sets of norms ( age specific or level of care specific) available for treatment attending youth. Therapists used whichever norm provided a greater contrast with participants' use.
89487012|NCT04949126||acute pain of pulpal origin|no intervention
89487013|NCT04949126||anxious group|no intervention
89487014|NCT02083601|Experimental|Psychological Support|The intervention group will participate in the 2-day, in-person Parent Forum and receive monthly phone calls from a mental health professional for 12 months.
89487015|NCT02083601|Other|No Psychological Support|This comparison group will attend the 2-day, in-person Parent Forum but will not receive long-term psychological support.
89487016|NCT02078531||Chemotherapy and anti-hormonal therapy|"cognitive assessment using CANTAB~Imaging to assess the effect of systemic therapy on brain function. Subjects may participate in the first part of the study without undergoing the imaging assessment or may participate in both parts of the study."
89487017|NCT02078531||chemotherapy only and healthy control group|"cognitive assessment using CANTAB~Imaging to assess the effect of systemic therapy on brain function. Subjects may participate in the first part of the study without undergoing the imaging assessment or may participate in both parts of the study."
89487018|NCT02078609|Experimental|LGH447 monotherapy arm|LGH447 monotherapy in patients with AML or MDS
89487019|NCT02078609|Experimental|LGH447 + midostaurin combination arm|LGH447 + midostaurin in patients with AML
89487020|NCT04958330||lateral prostate capsule sparing group|Patients will be preverved the lateral prostate capsule during the resection of bladder and prostate of the operation.
89487021|NCT04958330||non nerve sparing group|Patients will receive standard radical cystectomy (not preserve the neurovascular bundles or lateral prostate capsule) during the operation.
89487022|NCT02078687|Active Comparator|Group 1, HM|This group received breastfeeding (human milk, HM) solely throughout the 4 month of intervention. Randomisation for group 1 or group 2. Mothers own milk.
89487023|NCT02078687|Active Comparator|Group 2, HMF|This group received mothers own milk with fortification (human milk fortification, HMF) throughout the 4 month intervention period. Randomisation for group 1 og group 2. Enfamil HM fortifier, Mead Johnson.
89487024|NCT02078687|Active Comparator|Group 3, PF|This group received preterm formula (PF) throughout the intervention period of 4 month. This group was not randomised for ethical reasons. Enfalac Premature Formula, Mead Johnson Nutritionals
89487025|NCT03060356|Active Comparator|Melanoma|Intravenous infusion 1x10^8 total T cells modified with RNA anti-cMET CAR
89487026|NCT03060356|Active Comparator|Breast|Intravenous infusion 1x10^8 total T cells modified with RNA anti-cMET CAR
89487027|NCT04957940|Experimental|SMOF lipid 20% IV infusion|Intravenous fish-oil-based lipid (SMOF lipid 20%) emulsion supplementation to standard enteral nutrition.
89487028|NCT04957940|Placebo Comparator|Saline placebo IV infusion|Intravenous 0.9% saline supplementation to standard enteral nutrition.
89487029|NCT02078765||hypertension|75 patients with hypertension and chronic kidney disease (CKD stage I-II)
89487030|NCT02078765||healthy subjects|75 healthy subjects
89487031|NCT02083757||Resp|Fluid responsiveness is defined as a change of stroke volume stroke volume ≥ 10% after 250 ml rapid saline infusion in 10 minutes.
89487032|NCT02083757||Nonresp|Fluid responsiveness is defined as a change of stroke volume stroke volume < 10% after 250 ml rapid saline infusion in 10 minutes.
89487033|NCT03060200|Experimental|Active intervention|Self-administered online CBT plus therapist check in. Moderately depressed participants will be testing a depression app, employing a self administered plus therapist check in, online CBT intervention, for 6 weeks.
89487034|NCT03060200|No Intervention|Waiting list|Moderately depressed participants will be put on a wait list for 6 weeks, after which access to the depression app will be given.
89487035|NCT03060200|Placebo Comparator|Placebo|Sham self-administered online CBT plus therapist check in. Moderately depressed participants will be using a depression app - the same platform and largely in the same format as the tested app, employing a self administered plus therapist check in, online sham intervention, for 6 weeks. The intervention will include the same sections and features as the original app, except for the complete exercises and behavioral activation sections. In addition, the psychoeducation section, although mirroring the structure of the corresponding section in the original app, will include different content, elaborating on common sense information on psychological well being.
89487036|NCT02080793|Other|Patients phase pilote|
89487037|NCT02080793|Other|Patients phase réelle|
89487038|NCT03060278|Active Comparator|Standard Treatment|Participants randomized to Standard Treatment will receive a smartphone with active service, brief advice to quit smoking (self-help materials), an 8-week supply of nicotine replacement therapy (patches), and provided 5 proactive phone counseling sessions by a trained Certified Tobacco Treatment Specialist.
88953080|NCT01957969||Annex Population|Patients who do not respond to the temporary test for the neurostimulator implantation
88953081|NCT01957995|Experimental|Arm I (lowest dose NDLS)|Patients receive lowest dose nanosomal docetaxel lipid suspension IV over 1 hour.
89487039|NCT03060278|Experimental|Automated Treatment|Participants randomized to Automated Treatment will receive smartphone-delivered automated treatment that will provide tailored smoking cessation treatment by way of video clips, text and graphical messages. Participants will receive notifications on study provided smartphone once a week for an 8-week treatment period. Content delivered will be specific to the participants smoking status and motivation to quit.
89537845|NCT03290105||study population|Consecutive critically-ill patients admitted to the ICU and receiving invasive mechanical ventilation for more than 48 hours
88953082|NCT01957995|Experimental|Arm II (low dose NDLS)|Patients receive low dose nanosomal docetaxel lipid suspension IV over 1 hour.
88953083|NCT01957995|Experimental|Arm III (high dose NDLS)|Patients receive high dose nanosomal docetaxel lipid suspension IV over 1 hour.
88953084|NCT01957995|Experimental|Arm IV (highest dose NDLS)|Patients receive highest dose nanosomal docetaxel lipid suspension IV over 1 hour.
88953085|NCT01958034|Experimental|Dietary supplement with bilberry extract|Billberry powder 3 times daily for 2 months.
88953086|NCT01958034|No Intervention|Control|No dietary supplement with bilberry extract
88953087|NCT01958047|Experimental|ASP3652|One single dose
88953088|NCT01958099|Other|Injury Prevention Specialist|
88953089|NCT01958099|Experimental|Kiosk Intervention|
88953090|NCT01958138|Experimental|propofol with Isoflurane|Propofol with Isoflurane, Group-I is the intervention arm with combination of two drugs such as low dose propofol and Isoflurane MAC awake.
88953091|NCT01958138|Active Comparator|alone isoflurane|The group-II is the control arm of study by using the only Isoflurane 1.2 MAC
89487040|NCT02080949|Experimental|HSRT - 4fx x 5 Gy|It'll be recruited 3 patients to the initial regimen of four fractions of 5 Gy on each brain metastasis with HSRT and if no patient has unacceptable toxicity, more 3 patients for subsequent scheme will be recruited. If 2 patients had unacceptable toxicity, the study ends and it'll be considered that the study was initiated with toxic regimen. If 1 patient has unacceptable toxicity, it'll be recruited 3 more patients for this scheme and if 1 or more patients had unacceptable toxicity, the scheme will be considered toxic and the study will be closed. If no patient develops unacceptable toxicity, the study will follow to the next cohort of 3 more patients with the next dose level.
89487041|NCT02308449|Placebo Comparator|Iron-deficient, given placebo|Iron-deficient participants given an infusion of sodium chloride at conclusion of baseline experimental visit
89487042|NCT02308449|Active Comparator|Iron-deficient, given iron|Iron-deficient participants given an infusion of ferric carboxymaltose at conclusion of baseline experimental visit
89487043|NCT02308449|Placebo Comparator|Iron-replete, given placebo|Iron-replete participants given an infusion of sodium chloride at conclusion of baseline experimental visit
89487044|NCT02308449|Active Comparator|Iron-replete, given iron|Iron-deficient participants given an infusion of ferric carboxymaltose at conclusion of baseline experimental visit
89487045|NCT02083913|Experimental|Supervised physical activity|
89487046|NCT03242655|Experimental|HCV GET-UP (Group Intervention)|HCV GET-Up (Group Evaluation and Treatment Uptake)
89487047|NCT03242655|No Intervention|Control|Individual onsite HCV treatment at a primary care center
89487048|NCT02083991|Experimental|Steroid-free low TAC-arm|"Induction therapy: Thymoglobulin i.v. 2,5 mg/kg day 0 and 1, preceded by methylprednisolone i.v. 250 mg day 0 and 50 mg day 1.~Maintenance therapy: Advagraf(TAC) 0,2 mg/kg p.o. started day1 (target concentration 5-10 ng/ml, after 3 months 4-7 ng/ml; MMF 1g x 2 p.o. (target Area Under Curve, AUC 40-60 mg.h/L); No steroids p.o."
89487049|NCT02083991|Active Comparator|Standard low-TAC arm|"Induction therapy: Simulect i.v. 20 mg day 0 and 4; Steroids i.v. according to local practice.~Maintenance therapy: Advagraf(TAC) p.o. 0,2 mg/(target concentration 5-10 ng/ml, after 3 months 4-7 ng/ml); MMF 1g x 2 p.o. (target AUC 40-60 mg.h/L); Steroids p.o. according to hospital practice (but not less than 5mg daily after 6 months)."
89487050|NCT04948190||SARS-CoV-2 Infected/ positive group|Has tested positive for SARS-CoV-2 within appropriate timeframe (criteria vary for different study stages). Aged 16 years or older, willing and able to provide informed consent.
89487051|NCT04948190||SARS-CoV-2 negative group|Has tested negative for SARS-CoV-2 within appropriate timeframe (criteria vary for different study stages, and in phase 2 part 1, 2 and 4 enrolment may be accepted using symptoms-based criteria). Aged 16 years or older, willing and able to provide informed consent.
89487052|NCT03254901||health care workers|health care workers in Assiut health directorate, Abutig central hospital, El-Quseya central hospital and Sahil selim central hospital in Assiut governorate .All of them will be screened for hepatitis C infection and interviewed about mode of transmission of infection
89487053|NCT02081027|Experimental|Riluzole|The maximum dose of riluzole to be used in this study is 200 mg per day divided BID
89487054|NCT02081027|Placebo Comparator|Placebo|Placebo will be administered in the same manner as the riluzole group, in order to maintain subject assignment throughout the study.
89487055|NCT02455947|Experimental|Inquiry Based Stress Reduction (IBSR)|"IBSR intervention is the clinical implementation of a mindful-process, named The Work developed by Byron Katie.It teaches the individual to identify and question the thoughts that causes stress and suffering through four questions and turnarounds."
89487056|NCT02455947|No Intervention|Control group|A non interventional group/ The participants completed questionnaires before and after the intervention.
89487057|NCT03058172|Other|Odors (food and non-food)|Odorants diluted in mineral oil.
89487058|NCT03058172|Other|Pictures (food and non-food)|Pictures of objects or scenes.
89487059|NCT03239535|Experimental|Mesenchymal stem cells|Mesenchymal stem cells, Intramuscular injection
89487060|NCT03239535|Placebo Comparator|Normal saline|Normal saline, Intramuscular injection
89487061|NCT04965194|Experimental|Erector spinae plane block (ESPB)|20 ml of 0.25% bupivacaine will be administered to perform ESP block on each side
89487062|NCT04965194|Experimental|Quadratus lumborum plane block (QLPB)|The injectate (20ml of bupivacaine 0.25%) should ideally spread from the injection site inside the fascial plane between the QL and psoas major muscles to the thoracic paravertebral space with a goal to accomplish segmental somatic and visceral analgesia from T4 to L1.
89487063|NCT04965194|Placebo Comparator|Control group|patients received no regional block
89487064|NCT04964882|Experimental|C-E Mask ventilation under PIP 10 cmH2O|Two-handed C-E technique is performed during face mask ventilation using a mechanical ventilator with a peak inspiratory pressure of 10 cmH2O.
89487065|NCT04964882|Experimental|C-E Mask ventilation under PIP 15 cmH2O|Two-handed C-E technique is performed during face mask ventilation using a mechanical ventilator with a peak inspiratory pressure of 15 cmH2O.
89487066|NCT04964882|Experimental|C-E Mask ventilation under PIP 20 cmH2O|Two-handed C-E technique is performed during face mask ventilation using a mechanical ventilator with a peak inspiratory pressure of 20 cmH2O.
89487067|NCT04964882|Experimental|V-E Mask ventilation under PIP 10 cmH2O|Two-handed V-E technique is performed during face mask ventilation using a mechanical ventilator with a peak inspiratory pressure of 10 cmH2O.
89487068|NCT04964882|Experimental|V-E Mask ventilation under PIP 15 cmH2O|Two-handed V-E technique is performed during face mask ventilation using a mechanical ventilator with a peak inspiratory pressure of 15 cmH2O.
89204007|NCT00814242|Active Comparator|hepatectomy|Patients with HCC adjacent to major blood vessels recieved radical resection.
89487069|NCT04964882|Experimental|V-E Mask ventilation under PIP 20 cmH2O|Two-handed V-E technique is performed during face mask ventilation using a mechanical ventilator with a peak inspiratory pressure of 20 cmH2O.
89487070|NCT04957706||Acute injury|injury ≤ 2 months
89487071|NCT04957706||Chronic injury|injury > 2 months
89487072|NCT03238833|Experimental|luteal ovarian stimulation|The controlled ovarian stimulation in in vitro fertilization cycle was started since luteal phase.
89487073|NCT03238833|Active Comparator|follicular ovarian stimulation|The controlled ovarian stimulation in in vitro fertilization cycle was started since early follicular phase phase.
89487074|NCT04947878|No Intervention|Standard care|will not review a prompt list before their visit.
89487075|NCT04947878|Experimental|Prompt list|The patients in the intervention group will review a prompt list before their visit.
89487076|NCT04948034|Experimental|Treatment Arm|"A total of 68 metastatic colorectal cancer patients who have failed the first-line standard treatment will receive multisite SABR followed by Fruquintinib and Tislelizumab within two weeks from completion.~The dosing of Tislelizumab will continue for up to two years until disease progression, unacceptable toxicity or patient withdrawal."
89487077|NCT02453763||Transcranial direct current stimulation|All participants will receive transcranial direct current stimulation and an magnetic resonance imaging (MRI).
89487078|NCT03254511|Experimental|enoxaparin|In the enoxaparin group, patients are going to receive radiotherapy (median treatment dose will be 50.40 Gy in 25 to 32 fractions) with weekly concurrent chemotherapeutic combinations (paclitaxel [50 mg/m2] plus carboplatin [area under the carve=2]) with Enoxaparin Sodium 40 MG/0.2 ML Subcutaneous Injectable (40 mg daily).
89487079|NCT03254511|Active Comparator|control|In the control group, patients are going to receive radiotherapy (median treatment dose will be 50.40 Gy in 25 to 32 fractions) with weekly concurrent chemotherapeutic combinations (paclitaxel [50 mg/m2] plus carboplatin [area under the carve=2]) alone.
89487080|NCT04957004||OSA patients|Patients with OSA who have not been treated with CPAP
89487081|NCT04957004||control group|health control except OSA by using sleep monitorin
89487082|NCT04947566|Experimental|Naproxen|in this group patients were given Naproxen
89487083|NCT04947566|Experimental|Ibuprofen|in this group patients were given ibuprofen
89487084|NCT04948346||patient with ALS|
89487085|NCT04948346||patient'spouse(without ALS)|
89487086|NCT03254745|Experimental|Pharmacist intervention|"Disease education (General education about rheumatoid arthritis in a verbal and written manner)~Dietary and lifestyle modifications (General recommendations as well as specific ones based on patients' baseline health status)~Counseling regarding adherence (General lecture on adherence to medications and physical rehabilitation in rheumatoid arthritis as well as specific advice based on patients health status)~Advice on medication use (General counseling on medication use as well as patient centered counseling)."
89487087|NCT03254745|No Intervention|Usual care|Patients will not be counseled by pharmacist and will be allowed to take usual care.
89487088|NCT04964804|Experimental|real-time ultrasound-CT fusion imaging|The experimental group of patients underwent selective lumbar nerve root block puncture under real-time ultrasound-CT fusion imaging by sonographers
89487089|NCT04964804|Active Comparator|ultrasound alone|The control group underwent puncture under the guidance of ultrasound alone by sonographers
89487090|NCT04431986||NuAge participants|All Individuals of the NuAge study who agreed to be part of the NuAge Database for future research purposes
89487091|NCT03241875|Placebo Comparator|placebo|Patients receive 2 capsules as placebo 2 hours before anesthesia. The capsules are delivered by the hospital pharmacy.
89487092|NCT03241875|Experimental|pregabalin|patients receive 2 capsules of pregabalin (pregabalin 75), two hours before anesthesia.
89487093|NCT03241875|Experimental|gabapentin|patients receive 2 capsules of gabapentin (gabapentin 300), two hours before anesthesia.
89487094|NCT03057938|Experimental|18F-Florbetaben (FBB)|18F-Florbetaben
89487095|NCT03238521|Active Comparator|classical pedicle finder|Spinal osteosynthesis with classical pedicle finder
89487096|NCT03238521|Experimental|pedicle finder with impedancemetry|Spinal osteosynthesis with pedicle finder with impedancemetry
89487097|NCT04956614|Experimental|suture of Achilles tendon without immobilisation|
89487098|NCT04956614|Experimental|suture of Achilles tendon with immobilisation|
89487099|NCT03241953|Experimental|debridement made by ultrasonic tips|mechanical debridement made by ultrasonic polyetheretherketone coated tips developed for implant surface and combined air-flow debridement
89487100|NCT03241953|Active Comparator|implants were debrided with standard plastic curettes|dental implants were debrided with standard plastic curettes, debridement made by combined klorhegsidin rinse
89487101|NCT03058094|Experimental|AC0010|AC0010, 300mg, orally, BID with a 21-day cycle
89487102|NCT03058094|Active Comparator|Chemotherapy|pemetrexed 500 mg/m2 + cisplatin 75 mg/m2 on day one of 21-day cycle, with total of 4-6 cycles.
89487103|NCT03242187|Experimental|Trans-anal TME (TaTME)|Trans-anal total mesorectal excision(TaTME) will be offered to patients in this group (assisted by minilaparoscopy to control the IMA and splenic flexure mobilisation)
89487104|NCT03242187|Active Comparator|Lap. TME|Laparoscopic total mesorectal excision(Lap.TME) starting by IMA ligation then splenic flexure mobilisation and pelvic dissection
89487105|NCT03254121||Patients with SVR and developed HCC|HCV patients with SVR and developed HCC plus available tissue from HCC
89487106|NCT04431596|Active Comparator|Cooling|Participants will be actively cooled during rest breaks.
89487107|NCT04431596|No Intervention|No Cooling|"Participants will participant in passive cooling where they sit in a chair during rest."
89487108|NCT04486443|Experimental|Intervention Group|Patients in the intervention group received music therapy in 10-minutes sessions with the support of a specialist using the Turkish classical music (Hejaz and Rast modes) accompanied by a tambour. All forms were applied to the group before the music therapy, respectively. Prior to musical therapy, the patient's preferred classical music (Rast or Hejaz modes) was asked by the specialist and 10 minutes of music therapy was performed according to patient's choice. Clinical data and pain scores were obtained 5, 30 and 60 minutes after music therapy. 6 sessions of music therapy were applied on different days. Patient Follow-up Form was recorded before and after each therapy. The forms were evaluated 3 times, before the application, after the 3rd and 6th application.
89487109|NCT04486443|No Intervention|control group|The control group consisted of patients who only received analgesic treatment and underwent routine nursing care, and didn't have any interventions. All forms were assessed 3 times, before application, after the 3rd application and after the 6th application. The Patient Information Form and K-MASF were applied only once.
89487110|NCT04956380|Experimental|Joint Count + Early Inflammatory Arthritis Detection Tool|Rheumatologist reviews both the self-administered tender joint count (out of 68 joints on a homunculus) and self-administered Early Inflammatory Arthritis Detection Tool that were completed by the patient. Rheumatologist then uses the information provided in these tools by the patient to determine whether they should advance the urgency rating of the case.
89487111|NCT04956380|Experimental|Early Inflammatory Arthritis Detection Tool|Rheumatologist reviews both the self-administered Early Inflammatory Arthritis Detection Tool that was completed by the patient. Rheumatologist then uses the information provided in this tool by the patient to determine whether they should advance the urgency rating of the case.
89487112|NCT04956380|Experimental|Joint Count|Rheumatologist reviews both the self-administered Patient Tender Joint Count that was completed by the patient. Rheumatologist then uses the information provided in this tool by the patient to determine whether they should advance the urgency rating of the case.
89487113|NCT04956380|No Intervention|Control|Rheumatologist does not review any of the self-administered tools completed by the patient.
89487114|NCT03241797|Experimental|Patients who suggested having AIP|Patients who suggested having AIP and underwent EUS-FNA biopsy by using a standard 22-gauge aspiration needle were enrolled between January 2013 and May 2017.
89487115|NCT04944524|Experimental|Tofactitinib|partcipants would be given one tablet of tofacitinib (5mg per tablet), twice per day, the treatment duration will last 12 months during the whole follow-up period.
89487116|NCT04944524|Active Comparator|Methotrexate|partcipants would be given tablets of methotrexate (2.5mg per tablet) from the initial dose of 15mg (6 tablets) and add to the maximal and optimal dose of 20mg (8 tablets), once per week, the treatment duration will last 12 months during the whole follow-up period.
89487117|NCT04412876|Experimental|Duloxetine|Receive Duloxetine 30 mg treatment per day
89487118|NCT04412876|Active Comparator|Imipramine|Receive Imipramine 25 mg treatment per day
89487119|NCT02454231|Experimental|peripheral blood EPC injection|
89487120|NCT02454231|Active Comparator|bone marrow MNC injection|
89487121|NCT04955912|Experimental|Experimental group|Music medicine
89487122|NCT04955912|No Intervention|Control group|not routinely do anything to reduce premenstrual symptoms
89487123|NCT03241563|Active Comparator|without triamcinolone|sodium Deoxycholate without triamcinolone
89487124|NCT03241563|Active Comparator|with triamcinolone|sodium Deoxycholate with triamcinolone
89487125|NCT04955522||metastases|patients with spinal metastases
89487126|NCT04955522||multiple myeloma|patients with spinal multiple myeloma
89487127|NCT04946474|Experimental|Xingnaojing injection + Shuxuetong oral liquid|Xingnaojing injection (administered immediately after joining the group, once a day, treatment for 10 days) + Naoxueshu oral liquid treatment (administered on the 4th day of onset, 3 times a day, treatment for 30 days ).
89487128|NCT04946474|Placebo Comparator|Placebo group|Xingnaojing injection simulation agent + Naoxueshu oral liquid simulation agent treatment was given.
89204008|NCT00814242|Experimental|percutaneous radiationfrequency ablation|CT or Ultrasound-guided percutaneous radiofrequency ablation
89487129|NCT03241641|Experimental|Maintaining TAF monotherapy|- Tenofovir AlaFenamide (Vemlidy) Tablet, 25mg, Daily Oral, 96 weeks
89487130|NCT03241641|Active Comparator|Switching from TDF to TAF|"Tenofovir Disoproxil Fumarate (Viread) Tablet, 300mg, Daily Oral, 48 weeks~Tenofovir AlaFenamide (Vemlidy) Tablet, 25mg, Daily Oral, 48 weeks"
89487131|NCT03058562|Experimental|Crossover Sequence A|"Each in the fasting state:~Period 1: Single-dose matching placebo~Period 2: Single-dose ABX-1431"
89487132|NCT03058562|Experimental|Crossover Sequence B|"Each in the fasting state:~Period 1: Single-dose ABX-1431~Period 2: Single-dose matching placebo"
89487133|NCT03058562|Experimental|Crossover Sequence C|"Each with a standard high fat meal:~Period 3: Single-dose matching placebo~Period 4: Single-dose ABX-1431"
89487134|NCT03058562|Experimental|Crossover Sequence D|"Each with a standard high fat meal:~Period 3: Single-dose ABX-1431~Period 4: Single-dose matching placebo"
88953092|NCT01958151||Sedated colonoscopy|"Planned colonoscopies for screening under propofol sedation titrated to reach a bispectal index value of 60.~Anxiety levels are assessed before the procedure with State-Trait Anxiety Inventory Scores."
89204009|NCT00775502|Experimental|BIW-8962, monoclonal antibody|
88953093|NCT01958177|Other|BMMNC|Intravenous transfer of of Bone Marrow derived Mono Nuclear Stem Cell (BMMNCs)
88953094|NCT01958216|Other|Trans-intestinal cholesterol excretion in vivo|Measuring trans-intestinal cholesterol excretion in vivo in bile diverted patients
88953095|NCT01958229||CHB patients without cirrhosis|
89204010|NCT05582668||Cohort 1|Cohort 1: Older patients with overweight, obesity after bariatric surgery
89204011|NCT05582668||Cohort 2|Cohort 2: Older patients with overweight, obesity without bariatric surgery
89487135|NCT03058016|Experimental|Personalized recommendations for diet|"After measurement of individual's parameters changes as blood tests, gut microbiome, urine tests, blood pressure, heart performance, body circumferences, mood and mental status as well as monitoring each individual's food intake - a model to predict individual's body reaction according to lifestyle, eating and activity habits will be built.~Personalized recommendations for effective diet, lifestyle and activities based on the patient's parameters measurements and reactions will be provided on a bi-weekly basis, all Lab tests and dietician control will be performed twice a month."
89487136|NCT04486521||Experimental|anti-IL-6 drugs (tocilizumab and siltuximab)
89487137|NCT04486521||Active Comparator 1|Anti-IL-6 drugs (tocilizumab and siltuximab) and corticosteroids combination
89487138|NCT04486521||Active Comparator 2|corticosteroids alone
89487139|NCT04411472|Experimental|active|recombinant human alkaline phosphatase 1.6mg/kg 3 daily 1 hour infusions
89487140|NCT04411472|Placebo Comparator|placebo|matching placebo
89487141|NCT04486365|Active Comparator|Bifocal bone transport|The bifocal approach is a single osteotomy to create one transported bone segment between the osteotomy and the defect.
89487142|NCT04486365|Active Comparator|Trifocal bone transport|The trifocal approach is two osteotomies creating two separate transported bone segments between osteotomy and defect.
89487143|NCT04486287|Experimental|Sintilimab Arm|Sintilimab after Stereotactic Ablation Brachytherapy.
89487144|NCT03254199|Experimental|Experimental|
89487145|NCT03254199|Placebo Comparator|Placebo Comparator|
89487146|NCT04955834|Experimental|Insulin degludec injection|Insulin degludec injection subcutaneous administration once daily for 26 weeks in combination with Oral antidiabetic drugs (OADs) used before.
89487147|NCT04955834|Active Comparator|Tresiba®|Insulin degludec injection（Tresiba®）subcutaneous administration once daily for 26 weeks in combination with Oral antidiabetic drugs (OADs) used before.
89487148|NCT03254277|Experimental|Group 1A|HIV-uninfected individuals will be administered one infusion of 3BNC117-LS dosed at 3 mg/kg.
89487149|NCT03254277|Experimental|Group 1B|HIV-uninfected individuals will be administered one infusion of 3BNC117-LS dosed at 10 mg/kg.
89487150|NCT03254277|Experimental|Group 1C|HIV-uninfected individuals will be administered one infusion of 3BNC117-LS dosed at 30 mg/kg.
89487151|NCT03254277|Experimental|Group 2B|HIV-infected individuals on ART with HIV-1 plasma RNA levels < 20 copies/ml or off ART for at least 8 weeks with HIV-1 plasma RNA levels < 100,000 copies/ml, will be administered one infusion of 3BNC117-LS dosed at 10 mg/kg.
89487152|NCT03254277|Experimental|Group 2C|HIV-infected individuals on ART with HIV-1 plasma RNA levels < 20 copies/ml, or off ART for at least 8 weeks with HIV-1 plasma RNA levels < 100,000 copies/ml, will be administered one infusion of 3BNC117-LS dosed at 30 mg/kg.
89487153|NCT03254277|Experimental|Group 1D|HIV-uninfected individuals will be administered one infusion of 3BNC117-LS dosed at 30 mg/kg.
89487154|NCT03254277|Experimental|Group 2D|HIV-infected individuals on ART with HIV-1 plasma RNA levels < 20 copies/ml will be administered one infusion of 3BNC117-LS dosed at 30 mg/kg.
89487155|NCT03254277|Experimental|Group 1E|HIV-uninfected individuals will be administered a single 1 mL (approximately 150 mg) subcutaneous injection of 3BNC117-LS or placebo in a 3:1 ratio.
89487156|NCT03254277|Experimental|Group 1F|HIV-uninfected individuals will be administered a single 2 mL (approximately 300 mg) subcutaneous injection of 3BNC117-LS or placebo in a 3:1 ratio.
89487157|NCT04943978||Liver disease|Patients with either acute or chronic liver disease
89487158|NCT03241719|Experimental|Treatment|Subjects who receive transplantation and undergo IL-2 treatment
89487159|NCT03241407|Placebo Comparator|Placebo toothpaste|Fluoride toothpaste will be used by filling the individual silicone stent allowing it to come into contact with the implant area for 2 min.During an experimental 3-week period of undisturbed mechanical plaque accumulation in the implants, implants randomly assigned to Placebo group will be submitted to a chemical plaque control (three times per day) using a Triclosan toothpaste.
89487160|NCT03241407|Experimental|triclosan/copolymer/fluoride toothpaste|triclosan/copolymer/fluoride toothpaste will be used by filling the individual silicone stent allowing it to come into contact with the implant area for 2 min. During an experimental 3-week period of undisturbed mechanical plaque accumulation in the implants, implants randomly assigned to triclosan/copolymer/fluoride group will be submitted to a chemical plaque control (three times per day) using a triclosan/copolymer/fluoride toothpaste.
89487161|NCT04944056|Active Comparator|Control Group|It includes ultrasound therapy, glides, exercises and home plan.
88953096|NCT01958242|No Intervention|Preoperative blood harvesting|
88953097|NCT01958255|Other|Tobacco cessation counseling|planned intervention for tobacco cessation counseling
88953098|NCT01958333|Experimental|Exercise 1|Low-intensity, low-volume cardiorespiratory exercise and strength training
88953099|NCT01958333|Experimental|Exercise 2|Medium-intensity, medium-volume cardiorespiratory exercise and strength training
88953100|NCT01958333|Experimental|Exercise 3|High-intensity, High-volume cardiorespiratory exercise and strength training
88953101|NCT01958359|Experimental|Short IVR|IVR-based alcohol diary with feedback
88953102|NCT01958359|Experimental|Therapeutic IVR|IVR-based conversation offering a menu of exercises and vignettes.
89204012|NCT00775580|Experimental|1|atenolol 100 mg Capsules of Ranbaxy
89204013|NCT00775580|Active Comparator|2|Tenormin 100mg capsules
89487162|NCT04944056|Experimental|Experimental Group|It includes ultrasound therapy, glides, exercises, compression mobilization and home plan.
89487163|NCT03241095|No Intervention|Control|
89487164|NCT03241095|Sham Comparator|Sham OMT|
89487165|NCT03241095|Active Comparator|OMT|
89204014|NCT00654498|Other|Pramipexole|4 weeks of individual dose titration starting with Pramipexole 0.125 mg, next dose steps 0.25 mg, 0.5 mg and 0.75 mg, fixed dose for 2 weeks, once daily
89204015|NCT00654498|Other|Placebo|4 weeks of individual dose titration as for the investigational product, once daily
89487166|NCT03238287|Active Comparator|Manuel chest compression|In the application of advanced cardiac life support, chest compression is done with hands. rSO2 measurements are used to detect the impact of the compression on brain perfusion. The application is performed in accordance with the recommendations on advanced cardiac life support in the current guidelines.
89487167|NCT03238287|Active Comparator|Mechanical chest compression|In the application of advanced cardiac life support, chest compression is done with mechanical chest compression device. rSO2 measurements are used to detect the impact of the compression on brain perfusion. The application is performed in accordance with the recommendations on advanced cardiac life support in the current guidelines.
89487168|NCT03238131|Active Comparator|IVM annually (standard treatment)|The comparator (standard treatment) IVM 200 µg/kg body weight given at 0, 12 and 24 months plus vitamin pills at 6 and 18 months.
89487169|NCT03238131|Experimental|IVM plus ALB twice annually|IVM 200 µg/kg plus ALB 800 mg (regardless of weight) given at 0, 6, 12, 18, 24 months
89487170|NCT03238131|Active Comparator|IVM plus ALB once annually|IVM 200 µg/kg plus ALB 800 mg given at 0, 12, 24 months plus vitamin pills at 6 and 18 months.
89487171|NCT03238131|Active Comparator|IVM twice annually|IVM 200 µg/kg given 0, 6, 12, 18, and 24 months
89487172|NCT01369433|Experimental|tivozanib renal cell carcinoma (RCC)|Subjects who participated in a Phase 2 monotherapy study in RCC and showed tolerability and clinical benefit will be allowed access to tivozanib (AV-951).
89487173|NCT01369433|Experimental|tivozanib + temsirolimus|Subjects who participated in a Phase 1b study and showed tolerability and clinical benefit will be allowed continued access to the tivozanib (AV-951) + temsirolimus combination.
89487174|NCT01369433|Experimental|tivozanib + paclitaxel|Subjects who participated in a Phase 1b study and showed tolerability and clinical benefit will be allowed continued access to the tivozanib (AV-951) + paclitaxel combination.
89487175|NCT01369433|Experimental|tivozanib solid tumors - QTC|Subjects who participated in a Phase 1 and showed tolerability and clinical benefit will be allowed continued access to the tivozanib (AV-951).
89487176|NCT01369433|Experimental|tivozanib + capecitabine|After Ph 1b study tolerable to Tivo + Xeloda®
89487177|NCT01369433|Experimental|tivozanib Advanced RCC|After biomarker study tolerable to Tivo
89487178|NCT03241329||Case : endometriosis|Infertile patients with endometriosis that is the only cause of their infertility
89487179|NCT03241329||Control : tubal factor|infertile patients with tubal factor that is the only cause of their infertility
89487180|NCT04151108||Old medical patients|"Blood tests, frailty (CSHA Frailty Scale), risk of pressure ulcers (Braden Score), handgrip strength, chair-rise test, Orientation-Memory-Concentration test (OMC), screening for sarcopenia (SARC-F), screening for malnutrition (SNAQ), body composition.~Will be assessed at admission"
89487181|NCT04151108||Geriatric patients|"Blood tests, frailty (CSHA Frailty Scale), risk of pressure ulcers (Braden Score), handgrip strength, chair-rise test, gait-speed, Orientation-Memory-Concentration test (OMC), screening for sarcopenia (SARC-F), screening for malnutrition (SNAQ), body composition.~Blood tests, physical function measures and body composition will be assessed at both admission and discharge."
89487182|NCT03238209|Experimental|Exercise testing|The test consisted of a steady-state resting period of 3 min followed by 1 min of unloaded pedaling at 60 cycles/min for each individual; the exercise load was increased by 10 W each min until the test had to be stopped because symptoms prevented further exercise. After test results were recorded, EMGdi,es and each surface inspiratory EMG of maximal exercise capacity were analysed.
89204016|NCT00670046|Other|Arm I (standard of care)|Patients undergo observation according to the standard of care. Patients complete quality of life questionnaires at baseline, 6 months, and 1 year.
89204017|NCT00670046|Experimental|Arm II (valproic acid)|Patients receive oral valproic acid twice daily for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients complete quality of life questionnaires at baseline, 6 months, and 1 year.
89487183|NCT04946162|Experimental|Tadalafil Group|Each patient will be given tadalafil 40 mg one time
89487184|NCT04485819||Cleavage stage transfer|Poor responders who transfer their embryos in cleavage stage on day 3
89487185|NCT04485819||Blast stage transfer|Poor responders who transfer their embryos on blast stage on day 5/6
89204018|NCT00814398|Experimental|SET on day 3|Single embryo transfer on day 3 of embryo development
89204019|NCT00814398|Experimental|DET on day 3|Double embryo transfer on day 3 of embryo development
89487186|NCT04955288|Experimental|Aortic balloon Assisted resuscitation group|The aortic balloon-assisted resuscitation group uses aortic balloon occlusion technology on the basis of the traditional resuscitation mode, that is, when the cardiopulmonary resuscitation begins, the aortic balloon catheter is quickly punctured and inserted to the distal end of the aortic area I via ultrasound. (Septum level), then continue to inflate the balloon to block the aortic blood flow until the end of the cardiopulmonary resuscitation to deflate the balloon and remove the balloon catheter.
89487187|NCT04955288|Active Comparator|Traditional cardiopulmonary resuscitation group|The traditional cardiopulmonary resuscitation group uses the traditional manual chest compression mode, that is, referring to the latest version of the cardiopulmonary resuscitation guidelines, manual chest compressions are performed under the monitoring of the compression quality feedback device to ensure that the compression depth is 5-6cm, the frequency is 100-120 times/min, Conditions such as a fixed compression position and sufficient chest wall rebound.
89487188|NCT04955288|Experimental|Esophageal cooling group|The esophageal cooling group adopts a new transesophageal cooling method, that is, an esophageal cooling catheter is placed after resuscitation in patients with cardiac arrest, and then a small temperature-controlled water circulation system is continuously perfused with 4℃ cold water. After the patient's body temperature reaches the target temperature of 33℃, the temperature is adjusted Control the water circulation system to maintain the target body temperature of (33±0.5)°C for 24 hours, and then reheat to (37±0.5)°C normal body temperature at a rate of 0.25-0.5°C/h and maintain it for 24 hours.
89487189|NCT04955288|Active Comparator|Traditional cooling group|The traditional cooling group uses the traditional body surface ice blanket cooling method, that is, the patients with cardiac arrest lie on the temperature control blanket after resuscitation, and then use the ice blanket host to continuously infuse the temperature control blanket with 4℃ cold water, and wait until the patient's body temperature reaches the target temperature of 33℃ After that, adjust the ice blanket host to control the circulating water temperature to maintain the target body temperature of (33±0.5)°C for 24 hours, and then reheat to the normal body temperature of (37±0.5)°C at a rate of 0.25-0.5°C/h and maintain it for 24 hours.
89487190|NCT02084225||Course participants|Physicians, nurses and orthopedic officers who staff the emergency intake and orthopedic procedure area of HEAL hospital, Goma DRC, Black Lion Hospital, Addis Ababa and Kindu General Hospital in Kindu DRC. These participants recorded their nerve block intervention over one year for pain management and assessed patient pain level after 10 cc lidocaine.
89487191|NCT03237975|Experimental|Be the Expert for Your Own (BEYO)|BEYO is a group-based consultation project. Each group contains 1 facilitator, 1 assistant and 8 elderly patients. 5 weekly sessions are provided to let patients receive health knowledge, discuss problems and experiences, explore available resources and build up goals and solutions. Each session lasts for 40 minutes. Session 1 aims to build social network among group members and introduce group goals and tasks. Session 2-4 covers six topics: (i) healthy dietary, (ii) exercise and activity, (iii) taking medication, (iv) blood glucose monitoring, (v) reducing risks for complication, (vi) healthy coping with mental stress. Session 5 aims to review the process, summarize effective solutions, and set up plans for the future.
89487192|NCT03237975|Active Comparator|Routine health education|To neutralize the effect of extra attention from the facilitator, participants in control group will receive routine health education on topics related to type 2 diabetes. Contents for the routine education will be based on the national guideline of basic public health service for diabetes and specific implementation protocols in each community. Participants in control group will receive 5-weekly education packet at the same time with participants in intervention group. The patients will not be given any strengths-based information, but they are free to discuss their disease status with nurses or physicians at their regular follow-up appointments.
89487193|NCT02078843|Other|All patients|Subsequent performance of index test and standard test
89487194|NCT04946240|Experimental|Supervised (BRACE) Group|the self-developed protocol (BRACE) is used in the experiment with a combination of balance, resistance, aerobic and cognitive exercises for 12 weeks with repetition of different tasks
89487195|NCT04946240|Active Comparator|Conventional Balance Exercises Group|The unsupervised home plan included balance and resistance exercise was guided to conventional group
89487196|NCT02078921|Experimental|Treatment|Inorganic Nitrate
89487197|NCT02078921|Placebo Comparator|placebo|Placebo
89487198|NCT03254043|Active Comparator|Treatment-as-Usual|Participants will routine methadone clinic care.
89487199|NCT03254043|Experimental|"Take-home Dosing using MedMinder Jon Electronic Pill Box"|Participants will receive 50% of their methadone dose in the morning in the clinic and 50% of their dose will be dispensed in an electronic pill box for participants to take at home later that day.
89487200|NCT03254043|Other|Choice Phase|"Participants will be allowed to select one final Treatment-As-Usual or the MedMinder Jon Electronic Pill Box for the final phase of the study."
89487201|NCT02081261||Coronary artery bypass surgery|patients who underwent coronary artery bypass surgery between 2010 and 2012 in Samsung Medical Center
88953103|NCT01958359|No Intervention|Control|Untreated control group
89204020|NCT00814398|Experimental|SET on day 5|Single embryo transfer on day 5 of embryo development
89204021|NCT00814398|Experimental|DET on day 5|Double embryo transfer on day 5 of embryo development
88953104|NCT01958372|Experimental|Group I (squamous cell histology)|Patients receive etoposide IV over 1 hour on days 1-5 and 29-33, cisplatin IV over 1 hour on days 1, 8, 29, and 36, and undergo RT 5 days a week for 6.6 weeks. Within 48 hours of initiating treatment, patients receive soy isoflavones PO daily on days 1-90.
88953105|NCT01958372|Experimental|Group II (non-squamous cell histology)|Patients receive pemetrexed disodium IV over 10 minutes on days 1, 22, and 43 and cisplatin IV over 1 hour on days 1, 22, and 43. Patients also undergo RT and receive soy isoflavones as in Group I.
89537846|NCT04973319|Experimental|test group|Each subject in the test group will receive the test drug (pyrotinib) for 52 weeks, and will be followed up for at least 3 years from the start of randomization, until disease recurrence, intolerable toxicity, withdrawal of informed consent, or termination of the medication as per the investigator's judgment. The subject who has a second primary malignant tumor in a non-breast area will continue to be followed up until a recurrent disease or death due to primary breast cancer. The subjects who are hormone receptor-positive will be advised to receive endocrinotherapy simultaneously. Within 28 days after the last administration of the test drug, the subjects in the test group must complete the safety follow-up and the end-of-treatment visit and continue to receive the follow-up visit.
89537847|NCT04973319|Other|control group|Each enrolled subject will complete at least ≥ 24 weeks (8 drug delivery cycles) of trastuzumab combined with pertuzumab in the neoadjuvant and/or adjuvant treatment phase.
89537848|NCT03294161|Experimental|Immucillin DI4G|Meglumine Antimoniate by intravenous route at 20mg/kg/day during 20 days + Immucillin DI4G 2% by topical use once a day at the ulcer for 20 days .
89537849|NCT03294161|Active Comparator|Meglumine Antimoniate|Meglumine Antimoniate by intravenous route at 20mg/kg/day during 20 days + placebo for topical use once a day at the ulcer for 20 days.
89204022|NCT00560391|Experimental|Dasatinib, 70 mg + Lenalidomide, 15 mg + Dexamethasone, 40 mg|Participants received a combination of dasatinib, 70 mg QD, lenalidomide, 15 mg QD, and dexamethasone, 40 mg QD, weekly on Days 1, 8, 15, and 22, in 28-day cycles.
89537850|NCT04973241||OPG|
89537851|NCT04973241||CBCT|
89537852|NCT03294005||Subjects with nodular goiter|Enrolled subjects with nodular goiter had thyroid sonography and thyroidectomy from 2002 January to 2016 December in CMUH. Total enrolled subject about 2000. These subjects were confirmed by pathology. Each subject had been transverse and longitudinal views of thyroid ultrasonography with high-resolution ultrasound (7-14 MHz) (HP Image Point-HS, Toshiba SSA250, GE ,Aloka SSD-1200 and Siemens S2000) that was performed by our partners - endocrinologist in all patients. Gray scale ultrasonography was routinely performed in every subject. Color Doppler ultrasonography for blood flow and thyroid fine needle aspiration was not absolute done in routine procedure. All data at least was interpreted by 3 endocrinologists under the blind method. Each subject was analyzed under thyroid echogenicity, margin, calcification, inclusion, grooving change and size & ratio size of tall and transverse.
89537853|NCT03289871|Experimental|Excilor|2 applications per day for 6 months
89537854|NCT03289871|Active Comparator|Loceryl 5%|1 application per week for 6 months
89537855|NCT04979715|Experimental|intervention group (Group 1)|"From the first postoperative day, with the approval of the surgeon performing the operation, the postoperative exercise program will be started once a day under the supervision of a physiotherapist during the stay of the participants in the hospital.~At the same time, participants will be directed to moderate intensity aerobic exercise (walking, jogging…) for 150 min/week. Information will be given on the importance of physical activity and increasing the level of physical activity. In addition, a brochure containing explanatory information about the postoperative physiotherapy program after breast surgery will be given to the participants."
88953106|NCT01958385|Active Comparator|Treatment group|The treatment of obese patients with the placement of g-Cath EZ suture anchors along with Diet and Exercise
88953107|NCT01958385|Sham Comparator|Sham Group|The treatment of obese patients with the sham procedure along with Diet and Exercise
88953108|NCT01958398|Experimental|Promillekoll|Smartphone app monitoring alcohol use with feedback.
88953109|NCT01958398|Experimental|PartyPlanner|Smartphone-adapted web based app for simulating an event with alcohol consumption in advance, real time monitoring alcohol use with feedback during the event and the possibility to compare these two.
88953110|NCT01958398|No Intervention|Control|Untreated control group
89204023|NCT00560391|Experimental|Dasatinib, 70 mg + Lenalidomide, 20 mg + Dexamethasone, 40 mg|Participants received a combination of dasatinib, 70 mg QD, lenalidomide, 20 mg QD, and dexamethasone, 40 mg QD, weekly on Days 1, 8, 15, and 22, in 28-day cycles.
88953111|NCT01958411||18FDG-PET/CT|
88953112|NCT01958424||women with metabolic syndrome|women undergoing ivf treatment who have BMI>25 and meet the criteria for metabolic syndrome
88953113|NCT01958424||women without metabolic syndrome|women undergoing ivf treatment who have BMI>25 and who do not meet the criteria for metabolic syndrome
88953114|NCT01958450|Experimental|Er:YAG laser|acne scar treatment using Er:YAG laser
88953115|NCT01958450|Active Comparator|Bipolar radiofrequency with diode laser|Bipolar radiofrequency with diode laser
89487202|NCT03253965|Experimental|Walking: Treadmill then Overground|Walking while receiving auditory cueing intervals from a metronome and music. Testing performed using metronome normal, metronome slow, and metronome fast speed settings as well as music normal, music slow, and music fast tempos. Subjects will also walk with no auditory cueing.
89487203|NCT03253965|Experimental|Walking: Overground, then Treadmill|Walking while receiving auditory cueing intervals from a metronome and music. Testing performed using metronome normal, metronome slow, and metronome fast speed settings as well as music normal, music slow, and music fast tempos. Subjects will also walk with no auditory cueing.
89487204|NCT04945694|Experimental|Ultrasound-guided bilateral pecto-intercostal fascial block|Patients will receive bilateral ultrasound-guided pecto-intercostal fascial block
89487205|NCT04945694|Placebo Comparator|Intravenous fentanyl|Patients will receive only incremental doses of intravenous fentanyl
89487206|NCT02078999||Control Grup|"Daily clinical data collection~Quantitative tracheal aspirates (QTA) every 3 days~Deep freeze serum samples for posterior analysis every day (two aliquots).~In patients with documented pneumonia daily collection of the following variables will continue: CRP, PCT, ABG, mechanical ventilation parameters, ACCP/SCCM consensus conference criteria, simplified CPIS, SOFA."
89487207|NCT02078999||Patients with pulmonary infection|"Daily clinical data collection~Quantitative tracheal aspirates (QTA) every 3 days~Deep freeze serum samples for posterior analysis every day (two aliquots).~In patients with documented pneumonia daily collection of the following variables will continue: CRP, PCT, ABG, mechanical ventilation parameters, ACCP/SCCM consensus conference criteria, simplified CPIS, SOFA."
89487208|NCT02078999||Patients with extrapulmonary infection|"Daily clinical data collection~Quantitative tracheal aspirates (QTA) every 3 days~Deep freeze serum samples for posterior analysis every day (two aliquots).~In patients with documented pneumonia daily collection of the following variables will continue: CRP, PCT, ABG, mechanical ventilation parameters, ACCP/SCCM consensus conference criteria, simplified CPIS, SOFA."
89487209|NCT03253731||Healthy Volunteers|15 healthy volunteers
89487210|NCT04943276|Experimental|Embr Watch|Participants will receive the device and a technical onboarding video 3 days prior to study start to allow time for familiarization with the device and troubleshooting any technical questions or problems prior to study start. The study will consist of baseline measurements prior to using the Embr device and weekly outcome assessments at Week 1, 2, 3, and 4
89487211|NCT02084303|Other|Ferumoxytol MRI|Ferumoxytol injection after focal epileptic seizure followed by iron-sensitive MRI.
89487212|NCT03253653|Experimental|Waterpipe smoking|In a repeated measures design, 50 adult male and female exclusive WP smokers will smoke WP tobacco weekly over a 3-week study period with 3 WP smoking practices.
89487213|NCT03253653|No Intervention|Control|A total of 25 adult make and female nonsmokers will be recruited as a control.
89487214|NCT02084381|Experimental|MCO-Ci 400|MCO-Ci 400 is the investigational medical product applied in hemodialysis mode
89487215|NCT02084381|Active Comparator|Revaclear 400|the standard high flux dialyzer Revaclear 400 is used as an comparator in hemodialysis mode
89487216|NCT03241251||parents children pediatric cancer|Screening questionnaire psychosocial risk factors
89204024|NCT00560391|Experimental|Dasatinib, 100 mg + Lenalidomide, 20 mg + Dexamethasone, 40 mg|Participants received a combination of dasatinib, 100 mg QD, lenalidomide, 20 mg QD, and dexamethasone, 40 mg QD, weekly on Days 1, 8, 15, and 22, in 28-day cycles.
89487217|NCT03253887|Experimental|Ethanol-lock therapy (ELT) Group|This group received daily alcohol 70% (ethanol-lock) with intraluminal alcoholization of both lumens of the central venous catheters
89487218|NCT03253887|No Intervention|Control Group|This group did not receive the ethanol-lock, being only followed daily and treated according to the standard protocol in operation at this healthcare unit.
89487219|NCT03237663|Experimental|One enteric capsule|
89487220|NCT03237663|Experimental|Two enteric capsule|
89487221|NCT02453607||CD Monotherapy|Crohn's disease treated with infliximab (monotherapy)
89487222|NCT02453607||CD Combo therapy|Crohn's disease treated with infliximab in combination with thiopurine (a 6MP metabolite) (combo therapy)
89487223|NCT02453529|Experimental|WCK 4873|Oral tablets
89487224|NCT03241017|Experimental|Durvalumab|Durvalumab 1500 mg (day 1) given every 4 weeks for a total of 12 applications (1 year).
89487225|NCT03240705|Experimental|Gratitude journaling|Students perform gratitude journaling 3 times per week on a form. This activity consists of writing elements of their day that brought happiness to them. Can be in keyword form or in sentences.
89487226|NCT03240705|No Intervention|No intervention|Students proceed with their surgical clerkship as is standard in our institution.
89487227|NCT03237585|Experimental|i) Intervention arm- Receive Gender Centre's RRS package|
89487228|NCT03237585|No Intervention|No intervention|
89487229|NCT03253575||Squamous Carcinoma of the Head and Neck (HNSCC)|"1st line metastatic/locally advanced~2nd line metastatic/locally advanced"
89487230|NCT03253575||Triple Negative Breast Cancer (TNBC)|1. Triple Negative Breast Cancer (TNBC) A 1st line metastatic/locally advanced B ≥2nd line metastatic/locally advanced
89487231|NCT03253575||Non-small Cell Lung Cancer (NSCLC)|1. Non-small Cell Lung Cancer (NSCLC) A ≥2nd line Stage 3B or 4
88953116|NCT01958463|Experimental|Fecal microbiota transplantation|Fecal microbiota transplantation during colonoscopy.
88953117|NCT01958502|Experimental|mesenchymal stem cell|stem cells drived from iliac bone marrow with centrifuge and ficoll method then implant in collagenic 3-D scaffold with BMP-2 and put in non union site by surgical approach under general or spinal anesthesia as deemed appropriate by the anesthetist.
89487232|NCT03253575||Epithelial Ovarian Cancer (EOC)|1. Epithelial Ovarian Cancer (EOC) A 2nd line platinum-resistant Stage 3 or 4 B 2nd line platinum-sensitive Stage 3 or 4 C ≥3rd line platinum-sensitive Stage 3 or 4
89487233|NCT03253575||Colorectal Cancer (CRC)|1. Colorectal Cancer (CRC) A 1st line Stage 4 B Recurrent or progressive disease following treatment with both oxaliplatin- and irinotecan-containing regimens
89487234|NCT03240939|Active Comparator|Dutasteride&Tadalafil|Dutasteride 0.5 mg capsule and Tadalafil 5 mg Tablet, single dose
89487235|NCT03240939|Experimental|YY-201|YY-201 capsule, singe dose
89487236|NCT03237429||cancer patients|The first study population will represent patients scheduled for surgery for a new diagnosed cancer pathology
89487237|NCT03237429||non-cancer patients|The second study population will represent patients scheduled for surgery not for cancer disease
89487238|NCT02624492|Experimental|BI 836826-GemOx|
89487239|NCT02624492|Active Comparator|R-GemOx|
89487240|NCT03240783|Experimental|Arm 1|Betamethasone OR Dexamethasone Injectable CT - fluoroscopic guided transforaminal lumbar epidural steroid
89487241|NCT03240783|Experimental|Arm 2|Normal Saline Flush, 0.9% Injectable Solution CT - fluoroscopic guided transforaminal lumbar epidural normal saline
89487242|NCT03240783|Experimental|Arm 3|"Dexamethasone Oral Tablet:~Oral dexamethasone 15 day tapered dosing is as follows: (i) days 1-5, 4 mg morning and evening, (ii) days 6-10, 2 mg morning and evening, and (iii) days 11-15, 1mg morning and evening."
89487243|NCT03240783|Other|Arm 4|Sham Injection and/or oral placebo: CT/fluoroscopic guided (parameters set to zero) transforaminal lumbar sham (needle placement down to muscle and no injection of any fluid) AND placebo oral tablets taper.
89487244|NCT03240393|Experimental|cMET GCN ≥ 6|Pre-treated patients with cMET GCN ≥ 6 treated with INC280 at 400mg BID
89487245|NCT03240393|Experimental|cMET GCN ≥ 4 and < 6|Pre-treated patients with cMET GCN ≥ 4 and < 6 treated with INC280 at 400 mgBID
89487246|NCT03240393|Experimental|cMET mutations|Pre-treated patients with cMET mutations regardless of cMET GCN treated with INC280 at 400mg BID
89487247|NCT04955054||control|patients without coronary artery disease
89487248|NCT04955054||UAP|patients without unstable angina pectoris
89487249|NCT04955054||AMI|patients with acute myocardial infarction
89487250|NCT03237507||Chemotherapy Group|chemotherapy treatment（S-1 and Oxaliplatin） for patients until disease progress
89487251|NCT03237507||Chemotherapy plus HIPEC Group|Hyperthermic Intraperitoneal chemoperfusion（HIPEC）with Paclitaxel more than 2 cycles and plus chemotherapy
89487252|NCT04945226|Active Comparator|Propecia|Propecia Tablet, QD, PO
88953118|NCT01958515||Chemoradiation with Research Samples|Standard of care chemoradiation therapy will be given as clinically indicated by the treating physicians. 4 research blood and tissue samples will be obtained. One before treatment starts, 2 while treatments are being received and finally one after treatments are completed.
88953119|NCT01958541|Experimental|Behavioral Intervention I|This non-medication group treatment (Sleep Intervention I) consists of four 90-minute sessions.
88953120|NCT01958541|Active Comparator|Behavioral Intervention II|This non-medication group treatment (Sleep Intervention II) consists of four 90-minute sessions.
89487253|NCT04945226|Experimental|IVL3001 (A mg)|S.C, Single Dose.
89487254|NCT04945226|Experimental|IVL3001 (B mg)|S.C, Single Dose.
88953121|NCT01958554|Experimental|Intervention Group|The integrated intervention consisted of 12 week of program and group support, based on the freedom program by pet craven. The former component was provided covering beliefs held and tactics used by the domestic violence abusers and took about 45 minutes. It included protection and enhanced choice-making and problem-solving skills.
89204025|NCT00560391|Experimental|Dasatinib, 100 mg + Lenalidomide, 25 mg + Dexamethasone, 40 mg|Participants received a combination of dasatinib, 100 mg QD, lenalidomide, 25 mg QD, and dexamethasone, 40 mg QD, weekly on Days 1, 8, 15, and 22, in 28-day cycles.
89204026|NCT00560391|Experimental|Dasatinib, 140 mg + Lenalidomide, 25 mg + Dexamethasone, 40 mg|Participants received a combination of dasatinib, lenalidomide, and dexamethasone in varying doses in 28-day cycles.
89487255|NCT04945226|Experimental|IVL3001 (C mg)|S.C, Single Dose.
89487256|NCT03253419|Other|Home Safety Application|Use of Home Safety application as part of assessment for home safety. The only intervention is the use of the home safety application and identification of home safety issues by the patient using this application.
89487257|NCT01975831|Experimental|Escalation: 0.3 mg/kg Durva + 3 mg/kg Treme|Subjects received durvalumab (0.3 mg/kg every 2 weeks [Q2W] for 13 cycles) and tremelimumab (3 mg/kg every 4 weeks [Q4W] for 6 cycles, then every 12 weeks [Q12W]). Optional extended treatment comprised durvalumab monotherapy administered at the recommended fixed dose of 1500 mg Q4W.
89487258|NCT01975831|Experimental|Escalation: 1 mg/kg Durva + 3 mg/kg Treme|Subjects received durvalumab (1 mg/kg Q2W for 13 cycles) and tremelimumab (3 mg/kg Q4W for 6 cycles, then Q12W). Optional extended treatment comprised durvalumab monotherapy administered at the recommended fixed dose of 1500 mg Q4W.
89487259|NCT01975831|Experimental|Escalation: 3 mg/kg Durva + 3 mg/kg Treme|Subjects received durvalumab (3 mg/kg Q2W for 13 cycles) and tremelimumab (3 mg/kg Q4W for 6 cycles, then Q12W). Optional extended treatment comprised durvalumab monotherapy administered at the recommended fixed dose of 1500 mg Q4W.
89487260|NCT01975831|Experimental|Escalation: 3 mg/kg Durva + 1 mg/kg Treme|Subjects received durvalumab (3 mg/kg Q2W for 12 or 13 cycles) and tremelimumab (1 mg/kg Q4W for 6 cycles, then Q12W or Q4W for 4 cycles). Optional extended treatment comprised durvalumab monotherapy administered at the recommended fixed dose of 1500 mg Q4W.
89487261|NCT01975831|Experimental|Expansion: Ovarian Cancer|Subjects received durvalumab (10 mg/kg Q2W for 13 cycles or 1500 mg Q4W for 12 cycles) and tremelimumab (1 mg/kg or 75 mg Q4W for 4 cycles). Optional extended treatment comprised durvalumab monotherapy administered at the recommended fixed dose of 1500 mg Q4W.
89487262|NCT01975831|Experimental|Expansion: Colorectal Cancer|Subjects received durvalumab (10 mg/kg Q2W for 13 cycles or 1500 mg Q4W for 12 cycles) and tremelimumab (1 mg/kg or 75 mg Q4W for 4 cycles). Optional extended treatment comprised durvalumab monotherapy administered at the recommended fixed dose of 1500 mg Q4W.
89487263|NCT01975831|Experimental|Expansion: Non-triple Negative Breast Cancer|Subjects received durvalumab (10 mg/kg Q2W for 13 cycles or 1500 mg Q4W for 12 cycles) and tremelimumab (1 mg/kg or 75 mg Q4W for 4 cycles). Optional extended treatment comprised durvalumab monotherapy administered at the recommended fixed dose of 1500 mg Q4W.
89487264|NCT01975831|Experimental|Expansion: Renal Cell Carcinoma|Subjects received durvalumab (10 mg/kg Q2W for 13 cycles or 1500 mg Q4W for 12 cycles) and tremelimumab (1 mg/kg or 75 mg Q4W for 4 cycles). Optional extended treatment comprised durvalumab monotherapy administered at the recommended fixed dose of 1500 mg Q4W.
89487265|NCT01975831|Experimental|Expansion: Cervical Cancer|Subjects received durvalumab (10 mg/kg Q2W for 13 cycles or 1500 mg Q4W for 12 cycles) and tremelimumab (1 mg/kg or 75 mg Q4W for 4 cycles). Optional extended treatment comprised durvalumab monotherapy administered at the recommended fixed dose of 1500 mg Q4W.
89487266|NCT00700713|Experimental|One-Dose Menactra Group|Participants received one dose of Menactra® in Study MTA26
89487267|NCT00700713|Experimental|Two-Dose Menactra Group|Participants received two doses of Menactra® in Study MTA26
89487268|NCT00700713|Active Comparator|Menactra vaccine-naïve Group|Participants had never received Menactra® vaccine.
89487269|NCT04945070|Experimental|iGlarLixi|Subjects switched from MDI to iGlarLixi
89487270|NCT04945070|Active Comparator|Control|Patients continuing with previous MDI
89487271|NCT04944914|Experimental|Camrelizumab Plus Stereotactic Body Radiotherapy|Patients receive camrelizumab(200mg, iv drip for over 60min) every 2 weeks from 2 weeks before radiotherapy, and then receive stereotactic body radiotherapy until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, investigator decision or the upper limit of treatment duration of 1 year.
89487272|NCT04944914|Active Comparator|Camrelizumab|Patients receive camrelizumab(200mg, iv drip for over 60min) every 2 weeks until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, investigator decision or the upper limit of treatment duration of 1 year.
89487273|NCT03240471|Experimental|One week of plaster cast|One week of plaster cast after a non-reduced distal radius fracture.
89487274|NCT03240471|Other|Control; four-five weeks of plaster cast|Four-five weeks of plaster cast after a non-reduced distal radius fracture, usual care.
89487275|NCT04942652|Experimental|Itraconazole 200 mg under fasted condition|A single oral administration of itraconazole 200 mg under fasted condition
89487276|NCT04942652|Experimental|Itraconazole 200 mg under fed condition|A single oral administration of itraconazole 200 mg under fed condition
89487277|NCT04942652|Experimental|Esomeprazole 40 mg + Itraconazole 200 mg under fasted condition|Oral administration of esomeprazole 40 mg once daily for 6 days and then a single oral administration of itraconazole 200 mg under fasted condition
89487278|NCT03253497|Active Comparator|Chlorhexidine- benzidamine|before 15 minute anesthesia induction Chlorhexidine-benzidamine spray will be administrated to oropharynx
89487279|NCT03253497|No Intervention|Control|before 15 minute normal salin will be administrated to oropharynx
89487280|NCT04942418|Active Comparator|Multicolor feldspathic ceramic laminate veneers|the feldspathic ceramic blocks display the highest translucent properties of all ceramic blocks which make them the first choice in the esthetic zone. esthetic and translucency with polychromatic feature and resilience properties.
89487281|NCT04942418|Experimental|Multicolor hybrid ceramic laminate veneers.|Multi-shaded blocks have been recently introduced to the market, due to lack of evidence in clinical performance evaluating marginal adaptation and shade matching of the polychromatic newly introduced blocks comparing their different color gradient. Multicolor hybrid ceramic laminate veneers.
89487282|NCT03240549|No Intervention|conventional therapy group|Treatment with previous regimen of combined chemotherapy
89487283|NCT03240549|Experimental|bevacizumab group|Adding bevacizumab to the previous regimen of combined chemotherapy
89487284|NCT04933292|Experimental|Methylprednisolone and Mycophenolate mofetil|
89487285|NCT04933292|Active Comparator|Methylprednisolone and Azathioprine|
89487286|NCT03240315||COPD subjects|Subjects with GOLD stage I-IV COPD
89487287|NCT04942496|Active Comparator|Test Product 1 (4% CHG)|Product applied to patch and randomly assigned application site on right and left parascapular regions of upper back
89487288|NCT04942496|Active Comparator|Test Product 2 (2% CHG)|Product applied to patch and randomly assigned application site on right and left parascapular regions of upper back
89487289|NCT04942496|Active Comparator|Test Product 3 (2% CHG)|Product applied to patch and randomly assigned application site on right and left parascapular regions of upper back
89487290|NCT04942496|Active Comparator|Test Product 4 (4% CHG)|Product applied to patch and randomly assigned application site on right and left parascapular regions of upper back
89487291|NCT04942496|Active Comparator|Test Product 5 (4% CHG)|Product applied to patch and randomly assigned application site on right and left parascapular regions of upper back
89487292|NCT04942496|Active Comparator|Test Product 6 (4% CHG)|Product applied to patch and randomly assigned application site on right and left parascapular regions of upper back
89487293|NCT04942496|Active Comparator|Test Product 7 (4% CHG)|Product applied to patch and randomly assigned application site on right and left parascapular regions of upper back
89487294|NCT04942496|Active Comparator|Test Product 8 (4% CHG)|Product applied to patch and randomly assigned application site on right and left parascapular regions of upper back
89487295|NCT04942496|Active Comparator|Test Product 9 (4% CHG)|Product applied to patch and randomly assigned application site on right and left parascapular regions of upper back
89487296|NCT04942496|Placebo Comparator|0.1% Sodium Lauryl Sulfate|Product applied to patch and randomly assigned application site on right and left parascapular regions of upper back. Product with known irritancy potential.
89487297|NCT04942496|Placebo Comparator|Distilled Water|Product applied to patch and randomly assigned application site on right and left parascapular regions of upper back. Product known not to cause irritancy
89487298|NCT03237039|Other|X-ray examination, fall-risk and gait|simultaneous acquisition in upright position of two full-body radiographic images, one in the coronal plane and one in the sagittal plane. In addition, 40 out of 160 subjects will undergo fall-risk assessment and gait cycle analysis evaluation.
89487299|NCT04932668|Experimental|Home-based Electrical Stimulation Program for lower limb spasticity|Single arm prospective intervention study to assess the feasibility and impact of a home-based program. Patient will apply home-based NMES on their leg for 20 minutes, 5 days a week for 4 weeks. At the end of the study, an outcome measures will be assessed and patient will be required to answer a questionnaires on their experience.
89487300|NCT03240159|Active Comparator|Deg-24mg|"Single dose of Degarelix 24mg, on day 24th of previous luteal face cycle. On day 2 of the cycle: will be measured: LH levels, estradiol levels, and FSH levels.~ON day 1 of the stimulation (depending day of the cycle): will be measured: LH levels, estradiol levels, and FSH levels.~On day 6 of the stimulation( depending day of the cycle):will be measured: LH levels, estradiol levels, and FSH levels.~On day 8 of the stimulation( depending day of the cycle):will be measured: LH levels, estradiol levels, and FSH levels.~On day 10 of the stimulation( depending day of the cycle):will be measured: LH levels, estradiol levels, and FSH levels."
89487301|NCT03240159|Active Comparator|Deg-16mg|"Single dose of Degarelix 16mg, on day 24th of previous luteal face cycle. On day 2 of the cycle: will be measured: LH levels, estradiol levels, and FSH levels.~ON day 1 of the stimulation (depending day of the cycle): will be measured: LH levels, estradiol levels, and FSH levels.~On day 6 of the stimulation( depending day of the cycle):will be measured: LH levels, estradiol levels, and FSH levels.~On day 8 of the stimulation( depending day of the cycle):will be measured: LH levels, estradiol levels, and FSH levels.~On day 10 of the stimulation( depending day of the cycle):will be measured: LH levels, estradiol levels, and FSH levels."
89487302|NCT03240159|Active Comparator|Deg-12mg|"Single dose of Degarelix 12mg, on day 24th of previous luteal face cycle.On day 2 of the cycle: will be measured: LH levels, estradiol levels, and FSH levels.~ON day 1 of the stimulation (depending day of the cycle): will be measured: LH levels, estradiol levels, and FSH levels.~On day 6 of the stimulation( depending day of the cycle):will be measured: LH levels, estradiol levels, and FSH levels.~On day 8 of the stimulation( depending day of the cycle):will be measured: LH levels, estradiol levels, and FSH levels.~On day 10 of the stimulation( depending day of the cycle):will be measured: LH levels, estradiol levels, and FSH levels."
89487303|NCT04942262|Experimental|denture adhesive use|Participants were instructed to use a cream-type denture adhesive (Polident®, GlaxoSmithKline, Ireland) once a day in the morning and use it throughout the day. They applied denture adhesive onto the tissue surface of their maxillary and mandibular dentures using a spot method. The participants had to remove the DA and clean the denture every day after the last meal by soaking and brushing the CD with liquid soap and a soft toothbrush under running tap water. Two gauze pads were used to remove DA from the denture and oral mucosa. After the 1-month trial period of DA use. The outcomes were evaluated with all participants using DA, and they had to choose whether they wanted to continue or discontinue using DA for another 1 month. At 1-month after continuing or discontinuing DA use. At this time, some participants used DA during the outcome evaluations, while some did not, depending on the patient's decision on DA use.
89487304|NCT03253185|Experimental|SC-007|SC-007 intravenous (IV) (various doses and dose regimens)
89487305|NCT03237117|Experimental|GH group|35 women with a history of RIF with donated oocytes. For receiving donated oocytes, the women are treated with progressively increasing doses of oral estradiol followed by intravaginal progesterone after previous pituitary desensitization with GnRH agonist. Additionally, these patients are co-treated with growth hormone (GH).
89487306|NCT03237117|Active Comparator|non-GH group|35 women with a history of RIF with donated oocytes. For receiving donated oocytes, the women are treated with progressively increasing doses of oral estradiol followed by intravaginal progesterone after previous pituitary desensitization with GnRH agonist. The treatment protocol is identical to the GH group, only that no GH is added.
89487307|NCT03237117|No Intervention|positive control group|35 infertile women undergoing their first oocyte donation attempt are included as a positive control group. Women receiving donated oocytes are treated with progressively increasing doses of oral estradiol followed by intravaginal progesterone after previous pituitary desensitization with GnRH agonist. The treatment protocol is identical to the non-GH group, with no GH added.
89487308|NCT04944758|Other|Light therapy|Daily exposure on weekdays to a standard light device (e.g., fluorescent light box such as the Carex Day-Light Classic, emitting 4000 Kelvin white light rated at 10,000 lux at 14 inches from screen to cornea, with an ultraviolet filter) for 30 minutes as soon as possible after awakening, preferably between 7:00-8:00 am. Participants will also taper and discontinue their antidepressant medication.
89487309|NCT03239691|Experimental|ACT-709478 - Single dose administration|Up to 16 subjects with photosensitive epilepsy will be studied across a maximum of 4 dose levels. Each dose level will initially be investigated in cohorts of 4 subjects undergoing a fixed sequence of study treatment administration in fed condition
89487310|NCT03239691|Placebo Comparator|Placebo|Placebo will be administered on two study days
89487311|NCT04944446|Experimental|Group myofascial treatment|"The trial group will also be referred by the rehabilitating doctor to the physiotherapy room, these patients will be treated by two physiotherapists with training in myofascial release therapy with which they will carry out a treatment protocol that will consist of myofascial release of the shoulder blade angle, subscapularis and global pectoral technique as well as superficial myofascial release of said musculature with a during 12-15 minutes, in addition to a 30-minute session of active kinesitherapy with exercises and mechanotherapy. Same as the control group.~These mobilizations are carried out in the absence of pain, although the difference between joint tension or stretching and pain is explained to the patient."
89487312|NCT04944446|Active Comparator|Group Kinesitherapy treatment|"This group will be treated in a protocolized way with techniques such as passive kinesitherapy, active-assisted and active kinesitherapy to win mobility.~They consist of mobilizing the affected arm in the movements of flexion (upward), separation (towards the outer side) and rotation, these lateral decubitus (bring the hand to the nape of the neck) and internal (bring the hand to the lower back) trying to win joint amplitude.~These mobilizations are performed in the absence of pain, although the difference between joint tension or stretching and pain will be explained to the patient. The treatment will be carried out as usual with a duration of about 12-15 minutes of mobilization and about 30 minutes of active kinesitherapy with exercises and mechanotherapy, these consist of active shoulder mobility exercises. Emphasis will be placed on working with the pain threshold so as not to cause damage or negative nociceptive reactions."
89487313|NCT04945382|Experimental|Scotchbond universal 3M|Application of dental sealant with Scotchbond universal 3M adhesive.
89487314|NCT04945382|Active Comparator|Control (Single bond 3M)|Application of dental sealant with Single Bond 3M adhesive
89487315|NCT04944602|Experimental|SYN008|patients received a dose of SYN008 300 mg which consisted of two injections of omalizumab 150 mg vials every 4 weeks (Day 1, Week 4 and Week 8)
89487316|NCT04944602|Active Comparator|Omalizumab|patients received a dose of omalizumab 300 mg which consisted of two injections of omalizumab 150 mg vials every 4 weeks (Day 1, Week 4 and Week 8)
89487317|NCT03237273|Experimental|Single|All patients will undergo ultrasound scan using the HEAD-US Scoring System by a non-imaging specialist
89487318|NCT04932200||urgent-endoscopy group|the time interval from gastroenterologic consultation to the start of emergency endoscopy < 6 hours
89487319|NCT04932200||early-endoscopy group|the time interval from gastroenterologic consultation to the start of emergency endoscopy between 6 and 24 hours
89487320|NCT03237351|Active Comparator|Conventional therapy group|Patients in Conventional therapy group were received fluid therapy: intraoperative transfusion volume=maintenance fluids+deficit replacement+restoration of losses and with heart rate, mean arterial pressure, urine measurement ect.
89487321|NCT03237351|Experimental|Low value of PPV group|Patients in low value of PPV group were received fluid therapy according to PPV (3% ≤PPV < 5%) .
89487322|NCT03237351|Experimental|High value of PPV group|Patients in high value of PPV group were received fluid therapy according to PPV (5% ≤PPV < 8%) .
89487323|NCT03253029|Experimental|Treatment|(arm 1) consume five scoops total per day of Pure Encapsulations Branched Chain Amino Acid powder on an outpatient basis (take 2 scoops both in the morning and afternoon and 1 scoop in the evening)
89487324|NCT03253029|Placebo Comparator|Control|(arm 2): control group (no BCAAs provided)
89487325|NCT04921748||PD+FOG group|Patients affected by Parkinson's Disease with freezing of gait (PD+FOG group)
89487326|NCT04921748||PD-FOG group|Patients affected by Parkinson's Disease without freezing of gait (PD+FOG group)
89487327|NCT03253107||responder in palliative chemotherapy|After initial chemotherapy, responder (complete remission, partial remission)
89487328|NCT03253107||non-responder in palliative chemotherapy|After initial chemotherapy, disease progression
89487329|NCT03253107||responder in adjuvant chemotherapy|complete cure and no recurrence at least 1 year after treatment
89487330|NCT03253107||non-responder in adjuvant chemotherapy|non-complete cure or recurrence within 1 year after treatment
89487331|NCT03239847|Experimental|EndoPhys Sheath and Radial Arterial Line|This group of patients will have both the EndoPhys sheath and the radial arterial line placed during surgery.
89487332|NCT03239847|Experimental|EndoPhys Sheath|This group of patients will only receive the EndoPhys sheath during surgery.
89487333|NCT03252717|Experimental|blood sample|Pre-treatment blood samples will be collected: 8 samples
89487334|NCT03239925|Experimental|Experimental group|all participants in this group would hold a cell phone to their left ears in their left hands, in 'on' mode, for 15 min, and that they would thus be exposed to a 900-1800 MHz magnetic field (EMW) for 15 min.
89204027|NCT00767780||3|Patients suffering from ankle fractures and instability
89204028|NCT00767780||4|Patients suffering from hip osteoarthritis
89204029|NCT00767780||5|Patients who underwent total knee replacement or total hip replacement
89204030|NCT00767780||1|Patients suffering from bilateral knee osteoarthritis
89204031|NCT00767780||2|Patients suffering fron non specific low back pain
89487335|NCT03239925|Placebo Comparator|Control group|these would hold a cell phone to their left ears in their left hands for 15 min in 'off' mode
89487336|NCT04941014|Active Comparator|Light Physical Activity (LPA)|The guidelines from Rapid Assessment of Physical Activity (RAPA) participants were asked to perform Leisure Walk for 35 minutes
89487337|NCT04941014|Active Comparator|Moderate Physical Activity (MPA)|The guidelines from Rapid Assessment of Physical Activity (RAPA) participants were asked to perform Brisk Walk for 30 minutes
89487338|NCT04941014|Active Comparator|Vigorous Physical activity (VPA)|The guidelines from Rapid Assessment of Physical Activity (RAPA) participants were asked to perform jogging for 15 minutes
89487339|NCT03239769|Active Comparator|conventional access group (CA)|A 4- to 5-cm incision was created, subplatysmal flaps were raised, and the strap muscles were mobilized. Then, the superior pole of the thyroid gland was exposed and the gland was delivered through the surgical incision, and the thyroid isthmus was divided. Finally, CLND was performed. The strap muscles were re-approximated with No.1 silk suture. The full-thickness skin was closed with interrupted monofilament.
89487340|NCT03239769|Experimental|aesthetic principles access group (APA)|The key difference focused on the disposal incision using aesthetic principles, which are depicted below. The incision was protected by Vaseline ointment. Excessive skin traction was avoided to prevent the injury on the skin edge. Bleeding was stanched with a low-power bipolar coagulation device. The surgical field does not have to be pulled in every direction to show the full operation field. The cervical linea alba was closed by continuous sutures with 3-0 absorbable Vicryl sutures. Interrupted sutures of 4-0 Vicryl were used to re-approximate the subcutaneous tissues. The epidermis was fixed with 3M steri-strip elastic skin closures rather than skin sutures.
89487341|NCT03239769|Experimental|minimally invasive access group (MIA)|With the MIA approach, a shorter incision of between 3 and 4 cm was created. The procedure used the Harmonic scalpel as an auxiliary device. First, the isthmus was divided. Second, the lower pole of the thyroid was dissected from the adipose tissue, and the inferior thyroid vessels were divided close to the thyroid gland for mobilization. The RLN and parathyroid glands were carefully dissected. Third, the superior pole of the thyroid gland was disconnected. Finally, CLND was performed. The closure procedure for the incision was similar to that for APA.
89487342|NCT03236883|Experimental|GEM plus GPBSC|Gemcitabine chemotherapy with mobilized GPBSC infusion:Gemcitabine 1000mg/m2 +GPBSC(2-3)*10^8/kg
89487343|NCT03236883|Other|Gemcitabine|
89487344|NCT03236883|Other|GPBSC|
89487345|NCT03236961|Active Comparator|Intravenous & per oral antibiotics|Ertapenem 1 g x 1 for two days i.v. followed by p.o. levofloxacin 500 mg x 1 and metronidazole 500 mg x 3 for 5 days, duration of treatment one week.
89487346|NCT03236961|Active Comparator|Per oral antibiotics|Moxifloxacin 400 mg x 1 foe seven days, duration of treatment one week.
89487347|NCT03235323|Experimental|ECP group|Patients of ECP group are subjected to a standard ECP protocol one week postoperatively. A standard ECP protocol involves 35 one-hour sessions (once per day, 5 days a week) and continuous for 7 weeks. ECP consists of three sets of pneumatic cuffs attached to each of the patient's legs at the calf and lower and upper thigh. The inflation of the cuffs is triggered by a computer, and timing of the inflation is based on the R wave of the electrocardiogram. The ECP therapist adjusts the inflation and deflation timing to provide optimal blood movement per a finger plethysmogram waveform reading.
89204032|NCT00775736||A|
89487348|NCT03235323|No Intervention|Control group|Patients of Control group received routine medicine treatment postoperatively
88953122|NCT01958554|No Intervention|Wait list control group|The group was listed in wait list and were offered the same intervention and support on completion of study period.
88953123|NCT01958567|Experimental|Patients with clinical signs of scleritis or episcleritis|Optical Coherence Tomography for patients with scleral inflammation
88953124|NCT01958567|Experimental|Normal subjects with normal sclera|Optical Coherence Tomography on eyes with normal scleral
88953125|NCT01958580|Experimental|Treatment (gemcitabine, docetaxel, brachytherapy/IMRT, EBRT)|"CHEMOTHERAPY: Patients receive gemcitabine hydrochloride IV over 90 minutes on days 1 and 8 and docetaxel IV over 1 hour on day 8. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.~RADIATION THERAPY: Beginning week 10, patients undergo 3 fractions of brachytherapy or IMRT over 3 weeks. Patients then undergo EBRT QD 5 days a week for 5 weeks."
89487349|NCT04921592|Experimental|transcutaneous stimulation|"transcutaneous stimulation 60 sessions~Transcutaneous stimulation 40sessions~Transcutaneous stimulation 20 sessions"
89487350|NCT03239301|Active Comparator|Conventional Rehabilitation|Conventional rehabilitation program consisted range of motion (ROM) exercises, balance and coordination training, progressive resistive exercises, posture training, gait training, and occupational therapy as much as the patients tolerated. Conventional rehabilitation was tailored to the patient considering his requires and expectancies.
89487351|NCT03239301|Active Comparator|Robotic Rehabilitation + Conventional Rehab|The Armeo Spring HocomAG Inc. (Volketswil, Switzerland) device was used in robot assisted upper limb rehabilitation program. A
89487352|NCT04932044|Experimental|Early Sleep Facilitation Program|Perform sleep circadian rhythm training during hospitalization, and provide caregivers with nursing guidance to promote sleep of premature infants before discharge
89487353|NCT04932044|Active Comparator|routine care and provide general discharge care and nursing guidance|Routine care and provide general discharge care and nursing guidance.
89487354|NCT05234619|Active Comparator|Group one ( lidocaine or control LE ) Early deflation|Patients in group one (lidocaine or control group LE = 20): will receive 2% lidocaine 3mg/kg (maximum 200 mg) then distal tourniquet deflation occurs after 20 minutes.
89487355|NCT05234619|Active Comparator|Group two ( lidocaine , ketorolac LKE) Early deflation|Patients in group two (lidocaine ketorolac LKE = 20): will receive 2% lidocaine 3mg/kg (maximum 200 mg) plus ketorolac 0.5mg/kg (maximum 30mg) then distal tourniquet deflation occurs after 20 minutes.
89487356|NCT05234619|Active Comparator|Group three ( lidocaine Or control LL ) Late deflation|Patients in group three (lidocaine or control group LL = 20): will receive 2% lidocaine 3mg/kg (maximum 200 mg) then distal tourniquet deflation occurs after 40 minutes.
89487357|NCT05234619|Active Comparator|Group four ( lidocaine , ketorolac LKL ) Late deflation|Patients in group four (lidocaine ketorolac LKL = 20): will receive 2% lidocaine 3mg/kg (maximum 200 mg) plus ketorolac 0.5mg/kg (maximum 30mg) then distal tourniquet deflation occurs after 40 minutes.
89487358|NCT04921904|Experimental|Abemaciclib plus Ramucirumab|Abemaciclib 150mg dose administered orally twice daily every day plus Ramucirumab dose 8mg/kg iv every 2 weeks until evidence of disease
89487359|NCT03234933|Experimental|Mobility Tracker|"Each patient will be provided by the research team staff with a new mobility tracker~The standard pre-operative assessment, surgical procedure and post-operative care will still be done~Measurements of each patient (steps, distance and calories) will be obtained by the research staff"
89487360|NCT03229395||patients with Cushing's syndrome|Patients were selected by the PI at the diagnosis.
89487361|NCT03229395||control patients|Selected patients are matched for age and sex.
89487362|NCT02622386|Experimental|Riboflavin then Placebo|Riboflavin (Vitamin B2) 400 mg oral capsule taken once daily for 12 weeks, followed by 4 week washout period before crossover. At crossover, patients will no longer receive Riboflavin but matching placebo capsule for additional 12 weeks.
89487363|NCT02622386|Placebo Comparator|Placebo then Riboflavin|Placebo oral capsule taken once daily for 12 weeks, followed by 4 week washout period before crossover. At crossover, patients will no longer receive placebo but 400 mg Riboflavin (Vitamin B2) capsule for additional 12 weeks.
89487364|NCT02453451|Experimental|2D-/3D-TTE; 3D-TEE, Walking Test|6 months after the MitraClip procedure
89487365|NCT03120195|Experimental|EndoRotor® ablation|Prospective pilot study, to be performed in 30 patients with Barrett's esophagus that have an indication for ablation treatment. Barrett's ablation will be performed using the EndoRotor®.
89487366|NCT04430114|Experimental|TAAA spinal loop graft|
89487367|NCT04427618|Experimental|Intervention group|Intravenous 1g TXA (500mg/5ml, given intermittent over approximately 10 minutes) given within approximately 10 minutes before skin incision, and Intravenous oxytocin 5 units post delivery of the baby.
89487368|NCT04427618|Placebo Comparator|Control group|Intravenous 10ml normal saline (placebo) given within approximately 10 minutes before skin incision, and intravenous oxytocin 5 units post delivery of the baby
89487369|NCT03236727|No Intervention|Control|Data of SSEPs (amplitude and latency) before dexmedetomidine infusion.
89487370|NCT03236727|Active Comparator|Dexmedetomidine|Data of SSEPs (amplitude and latency) after dexmedetomidine infusion.
88953126|NCT01958632||N|nerve suture
88953127|NCT01958632||NT|nerve transplantation
88953128|NCT01958632||VM|vein-in-muscle conduit
88953129|NCT01958684||Group 1|The MIRENA intrauterine delivery system (initial release rate: 20 μg LNG /24 h)
88953130|NCT01958684||Group 2|Copper IUDs with different shape and with or without drugs
88953131|NCT01958697||AG-BMI < 10 pct|Patients who's peroperative BMI is less than the 10th centile
88953132|NCT01958697||AG-BMI >= 10th pct|Patients who's peroperative BMI equals or is greater than the 10th centile
88953133|NCT01958710||Embolisation|(preoperative) embolisation of the bronchial circulation
88953134|NCT01958710||Surgery|Any surgically treated patient with a functional lung resection (at least wedge resection)
88953135|NCT01958723||Hospitalists|Introduction of Problem Specific Templates
88953136|NCT01958736|Experimental|Experimental|Ballistic Strength Training
88953137|NCT01958736|Active Comparator|Control|Usual care Physiotherapy
88953138|NCT01958749|No Intervention|Fat graft without Platelet Rich Plasma|"Step 1. Under Local Anaesthetic (or General Anaesthetic if the patient is unable to tolerate this), a fat graft is taken from just behind the mastoid process, or more posteriorly just beneath the hairline if necessary. The graft is kept moist in 0.9% saline.The ear canal is injected with local anaesthetic and the edges of the perforation are freshened. Gelfoam is placed into the middle ear and the fat graft placed on top of this until it touches the underside of the TM and slightly bulges through. In an attempt to achieve standardisation of surgical technique between sites, surgeons will be provided with an operative video to watch beforehand.~Step 2. The fat graft will simply be covered with a piece of saline-soaked Gelfoam cut to completely cover the perforation and graft."
89487371|NCT03229161|Experimental|IWT-group|The IWT-group follows the standardized GDM care program for GDM patients at OUH and is prescribed to a 6-week non-supervised IWT-program consisting of 3 IWT sessions per week of 40-50 minutes each.
89487372|NCT03229161|No Intervention|Con-group|The con-group follows the standardized GDM care program for GDM patients at OUH
89487373|NCT04921202||without metabolic syndrome and BMI<24|100 volunteers aged between 35-70 years old with body mass index(BMI)<24 without Metabolic syndrome
89487374|NCT04921202||Metabolic Syndrome with BMI>27|80 Metabolic syndrome patients with BMI>27 were included in the study
89487375|NCT03236493|Experimental|PF-06700841|Multiple ascending doses of PF-06700841
89487376|NCT03236493|Placebo Comparator|Placebo|Multiple ascending doses of Placebo
89487377|NCT04921280||Treatment group|Patients who have received treatment for severe health anxiety at the Internet Psychiatry Clinic, Psychiatry Southwest, Karolinska University Hospital Huddinge between April 2018 to April 2021.
89487378|NCT03234855||LMD|Physician uses LMD during procedure.
89487379|NCT04931966|Active Comparator|Group A|Adductor canal block
89487380|NCT04931966|Active Comparator|Group B|Adductor canal block plus IPACK
89487381|NCT04931966|Active Comparator|Group C|Adductor canal block plus PAI
89487382|NCT03229005|Active Comparator|A1 thick-high|group with thick tissue and high prosthetic abutment tissue measurement implant insertion operculectomy prosthetic rehabilitation
89487383|NCT03229005|Experimental|A2 thick-low|group with thick tissue and low prosthetic abutment tissue measurement implant insertion operculectomy prosthetic rehabilitation
89487384|NCT03229005|Active Comparator|B1 thin-high|group with thin tissue and high prosthetic abutment tissue measurement implant insertion operculectomy prosthetic rehabilitation
89487385|NCT03229005|Experimental|B2 thin-low|group with thin tissue and low prosthetic abutment tissue measurement implant insertion operculectomy prosthetic rehabilitation
89487386|NCT04931186||all patients|
89487387|NCT03234777|Experimental|Whiteboard animation video|3 minute video on treatment, management of pediatric acute gastroenteritis
89487388|NCT03234777|Sham Comparator|Regular video|3 minute video on hand washing for infection control
89487389|NCT04921124|Experimental|Treatment|"Teriparatide, 20 µg Subcutaneous (S/C) per day.~Two doses in total."
89487390|NCT04921046|Active Comparator|Group Lignocaine|Group of 112 patients ASA-I and II (American Society of Anesthesiology)ages from 25-44 undergoing elective surgical procedure.
89487391|NCT04921046|Active Comparator|Group Midazolam|Group of 112 patients ASA-I and II ages from 25-44 undergoing elective surgical procedure.
89487392|NCT03229239|Experimental|corneal stroma implantation|implant the corneal stroma to the diseased cornea of keratoconus patients
89487393|NCT03234543|Experimental|Remote Ischemic Conditioning|The RIC intervention consists of 5 minutes of inflation of a pneumatic tourniquet placed mid-thigh followed by 5 minutes of deflation, repeated for 3 cycles. The pressure used will be 250 mmHg for the pre-operative intervention. Subsequent tourniquet pressures will be 50 mmHg above the patient's systolic blood pressure.
89487394|NCT03234543|Sham Comparator|No Remote Ischemic Conditioning|The No RIC group will receive a sham intervention at all the same time points. The thigh tourniquet will be inflated to only 20 mmHg (to mask the intervention from the subject).
89487395|NCT04940702|Experimental|Focal Vibration Group|"Training with Focal Vibration on rectus anterior, vastus medialis and vastus lateralis muscles with an intensity of 120 Hz and an amplitude of 1.2 mm. Time of training 20-25 min.~the training is the same as the contol group with the difference of FV addiction."
89487396|NCT04940702|Active Comparator|Blood Flow Restriction Group|"Training with Blood Flow Restriction a pressure cuff occludes in the proximal part of the lower limb. Time of training 20-25 min.~the training is the same as the contol group with the difference of BFR addiction."
89487397|NCT04940702|Active Comparator|Training Group|"Traditional training. 3 times a week~Warm-up:~Main work:~Aerobic training~Strength training~Balance and coordination training~Return to calm"
89487398|NCT02792231|Experimental|OMG 20 mg|"Ofatumumab 20 mg pre-filled syringes for subcutaneous injectionon on days 1~,7 ,14, week 4 and every 4 weeks thereafter and a teriflunomide-matching placebo, taken orally once daily"
89487399|NCT02792231|Active Comparator|TER 14 mg|Teriflunomide 14 mg oral capsule taken once daily and matching placebo for subcutaneous injections to ofatumumab on days 1, 7, 14, week 4 and every 4 weeks thereafter
89487400|NCT03234621|Experimental|conventional tidal group|provide tidal volume of 6ml/kg (predicted body weight) with positive end expiratory pressure of 5cmH2O during one-lung ventilation
89487401|NCT03234621|Experimental|low tidal group|provide tidal volume of 4ml/kg (predicted body weight) with positive end expiratory pressure of 5cmH2O during one-lung ventilation
89487402|NCT03234621|Experimental|high tidal group|provide tidal volume of 8ml/kg (predicted body weight) with positive end expiratory pressure of 5cmH2O during one-lung ventilation
89487403|NCT03236571|Experimental|Rehabilitation Program|It will consist of 2 sessions of 40 minutes per week, for 12 weeks on ergometric bicycle. Each session of 40 min will include 5 minutes of warm-up, 5 minutes of recovery and 6 sequences of 5 min. Each 5-minute sequence will alternate between 4 minutes of pedaling at a load corresponding to the 1st ventilatory threshold (determined in the initial maximum cardiorespiratory effort test) and 1 minute of pedaling at a load corresponding to 2nd ventilatory threshold (determined in the initial maximum cardiopulmonary stress test).
89487404|NCT04920968|Experimental|Obinutuzumab|Patients in reference arm (Arm A) will receive rituximab. Patients in experimental arm (Arm B) will receive obinutuzumab instead of rituximab in the same time-points.
89537856|NCT04979715|Active Comparator|control group (Group 2)|The patients in the control group will be informed about the postoperative physiotherapy program and patient education will be provided by the physiotherapist before the operation. Within the knowledge and approval of the surgeon performing the operation, preoperatively, respiratory control, diaphragmatic breathing, relaxation exercises, passive-active assistive-active range of motion exercises are shown by the physiotherapist, and patient education is provided with information about possible postoperative complications and what needs to be considered. will be given.
89537857|NCT04979715|No Intervention|routine follow-up (Group 3)|only preoperative patient information is given.
89537858|NCT03289793|Experimental|Group A|"Children will be assigned to this group in a random fashion according to a ratio 2:1 with respect to group B (see below).~20 subjects will be included in this group."
89537859|NCT03289793|Active Comparator|Group B|Children will be assigned in this group in a random fashion. 10 subjects will be included in this group.
89537860|NCT03289793|Active Comparator|Group C|"Will be included in this group children who meet the inclusion criteria and who, with their families, are motivated to participate in the study but cannot claim to be part of groups A or B (because of logistical constraints: living too far away to comply with the frequency of the visits required by the training).~Group C allows to follow the natural evolution of children with ADHD with no intervention."
89537861|NCT04972851|Experimental|UNITED|UNITED is premised on the idea that successful implementation in organizations like schools and early intervention systems requires a team-based approach, in which the team is thoughtfully assembled, develops a plan for implementation, assigns roles and responsibilities, and carefully tracks and supports implementation and sustainment in all its stages within a few meetings and ongoing coaching from the research staff.
89537862|NCT04972851|Active Comparator|Implementation as Usual (IAU)|The organizations will implement SDLMI as usual. The research team will be available to provide support on the SDLMI intervention as needed.
89537863|NCT02460809|Active Comparator|In-lab tDCS|Three people with chronic stroke will participate in finger tracking training while receiving transcranial direct current stimulation (tDCS) in a controlled laboratory environment with an investigator.
89537864|NCT02460809|Experimental|In-home tDCS|Three people with chronic stroke will participate in finger tracking training while receiving transcranial direct current stimulation (tDCS) in their own home. Patients will be taught how to use a blue-tooth enabled telerehabilitation module that is being controlled by an investigator in the lab on the University campus. For safety, an investigator will be in the home with each patient during tDCS use and finger tracking training but will only be supervising procedures.
89537865|NCT04972539|Experimental|Sequence A|Period 1: AJU-A51R1 tablet(Dapagliflozin) and AJU-A51R2 tablet(Linagliptin), single dose Period 2: AJU-A51(FDC tablet, Linagliptin/Dapagliflozin), single dose
89204033|NCT00942669|Experimental|SleepStrip OTC(TM)|Participants will receive the SleepStrip OTC(TM) for a night (or two) test at home, before or after undergoing an independent PSG test at the Sleep lab. The reading of both methods will be analyzed.
89204034|NCT01058629|Experimental|SynergEyes A2 Hybrid Contact Lens|
89537866|NCT04972539|Experimental|Sequence B|Period 1: AJU-A51(FDC tablet, Linagliptin/Dapagliflozin), single dose Period 2: AJU-A51R1 tablet(Dapagliflozin) and AJU-A51R2 tablet(Linagliptin), single dose
89537867|NCT03289715|Experimental|arm 1|on demand humidification
88953139|NCT01958749|Experimental|Fat graft with Platelet Rich Plasma|"Procedure as for as for Fat graft without PRP, but at Step 2 the Gelfoam will instead be soaked in PRP derived from the patient's own whole blood. The generation of PRP is descibed below: -~10-20 mL of autologous blood collected from an antecubital vein is placed in an adenosine citrate dextrose-acid (ACD-A) collection tube to prevent premature activation~Blood immediately placed in the centrifuge at 1100g for 10 minutes (once)~Supernatant removed and collected into syringe~Injected onto surface of fat graft~Rest added to piece of gelfoam~Place gelfoam + PRP on the TM perforation"
88953140|NCT01958775|Experimental|GLP=2|active treatment with a single dose of GLP-2 (1500mcg)
88953141|NCT01958775|Placebo Comparator|Placebo|placebo
88953142|NCT01958801|Active Comparator|Interscalene block|Interscalene block is performed under ultrasound guidance. Linear probe is placed on the ipsilateral interscalene groove visualizing the brachial plexus located between anterior and middle scalene muscles. Using in-plane technique, nerve stimulation needle is advanced into the brachial plexus sheath, into which 25 ml of 1.5% mepivacaine is injected.
89204035|NCT00537238|Active Comparator|B|
89204036|NCT00537238|Active Comparator|A|
89204037|NCT00772226|Active Comparator|music|
89204038|NCT00772226|Placebo Comparator|Pillow without music|
89204039|NCT00946413|Experimental|CBT plus parent education|
89204040|NCT00946413|Experimental|CBT alone|
89204041|NCT03982771|Experimental|BCD regimen|Bortezomib, cyclophosphamide and dexamethasone (the BCD regimen) would be utilized in newly diagnosed iMCD (idiopathic Multicentric Castleman's disease) patients
89204042|NCT00775814|Experimental|Candesartan + Hydrochlorothiazide QD|
89487405|NCT04920968|Active Comparator|Rituximab|Patients in reference arm (Arm A) will receive rituximab. Patients in experimental arm (Arm B) will receive obinutuzumab instead of rituximab in the same time-points.
89487406|NCT00700401||Peginterferon Alfa-2a + Ribavirin|
89487407|NCT04931108|Experimental|Sequence 1|One pill of nitrendipine/atenolol combination (5/10mg) once daily for 6 weeks first, and followed by monotherapy for another 6 weeks, when patients will evenly assigned to one pill of nitrendipine (10mg) or one pill of atenolol (25mg) once daily.
89204043|NCT00775814|Active Comparator|Hydrochlorothiazide QD|
89487408|NCT04931108|Experimental|Sequence 2|Monotherapy for 6 weeks first, when patients will evenly assigned to one pill of nitrendipine (10mg) or one pill of atenolol (25mg) once daily, followed by one pill of nitrendipine/atenolol combination (5/10mg) once daily for another 6 weeks.
89487409|NCT03228927||twin A|Sampling of the facial and fecal microbiome
89487410|NCT03228927||twin B|Sampling of the facial and fecal microbiome
89487411|NCT02084459|No Intervention|Control|Standard of care
89487412|NCT02084459|Experimental|Autonomy-supportive counselling (GSD)|GSD, an educational method, comprising 32 semi-structured reflection sheets inviting the patients in groups of 4 through 8 sessions of 150 minutes' duration to reflect on the patient's own situation and to be active in co-operation with the nurses.
89487413|NCT02453217|Experimental|Chinese CHIP|Chinese Health Improvement Profile (CHIP) screening and intervention
89487414|NCT02453217|No Intervention|Treatment as usual|Routine community mental health care and medical outpatient appointments
89487415|NCT02084537|Active Comparator|Endoscopic treatment|Treated by single or multiple transmural cystogastrostomy tracts, 15mm balloon dilation, two 7 French (Fr) double pigtail plastic stents or lumen-apposing metal stents and nasocystic drainage catheter, with or without endoscopic necrosectomy as needed.
88953143|NCT01958801|Experimental|Supraclavicular block|Supraclavicular block is performed under ultrasound guidance. Linear probe is placed on the ipsilateral supraclavicular fossa visualizing the brachial plexus located lateral to the subclavian artery. Using in-plane technique, nerve stimulation needle is advanced into the brachial plexus sheath, into which 25 ml of 1.5% mepivacaine is injected.
88953144|NCT01958814|Experimental|Salbutamol - Placebo|salbutamol at M0 and M60 placebo administration
88953145|NCT01958814|Experimental|Placebo - Salbutamol|placebo at M0 and M60 salbutamol administration
88953146|NCT01958866|Active Comparator|Acetaminophen|Acetaminophen administer 1000 mg every 4-6 hours when fever is presented
89204044|NCT03966885|Experimental|Brief Intervention (BI)|30 minute alcohol brief intervention delivered by lay provider during HIV clinic visit.
89487416|NCT02084537|Active Comparator|Minimally invasive surgical necrosectomy|Video-assisted retroperitoneal debridement (VARD) or laparoscopic approach. This includes laparoscopic cystogastrostomy with internal debridement.
89487417|NCT04920500|Experimental|Daunorubicin Cytarabine liposome for injection|Induction 1: Daunorubicin Cytarabine liposome for injection [100 U/m²] i.v. (120 min±10min) d1,3,5 Induction 2: Daunorubicin Cytarabine liposome for injection [100 U/m²] i.v. (120 min±10min) d1,3 Consolidation therapy: Daunorubicin Cytarabine liposome for injection [65 U/m²] i.v. (>90 min) d1,3
89487418|NCT04920500|Active Comparator|Vyxeos + Daunorubicin Cytarabine liposome for injection|Induction 1: Vyxeos[100 U/m²] i.v. (120 min) d1; Daunorubicin Cytarabine liposome for injection [100 U/m²] i.v. (120 min±10min) d3,5 Induction 2: Daunorubicin Cytarabine liposome for injection [100 U/m²] i.v. (120 min±10min) d1,3 Consolidation therapy: Daunorubicin Cytarabine liposome for injection [65 U/m²] i.v. (>90 min) d1,3
88953147|NCT01958866|Experimental|Tinospora Crispa-extract Product|Tinospora Crispa-extract tablet administer 500 mg every 4-6 hours when fever is presented
88953148|NCT01958866|Placebo Comparator|Placebo|Placebo 2 tablets will be administered every 4 hours when fever is presented
88953149|NCT01958879|Experimental|ringer with corticosteroid|Intra-articular irrigation was performed under local anesthesia with subcutaneous injection of 1%lidocaine solution (0.6 to 0.9 mL anaesthetic solution )was injected to block the auriculotemporal nerve. Then the skin on the TMJ was penetrated with a 21-gauge needle at the articular fossa followed by the injection of 3 mL Ringer solution to distend the joint space, pumping it in and out repeatedly. Another 21-gauge needle was inserted into the distended compartment in the area of the articular eminence, and the superior joint space was irrigated with 200 mL Ringer solution, allowing a free flow through the first needle in the both groups .In this group patients received 1mg dexamethasone after finishing the irrigation .
89021737|NCT04715789|Experimental|physical therapy intervention|"core stability exercises:~Multifidus exercises~Frontal & Side Plank exercise~Pelvic floor exercises~abdominal exercises~Strengthening exercises~Bridging~straight leg raise~gluteus medius strength~gluteus maximus strengthening for about 20 min to 30 min to strength back and proximal hip control muscles"
89204045|NCT03966885|Experimental|Brief Intervention + CETA|30 minute alcohol brief intervention delivered by lay provider during clinic visit followed by 6-12 weekly sessions of CETA.
89204046|NCT04048148|Other|Novel myopia control lenses|This group will be randomized to wear test lenses for 6 months followed by control lenses for 6 months and then test lenses for another 6 months
89204047|NCT04048148|Other|Single vision lenses|This group will be randomized to wear control lenses for 6 months followed by test lenses for 12 months
89204048|NCT00772460|Active Comparator|Forced Air|Warming with forced air (BairHugger)
89204049|NCT00772460|Experimental|Conductive Warming|Warming with the conductive device (HotDog)
89487419|NCT02453295|Experimental|Intervention Group|The IG will meet weekly for 2 hours for 8 weeks. All workshops will be recorded and transcribed, then analyzed qualitatively. Administration of questionnaires (Meaning of Illness, MIQ; Herth Hope Index, HHI; Short Form 12, SF-12; Lymphedema Quality of Life, LYMQOL) will take place over the phone. The questionnaires will be administered 3 days prior to workshop 1 (T0), between workshop 4 and 5 (T1), and 3 days following the completion of the intervention (T2). The questionnaires will also be administered at 4 weeks post-intervention (T3) and 8 weeks (T4) post-intervention. All participants will also complete a demographic questionnaire at T0, developed in S2.
89487420|NCT02453295|No Intervention|Comparison Group|The CG will receive LE treatment as usual, without the hope intervention. They will be administered the same questionnaires (by phone) as the IG at the same timepoints. Potential participants (n=46) will be screened based MIQ. The individuals scoring in the top ~30% (n=16) will be excluded from the study. The remaining 30 individuals scoring the lowest level of hope will be admitted into the study.
89487421|NCT02084615|Experimental|81mg aspirin|This arm will include perioperative 81 mg of aspirin.
89487422|NCT02084615|Experimental|325mg aspirin|Subjects will be taking 325mg of aspirin.
89487423|NCT02453139|Experimental|Exercise group|6 month supervised and home based moderate intensity aerobic exercise programme
89487424|NCT02453139|No Intervention|Control|Non-exercising control group receiving usual care
89487425|NCT04939688|Experimental|Patients requiring a CT scan in the search for cranial lesions following head trauma|All patients will undergo both conventional dose AND ultra low-dose CT scans in the search for cranial lesions following head trauma.
89487426|NCT02084693||COMPREHENSIVE|Evaluate Survivorship for the Biomet® Comprehensive® Reverse Shoulder Mini Baseplate.
89487427|NCT03236337|No Intervention|Control|No intervention
89487428|NCT03236337|Experimental|MOVI intervention|- MOVI-da Fit! is a high intensity interval training intervention that consists on: a) 4 h/week of a standardized recreative, non-competitive physical activity extracurricular program; and b) informative sessions to parents and teachers about how schoolchildren can became more active. It is aimed to enhance physical fitness, motor skills, physical activity time and active behaviours among 9-to-11 years old children.
89487429|NCT04931030|Experimental|Low carbohydrate diet (LCBD)|Subjects are given a dietary prescription of 20g of carbohydrate daily in addition to standard low protein diet of 0.6-0.7g/kg/day and low salt diet.
89487430|NCT04931030|No Intervention|Low protein diet only (LPD)|Subjects are given the standard dietary advice of chronic kidney disease of low protein diet of 0.6-0.7g/kg/day and low salt diet.
89487431|NCT02084771|Experimental|Oral Salt and Water|"Oral Salt and Water Loading:~Participants randomized to this arm of the trial will receive 0.1 g/kg of salt (NaCl) and 12 mL/kg of water. Patients weighing more than 110 kg will receive the same amount as per a 110 kg patient. One third of the oral salt and water will be given before the CT and 2/3 post-CT as in the intravenous saline arm. Specifically, 0.03 g/kg of NaCl and 4 mL/kg of water in the one hour before CT and 0.07 g/kg of NaCl and 8 mL/kg of water taken over 2 hours post-CT. The ingestion of the oral salt and water will be directly observed by the study nurse to ensure adherence to the protocol."
89487432|NCT02084771|Active Comparator|Intravenous Saline|Patients randomized to this arm will receive intravenous isotonic (0.9%) saline. The rate of isotonic saline will be 3 mL/kg give in the one hour before CT and 1 mL/kg/hour for 6 hours post-CT as per Canadian guidelines. Patients weighing more than 110 kg will receive the rate as per a 110 kg patient. The dose will be rounded up to the nearest 5 mL.
89487433|NCT02084849||Group 1|Group 1 will consist of 300 ADPKD individuals who are early in the course of their disease and demonstrate risk factors for progression to ESRD.
89487434|NCT02084849||Group 2|Group 2 will consist of ADPKD subjects who have progressed to a more advanced stage of their renal disease. There is no limit with regard to the number of subjects to be recruited into this group.
89487435|NCT03236415|Active Comparator|Xience Drug Eluting Stent|Patients with diabetes mellitus will be randomized to receive either a Xience drug eluting stent or an ABSORB bioresorbable vascular scaffold for treatment of obstructive coronary artery disease
89487436|NCT03236415|Active Comparator|ABSORB Bioresorbable Vascular Scaffold|Patients with diabetes mellitus will be randomized to receive either a Xience drug eluting stent or an ABSORB bioresorbable vascular scaffold for treatment of obstructive coronary artery diseasee
89487437|NCT03559751|Experimental|VLN Cigarettes (A)|Subjects will smoke VLN cigarettes
89487438|NCT03559751|Experimental|Usual Brand Cigarettes (B)|Subjects will smoke their usual brand cigarettes
89487439|NCT03559751|Experimental|Nicotine Gum (C)|Subjects will chew nicotine gum
89487440|NCT03234699|Experimental|Single Group|
89487441|NCT02621606|Experimental|Part 1, Healthy Participants|Healthy participants receive a single intravenous (IV) dose of ~370 megabecquerel (MBq) [11C]MK-6884 in Part 1 of the study.
89487442|NCT02621606|Experimental|Part 2, Healthy Elderly Participants|Healthy elderly participants receive two separate IV doses of ~370 MBq [11C]MK-6884 in Part 2 of the study. Administration of the two doses is separated by at least 3 hours.
89487443|NCT02621606|Experimental|Part 3, Participants with AD|Participants with AD receive a single IV dose of ~370 MBq [11C]MK-6884 in Part 3 of the study.
89487444|NCT02079155|Active Comparator|Arm I (RALP)|Patients undergo standard RALP.
89487445|NCT02079155|Experimental|Arm II (R-LESS RP)|Patients undergo R-LESS RP.
89487446|NCT03228771|Active Comparator|PRGF/ATV|"Group I (PRGF/ATV) : It was included 10 patients undergoing single tooth extraction followed by socket fill with 1.2% Atorvastatin loaded in PRGF derived fibrin scaffold then suturing the socket. All patients will receive implants after taking the bone biopsy after 8 weeks for histomorphometric analysis.~Intervention: Atorvastatin drug loaded in platelets rich in growth factors (PRGF)."
89487447|NCT03228771|Active Comparator|ATV gel|Group II (ATV gel) : Will include 10 patients undergoing single tooth extraction followed by socket fill with 1.2% Atorvastatin in methyl cellulose gel then suturing the socket. All patients will receive implants after taking the bone biopsy after 8 weeks for histomorphometric analysis.
89487448|NCT03228771|No Intervention|Empty socket|Group III Empty socket( control) : Will include 10 patients undergoing single tooth extraction then suturing the socket. All patients will receive implants after taking the bone biopsy after 8 weeks for histomorphometric analysis.
89487449|NCT02079233|Experimental|CLP 15 g QD|Cross-Linked Polyelectrolyte (CLP) study medication delivered immediately before bedtime
89487450|NCT02079233|Experimental|CLP 7.5 g BID|Cross-Linked Polyelectrolyte (CLP) Study medication delivered b.i.d. one hour before breakfast and dinner
89487451|NCT02079233|Experimental|CLP 5 g TID|Cross-Linked Polyelectrolyte (CLP) Study medication delivered t.i.d. one hour before breakfast, lunch and dinner
89487452|NCT02079233|Experimental|CLP 3.75 g QID|Cross-Linked Polyelectrolyte (CLP) Study medication delivered q.i.d on hour before breakfast, lunch, dinner and immediately before bedtime
89487453|NCT03234231|No Intervention|Control Group|This group receive nothing during the study period.
89487454|NCT03234231|Experimental|Intervention Group|A 3-month supervised tooth brushing programme will be provided to the students. An oral health education talk with written material delivered to the carers and the students
89487455|NCT02079389|Active Comparator|Lap+Lus|"The included patients randomly assigned either to the department's standard laparoscopic (Lap) surgery or standard laparoscopic surgery (lap) plus a LUS examination.~In the intervention arm the intra-abdominal conditions are also assessed by laparoscopy, but then supplemented with a LUS examination of the primary tumor, liver and retroperitoneum.~All the included patients are getting a CT scan of the abdomen after 3 months."
89487456|NCT02079389|No Intervention|laparoscopic examination (Lap)|"The included patients randomly assigned either to the department's standard laparoscopic (Lap) surgery or standard laparoscopic surgery (lap) plus a LUS examination.~In the standard arm (Lap) the conditions at the abdomen is only assessed by laparoscopy immediately prior to the resection.~All the included patients are getting a CT scan of the abdomen after 3 months."
89487457|NCT03228615|Experimental|Shared Decision Making Intervention|
89487458|NCT03228615|No Intervention|Usual Care Group|
89487459|NCT02452593|Active Comparator|"Tibial Nerve Stimulation"|"This group will do transcutaneous electrical stimulation of the tibial nerve at home.~Development of an innovative portable equipment, with domestic technology for home application of the posterior tibial nerve stimulation technique using the type SSP surface electrodes (Silver Spike Point). Frequency: 20 Hz, Pulse width: 200 us; duration: 15min daily"
89487460|NCT02452593|Active Comparator|"Pelvic Floor Exercises"|This group will make pelvic muscle training 3 times a day . In decubit dorsal posture, legs flexed and abductee. Perform pelvic floor contractions keeping 2 seconds and relaxing 4 seconds for 10 times, and contractions keeping 4 seconds and relaxing 8 seconds for 10 times.
89487461|NCT02079467|Active Comparator|Standard rehabilitation|"Patients randomized to the control group will be managed with hip precautions immediately following surgery. They will weight bear on the operative joint as tolerated after surgery. They will be managed as per usual protocol post total hip arthroplasty. They will be transferred from the operative table with an abduction pillow between their legs and will be asked to keep this pillow between their legs while resting in bed and during sleep throughout their course in hospital. During physiotherapy treatments they will not flex the operative hip beyond 90 degrees, internally or externally rotate the operative hip more than 45 degrees, or actively adduct the operative hip past neutral."
89487462|NCT02079467|Experimental|Unrestricted rehabilitation|Patients randomized to the treatment group will have no restrictions in their post-operative rehabilitation. They will weight bear on the operative joint as tolerated after surgery. They will be asked to participate in activity as their level of comfort permits and will have no positional restrictions while in bed or completing activities of daily living.
89487463|NCT04431362|No Intervention|Baseline|Participants will not listen to music for 5 to 15 days based on the baseline duration they were assigned.
89487464|NCT04431362|Experimental|Intervention|Participants will listen to music for 3 weeks.
89487465|NCT03228147|Experimental|Supportive Care (nutrition supplement)|Patients receive 10 different nutrition supplements PO and complete questionnaires based on each sample in a single session over 60-90 minutes.
89487466|NCT02081339||Macular diseases|ranibizumab, intravitreal injections, 0.5mg, monthly or less aflibercept,intravitreal injections, 2.0mg, monthly or less pegaptanib, intravitreal injections, 0.3mg, every 6-week pars plana vitrectomy, once verteporphin, iv, 6mg/㎡
89487467|NCT04939766|Other|Type 1 diabetic patients under CSII eligible for closed loop use|Diabetic patients age 13 or above under CSII with continuous glucose monitoring matching eligibility criteria for the use of a closed loop during a 6 months period. During the study, 4 physical appointments with a diabetologist and 3 phone contacts are anticipated.
89487468|NCT03228849|Active Comparator|Conservative Treatment|Patients were treated with 6 weeks with splinting and were then started on physical therapy for 2 weeks.
88953150|NCT01958879|Placebo Comparator|Ringer with out corticosteroid|Intra-articular irrigation was performed under local anesthesia with subcutaneous injection of 1%lidocaine solution (0.6 to 0.9 mL anaesthetic solution )was injected to block the auriculotemporal nerve. Then the skin on the TMJ was penetrated with a 21-gauge needle at the articular fossa followed by the injection of 3 mL Ringer solution to distend the joint space, pumping it in and out repeatedly. Another 21-gauge needle was inserted into the distended compartment in the area of the articular eminence, and the superior joint space was irrigated with 200 mL Ringer solution, allowing a free flow through the first needle in the both groups
88953151|NCT01958892||TURP|
89204050|NCT03965403|Experimental|Arm motor function retraining with BURT|All participants will receive 1 hour sessions, 2-3x/week for 6 weeks (total 18 sessions). Sessions will be organized with 30 minutes of robotic-assisted training and 30 minutes of hands-on training with a research therapist to work on the baseline goals of the subject. Hands-on training will be done with routinely employed techniques in therapy to transfer the skills gained with the robotic device in everyday life activities.
89204051|NCT00942747|Experimental|Temsirolimus|Weekly IV temsirolimus
89204052|NCT00776048||ABI|Acquired brain injury with lower limb spasticity
89204053|NCT00776048||Healthy Controls|Age matched healthy controls
89204054|NCT03863470|No Intervention|Pre-Intervention (Control)|There is no trial-driven approach to care. All hospitals contribute a minimum of 12 weeks of outcomes data prior to adopting the intervention. Pre-specified outcomes data will be electronically extracted for patients meeting eligibility criteria but there will be no attempt to influence delivery of usual care within the ICU. The length of the control phase will differ for each ICU cluster, depending on the sequence in which ICU-clusters are assigned to switch to the intervention phase.
89204055|NCT03863470|Active Comparator|Early mobilization intervention|The clinical team will set a standardized mobility goal for each patient during morning rounds and display the goal on the patient's door. A facilitator will be established in the ICU to communicate mobility goals and activities across clinical personnel shifts. Patient mobility scores will be displayed to clinical and administrative staff in the ICU via the ICU board.
89204056|NCT00946491|Experimental|1|Haloperidol 10 mg Tablets (Cord Laboratories)
89204057|NCT00946491|Active Comparator|2|Haldol 10 mg Tablets (McNeil Pharmaceuticals)
89204058|NCT00776126||1|All enrolled subjects will undergo digital breast tomosynthesis.
89204059|NCT03336190|Experimental|Intervention|Receives the full program, including the toolkit training and avatar interaction
89204060|NCT00776204|Active Comparator|1|Drug Eluting Stent
89204061|NCT00776204|Active Comparator|2|Drug Eluting Stent
89204062|NCT00776204|Active Comparator|3|Drug Eluting Stent
89204063|NCT04011969||Colorectal cancer suspects|Patients suspected with colorectal cancer who come to our hospital to conduct colonoscopy procedure will be recruited for this study and will undergo a series of examinations.
89204064|NCT05355610|Experimental|Vestibular severity index improvement|Improvement in vestibular symptoms with intratympanic gentamicin
89204065|NCT00552669|Experimental|A--Oral Rapamycin plus BMS|Oral sirolimus plus bare metal stent implantation
89204066|NCT00552669|Active Comparator|B -- Drug Eluting Stent|Drug Eluting Stents
89204067|NCT00768014||1|Healthy term pregnant women in labor without any pain relief
89204068|NCT00768014||2|Healthy term pregnant women received TENS
89204069|NCT00768014||3|Healthy term pregnant women received epidural anesthesia
89204070|NCT02557568|Experimental|Hemodialysis patients (HPs)|staphylococcus aureus carriage is measured in nose
89204071|NCT02557568|Experimental|Healthcare Workers (HCWs)|staphylococcus aureus carriage is measured in nose
89204072|NCT00768170|Experimental|1|MK0633
89204073|NCT00943059|Experimental|Acipimox|Subjects will receive Acipimox or a placebo in random order. Acipimox is a commercially available and registrated drug, that lowers free fatty acids by inhibiting hormone sensitive lipase in the peripheral adipose tissue. No serious side-effects are known other than rare anaphylactic reactions.
89204074|NCT00943059|Placebo Comparator|Cellulosum mycrocryst capsula|Subjects will receive Acipimox or a placebo in random order. Acipimox is a commercially available and registrated drug, that lowers free fatty acids by inhibiting hormone sensitive lipase in the peripheral adipose tissue. No serious side-effects are known other than rare anaphylactic reactions.
89487469|NCT03228849|Active Comparator|Surgical Treatment|Patients were treated with the new suture anchor technique and after 6 weeks were started on physical therapy for 2 weeks.
88953152|NCT01958892||TUERP|
89204075|NCT05553106||Study Group|Patients who are hospitalized in the coronary intensive care unit, who can take simple commands, and whose condition is physiologically stable.
89204076|NCT00943137|Experimental|5-FU dosage adjustments|The dose of continuous infusion 5-FU will be adjusted every cycle until patients reached the therapeutic plasma range (450 to 550 microgram/L).
89204077|NCT00772616|Experimental|1|Patients will receive propofol and remifentanil automatically administered (closed-loop administration using bispectral index as the single input for the controller).
89204078|NCT00772616|Active Comparator|2|Patients will receive propofol automatically administered (closed-loop administration using bispectral index as the single input for the controller) and sufentanil according to usual criteria
89204079|NCT00768326|Experimental|Zicronapine. Study Part A|
89204080|NCT00768326|Experimental|Zicronapine. Study Part B|
89204081|NCT00768326|Experimental|Zicronapine. Study Part C|
89204082|NCT00768326|Experimental|Zicronapine. Study Part D|
89204083|NCT00768326|Experimental|Zicronapine. Study Part E|
89204084|NCT00768326|Placebo Comparator|2A, 2B, 2C, 2D, 2E|
89204085|NCT00951717|No Intervention|Treatment as usual|Participants will receive standard postpartum education and discharge materials provided by the hospital and a list of community and Internet resources by mail.
89204086|NCT00951717|Experimental|Behavioral education|Participants will receive behavioral education on postpartum depression and a list of community and Internet resources by mail.
89204087|NCT00768404|Experimental|A|
89204088|NCT00951795||Adults|Adult men and women over age of 18
89204089|NCT00951795||Pediatrics|Pediatric boys and girls ages 12-18
89204090|NCT00776282|Experimental|1|loratadine 10 mg orally disintegrating tablets
89204091|NCT00776282|Active Comparator|2|loratadine 10 mg orally disintegrating tablets
89204092|NCT00943293|Experimental|Vaccine|
89204093|NCT00776360|Experimental|oxytocin, gastric emptying|Oxytocin is given to study the gastric emptying rate
89204094|NCT00776360|Placebo Comparator|oxytocin|sodium chloride is given to study gastric emptying rate
89204095|NCT00946725|Experimental|1|Atenolol 100 mg Tablets (Geneva Pharmaceutical, Inc.)
89204096|NCT00946725|Active Comparator|2|Atenolol (Tenormin) 100 mg Tablets Zeneca (Astra Zeneca Pharmaceutical)
89204097|NCT03041740|No Intervention|Usual Care (Control) Group|Control subjects will be treated as per standard of care for preterm infants with BPD.
89204098|NCT03041740|Active Comparator|Perfluorooctylbromide (PFOB) Group|Subjects in the PFOB group will be administered an initial PFOB treatment dose of 2.5 mL/kg and up to a total intra-pulmonary volume of 25 mL/kg for up to 10 days.
89204099|NCT00772694|Experimental|sorafenib|drug
89204100|NCT00951873|Experimental|A|
89204101|NCT00951873|Placebo Comparator|B|
89204102|NCT00951873|Experimental|C|
89204103|NCT00776438|Experimental|Study Group 1|Adult, age 18 to 40 years
89204104|NCT00776438|Experimental|Study Group 2|Adult, age 18 to 40 years
89204105|NCT00776438|Experimental|Study Group 3|Elderly, age 60 to 85 years
89204106|NCT00776438|Experimental|Study Group 4|Elderly, age 60 to 85 years
89204107|NCT00943371|Experimental|1|MK6349
89204108|NCT00943371|Placebo Comparator|2|Placebo to MK6349
89204109|NCT00552513|Other|Early Coronary Intervention|Coronary angiography and intervention (either percutaneous coronary intervention [PCI] or coronary artery bypass graft [CABG] surgery) as soon as possible (within 24 hours of randomisation).
89204110|NCT00552513|Other|Delayed Coronary Intervention|Delayed intervention: Coronary angiography and intervention (either percutaneous coronary intervention [PCI] or coronary artery bypass graft [CABG] surgery) any time after 36 hours after randomisation.
89204111|NCT00946803|Experimental|PC-CB Intervention|Patient-Controlled Cognitive-Behavioral Intervention
89204112|NCT00946803|No Intervention|Wait list|Wait list control group. Offered PC-CB Intervention after the study.
89204113|NCT00943449|Experimental|4SC-201|
89204114|NCT00943449|Experimental|4SC-201 + Sorafenib|
89204115|NCT00943527||1|Premenopausal Women who are not taking hormones or birth control. Ages 35-45 who have had a negative mammograph performed at the Mayo Clinic in Rochester within the last year.
89204116|NCT00943527||2|Women Initiating Hormone Therapy and have had a negative mammogram preformed at the Mayo Clinic Rochester within the last year.
89204117|NCT00943527||3|Women Initiating Tamoxifen who have had a negative mammogram preformed at the Mayo Clinic Rochester.
89204118|NCT00952029|Experimental|Maintenance with bevacizumab|FOLFIRI + Avastin and during the chemotherapy-free interval maintenance with bevacizumab
89204119|NCT00952029|Active Comparator|No maintenance with bevacizumab|FOLFIRI + Avastin and during the chemotherapy-free interval NO maintenance
89204120|NCT00560313|Experimental|4CMenB|
89204121|NCT00560313|Experimental|MenACWY CRM|
89204122|NCT00667862|Experimental|Panobinostat|Participants with metastatic hormone refractory prostate cancer received 20 milligrams per meter square (mg/m^2) of panobinostat intravenously (i.v.) on Days 1 and 8 of a 21-day cycle. Treatment continued until disease progression as per investigator, intolerable toxicity, start of new cancer therapy, death, or withdrawal of consent.
89204123|NCT00952107|Experimental|Imaging system operation|
89204124|NCT00772850||Antegrade nailing, humeral fractures|We included patient's age and gender, fracture location, fracture cause, presence of nail removal, post-operative period and comorbidity or associated disease as independent variables. Fracture location was either humeral neck or humeral shaft. Humeral neck fractures were defined as fractures above surgical neck of the humerus. Meanwhile, humeral shaft fractures were defined as fractures below surgical neck of the humerus and 5 cm above the olecarnon fossa. Humeral shaft fractures were separated into three groups: proximal third shaft fractures, middle third shaft fractures and distal third shaft fractures. Fracture causes included simple falls and traffic accidents.
89204125|NCT00776516|Experimental|1|mirabegron alone
89204126|NCT00776516|Experimental|2|mirabegron and rifampin
89204127|NCT00946959|Experimental|cardiac surgery|This arm will include patients older than 18 years and candidate to cardiac surgery.
89204128|NCT00946959|No Intervention|cardiac angiography|Patients older than 18 years who undergo coronary angiogram. This arm will include patients with coronary revascularization and patients without coronary revascularization.
89204129|NCT00768638|Active Comparator|Atorvastatin 10mg|
89204130|NCT00768638|Active Comparator|Atorvastatin 40mg|
89204131|NCT00952263|Experimental|MBL-HCV1|
89204132|NCT00773006||A|Stable/elective PCI patients
89204133|NCT00773006||B|NSTEMI PCI patients
89204134|NCT00773006||C|STEMI PCI patients
89204135|NCT02557958|Experimental|Azithromycin|Azithromycin 250mg daily, single daily use for 8 weeks
89204136|NCT02557958|Placebo Comparator|Placebo|Placebo daily for 8 weeks
89204137|NCT00776672|Experimental|1|fosinopril sodium 40 mg tablets of Ranbaxy
89204138|NCT00776672|Active Comparator|2|Monopril® 40mg tablets
89204139|NCT00535132|Experimental|002|Oral Risperidone 4 or 6 mg MG once daily for 0-2 weeks
89204140|NCT00535132|Experimental|001|Paliperidone ER 6, 9 or 12 MG once daily for 4-6 weeks
89204141|NCT00570908|Experimental|Study Group|capecitabine administered concurrently with WBRT followed by combination the combination of capecitabine with sunitinib
89204142|NCT00773084|Active Comparator|Drug|Aliskiren plus spironolactone vs. Lisinopril plus spironolactone
89204143|NCT00321919|Experimental|Early Epoetin Beta Therapy|Participants received immediate epoetin beta therapy starting at 2000 IU, subcutaneously once weekly up to four years to reach a target Hb level of 13-15 g/dL; with an individual Hb increase of at least 2 g/dL within approximately 3 months.
89204144|NCT00321919|Active Comparator|Late Epoetin Beta Therapy|Participants received epoetin beta treatment starting at 2000 IU, subcutaneously once weekly up to four years only when a decline in Hb levels to <10.5 g/dL had occurred in order to reach a target Hb of 10.5-11.5 g/dL.
89204145|NCT00781391|Active Comparator|Warfarin/placebo edoxaban|Warfarin tablets plus placebo Edoxaban tablets
89204146|NCT00781391|Experimental|high dose edoxaban/placebo warfarin|Edoxaban tablets (60mg) plus warfarin placebo tablets
89487470|NCT02079545|Experimental|Group 1|18 participants will receive a single intravenous (IV) infusion of 100 mg sirukumab
89204147|NCT00781391|Experimental|low dose edoxaban/placebo warfarin|Edoxaban tablets (30mg) plus warfarin placebo tablets
89204148|NCT00776750|Experimental|influenza vaccination|All participants received a standard dose of 0.5 ml commercially available trivalent split influenza vaccine (Vaxigrip®, Aventis Pasteur MSD) by intramuscular injection. The vaccine contained 15 μg hemagglutinin of each of the following influenza strains: A/ New Caledonia/20/99 (H1N1), A/ Panama/2007/99 (H3N2), and B/Shangdong/7/97, recommended by WHO as components of the influenza vaccine for the epidemic season 2003/2004.
89487471|NCT02079545|Experimental|Group 2|18 participants will receive a single subcutaneous (SC) injection of 50 mg sirukumab using a Pre-filled Syringe (PFS) fitted with the UltraSafe Passive™ Delivery System (PFS-U)
89487472|NCT02079545|Experimental|Group 3|18 participants will receive a single SC injection of 50 mg sirukumab using the SmartJect™ Autoinjector (PFS-AI)
89487473|NCT02079545|Experimental|Group 4|42 participants will receive a single SC injection of 100 mg sirukumab using a PFS-U
89487474|NCT02079545|Experimental|Group 5|42 participants will receive a single SC injection of 100 mg sirukumab using a PFS-AI
89487475|NCT04939376||Group A|Women with hysteroscopically or ultrasonographic detected uterine anomalies(adenomyosis,fibroid) intracavitary lesions ( like polyp, adhesion or septum) and those with detected endometrial abnormalities (like hypervascularization,pale endometrium) ,cervical lesion and cervical canal lesion or pelvic lesion
89487476|NCT04939376||Group B|Matched women (eg. Age,parity, BMI, ovarian reserve….) with no uterine or ovarian abnormalities assessed by hysteroscopy or ultrasonography.
89487477|NCT02084927|Experimental|HBOT|Group will be treated with HBOT for 60 treatments in 3 months.
89487478|NCT02084927|Other|Control/Crossover|Control for 3 months without treatment, and then HBOT for 60 treatments in 3 months.
89487479|NCT03234387||Cystic fibrosis (CF) with established CF-related diabetes|"Cystic fibrosis (CF) with established CF-related diabetes~Inclusion criteria:~Males and females ≥ 12 years of age~CF diagnosis based on clinical features, supported by an abnormal sweat test (sweat chloride > 60 mmol·L-1 > 100 mg sweat) and, where possible, diagnostic genotyping~Established CFRD in accordance with the most recent American Diabetes Association positional statement]. This statement recommends CFRD is diagnosed using a 2 hour OGTT. However, the present study will also include those based on fasting plasma glucose and glycated hemoglobin levels, when symptoms of diabetes are also present:~2 hour OGTT plasma glucose ≥ 200 mg.dL-1 (11.1 mmol.L-1)~Fasting plasma glucose ≥ 126 mg.dL-1 (7.0 mmol.L-1)~Glycated hemoglobin ≥ 48 mmol/mol~No contraindications to performing exhaustive exercise~Can understand and cooperate with the study protocol~No increase in symptoms or weight loss in the preceding 2 weeks"
89487480|NCT03234387||Cystic fibrosis (CF) without established CF-related diabetes|"Cystic fibrosis (CF) without established CF-related diabetes~Inclusion criteria:~Males and females ≥ 12 years of age~CF diagnosis based on clinical features, supported by an abnormal sweat test (sweat chloride > 60 mmol·L-1 > 100 mg sweat), where possible, diagnostic genotyping would also be desired~No evidence of established, gestational or exacerbation induced CFRD in accordance with the American Diabetes Association criteria (stated above; [110]).~No contraindications to performing exhaustive exercise~Can understand and cooperate with the study protocol~No increase in symptoms or weight loss in the preceding 2 weeks"
89487481|NCT03234387||Healthy controls|Age- and gender-matched healthy control participants.
89487482|NCT03235947|Experimental|Fosfomycin disodium|"Fosfomycin disodium 4 g intravenously: 3 hours before kidney transplant surgery, 3 hours before urinary catheter removal and 3 hours prior to ureteral catheter removal.~Trimethoprim / Sulfamethoxazole (160/800 mg) 1 tablet orally every 24 hours."
89487483|NCT03235947|Active Comparator|Trimethoprim / Sulfamethoxazole|"Trimethoprim / Sulfamethoxazole (160/800 mg) 1 tablet orally every 24 hours.~Intravenous placebo solution at the same time of application of fosfomycin disodium in the experimental arm."
89487484|NCT04930640|Experimental|SGF200 group|1 times a day, 1 capsule for 1 time, before breakfast meal[350 mg/day (Bacillus amyloliquefaciens spore 1x10^9 CFU/day, GF101 200 U/day)]
89487485|NCT04930640|Placebo Comparator|placebo group|1 times a day, 1 capsule for 1 time, before breakfast meal[350 mg/day (Bacillus amyloliquefaciens spore 0 CFU/day, GF101 0 U/day)]
89487486|NCT03236259|Active Comparator|Brainport high dose|
89487487|NCT03236259|Active Comparator|Brainport low dose|
89487488|NCT03236259|Placebo Comparator|Placebo|Maltodextrin
89487489|NCT03057470|Active Comparator|0% Bolus Insulin Correction|0% Bolus Insulin Correction
89487490|NCT03057470|Active Comparator|50% Bolus Insulin Correction|50% Bolus Insulin Correction
89487491|NCT03057470|Active Comparator|100% Bolus Insulin Correction|100% Bolus Insulin Correction
89487492|NCT03057470|Active Comparator|150% Bolus Insulin Correction|150% Bolus Insulin Correction
88953153|NCT01958905|Experimental|Artemether-Lumefantrine|All patients will receive Artemether-Lumefantrine and the endpoints will be compared between the two populations of severely malnourished and non-severely malnourished children
89487493|NCT03228225|Experimental|Tele cardiac rehabilitation|Following a standard intake process, patients will begin exercise in the institute and will gradually over a period of 6 months reduce the number of institution visits and will concomitantly increase the number of home \ community exercise sessions. During the entire period we will monitor program, coach and fine-tune the exercise program. Weekly exercise data will be securely transmitted to the rehabilitation team (heart rate zones, duration of exercise and type, step count, caloric expenditure, blood pressure and patients reported impressions)
89487494|NCT04919876|Experimental|fruit/vegetable supplement (FVS)|The experimental product will be prepared by combing Juice Plus+ Garden Blend, Juice Plus+ Orchard Blend, and Juice Plus+ Berry Blend in an equal proportion.
89487495|NCT04919876|Placebo Comparator|placebo|The placebo comprises microcrystalline cellulose and 0.5% magnesium stearate.
89487496|NCT04930718|Active Comparator|Control group|Wrist passive mobilizations; Actives exercises; Reeducation for Activity daily life;
88953154|NCT01958931||Patients Suspicious for Lung Cancer|Subjects are symptomatic of lung cancer and have one or more lung nodules or lung masses suspicious for lung cancer.
89487497|NCT04930718|Experimental|Experimental group|The experimental group will also carried out a proprioceptive exercise home program with a laptop.
89204149|NCT00534976|Experimental|Montelukast Sodium|"Participants 4-5 years: A single dose of 4 mg Montelukast chewable tablet daily, crossing over to matching placebo (Pbo) after a 3- to 7-day washout period (no participants 4-5 years were enrolled)~Participants 6-14 years: A single dose of 5 mg Montelukast chewable tablet daily, crossing over to matching Pbo after a 3- to 7-day washout period"
88953155|NCT01958944|Experimental|Nitric oxide + standard treatment|Inhalation of 160 ppm NO for 30 minutes, 3 times daily, for a duration of 10 working days with the exclusion of weekend days (Friday & Saturday) in which no treatment under this study will be provided.
89204150|NCT00534976|Experimental|Placebo|"Participants 4-5 years: A single dose of 4 mg Pbo chewable tablet daily, crossing over to Montelukast 4 mg chewable tablet after a 3- to 7-day washout period (no participants 4-5 years of age were enrolled)~Participants 6-14 years: A single dose of 5 mg Pbo chewable tablet daily, crossing over to Montelukast 5 mg chewable tablet after a 3- to 7-day washout period"
89204151|NCT00768794|Active Comparator|Acidolphilus|In the first part of the study, two participants will begin radiation therapy. When signs and symptoms of thrush are noted, such as smooth, creamy, white/yellow coating and/or patches on the tongue and inside of their mouth that are painful, subjects will begin taking acidophilus capsules twice each day until the last day of radiation therapy.
89204152|NCT00773162|Placebo Comparator|1|
89204153|NCT00773162|Active Comparator|2|
89204154|NCT00768950||Spondyloarthropathies|Patients with spondyloarthropathies (ankylosing spondylitis, reactive arthritis, psoriatic arthritis and spondylitis, enteropathic arthritis and spondylitis, juvenile-onset spondyloarthritis, and undifferentiated spondyloarthritis) as defined by the AMOR criteria
89204155|NCT00769028|Experimental|AIMSPRO|
89204156|NCT00769028|Placebo Comparator|Placebo|
89204157|NCT00321763|Experimental|GSK1247446A Lot 1 Group|Subjects aged 60 years or older at the time of vaccination received 1 dose of Lot 1 GSK1247446A vaccine adjuvanted with AS03 at Day 0. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
89204158|NCT00321763|Experimental|GSK1247446A Lot 2 Group|Subjects aged 60 years or older at the time of vaccination received 1 dose of Lot 2 GSK1247446A vaccine adjuvanted with AS03 at Day 0. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
89204159|NCT00321763|Experimental|GSK1247446A Lot 3 Group|Subjects aged 60 years or older at the time of vaccination received 1 dose of Lot 3 GSK1247446A vaccine adjuvanted with AS03 at Day 0. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
89204160|NCT00321763|Experimental|GSK1247446A Pooled Group|Subjects aged 60 years or older at the time of vaccination received 1 dose of Lot 1, 2 or 3 GSK1247446A vaccines adjuvanted with AS03 at Day 0. The vaccines were administered intramuscularly into the deltoid region of the non-dominant arm.
89204161|NCT00321763|Active Comparator|Fluarix Group|Subjects aged 60 years or older at the time of vaccination received 1 dose of FluarixTM vaccine adjuvanted with AS03 at Day 0. The vaccines were administered intramuscularly into the deltoid region of the non-dominant arm.
89204162|NCT02822716|Other|IRE treatment|Irreversible electroporation (IRE) is a form of non-thermal local ablation for solid tumors, it induces apoptosis of tumor cells by creating irreversible damage in the cell membrane using electric current. IRE treatment is given for a therapeutic purpose as a non-surgical alternative to those patients with an inoperable condition.
89204163|NCT00776828|Active Comparator|TAT|triple antiplatelet therapy : aspirin, clopidogrel and cilostazol
89204164|NCT00776828|Placebo Comparator|DAT|dual antiplatelet therapy : aspirin, clopidogrel
89204165|NCT04002466||Children (6-59 months)|
89204166|NCT04002466||Women of Reproductive Age (15-49 years)|
89204167|NCT04002466||Adult Men (15-49 years)|
89204168|NCT00776906|Experimental|1|PTX-coated balloon
89204169|NCT00776906|Active Comparator|2|Bare balloon
89204170|NCT00773240|Experimental|1|Grazax
89204171|NCT00773240|Placebo Comparator|2|
89204172|NCT01063933|Experimental|Cohort I|Cohort I: >/= 12 years to < 18 years. Peramivir administered daily for five days or until the day of hospital discharge, whichever comes first.
89204173|NCT01063933|Experimental|Cohort II|Cohort II: >/= 6 years to < 12 years
89204174|NCT01063933|Experimental|Cohort III|Cohort III: >/= 2 years to < 6 years
89204175|NCT01063933|Experimental|Cohort V|Cohort V: >/= 91 days to < 181 days
89204176|NCT01063933|Experimental|Cohort VII|Cohort VII: birth to < 31 days
89204177|NCT01063933|Experimental|Cohort VI|Cohort VI: >/= 31 days to < 91 days
89204178|NCT01063933|Experimental|Cohort IV|Cohort IV: >/= 181 days to < 2 years
89204179|NCT02556866|Experimental|rituximab|Prednisone treatment plus rituximab administered by slow intravenous infusion at 375 mg/m2 at D1, D8, D15 and D22.
89204180|NCT02556866|Placebo Comparator|placebo|Prednisone treatment plus placebo administered by slow intravenous infusion at day 1 (D1), D8, D15 and D22.
89204181|NCT01064011|Other|External Ventricular drainage, Intraventricular Thrombolysis|
89204182|NCT01064011|Other|External Ventricular Drainage and Endoscopic Evacuation|
89204183|NCT00769106|No Intervention|B (control group)|regular treatment and follow up
89204184|NCT00769106|Experimental|A (CIK group)|cytokine-induced killer cell treatment plus regular treatment and follow up
89204185|NCT01064089|Experimental|HSP990|dose escalation
89487498|NCT02871401|Experimental|Valganciclovir|Valganciclovir 450 mg, 2 pills by mouth one time per day x 12 weeks
89487499|NCT02871401|Placebo Comparator|Placebo|Placebo, 2 pills by mouth one time per day x 12 weeks
89487500|NCT03236181|Other|Saturated Fat/SFA|30 grams saturated fat (SFA) in the form of heavy whipping cream will be provided to subject in a mixed meal shake
89487501|NCT03236181|Other|Monounsaturated Fat/MUFA|30 grams monounsaturated fat (MUFA) in the form of olive oil will be provided to subject in a mixed meal shake
89487502|NCT03236181|Other|Polyunsaturated Fat Linoleic/PUFA|30 grams high linoleic polyunsaturated fat (PUFA) in the form of high linoleic sunflower oil will be provided to subject in a mixed meal shake
89487503|NCT03236181|Other|Polyunsaturated Fat Omega-3/LCn3|30 grams high omega-3 polyunsaturated fat (LCn3) in the form of fish oil will be provided to subject in a mixed meal shake
89487504|NCT04919720|Other|Human Factors Interventions|A 'bundle' of human factors interventions designed to improve response to deteriorating patients.
89487505|NCT03228303|Active Comparator|Chronic phase CML treated by nilotinib|Newly diagnosed
89487506|NCT03228303|Active Comparator|Chronic phase CML treated by imatinib|Newly diagnosed
89487507|NCT02085005|Experimental|Aflibercept|Intravenous (IV) infusion on Day 1 every 3 weeks, followed by CAPOX (capecitabine by oral administration on Day 1 to Day 14 and oxaliplatin intravenous (IV) infusion on Day 1 every 3 weeks) for the induction treatment period (6 cycles) after which the patient may enter the maintenance period during which the treatment is Aflibercept + Capecitabine
89487508|NCT04431440||Methicillin resistant staphylococcus aureus|
89487509|NCT04431440||vancomycin resistent staphylococcus aureus|
89487510|NCT03228381|Experimental|BOSS Device|Patients who are undergoing open chest cardiac surgery via sternotomy will receive the BOSS device to assess acute anatomical and geometric annular and ventricular changes that occur when strategically positioned an external inflatable chambers are applied to the outside of the heart.
89487511|NCT02085083|Experimental|Regular telephone and email access to an IBD Nurse|The IBD pediatric-adult transition nurse will send an email to each individual randomized to the intervention arm each month. The email will include the following: Brief Questionnaire;The Option For Direct Nurse Contact; Educational modules; MyHealth Passport and a Comprehensive Study Questionnaire.
89487512|NCT02085083|Active Comparator|Minimal Intervention|The IBD pediatric-adult transition nurse will send an email to each individual randomized to the control arm every 3 months. The email will include the following: MyHealth Passport and Study Questionnaire. This intervention is not expected to significantly improve outcomes.
89487513|NCT04938674||Standard process for blood collection using Ultrasonic Guided puncture|
89487514|NCT03227913|Active Comparator|Good chewing ability|
89487515|NCT03227913|Experimental|Impaired chewing ability|
89487516|NCT02079623||Pancreatic cancer|Patients with locally advanced pancreatic cancer.
89487517|NCT03235869|Experimental|Radiation Therapy + Durvalumab|Radiation to 1-3 cutaneous tumors: 20 Gy (4 Gy x 5 fractions) Durvalumab 1500mg IV over 1 hour administered within 2-7 days of initiation of radiation, then every 28 days.
89487518|NCT02079701|Experimental|23-valent pneumococcal vaccine|single dose, 23-valent pneumococcal vaccine, 0.5ml, intramuscular (IM)
89487519|NCT02079701|Placebo Comparator|placebo|0.5 ml injectible saline, IM
89487520|NCT03233919|Experimental|CORIC|"Comprehensive remote ischaemic conditioning (CORIC) will be induced using an automated RIC device:~Per-RIC consists of 5 cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on a lower limb. The first inflation began immediately following randomization after admission. In case 5 cycles of RIC were not fully completed when the first balloon inflation or thrombus aspiration was ready to be performed, PCI was not to be delayed.~Post-RIC consists of 5 cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on a lower limb immediately after PPCI.~Delayed-RIC consists of 5 cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on a lower limb once daily on 2-28 days after MI."
89487521|NCT03233919|No Intervention|Non-CORIC|Controls did not undergo comprehensive remote ischaemic conditioning.
89487522|NCT02079779|Experimental|Robotic-assisted therapy|All patients will receive a similar classical rehabilitation as a basis. The 30 patients of this group will receive a supplement of robotic-assisted therapy.
89204186|NCT00773318|Experimental|A|"Patients with histologically proven AJCC stages I - II - III prostate cancer including men with clinical T3N0M0 disease, men with PSA > 10 mg/ml, and men with Gleason score of 8-10. Prostate cancer patients scheduled for prostatectomy and pelvic lymph node dissection (CLND).~Arm A = SPECT/CT guided LM/SL versus CLND"
89204187|NCT03946306|Active Comparator|Group 1|5,25% NaOCl with syringe needle irrigation alone
89487523|NCT02079779|Active Comparator|Classical therapy|All patients will receive a similar classical rehabilitation as a basis. The 30 patients of this group will receive a supplement of classical rehabilitation.
89204188|NCT03946306|Active Comparator|Group 2|5,25% NaOCl with syringe needle irrigation, activated with sonic system EDDY (VDW, Munich, Germany)
89204189|NCT05356624|Experimental|Mulligan Mobilization|Mobilization with movement (3 sets per 10 repetitions).
89204190|NCT05356624|Experimental|Soft tissue mobilization|Soft tissue mobilization (3 sets per 10 repetitions)
89487524|NCT03233841||Living non-HSCT Farber Disease Patients|Patients with a confirmed diagnosis of Farber disease who are currently alive and have not undergone hematopoietic stem cell transplantation (HSCT).
89487525|NCT03233841||Living HSCT Farber Disease Patients|Patients with a confirmed diagnosis of Farber disease who are currently alive and have undergone hematopoietic stem cell transplantation (HSCT).
89487526|NCT03233841||Deceased Farber Disease Patients|Patients with a confirmed diagnosis of Farber disease who are deceased (including patients who may or may not have undergone hematopoietic stem cell transplantation).
89487527|NCT03559595|Experimental|Intervention group|All study participants will be exposed to the intervention
89487528|NCT03559439|Experimental|CD19 CAR T|CD19 CAR T cells transduced with a lentiviral vector to express anti-CD19 scFv CD3z:CD28 administered by IV infusion.
89537868|NCT03289637|Experimental|Active intervention|"In the group randomised to active treatment and with a screening level of 25-OH-vitamin D 25-50nmol/L an intervention with 1600IE daily of vitamin D will be given.~In those randomised to active treatment and with a screening level of 25-OH-vitamin D of <25nmol/L, an intervention of 2400IE of vitamin D will be given."
89487529|NCT03236025|Experimental|Experimental group|Video+one-sentence smoking cessation advice +general smoking cessation leaflet will be allocated to the participants in the experimental group. The videos which presented the health effects of smoking, especially emphasizing the importance of smoking cessation on the fetal and pregnancy, will be sent in sequence through the smart phone to the participants in the experimental group.
89487530|NCT03236025|Active Comparator|Conditional control group|Text-message+one-sentence smoking cessation advice +general smoking cessation leaflet will be allocated to the participants in the experimental group. Text-message contains the same content with videos and will be sent in the same frequency with the videos through the smart phone to the participants in the Conditional control group.
89487531|NCT03236025|Placebo Comparator|Placebo control group|Participants in the control group will be given a one-sentence smoking cessation advice during the baseline assessment. A leaflet showed the information related to the smoking cessation will be allocated to them at the same time.
89487532|NCT03057080|Other|PTA procedure|Percutaneous transluminal angioplasty (PTA) in patients with ischemic leg ulcer
89487533|NCT03558425|Experimental|TR group|Period 1: Test drug(CKD-381) Period 2: Reference drug(D026)
89487534|NCT03558425|Experimental|RT group|Period 1: Reference drug(D026) Period 2: Test drug(CKD-381)
89487535|NCT03057158||1|Women with Urgency Incontinence (At least three times per week) greater than three months, and without insulin resistance.
89487536|NCT03057158||2|Women with insulin resistance (pre-diabetes or diabetes based on Hemoglobin A1C).
89487537|NCT03057158||3|Women with both UUI (at least three times per week for over three months) and Insulin Resistance (pre-diabetes or diabetes based on Hemoglobin A1C).
89487538|NCT03057158||4|Healthy Volunteers
89487539|NCT03236103|Other|Subjects with VAD in place|Adult patients with VAD in place who are admitted to the hospital for acute medical illness. The investigators will provide clinical recommendations to the subject's primary care provider.
89487540|NCT02081495|Experimental|Sequence AB|Twenty-one participants will receive DOXIL/CAELYX reference product in Cycle 1 and DOXIL/CAELYX test product in Cycle 2. Each cycle will be separated by 28 days.
89487541|NCT02081495|Experimental|Sequence BA|Twenty-one participants will receive DOXIL/CAELYX test product in Cycle 1 and DOXIL/CAELYX reference product in Cycle 2. Each cycle will be separated by 28 days.
89487542|NCT03056846|Placebo Comparator|Placebo|Placebo will be taken as a capsule twice daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
89487543|NCT03056846|Experimental|Probiotic Combination|A commercially available probiotic mixture of Lactobacillus gasseri, Bifidobacterium bifidum, and Bifidobacterium longum will be taken as a capsule twice daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
89487544|NCT03056846|Experimental|Bifidobacterium bifidum|A commercially available probiotic strain (Bifidobacterium bifidum) will be taken as a capsule twice daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
89487545|NCT03056846|Experimental|Bifidobacterium longum|A commercially available probiotic strain (Bifidobacterium longum) will be taken as a capsule twice daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
89487546|NCT04431128||study group|Adenoid hypertrophy
89487547|NCT04431128||Control group|UTI, GE, vomiting, diarrhea
89487548|NCT02087969|Experimental|Dry Needling|Dry Needling to Triceps Surae
89487549|NCT02087969|Experimental|Stretching|Subjects will be given a home exercise program of stretches which are commonly prescribed to improve ankle dorsiflexion.
89487550|NCT02081651|Experimental|Parmigiano Reggiano cheese|Children treated Parmigiano Reggiano cheese for 12 months
89487551|NCT02081651|No Intervention|Control subjects|Children with cow's milk allergy not assuming Parmigiano Reggiano cheese
89487552|NCT03234075||Control group|Patients supported without regional organization for promotion of renal transplantation Setting : French Auvergne Rhone Alpes region and French Center region
89487553|NCT03234075||Intervention group|Patients supported with the regional organization for promotion of renal transplantation Setting : French Auvergne Rhone Alpes region
89487554|NCT04431284||Obese patients with binge eating disorders|Severely obese patients (with or without binge eating disorders, Binge Eating Sclae >= 16) who have been hospitalized for obesity assessment before the start of the lockdown in the Endocrinology department of the Lyon Hospital
89487555|NCT04431284||Obese patients without binge eating disorders|Severely obese patients (with or without binge eating disorders, Binge Eating Sclae >= 16) who have been hospitalized for obesity assessment before the start of the lockdown in the Endocrinology department of the Lyon Hospital
89487556|NCT03545269|Experimental|CartiLife®|
89487557|NCT03545269|Active Comparator|Microfracture|
89487558|NCT02088125|Active Comparator|Incentive Spirometry|The Incentive Spirometry was characterized by the use of the incentive spirometer volume, in which volunteer used a nasal clip and was instructed to inhale slowly and deeply through the mouthpiece of the equipment from functional residual capacity to total lung capacity.
89487559|NCT02088125|Active Comparator|Breath Stacking|Breath Stacking A mask was used with two one-way valves (inspiratory limb and expiratory limb), which was coupled to the patient's face allowing only inspiration, while the expiratory branch remained occluded for the individual only perform successive inspiratory efforts.
89487560|NCT03227679|Active Comparator|Metabolism-Informed Care (MIC)|Smoking Cessation Pharmacotherapy (varenicline, bupropion, and nicotine patch) recommendations were guided by Nicotine Metabolism as measured by the Nicotine Metabolite Ratio. Ultimately, after being educated about smoking cessation medication efficacy and side-effects, the participant could decide to take any medication for which they were medically cleared, but the recommendation was made based on rate of Nicotine Metabolism.
89487561|NCT03227679|Active Comparator|Guideline-Based Care (GBC)|Smoking Cessation Pharmacotherapy (varenicline, bupropion, and nicotine patch) was co-selected from those they were medically able to receive after educating participants about smoking cessation medication efficacy and side-effects.
89204191|NCT00308113|Active Comparator|1|CoenzymeQ10 taken once a day each morning by mouth.
89487562|NCT03057548|Active Comparator|Pulmonary Vein Isolation (PVI)|"Cryoablation only of Pulmonary Veins~or~Radiofrequency ablation only of Pulmonary Veins~Pulmonary Vein Isolation (PVI) alone."
89487563|NCT03057548|Experimental|PVI & Posterior Left Atrial Ablation|"Cryoablation of Pulmonary Veins plus RF ablation of Posterior Left Atrial Wall~or~Radiofrequency ablation of Pulmonary Veins plus RF ablation of Posterior Left Atrial Wall~PVI ablation plus ablation of the Posterior Left Atrial Wall (PLAW)"
89487564|NCT04886167|Active Comparator|120U abobotulinumtoxinA|"Treatment of platysmal bands using a total of 120 U abobotulinumtoxinA. This will involve 24 injection sites (6 injections per each of 4 platysmal bands), with each injection site receiving 0.025mL (5 U).~At the 14 day visit, an optional touch-up using up to 90 U of abobotulinumtoxinA can be performed. This will involve up to 18 injection sites, with each injection site receiving 0.025mL (5 U)."
89487565|NCT04886167|Active Comparator|180U abobotulinumtoxinA|"Treatment of platysmal bands using a total of 180 U abobotulinumtoxinA. This will involve 24 injection sites (6 injections per each of 4 platysmal bands), with each injection site receiving 0.0375mL (7.5 U).~At the 14 day visit, an optional touch-up using up to 90 U of abobotulinumtoxinA can be performed. This will involve up to 12 injection sites, with each injection site receiving 0.0375mL (7.5 U)."
89487566|NCT04886167|Active Comparator|240U abobotulinumtoxinA|"Treatment of platysmal bands using a total of 240 U abobotulinumtoxinA. This will involve 24 injection sites (6 injections per each of 4 platysmal bands), with each injection site receiving 0.05mL (10 U).~At the 14 day visit, an optional touch-up using up to 120 U of abobotulinumtoxinA can be performed. This will involve up to 12 injection sites, with each injection site receiving 0.05mL (10 U)."
89487567|NCT04882501|Active Comparator|Actual aromatherapy product|QUEASEEase quick tab Aromatherapy product 50 % chance of participant receiving based on randomization
89487568|NCT04882501|Placebo Comparator|Placebo product|Placebo product (normal saline) 50% chance of participant receiving based on randomization
89487569|NCT02088203|Experimental|Single Dose Sequence 1|Dose 1, Dose 2, Dose 0: Each subject will receive a single dose during each of three separate test periods.
89487570|NCT02088203|Experimental|Single Dose Sequence 2|Dose 1, Dose 0, Dose 2: Each subject will receive a single dose during each of three separate test periods.
89487571|NCT02088203|Experimental|Single Dose Sequence 3|Dose 0, Dose 1, Dose 2: Each subject will receive a single dose during each of three separate test periods.
89487572|NCT02088203|Experimental|Single Dose Sequence 4|Dose 3, Dose 4, Dose 0: Each subject will receive a single dose during each of three separate test periods.
89487573|NCT02088203|Experimental|Single Dose Sequence 5|Dose 3, Dose 0, Dose 4: Each subject will receive a single dose during each of three separate test periods.
89487574|NCT02088203|Experimental|Single Dose Sequence 6|Dose 0, Dose 3, Dose 4: Each subject will receive a single dose during each of three separate test periods.
89487575|NCT02088203|Experimental|Single Dose Sequence 7|Dose 5, Dose 6, Dose 0: Each subject will receive a single dose during each of three separate test periods.
89487576|NCT02088203|Experimental|Single Dose Sequence 8|Dose 5, Dose 0, Dose 6: Each subject will receive a single dose during each of three separate test periods.
89487577|NCT02088203|Experimental|Single Dose Sequence 9|Dose 0, Dose 5, Dose 6: Each subject will receive a single dose during each of three separate test periods.
89487578|NCT02088203|Experimental|Multiple Dose Sequence 1|Dose 1, Dose 0, Dose 2: Each subject will receive daily doses for 21 consecutive days during each of three separate test periods.
89487579|NCT02088203|Experimental|Multiple Dose Sequence 2|Dose 1, Dose 2, Dose 0: Each subject will receive daily doses for 21 consecutive days during each of three separate test periods.
89487580|NCT02088203|Experimental|Multiple Dose Sequence 3|Dose 0, Dose 1, Dose 2: Each subject will receive daily doses for 21 consecutive days during each of three separate test periods.
89204192|NCT00308113|Active Comparator|2|Prednisone taken once a day each morning by mouth
89204193|NCT00308113|Active Comparator|3|CoenzymeQ10 and prednisone each taken once a day in the morning by mouth.
89487581|NCT02088203|Experimental|Multiple Dose Sequence 4|Dose 2, Dose 0, Dose 6: Each subject will receive daily doses for 21 consecutive days during each of three separate test periods.
89487582|NCT02088203|Experimental|Multiple Dose Sequence 5|Dose 2, Dose 6, Dose 0: Each subject will receive daily doses for 21 consecutive days during each of three separate test periods.
89487583|NCT02088203|Experimental|Multiple Dose Sequence 6|Dose 0, Dose 2, Dose 6: Each subject will receive daily doses for 21 consecutive days during each of three separate test periods.
89487584|NCT02088203|Experimental|Multiple Dose Sequence 7|Dose 1, Dose 0, Dose 6: Each subject will receive daily doses for 21 consecutive days during each of three separate test periods.
89487585|NCT02088203|Experimental|Multiple Dose Sequence 8|Dose 1, Dose 6, Dose 0: Each subject will receive daily doses for 21 consecutive days during each of three separate test periods.
89487586|NCT02088203|Experimental|Multiple Dose Sequence 9|Dose 0, Dose 1, Dose 6: Each subject will receive daily doses for 21 consecutive days during each of three separate test periods.
88953156|NCT01958957|Experimental|Ginkgolides Meglumine Injection|Intravenous drip slowly. A 1 (25 mg), will be taken slowly into the 0.9% sodium chloride injection diluted in 250 ml before use, then slow intravenous drip, once a day. The dripping speed must be strictly controlled. For the first time when using, dripping speed should be controlled for 10 ~ 15 drops per minute. After 30 minutes treatment without discomfort, dripping speed can be appropriately increased, but no more than 30 drops per minute.
88953157|NCT01958970|Experimental|PINTA 745|
88953158|NCT01958970|Placebo Comparator|Placebo|
88953159|NCT01958983|Experimental|Music Therapy Group Session|Participants will receive 60-minute group session twice a week over 2 months of period. Each session will be led by a music therapist. The contents of the music therapy session include drumming, rhythm imitation, score reading, lyrics comprehension, singing, and song discussion.
89487587|NCT03235635||Preterm|newborn infants were born with a gestational age of less than 32 weeks
89487588|NCT03235635||Late preterm|newborn infants were born with a gestational age of greater than 32 weeks and less than 36 weeks
89487589|NCT03235635||full-term|newborn infants were born with a gestational age of greater than or equal to 37 weeks
89487590|NCT04919486|Experimental|Experiment group|non-weight bearing visual feedback intervention under the of Labview software, and used rowing machine equipment for exercise training for 30 minutes,then eselastic band exercise training for 30 minutes.
89487591|NCT04919486|Active Comparator|elastic band exercise|elastic band exercise under the Physiotherapist, and used elastic band for exercise training for 60 minutes,include muscles flexion the hip joint, muscles extention the hip joint,etc.
89487592|NCT01570465||All patients enrolled in the GIMEMA AML1310 study.|"All patients enrolled in the GIMEMA AML1310 study;~Signed written informed consent according to ICH/EU/GCP and national local laws."
89487593|NCT04919252|Experimental|Vedolizumab|"Crohn's disease (CD): If a subject does not respond to vedolizumab 300mg iv 0, 2, and 6 weeks for induction, an additional dose of vedolizumab 300 mg will be given at week 10. On the other hand, Maintenance therapy should be continued every 8 weeks from week 14 in responding patients, and for some patients who have experienced a decrease in their response, it can be given every 4 weeks. The maximum dosing period is 54 weeks.~Ulcerative colitis (UC): If a subject responds to vedolizumab 300mg iv 0, 2, and 6 weeks for induction, maintenance therapy should be continued every 8 weeks from week 14, and for some patients who have experienced a decrease in their response, it can be given every 4 weeks. The maximum dosing period is 54 weeks."
89487594|NCT03119961|Experimental|SONOCLOUD®|BBB opening by ultrasound
89487595|NCT04919174|Active Comparator|Control group|Patients receive dexmedetomidine for sedation
89487596|NCT04919174|Experimental|Test group|Patients receive remimazolam for sedation
89487597|NCT02085239|Active Comparator|Lidocaine alone|Lidocaine: 8-10 ml of Lidocaine by subcutaneous injection
89487598|NCT02085239|Experimental|Lidocaine Ropivacaine|"Lidocaine Ropivacaine~8-10 ml of Lidocaine given by subcutaneous injection~8-10 ml of Ropivacaine given by subcutaneous injection"
89487599|NCT03233997|Experimental|FT21018 Group|7 day at-home use of electronic cigarette FT21018 followed by a 2 day in-clinic period.
89487600|NCT03233997|Experimental|FT21033 Group|7 day at-home use of electronic cigarette FT21033 followed by a 2 day in-clinic period.
89487601|NCT03233997|Experimental|FT21034 Group|7 day at-home use of electronic cigarette FT21034 followed by a 2 day in-clinic period.
89487602|NCT03233997|Experimental|FT21035 Group|7 day at-home use of electronic cigarette FT21035 followed by a 2 day in-clinic period.
89487603|NCT03056768|Active Comparator|active control|Health promotion provided by local health bureau.
89487604|NCT03056768|Experimental|multidomain intervention|1-year multidomain health promotion (physical activities, cognitive training, nutritional sessions)
89487605|NCT02085317|Other|Lepromatous Patients|Composed of patients with lepromatous Leprosy acetylcholine Iontophoresis sodium nitroprusside Iontophoresis
89487606|NCT02085317|Other|Healthy Patients|Composed of patients without any disease acetylcholine Iontophoresis sodium nitroprusside Iontophoresis
89487607|NCT03544645|Active Comparator|control group|"This group received a printed material brochure as an educational material"
89487608|NCT03544645|Experimental|intervention group|"This group received an audiovisual material video as an educational material"
88953160|NCT01958983|No Intervention|No Music Therapy Session|Participants will receive pre- and post-assessments and evaluations at 0 and 2 months. No intervention will be provided. Music therapy sessions will be offered to participants in completion of their study participation.
88953161|NCT01958996|Experimental|idarubicin|
89204194|NCT00308113|No Intervention|4|Enhanced standard of care.
89487609|NCT03234153|Experimental|Durvalumab and Tremelimumab|Durvalumab 1500 mg i.v. every 4 weeks in combination with Tremelimumab 75 mg i.v. every 4 weeks for a total of 4 cycles before surgery.
89487610|NCT02085395|Experimental|SR-T100 ® Gel|Topical gel containing 2.3% of solamargine in Solanum undatum extract is used once daily with occlusive dressing for 16 weeks.
89487611|NCT03056924||Vedolizumab monotherapy|IBD patients on vedolizumab monotherapy, all patients will be treated with the standard vedolizumab dosing regimen of 300 mg infusions at 8 week intervals and receive Pneumococcal Pneumonia vaccine and/or Influenza vaccine and/or Hepatitis B vaccine.
89487612|NCT03056924||vedolizumab + immunomodulator|IBD patients receiving combination treatment with vedolizumab and concomitant immunomodulator therapy (methotrexate, azathioprine, or 6-mercaptopurine), will be treated with the standard vedolizumab dosing regimen of 300 mg infusions at 8 week intervals and/or receive Pneumococcal Pneumonia vaccine and/or Influenza vaccine and/or Hepatitis B vaccine.
89487613|NCT03056924||biologic + immunomodulator|IBD patients on other biologic therapy (infliximab, adalimumab, certolizumab, golimumab, ustekinumab) with concomitant immunomodulator therapy (methotrexate, azathioprine, or 6-mercaptopurine) and receivePneumococcal Pneumonia vaccine and/or Influenza vaccine and/or Hepatitis B vaccine.
89487614|NCT03056924||non-immunosuppressive therapy|IBD patients not taking any immunosuppressive therapy (these patients may be taking oral or topical 5-aminosalicylates) and recive Pneumococcal Pneumonia vaccine and/or Influenza vaccine and/or Hepatitis B vaccine.
89487615|NCT03227367|Experimental|Test group|Mononuclear cells isolated from the peripheral blood of 25 chronic periodontitis patients were interveened with 1ml/well preparation of Platelet rich fibrin(PRF), Biphasic calcium phosphate (BCP) and PRF and BCP combination in-vitro.
89487616|NCT03227367|Other|control group|Mononuclear cells isolated from the peripheral blood of healthy individuals in-vitro.
89487617|NCT02081729||high VZV ELISPOT results|high spot counts in ELISPOT
89487618|NCT02081729||low VZV ELISPOT results|low spot counts in ELISPOT
89487619|NCT02453061|Placebo Comparator|Placebo group|Subjects will receive safflower oil at 1g/kg/day for 6 months (months 0 - 6) and triheptanoin oil at 1g/kg/day for 6 months (months 7 - 12)
89487620|NCT02453061|Active Comparator|Triheptanoin group|Subjects will receive triheptanoin oil at 1g/kg/day for 6 months (months 0 - 6) and triheptanoin oil at 1g/kg/day for 6 months (months 7 - 12)
89487621|NCT04918862|Active Comparator|Granisetron 1 mg|Granisetron 1 mg: 105 patients received 1mg granisetron
89487622|NCT04918862|Active Comparator|Granisetron 3 mg|Granisetron 3 mg: 105 patients received 3mg granisetron
89487623|NCT02088281|Experimental|Indigo naturalis extract in oil ointment|Indigo naturalis extract in oil ointment: each gram of ointment contains 200 μg±20 μg of indirubin.
89487624|NCT04918706|Experimental|MSC week 4 and 3 before LVRS2|Allogeneic mesenchymal Stromal cells: 2 x 10^6/kg body weight MSC in a range of 1.5 x 10^6 MSC/ kg to 2.5 x 10^6 MSC/kg (at a maximum of 200 x10^6 MSC per study participant) with 5% DMSO iv
88953162|NCT01959009|Experimental|HFOV-sigh at start|"Each patient will be exposed to either HFOV alone (HFOV-only) or HFOV combined with sigh breaths (HFOV-sigh), but in different order.~MAP=mean airway pressure.~DURING HFOV-SIGH:~Frequency 3 breaths/min~Ti = 1s~Peak inspiratory pressure (PIP) = 30 cm H2O~For patients already on HFOV-sigh at study start:~• MAP-set will be left unchanged at pre-trial settings.~For patients on HFOV-only at study start:~• During periods with superimposed sigh breaths, MAP-set will be reduced in accordance with a calculation of MAP aiming to keep average mean airway-pressure (MAP) unchanged. (MAP=(PIP*Tinsp+PEEP*Texp)/(Tinsp+Texp)~DURING HFOV-ONLY~For patients on HFOV-sigh at study start:~• During HFOV-only, the MAP-set will be increased in accordance with a calculation of MAP, aiming to keep average mean airway-pressure (MAP) unchanged.~For patients on HFOV-only at study start:~• MAP-set will be left unchanged at pre-trial settings."
89204195|NCT03903640|Experimental|Optune + Ipilimumab + Nivolumab|"Ipilimumab at 3 mg/kg IV over 90 minutes on Day 1 of each 21-day cycle for 4 cycles.~Nivolumab at 1 mg/kg IV over 30 minutes on Day 1 of each 21-day cycle for 4 cycles, then at 240 mg IV over 30 minutes on Days 1 and 15 of each 28-day cycle for up to 20 doses~Within 2 weeks of the start of ipilimumab (before or after), treatment with Optune will begin. All patients will be required to shave their heads to initiate array placement and Optune therapy.~Treatment may continue for up to 1 year"
89487625|NCT04918706|Placebo Comparator|Placebo week 4 and 3 before LVRS2|Placebo: consisting of a 5% DMSO-solution in isotonic solution
89487626|NCT04918706|Experimental|MSC week 12 and 11 before LVRS2|Allogeneic mesenchymal Stromal cells: 2 x 10^6/kg body weight MSC in a range of 1.5 x 10^6 MSC/ kg to 2.5 x 10^6 MSC/kg (at a maximum of 200 x10^6 MSC per study participant) with 5% DMSO iv
89487627|NCT04918706|Placebo Comparator|Placebo week 12 and 11 before LVRS2|Placebo: consisting of a 5% DMSO-solution in isotonic solution
89487628|NCT03233685|Experimental|Experimental Group|Subjects will perform a visual training for 12 weeks
89487629|NCT03233685|Active Comparator|Control Group|Subjects will perform the normal training routine for 12 weeks
89487630|NCT03559361|Placebo Comparator|Olive oil Placebo|3 x 1 g capsules daily Placebo: olive oil
89487631|NCT03559361|Active Comparator|EPA-rich|3 x 1 g capsules daily containing a SMEDDS formulation of an EPA-enriched oil totalling 900 mg EPA and 360 mg of DHA
89487632|NCT03559361|Active Comparator|DHA-Rich|3 x 1 g capsules daily containing a SMEDDS formulation of an DHA-enriched oil totalling 900 mg DHA and 270 mg of EPA
89487633|NCT02088359||Cycled light|Approximately 12 hours of light on and 12 hours of light off.
89487634|NCT02088359||Near darkness|Continue near darkness
89487635|NCT02452905|Active Comparator|Nitazoxanide|Nitazoxanide 7.5mg/kg oral/nasogastric/nasoenteric tube three times per day for five days.
89487636|NCT02452905|Placebo Comparator|Placebo|The placebo is identical to the active drug described above except that it does not contain the active compound nitazoxanide. It is reconstitutes, administered and dosed as per the active study drug.
89487637|NCT04937426|Experimental|Fluorescent-labeled Urease Inhibitor Marker to Detect Helicobacter Pylori|During gastroscopy additional biopsies are taken in cases where infection with helicobacter pylori is suspected. It will then undergo laboratory analysis with fluorescent-labeled urease inhibitor marker. Results will be compared to standard analysis to determine efficacy.
89487638|NCT03235401||Pulmonary Arterial Hypertension patients|
89487639|NCT02085629|Experimental|M reg treatment|"Donor M reg (2.5-7.5 million cells/kg) IV infused (6-7d before Tx) into recipients of a LD renal Tx. Recipients also receive prednisolone, mycophenolate mofetil and tacrolimus, as detailed below:~Prednisolone~D 0: 500 mg IV~D 1: 125 mg IV~D 2 - 14: 20.0 mg/d (oral)~Wk 3 - 4: 15.0 mg/d~Wk 5 - 8: 10.0 mg/d~Wk 9 - 12: 5.0 mg/d~Wk 13 - 14: 2.5 mg/d~Wk 15 - End: Cessation~MMF (or biologic equiv.)~D -7 to -2: 500 mg/d (250mg 2x/d)~D -1 to 14: 2000 mg/d~Wk 3 - 36: 1000 mg/d~Wk 37 - 40: 750 mg/d~Wk 41 - 44: 500 mg/d~Wk 45 - 48: 250 mg/d~Wk 49 - End: Cessation NOTE: MMF tapering will only happen if a 36-Wk biopsy shows no signs of subclinical rejection or if there is no evidence of declining renal function or if the clinician has any other concern about dose reduction.~Tacrolimus (or biologic equiv.)~≤ 48 h pre-Tx to D 14: 3-12 ng/ml~Wk 3 - 12: 3-10 ng/ml~Wk 13 - 36: 3-8 ng/ml~Wk 37 - End: 3-6 ng/ml"
89487640|NCT04937114|Experimental|Flap will be approximated using conventional, simple continuous suturing with barbed sutures|After administration of adequate amount of local anesthesia, planned muco-gingival surgery will be performed and flap will be approximated using conventional, simple continuous suturing with unidirectional barbed sutures.
89487641|NCT04937114|Active Comparator|Flap will be approximated using conventional, simple continuous suturing with conventional sutures|After administration of adequate amount of local anesthesia, planned muco-gingival surgery will be performed and flap will be approximated using conventional, simple continuous suturing with conventional sutures.
89487642|NCT04918628|Experimental|Arm A|Neoadjuvant Chemotherapy Combined With CCRT Followed by Adjuvant Chemotherapy and Anti-PD-1 Antibody(Sintilimab 200mg intravenous drip every three weeks until PD or 2 years).
89487643|NCT02085707|Active Comparator|Total hip replacement arthroplasty|59 off 118 patients will be randomized to total hip replacement arthroplasty
89487644|NCT02085707|Active Comparator|Closed reduction and internal fixation|"59 off 118 patients will be randomized to closed reduction and internal fixation.~2 cancellous parallel hip pins"
89487645|NCT03235167|Experimental|CpG DNA|CpG DNA concentrate
89487646|NCT03235167|Placebo Comparator|placebo|placebo concentrate
89487647|NCT04929782|Active Comparator|Resin-based sealant|A dental isolation device was used (Mr. Thisty One Step, Zirc Dental, Buffalo, MN, USA) and the treatments were conducted by one operator according to following steps; Group 1: Etching with 37% phosphoric acid for 30 s (i-GEL N, i-dental, Lithuania), rinsing for 30 s with air-water spray and drying with oil-free air for 15 s, resin sealant (Conceal F, SDI, Australia) application into the occlusal and buccal/palatal pits and fissures with direct placement syringe system and light curing with 460-500 nm wavelength halogen light unit (Hilux Dental Curing Light Unit 250, Benlioğlu Dental Inc, Turkey) for 20s on each surface.
89487648|NCT04929782|Active Comparator|Giomer sealant|Group 2: Self-etch primer (BeautiSealant Primer, Shofu, Japan) application to the occlusal and buccal/palatal pits and fissures with fine microbrush and waiting for 5 s, homogenizing the bond layer with gentle air stream for 5 s, giomer sealant application (BeautiSealant Paste, Shofu, Japan) with direct placement syringe system and light curing with 460-500 nm wavelength halogen light unit (Hilux Dental Curing Light Unit 250, Benlioğlu Dental Inc, Turkey) for 20 s on each surface.
89487649|NCT02452827||Primary Chronic Neck Pain|Patients suffering for at least 3 years from neck pain without any underlying pathology who have undergone MRI. Biomechanical parameters of neck movements will be investigated.
89487650|NCT02452827||Control|Patients without neck pain who have undergone MRI for any reason. Biomechanical parameters of neck movements will be investigated.
89487651|NCT04929314|Experimental|Intervention|Participants in the intervention group receive specialised nursing care that focuses on the interactive communication model. The nurses who deliver care to participants in the intervention group receive specific education and training in order to be able to provide nursing based on the interactive communication model and more individualised nursing based on health literacy level.
89487652|NCT04929314|No Intervention|Control|The participants in the control group receive usual care. The 98 municipalities in Denmark have a specialised role in community care and rehabilitation where nursing and practical help is carried out in the patients' own homes. Community care is usually provided at regular intervals based on a clinical evaluation of the patients' needs.
89487653|NCT03233607||Antepartum Patients|Includes antepartum patients receiving prenatal care at the Broadway Practice who plan to deliver at Allen Hospital in New York City (NYC). On postpartum day 1 and day 2, a sample of blood will be drawn in the morning for hemoglobin and hematocrit estimation.
89487654|NCT04918394||Asthma patients unexposed to mold / moisture|No mold / moisture exposure is defined by a negative response to all of the 5 following questions, asked in the form of a parent-completed declarative questionnaire regarding the child's primary living home.
89487655|NCT04918394||Asthma patients exposed to mold / moisture|Mold / moisture exposure is defined by a positive response to at least one of the 5 following questions, asked in the form of a parent-completed declarative questionnaire regarding the child's primary living home.
89487656|NCT02452749|Experimental|Cardiovascular Health Dietary Supplement|The cardiovascular health dietary supplement will be administered at a dosage of 1 caplet po per day for a period of 6 months
89487657|NCT03227523||subjects with copd|
89487658|NCT03227523||subjects without pulmonary disease|
89204196|NCT03982849|Active Comparator|Hydroquinone group|Hydroquinone 4% cream Cream applied once daily at night on affected areas for 3 months.
89204197|NCT03982849|Experimental|Silymarin group|Silymarin 0.7% cream Cream applied twice daily on affecectec areas for 3 months.
89204198|NCT05357872|Experimental|BIS 40-50 Group|The anesthesiologist adjusted the intravenous speed of remifentanil and propofol to maintain the bispectral index (BIS, BIS monitor; Aspect Medical System, Newton, MA) between 40-50
89204199|NCT05357872|Experimental|BIS 50-60 Group|The anesthesiologist adjusted the intravenous speed of remifentanil and propofol to maintain the bispectral index (BIS, BIS monitor; Aspect Medical System, Newton, MA) between 50-60 during the operation.
89487659|NCT04929860|Active Comparator|handwashing|This arm receives a scalable social marketing campaign using innovative behaviour change approaches to improve handwashing. The intervention is delivered by a commercial social marketing business unrelated to the investigating organisations
89487660|NCT04929860|No Intervention|control|
89487661|NCT04918238|Active Comparator|conventional treatment Arm|All the participants will receive the conventional physical therapy protocol per session as following: Infrared radiation on the low back area for 15 minutes, Ultrasound waves (Digi sonic device) for 10 minutes on the trigger areas of the low back, Myofascial release of the thoracolumbar fascia, Stretching of the Paraspinal muscles and the hamstrings, Mobilization of the lumbar and thoracic spine from a prone lying position and strengthening of abdominal muscles, multifidus and transversal's abdominal muscle.
89487662|NCT04918238|Experimental|muscle energy technique arm|Group A received muscle energy technique with lateral recumbent positioning along with Conventional Physiotherapy Program
89487663|NCT03227133|Experimental|Single arm|Psychiatric interview, Neuropsychological evaluations, cardiovascular risk assessment
89487664|NCT02452281|Experimental|ipilimumab + HSPPC-96|"Ipilimumab is administered intravenously at a dose of 3 mg/kg one day (a minimum of 12 hours and not more than 48 hours) before HSPPC-96 every 21-25 days for a total of 4 cycles.~HSPPC-96 is administered at a dose of 25 μg by intradermal injection always 12 - 48 hours following ipilimumab on a weekly basis for the first 4 weeks and then every 3 weeks always 12 - 48 hours after ipilimumab.~Length of Treatment: 4 cycles of ipilimumab and at least 6 cycles of HSPPC-96 up to 12 doses.~Booster doses of HSPCC-96 following 6 administrations on subsequent cycles will be administered every 21-23 days according to availability of vaccine."
89487665|NCT03558113|Other|visual tactile method|visual tactile method using the modified USHPS critiria
89487666|NCT04937348||GDM G1|Mothers diagnosed with gestational diabetes mellitus, treated with diet; and their newborns
89487667|NCT04937348||GDM G2|Mothers diagnosed with gestational diabetes mellitus, treated with insulin; and their newborns
89487668|NCT04937348||non-GDM / control group|"Healthy, non-diabetic mothers, without disturbances in glucose metabolism; and their newborns.~Control group."
89487669|NCT02452125|Experimental|Nicotine Gum|Nicotine chewing gum administered for 30 minutes
89487670|NCT03233451|Experimental|Interventional group|Subjects receive guided psycho-behavioral intervention once a week for 8 weeks. After 8 weeks, the subjects will receive monthly psychological counseling for 7 months.
89487671|NCT03233451|No Intervention|control group|Subjects will receive usual care and be contacted as same frequent as the intervention group.
89487672|NCT04936802|Experimental|Transcatheter tricuspid valve repair system (Trialign)|Subjects who received transcatheter tricuspid valve repair with Trialign will be included in this arm.
89487673|NCT03226977|Experimental|NIPPV|NIPPV is used as a primary mode of ventilation in premature infants with respiratory distress syndrome
89487674|NCT03226977|Active Comparator|NCPAP|NCPAP is used as a primary mode of ventilation in premature infants with respiratory distress syndrome
89487675|NCT04936412|Experimental|Personalized brace group|Personalized brace for patients
89487676|NCT04936412|Active Comparator|Conventional brace group|Conventional brace for patients
89487677|NCT04486053||Patients with flexor tendon injury|Patients between the ages of 6-18 who have applied to orthopedics emergency department due to hand injury and have been operated with flexor tendon injury, for the last 3 years, were retrospectively scanned from hospital record. Eligible patients for the study were informed about the study by telephone and requested to come hospital for further evaluations including sensory, motor and functional assessments.
89487678|NCT03233373||Otolaryngology Clinic Patients|Healthy subjects with no present complaints of nasal obstructions. Patients visiting the clinic, once consented, will be asked which nostril they breathe better from. They will then be asked to perform 3-4 normal respiration cycles through their nose which will be recorded using our thermal imaging device, the Seek CompactPro thermal imager
89487679|NCT02619812|Active Comparator|Group A: SBI + Placebo|Serum-derived bovine immunoglobulin/protein isolate (SBI) 10 grams + placebo twice per day
89487680|NCT02619812|Active Comparator|Group B: Colesevelam + Placebo|Colesevelam 1.875 g + Placebo twice per day
89487681|NCT02619812|Active Comparator|Group C: Colesevelam + SBI|Colesevelam 1.875 g + Serum-derived bovine immunoglobulin/protein isolate (SBI) 10 grams twice per day
89487682|NCT02619812|Placebo Comparator|Group D: Double Placebo|Double placebo twice per day
89487683|NCT02451735|No Intervention|Intervention Development|Psychoeducational Intervention (PEI) development. PEIs include printed and DVD materials, and represent a commonly used and effective approach to implement theoretically based individual-level interventions. These materials serve as important sources of information for the general public, cancer patients, and survivors from a variety of backgrounds, including populations with limited health literacy. An interview and feedback collection process will take place to provide data to improve current PEI materials.
89487684|NCT02451735|Experimental|Intervention Pilot - Intervention Group|The intervention group will receive the PEI materials: video and booklet. Self-reported feedback will be collected and reviewed to compare response with the control group.
89487685|NCT02451735|Active Comparator|Intervention Pilot - Control Group|The control group will receive a patient factsheet about Genetic Counseling (GC). Self-reported feedback will be collected and reviewed to compare response with the intervention group.
89487686|NCT03055754|Experimental|Argon randomized arm|Endoscopic procedure with a full inventory, measurement of the anastomosis diameter, and an argon plasma coagulation. Followup of all patients by a multidisciplinary team (life, food orientations).
89487687|NCT03055754|Active Comparator|Control arm|Full inventory and measurement of the anastomosis diameter, without any intervention. Followup of all patients by a multidisciplinary team (life, food orientations).
89487688|NCT02451657||Cohort|
89487689|NCT03055676|Experimental|Early drain removal|Removing drain(s) on postoperative day 3 (n = 166)
89204200|NCT03983005||Patients with suspected lung cancer|Patients with pulmonary parenchymal lesions suspected for malignancy in contact or adjacent to the esophagus which can be sampled by EUS-B-FNA
89204201|NCT01061593|Experimental|ATT+Immunoxel|TB patients with DS-TB, MDR-TB, XDR-TB or TB-HIV on standard ATT + Immunoxel honey lozenge once per day day
89487690|NCT03055676|Active Comparator|Late drain removal|Removing drain(s) on postoperative day 5 or later (n = 166)
89487691|NCT03120117|Experimental|Cough Test following Sling Surgery|All subjects enrolled will undergo sling surgery for treatment of stress urinary incontinence and subsequently asked to do a standing cough test.
89487692|NCT03222765|Placebo Comparator|Placebo|"Placebo~Lifestyle modification (diet and physical activity recommendations)"
89487693|NCT03222765|Experimental|Metformin|"Metformin~Lifestyle modification (diet and physical activity recommendations)"
89487694|NCT03222765|Experimental|Linagliptin|"Linagliptin~Lifestyle modification (diet and physical activity recommendations)"
89487695|NCT03222765|Experimental|Linagliptin and Metformin|"Fixed dose combination of Linagliptin and metformin~Lifestyle modification (diet and physical activity recommendations)"
89487696|NCT04403126|Experimental|Forgiveness curriculum for 5th grade|"Classrooms randomly assigned to the experimental group will receive the forgiveness intervention. The forgiveness intervention will follow the curriculum - The Journey Toward Forgiveness -A Guided Curriculum for Children Ages 10-12 (Grade 5 in the US). The Forgiveness Curriculum Guide consists 14 lessons over 12 weeks. Each class meets weekly for 40 to 60 minutes to complete one lesson (in two of the weeks, there will be two lessons)."
89487697|NCT04403126|No Intervention|Regular school instruction|Classrooms randomly assigned to the control group will have instruction as usual.
89487698|NCT04485897|Experimental|icare HOME|
89487699|NCT03055598|Experimental|Ferric Citrate|Ferric Citrate (Auryxia) will be dosed initially at 2 tablets three times a day (with meals).
89487700|NCT03120039||Healthy adults|Healthy adults without any limitations in upper extremity movement or function.
89487701|NCT03055520|Experimental|arithmetic training (Kumon method)|
89487702|NCT03055520|Placebo Comparator|nonspecific recreation|
89487703|NCT04485585|Experimental|Sequence T/M/T+M|"A total of 36 subjects will be enrolled in one sequence group. The investigational products (IPs) will be administered according to the treatment groups(T, M, T+M) assigned to on sequence group in Period 1, Period 2, and Period 3.~Period 1(T): BR9006-1 (Tamsulosin HCL 0.2mg) - 1 capsule QD, five-day repeated-dose~Period 2(M): BR9006-2 (Mirabegron 50mg) - 1 tablet QD, eleven-day repeated-dose~Period 3(T+M): BR9006-1 (Tamsulosin HCL 0.2mg) 1 capsule + BR9006-2 (Mirabegron 50mg) 1 tablet QD, five-day repeated-dose~Washout period between Period 1 and Period 2: five days~Washout period between Period 2 and Period 3: none"
89487704|NCT03222453|Experimental|Intervention Patient|Hematopoetic stem cells differentiated from beta-thalassemia induced pluripotent stem cells.
89487705|NCT03222453|No Intervention|non-intervention Patient|No treatment
89487706|NCT03226743|Experimental|Intervention Group|collaborative and stepped care model for depressive, anxiety, somatoform and/or alcohol abuse disorders within a multiprofessional network
89487707|NCT03226743|No Intervention|Control Group|treatment as usual in German health care system
89487708|NCT03222687|Experimental|therapy group|Immunosuppressive therapy included tacrolimus and prednisone.
89487709|NCT03055442||Follicular Fluids|Follicular fluids obtained by 8 oocyte donors
89487710|NCT03222375||Autism|Individuals with autism will have either Image converter (iSQUED™) for Hysteresis of Spiral Autowaves, Sound converter (sSQUED™) for Drift of Spiral Autowaves or Electromagnetic converter (eSQUED™) for Annihilation Autowave reverberator.
89487711|NCT03226587|Experimental|Blue light|Each subject will be undergo a whole body exposure to blue light (453 nm wavelength) for 30 minutes.
89487712|NCT03226587|Placebo Comparator|Control exposure|Each participant will also undergo a control examination, where the body will be covered with a light tight foil during blue light exposure for 30 minutes.
89487713|NCT04928690||Arm 1: MCI amyloid positive|"Meet the National Institute of Aging - Alzheimer's Association (NIA-AA) core clinical criteria (2011) for MCI due to Alzheimer's~Positive amyloid PET or amyloid CSF status.~MMSE 23-30 (inclusive)"
89487714|NCT04928690||Arm 2: MCI amyloid negative|"Non-AD Mild Cognitive Impairment (MCI)~Negative amyloid PET or amyloid CSF status.~MMSE 23-30 (inclusive)"
89487715|NCT04928690||Arm 3: CN amyloid positive|"Absence of a diagnosis of cognitive disorder and/or subjectively reported cognitive decline~Positive amyloid PET or amyloid CSF status.~MMSE 26-30 (inclusive)"
89487716|NCT04928690||Arm 4: CN amyloid negative|"Absence of a diagnosis of cognitive disorder and/or subjectively reported cognitive decline~Negative amyloid PET or amyloid CSF status.~MMSE 26-30 (inclusive)"
89487717|NCT03226431|Experimental|ARINA-1|Ascorbic acid (ARINA-1) (inhaled ascorbic acid 88 mg/ml) will be nebulized twice daily for 3 months using a PARI eFlow nebulizer
89537869|NCT03289637|Placebo Comparator|Placebo|In the group randomised to placebo and with a screening level of 25-OH-vitamin D <50 mol/L, the participants will be given placebo.
89537870|NCT04854837||Hemodialysed patients received remdesivir|Remdesivir: day-1: 200 mg intravenously; day 2-5: 100 mg intravenously
89204202|NCT01061593|Placebo Comparator|ATT+Placebo|TB patients with DS-TB, MDR-TB, XDR-TB or TB-HIV on standard ATT + Placebo lozenge made of corn syrup once/day
89204203|NCT00769262|Active Comparator|Aggressive Weaning|Infants will be weaned from the isolette using our current NICU standard of care.
89204204|NCT00769262|Experimental|Conservative Weaning|Infants will be weaned from the isolette using a modified conservative weaning schedule.
89537871|NCT04854837||Hemodialysed patients not received remdesivir|Standard of care
89487718|NCT04917770|Experimental|Sintilimab in combination with Multimodality Radiotherapy group|The dose of sintilimab was 200mg per dose, intravenously, once every 3 weeks. Multimodal radiotherapy methods: ①SBRT: ≥1 independent lesion was selected, with a single dose of 8-10Gy and a total dose of 40-60Gy, divided into 5-6 times of radiotherapy. The final frequency and total dose of radiotherapy were determined by the radiologist.② Low-dose radiotherapy: ≥1 independent lesion was selected, and the single dose, the final frequency of radiotherapy and the total dose were determined by the radiologist.
89204205|NCT03979261||sex ratio evaluation|Valvular surgery is performed in 30-40% of cases. The Cardiology and Cardiac Surgery De la Timone services 1000 patients as part of their valvulopathy and 450 benefit from cardiac surgery. On the other hand, transcriptomic analysis by microarray will only be done on 40 patients because the analysis costs 150 € / patients.
89487719|NCT03222297||test group|Patients with craniocerebral injury were randomized into test group (n = 40) with early skull repair using titanium mesh within 1-3 months after decompression.
89487720|NCT03222297||control group|Patients with craniocerebral injury were randomized into control group (n = 46) with late-stage skull repair using titanium mesh within 6-12 months after decompression.
89204206|NCT00777218|Active Comparator|1|
89487721|NCT04918004|Experimental|Case group|Patients in the case group were given one-to-one sleep hygiene training by researchers and, a brochure containing 10 lifestyle changes related to sleep hygiene as well as they assessed at the first interview and the last interview, received routine health care, and
89487722|NCT04918004|No Intervention|Control group|Patients in the control group were assessed at the first interview and the last interview, received routine health care, and no intervention was performed during the research.
89487723|NCT02451579|Active Comparator|Cetirizine Hydrochloride|Prophylactic use of cetirizine hydrochloride prior to and after Topical 5-aminolevulinic Acid Photodynamic Therapy
89204207|NCT00777218|Active Comparator|2|
89204208|NCT00777218|Active Comparator|3|
89204209|NCT04047758|Experimental|Palbociclib + Letrozole group|210 patients will be randomly assigned to receive treatment with palbociclib and letrozole (palbociclib + letrozole group) .
89204210|NCT04047758|Placebo Comparator|Letrozole group|210 patients will be randomly assigned to receive treatment with letrozole (letrozole group).
89204211|NCT00922064|Experimental|ECT|
89204212|NCT05355064|Experimental|Single arm|Single treatment, no placebo.
89204213|NCT00307801|Experimental|Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027)|A blister consists of 28 tablets taken orally once a day for 28 days (one cycle): 2 days of 3 mg estradiol valerate (EV); 5 days of 2 mg EV + 2 mg dienogest (DNG); 17 days of 2 mg EV + 3 mg DNG; 2 days of 1 mg EV; 2 days of placebo.
89204214|NCT00307801|Placebo Comparator|Placebo|Matching placebo to be taken orally daily.
89487724|NCT02451579|Placebo Comparator|Placebo|Prophylactic use of placebo prior to and after Topical 5-aminolevulinic Acid Photodynamic Therapy
88953163|NCT01959009|Experimental|HFOV-only at start|"Each patient will be exposed to either HFOV alone (HFOV-only) or HFOV combined with sigh breaths (HFOV-sigh), but in different order.~MAP=mean airway pressure.~DURING HFOV-SIGH:~Frequency 3 breaths/min~Ti = 1s~Peak inspiratory pressure (PIP) = 30 cm H2O~For patients already on HFOV-sigh at study start:~• MAP-set will be left unchanged at pre-trial settings.~For patients on HFOV-only at study start:~• During periods with superimposed sigh breaths, MAP-set will be reduced in accordance with a calculation of MAP aiming to keep average mean airway-pressure (MAP) unchanged. (MAP=(PIP*Tinsp+PEEP*Texp)/(Tinsp+Texp)~DURING HFOV-ONLY~For patients on HFOV-sigh at study start:~• During HFOV-only, the MAP-set will be increased in accordance with a calculation of MAP, aiming to keep average mean airway-pressure (MAP) unchanged.~For patients on HFOV-only at study start:~• MAP-set will be left unchanged at pre-trial settings."
89487725|NCT04935788|Experimental|milk protein|milk protein supplement
89487726|NCT04935788|Experimental|micellar casein|casein supplement
89487727|NCT04935788|Experimental|pea protein|pea protein supplement
89487728|NCT04935788|Experimental|milk/pea protein|a blend of milk and pea protein
89487729|NCT03233295|Experimental|Vitamin D deficiency|
89487730|NCT04484805|No Intervention|Baseline|The subject wears their usual socket with an ambient temperature sensor and step counter for approximately one month.
89487731|NCT04484805|Experimental|ICE Unit|"The subject wears the experimental socket with an ICE Unit, which includes a TEC and will be actively cooling the leg whenever the device is powered on. An ambient temperature sensor and step counter is attached to the socket. The subject is only informed that each condition is a different level of cooling to reduce bias. This condition should last approximately one month."
89487732|NCT04484805|Sham Comparator|Sham Unit|"The subject wears the experimental socket with a Sham Unit, which excludes a TEC and will not be actively cooling the leg when the device is powered on. An ambient temperature sensor and step counter is attached to the socket. The subject is only informed that each condition is a different level of cooling to reduce bias. This condition should last approximately one month."
89487733|NCT02623322|Experimental|MHAA4549A 3600 milligrams (mg)|Participants will receive single-dose MHAA4549A, 3600 mg, by intravenous (IV) administration.
89487734|NCT02623322|Experimental|MHAA4549A 8400 mg|Participants will receive single-dose MHAA4549A, 8400 mg, by IV administration.
89487735|NCT02623322|Placebo Comparator|Placebo|Participants will receive single-dose placebo by IV administration.
89487736|NCT02452203|Experimental|Floating|The participant will float supine in water with a high concentration of Epsom salt for 90 minutes.
89487737|NCT02452203|Placebo Comparator|Chair|The participant will lay in the supine position while reclined in a zero-gravity chair for 90 minutes.
89487738|NCT03222219||low implant stability quotient|dental implant insertion with low torque values
89487739|NCT03222219||medium implant stability quotient|dental implant insertion with medium torque values
89487740|NCT03222219||high implant stability quotient|dental implant insertion with high torque values
89487741|NCT03222063|Experimental|Experimental group|"Experimental Group:~Experimental group consists of 30 hospitalized children.In Experimental group after taking pretest on 1st day play interventions were introduced to the children and instructions regarding the way to play with all the interventions were provided to the children. Though all the children were free to choose the play yet the younger children were given simple and easy play interventions such as drawing, coloring etc. to obtain more sensory experience whereas the older children were offered play interventions such as puzzle, building blocks, ludo etc. with high cognitive demand. The play interventions were administered for 1 hour daily for continuous 5 days.Post test assessment of anxiety was done on 5th day."
89487742|NCT03222063|No Intervention|Comparison group|Comparison Group: 30 hospitalized children were selected by purposive sampling in comparison group. Pretest anxiety was measured on 1st day . No intervention was administered. only usual medical and nursing care was administered to the hospitalized children. Post test assessment of anxiety was done on 5th day.
89487743|NCT04917458|Experimental|Cholecalciferol|-Vitamin D 25 (OH) 4000 IU capsules, tablet @ 1000 IU One capsule for once a day for 30 days of study period.
89487744|NCT04917458|Placebo Comparator|Control Group|Placebo will be administrated orally, One capsule once a day for 30 days of study period
89487745|NCT04927910|Experimental|True self-acupressure|1) two individual/group acupressure training sessions over 2 weeks and (2) self-acupressure for 6 weeks.
89487746|NCT04927910|Sham Comparator|Sham self-acupressure|Same protocol to the true self-acupressure group but on the sham acupoints
89487747|NCT04927910|Other|Usual care|General advise on managing symptoms provided by healthcare providers
89487748|NCT03233061|Active Comparator|NO|NON OBESE WOMEN GROUP ( same age and same physical activities ) cardiorespiratory exercise testing with evaluation of peak oxygen uptake, heart rate and maximal cycling power output. Cardiorespiratory functioning is assessed during household activities such as ironing,cleaning floor,walking and climbing stairs.
89487749|NCT03233061|Experimental|OB|OBESE GROUP cardiorespiratory exercise testing with evaluation of peak oxygen uptake,heart rate and maximal cycling power output.Cardiorespiratory functioning is assessed during household activities such as ironing, cleaning floor, walking and climbing stairs
89487750|NCT04935398|Experimental|Manual therapy|Football players with adductor tendinopathy undergoing treatment consisting of manual therapy and therapeutic exercise.
89487751|NCT04935398|Experimental|Electrotherapy|Footballers with adductor tendinopathy undergoing electrotherapy treatment
89487752|NCT03232905|Experimental|PF-06651600|Multiple ascending doses of PF-06651600
89487753|NCT03232905|Placebo Comparator|Placebo|Multiple ascending doses of Placebo
89487754|NCT03226041|Experimental|retroperitoneoscopic urologic surgery|All included patients will undergo retroperitoneoscopic renal or adrenal surgery with the transcutaneous carbon dioxide monitor.
89487755|NCT04917536|Active Comparator|rotator cuff approach|the nail is inserted through the supra-spinatus tendon, which is closed at the end of the surgery
89487756|NCT04917536|Experimental|rotator cuff split approach|the nail is inserted through the rotator cuff split, between the supra-spinatus tendon and the long part of the biceps
89487757|NCT03221907|Experimental|GLA5PR GLARS-NF1 & Pregabalin placebo|GLA5PR GLARS-NF1 150mg, 300mg tablet by mouth, every after dinner for about 3 months Pregabalin placebo 75mg, 150mg, 300mg capsules by mouth, every after breakfast and dinner for about 3 months
89487758|NCT03221907|Active Comparator|GLA5PR GLARS-NF1 placebo & Pregabalin|GLA5PR GLARS-NF1 placebo 150mg, 300mg tablet by mouth, every after dinner for about 3 months Pregabalin 75mg, 150mg, 300mg capsules by mouth, every after breakfast and dinner for about 3 months
89487759|NCT04927520||Endovascular therapy group|Unruptured middle cerebral artery aneurysms treated with coil embolization
89487760|NCT04927520||Clipping surgery group|Unruptured middle cerebral artery aneurysms treated with clipping surgery
89487761|NCT03226119|Experimental|HTLV Infected (n=50)|Serum/plasma specimens which are HTLV I, HTLV II or HTLV I/II known positive (KP)
89487762|NCT03226119|Experimental|Neurological Disorders (n=100)|Serum/plasma specimens with symptoms or any of the following neurological disorders: Acute Disseminated Encephalitis, Amyotrophic Lateral Sclerosis, Autonomic Dysfunction, Conus Medularis Syndrome, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Dermatomyositis, HAM-TSP, Meningitis, Mild Cognitive Impairment, Multiple Sclerosis, Polymyositis, Spastic Paraparesis, Sciatica
89487763|NCT04917380||Gram-negative bacteria group|Gram-negative bacteria intracranial infection after neurosurgery
89487764|NCT04917380||Gram-positive bacteria group|Gram-positive bacteria intracranial infection after neurosurgery
89487765|NCT03221985|Other|Questionnaires|
89487766|NCT03055130||Case group|Female IBD patients who had sexual life between 21-60 years-old were recruited.
89487767|NCT03055130||control group|Female people who perform physical examination in our hospital between 21-60 years-old were recruited as control during the study period.
89487768|NCT03225885|Active Comparator|Printed Handout|Participants in this arm will receive verbal prematurity counseling from a Neonatologist or Neonatal fellow as well as a printed gestational age specific handout about prematurity.
89487769|NCT03225885|Experimental|Multimedia Information|Participants in this arm will receive verbal prematurity counseling from a Neonatologist or Neonatal fellow as well as have bedside access to iPad multimedia information regarding prematurity.
89487770|NCT04935086||MACE Group|MACE Group includes the patients suffered from any component of MACE after RA-CABG until the latest follow-up.
89487771|NCT04935086||Non-MACE Group|Non-MACE Group includes the patients freed from any component of MACE after RA-CABG until the latest follow-up.
89487772|NCT04934930|Experimental|Reduced number of bendamustine cycles in patients with mid-induction MRD negativity|Patients with follicular lymphoma treated with obinutuzumab bendamustine & achieving MRD negativity as well as complete metabolic response on PET-CT at mid-induction would continue obinutuzumab treatment while omitting bendamustin after 4 cycles.
89487773|NCT04934774|Experimental|anti-CD7 CAR T cells|anti-CD7 CAR T cells Dose escalation phase: anti-CD7 CAR T cells transduced with a lentiviral vector to express CD7 chimeric receptor domain on T cells with an escalation approach, 1 e6 to 5 e6 CAR-T cells/kg.
89487774|NCT04484961|No Intervention|Control - Routine Rehab|Participants in this group received standard ACL rehab with no blood flow restriction therapy.
89487775|NCT04484961|Experimental|Experimental - BFR|Participants in this group received standard ACL rehab with the addition of blood flow restriction therapy.
89487776|NCT03057236|No Intervention|Standard of Care|This arm does not receive the behavioral intervention. Participants will complete HCV treatment per standard of care.
89487777|NCT03057236|Experimental|Cognitive Behavior Coping Skills|The CBCS intervention is a structured module-based group intervention involving 9, 2-hour sessions. Participants will participate in 4 weekly sessions before HCV treatment to learn and practice new cognitive behavioral skills, and 5 sessions during HCV treatment at weeks 2, 4, 6, 8, and 12.
89487778|NCT03056612||Group 1|Group 1 patients with high risk of ACLF development (CLIF-C AD score ≥ 50)
89487779|NCT03056612||Group 2|Group 2 patients with low risk of ACLF (CLIF-C AD score <50)
89487780|NCT03056612||ACLF|ACLF-patients were specified the patients who were admitted at hospital with ACLF,
89487781|NCT03107481|Active Comparator|Acetaminophen|
89487782|NCT03107481|Active Comparator|Hydromorphone|
89487783|NCT04934852|Experimental|ephedrine (4mg)|
89487784|NCT04934852|Experimental|ephedrine (8mg)|
89487785|NCT04934852|Experimental|ephedrine (12mg)|
89487786|NCT03119493|Experimental|Periodized aerobic interval training|The experimental groups will participate in a 16 week, three times a week based-program of periodized aerobic interval training that consist in warming [5 minutes of general stretching and 5 minutes of walking on treadmill with heart rate less than 20 percent of heart rate reserve (HHR)], followed by periodized aerobic interval training on treadmill, and cooling down [5 minutes of walk in treadmill with a heart rate less than 20 percent of HRR and 5 minutes of rest]
89487787|NCT03119493|No Intervention|Control group|Participants in the control group will be instructed not to take part in any regular exercise programs during the study period.
88953164|NCT01959022|Experimental|Doxazosin XL|Subjects will participate in a 2 week flexible-dose titration of doxazosin XL based on clinical response and adverse effects followed by 6 weeks of steady dose treatment.
88953165|NCT01959061|Experimental|Raltitrexed and Oxaliplatin|Raltitrexed and Oxaliplatin were mixed with 10-15 ml lipiodol by arterial chemoembolization on day 1 and during each 28-day cycle.
88953166|NCT01959074|Active Comparator|Naftopidil|This interventional group will receive analgesics and naftopidil 75mg po qd.
88953167|NCT01959074|Placebo Comparator|Control groups with only analgesics|Control groups will receive only analgesics
88953168|NCT01959100|Experimental|Azithromycine|250 mg x 3/week during a meal for a period of 2 years
88953169|NCT01959100|Placebo Comparator|Placebo|250 mg x 3/week during a meal for a period of 2 years.
89487788|NCT04934618|Experimental|Carelizumab Combined With Irinotecan and Apatinib|Second-line treatment of advanced gastric cancer with three-drug regimen（Carelizumab Combined With Irinotecan and Apatinib ）
89487789|NCT03107325|Other|F-18 FDG|Only patients scheduled for a whole body PET scan will be eligible. Subjects of all ages will be imaged after 4 h. The CT image from the routine scan will be used for the 2nd scan to avoid additional CT exposure. It is important to note that the patient volunteers will not receive any additional radiation exposure for inclusion in this study. They are only being ask to allow imaging at one additional time point.
89487790|NCT04916756|Experimental|baricitinib 2mg per day|
89487791|NCT03221361|Active Comparator|Thermoplastic resin group|Thermoplastic complete denture placement is done
89537872|NCT04972149||LC|laparoscopic surgery using conventional laparoscopic instruments
89021738|NCT04715789|Experimental|graded exposure and graded activity in addition to phycal therapy intervention|"Graded exposure:This approach followed a model where the patient was gradually exposed to previously pain provocative, feared and or avoided tasks. These activities are started at a diminished level that elicits minimal amounts of fear and then gradually increased to situations that elicit larger amounts of fear patients are asked to create a hierarchy of feared activities. The exposure starts with the least feared activity, and the therapist helps the patient appraise the exposure and its consequences and then address irrational and counterproductive beliefs, leading to reductions in the anxiety associated with the activity~Graded activity exercises: The new postural and movement behaviors were integrated into each person's nominated pain provocative functional activities linked to their goals in order to generalize learning and build self-efficacy the program focuses on functional activities for about 10 min before physical therapy program (strengthening)"
89021739|NCT00444834|Experimental|1|Egalet carvedilol
89487792|NCT03221361|Placebo Comparator|conventional acrylic resin group|conventional acrylic resin complete denture placement is done
88953170|NCT01959126|Experimental|Stress-reduction class|Study participants enrolled in a 12-week stress reduction course based on the principles of mindfulness. They attended four six-hour workshops and participated in 12 weekly hour-long web video conferencing calls to reinforce what was taught in the workshops. We have two groups: chronically-stressed maternal caregivers of children on the autism spectrum and control mothers whose children have no significant psychiatric or physical impairment.
88953171|NCT01959152|Experimental|HiRes90K™ Advantage Cochlear Implant|HiRes90K™ Advantage implant with HiFocus™ Mid-Scala electrode will be implanted in adults with a moderate level of hearing loss in the low frequencies and severe-to-profound hearing loss in the mid-to-high frequencies.
88953172|NCT01959191||Low platelet reactivity group|"Platelet reactivity will be measured after 7-days treatment of clopidogrel by VerifyNow system and the cohort will be divided by two group according to P2Y12 reactivity unit (PRU) cutoff value. Receiver operating characteristic (ROC) curves will be plotted to assess the optimal PRU cutoff value for differentiating between patients with and without subsequent MACEs after 1 year of follow-up. Low platelet reactivity indicates good response to clopidogrel and high platelet reactivity, resistance to clopidogrel. Groups will be Low platelet reactivity group and High platelet reactivity group"
89021740|NCT00444834|Active Comparator|2|Coreg
89021741|NCT04698486|Active Comparator|Type 2 Diabetes with NAFLD|"Patients with Type 2 Diabetes with NAFLD~MR spectroscopy verified no steatosis"
89021742|NCT04698486|Active Comparator|Type 2 Diabetes without NAFLD|"Patients with Type 2 Diabetes without NAFLD~MR spectroscopy verified steatosis"
89021743|NCT00337766|Active Comparator|Desmopressin (DDAVP)|
89487793|NCT04916522|Experimental|Colchicine|Colchicine 0.5 mg once daily
89487794|NCT04916522|Placebo Comparator|Placebo|Placebo once daily
89487795|NCT03225729|Experimental|CRYOBEAUTY MAINS ET DECOLLETE|"CRYOBEAUTY MAINS ET DECOLLETE is a new technology conceived to treat solar lentigo.~One side left, or right of neckline and/or hands is attributed to this device according to randomization protocol."
89487796|NCT03225729|Active Comparator|Liquid nitrogen|Liquid nitrogen is a classic cryotherapy device. One side, either left or right of neckline and/or hands are attributed to this device according to randomization protocol.
89487797|NCT03225495|Active Comparator|Standard Implant|
89487798|NCT03225495|Experimental|Ultra-narrow Implant|
89487799|NCT04934384||Positive prehospital eFAST|Patients with a positive prehospital eFAST, independently from their hemodynamic status or other vital signs
89487800|NCT04934384||Negative or not performed prehospital eFAST|Patients with a positive prehospital eFAST, independently from their hemodynamic status or other vital signs
89487801|NCT03221439|Experimental|Cognitive Functional Therapy|Cognitive Functional Therapy (CFT) is a behavioral intervention that addresses multiple aspects of low back pain. This approach focuses on changing the patient's beliefs, confronting their fears, educating them about pain mechanisms, increasing mental strength, and control of their body. This is done with functional tasks performed by individuals training them to reduce excessive muscle activity in the trunk and generate behavioral changes related to pain, from postures and provocative movements.
89487802|NCT03221439|Active Comparator|Manual Therapy and Exercise|The active comparator will be the combination of manual therapy and motor control exercises.
89487803|NCT03057392|Experimental|immersion and them sham procedure|"hemodialysis patients will do a 3 hours dialysis session while sitting in a bath and then have a dry session outside the bath"
89487804|NCT03057392|Sham Comparator|sham session and then immersion|dialysis patients will have a 3 hour dialysis session (dry session) and then immersion
88953173|NCT01959191||high platelet reactivity group|"Platelet reactivity will be measured after 7-days treatment of clopidogrel by VerifyNow system and the cohort will be divided by two group according to P2Y12 reactivity unit (PRU) cutoff value. Receiver operating characteristic (ROC) curves will be plotted to assess the optimal PRU cutoff value for differentiating between patients with and without subsequent MACEs after 1 year of follow-up. Low platelet reactivity indicates good response to clopidogrel and high platelet reactivity, resistance to clopidogrel. Groups will be Low platelet reactivity group and High platelet reactivity group"
89487805|NCT04934150|Active Comparator|M1 stimulation|10 Hz stimulation of left motor area
89487806|NCT04934150|Active Comparator|DLPFC stimulation|5 Hz stimulation of left dorsolateral prefrontal cortex
89487807|NCT04934150|Sham Comparator|Sham TMS|Sham TMS over the left M1 area
89487808|NCT02451501|Experimental|Lying|Nebulization in lying position
89487809|NCT02451501|Active Comparator|Sitting|Nebulization in sitting position
89487810|NCT04933994||Coronavirus disease; Influenza A(H1N1)|two independent cohorts of COVID-19 pneumonia (n=405) and H1N1 influenza pneumonia (n=78) retrospectively, all patients were confirmed by RT-PCR. Four hundred and five cases of COVID-19 pneumonia were confirmed in nine hospitals of Zhejiang province, China from January 21 to February 20, 2020. Seventy-eight cases of H1N1 influenza pneumonia were confirmed in our hospital from January 1, 2017 to February 29, 2020.
89487811|NCT03221283|No Intervention|control group|Participants only accept the regular scheduled in the compulsory isolated detoxification center.
89487812|NCT03221283|Experimental|Music therapy group|Use randomized controlled clinical trial design.The main content of music therapy is emotional experience , emotion regulation, emotional control and emotional expression. The experimental group received 13 group music sessions over a three-month period.
89487813|NCT04933604||LPN group|39 patients with high complexity renal tumors who underwent laparoscopic partial nephrectomy
89487814|NCT04933604||LRN group|39 patients with high complexity renal tumors who underwent laparoscopic radical nephrectomy
89487815|NCT04926506|Experimental|Xiyanping injection combined with routine treatment|
89487816|NCT04926506|No Intervention|routine treatment|
89487817|NCT04927130||Women in age 35 to 65 with confirmed breast cancer|
89487818|NCT04927130||Healthy Volunteers|
89487819|NCT03221205|Sham Comparator|Sham CPAP|Patients randomized to use sham CPAP via a nasal mask every night for three months, also with medical treatment for control of obesity, optimal medical treatment for diabetes mellitus.
89487820|NCT03221205|Experimental|Therapeutic CPAP|Patients randomized to use CPAP programmed to administer automatically pressure from 4 to 20 cm H2O via a nasal mask every night for three months, also with medical treatment for control of obesity, optimal medical treatment for diabetes mellitus.
89487821|NCT03225651|Experimental|Stem cell transplantation|Stem cell transplantation 2 intrathecal administrations of autologous bone marrow mononuclear cells at baseline and 6 months afterward
89487822|NCT03225651|Experimental|Psychological therapy and rehabilitation|Psychological therapy Rehabilitation in 3 months
88953174|NCT01959217|Experimental|PM Component Text Reminders|There will be a a single face-to-face intervention followed by tailored text reminders. The number of PM components (strategic encoding, monitoring, and cue salience) that will comprise the tailored text message reminders will be determined by Phase 1.
88953175|NCT01959256|Experimental|Learning|Visual perceptual learning (VPL) group
89487823|NCT03225339|Experimental|Lifestyle Intervention|The intervention includes the use of Low Energy Diet replacement products in combination with physical activity, followed by gradual introduction of food, and increasing physical activity. Behavioural support for the lifestyle intervention will also be provided.
89487824|NCT03225339|No Intervention|Usual Care|This will be based on current clinical practice aiming to reduce diabetes symptoms and complications, and general recommendations on diet and physical activity.
89487825|NCT04407650|Active Comparator|Metformin|Oral 1000 mg BD
89487826|NCT04407650|Experimental|Ursodeoxycholic acid|Oral 500 mg BD
88953176|NCT01959256|No Intervention|Control|Control group
88953177|NCT01959269||Regorafenib|Patients treated with Stivarga as 3rd or 4th line treatment, no intervention
88953178|NCT01959295|Experimental|ASP2151|
88953179|NCT01959295|Placebo Comparator|ASP2151 placebo|
88953180|NCT01959308||Immunosuppressive therapy|Liver Transplant recipients who are receiving various doses and types of immunosuppressive therapy
89487827|NCT03225261|Experimental|Citrus extract|Citrus extract
89487828|NCT03225261|Placebo Comparator|Placebo|Maltodextrin
89487829|NCT03055052|Active Comparator|Control Formula|Standard formula for preterm infants.
89487830|NCT03055052|Experimental|Experimental formula|Formula with higher protein and new fat blend for preterm infants.
89487831|NCT00105157|Experimental|1|MK0518 200 mg
89487832|NCT00105157|Experimental|2|MK0518 400 mg
89487833|NCT00105157|Experimental|3|MK0518 600 mg
89487834|NCT00105157|Placebo Comparator|4|Placebo
89487835|NCT03221049||chronic hepatitis B patients|ultrasound and radiomics
89487836|NCT03221049||patients with liver space occupying lesions|ultrasound and radiomics
89487837|NCT03221049||patients undergo ablation|ablation, ultrasound and radiomics
89487838|NCT04916366|Experimental|Kinesio taping|In this arm, patients will be treated with blue Kinesio taping in a muscle relaxation position during 4 days.
89487839|NCT04916366|Placebo Comparator|Placebo|In this arm, patients will be treated with conventional bandage in a muscle relaxation position during 4 days.
88953181|NCT01959360|Active Comparator|direct lateral|
88953182|NCT01959360|Experimental|minimal invasive|
89487840|NCT04916366|No Intervention|Control|In this arm, patients will be not treated but the outcomes will be measure after 4 days.
89487841|NCT03220815|Experimental|Biologic drilling drilling at low speed|
89487842|NCT03220815|Active Comparator|conventional drilling drilling at high speed|
89487843|NCT03232515|Experimental|Intervention group|Evaluation,estimation and modification of the dry weight by BIVA.
89487844|NCT04926428|Experimental|experimental arm|In situ thrombolysis with tPA
89537873|NCT04972149||LW|Using wristed laparoscopic instruments (Artisential Maryland dissector, Artisential Fenestrated grasper)
89537874|NCT04972149||RC|Conventional robotic surgery
89487845|NCT03225027|Experimental|Patients with schizophrenia|Emotional judgment task, post-experimental questionnaire, recognition task, detection task, questionnaire CAPE-42, trait emotional intelligence questionnaire and positive and negative syndrome scale.
89487846|NCT03225027|Experimental|Few psychotic experiences|Healthy participants with few psychotic experience. Participants with the lowest score to the CAPE-42 test. Mini International Neuropsychiatric Interview
89487847|NCT03225027|Experimental|Several psychotic experiences|Healthy participants with several psychotic experiences. Participants with the highest score to the CAPE-42 test. Mini International Neuropsychiatric Interview
89487848|NCT04926350|No Intervention|Control|Tracking of outcomes during a normal week
89487849|NCT04926350|Experimental|Resistance Exercise|Tracking of outcomes during a normal week with the addition of daily resistance exercise breaks (8 breaks per day)
89487850|NCT03220659|Placebo Comparator|Standard settings|Usual pacing programming
89487851|NCT03220659|Experimental|Multi-point pacing|MPP programming
89487852|NCT03752047||Suspicion of Sepsis|Patients who are admitted and are diagnosed with sepsis will be recruited for this investigation.
89487853|NCT03224715|Experimental|Actinic Cheilitis patients|
89487854|NCT04913402||Consultation|Patient who were administered sufentanil in acute trauma by paramedics after phone call consultation with medical doctor.
89487855|NCT04913402||Competency|Patient who were administered sufentanil in acute trauma by paramedics with competence to administer sufentanil without any consultation with medical doctor.
89487856|NCT03220971||proposed cross-section study|"100 subjects with NAFLD/NASH and negative anti-HCV Ab~50 subjects with HCC and negative anti-HCV Ab~50 subjects with HCC and positive for genotype-1 HCV~50 controls with all negative for NAFLD/NASH but positive for genotype-1 HCV~50 controls with all negative for NAFL, NASH and HCV"
89487857|NCT03220971||proposed longitudinal study|"50 NAFLD/NASH patients and positive for genotype-1 HCV with SVR~10 NAFLD/NASH patients and positive for genotype-1 HCV without SVR~10 HCC patients and positive for genotype-1 HCV with SVR~10 HCC patients and positive for genotype-1 HCV without SVR~50 chronic hepatitis C but not NAFLD patients with SVR~10 chronic hepatitis C but not NAFLD patients without SVR"
89487858|NCT04912934||MetS diagnosis|The research included individuals aged 18 years and older, who were not pregnant or breastfeeding, without any psychological disorder diagnosed by psychiatry, without diagnosis of COVID-19 and not using any psychiatric medications. The MetS group for the research included individuals with metabolic syndrome diagnosis according to IDF-2005 diagnostic criteria.
89487859|NCT04912934||non-MetS|The research included individuals aged 18 years and older, who were not pregnant or breastfeeding, without any psychological disorder diagnosed by psychiatry, without diagnosis of COVID-19 and not using any psychiatric medications. The non MetS group in the research included healthy individuals not using any psychiatric medications, without any chronic disorder, and with similar BMI to the individuals in the subject group.
89487860|NCT03232359||SPE/HELLP group|This group included 24 pregnant women (gestational age of >20 weeks) who were diagnosed as having TMA with provisional diagnosis of pre-eclampsia, HELLP syndrome. immature platelets fraction assessment within 12 hours of diagnosis
89487861|NCT03232359||TTP/HUS group|This group included 13 pregnant women (gestational age of >20 weeks) who were diagnosed as having TMA with provisional diagnosis of TTP/HUS. HELLP syndrome. immature platelets fraction assessment within 12 hours of diagnosis
89487862|NCT03232359||Control group|This group included 20 pregnant women (gestational age of >20 weeks) having normal pregnancy with normal blood pressure and platelet count.
89487863|NCT02143297||SAHS negative|Subjects derived to the sleep unit due to suspicion of suffering from sleep apnea which finally do not have the disease according to standard PSG
89487864|NCT02143297||SAHS positive|Subjects derived to the sleep unit due to suspicion of suffering from sleep apnea which finally have the disease according to standard PSG
89487865|NCT04915586|Experimental|Treatment Arm|"Intra-pleural Alteplase 16mg with Pulmozyme (DNase) 5mg for total 3 doses within 24 hours~Intervention Drug: Combination Alteplase and pulmozyme (DNase)"
89487866|NCT03232047|Experimental|Combined cognitive training|The training is combined executive function and memory training. The training is considered 'adaptive', which means that the difficulty level of the tasks increases during the sessions according to the individual level of mastering for each participant, making the patient work at their maximum capacity at all times.
88953183|NCT01959360|Experimental|modified minimal invasive|
89487867|NCT03232047|No Intervention|Waiting-list group|Participants in the control condition will conduct the same training as the intervention group after a 26-week waiting period. During the 26-week waiting period, the participants will receive assessment with the same protocol as the interventional group.
89487868|NCT04925726|Active Comparator|Land based exercise|Land based exercise
89487869|NCT04925726|Active Comparator|Water based exercise|Water based exercise
89487870|NCT03224559||Sham Stimulation|subject receives minimal transcranial electrical stimulation
89487871|NCT03224559||Left Side Stimulation|transcranial electrical stimulation on the left side of the head.
89487872|NCT03232125|Experimental|Ramosetron group|Randomly selected patients of the ramoseton group are given a 0.3 mg of ramosetron after induction.
89487873|NCT03232125|Placebo Comparator|Placebo group|In contrast, patients in the control group are given the same volume of normal saline after induction and given a 0.3 mg of ramosetron after measurement of QTc interval.
89487874|NCT02143375|Experimental|810 Diode Laser|810 nm Diode Laser, contact, continuous wave,320micron,
89487875|NCT03220269||Out-of-hospital cardiac arrest (OHCA)|An OHCA is defined as cessation of cardiac mechanical activity that occurs outside of the hospital setting and is confirmed by the absence of signs of circulation.
89487876|NCT03220269||In-hospital cardiac arrest (IHCA)|An IHCA is defined as cessation of cardiac mechanical activity that occurs inside of the hospital setting and is confirmed by the absence of signs of circulation.
89487877|NCT04915820|Active Comparator|Immediate iron treatment|intravenous iron carboxymaltose before vaccination
88953184|NCT01959373|Experimental|patients|
88953185|NCT01959373|Experimental|healthy volunteers|
89021744|NCT00337766|Placebo Comparator|Placebo|
89021745|NCT00444873|Experimental|28 day dose interval|
89021746|NCT00444873|Experimental|42 day dose interval|
89487878|NCT04915820|No Intervention|No iron treatment|no intravenous iron carboxymaltose before vaccination
89487879|NCT02147743|Experimental|CCP+MDFT|Multidimensional Family Therapy (MDFT) is a multisystemic, flexible intervention system (Liddle, 2002). It is a strengths-based approach promoting protective factors and reducing risk factors for delinquency, substance use, and school problems. MDFT organizes interventions in key areas of the teen's life: self of the adolescent (includes HIV-STD risk behaviors), parenting, family environment, and school/vocational functioning.
89487880|NCT02147743|Other|CCP+SAU|Services as Usual (SAU) are determined on a case-by-case basis by the CCP Case Manager. SAU includes a variety of services offered by a number of community partners.
89487881|NCT03224793|Experimental|BIIB059 20 mg|Participants will receive single subcutaneous (SC) dose of 20 milligram (mg) BIIB059 or matching placebo on Day 1.
89487882|NCT03224793|Experimental|BIIB059 50mg|Participants will receive single SC dose of 50 mg BIIB059 or matching placebo on Day 1.
89487883|NCT03224793|Experimental|BIIB059 150mg|Participants will receive single SC dose of 150 mg BIIB059 or matching placebo on Day 1.
89487884|NCT03224793|Experimental|BIIB059 450mg|Participants will receive single SC dose of 450 mg BIIB059 or matching placebo on Day 1.
89487885|NCT04913324|Experimental|Virtual Care|
89487886|NCT04913324|No Intervention|Standard of Care|
89487887|NCT03224637|Active Comparator|radiofrequency group|radiofrequency was done in the three genicular nerves upper medial and upper lateral and lower medial
89487888|NCT03224637|Active Comparator|conventional group|the patients received conventional paracetamol and non steroidal antiinflammatory
89487889|NCT02147821|No Intervention|Standard|Standard treatment will be defined as current practice whereby two mediastinal chest tubes are used for drainage, as well as an additional pleural tube if the pleura is opened during surgery. As part of current standard practice, the pleural and mediastinal spaces will be suctioned during the achievement of hemostasis prior to the insertion of chest tubes.
89487890|NCT02147821|Experimental|Intervention|The treatment arm of the study will involve standard placement of the mediastinal tubes with the exclusion of the pleural tube.
89487891|NCT04912700||Unvaccinated|Unvaccinated individuals are defined as having positive laboratory COVID-19 testing with no record of immunization against COVID-19 or first-dose vaccination after symptom onset.
89487892|NCT04912700||Partially vaccinated|Partially vaccinated individuals are defined as having positive laboratory COVID-19 testing and symptom onset after a single dose of either mRNA (Pfizer, Moderna) vaccine, or < 14 days after the second dose of either mRNA vaccine (Pfizer, Moderna) or < 14 days after the administration of the single dose of viral vector vaccine (Johnson & Johnson).
89487893|NCT04912700||Fully vaccinated|Fully vaccinated individuals are defined as having positive laboratory testing for COVID-19 and symptom onset >14 days since administration of second dose of either mRNA vaccine, or >14 days since administration of viral vector vaccine (Johnson & Johnson).
89487894|NCT00961831|Experimental|Arm 1|
89487895|NCT00961831|Experimental|Arm 2|
89487896|NCT03224871|Experimental|Nivolumab|Intralesional IL-2, Radiotherapy will be given to all patients. Immune checkpoint blockade with Nivolumab will be started on week 1 day 1, concurrent with radiotherapy and continue with cycles every 2 weeks.
89487897|NCT03224871|Experimental|Pembrolizumab|Intralesional IL-2, Radiotherapy will be given to all patients. Immune checkpoint blockade with Pembrolizumab will be started on week 1 day 1, concurrent with radiotherapy and continue with cycles every 3 weeks.
89487898|NCT02147977|Active Comparator|dietary supplement: n-3 PUFA|"n-3 polyunsaturated fatty acids from fish oil~capsules of 500 mg. 2 g a day."
89487899|NCT02147977|Placebo Comparator|olive oil|Capsules of 500 mg. 2 g a day.
89487900|NCT03220425|Experimental|Insulin detemir|
89487901|NCT03220425|Active Comparator|NPH insulin|
89487902|NCT04912778||Persons who had a covid-19 infection.|Male and female adults who were previously infected with covid-19.
89537875|NCT04972149||RSS|Use of single site system for reduced port robotic surgery
88953186|NCT01959386||HER2 Positive Breast Cancer Participants|Participants with HER2 positive tumors who are considered for treatment with trastuzumab SC according to the judgement of physician and according to the actual summary of product characteristics will be observed for a period of approximately 1 year and will be followed for an additional 2 years.
88953187|NCT01959399|Experimental|ASP015K + rosuvastatin|
89487903|NCT03544021|Experimental|CART-19|The relapsed/refractory ALL patients will receive allogenic or autologous CD19-Targeted CAR-T cells infusion after FC chemotherapy.
89487904|NCT04925258|No Intervention|Services-as-usual|Services-as-usual (referral list for online and telehealth parenting and family mental health services).
89537876|NCT04972149||RSP|Use of da Vinci SP system for reduced port robotic surgery
89537877|NCT04972149||RRI|A new surgical robot Revo-i developed by Meerae company in Korea
89537878|NCT03289559|No Intervention|Control|
89021747|NCT00444873|Experimental|56 day dose interval|
89021748|NCT00337805|Active Comparator|1 colloid|Boluses of fluids are a pentastarch (up to 1000 ml)
89021749|NCT00337805|Active Comparator|2. Crytalloid|Boluses are given as normal saline
89021750|NCT01580397|Experimental|INNO-206|
89021751|NCT04715594||CONNECT DES Registrty|
89021752|NCT02956707||No pre-operative steroids|"This is a prospectively enrolling group of 40 subjects.~Our current clinical practice has changed. We no longer administer pre-oeprative steroids to neonates undergoing surgery with cardiopulmonary bypass. These patients still receive their post-operative steroid infusion that starts after termination from bypass. This is their standard of care and does not change due to study enrollment.~Subject's enrolled in this trial have a ACTH stimulation test performed: pre-operative, immediately post-cardiopulmonary bypass prior to the initiation of their clinical steroids, and prior to leaving the cardiac intensive care unit."
89021753|NCT02956707||Pre-operative steroids|This is a retrospective group of 40 subjects who were previously administered pre-operative steroids. These subjects also had ACTH testing performed pre-operative and immediately post-separation from cardiopulmonary bypass.
89021754|NCT00338195|No Intervention|Delayed intervention control|
89487905|NCT04925258|Experimental|SPACE Parenting Program|"The experimental groups of Manitoba-based parent-child dyads (children ages 3-4 years old) include:~1. Weekly parenting materials, including online videos and mailed out parenting activities, that were developed for the Building Regulation in Dual Generations (BRIDGE) Therapy program. Also included are weekly drop-in group sessions with other parents facilitated by trained MA-level or higher psychology students or psychologists."
89487906|NCT02148055|Other|A group of 20 pregnant patients.|20 patients referred for intrauterine spontaneous fetal death explored by MRI and autopsy.
89487907|NCT04924868|Active Comparator|UDCA (Ursodeoxycholic Acid) group|"Patients receiving Ursodeoxycholic Acid, capsules containing 300 mg, 10 mg/Kg per day:~Patients 40 to 70 kg: 2 capsules/day >70 to 100 Kg: 3 capsules/day >100 kg: 4 capsules/day"
89487908|NCT04924868|Placebo Comparator|Placebo group|Capsules containing placebo, indistinguishable from active treatment.
89487909|NCT03220503|Experimental|Group (A)|consists of 25 patients will receive frozen embryo with endometrial scratching on day 7 of transfer cycle.
89487910|NCT03220503|No Intervention|Group (B)|consists of 25 patients will receive frozen embryo without endometrial scratching as control group.
89487911|NCT02451969|Experimental|Experimental Group|"Single intramuscular injection of the investigational vaccine (0.5 ml) on Day 0~Intervention: investigational 23-valent PPV"
89487912|NCT02451969|Active Comparator|Control Group|"Single intramuscular injection of the control vaccine (0.5 ml) on Day 0~Intervention: control 23-valent PPV"
89487913|NCT04912310|Experimental|Acute angle closure glaucoma|Argon laser peripheral iridoplasty
89487914|NCT03224247|Active Comparator|Transverse splitting|transverse cutting and/or pulling of lower uterine segment during lower segment cesarean section.
89487915|NCT03224247|Active Comparator|Vertical splitting|vertical splitting,of lower uterine segment during lower segment cesarean section.
89487916|NCT04402502|Experimental|Healthy Population|Healthy Individuals with no presence of neurological disorders, rheumatoid arthritis or comorbid health conditions, and are not pregnant.
89487917|NCT02148133|Experimental|Eltrombopag|Subjects were assigned the investigational product (eltrombopag 25 mg/day) orally once a day under fasting condition. The dose adjustment was done every 2 weeks according to the platelet count (increased by eltrombopag 25 mg/day every 2 weeks according to the platelet count up to 100 mg/day).
89487918|NCT03220191|Experimental|palbociclib tablet with/without PPI|palbociclib tablet formulation alone in period 1 + palbociclib tablet formulation plus rabeprazole in period 2
89487919|NCT03220113|Experimental|Dexamethasone,Lidocaine,Thiamine cohort|"Simultaneous administration of a combination of sterile dexamethasone phosphate total dose (bilaterally) of 20 mg, 4 mg/ml, Lidocaine Hydrochloride 1% 40 mg, 10 mg/ml, and Thiamine Hydrochloride 100 mg, 100 mg/ml in a single session into the accessible branches of the trigeminal nerve of the first, second, and third divisions, as well as into the greater and lesser occipital nerve. In first,patient placed in supine position then in prone position for comfortable access to injection site.~De-Novo Treatment medication 'Dexamethasone, Lidocaine, Thiamine Cohort' prepared in single 1 milliliter volume sterile syringes, using 27 Gauge-30 Gauge needles."
89487920|NCT04915430|Active Comparator|Supervised training regimen|"This training regimen consisted of 3 phases: the 1st focused on restoring motion, the 2nd on strengthening of the rotator cuff muscles, and the 3rd on strengthening of the scapular muscles. Stretching completed every training session.~Motion training consisted of 6 exercises.~Postural training: shoulder shrugs and shoulder retraction exercises.~Glenohumeral training: pendulum exercises, and active assisted flexion, abduction and external rotation.~Strengthening of the rotator cuff: side lying external rotation, internal rotation and scaption.~Strengthening of the scapular muscles: press-up, push-up with a plus, serratus anterior supine punch, standing rowing (low row), and seated rowing (high row).~Training sessions ended with 4 stretches: anterior shoulder stretch, posterior shoulder stretch, inferior capsular stretch, sleepers stretch.~Exercises were performed 3 times a week, with progression after the 1st week, and thereafter every 2nd week."
89487921|NCT04915430|Active Comparator|Home training regimen|"The program consisted of the following:~1 motion exercise: upper trapezius relaxation~3 strengthening exercises: serratus anterior strengthening exercise, humeral external rotation with the arm at the side of the body, and humeral external rotation with a rubber band and the arm at 90 degrees abduction.~2 stretching exercises: posterior shoulder and pectoralis minor stretching, Exercises were performed daily, with weekly progression."
89487922|NCT02143453|Experimental|High intensity interval training|
89487923|NCT02143453|Experimental|Endurance training|
89021755|NCT00451308|Experimental|1|Foley balloon wih 60cc fluid
89021756|NCT00451308|Active Comparator|2|Foley balloon with 30cc
89487924|NCT03219957|Experimental|AT-527|
89487925|NCT03219957|Placebo Comparator|Placebo|
89487926|NCT02254525|Experimental|800 mg intravenous ibuprofen|Treatment group: 800 mg IV ibuprofen, starting at the moment of skin closure and every 6 hours, infused over 15 minutes.
89487927|NCT02254525|Placebo Comparator|200 ml of saline solution|Placebo group: 200 ml of saline solution, starting at the moment of skin closure and every 6 hours, infused over 15 min.
89487928|NCT04915196||Ferrous Sulphate|Women age 18-50 yo that have been diagnosed with iron deficiency anemia secondary to abnormal uterine bleeding using Ferrous Sulphate for iron replacement
89487929|NCT04915196||Liposomally-bound Iron|Women age 18-50 yo that have been diagnosed with iron deficiency anemia secondary to abnormal uterine bleeding using Liposomally-bound Iron for iron replacement
89487930|NCT03231813|Experimental|SLS irritation model and Treatment|SLS induced irritation on two sites each on forearms and back Emollient cream treatment
89487931|NCT03231813|Placebo Comparator|SLS irritation model and No Treatment|SLS induced irritation on two sites each on forearms and back No treatment
89487932|NCT03231813|Sham Comparator|Sham irritation and Treatment|Sham irritation (water) on two sites each on forearms and back Emollient cream treatment
89487933|NCT03231813|No Intervention|Sham irritation and No Treatment|Sham irritation (water) on two sites each on forearms and back No treatment
89487934|NCT02254603|Other|Acupuncture controls|Acupuncture group will receive 30-minutes treatment three times a week for 3 months.
89487935|NCT02254603|Experimental|acupuncture and yoga exercise|Subject will receive a combination of acupuncture and yoga exercise three times a week for 3 months.
89487936|NCT04914962|Active Comparator|monolithic glazedcrowns|glazed Celtra due crowns
89487937|NCT04914962|Experimental|monolithic polished crowns|polished Celtra due crowns
89487938|NCT04485351||Diabetic patients from the University Hospital of Nancy|
89204215|NCT00671060|Active Comparator|2|Women in Group 1 will be administered two tablets (2 100 mcg misoprostol tablets), which she will be instructed to hold in her cheeks for 200 minutes, after which she will swallow any medication that remains. In cases where cervical dilation is not complete after six hours, women will be given a second dose of study drug. Study drug will continue to be administered at 6-hourly intervals through hour 42 after the study dose.
89487939|NCT02143531|Active Comparator|Group I|Patients will receive 4 mg of Ondansetron IV upon occurrence of nausea or vomiting
89487940|NCT02143531|Active Comparator|Group II|Patients will receive 1mg of Haloperidol IV upon occurrence of nausea or vomiting
89487941|NCT04914884||intraocular inflammation group|
89487942|NCT04914884||Cataract patients group|
89487943|NCT03219411|Active Comparator|Cinnamon|Cinnamon burmannii administered orally as 500-mg capsules three times daily over 12 weeks
89487944|NCT03219411|Placebo Comparator|Placebo|Placebo administered orally as capsules three times daily over 12 weeks
89487945|NCT02143609|Active Comparator|Oxygen|oxygen administration via a nasal cannula at a rate of 3 L/min during nights spent at 2048 m
89021757|NCT00338234||Cardiac surgery|Successive cardiac surgery patients
89487946|NCT02143609|Placebo Comparator|Sham oxygen|sham oxygen (room air) administration via a nasal cannula at a rate of 3 L/min during nights spent at 2048 m
89487947|NCT04485117|Active Comparator|Sevoflurane Group|Laryngeal mask airway is inserted and anesthesia is maintained with sevoflurane anesthesia under BIS monitoring.
89487948|NCT04485117|Active Comparator|Propofol Group|Laryngeal mask airway is inserted and anesthesia is maintained with propofol infusion under BIS monitoring.
89487949|NCT03224169|Experimental|Intervention|Directly observed hand hygiene
89487950|NCT03224169|No Intervention|Control|No directly observed hand hygiene
89487951|NCT03218943|Active Comparator|APRV ventilation|They will start on APRV mode with high pressure (Phi) 20 cmH2O , low pressure(Plo) 5 cmH2O with I:E ratio ( Phi phase: Plo phase ratio ) 4:1 for 3 hours Then, they will return to the initial settings ( PCV ) for 2 hours . then, they will be switched into BiPAP mode with high pressure (Phi) 20 cmH2O , low pressure(Plo) 5 cmH2O with I:E ratio ( Phi phase: Plo phase ratio ) 1:1 for 3 hours. Then left for ventilation according to the preference of the physician in charge.
89487952|NCT03218943|Active Comparator|BiPAP ventilation|They will start on BiPAP mode with high pressure (Phi) 20 cmH2O , low pressure(Plo) 5 cmH2O with I:E ratio ( Phi phase: Plo phase ratio ) 1:1 for 3 hours. Then, they will return to the initial settings ( PCV ) for 2 hours . then, they will be switched into APRV mode with high pressure (Phi) 20 cmH2O , low pressure(Plo) 5 cmH2O with I:E ratio ( Phi phase: Plo phase ratio ) 4:1 for 3 hours. Then left for ventilation according to the preference of the physician in charge.
89487953|NCT00803569|Experimental|ALVAC(2)-NY-ESO-1(M)/TRICOM + GM-CSF|Patients received SC injections with ALVAC(2)-NY-ESO-1(M)/TRICOM (0.5 mL) on Day 1 and the GM-CSF sargramostim (100 μg) on Days 1 through 4 in continuous 28-day cycles for up to 6 cycles.
89487954|NCT02451345|Experimental|Intervention|Personalized risk model+website+phone coaching
89487955|NCT02143687|Experimental|Moderate altitude sojourn|Sojourn at moderate altitude (2048 m)
89487956|NCT02143687|Experimental|Low altitude sojourn|Sojourn at low altitude (490 m, baseline)
89487957|NCT02143687|Active Comparator|Oxygen|Oxygen administration via a nasal cannula at a rate of 3 L/min during nights spent at 2048 m
89487958|NCT02143687|Placebo Comparator|Sham oxygen (room air)|Sham oxygen (room air) administration via a nasal cannula at a rate of 3 L/min during nights
89487959|NCT02451813|Experimental|Intervention|"A 22 GA 5 cm nerve block needle will be advanced to the following conditions:~Needle tip slightly indenting the fascia iliaca~Needle tip advanced through fascia iliaca~Needle tip slightly indenting the anterior surface of the femoral nerve~Needle tip withdrawn 1 mm from nerve.~At each of these conditions, 1 ml of dextrose solution will be injected and spread of injectate observed sonographically. A blinded observer will measure injection pressure. If opening pressure reaches 15 psi, this investigator will halt the injection. In addition, minimum threshold current required to elicit a motor response will be recorded for conditions 3 and 4."
89487960|NCT02143765|Experimental|Mitiglinide|Mitiglinide 10 mg three times a day, orally, for 12 weeks
89487961|NCT02143765|Active Comparator|Acarbose|Acarbose 50 mg three times a day, orally, for 12 weeks
89487962|NCT03231423|Experimental|DRAIN PLACEMENT|Effects of drainage
89487963|NCT03231423|No Intervention|DRAIN NOT PLACED|Effects of not using drain
89021758|NCT00338234||Surgical ICU|Successive patients admitted to the surgical ICU for more than 7 days, and experiencing anemia
89487964|NCT02143921|Experimental|Training Intervention|One service provider group received training
89487965|NCT02143921|No Intervention|Control|Control group service providers did not received intervention training
89487966|NCT03217695|Experimental|Mindfulness-based Yoga Arm|"8-week period, 1x/week for 45-60 minutes/session. Sessions 1-2: Participants instructed to focus their attention on their breath, and the physical sensations in their bodies while holding the yoga postures, to develop sustained and focused attention. Sessions 3-4: exploring the sensorial qualities of physical sensation in the body whether pleasant or unpleasant and to notice thoughts and label them (e.g., planning, remembering), and to the same with emotions (e.g., worry, frustration, fear) to practice disengaging from automatic associative thinking. Session 6-8: Instructor will guide participants to allow sensations of discomfort or effort to be as they are and to bring awareness to automatic patterns of reactivity. The goal is to foster distress tolerance, provide opportunities for participants to practice self-care, and allow an opportunity to observe and respond skillfully, instead of react automatically, to unpleasant stimuli (sensations, emotions)."
89487967|NCT02148289|Active Comparator|Nitrate rich beverage|Nitrate rich beverage will contain 140ml nitrate rich beetroot juice + 200ml blackcurrant juice containing 12.7mmol nitrate
89487968|NCT02148289|Placebo Comparator|Nitrate free beverage|Nitrate free beverage will 140ml water + 200ml blackcurrant juice containing <0.5mmol nitrate
89487969|NCT02451267|Experimental|positive CPR: research group|physical therapy treatment with aerobic exercise
89487970|NCT02451267|Experimental|negative CPR: research group|physical therapy treatment with aerobic exercise
89487971|NCT02451267|Active Comparator|positive CPR: control group|physical therapy treatment
89487972|NCT02451267|Active Comparator|negative CPR: control group|physical therapy treatment
89487973|NCT00629629|Experimental|Intervention|"Mothers in the intervention group received dietary advice based on Brazilian guidelines [Ten steps for the healthy eating: Feeding guidelines for Brazilian children from birth to two years ] during monthly home visits from 2 weeks to 6 months postpartum and then every 2 months thereafter until 1 y postpartum."
89487974|NCT00629629|No Intervention|Control|Mothers in the control group received routine medical assistance without any involvement of the research team. The study staff provided no materials to mothers on the Control Arm.
89487975|NCT03224013|Active Comparator|Hyperopic LASIK with crosslinking|group 1:hyperopic customized LASIK with concurrent prophylactic high-fluence cross-linking
89487976|NCT03224013|Active Comparator|Hyperopic LASIK only|group 2: hyperopic customized LASIK only
89487977|NCT02254369|Experimental|Cohort 1- GC021109|single dose, 0.0014 mg/kg GC021109
89487978|NCT02254369|Experimental|Cohort 2- GC021109|single dose, 0.014 mg/kg GC021109
89487979|NCT02254369|Experimental|Cohort 3-GC021109|single dose, 0.14 mg/kg GC021109
89487980|NCT02254369|Experimental|Cohort 4- GC021109|single dose, 1.4 mg/kg GC021109 subjects will receive GC021109 under fasting then under fed conditions separated by a washout of 14 (± 1) days after the first dose.
89487981|NCT02254369|Experimental|Cohort 5- GC021109|single dose, 4.2 mg/kg GC021109
89487982|NCT02254369|Placebo Comparator|Cohort 1- placebo|single dose, 0.0014 mg/kg matching placebo
89487983|NCT02254369|Placebo Comparator|Cohort 2- placebo|single dose, 0.014 mg/kg matching placebo
89487984|NCT02254369|Placebo Comparator|Cohort 3- placebo|single dose, 0.14 mg/kg matching placebo
89487985|NCT02254369|Placebo Comparator|Cohort 4- placebo|single dose, 1.4 mg/kg subjects will receive matching placebo under fasting then under fed conditions separated by a washout of 14 (+/- 1) days after the first dose.
89487986|NCT02254369|Placebo Comparator|Cohort 5- placebo|single dose, 4.2 mg/kg matching placebo
89487987|NCT03231501|Experimental|single arm|This is a single arm study. It is an open-label study. The intervention is eptinib succinate.
89487988|NCT02148367|Active Comparator|Erythropoietin (EPO)|Participants (n=20) will receive EPO with a dose of 40,000 IU EPO subcutaneously (s.c.) once weekly for 4 weeks.
89487989|NCT02148367|Placebo Comparator|placebo|Participants (n=10) will receive placebo s.c. once weekly for 4 weeks
89487990|NCT02451189|Experimental|Inulin acetate ester|Inulin acetate ester, 10g/day for 30 days
89487991|NCT02451189|Experimental|Inulin propionate ester|Inulin propionate ester, 10g/day for 30 days
89487992|NCT02451189|Experimental|Inulin butyrate ester|Inulin butyrate ester, 10g/day for 30 days
89487993|NCT02143999||Cohort|
89487994|NCT02451891|Active Comparator|Group 1a|MVA-EBO Z (1 x 10^8 pfu)
89487995|NCT02451891|Active Comparator|Group 1b|MVA-EBO Z (1.5 x 10^8 pfu)
89487996|NCT02451891|Active Comparator|Group 2|ChAd3-EBO Z (2.5 +/- 1.2 x 10^10 vp) and MVA-EBO Z (1 x 10^8 pfu) after 14 days
89487997|NCT02451891|Active Comparator|Group 3|ChAd3-EBO Z (2.5 +/- 1.2 x 10^10 vp) and MVA-EBO Z (1 x 10^8 pfu) after 28 days
89487998|NCT02451891|Active Comparator|Group 4|ChAd3-EBO Z (2.5 +/- 1.2 x 10^10 vp) and MVA-EBO Z (1.5 x 10^8 pfu) after 28 days
89487999|NCT00482833|Experimental|ARM A - ATO/ATRA|
89488000|NCT00482833|Active Comparator|ARM B - ATRA|
89488001|NCT03215823||1. Easy endotracheal intubation|Easy endotracheal intubation
89488002|NCT03215823||2. Difficult endotracheal intubation|Difficult endotracheal intubation
89021759|NCT00338273|Active Comparator|A1|
89021760|NCT00338273|Placebo Comparator|A2|
89021761|NCT04715672||copper|
89488003|NCT03223701|Other|Treatment group|The group will consist of 10 patients who would be examined for fusion rates of Transforaminal Lumbar Interbody Fusion with a standalone lumbar implant device and Solum IV and the patient's bone marrow concentrate and general fluid concentrate.
89021762|NCT04715672||no-copper|
89021763|NCT04715672||normal|
89488004|NCT03119727|Other|Automated oxygen adjustment|All patient in this study have automatic oxygen titration and automatic oxygen weanning
89488005|NCT02451033|Active Comparator|standard medical therapy|Standard medical therapy
89488006|NCT02451033|Active Comparator|G-CSF|Standard medical therapy plus G-CSF at the dosage of 5 µg/Kg subcutaneously every 12 hr for five consecutive days then every 3 monthly for 3 days till 1 year.
89488007|NCT02451033|Active Comparator|G-CSF plus growth hormone|Standard medical therapy plus G-CSF plus Growth Hormone therapy. Growth Hormone will be given in low dose of 1unit sc daily for 1 year.
89488008|NCT04485429|Experimental|Methylprednisolone + Standard treatment|Participants will receive the standard treatment and methylprednisolone.
89488009|NCT04485429|Experimental|Full-dose heparin + Standard treatment|Participants will receive the standard treatment and full-dose heparin,
89488010|NCT04485429|Experimental|Methylprednisolone + Full-dose heparin + Standard treatment|Participants will receive the standard treatment, methylprednisolone and full-dose heparin
89488011|NCT04485429|No Intervention|Standard treatment|Participants will receive the standard treatment
89488012|NCT03216057|Experimental|Omega-3 fatty acid 3 grams per day|Each capsule contains 400 mg of eicosapentaenoic acid and 200 mg of docosahexaenoic acid. We allocated five capsules per day, three in the morning and two at night, every 12 hours (8.00 am and 8:00 pm), therefore the subject ingest 2000 mg of eicosapentaenoic acid and 1000 mg of docosahexaenoic acid per day (3 grams of Omega 3 per day) by mouth for 12 weeks. The trademark is Omega Rx Dr.Sears Zone labs Inc.
89488013|NCT03216057|Placebo Comparator|Placebo|Each capsule contains 600 mg of soybean oil. We allocated five capusles per day, three in the morning and two at night, every 12 hours (8.00 am and 8:00 pm), therefore the subject ingest 3000 mg of soybean oil per day (3 gr soya oil per day) by mouth for 12 weeks.
89488014|NCT03223467|Active Comparator|Biliopancreatic diversion|Study participants will undergo biliopancreatic diversion which is a type of bariatric surgery where a part of the stomach are removed and the remaining stomach is attached to a distal segment of the small intestine.
89488015|NCT03223467|Active Comparator|Gastric sleeve|Study participants will undergo sleeve gastrectomy which is a restrictive form av bariatric surgery where the size of the stomach is reduced.
89488016|NCT03223467|Active Comparator|Gastric bypass|Study participants will undergo gastric bypass which is a type of bariatric surgery where a small pouch of the stomach is created and attached to a segment of the small intestine.
89488017|NCT03223467|No Intervention|No intervention|Study participants that do not want to undergo surgical treatment.
89488018|NCT02450955|Active Comparator|Massage|A superficial massage was performed for 10 minutes in the cervical region consisting of gentle rubbing and kneading.
89488019|NCT02450955|Experimental|Occiput-Atlas-Axis Technique|The technique is applied in two stages: in the first stage, a light core decompression is performed and then small circumductions are made with the aim of increasing viscoelasticity of tissues. Subsequently the appropriate joint barrier is sought by selective tension and high-velocity rotation manipulation is performed in a cranial helical motion without raising the subjects head.
89488020|NCT03215121|Active Comparator|One handed mask airway, switch to two hands|Induction of anesthesia started as follows while children are breathing spontaneously: One handed mask airway + chin lift - 20 sec and then switch to two hands + jaw thrust - 20 sec
89488021|NCT03215121|Active Comparator|Two handed mask airway + jaw thrust|Induction of anesthesia started as follows while children are breathing spontaneously: Two handed mask airway + jaw thrust - 40 sec
89488022|NCT03215121|Active Comparator|Two handed mask airway, switch to one hand|Induction of anesthesia started as follows while children are breathing spontaneously: Two handed mask airway + jaw thrust - 20 sec and then switch to one hand + chin lift - 20 sec
89488023|NCT03214809|Experimental|Thoracic ultrasound protocol|ABCDE algorithm with Thoracic ultrasound protocol
89488024|NCT03214809|No Intervention|No Thoracic ultrasound protocol|ABCDE algorithm without Thoracic ultrasound protocol
89488025|NCT00112957|Experimental|rV- and rF-NY-ESO-1|Patients received a single intradermal injection of rV-NY-ESO-1 (3.1 × 10^7 PFU) on Day 1, followed by subcutaneous injections of rF-NY-ESO-1 (7.41 × 10^7 PFU) on Days 29, 57, 85, 113, 141, and 169 or until observation of treatment-related ≥ grade 3 toxicity or disease progression.
89488026|NCT03231267||"Carrierof Ec-BLSE/EPC or Kp-BLSE/EPC"|During resuscitation, evaluation of the acquisition or not of phages able to lyse Ec-BLSE / EPC or Kp-BLSE / EPC
89488027|NCT03231267||Non-Carrier of Ec-BLSE/EPC orKp-BLSE/EPC|During resuscitation, evaluation of the acquisition or not of phages able to lyse Ec-BLSE / EPC or Kp-BLSE / EPC
89488028|NCT03223389|Experimental|10 gastric bypass operated patients|3 different oils ingested at separate study days will be tested against each others ability to induce gut hormone secretion.
89537879|NCT03289559|Placebo Comparator|GnRH antagonist + Placebo Gel|
89537880|NCT03289559|Active Comparator|GnRH antagonist + Testosterone Gel|
88953188|NCT01959438|Experimental|Selenite treatment|In the first part of the study, cohorts of 3 patients receive sodium selenite iv, starting with a dose of 0.5 mg/m2. If no serious adverse event the next cohort is treated according to a dose escalation schedule and this part has been completed. In the modified protocol, a continuous infusion over 2 days will be administered.
88953189|NCT01959451|Active Comparator|Prasugrel|Prasugrel 5 mg or 10mg daily for 12 months.
88953190|NCT01959451|Experimental|Prasugrel/Clopidogrel|Day 0 - 7 Prasugrel 5 or 10mg Day 8 - 14 Clopidogrel 75mg q/d. On Day 14 platelet function testing Patients with HPR will be switched to Prasugrel the others will remain on Clopidogrel for 11 1/2 months
88953191|NCT01959477|Experimental|Treatment (busulfan, etoposide, cyclophosphamide, transplant)|Patients receive busulfan IV over 3 hours on days -9 to -6, etoposide IV continuously over 24-36 hours on days -5 and -4, and cyclophosphamide IV over 4 hours on days -3 and -2. Patients then undergo autologous stem cell transplant on day 0.
88953192|NCT01959555||Retrospective collection of data|
88953193|NCT01959568|Experimental|Double tamponade|Vitrectomy and tamponade: subtotal vitrectomy, epiretinal membrane removal, perfluorodecalin tamponade, retinal photocoagulation. After that the surgeon replaces ½ of perfluorodecalin volume by silicone oil.
88953194|NCT01959568|Active Comparator|Silicone oil tamponade|Vitrectomy and tamponade: subtotal vitrectomy, epiretinal membrane removal, perfluorodecalin tamponade, retinal photocoagulation and perfluorodecalin-silicone oil exchange.
88953195|NCT01959594|Experimental|Cohort 1|
88953196|NCT01959594|Experimental|Cohort 2|
88953197|NCT01959594|Experimental|Cohort 3|
88953198|NCT01959594|Experimental|Optional Cohort 4|
88953199|NCT01959594|Experimental|Optional Cohort 5|
88953200|NCT01959620|No Intervention|Assessment only|Participants will receive assessment only.
89488029|NCT03223389|Experimental|10 healthy control subjects|3 different oils ingested at separate study days will be tested against each others ability to induce gut hormone secretion.
89488030|NCT02140801|Experimental|Ticagrelor|Ticagrelor 90mg tablet, twice daily
89488031|NCT02140801|Experimental|Clopidogrel|Clopidogrel 75mg tablet, daily
89488032|NCT03223233||No secondary suture|The participants who developed post-cesarean surgical site infection and follow-up only antibiotic treatment for their wound care.
89488033|NCT03223233||Secondary suture|The participants who developed post-cesarean surgical site infection and need a secondary suture for their wound care
89488034|NCT02148601|Experimental|Fecal Microbiota Transplantation|Fecal microbiota transplantation from healthy donors will be infused by colonoscopy
89488035|NCT02148601|Active Comparator|Standard Antibiotic Therapy|Standard antibiotic therapy according to European Guidelines (vancomycin and metronidazole) will be administered to the patients
89488036|NCT03231111|No Intervention|traditional group|
89488037|NCT03231111|Experimental|Multimedia group|
89488038|NCT02141035|Experimental|Acetyl-l-carnitine|Acetyl-l-carnitine will be administered for 2 months duration at a dosage of 3000 mg/d starting at the time of decompression surgery.
89488039|NCT02141035|Placebo Comparator|Placebo|Placebo will be given for 2 months starting at the time of decompression surgery
89488040|NCT03214653|Active Comparator|Propofol|Those who received target-controlled infusion of propofol using Schinder technique effect mode with the administration of maintenance agent was adjusted by the depth of sedation using bispectral index monitor with target of 45-50.
89488041|NCT03214653|Active Comparator|Sevoflurane|Those who received sevoflurane 1,5-2% as maintenance agent of anesthesia.
89488042|NCT02450877|Experimental|Azacitidine Treatment|: Subjects randomized to the experimental arm will receive up to 3 cycles of IV azacitidine on Days 1 through 7 at the dose selected from the safety run-in part.
89488043|NCT02450877|Other|Control Arm: 'Watch and Wait'|Subjects randomized to the control arm will undergo 'watch and wait' until clinical relapse (defined as at least 5% blasts in PB (peripheral blood) and/or BM (bone marrow) and/or proven histological extramedullary relapse).
89488044|NCT02148679|Experimental|DASH/SRD|"Patients receive Heart Failure Society of America pamphlet, How to eat a low sodium diet at hospital discharge~Study staff will phone patients at weeks 2 and 3 to confirm patients' understanding of dietary instructions~Intervention: pre-prepared, home delivered DASH/SRD-compliant meals for 4 weeks after hospital discharge"
89488045|NCT02148679|Placebo Comparator|Attention Control|"Patients receive Heart Failure Society of America pamphlet, How to eat a low sodium diet at hospital discharge~Study staff will phone patients at weeks 2 and 3 to confirm patients' understanding of dietary instructions"
89488046|NCT03223545|Experimental|Mindfulness-based cognitive therapy delivered by telephone|
89488047|NCT03223545|Placebo Comparator|Usual Care (UC)|
89488048|NCT02141113|Active Comparator|Guanfacine Hydrocholride|"mg Guanfacine Hydrochloride (orally, QD)~mg Guanfacine Hydrochloride (orally, QD)~mg Guanfacine Hydrochloride (orally, QD)~mg Guanfacine Hydrochloride (orally, QD)~mg Guanfacine Hydrochloride (orally, QD)~mg Guanfacine Hydrochloride (orally, QD)"
89488049|NCT02141113|Placebo Comparator|Sugar Pill Guanfacine Hydrocholride|"mg Guanfacine Hydrochloride (orally, QD)~mg Guanfacine Hydrochloride (orally, QD)~mg Guanfacine Hydrochloride (orally, QD)~mg Guanfacine Hydrochloride (orally, QD)~mg Guanfacine Hydrochloride (orally, QD)~mg Guanfacine Hydrochloride (orally, QD)"
89488050|NCT03214107|Active Comparator|Full snack given before exercise|A snack containing ~0.5g of carbohydrates per kilogram of body weight will be given 5 minutes before exercise
89488051|NCT03214107|Active Comparator|Distributed snack over exercise period|A snack containing ~0.5g of carbohydrates per kilogram of body weight distributed this way will be given: ~40% given 5 minutes before exercise, ~30% after 20 minutes of exercise and the last ~30% after 40 minutes of exercise.
89488052|NCT03543709||Behcet and fibromyalgia|Women with Behcet's disease with fibromyalgia
89488053|NCT03543709||Behcet|Women with Behcet's disease without fibromyalgia
89488054|NCT03213873|Experimental|HiBalance|The HiBalance program is based on scientifically well-established principles of exercise training and postural control as well as current research on training in PD. The training will be conducted as a progressive individually adjusted group program in order to challenge the specific balance disorder of every participant and endorse progression. The intervention will be performed for an hour, 2 times/week in groups of six to eight participants for a total of 10 weeks and one home training session on their own.
89488055|NCT03213873|Active Comparator|Speech therapy|The control group will receive a group treatment (2 times/w for 10 w + 1 home training session) consisting of speech and communication therapy performed by a speech therapist. This intervention will be performed in a sitting position. The speech and communication treatment will aim at increasing vocal loudness and improving articulatory precision. Level of difficulty is gradually increased by progressing from using loud voice and clear speech in short and automatized utterances, to using the same technique in more complex sentences and situations. The group format is used to practice techniques in communicative situations and also to introduce increasing level of multitasking by combining speech training with cognitively more challenging tasks in the group training.
89488056|NCT02141191|Experimental|HS/sham|Subjects will utilize inhaled hypertonic saline (7%) delivered using the tPAD device during one session and perform a sham treatment with the tPAD during the other. The order will be randomized.
89488057|NCT02141191|Experimental|sham/HS|Subjects will utilize inhaled hypertonic saline (7%) delivered using the tPAD device during one session and perform a sham treatment with the tPAD during the other. The order will be randomized.
89488058|NCT03213639|Experimental|study group|Patients will take esomeprazole single dose of 40 mg orally once a day
89488059|NCT03213639|Placebo Comparator|control group|Patients will take an inert tablet similar in appearance, color and consistency
89488060|NCT03231033|Experimental|Pioglitazone|Oral administration of Actos at 15 mg/day for 12 weeks, 30 mg/day for 12 weeks, and 45 mg/day for 12 weeks
89488061|NCT02141347|Other|Part A|Dose escalation of tremelimumab mono therapy for advanced solid malignancies
89488062|NCT02141347|Other|Part B|Combination therapy of tremelimumab and MEDI4736 for advanced solid malignancies
89537881|NCT03293927|Experimental|Fentanyl + Dexmedetomidine|
88953201|NCT01959620|Experimental|1-session exposure intervention|Participants will receive one session of exposure therapy.
88953202|NCT01959620|Experimental|3-session exposure intervention|Participants will receive three sessions of exposure therapy.
88953203|NCT01959646|Placebo Comparator|Placebo|Placebo Group
88953204|NCT01959646|Experimental|Aged Garlic Extract Supplementation|Aged Garlic Extract Supplementation Group
88953205|NCT01959659||Cohort|
89488063|NCT02141347|Other|Part C|Fixed dose of tremelimumab for malignant mesothelioma
89488064|NCT03213327|Other|Case management|Case management program Utilization of the StayOk web application
89488065|NCT02254759|Other|IV Midazolam Alone|A single 1 milligram (mg) dose of IV Midazolam on Day 1.
89488066|NCT02254759|Other|Oral Midazolam Alone|A single 5 mg oral dose of midazolam on Day 2.
89488067|NCT02254759|Experimental|RO5186582 Alone|RO5186582 240 mg oral tablet twice daily (BID) for 14 days from Days 3 to 16.
89488068|NCT02254759|Experimental|RO5186582 Plus IV Midazolam|RO5186582 240 mg BID oral tablet in combination with a single 1 mg IV dose of midazolam on Day 17.
89488069|NCT02254759|Experimental|RO5186582 Plus Oral Midazolam|RO5186582 240 mg BID in combination with a single 5 mg oral dose of midazolam on Day 18.
89488070|NCT03208257|Experimental|Esmolol|Intravenous esmolol will be administered as a continuous infusion according to protocol to control tachycardia with maximal infusion rates in the range of 10-40 mcg/kg/min.
89488071|NCT02254837|Experimental|Zilver PTX|
89488072|NCT02141425|Experimental|ASP015K low dose|
89488073|NCT02141425|Experimental|ASP015K medium dose|
89488074|NCT02141425|Experimental|ASP015K high dose|Optional, depending on safety review and regulatory authority input
89488075|NCT02141425|Placebo Comparator|Placebo|
89488076|NCT03212625|Experimental|Urea cream 20%|144 patients spread urea cream (urea 20%)
89488077|NCT03212625|Placebo Comparator|Placebo|144 patients spread placebo cream (urea 0%)
89488078|NCT02148757|Other|DVT|Doppler Ultrasound
89488079|NCT03212547|Experimental|Experimental group|"Verbal interventions made on infants (accompanied by their mothers) who presents sustained social withdrawal detected on the child consultations (at 2, 6 and 12 months of corrected gestational age), made by neonatologists certifieds in the assess of Alarm Distress Baby Scale. Theintervention is described in a guide for Promotion of verbal interventions for interaction , and will be supplemented with a written guideline for parents."
88953206|NCT01959711|Experimental|Posterior RA|Posterior retroperitoneoscopic adrenalectomy
88953207|NCT01959711|Active Comparator|Lateral transperitoneal LA|Lateral transperitoneal laparoscopic adrenalectomy
89488080|NCT03212547|No Intervention|Control group|Control group: infants will assist at child consultations (at 2, 6 and 12 months of corrected gestational age) whit non trained neonatologists. However, these group will receive a development stimulation guide adapted of the ministerial guides for the stimulation of development of the Ministry of Health of Chile.
89488081|NCT03212157|Experimental|GT1|Optimsation of glucose infusion protocol outside the Magnetic Resonance Imaging (MRI) scanner in healthy volunteers. To establish an optimised bolus and safety of infusion protocol of intravenous glucose to maximise exchange sensitive MRI signal.
89488082|NCT03212157|Experimental|GT2|Optimsation of glucose infusion protocol inside the Magnetic Resonance Imaging (MRI) scanner in patient volunteers. To assess the reproducibility of these techniques and initial proof-of-concept study in cancer patients
89488083|NCT03212157|Experimental|GT3|Use of glucoCEST technique in staging of head and neck SCC, lymphoma and gliomas and correlating diagnostic potential with standard imaging such as FDG PET. To apply exchange-sensitive MRI in selected cancer types to assess its diagnostic potential. To study of non-glucose endogenous exchange sensitive MRI signals in (a) Prostate Cancer and (b) high grade Glioma patients.
89488084|NCT02148913|Active Comparator|Cohort 1: Carfilzomib 15 mg/m2|Carfilzomib 15 mg/m2 on days -2, -1, +5, and +6 IV over 10 minutes.
89488085|NCT02148913|Active Comparator|Cohort 2: Carfilzomib 20 mg/m2|Carfilzomib 20 mg/m2 on days -2, -1, +5, and +6 IV over 10 minutes.
89488086|NCT02148913|Active Comparator|Cohort 2b: Carfilzomib 20 mg/m2|Carfilzomib 20 mg/m2 on days -2, -1 and +5 IV over 10 minutes.
89488087|NCT02148913|Active Comparator|Cohort 3: Carfilzomib 27mgm2|Carfilzomib 27 mg/m2 on days -2, -1 and +5 IV over 10 minutes.
89488088|NCT03230721|Active Comparator|ThuLEP group|Patients who underwent thulium-fiber laser enucleation of the prostate due to lower urinary tract symptoms caused by prostatic hyperplasia.
89488089|NCT03230721|Active Comparator|Monopolar enucleation group|Patients who underwent monopolar enucleation of the prostate due to lower urinary tract symptoms caused by prostatic hyperplasia.
89488090|NCT03230721|Active Comparator|HoLEP group|Patients who underwent Ho:YAG laser enucleation of the prostate due to lower urinary tract symptoms caused by prostatic hyperplasia.
89488091|NCT02148991||Irbesartan|Patients on irbesartan treatment
89488092|NCT03230799|Active Comparator|traditional cataract surgery|Central anterior continuous capsulorhexis (5-6 mm)+ irrigation/aspiration + posterior capsulorhexis + anterior vitrectomy（ACCC+ I/A + PCCC + Anti-vit)
89488093|NCT03230799|Experimental|minimal invasive lens surgery|Peripheral capsulorhexis opening (1.0-1.5 mm)+irrigation/aspiration
88953208|NCT01959724|Other|Vitrectomy|Vitreous surgery to treat macular detachment
88953209|NCT01959737|No Intervention|visual contact|After initial assessment/stabilization of the VLBW infant, visual contact of mother and infant is permitted for 5 minutes.
88953210|NCT01959737|Experimental|skin-to-skin contact|After initial stabilization mother and preterm infant are cared for skin-to-skin for 60 minuter. SSC is supervised by the attending neonatologist.
88953211|NCT01959750|Experimental|Intervention Group|
88953212|NCT01959750|No Intervention|Control Group|
88953213|NCT01959763|Experimental|weight loss counseling|Cognitive behavioral therapy-based weight loss counseling program including 8 group visits
88953214|NCT01959763|Experimental|ELVIRA-based weight loss counseling|Weight loss counseling program based on 2 group visits of ELVIRA counseling method
88953215|NCT01959763|Experimental|ICT-based weight loss counseling|ICT-based weight loss counseling program with 52 weekly tasks and information packages.
88953216|NCT01959776|Other|Vitrectomy|
88953217|NCT01959789||Control|Standard treatment
88953218|NCT01959789||2 days|bleaching treatments made in 2 days
88953219|NCT01959802|Other|Vitrectomy|Vitrectomy for macular pseudo hole
88953220|NCT01959828|Experimental|inhaled nitric oxide|"Adults: IK-3001 at start dose 20 ppm; may be increased to 40 ppm at the investigator's or subinvestigator's discretion (up to ~ 24 hrs).~Children: IK 3001 at start 10 dose ppm; may be increased to 20 ppm at the investigator's or subinvestigator's discretion (up to ~24 hrs).~Treatment with IK-3001 will continue until it is clinically indicated to begin the weaning process from IK-3001."
88953221|NCT01959854|Active Comparator|carboxymethylcellulose|1 drop in each eye four times a day for 30 days
89204216|NCT00671060|Placebo Comparator|1|Women in Group 1 will be administered two tablets (a 100 mcg misoprostol tablet and a placebo tablet made to resemble a 100 mcg misoprostol tablet), which she will be instructed to hold in her cheeks for 200 minutes, after which she will swallow any medication that remains. In cases where cervical dilation is not complete after six hours, women will be given a second dose of study drug. Study drug will continue to be administered at 6-hourly intervals through hour 42 after the study dose.
89204217|NCT00769418|Experimental|1|odanacatib (MK0822)
89204218|NCT00769418|Placebo Comparator|2|placebo to odanacatib (MK0822)
89488094|NCT03208101|Experimental|Test group|DTP-HepB-IPV-Hib vaccine
89488095|NCT03208101|Active Comparator|Control group|DTP-HepB-Hib vaccine & IPV
89488096|NCT02149225|Experimental|APVAC1 and 2 vaccine plus polyICLC and GMCSF concurrent to TMZ|
89488097|NCT03230955|Experimental|Psychological and psycho-educational support|The intervention group (IG) [that will receive telephone-based assistance to quit (including psychological and psycho-educational support and pharmacological treatment advice, if required) provided by trained nurses who will proactively call at one week, 15 day, a month, 3, 6 and 12 months after discharge, plus the calls made by the patients during the process]
89488098|NCT03230955|Active Comparator|Control Group|The control group (CG) [that will receive only a brief counselling session after discharge]
89488099|NCT03208335|Experimental|rh-endostatin combination|Continuous intravenous pumping (CIP) recombinant human endostatin(rh-endostatin) 30mg/d, from 5 days before radiotherapy,for 7days,21 per cycle.Standard radiotherapy for HCC is conducted concurrently.Those patients will receive 3-5 cycles rh-endostatin after the radiotherapy is finished,4-6 cycles in all.
89488100|NCT02149381|Experimental|CBASP|Cognitive Behavioral System of Psychotherapy is a manual-based group intervention for chr depression (20 weeks).
89488101|NCT02149381|Active Comparator|Befriending|Befriending is a social support intervention
89488102|NCT02149381|Active Comparator|Treatment as usual|Conventional psychiatric outpatient treatment (individual counseling)
89488103|NCT03211065|Experimental|Immunoglobulin therapy|Patients with abnormal humoral function following treatment with rituximab will be treated with 20% subcutaneous immunoglobulin.
89488104|NCT02149459|Experimental|treatment arm|Partial brain re-irradiation combined with metabolic intervention (low carbohydrate diet and/or metformin treatment)
89488105|NCT02376790|Active Comparator|Methotrexate Monotherapy|Participants received oral methotrexate 20 mg weekly plus placebo to etanercept subcutaneous injection once a week for 48 weeks.
89488106|NCT02376790|Experimental|Etanercept Monotherapy|Participants received etanercept 50 mg weekly by subcutaneous injection plus oral placebo to methotrexate for 48 weeks.
89488107|NCT02376790|Experimental|Methotrexate + Etanercept|Participants received etanercept 50 mg a week by subcutaneous injection plus oral methotrexate 20 mg weekly for 48 weeks.
89488108|NCT03210987|Active Comparator|patient case presentation Bedside|In the bedside presentation group, patient case presentation and discussions will be at bedside with direct involvement of the patient as needed.
89488109|NCT03210987|Active Comparator|patient case presentation Outside-the-room|In the outside the room condition, case presentation and discussions will take place outside without the patient being present. After the case presentation and discussions the team will enter the room and give the patient a short summary of the medical situation, complete the medical information and examine the patient, as needed, and discuss the next steps.
89488110|NCT02141737|Placebo Comparator|Group C|Induction protocol: patients will be given 2 ml normal saline solution, 1 minutes later, 0.3 mg/kg etomidate is injected within 30 to 60 s, and 90 s after the injection of etomidate, 0.2 mg/kg midazolam, 3 μg/kg fentanyl, 0.6 mg/kg rocuronium are given sequently.
89488111|NCT02141737|Experimental|Group L1|Induction protocol: patients will be given 2 ml diluted lidocaine injection in which 20 mg lidocaine is contained, 1 minutes later, 0.3 mg/kg etomidate is injected within 30 to 60 s, and 90 s after the injection of etomidate, 0.2 mg/kg midazolam, 3 μg/kg fentanyl, 0.6 mg/kg rocuronium are given sequently.
89488112|NCT02141737|Experimental|Group L2|Induction protocol: patients will be given 2 ml diluted lidocaine injection in which 30 mg lidocaine is contained, 1 minutes later, 0.3 mg/kg etomidate is injected within 30 to 60 s, and 90 s after the injection of etomidate, 0.2 mg/kg midazolam, 3 μg/kg fentanyl, 0.6 mg/kg rocuronium are given sequently.
89488113|NCT02141737|Experimental|group L3|Induction protocol: patients will be given 2 ml lidocaine injection in which 40 mg lidocaine is contained, 1 minutes later, 0.3 mg/kg etomidate is injected within 30 to 60 s, and 90 s after the injection of etomidate, 0.2 mg/kg midazolam, 3 μg/kg fentanyl, 0.6 mg/kg rocuronium are given sequently.
89488114|NCT03210441||Group 1|Patients affected by breast cancer and potentially treated with taxane chemotherapy
89488115|NCT03210441||Group 2|Patients affected by breast cancer and not potentially treated without taxane chemotherapy
89488116|NCT02254447|Experimental|Sequence ABC|Subjects in this arm will receive single dose of treatment A in period 1, treatment B in period 2 and treatment C in period 3 (one treatment per period), where treatment A= ATACAND as a reference treatment containing Candesartan cilexetil 16 mg, treatment B= Test formulation 1 containing Candesartan cilexetil 16 mg, and treatment C= Test formulation 2 containing Candesartan cilexetil 16 mg.
89488117|NCT02254447|Experimental|Sequence ACB|Subjects in this arm will receive single dose of treatment A in period 1, treatment C in period 2 and treatment B in period 3 (one treatment per period), where treatment A= ATACAND as a reference treatment containing Candesartan cilexetil 16 mg, treatment B= Test formulation 1 containing Candesartan cilexetil 16 mg, and treatment C= Test formulation 2 containing Candesartan cilexetil 16 mg.
89537882|NCT03293927|Experimental|Dexmedetomidine + Fentanyl|
89537883|NCT03293927|Experimental|Fentanyl only|
89537884|NCT03293927|Experimental|Dexmedetomidine only|
88953222|NCT01959854|Experimental|xanthan gum|1 drop in each eye four times a day for 30 days
89488118|NCT02254447|Experimental|Sequence BAC|Subjects in this arm will receive single dose of treatment B in period 1, treatment A in period 2 and treatment C in period 3 (one treatment per period), where treatment A= ATACAND as a reference treatment containing Candesartan cilexetil 16 mg, treatment B= Test formulation 1 containing Candesartan cilexetil 16 mg, and treatment C= Test formulation 2 containing Candesartan cilexetil 16 mg.
89488119|NCT02254447|Experimental|Sequence BCA|Subjects in this arm will receive single dose of treatment B in period 1, treatment C in period 2 and treatment A in period 3 (one treatment per period), where treatment A= ATACAND as a reference treatment containing Candesartan cilexetil 16 mg, treatment B= Test formulation 1 containing Candesartan cilexetil 16 mg, and treatment C= Test formulation 2 containing Candesartan cilexetil 16 mg.
89488120|NCT02254447|Experimental|Sequence CAB|Subjects in this arm will receive single dose of treatment C in period 1, treatment A in period 2 and treatment B in period 3 (one treatment per period), where treatment A= ATACAND as a reference treatment containing Candesartan cilexetil 16 mg, treatment B= Test formulation 1 containing Candesartan cilexetil 16 mg, and treatment C= Test formulation 2 containing Candesartan cilexetil 16 mg.
89488121|NCT02254447|Experimental|Sequence CBA|Subjects in this arm will receive single dose of treatment C in period 1, treatment B in period 2 and treatment A in period 3 (one treatment per period), where treatment A= ATACAND as a reference treatment containing Candesartan cilexetil 16 mg, treatment B= Test formulation 1 containing Candesartan cilexetil 16 mg, and treatment C= Test formulation 2 containing Candesartan cilexetil 16 mg.
89488122|NCT03207711|Active Comparator|Diet Education|All participants will receive instruction in the carbohydrate-restricted diet (CR).The study diet has approximately 10% of kcal coming from carbohydrate, typically 50 grams/day or fewer, not including fiber. Participants will be encouraged to eat a normal amount of protein, typically about 80-100 grams/day (about 20-25% of calories), and the rest of their calories from fat. Foods that are encouraged include green leafy and other non-starchy vegetables, nuts, seeds, oils (especially olive oil), fish, poultry, tofu, and avocados. Other foods consistent with the diet include berries (in modest amounts), meats, eggs, and cheese. Key foods to minimize include any sugar-sweetened foods or beverages, bread, pasta, potatoes, highly processed packaged foods, and other starchy foods.
89488123|NCT03207711|Experimental|Diet Education + Mindfulness|In addition to the carbohydrate-restricted diet described above, the Ed+MBI group will receive mindfulness training consisting of two integrated components: 1) use of a mindful eating app at home to learn and practice mindfulness skills for food-cravings and eating, and 2) in-person group-based meetings to discuss and troubleshoot how the mindfulness practices are working. Key mindfulness content includes helping people improve their relationship with food and control food cravings and using mindful eating approaches including paying attention, noticing habit loops, understanding brain science and food/sugar addiction, disrupting emotional and stress eating, cultivating acceptance and curiosity, lovingkindness, detaching from thoughts, using healthy restraint, and maintaining motivation.
89204219|NCT05257252|Experimental|"Persons With Disability Friendly Nursing Education Program"|Intervention group after determining the students according to the research criteria, they were randomized into intervention and control groups. Firstly, pre-tests were applied to the students in the experimental group.
89488124|NCT02141815|Experimental|Arabinoxylan-oligosaccharides|Arabinoxylan-oligosaccharides 10g BID
89488125|NCT02141815|Placebo Comparator|Maltodextrine|Maltodextrine BID
89488126|NCT03209739|Active Comparator|WhatsApp reminder|An additional WhatsApp reminder with same content of the written instruction and a video of explanation of bowel preparation by a nurse 4 days prior colonoscopy
89488127|NCT03209739|No Intervention|No reminder|No additional reminder will be given
89488128|NCT02149615|Experimental|isotretinoin|Retinal nerve fibre layer measurement in patients under isotretinoin treatment
89488129|NCT02149615|Active Comparator|lymecycline|Retinal nerve fibre layer measurement in patients under lymecycline treatment
88953223|NCT01959867|Experimental|SurgiMend® PRS (ADM)|Subjects enrolled in to this cohort will receive SurgiMend® PRS (ADM) product during the first stage of the reconstruction (expander insertion).
88953224|NCT01959867|Other|No Intervention|Subjects enrolled in to this cohort will not receive an acellular dermal matrix (ADM) product during the first stage of the reconstruction (expander insertion).
88953225|NCT01959906||R0|Complete resection
88953226|NCT01959906||R1|Incomplete resection, microscopical tumor residu left behind
88953227|NCT01959906||CRM<1mm|complete resection (R0), however tumor spreads till less than 1 mm from the section pane.
88953228|NCT01959958||Sickle cell disease|In this study, children and adolescents with sickle cell disease ages 6-18 years and their parents/guardians will complete a questionnaire/interview.
88953229|NCT01959971|Experimental|Placebo - Alirocumab|Injection through subcutaneous (SC) administration, placebo for 4 weeks then, alirocumab for 10 weeks
88953230|NCT01959984|Experimental|100g Standard Noodles|100g Standard Noodles
88953231|NCT01959984|Experimental|75g Oral Glucose|75g Oral Glucose
89204220|NCT05257252|No Intervention|"non-Persons With Disability Friendly Nursing Education Program"|Firstly, Pre-tests were applied to the students in the control group. No intervention was applied to this group. Posttests were made 3 months after pre-test.
89204221|NCT00773552|Experimental|solifenacin succinate|Group randomized into solifenacin succinate treatment
89204222|NCT00773552|Placebo Comparator|placebo|Group randomized into placebo
89204223|NCT04002700||Target Cohort 1|Participants will be analyzed for stroke-risk who are new users of typical antipsychotics aged 18 to 64 years without a recent dementia diagnosis.
88953232|NCT01959997|Active Comparator|Redo PVI|Therapeutic anticoagulation will be required for at least 3 weeks prior to ablation. An MRA will be performed to define cardiac and PV anatomy. Standard ablation technique will be employed. After gaining venous access, double transseptal puncture will be performed to permit left atrial access, guided by intracardiac ultrasound. A circular mapping catheter will be placed in each PV and any reconnections will be ablated by delivery of RF energy. Confirmation of re-isolation of all PVs will be performed at the conclusion of the procedure.
89021764|NCT03277833|Experimental|Gynostemma Pentaphyllum(Dungkulcha) Extract|Gynostemma Pentaphyllum(Dungkulcha) Extract (400mg/d)
89021765|NCT03277833|Placebo Comparator|Placebo|Placebo
89021766|NCT00338312|Placebo Comparator|1|Placebo patch
89488130|NCT02149615|Active Comparator|minocycline|Retinal nerve fibre layer measurement in patients under minocycline treatment
89488131|NCT02149615|Active Comparator|doxycycline|Retinal nerve fibre layer measurement in patients under doxycycline treatment
89488132|NCT03209895|Experimental|Joint Health Product|
89488133|NCT03209895|Placebo Comparator|Placebo|
89488134|NCT03209895|Active Comparator|Glucosamine / Chondroitin|
89488135|NCT02149693|Experimental|high-fidelity simulation and teamwork training|high-fidelity simulation and teamwork training
89488136|NCT02149693|Active Comparator|traditional resuscitation training|traditional resuscitation training
89488137|NCT03209817|Experimental|Red cherry tomato|300 grams of red cherry tomatoes per day for four weeks (each)
89488138|NCT03209817|Experimental|Yellow cherry tomato|300 grams of yellow cherry tomatoes per day for four weeks (each)
89488139|NCT03209817|No Intervention|Control No tomato|No tomato products consumption
89488140|NCT03544801||sample group ,300|CSVD patients after symptomatic stroke
89488141|NCT03544801||control group,100|community population
89488142|NCT03119415|Experimental|Cooperative Learning|Teachers in intervention schools are training in cooperative learning (CL).
89488143|NCT03119415|No Intervention|Business as Usual|Schools continue with business as usual.
89488144|NCT02141893|Active Comparator|CALMA|Participants only received a family education intervention (previously tested) known as CALMA
89488145|NCT02141893|Experimental|Calma plus|Participants in Arm 2 received the CALMA family education intervention and physician education and organizational change of the clinics were addressed with a culturally tailored program developed by adapting content from several evidence-based provider training programs.
89488146|NCT02141971||Non-demented; Ages 30-40|Four non-demented Down syndrome patients between the ages of 30-40 years old
89488147|NCT02141971||Non-demented; Ages 40-50|Four non-demented Down syndrome patients between the ages of 40-50 years old
89488148|NCT02141971||Demented; Ages 50-60|Four demented Down syndrome patients between the ages of 50-60 years old
89488149|NCT02149771|Experimental|TACE&Stents|chemoembolization combined with endovascular stents and iodine-125 seed strand implantation
89488150|NCT02149771|Active Comparator|TACE|Transartery chemoembolisation（TACE） by administering Doxorubicin and Oxaliplatin mixed with 5-20 mL iodised oil.Gelatine sponge was used to embolise the feeding artery of the tumour.Repeat if patients with viable lesions demonstrated by CT or MRI.
89488151|NCT03207633|Active Comparator|First group|First group (20 patients) receive for 10 sessions of low frequency rTMS targeting right DLPFC by means of a Butterfly coil using the following parameters: 120% RMT, 1 Hz, 3 trains, each of 500 pulses with a 40 seconds inter-train interval allowing the coil to cool.
89488152|NCT03207633|Active Comparator|Second group|The second group (20 patients) will receive 10 sessions of low-frequency rTMS over the right orbitofrontal cortex (OFC) by means of a Butterfly coil using the following parameters: 120% motor threshold, 1 Hz, 3 trains, each of 500 pulses with a 40 seconds inter-train interval allowing the coil to cool.
88956531|NCT04973436|Experimental|LiveWell: A Dialectical Behavioral Therapy Skills Training Protocol|"The intervention, LiveWell will teach participants dialectical behavioral therapy-based skills to reduce psychological distress through improved physical symptom management, emotion regulation, and tolerance of uncertainty. Informed by feedback from patients and providers collected in Phase of of the study, the LiveWell intervention consists of of 8 sessions delivered one-on-one, approximately weekly. Sessions will last approximately 45-60 minutes each."
89021767|NCT00338312|Experimental|2|testosterone patch (300 mcg/day) patch changed 2 times/week, for one year
89204224|NCT04002700||Target Cohort 2|Participants will be analyzed for stroke-risk who are new users of haloperidol aged 18 to 64 years without a recent dementia diagnosis.
89204225|NCT04002700||Target Cohort 3|Participants will be analyzed for stroke-risk who are new users of typical antipsychotics aged greater than or equal to (>=) 65 years.
89488153|NCT03207633|Sham Comparator|Third group|The third group (the sham condition) (20 patients) will receive sham stimulations of rTMS with the same pulse delivery as the other groups but with the coil placed perpendicular to the scalp.
89488154|NCT03230487|Experimental|BI 1015550|
89204226|NCT04002700||Target Cohort 4|Participants will be analyzed for stroke-risk who are new users of haloperidol aged >= 65 year.
89204227|NCT04002700||Target Cohort 5|Participants will be analyzed for stroke-risk who are new users of typical antipsychotics aged 18 to 64 years.
89204228|NCT04002700||Target Cohort 6|Participants will be analyzed for stroke-risk who are new users of haloperidol aged 18 to 64 years.
89204229|NCT04002700||Comparator Cohort 7|Participants will be analyzed for stroke-risk who are new users of atypical antipsychotics aged 18-64 years without a recent dementia diagnosis.
89021768|NCT00451425|No Intervention|control|standard maternity care
89204230|NCT04002700||Comparator Cohort 8|Participants will be analyzed for stroke-risk who are new users of atypical antipsychotics aged >= 65 years.
89204231|NCT04002700||Comparator Cohort 9|Participants will be analyzed for stroke-risk who are new users of atypical antipsychotics aged 18-64 years.
89204232|NCT00769496|Experimental|Arm 1|
89204233|NCT05354908||Colombian research groups in surgery|Colombian research groups in surgery
89488155|NCT03230487|Placebo Comparator|Placebo|
89488156|NCT02142127|Experimental|14C-labelled GFT505 120 mg|
89488157|NCT02376166|Experimental|Metformin|850 mg PO once daily for 4 weeks
89488158|NCT03207165|Active Comparator|Left ventricular [LV] +/- Biventricular dysfunction|Assessment of left ventricular [LV] or biventricular dysfunction will be based on clinical assessment, available imaging (echocardiogram, left ventriculogram, MUGA/RNA scan, cardiac MRI, etc.) and known past medical history (if available and contributory). Patients identified as having biventricular dysfunction will be randomized within the LV dysfunction arm of the trial. Patients in this arm will be randomized in a 1:1 fashion to Milrinone or Dobutamine.
88953233|NCT01959997|Active Comparator|PVI + RDN|"All patients who are randomized to Group II will undergo redo PVI exactly as described above.~At the conclusion of PVI, RDN will be performed. Real-time 3-dimensional aorta-renal artery maps will be constructed with the use of the same navigation system and catheter used for PVI after femoral artery access. Both mapping and ablation will performed under the same modified sedation. RF ablations of 8 to 10 watts will be applied discretely from the first distal main renal artery bifurcation all the way back to the ostium, for 2 min, and up to 6 lesions (separated by ≥ 5 mm). Lesions will be made both longitudinally and rotationally within each renal artery. To confirm renal denervation, high-frequency stimulation (HFS) will be used before the initial and after each RF delivery within the renal artery. RDN will be considered to have been achieved when the sudden increase of blood pressure (≥ 15 mm Hg from invasive arterial monitoring) is absent."
88953234|NCT01960023|Experimental|Arm 1: Cetuximab and Neratinib|Cetuximab 400 mg/m2 IV loading dose followed by weekly cetuximab 250 mg/m2 IV plus neratinib per oral daily until disease progression
88953235|NCT01960036|No Intervention|Treatment as usual (TAU)|Usual intensive outpatient treatment for substance use disorders
89488159|NCT03207165|Active Comparator|Right ventricular [RV] dysfunction|Assessment of right ventricular [RV] dysfunction will be based on clinical assessment, available imaging (echocardiogram, left ventriculogram, MUGA/RNA scan, cardiac MRI, etc.) and known past medical history (if available and contributory). Patients in this arm will be randomized in a 1:1 fashion to Milrinone or Dobutamine.
89488160|NCT03543475|Experimental|Pessary|Silicon device applied on the cervix
89488161|NCT03543475|Active Comparator|No Pessary|standard care, no pessary
89488162|NCT03230331||STN DBS|Parkinson's disease (PD) patients who underwent deep brain stimulation (DBS) of the subthalamic nucleus (STN)
89488163|NCT03230331||CONTROL|Parkinson's disease (PD) patients received optimized medical treatment according to published evidence based guidelines
89488164|NCT02142205|Experimental|BG00002 (natalizumab)|300 mg IV infusion every 4 weeks
89488165|NCT03209427|Active Comparator|Group I|intrathecal injection of 100 μg morphine
89488166|NCT03209427|Active Comparator|Group II|iIntrathecal injection of 200 μg morphine
89488167|NCT02311894|Experimental|Somatropin|Children will receive daily SC injections of somatropin at a dose of up to 0.043 milligrams per kilogram per day (mg/kg/day) for 1 year.
89488168|NCT03544723|Experimental|Ad-p53 with anti-PD-1/anti-PD-L1 100% of patients|Up to 40 patients, all patients treated with intra-tumoral Ad-p53 (dose determined by tumor size) in combination with IV physician's choice of approved immune checkpoint inhibitor
89488169|NCT03209661|Active Comparator|E-Cigarette 5.4% NBV|Subjects will be asked to inhale an E-Cigarette with 5.4% NBV for 6 min.
89488170|NCT03209661|Placebo Comparator|E-Cigarette 0% NBV|Subjects will be asked to inhale an E-Cigarette with 0% NBV for 6 min.
89488171|NCT03209661|Placebo Comparator|Menthol Inhaler|Subjects will be asked to inhale a sham methole inhaler (that looks identical in looks to E-cigarette) for 6 minutes. This arm is to control for a potential effect of menthole.
89488172|NCT02142439|Experimental|Intervention group 1|Exercise counseling 1 time/week, Strength training 3 times/week, dose: 5 RM x 3 sets.
89488173|NCT02142439|Experimental|Intervention group 2|Exercise counseling 1 time/week. Strength training 3 times/week, dose: 10 RM x 3 sets.
89488174|NCT02142439|Experimental|Intervention group 3|Exercise counseling 1 time/week. Strength training 3 times/week, dose: 30 RM x 3 sets
89488175|NCT02142439|No Intervention|Control group|Exercise counseling 1 time/week
89488176|NCT03209037|Experimental|experimental group|patients who were untreated ever in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly till 48 weeks.
89488177|NCT03209037|No Intervention|control group|patients who were untreated ever in immune-active phase took Nucleoside Analogues for maintenance treatment.
89488178|NCT02142517|Active Comparator|Duct to mucosa PJ group|Duct to mucosa PJ was performed by a two layer end to side PJ. The pancreatic capsule and jejunal serosa were anastomosed by interrupted silk suture 3/0 to form the outer layer in both the anterior and posterior wall of the anastomosis. Jejunostomy was done matched to the pancreatic duct diameter. The inner layer duct to mucosa was performed in eight to twelve stitches with 5/0 prolene. A pancreatic duct stent was inserted during anastomosis to allow easy and accurate suture placement, ensure adequate pancreatic duct exposure, and protect the opposite wall from being inadvertently held by needles then it was removed at the end of anastomosis.
88953236|NCT01960036|Experimental|Mindful Awareness in Body-oriented Therapy (MABT)|A mind-body intervention to teach interoceptive skills for self-care.
88953237|NCT01960036|Active Comparator|Womens Health Education|A comparative arm to control for time and attention that involves education about the human body relevant to women's health.
89488179|NCT02142517|Active Comparator|Invagination PJ group|Invagination PJ was performed as an end to side. The pancreatic capsule and jejunal serosa were anastomosed by interrupted silk suture 3/0 to form the outer layer in both the anterior and posterior wall of the anastomosis. Jejunostomy was done matched to the pancreatic stump diameter. The inner layer was performed with 5/0 prolene between pancreatic parenchyma and mucosa. The duct was taken posteriorly and anteriorly to jejunal mucosa. A pancreatic duct stent was inserted during anastomosis and removed at the end of taking the stitches. Reconstruction was completed by end to side hepaticojejunostomy (retrocolic) and gastrojejunostomy (GJ) (antecolic) end to side manually.
89488180|NCT03209115|Active Comparator|calcium hydroxide and chlorhexidine|Removal of old root canal filling and placing calcium hydroxide and chlorehexidine as intracanal medication
89488181|NCT03209115|Active Comparator|calcium hydroxide|Removal of old root canal filling and placing calcium hydroxide as intracanal medication
89488182|NCT03209193|Experimental|Sevoflurane|Sevoflurane (2 vol%) use as a maintenance volatile anesthetic drug during the surgery
88953238|NCT01960049|Placebo Comparator|MOTAP Catheter with Saline and IV PCA|Control group will have saline 20cc of 0.9% normal saline injected into the catheters and then run at 5ml/hr for 72 hours
89488183|NCT03209193|Experimental|Desflurane|Desflurane (6 vol%) use as a maintenance volatile anesthetic drug during the surgery
89488184|NCT02142595|Experimental|dexmeditomidine group D|The sedative solution was prepared as a 10µg /ml dexmedetomidine in an unlabeled 20ml syringe. The sedative solution administered intravenously started at rate of kg (weight of patient)*0.6 ml/h over a 10-min period and then at rate of kg (weight of patient)*0.15 ml/h through syringe pump to the end of surgery
89488185|NCT02142595|Experimental|Midazolam group M|The sedative solution was prepared as a 0.375mg/ml midazolam or normal saline in an unlabeled 20ml syringe. The sedative solution administered intravenously started at rate of kg (weight of patient)*0.6 ml/h over a 10-min period and then at rate of kg (weight of patient)*0.15 ml/h through syringe pump to the end of surgery
89488186|NCT02142595|No Intervention|group control|normal saline in an unlabeled 20ml syringe. The sedative solution administered intravenously started at rate of kg (weight of patient)*0.6 ml/h over a 10-min period and then at rate of kg (weight of patient)*0.15 ml/h through syringe pump to the end of surgery
89488187|NCT02310646|Active Comparator|Treatment group 1|Day 1 to 7: LEO 90100 aerosol foam Day 8 to 14: Daivobet® gel
89488188|NCT02310646|Active Comparator|Treatment group 2|Day 1 to 7: Daivobet® gel Day 8 to 14: LEO 90100 aerosol foam
89488189|NCT03209271|Experimental|Body temperature fluid|500ml Ringers Acetate infused over 15 minutes warmed to 38°C
89488190|NCT03209271|Active Comparator|Room temperature fluid|500ml Ringers Acetate infused over 15 minutes cooled to 22°C
89488191|NCT02450721||Acute stroke|"Patients in the acute phase of atherothrombotic stroke or TIAs with 50-99% ACAS within the first 3 days af vascular event.~Interventions to be administered: Biomarkers serum level measurement, history taking, neurological examination, duplex ultrasound, MMSE, National Institutes of Health Stroke Scale (NIHSS)"
89488192|NCT02450721||Stable carotid artery stenosis|"Patients with 50-99% ACAS without history of vascular events during one month before enrollment.~Interventions to be administered: Biomarkers serum level measurement, history taking, neurological examination, duplex ultrasound, MMSE"
89488193|NCT02450721||Control group|Healthy volunteers without ACAS Interventions to be administered:Biomarkers serum level measurement, history taking, neurological examination, duplex ultrasound, MMSE
89488194|NCT04898374|Experimental|Induction Arm|patients will receive three cycles of IC Gemcitabin/Cisplatin followed by radical CRT
89488195|NCT04898374|Active Comparator|Adjuvant Arm|Patients will receive radical CRT followed by three cycles of AC Gemcitabin/Cisplatin
88953239|NCT01960049|Active Comparator|MOTAP catheter with ropivocaine and IV PCA|20cc of 0.2% ropivacaine will be injected in two equal divided doses through the two catheters then run at 5ml/hr for 72 hours
88953240|NCT01960062|No Intervention|Control|Diabetes care with primary care practitioner supplemented with clinical pharmacy specialist
88953241|NCT01960062|Experimental|Intervention|Diabetes care with primary care practitioner and clinical pharmacy specialist, with the aid of a diabetes software and device to upload glucometer results from home
88953242|NCT01960088||Adolescents and their parents|Pharmacy demonstration project: HPV vaccine delivery
88953243|NCT01960101|Experimental|Lactoxeros milk product|Patient will take the milk product orally for 14 days as many times as needed per day(but not more than 6 times daily).
88953244|NCT01960101|Other|Aequasyal|Patients will take the oral spray for 14 days. The Aequasyal ® Oral Spray is a solution of oxidized glycerol triesters. The oral spray is applied by spraying on the inside of each cheek, 3-4 times per day. After each administration, users are instructed to gently spread the product around the mouth with the tongue. The Aequasyal ® Oral Spray is a Class I medical device, and is CE-marked.
88953245|NCT01960153|Experimental|Tadalafil|Tadalafil is supplied in 20 mg tablets. Subjects will take 20 mg (one tablet) once per day and will be titrated to 40 mg (two tablets once per day) after one week. Subjects are on study drug for the duration of the trial.
89021769|NCT00338390|No Intervention|1|Maintain antiretroviral treatment
89488196|NCT03230409|No Intervention|Phase 1, Retrospective|Routine outpatient follow-up visits were scheduled as follows: (a) in patients receiving primary chemoprophylaxis or Latent Tuberculosis Infection (LTBI) treatment: baseline visit, and 2 weeks and 3 months later (end of treatment in most cases); (b) in patients treated for Tuberculosis disease: baseline visit, 2 weeks later and on a monthly basis thereafter.
89488197|NCT03230409|Experimental|Phase 2, Prospective|"Four nurse-led interventions were implemented after Phase 1:~Intervention 1: at baseline visit, the parents or carers of the children, were given a leaflet in the mother tongue. This leaflet was available in 10 different languages: Spanish and Catalan (the two official languages of the country), English, French, German, Russian, Romanian, Chinese, Urdu and Arabic.~Intervention 2: a follow-up open telephone call was made 7-10 days after the baseline visit and whenever the patient failed to attend the scheduled visits.~Intervention 3: the Eidus-Hamilton test was performed twice, 2 weeks after the baseline visit and at the end of treatment. To prevent patients from only taking their medication occasionally, directly before their visits, they were not informed of the purpose of the urine test.~Intervention 4: a written questionnaire about adherence to anti-TB treatment on all the follow-up visits."
89488198|NCT03230253|Experimental|Sequential training group|Exercise training for 30 minutes followed by 30 minutes of cognitive-based intervention
89488199|NCT03230253|Experimental|Dual training group|Exercise training simultaneously combined cognitive-based intervention for 60 minutes
88953246|NCT01960153|Placebo Comparator|Placebo|Placebo of tadalafil. Subjects will take one tablet once per day and will be titrated to two tablets once per day after one week. Subjects are on study drug for the duration of the trial.
88953247|NCT01960166|Experimental|Active distraction|Child will use Ipad as active distraction
89488200|NCT03230253|Active Comparator|Control training group|non-aerobic exercise (e.g., stretch, range of motion exercise...) and unstructured cognitive rehabilitation programs (e.g., reading newspapers, playing board games...) for 60 minutes
89488201|NCT03207321||Intervention|In 15 intervention villages, a balanced protein-calorie supplement - made from locally available corn-soya ingredients and called 'upma' - was offered daily to pregnant women and children under six years of age during 1987-1990. The meal provided on average 500 kcal energy and 20-25g of protein to women and half of those amounts to children.
89488202|NCT03207321||Control|No supplement was provided in 14 control villages.
89488203|NCT02375698|Experimental|Gr 1 H56:IC31 5/500|5ug H56 + 500 ug IC31
89488204|NCT02375698|Placebo Comparator|Placebo|The placebo consists of 10mM Tris and 169 mM NaCl pH 7.4.
89488205|NCT03207477|Experimental|Prematurely born infants|Visual acuity measurement in prematurely born infants included in PREMAVISION study
89488206|NCT03207477|Active Comparator|Term born infants|Visual acuity measurement in term born control infants
89488207|NCT03208725||Hospitalized children with severe wasting or kwashiorkor (SWK)|Children recruited at admission to hospital and followed up for 180 days post-discharge.
89488208|NCT03208725||Community reference participants (CP)|Children recruited from the community who are seen a single appointment in the community.
89488209|NCT03208725||Hospitalized children with moderate wasting (MW)|Children recruited at admission to hospital and followed up for 180 days post-discharge.
89488210|NCT03208725||Hospitalized children without wasting (NW)|Children recruited at admission to hospital and followed up for 180 days post-discharge.
88953248|NCT01960166|Experimental|Passive Distraction|Child will watch movie as passive distraction (control)
88953249|NCT01960179|Experimental|lixisenatide|lixisenatide monotherapy by group (Group 1: 52-week treatment; Group 2: 24-week treatment)
88953250|NCT01960192|Experimental|FVD regimen|FVD regimen(fotemustine, teniposide and dexamethasone),fotemustine 100mg/m2 d1 ivgtt,teniposide 60mg/m2 d2-4 ivgtt,dexamethasone 40mg d1-5 ivgtt.Continued use to the end of chemotherapy .Every 21 days for one cycle and four cycles are required. Efficacy was evaluated every two cycles.
88953251|NCT01960192|Experimental|HD-MTX-Ara-C regimen|high-does metrotrexate 3.5g/m2 d1 ivgtt 6h,cytarabine 1g/m2 bid d2-3.Continued use to the end of chemotherapy .Every 21 days for one cycle and four cycles are required. Efficacy was evaluated every two cycles.
88953252|NCT01960205|Experimental|Standarddose Saxagliptin|Saxagliptin 5 mg (tablet) ,5mg a day and lifestyle intervention for 6 months
88953253|NCT01960205|Active Comparator|Lifestyle intervention|Lifestyle intervention for 6 months
88953254|NCT01960205|Active Comparator|Metformin|Metformin 500 mg (tablet) ,500mg three times a day and lifestyle intervention for 6 months
89488211|NCT02374918|Experimental|mTBI wavelength-1 bright light|30 minutes daily light exposure for 6 weeks
89488212|NCT02374918|Placebo Comparator|mTBI wavelength-2 bright light|30 minutes daily light exposure for 6 weeks
89488213|NCT02374918|Experimental|HC wavelength-1 bright light|30 minutes of light exposure
89488214|NCT02374918|Placebo Comparator|HC wavelength-2 bright light|30 minutes of light exposure
89488215|NCT03206697||Aneuploid mitochondria|Mitochondrial DNA content and metabolic parameters
89488216|NCT03119337|Experimental|Text-based VMMC follow-up|Follow-up conducted via daily text not through mandatory in person visits. Men may elect to come to the clinic if concerned about any complications but have no routine, scheduled follow-up visits.
89488217|NCT03119337|No Intervention|Routine VMMC follow-up care|Routine VMMC follow up care with in person visits according to national guidelines.
89488218|NCT02450643|Active Comparator|Test then Control|Subjects will perform a DBPCFC with the Test formula followed by the Control formula
88953255|NCT01960205|Experimental|low dose Saxagliptin|Saxagliptin 5 mg (tablet) ,2.5 mg a day and lifestyle intervention for 6 months
88953256|NCT01960218||acute decompensated heart failure|Adult subjects anticipating discharge from a hospitalization where the primary discharge diagnosis is acute decompensated heart failure and who are not excluded due to existing conditions.
88953257|NCT01960231||pancreas specific MODY-2|
89488219|NCT02450643|Active Comparator|Control then Test|Subjects will perform a DBPCFC with the Control formula followed by the Test formula
89488220|NCT03208881||Intensive dietary intervention|Supervised dietary weight loss program lasting 8 weeks
89488221|NCT02344576|No Intervention|Control: Usual Care|Patients and caregivers will receive the current usual education and consent process for DT LVAD at each hospital. This often means viewing consent forms and industry materials.
89488222|NCT02344576|Experimental|DT LVAD Decision Support Intervention|In the intervention phase of the study, patients and caregivers will receive the new decision support intervention, which consists primarily of decision aid materials about DT LVAD. The standard consent process will also still take place, but will be supplemented with additional decision support.
89488223|NCT02452515|Experimental|BAY1142524 (5 mg)|12 patients with left-ventricular dysfunction after myocardial infarction, 9 patients allocated to verum treatment, 3 patients allocated to placebo treatment
89488224|NCT02452515|Experimental|BAY1142524 (10 mg)|12 patients with left-ventricular dysfunction after myocardial infarction, 9 patients allocated to verum treatment, 3 patients allocated to placebo treatment
89488225|NCT02452515|Experimental|BAY1142524 (25 mg)|12 patients with left-ventricular dysfunction after myocardial infarction, 9 patients allocated to verum treatment, 3 patients allocated to placebo treatment
89488226|NCT02452515|Experimental|BAY1142524 (50 mg)|12 patients with left-ventricular dysfunction after myocardial infarction, 9 patients allocated to verum treatment, 3 patients allocated to placebo treatment
89488227|NCT03208647||AA Group|All the patients of AA group met a AA diagnostic criteria；
89488228|NCT03208647||Control Group|The control group were chosen from other departments who were under acute infection (such as pneumonia), acute abdominal emergency (such as appendicitis), cataract surgery;
89488229|NCT03206775||Healthy controls (Phase 1)|Participants will participate in Cognitive Assessments (Phase 1) developed by Posit Science
89488230|NCT03206775||Healthy Controls, Battery A (Phase 2)|Participants will complete the Cognitive Battery A (Phase 2) developed by Posit Science while at the Minnesota State Fair.
89488231|NCT03206775||Healthy Controls, Battery B (Phase 2)|Participants will complete the Cognitive Battery B (Phase 2) developed by Posit Science while at the Minnesota State Fair.
89488232|NCT03206775||Healthy Controls, Battery C (Phase 2)|Participants will complete the Cognitive Battery C (Phase 2) developed by Posit Science while at the Minnesota State Fair.
89488233|NCT03206775||Healthy Controls (Phase 3)|Participants will complete the full Posit Science cognitive assessment battery and self-report questionnaires for credit in the Research Experience Program at the University of Minnesota.
89488234|NCT03206775||Healthy Controls, Battery D (Phase 2)|Participants will complete the Cognitive Battery E (Phase 2) developed by Posit Science while at the Minnesota State Fair.
89488235|NCT03206775||Healthy Controls, Battery E (Phase 2)|Participants will complete the Cognitive Battery C (Phase 2) developed by Posit Science while at the Minnesota State Fair.
89488236|NCT03206775||Adolescents with anxiety diagnosis (Phase 4)|Participants will complete remote cognitive assessments and cognitive training programs developed by Posit Science.
89488237|NCT03206775||Adolescents, healthy controls (Phase 4)|Participants will complete remote cognitive assessments and cognitive training programs developed by Posit Science.
89488238|NCT02344342|Experimental|Health Buddy Web Management system|Patients randomized to the telemonitoring intervention will be assigned to use the Bosch Health Buddy Web management system.
89488239|NCT02344342|Experimental|Flexible Diuretic Regimen|Patients randomized into the Flexible Diuretic Regimen intervention will have a diuretic regimen specified by specific weight ranges.
89488240|NCT02450565||Neuropathic pain subjects|The diagnosis of neuropathic pain will be made by pain specialists based on a detailed history, physical examination, investigation results and medical records.
89488241|NCT02450565||Nociceptive pain subjects|The diagnosis of nociceptive pain will be made by pain specialists based on a detailed history, physical examination, investigation results and medical records.
89488242|NCT02452437|Experimental|control|Oxycodone will be administered and subjects will undergo hemodialysis
89488243|NCT02452437|Experimental|hemodialysis|Oxycodone will be administered and subjects will undergo hemodialysis
89488244|NCT03206619||Social, Local and Mobile|Patients having smoking cessation standard care (behavioral and pharmacological therapy) and using the SoLoMo mobile app that sends them motivational messages.
89488245|NCT03229707|Active Comparator|group 1 Color matching using Vita 3D master|"Outcome Name: Color Matching measured by :~Modified (USPHS) criteria"
89488246|NCT03229707|Experimental|group 2 Color matching using digital photography|"Outcome Name: Color Matching measured by Digital Photography using (Photoshop)~Software:~0 to 1: no difference in perception~1 to 2: only perceptible to a trained observer~2 to 3.5: perceptible difference~3.5 to 5: marked difference"
88953258|NCT01960270|Experimental|Alone controlateral stimulation|"Device: INTERSTIM II~Stimulator II activated~Stimulator I not activated~Measure of efficacy on bladder hyperactivity"
89488247|NCT03230019|Active Comparator|chest tube|VATS with chest tube placement
89488248|NCT03230019|Experimental|two-lumen catheter|VATS with two-lumen catheterization
89488249|NCT03208491|Experimental|serious games|
89488250|NCT03208491|Active Comparator|usual care|
89488251|NCT03208413|Experimental|thalidomide|Thalidomide with a dosage of 25 mg at bedtime daily one week (days 1-7), then 50 mg at bedtime daily for one week (days 8-14), then 75 mg at bedtime daily for one week (days 15-21), then 100 mg at bedtime daily for 12 weeks (days 22-105), in the absence of unacceptable toxicity or severe deterioration.
89488252|NCT03206853|Experimental|Hybrid operation group|Intervene with hybrid operating techniques, eg. microsurgical clipping+endovascular coiling or with the assistant of balloon occlusion.
89488253|NCT03206853|Other|Traditional therapy group|The aneurysms will be executed by traditional procedure, including microsurgical clipping, endovascular coiling or stenting, etc.
89488254|NCT03206541||Cases|The cases are defined as individuals that present with new onset of a neurological syndrome of unknown etiology, including but not limited to encephalitis, myelitis, meningitis, polyneuropathy/Guillain-Barre syndrome and cranial nerve involvement.
89488255|NCT03206541||Controls|"There are two age-matched control groups:~Household controls that have lived with the case for at least three months before the onset of neurological symptoms.~Controls with a febrile syndrome of unknown etiology that do not present neurological involvement and is recruited in the same center as the case."
89488256|NCT03201471|Experimental|treatment group|In this group, the patients will receive 2 courses of Chidamide+ R-CHOP regimen, the way of administration and dosage of the medicine used in the trial is as follows: Rituximab 375mg//m2, ivgtt,d1; CTX 750mg/m2, ivgtt,d2; EPI 70mg/m2, ivgtt,d2; VCR 1.4 mg/m2, ivgtt, d2; Pred 60 mg/m2, PO, d2-6; Chidamide 20mg/d,d1、4、8、11、14、18; one cycle every 21 days； abbreviation： CTX： cyclophosphamide；EPI：etoposide；VCR： vincristine；Pred：prednisone； R-CHOP：the chemo-therapy regimen composed of Rituximab, cyclophosphoamide; etoposide, vincristine and prednisone.
89488257|NCT03206385||CK Boost pelvis|
89488258|NCT03201237|Experimental|30 min AOT|
89488259|NCT03201237|Placebo Comparator|60 min AOT|
89488260|NCT03206229|Experimental|TPI-120 (PEG-rhG-CSF)|PEG-rhG-CSF (recombinant granulocyte-colony stimulating factor conjugated with monomethoxypolyethylene glycol) Adello Biologics, LLC, Chicago, IL
89488261|NCT03206229|Active Comparator|Neulasta (PEG-rhG-CSF)|Neulasta®, (PEG-rhG-CSF) Amgen, Thousand Oaks, CA
89488262|NCT03201081|Experimental|training group|The training group, based on motivational strategies were performed and a moderate intensity training (8 to 12 repetitions). The load was increased: during the 12 weeks from 65% 1-RM to 80% 1-RM, performing individual more than the prescribed number of repetitions (12 repetitions). A 1-2 minutes resting period was allowed between sets. There was no attempt to control the velocity of the repetitions performed. Prior to each training session, the volunteers performed a specific warmup, consisting of 10 repetitions with approximately 50% of the load used in the first and second exercises of the training session. A total of 36 sessions were performed during the training period. This group was compared with no interventions subjects.
89488263|NCT03201081|No Intervention|control group|The control group, did not participate in the motivational resistance-training program.
89488264|NCT03201159|Experimental|VLX103 150mg|In the first group, 150 mg dosing cohort, one VLX103 tablet will be administered daily for 14 days.
89488265|NCT03201159|Experimental|VLX103 300mg|In the second group, 300 mg dosing cohort, two VLX103 tablets will be administered daily for 14 days.
89488266|NCT03201159|Experimental|VLX103 450mg|In the third group, 450 mg dosing cohort, three VLX103 tablets will be administered daily for 14 days.
89488267|NCT03229785|Experimental|Human Umbilical Cord Blood Plasma|Six intravenous infusions of human umbilical cord blood plasma (HUCBP) during a twelve month study period. The amount of HUCBP being infused on each occasion is 50 mL.
89488268|NCT02149927|Experimental|Sevoflurane|Single arm: dose escalation of study medication
89488269|NCT03206307||Group 1|Group 1 will be questioned 36 months (in 2017) after their medical rehabilitation which was in 2013/2014.
89488270|NCT03206307||Group 2|Group 2 has the medical rehabilitation in 2017 and will be questioned at the end of the medical rehabilitation and 6, 12 and 18 months after that
89488271|NCT02142673|Active Comparator|Filling pressure 80|The hysteroscope filling pressure will be 80mm Hg
89488272|NCT02142673|Active Comparator|Filling pressure 60|The hysteroscope filling pressure will be to 50mm Hg
89488273|NCT02142673|Active Comparator|Filling pressure 40|The hysteroscope filling pressure will be to 40mm Hg
89021770|NCT00338390|Experimental|2|Change tenofovir to abacavir and increase didanosine dose to 400 mg/day if weight is > 60 Kg. or to 250mg/day if weight is < 60 kg.
89488274|NCT03205995|Experimental|OMS721|Administration of OMS721
89488275|NCT02150005|Experimental|Periodontal treatment|The test group received oral hygiene instructions, supragingival and subgingival scaling and root planning using curettes and an ultrasonic appliance.
89488276|NCT02150005|No Intervention|Control|
89021771|NCT00338390|Experimental|3|Change tenofovir and didanosine to abacavir + lamivudine (600mg+300 mg/day in one single tablet).
89021772|NCT00338429|Experimental|Treatment: FHP Sleep Program|Stratified with or without behavior Disorder Diagnosis (ADHD): 50% randomized to receive Better Days, Better Nights- sleep distance intervention
89021773|NCT00338429|No Intervention|Control: Usual Care|Stratified with/without behavior diagnosis (ADHD): 50% randomized to receive usual care for sleep disorder
89021774|NCT00445185|Experimental|1|Henogen Hepatitis B vaccine for uremic patients
89488277|NCT03205917|Experimental|Group 1A HIV-Uninfected|PGDM1400 low dose
89488278|NCT03205917|Experimental|Group 1B HIV-Uninfected|PGDM1400 mid dose
89488279|NCT03205917|Experimental|Group 1C HIV-Uninfected|PGDM1400 high dose
89488280|NCT03205917|Experimental|Group 2A HIV-Uninfected|PGDM1400 + PGT121 low dose
89488281|NCT03205917|Experimental|Group 2B HIV-Uninfected|PGDM1400 + PGT121 mid dose
89488282|NCT03205917|Experimental|Group 2C HIV-Uninfected|PGDM1400 + PGT121 high dose
89488283|NCT03205917|Experimental|Group 3A HIV-infected off ART|PGDM1400 + PGT121 + VRC07-523LS at 20mg/kg; HIV+ without ART
89021775|NCT00445185|Active Comparator|2|Fendrix hepatitis B vaccine for uremic patients
89021776|NCT00451503|Experimental|1|surgery
89021777|NCT00451620|Experimental|2.|GlucoNorm
89021778|NCT00451620|Experimental|1.|Glyburide
89021779|NCT00338858|Active Comparator|1|TD
89021780|NCT00338858|Experimental|2|TBI
89021781|NCT00338858|Experimental|a|Cerebral palsy
89488284|NCT03205917|Experimental|Group 3B HIV-infected off ART|PGDM1400 + PGT121 at high dose; HIV + without ART
89488285|NCT02142751|Experimental|Fosfomycin sodium intravenous|4g every 6 hours iv (60 min infusion)
89488286|NCT02142751|Active Comparator|Meropenem intravenous|1g every 8 hours (15-30 min infusion)
89488287|NCT02142751|Other|Ceftriaxone intravenous|1g every 24h (2-4 min)
89488288|NCT03119259|Active Comparator|ABC Clinical Program Only and Usual Care|Patients and informal caregivers randomized to the comparison group will receive care provided by the ABC Clinical Program and IUHP. The ABC Clinical Program is the standard of ADRD care at Eskenazi Health and Primary Care Visits at Indiana University Health is the usual care.
89488289|NCT03119259|Experimental|BCN Mobile App Plus ABC and BCN Mobile app only|Patients and caregivers randomized to the intervention group will continue to receive care in ABC clinical program and IUHP, and have the BCN software installed on either the caregiver's personal mobile device (assuming it meets minimal technical requirements) or a device provided by the study, per participant preference. A research assistant will orient participants to the device, provide training on the BCN software, and troubleshoot technical issues. Participants will receive daytime technical support by phone, electronic support request through a separate app, or printed and in-app help manuals. Hardware, software, and connectivity check-ups will be provided by study research personnel.
89488290|NCT02142829|Active Comparator|EXPAREL|EXPAREL (bupivacaine liposome injectable suspension)
89488291|NCT02142829|Active Comparator|On-Q Pain Ball|Device for delivering bupivacaine.
89488292|NCT03205683|Experimental|Intraneural facilitation therapy|The intraneural facilitation intervention is a novel manual physical therapy approach with anecdotal evidence in neuropathic pain symptoms through biasing blood flow from an artery through the nutrient vessels into the epineurium of an accompanying nerve. The main concept of intraneural facilitation is the use of two manual holds. The first hold is called facilitation hold and includes putting the contralateral joint in a maximal loose-pack position that is comfortable to the patient. The hypothesis with this initial hold is the nerve will have greater excursion the accompanying artery and the nutrient vessels that are clustered at the joint will be stretched. This stretch may enlarge the opening at the junction of the artery and bridging nutrient vessel, therefore consistently creating a vascular bias into the neural epineurial capillaries. Theoretically, this creates increased epifascicular vascular pressure which may be absent due to epineurial ischemia.
89488293|NCT03205683|Sham Comparator|Sham therapy|"Will be performed by a different therapist than actual INF. The patient will be asked to do the following combination of passive range of motion (PROM) and active ROM activities to promote blood flow in the affected arm Each visit will last about 45 minutes, twice a week for 6 weeks (total 12 sessions).~Missing > 4 sessions will invalidate subject outcomes."
89488294|NCT02150083|Experimental|OR retrograde fill|At completion of sling placement in the operating room, the bladder will be filled retrograde via a cystoscope with 300 mL sterile saline or water to inspect for bladder perforation. The cystoscope is removed and the foley catheter is NOT replaced for the duration of the surgery. The surgery is completed and the patient is transferred to the post-anesthesia care unit. Once she is able to ambulate, she will be instructed to void. The voided volume and residual volume will be recorded.
89488295|NCT02150083|No Intervention|PACU retrograde fill|At completion of sling placement in the operating room, the bladder will be filled retrograde via a cystoscope with 300 mL sterile saline or water to inspect for bladder perforation. The cystoscope is removed and the foley catheter is replaced for the duration of the surgery and when complete the patient is transferred to the post-anesthesia care unit. Once she is able to ambulate, she will undergo a retrograde bladder fill with 300 mL of normal saline. The foley catheter will be removed and she will be instructed to void. The voided volume and residual volume will be recorded.
89488296|NCT03200691|Experimental|Nimotuzumab with radiotherapy|"Patients will receive neoadjuvant radiotherapy with concurrent anti-PD-1 antibody SHR-1210. Radiation of primary tumor and local lymph nodes with 95% planning target volume (PTV) of 40Gy/20f.~SHR-1210 200mg fixed dose every 2 weeks delivered concurrent with radiation therapy.~After 2-4 weeks of neoadjuvant treatment, patients will be evaluated by a multidisciplinary teams (MDTs) and esophagectomy will be given for patients with resectable disease."
89488297|NCT02150161|Experimental|lidocaine/ ketamine infusion|lidocaine 1mg/Kg bolus, followed by continuous infusion 1 mg/kg/h AND ketamine 1mg/Kg bolus followed by continuous infusion 1 mg/kg/h
89488298|NCT02150161|Active Comparator|fentanyl|iv fentanyl, 3ug/kg bolus
89488299|NCT03205839|Experimental|Acceptance-based self-help|"Participants in this group will receive the self-help booklet.~Surviving to Thriving: ACT self-help for living well with a visible difference in appearance"
88953259|NCT01960270|Experimental|2 sides-stimulation|"Device: INTERSTIM II~Stimulator I and II activated~Measure of efficacy on bladder hyperactivity"
88953260|NCT01960283|Active Comparator|Group I|"The group I will receive the intervention :~Methotrexate + anti-H1"
88953261|NCT01960283|Placebo Comparator|Group II|The intervention in group II will include : placebo + anti-H1
88953262|NCT01960309|Experimental|1. TnI elevation|TnI 0.06-0.60ng/ml, no ischemia on ECG. Intervention: minimal invasive cardiac imaging
88953263|NCT01960309|Experimental|2. TnI elevation|TnI 0.61-6.00 ng/ml, no ischemia on ECG. Intervention: minimal invasive cardiac imaging
88953264|NCT01960309|Experimental|3. TnI elevation|TnI>6.00 ng/ml, no ischemia on ECG. Intervention: minimal invasive cardiac imaging
88953265|NCT01960309|Experimental|4. TnI elevation|TnI >6.00 ng/ml, ischemia on ECG and Hb<5.1. Intervention: minimal invasive cardiac imaging
88953266|NCT01960309|Experimental|5. TnI elevation|TnI >6.00 ng/ml, ischemia on ECG and Hb>5.0. Intervention: minimal invasive cardiac imaging
88953267|NCT01960309|Active Comparator|Control|TnI <0.06 ng/ml, no ischemia on ECG. Intervention: minimal invasive cardiac imaging
88953268|NCT01960322|Experimental|Telemetric|Enrolled patients will be followed for 12 months during which they will receive the study telemetry intervention.
88953269|NCT01960335|Active Comparator|Whey Protein Only|Ingestion of whey protein only (20 grams per serving) consumed 3X/day along with ad libitum diet for a total of 60 grams per day. One serving was consumed within 1 hour of waking in the morning; a second serving was consumed mid-afternoon; and a third serving was consumed within 2 hours of going to sleep at night.
89488300|NCT03205839|No Intervention|Waitlist control group|Participants in this group will be placed onto a waitlist for the four-week intervention period.
89488301|NCT02144311|Experimental|MRI with DW-MRI & DCE-MRI & FDG PET/CT|Study participants will have 1 scan within the 7 days immediately preceding surgery (PET/CT as standard of care and MRI as a research exam). MRI and PET/CT scanning procedures will be identical to those used in routine clinical examinations of the abdomen and pelvis.
89488302|NCT03205527|Experimental|Slip training for chronic stroke|Chronic stroke subjects in this training group will receive bilateral overground, slip perturbation training.
89488303|NCT03205527|No Intervention|Control for chronic stroke|Chronic stroke subjects, after baseline walking trials, will walk for about 30 trials at their preferred walking pace to match the total trials the other groups receive before receiving a single slip each randomly on their non-paretic and paretic sides.
89488304|NCT03205527|Experimental|Slip training for sub-acute stroke|Sub-acute stroke survivors in this training group will receive bilateral overground, slip perturbation training.
89488305|NCT03205527|No Intervention|Control for sub-acute stroke|Sub-acute stroke subjects, after baseline walking trials, will walk for about 30 trials at their preferred walking pace to match the total trials the other groups receive before receiving a single slip each randomly on their non-paretic and paretic sides.
89488306|NCT03200613|Experimental|Apixaban|Apixaban 2.5 mg orally twice daily
89488307|NCT03200613|Active Comparator|Low Molecular Weight Heparin|Either enoxaparin 40 mg or dalteparin 5000 units subcutaneously once daily
89488308|NCT02150239||postoperative pain|
89488309|NCT03118791|Placebo Comparator|Placebo|Capsules containing maltodextrin
89488310|NCT03118791|Active Comparator|80 mg ACN|Capsules containing 80 mg anthocyanins
89488311|NCT03118791|Active Comparator|160 mg ACN|Capsules containing 160 mg anthocyanins
89488312|NCT03118791|Active Comparator|240 mg ACN|Capsules containing 240 mg anthocyanins
89488313|NCT03118791|Active Comparator|320 mg ACN|Capsules containing 320 mg anthocyanins
89488314|NCT03118791|Active Comparator|480 mg ACN|Capsules containing 480 mg anthocyanins
89488315|NCT02142985|Experimental|crystalloid solution|vascular filling with 500 ml of crystalloid solution within 10 minutes
88953270|NCT01960335|Experimental|Whey Protein and Resistance Exericse|Ingestion of whey protein (20 grams per serving) 3X/day: one serving within an hour of waking in morning; a second serving mid-afternoon or within 1 hour immediately following a resistance exercise bout on exercise days; and a third serving within 2 hours of going to bed at night.
89488316|NCT02150317|Active Comparator|TACE+Sorafenib|TACE followed by Sorafenib
89488317|NCT02150317|Experimental|TACE|TACE alone
89488318|NCT02448147|Active Comparator|Interval training|
89488319|NCT02448147|Active Comparator|Continuous training|
89488320|NCT02448147|No Intervention|Control|
89488321|NCT02150395|Experimental|music therapy|pt received a protocolized music therapy intervention that included altered state induction, music driven guided visualiztion, and psychoeducation on relaxation techniques to be used during simulation for radiation therapy. Prescribed pre-recorded music program provided to be used during simulation.
89488322|NCT02150395|No Intervention|control|no intervention
89488323|NCT02310568|Experimental|PF 06372865 2.5 mg BID then placebo.|PF 06372865 2.5 mg tablet 2 times daily for 4 weeks (Stage 1), followed by placebo 2 times daily for 4 weeks (Stage 2).
89488324|NCT02310568|Experimental|PF 06372865 7.5 mg BID then placebo.|PF 06372865 2.5 mg tablet 2 times daily for one week, then PF 06372865 7.5 mg tablet 2 times daily for 3 weeks (Stage 1), followed by placebo (2 times daily) for 4 weeks (Stage 2).
88953271|NCT01960335|Experimental|Whey Protein and RISE exercise routine|Ingestion of whey protein (20 gram serving) 3X/day: one serving within an hour of waking in the morning; a second serving mid-afternoon or within 1 hour immediately following the RISE exercise bout; and a third serving within 2 hours of going to bed at night.
88953272|NCT01960361|Experimental|ICE dental implant|Subjects implanted with ICE implant
88953273|NCT01960374|Experimental|Japanese Arm|3 cohorts of 9 subjects. Each cohort will receive oral 25 mg, 50 mg (anticipated) or 75 mg (anticipated) selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate).
89488325|NCT02310568|Experimental|Placebo then PF 06372865 2.5 mg BID.|Placebo 2 times daily for 4 weeks (Stage 1), followed by PF 06372865 2.5 mg tablet 2 times daily for 4 weeks
89488326|NCT02310568|Experimental|Placebo then PF 06372865 7.5 mg BID.|Placebo 2 times daily for 4 weeks (Stage 1), followed by PF 06372865 2.5 mg tablet 2 times daily for one week, then PF 06372865 7.5 mg tablet 2 times daily for 3 weeks (Stage 2).
89488327|NCT02310568|Placebo Comparator|Placebo followed by placebo.|Placebo 2 times daily for 4 weeks (Stage 1) followed by Placebo 2 times daily for 4 weeks (Stage 2).
89488328|NCT03205215|Experimental|Immediate Treatment|This arm will receive hyperbaric oxygen therapy once consented.
89488329|NCT03205215|Experimental|Waitlist - to be treated|This arm will receive a hyperbaric oxygen therapy after waiting two months.
89488330|NCT02448069|Experimental|Argatroban treatment|Intravenous Argatroban delivered at 100mcg/kg bolus, then 12-hour infusion initiated at 3mcg/kg/min.
89488331|NCT02449863||Low risk ultrasound|Patients with a low risk ultrasound
89488332|NCT02449863||High risk ultrasound|Patients with a high risk ultrasound
89488333|NCT02449941||Helicobacter pylori(HP) positive|Participants who are diagnosed with Helicobacter Pylori infection through ESD(endoscopic submucosal dissection) will be treated with PPI (proton pump inhibitor).
89488334|NCT03205449|Experimental|MaPa Programme|Masayang Pamilya Parenting Program: A 12-session, a group-based parenting programme focused on reducing violence against children and improving child wellbeing in low-income families with young children
89488335|NCT03205449|Active Comparator|Treatment-as-usual|Parenting Effectiveness Service programme: A family strengthening programme delivered by trained service providers on a monthly basis.
89488336|NCT03200145||Control|The control group is made by persons living in nursing homes under usual care
89488337|NCT03204825|Experimental|Active TENS|Participants in the TENS groups will be provided with a TENS machine and training at the baseline visit to the Clinical research Facility (CRF). They will be instructed to use it daily as their symptoms require for 6 weeks. The active group will receive High Frequency-TENS (120 Hz, 200µs and a patient-determined intensity of ''strong but comfortable'').
89488338|NCT03204825|Placebo Comparator|Placebo TENS|Placebo TENS : Participants will receive the same model, programmed settings and instructions for use as those in the active group except that the device will be set to an ineffective stimulation (120 Hz, 200µs and a patient-determined intensity of '6mA). For the purpose of blinding, participants will be told that different dosages of TENS are being tested, some of which where the stimulation might not be perceivable even though the device is working.
89488339|NCT03204825|Experimental|Patient-Centred Education|Patient-Centred Education : a one-off three-hour workshop of structured group education (4-5 persons in each group) and three 2-weekly phone calls. The aim will be to modify patients' illness beliefs and perceptions about IC/PAD by educating them on disease pathology and management philosophy. After the workshop, each patient will be supported to set goals for walking, develop an action plan regarding how these goals will be met and encouraged to repeat this process for each new walking goal.
89488340|NCT03204825|Experimental|Patient-Centred Education + Active TENS|Combination of Patient-Centred Education arm and Active TENS arm.
89488341|NCT04484493|Experimental|mometasone nasal spray|Patients will receive topical corticosteroid nasal spray (mometasone furoate nasal spray) in appropriate dose of 2 puff in each nostril (100 µg once daily) beside olfactory training.
89488342|NCT04484493|No Intervention|control|Patients will not receive topical corticosteroid nasal spray but only olfactory training.
89488343|NCT03205059|Experimental|LST MS curriculum+ Bullying/Cyberbullying serious game|
89488344|NCT03205059|Active Comparator|LST MS curriculum|
89488345|NCT03204903|Experimental|Laser acupuncture|The subjects are treated at acupoints including BL2, TE23, ST2, LI4, ST36, and GB37 using laser acupuncture during 3 sessions per week for 12 weeks.
89488346|NCT03204903|Sham Comparator|Sham laser acupuncture|The subjects are treated at acupoints including BL2, TE23, ST2, LI4, ST36, and GB37 using sham laser acupuncture (without laser output) during 3 sessions per week for 12 weeks.
89488347|NCT03204747||Patients enrolled|"Patient with multiple sclerosis and lower urinary tract symptoms, age > 18, able to walk without human help on 50 meters, able to hold urine at least 3 minutes.~A first record of gait will be at strong desire to void. A second record will be after void Gait records consist on : 3 10meter walk test and 1 Timed up and Go test."
89488348|NCT02310100|Experimental|TactiCath Quartz|TactiCath Quartz treatment
89488349|NCT03200067|Experimental|Personalized rehabilitation service group|Breast cancer patients who use mobile healthcare service application and receive personal feedback from clinician
89488350|NCT03200067|No Intervention|Conventional group|Breast cancer patients with conventional care
89488351|NCT03200223|Experimental|Personalized lifestyle intervention group|Personalized lifestyle intervention group Patients who use mobile healthcare service application and receive personal feedback from clinician
89488352|NCT03200223|No Intervention|Conventional group|Patients with conventional care
89488353|NCT03199989|Active Comparator|adjuvant chemotherapy group|patients enrolled int the adjuvant chemotherapy group will receive adjuvant chemotherapy[CapeOX（Capecitabine+Oxaliplatin）] by the current guidelines
89488354|NCT03199989|Experimental|observation group|patients enrolled int the adjuvant chemotherapy group will not receive adjuvant chemotherapy just for observation
89488355|NCT03195933|Experimental|Cortisol first, Placebo second|Single oral administration of 20 mg cortisol capsule to pharmacologically elevate cortisol levels during first functional magnetic resonance imaging (fMRI) session; Identically appearing placebo capsule during second fMRI session.
89488356|NCT03195933|Experimental|Placebo first, Cortisol second|Placebo capsule during first fMRI session; Single oral administration of 20 mg cortisol capsule to pharmacologically elevate cortisol levels during second fMRI session.
89488357|NCT03195621|Experimental|Interventional therapy group|
89488358|NCT03195621|No Intervention|Conservative treatment group|
89488359|NCT03195543||Patients with PAH|Diagnostic tests will be performed on patients with Pulmonary Artery Hypertension in order to assess any blood coagulation disorders. Platelet function, coagulation and fibrinolysis will be evaluated by platelet function analyzer-100 (PFA-100), light transmission aggregometry, rotational thromboelastometry (ROTEM) and endogenous thrombin potential.
89488360|NCT03195543||Patients with CTEPH|Diagnostic tests will be performed on patients with Chronic Thromboembolic Pulmonary Hypertension in order to assess any blood coagulation disorders. Platelet function, coagulation and fibrinolysis will be evaluated by platelet function analyzer-100 (PFA-100), light transmission aggregometry, rotational thromboelastometry (ROTEM) and endogenous thrombin potential.
89021782|NCT04716023||Chronic Airflow obstruction / COVID-19|Patients with either chronic airflow obstruction of COVID-19
89488361|NCT03199833|Experimental|Arms|RETRAINER-S2 & Conventional Therapy 27 sessions, 3 sessions per week for a total of 9 weeks. Each session consists of 30-minute training with the RETRAINER-S2 system plus 60 minutes of conventional therapy. The training session is customized on the patients' need and can be adapted to their improvement during the intervention.
89488362|NCT03199833|Active Comparator|Conventional Therapy|27 sessions, 3 sessions per week for a total of 9 weeks. Each session lasts about 90 minutes and consists of different training modalities typically used in the rehabilitation of the arm after stroke. The training session is customized on the patients' need and can be adapted to their improvement during the intervention.
89488363|NCT03204591||LC with SALI|cirrhosis patients with severe acute liver injury
89488364|NCT03199677|Experimental|apatinib with 500mg qd po|Patients administrate apatinib with the dose of 500mg once per day,half an hour after a meal.
89488365|NCT02780167|Experimental|Cohort 1|10 mg of PF-04965842 QD
89488366|NCT02780167|Experimental|Cohort 2|30 mg of PF-04965842 QD
89488367|NCT02780167|Experimental|Cohort 3|100 mg of PF-04965842 QD
89488368|NCT02780167|Experimental|Cohort 4|200 mg of PF-04965842 QD
89488369|NCT02780167|Placebo Comparator|Cohort 5|placebo QD
89488370|NCT02447757||Parturients with remifentanil analgesia|Parturients after induction of remifentanyl analgesia during the delivery
89488371|NCT03204435|Other|Traditional therapy|Consists of microsurgical aneurysmal operating techniques, endovascular techniques for intracranial aneurysms, endovascular techniques for cerebrovascular stenosis, and carotid endarterectomy, which are presented by stages.
89021783|NCT00451776|Experimental|1|patients who received etomidate
89021784|NCT00451776|Active Comparator|2|patients who received propofol
88953274|NCT01960374|Experimental|Non-Japanese Asian Arm|3 cohorts of 9 subjects. Each cohort will receive oral 25 mg, 50 mg (anticipated) or 75 mg (anticipated) selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate).
89488372|NCT03204435|Experimental|Hybrid operation|Consists of microsurgical aneurysmal operating techniques, endovascular techniques for intracranial aneurysms, endovascular techniques for cerebrovascular stenosis, and carotid endarterectomy, which are presented in one-stage in hybrid operating theater.
89488373|NCT02447835|Active Comparator|Olanzapine|Olanzapine administration
89488374|NCT02447835|Placebo Comparator|Placebo|Placebo administration
89488375|NCT02447913|Experimental|Voucher|
89488376|NCT02447913|No Intervention|Control|
89488377|NCT02447679|Experimental|thalidomine|"Thalidomide 400mg/day for 1 year~tegafur-uracil 2 tables for 1 year."
89488378|NCT03199443||Overactive bladder patients|
89488379|NCT03199443||Non Obstructive Urinary Retention patients|
89488380|NCT03203967|Experimental|Epidural morphine|"Epidural morphine (2 mg morphine in 5 ml normal saline) is administered through the epidural catheter at the end of surgery.~Single femoral nerve block is performed with 20 ml of 0.5% ropivacaine under the guidance of ultrasonography and nerve stimulator after surgery.~Intravenous morphine analgesia is provided with a patient-controlled analgesia pump which is established with 100 ml of 0.5 mg/mL morphine, programmed to deliver a 2 ml bolus with a lockout interval of 8-10 min and a background infusion of 0.5 mL/h."
89488381|NCT03203967|Placebo Comparator|Epidural placebo|"Epidural placebo (5 ml normal saline) is administered through the epidural catheter at the end of surgery.~Single femoral nerve block is performed with 20 ml of 0.5% ropivacaine under the guidance of ultrasonography and nerve stimulator after surgery.~Intravenous morphine analgesia is provided with a patient-controlled analgesia pump which is established with 100 ml of 0.5 mg/mL morphine, programmed to deliver a 2 ml bolus with a lockout interval of 8-10 min and a background infusion of 0.5 mL/h."
89488382|NCT03748927||1/ Cohort 1|Subjects with FL-HCC.
89488383|NCT03204045|Active Comparator|fentanyl|fentanyl 1 ㎍/kg
89488384|NCT03204045|Active Comparator|oxycodone|oxycodone 0.08 mg/kg
89488385|NCT03204045|Placebo Comparator|control|isotonic saline
89488386|NCT03199521||Atrial Fibrillation newly diagnosed, starting apixaban|Patients will undergo the global thrombosis test (GTT), thromboelastography (TEG) and thrombin generation assays before and after stabilisation(4 weeks) of their anticoagulation. This will allow to compare the effect of apixaban on endogenous fibrinolysis before and after treatment.
88953275|NCT01960426|Active Comparator|Empiric Dose Intensification|Intensify treatment with the existing drug
88953276|NCT01960426|Active Comparator|Testing based strategy|Measurement of drug (Adalimumab/Infliximab) Testing-based strategy for the management of secondary loss of response that is based on drug/ ADA measurement
88953277|NCT01960439||Endoscopic evaluation|The study population contained a broad spectrum of endoscopic disease and clinical activity. At entry to the trial patients had active disease defined by the presence of a modified UCDAI score between 4 and 10.1 Only patients who had a MMCS endoscopy subscale score according to a single central reader (n= 194 of 281 participants) were eligible for assessment in the current study.
88953278|NCT01960452||Primary insomnia|
88953279|NCT01960452||Healthy sleeping controls|
89488387|NCT03199521||Atrial fibrillation on stable warfarin treatment|Patients will undergo the global thrombosis test (GTT), thromboelastography (TEG) and thrombin generation assays on stable anticoagulation treatment. This will allow to compare the effect of apixaban against warfarin on endogenous fibrinolysis on stable treatment.
89488388|NCT03199521||Atrial Fibrillation on stable aspirin treatment|Patients will undergo the global thrombosis test (GTT), thromboelastography (TEG) and thrombin generation assays on stable anticoagulation treatment. This will allow to compare the effect of apixaban against aspirin on endogenous fibrinolysis on stable treatment.
89488389|NCT03195153|Experimental|statin only|30 DAYS OF STATIN THERAPY ATORVASTATIN 80 MG)
89488390|NCT03195153|Experimental|allopurinol only|30 DAYS OF ALLOPURINOL (300 MG)
89488391|NCT03195153|Experimental|statin and allopurinol|30 DAYS OF CO-ADMINISTRATION OF ATORVASTATIN AND ALLOPURINOL
89488392|NCT03204201|Experimental|Urethral instillation of ICG|Urethral instillation of indocyanine green (ICG)
89488393|NCT03195309|Active Comparator|Group A|Group A patients received 0.08% ropivacaine plus 4 mcg /mL fentanyl
89488394|NCT03195309|Active Comparator|Group B|Group B patients received 0.08% ropivacaine plus 2mcg /mL fentanyl
89488395|NCT03195309|Active Comparator|Group C|Group C patients received 0.16 % ropivacaine plus 2 mcg /mL fentanyl
89488396|NCT03199131|Experimental|CTEPH|Patients undergoing pulmonary endarterectomy for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH).
89488397|NCT03199131|Other|Control group|Patients undergoing adult cardiac surgery without evidence of pulmonary hypertension.
89488398|NCT03198975||Preoperative imaging features|In this project, there is only one study group which comprises of patients with Hepatocellular Carcinoma (HCC) who will undergo preoperative Gd-EOB-DTPA enhanced magnetic resonance image.
89488399|NCT03203811|Experimental|Low Dose|2mg, HTI-2088 oral tablet or placebo, one dose, evaluate over 4 days
89488400|NCT03203811|Experimental|Middle Dose|3.75mg HTI-2088 oral tablet or placebo, one dose, evaluate over 4 days
89488401|NCT03203811|Experimental|High Dose|5mg HTI-2088 oral tablet or placebo, one dose, evaluate over 4 days
89488402|NCT03203577|Active Comparator|Hospital initiation|Initiation of mechanical ventilation in hospital initiation of Home Mechanical ventilation takes place in a hospital; this makes this arm the standard care.
89488403|NCT03203577|Experimental|Home initiation|Initiation of mechanical ventilation at home Initiation of mechanical ventilation in a patient's home setting with telemonitoring
89488404|NCT03198819||Rifampisin group|"Researchers will administer topical Rifampicin and intravenous cefotaxime~For Rifampicin; 10 mg/kg/day, 24 h infusion on defect area during 3 days~For cefotaxime; 50 mg/kg/day, twice a day, intravenous during 5 days."
89488405|NCT03198819||Control group|"Researchers will only administer intravenous cefotaxime~1) Doses; 50 mg/kg/day, twice a day, intravenous during 5 days."
89488406|NCT03195231|Experimental|Wuling Powder Group|Take Wuling Powder 3 times a day，3 pills each time for 12 weeks
89488407|NCT03195231|Placebo Comparator|Placebo Group|Take placebo drug which cannot be distinguished from the experimental drug 3 times a day，3 pills each time for 12 weeks
89488408|NCT03195387|Experimental|D-1/120 mg MMV390048|Treatment of cohort 1: subjects receive a single oral dose of MMV390048 on Day -1, prior to PfSPZ challenge on Day 0.
89488409|NCT03195387|Experimental|D-7/120 mg MMV390048|Treatment of cohort 2: subjects receive a single oral dose of MMV390048 on Day -7, prior to PfSPZ challenge on Day 0.
89488410|NCT03195387|Experimental|D-X/YY mg MMV390048|Treatment of cohort 3: subjects receive a single oral dose of MMV390048 (dose to be determined) on a day (to be determined) prior to PfSPZ challenge on Day 0. Dosage and day of administration will be determined on the basis of data emerging from the first two cohorts.
89488411|NCT03195387|Placebo Comparator|Placebo|MMV390048 placebo
89488412|NCT02447601|Experimental|Simvastatin and PEX168(200µg)|Simvastatin: 40mg, oral Administration. PEX 168: 200µg,injected subcutaneously,once a week.
89488413|NCT03203733|Experimental|'Cooral™'|oral cooling with use of cooling device
89488414|NCT03203733|Active Comparator|cryotherapy|Cryoterapy consists of ice cubes or crossed ice and used as standard treatment for oral cooling.
89488415|NCT02447523||Patients with metabolic syndrome|Patients fulfilling criteria to establish the diagnosis of metabolic syndrome
89488416|NCT02447523||Patients without metabolic syndrome|Patients not fulfilling criteria of the metabolic syndrome
89488417|NCT03118713|Experimental|ipragliflozin and metformin|Subjects will receive daily dosage of ipragliflozin and metformin as single tablets
89488418|NCT03118713|Experimental|glimepiride and metformin|Subjects will receive daily dosage of glimepiride and metformin as single tablets
89488419|NCT02450409|Active Comparator|gap technique (GT)|"The patients receive a total knee arthroplasty using the established gap technique (gold standard serving as control). The intervention is the implantation of a total knee arthroplasty with this specific technique.~Implantation of TKA using the gap technique is the intervention. Intervention is not a drug but a specific operative technique."
89488420|NCT02450409|Experimental|anatomical alignment (AA)|"The patients receive a total knee arthroplasty using the new anatomical alignment technique (experimental). The intervention is the implantation of a total knee arthroplasty with this specific technique.~Implantation of TKA using anatomical alignment Intervention is not a drug but a specific operative technique."
89488421|NCT02449629||TGMY in HIV Care|TGMY (16-24 years of age) currently in HIV care at an Adolescent Medicine Trials Unit (AMTU) site or elsewhere.
89488422|NCT02449629||TGMY Not in HIV Care|TGMY (16-24 years of age) not currently in care who are living with HIV, not living with HIV, or those who are unaware of their HIV status.
89488423|NCT02449629||Health Care and Social Service Providers|Health care and social service providers who work with TGMY at AMTU sites or elsewhere that serve TGMY within the AMTU cities.
89488424|NCT02449707|Active Comparator|Control|Lateral Window Technique Augmentation for Maxillary Sinus without the use of Ultrasound activated resorbable poly-D-L-lactide pins for the stabilization of membrane. Placement of Purus® Cancellous Allograft, stabilized by Biomend ™ Collagen membrane. Cone Beam CT image of the sinus will be taken to evaluate the bone formation. Trephine Biopsy will be performed after 1 year, at the time of placement of implant to check the quality of bone formed.
89488425|NCT02449707|Experimental|Ultrasonic Pins|Lateral Window Technique Augmentation for Maxillary Sinus with the use of Ultrasound activated resorbable poly-D-L-lactide pins for the stabilization of the Purus® Cancellous Allograft, and Resorb X Membrane.Cone Beam CT image of the sinus will be taken to evaluate the bone formation. Trephine Biopsy will be performed after 1 year, at the time of placement of implant to check the quality of bone formed.
89488426|NCT03198585|Active Comparator|Empagliflozin 10 mg|
88953280|NCT01960478|Other|bood test|
88953281|NCT01960491|Experimental|Device Closure of Atrial Septal Defect|
88953282|NCT01960504|Experimental|Drug Eluting Absorbable Metal Scaffold|DREAMS 2nd Generation Drug Eluting Absorbable Metal Scaffold
88953283|NCT01960517|Experimental|Catheter placed|
88953284|NCT01960543|Active Comparator|Bupivacaine|"Intrathecal administration of bupivacaine 0.5%~Doses:~Bupivacaine 7 mg plus fentanyl 15 ug for patients shorter than 160 cm. Bupivacaine 9 mg plus fentanyl 15 ug for patients equal or taller than 160 cm or hip replacement."
88953285|NCT01960543|Active Comparator|Levobupivacaine|"Intrathecal administration of levobupivacaine 0.5%:~Doses:~Levobupivacaine 7 mg plus fentanyl 15 ug for patients shorter than 160 cm. Levobupivacaine 9 mg plus fentanyl 15 ug for patients equal or taller than 160 cm or hip replacement."
88953286|NCT01960556||Simulation|Simulation Training part of education
88953287|NCT01960556||Non-Simulation Based Education|Did not receive simulation based education
89488427|NCT03198585|Placebo Comparator|Placebo|
89488428|NCT02447289|Experimental|Experimental|Intranasal administration of ketamine (4.0 mg/kg, max. 100 mg) and midazolam (0.2 mg/kg, max. 5 mg)
88953288|NCT01960569|Active Comparator|Arm 1 : active product (Thrombexx)|100 patients will have the active product(Thrombexx), their visits on days 1,4,8 and 16 for target parameters assessment
88953289|NCT01960569|Placebo Comparator|Arm 2 : Placebo|100 patients will have placebo , their visits on days 1,4,8 and 16 for target parameters assessment
88953290|NCT01960582|Experimental|New Practice Strategy|Structured strategy for assessment and evaluation before and after intervention
88953291|NCT01960582|No Intervention|Ordinary practice|Ordinary practice, not structured
88953292|NCT01960595|Experimental|IV fentanyl PCA|The patient receives post-OP IV fentanyl PCA
88953293|NCT01960595|Active Comparator|post-OP IV fentanyl PCA and local infiltration|pretreatment of local infiltration 0.25% bupivacaine 5 ml and post-OP IV fentanyl PCA
88953294|NCT01960595|Active Comparator|nerves block and post-OP IV fentanyl PCA|pretreatment of peroneal nerves 0.25% bupivacaine 10 ml and post-OP IV fentanyl PCA
88953295|NCT01960608||low sodium group|24_hours_urine_sodium < 100 mEq/L
88953296|NCT01960608||mid sodium group|24_hours_urine_sodium >= 100 mEq/L and < 200 mEq/L
88953297|NCT01960608||high sodium group|24_hours_urine_sodium >= 200 mEq/L
88953298|NCT01960608||low income group|the income 25% below the quartile
88953299|NCT01960608||low mid income group|the income 25% - 50% below the quartile
88953300|NCT01960608||mid income group|the income 50% - 75% below the quartile
89488429|NCT02447289|Active Comparator|Comparator|Oral administration of ketamine (4.0 mg/kg, max. 100 mg) and midazolam (0.5 mg/kg, max. 20 mg)
89488430|NCT02447289|Active Comparator|Control|Oral administration of midazolam (1.0 mg/kg, max. 20 mg)
89488431|NCT02447367|Experimental|JLP-1207, Fasted followed by fed|JLP-1207 dosing in the fasted state followed by fed dosing
89488432|NCT02447367|Experimental|JLP-1207, Fed followed by fasted|JLP-1207 dosing in the fed state followed by fasted dosing
89488433|NCT03203265|Other|A:Offline HIV testing and counseling|Participants in Group A will be invited to come to the Thai Red Cross Anonymous Clinic, RSAT or SWING drop-in centers in Bangkok, or SWING or Sisters drop-in centers in Pattaya. After registration, they will receive standard HIV Testing and Counseling (HTC) services.
89488434|NCT03203265|Other|B1:Offline|participants will be guided to access services at the 'Adam's Love Offline Clinic,' a clinic set up specifically to provide private and fast HIV testing and post-test counseling only.
89488435|NCT03203265|Other|B2: Online|participants will be mailed a rapid HIV test kit. A trained online counselor will guide the participant through an online HIV testing process which includes quality checking of the test kit, obtaining blood through finger prick, performing the testing steps, and reading the test result.
88953301|NCT01960608||high income group|the income 75% over the quartile
89488436|NCT03203655|Experimental|Intervention Group|The intervention group will be enrolled in the CareMessage™ Adult Obesity texting program, which sends a text message 3 to 5 times a week, encouraging lifestyle modifications (diet and exercise education, and behavioral strategies) that can lead to healthy weight loss.
89488437|NCT03203655|Other|Control Group|The control group will receive the control condition. They will hear an initial talk about weight loss but will not be enrolled in any program or intervention.
89488438|NCT02447445||Older inpatient at MOP|The group includes older patients who are admitted to one of the Medicine for Older Patients (MOP) wards. Grip strength will be part of the routine assessment of older patient when admitted to MOP.
89488439|NCT02447211|Active Comparator|doxepin cream|Patients use doxepin cream 5% twice daily for two weeks
89488440|NCT02447211|Placebo Comparator|Placebo|Patients use cream without doxepin ingredient twice daily for two weeks
89488441|NCT03198429|Experimental|Embedded fathering intervention|"This condition focuses on workers' practice with fathers who have been identified as perpetrators in cases of child exposure to domestic violence. Workers randomly assigned to this condition will receive:~a one-day training at the beginning of the study on the need to engage fathers as part of intervention in cases of child exposure to DV~access to a practice leader and consultant to respond to question and concerns about working with father perpetrators of DV~access to a 30-minute presentation, once a month, on issues of practice specific to working with this population In addition,~cases being assigned to ongoing service workers will be flagged by intake at the time they are opened to ongoing services as being a potentially appropriate referral to the Caring Dads program~clients who are then referred to CD as part of clinical service will be given access to this program at the earliest possible opportunity."
89488442|NCT03198429|Experimental|Embedding mother-child intervention|"Workers in the MIM condition will receive additional training and facilitated referral to MIM for eligible clients. Specifically, workers randomly assigned to this condition will receive:~a one-day training at the beginning of the study on the impact of DV on mothers, mothering, and child development~access to a practice leader and consultant to respond to question and concerns about working with women victims of DV on parenting issues~access to a 30-minute presentation, once a month, on issues of practice specific to working with this population In addition,~cases judged by intake workers as being appropriate referrals to the MIM program (see Methods) and being assigned to these workers for ongoing service will be flagged at the time of transfer as being potentially appropriate referrals to the Mothers in Mind program~clients who are then referred to MIM as part of clinical service will be given access to this program at the earliest possible opportunity."
89488443|NCT03198429|Experimental|Combined intervention|A final group of workers will be randomly assigned to receive all the training, support, and referral opportunities associated with both the Embedded Mothers in Mind condition and the Embedded Caring Dads condition.
89488444|NCT03198429|No Intervention|Treatment as usual|Workers in the service as usual condition will continue to provide in-home support to children and families in accordance with current practice. Workers will receive regular supervision from their supervisors. A review of practice reveals that, in general, workers make referrals to intervention programs in only a small minority of cases. Such referrals will continue under this study protocol - service will proceed as usual. This condition is not a placebo, families are continuing to receive the full child protection service that they would normally have received if this trail were not being run.
89488445|NCT03198273|Experimental|Clinical pilates exercises|Participants will exercise 3 times a week for 6 weeks (18 sessions in total, 45-60 minutes each session) in accompany with a physiotherapist. Since the chosen model for exercise training is clinical pilates exercises, separate patient training will be needed. First 3 weeks planned as Warming Phase, Exercise Phase (first 3 weeks), Cooling Phase; and Second 3 weeks planned as Warming Phase, Exercise Phase (first 3 weeks), Cooling Phase.
89488446|NCT03198273|Experimental|Physiotherapy Program|Standard physiotherapy program consisting of conservative treatment is applied to both groups. The conservative treatment schedule to be applied to planned as 10 sessions, 3 times a week.
88953302|NCT01960621|Experimental|2|
89488447|NCT03203499|Experimental|ANS-6637|Single ascending doses of ANS-6637 administered orally
88953303|NCT01960647|Other|Uncoated PTA balloon catheter|Dilatation with uncoated PTA balloon catheter
88953304|NCT01960647|Active Comparator|Freeway Paclitaxel balloon catheter|Dilatation with Freeway Paclitaxel (3 µg/mm2) coated balloon catheter
88953305|NCT01960660|Experimental|Investigational Product|Omega-3 fatty acids in the form of triglycerides
88953306|NCT01960660|Active Comparator|Comparator Product 1|Omega-3 fatty acids in the form of ethyl esters.
88953307|NCT01960660|Active Comparator|Comparator Product 2|Omega-3 fatty acids in the form of phospholipids from krill oil.
88953308|NCT01960660|Active Comparator|Comparator Product 3|Omega-3 fatty acids from salmon oil.
88953309|NCT01960673|Experimental|LMA proseal|"The investigator will use proseal LMA in this study. The cuff of the proseal LMA could be inflation. It is thought to fix the larynx shape.~The investigator wants to test the efficacy during 30,45,60 degree of head and neck position."
88953310|NCT01960673|Experimental|igel LMA|"igel LMA did not have cuff. The shape, softness and contours accurately mirror the perilaryngeal anatomy.~The investigator want to test the efficacy of the igel at 30,45,60 degree of head and neck position."
88953311|NCT01960673|Experimental|air Q LMA|"The air-Q LMA should be used routinely as a classic passive airway. It is user-friendly, placement in patients is easy and air movement is outstanding. It has the added benefit of allowing for intubation using standard ET Tubes.~It also has the cuff and the contour of the mask is thought to mimic the the shape of the perilaryngeal region.~The investigator want to test the efficacy of the air Q LMA at 30,45,60 degree of the head and neck position."
89488448|NCT03203499|Placebo Comparator|Placebo|Placebo administered orally
89488449|NCT03203343|Active Comparator|PIRS group|Patients operated laparoscopically - PIRS technique
89488450|NCT03203343|Active Comparator|Marcy group|Patients operated by open modified Marcy technique
89488451|NCT03203421|Active Comparator|Low Dose (Group 1)|One low dose of ChAdOx1 LS2 (5 x 10^9 vp) on day 0.
89488452|NCT03203421|Active Comparator|Prime-Boost (Group 2)|One high dose of ChAdOx1 LS2 (2.5 x 10^10 vp) on day 0 and one dose of MVA LS2 (2 x 10^8 pfu) on day 56.
88953312|NCT01960673|Experimental|ambu LMA|ambu LMA is also an cuff device LMA. The investigator wanted to test the efficacy about the leak pressure and the view at 30,45,60 degree of head and neck position.
88953313|NCT01960699||CPC < 3|Good neurological outcome
88953314|NCT01960699||CPC >/= 3|Unvavourable neurologic outcome
88953315|NCT01960712|No Intervention|Continued external drainage|Continued external drainage alone.
88953316|NCT01960712|Active Comparator|Continued external drainage + transpapillary stent|External drainage + transpapillary plastic stent (7-10 Fr).
89488453|NCT03203421|No Intervention|Control Group A|No vaccinations will be administered.
89488454|NCT03203421|No Intervention|Control Group B|No vaccinations will be administered.
89488455|NCT03198117|Experimental|Huaier Granule|Huaier Granule
88953317|NCT01960738|Experimental|Intervention|The intervention group received a pre-dive checklist and a post-dive log
88953318|NCT01960738|No Intervention|Control|The control group received the post-dive log only.
88953319|NCT01960751|Other|neurocognitive tests|neurocognitive tests battery (MMSE, SDS, SF-36, HAD, BPRS, RAVLT, FACT-Cog, MoCA)
88953320|NCT01960764|Experimental|Pre-Treatment|Prior to receiving the transplant, this arm will be washed with an antimicrobial regimen
88953321|NCT01960764|Placebo Comparator|Control|This arm will still be transplanted with the autologous microbiome transplant cream, however it will not be pre-treated with an antimicrobial regimen
88953322|NCT01960777|Experimental|Onstep|Participants in this group will have an inguinal hernia repair ad modum Onstep.
88953323|NCT01960777|Active Comparator|Laparoscopic repair|Participants in this group will receive an inguinal hernia repair by use of a laparoscopic approach.
89488456|NCT03198117|Placebo Comparator|placebo|placebo
89488457|NCT03198117|No Intervention|No-treatment Control|patients refused any treatment
89488458|NCT03194997|Experimental|Dance|The group randomized to Dance intervention will receive a 3-week intervention with belly dance classes. The classes will be divided in: Warm up and stretching (10 minutes), Main part with belly dance steps and movements (40 minutes) and relaxation (10 minutes).
89488459|NCT03194997|Experimental|Pilates|The group randomized to Pilates intervention will receive a 3-week intervention with Pilates Methods. The classes will be divided in: Warm up and stretching (10 minutes), Main part with Pilates exercises (40 minutes) and relaxation (10 minutes).
89488460|NCT03194997|No Intervention|Control|The group randomized to Control group will be invited to maintain routine activities and be contacted by phone every two months and will receive an explanatory booklet on the benefits of physical activity after diagnosis of breast cancer as well as instructions on lymphedema prevention. Also, this group will be invited to three meeting during the 16 weeks of intervention, the first meeting will focus on stretching exercise to develop at home, a second meeting will be about self-esteem and the last meeting will be about prevented of lymphedema. The women in this group will not receive a dance or pilates intervention.
89488461|NCT03203031||Neonates with abdominal surgery and quadratus lumborum block|0-6 months children with abdominal surgery. After standard induction of general anesthesia, patients will receive 0.5 ml/kg of ropivacaine (2 mg/ml) in a quadratus lumborum block. Ultrasonography will be used to guide the injection. In the postoperative period, pain scores and analgesics consumption will be recorded until the 48th hour post surgery.
88953324|NCT01960803|Experimental|IOERT arm|Intraoperative electron radiotherapy (IOERT) is delivered after completion of the lumpectomy and sentinel node procedure. IOERT is performed on a mobile self-shielded magnetron-driven X-band linear accelerator specifically developed for use in the operating room. This machine produces megavoltage electron beams of energy ranging between 4 and 12 MeV. The radiation is delivered from the device to the tumor bed through an attached applicator. A single dose of 21 Gy calculated to the 90% depth posterior to the tumor bed will be administered and will last approximately 2.5 minutes.
88953325|NCT01960829|Experimental|Everolimus|
88953326|NCT01960868|Experimental|patients|
88953327|NCT01960868|Other|control group|
88953328|NCT01960920|Active Comparator|Healthy Volunteers|Dilute diesel exhaust Filtered diesel exhaust Filtered air
89488462|NCT03118323||Patients in need of endodontic treatment|n = 200
89488463|NCT03118479|Experimental|Androgen only addback|Anastrozole 10 mg orally once daily for 3 months Testosterone gel 7.5 g transdermally daily for 3 months.
89488464|NCT03118479|Experimental|Combined sex steroid addback|Placebo (sugar pill) tablet once daily for 3 months Testosterone gel 7.5 g transdermally daily for 3 months.
89488465|NCT03118401|Experimental|Ritual of stool|During the first 4 weeks, data will be collected on an individual stool diary with usual care of the resident After randomization will start the implementation period of ritual of stool. From the stool diary: - will be determined the stool profile of each resident over 1 week and application of the ritual of stool the following week At the end of this second period, data will be collected on an individual stool diary in for 4 weeks
88953329|NCT01960920|Experimental|Heart Failure patients|Dilute diesel exhaust Filtered diesel exhaust Filtered air
89488466|NCT03118401|Other|Usual practice|"During the first 4 weeks, data will be collected on an individual stool diary with usual care of the resident After randomization will start 2 weeks without data collection. Patient will be follow in usual practice.~At the end of this second period, data will be collected on an individual stool diary in for 4 weeks"
88953330|NCT01960946|Active Comparator|Modified Citrus Pectin (MCP)|Dietary Supplement: Modified Citrus Pectin (MCP, PectaSol-C), 5 grams by mouth three times a day
88953331|NCT01960946|Placebo Comparator|Placebo|Matched placebo 5 grams by mouth three times a day
89204234|NCT04098653|Experimental|Decitabine + BUCY|For myeloid tumors undergoing allo-HSCT, Decitabine+BUCY conditioning regimen was Decitabine 20mg/m2/day on days -14 and -10, Busulfan (BU) 3.2 mg/kg/day on days -7 and -4, Cyclophosphamide (CY) 60 mg/kg/day on days -3 and -2.
89488467|NCT03197961|Experimental|DMPA with tenofovir/emtricitabine PrEP|the drug combination of tenofovir disoproxil fumarate 300mg and emtricitabine 200mg which is known as Truvada® will be taken orally once daily for 14 days by all participants. Drug concentrations will be measured (blood sampling) and one dose of Depot medroxyprogesterone acetate (DMPA) 150mg will be administered to each participant as an intramuscular injection after the first course of tenofovir disoproxil fumarate/emtricitabine is completed. Then, a second round of the combination of tenofovir disoproxil fumarate 300mg and emtricitabine 200mg (Truvada®) will be taken orally once daily for 14 days by all participants.
89488468|NCT03202875|Experimental|Test (T)|SAR341402: single dose injection
89488469|NCT03202875|Active Comparator|Reference 1 (R1)|NovoRapid®: single dose injection
89488470|NCT03202875|Active Comparator|Reference 2 (R2)|NovoLog®: single dose injection
89204235|NCT04098653|Active Comparator|BUCY|For myeloid tumors undergoing allo-HSCT, BUCY conditioning regimen was Busulfan (BU) 3.2 mg/kg/day on days -7 and -4, Cyclophosphamide (CY) 60 mg/kg/day on days -3 and -2.
89204236|NCT00769574|Experimental|1|Patients with coronary syndrome
89488471|NCT03202797||Patients|
89488472|NCT03202953|Experimental|1:1 I:E ratio VCV (Group I)|volume controlled ventilation with 1:1 inspiratory to expiratory ratio After trendelenburg position, Tidal volume : 8ml/kg, inspiration:expiration ratio = 1:1, FiO2 = 0.5, maintain end tidal CO2 around 40±5 mmHg. Positive end expiratory pressure will not used.
89488473|NCT03202953|Active Comparator|autoflow VCV (Group A)|autoflow volume-controlled ventilation After trendelenburg position, Tidal volume : 8ml/kg, inspiration:expiration ratio = 1:2, FiO2 = 0.5, maintain end tidal CO2 around 40±5 mmHg. Positive end expiratory pressure will not used.
89488474|NCT03197571|Experimental|Nant Urothelial Cancer Vaccine|avelumab, bevacizumab, capecitabine, cisplatin, cyclophosphamide, 5-fluorouracil, fulvestrant, leucovorin, nab-paclitaxel, lovaza, stereotactic body radiation therapy, ALT-803, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, and haNK.
89488475|NCT03197805|Experimental|Use of PAM 50 test in Her2 equivocal breast cancer patient|Patients with an equivocal-HER2 breast cancer (IHC Score 2 and equivocal ISH defined as HER2/Chr17 ratio <2 and 4 ≤HER2 gene number copy < 6) will be eligible for RNA genomic test (PAM 50 test).
89488476|NCT02446977|Experimental|Vitamin B2 Streuli®|20mg IV
89488477|NCT02446977|Placebo Comparator|Solution for injection|4ml IV
89488478|NCT02447055|Experimental|Arm 1 (Flu/Mel/PT-Cy & Tac/MMF for certain cases)|"Fludarabine 30 mg/m^2 intravenously (IV) on Days -5, -4, -3, and -2~Melphalan 140 mg/m^2 IV on Day -2~Tocilizumab 8 mg/m^2 (capped at 800 mg) IV on Day -1~Stem cell infusion on Day 0~Cyclophosphamide 50 mg/kg IV on Days +3 and +4~Tacrolimus 1 mg/day IV on Day +5 (for unrelated & haploidentical cases)~Mycophenolate mofetil 15 mg/kg orally three times per day on Day +5 (for unrelated & haploidentical cases)~Filgrastim 10 ug/kg/day subcutaneously until neutrophil recovery starting on Day +5"
89488479|NCT03202563|Experimental|Gemigliptin 50mg|"the subjects should visit a study site 4 times during the treatment period for about 12 weeks in total.~Drug: Gemigliptin Drug: Metformin Procedure: Diet/exercise questionnaire Procedure: Continuous Glucose Monitoring System(CGMS)"
89488480|NCT03202563|Active Comparator|Dapagliflozin 10mg|"the subjects should visit a study site 4 times during the treatment period for about 12 weeks in total.~Drug: Dapagliflozin Drug: Metformin Procedure: Diet/exercise questionnaire Procedure: Continuous Glucose Monitoring System(CGMS)"
89488481|NCT02449785|Experimental|Cystic fibrosis adults|
88953332|NCT01960972|Experimental|Salt substitute|"As described by Brown, in a stepped wedge design, an intervention is rolled-out sequentially to the trial participants (either as individuals or clusters of individuals) over a number of time periods. The order in which the different individuals or clusters receive the intervention is determined at random and, by the end of the random allocation, all individuals or groups will have received the intervention. Stepped wedge designs incorporate data collection at each point where a new group (step) receives the intervention.~Thus, the salt substitute will be implemented in each cluster (village) in a randomized fashion. Not arms are needed since the 6 randomly-selected villages will be implemented in some moment of the protocol."
88953333|NCT01960985|Experimental|Physicaltherapy|Exprerimental group I - motor training balance training Exprerimental group II - motor training associated with visual and auditory cues on the balance training Control group - recived general orientations.
89021785|NCT00445575|Experimental|1|treatment duration: 1 year
89204237|NCT00769574|Other|2|Subjects without coronary syndrome
89204238|NCT04002154|Experimental|A - papilocare alternative days|Arm A: scheme A (21 days / 1 cannula per day + 7 days rest) x 1 month + alternate days up to 6 months (except for menstruation days)
89204239|NCT04002154|Experimental|B - papilocare semiintensive|Arm B: scheme B (21 days / 1 cannula per day + 7 days rest) x 3 months + alternate days up to 6 months (except menstruation days)
89204240|NCT04002154|No Intervention|C - standard of care|Arm C: usual clinical practice: no treatment
89204241|NCT00777374|Experimental|1|Allergen containing patch
89204242|NCT00777374|Placebo Comparator|2|Placebo patch
89488482|NCT03197727|Other|GC Saliva-Check BUFFER|Saliva test pH Buffering capacity Flow rate
89488483|NCT03197493|Experimental|High Dose|carbidopa-levodopa 25-100 mg 2 tablets TID
89488484|NCT03197493|Experimental|Intermediate Dose|carbidopa-levodopa 25-100 mg 1 tablet TID
89488485|NCT02450175|No Intervention|Cases|Patients with cancer whose platelets are examined
89488486|NCT02450175|Placebo Comparator|Control|Patients without cancer whose platelets are examined for comparison
89488487|NCT03202485|Active Comparator|Toric Implantable Collamer Lens|Subjects in this group will implant Toric Implantable Collamer Lens for high myopic astigmatism
89488488|NCT03202485|Experimental|ICL+ Astigmatic keratotomy|Subjects in this group will implant Implantable Collamer Lens and combined with astigmatic keratotomy for high myopic astigmatism
88953334|NCT01960985|Experimental|physiotherapy|Exprerimental group I - motor training balance training Exprerimental group II - motor training associated with visual and auditory cues on the balance training Control group - recived general orientations.
89021786|NCT00445575|Placebo Comparator|2|treatment duration: 1 year
89204243|NCT05297123|Experimental|ATRA/arsenic Group|"ATRA 20mg 3 times a day for 8 weeks Arsenic can be given intravenously (ATO) or oral Realgar-Indigo naturalis formula(RIF) ATO 0.15mg/kg/d for 8 weeks (If the total daily amount is greater than 10mg, only 10mg/d can be given) RIF 60 mg/kg/d for 8 weeks The total dose can be appropriately adjusted according to the side-effects of the drug. 4 weeks for 1 course. If the patient has obvious side effects, the treatment should stop for 2 weeks. Each patient will be received at least two courses.~Quality of life assessments are performed every 2 months. After the end of the course of treatment, the condition is mainly evaluated based on the platelet count and bone marrow smear. If the treatment is effective, the above regimen can be continued; if not, the study is withdrawn."
89204244|NCT00654420|Experimental|Ph I: Dalotuzumab 5 mg/kg + Erlotinib|During the Phase I part of the study, participants receive dalotuzumab intravenously (IV) at 5 mg/kg weekly plus open-label erlotinib at 150 mg daily for 4 weeks. After 4 weeks of therapy, participants in Phase I who do not have disease progression and are satisfactorily tolerating study drug can continue to receive study drug.
89204245|NCT00654420|Experimental|Ph I: Dalotuzumab 10 mg/kg + Erlotinib|During the Phase I part of the study, participants receive dalotuzumab intravenously (IV) at 10 mg/kg weekly plus open-label erlotinib at 150 mg daily for 4 weeks. After 4 weeks of therapy, participants in Phase I who do not have disease progression and are satisfactorily tolerating study drug can continue to receive study drug.
89204246|NCT00654420|Experimental|Ph II: Dalotuzumab 10 mg/kg + Erlotinib|During the Phase II part of the study, participants are randomized to receive dalotuzumab intravenously (IV) at 10 mg/kg weekly plus open-label erlotinib at 150 mg daily until disease progression or occurrence of unacceptable toxic effects.
89204247|NCT00654420|Active Comparator|Ph II: Erlotinib|During the Phase II part of the study, participants are randomized to receive open-label erlotinib at 150 mg daily until disease progression or occurrence of unacceptable toxic effects.
89204248|NCT00773630|Active Comparator|A|Intake of Pletal 100 mg tablets dose together with 200 ml water
89204249|NCT00773630|Experimental|B|Intake of Pletal 100 mg ODT dose without water
89204250|NCT00773630|Experimental|C|Intake of Pletal 100 mg ODT dose together with 200 ml water
89204251|NCT00773630|Active Comparator|D|Intake of Pletal 100 mg ODT dose without water
89204252|NCT03683836||Study Group|
89204253|NCT00777452||1|active surveillance
89204254|NCT00777452||2|radical prostatectomy
89204255|NCT00777452||3|external beam radiotherapy
89204256|NCT00777452||4|high intensity focused ultrasound
89204257|NCT05353114|No Intervention|Standard Therapeutic Footwear prescription group|1) Patients that will acquire the therapeutic footwear size and model according to aesthetic preferences
89204258|NCT05353114|Experimental|Therapeutic Footwear prescription based on a 3D Foot scanner|2) Patients that will acquire a specific size and model according to result of a novel mobile app 3D feet scan (smart-fitting by Podiapp - Podartis s.r.l Unipersonale-Crocceta del Montello (TV), Italy).
89204259|NCT04016922||Group A|Patients with mild anemia (Hb concentration: 9.0-10.9 g\dl).
89204260|NCT04016922||Group B|Patients with moderate anemia (Hb concentration: 7.0-8.9 g\dl).
89204261|NCT04016922||Group C|Patients with severe anemia (Hb concentration: >7.0 g\dl).
89204262|NCT03646474|Active Comparator|tranexamic acid group|
89204263|NCT03646474|Placebo Comparator|placebo group|
89488489|NCT03202719|Active Comparator|IPV at ages 14 weeks and 18 months|Participants in this arm will receive bivalent oral poliovirus vaccine (bOPV) at 6, 10 and 14 weeks of age and inactivated poliovirus vaccine (IPV) at 14 weeks and 18 months of age
89488490|NCT03202719|Active Comparator|IPV at ages 14 weeks, 18 weeks and 18 months|Participants in this arm will receive bivalent oral poliovirus vaccine (bOPV) at 6, 10 and 14 weeks of age and inactivated poliovirus vaccine (IPV) at 14 weeks, 18 weeks and 18 months of age
88953335|NCT01961011||Cohort #1: Bilateral carpal tunnel release|Cohort #1: Patients undergoing simultaneous bilateral carpal tunnel release for treatment of bilateral carpal tunnel syndrome. Inclusion criteria includes any adult patient indicated for bilateral carpal tunnel release. Exclusion criteria include age less than 18, pregnancy, any protected patient population, and the lack of assistance at home during the early postoperative period.
88953336|NCT01961011||Cohort #2: Unilateral carpal tunnel release|Cohort #2: Patients undergoing unilateral carpal tunnel release fir bilateral carpal tunnel syndrome. Patients will chose which hand they wish to have operated on. Patient will plan on undergoing carpal tunnel release on the unoperated side at a later date. Inclusion criteria include any adult patient indicated for unilateral carpal tunnel release. Exclusion criteria include age less than 18, pregnancy, and any protected patient population.
88953337|NCT01961024||Type 2 diabetic men|
89488491|NCT03202719|Active Comparator|IPV at ages 14 weeks and 9 months|Participants in this arm will inactivated poliovirus vaccine (IPV) at 14 weeks and 9 months of age
89488492|NCT03202719|Active Comparator|IPV at ages 6 weeks and 9 months|Participants in this arm will inactivated poliovirus vaccine (IPV) at 6 weeks and 9 months of age
89488493|NCT03202719|Active Comparator|IPV at ages 6 and 14 weeks|Participants in this arm will inactivated poliovirus vaccine (IPV) at 6 and 14 weeks of age
89488494|NCT03202407|Placebo Comparator|calcium group|"will receive calcium-based phosphate binder (calcium carbonate ) 45-65 mg/kg orally divided 3 to 4 times/day for 3 months.~all the following investigation will be done before and after consecutive 3 months of administration :~Complete blood count~Kidney function tests (serum urea and creatinine)~Serum total calcium level.~Serum phosphorus level.~Calcium × phosphorus product.~Serum parathormone level.~Serum alkaline phosphatase level.~Lipogram (Total cholesterol, High density lipoprotein, Low density lipoprotein and triglycerides).~Echocardiography regular follow up of serum phosphate , calcium and parathyroid hormone will be done every month for dose adjustment of the drug"
89488495|NCT03202407|Experimental|sevelamer group|"will receive the recommended daily dose of the Sevelamer hydrochloride phosphate binder 120-160 mg/kg orally 3 times per day for 3 months.~all the following investigation will be done before and after consecutive 3 months of administration :~Complete blood count~Kidney function tests (serum urea and creatinine)~Serum total calcium level.~Serum phosphorus level.~Calcium × phosphorus product.~Serum parathormone level.~Serum alkaline phosphatase level.~Lipogram (Total cholesterol, High density lipoprotein, Low density lipoprotein and triglycerides).~Echocardiography regular follow up of serum phosphate , calcium and parathyroid hormone will be done every month for dose adjustment of the drug"
89488496|NCT03202329|Other|standard care|responsible surgeon has actively to ask for cardiology support (he decides whether a heart failure specialist should see the patient post-operatively)
89488497|NCT03202329|Other|nurse-based care|heart failure nurses visit postoperatively every (working-) day to check fluid balance, medication, rhythm and general condition
89488498|NCT03197649|No Intervention|Control|No laser phototherapy treatment
89488499|NCT03197649|Experimental|Laser phototherapy treatment|Laser phototherapy treatment administered in OR
89488500|NCT03197415|Experimental|PRP group|Intradisc injection of autologous platelet-rich plasma gel
89488501|NCT03197337|Experimental|Control manipulation first|Patients in this group will first undergo the control manipulation while the study manipulation will follow.
89488502|NCT03197337|Experimental|Study manipulation First|Patients in this group will first undergo the study manipulation while the control manipulation will follow.
89488503|NCT03197181|Experimental|anodal transcranial direct current stimulation|anodal transcranial direct current stimulation (current strength: 1 mA, duration: 20 min) over the frontopolar cortex
89488504|NCT03197181|Sham Comparator|sham transcranial direct current stimulation|sham transcranial direct current stimulation (current strength: 1 mA, duration: 0.5 min) over the frontopolar cortex
89488505|NCT02261077|Experimental|Buscopan, single rising doses|
89488506|NCT02261077|Experimental|Buscopan, multiple rising doses|
89488507|NCT02261077|Placebo Comparator|Placebo|
89488508|NCT03196869|Experimental|Chrono-chemotherapy group|Induction chrono-chemotherapy followed by cisplatin chrono-chemotherapy concurrent combined with intensity-modulated radiation therapy;Delivery time is different from the control group
89488509|NCT03196869|Other|Routine intravenous drip|control group:Induction routine-chemotherapy followed by cisplatin routine-chemotherapy concurrent combined with intensity-modulated radiation therapy
89488510|NCT02150473|Experimental|Adalimumab|receive adalimumab 40 mg eow injections in combination with MTX for 24 weeks
89488511|NCT02150473|Placebo Comparator|Placebo|receive placebo injections in combination with MTX for 24 weeks
89488512|NCT02446587||Stroke with Mechanical Thrombectomy|Eligible patients will be adults ≥18 with the final diagnosis of an acute ischemic infarction and large artery occlusion in anterior circulation strokes who undergo endovascular therapy with mechanical thrombectomy utilizing stent retrievers
89488513|NCT02446587||Stroke without Mechanical Thrombectomy|Patients who would have large artery occlusion treated with best medical management (IV-tPA if eligible) and not receiving endovascular therapy will be collected for a secondary analysis as a comparison group and to evaluate the selection methods in them as well
89488514|NCT02446509|Experimental|Experimental Group|The experimental group will receive a 7-week group psychoeducation intervention. Caregivers will meet once a week for 90-minute sessions in a group setting. Dates and times of the group sessions will be arranged according to the convenience of the subjects. The major content will include the causes of bipolar disorder, signs and symptoms of bipolar disorder, the role of stress and life events, types of medications and what they do, self-management of the disorder, understanding the course of the disorder, genetic and biological predispositions, how the family can help, management of relapse.
89488515|NCT02446509|Active Comparator|Wait List Control Group|Subjects in the wait list control group will receive the same 7 psychoeducation sessions after the experimental group receives these sessions.
88953338|NCT01961024||Age- and weight-matched controls|
88953339|NCT01961037|Experimental|Physical activity intervention|Tai Chi: Moving for Better Balance exercise program
88953340|NCT01961050|Experimental|Intervention|Dual-Focused Brief Physician Intervention (DFBPI)
88953341|NCT01961050|Other|Standard care|Services as usual including standard OB/GYN clinic visits; no experimental intervention is provided.
88953342|NCT01961076|Experimental|uncooked corn starch|Patients receive uncooked corn starch before bed-time
88953343|NCT01961076|Experimental|modified corn starch|Patients receive modified corn starch before bed-time
88953344|NCT01961076|Experimental|other carbohydrate (starch) containing meal|Patients receive a carbohydrate (starch) containing meal before bed-time
88953345|NCT01961128|Experimental|Exercise Intervention|220 minutes of exercise per week, including 2-3 supervised sessions for 6 weeks
89488516|NCT02779075|Placebo Comparator|Saline|0.9% NaCL (saline) intravenously for 6 hours.
89488517|NCT02779075|Active Comparator|Exendin-9,39|Exendin-9,39 intravenously for 6 hours.
89488518|NCT02446431|Experimental|Metronomic Therapy|"There is only one arm in this study. All subjects receive the same therapy for a period of 420 days (42 day cycles x 10 cycles).~Bevacizumab: IV, 10 mg/kg, Days 1, 8~Cyclophosphamide: PO, 25 mg/m2 Days 1-14 (max dose = 50mg/dose)~Valproic Acid: PO, 5 mg/kg, three times per day (TID), Days 22-35~Temsirolimus: IV, 25 mg/m2, Days 22, 29"
89488519|NCT02151409|Experimental|NNC 0151-0000-0000 i.v.|Dose escalation trial
89488520|NCT02151409|Experimental|NNC 0151-0000-0000 s.c.|Dose escalation trial
89488521|NCT02151409|Placebo Comparator|Placebo|
89488522|NCT02446275|Experimental|Sternocleidomastoid MTRP and stretching|The sternocleidomastoid was treated with ischemic compression.
89488523|NCT02446275|Experimental|Trapezius MTRP and stretching|The central MTRP of the trapezius was treated as described above for the sternocleidomastoid.
89488524|NCT03543241||MyoStrain|Patients with suspected CAD and scheduled for cardiac catheterization will receive traditional CMR wall motion stress testing with MyoStrain software analysis of myocardial ischemia and viability.
89488525|NCT02446353|Experimental|Megace : fed|Megace / Apetrol ES : comparator / test, fed
89488526|NCT02446353|Experimental|Apetrol ES : fed|Apetrol ES / Megace : test / comparator, fed, cross-over
89488527|NCT02446353|Experimental|Megace : fasting|Megace / Apetrol ES : comparator / test, fasting
89488528|NCT02446353|Experimental|Apetrol ES : fasting|Apetrol ES / Megace : test / comparator, fasting, cross-over
89488529|NCT02150551|Experimental|Mesenchymal Stromal Cells (MSCs)|A fixed dose of Mesenchymal Stromal Cells (MSCs) will be studied: 1 x 106 cells/kg administered intravenously (IV) weekly for 4 consecutive weeks, with the option of an additional 4 weeks of treatment, at the discretion of the principal investigator.
89488530|NCT03202173|Active Comparator|normal mucosa|Flat and relatively uniform polygonal epithelial cells with alternating dark and light bands were noted in pCLE images of normal mucosa after intravenous injecting 10% fluorescein.
89488531|NCT03202173|Experimental|lymphoid hyperplasia|An unorganized tissue architecture, irregular cells (difference of cell shape, color and size), slightly intensified fluorescein leakage, and vessels not assessable were found in the lymphoid hyperplasia of nasopharyngeal mucosa after intravenous injecting 10% fluorescein..
89488532|NCT03202173|Experimental|nasopharyngeal carcinoma|pCLE images of nasopharyngeal carcinoma, which was associated with crowded unorganized tissue architecture (a dark-gray background without identification of mucosal structures), irregular cells like cell clusters, amplified fluorescein leakage, and irregular vessels changes after intravenous injecting 10% fluorescein.
89488533|NCT03202095|Experimental|Open Label Treatment with Creatine|5 grams daily of oral creatine monohydrate powde
89488534|NCT02150629||SCI patients|
89488535|NCT02150629||Healthy subjects|
89488536|NCT02446197|Experimental|Patient Directed Exercise Group|Participants will complete a combination of PT and OT activities that will be individually prescribed based on an evaluation by the therapy team completed pre-intervention. The activities will be added to the comprehensive inpatient rehabilitation program.
89488537|NCT02446197|No Intervention|Standard of care|Standard of care comprehensive inpatient rehabilitation program.
89488538|NCT02144389|Active Comparator|Praziquantel (PZQ)|A single dose of praziquantel (40 mg/kg) was administered orally on day-1 only, and after 7 days, 1 g of corn oil/soybean oil (50%/50%), for 15 consecutive days of school.
89488539|NCT02144389|Experimental|Arachidonic acid (ARA)|A single daily dose of 1 g microbial arachidonic acid-rich oil administered orally for 15 consecutive days of school.
89488540|NCT02144389|Experimental|PZQ + ARA|A single dose of PZQ (40 mg/kg) was administered orally on day-1 only, and after 7 days, followed the next day by 1 g of microbial ARA-rich oil, administered orally as a single dose on 15 consecutive days of school.
89488541|NCT02144545|Experimental|Bougie Size 33Fr Distance pylorus 2 cm|Sleeve gastrectomy with a 33Fr bougie size and 2 cm distance from the pylorus.
89488542|NCT02144545|Experimental|Bougie Size 33Fr Distance pylorus 5 cm|Sleeve gastrectomy with a 33Fr bougie size and 5 cm distance from the pylorus
89488543|NCT02144545|Experimental|Bougie Size 42Fr Distance pylorus 2 cm|Sleeve gastrectomy with a 42Fr bougie size and 2 cm distance from the pylorus
89488544|NCT02144545|Experimental|Bougie Size 42Fr Distance pylorus 5 cm|Sleeve gastrectomy with a 42Fr bougie size and 2 cm distance from the pylorus
89488545|NCT03197103|Experimental|N-Acetylcysteine (NAC)|Breast enlargement with autologous fat graft obtained by liposuction with Pietruski solution (tumescent solution with NAC).
89488546|NCT03197103|No Intervention|Control|Contralateral breast enlargement with autologous fat graft obtained by liposuction with standard tumescent solution.
89488547|NCT02144623|Experimental|Valproate|
89488548|NCT03196947|Experimental|Single arm, APO010 Dose escalation|
89488549|NCT02151565|Experimental|HTEMS|High-tone external muscle stimulation 5 times within 10 days
89488550|NCT02151565|Active Comparator|TENS|Transcutaneous electrical nerve stimulation 5 times within 10 days
89488551|NCT03195075|Active Comparator|Group 1|20 Patients with malignant biliary obstruction after failed endoscopic retrograde cholangio-pancreaticography will be subjected to endoscopic ultrasonography guided biliary drainage
89488552|NCT03195075|Active Comparator|Group 2|20 Patients with malignant biliary obstruction after failed endoscopic retrograde cholangio-pancreaticography will be subjected to percutaneous trans-hepatic biliary drainage.
89488553|NCT03118635|Experimental|Intervention|Daily, four-hour physical activity intervention
88953346|NCT01961154|Other|Medication reduction|All participants undergo similar type of asthma medical reduction. Thus, there is only one arm.
89488554|NCT03118635|No Intervention|Control|No treatment control
89488555|NCT03118557|Experimental|Pilates pelvic floor strengthening exercise|
89488556|NCT03194919|Experimental|Negotiating quit date|Endre: a digital smoking cessation counsellor
89488557|NCT03194919|Active Comparator|Preset quit date|Endre: a digital smoking cessation counsellor
89488558|NCT03201783|Other|immediate group|the intervention: immediate frozen-thawed embryo transfer (FET) which means FET will be performed in the first cycle following the stimulated IVF cycle
89488559|NCT03201783|Other|delayed group|the intervention: delayed frozen-thawed embryo transfer (FET) which means FET will be performed at least in the second cycle following the stimulated IVF cycle
89488560|NCT03201861|Experimental|paclitaxel and cisplatin|Drug: paclitaxel, cisplatin, epirubicin and cyclophosphamide Patients will be administered paclitaxel (80 mg/m² i.v. given weekly on day 1 q day 8 for 12 weeks) and cisplatin (25 mg/m² weekly on day 1 ,8,and 15 q day 28 for 3 cycles) followed by epirubicin and cyclophosphamide (EC) (epirubicin 90mg/m² i.v.d1, cyclophosphamide 600mg/m² i.v.d1) for 4 cycles.
89488561|NCT03201861|Active Comparator|epirubicin and cyclophosphamide|"Drug：epirubicin, cyclophosphamide, paclitaxel and docetaxel~Investigators will declare one of the following regimens:~Patients with hormone receptor (HR) positive breast cancer wil be administered epirubicin (90mg/m² i.v.d1 q21d) and cyclophosphamide (600mg/m² i.v.d1 q21d) for 4 cycles followed by docetaxel (75mg/m² i.v.d1 q21d) for 4 cycles.~Patients with triple-negative breast cancer will be administered epirubicin (90mg/m² i.v.d1 q21d) and cyclophosphamide (600mg/m² i.v.d1 q21d) for 4 cycles followed by weekly paclitaxel (80 mg/m² i.v.d1) for 12 weeks or docetaxel (75mg/m² i.v.d1 q21d) for 4 cycles."
89488562|NCT03194841|Experimental|Heart Failure Application|A mobile application that allowed for input of physiologic data, qualitative questions about symptoms and education
89488563|NCT02450097|Other|Lifestyle counseling|"Intermittent Caloric restriction in 3 Groups:~I- 40 patients with diabetes type 2 BMI 25.1-37 II- 40 non diabetic over weight subjects with BMI 25.1-37 III- 20 non diabetic subject with BMI 23.1 - 25 and visceral fat"
89488564|NCT03194685|Experimental|Cohort 1: 10 mg|Orally once a day (QD) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01
89488565|NCT03194685|Experimental|Cohort 2: 20 mg|Orally once a day (QD) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01
89488566|NCT03194685|Experimental|Cohort 3: 35 mg|Orally once a day (QD) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01
89488567|NCT03194685|Experimental|Cohort 4: 50 mg|Orally once a day (QD) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01
89488568|NCT03194685|Experimental|Cohort 5: 75 mg|Orally once a day (QD) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01
89488569|NCT03194685|Experimental|Cohort 6: 100 mg|Orally once a day (QD) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01
88953347|NCT01961180|Active Comparator|active comparator|Drug: Cipralex
88953348|NCT01961180|Placebo Comparator|placebo comparator|Drug: Placebo
89204264|NCT00808002|Experimental|1|From Baseline to Week48: Raltegravir BID + Tenofovir/Emtricitabine QD + Maraviroc BID From W48 to W72: Raltegravir BID + Tenofovir/Emtricitabine QD
89204265|NCT00808002|Active Comparator|2|Start ARV treatment with : Raltegravir BID + Tenofovir/Emtricitabine
89204266|NCT00307489|Experimental|1|TDF
89204267|NCT00307489|Experimental|2|FTC/TDF
89204268|NCT04001764|Active Comparator|The first group|The radial artery catheterization with ultrasound-guided short axis out of plane intervention will be performed over 2 cm of the wrist for this group.
89204269|NCT04001764|Experimental|The second group|The radial artery catheterization will be performed in the distal 3/4 area of the forearm with ultrasound-guided short axis out of plane intervention.
89204270|NCT04001764|Experimental|The third group|The radial artery catheterization will be performed in the distal 1/2 area of the forearm with ultrasound-guided short axis out of plane intervention.
89204271|NCT04003168|Experimental|Human BCMA targeted T Cells Injection|"A single infusion of anti-BCMA CAR transduced T cells administered intravenously at a target dose of 3 to 9 x 10^6 CAR T +cells/kg. The classic 3+3 dose escalation will be applied."
89204272|NCT00808158||1|Children ages 9 to 10 years old, with a body mass index (BMI) in the 50th to 98th percentile range
89204273|NCT00812370|Experimental|open label|
89204274|NCT00645840|Experimental|Anakinra|After study enrollment, all subjects started anakinra (Kineret™; Amgen, Thousand Oaks, CA, USA) as a subcutaneous daily injection. Subjects weighing >25 kg at the time of enrollment received 100 mg daily, whereas those weighing <25 kg received 50 mg daily. Anakinra was continued for 28 d with no dose adjustment.
89204275|NCT00773708|Experimental|1|intensify their triple-drug therapy with Raltegravir (RAL)
89204276|NCT00773708|No Intervention|2|Continue with the same antiretroviral therapy
89204277|NCT00307333|Experimental|1|Very low birth weight infants with their HRC index continuously displayed. Clinicians can utilize the HRC score to develop treatment plan.
89204278|NCT00307333|No Intervention|2|Very low birth weight infants for whom the HRC index is not displayed. Infants receive standard of care treatment.
89204279|NCT00762359|Experimental|Lansoprazole 15 mg QD|
89204280|NCT00762359|Active Comparator|Gefarnate 50 mg BID|
89204281|NCT04003090|Experimental|Citicoline eyes|Patients had to administer 3 drops/day of an ophthalmic solution containing citicoline 1% eye-drops, 0.2% high molecular weight hyaluronic acid and 0.01% benzalkonium chloride for 14 days before surgery and 2 hours prior to surgery.
89204282|NCT00777530|Experimental|1|
89204283|NCT00814476|Active Comparator|2|Regular treated group in the first segment and CareLink treated group in the second segment
89204284|NCT00814476|Experimental|1. CareLink team supported group|CareLink team supported group
89204285|NCT04002856|Experimental|Profhilo®|"The 1st treatment was performed during T0 visit, after the basal evaluations planned by the study procedure and repeated after 1 month (T1).~2 mL of Profhilo® was injected into the middle-deep dermis by needle (29 G) using a bolus technique called BAP (Bio Aesthetic Point technique); this technique involves a series of 10 micro-wheals on 3 vertical-lines (3-4-3 ). The amount of product injected was 0.2 ml for each injection point."
89204286|NCT00769730||1|Patients with hepatocellular carcinoma caused by hepatitis B virus who will be treated by transcatheter arterial chemoembolization were included.
89204287|NCT01061749|Experimental|Treatment (selumetinib, cixutumumab)|Patients receive selumetinib PO BID on days 1-28 and cixutumumab IV on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89204288|NCT02551614|Experimental|Group 1: healthy subjects|Subjects will undergo inhaled challenge, either with lipopolysaccharide or saline in a 2:1 ratio, prior to imaging assessments. Assessments will be performed during one study day on an outpatient basis.
89204289|NCT02551614|Experimental|Group 2: COPD patients|Subjects will undergo imaging assessments during one study day on an outpatient basis. Approximately 10 of these COPD patients will repeat this study day 7-10 days after completion of the first study day to assess the reproducibility of the technique.
89204290|NCT05350306|Experimental|Chincup|Patients will be treated with occipital chincup and bonded bite block.
89204291|NCT05350306|Active Comparator|Untreated subjects|Patients will not undergone any treatment for 16 months.
89204292|NCT03978949|Experimental|Probiotics|Two weeks prior to the start of radiation therapy, the probiotics is administered three times daily until the end of radiation therapy.
89488570|NCT03194685|Experimental|Cohort 7: 150 mg|Orally once a day (QD) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01
88953349|NCT01961193|Experimental|bandage contact lens|A bandage contact lens will be inserted by a physician from the ophthalmology department within the first 24 hours of admission of the patient to the ICU. The position of the lens will be confirmed. The lens will remain in-situ as long as the patient is considered to require artificial lubrication or until discharge from the intensive care unit.
88953350|NCT01961193|Experimental|punctal plug|A punctal plug (Painless Silicon Plugs),will be inserted into each eye. Lubricant drops will be instilled four times daily into each eye. The punctal plug will remain in- situ as long as the patient is considered to require artificial lubrication or until discharge from the intensive care unit at which time it will be removed by a physician from the ophthalmology department.
88953351|NCT01961193|No Intervention|Control group|Hydroxyethylcellulose drops will be inserted into each eye four times a day and erythromycin ophthalmic ointment will be applied three times a day as well.
88953352|NCT01961206||Case Patients|Case Patients with Community-Onset Bacteremia Due toESBL producing E.coli or K.pneumoniae
88953353|NCT01961206||control group|bacteremia caused by ESBL producing E.coli or K.pneumoniae
88953354|NCT01961245|Active Comparator|nocturnal non-invasive ventilation|patients will undergo 12 nights of non-invasive ventilation during pulmonary rehabilitation
88953355|NCT01961245|No Intervention|no nocturnal non-invasive ventilation|patients will undergo pulmonary rehabilitation without nocturnal non-invasive ventilation
88953356|NCT01961258||Sever asthmatics in the comminity|Computerized data base analysis and sampling of patients for outpatient clinic evaluation.
88953357|NCT01961284|Active Comparator|Zygomatic Implants|2-4 zygomatic implants inserted into edentulous maxilla with no augmentation/grafting prior to providing patient with dental prosthesis
88953358|NCT01961284|Active Comparator|Bone Graft and Conventional implants|Edentulous maxilla which is deficient in bone is first grafted using bone grafting material derived from cows and then ordinary implants are placed into the augmented jaw bone approximately 6 monhts after grafting. Patients will be provided with a dental prosthesis following osseointegration.
88953359|NCT01961310||RA patients|"This group is composed of 25 patients with RA. The diagnosis of RA is based upon the American College of Rheumatology criteria.~Intervention: Plasma analysis for bacterial translocation~Intervention: Stool analysis"
89204293|NCT03978949|Placebo Comparator|Placebo|Two weeks prior to the start of radiation therapy, the placebo is administered three times daily until the end of radiation therapy.
89204294|NCT03876236||Rest|Quiet rest in supine position, 2 hrs.
89204295|NCT05356234|Experimental|Treatment Intervention: Responsible Parenting, Relationships, and Employment Services|Experimental: A series of workshops addressing responsible parenting and marriage and relationships as well as a complement of employment services and comprehensive case management will be conducted over a 12-week period.
89204296|NCT05356234|No Intervention|Wait-List Control|The Wait-List Control group will be placed on a wait-list and offered services as soon as they complete the study's final 24-week follow-up measures. Wait-List Control participants will not be assigned a Case Manager and will not receive any comparable services from our agency until they complete their 24-week measures.
89204297|NCT01061827||Dementia|
89204298|NCT01061827||Depression|
89204299|NCT01061827||Control|
89204300|NCT03327922|Experimental|Vicryl absorbable suture placed 2 cm apart|Wound closed with sutures spaced 2 centimeters apart will be treated in a simple, interrupted subdermal suture pattern
89204301|NCT03327922|Experimental|Vicryl absorbable suture placed 1 cm apart|Wound closed with sutures spaced 1 centimeter apart will be treated in a simple, interrupted subdermal suture pattern
89204302|NCT00770042|Experimental|Group 1|Ketoconazole 400 mg qd for 5 days (Days 2-6) plus a single dose of 50 mg avanafil on Days 1 and 6
89204303|NCT00770042|Experimental|Group 2|Erythromycin 500mg every 12 hours for 5 days (Days 2-6) plus a single dose of 200 mg Avanafil on Days 1 and 6.
89204304|NCT00770042|Experimental|Group 3|Ritonavir 300 mg bid for 1 day (Day 2), 400 mg bid for 1 day (Day 3), 600 mg bid for 5 days (Day 4-8) plus a single dose of 50 mg avanafil on Days 1 and 8
89204305|NCT03982615|Experimental|Laser-Lok abutment|Laser-etched abutment
89204306|NCT03982615|Active Comparator|Standard Healing abutment|Standard abutment which is not laser-etched
89204307|NCT00777686||MRI/MRS Scanning|Magnetic resonance imaging with magnetic resonance spectroscopy (MRI/MRS Scanning)
89204308|NCT00654186|Experimental|1|
89204309|NCT03275818|Experimental|nab-paclitaxel|"nab-paclitaxel (ABRAXANE) will be administered as follows:~Age ≥ 21: 125 mg/m2 days 1, 8 and 15 in cycles of 28 days~Age ≥ 6 months and ≤ 20 years: 240 mg/m2 (for patients weighing > 10 kg) and 11.5 mg/kg (for patients weighing ≤ 10 kg) on days 1, 8 and 15 in cycles of 28 days"
89204310|NCT03979105||Ketamine infusion|Ketamine infusion treatment for acute pain in adult population in all type of surgery that received adjuvant analgesia with ketamine 0.1mg/kg/h during 48 hours.
89204311|NCT00773942|No Intervention|Usual care|Study subjects receive usual care, without the intervention.
89204312|NCT00773942|Experimental|Basic medication therapy management|Subjects in this arm will receive medication reconciliation and drug related problem assessment by a medication therapy management clinician utilizing patient interview alone.
89021787|NCT00445575|Experimental|3|duration treatment: 3 years
89204313|NCT00773942|Experimental|Enhanced medication therapy management|Subjects in this arm will receive medication reconciliation and drug related problem assessment by a medication therapy management clinician utilizing patient interview and a brief chart synopsis including patient medical history, medication history, and relevant laboratory information.
89204314|NCT01061905|Experimental|Calorie information only|Posting calorie information of sugar-sweetened and zero-calorie beverages prominently on a poster.
89204315|NCT01061905|Experimental|Exercise Equivalent Information|Posting of only exercise equivalents (e.g. 45 minutes on a treadmill) for both sugar-sweetened and zero-calorie beverages, prominently on a poster.
89204316|NCT01061905|Experimental|Calorie and Exercise Equivalent information|Posting of both calorie and exercise equivalent information for both sugar-sweetened and zero-calorie beverages, prominently on a poster.
89204317|NCT00814554|No Intervention|control|no intervention was carried out in high school
89204318|NCT00814554|Experimental|Educational strategy|Educational strategy was carried out in high school.
89204319|NCT00814554|Experimental|Screening strategy|Screening strategy was carried out in high school.
89488571|NCT03194685|Experimental|Cohort 8: 225 mg|Orally once a day (QD) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01
88953360|NCT01961310||Healthy voluteers|"This group is composed of 25 healthy volunteers.~Intervention: Plasma analysis for bacterial translocation~Intervention: Stool analysis"
88953361|NCT01961336|Experimental|Testosterone|"Long depot follicular GnRH agonist protocol. On day 21 initiation of ovarian stimulation with recombinant FSH for ICSI. If necessary downregulation will be achieved with additional daily agonist s.c.~10 mg of testosterone gel applied on the external side of the thigh for 21 days starting from the first day of menstruation prior to initiation of ovarian stimulation with rFSH for IVF/ICSI."
89488572|NCT03194685|Experimental|Cohort 20: 50 mg|Orally twice daily (BID) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01
89488573|NCT03194685|Experimental|Cohort 21: 75 mg|Orally twice daily (BID) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01
89488574|NCT03194685|Experimental|Cohort 22: 100 mg|Orally twice daily (BID) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01
89488575|NCT00105079|Experimental|saquinavir/ritonavir|saquinavir mesylate 1000 mg twice daily (BID) + ritonavir 100 mg BID + emtricitabine/tenofovir disoproxil fumarate 200/300 mg orally every day for 48 weeks.
89488576|NCT00105079|Active Comparator|lopinavir/ritonavir|lopinavir/ritonavir 400/100 mg BID + emtricitabine/tenofovir disoproxil fumarate 200/300 mg orally every day for 48 weeks.
89488577|NCT02450019|Other|Traditional to protective ventilation|Traditional ventilation will be set with 9 ml/kg with predicted body weight of tidal volumes and no PEEP. Arterial CO2 partial pressure will be maintained between 30 and 35 mmHg. After intracranial pressure measurement ventilation will be switched to protective.
89488578|NCT02450019|Other|Protective to traditional ventilation|Protective ventilation will be set with 7 ml/kg tidal volume, 5 cm H2O PEEP, and 0.4 inspired O2 fraction (FiO2). Arterial CO2 partial pressure will be maintained between 30 and 35 mmHg. After intracranial pressure measurement ventilation will be switched to traditional.
89488579|NCT03196713|Other|Tailored supervision|
89488580|NCT03196713|Other|Regular supervision|
89488581|NCT03196557|Experimental|Arm A|Specified dose on specified days
89488582|NCT03196557|Placebo Comparator|Arm B|Specified dose on specified days
89488583|NCT02144779|Active Comparator|Usual care|No treatment for this group
89488584|NCT02144779|Experimental|Assigned to palliative care team|The intervention group will be assigned to a palliative care team member that will facilitate communication and meetings between families and the medical team
89488585|NCT03196401|Experimental|Durvalumab Plus Radiation Therapy|Durvalumab (1500mg administered intravenously every 28 days), concurrently with definitive radiation therapy to the solitary bone plasmacytoma to start within 14 days of the first dose of durvalumab.
89488586|NCT03543163|Active Comparator|subepithelial connective tissue graft|Subepithelial Connective Tissue graft from the hard palate with Coronally Advanced flap at the site of gingival recession.
89488587|NCT03543163|Experimental|non pedicled buccal fat pad graft|Non- Pedicled Buccal Fat Pad with Coronally Advanced flap at the site of gingival recession
89488588|NCT02150707||Dipeptidyl-Peptidase IV Inhibitors|Newly started on DPP4 inhibitor for hyperglycaemia
89488589|NCT02150707||Glucagon-Like Peptide 1|Newly started on GLP-1 for hyperglycaemia or obesity
89488590|NCT03196479|Active Comparator|ketamine:propofol ratio of 1:6|K16 group was received ketamine:propofol with ratio of 1:6, filled in 50 cc syringe, which consisted of 1 ml of ketamine (50 mg/ml), 30 ml of 1% propofol (10 mg/ml), and 19 ml of normal saline so that every ml of mixture consisted of 1 mg of ketamine and 6 mg of propofol
89488591|NCT03196479|Active Comparator|ketamine:propofol ratio of 1:4|K14 group was received ketamine:propofol with ratio of 1:4, filled in 50 cc syringe, which consisted of 1 ml of ketamine (50 mg/ml), 20 ml of 1% propofol (10 mg/ml), and 29 ml of normal saline so that every ml of mixture consisted of 1 mg of ketamine and 4 mg of propofol
89488592|NCT03194529|Experimental|FMT in children with disease remission|All children (with Crohn's disease in remission) will receive the equivalent of 50 g of stools from a healthy donor (FMT) into the jejunum through upper endoscopy.
89488593|NCT02777827|Experimental|Abediterol dry powder inhaler 0.156 μg|Dry powder for inhalation administered via dry powder inhaler 0.156 μg/inhalation; (1 inhalation)
88953362|NCT01961336|No Intervention|Control|Long depot follicular GnRH agonist protocol. On day 21 initiation of ovarian stimulation with recombinant FSH for ICSI. If necessary downregulation will be achieved with additional daily agonist s.c.
88953363|NCT01961388||Group 1|Acarbose_BAY G5421
88953364|NCT01961388||Group 2|Metformin
89488594|NCT02777827|Experimental|Abediterol dry powder inhaler 2.5 μg|Dry powder for inhalation, administered via dry powder, inhaler 2.5 μg/inhalation; (1 inhalation).
89488595|NCT02777827|Experimental|Abediterol pressurised metered-dose inhaler 0.05μg|Pressurised metered-dose, inhaler 0.025 μg/puff; (2 puffs).
89488596|NCT02777827|Experimental|Abediterol pressurised metered-dose inhaler 0.156 μg|Pressurised metered-dose, inhaler 0.078 μg/puff; (2 puffs).
89488597|NCT02777827|Experimental|Abediterol pressurised metered-dose inhaler 2.5μg|Pressurised metered-dose inhaler 1.25 μg/puff; (2 puffs).
89488598|NCT02777827|Placebo Comparator|Placebo|Pressurised metered-dose inhaler (2 puffs) and Dry powder for inhalation administered via dry powder inhaler (1 inhalation).
89488599|NCT02446041||ICS/LABA Patients|ICS/LABA Patients following standard of care
89488600|NCT02446119||Gastroparesis|"Inclusion criteria:~1. Subjects will be of either sex, 18 to 70 years of age.~patients with an established diagnosis of gastroparesis, either diabetic or idiopathic etiology. The gastroparesis subjects will have delayed gastric emptying on gastric scintigraphy defined as greater than 60% retention at 2 hours and/or greater than 10% retention at 4 hours. This gastric emptying test would have been done prior to the endoscopy and is not part of the research study. Patients will undergo EndoFlip during upper endoscopy."
89488601|NCT02446119||Normals|"Inclusion criteria:~1. Subjects will be of either sex, 18 to 70 years of age.~control subjects will be nondiabetic patients without gastroparesis or gastroesophageal reflux symptoms undergoing upper endoscopy. Patients will undergo EndoFlip during upper endoscopy."
89488602|NCT03201627|Experimental|treatment|
89488603|NCT02151721|Experimental|vorinostat, gefitinib, combination|single arm vorinostat plus gefitinib
89488604|NCT02449083||Arm 1|Patients with indication for MRI and coronary angiography
89488605|NCT02449083||Arm 2|Patients with atrioseptal or ventriculoseptal Shunt with indication to coronary angiography
89488606|NCT02449083||Arm 3|Patients with chronic obstructive pulmonary disease with indication to coronary angiography
89488607|NCT02150941|Experimental|BioVac Direct Suction Device|Experimental arm
89488608|NCT02150941|Active Comparator|Standard Endoscopy Suction|Control arm
89488609|NCT03201705|Experimental|Refractory neuropathic leg and low back pain|Patients with refractory neuropathic leg and low back pain as result of FBSS will be enrolled in the study and receive electrocatheter implant. Then, they will be observed for a two-weeks trial period in which the efficacy of the stimulation and the compliance of the patient is evaluated. During this trial a Tonic wave stimulation is administered by the external generator. After the trial, the definitive generator will be implanted. Tonic stimulation will be selected as wave form for four weeks. After this period, the stimulation will be switched into the combined waveform for 30 days. At the end of the study period, the final waveform setting of the SCS will be in accord with the patient's stimulation preference.
89488610|NCT02151799|Experimental|Body contouring surgery|
89488611|NCT02449317|Other|Control|standard hydration : 7.5% Sodium bicarbonate 150 ml + 5% dextrose in water 850 ml IV 1 ml/kg/hr in 6 hours
89488612|NCT02449317|Experimental|Bioimpedance guided|"Bioelectrical impedance analysis guided hydration therapy : 7.5% Sodium bicarbonate 150 ml + 5% dextrose in water 850 ml IV in 6 hours rate was adjusted regarding to extracellular water/total body water~extracellular water/total body water < 0.36 : 4 ml/kg/hr~extracellular water/total body water 0.36-0.4 : 2 ml/kg/hr~extracellular water/total body water > 0.4 : 1 ml/kg/hr"
89488613|NCT02151955|Experimental|Individual parent infant intervention|Children and parents will be offered an assessment and then a tailored individual 10 to 15 week based attachment and parent intervention to promote parent child relationship.
89488614|NCT02151097||High risk prostate cancer|Men ≥18 years of age diagnosed with high risk prostate cancer, defined as clinical stage ≥T2c, or Prostate Specific Antigen (PSA)>20 ng/ml, or Gleason Score 8-10, scheduled to have radical prostatectomy.
89488615|NCT03201393|Experimental|Low-Dose Naltrexone and Acetaminophen Combination|
89488616|NCT03201393|Placebo Comparator|Placebo|
89488617|NCT03119103|Other|Intervention of Functional Bed Sheet|Interventions will be non-invasive where healthy adults (over the age of 17, 10 male and 10 female) sleeps on the functional bed sheet overnight.
89488618|NCT03196323||Initial Cohort|"In Aim 1, the investigators will evaluate psychometrically RettBe 1.0 following, in part, previous studies including our examination of anxiety instruments and adaptation of the Anxiety, Depression and Mood Scale (ADAMS) for RTT, and their adaptations of the Aberrant Behavior Checklist-Community (ABC-C) for fragile X syndrome and Down syndrome. In Aim 1, the investigators will also refine RettBe 1.0 by adding new missing items based on parental input or clinician (PIs of sites involved) feedback. The resulting instrument, RettBe 2.0 will be tested in Aim 2."
88953365|NCT01961401|Experimental|High intensity exercise|High intensity, short duration exercise on bike
89021788|NCT00445575|Placebo Comparator|4|treatment duration: 3 years
89488619|NCT03196323||Validation Cohort|Testing of RettBe 2.0 will be carried out with a new (naïve) validation cohort of 300 subjects and two raters (preferentially both parents/caregivers, alternatively one teacher or therapist), to determine inter-rater reliability. One rater, preferentially a parent, will be asked to also complete three other behavioral measures (RSBQ, ADAMS, ABC-C) for comparisons. Scores for RettBe 2.0 will be analyzed in terms of psychometric properties, as performed for RettBe 1.0. However, in addition to structure (construct validity) and content validity, the investigators will also examine convergent and discriminant validity by correlating domain RettBe 2.0 scores with those of comparable and non-comparable domain scores of the RSBQ, ADAMS, and ABC-C, respectively.
89488620|NCT03118245|Experimental|AuraGain group|AuraGain is inserted for maintenance of general anesthesia. The size 1 is for children <5kg, size 2 for 5-10kg, size 2 for 10-20kg, and size 2.5 for 20-30kg.
89488621|NCT03118245|Experimental|I-gel group|I-gel is s inserted for maintenance of general anesthesia. The size 1 is for children weighted 2-5kg, size 2 for 5-12kg, size 2 for 10-25kg, and size 2.5 for 25-35kg.
89537885|NCT02730429|Placebo Comparator|Letrozole + placebo|"letrozole 2.5mg once daily days 1-28 every 28 days shall be administered until progression of disease or unacceptable toxicity. Letrozole is administered as standard of care in both study arms.~Placebo for palbociclib once daily days 1-21 every 28 days shall be administered until progression of disease or unacceptable toxicity."
89204320|NCT00814554|Experimental|Environmental strategy|Environmental strategy was carried out in high school.
89204321|NCT00814554|Experimental|Educational and Screening strategies|Educational strategy and Screening strategy were carried out in high school
89537886|NCT02730429|Experimental|Letrozole + palbociclib|"Palbociclib 125mg once daily days 1-21 every 28 days shall be administered until progression of disease or unacceptable toxicity.~letrozole 2.5mg once daily days 1-28 every 28 days shall be administered until progression of disease or unacceptable toxicity.~Letrozole is administered as standard of care in both study arms."
89537887|NCT02460731|Experimental|Fresh Frozen Plasma|Fresh Frozen Plasma [young (<30 years of age) healthy male donors]
89537888|NCT04979559|Experimental|mHealth apps|The participants in this arm will receive information regarding mobile health applications used for screening and early intervention of the prediabetic states.
89537889|NCT04979559|Active Comparator|Standard care|The participant in this arm will receive regular practice or standard care of screening and early intervention of prediabetic state.
89537890|NCT04979481|Experimental|BRAVE Intervention Arm|The BRAVE campaign included 3-5 text messages per week, including 1 role model video per week and a related image.
89537891|NCT04979481|Active Comparator|STEM Control Arm|The STEM campaign included 3-5 text messages per week for 8 weeks, including 1 role model video per week and a related image.
89537892|NCT04441463|Experimental|cohort|Mother-child couple
89537893|NCT03060993|Placebo Comparator|Placebo|35 mg of tetrahydrocannabinol/cannabidiol (LT1.0/LT1.0 %) in vaporized form. Placebo will be vaporized using the Volcano Medic vaporizer. Total volume of vapour administered to each patient will be 5.5 L.
89537894|NCT03060993|Active Comparator|Cannabis|35 mg of cannabis (tetrahydrocannabinol/cannabidiol; 18.0/LT1.0 %) in vaporized form. THC/CBD will be vaporized using the Volcano Medic vaporizer. Total volume of vapour administered to each patient will be 5.5 L.
89537895|NCT03293849|Experimental|Patient Navigation Arm|After an assessment of supportive care needs, a patient navigator will present assessment results and develop and implement a personalized supportive care intervention plan based on the findings in collaboration with a multidisciplinary supportive care team, formed by oncologists and pain and palliative care specialists. The developed plan will be sent to the treating oncologist and oncology team.
88953366|NCT01961401|Experimental|Moderate exercise|Moderate intensity exercise training on bike
88953367|NCT01961401|No Intervention|No exercise|No exercise, resting in the lab
88953368|NCT01961414|Experimental|Aflibercept|All patients will receive aflibercept 2.0mg intravitreal injection
88953369|NCT01961427|Active Comparator|sodium Nitrate 12mmol|Ingestion of a solution of inorganic nitrate, dosage: 12mmol
88953370|NCT01961427|Active Comparator|sodium Nitrate (6mmol)|ingestion of inorganic nitrate (6mmol solution)
88953371|NCT01961427|Active Comparator|sodium nitrate 3mmol|ingestion of inorganic nitrate (3mmol solution)
88953372|NCT01961427|Active Comparator|sodium nitrate (0mmol)|Ingestion of water as a placebo
88953373|NCT01961427|Active Comparator|Beetroot juice (12mmol)|ingestion of 170ml of concentrated beetroot juice (12mmol)
88953374|NCT01961427|Active Comparator|beetroot juice (6mmol)|ingestion of 85ml concentrated beetroot juice (6mmol)
88953375|NCT01961427|Active Comparator|Beetroot juice (3mmol)|Ingestion of 42.5ml of concentrated beetroot juice (3mmol)
88953376|NCT01961453|Active Comparator|Isosorbide Mononitrate, sustained release|One tablet containing 60 mg (Titration Stage 1) OR 120 mg (Titration Stage 2) of sustained-release ISMN administered at 8 AM.
88953377|NCT01961453|Placebo Comparator|Placebo capsule|One capsule of placebo administered once daily at 8 AM
88953378|NCT01961466||Diabetic patients|
88953379|NCT01961479|Experimental|Internet-based CBT for patients with PMS|The therapeutical intervention follows a treatment manual consisting of 14 modules. Patients work on up to two modules every week for eight weeks in a row. Modules comprise a) psychoeducation (e.g., information about PMS and its treatment); b) cognitive strategies (e.g., identifying and modifying dysfunctional cognitions, or coping with negative affects); and c) suggestions for lifestyle changes (e.g., sports, stress reduction, or balanced diet). Aim of the iCBT is to improve coping and thus to reduce the impairment due to premenstrual symptoms.
88953380|NCT01961479|Other|waiting list|During the waiting period, patients receive no treatment. After a waiting time of 2 months, patients of the waitlist receive the same iCBT treatment as the experimental group.
88953381|NCT01961492|Active Comparator|Fecal microbiota transplantation|A single fecal microbiota transplantation via colonoscope as an adjunct therapy to standard medical treatment
88953382|NCT01961492|No Intervention|Standard medical treatment|Standard medical treatment as recommended by the ECCO Guidelines of UC therapy.
88956532|NCT04972760|Experimental|baricitinib arm|Patients receive baricitinib plus prednisone taper plus one immunosuppressive drug (either methotrexate or azathioprine) for a duration of 24 weeks. Corticosteroids are tapered following a predefined protocol.
89488622|NCT03196089|Experimental|Supplemental oxygen|Supplemental oxygen will be applied via a mask during CPET
89488623|NCT03196089|Sham Comparator|Sham room air|Room air will be applied similarly to oxygen
89488624|NCT02445729|Active Comparator|Dressing Removal at 24 Hours|These patients are randomly assigned to have their dressing removed 24 hours after cesarean section.
89488625|NCT02445729|Active Comparator|Dressing Removal at 48 Hours|These patients are randomly assigned to have their dressing removed 48 hours after cesarean section.
89488626|NCT03192969|Experimental|Abatacept Combination Therapy|Abatacept subcutaneous injection (125 mg/mL prefilled syringe weekly) in combination with glucocorticoid therapy (up to 28-week taper of oral prednisone daily)
89488627|NCT03192969|Placebo Comparator|Placebo Monotherapy- 28 Weeks|Glucocorticoid therapy (28-week taper of oral prednisone daily) in combination with placebo subcutaneous injection (1 mL pre-filled syringe weekly)
89488628|NCT03192969|Placebo Comparator|Placebo Monotherapy- 52 Weeks|Glucocorticoid therapy (52 week taper of oral prednisone daily) in combination with subcutaneous placebo weekly
89488629|NCT03194295|Experimental|Community Support Intervention|Participants randomized to this condition will be scheduled to attend a 12-week (1x/wk for one hour) manual-guided Community Support Intervention Group, which requires methadone maintenance treatment (MMT) participants to attend the group with a drug-free family member or friend (community support person; CSP).
89488630|NCT03194295|Active Comparator|Standard Care|Participants randomized to this condition will be scheduled to attend a 12-week (1x/wk for one hour) manual-guided Substance Use Disorder Educational Group as an attention-control for the intervention described in the experimental condition.
89488631|NCT03194139|Experimental|Sentinel Cohort|
89488632|NCT03194139|Experimental|Crossover Design|
89488633|NCT02448927|Other|TAVI patients without balloon aortic valvuloplasty|Patients that will not undergo balloon aortic valvuloplasty (BAV) before transcatheter aortic valve intervention (TAVI) with the Medtronic Evolut R (or CoreValve).
89488634|NCT02448927|Active Comparator|TAVI patients with balloon aortic valvuloplasty|Patients that will undergo balloon aortic valvuloplasty (BAV) before transcatheter aortic valve intervention (TAVI) with the Medtronic Evolut R (or CoreValve).
89488635|NCT02448693|Experimental|WLE-NBI|Participants will be evaluated by same endoscopist, tandem colonoscopy. It consists of two revisions of the polypectomy scar using firstly High Definition White Light Endoscopy (WLE) and secondly Narrow Band Imaging. All suspected neoplasia will be classified macroscopically and resected and differentiated from both techniques. The rest of the gut will be inspected following conventional standards.
89488636|NCT02448693|Experimental|NBI-WLE|Participants will be evaluated by same endoscopist, tandem colonoscopy. It consists of two revisions of the polypectomy scar using firstly Narrow Band Imaging and secondly High Definition White Light Endoscopy (WLE). All suspected neoplasia will be classified macroscopically and resected and differentiated from both techniques. The rest of the gut will be inspected following conventional standards.
89204322|NCT00814554|Experimental|Screening and Environmental strategies|Screening strategy and Environmental strategy were carried out in high school
89488637|NCT02448849|Experimental|MSC recipients|The patients with nonunion fracture who underwent percutaneous implantation of bone marrow derived mesenchymal stem cells in combination with platelet lysate product.
89488638|NCT02448849|Placebo Comparator|Placebo|The patients with nonunion fracture who underwent percutaneous injection of placebo.
89488639|NCT03192813||Symetis ACURATE neo™ transfemoral TAVI system|Patient assigned to this group will be implanted with Symetis ACURATE neo™ transfemoral TAVI system.
89488640|NCT03192813||Medtronic CoreValve Evolut R TAVI System|Patient assigned to this group will be implanted with Medtronic CoreValve Evolut R Transcatheter Aortic Valve Implantation (TAVI) System.
89488641|NCT03118167|Experimental|Tea polyphenols & Acrylamide|TP 0.05g, 0.1g, 0.2g (starches filled, up to 0.35g) capsule by mouth, Acrylamide (Potato Chips) 12.6μg/kg b.w. by mouth, for one single oral dose
89488642|NCT03118167|Experimental|AOB-w & Acrylamide|AOB-w 0.35g capsule by mouth, Acrylamide (Potato Chips) 12.6μg/kg b.w. by mouth, for one single oral dose
89488643|NCT03118167|Active Comparator|Placebo & Acrylamide|Placebo (Starches) 0.35g capsule by mouth, Acrylamide (Potato Chips) 12.6μg/kg b.w. by mouth, for one single oral dose
89488644|NCT02445261|Active Comparator|normal growth|120 woman with normal fetal growth will be subjected to 15 minutes CTG trace recording before using mobile phone and repeated while the phone is in the dialing mode for 10 minutes. Umbilical artery (UA) Doppler ultrasound will be done after the initial CTG trace and was repeated 5 minutes after hanging up the mobile phone. UA resistance indices, number of fetal kicks, the loss of acceleration and variability, and the appearance of decelerations were assessed
89488645|NCT02445261|Active Comparator|growth restricted group|70 woman with l growth restricted fetus will be subjected to 15 minutes CTG trace recording before using mobile phone and repeated while the phone is in the dialing mode for 10 minutes. Umbilical artery (UA) Doppler ultrasound will be done after the initial CTG trace and was repeated 5 minutes after hanging up the mobile phone. UA resistance indices, number of fetal kicks, the loss of acceleration and variability, and the appearance of decelerations
89488646|NCT03118011|Active Comparator|No smoking|The ward where the patients can not go out to smoke
89488647|NCT03118011|Placebo Comparator|Smoking|The ward where the patients can go out to smoke.
89488648|NCT02445183||Lung Cancer|Confirmed diagnosis of lung cancer
89488649|NCT02445183||No Lung Cancer Controls|Unconfirmed lung cancer diagnosis, false positive
89488650|NCT02448459|Experimental|COOL-COS|All women will receive Letrozole, Clomiphene, and Corifollitropin Alfa for controlled ovarian stimulation
89021789|NCT00338975|Experimental|1|Cognitive Behavioral Social Skills Training (CBSST)
89021790|NCT00338975|Active Comparator|2|Goal-Focused Supportive Contact (GFSC)
89204323|NCT00814554|Experimental|Educational and Environmental strategies|Educational strategy and Environmental strategy were carried out in high school
89488651|NCT02712333|Experimental|Air purifiers|Participants in this group received an intervention of true air purifiers placed in the center of the room.
89488652|NCT02712333|Sham Comparator|Control|Participants in this group received an intervention of sham air purifiers, which were under the same conditions as the true purifiers except the filter gauze in them were removed.
89488653|NCT02445417||EES|Epidermal Electronic System
89488654|NCT02445417||Hydrogel Electrode|Hydrogel based EEG electrode
89488655|NCT02448615||Birth Cohort|The cohort will comprise approximately 1500 pregnant women and their unborn babies, enrolled to participate in the control arm of a cluster-randomized controlled intervention trial (NCT02208960).
89488656|NCT03192423||Expert|The physicians in the Expert-group will perform a LP following local standard procedure protocol.
89488657|NCT03192423||Intermediate|The physicians in the Intermediate-group will perform a LP following local standard procedure protocol.
89488658|NCT03192423||Novice|The physicians in the novice-group will perform a LP following local standard procedure protocol.
89488659|NCT02440113||Nellix|Patients with endovascular Nellix repair
89488660|NCT02444949|Experimental|endostar+DF+IMRT|patient first receive one periodicity chemotherapy(DDP (25mg/m2/d; ivgtt; d1～3)+5-FU (600mg/m2/d; ivgtt; d1～5)+endostar (150mg/5d; civ; d1～5)), then given IMRT (5 times per week, 6 weeks). After rest 4 weeks, continue to give the chemotherapy (21 days for a periodicity, 3 periodicities).
89488661|NCT02444949|Other|DF+IMRT|patient first receive one periodicity chemotherapy(DDP (25mg/m2/d; ivgtt; d1～3)+5-FU (600mg/m2/d; ivgtt; d1～5)), then given IMRT (5 times per week, 6 weeks). After rest 4 weeks, continue to give the chemotherapy (21 days for a periodicity, 3 periodicities).
89488662|NCT03192579|Experimental|Standard lipid lowering therapy|Start with only rosuvastatin 2.5mg and up to 20mg/day
89488663|NCT03192579|Active Comparator|Intensive lipid lowering therapy|Start EPA and rosuvastatin 10mg/day and up to 20mg/day
89488664|NCT03192657|Experimental|Basiliximab group|"Basiliximab: 20mg injection each time at day1 and day5, respectively. The first administration should be within 8 weeks after disease onset.~Calcineurin inhibitors: cyclosporin A 3-5mg/kg/d or tacrolimus 0.05-0.10mg/kg/d.~Steroids: 1mg/kg/d, calculated with prednisone."
89488665|NCT03192657|Active Comparator|control group|"Calcineurin inhibitors: cyclosporin A 3-5mg/kg/d or tacrolimus 0.05-0.10mg/kg/d.~Steroids: 1mg/kg/d, calculated with prednisone."
89488666|NCT03193983|Experimental|Flaps Coverage|Surgical group will undergo surgical coverage of the fingertip defect by V-Y flap using the skin on the volar aspect of the same finger designed as V shaped then mobilized dorsally to cover the defect and stitches to be Y shaped. Stitches are removed after 2 weeks.
89488667|NCT03193983|Experimental|Occlusive Dressing|Conservative group will undergo minimal trimming of the bone end and an occlusive dressing that is changed on a weekly basis till complete healing of the defect that occurs after 6 weeks.
89488668|NCT02444247|Other|High Dose Exercise vs Sedentary Option|Relative Reinforcing Value of high dose exercise (300 kcal expenditure per session) versus sedentary activity will be determined.
89488669|NCT02444247|Other|Low Dose Exercise vs Sedentary Option|Relative Reinforcing Value of low dose exercise (150 kcal expenditure per session) versus sedentary activity will be determined.
89488670|NCT02444247|Other|No Exercise vs Sedentary Option|Relative Reinforcing Value of no exercise (0 kcal expenditure per session) versus sedentary activity will be determined.
89021791|NCT00339014|Active Comparator|Group 1|Zonisamide SR 120 mg/day plus Bupropion SR 280 mg/day
89204324|NCT00814554|Experimental|the three strategies|Educational strategy, Screening strategy and Environmental strategy were carried out in high school.
89488671|NCT03194061|Experimental|Hypofractionated chemoradiation|20 fractions of 275cGy and concomitant weekly cisplatin 35mg/m2 x 4 cycles
89488672|NCT03190551|Active Comparator|retroclavicular approach|Patients in this group will be randomized to receive an retroclavicular approach to Ultrasound Guided Infraclavicular Brachial Plexus Nerve Block .
89488673|NCT03190551|Active Comparator|costoclavicular approach|Patients in this group will be randomized to receive an costoclavicular approach to Ultrasound Guided Infraclavicular Brachial Plexus Nerve Block .
89488674|NCT02343406|Experimental|ABT-414/temozolomide|Depatuxizumab mafodotin (ABT-414) administered once every 2 weeks in combination with temozolomide (TMZ) to adult participants
89488675|NCT02343406|Experimental|ABT-414_adult|Depatuxizumab mafodotin (ABT-414) administered once every 2 weeks to adult participants
89488676|NCT02343406|Active Comparator|Control_lomustine|Adult participants relapsing during temozolomide (TMZ) treatment or within the first 16 weeks after the first day of the last TMZ cycle received lomustine on Day 1 of every 42-day treatment period until one of the treatment withdrawal criteria was met, up to a maximum of 1 year.
89488677|NCT02343406|Active Comparator|Control_ temozolomide|Adult participants relapsing 16 weeks or more after the first day of the last temozolomide (TMZ) cycle received TMZ on Day 1 to Day 5 for the first 28-day cycle, with dose escalation in subsequent cycles in case of adequate tolerance and treatment continuing until one of the treatment withdrawal criteria was met.
89488678|NCT02343406|Experimental|ABT-414_ pediatric|Depatuxizumab mafodotin (ABT-414) administered once every 2 weeks to pediatric participants. Temozolomide (TMZ) was only allowed for pediatric participants if its use was in accordance with local clinical practice, and was not considered an investigational product for the study (unless this was a local requirement).
88953383|NCT01961505|Experimental|Topical Tripterygium group|Patients were treated with topical compound tripterygium for 1 hour, twice per day. Area dosages were as followed that each 1st to 5th metacarpophalangeal joints (MCPJs), 1st to 5th proximal interphalangeal joints (PIPJs) and wrist was 3 ml, each elbow and ankle was 5 ml, each knee was 10 ml.
89488679|NCT02444325|No Intervention|Routine Prenatal Care|Subjects randomized to routine care will receive their care in the usual diabetic clinic attended by residents and faculty. They will receive consultation with the diabetes educator at diagnosis and as needed. Patients are seen every 2 weeks (or more by provider discretion) until 37 weeks and weekly until delivery. Visits are 10-15 minutes and focus on routine screening tests and review of blood sugar logs/medication titration. Each subject's medical chart will be reviewed for demographics, antenatal management, maternal and neonatal outcomes.
89488680|NCT02444325|Experimental|Group prenatal care|Group visits will be held every 2 weeks in a continuous cycle through a four session curriculum. Women will have weekly visits beginning at 37 weeks with traditional prenatal visits on the weeks when the group does not meet. Groups of 4-12 women will meet for two hour visits and much of that time will be spent on pregnancy, behavioral health, diabetes and nutrition education. Groups will be co-facilitated by 2 CenteringPregnancy trained providers at each site and an obstetric provider. Women may be instructed to have additional visits in the traditional clinic at the discretion of the obstetric provider.
89488681|NCT02444091|Experimental|Cyclophosphamide|Cyclophosphamide, intravenous infusions four weeks apart. Six infusions in total. First infusion: 600 mg/m2. Infusions 2 to 6: 700 mg/m2
89488682|NCT02443935|Experimental|MGN1703|TLR-9 agonist MGN1703 administered to HIV-1 positive patients on cART
89488683|NCT02439801||Compliance|"Pulmonary compliance (or lung compliance) is a measure of the lung's ability to stretch and expand. In clinical practice it is separated into two different measurements, static compliance and dynamic compliance. Static lung compliance is the change in volume for any given applied pressure. Dynamic lung compliance is the compliance of the lung at any given time during actual movement of air.~Effects of intra-operative PEEP 0, PEEP 5, PEEP 8 treatment on static and dynamic compliance levels will be investigate."
89488684|NCT02439801||Pulmonary Function tests|"Pulmonary function testing has diagnostic and therapeutic roles and helps clinicians answer some general questions about patients with lung disease.~Effects of intra-operative PEEP 0, PEEP 5, PEEP 8 treatment on pulmonary function test values will be investigate."
89488685|NCT02439801||volatil agent elimination time|"Volatile anaesthetics are eliminated in the terminal phase via the lungs. A low blood:gas partition coefficient is therefore necessary for quick removal of the anaesthetic.~Effects of intra-operative PEEP 0, PEEP 5, PEEP 8 treatment on volatil agent elimination time will be investigate."
89488686|NCT02439723|Experimental|Regorafenib|All patients will be treated with 160 mg regorafenib taken orally once daily for the first 21 days of each 28-day cycle. Doses are to be taken immediately following a light breakfast. During the seven-day break period of cycle 1, patients will start pantoprazole 40 mg twice daily for 8 days
89488687|NCT02440035|Experimental|Group 1|Two subsequent Intramuscular injections of Ad35.RSV.FA2 (1x10^11 virus particles [vp]) on Day 1, Day 85 and an intramuscular injection of Ad26.RSV.FA2 (5x10^10 vp) on Day 169.
89488688|NCT02440035|Experimental|Group 2|Intramuscular injection of Ad35.RSV.FA2 (1x10^11 vp) on Day 1, an intramuscular injection of placebo control on Day 85 and an injection of Ad35.RSV.FA2 (1x10^11 vp) on Day 169.
89488689|NCT02440035|Experimental|Group 3|One intramuscular injection of Ad35.RSV.FA2 (1x10^11 vp) on Day 1 and an intramuscular injection of placebo control on Day 85 and an intramuscular injection of Ad26.RSV.FA2 (5x10^10 vp) on Day 169.
89488690|NCT02440035|Experimental|Group 4|Two subsequent intramuscular injections of placebo control on Day 1, Day 85 and an intramuscular injection of Ad26.RSV.FA2 (5x10^10 virus particles [vp]) on Day 169.
89488691|NCT03193827|Experimental|study group|In this group in-line filters (Pall, Dreieich, Germany) are connected to peripheral vascular access and used during anaesthesia and the following 96 postoperative hours.
89488692|NCT03193827|Active Comparator|control group|Patients randomised to standard care are managed without an in-line filter and according to local routine practice for intravenous drug administration in the adult patient.
89488693|NCT03193749|Experimental|Amiodarone Hydrochloride|Oral treatment for at least 6 months
89488694|NCT03193749|Placebo Comparator|Placebo|Oral treatment for at least 6 months
89488695|NCT03193671||Benign|Benign tumors, pre-and postmenopausal
89488696|NCT03193671||Malignant|Malignant tumors, pre-and postmenopausal
89488697|NCT03193671||Borderline|Borderline tumors, pre-and postmenopausal
89488698|NCT03193671||Malignant+borderline|Malignant+borderline tumors, pre-and postmenopausal
89488699|NCT03193905|Other|Cotton blanket|30 hypothermia patients undergo the standard procedure with a cotton blanket during major spinal surgery
88953384|NCT01961505|Placebo Comparator|Topical Placebo group|Patients were treated with topical placebo for 1 hour, twice per day. The dosage was the same as the topical tripterygium group.
88953385|NCT01961583|Experimental|Drug; 18F-Fluciclatide|18F-Fluciclatide, 0.14 mCi/kg (not to exceed 10 mCi), IV(in the vein) administration
89021792|NCT00339014|Active Comparator|Group 2|Zonisamide SR 120 mg/day plus Bupropion SR 360 mg/day
89488700|NCT03193905|Other|Bairhugger Full Access Underbody blanket|30 hypothermia patients undergo the Bairhugger Full Access Underbody blanket procedure during major spinal surgery (new procedure)
89488701|NCT02443779||Early Parkinson's disease patients|All subjects will undergo a complete neuro-ophthalmological examination, including assessment of best-corrected visual acuity, ocular motility, pupillary reflexes, slit-lamp biomicroscopy, intraocular pressure (IOP) measurement, and dilated fundus examination, followed by an optical coherence tomography study. Subjects will also have a DaTscan for striatal dopamine transporter visualization using single photon emission computed tomography (SPECT) brain imaging. A clinical examination will also be performed in order to document motor and cognitive functioning.
89537896|NCT03293849|No Intervention|Control Arm|Assessment results will be provided in printed and electronic form to the treating oncologist for their review. Referrals or interventions for patients allocated to the control arm will be coordinated by the treating oncologist without involvement from the patient navigator or the study team.
89488702|NCT02443779||Advanced Parkinson's disease patients|All subjects will undergo a complete neuro-ophthalmological examination, including assessment of best-corrected visual acuity, ocular motility, pupillary reflexes, slit-lamp biomicroscopy, intraocular pressure (IOP) measurement, and dilated fundus examination, followed by an optical coherence tomography study. Subjects will also have a DaTscan for striatal dopamine transporter visualization using single photon emission computed tomography (SPECT) brain imaging. A clinical examination will also be performed in order to document motor and cognitive functioning.
89488703|NCT03190629|Active Comparator|High-flux hemodialysis|3 times per week
89488704|NCT03190629|Experimental|On line-hemodiafiltration|3 times per week
89488705|NCT02444013|Active Comparator|Folic acid|Oral folic acid (5 mg, tid) were given at least two days before CTA/angiography/angioplasty and continued for two days after.
89488706|NCT02444013|Placebo Comparator|Placebo|Oral placebo (1 tablet, tid) were given at least two days before CTA/angiography/angioplasty and continued for two days after.
89488707|NCT02444637|Experimental|Rivastigmine (Exelon) Patch|For the first 4 weeks of the study, subjects will receive Rivastigmine patch 4.6mg/24 hours. Thereafter, subjects will receive Rivastigmine patch 9.5mg/24 hours.
89488708|NCT02710071|Experimental|Placebo, Nebivolol, Hydrochlorothyazide|Sequence: Placebo, Then Nebivolol 5mg for 2 weeks followed by nebivolol 10 mg for 4 weeks,Then Hydrochlorothiazide 12.5 mg for 2 weeks followed by hydrochlorothiazide 25 mg for 4 weeks.
89488709|NCT02710071|Experimental|Placebo, Hydrochlorothyazide, Nebivolol|Sequence: Placebo, Then Hydrochlorothiazide 12.5 mg for 2 weeks followed by hydrochlorothiazide 25 mg for 4 weeks, Then Nebivolol 5mg for 2 weeks followed by nebivolol 10 mg for 4 weeks.
89488710|NCT02443701|Experimental|Exercise|All 12 volleyball athletes performed a strength training and jump, to be held in both legs at the same time. The training will be held in a six-week period, a total of 18 training. Athletes will hold a warmup in stationary bike for 6 minutes, maximum isometric strengthening in leg extension (knee positioned at 60 ° of flexion and hip in 75 ° of flexion), 10 repetitions of 10 seconds with 30 seconds interval. After strengthening conduct a complete rest 5 minutes and jump training countermovement in 5 sets of 10 jumps (1 minute interval between each jump).
89488711|NCT02443701|Experimental|NEMES|All 12 volleyball athletes performed a strength training and jump, to be held in both legs at the same time. The training will be held in a six-week period, a total of 18 training. Athletes will hold a warmup in stationary bike for 6 minutes, maximum isometric strengthening in leg extension (knee positioned at 60 ° of flexion and hip in 75 ° of flexion), 10 repetitions of 10 seconds with 30 seconds interval. After strengthening conduct a complete rest 5 minutes and jump training countermovement in 5 sets of 10 jumps (1 minute interval between each jump).The healthy athletes electrical stimulation group will perform the same training program described above, but strength training is associated with electrical stimulation, medium frequency current (1kHz), modulated at 70Hz, cycle Work 10%, intensity used will vary according to the capacity and tolerable for each individua. The stimulated muscle group will be the quadriceps femoris
89488712|NCT02443701|Experimental|Phototherapy|All 12 volleyball athletes performed a strength training and jump, to be held in both legs at the same time. The training will be held in a six-week period, a total of 18 training. Athletes will hold a warmup in stationary bike for 6 minutes, maximum isometric strengthening in leg extension (knee positioned at 60 ° of flexion and hip in 75 ° of flexion), 10 repetitions of 10 seconds with 30 seconds interval. After strengthening conduct a complete rest 5 minutes and jump training countermovement in 5 sets of 10 jumps (1 minute interval between each jump). The 12 healthy athletes participating in the phototherapy group will undergo a phototherapy protocol before performing the strength and jump training. Phototherapy will be conducted through a cluster with 03 diodes with 850nm wavelength and the following parameters: Power 50mW diode, diode energy by 2J. The application sites will be six points on the belly of the quadriceps femoris muscles bilaterally.
89204325|NCT00761969||PAB|Subjects with stable peripheral arterial disease; ankle-brachial pressure index on at least one leg =< 0.90.
89488713|NCT02444403|Other|Police Education Program (PEP)|The entire police force mandated for periodic refresher training will be assigned to classes which receive one PEP course over 2 years.
89488714|NCT02439567|Experimental|Patients|Treatment with new oral antiviral drugs for HCV infection, Fibroscan: Liver and Spleen elastography
89488715|NCT02443857|Experimental|ChARMin|Single-arm only
88953386|NCT01961596|Experimental|cooling ice|"A bursts of the Cooling Ice Spray over a period of 10 seconds (15 cm distance) will be applied at the dominant foot in before each test.~After 2 days the measurements will be repeated with the other application."
88953387|NCT01961596|Placebo Comparator|water|"A bursts of the water spray (room temperature over a period of 10 seconds (15 cm distance) will be applied at the dominant foot in before each test.~After 2 days the measurements will be repeated with the other application."
88953388|NCT01961622|Experimental|Florence D2A Closed Loop Glucose control|Subjects glucose levels are controlled by Florence D2A or similar closed loop insulin delivery system
88953389|NCT01961622|Active Comparator|CSII with real-time CGM|Subject glucose level controlled by usual insulin pump therapy in conjunction with real time continuous glucose monitoring (FreeStyle Navigator CGM)
88953390|NCT01961635|Experimental|Zirconia Abutments|Place zirconia one-time one-abutment in subcrestal platform-switch dental implants on the day of implant installation, torque 20 n/cm2
89488716|NCT02439333|Active Comparator|Nasal high flow therapy|AECOPD patients with no severe respiratory insufficiency are given NHF therapy for at least 15 hours per day.
89488717|NCT02439333|Active Comparator|Conventional oxygen therapy|AECOPD patients with no severe respiratory insufficiency are given conventional oxygen therapy such as nasal catheter or venturi mask for at least 15 hours per day.
89488718|NCT02439489|Experimental|BKM120-CIS|BKM120 (60, 80 100 mg po continuously) and Cisplatin (iv 75 mg/m2)
89488719|NCT02439489|Experimental|BKM120-CARBO|BKM120 and (60, 80 100 mg po continuously) and Carboplatin (iv AUC 5)
89488720|NCT02444481|Experimental|Polygynax, antibiotic, vaginal treatment|Polygynax combinaison of nystatine, polymyxin, neomycin, Local treatment of vaginal infection during 12 days. One vaginal capsule every evening.
89488721|NCT02444559|Experimental|Ropivacaine+Clonidine|Adductor Canal Block Ropivacaine 20ml 5mg/ml+ Clonidine 150ug
89488722|NCT02444559|Placebo Comparator|Ropivacaine+Placebo|Adductor Canal Block Ropivacaine 20ml 5mg/ml+ saline
89488723|NCT04484103||251 patients from the MRI-FIRST trial|The mpMRIs were performed at 16 centers with 1.5T or 3T MR units. All mpMRIs included T2-weighted imaging, diffusion-weighted imaging and dynamic contrast-enhanced imaging.
89488724|NCT02439177|Experimental|Omnitest 3|Blood glucose monitoring system
89488725|NCT02439177|Experimental|Omnitest 5|Blood glucose monitoring system
89488726|NCT02443233||Maternal hepatitis B carrier|
88953391|NCT01961635|Experimental|Titanium Abutments|Place titanium one-time one-abutment in subcrestal platform-switch dental implants on the day of implant installation, torque 20 n/cm2
89488727|NCT02443233||Paternal hepatitis B carrier|
89488728|NCT02440191|Active Comparator|3DCRT|conventional 3-dimensional conformal radiotherapy on the breast, 50.4 Gy/28 fx and tumor bed boost, 9 Gy/5 fx will be irradiated for 6.5 weeks.
89488729|NCT02440191|Experimental|IMRT (Intensity modulated radiotherapy)|"Intensity-modulated radiotherapy (IMRT) with simultaneous integrated boost (SIB) on the whole breast, 50.4 Gy/28 fx and tumor bed, 57.4 Gy/28 fx will be irradiated for 5.5 weeks.~Unlike 3DCRT, concomittant boost technique is used in the IMRT arm."
89488730|NCT02439099||MDD|Currently unmedicated patients with a depressive episode in the context of unipolar major depression
88953392|NCT01961635|Experimental|Cad-Cam Acrylic abutments|Place cad-cam acrylic one-time one-abutment in subcrestal platform-switch dental implants on the day of implant installation, torque 20 n/cm2
88953393|NCT01961648|Active Comparator|Dead space|Participant will sleep connected to a mask with added dead space half of the night
88953394|NCT01961648|Sham Comparator|room air|Participant will sleep connected to a mask open to rrom air, half of the night
88953395|NCT01961661|Experimental|probiotic|Lactobacillus rhamnosus GG 5x10^9 colony forming units (CFU)per day
88953396|NCT01961661|Placebo Comparator|placebo|maltodextrins
88953397|NCT01961674|Experimental|Capsinoid arm|On capsinoids
88953398|NCT01961674|Placebo Comparator|Placebo arm|Placebo
89021793|NCT00339014|Active Comparator|Group 3|Zonisamide SR 240 mg/day plus Bupropion SR 280 mg/day
89488731|NCT02439099||Control|Healthy Controls
89488732|NCT02439099||Alzheimer's Disease|Patients with Alzheimer's disease
89488733|NCT02439099||Alcoholism|Subjects with alcoholism
89488734|NCT02439099||Schizophrenia|Subjects with before and schizophrenia prior to and during medication with clozapine, olanzapine or aripiprazole
89488735|NCT02439411||Dabrafenib|
89488736|NCT02439411||Dabrafenib plus Trametinib|Patients treated with Dabrafenib plus Trametinib
89488737|NCT03192735|Experimental|Apatinib Combined With SOX|In this group,subject will be given ApatinibMesylateTablets 500mg one time a day, from day1-day 21,per os; Oxaliplatin for Injection 130mg/m2 one time a day，ivgtt，in day1; Gimeracil and Oteracil Porassium Capsules twice times a day,from day1-day 14,per os,and the dosage according body surface area:<1.25m2, 40mg every time;1.25-1.5m2,50mg every time; >1.5m2, 60mg every time.A course of treatment need 21days. Every subject need 2-5 courses accrding to tumor assessment by clinician. The last course stop ApatinibMesylateTablets.
89488738|NCT02439021|Experimental|CobraPLA|Patients will randomly assign to either LMA or Cobra PLATM
89488739|NCT02439021|Experimental|LMA|Patients will randomly assign to either LMA or Cobra PLATM
89488740|NCT03796455|Experimental|Fish Oil|2.0 g EPA + DHA / day + placebo powder
89488741|NCT03796455|Experimental|Fish Oil and HMB|2.0 g EPA + DHA + 3.0 g HMB / day
89488742|NCT03796455|Placebo Comparator|Placebo|3 g/d soy oil: corn oil (50:50 ratio) + placebo powder
89488743|NCT02443467||HER2-positive early breast cancer|Human Epidermal Growth Factor Receptor 2 (HER2)-positive early breast cancer treated with loading dose of Herceptin (trastuzumab) administered as 6 mg/kg followed by once in 3 weeks administration at 4 mg/kg up to 12 months of treatment
89488744|NCT02443311|Experimental|Group I|Pimecrolimus 1% cream (Elidel, Novartis Pharmaceuticals, East Hanover, NJ)+ custom made hydrophilic Adhesive gel base (Department of Pharmaceutics and Industrial Pharmacy. Faculty of Pharmacy. Ain Shams University) 4 Times/day for 4 weeks
89488745|NCT02443311|Active Comparator|Group II|Betamethasone 17-valerate 0.1% cream (Betnovate, GlaxoSmithKline, Cairo, Egypt)+ custom made hydrophilic Adhesive gel base (Department of Pharmaceutics and Industrial Pharmacy. Faculty of Pharmacy. Ain Shams University) 4 Times/day for 4 weeks
89488746|NCT02442999|No Intervention|Usual care|
89488747|NCT02442999|Experimental|Screen for Sleep Apnea|Screen for sleep apnea, treat with continuous positive airway pressure (CPAP) if diagnosed with sleep apnea
89488748|NCT02373202|Experimental|Sarilumab 150 mg q2w + DMARDs|Participants received sarilumab 150 mg, subcutaneous (SC) injection, once every two weeks (q2w) along with non-MTX DMARDs (sulfasalazine, leflunomide, bucillamine, tacrolimus, and/or mizoribine) for up to 52 weeks.
89488749|NCT02373202|Experimental|Sarilumab 200 mg q2w + DMARDs|Participants received sarilumab 200 mg, SC injection, q2w along with non-MTX DMARDs (sulfasalazine, leflunomide, bucillamine, tacrolimus, and/or mizoribine) for up to 52 weeks.
89488750|NCT02373202|Experimental|Sarilumab 150 mg q2w|Participants received sarilumab 150 mg, SC injection, q2w for up to 52 weeks.
89488751|NCT02373202|Experimental|Sarilumab 200 mg q2w|Participants received sarilumab 200 mg, SC injection, q2w for up to 52 weeks.
89488752|NCT03192111|Experimental|Mild Renal Impairment|Subjects with mild renal impairment
89488753|NCT03192111|Experimental|Moderate Renal Impairment|Subjects with moderate renal impairment
89488754|NCT03192111|Experimental|Severe Renal Impairment|Subjects with severe renal impairment
89488755|NCT03192111|Experimental|Healthy Subjects|Healthy volunteers mean-matched to the mild, moderate, and severe renal impairment patients
89488756|NCT02622074|Experimental|Cohort A: KNp / KAC|Participants receive pembrolizumab (K) 200 mg on Cycle 1 Day 1 followed by pembrolizumab 200 mg in Cycles 2-5 on Day 1 (once every 3 weeks; Q3W) PLUS nab-paclitaxel (KNp) starting at 125 mg/m^2 in Cycles 2-5 on Days 1, 8 and 15 (once each week; QW). This will be followed by pembrolizumab (K) 200 mg in Cycles 6-9 on Day 1 (Q3W) PLUS doxorubicin (A) 60 mg/m^2 in Cycles 6-9 on Day 1 (Q3W) PLUS cyclophosphamide (C) 600 mg/m^2 in Cycles 6-9 on Day 1 (Q3W). All treatments will be administered via intravenous (IV) infusion except for doxorubicin (A), which will be administered via IV injection. Each cycle is 21 days.
89488757|NCT02622074|Experimental|Cohort B: KNpCb (Regimen 1) / KAC|Participants first receive KNpCb Regimen 1 which consists of: pembrolizumab (K) 200 mg on Cycle 1 Day 1 PLUS nab-paclitaxel (KNp) starting at 100 mg/m^2 in Cycles 2-5 on Days 1, 8 and 15 (QW) PLUS carboplatin (Cb) starting at Area Under the Curve (AUC) 6 in Cycles 2-5 on Day 1 (Q3W). This will be followed by pembrolizumab (K) 200 mg in Cycles 6-9 on Day 1 (Q3W) PLUS doxorubicin (A) 60 mg/m^2 in Cycles 6-9 on Day 1 (Q3W) PLUS cyclophosphamide (C) 600 mg/m^2 in Cycles 6-9 on Day 1 (Q3W). All treatments will be administered via IV infusion except for doxorubicin (A), which will be administered via IV injection. Each cycle is 21 days.
89488758|NCT02622074|Experimental|Cohort C: KNpCb (Regimen 2) / KAC|Participants first receive KNpCb Regimen 2 which consists of: pembrolizumab (K) 200 mg on Cycle 1 Day 1 PLUS nab-paclitaxel (KNp) starting at 125 mg/m^2 in Cycles 2-5 on Days 1, 8 and 15 (QW) PLUS carboplatin (Cb) starting at AUC 5 in Cycles 2-5 on Day 1 (Q3W). This will be followed by pembrolizumab (K) 200 mg in Cycles 6-9 on Day 1 (Q3W) PLUS doxorubicin (A) 60 mg/m^2 in Cycles 6-9 on Day 1 (Q3W) PLUS cyclophosphamide (C) 600 mg/m^2 in Cycles 6-9 on Day 1 (Q3W). All treatments will be administered via IV infusion except for doxorubicin (A), which will be administered via IV injection. Each cycle is 21 days.
89488759|NCT02622074|Experimental|Cohort D: KNpCb (Regimen 3) / KAC|Participants first receive KNpCb Regimen 3 which consists of: pembrolizumab (K) 200 mg on Cycle 1 Day 1 PLUS nab-paclitaxel (KNp) starting at 125 mg/m^2 in Cycles 2-5 on Days 1, 8 and 15 (QW) PLUS carboplatin (Cb) starting at AUC 2 in Cycles 2-5 on Days 1, 8 and 15 (QW). This will be followed by pembrolizumab (K) 200 mg in Cycles 6-9 on Day 1 PLUS doxorubicin (A) 60 mg/m^2 in Cycles 6-9 on Day 1 (Q3W) PLUS cyclophosphamide (C) 600 mg/m^2 in Cycles 6-9 on Day 1 (Q3W) in Cycles 6-9 on Day 1 (Q3W). All treatments will be administered via IV infusion except for doxorubicin (A), which will be administered via IV injection. Each cycle is 21 days.
89488760|NCT02622074|Experimental|Cohort E: KTCb (Regimen 1) / KAC|Participants first receive KTCb Regimen 1 which consists of: pembrolizumab (K) 200 mg on Cycle 1 Day 1 PLUS paclitaxel (T) starting at 80mg/m^2 in Cycles 2-5 on Days 1, 8, and 15 (QW) PLUS carboplatin (Cb) starting at AUC 5 in Cycles 2-5 on Day 1 (Q3W). This will be followed by pembrolizumab (K) 200 mg in Cycles 6-9 on Day 1 (Q3W) PLUS doxorubicin (A) 60 mg/m^2 in Cycles 6-9 on Day 1 (Q3W) PLUS cyclophosphamide (C) 600 mg/m^2 in Cycles 6-9 on Day 1 (Q3W). All treatments will be administered via IV infusion except for doxorubicin (A), which will be administered via IV injection. Each cycle is 21 days.
89488761|NCT02622074|Experimental|Cohort F: KTCb (Regimen 2) / KAC|Participants first receive KTCb Regimen 2 which consists of: pembrolizumab (K) 200 mg on Cycle 1 Day 1 PLUS paclitaxel (T) starting at 80mg/m^2 in Cycles 2-5 on Days 1, 8, and 15 PLUS carboplatin (Cb) starting at AUC 2 in Cycles 2-5 on Days 1, 8 and 15 (QW). This will be followed by pembrolizumab (K) 200 mg in Cycles 6-9 on Day 1 (Q3W) PLUS doxorubicin (A) 60 mg/m^2 in Cycles 6-9 on Day 1 (Q3W) PLUS cyclophosphamide (C) 600 mg/m^2 in Cycles 6-9 on Day 1 (Q3W). All treatments will be administered via IV infusion except for doxorubicin (A), which will be administered via IV injection. Each cycle is 21 days.
89488762|NCT02438709|Experimental|COX-2 Inhibitor|Patients who take COX-2 inhibitor
89488763|NCT02438943|Active Comparator|Audit and Physician intervention|The intervention will comprise the feedback of the results of the baseline audit, training in motivational interviewing for clinic staff, use of a physician reminder stamp in the patients' charts and distribution of patient education cards
89488764|NCT02438943|Sham Comparator|Audit only|The intervention will comprise the feedback of the results of the baseline audit only
89488765|NCT05438758|Other|Intranasal Esketamine with Addition of Almond TherapyTM|Intranasal Esketamine - Dose of 56 mg or 84 mg once a week for 4 weeks followed by 56 mg or 84 mg once every two weeks for 8 weeks.
89488766|NCT05438758|Other|Intranasal Esketamine with Treatment as Usual|Intranasal Esketamine - Dose of 56 mg or 84 mg once a week for 4 weeks followed by 56 mg or 84 mg once every two weeks for 8 weeks.
89488767|NCT02442921|Experimental|Colchicine|20 patients will receive up to 2 mg of colchicine for 18 months
89488768|NCT02442921|Placebo Comparator|Placebo|20 patients will receive placebo for 18 months
89488769|NCT04891510|Active Comparator|REVOLVE Advanced Adipose System|Participants will receive the REVOLVE Advanced Adipose System technique during breast reconstruction.
89488770|NCT04891510|Active Comparator|LipoGrafter|Participants will receive the LipoGrafter technique during breast reconstruction.
89488771|NCT04891510|Active Comparator|Standard Decantation|Participants will receive the Standard decantation technique during breast reconstruction.
89488772|NCT02438865|Active Comparator|Single instillation group|will receive single intravesical dose of epirubicin intravesical therapy (50 mg) within 48 hours of radical nephroureterectomy with open bladder cuff excision.
88953399|NCT01961700|Experimental|Physiotherapy|Physiotherapy (breathing exercises, mobilisation, exercises for upper limbs, advice on physical activity and exercise) provided daily during hospitalization.
88953400|NCT01961700|No Intervention|Control group|No physiotherapy.
88953401|NCT01961713||Prostatectomy|Subjects with prostate cancer diagnosed on prostate biopsy who undergo radical prostatectomy at Massachusetts General Hospital
89488773|NCT02438865|Active Comparator|Maintainance therapy group|will receive a single intravesical dose of epirubicin and an additional 6 weekly doses of intravesical therapy (50 mg) after surgery then monthly maintenance therapy for 1 year.
89488774|NCT04898140||Healthy volunteers|Individuals who were not infected and not having been demonstrated COVID-19 symptoms since December 2019.
89488775|NCT04898140||Recovered|Individuals who were recovered from COVID-19 with different severity.
89488776|NCT04898140||Vaccinated|"Individuals who were vaccinated against SARS-CoV-2 with Sputnik V vaccine."
89488777|NCT04898140||Special group|Individuals who recovered from COVID-19 concomitant with other immune-related comorbidities (tuberculosis, chronic obstructive pulmonary disease, HIV infection, hematological neoplasia).
89488778|NCT03189771|Experimental|occlusal surface reduction|occlusal surface reduction after single visit root canal treatment
89488779|NCT03189771|Placebo Comparator|no occlusal surface reduction|No occlusal surface reduction after single visit root canal treatment
89488780|NCT02308696|Experimental|Peer-to-peer support (non-randomized)|225 older adults that are currently receiving peer-to-peer support
89488781|NCT02308696|Active Comparator|Standard Services (non-randomized)|225 older adults will continue receiving standard community services
89488782|NCT03189927|Experimental|BD-Covered stent|Device: BD-Covered stent for refractory benign esophageal strictures with of without fistulae
89488783|NCT04924478||Severe Asthma Patients Treated with Mepolizumab|Following treatment, patients will be stratified into responders or non-responders
89488784|NCT04924634||Students|Students from 4 universities, regardless of field of study and academic year
89488785|NCT02442609||patient|patient schedulled for elective surgery, adult (> 18yrs), non emergency procedure, able to read questionaire
89488786|NCT04923932|Experimental|Savolitinib|GC
89488787|NCT02342704|Experimental|natalizumab|Open-label natalizumab 300 mg IV every 4 weeks (Q4W)
89488788|NCT02342704|Active Comparator|fingolimod|Open-label fingolimod 0.5 mg once daily orally
89488789|NCT02442843|Experimental|active tDCS|Investigators will use cathodal tDCS to inhibit the brain regions that may be associated with symptoms of PTSD (temporal cortex). Active tDCS will be provided at 2 miliamps (mA) for 20 minutes (with gradual increase and withdraw of stimulation during the first and last minute).
89488790|NCT02442843|Sham Comparator|sham tDCS|Participants randomized to the sham condition will receive stimulation during the first and final minutes of the 20 minute period (with gradual increase and removal of current during that time).
89488791|NCT02442843|No Intervention|Combat Controls|Participants without PTSD will undergo neuropsychological testing and a single fMRI scan.
89488792|NCT04912154|Experimental|Traditional rehabilitation protocol|Traditional rehabilitation protocol after the surgery will be conducted
89488793|NCT04912154|Active Comparator|Accelerated rehabilitation protocol|Accelerated rehabilitation protocol under ultrasonic monitoring after the surgery will be conducted
89488794|NCT02438553|Experimental|OSTNS Neurostimulator|Combined Occipital & Supraorbital Transcutaneous Neurostimulator.
88953402|NCT01961726|Placebo Comparator|Placebo|
88953403|NCT01961726|Experimental|30 mg dose of JVS-100|
88953404|NCT01961726|Experimental|45 mg dose of JVS-100|
88953405|NCT01961739|Experimental|2% lidocaine|topical application, two times per day for 15 consecutive days
88953406|NCT01961739|Placebo Comparator|placebo|vaseline base applied topically, two times per day for 15 consecutive days
89488795|NCT02438553|Placebo Comparator|Placebo OSTNS Neurostimulator|Placebo Combined Occipital & Supraorbital Transcutaneous Neurostimulator.
89488796|NCT04911842||TPU|Thermoplastic polyurethane
89488797|NCT04911842||HBM|Hydrophilic BioMaterial
89488798|NCT02442453|Active Comparator|curcuma longa|"curenext gel containing curcuma longa i.e. turmeric has strong antioxidant and antiinflammatory properties.~Test group:Topical application twice daily for ten minutes after brushing for four weeks."
89488799|NCT02442453|Placebo Comparator|Placebo gel|Placebo gel consists of corbopol 934 polymer and triethonalamine. Control group:Topical application twice daily for ten minutes after brushing for four weeks.
89488800|NCT04911764|Experimental|Three-min Step Test and Exercise desaturation detection in COPD|Each patient recruited will performed both field tests, being therefore his or her own witness.
88953407|NCT01961752|Placebo Comparator|Control group|
88953408|NCT01961752|Experimental|Bupivacaine only group|
88953409|NCT01961752|Active Comparator|Bupivacaine with triamcinolone group|
88953410|NCT01961765|Experimental|cabozantinib|Cabozantinib will be administered at a dose of 40mg daily by mouth in the first cohort. Dose escalation will occur in subsequent patient cohorts. We will evaluate 3-6 patients per dose level.
88953411|NCT01961791||TNM 7th edition|staged by the current TNM 7th edition of AJCC/UICC
88953412|NCT01961791||new TNM stage|staged by new TNM stage with new lymph node staging concept
88953413|NCT01961804|Other|Actual recommendations|Current guidelines recommend to perform a CT scan and realise the anticoagulation reversion only in case of intracranial bleeding diagnosed.
88953414|NCT01961804|Experimental|Preventive reversion|Realise a preventive reversion before performing any CT scan.
89021794|NCT00339014|Active Comparator|Group 4|Zonisamide SR 240 mg/day plus Bupropion SR 360 mg/day
89488801|NCT02438397|Active Comparator|metformin+premix insulin|metformin:500mg tid
89488802|NCT02438397|Experimental|acarbose+premix insulin|acarbose:100mg tid
89488803|NCT04914104|Experimental|Intervention|The intervention group will receive free access to the mobile app Headspace and directed to access the app three times a week for at least 15 minutes.
89488804|NCT04914104|No Intervention|Control|The control group will receive standard of care, which does not involve routine in-person or free access to mobile mindfulness therapy.
89537897|NCT03062241|Experimental|Cryoablation|The pulmonary vein (PV) isolation in patients randomized to intervention group.
89021795|NCT00339014|Active Comparator|Group 5|Zonisamide SR 360 mg/day plus Bupropion SR 280 mg/day
89204326|NCT00761969||Control|Subjects without peripheral arterial disease (palpable pedal pulses and a normal ankle-brachial pressure index of 0.91-1.30), age- and sex-matched to the stuy group with PAD
89488805|NCT02438319||patients with open angle glaucoma|patients with open angle glaucoma who had their optic discs routinely documented by fundus photography. Optic disc photographs will be analyzied by manual planimetry or automated planimetry.
89488806|NCT02438163|Experimental|Patients with MDD|the group of depressed patients undergo 2 Theta Burst Stimulations : iTBS and cTBS. There is one session per stimulation. Cerebral Plasticity is measured after each stimulation for each session
89488807|NCT02438163|Experimental|healthy Controls|the group of healthy controls undergo 2 Theta Burst Stimulations : iTBS and cTBS. There is one session per stimulation. Cerebral Plasticity is measured after each stimulation for each session
89488808|NCT03193359|Experimental|BOTOX®|BOTOX® (botulinum toxin Type A) 155U to 195U intramuscular (IM) injections to head/neck areas at Day 0 and Week 12.
89488809|NCT02442531|Experimental|CriPec® docetaxel|Docetaxel containing nanoparticle
89488810|NCT04913792||ZXR00|The ZXR00 group included 30 patients bilaterally implanted with the Tecnis Symfony IOL (Abbott Medical Optics, Inc.)
89488811|NCT02438241|Active Comparator|Conventional physiotherapy Group|Patients randomized to this group will receive only conventional physiotherapy. The treatment protocol will consist of weathered active exercises to manually lower limbs in bed (triple flexion, abduction and adduction, plantar / dorsiflexion), free active exercises of the upper limbs in the bed (shoulder flexion, shoulder flexion and horizontal functional diagonal shoulder), bronchial hygiene techniques, flow redirection, positive expiratory pressure and ventilatory blowing patterns.
89488812|NCT02438241|Placebo Comparator|Placebo TENS Group|Will be held the same procedure as TENS group, except that TENS will be offered to the patient only for 45 seconds, and in the first 30 seconds is reached the sensory threshold of the patient and in the last 15 seconds will turn off the electrical current by 29 remaining period minutes and 15 seconds off.
89488813|NCT02438241|Experimental|TENS group|Patients randomized to this group will receive conventional physical therapy for the control group, and the end of that service, will be applied TENS. TENS is accomplished through the use of an electrical stimulation device with symmetrical biphasic current pulse. The following parameters are used: frequency: 100 Hz, pulse width: 100 µs, intensity to the greatest sensory threshold of the patient and total session time: 30 minutes. Self-adhesive electrodes will be used (Valutrode, size 5x9 cm) to be positioned in the posterolateral portion of the chest to 2 cm skin incision both upper and lower.
89488814|NCT02442219||Coeliac|Persons with coeliac disease on a gluten free diet where diagnosis is confirmed by duodenal biopsy.
89488815|NCT02442219||Non coeliac gluten sensitive|Persons on a gluten free diet where coeliac disease is excluded by duodenal biopsy.
89488816|NCT02442219||Healthy control group|Persons on a gluten containing diet without known coeliac disease.
89488817|NCT02437929||Patients receiving standard procedures|
89488818|NCT03054974|Experimental|Modern rehabilitation treatment|Modern rehabilitation treatment
89488819|NCT03054974|Experimental|Modern rehabilitation &TCM|Modern rehabilitation treatment and traditional Chinese medicine
89488820|NCT03054974|Experimental|modern rehabilitation &Baimai Ruangao|modern rehabilitation treatment and Baimai Ruangao
89488821|NCT03054974|Experimental|modern rehabilitation &Tibetan medicine|modern rehabilitation treatment and Tibetan medicine treatment
88953415|NCT01961817|Other|Retromolar|"Patients in whom the vocal cord visualisation starts with the retromolar method, which has been randomized determined preoperatively.~The second visualization then will be performed with the conventional method."
88953416|NCT01961817|Other|Convenvtional|"Patients in whom the vocal cord visualisation starts with the conventional method, which has been randomized determined preoperatively.~The second visualization then will be performed with the retromolar method."
89488822|NCT03193203|Experimental|Sequence 1|SB4 (etanercept) 50 mg/mL PFS and AI
89488823|NCT03193203|Experimental|Sequence 2|SB4 (etanercept) 50 mg/mL AI and PFS
89488824|NCT04923698|Active Comparator|yoga|The yoga program consisted of 12 exercises, , 50 minutes daily, 7 days per week for 12 weeks (Total 84 sessions).
89488825|NCT04923698|Active Comparator|antidepressant|All women in group A were treated by antidepressant only for 12 weeks
89488826|NCT02442063|Experimental|Radium Ra 223 dichloride|Radium Ra 223 dichloride (Xofigo, BAY88-8223)
89488827|NCT04923152|Experimental|moderate dose statin|Patients 1 month post PCI, allocated to 5 mg rosuvastatin per day
89488828|NCT04923152|Active Comparator|high dose statin|patients 1 month post PCI, allocated to 40 mg rosuvastatin
89488829|NCT03369717|Experimental|Antibiotics|To receive postoperative antibiotics
89488830|NCT03369717|No Intervention|No antibiotics|Will not receive any postoperative antibiotics
89488831|NCT03054662|Experimental|Patients with Haemophilia|Male patients with severe and moderate haemophilia A and B in Ivory Coast
89488832|NCT03054662|Experimental|Carriers for Haemophilia|Carriers for severe and moderate haemophilia A and B in Ivory Coast
88953417|NCT01961830|Experimental|ME1100|ME1100 inhalation solution 0.6 mL for 90 mg, Single Dose ME1100 inhalation solution 3.0 mL for 450 mg, Single Dose
88953418|NCT01961843|Experimental|Abiraterone acetate with Prednisone|1000 mg Abiraterone daily by mouth, 4 x 250 mg tablets Prednisone administered as 5 mg orally twice a day
88953419|NCT01961856|Active Comparator|Ticagrelor|Ticagrelor 180mg loading dose
89204327|NCT00774020|Experimental|1|
89488833|NCT02441985|Experimental|Real rTMS Stimulation|rTMS will be delivered over each cerebellar hemisphere, using a 70mm figure-of-eight coil connected to a Magstim RapidStim2 machine while positioned 3 cm lateral to the inion on the line joining the inion and the external auditory meatus. 900 pulses will be delivered consecutively to each side with a frequency of 1 Hz and at an intensity of 90% of the resting motor threshold (RMT) for a total duration of 15 min for each cerebellar hemisphere. The RMT will be defined as the lowest stimulation intensity required to evoke a 50 μV potential in a target muscle. The inion will be taken as the boundary between the posterior cerebellum and the occipital cortex. Therefore the area stimulated will be caudal to the inion to stimulate the posterior cerebellum.
89488834|NCT02441985|Sham Comparator|Sham rTMS Stimulation|Patients randomized to receive sham treatment will undergo the same procedure for identifying stimulus location used in patients receiving real rTMS. Simulated rTMS will be administered using sham Magstim RapidStim2 Placebo which produces discharge noise and vibration similar to the real coil without stimulating the cerebral cortex. However, in addition to obvious coil discharge noise, rTMS also causes electrical stimulation of the scalp. The investigator will simulate this experience by attaching surface electrodes underneath the sham coil and in contact with the scalp. The investigator will use an electromyography to administer electrical shocks to the scalp simultaneous to each simulated rTMS train.
89488835|NCT04911374|Other|Anti-Aging Face Moisturizer and Eye Cream|"Dual Regimen:~Multi-ingredient anti-aging face moisturizer~Multi-ingredient anti-aging eye cream"
89488836|NCT04923074||DTI group|the patient in this group will receive DTI evaluation
89488837|NCT04923074||routine group|the patient in this group will receive routine evaluation
89021796|NCT00339014|Active Comparator|Group 6|Zonisamide SR 360 mg/day plus Bupropion SR 360 mg/day
89488838|NCT02437773|Active Comparator|Cognitive Behavioral Therapy - Adolescents|12 Cognitive-Behavioral Therapy sessions scheduled weekly over a 12-week period.
89488839|NCT02437773|Other|Stress Management Therapy - Adolescents|"12 SMT sessions scheduled weekly over a 12-week period.~After study completion, the OCD subjects who received SMT may derive benefit for non-OCD anxiety symptoms. They will be offered a 12-week course of CBT with a study therapist to directly target OCD symptoms (i.e., a partial cross-over)."
89488840|NCT02437773|Active Comparator|Cognitive Behavioral Therapy - Adults|12 CBT sessions scheduled weekly over a 12-week period.
89488841|NCT02437773|Other|Stress Management Therapy - Adults|"12 SMT sessions scheduled weekly over a 12-week period.~After study completion, the OCD subjects who received SMT may derive benefit for non-OCD anxiety symptoms. They will be offered a 12-week course of CBT with a study therapist to directly target OCD symptoms (i.e., a partial cross-over)."
89488842|NCT02437773|Other|Healthy Control - Adolescents|Healthy control adolescents matched to gender, race and socioeconomic status (SES) with adolescent patients with OCD will be enrolled. These healthy adolescents will be scanned with fMRI before and after 12 weeks, but without any intervention (i.e., no therapy).
89488843|NCT02437773|Other|Healthy Control - Adults|Healthy control adults matched to gender, race and socioeconomic status (SES) with adult patients with OCD will be enrolled. These healthy adults will be scanned with fMRI before and after 12 weeks, but without any intervention (i.e., no therapy).
89488844|NCT02437773|Other|Optional CBT - Adolescents|OCD adolescent participants who were randomized to the SMT and have completed all study procedures will be offered an additional 12 weeks of Optional Cognitive-Behavioral Therapy.
89488845|NCT02437773|Other|Optional CBT - Adults|OCD adult participants who were randomized to the SMT and have completed all study procedures will be offered an additional 12 weeks of Optional Cognitive-Behavioral Therapy.
89021797|NCT00339014|Placebo Comparator|Group 7|
89021798|NCT04715828||"control arm fresh"|Fresh semen treated without irradiation before cryopreservation
89021799|NCT04715828||"control arm cryopreserved"|cryopreserved semen without irradiation (n=60)
89488846|NCT02342548|Experimental|20 mg BID PF-02545920 non-titrated|Subjects who received 20 mg BID in completed study A8241021 will continue to receive 20 mg BID PF-02545920
89488847|NCT02342548|Experimental|20mg BID PF-02545920 titrated|Subjects who received either Placebo or 5mg BID of PF-02545920 in completed study A8241021 will be titrated up to 20 mg with 5mg increment per week, over 4 weeks (5mg increment/wk)
89488848|NCT04911296|Other|Swallow Group|
89488849|NCT02437617||Control Group #1|Participants who have had tumor molecular analysis performed with the similar clinical characteristics and genomic aberrations but who receive therapy not matched to their aberrations, or who have received results from Foundation Medicine that fail to demonstrate any molecular alteration.
89488850|NCT02437617||Control Group #2|Participants from historical archives of MD Anderson, no older than two years, who received therapy not matched to their aberrations and are matched not only on the basis of the clinical characteristics, but also, as much as possible, on the basis of genomic aberrations.
89488851|NCT02437617||Matched Targeted Therapy Group|Participants with tumor aberrations who received matched targeted therapy.
89488852|NCT04431050||Suspected influenza or other respiratory viral infection.|"Any adult presenting to the Accident & Emergency department with influenza like illness or a febrile illness associated with symptoms such as cough, sore throat or rhinorrhoea, and for whom a respiratory viral screen is clinically indicated.~For the purposes of this study one nasal swab will be taken from consenting adults."
89488853|NCT03190161|Experimental|Schizophrenia Patients|Clinician verification diagnosis of Schizophrenia or Schizoaffective Disorder
89488854|NCT04913714|Active Comparator|Intervention|A district where the radio intervention will be broadcast.
89488855|NCT04913714|No Intervention|Control|A district where the radio intervention will not be broadcast.
89488856|NCT03189615|Experimental|Patients with mild hepatic impairment (Group1)|
89488857|NCT03189615|Experimental|Patients with moderate hepatic impairment (Group 2)|
89488858|NCT03189615|Experimental|Healthy subjects (Group 3)|
89488859|NCT04913558|Active Comparator|Traditional Treatment Arm|This group will consist of thirty employed lactating women suffering from stress and fatigue. This group will receive the same lifestyle modification advice that will be given to the aerobic exercise group during the six weeks of the program period.
89488860|NCT04913558|Experimental|Aerobic exercise group|This group will consist of thirty employed lactating women suffering from stress and fatigue. These women will perform aerobic exercise for 30 minutes for each session, 5 times per week, for 6 weeks in the form of treadmill training (60- 70% of HR max) and do some modifications of their routine by following lifestyle modification advice given to them during the 6 weeks of the program period.
89488861|NCT03142191|Experimental|CC-90001 400 mg PO QD|55 subjects will be randomized to CC-90001 400mg
89488862|NCT03142191|Experimental|CC-90001 200 mg PO QD|55 subjects will be randomized to CC-90001 200mg
88953420|NCT01961856|Experimental|Clopidogrel and Ticagrelor|Clopidogrel 600mg loading dose followed by a Ticagrelor 180mg loading dose 2 hours later
88953421|NCT01961895|Active Comparator|Intravenous patient-controlled analgesia|Intravenous morphine solution 0.2 mg / ml in PCA mode without basal infusion, 1mg bolus demand and lockout of 8 minutes.
88953422|NCT01961895|Experimental|Continuous lumbar plexus (LP) block analgesia|"Continuous lumbar plexus (LP) block analgesia. Continuous infusion of a solution of 0.1% bupivacaine in PCA mode, programmed at 8 ml / h.~Rescue bolus 5 ml and 30 minutes lockout"
88953423|NCT01961908|Experimental|12 mg Proellex|12 mg capsules, orally, once daily for 8 months, including off-drug interval
89488863|NCT03142191|Placebo Comparator|Placebo PO QD|55 subjects will be randomized to placebo
89488864|NCT03142191|Experimental|CC-90001 400 mg PO QD- Sub-Study|30 subjects will be randomized to CC-90001 400mg
89488865|NCT03142191|Placebo Comparator|Placebo PO QD- Sub-Study|15 subjects will be randomized to placebo
89488866|NCT04922996||Ongoing|Patients already on calcium dobesilate treatment
89488867|NCT04922996||New|Patients with approved indication for calcium dobesilate treatment but not already on treatment
89488868|NCT03056378|Experimental|Pooled RBCs|Transfusion of an investigational transfusion blood component: POOLED-RBCs Phenotype matched/ compatible for ABO, D, C, E, and K (blood type of pool will be match patient's type), leukoreduced, and irradiated
89021800|NCT04715828||acute irradiation at low dose|Pelvis scanning : acute irradiation (1 or 2 second) using low dose (n=30),
89021801|NCT04715828||long irradiation at low dose|Bone scintigraphy : long irradiation (3h) using low dose (n=30),
89488869|NCT03056378|Active Comparator|Standard RBCs|Transfusion of standard transfusion blood component: additive solution leukoreduced, irradiated RBC product Phenotype matched/ compatible for ABO, D, C, E, and K (blood type of pool will be match patient's type)
89488870|NCT04913480|Experimental|Durvalumab and stereotactic body radiation therapy|"Durvalumab 750mg intravenous infusion once every 2 weeks for 26 cycles, starting 1 week before commencement of stereotactic body radiation therapy~Stereotactic body radiation therapy of 27.5Gy to 50Gy in 5 fractions to the liver tumors delivered over 5 to 14 days"
89488871|NCT05233683|Experimental|Caudal block and circumcision with Plastibell,|Caudal block will be performed with 0.75ml/kg of 0.25% bupivacaine containing 1 mic/kg dexmedetomidine. Circumcision will be done using plastibell. Paracetamol suppository will also be inserted per rectum in the dose of 15 mg/kg before the start of surgery. The surgery will be started 10 minutes after block placement to allow adequate time for the block to be effective.
89488872|NCT05233683|Experimental|Caudal block and circumcision with conventional dissection method|Caudal block will be performed with 0.75ml/kg of 0.25% bupivacaine containing 1 mic/kg dexmedetomidine. Circumcision will be done using the conventional dissection method. Paracetamol suppository will also be inserted per rectum in the dose of 15 mg/kg before the start of surgery. The surgery will be started 10 minutes after block placement to allow adequate time for the block to be effective.
89488873|NCT05233683|Active Comparator|Dorsal penile nerve block plus ring block and circumcision with Plastibell|Dorsal penile nerve block plus ring block with 0.25% bupivacaine. Circumcision will be done using plastibell.
89488874|NCT05233683|Active Comparator|Dorsal penile nerve block plus ring block and circumcision with conventional dissection method|Dorsal penile nerve block plus ring block with 0.25% bupivacaine. Circumcision will be done using the conventional dissection method
89488875|NCT04922918|Experimental|Probiotic arm|Administration of Ligilactobacillus salivarius MP101 (>9 log10cfu, daily) for 4 months
89488876|NCT02441907|Other|aflibercept treatment|aflibercept, 40 mg/mL Solution for Intravitreal Injection
89488877|NCT04913090|Experimental|Part A-experimental|Single Ascending Dose (SAD) phase
89488878|NCT04913090|Placebo Comparator|Part A-placebo|Single Ascending Dose (SAD) phase
89021802|NCT04715828||long irradiation at medium dose|Radioactive Iodine 131 therapy (RAT) applied for thyroid cancer : long irradiation (3h) using medium dose (n=60),
89021803|NCT00445614|Experimental|Marine trout|150 g/day of trout fed on marine based feed
89488879|NCT04913090|Experimental|Part B-experimental|multiple ascending dose (MAD) phase
89488880|NCT04913090|Placebo Comparator|Part B-placebo|multiple ascending dose (MAD) phase
89488881|NCT04913090|Experimental|Part C1-experimental|Food Effect (FE) phase
89488882|NCT04913090|Experimental|Part C2-experimental|Food Effect (FE) phase
89488883|NCT02437461|Active Comparator|single dose 20 mg|Intraarticular injection of triamcinolone hexacetonide
89488884|NCT02437461|Experimental|single dose 40 mg|Intraarticular injection of triamcinolone hexacetonide
89488885|NCT04903886||All patient colonized with ESBL-E in Brest Intensive Care unit|All patient colonized with ESBL-E in Brest Intensive Care unit, in a 5 years period (2015-2019)
89021804|NCT00445614|Experimental|Vegetable trout|150 g/d of trout fed on vegetable based feed
89021805|NCT00445614|Other|Poultry|150 g/d of poultry (for comparison)
89021806|NCT00339092|Experimental|Treatment|Participants who receive storefront modified directly observed therapy (MDOT) of prescribed antiretrovirals
89021807|NCT00339092|Active Comparator|Control|Participants who receive standard care
89021808|NCT00425204|Experimental|Open Label|Dose received in previous studies will be rolled over to this study. These regimens include: 2.5 mg/kg weekly; 6.0 mg/kg every 2 weeks; and 9.0 mg/kg every 3 weeks.
89021809|NCT00451893|Active Comparator|Heavy-weight|Lichtenstein operation performed with a heavy-weight mesh.
89021810|NCT00451893|Active Comparator|Light-weight|Lichtenstein operation performed with a light-weight mesh.
89021811|NCT00339170|Experimental|1|Participants receive a 12-month cognitive enhancement training program plus a 12-month work therapy program.
89021812|NCT00339170|Active Comparator|2|Participants receive a 12-month work therapy program alone.
89021813|NCT00445809||1|High Risk population for developing AKI during/after CABG surgery.
89488886|NCT04910516|No Intervention|Control Group|The nurses in the control group were informed about the purpose of working in a quiet room. STAI-D, STAI-S, SUD, P19-S scales were filled face-to-face by the investigator after their informed consent was obtained. The scales were filled again by the researcher after a break of 7 (seven) days.
89488887|NCT04910516|Experimental|Experiment Group|In order to avoid bias in the intervention applied in our study, the experimental group was started after the control group was finished. The participants were informed about the purpose of working face-to-face in a quiet room so that EFT, which will be applied online for 7 (seven) days by the researcher, can be applied effectively and accurately. STAI-D, STAI-S, SUD, P19-S scales were completed after their consent was obtained. The researcher, who has the EFT certificate, first showed the application steps on himself with the guidance of the EFT guideline, and ensured that the application steps were applied again simultaneously on both himself and the participant. After this application, it was provided to make EFT online for 7 (seven) days. STAI-D, STAI-S, SUD, P19-S scales were filled in after the last EFT application.
89488888|NCT02441829|Experimental|Mild Renal Impairment (CLcr 60-89 mL/min)|Participants with mild renal impairment and matched control participants with normal renal function will receive a single dose of eleclazine 30 mg (5 x 6 mg tablets).
88953424|NCT01961934|Experimental|Sodium Acetate C11 PET/CT Imaging|
89488889|NCT02441829|Experimental|Moderate Renal Impairment (CLcr 30-59 mL/min)|Participants with moderate impairment and matched control participants with normal renal function will receive a single dose of eleclazine 30 mg (5 x 6 mg tablets).
89488890|NCT02441829|Experimental|Severe Renal Impairment (CLcr 15-29 mL/min)|Participants with severe renal impairment and matched control participants with normal renal function will receive a single dose of eleclazine 30 mg (5 x 6 mg tablets).
89488891|NCT02441673|Active Comparator|Nefopam|"Premedication of IV (Intravenous)10mg Metoclopramide and 50mg Ranitidine would be given morning of surgery to all patients.~0.15mg/kg of Acupan(Nefopam) would be administered IV after the initiation of the subarachnoid block (Time 0) and presence and severity of shivering (the primary outcome) would be looked out for.~IV Ephedrine in 3mg alliquots would be given if hypotension occurs; IV oxytocin 30-50mg would be given after delivery of the baby to all patients and IV Pethidine 25mg would be given to abate any residual shivering if a repeat dose of Acupan is not satisfactory."
89488892|NCT02441673|Active Comparator|Tramadol|"Premedication of IV (Intravenous)10mg Metoclopramide and 50mg Ranitidine would be given morning of surgery to all patients.~1mg/kg of tramadol would be administered after the initiation of the subarachnoid block (Time 0) and presence and severity of shivering (the primary outcome) would be looked out for.~IV Ephedrine in 3mg alliquots would be given if hypotension occurs; IV oxytocin 30-50mg would be given after delivery of the baby to all patients and IV Pethidine 25mg would be given to abate any residual shivering if a repeat dose of Tramadol is not satisfactory."
89488893|NCT04910828|Experimental|Common foods of varying glycemic indices|Common foods of varying glycemic indices
89488894|NCT04910672|Active Comparator|Control Group|The control group (n = 30) will only carry out a bilateral global pelvic manipulation
89488895|NCT04910672|Experimental|Experimental Group|The experimental group (n = 30) will be treated following an osteopathic treatment, through a bilateral global pelvic manipulation and a specific internal technique for mobility of the cervix
89488896|NCT02437539|Experimental|68Ga-NOTA-AE105 PET|One injection of 68Ga-NOTA-AE105 (app. 200 MBq) followed by 3 PET/CT scans 10 minutes, 1 hour and 2 hours post injection
89488897|NCT02437227|Experimental|Experimental: CCT3833|The starting dose of CCT3833 is 20 mg, taken as two 10 mg capsules. The starting schedule is a once daily continuous dosing schedule, but other dosing regimens may be considered depending on tolerability and exposures.The first dose of continuous dosing defines Cycle 1 Day 1. All treatment cycles have a duration of 28 days.
89488898|NCT04910126|Experimental|experiment group|adriamycin and Camrelizumab
89488899|NCT04910126|Active Comparator|control group|adriamycin
89488900|NCT02441361|No Intervention|control|Subjects will undergo bariatric surgery and no exercise training will be prescribed.
89488901|NCT02441361|Experimental|exercise training|Subjects will undergo bariatric surgery and exercise training will be prescribed.
89488902|NCT04909892|Experimental|COVI-MSC 1 vial|Subjects will receive intravenous infusions of COVI-MSC (one vial, ~18.5 million cells) on Day 0, Day 2, and Day 4.
89488903|NCT04909892|Experimental|COVI-MSC 2 vials|Subjects will receive intravenous infusions of COVI-MSC (two vials, ~37 million cells) on Day 0, Day 2, and Day 4.
89488904|NCT02436837|Active Comparator|young|20 to 30 years old individuals used as a comparator for elderly group
89488905|NCT02436837|Experimental|elderly|target of treatment to improve the balance.
89488906|NCT04922450|Experimental|Camrelizumab，albumin paclitaxel and cisplatin.|Participants will be given intravenous administration of Camrelizumab (200mg)，Albumin Paclitaxel(260mg/m²) and Cisplatin（80mg/m²）,After completing three times every three weeks of neoadjuvant therapy, The Participants will undergo surgery and Postoperative intensity modulated chemotherapy. The duration of treatment will till death, or unacceptable toxicity show up.
89488907|NCT04903808|Experimental|Allium sativum oil|The pulp stumps of the molars are dressed with a cotton pellet that is made damp with Allium Sativum oil for 1 min .
89488908|NCT04903808|Active Comparator|Mineral Trioxide Aggregate|The material will be prepared according to the manufacturer's instructions , applied to the pulp chamber and a moistened cotton pellet was placed over the MTA paste to allow the material to set.
89488909|NCT03189537|Experimental|Ingavirin|Ingavirin (Imidazolyl Ethanamide Pentandioic Acid) capsules, 90 mg once daily for 7 days
89488910|NCT03189537|Placebo Comparator|Placebo|Placebo oral capsule, once daily for 7 days
89488911|NCT03052478|Experimental|vismodegib arm|. Vismodegib 150 mg will be administered orally once a day for 21 days as one cycle.
89488912|NCT04922372|Experimental|intervention arm copping veneered with composite resin|
89488913|NCT04922372|Active Comparator|control arm copping veneered with manual layering|
89488914|NCT03054272||Residents|Anesthesia residents from University of Montreal Anesthesia Department who were watching the video
89488915|NCT03054272||Attending Physicians|Attending physicians from University of Montreal Anesthesia Department who were watching the video
89488916|NCT03054194|Experimental|Cohort 1: Dose 1 E2730|Participants will receive Dose 1 of oral E2730 on Day 1.
89488917|NCT03054194|Placebo Comparator|Cohort 1: Matching placebo|Participants will receive matching oral placebo on Day 1.
89488918|NCT03054194|Experimental|Cohort 2: Dose 2 E2730|Participants will receive Dose 2 of oral E2730 on Day 1.
89488919|NCT03054194|Placebo Comparator|Cohort 2: Matching placebo|Participants will receive oral matching placebo on Day 1.
89488920|NCT03054194|Experimental|Cohort 3: Dose 3 E2730|Participants will receive Dose 3 of oral E2730 on Day 1.
89488921|NCT03054194|Placebo Comparator|Cohort 3: Matching placebo|Participants will receive oral matching placebo on Day 1.
89488922|NCT04922684|Active Comparator|Lower austic sub-group|16 times of mimicking emotional expressions
89488923|NCT04922684|Experimental|Higher austic sub-group|16 times of mimicking emotional expressions
89488924|NCT04922528|Experimental|Near-Infrared Fluorescence Cholangiography|Standard laparoscopic cholecystectomy completed with a combination of white light imaging and near-Infrared fluorescence cholangiography after administering 5 mg of a 25 mg/10 mL solution of indocyanine green (ICG) intravenously prior to the operation
89488925|NCT04922528|Active Comparator|White Light Imaging|Standard laparoscopic cholecystectomy completed with only standard white light imaging only
88953425|NCT01961947|Experimental|ASP7374 group|
88953426|NCT01961947|Active Comparator|TIV group|
88953427|NCT01961960|Experimental|ASP7374 group|
89204328|NCT04100447|Experimental|Treatment Arm|All subjects will receive 1 dose of study drug (split into 2 administrations), over the 12 hours prior to surgery.
89204329|NCT03274804|Experimental|Single arm, prospective, open-label trial|Eligible subjects will receive pembrolizumab beginning on Day 1 of each 3-week dosing cycle (d1, qd22) together with maraviroc administered perorally on day 1 to 21 of each cycle (d1-21; qd22).
88953428|NCT01961973|Active Comparator|Cultured chondrocytes|"Cultured chondrocytes:~This method has two stages. In the first stage, a knee arthroscopy is done to harvest viable cartilage cells which are then sent to a lab to be cultured for 6 weeks. In the second stage, an arthrotomy is performed. The area of cartilage deficiency is prepared and the cultured cells are transplanted onto it. After discharge from the hospital, the patient is advised partial weight bearing on the operated leg for 6 weeks after the surgery."
88953429|NCT01961973|Active Comparator|Cultured BMAC|This method also has two major stages. The first stage involves harvesting BMAC from the patient's iliac crest (hip bone), which are then sent to the laboratory for culture for 3 weeks. Simultaneously, an arthroscopy is performed on the affected knee and the area of cartilage deficiency is debrided and microfractured. In the second stage, the cultured BMAC are injected into the affected knee and cells attach themselves to the microfractured area. The patient is then recalled at 4, 5 and 6 weeks from the first stage for an injection of Hyaluronic Acid into the operated knee.
88953430|NCT01961999|Active Comparator|Early RRT|"In the early arm renal replacement therapy was started on the basis of refractory oliguria: urine output <0,5ml/Kg/h for > 6 hours"
88953431|NCT01961999|Active Comparator|Late RRT|"In the late arm at least one the following criteria must be fulfilled prior to initiation of renal replacement therapy:~persistent and refractory oliguria (<0,5 ml/Kg/h >12h), despite therapy~refractory extravascular fluid overload~azotemia > 40mmol/L or 240 mg/dL~metabolic acidosis (pH<7,2)~hyperkaliemia (k+>6 mmol/L)"
88953432|NCT01962012|Experimental|AcceleDent Aura|AcceleDent Aura device provides a light vibration at 0.25 Newtons and 30 Hz frequency for 20 minutes daily.
88953433|NCT01962012|Sham Comparator|Sham Device|Sham devices will look identical to active devices but will not deliver vibration to the patient.
88953434|NCT01962038|Active Comparator|Combined Aerobic and Resistance Exercise/Cognitive Training|
88953435|NCT01962038|Active Comparator|Stretching Exercises/Cognitive Training|
88953436|NCT01962051||Delivery system Entry|
88953437|NCT01962064|Experimental|Semantic demantia|cognitive assessment and Brain imaging examination MRI of patient with the semantic variant of primary progressive aphasia
88953438|NCT01962064|Experimental|Frontotemporal dementia|cognitive assessment and Brain imaging examination MRI of patients with the behavioral variant of frontotemporal lobar degeneration
89204330|NCT00770198||alcoholic liver disease|alcoholic liver disease patients undergoing a transjugular liver biospy in our institution
89488926|NCT04909814||Vaccinated women with positive screening test|All women in one Swedish county taking their first screening test within the organized cervical screening program
89488927|NCT04909736|Experimental|Music Exposure|Patient will listen to a specified duration of music.
89488928|NCT04894136||ICSI-TESE cycles for obstructive azoospermia|Couples who underwent ICSI-TESE cycles for obstructive azoospermia between January 2001 and December 2019 at Humanitas Fertility Center
89488929|NCT04894136||ICSI-TESE cycles for nonobstructive azoospermia|Couples who underwent ICSI-TESE cycles for nonobstructive azoospermia between January 2001 and December 2019 at Humanitas Fertility Center
89488930|NCT04397198||HIBRIDH-SG 01|Study subjects with documented ST segment Elevation Myocardial Infarction
89488931|NCT03053726|Experimental|Variable Frequency Stimulation|Subjects in this group received variable frequency stimulation of deep brain stimulation
89488932|NCT03053726|Sham Comparator|Constant Frequency Stimulation|Subjects in this group received constant frequency stimulation of deep brain
89488933|NCT04893980|Experimental|Low-dose interleukin-2 treatment group|Use Interleukin-2 to treat CSU during day1-day28.
89488934|NCT04893980|Other|Control group|Use Interleukin-2 to treat CSU during day15-day28.
89488935|NCT04149470|Experimental|Omeprazole|Participants will receive high dose PPI therapy (Omeprazole 20mg twice daily) and will be evaluated for histological improvement.
89488936|NCT04430816|Active Comparator|modified chevrel technique|22 participant with large midline incisional hernia underwent repair by double mesh modification of chevrel's technique
89488937|NCT04430816|Active Comparator|ON LAY mesh hernioplasty|21 participant with large midline incisional hernia underwent repair by online mesh hernioplasty
89488938|NCT04902716|Experimental|Precision Nursing, Frail women, Cognitive function, Sleep quality, Emotional state,|According to the characteristics of the elders in the community and making good use of health policies and local resources, a 12-week appropriate diversified curriculum is arranged as intervention measures.
89488939|NCT04894058|Active Comparator|10 ° reverse Trendelenburg|Patients who underwent ureteroscopic lithotripsy in the 10 ° reverse Trendelenburg position
88953439|NCT01962064|Experimental|Elderly|cognitive assessment and Brain imaging examination MRI of healthy elderly subjects
88953440|NCT01962064|Experimental|Young|cognitive assessment and Brain imaging examination MRI of young subjects
89488940|NCT04894058|Active Comparator|20 ° reverse Trendelenburg|Patients who underwent ureteroscopic lithotripsy in the 20 ° reverse Trendelenburg position
89488941|NCT04894058|Sham Comparator|Standard lithotomy|Patients who underwent ureteroscopic lithotripsy in standard lithotomy position
89488942|NCT04894292||Adenomyosis Group|
89488943|NCT04894292||Non-adenomyosis Group|
88953441|NCT01962077|Experimental|MedCem MTA pulpotomies|
88953442|NCT01962090|Experimental|Thoracic Spine Thrust in Seated Position|Thoracic spine thrust manipulation will be applied two times at each of two treatment sessions while the participant is in a seated position.
88953443|NCT01962090|Experimental|Thoracic Spine Thrust in Supine Position|Thoracic spine thrust manipulation will be applied two times at each of two treatment sessions while the participant is in the supine position.
88953444|NCT01962116|Placebo Comparator|Heparin lock|
88953445|NCT01962116|Experimental|Citrate lock|
88953446|NCT01962129||Patients affected by a syndrome OFD|
88953447|NCT01962129||Patients AFFECTED BY A SEVERE MENTAL RETARDATION SYNDROMIQUE|
88953448|NCT01962142||Exacerbated asthma patients|
88953449|NCT01962155||chronic infected with hepatitis B virus|patients infected with hepatitis B virus for at least 6 months and agreed with liver biopsy
88953450|NCT01962168||Evolution® Biliary Stent - Uncovered|
88953451|NCT01962181|Active Comparator|Ritalin|Ritalin treatment at different doses
88953452|NCT01962181|Placebo Comparator|Placebo|Two meetings, one of which will be given a placebo and the other will be given a low dose of Ritalin, randomly.
88953453|NCT01962194|Experimental|PD and OCD paients for DBS intervention|Parkinson's disease (PD; n=5) and obsessive-compulsive disorder (OCD; n=5) patients that are candidates for treatment with STN DBS will be recruited over a period of two years.
88953454|NCT01962220|No Intervention|Standard of Care|"Routine ANC, Delivery and Postpartum Care: All consenting women will receive routine ANC/Delivery and Postpartum care offered to pregnant women in Kenya as per national guidelines at the MCH of the respective facility.~Routine PMTCT and HIV Care: All newly diagnosed HIV-infected pregnant women are enrolled into HIV care in the MCH and receive PMTCT/HIV care per Kenya national guidelines (Revised 2012 PMTCT Guidelines)."
88953455|NCT01962220|Experimental|Study Intervention for Retention (APFU)|Participants randomized to the experimental arm of the study will receive routine antenatal and HIV services as described above per Kenya national guidelines. In addition each newly identified HIV-infected pregnant woman randomized to the experimental arm will be assigned an outreach worker/counselor (Mama Mshauri), who will perform numerous tasks described in the intervention. In addition to the Mama Mshauri, this arm will receive phone/SMS appointment reminders, and default patient tracking if participants miss an appointment.
88953456|NCT01962233|Experimental|mesenchymal stem cells|Umbilical Cord Derived Mesenchymal Stem Cells at a dose of 100-800 million by intravenous infusion
89488944|NCT04893902|Active Comparator|conventional ear impression|
89488945|NCT04893902|Experimental|digital auricular impression without marker using intra oral scanner|
89488946|NCT04893902|Experimental|digital auricular impression with marker using intra oral scanner|
89488947|NCT04902638|Active Comparator|Diabetic patients with steroid|
89488948|NCT04902638|Placebo Comparator|Diabetic patients without steroid|Injection of normal saline
89488949|NCT04902638|Active Comparator|Pre-diabetic patients with steroid|
89488950|NCT04902638|Placebo Comparator|Pre-diabetic patients without steroid|Injection of normal saline
89488951|NCT04902638|Active Comparator|Non-diabetic patients with steroid|
89488952|NCT04902638|Placebo Comparator|Non-diabetic patients without steroid|Injection of normal saline
89488953|NCT04893746|Placebo Comparator|Placebo|
89488954|NCT04893746|Experimental|TWK10-L|Low dose
89488955|NCT04893746|Experimental|TWK10-H|High dose
89488956|NCT03053882|Active Comparator|green tea and peppermint|
89488957|NCT03053882|Active Comparator|peppermint and green tea|
89488958|NCT03053804|Experimental|MR/PET|hypothesize that MR/PET can have better information than current CT image study
89488959|NCT02617628|Active Comparator|Before Re-entry|Extended Release Naltrexone, 380 mg injection, 1x monthly for 4 months
88953457|NCT01962259|Experimental|Vigorous intensity LTPA|Leisure time physical activity (LTPA): Exercise intensity: 70% of maximal oxygen uptake (VO2 max); Energy expenditure: Females: 1600 kcal/week; Males: 2100 kcal/week
88953458|NCT01962259|Experimental|Moderate intensity LTPA|Leisure time physical activity (LTPA): Exercise intensity: 50% VO2 max; Energy expenditure: Females: 1600 kcal/week; Males: 2100 kcal/week
88953459|NCT01962259|Experimental|Active commuting|Bicycling to/from work/school/university. No requirements for exercise intensity; Energy expenditure: Females: 1600 kcal/week; Males: 2100 kcal/week; Avg distance per day Females 9-15 km; Males 11-17 km
88953460|NCT01962259|No Intervention|Control|Receives no intervention.
88953461|NCT01962272|Experimental|Nutritional counseling and Forticare®|Weekly nutritional counseling and Forticare®. The goal being an intake that met the protein and energy requirements according to Harris-Benedict equation multiplied with an individual activity factor (1,1-1,5) and a stress factor (1,0-1,1). Daily protein requirements were estimated to 1,5 g/kg per day. In addition to the counseling, the patients in the intervention group were offered a high-protein nutrition supplement containing n-3 fatty acids (Forticare®, Nutricia). The recommended daily dose contained 2531 kJ, 33.8 g protein and 2.2 g EPA.
88953462|NCT01962272|Active Comparator|Control|"The control group was nutritionally instructed by the nurses with the possibility to call for a dietician not related to the study if needed. No fixed schemes.~Apart from the nutritional element the patients had the same care and therapy, including treatment of pain and side-effects to the treatment."
89204331|NCT00770198||chronic HCV hepatitis|chronic HCV hepatitis patients undergoing a transjugular liver biopsy in our institution
89204332|NCT05493449|No Intervention|Control Group|In this group, no milk (intervention) was provided
89204333|NCT05493449|Experimental|UHT Milk|In this group, UHT Milk intervention was provided
89204334|NCT05493449|Experimental|Flavored Milk|In this group, flavored milk was provided to participants
89204335|NCT00774098|Placebo Comparator|Control Group|Intravenous normal saline (NS 0.9) started just before induction, and titrated to hemodynamic parameters and urine output
89204336|NCT00774098|Experimental|GICP|
89204337|NCT00761891|Experimental|Chewable aspirin|81 mg daily for 2 weeks
89204338|NCT00777842|Experimental|1|Device
89204339|NCT00774176||1|Phase 1 & Gene Expression:Hospitalized COPD exacerbators
89204340|NCT00774176||2|Phase 2: COPD group
89204341|NCT00774176||3|Genetic Association Studies: COPD and Healthy Controls
89204342|NCT04002076|Experimental|Robot-assisted hand combined with occupational therapy|Ten participants in group A will undergo robot-assisted hand (with visual feedback) combined with occupational therapy. They will receive 60 minutes a day and 3 days a week robot-assisted hand and occupational therapy for six weeks.
89204343|NCT04002076|Active Comparator|Traditional occupational therapy|Another 10 participants allocated to the group B will receive 60 minutes a day and 3 days a week traditional occupational therapy for six weeks.
89204344|NCT00321685|Experimental|Treatment (bevacizumab and chemoradiotherapy)|See Detailed Description
89204345|NCT00778076|Active Comparator|HAG|Patients that will receive a Hyaluronic acid treatment course consisting of 3 consecutive injections one week apart.
89204346|NCT00778076|Placebo Comparator|PG|Those patients that receive 3 consecutive placebo injections one week apart.
89204347|NCT05196412|Experimental|Main study group|Normal subjects of at least 65 years of age
89204348|NCT05196412|Experimental|Endurance athlete group|Group consists of active endurance athletes of at least 50 years of age
89204349|NCT00779090|Experimental|Group A_RM|Patients with FRC after open endotracheal suctioning of more than 94% of baseline randomized to receive an alveolar recruitment manoeuvre.
89204350|NCT00779090|No Intervention|Group A_NRM|Patients with FRC after open endotracheal suctioning of more than 94% of baseline randomized to receive no alveolar recruitment manoeuvre.
89204351|NCT00779090|Experimental|Group B_RM|Patients with FRC after open endotracheal suctioning of less than 94% of baseline randomized to receive an alveolar recruitment manoeuvre.
89204352|NCT00779090|No Intervention|Group B_NRM|Patients with FRC after open endotracheal suctioning of less than 94% of baseline randomized to receive no alveolar recruitment manoeuvre.
89204353|NCT04002778|Active Comparator|ROSE by endosonographer|Submitted to fine-needle aspiration. Endosonographer's on-site evaluation of sample adequacy and categorization
89204354|NCT04002778|Other|non-ROSE|Submitted to fine-needle aspiration.
88953463|NCT01962285|Experimental|propofol slow infusion|"(healthy volunteers, non invasive monitoring and O2 supply via nasal cannula) Target controlled infusion of propofol using Schnider´s pharmacokinetic parameters in a slow, stepped fashion. beginning at Cp 0.5 mcg/ml and increasing in 0.5 mcg/ml every 7 minutes until LOC occurred, then a prolonged step of 14 minutes (2 samples), increase 2 steps further and then decrease in 0.5 mcg/ml steps until ROC and a 7 minute registry after ROC.~Blood sampling for propofol plasma level every 7 minutes (at the end of each step, allowing for pseudo-equilibrium condition.~32 channel-EEg and BIS continuous monitoring"
89204355|NCT01564342|Other|wounds irrigated with sterile normal saline|Patients in this arm had their wounds irrigated with sterile normal saline
89204356|NCT01564342|Other|wound irrigation with tap water|Patients in the arm had their wounds irrigated with tap water
89204357|NCT00779480|Experimental|KW-2449|Sequential dose escalation in separate cohorts of 3+3 design from 450 mg/day to 800 mg/day total daily dose.
89204358|NCT03902392|Active Comparator|NATUR-OX Group (A)|Administration, for three months (T1), of NATUR-OX® capsule/day. NATUR-OX® which is a dietary supplement containing grape seed extracts from Nero di Troia (Vitis vinifera). Each capsule contains 280 mg of proanthocyanidins where Ni contamination of capsule is below 0.24 ppm
89204359|NCT03902392|Placebo Comparator|Placebo Group (B)|Administration with placebo one capsule/daily for three months. The placebo capsules had the same appearance and composition of the supplement except for the active ingredient (polyphenols)
89204360|NCT00306787|Experimental|Famciclovir|Patients received Famciclovir 1000 mg (2 x 500 mg tablets) twice a day for one day. The first dose was to be taken within 6 hours after onset of prodromal symptoms or genital herpes lesions and the second dose approximately 12 hours later. Patients also received 1 valacyclovir placebo capsule, beginning with the first famciclovir dose, twice a day for 3 days, each taken about 12 hours apart.
89488960|NCT02617628|Active Comparator|After Re-entry|Extended Release Naltrexone, 380 mg injection, 1x monthly for 4 months
88953464|NCT01962311|Experimental|All patients|lumbar puncture
88953465|NCT01962350|Experimental|Active H1-Coil deep brain rTMS|"Deep Brain Transcranial Magnetic Stimulation~18Hz Active H1-Coil deep brain rTMS for 4-weeks over the cortex prefrontal. n=25"
89488961|NCT03053648|Experimental|Self-acupressure Group|Subjects in this group will attend two weekly 120-minute self-acupressure training sessions in a classroom at the School of Nursing, the Hong Kong Polytechnic University. The subjects will be instructed on how to perform the self-acupressure treatment by a trained instructor. To enhance interaction and ensure the quality of teaching, each course will be conducted in a small group of 6 participants. Subjects will perform self-acupressure daily for 4 consecutive weeks.
89488962|NCT03053648|Active Comparator|Sleep Hygiene Education Group|To control the contact time with professional person in the treatment group, participants in this group will receive two sessions of 120-minute sleep hygiene training session. The participants will be asked to follow the health hygiene instructions daily for 4 consecutive weeks.
89488963|NCT03052244|Experimental|intervention tDCS+VI|The anode will be placed over C3-C4 (EEG 10/20 system) to target M1 and the cathode over the contralateral supraorbital area. The stimulation will apply to the hemisphere which contralateral to the more painful hemi body. 2mA will be delivered over 20 min via neuroConn DC stimulator combined with video presenting walking legs. A total of 10 sessions (5 per week) will be administrated at the same manner.
89488964|NCT03052244|Sham Comparator|tDCS Sham+VI Sham|The stimulation will be turned on for only short duration (up to 30 sec), the video film will contains graphical illustrations or nature movie without human movement.
89488965|NCT03053336|Experimental|App-technology group|"Participants in the intervention group (App-technology) will use a newly developed smartphone application (app) in which steps are automatically measured and laboratory values from blood sampling within primary care will be shown.~Intervention: App-technology to increase physical activity"
89488966|NCT03053336|No Intervention|Control group|The control group will receive standard care
89488967|NCT03053570|Experimental|Cryoballoon|
89488968|NCT03053570|Experimental|Radiofrequency Energy(Contact Force)|
89488969|NCT04893668||Exposed with COVID 19|The participant with confirmed RT-PCR Covid 19 at the beginning of the study
89488970|NCT04893668||Unexposed with COVID 19|The participant without confirmed RT-PCR Covid 19 at the beginning of the study until 6 month follow up period
89488971|NCT04893200||Lung adenocarcinoma|Imaging from patients with surgically treated lung adenocarcinoma were collected and processed for the construction of the radiomics-based prediction model
89488972|NCT03053414|Active Comparator|Treatment Arm # 1|50,000 IU oral vitamin D2 per week for 12 weeks + Dietary counseling
89488973|NCT03053414|Active Comparator|Treatment Arm # 2|50,000 IU oral vitamin D2 per week x 12 weeks then 800 IU/day oral vitamin D3 for 6 months + Dietary counseling
89488974|NCT03053414|Active Comparator|Treatment Arm # 3|50,000 IU oral vitamin D2 per week x 12 weeks then 5,000 IU/day oral vitamin D3 for 6 months+ Dietary counseling
88953466|NCT01962350|Experimental|Sham H1-Coil deep brain rTMS|"Deep Brain Transcranial Magnetic Stimulation~Sham H1-Coil deep brain rTMS for 4-weeks over the cortex prefrontal. n=25"
88953467|NCT01962363|Experimental|EPI-743|EPI-743, oral, 400mg three times daily for 3 months
89488975|NCT03053414|Active Comparator|Treatment Arm # 4|5,000 IU oral daily vitamin D3 for 9 months + Dietary counseling
89488976|NCT03053258||Diagnostic Breath Analysis: VAP|Collection of exhaled breath samples
89488977|NCT03053024||Cohort 1: Relapse/refractory MCL (rrMCL ) Participants|Participants characteristics and treatment pattern of relapsed/refractory mantel cell lymphoma [rrMCL]) participants treated by Bortezomib (BTZ) will be observed for cohort 1.
89488978|NCT03053024||Cohort 2: Newly Diagnosed MCL Participants|Participants characteristics and treatment pattern of newly diagnosed MCL participants (if more than 20% of total BTZ-treated MCL) will be analysed for cohort 2.
89488979|NCT04892810||RFA|Patient with HCC and decision of treatment with ablation
89488980|NCT04892810||MWA|Patient with HCC and decision of treatment with ablation
89488981|NCT02308540|Experimental|Adult SIILPCV10|Single dose of SIILPCV10 on day 0
88953468|NCT01962376|Active Comparator|Bevacizumab,postoperative chemotherapy|"Groups 1 drug: Oxaliplatin;Capecitabine;Bevacizumab A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk、Oxaliplatin 130 mg/m2 D1 q3wk add and subtract. Bevacizumab 7.5mg/kg D1 q3wk.Evaluation for every two cycles.~Groups 2 drug: Oxaliplatin;Capecitabine A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk、Oxaliplatin 130 mg/m2 D1 q3wk.Evaluation for every two cycles.~placebo:Physiological saline"
89488982|NCT02308540|Active Comparator|Adult Pneumovax 23|Single dose of Pneumovax 23 on day 0
89488983|NCT02308540|Experimental|Toddler SIILPCV10|Single dose of SIILPCV10 on day 0
89488984|NCT02308540|Active Comparator|Toddler Prevenar 13|Single dose of Prevenar 13 on day 0
89488985|NCT02308540|Experimental|Infants SIIL PCV10|A three-dose series of SIILPCV10 on day 0, day 28, and day 56
89488986|NCT02308540|Active Comparator|Infants Prevenar 13|A three-dose series of Prevenar 13 on day 0, day 28, and day 56
89488987|NCT02308540|Experimental|Infant Booster Dose SIILPCV 10|One dose of SIILPCV 10 at 9 months of age
89488988|NCT02308540|Active Comparator|Infant Booster Dose Prevenar 13|One dose of SIILPCV 10 at 9 months of age
89488989|NCT04909580|Experimental|decision coaching|Decision coaching with a patient decision aid guided by the Ottawa Decision Support Framework
89488990|NCT04893044|Experimental|Exposure|These participants watched a 3 minute long video prior to a long weekend. The intent was to see if watching the video altered their alcohol consumption compared to a group that did not watch the video. Urine alcohol metabolites were measured before and after the weekend.
89488991|NCT04893044|No Intervention|Control|These participants did not watch a video, and their urine alcohol metabolites were measures at the same dates as the exposure group above.
89488992|NCT04909658|Experimental|ACT matrix protocol|Parents of childrens with Autism Spectrum Disorders (ASD). The ACT protocol group received exercises to improve the psychological well-being of the parents.
89488993|NCT04909658|Active Comparator|PT protocol|Parents of childrens with Autism Spectrum Disorders (ASD).
89488994|NCT04892576|Active Comparator|Control group|Participants in this group received the standard physical rehabilitation program.
89488995|NCT04892576|Experimental|SSC group|Participants in this group received the standard physical rehabilitation program as the control group in addition to the SSC exercise program
89488996|NCT04909268||Patients with positive pneumococcal antigenuria|
89488997|NCT04909034|Experimental|MS-20 oral solution|Oral Solution 8 c.c per day divided twice daily (BID) for 48 weeks.
89488998|NCT04909034|Placebo Comparator|Placebo|Oral Solution 8 c.c per day divided twice daily (BID) for 48 weeks.
89488999|NCT04901780|Experimental|PPCS|Novel intervention
89489000|NCT04901780|Active Comparator|CBS|Cross arm stretch gave to individuals
89489001|NCT02308228|Experimental|Metformin|Participants will be randomized to receive Metformin (1700 mg/day) for a period of 16 weeks; 2 weeks of Metformin only followed by 14 weeks of continued Metformin use in combination with progressive resistance training.
89489002|NCT02308228|Placebo Comparator|Placebo, Sugar Pill|Participants will be randomized to receive placebo sugar pills (1700 mg/day) for a period of 16 weeks; 2 weeks of placebo only followed by 14 weeks of continued placebo use in combination with progressive resistance training. Placebos will be almost identical to the Metformin medication.
89489003|NCT04901000||Carotid Endarterectomy under Local Anaesthetic Pre-CABG|Patients that underwent carotid endarterectomy under local anaesthetic prior to coronary artery bypass operations in staged fashion within 6 months.
89489004|NCT04901000||Carotid Endarterectomy under General Anaesthetic Pre-CABG|Patients that underwent carotid endarterectomy under general anaesthetic prior to coronary artery bypass operations in staged fashion within 6 months.
89489005|NCT03051932|Active Comparator|Ofiramev®( IV Acetaminophen)|Patients randomized to the treatment arm will receive 1 g (100 mL) intravenous acetaminophen infused over 15-minutes every 6 hours for 4 doses total.
89489006|NCT03051932|Placebo Comparator|Placebo IV administration|Patients randomized to the placebo arm will receive 100 mL of normal saline infused over 15 minutes every 6 hours for 4 doses total
89489007|NCT04900610|Active Comparator|Vitamin K2|1mg/day per os
89489008|NCT04900610|Placebo Comparator|Placebo|matching placebo
89489009|NCT04908566|Experimental|PD-1 antibody combined with FOLFIRINOX regimen|
88953469|NCT01962376|Experimental|Preoperative Chemotherapy|"Groups 1 drug: Oxaliplatin;Capecitabine;Bevacizumab A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk、Oxaliplatin 130 mg/m2 D1 q3wk add and subtract. Bevacizumab 7.5mg/kg D1 q3wk.Evaluation for every two cycles.~Groups 2 drug: Oxaliplatin;Capecitabine A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk、Oxaliplatin 130 mg/m2 D1 q3wk.Evaluation for every two cycles.placebo:Physiological saline"
88953470|NCT01962389|Experimental|Winsor Laser Catheter|
89489010|NCT04908566|Active Comparator|PD-1 antibody combined with SOX program|
89489011|NCT03052946|Active Comparator|Bulking agent|Bulking agent in fecal incontinence
89489012|NCT03052946|Placebo Comparator|Endoanal electrostimulation|Endoanal electrostimulation in fecal incontinence
89489013|NCT03052868|Other|Data Collection|The study visit will be scheduled for three to six months after completing adjuvant chemotherapy treatment. At the study visit, informed consent will be obtained and neurocognitive attention testing will be performed. The assessments chosen were carefully selected based on breadth, psychometric properties, standardized broad clinical use, good external validity and time efficiency. The testing time for the battery of neuropsychological tests is approximately 45-60 minutes. Participants will also be asked to complete a packet of several questionnaires including several self-rated measures of mood and quality of life, in addition to a brief questionnaire to obtain information about exercise, sleep, and education and employment backgrounds. It is estimated that questionnaire completion will require no more than 30 minutes. Participants will be seen on only one occasion, and may receive, upon request, written feedback about the results of the evaluation.
89489014|NCT03052790|Active Comparator|manually instrumented total knee arthroplasty|Manually instrumented implantation of a total knee prosthesis involves use of cutting guides or jigs that are secured to the femur and the tibia. The femoral guide is secured to the femur after an intramedullary referenced guide is placed into the femur and the rotational alignment is then assessed with use of the epicondylar axis. An extra-medullary tibial alignment guide will be used to create the tibial cut.
88953471|NCT01962402|Experimental|Lorcaserin with intensive diet counseling|Patients will be taking lorcaserin 10mg tablet by mouth twice daily. In addition, patients will be provided with intensive dietary counseling to promote weight loss.
88953472|NCT01962454|Experimental|Arm 1|Run-in Phase: All participants will receive oral deuterated water (D2O) for 3 weeks prior to the Treatment Phase of the study. The participants will consume 50mL 70% D2O three times per day (TID) for 7 days, followed by a 50ml 70% D2O dose twice daily (BID) for the next 2 weeks. Treatment Phase: Subjects will receive testosterone matching placebo IM injection one per week and 50 mL 70% D2O dose BID for 3 weeks.
89489015|NCT03052790|Experimental|robotic assisted total knee arthroplasty|Robotically assisted surgery is used in conjunction with the preoperative CT scan and intra-operative bony registration of the patient's knee. Femoral and tibial trackers are placed and then the bone is registered using bony landmarks to allow the computer and robot to know where the patients' femur and tibia are in space. Once this is complete the preoperative templated surgical plan (performed by the PI) is used to register where to make the bony cuts in order to implant the knee components. The cutting process is performed by the surgeon with the robot assisting in guiding the cuts based on the registered CT anatomy. The surgeon has complete control of the cutting process with the assistance of the robot for placement of the cuts.
89489016|NCT04892654|Experimental|Immediate Switch|Two-pill regimen, doravirine (100 mg) + dolutegravir (50 mg) tablets taken orally once daily for 96 weeks.
89489017|NCT04892654|Other|Delayed Switch|Participants will continue their current triple cART regimen for 48 weeks. Patients will then be switched to two-pill regimen, doravirine (100 mg) + dolutegravir (50 mg) tablets taken orally once daily for 48 weeks.
89489018|NCT04900142|Experimental|1500 mW|1500 mW of Power
89489019|NCT04900142|Active Comparator|1000 mW|Standard treatment, 1000 mW
89489020|NCT03052166||Cohort A|The group of asymptomatic subjects who have been given BI-RADS 1 or 2 based on their most recent standard of care assessment. All subjects will receive a QT Ultrasound scan.
89489021|NCT03052166||Cohort B|The group of asymptomatic women who have been given BI-RADS categories 4 or 4a, 4b, 4c or 5 based on their most recent standard of care assessment. All subjects will receive a QT Ultrasound scan.
89489022|NCT03052166||Cohort C|The group of women who have been given BI-RADS categories 1, 2, 3, 4 or (4a, 4b, 4c), 5 or 6 based on their most recent standard of care assessment. All subjects will receive a QT Ultrasound scan. Subjects are assigned to Cohort C when it has been determined they cannot be assigned to Cohort A or Cohort B.
89489023|NCT04892030|Experimental|Intervention|All participants will be prescribed a non-energy-restricted whole food plant-based diet and will learn behavioral weight loss strategies remotely, through an e-learning platform.
89489024|NCT04892108|Experimental|Group STARR|Patients undergoing transanal prolassectomy with mechanical stapler (STARR: Stapled Trans Anal Rectal Resection) randomly
89489025|NCT04892108|Experimental|Group LVR|Patients undergoing Laparoscopic suspensory correction of rectal prolapse by ventral rectopexy with biological prosthesis (LVR) randomly
89489026|NCT04891874|Experimental|SBRT group|Participants in SBRT group will receive SBRT as adjuvant radiotherapy for hepatocellular carcinoma with microvascular invasion and narrow resection margin.
89489027|NCT04891874|No Intervention|Surgery alone group|Participants in surgery alone group will not receive any adjuvant therapy after surgery for hepatocellular carcinoma.
89489028|NCT04899674|Experimental|Bupropion (Reference, R) - BI 1358894 + Bupropion (Test, T)|
89489029|NCT04891562|Experimental|pDCD (hildren with (probably) Developmental Coordination Disorder)|children with (probably) Developmental Coordination Disorder (pDCD)
89489030|NCT04891562|Active Comparator|TDC (Typically Developing Children)|Typically Developing Children
89489031|NCT04890782||MMD group|Consecutive patients diagnosed with MMD during hospitalization in Beijing Tiantan Hospital, Capital Medical University will be recruited.
89489032|NCT04890782||Healthy control group|Age and sex matched subjects will be invited to join the study as the control.
89489033|NCT03051854|Experimental|ICC-T|Intervention: Interaction Competencies with children - for teachers (ICC-T) 5.5 days with 8 hours of training for teachers. Core training components include teacher-student interaction, maltreatment prevention, effective discipline strategies, identifying and supporting burdened students and implementation of the training materials into the school setting
89489034|NCT03051854|No Intervention|Control schools|The control school do not receive any intervention.
88953473|NCT01962454|Placebo Comparator|Arm 2|Run-in Phase: All participants will receive oral D2O for 3 weeks prior to the Treatment Phase of the study. The participants will consume 50 mL 70% D2O TID for 7 days, followed by a 50mL 70% D2O dose BID for the next 2 weeks. Treatment Phase: Subjects will receive testosterone IM injection one per week and 50 mL 70% D2O dose BID for 3 weeks
88953474|NCT01962467|Experimental|Arm 1|Each subject will receive 7 once daily doses of one of the 3 treatments (FF/LEV FDC or FF or LEV) administered as two 50 µL sprays per nostril in the morning, during each of the 3 treatment periods, as per one of the 6 possible randomization sequences. Each treatment period will be separated by a minimum washout period of 14 days
88953475|NCT01962480|Active Comparator|sutured closure of the hernia gap|The hernia gap is sutured intracorporally
89489035|NCT04908098|Experimental|Laser group|Root-planning was performed using Gracey curettes in the areas where periodontal pockets were diagnosed after scaling. Laser application was then applied to the areas where root planning was applied. Laser was applied in continuous phase at 0.80W power, 940 nm wavelength and 0.80 J / s energy level.
89489036|NCT04908098|Active Comparator|Control group|Root-planning was performed using Gracey curettes in the areas where periodontal pockets were diagnosed after scaling.
88953476|NCT01962480|No Intervention|No closure of the hernia gap|Physiomesh is placed with at least 5 cm overlap of the gap and fixated with double crown technique
88953477|NCT01962519|Experimental|Early oral feeding|Early oral feeding starting with liquids on postoperative day (POD) 1, followed by a soft diet on POD 2, and solid foods on day 3
88953478|NCT01962519|No Intervention|Delayed oral feeding|Delayed oral feeding starting with liquids on postoperative day (POD) 4, followed by a soft diet on POD 5, and solid foods on day 6
88953479|NCT01962532|Experimental|Part 1: Dose Escalation (Daily Dosing)|Dose escalation of JNJ-42756493 is to occur until a dose at which <33 percent of participants experience a dose-limiting toxicity, the maximum concentration of JNJ-42756493 is less than the protocol-defined cardiovascular threshold, and JNJ-42756493 is biologically active. Participants will receive study drug once day on Day 1 of Cycle 1 followed by a 2-day drug-free period (Days 2 and 3 of Cycle 1) and continues throughout the 21 day cycle. For all subsequent cycles once a day for 21 days.
88953480|NCT01962532|Experimental|Part 1: Dose Escalation (Intermittent Dosing)|Intermitting dosing regimen will be 28 days (7 days on and 7 days off). Participants will receive JNJ-42756493 on Days 1 to 7 and Days 15 to 21 of each cycle; JNJ-42756493 will not be administered on Days 8 to 14 and Days 22 to 28 of each cycle.
88953481|NCT01962532|Experimental|Part 2: Dose Expansion|Participants will receive the recommended Phase 2 JNJ-42756493 dose determined in Part 1 as Intermitting dosing regimen (28 days, 7 days on and 7 days off). Participants who are tolerating study drug treatment and achieve clinical responses or stable disease will continue to receive study drug at the same dose until disease progression, unacceptable toxicity, or withdrawal of consent.
88953482|NCT01962545|Experimental|OAC alone|OAC includes warfarin or NOAC. The dose of warfarin should be adjusted with the target international normalized ratio (INR) range of 2.0-3.0 for those <70 years and 1.6-2.6 for those =>70 years, which is recommended in the Japanese guidelines. NOAC includes dabigatran 150mg or 110mg twice daily, rivaroxaban 15mg daily with the reduced dose of 10mg daily, apixaban 5mg twice daily with the reduced dose of 2.5mg twice daily, and edoxaban 60mg daily with the reduced dose of 30mg daily.
88953483|NCT01962545|No Intervention|OAC plus single APT|"OAC includes warfarin or NOAC. The dose of warfarin should be adjusted with the target INR range of 2.0-3.0 for those <70 years and 1.6-2.6 for those =>70 years, which is recommended in the Japanese guidelines. NOAC includes dabigatran 150mg or 110mg twice daily, rivaroxaban 15mg daily with the reduced dose of 10mg daily, apixaban 5mg twice daily with the reduced dose of 2.5mg twice daily, and edoxaban 60mg daily with the reduced dose of 30mg daily.~Single APT includes aspirin or clopidogrel. The dose of aspirin is 81-324mg/day and the dose of clopidogrel is 75mg/day."
88953484|NCT01962571|Experimental|Erythropoietin alfa|Recombinant human EPO (Epoetin alfa HEXAL®) will be given as an i.v. bolus injection on days 1, 2 and 3. The dosage per day will be 33.000 IU in accordance with previous trials.
88953485|NCT01962571|Placebo Comparator|Placebo|As matched placebo for this study, sterile normal saline (0.9% sodium chloride for i.v. administration) will be used. It will be given as a bolus injection in the same manner as EPO.
88953486|NCT01962584||SAM|patients with suspected acute myocarditis
88953487|NCT01962584||HC|Healthy controls
88953488|NCT01962597|Active Comparator|aerobic exercise|patients will undergo supervised exercise on a bike ergometer for 30 minutes three times per week during hemodialysis
88953489|NCT01962597|Active Comparator|resistance training|patients will undergo supervised lower extremity strength training three times per week pre-hemodialysis
88953490|NCT01962597|Experimental|aerobic exercise and resistance training|patients will undergo a combination of aerobic exercise and resistance training on an alternating schedule three time per week
88953491|NCT01962610|Experimental|ePCA and Pain keycept intervention|Study designed ePCA and pain keycept interventions are embedded in electronic medical record during patient ED visit
88953492|NCT01962610|No Intervention|Usual Care|No study designed ePCA and pain keycept interventions are embedded in electronic medical record during patient ED visit
88953493|NCT01962623|Active Comparator|Treatment as Usual (TAU)|Participants who are not randomly assigned to the IPT-MBD group will continue with treatment at usual, which is considered routine care.
88953494|NCT01962623|Other|IPT-MBD|Weekly Interpersonal Therapy for SMD/DMDD (IPT-MBD) sessions, which emphasizes building skills in managing relationships, helping with problem solving, strengthening communication skills and other skills.
88953495|NCT01962649|Experimental|ICG & Optical Molecular Imaging|All patients will receive a dose of ICG 0.5mg/kg, with a maximum dose of 40mg, one day prior to the scheduled procedure. The patients will then undergo a routine image-guided biopsy on the day of the procedure; immediately prior to obtaining the biopsy sample, fluorescence intensity within the target lesion will be measured by a handheld optical molecular imaging device, which will be passed through the biopsy needle. Once the core sample is obtained using a standard biopsy needle, the specimen will be imaged using an epifluorescence, point-of-care imaging system and will then be submitted for standard pathologic analysis.
88953496|NCT01962662|Experimental|variable practice|EMG biofeedback training on force control muscle the goal of force level control training is 25%, 50%, 75%, and 100% of maximal strength.
88953497|NCT01962662|Experimental|constant practice group|EMG biofeedback training on force control muscle the goal of force level control training is 100% of maximal strength.
88953498|NCT01962662|Other|control group|U/E exercise
88953499|NCT01962701||OCT-group|OCT prior to C-section
88953500|NCT01962701||None-OCT-group|No OCT prior to C-section
88953501|NCT01962740|Active Comparator|Xience EES|This arm of patients will receive Xience Everolimus Eluting Stents(EES) as part of their clinically indicated PCI procedure and they will undergo Optical Coherence Tomography Imaging
88953502|NCT01962740|Active Comparator|Resolute Integrity ZES|This arm of patients will receive Resolute Integrity Zotaralimus Eluting Stents (ZES) as part of their clinically indicated PCI procedure and they will undergo Optical Coherence Tomography Imaging
88953503|NCT01962740|Active Comparator|Promus Element EES|This arm of patients will receive Promus Element Everolimus Eluting Stents (EES) as part of their clinically indicated PCI procedure and they will undergo Optical Coherence Tomography Imaging
89489037|NCT04908332|Experimental|Kangaroo baby Massage|The mother will apply the massage. The baby kangaroo will be exposed to the KBM for 10 minutes once a day during the time that the infant need to stay in kangaroo position at home. If the baby wakes up and wants to eat the KBM will be interrupted immediately and the baby will be fed, The temperature will be measured before and after the intervention. The massage will begin 60 minutes after the feed.
88953506|NCT01962779|Experimental|Continuous positive airway pressure|Moderate to severe SDB subjects will be offered a 6-month therapy with continuous positive airway pressure (CPAP).
89489038|NCT04908332|Active Comparator|Kangaroo position|The infant must be in Kangaroo position with the mother semi sitting on bed with elevation of at least 30 degrees during 10 minutes every day until the infant doesn´t need to stay in kangaroo position at home.The temperature will be measured 60 minutes after the feed and 10 minutes after KP. If the baby wakes up and wants to eat the KP will be interrupted immediately and the baby will be fed, then the KP will be completed of time ( 10 minutes) to measure the temperature.
89489039|NCT04907708|No Intervention|Normal healthy controls|females in second trimester with normal glucose levels
89489040|NCT04907708|No Intervention|Diet controlled|females in second trimester with blood sugar levels below 129mg/dl
89489041|NCT04907708|Experimental|Metformin|females in second trimester with blood sugar levels above 130mg/dl treated with Metformin
89489042|NCT04907708|Experimental|Insulin|females in second trimester with blood sugar levels above 130mg/dl being treated with Insulin
89489043|NCT04890626|Experimental|Main randomization.Arm: Emtricitabine / Tenofovir disoproxil fumarate|Emtricitabine / Tenofovir disoproxil fumarate
89489044|NCT04890626|No Intervention|Main randomization.Arm: No treatment|No treatment
89489045|NCT04890626|Other|Rescue randomization: Arm: Dexamethasone + Baricitinib|Rescue randomization: patients with oxygen requirements, O2 Sat <95% at any time, and at least one of the following inflammation markers: IL-6, CRP, D-dimer, LDH or ferritin above the upper limit of the normal range. Arms: Dexamethasone + Baricitinib or Dexamethasone.
89489046|NCT04890626|Other|Rescue randomization: Arm: Dexamethasone|Rescue randomization: patients with oxygen requirements, O2 Sat <95% at any time, and at least one of the following inflammation markers: IL-6, CRP, D-dimer, LDH or ferritin above the upper limit of the normal range. Arms: Dexamethasone + Baricitinib or Dexamethasone.
89489047|NCT04908254|Experimental|Dayspring Active Wearable Compression Device|The Dayspring Active Wearable Compression Device is an FDA cleared calibrated active gradient pressure full-arm compression garment that is segmental and programmable and applies controlled sequential pressure from the distal to proximal-end of the limb in a cyclic manner.
89489048|NCT04908254|Active Comparator|Advanced Pneumatic Compression Device|A commercially available advanced pneumatic compression device that is FDA-cleared for the same indication for use as the Dayspring Wearable Compression Device.
89489049|NCT04907942|Active Comparator|EMA Alone|3 weeks of EMA, consisting of 2 surveys per day delivered via text message and email during waking hours to prompt participants to complete the survey.
88953507|NCT01962779|No Intervention|No intervention|Subjects that refuse treatment with CPAP or that have a poor long-term compliance will be considered controls.
88953508|NCT01962805|Experimental|Proellex Schedule A|Proellex vaginal capsule, 12 mg, once a day for up to 7 days
88953509|NCT01962805|Experimental|Proellex Schedule B|Proellex vaginal capsule, 12 mg, once a day for up to 7 days
88953510|NCT01962831|Experimental|dinoprostone|Group of women that will receive dinoprostone for induction of labour dinoprostone 10 mg in vagina to be reassessed every 24 hours
88953511|NCT01962831|Experimental|Single balloon foley catheter|Group of women that will have a single balloon foley catheter inserted for induction of labour
88953512|NCT01962844|Other|Nutritional treatment|All patients received an individualized diet plan and balanced. The diet was calculated according to the nutritional status and the protein 15-20% of total energy value, lipids 25-30% of daily energy intake and carbohydrate 50-60% of of total energy value
88953513|NCT01962844|Experimental|extra virgim coconut oil group|Oil from coconuts (cocos nucifera L.) contains a high proportion of medium chain fatty acids, principally the lauric acid (12:0), in proportions that range from 45 to 50%
88953514|NCT01962857|Experimental|Exercise|4 week supervised high-intensity shuttle running intervention, with 3 sessions per week (12 sessions in total)
88953515|NCT01962857|No Intervention|Control|No intervention - participants maintain usual lifestyle
88953516|NCT01962883|No Intervention|Control group|Osteopathic evaluation Cognitive and Physical Rest
88953517|NCT01962883|Experimental|Osteopathic Treatment Group|4 osteopathic treatments following a set protocol to which only the osteopathic lesions found within the subjects assessment will be treated.
88953518|NCT01962909|Experimental|PTP-01|single IV bolus dose 24 hours prior to surgery
88953519|NCT01962935|Experimental|Part A AZD4721|Part A of the study, multiple ascending doses of AZD4721 will be administrated once daily for 10 days
89489050|NCT04907942|Experimental|EMA + Automated Text Message Intervention|"1 week of EMA, consisting of 2 surveys per day delivered via text message and email during waking hours to prompt participants to complete the survey followed by~2 additional weeks of EMA in combination with 2 text messages per day with content related to stress management techniques."
89489051|NCT04907864|Experimental|MIC|Multi-modal intervention
89489052|NCT04907864|No Intervention|CPC|Conventional Palliative Care
89489053|NCT04899128||Observational Group|Patients receive pyrotinib-based therapy after lapatinib progression.
89489054|NCT03051542|Experimental|NK/T-cell lymphoma patients with 18F-FDG PET/CT|18F-FDG PET/CT scans is to be evaluated using liver SUVmax-based criteria, Deauville 5-point criteria and reduction of SUVmax criteria
89489055|NCT04898972|Experimental|Mindfulness-based stress reduction intervention|Patient-family caregiver dyads will take part in 8-week Mindfulness-based stress reduction intervention (MBSR).
89489056|NCT04898972|Active Comparator|information booklet|Patient-informal caregiver dyads will receive an informative booklet on stress reduction strategies
89489057|NCT04890704|Experimental|Curcumioids|The investogators prescribed curcuminoids 1,500 mg/day . The regimen was curcuminoids 500 mg three times a day from three days before the procedure until two days after. All patients also received standard prophylaxis protocol which included 0.9% sodium chloride 1 mL/kg/hour, given 12 hours before and 12 hours after CAG unless contraindicated.
89489058|NCT04890704|Placebo Comparator|Placebo|The placebo was identical capsule given three times daily and the remaining protocols were the same as the active group
89489059|NCT04907786||Study population|All patients eligible for participation in this registry are aged 18-80 years old and undergoing invasive coronary angiography because of abnormalities found on CCTA in either the left or right coronary artery and no or minimal stenosis (CAD-RADS 0-1; 0-24% stenosis) in the contralateral coronary artery. Patients will be asked for written informed consent to register their clinical data in an anonymized database. The period between CCTA and ICA may not exceed 90 days, in order to prevent possible aggravation of coronary artery disease between both examinations.
89489060|NCT04412330|Experimental|ICU followup + physical therapy|Patients surviving ICU admission for Covid-19 will receive ICU follow-up care in an ICU Recovery Clinic plus 8 weeks of physical therapy interventions. ICU Recovery Clinic is standard of care for patients surviving medical ICU admission at University of Kentucky with potential to attend in person or complete through telemedicine up to 5 appointments in the first year after hospital discharge. Physical therapy interventions completed at an outpatient pulmonary rehabilitation center or through telemedicine is not currently standard of care for patients in the short-term recovery phase (1-6 months after hospital discharge) after critical illness.
89489061|NCT04907474|Other|1 Mist|One mist of tropicamide-phenylephrine fixed combination solution administered to each eye with the MAP Dispenser
89489062|NCT04907474|Other|2 Mists|Two mists of tropicamide-phenylephrine fixed combination solution administered to each eye with the MAP Dispenser
89489063|NCT04907630|Experimental|intervention group-antenatal education of health literacy (HL-AE)|It is the group that is given antenatal education based on improving health literacy (HL-AE).
89489064|NCT04907630|Experimental|intervention group-Antenatal Education (AE)|It is the group that gives antenatal education (AE)
89489065|NCT04907630|Experimental|Control group|No Intervention
89489066|NCT04898738|Active Comparator|Alcohol-based hand sanitizer|Half the study households with receive ABHS through the course of the study
89489067|NCT04898738|No Intervention|No Alcohol-based hand sanitizer|Half the study households with not receive ABHS through the course of the study
89489068|NCT04898582|Other|20 women 20-60 years old with sensitive skin and persistent centrofacial erythema of rosacea|"The subjects applied the product M89 Probiotic Fractions on half a face, twice a day, in the morning and in the evening, for 30 days. They put two drops of the product in the palm of their hand and gently massage with their fingertips on half face. The face skin had to be cleaned and dried before the application of the product. The subjects used their standard skin care product on the side of the face not treated with M89 Probiotic Fractions. The subjects were allowed to use their habitual foundation and makeup products on the whole face.~The side of application of the product M89 Probiotic Fractions (right or left side of the face) was randomized among the subjects.~The assignment of subject number and subsequent placement on the randomization chart were made in order of appearance at the study centre on the first day."
89489069|NCT04890392|Experimental|PD-1 with SOX|S-1: 40~60mg Bid，d1~14, q3w Oxaliplatin：130mg/m2，iv drip for 2h，d1, q3w PD-1（Tislelizumab）:200mg,iv drip for at least 1h,d1,q3w
89489070|NCT04907318||ANKORIS|Cataract surgery performed with POD26PAYT
89489071|NCT04907318||FINEVISION TORIC|Cataract surgery performed with POD26PAYFT
89489072|NCT02616614|Active Comparator|Onexton gel|Clindamycin 1.2% and benzoyl peroxide 3.75% topical gel Applied a thin film of medication onto 6 areas of the face (chin, left cheek, right cheek, nose, left forehead, and right forehead) once daily
89489073|NCT02616614|Experimental|Clindamycin/benzoyl peroxide gel|Generic clindamycin 1.2% and benzoyl peroxide 3.75% topical gel. Applied a thin film of medication onto 6 areas of the face (chin, left cheek, right cheek, nose, left forehead, and right forehead) once daily
89489074|NCT02616614|Placebo Comparator|Placebo|A vehicle gel. Applied a thin film of medication onto 6 areas of the face (chin, left cheek, right cheek, nose, left forehead, and right forehead) once daily
89489075|NCT04408040|Other|Critical Patients|
89489076|NCT04408040|Other|Severe Patients|
89489077|NCT04408040|Other|High Risk|
89489078|NCT04408040|Other|Health Care Providers|
89489079|NCT03050996||robotic radical prostatectomy patients|Patient scheduled to undergo robotic assisted radical prostatectomy
89489080|NCT04898426|No Intervention|Standard Bowel Preparation Instruction|Patients receive the standard-of-care bowel preparation instruction.
89489081|NCT04898426|Experimental|Enhanced Bowel Preparation Instruction|Patients receive enhanced instructions (SMS, phone call, info website) in addition to the standard-of-care bowel preparation instruction.
89489082|NCT04890080|Experimental|PR Group|Patients diagnosed with COPD according to GOLD and completed the 2-day / 8-week PR program
89489083|NCT04889768|Experimental|Experimental: HIPEC, anti-PD-1 antibody Camrelizumab (SHR-1210), Chemotherapy and Surgery|"surgical exploration, if PCI<20, then we perform this study.~HIPEC: Taxol (Paclitaxel Injection) 75 mg/m2, d1, d3 within 72 hours after surgical exploration; oral chemotherapy:S-1: 80mg/m2, twice daily for d1-d14, and then suspend for one week; Intravenous drip anti-PD-1 antibody Camrelizumab (SHR-1210) 200mg fixed dose every 3 weeks.~Chemotherapy and PD-1 treatment (4 cycles) : Taxol 150mg/m2,d1; S-1: 80-120mg/m2, twice daily for two weeks, and then suspend for one week; Camrelizumab (SHR-1210) 200mg fixed dose every 3 weeks.~Surgery: Secondary surgical exploration: if PCI less than 20, then assess the patient's condition and consider whether perform the cytoreductive surgery (resection of primary tumors and metastases ). For inoperable patients, continue to use this program for treatment.~After the surgery, HIPEC for two cycles, anti-PD-1 antibody Camrelizumab (SHR-1210) for 4 cycles, and PS chemotherapy for 4 cycles."
89489084|NCT04906538|Active Comparator|anterior cruciate ligament reconstruction with internal suture augmentation technique|This group will be operated by using all-inside ACLR technique with internal suture augmentation technique
89021814|NCT00445809||2|Medium Risk population for developing AKI during/after CABG surgery.
89489085|NCT04906538|Active Comparator|anterior cruciate ligament reconstruction without internal suture augmentation technique|This group will be operated by using all-inside ACLR technique without internal suture augmentation technique
89489086|NCT03050840|Other|Self-monitoring|Participants will wear a Fitbit, to self-monitor steps per day, and will report sugar sweetened beverage (SSB) consumption via text messaging. The Way to Health platform will record data.
89489087|NCT03050840|Experimental|Self-monitoring plus gamification|Participants will wear a Fitbit, to self-monitor steps per day, and will report sugar sweetened beverage consumption via text messaging. Participants will be awarded medals and points based on meeting step per day and SSB consumption goals The Way to Health platform will be used to record data.
89489088|NCT04898270|Experimental|MARTAs combined with flupentixol|"Flupentixol tablets are indicated for:~• maintenance therapy of chronic schizophrenic patients whose main manifestations do not include excitement, agitation, or hyperactivity.~Other Names:~Fute tables, Fluanxol~Multi-acting receptor-targeted antipsychotics (MARTAs): clozapine, olanzapine, quetiapine."
89489089|NCT04898270|Active Comparator|Multi-acting receptor-targeted antipsychotics (MARTAs)|clozapine, olanzapine, quetiapine
89489090|NCT04889612|Experimental|motor coordination and grip strength in dominant/non-dominant hand|Dominant and non-dominant hand motor coordination and grip strength were tested in the stable position of the trunk and the upper arm, in post-stroke patients (study group) and in healthy subjects (control group).
89489091|NCT04889456|No Intervention|Surgical variations laparoscopic right hemicolectomy|
89489092|NCT04889456|Active Comparator|Implementing standardised laparoscopic right hemicolectomy with proctoring|
89489093|NCT04889456|Active Comparator|Implementing standardised laparoscopic right hemicolectomy without proctoring|
89489094|NCT04897724|Other|patients have carious lesions in one or more surface of molars and premolars|patients received direct composite restorations using a nanohybrid and a nonofil composite restorations
89489095|NCT03051776|Experimental|Kinesio Taping|It was done a four week phase with Kinesio Taping in the arm affected with lymphedema.
88953520|NCT01962935|Placebo Comparator|Placebo|Part A of the study, multiple ascending doses of matching Placebo will be administrated once a daily for 14 days
88953521|NCT01962935|Active Comparator|AZD5069, then AZD4721|Part B of the study, subject will participate in two treatment periods (one with AZD5069 administrated for 3 days and the second period with AZD4721 administrated for 14 days) separated by a wash-out period of 6-10 days between the two periods.
88953522|NCT01963000||CAP|A patient with CAP was identified by encoding pneumonia without severe immunosuppression (HIV infection, solid organ or bone marrow/stem cell transplants, severe neutropenia) as the main diagnosis (ICD 10 GM) of hospital admission.
88953523|NCT01963013|Experimental|Non-returning catheter valve|Non-returning catheter valve (UnometerTM SafetiTM Plus) was used in experimental group only.
89489096|NCT03051776|Active Comparator|Compression garment|It was done a four week phase with Compression garment in the arm affected with lymphedema.
89489097|NCT03052712|Active Comparator|Patients|battery of tests of social cognition
89489098|NCT03052712|Active Comparator|Control|battery of tests of social cognition
89489099|NCT04906304|Experimental|Evrolimus|The treatment regimen in everolimus group was 0.75 mg/bid everolimus with everolimus C0 3-8 ng/mL plus Sandimmun (Neoral) low dose pluse cellcept
89489100|NCT04906304|Active Comparator|Control|0.75 mg/bid everolimus with everolimus C0 3-8 ng/mL plus Sandimmun (Neoral)standard dose plus cellcept
89489101|NCT04889690|Experimental|Cohort 1: 200 mg|All participants under fasted conditions received 200 mg of danicopan or placebo twice daily (BID) over a 14-day period.
89489102|NCT04889690|Experimental|Cohort 2: 500 mg|All participants under fasted conditions received 500 mg of danicopan or placebo BID over a 14-day period.
88953524|NCT01963013|Active Comparator|Conventional urine bag|Conventional urine bag hasn't the non-returning catheter valve.
88953525|NCT01963026|Experimental|ToCUEST (constant or variable practice)|After therapy as usual (intervention A), the Task-oriented Client-centred Upper Extremity Skill Training (ToCUEST) module (Spooren et al., 2011) will be given. In this program individual goals will be extracted using the COPM (Canadian Occupational Performance Measure) and the training program is based on a task-analysis and uses principles of training physiology and motor learning. Intervention B will consist of the ToCUEST program, including the component 'practice variability' (ToCUEST variability). Intervention C will consist of a modified ToCUEST program in which the component 'practice variability' will be replaced by 'constant practice' (ToCUEST constant) in order to evaluate the contribution of these components. Intervention A' will be therapy as usual.
88953526|NCT01963039|Active Comparator|percutaneous vertebroplasty|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine). For the vertebroplasty procedure, 11-gauge or 13-gauge needles are passed into the central aspect of the target vertebra or vertebrae. Bone cement (PMMA) is prepared on the bench and injected under constant fluoroscopy into the vertebral body. Injection is stopped when the cement reaches to the posterior aspect of the vertebral body or leaks into an extraosseous space, such as the intervertebral disk or an epidural or paravertebral vein.
89021815|NCT00339326||Cases with Kaposi's Sarcoma|Cases with Kaposi's Sarcoma from Southern Italy.
89021816|NCT00339326||Controls without KS|Controls from Southern Italy.
89021817|NCT00452010|Experimental|1|transcutaneous electrical nerve stimulation
89021818|NCT00452010|Placebo Comparator|2|No transcutaneous electrical nerve stimulation
89489103|NCT04889690|Experimental|Cohort 3: 800 mg|All participants under fasted conditions received 800 mg of danicopan or placebo BID over a 14-day period.
89489104|NCT04889690|Experimental|Cohort 4: 75 mg|All participants under fasted conditions received 75 mg of danicopan or placebo thrice daily (TID) over a 7-day period.
89489105|NCT04398446|Experimental|Hemp-based CBD|
89489106|NCT04398446|Placebo Comparator|Placebo Oral Tablet|
89489107|NCT04888910||asthma with nasal polyps|severe asthma with involvement of the upper airways (chronic rhinosinusitis with nasal polyps)
89489108|NCT04888910||severe asthma without nasal polyps|severe asthma without involvement of the upper airways
89489109|NCT04905992|Experimental|Single daily session (Hypertonic saline + airway clearance techniques)|The experimental group will perform a daily session at home including nebulisation of 5 mL of hypertonic saline (at 6%) followed by 15 min of airway clearance techniques (oscillating positive expiratory pressure therapy) for 6 months.
89489110|NCT04905992|Active Comparator|Twice daily session (Hypertonic saline + airway clearance techniques)|The control group will perform two daily sessions at home involving nebulisation of 5 mL of hypertonic saline (at 6%) followed by 15 min of airway clearance techniques (oscillating positive expiratory pressure therapy) for 6 months.
89489111|NCT04897178||Fetuses with normal anatomy|Fetuses with normal anatomy scan who demonstrate no structural abnormalities of different systems (CNS, chest and heart, abdomen, skeletal system)
89489112|NCT04897178||Fetuses with abnormal anatomy|Fetuses with abnormal anatomy scan who demonstrate any structural abnormalities that can be detected with ultrasound
89489113|NCT03050762||Endocrine Disease Group|"Information from the medical record recorded and entered into a research database.~Starting about 2-3 years after testing and/or diagnosis and/or treatment and continuing for up to 15 years after surgery, research team will contact participant by phone to follow up."
89489114|NCT04896710|Experimental|Self administration|The participant will self administer the SD Biosensor. Their rapid antigen test result will be compared to health care professional administered SD Biosensor
89489115|NCT03051698|Experimental|C1-inhibitor|One gift of intravenous administration of C1-inhibitor (Cinryze, 100U/kg) during one hour
89489116|NCT03051698|Placebo Comparator|Saline|One gift of intravenous administration of 0.9% NaCl during one hour.
89489117|NCT03051698|Experimental|Antibiotics|broad spectrum antibiotics (vancomycin, ciprofloxacin, metronidazole) for 7 days (washout 36 hours before study day).
89489118|NCT03052556|Other|Cohort of women with cystic fibrosis|Includable patients are adult women, transplanted or not, followed at Lyon CRCM (Centre de Ressources et de Compétences de la Mucoviscidose).
89489119|NCT04905602|Experimental|Cohort 1|A single subcutaneous injection of SHR-1905/placebo dose 1 in healthy subjects
89021819|NCT00339365|Experimental|1|Promoting first relationships group
89021820|NCT00339365|Active Comparator|2|Early education support group
89021821|NCT00452088|Experimental|1|15 microgramme candidate vaccine group
89021822|NCT00452088|Active Comparator|2|Hepatitis B comprator group
89021823|NCT00452088|Experimental|3|30 microgrammes candidate vaccine group
89021824|NCT00452088|Active Comparator|4|Hepatitis B vaccine group
89021825|NCT00339521||Case-Parent Triad|Childhood Asthmatics (aged 4-17) are Cases; biologic parents of cases are genetic Controls.
89489120|NCT04905602|Experimental|Cohort 2|A single subcutaneous injection of SHR-1905/placebo dose 2 in healthy subjects
89489121|NCT04905602|Experimental|Cohort 3|A single subcutaneous injection of SHR-1905/placebo dose 3 in healthy subjects
89489122|NCT04905602|Experimental|Cohort 4|A single subcutaneous injection of SHR-1905/placebo dose 4 in healthy subjects
89489123|NCT04905602|Experimental|Cohort 5|A single subcutaneous injection of SHR-1905/placebo dose 5 in healthy subjects
89489124|NCT04905602|Experimental|Cohort 6|A single subcutaneous injection of SHR-1905/placebo dose 6 in subjects with mild asthma
89489125|NCT04905680|No Intervention|Control group|The health screening before the study and at the end of study will collect anthropometric data (height, weight, waist and hip circumference), blood pressure data, and blood samples (for testing of HbA1c, fasting blood glucose, fasting insulin and lipid profile). Individuals are provided with an educational brochure upon receiving their screening results. Participants will then go through a baseline lifestyle tracking session using a study-issued smartphone and smartwatch, pre-installed with certain study applications. For participants in the control arm, there is no health coaching or study activities until the end of the study, where individuals will attend a 20- to 30-minute session with a coach to have their baseline lifestyle tracking results explained to them and receive personalised suggestions on lifestyle modifications.
89489126|NCT04905680|Experimental|Experimental group|The activities during health screening before the study and at the end of study is similar to the control. Individuals are provided with an educational brochure upon receiving their screening results. Participants will then go through a baseline lifestyle tracking session using a study-issued smartphone and smartwatch, pre-installed with certain study applications, which will be used for the lifestyle tracking sessions. The experimental arm will go through 4 additional lifestyle tracking sessions (i.e., total of 5 including baseline), of which 1 will include Continuous Glucose Monitoring (CGM) tracking. For this CGM tracking session, participants will receive real-time feedback through the study applications, which will display the CGM trace. The data collected during the lifestyle tracking sessions will be discussed with the participants during 3 face-to-face coaching and 2 tele-coaching sessions, where the participants will develop and implement lifestyle change action plans.
89489127|NCT04905758|Experimental|Maxi-Z plus dental implant|platform switched dental implants
89489128|NCT04905758|Active Comparator|Maxi-Z dental implant|platform matched dental implants
89489129|NCT04888520|Experimental|Tensioning protocol of the elastic bandage (WT)|The group will have progressive tension throughout the week - based on the reduction of the tape in relation to the size of the applied area (which will always be the same), which generates a longitudinal tension of the tape in relation to the participant's skin. The Therapy Tex® brand has the elastic deformation capability of up to 40%. The tensioning protocol of the elastic bandage will work with 20% of the elastic deformation capacity of the bandage. The tension will be given from point A to point B in order to generate excitatory stimuli. The percentage of 20% reduction in tension will be distributed over the 7 weeks of intervention, and the first week of the protocol included application without tension. The tape reduction will be controlled by the formula: (size of the application area on the skin*20% /7 weeks= size of the tape to be cut in each of the 7 applications starting from the second week. Tape size and tape application area will be calculated in centimeters (cm).
89489130|NCT04888520|Placebo Comparator|Free tension|The group will have no tension in any of its tape applications; that way the size of the tape over the applied area will always be the same.
89489131|NCT04888442|Experimental|pCAR-19B cells|Infusion of pCAR-19B cells by dose-escalating
89489132|NCT04905056|Experimental|ablation therapy in the treatment of lung cancer presenting as ground-glass nodules|
89489133|NCT04888130||Cases|This study comes following an outbreak signal that occurred in May 2020, after the detection of numerous cases of cutaneous leishmaniasis in military personnel probably contaminated during a training course (Training Center in the Equatorial Forest, CEFE) in the town of Regina. To date, around 40 cases have been detected.
89489134|NCT04888130||Controls|A case-control study can therefore be carried out using a questionnaire offered to all course participants over the 1st semester of 2020. The controls will then be participants who have not been infected. A comparison can also be made between the military personnel present in French Guiana during the first half of 2020 and having carried out missions in the forest, by opposing the participants and non-participants of the CEFE.
89489135|NCT04904666||Bleach baths with .0125%|
89489136|NCT04904666||Clorhexidine 2%|
89489137|NCT04904666||Soap and water|
89489138|NCT04904666||Bleach baths with .005%|
89489139|NCT04896788|Other|Monitoring of the immune response|Immune response controlled with blood sample at 3, 6, 12, 18 and 24 months
89489140|NCT04896554|Active Comparator|quit smoking|patients who have quit smoking
89489141|NCT04896554|Active Comparator|not quit smoking|patients who have not quit smoking
88953527|NCT01963039|Sham Comparator|Sham procedure|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine). During the sham intervention, verbal and physical cues, such as pressure on the patient's back, are given, and the bone cement(PMMA) is prepared to simulate the odor associated with mixing of polymethacrylate , but the needle is not placed and cement is not injected.
88953528|NCT01963052|Experimental|Part A: AGS-15E Dose Escalation (Dose Levels 1-6)|Subjects will receive a single 30 minute intravenous (IV) infusion of AGS15E once weekly for 3 weeks of every 4 weeks (Days 1, 8, and 15). A cycle is 4 weeks. Additional subjects may be enrolled for expansion of these dose levels to further evaluate the safety and efficacy, as recommended by a data review team (DRT).
88956533|NCT04972760|Placebo Comparator|placebo arm|Patients receive placebo plus prednisone taper plus one immunosuppressive drug (either methotrexate or azathioprine) for a duration of 24 weeks. Corticosteroids are tapered following a predefined protocol.
89489142|NCT02616380||Adalimumab|Participants diagnosed with rheumatoid arthritis who were prescribed adalimumab according to their physician's discretion and routine clinical practice.
89489143|NCT04888208|Experimental|Behavioral|The intervention group will benefit from discussion sessions on tobacco within the virtual world, with a group of pairs and 2 facilitators (public health researchers).
89489144|NCT04888208|No Intervention|Control Arm|The control group will be offered sources of conventional health information (government and institutional websites) on a terminal located in the virtual world.
89489145|NCT04888052|Experimental|Group 1|
89489146|NCT04887818|Experimental|Topical diltiazem + lidocaine|
89489147|NCT04887818|Active Comparator|Topical nifedipine + lidocaine|
89489148|NCT03050684|Active Comparator|vaginal lavage group|We will make vaginal lavage with steril %0.9 NaCl serum ( 20cc) before inserting dinoprostone (Propess ®) 10 mg vaginal ovule
89489149|NCT03050684|Placebo Comparator|Control group|We will insert dinoprostone (Propess ®) vaginal ovule without vaginal lavage.
89489150|NCT04904198|Experimental|Care Management Intervention for Non-cardiac chest pain|Multicomponent care management intervention.
89489151|NCT03050528|Experimental|Combined Exercise and ACT treatment|Participants will attend a weekly group-based multidisciplinary pain programme for a period of eight weeks. The programme will combine exercise with the psychological approach acceptance and commitment therapy (ACT).
89489152|NCT03050528|Active Comparator|Standalone supervised exercise|Participants will attend a weekly group-based supervised exercise class for a period of eight weeks.
89489153|NCT03050138||Dabigatran|In the RE-COVER- and RE-COVER II studies, one group of DVT and/or PE patients were randomized to receive 6 months of treatment with dabigatran (150 mg twice daily). All patients received an initial 5-7 day phase of parenteral anticoagulant treatment.
89489154|NCT03050138||Warfarin|In the RE-COVER- and RE-COVER II studies, the other group of DVT and/or PE patients were randomized to receive 6 months of treatment with warfarin (once daily to maintain international normalized ratio (INR) 2.0-3.0). All patients received an initial 5-7 day phase of parenteral anticoagulant treatment.
89489155|NCT04895540||Diagnosed ACM patients|
89489156|NCT04895540||First degree relatives of ACM patients|
89489157|NCT04895540||Relatives of ACM patients who have suffered an SCD|
89489158|NCT03050606|Experimental|Pilates|"This group will perform a modified Pilates exercise program, which will be performed using mat, accessories and studio apparatus, in individual sessions, twice a week, lasting 60 minutes.~Both groups will also receive an educational booklet with information on fibromyalgia and self-care strategies for pain management, sleep improvement, depression improvement, stress and fatigue control."
89489159|NCT03050606|Active Comparator|Aerobic|"This group will perform aerobic exercise, performed on the treadmill or stationary bike according to the choice of the patient. The training will be performed controlling the heart rate of training. The exercises will be performed individually, twice a week and each session will last 60 minutes.~Both groups will also receive an educational booklet with information on fibromyalgia and self-care strategies for pain management, sleep improvement, depression improvement, stress and fatigue control."
89489160|NCT03051230||Studied group|Women exposed to ovarian hyperstimulation for In Vitro fertilisation
89489161|NCT03051386|Experimental|VEE Vaccine|0.5 mL of VEE vaccine, Live, Attenuated TC-83, NDBR 102, Lot 4, Run 3
89489162|NCT03051308|Experimental|First Application in Hour 0|Viability, Calcium-sensing receptor, Vitamin D receptor and parathormone levels of Parathyroid cells (10^7 cells) at 'First Application in Hour 0' non-cold ischemia tissue group
89489163|NCT03051308|Experimental|First Application in Hour 6|Viability, Calcium-sensing receptor, Vitamin D receptor and parathormone levels of Parathyroid cells (10^7 cells) at 'First Application in Hour 6' cold ischemic tissue group
89489164|NCT03051308|Experimental|First Application in Hour 12|Viability, Calcium-sensing receptor, Vitamin D receptor and parathormone levels of Parathyroid cells (10^7 cells) at 'First Application in Hour 12' cold ischemic tissue group
89489165|NCT03051308|Experimental|First Application in Hour 18|Viability, Calcium-sensing receptor, Vitamin D receptor and parathormone levels of Parathyroid cells (10^7 cells) at 'First Application in Hour 18' cold ischemic tissue group
89489166|NCT03051308|Experimental|First Application in Hour 24|Viability, Calcium-sensing receptor, Vitamin D receptor and parathormone levels of Parathyroid cells (10^7 cells) at 'First Application in Hour' 24 cold ischemic tissue group
89489167|NCT04887974|Experimental|Canine retraction|The canines will be retracted by extending short silver elastomeric chains between the power arms in the canine brackets and the TADs. The applied force will be checked and adjusted to 150 g.
89489168|NCT03051152|Experimental|Elderly with CCS>5 - D1 gastrectomy|Patients aged >75 years with Charlson Comorbidity Score > 5 undergoing gastrectomy with limited lymphadenectomy
89489169|NCT03051152|Experimental|Elderly with CCS>5 - D2 gastrectomy|Patients aged >75 years with Charlson Comorbidity Score > 5 undergoing gastrectomy with extended lymphadenectomy
89489170|NCT04887272|Active Comparator|Exercise Training (EXT)|Research participants will complete six weeks of supervised progressive aerobic and resistance exercise training (EXT). Cardiopulmonary, cerebral and peripheral vascular function will be measured pre and post EXT.
89489171|NCT04887272|Experimental|Inspiratory Muscle and Exercise Training (IMET)|Research participants will complete six weeks of supervised aerobic and resistance exercise training in addition to supervised respiratory muscle training (IMET). IMET sessions will be performed similar to EXT, with the exception of having sessions of at-home IMT training. On these days, all training will be spread out over a 2-hour session with periods of IMT training occurring at the beginning, middle, and end of the session. Cardiopulmonary, cerebral and peripheral vascular function will be measured pre and post IMET.
89489172|NCT04884230||Group A|We selected 225 patients (group A) from the period 2019-2020 where the stapling line of the gastric remnant was oversewn and another group of 225 patients (group B) from the period of 2017-2018 with stapling alone.
89489173|NCT04884230||Group B|We selected 225 patients (group A) from the period 2019-2020 where the stapling line of the gastric remnant was oversewn and another group of 225 patients (group B) from the period of 2017-2018 with stapling alone.
88953529|NCT01963052|Experimental|Part B: AGS-15E Cisplatin Therapy -ineligible Expansion|Urothelial subjects who have not received any prior lines of therapy an who are unfit for Cisplatin therapy (Cis-ineligible) will receive a single 30 minute intravenous (IV) infusion of AGS15E once weekly for 3 weeks of every 4 weeks (Days 1, 8, and 15). A cycle is 4 weeks. Subjects will initially be dosed one dose level below the preliminary recommended phase 2 dose (RP2D).
88953530|NCT01963052|Experimental|Part C: AGS15E Immune Checkpoint Inhibitor Treated Expansion|Subjects previously treated with immune checkpoint inhibitors (CPI) in the metastatic setting will receive a single 30 minute intravenous (IV) infusion of AGS15E once weekly for 3 weeks of every 4 weeks (Days 1, 8, and 15). A cycle is 4 weeks. Subjects will be dosed at the RP2D.
89489174|NCT04884074|Experimental|The study group|The procedure done to this group is Sleeve Gastrectomy with Anterior Crural Repair (ACR)
89489175|NCT04884074|Other|The control group|The procedure done to this group is the Standard Sleeve Gastrectomy (SSG)
89489176|NCT04883996|Active Comparator|EXP039|At Visit 1, single dose 1 drop of EXP039 1% is adminstered, followed by washout period of 1-10 days. Subsequently, subjects will crossover to single dose 1 drop saline at Visit 2.
89489177|NCT04883996|Placebo Comparator|Saline control|At Visit 1, single dose 1 drop of saline is adminstered, followed by washout period of 1-10 days. Subsequently, subjects will crossover to single dose 1 drop EXP039 1% at Visit 2.
89489178|NCT04895228|Active Comparator|SpA patients recieving local steroid injection|the active group will receive triamcinilone 40 mg injection (Kenacort) + 4 ml of .5 % lidocaine hydrochloride (Xylocaine) under ultrasound guidance.
89489179|NCT04895228|Placebo Comparator|placebo group|Group 2 will receive similar amount of saline injecteed subcutaneously
89489180|NCT04392206|Experimental|Adipose Derived Mesenchymal Stem Cells|Subjects diagnosed with End Stage Renal Disease (ESRD) and are currently on hemodialysis therapy with planned creation of a new upper extremity arteriovenous fistula will receive Adipose Derived Mesenchymal Stem Cells treatment.
89489181|NCT04894604|Experimental|Subjects with a low to moderate exuding surgically closed incision|Up to 34 study Subjects with a low to moderate exuding surgically closed incision deemed adequate by the Principal Investigator and clinical team for NPWT treatment.
89489182|NCT04884464||Hyaluronic acid-based gel|The composition of the gel, ranked by weight is: xylitol, glycerin, Rosa damascena petal extract, xanthan gum, polycarbophil, hyaluronic acid sodium salt (0.24%), pectin, potassium sorbate, sodium benzoate, panthenol, Aloe barbadensis leaf extract, stevia.
89489183|NCT04884464||Chlorhexidine gluconate|Chlorhexidine gluconate at a concentration of 0.2%.
89489184|NCT04430270||Comparison of Perceptions of X-ray, CT and 3D Model|The study group consisted of 11 orthopaedic residents of University Hospital. Selection criteria for the 4 cases was the involved patients who required orthopaedic surgery. 4 cases for orthopaedic procedures were determined with the consensus of experts. As data collection tool was used to evaluate the perceptions of each of these imaging methods in terms of their usefulness in seeing the surgical problem, their efficiency in differential diagnosis and presurgical planning. CT images were converted into in the 3D model was prepared. The survey utilized by our group, addressed the issues in understanding bone anatomy, seeing pathology, and preparation for unexpected events. A multi-item survey was prepared to assess fellow's perception of residency training. Residents who completed their examination in the stations answered the questions on a scale of 10. Descriptive statistics and Friedman test were used for comparison analysis using IBM SPSS Statistics, version 24.
89489185|NCT03048734||Group (1): Men with Nocturia ≥2.|
89489186|NCT03048734||Group (2): Men with no nocturia (0-1).|
88953531|NCT01963052|Experimental|Part A: AGS15E Dose Expansion|Subjects will receive a single 30 minute intravenous (IV) infusion of AGS15E once weekly for 3 weeks of every 4 weeks (Days 1, 8, and 15). A cycle is 4 weeks.
88953532|NCT01963104|Experimental|Automated hearing test|Subjects will take an abbreviated automated hearing test and then receive recommendations for hearing healthcare follow-up.
88953533|NCT01963104|Experimental|Pure-tone Screener test|Subjects will take a pure-tone hearing screening test and then receive recommendations for hearing healthcare follow-up.
88953534|NCT01963104|Experimental|Digits-in-noise test|Subjects will take a digits-in-noise test and then receive recommendations for hearing healthcare follow-up.
88953535|NCT01963104|Experimental|No screening test|This group of subjects will not receive a screening test.
88953536|NCT01963104|Experimental|Automated hearing test/Motivation video|Subjects will take an abbreviated automated hearing test and then receive recommendations for hearing healthcare follow-up. They will then watch a brief video that shows how hearing works and learn about the different types of hearing loss.
89489187|NCT04886882|Placebo Comparator|Group placebo|Isotonic solution will be administered daily to 6 female rats.
89489188|NCT04886882|Sham Comparator|Group sham|Base cream to be applied twice a day to 6 female rats.
89489189|NCT04886882|Experimental|Group %1 mgso4|Cream containing 1% MgSO4 will be applied twice a day to 6 female rats.
89489190|NCT04886882|Experimental|Group %10 MgSO4|Cream containing 10% MgSO4 will be applied twice a day to 6 female rats.
89489191|NCT04886882|Active Comparator|Group positive control|Cream containing centella asiatica will be applied twice a day to 6 female rats.
89489192|NCT04886648|Experimental|Mother Voıce|Premature baby group with mother voıce application.
88953537|NCT01963104|Experimental|Pure-tone Screener/Motivation video|Subjects will take a pure-tone hearing screening test and then receive recommendations for hearing healthcare follow- up. They will then watch a brief video that shows how hearing works and learn about the different types of hearing loss.
88953538|NCT01963104|Experimental|Digits-in-noise test/Motivational video|Subjects will take a digits-in-noise test and then receive recommendations for hearing healthcare follow-up.They will then watch a brief video that shows how hearing works and learn about the different types of hearing loss.
88953539|NCT01963104|Experimental|No screening test/Motivational video|This group of subjects will not receive a screening test. They will watch a brief video that shows how hearing works and learn about the different types of hearing loss
89489193|NCT04886648|Experimental|Lullably|Premature baby group with lullably application.
89489194|NCT04886648|No Intervention|Control|Premature baby group with no application
89489195|NCT04883294||Disease Group|A disease group including patients older than 18 years old with any kind of histopathologically proven malignancy of the thyroid gland (including Papillary thyroid cancer (PTC), Follicular thyroid cancer (FTC), Medullary thyroid cancer (MTC), and Anaplastic thyroid cancer);
89489196|NCT04883294||Control|A control group including patients older than 18 years old with any kind of histopathologically proven benign thyroid gland disease (including adenoma, hyperplasia).
89489197|NCT05165264||Cohort 1|Participants with previously untreated advanced or metastatic gastric cancer (GC), gastro-oesophageal junction (GEJ) or oesophageal adenocarcinoma (EAC)
89489198|NCT03048968|Experimental|study group1: elderly adults|Gait, sit-to-stand movement, stair climbing and treadmill gait with GEMS and without GEMS
89489199|NCT03048968|Experimental|study group2: stroke patients|Sit-to-stand movement and treadmill gait with GEMS and without GEMS
89489200|NCT05028608|Experimental|Period 1|Fixed treatment sequence starting with 2 single oral doses of midazolam and a single dose of elinzanetant.
89489201|NCT05028608|Experimental|Period 2|Up titration of carbamazepine over 4 days (dose 1, 2, 3) continued by fixed dose 3 of carbamazepine prior to administration of midazolam / elinzanetant, followed by carbamazepine administration.
89489202|NCT03048344|Experimental|Part 1|Subjects will receive oral ORH-2014 at a planned starting dose of 5 mg once daily (QD) in the fasted state. If escalation criteria are met, the administered dose will increase by 5 mg increments to a maximum of 50 mg QD. The starting daily dose is approximately half the typical IV dose (0.15 milligram per kilogram [mg/kg]) extrapolated to a 70-kg person.
89489203|NCT03048344|Experimental|Part 2|Subjects will receive a daily oral dose of ORH-2014 at the recommended dose identified in Part 1. ORH-2014 will be administered in the fasted state.
89489204|NCT04882826|Other|Sequence TR|22 subjects assigned to the sequence TR will receive a single 100 mg dose of the test product Sildenafil (1 x 100 mg tablet), marked as T in the sequence, in Period 1 and a single 100 mg dose of the reference product Viagra® (1 x 100 mg tablet), marked as R in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
89489205|NCT04882826|Other|Sequence RT|22 subjects assigned to the sequence RT will receive a single 100 mg dose of the reference product Viagra® (1 x 100 mg tablet), marked as R in the sequence, in Period 1 and a single 100 mg dose of the test product Sildenafil (1 x 100 mg tablet), marked as T in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
89489206|NCT04886336||Tenofovir Disoproxil Fumarate(TDF) switch to TAF|The indications of TDF switching to TAF due to adverse events of TDF or physician's judgement according to clinical conditions.
89489207|NCT04886336||Entecavir(ETV)switch to Tenofovir Alafenamide(TAF)|In entecavir switch group, at least 30 patients should have baseline BW data before entecavir treatment. The indications of entecavir switching to TAF include suboptimal HBV suppression (defined as detectable HBV DNA after at least one year of entecavir treatment), adverse events due to entecavir, physician's judgement according to clinical conditions.
89489208|NCT04886336||observation groups with take either entecavir (25patients) or TDF (25 patients).|observation groups with total 50 patients who continuously take either entecavir (25patients) or TDF (25 patients) will be enrolled.Examination schedules for these two additional groups are the same as switching groups.
89489209|NCT04885088||Interventions|"Device: Wisdom bracelet~Other Names:~control group (routine medical)"
89489210|NCT04885088||control|routine medical Non-invasive Wearable Device
89489211|NCT03049982|Other|AMP test group|All individuals will undergo a test using the auto-titrating mandibular positioner.
89489212|NCT04882670||hip fracture|
89489213|NCT04881968|No Intervention|Control: Usual Care|The control arm occurs prior to receipt of the video game intervention and reflects usual care. Each hospitalist 'crosses over' from control to intervention at a single time point.
88953540|NCT01963104|Experimental|Home Hearing Screening Test|Subjects will be taught the set-up for a home hearing screening test, take an abbreviated automated hearing test and then receive recommendations for hearing healthcare follow-up.
88953541|NCT01963104|Experimental|Home Hearing Screening Test/Brief video|"Subjects will be taught the set-up for a home hearing screening test, take an abbreviated automated hearing test and then receive recommendations for hearing healthcare follow-up.~They will then watch a brief video that shows how hearing works and learn about the different types of hearing loss."
89489214|NCT04881968|Experimental|Video Game Intervention|Each hospitalist 'crosses over' from control to intervention at a single time point by receiving a link to the Hopewell Hospitalist game via email and logging in to play the video game.
89489215|NCT04734860|Experimental|COVI-AMG|A single injection of 40 mg, 100 mg, or 200 mg of COVI-AMG will be administered
89489216|NCT04734860|Placebo Comparator|Placebo|A single injection of placebo will be administered
89489217|NCT04729400|Experimental|Experimental group|Therapeutic Percutaneous Electrolysis and Vacuum Myofascial Therapy device once week for four weeks associated with eccentric exercises devices at home.
88953542|NCT01963130||drug (metformin and gliclazide)|The first group (Group 1) consisted of patients that used metformin (1000 mg bid) and gliclazide (60 mg qd).
89489218|NCT04729400|Experimental|CONTROL GROUP|The multimodal physical therapy program includes 10 sessions of ultrasound pulsatil therapy (US) and massage associated with eccentric exercises devices at home.
89489219|NCT03048656|Experimental|Individuals with leg-length discrepancy|Patients of Department of Paediatric Orthopaedics and Traumatology, Poznan University of Medical Sciences diagnosed with leg-length discrepancy. The examination of participants included a measurement of the length of lower limbs and the weight distribution as well as performing the static posturography.
89489220|NCT03048656|Active Comparator|control group|The group with healthy individuals; without leg-length discrepancy. The examination of participants included a measurement of the weight distribution as well as performing the static posturography.
89489221|NCT04886024||women with endometriosis|It consists of women between the ages of 18-45 who have been diagnosed with endometriosis by surgery or ultrasonography.
89489222|NCT04886024||control|It consists of healthy women between the ages of 18-45
89489223|NCT04430504|Experimental|Telerehabilitation (TR)|Multidisciplinary, weekly video meetings, self-exercises at home, digital diary recordings, follow-up assessments
89489224|NCT03049592|Experimental|HIBISCUS counseling|Subject receives a third trimester prenatal appointment with a family planning specialist for contraceptive counseling (utilizing the Contraceptive CHOICE counseling script emphasizing the WHO birth-to-pregnancy recommendation of 18 months) and a follow up postpartum contraception visit with a family planning specialist.
89489225|NCT03049592|No Intervention|Standard counseling|Subect receives standard high-risk prenatal care and postpartum contraception provision by the referring community clinic. The community clinic offer standard family planning counseling that does not emphasize utilizing of long-acting reversible contraception to promote birth-to-pregnancy spacing of 18 months. This scenario is current the standard practice at the institutions.
89489226|NCT03049904|No Intervention|Wait List Control|Participants wait 3 weeks before receiving the intervention.
89489227|NCT03049904|Experimental|Experimental Vr2L 2Spirit|Participants immediately begin their participation in the virtual world.
89489228|NCT04885556|Experimental|Immediate Use|Subjects in this arm will be instructed to use the study device for 2 minutes and remove
89489229|NCT04885556|Experimental|1 hour use|Subjects in this arm will be instructed to use the product for one hour and then remove
89489230|NCT04885478||Healthy health care workers|"≥ 18 years of age~Accept to take part in the study and sign the informed consent according to the Declaration of Helsinki.~To be a health care professional worker infected or exposed to SARS-CoV-2~RT-PCR (SARS-CoV2), negative at baseline or follow up~Anti-SARS-CoV-2 IgG and IgM antibodies (Nucleopcapside), negative positive at baseline or follow up"
89489231|NCT04885478||Infected health care workers|"≥ 18 years of age~Accept to take part in the study and sign the informed consent according to the Declaration of Helsinki.~To be a health care professional worker infected or exposed to SARS-CoV-2~RT-PCR (SARS-CoV2), positive at baseline or follow up~Anti-SARS-CoV-2 IgG and IgM antibodies (Nucleopcapside), positive at baseline or follow up"
89489232|NCT03049670||latent available chlorine (LAC)|applying LAC on infected wounds
89489233|NCT04410770|Active Comparator|Active intervention|Participants assigned to the active treatment arm are trained to use the mood tracker app and instructed to complete multiple self-ratings each week. Each the participant receives a support call each week for 6 weeks to engage the participant in the study and to address any problems the participant may have in completing self ratings. After 6 weeks of self-ratings, the participant complete the 6 week outcome. The participant is encouraged to continue completing the self-ratings, but does not receive any more support calls. After 6 more weeks, the 12 week outcome is assessed the participant's involvement with the study ends.
88953543|NCT01963130||drug (metformin, gliclazide and vildagliptin)|The second group (Group 2) consisted of patients that used vildagliptin (50 mg bid) in addition to the same amount of metformin and gliclazide since their HbA1c were detected 7 % or over.
89489234|NCT04410770|No Intervention|Wait list|Wait list participants have no study activities for 6 weeks after completing the baseline assessment. After 6 weeks, list participants complete the 6 week assessment. After completing the assessment. wait list participants are trained to use the mood tracker app and instructed to complete multiple self-ratings each week. Each the participant receives a support call each week for 6 weeks to engage the participant in the study and to address any problems the participant may have in completing self ratings. After 6 weeks of self-ratings, the participant complete the 12 week outcome and the participant's involvement with the study ends.
89489235|NCT04882436||severe pneumonia|Patients with severe pneumonia
89489236|NCT04436822|Experimental|Subjects with diabetes wearing DS5|Subjects wearing DS5 over 7 days and participating in FSTs.
89489237|NCT04309916|Experimental|Tegoprazan 50mg|Tegoprazan 50mg tablet, once daily, oral administration
89489238|NCT04309916|Active Comparator|Esomeprazole 40mg|Esomeprazole 40mg tablet, once daily, oral administration
89489239|NCT04387448|Experimental|GFB-887 multiple ascending dose (MAD) active|GFB-887 active once-daily dosing
89489240|NCT04387448|Placebo Comparator|GFB-887 MAD placebo|GFB-887 placebo once-daily dosing
89489241|NCT01596062|Active Comparator|Simulect 40mg + Neoral + Myfortic + steroids|A cumulative dose of 40 mg of Simulect® (20mg at Day 0 (D0) and 20mg at Day 4 (D4)+ Neoral® + Myfortic® + corticosteroids
88953544|NCT01963156|Experimental|Prescription synchronization|
88953545|NCT01963156|No Intervention|Control|
88953546|NCT01963182|Experimental|irinotecan dose based on genetic polymorphism of UGT1A1|
88953547|NCT01963195|Experimental|Icotinib|Patients can accept the treatment with Icotinib (250/375/500mg tid) until disease progression or unacceptable toxicity occurred. The overall study period takes about 24 months
88953548|NCT01963221|Other|fluodeoxyglucose (18f)|
88953549|NCT01963247||Healthy Athletes|
88953550|NCT01963247||Concussed Athletes|
88953551|NCT01963273|Experimental|pilonidal sinuses|All consecutive patients with diagnosis of chronic sacrococcygeal pilonidal sinus will be screened for the enrollment in our study.
88953552|NCT01963286|Other|Enhanced SVT discriminators|Patients with activated enhanced SVT discriminators (in accordance with predefined mandatory study settings)
88953553|NCT01963299|Active Comparator|Ropivacaine alone group|
88953554|NCT01963299|Experimental|Ropivacaine/Clonidine group|
89489242|NCT01596062|Experimental|Simulect 80mg + Neoral + Myfortic + steroids|A cumulative dose of 80 mg of Simulect® (40mg at D0 and 40mg at D4) + Neoral® + Myfortic® + corticosteroids
89489243|NCT01596062|Experimental|Simulect 80mg + Certican + Myfortic + steroids|A cumulative dose of 80 mg of Simulect® (40mg at D0 and 40mg at D4) + Certican® + Myfortic® + corticosteroids
89489244|NCT04090658|Experimental|RSV_PreF3_AS01B Group|Subjects aged 60 to 80 years received 2 doses of the investigational adjuvanted RSV_PreF3 vaccine (GSK3844766A), at Day 1 and Day 61, by intramuscular (IM) injection into the deltoid region of the non-dominant arm preferably.
89489245|NCT04090658|Placebo Comparator|Placebo Group|Subjects aged 60 to 80 years received 2 doses of placebo as control, at Day 1 and Day 61, by IM injection into the deltoid region of the non-dominant arm preferably.
89489246|NCT03987464|Experimental|Patients with MCI|Participants diagnosed with mild cognitive impairment (MCI) and their study partners
89489247|NCT04885010|Experimental|Probiotics|participants will train for 15 days while consuming the dietary supplement. During the last 8 days the intensity of training will increase to induce overreaching.
89489248|NCT04885010|Placebo Comparator|Placebo|participants will train for 15 days while consuming the dietary supplement. During the last 8 days the intensity of training will increase to induce overreaching.
89489249|NCT02614898||Eculizumab|The targeted population consists of pediatric and adult participants with aHUS who received eculizumab at the discretion of the treating physician.
89489250|NCT04881734||the control group and the overtime group|Patients who started surgery between 8:00 and 16:59 were included in the control group.
89489251|NCT04881734||the overtime group|Patients who started surgery from 17:00 to 22:00 were included in the overtime group.
89204361|NCT00306787|Active Comparator|Valacyclovir|Patients received Valacyclovir 500 mg capsule twice a day approximately 12 hours apart for 3 consecutive days. The first dose was to be taken within 6 hours after onset of prodromal symptoms or genital herpes lesions. On the first day patients also received 2 famciclovir placebo tablets taken with the first 2 doses of Valacyclovir.
89204362|NCT00778154||Alendronate 3 to < 5 years|Alendronate (any combination of 10 mg daily or 70 mg once weekly) 3- 5 years.
89204363|NCT00778154||Risedronate 3 to < 5 Years|Risedronate (any combination of 5 mg daily or 35 mg once weekly) 3-5 years.
89489252|NCT04884932|Experimental|30 kHz stimulation|"Percutaneous application of high frequency electrical current at 30 kHz over the median nerve for a 20 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold."
89489253|NCT04884932|Experimental|Sham stimulation|Electrodes are placed over the median nerve for 20 minutes in the same manner as experimental group but will be applied a sham electrical stimulation increasing the current intensity during the first 30 seconds.
89489254|NCT03747991||Control Infants|Infants ages 2 months to 12 months who are not on H2RA medication.
89489255|NCT03747991||Treated Infants|Infants ages 2 months to 12 months who are taking H2RA medication.
89489256|NCT02145013||Portal hypertension|Hepatectomy
89489257|NCT02145013||No portal hypertension|Hepatectomy
89489258|NCT02145091|Experimental|One all-day session|"Participants will complete on all-day study session with a moderately-high dose of psilocybin.~Preparation will include two days of screening, and an additional 8 hours of session preparation over at least 2 days. Follow-up will consist of an interview and MRI scan one day after the all-day session, a questionnaire follow-up 2 months after the all-day session, and a final follow-up 12-18 months after the all-day session."
88953555|NCT01963312|Experimental|Transarterial Supraselective Embolization|Transarterial supraselective embolization of prostatic arteria with Bead Block 300-500 μm
88953556|NCT01963312|Active Comparator|Transurethral Resection|Surgery to remove part of the prostate gland
89489259|NCT02145091|Experimental|Two all-day sessions|"Participants will complete two all-day study sessions, the first with placebo and the second with a moderately-high dose of psilocybin.~Preparation will include two days of screening and 8 hours of session preparation over at least 2 days, before the first all-day session. Follow-up will consist of an interview and MRI scan one day after each all-day session, a questionnaire follow-up 2 months after each all-day session, and a final follow-up 12-18 months after the second all-day session."
88953557|NCT01963325|Experimental|S-1 plus Abraxane|Patients will receive Abraxane at 100 mg/m2 X 3 doses on Days 1, 8. S-1 chemotherapy was given based on the body surface area, <1.25 m2: 80mg/day, 1.25~1.5 m2: 100mg/day, ≧1.5 m2: 120mg/day. Given orally twice daily for 14 days, followed by 7 days without treatment.
88953558|NCT01963338|Experimental|Intradermal group|These group participants received two intradermal injections with the newly developed device, one in the forearm and one in the upper arm (deltoid region).
89489260|NCT02145091|Experimental|Three all-day sessions|"Participants will complete three all-day study sessions, the first two with placebo and the third with a moderately-high dose of psilocybin. The majority of participants (over 90%) will be assigned to either one or two all-day sessions. A small minority of participants (less than 10%) will be assigned to three all-day sessions.~Preparation will include two days of screening and 8 hours of session preparation over at least 2 days, before the first all-day session. Follow-up will consist of an interview and MRI scan one day after each all-day session, a questionnaire follow-up 2 months after each all-day session, and a final follow-up 12-18 months after the third all-day session."
89489261|NCT02145091|Experimental|MRI of the acute effects of psilocybin|This is an optional arm consisting of two sessions where either placebo, a very-low dose of psilocybin, or a moderately-low dose of psilocybin will be administered. During each session, participants will undergo MRI scanning shortly after the administration of each dose. Study sessions may occur over one or two days. Participants who have previously completed an all-day session with psilocybin in this study will be eligible to volunteer for this arm.
89489262|NCT02152111|Experimental|Dietary Supplement: Coconut flour|Diet hipoernergetic plus 26g/day coconut flour during three months (12weeks).
89489263|NCT02152111|Active Comparator|Nutritional Treatment|All patients received an individualized diet plan and balanced. The diet was calculated to the nutritional status and the protein 15-20% of total energy value, lipids 25-30% of daily energy intake and carbohydrate 50-60% of total energy value
89489264|NCT03544411|Experimental|Type 2 Diabetes Mellitus group 1|The group supplemented with 15 ml / day of olive oil and 15 ml / day of bran oil
89489265|NCT03544411|Experimental|Type 2 Diabetes Mellitus group 2|this group supplemented with 15 ml / day of olive oil and 15 ml / day of bran oil
89489266|NCT03811028|Experimental|SOBI003|"SOBI003 solution, 20 mg/mL, is mixed with NaCl 0.9% infusion solution prior to administration. For a bodyweight < 25 kg, the total infusion volume is 100 mL. For a bodyweight ≥ 25 kg, the total infusion volume is 250 mL.~SOBI003 is administered as i.v. infusions given once weekly for a duration of 80 weeks (from Week 25 until Week 104 following the first 24 weeks of SOBI003 administration in the FIH study (SOBI003-001) study. The SOBI003 dose will be adjusted to the highest dose that has been declared safe by the safety review committee on the FIH study.Hence, dose adjustments may occur a couple of times on the extension study until the final decided dose has been determined."
89489267|NCT04872062||Chronic hypercapnic respiratory failure treated by home non-invasive ventilation (NIV)|
89489268|NCT03441464|Experimental|1st Tier Dose Level|3 patients administered single dose of LUM015 at 0.5 mg/kg. Imaging with the LUM imaging device will be performed ex vivo on resected tissue.
89489269|NCT03441464|Experimental|2nd Tier Dose Leel|3 patients administered single dose of LUM015 at 1.0 mg/kg. Imaging with the LUM imaging device will be performed ex vivo on resected tissue.
89489270|NCT03441464|Experimental|3rd Tier Dose Level|After evaluation of the fluorescence signal observed with the LUM imaging device in the three other cohorts,the subsequent 3 patients will receive a dose of 0.5-1.5 mg/kg.
89489271|NCT03441464|No Intervention|Auto-fluorescence|No LUM015 injection will be given to three (3) patients to measure baseline tissue fluorescence. The tissue will still be imaged ex-vivo using the LUM Imaging Device
88956534|NCT04972071|Other|CSRS practice recommendation|Knowledge translation of the Canadian Syncope Risk Score (CSRS) based practice recommendations
89489272|NCT02776033|Experimental|GSK2982772 receivers in Cohort 1|Randomized subjects will receive GSK2982772 BID (approximately 12 hours apart) via oral route for 84 days.
89489273|NCT02776033|Placebo Comparator|Placebo receivers in Cohort 1|Randomized subjects will receive placebo BID via oral route for 84 days.
89489274|NCT02776033|Experimental|GSK2982772 receivers in Cohort 2|Randomized subjects will receive GSK2982772 TID (approximately 8 hours apart) via oral route for 84 days
89489275|NCT02776033|Placebo Comparator|Placebo receivers in Cohort 2|Randomized subjects will receive placebo TID via oral route for 84 days.
89489276|NCT04881422|Experimental|Experimental group|A group of pwMS participate in a multidimensional integrate high-motivating rehabilitation program for the change of lifestyle and bad habits.
89489277|NCT04881344|Experimental|The laser hemorrhoidoplasty (laser group, intervention group)|
89489278|NCT04881344|Active Comparator|The hemorrhoidopexy (mucopexy group, control group)|
89489279|NCT02145325|Experimental|Expanded Tregs|Immune cells in the blood will be removed by leukopheresis procedure and stored for later manufacture of subject's Expanded Tregs cellular product. Two months following subject's kidney transplantation, subject will be given an Expanded Tregs infusion intravenously in the Northwestern Clinical Research Unit.
89489280|NCT03352934|Experimental|Avelumab|10 mg/kg Avelumab every 2 weeks
89489281|NCT03741829||Samples from transbronchial Biopsy|Samples from participants with SCLC.
89489282|NCT04871828|Experimental|Treatment|"Zafirlukast plus the standard treatment according to Saudi CDC protocol (combination experimental arm)~Description of investigational drug Zafirlukast is leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma. It is available as a tablet and is usually dosed twice daily. It is approved by USFDA and currently commercially marketed under the name of Accolate 20 mg oral tablet. The drug will be acquired from the pharmacy and will be received by the patient during the hospital admission via research coordinator. The study drug will be stored in at room temperature (15 - 25 c) in the hospital's pharmacy and a delegated pharmacist will be responsible for dispensing and return of any drugs.~The study drug will be administrated to the patient in the dose of 20 mg orally twice daily for 10 days (fixed dose with no staring or escalating dose)."
89489283|NCT04871828|Placebo Comparator|Control|placebo plus the standard treatment according to Saudi CDC protocol
89489284|NCT02777125|Active Comparator|Albuterol by Metered Dose Inhaler|Albuterol administered via MDI and spacer device with weight and severity based dosing. For weight less than 20 kg: mild and moderate disease 540mcg of albuterol per dose. For weight greater than or equal to 20 kg: mild disease 540 mcg of albuterol per dose and moderate disease 1080 mcg of albuterol per dose.
89489285|NCT02777125|Active Comparator|Albuterol Breath Actuated Nebulizer|Subjects randomized to BAN were evaluated for proper breath actuation technique. For subjects unable to coordinate breath actuation, the RT attached an appropriately sized mask to the device, changed the setting to continuous nebulization and returned upon completion of the treatment. Albuterol dosing was based upon the subject's weight and presenting symptom severity. Children presenting in the mild and moderate severity category weighing less than 20kg, received 2500mcg of albuterol. Children weighing more than 20kg, received 2500mcg of albuterol if their presentation met mild severity criteria, or 5000mcg if they met moderate criteria.
89489286|NCT04881266||Post Critical Illness due to COVID-19|
89489287|NCT04881266||Caregivers of Post critically ill COVID-19 patients|
89489288|NCT04871906|Experimental|Stretching exercises|Interventions are home-based stretching exercises. The experimental group will receive 6 stretching exercises which stretch 20-30 seconds, relax for 10 seconds, and repeat 5 times for each side. It will take 25-30 minutes every day for continuous 8 weeks.
89489289|NCT04871906|No Intervention|Control group|Maintain their daily activity level in the 8 weeks. We use the study desigh-''waiting list control'' in this group.
89489290|NCT02152189||Screening population|
89489291|NCT04881110|Experimental|Liraglutide group|Patients in this arm will receive liraglutide, according to the current clinical practice.
89489292|NCT04881110|Other|Control group|Patients in this arm will be strictly monitored with optimization of the therapy for atherosclerosis major risk factors.
89489293|NCT02152267|Experimental|tDCS 1mA|the parameters used in the TDCS will be 1mA, cathodal over right DLPFC and anodal over supraorbital contralateral area.
89489294|NCT02152267|Experimental|tDCS 2mA|the parameters used in the TDCS will be 2mA, cathodal over right DLPFC and anodal over supraorbital contralateral area.
89489295|NCT02152267|Sham Comparator|tDCS Sham|the parameters used in the TDCS will be sham, cathodal over right DLPFC and anodal over supraorbital contralateral area.
89489296|NCT04880954|Experimental|Soft Tissue Mobilization|
89489297|NCT04880954|Experimental|Rehabilitation|
89489298|NCT04880954|Experimental|Soft Tissue Mobilization and Rehabiliation|
88953559|NCT01963338|Experimental|Intramuscular group|These group participants received one intramuscular injection in the upper arm(deltoid region) using needle and syringe and one intradermal injection in the forearm using the newly developed device.
88953560|NCT01963351||Locally advanced and metastatic nsclc|non squamous
88953561|NCT01963364|Experimental|Intervention group|All healthy volunteers
88953562|NCT01963377|Experimental|1. Nasal Cannulae / 2. Bronchoscope channel|Supplementation of O2 through will take place first through the aspiration channel of the bronchoscope, in second phase of the study O2-supplementation will be done through nasal cannulae.
88953563|NCT01963377|Experimental|1. Bronchoscope channel / 2. Nasal Cannulae|Supplementation of O2 through will take place first through nasal cannulae, in second phase of the study O2-supplementation will be done through the aspiration channel of the bronchoscope.
88953564|NCT01963390||Testosterone therapy|The study population is a cohort of testosterone deficient men who are planning on undergoing testosterone therapy at an outpatient men's health clinic.
89489299|NCT02145481|No Intervention|Survey development|Patients with coronary artery disease will be given a survey to complete assessing their knowledge, communication with physicians, involvement, and treatment preferences after completing the treatment decision-making process.
89489300|NCT02145481|Experimental|Decision Aid|Patients with stable coronary artery disease will be given a decision aid to review prior to making a treatment decision.
89489301|NCT02145481|Active Comparator|CAD Education|Patient with coronary artery disease will be given a general educational handout on coronary artery disease.
89489302|NCT04880798|Experimental|124I PET/CT|All eligible patients will be allocated to this arm (single-arm study).
89489303|NCT02152423|Other|LOVENOX|patients are given a curative dose of Enoxaparin (LOVENOX)
89489304|NCT02152423|Active Comparator|ENOXAMED|patients are given a curative dose of Enoxaparin (ENOXAMED)
89489305|NCT02145559|Experimental|Metformin XR|All eligible patients with histologically-confirmed advanced solid tumors will be started on sirolimus (3 mg daily) alone for the first 7 days. On day 8, patients will recieve metformin XR (500 mg daily with the evening meal)(through day 21). On day 15, patients randomized to metformin XR will have their dose increased to 1000 mg daily if there is no grade ≥ 2 toxicity due to metformin XR. Patients who develop grade 2 toxicity due to metformin will be maintained on metformin XR 500 mg daily for the rest of the study, while patients who develop > grade 2 toxicity will be taken off study. From day 22 onwards, all patients will be on combination of sirolimus and metformin.
89489306|NCT02145559|Active Comparator|Delayed Metformin|All eligible patients with histologically-confirmed advanced solid tumors will be started on sirolimus (3 mg daily) alone for the first 7 days. On day 8, patients will be randomized to receive no metformin for two weeks (through day 21). From day 22 onwards, all patients will be on combination of sirolimus and metformin. Patients who were initially not randomized to metformin XR will begin taking it at 500 mg daily with an evening meal and titrated up to 1000 mg daily after one week, as above. Each cycle will be 4 weeks.
89489307|NCT02145637|Experimental|Afatinib plus Ruxolitinib combination (single arm)|
89489308|NCT02155621|Experimental|Genome Sequencing|There is only one arm to this study.
89489309|NCT02152501|Experimental|Exercise Energy Expenditure 300 kcal/day|Subjects will be randomly assigned to this group and will exercise energy expenditure of 300 kcal/day.
89489310|NCT02152501|Experimental|Exercise Energy Expenditure 600 kcal/day|Subjects will be randomly assigned to this group and will exercise energy expenditure of 600 kcal/day.
89489311|NCT03154580|Placebo Comparator|N-acetylcysteine 0mg X Cue Exposure (neutral)|
89489312|NCT03154580|Placebo Comparator|N-acetylcysteine 0mg X Cue Exposure (marijuana)|
88953565|NCT01963416|Placebo Comparator|Control|macro- and micro-nutrient matched control (240 ml)
88953566|NCT01963416|Experimental|Orange juice|commercial orange juice (240 ml)
88953567|NCT01963416|Experimental|whole orange|whole orange fruit (240 ml)
89489313|NCT03154580|Active Comparator|N-acetylcysteine 2400mg X Cue Exposure (neutral)|
89489314|NCT03154580|Active Comparator|N-acetylcysteine 2400mg X Cue Exposure (marijuana)|
89489315|NCT02145715|Experimental|Velcade, Thalidomide, Dexamethasone (VTD) + Panobinostat|"Up to 16 cycles of VTD+Panobinostat followed by panobinostat maintenance for 1 year or until disease progression.~Induction - Cycles 1-16 (21-day cycle)~Velcade: 1.3mg/m2 (subcutaneous) on days 1 and 8~Thalidomide: 100mg (PO)on days 1 -21~Dexamethasone: 20 mg (PO) on days 1, 2, 8 and 9~Panobinostat: 10mg, 15mg or 20mg days 1, 3, 5, 8, 10 and 12 Dose depends on cohort entry at registration during the dose escalation phase. The recommended dose will be used during the expansion phase.~Panobinostat monotherapy maintenance for 1 year. Panobinostat will be given at the same dose as the recommended dose during expansion phase"
89489316|NCT04871750|Experimental|Soy protein|30 g powder/day, contains 50 mg of isoflavones
89021826|NCT00446004|Other|A|On an 18-day schedule, Omeprazole (PPI) once daily on days 10 through 16; and Gleevec® once daily on days 1 and 15 (i.e., Gleevec® alone on day 1, and combination of Gleevec® and PPI on day 15).
89489317|NCT04871750|Placebo Comparator|Casein protein|30 g powder/day, no isoflavones
89489318|NCT04871126||LVT group|left ventricular thrombus in acute anterior myocardial infarction patients with left ventricular dysfunction
89489319|NCT04871126||non-LVTgroup|acute anterior myocardial infarction patients with left ventricular dysfunction while without LVT
89489320|NCT03542929|Active Comparator|healthy elderly|healthy elderly were use the Whole body vibration intervention during 10 minutes
89489321|NCT03542929|Experimental|diabetic elderly|diabetic elderly were use the Whole body vibration intervention during 10 minutes
89489322|NCT02145793|Active Comparator|ADHD Group Curriculum|Participants assigned to the group visit intervention agree to participate in 5 group visits every 3 months rather than individual ADHD follow-up visits to the clinic. Parents and children participate in separate but simultaneously run groups. Group portion is 60 minutes and then parent-child dyads complete individual visits for medication titration and physical exam.
89489323|NCT02145793|No Intervention|Control|Participants continue to go to the clinic for 5 routine ADHD follow-up visits to the clinic every 3 months as usual clinical protocol.
89489324|NCT01613144||OsseoScrew|Test Product: OsseoScrew Spinal Fixation System
89489325|NCT01613144||Fenestrated Screw|Control Product: Any commercially available fenestrated screw system augmented with PMMA
89489326|NCT02152579|Experimental|Isosorbide-5-mononitrate, tablet|Single treatment arm.
89489327|NCT04880564|Experimental|A (CN1 0.5mg/kg and CN401 400mg)|"Patients were administered with CN1, 0.5mg/kg, once every three week in combination with 400mg CN401 twice a day, fasted.~Dosage/Route of admin: CN1- Intravenous Infusion(IV); CN401- Tablet, Oral~Three to six patients are expected to be enrolled in each arm."
89489328|NCT04880564|Experimental|B (CN1 1mg/kg and CN401 600mg)|"Patients were administered with CN1, 1mg/kg, once every three week in combination with 600mg CN401 twice a day, fasted.~Dosage/Route of admin: CN1- Intravenous Infusion(IV); CN401- Tablet, Oral~Three to six patients are expected to be enrolled in each arm"
89489329|NCT04880564|Experimental|C (CN1 1mg/kg and CN401 800mg)|"Patients were administered with CN1, 1mg/kg, once every three week in combination with 800mg CN401 twice a day, fasted.~Dosage/Route of admin: CN1- Intravenous Infusion(IV); CN401- Tablet, Oral~Three to six patients are expected to be enrolled in each arm"
89489330|NCT04880564|Experimental|D (CN1 3mg/kg and CN401 800mg)|"Patients were administered with CN1, 3mg/kg, once every three week in combination with 800mg CN401 twice a day, fasted.~Dosage/Route of admin: CN1- Intravenous Infusion(IV); CN401- Tablet, Oral~Three to six patients are expected to be enrolled in each arm"
89489331|NCT04880564|Experimental|E (CN1 10mg/kg and CN401 800mg)|"Patients were administered with CN1, 10mg/kg, once every three week in combination with 800mg CN401 twice a day, fasted.~Dosage/Route of admin: CN1- Intravenous Infusion(IV); CN401- Tablet, Oral~Three to six patients are expected to be enrolled in each arm"
89489332|NCT02155777|No Intervention|No intervention|No intervention.
89489333|NCT02155777|Active Comparator|OrthoNovum 1/35|OrthoNovum 1/35
89489334|NCT02155855|Experimental|Telemedicine|"Telemedicine group will test blood glucose at least 4 times a day Each time the meter time-stamps the reading. All meter readings will upload to the cloud via Myglucohealth website, where they can be accessed by caregivers, including providers and parents. Parents will be notified by device about the blood glucose testing results. Provider will set device to alert patient or patient's family or send alerts if uploaded numbers are outside an identified range (<70 mg/dL > 300 mg/dL). As per the standard of care, parents are trained to administer sugar containing liquids, or inject extra insulin for hyperglycemia correction. Parents will be encouraged to contact study personnel if they are concerned about the diabetes control. Study personnel will access home blood glucose monitor data, and provide insulin dosing advice. Parents will be asked to upload blood glucose readings prior to each visit."
89489335|NCT02155855|Active Comparator|Control|Control Subjects will continue routine care which requires blood glucose testing at least 4 times a day. Parents will use customary ways to communicate (pager, email, fax or phone) with the Diabetes team, if they are concerned about glycemic control..
89204364|NCT00778154||Alendronate ≥ 5 Years|Alendronate (any combination of 10 mg daily or 70 mg once weekly) for greater than or equal to 5 years.
89489336|NCT04870892||Norepinephrine variation|Patients with septic shock, cardiac output monitoring device with the PICCO2 system and decision by the physician in charge to modify the norepinephrine dose.
89489337|NCT04870892||Fluid infusion|Patients with septic shock, cardiac output monitoring device with the PICCO2 system and decision by the physician in charge to give fluid infusion
89489338|NCT02152657|Experimental|Mesenchymal stem cell transplantation|
89489339|NCT04879784||Stored antenatal sera|Antenatal sera from women booking for antenatal care at six centres in England
89489340|NCT04880018|Experimental|Capsular Tension Ring from Eyebright Medical Technology (Beijing) Co., Ltd|Specification model: CTR1109、CTR1210、CTR1311、CTR1412、CTR1513 Manufacturer: Eyebright Medical Technology (Beijing) Co., Ltd.
89489341|NCT04880018|Active Comparator|Capsular Tension Ring from Carl Zeiss Medical Technology Co., Ltd|Specification model: TENSIOBAG 10、TENSIOBAG 11、TENSIOBAG 12、TENSIOBAG 13、TENSIOBAG14 Manufacturer: Carl Zeiss Medical Technology Co., Ltd.
89489342|NCT02145949|Experimental|Essential Amino Acids (EAA)|"Aim 1: Twice-daily ingestion of 20 g of EAA for 1 wk before through 6 wk after TKA.~Supplement composition for the EAAs: histidine, 2.2 g (11% of total); isoleucine, 2.0 g (10%); leucine, 3.6 g (18%); lysine, 3.2 g (16%); methionine, 0.6 g (3%); phenylalanine, 3.2 g (16%); threonine, 2.8 g (14%); and valine, 2.4 g (12%).~Aim 2: Twice-daily ingestion of 23 g of EAA for 1 wk before through 6 wk after TKA.~Supplement composition for the EAAs: histidine, 1.28 g (5% of total); isoleucine, 1.8 g (8%); leucine, 7.4 g (32%); lysine, 3.6 g (15%); methionine, 1.76 g (8%); phenylalanine, 3.1 g (13%); threonine, 1.9 g (8%); valine, 2.08 g (9%); and tryptophan, 0.5 g (2%)."
89204365|NCT00778154||Risedronate ≥ 5 Years|Risedronate (any combination of 5 mg daily or 35 mg once weekly) for greater than or equal to 5 years.
89204366|NCT00778232|Experimental|1|Gabapentin tablets 800 mg by Ranbaxy Laboratories Limited
89204367|NCT00778232|Active Comparator|2|Neurontin ® 800 mg tablets of Parke Davis Pharmaceuticals Ltd
89537898|NCT03062241|No Intervention|Conventional treatment|Pharmacological treatment according to 2016 ESC (European Society of Cardiology) guidelines for the diagnosis and treatment of acute and chronic heart failure and to 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with European Association for Cardio-Thoracic Surgery (EACTS).
89537899|NCT03289403|Experimental|Study group|Patients will receive thyroxine , low dose aspirin , low dose selenium, Calcium and vitamin D and immunomodulatory drugs(prednisolone, hydroxychloroquine, azathioprin, IV immunoglobulins)
89537900|NCT03289403|Active Comparator|Control group|Patients will receive thyroxine , low dose aspirin , low dose selenium, Calcium and vitamin D.
89537901|NCT03289247|No Intervention|Regular|"Regular closure:~The standard 3-layer closure is performed using: 1) size 2 coated VICRYL® Plus Antibacterial suture for capsule closure 2) size 2-0 coated VICRYL® Plus Antibacterial suture for subcutaneous tissue closure and 3) stainless steel stables using PROXIMATE® Fixed-Head stapler for cutaneous closure."
89537902|NCT03289247|Experimental|Additional tissue adhaesive|The standard 3-layer closure is performed using: 1) size 2 coated VICRYL® Plus Antibacterial suture for capsule closure 2) size 2-0 coated VICRYL® Plus Antibacterial suture for subcutaneous tissue closure and 3) stainless steel stables using PROXIMATE® Fixed-Head stapler for cutaneous closure. tissue adhesive (Leukosan®) is applied on top of the staples according to manufacturer instructions. One layer (one tube) of tissue adhesive is applied following air-drying for 30 seconds, followed by a placement of a second layer with a second layer (one tube), and a second air-drying period of 60 seconds
89537903|NCT03061929||Undernourised|Mother's with BMI less than 18.5
89537904|NCT03061929||Normally Nourished|Mother's with BMI greater than or equal to 18.5 to less than or equal to 25.
89537905|NCT03061929||Overnourished|Mother's with BMI over 25 to less than or equal to 35.
89537906|NCT03293771||Stage 1 Focus Groups|The focus groups will involve transgender women who have completed gender confirmation surgery who volunteer to discuss their postoperative experience regarding bladder function, genital complaints, and sexual function.
89537907|NCT03293771||Stage 2 Questionnaire Groups|Stage 2 participants will be asked to complete a questionnaire packet after surgery followed by a second questionnaire completion 2 weeks later. Participants' operative notes and postoperative visit records will be reviewed.
89537908|NCT04971759|Experimental|Group L|30 Patients will receive Levobupivacaine 5%
89537909|NCT04971759|Experimental|LD group|30 patients will receive Levobupivacaine 5% + 1 µg/kg dexmedetomidine.
89537910|NCT04971759|Experimental|LF group|30 patients will receive Levobupivacaine 5% + 1µg/kg fentanyl
89537911|NCT03289169|Experimental|MEDITOXIN|Meditoxin(Botulinum toxin type A)
88953568|NCT01963416|Experimental|processed whole orange|processed whole orange (240 ml)
88953569|NCT01963429|Experimental|A(radiofrequency ablation )|radiofrequency ablation
88953570|NCT01963429|Experimental|B(Proton)|hypofractionated proton beam therapy
89537912|NCT03289091|Experimental|water-based continuous aerobic training|Participants who will be randomized for the intervention in the continuous aerobic training group will carry out exercises with no interval for exercise change. Intensity will be increased every mesocycle. In the first mesocycle (weeks 1-4), participants will carry out three 4-minute series of each exercise whose intensity corresponds to the Rating of Perceived Exertion (RPE) 13. In the second mesocycle (weeks 5-8), participants will perform four 3-minute series of each exercise corresponding to RPE 14. In the third mesocycle, participants will perform six 2-minute series of each exercise at intensity corresponding to RPE 15 from weeks 9-10, whereas intensity corresponding to RPE 16 will be experienced from weeks 11-12.
88953571|NCT01963442|Active Comparator|Amoxicillin/Clavulanic acid treatment|after 3 day treatment of β-lactams, the subjects receive 5-day treatment of Amoxicillin/clavulanic acid. Chest X-ray performed at admission and Day 30 and replapses. 'blood sampling /Cell Counts/CRP/Biochemistry' performed at Day 0, Day 30 and relapse
88953572|NCT01963442|Placebo Comparator|placebo treatment|after 3-day treatment of β-lactams, the subjects receive 5-day treatment of placebo. Chest X-ray performed at admission and Day 30 and replapse. blood sampling /Cell Counts/CRP/Biochemistry' performed at Day 0, Day 30 and relapse
88953573|NCT01963455|Experimental|MDCs transplant|The women who have stress urinary incontinency.
88953574|NCT01963468|Experimental|Early language intervention|"Children will receive 6 months of weekly parent-implemented intervention sessions.~Children will be assessed monthly via audio recordings and language checklists to monitor language development more closely."
89489343|NCT02145949|Placebo Comparator|Placebo (Alanine)|"Aim 1: Twice-daily ingestion of 20 g of Alanine (Non-essential amino acid) for 1 wk before through 6 wk after TKA.~The placebo supplement consists of 20 g (100%) alanine.~Aim 2: Twice-daily ingestion of 23 g of Alanine (Non-essential amino acid) for 1 wk before through 6 wk after TKA.~The placebo supplement consists of 23 g (100%) alanine."
88953575|NCT01963468|No Intervention|Monthly language check-ups|Children will be assessed monthly via home observations and parents will complete a language checklist to monitor language development more closely.
88953576|NCT01963494|Experimental|Dyadic planning intervention|A general motivational treatment is provided to each participant. For randomly assigned couples, randomly selected target persons form action plans to increase daily physical activity together with their partners.
89489344|NCT02152735|Active Comparator|Cleaning the uterine cavity|Cleaning the uterine cavity: participants will have their uterine cavities cleaned with a dry laparotomy sponge after delivery of the placenta. Per standard protocol, the uterus will be explored with one hand holding a sponge to remove any remaining membranes or placental tissue, while the other hand is placed on the fundus to stabilize the uterus.
89489345|NCT02152735|No Intervention|Not cleaning the uterine cavity|These participants will have their uterine cavities left alone after complete delivery of the placenta. The placenta will be inspected after delivery to make sure it is complete, including the membranes.
89489346|NCT03047018|Experimental|CHANGE Program|Participants with ASD will complete the The Changing Health in Autism through Nutrition, Getting fit and Expanding variety (CHANGE) program.
89489347|NCT02146027|Experimental|Fermented Milk Drink Yakult 40|"Lactobacillus casei Shirota, contained in the Fermented Milk Drink Yakult 40~Once daily Lactobacillus casei Shirota, with 40 billion bacteria per 80 g (concentration of 5 x 10^8 CFU/g). Intervention will be used for 12 weeks."
89489348|NCT02146027|Placebo Comparator|Placebo|"The placebo would be an analogous product without Live Lactic Bacteria (Lactobacillus casei Shirota) presented in the same bottle and similar flavor.~Both, Yakult 40 and placebo should be stored refrigerated between 1° and 10°C and"
89489349|NCT00806390|Active Comparator|Metoprolol|Receiving metoprolol
89489350|NCT00806390|No Intervention|Control|Not receiving metoprolol
89489351|NCT00566618|Experimental|Dasatinib + Zoledronic Acid|"Dasatinib Phase I: First Cohort = 100 mg PO Daily x 28 days; Next Cohort = Dose Expansion or Reduction Based on Dose Limiting Toxicity (DLT) in Initial Cohort.~Zoledronic Acid Phase I: First Cohort = 4 mg IV Over 15 min. every 4 Weeks; Next Cohort = Dose Expansion or Reduction Based on Dose Limiting Toxicity (DLT) in Initial Cohort. Phase II: Recommended Phase II Dose (RP2D) as determined with Phase I."
89489352|NCT00095420|Experimental|1|Participants with autism will receive social skills training targeting children with autism
89489353|NCT00095420|Experimental|2|Participants without autism will receive social skills training to increase acceptance of peers with autism
89489354|NCT00095420|Experimental|3|Participants with and without autism will receive a combination treatment of social skills/education about autism
89489355|NCT00095420|Active Comparator|4|Participants with and without autism will receive usual training provided by their school district
89489356|NCT04877600||gender difference|dual task performance
89489357|NCT03046940|No Intervention|Control group|No communication with a doctor
89489358|NCT03046940|Experimental|Patient-centered|Participants communicate with a doctor that uses a patient-centered style of communication
89489359|NCT03046940|Experimental|Doctor-centered|Participants communicate with a doctor that uses a doctor-centered style of communication
89489360|NCT02769481|Active Comparator|Bexagliflozin|Subjects will receive a bexagliflozin tablet, 20 mg, once daily for the duration of the study. Subjects will continue taking metformin and receive placebo for glimepiride daily for the duration of the study.
89489361|NCT02769481|Active Comparator|Glimepiride|Subjects will receive a glimepiride capsule, 2, 4 or 6 mg, once daily for the duration of the study. Subjects will continue taking metformin and receive placebo for bexagliflozin for the duration of the study.
89489362|NCT04410692|No Intervention|Control|Participants' COVID-19 predictions are elicited via a survey
89204368|NCT01564264|Experimental|Sentinel Node Biopsy|Each participant will have both measurements, the new diagnostic test (sentinel node biopsy) and the gold standard (complete lymphadenectomy)
89489363|NCT04410692|Experimental|Treatment|Participants' COVID-19 predictions are elicited via a prediction market
89489364|NCT04879316||adult patients with NSCLC initiating nivolumab or pembrolizumab|Patients underwent a multidisciplinary evaluation including consultation with an oncologist and a dietitian. Such an assessment includes subjective and objective parameters such as medical history, weight loss, current dietary intake (including energy and protein balance), physical examination and anthropometric measurements, functional and mental assessment, medications, Resting Energy Expenditure measurement using indirect calorimetry and laboratory values.
88953577|NCT01963494|Active Comparator|Individual planning intervention|A general motivational treatment is provided to each participant. For randomly assigned couples, target persons form action plans individually to increase daily physical activity and partners receive a distraction task.
88953578|NCT01963494|Active Comparator|No-planning control condition|A general motivational treatment is provided to each participant. For randomly assigned couples, target persons do not receive instructions for action planning, but perform a distraction task together with their partners.
88953579|NCT01963507|Experimental|Resistance training|Resistance training performed three times at week for 16 weeks, in 8 exercises for the main muscles, the protocol of 3 sets of 10 repetitions with intensity of 50% of 1 maximum repetition (MR).
88953580|NCT01963507|No Intervention|Control|
88953581|NCT01963546|Other|Intravenous anesthesia|We use total intravenous anesthesia to assess the stress response.
88953582|NCT01963546|Other|Intravenous and Inhalation anesthesia|We use intravenous and inhalation anesthesia during the surgery.
88953583|NCT01963546|Other|Inhalation anesthesia|We use inhalation anesthesia during the surgery.
88956535|NCT04971226|Experimental|Asciminib|Patients will take asciminib 80 mg QD under fasting conditions on ongoing basis; Patients will be randomized 1:1 asciminib versus Investigator selected TKIs
89204369|NCT01066195|Experimental|gefitinib|
89204370|NCT01066195|Active Comparator|pemetrexed|
89204371|NCT00774644|Experimental|1|clarithromycin 500 mg tablets of Ranbaxy Laboratories Limited
89204372|NCT00774644|Active Comparator|2|BIAXIN® 500 mg tablets containing clarithromycin 500mg tablets
89489365|NCT02152813|Active Comparator|1. Bilateral TENS (Bi-TENS) group|Subjects having bilateral electrical stimulation and task-orientated exercises
89489366|NCT02152813|Placebo Comparator|Unilateral TENS (Uni-TENS) group|Subjects having unilateral TENS over their affected lower limb only, and task-oriented exercises
89489367|NCT04877210|Experimental|Topical Insulin|Insulin (Actrapid) diluted in normal saline
89489368|NCT04877210|Placebo Comparator|Normal Saline|Normal saline eyedrops
89489369|NCT04877210|Active Comparator|Standard Artifical Tear|Gutt systane ultra
89489370|NCT02152891|Experimental|CHAP-EMS/CP@clinic Program Intervention|12 month implementation of the intervention
89489371|NCT02152891|No Intervention|Control|Will complete a survey at baseline and at 1 year, no program or intervention provided
89489372|NCT02146183|Placebo Comparator|placebo / Corn starch|Carbohydrate-containing composition that comprises 2 g carbohydrate per kg of body weight. This composition will be 500 mg placebo starch corn.
89489373|NCT02146183|Active Comparator|Carbohydrate steviol glycosides|500 mg steviol glycosides.
89489374|NCT02152969|Other|Part B|Arm to evaluate influence of Chlorthalidone on pharmacokinetics of amlodipine and telmisartan.
89489375|NCT02152969|Other|Part A|Arm to evaluate influence of amlodipine and telmisartan on pharmacokinetics of Chlorthalidone.
89489376|NCT04876976|Experimental|Cases of group (I) cyanoacrylate glue|Cases of group (I) underwent multilayered closure using dartos facial flap and cyanoacrylate glue as an interposition layer.
89489377|NCT04876976|Active Comparator|Cases of the control group (II) , classic repair|Cases of the control group (II) underwent the same procedure without using cyanoacrylate.
89489378|NCT04879004|Experimental|Ropivacaine Group|ESPB performed with infusion of Ropivacaine 0,375% (20 ml at ech side)
89489379|NCT04879004|Placebo Comparator|Control Group|ESPB performed with infusion of N/S 0,9% (20 ml at each side)
89489380|NCT02156011||Instrumented knee implant|"4-6 subjects with an instrumented TKA, that has been implanted within the study Kniemessprothese: Belastungsmessung bei Patienten mittels einer instrumentierten Knie-Endoprothese (EA4/069/06) approved and conducted at the Charité- Universitätsmedizin in Berlin, Germany, will be involved in this project."
89489381|NCT04870736||Professional Adult Medium Skin CPR-AED Training Manikin with CPR Monitor (Prestan)|medical students trained as BLS trainers and medical students trained in BLS will provide 2 minutes cycle of BLS according to ERC guidelines 2021 wearing the breathable self-sterilizing nanofiber respirators with accelerated copper
89204373|NCT03979027|No Intervention|No Breakfast|Fasting. Ad libitum water intake permitted.
89204374|NCT03979027|Experimental|Breakfast|Ad libitum intake of ready-to-eat-cereal with milk. Participants were given a choice of four commercially available RTECs with 1.8% fat cow's milk. Ad libitum water intake was also permitted. The four ready-to-eat-cereals were corn flakes, toasted rice, shredded whole wheat pieces with a sugar topping, and wheat, corn and oat shapes.
89489382|NCT04870736||Resusci Anne QCPR AED (Laerdal)|medical students trained as BLS trainers and medical students trained in BLS will provide 2 minutes cycle of BLS according to ERC guidelines 2021 wearing the breathable self-sterilizing nanofiber respirators with accelerated copper
89489383|NCT04870736||Resusci Baby QCPR (Laerdal)|medical students trained as BLS trainers and medical students trained in BLS will provide 2 minutes cycle of BLS according to ERC guidelines 2021 wearing the breathable self-sterilizing nanofiber respirators with accelerated copper
89489384|NCT02153125|Experimental|Eplerenone|25mg eplerenone given daily for a week, followed by 50mg given for a total of 3 months since commencement of treatment
89489385|NCT02153125|Placebo Comparator|Placebo|
89489386|NCT03046628|Experimental|Patients with diabetic feet ulcers|Each patient will be examined twice, first with TcPO2 (TCM400, Radiometer Medical ApS, Denmark) and then with a green laser (harmonic of continuous neodymium-doped yttrium aluminium garnet laser 532-nm wavelength and fast camera (PixelLink PLE531) system.
89489387|NCT04879472||Age 50 years and below|"Type of surgery (modality of treatment) either osteosynthesis, Hemiarthroplasty or Total hip replacement~Surgical approach either posterior, lateral or anterolateral~Type of anaesthesia either general or spinal~Presence or absence of comorbidities~Sex"
89489388|NCT04879472||Age more than 50 years|"Type of surgery (modality of treatment) either osteosynthesis, Hemiarthroplasty or Total hip replacement~Surgical approach either posterior, lateral or anterolateral~Type of anaesthesia either general or spinal~Presence or absence of comorbidities~Sex"
89489389|NCT02255071|Experimental|Acupressure|Patients will band a acupressure wristband over Neiguan (P6 point) and acupressure for seven days.
89489390|NCT02255071|Sham Comparator|Sham-Acupressure|Patients will band a sham wristband over wrist but no acupressure for seven days.
89489391|NCT04878926|Active Comparator|Group A (n=30)|IV Sedation + TAP block
88953584|NCT01963546|Experimental|Dexmedetomidine|"the effect of dexmedetomidine on the stress responses generated by patients with diabetic given gastric-bypass surgery : Group A group given the best anesthetic technique from preliminary work + dexmedetomidine Dexmedetomidine as a inducer was given intravenous infusion loading dose 1.0μg/kg for 10min, maintained intravenous infusion by 0.4μg/kg/h.~Group B group given the best anesthesia method from preliminary work(not using dexmedetomidine)."
88953585|NCT01963559|Other|Diabetic patients with MPP|
88953586|NCT01963559|Other|Diabetic patients without MPP|
88953587|NCT01963572|Experimental|surveillance group (SG)|SG will have health education brochure and free class from the first visit post-operatively but CG will only have the brochure. Moreover, SG will be screened every time when they visit the clinics. If there is any early sign of impairment, professional advice and counseling will be given additionally.
88953588|NCT01963572|No Intervention|general care group (CG)|CG raises any health-related question, they can be answered.
88953589|NCT01963585||Negative metacholine|Healthy control
88953590|NCT01963585||Positive metacholine|Hyperreactive airway disease - study group
88953591|NCT01963624||Breast masses detected with screening US|Those assessed with conventional B-mode US alone and those assessed with combined elastography and color doppler ultrasonography along with B-mode US.
88953592|NCT01963637|Experimental|Patients with morbid obesity|Patients with morbid obesity and who requires a gastric bypass or a Sleeve gastrectomy as a 1st bariatric procedure.
88953593|NCT01963650||No treatment|
88953594|NCT01963663|Active Comparator|Metformin|patients receiving fixed dose metformin 1000 mg daily
88953595|NCT01963663|Active Comparator|Pioglitazone|patients receiving fixed dose pioglitazone 30 mg daily
88953596|NCT01963689|Placebo Comparator|Intervention Group 2|Individuals belonging to Group 2 received a bottle containing aromatic gel enriched with ylang ylang essence only in 2% concentration and used massage with essential oil 3 times a day: leaving home to go to work, leaving the shift and before bedtime. The points indicated were the two handles and the sternum. Gel was applied and massaged in a circular motion for 30 seconds.
88953597|NCT01963689|Experimental|Intervention Group 1|Individuals belonging to Group 1 received a bottle containing aromatic gel enriched with essential oil of ylang ylang in a concentration of 2% and used massage with essential oil 3 times a day: leaving home to go to work, leaving the shift and before bedtime. The points indicated were the two handles and the sternum. Gel was applied and massaged in a circular motion for 30 seconds.
89021827|NCT00446004|Other|B|On an 18-day schedule, Omeprazole (PPI) once daily on days -4 through 1; and Gleevec® once daily on days 1 and 15 (i.e., combination of Gleevec® and PPI on day 1, Gleevec® alone on day 15).
89489392|NCT04878926|Active Comparator|Group B (n=30)|IV Sedation + LA infiltration
89489393|NCT04879082||ILD|Patients with ILD, whose file has been discussed in a multidisciplinary meeting since May 2020 at the Louis Pradel Pneumological Hospital, and who have benefited from a professional interview in the Occupational pathology consultation center of the Hospital Center Lyon Sud.
89489394|NCT04878848|Experimental|Proprioceptive Neuromuscular Facilitation Group|"Participants in the proprioceptive neuromuscular facilitation group will be given a treatment protocol consisting of rhythmic initiation, repeated stretch and hold-relax PNF techniques for upper extremity flexion-abduction-external rotation pattern and the scapular patterns of anterior elevation, posterior depression, anterior depression, posterior elevation for a total of 4 weeks, 3 days a week for 45 minutes. Assessments will be applied in the baseline and at the end of 4 weeks."
89489395|NCT04878848|Experimental|Conventional Rehabilitation Group|Participants in the conventional rehabilitation group will be given a treatment protocol consisting of stretching, strengthening exercises and joint mobilization techniques for a total of 4 weeks, 3 days a week for 45 minutes. Assessments will be applied in the baseline and at the end of 4 weeks.
89489396|NCT04876664|Experimental|Ambulatory monitoring solution|this study has only one arm
89489397|NCT02156245|Experimental|"Conventional group"|
89489398|NCT02156245|Experimental|"Combined group"|
89489399|NCT02153203|Experimental|Behavioral approach|The Prevent-Teach-Reinforce Model will be implemented with families in their home settings.
89489400|NCT02153203|Active Comparator|Educational approach|Each child's parent will participate in one 2- to 3-hour individual parent training session on the assessment and treatment of problem behavior in children with autism spectrum disorders.
89489401|NCT02146261|Experimental|1|Subcutaneous administration of E6011 50 mg
89489402|NCT02146261|Experimental|2|Subcutaneous administration of E6011 100 mg
89489403|NCT02146261|Experimental|3|Subcutaneous administration of E6011 200 mg
89489404|NCT02146261|Experimental|4|Subcutaneous administration of E6011 400 mg
89489405|NCT02146261|Placebo Comparator|5|Subcutaneous administration of placebo
89489406|NCT02153281|Experimental|Phenelzine treatment|Subjects will undergo a PET and MRI scan before and after the treatment.
89489407|NCT02146339|Experimental|Unfortified-3g-5g milk polar lipid fortified cheese product|Each subject will receive a single dose of each cheese product (100 g) containing no or 3g or 5g of milk polar lipids, 300 mg of [1,1,1]-13C-triolein and 45 mg of 2H6-cholesterol. The wash-out period is four weeks.
89489408|NCT02146339|Experimental|Unfortified-5g-3g milk polar lipid fortified cheese product|Each subject will receive a single dose of each cheese product (100 g) containing no or 3g or 5g of milk polar lipids, 300 mg of [1,1,1]-13C-triolein and 45 mg of 2H6-cholesterol. The wash-out period is four weeks.
89489409|NCT02146339|Experimental|3g-5g milk polar lipid fortified-unfortified cheese product|Each subject will receive a single dose of each cheese product (100 g) containing no or 3g or 5g of milk polar lipids, 300 mg of [1,1,1]-13C-triolein and 45 mg of 2H6-cholesterol. The wash-out period is four weeks.
88953598|NCT01963689|Experimental|Intervention Group 3|The subjects in Group 3 were responsible for before the beginning of their working, put a drop of essential oil of ylang ylang in cotton located within the freshener personal and should be used throughout your work shift
88953599|NCT01963702|Experimental|Docetaxol ＆Capecitabine (TX)|Docetaxol: 75 mg/m2 d1, (From MAY 15th 2013, the dose was reduced to 60mg/m2 for high incidence of G3/4 myelosuppression after approved by institute Ethics Committee) ; Capecitabine 1000 mg/m2 bid ×14d; Repeat every 3 weeks, until disease progression or intolerable toxicity or patients withdrawal of consent,or total 8 cycles
89489410|NCT02146339|Other|3g-Unfortified-5g milk polar lipid fortified cheese product|"Each subject will receive a single dose of cheese n°1, then cheese n°2 after a wash-out period of 4 weeks, then cheese n°3 after a wash-out period of 4 weeks.~Cheese n°1 = unfortified cheese product Cheese n°2 = 3 g milk polar lipid fortified cheese product Cheese n°3 = 5 g milk polar lipid fortified cheese product"
89489411|NCT02146339|Experimental|5g-unfortified-3g milk polar lipid fortified cheese product|Each subject will receive a single dose of each cheese product (100 g) containing no or 3g or 5g of milk polar lipids, 300 mg of [1,1,1]-13C-triolein and 45 mg of 2H6-cholesterol. The wash-out period is four weeks.
89489412|NCT02146339|Other|5g-3g milk polar lipid fortified-unfortified cheese product|Each subject will receive a single dose of each cheese product (100 g) containing no or 3g or 5g of milk polar lipids, 300 mg of [1,1,1]-13C-triolein and 45 mg of 2H6-cholesterol. The wash-out period is four weeks.
89489413|NCT02146417|Active Comparator|Normal pressure pneumoperitoneum & deep neuromuscular block|Normal pressure pneumoperitoneum
89021828|NCT00339560||Cases will bile duct CA|Patients with bile duct cancer
89021829|NCT00339560||Cases with Gallbladder CA|Patients with gallbladder cancer
89021830|NCT00339560||Controls with gall stones|Patients undergoing cholecystectomy for gall stones
89021831|NCT00339560||Controls without cancer|Hospital controls with cancer
89021832|NCT00446082|Experimental|SOM230 LAR|
89021833|NCT00339677||Volunteers|Volunteers
89021834|NCT03275376|Experimental|Statin treated group|
89021835|NCT03275376|Placebo Comparator|Control group|
89021836|NCT00339716||Belarus in utero|subjects exposed to I131 in utero
89021837|NCT00339716||Main BelAm|subjects exposed to I131 at age less than 18 year
89021838|NCT03275337|Experimental|Anodal tDCS|Anodal tDCS will be performed over bilateral cerebellar hemispheres for 20-minutes.
89021839|NCT03275337|Experimental|Cathodal tDCS|Cathodal tDCS will be performed over bilateral cerebellar hemispheres for 20-minutes.
89021840|NCT03275337|Active Comparator|Sham tDCS|Sham tDCS will be performed over bilateral cerebellar hemispheres for 20-minutes.
89021841|NCT03275259|Experimental|Extracorporeal shock waves|Composed of 30 female patients with glandular lipodystrophy in the buttocks and posterior thigh and fat located in abdomen and flanks that received the treatment of extracorporeal shock waves with energy between 100 and 180mJ, frequency of 15Hz and 6000 shots in abdomen, glutes and thigh Back and flanks 3000 shots with radial applicator and 15mm tip. The treatment is performed twice a week for 1 hour and 30 minutes each session.
89021842|NCT00339950||1|Asymptomatic women between the ages of 40 and 75 referred to regional military medical centers for routine colorectal screening
89021843|NCT00339989||Women undergoing colposcopy|women attending the University of Oklahoma Colposcopy Clinic
89021844|NCT04698447|Experimental|Dietary Supplement blinded|20 subjects with the metabolic syndrome receiving natural supplement containing nanovesicles delivered from Citrus Limon (L.) juice (1000 mg/day)
89021845|NCT04698447|Placebo Comparator|Placebo blinded|20 subjects with the metabolic syndrome receiving placebo (without any active ingredients)
89021846|NCT04698447|Active Comparator|Dietary Supplement open-label|20 healthy volunteers receiving natural supplement containing nanovesicles delivered from Citrus Limon (L.) juice (1000 mg/day)
89489414|NCT02146417|Experimental|Low pressure pneumoperitoneum & deep neuromuscular block|Low pressure pneumoperitoneum
89489415|NCT02156323|Experimental|Treatment Sequence 1|Participants will be randomized to one of two treatment sequences. Sequence 1 is: Period 1, RO7033877; Period 2, CMS; Period 3, RO7033877 + CMS. Each period is separated by a wash-out period of at least 6 days between last dose and start of next treatment.
89021847|NCT00446238|Experimental|Cognitive Behavioral Therapy|CBT enhanced with physical illness narrative, family education, and social skills components.
89021848|NCT00446238|Active Comparator|Standard of Community Care Treatment|Standard of Community Care Treatment
89021849|NCT00340262||FIT Participants|
89021850|NCT04698408|Experimental|high-protein, carbohydrate-reduced diet|
89021851|NCT04698408|Active Comparator|Dutch Nutritional Guidelines|
89021852|NCT00446316|Experimental|Gleevec plus antacids|Gleevec® will be administered at a dose of 400 mg, and the antacid (Maximum Strength Maalox®Max® Antacid/Anti-gas) at a dose level of 20 mL (equivalent to 1600 mg aluminum hydroxide and 1600 mg magnesium hydroxide). Half of the subjects will receive Gleevec® and antacid on day 15 and Gleevec® alone on day 1.
89021853|NCT00446316|Experimental|Imatimib Mesylate (Gleevec®)|Gleevec® will be administered at a dose of 400 mg. Half of the subjects will receive Gleevec® and antacid on day 15 and Gleevec® alone on day 1. The other half will be treated in reverse order, i.e., they will receive the combination of Gleevec® and antacid on day 1, and Gleevec® alone on day 15. The antacids will be administered 15 minutes before the Gleevec® dose.
89021854|NCT00340340||Cases|Newly diagnosed lung cancer cases
89021855|NCT00340340||Controls|Population-based controls
89021856|NCT00446394|Experimental|1|
89021857|NCT00446394|Active Comparator|2|
89021858|NCT00340457||Cases|African American patients with renal cancer from two geographic areas of the US
89021859|NCT00340457||Controls|African American participants without renal cancer from two geographic areas of the US
89021860|NCT03275181||Prostate cancer patient/survivor with ADT history|Prostate cancer patients or survivors who have a treatment history that includes androgen deprivation therapy. This includes 1) orchiectomy (surgical castration), 2) luteinizing hormone-releasing hormone (LHRH) agonists (also called LHRH analogs or Gonadotrophin-releasing hormone (GnRH) agonists), 3) LHRH antagonist, 4) CYP17 inhibitor, or 5) anti-androgen.
89021861|NCT03275181||Prostate cancer patient/survivor without ADT history|Prostate cancer patients or survivors who have never been treated with androgen deprivation therapy.
89021862|NCT03275181||Control|Individuals with no history of prostate caner androgen deprivation therapy. Free of known clinical cardiovascular disease
89021863|NCT00340535||Individuals|Individuals recruited at U of Pittsburgh
89021864|NCT03275025|Experimental|YRA-1909 low dose|
89021865|NCT03275025|Experimental|YRA-1909 medium does|
89021866|NCT03275025|Experimental|YRA-1909 high dose|
89021867|NCT03275025|Placebo Comparator|YRA-1909 Placebo|
89021868|NCT00452244|Experimental|study arm|Iressa (gefitinib) + simvastatin
89021869|NCT00452244|Active Comparator|control arm|Iressa (gefitinib) only
89489416|NCT02156323|Experimental|Treatment Sequence 2|Participants will be randomized to one of two treatment sequences. Sequence 2 is: Period 1, CMS; Period 2, RO7033877; Period 3, RO7033877 + CMS. Each period is separated by a wash-out period of at least 6 days between last dose and start of next treatment.
89489417|NCT03542851|Experimental|Subject Receives BTD001 first|
89489418|NCT03542851|Experimental|Subject Receives Placebo first|
89489419|NCT02769247|Experimental|Placebo|Patient will receive placebo oral medication and intrauterine normal saline prior to IUD insertion
89489420|NCT02769247|Experimental|Naproxen/Normal saline|Patient will receive naproxen and intrauterine normal saline prior to IUD insertion
89489421|NCT02769247|Experimental|Placebo oral medication/Lidocaine|Patient will receive placebo oral medication and intrauterine lidocaine prior to IUD insertion
89489422|NCT02769247|Experimental|Naproxen/Lidocaine|Patient will receive naproxen and intrauterine lidocaine prior to IUD insertion
89489423|NCT02146573|Experimental|CCI Provider for Parent-patient dyad|Parents and patients are randomly assigned to a Continuity Care Intensivist (CCI) Provider who has received specialized communication training. The parent-patient dyad will receive standardized care from the CCI throughout their time in the PICU in addition to being assigned a rotating physician of record.
89489424|NCT02146573|No Intervention|Usual Care for Parent-patient dyad|Patients and parents randomly assigned to usual care in the PICU which includes the rotation of the physician of record approximately every 7 days. There is no standardized process by which patients may be assigned a primary attending who would follow them throughout their stay. In the usual care arm it may never happen that they are assigned a primary intensivist, regardless of the length of their hospitalization.
89489425|NCT02146651|Experimental|BioChaperone insulin lispro 0.2U/Kg|BioChaperone insulin lispro 0.2U/Kg
89489426|NCT02146651|Experimental|BioChaperone insulin lispro 0.1U/Kg|BioChaperone insulin lispro 0.1U/Kg
89489427|NCT02146651|Experimental|BioChaperone insulin lispro 0.4U/Kg|BioChaperone insulin lispro 0.4U/Kg
89489428|NCT02146651|Active Comparator|Humalog® 0.2U/Kg|Humalog® 0.2U/Kg
89489429|NCT02153515|Experimental|Fingerprick of autologous blood (FAB)|Fingerprick of autologous blood (FAB) four times a day for 2 months
89489430|NCT02156401||Cohort 1: Suspect of Pulmonary Embolism (PE)|
89489431|NCT02156401||Cohort 2: Suspect of Deep Vein Thrombosis (DVT)|
89489432|NCT02156401||Cohort 3: Incidental Venous Thromboembolism (VTE)|
89489433|NCT02773537|Active Comparator|Randomization Group 1|Femoral nerve catheter and sciatic nerve block
89489434|NCT02773537|Active Comparator|Randomization Group 2|Adductor canal catheter and selective tibial block
89489435|NCT02773537|Active Comparator|Randomization Group 3|Adductor canal catheter only
89489436|NCT03542149|Experimental|A|"200mg of OZ439 and 480 mgPQP.~(OZ439 + α-tocopherol polyethylene glycol 1000 succinate (TPGS) granules for oral suspension).~The data will be used to determine the relationship between OZ439 and PQP concentrations and parasitaemia levels."
89489437|NCT03542149|Experimental|B|"200mg of OZ439 and 640 mg PQP.~(OZ439 + α-tocopherol polyethylene glycol 1000 succinate (TPGS) granules for oral suspension).~The data will be used to determine the relationship between OZ439 and PQP concentrations and parasitaemia levels."
89489438|NCT03542149|Experimental|C|"400mg of OZ439 and 480 mg PQP.~(OZ439 + α-tocopherol polyethylene glycol 1000 succinate (TPGS) granules for oral suspension).~The data will be used to determine the relationship between OZ439 and PQP concentrations and parasitaemia levels."
89489439|NCT03542149|Experimental|D|"400mg of OZ439 and 640 mg PQP.~(OZ439 + α-tocopherol polyethylene glycol 1000 succinate (TPGS) granules for oral suspension).~The data will be used to determine the relationship between OZ439 and PQP concentrations and parasitaemia levels."
89489440|NCT02146729|Experimental|Percutaneous Pedicle Screw Fixation|Percutaneous Pedicle Screw Fixation
89489441|NCT02146729|Active Comparator|Open Treatment|Midline posterior incision with instrumentation.
89489442|NCT02153593|Experimental|Tranexamic acid|Tranexamic acid, 1g intra-articular before closing the surgery wound
89489443|NCT02153593|Experimental|Fibrin glue|One intra-articular dose of fibrin glue (Evicel 5mL) before closing the wound surgery
89489444|NCT02153593|Active Comparator|Usual hemostasia|Electrocauterization
89489445|NCT03544177|Experimental|BFR-Walking|Interval walking training with blood flow restriction.
89489446|NCT03544177|Active Comparator|Conventional therapy|Conventional therapy
89489447|NCT02156479||Allo-HSCT recipients|Patients receiving an allogeneic hematopoietic stem cell transplantation for the first time, being either CMV seropositive or receiving a graft from a CMV seropositive donor or both, donor and recipient are CMV seropositive
89489448|NCT02153749|Experimental|Cognitive Regulation of Craving|Training in craving regulation component of Cognitive Behavioral Therapy(CBT) for addictions.
89489449|NCT02153749|Experimental|Mindfulness-Based Regulation of Craving|Training in craving regulation component of Mindfulness Based Therapy(MBT) for addiction.
89489450|NCT02153749|No Intervention|No training control|No training sessions will be provided in this arm.
89021870|NCT00446472|Experimental|1|Randomized to Regranex gel
89489451|NCT02156557|Experimental|peptide application|"Investigational Agent Administration~KCCFPAQ-GGGSK-(5-FITC)-NH2~1.2 mg lyophilized powder per single-use amber vial~Lyophilized powder reconstituted with 10 mL of 0.9% NaCl~Final concentration of 76.4 μM for single, one-time topical application~The entire 10 mL solution will be sprayed topically onto area of interest by the Clinical Research Associate (CRA)/physician during the procedure through a standard endoscopy spray catheter (Olympus Medical, Tokyo Japan, PW-5V-1)"
89021871|NCT00446472|Active Comparator|2|Placebo hydrogel will be used for a total of 16 weeks
89021872|NCT04715711|Active Comparator|Active Cooling|Participants will be actively cooled during rest breaks
89489452|NCT02780713|Experimental|AZD9496|"This is a fixed sequence study with 5-sequential treatment periods in healthy volunteers. Each volunteer will receive 5 single doses of AZD9496 in different forms, formulations and doses.~Treatment period 1 will assess AZD9496 Variant A: 100mg.~Treatment period 2 will assess AZD9496 Reference: 100mg.~Treatment period 3 will assess one of AZD9496 Variants, B, C or D: 100mg.~Treatment period 4 will assess one of AZD9496 Variants, B, C or D: 100mg.~Treatment period 5 will assess one of AZD9496 Variants A, B, C or D: *300mg. *Based on a review of PK and safety results from Treatment Periods 1, 3 and 4, a lower dose of 200 mg may be administered in Treatment Period 5"
89489453|NCT02146807|Experimental|Picosecond Laser System|
89489454|NCT02154217|Experimental|Bimatoprost|once daily
89489455|NCT02154217|Experimental|Latanoprost/Timolol|once daily
89489456|NCT02146963||alcohol withdrawal|
89489457|NCT02147041|Experimental|EGCG(Epigallocatechin Gallate)|EGCG(Epigallocatechin Gallate)(500 mg, three times a day, 12 weeks)
89489458|NCT02147041|Placebo Comparator|placebo|cellulose (500mg, three times a day, 12 weeks)
89489459|NCT02147119||Patients post- cardiac catheterisation|
89489460|NCT02147275||hypertension disease|patients have hypertension disease, whether well-controlled or uncontrolled, more than 3 year
89489461|NCT02156635|Experimental|Active tdcs / CIMT|Participants in the acute post-stroke stage will receive active tDCS associate to rehabilitation (CIMT)
89489462|NCT02156635|Sham Comparator|Sham stimulation / CIMT|Participants in the acute post-stroke stage will receive sham stimulation associate to rehabilitation (CIMT)
89489463|NCT02767765|Experimental|r-HuEPO|Anemic cancer participants will receive r-HuEPO for 4 weeks.
89489464|NCT02156713|Experimental|CIMT Camp|Members of this study will participate in the group CIMT camp.
89489465|NCT02156791|Experimental|gpASIT+TM|
89489466|NCT02156869|Experimental|Intervention arm|The intervention was the use of a decision aid.
89489467|NCT02156869|No Intervention|Control arm|Usual care
89489468|NCT02156947||Chronic cholecystitis|Laparoscopic cholecystectomy was performed. Gallbladder adhesion score and intraoperative findings of patients were assessed. Adhesion score, gallbladder perforation during the dissection, convertion to open cholecystectomy, operation time, drain usage and intraoperative complications were recorded.
89489469|NCT02156947||Acute cholecystitis|Laparoscopic cholecystectomy was performed. Gallbladder adhesion score and intraoperative findings of patients were assessed. Adhesion score, gallbladder perforation during the dissection, convertion to open cholecystectomy, operation time, drain usage and intraoperative complications were recorded.
89489470|NCT02772757|Active Comparator|Standard of Care group|Standard of Care group will receive the standard, face-to-face hearing aid fitting and verification approach
89021873|NCT04715711|Placebo Comparator|No Intervention|"Participants will participant in passive cooling where they sit in a chair during rest."
89489471|NCT02772757|Experimental|Average RECD group|This group will have their hearing aid fitting via the coupler using average RECD values during the fitting
89489472|NCT02772757|Experimental|Measured RECD group|This group will have their hearing aid fitting via the coupler using measured RECD values during the fitting
89489473|NCT02147431|Experimental|Semaglutide|
89021874|NCT00446589|Experimental|F|HD pts suffering from osteoporosis and adynamic bone disease who received teriparatide
89021875|NCT00446589|Experimental|I|Hemodialysis pts suffering from osteoporosis who received iv ibandronate
89021876|NCT00340808||endometrial cancer cases|endometrial cancer cases
89021877|NCT00446628|Experimental|intervention|Five elementary school received intervention consistin of training in hand and respiratory hygiene, and access to hand sanitizer
89021878|NCT00446628|No Intervention|control|Five elementary school received no training or hand sanitizer.
89021879|NCT00452478|Experimental|1|
89021880|NCT00452556|Active Comparator|Standard Radiotherapy Sequence Arm|Standard sequence of radiotherapy = whole pelvic lymphatics, proximal seminal vesicles, prostate (or prostate bed) first, then prostate/prostate bed last
89021881|NCT00452556|Experimental|Experimental Radiotherapy Sequence Arm|Experimental sequence of radiotherapy = whole pelvic lymphatics, proximal seminal vesicles, prostate (or prostate bed) last, prostate/prostate bed first
89021882|NCT00446667|Experimental|1|
89021883|NCT03277755|Experimental|Cohort1:Participants With Moderately Impaired Hepatic Function|Participants With moderately impaired hepatic function will receive a single oral dose of AL-335 800 milligram (mg) (2 tablets of 400 mg AL-335) on Day 1 of Part 1 followed by a single oral dose of odalasvir (ODV) 25 mg (1 tablet of 25 mg ODV) on Day 8 of Part 1 and a combination of AL-335 800 mg (2 tablets of 400 mg AL-335) + ODV 25 mg (1 tablet of 25 mg ODV) + simeprevir (SMV) 75 mg (1 capsule of 75 mg SMV) once daily on Day 1 to 14 of Part 2. There will be a washout period between Part 1 and Part 2 of at least 14 days. Day 8 of Part 1 will be the start of the washout period. Prior to the start of study drug administration in Part 2, a safety review will be performed by the Sponsor.
89489474|NCT02147431|Placebo Comparator|Placebo|
89489475|NCT02154295|Active Comparator|Eagle Eye Platinum|Eagle Eye Platinum Catheter as the comparator.
89489476|NCT02154295|Active Comparator|Revolution|Revolution Catheter as the comparator
89489477|NCT02154295|Active Comparator|TVC Insight 40MHz|TVC Insight as comparative catheter.
89489478|NCT02154295|Active Comparator|Atlantis Pro|Atlantis Pro catheter as comparator
89489479|NCT02147509|Experimental|Severe dry eye|"0.02% Fm, SH~0.02% Fm, SH, AS~0.02% Fm, SH, 0.05% CsA~0.02% Fm, SH, tBCL (0.05% CsA: 0.05% cyclosporin A; tBCL: therapeutic bandage contact lenses; 0.02% Fm: 0.02% Fluorometholone; AS: Autologous Serum; SH: Sodium Hyaluronate)"
89489480|NCT00103207|Experimental|Cetuximab|Cetuximab was given as a weekly intravenous (IV) infusion (over 60 minutes) at 250 mg/m2 from week 2 onwards after an initial loading dose of 400 mg/m2 (over 120 minutes) on week 1 until disease progression or unacceptable toxicity. The infusion rate of cetuximab could not exceed 5 mL/min. Each cycle will be 28 days in length. To prevent a hypersensitivity reaction, all patients were premedicated with diphenhydramine hydrochloride 50 mg (or an equivalent antihistamine) by IV (over 30-60 minutes) prior to the first dose of cetuximab. Premedication might be administered prior to subsequent doses, but at the investigator's discretion, the dose of diphenhydramine (or a similar agent) was reduced.
89537913|NCT03289091|Experimental|water-based interval aerobic training|Participants who will be randomized for the intervention in the interval aerobic training group will carry out exercises which associate effort phases, at higher intensity and recovery phases, at lower intensity, with no interval for exercise change. Intensity will be increased every mesocycle. The first mesocycle (weeks 1-4) comprises three 4-minute series of each exercise whose intensity corresponds to the RPE 16 for 2 minutes and RPE 11 for 2 minutes. The second mesocycle (weeks 5-8) includes four 3-minute series of each exercise whose intensity corresponds to the RPE 17 for 1.5 minutes and RPE 11 for 2 minutes. The third mesocycle (weeks 9-12) comprises six 2-minute series of each exercise whose intensity corresponds to the RPE 18 for 1 minute and RPE 11 for 1 minute.
89537914|NCT03061851|Experimental|conventional treatment|given conventional hypoglycemic drug treatment, the treatment plan by the investigators according to the patient's condition may be, this study does not interfere.
89537915|NCT03061851|Experimental|conventional treatment + maltose app|the patients were treated with conventional hypoglycemic drugs. The treatment plan was decided by the investigators according to the patient's condition. The intervention was not done in this study.And joint: maltose App intervention.
89537916|NCT03289013|Experimental|Testing of new adhesive strips|"Each subject will test six adhesive strips on pre-stripped skin.~Standard adhesive 1~Standard adhesive 2~LT-2~LT-21~LT-25~33-20~The six strips are applied on the abdominal skin. The order of the adhesive strips on the skin is randomized. The subjects will change the adhesive strips at home and the adhesion of adhesive strips will be measured at 5 visits."
89537917|NCT04971603|Experimental|Acupuncture treatment group|The patients will receive 24-week acupuncture treatment and 12-week follow up. Seven visits will be arranged within the 24-wk treatment period and at the end of study at wk 6, 10, 14, 18, 22, 26 and 38 for medical consultation and investigation.
89537918|NCT03293693|Experimental|Test meal 1|Test meal with 0.5 g beta-glucan
89537919|NCT03293693|Experimental|Test meal 2|Test meal with 3.5 g beta-glucan
89537920|NCT03293693|Experimental|Test meal 3|Test meal with 8 g beta-glucan
89537921|NCT03288935|Active Comparator|Group 1 (TICM only)|Assigned to TICM group after reception & placement.
89537922|NCT03288935|Active Comparator|Group 2 (TICO only)|Assigned to TICO group after reception & placement.
89537923|NCT03288935|Active Comparator|Group 3 (TICM & TICO)|Assigned to both TICM and TICO group after reception & placement.
89537924|NCT03288935|No Intervention|Group 4 (None)|No additional intervention after reception & placement
89537925|NCT04971369|Experimental|89Zr-NY001 injection|Patients will receive a tracer (5 mg, IV) dose of Zr-89 (1.5-2 mCi) labeled NY001 (89Zr-NY001)
89537926|NCT03293537|Experimental|Patients with dementia|The subject will be informed of the procedure and their task before the sensors are attached. Electrodermal activity (EDA) and heart rate (HR) will be continuously monitored while the subject views the image sequence on a PC monitor. EDA will be measured using electrodes attached to the middle (D3) and ring finger (D4). Heart rate will be measured using an infrared pulseoximeter attached to one of the free digits of the hand. A pulseoximeter is a non-invasive sensor, using tissue absorption of infrared light to determine blood-oxygen saturation (SaO2). EDA and HR will be recorded concurrently using commercial software. Data analysis will involve both commercial and in-house software.
89021884|NCT03277755|Experimental|Cohort 2: Participants With Normal Hepatic Function|Participants with normal hepatic function will receive a single oral dose of AL-335 800 mg (2 tablets of 400 mg AL-335) on Day 1 of Part 1 followed by a single oral dose of ODV 25 mg (1 tablet of 25 mg ODV) on Day 8 of Part 1 and a combination of AL-335 800 mg (2 tablets of 400 mg AL-335) + ODV 25 mg (1 tablet of 25 mg ODV) + SMV 75 mg (1 capsule of 75 mg SMV) once daily on Day 1 to 14 of Part 2. There will be a washout period between Part 1 and Part 2 of at least 14 days. Day 8 of Part 1 will be the start of the washout period. Prior to the start of study drug administration in Part 2, a safety review will be performed by the Sponsor.
88953600|NCT01963702|Active Comparator|Oxaliplatin ＆Capecitabine (XELOX)|Oxaliplatin: 130 mg/m2 d1; Capecitabine 1000 mg/m2 bid ×14d; Repeat every 3 weeks, until disease progression or intolerable toxicity or patients withdrawal of consent,or total 8 cycles
88953601|NCT01963715|Experimental|EGFR+ Solid Tumor|EGFR+ Solid Tumor
89021885|NCT03277677|Active Comparator|normal saline|
89021886|NCT03277677|Active Comparator|balanced solution|
89021887|NCT00341315||Cohort|A primarily African-American population living in the vicinity of a DDT production plant inAlabama.
89021888|NCT02956980|Experimental|Group 1: non-pubescent children|70 non-pubescent children (25 healthy boys, 25 healthy girls, 10 boys with Klinefelter syndrome and 10 girls with Turner syndrome) Two 7 ml tubes of blood will be taken to perform the functional assays as well as the quantification of Blood Plasmacytoid dendritic cells (pDCs) absolute number in this 70 non-pubescent children.
88953602|NCT01963741|Experimental|leukotriene D4|Nasal provocation test was induced by leukotriene D4 with a stepwisely concentration method (4 mcg/ml, 8 mcg/ml, 16 mcg/ml).
88953603|NCT01963741|Experimental|histamine|Nasal provocation test was induced by histamine with a stepwisely concentration method (0.4 mg/ml, 0.8 mg/ml, 1.6 mg/ml, 3.2mg/ml).
88953604|NCT01963754|Experimental|Subepriosteal Articaine|Administer Subperiosteal 1:100.000 Articaine 4% epinephrine, buccal and lingually, for Dental Implants in Posterior mandible
88953605|NCT01963754|Active Comparator|Loco-regional Articaine|Administer Loco-regional 1:100.000 articaine 4% epinephrine, for Dental Implants in Posterior Mandible
88953606|NCT01963806|Experimental|Smartphone-supplemented iCBT with therapist support|n = 50
88953607|NCT01963806|Experimental|Smartphone-supplemented iCBT without therapist support|n = 50
88953608|NCT01963806|Active Comparator|Active waiting list control group with delayed treatment|n = 50
88953609|NCT01963819|No Intervention|Control|Standard treatment
88953610|NCT01963819|Experimental|Intervention|Endometrial biopsy before standard treatment
88953611|NCT01963832|Experimental|eCMIT and Fluoxetine|expanded form of Constraint Induced Movement Therapy (eCIMT) combined with Fluoxetine (FLX)
88953612|NCT01963832|Experimental|eCIMT and placebo|expanded form of Constraint Induced Movement Therapy (eCIMT) combined with placebo
88953613|NCT01963832|Experimental|Usual care and fluoxetine|Ususal physical care combined with Fluoxetine (FLX)
88953614|NCT01963832|Experimental|Usual care and placebo|Usual physical care combined with placebo
89489481|NCT02254915|Experimental|Synergo + MMC|Synergo radiofrequency (RF)-Induced hyperthermia-chemotherapy (SHTC) with mitomycin C (RITE) intravesical therapy as first-line adjuvant treatment for intermediate and high-risk NMIBC,
89489482|NCT02254915|Active Comparator|Bacillus Calmette-Guérin|Intravesical BCG therapy as first-line adjuvant treatment for intermediate and high-risk NMIBC,
89489483|NCT02157181|Experimental|HCL, 2CdA +/- Rituximab|"Risk stratification~HCL variant will be treated with cladribine plus rituximab, independent of previous therapy~Relapses of HCL will be treated with cladribine plus rituximab, duration of remission of the previous therapy is < 3 years.~All repeated relapses (> 1st relapse) after previous therapies with purine analogues and/or interferon will be treated with cladribine plus rituximab.~Cladribine (LITAK®) 0.14 mg/kg daily Days 8-12 subcutaneous bolus injection Rituximab (Mabthera®) 375 mg/m2 daily Days 1, 8, 15, 22 infusion~Relapses of HCL will be treated with cladribine monotherapy, if the duration of remission of the previous therapy is > 3 years.~Cladribine (LITAK®) 0.14 mg/kg daily Days 1-5 subcutaneous bolus injection"
89489484|NCT02147665|Experimental|Hookah smoking|Healthy habitual Hookah smokers will undergo microneurography, myocardial contrast echocardiogram or venous occlusion plethysmography before and after Hookah smoking.
89489485|NCT02159287|Experimental|Low molecular-weight heparin|these patients will receive 1 mg of enoxaparin (clexane) per kilogram of body weight subcutaneous every 12 hour with warfarin 5mg QD and both drugs will be continued until the target INR level (2.5) is reached then clexane will be discontinued.
89489486|NCT02159287|Active Comparator|unfractionated heparin|This group will receive continuous intravenous unfractionated heparin sodium infusion 1000 unit per hour initially and then the dose will be adjusted to maintain a therapeutic aPTT level (two times to baseline) then warfarin will be started (5 mg QD).
89489487|NCT03738631||Under 35 years|
89489488|NCT03738631||Over 44 years|
89489489|NCT02159443||Study Participants|Those who meet eligibility criteria and consent to participate in the study.
89489490|NCT02154607|No Intervention|Symptomatic treatment|Symptomatic analgetic Treatment only was performed without any Manipulation of OLP lesions.
88953615|NCT01963858|Experimental|Functional relaxation|Functional relaxation
88953616|NCT01963858|Active Comparator|No relaxation|No relaxation
88953617|NCT01963871|Experimental|Yoga in Chronic Low Back Pain|12 weeks of no yoga followed by 12 weeks of yoga, 2 times per week for individuals with chronic low back pain
88953618|NCT01963884||Alveolar Socket Below Basal Bone|Tooth and the alveolar socket are positioned below basal bone. Measure Alveolar Socket remodeling, after Tooth Extraction with cone-beam technology evaluation
88953619|NCT01963884||Alveolar Socket in Basal Bone (imbedded)|Tooth and alveolar socket are positioned in basal bone. Measure Alveolar Socket remodeling, after Tooth Extraction with cone-beam technology evaluation
88953620|NCT01963884||Alveolar Socket Buccal to Basal Bone|Tooth and alveolar socket are positioned buccally in relation to maxillary basal bone. Measure Alveolar Socket remodeling, after Tooth Extraction with cone-beam technology evaluation
89204375|NCT00778388|Active Comparator|IC43 50|IC43 50 mcg with AI(OH)3
89489491|NCT02154607|Active Comparator|CO2-Laser Treatment|CO2-Laser Vaporisation was performed of OLP lesions under local anaesthesia.
89489492|NCT02157337|Experimental|atrovastatin|
89489493|NCT02157337|Placebo Comparator|placebo|
89489494|NCT02159599|Active Comparator|Darunavir/Ritonavir + 2 nucleos(t)idos|Darunavir/Ritonavir ( (800mg/100mg) + Tenofovir/emtricitabine (300mg/200mg) or Abacavir/lamivudine (600 mg/300mg)
89489495|NCT02159599|Experimental|Darunavir/ritonavir + Lamivudine|Darunavir/Ritonavir (800mg7100mg) + lamivudine (300mg)
89489496|NCT05004571|Placebo Comparator|Placebo|"Matched placebo control 10 mg capsules or 20 mg capsules totaling 20 mg, 40 mg, 80 mg, or 120 mg will be given once orally to placebo subjects in the SAD portion of the study.~10 mg capsules or 20 mg capsules totaling 20 mg, 40 mg, 80 mg, or 120 mg will be given once daily for 14 days orally to placebo subjects in the SAD portion of the study."
88953621|NCT01963910|Active Comparator|Mannitol in vehicle cream|Once the capsaicin has been removed, .2 mL of 30% mannitol in vehicle cream will be applied to one half of the upper lip and kept there for 10 minutes.
88953622|NCT01963910|Placebo Comparator|Vehicle Cream|Once the capsaicin has been removed, .2 mL of vehicle cream will be applied to the other half of the upper lip and kept there for 10 minutes.
88953623|NCT01963936|Experimental|Supreme LMA|
88953624|NCT01963936|Active Comparator|Facial mask|
89489497|NCT05004571|Experimental|Study drug EQU-001|"10 mg capsules or 20 mg EQU-001 capsules totaling 20 mg, 40 mg, 80 mg, or 120 mg will be given once orally to active-treatment subjects in the SAD portion of the study.~10 mg capsules or 20 mg EQU-001 capsules totaling 20 mg, 40 mg, 80 mg, or 120 mg will be given once daily for 14 days orally to active treatment subjects in the SAD portion of the study."
89489498|NCT02154685|Other|Retrieval-Extinction: Smoking Cues|A relatively brief exposure to cues prior to conducting more protracted cue exposure. This is referred to as retrieval-extinction training.
89489499|NCT02154685|Other|Non-Retrieval Extinction: Neutral Cues|This is the group that will not receive retrieval-extinction training and will be exposed to neutral cues.
89489500|NCT03738085||Previous abdominal surgery group|Previous abdominal surgery group underwent total laparoscopic hysterectomy
89489501|NCT03738085||No previous abdominal surgery group|No Previous abdominal surgery group underwent total laparoscopic hysterectomy
89489502|NCT03738085||Obese patients underwent TAH|BMI≥30 kg/m2
89489503|NCT03738085||Obese patients underwent TLH|BMI≥30 kg/m2
89489504|NCT03541681|Active Comparator|Glucocorticoid Injections|A series of three cervical transforaminal local anesthetic (0,5 ml Bupivacain) injections with glucocorticoid (1 ml Dexamethasone) within 3 months.
89204376|NCT00778388|Active Comparator|IC43 100 with|IC43 100 mcg with AI(OH)3
89489505|NCT03541681|Active Comparator|Local Anesthetic Injections|A series of three cervical transforaminal local anesthetic (0,5 ml Bupivacain) injections without glucocorticoid (Dexamethasone) within 3 months.
89489506|NCT03542071|Experimental|Carbohydrate restricted diet|Dietary intervention: moderately carbohydrate restricted diet. Parallel phase starts after study period I and the diet is followed until labor.
89489507|NCT03542071|Experimental|Plant-protein based diet|Dietary intervention: plant-protein based diet, en emphasis on healthy Nordic foods. Parallel phase starts after study period I and the diet is followed until labor.
89489508|NCT02154841|Experimental|Questionnaire, taste test, visual food test|The participants will complete a questionnaire that asks them about their taste preferences. They will also will be shown photos of various food stuffs and asked to choose their preferred meal. They will also be asked to put five sponge sticks (a single use item commonly used for mouth care) dipped in one of a five different liquids into their mouths and give their comments what each taste was and on how much they enjoyed it. These five liquids represent the four well-described tastes (sweet, sour, salty, bitter) and a more recently proposed taste, savoury. The intention of this part of the trial is to assess the patient's ability to detect alteration in pure taste and to identify if any of these tastes are preferred.
89489509|NCT02157415|Experimental|Long-term catherized patients|Uro-Tainer Polihexanide 0.02% 100ml rinsing solution
89489510|NCT02154919||complete revascularization group|this group underwent second PCI procedure on the non-culprit vessels and reveived 100-120 IU/kg unfractionated heparin during PPCI, followed by 3 days administration of low molecular weight heparin or Fondaparinux sodium after procedure. Patients in the CP group and CR group after second PCI procedure were given conservative medicine such as Statins which were not contraindicated to the patients.
89489511|NCT02154919||conservative pharmacotherapy group|patients in conservative group undergoing pharmacotherapy after PPCI. The drugs were the same between two groups.
89489512|NCT02157571|Experimental|Prulifloxacin|"Prulifloxacin film-coated tablet : 600 mg/tablet, oral administration of a single tablet.~Placebo of levofloxacin hydrochloride tablet, without active components."
89489513|NCT02157571|Active Comparator|Levofloxacin|"Levofloxacin hydrochloride tablet 500 mg/tablet, oral administration of a tablet daily.~Placebo of prulifloxacin film-coated tablet without active components."
89489514|NCT01369355|Placebo Comparator|001|Participants who were responders to Intravenous (IV) infusion of ustekinumab induction will be randomized to receive a single dose of placebo subcutaneously (SC) every 4 weeks (q4w).
89489515|NCT01369355|Experimental|002|Participants who were responders to IV ustekinumab induction will be randomized to receive a single dose of ustekinumab 90 milligram (mg) SC every 12 weeks (q12w).
89489516|NCT01369355|Experimental|003|Participants who were responders to IV ustekinumab induction will be randomized to receive a single dose of ustekinumab 90 mg SC every 8 weeks (q8w).
89489517|NCT01369355|Experimental|004|Participants who were nonresponders to IV ustekinumab induction will receive a single dose of ustekinumab 90 mg SC and one placebo IV at week 0, if then respond will continue to receive one ustekinumab 90 mg SC q8w.
89489518|NCT01369355|Experimental|005|Participants who were nonresponders to IV placebo induction will receive a single dose of ustekinumab 130 mg IV and one placebo SC at week 0, if then respond will continue to receive one ustekinumab 90 mg SC at week 8 then q12w.
89489519|NCT01369355|Placebo Comparator|006|Participants who were responders to IV placebo induction will receive one dose of placebo SC q4w.
89489520|NCT03541993|Experimental|Resveratrol Hypoxia|500 mg of trans-resveratrol, tested at a 12.7% atmospheric oxygen level; the equivalent to 4000m above sea level.
89489521|NCT03541993|Placebo Comparator|Placebo Hypoxia|Pharmaceutical grade fumed silica, tested at a 12.7% atmospheric oxygen level; the equivalent to 4000 m above sea level.
89489522|NCT03541993|Experimental|Resveratrol Normoxia|500 mg of trans-resveratrol, tested at a 20.9% atmospheric oxygen level; the equivalent to sea level.
89489523|NCT03541993|Placebo Comparator|Placebo Normoxia|Pharmaceutical grade fumed silica, tested at a 20.9% atmospheric oxygen level; the equivalent to sea level.
89489524|NCT02154997||Type 1 and Type 2 Diabetes|pregnant women which have a known condition of type 1 or type 2 diabetes
89489525|NCT02154997||Gestational diabetes|pregnant women which have developed Gestational diabetes
89489526|NCT02154997||Control group|Pregnant women whom do not suffer from any altered glucose metabolism
89489527|NCT02157649|Experimental|ER Tablet under Fasted Conditions|Administration of a single dose of two ER Tablets, combination of Codeine/Guaifenesin 30gm/600mg, to subjects under fasted conditions.
89489528|NCT02157649|Active Comparator|IR Tablet under Fasted conditions|IR Tablet combination tablet of Codeine/Guaifenesin 20mg/400mg administered under fasted conditions as a single tablet every 4 hours during a 12 hour study [three doses]
89489529|NCT02157649|Experimental|ER Tablet under Fed Conditions|Administration of a single dose of two ER Tablets, combination of Codeine/Guaifenesin 30gm/600mg, following a standard high-fat breakfast.
89489530|NCT02157727||Exposed group, during Tele-expertise|Infants hospitalized in health facilities performing tele-expertise
89489531|NCT02157727||Exposed group, Prior Tele-expertise|Infants hospitalized in health facilities performing Tele-expertise prior implementation of Tele-expertise
89204377|NCT00778388|Active Comparator|IC43 100 w/o|IC43 100 mcg w/o AI(OH)3
89204378|NCT00778388|Active Comparator|IC43 200|IC43 200 mcg with AI(OH)3
89204379|NCT00778388|Placebo Comparator|Placebo|Placebo (0,9% NaCl)
89489532|NCT02157727||Control group, Prior Tele-expertise|
89489533|NCT02157727||Control group, during Tele-expertise|Infants hospitalized in health facilities not performing Tele-expertise while the exposed group use Tele-expertise
89489534|NCT02157805|Active Comparator|rare beef meat|beef meat cooked during 5 minutes at 55°C
89489535|NCT02157805|Active Comparator|well cook beef meat|beef meat cooked during 30 minutes à 90°C
89021889|NCT02956980|Experimental|Group 2: pubescent healthy children|50 pubescent healthy children (25 boys and 25 girls) Two 7 ml tubes of blood will be taken to perform the functional assays as well as the quantification of Blood Plasmacytoid dendritic cells (pDCs) absolute number in this 50 pubescent healthy children.
89489536|NCT02614196|Experimental|Galcanezumab 120mg|Galcanezumab 240mg given as loading dose at first dosing visit followed by galcanezumab 120mg once a month for 5 months by subcutaneous (SC) injection.
89489537|NCT02614196|Experimental|Galcanezumab 240mg|Galcanezumab 240mg given by SC injection once a month for 6 months.
89489538|NCT02614196|Placebo Comparator|Placebo|Placebo given by SC injection once a month for 6 months.
89489539|NCT02614196|Experimental|Galcanezumab 120mg Maximum Extended Enrollment Cohort|Galcanezumab 240mg given as loading dose at first dosing visit followed by galcanezumab 120mg once a month for 5 months by subcutaneous (SC) injection.
89489540|NCT02614196|Experimental|Galcanezumab 240mg Maximum Extended Enrollment Cohort|Galcanezumab 240mg given by SC injection once a month for 6 months.
89489541|NCT02614196|Placebo Comparator|Placebo Maximum Extended Enrollment Cohort|Placebo given by SC injection once a month for 6 months.
89489542|NCT02159677||Healthy Subjects|Healthy subjects aged 21-80 years with no history of present or past disabling back or neck pain, sciatica, cervical radiculopathy, or any generalized neuromuscular condition except for mild polyneuropathy or common mononeuropathies (e.g. carpal tunnel syndrome, ulnar neuropathy at the elbow.) Additionally, subjects cannot have any history of any moderate-to-severe ongoing medical condition producing generalized disability, such as advanced cardiac or renal disease, or metal spine implants of any type.
89489543|NCT02159677||Radiculopathy Subjects|Subjects aged 21-80 years with a history consistent with radiculopathy based on clinical, radiologic, and standard electrophysiological criteria, as determined by spine expert.
89489544|NCT02159677||Musculoskeletal Back Pain Subjects|Subjects aged 21-80 years with low back or neck pain without evidence to suggest neuropathic component; i.e. without radiation of pain, sensory loss or weakness.
89489545|NCT02159677||Undiagnosed Lower Back or Neck Pain Subjects|Subjects aged 21-80 years with a major complaint of lower back or neck pain.
89489546|NCT02765035|Experimental|C-Leg 3, then C-Leg 4|Participants are first fitted with a C-Leg 3, receive physical therapy, acclimate for 90 days and are then assessed in the clinic. They then receive a C-Leg 4, receive additional physical therapy and acclimate for 30 days after which they are again assessed in the clinic.
89489547|NCT02765035|Experimental|C-Leg 4, then C-Leg 3|Participants are first fitted with a C-Leg 4, receive physical therapy, acclimate for 90 days and are then assessed in the clinic. They then receive a C-Leg 3, receive additional physical therapy and acclimate for 30 days after which they are again assessed in the clinic.
89489548|NCT02088437|Active Comparator|Usual care|usual care physiotherapy - once daily treatment whilst inpatient in acute hospital
89489549|NCT02088437|Experimental|Intensive physiotherapy|additional once daily physiotherapy and once daily allied health assistant intervention
89489550|NCT02159911||200 mcg misoprostol|Misoprostol administered orally one hour before surgery
89489551|NCT02159911||400 mcg misoprostol|Misoprostol administered orally one hour before surgery
89489552|NCT04876508|Experimental|Acupressure group|Patients in the acupressure group will be given acupressure once a day for 7 consecutive days. Acupressure application will be applied by researchers who have been trained and certified on this subject. While the patients are in supine position, pressure will be applied to each acupressure point around the navel, respectively, Zhongwan (CV12), Guanyuan (CV4) and Tianshu (ST25) for 2 minutes for a total of 6 minutes.
89489553|NCT04876508|No Intervention|Control group|No intervention will be applied
89489554|NCT02082041||Wounds on leg|
89489555|NCT03542617|Placebo Comparator|Normal Saline Solution|The control group receive sterile normal saline solution, as placebo, intravenous immediately prior to induction of spinal anesthesia .
89489556|NCT03542617|Active Comparator|10 mg Dexamethasone|The steroid group will receive Dexamethasone 10 mg IV immediately prior to induction of spinal anesthesia
89489557|NCT03542617|Active Comparator|40 mg Dexamethasone|The steroid group will receive Dexamethasone 40 mg IV immediately prior to induction of spinal anesthesia
89489558|NCT04878770|Active Comparator|Topical corticosteroids (control)|This group will receive topical corticosteroids.
89489559|NCT04878770|Active Comparator|Systemic cyclosporine|This group will receive topical corticosteroids and systemic cyclosporin.
89021890|NCT01580436|Experimental|Tricuspid Valve Annuloplasty|Patients, undergoing mitral valve surgery with no significant tricuspid valve regurgitation despite tricuspid annular dilation, randomized to concomitant tricuspid valve annuloplasty.
89021891|NCT01580436|No Intervention|Conservative arm|Patients, undergoing mitral valve surgery with no significant tricuspid valve regurgitation despite tricuspid annular dilation, randomized to mitral valve surgery without concomitant tricuspid valve annuloplasty.
89021892|NCT02956668|Experimental|Blindsight training associated to tDCS|"During the blindsight training (one-hour time), the patient is asked to maintain central fixation and is exposed to visual stimuli in his blind hemifield. The patient task is detection and/or discrimination of stimuli.~During each session the patient is subjected to around 700 different stimuli variously associated in space and/or time.~tDCS stimulation start at the beginning of the rehabilitation session, and continue for 30 min, during treatment.~Anode is placed over the parieto-occipital cortex. The cathode is placed in the contralateral supraorbital position."
89489560|NCT04878770|Active Comparator|Systemic dupilumab|his group will receive topical corticosteroids and systemic dupilumab.
89489561|NCT04878692|Experimental|Onco-Rash arm|"In this arm label, patients will apply the Onco-Rash cream on selected zones (face, neck, thorax,…) twice a day, during 6 weeks.~This arm will be compared to the Onco-Neutral arm, in which the Onco-Neutral cream will be applied on selected zones (face, neck, thorax,…) twice a day, during 6 weeks."
89537927|NCT03288857|No Intervention|Bulb Aspirator|If randomized to the bulb aspirator group, the patient will be sent home with a bulb aspirator to use for home nasal secretion management
89021893|NCT02956668|Active Comparator|Blindsight training alone|"During the blindsight training (one-hour time), the patient is asked to maintain central fixation and is exposed to visual stimuli in his blind hemifield. The patient task is detection and/or discrimination of stimuli.~During each session the patient is subjected to around 700 different stimuli variously associated in space and/or time."
89537928|NCT03288857|Experimental|Nasal Oral Aspirator (NeilMed Naspira)|If randomized to the nasal oral aspirator group, patient will be sent home with a nasal oral aspirator to use for home nasal secretion management
89537929|NCT04979013|Experimental|Smoking Abstinence|14-day Smoking Abstinence
88953625|NCT01963949||Primary Liver Cancer|Patients that have liver masses suspicious for primary liver cancer.
88953626|NCT01963962||Copper IUD|Women selecting the copper IUD for emergency contraception and to use for contraception after
88953627|NCT01963962||Levonorgestrel IUD|Women who select oral levonorgestrel for emergency contraception and begin the levonorgestrel IUD for ongoing contraception at the same time.
88953628|NCT01963988||Transurethral Coagulation (TUC)|This cohort patients will be managed with Transurethral Coagulation (TUC) of IC ulcer lesion
88953629|NCT01963988||Transurethral Resection(TUR)|This cohort patients will be managed with transurethral resection(TUR) of IC ulcer lesion
88953630|NCT01964001|Placebo Comparator|Placebo|starch
88953631|NCT01964001|Experimental|Dietary supplements|Vitamin B-6/Coenzyme Q10/vitamin B6+Coenzyme Q10
88953632|NCT01964014|Experimental|advagraf|The same capacity advagaf + sirolimus
88953633|NCT01964027|Experimental|Irinotecan plus epirubicin|Irinotecan(Camptosar)150mg /m2 d1,（intravenous infusion of 30-90 minutes) + epirubicin(Pharmorubicin) 50mg/m2 (total dose does not exceed 700mg/m2) every 21days for 1 treatment * 6 cycles as the second line chemoregime for advanced gastric cancer
88953634|NCT01964040|Placebo Comparator|group B: control bupivacaine group|Patient in this group will receive 25 ml bupivacaine 0.5% plus 0.5 ml normal saline peri-neurally and 0.5 ml subcutaneous normal saline.
88953635|NCT01964040|Experimental|Group B-peri-DEX: Peri-neural Dexmedetomidine|Patients in this group will receive 25 ml of 0.5% bupivacaine plus 0.5 ml (50 microgram) Dexmedetomidine peri-neurally and 0.5 ml subcutaneous normal saline
89537930|NCT03293459|Experimental|Shunt Occlusion +SMT|Shunt Occlusion +SMT
89537931|NCT03293459|Active Comparator|Standard Medical Treatment (SMT)|
89537932|NCT04971291|Experimental|AXS-05|45 mg dextromethorphan-105 mg bupropion
89537933|NCT04971291|Active Comparator|Bupropion SR|150 mg bupropion
89537934|NCT03288701|Experimental|Body Composition Analysis|Daily measurement of the Body Composition using electrical Bioimpedance Analysis in a scale (seca mBCA 515). Including total body water and weight.
89537935|NCT04360811|Other|Unexposed group : COVID 19 negatif pregant woman|COVID-19 negative women (not immunize
89537936|NCT04360811|Other|Exposed group : COVID 19 positif pregant woman|Women positive for COVID-19 (symptomatic and asymptomatic) COVID-19 negative women with long-standing immunity
89537937|NCT04971135|Experimental|SAN711 (SAD)|6 out of 8 participants per cohort (up to 7 cohorts) will be randomized to receive a single dose of SAN711
88953636|NCT01964040|Active Comparator|Group B-sys-DEX:Systemic Dexmedetomidine|Patients in this group will receive 25 ml bupivacaine plus 0.5 ml saline peri-neurally and 0.5 ml (50 microgram) subcutaneous Dexmedetomidine.
88953637|NCT01964053|Experimental|PATCH Intervention|The intervention group will receive usual care and the PATCH intervention. The intervention is comprised of two phases in which the in-hospital discharge education session is followed by 12 weeks of post-discharge education sessions delivered by telephone. The focus of this study is to test the mechanism of the proposed patient activation intervention on HF self-management adherence and associated health outcomes.
88953638|NCT01964053|Active Comparator|Usual Care|The usual care group will receive standardized discharge written information and scheduled doctor appointments. Standardized discharge instruction, as recommended by CMS and the Joint Commission, includes: activity level, diet, discharge medications, follow-up doctor appointment, weight monitoring, and what to do if symptoms worsen. No further follow-ups are routinely done by the hospital and patients are told to see their primary care provider if problems occur.
88953639|NCT01964066|Experimental|ERCP & Thoracic epidural analgesia|Used thoracic epidural analgesia (ropivacaine 0.5% -10ml) for pain relief ERCP.
88953640|NCT01964066|Active Comparator|ERCP & Premedication|Used Premedication (trimeperidine 2% -1ml intravenously) for pain control ERCP.
89021894|NCT00452634|Experimental|study arm|
89021895|NCT03277599|Active Comparator|Grup Y|ultrasound guided superficial cervical plexus blockage with 10 ml % 0.25 bupivacaine+IV patient-controlled analgesia (PCA) tramadol
89537938|NCT04971135|Placebo Comparator|Placebo (SAD)|2 out of 8 participants per cohort (up to 7 cohorts) will be randomized to receive a single dose of Placebo
89537939|NCT04971135|Experimental|SAN711 (MAD)|6 out of 8 participants per cohort (up to 3 cohorts) will be randomized to receive 14 daily doses of SAN711
89537940|NCT04971135|Placebo Comparator|Placebo (MAD)|2 out of 8 participants per cohort (up to 3 cohorts) will be randomized to receive 14 daily doses of Placebo
89537941|NCT04978623||Patient with CIDP|CIDP, is an acquired chronic inflammatory neuropathy characterised by : progressive symmetrical weakness of the proximal and to a lesser extent distal muscles of the lower and/or upper limbs, altered sensitivity and a decrease/abolition of the osteotendinous reflexes. The condition can be relapsing (30% of cases), chronically progressive (60%), or monophasically with total subsequent recovery (10%). Cranial nerve involvement is possible (5-30% of cases). Neuropathic pain as well as respiratory muscle and sub-clinical central nervous system involvement are described.
89489562|NCT04878692|Placebo Comparator|Onco-Neutre arm|"In this arm label, patients will apply the Onco-Neutre cream on selected zones (face, neck, thorax,…) twice a day, during 6 weeks.~Onco-Neutral cream will be used as an experimental comparator to Onco-Rash cream.~This arm will be compared to the Onco-Neutral arm, in which the Onco-Neutral cream will be applied on selected zones (face, neck, thorax,…) twice a day, during 6 weeks."
88953641|NCT01964079|Active Comparator|CCB (amlodipine)|For patients who fail to respond to 5 mg oral amlodipine daily, the dose will be titrated up to 10 mg amlodipineh. At subsequent visits, additional antihypertensive therapy (hydrochlorothiazide) will be added if systolic (>140 mmHg) or diastolic (>90 mmHg) BP is inadequate. Study drugs are administered once a day for 24 weeks. The dose will be titrated up if SBP is over 90 mmHg or there are no symptoms of hypotension (syncope, loss of consciousness, or orthostatic hypotension). If up-titration is not tolerable, because of side effects or hypotension, the previous dose will be administered as the final tolerable dose.
89489563|NCT02086019|Other|Conservative Arm- Medical therapy|Medical therapy
89489564|NCT02086019|Other|Invasive Arm-angiogram with PCI or CABG|same medical drug therapy as conservative arm, and angiogram with PCI (percutaneous coronary intervention) or CABG (coronary artery bypass grafting) revascularisation if appropriate
89489565|NCT02082197|Experimental|ABT-SLV176|ABT-SLV176 administered daily
89489566|NCT03046706|Active Comparator|standard voice rest|This group maintains postoperative voice rest. Namely, absolute voice rest for a week, followed by a week of relative voice rest sound (talking is allowed for 20 minutes a day). post operative voice rest
89489567|NCT03046706|Experimental|no voice rest|This group has no limitations regarding post operative speech. Members can talk indefinitely after surgery with no special restrictions.
89489568|NCT02086097|Experimental|dexketoprofen trometamol|Administration of 25mg of Dexketoprofen Trometamol, 1 pill right after clinical procedure, the other 3 every 8 until the 24 hours administration period is completed
89489569|NCT02086097|Active Comparator|IBUPROFEN|Administration of 600mg of Ibuprofen, 1 pill right after clinical procedure, the other 3 every 8 until the 24 hours administration period is completed
89489570|NCT02086097|Placebo Comparator|PLACEBO|4 doses of sugar pills, 1 pill right after clinical procedure, the other 3 every 8 until the 24 hours administration period is completed
89489571|NCT03046784||Pregnant women in third trimester|"Non-labouring pregnant women hospitalised during their third trimester of pregnancy has an haemodynamic evaluation with Nexfin technology and transthoracic cardiac ultrasonography.~Evaluation is performed in two positions : dorsal decubitus and left lateral decubitus."
89489572|NCT02307682|Experimental|Brolucizumab 3 mg|Single intravitreal (IVT) injection of brolucizumab ophthalmic solution administered as a 3 mg/50 microliter (μL) dose at Day 0, Week 4, and Week 8, followed by 1 injection every 8 weeks/1 injection every 12 weeks (q8w/q12w) maintenance regimen until study exit
89489573|NCT02307682|Experimental|Brolucizumab 6 mg|Single IVT injection of brolucizumab ophthalmic solution administered as a 6 mg/50 μL dose at Day 0, Week 4, and Week 8, followed by q8w/q12w maintenance regimen until study exit
89489574|NCT02307682|Active Comparator|Aflibercept 2 mg|Single IVT injection of aflibercept ophthalmic solution administered as a 2 mg/50 μL dose at Day 0, Week 4, and Week 8, followed by q8w maintenance regimen until study exit
88956536|NCT04971226|Active Comparator|Investigator selected TKIs|"Patients will take on ongoing basis the Investigator selected TKIs that will include one of the below treatments:~Imatinib 400 mg QD administered with food Nilotinib 300 mg BID administered under fasting conditions Dasatinib 100 mg QD administered with or without a meal Bosotunib 400 mg QD administered with food"
89489575|NCT02088515|Experimental|experimental group|experimental group: Nedaplatin(（80 mg/m2, i.v Day1）in combination with Docetaxel（75 mg/m2, i.v Day1）for each cycle, 4 cycles in total.
89489576|NCT02088515|Active Comparator|comparative group|comparative group:Cisplatin (（75 mg/m2, i.v Day1 or 25 mg/m2 Day1-3）in combination with Docetaxel（75 mg/m2, i.v Day1）for each cycle, 4 cycles in total
89489577|NCT02615990|Experimental|Erigo Pro plus standard Physical Therapy|The Erigo device therapy is a combination of tilt table with robotic stepper device allowing for cyclic leg loading. It also includes Functional Electrical Stimulation to optimize active neuromuscular stimulation. It will be used once a day to replace one of the standard PT therapies. The exercise mimics walking beyond what regular range of motion provides. Patients will have 2 additional PT therapies 20 minutes of standard range of motion movements.
89489578|NCT02615990|Active Comparator|Standard Physical Therapy|Patients will have 3 standard Physcial Therapy session. Patients will have 2 additional PT therapies 20 minutes of standard range of motion movements.
89489579|NCT03559283|Experimental|Walking and Record Cortical Activity|A sensor placement will be performed on the patient's forehead to record brain activity when walking, when performing a mental task, and when performing both tasks at the same time. In parallel, walking will be on a carpet that will record the spatio-temporal parameters of walking.
89489580|NCT02082275|Experimental|OB Nest|OB Nest is designed to reduce the number of pre-planned visits with their OB provider and replace the in-clinic visits with a direct and constant support from an assigned nursing team. OB Nest will empower moms-to-be to take ownership of their prenatal care by providing a wealth of resources.
89489581|NCT02082275|No Intervention|Traditional Prenatal care|Traditional prenatal visits in clinic with OB providers.
89489582|NCT04870814|Active Comparator|SOFTT® Gen 4 tactical tourniquet|The SOFTT® Gen 4 (Tactical Medical Solutions, Anderson) tactical tourniquet will be assessed.
89489583|NCT04870814|Active Comparator|CAT® Gen 7 tactical tourniquet|The CAT® Gen 7 (C-A-T® Resources, Rock Hill) tactical tourniquet will be assessed.
89489584|NCT04870814|Active Comparator|SAM XT® tactical tourniquet|The SAM XT® (SAM Medical Products®, Wilsonville) tactical tourniquet will be assessed.
89489585|NCT04870814|Active Comparator|RMT® 1.5 tactical tourniquet|The RMT® 1.5 (m2®, Winooski) tactical tourniquet will be assessed.
89489586|NCT03558035|Experimental|Induction chemotherapy and concurret chemoradiotherapy group|Patients receive 2 cycles of paclitaxel, cisplatin and 5-Fluorouracil chemotherapy followed by Surgery or Chemo-radiotherapy according to the response status after induction chemo.
89489587|NCT03558035|Active Comparator|Concurrent chemoradiotherapy group|Patients receive single-agent cisplatin chemotherapy concurrent with Radiotherapy
89489588|NCT04878146|Active Comparator|Sacrocolpopexy|Used as the standard intervention for prolapse
89489589|NCT04878146|Experimental|Sacro-spinous fixation|To be demonstrated as non inferior
89489590|NCT03558347|Experimental|short implants with splinted crowns|Patients of that group received splinted crowns on the two adjacent implants Intervention: short implants with splinted crowns
89489591|NCT03558347|Experimental|short implants with non-splinted crowns|Patients of that group received single crowns on the two adjacent implants Intervention: short implants with non-splinted crowns
89489592|NCT04877912||Biopsy Group|We will scan 50 women who are scheduled for a breast biopsy. Subjects will receive an MRI exam that is research-only prior to the biopsy.
89489593|NCT04877912||MRI Unknown Cancer Status Group|We will scan 150 women with dense breasts and/or women who have intermediate risk of breast cancer for this study. Subjects will receive an MRI exam that is research-only.
89489594|NCT04878068||Rapid Antigen Saliva Test|Participants who have had a COVID-19 PCR test will self-administer the saliva test. The research team will conduct the processing of the test for the results of positive, negative or inconclusive
89489595|NCT03559127|Experimental|Group A. Cold Protocol with 6 oC|"Use of 20 mL cold (6 oC) sterile saline solution.~After the clinical procedure cryotherapy was applied. 5 mL cold (6 oC) 17% EDTA followed with 20 mL cold (6 oC) sterile saline solution dispensed to the WL using a cold (6 oC) metallic micro-cannula included in the Endo Vac System for five minutes."
89489596|NCT03559127|Experimental|Group B. Cold Protocol with 2.5 oC|"Use of 20 mL cold (2.5 oC) sterile saline solution~After the procedure cryotherapy was applied. 5 mL cold (2.5 oC) 17% EDTA followed with 20 mL cold (2.5 oC) sterile saline solution dispensed to the WL using a cold (2.5 oC) metallic micro-cannula included in the Endo Vac System for five minutes."
89489597|NCT03559127|Experimental|CG. Room temperature Protocol|"Use of 20 mL (at room temperature) sterile saline solution~The group will receive irrigant at room temperature. 5mL of 17% EDTA and 20 mL of sterile saline usingmetallic micro-cannula included in the Endo Vac System for five minutes."
89489598|NCT04875962|Experimental|Cohort 1 - UCB0599|Participants will be randomized to receive a predefined dosage of UCB0599.
89489599|NCT04875962|Experimental|Cohort 2 - UCB0599|Participants will be randomized to receive a predefined dosage of UCB0599.
89489600|NCT04875962|Placebo Comparator|Cohort 1 - Placebo|Participants will be randomized to receive a predefined dosage of Placebo.
89489601|NCT04875962|Placebo Comparator|Cohort 2 - Placebo|Participants will be randomized to receive a predefined dosage of Placebo.
89489602|NCT02086253|Experimental|BQ-788|Effect of BQ-788 on the magnitude of sustained flow-mediated dilatation
89489603|NCT02086253|Experimental|BQ-123|Effect of BQ-123 on the magnitude of sustained flow-mediated dilatation
89489604|NCT02086253|Experimental|BQ-788 + BQ-123|Effect of BQ-788+BQ-123 on the magnitude of sustained flow-mediated dilatation
89489605|NCT04876118|Experimental|Fat Reduction|The treatments are designed to see if the appearance of cellulite can be reduced on the outer thigh with a new applicator design.
89489606|NCT05502809|Experimental|Deep-frozen platelets|-80°C stored fresh, leukocyte depleted (leukodepleted) platelet concentrates.
89489607|NCT05502809|Active Comparator|Room-temperature stored platelets|+22°C stored platelets
89489608|NCT04875650|Experimental|Physics Forceps|
89489609|NCT04875650|Other|Conventional Forcep|
89489610|NCT03557879||Hearing impaired families|Samples from families presenting with familial hearing impairment, underlying the genetic basis, for whom 74 deafness genes have already been excluded (no evidence of pathogenic genotype)
89489611|NCT04870502|Active Comparator|Clomiphene citrate and Ubiquinol|Controlled ovarian stimulation (COS) was done by Clomiphene Citrate (Fertab® 50 mg tablets, Zynova. SITCO Pharma.) as 150 mg (3 tablets) daily for 5 days (from 2nd day till 6th day of the cycle) together with Ubiquinol (active form of Coenzyme Q10) starting from 2nd day till the day of human Chorionic Gonadotropin (hCG) triggering in a dose of 100 mg capsules orally once daily, immediately after meal (Nutraquinol®; Jamjoom Pharma Nutraceuticals).
89489612|NCT04870502|Active Comparator|Human Menopausal Gonadotropins (hMG)|Controlled ovarian stimulation (COS) was done by Human Menopausal Gonadotropins (hMG) (Merional® 75 I.U. vials, IBSA.) IM was given from 2nd day of the cycle in a dose ranging from 75 to 225 IU according to the patient's response.
89489613|NCT04870268||PD group|percutaneous drainage group
89489614|NCT04870268||END group|endoscopic approach group
89489615|NCT04870268||INT group|surgical internal derivation of WON group
89489616|NCT04870268||NE group|surgical necrosectomy group
89489617|NCT02088671||Anesthesia|"A single study group undergoing general anesthesia procedure to observe post-hoc the effect on the NeuroSENSE monitor readings.~Interventions of interest:~Drug: Propofol induction followed by randomized doses of desflurane; Emergence by stepping down the desflurane ET - See intervention descriptions.~Device: Recording of EEG using NeuroSENSE (blinded to clinicians) - See intervention descriptions.~Other: Data Collection - See intervention descriptions"
89489618|NCT03049124|Experimental|Exercise|Participants will be asked to complete a 12-week exercise intervention and all study assessments.
89489619|NCT04870190|Experimental|Almonertinib|Almonertinib will be administered orally at a dose of 165 mg per time, Q.D.
89489620|NCT04870190|Active Comparator|Osimertinib|Osimertinib will be administered orally at a dose of 80 mg per time, Q.D.
89489621|NCT03049358|Experimental|Arm I (olfactory training)|Patients undergo olfactory training by smelling 4 essential oils in vials (rose, lemon, clove, and eucalyptus) over 15 seconds each, twice daily for 12 weeks.
89489622|NCT03049358|Sham Comparator|Arm II (sham training)|Patients undergo sham training by smelling canola oil in 4 vials over 15 seconds each, twice daily for 12 weeks.
89489623|NCT03049046|Active Comparator|CC100 250 mg|CC100 250 mg once daily by mouth for 7 days
89489624|NCT03049046|Active Comparator|CC100 500 mg|CC100 500 mg once daily by mouth for 7 days
89489625|NCT03049046|Active Comparator|CC100 1000 mg|CC100 1000 mg once daily by mouth for 7 days
89489626|NCT03049046|Placebo Comparator|Placebo|Placebo once daily by mouth for 7 days
89489627|NCT04385966|Active Comparator|Standard Volume Dose|24 patients will be included in the Standard Volume Dose arm. 20 ml Levobupivacaine Hydrochloride 2.5 MG/ML will be administered in the Interscalene brachial plexus block before the arthroscopic shoulder surgery.
89489628|NCT04385966|Experimental|Low Volume Dose|24 patients will be included in the Low Volume Dose arm. 10 ml Levobupivacaine Hydrochloride 2.5 MG/ML will be administered in the Interscalene brachial plexus block before the arthroscopic shoulder surgery.
89489629|NCT04869800|Experimental|Sequence 1|"Period 1: Reference drug(CKD-501, D745)~Period 2: Test drug(CKD-398)"
89489630|NCT04869800|Experimental|Sequence 2|"Period 1: Test drug(CKD-398)~Period 2: Reference drug(CKD-501, D745)"
89489631|NCT04875572|Experimental|Study group|Since this is a single group study, all patients enrolled will receive the same care, as described in the study description above.
89489632|NCT04875182||group delirium|"Patients who are over 65 years of age and scheduled for femur fixation surgery will be included in the study. Blood samples for zonulin and interleukin-8 levels will be taken at the day prior to the surgery. All patients will be evaluated by Delirium Rating Scale for delirium development at the postoperative 1., 2. and 3. days. Patients with a Delirium Rating Scale score over 14 points will be included in the Group Delirium. And second blood samples for zonulin and interleukin-8 levels will be taken at the time of diagnosis.~Postoperative pain scores of the patients will recorded by using a numerical rating scale."
89489633|NCT04875182||group control|"Patients who are over 65 years of age and scheduled for femur fixation surgery will be included in the study. Blood samples for zonulin and interleukin-8 levels will be taken at the day prior to the surgery. All patients will be evaluated by Delirium Rating Scale for delirium development at the postoperative 1., 2. and 3. days. Patients with a Delirium Rating Scale score under 14 points for postoperative 72 hours will be included in the Group Control. And second blood samples for zonulin and interleukin-8 levels will be taken at the postoperative 72. hour.~Postoperative pain scores of the patients will recorded by using a numerical rating scale."
89489634|NCT04875494|Experimental|Physical Exercise|
89489635|NCT04875494|Active Comparator|Counseling/support group therapy|
89489636|NCT04875494|No Intervention|Control|no intervention
89489637|NCT05258006|Placebo Comparator|Open flap debridement + allograft bone (Maxgraft)|
89489638|NCT05258006|Active Comparator|Open flap debridement + Autogenous demineralized nanoparticles|
89489639|NCT02613884|Experimental|Treatment|All patients with a 25OHD level <30 ng/dL will be given 250,000 IU D3 (cholecalciferol) orally at one point in time and during CF clinic.
89489640|NCT04869566||Athletes with traumatic knee injury|Youth athletes, aged 16-19, with traumatic knee injury
89489641|NCT05257616|Other|Control Group|Questionnaires were given to the participants. Before the initiation of treatment, procedure and consent details were explained and verbally translated into the native languages of participants, followed by the written signed approval on the questionnaire. Cervical ranges were measured using inclinometer which included neck flexion, extension, left and right side bending. Succeeding it were vitals in which oxygen saturation, heart rate, blood pressure, ventilation rate were jotted along with pain measurement using NPRS scale.
89489642|NCT05257616|Active Comparator|Experimental Group|Questionnaires were given to the participants. Before the initiation of treatment, procedure and consent details were explained and verbally translated into the native languages of participants, followed by the written signed approval on the questionnaire. Cervical ranges were measured using inclinometer which included neck flexion, extension, left and right side bending. Succeeding it were vitals in which oxygen saturation, heart rate, blood pressure, ventilation rate were jotted along with pain measurement using NPRS scale.
89489643|NCT03049436||Patients with program of adapted physical activity|
89489644|NCT03046550|Experimental|Cohort A|Cohort A will have 8 total subjects. 6 subjects will receive 0.33 mg/kg of NTM-1634 and 2 subjects will receive placebo.
89206297|NCT04090307|No Intervention|Traditional Prenatal Care|Subjects randomized to routine care will receive their prenatal care with their primary obstetric provider. Patients are seen for 10-15 minutes every four weeks until 28 weeks' gestation, every two weeks (or more by provider discretion) until 37 weeks and weekly until delivery. Visits focus on routine screening tests and prenatal care. Traditional care participants will receive a phone call once a month, until 28 weeks gestation, from a nurse practitioner to check-in on pregnancy goals, healthy eating, and exercise. Each subject's medical chart will be reviewed for demographics, antenatal management, maternal and neonatal outcomes.
89489645|NCT03046550|Experimental|Cohort B|Cohort B will have 8 total subjects. 6 subjects will receive 0.66 mg/kg of NTM-1634 and 2 subjects will receive placebo.
89489646|NCT03046550|Experimental|Cohort C|Cohort C will have 8 total subjects. 6 subjects will receive 1 mg/kg of NTM-1634 and 2 subjects will receive placebo.
89489647|NCT03046394|Active Comparator|C-SACH|All the interventions will be administered to the patient in this single-subject trial, each 6 times
89489648|NCT03046394|Active Comparator|B-DER|All the interventions will be administered to the patient in this single-subject trial, each 6 times
89489649|NCT03046394|Active Comparator|A-DER|All the interventions will be administered to the patient in this single-subject trial, each 6 times
89489650|NCT03046316|Other|local consolidative treatment|Patients will be referred to multiple disciplinary treatment discussion for the decision of local consolidative treatment to primary or metastatic lesions including surgery, radiotherapy or interventional therapy.
89489651|NCT04874090|Experimental|Interventional group|Investigator will apply the acupuncture treatment to the first group to the neck area. BL-15, BL-18, BL-23, BL-25, KB-4, Du-20, GB-20, CV-14, KB-10, Ex-26, Yin Tang, Ah-shi points will be used. 0.25x25 mm, sterile, steel, disposable, acupuncture needle will be used for acupuncture points and painful trigger points. The treatment will be applied twice a week, on average 10 sessions. Dry needling treatment will be applied to the patients by a certified physician. All patient will be performed the neck exercises program.
89489652|NCT04874090|Other|Exercises group|Patients will perform only neck exercises.
89489653|NCT04869722|Experimental|Liquid Model|Whey protein beverages varying in protein levels
89489654|NCT04869722|Experimental|Solid Model|Protein fortified scones varying in fat levels
89489655|NCT03048110|Experimental|ODM-201|All subjects will receive a single dose of BAY1841788 (ODM-201) (600 mg) in the first treatment period of the study, then all subjects will receive twice daily 200 mg itraconazole on 1 day and once daily 200 mg itraconazole for the following 6 days and a single dose of BAY1841788 (ODM-201) (600 mg) in the second treatment period, then all subjects will receive once a day 600 mg rifampicin for 10 days and a single dose of BAY1841788 (ODM-201) (600 mg) in the third treatment period
89489656|NCT03047876||All neonates and infants undergoing aortic arch surgery|Children, from neonatal age to late infancy, undergoing aortic arch surgery (n=20) will have cerebral perfusion measurements during surgery, including during the cooling and rewarming phase, whilst on cardiopulmonary bypass and during the recovery period in the intensive care unit
89489657|NCT05256758|Experimental|OxFAST Fibrate group|49 patients randomised to receive fenofibrate 200mg capsules.
89489658|NCT05256758|Placebo Comparator|OxFAST placebo group|13 patients randomised to receive placebo will act as controls.
88956537|NCT04944901|Experimental|SB-121|"One dose of SB-121 daily for 28 days according to the treatment group to which they are allocated.~Administration: Oral"
89489659|NCT04869332|Active Comparator|three-screw group|three cancellous screws with an inverted triangle pattern are used to fix the fracture of femoral neck
89489660|NCT04869332|Experimental|four-screw group|the fourth screw will be implanted in the horizontal direction of the femoral distance on the basis of the three screws.
89489661|NCT03047798|Experimental|aqueous single-phase mouthrinse|This contained sodium fluoride and the additional ingredients of bamboo salt, magnolia bark and centella asiatica extracts in aqueous single-phase form.
89489662|NCT03047798|Experimental|oil-water two-phase mouthrinse|This contained sodium fluoride and the additional ingredients of bamboo salt, magnolia bark and centella asiatica extracts in oil-water two-phase form.
89489663|NCT03047798|Placebo Comparator|Control|The control mouthrinse only contained sodium fluoride
89489664|NCT02791763|Experimental|Daprodustat in ND participants|Eligible ND participants will receive oral daprodustat (1, 2, 4, 6, 8, 12, 18 or 24 milligrams [mg] as recommended) dose once daily for 52 weeks.
89206298|NCT04093115|Experimental|CX1106|CX1106 740 mg/m2 as a 24-hour continuous infusion for 5 days every 3 weeks (3 weeks/cycle, 4-6 cycles)
89489665|NCT02791763|Active Comparator|Epoetin beta pegol in ND participants|Eligible ND participants will receive subcutaneous (SC) epoetin beta pegol (25, 50, 75, 100, 150, 200 or 250 microgram [µg] as recommended) dose once every 2 or 4 weeks for 52 weeks.
89489666|NCT02791763|Experimental|Daprodustat in PD participants|Eligible PD participants will receive oral daprodustat (1, 2, 4, 6, 8, 12, 18 or 24 mg as recommended) dose once daily for 52 weeks.
89489667|NCT02082353||Retrospective CGD Cohort|Longitudinal analysis
89489668|NCT02082353||Prospective CGD Cohort|Longitudinal analysis
89489669|NCT02082353||HCT CGD Cohort|Cross-sectional analysis
89489670|NCT02082353||Conventional Non-Transplant CGD Cohort|Longitudinal analysis
89489671|NCT02086409|Experimental|Yogurt supplemented with vitamin D and calcium|20 participants take yogurt supplemented with vitamin D and calcium during 12 weeks
89206299|NCT02548026|Experimental|High Eating Frequency (High EF)|8 Eating Occasions
89206300|NCT02548026|Experimental|Low Eating Frequency (High EF)|3 Eating Occasions
89489672|NCT02086409|Active Comparator|Yogurt not supplemented with vitamin D and calcium|20 participants take yogurt not supplemented with vitamin D and calcium during 12 weeks
89489673|NCT02086487|Experimental|Nilotinib 300 mg|"Patients diagnosed with chronic myeloid leukemia receiving treatment of Imatinib 400 mg but show sub-optimal response on Imatinib therapy as per the ELN 2013 guidelines will be switched to Nilotinib 300 mg twice daily and will be assessed for timely.~In the absence of safety concerns, nilotinib could be escalated to 400 mg twice daily if patients had not obtained any of the following milestones:~BCR-ABL1 transcript level ≤ 10% at 3 months;~CCyR at 6 months,~BCR/ABL1 ≤ 1% at 6 months~MMR at 12 months, or~if they showed loss of cytogenetic or molecular response or disease progression at any time. Failure and thus, stopping nilotinib will be considered if any of above milestones happened while on the 400mg twice daily dose."
89489674|NCT02088827|Other|Activity|During a 4 hour Meal Test subjects will cycle for 2 minutes every 20 minutes
89489675|NCT02088827|Other|Inactivity|During a 4 hour Meal Test study subjects will remain inactive (remain lying on a bed)
89489676|NCT02603471|Experimental|Text Messaging CBT (TXT-CBT)|This condition will receive CBT based text messaging (TXT-CBT). Those assigned to TXT-CBT will also be given a treatment manual (developed in Phase I) containing descriptions of core therapeutic content/topics for each week. HIV-infected participants will have an initial meeting with a CBT clinician to review the Life-Steps concepts. The 3 most applicable medication adherence skills will be identified for emphasis in tailored messages. A research coordinator will meet with the participants weekly at data collection visits throughout the intervention phase to answer any technical questions and ensure that the intervention program is working properly.
89489677|NCT02603471|Active Comparator|Informational group|A pamphlet with information about HIV, the importance of ART adherence, and relapse prevention will be provided to participants in this condition.
89489678|NCT02082509||Traumatic Brain Injury (TBI)|Patient who have sustained a TBI over 1 month prior to enrollment, and endorse at least 1 post-concussive symptom at the time of enrollment.
89489679|NCT02082509||Healthy Controls (no TBI)|Subjects who match the TBI group's demographic characteristics, except that they have not sustained a TBI and they are otherwise physically and mentally healthy.
89489680|NCT02082587||QOL Assessment|
89489681|NCT02613572|Experimental|alpha lipoic acid (ALA) 600mg once daily x 5 days|All 15 patients recruited to the Phase I part will take escalating doses of alpha lipoic acid (ALA) open label. Each enrolled subject will take 600 mg of oral ALA once daily with a meal for 5 days. If well-tolerated, each subject will then take 800 mg of oral ALA once daily with a meal for 5 additional days. If 800 mg of oral ALA is well-tolerated, then subjects will then take 1200 mg of oral ALA once daily with a meal for 5 days.
89489682|NCT02613572|Experimental|alpha lipoic acid 800mg|once daily with meal x 5 days
89489683|NCT02613572|Experimental|alpha lipoic acid 1200mg|once daily x 5 days
89489684|NCT02613572|Placebo Comparator|Placebo 600mg|All 50 subjects in Phase II will be double blinded and randomized to either placebo or ALA. Each will take one 600mg capsule of ALA (or placebo) once daily with a meal for 2 weeks and then increase to two 600 mg capsules of ALA (or placebo) once daily with a meal for the
89489685|NCT02613572|Experimental|ALA 600 mg|once daily with a meal for 2 weeks
89489686|NCT02613572|Placebo Comparator|Placebo 1200mg|Two 600mg capsules once daily with a meal for the entire remainder of the 18 month period of the study
89489687|NCT02613572|Experimental|ALA 1200mg|Two 600mg capsules once daily with a meal for the entire remainder of the 18 month period of the study
89489688|NCT02088983|Experimental|CDP-Choline|Single dose of 500 mg, 1000 mg, or 2000 mg given in one of 4 test sessions
89489689|NCT02088983|Placebo Comparator|Placebo (cellulose)|Given randomly in one of the 4 testing sessions as a comparison
89489690|NCT02089061|Experimental|Cohort 1: Rosuvastatin + BMS-919373|"Rosuvastatin 10 mg tablet orally once for Day 1 and 5~BMS-919373: 100 mg dose on Day 4 and 30 mg dose once daily on Days 5, 6 and 7 of Microcrystalline suspension"
89489691|NCT02089061|Experimental|Cohort 2: Atorvastatin + BMS-919373|"Atorvastatin 40 mg tablet once for Days 1 and 5~BMS-919373: 100 mg dose on Day 4 and 30 mg dose once daily on Days 5, 6 and 7 of Microcrystalline suspension"
89489692|NCT02086643|Experimental|Retroclavicular block|Retroclavicular block
89489693|NCT02086721|Experimental|Oligometastatic cancer patients; N=18|
89489694|NCT03046160|Experimental|experimental group|"where treatment will involve conventional and Manual therapy (Mobilization with movement)+ tape (postural correction of scapular anterior tilt)~The Manual therapy (Mobilization with movement)intervention was of grade III mobilizations with movement performed in sitting for 6-10 repetitions for 3 sets~tape (postural correction of scapular anterior tilt)~A program of 12 neck and scapular exercises."
89489695|NCT03046160|Active Comparator|control group|"treatment will consist of the conventional approach+ tape (postural correction of scapular anterior tilt)~tape (postural correction of scapular anterior tilt)~A program of 12 neck and scapular exercises."
89489696|NCT02086799|Experimental|IV thyroxin|IV thyroxin
89489697|NCT02086799|Placebo Comparator|control IV saline|Placebo
89489698|NCT05256602||survey respondant|
89489699|NCT02082665|Experimental|Arm 1|On Day 1 subjects will simultaneously receive single dose of Rosuvastatin 10 mg tablet and Midazolam 3 mg syrup administered orally in the morning.
89489700|NCT03046004|Experimental|Decision aid|Women in the intervention arm will receive a leaflet with detailed information on the benefits (breast cancer mortality reduction, less intensive treatments) and harms (false positive results and overdiagnosis).
89489701|NCT03046004|Active Comparator|Control|Women in the control arm will receive a standard leaflet that does not mention harms and recommends accepting the invitation to participate in the biennial exams of the EDBCP.
89489702|NCT02082743|Experimental|Outdoor activity|Outdoor activity in recess time
89489703|NCT02082743|No Intervention|Control|
89489704|NCT05256524||Patients with critical COVID-19 responding to LMWH treatment|Responders are defined as patient who achieve aFXa-levels, peak or trough, within target-range as excepted from the given dose of LMWH.
89489705|NCT05256524||Patients with critical COVID-19 not responding to LMWH treatment|Non-responders are defined as patients who do not achieve aFXa-levels, peak or trough, within target-range as excepted from the given dose of LMWH.
89489706|NCT02086877||ICU Survivors who required > 72 hrs mechanical ventilation|No intervention
89489707|NCT03047954|Experimental|Broncho-Vaxom|1 capsule (3.5 mg) per day, administered over 9 months
89489708|NCT03047954|Placebo Comparator|Placebo|Matching placebo capsule
89489709|NCT02086955|No Intervention|Standard care|All participants receive three specially-developed brochures with information regarding the diabetic foot condition. The brochures containes explanations to a) the cause and warning signs of diabetic foot ulcers, b) the precautions patients can take in their daily life, and c) helpful foot gymnastics to be practiced at home.
89489710|NCT02086955|Experimental|Nursing counseling|The participants who are randomized in the intervention group receive standardized education regarding diabetic foot care. The nurse-led outpatient intervention go on for five weeks. During a period of five weeks, the participants are provided with weekly education, skill training, and counseling sessions on foot care.
89489711|NCT03048032||Acute heart failure patients|Adult patients (18 years and older) who are admitted to the emergency department (Vilnius University Hospital Santariškių Klinikos and Hospital of Lithuanian University of Health Sciences Kauno Klinikos) due to acute dyspnea and have an adjudicated diagnosis of acute heart failure. Blood sampling and echocardiography examination will be performed.
89489712|NCT03048032||Control group|Patients who are admitted to the emergency departments of participating centers due to acute dyspnea with an adjudicated diagnosis other than heart failure (pulmonary causes of dyspnea such as pulmonary embolism, acute infections, cancer and other reasons). Blood sampling and echocardiography examination will be performed.
89489713|NCT02089139|Experimental|DISCOGEL|Percutaneous intradiscal injection of Discogel
89489714|NCT02089139|Active Comparator|conventional treatment|conventional treatment based on current guidelines regarding the management of discogenic low back pain, including but not limited to: medications (analgesics, NSAIDs, muscle relaxants), physical therapy, manual techniques, transcutaneous electrical nerve stimulation (TENS), blocks
89489715|NCT03048266||MEN1 Patients Who Have Developed Aggressive PNETs-Cases|
89489716|NCT03048266||MEN1 Patients Who Have Developed Non-Aggressive PNETs-Controls|
89489717|NCT04869410|Active Comparator|Broselow Tape|Patient will given an intubation using uncuffed endotracheal tube size based on Modified Broselow Tape
89489718|NCT04869410|Active Comparator|Cole Formula|Patient will given an intubation using uncuffed endotracheal tube size based on Cole Formula
89489719|NCT03558971|Experimental|Patient self-administration of cortisol|Intervention is patient self-administration of cortisol.
89489720|NCT04873544|Experimental|Common protocols for TKA|Common protocols for TKA
89489721|NCT05475509|Experimental|virtual reality group (nature videos were watched by wearing virtual reality glasses)|In the experimental group, saliva sample will be taken before chemotherapy, Personal Information Form, State Anxiety Scale and VAS pre-test questionnaires will be applied, pre-test questionnaires will be applied to measure vital signs, and then virtual reality glasses will be introduced to the patients and the duration will vary between 3-10 minutes for a total of 30 minutes. A saliva sample will be taken and a post-test will be applied, with virtual reality glasses, videos with music background, park, nature and seaside walks, underwater, museum trips, videos that the patient wants to watch and can change whenever they want. Each patient will be shown the same video.
89489722|NCT05475509|No Intervention|Control Group|Personal Information Form, State Anxiety Scale and VAS pre-test questionnaires will be applied to the patients who accepted to participate in the study, saliva sample will be taken from the control group before chemotherapy, vital signs measurements will be made and post-test questionnaires will be applied at the 30th minute of chemotherapy, vital signs measurements will be made and saliva sample will be taken.
89489723|NCT02087189||ICD/ CRT-D therapy|
89489724|NCT02341456|Experimental|AZD1775|AZD1775 will be administered orally as a single dose on Day 1 Cycle 0. Following a 5±2 days washout period, AZD1775 (5 doses BID over 2.5 days) will be taken in combination with paclitaxel and carboplatin in each 21-day cycle for 6 cycles. Following 6 cycles of combination treatment, patients may continue on AZD1775 monotherapy (5 doses BID Day 1 to Day 2.5 in each 21-day cycle) at the investigator's discretion.
89489725|NCT02341456|Experimental|Paclitaxel|Commercially available paclitaxel will be administered at a dosage of 175 mg/m2 as a 3-hour IV infusion on Cycle Day 1 of a 21-day cycle for 6 cycles.
89489726|NCT02341456|Experimental|Carboplatin|Following the paclitaxel infusion, carboplatin will be administered at a dose of AUC 5 as an IV infusion on Cycle Day 1 of a 21-day cycle for 6 cycles. According to the Cancer Therapy Evaluation Program Information Letter Regarding the AUC Based Dosing of Carboplatin, the maximum carboplatin dose should not exceed the target AUC (mg*min/mL)*150 mL/min, but it may be less (Ivy et al 2010). For this study, the maximum dose of carboplatin cannot exceed a total dose of 750 mg.
89489727|NCT02087345||Dental erosions|
89489728|NCT02082899|Active Comparator|Active Comparator EBI-005 5 mg/mL|Administered 3 times per day
89489729|NCT02082899|Placebo Comparator|Placebo Comparator|Administered 3 times per day
89021896|NCT03277599|Active Comparator|Grup B|ultrasound ultrasound guided Great Auricular nerve blockage with 5 ml % 0.25 bupivacaine +IV patient-controlled analgesia (PCA) tramadol
89021897|NCT00341549||Myopia|The subject population will be adult individuals and their children, in good health with the exception of myopia.
89489730|NCT02083055|Experimental|dexmedetomidine|Intraoperative controlled hypotension by dexmedetomidine
89021898|NCT00341588||Cases|Male U.S. serviceman, age 18-45 years old with TGCT
89489731|NCT02083055|Active Comparator|nitroglycerin|Intraoperative controlled hypotension by nitroglycerin
89489732|NCT02089295|Experimental|Treatment A|Single dose of 5 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
89489733|NCT02089295|Experimental|Treatment B|Single dose of 20 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
89489734|NCT02089295|Experimental|Treatment C|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
89489735|NCT02370784|Active Comparator|Active Drug|atorvastatin 40 mg once daily for sixteen weeks
89489736|NCT02370784|Placebo Comparator|Placebo control|receive a placebo of similar appearance once daily for sixteen weeks
89489737|NCT02083133||End Stage Renal Disease|GFR 15 ml/min or less or on Dialysis
89489738|NCT02083133||Chronic Kidney Disease Stage 4|GFR 15-30 ml/min
89489739|NCT02083133||Chronic Kidney Disease Stage -3|GFR 30-60 ml/min
89489740|NCT03558269|Experimental|Study group|This group will receive UCB after the first palliative surgery
89489741|NCT03558269|No Intervention|Control group|This group will not receive any treatment
89489742|NCT04897750|Experimental|Active|a target dose of intranasal sufentanil 0,5 mcg/kg + ketamine 0,5 mg/kg, (2-4 puffs) and an additional dose if needed as premedication before placement of a PVC for induction of anaesthesia.
89021899|NCT00341588||Controls|Male U.S. serviceman, age 18-45 years old without TGCT
89021900|NCT00446745||Abdominal obesity|60 males were recruited according to waist circumference, from lean to obese values
89021901|NCT00341627||1|Population-based sampling of individuals affected with Chordoma
89021902|NCT00452829|Experimental|Study Group|5 mg folic acid (the standard UK supplement for pregnancies at high risk of NTD) and 1 g inositol,
89489743|NCT02083211|Experimental|mAb Nimotuzumab + chemotherapy|
89489744|NCT02083211|Placebo Comparator|placebo + chemotherapy|
89489745|NCT02307370|Experimental|Turbo-Elite Atherectomy|
89489746|NCT05483777|Experimental|PRF|If the patient is in the experimental group, platelet rich fibrin will be applied to the diabetic foot wound.
89489747|NCT05483777|No Intervention|CWD|If the patient is in the control group, classic wound dressing will be applied to the diabetic foot wound.
89489748|NCT03557645|Sham Comparator|Baseline Mechanical Ventilation|The subjects will be kept in Volume Control Continuous Mandatory Ventilation (VC-CMV) with an inspiratory flow = 60Lpm and tidal volume = 6mL/IBW. Positive end-expiratory pressure and the inspired oxygen fraction will not be modified.
89489749|NCT03557645|Experimental|VHI With Inspiratory Pause|Application of a ventilator hyperinflation intervention with Volume Control Continuous Mandatory Ventilation (VC-CMV). The inspiratory flow will be set at 20Lpm, the tidal volume will be increased in steps of 200mL until the peak airway pressure of 40cmH2O is achieved, and an inspiratory pause will be applied at the end of inspiration. After achieving the target pressure, this ventilatory regimen will last 15 minutes. Positive end-expiratory pressure and the inspired oxygen fraction will not be modified.
89489750|NCT03557645|Experimental|VHI Without Inspiratory Pause|Application of a ventilator hyperinflation intervention with Volume Control Continuous Mandatory Ventilation (VC-CMV). The inspiratory flow will be set at 20Lpm and the tidal volume will be increased in steps of 200mL until the peak airway pressure of 40cmH2O is achieved. After achieving the target pressure, this ventilatory regimen will last 15 minutes. Positive end-expiratory pressure and the inspired oxygen fraction will not be modified.
89489751|NCT02370394|Experimental|ROSE Program|Participants received a 35-40-minute intervention on the Tablet PC and an in-person 10-15-minute booster session conducted by interventionists within a month after the intervention. Participants in this condition completed a baseline assessment as well as a follow-up assessment 3 months later.
89489752|NCT02370394|No Intervention|Control Condition|Control Condition consisted of a series of questions regarding television show preferences and then viewed a brief series of videos of popular entertainers/shows, with subsequent requests for ratings of subjective preference. Participants in this condition completed a baseline assessment as well as a follow-up assessment 3 months later.
89489753|NCT02089373|Experimental|Probe-based confocal laser endomicroscopy|
89489754|NCT02089373|Active Comparator|White light endoscopy|
89489755|NCT01595438|Experimental|Ceftazidime - Avibactam ( CAZ-AVI)|IV treatment
89489756|NCT01595438|Active Comparator|Doripenem|IV treatment
89489757|NCT03558815||Adults with mild, moderate, severe or profound ID|Adults with mild, moderate, severe or profound ID in contact with either a sheltered workshop and/ or sheltered living Institution in Saxony.
89489758|NCT02089451|Experimental|FIAsp|Each subject will be randomised to a treatment sequence consisting of 5 treatment periods
89489759|NCT02340520|Experimental|thophylline and roflumilast|Theophylline for one week, followed by the addition of Roflumilast for a further one week.
89489760|NCT02087579|Experimental|Cohort A: Aripiprazole|Administration of oral formulation will continue at a participant's usual dose and dosing schedule.
89489761|NCT02087579|Experimental|Cohort B: Olanzapine|Administration of oral formulation will continue at a participant's usual dose and dosing schedule.
89489762|NCT02087579|Experimental|Cohort C: Paliperidone|Administration of prolonged-release (extended-release) tablets or long-acting injectables (LAI) will continue at a participant's usual dose and dosing schedule.
89489763|NCT02087579|Experimental|Cohort D: Quetiapine|Administration of oral formulation will continue at a participant's usual dose and dosing schedule.
89489764|NCT02087579|Experimental|Cohort E: Risperidone|Administration of oral formulation or LAI will continue at a participant's usual dose and dosing schedule.
89489765|NCT02339584|Experimental|Brinz/Brim|Vehicle solution, 1 drop, followed by Brinzolamide 10 mg/mL / Brimonidine 2 mg/mL fixed combination eye drops, suspension, 1 drop, administered at least 5 minutes apart in the treated eye(s) twice daily (BID) for 3 months
89489766|NCT02339584|Active Comparator|Brinz+Brim|Brimonidine 2 mg/mL eye drops, solution, 1 drop, followed by Brinzolamide 10 mg/mL eye drops, suspension, 1 drop, administered at least 5 minutes apart in the treated eye(s) BID for 3 months
89489767|NCT02087657|Experimental|Hyperbaric Oxygen Treatment|Administration of hyperbaric oxygen on the morning of stem cell transplant (Day 0).
89489768|NCT02339506|Active Comparator|Cosyntropin|Subjects will receive cosyntropin infusion at 70 mcg/hr for two sessions of 2.5 hours each on day 2 of a three day admission to our research center.
89489769|NCT02339506|Placebo Comparator|Normal saline (Placebo)|Subjects will receive normal saline infusion for two sessions of 2.5 hours each on day 2 of a three day admission to our research center.
89489770|NCT02087735|Experimental|cranberry extract 1|One capsule with a proanthocyanidin standardized cranberry extract of 36 mg and one capsule of placebo cranberry extract.
89489771|NCT02087735|Experimental|cranberry extract 2.|Two capsules with a proanthocyanidin standardized cranberry extract of 36 mg.
89489772|NCT02087735|Placebo Comparator|cranberry extract 3.|Two capsules with a proanthocyanidin standardized cranberry extract of 2 mg.
89489773|NCT04886128||Aim 1/Outcome 1|Secondary analysis of frozen plasma samples from the existing STRATIFY cohort of patients with and without acute heart failure presenting to emergency departments. n= ~900
89489774|NCT04886128||Aim2/Outcome 2|Secondary analysis of frozen plasma samples from the existing EMROC cohort of patients with and without acute heart failure presenting to emergency departments. n= ~900
89489775|NCT04886128||Aim 3/Outcome 3|Prospective recruitment of approximately 1000 patients with and w/o acute heart failure presenting to emergency departments.
89489776|NCT02087813|Experimental|A1AT|Alpha1-antitrypsin 120mg/kg once weekly for a total of 4 doses, to be given intravenously. This will be given in addition to standard of care 3-5 days of 1000mg IV methylprednisolone.
89489777|NCT02087813|Active Comparator|Standard of care|Patients that do not wish to receive study treatment but agree to otherwise follow study protocol will also be enrolled in an observational cohort. They will receive the standard of care 3-5 days 1000mg IV methylprednisolone.
89489778|NCT03048812|Experimental|O'Ring attachment (A)|One arm of our research will receive O'Ring attachment for 3 months and after this period they will recieve the second attachment Equator for more 3 months
89489779|NCT03048812|Experimental|Equator attachment (B)|The second arm of our research will receive Equator attachment for 3 months and after this period they will recieve the second attachement O Ring for more 3 months
89489780|NCT02089529|Active Comparator|Ibuprofen/Ibumetin|Ibumetin is administrated. Intervention: No information about the effect.
89489781|NCT02089529|Placebo Comparator|Placebo|Placebo is administrated. Intervention: No information about the effect.
89489782|NCT02089529|Active Comparator|Ibuprofen/Ibumetin+positive information|Ibumetin is administrated. Intervention: The patient receive written information that the capsule is Ibumetin.
89489783|NCT02089529|Placebo Comparator|Placebo+positive information|Placebo is administrated. Intervention:The patient receive written information that the capsule is Ibumetin.
89489784|NCT02089529|Active Comparator|Ibuprofen/Ibumetin+neutral information|Ibumetin is administrated. Intervention: The patient receive written information that the capsule is Ibumetin.
89489785|NCT02089529|Placebo Comparator|Placebo+neutral information|Placebo is administrated. Intervention:The patients receive information that the capsule is placebo.
89489786|NCT02089529|No Intervention|Control|Control condition
89489787|NCT03048890||Patients with PAD|Patients with PAD will be in 1 cohort and will have their physical activity levels closely monitored by researchers and physicians.
89489788|NCT03048890||Patients without PAD|Patients without PAD will be allowed to contribute their data to the application, but they will not be as closely monitored.
89489789|NCT03557567||MO patients|
89489790|NCT03557567||OI patients|
89489791|NCT03557489|Experimental|Experimental group|Patients use gel pad(in usual) in addition to(Mepilex Border Sacrum)foam pad during surgery.
89489792|NCT03557489|No Intervention|Control group|patients use gel pad(in usual) during surgery.
89489793|NCT04352738||Healthy adults (group I)|
89489794|NCT04352738||Adults with type 1 diabetes (group II)|"T1D for ≥2 years or evidence of undetectable C-peptide (<100pmol/l with concomitant plasma glucose≥4.0mmol/l).~HbA1c≤8.0mmol/l (64mmol/mol)."
89489795|NCT04352738||Adults after bariatric surgery (group III)|"Female.~Bariatric surgery (Roux-en-Y gastric bypass or sleeve gastrectomy) ≥1 year ago.~Lack of a history of diabetes or pre-diabetes (HbA1c≤5.6% in the absence of anaemia)."
89489796|NCT03557411|Experimental|SHR-1210 +Hypofraction radiotherapy|SHR-1210 （an Anti-PD-1 Inhibitor） Simultaneously Combined with Hypofraction Radiotherapy
89489797|NCT02305888|Experimental|LEO 43204, 0.018% once daily for 3 days|
89489798|NCT02305888|Experimental|LEO 43204, 0.037% once daily for 3 days|
89489799|NCT02305888|Experimental|LEO 43204, 0.1% once daily for 3 days|
89489800|NCT02090933|Experimental|Treatment (celecoxib)|Participants undergo UV-irradiation to the right buttock at baseline, receive celecoxib PO BID for 10 days, and then undergo UV-irradiation to the left buttock.
89489801|NCT04349774|Active Comparator|Control Group|Continuous Erector Spinae Plane block with 20ml 0.375% Bupivacaine and continuous infusion of 0.25% Lidocaine @ 12ml/hr, with single shot Serratus Anterior Plane block with 20ml 0.375% Bupivacaine
89489802|NCT04349774|Active Comparator|Treatment Group|Continuous Erector Spinae Plane block with 20ml 0.375% Bupivacaine and continuous infusion of 0.25% Lidocaine @ 12ml/hr, with single shot Serratus Anterior Plane block with 20ml Normal Saline.
89489803|NCT02091323|Experimental|BMI<28kg/m2|Indicators monitored preoperatively and at 1,3,6,12 months after surgery in BMI<28kg/m2 group.
89489804|NCT02091323|Other|control|Indicators monitored preoperatively and at 1,3,6,12 months after surgery in BMI>28kg/m2 group as well.
89489805|NCT02338882|Experimental|Bi flex M multifocal intraocular lens|Subjects implanted bilaterally with the Bi flex M multifocal intraocular lens
89489806|NCT02338882|Active Comparator|Bi flex 1.8 monofocal intraocular|Subjects implanted bilaterally with the Bi flex 1.8 monofocal intraocular lens
89489807|NCT03046238|Active Comparator|dexmetedomedine|preoperative ultrasound guided modified Pecs block with 30 mL of 0.25% bupivacaine plus Dexmedetomidine (1 µg/kg)
89489808|NCT03046238|Placebo Comparator|control|preoperative ultrasound guided modified Pecs block with 30 mL of 0.25% bupivacaine
89489809|NCT05231096|Experimental|Group A: SRD & Gingival massage with Aloe-vera gel.|Group A: Scaling and Root Debridement & Gingival massage with Aloe-vera gel.
89489810|NCT05231096|Experimental|Group B: SRD & Gingival massage with Sidr honey|Group B: Scaling and Root Debridement & Gingival massage with Sidr honey
89489811|NCT05231096|Other|Group C SRD only.|Group C Scaling and Root Debridement only.
89489812|NCT02089763|Experimental|PEG-BCT-100|pegylated recombinant human arginase 1
89489813|NCT04884802|Experimental|Tight pressure management|In patients assigned to tight blood pressure control, angiotensin converting enzyme inhibitors and angiotensin receptor blockers will not be given the morning of surgery. Other chronic antihypertensives will only be given as necessary to treat hypertension. Norepinephrine or phenylephrine infusion will be infused at a rate sufficient to maintain intraoperative MAP ≥ 85 mmHg.
89489814|NCT04884802|Other|Routine pressure management|ACEIs, ARBs, and/or calcium channel blockers can be given the morning of surgery if deemed appropriate by the attending anesthesiologist. Intraoperative blood pressure will be managed per clinical routine.
89489815|NCT02089841|Experimental|Artemether/lumefantrine|In this single-arm study, patients will be treated with Artemether/lumefantrine, and the first, third and fifth doses of the drug will be given under the direct observation of the health workers. The patients will be followed-up for 42 days, on day 1, 2, 3, 7, 14, 21, 28 and 42 to assess the efficacy of the drug.
89489816|NCT04873076|Experimental|Audiovisual distraction using 2d video glasses from HappyMed GmbH|"During the catheter ablation, the patients in the intervention group receive 2D video glasses with headphones. Immediately before and after the procedure they receive a questionnaire. During the procedure vital parameters of all patients regardless of the studygroup are monitored using Zoll X-Series Monitor Defibrillator. The study includes blood pressure (in mmHg), heart rate (in beats per minute) and patient's level of alertness, which is assessed using the Richmond Agitation-Sedation Scale(RAAS). During the procedure the patients in the intervention group receive the glasses and remote control. All patients receive their individual dosage to ensure painless ablation. The drugs used are limited to the opioids remifentanil and benzodiazepine midazolam."
89489817|NCT04873076|No Intervention|Controll arm|"In patients in the control group, catheter ablation is performed as usual without the use of video glasses. They receive immediately before and after the ablation the same questionnaire as the patients in experimental arm. (Omitting the question about the videoglasses).~While the procedure is performed, the analgosediation is as well in the controll arm as in the experimental arm titrated until the patient is treated, sedated and painless."
89489818|NCT03045848||Biofreedom drug-coated stent|Subject implanted Biofreedom DCS for coronary artery disease
89489819|NCT02250365|Experimental|Continuous, suprasensory ESS|
89489820|NCT02250365|Active Comparator|Intermittent, suprasensory ESS|
89489821|NCT03045770|Experimental|mFOLFOX|The mFOLFOX regimen consisted of oxaliplatin (85 mg/m2) and calcium levofolinate (200 mg/m2).Subsequently, a 48-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days till progressive disease or intolerable toxicities.
89489822|NCT03045770|Experimental|mFOLFIRI|The mFOLFIRI regimen consisted of irinotecan (180 mg/m2) and calcium levofolinate (200 mg/m2).Subsequently, a 48-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days till progressive disease or intolerable toxicities.
89489823|NCT03045770|Experimental|FOLFPTX|The FOLFPTX regimen consisted of paclitaxel (95 mg/m2) and calcium levofolinate (200 mg/m2).Subsequently, a 48-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days till progressive disease or intolerable toxicities.
89489824|NCT04389086|Experimental|Induction chemotherapy + chemoradiotherapy + surgery|Induction chemotherapy followed by neoadjuvant chemoradiotherapy and surgery
89489825|NCT04389086|Active Comparator|Neoadjuvant chemotherapy + surgery|Neoadjuvant chemoradiotherapy followed by surgery
89489826|NCT02095847|Experimental|Hysteroscope Imaging|All patients entered in study will undergo cervical dilation after induction of general anesthesia. Once the cervix has been dilated, a hysteroscope will be introduced in the uterine cavity to evaluate for presence of tumor. Location and size of tumor documented. White-light images obtained using the High-Resolution Microendoscopy (HRME) camera introduced through the hysteroscope. Once completed; the hysteroscope will be removed and the uterine cavity will be infused with 10 mL of proflavine (an acridine dye) (0.01% Proflavine (10ml)). A resectoscope will then be introduced in the uterine cavity and fluorescent images obtained using the HRME camera. The resectoscope will then be used to remove all tumor as guided through HRME images. The entire imaging and tumor resection process is estimated to take 45 minutes or less.
89489827|NCT02091401|Active Comparator|IV|Women randomized into this treatment group will receive magnesium sulfate via an IV loading dose administered manually by study staff and an IV maintenance regimen.
89489828|NCT02091401|Experimental|Springfusor|Women randomized into this treatment group will receive magnesium sulfate via IV infusion (with the Springfusor® pump).
89489829|NCT01594970|Experimental|Bimatoprost 0.01% (Naive Monotherapy)|1 drop in the affected eye(s), administered in the evening in previously treatment naive subjects for 12 weeks.
89489830|NCT01594970|Experimental|Bimatoprost 0.01% (Switched Monotherapy)|1 drop in the affected eye(s), administered in the evening in subjects who were previously on another monotherapy treatment for 12 weeks.
89489831|NCT01594970|Experimental|Bimatoprost 0.01% (with Adjunctive Therapy)|1 drop in the affected eye(s), administered in the evening in subjects who are also receiving adjunctive therapy for 12 weeks.
89489832|NCT02091557||GnRH-analogue|CA125 levels and VAS pain score changes will be assessed after GnRH-a administration in all patients
89489833|NCT04869176|Experimental|On Caffeine, maintenance dose|During receiving maintenance dose of 5 mg/kg caffeine citrate (i.e. 2,5 mg/kg caffeine) in the form of solution, orally or intravenously, Holter electrocardiogram and vital functions were monitored for 40 minutes.
89489834|NCT04869176|Experimental|Off caffeine|100 hours after caffeine withdrawal Holter electrocardiogram and vital functions were monitored for 40 minutes.
88953642|NCT01964079|Active Comparator|ARB (losartan)|For patients who fail to respond to 50 mg oral losartan daily, the dose will be titrated up to 100 mg losartan. At subsequent visits, additional antihypertensive therapy (hydrochlorothiazide) will be added if systolic (>140 mmHg) or diastolic (>90 mmHg) BP is inadequate. Study drugs are administered once a day for 24 weeks. The dose will be titrated up if SBP is over 90 mmHg or there are no symptoms of hypotension (syncope, loss of consciousness, or orthostatic hypotension). If up-titration is not tolerable, because of side effects or hypotension, the previous dose will be administered as the final tolerable dose.
88953643|NCT01964118|Other|Control group|The participants randomized to the crossover group begin study participation as a control group (no changes in food intake) for the first 6 months and switch to IF for the remaining 6 months of the study.
89489835|NCT02089919|Placebo Comparator|non-cancer stem cell vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
89489836|NCT02089919|Experimental|giving low dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
89489837|NCT02089919|Experimental|giving middle dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
89489838|NCT02089919|Experimental|giving high dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
89489839|NCT03047408|Experimental|patients with PD-RBD|"patients with PD-RBD having already underwent vPSG, clinical and neuropsychological in clinical setting or in the study RBHP 2013 DURIF  at least three years ago."
89489840|NCT02091635|Active Comparator|Motilitone|Eligible subjects were randomly allocated in a 1 : 1 ratio to receive either 60 mg motilitone (motilitone group) or placebo (placebo group) three times daily (before meals) for 5 days (days 1-5).
89489841|NCT02091635|Placebo Comparator|Placebo (for Motilitone)|Eligible subjects were randomly allocated in a 1 : 1 ratio to receive either 60 mg motilitone (motilitone group) or placebo (placebo group) three times daily (before meals) for 5 days (days 1-5).
89489842|NCT02338492|Experimental|Photodynamic Bone Stabilization System|Photodynamic Bone Stabilization System (PBSS) is comprised of an inflatable, thin walled polyethylene terephthalate (PET; Dacron™) balloon mounted on an insertion catheter. This balloon catheter system is designed to deliver the monomer cement to the fracture site via the medullary canal of the bone
89489843|NCT04869254||Hematopoietic stem cells transplantation|patients undergone allogeneic or autologous bone marrow transplant who received immunomodulatory therapy with Thymoglobulin
89489844|NCT03557255|Active Comparator|levosimendan|Levosimendan was prepared in a concentration of 25 µg/ml and infusion was commenced at a rate of 0.1 µg/kg/minute without loading and continued for 24 hours before surgery.The dose was doubled if an increase of > 20 mmHg in systolic blood pressure (SBP) could not be obtained within 2 hours after starting the infusion. Indications for dose reduction were the development of hypotension (SBP < 80 mmHg) or tachycardia (heart rate > 120 beats/min) persisting for more than 10 minute or (premature beats in a frequency exceeding 6/min or occurrence of a significant arrhythmia occurring in runs). The infusion medication would be discontinued should such occurrences persist despite dose reduction.
88956538|NCT04944901|Placebo Comparator|Placebo|"One dose of placebo daily for 28 days according to the treatment group to which they are allocated.~Administration: Oral"
89489845|NCT03557255|Active Comparator|control|In the control group ,an identical saline infusion regimen was employed instead of levosimendan . Both patient and care giver were blinded for the study.
89489846|NCT03047564|Experimental|Coated Total Knee Arthroplasty|Implantation of a coated Total Knee Arthroplasty
89489847|NCT03047564|Active Comparator|Standard Total Knee Arthroplasty|Implantation of a Standard Total Knee Arthroplasty
89489848|NCT02091713||Experimental/Functional movement screen|300 subjects from three different combat units will undergo functional movement screening
89489849|NCT02095925||cancer patients|Patients with stage III or IV esophageal carcinoma, gastric carcinoma, intestinal carcinoma, pancreatic carcinoma, ovarian cancer, breast carcinoma, prostate cancer, urothelial cell carcinoma or lung carcinoma (small cell or non-small cell) who have started chemotherapy no more than 3 months ago
89489850|NCT03047642||Malawi febrile patients|Children and adults with fever presenting at the outpatient department
89489851|NCT03047642||Brazil febrile patients|Children and adults with fever presenting at the outpatient department
89489852|NCT03047642||Gabon febrile patients|Children with fever or with a recent history of fever presenting at the outpatient department
89489853|NCT02091791|Experimental|LT10|"Long duration (30 minutes) traction sessions of low force (10% of body weight) for 2 weeks (5 sessions/week)."
89489854|NCT02091791|Experimental|LT50|"Long duration (30 minutes) traction sessions of high force (50% of body weight) for 2 weeks (5 sessions/week)."
89489855|NCT03045692|Active Comparator|Control group|creatinine based eGFR (which is not revised value with standardized body surface area, that is, 1.73m2) are used to decide colistin maintenance dosage.
89489856|NCT03045692|Experimental|Study group|4 hour creatinine clearance is used to decide colistin maintenance dosage.
89489857|NCT02091947|Experimental|experimental group|Real FMS, 5 Hz, 20 minutes per day, for 10 weekdays.
89489858|NCT02091947|Sham Comparator|sham group|sham FMS, 5 Hz, 20 min per day, for 10 weekdays.
89489859|NCT04868552|Experimental|Naloxone education|These participants will receive a pre-hospital naloxone education module during their pre-operative joint class
89489860|NCT04868552|No Intervention|Standard Education|These participants will receive the standard pre-hospital education including pain management and opioid safety, but will not specifically be given the new naloxone-education module in the pre-hospital setting
89489861|NCT04872764||COVID-19 patients with acute kidney injury|COVID-19 patients with acute kidney injury
89489862|NCT04872764||COVID-19 patients without acute kidney injury|COVID-19 patients without acute kidney injury
89489863|NCT02092103|No Intervention|Delayed Clamping|"The American Congress of Obstetricians and Gynecologists (ACOG) recommends delayed cord clamping for preterm infants. Infants randomized to this group will follow the protocol below:~Infant held at or below level of perineum (vaginal delivery) or incision (cesarean delivery)~Once infant is delivered designated RN starts timer~Infant warming bag on delivery table~Infant placed into warming bag then wrapped in a towel~Assistant to deliver preps cord clamps~Registered Nurse (RN) notifies provider at 30 seconds~Cord clamped and cut~Infant handed off to waiting staff~Exceptions: Placental separation, cord stops pulsating, need for immediate resuscitation, all would result in clamping prior to 30 seconds"
89489864|NCT02092103|Experimental|Cord Milking|"Infants randomized to the cord milking group will follow the protocol below:~Infant held at or below level of perineum (vaginal delivery) or incision (cesarean delivery)~Infant held and the cord is milked from perineum to infant four times~Assistant to deliver preps cord clamps~Cord clamped and cut~Infant handed off to waiting staff"
89489865|NCT02090153|Experimental|S-1 plus LV|All patients were orally treated with S-1 in doses of 40 mg (body surface area (BSA)<1.25 m2), 50 mg (1.25≤BSA<1.50 m2) and 60 mg (BSA≥1.50 m2) b.i.d. on days 1-7 in combination with LV given simultaneously at a ﬁxed dose of 25 mg b.i.d. on days 1-7, followed by a 7 day rest. Treatment courses were repeated every 2 weeks.
89489866|NCT04872530|Experimental|Pea-protein concentrate|Pea-protein concentrate dosed at 0.33 g/kg body mass in 500 ml of water.
89489867|NCT04872530|Experimental|Fava-bean protein concentrate|Fava-bean protein concentrate dosed at 0.33 g/kg body mass in 500 ml of water.
89489868|NCT04872530|Experimental|Chickpea protein concentrate|Chickpea protein concentrate dosed at 0.33 g/kg body mass in 500 ml of water.
89489869|NCT04872530|Experimental|Red lentil protein concentrate|Red lentil protein concentrate dosed at 0.33 g/kg body mass in 500 ml of water.
89489870|NCT04872530|Experimental|Non-essential amino acid blend|Non-essential amino acid blend dosed at 0.33 g/kg body mass in 500 ml of water.
89489871|NCT04872530|Experimental|Whey protein concentrate|Whey protein concentrate dosed at 0.33 g/kg body mass in 500 ml of water.
89489872|NCT03044756|Experimental|-ve arm|The women who do not receive the GnRH antagonist dose on the day of triggering of ovulation (omitted GnRH antagonist arm)
89204380|NCT05123092|Active Comparator|Group ( ultrasound guided erectae spinae block)|The same anesthesiologist who is experienced in US guided regional anesthesia will perform the block. In the group ESP, a high frequency linear US probe (HFL_50, 15_6MHz) will be placed vertically and nearly 3 cm lateral to the vertebra in the middle of the incision line. The transverse process and the overlaying erector spinae muscles (ESM) will be identified under parasagittal scanning A22 G,50 mm block needle (SONOTAP,Pajunk, Geisingen,Germany) will be inserted at a 30-40° angle in the cranial to caudal direction via an in-plane approach and advanced into the plane between the fascia of ESM and transverse process under sterile conditions. The correct needle position will be confirmed after a hydro dissection with 3 ml of isotonic saline, and then 20 ml of 0.25% bupivacaine will be injected in the interfascial plane between the rhomboideus major muscle and ESM. The local anesthetic spread will be visualized in a fascial longitudinal pattern deep to the ESM.
89204381|NCT05123092|Active Comparator|Group (Intrathecal morphine)|In the group of intrathecal morphine , a lumbar puncture will be done in the lateral position via a midline approach into the level of the vertebra which exists in the middle of the incision with complete aseptic condition using 25 gauge Quincke spinal needle to give 0.3 mg of morphine (preservative free form) suspended in 0.4 ml of normal saline .
89489873|NCT03044756|No Intervention|+ve arm|The women who receive the routine dose of GnRH antagonist on the day of triggering of ovulation (the usual protocol)
89489874|NCT00358163|Experimental|PTK787/ZK 222584|
89204382|NCT05356156|Experimental|Closure of the mesenteric defects|Closure of the mesenteric defects will be performed after radical gastrectomy in patients with gastric or esophagogastric junction adenocarcinoma.
89204383|NCT05356156|Active Comparator|Non-closure of the mesenteric defects|Non-closure of the mesenteric defects will be performed after radical gastrectomy in patients with gastric or esophagogastric junction adenocarcinoma.
89204384|NCT04001530|Experimental|Half-normal saline|Use of half-normal saline (0.45% NaCl) as an irrigant for open-irrigated ablation catheters
89204385|NCT04001530|Active Comparator|Normal saline|Use of normal saline (0.9% NaCl) as an irrigant for open-irrigated ablation catheters
89489875|NCT03044600||Young MEN1 Negative Group|Participants under 50 years of age who have been diagnosed with MEN1-negative primary hyperparathyroidism.
89489876|NCT02096237|Experimental|apheresis, IgE adsorber|9 apheresis treatments with the new IgE adsorber in a period of 3 months with 3 cycles of 3 treatments each every month.
89489877|NCT02096237|No Intervention|Conventional drug treatment|Patients treated with conventional asthma treatment as prescribed before study entry. No intervention in prescription
89489878|NCT03044834||Pleuropulmonary Blastoma|"Patients born between 01/01/2000 and 01/01/2016 ;~Followed up for PPB~Treated in a French department of paediatric oncology or paediatric surgery~Study agreement"
89489879|NCT02096315|Experimental|POL7080|POL7080 administered daily
89489880|NCT04868864||Moderate to severe COVID-19 infection|COVID-19 patients with radiographic changes on CXR or CT which had not resolved or had persistent hypoxia due to COVID-19 at the time of discharge will be enrolled. All participants will undergo a LDCT and PFT.
89489881|NCT04868864||Persistent LDCT or PFT abnormalities|Participants with abnormalities on LDCT and or PFT will be invited to continue with a follow-up sub-study. This will involve follow up with repeated LDCT and PFT at subsequent time points to monitor and manage the abnormalities detected until the abnormalities fully resolve or to the last time point at 9 months of the study.
89489882|NCT03556397|Experimental|cN0 before and after neoadjuvant th., SLNB - negative, no AD|Patients with cN0 before and after neoadjuvant therapy, SLNB - negative, without AD
89489883|NCT03556397|Experimental|cN0 before and after neoadjuvant th., SLNB - posit., AD|Patients with cN0 before and after neoadjuvant therapy, SLNB - positive, AD (separated histological examination of lymph nodes in levels I and II)
89489884|NCT03556397|Experimental|cN1 before neoadj. th., cN0 after neoadj. th., SLNB, AD|Patients with cN1 before neoadjuvant th., cN0 after neoadjuvant therapy, SLNB, AD (separated histological examination of lymph nodes in levels I and II)
89489885|NCT03556397|Experimental|cN1 after neoadjuvant therapy, SLNB, AD|Patients with cN1 after neoadjuvant therapy, SLNB, AD.
89489886|NCT04865822|Experimental|Pain Education|Participant will attend a single session pain education course
89489887|NCT04865822|No Intervention|wait list control|Participants will be wait listed then receive intervention
89489888|NCT02337946|Active Comparator|Group A|Panitumumab (Pmab) 6 mg/kg, intravenous drip infusion (DIV), at Day 1, oxaliplatin (OXA) 85 mg/m^2, DIV, at Day 1, levofolinate (l LV) 200 mg/m^2, DIV, at Day 1, fluorouracil (5-FU) 400 mg/m^2, intravenous (IV) at Day 1, 5-FU 2400 mg/m^2, continuous intravenous infusion (CIV), at Day 2 once every two weeks from cycle 1 through cycle 6 as protocol treatment 1 followed by Pmab 6 mg/kg, DIV, at Day 1, OXA 85 mg/m^2, DIV, at Day 1, l LV 200 mg/m^2, DIV, at Day 1, 5-FU 400 mg/m^2, IV, at Day 1, 5-FU 2400 mg/m^2, CIV, at Day 2 once every two weeks from cycle 7 until progressive disease or intolerance.
89204386|NCT05344846|Experimental|Guided imagery Group|Guided imagery after cesarean
89489889|NCT02337946|Experimental|Group B|Pmab 6 mg/kg, DIV, at Day 1, OXA 85 mg/m^2, DIV, at Day 1, l LV 200 mg/m^2, DIV, at Day 1, 5-FU 400 mg/m^2, IV, at Day 1, 5-FU 2400 mg/m^2, CIV, at Day 2 once every two weeks from cycle 1 through cycle 6 as protocol treatment 1 followed by Pmab 6 mg/kg, DIV, at Day 1, l LV 200 mg/m^2, DIV, at Day 1, 5-FU 400 mg/m^2, IV, at Day 1, 5-FU 2400 mg/m^2, CIV, at Day 2 once every two weeks from cycle 7 until progressive disease or intolerance.
89489890|NCT04868084|Experimental|Intervention group|"Physical Literacy in the early years. The intervention was delivered by an external provider and designed to provide nursery teachers, teaching assistants and others working with children under age five the knowledge, skills and confidence to deliver enjoyable and engaging lessons which focus on the development of core fundamental skills. The course was developed in conjunction with leading Physical Education (PE) consultants, Sports Scientists and Office for Standards in Education, Children's Services and Skills (Ofsted) advisors which covered both the theory about FMS and physical literacy, and practical demonstrations of age-appropriate ways to teach and develop FMS. Staff from the Intervention settings received the six-hour training session. After the training session, school nurseries which were encouraged to speak with the training provider to follow-up the understanding of the training and provide additional help for implementation of the practice learned."
89489891|NCT04868084|No Intervention|Control|The control nurseries followed their usual practice.
89489892|NCT02091479|Experimental|UFH Early group|anticoagulant (UFH or LMWH) reintroduction at 48h to 72h after hemorrhage
89489893|NCT02091479|Active Comparator|UFH Late group|anticoagulant (UFH or LMWH) réintroduction 120h to 144h after hemorrhage
89489894|NCT04865666|Experimental|movr App Group|Participants were instructed to maintain their usual physical activity, diet, and sleep behavior for the 8-week intervention period and to avoid any specialized exercise training for that time period, but they were also asked to use the movr app to supplement their current activity.
89489895|NCT04865666|No Intervention|Waitlist Control Group|Participants were instructed to maintain their usual physical activity, diet, and sleep behavior over the 8-week study period and to avoid any specialized exercise training for that time period. Following the 8-week study period, individuals in the control group were permitted to download and use the movr app if they chose to.
89489896|NCT02090231|Experimental|Real 5 Hz rTMS|real 5 Hz rTMS, 10 minutes per day, for 10 weekdays.
89489897|NCT02090231|Sham Comparator|sham 5 Hz rTMS|sham 5Hz rTMS, 10 minutes per day, for 10 weekdays.
89489898|NCT04865510|Active Comparator|Citrate|The RCA group CRRT were performed with Prisma flex or (Baxter Healthcare/Gambro Spain) or Informed machine with citrate pump. The function mode was continuous venovenous hemodiafiltration (CVVHDF) in postdilution mode with ST 150 filter sets. The substitution fluid was Accusol or Prismocal B22 .The dose of dialysis was 20-25 ml/kg/hr with blood flow 150-200 ml/min. Trisodium citrate solution (4%,136mmol/L) was infused into the arterial line prior to the blood pump at a dose of 4 mmol/L of plasma flow. Calcium chloride (5% 340 mmol/L elemental calcium) was infused into the venous return to maintain systemic ionized calcium in the normal range (0.99-1.30 mmol/L) and the targets values for ionized calcium (iCa2+) after the dialysis membrane were 0.25-0.35 mmol/L. The rale of calcium infusion was adjusted in a timely manner based on repeated measurements of calcium concentration
89489899|NCT04865510|Placebo Comparator|Heparin-free|The heparin- free group The circuit was periodically flushed with 50 ml saline via access limb every 30 minutes .When pre-filter pressure started to rise, additional saline flushes would be given.
89489900|NCT02090309|Active Comparator|Hydrocortisone injection|I.V Hydrocortisone 100 mg single bolus.
89489901|NCT02090309|Placebo Comparator|normal saline|I.V normal saline 0.9% a single bolus of 5 ml.
89489902|NCT04865120|Active Comparator|merocyanine|
89489903|NCT04865120|Placebo Comparator|placebo|
89489904|NCT02092337|Experimental|computer assisted speech training|computer assisted speech training
89489905|NCT03047252|Experimental|Experimental group|"Home-based rehabilitation sessions performed with the novel digital biofeedback system.~Patients will be instructed to perform exercise sessions in at least 5 days per week, but compliance to this schedule is not mandatory per protocol."
89489906|NCT03047252|Active Comparator|Conventional rehabilitation group|Home-based rehabilitation sessions provided by a Physical Therapist, 3 times a week for 8 weeks. Each session will have a duration of 60 minutes. Patients will be instructed to perform additional unsupervised sessions in at least two other days, but compliance to these extra sessions is not mandatory per protocol.
89489907|NCT03047096|Experimental|HA & CS group|hyaluronic acid and corticosteroids
89489908|NCT03047096|Experimental|HA group|hyaluronic acid
89489909|NCT02092493|No Intervention|Non-ScopeGuide|This arm will have patients undertaking the procedure without ScopeGuide. All outcome measures will be recorded as usual
89489910|NCT02092493|Experimental|ScopeGuide|Patients have their colonoscopy done with ScopeGuide
89489911|NCT04872296|Active Comparator|Early weight bearing|Participants treated for an ankle fracture will be allowed to weight bear early after surgery starting at 2 weeks post operatively
89204387|NCT05344846|No Intervention|Standard care|The participants in the control group will perform routine care of the clinic.
89204388|NCT05282056|Experimental|CAD analysis|The XVision COVID-19 computer aided diagnostic software is used by radiologist at CT analysis time
89204389|NCT05282056|No Intervention|No CAD analysis|No CAD analysis is shown to radiologist.
89204390|NCT05278936|Other|A simplified sclero-cornel tunnel/incision in performing the congenital/pediatric cataract surgery|Participitant
89204391|NCT00991900||Healthy subjects|
89204392|NCT00769067|Active Comparator|A|
89204393|NCT00769067|Experimental|B|
89204394|NCT00321373|Experimental|GSK1247446A-AS03 Group|Subjects aged 60 years or older at the time of the vaccination who received 1 dose of GSK1247446A vaccine adjuvanted with AS03. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
89489912|NCT04872296|Active Comparator|Postponed weight bearing|Participants treated for an ankle fracture will be treated with standard protocol of non-weight bearing for 6 weeks post operatively.
89489913|NCT04872374|Experimental|Young adults|participants will perform an eccentric exercise bout after 10 days of dietary supplementation
89489914|NCT04872374|Active Comparator|Older adults|participants will perform an eccentric exercise bout after 10 days of dietary supplementation
89489915|NCT02090387|Active Comparator|Control ONS|ONS without AN777
89489916|NCT02090387|Experimental|Investigational ONS|ONS containing AN777
89489917|NCT02092727|No Intervention|Control|Standard of care arm will receive no specific interventions, but will have access to standard educational materials and quality improvement through End Stage Renal Disease Network 6.
89489918|NCT02092727|Experimental|Behavioral Intervention|A variety of dialysis facility-level, behavioral interventions will be examined.
89489919|NCT04871984||Holmium laser lithotripsy|Stone fragmentation are performed with Holmium laser in ureteroscopy
89489920|NCT04871984||Thulium laser lithotripsy|Stone fragmentation are performed with Thulium laser in ureteroscopy
89489921|NCT02090465||all eligible patients|Treatment with Picato according to Summary of Product Characteristics (SmPC)
89489922|NCT03045458|Active Comparator|Tissue level dental implant|Tissue level dental implants (Straumann AG, Waldenburg, Switzerland) were inserted in patients group I (n=20).
89489923|NCT03045458|Active Comparator|Bone level dental implant|Bone level dental implants (Straumann AG, Waldenburg, Switzerland ) were inserted in patients group II (n=20).
89489924|NCT02090543||Group 1|300 AF patients, with at least 3 month of anticoagulation therapy with VKAs (VKA-experienced patients)
89489925|NCT02090543||Group 2|300 AF patients, with at least 3 month of rivaroxaban therapy (rivaroxaban-experienced patients)
89489926|NCT04859036||Transchateter VSD closure group|VSD cases treated with transcatheter closure method.
89489927|NCT04859036||Control group|Healty children
89489928|NCT02090621|Experimental|Extracorporeal Photopheresis|Extracorporeal Photopheresis
89489929|NCT03556241|Experimental|Intervention: No change group|Case management consists keeping patient's current pacemaker mode during surgery
89489930|NCT03556241|No Intervention|Control: Mode change group|Usual care consists changing pacemaker mode to VOO before surgery
89021903|NCT00452829|Placebo Comparator|Control Group|5 mg folic acid (the standard UK supplement for pregnancies at high risk of NTD)and 1 g placebo
89489931|NCT03556163|Experimental|Test Group|Modified vertical internal mattress sutures + MWF surgery.
89489932|NCT03556163|Active Comparator|Control Group|Simple loop interrupted sutures + MWF surgery.
89489933|NCT02092805|Sham Comparator|Sham rTMS|Sham-rTMS was applied using the same parameters but with the coil elevated and angled away from the head to reproduce some of subjective sensation of rTMS.
89489934|NCT02092805|Active Comparator|Real rTMS|The active group recieved real-rTMS over the motor cortical area corresponding to the hand of painful side. Each train consist of 2000 pulses at 20 Hz and 80% RMT (total duration 10s). The treatment was repeated every day for 5 consecutive days in week for two weeks (the total number of sessions had be given was 10 sessions).
89489935|NCT02096627||conventional|Patients who undergo routine cataract surgery using conventional phacoemulsification technique
89489936|NCT02096627||FLACS|Patients who undergo femtosecond laser assisted cataract surgery
89204395|NCT00321373|Experimental|GSK1247446A Group|Subjects aged 60 years or older at the time of the vaccination who received 1 dose of non-adjuvanted GSK1247446A vaccine. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
89204396|NCT00321373|Active Comparator|Fluarix Group|Subjects aged 60 years or older at the time of the vaccination who received 1 dose of Fluarix vaccine. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
89489937|NCT02090699||Myocardial Iron Overload|chronic blood transfusion related myocardial iron overload
89489938|NCT02090699||Healthy Volunteers|age matched healthy volunteers
89489939|NCT02092883|Experimental|Infantile Spasms|
89489940|NCT03557021|Experimental|Individualized therapy arm|HIV Treatment failure patients will undergo an HIV Drug resistance testing and the followed therapy will be adjusted with in this setting available medications to the outcome of the resistance profile
89489941|NCT03557021|Active Comparator|standard therapy arm|HIV Treatment failure patients will undergo an HIV Drug resistance testing and the national defined standard therapy will be applied as second line treatment.
89489942|NCT02093039|Experimental|Decision aid group|Women allocated to the decision aid group received an invitation to participate in the national breast cancer screening program and the specially-designed decision aid (a leaflet), by mail.
89489943|NCT02093039|No Intervention|Control group|Women in the control group received an invitation and the usual standard information by mail.
89489944|NCT02096783|Active Comparator|Arm I (standard counseling)|Patients receive standard counseling at both the pre-operative and 2-4 week post-operative visit.
89204397|NCT02826928|Experimental|patients with small-intestine neuroendocrine tumors|
89489945|NCT02096783|Experimental|Arm II (standard counseling, scripted intervention)|Patients receive standard counseling at the pre-operative visit and the scripted sexual health intervention at the 2-4 week post-operative visit.
89489946|NCT02096783|Experimental|Arm III (standard counseling, scripted intervention)|Patients receive standard counseling and the scripted sexual health intervention at the pre-operative visit and standard counseling at the 2-4 week post-operative visit.
89204398|NCT02826928|Experimental|control subjects with irritable bowel syndrome|
89204399|NCT04001608|Experimental|Seraprevir and sofosbuvir|Subjects will receive oral tablets of Seraprevir 100mg twice a day along with oral tablet of sofosbuvir 400 mg,once a day from Day 1 up to Week 12.
89489947|NCT02096783|Experimental|Arm IV (standard counseling, scripted intervention)|Patients receive standard counseling and the scripted sexual health intervention at both the pre-operative and 2-4 week post-operative visit.
89489948|NCT02093117|Experimental|Recruitment maneuver|The recruitment maneuver will involve application of continuous positive airway pressure of 30 cm of water for 30 seconds.
89489949|NCT02093117|Sham Comparator|Sham recruitment maneuver|The sham recruitment maneuver will involve application of continuous positive airway pressure of 5 cm of water for 30 seconds.
89489950|NCT02093195|Experimental|Bosentan|Bosentan,125mg,po,bid combined with inhaled Symbicort turbuhaler, 320/9μg, bid.
89489951|NCT02093195|Active Comparator|Control|Inhaled Symbicort turbuhaler, 320/9μg, bid.
89489952|NCT02096939||Primary aldosteronism|Patients with primary aldosteronism, who undergo surgery or will be started on antihypertensive medication, including mineralocorticoid receptor antagonists
89489953|NCT02096939||Essential hypertension|Patients with essential hypertension who will be started on antihypertensive medication
89489954|NCT03555617|Experimental|TD-1473 formulation bridging & food effect|Subjects will receive, on Day 1 of each period, a single 100 mg oral dose of the tablet formulation of TD-1473 in the fed or fasted state, or the PIC formulation of TD-1473 in the fasted state, as part of a 3-period, crossover design.
89489955|NCT03555617|Experimental|TD-1473 with Itraconazole|Subjects will receive a single 100 mg oral dose of the tablet formulation of TD-1473 in the fasted state on Day 1 of Period 1. In Period 2, subjects will receive, in the fasted state, single oral doses of 200 mg itraconazole solution on Days -4 through 7 for a total of 11 days, with a single 100 mg oral dose of the tablet formulation of TD-1473 co-administered on Day 1.
89489956|NCT03555617|Experimental|TD-1473 without Itraconazole|Subjects will receive a single 100 mg oral dose of the tablet formulation of TD-1473 in the fasted state on Day 1 of Period 1.
89489957|NCT03555539|Experimental|Part 1: Healthy Match|Single 200-milligram (mg) dose of danicopan on Day 1 in healthy participants (matched control group with normal hepatic function).
89489958|NCT03555539|Experimental|Part 1: Moderate HI|Single 200-mg dose of danicopan on Day 1 in participants with moderate HI.
89489959|NCT02093273|Active Comparator|tOPV commercial batch (Bio Farma)|tOPV (Bio Farma) one dose correspond to 2 drops (0.1ml)
89489960|NCT02093273|Experimental|tOPV pilot batch|tOPV (Bio Farma), one dose correspond to 2 drops (0.1ml)
89489961|NCT02098811|Experimental|1064nm laser Treatment Before Abdominoplasty|Patient will be treated with 1064nm Laser prior to abdominoplasty
89204400|NCT00667394|Experimental|Tandutinib & Bevacizumab in GBM Patients|GBM (glioblastoma multiforme) Tandutinib 500 mg by mouth daily dose twice a day. Bevacizumab 10 mg/kg dose intravenous repeated once every 2 weeks.
89204401|NCT00667394|Experimental|Tandutinib & Bevacizumab in AG Patients|AG (anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic mixed oligoastrocytoma, and malignant astrocytoma NOS (not otherwise specified)) Tandutinib 500 mg by mouth daily dose twice a day. Bevacizumab 10 mg/kg dose intravenous repeated once every 2 weeks.
89204402|NCT04103021|Experimental|Port-a-cath|Ultrasound guided Port-a-cath insertion
89489962|NCT02098811|Experimental|940nm Laser Treatment Before Abdominoplasty|Patient will be treated with 940nm Laser prior to abdominoplasty
89204403|NCT05357326|Active Comparator|0.01% atropine|use atropine sulfate 0.01% eye drop every night before sleep for two years
89204404|NCT05357326|Experimental|0.04% atropine|use atropine sulfate 0.04% eye drop every night before sleep for two years
89489963|NCT02098889|Active Comparator|hyoscine-N-butyl bromide|A single dose intravenously(IV) 20ml hyoscine-N-butyl bromide(HBB) versus placebo ( a single dose 20ml IV NaCl) on the active phase of labor
89537942|NCT04978623||Patient with MMNCB|Patients with MMNCB are at the crossroads between chronic demyelinating neuropathies and motor neuron diseases, the latter for which they constitute a differential diagnosis. The disease usually presents asymmetrically and affects the upper limbs more frequently. The course of the disease is unpredictable, and may be limited to one or two motor nerves or progress to other motor nerves in the contralateral upper limb and possibly the lower limbs. In all cases, the motor deficit is asymmetrical, multi-truncular in distribution, and is usually accompanied by cramps and fasciculations, and eventually by amyotrophy. Osteotendinous reflexes are usually diminished or abolished in the affected areas, but they may also be preserved in the initial attacks. There is no sensory deficit, although some patients occasionally present with paresthesias, and exceptionally with damage to the cranial nerves (especially CN XII).
88953644|NCT01964118|Experimental|Intermittent Fasting group|Participant with a BMI between 28 and 35 kg/m2 will fast 3 non-consecutive days per week, whereas participant with a BMI between 24 and 27.9 kg/m2 will fast 2 non-consecutive days per week. Individuals following intermittent fasting (IF) will work with the study dietitian to design their weekly meal plans and menus for the non-fasting days. The subjects following IF will be asked to skip breakfast, lunch, dinner, snacks, and calorie-containing beverages on the fast days, but we will give them the option to consume at dinner a big salad (i.e. non-starchy raw and/or cooked vegetables dressed with 2 tablespoons of salad dressing prepared with vegetable oil, vinegar and seasonings).
88953645|NCT01964131|Experimental|D961H sachet 20 mg|Pellets contains esomeprazole 20 mg (esomeprazole magnesium trihydrate 22.3 mg) and excipient granules filled into single-use aluminium sachets
89489964|NCT02098889|Placebo Comparator|Saline(0,9NaCl)|Placebo ( a single dose of 20ml IV NaCl) versus A single dose intravenously(IV) 20 mg (20ml) hyoscine-N-butyl bromide(HBB)on the active phase of labor
89489965|NCT03772301||Group 1|At least 200 Jewish Holocaust survivors of the first generation living in Germany and Israel - an equal number in each country
88953646|NCT01964131|Other|D961H HPMC capsule 20 mg|Pellets contains esomeprazole 20 mg (esomeprazole magnesium trihydrate 22.3 mg) in HPMC capsule
89489966|NCT03772301||Group 2|The second generation, whose parents lived in Europe during the Second World War, now live in Germany (originating from Western and Eastern Europe) - at least 200 participants.
89489967|NCT03772301||Group 3|Third generation of Jewish Holocaust survivors who participated in the first phase, currently living in Germany and Israel - at least 200 participants including at least 100 subjects in each country. These are adults only. The research program does not include children and adolescents
89489968|NCT01369199|Experimental|Peginterferon and entecavir|A combination of 8 weeks of entecavir followed by 40 weeks of both entecavir and peginterferon.
89489969|NCT02093507|Experimental|parents manipulation|parents manipulation
89489970|NCT02093507|No Intervention|no manipulation|no manipulation
89489971|NCT02097095||Vaccine group|TB vaccine GSK 692342 (M72/AS01E) administered on study TB-018
89489972|NCT02097095||Placebo Comparator|Placebo administered on study TB-018
89489973|NCT02098967|Experimental|Acute myeloid leukemia patients|
89489974|NCT02098967|Experimental|Cohort 0|
89489975|NCT02098967|Experimental|Solid tumor patients|
89489976|NCT02097173|Other|SC MTX followed by IM MTX|1 subcutaneous injection of 30 mg methotrexate administered by a prefilled pen (50mg/mL) followed by 1 intramuscular injection of 30 mg methotrexate (comparator) after a wash-out phase of 1 week
88953647|NCT01964144|Experimental|Dovitinib arm|
89489977|NCT02097173|Other|IM MTX followed by SC MTX|1 intramuscular injection of 30 mg methotrexate (comparator) followed by 1 subcutaneous injection of 30 mg methotrexate by a prefilled pen (50mg/mL) after a wash-out phase of 1 week
89489978|NCT02097329|Experimental|Cohort 1: Palbociclib under fed conditions|
89489979|NCT02097329|Experimental|Cohort 2: Palbociclib under fed conditions|
89489980|NCT02099201|Experimental|Group A1|Ten subjects will receive ACT-389949 40 mg and 3 subjects will receive placebo, once a day for 9 days Medication will be administered orally, in the morning, following an overnight fast.
89489981|NCT02099201|Experimental|Group A2|Ten subjects will receive ACT-389949 (Predicted to be 200 mg) and 3 subjects will receive placebo, once a day for 9 days Medication will be administered orally, in the morning, following an overnight fast.
89489982|NCT02099201|Experimental|Group A3|Ten subjects will receive ACT-389949 (Predicted to be 800 mg) and 3 subjects will receive placebo, once a day for 9 days Medication will be administered orally, in the morning, following an overnight fast.
89489983|NCT02099201|Experimental|Group B1|Ten subjects will receive ACT-389949 200 mg and 3 subjects will receive placebo, every 3 days for 13 days (a total of 5 doses), administered orally, in the morning, following an overnight fast.
89489984|NCT02099201|Experimental|Group B2|Ten subjects will receive ACT-389949 (provisionally 200 mg) and 3 subjects will receive placebo, every 2 days for 9 days (a total of 5 doses), administered orally, in the morning following an overnight fast. The actual dose will depend on the emerging data from Group B1.
89489985|NCT02099201|Experimental|Group C1|10 subjects will receive ACT-389949 and 3 subjects on placebo. The actual dose will depend on the emerging data from the previous groups but will be within the dose range or lower than the dose range tested in Part A. The dosing schedule will be one of those already tested in Part A and/or Part B.
88953648|NCT01964157|Experimental|LDK378 arm|
89204405|NCT05357326|Experimental|orthokeratology|wear orthokeratology lens every night for two years
89204406|NCT00778466|Experimental|1|metformin hydrochloride 1000 mg tablets of ranbaxy
89489986|NCT02099201|Experimental|Group C2|10 subjects will receive ACT-389949 and 3 subjects on placebo. The actual dose will depend on the emerging data from the previous groups but will be within the dose range or lower than the dose range tested in Part A. The dosing schedule will be one of those already tested in Part A and/or Part B.
89489987|NCT02099279||echocardiography examination|
89489988|NCT02093585|Experimental|Tenofovir to abacavir|Patients switching from tenofovir (245 mg QD) to abacavir (600 mg QD)
89489989|NCT02093585|Experimental|Abacavir to tenofovir|Patients switching from abacavir (600 mg QD) to tenofovir (245 mg QD)
89489990|NCT02099357|Placebo Comparator|Placebo|Daily supplementation with 3g of dextrose during eight weeks and placebo ampoules each two weeks.
89489991|NCT02099357|Experimental|Creatine|Daily supplementation with 3g of monohydrate creatine during eight weeks. Placebo ampoules each two weeks.
89489992|NCT02099357|Active Comparator|Vitamin D|Daily supplementation with 3g of dextrose during eight weeks. Vitamin D supplementation, 25000 IU each two weeks.
89489993|NCT02093741||ADVATE - 2mL|
89489994|NCT02099435||Hemospray to treat lower GI bleeds|
89489995|NCT02097407|Experimental|Group D : Dexmedetomidine + propofol group|In Group D, DEX (1 µg kg-1) was intravenously loaded for 10 min before induction of anaesthesia.
89489996|NCT02097407|Placebo Comparator|Group C : Saline + propofol group|In Group C, 0.9% of normal saline (1 µg kg-1) was loaded 10 min before induction of anaeshtesia.
89489997|NCT02250053|Experimental|exercise|aerobic exercise on soluble intercellular adhesion molecules
89489998|NCT02097563|Experimental|High Intensity Training|High intensity training: clinician attends a 6-hr live workshop in family-focused treatment techniques, and then, after taking on a case, gets weekly technical consultation sessions (by telephone) in FFT from an expert after every session;
89489999|NCT02097563|Active Comparator|Low Intensity Training|Low Intensity Training: clinician completes online workshop in FFT and then, after taking on a case, gets telephone consultation sessions after every third session.
89490000|NCT01368965|Experimental|Ulthera® System treatment|
89490001|NCT02250599|Active Comparator|carboplatin and paclitaxel|carboplatin and paclitaxel :paclitaxel 175 mg/m2 IV and carboplatin AUC 6 IV on Day 1 of each 3-week cycle
89490002|NCT02250599|Experimental|AVASTIN and carboplatin and paclitaxel|AVASTIN and carboplatin and paclitaxel: Bevacizumab(AVASTIN) 7.5 mg/kg intravenously (IV) infusion on Day 1 of each 3-week cycle; paclitaxel 175 mg/m2 IV and carboplatin AUC 6 IV on Day 1 of each 3-week cycle
89490003|NCT02250677||Patients with myalgia|Patients with myalgia as a side effect to treatment with Simvastatin (minimum 20 mg daily)
89490004|NCT02250677||Patients without myalgia|Patients treated with Simvastatin (minimum 20 mg daily) without any side effects to the treatment
89490005|NCT02250677||Control group|Patients with elevated serum cholesterol not treated with cholesterol lowering drugs
89490006|NCT02093975|Experimental|Video consultation|Patients in this arm receive video consultation from physician in doctor manned rapid response vehicle.
89490007|NCT02093975|Active Comparator|Telephone consultation|Patients receiving prehospital care by ambulance personnel whom receive telephone consultation/supervision by physician in rapid response vehicle.
89490008|NCT02094053|Experimental|E2020 3 mg|3 mg of E2020 (oral) once daily, for 24 weeks
89490009|NCT02094053|Experimental|E2020 5 mg|5 mg of E2020 (oral) once daily, for 24 weeks
89490010|NCT02094053|Placebo Comparator|Placebo|placebo (oral) once daily, for 24 weeks
89490011|NCT02099669|Experimental|Liberal transfusion strategy|"Intervention: Red Blood Cell transfusions. Transfuse pRBC at a higher threshold- maintain Hb level between 110 and 120 g/L: to achieve this, 2 units of pRBCs are transfused when Hb level is < 105 g/L and 1 unit of RBCs when Hb level is 105-110 g/L.~Transfusions administered more frequently."
89490012|NCT02099669|Active Comparator|Restrictive transfusion strategy|Intervention: Red Blood Cell transfusions. Transfuse pRBC at standard of care thresholds- maintain Hb level between 85 and 100 g/L: to achieve this, 2 units of packed red blood cells (pRBCs) will be transfused when the Hb level is < 80 g/L and 1 unit of pRBCs when Hb level is 80-85 g/L: standard administration
89490013|NCT02099747|Active Comparator|hATG + CsA|Control Arm
89490014|NCT02099747|Experimental|hATG + CsA + Eltrombopag|Experimental
89490015|NCT02097797|Experimental|Fecal Transplantation|patients receiving the fecal transplant (fecal microbiota from a healthy donor)
88953649|NCT01964170|Experimental|ASP3550 PART 1 and PART 2|Part 1 for 1 year treatment and Part 2 for an extended period of treatment
89204407|NCT00778466|Active Comparator|2|GLUCOPHAGE® (metformin hydrochloride) 1000 mg tablets
89204408|NCT00761735|Other|PEG-IFN + RBV: LTFU|Pediatric participants who completed treatment with peginterferon alfa-2b (PEG-IFN) plus ribavirin (RBV) in P02538 Part 1 of this study (NCT00104052) were enrolled in a 5-year Long Term Follow-Up (LTFU) during P02538 Part 2 (NCT00761735). No study treatment was administered in Part 2.
89204409|NCT00569946|Experimental|AG-013736|
89490016|NCT02097797|Sham Comparator|Sham Transplantation|patients receiving the vehicle (Physiological serum)
89490017|NCT03555929|Experimental|Dexamethasone|Dexamethasone 8 mg/2cc I.V. 90 minutes after axillary block
89490018|NCT03555929|Placebo Comparator|Normal saline|Normal saline 2cc I.V., 90 minutes after axillary block
89490019|NCT02097875|Experimental|BLZ-100|A single dose of BLZ-100 (1, 3, 6, 12 or 18 mg) will be administered by intravenous injection approximately 48 hours prior to planned excision of skin tumor.
89490020|NCT02094131|Experimental|Cliniflo group (CG)|Training using flow-oriented incentive spirometry Cliniflo
89490021|NCT02094131|Experimental|Voldyne group (VG)|Training using volume-oriented incentive spirometry Voldyne
89490022|NCT02094131|No Intervention|Control group (CONG)|No intervention. Assessment and reassessment after 5 weeks.
89490023|NCT02099903|No Intervention|Medical therapy for heart failure|Standard optimized medical therapy for heart failure.
89490024|NCT02099903|Experimental|Renal denervation + medical therapy.|Transcatheter Renal Denervation with irrigated radiofrequency catheter + standard medical therapy.
89490025|NCT02099981|Experimental|Control Group|Control subjects will receive AG.
89490026|NCT02099981|Experimental|Type 1 diabetes|Type 1 diabetic subjects will receive AG.
89490027|NCT02100059|Experimental|Electrical Stimulation (TENS)|The TENS (transcutaneous electrical nerve stimulation) electrodes will be applied on the medial and lateral superior, as well as the medial and lateral inferior, borders of the patella. A continuous biphasic pulsatile current (150 Hz, phase duration 150 µs) will be applied at an intensity that produces a comfortable sensation but not a muscle contraction. The duration of intervention will be 40 minutes.
89490028|NCT02100137||Women with endometrial hyperplasia|
89490029|NCT03555773|Experimental|Lipogems|Lipogems injection into the submucosa surrounding the internal fistula orifice and in the perianal tissue along the residual fistula tract
89490030|NCT02250209|Experimental|Trastuzumab,Capecitabine,Oxaliplatin|"Patients receive eight 3-week cycles of oral capecitabine (800-1000 mg/m2 twice daily on days 1-14 of each cycle) ,intravenous oxaliplatin (130 mg/m2 on day 1 of each cycle) plus intravenous Trastuzumab (440mg on day 0 of each cycle).~Number of cycle:capecitabine and oxaliplatin --8 cycles; Trastuzumab--14-16 cycles."
89490031|NCT02097953|Experimental|Daptomycin and Rifampin|Drug: Daptomycin Daptomycin 6 mg/kg will be given by IV infusion on the first study day Drug: Rifampin Rifampin 600 mg capsules will be given orally once daily for 14 days starting on study day 2 Drug: Daptomycin Daptomycin 6 mg/kg will be given by IV infusion on study day 15
88953650|NCT01964170|Active Comparator|Goserelin|part 1 for 1 year treatment
88953651|NCT01964183|Experimental|treatment group|
88953652|NCT01964196|Experimental|ASP1517 low dose group|Oral
88953653|NCT01964196|Experimental|ASP1517 middle dose group|Oral
88953654|NCT01964196|Experimental|ASP1517 high dose group|Oral
88953655|NCT01964196|Placebo Comparator|Placebo group|Oral
89204410|NCT00778544|Experimental|1|amoxicillin-clavulanic acid 600 mg- 42.9 mg/ 5 mL oral suspension of Ranbaxy
89204411|NCT00778544|Active Comparator|2|Augmentin ES-600
89204412|NCT04001374||Ticagrelor|Ticagrelor 90mg tablet bid for 12 months
89204413|NCT04001374||Ticagrelor + ASA|Ticagrelor 90mg tablet bid for 12 months and enteric coated aspirin 81mg-100mg daily p.o. for 12 months
89490032|NCT02098031|No Intervention|control|
89490033|NCT02098031|Experimental|intervention|Nutritional intervention (nutrition education)
89490034|NCT03556787|Experimental|Patients with knee pain|Adults patients suffering from osteoarthritis pain or general knee pain
89490035|NCT03556709|Experimental|Treadmill Ankle Robot Training|
89490036|NCT02094287|Experimental|verum, instruction, conditioning|This group received dimetindene and instructions about dimetindene and its effectiveness. One classical conditioning process with saline was applied during the skin prick test procedures.
89490037|NCT02094287|Experimental|verum, instruction, no conditioning|This group received dimetindene and instructions about dimetindene and its effectiveness. No conditioning process were applied
89490038|NCT02094287|Experimental|placebo, instruction, conditioning|This group received a placebo (saline) as intravenously administered substance. But instructions about receiving dimetindene and its effectiveness were given. One classical conditioning process was applied during the skin prick test procedures.
89490039|NCT02094287|Experimental|verum, no instruction, no conditioning|Dimetindene was covertly administered (unawareness of treatment). No instruction and no conditioning were given.
89490040|NCT02094365|Experimental|ALS-008176|ALS-008176 drug substance for oral suspension
89490041|NCT02094365|Placebo Comparator|vehicle alone|Vehicle alone
89490042|NCT02100215|Experimental|Expert Modeling|Participants will have access to 70 minutes of expert modeling videos available over 5 weeks on an online learning management system. The investigator will be the expert model in the videos. Expert modeling videos will address content related to seven concepts: Taking report with a graphic organizer worksheet, prioritizing patient care, delegating to unlicensed assistive personnel, safety checks in patient rooms, focused physical assessments, safe medication administration, and using a standardized healthcare provider communication tool on the telephone.
89490043|NCT02100215|Active Comparator|Voice Over PowerPoint|Participants will have access to 60 minutes of voice over PowerPoint slides, available over 5 weeks on an online learning management system, specifically to match exposure and content with the expert modeling video group. The script for PowerPoint will contain content related to the aforementioned seven concepts. There will be static photos, but no expert modeling videos, on PowerPoint slides. The investigator will narrate the voice over PowerPoint.
89490044|NCT02100215|Placebo Comparator|Reading|Participants will have access to articles, policies, and procedures on an online learning management system. The estimated time required for participants to review these materials is 45 minutes
89490045|NCT02100293|Active Comparator|standard dose rocuronium group|pretreatment of saline 100ml and rocuronium 0.6 mg/kg
89490046|NCT02100293|Active Comparator|low dose rocuronium group|pretreatment of saline 100ml and rocuronium 0.45 mg/kg
89490047|NCT02100293|Active Comparator|low dose rocuronium plus magnesium group|pretreatment of magnesium sulfate 30 mg/kg and rocuronium 0.45 mg/kg
89490048|NCT02094521|Experimental|NNC0113-0987|
89490049|NCT02100371|Experimental|BMS-833923|BMS-833923, by mouth, at the dose and schedule administered while enrolled in CA194002.
89490050|NCT02099045||Ultrasound examination|All patients over the age of 18 presenting in the emergency department.
89490051|NCT02094599|Experimental|All Enrolled Participants|Each participant receives all treatments (of placebo, dronabinol 10 mg and dronabinol 30 mg) in a 5-way crossover design. At each treatment visit, participants receive a single dose, contained in two syringes of oral solution and three capsules. When dronabinol is in syringes, placebo is in capsules, and when dronabinol is in capsules, placebo is in syringes. When assigned to take placebo only, placebo is in both the syringes and the capsules.
89490052|NCT02094833|Experimental|Group A|Participants will receive 3 injections of the study vaccine (DTaP-IPV-Hep B-PRP~T combined vaccine) at 2, 4, and 6 months of age
89490053|NCT02094833|Active Comparator|Group B|Participants will receive 2 injections of monovalent Hep B vaccine (Euvax B®) at age 1 and 6 months and 3 injections of DTaP IPV//PRP~T vaccine (Pentaxim™) at age 2, 4, and 6 months
89490054|NCT02100527|Experimental|PF-05175157|
89490055|NCT02100527|Placebo Comparator|Placebo|
89490056|NCT02100605|Active Comparator|Phytosun, decongestant, nasal spray|"Phytosun, decongestant, nasal spray~Nasal spray 20 ml contains:~22g/l hypertonic seawater Essential oils of Eucalyptus, Niaouli and Wild menthol~Instructions for use:~Shake the bottle before use~Tilt the bottle to one side; press the nozzle firmly for at least one second, repeat until obtaining the 1st spray.~Spray in each nostril with the head upright"
89490057|NCT02100605|Placebo Comparator|Isotonic saline, nasal spray|"Isotonic saline, nasal spray~20 ml nasal spray contains Isotonic water solution 0.9% sodium chloride"
89490058|NCT02100761||invasive pulmonary aspergillosis|Patients with invasive pulmonary aspergillosis and will be treated with voriconazole according to their physician decision in five hospital, Jinan, China
89490059|NCT05420051|Experimental|Positive Psychology + Motivational Interviewing|Each week, participants in the PP-MI intervention group will complete a PP activity and work towards a physical activity goal, then complete a phone session with a study trainer. Each phone session will include PP and goal setting portions. In the PP portion, the study trainer will (a) review the week's PP exercise, (b) discuss the rationale of the next week's PP exercise through a guided review of the PP-MI manual, and (c) assign the next week's PP exercise. In the goal-setting portion, the trainer will (a) review the participant's physical activity goal from the prior week, (b) discuss techniques for improving physical activity (e.g. tracking activity), and (c) help the participant to set a physical activity goal for the next week. Participants also will receive supplemental text messages throughout the 8 weeks of the intervention and during the initial follow-up period (Week 9-16).
89490060|NCT05420051|Active Comparator|Motivational Interviewing|Each week, participants in the MI-alone group will complete an activity related to a health behavior (e.g., thinking about the pros and cons of changing the behavior), then complete a phone session with a study trainer. During the phone session, the trainer will (a) review the prior week's topic, (b) discuss techniques for improving adherence to health behaviors (e.g. tracking activity), and (c) problem-solve barriers and encourage the use of resources. Participants also will receive supplemental text messages throughout the 8 weeks of the intervention and during the initial follow-up period (Week 9-16).
88953656|NCT01964235|Experimental|INC280 plus best supportive care|Approximately 46 patients will be treated with INC280 600 mg twice a day plus best supportive care.
88953657|NCT01964235|Placebo Comparator|Placebo plus best supportive care|Approximately 23 patients will be treated with matching placebo twice a day plus best supportive care.
89490061|NCT02100917|Experimental|DMB-3111|6 mg/kg is once given in intravenous drip infusion taking 90 min
89490062|NCT02100917|Active Comparator|trastuzumab|6 mg/kg is once given in intravenous drip infusion taking 90 min
89490063|NCT02098187|Active Comparator|Below target dose MP-3180|0.5 µmol/kg (0.186 mg/kg) dose of MP-3180 by IV one time over 2 minutes.
89490064|NCT02098187|Active Comparator|2 times above target dose MP-3180|2 µmol/kg (0.744 mg/kg) dose of MP-3180 by IV one time over 2 minutes.
89490065|NCT02098187|Active Comparator|4 times above target dose MP-3180|4 µmol/kg (1.488 mg/kg) dose of MP-3180 by IV one time over 2 minutes.
89490066|NCT02098187|Active Comparator|At target dose MP-3180|1 µmol/kg (0.186 mg/kg) dose of MP-3180 by IV one time over 2 minutes.
89490067|NCT02098421|No Intervention|Control|No oxytocin while the Foley bulb is in place
89490068|NCT02098421|Experimental|Oxytocin|Use of oxytocin while the Foley bulb is in place
89490069|NCT02098421|Experimental|PROMS Foley and oxytocin|Subjects who are induced due to premature rupture of membranes randomized to use of Foley bulb and oxytocin once the bulb is removed.
89490070|NCT02098421|No Intervention|PROMS no Foley bulb|Subjects who are induced due to premature rupture of membranes randomized to no Foley bulb.
89490071|NCT02098499|Active Comparator|Haloperidol and Diphenhydramine|Haloperidol 5mg IV X1 and Diphenhydramine 25mg IV X1
89490072|NCT02098499|Active Comparator|Metoclopramide and Diphenhydramine|Metoclopramide 10mg IV X1 and Diphenhydramine 25mg IV X1
89490073|NCT02100995|Experimental|STOP Intervention|The STOP treatment includes content designed to simultaneously and explicitly target both chronic pain and obesity. Treatment components are drawn from evidence-based interventions for chronic pain and obesity, separately.
89490074|NCT02100995|Active Comparator|Standard Care Weight (SCW)|The weight loss intervention includes content focused around nutrition and eating habits, stimulus control and behavioral change, and physical activity. This content has been chosen because of its demonstrated effectiveness and importance in behavioral interventions to reduce weight.
89490075|NCT02100995|Active Comparator|Standard Care Pain (SCP)|The chronic pain intervention is focused around reconceptualization of pain, decreasing catastrophizing, and increasing self-efficacy for pain. This content has been chosen because of its demonstrated effectiveness and importance in non-pharmacological interventions to improve pain management.
88953658|NCT01964248|Experimental|Lidocaïne/prilocaïne|"Lidocaine/prilocaine eutectic mixture 5% incorporated in a cream base~Single dose: 2 grams (one tube of cream)~Cream applied 2 hours before blood sample"
88953659|NCT01964248|Placebo Comparator|Placebo|"Single dose: 2 grams (one tube of cream)~Cream applied 2 hours before blood sample"
88953660|NCT01964274||Surgical patients|Adult male and female patients undergoing surgery
88953661|NCT01964287|Experimental|Gembrax followed by Folfirinox|"Gembrax:~Albumin-bound paclitaxel followed by Gemcitabine Day 1,8,15 followed by 2 weeks of rest~Folfirinox:~Oxaliplatin, irinotecan, leucovorin, 5FU bolus and continuous"
88953662|NCT01964313||ACS cohort|Patients diagnosed with acute coronary syndrome.
88953663|NCT01964339||BMI greater than or equal to 30kg/m2 -venous|BMI greater than or equal to 30kg/m2 scheduled for PSG as part of routine clinical care. Participants will undergo blood draw (venous blood gas and metabolic panel) and data collection from PSG study.
89490076|NCT02094911|Experimental|Combined lifestyle intervention|Lifestyle counselling (nutrition and physical activity) by dietician and physiotherapist during 10-month intervention period
89490077|NCT02094911|Other|Usual care group|Subjects receive brochures on healthy lifestyle at baseline, and during the 10-month intervention period only usual care as provided by their own general practitioner.
89490078|NCT02094989||diagnostic|
89490079|NCT02097017|Active Comparator|lidocaine spray group|
89490080|NCT02097017|Placebo Comparator|placebo arm|
89490081|NCT02095067|Experimental|Video consultation|Patients in this arm receive video consultation from physician at the emergency medical dispatch center
89490082|NCT02095067|No Intervention|Telephone consultation|Patients receiving prehospital care by ambulance personnel whom receive telephone consultation/supervision by physician at the emergency medical dispatch center.
89490083|NCT02098577||PD patients cross-over treatment|30 PD patients (according to Gelb et al) in Hoen&Yahr stage 3, underwent cross-over treatment with the ability to walk without any assistance with mini-mental state examination score >26.
89490084|NCT02098577||PD patients stabilometric platform|30 PD patients (according to Gelb et al) in Hoen&Yahr stage 3, underwent stabilometric platform treatment, with the ability to walk without any assistance with mini-mental state examination score >26.
89490085|NCT02095301|Experimental|Control plus herbal extract|Control plus herbal extract
89490086|NCT02095301|Placebo Comparator|Caffeine-free, carbonated soft drink|Caffeine-free, carbonated soft drink
89490087|NCT02095379||oligosecretary|Multiple myeloma (MM) characterized by low levels of serum and urine monoclonal (M) protein below thresholds of measurable disease (a serum M protein ≥ 1g/dL, a urine M protein ≥ 200mg/day)
89490088|NCT02095457|Active Comparator|Frequent Monitoring and Feedback|In the intervention arm, patients routinely fill short monitoring questionnaires, the results of which are fed back to their therapists and staff. The frequency of monitoring is between once a week to once every three months, depending on the type of therapy
89490089|NCT02095457|Sham Comparator|Infrequent monitoring without feedback|In the control arm, patients will infrequently fill short monitoring questionnaires, the results of which are not fed back to their therapists and staff. The frequency of monitoring is between about once a year
89490090|NCT02098655||30 patients with PD|30 patients (12 M, 18 F, mean age 66,8 ± 8,7) with PD in stage 3 of H&Y will undergo training of balance using a stabilometric platform
89490091|NCT02098655||12 healthy volunteers|12 healthy volunteers (3 M, 9 F, mean age 66,5 ± 6,0) served as controls will undergo training of balance using a stabilometric platform
89490092|NCT02101073|Experimental|ALX-0061 low dose i.v.|
89490093|NCT02101073|Experimental|ALX-0061 high dose i.v.|
89490094|NCT02101073|Experimental|ALX-0061 low dose s.c.|
89490095|NCT02101073|Experimental|ALX-0061 middle dose s.c.|
89490096|NCT02101073|Experimental|ALX-0061 high dose s.c.|
89490097|NCT02101151|Experimental|Vitamin D3 group|supplemented with 6000IU cholecalciferol/day for 3 months, followed by 3000 IU cholecalciferol/day for next 3 months
89490098|NCT02101151|Placebo Comparator|Placebo group|Placebo (starch) capsules identical to vitamin D capsules in appearance
89490099|NCT03556553|Experimental|Vertise Flow|Superficial Class I cavities restored with Vertise Flow
89490100|NCT03556553|Experimental|LuxaFlow|Superficial Class I cavities restored with LuxaFlow
89490101|NCT02101229|No Intervention|unsual treatment|The patient will have his usual treatment in this arm
89490102|NCT02101229|Experimental|The Diabeloop algorithm|In this arm, the insulin Asp(B28) dose is calculated by the algorithm based on the usual treatment of the patient, the ratio I / C, the intensity of physical activity and blood glucose sensor.
89490103|NCT02095613|Active Comparator|Corn-soy-blend plus|food A type of ground meal called corn-soy-blend plus
89490104|NCT02095613|Active Comparator|Ready-to-use-supplementary food|food A nutrient dense food comprised of peanuts, oil, multivitamins.
89490105|NCT02101307||RA Patients on RoActemra/Actemra treatment|
89490106|NCT02106143|Experimental|RejuvenAir™ Radial Spray Cryotherapy|Subjects will receive Rejuvenair Radial SCT prior to lobectomy.
89490107|NCT05402969||Patients with long-term implantation|Patients undergone CI more than 6 months ago. After the study is presented to the patient and the egligibility criterias are verified, the patient is proposed to sign a consent form (visit 0). Once the consent form is signed, the visit 1 is scheduled (0 to 90 days after the visit 0). During the visit 1 TIM measurements are performed, including depth sounding and spectroscopy, and adversed affects if any are collected.
89490108|NCT05402969||Recently implanted patients|Patients enrolled at their pre-op appointments (visit 0 - egligibilty criterias are verified and the consent collected). Visit 1 (0 to 90 days after visit 0) is a surgery. TIM measurements, icluding deep sound and spectroscopy, are performed after the CI and all adverse events are noted. CBCT is routinely done the next day after CI. TIM measurements (as well as adverse event collection) are repeated during visits 2, 3, 4, 5 and 6 (appoitments 15 days, 1, 2, 3 and 6 months after the surgery).
89490109|NCT02106221|Experimental|Intervention|Financial incentives will be provided based on performance in areas determined to be of high-value.
89490110|NCT02106221|Active Comparator|Control|Financial incentives are a flat rate which can be reduced if an appropriate amount of effort or improvement is not met
89490111|NCT03554525|Experimental|Experimental product : FAT-BINDER DAMM|3 sticks of the dietary supplement (1.4 grams/stick) during 12 months: 2 sticks should be consumed before lunch and 1 stick before dinner.
89490112|NCT03554525|Placebo Comparator|Control product : PLACEBO|3 sticks of the dietary supplement (1.4grams/stick) during 12 months: 2 sticks should be consumed before lunch and 1 stick before dinner.
89490113|NCT02102555|Active Comparator|IV acetaminophen|Patients in the IV acetaminophen arm will receive a one gram dose of IV acetaminophen in the pre-operative area prior to their surgery.
89490114|NCT02102555|Placebo Comparator|Placebo|Patients in the placebo arm will receive normal saline in the pre-operative area.
89490115|NCT02102633|Experimental|Dabigatran|Dabigatran 150 mg orally
89490116|NCT02102633|Experimental|Dabigatran + Bosutinib|Dabigatran 150 mg co-administered with Bosutinib 500 mg orally
89490117|NCT02101463|Other|surgeon-modified fenestrated-branched stent-grafts (sm-FBSG)|
89490118|NCT02250755|Experimental|MRI T1 T2 sequences|comparison of perfusion sequences T1 T2 in patients with brain metastase cancer
89490119|NCT02101541|Experimental|FIRM ablation|"The first part of this within-patient trial investigate the efficacy of focal impulse and rotor modulation in 20 patients with paroxysmal atrial fibrillation, evaluated by continuous pre- and post-procedural heart rhythm monitoring.~The second part consists of 20 patients with persistent or longstanding persistent atrial fibrillation following the same scheme."
89490120|NCT02106299|Experimental|Regen Sling|Subjects of this group were submitted to surgical treatment of stress urinary incontinence with a Regen Sling (medprin).
89490121|NCT02106299|Active Comparator|tension-free vaginal tape-obturator|Subjects of this group were submitted to surgical treatment of stress urinary incontinence with a transobturator sling TVT-O™ (gynecare™, USA).
89490122|NCT02101619||Moderate aortic stenosis.|
89490123|NCT02101619||Severe aortic stenosis.|
89490124|NCT02106533|Experimental|Group 1 peak VO2 <17.5 ml/kg/min|The exercise training program was comprised of three 60-minute exercise sessions per week over a 3-month period. Each exercise session consisted of a 5 minute warm up, 30-50 minutes of aerobic exercise performed on a treadmill and 5 minutes of cool-down exercises. Aerobic exercise intensity was set at the corresponding heart rate between the VAT and RCP.
89490125|NCT02106533|Experimental|Group 2 peak VO2 > 17.5 < 24.5 ml/kg/min|The exercise training program was comprised of three 60-minute exercise sessions per week over a 3-month period. Each exercise session consisted of a 5 minute warm up, 30-50 minutes of aerobic exercise performed on a treadmill and 5 minutes of cool-down exercises. Aerobic exercise intensity was set at the corresponding heart rate between the VAT and RCP. All patients were able to achieve the set aerobic training intensity.
89490126|NCT02106533|Experimental|Group 3 peak VO2 > 24.5 ml/kg/min|The exercise training program was comprised of three 60-minute exercise sessions per week over a 3-month period. Each exercise session consisted of a 5 minute warm up, 30-50 minutes of aerobic exercise performed on a treadmill . Aerobic exercise intensity was set at the corresponding heart rate between the VAT and RCP. All patients were able to achieve the set aerobic training intensity.
89490127|NCT02101697|Experimental|HIV Stigma Reduction Intervention|The HIV stigma reduction arm group will participate in a promising intervention designed to reduce HIV stigma among health professionals. The intervention builds on results of our previous research, identifying prevalence and drivers of stigma and discrimination in Indian healthcare settings among PLHIV, health care providers, and uninfected patients.The HIV stigma reduction intervention consists of two computer-administered sessions and one group session.
89490128|NCT02101697|Placebo Comparator|Time Matched Control Group|The time-matched control group will also receive three sessions; two administered by computers and one in small group format to control for attention effects. However, rather than AIDS stigma, the content will be focused on diabetes management (a disease not considered to be stigmatized).
89490129|NCT02102711|Experimental|vitaminA drops|3000 IU/kg/die of Vitamin A oral drops, for 4 weeks.
89490130|NCT02102711|No Intervention|control|Control of matched infants not supplemented with vitamin A ( beyond standard/routine needed)
89490131|NCT02106767|Active Comparator|Rosuvastatin|
89490132|NCT02106767|Experimental|Rifampin plus rosuvastatin|
89490133|NCT02102945|Other|Computed tomography perfusion|Participants will undergo CT perfusion of the head after cooling following cardiac arrest.
89490134|NCT02103023|Experimental|ID TIV + imiquimod|imiquimod ointment followed by intradermal influenza vaccine
89490135|NCT02103023|Sham Comparator|ID sham + imiquimod|imiquimod ointment followed by sham intradermal influenza vaccine
89490136|NCT02103023|Active Comparator|IM TIV + aq|aqueous cream followed by intramuscular influenza vaccine
89490137|NCT02103023|Active Comparator|ID TIV + aq|aqueous cream followed by intradermal influenza vaccine
89490138|NCT02101931|Experimental|Urine spectral analysis|The patient must drink water then the urine will be collected after 4, 8 and 12 hours of taking Amino levulinic Acid and the samples will be analyzed by photodynamic diagnostic procedure. Amino levulinic Acid gets metabolized into certain types of porphyrins which selectively bind on to the tumor tissues (for a longer time than the normal tissues).The above samples is taken in a four side polished quartz cuvette of 1cmx1cmx4cm and put into the table top spectral scan. This consists of a 5 mw, blue diode laser, of 405nm wavelength. The collimated laser beam falls on the urine sample and excites fluorescence and Raman signals from the porphyrin molecules which have been metabolized from the oral administration of Amino levulinic Acid.
89490139|NCT02102009|Experimental|Vitafos|Complete enteral formula
89490140|NCT02102009|Active Comparator|Dietary Advise|Dietary advise according to the hospital routine clinical practice.
89490141|NCT02106845|Experimental|P-gp probe substrate(digoxin)+regorafenib|
89490142|NCT02106845|Experimental|Group B: BCRP probe substrate (rosuvastatin) + regorafenib|
89490143|NCT02102087|Experimental|Initial Specimen Diversion Device (ISDD)|The ISDD will be used in conjunction with standard blood culture bottles.
89490144|NCT02102087|Active Comparator|Lab standard practice (LSP)|A standard blood culture kit will be used.
89490145|NCT03554447|Experimental|Pentoxifylline group|Escitalopram 20 mg tablet once daily for 12 week plus Pentoxifylline 400 mg tablet twice daily for 12 weeks
89490146|NCT03554447|Placebo Comparator|Control group|Escitalopram 20 mg tablet once daily for 12 week plus placebo tablet twice daily for 12 weeks
89490147|NCT02103101|Other|Study cohort|"Measurement of Plasma Concentrations of NOACs Identification of ABCB1 polymorphisms coding for P-gp~All patients aged over 18 and less than 80 years admitted for a serious adverse event (bleeding or thrombo-embolic complication) while under treatment with any of the following oral anticoagulant agents: dabigatran, rivaroxaban or apixaban. Blood samples will be drawn to measure plasma concentrations of the oral anticoagulant agent at the time of the adverse event, and presence of polymorphisms of ABCB1 will be investigated."
89490148|NCT02103179||ECC patients|Extrahepatic cholangiocarcinoma patients treated by surgical treatment
89490149|NCT02103257|Experimental|Sequential icotinib plus chemotherapy|Sequential icotinib plus chemotherapy : pemetrexed 500mg/m2 iv d1, cisplatin 75mg/m2 d1, icotinib 125 mg is administered orally three times per day d 8-21, every 3 weeks for a cycle. After receiving a maximum of 4 cycles treatment, non-progressive patients continue to receive icotinib as maintenance treatment until disease progression or intolerable toxicity.
89490150|NCT02103257|Active Comparator|Icotinib|Icotinib 125 mg is administered orally three times per day until disease progression or intolerable toxicity.
89490151|NCT02103335|Experimental|Single Group Assignment|Combination Pomalidomide, low-dose Dexamethasone, and Marizomib:
89490152|NCT02250911|Experimental|This web-based CCC Workshop|The Care for the Cancer Caregivers (CCC) workshop is composed of six webcasts. The Introductory Webcast is based upon Sessions 1 and 2 of Meaning-Centered Psychotherapy for Cancer Caregivers (MCP-C) and provides participants with an introduction to the CCC Workshop, an overview of the different meaning-centered modules (i.e., legacy, choice, creativity, and connectedness), and a discussion about identity and how caregivers' identities have or have not changed since taking on this role.
89490153|NCT02250911|Active Comparator|Waitlist Control|"Participants randomized to the waitlist control arm will be offered what is considered usual care at the ACS: the provision of the ACS Telephone Hotline number (1-800- 227-2345) and direction to the ACS website (www.cancer.org) where participants can find many resources for caregivers, including links to the ACS Caregiver ToolKit. They will complete assessments at time points that correspond with the completion of assessments in the CCC Workshop arm: after consent as soon as they are able (T1), about 2 months (± 4 weeks) after T1 (T2), and about 2-3 months after T2 (T3). Upon completion of all study assessments the waitlist control arm participants will be offered the opportunity to complete the CCC Workshop."
89490154|NCT02103413|Experimental|EUS-BD|EUS-BD using a fully or partially covered self-expanding metallic stent will be performed by EUS guided 19 G needle puncture.
89490155|NCT02103413|Experimental|PTBD|PTBD with 8.5F catheter will be inserted under fluoroscopic and/or ultrasonography guidance by experienced interventional radiologists.
89490156|NCT02610140|Experimental|BAY94-9343|Drug Anetumab ravtansine given Intravenously (IV)
89490157|NCT02610140|Active Comparator|Vinorelbine|Drug Vinorelbine given Intravenously
89490158|NCT02102321|Experimental|albendazole|albendazole 400 mg
89490159|NCT02102321|Active Comparator|placebo|placebo
89490160|NCT03555227|Active Comparator|Group X|"PECS group~USG PECS2 with Drug A (active) Wound infiltration with Drug P (placebo)"
89490161|NCT03555227|Active Comparator|Group Y|"LA (local anaesthetic) infiltration group~USG PECS2 with Drug P (placebo) Wound infiltration with Drug A (active)"
89490162|NCT02250989||Hyperinsulinemia/Euglycaemia|In this group study, a condition of Hyperinsulinemia/Euglycaemia will be held trough clamp study, during witch FMD will be measured before and after ischemia/reperfusion injury.
89490163|NCT02250989||Hyperinsulinemia/Hyperglycemia|In this group study, a condition of Hyperinsulinemia/Hyperglycemia will be held trough clamp study, during witch FMD will be measured before and after ischemia/reperfusion injury.
89490164|NCT02250989||Hypoinsulinemia/Hyperglycemia group|In this group study, a condition of Hypoinsulinemia/Hyperglycemia will be held trough clamp study, during witch FMD will be measured before and after ischemia/reperfusion injury.
89490165|NCT02103569|Experimental|Arm 1: FDC of NE/EE + DCV 3DAA FDC + BMS-791325|"Cycle 1- Low dose FDC of Norethindrone and Ethinyl Estradiol tablet orally on specified days~Cycle 2- High dose FDC of Norethindrone and Ethinyl Estradiol tablet orally on specified days and High dose FDC of Norethindrone and Ethinyl Estradiol + FDC of Daclatasvir, Asunaprevir and BMS-791325 + BMS-791325 tablets orally on specified days"
89490166|NCT03042338|Experimental|Central Executive Training1|Training tasks targeting working memory
89490167|NCT03042338|Active Comparator|Central Executive Training2|Training tasks targeting inhibitory control and response speed
89490168|NCT02251067|Active Comparator|VPI-2690B low dose|6 mg, VPI-2690B Injection, administered subcutaneously every 2 weeks for 48 weeks
89490169|NCT02251067|Active Comparator|VPI-2690B medium dose|18 mg, VPI-2690B Injection, administered subcutaneously every 2 weeks for 48 weeks
89490170|NCT02251067|Placebo Comparator|Placebo|6 or 18 mg Placebo, administered subcutaneously every 2 weeks for 48 weeks
89490171|NCT02251067|Active Comparator|VPI-2690B high dose|48 mg, VPI-2690B Injection, administered subcutaneously every 2 weeks for 48 weeks
89490172|NCT04868162|Experimental|MRG003|On the first day of every 3 weeks, MRG003 will be administered via intravenous infusion at 2.0 mg/kg calculated based on the actual body weight
89490173|NCT02103647|Active Comparator|Immediate release capsule(lyrica capsule 150mg)|Immediate release capsule repeat treatment for 3days under fasted condition
89490174|NCT02103647|Experimental|sustained release tablet|sustained release tablet repeat treatment for 3days under fasted condition
89490175|NCT02107001||Patients with pleuritic chest pain|Study investigators will perform lung ultrasound in each patient with pleuritic chest pain at inclusion
89490176|NCT02109965|Active Comparator|Control|Use midazolam or propofol for sedation
89490177|NCT02109965|Experimental|Dexmedetomidine|Use dexmedetomidine for sedation
89490178|NCT02789657|Experimental|Optimal- 18 weeks|18 weeks (6 cycles) of paclitaxel, carboplatin, trastuzumab and pertuzumab. Post treatment, patients will undergo surgery.
89490179|NCT02789657|Experimental|Sub-optimal with AC|12 weeks (4 cycles) of paclitaxel, carboplatin, trastuzumab and pertuzumab. Post 12 weeks, initiation of doxorubicin and cyclophosphamide for 4 cycles (6 weeks), followed by surgery.
89490180|NCT02789657|Experimental|Optimal with AC|Less than 18 weeks (6 cycles) of paclitaxel, carboplatin, trastuzumab and pertuzumab, followed by initiation of doxorubicin and cyclophosphamide. Post treatment, patients will undergo surgery.
89490181|NCT02789657|Experimental|Sub-optimal no AC|18 weeks (6 cycles) of paclitaxel, carboplatin, trastuzumab and pertuzumab. Post treatment, patients will undergo surgery.
89490182|NCT02110043|Experimental|training + tDCS|Combination of intensive training of visual-spatial abilities (LOCATO task) with anodal transcranial direct current stimulation (tDCS)
89490183|NCT02110043|Sham Comparator|training + sham stimulation|Combination of intensive training of visual-spatial abilities (LOCATO task) with sham stimulation
89490184|NCT03555071|Experimental|Experimental Group1|"The investigated vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd at commercialized scale.~Intervention: Live attenuated varicella vaccine manufactured at commercialized scale"
89490185|NCT03555071|Experimental|Experimental Group2|"The investigated vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd at commercialized scale.~Intervention: Live attenuated varicella vaccine manufactured at commercialized scale"
89490186|NCT03555071|Experimental|Experimental Group3|"The investigated vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd at commercialized scale.~Intervention: Live attenuated varicella vaccine manufactured at commercialized scale"
89490187|NCT03555071|Active Comparator|Control Group|"The control vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd at trial-scale.~Intervention: Live attenuated varicella vaccine manufactured at trial-scale"
89490188|NCT02609984|Experimental|CMB305 (sequentially administered LV305 and G305)+Atezolizumab|Participants received CMB305 treatment in combination with 1200 mg/day atezolizumab administered by intravenous (IV) infusion every 3 weeks (Q3W) for up to approximately 2 years. CMB305 treatment consisted of 2 doses of LV305 administered intradermally (ID) on Days 0 and 14 followed every 2 weeks with alternating doses of G305 administered intramuscularly (IM) and LV305. LV305 was administered at a dose of 1×10^10 vector genomes and G305 at a dose of 5 mcg glucopyranosyl lipid A stable emulsion mixed with 250 mcg of NY ESO-1 protein.
89490189|NCT02609984|Active Comparator|Atezolizumab|Participants received 1200 mg/day atezolizumab by IV infusion Q3W for up to approximately 2 years.
89490190|NCT02107079|Active Comparator|melatonin 1 mg immediate release tablet|
89490191|NCT02107079|Active Comparator|melatonin 2,5mg immediate release capsule|
89490192|NCT02107079|Active Comparator|melatonin 0.1 mg oromucosal tablet|
89490193|NCT02107235|Experimental|Rigosertib + Cisplatin + Radiation|"Oral rigosertib will be started 7 days before initiation of concurrent treatment with cisplatin and radiation therapy and will be administered on a continuous basis for a fixed duration of 8 weeks. Three oral rigosertib escalating doses will be sequentially evaluated: 70 mg 3 times a day (TID), 140 mg TID and 280 mg TID.~Cisplatin will be administered intravenously at a dose of 40 mg/m^2 on Days 1, 8, 15, 22, 29, 36, and 43 of the 7-week concurrent treatment course.~The prescribed radiotherapy dose will be 70 Gray (Gy) in 2 Gy once-daily fraction size (total of 35 fractions) over the 7-week concurrent treatment course. The initial target volume encompassing the gross and subclinical disease sites will receive 2.0 Gy per fraction, 5 fractions per week."
89490194|NCT04867772|Other|Usual Care|Participants will receive the care that would usually be received in the local hospital setting. this has been determined as between 1 and 6 sessions of physiotherapy
89490195|NCT04867772|Experimental|Intervention|Participants will receive a home based rehabilitation programme with 1-7 sessions of physiotherapy delivered over 12 weeks.
89490196|NCT02103725|Experimental|pimecrolimus 10 mg/g cream|Active drug
89490197|NCT02103725|Placebo Comparator|Vehicle cream|Placebo drug
89490198|NCT03554993|Experimental|CC-99677 Under Fasted Conditions|CC-99677 Under Fasted Conditions
89490199|NCT03554993|Experimental|Placebo|Placebo under fasted conditions
89490200|NCT03554993|Experimental|CC-99677 Under Fed Conditions|CC-99677 Under Fed Conditions
89490201|NCT03042260|Experimental|Trimethoprim-Sulfamethoxazole (TMP-SMX)|Trimethoprim-Sulfamethoxazole 180mg/800mg oral tablet, 3 times a week, for 6 months. Subjects may remain on the drug longer (maximum 1 year), if they continue to receive intermediate or high dose steroids at the end of 6 months.
89490202|NCT03042260|Placebo Comparator|Placebo|"Tablets that look exactly the same as the experimental drug, 3 times a week, for 6 months.~Subjects may remain on the placebo longer (maximum 1 year), if they continue to receive intermediate or high dose steroids at the end of 6 months."
89490203|NCT02110355|Experimental|AMG 232 with Trametinib and Dabrabenib|Arm 1 of Part 1 and 2 and Part 3
89490204|NCT02110355|Experimental|AMG 232 with Trametinib|Arm 2 of Part 1 and 2
89490205|NCT02110355|Active Comparator|Trametinib and Dabrafenib|Part 3
89490206|NCT04864730||CT scans|No intervention Data of voxels will be integrated to the final model
89490207|NCT02107391|Experimental|DCVAC/PCA added Standard Hormone Therapy|Combination therapy with Dendritic Cells DCVAC/PCa added on to a Standard of Care Hormone Therapy
89490208|NCT02107391|Active Comparator|Standard of Care Hormone Therapy|Standard of Care Hormone Therapy as an Active Comparator Goserelin Acetate Leuprolide Acetate
89490209|NCT03045536||Patients with TFR|Patients treated with TFR for oncologic or non-oncologic reason
89490210|NCT04864574|Experimental|Group 1 - Intervention|Participating children have daily access to the fruit and vegetable garden beginning Year 1.
89490211|NCT04864574|Experimental|Group 2 - Wait-list control (delayed intervention)|Participating children have daily access to the fruit and vegetable garden beginning Year 2.
89490212|NCT04864574|No Intervention|Group 3 - Control|No intervention
89490213|NCT02110433|Other|Placebo group|Patients will be managed per consensus guidelines Clinicians could see the patients as many times as necessary in order to optimize their therapy and could make BNP measurement (but not using Home BNP monitoring)
89490214|NCT02110433|Experimental|Cordiva System (R)|Patient will see their cardiologist every three months and benefit from telemonitoring of their weight and general well being through a specific communicant device.
89490215|NCT02110433|Active Comparator|BNP and Cordiva (R) monitoring system|In this group, patients and doctors have access to the platform detailed above (Cordiva (R) monitoring system) and had also access to BNP home monitoring (BNP heartcheck).
89490216|NCT03045380|Experimental|Game based rehabilitation|Game based rehabilitation will be administered once a week for 8 weeks.
89490217|NCT03045380|Active Comparator|Conventional rehabilitation|Conventional physiotherapy program will be administered once a week for 8 weeks.
89490218|NCT03045380|No Intervention|No intervention|Waitlist
89490219|NCT02110511|Experimental|alpha-gal & blended lentils|3 capsules of alpha-gal taken with blended lentils
89490220|NCT02110511|Experimental|alpha-gal & whole lentils|3 calpsules of alpha-gal taken with whole lentils
89490221|NCT02110511|Experimental|alpha-gal & no lentils|3 capsules of alpha-gal taken with no lentils control
89490222|NCT02110511|Placebo Comparator|Placebo & blended lentils|3 capsules of placebo taken with blended lentils
89490223|NCT02110511|Placebo Comparator|Placebo & whole lentils|3 capsules of placebo taken with whole lentils
89490224|NCT02110511|Placebo Comparator|Placebo & no lentils|3 capsules of placebo taken with no lentils control
89490225|NCT04864340|Experimental|threshold stimulation (tetanic)|
89490226|NCT04864340|Experimental|upper threshold stimulation (tetanic)|
89490227|NCT04864340|Experimental|threshold stimulation (pressure)|
89490228|NCT04864340|Experimental|upper threshold stimulation (pressure)|
89490229|NCT04864340|Placebo Comparator|non nociceptive procedure (fine touch)|
89490230|NCT02103881|Experimental|Ketamine|Patients enrolled in this arm will be given 500 mg of intramuscular ketamine for their severe agitation they experience in the prehospital environment.
89490231|NCT02103881|Experimental|Haloperidol|Patients enrolled in this arm will be given 10 mg of intramuscular haloperidol for their severe agitation they experience in the prehospital environment.
89490232|NCT02103959|Experimental|CMX-2043 2.4 mg/Kg|Bolus injection of investigational product given prior to the cardiac catheterization and placebo given 24 hours after the first dose.
89490233|NCT02103959|Experimental|CMX-2043 3.6 mg/kg|Bolus injection of investigational product given prior to the cardiac catheterization and placebo given 24 hours after the first dose.
89490234|NCT02103959|Experimental|CMX-2043 2.4 mg/kg given twice|Bolus injection of investigational product given prior to the cardiac catheterization and again 24 hours after the first dose.
89490235|NCT02103959|Placebo Comparator|Placebo comparator|Placebo comparator (PBS) given prior to cardiac catheterization and again 24 hours after the first dose.
89206301|NCT04092959|Experimental|Walking group|A total of 240 hypertensive subjects aged 40-69 years (including 126 patients complicated with diabetes) will be included in a few communities in Beijing, and will be divided into 3 groups according to the individual wishes of the subjects: walking group(n=80, including 42 patients complicated with diabetes), Chinese square dancing group(n=80, including 42 patients complicated with diabetes) and control group(n=80, including 42 patients complicated with diabetes).
89490236|NCT04858646|Experimental|Aerobic exercises|Subjects in A group was treated with different types of aerobic exercises such as 10 minute walking, 10 minute trampoline exercise and 10 minutes ball throwing activities
89490237|NCT04858646|Active Comparator|Conventional physical therapy|Traditional physical therapy The group B was treated with conventional therapy. Conventional treatment protocol passive ROM and stretching passive ROM for 15 minutes and stretching for 15 minutes. Treatment duration for both groups will be 30 minutes. Each subject received total 30 sessions of the treatment, with 5 treatment sessions per week for 6 weeks. Post treatment reading were collected after end of 6th weeks.
89490238|NCT02107469|Experimental|Ancient herbal treatment|"Phyllanthus niruri 3g fine dry powder 3 times a day with warm water before meals for 8 weeks~Sida cordifolia 7g coarse dry powder 2 times a day prepared as traditional decoction before meals for 8 weeks. Decoction: Take provided measurement cup full of water (112ml) and soak one portion (pe-packed) of the powder for 12 hours, then boil it until the upper level has been reduced to 1/4, filter, cool down to room temperature, drink"
89490239|NCT02107469|Experimental|Modern extract herbal treatment|"Phyllanthus niruri extract 2 capsules 3 times a day with warm water before meals for 8 weeks~Sida cordifolia roots extract 2 capsules 2 times a day with warm water before meals for 8 weeks"
89490240|NCT02107469|Placebo Comparator|Placebo|"Phyllanthus niruri placebo 2 capsules 3 times a day with warm water before meals for 3 weeks~Sida cordifolia placebo 2 capsules 2 times a day with warm water before meals for 3 weeks"
89490241|NCT03045146||Multimodal brain imaging|Consecutive patients experiencing an acute ischemic stroke treated by thrombectomy according to the current recommendations. Clinical outcome will be compared according to the baseline imaging profile processed after patient treatment.
89490242|NCT03554915||Ketamine-based Protocol|The first 6 month period of the study will employ a ketamine-based protocol for prehospital agitation. There will be a tiered dosing protocol based on degree of agitation.
89490243|NCT03554915||Midazolam-based Protocol|The second 6 month period of the study will employ a midazolam-based protocol for prehospital agitation. There will again be a tiered dosing protocol based on degree of agitation.
89490244|NCT03044522|No Intervention|No Nurse Education|Subjects who are enrolled into study arm with no Nurse Pain Educator will be monitored every month to assess their use of their medication, quality of life, physical and mental well-being. No intervention will be conducted with these subjects beyond that of standard of care at the facility.
89490245|NCT03044522|Other|Nurse Education|Subject enrolled into the Nurse Pain Educator arm will be educated (Opioid Education) on different opioid pain management topics with a focus on safe and appropriate use and consumption of opioid analgesics.
89490246|NCT03044366||Characteristics of Anesthesia management|Evaluate the average value of these data.
89490247|NCT03044366||Comorbidities|Evaluate the average value of these data.
89490248|NCT02110589|Experimental|Patient Group 1|"Testing of Epidetect:~Adult Patients with difficult to control tonic-clonic (convulsant) epilepsy undergoing hospitalised video telemetry monitoring. Patients will be hospitalised as part of their normal investigation of the epilepsy and patients will be consented 1 week before hospitalisation. Epidetect will be used in conjunction with the normal EEG monotoring and video telemetry. The patient will be fitted with the topical sensors at the start of monotoring and then depending on the seizure activity will wear the sensors until enough data is gathered. Hospitalisation under these circumstances typically lasts no more than five days, so monitoring with the topical sensor will be no longer than this."
89490249|NCT02110589|Experimental|Patient Group 2|"Testing of Epidetect:~Paediatric patients (over 7 years) where parental consent will enable the epilepsy monitor to be used at home for 1 week and brought back in for analysis along with video evidence. This will not constitute any change in normal care or treatments, and the video evidence provided represents enhanced care through accurate seizure diary reporting. Suitable families and children will be selected and consented through scheduled clinics in paediatric neurology."
89490250|NCT02110589|Experimental|Patient group 3|"Testing of Epidetect:~Patients where the epilepsy is suspected to be psychogenic (pseudo-seizures) rather than organic epilepsy. We will test whether the epilepsy monitor will be able to differentiate between epilepsy and psychogenic seizures in the medical setting when patients are hospitlised for seizure investigation. Suitable patients will be selected and consented through scheduled clinics in paediatric neurology (under 16) and adult neurology."
89490251|NCT02110589|Experimental|Patient Group 4|"Testing of Epidetect:~Internal negative Controls. Juveniles or adults with other forms of epilepsy that do not have a hypertonic (increased muscle stiffening) phenotype e.g. absence seizures."
89490252|NCT02110589|Other|Control Group 1|"Testing of Epidetect:~Volunteers who do not have a history of seizures / epielsy, head trauma, migraine, neurological or muscular-skeletal disorders. This is to produce the baseline data for the Monitor."
89490253|NCT02107625|Experimental|Diet A i.e. Low FODMAP diet|The patients are thoroughly informed verbally and in writing how to eat according to the low FODMAP diet. The diet imply restrictions in carbohydrate intake and the patients need to follow a list with yes/no-foods for 4 weeks.
89490254|NCT02107625|Experimental|Diet B, i.e. Traditional IBS diet|The patients are thoroughly informed verbally and in writing how to eat according to traditional IBS dietary advices. The diet imply adapting to regular dietary habit with meals 6 times a day, no to big meals, to chew food thoroughly, to peel fruits and vegetables, no carbonated beverages, no chewing gum, no soft drinks, no sugar-free candies, or cookies. Reduce spicy foods, coffee, alcohol, onion, pulses, and fatty foods. Keep strictly to the dietary advice for 4 weeks.
89490255|NCT02110667||Prostate cancer, post-prostatectomy|
89490256|NCT02104037|Experimental|Liraglutide treated patients|
89490257|NCT02250833|Experimental|CKD-828(Fixed Dose Combination)|FDC tablet consisting of Telmisartan 80mg/S-Amlodipine 5mg
89490258|NCT02250833|Active Comparator|Combination Therapy|Coadministration of Telmisartan 80mg and S-amlodipine 5mg
89490259|NCT04336670|Experimental|Virtual Reality group|Immersive Virtual Reality exercise program + Usual center therapies
89490260|NCT04336670|Active Comparator|Usual activities group|Usual center therapies
89490261|NCT02107781||Patients with open abdomen|Patients in a critical care unit with abdomen that was not closed during initial operation & will have intra-abdominal pressure monitoring using the AbViser abdominal compartment pressure measuring device.
89490262|NCT02609672|Experimental|Exercise|The participants in this arm were asked to attend 3 group classes per week for 12 weeks taught by a certified exercise instructor. Four class times were offered per week. These classes included a warm-up, static poses shown to decrease knee joint loading, and a cool down including flexibility exercises. Measurements were obtained at baseline (before intervention) and at follow-up (following intervention). Outcomes included clinical mobility; pain; isometric leg strength; cardiovascular fitness; and resilience.
89490263|NCT02609672|Other|No Exercise|The participants in this arm were asked to refrain from changing their physical activity over the 12 weeks and maintain any strategies typically used to manage knee and/or hip pain. Since it is known that exercise is beneficial for pain management and strengthening in knee OA, participants randomized to the no exercise group were offered a free exercise pass following completion of the study. Measurements were obtained at baseline (before intervention) and at follow-up (following intervention). Outcomes included clinical mobility; pain; isometric leg strength; cardiovascular fitness; and resilience.
89490264|NCT02110745|Experimental|Sevofluorane|Sevofluorane 8% in induction
89490265|NCT02110745|Experimental|Propofol|Propofol 2.5 mg/kg intravenous in induction
89490266|NCT03553745|Experimental|Gentle Yoga Program|Program will meet twice a week for a 10-week period. Participants will be a part of gentle yoga sessions led by instructors specializing in the area.
89490267|NCT03553745|Experimental|Rigorous Yoga Program|Program will meet twice a week for a 10-week period. Participants will be a part of rigorous yoga sessions led by instructors specializing in the area.
89490268|NCT03553745|Experimental|Cardiovascular Exercise Program|Program will meet twice a week for a 10-week period. Participants will be a part of cardiovascular exercise sessions led by instructors specializing in the area.
89490269|NCT04867304||Healthy controls|Individuals without any known illnesses and normal labs./USG w/a. This group was used to compare baseline depression, magnetic resonance spectroscopy and plasma metabolites.
89490270|NCT04867304||Chronic pancreatitis without depression|This group contains patients with CP who does not have depression based on the Beck Depression inventory.
89490271|NCT04867304||Chronic pancreatitis with depression|This group contains patients with CP who has depression based on the Beck Depression inventory.
89490272|NCT03554213||Phase 1: TCV in 2018|Children receiving TCV (typhoid conjugate vaccine) in 2018 vaccination campaign by NMMC.
89490273|NCT03554213||Phase 2: TCV in 2019|Children receiving TCV (typhoid conjugate vaccine) in 2019 vaccination campaign by NMMC.
89490274|NCT04857554|Experimental|Glucose as reference food|Twelve healthy, normal weight subjects (male: 6, female: 6) after 10-14 hr fast, consumed 25g available carbohydrate from D-glucose, three times, in different weeks as reference food along with 250ml water; and 25g available carbohydrates from white bread, white bread and apricot jam, cereal bar with cranberries, and cocoa drink, tested once, in different weeks along with 250ml water or 500ml fat-free milk for the cocoa drink. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
89490275|NCT04857554|Experimental|White bread as reference food|Twelve healthy, normal weight subjects (male: 6, female: 6) after 10-14 hr fast, consumed 25g available carbohydrate from D-glucose, three times, in different weeks as reference food along with 250ml water; and 25g available carbohydrates from white bread, white bread and apricot jam, cereal bar with cranberries, and cocoa drink, tested once, in different weeks along with 250ml water or 500ml fat-free milk for the cocoa drink. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
89490276|NCT04857554|Experimental|White bread with apricot jam|Twelve healthy, normal weight subjects (male: 6, female: 6) after 10-14 hr fast, consumed 25g available carbohydrate from D-glucose, three times, in different weeks as reference food along with 250ml water; and 25g available carbohydrates from white bread, white bread and apricot jam, cereal bar with cranberries, and cocoa drink, tested once, in different weeks along with 250ml water or 500ml fat-free milk for the cocoa drink. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
89490277|NCT04857554|Experimental|Cereal bar with cranberries|Twelve healthy, normal weight subjects (male: 6, female: 6) after 10-14 hr fast, consumed 25g available carbohydrate from D-glucose, three times, in different weeks as reference food along with 250ml water; and 25g available carbohydrates from white bread, white bread and apricot jam, cereal bar with cranberries, and cocoa drink, tested once, in different weeks along with 250ml water or 500ml fat-free milk for the cocoa drink. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
89490278|NCT04857554|Experimental|Cocoa drink|Twelve healthy, normal weight subjects (male: 6, female: 6) after 10-14 hr fast, consumed 25g available carbohydrate from D-glucose, three times, in different weeks as reference food along with 250ml water; and 25g available carbohydrates from white bread, white bread and apricot jam, cereal bar with cranberries, and cocoa drink, tested once, in different weeks along with 250ml water or 500ml fat-free milk for the cocoa drink. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
89490279|NCT03553979|Experimental|Stress management program (SM)|The stress management program (SM) is a program which has been tailored to meet the specific needs of low-SES participants. The SM consists of 4-weekly sessions (1.5hours/session) and a follow-up session 8 weeks later. A core element of SM is its group-based format in which psycho-educative topics on stress responses and coping and motivation to stop smoking link up with cognitive and behavioural technique activities.
89490280|NCT03553979|Experimental|Stress management + Buddy program (SM-B)|The stress management + buddy program (SM-B) includes the same psycho-educative topics and exercises, cognitive and behavioural technique activities as the SM condition. The SM-B in addition to SM utilises one-to-one support through a buddy selected by a participant. A buddy, 18 year or older is a student or a volunteer who is recruited and trained by Indigo Rijnmond. The buddy pairs up with a participant and provides the following: supports participant in managing and filling in tax/welfare papers; 2) helps a participant to get a grip over his/her personal finances; and 3) helps a participant to overcome daily barriers (eg. arranging childcare). Over the duration of the course, the buddy meets up 6 times with a participant every second week in a public area.
89490281|NCT03553979|No Intervention|Control|Participants in the control condition are instructed to continue with their normal daily behaviour. They will be invited to complete the questionnaires and objective measurements at the equivalent times as the intervention groups, thus at baseline, 4 weeks after baseline and 12 weeks after baseline. After the control period, participants in the control condition will be offered the intervention.
89490282|NCT03042026||Acromegaly patients|Acromegaly patients
89490283|NCT03042026||Healthy subjects|Healthy volunteers
89490284|NCT02104115|Other|Gluten free white bread|Sliced loaf of gluten free white bread
89490285|NCT02104115|Other|Normal gluten content white wheat bread|Sliced loaf of normal gluten content white wheat bread
89490286|NCT02104115|Other|High gluten content white wheat bread|Sliced loaf of high gluten content white wheat bread
89490287|NCT03041948|Active Comparator|Caudal-epidural nerve block|All patients will receive acetaminophen (15mg/kg) within one hour of induction of anesthesia. Inhalation induction of anesthesia will be performed with sevoflurane in 100% O2. A single dose of up to 2-4 mg/kg of propofol and Remifentanil 0.5-1mcg/kg will be given prior insertion of a laryngeal mask airway or endotracheal tube. Anesthesia will be maintained with Propofol and Remifentanil (2.5mcg/ml) which will be started at 300 mcg/kg/min and titrated to effect. If necessary additional boluses of Propofol (1mg/kg) and/or Remifentanil (0.5-1mcg/kg) and/or Morphine 0.05mg/kg boluses IV will be administered. Ondansetron (0.1mg/kg) and Dexamethasone (0.15mg/kg) will be given as antiemetic prophylaxis for all patients. Ketorolac 0.3mg/kg will be given to each patient. The CE group will receive an US-confirmed CE nerve block with 0.8 mL/kg of 0.2% ropivacaine (maximum 15 mL).
89490288|NCT03041948|Experimental|ilioinguinal/iliohypogastric nerve block|All patients will receive acetaminophen (15mg/kg) within one hour of induction of anesthesia. Inhalation induction of anesthesia will be performed with sevoflurane in 100% O2. A single dose of up to 2-4 mg/kg of propofol and Remifentanil 0.5-1mcg/kg will be given prior insertion of a laryngeal mask airway or endotracheal tube. Anesthesia will be maintained with Propofol and Remifentanil (2.5mcg/ml) which will be started at 300 mcg/kg/min and titrated to effect. If necessary additional boluses of Propofol (1mg/kg) and/or Remifentanil (0.5-1mcg/kg) and/or Morphine 0.05mg/kg boluses IV will be administered. Ondansetron (0.1mg/kg) and Dexamethasone (0.15mg/kg) will be given as antiemetic prophylaxis for all patients. Ketorolac 0.3mg/kg will be given to each patient. The IIG/IHG group will receive a unilateral US guided IIG/IHG with 0.4mL/kg of ropivacaine 0.2% (max 12 mL).
89490289|NCT02104193|Experimental|simvastatin|they will receive simvastatin in addition to radiation therapy
89490290|NCT02104193|Active Comparator|control|they will receive radiation therapy only
89490291|NCT03042182|Experimental|Single pill of V3-X vaccine administered once daily|One pill of oral therapeutic vaccine V3-X administered to patients with cholangiocarcinoma for two months and changes in CA19.9 tumor marker from baseline levels versus post-treatment levels will be assessed as correlates of changes in tumor burden
89490292|NCT03044444|Experimental|high dose citrus extract|this group will receive a high dose (500mg/day) of the citrus extract for 8 weeks
89490293|NCT03044444|Experimental|low dose citrus extract|this group will receive a low dose (400mg/day) of the citrus extract for 8 weeks
89490294|NCT03044444|Placebo Comparator|placebo|this group will receive a placebo (500mg maltodextrin per day) for 8 weeks
89490295|NCT03041870|Experimental|Dominance|Healthy subjects
89490296|NCT02104271|Experimental|Argon Plasma Coagulation|"Argon Plasma Coagulation (APC) treatment will be delivered using a spray-painting technique, with short applications at 40W power and argon gas flow of 1.2 L/min. The APC equipment consists of a high frequency electrosurgical generator combined with a source of argon gas (Argon + SS601MC 4 , WEM Electronic Equipment Ltda , Ribeirão Preto , Brazil ). A flexible catheter of 2.3 mm diameter ( WEM ) Teflon coated and with a hint of heat resistant ceramic is inserted through the working channel of the colonoscope and connected to the current generator and the gas source for APC implementation."
89490297|NCT02104271|Active Comparator|Historical control|"Argon Plasma Coagulation (APC) treatment was delivered using a spray-painting technique, with short applications at 40-50W power and argon gas flow of 2.0 - 2.5 L/min. The APC equipment consists of a high frequency electrosurgical generator combined with a source of argon gas (Argon + SS601MC 4 , WEM Electronic Equipment Ltda , Ribeirão Preto , Brazil ). A flexible catheter of 2.3 mm diameter ( WEM ) Teflon coated and with a hint of heat resistant ceramic is inserted through the working channel of the colonoscope and connected to the current generator and the gas source for APC implementation."
89490298|NCT04429412|Experimental|Metacognitive Training (MCT+)|"MCT+ combines the process-oriented approach of metacognitive group training with elements of individual cognitive-behavioral therapy.~The metacognitive training program is comprised of 10 modules targeting common cognitive errors in schizophrenia. (Moritz et al, 2013).~The modules are: 1:Therapeutic alliance, 2: Introducyion to MCT+, 3:Disease model, 4: Attributional style, 5: Decision making, 6: Changing beliefs, 7: Empathizing, 8: Memory, 9: Depression and self-steem, 10: Relapse prevention.~The treatment consist of 10 weekly sessions of 45-60 minutes."
89490299|NCT04429412|No Intervention|TAU|Treatment as usual.
89490300|NCT02104661|Experimental|OxCarbazepine Treatment|Treated for 48 weeks with OxCarbazepine 150mg twice a day alongside current DMDs.
89490301|NCT02104661|Placebo Comparator|OxCarbazepine Placebo|Treated for 48 weeks with matched placebo 1 tablet twice a day alongside current DMDs
89490302|NCT04863560||Hoehn & Yahr stage I (H&YI)|- 20 Hoehn & Yahr stage I (early disease, minimal symptoms)
89490303|NCT04863560||Hoehn & Yahr stage II (H&YII)|- 30 Hoehn & Yahr stage II (mild disease, no balance issues)
89490304|NCT04863560||Hoehn & Yahr stage III (H&YIII)|- 30 Hoehn & Yahr stage III (moderate disease, balance issues)
89490305|NCT02104973|Experimental|Lifestyle counseling|After obtaining the approval of schools and parents, will be established in schools, units in which individual attention is given to children, parents and teachers that request: the advice is aimed at training users on healthy diet and constant physical activity. Workshops with children, in which selected topics will be discussed based on the analysis of depth interviews with children, parents and teachers, and information on habits and resources gathered through questionnaires will be conducted. The intervention included the provision of information and feedback with the population through a website. The work will include participation in the selection of foods sold in schools.
89490306|NCT02104973|No Intervention|Control|Usual care
89490307|NCT04429490|Experimental|"Group Cases"|patients with pancreatic adenocarcinoma
89490308|NCT04429490|Other|"Group Controls"|patients without pancreatic adenocarcinoma
89490309|NCT02110979|Experimental|PDA|Subjects receive an internet-based patient decision aid video. The PDA is viewed outside of the doctor's office via a personal computer in preparation for regularly scheduled face to face interaction between patients and clinicians.
89490310|NCT02110979|No Intervention|Usual care|Patients receive usual care as determined by their clinician.
89490311|NCT02111057||Perioperative RA|Patients with Rheumatoid Arthritis undergoing a primary or secondary total hip replacement, between the ages of 18 and 90.
89490312|NCT02108093|Experimental|RAP (retrograde autologous priming) group|In the RAP (retrograde autologous priming) group, the priming solution is partially replaced by the patient's own circulating blood, before initiation of CPB. After initiation of cardiopulmonary bypass the priming volume is approximately 900 ml.
89490313|NCT02108093|No Intervention|Control group|In the control group, the priming volume of the arterial and venous line will not be replaced by patient's own blood. The priming volume of cardiopulmonary bypass is 1300 ml in the control group.
89490314|NCT02108249||Annex Group|Patients prospectively treated with Annex™ Adjacent Level System
89490315|NCT02108249||Retrospective Control|Patients previously treated for adjacent level disease using other systems
89490316|NCT02108327|Experimental|surgical blade|
89490317|NCT02108327|Active Comparator|Unipolar electrocautery|
89490318|NCT02105129|Experimental|HMPL-523|Single/Multiple Ascending Dose. oral administration, a single dose of 5, 20, 50, 100, 200 and 300 mg (Part A) and multiple dose of HMPL-523 at dose level based on result of Part A
89490319|NCT02105129|Placebo Comparator|Placebo|Placebo: oral administration
89490320|NCT02111135|Experimental|Group 1|b-OPV, m-IPV HD and m-OPV2
89490321|NCT02111135|Active Comparator|Group 2|b-OPV, t-IPV and m-OPV2
89490322|NCT02611778|Experimental|FYB201|FYB201 is provided as single use vials and will be administered by intra-vitreal injection.
89490323|NCT02611778|Active Comparator|Lucentis|Lucentis® is provided as single use vials and will be administered by intra-vitreal injection.
89490324|NCT04867226|Active Comparator|colchicine drug|participant in this group will be given a colchicine tablet alone or add to their Current treatment, Colchicine 0.5 mg twice daily (reduced to 0.5 mg/day, in patients with low body weight or develop side effect like gastrointestinal symptoms ),For 14 days or until symptoms subsides.
89490325|NCT04867226|Active Comparator|usual care|control group will receive usual care COVID-19 treatment according to Iraqi protocol guideline and will not receive colchicine.
89490326|NCT04857086||Group1|About 1400 DTC patients with more than 5 years long-term follow-up from the date of signing the informed consent form (ICF) in DTCC 1st to signing ICF in DTCC 2nd will be collected data retrospectively.
89490327|NCT04856852|Experimental|Iodine-125+Chemotherapy|Iodine-125; Temozolomide
89490328|NCT04856852|Active Comparator|Surgical resection+Radiochemotherapy|Surgical resection; Radiotherapy; Temozolomide:
89490329|NCT04856774|Experimental|SHR -1701 + BP102|
89490330|NCT04867148|Experimental|Gait analysis|Gait analysis of patients with ankylosing spondylitis, patients with adoldescent idiopathic scoliosis and control group.
89490331|NCT04866836|Experimental|tislelizumab combined with radiotherapy|To observe and evaluate the effectiveness and safety of tislelizumab combined with radiotherapy in the treatment of patients with advanced biliary malignancies.
89490332|NCT04810130|Sham Comparator|Kicking|Subjects will complete a suite of clinical and neurophysiological assessments at 3 timepoints (Pre, 0-hour post, and 16-72 hour post soccer kicking intervention).
89490333|NCT04810130|Experimental|Soccer Heading (Frontal)|Subjects will complete a suite of clinical and neurophysiological assessments at 3 timepoints (Pre, 0-hour post, and 16-72 hour post soccer heading intervention).
89490334|NCT04810130|Experimental|Soccer Heading (Oblique)|Subjects will complete a suite of clinical and neurophysiological assessments at 3 timepoints (Pre, 0-hour post, and 16-72 hour post soccer heading intervention).
89490335|NCT04866446||normal airway manikin with standard uniform|The participants will carry out intubation procedure using macintosh direct laryngoscope, GlideScope video laryngoscope, C-Mac video laryngoscope and Frova intubation catheter and laryngeal mask insertion using ProSeal LMA and I-gel LMA, respectively.
89490336|NCT04866446||normal airway manikin with personal protective equipment|The participants will carry out intubation procedure using macintosh direct laryngoscope, GlideScope video laryngoscope, C-Mac video laryngoscope and Frova intubation catheter and laryngeal mask insertion using ProSeal LMA and I-gel LMA, respectively.
89490337|NCT04866446||difficult airway manikin with standard uniform|The participants will carry out intubation procedure using macintosh direct laryngoscope, GlideScope video laryngoscope, C-Mac video laryngoscope and Frova intubation catheter and laryngeal mask insertion using ProSeal LMA and I-gel LMA, respectively.
89490338|NCT04866446||difficult airway manikin with personal protective equipment|The participants will carry out intubation procedure using macintosh direct laryngoscope, GlideScope video laryngoscope, C-Mac video laryngoscope and Frova intubation catheter and laryngeal mask insertion using ProSeal LMA and I-gel LMA, respectively.
89490339|NCT04863482|Active Comparator|Critical view of Safety (CVS-WL)|Group CVS-WL (control group): the visualization of the biliary tree is achieved in white light, without the utilization of an intraoperative imaging technique, the CVS in white light was selected as the control group since it constitutes the actual recognized standard in clinical practice.
89490340|NCT04863482|Experimental|Intra-operative Cholangiography (IOC)|Group IOC: the visualization of the biliary tree is achieved with the help of intraoperative cholangiography
89490341|NCT04863482|Experimental|Near-Infra Red Cholangiography (NIR-C)|Group NIR-C: the visualization of the biliary tree is achieved with the help of near-infrared fluorescence cholangiography
89490342|NCT04863326|Experimental|Making Proud Choices|This evaluation tests the effect of the MPC School Edition, the version of the MPC 5th Edition designed for implementation in school. This edition includes 9.5 hours of content implemented in 14 40-minute modules. Schools assigned to the MPC condition received MPC in a targeted class.
89490343|NCT04863326|Active Comparator|Business as usual|The control group continued with their regular programming in the targeted class, which was often a health or Reserve Officer Training Corps (ROTC) class.
89490344|NCT02441595|Experimental|MBCP intervention|The intervention involves eight 2.5 h weekly group sessions in which exercises in mindfulness are practiced and associated theory is taught to increase metacognition, emotional regulation and body awareness.
89490345|NCT02441595|Active Comparator|Control condition|Participants in the control condition are being offered a standardized course in psychoprophylaxis.
89490346|NCT03044132|Experimental|DermACELL AWM|Human acellular dermal matrix (ADM) recovered from human donors, decellularized, provided with at least 97% DNA removal, terminally sterilized in its final package, and ready to use.
89490347|NCT02441049|Experimental|Home-based promotora intervention|Study participants and their families received the home-based promotora family intervention
89490348|NCT02441049|No Intervention|Delayed treatment control|Study participants received intervention materials after the final study evaluation measures were taken, 10 months post-baseline.
89490349|NCT01453179|Experimental|Aldara 5% Cream|
89490350|NCT01453179|Active Comparator|Solaraze 3% Gel|
89490351|NCT04866212||Children with Type 1 Diabetes Group|"Children with type 1 diabetes were evaluated in terms of their hand skills, visual motor integration, participation in daily life activities and academic success.~Hand skills were evaluated using the Jebsen Taylor Hand Function Test. Participation was evaluated with Participation and Environment Measurement-Children and Youth. Visual motor integration was evaluated with Beery-Buktenica Developmental Test of Visual Motor Integration. Academic success was evaluated with the course success score."
89490352|NCT04866212||Children without Type 1 Diabetes Group|"Children without type 1 diabetes were evaluated in terms of their hand skills, visual motor integration, participation in daily life activities and academic success.~Hand skills were evaluated using the Jebsen Taylor Hand Function Test. Participation was evaluated with Participation and Environment Measurement-Children and Youth. Visual motor integration was evaluated with Beery-Buktenica Developmental Test of Visual Motor Integration. Academic success was evaluated with the course success score."
89490353|NCT04856384|Experimental|persons with Multiple Sclerosis|
89490354|NCT04856384|Experimental|Healthy controls|
88953664|NCT01964339||BMI greater than or equal to 30kg/m2 - arterial|BMI greater than or equal to 30kg/m2 scheduled for PSG as part of routine clinical care. Participants will undergo blood draw (arterial blood gas and metabolic panel) and data collection from PSG study.
88953665|NCT01964365|Experimental|Rosuvastatin|multiple dose of Rosuvastatin 20mg
88953666|NCT01964365|Experimental|Fenofibric acid|multiple dose of Fenofibric acid 135mg
89490355|NCT02437149|Experimental|Video and Brochure|Real stories video presentation and a brochure with information about distracted driving will be given to the participant.
89490356|NCT02437149|Experimental|Power Point and Brochure|Brief power point presentation and a brochure with information about distracted driving will be given to the participant.
89490357|NCT02437149|Experimental|Brochure Only|Only a brochure with information about distracting driving will be given to the participant.
89490358|NCT04856306||Myomectomy|After routine patient counseling on fibroid treatments, this group chooses surgical myomectomy of any type (abdominal/laparoscopic/hysteroscopic)
89490359|NCT04856306||Uterine artery embolization|After routine patient counseling on fibroid treatments, this group chooses uterine artery embolization procedure.
89490360|NCT04856306||Elagolix|After routine patient counseling on fibroid treatments, this group chooses the following medication: every morning (AM), 300mg elagolix, 1mg estradiol, and 0.5mg norethindrone acetate capsules taken in one combined capsule and every evening (PM), 300mg elagolix capsule. In our study, this medication will be administered for 12 months unless the subject withdraws from the study. It is FDA-approved for continuous use of up to 24 months.
89490361|NCT02441205|Experimental|HIIT Aging|all subjects will undergo high intensity interval training 3 x per week for 10-12 weeks. the intervals of high-intensity (~85% of maximal capacity) will be 5 to 10 bouts of 30 seconds at this intensity with rest periods in between intervals that range from 30 seconds to 2 minutes
89490362|NCT02441127|Experimental|Diode laser group|In the test sites, an aluminum, gallium, and arsenide diode laser (wavelength 810 nm and power of 1W) was applied in continuous mode.
89490363|NCT02441127|Active Comparator|Scalpel control group|The surgical technique used in the control group was a FGG harvested by two horizontal and two vertical incisions by scalpel defining the area to be harvested .
89490364|NCT03192033|Other|Arterial closure device used is Proglide® (Abbott)|
89490365|NCT03192033|Other|Arterial closure device used is Femoseal® (Terumo)|
89490366|NCT04863404|Experimental|Bone-anchored maxillary protraction group|Face mask with hybrid-hyrax
89490367|NCT04863404|Experimental|Tooth-borne maxillary protraction group|Face mask with conventional bonded RME
89490368|NCT04863404|No Intervention|Control group|Control group consisting of 14 non-treated Class III malocclusion subjects
89490369|NCT04380896||SARS-CoV-2 Seropositive Cases|"It will be formed of approximately N= 200 to 350 staff members~Core Group of PCR Confirmed Cases N ~ 150 to 250:~A) Symptoms consistent with SARS-CoV-2 infection and SARS-CoV-2 PCR Positive N ~ 150 to 250 OR~Other SARS-CoV-2 Sero-positives N ~ 50 to 100:~B) Symptoms consistent with SARS-CoV-2 infection and SARS-CoV-2 PCR Negative cases. OR C) No symptoms consistent with SARS-CoV-2 infection and PCR Not Tested cases"
89490370|NCT04380896||SARS-CoV-2 Seronegative Comparison Group|"It will be formed of approximately N= 800 to 900 staff members~Core Comparison Group N ~ 800 A) Have not had clinical symptoms consistent with SARS-CoV-2 infection OR~Other Seronegatives N ~ 100 B) Have had sympoms of SARS-CoV-2 infection but have been tested and were PCR positive or negative but have not developed antibodies at 21 days"
89490371|NCT02436603|Other|Nutrition/Mind-Body Coaching|The intervention will consist of weekly group sessions lasting 75-90 minutes during which participants will receive training in the FODMAP diet and mind-body skills.
89490372|NCT02436603|No Intervention|Waitlist Control Group|Waitlist subjects. At the end of the 12-week study period, waitlist subjects will be offered the four-week nutrition and mind-body intervention.
89490373|NCT02709369|Experimental|Active HIRREM|This is a single site, single-arm, open-label, developmental study. Participants are recruited to receive eight to twenty sessions of High-resolution, relational, resonance-based electroencephalic mirroring (HIRREM), in addition to their usual care.
89490374|NCT02436525|Active Comparator|Group I:|"will be treated using conventional stainless steel orthodontic brackets ligated with stainless steel ligature. Oromco - USA.~."
89490375|NCT02436525|Experimental|Group II|: will be treated using passive self-ligating stainless steel orthodontic brackets Oromco - USA.
89490376|NCT02436525|Experimental|Group III:|will be treated by active self-ligating stainless steel orthodontic brackets Oromco - USA .
89490377|NCT02613182|Experimental|Open Label|Open Label Study Drug NEOD001
89490378|NCT06101056|Experimental|Code of Respect (X-CoRe) Multi-Level Sexual Assault (SA) and Harassment (SH) Prevention Program|
89490379|NCT06101056|Other|Control Condition|
88953667|NCT01964365|Experimental|Rosuvastatin + Fenofibric acid|multiple dose of the combination of Rosuvastatin 20mg and Fenofibric acid 135mg
88953668|NCT01964391|Experimental|Trastuzumab|In adjuvant setting trastuzumab will be administered in the following treatment regimens: (a) trastuzumab following surgery, chemotherapy (neo-adjuvant or adjuvant) and radiotherapy (if applicable); (b) trastuzumab following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel; (c) trastuzumab in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin. In neo-adjuvant setting, trastuzumab will be administered in combination with neo-adjuvant chemotherapy followed by adjuvant trastuzumab, for locally advanced (including inflammatory) breast cancer or tumors greater than (>) 2 centimeters (cm) in diameter.
89490380|NCT06100926|Active Comparator|Virtual reality group|subjects who undergo virtual reality immersion scene ab initio
89490381|NCT06100926|Other|control group|subjects who undergo virtual reality immersion scene in a second phase
89490382|NCT06100848|Active Comparator|Caries treatment|The Koch sedimentation method was used to evaluate the aerobic bacterial content in the dental office air. Thirty plates were opened and then sealed 40 minutes after the initiation of caries treatment.
89490383|NCT06100848|Active Comparator|Caries treatment and fumigation|The Koch sedimentation method was employed to evaluate the aerobic bacterial content in the dental office air. Thirty plates were opened and subsequently sealed 60 minutes after the commencement of caries treatment. Fumigation was conducted for 20 minutes.
89490384|NCT06100809|Active Comparator|Control|No coaching provided. Nutrional handout only
89490385|NCT06100809|Experimental|Intervention|Coaching provided. Nutrition handout also provided
89490386|NCT06100783|Experimental|Women using DMPA after 6 weeks postpartum|
89490387|NCT06100783|Experimental|Women using DMPA after 1 week postpartum|
89490388|NCT06100757|Active Comparator|Conventional pacing|24 patients underwent the implantation of a conventional VVI pacing system (Medtronic) with placement of a ventricular pacing lead Medtronic 5076-58 in the right ventricle.
89490389|NCT06100757|Experimental|leadless pacing|27 patients underwent the implantation of a leadless pacing system Micra TPS
89490390|NCT06100731|Active Comparator|Active tDCS|Current will be ramped in/out for 15 seconds at the beginning and end of a 15-minute period and a constant current will be delivered for the 15-minutes between ramping
89490391|NCT06100731|Sham Comparator|Shame tDCS|Current will be ramped in/out for 15 seconds at the beginning and end of a 15-minute period during which no stimulation will be delivered.
89490392|NCT06100718||Study group|Acute ischemic stroke patients at high-risk for underlying occult cancer (elevated D-dimer and suspicion of ESUS at admission)
89490393|NCT06100679|No Intervention|Control|Standard of care. Participants will have access to existing health centers and early childhood development centers.
89490394|NCT06100679|Experimental|Intervention|Participants will engage in the Responsible, Engaged and Loving (REAL) Fathers Intervention-an evidence-based community mentoring education program for young fathers and their spouses. Over 7 months, fathers receive monthly home visits from a community-identified male mentor. Mentors share information and skills-building tools on conflict resolution, non-violent discipline, family planning, and couple communication. At the end of each month, pairs or trios of mentors hold group reflection sessions with all mentored fathers. In months 5 and 6 of the intervention, spouses join the home visits and group sessions. Community-level intervention components include: 1) monthly educational poster campaigns that showcase nonviolent discipline and conflict resolution strategies; 2) community-hosted celebrations at the end of the intervention to acknowledge the accomplishments of the young fathers.
89490395|NCT06100666||Adults|Academic and administrative staff working at Tarsus University
89490396|NCT06100640||positive paracervical pouch|The first group will include patients in whom a paracervical pouch is detected by transvaginal ultrasound.
89490397|NCT06100640||negative paracervical pouch|the second group will include patients in whom the pouch is not detected by transvaginal ultrasound
89490398|NCT06100627|Experimental|2.10 g/day of AP301|
89490399|NCT06100627|Experimental|4.20 g/day of AP301|
89490400|NCT06100627|Experimental|6.30 g/day of AP301|
89490401|NCT06100627|Experimental|8.40 g.day of AP301|
89490402|NCT06100601|Experimental|Autonomic nervous system (ANS) regulation therapy|HRV biofeedback is a non-invasive intervention that focuses on increasing heart rate oscillations through real-time feedback and slow-paced breathing training (Lehrer et al., 2020; Laborde et al., 2022; Pizzoli et al., 2021). Participants will practice 20 min a day (2 sessions of 10 min) for 1 month. One weekly session will be organized in the clinic under the guidance of the therapist (individual sessions), the other sessions will be organized at home, and tracked by a chest strap heart rate monitor (Polar H10) and the Elite HRV app (elitehrv.com). First, the resonance frequency (RF) (i.e. respiration rate with the highest HRV) will be personalized for each participant. Biofeedback slow-paced breathing exercises in the app will then be customized based on this RF (40% inhale, 60% exhale: e.g. 6 bpm: 4s inhale, 6s exhale). Participants will be asked to breathe in through the nose and breathe out through pursed lips, following the breath pacer with visual feedback.
89490403|NCT06100601|Active Comparator|conventional voice therapy (CVT)|The CVT will be based on Meerschman et al. (2019). This therapeutic program has been proven effective in voice therapy and is the standard clinical care for FD patients. The program is a combination of education, vocal hygiene, posture, local relaxation, costo-abdominal breathing, resonant voice, voice placing, forward focus, voice onset, semi-occluded vocal tract exercises and laryngeal manipulation. Identical to the ANS regulation therapy, participants will practice 20 min a day for 1 month. One weekly session will be organized in the clinic under the guidance of the therapist (individual sessions), the other sessions will be organized at home and tracked by the RedCap app.
89490404|NCT06100601|Active Comparator|ANS regulation therapy + CVT|The third group will receive a combination of both therapies. The same frequency and duration of practice (20 min a day for 1 month) will apply. They will also receive one weekly session in the clinic under the guidance of the therapist (individual sessions) and the other sessions will be completed at home, tracked by the Elite HRV app and the RedCap app.
89490405|NCT06100562|Experimental|Dance Program|10-week adapted dance program (20 hours)
89490406|NCT06100536|Experimental|Treatment group|Music-with-movement intervention supported by the stand-alone music-with-movement system.
89490407|NCT06100523|Experimental|Arm A (interventional)|Analysis of the responses to the self-administered questionnaires with, if necessary, protocol interview concerning environmental and occupational factors, which will determine the consultations to be planned for their follow-up by the platform
89490408|NCT06100523|Active Comparator|Arm B (standard management)|Care path according to the usual modalities of the assisted reproductive treatment (ART) center
89490409|NCT06100510|No Intervention|Placebo (non-intervention) Arm|Participants who will have PFA 100 testing performed without the ingestion of aspirin.
89490410|NCT06100510|Active Comparator|Aspirin Arm|Participants who will have PFA 100 testing performed after the ingestion of aspirin.
89490411|NCT06100458||Protocol arm|The skin and leakage protocol was used over a 5 day baseline period. The follow up was done 25 days later by another 5 day period of protocol use to observe any changes in continence care.
89490412|NCT06100406|Experimental|Intervention|"Biofield Tuning is a non-invasive, non-medical therapeutic practice in which a resonating tuning fork is used to identify and re-balance off-the-body sites at which perturbations in the tuning fork sound are detected. The description of the intervention has been provided by Biofield Tuning Practitioners and thus describes the practitioner's experience and process while performing the intervention.~For this study, the Biofield Tuning practitioner will be using a hologram of the participant's body since the intervention will be performed remotely. A hologram is when a BT practitioner imagines the body of the participant on the table in front of them. This approach was used successfully for our last feasibility study suggesting an impact of the virtually delivered BT intervention on anxiety."
89490413|NCT06100406|No Intervention|Waitlist control|The waitlist control group will complete the same weekly self-report questionnaires outlined in the protocol as the intervention group and weekly audio recordings. Following their one-month follow-up questionnaire, those in the waitlist group will be offered a BT session at no cost.
89490414|NCT06100380||patients with Thromboembolic event and Hemorrhage group|patients who present a hemorrhage or a thromboembolic event
89490415|NCT06100380||patients without Thromboembolic event and Hemorrhage|patients who don't present a hemorrhage or a thromboembolic event
89490416|NCT06100354||Preference study|Patients answering the questionnaire with choice sets
89490417|NCT06100328||Cardiac myxoma group|patients who are diagnosed as cardiac myxoma
89490418|NCT06100328||Cardiac fibroma group|patients who are diagnosed as cardiac fibroma
89490419|NCT06100328||Cardiac lipoma group|patients who are diagnosed as cardiac lipoma
89490420|NCT06100328||Cardiac hemangioma group|patients who are diagnosed as cardiac hemangioma
89490421|NCT06100328||Cardiac malignant tumor group|patients who are diagnosed as cardiac malignant tumor
89490422|NCT06100315||Bupivacaine|30 patients will receive SMB using bupivacaine 0.125% of 0.2 ml/kg on each side (with maximum volume of 4 ml).
89490423|NCT06100315||Bupivacaine and Nalbuphine|30 patients will receive SMB using bupivacaine 0.125 of 0.2 ml/kg + 0.1 mg/kg nalbuphine on each side (with maximum volume of 4 ml).
89490424|NCT06100302||MD group|Patients with depression who met the inclusion criteria
89490425|NCT06100302||HC group|Healthy subjects meeting enrollment criteria
88953669|NCT01964404|Experimental|Marijuana cigarette and placebo capsule|3-5% tetrahydrocannabinol cannabis cigarette smoked immediately prior to the second functional MRI and a placebo capsule (for dronabinol) by mouth taken approximately 2.75 hours prior to the second functional MRI.
89490426|NCT06100263|Experimental|Intervention (Supervised exercise)|The individualized resistance exercise program is based on participants' baseline 1-repetition maximum muscular strength assessment (i.e., the maximum lifted for 1 repetition) and is aligned with current cancer-specific exercise recommendations. The resistance exercise program will follow the FITT principle (frequency, intensity, time, and type). Sessions will be 35-45 minutes in duration.
89490427|NCT06100263|Active Comparator|Control|Participants randomized to health education control condition will receive the American Cancer Society Physical Activity and the Person with Cancer summary for patients and American College of Sports Medicine Exercise is Medicine Effects of Exercise on Health-Related Outcomes in Those with Cancer infographic
89490428|NCT06100211||ART switch group|These are individuals who complete a planned switch of ART regimen from one class of drugs or delivery method to another.
89490429|NCT06100211||Control group|This group continue on their stable ART regimen.
89490430|NCT06100159|Experimental|Tympanostomy tube|Insertion of tympanostomy tubes after 3 months observation for chronic otitis media with effusion (OME) according to the National guidelines in Denmark. Sleep measurements with accelerometer 7 nights before and 7 nights after intervention. Caregivers report use of paracetamol during nights with sleep measurements.
89490431|NCT06100159|No Intervention|Control|"No tympanostomy tube treatment up to 1 month after enrollment in control group. Sleep measurements with accelerometer 7 nights at time of inclusion. Caregivers report use of paracetamol during nights with sleep measurements.~After 1 month tympanic tube insertion is allowed if still chronic OME. If tympanostomy tubes are needed the children will undergo same evaluation as the intervention group."
89490432|NCT06100133|Experimental|Ketone Ester|Up to 100g ketone ester daily for 56 days
89490433|NCT06100107|Experimental|Group A - Mirror Therapy|Group A carried out a ten-minute Mirror Therapy exercise daily, for a total duration of six weeks.
89490434|NCT06100107|Experimental|Group B - control period followed by Mirror Therapy|Group B acted as a control group for six weeks (no Mirror Therapy) followed by six weeks of Mirror Therapy with the same characteristics as Group A.
88953670|NCT01964404|Experimental|Dronabinol and placebo cigarette|Dronabinol 15mg 3-5% by mouth taken approximately 2.75 hours prior to the second functional MRI and a placebo cigarette (for marijuana) smoked immediately prior to the second functional MRI.
89204414|NCT02602067|Experimental|131I-Tenatumomab|"Diagnostic: each patient will receive one single i.v. infusion of 370 MBq±10% 131I-Tenatumomab in 10 ml of saline (conveyed by 10 ±10%, 20 ±10%, 40 ±10% mg of Tenatumomab). It will be administered as a short infusion in approximately 30 minutes (333 ° µl / min).~Therapeutic: each patient will receive one single i.v. infusion, escalating 131I-Tenatumomab dose starting at 2.5 GBq±10%,with escalation steps of 1 GBq, up to 5.5 GBq±10% in 10 ml of saline, (conveyed by 10 ±10% , 20 ±10%, 40 ±10% mg of Tenatumomab). It will be administered as a short infusion in approximately 30 minutes (333° µl / min)"
89490435|NCT06100094||juvenile sex offender psychoeducation group|The psychoeducation group consists of 10 sessions of approximately 1.5 hours each, once a week or every two weeks depending on the availability of the therapists. Among the sessions, 9 correspond to a specific theme: reminder of the law and violence, sexism, consent, control, social pressure, self-control, empathy, seduction and romantic relationships, sex under the influence. The last session is devoted to a resumption of all the themes previously discussed. Semi-structured qualitative interviews addressing their feelings regarding the psychoeducation group, what they learned from it, what they had difficulty with.
89490436|NCT06100081|Experimental|Patients|Patients with cancer of unknown primary most probable originating from the head and neck area
89490437|NCT06100055|Active Comparator|Low-volume rectal irrigation|This system consists of a small reservoir attached to a cone. Depending on the manufacturer, the reservoir can hold approximately between 110ml and 300ml of water. This reservoir is squeezed to inject water into the rectum. The regime will be such that participants will be asked to use rectal irrigation daily for two weeks. They will be restricted to not use rectal irrigation for more than once in a day. Every day they can use up to 300ml for irrigation. After two weeks participants can then adjust the number of irrigation days per week as well as volume used for irrigation but not exceeding irrigation therapy more than once a day and not more than 300ml per irrigation. Volume and frequency of rectal irrigation will be recorded by participant in participant journal. This will be used to check their compliance and average weekly irrigation sessions and volume used for satisfactory outcome.
89490438|NCT06100055|Active Comparator|High-volume rectal irrigation|The high-volume irrigation system consists of an irrigation bag connected to a tube. The water flows into the rectum, either by gravity or by using a pump. Some systems use balloon to hold the device in place during irrigation; others require the user to hold it in place. The mechanism of action is the same for all systems. Participants will start irrigation with 300ml and increase this by 100ml every 2 days until satisfactory defaecation is achieved, or the procedure becomes uncomfortable, up to a maximum of 1500ml. Initial frequency of irrigation is the same as for low-volume irrigation: i.e. once daily for two weeks followed by participant adjustment of number of irrigation days per week as well as volume used for irrigation but no more than 1500ml a day. Participants will be restricted to using high-volume irrigation to not more than once a day.
89490439|NCT06100029|Experimental|Intervention group|The modified GGLM decoction
89490440|NCT06100029|Placebo Comparator|Control group|the A2F bundle
89490441|NCT06099990|Experimental|dalpiciclib+ abiraterone+ prednisone|
89490442|NCT06099990|Placebo Comparator|placebo+abirarerone+prenisone|
89490443|NCT06099951|Experimental|Serplulimab+FOLFOXIRI|
89490444|NCT06099938||Group S|intrathecal injections of sufentanil
89490445|NCT06099938||Group R|intrathecal injections of ropivacaine
89490446|NCT06099925|Experimental|Hetrombopag|All the 48 patients will be given hetrombopag 5mg/day within 24 hours after chemotherapy
89490447|NCT06099899||child|The child's age ranges from 8 to 18 years old. They have undergone hematopoietic stem cell transplantation for at least one month. They do not have any mental disorders or consciousness impairments. The child is capable of independent walking. The interviewees are able to express their thoughts clearly.
89490448|NCT06099899||parent|The primary caregivers during the home care period for these children.
89490449|NCT06099873|Experimental|ZX-7101A|40 mg in a single dose
89490450|NCT06099873|Placebo Comparator|Placebo group|
89490451|NCT06099860|Experimental|Group A|KBT Group
89490452|NCT06099860|Experimental|Group B|BT Group
89490453|NCT06099847|Experimental|Chronic Pelvic Pain Patients with TENS|19 patients with chronic pelvic pain have been received sacral TENS intervention.
89490454|NCT06099847|Sham Comparator|Chronic Pelvic Pain Patients with Sham Stimulation|19 patients with chronic pelvic pain have been received sham stimulation intervention.
89490455|NCT06099808|Experimental|Audit and Feedback (AF)|Pharmacists randomized to audit and feedback will receive a monthly email containing information including their total medication titration encounters over a 3 month period, as well as the site and VISN level for comparison. The audit and feedback email will also contain rates of medical therapy and percentage of patients on >50% of the target dose of medical therapy stratified by site, VISN and national. This data will be obtained from VHA national HF dashboard. Pharmacists in AF will also receive invitations to monthly educational sessions and access to shared resources on HF medication management.
89490456|NCT06099808|Experimental|Audit and Feedback with Patient Specific Targets (AF+)|Pharmacists randomized to the AF+ group will receive the audit and feedback intervention described above with the addition of a list of 5-7 HF patients who are potentially eligible for pharmacist HF medication titration. These patients will be identified using the VHA national HF dashboard.
89490457|NCT06099808|Active Comparator|Usual Care|Pharmacists randomized to the usual care arm will have access to monthly educational sessions and to shared resources on HF medication management. They will receive no additional feedback.
89490458|NCT06099795|Experimental|Patients likely to be affected by COVID-19|The study population consists of adult people who are likely to be affected by COVID-19 (symptomatic or close contacts) consulting for RT-PCR screening.
89490459|NCT06099743|No Intervention|ASCENT Stakeholder Interviews|Enrolled stakeholders will be sent the study description and proposed intervention content to review. They will complete a semi-structured interview with trained study staff to obtain feedback on the proposed intervention.
89490460|NCT06099743|Experimental|ASCENT Open Pilot|"Enrolled patients will receive an intervention manual and will participate in six weekly or biweekly individual sessions with a clinician (e.g. nurse or behavioral health specialist).~Participants will be asked to complete surveys at baseline, 6 weeks, 12 weeks, and 16 weeks, as well as an exit interview after the intervention."
89490461|NCT06099743|Experimental|Pilot RCT: ASCENT Arm|"Enrolled patients will receive an intervention manual and will participate in six weekly or biweekly individual sessions with a clinician (e.g. nurse or behavioral health specialist).~Participants will be asked to complete surveys at baseline, 6 weeks, 12 weeks, and 16 weeks."
89490462|NCT06099743|Active Comparator|Pilot RCT: Control Arm|"Participants will receive usual supportive care, which includes referral to cancer center supportive care services (e.g., social work) upon request from the patient, caregiver, or clinician.~Participants will be asked to complete surveys at baseline, 6 weeks, 12 weeks, and 16 weeks."
89490463|NCT06099717|Experimental|Test|Dual-cantilevered single implant bridge
89490464|NCT06099717|Active Comparator|Control|3-unit implant fixed dental prosthesis
89490465|NCT06099626||A:autoimmune hepatitis|
89490466|NCT06099626||B:autoimmune hepatitis/primary biliary cirrhosis|
89490467|NCT06099626||C:/primary biliary cirrhosis|
89490468|NCT06099626||D:Subjects tested positive for COVID-19 antigen or COVID-19 nucleic acid|
89490469|NCT06099626||E|Subjects who have no previous history of COVID-19 infection and have been vaccinated against COVID-19.
89490470|NCT06099600|Experimental|pre-habilitation stays|Pre-habilitation involves taking part in a half-day information session led by a physiotherapist and a nurse prior to surgery. Patients will benefit from digital monitoring via the Orthense application, as well as scheduled surgery (anterior cruciate ligament reconstruction) and the usual peri-operative medical follow-up.
89490471|NCT06099600|Active Comparator|conventional care|During their pre-operative visit with the surgeon, patients will receive a booklet containing information on the peri-operative period, possible complications, how to prevent them and what to do should they occur. Patients will benefit from standard computerized follow-up, as well as the scheduled surgical procedure (anterior cruciate ligament reconstruction) and the usual peri-operative medical follow-up.
89490472|NCT06099587|Experimental|SCD+|"Patients with subjective cognitive decline-plus due to Alzheimer's disease (or DCS in french)"
89490473|NCT06099587|Experimental|MCI|"Patients with mild neurocognitive impairment due to Alzheimer's disease (or TCL in french)"
89490474|NCT06099561||Study group|Individuals with current severe, imminent and lethal self-harm with a history of at least two interventions without sufficient reduction of self-harm or suffering.
89490475|NCT06099548|Experimental|HR-PCI patients|Patients undergoing non-emergent, high-risk percutaneous coronary interventions
89490476|NCT06099535|Experimental|LNK01001 Dose A|Participants will receive LNK01001 Dose A orally BID for up to 24 weeks.
89490477|NCT06099535|Experimental|LNK01001 Dose B|Participants will receive LNK01001 Dose B orally BID for up to 24 weeks.
89490478|NCT06099535|Placebo Comparator|placebo/LNK01001 Dose A|Participants will receive a placebo orally BID for 12 weeks in Period 1. Participants will be re-randomized at Week 13 in a 1:1 ratio to receive LNK01001 Dose A orally BID for up to 24 weeks.
89490479|NCT06099535|Placebo Comparator|placebo/LNK01001 Dose B|Participants will receive a placebo orally BID for 12 weeks in Period 1. Participants will be re-randomized at Week 13 in a 1:1 ratio to receive LNK01001 Dose B orally BID for up to 24 weeks.
89490480|NCT06099496||Disease group|Collect data from patients with cardiovascular and neurological diseases, including blood and stool samples. Genome and transcriptome sequencing was performed on the collected blood samples. For fecal samples, metagenomic sequencing and metometabolic and proteomic sequencing were performed.
89490481|NCT06099496||Healthy control group|Collect data from healthy people, including blood and stool samples. Genome and transcriptome sequencing was performed on the collected blood samples. For fecal samples, metagenomic sequencing and metometabolic and proteomic sequencing were performed.
89490482|NCT06099470|Experimental|Real-time synchronized telerehabilitation program (STP).|Subjects in this group will have face to face real-time video tele-habilitation sessions twice a week using Zoom
89490483|NCT06099470|Experimental|Pre-recording non-synchronized telerehabilitation program (NSTP)|Subjects in this group will receive their therapeutic exercises through instructional videos sent via Email or WhatsAPP.
89021904|NCT03277443|Active Comparator|Conventional Model Surgery|"Lateral Cephalogram with analysis and tracing of facial profile.~Modified model surgical tecnique:~Obtain wax bite registration.~Record face-bow transfer.~Duplication of articulating model for surgical simulation.~Measure all casts and bases in standard model surgery fashion.~Fabricate intermediate splint & Final splint.~Condylar repositional splint."
89021905|NCT03277443|Experimental|Computer guided surgery|"Preoperative surgical simulation and immediate postoperative evaluation will be carried out using Multi Slice CT scan.~Computer-aided planning for study group:~All planning will be done using specialized software (Anatomage Invivo 5.3) for preoperative surgical simulation and immediate postoperative evaluation.~Pre-operative Fabrication of computer aided surgical splint:~In the study group a stereo splint will be fabricated using rapid prototyping (RP) technique to guide the osteotomy and another one will be fabricated after virtual osteotomy to guide the surgical cuts. And stent for guided holes.~So that the osteotomy will be accomplished by the aid of computer guided templates that simulates the proper bite achieved preoperatively during surgical simulation and Planning."
89021906|NCT00452907|Experimental|1|Arsucam® (AS 50mg/Aq153mg),oad, per os, 3 days of treatment
89021907|NCT00452907|Active Comparator|2|Arsumax (AS 50mg) + Sulfadoxine-Pyrimethamine (SP=SDX 500mg/PYR 25mg), oad, per os
89021908|NCT00452907|Active Comparator|3|Coartem (arthemether 20mg+ lumefantrine 120 mg), bid, per os. Duration of treatment: 3 days
89021909|NCT00452985||1|"Injection of Docetaxel~3-hour gap~Injection of carboplatin"
89021910|NCT00341900||Case|Male pilots with high cosmic radiation exposure
89021911|NCT03277404|Experimental|Smear Layer Positive|Root canal treatment without smear layer removal: Root canal treatment and Irrigation with 1 ml of 2.5% sodium' hypochlorite for 1 min, followed by ultrasonic activation of 3 ml of 2.5% sodium hypochlorite for 1minute.
89021912|NCT03277404|Active Comparator|Smear layer negative|root canal treatment with smear layer removal:Root canal treatment and Irrigation with 1 mL of 17% EDTA solution and ultrasonic activation, followed by ultrasonic activation of 3 ml of 2.5% sodium hypochlorite for 1 minute.
89021913|NCT03277326|Active Comparator|ISB|Interscalene brachial plexus block
89021914|NCT03277326|Active Comparator|aSSB|Anterior Suprascapular Block
89021915|NCT03277326|Active Comparator|pSSB|Posterior Suprascapular Block
89021916|NCT03277287|Experimental|Group A|Fractional CO2 laser will be applied on cleft lip scar 3 weeks post-surgical
89021917|NCT03277287|Experimental|Group B|Fractional CO2 laser will be applied on cleft lip scar 3 months post-surgical
89021918|NCT03277287|No Intervention|Group C|No intervention
89021919|NCT03277209|Experimental|All Subjects|Plerixafor will be administered via IV as a continuous 7 day intravenous infusion starting at a dose of 20 ug/kg/hr and subsequent dose levels of 40, 80 and 120 ug/kg/hr
89021920|NCT00342173||Women in Costa Rica|Examining the natural history of HPV and cervical neoplasia in Costa Rican women.
89021921|NCT03277092|Experimental|VeinViewer® group|Use of near infrared light to perform blood draw (VeinViewer®)
89021922|NCT03277092|Active Comparator|Usual care group|Blood drawing performed traditionally
89490484|NCT06099470|Other|Home non-supervised control group (HCG)|Minimum intervention which is a PDF file containing the same exercises with no follow ups.
89490485|NCT06099431|Other|Surgery/Device|Mandibular marginal resection and reconstruction using a mandibular osteosynthesis a 2.3mm reconstruction bone plate
89021923|NCT00453219||1|Women ages 18-35 years with regular ovulatory menstrual cycles
89021924|NCT00453219||2|Women ages 18-35 years with irregular or absent menstrual periods due to functional hypothalamic amenorrhea (FHA) also called stress-induced anovulation
89021925|NCT00453219||3|Women ages 18-35 years with irregular or absent menstrual periods due to polycystic ovary syndrome(PCOS).
89490486|NCT06099418|Experimental|VB10.16 + placebo|"9 mg VB10.16 via i.m. needle free injections in the deltoid muscles and quadricep or gluteus muscle.~Placebo will be given via IV infusions."
89490487|NCT06099418|Experimental|VB10.16 + atezolizumab|"9 mg VB10.16 via i.m. needle free injections in the deltoid muscles and quadricep or gluteus muscle.~Atezolizumab will be given via IV infusions."
89490488|NCT06099405|Experimental|High-speed, Cognitive Challenge Yoga|Participants in this group will receive high-speed yoga training for 24 consecutive weeks for a total of 72 training sessions.
89021926|NCT03277053|Sham Comparator|control|Patients receive an ipad with no app.
89021927|NCT03277053|Experimental|Mobile application no stoma|Patients who did not receive a stoma receive an ipad containing the app and are instructed how to use it.
89021928|NCT03277053|Experimental|Mobile application stoma|Patients who receive a stoma receive an ipad containing the app and are instructed how to use it.
89021929|NCT00421070|No Intervention|Treatment as usual|Observational component
89021930|NCT00421070|Active Comparator|Intervention|Massage therapy adjunct comparator
89021931|NCT03274908||Group|
89021932|NCT00421109|Experimental|1|Bilastine 20 mg
89021933|NCT00421109|Active Comparator|2|Levocetirizine 5 mg
89021934|NCT00421109|Placebo Comparator|3|Placebo
89021935|NCT02273583|Experimental|Maintenance therapy|73 weeks of continuous oral low dose chemotherapy with cyclophosphamide (CPM) and methotrexate (MTX) following 31 weeks of MAP.
89021936|NCT02273583|No Intervention|Control|31 weeks of MAP.
89021937|NCT00453258||Study Subject|Subjects receiving eye examination
89021938|NCT00342368|Active Comparator|1|CPAP through an helmet
89021939|NCT00342368|No Intervention|2|O2 therapy with conventional face mask
89021940|NCT00446901|Placebo Comparator|Placebo|Placebo
89021941|NCT00446901|Experimental|Selenium (selenized yeast)|Selenium (selenized yeast) tablets, 300 ug/day
89021942|NCT00342407||Cohort|Female flight attendants
89021943|NCT00453375|Experimental|1|BHT-3021
89021944|NCT00453375|Placebo Comparator|2|BHT-Placebo
89204415|NCT02556320|Experimental|Epileptic patient|Blood sampling is done for Patient who initiate anti-epileptic drug (sodium valproate, divalproate sodium, valpromide, lamotrigine, carbamazepine, oxcarbazepine, eslicarbazepine acetate)
89490489|NCT06099405|Active Comparator|Traditional Yoga|Participants will perform standard Hatha yoga with slow controlled speed movements for 24 consecutive weeks for a total of 72 training sessions.
89490490|NCT06099392|Experimental|TEA group|TEA at ST36 (Zusanli) combined with 2L Polyethylene Glycol Electrolytes Powder for bowel preparation
89490491|NCT06099392|No Intervention|Sham-TEA group|2L Polyethylene Glycol Electrolytes Powder for bowel preparation
89490492|NCT06099366|Experimental|Standard-low (SL)|Induction-> SL Consolidation(4weeks)-> Interim Maintenance 1st-> Delayed Intesificaion-> Interim Maintenance 2nd-> Maintenance
89490493|NCT06099366|Experimental|Standard-average (SA)|Induction-> SH Consolidation(8weeks)-> Interim Maintenance 1st-> Delayed Intesificaion-> Interim Maintenance 2nd-> Maintenance
89490494|NCT06099366|Experimental|Standard-high 1 (SH1)|Induction-> SL Consolidation(4weeks)-> SH Consolidattion(4weeks)-> Interim Maintenance 1st-> Delayed Intesificaion 1st-> Interim Maintenance 2nd-> Delayed Intestificaion 2nd-> Maintenance
89490495|NCT06099366|Experimental|Standard-high 2 (SH2)|Induction-> SH Consolidattion(8weeks)-> Interim Maintenance 1st-> Delayed Intesificaion 1st-> Interim Maintenance 2nd-> Delayed Intestificaion 2nd-> Maintenance
89490496|NCT06099340|Experimental|"Experimental  EXC "|eccentric strengthening + conventional rehabilitation
89490497|NCT06099340|Active Comparator|"Comparator  CONC "|concentric strengthening + conventional rehabilitation
89490498|NCT06099340|No Intervention|"Control  CTL "|no strengthening (control, conventional rehabilitation only)
89490499|NCT06099314||Fruquintinib Rechallenge|"third-line treatment with fruquintinib combined with PD-1 inhibitors~fourth-line treatment with fruquintinib combined with TAS-102"
89490500|NCT06099262||Tower Hamlets 1|Delivering the GenPMTO programme to one group of caregivers within the Tower Hamlets borough.
89490501|NCT06099262||Tower Hamlets 2|Delivering the GenPMTO programme to a second group of caregivers within the Tower Hamlets borough.
89490502|NCT06099262||Brent 1|Delivering the GenPMTO programme to one group of caregivers within the Brent borough.
89490503|NCT06099262||Brent 2|Delivering the GenPMTO programme to a second group of caregivers within the Brent borough.
89490504|NCT06099262||Barking & Dagenham 1|Delivering the GenPMTO programme to one group of caregivers within the Barking & Dagenham borough.
89490505|NCT06099262||Barking & Dagenham 2|Delivering the GenPMTO programme to a second group of caregivers within the Barking & Dagenham borough.
89490506|NCT06099249||No_AFib_Group|Subjects enrolled into No_AFib_Group must have no known medical history of AFib and in normal sinus rhythm at the time of screening.
89490507|NCT06099249||AFib_Group|Subjects enrolled into AFib_Group must have a known diagnosis of persistent or permanent AFib and be in AFib at the time of screening.
89490508|NCT06099197|Experimental|Brain CareNotes|The Brain CareNotes mobile telehealth app is used by unpaid caregivers for BPSD management. It includes remote communication with an external human support person-a care coach-as well as features for users to independently perform health-related activities.
89490509|NCT06099197|Active Comparator|Attention Control App|"Dementia Guide Expert provides education only and no interactive BPSD management support, coaching, assessment, or external response. It contains evidence-based expert information on what dementia is, types, contributing factors, risks, symptoms, stages, diagnosis, tests, treatment, management, communication techniques, and links to resources and support services."
89490510|NCT06099158|Experimental|HeartLogic-guided management|HeartLogic alerts will be transmitted to the central site, which will subsequently contact the participant to assess any treatment needs. Treatment needs will be assessed according to current clinical practice guidelines.
89490511|NCT06099158|No Intervention|Standard care|The control group will receive usual HF care in the Danish health system.
89490512|NCT06099145|No Intervention|Standard care|Patient who received inhaled treatment with Innovair® or Trimbow® as a part standard care for 6 months
89021945|NCT00446979|Experimental|1|UC 781 0.1% carbomer gel
89021946|NCT00446979|Experimental|2|UC 781 0.25% carbomer gel
89021947|NCT00446979|Placebo Comparator|3|Placebo vaginal gel
89490513|NCT06099145|Experimental|Hephai|Patient using the Hephaï medical device as a tool who received inhaled treatment with Innovair® or Trimbow® as a part standard care for 6 months
89490514|NCT06099119|Experimental|experimental arm|Creon 35.000 Ph.U (R) at a fixed dose of 3 capsules orally with main meals (breakfast, lunch and dinner) and 2 capsules with snacks over 6 months post randomization.
89490515|NCT06099119|Other|control arm|Creon 35.000 Ph.U (R) at a fixed dose of 3 capsules orally with main meals (breakfast, lunch and dinner) and 2 capsules with snacks during the last 3 months post randomization.
89490516|NCT06099106|Experimental|Implantable device|Endomatic SEPIOLA System
89490517|NCT06099093|Experimental|18F-DCFPYL-PSMA PET|"Study procedures will be conducted as follows:~Baseline screening visit with PSMA-PET/CT scan with Ga-PSMA-11.~In-clinic visit with exam and PSMA-PET/CT scan with 18F-DCFPyl per standard institutional procedures.~Standard of care therapy.~Follow up every 3 months via chart review for 12 months, with the purpose of seeing how participants respond to 177Luvipivotide tetraxetan treatment."
89490518|NCT06099067||CANVAS Canagliflozin|CANVAS expousre Group
89490519|NCT06099067||CANVAS DPP4i|CANVAS reference Group
89490520|NCT06099067||LEADER Liraglutide|LEADER exposure Group
89490521|NCT06099067||LEADER DPP4i|LEADER reference Group
89490522|NCT06099067||SAVOR-TIMI Saxagliptin|SAVOR-TIMI exposure Group
89490523|NCT06099067||SAVOR-TIMI 2nd generation Sulfonylurea|SAVOR-TIMI reference Group
89490524|NCT06099054|Experimental|pigtail group|composed of 40 patients in which pleural effusion will be drained using pigtail catheter under US guidance
89021948|NCT00453453|Experimental|Nesiritide|Subjects who come into the ED with CHF will be treated with nesiritide
89021949|NCT00453453|No Intervention|Standard care|Subjects who come into the ED with CHF will receive standard care treatment
89021950|NCT00342875||Population Controls|Control subjects were selected randomly from state Department of Motor Vehicle and Centers for Medicare and Medicaid Services (CMS) beneficiary records.
89021951|NCT00342875||Urinary Bladder Cases|patients with histologically confirmed carcinoma of the urinary bladder
89021952|NCT00342953||Cohort|Women receiving implants and other plastic surgery.
89021953|NCT00342992||Healthy Volunteers|Male smokers in Southwestern Finland
89021954|NCT05649033||"group recently graduated midwives practicing in the delivery room"|Midwives graduated for less than three years and practicing in the delivery room
89021955|NCT00447096|Experimental|Treatment Arm|Treatment arm will receive treatment 5 days a week for 6 weeks. Repetitive transcranial magnetic stimulation (rTMS) treatment.
89021956|NCT00447096|Sham Comparator|Sham Arm|Sham Arm will not receive any stimulation 5 days a week for 6 weeks. Sham transcranial magnetic stimulation.
89021957|NCT00453570|Experimental|1|DTacP IPV// PRP~T combined vaccine at 2, 3 and 4 months of age, and a booster dose at 18-20 months of age.
89021958|NCT00453570|Experimental|2|DTacP-IPV// PRP~T combined vaccine at 3, 4 and 5 months of age and a booster dose at 18-20 months of age.
89021959|NCT00453570|Active Comparator|3|Control vaccines at 3, 4 and 5 months of age and a booster dose at 18-20 months of age
89021960|NCT00447174|Experimental|treatment|treatment manual
89021961|NCT00447174|No Intervention|control group|
89021962|NCT00343265|Active Comparator|1|Progesterone gel
89490525|NCT06099054|Active Comparator|ICT group|composed of 40 patients in which pleural effusion will be drained using ICT
89490526|NCT06099028||HF center|heart failure patients enrolled from heart failure center hospitals
89490527|NCT06099028||non-HF center|heart failure patients enrolled from non-heart failure center hospitals
89490528|NCT06099015||Cera Vascular Plug Subjects|Patients who need arterial or venous embolization in the peripheral vasculature.
89021963|NCT00343265|Placebo Comparator|2|Vaginal gel with no medication
89021964|NCT00447213|Experimental|1|
89021965|NCT00447213|Experimental|2|
89021966|NCT00453648|Placebo Comparator|White-fleshed Sweet Potato|0 ug retinol activity equivalents (RAE)/d as boiled white-fleshed sweet potatoes (WFSP) and a corn oil capsule, 6d/wk for 10 wk
89021967|NCT00453648|Experimental|Orange-fleshed Sweet Potato (boiled)|600 ug RAE/d as boiled orange-fleshed sweet potato and a corn oil capsule, 6d/wk for 10 wk
89021968|NCT00453648|Experimental|Orange-fleshed Sweet Potato (fried)|600 ug RAE/d as fried orange-fleshed sweet potato and a corn oil capsule, 6d/wk for 10 wk
89021969|NCT00453648|Active Comparator|White-fleshed Sweet Potato and retinyl palmitate capsule|0 ug RAE/d as white-fleshed sweet potato and 600 ug retinol/d as retinyl palmitate, 6d/wk for 10 wk
89021970|NCT00343421|Experimental|Group 1|PEDIACEL co-administered with Prevenar
89021971|NCT00343421|Active Comparator|Group 2|Infanrix-IPV+Hib co-administered with Prevenar
89021972|NCT00453687|Experimental|Arm 1|Drug
89021973|NCT04715360|Other|Control|Only received standard medication (avigan) for severe COVID-19 management
89021974|NCT04715360|Experimental|PRP Group|received standard medication (avigan) for severe COVID-19 management and autologous activated platelet-rich plasma transfusion
89021975|NCT00343616|Experimental|Tamoxifen for 5 years|Patients treated with tamoxifen for 5 years after randomization.
89021976|NCT00343616|Experimental|Letrozole for 5 years|Patients treated with letrozole for 5 years after randomization.
89021977|NCT00343616|Experimental|Tamoxifen 2 years plus letrozole 3 years|Patients treated with tamoxifen for 2 years and afterwards with letrozole for 3 years.
89021978|NCT00343616|Experimental|Letrozole for 2 years plus tamoxifen for 3 years|Patients treated with letrozole for 2 years and afterwards with tamoxifen for 3 years.
89021979|NCT00453765|Experimental|A|montelukast
89021980|NCT00453765|Placebo Comparator|B|placebo
89021981|NCT00447408|Active Comparator|A|Education in the hemodialysis diet.
89021982|NCT00447408|Experimental|B|Education in the hemodialysis diet. Behavioral counseling paired with PDA-based self-monitoring of dietary sodium intake.
89021983|NCT00343928|Experimental|1|
89021984|NCT00453843|Experimental|proximal to distal training|
89021985|NCT00453843|Experimental|distal to proximal|
89021986|NCT00453843|Experimental|proximal and distal on alternate days|
89021987|NCT00453843|Experimental|proximal and distal same day|
89021988|NCT00343031||Pregnant women delivering male infants|Male newborns and their mothers living in Tapachula (Chiapas, Mexico) and surrounding areas exposed to DDT through house spraying programs to control malaria, grouped by level of DDT exposure.
89021989|NCT00447525|Experimental|1|
89021990|NCT00447525|Active Comparator|2|
89021991|NCT00344006|Experimental|Arm 1|
89021992|NCT02273661|Placebo Comparator|Control|An aerosol of isotonic saline x 1/ week will be administered during 6 months
89021993|NCT02273661|Experimental|Ambisome|An aerosol of Liposomal Amphotericin B (Ambisome®) at 25 mg x 1/ week will be administered during 6 months
89021994|NCT00447642|Experimental|LX201 0.50 inch implant|LX201 implant contained 30% cyclosporine A by weight and 0.50 inch in length
89490529|NCT06098989|Active Comparator|Normal voltage in LA posterior wall - PVI alone|Patients with normal LA posterior wall will be assigned directly to arm 1, receiving PVI alone.
89490530|NCT06098989|Active Comparator|Low voltage in LA posterior wall - PVI alone|Patients with low voltage/scar on the LA posterior wall will be randomized to arm 2, receiving PVI alone.
89490531|NCT06098989|Active Comparator|Low voltage in LA posterior wall - PVI + PWI|Patients with low voltage/scar on the LA posterior wall will be randomized to arm 3, receiving PVI + PWI.
89490532|NCT06098976|Experimental|Water Jet|The patients were taught how to clean their teeth with the Water Jet device (Water Jet, JollyDent, Damascus, Syria) before starting the dental cleaning procedures. Special heads for patients undergoing orthodontic treatment provided by the company were used with each device. The patient applied the Water Jet device on each tooth separately for 10 seconds starting from the upper jaw to the lower jaw.
89490533|NCT06098976|Active Comparator|Manual toothbrush|Manual toothbrush: The patients were taught to use the modified vertical method, and the patient brushed the teeth of the upper and lower jaws using traditional toothbrushes (Diamond, JolleyDent, Damascus, Syria), and anti-plaque toothpaste (Elgydium, UniPharma Co., Ltd, Ashrafiyat Sahnaya, Syria).
89021995|NCT00447642|Experimental|LX201 0.75 inch implant|LX201 implant contained 30% cyclosporine A by weight and 0.75 inch by length
89490534|NCT06098950|Experimental|AI model biased for heart failure, no AI explanation|Participants in this arm will be shown standard AI model predictions during 3 patient clinical vignettes within the survey and systematically biased AI model predictions during 3 clinical vignettes. When shown systematically biased AI model predictions, the model will be biased against heart failure, always predicting that heart failure is present with high likelihood in patients with a body mass index (BMI) at or above 30. Standard predictions will be shown for the other 2 diagnoses. Participants in this arm will not be shown an AI explanation when shown AI model predictions.
89490535|NCT06098950|Experimental|AI model biased for pneumonia, no AI explanation|Participants in this arm will be shown standard AI model predictions during 3 patient clinical vignettes within the survey and systematically biased AI model predictions during 3 clinical vignettes. When shown systematically biased AI model predictions, the model will be biased against pneumonia, always predicting that pneumonia is present with high likelihood in patients 80 years or older. Standard predictions will be shown for the other 2 diagnoses. Participants in this arm will not be shown an AI explanation when shown AI model predictions.
89490536|NCT06098950|Experimental|AI model biased for COPD, no AI explanation|Participants in this arm will be shown standard AI model predictions during 3 patient clinical vignettes within the survey and systematically biased AI model predictions during 3 clinical vignettes. When shown systematically biased AI model predictions, the model will be biased against COPD, always predicting that COPD is present with high likelihood when a pre-processing filter was applied to the patient's X-ray. Standard predictions will be shown for the other 2 diagnoses. Participants in this arm will not be shown an AI explanation when shown AI model predictions.
89490537|NCT06098950|Experimental|AI model biased for heart failure, Image-based AI explanation presented|Participants in this arm will be shown standard AI model predictions during 3 patient clinical vignettes within the survey and systematically biased AI model predictions during 3 clinical vignettes. When shown systematically biased AI model predictions, the model will be biased against heart failure, always predicting that heart failure is present with high likelihood in patients with a body mass index (BMI) at or above 30. Standard predictions will be shown for the other 2 diagnoses. Participants in this arm will also be shown AI explanation when shown AI model predictions.
89490538|NCT06098950|Experimental|AI model biased for pneumonia, Image-based AI explanation presented|Participants in this arm will be shown standard AI model predictions during 3 patient clinical vignettes within the survey and systematically biased AI model predictions during 3 clinical vignettes. When shown systematically biased AI model predictions, the model will be biased against pneumonia, always predicting that pneumonia is present with high likelihood in patients 80 years or older. Standard predictions will be shown for the other 2 diagnoses. Participants in this arm will also be shown AI explanation when shown AI model predictions.
89490539|NCT06098950|Experimental|AI model biased for COPD, Image-based AI explanation presented|Participants in this arm will be shown standard AI model predictions during 3 patient clinical vignettes within the survey and systematically biased AI model predictions during 3 clinical vignettes. When shown systematically biased AI model predictions, the model will be biased against COPD, always predicting that COPD is present with high likelihood when a pre-processing filter was applied to the patient's X-ray. Standard predictions will be shown for the other 2 diagnoses. Participants in this arm will also be shown AI explanation when shown AI model predictions.
89490540|NCT06098937|Experimental|Kalifilcon A Daily Disposable Toric|Kalifilcon A Daily Disposable Toric
89490541|NCT06098937|Active Comparator|Total1 for Astigmatism|Total1 for Astigmatism
89490542|NCT06098937|Active Comparator|Precision1 for Astigmatism|Precision1 for Astigmatism
89490543|NCT06098937|Active Comparator|MyDay Toric|MyDay Toric
89490544|NCT06098898|Experimental|Group A (low-dose NK510 monotherapy)|NK510 9×10^9 NK cells/dose.
89021996|NCT00447642|Placebo Comparator|Placebo 0.75 inch implant|Silicone implant not containing cyclosporine A, 0.75 inch in length
89021997|NCT00344123|Other|Tipranavir/ritonavir|"On Day 1, subjects will receive a single 10 mg dose of rosuvastatin.~Beginning on Day 3, subjects will receive a combination of TPV 500mg/RTV 200 mg twice daily for 11 days (Days 3-13).~On Day 12, subjects will receive a single 10 mg dose of rosuvastatin co-administered with TPV/r."
89490545|NCT06098898|Experimental|Group B (low-dose NK510 combined mAbs)|NK510 9×10^9 NK cells/dose. PD-1 blockade or anti-HER2 mAbs.
89490546|NCT06098898|Experimental|Group C (high-dose NK510 combined mAbs)|NK510 12×10^9 NK cells/dose. PD-1 blockade or anti-HER2 mAbs.
89490547|NCT06098885||extraction treatment|patients treated with bilateral upper first premolar extraction orthodontic treatment with moderate anchorage.
89490548|NCT06098885||distalization treatment|patients treated by distalization orthodontic treatment.
89490549|NCT06098859|Active Comparator|Thoracic epidural analgesia|Thoracic epidural analgesia have been started preoperatively and coninuoed until postoperative 48 hours
89490550|NCT06098859|Active Comparator|Erector spinae plane block|Erector spinae plane blockwas applied preoperatively
89490551|NCT06098859|No Intervention|Intravenous opioid analgesia|Intravenous opioid analgesia was administered during the surgery
89490552|NCT06098833|Active Comparator|Sildenafil|Sildenafil per os twice a day for seven consecutive days (from day 2 of life to day 9 of life) if brain injury on day 2 of life (dose 1=2mg/kg/dose, dose 2=2.5mg/kg/dose, and doses 3-14=3mg/kg/dose)
88953671|NCT01964404|Placebo Comparator|Placebo cigarette and placebo capsule|Placebo cigarette (for marijuana) smoked immediately prior to the second functional MRI and a placebo capsule (for dronabinol) by mouth taken approximately 2.75 hours prior to the second functional MRI.
88953672|NCT01964417|Active Comparator|4L-split Dose of PEG Solution|4L-split Dose of PEG Solution for bowel preparation
88953673|NCT01964417|Active Comparator|Low-volume PEG Plus Ascorbic Acid|Low-volume PEG Plus Ascorbic Acid for bowel preparation
88953674|NCT01964443||all included patients|Men and women, 18 years of age and older, who have had the onset of the first symptoms of plaque psoriasis less than 10 years before study entry, are naïve or experienced to topical treatment, and are eligible for phototherapy or systemic treatment
88953675|NCT01964456|Active Comparator|Patients|Patients suffering of anorexia
89490553|NCT06098833|Placebo Comparator|Ora-Blend|Ora-Blend per os twice a day for seven consecutive days (from day 2 of life to day 9 of life) if brain injury on day 2 of life (dose 1=2mg/kg/dose, dose 2=2.5mg/kg/dose, and doses 3-14=3mg/kg/dose)
89490554|NCT06098820|Experimental|Group 1 (UV-C mushroom+normal bread group)|UV-C mushroom+normal bread group
89490555|NCT06098820|Experimental|Group 2 (UV-C mushroom + UV-C bread group)|UV-C mushroom + UV-C bread group
89490556|NCT06098820|Experimental|Group 3 (normal mushroom + normal bread group)|normal mushroom + normal bread group
89490557|NCT06098820|Experimental|Group 4 (normal mushroom+normal bread+supplemente group)|normal mushroom + normal bread + supplement group
89490558|NCT06098794|Experimental|Sodium Bicarbonate - Placebo|First exercise performance assessment after ingesting sodium bicarbonate. Second exercise performance assessment after ingesting placebo
89490559|NCT06098794|Experimental|Placebo - Sodium Bicarbonate|First exercise performance assessment after ingesting placebo. Second exercise performance assessment after ingesting sodium bicarbonate
89490560|NCT06098768|Other|Floreo BSC|Subjects and their caregiver will engage in the Floreo VR Building Social Connections VR sessions: three sessions per week, for 12 weeks. Each session will consist of 2 VR (Floreo BSC) lessons separated by a brief break, for a total of approximately 15 minutes of direct VR time over a 30-minute period. Treatment sessions will be scheduled over a 12-week period, with an allowance of up to 15 weeks for make-up sessions (e.g., illness or travel).
89490561|NCT06098703|Experimental|CARD (multi-faceted intervention)|CARD will be integrated in the pharmacy vaccination process. This includes education, environment (e.g., clinic spaces), engagement (interactions), and evaluation (surveys/feedback).
88953676|NCT01964456|Placebo Comparator|Control|Subjects controls (not suffering of anorexia)
88953677|NCT01964469|Placebo Comparator|Written self-management action plan|Usual Care: Evidence-based best practice within the primary care asthma program including written self-management action plan and regular clinical review.
88953678|NCT01964469|Experimental|mobile & web based action plan|Evidence-based best practice within the primary care asthma program, replacing the written action plan with the Breathe mobile health and web-based application.
88953679|NCT01964469|No Intervention|Administrative data set|Health services use will be evaluated comparatively against our intervention population and our control and we will include health services utilization data from one year prior randomization.
89490562|NCT06098703|No Intervention|Control (standard care)|There are no specific procedures being undertaken to plan or execute vaccine clinics. Usual practices will be instituted by participating pharmacies.
89490563|NCT06098209|Experimental|Group D (Dexmedetomidine)|Patient will receive dexmedetomidine 0.2-1.4 μg/kg/h. Patients will be randomized to receive dexmedetomidine intravenously at rates of 0.2-1.4 μg/kg/h and 0.3-4 mg/kg/h for 2 days, respectively, to maintain the Richmond Agitation-Sedation Scale (RASS) within the range of +1 to -2.
88953680|NCT01964482|Experimental|Strength training|Supervised strength training daily during hospitalization and 3 times per week for 4 weeks after discharge in the participant's home
88953681|NCT01964482|No Intervention|Usual care|Usual care
88953682|NCT01964534|Active Comparator|ARM 1 ABI-007 + Gemcitabine|ABI-007 : 125mg/m² IV / 30min (day 1, day 8, day 15) Gemcitabine : 1000mg/m² IV /30 min (day 1, day 8, day 15) One cycle every four weeks treatment until progression or limiting toxicity
88953683|NCT01964534|Experimental|Arm 2 ABI-007 + simplified LV5FU2|ABI-007 : 125mg/m² IV /30 min (day 1, day 15) folinic acid : 400mg/m² IV /2h (day 1, day 15) Bolus 5-FU : 400mg/m² IV /15min 5-FU infusion : 2400mg/m² IV / 46h (day 1-2, day 15-16) One cycle every four weeks Treatment until progression or limiting toxicity
88953684|NCT01964573|Experimental|Rotigotine group|
88953685|NCT01964573|Placebo Comparator|Placebo group|Placebo matched to rotigotine will be administered in the same way as within the Rotigotine group.
88953686|NCT01964586|Active Comparator|Lidocaine plus Adrenaline|Lidocaine and adrenaline diluted to 10 ml with normal salin and infiltrated to both side of the nasal septum before 10 minutes from the surgery.
88953687|NCT01964586|Active Comparator|Dexmedetomidine|2 mcg/kg dexmedetomidine diluted to 10 ml with normal salin and infiltrated to both side of the nasal septum before 10 minutes the surgery.
89490564|NCT06098209|Experimental|Group P (Propofol)|Patient will receive propofol 0.3-4 mg/kg/h. Patients will be randomized to receive propofol intravenously at rates of 0.2-1.4 μg/kg/h and 0.3-4 mg/kg/h for 2 days, respectively, to maintain the Richmond Agitation-Sedation Scale (RASS) within the range of +1 to -2.
89490565|NCT06098105|Active Comparator|Ultrasound-guided transversus abdominis plane block|This group will receive Ultrasound-guided transversus abdominis plane block by using 1 ml/kg of bupivacaine 0.25% with a maximum volume of 20 mL as a control group.
89490566|NCT06098105|Experimental|Laparoscopic-assisted transversus abdominis plane block|Patients will receive Laparoscopic-assisted transversus abdominis plane block by using 1 ml/kg of bupivacaine 0.25% with a maximum volume of 20 mL.
88953688|NCT01964599|Other|PF-RS|14 days consuming the PF-RS containing 30 g fiber and then 14 days consuming the control containing no fiber
88953689|NCT01964599|Other|PF-RO1|14 days consuming the PF-RO1 containing 30 g fiber and then 14 days consuming the control containing no fiber
88953690|NCT01964599|Other|PF-RO2|14 days consuming the PF-RO2 containing 30 g fiber and then 14 days consuming the control containing no fiber
88953691|NCT01964625|Experimental|PET-CT|Patients who have a negative routine PET-CT evaluation followed by onset and confirmation in accordance with NIH guidelines, will receive another PET-CT scan prior to initiation of therapy for chronic GvHD.
88953692|NCT01964638|Other|Targeted Biopsy|Men being evaluated for prostate cancer based upon standard of care clinical parameters (e.g. elevated PSA levels, abnormal DRE, mpMRI) will be considered for enrollment. Men who have undergone prostate mpMRI that has revealed an area(s) of suspicion for prostate cancer are eligible for enrollment. All men enrolled in the study undergo fusion targeted biopsy, visual estimation biopsy, and systematic biopsy. As a result the study includes a single arm with direct comparison of biopsy techniques.
88953693|NCT01964651|Experimental|Cohort A (Part 1)|Healthy male participants, 18 to 55 years of age.
88953694|NCT01964651|Experimental|Cohort B (Part 1)|Healthy male participants, 18 to 55 years of age.
88953695|NCT01964651|Experimental|Cohort C (Part 2)|Healthy female participants of nonchildbearing potential (surgically sterile or postmenopausal), 18 to 58 years of age.
88953696|NCT01964651|Experimental|Cohort D (Part 2)|Healthy elderly male or female participants, from 65 to 85 years of age.
88953697|NCT01964664|Experimental|Mindfulness meditation training|6-week, one-on-one, mindfulness meditation intervention based on Mindfulness-Based Cognitive Therapy program
89490567|NCT06098105|Experimental|Laparoscopic-assisted intraperitoneal instillation|This group will receive Laparoscopic-assisted intraperitoneal instillation by using 1 ml/kg of bupivacaine 0.25% with a maximum volume of 20 mL will be instilled into the peritoneal cavity immediately after gas insufflation.
89490568|NCT06097962|Experimental|Group A (low-dose group)|"NK510 will be administered once a week for a total of six weeks.1×10^9 NK cells/dose.~PD-1 blockade will be administered every 3 weeks."
89490569|NCT06097962|Experimental|Group B (medium-dose group)|"NK510 will be administered once a week for a total of six weeks.9×10^9 NK cells/dose.~PD-1 blockade will be administered every 3 weeks."
89490570|NCT06097962|Experimental|Group C (high-dose group)|"NK510 will be administered once a week for a total of six weeks.12×10^9 NK cells/dose.~PD-1 blockade will be administered every 3 weeks."
89490571|NCT06097416|Active Comparator|Neoadjuvant chemoradiotherapy|The NARCT regimen is prescribed specifically as standard 5-FU over several weeks. The CRT regimen consists of the standard algorithms: a total of 5400-5600 cGy of radiation (4500 cGy to the pelvis, with an integrated boost to the primary tumour and involved nodes of 500 cGy followed by an option boost to the primary tumour and involved nodes) delivered in 27-28 fractions, respectively, of 180-200 cGy each over a 5-6 week period.
89490572|NCT06097416|Active Comparator|Total Neoadjuvant Therapy|Sequence of TNT regimen can be classified as induction (chemotherapy first) or consolidation (radiation first) treatment. All patients received the same chemotherapy (FOLFOX) and long-course chemoradiotherapy (50.4 Gy in 28 fractions) before surgery. However timing of TNT can differ depending on concerns of local and distal failure.
89490573|NCT06097039||NAFLD subjects group|The group including 50 cases with NAFLD, the diagnosis was based on abdominal U/S and Fibroscan with CAP with or without elevated liver enzymes
89490574|NCT06097039||Healthy subjects group|The group including 50 healthy subjects as a control group with normal liver in transabdominal ultrasonography and normal liver enzymes
89490575|NCT06096610|Experimental|Resistance exercise training|Participants undergo 24 sessions of resistance exercise training over about 8 weeks.
89490576|NCT06096610|No Intervention|Control|Participants do not perform resistance exercise training.
89490577|NCT06096298|Active Comparator|Vitamin B12 bread|Daily dose of bread containing B12 (15 µg of vitamin B12/d) and placebo tablet (0 µg of vitamin B12/d) for 2 consecutive days.
89490578|NCT06096298|Active Comparator|Positive control|Daily dose of control bread (0 µg of vitamin B12/d and B12 tablet (15 µg of vitamin B12/d) for 2 consecutive days.
89490579|NCT06096298|Placebo Comparator|Negative control|Daily dose of control bread (0 µg of vitamin B12/d and placebo tablet (0 µg of vitamin B12/d) for 2 consecutive days.
89490580|NCT06096142|Experimental|AVF Treatment|Participants on dialysis via AV fistula will be treated with percutaneous transluminal angioplasty (PTA) followed by Solaris DE implantation.
89490581|NCT06096142|Sham Comparator|AVF Control|Participants on dialysis via AV fistula will be treated with percutaneous transluminal angioplasty (PTA) alone.
89021998|NCT00453960|Experimental|Genistein|Genistein 54 mg/day
89490582|NCT06096142|Experimental|AVG Treatment|Participants on dialysis via AV graft will be treated with percutaneous transluminal angioplasty (PTA) followed by Solaris DE implantation.
89490583|NCT06096103|Placebo Comparator|Placebo|Take the test treatment once a day with food
89490584|NCT06096103|Experimental|Botanical Extract Standardised for Iron + Vitamin C|The botanical extract standardised for iron and vitamin c is specially formulated for iron deficiency anaemia or anaemia. Vitamin C can promote the Iron absorption
89490585|NCT06096103|Experimental|Botanical Extract Standardised for Iron|The botanical extract standardised for iron is formulated for iron deficiency anaemia or anaemia
89490586|NCT06095999|Experimental|'Perfect Fit' virtual coaching intervention|Due to the single-arm design, all participants will receive the Perfect Fit intervention, a personalized eHealth intervention that supports them to stop smoking and increase their PA using a virtual coach (i.e., chatbot).
89490587|NCT06093841|Experimental|Relmacabtagene Autoleucel|Experimental: Relmacabtagene Autoleucel Participants will receive cyclophosphamide250 mg/m^2/day intravenously (IV) and fludarabine 25 mg/m^2/day IV conditioning chemotherapy for 3 days followed by Relmacabtagene Autoleucel administered as a single IV infusion at a target dose of 1 x 10^8 anti-cluster of differentiation (CD)19 chimeric antigen receptor (CAR) transduced autologous T cells on Day1.
89490588|NCT06093334|Experimental|Early therapeutic effects|Diagnosed acute lymphatic leukemia or Hodgkin's disease (HD) and completed induction therapy or radiotherapy, from 5 years to <18 years
89490589|NCT06093334|Experimental|Late therapeutic effects|Diagnosed acute lymphatic leukemia or Hodgkin's disease (HD) and completed intensive therapy or radiotherapy, Patient in follow-up care, from 5 years to <18 years
89490590|NCT06093334|Experimental|Effects of hematopoietic stem cell transplantation|Diagnosed acute lymphatic leukemia, completed hematopoietic stem cell transplantation, from 5 years to <18 years
89490591|NCT06093178||Residents of Athy, Co. Kildare|Anyone who lives, works or plays in Athy and the surrounding 5 Km who is over 18 years is invited to take part.
89490592|NCT06091917|Sham Comparator|Control group|Use of unmodified infant formula for 12 weeks
89490593|NCT06091917|Experimental|Betaine supplementation group|Use of infant formula supplemented with betaine (final concentration of 100 µmol/L) for 12 weeks
89490594|NCT06091501|Experimental|Lev Livet|The participants will receive the 9 weeks of Lev Livet intervention
89490595|NCT06091501|No Intervention|Lev Livet control|The participants will attend 5 months of waiting list
89490596|NCT06091501|Experimental|Lev Livet + HiiT|The participants will receive the 9 weeks of Lev Livet intervention AND 9 weeks of HiiT training
89490597|NCT06091501|No Intervention|Lev Livet + HiiT control|The participants will attend 5 months of waiting list
89490598|NCT06086470|Experimental|Experimental Treatment Arm|Patients will receive one treatment of hemodialysis through the Qidni/D Hemodialysis System.
89490599|NCT06077344||Wide - Awake Local Anesthesia No Tourniquet|"WALANT solution used in our institution is prepared by mixing 20 ml of 2% lidocaine, with 0,4 ml 1:1000 (1 mg/ml) adrenaline in addition to 20 ml of 0,9% normal saline as described by Barros~In the study, perop parameters to be checked are perop Visual Analogue Scale (VAS; at regular intervals (every 15 minutes, etc.) VAS evaluation, the highest value will be recorded), the time spent in the operating room~Early postoperative parameters; Morphine consumption in PCA (in PCA device) the amount of morphine used in the postoperative 24 hours), the postoperative VAS (the postoperative 24th hour VAS) evaluation;)."
89490600|NCT06077344||Applied Under Spinal Anesthesia|"Applied Under Spinal Anesthesia~Early postoperative parameters; Morphine consumption in PCA (in PCA device) the amount of morphine used in the postoperative 24 hours), the postoperative VAS (the postoperative 24th hour VAS) evaluation;)."
89490601|NCT06077266||Normalizing weight|Children classified as having normalized weight (iso-BMI 18.5-25 for age and sex) at the last observation defined by IOTF.
89490602|NCT06077266||Overweight or obesity|Children classified as having overweight or obesity (iso-BMI 25 ≤ for age and sex) at the last observation defined by IOTF.
88953698|NCT01964664|Active Comparator|Audio Group|6 weeks of listening to podcasts daily (same length as guided meditations), and discussing podcast content with research assistant during weekly study visits
88953699|NCT01964677|Experimental|MR-HIFU of painful bone metastases|
89490603|NCT06073600|Experimental|First group of healthy volunteers|The first group of healthy volunteers, defined by randomization
89021999|NCT00453960|Active Comparator|Norethisterone Acetate|Norethisterone Acetate 10mg/day
89490604|NCT06073600|Active Comparator|Second group of healthy volunteers|The second group of healthy volunteers, defined by randomization
89490605|NCT06069843|Experimental|Treatment|Single dose of IV ketamine administered at the standard dose used for depression treatment (0.5 mg/kg)
89490606|NCT06066320|Experimental|MMST|
89490607|NCT06066320|Active Comparator|TSST|
89490608|NCT06064656||Sub-Cohort 1|All patients with active enrollment (closed claims) during part or all the study period.
89490609|NCT06064656||Sub-Cohort 2|All patients with active enrollment (closed claims) augmented with open claims
89490610|NCT06059222|Active Comparator|Group 1 - ROMO 12 months, ZOL 12 months|90 patients 12 months of romosozumab (ROMO) followed by 12 months of zoledronate (ZOL)
89490611|NCT06059222|Active Comparator|Group 2 - ROMO 6 months, ZOL 12 months, ROMO 6 months|90 patients 6 months of romosozumab followed by 12 months of zoledronate and lastly 6 months of romosozumab.
89490612|NCT06059222|Active Comparator|Group 3 - ROMO 6 months, ZOL 18 months|"90 patients 6 months of romosozumab followed by 18 months of zoledronate~."
89490613|NCT06053450|Experimental|Essential Oil Ptach|The nursing staff will wear an essential oil patch for 2 weeks.
89490614|NCT06043141||Patients with carpal tunnel syndrome|Patients with carpal tunnel syndrome
89490615|NCT06041997|Experimental|Smartphone restriction|"Patients with headache with history of high smartphone use will be randomized into restriction and no-restriction arm.~Restriction method:~In the 'run-in' period of four weeks, the smartphone usage will be assessed in terms of number of overall use. The patients will then be advised to cut down the usage by one-third in terms of usage hours. The compliance will be checked at the time of outcome assessment."
89490616|NCT06041997|No Intervention|Control|"Comparison:~In the 'run-in' period of four weeks, the smartphone usage will be assessed in terms of number of overall use. In the non-intervention group only the smartphone usage data will be collected in the study period. The non-smartphone users will be as another control arm."
89490617|NCT06031844|Experimental|Treatment Sequence 1|Participants will be administered Placebo and different doses of DFV890
88953700|NCT01964703|Placebo Comparator|control|
88953701|NCT01964703|Active Comparator|Rubus occidentalis extract 900mg|taking Rubus occidentalis extract 900mg/day for 12weeks
88953702|NCT01964703|Active Comparator|Rubus occidentalis extract 1800mg|taking Rubus occidentalis extract 1800mg/day for 12weeks
88953703|NCT01964729|Sham Comparator|Sham rTMS|Sham Comparator: For the placebo-controlled condition, we will use the same TMS equipment coupled with a placebo coil that produces the same active sound produced by the active coil.
88953704|NCT01964729|Experimental|Transcranial Magnetic Stimulation|We will deliver high frequency rTMS at 10 Hz rate was over right M1 in sessions consisting of of 4 seconds of stimulation followed by 26 second intervals, with a total of 1600 pulses per session.
88953705|NCT01964742|Experimental|HIV-HCV co-infected patients|
88953706|NCT01964781|Experimental|topical tranexamic acid|tranexamic acid to be smeared on surgical wounds before closure
88953707|NCT01964781|Experimental|topical adrenaline|adrenaline solution to be smeared on surgical wounds before closure
88953708|NCT01964781|Experimental|topical bupivacaine|bupivacaine to be smeared on surgical wounds before closure
88953709|NCT01964781|Experimental|topical adrenaline plus tranexamic acid|tranexamic acid and adrenaline to be smeared on surgical wounds before closure
88953710|NCT01964781|Placebo Comparator|placebo control|saline to be smeared on surgical wounds before closure
88953711|NCT01964781|Placebo Comparator|tranexamic acid and placebo control|tranexamic acid and saline to be smeared on surgical wounds before closure
88953712|NCT01964820|Experimental|Positive affect skills intervention|Participants receive a 5-week intervention providing training in 8 skills for generating positive affect.
89490618|NCT06031844|Experimental|Treatment sequence 2|Participants will be administered Placebo and different doses of DFV890
89490619|NCT06031844|Experimental|Treatment sequence 3|Participants will be administered different doses of DFV890
89490620|NCT06031844|Placebo Comparator|Treatment sequence 4|Participants will be administered Placebo
89490621|NCT06028139|Experimental|Intervention|
89490622|NCT06028139|Other|Control|
89490623|NCT06019611|Experimental|Percutaneous Epidural Stimulation|Epidural spinal stimulation will be delivered via percutaneously implanted electrodes during rehabilitation. All implanted electrodes will be removed at the end of trial participation. The effects of epidural stimulation will be recorded via electrophysiological and biomechanical metrics described within the outcomes measures.
89490624|NCT06017947|No Intervention|standard process|
89490625|NCT06017947|Experimental|Musical intervention|
89490626|NCT06016075|Other|Hyperpolarised MRI|Hyperpolarised 13C-pyruvate injection while laying in the MRI scanner. Non-radioactive, no risk, approved for use in humans.
89537943|NCT04978623||Patient with Anti-MAG|Anti-MAG is a demyelinating neuropathy characterized clinically by a chronic progressive distal and symmetrical predominantly sensory involvement. This neuropathy belongs to the group of symmetrical acquired demyelinating neuropathies (Distal Acquired Demyelinating Neuropathy (DADS)) which is distinguished from PIDC by: 1. an essentially distal and rather sensitive clinical involvement (unlike PIDC which is proximal and distal with predominantily motor involvement); 2. a strong association with a monoclonal gammopathy of the IgM type (67% of DADS vs 22% of PIDC according to Katz et al, 3. a poor therapeutic response to first line of immunosuppressive drugs (in contrast to PIDC which generally responds well). Certain electrophysiological parameters, such as the demonstration of demyelinating damage with accentuated slowing of distal nerve conduction, make it possible to distinguish anti-MAG neuropathy from CIDP.
88953713|NCT01964820|No Intervention|Emotion reporting|Participants report emotions on the same regular basis as intervention participants, but receive no intervention.
88953714|NCT01964833|Sham Comparator|Periodontal treatment|Conventional periodontal treatment with hygiene orientation, calculus removal and root scaling and planing. Sham PDT.
89537944|NCT04978623||Patient with L-S|Lewis-Sumner syndrome is an acquired demyelinating polyradiculoneuritis characterised by distal asymmetric upper and lower limb weakness and motor dysfunction that develops in adulthood. It is considered a variant of chronic inflammatory demyelinating polyradiculoneuritis. It has a prevalence of 1-9 per 1,000,000. The diagnosis is made with electroneuromyography (ENMG) which shows marked and persistent conduction blocks, in at least two nerves, having an asymmetric topography, mainly affecting the upper limb, outside the usual areas of compression. Lower limb blocks are much rarer (anterior tibial nerve), and are always located below the fibular neck.
89537945|NCT03107507|Active Comparator|Levetiracetam|"Levetiracetam given in oral form via oro-gastric tube, first a bolus dose 40-50mg/kg then maintenance dose 10-30 mg/kg/day divided every 12 hours.~Duration: until seizure free"
89537946|NCT03107507|Active Comparator|Phenobarbital|"Phenobarbital given in IV form, loading dose 20mg/kg that can be repeated after a 20 minute interval not to exceed 40mg/kg then maintenance dose 2-4 mg/kg/day divided every 12 hours.~Duration: until seizure free"
89537947|NCT04978935|No Intervention|Control group|In the control group (n=40), interventions for the position, mobilization and spirometry of the patient are applied to all patients in the clinic where the study was conducted. However, these applications are not made in accordance with a certain order and protocol. Shoulder exercises are not routinely taught to patients. In the study, no additional application will be made to the control group other than the routine treatment and care practice of the clinic.
89204416|NCT05330494|Experimental|S1|TEAS treatment initiated at 30 minutes before induction and lasted for 30min,TEAS treatment(disperse-dense waves; frequency, 2/100 Hz)on acupoints Hegu(LI4) , Neiguan(PC6) and Zusanli（ST 36）of both sides, and the present intensity(8～12 mA) was the maximum current that could be tolerated.Then, the TEAS treatment was administered twice a day (once in the morning and once in the afternoon) on the first and second postoperative day, which lasted for 30 minutes each time.
89204417|NCT05330494|Experimental|S2|TEAS treatment initiated immediately after induction and stopped at the end of surgery,TEAS treatment(disperse-dense waves; frequency, 2/100 Hz)on acupoints Hegu(LI4) , Neiguan(PC6) and Zusanli（ST 36）of both sides, and the present intensity(8～12 mA) was the maximum current that could be tolerated.Then, the TEAS treatment was administered twice a day (once in the morning and once in the afternoon) on the first and second postoperative day, which lasted for 30 minutes each time.
88953715|NCT01964833|Experimental|Periodontal Treatment and PDT|Conventional periodontal treatment with hygiene orientation, calculus removal, root scaling and planing. Active PDT with diode laser and methylene blue photosensitizer
88953716|NCT01964846|Experimental|Resveratrol, curcumin|Subjects will take 2 capsules of resveratrol and curcumin. Thirty (30) minutes later, subjects will be given an oral lipid tolerance test in the form of a fat-rich meal. Blood samples will be collected at different time points.
88953717|NCT01964846|Placebo Comparator|Placebo|Subjects will take 2 capsules of Placebo. Thirty (30) minutes later, subjects will be given an oral lipid tolerance test in the form of a fat-rich meal. Blood samples will be collected at different time points.
88953718|NCT01964872|Experimental|JNJ-38877618|
88953719|NCT01964872|Placebo Comparator|Placebo|
88953720|NCT01964885|Active Comparator|IQP-AS-105|One tablet daily
88953721|NCT01964885|Placebo Comparator|Placebo|One tablet daily
88953722|NCT01964911|Experimental|Ropivacaïne|
88953723|NCT01964937|Experimental|Group 1|"At Months 0 and 1, participants in Group 1 will receive one injection of AIDSVAX B/E ® administered intramuscularly (IM) in the right deltoid and two injections of placebo vaccine administered IM in the left deltoid.~At Months 3 and 6, participants will receive two injections of NYVAC vaccine (NYVAC-HIV-PT1 and NYVAC-HIV-PT4) administered IM in the left deltoid and one injection of placebo vaccine administered IM in the right deltoid."
88953724|NCT01964937|Experimental|Group 2|"At Months 0 and 1, participants in Group 2 will receive two injections of NYVAC vaccine (NYVAC-HIV-PT1 and NYVAC-HIV-PT4) administered IM in the left deltoid and one injection of placebo vaccine administered IM in the right deltoid.~At Months 3 and 6, participants will receive the AIDSVAX ® B/E vaccine administered IM in the right deltoid and two injections of placebo vaccine administered IM in the left deltoid."
89022000|NCT00453960|Placebo Comparator|Placebo|Placebo tablets, daily
89204418|NCT05330494|Experimental|S3|TEAS treatment initiated immediately after extubating and lasted for 30 minutes,TEAS treatment(disperse-dense waves; frequency, 2/100 Hz)on acupoints Hegu(LI4) , Neiguan(PC6) and Zusanli（ST 36）of both sides, and the present intensity(8～12 mA) was the maximum current that could be tolerated.Then, the TEAS treatment was administered twice a day (once in the morning and once in the afternoon) on the first and second postoperative day, which lasted for 30 minutes each time.
89490627|NCT06016075|Other|Sodium MRI|MRI procedure as a regular MRI scan, the only change is us using a different sort of equipment so we are able to detect sodium.
89204419|NCT05330494|Sham Comparator|control|the control group was given all manipulations without electrical stimulation, electrodes were placed on the same acupoints, but no current was given
88953725|NCT01964937|Experimental|Group 3|"At Months 0 and 1, participants in Group 3 will one injection of the AIDSVAX B/E vaccine administered IM in the right deltoid and one injection of placebo vaccine administered IM the left deltoid.~At Months 3 and 6, participants will receive one injection of the DNA-HIV-PT123 vaccine administered IM in the left deltoid and one injection of placebo vaccine administered IM in the right deltoid."
88953726|NCT01964937|Experimental|Group 4|"At Months 0 and 1, participants in Group 4 will receive one injection of the DNA-HIV-PT123 vaccine administered IM in the left deltoid and one injection of placebo vaccine administered IM in the right deltoid.~At Months 3 and 6, participants will receive one injection of the AIDSVAX B/E ® vaccine administered IM in the right deltoid and one injection of placebo vaccine administered IM the left deltoid."
88953727|NCT01964937|Experimental|Group 5|At Months 0, 1, 3, and 6, participants in Group 5 will receive one injection of the DNA-HIV-PT123 vaccine administered in the left deltoid and one injection of the AIDSVAX B/E ® vaccine administered IM in the right deltoid.
88953728|NCT01965015|Experimental|V-Wave shunt implant|Implantation of the V-Wave inter-atrial shunt
88953729|NCT01965028|Experimental|Transcranial random noise stimulation (tRNS)|High frequency tRNS (Neuroconn, Eldith DC-Stimulator Plus): 100-650Hz, 2mA, 20min, 10s ramp time, left and right auditory cortex, 5x7cm electrode with the inferior middle part over T3/T4
89490628|NCT06016075|Other|Deuterium metabolic imaging (DMI) MRI|Drink of a sugar drink 90min before the MRI scan. Non-radioactive, no risk, approved for use in humans.
89490629|NCT06014099|Experimental|Midline catheter|The test group2 used MC for blood collection.
89490630|NCT06014099|Experimental|Long peripheral venous catheters|In the test 1 group, blood was collected using LPC.
89490631|NCT06014099|Other|short peripheral venous catheters|In the control group,blood was collected using SPC.
89490632|NCT06013722|Experimental|Patients of groups III and IV|Patients who are categorized after calcium score determination as presenting an intermediate risk to produce atheromatous plaques (group III : between the 40th percentile and the 65th percentile) or presenting a high risk to produce such plaques (group IV: >65th percentile).
89490633|NCT05994378|Experimental|Experimental group|
89490634|NCT05994378|Active Comparator|Control group|
89490635|NCT05978739|Experimental|Orelabrutinib high dose|
89490636|NCT05978739|Experimental|Orelabrutinib low dose|
89490637|NCT05978583|Other|physical and occupational therapy|Physical and occupational therapy consultation might be used to provide targeted prehabilitation interventions.
89490638|NCT05964907|Other|VL+UVA1|Participants will be treated with VL + UVA1 light source
89490639|NCT05959200|Other|LID226397, then AOfAHP|Serafilcon A toric contact lenses worn in Period 1, with senofilcon A toric contact lenses worn in Period 2. Each product will be worn bilaterally (in both eyes) during waking hours for approximately 14 days. CLEAR CARE will be used for nightly contact lens cleaning and disinfection.
89490640|NCT05959200|Other|AOfAHP, then LID226397|Senofilcon A toric contact lenses worn in Period 1, with serafilcon A toric contact lenses worn in Period 2. Each product will be worn bilaterally (in both eyes) during waking hours for approximately 14 days. CLEAR CARE will be used for nightly contact lens cleaning and disinfection.
89490641|NCT05939388|Experimental|Auricular Acupressure Pad Group|All subjects who qualify and agree to be in the study will be given Auricular Acupressure using an acupressure pad containing acupressure seeds for 4 days in addition to their regular standard of care pain medication.
89490642|NCT05929768|Active Comparator|Arm I (usual chemo-immunotherapy)|Patients receive paclitaxel IV, carboplatin IV, and pembrolizumab IV on study. Patients then receive doxorubicin IV, cyclophosphamide IV, and pembrolizumab IV on study. Patients then undergo surgery. Patients may receive pembrolizumab after surgery. Patients may optionally undergo collection of blood samples throughout the trial.
89490643|NCT05929768|Experimental|Arm II (shorter chemo-immunotherapy)|Patients receive docetaxel IV, carboplatin IV, and pembrolizumab IV on study. Patients then undergo surgery. Patients may receive pembrolizumab after surgery. Patients may optionally undergo collection of blood samples throughout the trial.
89490644|NCT05928741|Experimental|Orange juice with vitamin D3, n-3 fatty acids, and probiotics as preload|Twenty-three healthy adults with normal weight and twenty-three healthy adults with overweight consumed a standardized breakfast after a 12-hour fast. Two hours later they were given 50 g of available carbohydrates from the two preloads (enriched orange juice or control orange juice) in a random order, and 3 hours after the preload they were offered an ad libitum lunch. Foods were weighed at the time of serving and any leftovers were weighed again after lunch to determine the amount of food consumed. There was a washout period of at least one week between the two visits. Fingertip capillary blood glucose samples were collected at baseline and at several time points after food intake. Visual analog scales (VAS) of 100 mm were collected to assess subjective appetite. Blood pressure was measured at several time-points.
89490645|NCT05928741|Experimental|Control orange juice without vitamin D3, n-3 fatty acids, and probiotics as preload|Twenty-three healthy adults with normal weight and twenty-three healthy adults with overweight consumed a standardized breakfast after a 12-hour fast. Two hours later they were given 50 g of available carbohydrates from the two preloads (enriched orange juice or control orange juice) in a random order, and 3 hours after the preload they were offered an ad libitum lunch. Foods were weighed at the time of serving and any leftovers were weighed again after lunch to determine the amount of food consumed. There was a washout period of at least one week between the two visits. Fingertip capillary blood glucose samples were collected at baseline and at several time points after food intake. Visual analog scales (VAS) of 100 mm were collected to assess subjective appetite. Blood pressure was measured at several time-points.
88953730|NCT01965041|Experimental|Eyelea, ophthalmic exam, photgraphy|2.0 mg intravitreal aflibercept injection is formulated as a sterile liquid to a final concentration of 40 mg/mL aflibercept in 5% sucrose, 10 mM sodium phosphate pH 6.3, 0.03% polysorbate 20, and 40 mM NaCl
89490646|NCT05911620|Experimental|Cushing's Syndrome|Patients with proven autonomic cortisol secretion (Cushing's Syndrome)
89490647|NCT05911620|Experimental|Suspected Cushing's Syndrome|Patients with possible autonomic cortisol secretion (Suspected Cushing's Syndrome)
89490648|NCT05911620|Active Comparator|Metabolic Syndrome|Patients with metabolic syndrome
89490649|NCT05905328|Experimental|CTO1681 30 μg Total Daily Dose|Participants receive 10 μg CTO1681 orally 3 times daily (total daily dose of 30 μg) for 15 days.
89490650|NCT05905328|Experimental|CTO1681 60 μg Total Daily Dose|Participants receive 20 μg CTO1681 orally 3 times daily (total daily dose of 60 μg) for 15 days.
89490651|NCT05905328|Experimental|CTO1681 90 μg Total Daily Dose|Participants receive 30 μg CTO1681 orally 3 times daily (total daily dose of 90 μg) for 15 days.
89490652|NCT05885191|Experimental|2H intrinsically-labeled T.molitor|1 portion of bread and vegetable soup prepared with dried 2H intrinsically labeled T.molitor and 13C labeled reference amino acid mixture
89490653|NCT05881135|Experimental|IV 1 mg/kg/day Citicoline|i.v. bolus of 10 ml normal saline containing citicoline 1 mg/kg, administered twice daily for 5 days.
89490654|NCT05881135|Experimental|IV 5 mg/kg/day Citicoline|i.v. bolus of 10 ml normal saline containing 5 mg/kg citicoline, administered twice daily for 5 days.
89490655|NCT05881135|Experimental|IV 10 mg/kg/day Citicoline|i.v. bolus of 10 ml normal saline containing 10 mg/kg citicoline, administered twice daily for 5 days.
89490656|NCT05881135|Placebo Comparator|IV 10 ml normal saline|i.v. bolus of 10 ml normal saline (without active ingredient) administered i.v., twice daily for 5 days.
89490657|NCT05876442|Experimental|Group A: ESWT plus HILT in addition to Traditional Physical Therapy Exercise .|patients will receive Extraporeal Shock wave therapy at the area of the wrist for 5 minutes 1 time a week for 2 months, then High-intensity laser therapy at the site of the carpal bones for 5 minutes 2 times a week. Then a program of traditional physical therapy exercises for post-burn carpal tunnel syndrome for 30 minutes of stretching exercise for the wrist and carpal region with the fingers flexed and extended. Followed by strengthening exercises for the wrist flexors, extensors, radial and ulnar deviation muscles. Mobilizing exercise, tendon gliding exercise, and instructed to wear a wrist splint at night.
89490658|NCT05876442|Experimental|Experimental: Group B: ESWT plus Traditional Physical Therapy Exercise .|Patients will receive Extraporeal Shock wave therapy at the area of the wrist for 5 minutes 1 time a week for 2 months, Then a traditional physical therapy exercise program for the post-burn carpal tunnel syndrome for 30 minutes of stretching exercise for the wrist and carpal region with the fingers flexed and extended. They were followed by strengthening exercises for the wrist flexors, extensors, and radial and ulnar deviation muscles. Mobilizing exercise, tendon gliding exercise, and instructed to wear a wrist splint at night
88953731|NCT01965054|Experimental|Fish Oil Supplement Group|Receive the daily DHA pill and given a validated Itching Survey to assess maternal symptoms on admission and then weekly thereafter
88953732|NCT01965054|No Intervention|Control Group|Given a validated Itching Survey to assess maternal symptoms on admission and then weekly thereafter.
88953733|NCT01965080|Experimental|Exemestane|Exemestane 25 mg daily
88953734|NCT01965093||perioperative desaturation|children aged 0-5 years who received general anesthesia and developed perioperative desaturation
88953735|NCT01965093||no perioperative desaturation|children aged 0-5 years who received general anesthesia and did not developed perioperative desaturation
88953736|NCT01965119|Experimental|Ruxolitinib|20 mg orally twice a day for 4 weeks (One cycle) Treatment continued until documented disease progression or unacceptable toxicity.
88953737|NCT01965145|Experimental|Gevokizumab|Solution for subcutaneous injection, Dose 1
88953738|NCT01965145|Placebo Comparator|Placebo|Solution for subcutaneous injection, placebo
88953739|NCT01965210|Experimental|Rye + high dose inulin + low dose gluten|Rye porridge supplemented with a high dose of the fermentable dietary fibre inulin and low dose of the plant protein gluten.
88953740|NCT01965210|Experimental|Rye + equal doses of inulin & gluten|Rye porridge supplemented with equal doses of the fermentable dietary fibre inulin and the plant protein gluten.
88953741|NCT01965210|Experimental|Rye + low dose inulin + high dose gluten|Rye porridge supplemented with a low dose of the fermentable dietary fibre inulin and a high dose of the plant protein gluten.
88953742|NCT01965210|Experimental|Large non-supplemented rye|Large portion of rye porridge without supplements.
88953743|NCT01965210|Experimental|Small non-supplemented rye|Small portion of rye porridge without supplements.
88953744|NCT01965210|Active Comparator|Refined wheat bread|Refined wheat bread.
88953745|NCT01965223|Experimental|Multi-fraction SABR|Radiotherapy: 48Gy delivered in 4 fractions, delivered over 2 weeks, with each fraction delivered 48 hours apart.
88953746|NCT01965223|Experimental|Single fraction SABR|Radiotherapy: 28Gy delivered in 1 fraction
88953747|NCT01965236|Experimental|Group 1|Patients are given 5 pills (1 g per pill) of sodium chloride per day for 6 weeks. After a one-week wash out period, a second period of 6 weeks is started with 5 placebo (microcrystalline cellulose) pills per day.
89490659|NCT05876442|Experimental|Experimental: Group C:HILTplus Traditional Physical Therapy Exercise.|patients will receive High-intensity laser therapy at the area of the carpal bones for 5 minutes 2 times a week for 2 monthes. Then a program of traditional physical therapy exercises for post-burn carpal tunnel syndrome for 30 minutes of stretching exercise for the wrist and carpal region with the fingers flexed and extended. Followed by strengthening exercises for the wrist flexors, extensors, and radial and ulnar deviation muscles. Mobilizing exercise, tendon gliding exercises, and instructed to wear a wrist splint at night
89490660|NCT05876442|Active Comparator|Traditional Physical Therapy Exercise.|patients will receive a program of traditional physical therapy exercise for post-burn carpal tunnel syndrome for 30 minutes of stretching exercise for the wrist and carpal region with the fingers flexed and extended. They were followed by strengthening exercises for the wrist flexors, extensors, and radial and ulnar deviation muscles. Mobilizing exercise, tendon gliding exercise, and instructed to wear a wrist splint at night.
89490661|NCT05867303|Experimental|RC198 Injection|RC198 injection will be administered subcutaneously on Day 1 of Week 1 to Week 4 (inclusive) of each 6-week (42-day) cycle.
89490662|NCT05843149|Experimental|Manual Therapy/Exercises|Three individual therapy sessions and nine group sessions manual therapy/exercises of 60 min. duration under the guidance of a trained therapist.
89490663|NCT05843149|Experimental|Physiotherapy/Back School|Three individual therapy sessions and nine group sessions physiotherapy/back school of 60 min. duration under the guidance of a trained therapist.
89490664|NCT05843149|No Intervention|Waiting List|Study arm 3 consists of a waiting list control group, combined with the offer to participate in one of the above mentioned interventions after 6 months.
89490665|NCT05817617||Head and Neck cancer patients|candidate to receive definitive or adjuvant radiation therapy with bilateral neck irradiation
89490666|NCT05793281||Patients with solid tumor and genome profiling results|Retrospective data analysis, the dataset for this study will be extracted from the C-CAT database.
89490667|NCT05786716|Experimental|Treatment Arm 04: trastuzumab in combination with pertuzumab|This trastuzumab and pertuzumab treatment arm is for adult, TYA and paediatric participants with malignancies with HER2 amplification or activating mutations.
89490668|NCT05781035|Active Comparator|dexmedetomidine group|
89490669|NCT05781035|Active Comparator|general anesthesia group|
89490670|NCT05768802|Experimental|MIRA Device|All participants enrolled in the study and who meet eligibility criteria will be implanted with the MIRA device in their residual limb. There is no control group.
89490671|NCT05768178|Experimental|Treatment Arm 05- Vemurafenib and Cobimetinib|This vemurafenib and cobimetinib appendix is for BRAF V600 mutation-positive malignancies occurring in adults.
89490672|NCT05764824|Active Comparator|Blueberry group|Blueberry arm
89490673|NCT05764824|Placebo Comparator|Control group|Control arm
89490674|NCT05755399|Experimental|Experimental group|Participants scheduled for brain surgery
89490675|NCT05750173||Prospective cohort|100 consecutive patients that are not already diagnosed with severe (≥50%) proximal stenosis of the left anterior descending artery (LAD) OR the left main coronary artery (LM).
89490676|NCT05750173||Retrospective cohort|"50 consecutive patients from the participating centers that already underwent CTA and ICA prior to TAVI will serve as a historical control group."
89490677|NCT05748210|Experimental|Intervention group|Child-caregiver dyads in the intervention group will use the mHealth app for 12 weeks with personalised nurse support via interactive communication technologies. The design of the app will be guided by the theory of unpleasant symptoms.
89490678|NCT05748210|Active Comparator|Wait-list control group|To ensure the equity of access to a potentially desirable and effective intervention (i.e., mHeath app for symptom management), participants in the wait-list control group will be invited to receive the same intervention as participants in the intervention group after the completion of all assessments on a voluntary basis.
89490679|NCT05732909|Experimental|First Ketone, then placebo|Ingestion of ketone monoester D-β-hydroxybutyrate / D 1,3 butanediol monoester on first experimental day and ingestion of a fat placebo drink on the second experimental day.
89490680|NCT05732909|Experimental|First placebo, then ketone|Ingestion of a fat placebo drink on the first experimental day followed by ingestion of ketone monoester D-β-hydroxybutyrate / D 1,3 butanediol monoester on the second experimental day.
89490681|NCT05726838||Inclisiran|Patients prescribed inclisiran on top of standard of care lipid-lowering therapy
89490682|NCT05711979|Experimental|AARC Intervention|Participants in the AARC Intervention Arm will receive a 10 week intervention.
89490683|NCT05710900|Experimental|Low-calorie diet group|A low-calorie diet involving will involve a commercial weight loss program (pre-packaged foods from Ideal Protein, select lean protein sources, non-starchy vegetables) and be led by the pharmacist and registered dietitian (RD) involving in-person and virtual appointments.
89490684|NCT05710900|Experimental|Low-carbohydrate diet group|The low-carbohydrate diet will involve an individualized whole-food diet (30-130 grams carbohydrate per day) led through virtual visits with a registered dietitian.
89490685|NCT05710770|Active Comparator|Immunoadsorption|"Immunoadsorption will be conducted with the TheraSorb LIFE 21 apheresis system in combination with the TheraSorb-Ig omni 5 adsorber over a period of 9-12 days: each participant will receive five immunoadsorption cycles treating 2.0 - 2.5 patient's plasma volumes every other day. Initial pilot studies have demonstrated this dose finding to be effective and well tolerated (Scheibenbogen et al., 2018; Tolle et al., 2020). The immunoapheresis material will be provided by the Miltenyi company at the beginning of the study.~Concerning the high effectiveness of immunoadsorption therapy in patients with other neuroimmunological diseases and the invasiveness of a sham-apheresis, a 2:1 randomization was chosen in order to ensure that more patients will receive a verum IA treatment."
89490686|NCT05710770|Sham Comparator|Sham-apheresis|To have identical conditions to the immunoadsorption, sham apheresis will also be conducted with the TheraSorb LIFE 21 apheresis system over a period of 9-12 days: each participant will receive five sham cycles. For the sham apheresis, a TheraSorb LIFE 21 unit with blocked Ig adsorbers and without regeneration of the adsorbers during the treatment will be used, ensuring that the patient and the investigator are blinded. The study nurses applying the treatment (a specific person only in charge of the patient during the treatment) cannot be blinded.
89490687|NCT05687474||Newborns with consent|Newborns with parent's consent
89490688|NCT05670964|Experimental|UPLUG Arm|Patients will have regular central veinous catheter and UPLUG device for their dialysis sessions.
89490689|NCT05670964|Other|Standard Of Care Arm|Patients will have regular central veinous catheter (standard of care) for their dialysis.
89490690|NCT05670821||Patients with generalized pustular psoriasis (GPP)|
89490691|NCT05668351|Experimental|SUPR-SABR treatment|The prescription dose of this study will be 40 Gy in 5 fractions assigned to PTV_4000 which permits sparing of the rectum, urethra and pudendal artery. There will be a secondary dose level of 36.25 Gy in 5 fractions. A minimum dose of 36.25 Gy will be given to the entire prostate PTV_3625. 36.25 Gy in five fractions is currently endorsed as a standard of care for localized prostate cancer by the National Comprehensive Cancer Network guidelines in prostate cancer. Escalating the therapeutic radiation dose above 36.25 Gy provides potential for improved biochemical control of prostate cancer and decrease in relapse free survival.
89490692|NCT05638126|Experimental|Part 1|HRS-1780 table or placebo single dose
89490693|NCT05638126|Experimental|Part 2|HRS-1780 table or placebo single dose with food effect
88953748|NCT01965236|Experimental|Group 2|Patients are given 5 placebo (microcrystalline cellulose) pills per day for 6 weeks. After a one-week wash out period, a second period of 6 weeks is started with 5 pills (1 g per pill) of sodium chloride per day.
88953749|NCT01965275|Experimental|Erlotinib or Gefitinib|Patients received the treatment with high-dose, pulsatile Erlotinib(600 mg every 4 days) or Gefitinib (1000 mg every 4 days) until disease progression or unacceptable toxicity occurred. The overall study period takes about 12 months
88953750|NCT01965301|Experimental|BP1.5375|Single oral administration ranging from 0.5 mg to 100 mg
88953751|NCT01965301|Active Comparator|Diphenhydramine|Single oral dose of diphenhydramine 50mg
88953752|NCT01965301|Placebo Comparator|Placebo|Single oral dose
88953753|NCT01965314|Placebo Comparator|Traditional Training Group|These subjects will be offered multimodal training. This will be comprised of demonstration by suitably trained individuals of relevant anatomy using pre-existing cadaveric samples, performing ultrasound scans of the relevant areas on volunteers under expert supervision, and the practice of needle insertion under ultrasound-guidance using commonly used tissue phantoms (turkey breasts).
89490694|NCT05638126|Experimental|Part 3|HRS-1780 table or placebo multiple dose
89490695|NCT05627895||Patient cohort|All patients will undergo both the SMA and the basal ganglia condition
89490696|NCT05622955|Experimental|Endometriosis group care|Groups of 6-10 patients with endometriosis and chronic pelvic pain will attend eight weekly two-hour sessions.
89490697|NCT05618912|Experimental|hydrocolloid dressing arm|After informed consent and closing the wound with the sutures, the scar will be covered by a hydrocolloid dressing, which will be left in place for 7 days (Experimental)
89490698|NCT05618912|Active Comparator|Petrolatum jelly dressing arm|and the other group of patients (control), after closing the wound with the sutures, the scar will be covered with petrolatum jelly during this time period, which has to be re-applied daily.
89490699|NCT05618587|Experimental|Lithium|Lithium 10mg po qd
89490700|NCT05618587|Placebo Comparator|Placebo|Placebo identically matching the lithium pills
89490701|NCT05607472|Other|All patient with Dengue prognostic purpose|blood samples for bio collection clinical exam : Fitzpatrick phototype classification , Charlson comorbidity classification questionaries : SHERE and EHAD (emotional evaluation), SF-12, EQ-5D-5L, MFIS-5 (Fatigue evaluation)
89490702|NCT05593484|Other|Standard Referral|
89490703|NCT05593484|Other|Specialty Telemedicine Access for Referrals (STAR)|
89490704|NCT05567198||Group 1|SLE patients receiving CYC alone
89490705|NCT05567198||Group 2|SLE patients receiving both CYC and leuprolide acetate (GnRH-a)
89490706|NCT05567198||Group 3|Control subjects, Age-matched female SLE patients without a history of reproductive disorders
89490707|NCT05565625|Experimental|Sunscreen|Participants will receive two of six sunscreens (A, B, C, D, E, and F) at Visit 1 (Day 1) to apply to whole lower legs (1 sunscreen per lower leg), between the knee and ankle. Participant will then select one of the two sunscreens randomly assigned to lower legs and apply the selected sunscreen to full face. After lower legs and facial applications are completed, a trained designee will delineate six 4 centimeters (cm)*4 cm test sites on the participants' volar forearms (3 test sites per volar forearm). The six sunscreens will be randomly assigned to the six test sites at a dose of 2.00 +- 0.05 milligrams per centimeter square (mg/cm^2) using a 1cc tuberculin syringe (without a needle) and a clean finger cot for approximately 20 to 50 seconds and applied by a trained designee.
89490708|NCT05562128|Experimental|Active forest therapy|
89490709|NCT05562128|Active Comparator|Passive forest therapy|
89490710|NCT05562128|No Intervention|Waiting list|
89490711|NCT05561517|Active Comparator|Competition|Participation in a 5 K competition (running)
89490712|NCT05561517|Active Comparator|Training|Performing a 5 K up-tempo training bout (running)
89490713|NCT05561387|Active Comparator|Arm I (VRd-Lite)|"INDUCTION CYCLES 1-9: Patients receive bortezomib SC on days 1, 8, 15, and 22 of each cycle, lenalidomide PO on days 1-21 of each cycle, and dexamethasone PO on days 1, 8, 15, and 22 of each cycle. Treatment repeats every 28 days for up to 9 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE CYCLES 10+: Patients receive lenalidomide PO on days 1-21 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
89490714|NCT05561387|Experimental|Arm II (DRd-R)|"INDUCTION CYCLES 1-9: Patients receive daratumumab and hyaluronidase-fihj SC on days 1, 8, 15, and 22 of cycles 1-2, days 1 and 15 of cycles 3-6, and day 1 of cycles 7-9, lenalidomide PO on days 1-21 of each cycle, and dexamethasone PO on days 1, 8, 15, and 22 of each cycle. Treatment repeats every 28 days for up to 9 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE CYCLES 10+: Patients receive lenalidomide PO on days 1-21 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
89490715|NCT05561387|Experimental|Arm III (DRd-DR):|"INDUCTION CYCLES 1-9: Patients receive daratumumab and hyaluronidase-fihj SC on days 1, 8, 15, and 22 of cycles 1-2, days 1 and 15 of cycles 3-6, and day 1 of cycles 7-9, lenalidomide PO on days 1-21 of each cycle, and dexamethasone PO on days 1, 8, 15, and 22 of each cycle. Treatment repeats every 28 days for up to 9 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE CYCLES 10+: Patients receive daratumumab and hyaluronidase-fihj SC on day 1 of each cycle and lenalidomide PO on days 1-21 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
89490716|NCT05559489|Experimental|Enteral-based Protocolized Resuscitation|Administration of Enteral-based Resuscitation using Oral Rehydration Solution (ORS) either by mouth or via naso-enteric access for moderate sized burn injuries (15-40% TBSA) per resuscitation protocol for burn-injured patients. Resuscitation will be administered in the acute resuscitation phase of burn injury (24-72 hours post injury). Patients will receive supplemental Intravenous Fluid (IV Fluid) resuscitation using Lactated Ringer's solution as needed per protocol.
89490717|NCT05559489|Active Comparator|Intravenous Fluid Protocolized Resuscitation|Administration of Intravenous Fluid using Lactated Ringer's solution per standard of care resuscitation protocol for patients with moderate sized burn injuries (15-40% TBSA).
89490718|NCT05520359|Experimental|Neurologic Disorders|Evaluation of individual and combined effects of mobility devices and spinal stimulation for individuals with neurologic disorders.
89490719|NCT05517655|Experimental|Pre Trikafta|129Xe MRI
89490720|NCT05517655|Experimental|Post Trikafta|129Xe MRI
89490721|NCT05511948|Experimental|DBI-102|Topical DBI-102 Gel, 0.8% twice daily for 12 weeks for the randomized cohort
89204420|NCT05265910|Active Comparator|Pataday® Once Daily Relief Extra Strength and Placebo tablet|Pataday® Once Daily Relief Extra Strength (olopatadine hydrochloride ophthalmic solution 0.7%) will be administered bilaterally and Placebo tablet will be administered orally (within 5 minutes of eyedrop) at Visits 3 and 4a.
89490722|NCT05511948|Placebo Comparator|Vehicle gel|Inactive comparator
89490723|NCT05511948|Active Comparator|Hydroquinone cream|4% Hydroquinone cream, Acella (approved), twice daily for 12 weeks
89490724|NCT05499728|Experimental|Telerehabilitation|Subjects who are randomized to telerehabilitation will be provided access to telemedicine visits with a physical therapist. Patients will have one in-person physical therapy visit before starting telerehabilitation, and another in-person visit at 3 months to assess progress. Telerehabilitation visits will be performed via secure usage of the electronic medical record (EMR). To ensure uniformity, and to allow for appropriate access to telehealth services, all telehealth visits will be carried out through the study institution's Department of Physical Therapy. It is expected most patients will complete formal physical therapy by 6 months postoperative measured by the time at which patient's regain functional range of motion or patients are satisfied with their results. Shoulder range of motion will be measured with a goniometer preoperatively, as well as 3,6, 12, and 24 months postoperatively at their regularly scheduled clinic visit.
89490725|NCT05499728|No Intervention|Traditional In-Person Physical Therapy|Subjects who are randomized to in-person therapy will present to a physical therapist of their choice with a established written protocol. The therapy protocol is developed in conjunction with the Department of Orthopaedic Surgery and the Department of Physical Therapy. Subjects are recommended to attend in-person appointments at least once a week as well as perform home exercises. Progress with therapy will be collected with weekly phone calls from the research team. It is expected most subjects will complete formal physical therapy by 6 months postoperative attending on average 5-6 visits, measured by the time at which patient's regain functional range of motion or are instructed by their therapist to discontinue. Shoulder range of motion will be measured with a goniometer preoperatively, as well as 3,6, 12, and 24 months postoperatively at their regularly scheduled clinic visit.
89490726|NCT05465655|Experimental|Patients undergoing TAVR|Study subjects will be studied during the TAVR procedure and their 12 lead ECGs collected and analyzed notifying for New-Onset Conduction Disturbances (NOCD) using Cara Monitor.
89490727|NCT05461092|Active Comparator|Standard of Care Anesthesia without Thoracolumbar Interfascial Plane (TLIP) Block of bupivicaine.|Subjects will receive standard of care anesthesia without TLIP Block of bupivicaine.
89490728|NCT05461092|Experimental|Standard of Care Anesthesia with Thoracolumbar Interfascial Plane (TLIP) Block of bupivacaine|Patient receives standard of care anesthesia with TLIP Block of bupivacaine (local anesthetic) intraoperatively after anesthesia administration and before spinal fusion.
89490729|NCT05456841|Experimental|Oncology Care Providers/OCP-intervention group|Providers participate in Empathic Communication Skills (ECS) training
89490730|NCT05456841|Active Comparator|Oncology Care Providers/OCP-control group|Providers complete all study measures and are offered ECS training after data collection is completed at their site.
89490731|NCT05456841|Experimental|Participants with Lung Cancer-intervention group|Participants will engage with oncology care providers/OCP who have undergone Empathic Communication Skills (ECS) training
89490732|NCT05456841|Active Comparator|Participants with Lung Cancer-control group|Waitlist control group - WLC
89490733|NCT05451212|Experimental|MuSK-CAART|"Cohort A: Infusion of MuSK-CAART at various dose levels with or without pre-treatment (6 groups planned).~Cohort B: Infusion of MuSK-CAART at the dose regimen selected from Part A."
89490734|NCT05424913|Other|Subjects with Dunnigan's Lipodystrophy|
89490735|NCT05424913|Other|Non-lipodystrophic insulin-resistant subjects|
89490736|NCT05424913|Other|Insulin-sensitive non-lipodystrophic subjects|
89490737|NCT05422079|Experimental|Non-specific lumbar exercise group|Subjects perform a conventional lumbar exercise program twice a week for four weeks.
89490738|NCT05422079|Experimental|Group motor control lumbar exercises|Subjects perform a lumbar stabilization exercise program twice a week for four weeks.
89490739|NCT05422079|Experimental|Group motor control lumbar exercises with ultrasound echography feedack|Subjects perform a lumbar stabilization exercise program in conjunction with a video where participants can see how the muscles contract.
89490740|NCT05420935|Other|IgG group|Patient in the IgG group will benefit from a blood sampling of 5 ml (for realization of a basophil activation test) and a blood sampling of 250 ml
89490741|NCT05420935|Other|IgE group|Patient in the IgE will benefit from a blood sampling of 5 ml (for realization of a basophil activation test) and a bone marrow sampling (approx 2 ml)
89490742|NCT05420935|Other|IgG group + IgE group|Patient in the IgG + IgE will benefit from a blood sampling of 5 ml (for realization of a basophil activation test), a blood sampling of 250 ml and a bone marrow sampling (approx 2 ml)
89490743|NCT05414032|Experimental|MRD positive Cohort - Arm A (treatment)|"Dose formulation- AZD2936 is supplied as a liquid drug product in a 20R vial containing 750 mg (nominal) of active AZD2936. The solution contains 50 mg/mL AZD2936 in 20 mM L-histidine/L- histidine-hydrochloride, 240 mM sucrose, 0.04% (w/v) poloxamer 188, at pH 6.0.~Unit dose strength(s)- 750 mg/vial (50 mg/mL) Dosage levels- 750mg administered Q3W Route of administration- IV infusion over 1 hour"
89490744|NCT05414032|No Intervention|MRD positive Cohort - Arm B (observation)|Observation
89490745|NCT05414032|No Intervention|MRD negative Cohort|Observation
89490746|NCT05413720|Other|Patient with leptospirosis|
88953754|NCT01965314|Active Comparator|Simulation Training Group|In addition to traditional training the SG group will participate in a period of simulator based training. Following initial familiarization with the simulator these participants will identify relevant structures and follow their course in the virtual arm. They will insert a virtual needle into the virtual environment and advance it using an in-plane technique towards various target structures. They will be given immediate directed computer generated feedback and offered the opportunity for repetitive, deliberate practice. The simulator, which these participants will use, will comprise of a PHANTOM Desktop (http://www.sensable.com/), an haptic immersive workbench and the H3D API (http://www.sensegraphics.se/). The SG subject will scan and perform procedure specific tasks on a virtual arm. Training will continue until they reach proficiency levels set by experts using the same simulator.
88953755|NCT01965340|Experimental|Patients with systematic TDM of anti-infective agents|Patients with systematic TDM of anti-infective agents and dosages adapted accordingly
89490747|NCT05409846||Group A|Idiopathic hypertrophic cardiomyopathy
89490748|NCT05409846||Group B|Idiopathic left ventricle hypertrophy
89490749|NCT05409846||Group C|Idiopathic burned-out hypertrophic cardiomyopathy
89490750|NCT05409846||Group D|Idiopathic dilated cardiomyopathy
88953756|NCT01965340|No Intervention|Patients treated as usual|
89490751|NCT05395767|Experimental|endoscopic ACL reconstruction with parent allograft tendon|
89490752|NCT05384288||Pediatric Influenza Vaccine Recipients|Pediatric patients eligible to receive seasonal influenza vaccine.
89490753|NCT05374447|Active Comparator|EBUS-TBNA|These will be the patient who undergo EBUS-TBNA only without EBUS-IFB
89490754|NCT05374447|Experimental|EBUS-TBNA + EBUS-IFB|These will be the individuals who undergo EBUS-TBNA followed by EBUS-IFB in the same procedure
88953757|NCT01965353|Experimental|Panobinostat|"Panobinostat - single oral dose on days 1, 3, 5, 8, 10 and 12 and followed by a 9-day rest period.~Bortezomib - subcutaneous injection twice a week during the first two weeks of each 21 day cycle.~Dexamethasone oral dose on the days of and after bortezomib administration during Cycles 1-8, and on days 1, 8 and 15 for Cycles 9 and beyond.~Lenalidomide - oral dose once daily on days 1-14 of each cycle. Accrual to the next higher dose level will not occur until the safety and tolerability of the prior dose level(s) has been determined at the end of the first cycle.~Each cycle of treatment will consist of 21 days. Accrual to the next higher dose level will not occur until the safety and tolerability of the prior dose level(s) has been determined at the end of the first cycle"
88953758|NCT01965379|Active Comparator|Intervention|Restriction on food containing phosphorus additives.
88953759|NCT01965379|Placebo Comparator|Control|Standard care.
89490755|NCT05373641|Experimental|Pain documentation audit and repeated feedback|Pain documentation audit and repeted feedback
89490756|NCT05373641|Active Comparator|Pain documentation audit|Pain documentation audit
89490757|NCT05371288|Experimental|Arm A|"Subjects randomized into Group A will take the following amount for 28 days~4 capsules of NAC (600mg each) once in the morning and once in the evening~1 tablet (600mg) of Alamax CR once in the morning and once in the evening~8 capsules (250 mg each) of liposomal GSH in the morning and in the evening"
89490758|NCT05371288|Active Comparator|Arm B|"Subjects randomized into Group B will be taking a multivitamin and magnesium for 14 days. Afterwards, they will take the following for 14 days.~4 capsules of NAC (600mg each) once in the morning and once in the evening~1 tablet (600mg) of Alamax CR once in the morning and once in the evening~8 capsules (250 mg each) of liposomal GSH in the morning and in the evening"
89490759|NCT05366465||SMA adult patients|
89490760|NCT05355012|Experimental|5A-QUIT-N intervention|"The 5A-QUIT-N intervention can be defined as multilevel, i.e., it is based on a territorial organization with expected results at the level of professional practice (structuring of practices around the 5A method) and therefore of the care of pregnant women who smoke tobacco.~This project is based on three strategic axes:~A gradation of the care offer~Personalized care by developing specific treatment paths~Coordination of territorial resources to support pregnant women in quitting smoking.~These elements will make it possible to propose a partnership-based, multi-professional, coordinated and integrated approach to the territory, supported by the technical resources and expertise available in the territory. It invites a majority of non-specialized actors to invest in the process of supporting pregnant women in quitting smoking, multiplying and potentiating their actions with this population."
89490761|NCT05355012|No Intervention|5A-QUIT-N control|Usual care in the care of pregnant women who smoke tobacco.
89490762|NCT05346887|Experimental|Home-based Therapy|
89490763|NCT05345184|Experimental|Cognitive Behavioral Suicide Prevention for psychosis (treatment group)|Cognitive Behavioral Suicide Prevention for psychosis (CBSPp) is a behavioral treatment and will be delivered in 10 weekly individual therapy sessions in addition to standard/current services.
89490764|NCT05345184|Active Comparator|Services as Usual (SAU; comparison group)|Services as usual involve standard and current services that clients are eligible for receiving.
89490765|NCT05328856|Active Comparator|Vital shower|Participants receive the installation of a shower prototype from Hansgrohe and training including a handout. After installation, participants are asked to shower daily for four weeks according to a predefined shower protocol with alternating warm and cold water application.
89490766|NCT05328856|No Intervention|Regular shower|Participants are advised not to change their showering behaviour; at the end of the study, the participants receive an offer of a shower head for free.
89490767|NCT05325853|Experimental|AG-920|Articaine Sterile Topical Ophthalmic Solution (AG-920) is a sterile, isotonic, non-preserved aqueous solution containing the active ingredient Articaine HCl 8%.
89490768|NCT05325853|Active Comparator|Proparacaine|0.5% Proparacaine Hydrochloride
89490769|NCT05321615|Other|Study arm|All patients will undergo a standard VATS pleuroscopy to visually search for the nodule and its position. Sequential assessment using a grasper, the Palpator, the VATS ultrasound probe, and then finger palpation will be done to detect the nodule.
89490770|NCT05320809|Experimental|3D189|
88953760|NCT01965392|Experimental|healtn education|one group received an educational program
88953761|NCT01965418|Active Comparator|Fufang Biejia Ruangan Tablet|Fufang Biejia Ruangan Tablet will be administered to all of subjects in this arm.
88953762|NCT01965418|Placebo Comparator|placebo|placebo of Fufang Biejia Ruangan Tablet
88953763|NCT01965483|Experimental|Weekly radiation|once-weekly breast irradiation
88953764|NCT01965496|Experimental|PEX168 100 microgram|PEX168 100 microgram qw sc. and the medication continued for 14 weeks
88953765|NCT01965496|Experimental|PEX168 200 microgram|PEX168 200 microgram qw sc. and the medication start form 100 microgram qw for 4 weeks and then increased to 200 microgram qw for the 10 weeks.
88953766|NCT01965496|Experimental|PEX168 300 microgram|PEX168 300 microgram qw sc. and the medication start form 100 microgram qw for 4 weeks and then increased to 300 microgram qw for the 10 weeks.
88953767|NCT01965509|Experimental|PEX168 100 microgram|PEX168 100 microgram qw sc. and the medication continued for 12 weeks
88953768|NCT01965509|Experimental|PEX168 200 microgram|PEX168 200 microgram qw sc. and the medication continued for 12 weeks
89490771|NCT05312255|Experimental|Module A (strength training, behavioral intervention)|Patients undergo strength training sessions twice weekly supervised by a licensed and specialized personal trainer via the internet (e.g., remote access) for 6 months. Patients also wear a FitBit device and receive prompts via email or text on a cell phone or other electronic device to incrementally increase physical activity over 6 months.
89490772|NCT05312255|Experimental|Module B (intermittent fasting)|Patients undergo intermittent fasting for 1 month. This consists of restricting all eating to a consecutive 8-hour time period each day followed by 16 consecutive hours of not eating.
89490773|NCT05312255|Experimental|Module C Group I (propranolol)|Patients receive propranolol PO BID for 3 months.
89490774|NCT05312255|Active Comparator|Module C Group II (propranolol)|Patients continue receiving beta-blocker regimen as per SOC for 3 months.
89490775|NCT05304819||AchilloCordPLUS|End to end repair for acute Achilles tendon rupture with AchilloCordPLUS
89490776|NCT05283018||Surgery under general anesthesia|Patients undergoing urgent or scheduled surgery at Lariboisière Hospital
88953769|NCT01965509|Placebo Comparator|Placebo|Placebo qw sc. and the medication continued for 12 weeks
88953770|NCT01965522|Experimental|Melatonin and Vitamin D|
89490777|NCT05276219|Active Comparator|Furosemide only|• Boluses of 40 mg furosemide given as soon as possible and repeated up to 10 times by the discretion of the treating physician.
89490778|NCT05276219|Active Comparator|isosorbide dinitrate|• Boluses of 3 mg IV isosorbide dinitrate given as soon as possible and repeated up to 10 times by the discretion of the treating physician.
89490779|NCT05276219|Active Comparator|isosorbide dinitrate + furosemide|• Boluses of both 3 mg IV isosorbide dinitrate + of 40 mg furosemide given as soon as possible and repeated up to 10 times by the discretion of the treating physician.
89490780|NCT05272488|Experimental|Manual therapy and nervous vagus stimulation|Subjects will received manual therapy combined with nerve vagus stimulation.
89490781|NCT05272488|Active Comparator|Manual therapy|Subjects will received isolated manual therapy techniques.
89490782|NCT05268055|Experimental|"Sign Here training intervention"|"Participants randomized to the experimental condition will view the new Sign Here training film for healthcare providers."
89490783|NCT05268055|Other|Intervention as usual|"Participants randomized to intervention as usual will review Communicating with People Who Are Deaf or Hard of Hearing in Hospital Settings (https://archive.ada.gov/hospcombrprt.pdf)"
89490784|NCT05265052|Experimental|3D1002 50 mg group (Phase IIa)|3D1002 is given 50 mg twice a day for 2 weeks.
89490785|NCT05265052|Experimental|3D1002 100 mg group (Phase IIa)|3D1002 is given 100 mg twice a day for 2 weeks.
89490786|NCT05265052|Experimental|3D1002 150 mg group (Phase IIa)|3D1002 is given 150 mg twice a day for 2 weeks.
89490787|NCT05265052|Experimental|3D1002 monotherapy group (Phase IIb)|3D1002 at recommended dose plus mimic OxyContin tables, will be given twice a day for 2 weeks.
89490788|NCT05265052|Experimental|OxyContin monotherapy group (Phase IIb)|OxyContin initiating at 10mg per dose plus mimic 3D1002 tablets, will be given twice a day for 2 weeks.
89490789|NCT05265052|Experimental|3D1002 + OxyContin group (Phase IIb)|3D1002 at recommended dose plus OxyContin initiating at 10 mg per dose, will be given twice a day for 2 weeks.
89490790|NCT05255484|Experimental|LM-108 Dose Escalation|Drug: LM-108 Administered intravenously
89490791|NCT05255484|Experimental|LM-108 Dose Expansion|Drug: LM-108 Administered intravenously
89490792|NCT05255484|Experimental|LM-108 Combination Dose Escalation|Drug: LM-108 Administered intravenously Drug: An Anti-PD-1 Antibody Administered intravenously
89490793|NCT05255484|Experimental|LM-108 Combination Dose Expansion|Drug: LM-108 Administered intravenously Drug: An Anti-PD-1 Antibody Administered intravenously
89490794|NCT05254678|Active Comparator|Standard exercise program|Participants in this group will take part the general exercise program delivered through the Active Living module of the HEAL-ME application. The program comprises (1) supervised group exercise sessions (connection via zoom platform embedded in HEAL-ME), (2) independent exercise workouts within the application, and (3) exercise specific education within the Education Module of the HEAL-ME application.
89490795|NCT05254678|Experimental|Integrated physiotherapy and exercise|Participants in this group will take part in an integrated physiotherapy and exercise intervention delivered through the Active Living module of the HEAL-ME application. The program comprises (1) supervised group physiotherapeutic exercise sessions (connection via zoom platform embedded in HEAL-ME), (2) independent physiotherapeutic exercise workouts, and (3) breast cancer specific physiotherapy education delivered through weekly modules.
89490796|NCT05243368|Experimental|Nutritional Intervention (NI)|In addition to the usual treatment, will receive dietary advice and a nutritional supplement, according to the results of their evaluation in the Endocrinology Service
89490797|NCT05243368|No Intervention|Control (C)|Who will continue with their usual treatments in the Diabetic Foot Unit and they will receive dietary advice
89490798|NCT05211401|Experimental|Active arm 200 mg|Active arm 200 mg: 1 bag containing 200 mg of rituximab (MabThera® or biosimilar ) in 100ml of NaCl 0.9%; 1 bag of 400 ml of NaCl 0.9%.
89490799|NCT05211401|Experimental|Active arm 1000 mg|Active arm 1000 mg: 1 bag containing 200 mg of rituximab (MabThera® or biosimilar ) in 100ml of NaCl 0.9%; 1 bag containing 800 mg rituximab (MabThera® or biosimilar ) in 400 ml of NaCl 0.9%.
89490800|NCT05211401|Placebo Comparator|Placebo arm|1 bag of 100 ml of NaCl 0.9%; 1 bag of 400 ml of NaCl 0.9%.
89490801|NCT05203939|Experimental|Cohort 1 (Low Dose)|Biallelic autosomal recessive NR2E3 mutations subgroup or Autosomal dominant NR2E3 mutation or RHO mutations subgroup
89490802|NCT05203939|Experimental|Cohort 2 (Mid Dose)|Biallelic autosomal recessive NR2E3 mutations subgroup or Autosomal dominant NR2E3 mutation or RHO mutations subgroup
89490803|NCT05203939|Experimental|Cohort 3 (High Dose)|Biallelic autosomal recessive NR2E3 mutations subgroup or Autosomal dominant NR2E3 mutation, RHO mutations subgroup and LCA patients with CEP290
89490804|NCT05203939|Experimental|Pediatric Arm|Pediatric subjects will receive the medium dose concentration and will have subjects with RP and LCA
88953771|NCT01965522|Experimental|Placebo and Vitamin D|
88953772|NCT01965522|Experimental|Melatonin and Placebo|
88953773|NCT01965522|Placebo Comparator|Placebo and Placebo|
88953774|NCT01965548||Splenic injury|All patients admitted at the University Hospital North Norway Tromsø with a splenic injury following trauma, are included in the study.
88953775|NCT01965574|Experimental|Single arm|
88953776|NCT01965587|Active Comparator|novasure mirena IUS combined|novasure mirena IUS combined therapy
88953777|NCT01965587|Active Comparator|novasure alone|Sole treatment with Novasure
88953778|NCT01965626|Active Comparator|Oseltamivir Combining HD-DXM|"Oseltamivir 75 mg twice per day, 10consecutive days~HD-DXM (orally at 40 mg daily for 4d )"
88953779|NCT01965626|Active Comparator|HD-DXM|HD-DXM (orally at 40 mg daily for 4d )
88953780|NCT01965639|Experimental|High Risk group|Extension of Care
88953781|NCT01965678|Experimental|OMT|
89490805|NCT05203939|No Intervention|Natural History Study (OCU400-104)|"A Prospective and Retrospective Natural History Study of RP and LCA:~This is an observatory study for the prospective natural history of RP and LCA in adult and pediatric subjects. The study will also collect and review retrospective data and ophthalmology examination of natural history and progression of disease for all subjects starting with earliest timepoint on or after the date of their diagnosis of RP or LCA.~Subjects will be seen up to a total of four times during the 12 months of the Observational Period, at baseline, 3 months, 6 months and 12 months.~A total of up to 100 subjects will be enrolled in the study, including:~Approximately 76 newly enrolled subjects consisting of 50 adult RP subjects 6 adult LCA subjects 20 pediatric RP/LCA subjects. Up to 24 subjects that reconsent from the OCU400-101 study (subjects from OCU400-101 will provide data on their untreated eye)"
89490806|NCT05203939|Experimental|Adult Arm|Following DSMB confirmation, adult LCA subjects with CEP290 mutation will receive a medium dose concentration of OCU400.
89490807|NCT05199714|Experimental|Fiasp-and-pramlintide fully automated system (8μg)|Fiasp and pramlintide artificial pancreas with no meal announcement. Ratio of 1 unit of insulin for 8μg of pramlintide.
89490808|NCT05199714|Active Comparator|Fiasp-alone with carbohydrate-matched boluses|The Fiasp-alone intervention will have a 14 hour duration. During which, carbohydrate counting will inform insulin bolus doses based on insulin to carbohydrate ratios.
89490809|NCT05199714|Experimental|Aspart-and-pramlintide fully automated system (10μg)|Aspart and pramlintide artificial pancreas with no meal announcement. Ratio of 1 unit of insulin for 10μg of pramlintide.
89490810|NCT05199714|Experimental|Fiasp-and-pramlintide fully automated system (10μg)|Fiasp and pramlintide artificial pancreas with no meal announcement. Ratio of 1 unit of insulin for 10μg of pramlintide.
89490811|NCT05199714|Experimental|Aspart-and-pramlintide fully automated system (8μg)|Aspart and pramlintide artificial pancreas with no meal announcement. Ratio of 1 unit of insulin for 8μg of pramlintide.
89490812|NCT05196919|Experimental|0.15mg XT-150|0.15mg XT-150 administered in 1.0 mL total delivered by two 0.5 mL injections on Day 0 and Day 90.
89490813|NCT05196919|Experimental|0.45mg XT-150|0.45mg XT-150 administered in 1.0 mL total delivered by two 0.5 mL injections on Day 0 and Day 90.
89490814|NCT05196919|Placebo Comparator|Placebo|Placebo administered in 1.0 mL total delivered by two 0.5 mL injections on Day 0 and Day 90.
89490815|NCT05150093|Experimental|Electrophysiological signal data collection|Patients diagnosed with dystonia or tremor who are recommended for DBS surgery. Electrophysiological data will be collected at the time of DBS surgery.
89490816|NCT05149573|Active Comparator|4-Week Treatment with no Maintenance Period|Treatment will be provided via self-administration of pulsed electromagnetic field (PEMF) therapy using the B. Body (full body mat) and B. Pad (targeted pelvic pad). The participant will lie the B. Body mat on any flat surface and lay on the mat with the smaller B. Pad placed directly over the pelvic area. The PEMF device (attached to the control unit) has been pre-programmed to deliver the same level of energy every time. Participants will be instructed to administer this home treatment twice a day (morning and evening) for 8-minute sessions over a 4-week period. After 4 weeks, participants will return the device and complete one set of electronic questionnaires during the last week of the month for the following 3 months.
89490817|NCT05149573|Sham Comparator|4-Week Sham Treatment with no Maintenance Period|Participants will be provided with a sham B. Body and B. Pad that appears identical to the active pulsed electromagnetic field (PEMF) device. The participant will lie the sham B. Body mat on any flat surface and lay on the mat with the smaller sham B. Pad placed directly over the pelvic area. The participant will be instructed to administer this sham treatment twice a day (morning and evening) for 8-minute sessions over a 4-week period. After 4 weeks, participants will return the sham device and complete one set of electronic questionnaires during the last week of the month for the following 3 months.
89490818|NCT05149573|Active Comparator|4-Week Treatment with 1-Week-Per-Month Maintenance Period for an Additional 3 Months|Treatment will be provided via self-administration of pulsed electromagnetic field (PEMF) therapy using the B. Body (full body mat) and B. Pad (targeted pelvic pad). The participant will lie the B. Body mat on any flat surface and lay on the mat with the smaller B. Pad placed directly over the pelvic area. The PEMF device (attached to the control unit) has been pre-programmed to deliver the same level of energy every time. Participants will be instructed to administer this home treatment twice a day (morning and evening) for 8-minute sessions over a 4-week period. After 4 weeks, participants will keep the device and use it for 1 week (7 days) during the last week of the month for the following 3 months. Each participant in this group will be asked to complete a set of electronic questionnaires immediately following their week-long maintenance treatment during the last 3 months of the study.
89490819|NCT05139147|Experimental|DAISe Thrombectomy System|Mechanical thrombectomy utilizing the DAISe Thrombectomy System, consisting of the DAISe Thrombectomy Device and DAISe Delivery Catheter, used with aspiration.
89490820|NCT05137392|Experimental|Test group|The test group will receive the novel regimen of oral hygiene instruction, including use of a commercially available intelligent toothbrush connected to the Chinese consumer version of an application and receiving targeted oral health message as well as use of interdental toothbrush
89490821|NCT05137392|Other|Control group|The test group will receive the standard regimen of oral hygiene instruction, including use of a commercially available manual toothbrush and receiving a brochure for oral hygiene instruction as well as use of interdental toothbrush
89490822|NCT05121974|Experimental|Tebipenem-pivoxil arm (Pilot study)|Oral Tebipenem-pivoxil in children with shigellosis
89490823|NCT05121974|Active Comparator|Azithromycin arm (Pilot study)|Oral Azithromycin in children with shigellosis
88953782|NCT01965691|Experimental|Protein intake|Protein intake- Dietary supplement
88953783|NCT01965730|Active Comparator|epsilon-aminocaproic acid (EACA)|75mg/kg loading dose with infusion 15mg/kg/hr
88953784|NCT01965730|Experimental|EACA|125mg/kg loading dose of EACA followed by an infusion of EACA at 25mg/kg/hr for length of cardiac surgery.
88953785|NCT01965743|Other|Contraception Information Packet|Everyone in the study will receive the intervention, which is an information packet designed to facilitate conversations among peers about intrauterine contraception.
88953786|NCT01965769|Experimental|no gastric residual evaluation|Infants will not receive routine gastric residual evaluation prior to feeding
88953787|NCT01965769|No Intervention|gastric residual evaluation|Infants will receive routine gastric residual evaluation
89204421|NCT05265910|Active Comparator|Tears Naturale® II and Claritin® Tablet 24-Hour|Tears Naturale® II will be administered bilaterally and Claritin® Tablet 24-Hour (loratadine 10 mg) will be administered orally (within 5 minutes of eyedrop) at Visits 3 and 4a.
89204422|NCT02601521|Experimental|Internal coaching program|The internal coaching program uses a chronic disease management strategy to treat tobacco use and dependence. The program provides evidence-based treatment consisting of up to 12 months of services from a tobacco coach based at Partners HealthCare. The tobacco coach offers (1) repeated smoking cessation counseling delivered by proactive telephone calls, emails, and interactive voice response [automated phone calls] and (2) facilitated access to a new Partners HealthCare Inc., health insurance benefit that provides access to all FDA-approved smoking cessation medications without copay or prior approval.
89022001|NCT04715282|Other|Epley maneuver|The Epley maneuver was performed for all patients (both EpleyM and EpleyM&Exe groups) included in this study until nystagmus had disappeared in each position. If nystagmus/vertigo was not seen, the Epley maneuver was not performed for patients at the 1st, 3rd, and 6th week assessments.
89204423|NCT02601521|Active Comparator|External coaching program|The external coaching program consists of referral to the Massachusetts Tobacco Control Program's Smokers Helpline, a free program offering multi-session proactive telephone counseling for 3 months to individuals who are ready to quit smoking. Individuals in this arm also receive information about Partners HealthCare, Inc.'s new health insurance benefit that provides access to all FDA-approved smoking cessation medications without copay or prior approval.
89204424|NCT00814866|Other|Adalimumab|Open label
89204425|NCT00991978|Experimental|89Zr-bevacizumab PET|89Zr-bevacizumab PET
89490824|NCT05121974|Experimental|Tebipenem-pivoxil arm (Main trial)|Oral Tebipenem-pivoxil in children with shigellosis
89490825|NCT05121974|Active Comparator|Ceftriaxone arm (Main trial)|Intravenous Ceftriaxone in children with shigellosis
89490826|NCT05085704||Adolescents and adults with Glut1 deficiency|"Adolescents and adults with previously documented diagnosis of Glut1 Deficiency with diagnosis genetically confirmed or confirmed by PET scan of the brain.~Ages 16 to 65~Persons with dental fillings, dental crowns, and short (max.4 cm) dental retainer wires can be included."
89490827|NCT05085704||Normal healthy adolescents and adults|"Adolescents or adults in good general health.~Ages 16 to 65.~Persons with dental fillings, dental crowns, and short (max. 4 cm) dental retainer wires can be included."
89490828|NCT05080842|Experimental|AC682|This arm will evaluate AC682 monotherapy administered in 28-day cycles. Up to 30 participants will participate in this dose escalation arm.
89490829|NCT05080101|Active Comparator|Conventional Physiotherapy Group|Patients in control group (n=14) will receive 40-mins conventional physiotherapy session for 3-days per week, over 6 weeks. Conventional physiotherapy will consist of stretching and strengthening exercises, postural alignment exercises, as well as electrotherapy such as transcutaneous electric magnetic stimulation (TENS) which will be applied to lumbar region with a frequency of 100 Hz, 50-100 μsec current duration for 20 minutes, hotpack which will be applied to lumbar region for 20 mins, and ultrasound application which will be applied to the lumbar region with a Chattanooga Intelect Mobile device at a frequency of 1 MHz, at a dose of 1.5 W/cm2, for 6 minutes using a 10 cm2 head.
89490830|NCT05080101|Experimental|Basic Body Awareness Therapy Group|Patients in study group (n=14) will receive Basic Body Awareness Therapy (BBAT) 3 days in a week, over 6 weeks in addition to conventional physiotherapy. BBAT will consist of flexibility exercises and various cognitive exercises in supine, position, sitting position and standing position. These exercises will be consist of exercises such as body scanning, breathing, sound resonance.
89490831|NCT05041257|Experimental|Mirvetuximab Soravtansine|Participants will receive MIRV 6.0 mg/kg adjusted by ideal body weight (AIBW)
89490832|NCT05036642|Experimental|Stroke Survivors|Stroke survivors with upper extremity motor impairments
89490833|NCT05026996|Experimental|Mild hepatic impairment patients|Participants with mild hepatic impairment
89490834|NCT05026996|Experimental|Healthy participants|Matched healthy participants with normal hepatic function
89490835|NCT05025267|Other|Enteral Tube-fed Adults|Adults being fed an enteral formula with a feeding tube
89490836|NCT04995562|Experimental|Oxygen with nasal cannula|6 infants on oxygen with nasal cannula
89490837|NCT04995562|Experimental|HFNC, CPAP, or RAM cannula|6 infants currently requiring respiratory support with high flow nasal cannula (HFNC), continuous positive airway pressure (CPAP) or RAM cannula
89490838|NCT04975711|Experimental|Test drug(HIP2105) or Reference drug(RLD2104) Sequence 1|Period 1: RLD2104 Period 2: HIP2105
89204426|NCT00645528|Experimental|Insulin Education Class Participants|Participation in an insulin educational class at week 0 and again at week 2
89490839|NCT04975711|Experimental|Test drug(HIP2105) or Reference drug(RLD2104) Sequence 2|Period 1: HIP2105 Period 2: RLD2104
89490840|NCT04942067|Experimental|APG-2575 +Pd or LD|APG-2575+ Pomalidomide 4mg QD x 21 days + dexamethasone
89490841|NCT04942067|Experimental|APG-2575+LD|APG-2575+ Lenalidomide +Dexa Days 1 through 21 of each 28-day cycle,
89490842|NCT04922255|Active Comparator|disposable urethral support device|disposable urethral support device
89490843|NCT04922255|Active Comparator|Reusable Underwear|Reusable Underwear
89490844|NCT04922255|Active Comparator|pelvic floor muscle therapy (PFMT)|Pelvic floor muscle therapy
89490845|NCT04897139|Experimental|treatment arm|treatment arm
89490846|NCT04895813|Experimental|Group 1:|The patient will be given training on the day the appointment is made for colonoscopy, educational material will be given as a reminder, information will be given on the phone and the training will be reminded on the day he should start diet for colonoscopy. No different application will be made on the day and after the colonoscopy.
89490847|NCT04895813|No Intervention|Group 2|Routine information in the service will be made
89490848|NCT04891497|Experimental|Intraarterial Treatment plus Dimethyl Fumarate|Dimethyl fumarate 240mg orally twice daily for 3 consecutive days
89490849|NCT04891497|Placebo Comparator|Intraarterial Treatment plus placebo|Placebo 240mg orally twice daily for 3 consecutive days
89490850|NCT04890379|Experimental|standard management plus Dimethyl Fumarate|
89490851|NCT04890379|Placebo Comparator|standard management plus placebo|
89490852|NCT04890353|Experimental|standard management plus Dimethyl Fumarate|
89490853|NCT04890353|No Intervention|standard management|
89490854|NCT04887298|Experimental|Liposomal Annamycin (L-Annamycin)|
89490855|NCT04843579|Experimental|Selinexor, Clarithromycin, Pomalidomide and Dexamethasone (ClaSPd)|"Selinexor~• Given orally at a dose of 60 mg on days 1, 8, and 15 of a 28-day cycle.~Dexamethasone~Given orally at a dose of 40 mg on days 1, 8, 15 and 22 of a 28-day cycle.~Subjects will receive a prescription for dexamethasone 4 mg tablets (generic).~Clarithromycin~Given orally at a dose of 500 mg twice a day on days 1-28 of a 28-day cycle.~Subjects will receive a prescription for clarithromycin 250 or 500 mg tablets (generic) for oral administration.~Pomalidomide~Given orally at a dose of 4 mg daily on days 1-21 of a 28-day cycle.~Subjects will receive a 21-day supply of pomalidomide 1, 2, 3, or 4 mg capsules for oral administration for each treatment cycle."
89490856|NCT04837833|Experimental|research ultrasound (rUS1)|Participants will undergo research ultrasound (rUS1) within three days of their routine contrast enhanced CT scan (CECT). A subset of participants (up to 10) will undergo a second research US (rUS2) at 3-4 weeks after rUS1 and at least one month prior to the next planned clinical CECT.
89490857|NCT04827446|Experimental|Intervention Arm|Light intervention delivered through SYNC app + blue-light blocking glasses.
89490858|NCT04827446|Active Comparator|Control Arm|Placebo light intervention delivered through SYNC app + clear glasses.
89490859|NCT04794777|Experimental|Experimental arm|Individualised therapy based on results of the PSMA PET/CT.
89490860|NCT04794777|Active Comparator|Control arm|Standard salvage therapy. Results of PSMA PET/CT blinded.
89490861|NCT04792463||Patients with personal and/or family history suggestive of hereditary BAP1|Personal history of one cancer reported in BAP1 cancer predisposition syndrome and family history of at least two 1st or 2nd degree relatives with cancer reported in hereditary BAP1 cancer predisposition syndrome such as UM, CM, mesothelioma, RCC, cholangiocarcinoma, hepatocellular carcinoma and meningioma
89490862|NCT04792463||Pathogenic, likely pathogenic variants in BAP1 and variants of uncertain significance|"Affected and unaffected individuals with pathogenic or likely pathogenic variant in BAP1 and their family members~Patients with personal family history of any of the BAP1 associated cancer and a variant of uncertain significance of BAP1"
89490863|NCT04781491|Experimental|Forest Therapy (Düppeler Forst - Berlin-Wannsee)|Subjects receive a 90-minute Forest Therapy session once per week for 8 weeks with a licensed nature therapist, who explains exercises on perceiving nature and the connection between nature and health.
89490864|NCT04781491|No Intervention|Waiting list|Subjects don't receive any therapy but are offered the same treatment after trial is finished.
89490865|NCT04780646|Experimental|Nature therapy in urban nature|Subjects receive a 90-minute nature therapy session once per week for 8 weeks with a licensed nature therapist, who explains exercises on perceiving nature and the connection between nature and health.
89490866|NCT04780646|Active Comparator|City Walk|Subjects receive a 90-minute city walk through urban sourroundings once per week for 8 weeks with a city guide, who talks about city architecture and gives information about the history of the surroundings.
89490867|NCT04780646|No Intervention|Waiting List|Subjects don't receive any therapy.
89490868|NCT04768244||COVID19|- Women with SARS-CoV-2 infections
89490869|NCT04723147|Experimental|Carbidopa Levodopa followed by Placebo|Participants will receive first Carbidopa Levodopa at doses ranging from 150 to 450 mg administered at a ratio of 1 mg carbidopa for every 4 mg L-DOPA with a starting dose of 150 mg/day with dose escalation 150 mg/day per week to a final dose of 450 mg/day; and then placebo.
89490870|NCT04723147|Experimental|Placebo followed by Carbidopa Levodopa|Participants will receive first placebo, and then Carbidopa Levodopa (L-DOPA) at doses ranging from 150 to 450 mg administered at a ratio of 1 mg carbidopa for every 4 mg L-DOPA with a starting dose of 150 mg/day with dose escalation 150 mg/day per week to a final dose of 450 mg/day.
89490871|NCT04669158|Experimental|Idebenone|Participants will take Idebenone 200 mg for 48 weeks, with study visits in clinic for physical and laboratory assessments at weeks 0, 2, 4, 12, 24, 36, and 48 weeks during treatment period and at 4, and 12 weeks after the last dose.
89490872|NCT04669158|Placebo Comparator|Placebo|Participants will take Placebo for 48 weeks, with study visits in clinic for physical and laboratory assessments at weeks 0, 2, 4, 12, 24, 36, and 48 weeks during treatment period and at 4, and 12 weeks after the last dose.
89490873|NCT04652973||1/Prostate cancer dataset|Biopsy-proven prostate cancer patients who have abdomen CT studies that were available in the clinical PACS (picture archiving system) in the Clinical Center.
89490874|NCT04652973||2/Multiphase CT dataset|Men or women of all age and race, who have Multiphase abdomen-pelvic CT studies that were available in the PACS.
89490875|NCT04646200|Experimental|Cognitive Behavioral Therapy-Insomnia|CBT-I addresses cognitive, arousal and behavioral factors related to sleep difficulties. Sessions combine assessment, conceptualization, psychoeducation, behavioral strategies and cognitive therapy, using a consistent structure including review of participants' sleep log and adherence to behavioral guidelines, modification of time in bed, cognitive therapy, and relaxation techniques. CBT-I also incorporates psychoeducation about biological and psychological elements that regulate sleep. Other strategies include stimulus control (i.e., getting out of bed when not sleepy) to extinguish the conditioned arousal common in insomnia, and relaxation techniques to reduce arousal associated with the bed, bedroom, or bedtime.
89490876|NCT04646200|Active Comparator|Health and Wellness|Health and Wellness is a general self-management curriculum focused on providing education and support for managing physical and emotional well-being. Each session follows a basic structure including review of previous session material, new educational information and discussion on several topics over the course of single or multiple sessions. Each session will focus on the impact of the topic on overall health and wellness, identifying benefits and challenges to improving or maintaining health in that area, and strategies that clients may find helpful to address challenges in that area. Example topics include physical activity/exercise, nutrition/healthy eating, managing medications and side effects, and addictive behaviors (e.g., substance use, gambling, eating).
89490877|NCT04635865|Experimental|3D-printed patient-specific plate group|3D-printed patient-specific plate will be used for reconstruction in this patient group
89490878|NCT04635865|Active Comparator|Conventional plate group|conventional commercial plates will be used for reconstruction in this patient group
89490879|NCT04632030|Active Comparator|Control|The tobacco power wall and number of products appears in a typical format: large power wall with a large number of products (defined here as three large cabinets)
89490880|NCT04632030|Experimental|Small|The tobacco power wall and number of tobacco products appear in their smallest format: small power wall with a small number of products displayed (defined here as one large cabinet)
89490881|NCT04632030|Experimental|Medium|The tobacco power wall and number of tobacco products appear in a format sized between the control and small conditions: a medium sized power wall with a medium number of products displayed (defined here as two large cabinets).
89490882|NCT04613154|Active Comparator|Magnesium|Given 1000 mg oral magnesiumcitrate once daily (4*250mg) during the day of surgery and the next 6 Days.
89490883|NCT04613154|Placebo Comparator|Placebo|Given placebo once daily during the day of surgery and the next 6 Days.
89490884|NCT04596345||University students|"This group will include all those participants who declare to be attending a study program to get a higher education degree.~No intervention will be applied."
89490885|NCT04596345||Non-university-attending peers|"This group will include all those participants who are not attending a study program to get a higher education degree.~No intervention will be applied."
89490886|NCT04594980|Other|Minimally invasive TLIF|Patients will undergo a single level decompression and fusion using a minimally invasive technique. Followed posterior screw fixation is mandatory.
89490887|NCT04594980|Other|Open TLIF|Patients will undergo a single level decompression and fusion using an open traditional technique. Followed posterior screw fixation is mandatory.
89490888|NCT04572230||Evolve EU|Selected hospitals for participation
89490889|NCT04572230||Evolve FR|All hospitals in France using the device
89490890|NCT04567693|Experimental|Early 1|Advance to spaced-out appointments at month 6 after a single viral load is measured.
89490891|NCT04567693|Experimental|Early 2|Advance to spaced-out appointments at month 6 after two viral loads are measured.
89490892|NCT04567693|No Intervention|Usual Care|Do not advance to spaced-out appointments during study period
89490893|NCT04566731|Active Comparator|tDCS + CILT|Participants will undergo 10 daily sessions (Monday-Friday, x2 weeks) of tDCS for 20 minutes using a montage in which an anode (1.5 mA) is placed over F7 (left frontotemporal lobe) and the cathode will be place on O1 (left occipital) using the 10-20 EEG mapping system. Subjects will participate in a modified constraint-induced language therapy.
89490894|NCT04566731|Sham Comparator|Sham tDCS + CILT|Participants will undergo 10 daily sessions (Monday-Friday, x2 weeks) of sham tDCS for 20 minutes using a montage in which an anode is placed of F7 and cathose is placed over O1. Subjects will participate in a modified constraint-induced language therapy,
89490895|NCT04549077||Cystic Fibrosis Patients|Patients with Cystic Fibrosis.
89490896|NCT04549077||Historical Controls|Patients diagnosed with solid tumors, who have had a normal chest CT scan during screening for possible metastasis
89490897|NCT04501627||Participants with RE|Participants diagnosed with RE who have received 20 milligram (mg) of vonoprazan in routine clinical practice, will be observed prospectively. Data will be collected from participants' medical records, self-reported questionnaires and recorded information on symptom via diaries.
89204427|NCT04001140|Active Comparator|Intervention group|The intervention group will take part in the sessions of the intervention, in which they learn different skills for the purpose of emotion regulation. All participants will complete the questionnaires and take part in the experiment again. This group prevention program, which is short-term, entailing 7 sessions, synthesizes techniques from three therapeutic models: Cognitive-Behavioral Therapy, Dialectical-Behavioral Therapy and Acceptance and Commitment Therapy.
89490898|NCT04484740|Experimental|Gepotidacin|
89490899|NCT04481347||Patients undergoing general anesthesia|Patients eligible for interventional neuroradiology or surgery performed under general anesthesia. Patients will be included if they are admitted for a non-emergency scheduled procedure.
89490900|NCT04475146||Standard information and video visualization|Standard information and video visualization
89490901|NCT04475146||Standard information, no video|Standard information, no video
89490902|NCT04472065|Active Comparator|Subjects receiving Probiotic Dietary Supplement|
89490903|NCT04472065|Placebo Comparator|Subjects receiving Placebo|
89490904|NCT04469530|Experimental|Maintenance Chemotherapy Regimen|"Participants with metastatic osteosarcoma, metastatic Ewing sarcoma, high-risk rhabdomyosarcoma, metastatic non-rhabdomyosarcoma soft tissue sarcoma (NRSTS), desmoplastic small round cell tumor (DSRCT), and malignant rhabdoid tumor (MRT) in first complete remission (cohort 1) or participants with recurrent solid tumors (any histology) in second complete remission (cohort 2), receiving a maintenance chemotherapy regimen administered as a 12-month course of continuous sirolimus with celecoxib and low-dose oral etoposide alternating every 21 days with low-dose oral cyclophosphamide following the completion of standard therapy."
89490905|NCT04469530|No Intervention|Historical Control Cohort Receiving Standard Therapy|This study arm is a historical control cohort of patients matched with cohort 1 on diagnosis, age, metastatic site, and date of diagnosis. The matched historical controls will be obtained from the same treating institution as the corresponding case to account for institutional differences in treatment and supportive care. Patients in the historical control cohort received standard therapy.
89490906|NCT04445740|Experimental|Intervention|Participants will receive an intervention and will participate in assessments
89490907|NCT04445740|No Intervention|Control|Participants will not receive an intervention, but will participate in assessments
89490908|NCT04443023|Active Comparator|Sapien|Patients randomized to treatment
89490909|NCT04443023|Active Comparator|Myval|Patients randomized to treatment
89490910|NCT04423679||CIN2+|Cases of cervical precancer will include women diagnosed with cervical intraepithelial grades 2 or 3 (CIN2/3) or adenocarcinoma in situ (AIS). If any women are diagnosed with cancer in the study, they will be included in this group.
89490911|NCT04423679||< CIN2|Non-cases will include those with <CIN2 on colposcopy/biopsy and women who did not have an indication for colposcopy (because of a negative screening test).
89490912|NCT04401761||CAD/PAD-patients|Adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) who are treated with a combination of rivaroxaban and acetylsalicylic acid.
89490913|NCT04329975||Participants with Nocturia|Participants with nocturia due to nocturnal polyuria treated with MINIRINMELT OD Tablet 25μg or 50μg as per daily clinical practice.
89490914|NCT04324905|Experimental|Sequence 1|
89490915|NCT04324905|Experimental|Sequence 2|
89490916|NCT04303078|Experimental|Children with Cerebral Palsy (Cases)|Children meeting inclusion/exclusion criteria with a diagnosis of cerebral palsy.
89490917|NCT04303078|Other|Typically Developing Children (Controls)|Children meeting inclusion/exclusion criteria without a diagnosis of cerebral palsy or other condition.
89490918|NCT04288869||Interventional radiology or surgery under general anesthesia|Monitoring of patients (mean arterial blood pressure, Transcranial Doppler , bispectral index, near infrared spectroscopy) who benefit from intraoperative hemodynamic optimization with norepinephrine (as noradrenaline tartrate) for maintaining blood pressure under general anaesthesia during the interventional neuroradiology or orthopedic surgery in adults .
89490919|NCT04269811|Experimental|Flu-Bu-Mel|Fludarabine 150mg/m2 + Busulfan 3.2mg/kg 2 days + melphalan 50-70mg/m2
89490920|NCT04260217|Experimental|APG2575 400 mg|APG2575 400mg ramp up arm
89490921|NCT04260217|Experimental|APG2575 600 mg|APG2575 600 mg ramp up arm
89490922|NCT04260217|Experimental|APG2575 800 mg arm|APG2575 800 mg arm ramp up
89490923|NCT04248569|Experimental|DNAJB1-PRKACA peptide vaccine, Nivolumab, and Ipilimumab|
89490924|NCT04238663|Experimental|MB02 (Bevacizumab Biosimilar)|Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.
89490925|NCT04238663|Active Comparator|EU approved Avastin®|Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.
89490926|NCT04238663|Active Comparator|US licenced Avastin®|Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.
89490927|NCT04235660|Active Comparator|Yttrium-90 Radiation Segmentectomy|
89490928|NCT04235660|Active Comparator|Stereotactic Body Radiation Therapy|
89490929|NCT04227977|Experimental|Treatment|JuxtaFlow
89490930|NCT04192929|Placebo Comparator|High definition white light endoscopy|colonoscopy performed using high definition equipment
89490931|NCT04192929|Active Comparator|Chromoendoscopy|indigo carmine is sprayed on the colon mucosa during withdrawal phase
89490932|NCT04192929|Experimental|Narrow band imaging|Narrow band imaging is used during withdrawal phase
89490933|NCT04180423||Off-the-Shelf Total Knee Arthroplasty Patients|
89490934|NCT04180423||Conformis iTotal Total Knee Arthroplasty Patients|
89490935|NCT04142957||Focus Groups|"The investigators will invite 13-15 participants to attend the focus groups, of which it is expected that 10-12 to attend. Participants will be asked to bring a smart phone. An Informed Consent Form will be signed by the participant and a delegated researcher before the focus groups begin.~The current generation of COPD Pal will be downloaded onto the participants' own smart phones (see Appendix 1 for current screenshots of app), participants will then be explained the purpose of the app, and asked to interact with it for 15-60 minutes, as required.~A semi-structured focus group will then be conducted with the participants to facilitate conversation and discussion regarding COPD Pal. Once introductions have been completed, questions will be asked relating to the usability and acceptability of COPD Pal (see the Interview Schedule, Appendix 2). The focus group will last 30-60 minutes, as required."
89490936|NCT04139642||Group AB|A block randomization scheme by clinic type will be used to assign which clinics receive the Balance+Weight device in the first 9 months and which clinics receive the Balance+Weight device in the second 9 months. The block randomization scheme is proposed instead of simple randomization because of the expected variation between clinics in the types of patients they see. At the 9-month point, OSU personnel will go to every site to reprogram each device from Balance+Weight mode to Weight Only mode or vice versa, and to move the immediate feedback kiosks to the new Balance+Weight sites.
89490937|NCT04139642||Group BA|A block randomization scheme by clinic type will be used to assign which clinics receive the Balance+Weight device in the first 9 months and which clinics receive the Balance+Weight device in the second 9 months. The block randomization scheme is proposed instead of simple randomization because of the expected variation between clinics in the types of patients they see. At the 9-month point, OSU personnel will go to every site to reprogram each device from Balance+Weight mode to Weight Only mode or vice versa, and to move the immediate feedback kiosks to the new Balance+Weight sites.
89490938|NCT04136912|Experimental|Breast Imaging Cohort|A total of 15 women with known breast lesions that are already scheduled to undergo a clinical biopsy
89490939|NCT04136912|Experimental|Thyroid Imaging Cohort|A total of 15 participants with known thyroid lesions that are already scheduled to undergo a clinical biopsy
89490940|NCT04136912|Experimental|Healthy Volunteers Cohort|A total of 15 participants will be included to optimize imaging parameters.
89490941|NCT04129580|Experimental|Treatment-As-Usual (TAU) + reSET-O|Participants randomly assigned to this arm will receive their TAU alongside the use of the app, reSET-O.
89490942|NCT04129580|No Intervention|TAU only|Participants randomly assigned to this arm will receive their TAU only (no use of the app, reSET-O).
89490943|NCT04102020|Experimental|Part 1: Dose Confirmation|Participants will receive venetoclax once daily (QD) (Days 1-28) for up to 48 cycles, azacitidine (AZA) QD on Days 1-5 of each 28 day cycle for up to 6 cycles.
89490944|NCT04102020|Experimental|Part 3 (Dose Finding): Dose Escalation|Participants will receive venetoclax QD for up to 24 cycles, CC-486 QD on Days 1 to 14 of each 28-day cycle for up to 24 cycles to determine recommended phase 3 dose (RPTD).
89490945|NCT04102020|Experimental|Part 3 (Dose Finding): Safety Expansion|Participants will receive venetoclax QD for up to 24 cycles, CC-486 QD on Days 1 to 14 of each 28-day cycle for up to 24 cycles at the RPTD.
89490946|NCT04090502|Experimental|Grupo A. Dry needling in Trigger point|Participants will be treated in the most hyperalgesic foci within the hamstring musculature.
89490947|NCT04090502|Placebo Comparator|Grupo B. Dry needling in non-hyperalgesic areas|Participants will be treated in non-hyperalgesic areas within the hamstring muscles.
89490948|NCT04060017|Experimental|L-leucovorin calcium|The liquid form of leucovorin calcium will be dosed by weight, with a target dose of 1mg/kg/day, divided into two daily doses. This product may be taken alone or mixed with liquid. Participants randomized to this arm will receive active treatment for both 12-week phases of the study.
89490949|NCT04060017|Placebo Comparator|Placebo|The placebo will mimic the experimental treatment in flavor, odor, packaging, and dosing instructions. Participants randomized to this arm will receive placebo for the first 12 weeks of the study, then active treatment for the remaining 12 weeks.
89490950|NCT04052698|Experimental|All patients|Patients with type 3, type 2 (except 2N), or severe type 1 VWD aged ≥6 years at screening receiving Wilate for prophylactic treatment.
89490951|NCT04046991|Active Comparator|HD-tDCS+mCILT|Participants will undergo 10 daily sessions (Monday-Friday, x2 weeks) of HD-tDCS for 20 minutes using a montage in which a central electrode (1.5mA) is placed over the left frontotemporal area and four surrounding cathodes (.375mA each). Subjects will participate in a modified constraint-induced language therapy.
89490952|NCT04046991|Sham Comparator|Sham+mCILT|Participants will undergo 10 daily sessions (Monday-Friday, x2 weeks) of sham for 20 minutes using a montage in which a central electrode is placed over the left frontotemporal area and four surrounding cathodes. Subjects will participate in a modified constraint-induced language therapy,
89490953|NCT04039568|Active Comparator|Active Control Group|"Ten to fifteen participants in the HEP arm will participate in the program for 4 consecutive days (2hrs/day) in the 1st week, followed by 75 min/week reinforcement sessions for 11 weeks.~The Health-Enhancement Program (HEP) was designed and used as a manualized active control in meditation-based intervention trials. HEP controls for several non-specific factors found in a meditation groups, including: group support and morale, behavioural activation, reduction of stigma, facilitator attention, treatment duration, and time spent on at-home practice. HEP is tailored to be structurally equivalent to SSM with similar-sized groups, meeting schedule, total contact hours, amount of home practice and encouragement to keep practice logs."
89490954|NCT04039568|Experimental|Intervention Group|"Ten to fifteen participants in the SSM arm will be trained for 4 consecutive days (2hrs/day) in the 1st week, followed by 75 min/week reinforcement sessions for 11 weeks.~This standardized, manualized therapy will be delivered by certified meditation instructors. On day 1, participants will learn the nature of meditation, and then undergo personal guided meditation. Training on days 2-4 includes understanding the nature of the mind and the thoughts arising from it, guided meditations by the instructor, and a discussion of meditation processes. Weekly 75 min reinforcement sessions will include 20 minutes of guided meditation practice, and then focus on participants' experiences with meditation during the week, additional observations, and a review of relevant knowledge to support their home practice. Participants will also be encouraged to practice twice daily at home for 20 minutes per session."
89490955|NCT03862716|Experimental|Intervention|Drug: IDegLira - sc injection; Drug: metformin - oral administration; Drug: insulin degludec - sc injection; Behavioral: lifestyle therapy, diet and exercise
89490956|NCT03862716|No Intervention|Standard Care|Standard glycemic care as informed by the current clinical practice guidelines
89490957|NCT03840239|Experimental|TNT arm|"Drug: Neoadjuvant chemotherapy Capeox (Capecitabine + Oxaliplatin), 6 cycles; adjuvant chemotherapy, Capecitabine, 2 cycles or physicians' decision.~External beam radiotherapy: Neoadjuvant, 50 Gy, 2 Gy/session; 25 fractions. Procedure: 'Watch and wait strategy' or surgery including local excision, intersphincter resection or total mesorectal excision or other kinds of surgeries."
89490958|NCT03833661|Experimental|M7824|
89490959|NCT03824808|Active Comparator|Treatment group|Lidocaine Hydrochloride 0.8% in Dextrose 5% Solution
89490960|NCT03824808|Placebo Comparator|Control group|0.9% Sodium Chloride Injection
89490961|NCT03813537|No Intervention|Standard of Care|The control will be discharged with standard of care follow-up instructions and scheduled for a standard follow-up clinic visit within 2-3 weeks post-op.
89204428|NCT04001140|No Intervention|Waiting-list group|The waiting-list group will receive the intervention 7 weeks after the intervention group finishes. The intervention group will finish the research in week 7, while the waiting-list group will start to attend the intervention. They will complete the questionnaires and the experiment.
89204429|NCT00812448|Experimental|tea catechin extracts containing mask|wearing the tea catechin extracts containing mask
89204430|NCT05326672|Experimental|Benvitimod Cream|Benvitimod cream, 1%, applied twice daily for 8 weeks after enrolment.
89204431|NCT05326672|Placebo Comparator|Placebo|Placebo, applied twice daily for 8 weeks after enrolment.
89204432|NCT00295633|Experimental|Saxagliptin plus open-label TZD (A)|"Saxagliptin PLUS pioglitazone OR rosiglitazone~PLUS open-label metformin (as needed as rescue medication)"
89204433|NCT00295633|Experimental|Saxagliptin plus open-label TZD (B)|"Saxagliptin PLUS pioglitazone OR rosiglitazone~PLUS open-label metformin (as needed as rescue medication)"
89490962|NCT03813537|Experimental|Phone Call|The experimental group will receive a phone call intervention 3 days post-op. During this phone call, the patient will be asked questions using a study questionnaire based on the most frequent indications for readmission post colorectal surgery. Based on the responses, patients will be advised to maintain the scheduled appointment, visit the clinic within 48 hours, or go to the Emergency Department immediately.
88953788|NCT01965795|Placebo Comparator|Nutrim|"Nutrim will be capsulated in size 1 gelatin capsules, white and blue, distributed in brown plastic bottles (28 caps/bottle: enough for 14 days of treatment). The first bottle will be provided at the time of randomization, and the second bottle will be provided on day 14 for dosing on days 15-28. The bottle will be labeled with the ABC logo and treatment code.~A dose of 100 mg will be administered twice daily (once before breakfast and again before dinner)."
88953789|NCT01965795|Experimental|Whole Coffee Fruit Concentrate (WCFC)|"WCFC is in powder form, and will be capsulated in size 1 gelatin capsules, white and blue, distributed in brown plastic bottles (28 caps/bottle: enough for 14 days of treatment). The first bottle will be provided at the time of randomization, and the second bottle will be provided on day 14 for dosing on days 15-28. The bottles will be labeled with the ABC logo and treatment code.~A dose of 100 mg will be administered twice daily (once before breakfast and again before dinner)."
88953790|NCT01965808|Experimental|LY2157299 (Fasted)|Single dose of 150 mg LY2157299 administered orally in fasted state in one of two study periods.
88953791|NCT01965808|Experimental|LY2157299 (Fed)|Single dose of 150 mg LY2157299 administered orally in fed state in one of two study periods.
88953792|NCT01965821|Other|Continuous control of Pcuff followed by manual control|Patients receive continuous control of cuff pressure with Mallinckrodt electronic device for 24h, followed by discontinuous control (every 8 hours) with a manual manometer for 24h.
88953793|NCT01965821|Other|Manual control of Pcuff followed by continuous control|Patients receive the reverse sequence (manual control followed by continuous control of Pcuff)
88953794|NCT01965847|Active Comparator|AM dosing|The study student pharmacist will perform medication therapy management with a focus on antihypertensive medications and specifically on the once daily antihypertensive assigned to MORNING dosing. Medication therapy management will take place in the clinic or by phone. Medication therapy management will include review of antihypertensive medications, patient empowerment and education, and provision of a personal medication record to the participant with specific instructions regarding the once daily antihypertensive medication assigned to morning versus evening. If a patient is taking more than one antihypertensive medication, only one will be used for the current study.
89204434|NCT00295633|Placebo Comparator|Placebo plus open-label TZD (C)|"Placebo PLUS pioglitazone OR rosiglitazone~PLUS open-label metformin (as needed as rescue medication)"
89204435|NCT02368444|Experimental|Intervention Group|Cognitive Behavioral Therapy and Yoga
89204436|NCT05068596|Experimental|study groip|received the designed physical therapy program as the control group. In addition, they received progressive resistive functional strength training in the plantigrade foot position.
89204437|NCT05068596|Other|control group|received a designed physical therapy program
89490963|NCT03804060|Experimental|Cooling + Recanalization|The subjects will be considered to be enrolled in the Test Arm of the trial when all inclusion and exclusion criteria have been met, the informed consent form has been signed, and randomization to the Test Arm of the trial to allow cooling with the Thermogard XP3 IVTM System before and after recanalization.
89204438|NCT00570674|Experimental|Phase I Dose Level 1: ACE-RT|Phase I Dose Level 1 participants received Abraxane 20mg/m2 IV then carboplatin AUC 1.5 IV weekly during the period of radiotherapy for a total of 7 weeks. One dose (400 mg/m2 IV) of Erbitux was given prior to start of radiation, then weekly at 250 mg/m2 IV. Intensity-modulated radiotherapy (IMRT) was delivered 5 days per week with the prescribed dose of 70 Gy to the gross tumor volume, given in 2 Gy daily fractions for a total of 35 fractions.
89204439|NCT00570674|Experimental|Phase I Dose Level -1: AC-RT|Phase I Dose Level -1 participants received Abraxane 20mg/m2 IV then carboplatin AUC 1.5 weekly IV during the period of radiotherapy for a total of 7 weeks. Intensity-modulated radiotherapy (IMRT) was delivered 5 days per week with the prescribed dose of 70 Gy to the gross tumor volume, given in 2 Gy daily fractions for a total of 35 fractions.
89204440|NCT00570674|Experimental|Phase I Dose Level 2: AC-RT|Phase I Dose Level 2 participants received Abraxane 30mg/m2 IV then carboplatin AUC 1.5 weekly IV during the period of radiotherapy for a total of 7 weeks. Intensity-modulated radiotherapy (IMRT) was delivered 5 days per week with the prescribed dose of 70 Gy to the gross tumor volume, given in 2 Gy daily fractions for a total of 35 fractions.
89204441|NCT00570674|Experimental|Phase I Dose Level 3: AC-RT|Phase I Dose Level 3 participants received Abraxane 40mg/m2 IV then carboplatin AUC 1.5 IV weekly during the period of radiotherapy for a total of 7 weeks. Intensity-modulated radiotherapy (IMRT) was delivered 5 days per week with the prescribed dose of 70 Gy to the gross tumor volume, given in 2 Gy daily fractions for a total of 35 fractions.
89204442|NCT00570674|Experimental|Phase I Dose Level 4: AC-RT|Phase I Dose Level 4 participants received Abraxane 50mg/m2 IV then carboplatin AUC 1.5 IV weekly during the period of radiotherapy for a total of 7 weeks. Intensity-modulated radiotherapy (IMRT) was delivered 5 days per week with the prescribed dose of 70 Gy to the gross tumor volume, given in 2 Gy daily fractions for a total of 35 fractions.
89204443|NCT00808314|Active Comparator|LL for CAD|Subjects with <5% pre-test low likelihood for CAD based on Diamond and Forrester criteria will be recruited to undergo both rest/stress dipyridamole PET followed by a rest/stress Lexiscan(TM) PET with 30 days.
89204444|NCT00808314|Active Comparator|CAD|Subjects with existing mild-moderate ishemia demonstrated by a recent (< 1 month) rest/stress dipyridamole PET will undergo a rest/stress Lexiscan(TM) PET.
89204445|NCT00768989|Experimental|Atazanavir + Raltegravir|Atazanavir 300 mg twice daily + Raltegravir 400 mg twice daily
89204446|NCT00768989|Active Comparator|Atazanavir + Ritonavir + Tenofovir /Emtricitabine|Atazanavir, 300 mg once daily, + Ritonavir, 100 mg once daily, + Tenofovir 300 mg/Emtricitabine, 200 mg once daily
89204447|NCT04991038|Experimental|DAISe Thrombectomy Device|Mechanical Thrombectomy with DAISe
89204448|NCT04991038|Active Comparator|Stent Retriever|Mechanical Thrombectomy with TREVO or Solitaire Device
89204449|NCT00779714|Experimental|A (individualized combined chemotherapy)|
89204450|NCT00779714|Active Comparator|B (DTIC monochemotherapy)|
89204451|NCT00812760|Experimental|1|
89204452|NCT00814944|Experimental|Dose Group 1|
88956542|NCT04927247|Experimental|inclacumab 30 mg/kg|Inclacumab 30 mg/kg administered intravenously (IV)
89204453|NCT00814944|Experimental|Dose Group 2|
89204454|NCT00814944|Experimental|Dose Group 3|
89204455|NCT00814944|Placebo Comparator|Dose Group 4|
89204456|NCT05308498||ESView software with ProScan|evaluate the performance of the NaviCam SB Capsule System ProScan software feature in comparison with the PillCam SB3 Capsule system SBI feature
89204457|NCT05308498||Rapid software with SBI|evaluate the performance of the NaviCam SB Capsule System ProScan software feature in comparison with the PillCam SB3 Capsule system SBI feature
89204458|NCT02551536|Active Comparator|Group A|FDC tablet of montelukast 10 mg and levocetrizine 5 mg was given once daily for 4 weeks
89204459|NCT02551536|Experimental|Group B|FDC tablet of montelukast 10 mg and fexofenadine 120 mg was given once daily for 4 weeks
89204460|NCT02556164|Experimental|Real EA|"Real EA as intervention is performed at the selected standard acupuncture points and De-qi is achieved with needle manipulation before electric stimulation is delivered."
89204461|NCT02556164|Sham Comparator|Sham EA|Sham EA as intervention is performed for the control group at non-acupuncture points without needle manipulation. The electric stimulation in sham acupuncture was performed in a similar fashion to the real EA.
88956543|NCT04927247|Placebo Comparator|placebo|Placebo administered IV
89204462|NCT00815022|Active Comparator|1|Mixture of anesthetic including hyperbaric bupivacaine 12 mg, fentanyl 10 microg and morphine 200 microg, with the temperature of 20 degree celsius
89204463|NCT00815022|Experimental|2|Mixture of anesthetic including hyperbaric bupivacaine 12 mg, fentanyl 10 microg and morphine 200 microg, with the temperature of 10 degree celsius
89204464|NCT00815022|Experimental|3|Mixture of anesthetic including hyperbaric bupivacaine 12 mg, fentanyl 10 microg and morphine 200 microg, with the temperature of 15 degree celsius
89204465|NCT00815022|Experimental|4|Mixture of anesthetic including hyperbaric bupivacaine 12 mg, fentanyl 10 microg and morphine 200 microg, with the temperature of 25 degree celsius
89204466|NCT00815022|Experimental|5|Mixture of anesthetic including hyperbaric bupivacaine 12 mg, fentanyl 10 microg and morphine 200 microg, with the temperature of 30 degree celsius
89204467|NCT00815022|Experimental|6|Mixture of anesthetic including hyperbaric bupivacaine 12 mg, fentanyl 10 microg and morphine 200 microg, with the temperature of 35 degree celsius
89204468|NCT00774722|Experimental|Metronidazole|
89204469|NCT00774722|Placebo Comparator|Placebo|
89204470|NCT00808392|Experimental|1|
89204471|NCT00808392|Active Comparator|2|
89204472|NCT00779948||Targon FN|
89204473|NCT00779948||DHS|
89204474|NCT04045548|Experimental|dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia & Upjohn, Puurs, Belgium) inserted by the study nurse 2 hours before IUD insertion.
89204475|NCT04045548|Placebo Comparator|placebo|one tablet of placebo inserted by the study nurse 2 hours before IUD insertion.
89490964|NCT03804060|Active Comparator|Recanalization only|The subjects will be considered to be enrolled in the Control Arm of the trial when all inclusion and exclusion criteria have been met, the informed consent form has been signed, and randomization to the Control Arm of the trial to allow recanalization only.
89022002|NCT04715282|Other|Cawthorne-Cooksey exercises combined with the Epley maneuver|Additional Cawthorne-Cooksey exercises were prescribed to the EpleyM&Exe group. The physiotherapist explained and demonstrated the exercises to each patient and the patients practiced the exercises until they performed them correctly. Then the exercises were prescribed twice a day and repeated 10 times for 6 weeks as a home exercise program.
89490965|NCT03798691|Active Comparator|Anti-TNF monotherapy|Patients with IBD on Anti-TNF monotherapy will be given the shingrix vaccine. Dose and Schedule: Two doses (0.5 mL each) administered intramuscularly according to the following schedule: A first dose at Month 0 followed by a second dose administered anytime between 2 and 6 months later.
89490966|NCT03798691|Active Comparator|Vedolizumab|"Patients with IBD on vedolizumab monotherapy will be given the shingrix vaccine.~Dose and Schedule: Two doses (0.5 mL each) administered intramuscularly according to the following schedule: A first dose at Month 0 followed by a second dose administered anytime between 2 and 6 months later."
89490967|NCT03769116|Experimental|Delandistrogene Moxeparvovec in Part 1 Followed by Placebo in Part 2|Participant will receive delandistrogene moxeparvovec at Part 1 followed by matching placebo at Part 2 followed by an open-label extension at Part 3.
89490968|NCT03769116|Experimental|Placebo in Part 1 Followed by Delandistrogene Moxeparvovec in Part 2|Participant will receive matching placebo at Part 1 followed by delandistrogene moxeparvovec at Part 2 followed by an open-label extension at Part 3.
89490969|NCT03768492|Experimental|Caffeine Based Cream|caffeine based cream during and for 4 weeks following radiation
89490970|NCT03768492|Placebo Comparator|Placebo|placebo cream during and for 4 weeks following radiation
89490971|NCT03737383|Experimental|Feasibility and Preliminary Efficacy|We will be administering Narrative Exposure Therapy to determine participant responses to the intervention, whether the intervention can be delivered successfully in this setting, and preliminary outcomes.
89490972|NCT03733691|Experimental|Ixazomib Only|The prescribed dose administration of ixazomib in this study is 3mg orally on Days 1, 8, and 15 of a 28-day cycle.
89490973|NCT03733691|Experimental|Ixazomib + Lenalidomide|"The prescribed dose administration of ixazomib in this study is 3mg orally on Days 1, 8, and 15 of a 28-day cycle.~The prescribed dose administration of lenalidomide in this study is the same as the dose of the patient's front-line treatment taken in the last treatment cycle unless otherwise clinically indicated per investigator's discretion, taken orally on days 1-28 of a 28-day cycle. If patient was receiving lenalidomide at a higher dose than 10 mg, then the dose of lenalidomide on this study will be adjusted to 10 mg daily on days 1-28 of a 28-day cycle"
89490974|NCT03686124|Experimental|Dose Escalation A|Dose escalation of IMA203
89490975|NCT03686124|Experimental|Extension Cohort A|IMA203 at RP2D
89490976|NCT03686124|Experimental|Extension Cohort B|IMA203 at RP2D + nivolumab
89490977|NCT03686124|Experimental|Extension Cohort C|IMA203CD8 at provisional RP2D
89490978|NCT03686124|Experimental|Dose Escalation B|Dose escalation of IMA203CD8
89490979|NCT03657693||BPD|Infants born premature requiring oxygen
89490980|NCT03657693||Controls|
89490981|NCT03632863|Experimental|Electronic Patient Decision Aid|Participants login to a website where they access the interactive PDA as well as access standard published information and resources.
89490982|NCT03632863|Sham Comparator|Standard Resource Sheet|Participants login to a website where they access standard published information and resources.
89022003|NCT00447720|Experimental|PATH counseling|These participants received the PATH intervention
89022004|NCT00447720|Active Comparator|Treatment as Usual|These individuals receive treatment as they normally would receive in the community
89022005|NCT00344474|Experimental|learning to cope with your impulsivity|cognitive behavioural intervention teaching high impulsive youth how to manage their impulsive thinking and behaviours
89204476|NCT02262988|Experimental|Tourniquet used with intramedullary rod|Patients will undergo a total knee replacement with a tourniquet and intramedullary rod.
89204477|NCT02262988|Experimental|No tourniquet with intramedullary rod|Patients will undergo a total knee replacement without a tourniquet and with an intramedullary rod.
89204478|NCT02262988|Experimental|Tourniquet without intramedullary rod|Patients will undergo a total knee replacement with a tourniquet and without an intramedullary rod.
89490983|NCT03528187||Patient Cohort 1|"Age 18 or over~BMI greater than or equal to 30 (greater than or equal to 27.5 for patients of Asian origin)~Due to undergo or referred for a formal treatment intervention for obesity (lifestyle modifications [dietary change, behavioural therapy, increased physical activity], surgical intervention or pharmacological treatment) as part of their usual clinical care~Informed written consent~Able to tolerate MRI"
89490984|NCT03528187||Patient Cohort 2|"Age 18 or over~Attending weight management service at UCLH~Informed written consent~Able to tolerate MRI"
89490985|NCT03528187||Controls|"Age 18 or over~BMI less than 25~Informed written consent~Able to tolerate MRI"
89490986|NCT03527927|Experimental|LABA/LAMA inhaler|Patients on a combination of inhaled corticosteroid (ICS), long acting beta agonist (LABA) and long acting muscarinic antagonist (LAMA) will be taken off their current ICS/LABA/LAMA combination inhalers and will commence on a single LABA/LAMA inhaler (any LABA/LAMA) of their choice.
89490987|NCT03525756||Cystogram on Post-Op Day 2|An indwelling Foley catheter is placed intraoperative and continued postoperative. All patients who consent to participate would undergo a cystogram on postoperative day two. The cystogram will be conducted by a radiologist and technician well-trained in the techniques and interpretation of the study. The colorectal surgery enhanced recovery protocol will be followed on all patients with the exception of the cystogram being conducted on post-op day two.
89490988|NCT03510468|Experimental|Pharmacokinetic study in healthy volunteers|Healthy volunteers received Tenofovir alafenamide (TAF) 25 mg once daily for 14 days followed by TAF 25 mg once daily and Rifapentine (RPT) dosed by weight in 150-mg tablet increments (maximum oral dose of 900 mg) 750 or 900 mg (depending on weight) and Isoniazid (INH+ pyridoxine), 15 mg/kg (up to 900 mg) once weekly from days 15-31.
89490989|NCT03504709||Patient (n=50)|Adults with acute severe traumatic brain injury who undergo advanced neuroimaging and electrophysiological studies while in the intensive care unit and are followed for 6 months post injury.
89022006|NCT00344474|Experimental|learning to cope with your sensation seeking|cognitive-behavioural intervention teaching high sensation seeking youth how to manage their need for stimulation and excitement
89022007|NCT00344474|Experimental|learning to cope with your anxiety sensitivity|cognitive behavioural intervention targeting catastrophic thinking in high anxiety sensitive youth
89022008|NCT00344474|Experimental|learning to manage your negative thinking|cognitive behavioural intervention targeting pessimistic and negative thinking in hopeless youth
89022009|NCT00447759|Experimental|Celecoxib|Celecoxib. Celebrex 200-400mg daily in divided doses
89022010|NCT00447759|Active Comparator|Diclofenac|continue usual nsNSAID
89022011|NCT00454155|Experimental|Opebacan|
89022012|NCT00344552|Experimental|1|
89022013|NCT00447798|Experimental|Prevention Care Advocate|Prevention Care Advocate (PCA) intervention contains elements based on cognitive-behavioral theories and strengths-based case management. Intervention arm participants will undergo an 8 session intervention comprised of three components: 1) An individual strengths-based case management approach aimed at motivating participants to seek or maintain their engagement with HIV primary care and drug treatment; 2) A cognitive-behavioral, skills-building approach to increase participants' risk reduction knowledge, skills, and perceived self-efficacy as well as intention to change high risk transmission behaviors; and 3) A community placement in which study participants will have the opportunity to practice their advocacy skills in prevention and care setting.
89022014|NCT00447798|No Intervention|Standard of Care|"Standard of Care (SOC) condition involves standard practice, consisting of usual inpatient/hospital services provided within normal clinical practice, plus a brief educational session consisting of the review of the topics in the Living with HIV brochure published by the Centers for Disease Control and Prevention (CDC)."
89022015|NCT00447837|Experimental|1|
89022016|NCT00447837|Experimental|2|
89022017|NCT00447837|Placebo Comparator|3|
89022018|NCT00344591|Experimental|Tailored SET program|tailored SET program for reducing sexual and drug-related HIV transmission risk factors and increasing HIV treatment adherence in HIV infected men who have recently been released from prison
89022019|NCT00344591|Active Comparator|Individually focused therapy|Individually focused therapy program for reducing sexual and drug-related HIV transmission risk factors and increasing HIV treatment adherence in HIV infected men who have recently been released from prison
89022020|NCT00447915|Experimental|1|
89022021|NCT00447915|Experimental|2|
89022022|NCT00447915|Active Comparator|3|
89022023|NCT03274791||Healthy subjects|"Healthy non-smoking subjects were never smokers with normal spirometry and did not have a history of lung disease or chronic respiratory symptoms.~Information about respiratory symptoms and comorbidities were collected. Healthy subjects underwent pulmonary function tests (Spirometry). Induced sputum was collected to determine total and differential inflammatory cells counts as well as inflammatory mediators (Interleukin-8 and tumor necrosis factor-alpha)."
89022024|NCT03274791||COPD Never smokers|"Never smokers referred to subjects who had never smoked Airflow limitation in COPD was defined as a post-bronchodilator forced expiratory volume in 1 second (FEV1) to forced vital capacity (FVC) ratio <70% and FEV1 reversibility of <12% and 200 mL from baseline values after inhalation of 400 µg of Salbutamol.~Information about respiratory symptoms and comorbidities were collected. Never smoking subjects with COPD underwent pulmonary function tests (Spirometry). Induced sputum was collected to determine total and differential inflammatory cells counts as well as inflammatory mediators (Interleukin-8 and tumor necrosis factor-alpha)."
89022025|NCT03274791||COPD Smokers|"Smokers were defined as persons who had smoked > 20 packs of cigarettes in a lifetime and who continue smoking every day.~Airflow limitation in COPD was defined as a post-bronchodilator forced expiratory volume in 1 second (FEV1) to forced vital capacity (FVC) ratio <70% and FEV1 reversibility of <12% and 200 mL from baseline values after inhalation of 400 µg of Salbutamol.~Information about respiratory symptoms and comorbidities were collected. Smoking subjects with COPD underwent pulmonary function tests (Spirometry). Induced sputum was collected to determine total and differential inflammatory cells counts as well as inflammatory mediators (Interleukin-8 and tumor necrosis factor-alpha)."
89022026|NCT03274713|Experimental|Electro-acupuncture group|After recruiting, patients are assigned to the electro-acupuncture group by randomization,and then receive electro-acupuncture treatment.Both treatments consist of 24 sessions of 30 minutes duration, administered over 8 weeks (usually three sessions per week). Participants in both groups will be evaluated at baseline, 4 weeks, 8 weeks, 12 weeks and 16 weeks.
89022027|NCT03274713|Experimental|Manual acupuncture group|After recruiting, patients are assigned to the manual acupuncture group by randomization,and then receive manual acupuncture treatment.Both treatments consist of 24 sessions of 30 minutes duration, administered over 8 weeks (usually three sessions per week). Participants in both groups will be evaluated at baseline, 4 weeks, 8 weeks, 12 weeks and 16 weeks.
89022028|NCT00344786|Experimental|CNF2024|
89022029|NCT03274674|Experimental|I-PRF|Venous blood will be taken from the patient every session and I-PRF will be created in the centrifuge.I-PRF injected on one side of bilateral thin gingival thickness.Apply once a week and one month after the end of the injections, the patient will be called to the control.
89204479|NCT02262988|Experimental|No tourniquet without intramedullary rod|Patients will undergo a total knee replacement without a tourniquet nor an intramedullary rod.
89490990|NCT03504709||Healthy (n=25)|Healthy adults with no neurological, psychiatric, or medical disease.
89490991|NCT03472599|Experimental|Genital Nerve Stimulation|Study participants in this arm will use take-home genital nerve stimulation for 24+ months in order to assess its effectiveness at decreasing urinary incontinence. In order to set effective genital nerve stimulation parameters, study participants will undergo clinical urodynamics every 6 months in which sensitivity to and tolerance of electrical stimulation are assessed.
89490992|NCT03374202|Experimental|Group 1: AAV8-VRC07 (5 x 10^10 vg/kg IM)|AAV8-VRC07 (5 x 10^10 vg/kg) administered by intramuscular (IM) injection (Day 0)
89490993|NCT03374202|Experimental|Group 2: AAV8-VRC07 (5 x 10^11 vg/kg IM)|AAV8-VRC07 (5 x 10^11 vg/kg) administered by IM injection (Day 0)
89490994|NCT03374202|Experimental|Group 3: AAV8-VRC07 (2.5 x 10^12 vg/kg IM)|AAV8-VRC07 (2.5 x 10^12 vg/kg) administered by IM injection (Day 0)
89490995|NCT03312920|Experimental|active anodal tDCS|active anodal tDCS with Face Name associate Memory task
89490996|NCT03312920|Sham Comparator|Sham tDCS|sham tDCS with Face Name associate Memory task
89490997|NCT03312920|Experimental|active cathodal tDCS|active cathodal tDCS with Face Name associate Memory task
89490998|NCT03289754|Experimental|ConforMIS iTotal Knee with iPoly Insert|The tibial insert being utilized in this study will be a highly-crosslinked, Vitamin-E enriched UHMWPE (iPoly XE) instead of traditional tibial inserts.
89490999|NCT03289000||ConforMIS PS Group|Patients who have undergone a total knee replacement with the ConforMIS iTotal PS Knee Replacement System
89491000|NCT03266653|Experimental|Refractory EBV|Patients with refractory EBV will get one dose of EBV specific CTLs. If they don't show a response based on EBV PCRs, patients may get up to another 4 doses of EBV-CTLs (5 doses maximum)
89491001|NCT03266640|Experimental|Refractory CMV|Patients with refractory CMV will be given one dose of CMV specific CTLs. HLA matched donors will get Dose 2.5 × 10(4) CD3/kg recipient weight; HLA mismatched will get 0.5x10(4) CD3/kg recipient weight. Additional doses may be given for a total of 5 doses if patients do not have a response to the first dose with a reduction in viral load to normal limits.
89491002|NCT03266627|Experimental|patients with adenoviral infection|patients will receive CTL dose x 1 with 2.5 × 10(4) CD3/kg for matched related donor and 0.5 × 104 CD3/kg for mis-matched related donor. Patients who don't respond to the first infusion may receive up to a total 5 CTL infusions.
89491003|NCT03248739|Active Comparator|Clear Bactiseal 'large' catheter (EVD)|All EVDs will be placed by neurological surgeons in either the major operating suite or in an ICU setting using a previously published protocol. This protocol includes using a burr hole entry point 1 cm anterior to the coronal suture in the mid-pupillary line, prep and sterile drape, pre-procedural antibiotic administration, and tunneling the catheter to an exit site at least 5 cm from the incision. In general, physicians are instructed to first attempt distal irrigation of the drainage chamber using sterile techniques (rarely effective), followed by gentle aspiration of the proximal system and catheter if distal flushing is not effective. If these do not restore patency, a small volume of sterile saline, 3 ml or less, is flushed proximally into the catheter. Patency is checked by lowering the EVD drainage system and evaluating for spontaneous flow through the EVD.
89491004|NCT03248739|Active Comparator|Orange Bactiseal 'small' catheter (EVD)|All EVDs will be placed by neurological surgeons in either the major operating suite or in an ICU setting using a previously published protocol. This protocol includes using a burr hole entry point 1 cm anterior to the coronal suture in the mid-pupillary line, prep and sterile drape, pre-procedural antibiotic administration, and tunneling the catheter to an exit site at least 5 cm from the incision. In general, physicians are instructed to first attempt distal irrigation of the drainage chamber using sterile techniques (rarely effective), followed by gentle aspiration of the proximal system and catheter if distal flushing is not effective. If these do not restore patency, a small volume of sterile saline, 3 ml or less, is flushed proximally into the catheter. Patency is checked by lowering the EVD drainage system and evaluating for spontaneous flow through the EVD.
89491005|NCT03218826|Experimental|Treatment (docetaxel, PI3Kbeta inhibitor AZD8186)|Patients receive docetaxel IV over 1 hour on day 1 and PI3Kbeta inhibitor AZD8186 PO BID for 5 days each week. Cycles repeat every 21 days until April 30, 2022 in the absence of disease progression or unacceptable toxicity.
89491006|NCT03192501||Study group (A group)|In this group, we perform whole exome or genome sequencing of tumor sample in compared to blood sample, screen tumor-related special mutations by using biomedical informatics analysis procedure and utilized the iCAGES system to rank the most appropriate drugs available and then manually examine this list to select the best therapeutic strategy for the patient based on availability of drug and expert knowledge. The PFS, OS, and quality of life (QOL) will be recorded and compared with that from standard care.
89491007|NCT03192501||Control group (B group)|In this group, patients with advanced cancers (matched with Group A) will be treated under the guidance of NCCN, without performing iCAGES analysis.
89491008|NCT03192501||Control group (C group)|In this group, patients with advanced cancers (matched with Group A) will be treated with appropriate targeted drugs according to IHC detection of more than 20 protein molecules with blank tissue slides from the cancer.
89491009|NCT03152357||Patients implanted with a ConforMIS device|Previously underwent surgical implantation of a ConforMIS iUni, iDuo or iTotal knee replacement
89491010|NCT03149809|Active Comparator|Behavioral therapy|Pelvic floor muscle exercise-based behavioral therapy
89491011|NCT03149809|Active Comparator|Drug Therapy|Daily solifenacin drug therapy
89491012|NCT03146819||iTotal PS KRS|Patients who have had an iTotal (posterior stabilized) knee replacement at least 6 months prior to testing.
89491013|NCT03146819||Off-the-Shelf KRS|Patients who have had an off-the-shelf (posterior stabilized) knee replacement at least 6 months prior to testing.
89491014|NCT03063632|Experimental|Group I (pembrolizumab, interferon gamma-1b)|Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 3 weeks for up to 2 years in the absence of disease progression or unexpected toxicity. Patients also receive interferon gamma-1b SC 3 times per week for 12 weeks, and then follow 3 weeks on and 3 weeks off schedule for up to 2 years in the absence of disease progression or unexpected toxicity.
88956544|NCT04925284|Experimental|XB002 Single-Agent Dose-Escalation Cohorts|Subjects (Cohort A) will accrue in cohorts of 3-12 subjects in a modified i3+3 design.
89204480|NCT02556944|Experimental|Mix and matched patients|Mix and matched patients will get phacoemulsification with multifocal intraocular lens implantation with two different add power (+2.75 diopters (D) or +3.25 D, respectively) in each eye of a patient, contralaterally.
89204481|NCT00808548||Lifestyle counseling|
89204482|NCT04920136|Experimental|Strip Free gingival graft (SGG) + Acellular Dermal Matrix graft (ADM)|"A horizontal incision is then placed at the middle of residual KT. Two vertical releasing incisions are followed to allow for apical displacement of the flap. The recipient site should ideally retain intact periosteum that is firmly attached to bone with no loose fibers, no irregularities and no perforations.~A strip of a free gingival graft is then harvested from the patient's palate. This strip is only 2 to 3 mm wide ,1 to 1.5 mm thick and has an appropriate length to cover the full apical extension of the recipient site. The strip is sutured immediately with 6-0 monocryl sutures. Coronal to the strip, the periosteal bed is covered with ADM, which is already rehydrated in sterile saline for 10 min, trimmed and customized to fit the available space. The ADM is then stabilized on the periosteal bed with the epithelium side facing upward. The ADM is fixed on the recipient bed by periosteal 6-0 monocryl sutures."
89204483|NCT04920136|Active Comparator|Free gingival graft.|Two vertical incisions are made, and a partial thickness flap are designed to provide a firm and immobile periosteal bed. The raised partial thickness flap will be excised. Muscle and unattached connective tissue fibers are thoroughly scraped with a scalpel to prevent graft mobility. Autogenous FGG was harvested with #15C scalpel blade from hard palate at the same side randomly selected to receive the FGG. Donor area will be sutured with 5-0 gut sutures. FGG, is placed and stabilized with simple interrupted 5-0 vicryl sutures at recipient site coronal border and horizontal or periosteal anchorage sutures over the graft.
89204484|NCT00780104|Experimental|Rapamycin + MEC|
89204485|NCT00815100|Placebo Comparator|Placebo|
89204486|NCT00815100|Active Comparator|Ivabradine|
89204487|NCT00992212|Experimental|Group A (Seasonal TIV + 7.5mcg HA+ full dose MF59)|
89204488|NCT00992212|Experimental|Group B (Ajuvanted Seasonal TIV + 7.5mcg HA+ full dose MF59)|
89204489|NCT00992212|Experimental|Group C (7.5mcg HA+ full dose MF59)|
89204490|NCT00992212|Experimental|Group D (7.5mcg HA+ full dose MF59 + Seasonal TIV)|
89204491|NCT00992212|Experimental|Group E (3.75mcg HA+ ½ dose MF59+ Seasonal TIV)|
89204492|NCT04047680||SOF-based DAAs|Patients receiving sofosbuvir (SOF)-based direct acting antiviral agents (DAAs) for 12 weeks
89204493|NCT04047680||SOF-free DAAs|Patients receiving sofosbuvir (SOF)-free direct acting antiviral agents (DAAs) for 12 weeks
89204494|NCT00815178|Experimental|Inspiratory muscle training|
89204495|NCT00815178|Placebo Comparator|Placebo|
89204496|NCT00774878|Experimental|Arm A|
89204497|NCT00774878|Active Comparator|Arm B|
89204498|NCT04917172||Pancreaticoduodenectomy patients|Patients scheduled to receive elective Pancreaticoduodenectomy (PD) (according to Kausch-Whipple or Longmire-Traverso) for all kinds of pancreatic disease (benign, malignant or premalignant) will be enrolled, after having signed a proper informed consent. Each patient will undergo PD once checked the presence of a resectable mass as provided by the normal clinical practice through high-quality cross-sectional imaging. Pre-operative management will follow institutional standards, serum pancreatic amylase and lipase activity will be measured as a part of the standard pre-operative evaluation.
89204499|NCT00815256|Experimental|Cross linking (CXL)|Patients with progressive mild and moderate grades of ketatoconus are randomized and allocated to this group and submitted to the treatment with riboflavin and ultraviolet -A light. They do not match any of the exclusion criterion: pregnancy, corneal thickness less than 400 μm, history of corneal surgery, herpes ocular infection, other corneal disease or scarring, chemical injuries and riboflavin allergy.
89204500|NCT00774956|Experimental|1|Subject with shoulder impingement
89204501|NCT00774956|Active Comparator|2|Healthy persons
89204502|NCT00815334|Experimental|Patients with decreased bladder compliance|Patients who have decreased bladder compliance
89204503|NCT00815334|Active Comparator|Patients with normal bladder compliance|Patients who have normal bladder compliance
89204504|NCT00778778|Experimental|1|Cefprozil 500mg tablets of ranbaxy
89204505|NCT00778778|Active Comparator|2|CEFZIL ® 500 mg cefprozil tablets of BMS, USA
89204506|NCT00778778|Active Comparator|3|CEFZIL ® 500 mg tablets, BMS Canada
89204507|NCT00815412|Active Comparator|Counseling in use of health care|
89204508|NCT00815412|Active Comparator|Counseling in diet, exercise|
89204509|NCT00815412|Placebo Comparator|Contol group|
89204510|NCT00305773|Experimental|Arm I (once daily vorinostat)|Patients receive oral vorinostat (SAHA) once a day on days 1-21. In both arms, treatment repeats every 21 days for up to 17 courses in the absence of disease progression or unacceptable toxicity.
89204511|NCT00305773|Experimental|Arm II (thrice daily vorinostat)|Patients receive oral SAHA three times a day on days 1-14. In both arms, treatment repeats every 21 days for up to 17 courses in the absence of disease progression or unacceptable toxicity.
89204512|NCT00778856|Experimental|Hand Transplant|
89491015|NCT03063632|Experimental|Group II (pembrolizumab, interferon gamma-1b)|Patients pembrolizumab IV over 30 minutes on day 1 and interferon gamma-1b SC once a week. Cycles repeat every 3 weeks for up to 2 years in the absence of disease progression or unexpected toxicity.
89491016|NCT03042975||Laryngeal Dystonia|Patients with laryngeal dystonia will undergo an MRI of the brain and a blood draw.
89491017|NCT03042975||Unaffected relatives of laryngeal dystonia patients|Unaffected relatives of patients with laryngeal dystonia will undergo an MRI of the brain and a blood draw.
89491018|NCT03042975||Voice tremor|Patients with voice tremor will undergo an MRI of the brain and a blood draw.
89491019|NCT03042975||Muscle tension dysphonia|Patients with muscle tension dysphonia will undergo an MRI of the brain and a blood draw.
89491020|NCT03016169|Other|Treatment|All subjects will receive the Trifecta GT valve
89491021|NCT03001830|Experimental|Treatment Arm|Treatment with AAV2/8-HLP-FVIII-V3
89491022|NCT02975661||Observational 1|Huaier Granule
89491023|NCT02975661||Observational 2|Radiotherapy or chemotherapy
89491024|NCT02975661||Observational 3|treatment abandoned
89491025|NCT02975661||Observational 4|Huaier Granule & Radiotherapy or chemotherapy
89491026|NCT02955082|Experimental|Carboplatin|Patients with a germline DNA repair gene mutation identified in part 1 of the study, or who are already known to have a germline mutation will undergo assessment for inclusion in part 2 of the study to receive Carboplatin treatment.
89491027|NCT02947750|Experimental|Exercise training + 6R-BH4|Participants randomized to this arm will exercise on a stationary bicycle for 20-45 minutes, 3 times per week, for 6-12 weeks. This arm will also take the study drug 6R-BH4.
89491028|NCT02947750|Active Comparator|Exercise training + 6R-BH4 placebo|Participants randomized to this arm will exercise on a stationary bicycle for 20-45 minutes, 3 times per week, for 6-12 weeks. This arm will also take a placebo to match the study drug 6R-BH4.
89491029|NCT02947750|Active Comparator|Stretching + 6R-BH4|Participants randomized to this arm will do muscle stretching and toning for 20-45 minutes, 3 times per week, for 6-12 weeks. This arm will also take the study drug 6R-BH4.
89491030|NCT02947750|Placebo Comparator|Stretching + placebo|Participants randomized to this arm will do muscle stretching and toning for 20-45 minutes, 3 times per week, for 6-12 weeks. This arm will also take a placebo instead of the active study drug.
89491031|NCT02947750|Active Comparator|Exercise training + histidine and beta-alanine|Participants randomized to this arm will exercise on a stationary bicycle for 20-45 minutes, 3 times per week, for 6-12 weeks. This arm will also take histidine and beta-alanine supplementation.
89491032|NCT02947750|Active Comparator|Exercise training + histidine and beta-alanine placebo|Participants randomized to this arm will exercise on a stationary bicycle for 20-45 minutes, 3 times per week, for 6-12 weeks. This arm will also take a placebo to match the histidine and beta-alanine supplementation.
89491033|NCT02890160|Experimental|Firesorb|Implantation of the Sirolimus Target Eluting Bioresorbable Vascular Scaffold （Firesorb）
89491034|NCT02890160|Active Comparator|XIENCE|Implantation of the XIENCE Everolimus Eluting Coronary Stent System
89491035|NCT02862418||Pulmonary disease|UTE MRI
89491036|NCT02862418||Control|UTE MRI
89491037|NCT02848560||Treatment|Observation of lung changes over time by hyperpolarized xenon MRI on CF patients homozygous for F508del CFTR mutation as they age into the FDA approved treatment window for the CFTR modulator orkambi. Subjects will be observed at 2 time points before starting clinically prescribed treatment (orkambi) and 2 time points while on orkambi.
89491038|NCT02848560||Control|Observation of lung changes over time by hyperpolarized xenon MRI on CF patients heterozygous for F508del CFTR mutation at similar timepoints to treatment group. Control subjects are not be eligible to be clinically prescribed orkambi based on FDA approval.
89491039|NCT02839915|Experimental|Folinic Acid|Subjects randomized to receive Folinic Acid will take Liquid levo-leucovorin via oral route. The target dose is 1 mg/kg/day with a maximum of 25 mg/day, divided in two daily doses. A two- to four-week supply of 15 ml vials will be dispensed in line with the visit schedule. With the exception of children in the lowest weight group (≥ 15 - < 20 kg) from days 1-14, parents will administer the prescribed dose twice a day at the same time each day.
89491040|NCT02839915|Placebo Comparator|Placebo Control|Subjects randomized to receive placebo will take placebo twice a day (Exception: children in the lowest weight group ( ≥ 15 - < 20 kg) will start once a day for Days1-13). The pattern of dose escalation will be the same as the active compound. After 12 weeks, the blind will not be broken and subjects will be offered treatment for a 12-week open-label extension phase.
89491041|NCT02792257|Experimental|Dronabinol|Study medication will be administered twice daily. Capsules of dronabinol will contain 2.5 mg per dose (5mg daily) during Week 1, then increase to 5 mg per dose (10mg daily) for Weeks 2 and 3.
89491042|NCT02792257|Placebo Comparator|Placebo|Placebo medication will be administered twice daily.
89491043|NCT02767778|Experimental|REAL Pulsed ELF-MF stimulation|Patients will receive REAL pulsed ELF-MF stimulation and the standard of care for acute ischemic stroke, according to current guidelines.
89491044|NCT02767778|Sham Comparator|SHAM Pulsed ELF-MF stimulation|Patients will receive SHAM pulsed ELF-MF stimulation and the standard of care for acute ischemic stroke, according to current guidelines.
88953795|NCT01965847|Experimental|PM dosing|The study student pharmacist will perform medication therapy management with a focus on antihypertensive medications and specifically on the once daily antihypertensive assigned to EVENING dosing. Medication therapy management will take place in the clinic or by phone. Medication therapy management will include review of antihypertensive medications, patient empowerment and education, and provision of a personal medication record to the participant with specific instructions regarding the once daily antihypertensive medication assigned to morning versus evening. If a patient is taking more than one antihypertensive medication, only one will be used for the current study.
88953796|NCT01965405|Experimental|Phase 1: Standard of Care (A)|Brief counseling and bupropion
88953797|NCT01965405|Experimental|Phase 1: Standard of Care (B)|Brief counseling, bupropion, and brief high-magnitude prize contingency management.
88953798|NCT01965405|Experimental|Phase 2a Non-Responders (A)|Bupropion, continued counseling, monitored support to quit smoking.
88953799|NCT01965405|Experimental|Phase 2a: Non-Responders (B)|Bupropion, monitored support to quit smoking, prize contingency management for abstinence.
89491045|NCT02759731|Experimental|Baricitinib|"Single arm, intra-patient dose escalation. Arm 1 (starting dose) -Baricitinib starting at a dose of 2mg daily for 12 weeks. If the response at 12 weeks is a complete response (CR) and there has not been a dose-limiting toxicity (DLT), the dose will remain at 2mg daily for an additional 12 weeks. Arm 2 (dose escalation) - If the response is a partial response (PR) or stable disease (from cohort 1), the dose will be increased to 4mg daily for an additional 12 weeks. If there has been a DLT within the first 4 weeks will have a dose reduction back to 2mg daily.~Each participant is exposed to both dose levels (with the exception of participants who developed toxicity or progressive disease that caused them to discontinue study early before they were able to undergo the per-protocol dose escalation at 12 weeks)."
89491046|NCT02756962|Experimental|Cohort A: HiDAC|"At the time of diagnostic bone marrow biopsy, samples will be clinically sequenced via ClinSeq~Patients who have clearance of their leukemia-associated mutations, defined as a LAM VAF <2.5% will be assigned to the high-dose cytarabine consolidation (HiDAC) arm.~HiDAC = Standard regimen of cytarabine 1.5 g/m^2 or 3 g/m^2 over 2-3 hours twice a day on Days 1, 3, & 5 of each 28 day cycle for 3-4 cycles. Can be replaced by Onureg with permission from PI.~For patients with the FLT3-ITD or a FLT3-TKD mutation, therapy with the FDA-approved FLT3 inhibitor midostaurin is permitted at the discretion of the treating physician."
89491047|NCT02756962|Experimental|Cohort B: Investigator's choice (HiDAC, AlloSCT)|"At the time of diagnostic bone marrow biopsy, samples will be clinically sequenced via ClinSeq~Patients who have persistent leukemia-associated mutations, defined as a LAM VAF ≥2.5% will be assigned to the investigator's choice arm.~Patients assigned to this arm may received either HiDAC or AlloSCT.~HiDAC = Standard regimen of cytarabine 1.5 g/m^2 or 3 g/m^2 over 2-3 hours twice a day on Days 1, 3, & 5 of each 28 day cycle for 3-4 cycles. Can be replaced by Onureg with permission from PI.~The source of stem cell product, donor selection, conditioning regimen, graft-versus-host-prophylaxis, and supportive care will be at the discretion of the treatment physician~For patients with the FLT3-ITD or a FLT3-TKD mutation, therapy with the FDA-approved FLT3 inhibitor midostaurin is permitted at the discretion of the treating physician."
89491048|NCT02665117|Active Comparator|KMgCit + Chlorthalidone|After a run-in period of 2-3 weeks on Chlorthalidone, patients will be randomized to the addition of KMgCit for 4 months.
89491049|NCT02665117|Active Comparator|KCl + Chlorthalidone|After a run-in period of 2-3 weeks on Chlorthalidone, patients will be randomized to the addition of KCl for 4 months.
89491050|NCT02659254|Experimental|Firesorb Implantation|Implantation of the Sirolimus Target Eluting Bioresorbable Vascular Scaffold （Firesorb）in patients with coronary artery lesions.
89491051|NCT02617485|Experimental|MabionCD20|"A course of MabionCD20 consists of intravenous infusions in dose 375 mg/m2 body surface area, administered on day 1 of each chemotherapy cycle for 8 cycles.~Intervention: Drug: Rituximab"
89491052|NCT02617485|Active Comparator|MabThera|"A course of MabThera consists of intravenous infusions in dose 375 mg/m2 body surface area, administered on day 1 of each chemotherapy cycle for 8 cycles.~Intervention: Drug: Rituximab"
89491053|NCT02543905||Family History Cohort|"Men of any ethnicity with a family history of prostate cancer defined as:~Men with a first degree relative (or second degree if through female line) with histologically or death certificate proven PrCa diagnosed at <70 years~Men with two relatives on the same side of the family with histologically or death certificate proven PrCa where at least one is diagnosed at <70 years~Men with three relatives on the same side of the family with histologically or death certificate proven PrCa diagnosed at any age"
89491054|NCT02543905||Black African / Black African-Caribbean Cohort|"Men of black African or black African-Caribbean ancestry defined as:~Both parents and all 4 grandparents being of black African or black African-Caribbean ancestry."
89491055|NCT02543905||High-risk gene mutation cohort|Men of any ethnicity with a genetic predisposition to having prostate cancer e.g., being known to have inherited a gene mutation that increases risk of prostate cancer (gene mutation including BRCA1, BRCA2, ATM, PALB2, MLH1, MSH2, MSH6, CHEK2 and other DNA repair gene mutations as listed in the study protocol); and/or being known to have a high polygenic risk score (PRS) (defined as being in the top tenth percentile prior to enrolment).
89491056|NCT02485860|No Intervention|standard dressings|"In general, the dressings made are either of the type :~Algosteril® (round or flat wick) + Mepilex® border~or AquacelTM ExtraTM + AquacelTM Foam"
89491057|NCT02485860|Experimental|standard dressings with sterile honey|Melectis G
89491058|NCT02385123|Experimental|Seasonal Flu Vaccine/Healthy Adult Volunteers|0.5 ml of seasonal inactivated influenza vaccine (IIV) was administered intramuscularly (IM) on Day 0 of each study season, for this multi-year study. A total of 60 participants were enrolled in this study.
89491059|NCT02251522||ConforMIS iTotal Knee Replacement System|Patients who have had an iTotal knee replacement at least 6 months prior to testing
89491060|NCT02251522||Off-the-Shelf Knee Replacement System|Patients who have had an off-the-shelf knee replacement at least 6 months prior to testing
89491061|NCT02138357|Placebo Comparator|Placebo Patch|"The Placebo is in the form of a patch. We will be using placebo patches labeled 5mcg/hour, 10mcg/hour, and 20mcg/hour that will be changed every 7 days.~Each subject will participate in this arm of the study for four weeks."
88953800|NCT01965405|Experimental|Phase 2b: Responders (A)|Bupropion, no additional treatment.
88953801|NCT01965405|Experimental|Phase 2b: Responders (B)|Bupropion, continued monitoring and low intensity prize contingency management.
89204513|NCT02552004|Experimental|pCLE|Patients subject to endocrine or digestive surgery will have intraoperative pCLE examination. The installation and surgical opening will be performed according to standard protocols. The contrast agent, fluorescein, will be injected intravenously to allow tissue visualization with pCLE. During the surgery, the surgeon will perform the pCLE examination, to obtain and record video sequences of in situ structures. Frozen sections will be obtained on the same samples and will further guide the surgical decision-making.
89491062|NCT02138357|Experimental|buprenorphine transdermal delivery system (BTDS)|"buprenorphine transdermal delivery system (BTDS), brand name Butrans. Butrans is in the form of a patch. We will be using 5mcg/hour, 10mcg/hour, and 20mcg/hour patches that will be changed every 7 days.~Each subject will participate in this arm of the study for four weeks."
89491063|NCT02115295|Experimental|Treatment (cladribine, cytarabine, idarubicin)|"INDUCTION: Patients receive cladribine IV and cytarabine IV over 1-2 hours on days 1-5 and idarubicin IV over 30-60 minutes on days 1-3. Patients with untreated AML and MDS also receive venetoclax PO on days 2-8. AML patients with known FLT3-ITD or FLT3 kinase domain mutations may receive midostaurin PO BID on days 6-19 or gilteritinib PO QD on days 1-14. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Patients receive cladribine IV and cytarabine IV over 1-2 hours on days 1-3 and idarubicin IV over 30-60 minutes on days 1-2. Patients with untreated AML and MDS also receive venetoclax PO on days 2-8. AML patients with known FLT3-ITD or FLT3 kinase domain mutations may receive midostaurin PO BID on days 6-19 or gilteritinib PO QD. Treatment repeats every 28 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity."
89491064|NCT02109614|Experimental|Extended release Niacin|Taking 1500-2000mg niacin daily
89491065|NCT02109614|Placebo Comparator|No Naicin|Placebo Comparator arm will be taking 1500mg of placebo daily
89491066|NCT02097420|Other|Single device arm|Mitral valve replacement
89491067|NCT02000115|Experimental|Randomized IDE Cohort, Portico Valve|"Portico transcatheter aortic valve and Portico delivery system.~Status: ACTIVE, NOT ENROLLING."
89491068|NCT02000115|Active Comparator|Randomized IDE Cohort, CAV|"Any FDA approved, commercially-available transcatheter aortic valve (CAV).~Status: ACTIVE, NOT ENROLLING."
89491069|NCT02000115|Experimental|Nested Valve-in-Valve Registry|"Subjects who have documented failed aortic surgical valve prosthesis and are deemed eligible to receive a transcatheter Portico valve~Status: ACTIVE, ENROLLING."
89491070|NCT02000115|Experimental|FlexNav Delivery System Study|"Portico transcatheter aortic valve and FlexNav delivery system~Status: ACTIVE, NOT ENROLLING"
89491071|NCT01899417||ConforMIS iTotal® Knee Replacement|knee joint replacement
89204514|NCT00780182|Experimental|1|All subjects will receive three 40mg doses of CMX001 as 1)solution fasted, 2)tablet fasted and 3)tablet following a high-fat breakfast. The order in which each subject receives each of the doses will be determined by a randomization code.
89204515|NCT00812994|Placebo Comparator|Placebo|
89204516|NCT00812994|Experimental|Escitalopram|
89491072|NCT01899417||Standard Knee Replacements|knee joint replacement
89491073|NCT01882751||ConforMIS|Patients with ConforMIS implants
89491074|NCT01882751||Standard Total Knee Implant|Patients implanted with standard total knee implant
89491075|NCT01861028||Phase I|A series of 50 consecutive primary iTotal patients will be compared to assess the fit of the tibial tray intra-operatively. These patients will have a series of tibial templates from Standard TKR implant sets trialed on the operative knee. Each template will be optimally sized and positioned based on the surgeon's judgment. Implant fit data (overhang and underhang) on the tibia for all templates will be taken from intra-operative measurements
89491076|NCT01861028||Phase II|The Phase I (50 consecutive primary iTotal patients) will also have implant fit data assessed for the femur. After final implantation is complete measurement will be assessed and recorded. A series of 25 primary knees that are scheduled for Standard TKR implants will then undergo the same measurements of the femur.
89491077|NCT01820676||iUni G2+|iUni G2+ in all patients
89204517|NCT00780260|Experimental|1|5 session strengths-based case management intervention delivered by a professional case manager and a peer support specialist team
89204518|NCT00780260|Active Comparator|2|5 session strengths-based case management intervention delivered by a professional case manager.
89204519|NCT00784394|Experimental|Arm I (diindolylmethane)|Participants receive a single dose of diindolylmethane PO on day 1.
89204520|NCT00784394|Placebo Comparator|Arm II (placebo)|Participants receive a single dose of placebo orally (PO) on day 1.
89204521|NCT00778934|Experimental|1|Intimate Health Gel
89204522|NCT04047524|Other|Prehabilitation|These participants will receive a home based prehabilitation programme for a period of 2-6 weeks prior to surgery and will be provided with a Fitbit Charge 2.
89491078|NCT01717001||ConforMIS|Patients with ConforMIS implants
89491079|NCT01717001||Standard Total Knee Implant|Patients implanted with standard total knee implant
89491080|NCT01564654||iTotal KRS|
89491081|NCT01564641||iDuo G2|iDuo G2 to be implanted in the patient.
89491082|NCT01541761|Experimental|Family groups|Intervention group members will participate in family groups focused on early childhood obesity prevention in addition to standard care from pediatricians at the primary care clinic.
89491083|NCT01541761|No Intervention|Standard care|Mothers enrolled into the control group will continue to receive care from their pediatrician in the primary care clinic.
89491084|NCT01117571||open label|iUni® Unicompartmental Knee Resurfacing Device
89491085|NCT00893516|Experimental|1|CHOP chemo therapy + CD4 therapy
89491086|NCT00893516|Active Comparator|2|CHOP chemotherapy
89491087|NCT00601939|Experimental|Psychoeducational intervention (PEI)|Culturally competent group empowerment psychoeducational treatment (group intervention that is culturally informed and educational in nature)
89491088|NCT00601939|Active Comparator|Enhanced Treatment as Usual|Enhanced treatment as usual that includes an adherence protocol (regular care at the hospital plus an adherence protocol)
89491089|NCT00113360|Experimental|RAD001 plus Depot Octreotide|RAD001 at 5 or 10 milligrams orally once a day plus Octreotide Depot 30 milligrams intramuscularly once every 28 days.
89491090|NCT00087685|Experimental|RAD001|RAD001 10 mg by mouth Daily
89491091|NCT02436447|Experimental|Normal renal function|
89491092|NCT02436447|Experimental|Mild renal impairment|
88953802|NCT01965873|Experimental|Enteral nutrition|In the enteral nutrition group a nasojejunal feeding tube will be placed via esophagogastroduodenoscopy and the position confirmed radiographically. Nutritional support will be started within 24 hours of enrollment, supplying daily 105 kJ (25 kcal)/kg, and 1.5 g/kg of protein based on ideal body weight. An elemental product for enteral nutrition will be infused at a rate of 25 ml/h, and increased by 10 ml/h every 6 hours, until the target rate of 100 ml/h will be achieved within 24-48 hours.
88953803|NCT01965873|No Intervention|Nil-by-mouth treatment|The nil-by-mouth treatment consists intravenous fluid replacement according to assessed needs via peripheral veins. This will include crystalloid (0.9% saline and 5% glucose), and colloid (10% hydroxyethyl starch and 3.5% plasma expander - haemaccel) solutions.
88953804|NCT01965886|Active Comparator|Medial approach|Medial parapatellar approach (classic approach)
88953805|NCT01965886|Experimental|Keblish approach|Lateral parapatellar approach (Keblish approach)
88953806|NCT01965925|Experimental|Modafinil|Modafinil will be administered at baseline with a single dose of 100 mg/day QAM increased at week 1 to a single dose 200mg/day QAM. Patients will take drug upon waking with no adjustment in sleep schedule. Dosing will be flexible based on side effects with a maximum dose of 200 mg/day. Subjects will be discontinued if 100mg/day is not tolerated.
88953807|NCT01965925|Placebo Comparator|Placebo|Subjects will take placebo upon waking once per day.
88953808|NCT01965951|Experimental|Experimental Treatment|Computerized Plasticity-based Adaptive Cognitive Training requiring a total maximum of 39 treatment sessions, 4-5 times weekly, ~30 mins each session.
89491093|NCT02436447|Experimental|Moderate renal impairment|
89491094|NCT02436447|Experimental|Severe renal impairment|
89491095|NCT04855994|Active Comparator|paravertebral group|The investigators performed Paravertebral block to that patient group for postoperative analgesia
89491096|NCT04855994|Active Comparator|pectoral group|The investigators performed pectoral block to that patient group for postoperative analgesia
89491097|NCT03188445|Experimental|IV administration|Iron isomaltoside (Monofer) Administered iv
89491098|NCT03188445|Active Comparator|Oral administration|Ferrous fumarate with ascorbic acid Administered oral
89491099|NCT04379960||Peptides|PBMCs will be incubated with peptides.
89491100|NCT04379960||W/o peptides|PBMCs will be incubated without peptides.
89491101|NCT02440893||Corus CAD (ASGES) Post-metformin|Corus CAD (ASGES) second sample draw results to compare to Corus CAD (ASGES) first draw results (per patient).
89491102|NCT04866368|Active Comparator|The erector spinae plane block|The ultrasound-guided Erector spinae plane block (ESPB) with 1 ml/kg 0,25 % bupivacaine at the lumbar vertebral level will perform before surgery to all patients in the ESPB group.
89491103|NCT04866368|Active Comparator|The penile block|The penile block with 0,5ml/kg 0,25 % bupivacaine will be performed after the patients give standard general anesthesia and a laryngeal mask is applied.
89491104|NCT03191955||Cancer|Patients with oesophagogastric, hepatobiliary, and colorectal cancer for resectional surgery
89491105|NCT03191955||Non-cancer|Patients undergoing abdominal operation for non-inflammatory, non-cancer conditions
89491106|NCT03044288|Experimental|Cohort 9|"This is a sub-study testing the effect of real output applied under two adhesive strips on the skin.~Standard adhesive strip and a strip with a newly developed adhesive (new adhesive strip)"
88953809|NCT01965951|Active Comparator|Active Comparator|Commercially available computerized training requiring a total maximum of 39 treatment sessions, 4-5 times weekly, ~30 mins each session.
88953810|NCT01965977|Experimental|Bortezomib|bortezomib 1.3mg/m2 subcutaneous on day 1 and15
89491107|NCT04483635|Placebo Comparator|Placebo|"10 placebo tablets taken orally at baseline, followed by 1 placebo tablet once a week for 16 weeks~Note that the study may be prolonged according to the overall infection rate monitored monthly."
89491108|NCT04483635|Experimental|Vitamin D3|"10 tablets containing 10,000 IU (total : 100,000 IU) of Vitamin D3 taken orally at baseline, followed by 10,000 IU once a week for 16 weeks.~Note that the study may be prolonged according to the overall infection rate monitored monthly."
89491109|NCT04855916|Experimental|ABLE Exoskeleton - KAFO|Participants belonging to this arm start the study by performing the training program using the ABLE Exoskeleton. After the resting period, they repeat the training program using KAFO orthoses.
89491110|NCT04855916|Experimental|KAFO - ABLE Exoskeleton|Participants belonging to this arm start the study by performing the training program using the KAFO orthoses. After the resting period, they repeat the training program using the ABLE Exoskeleton.
89491111|NCT03041558|Experimental|SafeCare+ (SC+)|SafeCare intervention with the additional Healthy Relationships (HR) module
89491112|NCT03041558|Active Comparator|SafeCare (SC)|SafeCare intervention as usual
89491113|NCT02436291|Experimental|CURE-EX device|twice daily treatment with CURE-EX device for 24-30 weeks
89491114|NCT04855682||A|Endoscopic discectomy
89491115|NCT04855682||B|Microdisectomy
89491116|NCT04855682||C|Hemilaminectomy
89491117|NCT03191877|Experimental|COFFEE|they will start to drink coffee 6 hours postoperative for maximum 3 doses (100ml), 8 hours apart, diet will start after 1st audible bowel sound.
89491118|NCT03191877|Active Comparator|oral fluid|"they will drink plain fluid (water) 6 hours postoperative. Diet will start after 1st audible bowel sound.~Women in this group will not receive either coffee."
89491119|NCT03191877|No Intervention|control|the control group and they will be NPO for 24 hours on IV fluid (3 LITRES/24 HOURS). Diet will start after 1st audible bowel sound
89491120|NCT03041714||Normal volunteers|people who are healthy and without tremor
89491121|NCT03041714||Essential tremor|Patients with essential tremor
89491122|NCT03041714||Dystonic tremor|patient with tremor who also have dystonia
89204523|NCT04047524|Other|Control|These participants will receive a Fitbit Flex and told to continue with their every day activity levels for a period of 2-6 weeks prior to surgery
89204524|NCT02556398|Experimental|Intervention - Educ Module and App|"Participants in this arm to be given smartphone app (Sugar Sleuth) and educational module."
89491123|NCT04865900||Covid19 Vaccinated Patients|Patients who are planning to receive Pfizer-BioNTech BNT162b2 vaccines against Covid19
89491124|NCT02434341||septic patients|wake septic patients on mechanical ventilation
89491125|NCT02434341||COPD patients|wake COPD patients on mechanical ventilation
89491126|NCT04855448|Experimental|Surgeon A|This group is consisted of 56 cases performed using the Micro Hand S robot and da Vinci robot by one single surgeon in low anterior resection for rectal cancer
89491127|NCT04855448|Active Comparator|Surgeon B|This group is consisted of 56 cases performed using the da Vinci robot by one single surgeon in low anterior resection for rectal cancer
89491128|NCT03191721|Experimental|Test: Triclosan toothpaste|"To brush twice a day with a toothpaste containing 0.3% triclosan and 1450 ppm sodium fluoride in a regular maintenance program for 24 months.~Two months earlier, subjects received Surgical anti-infective therapy for implants with peri-implantitis, periodontal treatment and oral hygiene instruction."
89491129|NCT03191721|Placebo Comparator|Control: Fluoride toothpaste|"To brush twice a day with a toothpaste containing 1450 ppm sodium monofluorphosphate in a regular maintenance program for 24 months.~Two months earlier, subjects received Surgical anti-infective therapy for implants with peri-implantitis, periodontal treatment and oral hygiene instruction."
89491130|NCT04855292|Experimental|TG103 injection 15 mg|TG103 injection (15 mg, N=12) and Placebo (N=4) will be administered subcutaneously once weekly in overweight/obese non-diabetic subjects.
89491131|NCT04855292|Experimental|TG103 injection 22.5 mg|TG103 injection (22.5 mg, N=12) and Placebo (N=4) will be administered subcutaneously once weekly in overweight/obese non-diabetic subjects.
89491132|NCT04855292|Experimental|TG103 injection 30 mg|TG103 injection (30 mg, N=12) and Placebo (N=4) will be administered subcutaneously once weekly in overweight/obese non-diabetic subjects.
89491133|NCT04864496|Active Comparator|Prescribe N-acetylcysteine tablets|
89491134|NCT04864496|Placebo Comparator|Prescribe placebo tablets|
89491135|NCT02434887|Experimental|Experimental group|
89491136|NCT04855214||Body-powered Prosthesis User|Individuals who use a prosthesis that relies on a system of cables or harnesses which are operated using other parts of the body like the shoulders, chest, or elbows.
89491137|NCT04855214||Single degree-of-freedom (DOF) myoelectric prosthesis users|Individuals who use a myoelectric prosthesis that can perform only one movement.
89491138|NCT04855214||Multi-DOF myoelectric prosthesis users|Individuals who use a myoelectric prosthesis that can perform more than one movement.
89491139|NCT04855214||Sensory Augmentation|Individuals who experience augmented prosthesis sensory feedback through vibrating devices or pressure bladders, using electrical stimulation applied to the residual limb, or using neural implants.
89491140|NCT03191409||Control Group|Health adults with no evidence of brain lesions on conventional magnetic resonance imaging(MRI) and no neural developmental disorders.
89204525|NCT00305695|Experimental|Arm I (zoledroic acid)|Beginning 60-90 days after surgery, patients receive zoledronate IV over 15 minutes once in months 3, 9, and 15.
89491141|NCT03191409||Patients Group|ESRD patients pre-hemodialysis will be collected.The following exclusion criteria were applied in this study: (a)history of drug or alcohol abuse, (b) brain lesions such as a tumor or stroke assessed on the basis of medical history, (c) history of or current psychiatric disorders, and (d) head motion more than 1.0 mm or 1.0°during magnetic resonance imaging. All patients completed laboratory tests to evaluate renal function,serum creatinine, and urea levels within the 12 hours before magnetic resonance imaging.
89491142|NCT02440815|Other|Problem Solving Therapy|Problem Solving Therapy (PST) is a brief evidence based psychotherapy that is commonly utilized for treatment of LLD. The problem solving therapy includes 12 weekly in person 50 minute sessions.
89491143|NCT04862546|Experimental|Laser Acupoint|Laser will be performed 3 times per week for 2-week measurement. The duration of each cession will be 10 minutes treatment.
89491144|NCT04862546|Active Comparator|Tap water iontophoresis|Tap water iontophoresis will be performed 3 times per week for 2-weeks. The duration of each cession will be 20 minutes treatment session.
89491145|NCT03188289|Placebo Comparator|Placebo gel|The placebo gel is used by all patients on one side of the mouth and serves as a control group.
89491146|NCT03188289|Active Comparator|Clorhexidine gel|Chlorhexidine gel is one of three gels used to compare the placebo gel and will be used on the contralateral side to the side assigned as placebo in a third of the participants.
89204526|NCT00305695|No Intervention|Arm II (clinical observation)|Patients are observed for 18 months after surgery.
89204527|NCT00784472|Active Comparator|oxycodone|
89204528|NCT00784472|Active Comparator|morphine|
89204529|NCT00779012|Experimental|Remicade|
89491147|NCT03188289|Active Comparator|Clorhexidine-Chitosan gel|Clorhexidine-chitosan gel is one of three gels used to compare the placebo gel and will be used on the contralateral side to the side assigned as placebo in a third of the participants.
89491148|NCT03188289|Active Comparator|Hyaluronic acid gel|Hialuronic acid gel is one of three gels used to compare the placebo gel and will be used on the contralateral side to the side assigned as placebo in a third of the participants.
89491149|NCT03044912|Experimental|treatment group|Mirabegron 50 mg for comparison
89491150|NCT03044912|Active Comparator|Comparative group|Patient take Mirabegron 25 mg
89491151|NCT03044678|Experimental|Experimental: REACH for Success|Experimental: Exposure-based, cognitive and behavioral, social skills training intervention 6-weeks - 6 session -20-30 min each
89491152|NCT03044678|Active Comparator|Active Comparator: Self-study|"Active Comparator: Books What to do when you are scared and worried?How to do homework without throwing-up? How to get organized without losing it? Reading at home"
89491153|NCT02436057|No Intervention|Usual care|Individuals in this arm will undergo usual care with their physician.
89491154|NCT02436057|Experimental|AEGIS (Automated Evaluation of Gastrointestinal Symptoms)|Individuals in the AEGIS arm will be invited to use AEGIS/My GI Health prior to their clinic visit. For those who complete AEGIS/My GI Health, their physician will have access to their AEGIS symptom report (includes a GI symptom heat map and GI history) and tailored education prescription.
89491155|NCT04849286|Experimental|Group 1|10 mg dose, CSF sample 2 hours post-dose
89491156|NCT04849286|Experimental|Group 2|10 mg dose, CSF sample 6 hours post-dose
89491157|NCT04849286|Experimental|Group 3|20 mg dose, CSF sample 2 hours post-dose
89491158|NCT04849286|Experimental|Group 4|20 mg dose, CSF sample 6 hours post-dose
89491159|NCT02440737|Experimental|NEST Intervention|Patients (PTs) and their caregivers (CGs) receive educational intervention, follow-up care, psychosocial assessment and care, and questionnaire administration interventions by completing psychosocial questionnaires and meeting with a nurse practitioner (NP) or nurse navigator (NN) for an initial survivorship care planning session to review the expected course of therapy and recovery, identify resources that may be needed and provide recommendations for follow-up. At the end of their treatment EOT), PTs and their CGs complete a 2nd set of questionnaires and meet with the NP/NN for a booster survivorship care planning session. They will receive an individualized final survivorship care plan and related materials. 2 months after EOT, PTs and their CGs complete a final set of questionnaires.
89491160|NCT02436369|Experimental|low fat yogurt enriched with flaxseed|200 gr low fat yogurt enriched with 30 gr flaxseed
89491161|NCT02436369|Placebo Comparator|low fat yogurt|200 gr low fat yogurt
89491162|NCT04862702|Active Comparator|ProTaper Next rotary file system (Dentsply Sirona)|
89491163|NCT04862702|Experimental|TruNatomy rotary system (Dentsply Sirona)|
89491164|NCT02435979|Experimental|Proximal strengthening + hand therapy|Patients in this group will perform traditional hand therapy for 30 minutes and proximal strengthening of the core, cervical spine, and shoulder complex for up to 30 minutes
89491165|NCT02435979|Active Comparator|Traditional hand therapy|This group will receive traditional hand therapy for 45-60 minutes each session.
89491166|NCT02610842|Experimental|Handbook group|"Patients will receive a home based program named Hands on - a hand care guide in Systemic Sclerosis which includes a handbook with instructions about the disease and hand exercises. Patients will be asked to follow the program instructions and carry out the exercises daily during the following 12 weeks."
89491167|NCT03188211|Other|Intervention|Clinicians allocated to intervention arm will receive an e-learning educational program based on simulation-based technologies (Dr Sim). Dr Sim provides a powerful editing system that allows to create clinical cases according to the educational need and purposes. It will be distributed on an e-learning platform, allowing the user to act in a highly interactive learning environment. Management of the virtual patients is carried out interactively and each diagnostic and or therapeutic choice will be supported by any scientific data, guidelines recommendations, drug descriptions and literature references useful to address the best choice for that specific patient as it should be in real practice.
89491168|NCT03188211|Other|Control|Clinicians allocated to control arm will not receive the e-learning educational program based on simulation-based technologies (Dr Sim).
89491169|NCT03041480||GROUP I|Estimation of serum lipid levels and Lp-PLA2 in generalized severe chronic periodontitis
89491170|NCT03041480||GROUP II|Estimation of serum lipid levels and Lp-PLA2 in generalized moderate chronic periodontitis
89491171|NCT03041480||GROUP III|Estimation of serum lipid levels and Lp-PLA2 in systemically and periodontally healthy controls
89491172|NCT03191643||differentiated thyroid cancer|Patients with locally recurrent thyroid cancer, treated with radical radiotherapy after total thyroidectomy +/- central compartment and/or laterocervical lymphadenectomy, previously treated with one or more cycles of 131 Iodine-ablation (RAI) and TSH suppression.
89491173|NCT03041402|Active Comparator|PSP ventilation|PSP, setting the inspiratory pressure support ≥8 cmH2O to obtain a tidal volume of 6-8 mL•kg-1 of body weight, the fastest rate of pressurization (0.0 sec) and I/E cycling at 35% of peak inspiratory flow
89491174|NCT03041402|Active Comparator|NAVA ventilation|NAVA, adjusting the NAVA level in order to achieve a comparable peak EAdi (EAdipeak) as during PSP with a safety Paw upper limit of 30 cmH2O
89491175|NCT03041402|Experimental|PSN ventilation|PSN, setting the NAVA level at its maximum (i.e; 15 cmH2O/mcV), and an upper Paw limit such to obtain the same overall Paw applied during PSP
89491176|NCT03188367|Active Comparator|1A - NCGS|Seventy subjects with nonceliac gluten sensitivity will be given 14 gastrosoluble capsules containing purified wheat gluten corresponding to a daily gluten intake of 8.4 grams for five days. At the end of the first five day-long treatment, subjects will continue only their wash-out from gluten for two weeks, without taking any capsule. At T3, individuals will be given 14 daily gastrosoluble capsules containing placebo (rice starch) for five days. In both first and second five day-long treatment the 14 capsules will be ingested in no more than two times using a glass of water over the day.
89491177|NCT03188367|Active Comparator|1B - NCGS|Seventy subjects with nonceliac gluten sensitivity will be given 10 gastrosoluble capsules containing purified wheat gluten corresponding to a daily gluten intake of 6.0 grams for five days. In order to maintain the double-blind, patients will be also given 4 capsules of placebo (rice starch) per day. At the end of the first five day-long treatment, subjects will continue only their wash-out from gluten for two weeks, without taking any capsule. At T3, individuals will be given 14 daily gastrosoluble capsules containing placebo (rice starch) for five days. In both first and second five day-long treatment the 14 capsules will be ingested in no more than two times using a glass of water over the day.
88953811|NCT01965990||NEP|Patients undergoing the administration of a homemade very low-calorie protein-based formula (2000 mL per day) by enteral route for 14 days
88953812|NCT01966016|Experimental|biventricular pacing|The first configuration will be biventricular pacing (RV and postero-lateral branch of CS for LV pacing), as accepted
89537948|NCT04978935|Experimental|Intervention|Care protocol will be applied to the study group (n=40), starting from the first day spent in the intensive care unit.Care protocol consists of patient's position, mobilization, use of spirometer and shoulder exercises. The bed head of the patient will be raised 30°-45° in line with the application steps. In the study, the patient's in-bed and out-of-bed mobilization will be provided by considering the mobilization application steps, and the patient will be asked to stay out of bed for two hours on the 0 th day after surgery. The patient will be asked to stay out of bed for six hours from the first postoperative day until discharge. After the thoracotomy, the conditions that the doctor considers as complications will be recorded.The time of chest tube removal and the day of discharge will be recorded. In the study, the use of spirometry and shoulder exercises will be carried out by taking into account the implementation steps of the care protocol.
89537949|NCT03293303|Experimental|Stay Active at Home|One group of homecare professionals receives a training programme. In this training they learn to motivate their clients to be more active in daily and physical activities.
89537950|NCT03293303|No Intervention|Usual care|Second group of homecare professionals will get no training and their clients will receive usual homecare.
89537951|NCT02711137|Experimental|Part1/Treatment Group A : 8mg QD INCB057643|"Initial cohort dose of INCB057643 monotherapy at the protocol specified starting dose in the TGA.~Treatment Group A included solid tumors and lymphoma"
89537952|NCT02711137|Experimental|Part1/Treatment Group A : 12mg QD INCB057643|"Initial cohort dose of INCB057643 monotherapy at the protocol specified starting dose in the TGA.~Treatment Group A included solid tumors and lymphoma"
88953813|NCT01966016|Experimental|triventricular pacing|The second configuration will be triventricular pacing (RV+ postero-lateral branch of CS for LV pacing+ antero-lateral branch of CS for LV pacing) i.e. multisite LV pacing
88953814|NCT01966029|Experimental|Treatment|All patients receive treatment with BMN 110
88953815|NCT01966055|Experimental|Solithromycin|
88953816|NCT01966081|Other|Cases|
88953817|NCT01966081|Other|controls|
88953818|NCT01966094||HIV+ subjects with HAND|Human immunodeficiency virus (HIV) positive subjects with HIV-associated neurocognitive disorder (HAND) and either antiretroviral therapy (ART) naïve or ART-experienced off treatment for at least 6 months
88953819|NCT01966094||HIV+ subjects without HAND|Human immunodeficiency virus (HIV) positive subjects without HIV-associated neurocognitive disorder (HAND) and either antiretroviral therapy (ART) naïve or ART-experienced off treatment for at least 6 months
88953820|NCT01966133|No Intervention|Control|no interventions were assigned
88953821|NCT01966133|Active Comparator|TACE('Ethiodized Oil + Doxorubicin)|TACE using Ethiodized Oil + Doxorubicin mixture was infused through catheter placed at hepatic artery followed by gelfoam embolisation. This is performed 4-6 weeks after surgery.
88953822|NCT01966146|Experimental|TAVI|Echocardiography after TAVI
88953823|NCT01966146|Experimental|MitraClip|Echocardiography after MitraClip procedure
88953824|NCT01966172|Experimental|Multimodal|oral Ibuprofen 400mg 4 times daily oral Gabapentin 300mg twice daily oral Paracetamol 1000mg 4 times daily
88953825|NCT01966172|Active Comparator|Morphine|oral Morphine 10mg 4 times daily oral paracetamol 1000mg 4 times daily
88953826|NCT01966185|No Intervention|Tutor function off|The tutor function will be off for 12 out of 12 repeat simulations.
88953827|NCT01966185|Experimental|Tutor function on|The group will have the tutor function on for the 5 first out of 12 repeat simulation sessions.
88953828|NCT01966198|Experimental|all patients|tilt
88953829|NCT01966224|Experimental|2mg CryJ2-DNA-LAMP plasmid vaccine Group 1|"Healthy male and female subjects 18 to 63 years of age that participated in the previous Phase 1A study, from Group 1, who were skin test negative at Day 0 and remained negative at Day 132.~Group 1: These subjects will be re-vaccinated with one dose of 2mg Biological/Vaccine: CryJ2-DNA-LAMP plasmid vaccine administered by Intramuscular injection (IM) approximately 200-250 days after the last of the 4 vaccinations administered under the Phase IA study. These subjects will receive the same batch vaccine used in Phase 1A."
88953830|NCT01966224|Experimental|2mg CryJ2-DNA-LAMP plasmid vaccine Group 2|"Healthy male and female subjects 18 to 63 years of age that participated in the previous Phase 1A study, from Group 2, who were skin test positive at Day 0 and remained positive or converted to negative for any JRC-related allergens at Day 132.~Group 2: These subjects will be re-vaccinated with one dose of 2mg Biological/Vaccine: CryJ2-DNA-LAMP plasmid vaccine administered Intramuscularly (IM) approximately 200-250 days after the last of the 4 vaccinations administered under the Phase IA study. These subjects will receive the same batch vaccine used in Phase 1A."
88953831|NCT01966224|Experimental|2mg CryJ2-DNA-LAMP plasmid vaccine Group 3|"Healthy male and female subjects 18 to 63 years of age that participated in the previous Phase 1A study, from Group 3, who were skin test positive at Day 0 and remained positive or converted to negative for any JRC-related allergens at Day 132.~Group 3: These subjects will be re-vaccinated with one dose 2mg of Biological/Vaccine: CryJ2-DNA-LAMP plasmid vaccine administered Intramuscularly (IM) approximately 200-250 days after the last of the 4 vaccinations administered under the Phase IA study."
88953832|NCT01966237||Acute kidney injury|AKI defined by an elevation in urinary AKI biomarkers
88953833|NCT01966237||No acute kidney injury|No AKI defined by normal urinary AKI biomarkers
88953834|NCT01966250|Experimental|Electroacupuncture and Usual care|15 minutes of electroacupuncture and usual care. Usual care contains 15 minutes ICT(Interferential Current Therapy), 10 minutes hot pack or ice pack and education of patients.
89206302|NCT04092959|Experimental|Chinese Square Dancing group|A total of 240 hypertensive subjects aged 40-69 years (including 126 patients complicated with diabetes) will be included in a few communities in Beijing, and will be divided into 3 groups according to the individual wishes of the subjects: walking group(n=80, including 42 patients complicated with diabetes), Chinese square dancing group(n=80, including 42 patients complicated with diabetes) and control group(n=80, including 42 patients complicated with diabetes).
88953835|NCT01966250|Active Comparator|usual care|15 minutes ICT, 10 minutes hot pack or ice pack and education of patients
88953836|NCT01966276|Experimental|Methyl-P plus Nutrient Formula|"Methylphenidate hydrochloride plus a CFS Nutrient Formula, both taken twice daily.~The CFS Nutrient Formula is a broad-spectrum CFS-specific dietary supplement that provides CFS patients with cellular fuel and cofactors (amino acids, antioxidants, and mitochondrial cofactors) while the low-dose CNS stimulant (methylphenidate hydrochloride) provides a metabolic catalyst to enhance cellular metabolism."
88953837|NCT01966276|Placebo Comparator|Methyl-P plus Nutrient matched placebos|Methylphenidate matched placebo + CFS Nutrient Formula matched placebo, both taken twice daily.
88953838|NCT01966289|Experimental|Cohort 1:CY/GVAX concurrently with SGI-110|During each of the four cycles, Cyclophosphamide (CY) is administered on Day 1 at 200 mg/m2, the colon cancer tumor vaccine (GVAX) is administered on Day 2 at 5E8 colon cancer cells + 5E7 Granulocyte macrophage-colony stimulating factor (GM-CSF) secreting cells, and SGI-110 is administered on Days 1-5 at 60 mg/m2. Each cycle is 28 days. Enrollment will begin first in Cohort 1 and 2. If a response to the treatment is seen in Cohorts 1 and 2, enrollment in Cohort 3 and 4 will begin.
88953839|NCT01966289|Experimental|Cohort 2: CY/GVAX after SGI-110|During each of the four cycles, SGI-110 is administered on Days 1-5 at 60 mg/m2, Cyclophosphamide (CY) is administered on Day 8 at 200 mg/m2, and the colon cancer tumor vaccine (GVAX) is administered on Day 9 at 5E8 colon cancer cells + 5E7 GM-CSF secreting cells. Each cycle is 28 days. Enrollment will begin first in Cohort 1 and 2. If a response to the treatment is seen in Cohorts 1 and 2, enrollment in Cohort 3 and 4 will begin.
88953840|NCT01966289|Experimental|Cohort 3: CY/GVAX|During each of the four cycles, Cyclophosphamide (CY) is administered on Day 1 at 200 mg/m2 and the colon cancer tumor vaccine (GVAX) is administered on Day 2 at 5E8 colon cancer cells + 5E7 GM-CSF secreting cells. Each cycle is 28 days. Enrollment will begin first in Cohort 1 and 2. If a response to the treatment is seen in Cohorts 1 and 2, enrollment in Cohort 3 and 4 will begin.
88953841|NCT01966289|Experimental|Cohort 4: SGI-110|During each of the four cycles, SGI-110 is administered on Days 1-5 at 60 mg/m2. Each cycle is 28 days. Enrollment will begin first in Cohort 1 and 2. If a response to the treatment is seen in Cohorts 1 and 2, enrollment in Cohort 3 and 4 will begin.
88953842|NCT01966302|Experimental|Beraprost open label|Compassionate use access to open label BPS-314d-MR
88953843|NCT01966315||Dexmedetomidine group|"Dexmedetomidine group is the patients who sedated with dexmedetomidine in intensive care unit. We will randomly allocate using www.randomizer.org.~They will sedate at the level of RASS -2. The dose of dexmedetomidine will be 0.2-0.7ug/kg/hr."
88953844|NCT01966315||Midazolam group|"Midazolam group is the patients who sedated with midazolam in intensive care unit. We will randomly allocate using www.randomizer.org.~They will sedate at the level of RASS -2. The dose of midazolam will be 0.05-0.1 mg/kg/hr."
89491178|NCT03188367|Active Comparator|1C - NCGS|Seventy subjects with nonceliac gluten sensitivity will be given 7 gastrosoluble capsules containing purified wheat gluten corresponding to a daily gluten intake of 4.2 grams for five days. In order to maintain the double-blind, patients will be also given 7 capsules of placebo (rice starch) per day. At the end of the first five day-long treatment, subjects will continue only their wash-out from gluten for two weeks, without taking any capsule. At T3, individuals will be given 14 daily gastrosoluble capsules containing placebo (rice starch) for five days. In both first and second five day-long treatment the 14 capsules will be ingested in no more than two times using a glass of water over the day.
89491179|NCT03188367|Placebo Comparator|2C - NCGS|Seventy subjects with nonceliac gluten sensitivity will be given 14 daily gastrosoluble capsules containing placebo (rice starch) for five days. At the end of the first five day-long treatment, subjects will continue only their wash-out from gluten for two weeks, without taking any capsule. At T3, individuals will be given 7 daily gastrosoluble capsules containing purified wheat gluten corresponding to a daily gluten intake of 4.2 grams for five days. In order to maintain the double-blind, patients will be also given 7 capsules of placebo (rice starch) per day. In both first and second five day-long treatment the 14 capsules will be ingested in no more than two times using a glass of water over the day.
89491180|NCT03188367|Placebo Comparator|2B - NCGS|Seventy subjects with nonceliac gluten sensitivity will be given 14 daily gastrosoluble capsules containing placebo (rice starch) for five days. At the end of the first five day-long treatment, subjects will continue only their wash-out from gluten for two weeks, without taking any capsule. At T3, individuals will be given 10 daily gastrosoluble capsules containing purified wheat gluten corresponding to a daily gluten intake of 6.0 grams for five days. In order to maintain the double-blind, patients will be also given 4 capsules of placebo (rice starch) per day. In both first and second five day-long treatment the 14 capsules will be ingested in no more than two times using a glass of water over the day.
89491181|NCT03188367|Placebo Comparator|2A - NCGS|Seventy subjects with nonceliac gluten sensitivity will be given 14 daily gastrosoluble capsules containing placebo (rice starch) for five days. At the end of the first five day-long treatment, subjects will continue only their wash-out from gluten for two weeks, without taking any capsule. At T3, individuals will be given 14 daily gastrosoluble capsules containing purified wheat gluten corresponding to a daily gluten intake of 8.4 grams for five days. In both first and second five day-long treatment the 14 capsules will be ingested in no more than two times using a glass of water over the day.
89491182|NCT03188367|Active Comparator|1A - HV|Seventy healthy volunteers will be given 14 gastrosoluble capsules containing purified wheat gluten corresponding to a daily gluten intake of 8.4 grams for five days. At the end of the first five day-long treatment, subjects will continue only their wash-out from gluten for two weeks, without taking any capsule. At T3, individuals will be given 14 daily gastrosoluble capsules containing placebo (rice starch) for five days. In both first and second five day-long treatment the 14 capsules will be ingested in no more than two times using a glass of water over the day.
89491183|NCT03188367|Active Comparator|1B - HV|Seventy healthy volunteers will be given 10 gastrosoluble capsules containing purified wheat gluten corresponding to a daily gluten intake of 6.0 grams for five days. In order to maintain the double-blind, patients will be also given 4 capsules of placebo (rice starch) per day. At the end of the first five day-long treatment, subjects will continue only their wash-out from gluten for two weeks, without taking any capsule. At T3, individuals will be given 14 daily gastrosoluble capsules containing placebo (rice starch) for five days. In both first and second five day-long treatment the 14 capsules will be ingested in no more than two times using a glass of water over the day.
89491184|NCT03188367|Active Comparator|1C - HV|Seventy healthy volunteers will be given 7 gastrosoluble capsules containing purified wheat gluten corresponding to a daily gluten intake of 4.2 grams for five days. In order to maintain the double-blind, patients will be also given 7 capsules of placebo (rice starch) per day. At the end of the first five day-long treatment, subjects will continue only their wash-out from gluten for two weeks, without taking any capsule. At T3, individuals will be given 14 daily gastrosoluble capsules containing placebo (rice starch) for five days. In both first and second five day-long treatment the 14 capsules will be ingested in no more than two times using a glass of water over the day.
89491185|NCT03188367|Placebo Comparator|2C- HV|Seventy healthy volunteers will be given 14 daily gastrosoluble capsules containing placebo (rice starch) for five days. At the end of the first five day-long treatment, subjects will continue only their wash-out from gluten for two weeks, without taking any capsule. At T3, individuals will be given 7 daily gastrosoluble capsules containing purified wheat gluten corresponding to a daily gluten intake of 4.2 grams for five days. In order to maintain the double-blind, patients will be also given 7 capsules of placebo (rice starch) per day. In both first and second five day-long treatment the 14 capsules will be ingested in no more than two times using a glass of water over the day.
89491186|NCT03188367|Placebo Comparator|2B - HV|Seventy healthy volunteers will be given 14 daily gastrosoluble capsules containing placebo (rice starch) for five days. At the end of the first five day-long treatment, subjects will continue only their wash-out from gluten for two weeks, without taking any capsule. At T3, individuals will be given 7 daily gastrosoluble capsules containing purified wheat gluten corresponding to a daily gluten intake of 4.2 grams for five days. In order to maintain the double-blind, patients will be also given 7 capsules of placebo (rice starch) per day. In both first and second five day-long treatment the 14 capsules will be ingested in no more than two times using a glass of water over the day.
89537953|NCT02711137|Experimental|Part1/Treatment Group A : 16mg QD INCB057643|"Initial cohort dose of INCB057643 monotherapy at the protocol specified starting dose in the TGA.~Treatment Group A included solid tumors and lymphoma"
88953845|NCT01966328|Experimental|36% Resolvine|Patients in this arm will be given one dose of 36% Resolvine intravitreal injection, with the possibility of a second dose at Day 30
88953846|NCT01966328|Active Comparator|9% Resolvine|Patients in this arm will be given one dose of 9% Resolvine intravitreal injection, with the possibility of a second dose at Day 30
89491187|NCT03188367|Placebo Comparator|2A - HV|Seventy healthy volunteers will be given 14 daily gastrosoluble capsules containing placebo (rice starch) for five days. At the end of the first five day-long treatment, subjects will continue only their wash-out from gluten for two weeks, without taking any capsule. At T3, individuals will be given 14 daily gastrosoluble capsules containing purified wheat gluten corresponding to a daily gluten intake of 8.4 grams for five days. In both first and second five day-long treatment the 14 capsules will be ingested in no more than two times using a glass of water over the day.
89491188|NCT03041246|Experimental|Study group - Treatment with PFFM|Manual treatment for the pelvic floor will be provided in two sessions two weeks apart as long as guidance towards exercise for strengthening of the pelvic floor
89491189|NCT03041246|No Intervention|Control group -|Guidance towards exercise for strengthening of the pelvic floor with no other interventional treatment.
89491190|NCT02435823|Experimental|PulseRider|Endovascular treatment of intracranial aneurysms
89491191|NCT02435745||Ehlers-Danlos Syndrome|Patients with the diagnosis of Ehlers-Danlos syndrome
89491192|NCT02435745||Controls|Patients/Subjects without the diagnosis of Ehlers-Danlos syndrome
89204530|NCT00784706|Experimental|CIT with eye-patching|The CIT addressed forced use of the affected UE and restricted the unaffected UE during training. Shaping skills were delivered while participants were forced to use their affected UE in the mass practice of functional tasks, such as drinking water and opening a jar. Participants wore a mitt on their unaffected hand and wrist for 6 hours/day during the 3-week training and reported their compliance in a daily log. Participants were also asked to wear glasses with a patch on the right lens to block the visual stimuli from the right side and force them to receive the stimuli from the left-side visual field.
89491193|NCT03191487|Experimental|ChimioPal|Systematic collection of clinical and laboratory toxicities.
89491194|NCT03191487|Active Comparator|Standard|The usual management and logistic pathways will be respected.
89491195|NCT04849754|Other|Patients with transthyretin related cardiac amyloidosis|Bone scintigraphy
89491196|NCT02435667|Experimental|Resistance Exercise Training|Entails 36 supervised resistance exercise training sessions (3 sessions per week for 12 weeks). Each exercise session will be supervised by a trained, certified Exercise Physiologist specializing in Cardiac Rehabilitation. The specific resistance exercise training will include Aerobic Exercise, Resistance Exercise, and Core Strengthening Exercises. Other baseline and follow-up tests include: DEXA bone scan, Blood Draw, Cardiopulmonary Max Exercise Test, Quality of Life Questionnaire, and a Submaximal Exercise Test.
89491197|NCT02435667|Placebo Comparator|Standard Care|No resistance exercise training. Patients will stay on their current healthcare regimen as previously assigned by their physician. Patients will still undergo baseline and follow-up tests similar to the Resistance Exercise Training group, including: DEXA bone scan, Blood Draw, Cardiopulmonary Max Exercise Test, Quality of Life Questionnaire, and a Submaximal Exercise Test.
89491198|NCT03041012|Placebo Comparator|antiretrovirals|Standard of care
89491199|NCT03041012|Active Comparator|antiretrovirals + romidepsin|Standard of care + LRA
89491200|NCT03041012|Active Comparator|antiretrovirals + 3BNC117|Standard of care + bNAb
89491201|NCT03041012|Active Comparator|antiretrovirals + romidepsin + 3BNC117|Standard of care + LRA + bNAb
89491202|NCT03188133|Experimental|VH|schizophrenia patients with visual hallucinations
89491203|NCT03188133|Active Comparator|AH/NH|schizophrenia patients with auditory hallucinations or no hallucinations
89204531|NCT00784706|Experimental|constraint-induced therapy|The intervention in this group resembled the intervention of the CIT+EP group, except participants did not wear the EP glasses.
89204532|NCT00784706|Active Comparator|conventional therapy|traditional occupational therapy matched in intensity and duration with the other groups. The training program included stretching and weight bearing of the affected UE, improving the range of motion of the affected UE, muscle strengthening, and the practice of tasks used for functional training might involve the unaffected UE to assist in the affected UE; for example, stabilizing a bottle while opening its lid or moving pegs into holes on a board.
89204533|NCT00647556|Active Comparator|adapalene|adapalene
89204534|NCT00647556|Active Comparator|tretinoin|Tretinoin
89491204|NCT03188133|Active Comparator|C|healthy controls
89491205|NCT04804202|Other|Virtual Reality|This is a single arm study in which all participants will execute the same tasks over two sessions.
89204535|NCT03978559|Experimental|CAS with TMP/SMZ|
89204536|NCT03978559|Active Comparator|TMP/SMZ|
89204537|NCT03981133|Experimental|A: unrestricted pacifier|recommendation to offer a pacifier at the facility providing maternity and newborn services the first days of life
89204538|NCT03981133|Active Comparator|restricted pacifierr|recommendation not to offer a pacifier to normal new born infant at the maternity thre first days of live
89204539|NCT00813072|Experimental|1. PEP02|liposome irinotecan
89204540|NCT00813072|Active Comparator|2. irinotecan|
89204541|NCT00813072|Active Comparator|3. docetaxel|
89204542|NCT03980821|Experimental|AZD4635 monotherapy|Dose escalation of AZD4635 monotherapy for patients with advanced solid malignancies
89204543|NCT00320593|Active Comparator|Progressive addition lenses (PALs)|Varilux Ellipse progressive addition lenses (PALs) with a +2.00 D addition
89204544|NCT00320593|Active Comparator|Single vision lenses (SVLs)|Single vision lenses
89204545|NCT00813306|Experimental|A|AZD2066
89204546|NCT00813306|Placebo Comparator|B|Placebo
89204547|NCT00813306|Experimental|C|AZD2066
89204548|NCT00813306|Experimental|D|AZD2066
89204549|NCT00813306|Placebo Comparator|E|Placebo
89022030|NCT03274674|Active Comparator|I-PRF and Microneedling|Venous blood will be taken from the patient every session and I-PRF will be created in the centrifuge.Microneedle application plus I-PRF injected on the other side in patients with bilateral region with thin gingival phenotype.Apply once a week and one month after the end of the injections, the patient will be called to the control.
89022031|NCT04715165|Active Comparator|Group I|Patients will receive USG-STAP block with bupivacaine and dexmedetomidine in both sides ten minutes before skin incision and intraperitoneal normal saline.
89022032|NCT04715165|Placebo Comparator|Group II|Patients will receive bupivacaine and dexmedetomidine through the intraperitoneal route and USG-STAP block with normal saline at the end of surgery
89491206|NCT03191565|Experimental|App-Condition|In this condition the intervention is that participants enter their skills-use and mood on a smartphone. They can follow their progress on graphs on the smartphone, get reminders to train skills, get psychoeducation about what the different emotion regulation coping skills can do, and how to do the skills. therapists can watch patient progress online, and review skill use together with the patients while in psychotherapy. The intervention is using a smartphone as an adjunct to the treatment.
89491207|NCT03191565|Active Comparator|Paperdiary-condition|Patients are, weekly, given a paper diary sheet to fill out on a daily basis at home No prompting, no accumulative overview of progress. Patients are supposed to bring this paper to the weekly therapysession
89491208|NCT03189225|Other|Capillary And Venous Accuracy|All subjects provided blood sample(s) to be tested on three Blood Glucose Monitoring Systems ( OneTouch Ultra 2, OneTouch Verio (Rice), OneTouch SelectPlus), LifeScan reference instrument ( YSI 2300) and hospitals own biochemistry analysers.
89491209|NCT02435589|Experimental|Intervention group|"Intervention:~systematic pain assessment~Notification of results of assessments to nurses and physicians. Pain Assessments will be done with the use of 2 different behavioral pain tools by independent assessors and the results of the assessments will be notified to the nurses and physicians and their respond will be observed and documented"
89491210|NCT02435589|Active Comparator|Control Group|Intervention. Systematic pain assessments. Assessments of pain will be done by independent assessors but results will not be notified to nurses or physicians
89491211|NCT03187899|Sham Comparator|"Interscalene block plus sham"|"Patients in this group will receive a traditional interscalene block and a sham superficial plexus block with ropivacaine and 5-10cc of normal saline. N = 20"
89491212|NCT03187899|Active Comparator|Interscalene plus superficial plexus block|Patients in this group will receive a traditional interscalene block and a superficial plexus block with ropivacaine . N = 20
89491213|NCT01648582|Experimental|1.5 mg Dulaglutide|1.5 milligrams (mg) dulaglutide administered as one subcutaneous (SC) injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea for up to 52 weeks. Participants are blinded to the dulaglutide dose.
89491214|NCT01648582|Experimental|0.75 mg Dulaglutide|0.75 mg Dulaglutide administered as one SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea for up to 52 weeks. Participants are blinded to the dulaglutide dose.
89491215|NCT01648582|Active Comparator|Insulin Glargine|Insulin glargine administered based on fasting blood glucose concentrations per the dosing titration schedule as once daily SC injection at bedtime added to participant's pre-study prescribed dose of metformin and /or a sulfonylurea for up to 52 weeks.
89491216|NCT02440269||A：day|the patients who receive surgery and anesthesia during 8:00 am to 6:00 pm
89022033|NCT00454233|Experimental|1|Dose 1
89491217|NCT02440269||B：night|the patients who receive surgery and anesthesia during 10:00 pm to 5:00 am next day
89491218|NCT02440347|Experimental|Computer controlled anesthetic delivery by Anaeject|Patients received single dose of 0.6 ml of 4% articaine with epinephrine (1:100.000) by computer controlled anesthetic delivery system (C-CLADS) for AMSA nerve block
89491219|NCT02440347|Active Comparator|Conventional anesthetic delivery by carpule syringe|Patients received single dose of 0.6 ml of 4% articaine with epinephrine (1:100.000) by conventional anesthetic delivery for AMSA nerve block
89491220|NCT04848818|Active Comparator|K-wire group|Children with closed or grade I. open, severly displaced distal radial and/or complete forearm metaphyseal fractures between the age 3-13.
89491221|NCT04848818|Active Comparator|Activa-IM Nail group|Children with closed or grade I. open, severly displaced distal radial and/or complete forearm metaphyseal fractures between the age 3-13.
89491222|NCT03191331|Experimental|Intervention group|Dietary intervention. Intervention group will receive written material on healthy diet during pregnancy, nutritional guidance given by public health nurses at each maternity care clinic visit and group meeting with dietician x2.
89491223|NCT03191331|No Intervention|Control group|The control group will receive written material on healthy diet during pregnancy, otherwise basic care and guidance at maternity care clinics.
89491224|NCT03043742|Experimental|Phase I Open Label|"open label bone marrow derived autologous CD133+ selected stem cell application in patients receiving trans-myocardial laser revascularization to improve regional myocardial function as detailed below:~Drug: CD133+ selected stem cells Dosage: Single injection of 0.1-0.2 ml around each laser channel Frequency: 10-20 channels Duration: Trans-Myocardial Revascularization"
89491225|NCT03043898||Part A(i) Healthy Volunteers|50 healthy volunteers. Intervention: Lung sound recording for part A(i) of the study.
89491226|NCT03043898||Part A(ii) Patients|100 patients with wheezing and/or crackles due to respiratory disease. Intervention: Lung sound recording for part A(ii) of the study.
89022034|NCT00454233|Experimental|2|Dose 2
89022035|NCT00454233|Experimental|3|Dose 3
89022036|NCT00454233|Experimental|4|Dose 4
89022037|NCT00454233|Active Comparator|5|
89022038|NCT00454233|Placebo Comparator|6|
89022039|NCT04715477||Hospital Anxiety Depression Measure|Hospital Anxiety Depression Measure
89022040|NCT04714931|Other|Sentinel Lymph Node|Sentinel lymph nodes which can be identified with the tracer involvement will be removed. Then, systematic lymphadenectomy will be performed according to the routine practice.
89022041|NCT00454272|Active Comparator|1, Vancomycin|Vancomycin
89022042|NCT00454272|Active Comparator|2, Teicoplanin|Teicoplanin
88953847|NCT01966341|Active Comparator|Routine Management|All patients will be given a prescription for the use of antispasmodics. If patients demonstrate symptoms consistent with constipation predominant IBS they will be treated with laxatives. If symptoms are more consistent with diarrhea predominant IBS they will be treated with bulking agents (fiber) +/- antibiotics. Patient will be called every week while enrolled in the study in order to titrate doses, and answer questions.
89491227|NCT03043898||Part B(i) 'normal' lung structure|"25 patients who are scheduled to have a Bronchoscopy as part of their standard care and are identified by a medical professional as having a 'normal' lung structure.~Intervention: Lung sound transmission measurement for part B(i) of the study."
89491228|NCT03043898||Part B(ii) 'abnormal' lung structure|"25 patients who are scheduled to have a Bronchoscopy as part of their standard care and are identified by a medical professional as having an 'abnormal' lung structure.~Intervention: Lung sound transmission measurement for part B(ii) of the study."
89491229|NCT03187821|Active Comparator|Superior|Laser peripheral iridotomy done at superior part of iris.
89491230|NCT03187821|Active Comparator|Nasal/temporal|Laser peripheral iridotomy done at temporal/nasal part of iris.
89491231|NCT03043820|Active Comparator|Raloxifene|Raloxifene 120 mg (2 tablets of 60mg) daily for 12 weeks.
89491232|NCT03043820|Placebo Comparator|Placebo|Placebo 2 tablets daily for 12 weeks.
89491233|NCT02435355|No Intervention|standard support|All patients in this study underwent this procedure, which is the regular procedure in France.
89491234|NCT02435355|Experimental|coached group|In the coached group (CG), patients received standard support completed by 5 sessions (day 3, 10, 30, 60, 90 with equipment at home) of telephone-based counselling session by competent staff. Sessions were performed by a qualified person in education, qualifies by a university degree (Paul Sabatier University, Toulouse, France). The dates of phone calls were planned with the patient availabilities.
89491235|NCT02435043|Experimental|Nature based rehabilitation|ten weeks of nature-based rehabilitation, as add-on to standard management
89491236|NCT02435043|Active Comparator|Treatment as usual|standard management after stroke
89491237|NCT04854902|Experimental|Cyanoacrylate|The graft is stabilized and the donor site is coated with cyanoacrylate.
89491238|NCT04854902|Active Comparator|Suture|6/0 polyvinylidene fluoride sutures are used for stabilization, while the donor site is left untreated.
89491239|NCT03191175||HIV patients|
89491240|NCT03191175||Control patients|
89491241|NCT03040622||Watchman Left Atrial Appendage Closure|
89491242|NCT03191097|Experimental|Ingavirin|
89491243|NCT03191097|Placebo Comparator|Placebo oral capsule|
89491244|NCT04420234|Experimental|Pharmacokinetics study of single and multiple administration|During the study session, 30 healthy subjects will be administered a single and multiple dose of narfurine hydrochloride orally disintegrating tablets 5 µg (2.5 µg/table) to evaluate the pharmacokinetic parameters and the safety profile.
89491245|NCT04884022|Experimental|Miniplates in mandibular symphysis & infrazygomatic|
89491246|NCT04884022|Active Comparator|Miniplates in external oblique ridge & anterior maxillary region|
89491247|NCT04884022|No Intervention|Growing skeletal Class II subjects|
89491248|NCT02435199|Experimental|EMA401 600mg|2 X 150mg BID
89491249|NCT02435199|Placebo Comparator|Placebo|Placebo to match, 2 capsules BID
89491250|NCT04848350|Placebo Comparator|placebo group|Only a saline solution was applied to the placebo group
89491251|NCT04848350|Active Comparator|lavender group|The lavender essential oil was added to the nebulizer and operated on in the SWL room before the procedure,
89491252|NCT04848350|Active Comparator|frankincense group|The frankincense essential oil was added to the nebulizer and operated on in the SWL room before the procedure,
88953848|NCT01966341|Experimental|CBT/ Hypnotherapy|The CBT (cognitive behavior therapy) program will consist of 7 sessions that will encompass the following skills of Symptom monitoring, Stress Management, Coping Skills, Relaxation training, Problem solving, and Cognitive Restructuring.The hypnotherapy program will be modeled after the North Carolina Standardized Hypnosis Treatment for Irritable Bowel Syndrome
89022043|NCT00344825||Group 1|
89491253|NCT02434965|Experimental|Autologous Cord Blood and HPDSC|Autologous cord blood and placental blood will be collected after birth of child and administered in divided aliquots during the first week of life.
89491254|NCT04854356|Experimental|HIE with BFR during exercise phase|BFR with 40% Arterial occlusive pressure cycling at 85% VO2max for 3 minutes and rest interval for 3 minutes (4 sets) each time during exercise
89491255|NCT04854356|Active Comparator|HIE with BFR during interval phase|BFR with 40% Arterial occlusive pressure cycling at 85% VO2max for 3 minutes and rest interval for 3 minutes (4 sets) each during the interval
89491256|NCT04854356|No Intervention|HIE without BFR|Cycling at 85% VO2max for 3 minutes and rest interval for 3 minutes (4 sets) each time during exercise
89491257|NCT03189069||Patients prescribed apixaban|
89491258|NCT03189069||Patients prescribed dabigatran|
89491259|NCT03189069||Patients prescribed rivaroxaban|
89491260|NCT03189069||Patients prescribed warfarin|
89491261|NCT03040934|Active Comparator|Firehawk implantation|98 subjects will be enrolled to receive a test device (Firehawk™).
89491262|NCT03040934|Active Comparator|XIENCE implantation|98 subjects will be enrolled to receive a control device (XIENCE).
89491263|NCT03189147|Experimental|Biceps Tenodesis|Patients in this group will received biceps tenodesis intervention to address their labral lesion
89491264|NCT03189147|Active Comparator|Debridement|Patients in this group will received debridement intervention to address their labral lesion
89491265|NCT04861376|Experimental|Pueraria lobata group|Pueraria lobata will be made into granules.
89491266|NCT04861376|Experimental|Pueraria thomsoni group|Pueraria thomsoni will be made into granules.
89491267|NCT04861376|Placebo Comparator|Placebo group|The dosage form, specifications and packaging of the placebo will be no different from those of Pueraria lobata and Pueraria thomsoni Granules, and the smell and taste will be basically the same.
89491268|NCT03187587|Experimental|imILT treatment|Immunostimulating Interstitial Laser Thermotherapy (imILT)
89491269|NCT03187587|Active Comparator|Standard chemotherapy treatment|This study arm recieves chemotherapy treatment as standard care at the clinical study site.
89491270|NCT04861142||Patients adherent to the anti-osteoporotic medication|
88956545|NCT04925284|Experimental|XB002 Single-Agent Expansion Cohorts|The MTD or recommended dose from the dose-escalation stage may be further explored in subjects with non-small cell lung cancer [NSCLC] (Cohort B), epithelial ovarian cancer (Cohort D), cervical cancer (Cohort E), SCCHN (Cohort F), pancreatic cancer (Cohort G), Esophageal SCC (Cohort H), metastatic castration-resistant prostate cancer (Cohort I), triple-negative breast cancer (Cohort J), hormone-receptor positive breast cancer (Cohort K), endometrial cancer (Cohort L) and tumor agnostic tissue factor-expressing solid tumors (Cohort M).
89491271|NCT04861142||Patients non-adherent to the anti-osteoporotic medication|
89491272|NCT03187665||1-6 years|12 subjects in the age range of 1-6 years old.
89491273|NCT03187665||6-10 years|12 subjects in the age range of 6-10 years old.
89491274|NCT03187665||11-17 years|12 subjects in the age range of 11-17 years old.
89491275|NCT02434731|Experimental|Buzzy® device|The Buzzy® device will be applied just above the selected site of the venipuncture; a ice pack will be attached under the device; the device will be turned on and after 15 second the procedure will be carried out.
89491276|NCT02434731|No Intervention|No intervention|No intervention for pain relief
89491277|NCT03117855|Experimental|Treatment (capecitabine, yttrium Y-90 radioembolization)|Patients undergo yttrium Y 90 resin microspheres radioembolization over 60-90 minutes on day 1. Patients receive capecitabine PO BID on days 1-14.
89491278|NCT02434419|Experimental|PENS with training|Patients undergoing percutaneous electrostimulation (PENS) of the pectoral muscle combined with specific training during 12 weeks postoperatively
89491279|NCT02434419|Active Comparator|Specific training|Patients undergoing specific training during 12 weeks postoperatively
89491280|NCT02434419|No Intervention|No intervention|No specific treatment was assigned to these patients postoperatively
89491281|NCT02607800|Experimental|SOF/VEL/VOX|SOF/VEL/VOX tablet for 8 weeks
89491282|NCT02607800|Active Comparator|SOF/VEL 12 weeks|SOF/VEL tablet for 12 weeks
89491283|NCT02433951||healthy individuals|Age, gender and BMI matched healthy subjects without any chronic disease or physical disability, and being sedentary.
89491284|NCT02433951||CABG patients|Age, gender and BMI matched CABG patients, without neurologic, nephrologic, respiratory disease.
89491285|NCT02433951||endo-ACAB patients|Age, gender and BMI matched endo-ACAB patients without neurologic, nephrologic, respiratory disease.
89491286|NCT02304484|Experimental|Evolocumab|Participants received 420 mg evolocumab once a month for up to 2 years.
89491287|NCT03190707|Experimental|Intervention|The intervention consists of three key components aiming at promoting a better attachment between child and mother/parents and through that giving the child the best possible beginning of life. The three components aim at: 1) detecting ill-being in vulnerable pregnant woman and initiation of potential treatment, 2) strengthening knowledge sharing and organizing the course for the families across the sectors, 3) strengthening parenting skills.
89491288|NCT03190707|No Intervention|Control|The existing practice for psychosocial vulnerable pregnant women on Gentofte-Herlev Hospital, Denmark, will be offered for women allocated to the control group. The control group will be measured at the same follow-up periods as the intervention group.
89491289|NCT02433873|Placebo Comparator|Placebo|Ingredients that are in the placebo are: high maltose corn syrup (Satin Sweet™), water, and mannitol. Both Supplement A and Supplement B will be compared to this placebo arm.
89491290|NCT02433873|Experimental|Supplement A|Ingredients that are in the supplement are: isomalto-oligosaccharide, water, mannitol, maltose, glucose, and glycerol. Supplement A and B differ by degrees of polymerization.
89491291|NCT02433873|Experimental|Supplement B|Ingredients that are in the supplement are: isomalto-oligosaccharide, water, mannitol, maltose, glucose, and glycerol. Supplement A and B differ by degrees of polymerization.
89491292|NCT02434029|Experimental|Budesonide|Budesonide 1mg orodispersible tablet twice daily
89491293|NCT02434029|Placebo Comparator|Placebo|Placebo orodispersible tablet twice daily
89491294|NCT03043352|Experimental|Group A (intervention)|'Management of SAM at home' LHWs will identify and treat all cases of severe acute malnutrition (SAM) as per the study eligibility criteria (MUAC < 11.5 cm) and manage all cases of SAM without complications at home with 'Standard CMAM program'. The LHWs will also identify SAM with complications for further assessment to the BHU Doctor and subsequent referral to the stabilization center . They will also provide one to one health and Infant and Young Child Feeding (IYCF) counselling to care takers of children in their catchment area.
88956546|NCT04925284|Experimental|XB002 + Nivolumab Dose Escalation Cohorts|Subjects (Cohort AN) will accrue in cohorts of 3-12 subjects in a modified i3+3 design.
89491295|NCT03043352|Active Comparator|Group B (Control)|'Management of SAM at facility' LHWs will identify SAM as per 'Standard CMAM program' (MUAC < 11.5cm) and will refer all cases to the health facility BHU/ satellite site (ACF) for further management and counselling by health workers (ACF CMAM Nurse) at facility level.
89491296|NCT03187431|Experimental|IPF patients|autologous bone marrow mesenchymal stem cells
88956547|NCT04925284|Experimental|XB002 + Nivolumab Dose Expansion Cohorts|The MTD or recommended dose from the dose-escalation stage may be further explored in subjects with non-small cell lung cancer [NSCLC] (Cohort BN), SCCHN (Cohort FN), Esophageal SCC (Cohort HN).
89491297|NCT03043508||Participants With Confirmed MEN1 With PNET|"Retrospective review of a prospectively maintained MEN1 database.~Participants sent an email questionnaire to complete regarding their pregnancy and hormone use history."
89491298|NCT03043508||Participants With Confirmed MEN1 Without PNET|"Retrospective review of a prospectively maintained MEN1 database.~Participants sent an email questionnaire to complete regarding their pregnancy and hormone use history."
89491299|NCT02708355|Experimental|Esomeprazole 20 mg once daily|Esomeprazole 20 mg administered orally in the morning and placebo administered orally in the evening
89491300|NCT02708355|Experimental|Esomeprazole 20 mg twice daily|Esomeprazole 20 mg administered orally in the morning and esomeprazole 20 mg administered orally in the evening
89491301|NCT02708355|Placebo Comparator|Placebo|Placebo administered orally in the morning and placebo administered orally in the evening
89537954|NCT02711137|Experimental|Part1/Treatment Group B : 8mg QD INCB057643|Initial cohort dose of INCB054763 monotherapy at the protocol-specified cohort escalation treatment group B (TGB), based on protocol-specific criteria. Treatment Group B included any acute leukemia, HRMDS, MDS/MPN, or MF
89204550|NCT00813384|Experimental|Dose Escalation|The dose escalation part of the study is aimed at determining the maximum tolerated dose (MTD), if feasible, and evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of AMG 208.
89491302|NCT04854044|Experimental|Arm I (ONC201, radiation therapy, resection)|Patients undergo radiation therapy for 10 fractions over 2 weeks, and receive ONC201 PO daily on days 1, 2, 8, and 9. Beginning 24 hours after completion of radiation therapy, patients undergo surgical resection. Beginning 7 days from last pre-surgery dose of ONC201, patients receive ONC201 PO daily on two consecutive days weekly (2 days on/5 days off) in the absence of disease progression or unacceptable toxicity.
89491303|NCT04854044|Experimental|Arm II (ONC201, radiation therapy, resection)|Patients undergo radiation therapy for 10 fractions over 2 weeks. Beginning 24 hours after completion of radiation therapy, patients undergo surgical resection. After recovery from surgery, patients receive ONC201 PO daily on two consecutive days weekly (2 days on/5 days off) in the absence of disease progression or unacceptable toxicity.
89491304|NCT03187275|Experimental|Swedish Massage Therapy|Participants in this arm will receive Swedish massage, which is the most commonly offered and best-known type of massage.
89491305|NCT03187275|Active Comparator|Light Touch Intervention|Participants in this arm will receive light touch only.
89491306|NCT02708277|Experimental|Group A|At the end of the procedure the surgery loop-shaped intrauterine contraceptive device (IUCD) was placed in the uterine cavity.
89491307|NCT02708277|Experimental|Group B|At the end of the procedure the surgery an intrauterine balloon (Cook Medical) was placed in the uterine cavity.
89491308|NCT04847570|Experimental|Music listening experience|It is a single-arm non-randomised study. The same inclusion and exclusion criteria applies to all the participants.
89491309|NCT02337478|Experimental|Treatment (vincristine sulfate liposome)|Patients receive vincristine sulfate liposome via injection on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89491310|NCT02303704|Active Comparator|multiport antegrade cardioplegia|Patients who received multiport antegrade cardioplegia and continuous controlled warm blood perfusion through vein grafts.
89491311|NCT02303704|Active Comparator|Aortic root antegrade cardioplegia|Patients who underwent routine conventional CABG with antegrade aortic root cardioplegia without warm blood perfusion
89491312|NCT04860908||covid exposed|women who were exposed to covid 19 during pregnancy
89491313|NCT04860908||covid vaccinated|women who were vaccinated to covid 19 during pregnancy
89491314|NCT03187041|Experimental|Skin surface pressures under tourniquets and sensation|"Phase 1: Each phlebotomist will apply the tourniquet 10 separate times to the right arm of each subject. The tourniquet will remain on the arm for approximately ten seconds, to be able to allot enough time to collect an accurate pressure measurement. All 10 tourniquet skin pressure measurements will take place on the same day for a subject.~Phase 2: 20 subjects will be subjected to a prolonged blood-draw tourniquet application for a duration of 1 hour. The purpose of phase 2 is to determine whether there is an effect on sensation from prolonged blood tourniquet use."
89491315|NCT04376918|Active Comparator|Begin with BVGA|"After initial anesthesia induction, anesthetized volunteers will be ventilated through through the BVGA for 2 minutes and then through the face-mask for 2 minutes. The normal anesthesia procedures will then be resumed.~The BVGA enables the direct connection of a bag valve device to a Guedel, eliminating the need for a face mask during ventilation The Mask is a classic face mask"
89491316|NCT04376918|Active Comparator|Begin with Face-mask|"After initial anesthesia induction, anesthetized volunteers will be ventilated through the face mask for 2 minutes and then through the BVGA for 2 minutes. The normal anesthesia procedures will then be resumed~The BVGA enables the direct connection of a bag valve device to a Guedel, eliminating the need for a face mask during ventilation The Mask is a classic face mask"
89491317|NCT04483401|No Intervention|Waitlist|"Waitlist Participants are first allocated to a waitlist condition. After the first MRI scan, participants wait for 12 weeks and have a second MRI scan."
89491318|NCT04483401|Experimental|Treatment arm|Upon completion on the waitlist time of 12 weeks, participants then are allocated to the treatment group. Participants are assessed by an independent occupational therapist (before and after intervention) and participate in 10 treatment sessions with a treating occupational therapist. Following the post-treatment assessment, participants have a third MRI scan.
89491319|NCT02608892|Experimental|Intervention|BSweet2Babies video
89491320|NCT02608892|No Intervention|Control|Usual care
89491321|NCT03186963|Experimental|No immobilization|Patients receive a conventional dressing made with gauze, cotton padding and inelastic bandage after the surgery. They are instructed to start light wrist movements on the first postoperative day and progress as tolerated, beginning rehabilitation with physiotherapy after 2 weeks postoperatively.
89491322|NCT03186963|Active Comparator|Volar splint|Patients receive a volar plaster splint with inelastic bandage after the surgery, and are instructed not to remove the immobilization for 2 weeks. After this period, the immobilization is removed and patients begin rehabilitation with physiotherapy.
89491323|NCT03186885|Experimental|In-Person Family Intervention|Healthy Frio In-Person Family-focused Intervention; In-person group setting at a community center
89491324|NCT03186885|Experimental|Remote Technology Family Intervention|Healthy Frio Remote Technology Family-focused Intervention; Home-based delivered remotely with technology
89491325|NCT03186885|Active Comparator|Control|Control; Participants will receive standard health education materials, a community resource guide, and encouragement to follow up with their primary care provider for office-based counseling.
89491326|NCT03186573|No Intervention|Control Group|The athletes will not receive any drink and will do the simulations of the fight.
89491327|NCT03186573|Active Comparator|Intervention group|(Intervention, grape juice) - athletes will receive 400 ml per day of grape juice (containing 66g of carbohydrates) for 14 days and will do the fight simulations.
89491328|NCT03186573|Placebo Comparator|Placebo Group|(Placebo, grape-flavored maltodextrin carbohydrate) - athletes will receive400ml of drink daily with 66g of maltodextrin for 14 days and will do the fight simulations; The amount of maltodextrin is equal to the amount of carbohydrate present in grape juice.
89491329|NCT04847492|Active Comparator|Traditional corticotomy|Adult patients will be treated by en-masse retraction associated with traditional corticotomy.
89491330|NCT04847492|Experimental|Flapless corticotomy|Adult patients will be treated by en-masse retraction associated with flapless corticotomy.
89491331|NCT02434653|Experimental|Postpartum anemia diagnosis following symptoms|Post partum anemia will be assessed by taking hemoglobin level following symptoms consistent with anemia, severe postpartum hemorrhage or hemoglobin level below 8 g/dL in the first 5 days following delivery
89491332|NCT02434653|Experimental|Postpartum anemia diagnosis following patients screening|Post partum anemia will be assessed by taking hemoglobin level in patients at increased risk to develop post-partum anemia in the first 5 days following delivery, defined as patients with initial (before or immediately after delivery) hemoglobin level of 10.5 g/dl or less regardless of symptoms, or in cases of severe post partum hemorrhage.
89491333|NCT03043196|Active Comparator|Rosuvastatin Group|Oral prophylaxis followed by 1.2% Rosuvastatin drug in gel form placed in intrabony defects
89491334|NCT03043196|Placebo Comparator|Placebo Group|Oral prophylaxis followed by placebo gel placement in intrabony defects
89491335|NCT03040544|Experimental|LTB-Curriculum|First group/arm undergo MIS training according to the LTB curriculum after the first own laparoscopic cholecystectomy in the OR as a baseline. After 6 weeks, the participants in this group/arm will perform their second CHE. The video recordings of the MIS procedures will be analysed and compared using the Global Operational Assessment of Laparoscopic Skill (GOALS) score.
89491336|NCT03040544|Active Comparator|no LTB-Curriculums|Second group/arm will not undergo any MIS trains after their first laparoscopic CHE in the OR. After 6 weeks, the participants in this group/arm will perform their second CHE. The video recordings of the MIS procedures will be analysed and compared using GOALS score.
89491337|NCT03188835|Other|Isocaloric Diet|Two weeks of isocaloric diet
89491338|NCT03188835|Other|Fructose diet|Two weeks of hypercaloric diet supplemented with fructose
89491339|NCT03188835|Other|Glucose diet|Two weeks of hypercaloric diet supplemented with glucose
89491340|NCT04847414||prospective group|all needed data will be collected from patients in this group through performing full medical examination and doing all necessary investigations for them
89491341|NCT04847414||retrospective group|all needed data will be collected from medical records either electronic or paper based from different diabetes clinics in upper Egypt
89491342|NCT04847180|Experimental|Instability shoulder group|Patients operated for an antero-inferior shoulder instability
89491343|NCT04847180|Other|Non instability shoulder group|Patients without shoulder instability, operated for another reason.
89022044|NCT00448110|Experimental|A|intravenous diclofenac dosage level 1
89491344|NCT04847024|Experimental|Parecoxib|Parecoxib 40 mg reconstituted in 2ml of saline solution, to pass IV as a bolus, every 12hrs + acetaminophen 1g in 100cc of saline solution to pass IV in 15 minutes, every 6hrs.
89491345|NCT04847024|Experimental|Dexketoprofen|Dexketoprofen 50 mg in 100 cc of saline solution, protected from sunlight, to be given IV in 15 minutes, every 8hrs + acetaminophen 1g in 100 cc of saline solution to be given IV in 15 minutes, every 6hrs.
89491346|NCT03188757|Experimental|hyperglycaemic clamp|
89491347|NCT04860674|Experimental|PD-1+ICE|PD-1 inhibitor combined with icyclophosphamide, carboplatin, etoposide chemotherapy
89022045|NCT00448110|Experimental|B|intravenous diclofenac dosage level 2
89022046|NCT00448110|Active Comparator|C|intravenous ketorolac
89022047|NCT00448110|Placebo Comparator|D|placebo
89491348|NCT03188679|Other|mRNA sequencing|amniotic fluid for patients with CMV seroconversion during pregnancy will undergo mRNA sequencing
89491349|NCT04847336||Women|Women of any age who gave births in hospitals from WHO European Region, from 1 march 2020
89491350|NCT04847336||Health workers|Health workers directly involved in assistance at childbirth (pregnancy, childbirth and peripartum) at hospital level in WHO European Region, from 1 march 2020
89491351|NCT04853342|Experimental|Furmonertinib|Furmonertinib (80 mg orally, once daily), in accordance with the randomization schedule.
89491352|NCT04853342|Placebo Comparator|Placebo Furmonertinib|Matching placebo for Furmonertinib (80 mg orally, once daily), in accordance with the randomization schedule.
89491353|NCT02430285|Other|Endoscopic Ultrasound|All consecutive patients entering the emergency department due to acute abdominal pain and showing biochemical and/or radiological findings consistent with possible acute biliary pancreatitis, undergo Endoscopic Ultrasound with linear array Olympus 180 series echoendoscopes (Olympus Europa Holding, Hamburg, Germany).
89491354|NCT02430207|Experimental|Femoral Vein|patients receiving temporary pacing via femoral vein
89491355|NCT02430207|Experimental|Subclavian Vein|patients receiving temporary pacing via subclavian vein
89491356|NCT04853030|Experimental|Minimed 670G 4.0 closed loop with Faster Insulin aspart|
89491357|NCT04853030|Active Comparator|Minimed 670G 4.0 closed loop with Standard Insulin aspart|
89491358|NCT02430519|Experimental|11 Patients with Grade II Manibular Molar Furcation|Group A- Furcation Treatment with PRF
89491359|NCT02430519|Experimental|11 Patients with Grade II Mandibular Molar Furcation D|Group B- Furcation Treatment with Allograft and GTR
89491360|NCT03040700|No Intervention|Clinical|Regular medical visits every 6 months.
89491361|NCT03040700|Experimental|Myocardial Perfusion Scan|Myocardial perfusion stress test using cardiac scintigraphy (Sestamibi) at rest and during pharmacological stress (dipyridamole)
89491362|NCT03040700|Experimental|Coronary CTA|Coronary computed tomography angiography
89491363|NCT02430363|Active Comparator|MK-3475|"Pembrolizumab (MK-3475) is a humanized monoclonal antibody. Information from these studies suggests that Pembrolizumab (MK-3475) may be beneficial in Glioblastoma / Gliosarcoma.~Patients enrolling in phase 1 receive MK-3475 every 3 weeks, with the dose to be determined.~MK-3475 will be given intravenously over the course of 30 minutes"
89491364|NCT02430363|Experimental|Suppressor of the PI3K/Akt pathways|"Pictilisib (GDC-0941) is a potent inhibitor of PI3Kα/δ. Patients will take the Pictilisib (capsules) orally with food. The dose should be taken every 3 weeks.~BEZ235 (NVP-BEZ235) is a dual ATP-competitive PI3K and mTOR inhibitor. Inhibits ATR whileshown to be a poor inhibitor to Akt and PDK1.~Patients will take the BEZ235 (capsules) orally with food. The dose should be taken every 3 weeks.~Ipatasertib (GDC-0068) is a highly selective pan-Akt inhibitor targeting Akt1/2/3 .~Patients will take the Ipatasertib (capsules) orally with food. The dose should be taken every 3 weeks.~The suggested dosage of inhibitors of the PI3K/Akt pathway orally as a single dose in capsule and Packed in plastic boxes, so that preparations can be taken at home"
89491365|NCT04852406|Experimental|Intervention group|Participants in this group receive protocol-based management of perioperative antithrombotic therapy.
89491366|NCT04852406|Sham Comparator|Control group|Participants in this group receive routine management of perioperative antithrombotic therapy.
89491367|NCT02430051|No Intervention|Regular Dental Environment|There are two dental environments - the regular dental environment and the sensory dental environment; each child will be randomized to which is first. In the Regular dental environment no sensory characteristics of the dental environment are altered, the cleaning is conducted as per usual.
89491368|NCT02430051|Experimental|Sensory Adapted Dental Environment|In the Sensory Adapted Dental Environment the sensory characteristics of the dental environment are altered (visual, auditory, tactile adaptations).
89491369|NCT03042806|Other|experimental group|COPD patients will be asked to fill in the Maugeri Physical Activity Questionnaire (MaPAct) to assess self perceived physical activity.
89491370|NCT04860440||End-Stage Renal Disease on haemodialysis|Wearing accelerometer (fitness tracker) for 7 days.
89491371|NCT04860440||Low clearance pre-dialysis patients|Wearing accelerometer (fitness tracker) for 7 days.
89491372|NCT02429973|Experimental|Experimental|6 cycles of gemcitabine plus rapamycin
89491373|NCT03043040|Experimental|Telephone follow up|"Patients discharged from hospital A and B after a suicide attempt receive a protocolized telephone follow which is added to their usual treatment (TAU). Calls are made by nurses at weeks 1,2,4,12 and 24 after the index suicide attempt.~TAU: Includes whatever treatment the doctor decides to offer to that patient (psychopharmacology, psychotherapy etc)."
89491374|NCT03043040|Active Comparator|Control|Patients discharged from hospital C after a suicide attempt receive treatment as usual (whatever treatment the doctor decides to offer to that patient: psychopharmacology, psychotherapy etc).
89491375|NCT03186651|Experimental|Trans Vagina Support|Tension Free Vaginal Support (TVS):The subjects in the TVS Group used pads during week 1 (Baseline), fitted, trained and selected device size week 2 and used the selected device size during week 3 (treatment week).
89491376|NCT03186651|No Intervention|Standard Care|Standard of care (SoC): The subjects in the SoC group continued with conventional treatment i.e. using pads during week 1, 2 and 3. They were offered to use the TVS device for two weeks after completion of week 3.
89491377|NCT04860284|Active Comparator|Intervention arm|Participants will receive 400mg of hydroxychloroquine tablets 12-hourly on day 1 and 200mg 12-hourly on day 2 to day 5 in addition to standard of care treatment for COVID-19
89491378|NCT04860284|No Intervention|Control arm|Participants will receive only standard of care treatment for COVID-19
89022048|NCT00454311|Active Comparator|One cell biopsy|
89491379|NCT04846634|Experimental|neoadjuvant Penpulimab + chemotherapy followed by adjuvant Penpulimab|
89491380|NCT04846634|Experimental|neoadjuvant Penpulimab + chemotherapy + Anlotinib followed by adjuvant Penpulimab + Anlotinib.|
89491381|NCT04846634|Experimental|neoadjuvant Penpulimab + Anlotinib followed by adjuvant Penpulimab + Anlotinib.|
89491382|NCT03190395|Experimental|CPVI Group|CPVI Group: Pure Circumferential pulmonary vein isolation(CPVI)
89491383|NCT03190395|Active Comparator|CPVI+LARA Group|CPVI+LARA Group: Circumferential pulmonary vein isolation combine with Left Atrium Roofline Ablation
89491384|NCT04860362|Experimental|Treatment|PEERS weekly sessions - parallel teens and parent/caregiver groups
89491385|NCT04860362|Other|Wait List Control|Offered intervention at a later date
89491386|NCT02429895|Experimental|All subjects (open-label extension)|All subjects will start treatment with ABT-122
89491387|NCT03043118|Experimental|Variety|Children receive three servings of vegetables each prepared with a different herb and spice blend.
89491388|NCT03043118|No Intervention|No Variety - Control|Children receive three servings of vegetables each prepared with the same herb and spice blend.
89491389|NCT02425371|Experimental|Intervention|screening and treatment of comorbidities
89491390|NCT02425371|Placebo Comparator|Control|No screening of comorbidity
89491391|NCT04852250||FOLFOXIRI plus bevacizumab and centralized tumour board|
89491392|NCT04852250||FOLFOXIRI plus bevacizumab but no centralized tumour board|
89491393|NCT02429739|Experimental|Working Memory Training|Behavioral: Cogmed RM working memory training. After baseline assessment participants will be randomized to active training or treatment as usual (waiting). The active group will start immediately and will have 6 weeks to perform the 25 training sessions.
89491394|NCT02429739|No Intervention|Passive control group|"The control group will receive treatment as usual (Ordinary school days, special education if normally received)."
89491395|NCT04851938|Active Comparator|Active TENS 1 Group|
89491396|NCT04851938|Active Comparator|Active TENS 2 Group|
89491397|NCT04851938|Placebo Comparator|Placebo Group|
89491398|NCT04851938|Sham Comparator|Control Group|
89491399|NCT02429661|Experimental|RC (Girls First Resilience Curriculum)|The Girls First Resilience Curriculum is delivered in peer support groups of 12-15 students per group over 23 weekly 1-hour sessions. The curriculum draws from fields such as positive psychology, emotional competence/intelligence, and restorative practices, and aims to improve students' psychosocial assets and wellbeing.
89491400|NCT02429661|Experimental|HC (Girls First Health Curriculum)|The Girls First Health Curriculum is delivered in peer support groups of 12-15 students per group over 21 weekly 1-hour sessions. The curriculum covers topics such as nutrition, sexual and reproductive health, clean water, hygiene, and common diseases, and aims to improve students' physical health and wellbeing.
89491401|NCT02429661|Experimental|RC+HC (Girls First)|Girls First is a combination of the Girls First Resilience Curriculum (RC) and the Girls First Health Curriculum (HC).
89491402|NCT02429661|No Intervention|SC (School-as-usual control)|Participants receive no intervention and attend school as they usually would.
89491403|NCT02433717|Experimental|Paliperidone ER|Six-week paliperidone ER
89491404|NCT04846166||Control|
89491405|NCT04846166||Periodontitis|
89491406|NCT02433561|Active Comparator|Intraplexic catheter|Intraplexic approach (Patients will have the catheter placed within the plexus, classical approach)
89491407|NCT02433561|Experimental|Extraplexic catheter|Extraplexic approach (Patients will have the catheter placed out of the plexus.)
89491408|NCT03042884|Experimental|Wearable Exercise Trackers - Inpatient Group|"Questionnaires completed at baseline and within 24 hours of discharge.~Participant given a wearable exercise tracker to be worn 24 hours a day while in the acute inpatient rehabilitation unit."
89491409|NCT03042884|Experimental|Wearable Exercise Trackers - Outpatient Group|"Questionnaires completed at baseline and again in 14 days.~Participant given a wearable exercise tracker to be worn 24 hours a day for 14 days."
89491410|NCT02429817|Active Comparator|Aeroneb Solo|Subjects inhaled radiolabelled aerosol via the Aeroneb Solo connected to the high flow nasal cannula.
89491411|NCT02429817|Active Comparator|Standard Jet Nebulizer|Subjects inhaled radiolabelled aerosol via the jet nebulizer connected to the high flow nasal cannula.
89491412|NCT03042728|Active Comparator|Dog interaction|Dog interaction will be received by patients in addition to usual care of fibromyalgia.
89491413|NCT03042728|Active Comparator|Human Interaction|Human interaction will be received by patients in addition to usual care of fibromyalgia.
89491414|NCT04851782|Experimental|Braun Infusomat Pump and ivEAD tubing|ivEAD tubing
89491415|NCT04851782|No Intervention|Braun Infusomat Pump and standard tubing|Standard tubing
89491416|NCT04851782|Experimental|Standard pump and ivEAD tubing|ivEAD tubing
89491417|NCT04851782|No Intervention|Standard infusion pump and standard tubing|Standard tubing
89491418|NCT04852094||Parents|parents of hospitalized children, speaking and understanding enough French, not presenting psychiatric disorders, voluntary to participate in focus groups
89491419|NCT04852094||Professionals|Nurses, assistant nurses, psychologist, physiotherapist, physicians, residents and fellows
89491420|NCT04846010|Active Comparator|antigen|The antigen is the cell that is destroyed by inflammation, which can perform as swollen, fatty, apoptosis, necrosis, and lethal pathological states. Some pathological cells can be saved and returned to customary conditions, like swollen, fatty, early apoptosis, but necrosis, lethal.
89491421|NCT04846010|Active Comparator|Internal environment|The internal environment is critical to the damaged cells recovering. Mainly it is covered by two major parts: metabolites and thrombus.
89491422|NCT04846010|Active Comparator|Communication between cells|The communication between organs, cells, helps the damaged cells recover and reduce symptoms.
89491423|NCT04851860|Other|allergic rhintis children|sublingual immunotherapy is used for allergic rhintis children by dosing Allergen immunotherapy extract as sublingual drops which were kept under the tongue for a couple of minutes and then swallowed. The sublingual drops were administered in the morning on an empty stomach .
89491424|NCT04851548|Active Comparator|Group A (control)|"preoperative cone-beam computed tomography (CBCT) scans N=9~open flap debridement.~use membrane without hyaluronic acid. (The first monitor will be done after three months. The data will be recorded. After another three months, the patients will undergo an x-ray check again, and the data will be registered. The goal is to have the patients exposed to x-ray twice not to be compromised to a high radiation dose. The evaluation to be done for the 3-month interval will only be clinical assessments|)"
89491425|NCT04851548|Active Comparator|Group B (test)|"preoperative cone-beam computed tomography (CBCT )scans N= 9~open flap debridement.~use membrane and 8% hyaluronic acid gel (The first monitor will be done after three months. The data will be recorded. After another three months, the patients will undergo an x-ray check again, and the data will be registered. The goal is to have the patients exposed to x-ray twice not to be compromised to a high radiation dose. The evaluation to be done for the 3-month interval will only be clinical assessments|)."
89491426|NCT03042572|Experimental|Allogeneic Mesenchymal Stromal Cell|Intramuscular Allogeneic Bone marrow-derived Mesenchymal Stromal Cell Injection
89491427|NCT03042572|Placebo Comparator|Placebo|Intramuscular placebo injection
89491428|NCT04845698|Experimental|With i-Dashboard|Multi-disciplinary rounds are conducted with the assistance of i-Dashboard.
89491429|NCT04845698|No Intervention|Without i-Dashboard|Multi-disciplinary rounds are conducted without the assistance of i-Dashboard. The team members collect data using standard electronic medical records.
89491430|NCT04851626|Experimental|Intervention group - hypnotic intervention for persistent pelvic pain|Participants underwent education about persistent pain and a 7 week 7 recording online hypnotic intervention. Women with persistent pelvic pain.
89491431|NCT04851626|Other|Control group - waitlist control|Control group of women with persistent pelvic pain no intervention completed assessment and concluding measures but did not undergo hypnotic intervention.
89022049|NCT00454311|Other|Two cell biopsy|
89491432|NCT04851392|Experimental|THC condition|"THC condition: Cannabis with delta-9-tetrahydrocannabinol (THC) and no cannabidiol (CBD). 0.107mg/kg of THC. A 75kg person receives 8mg of THC.~Route of administration: vaporised and inhaled.~Frequency: once.~Duration: inhaled in < 18 minutes."
89491433|NCT04851392|Experimental|THC+CBD condition|"THC+CBD condition: Cannabis with THC and CBD (i.e. THC+CBD condition). 0.107mg/kg of THC and 0.320mg/kg of CBD. A 75kg person receives 8mg of THC and 24mg of CBD.~Route of administration: vaporised and inhaled.~Frequency: once.~Duration: inhaled in < 18 minutes."
89491434|NCT04851392|Placebo Comparator|PLA condition|"PLA condition: Placebo cannabis with no THC or CBD.~Route of administration: vaporised and inhaled.~Frequency: once.~Duration: inhaled in < 18 minutes."
89491435|NCT04859894||Covid19|Patients aged >18 years with confirmed Covid19 disease with symptoms >12 weeks, not better explained by other disease
89491436|NCT03185325||Non hodgkin lymphoma patients|bone marrow puncture and venous blood samples
89491437|NCT03185325||healthy voulnteers|venous blood samples
89491438|NCT04845464||Study Group|A group of young adults aged between 18 to 25
89491439|NCT02429193|Experimental|Abiraterone / enzalutamide|Abiraterone + prednisone; Enzalutamide
89491440|NCT04859738|Experimental|Experiment I Group (Lidocaine Spray)|Lidocaine Spray was applied to Experiment I group before peripheral intravenous catheter application.
89491441|NCT04859738|Experimental|Experiment II Group (Benzokain Sprey)|Benzokain Sprey was applied to Experiment II group before peripheral intravenous catheter application.
89537955|NCT02711137|Experimental|Part1/Treatment Group B : 12mg QD INCB057643|Initial cohort dose of INCB054763 monotherapy at the protocol-specified cohort escalation treatment group B (TGB), based on protocol-specific criteria. Treatment Group B included any acute leukemia, HRMDS, MDS/MPN, or MF.
89537956|NCT02711137|Experimental|Part1/Treatment Group C : 8mg QD INCB057643|Initial cohort dose of INCB054763 monotherapy at the protocol-specified cohort escalation treatment group C (TGC), based on protocol-specific criteria. Treatment Group C includes subjects with MM
89022050|NCT00448149|Experimental|1|To establish the maximally tolerated dose (MTD) of RAD001 in combination with Nexavar®
89537957|NCT02711137|Experimental|Part2/Treatment Group A : 12 mg INCB057643 Expansion Cohort|Initial cohort dose of INCB054763 monotherapy at the specified RP2D dose selected in Part 1 cohort escalation treatment group A (TGA), based on protocol-specific criteria. Part 2 Treatment Group A expansion included pancreatic adenocarcinoma, castration-resistant prostrate cancer, breast cancer, high grade serious ovarian cancer, glioblastoma multiform, non-hodgkin's lymphoma, ewing's sarcoma, and solid tumor or lymphoma.
89537958|NCT02711137|Experimental|Part2/Treatment Group B : 12 mg INCB057643 Expansion Cohort|Initial cohort dose of INCB057463 monotherapy at the specified RP2D dose selected in Part 1 cohort escalation treatment group B (TGB), based on protocol-specific criteria. Part 2 Treatment Group B expansion included pancreatic adenocarcinoma, castration-resistant prostrate cancer, breast cancer, high grade serious ovarian cancer, glioblastoma multiform, non-hodgkin's lymphoma, ewing's sarcoma, and solid tumor or lymphoma.
89537959|NCT02711137|Experimental|Part3/Treatment Group A : 8 mg INCB057643 + Gemcitabine 1000mg|Initial cohort dose of INCB057643 monotherapy based on protocol-specific criteria. Part 3 will determine the MTD and/or a tolerated dose of the combination of INCB057643 and one of the SOC agents (Gemcitabine) in relapsed or refractory advanced or metastatic solid tumors and hematologic malignancies where Gemcitabine is relevant
89537960|NCT02711137|Experimental|Part3/Treatment Group B : 8 mg INCB057643 + Paclitaxel 80mg|Initial cohort dose of INCB054763 monotherapy based on protocol-specific criteria. Part 3 will determine the MTD and/or a tolerated dose of the combination of INCB057643 and one of the SOC agents (Paclitaxel) in relapsed or refractory advanced or metastatic solid tumors and hematologic malignancies.
89537961|NCT02711137|Experimental|Part3/Treatment Group C : 8 mg INCB057643 + Rucaparib 600mg|Initial cohort dose of INCB054763 monotherapy based on protocol-specific criteria. Part 3 will determine the MTD and/or a tolerated dose of the combination of INCB057643 and one of the SOC agents (Rucaparib) in relapsed or refractory advanced or metastatic solid tumors and hematologic malignancies.
89022051|NCT00344942|Experimental|1|
89537962|NCT02711137|Experimental|Part3/Treatment Group D : 8 mg INCB057643 + Abir +Predni|Initial cohort dose of INCB054763 monotherapy based on protocol-specific criteria. Part 3 will determine the MTD and/or a tolerated dose of the combination of INCB057643 and one of the SOC agents (Abiraterone + Prednisone) in Castration Resistant Prostrate Cancer
89537963|NCT02711137|Experimental|Part3/Treatment Group E : 8 mg INCB057643 + Ruxolitinib 20mg|Initial cohort dose of INCB054763 monotherapy based on protocol-specific criteria. Part 3 will determine the MTD and/or a tolerated dose of the combination of INCB057643 and one of the SOC agents (Ruxolitinib) in Myelofibrosis.
89537964|NCT02711137|Experimental|Part3/Treatment Group F : 8 mg INCB057643 + Azacitidine 75mg|Initial cohort dose of INCB054763 monotherapy based on protocol-specific criteria. Part 3 will determine the MTD and/or a tolerated dose of the combination of INCB057643 and one of the SOC agents (Azacitidine) in Acute Myeloid Leukemia and Myelodysplastic Syndrome
89537965|NCT03288623|Experimental|Dark Chocolate|Dark chocolate (85% cocoa) 40 mg per day for 30 days
89537966|NCT03288623|Placebo Comparator|White/Milk Chocolate|White chocolate or Milk chocolate administration in tablet (<35% cocoa) per day for 30 days
89537967|NCT03293225||add H2RA|Add antihistamines to standard drug therapy
89537968|NCT03293225||change ns-H1RA|Change to ns-H1RA in standard medication
89537969|NCT03293225||ns-H1RA(3-4 tabs)|Standard treatment with ns-H1RA 4X dose
89537970|NCT03293225||ns-H1RA(3-4kinds)|Use of NS 4 kinds for standard treatment
89537971|NCT04970979||patients with coronary artery disease|patients with coronary artery disease
89537972|NCT04970823|Experimental|The somatosensory interactive game|The somatosensory interactive game, an independent nursing intervention, promotes pain relief on the experimental group.
89022052|NCT00344942|Placebo Comparator|2|
89022053|NCT00454389|Experimental|A|Epi-Rad90™ Ophthalmic System procedure + Lucentis
89022054|NCT00454389|Active Comparator|B|Lucentis only
89022055|NCT00448266|Experimental|2|1 course ddAc, 2 courses IAA with PBPC support
89022056|NCT00448266|Active Comparator|1|3 courses ddAC
89022057|NCT00345059|Active Comparator|docetaxel|single agent docetaxel
89022058|NCT00345059|Experimental|docetaxel + vinorelbine OR gemcitabine|docetaxel in combination with either vinorelbine or with gemcitabine
89022059|NCT00345059|Experimental|docetaxel + capecitabine|docetaxel in combination with capecitabine
89022060|NCT03274635|Active Comparator|Usual Delayed Compensation, Money|Will receive delayed monetary compensation with Amazon gift card, non performance-contingent.
89537973|NCT04970823|Experimental|A VR (virtual reality) game|A VR (virtual reality) game promotes pain relief on the experimental group.
89537974|NCT04488653|Experimental|Oligopin®|Oligopin® contains French Maritime Pine Bark Extract
89537975|NCT04488653|Placebo Comparator|Placebo|Placebo is a mixture of different inert compounds
88953849|NCT01966367|Experimental|CliniMACS PLUS followed by chemotherapy|"Patients will receive a pre-transplant conditioning regimen of Busulfan Fludarabine and Alemtuzumab. For patients with pre-transplant hepatic dysfunction, Melphalan will be substituted for the Busulfan. For patients receiving a second transplant or a boost, pre-transplant conditioning based on the clinical condition of the patient will be determined by the Principal Investigator and the patient's bone marrow transplantation (BMT) physician. The donor peripheral blood stem cells will undergo CD34+ selection (Biological/Vaccine: CD34 Stem Cell Selection Therapy). The CliniMACS (PLUS) Reagent System will be used to remove T-cells from the peripheral blood stem cell transplant in order to decrease the risk of acute and chronic graft versus host disease (GVHD)."
89537976|NCT04970745||high-risk|After performing midbrain ultrasound and tremor analysis, patients with positive results of both tests are considered very high-risk patients,
88953850|NCT01966393|Active Comparator|Dual-hormone closed-loop strategy|In dual-hormone closed-loop strategy, variable subcutaneous insulin and glucagon infusion rates will be used to regulate glucose levels
88953851|NCT01966393|Active Comparator|Single-hormone closed-loop strategy|In single-hormone closed-loop strategy, variable subcutaneous insulin infusion rate will be used to regulate glucose levels
88953852|NCT01966393|Active Comparator|Conventional insulin pump therapy|In control visit, subjects will use conventional pump therapy to regulate glucose levels.
88953853|NCT01966406|Experimental|No nasogastric tube insertion before pancreaticoduodenectomy|The patients receiving pancreaticoduodenectomy will not undergo NG tube insertion before operation
88953854|NCT01966406|Active Comparator|Pre-operative NG tube use|The patients receiving pancreaticoduodenectomy will undergo NG tube insertion before operation
88953855|NCT01966484|Active Comparator|Succinylcholine|Patient receive succinylcholine as a muscle relaxant (0,5mg/kg) after induction of general anaesthesia for rigid bronchoscopy.
88953856|NCT01966484|Active Comparator|Mivacurium|Patients receive mivacurium (0,08mg/kg) as a muscle relaxant after induction of general anaesthesia for rigid bronchoscopy. At the end of the procedure and a twitch of 25% mivacurium was reversed with neostigmine (50 microg/kg) and atropin (10 microg/kg)
88953857|NCT01966497||Core study therapy|"idarubicin for both induction and consolidation courses~if Cr, two cycles of IDAC alone (1.5g/m2 per infusion every 12hours, on D1, 3 and 5 of each cycle)"
88953858|NCT01966510|Experimental|Cord blood transplantation|Two cord blood units containing both together more than 3x10^7 frozen nucleated cells/Kg with no more than 2 out of 6 HLA mismatches between them and with the patients.
88953859|NCT01966523|Experimental|Intervention|Provider Training: i. on-line education course and ii. algorithms and checklists. The course consists of 4 cases: 2 for urinary tract infection and 2 for lower respiratory tract infections with multiple choice questions and evidence-based feedback. To reinforce provider learning, posters displaying algorithms guiding appropriate antimicrobial initiation for infections will be placed in all nursing home units. Laminated pocket cards with the algorithms will be given to providers. Providers will complete simple checklists for each suspected infection throughout the study. B. Proxy Information: The printed material explains, in a lay fashion: i. the nature of infection in advanced dementia, ii. treatment options, iii. concerns about antimicrobial overuse, and iv. features of appropriate antimicrobial use.
88953860|NCT01966523|Other|Usual Care|Residents will receive usual care for infections
88953861|NCT01966536|Experimental|Poor ovarian reserve|Autologous transplantation of CD133+ cells into ovarian artery
88953862|NCT01966562|Experimental|WBV TRAINING|WHOLE-BODY VIBRATION TRAINING
88953863|NCT01966562|Active Comparator|MC TRAINING|MULTICOMPONENT TRAINING
88953864|NCT01966562|No Intervention|CG|Control group
88953865|NCT01966575|Experimental|No withdrawal bleed|No progestin prior to ovulation induction with clomiphene citrate
88953866|NCT01966575|No Intervention|Withdrawal Bleed|Progestin prior to beginning ovulation induction with clomiphene citrate (standard care)
88953867|NCT01966588||Metabolic Arm|Blood samples for whole genomic/transcriptomic sequencing; administration of the UKU Side Effect Rating Scale.
88953868|NCT01966588||Neutropenia/Immune System Arm|Blood samples for whole genomic/transcriptomic sequencing
88953869|NCT01966614|Experimental|PRX302|PRX302 injection
88953870|NCT01966614|Placebo Comparator|Placebo|Placebo (Vehicle-only injection)
88953871|NCT01966627||Pediatric NAFLD Cohort|Overweight and obese children and adolescents at risk for non alcoholic fatty liver disease will undergo oral glucose tolerance testing (ogtt), genotyping, abdominal and liver magnetic resonance imaging (mri), and will provide a stool sample at baseline and at 2 year follow up. A small subset will undergo liver biopsy to test for hepatic steatosis and nonalcoholic steatohepatitis.
88953872|NCT01966653|Active Comparator|nitrofurantoin|Nitrofurantoin will be given orally at a dose of 100 mg three times daily for 5 days.
88953873|NCT01966653|Active Comparator|fosfomycin|A single 3g dose of oral fosfomycin will be given.
88953874|NCT01966666|Experimental|TPI-287 low dose|2 mg/m2 of TPI-287 administered as a 1-hour intravenous infusion once every 3 weeks for 9 weeks (for a total of 4 infusions)
88953875|NCT01966666|Experimental|TPI-287 moderate dose|6.3 mg/m2 of TPI-287 administered as a 1-hour intravenous infusion once every 3 weeks for 9 weeks (for a total of 4 infusions)
88953876|NCT01966666|Experimental|TPI-287 high dose|20 mg/m2 of TPI-287 administered as a 1-hour intravenous infusion once every 3 weeks for 9 weeks (for a total of 4 infusions)
88953877|NCT01966666|Placebo Comparator|Placebo|
88953878|NCT01966679|Active Comparator|Double-blind (active versus placebo)|AZD7325 versus placebo
88953879|NCT01966679|Placebo Comparator|Placebo|
88953880|NCT01966692|Active Comparator|Fluticasone Propionate Formulation 1|"Fluticasone Propionate Drug formulation 1 administered via Plastiape Monodose Dry powder Inhaler , 500mcg single dose.~See Formulation Development in Detailed Description for details regarding differences in formulations"
88953881|NCT01966692|Active Comparator|Fluticasone Propionate Formulation 2|"Fluticasone Propionate Drug formulation 2 administered via Plastiape Monodose Dry powder Inhaler , 500mcg single dose.~See Formulation Development in Detailed Description for details regarding differences in formulations"
89537977|NCT04970745||risk|After performing midbrain ultrasound and tremor analysis, patients with positive results of 1 out of 2 tests are considered risk patients
89537978|NCT04970745||low-risk|After performing midbrain ultrasound and tremor analysis, patients with negative results of both tests are considered risk patients
89491442|NCT04859738|Placebo Comparator|Placebo Group|Alcohol was administered to the placebo group prior to peripheral intravenous catheter application.
89491443|NCT02429271|Active Comparator|Ticagrelor|1st day 270 mg & from then onwards 180 mg per day
89491444|NCT02429271|Active Comparator|Clopidogrel|1st day 300 mg & from then onwards 75 mg per day
89491445|NCT02429505||Miltefosine|Miltefosine : target of 2.5 mg/kg/day for 28 days. Patients 45 kg or greater were to receive one 50 mg capsule 3 times daily for 28 consecutive days. This prospective observational study in which patients undergoing treatment for leishmaniasis with miltefosine in the United States who weighed >75 kg could volunteer to provide information about their clinical response to treatment up to 6 months after the start of treatment.
89491446|NCT04850924||children impact by the Alex storm|
89491447|NCT04851002|Experimental|CGF TEST GROUP|Concentrated growth factor liquid applied into the implant cavity. Also CGF membrane covered the implant and the socket. That is the only difference between CGF control group and CGF test group
89491448|NCT04851002|Experimental|A-PRF TEST GROUP|Advanced Platelet Rich Fibrin liquid applied into the implant cavity. Also A-PRF membrane covered the implant and the socket. That is the only difference between A-PRF control group and A-PRF test group
89491449|NCT04851002|Experimental|CGF CONTROL GROUP|Dental implant applications were made with traditional methods.
89491450|NCT04851002|Experimental|A-PRF CONTROL GROUP|Dental implant applications were made with traditional methods.
89491451|NCT02708121|Experimental|Intervention arm|Participant receives intervention to motivate weight loss treatment initiation and access to weight loss treatment.
89491452|NCT02708121|Active Comparator|Comparator Arm|Participant receives access to weight loss treatment alone.
89491453|NCT04844996|Experimental|Ezetimibe group|The endometriosis model was developed surgically in all 18 rats and pretreatment sizes of the endometriotic explants were measured. After randomization Ezetimibe (1 mg/kg/day (Ezetrol®, Merck Sharp Dohme, Istanbul, Turkey) was administered orally with gavage methodology to the 9 rats in the ezetimibe group for 28 days postoperatively.
89491454|NCT04844996|Placebo Comparator|Control groups|The endometriosis model was developed surgically in all 18 rats and pretreatment sizes of the endometriotic explants were measured. After randomization saline (1 ml/kg/day) was administered orally with gavage methodology to the 9 rats in the control group for 28 days postoperatively.
89491455|NCT02433639|Experimental|treatment|single arm study: TH-302 monotherapy is given
89491456|NCT02425293|Experimental|Intervention|Patients participating in a patient education seminar
89491457|NCT02425293|No Intervention|Control|Patients not participating in a patient education seminar
89491458|NCT04851080||Schoolchildren|Schoolchildren of Vladikavkaz secondary schools aged 13-16 years
89491459|NCT04851080||Students|Students of North-Ossetian State Medical Academy at the age of 19-22 years
89491460|NCT04851080||Volunteers|Scientists of the North Caucasian Research Institute of Mountain and Foothill Agriculture at the age of 30-56 years
89491461|NCT02433405||Group 1|Chronic Periodontitis-serum amyloid A, Fetuin-A
89491462|NCT02433405||Group 2|Plaque induced Gingivitis-serum amyloid A, Fetuin-A
89491463|NCT02433405||Group 3|Control Group-serum amyloid A, Fetuin-A
89491464|NCT02425059|Experimental|IRE Group|irreversible electroporation for Unresectable Rectal Neoplasms
89491465|NCT02425059|No Intervention|Control|The patients without treatment
89491466|NCT02425137|Experimental|S-1/Gemcitabine|single-arm
89491467|NCT02429349|Experimental|Diagnostic Procedure|Surgery - Unilateral surgical removal of ovary, freezing of tissue, post cancer cure autotransplant
89204551|NCT00813384|Experimental|Dose Expansion|The dose expansion will consist of up to 30 subjects and the dose level of AMG 208 will be dependent upon emerging safety and PK data from the dose escalation part of the study.
89491468|NCT04859348|Experimental|Group-A ( RPT+ Insulin Therapy)|Group A includes participants received the routine physical therapy only.
89491469|NCT04859348|Experimental|Group-B (RPT+ Antenatal Exercises+ Insulin therapy)|Group B includes participants were given antenatal exercise program from 20- 24 weeks of gestation to till the date of delivery, with addition of the routine physical therapy plan.
89491470|NCT02424981|Experimental|inspiratory muscle training|Muscle training
89491471|NCT02424981|No Intervention|control|Control group
89491472|NCT03184857|Active Comparator|two stage sinus lifting using bovine bone particles|Open maxillary sinus lifting will be done with sinus augmentation using bovine bone particles
89491473|NCT03184857|Experimental|two sage sinus lifting using Nano HA bone particles|Open maxillary sinus lifting will be done with sinus augmentation using Nano HA bone particles
89491474|NCT03038906||Cohort|Patients enrolling in NHLBI PETAL Network ROSE study of cisatracurium for moderate/severe ARDS at participating centers
89491475|NCT03185169|Other|Replens and coconut oil|Commercially available Replens applied via prefilled applicator into the vagina and coconut oil applied at the vaginal introitus and vulva. Both are to be administered by the patient 2 times per week, interval between dosing to be approximately 2 days. Patients will be encouraged to apply Preseed, coconut oil, or patient's personal lubricant of choice into the vagina prior to sexual activity.
89491476|NCT03182517||chronic kidney diseases|patients with chronic renal failure on dialysis since 3-5 years
89491477|NCT02433249|Active Comparator|1 Physical Activity|Small groups (4-7 people) meeting in community centers weekly for 90 minutes, over the course of 8 weeks. Curricula for meetings are manualized and include introducing and practicing Otago exercises, progressed according to individual capacity and preference, as well as falls prevention. All participant receive Fitbit Ones and are asked to use them on a daily basis.
89491478|NCT02433249|Experimental|2 Interpersonal Motivation|Small groups (4-7 people) meeting in community centers weekly for 90 minutes, over the course of 8 weeks. Curricula for meetings are manualized and include introducing and practicing Otago exercises, progressed according to individual capacity and preference, as well as falls prevention. The interventionist also facilitates discussions addressing the interpersonal motivational intervention content. All participant receive Fitbit Ones and are asked to use them on a daily basis: Fitbit Ones are included in weekly discussions.
89537979|NCT04970589|Placebo Comparator|Lean/Placebo Capsule|Participants (Lean:BMI 18-23) will be asked to take 400g of mango and a placebo capsule every day for 8 weeks
89537980|NCT04970589|Experimental|Lean/Probiotics|Participants (Lean:BMI 18-23) will be asked to take 400g of mango and a probiotic capsule every day for 8 weeks
89491479|NCT02433249|Experimental|3.Intrapersonal Motivation|Small groups (4-7 people) meeting in community centers weekly for 90 minutes, over the course of 8 weeks. Curricula for meetings are manualized and include introducing and practicing Otago exercises, progressed according to individual capacity and preference, as well as falls prevention. The interventionist also facilitates discussions addressing the intrapersonal motivational intervention content. All participant receive Fitbit Ones and are asked to use them on a daily basis: Fitbit Ones are included in weekly discussions.
89491480|NCT02433249|Experimental|4.Full Intervention|Small groups (4-7 people) meeting in community centers weekly for 90 minutes, over the course of 8 weeks. Curricula for meetings are manualized and include introducing and practicing Otago exercises, progressed according to individual capacity and preference, as well as falls prevention. The interventionist also facilitates discussions addressing the intrapersonal and interpersonal motivational intervention content. All participant receive Fitbit Ones and are asked to use them on a daily basis: Fitbit Ones are included in weekly discussions.
89491481|NCT04850690||Children with hemiparetic Cerebral palsy|15 children with CP, between 9-15 years old
89491482|NCT02433327|Active Comparator|PEWS - trigger tool|"Paediatric Early Warning Score:~Children randomized to PEWS - trigger tool"
89491483|NCT02433327|Active Comparator|RM - trigger tool|"Paediatric Early Warning Score:~Children randomized to Central Denmark Region (RM)- trigger tool"
89491484|NCT04850768||Periodontitis|Individuals with Periodontitis
89491485|NCT04850768||Gingivitis|Individuals with Gingival Inflammation
89491486|NCT04850768||Healthy|Individuals with Periodontally Healthy
89491487|NCT04483323|Active Comparator|Group I: Intraarticular group ( IA )|Patients will receive 20 ml of 0.25% bupivacaine intra-articularly through the surgical port
89491488|NCT04483323|Experimental|Group II: Erector Spinae Plane Block group ( ES )|Patients will receive an ultrasound guided erector spinae plane block using 20 ml of 0.25% bupivacaine at the level of T2 transverse process
89491489|NCT03182595|Experimental|open---label|An open---label, single centre, nonrandomized clinical study in healthy volunteers, with intervention over a 13---week period.
89491490|NCT02428959|Experimental|Amyl Nitrite|Amyl nitrite is the chemical compound with the formula C5H11ONO. It relaxes vascular smooth muscle.The method of administration is via inhalation with onset of action within of 30 seconds and ends 2-3mins. In a study by Dodds et al., amyl nitrite is used as part of radiologic esophagram test in order to distinguish patients with pseudoachalasia from those with idiopathic achalasia since amyl nitrite has transient effect on the lower esophageal sphincter (LES). The study revealed that the LES pressure in achalasia patient decreases substantially in response to amyl nitrite with the measurable increase in LES diameter of 3 mm to an average of 4.6m. In contrast, amyl nitrite does not relax the LES segment in pseudoachalasia and has no change in LES diameter. Thus, the investigators anticipate amyl nitrite inhalation will be beneficial at the LES during HREM.
89491491|NCT02429037|Experimental|rAd-p53 plus radiation and chemotherapy|rAd-p53 tumor injection combined with radio- and chemo-therapy.
89491492|NCT02429037|Active Comparator|radiation and chemotherapy|radiation combined with chemotherapy
89491493|NCT04833530||Woman undergoing an gastric ultrasound assessment.|Woman undergoing general anesthesia for oocyte retrieval during in vitro fertilization, will undergo an gastric ultrasound assessment.
89491494|NCT04833608|Active Comparator|Vktory Carbon fiber insoles|VKTRY insoles were initially designed to increase ground force leading to a harder push off for faster running or higher jumping. To enable energy return the insole needed to be extremely rigid and therefore consists out of a full length Carbon-Fiber base. Unexpectedly the Carbon fiber base makes this a highly rigid construct which will likely benefit those patients with MTP arthritis as it will take away much movement of the MTP joint, without having an uncomfortable shape, i.e. patients can use this insole in their own shoes, possibly leading to a higher patient compliance and, simultaneously, to better outcome
89491495|NCT04833608|Active Comparator|Morton's extension insoles|Based on expert opinions, it seems the Morton extensions may alleviate pain but are also poorly tolerated by patients due to its uncomfortable shape, coincidently leading to a low patient compliance rate.
89491496|NCT03182439|Active Comparator|Fit Bit Blaze|Fit Bit Blaze Heart Rate Monitoring Device
89491497|NCT03182439|Active Comparator|Garmin Forerunner 235|Garmin Forerunner 235 Heart Rate Monitoring Device
89491498|NCT03182439|Active Comparator|Tom Tom Spark Cardio|Tom Tom Spark Cardio Heart Rate Monitoring Device
89491499|NCT03182439|Active Comparator|Apple Watch|Apple Watch Heart Rate Monitoring Device
89491500|NCT03040232|Experimental|MPFl Reconstruction|subjects that have had MPFL reconstruction surgery
89491501|NCT03040232|Active Comparator|Active Controls|subjects that have not had MPFL reconstruction surgery
89491502|NCT04833686|Active Comparator|Sonata for 2 pianos in D major, K.488 by Mozart|An Mp3 player, upload with music by Mozart. Music was played using headphones suitable and approved for use in children.
89491503|NCT04833686|Active Comparator|"Instrumental music (To the Point, by Dean Evenson & Tom Barabas)"|An Mp3 player, upload with instrumental music. Music was played using headphones suitable and approved for use in children.
89491504|NCT04833686|Active Comparator|Silence|An Mp3 player, upload with silence. Silence was played using headphones suitable and approved for use in children.
89491505|NCT02424903||with prosthetic joint infection|Patients admitted for a septic revision surgery
89491506|NCT02424903||without prosthetic joint infection|Patients admitted for an aseptic revision surgery
89491507|NCT02428881|Experimental|Complete retention- onabotulinumtoxinA|Women in complete urinary retention receiving onabotulinumtoxinA
89491508|NCT02428881|Experimental|Obstructed voiding- onabotulinumtoxinA|Women with obstructed voiding receiving onabotulinumtoxinA
89491509|NCT03039062||Chemotherapy group|A total of 120 malignant tumor patients who need to receive chemotherapy are involved for miR-122 detection. They are from 3 centers, 40 for each center. For the first cycle of chemotherapy, the investigators will collect 0.5-1ml blood from the remained blood sample after routine blood test during chemotherapy for each patient.Each patient will have a routine blood test before(±3 days) each cycle of chemotherapy and 7(±3)days after chemotherapy. A routine blood test will include the test of ALT,AST,ALP and TBIL. Sample collection will stop after 4 cycles of chemotherapy. All blood samples collected by investigators are the remained sample after routine tests. Patients in routine care will also have blood tests before each cycle and on day 7(+/- 3) of each cycle of chemotherapy. These patients will also have blood test at these time points even if they are not in this trial.
89491510|NCT03039062||Healthy population|Twenty healthy women or men who come to hospitals for annual physical examinations are enrolled in this study for miR-122 detection. Investigators will collect 0.5-1 ml blood from the remained blood samples after routine blood tests during their annual physical examinations.
89491511|NCT03039062||Patients of intensive care unit|Fourty patients are enrolled in this group for miR-122 detection. The investigators will collect 0.5-1ml blood from the remained blood samples of their routine blood tests or when they need blood tests.
89491512|NCT02428725|Experimental|Acute coronary syndrome patient|Acute coronary syndrome patient undergoing PCI and eligible for ticagrelor therapy according to the guidelines accepting blood samples measuring platelets reactivity
89491513|NCT02433093|Experimental|Basimglurant: Healthy Cohort (1)|Healthy participants assigned to basimglurant will receive a 22-day ascending dose regimen. Cohort 1 will receive a prespecified titration scheme; however, adaptive titration schemes may be applied in subsequent cohorts.
89491514|NCT02433093|Experimental|Basimglurant: Healthy Cohort (2)|Healthy participants assigned to basimglurant will receive a 22-day ascending dose regimen. The dosing scheme for Cohort 2 will be selected in accordance with decision criteria on the basis of the incidence of severe AEs in Cohort 1.
89491515|NCT02433093|Experimental|Basimglurant: Healthy Cohort (3)|Healthy participants assigned to basimglurant will receive a 22-day ascending dose regimen. The dosing scheme for Cohort 3 will be selected in accordance with decision criteria on the basis of the incidence of severe AEs in preceding Cohorts 1 and 2.
89491516|NCT02433093|Experimental|Basimglurant: Healthy Cohort (4)|Healthy participants assigned to basimglurant will receive a 22-day ascending dose regimen. The dosing scheme for Cohort 4 will be selected in accordance with decision criteria on the basis of the incidence of severe AEs in preceding Cohorts 1, 2, and 3.
89491517|NCT02433093|Experimental|Basimglurant: MDD Cohort (5)|Participants with MDD assigned to basimglurant will receive a 22-day ascending dose regimen. The dosing scheme for Cohort 5 may differ from those previously evaluated; however, the titration steps and the highest dose tested will remain equal to or lower than the doses tested in Cohorts 1 to 4.
89491518|NCT02433093|Placebo Comparator|Placebo: Healthy Cohorts (1 to 4)|Healthy participants will receive a 22-day regimen of matching placebo capsules.
89491519|NCT02433093|Placebo Comparator|Placebo: MDD Cohort (5)|Participants with MDD will receive a 22-day regimen of matching placebo capsules.
89491520|NCT02434575||PAE|Men with LUTS BPE who have opted for PAE at a participating site, and have consented to take part in the UK ROPE Register Study.
89491521|NCT02434575||TURP|Men with LUTS BPE who have consented to TURP at a participating site, and have consented to the UK ROPE Register Study.
89491522|NCT02434575||Other|Men with LUTS BPE who have had an Open Prostatectomy or laser surgery at a participating site, and have consented to the UK ROPE Study.
89491523|NCT02433171||Melanoma Brain Metastases|Stage 4 cancer patient population with melanoma with brain metastases previously treated with SRS
89491524|NCT02433171||Lung Cancer Brain Metastases|Stage 4 cancer patient population with non-small cell lung cancer with brain metastases previously treated with SRS
89491525|NCT02433015|Active Comparator|Tobacco Cigarette Group|This group will not receive an electronic cigarette and will continue to smoke combustible tobacco cigarettes as previously.
89491526|NCT02433015|Experimental|Electronic Cigarette Group|This group will receive an electronic cigarette to use for the duration of the study.
89491527|NCT04833842|Experimental|Web-based birth preparation program supported by motivational interview|A web-based childbirth preparation program prepared based on the Health Belief Model and supported by motivational interviews will be applied to primigravida women in the initiative group.
89491528|NCT04833842|Experimental|web-based birth preparation program|A web-based birth preparation program based on the Health Belief Model will be applied to primigravida women in the control group.
89491529|NCT02428569|No Intervention|Usual Care|Participants randomized to this arm of the study will receive usual care from their physician.
89537981|NCT04970589|Experimental|Obese/Placebo Capsule|Participants (Obese:BMI 27-35) will be asked to take 400g of mango and a placebo capsule every day for 8 weeks
89491530|NCT02428569|Experimental|PREPARED Decision Support|Participants randomized to this arm of the study will receive the PREPARED educational book and video.
89491531|NCT04833452|Active Comparator|Wide fenstrum Endoscopic DCR|
89491532|NCT04833452|Active Comparator|Narrow Fenstrum Endoscopic DCR|
89491533|NCT02424669|Experimental|recently diagnosed ALS patients|
89491534|NCT02424669|Experimental|not recently diagnosed ALS patients|
89491535|NCT02424669|Active Comparator|patients with peripheral neuropathy, recently diagnosed|
89491536|NCT03040310|Experimental|Back Rx program|Study patients will use their smartphone apps to view their Back Rx program content, exercises, and videos.
89491537|NCT03186807||low risk pregnancy|"Inclusion criteria - Women aged 18-45 years old ,Pregnant women between 14+0 and 34+0 weeks.speaking Hebrew language and eligible for obtaining informed consent.~Gestation who had a singleton fetus in cephalic presentation, with well documented gestational age by first trimester US scan CRL.~Biometric measurement within 10th to 90th percentile.and low risk for fetal brain developmental disorders."
88953882|NCT01966692|Active Comparator|Fluticasone Propionate Formulation 3|"Fluticasone Propionate Drug formulation 3 administered via Plastiape Monodose Dry powder Inhaler , 500mcg single dose.~See Formulation Development in Detailed Description for details regarding differences in formulations"
89491538|NCT02432859|Active Comparator|Electrical stimulation|In the electrical stimulation group, group who received direct current ES at sensory threshold intensity for 1 h/day, 3 days/week, for 4 weeks (12 sessions)
88953883|NCT01966692|Active Comparator|Fluticasone Propionate Formulation 3*|Fluticasone Propionate Drug formulation 3 administered via Plastiape Monodose Dry powder Inhaler , 500mcg single dose. * (The asterisk) A different batch of the formulation 3 is given to the patient to ensure that the study is sufficiently powered to show bioequivalence between two batches of the same formulation.
89491539|NCT02432859|Placebo Comparator|Placebo|In the placebo group, the treatment procedure was the same as that the ES group, but the current intensity was zero
89491540|NCT04833218|Active Comparator|propranolol group|we will give propranolol 40 milligram tablet twice daily in orogastric or nasogastric tube
89491541|NCT04833218|Active Comparator|propranolol clonidine|we will give propranolol 20 milligram tablet twice daily and clonidine 150 microgram tablet twice daily in orogatric or nasogastric tube
89491542|NCT04833218|No Intervention|control group|we will give conventional treatment, no propranolol nor clonidine
89491543|NCT02424747||De Novo Acute Kidney Injury|Patients who developed Acute Kidney Injury during intensive care admission and not previously diagnosed with chronic kidney disease or end stage renal disease.
89491544|NCT02424747||No Acute Kidney Injury.|Intensive care patients not diagnosed with acute kidney Injury during admission and not previously diagnosed with Chronic Kidney Disease or End Stage Renal Disease.
89491545|NCT03182127|Other|one Group|Magnetic resonance imaging and ultrasound will be done for all patient
89491546|NCT04843748|Experimental|single arm|single arm open label study
89491547|NCT04840160|Placebo Comparator|Placebo|Participants supplied with 30 ml of a low fruit (<1%) cordial mixed with maltodextrin and protein diluted in 100 ml water twice daily, once in the morning and evening.
89491548|NCT04840160|Experimental|Cherry juice|Participants supplied with 30 ml of a tart cherry juice concentrate (CherryActive, United Kingdom; (containing 36.8 mg of anthocyanins) diluted in 100 ml of water twice daily, once in the morning and evening.
89491549|NCT04833374|Experimental|1-2-3 Group|Patients in 1-2-3Group will receive 0.5g/d methylprednisolone intravenously for 3 consecutive days in the 1st-2nd-3rd month, then oral prednisone 0.5mg/kg/d on alternate days for 6 months.
89491550|NCT04833374|Active Comparator|1-3-5 Group|Patients in 1-3-5 Group will receive 0.5g/d methylprednisolone intravenously for 3 consecutive days in the 1st-3rd-5th month ,then oral prednisone 0.5mg/kg/d on alternate days for 6 months.
89491551|NCT03036410|Other|bimodal user|wearing one hearing aid and one CI Intervention: Standard Phone, DECT Phone, Easy Call, Duo Phone
88953884|NCT01966705|Experimental|Therapist-guided Internet-based Cognitive Behavior Therapy|Cognitive Behavior Therapy delivered via the Internet: 12 weeks, supported self-help
88953885|NCT01966705|Experimental|Unguided Internet-based Cognitive Behavior Therapy|Cognitive Behavior Therapy delivered via the Internet: 12 weeks, self-help only
88953886|NCT01966705|Experimental|Cognitive Behavior Therapy-based bibliotherapy|Cognitive Behavior Therapy delivered in book form: 12 weeks, self-help only
88953887|NCT01966705|No Intervention|Waiting-list condition|No intervention: 12 weeks
88953888|NCT01966744||Clinicians/Nurses|Clinicians and nurses who treat patients diagnosed with IBD will be recruited to interact with and use the SMART portal to provide feedback on optimization.
89491552|NCT03036410|Other|unilateral hearing aid users|wearing one hearing aid Intervention: Standard Phone, DECT Phone, Easy Call, Duo Phone
89491553|NCT03036410|Other|bilateral hearing aid users|wearing two hearing aids Intervention: Standard Phone, DECT Phone, Easy Call, Duo Phone
89491554|NCT03036410|Other|CI users|wearing CI Intervention: Standard Phone, DECT Phone, Easy Call, Duo Phone
89491555|NCT04843826|Experimental|delayed implant|"Patients 18 years or older.~Periodontally and systemically healthy.~Sufficient bone width and height for implant placement~Adequate mesiodistal width and inter-arch space for placement of a delayed implant.~Full mouth plaque index less than 15% (Bentley and Disney, 1995)~cooperative patients who will comply to follow up visits"
89491556|NCT04840316||Post operative|Nil Intervention - observational cohort study
89491557|NCT04843670||patients operated for pancreas tumors|duodenopancreatectomy for head of the pancreas tumors
89491558|NCT04840082|Experimental|Collecting of Clinical Specimens for COVID-19 Testing|Nasopharyngeal swab is performed on all participants to collect specimens for Rapid antigen COVID-19 Testing
89491559|NCT04833062||Diabetes mellitus group|Based on DM type, all women will be divided into four groups: prepregnancy/preexisting DM insulin-dependent or independent (types I and II; classes B, C, and D) and gestational DM (GDM) with or without the need for insulin therapy (DM classes A1 and A2). In the case of gestational DM, the gestational week at the time of diagnosis will be registered. We will consider whether women are diagnosed with another preexisting disease (endocrinological or another one) before or during pregnancy, in order to check the relationship of this disease and their DM and potential risks for pregnancy.
89491560|NCT04833062||Nondiabetic group|Nondiabetic women who received birth assistance at our referral centers and who agreed to participate in the study were included in the control group. A control of healthy (non-diabetic women) mothers so to compare characteristics and outcomes across diabetic groups will comprise the control group.
89491561|NCT04843592||Type II diabetes|using mobile app
89491562|NCT02707965|Active Comparator|Sequence 1|This is a crossover study with 4 treatment periods consisting of 2 Test periods(generic drug) and 2 Reference periods (brand name drug). Each treatment period lasts about 2 weeks, and patients will be randomized into one of the two sequences. All drugs are administered orally, and dosage will depend on a patient.
89491563|NCT02707965|Active Comparator|Sequence 2|This is a crossover study with 4 treatment periods consisting of 2 Test periods(generic drug) and 2 Reference periods (brand name drug). Each treatment period lasts about 2 weeks, and patients will be randomized into one of the two sequences. All drugs are administered orally, and dosage will depend on a patient.
88953889|NCT01966744||Patients|Patients age 11-18 years diagnosed with IBD will be recruited to interact with and use the SMART portal to provide feedback on optimization.
89491564|NCT04839926|Experimental|0.5mg CY150112|single oral CY150112 while fasting on day 1.
89491565|NCT04839926|Experimental|1.5mg CY150112|single oral CY150112 while fasting on day 1.
89491566|NCT04839926|Experimental|4.5mg CY150112|single oral CY150112 while fasting on day 1.
89491567|NCT04839926|Experimental|10mg CY150112|single oral CY150112 while fasting on day 1.
88953890|NCT01966744||Caregivers|Caregivers of patients diagnosed with IBD will be recruited to interact with and use the SMART portal to provide feedback on optimization.
88953891|NCT01966757||Neuronal ceroid lipofuscinosis patients|Caregiver of patient with NCL to provide information regarding patient's sleep habits
88953892|NCT01966783|Experimental|Budesonide dosage 1|Budesonide 2 mg suppository
88953893|NCT01966783|Experimental|Budesonide dosage 2|Budesonide 4 mg suppository
88953894|NCT01966783|Active Comparator|Mesalazine|Mesalazine 1g suppository
89491568|NCT04839926|Experimental|18mg CY150112|single oral CY150112 while fasting on day 1.
89491569|NCT04839926|Experimental|24mg CY150112|single oral CY150112 while fasting on day 1.
89491570|NCT04839536|Active Comparator|Target controlled infusion (TCI) propofol|For TCI propofol group, all patients will receive nasal CPAP mask and nasal breathing with oxygen of 3 litre/min. We will utilize the Schneider model to target effect-site (Cet) starting from 0.5 mcg/ml and with a gradual 0.5mcg/ml increment every 30s until OAAS score of 3 is achieved. For any patients with OAAS score < 3, Cet will be decreased by a decremental 0.5 mcg/ml. The deepest level of sedation will be recorded.
89491571|NCT04839536|Experimental|Sevoflurane sedation|Patients randomised to this arm will be given time to familiarise with the nasal continuous positive airway pressure (CPAP) mask and nasal breathing with oxygen 3 litre/min via a Bain anaesthetic circuit before the introduction of sevoflurane. Once the patient starts to adapt to nasal CPAP mask, sevoflurane will be delivered, starting with a concentration of 0.2% and increase stepwise by 0.2% every 30s until sedation score of OAAS of 3 is achieved. Anaesthetist in charge will assess and maintain sedation endpoint to OAAS 3. If patient is over sedated, sevoflurane concentration will be reduced by 0.2% until OAAS 3. The deepest level of sedation will be recorded.
89491572|NCT02428257|Experimental|hypobaric|continuous spinal anesthesia with 2,5 mg boluses of hypobaric bupivacaine, prepared diluting each 1 ml of 0.5% isobaric bupivacaine with 1 ml of sterile water.
89491573|NCT02428257|Active Comparator|isobaric|continuous spinal anesthesia with 2,5 mg boluses of 0.5% isboaric bupivacaine
89491574|NCT04839224|Experimental|Carbogen group|
89491575|NCT04839224|Active Comparator|Phenylephrine group|
89491576|NCT03182283|No Intervention|Pre-intervention|All patients at the psychosis wards receive care as usual before staff goes through educational intervention.
89491577|NCT03182283|Other|Post-intervention|After staff attended educational intervention and implemented Person-centered psychosis care in the wards all patients admitted will receive person-centered care.
89491578|NCT03036644|Experimental|e-cigarette nic_O LT|e-cigarette (without nicotine; low temperature)
89491579|NCT03036644|Experimental|e-cigarette Nic_1 LT|e-cigarette (with nicotine; low temperature)
89491580|NCT03036644|Experimental|e-cigarette Nic_0 HT|e-cigarette (without nicotine; high temperature)
89491581|NCT03036644|Experimental|e-cigarette NIC_1 HT|e-cigarette (with nicotine; high temperature)
89491582|NCT03036644|Active Comparator|Tobacco cigarette|Tobacco cigarette
89491583|NCT03036644|Placebo Comparator|Placebo|No E-cigarettes, Nor tobocco cigarettes
89491584|NCT02424825|Experimental|Rouxbe|Subjects will attend a one-month online cooking course, and be followed before, during, and after their participation for quality-of-life, fatigue, and blood biomarker changes.
89491585|NCT03184779|Experimental|Intervention|The intervention group will receive an educational video containing safety messages and an injury prevention component with the intent of reducing behaviours and actions on the hill than can potentially lead to injury.
89491586|NCT03184779|No Intervention|Control|The control group will receive the usual procedures associated with school outings where students have the opportunity to watch the standard welcome video (~8 minutes) with information on how their day will go and how to use and put on safety equipment. The information given in the control procedure emphasizes preparation and how to use and put on equipment rather than safety messages oriented towards preventing injury and collisions. Students in the control group will watch the video prior to participating in the ski area school program.
89491587|NCT03184467|Placebo Comparator|Control group|Normal saline 0.9%
89491588|NCT03184467|Experimental|Study group 1|GV1001 0.56 mg
89491589|NCT03184467|Experimental|Study group 2|GV1001 1.12 mg
89491590|NCT03186495|Experimental|Normal renal function|Subjects with normal renal function
89491591|NCT03186495|Experimental|Mild renal impairment|Subjects with mild renal impairment
89491592|NCT03186495|Experimental|Moderate renal impairment|Subjects with moderate renal impairment
89491593|NCT03186495|Experimental|Severe renal impairment|Subjects with severe renal impairment
89491594|NCT03186495|Experimental|Requiring haemodialysis treatment|Subjects requiring haemodialysis treatment
89491595|NCT02424513|Experimental|[89Zr]Df-IAB2M|A single intravenous infusion of 2.5 mCi of [89Zr]Df-IAB2M in a mass dose of 10 mg.
89491596|NCT02424201|Experimental|study|Intramuscular oxytocin 10 units, 400 micrograms of misoprostol
89491597|NCT02424201|Other|control|Intramuscular oxytocin 10 units, 2 tablets of placebo which will be vitamin c
89491598|NCT03186105|Experimental|Ambulatory appendicectomy|The intervention consist of an ambulatory care by appendicectomy of the acute appendicitis. The normal care is an appendicectomy and an hospitalisation during 2 or 3 days.
89491599|NCT03186183|Experimental|GPS program|"The individual GPS motivational interviewing counseling program has 4-6 sessions.~Week 1: information on sexually transmitted infections and HIV disclosure laws is reviewed. Participants are introduced to the sex diary, stress exercise, and stages of change model.~Week 2: a decisional balance exercise about the participant's current sexual behavior is completed and a behavioral goal is chosen.~Week 3: participants explore their greatest fears and hopes about the goal, and the importance of and their confidence in achieving it.~Week 4: the facilitator and participant identify triggers, automatic thoughts, counters, strategies, supports, and rewards pertaining to the pursuit of the goal and role play the new goal.~1-2 supplemental sessions may be added as needed."
89491600|NCT02428179||Control group without Study intervention|Control group without Study intervention
89491601|NCT02428179||Group with Study intervention|Group with Study intervention
89491602|NCT04440423|Experimental|Clotiazepam Test Product|
89491603|NCT04440423|Active Comparator|Clotiazepam Reference Product|
89491604|NCT02428023||GrThalasaemia|estimation of IMT of the carotides arteries and calcium scoring
89491605|NCT02428023||GrNormal|estimation of IMT of the carotides arteries and calcium scoring
88953895|NCT01966783|Experimental|Combination|Budesonide 2 mg suppository/Mesalazine 1 g suppository
88953896|NCT01966822|Experimental|Dolutegravir 50mg|Dolutegravir 50mg every 24 hours + Kivexa (ABC+3TC)
88953897|NCT01966822|Active Comparator|Protease Inhibitor/ritonavir|Protease Inhibitor/ritonavir + Kivexa (ABC+3TC)
88956550|NCT04908280|Experimental|Discoid lupus erythematosus|Patients with discoid lupus erythematosus will be given ruxolitinib cream to be used twice daily for 12 weeks.
88956551|NCT04905095|Experimental|EWS|Early Warning Score will be implemented in the computer system of the nursing station
88956552|NCT04905095|Active Comparator|Control|Nursing supervision will be carried out in the usual way.
89491606|NCT03117231|Experimental|Active tDCS|Subjects will undergo low-intensity transcranial electrical stimulation for 20 minutes.
89491607|NCT03117231|Sham Comparator|Sham tDCS|Subjects will undergo low-intensity transcranial electrical stimulation for 20 minutes.
89491608|NCT02427945|Experimental|Control|Provision of information on safe water
89491609|NCT02427945|Experimental|Treatment traditional|Provision of information on safe water and child nutrition. The information will be targeted to the mother of the child aged between 6 and 24 months old.
89491610|NCT02427945|Experimental|Treatment couple|Provision of information on safe water and child nutrition. The information will be targeted to the mother of the child aged between 6 and 24 months old, and her husband.
89491611|NCT02427789|No Intervention|Control|In this group patients will not have physical exercises
89491612|NCT02427789|Active Comparator|Physical Exercise|In this group patients will make physical exercise
89491613|NCT02432781|Experimental|Carbohydrate group|Carbohydrate-rich drink 400 mL 3 h before surgery
89491614|NCT02432781|Active Comparator|Control group|10% dextrose solution mixed with insulin 16 unit 100 mL/h
89491615|NCT01667900|Experimental|0.5 mg Dulaglutide (Part A-Healthy)|0.5 milligrams (mg) dulaglutide administered once subcutaneously (SQ) to healthy participants in 1 of 3 treatment periods
89491616|NCT01667900|Experimental|0.75 mg Dulaglutide (Part A-Healthy)|0.75 mg dulaglutide administered once SQ to healthy participants in 1 of 3 treatment periods
89491617|NCT01667900|Experimental|1.5 mg Dulaglutide (Part A-Healthy)|1.5 mg dulaglutide administered once SQ to healthy participants in 1 of 3 treatment periods
89491618|NCT01667900|Placebo Comparator|Placebo (Part A-Healthy)|Placebo administered once SQ to healthy participants in 1 of 3 treatment periods
89491619|NCT01667900|Experimental|0.5 mg Dulaglutide (Part B-T2DM)|0.5 mg dulaglutide administered to participants with Type 2 diabetes mellitus (T2DM) once weekly SQ for 4 weeks
89491620|NCT01667900|Experimental|0.75 mg Dulaglutide (Part B-T2DM)|0.75 mg dulaglutide administered to participants with T2DM once weekly SQ for 4 weeks
89491621|NCT01667900|Experimental|1.5 mg Dulaglutide (Part B-T2DM)|1.5 mg dulaglutide administered to participants with T2DM once weekly SQ for 4 weeks
89491622|NCT01667900|Placebo Comparator|Placebo (Part B-T2DM)|Placebo administered to participants with T2DM once weekly SQ for 4 weeks
89491623|NCT02432937|Placebo Comparator|Corever middle dose|
89491624|NCT02432937|Placebo Comparator|Corever high dose|
89491625|NCT02432937|Placebo Comparator|Placebo|
89491626|NCT03116919|Other|Potato arm|One group will be fed an extra serving of boiled, baked or mashed potatoes daily for 1 week
89491627|NCT03116919|Other|Non-starchy vegetable|Then crossover to an extra serving of a non-starchy vegetable
89491628|NCT03040076|Experimental|Cognitive Bias Treatment|Intervention condition
89491629|NCT03040076|Active Comparator|Relaxation Condition|Active control condition
89491630|NCT03181581|Experimental|High grade gliomas stage 1 ACF|In the first stage 12-15 patients with high-grade gliomas will be included in the trial (acoustic coupling fluid) group.
89491631|NCT03181581|Experimental|Low-high grade gliomas stage 2 ACF|If the interim safety assessments validate that the study can continue, the second stage involves inclusion in the trial (acoustic coupling fluid) group of 22-25 patients with both low-grade and high-grade glioma
89491632|NCT03181581|Active Comparator|High grade gliomas stage 1 control|In the first stage 12-15 patients with high-grade gliomas will be included in the Ringer's acetate (control) group.
89491633|NCT03181581|Active Comparator|Low-high grade gliomas stage 2 control|If the interim safety assessments validate that the study can continue, the second stage involves inclusion in the Ringer's acetate (control) group of 22-25 patients with both low-grade and high-grade glioma
89491634|NCT04843280|Active Comparator|Traditional Physical Therapy|Participants who have undergone primary unilateral knee arthroscopy will undergo 6 weeks of formal outpatient physical therapy
89491635|NCT04843280|Active Comparator|Internet Based Physical Therapy|Participants who have undergone primary unilateral knee arthroscopy will undergo 6 weeks of internet based rehabilitation regime in the home through the online recovery program, FORCE Therapeutics
89491636|NCT03184389|Other|Within-participant micro-randomization|Each minute when participant is available is randomly assigned to either intervention (to practice a stress management exercise) vs. no intervention prompt. When intervention occurs, participant's smartphone vibrates and relaxation app opens, prompting performance of a relaxation exercise.
89491637|NCT04832828||COVID+ Group|Patients diagnosed with Covid19 positive in last 7 days
89491638|NCT03181737|Experimental|Covivio|"Covivio is an internet intervention for people with diabetes mellitus type 2. Content is continuously adapted to patients´ concerns and needs. Techniques to promote the disease self-management (i.e. nutrition, exercise), the motivation for health behavior (i.e. discussing pros and cons) conveying goal setting, mediating knowledge about diabetes (i.e. basics, symptoms & complications, diagnosis, therapy) , and reducing depressive symptoms (i.e. increasing activation, mindfulness exercises) are conveyed in interactive sequences that are accompanied by audio recordings, illustrations, and worksheets.~Patients are also prompted complete brief adherence self-monitoring questionnaires (adherence index) regularly. Optional text messages with motivational content accompany the program daily. The program can be accessed for 56 days after registration."
89491639|NCT03181737|Active Comparator|Relaxio|Relaxio is a psychological online-relaxation-training. The purpose of the program is to improve the self-management of diabetes by relaxation and stress reduction. The program consist of three types of exercises (1) imagination (i.e. sunset, mountain lake), (2) breathing techniques (i.e. balancing, calm breathing), and (3) body exercises (i.e. relaxing body journey, progressive muscle relaxation (PMR)). The exercises are supported by audio files (optionally also for reading). Optional weekly text messages with motivational content accompany the program. The program can be accessed for 56 days after registration.
89491640|NCT03181737|No Intervention|Care-as-Usual (CAU) / wait list|In the CAU/wait list control group, participants are free to continue to engage with any treatment they require (i.e., CAU). However, they will receive access to Covivio six months post-baseline (i.e., wait list with respect to Covivio access).
89491641|NCT04832906|Active Comparator|"Group A Ulipristal Acetate (UA) - Fibristal group (n=35)"|Patients within this group received oral Ulipristal Acetate (Fibristal ©) 5 mg / day starting from the first day of menstrual bleeding, and for 3 months (period of the study).
89491642|NCT04832906|Active Comparator|"Group B Uterine artery embolization (UAE) group (n=35)"|Patients within this group underwent bilateral selective uterine artery embolization, during which polyvinyl alcohol (PVA) particles was administered via a catheter followed by capping with a plug of gelatin sponge. The end point for embolization is to have a static column of contrast in the uterine artery, with only a stump filling when the internal iliac artery was injected. The gelatin sponge cap was thought to both complete the occlusion of the uterine artery and to prevent PVA particles from being drawn out of the uterine artery by the Venturi effect, which would result in non-target embolization.
89491643|NCT03182205|Experimental|Inspiratory muscle exercise (IME)|Participants will be submitted to a linear pressure resistance (PowerBreathe) with an inspiratory load of 40% of maximal inspiratory pressure.
89491644|NCT03182205|Sham Comparator|Sham IME|Participants will be submitted to inspiratory muscle exercise with the same equipment as the intervention group, but without a load generating resistance.
89491645|NCT04843358|Experimental|Emotional Disclosure|Participants in the emotional disclosure arm will be told to write continuously for 20 min about their deepest thoughts and feelings regarding their breast cancer experience
89491646|NCT04843358|Active Comparator|Non-Emotional Writing|Participant allocated to the control group will be asked to describe in detail their daily activities in a non-emotional manner in accord with Pennebaker's published instructions
89491647|NCT03182049||GPA (Wegener's granulomatosis) patients|
89491648|NCT04832672||The upfront radiotherapy group|
89491649|NCT04832672||The upfront targeted-therapy group|
89491650|NCT04839068||First is retrospective part|: by obtaining the data from the patients records in a period between January 1st 2019 to December 31st 2019, and from May 1st 2020 to December (excluding women conceived before April 1st 2020)
88956553|NCT04905069|No Intervention|No-Spacer Control|Subjects will receive radiotherapy without the use of the SpaceOAR Vue.
88956554|NCT04905069|Experimental|SpaceOAR Vue|Subjects will receive radiotherapy following injection of the SpaceOAR Vue hydrogel.
88956555|NCT04903197|Experimental|Arm 1A|VAY736 single agent dose escalation in patients with NHL subtypes of diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL)
88956556|NCT04903197|Experimental|Arm 1B|VAY736 single agent dose expansion in patients with DLBCL
89022061|NCT03274635|Active Comparator|Usual Delayed Compensation, Food|Will receive delayed compensation with food-based gift card, non performance-contingent.
89491651|NCT04839068||Second is prospective part|the same data will be obtained from the patient records in the same way in a period from the January 1st 2021 to the December 31st to assess the pregnancy outcomes in pregnant women who conceived after occurrence of Covid 19 pandemic in Egypt.
89491652|NCT00702273||150 µg Corifollitropin Alfa|Participants from the base study P05787 (NCT00696800), received a single subcutaneous (SC) injection of 150 µg Corifollitropin Alfa (Org 36286) on menstrual cycle Day 2/3 (Day 1); 7 daily SC injections from Days 1 to 7 with placebo-recombinant Follicle Stimulating Hormone (recFSH); followed by daily SC injections with 200 IU recFSH up to the day of human chorionogonadotropin (hCG). Daily SC injections of Ganirelix were given from Day 5 to the day of hCG; at which time a single dose of hCG was given when 3 follicles >= 17 mm. On the day of oocyte pick up (OPU) daily doses of progesterone were started, for up to 6 weeks or menses. Eligible participants from the base study were enrolled in follow up study P05716, where no study treatments were given, and embryos obtained in the base study underwent FTET cycles.
89491653|NCT00702273||200 IU RecFSH|Participants from the base study P05787 (NCT00696800), received a single SC injection of placebo Corifollitropin Alfa on menstrual cycle day 2/3 (Day 1); 7 daily SC injections with 200 IU recFSH from Days 1 to 7; followed by daily SC injections with 200 IU recFSH up to the day of hCG. Multiple daily SC injections of Ganirelix were given from Day 5 to the day of hCG; at which time a single dose of hCG was given when 3 follicles >= 17 mm. On the day of OPU daily doses of progesterone were started and continued for up to 6 weeks or menses. Eligible participants from the base study were enrolled in follow up study P05716, where no study treatments were given, and embryos obtained in the base study underwent FTET cycles.
89491654|NCT04842812|Experimental|TILs/CAR-TILs treatment|Obtain TILs/CAR-TILs from advanced solid tumor patients and infuse them back to evaluate safety and clinical efficacy of the treatment.
89491655|NCT03181659|Experimental|Group 1: patients with NSCLBP who do not seek care|Manual Therapy, Therapeutic Education, Therapeutic Exercice
89491656|NCT03181659|Experimental|Group 2: patients with NSCLBP who do not seek care|Therapeutic Education, Therapeutic Exercice
89491657|NCT03181659|Experimental|Group 3: patients with NSCLBP who seek care|Manual Therapy, Therapeutic Education, Therapeutic Exercice
89491658|NCT03181659|Experimental|Group 4: patients with NSCLBP who seek care|Therapeutic Education, Therapeutic Exercice
89491659|NCT04842656|Experimental|Active release technique alongwith conventional treatment|Patients in Group A will receive active release technique. ART will be applied with patient in prone lying, knee flexed at 90. The therapist will place his elbow tip on taut band of piriformis and direct pressure is applied, patient is then asked to do internal rotation of hip, in order to achieve lengthening of the muscle. This will be repeated 5-7 times(22).
89491660|NCT04842656|Experimental|Post isometric relaxation alongwith conventional treatment|Patients in group B will receive post isometric relaxation technique. Patient lying in supine position, with the treated leg is placed into flexion at the hip and knee, so that the foot rests on the table lateral to the contra lateral knee (the leg on the side to be treated is crossed over the other). Therapist places one hand on the contra lateral ASIS to prevent pelvic motion, while the other hand is placed against the lateral flexed knee as this is pushed into resisted abduction to contract piriformis (PIR MET). The starting position will be the 1st sign of resistance towards end range. Therapist Force will be same as patient's force. Initial effort is approximately 20% of patient's strength. Duration of contraction is 7-10 seconds with three repetitions(32)
89491661|NCT02433795|Experimental|Bendamustine plus rituximab(BR)|Intravenous bendamustine plus rituximab intravenously at 1st cycle and subcutaneously from 2nd cycle (to maximum 8th cycle).
89491662|NCT03038516|Active Comparator|Vitamin D|Cholecalciferol (Detremin) solved in MIGLYOL® 812
89491663|NCT03038516|Placebo Comparator|Placebo|MIGLYOL® 812
89491664|NCT02424279|Active Comparator|Surgical treatment|Patients from the first group will undergo thoracoscopic splanchnicectomy. The surgery will be performed in general anaesthesia, with tracheal intubation in prone position. The greater splanchnic nerve will be identified at its origin in sympathetic trunk, dissected together with all collaterals all the way down to the diaphragm and excised. Additional splanchnic nerves (smaller, minimus) will be incised or excised if connected to the greater splanchnic nerve. Single sutures will be applied to the skin. Then the procedure will be repeated on the contralateral side.
89491665|NCT02424279|No Intervention|Conservative Treatment|Patients from the second group will be offered best available conservative pain treatment. The list of medication on stage 1 will include: paracetamol, ibuprofen, diclofenac. On stage 2: stage 1 + codeine and tramadol. On stage 3: stage 2 + morphine, fentanyl, oxycodone, pethidine. Oral and transcutaneous routes will be preferred to intravenous, intramuscular and subcutaneous. A need for elevation to the next step of analgesic ladder will be considered when the pain will be stronger than 6 points in Numeric Rating Scale (NRS) and will be present for more than 5 days.
89491666|NCT02432469|Experimental|Intervention group|APP specific for this study, with reminder, education materials and feedback mechanism for improving secondary medications
89491667|NCT02432469|No Intervention|Control group|Usual Care
89491668|NCT04832126||Patient|patients with channelopathies
89491669|NCT04832126||Family|relatives of patients with channelopathies
89491670|NCT02424435|Experimental|Methylprednisolone|This is an open-label study of methylprednisolone in patients with FRDA. Subjects will begin oral administration of 48 mg methylprednisolone at day 1 and will decrease their administered dose by 8 mg per day. After 6 days, subjects will spend 22 days off medication before repeating the same treatment cycle. Last dosing cycle of methylprednisolone will be administered at 24 weeks after baseline. Visits will occur at weeks 2, 6, 14, 26, and 30 following baseline.
89491671|NCT04832048|Experimental|High intensity training (HIT) group|The HIT group performed the exercises with loads at 80-90% of HRF.
89022062|NCT03274635|Experimental|Individual Immediate Contingent Reward, Money|Will receive daily performance-contingent monetary compensation with Amazon gift card.
89204552|NCT01061983|Experimental|Deep Brain Stimulation|Participants will receive deep brain stimulation.
89204553|NCT00808626|Experimental|99mTc-rBitistatin|
89204554|NCT04017078||Patients who referred for periodontal therapy|Patients who referred to Baskent University, Faculty of Dentistry, Department of Periodontology, during 2016-2018
89204555|NCT00817518|Experimental|1|
89204556|NCT00817518|Experimental|2|
89204557|NCT00320515|Experimental|A|
89204558|NCT01066273|Experimental|P-Stim device|Receiving the device that is activated
89204559|NCT00808782|Sham Comparator|Sham rTMS|Sham 5Hz rTMS.
89204560|NCT00808782|Experimental|rTMS|Active 5Hz deep TMS.
89204561|NCT02550834|Experimental|Experimental : Curling group|
89204562|NCT02550834|No Intervention|Control : Usual care group|
89204563|NCT00662012|Experimental|Sodium Stibogluconate (SSG) 20 mg/kg|All consented subjects who meet all inclusion and no exclusion criteria will enter this open label protocol and be treated with 20 mg/kg once daily intravenously with SSG.
89204564|NCT00808860|Placebo Comparator|Placebo group|Gliclazide + Placebo tea
89204565|NCT00808860|Active Comparator|GP group|Gliclazide + Gynostemma pentaphyllum tea
89204566|NCT00817674||1|CKD subjects
89204567|NCT00817674||2|Healthy Controls
89204568|NCT04045002|Experimental|Intervention|Intervention group receive 'MyPinkMom' educational intervention delivered through WhatsApp application for 2 weeks and routine antenatal care.
89204569|NCT04045002|No Intervention|Control|Control group receive information on anaemia in pregnancy placed at respondents' antenatal card and routine antenatal care
89491672|NCT04832048|Experimental|Low-moderate intensity training (LMIT) group|The HIT group performed the exercises with the loads at 50-70% of the HRF
89204570|NCT00815568|Experimental|Regimen|Conditioning regimen for AML with FLT3 mutation, AML/MDS unfavorable cytogenetic risk group, chemorefractory NHL or HD, or ALL/CML
89204571|NCT00815646|Experimental|Sildenafil|Measurements of pulmonary and systemic pressures during cold water immersion before and after sildenafil 50 mg orally.
89204572|NCT01066351|Experimental|Erythropoietin|The patients were assigned to receive beta erythropoietin (Recormon) dose 200 unit/kg at 3 day before cardiac surgery and 100 unit/kg in the morning before cardiac surgery.
89204573|NCT01066351|Placebo Comparator|placebo|The patients were assigned to receive normal saline same volume at 3 day before cardiac surgery and in the morning before cardiac surgery.
89204574|NCT03869580||Stent infection|Patients diagnosed with urinary tract infection associated with double J stent
89204575|NCT03869580||No stent infection|Patients with double J stent without infection during the study period
89204576|NCT00817752|Experimental|1|Receives Ashwagandha herb.
89204577|NCT03980353||Children before entrance in primary school|Children with type 1 diabetes, who are too young to go to primary school at the start of the school year 2018-2019, followed in the Diabetology Department of Lyon Pediatric Hospital.
89204578|NCT00808938|Experimental|Active Treatment|
89204579|NCT02532361||Cohort 1 / Hysteroscopic device placement|Patients that had undergone sterilization through hysteroscopic device placement
89204580|NCT02532361||Cohort 2 / Tubal ligation|Patients that had undergone sterilization through tubal ligation
89204581|NCT03980431|Experimental|FBY in suspected malignant brain tumor|This arm investigates the metabolic characteristics of FBY in suspected malignant brain tumor patients who consider for surgical operations. A single dose of 0.10 mCi/kg FBY will be intravenously injected and PET examination will carry out 30 minutes later. Surgical operations, if recommended after multiple examination, will be carried out within 1 week after FBY PET scan.
89204582|NCT03980431|Experimental|FBY in suspected recurrent glioma|This arm investigates the value of FBY to differentiate tumor progression from pseudoprogression. A single dose of 0.10 mCi/kg FBY will be intravenously injected and PET examination will carry out 30 minutes later. Surgical operation, MRI follow up or change of treatment strategy, according to specific conditions, will be recommended for the definitive diagnosis as well as the management of patients.
89204583|NCT00817830|Experimental|lodenafil carbonate|Evaluate cardiovascular safety of lodenafil carbonate in patients with coronary artery disease undergoing physical effort, before and after using lodenafil carbonate.
89204584|NCT00815724|Experimental|1|Participants will take part in a distance learning group.
89204585|NCT00815724|No Intervention|2|Participants in the control group will not receive any study materials or take part in any study activities.
89204586|NCT00817908||1|Patients at high risk for CMV infection (CMV serostatus: D+/R-) who are expected to receive three months of antiviral prophylaxis.
89204587|NCT02552862|Active Comparator|Vivomixx®|"Vivomixx® is a probiotic mixture of 8 proprietary strains. Thirty consecutive patients with cirrhosis and SBP will be randomized to receive Vivomixx® , sachets containing 450 x 109 bacteria, 2 every 12 hours during all the hospitalization until a maximum of 30 days (n=15), or placebo (n=15).~All patients will receive endovenous antibiotics and also intravenous albumin 1.5 g/kg weight the first day and 1 g/kg weight the third day of treatment. The management of patients will follow current guidelines."
89204588|NCT02552862|Placebo Comparator|Placebo|Placebo will be formulated as identical in appearance and administered according to the same schedule as the active agent. Placebo contains maltose and silicon dioxide as inactive agent.
89204589|NCT00661778|Experimental|Bevacizumab + cisplatin + docetaxel|Participants received bevacizumab 15 mg/kg intravenously (IV) followed by docetaxel 75 mg/kg IV in combination with cisplatin 75 mg/m^2 IV on Day 1 of each 3-week cycle for a maximum of 6 cycles. After completing the 6 cycles of combined chemotherapy, participants received bevacizumab 15 mg/kg IV until disease progression, unacceptable toxicity, or withdrawal of consent.
89204590|NCT00789932|Experimental|CBT|
89204591|NCT00789932|Active Comparator|Usual Care|
89204592|NCT04047212||Smokers|
89204593|NCT04047212||non-Smokers|
89204594|NCT00319735|Experimental|Investigational Treatment|"Cetuximab 400 mg/m2 IV over 120 minutes Day -14 (Loading Dose)~Cetuximab 250 mg/m2 IV over 60 minutes Day -7~Cetuximab 250 mg/m2 IV over 60 minutes Days 1, 8, 15, 22, 29 and 36~Combined with radiation therapy for six weeks.~Surgery for esophageal resection after 6 to 8 week rest period.~Subjects who consent will provide tissue samples."
89204595|NCT02556242|Experimental|Targeted indoor residual spraying|The intervention arm of the trial will receive Indoor Residual Spraying delivery through targeted spraying in the neighbourhood of recent local cases only.
89204596|NCT02556242|Active Comparator|Generalised Indoor residual spraying|The reference (control) arm of the trial will receive Indoor Residual Spraying through generalised annual spraying of all structures, as is the current standard practice.
89204597|NCT01062139|Experimental|Petasites extract, levocetirizine|Cosalin (Petasites hybridus CO2 extract), Xarlin (levocetirizine) combination therapy group
89204598|NCT01062139|Active Comparator|Cosalin (Petasites hybridus CO2 extract)|Cosalin monotherapy
89204599|NCT00780650|Experimental|1|
89491673|NCT04832048|Placebo Comparator|No training group|They did not perform any type of programmed physical exercise during the study.
89491674|NCT02427711|Active Comparator|Bipolar sealer|Prospective use of bipolar sealer for skin and knee capsule incision revisions of non-septic knee arthroplasty.
89491675|NCT02427711|Placebo Comparator|Scalpel|Conventional surgical incision with scalpel - data extracted from a retrospective group.
89491676|NCT04842968|Experimental|Methylene blue|Methylene blue solution (50 mg in 30 ml of saline solution) was injected in the cannulated main supplying artery of the freshly removed specimen, ex vivo. Colorectal specimen was then processed in the routine pathological work-up way.
89491677|NCT04842968|No Intervention|Control|Colorectal specimens were processed in the routine pathological work-up way.
89491678|NCT02423967|Active Comparator|Transplant uses fresh familial stool|Undergoes Fecal Microbial Transplant using fresh stool from a screened family member Followed up and assessed for eradication of Clostridium difficile Quality of life assessed Stool assessed for inflammation and microbiome
89491679|NCT02423967|Experimental|Transplant uses frozen anonymous stool|Undergoes Fecal Microbial Transplant using stool collected from screened anonymous donor that has been frozen until time of Fecal Microbial Transplant Followed up and assessed for eradication of Clostridium difficile Quality of life assessed Stool assessed for inflammation and microbiome
89491680|NCT04832204|Experimental|solid tumor with only liver metastases after first line treatment|Apatinib 250mg, Qd, oral administration,SHR-1210 200mg, q3w one week later, intravenous administration, continuous administration until the disease progresses or an intolerable adverse reaction occurs.
89491681|NCT02427633|No Intervention|Control|Randomized to standard care (control group) - observations only
89491682|NCT02427633|Experimental|UKRC 1997|Randomized to modified UKRC 1997 - Intervention and Observations
89491683|NCT02427633|Experimental|UKRC 2010|Randomized to modified UKRC 2010 - Intervention and Observations
89491684|NCT04842578|Experimental|group of thin cross- section of CT|Anatomic Segmentectomy with the Guidance of Thin Cross- Section of CT
89491685|NCT04842578|Active Comparator|group of thin 3D simulation|Anatomic Segmentectomy with the Guidance of 3D simulation
89491686|NCT02427555|Experimental|Barley kernel bread|
89491687|NCT02427555|Sham Comparator|Whit wheat flour bread|
89491688|NCT03038282|Experimental|Chromium Chloride|Participants transdermal chromium chloride 50 to 600 mcg/day.
89491689|NCT03038282|Experimental|Individual Exercise|Exercise 150 minutes per week (over 3 to 5 days) for 12 weeks.
89491690|NCT03038282|No Intervention|Control Group|Participants or participant's caregiver will be provided educational materials on starting an exercise program and instructions for the application of transdermal chromium chloride, but will receive no formal support for their exercise program.
89491691|NCT02424045|Other|BCD chemotherapy|"All patients are scheduled to receive 2 cycles of three-weekly Bendamustine, carboplatin and dexamethasone combination chemotherapy(BCD Chemotherapy).~D1,D2 Bendamustine 80mg/m2 IV over 30-60min D1 Carboplatin AUC 5.0 IV D1-4 Dexamethasone 40mg #2 PO or IV"
89491692|NCT03039998||HAP Patients|HAP, intubated and mechanically ventilated.
89491693|NCT02427321||Cystoscopy cohort|"Video recording of flexible cystoscopic examination. All participants enrolled on the study will have video from their flexible cystoscopic examination recorded.~Diagnosis and pathology information will be collected from the participants medical notes for a period of eight weeks following the recorded cystoscopy."
89491694|NCT03038204||PMA+MVA+CABG|patients with ischemic cardiomyopathy and mitral regurgitation who underwent coronary artery bypass grafting, mitral annuloplasty, and papillary muscles approximation.
89491695|NCT03038204||MVA+CABG|patients with ischemic cardiomyopathy who underwent coronary artery bypass grafting and mitral valve annuloplasty.
88956557|NCT04903197|Experimental|Arm 2A|VAY736 + lenalidomide dose escalation in patients with DLBCL, follicular lymphoma (FL), mantle cell lymphoma (MCL) and marginal zone lymphoma (MZL). Enrollment has been halted in this arm.
88956558|NCT04903197|Experimental|Arm 2B|VAY736 + lenalidomide dose expansion in patients with DLBCL. This arm will not be conducted.
89204600|NCT00780650|Placebo Comparator|2|
89204601|NCT00653328|Experimental|Therapeutic Intervention|
89204602|NCT01664182|Experimental|Arm I (trebananib monotherapy)|Patients receive trebananib IV over 30-60 minutes on days 1, 8, 15, 22, 29, and 36. Cycles repeat every 42 days in the absence of disease progression or unacceptable toxicity.
89204603|NCT01664182|Experimental|Arm II (trebananib and anti-VEGF therapy)|Patients receive trebananib as in Arm I and either bevacizumab IV over 30-90 minutes on days 1, 15, and 29, pazopanib hydrochloride PO QD on days 1-42, sorafenib tosylate PO BID on days 1-42, or sunitinib malate PO QD on days 1-28. Cycles repeat every 42 days in the absence of disease progression or unacceptable toxicity.
89204604|NCT00780728|Active Comparator|Sildenafil|
89204605|NCT00809172|Active Comparator|1|Ciclosporin
89204606|NCT00809172|Experimental|2|Methotrexate
89491696|NCT02432391|No Intervention|Routine Care|Participants continue their routine medical care for type 2 diabetes
89491697|NCT02432391|Experimental|GEM|Participants receive the GEM (Glycemic load, Exercise, and Monitoring blood glucose) lifestyle modification program and continue their routine medical care for type 2 diabetes.
89491698|NCT04842344|Experimental|Noninvasive ventilation and ECCO2R|
89491699|NCT04842344|No Intervention|Noninvasive ventilation|
89491700|NCT02432313|Experimental|Modified Release Formulation x (MRx)|Various formulations of Modified Release anatabine citrate tablets
89491701|NCT04831814|Experimental|Near Focus NBI|Use of the Near Focus NBI to make optical diagnosis
89204607|NCT02552940||Rheumatoid Arthritis participants treated with Tocilizumab SC|Participants with RA receive TCZ SC, as per routine clinical practice and are followed for approximately 6 months.
89204608|NCT00780806|Experimental|1|Immunization with one dose of MnB rLP2086 vaccine at 0, 1 and 6 months
89204609|NCT02551380|Experimental|Treated|treatment with Folinoral (folinic acid) 5mg twice a day (10 mg per day) during 12 weeks
89491702|NCT04831814|Active Comparator|Standard Focus NBI|Use of the Standard Focus NBI to make optical diagnosis
89491703|NCT02432157|Experimental|Hypertonic saline (HTS)|A protocol of prophylactic 3% HTS as a volume expander with bolus (over 30 minutes) of 3% HTS at a dose of 250 ml every 6 hours for 7 days. This will be given through a central line as soon as possible and within 72 hours of onset of SAH symptoms.
89491704|NCT02432157|Active Comparator|Standard fluid|Routine fluid management strategy as pre-specified by our SAH management protocol at Jefferson University Hospital according to the American Heart Association and Neurocritical Care Guidelines for the management of SAH (this includes conventional intravenous fluids or normal saline solutions to maintain a normal hydration status and guided by the treating doctor and daily assessments of fluid balance).
89491705|NCT04842188|Active Comparator|L-PRF|Leukocyte platelet rich fibrin as a sole graft material in class II furcation
89491706|NCT04842188|Active Comparator|L-PRF with aPDT|Leukocyte platelet rich fibrin combined with antibacterial photodynamic therapy in class II furcation
89491707|NCT03183999|Experimental|GINST group|Experimental group was randomly assigned among the volunteers who met the inclusion criteria: men between the ages of 18 and 60 who had sperm motility of less than 32%. Fermented ginseng (GINST) was supplied.
89491708|NCT03183999|Placebo Comparator|Control group|Control group was randomly assigned among the volunteers who met the inclusion criteria: men between the ages of 18 and 60 who had sperm motility of less than 32%. Placebo was supplied.
89491709|NCT03037970|Experimental|ABSOLVE|Type I collagen sheet soaked in a solution containing rhPDGF-BB.
89204610|NCT02551380|Placebo Comparator|control|treatment with one capsule of placebo twice a day during 12 weeks
89204611|NCT00784862|Active Comparator|1|Arimidex 1mg + Nolvadex placebo
89204612|NCT00784862|Active Comparator|2|Arimidex placebo + Nolvadex 20mg
89491710|NCT03037970|Placebo Comparator|Placebo|Collagen sheet soaked with saline solution.
89491711|NCT04842110|Experimental|1064 Full Abdomen|eonTM FR 1064 nm device Patient will be treated with the eonTM FR 1064 nm device
89491712|NCT02423889|Experimental|1|Stereotactic radiotherapy with a total dose of 36.25 Gy in 5 fractions (7.25 Gy per fraction, 2 fractions per week) in low risk prostate cancer patients is delivered to evaluate acute and subacute toxicty
89491713|NCT02427087|Active Comparator|Continuous Aerobic training|Aerobic training continuous (n=19 patients) carry a protocol continuous aerobic training twice a week for 24 weeks and the session will last 60 minutes/2 days/week with recommendation for healthy diet.
89491714|NCT02427087|Active Comparator|Healthy diet|Diet group (n=21 patients) only recommendation for healthy diet.
89491715|NCT04841720|Experimental|HSK16149|HSK16149（D1-D5）
89491716|NCT04841720|Experimental|Metformin|Metformin
89491717|NCT04841720|Experimental|HSK16149+Metformin|HSK16149+Metformin
89491718|NCT03181425||Imaging assessment|All subject of the study have a knee osteoarthritis (OA) and are going to have a knee prosthetic surgery with cartilage excision. Imaging measurements are conducted on human cartilage samples (2 samples per patient are selected : healthy and severely degraded).
89491719|NCT04831346|Experimental|low level laser|"A low-level gallium arsenide diode (Biolase, USA) at a 940 nm wavelength with 0.2 W output power and 2 J energy. The device was calibrated, and the probe was disinfected prior to every treatment.~The Masseter and Temporalis muscles will be bilaterally assessed with constant pressure to define tenderness.~LLLT applied perpendicular to each tender point of the intended muscles for 10 seconds with an energy density of 2.5 J/cm2.~Sessions are scheduled 3 days a week (every other day)"
89022063|NCT03274635|Experimental|Individual Immediate Contingent Reward, Food|Will receive daily performance-contingent food-based gift card.
89204613|NCT00784862|Active Comparator|3|Arimidex 1mg + Nolvadex 20mg
89204614|NCT02556476||ICU patients|The actual cohort of 148 critically ill medical patients that received the treatment in the intensive care unit (ICU). The interventions include interventions that are usually performed within the ICU such as mechanical ventilation, non-invasive ventilation, neuromuscular blockade, renal replacement therapy.
89491720|NCT04831346|Experimental|Occlusive splint therapy|"A soft occlusal splint (vacuum-formed ) made from a 2-mm-thick elastic rubber sheets will be used.~Splints were individually designed ( in the out patient clinic of the college of dentistry) for the upper arch of each patient. An alginate imprint of the maxillary arch will be taken to fabricate a master cast of the maxilla.~A vacuum pressure device was utilized for molding the rubber sheets (13 x 13 cm /2-mm thickness).~Sheets were removed after it has been appropriately adjusted to the mold in the vacuum former. Edges will be properly trimmed, and the palate part is detached to obtain the end shape.~Participants are instructed to wear the splint at all times except during mealtimes and oral hygiene."
89491721|NCT04831346|No Intervention|Control|This group will be a wait list group recieving no intervention except for the regular analgesic prescribed by the reffering dentist
89491722|NCT03181347|Experimental|Roux-en-Y Gastric Bypass (RYGB)|Severely obese patients scheduled for Roux-en-Y Gastric Bypass surgery
89491723|NCT03181347|Experimental|Sleeve Gastrectomy (SG)|Severely obese patients scheduled for Sleeve Gastrectomy surgery
89491724|NCT03181347|Active Comparator|Non-surgical|Severely obese controls with dietary and activity modifications and excludes meal replacement or pharmacologic interventions
89491725|NCT03036020|Experimental|Contraindication anesthesiologists|Ability of anesthesiologists to detect contraindications to thrombolysis in acute stroke patients prehospital by interpretation of prehospital cerebral CT scans
89491726|NCT03181269|Experimental|Intervention education|Participants will receive the intervention education and data recording package.
89491727|NCT03181269|Placebo Comparator|Placebo education|Participants will receive the placebo educational and data recording package.
89491728|NCT03039842|Experimental|30 mg DM|30mg dextromethorphan+valproate
89491729|NCT03039842|Experimental|5 mg MM|5mg memantine+valproate
89491730|NCT03039842|Experimental|DM+MM|dextromethorphan+memantine+ valproate
89491731|NCT03039842|Placebo Comparator|placebo|Placebo+valproate
89491732|NCT03181815|Experimental|treatment arm|The patients in this arm will receive C-CAG regimen for salvage treatment,detailed as following: Cladribine 5mg/㎡，d1-5；G-CSF 300ug,d0-9; aclarubicin 10mg,d3-6;cytarabine 10mg/㎡ q12h, SC, d3-9;4 weeks a cycle
89491733|NCT04369040|Other|High-flow nasal oxygen therapy|Ventilation with High-flow nasal oxygen therapy
88953898|NCT01966835|Experimental|High intensity aerobic interval training|The intervention consists of a total of 18 moderate-to-high intensity aerobic interval training sessions (20-30 minutes/session) spread over a maximum of eight weeks (2-3 times/week) as shown in Table 1. The training sessions are performed on bicycle ergometers (Kettler) and supervised by physiotherapists. Each session is built up by brief periods of high-intensity aerobic exercise (70-80 %) separated by recovery periods of lower-intensity (40-50%). Each session is introduced by a 5-minute warm-up and ends with a 5-minute cool-down (equivalent to 40-50% watt max). The absolute exercise intensity/workload (watt) is determined individually for each participant based on the watt max test performed at baseline.
89491734|NCT04369040|Experimental|Flow Controlled Ventilation|Ventilation with laryngeal tri-tube with Flow Controlled Ventilation technique
89491735|NCT05115669|Experimental|Wortie freeze plus|"Cryogenic medical device (dimethylether-based product) + conductive gel + protective foam plasters.~Up to 3 applications one every 14 days"
89491736|NCT03038048|Experimental|33 g needle - right eye|33 g needle for intravitreal injection of Lucentis or Eylea for right eye and 30 g needle for left eye
89491737|NCT03038048|Experimental|33 g needle - left eye|33 g needle for intravitreal injection of Lucentis or Eylea for left eye and 30 g needle for right eye
89491738|NCT03185871|Experimental|Celecoxib|"The participants will be scheduled for the two quantitative breast MRI exams. Following the first MRI exam, participants will start taking celecoxib 200mg twice a day with food. Subjects will take a minimum of 26 doses and no more than 32 doses of celecoxib during the study.~Participants will intake 200mg of celecoxib two times a day (400mg/day total) for 2 weeks after biopsy. Histologic tissue samples will be obtained for evaluation at time of biopsy of the tumor and at time of surgery removal of the tumor."
89491739|NCT04831268|Experimental|Glucose as reference food|"Twelve healthy, normal weight subjects (male: 7, female:~7) after 10-14 hr fast, consumed 25g available carbohydrate from D-glucose, three times, in different weeks as reference food along with 250ml water; and 25g available carbohydrates from lentils and lupins, trahanas with tomato sauce and halva with currants, tested once, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first bite of food or drink."
89491740|NCT04831268|Experimental|Lentils and lupins mixed meal|"Twelve healthy, normal weight subjects (male: 7, female:~7) after 10-14 hr fast, consumed 25g available carbohydrate from D-glucose, three times, in different weeks as reference food along with 250ml water; and 25g available carbohydrates from lentils and lupins, trahanas with tomato sauce and halva with currants, tested once, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first bite of food or drink."
89491741|NCT04831268|Experimental|Trahanas with tomato sauce mixed meal|"Twelve healthy, normal weight subjects (male: 7, female:~7) after 10-14 hr fast, consumed 25g available carbohydrate from D-glucose, three times, in different weeks as reference food along with 250ml water; and 25g available carbohydrates from lentils and lupins, trahanas with tomato sauce and halva with currants, tested once, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first bite of food or drink."
89491742|NCT04831268|Experimental|Halva with currants mixed meal|"Twelve healthy, normal weight subjects (male: 7, female:~7) after 10-14 hr fast, consumed 25g available carbohydrate from D-glucose, three times, in different weeks as reference food along with 250ml water; and 25g available carbohydrates from lentils and lupins, trahanas with tomato sauce and halva with currants, tested once, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first bite of food or drink."
89491743|NCT03181191|Active Comparator|Totally pancreatectomised patients|Oral glucose tolerance test and biopsies
89491744|NCT03181191|Active Comparator|Type 2 diabetes patients|Oral glucose tolerance test and biopsies
89491745|NCT03181191|Active Comparator|Healthy control subjects|Oral glucose tolerance test and biopsies
89491746|NCT03181113||peginterferon alfa 2b|
89491747|NCT03181113||peginterferon alfa 2a|
89491748|NCT03036176|Other|SAM intervention group|Children in the intervention group received routine medical treatment and nutritional rehabilitation services in hospital; their primary caregivers were given basic orientations on child care, feeding and nutrition. Children attended play-based stimulation sessions in which trained nurses demonstrated caregivers on how to stimulate the SAM child using play materials and facilities at playroom and playground of the hospital. After discharge from hospital, they were followed up at home and visited three times over a period of six months. During the visits, new play materials were provided and caregivers were shown how to use them to stimulate the SAM child.
89491749|NCT03036176|Other|SAM control Group|The control children received routine medical treatment and nutritional rehabilitation services in hospital. Though they had access to playground facilities neither the control children nor their caregivers had access to the playroom materials and the basic orientation on child care, feeding and stimulation.
89491750|NCT03183921||Cases|All ICU patients with nosocomial lower respiratory tract infection
89491751|NCT02605928|Experimental|BIP Needle|Injeq Bioimpedance Probe (BIP) Needle is an injection needle that has bioimpedance measurement capability. It measures bioimpedance and detects synovial fluid during inta-articular injection.
89491752|NCT03180957|Experimental|Anti-TNF|adalimumab
89491753|NCT03180957|Placebo Comparator|Placebo|saline
89491754|NCT04830644|Experimental|Iguratimod 1|orally 25mg twice a day
89491755|NCT04830644|Experimental|Iguratimod 2|orally 20mg twice a day
89491756|NCT04830644|Experimental|Iguratimod 3|orally 10mg twice a day
89491757|NCT04830644|Placebo Comparator|Placebo|orally twice a day
89491758|NCT02432001||Image-Guided Biopsies|Image-guided biopsies will be performed at the Dream Team Site enrolling the patient. Lesions will be chosen based upon the strength of the evidence suggesting the presence of metastasis and with the goal of minimizing patient risk. Soft tissue lesions and lesions with documented radiologic progression should be prioritized for biopsy. If the Radiologist in charge of the procedure cannot identify a lesion amenable for biopsy, the patient will be considered a screening failure.
89491759|NCT02427165|Placebo Comparator|Placebo|Single dose of nebulised placebo solution
89491760|NCT02427165|Experimental|RPL554 Dose 1|0.4 mg single dose nebulised RPL554
89491761|NCT02427165|Experimental|RPL554 Dose 2|1.5 mg single dose nebulised RPL554
89491762|NCT02427165|Experimental|RPL554 Dose 3|6 mg single dose nebulised RPL554
89491763|NCT02427165|Experimental|RPL554 Dose 4|24 mg single dose nebulised RPL554
89491764|NCT02427165|Active Comparator|Salbutamol Dose 1|2.5 mg single dose nebulised salbutamol
89491765|NCT02427165|Active Comparator|Salbutamol Dose 2|7.5 mg single dose nebulised salbutamol
89491766|NCT04830722|Active Comparator|Sculptra Aesthetic Side|the treatment area side (an area side is considered either buttock and/or thigh) (left or right-depends on randomization) will receive up to two vials of Sculptra Aesthetic, for a total of 4 vials in one treatment session if 2 areas qualify.
89491767|NCT04830722|Placebo Comparator|Placebo side|the treatment area side (an area side is considered either buttock and/or thigh) (left or right-depends on randomization) will receive 16 cc of bacteriostatic water, for up to 64 ccs of bacteriostatic water to match the volume injected on the active side
89491768|NCT04838366|Experimental|Intervention|The study group will be intervened with carbohydrate loading as the protocol made by ERAS(Li et al., 2021). We will provide glucose-D.
89491769|NCT04838366|No Intervention|Usual care|The control group will be kept in fasting condition from midnight as a traditional practice in existence.
89491770|NCT03039764|No Intervention|Standard occupational therapy|This group will receiving standard occupational therapy for the treatment of acute stroke.
89491771|NCT03039764|Experimental|SOT plus VR Rapael|This group will receive virtual reality-based rehabilitation intervention wearing Rapael glove made by Neofect supplemented with standard occupational services per conventional protocols.
89491772|NCT02706717|Active Comparator|Visbiome Extra Strength|
89491773|NCT02706717|Placebo Comparator|Placebo for Visbiome Extra Strength|
89491774|NCT03037736|Placebo Comparator|Placebo|Patients will receive 0.1mL of normal saline injected subconjunctival in the area of the excised pterygium and 1 and 2 months postoperative.
89491775|NCT03037736|Active Comparator|5-Fluorouracil|Patients will receive 0.1mL of 5-Fluorouracil, 5mg/0.1mL, injected subconjunctival in the area of the excised pterygium and 1 and 2 months postoperative.
89491776|NCT03037736|Active Comparator|Bevacizumab|Patients will receive 0.1mL of bevacizumab, 2.5mg/0.1mL, injected subconjunctival in the area of the excised pterygium and 1 and 2 months postoperative.
89491777|NCT04838132|Experimental|Transversus thoracis muscle plane and rectus sheath block with ropivacaine|Using the plane technique to place a 22-gauge, 80-mm needle obliquely upwards until the needle tip is located at the plane between the internal intercostal muscles and the transverse pectoralis muscle (TTP block) and rectus sheath block, give 15ml and 10ml 0.3% ropivacaine respectively.
89491778|NCT04838132|Experimental|Transversus thoracis muscle plane and rectus sheath puncture with saline|Using the plane technique to place a 22-gauge, 80-mm needle obliquely upwards until the needle tip is located at the plane between the internal intercostal muscles and the transverse pectoralis muscle (TTP block) and rectus sheath block, give 15ml and 10ml 0.9% saline respectively.
89491779|NCT03037892|Active Comparator|Midazolam and Fentanyl|Midazolam and Fentanyl Two minutes before the colonoscopy procedure, a bolus of midazolam 0.03mg/Kg and 1.5microgram/Kg fentanyl will be given intravenously over 60 sec in group 1. 0.5 mg of midazolam intravenously can be given every two minutes till the patient is sufficiently sedated (sleeping but arousable on calling). The colonoscopy can start at this end point. Increments of 0.5mcg/Kg of fentanyl will be given if patient complains of pain, which can be repeated every 5 minutes if there is persistent pain
89491780|NCT03037892|Experimental|Midazolam and Remifentanil|Midazolam and Remifentanil Target controlled infusion of Remifentanil to 3.0 ng/ml will be started 2 minutes before procedure. The patient will then be given same doses of midazolam in 0.5 mg increments till sedated sufficiently (sleeping but arousable on verbal command). During Colonoscopy the dose of Remifentanil could be increased by 0.5ng/ml if patient complained of pain upto 4.0ng/ml.
89491781|NCT03037892|Experimental|Remifentanil|Remifentanil Group Patients will receive only Remifentanil in the same doses as given in group 2. During the procedure if the pain is excessive and persistent in spite of increasing the respective doses as prescribed in each group, or causing loss of cooperation of patient and interfering in the performance of procedure, the patients will be given sleep dose of Inj Propofol and further anaesthesia care as required will be provided for same.
89491782|NCT03183765|Experimental|MMR vaccine|Measles-Mumps-Rubella Vaccine will be injected 0.5 ml into the largest wart at 2-week intervals until complete clearance was achieved or for a maximum of 3 treatments
89491783|NCT03183765|Active Comparator|Cryotherapy|patients received cryotherapy with liquid nitrogen once every 2 weeks until complete clearance or for a maximum of 3 sessions
89491784|NCT04830176|Active Comparator|moringa|First phase of subjects were given dentifrice for brushing
89491785|NCT04830176|Active Comparator|miswak|second phase of subjects were given dentifrice for brushing
89491786|NCT04841174|Experimental|Abdominal Massage|"Participants in the experimental group will be given an abdominal massage twice a day for 15 minutes and three days in a row by the researcher. The massage will be done 2 hours after the child has been fed. Abdominal massage will be done using the I love u technique."
88953899|NCT01966835|No Intervention|control group|no exercise intervention
89491787|NCT04841174|No Intervention|Intraabdominal pressure|Intra-abdominal pressure measurements will be made twice a day before the abdominal massage is given to the participants. This measurement will be made in line with a protocol. The intraabdominal pressure will be measured using the bladder passage method. This measurement will be made in both control and experimental groups.
89491788|NCT04841174|No Intervention|Gastric measurements|In the experimental and control groups, the abdominal circumference will be measured by the researcher twice a day for three days in a row. The gastric residual volume will be checked during the nurses' care time. The presence of vomiting and defecation will be checked during the care time of the nurses.
89491789|NCT03183843|Active Comparator|Dabigatran|Dabigatran etexilate 150 mg by mouth every 12 hours for a year
89491790|NCT03183843|Active Comparator|Warfarin|Warfarin by mouth every 24 hours in a dose providing international normalized ratio (INR) 2.5-3.5 for a year
89491791|NCT04830332|Other|Study group|Women with endometrial carcinoma
89537982|NCT04970589|Experimental|Obese/Probiotics|Participants (Obese:BMI 27-35) will be asked to take 400g of mango and a probiotic capsule every day for 8 weeks
88953900|NCT01966848|Active Comparator|Vanguard CR|Patients will receive the posterior cruciate retaining Vanguard CR prosthesis
89491792|NCT04830254|Active Comparator|study group(A)|Group (A) included 20 patients who received low-frequency TENS (frequency 4 Hz, pulse duration 200 μs) for 45 min per session, three times per week, and for 12 weeks.
89491793|NCT04830254|Sham Comparator|Control group(B)|The control group(B) included 20 patients who received placebo TENS stimulation but with a voltage level falling to zero after 10 s of stimulation
89491794|NCT02431689|Active Comparator|Antagonist|"Antagonist protocol (fixed) for IVF/ICSI, with starting dose of human menopausal gonadotrophins (HMG) from 300-450 IU from day 1 of the cycle, antagonist start from day 6 stimulation. Follow-up by ultrasound and serum estradiol will be done. Triggering of ovulation using human chorionic gonadotrophin (HCG) 10000 IU I.M. when at least 2-3 follicles reach 17mm in diameter.~Cryopreservation of all embryos at will be done. Frozen embryo transfer in the following cycle will be attempted using estradiol valerate (6mg) for endometrial preparation after pituitary down regulation using long acting GnRH analogue . A maximum of 3 good quality embryos will be transferred."
89491795|NCT02431689|Active Comparator|Short|"Short protocol for IVF/ICSI, gonadotrophin releasing hormone analogue (GnRHa) starts from day 1 of the cycle, HMG starts in a dose from 300-450 IU from day 3, Follow-up by ultrasound and serum estradiol will be done. Triggering of ovulation using human chorionic gonadotrophin (HCG) 10000 IU I.M. when at least 2-3 follicles reach 17mm in diameter.~Cryopreservation of all embryos at will be done. Frozen embryo transfer in the following cycle will be attempted using estradiol valerate (6mg) for endometrial preparation after pituitary down regulation using long acting GnRH analogue . A maximum of 3 good quality embryos will be transferred."
89491796|NCT03180879|Experimental|1|Treatment Order: Test, Reference, Comparator
89491797|NCT03180879|Experimental|2|Treatment Order: Test, Comparator, Reference
89491798|NCT03180879|Experimental|3|Treatment Order: Reference, Test, Comparator
89491799|NCT03180879|Experimental|4|Treatment Order: Reference, Comparator, Test
89491800|NCT03180879|Experimental|5|Treatment Order: Comparator, Test, Reference
89491801|NCT03180879|Experimental|6|Treatment Order: Comparator, Reference, Test
89491802|NCT04830098|Experimental|Stabilization group|Stabilization group will be given stabilization exercises for a total of 18 sessions, 3 times a week for 6 weeks, each session for 45 minutes.
89491803|NCT04830098|Experimental|Manipulation group|Manipulation group be applied high-speed low-amplitude (HVLA) chiropractic manipulation for a total of 6 sessions, once a week for 6 weeks.
89491804|NCT04830098|Experimental|Stabilization and Manipulation group|Stabilization and Manipulation group will be given both stabilization exercises and manipulation exercises.
89491805|NCT04830098|No Intervention|Control group|No application will be made in the control group.
89491806|NCT04829708|Active Comparator|PCI Arm|Patients received PCI (recommended hippocampal protection) within 6 weeks after first-line treatment, with a total dose of 25 Gy, 2.5 Gy each time, once a day, 5 times a week, a total of 10 times. Brain enhancement MRI examination is performed every 3 months in first two years, and then performed every 6 months until the brain metastasis occur.
89491807|NCT04829708|Experimental|MRI Arm|Patients undergo enhancement MRI examination every 3 months in first two years, and then performed every 6 months until the brain metastasis occur. Once brain metastases occur, brain radiotherapy and systemic treatment should be conducted with the follow-up observation of brain enhancement MRI continuing.
89491808|NCT03185715|Other|Counseling policy embryo transfer|All recipients completed a validated self-report questionnaire on the preference on the number of embryos to be transferred and the relevance for the decision-making process attributed to certain factors. The questionnaire also included questions on sociodemographic characteristics, medical-reproductive background and cycle's results and risks perception. All recipients received oral and written counselling. After counselling, during the treatment, the recipients completed a second questionnaire in order to check if their decision had changed.
89491809|NCT03037814|Other|Compomer|Adhesive agent+Compomer
89491810|NCT03037814|Other|RMGIC|Primer+RMGIC
88953901|NCT01966848|Active Comparator|Vanguard XP|Patients will receive the bi-cruciate retaining Vanguard xp prosthesis
88953902|NCT01966861|No Intervention|usual care|Weaning as protcolised by the units' daily practice (SBT)
88953903|NCT01966861|Experimental|Weaning guided by lung ultrasound|Predictive early signs of respiratory distress are assessed by lung ultrasound and if found will trigger protocolised intervention (eg- fluid balance,diuretics, thoracocentesis)
88953904|NCT01966874||Study population|"All study participants will receive 200 mg of the mifepristone product Zacafemyl, followed 24-48 hours later by 800 mcg of misoprostol."
89491811|NCT03037814|Other|Giomer|Adhesive Agent+ Giomer
89491812|NCT03037814|Other|Amalgam|Amalgam
88953905|NCT01966887|Experimental|MYDICAR-single intracoronary infusion|Genetic / AAV1 Serca2a (MYDICAR)
88953906|NCT01966887|Placebo Comparator|Placebo; single intracoronary infusion|Placebo comparator
89491813|NCT03180723|Experimental|study group|Rituximab is given in 2 doses (1 gm each dose) to a group of15 patients with primary membranoproliferative glomerulonephritis at (0 - after 2 weeks)
89491814|NCT03180723|Active Comparator|control group|Cyclosporine is given orally in a dose of 2mg/kg/d for 3 months to another group of patients with primary membranoproliferative glomerulonephritis.
89491815|NCT02427009|Experimental|The study population|"The study population consists of adult women requiring an epidural blood patch for the treatment of post-dural puncture headache following vaginal delivery. Women who delivered by cesarean section are not included due to the discomfort of the prone position while there is an abdominal scar.~Intervention: Prone position for 1 hour after blood patch"
89491816|NCT03180567|Experimental|Warfarin resistant patients|Genetic Mutations
89491817|NCT03180567|Placebo Comparator|Control|Genetic Mutations
89491818|NCT02427243|Experimental|Crenezumab Formulation 2|A single dose given as two subcutaneous injections on Day 1
89491819|NCT02427243|Experimental|Crenezumab Formulation 3|A single dose given as two subcutaneous injections on Day 1
89491820|NCT03037658|Experimental|Personal - self|Participants had the opportunity to earn money for themselves by increasing their average steps per day.
89491821|NCT03037658|Experimental|Prosocial - loved one|Participants had the opportunity to earn money for a loved one of their choice by increasing their average steps per day.
89022064|NCT03274635|Experimental|Joint Immediate Contingent Reward, Money|Will receive daily performance-contingent monetary compensation with Amazon gift card, with additional compensation contingent on pedaling activity of co-worker participant.
89491822|NCT03037658|Experimental|Prosocial - charity|Participants had the opportunity to earn money for a charity of their choice by increasing their average steps per day.
89491823|NCT03037658|Experimental|Choice|Participants were given the choice to earn money either for themselves, a loved one, or a charity by increasing their average steps per day.
89491824|NCT03037658|No Intervention|Control|Participants were not offered a financial incentive to increase their average steps per day. They simply wore the pedometer for three weeks.
89491825|NCT02426853|Experimental|Group 1 - UV Photography Group|Participants complete 1 questionnaire at beginning of study, 1 after receiving education about how to protect skin from sun and how to avoid tanning beds, and 1 at about 3 months after receiving skin protection education. Participants given handouts that discusses skin cancer prevention, sun protection, and how to avoid tanning beds. At beginning of study, 2 photos taken of the face. One photo is a standard photo, the other photo is taken with an ultraviolet (UV) filter.
89491826|NCT02426853|Active Comparator|Group 2 - Comparison Group|Participants complete 1 questionnaire at beginning of study, 1 after receiving education about how to protect skin from sun and how to avoid tanning beds, and 1 at about 3 months after receiving skin protection education. Participants given handouts that discusses skin cancer prevention, sun protection, and how to avoid tanning beds.
89491827|NCT03039920|Active Comparator|Electronic cigarette with or without nicotine|Electronic cigarette assisted cessation program
89491828|NCT03039920|Active Comparator|Smoker control|Conventional cigarette smoking continuation
89491829|NCT03037502|Experimental|Intervention: Tailor Made|Intervention Arm: In the pilot intervention, participants will receive: tailored goals/ messages, self-monitoring, weekly small groups to receive health education and community-based information and resources. Participants will also complete two assessment with blood work and anthropometric measurements. These intervention components were selected based on investigator's formative research and experience using them in prior studies. These components will be implemented simultaneously as they complement one another. While all of these components have not been tested together in an intervention for this population, they are variations and enhancements of previous interventions by the investigators.
89491830|NCT03037502|No Intervention|Comparison|Comparison Condition: Participants in the attention control group will receive self-help materials on how to improve healthy eating, physical activity and weight loss, self-monitoring, and complete two assessments with blood work and anthropometric measurements. Participants in this condition will receive a copy of their assessment data and the nurses will provide this personalized information as well as answer any questions participants may have about their assessment results.
89491831|NCT02431611|Active Comparator|Control condition|Control behavioral phone-based smoking cessation intervention
89491832|NCT02431611|Experimental|Biomarker Feedback Intervention|Biomarker feedback plus behavioral phone-based smoking cessation intervention
89491833|NCT03037268||Patients undergoing dilated examination|"examined in the Retina Service of Wills Eye Hospital~with and without visually significant posterior retinal or optic nerve pathology~imaged with a Lytro Plenoptic Camera and 28D lens"
89491834|NCT03180333|Experimental|PNA 1|Multiple dosing tolerance test:Metacavir Enteric-coated Capsules 160mg/320mg,once a day,continuous administration for 7 days;
89491835|NCT03180333|Placebo Comparator|PNA placebo|Multiple dosing tolerance test:Metacavir Enteric-coated Capsules placebo 160mg/320mg,once a day,continuous administration for 7 days
89491836|NCT03180333|Experimental|PNA 2|Single dosing pharmacokinetic test:Metacavir Enteric-coated Capsules 80mg/160mg/320mg,single-dose;
89491837|NCT03180333|Experimental|PNA 3|Multiple dosing pharmacokinetic test:Metacavir Enteric-coated Capsules 160mg/320mg,once a day,continuous administration for 6 days;
89022065|NCT03274635|Experimental|Joint Immediate Contingent Reward, Food|Will receive daily performance-contingent monetary compensation with food gift card, with additional compensation contingent on pedaling activity of co-worker participant.
89491838|NCT03180333|Experimental|PNA 4|The effect of diet:Metacavir Enteric-coated Capsules 160mg,before and after meal.
89491839|NCT04829942|Experimental|experimental|A 12-week training program will be applied to the experimental group. Pre-tests will be applied before the trainings begin, and height and weight measurement, nutrition, health perception and behavior scale and physical activity scale will be applied to the experimental group and the control group within the 3rd and 6th month after the training program begins. Scale applications will be applied within 2 days, taking into account the attention span of the students.
89491840|NCT04829942|No Intervention|no intervention|Power point presentations will be given to the control group
89491841|NCT02431377|Experimental|S-26 Gold|Standard Infant Formula containing enriched with alpha-lactalbumin
89491842|NCT04829786|Experimental|Japanese group|The subjects will receive in Period 1 either the low-dose or high-dose first, and in Period 2 they will receive the alternate dose. There is a washout period between periods.
89537983|NCT03193099|Other|Premanifest HTT mutation carriers|
89022066|NCT00448305|Experimental|1|EndoTAG-1 + Paclitaxel
89022067|NCT00448305|Experimental|2|EndoTAG-1
89022068|NCT00448305|Active Comparator|3|Paclitaxel
89022069|NCT00448383|Experimental|1|Open-label adalimumab
89022070|NCT00448461|Active Comparator|1|heparin
89022071|NCT00448461|Active Comparator|2|bivalirudin
88953907|NCT01966913|Experimental|bevacizumab|"Two intensified treatments at 6-week intervals will start on D69 (max D76) and D111 (max J118) respectively, combining:~A bevacizumab treatment: 7.5 mg/kg every 3 weeks from D1 to the first intensified treatment for a total of 4 injections.~The ICE chemotherapy regimen:~Etoposide, 300 mg/m²/d in two daily injections at 12-h intervals,~Carboplatin, AUC 4/d by injections adjusted daily to the creatinine clearance,~Ifosfamide, 2400 mg/m²/d,~For 5 consecutive days followed by HSC reinjection and G-CSF (filgrastim- Neupogen) on D11 of each intensive cycle"
89491843|NCT04829786|Experimental|non-Asian group|The subjects will receive in Period 1 either the low-dose or high-dose first, and in Period 2 they will receive the alternate dose. There is a washout period between periods.
88953908|NCT01966939||Surgery|Craniotomy or Craniectomy
88953909|NCT01966939||Control|age, gender and teeth condition matched
88953910|NCT01966952||Resistant Hypertension|Resistant hypertension as described as; patients with uncontrolled hypertension on 3 or more antihypertensive medications with no secondary causes for hypertension (i.e. hyperaldosteronism, renal artery stenosis)
88953911|NCT01966965|Experimental|PIOLIN®|PIOLIN® SHAMPOO 5 DAYS CONTINUOUSLY STOP A WEEK AND APPLY AGAIN
88953912|NCT01966965|Active Comparator|NEDAX|FOLLOWING THE LEAFLET TREATMENT
89491844|NCT02426697|Experimental|Pecfent|Patients will receive 100 µg of transmucosal Pecfent before radiotherapy session (or 200 µg in patients with a stable opioid background pain treatment)
89491845|NCT02426697|Placebo Comparator|Placebo|Patients will receive 100 µg of transmucosal placebo before radiotherapy session or 200 µg in patients with a stable opioid background pain treatment)
89491846|NCT03039608|Experimental|combination group|combination of local steroid injection（triamcinolone ）with oral steroid administration（prednisone）
89491847|NCT03039608|Active Comparator|control group|oral steroid administration（prednisone）
89491848|NCT02423811|Experimental|CCRT plus Fursultiamine|"Fursultiamine 100mg tid, po Radiotherapy 36Gy/18Fx Chemotherapy will include Cisplatin and 5-FU. Cisplatin 60-75 mg/m2 on days 1 and 29 with standard prehydration and antiemetic therapy.~5-FU 600-1000 mg/m2day administered as a continuous intravenous infusion for 96 hours after completion of the cisplatin on days 1 through 4 and 29 through 32"
89491849|NCT04837664|Experimental|Rose Bengal-mediated Photodynamic therapy|Participants belonging to the rose bengal mediated photodynamic therapy, their dentures and oral cavity were illuminated using the LED device for 26 minutes (37.5 J/cm2). The photosensitizer rose bengal was sprayed on the palate and dentures for half-hour. To irradiate the palate, the investigator handled the other LED device; the circular platform having LEDs was put within the patient's oral cavity and the illumination of the palate was carried out for 20 minutes (122 J/cm2). The PDT was carried out thrice per week for a half month (6 sessions) in each participant.
89491850|NCT04837664|Experimental|Curcumin-mediated photodynamic therapy|Participants belonging to the curcumin mediated photodynamic therapy, their dentures and oral cavity were illuminated using the LED device for 26 minutes (37.5 J/cm2). The photosensitizer curcumin was sprayed on the palate and dentures for half-hour. To irradiate the palate, the investigator handled the other LED device; the circular platform having LEDs was put within the patient's oral cavity and the illumination of the palate was carried out for 20 minutes (122 J/cm2). The PDT was carried out thrice per week for a half month (6 sessions) in each participant.
89491851|NCT04837664|Active Comparator|Nystatin therapy|Participants belonging to the Nystatin group were administered the topical nystatin-based antifungal drug.
89491852|NCT03039374||OASI patients|All patients older than 18 and a 3rd or 4th degree perineal tear during birth meet the inclusion criteria. All women who have obtained such a injury during birth in the Vaasa or Seinäjoki Central hospitals will be evaluated for eligibility.
89491853|NCT02423733|No Intervention|Control|In addition to their usual clinical care will also be given written information about web sites that provide information on depression but will not be specifically directed to The Journal.
89491854|NCT02423733|Experimental|Computerized Therapy|In addition to their usual clinical care they will receive an invitation to use The Journal supported by an e-therapy coach who will provide patients with weekly email or telephone contact. The e-therapy coach will have a guideline script for each lesson of The Journal to reinforce the topic of each lesson, help identify and support patients in their goals and to coach them in goal setting and the techniques of problem solving.
89491855|NCT04837898|Active Comparator|Haskap berry|A commercially available haskap berry freeze-dried) powder
89491856|NCT04837898|Placebo Comparator|Placebo|Black cherry KoolAid (Kraft Foods, USA) with added maltodextrin to match carbohydrate and calorie content
89491857|NCT04841330||Healthy volunteers|A minimum of 100 healthy volunteer participants (14yo and older)
89491858|NCT01331837|Active Comparator|Etanercept|
89491859|NCT01331837|Experimental|Tocilizumab|
89491860|NCT02706483|Experimental|Plecanatide|Plecanatide 6.0 mg tablets
89491861|NCT04837274|Placebo Comparator|Placebo|Dextrose (480 mg)
89491862|NCT04837274|Experimental|Active|Tart Cherry (480 mg)
89491863|NCT03037424|Active Comparator|Fibrinogen concentrate Octafibrin|
89491864|NCT03037424|Active Comparator|Cryoprecipitate|
89491865|NCT04829552||Control group: low dose group.|patients treated with subcutaneous low molecular weight heparin 40 mg once daily or unfractionated heparin 5000 IU twice or three times daily for at least 5 days.
89491866|NCT04829552||Study group: high dose group.|Patients treated with subcutaneous low molecular weight heparin 1 mg/kg twice daily or 1.5 mg/kg daily or a continuous intravenous infusion of unfractionated heparin for at least 5 days.
89537984|NCT03193099|Other|non HTT mutation carriers|
89537985|NCT02460653|No Intervention|Current|Current level of HFNC support
89537986|NCT02460653|Experimental|Low|Low flow range per kg.
89537987|NCT02460653|Experimental|Medium|Medium flow range per kg.
89537988|NCT02460653|Experimental|High|High flow range per kg
89537989|NCT04155411|Experimental|Dasatinib 70 mg|
89537990|NCT03292757|Experimental|Mesenteric ICG|Indocyanine green injected into the small bowel mesentery during oesophagectomy.
89491867|NCT04829396|Experimental|Fibre mixture|"Dietary supplement. A mixture of fibres will be administered consisting of 10g of acacia gum powder and 3g of carrot powder.~The study product is a fibre mixture consisting of a mix of 10 g of Acacia Gum and 3 g of carrot fibre taken p.o. o.d. in powder form for a total of approximately 10 g of dietary fibre per day."
89491868|NCT04829396|Placebo Comparator|Placebo for Fibre mixture|A placebo of the mixture of fibres will be administered.
88953913|NCT01966991||Surveyed DNAFirst users|Women who opted for DNAFirst testing and who provided written permission (attested by signature and provision of telephone number)for DNAFirst Study staff to telephone them and conduct a brief telephone survey about their experiences.
89022072|NCT00454662|Active Comparator|1|olmesartan medoxomil, Calcium channel blockers (amlodipine, azelnidipine)
89491869|NCT03183375|Experimental|Hydroxyurea arm|This arm will be given investigational drug that is Hydroxyurea .This intervention will be given along with the standard treatment that is blood transfusion and iron chelation.
89491870|NCT03183375|No Intervention|Standard arm|this arm will only receive the standard treatment which is blood transfusion and iron chelation
89491871|NCT03183297|Experimental|JMI-001|JMI-001 is a combination product of naproxen 220mg and fexofenadine 60mg (Dose Level one) then a combination product of naproxen 440mg and fexofenadine 120mg (Dose Level Two).
89491872|NCT03183297|Active Comparator|Naproxen|Naproxen 220mg or 440mg
89491873|NCT03183297|Active Comparator|Fexofenadine|fexofenadine 60mg or 120mg
89491874|NCT03183297|Placebo Comparator|Placebo|
89491875|NCT04829162|Experimental|Mother with obesity, daughter with obesity|Image of a mother with obesity and a daughter with obesity.
89491876|NCT04829162|Experimental|Mother with obesity, daughter without obesity|Image of a mother with obesity and a daughter without obesity.
89491877|NCT04829162|Experimental|Mother without obesity, daughter with obesity|Image of a mother without obesity and a daughter with obesity.
89491878|NCT04829162|Experimental|Mother without obesity, daughter without obesity|Image of a mother without obesity and a daughter without obesity.
89491879|NCT04829162|Experimental|Mother with obesity, son with obesity|Image of a mother with obesity and a son with obesity.
89491880|NCT04829162|Experimental|Mother with obesity, son without obesity|Image of a mother with obesity and a son without obesity.
89491881|NCT04829162|Experimental|Mother without obesity, son with obesity|Image of a mother without obesity and a son with obesity.
89491882|NCT04829162|Experimental|Mother without obesity, son without obesity|Image of a mother without obesity and a son without obesity.
89491883|NCT04829162|Experimental|Father with obesity, daughter with obesity|Image of a father with obesity and a daughter with obesity.
89491884|NCT04829162|Experimental|Father with obesity, daughter without obesity|Image of a father with obesity and a daughter without obesity.
89491885|NCT04829162|Experimental|Father without obesity, daughter with obesity|Image of a father without obesity and a daughter with obesity.
89491886|NCT04829162|Experimental|Father without obesity, daughter without obesity|Image of a father without obesity and a daughter without obesity.
89491887|NCT04829162|Experimental|Father with obesity, son with obesity|Image of a father with obesity and a son with obesity.
88953914|NCT01967004|Experimental|Functional Assessment|Participant will be asked to perform a series of tasks involving their prosthesis. These tasks can involve switching grips as well as moving objects.
88953915|NCT01967017|Experimental|Lidocaine|Paracervical block using 15 mL of 1 % lidocaine
88953916|NCT01967017|Placebo Comparator|Placebo|paracervical block using 15 mL of bacteriostatic saline
88953917|NCT01967043|Experimental|Oraxol Arm 1|"HM30181AK-US tablet administered as a single oral dose of xmg on Days x, y, and z of each cycle~Paclitaxel administered as a fixed oral daily dose of xmg (nine xmg capsules) starting on Days x, y, and z of each cycle. Depending on the cohort, subjects will receive 2, 3, 4, or 5 consecutive days of paclitaxel per week."
89491888|NCT04829162|Experimental|Father with obesity, son without obesity|Image of a father with obesity and a son without obesity.
89491889|NCT04829162|Experimental|Father without obesity, son with obesity|Image of a father without obesity and a son with obesity.
89491890|NCT04829162|Experimental|Father without obesity, son without obesity|Image of a father without obesity and a son without obesity.
89491891|NCT02426775|No Intervention|Methylmalonic Acidemia Control Arm|patients with Methylmalonic Acidemia will receive standard therapy only (protein restricted diet, L-carnitine, metronidazole and vitamin B12)
89491892|NCT02426775|Experimental|Methylmalonic Acidemia Active arm|patients with Methylmalonic Acidemia will receive Carglumic Acid in addition to standard therapy (protein restricted diet, L-carnitine, metronidazole and vitamin B12)
89491893|NCT02426775|No Intervention|Propionic Acidemia Control Arm|patients with Propionic Acidemia will receive standard therapy only (protein restricted diet, L-carnitine, metronidazole and biotin)
89491894|NCT02426775|Experimental|Propionic Acidemia Active arm|patients with Propionic Acidemia will receive Carglumic Acid in addition to standard therapy (protein restricted diet, L-carnitine, metronidazole and biotin)
89491895|NCT03039452|Experimental|High intensity interval training|
89491896|NCT02426931|Experimental|tf-URS|Participants in tf-URS group undergo ureteroscopy using the tip-flexible ureterorenoscope.
89491897|NCT02426931|Active Comparator|f-URS|Participants in f-URS group undergo ureteroscopy using the classic flexible ureteroscope.
89491898|NCT03039218|Active Comparator|Active|Subjects assigned to this group will receive Active treatments using the Dornier Aries 2.
89491899|NCT03039218|Placebo Comparator|Placebo / Sham|Subjects assigned to this group will receive placebo / sham (no active treatment).
89491900|NCT03037190|Experimental|Group A|Group A:withdrawal of gluten from the diet, Group A will have a gluten free diet for a year after the onset of diabetes
89491901|NCT03037190|No Intervention|B normal diet|Group B will have normal not glutenfree diet, no planned intervention
89022073|NCT00454662|Active Comparator|2|AT1 subtype angiotensin II receptor antagonist/low dose diuretic
89022074|NCT00345644|Experimental|1|
89491902|NCT03185559|Active Comparator|Relievion device- Treatment stimulation|Relievion Device- Treatment combined occipital and supraorbital transcutaneous nerve stimulation
89491903|NCT03185559|Sham Comparator|Relievion device- Sham Stimulation|Relievion Device- Sham combined occipital and supraorbital transcutaneous nerve stimulation
89491904|NCT03117153|Experimental|DA-5502 liquid toothpaste|"SMFP 760mg, CPC 50mg, tocopherol acetate 10mg, panthenol 100mg, Dipotassium glycyrrhizinate 20mg.~everyday 3 times for 6 weeks"
89491905|NCT03117153|Placebo Comparator|placebo|"no active ingredients~everyday 3 times for 6 weeks"
89491906|NCT02108405||Sepsis|Sepsis Forty eight patients developed septic complication during ICU stay (sepsis group).
89491907|NCT02108405||SIRS group|SIRS group Forty seven patients were critically ill without evidence of infectious organism (SIRS group).
89491908|NCT02426619|Experimental|SDF regular|3 applications of a 30% SDF solution will be applied onto the surface of dental caries lesions by a small brush regularly once a year
89491909|NCT02426619|Experimental|SDF intensive|3 applications of a 30% SDF solution will be applied onto the surface of dental caries lesions by a small brush at weekly interval at baseline
89491910|NCT02426619|Active Comparator|NaF varnish|3 applications of a 5% NaF varnish will be applied onto the surface of dental caries lesions by a small brush at weekly interval at baseline
89491911|NCT02108483|Experimental|All participants|Dapsone gel and dapsone gel vehicle applied to the skin by separate occlusive patches on Day 1.
89491912|NCT04828616|Experimental|DP303c injection|"Part1:Patients with HER2-expressing advanced ovarian cancer will be treated with DP303c injection at 2.0 mg/kg or 3.0 mg/kg every 3 weeks (Q3W) to determine the recommended phase 2 dose (RP2D).~Part2a:Patients with HER2-overexpressing advanced ovarian cancer will be treated with DP303c injection at RP2D.~Part2b:Patients with HER2-lowexpressing advanced ovarian cancer will be treated with DP303c injection at RP2D."
89491913|NCT03117075|Experimental|Experimental|"using device for scoring pain scale, named ANAPA®"
89491914|NCT01648348|Experimental|Arm I (bevacizumab and TRC105)|Patients receive bevacizumab IV over 30-90 minutes on day 1 and anti-endoglin monoclonal antibody TRC105 IV over 1-4 hours on days 8 and 11 of course 1 and days 1 and 8 of all subsequent courses. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
89491915|NCT01648348|Active Comparator|Arm II (bevacizumab)|Patients receive bevacizumab as in arm I. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
89491916|NCT03039530|Experimental|Treatment Group|Group CBT for PPD. Women in the treatment group will attend a 9-week group CBT intervention for PPD. This intervention was developed at the Women's Health Concerns Clinic (WHCC) at St. Joseph's Healthcare Hamilton. It was designed to be brief, simple, and applicable to women in community settings. It consists of 9 weekly 2-hour sessions where core CBT skills are learned and practiced, and a new psychoeducational topic is introduced and discussed by women each week.
89491917|NCT03039530|Active Comparator|Control Group|Standard Care. The usual care group will receive standard care from their family physician and midwife or obstetrician. They will also be made aware of the perinatal programming available to them through Niagara Region Public Health. Women and family physicians will also receive a copy of the Canadian Practice Guidelines for the Treatment of Perinatal Depression.
89491918|NCT02108561||Breast Cancer|Post Surgical Her2 testing
89491919|NCT03180255|Experimental|EGP-437|40 mg/ml dexamethasone phosphate solution delivered by iontophoresis treatment consisting of 4.5 mA-min at 3.0 mA
89491920|NCT03180255|Placebo Comparator|Placebo|100 mM sodium citrate buffer solution (placebo) delivered by iontophoresis treatment consisting of 4.5 mA-min at 3.0 mA
89491921|NCT02431221|Experimental|Intervention|Perhexiline maleate will be supplied in 100 mg and 25 mg tablets. It will be initially administered at a dose of 200 mg once a day in tablet form for at least six months. After initiation of dosing, perhexiline dosing will be determined using plasma level guided dose adjustment. Dosing decisions will be made by an unblinded dose control center.
89491922|NCT02431221|Placebo Comparator|Placebo|Placebo will be administered once a day in tablet form for at least six months. Tablets will be identical in size and shape to perhexiline tablets. Adjustments in placebo dosing will be made by an unblinded dose control center to mimic decisions made for subjects in the experimental arm.
89491923|NCT02108639|Experimental|DCV 3DAA FDC + BMS-791325|"Group A to D: DCV 3DAA FDC + BMS-791325 oral tablets on specific days~Group E: DCV 3DAA FDC + BMS-791325 oral tablets on specific days"
89491924|NCT04795466|Experimental|Canakinumab|increasing doses of sub-cutaneous injections
89491925|NCT04795466|Placebo Comparator|Placebo|Matching placebo sub-cutaneous injections
89491926|NCT02426385||1POD26PFT|Patients implanted with the POD 26% FineVision Toric
89491927|NCT02426385||2POD26PT|Patients implanted with the POD 26% Toric
89491928|NCT02111291|Experimental|SANTYL®|
89491929|NCT02111291|Sham Comparator|Supportive Care|
89491930|NCT03180099|Active Comparator|Thoracolumbar Interfascial Plane Block|Bilateral ultrasound guided thoracolumbar interfascial plane block
89491931|NCT03180099|Active Comparator|Epidural Block|Epidural Block
88953918|NCT01967043|Experimental|Oraxol Arm 2|"HM30181AK-US tablet administered as a single oral dose of xmg daily with each dose of Paclitaxel~Paclitaxel administered as a fixed oral daily dose of xmg (nine xmg capsules) starting on Days x, y, and z of each cycle. Depending on the cohort, subjects will receive 2, 3, 4, or 5 consecutive days of paclitaxel per week."
89491932|NCT03180177|Experimental|Experimental group|"Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with paclitaxel 175 mg/m^2 and cisplatin 75 mg/m^2 intraperitoneally in succession~2 cycles of neoadjuvant chemotherapy: paclitaxel 175 mg/m^2 IV>3 hour+ carboplatin AUC = 5-6 IV>1 hour, every 3 weeks~Interval debulking surgery~Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with paclitaxel 175 mg/m^2 and cisplatin 75 mg/m^2 intraperitoneally in succession~2 cycles of adjuvant chemotherapy: paclitaxel 175 mg/m^2 IV>3 hour+ carboplatin AUC = 5-6 IV>1 hour, every 3 weeks"
89491933|NCT03180177|Active Comparator|Control group|"3 cycles of neoadjuvant chemotherapy: paclitaxel 175 mg/m^2 IV>3 hour+ carboplatin AUC = 5-6 IV>1 hour, every 3 weeks~Interval debulking surgery~3 cycles of adjuvant chemotherapy: paclitaxel 175 mg/m^2 IV>3 hour+ carboplatin AUC = 5-6 IV>1 hour, every 3 weeks"
89491934|NCT02108717|Experimental|Group I|"The raters in this group one firstly reviewed the CT scans numbered from one to 60 using LCD monitor and after mandatory rests of 20 minutes, reviewed the remaining CT examinations numbered from 61 to 120 using iPhone with TeamViewer at their first visit.~They visited twice with an interval of four weeks and reviewed the CT scans using revered devices at each session."
89491935|NCT02108717|Experimental|Group II|"The raters in this group II firstly reviewed the CT scans numbered from one to 60 using iPhone with TeamViewer and 61 to 120 with the LCD monitor.~They visited twice with an interval of four weeks and reviewed the CT scans using revered devices at each session."
89491936|NCT03179709||Intervention|The investigators will interview physicians, nurses, respiratory therapists and other clinicians who have cared for patients enrolled in the active treatment arm of ROSE.
89491937|NCT03179709||Control|The investigators will interview physicians, nurses, respiratory therapists and other clinicians who have cared for patients enrolled in the control treatment arm of ROSE.
89491938|NCT03179709||Refusal|The investigators will interview physicians who have refused to allow their patients to be enrolled in ROSE.
89491939|NCT04794608|Experimental|HypnoVR Arm|During the three days of study in protector isolation, patients benefit from a 20-minute session of medical hypnosis in virtual reality.
89491940|NCT04794608|No Intervention|Control Arm|During the three days of study in protector isolation, patients benefit from a 20-minute session of activity among those currently proposed in the service of hematology (reading, music, television).
89491941|NCT03180021||Patients with Lupus Nephritis|
89491942|NCT03180021||Patients with IgA Neuropathy|
89491943|NCT02251145|Experimental|tipranavir/ritonavir low dose|
89491944|NCT02251145|Experimental|tipranavir/ritonavir high dose|
89022075|NCT00345644|Placebo Comparator|2|
89491945|NCT04792424|Experimental|No monitoring of post filter ionized calcium|"Starting dialysis with continuous renal replacement therapy with regional citrate anticoagulation.~Patients will receive standard treatments such as anti-bacterial agents, mechanical ventilator, vasopressors as appropriate.~Citrate dose start at 4 mmol/L and no adjustment of citrate dose. Post-filter ionized calcium result will blind for physician.~Other laboratory such as pre-filter ionized calcium, electrolyte, ABG, calcium, the ratio of total calcium to systemic ionized calcium will monitor every 8 hour."
89491946|NCT04792424|Placebo Comparator|Monitoring of post filter ionized calcium|"Starting dialysis with continuous renal replacement therapy with regional citrate anticoagulation.~Patients will receive standard treatments such as anti-bacterial agents, mechanical ventilator, vasopressors as appropriate.~Citrate dose start at 4 mmol/L with adjustment of citrate dose to acheive post-filter ionized calcium at 0.25-0.35 mmol/L.~Other laboratory such as pre-filter ionized calcium, electrolyte, ABG, calcium, the ratio of total calcium to systemic ionized calcium will monitor every 8 hour."
89491947|NCT00709371|Placebo Comparator|Placebo|Combination tablet containing Zonisamide SR placebo plus bupropion SR placebo SR = Sustained Release
89491948|NCT00709371|Active Comparator|Bupropion 360|Combination tablet containing Zonisamide SR placebo plus bupropion SR 360 mg/day; SR = Sustained Release
89491949|NCT00709371|Active Comparator|Zonisamide 120|Combination tablet containing Zonisamide SR 120 mg/day plus bupropion SR placebo; SR = Sustained Release
88953919|NCT01967082|Experimental|Prevention (focus group, APPSPIRE app, survey)|Participants attend an audio-taped focus group over 1 hour and are given the APPSPIRE app. After 1 and 4 months of using the app, participants complete a telephone survey over 1 hour to discuss how they liked the app and its usefulness.
88953920|NCT01967095|Experimental|erlotinib|"This protocol is a phase 1, single arm, open label study of combination daily low dose erlotinib plus twice weekly high dose erlotinib in patients with EGFR-Mutant lung cancer who have not yet received erlotinib or gefitinib. Six dose levels are planned for escalation, with the pulse dose erlotinib increasing.~Expansion cohort A: Treat an additional 19 pts at the MTD with CNS involvement at diagnosis"
89491950|NCT00709371|Active Comparator|Zonisamide 360|Combination tablet containing Zonisamide SR 360 mg/day plus bupropion SR placebo; SR = Sustained Release
89491951|NCT00709371|Experimental|Zonisamide 120/Bupropion 360|Combination tablet containing Zonisamide SR 120 mg/day plus bupropion SR 360 mg/day; SR = Sustained Release
89491952|NCT00709371|Experimental|Zonisamide 360/Bupropion 360|Combination tablet containing Zonisamide SR 360 mg/day plus bupropion SR 360 mg/day; SR = Sustained Release
89491953|NCT03553901|Experimental|Acupressure|Acupressure is applied before injection
89491954|NCT03553901|No Intervention|Control group|acupressure is not applied before injection
89491955|NCT03553667|Active Comparator|Standard group|Adult patients, Creatinine clearance >= 30ml/min, with limb lymphedema, receiving lymphatic venous anastomosis
89491956|NCT03553667|Experimental|ClearSight|Adult patients, Creatinine clearance >= 30ml/min, with limb lymphedema, receiving lymphatic venous anastomosis
89491957|NCT04790630|Experimental|Computerized Cognitive Remediation of Executive Functioning (CCR-EF)|"Initially 10 hours of processing speed exercises from Brain HQ, (the 3 exercises are auditory tone sweep, visual processing [Double Decision], visual sweep).~Following the 8-10 hours of Brain HQ, participants complete 8-10 hours of Ultimate Word Master before completing 16-20 hours of Neurogrow (formerly called Catch the Ball).~Participants are asked to complete approximately 28-42 hours of computerized brain training over 4-6 weeks."
89491958|NCT04790630|Active Comparator|Active Control|Patients in the active control arm will complete three activities according to a standard protocol: 1) play a visuospatially oriented computer game (Myst), 2) watch computer-based educational programs on art, history, literature, and 3) play computer games online through the Brain HQ platform; games include crossword puzzles, soduko, paddleboard, and word search. Participants will complete a total of 32-42 hours of training over 4-6 weeks. Time spent on each task will be evenly divided (15 minutes of each task everday).
89491959|NCT02426463|Active Comparator|Propofol|Plasma samples and patient data are collected prospectively from 40 neonates who receive propofol as part of their care in the neonatal intensive care unit at the Turku University Hospital, Turku, Finland.
89491960|NCT02426463|Active Comparator|Oxycodone|Plasma samples and patient data are collected prospectively from 40 neonates who receive oxycodone as part of their care in the neonatal intensive care unit at the Turku University Hospital, Turku, Finland.
89491961|NCT02105207|Experimental|Lung Ultrasound|In Patients allocated to this arm Lung ultrasound for detection of interstitial syndrome will be performed before chest radiography.
89491962|NCT02105207|Experimental|Chest Radiography|In Patients allocated to this arm chest radiography will be performed for the detection of indirect signs of pulmonary congestion/ADHF without ultrasound evaluation.
89491963|NCT02426229|Experimental|dabigatran 75mg|dabigatran etexilate 75mg orally twice daily for 6 months
89491964|NCT01648270|Experimental|Study Arm|"Subjects will be studied on four occasions. Sessions and drugs are:~Intravenous buprenorphine~Sublingual buprenorphine~Cyclosporine plus intravenous buprenorphine~Cyclosporine plus sublingual buprenorphine"
89491965|NCT05619380|Active Comparator|Physiotherapeutic procedures: auto-therapy (therapeutic exercises)|"Specialized therapeutic exercises:~Gerry's exercise - Starting position: tongue placed on the palate. Movement: slowly opening and closing the mouth. The number of repetitions: 6 times a day for 10 movements.~Active lateral movements of the mandible:~Starting position: separable teeth. Movement: slow movements of the lower jaw to the right and left. The number of repetitions: 6 times a day for 10 movements.~Protrusion and mouth opening:~Starting position: teeth separated. Movement: a) lowering the jaw forward, b) opening the mouth c) closing the mouth d) retracting the lower jaw.~Number of repetitions: 6 times a day for 10 movements."
89491966|NCT05619380|Active Comparator|Physiotherapeutic procedures: manual therapy (massage) and auto-therapy (therapeutic exercises)|"Manual therapy of soft tissues in the masseter muscle:~Extraoral massage of the masseter muscle (duration 5 minutes)~Intraoral massage of the masseter muscle (duration 5 minutes)~Functional massage of the masseter muscle (duration 5 minutes)~Auto-therapy: The patient will receive instructions on how to perform therapeutic exercises at home."
89491967|NCT05619380|Active Comparator|Physiotherapeutic procedures: manual therapy (PIR) and auto-therapy (therapeutic exercises)|"Manual therapy of soft tissues in the masseter muscle:~1. Post-isometric relaxation of the masseter muscle (duration 15 minutes).~Auto-therapy: The patient will receive instructions on how to perform therapeutic exercises at home."
89491968|NCT02108795|Experimental|remifentanil group|Remifentanil 0.05 ug/kg/min is infused to the patients.
89491969|NCT02108795|Placebo Comparator|control|Normal saline 0.2 ml/kg/hour is infused to the patients
89491970|NCT02431143|Experimental|Miltefosine|allometric dosing
89491971|NCT02108873||Retrospective Cohort|Adult patients who had scheduled an appointment for outpatient primary care. Patients were divided into two groups, including those who attended their scheduled appointment and those who missed it.
89491972|NCT02423499||Autism Spectrum Disorder|Autism Spectrum Disorder adults without intellectual disability
89491973|NCT02423499||Bipolar Disorder|Bipolar Disorder adults during normothymic phase of illness
89491974|NCT02423499||Healthy Volonteers|Healthy adults
89491975|NCT04825340|Experimental|Study vaccine|Nasal Spray Lyophilized Live Attenuated Influenza Vaccine
89491976|NCT04825340|Placebo Comparator|Placebo|commercial normal saline
89491977|NCT02302846|Experimental|Ixazomib|Participants receive 4 mg oral dose of Ixazomib on Days 1, 8 and 15 of each 28-day cycle.
89491978|NCT02105363||Age 11-15|
89491979|NCT02105363||Age 16-20|
89491980|NCT02105363||Age 21-25|
89491981|NCT02105363||Age 26-30|
89491982|NCT02105363||Age 31-35|
89491983|NCT02105363||Age 36-40|
89491984|NCT02105363||Age 41-45|
89491985|NCT02105363||Age 46-50|
89491986|NCT02105363||Age 51-55|
89491987|NCT02105363||Age 56-60|
89491988|NCT02105363||age 61-65|
89491989|NCT02105363||Age 66-70|
89491990|NCT02105363||Age 71-75|
89491991|NCT02105363||Age 76-80|
89491992|NCT02105363||Age 81-85|
89491993|NCT02105363||Age 86-90|
89491994|NCT02105363||Age 91-95|
89491995|NCT02105363||Age 96-100|
89491996|NCT02105363||Age 0-5|
89491997|NCT02105363||Age 6-10|
89491998|NCT02431065|Experimental|Group 3, Direct injection group|Test group 2, Rectus sheath block will be performed under direct visualization. Ropivacaine (0.75%, 10ml) will be directly injected into the right and left rectus sheath at the end of the operation.
89491999|NCT02431065|Active Comparator|Group 2, ultrasonography group|Test group 1, Rectus sheath block will be performed under sonographic guidance. Ropivacaine (0.75%, 10ml) will be injected into the right and left rectus sheath under ultrasonographic guidance at the end of the operation.
89492000|NCT02431065|Placebo Comparator|Group 1|Control group, Rectus sheath block will be performed under sonographic guidance. Normal saline 10 ml will be injected into the right, left rectus sheath under ultrasonography guidance at the end of the operation.
89492001|NCT04836806|Experimental|cetirizine and famotidine|Participants testing positive for COVID-19 who are randomized to take cetirizine and famotidine for 10 days.
89492002|NCT04836806|Placebo Comparator|Placebo|Participants testing positive for COVID-19 who are randomized to take a placebo to match cetirizine and famotidine for 10 days.
89492003|NCT04836728|Experimental|arm 1|IBI308 intravenous infusion 200mg d1; Pemetrexed intravenous infusion 500mg/m2 d2 or Albumin paclitaxel intravenous infusion 260mg/m2 d2; Carboplatin intravenous infusion AUC5 d2; CIK cells, 1x10^10 (10 billion ), intravenous infusion,d14; Q3W.
89492004|NCT04836728|Active Comparator|arm 2|IBI308 intravenous infusion 200mg d1; Pemetrexed intravenous infusion 500mg/m2 d2 or Albumin paclitaxel intravenous infusion 260mg/m2 d2; Carboplatin intravenous infusion AUC5 d2;
89492005|NCT02430831|Active Comparator|Reuteri group|Milk formula added with probiotic L reuterii DSM 17938
89492006|NCT02430831|Placebo Comparator|Placebo|Milk formula without probiotic L reuterii DSM 17938
89492007|NCT02426151|Experimental|BEPO-A|Single subcutaneous injection of BEPO-A 4000 IU (Bioreactor manufacturing process)
89492008|NCT02426151|Active Comparator|REPO-A|Single subcutaneous injection of REPO-A 4000 IU (Roller bottle manufacturing process)
89492009|NCT04836572|Other|Wear Period|
89492010|NCT02109185|Active Comparator|Mometasone Furoate Monohydrate Nasal Spray,50 μg/act.|Days 1 through 7, each subject received a placebo run-in. Days 8 through 21, 2 sprays (2 × 50 μg) of Mometasone Furoate Monohydrate Nasal Spray per nostril once daily for 14 days. Total Daily Dose = 4 × 50 μg = 200 μg.
89492011|NCT02109185|Active Comparator|Nasonex® Nasal Spray, 50 μg/actuation|Days 1 through 7, each subject received a placebo run-in. Days 8 through 21, 2 sprays (2 × 50 μg) of Nasonex® Nasal Spray per nostril once daily for 14 days, Total Daily Dose = 4 × 50 μg = 200 μg.
89492012|NCT02109185|Active Comparator|Nasonex® Nasal Spray Suspnsn, 50 μg/actuation|Days 1 through 7, each subject received a placebo run-in. Days 8 through 21, 2 sprays (2 × 50 μg) of Nasonex® Nasal Spray Suspension per nostril once daily for 14 days, Total Daily Dose = 4 × 50 μg = 200 μg.
89492013|NCT02109185|Placebo Comparator|Placebo Nasal Spray, 50 μL/actuation|Days 1 through 7, each subject received a placebo run-in. Days 8 through 21, 2 sprays of placebo nasal spray per nostril once daily.
89492014|NCT04824950|Other|Monitoring of Circulating Tumor DNA|
89492015|NCT02105441||cochlear implant|How well patients with cochlear implants understand speech in noise with implant on, compared to implant off.
89492016|NCT02425995|Experimental|Arthroscopic intercondylar and posteromedial portal|
89492017|NCT04824716|Experimental|postconditioning|Patients that underwent postconditioning after primary percutaneous coronary intervention.
89492018|NCT04824716|Other|control|Patients that underwent primary percutaneous coronary intervention.
89492019|NCT02430909|Placebo Comparator|CZP / CZP + PBO / CZP|"Certolizumab Pegol (400 mg at Weeks 0, 2, and 4 followed by 200 mg every two weeks) until Week 30~+Placebo from Week 8 to Week 18"
89492020|NCT02430909|Experimental|CZP / CZP + UCB4940 / CZP|"Certolizumab Pegol (400 mg at Weeks 0, 2, and 4 followed by 200 mg every two weeks) until Week 30~+ UCB4940 from Week 8 until Week 18"
89492021|NCT02430909|Other|CZP / CZP/ CZP|Certolizumab Pegol (400 mg at Weeks 0, 2, and 4 followed by 200 mg every two Weeks) until Week 30
89492022|NCT02105519|No Intervention|The group receiving no influenza vaccine|Participants in this group will not receive any influenza vaccine (negative control group).
89204615|NCT00642642|Experimental|Double blinded active|Subject will receive autologous fibroblast treatment on either their left or right side of their face
89492023|NCT02105519|Experimental|One dose of AdimFlu-S group|Participants in this group will receive one dose of the seasonal trivalent influenza vaccine (one dose of AdimFlu-S group), formulation 2013-2014, at the initiation of the study. Each administered dose contain 15 ug virus antigen for each virus strain.
89492024|NCT02105519|Experimental|Two dose of AdimFlu-S group|Participants in this group (Two dose of AdimFlu-S group)will receive the seasonal trivalent influenza vaccine, formulation 2013-2014, at the week 0 and 4 weeks after the initiation of the study. Each administered dose contain 15 ug virus antigen for each virus strain.
89492025|NCT04836650|Placebo Comparator|Flat Insole (no metatarsal bar)|Postural stability and electromyographic activity in the dominant leg will be assessed with the subject shod (closed clog) and with 1.2 millimeters flat polyester resin insoles.
89492026|NCT04836650|Experimental|Flat Insole (with 2 millimeters metatarsal bar)|Postural stability and electromyographic activity in the dominant leg will be assessed with the subject shod (closed clog) and with 1.2 millimeters flat polyester resin insoles with a 2 millimeters polyester resin metatarsal bar.
89492027|NCT02109263|Experimental|saccharose|20% saccharose
89492028|NCT02109263|Placebo Comparator|breast-feeding|breast-feeding
89492029|NCT02423655|Experimental|Deffered Dialysis Initiation|"Algorithm for deferred dialysis intervention:~initiating dialysis in the absence of symptoms in patients with an eGFR of 5 ml/min /1.73 m2 or less"
89492030|NCT02423655|Active Comparator|Routine dialysis Initiation|"Algorithm for routine dialysis intervention:~initiating dialysis in the absence of symptoms in patients with an eGFR of 7 ml/min /1.73 m2 (which is the average GFR for patients in Beijing to start dialysis )"
89492031|NCT04825028||Internal Diagnostic Accuracy Cohort|Consecutive patients with available CZT-SPECT within 3 months of measuring FFR in the left anterior descending coronary artery. In these patients, correlation between angiography-derived IMR and hyperemic microvascular resistance will be assessed.
89492032|NCT04825028||External Diagnostic Accuracy Cohort|Patients are subgroup of previously published study (J Nucl Cardiol. 2020 Sep 30. doi: 10.1007/s12350-020-02252-8.), INOCA patients and normal controls confirmed by CZT-SPECT and angiography will be included for the assessment of angiography-derived IMR in diagnosing microvascular dysfunction.
89492033|NCT04825028||Prognosis Cohort|Prognosis cohort, in which angiography-derived IMR will be measured in the target vessel after successful revascularization. Those patients have follow-up data after 2 years from index procedure.
89492034|NCT02105597|Experimental|Mobile application|
89492035|NCT02105597|No Intervention|Standard care|
88953921|NCT01967108|Experimental|chest physiotherapy|chest physiotherapy in patient's bed, including deep breathing, directed cough, arm movment and more.
89492036|NCT02425761|Active Comparator|Anterior Entry SIte|"Anterior entry site is defined as shunt surgery with catheter entry into the brain from an opening near the coronal suture, on the top of the head and near the front. Specifically, anterior entry is defined as ventricular catheter entry less than 1 centimeter anterior to the coronal suture near the mid-pupillary line.~Subjects randomized to this arm will undergo ventriculoperitoneal shunt insertion surgery using an anterior entry site."
89492037|NCT02425761|Active Comparator|Posterior Entry Site|"Posterior entry site is defined as shunt surgery with catheter entry into the brain from an opening near the lambdoid suture, on the back of the head. Specifically, posterior entry is defined as ventricular catheter entry 4 to 7 centimeters above the external occipital protuberance (inion), near the mid-pupillary line.~Subjects randomized to this arm will undergo ventriculoperitoneal shunt insertion surgery using a posterior entry site."
89492038|NCT04836338||Participants|Anesthesia and emergency medicine providers who perform pediatric orotracheal intubations
89492039|NCT02105675|Experimental|DCVAC/PCa add on to Standard of Care|Combination therapy with Dendritic Cells DCVAC/PCa and Standard of Care
89492040|NCT02105675|Active Comparator|Standard of Care|Docetaxel as an Active Comparator
89492041|NCT02336230|Experimental|Remestemcel-L 2×10^6 MSCs/kg|Participants were treated with intravenous (IV) remestemcel-L at a dose of 2×10^6 mesenchymal stromal cells (MSCs)/kilogram (kg) actual body weight at Screening, twice per week, for each of 4 consecutive weeks (initial therapy) given at least 3 days apart and no more than 5 days apart for any infusion. Eligible participants received an additional once per week infusion, for each of 4 consecutive weeks (continued therapy) of remestemcel-L and twice per week infusions, for each of 4 consecutive weeks (aGVHD flare therapy) of remestemcel-L at the same initial therapy dose of 2×10^6 MSCs/kg actual body weight at Screening.
89492042|NCT02105753|Experimental|1210nm axillary laser treatments|two laser treatments right axilla and one treatment left axilla
89492043|NCT02105753|Experimental|1210nm laser treatments to the axilla|two laser treatments left axilla and one treatment right axilla
89492044|NCT04835948||Multiple doses of anti-thymocyte globulin (ATG)|Control group that received fractionated doses of 1.5 mg/kg adding up to a total of 6 mg/kg
89492045|NCT02111759|Other|knee flexion angle 2|30 degrees of knee flexion during ACL graft fixation
89492046|NCT02111759|Other|knee flexion angle 1|0 degrees of knee flexion during ACL graft fixation
89492047|NCT02302222|Active Comparator|Standard of Care|dry sterile dressing/gauze and steristrips
89492048|NCT02302222|Experimental|Customizable|Prevena Customizable Dressing with ActiV.A.C. Therapy Unit
89492049|NCT02111837|Placebo Comparator|Standard infant formula|Standard infant formula fed ad libitum
89492050|NCT02111837|Experimental|Standard infant formula with PL1|Standard infant formula enriched with PL1 lipid fraction fed ad libitum
89492051|NCT02111837|Experimental|Standard infant formula with PL2|Standard infant formula enriched with PL2 lipid fraction fed ad libitum
89492052|NCT04824560|Other|BP Education|All participants enrolled receive blood pressure education.
89204616|NCT00642642|Placebo Comparator|Double blinded placebo|Subject will receive placebo treatment on the opposite side of the face from active treatment
89204617|NCT00780884|Experimental|acupuncture needles|Acupuncture needles named acuzone needles. The acuzone needles are sterile and single use, manufactured by DONG BANG MEDICAL CO.,LTD.
89204618|NCT00818064|Experimental|A, HV|Dose cohort 1 (3 subjects active, 1 placebo)
89492053|NCT02111915|Other|Enhanced Usual Care (EUC)|EUC will comprise communicating the results to the mother's Lady Health Worker and medical officer (MO) at the Basic Health Unit (BHU) of her area, providing the MO with the WHO mental health gap (mhGAP) guidelines for the treatment of depression, and providing guidance on referral of depressed mothers to mental health services
89492054|NCT02111915|Experimental|THPP-P|Trial participant s who are in the THPP group will receive, in addition to EUC, 14 sessions of THPP (simplified cognitive behaviour therapy) starting from their recruitment in the third trimester until up to 5 months after child birth.
89204619|NCT00818064|Experimental|B, HV|Dose cohort 2 (3 subjects active, 1 placebo)
89537991|NCT03292757|Experimental|Feeding jejunostomy ICG (cream)|Indocyanine green mixed with cream infiltrated into the feeding jejunostomy.
88953922|NCT01967108|No Intervention|control group|This patients will not recive chest physiotherapy after extubation, unless developing respiratory deterioration
88953923|NCT01967186|Experimental|Intraportal islet transplantation|Subject randomized to the protocol with intraportal islet transplantation and kidney transplantation
88953924|NCT01967186|Experimental|Intramuscular islet transplantation|Subject randomized to the protocol with intramuscular islet transplantation and kidney transplantation
89204620|NCT00818064|Experimental|C, HV|Dose cohort 3 (3 subjects active, 1 placebo)
89204621|NCT00818064|Experimental|D, HV|Dose cohort 4 (3 subjects active, 1 placebo)
89204622|NCT00818064|Experimental|E, HV|Dose cohort 5 (3 subjects active, 1 placebo)
88953925|NCT01967186|Experimental|Intramuscular transpl with stemcells|Subject randomized to the protocol with intramuscular islet transplantation and where islets have been incubated autologous mesenchymal stemcells. Will also receive kidney transplant
89022076|NCT00454701||1. Amevive Exposure|Patients treated with alefacept for chronic plaque psoriasis
89492055|NCT04824404|No Intervention|Standard Treatment As Usual (TAU)|Participants in the standard of care condition will receive the standard treatment at the recovery program, which consists of weekly or bi-weekly visits (at the discretion of the provider) to the clinic to meet with their provider and provide a sample of blood.
89492056|NCT04824404|Experimental|CBT4CBT-Buprenorphine + Recovery Coach|This condition will consist of the CBT4CBT-Buprenorphine intervention alongside weekly coaching sessions from a recovery professional
89492057|NCT02109341|Experimental|Nab-FOLFIRI|"In the phase I study, all pts enrolled in this arm will receive Nab-FOLFIRI: Irinotecan, 180 mg per square meter of body surface area (m2 ) + Leucovorin, 400 mg/m2 and 5-Fluorouracil, 400 mg/m2 given as a bolus followed by 2400 mg/m2 given as a 46-hour continuous infusion, plus Nab-p per cohort escalation assignment starting with 90 mg/m2 every 2 weeks. Pts continued treatment until a total of 12 administrations, disease progression or unacceptable toxicity.~Pts enrolled in arm A for phase II will receive the dose of Nab-FOLFIRI as determined in the Phase I and in the same sequence."
89492058|NCT02109341|Experimental|Nab-FOLFOX|"In the phase I study, all pts enrolled in this arm will receive Nab-FOLFOX: Oxaliplatin 85 mg/m2 +Leucovorin, 400 mg/m2 and 5-Fluorouracil, 400 mg/m2 given as a bolus followed by 2400 mg/m2 given as a 46-hour continuous infusion, plus Nab-p per cohort escalation assignment starting with 90 mg/m2, every 2 weeks.~Pts continued treatment until a total of 12 administrations, disease progression or unacceptable toxicity.~Pts enrolled in arm B for phase II will receive the dose of Nab-FOLFOX as determined in the Phase I and in the same sequence"
89492059|NCT03553589||Cases|Women older than 18 years and diagnosed with endometrial cancer will be included. Blood sampling will be performed on all subjects and will be used for proteomics and metabolomics analyses.
89492060|NCT03553589||controls|Women older than 18 years and with a benign endometrial disturbance will be included. Blood sampling will be performed on all subjects and will be used for proteomics and metabolomics analyses.
89492061|NCT04835792||Previously Treated for Lyme Disease|
89492062|NCT04835792||Healthy Volunteers|
89492063|NCT02112071|Experimental|Exercise|blended supervised-hombased exercise training 3-4 times/week for 12 weeks
89492064|NCT02112071|No Intervention|control|control group asked to continue usual activities
89492065|NCT04824170|Experimental|Neural glide|Neural mobilization of median nerve which includes gliding and sliding was given
89492066|NCT04824170|Experimental|Rhythmic stabilization technique|Proprioceptive Neuromuscular Facilitation (Rhythmic stabilization technique will be Given)
89492067|NCT02105831||CEU skeletal muscle perfusion imaging|Heart failure with LVAD Contrast ultrasound skeletal muscle perfusion imaging
89492068|NCT02335450|Experimental|Single Arm|All five participants in the study will receive this intervention. The participants will be visited in their homes by a physical therapist once a week. The physical therapist will use a coaching technique called motivational interviewing to help the participant develop personal physical activity goals. The participant will discuss their physical activity challenges, and with the help of the physical therapist the participant will set up personal physical activity goals for the following week. The participant will be given a wristband physical activity monitor to wear during the day for four weeks to track their progress in meeting their activity goals.
89492069|NCT03037112|Active Comparator|Education|All providers will receive identical training on the appropriate prescribing of antibiotics for ARTIs in a 20 minute presentation. Follow up refresher video clips will also be available for all providers to view at their convenience throughout the study. Parents in both arms will receive identical high quality education on the pros and cons of antibiotics and tips for communicating with their provider.
89492070|NCT03037112|Active Comparator|Communication Skills|Providers randomized to the communication intervention will receive additional training on communication skills in a 40 minute communication skills training session. This training session will include good and bad communication examples, training on positive and negative behavioral framing, and education regarding key drivers of patient satisfaction.
89492071|NCT02105909|Experimental|obese subjects|DNA analysis
89492072|NCT02105909|Placebo Comparator|lean subjects|DNA analysis
89492073|NCT04428710||patients admitted to cancer genetic counseling test|Participants were recruited from all consecutive patients referred to the Cancer Genetic Program at the Hospital Universitari i Politècnic la Fe.
89492074|NCT03013517|Experimental|Viaskin Peanut 250µg|
89204623|NCT00818064|Experimental|A, RA|Dose cohort 1 (3 subjects active, 1 placebo)
89022077|NCT00345761|Experimental|Step 1|
89022078|NCT00345761|Experimental|Step 2|
89022079|NCT00345761|Experimental|Step 3|
89022080|NCT00345800|Experimental|Sodium Oxybate|"Active Substance: Sodium Oxybate~Pharmaceutical form: Oral Solution~Concentration: 500 mg/mL oral solution from 4.5 to 9 g/day divided into two equal doses during 12 weeks~Route of administration: Oral"
88953926|NCT01967186|Active Comparator|Kidney transplantation only|Subject that only undergoes kidney transplantation
88953927|NCT01967199|Active Comparator|Drug Eluting Stent|Everolimus-eluting balloon expandable stent (Xience Prime or Xience Xpedition or Xience Alpine)
88953928|NCT01967199|Experimental|paclitaxel eluting balloon|paclitaxel eluting balloon (SeQuent Please)
88953929|NCT01967212|Experimental|Game-based swallow biofeedback|swallowing training combined with game-based biofeedback in stroke dysphagia patient.
88953930|NCT01967212|Active Comparator|Swallow training without biofeedback|
89022081|NCT00454740|Experimental|1|
89022082|NCT03276897|Experimental|Nutriage SPF 30 day cream and Nutriage night cream|Application of the study products (day cream at the morning and night cream at the evening), for an uninterrupted period of 3 months.
89022083|NCT03276858|Experimental|CRN00808 Oral Solution|CRN00808 oral solution, single-dose
89204624|NCT00818064|Experimental|B, RA|Dose cohort 2 (3 subjects active, 1 placebo)
89204625|NCT00818064|Experimental|C, RA|Dose cohort 3 (3 subjects active, 1 placebo)
89204626|NCT00784940|Active Comparator|1|Arimidex 1mg + Nolvadex placebo
89204627|NCT00784940|Active Comparator|2|Arimidex placebo + Nolvadex 20mg
89492075|NCT02113709|Experimental|Visual improvement|To see how efficiently visual improvement occurs by Full-time Occlusion therapy with an eye patch in severe amblyopia.
89492076|NCT04824326|Experimental|Pythagorean Self Awareness Intervention for Children and Adolescence(PSAI-CA)|"The intervention is based on the principles of the teaching of the ancient Greek philosopher Pythagoras. These principals set a basic framework for behavior on the basis of experiential learning and weekly evaluation of the implementation of 12 virtues. The technique is practiced twice a day(before night sleep and in the morning before getting up from bed) and evolves into five successive steps;1)reading of the 12 virtues and diaphragmatic breathing, 2)recall every event og the day,3)third person visualization and self-observation, 4)self-dialogue What have I done wrong?, What have I done right?, What have I omitted that I ought to have done? Endorsement or disapproval of actions according to the 12 virtues and the instructions for a healthy lifestyle, 5) next morning brief revision of the previous night's conclusions and setting of goals for the upcoming day."
89492077|NCT02113787|Active Comparator|Pharmacokinetic study, topamed|"For pharmacokinetics, blood samples was taken after receiving Topamax 100mg twice a day in first visit day.~For pharmacokinetics, blood samples was taken after receiving Topamed 100mg twice a day in second visit day.~For pharmacokinetics, blood samples was taken after receiving Topamax 100mg twice a day in third visit day.~For pharmacokinetics, blood samples was taken after receiving Topamed 100mg twice a day in third visit day."
89492078|NCT02113787|Active Comparator|Pharmacokinetic study, topamax|"For pharmacokinetics, blood samples was taken after receiving Topamed 100mg twice a day in first visit day.~For pharmacokinetics, blood samples was taken after receiving Topamax 100mg twice a day in second visit day.~For pharmacokinetics, blood samples was taken after receiving Topamed 100mg twice a day in third visit day.~For pharmacokinetics, blood samples was taken after receiving Topamax 100mg twice a day in third visit day."
89204628|NCT00784940|Active Comparator|3|Arimidex 1mg + Nolvadex 20mg
89492079|NCT04367168|Active Comparator|Colchicine|Colchicine PO
89492080|NCT04367168|Placebo Comparator|Placebo|Placebo PO
89492081|NCT02113865||Grupo 0|Null or mild fibrosis
89492082|NCT02113865||Grupo 1|Cirrhosis
89492083|NCT02113865||Grupo 2|HCC diagnosis
89492084|NCT04835558||Group I|Subjects with obesity hypoventilation sydrome (30 < body mass index < 40 kg/m2)
89492085|NCT04835558||Group II|Subjects with obesity hypoventilation sydrome (body mass index > 40 kg/m2)
89492086|NCT04835558||Control Group|Age and sex-matched obese subjects (30 < body mass index < 40 kg/m2) with low risk of obstructive sleep apnea (STOP-BANG score < 3)
89492087|NCT04823936|No Intervention|control group|received the selected physical therapy program for one hour, three times weekly for two successive months including facilitation of balance and protective reactions from kneeling, half kneeling and standing position, standing alone on balance board, standing on one leg, open gait training alone (walking on the balance beam, walking on the stepper and walking on wedges), training stair climbing, and strengthening of the back and abdominal muscles.
89492088|NCT04823936|Active Comparator|study group|received the selected physical therapy program for one hour, three times weekly in addition to core stability training program for 30 minutes
89492089|NCT02114021|Experimental|betamethasone gel|betamethasone gel (over tracheal tube cuff) compared with distilled water on the post intubation syndrome incidence.
89492090|NCT02114021|Experimental|lidocaine jelly|lidocaine jelly (over tracheal tube cuff) compared with distilled water on the post intubation syndrome incidence.
88953931|NCT01967251|Experimental|Udenafil 25 mg|Udenafil 25 mg, tablets, orally, once daily for 12 weeks.
88953932|NCT01967251|Experimental|Udenafil 50 mg|Udenafil 50 mg, tablets, orally, once daily for 12 weeks.
88953933|NCT01967251|Experimental|Udenafil 75 mg|Udenafil 75 mg, tablets, orally, once daily for 12 weeks.
88953934|NCT01967251|Placebo Comparator|Placebo|Udenafil placebo-matching tablets, orally, once daily for 12 weeks.
88953935|NCT01967264|Experimental|Udenafil 150 mg + Udenafil 150 mg|Udenafil 150 mg, tablet, orally, once on Day 1, followed by udenafil 150 mg, tablet, orally, once on Day 3.
88953936|NCT01967264|Experimental|Udenafil 150 mg + Placebo|Udenafil 150 mg, tablet, orally, once on Day 1, followed by placebo, tablet, orally, once on Day 3.
88953937|NCT01967264|Experimental|Placebo + Udenafil 150 mg|Placebo, tablet, orally, once on Day 1, followed by udenafil 150 mg, tablet, orally, once on Day 3.
88953938|NCT01967264|Placebo Comparator|Placebo + Placebo|Placebo, tablet, orally, once on Day 1, followed by placebo, tablet, orally, once on Day 3.
88953939|NCT01967290|Experimental|Hand-to-mouth task - vibratory feedback|Hand-to-mouth task under vibratory feedback and 3D movement analysis. The SWORD device is in place over the patient arm, performs continuous 3D movement analysis and provides vibratory feedback according to quality performance settings established by the clinician after patient assessment. If movement is of lower amplitude or slower than prescribed a vibratory stimulus is delivered at the wrist of the patient. The intervention is repeated on the hemiparetic and normal sides and the duration of the task is defined according to the patient cardiovascular status.
88953940|NCT01967290|Active Comparator|Hand-to-mouth task - no vibratory feedback|Hand-to-mouth task in the same conditions as the experimental arm but without vibratory feedback, only 3D movement analysis. The SWORD device is in place over the patient arm, performs continuous 3D movement analysis but does not provides vibratory feedback according to quality performance settings established by the clinician after patient assessment. If movement is of lower amplitude or slower than prescribed NO vibratory stimulus is delivered at the wrist of the patient. The intervention is repeated on the hemiparetic and normal sides and the duration of the task is defined according to the patient cardiovascular status.
89492091|NCT02114021|Placebo Comparator|distilled water|betamethasone gel and lidocaine jelly (over tracheal tube cuff) compared with distilled water on the post intubation syndrome incidence.
89492092|NCT04826822|Experimental|Treatment|"After randomisation (Day 1): Spironolactone [100 mg 1x/day] + dexamethasone [2 mg 2x/day, 12/12h] Days 2-12*: Spironolactone [50 mg 2x/day, 12/12h] + dexamethasone [2 mg 2x/day, 12/12h] Days 13-20: Spironolactone [25 mg 2x/day, 12/12h] Days 21-28: Spironolactone [25 mg 1x/day] Standard treatment is according to the treatment protocol for 2019-nCoV infection.~*In case of cortisol levels above 100 nmol/L on days 3 and 4, the dexamethasone dose should be increased to 3 mg in the morning and in the evening (total 6 mg per day)."
89492093|NCT04826822|Active Comparator|Control|Patients receiving standard-of-care treatment for SARS-CoV-2 infection as regulated by the relevant guidelines of the Ministry of Healthcare of the Russian Federation
89492094|NCT02251457|Experimental|ranolazine|ranolazine 500mg, twice daily for two weeks; 1000mg twice daily for 2 weeks
89492095|NCT04835246|Experimental|Spectra IMDx|"The physician will be asked to give a diagnosis of the lesion under White light endoscopy (WLE) firstly and the endoscopic diagnosis result will be recorded on case report form. Then the physician will introduce the probe of Spectra IMDx system to contact and assess the lesion. The Spectra IMDx system will detect the scattering light signal from the lesion and assess the risk of the lesion being high-grade intraepithelial neoplasia or gastric cancer, and display the result on the Spectra IMDx screen. The Spectra IMDx assessment will be recorded on case report form. Both the patient and doctor will be blinded from the results from Spectra IMDx system.~After Spectra IMDx system examination, the physician takes biopsy sample(s) in suspected lesion for further histopathological diagnosis."
89492096|NCT02112149|Experimental|LIVESTRONG Program|Participants randomized to the LIVESTRONG exercise program will attend a 12-week LIVESTRONG Program at one of the participating YMCA's in the greater Boston area or CT. We will have monthly teleconferences to discuss the study, recruitment, and the exercise program. Lastly, throughout the 12-week program, participants will record their attendance at the LIVESTRONG program as well as any exercise done outside of the program. We will provide them with a Physical Activity Log book to record their exercise.
89492097|NCT02112149|No Intervention|Wait-List Control|Baseline data will be collected from all study participants before randomization. If a participant is randomized to wait-list control, then he/she will be told that he/she will start the LIVESTRONG program after three months and after he/she returns to Yale or DFCI to complete the 3-month clinic visit.
89492098|NCT03553511|Experimental|Uterosacral ligaments suspension|Women affected by stage II-III pelvic organ prolapse undergoing total laparoscopic hysterectomy with vaginal vault suspension to the uterosacral ligaments.
89492099|NCT03553511|Active Comparator|McCall culdoplasty|Women affected by stage II-III pelvic organ prolapse undergoing vaginal hysterectomy with McCall culdoplasty.
89492100|NCT02112227|Active Comparator|Discharge planning services|Proven effective discharge-planning services will be grouped into 'patient-centered care transitions in heart failure' patients. This will be known as the PACT-HF model.
89492101|NCT02112227|No Intervention|Standard Care|Standard of care will be provided to HF patients at discharge.
89492102|NCT02112305|Experimental|isotonic magnesium sulphate|2.5 ml of isotonic magnesium sulphate (150 mg, 245 mmol/L) on three occasional at 20 minutes interval
89204629|NCT00790166|Active Comparator|CPAP + ThermoSmart™ humidity|
89492103|NCT02112305|Active Comparator|50% magnesium sulphate|magnesium sulphate 50mg/kg/dose intravenous drip in 20 minutes for one dose
89492104|NCT02112383|Experimental|Internet-based cognitive behavior therapy|
89492105|NCT02112383|Experimental|Cognitive behavior group therapy|
89492106|NCT02109575||Heart Transplant Recipients|Up to 10 cc of blood will be drawn from heart transplant recipients at various time points prior to and after transplant. Blood draw is the only research activity that study participants will undergo. In addition to blood draw, data will be collected from clinical records representing the participant's transplant course such as the medical record, imaging, and biopsy slides with pathology reports.
89492107|NCT02112461|Experimental|Intervention Group|SCP-Hospice Alert
89022084|NCT03276858|Experimental|CRN00808 Oral Capsule|CRN00808 oral capsule, single-dose and multiple-doses
89022085|NCT03276858|Placebo Comparator|Placebo Oral Solution|Placebo oral solution, single-dose
89537992|NCT03192865||diaphragmatic paralysis/paresis group|"Diaphragmatic paralysis can be associated with regional anesthesia procedure in arthroscopic shoulder surgery as phrenic nerve is close to the brachial plexus.~Diaphragmatic paralysis will be defined using ultrasounds."
89537993|NCT03192865||No diaphragmatic paralysis/paresis group|Some strategies of peripheral nerve block are able to spare diaphragmatic paralysis.
89204630|NCT00790166|Active Comparator|CPAP + Conventional humidity|
89022086|NCT03276858|Placebo Comparator|Placebo Oral Capsule|Placebo oral capsule, single-dose and multiple doses
89022087|NCT03276858|Other|Midazolam Oral Solution|Midazolam oral solution, two single-doses as part of the drug-drug interaction arm of the study
89204631|NCT00790166|Active Comparator|CPAP + No added humidity|
89537994|NCT04970667|Experimental|Flupentixol melitracen tablets|The patients were treated with Flupentixol melitracen tablets according to their own conditions
89537995|NCT05233813|Experimental|ABM intervention group|The intervention group received three, 45-min group exercise lessons for 12 weeks. The group exercise lessons were taught by two experienced instructors.. Each participant in the intervention group received a Fitbit (Model InspireHR) activity tracker to self-monitor their daily PA, 5 days per week for 12 weeks.
89022088|NCT00421187|Experimental|1|AmBisome® will be given on day 0 (10 mg/kg), day 2 (5 mg/kg), and day 5 (5 mg/kg)
89022089|NCT00421187|Active Comparator|2|AmBisome as a constant daily dose of 3 mg/kg for a maximum of 14 days or until the resolution of fever and neutropenia
89022090|NCT00454896|Experimental|1|
89022091|NCT00454896|Placebo Comparator|2|
89022092|NCT03276624|Other|patients with low EF undergoing CABG|Chronic Unstable Angina patients with low ejection fraction and a viable myocardium will undergo surgical revascularization CABG
89022093|NCT00346229|Experimental|Thermodox|ThermoDox20-40mg/m2 every 21-35 days followed by Chest Wall Hyperthermia
89537996|NCT05233813|No Intervention|Comparison group|The comparison group continued their usual activities.
89537997|NCT03288467|Active Comparator|Root canal treatment with 5% NaOCl|Root canal treatment with 5% NaOCl: 5 ml of 5% sodium hypochlorite was used during root canal treatment after each instrument change.After root canal instrumentation, canals irrigated with 5ml of 17% EDTA solution for 1 minute followed by final wash with 5ml of 5% sodium hypochlorite.
89537998|NCT03288467|Active Comparator|Root canal treatment with 1% NaOCl|5 ml of 1% soium hypochlorite was used during root canal treatment after each instrument change.After root canal instrumentation, canals irrigated with 5ml of 17% EDTA solution for 1 minute followed by final wash with 5ml of 1% sodium hypochlorite.
89537999|NCT02446327|Other|Diastolic heart failure cohort|This is a prospective cohort of patients with diastolic heart failure. Blood sampling for biomarker assessment
89538000|NCT04978233||MUHC COVID-19 patients|COVID-19 infected patients, newly diagnosed at the RI-MUHC
89538001|NCT03288389|Placebo Comparator|Placebo|Participants will take 4 placebo wafers per day for 42 days. Subjects will be asked to take the Fibromyalgia Combined Symptom Survey (see attachments, based on validated survey instruments) on-line on Day 0 (before starting supplement/placebo) and on Days 1, 2, 3, 7, 14, 21, 30 and 42.
89538002|NCT03288389|Active Comparator|NTFactor Lipids®|Participants will take 4 NTFactor Lipid® wafers (4 g) per day for 42 days. Subjects will be asked to take the Fibromyalgia Combined Symptom Survey (see attachments, based on validated survey instruments) on-line on Day 0 (before starting supplement/placebo) and on Days 1, 2, 3, 7, 14, 21, 30 and 42.
89538003|NCT03192631|Experimental|with financial incentive|Patients randomized to this arm will start with receiving the financial incentive. Cross-over after 9 months to treatment as usual.
89538004|NCT03192631|No Intervention|treatment as usual|Patients randomized to this arm will start with receiving treatment as usual, cross-over after 9 months to incentive arm.
88953941|NCT01967303||Patients with stroke or transient ischemic attack|Interview regarding restless legs syndrome
88953942|NCT01967303||Subjects without stroke or transient ischemic attack|Interview regarding restless legs syndrome
88953943|NCT01967329|Active Comparator|Standard Triple, treatment naive|"Standard Triple Therapy for H. pylori:~Oral twice-daily doses of rabeprazole (20 mg), amoxicillin (1 g) and clarithromycin (500 mg)~One of two treatments randomly assigned to treatment naive participants in Aklavik"
88953944|NCT01967329|Active Comparator|Sequential, treatment naive|"Sequential Therapy for H. pylori:~Oral twice-daily doses of rabeprazole (20 mg) and amoxicillin (1 g) on days 1-5, and on days 6-10, rabeprazole (20 mg), metronidazole (500 mg) and clarithromycin (500 mg)~One of two treatments randomly assigned to treatment naive participants in Aklavik, Old Crow, Tuktoyaktuk & Fort McPherson"
89022094|NCT00455052|Experimental|XMT-1001|XMT-1001 is administered I.V. every 21 days. Groups of 3 patients are given one dose and the dose increases for each group. The first dose level is 17 mg/m^2, the next dose level is 30 mg/m^2, followed by dose levels: 50 mg/m^2, 80 mg/m^2, 120 mg/m^2, 150 mg/m^2, and 190 mg/m^2 until disease progressions or unacceptable side effects are experienced.
89022095|NCT00346502|Experimental|Ointment|Treatment will consist of four weeks of daily application of 20% BA ointment to the dysplastic nevi, after which it will be removed surgically and examined. A similar dysplastic nevi will be removed as a control. Four groups of patients will be enrolled. The first group will apply the ointment once a day, the second twice a day, the third three times a day, and the fourth four times a day.
89022096|NCT04699344||Pre-tissue biopsy patients|Pre-tissue biopsy patients with suspected prostate carcinoma will be the experimental group to determine the sensitivity and specificity of PROUD analysis, the result will be compared with histological results and PCA3 test.
89204632|NCT02552706|Experimental|probiotics group|Administration of probiotics 500mg begins by mouth within 4 hours of life with 1-3 consecutive doses; the frequency depends on the feeding times. Study is continuous until preterm infants grow up to 36 weeks post menstrual age.
89492108|NCT02112461|No Intervention|Usual Care|Caregiver calls into monitoring system to report the patient's end of life symptoms but does not receive feedback about the symptoms and the hospice nurse does not receive the information.
89492109|NCT02114099|Experimental|Atorvastatin|prescribe Atorvastatin to see its effect
89492110|NCT02114255|Experimental|BCG vaccination|BCG vaccination
89492111|NCT02114255|Placebo Comparator|NaCl 0.9%|administration of NaCl 0.9%.
89492112|NCT02251223|Experimental|TPV/r low dose|
89492113|NCT02251223|Experimental|TPV/r medium dose|
89492114|NCT02251223|Experimental|TPV/r high dose|
89492115|NCT02112539||ADP Blockers|platelet aggregation in response to antiplatelet drugs
89492116|NCT02109653|Experimental|LGX818|Adult patients, with confirmed diagnosis of BRAF V600E mutant advanced or metastatic NSCLC who have progressed on or after at least one prior systemic anticancer therapy.
89492117|NCT02114333|Active Comparator|A - Live zoster vaccine|"No previous zoster vaccine; stratified between age groups 50-59 and 70-85~First dose live vaccine, Zostavax (0.65ml, subcutaneous)~Second dose placebo, normal saline (0.65ml. subcutaneous)"
89492118|NCT02114333|Active Comparator|B - recombinant zoster vaccine|"No previous zoster vaccine; stratified between age groups 50-59 and 70-85~First dose recombinant vaccine, HZ/su (0.5ml, intramuscular)~Second dose recombinant vaccine, HZ/su (0.5ml, intramuscular)"
89492119|NCT02114333|Active Comparator|C - Live zoster vaccine|"One previous dose of zoster vaccine at least 5 years previously, age 70-85~First dose live vaccine, Zostavax (0.65ml, subcutaneous)~Second dose placebo, normal saline (0.65ml. subcutaneous)"
89492120|NCT02114333|Active Comparator|D - recombinant zoster vaccine|"One previous dose of zoster vaccine at least 5 years previously, age 70-85~First dose recombinant vaccine, HZ/su (0.5ml, intramuscular)~Second dose recombinant vaccine, HZ/su (0.5ml, intramuscular)"
89492121|NCT02114411||Dyspeptic patients|Patients (45 years and older, both genders) with dyspepsia referred for the GastroPanel test and gastroscopy with multiple bisopies at Homerton University Hospital (London, United Kingdom).
89492122|NCT02114489|Experimental|Ibandronate|Unique perfusion of ibandronate 3 mg IV
89492123|NCT02114489|Placebo Comparator|Placebo|Unique perfusion of NaCl 3mg IV
89492124|NCT02114567|Experimental|PSV ventilation|AECOPD Patients who were ventilated wiht PSV, PEEP was titrated and set at 0, 40%, 80% and 120% PEEPi. Pressure support was set to get the tidal volume of 6ml/kg.
89492125|NCT02114567|Experimental|NAVA ventilation|AECOPD patients who were ventilated with NAVA, PEEP was titrated and set at 0, 40%, 80% and 120% PEEPi. NAVA level was set to get the tidal volume of 6ml/kg.
89492126|NCT02114645|Active Comparator|LongGnRH agonist protocol(controlgroup)|Long GnRH agonist protocol ( control group) Luteal Phase Support: Vaginal progesterone + 4mg oral estradiol valerate
89492127|NCT02114645|Experimental|Long protocol-leuprolide acetate|Long GnRH agonist protocol Luteal Phase Support: Vaginal progesterone+oral estradiol valerate subcutaneous 0.5mg leuprolide acetate fifth and tenth day after embryo transfer
89492128|NCT02114645|Active Comparator|GnRHantagonist protocol(control group)|GnRH antagonist protocol ( control group) Luteal Phase Support: Vaginal progesterone + 4mg oral estradiol valerate
89492129|NCT02114645|Experimental|antagonist protocol-leuprolide acetate|GnRH antagonist protocol Luteal Phase Support: Vaginal progesterone + 4mg oral estradiol valerate + subcutaneous 0.5mg leuprolide acetate fifth and tenth day after embryo transfer
89492130|NCT02114723|Active Comparator|Medical Taping Concept|"3 band of a special and hypoallergenic tape, called Cure Tape ® (2 strips of 12 x 5 cm and 1 strip of 20 cm x 5 cm) are attached to the abdominal and lower back. One piece of 12 cm in length is applied right from below the navel and reached to where the pubic hair below, and another piece of 12 cm in length is applied to make a cross shape with the first piece (inside 11-12 dermatomes area). The piece of 20cm in length is placed horizontally to the lower back.~The bandage is applied at the time that menstrual pain begins and is stuck to the skin for 4-5 days until menstrual pain disappears"
89492131|NCT02114723|Placebo Comparator|Cross tape|Two pieces of special and squared tape of 2.5 x 2 cm called Cross Tape ® are attached to the external side of the thigh at the hip joint area (outside 11-12 dermatomes area)
89492132|NCT02109887||PCP with true CMV co-infection|
89492133|NCT02109887||PCP with innocent bystander CMV|
89492134|NCT02109887||PCP without any evidence of CMV|
89492135|NCT02112617|Experimental|Proton Beam Radiation Therapy (PBRT)|Proton radiation will be delivered daily for 3-4 weeks, depending on the dose prescribed by study doctor. Treatment is delivered (Monday - Friday) for 5 days (no weekends or holidays). Each treatment the participant will lie on a table for 30-45 minutes.
89204633|NCT02552706|Placebo Comparator|control group|control group received 1 mL of a 5% glucose solution. Administration of control group begins by mouth within 4 hours of life with 1-3 consecutive doses; the frequency depends on the feeding times. Study is also continuous until preterm infants grow up to 36 weeks post menstrual age.
89204634|NCT00790244|Experimental|Arm 2|"<70y: 6 cycles with doxorubicin 60mg/m2+ifosfamide 6g/m2 of each 21day cycle and radiotherapy 36Gy (1.8Gy per fraction, two fractions daily) will be given between cycle 3 and 4.~(>=70y: doxorubicin 50mg/m2+ifosfamide 5g/m2)"
89204635|NCT00790244|Experimental|Arm 3|"<70y: 6 cycles with doxorubicin 60mg/m2+ifosfamide 6g/m2 of each 21day cycle and radiotherapy 45Gy (1.8Gy per fraction, two fractions daily) will be given between cycle 3 and 4.~(>=70y: doxorubicin 50mg/m2+ifosfamide 5g/m2)"
89204636|NCT00790244|Experimental|Group B|"<70y: 6 cycles with doxorubicin 60mg/m2+ifosfamide 6g/m2 of each 21day cycle and radiotherapy 36Gy (1.8Gy per fraction, two fractions daily) will be given between cycle 2 and 3.~(>=70y: doxorubicin 50mg/m2+ifosfamide 5g/m2)"
89204637|NCT00790244|Experimental|Arm 1|<70y: 6 cycles with doxorubicin 60mg/m2+ifosfamide 6g/m2 of each 21day cycle (>=70y: doxorubicin 50mg/m2+ifosfamide 5g/m2)
89204638|NCT00818142||eating disorder, type 1 diabetes|Individuals diagnosed with type 1 diabetes and an eating disorder who withhold their insulin.
89204639|NCT00815958|Experimental|A|Reaming with Synthes RIA (Reamer-Irrigator-Aspirator)
89204640|NCT00815958|Active Comparator|B|Reaming with conventional reamer
89204641|NCT00785018|Active Comparator|C1-esterase inhibitor|Endotoxin 2ng/kg followed by C1- esterase inhibitor 100 U/kg infusion
89204642|NCT00785018|Placebo Comparator|Placebo|Endotoxin 2ng/kg followed by saline 0.9%(placebo) infusion
89204643|NCT00821340|Experimental|rAAV2-hRPE65|
89204644|NCT00790322|Experimental|Active|
89204645|NCT00790322|Placebo Comparator|Placebo|
89204646|NCT00534352|Experimental|001|TMC125; darunavir; ritonavirTMC125 400mg once daily for 4 weeks; Darunavir-800mg once daily for 48 weeks; Ritonavir-100mg once daily for 48 weeks
89204647|NCT00642174|Experimental|Prasugrel|Oral prasugrel 60-mg loading dose, followed by 6 to 9 days of prasugrel 10-mg/day tablet maintenance dose.
89204648|NCT00642174|Active Comparator|Clopidogrel|Oral clopidogrel 600-mg loading dose, followed by 6 to 9 days of clopidogrel 150-mg/day tablet maintenance dose.
89204649|NCT04001296|Experimental|21 day Brush Day and Night intervention|The 21 day Brush Day and Night programme aims to instruct on and encourage twice a day brushing with a fluoridated toothpaste.
89204650|NCT04001296|No Intervention|Control schools|Schools / children who receive only toothpaste / toothbrushes, no 21 day Brush Day and Night intervention
89204651|NCT00992290|Experimental|Lactobacillus GG|
89204652|NCT00992290|Placebo Comparator|Placebo|
89204653|NCT02550444|Placebo Comparator|Control|Intravenous and intrathecal Placebo (Saline 0,9%); Intrathecal heavy Bupivacaine 0,5% (15mg), morphine 0,02 (80mcg) and fentanyl (10mcg).
89204654|NCT02550444|Experimental|Intrathecal Clonidine|Intrathecal Adjuvant Clonidine 75 mcg; Intravenous Placebo (Saline 0,9%); Intrathecal heavy Bupivacaine 0,5% (15mg), morphine 0,02 (80mcg) and fentanyl (10mcg).
89204655|NCT02550444|Experimental|Intravenous Clonidine|Intravenous Clonidine 75 mcg; Intrathecal Placebo (Saline 0,9%); Intrathecal heavy Bupivacaine 0,5% (15mg), morphine 0,02 (80mcg) and fentanyl (10mcg).
89204656|NCT00665366|Placebo Comparator|Placebo + valproate or lithium|Participants randomly received placebo (1:1 to study drug) as adjunctive therapy to current ongoing treatment with valproate or lithium for 12 weeks.
89492136|NCT02112695|Experimental|sportswomen|3 micrograms [11C]diprenorphine
89492137|NCT02112695|Experimental|control subjects|3 micrgrams [11C]diprenorphine
89492138|NCT02251301|Active Comparator|Macronutrient isoenergetic control|Participants will also engage in twelve weeks of high intensity interval training with consumption of one serving (250 mL) of macro nutrient matched isoenergetic control (whey/casein protein and dextrose/lactose) consumed immediately and 1 h after each training session
89492139|NCT02251301|Experimental|Skim Milk|Participants will also engage in twelve weeks of High intensity interval training with consumption of one serving (250 mL) of fat-free fluid milk immediately and 1 h after each training session
89492140|NCT02251301|Placebo Comparator|Placebo|Participants will also engage in twelve weeks of high intensity interval training with consumption of one serving (250 mL) of placebo (water) consumed immediately and 1 h after each training session.
89492141|NCT02114801|Experimental|manual brushing|manual brushing; Oral-B®, Stages 4, Rio de Janeiro, Rio de Janeiro;
89492142|NCT02114801|Experimental|electric toothbrush linked|electric toothbrush linked; Braun - Oral-B®, D2010K, Rio de Janeiro, Rio de Janeiro
88953945|NCT01967329|Active Comparator|Quadruple, treatment naive|"Quadruple Thearpy for H. pylori:~Oral doses of rabeprazole (20 mg) twice daily, metronidazole (500 mg) three times daily, bismuth subsalicylate (Pepto-Bismol) (2 tablets) four times daily and tetracycline (500 mg) four times daily~One of two treatments randomly assigned to treatment naive participants in Old Crow, Tuktoyaktuk & Fort McPherson"
88953946|NCT01967329|Active Comparator|Sequential, previous failure(s)|"Sequential Therapy for H. pylori:~Oral twice-daily doses of rabeprazole (20 mg) and amoxicillin (1 g) on days 1-5, and on days 6-10, rabeprazole (20 mg), metronidazole (500 mg) and clarithromycin (500 mg)~One of two treatments randomly assigned to participants who previously failed one or more treatments in Aklavik, Old Crow, Tuktoyaktuk & Fort McPherson"
88953947|NCT01967329|Active Comparator|Quadruple, previous failure(s)|"Quadruple Therapy for H. pylori:~Oral doses of rabeprazole (20 mg) twice daily, metronidazole (500 mg) three times daily, bismuth subsalicylate (Pepto-Bismol) (2 tablets) four times daily and tetracycline (500 mg) four times daily~One of two treatments randomly assigned to participants who previously failed treatment in Aklavik, Old Crow, Tuktoyaktuk & Fort McPherson"
89022097|NCT04699344||Non-cancer participants|Patients being treated for other diseases but without any tumor will provide a negative control to provide data for determining the sensitivity and specificity of PROUD analysis.
89492143|NCT02114801|Experimental|off electric toothbrush|off electric toothbrush; Braun - Oral-B®, D2010K, Rio de Janeiro, Rio de Janeiro
89492144|NCT04834856|Experimental|ensovibep dose 1|
89492145|NCT04834856|Experimental|ensovibep dose 2|
89492146|NCT04823546|Experimental|Activity based therapy|"Activity based training was done in 2 phases. exercise involve~Standing and reaching~Sit-to-stand~Stepping forward and backward Phase 2 Phase 2 started after 3 weeks. Phase 2 included the phase 1 exercise along with below exercise.~(10) Walking on a treadmill;"
89492147|NCT04823546|Active Comparator|strength training|Strength training for hip • flexor and extensors and abductors, knee extensors, and ankle dorsi flexors and plantar •flexors. Apart from using body weight, sandbag weights and Therabands of eight different resistances
89492148|NCT04361162|Experimental|Nivolumab + Ipilimumab + Radiation|"The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits, (Study cycles are 6 weeks.)~Nivolumab via iv, at predetermined dose every 2 weeks for duration of study.~Ipilimumab via iv at a predetermined dose on day 1 of 4 study cycles.~Radiation treatments will be administered every other weekday or 2 days during week 1 of cycle 1."
89492149|NCT03036878|Experimental|ReNu Injection|Injection of ReNu allograft into the joint capsule.
89492150|NCT04834934||COVID-19 first wave patients|1700 patients retrospectively enrolled in 15 Italian hospitals from 16/2/2020 to 29/4/2020.
89492151|NCT04834934||COVID-19 second wave patients|300 patients prospectively enrolled in IRCCS San Raffaele Hospital from 19/10/2020 to 31/12/2020.
89492152|NCT04835012||Treatment|"Subjects in this treatment group had their medical debt forgiven by a non-profit charity, RIP Medical Debt. This protocol will administer a survey to measure subjects' health care utilization, mental health, and subjective well-being."
89492153|NCT04835012||Control|"No intervention was given to subjects in this control group. This protocol will administer a survey to measure subjects' health care utilization, mental health, and subjective well-being."
89492154|NCT04823390|Other|Anesthetist controlled group|15 patients undergoing cataract surgery will receive sedation given by the anesthetist together with local anesthesia according to the depth of sedation in the form of intravenous Midazolam and Fentanyl.
89492155|NCT04823390|Other|Patient-controlled group|15 patients undergoing cataract surgery under local anesthesia will administer sedation to themselves through a pump.
89492156|NCT02302066|Experimental|Group 1 (TDV 2-Dose)|Takeda's tetravalent dengue vaccine candidate (TDV), 0.5 mL, subcutaneous injection on Days 1 and 91. Placebo-matching vaccine, 0.5 mL, subcutaneous injection on Day 365.
89492157|NCT02302066|Experimental|Group 2 (TDV 1-Dose)|Takeda's tetravalent dengue vaccine candidate (TDV), 0.5 mL, subcutaneous injection on Day 1. Placebo-matching vaccine, 0.5 mL, subcutaneous injection on Days 91 and 365.
89492158|NCT02302066|Experimental|Group 3 (TDV 1-Dose + Booster)|Takeda's tetravalent dengue vaccine candidate (TDV), 0.5 mL, subcutaneous injection on Days 1 and 365. Placebo-matching vaccine, 0.5 mL, subcutaneous injection on Day 91.
89492159|NCT02302066|Placebo Comparator|Group 4 (Placebo Control)|Placebo-matching vaccine, 0.5 mL, subcutaneous injection on Days 1, 91 and 365.
89492160|NCT04834700|No Intervention|hands-on group|The doctors who participated in the study will be educated ocular ultrasound scanning method by hands-on about 20 minutes, and perform ocular ultrasound scans on two standard patients.
89492161|NCT04834700|Other|online group|The doctors who participated in the study will be educated ocular ultrasound scanning method by online lecture about 20 minutes, and perform ocular ultrasound scans on two standard patients.
89492162|NCT04834544|Experimental|DCVAC/OvCa arm|
89492163|NCT04834544|Placebo Comparator|Placebo arm|
89492164|NCT04823000|Experimental|Repeated MSCs treatment in MS patients|Treatment with intrathecal and intravenous injection of autologous MSC (1 million cells per Kg of body weight)
89492165|NCT04823312|Experimental|Medtronic Duo Extended Set|These subjects will be using 4 Duo Extended sets that will serve as an exploratory pilot study to assess the 7-day survival of the Duo Extended set.
89492166|NCT04823078|Active Comparator|Activity base therapy|
89492167|NCT04823078|Other|Strength training|
89492168|NCT04822922|Experimental|low dose|hUC-MSCs 4*10^5/kg/each time
89492169|NCT04822922|Experimental|middle dose|hUC-MSCs 8*10^5/kg/each time
89492170|NCT04822922|Experimental|high dose|hUC-MSCs 12*10^5/kg/each time
89492171|NCT04826510|Active Comparator|Lithium carbonate group|Lithium carbonate treatment, stable blood lithium concentration 0.5-1.2 mmol / L, course of 8 weeks.
89492172|NCT04826510|Experimental|Perospirone hydrochloride group|The dosage of perospirone hydrochloride tablets was 16-36 mg / D for 8 weeks.
89492173|NCT04826510|Experimental|Lithium carbonate + perospirone hydrochloride group|The stable blood lithium concentration was 0.5-1.2 mmol / L, and the dose of perospirone hydrochloride tablets was 16-36 mg / D for 8 weeks.
89492174|NCT05618288|Active Comparator|Standard of Care|Standard of care breastfeeding counseling. The ongoing antenatal, delivery and postnatal breastfeeding and lactation counseling that is provided by the Naivasha sub-County Referral Hospital.
89492175|NCT05618288|Experimental|mobile Health (mHealth)|Simple messaging service counseling intervention with healthcare providers. This arm will involve two-way messaging with healthcare providers Unstructured Supplementary Service Data application that provides session-based interaction with breastfeeding and lactation support content.
89492176|NCT04833998|Placebo Comparator|Placebo|Placebo will be cream without the active ingredient. It will be matched in appearance, smell, consistency, and color to Extremecare topical cream. Patients will be instructed to apply the placebo cream to the hand and feet.
89492177|NCT04833998|Experimental|Extremecare|Extremecare is a moisturizing cream based on Thoitaine, Aloe Vera and Calendula for topical use. Patients will be instructed to apply the moisturizing cream to the hand and feet.
89492178|NCT03036800|Experimental|Targeted Prescribing Pathway (LIRA 3mg + Standard Care)|Standard care plus targeted use of the intervention Liraglutide (LIRA) 3mg when pre-specified stopping rules for the medication apply
89492179|NCT03036800|Active Comparator|Standard Care|standard Tier 3 obesity specialist service care
89492180|NCT02301988|Experimental|Ipatasertib + Paclitaxel|Participants will receive ipatasertib orally daily on Days 1-21 of each 28-day cycle for 3 cycles and paclitaxel intravenous (IV) infusion every week (QW) for 3 cycles (12 total doses).
89492181|NCT02301988|Placebo Comparator|Placebo + Paclitaxel|Participants will receive placebo (matching to ipatasertib) orally daily on Days 1-21 of each 28-day cycle for 3 cycles and paclitaxel IV infusion QW for 3 cycles (12 total doses).
89492182|NCT02114957|Experimental|study herb|
89492183|NCT04326920|Active Comparator|Active sargramostim treatment group|Inhaled sargramostim 125mcg twice daily for 5 days on top of standard of care. Upon progression to ARDS and initiation of mechanical ventilator support within the 5 day period, inhaled sargramostim will be replaced by intravenous sargramostim 125mcg/m2 body surface area once daily until the 5 day period is reached. From day 6 onwards, progressive patients in the active group will have the option to receive an additional 5 days of IV sargramostim, based on the treating physician's assessment
89492184|NCT04326920|Placebo Comparator|Control group|standard of care. Subjects progressing to ARDS and requiring invasive mechanical ventilatory support, from day 6 onwards, will have the option (clinician's decision) to initiate IV sargramostim 125mcg/m2 body surface area once daily for 5 days
89492185|NCT02112851|Placebo Comparator|Orange flavored beverage|240ml orange beverage
89492186|NCT02112851|Experimental|Orange flavored beverage - Test1|240ml processed whole orange low dose
89492187|NCT02112851|Experimental|Orange flavored beverage - Test2|240ml processed whole orange high dose
89492188|NCT05369884|Experimental|Experimental group|Oral administration of WPQW granule with warm water，2 sachets each time, 3 times a day, 1.5-2 hours after a meal. The medication period was 4 weeks.
89492189|NCT05369884|Placebo Comparator|Control group|Oral administration of WPQW granule simulant，which containing 5% WPQW granule，with warm water，2 sachets each time, 3 times a day, 1.5-2 hours after a meal. The medication period was 4 weeks.
89492190|NCT02118779|Experimental|Behavioural change intervention|Cognitive behavioural therapy (CBT) combined with exercise
89492191|NCT02118779|No Intervention|Standard Patient Management|Standard care like usual (i.e. annual checks with neurologist, checks with cardiologist, if needed physical therapy)
89492192|NCT04825808||Patients|Consecutive elderly (≥55 years) patients, recruited and registered in the stroke database of two centres (Nîmes University Hospital and Montpellier University Hospital, France), presenting with cSAH with suspected, possible, or probable CAA.
89492193|NCT02112929|Experimental|Inhalation of hyperpolarized xenon|One litre of hyperpolarized xenon to be inhaled during MRI scan of the lungs
89492194|NCT04826120|Active Comparator|PCEA group|Patients of this group had intermittent epidural analgesia via PCEA associated to systematic 8 ml boluses every 60 min during the second stage of labor.
89492195|NCT04826120|Experimental|CEI Group|Patients of this group had continuous epidural infusion at the rate of 8 ml/h during the second stage of labor.
89492196|NCT02334748|Experimental|canakinumab|Patients will continue the same dose as their last dose administered in the study CACZ885G2301E1, CACZ885N2301 or CACZ885G2306. For all indications, the maximum canakinumab dose is 4 mg/kg or 300 mg for patients ≥ 40 kg. Ilaris® dosage may be adjusted (or interrupted) according to the clinical response and to investigators judgment.
89492197|NCT03553355|Experimental|Infrared Laser Moxibustion Therapy|Each patient will receive this treatment twice per week for six weeks (12 sessions total).
89492198|NCT03553355|Sham Comparator|Sham Infrared Laser Moxibustion Therapy|The patients will receive treatment from sham laser moxibustion instrument.
89492199|NCT03553355|No Intervention|Waitlist Controls|The patients maintain their usual treatment and self-care,
89492200|NCT04825418|Experimental|Therapeutic Hypothermia Group|Therapeutic hypothermia using surface cooling device (Arctic Sun) Decompressive Hemicraniectomy care based on international guidelines except therapeutic hypothermia using surface cooling device.
89492201|NCT04308122|Active Comparator|Cervical Orthosis (CO)|Cervical orthosis will be worn at all times for 6 weeks according the standard of care after posterior cervical fusion
89492202|NCT04308122|Experimental|No Orthosis (NO)|No cervical orthosis will be worn after posterior cervical fusion
89492203|NCT02118857||Omnivore, vegetarian and vegan subjects.|These subjecs followed the diet from at least two years.
89492204|NCT02118935|Active Comparator|Previously marketed cow's milk-based infant formula|
89492205|NCT02118935|Experimental|Marketed cow's milk-based infant formula with prebiotics|
89492206|NCT04822532|Experimental|Pharmacogenetic based-model (GSTA1)|
89492207|NCT04822532|Active Comparator|The most performing method based on age and weight - McCune's model|
89492208|NCT02113085|Experimental|Self-determination enhancement|Self-determination enhancement through one-on-one coaching and mentoring workshops
89492209|NCT02119013|Experimental|OCTEOTRIDE|Octeotride, 20 mg monthly intramuscular injection for 3 years
89492210|NCT02119013|Placebo Comparator|PLACEBO|Placebo (salin soluction), intramuscular injection monthly for 3 years
89492211|NCT02119091|Experimental|Moxifloxacin|Single oral dose 400 mg
89492212|NCT02119091|Placebo Comparator|Placebo|Single oral dose
89492213|NCT02332876|Experimental|Exercise Intervention|This arm will receive a 12-week individually tailored phone and email-based exercise program.
89492214|NCT02332876|Active Comparator|Wellness Waitlist Control|This arm will receive emails on the same schedule as the exercise arm, that cover a variety of health and wellness topics. At the end of the 12 weeks, participants will be able to start the exercise program.
89492215|NCT05618600||Paxlovid Cohort|Participants will be separated into 2 arms that are self-selected through the decision to opt in or out of Paxlovid. After patients are offered a 5-day course of Paxlovid and have made a treatment decision they will be eligible to join the study. Arm 1 will include 400 participants that opt to take the 5-day course of Paxlovid. Participation will look identical in this study.
89492216|NCT05618600||Control Cohort|Participants will be separated into 2 arms that are self-selected through the decision to opt in or out of Paxlovid. After patients are offered a 5-day course of Paxlovid and have made a treatment decision they will be eligible to join the study. Arm 2, control, will include 400 participants that opt out of taking the 5-day course of Paxlovid. Participation will look identical in this study.
89492217|NCT02115035|Experimental|Vermurafenib|Vermurafenib dosing will be given twice daily by oral administration in cycles of 28 days
89492218|NCT05618522|Other|the lens loaded with Omnigen|patients with acute chemical eye injury treated with omnigen
89492219|NCT02119169|Experimental|pigtail catheter|Pigtail catheter for pleural drainage of recurrent hepatic hydrothorax
89492220|NCT03037034|Experimental|Forcep Strip Method Treatment|patients who have Gastrointestinal Subepithelial Tumors Originating from the Muscularis Propria are enrolled
89492221|NCT03036722|Experimental|Flaxseed porridge group|22 volunteer will be given 80g of a pre prepared porridge meal containing 40 g of ground (flaxseed) to consume daily.
89492222|NCT03036722|Placebo Comparator|Placebo control porridge group|22 volunteer will be given 78.5g preprepared control porridge matched for energy and fat content to consume daily ( Matching food products: 22g MCT (medium chain Triglyceride), 5.5g pure egg white powder, 11g cream of rice).
89492223|NCT02113319|Experimental|dasatinib|
89492224|NCT03036332|Experimental|intervention|Aerobic interval training
89492225|NCT03036332|No Intervention|Control group|The participants performed only initial evaluation and at the end of the study
89492226|NCT04822454|Experimental|Night shift shadowing program|Medical students who participated in a night shift shadowing program prior to their first official night shifts
89492227|NCT04822454|No Intervention|No night shift shadowing program|Medical students who did not participate in the night shift shadowing program prior to their first official night shifts
89492228|NCT02119247|Experimental|CHF6001 dry powder for inhalation via NEXThaler®|4 inhalations of CHF 6001 NEXThaler®
89492229|NCT02119247|Active Comparator|CHF 6001 DPI capsules for inhalation via Aerolizer|3 inhalations of CHF 6001 capsules via Aerolizer®
89492230|NCT04822844|Experimental|Aromatherapy with Essential Oil|Within 5 minutes of arrival at the PACU, the PACU nurse will proactively offer the patient a 2x2 gauze with two drops of essential oil (patient's choice of ginger or lavender essential oil) for all patients who have opted to participate, regardless of their nausea and vomiting status. Participating patients will continue to use the essential oil during their stay in the PACU, which is typically 45-60 minutes.
89492231|NCT02113397||Continuous Therapy|TOBI™ Podhaler™ 112 mg inhaled by mouth twice daily for 30 days followed by a 30-day cycle colistimethate 75 mg inhaled two times daily. Repeat cycle.
89492232|NCT02113397||Cyclic therapy|TOBI™ Podhaler™ 112 mg inhaled by mouth twice daily for 30 days followed by a 30-day period during which no inhaled antibiotics are used. Repeat cycle.
89492233|NCT02332798|Experimental|PF-04958242 0.25 mg|All participants who received PF-04958242 0.25 milligram (mg) twice daily (BID) for 14 consecutive days with the last dose occurring in the morning on Day 14.
89492234|NCT02332798|Experimental|PF-04958242 0.475 mg|All participants who received PF-04958242 0.475 mg BID for 14 consecutive days with the last dose occurring in the morning on Day 14.
89492235|NCT02332798|Placebo Comparator|Matching Placebo|All participants who received placebo BID for 14 consecutive days with the last dose occurring in the morning on Day 14.
89492236|NCT04833920|Active Comparator|active tDCS|tDCS targeting the primary motor cortex of the contralateral side of the painful side for 20 minute duration for five sessions in five consecutive days
89492237|NCT04833920|Sham Comparator|sham tDCS|tDCS over the primary motor cortex in the same stimulation parameters will be used but the device will be turned off without patient knowledge after 30 seconds
89492238|NCT04428242||Group 1|Subjects with normal macular thickness in one or both eyes.
89492239|NCT04428242||Group 2|Subjects with center-involving macular edema due to w/AMD in one or both eyes.
89492240|NCT04428242||Group 3|Subjects with center-involving macular edema due to DR or RVO in one or both eyes.
89492241|NCT02790437|Experimental|Treatment IdeS|IdeS intravenous infusion
89492242|NCT03553433|Experimental|Verum|Apremilast 30mg bd
89492243|NCT03553433|Placebo Comparator|Placebo Oral Tablet|Excipiens
89538005|NCT03118141|Active Comparator|PGS group|Subjects in the PGS group will have blastocyst biopsy and sequencing done with 3 good-quality embryos on Day 5. Principle of freeze-all and single thawed blastocyst transfer will be applied. The transfer order of euploid embryos will be determined by blastocyst morphologic score. The outcome of all euploids transfers within 1 year after randomization will be followed up. During study, every subject will have at most one live birth.
89538006|NCT03118141|Active Comparator|IVF group|Subjects in the IVF group will also comply with the principle of freeze-all and single thawed blastocyst transfer. The order of transfer will be determined by blastocyst morphologic score. The outcome of up to 3 transfers within 1 year after randomization will be followed up. During study, every subject will have at most one live birth.
89538007|NCT03292445|Experimental|Immune tolerance after kidney transplant|Immune tolerance after kidney transplant will be induced by transfusion of enriched donor blood stem cells and T cells to initiate blood cell mixed chimerism in patients conditioned with total lymphoid irradiation and rabbit anti-thymocyte globulin after kidney transplant. Patients will receive corticosteroids for 14 weeks with gradual dose reduction. They will also receive 12 months of mycophenolate mofetil and 18 months of tacrolimus with dose tapering beginning 9 months post-transplant and continuing as long as mixed chimerism is maintained and there is no evidence of graft versus host disease and no kidney rejection evident. Patients losing chimerism will continue on low dose immunosuppressive drug doses unless additional kidney rejection therapy is needed.
89538008|NCT02449057|Experimental|JUST|Juveniles Under Supervision and Treatment. This entails swift, certain, and modest sanctions for violations of terms of community supervision.
89538009|NCT02449057|No Intervention|Probation-as-Usual|Juvenile probation-as-usual.
89538010|NCT03196141|Active Comparator|Healthy volunteers|"Part#1: 15 healthy volunteers; 2 assessment sessions. Session 1: StO2 vs. EndoPAT Method comparison analysis; both StO2 and EndoPAT will be applied simultaneously & pulse oximeter probes placed bilaterally on fingers. Baseline readings will be taken for 5 minutes. The blood pressure cuff will be inflated to suprasystolic pressure and StO2 and pulsatile volume changes will be measured by peripheral arterial tonometry, continuous measurement for 3 min and repeated every 10 minutes for 3 sessions.~Session 2: This session will occur within 1 week of session 1. This session is to determine the consistency of the response.~All probes will be applied as in session 1 and cycles of 10 minutes for 3 sessions will be done. All the measurements in session 1 will be captured in session 2.~This will determine inter-day variability. (total time is 53 min)."
89204657|NCT00665366|Active Comparator|Aripiprazole + valproate or lithium|Participants randomly received aripiprazole as adjunctive therapy to current ongoing treatment with valproate or lithium for 12 weeks. Aripiprazole was provided in 5-, 10-, or 15-mg oral tablets and administered at a starting dose of 5 mg per day for Week 1. For Weeks 2 through 3, the dose was titrated up to 10 mg per day, and for Weeks 4 through 6, the dose increased to 15 mg per day. Flexible doses of either 15 or 30 mg per day were administered for Weeks 7 through 12. If participants were unable to tolerate the dose of 15 mg per day of study drug, the dose was decreased to 10 mg per day for Weeks 7 through 12.
88953948|NCT01967329|Active Comparator|Sequential, clarithromycin-resistant|"Sequential Therapy for H. pylori:~Oral twice-daily doses of rabeprazole (20 mg) and amoxicillin (1 g) on days 1-5, and on days 6-10, rabeprazole (20 mg), metronidazole (500 mg) and clarithromycin (500 mg)~One of two treatments randomly assigned to participants with known clarithromycin resistance in Aklavik"
88953949|NCT01967329|Active Comparator|Quadruple, clarithromycin-resistant|"Quadruple Therapy for H. pylori:~Oral doses of rabeprazole (20 mg) twice daily, metronidazole (500 mg) three times daily, bismuth subsalicylate (Pepto-Bismol) (2 tablets) four times daily and tetracycline (500 mg) four times daily~One of two treatments randomly assigned to participants with known clarithromycin resistance in Aklavik"
88953950|NCT01967355|Experimental|Lipid apheresis|Lipid apheresis: lipid removing therapy,frequency and duration depending on the symptoms of mother and fetus.
88953951|NCT01967368|Experimental|Intanza|intradermal injection (15ug hemagglutinin 2013/2014 trivalent influenza vaccine) delivered with the Intanza, single dose injection
88953952|NCT01967368|Active Comparator|Vaxigrip|intramuscular injection (15ug hemagglutinin 2013/2014 trivalent influenza vaccine) delivered with the Vaxigrip, single dose injection
88953953|NCT01967381|Placebo Comparator|Arm 1|Subjects will be maintained on oral placebo.
88953954|NCT01967381|Experimental|Arm 2|Subjects will be maintained on oral oxazepam (Serax®).
88953955|NCT01967381|Experimental|Arm 3|Subjects will be maintained on oral naltrexone (Revia®).
88953956|NCT01967381|Experimental|Arm 4|Subjects will be maintained on oral naltrexone (Revia®) and oral oxazepam (Serax®).
88953957|NCT01967394|Experimental|Intervention County|Use of internet based social marketing intervention
88953958|NCT01967394|Placebo Comparator|Control County|No use of social media
88953959|NCT01967407|Experimental|renal tumor <4cm, suspected RCC|Intervention/ Time point: Irreversible Electroporation at day 0 of each patient.
89492244|NCT02115425||Age 10-17|Participants age 5 - 17 will complete the following Body Measurements Body Composition and Circumference Measurements Whole Body DXA Scan Bioelectrical Impedance Analysis (BIA)
89492245|NCT02115425||Age 18-80|Age 18-80 years Participants age 18-80 will complete the following Body Measurements Body Composition and Circumference Measurements Whole Body DXA Scan Bioelectrical Impedance Analysis (BIA)
89492246|NCT03553277|Experimental|Transfluthrin|transfluthrin
89492247|NCT03553277|Placebo Comparator|Placebo|inert ingredients
89492248|NCT02119403|Experimental|Hand Held NitrousTM|There are no other interventions to this device
89492249|NCT02119481|Experimental|Mindfulness-based stress reduction|Mindfulness-based stress reduction training
89492250|NCT02119481|Active Comparator|Expressive writing condition|Expressive writing
89492251|NCT02119481|No Intervention|Waiting-list control condition|Waiting list
89492252|NCT02119559|Other|CTC assay, Cetuximab|Detection & characterization of viable CTC in the peripheral blood.
89492253|NCT02604212|Placebo Comparator|Placebo Low Dose Comparator|Placebo (low dose comparator) once every 4 weeks for 4 doses, plus entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg/day)
89492254|NCT02604212|Placebo Comparator|Placebo High Dose Comparator|Placebo (high dose comparator) once every 4 weeks for 4 doses, plus entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg/day)
89492255|NCT02604212|Experimental|ARC-520 1.0 mg/kg|Low dose (1.0 mg/kg) ARC-520 once every 4 weeks for 4 doses, plus entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg/day)
88953960|NCT01967420|Experimental|Cognitive remediation plus social cognition training|A combined intervention of 60 minutes of computerised cognitive remediation and 30 minutes of computerised social cognition training.
88953961|NCT01967420|Active Comparator|Cognitive remediation alone|An active control condition consisting of 60 minutes of computerised cognitive remediation and 30 minutes of free computer time.
89492256|NCT02604212|Experimental|ARC-520 2.0 mg/kg|High dose (2.0 mg/kg) ARC-520 once every 4 weeks for 4 doses, plus entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg/day)
89492257|NCT02115659|Placebo Comparator|Placebo|Placebo plus standard treatment. Anti-hypertension drug(s) for hypertension; Antibiotics for cyst infections; cause oriented treatment for flank pain.
89492258|NCT02115659|Experimental|Triptolide-Containing Formulation|Triptolide-Containing Formulation (1mg/kg/d) was prescribed; Dosage will be adjusted if necessary according to the adverse events monitoring.
89492259|NCT02113631|Active Comparator|Telaprevir|Telapravir was administer with Peg-IFN and Ribavirin as per package insert Dose Telaprevir : PO, tablet 1125 mg BID for 12 weeks
89492260|NCT02113631|Active Comparator|Boceprevir|Boceprevir was administer with Peg-IFN and Ribavirin as per package insert Dose Boceprevir PO capsule, 800mg TID for up to 44 weeks
89492261|NCT02119637||Study 1 TMS to S1|Cohort of healthy participants received screening, brain MRI, TMS to S1 and vertex, and somatosensory testing, including 2-point discrimination and gentle brushing.
88953962|NCT01967459|Active Comparator|High dose vitamin D|Volunteers assigned to this arm will receive a single dose of oral cholecalciferol 300 000 IU, in the form of 3 ml D-cura drink 100 000 IU/ml
89204658|NCT00992368|Active Comparator|reduction mammaplasty|submitted to surgery
89204659|NCT00992368|No Intervention|not reduction mammaplasty|not submitted to surgery
89204660|NCT01141738|Experimental|Caregiver Problem-Solving Intervention (CPSI)|The experimental treatment will provide structured information, guided problem-solving, and training in skills for coping with stress and emotional responses (e.g., relaxation, cognitive reframing, changing negative problem orientation, problem-solving (PS) skills).
89204661|NCT01141738|Active Comparator|Wait List Control (WLC)|WLC subjects will be offered an intervention after the 6 month assessment. Both groups will receive standard services provided by the rehabilitation team to caregivers (CGs) of stroke survivors.
89204662|NCT00775684|Experimental|Exenatide|Exenatide (Byetta®)-5 µg injected subcutaneously twice daily and increased after 1 month to 10 µg twice daily as tolerated by gastrointestinal effects
89204663|NCT00775684|Experimental|Sitagliptin|Sitagliptin (Januvia®)-100 mg by mouth every morning
89204664|NCT00775684|Active Comparator|Glimepiride|Glimepiride (Amaryl®)-0.5 mg by mouth every morning and then increased by 0.5 - 1.0 mg at each monthly visit to achieve an average fasting glucose < 110mg/dl
89204665|NCT04001218|Experimental|Painful condition|Participants will be injected with 0.5ml hypertonic saline (5.8%) into a neck muscle
89204666|NCT04001218|Experimental|Control condition|Participants will be injected with 0.5ml Isotonic saline (0.9%) into a neck muscle
89204667|NCT00992524|Active Comparator|Oral Titrated Misoprostol Solution|
89204668|NCT00992524|Active Comparator|Vaginal Misoprostol|
89204669|NCT00785096||Patients|Patients who admit for a minor or major surgical intervention
89204670|NCT00785096||Nurses|Medical staff of the University Hospital of Zurich
89204671|NCT00785096||Physicians|Medical staff of the University Hospital of Zurich and other institutions
89204672|NCT00998842||healthy subjects|five male, five female, ages 18-64
89204673|NCT00781040||Neutropenic patients|Adult AML and ASCT patients with neutropenic fever.
89204674|NCT00995254|No Intervention|Control group|Control group will ONLY receive SHI after completion of the study
89204675|NCT00995254|Experimental|Intervention group|Intervention group will receive smoking hygiene intervention (SHI) at three individualized contacts.
89204676|NCT00785174|Active Comparator|continuous positive airway pressure|respiratory assistance
89204677|NCT00785174|Active Comparator|NIPSV|respiratory assistance using face mak and ventilator to provide inspiratory pressure support and positive end expiratory pressure
89204678|NCT00992680|Experimental|Group A|Anastomotic Coupler System + standard of care per GOLD
89204679|NCT00992680|No Intervention|Group B|Standard of care per GOLD alone
89204680|NCT00642018|Active Comparator|A: Docetaxel|Standard of care (SOC) docetaxel 75 mg/m² intravenously every 3 weeks and prednisone 5 mg orally twice daily continuously while receiving docetaxel therapy
89492262|NCT02119637||Study 2 TMS targeting S2/insula|Cohort of healthy participants received screening, brain MRI before and after TMS, TMS to S2/insula and vertex, and somatosensory testing, including 2-point discrimination and gentle brushing.
88953963|NCT01967459|Active Comparator|Low dose vitamin D|Volunteers assigned to this arm will receive a single dose of oral cholecalciferol 75000 IU, in the form of 3 ml D-cura drink 25 000 IU/ml
89204681|NCT00642018|Experimental|B: LY2181308 + Docetaxel|LY2181308 administered with docetaxel 75 mg/m² intravenously every 3 weeks and prednisone 5 mg orally twice daily continuously while receiving docetaxel
89204682|NCT00532948|Experimental|1|
89204683|NCT00998920|Experimental|10mg BID|S-equol capsule, oral, single dose
89204684|NCT00998920|Experimental|20 mg BID|
89204685|NCT00998920|Experimental|40mg BID|
89204686|NCT00998920|Experimental|80 mg BID|
89204687|NCT00998920|Experimental|160 mg BID|
89204688|NCT00998920|Placebo Comparator|Placebo|
89204689|NCT00998998|Experimental|1|6 or 12 month old infants with iron deficiency anemia assigned to receive home stimulation program via weekly home visits over 1 year
89204690|NCT00998998|Active Comparator|2|6 or 12 month old infants with iron deficiency anemia assigned to surveillance (weekly visits to monitor health and iron supplement) over 1 year
89492263|NCT04428320|Experimental|Bupivicaine pelvic floor muscle injection|Five injections at pre-specified locations at pelvic floor muscle bilaterally after induction of general anesthesia for vaginal pelvic prolapse surgery
89492264|NCT04428320|No Intervention|Standard of care (no injection) preoperatively|No injection - standard analgesia
88953964|NCT01967472|Active Comparator|co-formulated Amodiaquine-Artesunate|"Sanofi Coarsucam Infant dose (2-12 months/4.5-8kg), amodiaquine:67.5mg/artesunate 25mg; 1 tablet once a day for 3 days.~Sanofi Coarsucam Young Child (13-59 months/9-17kg), amodiaquine: 136mg/artesunate 50mg; 1 tablet once a day for 3 days."
89204691|NCT00998998|Experimental|3|Nonanemic infants identified at 6 or 12 months assigned to receive home stimulation program via weekly home visits over 1 year
89204692|NCT00998998|Active Comparator|4|Nonanemic infants identified at 6 and 12 months assigned to surveillance (weekly visits to monitor health) over 1 year
89204693|NCT00999076||Sputum with positive AFB smear|
89204694|NCT00992758|Experimental|Treatment, Non-Randomized, Open Label|Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
88953965|NCT01967472|Active Comparator|artemether-lumefantrine|"Novartis coartem infant dose (2-11 months/5-14kg), artemether 20mg/lumefantrine 120mg; 1 tablet twice a day for 3 days.~Novartis coartem child dose (12-59 months/15-24kg), artemether 20mg/lumefantrine 120mg; 2 tablets twice a day for 3 days"
88953966|NCT01967485|Experimental|Text Messaging|Text messaging to the parents of children. Children will receive open treatment for Attention Deficit/Hyperactivity Disorder (ADHD) with stimulant medication.
89204695|NCT00641706|Experimental|Stratum 1 (not undergoing surgery)|Patients receive oral vorinostat (SAHA) once daily on days 1-14 and bortezomib IV on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89492265|NCT02122991||Able-Bodied Controls|Subjects must be between the ages of 30 and 64 years old, be English-literate and able to provide informed consent. They must score at least 20/60 minimum acuity in their worst eye on the Snell Eye Exam, and score at least 22 on the Montreal Cognitive Assessment. Subjects MUST NOT HAVE: an acute illness or infection, history of stroke, recent illicit drug abuse (<6 months), unstable/uncontrolled seizures, neurodegenerative disease, Severe Traumatic Brain Injury (as determined by TBI screening tool), any significant history of neurological disease/disorder, any significant systemic illness or unstable medical condition (uncontrolled diabetes, hypo- or hyperthyroidism, systemic cancer), history of schizophrenia or bipolar disorder or any active psychosis, or alcohol/substance abuse or dependence (<6 months).
89492266|NCT02122991||Spinal Cord Injury|Subjects must be between the age of 30 and 64 years old, be English-literate and able to provide informed consent. They must be at least 1 year from the date of their spinal cord injury. They must score at least 20/60 minimum acuity in their worst eye on the Snell Eye Exam, and score at least 22 on the Montreal Cognitive Assessment. Subjects MUST NOT HAVE: an acute illness or infection, history of stroke, recent illicit drug abuse (<6 months), unstable/uncontrolled seizures, neurodegenerative disease, Severe Traumatic Brain Injury (as determined by TBI screening tool), any significant history of neurological disease/disorder, any significant systemic illness or unstable medical condition (uncontrolled diabetes, hypo- or hyperthyroidism, systemic cancer), history of schizophrenia or bipolar disorder or any active psychosis, or alcohol/substance abuse or dependence (<6 months).
89492267|NCT02123069||Women with uterine fibroids|"Brachial artery catheter~Acetylcholine~Nitroprusside~Norepinephrine~Nitroprusside and phenylephrine"
89492268|NCT02123069||Women without uterine fibroids|"Brachial artery catheter~Acetylcholine~Nitroprusside~Norepinephrine~Nitroprusside and phenylephrine"
89492269|NCT02115737|Experimental|Dialectical Behavior Therapy Skills Group|Twelve week skills based group therapy include four modules: mindfulness, emotion regulation, distress tolerance, and walking the middle path
89492270|NCT02115737|Experimental|Psychoeducation group treatment|The comparison group used in the present study is based on a publicly available treatment manual from the Services for Teens At Risk (STAR) Center at the University of Pittsburgh
89492271|NCT02115893|Active Comparator|Sodium Nitrate|Dietary Supplement: Sodium nitrate 800 mg of nitrate in sodium nitrate added with water to get a 140 mL solution (BASF, Ludwigshafen, Germany)
89492272|NCT02115893|Placebo Comparator|Sodium Cloride|Dietary Supplement: Sodium chloride 800 mg of sodium chloride added with water to get a 140 mL solution (Frisia Zout BV, Harlingen, The Netherlands)
89492273|NCT04807634|Other|Group A (control)|Group A (control): that will receive the traditional supportive treatment for acute antipsychotic drugs overdose
89492274|NCT04807634|Other|Group B (case)|that will receive the traditional supportive treatment for acute antipsychotic drugs overdose plus administration of 1.5 ml/kg ILE (20%) as a bolus over 1-2 minutes, followed by a continuous rate infusion of 0.25 ml/kg/min for the next 30 to 60 minutes
89492275|NCT04816370|Experimental|pSS group|primary Sjögren's syndrome group
89492276|NCT04816370|Experimental|Control Group|Control group
89492277|NCT04816370|Experimental|pSS Premenopausal|primary Sjögren's syndrome premenopausal patients
89492278|NCT04816370|Experimental|pSS Postmenopausal|primary Sjögren's syndrome postmenopausal patients
89492279|NCT02789111|Active Comparator|Alvimopan|12 mg alvimopan twice a day (either by mouth or by (NG) nasogastric tube) for up to seven days post-operatively, or until the time of discharge, whichever occurs first, to a maximum of 15 doses.
89492280|NCT02789111|Placebo Comparator|Placebo|Placebo twice a day (either by mouth or by (NG) nasogastric tube) for up to seven days post-operatively, or until the time of discharge, whichever occurs first, to a maximum of 15 doses.
89492281|NCT04807010|Active Comparator|Prostate artery embolization|
89492282|NCT04807010|Sham Comparator|Sham|
89492283|NCT02119715|Experimental|Pegylated rhG-CSF 100μg/kg|Chemotherapy naive patients receiving chemotherapy and Pegylated rhG-CSF（HHPG-19K） 100µg/kg in cycle 2 to 4
89492284|NCT02119715|Experimental|Pegylated rhG-CSF 150μg/kg|Chemotherapy naive patients receiving chemotherapy and Pegylated rhG-CSF（HHPG-19K)150 μg/kg in cycle 2 to 4
89492285|NCT02119715|Active Comparator|G-CSF 5 μg/kg/d|Chemotherapy naive patients receiving chemotherapy and rhG-CSF 5μg/kg/day in cycle 2 to 4
89492286|NCT04816292|Active Comparator|Hot Snare Polypectomy|If an eligible polyp 5-15 mm (as compared by the size of the snare) is found, according to the randomized group, HSP is performed for the removal of all eligible polyps in this patient. After polypectomy, the resection site is washed thoroughly with saline water. After the endoscopist carefully examines the resection site for residual adenomatous tissue, eventually another resection with the same method is indicated. Afterwards 2 biopsies (polyps 5-9mm) or 4 biopsies (polyps 10-15mm) are performed from the resection margin to reveal presence or absence of residual neoplastic tissue.
88953967|NCT01967485|Active Comparator|No Text Messaging|Children will receive open treatment for ADHD with stimulant medication. This group will not get the text messaging intervention, but will receive treatment as usual.
88953968|NCT01967498|Experimental|montelukast|this arm will receive montelukast as the active intervention of the study
88953969|NCT01967498|Placebo Comparator|placebo|
88953970|NCT01967524|Experimental|botulinum toxin A + ropivacaïne|
88953971|NCT01967524|Active Comparator|Ropivacaïne|
88953972|NCT01967589|Experimental|DC (dosing condition)|Escalation design.
88953973|NCT01967589|Experimental|Oral A|Escalation design. Planned end-dose is 5 mg.
89204696|NCT00641706|Experimental|Stratum 2 (undergoing surgery)|Patients receive oral SAHA once daily for 2 days prior to surgery and then on the day of surgery. Patients also receive bortezomib IV on the day of surgery. After receiving the 3rd dose of SAHA, patients undergo surgery to remove the tumor. Beginning at least 7 days after surgery, patients receive SAHA and bortezomib as in stratum 1.
88953974|NCT01967589|Experimental|Oral B|Escalation design. Planned end-dose is 10 mg.
88953975|NCT01967589|Experimental|Oral C|Escalation design. Planned end-dose is 20 mg.
88953976|NCT01967654|Experimental|Technical assistance, training, plus clinical reminder system|To assess the contextual factors of the intervention settings (district level policies and organizational level characteristics) that may influence tobacco use treatment in CHCs and to inform additional modifications to the proposed implementation strategies.
88953977|NCT01967654|Experimental|TTC + referral to community health workers|To compare the effectiveness and cost effectiveness of two multi component implementation strategies.
88953978|NCT01967667|Experimental|Liposomal glutathione|dose steps
88953979|NCT01967667|Placebo Comparator|Placebo|dose steps
88953980|NCT01967680|Active Comparator|Sedation with daily wake-up trial|The control group is sedated with continuous infusion to Ramsay score 3-4. During daytime, the patient is awakened as the intravenous infusion of sedatives is discontinued. After a successful wake-up, the infusion of sedative is resumed, starting on half of the pre-wake-up dose. If the patient becomes uncomfortable or agitated during the awakening, sedation is resumed, again starting with half the dosage. The infusion of sedatives is then adjusted to Ramsey score 3-4.
88953981|NCT01967680|Experimental|Non-sedation|"This group will not receive sedatives. Patients are thoroughly and repeatedly informed by the staff of where they are, what have happened, and what type of treatment they are going to receive.~Participants in the non-sedated group are awake and have a natural sleep rhythm. In case these patients develop and outward delirium, it is necessary to have a nurse or other caregiver at the bedside in order to calm the patient. Patients with delirium are treated with haloperidol according to the U.S. guidelines, 2002 and the Danish national guidelines.~If, despite these measures, it is necessary to sedate an agitated patient more than twice, or where sedation might be necessary to ensure sufficient oxygenation or prone position, the patient is sedated and treated like the control-group. Every day during the wake-up trial it is evaluated whether the patient is able to continue the intervention of non-sedation."
88953982|NCT01967745||laparoscopic appendectomy|The laparoscopic appendectomy was performed with three trocars, placed in the periumbilical area, right midabdomen, and forceps.
88953983|NCT01967745||open appendectomy|The open appendectomy was carried out in the standard way with McBurney muscle splitting incision (in supine position).
88953984|NCT01967758|Experimental|Cohort 1|Patients in Cohort 1 will receive ADU-623 at a dose of 3 x 10^7cfu by intravenous infusion (IV) over 2 hours on Day 0, Day 21, Day 42, and Day 63. Each dose is followed by a 3-day course or antibiotics. Patients will receive a 7-day course of antibiotics starting at the end of treatment visit.
88953985|NCT01967758|Experimental|Cohort 2|Patients in Cohort 2 will receive ADU-623 at a dose of 3 x 10^8cfu by intravenous infusion (IV) over 2 hours on Day 0, Day 21, Day 42, and Day 63. Each dose is followed by a 3-day course or antibiotics. Patients will receive a 7-day course of antibiotics starting at the end of treatment visit.
88953986|NCT01967758|Experimental|Cohort 3|Patients in Cohort 3 will receive ADU-623 at a dose of 3 x 10^9cfu by intravenous infusion (IV) over 2 hours on Day 0, Day 21, Day 42, and Day 63. Each dose is followed by a 3-day course or antibiotics. Patients will receive a 7-day course of antibiotics starting at the end of treatment visit.
88953987|NCT01967771|Experimental|DTG/CBZ|All subjects will be assigned to a single-sequence of three treatment periods without washout. Subjects will receive DTG 50 mg once daily (OD) for 5 days (Period 1), followed by CBZ 100 mg twice daily (BID) for 3 days (days 1-3 of Period 2), CBZ 200 mg BID for 3 days (days 4-6 of Period 2), CBZ 300mg BID for 10 days (days 7-16 of Period 2), followed by DTG 50 mg OD in combination with CBZ 300mg BID for 5 days (Period 3).
88953988|NCT01967797|Experimental|5As Team Intervention|The intervention group will participate in an additional 6 month intensive learning collaborative model designed around the 5As of obesity management, but which addresses areas identified as barriers (i.e. weight bias, clinical environment, clinic processes & team based care, mental health, counseling around emotional eating, caregiver fatigue, designing appropriate patient follow-up, and additional topics identified by the professionals). A clinical Champion identified by our partner SSPCN will be available to provide 1:1 support and coaching of the practitioners & teams as needed. The practitioners will work collaboratively to do their own needs assessment, and will identify additional resources or tools that they need to overcome the barriers to weight management in their setting. The research team will use a Practice Facilitation model to provide additional resource and support to the change process for the practitioners.
89204697|NCT00995332|Experimental|ATRA+valproc acid+low-dose cytarabine|
89204698|NCT00992914|Active Comparator|Lidocaine injection|Stellate Ganglion Injection with Lidocaine
89204699|NCT00992914|Placebo Comparator|saline injection|Superficial subcutaneous injection
89204700|NCT00999232|Experimental|Erythromycin|
88953989|NCT01967797|No Intervention|Control|Though the controls will have knowledge of the '5A's of Obesity Management', they will not be receiving 5As Team Intervention.
88953990|NCT01967823|Experimental|1/Cyclophosphamide & Fludarabine + Anti-ESO murine TCR transduced PBL + HD Aldesleukin|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + anti-ESO murine T-cell receptor (TCR) transduced PBL + high-dose (HD) aldesleukin
88953991|NCT01967875|Active Comparator|H-A: ERCC1 High Expression Group A|XP：Capecitabine+Cisplatin
88953992|NCT01967875|Experimental|H-B: ERCC1 High Expression Group B|DX：Docetaxel+Capecitabine
88953993|NCT01967875|Active Comparator|L: ERCC1 Low Expression Group|XP：Capecitabine+Cisplatin
89204701|NCT00999232|Placebo Comparator|Placebo|
89204702|NCT00999310||Klinefelter syndrome|
89204703|NCT00999310||Control men|
89204704|NCT00999310||Control women|
89492287|NCT04816292|Experimental|Cold Snare Polypectomy|If an eligible polyp 5-15 mm (as compared by the size of the snare) is found, according to the randomized group, CSP is performed for the removal of all eligible polyps in this patient. After polypectomy, the resection site is washed thoroughly with saline water. After the endoscopist carefully examines the resection site for residual adenomatous tissue, eventually another resection with the same method is indicated. Afterwards 2 biopsies (polyps 5-9mm) or 4 biopsies (polyps 10-15mm) are performed from the resection margin to reveal presence or absence of residual neoplastic tissue.
89492288|NCT02119793|Experimental|YVOIRE contour|
89492289|NCT04821518||The study group (post-stroke)|The study group consisted of 26 patients in whom ischaemic brain stroke occurred within 14 days before the admission to the Clinical Department, and were hospitalised at the Department of Neurological Rehabilitation of the Clinical Department of Rehabilitation in the Wiktor Dega Orthopaedic and Rehabilitation Clinical Hospital in Poznań
89492290|NCT04821518||The control group|The control group was composed of 26 healthy individuals recruited from the hospital staff who did not experience stroke.
89492291|NCT02115971|Experimental|Jumping exercise|"Physical therapy with a focus on specific jumping exercise. The jumping exercise will be performed for 12 weeks (3x/week), with a break of day between workouts. The 40-minute workout is completed 2 times under supervision in the clinic's internal training group for outpatients. 1 time they train on their own at home, based on a defined training program. The training process is documented by the training protocol.~The incipient exercise intensity is taking personal performance into account. The exercise intensity is increased by a progressive scheme."
89492292|NCT02115971|Active Comparator|Strength exercise|"Physical Therapy with a focus on stability and strength exercise. Strength exercise arm has also same duration of 12 weeks with comparable intensity. The program is according to a predetermined program. The 60-minute training is completed twice under supervision in the clinic's internal training group for outpatients.There is no contact with participants of other group.~Between the two exercise sessions there is a training free day. The training process is documented by the training protocol. The incipient exercise intensity is considering personal performance. The intensity is increased after workout usual principles. The exercises are described with clear image and load parameters. The training exercises are regularly monitored."
89492293|NCT04807166|Experimental|Anlotinib Combined With Carboplatin/Paclitaxel|Anlotinib Combined With Carboplatin/Paclitaxel
89492294|NCT02116049|Active Comparator|Attention Control Case Management|"Comprehensive Risk Counseling and Services (CRCS) will be used to guide the case management activities. CRCS combines traditional case management and HIV risk-reduction in an individualized, client-centered program which focuses on the reduction of risk behavior and addresses a client's psychosocial and medical needs. CRCS focuses on seven core elements: recruitment and engagement; screening, enrolling, and assessing; prevention planning; risk reduction counseling; referrals and service coordination; monitoring; and discharge and maintenance. These core elements represent the framework of the intervention, and provide enough flexibility to allow implementation that most appropriately serves the needs of clients. This project's case management will mimic the experimental condition with a meeting schedule reflective of the experimental arm plus a booster session at 3 months."
89492295|NCT02116049|Experimental|Disclosure Intervention|The experimental condition is a 4-session + 3 month booster intervention. Session 1 includes an introduction to the project, goal setting, assessment of disclosure strategies or tactics utilized, and disclosure triggers. Session 2 focuses on the costs and benefits of disclosing to casual sexual partners and previous best and worst disclosure experiences. Session 3 begins with the delivery of the encouraging messages and review of the disclosure strategies already employed. Session 4 is a continuation of session 3 activities with an additional focus on expanding the participant's repertoire of strategies; discussion of methods of sexual negotiation, and rehearsal. The booster session includes a discussion of what strategies have been used in the preceding months, which strategies worked and how can these be enhanced, which strategies did not work with opportunities for troubleshooting, and an examination of rewards experienced or costs encountered.
89492296|NCT02116127|Experimental|Active tDCS|The intervention is active 2mA transcranial direct current stimulation (tDCS). Direct current will be transferred with a pair of saline soaked sponge electrodes (contact area 5 x 7cm), and delivered for 30 minutes. The electrodes will be placed over F3 and F4 according to the 10-20 international system for EEG placement.
89492297|NCT02116127|Sham Comparator|Sham tDCS|The sham intervention is transcranial direct current stimulation (tDCS). 2mA of direct current will be transferred with a pair of saline soaked sponge electrodes (contact area 5 x 7cm), and the current will be turned off after 54 seconds.The electrodes will be placed over F3 and F4 according to the 10-20 international system for EEG placement.
89492298|NCT04821596|Experimental|Multiple Sclerosis Patients|Multiple Sclerosis Patients usually followed by Dr. Bourre as part of his consultation at the Rouen University Hospital will be offered the opportunity to participate in this study if they meet the selection criteria.
89492299|NCT04807322||Elective cases|Patients, who received a RTSA for degenerative reasons like cuff arthropathy or osteoarthritis
89492300|NCT04807322||Fracture cases|Patients, who received a RTSA for a proximal humerus fracture
89492301|NCT04807244|Other|Treatment of deep carious lesions: Randomized-controlled trail|Teeth with reversible pulpitis will be included accordingly to the inclusion criteria (see below). After randomization, teeth will be treated either with selective caries removal (indirect pulp capping) or partial pulpotomy pursuant to the below described clinical protocol. The intention of this study arm is to evaluate both therapies.
89492302|NCT04807244|Other|Treatment of deep carious lesions: Prospective non-controlled intervention trial|Teeth with reversible pulpitis according to the inclusion criteria (see below) will be included. Depending on the clinical situation, a partial or full pulpotomy will be conducted accordingly to the defined clinical protocols (see below). In this study arm, we want to evaluate 1) different times of pulpal bleeding before pulp capping and 2) partial versus full pulpotomy on the clinical outcome in teeth with irreversible pulpitis.
89492303|NCT02123147||Sjogren's syndrome|Patients who are diagnosed with Sjogren's syndrome. Blood will be collected once every 3-6 months for up to 3 years.
89492304|NCT02123147||Healthy Control|Patients who are diagnosed with healthy control. Blood will be collected once every 6 months for up to 3 years.
89492305|NCT04815980|No Intervention|Control|The control group performed no Pilates intervention. They continued with their typical activities of daily living.
88953994|NCT01967901|Active Comparator|Sequence: ABBA A=usual care, B=self-care|"The usual care consists of patients' follow up by their usual nephrologist and endocrinologist or general practitioner.~Self-care management consists of a the addition of a multidisciplinary self-management program that includes additional home and clinic visits and telephone follow-ups made by the self-care management nurse and clinic visits to the dietician.~In this sequence, patients will receive the usual care for 3 months. Then, they will cross-over to receive a multidisciplinary self-management for the following 6 months and then cross-over to a 3 months of usual care."
89492306|NCT04815980|Experimental|Pilates|Participants in this group performed a 30 minute mat-based Pilates intervention 3 times/week for 12 weeks.
89492307|NCT02251925|Experimental|Natural cycle|In natural cycle without hCG, daily monitoring of urinary LH is started from day eight of the cycle and frozen-thawed embryo transfer is planned 3-5 days after detection of LH surge, observing mature follicles in ultrasound and endometrial thickness over 7mm for cleavage embryos.
88953995|NCT01967901|Active Comparator|Sequence BAAB|Patients will receive the multidisciplinary self-management program for 3 months. Then, they will cross-over to usual care for the following 6 months and then cross-over to 3 months of multidisciplinary self-management
89492308|NCT02251925|Experimental|Natural cycle + hCG for ovulation induction|In natural cycle with hCG, after detection of mature follicles in ultrasound and endometrial thickness over 7mm, 10,000IU hCG is injected for ovulation and embryo transfer is performed 3-5 days later in cleavage stage.
89492309|NCT02251925|Experimental|Hormonally controlled cycle with GnRH-a|In this group , injection of GnRH agonist (Superfact) at a subcutaneous daily dose of 0.5 mg is started on the day 17-19 of the natural menstrual cycle. Once pituitary desensitization is confirmed, hormonal treatment is commenced with 4mg/day oral Estradiol valerate and after 7 days if endometrial thickness is adequate, Estradiol administration will be continued with the same dose and 100mg Progesterone is administered before embryo transfer, otherwise patients are candidates for higher dosage of Estradiol till favourable endometrial thickness is achieved.
89492310|NCT02251925|Experimental|Hormonally controlled cycle without GnRH-a|In the hormonal group without GnRH-a, endometrial preparation will be started with daily administration of 6 mg Estradiol valerate from the 2nd day of the natural menstrual cycle for 6 days. Then treatment will be continued similar to the 3rd group.
89492311|NCT03552653|Experimental|Vitafusion Extra Strength Vitamin D3 Gummy|Single oral dose of gummy vitamin D3 to monitor vitamin D blood levels
89492312|NCT03552653|Active Comparator|Nature Made Vitamin D3 Tablet|Single oral dose of tablet vitamin D3 to monitor vitamin D blood levels
89492313|NCT02116439||Violent events|People in this group were observed to manifest violence.
89492314|NCT02116439||Victims|People in this group are the victims of the other group.
89492315|NCT02119949|Experimental|Working memory training|
89492316|NCT02119949|Placebo Comparator|Placebo training|
89492317|NCT02116517|Experimental|green tea extract first|green tea extract (EGCG) 500mg tid for 6 weeks, then wash-out for 2 weeks, and finally cellulose 500mg tid for 6 weeks total 14 weeks
89492318|NCT02116517|Placebo Comparator|Placebo first|cellulose 500mg tid for 6 weeks, then wash-out for 2 weeks, and finally EGCG 500mg tid for 6 weeks total 14 weeks
89492319|NCT02116595|Experimental|feeding a high acid diet x 24 hrs|2 diets, one low and one high net acid loads
89492320|NCT02116595|Active Comparator|low acid diet|
89492321|NCT02116673|Other|Control|The control arm receives usual care discharge instructions.
89492322|NCT02116673|Experimental|Cognitive rest|The intervention is providing discharge instructions instructing cognitive rest and graduated return to usual activities in patients whom have experienced minor traumatic brain injury.
89492323|NCT02120105||Cystinuria|
89492324|NCT01359644|Experimental|Treatment A: PSI-7977 + Daclatasvir|Genotype 1a or 1b
89492325|NCT01359644|Experimental|Treatment B: PSI-7977 + Daclatasvir|Genotype 2 or 3
89492326|NCT01359644|Experimental|Treatment C: PSI-7977 + Daclatasvir|Genotype 1a or 1b
89492327|NCT01359644|Experimental|Treatment D: PSI-7977 + Daclatasvir|Genotype 2 or 3
88953996|NCT01967901|Active Comparator|Sequence AABB|Patients will receive the usual care for two periods of three months, then they will cross-over to a period of 6 months of a multidisciplinary self-management
89492328|NCT01359644|Experimental|Treatment E: PSI-7977 + Daclatasvir + Ribavirin|Genotype 1a or 1b
89492329|NCT01359644|Experimental|Treatment F: PSI-7977 + Daclatasvir+ Ribavirin|Genotype 2 or 3
89492330|NCT01359644|Experimental|Treatment G: PSI-7977 + Daclatasvir|"Hepatitis C virus genotype 1, treatment-naive patients~Genotype 1a or 1b"
89492331|NCT01359644|Experimental|Treatment H: PSI-7977 + BMS-790052 + Ribavirin|"Hepatitis C virus genotype 1, treatment-naive patients~Genotype 1a or 1b"
89492332|NCT01359644|Experimental|Treatment I: PSI-7977 + Daclatasvir|"Patients who experienced telaprevir/boceprevir treatment failure~Genotype 1a or 1b"
89492333|NCT01359644|Experimental|Treatment J: PSI-7977 + Daclatasvir + Ribavirin|"Patients who experienced telaprevir/boceprevir treatment failure~Genotype 1a or 1b"
89492334|NCT04821206||Cases|Patients with diagnosis of RA, PsA and SpA
89492335|NCT04821206||Controls|Patients with diagnosis of RA, PsA and SpA
89492336|NCT04806932|Active Comparator|The modified approach|The first three attempts via the modified approach will be performed. If the first three attempts failed, the location or operator of the subsequent attempts of artery puncture will be changed.
89492337|NCT04806932|Placebo Comparator|The conventional approach|The first three attempts via the conventional approach will be performed. If the first three attempts failed, the location or operator of the subsequent attempts of artery puncture will be changed.
89492338|NCT04806698|Experimental|Menicon Z Night|The experimental arm includes a group of children wearing Menicon Z Night orthokeratology contact lenses for 7 years
89492339|NCT04806698|Active Comparator|Control|The active comparator arm includes a control group of children wearing distance, single-vision glasses or soft contact lenses
89492340|NCT04807088|Experimental|Intervention Group|Tactile-kinesthetic stimulation (TKS) was performed with a specific baby oil provided by the investigator. Tactile stimulation was performed while the neonate was in prone position. Light massage was applied in the head, shoulder, back, legs and arms of the infants. Every massage was performed for 2 × 5 seconds, with a total duration of 5 minutes. Kinesthetic stimulation, including elbow flexion-extension movement, palm massages, flexion-extension of the knees and legs and plantar massages, was applied while the neonate was in supine position. Each kinesthetic stimulation was performed for 2 × 5 seconds. Each movement was repeated six times, with a total duration of 5 minutes. Tactile stimulation was repeated once after kinesthetic stimulation. The total duration of TKS was 15 minutes which was performed three times daily preferably between breastfeeding or bottle feeding for 10 consecutive days.
89204705|NCT00999310||parents of Klinefelter groupe|
89492341|NCT04807088|Placebo Comparator|Control Group|Control group was not given TKS.
89492342|NCT04806542|Experimental|TMR-group|8-week program for schoolchildren called TMR (Training for Resilience and Mindfulness).
89492343|NCT04806542|Active Comparator|Treatment as Usual|Individual counselling.
89492344|NCT04806308|Experimental|Intervention group|Cross over study so each participant will have 3 control days without intervention and 3 intervention days with stretching exercise.
89492345|NCT04806308|No Intervention|Control group|Cross over study so each participant will have 3 control days without intervention and 3 intervention days with stretching exercise.
89492346|NCT04806464|Experimental|Single Arm|"Part1:~1.0*10^8 PFU on Day 1~1.0*10^8 PFU on Days 1 to 2~1.0*10^8 PFU on Days 1 to 3~1.0*10^8 PFU on Days 1 to 4~1.0*10^8 PFU on Days 1 to 5~Part2:~Depends on the recommended dose in Part1"
89492347|NCT04806230||Observed|
89492348|NCT04816136||patients with a sleep recording performed|patients with a sleep recording performed in the sleep unit in Montpellier University Hospital, who had an ischemic stroke before the recording.
89492349|NCT05617274||Mandibular flexure before sectioning of full arch fixed prosthesis|
89492350|NCT05617274||Mandibular flexure after sectioning of full arch fixed prosthesis|
89492351|NCT04815512||exposed group|workers in The Petroleum Pipelines Company who are occupationally exposed to petroleum products will be included in the study.
89492352|NCT04815512||Comparison group (control group)|healthy administrative workers in assiut university
89492353|NCT01532258|No Intervention|Control Group|No intervention provided. These participants will receive access to the Go! Foods for You program after the research trial has been completed (12 weeks after registration).
89492354|NCT01532258|Active Comparator|GFFY-1 without weekly MA support|Utilization of the 8-week online nutrition program Go! Foods for You without weekly contact from staff at the medical provider's office.
89492355|NCT01532258|Active Comparator|GFFY-2 with weekly MA support|Utilization of the 8-week online nutrition program combined with weekly contact from the staff at the medical provider's office.
89492356|NCT04821050|Experimental|Treatment|Sacral nerve stimulation
89492357|NCT04821050|Sham Comparator|Control|Sham stimulation
88953997|NCT01967901|Active Comparator|Sequence BBAA|Patients will receive the multidisciplinary self-management for two periods of three months, then they will cross-over to a period of 6 months of usual care.
89492358|NCT04412174|Experimental|GC022F|The patients will receive GC022F CAR-T treatment. GC022F dosage ranges from 3×10^5 to 1×10^6 CAR+T/Kg.
89492359|NCT04806152|Experimental|Sarcopenia and combined-modality high intensity supervised exercise training|Participants were given Treadmill exercise training, lower extremity progressive resistance training using a Cybex leg press machine, and a 1-hour adaptive physical activity (APA) programme in which participants were required to walk for 12 minutes through an obstacle course in which they must clear 10 cm high boards, climb 3 steps and walk sideways through hula-hoops placed on the floor all the while dual-tasking i.e. waving at strategically placed signs, conversing while walking and picking up objects. Participants also performed exercises at the parallel bars which included weight-shifting from leg to leg and half-squatting; they were also guided through seated upper- and lower-limb stretching exercises for range of motion and trunk mobility. All exercise sessions were supervised by physiotherapists. For two of the weekdays on which participants did not attend supervised training, they were asked to walk for 30 minutes at home and perform the APA exercises described above.
89492360|NCT04806152|Active Comparator|Sarcopenia and 'usual care' unsupervised exercise|Participants were required to do 5-12 chair rises and also 30-minutes walking 5 days per week. Upper limb and trunk flexibility exercises were also taught.
89492361|NCT04821128||Patients who improved surgical treatment for oral cavity cancer|T1 T2 and T3 OSCC tumor, patients who have a recent evaluation cervico thoracic scanner in their medical files.
89492362|NCT02603120|Experimental|Blinded Phase: B/F/TAF|B/F/TAF + ABC/DTG/3TC placebo for at least 48 weeks
89492363|NCT02603120|Active Comparator|Blinded Phase: ABC/DTG/3TC|ABC/DTG/3TC + B/F/TAF placebo for at least 48 weeks
89492364|NCT02603120|Experimental|Open-Label Phase|At the End of Blinded Treatment Visit, if safety and efficacy of B/F/TAF is demonstrated following review of unblinded data, participants in a country where B/F/TAF FDC is not available will be given the option to receive B/F/TAF FDC in an open-label extension phase for up to 96 weeks, or until the product becomes accessible to subjects through an access program, or until Gilead Sciences elects to discontinue the study in that country, whichever occurs first.
89492365|NCT04805684|Active Comparator|lung ultrasound 12|12 zone lung ultrasonography protocol
89492366|NCT04805684|Active Comparator|lung ultrasound 14|14 zone lung ultrasonography protocol
89492367|NCT04820504|Placebo Comparator|Blinded to visual feedback from AIR device|Providers did not receive AIR device feedback during newborn mannequin ventilation
88953998|NCT01967914||Women undergoing cesarean delivery under spinal anesthesia|
89204706|NCT00993070|Experimental|Capsaicin|
89204707|NCT00993070|Placebo Comparator|placebo|
89204708|NCT00993304|Experimental|A|
89204709|NCT00993304|Placebo Comparator|B|
88953999|NCT01967927|Experimental|GRID 18F-MISO|
88954000|NCT01967953|No Intervention|Standard Group|"Recipients of lungs procured from brain death donors deemed suitable for transplantation according to standard criteria.~Events: lung procurement, cold storage on ice, transplantation."
88954001|NCT01967953|Experimental|EVLP Group|"Recipients of marginal lungs procured from brain death donors and reconditioned with ex-vivo lung perfusion (EVLP).~Events: lung procurement, cold storage on ice, reconditioning by EVLP, cold storage on ice, transplantation."
88954002|NCT01967966|Experimental|Bioavailability|
89492368|NCT04820504|Experimental|Not blinded to visual feedback from AIR device|Providers did receive AIR device feedback during newborn mannequin ventilation
89492369|NCT04820816||Posterior pelvic tilt group|"patients with chronic low back pain or repeated non-specific back pain for more than three months.~Both sex with posterior pelvic tilt (-0.7 ± 6.5°) and decreased lumbar lordosis~Their ages were ranged from 20-35 years~Body Mass Index from 18-25 Kg/m²"
89492370|NCT04820816||Normal anterior pelvic tilt group|"patients with chronic low back pain or repeated non-specific back pain for more than three months.~Both sex with anterior pelvic tilt (5° and 13°) and normal lumbar lordosis~Their ages were ranged from 20-35 years~Body Mass Index from 18-25 Kg/m²"
89492371|NCT04805372|Experimental|VD+VF group|where they should review a video of an expert performing central vein operation and a video of their own most recent operation, before returning to do another operation. This will be repeated for a total of 5 central vein cannulation encounters and 5 video reviews.
89492372|NCT04805372|Placebo Comparator|VD group|where they should review a video of an expert performing central vein operation before returning to do another operation. This will be repeated for a total of 5 central vein cannulation encounters and 5 video reviews.
89492373|NCT05617976|Active Comparator|Group L (levobupivacaine only group)|Caudal block was done in this group using levobupivacaine 0.25% with the dose of 1 ml /kg plus one ml normal saline after induction of general anesthesia.
89492374|NCT05617976|Active Comparator|Group L+N(levobupivacaine plus nalbuphen group)|Caudal block was done in this group using levobupivacaine 0.25% with the dose of 1 ml /kg and nalbuphine 0.1 mg /kg in one ml normal saline after induction of general anesthesia.
89492375|NCT04805606|Experimental|Sequence 1|CKD-843 A - 27mg, Single Dose
89492376|NCT04805606|Experimental|Sequence 2|CKD-843 A - 45mg, Single Dose
89492377|NCT04805606|Experimental|Sequence 3|CKD-843 A - 56mg, Single Dose
89492378|NCT04805606|Experimental|Sequence 4|CKD-843 B - 45mg, Single Dose
89492379|NCT04805606|Active Comparator|Sequence 5|CKD-843-R
89492380|NCT04820738|Experimental|Experimental group|Sensorimotor training exercises include wall slides , core exercises (Planks, leg raises, crunches, bridging) balance exercises (single leg side lift, leg lift with dumble, balance on stability ball) on unstable surface for 50-60 min (3 sets of 10 rep) of exercises and gait training (different patterns of walking).
89492381|NCT04820738|Active Comparator|Control group|Cut back on high-fat foods. Drink plenty of water Use sugar and salt in moderation. Eat fruits and vegetables Get enough calcium Pump up your iron. Get enough fiber
89492382|NCT04805060|Experimental|TQB2858 injection|TQB2858 administered intravenously (IV) once every 3 week
89492383|NCT04815434||Adults with disabilities and complex health conditions|Interviews, experience of the mouth and oral health and function
89492384|NCT04815122||Carriers of the Met allele of the COMT Val158Met polymorphism|Women with obesity carriers of the Met allele of the COMT Val158Met polymorphism
89492385|NCT04815122||Non-carriers of the Met allele of the COMT Val158Met polymorphism|Women with obesity non-carriers of the Met allele of the COMT Val158Met polymorphism
89492386|NCT04820660|Experimental|Task oriented Strength training group|Standing and reaching in different directions Sit-to-stand Stepping forward and backward Stepping sideways onto blocks
89492387|NCT04820660|Experimental|Balance Training|Stepping forward, backward, and sideways on the exercise step; Stepping over blocks of various heights; Standing up from a chair, From a sitting position on a 65-cm Swiss ball, Arms; bending the trunk forward and side to side); Performing double-legged stance Performing tandem stance Rising from a chair without the use of the arms; Walking forward and backward with a tandem walking pattern Performing single- legged stance
89492388|NCT04804670|Experimental|Sonic-Floss toothbrush and small brush head|sonic toothbrush used for 2 minutes and water flosser used for 1 minute
89492389|NCT04804670|Experimental|Sonic-Floss toothbrush and full size brush head|sonic toothbrush used for 2 minutes and water flosser used for 1 minute
89492390|NCT04804670|Active Comparator|Manual brushing and flossing|American Dental Association standard manual toothbrush used for 2 minutes and dental floss all teeth
89492391|NCT04820270|Experimental|Autologous Tregs in allogenic islet transplantation|Autologous Tregs are given simultaneously to the patient with the islets
89492392|NCT04426760||Women with submucosal leiomyoma(s)|Women with submucosal leimyomas undergoing hysteroscopical removal of the leiomyoma
89492393|NCT04426760||Women with intramural leiomyomas|Women with intramural leiomyomas undergoing myomectomy
89492394|NCT04426760||Infertility patients|Patients treated at the Department for Reproductive Medicine at the Oslo University hospital failing to conceive after 3 or more embryo transfers with good quality embryos.
89492395|NCT04426760||Fertile women|Healthy, volunteering women with proved fertility with 1 or more deliveries and no history of infertility
88954003|NCT01967966|Experimental|Elimination & PK|
88954004|NCT01967979|Experimental|Cohort 1 (Itraconazole DDI)|
88954005|NCT01967979|Experimental|Cohort 2 (Fluoxetine DDI)|
89204710|NCT05189002|Experimental|Group 1a|Patients from groups 1a took the study product once a day in doses 40 mg per os and saline solution subcutaneously. Dose was blinded for a patient and investigator (double-blind method) using six tablets for each administration, some of them contained Dimolegin - DD217, and others were masked as Placebo of the study product.
89492396|NCT04804436|Experimental|Patients with nephrolithiasis|The real-time PCR amplification was performed in a final volume of 20μL reaction mixture, including 10 ng of genomic DNA, 5 µL of TaqMan® Universal PCR Master Mix, and 0.5 µL of 40X TaqMan® assay. Thermal cycling conditions were as follows: initial denaturation at 94℃ for 3 min, 40 cycles of 94℃ for 15 s, and 60°C for 1 min. The Rotor-Gene Q Series Software Version Q 2.3.1 (Rotor-Gene Q Series, Ziagen) was used for allelic discrimination.
89492397|NCT04804436|Experimental|Healthy control group|he real-time PCR amplification was performed in a final volume of 20μL reaction mixture, including 10 ng of genomic DNA, 5 µL of TaqMan® Universal PCR Master Mix, and 0.5 µL of 40X TaqMan® assay. Thermal cycling conditions were as follows: initial denaturation at 94℃ for 3 min, 40 cycles of 94℃ for 15 s, and 60°C for 1 min. The Rotor-Gene Q Series Software Version Q 2.3.1 (Rotor-Gene Q Series, Ziagen) was used for allelic discrimination.
89492398|NCT04427696|Active Comparator|Aerobic walking|The participants in this arm were obligated to carry out one hour aerobic walking (goal setting walking) daily. The goal of aerobic walking: 1. at least 60 steps per minute; 2. continuously walking for 10 minutes.
89492399|NCT04427696|Placebo Comparator|No aerobic walking|The participants in this arm were requested to maintain sedentary life, without joining other physical exercise programmes.
89492400|NCT04815200|Other|Nickel titanium NiTi arch wire (Gold Standard, control group)|Patient will receive 0.014 round Nickel titanium NiTi archwire and will be ligated using a ligature wire with Follow up for 2 months.
89492401|NCT04820114|Active Comparator|Control group|Wrist passive mobilizations; Actives exercises; Reeducation for Activity daily life.
89492402|NCT04820114|Experimental|Experimental group|The experimental group will also carried out a proprioceptive exercise program divided in three phases of 2 weeks per phase.
89492403|NCT04803968|Experimental|control group|"After the evaluations are completed, the participants will be randomly divided into two groups using a computer-assisted randomization program.~The cardiac rehabilitation program will be a total of 30 sessions, 5 days a week x 6 weeks. All patients in the control and study groups will participate in the routine lower extremity bicycle ergometer training"
89492404|NCT04803968|Experimental|intervention group|The combined upper and lower extremity training group will participate in the arm ergometer exercise separately from the lower extremity training group.
89492405|NCT04426916||normal lumbar spine|Patient without spondylolisthesis or significant spinal anatomic deformity. (ex> severe spondylosis, spinal stenosis, scoliosis, etc..)
89492406|NCT04426916||spondylolisthesis|Spondylolisthesis patients, with whom the deformity is at just one level. The patients should not have any other significant spinal deformity. (ex> severe spondylosis, spinal stenosis, scoliosis, etc..)
89492407|NCT04426994||Case|Patients admitted with hypomagnesemia are evaluated for proton pump inhibitor use and likelihood of hypomagnesemia due to proton pump inhibitor use
89492408|NCT04426994||Control|Patients on long-term proton pump inhibitor without documented hypomagnesemia
89492409|NCT04814576|Experimental|Group 1|Collaborative nursing care
89492410|NCT04814576|No Intervention|Group 2|Traditional nusing care
89492411|NCT04427774|Experimental|Surufatinib plus Sintilimab|
89492412|NCT04803890|Experimental|No touch radiofrequency ablation|A total of 150 patients who have decided to participate in the study will be included, and prospective study will be performed to these patients for radio-frequency ablation using octopus electrodes, combined high-frequency transmission mode, and the 'No touch' technique.
89492413|NCT04820192||Post-acute concussion (<6 months) or Post-Concussion Syndrome (PCS) (≥ 6 months)|Patients were divided into cohort groupings to compare outcomes of applying CranioSacral Therapy to their unique constellations of persistent symptoms attributed to their concussion injury. Symptoms less than 3-6 months duration may be part of the usually rate of injury resolution through rest along. Symptoms persisting after 6 months are considered PCS. Less than 6 months since injury were considered post-acute concussion stage of recovery.
89492414|NCT04820192||Athletes (A) or Non-athletes (NA)|Reporting of symptoms that exist and/or persist may differ between patients who are/were athletes and concussions were sustained during their sporting events. Non-athletes may report differently. The types of injuries involved in the concussion were also captured.
89492415|NCT04820192||Traditional gender.|Symptoms and response to rest has been reported to have differences between male and female patients. Age under 14 years was considered an exclusion due to immaturity in insight and reporting. Thus, young adult ages and older were included and observations between gender reporting was noted.
89492416|NCT04427852|Experimental|30 day Beef consumption|One serving of beef is consumed each day for 30 days.
89492417|NCT04427852|Placebo Comparator|30 day Veggie Patty consumption|One serving (1 patty) of a vegetable based protein source is consumed each day for 30 days. The weight of the food, total calories, grams of protein, and total fat are the same as the beef serving.
89204711|NCT05189002|Experimental|Group 1b|Patients from groups 1b took the study product once a day in doses 60 mg per os and saline solution subcutaneously. Dose was blinded for a patient and investigator (double-blind method) using six tablets for each administration, some of them contained Dimolegin - DD217, and others were masked as Placebo of the study product.
89492418|NCT04803656|Other|Assesment|Demographic information of all subjects (age, gender, educational status, occupation, body weight, height, body mass index), clinical (diagnosis period) and medical status, personal history and family history, COPD stage, COPD Assessment Test (CAT) score, emergency and hospital admissions numbers in the last 3 months, exacerbation and hospitalization numbers in the last one year were recorded. Respiratory and peripheral muscle strengths are evaluated. Also pulmonary functions test results obtained.
89492419|NCT05617196|Active Comparator|Standard Care|
89492420|NCT05617196|Experimental|Virtual PREHAB|In addition to standard care, participants randomized to the The virtual PREHAB program will be delivered by the Hearts and Health in Motion cardiac rehabilitation CR health care team including a medical director nurse, dietician, and physiotherapist who routinely deliver CR postoperatively. The virtual PREHAB program will be up to 8-weeks in duration and deliver the core components of CR online or by telephone.
89492421|NCT04819802||Covid-19 patients|Adult Covid-19 patients admitted to intensive care units
89492422|NCT04819412|Experimental|ROTAVAC 5C -F1|ROTAVAC 5C formulation BBIL-R2014-1
89492423|NCT04819412|Experimental|ROTAVAC 5C -F2|ROTAVAC5C formulation BBIL-R2014-2
89492424|NCT04819412|Active Comparator|ROTAVAC®|ROTAVAC® with 5 minutes prior administration of 2.5 ml of buffer
89492425|NCT04814030|Experimental|AIPD-1|Trans hepatic artery infusion of PD-1 antibody, chemoembolization, FOLFOX-based infusion chemotherapy
89492426|NCT04819724|Other|Group 1: patient group (unilateral rotator cuff tear)|Group 1: 25 patients with unilateral symptomatic rotator cuff tear
89492427|NCT04819724|Other|Group 2: control group (asymptomatic volunteers)|Group 2: (asymptomatic volunteers) 25 asymptomatic control subjects (age and sex distribution matching the patient group)
89492428|NCT04819724|Other|Group 2: young control group (young asymptomatic volunteers)|Group 3: (young asymptomatic volunteers) 25 asymptomatic control subjects, 20 to 30 years (sex distribution matching the patient group)
89492429|NCT04412252|Experimental|Tofacitinib|Participants will receive tofacitinib 10 mg twice per day for 14 days and standard of care therapy.
89492430|NCT04412252|Placebo Comparator|Placebo|Participants will receive tofacitinib-matching placebo twice per day for 14 days and standard of care therapy.
89492431|NCT05617586||DCD Parents|An in-depth interview will be conducted of parents of a child with DCD. Parents will be asked to complete a Developmental Coordination Disorder Questionnaire (DCD-Q).
89492432|NCT04813952|Active Comparator|Group M|Group M is minimal flow anesthesia group with fresh gas flow 0,5 L.min-1. Thirty five patients with ASA class I-II and between the ages of 18-65 undergoing elective laparoscopic cholecystectomy will be included. These patients were planned to be administered sevoflurane anesthesia with 0,5 L.min-1 flow under general anesthesia.
89492433|NCT04813952|Active Comparator|Group H|Group H is high flow anesthesia group with fresh gas flow 4 L.min-1. Thirty five patients with ASA class I-II and between the ages of 18-65 undergoing elective laparoscopic cholecystectomy will be included. These patients were planned to be administered sevoflurane anesthesia with 4 L.min-1 flow under general anesthesia.
89492434|NCT04813874||neuraxial analgesia only|Receiving neuraxial analgesia only for labor
89492435|NCT04813874||NO2 and neuraxial analgesia|Receiving nitrous oxide and neuraxial analgesia for labor
89492436|NCT04803578||Knee Arthroplasty Group|Subjects that received knee arthroplasty 2-3 days before admission to undergo a rehabilitation period in our rehabilitation hospital.
89492437|NCT04803578||Hip Arthroplasty Group|Subjects that received hip arthroplasty 2-3 days before admission to undergo a rehabilitation period in our rehabilitation hospital.
89492438|NCT04803578||Age-Matched healthy Group|Subjects age-matched with those included in the knee and hip group. Subjects are asked to walk at their self-selected speed and at low speed matchable with those of the knee and hip group
89492439|NCT04803500|Active Comparator|Simvastatin group|simvastatin gel (1.2 mg/0.1 ml of solid lipid nanoparticles) was locally applied to fill the jumping distance.
89492440|NCT04803500|Placebo Comparator|Control group|the solid lipid nanoparticles carrier was injected into the jumping distance.
89492441|NCT04803188|Experimental|A: patients will perform non-contrast MRI|A: 355 patients will perform non-contrast MRI regardless their serum PSA value
89492442|NCT04803188|Experimental|B: patients will perform non-contrast MRI|B: 355 patients will perform non-contrast MRI when serum PSA value is increased (>4 ng/ml or 2.5 ng/ml if positive family history)
89492443|NCT04803266|Experimental|Internal mammary node irradiation|
89492444|NCT04803266|Active Comparator|No internal mammary node irradiation|
89492445|NCT04803344|Experimental|Experimental Group|After the childbirth, writing group participants has been asked to write for 3 consecutive days, 20 minutes each days, all the deepest emotions and feelings related to the pregnancy.
89492446|NCT04803344|Active Comparator|Control Group|
89492447|NCT04426682||post-operative urinary incontinents|In patients who have previously had incontinence surgery due to stress incontinence, symptoms may return in the following years, and the patient may reapply with urinary incontinence. The first group will consist of postoperative urinary incontinence recurrent patients. Patients whose urodynamics are reperformed due to recurrence are the study group.
89492448|NCT04426682||without postoperative urinary incontinence|Patients who previously had incontinence surgery due to stress incontinence and who did not have postopertive urinary incontinence but whose urodynamics were repeated during the routine controls will constitute the control group.
89492449|NCT02120183|Experimental|Psycho-educational support group therapy|4 week psycho-educational support group focusing on topics specific to psychosocial and emotional aspects of the cancer caregiving role
89492450|NCT04803032|Experimental|Superficial parotidectomy using trident landmark technique|A modified Blair incision was made along the preauricular skin crease with the same steps of the routine parotid surgery. Dissection was performed using bipolar cautery and blunt instrument; from the tragal cartilage (the anterior surface) until the bony anterior wall of the external auditory canal (EAC); from there, the dissection was done using a blunt instrument. The styloid process's base is the upper point of the trident landmark; it is the superior portion of the trident landmark. Identification of the posterior belly of the digastric muscle till its origin was performed deep to the sternocleidomastoid muscle; it is the lower point of the landmark. The facial nerve is located in the region between these two structures.
89492451|NCT04813640|Placebo Comparator|Single Vision Spectacles|Commercially available conventional single vision spectacles
89492452|NCT04813640|Active Comparator|Commercially available myopia control spectacles|Commercially available myopia control spectacles
89492453|NCT04813640|Experimental|Novel Myopia control spectacles - Prototype I|Experimental myopia control spectacles
89492454|NCT04813640|Experimental|Novel Myopia control spectacles - Prototype II|Experimental myopia control spectacles
89492455|NCT04813406|Experimental|Anlotinib + Sintilimab|
89492456|NCT01331291|Experimental|Arm A|Patients who are surgical candidates. Participants are given oral bosutinib, 400mg daily, for 7-9 days prior to resection. After at least 10 days elapsed post-operatively, bosutinib dosing was resumed.
89492457|NCT01331291|Experimental|Arm B|Patients that are not surgical candidates. Participants are given oral bosutinib, 400 mg daily in 28 day cycles until disease progression, intolerability or withdrawal of consent.
89492458|NCT02120339|Experimental|Carvedilol|Carvedilol 0-3.125 mg daily Escalating to 6.25 twice a day
89492459|NCT03553199|Experimental|TRS|TRS, Tissue resection system
89492460|NCT02123303||Veterans|
89492461|NCT02123381|Experimental|Arm A|All patients in the arm receive cetuximab combined with preoperative radiotherapy at first. 4-6 weeks after the rdiaotherapy，patients receive right thoracotomy with three incisions radical surgery.
89492462|NCT02123537|Experimental|Bioness L300 Foot Drop System|Participants will use the Bioness L300 Foot Drop System for walking daily during the 12 weeks of the study.
89492463|NCT02120495|Experimental|intraoral condylectomy via coronoid process resction|This procedure has no facial nerve injury and skin scar,little injury to TMJ anatomy and function.
89492464|NCT02120573|Active Comparator|medical students|medical students took part in workshop
89492465|NCT02120573|Active Comparator|general population|general population took part in workshop
89492466|NCT02120573|Active Comparator|nonmedical students|all students from different subjects, non medical and paramedical
89492467|NCT02116829|Experimental|Danish butter, dairy|
89492468|NCT02116829|Active Comparator|Olive oil, refined|
89492469|NCT02123615|Experimental|Gadolinium For abdomen|"Gadolinium For abdomen Total Persistent % subdermally, For abdomen Total Persistent % subcutaneously, and For abdomen Relative Prolongation Ability Score.~Gadolinium Magnevist® (gadopentetate dimeglumine)~1cc/ diluted with 19cc normal saline (for <40kg) or 29cc normal saline (for >40kg), subcutaneously for 30 patients, and subdermally with ASIS Device for 30 patients."
89492470|NCT02123615|Experimental|Gadolinium For lower back|"1cc/ diluted with 19cc normal saline (for <40kg) or 29cc normal saline (for >40kg), subcutaneously for 30 patients, and subdermally with ASIS Device for 30 patients.~Gadolinium For lower back Total Persistent % subdermally, For lower back Total Persistent % subcutaneously, and For lower back Relative Prolongation Ability Score."
89492471|NCT02123615|Experimental|subjects (%) of any infections|subjects (%) of any infections as Efficacy of Gammagard subcutaneously at Week 12, Efficacy of Gammagard subcutaneously at Week 24, and Efficacy of Gammagard subcutaneously at Week 36, vs. Efficacy of Gammagard subdermally at Week 12, Efficacy of Gammagard subdermally at Week 24, and Efficacy of Gammagard subdermally at Week 36.
89492472|NCT02123615|Experimental|Annual rate of any infections|Annual rate of any infections as Efficacy of Gammagard subcutaneously at Week 12, Efficacy of Gammagard subcutaneously at Week 24, and Efficacy of Gammagard subcutaneously at Week 36, vs. Efficacy of Gammagard subdermally at Week 12, Efficacy of Gammagard subdermally at Week 24, and Efficacy of Gammagard subdermally at Week 36.
89492473|NCT02123615|Experimental|subjects (%) with Antibiotic use|subjects (%) with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 12, Efficacy of Gammagard subcutaneously at Week 24, and Efficacy of Gammagard subcutaneously at Week 36, vs. Efficacy of Gammagard subdermally at Week 12, Efficacy of Gammagard subdermally at Week 24, and Efficacy of Gammagard subdermally at Week 36.
89492474|NCT02123615|Experimental|Annual rate with Antibiotic use|Annual rate with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 12, Efficacy of Gammagard subcutaneously at Week 24, and Efficacy of Gammagard subcutaneously at Week 36, vs. Efficacy of Gammagard subdermally at Week 12, Efficacy of Gammagard subdermally at Week 24, and Efficacy of Gammagard subdermally at Week 36.
89492475|NCT02123615|Experimental|subjects (%) with Days out of work|subjects (%) with Days out of work as Efficacy of Gammagard subcutaneously at Week 12, Efficacy of Gammagard subcutaneously at Week 24, and Efficacy of Gammagard subcutaneously at Week 36, vs. Efficacy of Gammagard subdermally at Week 12, Efficacy of Gammagard subdermally at Week 24, and Efficacy of Gammagard subdermally at Week 36.
89492476|NCT02123615|Experimental|Annual rate with Days out of work|Annual rate with Days out of work as Efficacy of Gammagard subcutaneously at Week 12, Efficacy of Gammagard subcutaneously at Week 24, and Efficacy of Gammagard subcutaneously at Week 36, vs. Efficacy of Gammagard subdermally at Week 12, Efficacy of Gammagard subdermally at Week 24, and Efficacy of Gammagard subdermally at Week 36.
89492477|NCT02123615|Experimental|(%) with hospitalized infections|(%) with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 12, Efficacy of Gammagard subcutaneously at Week 24, and Efficacy of Gammagard subcutaneously at Week 36, vs. Efficacy of Gammagard subdermally at Week 12, Efficacy of Gammagard subdermally at Week 24, and Efficacy of Gammagard subdermally at Week 36.
89492478|NCT02123615|Experimental|Annual rate hospitalized infections|Annual rate hospitalized infections as Efficacy of Gammagard subcutaneously at Week 12, Efficacy of Gammagard subcutaneously at Week 24, and Efficacy of Gammagard subcutaneously at Week 36, vs. Efficacy of Gammagard subdermally at Week 12, Efficacy of Gammagard subdermally at Week 24, and Efficacy of Gammagard subdermally at Week 36.
89492479|NCT02123615|Experimental|Adverse Injection Local Reactions|Adverse Injection Local Reactions as Adverse Reactions of Gammagard subcutaneously at Week 12, Adverse Reactions of Gammagard subcutaneously at Week 24, and Adverse Reactions of Gammagard subcutaneously at Week 36, vs. Adverse Reactions of Gammagard subdermally at Week 12, Adverse Reactions of Gammagard subdermally at Week 24, and Adverse Reactions of Gammagard subdermally at Week 36.
89492480|NCT02123615|Experimental|Adverse Reactions Headache|Headache as Adverse Reactions of Gammagard subcutaneously at Week 12, Adverse Reactions of Gammagard subcutaneously at Week 24, and Adverse Reactions of Gammagard subcutaneously at Week 36, vs. Adverse Reactions of Gammagard subdermally at Week 12, Adverse Reactions of Gammagard subdermally at Week 24, and Adverse Reactions of Gammagard subdermally at Week 36.
89492481|NCT02123615|Experimental|Adverse Reactions Fever|Fever as Adverse Reactions of Gammagard subcutaneously at Week 12, Adverse Reactions of Gammagard subcutaneously at Week 24, and Adverse Reactions of Gammagard subcutaneously at Week 36, vs. Adverse Reactions of Gammagard subdermally at Week 12, Adverse Reactions of Gammagard subdermally at Week 24, and Adverse Reactions of Gammagard subdermally at Week 36.
89492482|NCT02123615|Experimental|Adverse Reactions Nausea|Nausea as Adverse Reactions of Gammagard subcutaneously at Week 12, Adverse Reactions of Gammagard subcutaneously at Week 24, and Adverse Reactions of Gammagard subcutaneously at Week 36, vs. Adverse Reactions of Gammagard subdermally at Week 12, Adverse Reactions of Gammagard subdermally at Week 24, and Adverse Reactions of Gammagard subdermally at Week 36.
89492483|NCT02123615|Experimental|Adverse Reactions Vomiting|Vomiting as Adverse Reactions of Gammagard subcutaneously at Week 12, Adverse Reactions of Gammagard subcutaneously at Week 24, and Adverse Reactions of Gammagard subcutaneously at Week 36, vs. Adverse Reactions of Gammagard subdermally at Week 12, Adverse Reactions of Gammagard subdermally at Week 24, and Adverse Reactions of Gammagard subdermally at Week 36.
89492484|NCT02123615|Experimental|Adverse Reactions Fatigue|Fatigue as Adverse Reactions of Gammagard subcutaneously at Week 12, Adverse Reactions of Gammagard subcutaneously at Week 24, and Adverse Reactions of Gammagard subcutaneously at Week 36, vs. Adverse Reactions of Gammagard subdermally at Week 12, Adverse Reactions of Gammagard subdermally at Week 24, and Adverse Reactions of Gammagard subdermally at Week 36.
89492485|NCT02123615|Experimental|Adverse Reactions Diarrhea|Diarrhea as Adverse Reactions of Gammagard subcutaneously at Week 12, Adverse Reactions of Gammagard subcutaneously at Week 24, and Adverse Reactions of Gammagard subcutaneously at Week 36, vs. Adverse Reactions of Gammagard subdermally at Week 12, Adverse Reactions of Gammagard subdermally at Week 24, and Adverse Reactions of Gammagard subdermally at Week 36.
89492486|NCT02123615|Experimental|Adverse Reactions Asthma|Asthma as Adverse Reactions of Gammagard subcutaneously at Week 12, Adverse Reactions of Gammagard subcutaneously at Week 24, and Adverse Reactions of Gammagard subcutaneously at Week 36, vs. Adverse Reactions of Gammagard subdermally at Week 12, Adverse Reactions of Gammagard subdermally at Week 24, and Adverse Reactions of Gammagard subdermally at Week 36.
89492487|NCT02123615|Experimental|Adverse Reactions Oropharyngeal|Oropharyngeal as Adverse Reactions of Gammagard subcutaneously at Week 12, Adverse Reactions of Gammagard subcutaneously at Week 24, and Adverse Reactions of Gammagard subcutaneously at Week 36, vs. Adverse Reactions of Gammagard subdermally at Week 12, Adverse Reactions of Gammagard subdermally at Week 24, and Adverse Reactions of Gammagard subdermally at Week 36.
89492488|NCT02123615|Experimental|Adverse Reactions Abdominal Pain|Abdominal Pain as Adverse Reactions of Gammagard subcutaneously at Week 12, Adverse Reactions of Gammagard subcutaneously at Week 24, and Adverse Reactions of Gammagard subcutaneously at Week 36, vs. Adverse Reactions of Gammagard subdermally at Week 12, Adverse Reactions of Gammagard subdermally at Week 24, and Adverse Reactions of Gammagard subdermally at Week 36.
89492489|NCT02123693|Experimental|Osteopathic Manipulative Treatment|5 sessions of treatment will be carried out: the first 3 weekly, and the remaining 2 after 15 days. The type of treatment will be based on indirect techniques
89492490|NCT02123693|Sham Comparator|Sham therapy|5 sessions of treatment will be carried out: the first 3 weekly, and the remaining 2 after 15 days. The type of treatment will be based on specific parameters set out previously based on a predetermined protocol
89492491|NCT02123693|Other|No intervention|Patients in this group will not receive any type of intervention, both therapeutic than fictitious, and will not be evaluated by any operator
89492492|NCT02116907|Experimental|Perampanel|14C-labeled perampanel dissolved in ethanol and administered using a capsule formulation in a single dose, one day
89492493|NCT02116985|Experimental|Dual-Loop TCI|the controller in the current study measures and calculates the error(NI error),which is the difference between the set point(NI=36)and the measured NI.If the NI error is different from 0,the controller determines a new propoflo and/or remifentanil concentration.
89492494|NCT02116985|Placebo Comparator|manual|the investigator modified the effect-site target concentrations of both drugs without minimum or maximum concentration limits without using the Narcotrend monitor only depend on the experience of anesthesiologist.
89492495|NCT03553121|Active Comparator|Walk preoperativelying|Patients will be operated gynecologic cancers and have American Society of Anesthesia score 1 or 2. Subjects will walk during one hour with average speed 3 km/hour 12 hour before surgery.
89492496|NCT03553121|Active Comparator|not walking preoperatively|Patients will be operated gynecologic cancers and have American Society of Anesthesia score 1 or 2. Subjects will not walk preoperatively.
89492497|NCT02120651|Active Comparator|Fibrin monomer|40 patients, the material was ready to use in the case of the fibrin monomer it was maintained in cooling according to the indications of lab maintenance and it was taken out a few minutes before using the material to prepare it according to instructional use and thus ensure that the conditions of maintenance of equipment are appropriate to the best outcome with their use.
89492498|NCT02120651|Placebo Comparator|Hemostatic sponge|40 patients, the material was ready to use in the case of the hemostatic sponge was cut into small size, prepared and impregnated with hydrocortisone as in the standard procedure.
89022098|NCT02273700||the Study Population|"The study population consists of patients in the cardiology department at the Nîmes University Hospital with non-valvular atrial fibrillation and who are candidates for treatment with a direct oral anticoagulant: Rivaroxaban (Xarelto®). Patients will be selected according to criteria designed to result in a homogeneous population (associated anticoagulants, etc., see below). For this study, patients must not have had a direct oral anti-Xa (activated Factor 10) in the 6 months preceding enrollment.~Intervention: Rivaroxaban"
89022099|NCT02273778|Other|Routine radiotherapy treatment plus MRI scan and PET-CT scan|
89022100|NCT02273778|Other|Routine radiotherapy treatment|
89022101|NCT02959658|Active Comparator|Active drug|Dimethyl fumarate, 240mg twice daily for 48 weeks
89022102|NCT02959658|Placebo Comparator|Placebo|Placebo Oral Capsules, 2 tablets twice daily for 48 weeks
89022103|NCT04698213|Experimental|intermittent axitinib plus Avelumab|"All patients enrolled in the trail will receive axitinib at 5 mg BID plus avelumab at 10 mg/Kg every two weeks.~Treatment will be continued until progression of disease during the first 36 weeks of therapy. At week 36, patients achieving a tumor decrease ≥ 30% will discontinue axitinib and continue avelumab until progression of disease defined as ≥ 20% increase compared to the tumor burden measured at week 36. At disease progression, axitinib will be restarted at the same dosage used before discontinuation for at least 24 weeks if progression did not occur before. Patients who achieved again tumor decrease of ≥ 30% after 24 weeks of therapy rechallenge with axitinib and avelumab may discontinue axitinib and maintain avelumab until progression of disease in an intermittent manner."
89022104|NCT02273817|Experimental|Ciclesonide Nasal Spray (Apotex, Inc.)|"Ciclesonide nasal spray~Dosage form: contain the aqueous medium of each metered-dose pump spray formulation unit plus the active ingredient, ciclesonide.~Strength: 50 μg per actuation.~Batch/Lot number (Expiry date): JM6697 (May 2012)~Manufacturer: Apotex, Inc."
89022105|NCT02273817|Active Comparator|Omnaris™ nasal spray|"Omnaris™ Nasal Spray,~Dosage form: contain the aqueous medium of each metered-dose pump spray formulation unit plus the active ingredient, ciclesonide~Strength: 50 μg per actuation~Batch/Lot number (Expiry date): 131657 (03/2012)~Manufacturer: Sepracor, Inc."
89022106|NCT02273817|Placebo Comparator|Placebo|"Placebo~Dosage form: Contain the aqueous medium of each metered-dose pump spray formulation unit minus the active ingredient, ciclesonide.~Batch/Lot number (Expiry date): JR3808 (Nov 2012)~Manufacturer: Apotex, Inc."
89492499|NCT02117219|Experimental|MEDI4736 Evaluate MEDI4736 in MDS|Evaluate MEDI4736 monotherapy and MEDI4736 in combination with azacitidine after monotherapy progression in MDS
89492500|NCT02117219|Experimental|MEDI4736 + tremelimumab|Evaluate MEDI4736 in combination with tremelimumab
89492501|NCT02117219|Experimental|MEDI4736 + tremelimumab + azacitidine|Evaluate MEDI4736 in combination with tremelimumab and azacitidine
89492502|NCT03553043|Experimental|Energy Label 1|Alcoholic beverage displayed with Energy label 1
89492503|NCT03553043|Experimental|Energy Label 2|Alcoholic beverage displayed with Energy Label 2
89492504|NCT03553043|Experimental|Energy Label 3|Alcoholic beverage displayed with Energy Label 3
89492505|NCT03553043|Placebo Comparator|Unlabelled|Alcohol beverage displayed unlabelled.
89492506|NCT02117375|Experimental|Patients with multiple sclerosis|80 patients / clinical Follow-up at M0, M6, M12, M18, M24, M30, M36, M42, M48, M54 and M60 / spinal cord MRI follow-up at M0, M12, M24, M36 and M60 / brain MRI follow-up at M0, M12, M24, M36 and M60
89492507|NCT02117375|Experimental|Healthy volunteers|20 healthy volunteers (stability of spinal cord imaging) / spinal cord MRI follow-up at M0 and M24
89492508|NCT02117453|Experimental|Group I|Rosuvastatin 20 mg/day
89492509|NCT02117453|Placebo Comparator|Group II|Placebo
89492510|NCT02117609|Experimental|New DELICAL formula|New high-protein oral nutrient supplement
89492511|NCT02117609|Active Comparator|Standard DELICAL formula|Standard isoenergetic isoprotein formula
89492512|NCT02123771||Helicobactor Pylori Infection|Comparison on the presence/absence of GGT antigen in the stool will be compared between H. pylori-positive and H. pylori-negative subjects. Rapid urease test result from the respective patients will be used as the golden standard. Should the GGT antigen in stool samples show promise in distinguishing between H. pylori-infected and uninfected individuals, sensitivity and specificity of the stool antigen test can then be established.
89492513|NCT02123927|Experimental|Step 1: TAK-438 1 mg|TAK-438 1 mg, tablets, orally, once on Day 1.
89492514|NCT02123927|Experimental|Step 2: TAK-438 5 mg|TAK-438 5 mg, tablets, orally, once on Day 1.
89492515|NCT02123927|Experimental|Step 3: TAK-438 10 mg|TAK-438 10 mg, tablets, orally, once on Day 1.
89492516|NCT02123927|Experimental|Step 4: TAK-438 20 mg|TAK-438 20 mg, tablets, orally, once on Day 1.
89492517|NCT02123927|Experimental|Step 5: TAK-438 40 mg|TAK-438 40 mg, tablets, orally, once on Day 1.
89492518|NCT02123927|Experimental|Step 6: TAK-438 80 mg|TAK-438 80 mg, tablets, orally, once on Day 1.
89492519|NCT02123927|Experimental|Step 7: TAK-438 120 mg|TAK-438 120 mg, tablets, orally, once on Day 1.
89492520|NCT02123927|Placebo Comparator|Steps 1-7: Placebo|TAK-438 placebo-matching tablets, orally, once on Day 1.
89022107|NCT00346853|Experimental|1|
89022108|NCT00346853|Placebo Comparator|2|saline
89022109|NCT00346970|Experimental|1|Extended-release Niacin
89022110|NCT00346970|Placebo Comparator|2|Placebo
89022111|NCT00347048|Experimental|1|
89022112|NCT00347048|Placebo Comparator|2|
89022113|NCT00455169||1|Premature infants
89022114|NCT00455169||2|Full term infants
89022115|NCT03276429||Lung Cancer patients|All patients with lung cancer that referred to a tertiary Oncology Unit.
89022116|NCT00448851|Experimental|1|inhaled allergen challenge
89022117|NCT00347321|Experimental|Dilatational Percutaneous tracheostomy|Dilatational Percutaneous tracheostomy
89022118|NCT00448929|Experimental|Trabeculectomy with Oculusgen|
89022119|NCT00448929|No Intervention|Trabeculectomy without Oculusgen or antifibrotic agents|
89022120|NCT00347555|Experimental|Group D|18 subjects 160 micrograms EBA-175+500 micrograms aluminum adjuvant; 2 subjects placebo.
89022121|NCT00347555|Experimental|Group A|18 subjects 5 micrograms EBA-175+500 micrograms aluminum adjuvant; 2 subjects placebo.
89022122|NCT00347555|Experimental|Group B|18 subjects 20 micrograms EBA-175+500 micrograms aluminum adjuvant; 2 subjects placebo.
89538011|NCT03196141|Active Comparator|Pregnant women with normal BP|"Part #2: 20 participants, 10 normotensive and 10 pre-eclamptic pregnant women during their visit to labor floor.~Session 1: Both StO2 and EndoPAT will be applied simultaneously to the same arm below a BP cuff. Baseline readings will be taken for 5 minutes, the blood pressure cuff will be inflated to suprasystolic pressure StO2 and pulsatile volume changes will be measured by peripheral arterial tonometry, continuous measurement for 3 min and repeated every 10 minutes for 3 sessions.~Additionally, vascular stiffness with be measured by SphygmoCor to measure pulse wave velocity (PWV).~Participants must also agree to participate OB/GYN biobanking protocol HIC# 1601017004 to be in this study.~All participants will have follow-up at 48 hours, including a blood draw, assessment of endothelial function and vascular stiffness."
89538012|NCT03196141|Active Comparator|Pregnant women with high BP|"Part #2: 20 participants, 10 normotensive and 10 pre-eclamptic pregnant women during their visit to labor floor.~Session 1: Both StO2 and EndoPAT will be applied simultaneously to the same arm below a BP cuff. Baseline readings will be taken for 5 minutes, the blood pressure cuff will be inflated to suprasystolic pressure StO2 and pulsatile volume changes will be measured by peripheral arterial tonometry, continuous measurement for 3 min and repeated every 10 minutes for 3 sessions.~Additionally, vascular stiffness with be measured by SphygmoCor to measure pulse wave velocity (PWV).~Participants must also agree to participate OB/GYN biobanking protocol HIC# 1601017004 to be in this study.~All participants will have follow-up at 48 hours, including a blood draw, assessment of endothelial function and vascular stiffness.~Participants with hypertension will be followed in conjunction with routine clinical follow-up at 2, 6 and 12 weeks post-partum."
89538013|NCT03292367||ldTRA|Patients who are planned to perform coronary angiography will be enrolled via left distal radial artery
89538014|NCT03196375|Experimental|Experimental|
89538015|NCT03196375|Placebo Comparator|Placebo Comparator|
88954006|NCT01967992|Active Comparator|American Diabetes Association recommended diet|"Participants in the American Diabetes Association (ADA) diet group will receive standard ADA advice. The diet includes high-fiber foods (such as vegetables, fruits, whole grains, and legumes), low-fat dairy products, fresh fish, and foods low in saturated fat. They will be asked to use the plate method to guide their nutritional choices."
88954007|NCT01967992|Experimental|Low Carbohydrate Diet|"Participants will be instructed to follow a low carbohydrate, ketogenic diet: carbohydrate intake 20-35 grams a day not including fiber. Foods permitted include: meats, poultry, fish, eggs, cheese, cream, some nuts and seeds, green leafy vegetables, and most other non-starchy vegetables. Because most individuals self-limit caloric intake, no calorie restriction will be recommended.~Participants will also be taught information about mindfulness and positive affect practices. The mindfulness-based curriculum will focus on the following elements: training on topics such as mindful meditation, mindful eating, awareness of fullness and hunger signals, and taste satiety. The positive emotion curriculum will include: training on topics such as noticing and savoring positive events, gratitude, positive reappraisal, personal strengths, attainable goals, and acts of kindness."
88954008|NCT01968005|Placebo Comparator|Placebo|Therapy with placebo
88954009|NCT01968005|Experimental|Etoreat®(Etodolac-Lidocaine Topical Patch)|Therapy with experimental drug
88954010|NCT01968018|Experimental|Tramadol HCI + acetaminophen|
88954011|NCT01968044|Experimental|Gemigliptin|Participant will remain gemigliptin 50mg throughout entire study (52 weeks).
88954012|NCT01968044|Other|Placebo to linagliptin|Participant who is randomized to placebo will be switched to linagliptin after 12 week and administered linagliptin by week 52.
88954013|NCT01968083|Experimental|RSV cps2 Vaccine|Participants will receive one dose of the RSV cps2 vaccine administered as nose drops at study entry.
88954014|NCT01968083|Placebo Comparator|Placebo|Participants will receive one dose of placebo administered as nose drops at study entry.
88954015|NCT01968096|No Intervention|SCI subjects|Stage 1 subjects: pilot study:understand post activation depression with spinal cord injury to avoid the influence of the suprasegmental level.
88954016|NCT01968096|No Intervention|Incomplete SCI subjects|Stage 2 subjects: pilot study:The strength of depression will be evaluated in individuals with and without SCI.
89022123|NCT00347555|Experimental|Group C|18 subjects 80 micrograms EBA-175+500 micrograms aluminum adjuvant; 2 subjects placebo.
89492521|NCT02123927|Experimental|Step 8A: TAK-438 10 mg|TAK-438 10 mg, tablets, orally, under fasted conditions, once on Day 1, Period 1, followed by a 13 day washout period, followed by TAK-438 10 mg, tablets, orally, under fed conditions, once on Day 1, Period 2.
89492522|NCT02123927|Experimental|Step 8 B: TAK-438 10 mg|TAK-438 10 mg, tablets, orally, under fed conditions, once on Day 1, Period 1, followed by a 13 day washout period, followed by TAK-438 10 mg, tablets, orally, under fasted conditions, once on Day 1, Period 2.
89492523|NCT02123927|Experimental|Step 9A: TAK-438 40 mg|TAK-438 40 mg, tablets, orally, under fasted conditions, once on Day 1, Period 1, followed by a 13 day washout period, followed by TAK-438 40 mg, tablets, orally, under fed conditions, once on Day 1, Period 2.
89492524|NCT02123927|Experimental|Step 9B: TAK-438 40 mg|TAK-438 40 mg, tablets, orally, under fed conditions, once on Day 1, Period 1, followed by a 13 day washout period, followed by TAK-438 40 mg, tablets, orally, under fasted conditions, once on Day 1, Period 2.
89492525|NCT02123927|Placebo Comparator|Steps 8 (A & B) and 9 (A & B): Placebo|TAK-438 placebo-matching tablets, orally, once on Day 1, Period 1, followed by a 13 day washout period, followed by TAK-438 placebo-matching tablets, orally, once on Day 1, Period 2.
89492526|NCT02124005|Experimental|Femoral block, ultrasound, bupivacaine|
89492527|NCT02120729|No Intervention|Standard of Care|Patients assigned to standard-of-care pharmacotherapy, for whom CYP2D6 genotype is determined but not utilized to guide drug prescription and psychotropic therapy follows the institutional norm.
89492528|NCT02120729|Active Comparator|Genotype-guided Care|Patients assigned to genetically-guided pharmacotherapy, for whom CYP2D6 genotype is determined but not utilized to guide drug prescription as part of psychotropic therapy.
89492529|NCT02120885|Experimental|Exercise group|physical activity intervention
89492530|NCT02120885|No Intervention|Control group|
89492531|NCT02117765|Experimental|Treatment|"Four cohorts of 5 subjects will be recruited:~Group 1: Five subjects will be given Ustekinumab 45mg SC at 0, 4, 16, 28 and 40 weeks.~Group 2: Five subjects will be given Ustekinumab 90mg SC at 0, 4, 16, 28 and 40 weeks.~Group 3: Five subjects will be given Ustekinumab 45 mg SC at 0,4 and 16 weeks.~Group 4: Five subjects will be given Ustekinumab 90mg SC at 0, 4 and 16 weeks."
89492532|NCT02251535|Experimental|test group 1|Retrospective test group 1 (n=10, ATTUNE® Knee System, rotating platform, cruciate retaining) with intraoperative high level rollback
89492533|NCT02251535|Experimental|test group 2|Retrospective test group 2 (n=10, ATTUNE® Knee System, rotating platform, cruciate retaining)with intraoperative low level rollback
89492534|NCT02251535|Experimental|control group|Control group (n=10, PFC® SIGMA® Knee System, rotatinq platform, cruciate retaininq)
89492535|NCT02120963|Experimental|intervention program|Person-centered physical therapy intervention program
89492536|NCT02120963|No Intervention|Control group|Health care as usual
89492537|NCT02121119|Active Comparator|Lidocaine|0.5% lidocaine infusion hour to 5 ml Baxter Infusor elastomeric pump 5 ml / hr.
89492538|NCT02121119|Placebo Comparator|Bupivacaine|Infusion of 0.1% bupivacaine hour to 5 ml Baxter Infusor elastomeric pump 5 ml / hr.
89492539|NCT02124239|Experimental|Scalp|Treatment of scalp with 0.027% ingenol mebutate once daily for 3 days
89492540|NCT02124239|Experimental|Arm|Treatment of arm with 0.06% ingenol mebutate once daily for 4 days
89492541|NCT02124239|Experimental|Face|Treatment of face with 0.027% ingenol mebutate once daily for 3 days
89492542|NCT02124317|Experimental|nanoparticle albumin-bound paclitaxel, S-1|nanoparticle albumin-bound paclitaxel is given at 120 mg/m2 intravenously on day 1 and 8, in combination with S-1 which is orally administered (40-60 mg according to the body surface, twice a day) on day 1-14 of each 21 day cycle. Number of cycle: 6 cycles.
89492543|NCT02601560|Experimental|MEDI6012 24 mg IV|Participants received a single IV dose of 24 mg MEDI6012 on Day 1.
89492544|NCT02601560|Experimental|MEDI6012 80 mg IV|Participants received a single IV dose of 80 mg MEDI6012 on Day 1.
88954017|NCT01968096|No Intervention|Health subjects|Stage 2 subjects: pilot study:The strength of depression will be evaluated in individuals with and without SCI.
88954018|NCT01968096|Experimental|SCI subjects with high muscle tone (High frequency)|Stage 3 subjects:A rehabilitation program of machine driven passive stretch(High frequency) will be executed .
89492545|NCT02601560|Experimental|MEDI6012 240 mg IV|Participants received a single IV dose of 240 mg MEDI6012 on Day 1.
89492546|NCT02601560|Experimental|MEDI6012 800 mg IV|Participants received a single IV dose of 800 mg MEDI6012 on Day 1.
89492547|NCT02601560|Experimental|MEDI6012 80 mg SC|Participants received a single SC dose of 80 mg MEDI6012 on Day 1.
89492548|NCT02601560|Placebo Comparator|Placebo Intravenous (IV)|Participants received a single IV dose of placebo matched to MEDI6012 on Day 1 of the study.
89492549|NCT02601560|Experimental|MEDI6012 600 mg SC|Participants received a single SC dose of 600 mg MEDI6012 on Day 1.
89492550|NCT02601560|Placebo Comparator|Placebo Subcutaneous (SC)|Participants received a single SC dose of placebo matched to MEDI6012 on Day 1 of the study.
89492551|NCT02117843|Experimental|AVI® Arsenic trioxide drug eluting stent|The Arsenic trioxide as AVI eluting drug, biodegradable polylactic acid as drug carrier.
89022124|NCT00455598|Placebo Comparator|A|Sulfonylurea + 100 mg/week ISIS 113715 or placebo
89492552|NCT02117921|Experimental|MBS therapy education|
89492553|NCT02121353|Experimental|PF582|PF582 is provided as single use vials and will be administered by intra-vitreal injection on Day 1, 28 and 56.
89492554|NCT02121353|Active Comparator|Lucentis|Lucentis® is provided as single use vials and will be administered by intra-vitreal injection on Day 1, 28 and 56.
88954019|NCT01968096|Experimental|SCI subjects with high muscle tone(low frequency)|Stage 3 subjects:A rehabilitation program of machine driven passive stretch(Low frequency) will be executed.
88954020|NCT01968096|No Intervention|SCI subjects with high muscle tone|Stage 3 subjects:Control subjects
89492555|NCT02118077|Experimental|G17DT|250 µg administered at Weeks 0,1,3 and 24 by intramuscular injection, followed by additional injections (boosters) of 250 µg every 6 months at investigator's discretion.
89492556|NCT02118077|Placebo Comparator|Placebo|Placebo administered at Weeks 0, 1, 3, and 24 by intramuscular injection followed by additonal injections of placebo every 6 months.
88954021|NCT01968122||aggressive medical treatment|administer Aspirin (100mg/d) + Clopidogrel (75mg/d) for more than 5d before the operation (but Clopidogrel of loading dose 200mg in case of emergency operation for TIA); administer Aspirin (100mg/d) + Clopidogrel (75mg/d) for 90d and subsequent monoclonal antibody after the operation; control the primary risk factors (e.g. hypertension and high LDL); control the secondary risk factors (e.g. diabetes, blood lipid of not high LDL, smoking, obesity and hypomotility); and intervene the life style. Primary risk factors: target systolic pressure of <140mmHg (or <130mmHg in the diabetes patients); and LDL <70mg/dl (1.81mmol/L) or drop by 50%.
88954022|NCT01968161|Other|Asenapine|Open label switch to asenapine: asenapine will be introduced at the target dose (5 mg bid)
89204712|NCT05189002|Active Comparator|Group 2|Patients from the control group (group 2) were received Fragmin in accordance with the instruction for medical use (5000 IU s/c once a day with 24-hour interval) and six Placebo tablets masked as study product Dimolegin - DD217 once a day.
89492557|NCT02124473|Experimental|Homeopathy|A range of homeopathic potencies were used as per the individualized requirement, decided by the treating physicians.Each dose, administered orally, (in centesimal potencies).
89492558|NCT02124473|Placebo Comparator|Placebo|Placebo, identical in appearance, consisted of 83.1% ethanol in 10 ml distilled water and was served in identical amber-coloured glass vials
89492559|NCT02121431|Experimental|Online-Delivered Parenting Intervention|The Online-Delivered Parenting Intervention, which is based on the Triple P--Positive Parenting Program system of interventions, is an interactive website designed to engage and activate the participant through sequenced, personalized, interactive, and video-based content. The intervention emphasizes a self-regulatory process, parent specification of goals, practical and straightforward parenting strategies, modeling, and action activation.
89492560|NCT02121431|Active Comparator|Staff-Delivered Parenting Intervention|The Staff-Delivered Parenting Intervention is based on the Triple P--Positive Parenting Program system and involves 10 face-to-face sessions with each family. This intervention is the well-established Level 4 Standard Triple P program.
89492561|NCT03551717||High cardiovascular risk patients|Adult patients hospitalized in the Cardiology Department of the University Hospital of Dijon Burgundy for acute coronary syndrome, patients between D1 and D5 of acute coronary syndrome, who can be moved for an ophthalmology consultation where the retinal imaging is done (heart monitoring in the presence of an experienced cardiologist if necessary)
89492562|NCT03551717||Low cardiovascular risk patients|"Adult patients recruited in the Ophthalmology Department of the University Hospital of Dijon Burgundy following a standard consultation for cataract surgery.~The age balance of the patients included in the two groups will be checked regularly."
89492563|NCT05617430|Experimental|HAIC + Sintilimab + Bevacizumab|HAIC combine with Sintilimab and bevacizumab biosimilar
89492564|NCT03552887||Postoperative patients|Cohort of patients undergoing cardiac surgery, aged ≥ 18 years old, who had received any physiotherapy intervention
89492565|NCT04813094|Experimental|Internet-Based integrated-management Program|The Internet-based integrated management Program system have five domains that included patient's information collection, AF knowledge area, instructions on anticoagulation medicine, self-monitoring of symptom area, and professional consultation. Participants will have their own account and passwords to log in to the system via mobile phones or computers. Everyone will have their own area to ensure the privacy of participants. The research nurse will have sent messages every day to care about the participant's condition.
89492566|NCT04813094|Active Comparator|Control group|Patients in the control group will receive standard nurse consultations and three-time telephone coaching.
89492567|NCT02118155|Sham Comparator|Connective tissue graft (CTG)|The gingival recession defects were treated by connective tissue graft surgical procedure and received the sham application os low-intensity laser therapy.
89492568|NCT02118155|Experimental|Connective tissue graft plus laser (CTG+L)|The gingival recession defects were treated by connective tissue graft associated with the application of a LILT protocol
89492569|NCT02118233||Carotid Endarterectomy (CEA)|Surgical Revascularization- Carotid Endarterectomy (CEA)
89492570|NCT02118233||Carotid Angioplasty and Stenting (CAS)|Surgical Revascularization- Carotid Angioplasty and Stenting (CAS)
88954023|NCT01968174||eyelid displacement|patients suffering from eyelid disposition due to ptosis, blepharochalasis and are registered for eyelid surgeries will be assigned for the study
88954024|NCT01968239|Experimental|OCT guided group|Patients randomized to this group will get the intravitreal injection of 0.5 mg ranibizumab if the morphological macular changes for recurrence of macular edema (microcystic changes with or without increase of central retinal thickness) will be detected by OCT.
88954025|NCT01968239|Active Comparator|Standard treatment|Patients randomized to this group will get the intravitreal injection of 0.5 mg ranibizumab according to the in SmPC defined re-treatment criteria (re-injection if decrease of BCVA will be detected).
89022125|NCT00455598|Placebo Comparator|B|Sulfonylurea + 200 mg/week ISIS 113715 or placebo
89022126|NCT00347594|Experimental|Next Generation Diagnostic Instrument|Next Generation Diagnostic Instrument (NGDI)
89492571|NCT02118233||Control Group- Medical Management|Control Group- Medical Management
89492572|NCT02251691|Experimental|Advagraf|Take Advagraf once daily
89492573|NCT02251691|Active Comparator|Prograf|Take tacrolimus twice daily
89492574|NCT02595398|Experimental|4mg CLS-TA Suprachoriodal Injection|Suprachoroidal injection of 40 mg/mL (4 mg in 100 µL) of CLS-TA
89492575|NCT02595398|Sham Comparator|Sham Procedure|Matching suprachoroidal syringe with sham procedure
89204713|NCT00644358|Experimental|Vilazodone|Vilazodone titrated up to 40 mg/day for 1 year.
89204714|NCT01564498|Placebo Comparator|White potato|Participants will consume 300-500 g of cooked white potatoes per day
89492576|NCT02251769|Experimental|Sequential administration|
89538016|NCT03292211|Experimental|early mobilization|early mobilization group will commence rehabilitation consisting of out-of-bed mobilization (including supine to sit training, sit on the edge of bed without supporting, standing with hand supporting, stepping while standing etc.)
89538017|NCT03292211|Other|early standard intervention|early standard intervention included bed exercises including the joint range of motion exercise, bridge exercise, the straight leg raising exercise, stretching exercises, and the facilitation techniques during the period in a stroke center.
89204715|NCT01564498|Experimental|Purple Potato|Participants will consume 300-500 g of cooked purple potato per day
89492577|NCT03552809|Active Comparator|Conventional Frenectomy|For the conventional surgery, after application of local infiltration anesthesia of articaine HCL associated with epinephrine 1:100,000, the frenulum was grasped with a straight haemostat inserted into the depth of the vestibule; the tissue adjacent to the upper and lower surfaces of the haemostat was incised with a no.15 scalpel. After the diamond shaped resected portion of the frenulum was removed with the haemostat, muscle dilatations were excised on the submucosa of the lateral walls of the cavity. Horizontal incision was made on the periosteum with the help of a scalpel following the procedure. At the end of the operation, the wound was closed with absorbable sutures (4-0, Pegelak®, Doğsan Turkey).
89492578|NCT03552809|Experimental|Diode Laser Frenectomy|For the laser frenectomy, a diode laser device (λ = 810 nm, W: 4, GIGA Cheese II, China) was used to perform the procedure. The procedure was performed under local infiltration anesthesia with articaine HCL associated with epinephrine 1:100,000. The frenlum was held by a haemostat inserted into the depth of the vestibule while laser energy was applied to the upper and lower parts of the frenulum adjacent to the haemostat via a fibre tip (400 µm diameter, plain-ended, optical ﬁbre). The laser was carefully applied to the tissue and care was taken to avoid local necrosis of the periosteum or any bone structure.Following the bleeding control, the wound site was left to secondary healing. No sutures were necessary after procedure.
89492579|NCT03552809|Experimental|Laser Frenectomy with Incision|For the laser frenectomy, a diode laser device (λ = 810 nm, W: 4, GIGA Cheese II, China) was used to perform the procedure. The procedure was performed under local infiltration anesthesia with articaine HCL associated with epinephrine 1:100,000. The frenulum was held by a haemostat inserted into the depth of the vestibule while laser energy was applied to the upper and lower parts of the frenulum adjacent to the haemostat via a fibre tip (400 µm diameter, plain-ended, optical ﬁbre). The laser was carefully applied to the tissue and care was taken to avoid local necrosis of the periosteum. Horizontal incision was made on the periosteum with the help of a scalpel, additionally. No sutures were necessary after procedure.
89492580|NCT02121587||Pain self-management course|This is a single group observational cohort study. Participants are adults with persistent musculoskeletal pain who choose to participate in an optional, six week pain self-management course which integrates mindfulness and acceptance-based exercises into osteopathic manual therapy treatment for individual patients.
89492581|NCT04818710|Placebo Comparator|skin incision with a scalpel|In the scalpel group, the incision was made by the traditional method, with proper homeostasis by applying pressure to skin blood vessels and ligating the subcutaneous bleeding.
89492582|NCT04818710|Active Comparator|skin incision with diathermy|In the diathermy group, the incision made using a small flat blade pen electrode, set on cutting mode and delivering a 120 watt (maximum) sinusoidal current, electrosurgical cutting performed without pressure or mechanical displacement.
89492583|NCT04813250|Sham Comparator|Group R|IMV(intermittent mandatory ventilation) Regular Ventilation with Tidal volume with 7ml/ kg (Predicted body weight)
89492584|NCT04813250|Experimental|Group RP|Regular Ventilation with Tidal volume with 7ml/ kg (Predicted body weight) + PEEP : 6 cm H2O
89492585|NCT04813250|Experimental|Group RI|Regular Ventilation with Tidal volume with 7ml/ kg (Predicted body weight) + Reverse IE ratio ventilation( I:E=1:1)
89492586|NCT04813250|Experimental|Group RPI|Regular Ventilation with Tidal volume with 7ml/ kg (Predicted body weight) + PEEP : 6 cm H2O + Reverse IE ratio ventilation( I:E=1:1)
89492587|NCT02118311|Experimental|TREG|T regulatory cells after non-myeloablative (using fludarabine, cyclophosphamide, and total body irradiation) umbilical cord transplant.
89492588|NCT02118311|Experimental|Non-Myeloablative Only|Non-myeloablative (using fludarabine, cyclophosphamide, and total body irradiation) umbilical cord transplant.
89538018|NCT03288233||Primary Group|
88954026|NCT01968252||Intraoperative Patient|All patients in the cohort will be scheduled to undergo a planned surgical procedure in which the subject will undergo general anesthesia and the procedure and/or the patient will require transesophageal echocardiographic monitoring for the procedure.
88954027|NCT01968265|Placebo Comparator|Placebo|
88954028|NCT01968265|Active Comparator|ISIS-GCCRRx|
88954029|NCT01968278|Experimental|Baked milk group|BM (baked milk)
88954030|NCT01968278|No Intervention|Control|IgE-cow's milk allergic patients not treated with OIT
88954031|NCT01968291|Experimental|Teach-back|Patients are prompted to state back in their own words their comprehension of the information given to them at discharge.
88954032|NCT01968291|No Intervention|Standard Discharge Instructions|Patient receives usual discharge instructions as administered by the nurse assigned to the patient.
88954033|NCT01968304|No Intervention|Iron status follow up|
88954034|NCT01968330|Experimental|Go!®to sleep|Patients in the sleep intervention arm will undergo a sleep wellness program entitled Go!®to sleep as part of their group prenatal visits. This intervention is a six-week online program developed by the Cleveland clinic for non-pregnant patients suffering from insomnia. In collaboration with the Cleveland clinic sleep disorders center researchers will modify the program to fit the specific needs of a pregnant population. Subjects will receive access to the program and instructed on its use at their initial group prenatal visit. In subsequent visits subjects will be able to discuss their experience with the program.
88954035|NCT01968330|No Intervention|Routine prenatal care|Patients in the routine prenatal care arm will complete prenatal care in a group setting and will not complete the sleep intervention.
88954036|NCT01968343|Experimental|Group cognitive-behavioral therapy|22 subjects, all of whom met the criteria for a diagnosis of trichotillomania established in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Subjects receive 22 sessions of group cognitive-behavioral therapy.
88954037|NCT01968343|Active Comparator|Group supportive therapy (control)|22 subjects, all of whom met the criteria for a diagnosis of trichotillomania established in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Subjects receive 22 sessions of group supportive therapy (control).
88954038|NCT01968369|Active Comparator|tomato sauce (+/- high fat meal)|80 gr for 7 days= total load 560 mg (+/- high fat meal)
88954039|NCT01968369|Placebo Comparator|diet without tomato (+/- high fat meal)|diet without tomato (+/- high fat meal)
88954040|NCT01966640|Experimental|Child food allergy suspicion|Basophil Activation Test realized in case of Child food egg and peanut allergy suspicion
88954041|NCT01968395|Other|Caspofungin 70 mg|Infusion of one dose of Caspofungin 70 mg
89492589|NCT04812782|Experimental|EVOO-Butter|All patients and control subjects who met inclusion and exclusion criteria, and signed the Informed Consent, were scheduled for the two study visits, one week apart, during which each participant received two types of high GI meal: the first enriched with EVOO and the second with butter.
89492590|NCT04812782|Experimental|Butter-EVOO|All patients and control subjects who met inclusion and exclusion criteria, and signed the Informed Consent, were scheduled for the two study visits, one week apart, during which each participant received two types of high GI meal: the first enriched with Butter and the second with EVOO
89492591|NCT02121665|Experimental|Probiotic (Inersan) Arm|Inersan Lozenges (4 Lozenges per day; 1 lozenge in morning,1 lozenge in the afternoon and 2 lozenges in the night). Each probiotic lozenge contains not less than 1 billion CFU of L. brevis CD2
89492592|NCT02121665|Placebo Comparator|Placebo Arm|Placebo Lozenges (4 Lozenges per day; 1 lozenge in morning,1 lozenge in the afternoon and 2 lozenges in the night). Each placebo lozenge contains all excipients except the active constituent (Lactobacillus brevis CD2)
89492593|NCT02118389|Experimental|Glucerna,Meal Replacement|Glucerna 52g instead of night meal 5weeks
89492594|NCT04802252||62 patients with benign prostatic hyperplasia in the experimental group|The pulse sound waves of three parts and five layers of each of the two hands of 62 patients with benign prostatic hyperplasia were collected by acoustic pulse detection system.
89492595|NCT04802252||62 relatively healthy men without benign prostatic hyperplasia in the control group|The pulse sound waves of three parts and five layers of each of the two hands of 62 relatively healthy men without benign prostatic hyperplasia were collected by acoustic pulse detection system.
89492596|NCT03552263|Experimental|T89 low-dose group|"T89 capsule is a botanical drug containing 75mg active substance which is the water extract of Danshen and Sanqi. Placebo capsule does not contain any amount of active substance.~Subjects in this group will use three T89 capsules and one Placebo capsule each time by oral administration twice daily for 19 days."
89492597|NCT03552263|Experimental|T89 high-dose group|"T89 capsule is a botanical drug containing 75mg active substance which is the water extract of Danshen and Sanqi. Placebo capsule does not contain any amount of active substance.~Subjects in this group will use four Placebo capsules each time by oral administration twice daily for 12 days followed by using four T89 capsules each time by oral administration twice daily for 7 days"
89492598|NCT03552263|Placebo Comparator|Placebo group|Placebo capsule does not contain any amount of active substance. Subjects in this group will use four Placebo capsules each time by oral administration twice daily for 19 days.
88954042|NCT01968408|Active Comparator|L. reuteri DSM 17938|"Lactobacillus reuteri DSM 17938,10(9)CFU/daily (for the duration of hospitalization)~ARM I: Rotavirus vaccinated patients~ARM II: Non-rotavirus vaccinated patients"
88954043|NCT01968408|Placebo Comparator|Placebo|"Placebo consists of an identical formulation in all respects except that the live probiotic bacteria were excluded~for the duration of hospitalization"
88954044|NCT01968473|Experimental|NMES Device comfort|NMES Device comfort, establishing Sensory, Motor and Pain thresholds. Max Pain tolerance is also established.
88954045|NCT01968486|Experimental|PDT Standard Fluence, ranibizumab|verteporfin (6 mg/m2) SF (wavelength, 689 nm; dose, 50 J/cm2; light intensity, 600 milliwatt(mW)/cm2 for 83 s) plus 0.5 mg intravitreal ranibizumab
88954046|NCT01968486|Experimental|PDT Reduced Fluence, ranibizumab|verteporfin (6 mg/m2) RF ( wavelength, 689 nm; dose, 25 J/cm2 ; light intensity, 300 mW/cm2 for 83 s) plus 0.5 mg intravitreal ranibizumab
88954047|NCT01968486|Experimental|ranibizumab|0.5 mg (10 mg/ml) intravitreal ranibizumab.
88954048|NCT01968499||All recruited patients|Patients who receive stent implantation and aged >18 years.
89492599|NCT04802486|Experimental|Arm 1: Exercise Intervention and Standard Care|A home-based exercise intervention as well as standard care for your cancer as prescribed by your oncologist
89492600|NCT04802486|No Intervention|Arm 2: Standard Care|Standard care for your cancer as prescribed by your oncologist
89492601|NCT04818476||HR-T1a|Patients who weretreated by radical endoscopic resection for a high-risk mucosal EAC (HR-T1a N0M0)
89492602|NCT04818476||LR-T1b|Patients who were treated by radical endoscopic resection for a low-risk submucosal EAC (LR-T1b N0M0)
89492603|NCT04818476||HR-T1b|Patients who were treated by radical endoscopic resection for a high-risk submucosal EAC (HR-T1b N0M0)
89492604|NCT01368497|Experimental|Entecavir and peginterferon|Entecavir for 8 weeks followed by 40 weeks of both entecavir and peginterferon
89492605|NCT04802330||Female genital mutilation|Assessment of FGM prevalence in Beni Suef localities and its impact on studied women.
89492606|NCT02595008|Experimental|DSXS topical product|treatment with DSXS twice daily for 28 days
89492607|NCT02118545||vWF and postoperative Outcome|An independent prospective validation cohorts will be obtained from 4 different Institutions: 2 in Vienna , 1 in Salzburg and 1 in Bern
89538019|NCT03117829|Experimental|Improve Brain Blood Flow|12 week diet and exercise program to improve brain blood flow
88954049|NCT01968512|Experimental|Transcranial Direct Current Stimulation|Subjects will undergo to Transcranial Direct Current Stimulation with anode in left dorsolateral prefrontal cortex and cathode in right supra orbicular region. The stimulus will be 1mA for 20 minutes.
89022127|NCT00347594|Active Comparator|Zyoptix Diagnostic Workstation|Zyoptix Diagnostic Workstation (ZDW)
89538020|NCT03288155|Experimental|Flavonoid rich cocoa|Dark cocoa beverage rich in flavonoids
89538021|NCT03288155|Placebo Comparator|Low flavonoid cocoa|A control cocoa beverage low inn flavonoids
89538022|NCT04484233||Control Group|Anesthesiologists would have to respond to an online questionnaire about 10 hypotheticals clinical situations regarding patient blood management.
89492608|NCT04812704|Experimental|Nutritional complement|"A prospective study will be carried out including adult patients with neoplasia who should benefit in their therapeutic strategy from oncological surgery. About fifty patients will be recruited in the oncology / surgery department at the Saint-Luc University Clinics in Brussels. Patients will be assessed at the initial consultation and after the pre-habilitation period, ie the day before the operation.~Dietary monitoring will be carried out in parallel with a physical and respiratory preparation program (prehabilitation) and the intake of protein nutritional supplements in the form of powder to be diluted will be carried out after each exercise session."
89492609|NCT02118623|Active Comparator|Level 1|Moderated discussion board only
89492610|NCT02118623|Active Comparator|Level 2|Moderated discussion board plus psychoeducation
89492611|NCT02118623|Active Comparator|Level 3|Moderated discussion board plus psychoeducation plus interactive psychosocial tools.
89492612|NCT04812860|Experimental|HR18042 100mg|
89492613|NCT04812860|Experimental|HR18042 125mg|
89492614|NCT04812860|Experimental|HR18042 200mg|
89492615|NCT04812860|Active Comparator|Tramadol hydrochloride ER 100mg|
89492616|NCT04812860|Placebo Comparator|Placebo to match HR18042 and Tramadol hydrochloride ER|
89492617|NCT02118701|Experimental|SDM care planning|
89492618|NCT04812236|Experimental|Single decoction group: Wulingsan single decoction granules|Wulingsan single decoction granules, Alisma orientalis (15g), Polyporus (10g), Baizhu (10g), Poria (10g), Guizhi (6g). Take 1 bag each time with warm water twice a day.Take 12 weeks as a course of treatment.
89492619|NCT04812236|Other|Co-decocting group: Wulingsan co-decocting granules|Wulingsan co-decoction granules, Alisma orientalis (15g), Polyporus (10g), Atractylodes (10g), Poria (10g), Guizhi (6g). Take 1 bag each time with warm water twice a day.Take 12 weeks as a course of treatment.
89492620|NCT04812236|Other|Powder group: Wuling powder powder|Wuling powder is composed of Alisma, Polyporus, Atractylodes, Poria, Guizhi. Take 5g each time with warm water twice a day.Take 12 weeks as a course of treatment.
89492621|NCT04812236|Placebo Comparator|Simulant group: Simulant of granular dosage form|Granule simulant, the composition is Alisma orientalis (15g), Polyporus (10g), Atractylodes (10g), Poria (10g), Guizhi (6g). Take 1 bag each time with warm water twice a day. Take 12 weeks as a course of treatment.
89492622|NCT04817930|Experimental|Patient specific chin implant|A patient specific chin peek implant was used for chin augmentation
89492623|NCT04817930|Experimental|computer guided advancement genioplasty|Computer guided advancement genioplasty using patient specific cutting and positioning guides
89492624|NCT02126813|Active Comparator|500 ml.|A bladder volume of 500 ml. or more, and incapability of voluntary micturition, is used as interventional threshold for urinary bladder catheterization.
89492625|NCT02126813|Experimental|800 ml|A bladder volume of 800 ml. or more, and incapability of voluntary micturition, is used as interventional threshold for urinary bladder catheterization.
89492626|NCT04817852|Experimental|CBCT data of C-shaped canal in mandibular second molar will Be assessed for age.|Detection of variation in root canal morphology by using CBCT.
89492627|NCT03551561|Active Comparator|CSAAC group|The CSAAC group (chlorhexidine-based soap + ethyl alcohol + alcoholic chlorhexidine): skin preparation process with 4% chlorhexidine-based soap for a period of 5 minutes, followed by a sterile and soaked with 70% alcohol compress. After removing the chlorhexidine-based soap excess, antisepsis was performed with alcoholic chlorhexidine and surgical drapes and gowns. Cultures were performed in the mannitol and EMB (Eosin Methylene Blue) media after being collected at the pre-skin preparation, post-skin preparation process and end of the surgical procedure.
89492628|NCT03551561|Active Comparator|CSAC group|The CSAC group (chlorhexidine-based soap + alcoholic chlorhexidine): skin preparation process with 4% chlorhexidine-based soap for a period of 5 minutes and the of a simple, dry and sterile compress to remove the excess. After removing the excess, antisepsis was performed with alcoholic chlorhexidine and surgical drapes and gowns. Cultures were performed in the mannitol and EMB media after being collected at the pre-skin preparation, post-skin preparation process and end of the surgical procedure.
89492629|NCT02598128|Experimental|RELiZORB|Treatment (RELiZORB)
89492630|NCT02598128|Placebo Comparator|Control|Placebo control
89492631|NCT02124785|Experimental|HAV Group|Subjects who were previously vaccinated with Havrix in primary studies.
89492632|NCT04817384|Experimental|Graston technique group|For Graston practice, instruments made of stainless steel material of a type suitable for the body structures and sizes of the children will be preferred. The treatment time takes approximately 20-25 minutes depending on the area being treated. The instant effects of the people will be looked at.
89492633|NCT04817384|Experimental|Classical massage group|The trapezius, erector spina and levator scapula muscles will be applied with one hand or both hands, starting with general stroking. The intermediate to be used is baby oil or natural oils. The application time will be approximately 20 minutes.
89492634|NCT02121821|No Intervention|Control|A control group of pregnant women receiving no intervention (i.e. no SMS reminders).
89492635|NCT02121821|Experimental|SMS reminder messages|The intervention group will be composed of pregnant women receiving SMS reminder messages via the SMS Mother Reminder system.
89492636|NCT04427540|Experimental|Oxytocin|Single IM injection Oxytocin 17 micrograms
89492637|NCT02125097|Experimental|Intracranial Aneurysm Treatment|Barrel™ Vascular Reconstruction Device (VRD) is Intended for use with embolic coils for the treatment of wide-neck bifurcating or branch intracranial aneurysms arising from a parent vessel with a diameter of ≥ 2.0 mm and ≤ 4 mm, measured by 2D Digital Subtraction Angiography (DSA). Wide-neck is defined as having a neck width ≥ 4 mm or a dome-to-neck ratio < 2.
89492638|NCT05616962|Other|Vasculera|Vasculera 630 milligrams, two times per day
89492639|NCT02126891|Experimental|Canoeists|13 canoeists from a training center of the French canoeing team
89492640|NCT02126891|Experimental|Military|10 young recruits in military school of officers in ground forces of the French army
89492641|NCT02252003|Experimental|Pain scales testing|
89492642|NCT04801940|No Intervention|Standard Care|Participant receives usual post-hospital care.
89492643|NCT04801940|Active Comparator|Apixaban|Intervention: Drug: Apixaban.
89492644|NCT04801940|Active Comparator|Atorvastatin|Intervention: Drug: Atorvastatin.
89492645|NCT02251847|Active Comparator|R5|Rosuvastatin 5mg
89492646|NCT02251847|Active Comparator|R10|Rosuvastatin 10mg
89492647|NCT02251847|Active Comparator|R20|Rosuvastatin 20mg
89492648|NCT02251847|Experimental|R5/E10|Rosuvastatin 5mg/ezetimibe 10mg
89492649|NCT02251847|Experimental|R10/E10|Rosuvastatin 10mg/ezetimibe 10mg
89492650|NCT02251847|Experimental|R20/E10|Rosuvastatin 20mg/ezetimibe 10mg
89492651|NCT02252159||Cohort A|"Patients with clinically overt PV (and not exhibiting any of the characteristics listed for Cohort B), managed with:~Watchful waiting (with or without aspirin)*, or~Phlebotomy (PHL) alone (with or without aspirin)* - or~HU alone (without concomitant PHL, with or without aspirin).~(*Unless patient has a history of intolerance or clinical resistance/ refractoriness to hydroxyurea [HU] (as assessed by the treating physician) - in which case, s/he belongs to Cohort B)"
89492652|NCT02252159||Cohort B|"Patients with clinically overt PV, with one or more of the following disease characteristics:~Treatment with HU and PHL in combination or~Treatment with any agent other than HU or aspirin (e.g., recombinant interferon (IFN) or pegylated IFN preparations, busulfan, anagrelide) or~A history of thrombosis (venous or arterial) or~A history of intolerance or clinical resistance/ refractoriness to HU (as assessed by the treating physician) or~Presence of documented splenomegaly (clinically assessed by palpation) or~Presence of one or more of the following uncontrolled symptoms related to PV despite therapy (Symptoms deemed uncontrolled as per physician's judgment)~Tiredness~Difficulty sleeping~Itching~Muscle aches and/or bone pain~Night sweats~Sweats while awake~Other"
89492653|NCT04811846|Active Comparator|TURBT (Transurethral Resection of Bladder Tumor)|For patients undergoing bipolar transurethral resection, bladder tumor is resected in a piecemeal manner.
89492654|NCT04811846|Active Comparator|PKVB (Plasma Kinetic Vaporization of Bladder Tumor)|For patients undergoing bipolar plasma kinetic vaporization of bladder tumor, bladder tumor is vaporized.
89492655|NCT06173479|Experimental|HeBSaPU|HeBSaPU is an acronym for educational interventions for safe pesticide use based on the health belief model. The HeBSaPU arm will get interventions for 12 weeks. HeBSaPU include educational posters, free personal protective equipment (PPE) incentives, reminder short messages, and demonstration components about correct PPE usage.
89492656|NCT06173479|Active Comparator|Control|The control arm will not take any interventions.
89492657|NCT06173388|Experimental|The structured exercise training program|Th study group received the structured exercise training program (composed of cervical stretching, strengthening and stabilizing exercises) plus the swallow resistance exercise.
89492658|NCT06173388|Other|The swallow resistance exercise|The control group: received only the swallow resistance exercise.
89492659|NCT06173362|Experimental|Arm I (abiraterone, prednisone)|Patients receive abiraterone and prednisone per SOC. Treatment continues for 1 year in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood samples during screening and on study.
89492660|NCT06173362|Experimental|Arm II (darolutamide)|Patients receive darolutamide per SOC. Treatment continues for 1 year in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood samples during screening and on study.
89492661|NCT06173349|Experimental|PLZ4-coated paclitaxel loaded micelles (PPM)|Patients receive PPM intravesically over 1 hour QW for 6 weeks in the absence of disease progression or unacceptable toxicity. Patients also undergo CT, MRI, or PET, and cystoscopy with biopsy at screening and follow up and undergo collection of blood samples throughout the trial.
89492662|NCT06173336|Active Comparator|Single pyloromyotomy gastric per-oral endoscopic myotomy (G-POEM)|Single cut pyloromyotomy technique during gastric per-oral endoscopic myotomy (G-POEM) procedure
89492663|NCT06173336|Active Comparator|Double pyloromyotomy gastric per-oral endoscopic myotomy (G-POEM)|Double cut pyloromyotomy technique during gastric per-oral endoscopic myotomy (G-POEM) procedure
89492664|NCT06173271|No Intervention|control|Exercise only (3 times/wk)
89492665|NCT06173271|Experimental|plant protein group|Soymilk (230ml) and sweet potato (60g) supplementation after exercise (3 times/wk) plus nutrition education (once a wk)
89492666|NCT06173271|Experimental|animal protein group|Milk (240ml) and sweet potato (60g) supplementation after exercise (3 times/wk) plus nutrition education (once a wk)
89492667|NCT06173245|Experimental|Intravitreal injection of ranibizumab|These patients were received three intravitreal injection of ranibizumab with one month interval.
89492668|NCT06173232||Group 1|Subjects with ETDRS ≥ 35 with or without DME
89492669|NCT06173232||Group 2|Subjects with ETDRS 20 or less and no DME
89492670|NCT06173206|Active Comparator|Sulfadoxine-pyrimethamine (SP)|Groups in the SP group will receive a 7-day course of placebo artesunate (at day -7, -6, -5, -4, -3, -2, and -1), followed by a single course of SP plus placebo AQ for 3 days.
89492671|NCT06173206|Active Comparator|Sulfadoxine-pyrimethamine plus amodiaquine (SPAQ)|Groups in the SPAQ group will receive a 7-day course of placebo artesunate (at day -7, -6, -5, -4, -3, -2, and -1), followed a single course of placebo SP placebo plus AQ for 3 days.
89492672|NCT06173206|Active Comparator|Artesunate monotherapy (AS)|Groups in the AS group will receive a 7-day course of active artesunate (at day -7, -6, -5, -4, -3, -2, and -1), followed a single course of placebo SP plus placebo AQ for 3 days.
89492673|NCT06173193|Experimental|multicomponent exercise group|8 months of multicomponent exercise (3 sessions/week).
89492674|NCT06173193|Active Comparator|Reference group|8 months of standard rehabilitative care based home exercises.
89492675|NCT06173180|Active Comparator|VACS-Minifiks (VACS-D)|During the surgical procedure, this group operated with VACS-Minifiks.
89492676|NCT06173180|Active Comparator|Transobturator Tape (TOT)|During the surgical procedure, this group operated with the commercially available Transobturator Tape (TOT).
89492677|NCT06173141|Active Comparator|Group A (low- to moderate-continuous intensity cycling exercises:|"Patients performed aerobic exercise during dialysis using Pedal machine at low- to moderate continuous intensity rating from 11 to 13 on the Borg scale for 15-30 minutes.~warming up and cool down (approximately 10 minutes) in form of free active exercise of the lower extremities"
89492678|NCT06173141|Active Comparator|Group B (moderate- to high-interval intensity cycling exercises),|"Patients performed aerobic exercise during dialysis using Pedal machine at moderate-to-high interval intensity rating from 12 to 15 on the Borg scale for 15-30 minutes.~warming up and cool down (approximately 10 minutes) in form of free active exercise of the lower extremities"
89492679|NCT06173141|Sham Comparator|group (C)|received the hemodialysis sessions only.
89022128|NCT00347672|Experimental|1|Two vaccinations of H5N1 VN 2004/AA vaccine at the highest dose
89492680|NCT06173128||Antibody deficient participants|Provider referred patients that have antibody deficiency.
89492681|NCT06173128||Controls|Patients without antibody deficiency from the allergy and immunology clinic at Boston Medical Center and from healthy volunteers at the BU School of Medicine.
89492682|NCT06173102|Experimental|Early Cranial Orthosis|Early cranial orthosis (reception 1 week after initial visit)
89492683|NCT06173102|Other|Usual Cranial Orthosis|Usual cranial orthosis (reception 7 weeks after initial visit)
89492684|NCT06173063|Experimental|Mobility+ Arm|Adult patients using Mobility+ novel enteral feeding system for nutritional intake.
89492685|NCT06173050|Other|PAP System A (with Amalfi) then PAP System B (with CLA11)|Participants will be asked to take home the investigational PAP system (Amalfi) to use at night while they sleep in place of their own PAP system. The participant's therapy and comfort settings will not be altered. Participants will be randomized as to the order they will trial PAP System A and PAP System B. This arm will first use the Amalfi for 7 days and then use the CLA 11 for 7 days.
89492686|NCT06173050|Active Comparator|PAP System B (with CLA11) then PAP System A (with Amalfi)|Participants will be asked to take home the comparator PAP system B (CLA 11) to use at night while they sleep in place of their own PAP system. The participant's therapy and comfort settings will not be altered. Participants will be randomized as to the order they will trial PAP System B and PAP System A. This arm will first use the CLA 11 for 7 days and then use the Amalfi for 7 days.
89492687|NCT06173037|Experimental|RC88 for Injection|RC88 for Injection Arm all patients will receive single-agent RC88 at 2.0 mg/kg administered on Day 1 of every 3-week cycle (Q3W).
89492688|NCT06173011|Experimental|QL2107|QL2107, intravenous infusion 35 min (±5min, minimum infusion 30min), D1 (Day 1, single dose)
89492689|NCT06173011|Active Comparator|Keytruda®(china)|Keytruda® (china), intravenously infusion 35 min (±5min, at least 30min), D1 (Day 1, single dose);
89492690|NCT06173011|Active Comparator|Keytruda®(US)|Keytruda® (US), intravenously infusion 35 min (±5min, at least 30min), D1 (Day 1, single dose);
89492691|NCT06172998|No Intervention|healthy subject|
89492692|NCT06172998|No Intervention|low BPV group|
89492693|NCT06172998|Experimental|high BPV group|
89492694|NCT06172985||Suspected patients with coronary heart disease.|The coronary CT angiography (CCTA) images collected by each center within a certain period of time will be desensitized after the screening is successful. The final CCTA images were sent to an independent judgment expert group for diagnosis, the results of the test group and the independent judgment expert group were compared, and the clinical application of the coronary artery CT angiography image vascular stenosis auxiliary triage software developed by Keya Medical Technology Co., Ltd. was evaluated. Validity and Accuracy
89492695|NCT06172972|Experimental|Atraumatic nursing care group|Before the phlebotomy, children in the intervention group were allowed to choose a distracting method (foam balloons, stress balls, musical books) to be occupied with during the procedure. It was ensured that the parent was staying with the child and that the child played with this material during the procedure (making a foam balloon, squeezing the ball with the hand in which the procedure was not carried out and reading the book with the parent
89492696|NCT06172972|No Intervention|Control group|The parents of the children in the control group were ensured to stay with their children during the procedure, and the child's attention was distracted by the nurse asking questions about the child's name, age, and what grade the child was in. This is one of the methods frequently used in Turkiye.
89492697|NCT06172946|Experimental|INSPIRATORY MUSCLE TRAINING|"Power Breathe:~(3times/week for 8 weeks) The patient should inhale and exhale through the mouthpiece 30 times maximum. The training load is adjustable and should be set at a level appropriate for the patient to effectively train the inspiratory muscles. (Lázaro et al., 2021)"
88954050|NCT01968512|Sham Comparator|TDCS-Sham|Subjects will undergo to procedure similar to the Transcranial Direct Current Stimulation with anode in dorsolateral prefrontal cortex and left cathode region supraorbicular right. They will receive a stimulus of 1mA only in initial 30 seconds and it will change the electrical charge for 0mA after this time, however the electrodes will be kept for 20 minutes as the active arm.
89492698|NCT06172946|Active Comparator|TRANSCUTANEOUS ELECTRICAL DIAPHRAGMATIC STIMULATION|"Transcutaneous electrical Diaphragmatic Stimulation(TEDS):~(3times/week for 8 weeks) During each session, rectangular electrodes were placed on the parasternal region beside the xiphoid process; the sixth and seventh intercostal spaces in line with the mid-axillary line. The electrical current is pulsed, biphasic and symmetric, with the following parameters: frequency of 30 Hertz; 0.4ms phase width, rise time of 0.7 seconds; respiratory rate of 14 rpm; intensity is the minimum necessary to obtain diaphragm muscle contraction. TEDS intensity was gradually increased until visible muscle contraction was observed. (Hsin et al., 2022)"
89492699|NCT06172920|Active Comparator|Tramadol|Tramadol receiving group
88954051|NCT01968525|Experimental|Group A|the hemoglobin is >12g/L in patients from group A.
88954052|NCT01968525|Experimental|Group B|Hb 9-12g/L
88954053|NCT01968525|Experimental|Group C|Hb<9g/L
88954054|NCT01968564|Experimental|High-dose curcumin pill|
88954055|NCT01968564|Experimental|Low-dose curcumin pill|
88954056|NCT01968564|Placebo Comparator|Placebo pill|
88954057|NCT01968577|Experimental|Rosuvastatin 40 mg|Administration of rosuvastatin 40 mg 2 to 6 hours before percutaneous coronary intervention
88954058|NCT01968577|No Intervention|Control group|The group of patients that do not receive rosuvastatin, 40 mg, before percutaneous coronary intervention.
88954059|NCT01968616|Other|Intravitreal Lucentis 0.5mg|One arm
88954060|NCT01968629|Experimental|Eovist at 24 Hour Delayed Imaging|This study will evaluate uptake of the hepatobiliary magnetic resonance imaging (MRI) contrast agent gadolinium ethoxybenzyl dimeglumine, or Eovist (Bayer Imaging, Wayne, NJ) within hepatocellular carcinomas (HCCs) at delayed, 24 hour imaging. The recommended dose of Eovist is 0.1 mL/kg, or 0.025 mmol/kg.
89022129|NCT00347672|Experimental|2|One vaccination of H5N1 VN 2004/AA vaccine at a dose in-between the lowest and highest doses
89022130|NCT00347672|Experimental|3|One vaccination of H5N1 VN 2004/AA vaccine at the lowest dose
89022131|NCT02956863|Active Comparator|Exercises|Individuals with neck pain will receive a exercises program. Participants will receive treatments during 4 weeks, 1 treatments per week.
89204716|NCT01564498|Placebo Comparator|Orange carrots|Participants will consume 200-300 g typical varieties of orange carrots during the intervention
89492700|NCT06172920|Active Comparator|Aldolan|Aldolan receiving group
89492701|NCT06172920|Active Comparator|Morphine|Morphine receiving group
89492702|NCT06172842||primary electrical disease|
89492703|NCT06172842||control|
89492704|NCT06172816||PLWH|the people living with HIV
89492705|NCT06172816||HC|the people without disease
89492706|NCT06172803|Experimental|RESToRE|Participants will receive RESToRE, an interdisciplinary, hybrid 8- week intervention.
89492707|NCT06172803|Active Comparator|Light Stretching Exercise|The control group will receive 8-week, attention-matched, stretching and breathing exercises, supervised by a rehabilitation clinician.
89492708|NCT06172777||suspected asthma|enrollment 200 subjects
89492709|NCT06172777||Suspected COPD|enrollment 200 subjects
89492710|NCT06172777||confirmed asthma|enrollment 200 subjects
89492711|NCT06172777||confirmed COPD|enrollment 200 subjects.
89492712|NCT06172738|Experimental|group A.|surgical closure of the left atrial appendage.
89492713|NCT06172738|No Intervention|group B.|There was no surgical closure of the left atrial appendage.
89492714|NCT06172725|Experimental|High-Protein Vegetarian Diet|High-protein vegetarian diet (no meat/fish)
89492715|NCT06172725|Active Comparator|High-Protein Omnivorous Diet|High-protein omnivorous diet
89492716|NCT06172686|Experimental|Arm1|The first arm will receive Piperaquine tablets , that will be administered orally. Sub-curative regimen will be given as two tablets of 320mg and 160mg (total of 480mg).
89492717|NCT06172686|Experimental|Arm 2|The second arm will receive Doxycycline (100mg tablets strength as Doxycycline hyclate) that will also be administered orally. Sub-curative regimen will be given as 1 tablet (100mg) once daily for 7 days.
89492718|NCT06172660||ARI Cases|Cases will be defined as infants ≤12 months old who had a clinical encounter for acute respiratory illness (ARI) and tested positive for RSV using polymerase chain reaction (PCR).
88954061|NCT01968642|Experimental|Educational Intervention|"Attending physicians in the intervention arm will receive the following multi-faceted educational intervention on transthoracic echocardiogram appropriateness: 1) a lecture at the beginning of the study period, which describes Appropriate USe Criteria (AUC) and highlights common clinical scenarios for which outpatient echocardiograms are ordered, 2) an electronic pocket cared via email that provides tips on appropriate ordering of echocardiograms, and 3) an individualized monthly feedback report that categorizes echocardiograms ordered over the preceding month. The feedback report will contain the number of echocardiograms ordered during the month and how many are classified as appropriate, inappropriate, or uncertain based on the 2011 AUC."
88954062|NCT01968642|No Intervention|Control Group|Attending physicians in the control arm will have their echocardiogram orders tracked and classified, but will not receive any feedback on their ordering behavior.
88954063|NCT01968668|Experimental|BAY94-8862 (1.25 mg)|
88954064|NCT01968668|Experimental|BAY94-8862 (2.5 mg)|
88954065|NCT01968668|Experimental|BAY94-8862 (5 mg )|
88954066|NCT01968668|Experimental|BAY94-8862 (7.5 mg)|
88954067|NCT01968668|Experimental|BAY94-8862 (10 mg)|
88954068|NCT01968668|Placebo Comparator|Placebo|
88954069|NCT01968668|Experimental|BAY 94-8862 (15 mg)|
88954070|NCT01968668|Experimental|BAY 94-8862 (20 mg)|
88954071|NCT01968681|Experimental|Alexandrite laser treatment|
89492719|NCT06172660||Healthy Controls|Healthy controls will be individually matched to enrolled vaccine failures (immunized and RSV+) by date of birth (±1 month), sex, and immunoprophylactic agent received (i.e., maternal vaccine or monoclonal antibody).
89492720|NCT06172660||ARI Controls|Controls will be individuals with ARI who test negative for RSV and will be frequency matched based on time and clinical setting.
89492721|NCT06172647||Active Microscopic Colitis (MC) patients|
89492722|NCT06172647||Chronic watery diarrhoea patients|
89492723|NCT06172647||Patients with Advanced Colon Adenomas|
89492724|NCT06172647||Healthy controls|
89492725|NCT06172634|Experimental|DC + ICI|
89492726|NCT06172595|Experimental|FET PET|"Upon recruitment, a single study visit will be scheduled where subjects undergo a limited 18F-FET PET/CT of the brain in SGH.~After the study visit, from time of recruitment, they will continue their regular clinic visits as clinically indicated, where they will be monitored for at least a year for stability or deterioration. If clinically indicated, they may undergo conventional MRI, alternative MRI imaging and/or histopathological correlation in their respective primary institutions.~During these follow-up visits, any adverse effects possibly attributed to the 18F-FET PET/CT can also be flagged up.~Any alternative MRI imaging performed (as part of clinical practice in the respective primary institutions) within 4 weeks of the 18F-FET PET/CT study will also be included in the comparative analysis."
89492727|NCT06172543|Experimental|Creatine Monohydrate Group|25 grams of Whey Protein Isolate + 25 grams of Carbohydrate Powder + 5 grams of Creatine
89492728|NCT06172543|Placebo Comparator|Non Creatine Group|25 grams of Whey Protein Isolate + 25 grams of Carbohydrate Powder only
89492729|NCT06172517|Experimental|Othesis intervention|This group with custom-made foot orthotics prescribed by podiatrists (foot impression, polypropylene orthotics and covering at podiatrists' discretion).
89492730|NCT06172517|No Intervention|Control group|Without orthesis prescriptions by podiatrists.
89492731|NCT06172491||No Delirium Severity|Patients who did not experience a level of delirium severity (subsyndromal, mild, moderate, severe)
89492732|NCT06172491||Delirium Severity|Patients who did experience a level of delirium severity (subsyndromal, mild, moderate, severe)
88954072|NCT01968746||ED patients with suspected infection|
88954073|NCT01968759|Active Comparator|Ramipril and Irbesartan|Best available therapy including dual RAS blockade with Ramipril and Irbesartan
88954074|NCT01968759|Experimental|Sevelamer|Two tablets of Sevelamer carbonate 800 mg will be orally administered three times per day during the meals for 3 months.
88954075|NCT01968772|Other|Transdermal Magnesium Chloride|This is a clear, odorless liquid that dries rapidly on the skin and leaves no oily residue. Its ingredients are water, magnesium chloride, and a proprietary blend of less than two-tenths of 1% trace minerals (Boron, Selenium, and Manganese).
89492733|NCT06172439|Experimental|experimental group|Women in the intervention group will receive acupressure for 12 minutes.
89492734|NCT06172439|No Intervention|control group|Women in the control group will not receive acupressure and will continue with routine care.
89492735|NCT06172426||MarketScan® secukinumab, other biologics/apremilast, and any biologics/apremilast cohort|
89492736|NCT06172426||BADBIR secukinumab cohort|
89492737|NCT06172387|Experimental|intra-arterial group|20% human serum albumin (0.6g/kg) solution will be injected into the artery after revascularization in acute ischemic stroke. All participants will receive mechanical thrombectomy and a standard clinical therapy.
89492738|NCT06172387|Other|sham group|All participants have no intra-arterial albumin.
89492739|NCT06172361|Experimental|Treatment group|Prednisone (or equivalent dose of methylprednisolone) + Tofacitinib
89492740|NCT06172361|Active Comparator|Positive control group|prednisone (or equivalent dose of methylprednisolone)
89492741|NCT06172322|Experimental|NTQ1062 with Fulvestrant|NTQ1062 Tablets（200-500）+ Fulvestrant（500mg)
89492742|NCT06172309|Experimental|NTQ1062|NTQ1062 Tablets will be administered orally QD in a 28-day cycle (21 days on treatment followed by 7 days off treatment) in sequential cohorts.
89492743|NCT06172283|Experimental|Intermittent Fasting|Patients will undergo 16h periods of fasting everyday. Optionally, patients will be offered to undergo a plant-based diet consisting of 20% plant based protein, 50% carbohydrates, and 30% fat for the duration of the study.
89492744|NCT06172270||Benign breast tumors|Performing contrast-enhanced ultrasound on benign breast tumors and analyzing the video images
89492745|NCT06172270||Malignant breast tumors|Performing contrast-enhanced ultrasound on malignant breast tumors and analyzing the video images.
89492746|NCT06172244|Experimental|Whole body vibration|A total of 5 sets of vibration will be given at 30 Hz, 2 mm amplitude, 1 minute of application and 1 minute of rest.
89492747|NCT06172231|Active Comparator|Group A ( Conventional physiotherapy)|5 min moist Hot pack ,Patellar joint mobilizations and Tibiofemoral ,Maitland grades III and IV (5 oscillations in first week) ,PROMs of knee joint ( 5 reps) ,Quad sets ( 5 reps with 5 sec hold)Progression: 5 repetition of each exercise would be add in every week ,Frequency: 4 sessions in 4-week period Duration: 15_ 35 min each session.
89492748|NCT06172231|Experimental|Group B ( IASTM along with conventional physiotherapy))|rst conventional Physiotherapy same as group A thenIASTM protocol.The treatment processes consist of Four phases: warm up (heat), Graston Technique®, passive stretching and cryotherapy.6_10 long strokes on Hamstring and Rectus femoris by using G1 instrument .Brief bouts (30 - 60 s) of deeper and more specific.Frequency: 4 sessions in 4-week period.Duration: 15_35 min each session.
89492749|NCT06172218|Experimental|Micronized Amniotic Membrane|Injection of micronized amniotic membrane reconstituted in 2.0 mL sterile, preservative free 0.9% NaCl
89492750|NCT06172218|Placebo Comparator|Preservative Free Normal Saline|2.0 mL sterile, preservative free 0.9% NaCl
89492751|NCT06172205|Experimental|Infusional FOLFOX|Infusional mFOLFOX7 plus Camrelizumab and apatinib
89492752|NCT06172205|Active Comparator|HAIC-FOLFOX|HAIC-FOLFOX plus Camrelizumab and apatinib
89492753|NCT06172192|Active Comparator|Group A|"Group A will perform Core Strengthening exercises. In addition to core strengthening protocol, non-resistive Diaphragmatic training group will perform self-diaphragm breathing exercises~Core strengthening protocol will comprise of following three phases:~Warm up phase:~Core strengthening phase:~Cool down phase:~After performance of Core Strengthening protocol, Group A will perform Self-Diaphragmatic breathing exercises."
89492754|NCT06172192|Experimental|Group B|"Group B will perform Core Strengthening exercises. In addition to core strengthening protocol, resistive Diaphragmatic training group will perform resisted-diaphragm breathing exercises.~Core strengthening protocol will comprise of following three phases:~Warm up phase~Core strengthening phase~Cool down phase~After performance of Core Strengthening protocol, group B will perform Resistive Diaphragmatic Exercises."
89492755|NCT06172179||Sun Yat-sen memorial hospital|
89492756|NCT06172179||Second People's Hospital of Foshan City|
89492757|NCT06172179||The Fifth People's Hospital of Nanhai District, Foshan City|
89492758|NCT06172166|Experimental|Transdisciplinary Care for Transition|
89492759|NCT06172166|No Intervention|Standard Clinical Care|
89492760|NCT06172153||Sun Yat-sen memorial hospital|Patients who were suspected of Spinal infection.
89492761|NCT06172140|Experimental|Ciprofol group|Intravenous injection of ciprofol
89492762|NCT06172140|Experimental|Propofol group|Intravenous injection of propofol
88954076|NCT01968798|Active Comparator|Aspirin|100 mg enteric-coated aspirin
89492763|NCT06172127|Experimental|T-DXd induction treatment phase followed by PHESGO maintenance treatment phase|"All patients will receive a 6-cycle induction phase with T-DXd 5.4 mg/kg body weight administered as an intravenous (IV) infusion on day 1 (D1) of each 21-day cycle (Q3W).~Participants may continue with PHESGO if T-DXd is discontinued prematurely due to unacceptable toxicity prior to disease progression and following recovering to Grade ≤ 1 toxicity, to Grade 0 in case of ILD/pneumonitis, or to Grade 2 for alopecia/other toxicities not considered a safety risk. If any T-DXd unacceptable toxicity occurs during the first 6 cycles of induction phase with T-DXd, participants may receive taxane-based chemotherapy concomitantly with PHESGO treatment at the discretion of the investigator.~During the maintenance phase, all participants will receive PHESGO with a loading dose of 1200 mg pertuzumab/600 mg trastuzumab as a SC injection for 8 minutes on D1 of the first 21-day cycle, and with a maintenance dose of 600 mg pertuzumab/600 mg trastuzumab as a SC Q3W."
89492764|NCT06172088|Experimental|Therapeutic fasting for the reduction of physical of limitations in physical well-being and qol|
89492765|NCT06172062||LPD cohort|surgical videos of laparoscopic pancreaticoduodenectomy with label to build and test the algorithms.
89492766|NCT06172049||CRC cases|
89492767|NCT06172036|Experimental|Arm A|Preoperative adliberlizumab + irinotecan liposome + oxaliplatin + 5-FU / LV (28 days as one cycle, 2 treatment cycles). Surgery was performed within 2 to 4 weeks after completion of neoadjuvant therapy and addebelizumab + irinotecan liposomes + oxaliplatin + 5-FU / LV (28 days as one cycle, 4 treatment cycles) within 4 to 6 weeks after surgery, followed by maintenance therapy with addebelizumab until disease progression or intolerable toxicity. The cumulative postoperative duration of adbelizumab should not exceed 1 year. Tumor recurrence, safety and survival follow-up was evaluated after completion of the drug.
89022132|NCT02956863|Experimental|Osteopathic manipulative treatment|Individuals with neck pain in this group will also receive a exercises program and the participants will receive treatments during 4 weeks, 1 treatments per week associated with Osteopathic Manipulative Treatment (OMT)
89022133|NCT00455637|Experimental|Dysport 5 units|
89022134|NCT00455637|Experimental|Dysport 10 units|
89022135|NCT00455637|Experimental|Dysport 15 units|
89022136|NCT03276312|Experimental|Intervention|Lipogems - local injection of autologous micro-fragmented adipose tissue
89022137|NCT03276312|No Intervention|Control|Routine clinical practice
89492768|NCT06172036|Experimental|Arm B|Irinotecan liposome + oxaliplatin + 5-FU / LV (28 days one cycle, 2 treatment cycles), 2-4 weeks after completion of neoadjuvant therapy and 4-6 weeks after surgery, adjuvant irinotecan liposome + oxaliplatin + 5-FU / LV (28 days one cycle, 4 treatment cycles). Tumor recurrence, safety and survival follow-up were performed after the end of the adjuvant treatment phase.
89492769|NCT06172036|Active Comparator|Arm C|Upfront surgery, and postoperative adjuvant regimen as with ArmB. Tumor recurrence, safety and survival follow-up were performed after the end of the adjuvant treatment phase.
89022138|NCT00449124|Experimental|Part I-group 1|Part I/Group 1: Cycle 1-TG4040 10^6 PFU days 0, 7 and 14; Cycle 2-Placebo days 0, 7 and 14; Cycle 3-Placebo days 0, 7 and 14.
89022139|NCT00449124|Experimental|Part IIa-group 1|Part IIa/Group 1: Cycle 1-TG4040 10^8 PFU days 0, 7 and 14; Cycle 2-Placebo days 0, 7 and 14.
89022140|NCT00449124|Experimental|Part IIa-group 2|Part IIa/Group 2: Cycle 1-Placebo days 0, 7 and 14; Cycle 2-TG4040 10^8 PFU days 0, 7 and 14.
89022141|NCT00449124|Experimental|Part I-group 3|Part I/Group 3: Cycle 1-Placebo days 0, 7 and 14; Cycle 2-Placebo days 0, 7 and 14; Cycle 3-TG4040 10^8 PFU days 0, 7 and 14.
89022142|NCT00449124|Experimental|Part I-group 2|Part I/Group 2: Cycle 1-Placebo days 0, 7 and 14; Cycle 2-TG4040 10^7 PFU days 0, 7 and 14; Cycle 3-Placebo days 0, 7 and 14.
89022143|NCT00449124|Experimental|Part IIb-group 1|Part IIb/Group 1: Cycle 1-TG4040 10^8 PFU days 0, 7 and 14; Cycle 2-Placebo days 0, 7 and 14.
89022144|NCT00449124|Experimental|Part IIb-group 2|Part IIa/Group 2: Cycle 1-Placebo days 0, 7 and 14; Cycle 2-TG4040 10^8 PFU days 0, 7 and 14.
89022145|NCT00455793||1|HIV
89022146|NCT00455793||2|Non-HIV infected controls
89022147|NCT00455871|Active Comparator|Lucentis plus Reduced Fluence PDT same day|
89022148|NCT00455871|Active Comparator|Lucentis plus reduced fluence PDT 1-2 weeks later|
89022149|NCT00449280|Experimental|A|Sorafenib two times a day every day for 28 days. Beginning on Day 15 (Week 2), rapamycin will be taken once a week until the end of the cycle (Day 28). After Day 28, weekly rapamycin and daily sorafenib will continue until disease progression or serious side effects are experienced.
89022150|NCT00449280|Experimental|B|Sorafenib two times a day every day for 28 days. Beginning on Day 15 (Week 2), rapamycin will be taken every day until the end of the cycle (Day 28). After Day 28, rapamycin and sorafenib can continue to be taken daily until the cancer gets worse or serious side effects are experienced.
89022151|NCT00449280|Experimental|C|Rapamycin once a week starting on Day 1. Beginning on Day 15 (Week 2), sorafenib will be taken twice a day every day until the end of the cycle (Day 28). After Day 28, weekly rapamycin and daily sorafenib will continue until disease progression or serious side effects are experienced.
89022152|NCT00449280|Experimental|D|Rapamycin every day beginning on Day 1. Starting on Day 15 (Week 2), sorafenib will be taken twice a day every day until the end of the cycle (Day 28). After Day 28, rapamycin and sorafenib can continue to be taken daily until the cancer gets worse or serious side effects are experienced.
89022153|NCT00348335|Active Comparator|1: Restasis|
89022154|NCT00348335|Active Comparator|2: Refresh Endura|
89022155|NCT03274323|Experimental|2 iStent with travoprost or latanoprost|2 iStents will be injected into the trabecular meshwork and patients will be administered topical latanoprost or travoprost following surgery
89022156|NCT03274323|Active Comparator|trabeculectomy|Standard trabeculectomy
89022157|NCT00348569|Experimental|64 Channel VCT|All subjects underwent Coronary Computed Tomographic Angiography (CCTA) after receiving an intravenous (IV) administration of Visipaque (320 mgI/mL), to be followed 2 to 21 days later by catheter coronary angiography (CATH).
89022158|NCT03274284|Experimental|chemoradiotherapy|Chemoradiation in the form of cisplatin plus conformal radiotherapy 55GY/20 fractions which is biologically effective to 64GY/32 fractions fr
89022159|NCT00348608|Experimental|Visipaque Injection|All participants will receive intravenous (IV) administration of 80 mL Visipaque (iodixanol) 320 mg-I/mL at a rate of 4-5 mL per second via power injector followed by a saline injection of 40-50 mL 0.9% sodium chloride solution at a rate of 4-5 mL per second.
89022160|NCT03274245|Experimental|Latrine Use|Men and women in villages randomized to the latrine use arm will receive the intervention package that includes activities at the community and household levels, with additional activities and hardware for mothers of children under five.
89022161|NCT03274245|No Intervention|Control Group|Men and women in villages randomized to the control group will not receive an intervention.
89022162|NCT03274245|Experimental|Qualitative Research Group|Six villages unassociated with the randomized villages will engage in qualitative research. Three villages will receive the intervention. Three villages will not receive the intervention.
89022163|NCT00448734|Experimental|1|"The treatment regimen will be the assigned dose of picoplatin plus docetaxel, 60 mg/m2 or 75 mg/m2, once every three weeks, plus prednisone (or prednisolone, if prednisone is not available), 5 mg orally twice daily beginning on day 1 and continuing daily until therapy is discontinued.~Docetaxel will be given intravenously over 60 minutes, followed 30 minutes later by picoplatin as a 1-2 hour intravenous infusion."
89022164|NCT00448734|Active Comparator|2|Docetaxel
89204717|NCT01564498|Experimental|Purple Carrots|Participants will consume 200-300 g raw purple carrots instead of orange carrots in the control arm
89492770|NCT06172023|Experimental|Silver Nanoparticles Irrigant|
89492771|NCT06172023|Experimental|Chitosan Nanoparticle Irrigant|
89492772|NCT06172023|Active Comparator|2.6% NaOCl and 17% EDTA sol|
89492773|NCT06172010|Active Comparator|Oral rifampicin-based combination therapy|rifampicin 450mg BID + levofloxacin 500mg BID in the oral treatment phase with a total duration of antibiotics of 12 weeks
89492774|NCT06172010|Experimental|Oral monotherapy with clindamycin|clindamycin 600mg TID in the oral treatment phase with a total duration of antibiotics of 12 weeks
89492775|NCT06171958||ICM|Patients receiving ICM at CT
89492776|NCT06171958||No ICM|Patients not receiving ICM at CT
89492777|NCT06171932||HYDROCORTISONE|Group A will comprise of 30 patients will be treated with 200 mg hydrocortisone followed by 3 doses of hydrocortisone 100 mg 6 hours apart for next 24hrs
89492778|NCT06171932||METHYLPREDNISOLONE|Group B will be treated with methylprednisolone 125 mg stat
89492779|NCT06171919|Experimental|CTI-MLP approach|To finalize protocols and a medical-legal partnership training manual for health and social service providers at Hope and Help Inc.
89492780|NCT06171919|Experimental|CTI-MLP assessment|To assess the feasibility and acceptability of a comprehensive critical-time intervention medical legal partnership (CTI-MLP) approach to improve HIV care continuum outcomes among formerly incarcerated individuals and determine the most efficient mechanisms for CTI-MLP delivery
89492781|NCT06171906|Experimental|MSCs treatment group|
89492782|NCT06171880|Experimental|Treatment(Experimental): JLP-1901|Group I(Peroid I-Comparator[JLP-2008], Peroid II-Treatment[JC-001], Period III-Comparator[JLP-2008], Peroid IV-Treatment[JC-001]), Group II(Peroid I-Treatment[JC-001]Comparator[JLP-2008], Peroid II-Comparator[JLP-2008], Period III-Treatment[JC-001], Peroid IV-Comparator[JLP-2008])
89492783|NCT06171880|Active Comparator|Control(Active Comparator): JC-001|Group I(Peroid I-Comparator[JLP-2008], Peroid II-Treatment[JC-001], Period III-Comparator[JLP-2008], Peroid IV-Treatment[JC-001]), Group II(Peroid I-Treatment[JC-001]Comparator[JLP-2008], Peroid II-Comparator[JLP-2008], Period III-Treatment[JC-001], Peroid IV-Comparator[JLP-2008])
89492784|NCT06171828|No Intervention|Control Group (Traditional Training)|This arm of the study involves participants who will engage in a traditional learning process. After an initial pre-survey, they will start the ultrasound training phase. During this phase, participants will utilize pre-made educational videos for learning. Then participants will perform an ultrasound on an abdominal ultrasound phantom using a handout based on the pre-made video. When assistance is needed, participants will physically move to a different location to seek help from a supervisor. This face-to-face interaction allows for direct guidance and feedback. After completing the training sessions, participants will take a post-survey, which includes NASA-TLX, System Usability Scale (SUS), and a self-confidence assessment, to evaluate the training experience and measure the perceived workload, system usability, and confidence level changes due to the training.
89492785|NCT06171828|Experimental|Experimental Group (Remote Training)|In this arm, participants will undergo a remote learning process. Similar to the control group, they begin with a pre-survey followed by the training phase using the same educational videos. Participants view a handout on a head-mounted display(HMD) and perform an ultrasound on an abdominal ultrasound phantom. The key difference is that when they require assistance, they will use a HMD to communicate with a supervisor remotely. This allows the supervisor to provide guidance without being physically present, utilizing the HMD and potentially other remote communication tools for real-time interaction. The training phase is intended to mimic the in-person guidance as closely as possible through technological means. Following the training, the participants will also complete the same post-survey as the control group to assess the impact of remote training on their learning experience.
89492786|NCT06171815|Experimental|First Arm|Students in the first arm received simulation training under the leadership of a peer facilitator on the first day, and under the leadership of an instructor facilitator on the second day.
89492787|NCT06171815|Experimental|Second Arm|Students in the second arm received simulation training under the leadership of an instructor facilitator on the first day and under the leadership of a peer facilitator on the second day.
89492788|NCT06171776|Active Comparator|fuji XI|chemically cured glass ionomer
89492789|NCT06171776|Experimental|RetroMTA|cacium silicat cement
89492790|NCT06171776|Experimental|Theracal LC|resin based calcium silicate cement
89492791|NCT06171737|No Intervention|Control (usual care)|This group will receive usual care without any support for using the decision aid and without any access to the clinician training.
89492792|NCT06171737|Active Comparator|Intervention|"The patients in this group will receive a decision aid that covers the main treatment options for aortic stenosis.~The clinicians in this group will receive a 60-minute online training session that will provide practical tips, interactive case studies and tools for conducting shared decision making conversations covering core competencies"
89492793|NCT06171685|Other|Sub-protocol A|
89492794|NCT06171685|Other|Sub-protocol B|
89492795|NCT06171672||semi-structured interview for nurses|Pediatric intensive care nurses in Hong Kong will be invited to join an individual in-depth semi structured interview.
89492796|NCT06170437|Experimental|Intervention|The study's investigators will train bilingual study staff to deliver the intervention to residents using a script that matches the content in the smoke-free home intervention pamphlet. The in-person delivery of the intervention and pamphlet will be the primary modes of intervention delivery to residents. The pamphlet will include: (1) the harms of tobacco, e-cigarette use, cannabis use and exposure (secondhand and thirdhand), (2) an exercise to calculate personal cost of tobacco use, (3) benefits of a smoke-free home, (4) skill-building on how to adopt a smoke-free home, and (5) motivational language on smoke-free home adoption. The study staff will qualitatively assess participants' knowledge by prompting questions on the topics covered and will refer participants to lay-health workers (LHWs) for one-on-one coaching. Participants will receive a pledge to designate their homes smoke-free.
88954077|NCT01968798|Placebo Comparator|Placebo|Placebo
88954078|NCT01968824|No Intervention|General Anesthesia|general anesthesia only
88954079|NCT01968824|Experimental|Brachial Plexus Nerve Block|brachial plexus nerve block
88954080|NCT01968837|No Intervention|Cervical cancer screening|
89204718|NCT00993538|Experimental|1|
89492797|NCT06170437|No Intervention|Waitlist Control Group|The current standard of care does not include any interventions for smoke-free home adoption or referrals to tobacco treatment resources. At the end of the primary endpoint (6 months), control participants will be offered the intervention.
89492798|NCT06169098|Experimental|AA-SA|"Order: auricular acupressure on the left ear, auricular acupressure on the right ear, sham auricular acupressure on the left ear.~There will be a 30-minute break between each stage."
89492799|NCT06169098|Experimental|SA-AA|"Order: sham auricular acupressure on the left ear, auricular acupressure on the right ear, auricular acupressure on the left ear.~There will be a 30-minute break between each stage."
89492800|NCT06167720||Cancer patients cohort in SEER database|A retrospective cohort of cancer patients based on the Surveillance, Epidemiology, and End Results (SEER) program database was used to assess the association of socioeconomic factors, clinical characteristics and meteorological factors with cancer patients' suicide, and to establish prediction model with multiple predictors for cancer patient
88954081|NCT01968850|No Intervention|no bone anti-resorptive therapy|(standard of care)
88954082|NCT01968850|Experimental|24-week tx of alendronate/vitamin D|Concomitant initiation of a 24 week course of co-formulated alendronate/vitamin D
88954083|NCT01968850|Experimental|Delayed 24-week tx of alendronate/vitamin D|a 24 week delay in initiation of a 24 week course of alendronate/vitamin D
88954084|NCT01968876|No Intervention|Standard Care|The control group will not use the medication adherence app
88954085|NCT01968876|Experimental|Medication Adherence Smartphone App|The experimental group will receive the medication adherence app on their smartphone and will have their entire outpatient medication list pushed to the application. Text message reminders will be sent to their phones at the appropriate times.
88954086|NCT01968889||Critical illness neuromyopthy|Non invasive phrenic nerve stimulation allowing to measure the twitch airway pressure during airway occlusion
89492801|NCT06167720||Cancer patients cohort in SMCHBDP|Retrospective cohort conducted from Shandong Multi-Center Healthcare Big Data Platform (SMCHBDP) was used to verify the predictive ability and generalization ability of the prediction model.
89492802|NCT06166745|Experimental|Sensi-IP toothpaste|Sodium Fluoride Toothpaste with Sensi-IP
89492803|NCT06166745|Active Comparator|Sodium fluoride toothpaste|Sodium Fluoride Toothpaste
89492804|NCT06166693|Experimental|Treatment group|Adults between the ages of 18 and 60 were recruited and randomly assigned to the treatment group and waitlist group in the ratio of 2:1. Based on the screening results, 75 participants were assigned to each of the four intervention programs within MINDLiNG (Riggy, Pleaser, Shelly, and Jumpy).
89492805|NCT06166693|No Intervention|Waitlist group|Adults between the ages of 18 and 60 were recruited and randomly assigned to the treatment group and waitlist group in the ratio of 2:1. Based on the screening results, 25 participants were assigned to each of the four intervention programs waitlist.
89492806|NCT06166602|Active Comparator|Group 1|PENG block was planned to be applied to group 1 patients with 20 cc of 0.25% bupivacaine.
89492807|NCT06166602|Active Comparator|Group 2|PENG block was planned to be applied to group 2 patients with 10 cc of 0.25% bupivacaine.
89492808|NCT06165458|Experimental|HP6V|6% hydrogen peroxide gel + violet LED
89492809|NCT06165458|Experimental|HP6B|6% hydrogen peroxide gel + blue LED
89492810|NCT06165458|Experimental|HP35V|35% hydrogen peroxide gel + violet LED
89492811|NCT06165458|Experimental|HP35B|35% hydrogen peroxide gel + blue LED
88954087|NCT01968902|Active Comparator|incabotulinumtoxinA|intramuscular injection, 200 to 400 units, 1 injection visit only
89204719|NCT00821418|Experimental|PulsHaler first|
89492812|NCT06165380|Experimental|Cardenilimab Combined With Chemotherapy|
89492813|NCT06165263|No Intervention|Control Group|"The researcher will present 2 hours of basic earthquake education to control group.~The control group will not receive any other intervention. Control group will consist of 80 students."
89492814|NCT06165263|Experimental|Mobile earthquake education|"The researcher will present 2 hours of basic earthquake education to experimental group.~The students in the experimental group will use mobile earthquake education for 4 weeks.~İnterventional group will consist of 80 students."
89492815|NCT06165068|Active Comparator|Antiplatelet drug|In this study, antiplatelet drugs are medications that patients take to treat their underlying condition, such as aspirin 81 mg/day or clopidogrel 75 mg/day.
89492816|NCT06165068|Experimental|Antiplatelet drug with antioxidant|Antiplatelet drugs are medications that patients take to treat their underlying condition, such as aspirin 81 mg/day or clopidogrel 75 mg/day combined with N-acetylcysteine 600 mg/day.
89492817|NCT06165068|No Intervention|No medication|Patient with no medication used.
89492818|NCT06164795||Romo-Zol group|Postmenopausal women treated with romosozumab for 12 months will receive a single zoledronate infusion (5mg) at 1 month after the last romosozumab dose
89492819|NCT06164795||Romo-Dmab group|Postmenopausal women treated with romosozumab for 12 months will receive subcutaneous denosumab injections (60mg) bi-annually for 12 months starting at 1 month after the last romosozumab dose
89492820|NCT06164795||Romo-TPTD group|Postmenopausal women treated with romosozumab for 12 months will receive daily injections of teriparatide 20μg for 12 months starting at 1 month after the last romosozumab dose
89492821|NCT06164795||TPTD-Zol group|Postmenopausal women treated with teriparatide for 24 months will receive a single zoledronate infusion (5mg) at 1 month after the last romosozumab dose
89492822|NCT06164795||TPTD-Dmab group|Postmenopausal women treated with teriparatide for 24 months will receive subcutaneous denosumab injections (60mg) bi-annually for 12 months
89492823|NCT06164795||TPTD-Romo group|Postmenopausal women treated with teriparatide for 24 months will receive month injections of romosozumab for 12 months
89492824|NCT06164769|Experimental|blockade of arteries in laparoscopic pancreatic enucleation|In the pancreatic enucleation, Kocher Maneuver was routinely performed at first. Then free the left side of the abdominal trunk and superior mesenteric artery, loose tissues easy to free.After Kocher Maneuver and other surgical procedures, the abdominal trunk and superior mesenteric artery exposed. Before resection of pancreatic tumors, a vascular occlusion clamp clip was used to block the root of both the abdominal trunk and superior mesenteric artery to control the pancreatic blood flow.
88954088|NCT01968902|Placebo Comparator|Placebo|intramuscular injection, saline 200 - 400 units , 1 injection visit only
88954089|NCT01968915|Experimental|LCL161|Dose escalation part: Eligible patients will start to receive oral LCL161 once a week and will receive weekly paclitaxel, at 80 mg/m2 intravenous infusion over 1 hour, in combination with LCL161 from cycle 2. Dose expansion part: Eligible patients will receive oral LCL161 at the maximum tolerated dose and/or recommended dose in combination with weekly paclitaxel, at 80 mg/m2 intravenous infusion over 1 hour from cycle 1.
88954090|NCT01968928||drug-resistant|specimens com from drug-resistant bladder urothelial carcinoma patients.
88954091|NCT01968928||normal|specimens come from normal bladder urothelial carcinoma patients.
88954092|NCT01968928||non-tumoral|specimens come from non-tumoral patients.
89492825|NCT06164444|Experimental|Intervention: Reusable drapes and gowns|"Reusable drapes and gowns are made from cotton and polyester and are protective against fluid contamination and, to a certain extent, mechanical stress.~Reusable drapes and gowns are usually autoclaved and laundered using pressurised steam. This ensures that bacteria and other microorganisms are killed, sterilising the fabric so it is suitable for re-use. In this pragmatic trial, a specific sterilisation protocol is not mandated, but details of the sterilisation processes in place at each hospital will be captured in the Hospital-level Questionnaire before site opening. We may report this in a paper ahead of the main trial publication."
89492826|NCT06164444|Active Comparator|Comparator: Disposable (single-use) drapes and gowns|"Single-use surgical gowns and drapes are generally made from non-woven plastic polymers that are protective against fluid contamination and, to a certain extent, mechanical stress.~They are intended for use during a single operation and are then disposed of as biohazard waste for incineration.~Typically, four drapes are needed for an abdominal operation (two larger and two smaller drapes), although more may be needed for some procedures.~A range of disposable gowns are available. The choice of disposable gown will be at the hospital PI's discretion and will be captured in the Hospital-level Questionnaire."
89492827|NCT06164301|Experimental|Elemental Amino group|Elemental Amino group ; post-operative within the first 3 hours the patient will receive 250 ml of elemental protein( 250 ml Peptamen = 6 scoops (55g) + 210ml water ) repeated at ( 6, 8 , 10 , 12 hours postoperative ) in order to reach total protein in order to reach total protein 50 mg in the first 12 hour post-operative, Second day ordinary food will be introduced supplemented by half the dose of the first day from elemental protein (250 ml / 6 hours ) or to the dose to achieve the daily protein adequacy 1.3 mg/kg/day.
89492828|NCT06164301|Active Comparator|standard|Standard group; The patients in this group will receive the standard protocol in which they will be made NPO till the return of bowel functions. Thereafter, water and clear fluids will be given followed by soft food and, eventually a regular diet.
89492829|NCT06163651|Experimental|Treatment Group|The treatment group consists of pregnant or parenting people who meet our eligibility criteria. Mothers in the treatment group will receive PCAP-1 services through the work of highly trained, closely-supervised case managers.
88954093|NCT01968993|Experimental|nanOss Bioactive - posterolateral gutter|Participants will undergo instrumented PLF at one or two adjacent levels from L2-S1 with PEEK interbody cages (containing allograft or autograft) using nanOss Bioactive in combination with autograft and bone marrow aspirate in the posterolateral gutter on one side. Autograft alone will be used in the opposite posterolateral gutter.
88954094|NCT01969006|Experimental|Injection of Marcaine ½ %|Injection of 40 ml of Marcaine ½ % 2 cm medial, 2 cm downwards from the Anterior Iliac Spine
88954095|NCT01969006|Placebo Comparator|Needle prick|Needle prick 2 cm medial and 2 cm downwards from the Anterior Iliac spine
88954096|NCT01969019|Active Comparator|methylprednisolone|intravenous MP: 0.5g weekly for six weeks followed by 0.25g weekly for six weeks
88954097|NCT01969019|Active Comparator|methylprednisolone plus prednisone|intravenous MP 0.5g daily for three days per week, twice, followed by 0.25g daily for three days per week, twice, and followed by tapering oral prednisone (starting with 60mg/d, then10 mg less/week than each previous week for the next 3 weeks, then20mg/week at the 5th week followed with 5mg less/week than each previous week for the next 3 weeks)
88954098|NCT01969032|Experimental|2 consequent anthracycline-taxane based chemotherapy regimens|Paclitaxel 60 mg/m2 IV weekly plus Carboplatinum AUC2 IV weekly for 9 weeks, then Doxorubicin 25 mg/m2 IV weekly plus Endoxan 50 mg per os q.i.d. plus Capecitabine 500 mg t.i.d for 9 weeks
88954099|NCT01969045|Experimental|Working channel|Patients will receive local anaesthetics via the working channel of the bronchoscope.
88954100|NCT01969045|Experimental|Enk Fiberoptic Atomizer|Patients will receive the local anaesthetics for the flexible bronchoscopy via the nebulizer Enk Fiberoptic Atomizer.
88954101|NCT01969071|Active Comparator|Levosimendan, inotropic agent|In the levosimendan group, levosimendan will be used in addition to standard inotropic therapy (one or more agent including; dopamine, dobutamine, noradrenaline, adrenaline)for 24 hours.Levosimendan dosage; a loading dose of levosimendan (6 μg kg-1) will be administered after removal of the aortic cross-clamp, followed by an infusion of levosimendan at a dose of 0.1 μg kg-1 min-1.
88954102|NCT01969071|Active Comparator|Control|In the control group, only standard inotropic therapy (one or more agent including; dopamine, dobutamine, noradrenaline, adrenaline)will be administered
88954103|NCT01969097|Experimental|Dual tDCS + motor training|Motor training of the affected upper extremity combined with dual transcranial direct current stimulation (tDCS).
88954104|NCT01969097|Active Comparator|Anodal tDCS + motor training|Motor training of the affected upper extremity combined with anodal tDCS.
88954105|NCT01969097|Sham Comparator|Sham tDCS + motor training|Motor training of the affected upper extremity combined with sham tDCS.
88954106|NCT01969110|Active Comparator|Perioperative|Oral IMPACT (1 L/day) for 5 days before surgery and by enteral feeding after surgery
88954107|NCT01969110|Active Comparator|Preoperative|Oral IMPACT 1000ml/day for 5 days (1 L/day) before surgery
89492830|NCT06163651|No Intervention|Control Group|"The control group consists of pregnant or parenting people who meet our eligibility criteria and are enrolled in the original PCAP trial. Mothers in the control group are provided with a service and referral resource and can access services as usual in the community, but will not receive PCAP in any form."
89492831|NCT06163443|Experimental|Vitamin B group|Patients with polymorphisms in the MTHFR, MTR, and MTRR will take methylfolate, P5P, and methylcobalamin genes 2 capsules/day.
89492832|NCT06163443|Placebo Comparator|Placebo group|Patients with polymorphisms in the MTHFR, MTR, and MTRR will take placebo capsules will be identical in appearance, matched for color coating, shape, and size - 2 capsules/day..
89492833|NCT06162013|Active Comparator|Intervention|Following our basket trial design, there will be three parallel intervention cohorts (one per disease/cohort)
89492834|NCT06162013|Placebo Comparator|Placebo|Following our basket trial design, there will be three parallel placebo cohorts (one per disease/cohort)
89492835|NCT06161844|Experimental|Semaglutide injection (HD1916)|Up to 1.0 mg semaglutide (HD1916) Metformin ≥ 1500 mg/day (or maximum tolerated dose ≥ 1000 mg/day).
89492836|NCT06161844|Active Comparator|Ozempic|Up to 1.0 mg semaglutide (Ozempic) Metformin ≥ 1500 mg/day (or maximum tolerated dose ≥ 1000 mg/day).
89492837|NCT06161675|Experimental|QuitAid + SmokefreeTXT + NRT (Patch + Lozenge)|Participants will receive QuitAid, a medication therapy management delivered by their pharmacist, a texting intervention to help quit smoking, and up to 8 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch + lozenge.
89492838|NCT06161675|Active Comparator|SmokefreeTXT + NRT (Patch + Lozenge)|Participants will receive a texting intervention to help quit smoking and up to 8 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch + lozenge.
89492839|NCT06156371|Experimental|Lymphatic drainage massage|In the lymphatic drainage massage group, a patient will receive a total of 12 treatments, 20 minutes a day, 3 days a week for 4 weeks. Face-to-face manual lymphatic drainage massage will be performed at least 1 hour after the patient starts hemodialysis treatment, according to the morning and afternoon work schedules of the institutions. Manual lymphatic drainage massage will be performed by a certified researcher in accordance with the application steps.
89492840|NCT06156371|Active Comparator|Classic massage|"A patient in the classical massage group will receive a total of 12 treatments, 15 minutes a day, 3 days a week for 4 weeks. The classical face-to-face massage application will be performed at least 1 hour after the patient starts hemodialysis treatment, according to the morning and afternoon work schedules of the institutions.~Classical massage application will be performed by the researcher. The order of application is upper leg, lower leg and feet. During the application, appropriate methods such as effleurage (stroking), kneading, friction, impact and vibration, which are frequently used in classical massage, will be used. Olive oil will be used as essential oil during application."
89492841|NCT06156371|No Intervention|Control|No intervention other than the first and last evaluation will be applied to the control group. Patients in this group will continue to receive their usual hemodialysis treatment and care.
89492842|NCT06156007|Experimental|progressive muscle relaxation exercises|Women will be given one-time progressive muscle relaxation exercise training prepared by the researcher. In the training, the exercise will be demonstrated through demonstration method. Following training, women will be asked to perform progressive relaxation exercise at least 3 times a week (every other day). Women will be followed for 8 weeks with a progressive muscle relaxation exercise daily follow-up chart prepared by the researcher, and weekly reminders will be made (via WhatsApp® or text message). The final test will be administered to women online at the end of 8 weeks. RLS Severity Rating Scale form, Johns Hopkins Restless Legs Syndrome Quality of Life Scale and Pittsburg Sleep Quality Index will be used in the pre-test and post-test applications.
89492843|NCT06156007|No Intervention|no intervention|No intervention will be applied to women. Posttest application to women; It will be conducted online 8 weeks after the pre-test application. RLS Severity Rating Scale form, Johns Hopkins Restless Legs Syndrome Quality of Life Scale and Pittsburg Sleep Quality Index will be used in the pre-test and post-test applications.
89492844|NCT06155357|Experimental|Lifestyle Interventions Pre-Procedure|Subjects with paroxysmal or persistent atrial fibrillation (AF) who are scheduled to undergo elective catheter ablation of AF will participate in a 12-week multicomponent lifestyle intervention program.
89492845|NCT06155357|No Intervention|Standard of Care|Subjects who have previously undergone catheter ablation of atrial fibrillation (AF) as part of their standard of care will have medical chart review completed to gather information.
89492846|NCT06155045|Experimental|Modified Carbo-dissection technique|The carbo-dissection technique is performed using an improvised instrument that combines an electrocautery pencil (ValleylabTM Force FX electrocautery Pencil, Covidien, USA) with a CO2 mister blower (PerfX® Heart Lung pack Blower/Mister Kit, B L Lifesciences, Noida, India) and the instruments are fixed together using silk ties.The electrocautery is used in the coagulation mode at a setting of 10 to 15. The C02 flow is set at 2 to 3 litres/minute. Saline flow is adjusted to a level that does not hinder the effective coagulation but still prevents drying and desiccation of the tissues. Following the dissection of LIMA by the techniques mentioned above, blood flow from the harvested LIMA for one whole minute was noted(1 min post division of LIMA). The operative time required for LIMA dissection was also noted and entered. Patient's s demographic data were also collected and entered.
89492847|NCT06155045|Active Comparator|Conventional Arm|The conventional technique is performed using an electrocautery pencil (ValleylabTM Force FX electrocautery Pencil, Covidien, USA). The electrocautery is used in the coagulation mode at a setting of 10 to 15. Following the dissection of LIMA, blood flow from the harvested LIMA for one whole minute was noted(1 min post division of LIMA). The operative time required for LIMA dissection was also noted and entered. Patient's s demographic data were also collected and entered.
89492848|NCT06154408|Experimental|omega-3 fatty acids group|
89492849|NCT06154408|Placebo Comparator|placebo group|
89492850|NCT06154148|Experimental|Sustained Diagonal Flexion positioning|This position is a semi reclined positioning, the premature infant is off-center and semi-reclined on the mother's chest its body-axis is slightly flexed, with the limbs retracted in a preventive posture and the head in line with the body axis, moderately externally rotated hips in flexion-abduction, with adducted shoulders. The infants's head turns toward the mother's face and is located between the nipple and the clavicle. Their arms and legs are flexed, in a naturally adopted asymmetrical tonic neck posture, according to the infants's term and comfort. The infant is naked and positioned inside the mother's clothes.
89492851|NCT06154148|Active Comparator|Traditional prone position|The infants are placed vertically between the mother's breasts firmly attached to the chest and below their clothes.
89492852|NCT06151431|Active Comparator|Standard group|The maternal systolic blood pressure was consistently maintained above 80% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
89492853|NCT06151431|Experimental|Intensive group|The maternal systolic blood pressure was consistently maintained above 90% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
89492854|NCT06147193|Active Comparator|Power training Group|with baseline intervention and power training interventions
89492855|NCT06147193|Other|Baseline Group|baseline interventions and without power training interventions
89492856|NCT06145997||Persons with chronic pain|Standard acupuncture care will be provided to persons (n=50) with chronic pain. Standard care is defined as the care a participant was already receiving and that care will not be interrupted in any way for any study participant.
89492857|NCT06145893|Experimental|Hemay005 high dose group|In Core-treatment period, subject will take Hemay005 60mg twice daily for 12 weeks, and in the following extend-treatment period, subject will take Hemay005 60mg twice daily for 40 weeks.
89492858|NCT06145893|Experimental|Hemay005 lower dose group|In Core-treatment period, subject will take Hemay005 45mg twice daily for 12 weeks, and in the following extend-treatment period, subject will take Hemay005 45mg twice daily for 40 weeks.
89492859|NCT06145893|Placebo Comparator|Placebo|In Core-treatment period, subject will take placebo for 12 weeks, and in the following extend-treatment period, subject will take Hemay005 60mg or hemay005 45mg twice daily according to pre-allocation at randomization visit for 40 weeks.
89492860|NCT06137742|Experimental|PF-07868489|single subcutaneous injection (Part A); 6 subcutaneous injections at regular intervals (Part B)
89492861|NCT06137742|Placebo Comparator|Placebo|single subcutaneous injection (Part A); 6 subcutaneous injections at regular intervals (Part B)
89492862|NCT06135961|Active Comparator|eCTG monitoring|"eCTG monitoring with the Nemo Fetal Monitoring System (Nemo Healthcare B.V., Veldhoven, the Netherlands).~The NFMS consists of a wireless and beltless electrode patch on the maternal abdomen. It monitors fetal heart rate by fetal electrocardiography, maternal heart rate by maternal electrocardiography and the electrical activity of the uterine muscle by electrohysterography.~The advantage of the NFMS is that it is a safe method that can be used in all situations that are contraindicated for invasive monitoring. Furthermore, it can be used when the membranes are not ruptured and the patch does not have to be repetitively repositioned during labor. Because the NFMS is wireless, it gives women more freedom of movement during labor."
89492863|NCT06135961|No Intervention|Conventional CTG monitoring|"Philips Avalon FM 30 (Philips Healthcare, Eindhoven, the Netherlands).~The fetal heart rate is measured non-invasively by doppler ultrasound or invasively by fetal scalp electrode. The uterine activity and maternal heart rate is measured by tocodynamometry."
89492864|NCT06135298|Active Comparator|OSTEOSYNTHESIS + SYSTEMIC ZOLEDRONIC ACID|After osteosynthesis, systemic Zoledronic acid 5mg will be given intravenously at day 5 after surgery, during hospitalization.
89492865|NCT06135298|Experimental|OSTEOSYNTHESIS + LOCAL CERAMENT BONE VOID FILLER (BVF) + SYSTEMIC ZOLEDRONIC ACID|During osteosynthesis, cerament BVF will be used for the augmentation of the helical blade. Then, systemic Zoledronic acid 5mg will be given intravenously at day 5 after surgery, during hospitalization.
89492866|NCT06129929|Experimental|Hospital Jujutsu Group, HJJ Group|The intervention group participants who received the theoretical-based BJJ educational intervention.
89492867|NCT06129929|Active Comparator|Traditional lecture Group|The control group participants who received the traditional violence-prevention educational intervention.
89492868|NCT06127875||Home Ovulation Monitoring Group|timed intercourse by predicting the ovulation period or using ovulation test strips
89492869|NCT06127875||Hospital Ovulation Monitoring Group|timed intercourse by ultrasound ovulation monitoring
89492870|NCT06113666|Experimental|Digital cognitive behavioral therapy for insomnia|Behavioral: digital cognitive behavioral therapy (dCBT-I)
89492871|NCT06113666|Active Comparator|Patient Education about insomnia|Behavioral: Digital patient education about insomnia (PE)
89492872|NCT06112093|Active Comparator|Repetitive transcranial magnetic stimulation (rTMS)|12 sessions (3 sessions/week) of active rTMS at the left motor cortex to upregulate brain excitability and reduce headaches and post-concussion symptoms.
89492873|NCT06112093|Sham Comparator|Sham rTMS|12 sessions (3 sessions/week) of sham rTMS will be administered at the same location and duration as the active rTMS but will not modulate brain function. After the study is completed, participants will be offered an opportunity to receive active rTMS.
89492874|NCT06103721|Experimental|Group Dexmedetomidine|This will be the intervention group. Patients entering this group through computer generated random numbers will receive nebulization Dexmedetomidine in the pre-operative area under the supervision of consultant anesthetist.
89022165|NCT00456105|Active Comparator|1|Subjects with diabetes who plan to undergo elective infrainguinal bypass surgery will receive standard diabetes care by their admitting physician, post operatively until hospital discharge and post discharge in the community.
89492875|NCT06103721|Placebo Comparator|Group Normal Saline|This will be the placebo or control group. Patients entering this group through computer generated random numbers will receive nebulization with Normal Saline (placebo) in the pre-operative area under the supervision of consultant anesthetist.
89492876|NCT06092957|Active Comparator|Induction chemotherapy plus conventional concurrent chemoradiotherapy|
89492877|NCT06092957|Experimental|Induction chemotherapy plus reduced-dose radiotherapy and concurrent chemotherapy|
89204720|NCT00821418|Placebo Comparator|Placebo first|
89492878|NCT06092957|Experimental|Induction chemotherapy plus reduced-dose radiotherapy alone|
89492879|NCT06086522|Other|Cohort 1|Starting dose in dose escalation
89492880|NCT06086522|Other|Cohort 2|2nd cohort in dose escalation
89204721|NCT04000828|Other|single Arm|all patients receive the measurement with Sensimed Triggerfish
89204722|NCT00640926|Experimental|1|Radezolid 300 mg
89204723|NCT00640926|Experimental|2|Radezolid 450 mg
89204724|NCT00640926|Experimental|3|Radezolid 450 mg BID
89022166|NCT00456105|Experimental|2|Subjects with diabetes who plan to undergo elective infrainguinal bypass surgery will receive diabetes care under the direction of the Diabetes Action Team post operatively until hospital discharge and post discharge in the community. The Diabetes Action team will consist of a nurse coordinator who is a Certified Diabetes Educator (CDE) and a team of physicians specialized in the management of diabetes.
89022167|NCT00456105|Placebo Comparator|3|Subjects without diabetes will have their blood glucose levels monitored while in the hospital.
89022168|NCT03276156|Experimental|Apatinib plus S-1|Apatinib (425/500/675/750mg,qd,p.o.) concomitantly with S-1 (80mg to 120 mg, qd,days1-14, q3w, p.o.)
89492881|NCT06070688|Experimental|MeMed BV® biomarker test and standard of care|In addition to the standard of care for acute respiratory infections, the experimental arm shall reveal the results of the 'BV' test to the clinician co-investigators. The BV test reports a clinical score from 1-100 that as an adjunct to usual care, may help the clinician better direct appropriate resources towards the patient.
89492882|NCT06070688|Active Comparator|Usual Care|The co-investigators shall evaluate, diagnose and manage the acute respiratory infection presenting to the ED using the standard practice known in the community. This may include hospital sepsis practice protocols, clinical judgement, and national or local practice standards.
89492883|NCT06069570|Experimental|KB-GDT-01 cells|Dose Level 1: 400 x10^6, 800 x10^6 or 1600 x10^6 KB-GDT-01 cells + radiation (1.0 Gy/fraction)
89492884|NCT06066216|Experimental|Cadonilimab+carboplatin/cisplatin+paclitaxel|Cadonilimab (10 mg/kg, administered on the first day of each cycle, Q3W, until there is no clinical benefit)+ carboplatin(AUC=4-5, d1, Q3W, 6cycles) or cisplatin(75 mg/m2, d1, Q3W, 6cycles), +Paclitaxel(175 mg/m2, d1, Q3W, 6cycles), every 3 weeks (21 days) is a treatment cycle
89492885|NCT06061471|Experimental|Experimental: AK111 regimen 1|
89492886|NCT06061471|Experimental|Experimental: AK111 regimen 2|
89492887|NCT06051162|Experimental|HPI|Managing intraoperative hemodynamic condition under the HPI guidance
89492888|NCT06051162|No Intervention|Control|Managing intraoperative hemodynamic condition with standard anesthesia care (blinding the HPI monitor screen)
89492889|NCT06048952|Active Comparator|Music Therapy|30 Minutes before evaluate PONV at 2nd,4th,6th,12th,24th hours
89492890|NCT06048952|No Intervention|No Intervention|No intervention performed PONV evaluated at 2nd,4th,6th,12th,24th hours
89492891|NCT06044324|Active Comparator|Repetitive Transcranial Magnetic Stimulation|Stimulation site: According to the localization of neural orientation navigation system, magnetic resonance data was read in Brainsight software, and three-dimensional brain reconstruction was carried out. The stimulation target was located in the coordinates of Montreal Neurological Institute (MNI), which was located in the left middle temporal (-43, -73, 10). Treatment intensity was 100% exercise threshold, continuous 10Hz stimulation, repeated 75 times, that is, 3000 pulses per treatment, 2 times a day, stimulation lasted for 4 seconds with a 26-second interval for 37.5 minutes, continuous stimulation for 5 days, 2 days rest interval, and 5 days of continuous stimulation.
89492892|NCT06044324|No Intervention|HC observation|Collect data on healthy controls without stimulation. The subjects get clinical evaluation, blood sample collection, positron emission tomography-magnetic resonance scanning, and electrophysiological monitoring.
89492893|NCT06039527||Young adults|N=50 of this group No intervention. Sampling at timepoint 0 and for 50% of the group another sample at 3 months If respiratory symptoms develop in the 3 months after timepoint 0, participants are invited to provide a NPS/OPS to identify causative agent, and if one is established, individuals are sampled 3 more times at months 1, 3 and 5 post symptom onset
89492894|NCT06039527||Vital elderly|N=60 of this group No intervention. Sampling at timepoint 0 and for 50% of the group another sample at 3 months If respiratory symptoms develop in the 3 months after timepoint 0, participants are invited to provide a NPS/OPS to identify causative agent, and if one is established, individuals are sampled 3 more times at months 1, 3 and 5 post symptom onset
89492895|NCT06039527||Frail elderly|N=60 of this group. Half with recurring respiratory infections, and half without No intervention. Sampling at timepoint 0 and for 50% of the group another sample at 3 months If respiratory symptoms develop in the 3 months after timepoint 0, participants are invited to provide a NPS/OPS to identify causative agent, and if one is established, individuals are sampled 3 more times at months 1, 3 and 5 post symptom onset
89492896|NCT06038123|Experimental|Subjects with market released 3.0T conditional CIED systems receive 3.0T MRI scans|Signal arm, To confirm safety and effectiveness of the SureScan CIED System in the clinical MRI environment
89492897|NCT06026319|Experimental|CD79b-19 CAR T cells|"Prior to receiving CD79b-19 CAR T cells, participants will undergo two preparatory processes:~Leukapheresis: During Week -3 white blood cells will be collected.~Lymphodepletion: On days, -5 to -3 participants will receive 3 days of chemotherapy to decrease the number of lymphocytes~CD79b-19 CAR T cells will be administered intravenously on day 0 only. The dose you will receive will depend on the number of participants who have been enrolled prior and how well the dose was tolerated. The CD79b-19 CAR T cells will be administered over approximately 1 hour."
89492898|NCT06025877||Cohort A|One time clinician survey post-test following the receipt of the PrecivityAD2 blood test result
89492899|NCT06025877||Cohort B|Pre-test as well as post-test and close-out survey following the receipt of the PrecivityAD2 blood test result
89492900|NCT06019637||Spinal Muscular Atrophy Patients|Brazilian pediatric patients with a confirmed diagnosis of Spinal Muscular Atrophy treated with Onasemnogene Abeparvovec
89492901|NCT06017336|Experimental|Inspiratory Muscle Training Group|Patients in the training group will be performed inspiratory muscle training with the PowerBreathe® (inspiratory muscle training device) device at 50% of the maximal inspiratory pressure.
89492902|NCT06017336|Sham Comparator|Control Group|Control group will be given breathing exercises as a home program for 8 weeks.
89492903|NCT06006156|Experimental|dental implant with a convergent collar|One implant with a converging collar with micro threads will be installed in each patient according to the site randomization in the esthetic region of the upper jaw (between the second premolars).
89492904|NCT06006156|Active Comparator|dental implant with a divergent collar|One implant with a diverging polished collar will be installed in each patient according to the site randomization in the esthetic region of the upper jaw ( between the second premolars).
89492905|NCT06001047|Experimental|Group A (acupuncture group)|Treatment patients with residual symptoms after successful manual repositioning by electroacupuncture
89022169|NCT04715009||participants use smartphone less than 4 hours per day|participants use smartphone less than 4 hours per day
89022170|NCT04715009||participants use smartphone more than 4 hours per day|participants use smartphone more than 4 hours per day
89022171|NCT00456144||Group 1|GnRH agonist for 24 months
89492906|NCT06001047|Active Comparator|Group B (betahistine group)|Treatment patients with residual symptoms after successful manual repositioning by oral betahistine
89492907|NCT05999708|Experimental|Part 1: Cohort 1 - GSK4381406 or placebo|Participants in Part 1 Cohort 1 will receive a single dose of GSK4381406 dose level 1 or placebo in Treatment Period 1 in fasted state, followed by GSK4381406 dose level 3 or placebo in Treatment Period 2 in fasted state with washout period of at least 40 days between each dose.
89492908|NCT05999708|Experimental|Part 1: Cohort 2 - GSK4381406 or placebo|Participants in Part 1 Cohort 2 will receive a single dose of GSK4381406 dose level 2 or placebo in Treatment Period 1 in fasted state, followed by GSK4381406 dose level 4 or placebo in Treatment Period 2 in fasted state with washout period of at least 40 days between each dose.
89492909|NCT05999708|Experimental|Part 1: Cohort 3 - GSK4381406 or placebo|Participants in Part 1 Cohort 3 will receive a single dose of GSK4381406 dose level 5 or placebo in Treatment Period 1 in fasted state, followed by GSK4381406 dose level 7 or placebo in Treatment Period 2 in fasted state with washout period of at least 40 days between each dose. Note: Requirement for Treatment Period 2 (dose level 7) will be determined by PK data of previous doses.
89492910|NCT05999708|Experimental|Part 1: Cohort 4 - GSK4381406 or placebo|Participants in Part 1 Cohort 4 will receive a single dose of GSK4381406 dose level 6 or placebo in Treatment Period 1 in fasted state, followed by GSK4381406 dose level 6 in Treatment Period 2 in fed state with washout period of at least 40 days between each dose.
89492911|NCT05999708|Experimental|Part 2: Cohort 5 - GSK4381406 or placebo|Participants in Part 2 Cohort 5 will receive 14 days of once daily repeat dosing of GSK4381406 dose level A or placebo in fasted state.
89492912|NCT05999708|Experimental|Part 2: Cohort 6 - GSK4381406 or placebo|Participants in Part 2 Cohort 6 will receive 14 days of once daily repeat dosing of GSK4381406 dose level B or placebo in fasted state.
89492913|NCT05999708|Experimental|Part 2: Cohort 7 - GSK4381406 or placebo|Participants in Part 2 Cohort 7 will receive 14 days of once daily repeat dosing of GSK4381406 dose level C or placebo in fasted state.
89492914|NCT05999708|Experimental|Part 3 - GSK4381406 or Placebo and Indomethacin|Participants in Part 3 will receive 3 days of once daily repeat dosing of GSK4381406 in Treatment Period 1 followed by placebo in Treatment Period 2, or placebo in Treatment Period 1 and GSK4381406 in Treatment Period 2 in a cross-over design with a washout period of at least 14 days between each dosing period. Participants will be dosed in fasted state. The participants will be challenged with indomethacin during the final 2 days of each dosing period.
89492915|NCT05990387|Placebo Comparator|Placebo|Given once, followed by observation for up to 4 hours in a progressively cold water challenge
89492916|NCT05990387|Experimental|100 mg Mirabegron|Given once, followed by observation for up to 4 hours in a progressively cold water challenge
89492917|NCT05989152|Experimental|Definite prosthetic valve endocarditis|adult patients with a valvular prosthesis presenting a definite infective endocarditis (IE) according to the ESC classification in force, not operated on in the acute phase (before the PET scan at the end of treatment) and presenting a pathological FDG uptake on the prosthetic valve at the start of curative antibiotic treatment.
89492918|NCT05984979||People without diabetes|
89492919|NCT05984979||People with type 1 diabetes|
89492920|NCT05984979||People with type 2 diabetes|
89492921|NCT05977959|Experimental|Mentoring Program|Participants in this group will receive the Mentoring Program strategy in addition to Healthy School Recognized Campus.
89492922|NCT05977959|Experimental|Enhanced Resources|Participants in this group will receive the Enhanced Resources strategy in addition to Healthy School Recognized Campus.
89492923|NCT05977959|Experimental|Enhanced Engagement|Participants in this group will receive the Enhanced Engagement strategy in addition to Healthy School Recognized Campus.
89492924|NCT05977959|No Intervention|No Intervention|All schools will participate in the HSRC initiative. The requirements for the initiative are to complete a school-wide walking program, 1 youth, and 1 adult program from a list of available programs that make up the initiative.
89492925|NCT05977959|Experimental|Mentoring + Enhanced Resources|Participants in this group will receive the Mentoring Program and Enhanced Resources strategies in addition to Healthy School Recognized Campus.
89492926|NCT05977959|Experimental|Mentoring + Enhanced Engagement|Participants in this group will receive the Mentoring Program and Enhanced Engagement strategies in addition to Healthy School Recognized Campus.
89492927|NCT05977959|Experimental|Enhanced Resources + Enhanced Engagement|Participants in this group will receive the Enhanced Resources and Enhanced Engagement strategies in addition to Healthy School Recognized Campus.
89492928|NCT05977959|Experimental|Mentoring + Enhanced Resources + Enhanced Engagement|Participants in this group will receive the Mentoring Program, Enhanced Resources, and Enhanced Engagement strategies in addition to Healthy School Recognized Campus.
89492929|NCT05974280||Alofisel group (routine care)|The patient receives Alofisel injection as in routine care
89492930|NCT05974280||Autologous fat injection (routine care)|The back-up patient receives autologous fat stem cells injection as in routine care
89022172|NCT00456144||Group 2|GnRH agonist for 6 months
89022173|NCT00348920|No Intervention|1- General Anesthesia|General Anesthesia includes administration of a routine cardiac anesthetic as per institutional norms.
89022174|NCT00348920|Experimental|2- High Spinal and General Anesthesia|High Spinal and General Anesthesia includes a high dose intrathecal anesthetic administered prior to the induction of a standardized cardiac general anesthetic.
89204725|NCT03892564|Experimental|MC2-01 Cream, irradiation|One applications with MC2-01 Cream (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%) cream, followed by irradiation
89022175|NCT00456222||Luteal|
89022176|NCT00456222||Follicular|
89022177|NCT00449553||Pioglitazone 15 mg QD + Sulphonylurea|
89022178|NCT00449553||Pioglitazone 30 mg QD + Sulphonylurea|
89492931|NCT05973565|Experimental|synchronous learning format|Volunteers will be asked to attend synchronous learning format MSK Training. The exercise protocol has a duration of 45 minutes of rhythmic training and includes sections of warming-up, stretching, breathing, movement combinations, a dance sequence and recovery. Each exercise is accompanied with music that provides a clear and predictable rhythm. More specifically, the beat or rhythm of the music is used as a guide for the timing and duration of specific movements, allowing people with PD to coordinate their movements with the music. Simple values are going to be introduced such as whole notes, half notes and quarter notes; clapping and tapping, breathing and sounds. Class will be accompanied by recorded classical piano music, to meet the needs of synchronous learning format and asynchronous remote video-based format. The intensity of the class is moderate approximately 3 MET. The instructor is an experienced dance teacher in musicokinetic education.
89492932|NCT05973565|Experimental|Asynchronous remote video-based format|"Volunteers will be asked to attend asynchronous remote video-based format MSK Training.~The exercise protocol is the same as the synchronous format but delivered via a video-based format"
89492933|NCT05973565|No Intervention|Control|Volunteers will not be asked to sit quietly for a 45-minute period
89492934|NCT05967403|Active Comparator|Conventional CLADS group|Propofol administration rate will be controlled by a feedback loop facilitated by BIS monitoring using the conventional (prototype) closed-loop anaesthesia delivery system (CLADS). A BIS value of 50 will be used as the target point for induction and maintenance of anesthesia
89492935|NCT05967403|Active Comparator|Hermetic CLADS group|Propofol administration rate will be controlled by a feedback loop facilitated by BIS monitoring using the hermetic closed-loop anaesthesia delivery system (CLADS).[(Clarity Medical Private Ltd., Mohali, Punjab India]. A BIS value of 50 will be used as the target point for induction and maintenance of anesthesia
89492936|NCT05953285|Experimental|Restricted sleep on blood markers and subjective markers of homeostatic, and hedonic appetite|The proposed study will take the form of a within-subjects, randomized crossover experimental design. The data will be quantitative. The study will take place for total of approximately 5 weeks / 37 days (+ up to 6 weeks depending on their schedule: Minimum duration = 5 weeks (37 days), Maximum duration = Approximately 11 weeks (79 days).
89492937|NCT05953285|Experimental|Restricted sleep on gastric emptying|The proposed study will take the form of a within-subjects, randomized crossover experimental design. The data will be quantitative. The study will take place for total of approximately 5 weeks / 37 days (+ up to 6 weeks depending on their schedule: Minimum duration = 5 weeks (37 days), Maximum duration = Approximately 11 weeks (79 days).
89492938|NCT05933616|Experimental|Study Arm|Participants in the study arm will undergo the study procedure which are different induced glycaemic states.
89492939|NCT05932290||Elranatamab|Patients treated with elranatamab from the MagnetisMM-3 trial
89492940|NCT05932290||Standard of care|Patients treated with standard-of-care therapies from real-world data sources
89492941|NCT05920109|Experimental|experimental group|Patients in the experimental group will have a continuous Erector Spinae Plane Block within the first 6 hours post-admission, with a continuous 1ml/h infusion of Ropivacaine (2mg/ml) associated with a 25 ml bolus every 6h.
89492942|NCT05920109|No Intervention|control group|Patients in the control group will receive intravenous multimodal analgesia in the trauma bay. Thoracic epidural analgesia or continuous paravertebral block or serratus plane block will be performed within the first 12 hours post-admission if the pain is not controlled according to our national guidelines.
89492943|NCT05917132|Experimental|Single|All participating subjects will undergo 3 feeding phases : 3 days of a run-in diet, 2 days of a polyunsaturated fatty acid (PUFA) diet and 2 days of a saturated fatty acid (SFA) diet.
89492944|NCT05910749|Experimental|QEEG-guided sLoreta Neurofeedback|Brainmaster Discovery 24 EEG amplifier and BrainAvatar software will be used to conduct the neurofeedback sessions
89492945|NCT05902663||Patients diagnosed with Netherton Syndrome|
89492946|NCT05901662|Experimental|Competence training program|This group received a 3-hour weekly course training session in four consecutive weeks and provided services to community-dwelling older adults for two months.
89492947|NCT05901662|Active Comparator|Control|This group provided their routine services at senior activity centers.
89492948|NCT05897632|Other|Outpatient Evaluation|Patients randomized to this arm are discharged and receive outpatient evaluation, or cardiovascular ambulatory rapid evaluation (CARE), focused on medical management for cardiovascular risk factors (e.g. hypertension) within 72 hours of Emergency Department discharge.
89492949|NCT05897632|Other|Hospitalization Evaluation|Patients randomized to this arm receive evaluation for their symptoms in a hospital ward, observation unit, or emergency department boarding.
89492950|NCT05892718|Experimental|HCB101|"HCB101 in subjects with advanced solid tumors or relapsed and refractory non-Hodgkin lymphoma.~Dosage levels: 0.08 mg/kg, 0.16 mg/kg, 0.32 mg/kg, 0.64 mg/kg, 1.28 mg/kg, 2.56 mg/kg, and 5.12 mg/kg sequentially."
89492951|NCT05892133|Experimental|Maximal strength training|eight weeks of leg press strength training prior to knee surgery
89492952|NCT05892133|No Intervention|Control|treatment as usual prior to knee surgery
89492953|NCT05865522|Experimental|Trapezius Massage Group|"A patient information form will be given to each patient and the pre-test Pain Scale, Revise Fibromyalgia Impact Questionnaire and SF36 quality of life scale will be filled face-to-face.~The patients inTrapezius Massage Group will be given classical massage to the trapezius muscle for 6 weeks, 2 sessions per week (12 sessions in total) by the researcher in the physical therapy unit.~Patients in Trapezius Massage Group will be called weekly by phone throughout the study and pain will be questioned with VAS. Pain follow-up of the patients in trapezius massage will be performed 48 hours after the massage.~Pain Scale, Fibromyalgia Impact Questionnaire and SF36 Quality of Life Scale will be administered face-to-face to the patients in Trapezius Massage Group at the end of 6 weeks (post-test)"
89538023|NCT04484233||Clinical Decision Support Group|Anesthesiologists would have to respond to an online questionnaire about 10 hypotheticals clinical situations regarding patient blood management helped by dedicated clinical decision support systems for patient blood management (iAnemia, Intelligence Anesthesia).
89538024|NCT03288077|Experimental|Triptophan beverage|Proprietary blend of nutritional interventions aimed at increasing sleepiness
89538025|NCT03107065|Experimental|single treatment|Percutaneous-Temperature Controlled-Radiofrequency Electrocoagulation Used To Contract Tissue Associated With Axillary Sweat Glands
89022179|NCT00449553||Pioglitazone 15 mg QD + Metformin|
89022180|NCT00449553||Pioglitazone 30 mg QD + Metformin|
89022181|NCT00449592|Experimental|1|Oral zinc therapy, intervention
89022182|NCT00449592|Placebo Comparator|2|oral placebo
89492954|NCT05865522|Experimental|Foot Massage Group|"A patient information form will be given to each patient and the pre-test Pain Scale, Revise Fibromyalgia Impact Questionnaire and SF36 quality of life scale will be filled face-to-face.~The patients in Foot Massage Group will be given foot massage for 6 weeks, 2 sessions per week (12 sessions in total) by the researcher in the physical therapy unit.~Patients in Foot Massage Group will be called weekly by phone throughout the study and pain will be questioned with VAS. Pain follow-up of the patients in Foot Massage Group will be performed 48 hours after the massage.~Pain Scale, Fibromyalgia Impact Questionnaire and SF36 Quality of Life Scale will be administered face-to-face to the patients in Foot Massage Group Group at the end of 6 weeks (post-test)"
89492955|NCT05865522|No Intervention|Control Group|"A patient information form will be given to each patient and the pre-test Pain Scale, Revise Fibromyalgia Impact Questionnaire and SF36 quality of life scale will be filled face-to-face.~Patients in Control Group will not receive massage. Patients in Control Group will be called weekly by phone throughout the study and pain will be questioned with VAS.~Pain Scale, Fibromyalgia Impact Questionnaire and SF36 Quality of Life Scale will be administered face-to-face to the patients in Control Group at the end of 6 weeks (post-test)"
89492956|NCT05865327|Experimental|Cryoneurolysis Group|In addition to all standard of care analgesia treatments, CN will be performed on the ICN of each broken rib using the Iovera CN device and Generation 2 Iovera tip under ultrasound guidance.
89492957|NCT05865327|Sham Comparator|Standard Care Group|Participants in the control group will receive all standard of care analgesia treatments as well as sham CN (i.e., application of device without skin puncture or activation of unit) to maintain participant blinding.
89492958|NCT05861895|Experimental|Dose escalation cohort 1: HF158K1 given Q3W at 2 mg/m²|Participants in this dose group(2 mg/m²) will receive HF158K1 on D1 of each treatment cycle (3 weeks as a treatment cycle) through intravenous infusion.
89492959|NCT05861895|Experimental|Dose escalation cohort 1: HF158K1 given Q3W at 6 mg/m²|Participants in this dose group(6 mg/m²) will receive HF158K1 on D1 of each treatment cycle (3 weeks as a treatment cycle) through intravenous infusion.
89492960|NCT05861895|Experimental|Dose escalation cohort 1: HF158K1 given Q3W at 15 mg/m²|Participants in this dose group(15 mg/m²) will receive HF158K1 on D1 of each treatment cycle (3 weeks as a treatment cycle) through intravenous infusion.
89492961|NCT05861895|Experimental|Dose escalation cohort 1: HF158K1 given Q3W at 30 mg/m²|Participants in this dose group(30 mg/m²) will receive HF158K1 on D1 of each treatment cycle (3 weeks as a treatment cycle) through intravenous infusion.
89492962|NCT05861895|Experimental|Dose escalation cohort 1: HF158K1 given Q3W at 45 mg/m²|Participants in this dose group(45 mg/m²) will receive HF158K1 on D1 of each treatment cycle (3 weeks as a treatment cycle) through intravenous infusion.
89492963|NCT05861895|Experimental|Dose escalation cohort 1: HF158K1 given Q3W at 60 mg/m²|Participants in this dose group(60 mg/m²) will receive HF158K1 on D1 of each treatment cycle (3 weeks as a treatment cycle) through intravenous infusion.
89492964|NCT05858593|Experimental|Treatment|In the treatment group, the child will receive the VR-based curriculum in addition to receiving the devices to use for 8 weeks.
89492965|NCT05858593|Active Comparator|Control|In the control group, the child will still receive the devices to use for 8 weeks, but will not have the VR-based curriculum.
89492966|NCT05854381|Experimental|VIR-1388, 5×10^4 ffu|Study intervention will be administered at Day 1 and Day 85 via subcutaneous (SC) injections.
89492967|NCT05854381|Experimental|VIR-1388, 5×10^5 ffu|Study intervention will be administered at Day 1 and Day 85 via subcutaneous (SC) injections.
89492968|NCT05854381|Experimental|VIR-1388, 5×10^6 ffu|Study intervention will be administered at Day 1 and Day 85 via subcutaneous (SC) injections.
89492969|NCT05854381|Placebo Comparator|Placebo|Study intervention will be administered at Day 1 and Day 85 via subcutaneous (SC) injections.
89492970|NCT05846633|Experimental|VR treadmill|"The intervention of this study will be C-Mill virtual reality treadmill (Motekforce Link, Amsterdam/Culemborg, The Netherlands).~Sixteen participants will be included in the c-mill treadmill program for 50 minutes per session / two sessions per week, over six successive weeks (a total of 12 sessions).~Every participant will be trained for (50 minutes) as follows: warming up by walking on the treadmill with a comfortable walking speed upon individual's capability for 5 minutes. The speed should be determined for each one. Then participants continue training on the treadmill for 20 minutes. Visually guided stepping exercises will be applied. Participants should get a (5-min break) and then resume training on the treadmill for 25 minutes. Obstacle avoidance exercises and Walking area practice will be applied."
89492971|NCT05846633|Active Comparator|Conventional group|Like group I, each participant will be trained on a conventional treadmill for (50 minutes) as follows: warming up by walking on the treadmill belt with a comfortable walking speed suitable for each participant for 5 minutes. The speed should be determined Then participants continue training on the treadmill for 20 minutes; no VR will be used or applied. Participants should get a 5-min break and then resume training on the treadmill again for 25 minutes.
89492972|NCT05840978|Experimental|Probiotics combined strains|Probiotics combined strains administered as oral capsules once daily
89022183|NCT00349076|Experimental|1|"Preoperative simultaneous radiochemotherapy: 5-Fluorouracil und Oxaliplatin:~Radiotherapy starts on day 1 of chemotherapy; 28 fractions; single dose: 1,8 Gy once per day, monday through friday; Total dose: 50,4 Gy; Oxaliplatin: 50 mg/m² i.v., days 1, 8, 22 und 29; 5-Fluorouracil: 250 mg/m²/d continuous infusion, days 1-14 and 22-35~Adjuvant Chemotherapy:~Oxaliplatin: 100 mg/m² i.v. on day 1; Calciumfolinate: 400 mg/m² on day 1; 5-Fluorouracil: 2400 mg/m² continuous infusion for 46 hours; repeat day 15, 8 cycles"
89022184|NCT00349076|Active Comparator|2|"Preoperative simultaneous radiochemotherapy: 5-Fluorouracil Radiotherapy starts on day 1 of chemotherapy; 28 fractions; single dose: 1,8 Gy once per day, monday through friday; Total dose: 50,4 Gy; 5-Fluorouracil: Days 1-5 and 29-33: 120h-continuous infusion 1000 mg/m²/d~Adjuvant Chemotherapy: 5-Fluorouracil: 500 mg/m² on 5 consecutive days (day 1-5) i.v. bolus fot 2-5 minutes; repeat day 29, 4 cycles"
89022185|NCT00349193|Active Comparator|Laquinimod 0.3 mg|Laquinimod 0.3 mg
89022186|NCT00349193|Active Comparator|Laquinimod 0.6 mg|Laquinimod 0.6 mg
89022187|NCT00349193|Placebo Comparator|Placebo|Blinded Placebo
89492973|NCT05840978|Experimental|Probiotics single strain|Probiotics single strain administered as oral capsules once daily
89492974|NCT05840978|Placebo Comparator|Placebo|Placebo capsule administered orally once daily
89492975|NCT05833126|Experimental|Hepatic arterial infusion chemotherapy + Atezolizumab and bevacizumab|"Hepatic arterial infusion chemotherapy: percutaneous introduction of a standard hepatic arterial catheter through the femoral artery. FOLFOX was sequentially transfused by a fixed catheter. Drugs:FOLFOX regimen: oxaliplatin, calcium folinate, and 5-FU.~Atezolizumab: About 3 to 7 days after HAIC treatment, when liver function is stable (TBILI<2 times the upper limit of normal), Atezolizumab therapy can be started. The dosage was 1200mg and was given intravenously for at least 1 hour, once every 3 weeks. The longest course of treatment is 24 months.~Bevacizumab: About 3 to 7 days after HAIC treatment, when liver function is stable (TBILI<2 times the upper limit of normal), bevacizumab therapy can be started. The dosage was 15mg/kg and was given intravenously for no less than 1 hour, once every 3 weeks. The longest course of treatment is 24 months."
89492976|NCT05819658|Placebo Comparator|Placebo|Placebo SC injection will be administered once weekly for 4 weeks then every 2 weeks through Week 24 for double blind phase.
89492977|NCT05819658|Experimental|GV1001 0.56 mg|GV1001 0.56 mg SC injection will be administered once weekly for 4 weeks then every 2 weeks through Week 24 for double blind phase.
89492978|NCT05819658|Experimental|GV1001 1.12 mg|GV1001 1.12 mg SC injection administered once weekly for 4 weeks then every 2 weeks through Week 24 for double blind phase.
89492979|NCT05818735|Experimental|the electroacupuncture group|the electroacupuncture and the placebo drug
89492980|NCT05818735|Placebo Comparator|the drug group|the sham acupuncture and the drug Escitalopram
89492981|NCT05817240|Experimental|Experimental|
89492982|NCT05803876||General anesthesia|Patients undergoing surgery under general anesthesia with an intravenous anesthesia protocol with a concentration target (Orchestra® Base Primea - Fresenius Kabi France), a vasopressor support by norepinephrine and blood pressure optimisation.
89492983|NCT05801237|Experimental|Dose Escalation|
89492984|NCT05796661|Experimental|Qb150|"This group will be exposed to continuous venovenous therapy with a blood flow of 150ml/min; already standardized by the institution; for a maximum time of 72 hours or interrupted sooner if the system clots or the filter loses patency.~Both groups will have a wash out of 6 hours before crossing the arms of the work."
89492985|NCT05796661|Active Comparator|Qb 250|"This group will be exposed to continuous venovenous therapy with a blood flow of 250ml/min; experimental group to evaluate increased blood flow and filter durability; for a maximum time of 72 hours or interrupted sooner if the system clots or the filter loses patency.~Both groups will have a wash out of 6 hours before crossing the arms of the work."
89492986|NCT05782881|Experimental|Protocol treatment group|Strictly intervene blood glucose, blood pressure and blood lipids
89492987|NCT05782881|Placebo Comparator|Conventional treatment group|Treatment and management according to the guidelines
89492988|NCT05781425||Multiple Myeloma patients|Treatment naïve multiple myeloma patients. There is no intervention.
89492989|NCT05780073|Experimental|Dasatinib|Dasatinib 70 mg/daily, orally administered, for 24 weeks
89492990|NCT05780073|Placebo Comparator|Placebo|Investigational Medicinal Product-like appearance capsule containing an inert substance,orally administered, once daily, for 24 weeks
89492991|NCT05779345|Active Comparator|short implants|short 6 mm straumann blx implants
89492992|NCT05779345|Active Comparator|regular length + internal sinus lift|regular length implant 10 mm, in addition to internal sinus lift procedure
89492993|NCT05777525|No Intervention|Echography|Ultrasound skin measurements will be taken before and after the enriched cream treatment.
89492994|NCT05777525|No Intervention|"Visiopor PP-34 camera"|"Measurements of the skin will be taken by Visiopor PP-34 camera before and after the treatment with enriched cream."
89492995|NCT05777525|No Intervention|Mycological culture|Skin samples will be taken and analyzed by mycological culture before and after treatment with enriched cream
89492996|NCT05777525|Experimental|treatment application|The essential oil enriched cream will be applied to study participants.
89492997|NCT05774340|Experimental|CM326 Low Dose|CM326 220 mg/2 mL, subcutaneous at low dose
89492998|NCT05774340|Experimental|CM326 High Dose|CM326 220mg/2mL, subcutaneous at high dose
89492999|NCT05774340|Placebo Comparator|Placebo|Placebo 2mL, subcutaneous
89493000|NCT05771064|Experimental|Gentle Moves|Three-month physical activity intervention.
89493001|NCT05771064|No Intervention|Usual Care|Usual care provided by neuropsychologist.
89493002|NCT05766943|Active Comparator|Smart Pass ON|Smart Pass filter will be programmed ON in the S-ICD while performing exercise testing.
89493003|NCT05766943|Placebo Comparator|Smart Pass OFF|Smart Pass filter will be programmed OFF in the S-ICD while performing exercise testing.
89493004|NCT05761028|Experimental|CM310 high dose|CM310 is injected subcutaneously (SC) with a loading dose at the first dose, and then high dose thereafter, once every 2 weeks (Q2W) for a total of 26 doses.
89493005|NCT05761028|Experimental|CM310 low dose|CM310 is injected subcutaneously (SC) with a loading dose at the first dose, and then low dose thereafter, once every 2 weeks (Q2W) for a total of 26 doses.
89493006|NCT05761028|Placebo Comparator|Placebo|Subcutaneous injection (SC), once every 2 weeks (Q2W) for a total of 26 doses.
89493007|NCT05755789|Experimental|Intervention group (innovative administration scheme)|Continuous infusion of cefoxitin + Intermittent placebo
89493008|NCT05755789|Active Comparator|Control group (recommended administration scheme)|Intermittent cefoxitin + Continuous infusion of placebo
89493009|NCT05745077|Experimental|Telemedicine Consultation|Patient will schedule a Telemedicine Consultation in place of traditional in-person visit.
89493010|NCT05745077|Active Comparator|Traditional In-Person Care|Patient will schedule a traditional in-person visit as per usual care.
89493011|NCT05738239|Experimental|Active|Application of photo-biomodulation
89493012|NCT05738239|Placebo Comparator|Placebo|Inactive PBMT
89493013|NCT05731687|Other|Hybrid DEB|Patients randomized to hybrid DEB group will receive application of DEB in the side branch.
89493014|NCT05731687|Other|Two-stent strategy|Patients randomized to two-stent strategy will receive implantation of a second DES in the side branch, using Culotte or TAP/T technique.
89493015|NCT05724823|Experimental|10-week group|Will receive a 10-week seated exercise program, occurring 3 times per week. Sessions will be 60 minutes in duration.
89493016|NCT05724823|No Intervention|Delayed 2-week group (Boot Camp)|The Boot Camp group will complete a 2-week seated exercise program following the 10-week active trial period.
89493017|NCT05702970|Active Comparator|Ferric Carboxymaltose|Control Group
89493018|NCT05702970|Experimental|Sucrosomial iron|Experimental arm 1
89493019|NCT05702970|Experimental|Sucrosomial iron and vitamin D|Experimental arm 2
89493020|NCT05689619|Experimental|Silibinin|Silibinin (STAT3 inhibitor) 1 g/day taken orally every day
89493021|NCT05689619|Placebo Comparator|Placebo|Placebo 1 g/day taken orally every day
89493022|NCT05686798|Experimental|Ad5-yCD/mutTKSR39rep-ADP adenovirus and fSRS Arm|Subjects will receive a single intratumoral injection of the Ad5-yCD/mutTKSR39rep-ADP adenovirus at one of three dose levels beginning at 1 x 1011 vp and escalating in half-log (3-fold) increments to 1 x 1012 vp, along with the same dose of fractionated stereotactic radiosurgery until unacceptable toxicity, disease progression, or withdrawal of consent.
89493023|NCT05681078|Experimental|A Matter of Balance Program|
89493024|NCT05674994|Experimental|MethylPrednisone/Prednisone|"Day 1, 2 and 3: Intravenous Methylprednisolone 10 mg/kg/d (without exceeding 1000 mg/d) Vials of injectable solution of methylprednisolone® are diluted in 100 ml of NaCl 0.9% or G5%. Perfusion duration is between 20 to 30 minutes. The commercialized form for methylprednisolone injectable solution is not imposed and is taken from the stock of each pharmacy of the participating centers.~From day 4 to Day 30: Oral Prednisone slow tappering~1 mg/kg/d for 7 days~0.5 mg/kg/d for 7 days~0.25 mg/kg/d for 7 days,~10 mg/d until Day 30. For 10mg/kg, 1 mg/kg, 0.5 mg/kg, 0.25 mg/kg; rounding to 5 decimal lower if decimal ≤ 7 and the top ten if decimal ≥ 8."
89493025|NCT05674994|Placebo Comparator|Placebo|"Day 1, 2 and 3: Intravenous Methylprednisolone-Placebo~From Day 4 to Day 30: Oral Prednisone-Placebo"
89493026|NCT05666700|Experimental|Cilta-cel|
89493027|NCT05666687|Experimental|Cohort 1|MIJ821, starting dose
89493028|NCT05666687|Experimental|Cohort 2|MIJ821, dose will be defined based on the results of the previous cohort(s).
89493029|NCT05666687|Experimental|Cohort 3|MIJ821, dose will be defined based on the results of the previous cohort(s).
89493030|NCT05666687|Experimental|Cohort 4|MIJ821, dose will be defined based on the results of the previous cohort(s).
89493031|NCT05666687|Experimental|Cohort 5|MIJ821, dose will be defined based on the results of the previous cohort(s).
89493032|NCT05654870|Experimental|Valbenazine|Valbenazine once daily
89493033|NCT05654870|Placebo Comparator|Placebo|Placebo once daily
89493034|NCT05626244|Experimental|Intervention Group|The intervention group will be receiving the parenting intervention (name of the intervention: Being a Parent).
89493035|NCT05626244|No Intervention|Waitlist Control Group|The control group will be in a waitilist condition, in which they will not receive any intervention during the trial, but posteriorly will have the opportunity to receive the parenting intervention.
89493036|NCT05625971||Myeloma Group|Patients with newly diagnosed and previously treated multiple myeloma will receive bone marrow sampling and functional imaging.
89493037|NCT05621538|Experimental|Neurofeedback-active + TMS-active|4 sessions of: TMS (protocol: 10 Hz pulses delivered at 110% of MT in 60 x 5 sec trains with 25 sec ITI) Neurofeedback (protocol: presentation of own brain activity from multiple ROIs measured using fMRI)
89493038|NCT05621538|Active Comparator|Neurofeedback-active + TMS-sham|4 sessions of: TMS (protocol: 10 Hz pulses delivered using the Sham TMS coil in 60 x 5 sec trains with 25 sec ITI) Neurofeedback (protocol: presentation of own brain activity from multiple ROIs measured using fMRI)
89204726|NCT03892564|Experimental|MC2-01 Cream, no irradiation|One application of MC2-01 Cream (CAL/BDP, 0.005%/0.064%), no irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
89204727|NCT03892564|Experimental|MC2-01 vehicle, irradiation|One application of MC2-01 vehicle, followed by irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
89204728|NCT03892564|Experimental|MC2-01 vehicle, no irradiation|One application of MC2-01 vehicle, no irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
89204729|NCT03892564|Experimental|Control, irradiation|Untreated, irradiated site. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
89493039|NCT05621538|Active Comparator|Neurofeedback-sham + TMS-active|4 sessions of: TMS (protocol: 10 Hz pulses delivered at 110% of MT in 60 x 5 sec trains with 25 sec ITI) Neurofeedback (protocol: presentation of other's brain activity from multiple ROIs measured using fMRI)
89493040|NCT05621538|Sham Comparator|Neurofeedback-sham + TMS-sham|4 sessions of: TMS (protocol: 10 Hz pulses delivered using the Sham TMS coil in 60 x 5 sec trains with 25 sec ITI) Neurofeedback (protocol: presentation of other's brain activity from multiple ROIs measured using fMRI)
89493041|NCT05621538|No Intervention|Check-In Only|4 sessions of: Completing typical pre-TMS/MRI procedures Being prompted to reflect on outside treatment (TAU)
89493042|NCT05620290|Experimental|Treatment Arm|Malignant Melanoma patients undergoing MRI-guided ultrasound-stimulated microbubble treatment plus radiation therapy
89493043|NCT05616689|Experimental|Bundled hyperpolypharmacy intervention|Eligible participants with physician authorization who are randomly assigned to intervention
89538026|NCT00777127|Experimental|1|Aldara 5% Cream
89022188|NCT03274206|Experimental|BLS-ILB-E710c|"Drug: BLS-ILB-E710c 1,000mg~Dosage and duration: 4 capsules per day for 5 consecutive days at week 1,2,4, and 8)"
89493044|NCT05616689|No Intervention|Control|Eligible participants with physician authorization who are randomly assigned to usual care
89493045|NCT05611502|Experimental|TMS A|TMS administered over right frontal eye field at 10 Hz, 110% of MT, 60 x 5 sec trains, 25 sec ITI
89493046|NCT05611502|Active Comparator|TMS B|TMS administered over right frontal eye field at 1 Hz, 110% of MT, 7 x 225 sec trains, 30 sec ITI
89493047|NCT05611268|No Intervention|No treatment group|24 patients that will continue receiving routine treatment for PAH
89493048|NCT05611268|Other|Pentoxifylline|24 patients that will receive pentoxifylline and the routine treatment for PAH
89493049|NCT05607719|Experimental|Bretzri followed by Bevespi Group|Participants in this group will receive Bretzri for 4-weeks followed by 8-weeks of Bevespi.
89493050|NCT05607719|Experimental|Bevespi followed by Bretzri Group|Participants in this group will receive Bevespi for 8-weeks followed by 4-weeks of Bretzri.
89493051|NCT05604482|Experimental|CXCR4-PET experimental group|In addition to the current standard of imaging in GCA, using FDG-PET/CT, participants receive CXCR4-PET.
89493052|NCT05593458|Experimental|Arterial infusion group|"3 cycles of neoadjuvant chemotherapy: Oxaliplatin arterial infusion+S-1~3 cycles of immunotherapy: sintilimab~surgery and 3 cycles of adjuvant chemotherapy using SOX regimen plus sintilimab.~S-1 administration till 1 year after surgery"
89493053|NCT05593458|Active Comparator|SOX group|"3 cycles of neoadjuvant chemotherapy: SOX regimen~3 cycles of immunotherapy: sintilimab~surgery and 3 cycles of adjuvant chemotherapy using SOX regimen plus sintilimab.~S-1 administration till 1 year after surgery"
89493054|NCT05587517|Experimental|EMPOWER arm|"The EMPOWER arm includes six 15 minute modules delivered in a 1-on-1 format with the same interventionist, and 2 boosters (approximately 45 minutes each) conducted by phone.~Subjects who meet eligibility criteria will receive up to 4 sequential assessments before and after the EMPOWER intervention within 3 months conducted in person and by phone."
89493055|NCT05587517|Placebo Comparator|Supportive Conversation arm|"The Supportive Conversation (SC) arm includes a supportive, empathic encounter without specific skill-building for approximately the same amount of time as EMPOWER.~Subjects who meet eligibility criteria will receive up to 4 sequential assessments before and after SC within 3 months conducted in person and by phone."
89493056|NCT05580692|Experimental|Patient Cohort|All Patients are within the same arm
89493057|NCT05579444||Ulcerative Colitis|Participants with ulcerative colitis.
89493058|NCT05579444||Crohn's Disease|Participants with Crohn's disease.
89493059|NCT05579444||Obesity|Participants that are obese.
89493060|NCT05579444||Colon Polyps|Participants with colon polyps.
89493061|NCT05579444||Eosinophilic esophagitis|Participants with Eosinophilic esophagitis
89493062|NCT05579444||Gastroesophageal Reflux Disease (GERD)|Participants with Gastroesophageal Reflux Disease (GERD).
89493063|NCT05579444||Gastritis|Participants with gastritis.
89493064|NCT05579444||Gastric ulcers|Participants with gastric ulcers.
89493065|NCT05579444||Duodenal ulcers|Participants with duodenal ulcers.
89493066|NCT05579444||Intestinal metaplasia|Participants with intestinal metaplasia (risk factor for esophageal cancer).
89493067|NCT05579444||Gastric Cancer|Participants with gastric cancer.
89493068|NCT05579444||Lymphocytic/Microscopic Colitis|Participants with Lymphocytic/Microscopic Colitis.
89493069|NCT05579444||Celiac Sprue|Participants with Celiac Sprue.
89493070|NCT05579444||Irritable Bowel Syndrome (IBS)|Participants with IBS.
89493071|NCT05579444||Small intestinal bacterial overgrowth (SIBO)|Participants with SIBO.
89493072|NCT05579444||Non-alcoholic Fatty Liver Disease (NAFLD)|Participants with NAFLD.
89493073|NCT05579444||Gallstone disease|Participants with Gallstone disease.
89493074|NCT05577754|Placebo Comparator|Group A|
89493075|NCT05577754|Experimental|Group B|
89493076|NCT05567562|Experimental|COPD Cases: Dual antiplatelet therapy first, then placebo|Dual antiplatelet therapy (aspirin 81mg and clopidogrel 75mg) will be given for 2 weeks, followed by 2 weeks without intervention, then 2 weeks of placebo
89538027|NCT00777127|Active Comparator|2|Solaraze 3% Gel
89538028|NCT00761371|Experimental|Imiquimod|Imiquimod 5% cream
89493077|NCT05567562|Placebo Comparator|COPD Cases: Placebo first, then dual antiplatelet therapy|Placebos for each therapy (2 pills) will be given for 2 weeks, followed by 2 weeks without intervention, then 2 weeks of dual antiplatelet therapy
88954108|NCT01969123|Experimental|Experimental: EVP-6124, low dose|low dose, Tablet, Once Daily, Day 1 through Day 182
89493078|NCT05567562|Active Comparator|Controls: Dual antiplatelet therapy first, then placebo|Dual antiplatelet therapy (aspirin 81mg and clopidogrel 75mg) will be given for 2 weeks, followed by 2 weeks without intervention, then 2 weeks of placebo
89493079|NCT05567562|Placebo Comparator|Controls: Placebo first, then dual antiplatelet therapy|Placebos for each therapy (2 pills) will be given for 2 weeks, followed by 2 weeks without intervention, then 2 weeks of dual antiplatelet therapy
89493080|NCT05566431|Active Comparator|ICP monitoring based Protocol|Arm one will use a consensus-developed management protocol for paediatric severe traumatic brain injury based on recommendations from the Brain Trauma Foundation Guidelines, which uses invasive intracranial pressure monitoring
89493081|NCT05566431|Active Comparator|No ICP Monitoring Protocol CREVICE|Arm two will use the Consensus-Revised Imaging and Clinical Examination (CREVICE) management protocol for paediatric severe traumatic brain injury based on imaging and clinical examination in the absence of invasive intracranial pressure monitoring
89493082|NCT05565339||1|"Total Ossicular Replacement Prostheses:~The primary objective for the total ossicular replacement prostheses was to achieve an ABG ≤ 20 dB by at least 25 % of the patients after the PMEI implantation"
89493083|NCT05565339||2|"Partial Ossicular Replacement Prostheses:~The primary objective for the partial ossicular replacement prostheses was to achieve an ABG ≤ 20 dB by at least 53.8 % of the patients after the PMEI implantation."
89493084|NCT05565339||3|"Stapesplasty Prostheses:~The primary objective for the stapes prostheses was to achieve an ABG ≤ 20 dB by at least 86 % of the patients after the PMEI implantation."
89493085|NCT05560516|Experimental|Patients with chemotherapy-induced peripheral neuropathy who receive Qutenza|
89493086|NCT05560516|Active Comparator|Patients with chemotherapy-induced peripheral neuropathy who receive Duloxetine|
89493087|NCT05554419|Active Comparator|ARM A (cytarabine)|Patients receive cytarabine IV on study. Patients undergo bone marrow aspiration and biopsy on study. Patients may also undergo ECHO and/or MUGA as clinically indicated.
88954109|NCT01969123|Experimental|Experimental: EVP-6124, high dose|high dose, Tablet, Once Daily, Day 1 through Day 182
88954110|NCT01969123|Placebo Comparator|EVP-6124 Placebo|Placebo, Tablet, Once Daily, Day 1 through Day 182
88954111|NCT01969136|Experimental|Experimental: EVP-6124, low dose|low dose, Tablet, Once Daily, Day 1 through Day 182
88954112|NCT01969136|Experimental|Experimental: EVP-6124, high dose|high dose, Tablet, Once Daily, Day 1 through Day 182
89493088|NCT05554419|Experimental|ARM B (cytarabine, venetoclax)|Patients receive cytarabine IV and venetoclax PO on study. Patients undergo bone marrow aspiration and biopsy on study. Patients may also undergo ECHO and/or MUGA as clinically indicated.
89493089|NCT05554419|Experimental|ARM C (liposomal daunorubicin-cytarabine, venetoclax)|Patients receive liposome-encapsulated daunorubicin-cytarabine IV and venetoclax PO on study. Patients undergo bone marrow aspiration and biopsy on study. Patients may also undergo ECHO and/or MUGA as clinically indicated.
89493090|NCT05554419|Experimental|ARM D (azacitidine, venetoclax)|Patients receive azacitidine IV or SC and venetoclax PO on study. Patients undergo bone marrow aspiration and biopsy on study. Patients may also undergo ECHO and/or MUGA as clinically indicated.
88954113|NCT01969136|Placebo Comparator|EVP-6124, Placebo|Placebo, Tablet, Once Daily, Day 1 through Day 182
88954114|NCT01969149|Experimental|Exenatide group|"Exenatide. Exenatide: bolus of 0.05 µg/min infused during the 1st hour of treatment, followed by a continuous infusion of 0.025 µg/min until the end of treatment.~The exenatide therapy will begin as soon as a blood glucose level is above 140 mg/dl will be measured. A of exenatide will be intravenously .~The treatment will be administrated during the first postoperative 48 hours in the intensive care unit or until intensive care unit discharge if this event occurs earlier."
89022189|NCT03274206|Placebo Comparator|BLS-ILB-E710c-placebo|"Drug: BLS-ILB-E710c-placebo~Dosage and duration: 4 capsules per day for 5 consecutive days at week 1,2,4, and 8)"
89204730|NCT00821496|Experimental|Oral Contraceptive|
89493091|NCT05548634|Other|Part 1 Cohort 0|IV infusion of TAVO412
89493092|NCT05548634|Other|Part 1 Cohort 1|IV infusion of TAVO412
89493093|NCT05548634|Other|Part 1 Cohort 2|IV infusion of TAVO412
89493094|NCT05548634|Other|Part 1 Cohort 3|IV infusion of TAVO412
89493095|NCT05548634|Other|Part 1 Cohort 4|IV infusion of TAVO412
89493096|NCT05548634|Other|Part 1 Cohort 5|IV infusion of TAVO412
89493097|NCT05548634|Other|Part 2 Cohorts|IV infusion of TAVO412
89493098|NCT05545956|Active Comparator|Hand Wrung|Hand wrung refers to manually wringing surgical sponges by hand.
89493099|NCT05545956|Experimental|ProCell Wrung|ProCell wrung refers to automated wringing surgical sponges by an FDA approved suction device (ProCell).
88954115|NCT01969149|Active Comparator|Insulin group|"Insulin: Humalog (insulin lispro human analog). The insulin therapy will begin as soon as a blood glucose level is above 140 mg/dl will be measured.~The dose of insulin intravenously infused will be adapted to blood glucose measurements, following the insulin therapy protocol used in our department.~The insulin therapy protocol used in our department and prescribed as the benchmark treatment in the present study has been validated in a previous study. It has been derived from the protocol validated by Goldberg et al."
88954116|NCT01969175|Experimental|Intervention Diet|
88954117|NCT01969175|Placebo Comparator|Control|
89493100|NCT05545930|Active Comparator|Hand Wrung|Hand wrung refers to manually wringing surgical sponges by hand.
89493101|NCT05545930|Experimental|ProCell Wrung|ProCell wrung refers to automated wringing surgical sponges by an FDA approved suction device (ProCell).
89493102|NCT05542264|Active Comparator|Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole)|
89493103|NCT05542264|Experimental|SEP-363856|
89538029|NCT03287999||Haemophilia patients|Persons with haemophilia A or B - 240 to be recruited
89538030|NCT03287999||Healthy volunteers|Healthy volunteers - 10 to be recruited
89538031|NCT03287921||mono bronchodilatation|patients with COPD and features of hyperinflation and small airway disease
89538032|NCT03287921||dual bronchodilatation|patients with COPD and features of hyperinflation and small airway disease
89022190|NCT00349271|Experimental|Stem Cell therapy|Stem Cell therapy
89022191|NCT00349271|Active Comparator|Standart therapy|Standart therapy
89022192|NCT03274167|Experimental|Gabapentin|300 mg per day once daily before bedtime
89022193|NCT03274167|Placebo Comparator|Control|Capsule identical to the experimental arm, one tablet once daily before bedtime
89022194|NCT00349427|Experimental|Rosiglitazone|4mg
89022195|NCT00349427|Placebo Comparator|Rosiglitazone placebo|4mg
89022196|NCT00456690|Experimental|1|Thalassemia Mayor Patients
89022197|NCT00349856|Active Comparator|1|
89022198|NCT00349934|Experimental|A|IMP321
89022199|NCT00450099|Experimental|1|Epidural, bupivacaine
89204731|NCT00818220|Experimental|1-Delayed Cord Clamping (DCC)|Immediately after birth, the infant is placed in a warm blanket and held lower than the placenta. The research nurse counts out 30 to 45 seconds for the obstetrician. The cord is milked once and then clamped at 30 to 45 seconds after birth.
89538033|NCT03196063|Active Comparator|Eccentric|"Patients allocated in this group will perform three sets of 15 unipodal squats with the affected limb on an inclined plane. The patient will be instructed to perform only the eccentric phase of the exercise, keeping the torso erect and flexing the knee up to 90 degrees. The return to the initial position will be performed with the unaffected leg. To increase exercise load, the patient will carry a bag with washers. This protocol will last eight weeks, with 24 face-to-face sessions.~Both groups will also receive a protocol with complementary isotonic exercises, focusing on the strengthening of gluteus maximus, gluteus medius, hamstrings and calves."
89022200|NCT00350012||1|Persons who have had a stroke and either have, or do not have, a pathological asymmetry of perception, attention and action causing functional disability (spatial neglect; Barrett and Burkholder, 2006).
89022201|NCT00350012||2|Healthy age- and education-matched volunteers
89022202|NCT00450138|Experimental|1|Radiation + vandetanib
89022203|NCT00450138|Experimental|2|Radiation + cisplatin + vandetanib
89022204|NCT00350051|Experimental|Arm 1|
89022205|NCT04699110|Experimental|Treatment group|Patients receiving intracoronary adrenaline
89022206|NCT04699110|Active Comparator|Control group|Patients receiving intracoronary adenosine
89022207|NCT04698759||Stunted subject|Children with stunted status condition based on Z score criteria
89022208|NCT04698759||Normal subject|Children with normal status condition based on Z score criteria
89022209|NCT03274089|Experimental|Kiosk intervention group|
89022210|NCT03274089|No Intervention|Nurse clinician control group|
89022211|NCT00350285|Experimental|1|Motivational enhancement therapy
89022212|NCT00350285|Active Comparator|2|Marijuana education
89022213|NCT00350285|No Intervention|3|Delayed treatment control condition
89022214|NCT00105534|Experimental|AzaSite|
89022215|NCT00105534|Sham Comparator|Vehicle|
89022216|NCT00350753|Experimental|Erlotinib and bevacizumab|
89022217|NCT00457119|Experimental|Step 1 Arm 1|5mg/day RAD001 + Carboplatin + Paclitaxel
89022218|NCT00457119|Experimental|Step 1, Arm 2|30mg/week RAD001 + Carboplatin + Paclitaxel
89022219|NCT00457119|Experimental|Step 2, Arm 1|5mg/day RAD001 + Carboplatin + Paclitaxel + Bevacizumab
89022220|NCT00457119|Experimental|Step 2, Arm 2|30mg/week RAD001 + Carboplatin + Paclitaxel + Bevacizumab
89022221|NCT00350909|Experimental|1|One arm was a 2-session brief intervention with both sessions involving only the adolescent. Each session was a 60 minute individual session with the counselor.
89022222|NCT00350909|Active Comparator|2|The other arm was a 3-session brief intervention, with 2 sessions involving the adolescent and one session with the parent. Each of these individual sessions were 60 minutes.
89022223|NCT00350948|Experimental|Telcyta + Liposomal Doxorubicin|Telcyta at 1000 mg/m2 followed by Liposomal Doxorubicin at 50 mg/m2 on Day 1 of each four-week treatment cycle
89022224|NCT00350948|Active Comparator|Liposomal Doxorubicin|Liposomal Doxorubicin at 50 mg/m2 on Day 1 of each four-week treatment cycle
89022225|NCT00457158|Experimental|1|ALN optional filter
89022226|NCT00457158|No Intervention|2|No ALN optional filter
89022227|NCT00350987|Experimental|PCT|PCT guidance
89022228|NCT00350987|Active Comparator|Guidelines|enforced guidelines
89022229|NCT00421538|Active Comparator|LMWH|Therapeutic dose of Nadroparin
89022230|NCT00421538|Placebo Comparator|Placebo|Injectable placebo
89022231|NCT03276039||25 patients with non-alcoholic fatty liver disease|
89022232|NCT03276039||25 patients with NAFLD and chronic HCV|
89022233|NCT03276039||20 healthy controls|
89204732|NCT00818220|Active Comparator|2-Immediate Cord Clamping (ICC)|Routine care which is immediate cord clamping
89493104|NCT05541536|Experimental|General information pamphlet plus Consultation meeting|Study team member will approach mothers < 24 hrs (up to 5 min prior) of CRC approach for NRN trial. During the consultation meeting (5 minutes), the study team member will review the pamphlet and answer any questions. Visits will ideally occur in person. If the mother is not at bedside, 1 attempt will be made to reach the mother by phone in which case the pamphlet will be forwarded by mail.
89493105|NCT05541536|Active Comparator|Usual Care|Study participants will not receive the general information pamphlet or consultation.
89493106|NCT05490875||Carotid Ultrasound Group|Head and neck cancer survivors treated with radiotherapy, at least 2 years since end of radiotherapy with no evidence of disease will receive a carotid ultrasound to measure carotid velocities and intima-media thickness of the carotid arteries.
89493107|NCT05489445||Patients undergoing EP|Patients already clinically indicated for undergoing catheter-based eletrophysiological intervention, in which the FDA approved medical device KODEX-EPD system will be used.
89493108|NCT05464615|Experimental|Amoxicillin Graded Challenge|"Obtain baseline vitals (heart rate, O2 saturation, blood pressure and respiratory rate).~Administer 0.7 ml (56 mg) of amoxicillin 400 mg/ 5ml orally followed by 30 minutes of observation for allergy symptoms and other adverse reactions (e.g., itching, hives, swelling, coughing, wheezing, throat tightness, difficulty breathing, abdominal pain, vomiting, lightheadedness, hypotension, low oxygen saturation, tachycardia)~If no allergy or adverse symptoms are noted, administer 2.5 ml (200 mg) of amoxicillin followed by 90 minutes of observation"
89493109|NCT05457842|Experimental|Breast Cancer|Participants will receive a single dose of ASP5354. Up to 6 dose levels will be administered.
89493110|NCT05457842|Experimental|Melanoma|Participants will receive a single dose of ASP5354. Up to 5 dose levels will be administered.
89493111|NCT05432206|Experimental|Cannabis Sativa Oil first, then Placebo|This arm will start with the active comparator for the first period and change to the placebo in the second period
89493112|NCT05432206|Experimental|Placebo first, then Cannabis Sativa Oil|This arm will start with the placebo for the first period and change to the active comparator in the second period
89493113|NCT05417412|Experimental|STEP-UP (brief behavioral therapy)|Intervention arm of open trial
89493114|NCT05404932|Experimental|Intervention arm (aliquoted plasma application into the conjunctiva)|"This is the only arm of the study. The intervention is administration of aliquoted plasma provided by Canadian Blood Services in eye droppers (3 ml aliquots in 7 ml vials) in the patient's conjunctiva.~The duration of therapy can be 2 to 6 months depending on response The intra-ocular drops will be administered every 1-5 hours daily in the affected eye based on disease severity and may be repeated"
89493115|NCT05403827|Experimental|K-161|K-161 Ophthalmic Solution
89493116|NCT05403827|Placebo Comparator|Placebo|Vehicle Solution
89493117|NCT05369975|Experimental|Imlifidase|Imlifidase, is provided as a freeze-dried powder for concentrate for solution for infusion, 11 mg per vial. After reconstitution with sterile water for injection, the concentrate contains 10 mg/mL imlifidase. Imlifidase is administered intravenously as one infusion of 0.25 mg/kg over 15 minutes within 24 hours prior to transplantation. A second dose of 0.25 mg/kg may be given if the first imlifidase dose is considered not to have had sufficient effect. The second dose can be administered within 24 hours after the first dose.
89493118|NCT05369975|Other|Non-Comparative Concurrent Reference Cohort|Patients in the non-comparative prospective concurrent reference cohort (with any grade of sensitization and negative XM) will receive medications, both pre- and post-transplant, in accordance with each clinic's routine for kidney transplanted patients.
89493119|NCT05369975|Other|Non-Comparative Historical Reference Cohort|Patients in the non-comparative historical reference cohort (with less sensitization and negative XM) randomly selected from the CTS registry have been transplanted and treated in accordance with standard-of-care for kidney transplanted patients. Patients transplanted in 2010 and onwards will be selected to optimize the probability that these patients will have received about the same maintenance immunosuppressive treatment as the patients in the current trial will receive.
89493120|NCT05363891|Experimental|Natrunix 200mg with MTX(+Folate)|Natrunix 200mg, subcutaneous injection in combination with Methotrexate (+Folate).This arm will enroll 70 subjects.
89493121|NCT05363891|Experimental|Natrunix 400mg with MTX(+Folate)|Natrunix 400mg, subcutaneous injection in combination with Methotrexate (+Folate).This arm will enroll 70 subjects.
89493122|NCT05363891|Placebo Comparator|Placebo with MTX(+Folate)|Placebo in combination with Methotrexate (+Folate).This arm will enroll 70 subjects.
89493123|NCT05361616|Active Comparator|PBM Ortho Active device|PBM Ortho Active group will be given an active device.
89493124|NCT05361616|Sham Comparator|PBM Ortho Sham|PBM Ortho Sham device group will be given a non-active device that will not emits light.
89204733|NCT03891862|Experimental|Open-label Valbenazine|Participants received valbenazine 40 mg once daily for 1 week, then 80 mg once daily for the remainder of the 8-week open label period.
89493125|NCT05360537|Experimental|patients treated with Insulin Degludec/Liraglutide|Diabetes therapy with Insulin Degludec/Liraglutide and various combinations of metformin, repaglinide, sulfonylureas.
89493126|NCT05360537|Active Comparator|patients treated with Insulin regime Basal Bolus|Diabetes therapy with the combination of a single administration of glargine insulin and three administration of Aspart Insulin.
89493127|NCT05355363|Experimental|Colonoscopy|Standard colonoscopy: All optically diagnosed polyps will be removed and sent to the CHUM pathology laboratory for histopathological evaluation according to institutional standards.
89493128|NCT05344521|Active Comparator|Control|After removal of the temporary wound coverage (allograft), Integra® is applied directly onto the wound surface.
89493129|NCT05344521|Experimental|Integra®-SC|After removal of the temporary wound coverage (allograft), Integra®-SC is applied to the contralateral area of the site where Integra® is applied.
89493130|NCT05334784|Experimental|Impella ECP Device|Subjects receiving the Impella ECP.
89493131|NCT05319925||Study 1|"Initial examination of the developed questionnaire in the first 100 participants to identify problematic questions and to optimise the instrument.~To evaluate test-retest reliability, collected data of the first 100 patients will be used as baseline value and re-assessed in Study 2."
89493132|NCT05319925||Study 2|"Second examination in 300 additional participants and re-assessment in participants from Study 1 (n=400) to validate modified questionnaire in its final form.~To evaluate test-retest reliability, data of Study 1 is compared against Study 2 of the same participant sample (n=100)."
89493133|NCT05309200|Placebo Comparator|OCE-205 Cohort 1|Placebo, intravenous infusion
89493134|NCT05309200|Experimental|OCE-205 Cohort 2|OCE-205, 8 µg/hr, intravenous infusion
89493135|NCT05309200|Experimental|OCE-205 Cohort 3|OCE-205, 15 µg/hr, intravenous infusion
89493136|NCT05309200|Experimental|OCE-205 Cohort 4|OCE-205, 30 µg/hr, intravenous infusion
89493137|NCT05309200|Experimental|OCE-205 Cohort 5|OCE-205, 50 µg/hr, intravenous infusion
89493138|NCT05304715|Placebo Comparator|Placebo|Patients will be treated with 250ml of normal saline 0.9% or 5% dextrose water as single intravenous infusion of one hour within 72 hours from the start of standard-of-care treatment. Standard-of-care treatment will be prescribed to all patients at the discretion of the attending physicians according to local guidelines or to their own decision.
89493139|NCT05304715|Active Comparator|Bezlotoxumab|Patients will be treated with bezlotoxumab at a dose of 10mg per kg of body weight (up to maximum of 1000mg) dissolved in 250ml of normal saline 0.9% or 5% dextrose water as single intravenous infusion of one hour within 72 hours from the start of standard-of-care treatment. Standard-of-care treatment will be prescribed to all patients at the discretion of the attending physicians according to local guidelines or to their own decision.
89493140|NCT05299021|Experimental|Double-point SAPB|SAPB will be performed simultaneously in both the third and fifth rib levels.
89493141|NCT05299021|Experimental|Single-point SAPB|SAPB will be performed only in the fifth rib level.
89493142|NCT05268744|Experimental|Micronutrient|In this open-label trial, all subjects will receive the daily dose of micronutrient, in the form of one lightning stick per day, which contains 2.9 grams of micronutrients per stick. It will be delivered in a powder form taken sublingually.
89493143|NCT05254873||AD-TAR|AD subjects who took part to Facial Emotion Recognition rehabilitation (TAR) during EYE-TAR(MA) study
89493144|NCT05254873||AD-Cognitive Stim|AD subjects who took part to cognitive stimulation session (12 sessions during 4 weeks) during EYE-TAR(MA) study
89493145|NCT05251129|Experimental|Higher Intensity Statin|Atorvastatin 80 mg daily
89493146|NCT05251129|Active Comparator|Lower Intensity Statin|Pravastatin 40 mg daily
89493147|NCT05214963|Active Comparator|Active neurostimulation|Noninvasive peripheral nerve stimulation device programmed to deliver active stimulation
89493148|NCT05214963|Sham Comparator|Sham neurostimulation|Noninvasive peripheral nerve stimulation device programmed to deliver non-therapeutic (sham) stimulation
89493149|NCT05211713|Experimental|Intervention group receiving Opp|The effectiveness study will be conducted as a randomized controlled trial with an intervention group and a waiting-list control group. Data will be collected at baseline (T1, pre intervention) and after about six weeks of intervention (T2, post intervention).
89493150|NCT05211713|No Intervention|Control group|The waiting list control group will receive the intervention after study completion.
89493151|NCT05203926|Experimental|Crohn's disease (CD) subjects|These subjects will then undergo T1 and STIR sequence MRI of SI joints (pelvis MRI) as well as SIJ plain X-ray for assessment of radiographic sacroiliitis.
89493152|NCT05184023|Experimental|Treatment group|
89493153|NCT05184023|Sham Comparator|Sham group|
89493154|NCT05179356|Active Comparator|Dapagliflozin 10 mg once daily|Dapagliflozin 10 mg (Farxiga 10 mg) given once daily for three months
89493155|NCT05179356|Placebo Comparator|Matching placebo|Placebo given once daily for three months
88954118|NCT01969266|Experimental|PCI-32765|PCI-32765 840 mg will be administered as capsule (Treatment A in Period 1) and solution (Treatment B in Period 2) formulations. All participants will receive both treatments with a 7-day washout period between doses.
89493156|NCT05153226|Experimental|Cyclophosphamide|Cyclophosphamide 50 mg/kg (AIBW) i.v. d+3, d+4 post transplant
89493157|NCT05153226|Active Comparator|ATG|ATG Grafalon 10 mg/kg i.v. d-3, d-2, d-1 pre-transplant
89493158|NCT05150236|Experimental|Combination 177Lu-PSMA-617, Ipilimumab & Nivolumab|177Lu-PSMA (7.5GBq) given every 6 weeks up to 6 cycles in combination with concurrent ipilimumab (3mg/kg Q6W x 4 doses) and nivolumab (1mg/kg Q3W x 8 doses) followed by nivolumab monotherapy (480mg Q4W up to 18 doses) or until disease progression or unacceptable toxicity.
89493159|NCT05150236|Experimental|177Lu-PSMA-617|177Lu-PSMA (7.5GBq) given every 6 weeks up to 6 cycles or until disease progression or unacceptable toxicity.
89493160|NCT05141266|Experimental|Brief Intervention Medication Therapy Management (BI-MTM)|Brief Intervention Medication Therapy Management (BI-MTM) is the overarching model made up of 4 evidence-based components: Medication Therapy Management (MTM); Screening, Brief Intervention, and Referral to Treatment (SBIRT); naloxone dispensing, and Patient Navigation (PN). Each component is sequentially delivered within the model and addresses a critical aspect of opioid medication misuse and risk. The pharmacy-based portion of BI-MTM (MTM+SBIRT+naloxone) will be delivered by a PharmD level pharmacist, and PN will be delivered by a bachelor's level interventionist.
89493161|NCT05141266|Other|Standard of Care|Standard of Care is the treatment as usual condition, which follows federal and Utah state pharmacy requirements for pharmacists where in patients filling prescriptions receive information and opt-in counseling. Specifically, SMC in Utah requires pharmacists to: (1) offer counseling, (2) document counseling has been offered, (3) offer a counseling process for patients not present, and (4) discuss generic substitution.The duration of SMC in the current study is a single 5-10 minute session delivered by a University of Utah pharmacist other than the study pharmacist that possesses a similar level of education and professional licensing.
89493162|NCT05137730|Experimental|Part I: Sequence AB|Participants will receive a single SC injection of 100 microgram (mcg) rhPTH(1-84) (Formulation A) on Day 1 of treatment period 1 followed by 100 mcg rhPTH(1-84) (Formulation B) on Day 1 of treatment period 2. A washout period of 96 hours will be maintained between each treatment period.
89493163|NCT05137730|Experimental|Part I: Sequence BA|Participants will receive a single SC injection of 100 microgram (mcg) rhPTH(1-84) (Formulation B) on Day 1 of treatment period 1 followed by 100 mcg rhPTH(1-84) (Formulation A) on Day 1 of treatment period 2. A washout period of 96 hours will be maintained between each treatment period.
89493164|NCT05137730|Experimental|Part II: Sequence CDEF|Participants will receive a single SC injection of 25 mcg (dose C) rhPTH(1-84) on Day 1 of treatment period 1 followed by 50 mcg (dose D) rhPTH(1-84) on Day 1 of treatment period 2 followed by 75 mcg (dose E) rhPTH(1-84) on Day 1 of treatment period 3 followed 200 mcg (dose F) rhPTH(1-84) on Day 1 of treatment period 4. A washout period of 48 hours will be maintained between each treatment period 1,2,3 and 4.
89493165|NCT05137730|Experimental|Part II: Sequence DFCE|Participants will receive a single SC injection of 50 mcg (dose D) rhPTH(1-84) on Day 1 of treatment period 1 followed by 200 mcg (dose F) rhPTH(1-84) on Day 1 of treatment period 2 followed by 25 mcg (dose C) rhPTH(1-84) on Day 1 of treatment period 3 followed by 75 mcg (dose E) rhPTH(1-84) on Day 1 of treatment period 4. A washout period of 48 hours will be maintained between each treatment period 1,2,3 and 4.
89493166|NCT05137730|Experimental|Part II: Sequence ECFD|Participants will receive a single SC injection of 75 mcg (dose E) rhPTH(1-84) on Day 1 of treatment period 1 followed by 25 mcg (dose C) rhPTH(1-84) on Day 1 of treatment period 2 followed by 200 mcg (dose F) rhPTH(1-84) on Day 1 of treatment period 3 followed by 50 mcg (dose D) rhPTH(1-84) on Day 1 of treatment period 4. A washout period of 48 hours will be maintained between each treatment period 1,2,3 and 4.
89493167|NCT05137730|Experimental|Part II: Sequence FEDC|Participants will receive a single SC injection of 200 mcg (dose F) rhPTH(1-84) on Day 1 of treatment period 1 followed by 75 mcg (dose E) rhPTH(1-84) on Day 1 of treatment period 2 followed by 50 mcg (dose D) rhPTH(1-84) on Day 1 of treatment period 3 followed by 25 mcg (dose C) rhPTH(1-84) on Day 1 of treatment period 4. A washout period of 48 hours will be maintained between each treatment period 1,2,3 and 4.
89493168|NCT05120531||Down Syndrome patients undergoing otolaryngologic surgery with anesthesia|
89493169|NCT05120531||Non-Down Syndrome patients undergoing otolaryngologic surgery with anesthesia|
89493170|NCT05088616|Experimental|Virtual Diabetes Wellness Classes and Medically Tailored Meals|"All participants will receive the same intervention: four weeks of virtual diabetes wellness classes and 12 weeks of medically tailored meals. Additionally, participants will be paired with one to two buddies to provide support to each other."
89493171|NCT05087446|Experimental|Early assessment group|
89493172|NCT05087446|Active Comparator|Usual admission procedure group|
89493173|NCT05070624|Experimental|Intervention|"After informed consent, we will assign participants in a 1:1 ratio to the intervention or control group using Randomize.net.~Participants randomized to intervention group will get access to the Virtual Peer Support Program."
89493174|NCT05070624|No Intervention|Control|Control group: Those randomized to the waitlist control will be given access to the peer support intervention on completion of the first 12-week program. A waitlist control group is an ethical alternative to no-treatment control groups when studying psychological and behavioral interventions 21. will have access to informational resources via the aTouchAway™ App and will also receive the intervention at the end of the trial.
89493175|NCT05070156|Experimental|Experimental: B010-A injection for patient with GPC3 Positive Hepatocellular Carcinoma|
89493176|NCT05068219|Active Comparator|Usual technique|Standard rehabilitation
89493177|NCT05068219|Experimental|CR technique|Standard rehabilitation + 3 CR
89493178|NCT05050188|Experimental|cohort 1: H008 20mg|H008 20mg tablets, orally, once, daily, for 7 days
89493179|NCT05050188|Experimental|cohort 1: H008 placebo 20mg|H008 placebo 20mg tablets, orally, once, daily, for 7 days
89493180|NCT05050188|Experimental|cohort 1: Lansoprazole 30mg|Lansoprazole 30mg capsule, orally, once, daily, for 7 days
89493181|NCT05050188|Experimental|cohort 2: H008 40mg|H008 40mg tablets, orally, once, daily, for 7 days
89493182|NCT05050188|Experimental|cohort 2: H008 placebo 40mg|H008 placebo 40mg tablets, orally, once, daily, for 7 days
89493183|NCT05050188|Experimental|cohort 2: Lansoprazole 30mg|Lansoprazole 30mg capsule, orally, once, daily, for 7 days
89493184|NCT05045196|Experimental|Patient and family member of patient undergoing elective open heart surgery- Intervention|Family randomized to the intervention group receiving Health-promoting conversation intervention
89493185|NCT05045196|No Intervention|Patient and family member of patient undergoing elective open heart surgery- Control|Family of a patient undergoing elective open-heart surgery randomized to the intervention group receiving standard care
89493186|NCT05041439|Experimental|Community health worker (CHW) group|Participants in the intervention arm will receive 5 one-on-one sessions over 6 months with a CHW, as well as a manual and written materials on child development. At baseline and exit, all participants will be assessed using instruments to measure demographics and self-perceived barriers.
89493187|NCT05041439|No Intervention|Enhanced care condition (ECC)|Participants in this arm will receive 5 outreach calls at the same interval as the intervention arm, as well as written materials on child development. At baseline and exit, all participants will be assessed using instruments to measure demographics and self-perceived barriers.
89493188|NCT05037409|Experimental|PF-06823859 low|Participants will receive single intravenous infusion.
89493189|NCT05037409|Experimental|PF-06823859 high|Participants will receive single intravenous infusion.
89493190|NCT05037409|Placebo Comparator|Placebo|Participants will receive single intravenous infusion.
88954119|NCT01969292|Experimental|Colometer|Colometer software will be engaged during the colonoscopy to provide real time feedback to the endoscopist.
89493191|NCT05030038||Aromatase inhibitor for breast cancer treatment|Participants will receive their standard of care for breast cancer treatment which includes an aromatase inhibitor. Pre-study assessments will be done at baseline as well as stool and blood samples at baseline, then again at 4 weeks and at 12 weeks during the course of the trial.
89493192|NCT05029791|Other|Metastatic melanoma|Patients with stage III or IV melanoma eligible for an immunotherapy or targeted therapy
89493193|NCT05017103|Experimental|Treatment (sintilimab)|Patients receive sintilimab IV over 30-60 minutes on day 1. Cycles repeat every 3 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity.
89493194|NCT04999111|Experimental|Cohort 1: Group 1: Ad26.COV2.S (Dose Level 1)|Participants who have previously received primary vaccination with Ad26.COV2.S will receive single intramuscular (IM) injection of Ad26.COV2.S booster vaccination at dose level 1 on Day 1.
89493195|NCT04999111|Experimental|Cohort 1: Group 2: Ad26.COV2.S (Dose Level 2)|Participants who have previously received primary vaccination with Ad26.COV2.S will receive single IM injection of Ad26.COV2.S booster vaccination at dose level 2 on Day 1.
89022234|NCT04714697|Experimental|Cohort 1(post nivolumab and ipilimumab combination)|the subject who failed one prior line by nivolumab and ipilimumab
89493196|NCT04999111|Experimental|Cohort 1: Group 3: Ad26.COV2.S (Dose Level 3)|Participants who have previously received primary vaccination with Ad26.COV2.S will receive single IM injection of Ad26.COV2.S booster vaccination at dose level 3 on Day 1.
89493197|NCT04999111|Experimental|Cohort 2: Group 4: Ad26.COV2.S (Dose Level 1)|Participants who have previously received primary vaccination with BNT162b2 will receive single IM injection of Ad26.COV2.S booster vaccination at dose level 1 on Day 1.
89493198|NCT04999111|Experimental|Cohort 2: Group 5: Ad26.COV2.S (Dose Level 2)|Participants who have previously received primary vaccination with BNT162b2 will receive single IM injection of Ad26.COV2.S booster vaccination at dose level 2 on Day 1.
89493199|NCT04999111|Experimental|Cohort 2: Group 6: Ad26.COV2.S (Dose Level 3)|Participants who have previously received primary vaccination with BNT162b2 will receive single IM injection of Ad26.COV2.S booster vaccination at dose level 3 on Day 1.
89493200|NCT04986969|Active Comparator|real-time, face-to-face, video-conferenced CBT (vcCBT)|vcCBT is cognitive behavioral therapy that consists of eight face-to-face video-conferencing sessions via tablet computers lasting approximately 45 minutes each.
89493201|NCT04986969|Active Comparator|self-administered internet-based CBT (iCBT)|iCBT is self-directed cognitive behavioral therapy using an interactive internet program, MoodGYM, which does not include direct interactions with a therapist.
89493202|NCT04978818|Active Comparator|Vaxelis|165 infants will be randomized to the Vaxelis group, which is licensed for primary vaccination at 2, 4 and 6 months of age.
89493203|NCT04978818|Active Comparator|PedvaxHIB arm|165 infants will be randomized to the PedvaxHIB group, which is licensed for primary vaccination at 2 and 4 months of age.
89493204|NCT04978766|Experimental|Interactive Book Reading Group|Participants in this arm will take baseline measures, will receive the intervention and will take posttest measures.
89493205|NCT04978766|No Intervention|Control Group|Participants in this arm will take baseline and posttest measures. For ethical purposes, they will receive the intervention after posttest measures are taken.
89493206|NCT04974125|Experimental|Arm A :Aspiration of peritoneal gas through a drain|"Patients in experimental arm will receive surgery (either laparoscopic or robotised laparoscopic surgery). The exsufflation will be carrying out by a drain.~Then, patients will be followed-up during 7 days after surgery."
89493207|NCT04974125|Active Comparator|Arm B : Manual evacuation of the peritoneal gas, via the trocar|"Laparoscopic or robotised laparoscopic surgery + Trocar~Patient in this experimental arm will receive surgery (either laparoscopic or robotised laparoscopic surgery). The exsufflation will be carrying out carried out manually using the trocar (standard of care).Then, patient will be followed-up during 7 days after surgery."
89493208|NCT04970082|Experimental|FFR followed by FFR-DWP (investigation)|The FFR measurement is performed with the standard method first followed by the FFR measurement with the DWP method.
89493209|NCT04970082|Experimental|FFR-DWP (investigation) followed by FFR|The FFR measurement is performed with the DWP method first followed by the FFR measurement with the standard method.
89493210|NCT04964557|Experimental|AZD8233|AZD8233 for subcutaneous use
89493211|NCT04964557|Placebo Comparator|Placebo|Placebo solution for subcutaneous injection
89493212|NCT04959565|Experimental|16 online lectures in sports nutrition + 8 individual consultations for 16 weeks|"Non-smoking, non-contraceptive using, competitive female endurance athletes, 18-35 years of age, training a minimum of five times per week will be recruited through social media and endurance sports clubs (running, cycling, orienteering, triathlon, biathlon, and cross-country skiing) in Norway, Sweden, Germany, and Ireland.~Athletes with a LEAF-Q score ≥8 + EDE-Q score < 2.5 who meets the other inclusion criteria will be invited for further participation.~The lectures are designed for female endurance athletes at risk of RED-S. The participants will get access to a new lecture every week during the intervention."
89493213|NCT04959565|No Intervention|Control|"Non-smoking, non-contraceptive using, competitive female endurance athletes, 18-35 years of age, training a minimum of five times per week will be recruited through social media and endurance sports clubs (running, cycling, orienteering, triathlon, biathlon, and cross-country skiing).~Athletes with a LEAF-Q score ≥8 + EDE-Q score < 2.5 who meets the other inclusion criteria will be invited for further participation."
89493214|NCT04959565|Experimental|16 online lectures in sports nutrition for 16 weeks|"Non-smoking, non-contraceptive using, competitive female endurance athletes, 18-35 years of age, training a minimum of five times per week will be recruited through social media and endurance sports clubs (running, cycling, orienteering, triathlon, biathlon, and cross-country skiing) in Norway, Sweden, Germany, and Ireland.~Athletes with a LEAF-Q score ≥8 + EDE-Q score < 2.5 who meets the other inclusion criteria will be invited for further participation.~The lectures are designed for female endurance athletes at risk of RED-S. The participants will get access to a new lecture every week during the intervention."
89022235|NCT04714697|Experimental|Cohort 2 (post pembrolizumab plus axitinib, pembrolizumab plus lenvatinib, or avelumab and axitinib)|the subject who failed one prior line by PD-1/PD-L1 inhibitors in combination with VEGF TKI
89022236|NCT04714697|No Intervention|Cohort 3 (post sequential immunotherapy after VEGFR TKI)|the subject who failed the second line by immunotherapy (PD-1 antibody or PD-L1 antibody) following the first line VEGFR TKI
89022237|NCT03275961|Experimental|Depressed Subjects|Subjects will undergo an 8 week behavioral program with Stress Management and Resiliency Training.
89022238|NCT00351026|Active Comparator|1|25 HIV negative opiate dependent patients all treated with methadone
89022239|NCT00351026|Active Comparator|2|25 HIV positive opiate dependent patients all treated with methadone
89022240|NCT00457314|Experimental|1|Participants will partake in regular exercise training for 6 months. After 6 months, they will switch to no exercise training for 6 months. Participants will then be encouraged to continue exercise training for an additional 1 year.
89022241|NCT00457314|Experimental|2|Participants will not partake in regular exercise training for 6 months. After 6 months, they will switch to exercise training for 6 months. Participants will then be encouraged to continue exercise training for an additional 1 year.
89022242|NCT04714658|Experimental|Immediate PTE|
89022243|NCT04714658|Other|6-month deferred PTE|
89022244|NCT00457353|Active Comparator|1|Administration of oral rehydration therapy with Bacillus clausii probiotic strain (1 vial twice daily, each vial containing 2 billion spores of Bacillus clausii)
89022245|NCT00457353|Placebo Comparator|2|Administration of Oral rehydration therapy
89022246|NCT03275922|Other|Run-in - ZNS - Placebo - OLE|After Run-in period, subjects will be randomized to ZNS followed by placebo ZNS. Upon successful completion of Part 1, subjects may enroll into OLE (Part 2).
89022247|NCT03275922|Other|Run-in - Placebo - ZNS - OLE|After Run-in period, subjects will be randomized to placebo ZNS followed by ZNS. Upon successful completion of Part 1, subjects may enroll into OLE (Part 2).
89022248|NCT00351143|Experimental|Interventional group: Period 2|Randomized subjects will receive salmeterol/fluticasone propionate 50/250 µg + 3 training sessions of compliance enhancement training in Period 2
89493215|NCT04951063|Experimental|Split-course adaptive HRT-CHT|"In keeping the same total radiation dose (60Gy), we escalate the fraction dose to find the maximum tolerable fraction dose.~Level 1: DT 4500cGy/15 daily fractions/300cGy in the first course，DT 1500cGy/5 daily fractions/300cGy in the second course;~Level 2: DT 4000cGy/10 daily fractions/400cGy in the first course， DT 2000cGy/5 daily fractions/400cGy in the second course;~Level 3: DT 3000cGy/6 daily fractions/500cGy in the first course， DT 3000cGy/6 daily fractions/500cGy in the second course.~RT is delivered using the IMRT technique with daily cone-beam CT image guidance. The dose limitation of organ at risk (OAR) are shown in Table 1. Patients receive a weekly infusion of docetaxel (25mg/m2) and cisplatin (25mg/m2) during RT. Consolidative immunotherapy (PD-1 or PD-L1 inhibitor) up to 1 year is administered for those without disease progression after HRT-CHT."
89493216|NCT04939272|Experimental|Treatment (copanlisib hydrochloride, venetoclax)|Patients receive copanlisib hydrochloride IV over 1 hour on days 1, 8, and 15, and venetoclax PO QD on days 1-28. Treatment repeats every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity. Copanlisib will be given at 30mg, 45mg, or 60 mg depending on the assigned dose level. Venetoclax will have a weekly dose ramp up from 20mg, 50mg, 100mg, 200mg, and then 400mg thereafter.
89493217|NCT04936178|Experimental|Dose Escalation Phase and Dose Expansion Phase|"Dose escalation cohort:~NB003 tablets will be administered orally twice daily for repeated 28-day cycles until discontinuation criteria are met.~RP2D: one or more putative RP2D(s) will be explored in dose escalation phase with approximately 15 patients for each provisional RP2D(s)~Dose expansion phase:~In the dose expansion phase, additional patients will be enrolled at RP2D to further explore the safety, tolerability, PK, efficacy and biological activity of NB003 in specific disease cohorts, including GIST and other malignancies harboring genomic alterations of KIT or PDGFRα."
89493218|NCT04916496|Experimental|ACT-LCP Group|An Acceptance and Commitment Therapy-based healthy lifestyle counselling programme (ACT-LCP) and routine psychiatric outpatient/rehabilitation services of the study hospital.
89493219|NCT04916496|Placebo Comparator|Control Group|A healthy lifestyle talk and routine psychiatric outpatient/rehabilitation services of the study hospital.
89493220|NCT04891705||Pleural Effusion|Adult and pediatric subjects with suspicion of pleural effusion
89022249|NCT00351143|Active Comparator|Control group: Period 2|Randomized subjects will receive salmeterol/fluticasone propionate 50/250 µg in treatment Period 2
89204734|NCT03891862|Placebo Comparator|Placebo-controlled Placebo|Participants received placebo (matching valbenazine) once daily for 8 weeks. Randomization into this arm occurred after open-label treatment with valbenazine once daily for 8 weeks.
89204735|NCT03891862|Experimental|Placebo-controlled Valbenazine|Participants received valbenazine 80 mg once daily for 8 weeks. Randomization into this arm occurred after open-label treatment with valbenazine once daily for 8 weeks.
89493221|NCT04891705||Lung Consolidation|Adult and pediatric subjects with suspicion of lung consolidation
89493222|NCT04882254|Experimental|Normothermic machine perfusion|Additional 2 hours of normothermic machine perfusion of donor kidney with a red cell based perfusate.
89493223|NCT04882254|No Intervention|Standard-of-care|Standard-of-care, which is hypothermic kidney machine perfusion in the Netherlands.
89493224|NCT04882085|Experimental|CAZ-AVI|ceftazidime 2g plus avibactam 0.5g
89493225|NCT04882085|Active Comparator|Best Available Treatment|Based on investigative site practice and local epidemiology and guideline
89493226|NCT04857112|Experimental|Low Dose|MT-1303 loading dose of 0.4 mg once daily (QD) (Day 1-14) then maintenance dose of 0.2 mg QD (Day 15-85)
89493227|NCT04857112|Experimental|High Dose|MT-1303 loading dose of 0.8 mg QD (Day 1-14) then maintenance dose of 0.4 mg QD (Day 15-85)
89493228|NCT04857112|Placebo Comparator|Placebo|Matching placebo, QD (Day 1-85)
89493229|NCT04855201|Experimental|Bocidelpar (ASP0367)|Participants will receive Bocidelpar (ASP0367) once daily in the morning for 6 weeks.
89493230|NCT04855201|Placebo Comparator|Placebo|Participants will receive placebo once daily in the morning for 6 weeks.
89493231|NCT04821739|Experimental|Treatment with AGN1 LOEP SV Kit|VCF is treated with the AGN1 LOEP SV Kit
89493232|NCT04812275|Active Comparator|Non absorbable suture|Wound closure with non absorbale suture. Dimension and brand at the discretion of the surgeon.
89493233|NCT04812275|Experimental|Absorbable suture|Wound closure with absorbale suture. Dimension and brand at the discretion of the surgeon.
89493234|NCT04798027|Experimental|Sentinel Cohort: SARS-CoV-2 Vaccine Ultra Low dose|Participants received two intramuscular (IM) injections of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) Vaccine ultra-low dose on Day 1 and at Day 22, respectively.
89493235|NCT04798027|Experimental|Sentinel Cohort: SARS-CoV-2 Vaccine Low dose|Participants received two IM injections of SARS-CoV-2 Vaccine low dose on Day 1 and at Day 22, respectively.
89493236|NCT04798027|Experimental|Sentinel Cohort: SARS-CoV-2 Vaccine Medium dose|Participants received two IM injections of SARS-CoV-2 Vaccine medium dose on Day 1 and at Day 22, respectively.
89493237|NCT04798027|Experimental|FEC Cohort 1: SARS-CoV-2 Vaccine Ultra Low dose|Participants received a single IM injection of SARS-CoV-2 Vaccine ultra-low dose on Day 1.
89493238|NCT04798027|Experimental|FEC Cohort 1: SARS-CoV-2 Vaccine Low dose|Participants received a single IM injection of SARS-CoV-2 Vaccine low dose on Day 1.
89493239|NCT04798027|Placebo Comparator|FEC Cohort 1: Placebo|Participants received a single IM injection of placebo matched to SARS-CoV-2 Vaccine on Day 1.
89493240|NCT04798027|Experimental|FEC Cohort 2: SARS-CoV-2 Vaccine Ultra Low dose|Participants received two IM injections of SARS-CoV-2 Vaccine ultra-low dose on Day 1 and at Day 22, respectively.
89493241|NCT04798027|Experimental|FEC Cohort 2: SARS-CoV-2 Vaccine Low dose|Participants received two IM injections of SARS-CoV-2 Vaccine low dose on Day 1 and at Day 22, respectively.
89493242|NCT04798027|Placebo Comparator|FEC Cohort 2: Placebo|Participants received two IM injections of placebo matched to SARS-CoV-2 Vaccine on Day 1 and at Day 22, respectively.
88954120|NCT01969292|Sham Comparator|Sham Software|An identical set-up to the experimental arm but with a green band showing across the top for the duration of the colonoscopy.
89493243|NCT04796766|Experimental|Healthy volunteers|HFS / LFS in healthy volunteers at two different points in time
89493244|NCT04796766|Experimental|Migraine patients|HFS / LFS in migraine patients at a single point in time
89493245|NCT04796766|Experimental|Patients with Botulinum toxin or CGRP-targeted therapy|HFS / LFS before and under treatment with Botulinum toxin or CGRP-targeted therapy
89493246|NCT04793880|Experimental|Medication checklist with cost information|Participants with chronic heart failure with reduced ejection fraction (HFrEF) having a clinic visit at a site randomized to the medication checklist with cost information intervention.
88954121|NCT01969292|No Intervention|Control|Recordings of colonoscopies made without Colometer or sham feedback during the course of the colonoscopy will be evaluated retrospectively using the Colometer software.
88954122|NCT01969305|Experimental|Kazakhstani Family Together (KFT)|Usual Care Plus KFT: Family-based multi-media HIV and drug abuse prevention intervention
88954123|NCT01969305|Experimental|Health education curriculum|Usual Care Alone: Health education curriculum on HIV and drug use prevention
88954124|NCT01969318|Placebo Comparator|Placebo/Metformin|
88954125|NCT01969318|Experimental|SP2086 (50mg q.d)/Metformin|
88954126|NCT01969318|Experimental|SP2086 (100mg q.d.)/Metformin|
88954127|NCT01969331|Placebo Comparator|Placebo|"maltodextrin, microcrystalline cellulose; hypromellose, silicium dioxide (E551), magnesium stearate, colouring agent: titanium dioxide ( E171) Placebo as an addition to standard H. Pylori eradication therapy 7 days of initial therapy (2 antibiotics + PPI), followed by 21 days of PPI only therapy.~Two weeks after the end of PPI therapy subjects are seen at the follow up visit."
88954128|NCT01969331|Active Comparator|Normia|Lactobacillus rhamnosus GG, LGG® and Bifidobacterium, BB-12® Normia® probiotic as an addition to standard H. Pylori eradication therapy 7 days of initial therapy (2 antibiotics + PPI), followed by 21 days of PPI only therapy. One capsule twice per day/14 days Two weeks after the end of PPI therapy subjects are seen at the follow up visit.
88954129|NCT01969357|Placebo Comparator|Placebo|
88954130|NCT01969357|Experimental|50 mg SP2086|
88954131|NCT01969357|Experimental|100 mg SP2086|
88954132|NCT01969357|Experimental|200 mg SP2086|
88954133|NCT01969357|Active Comparator|100 mg Sitagliptin|
88954134|NCT01969370|Experimental|Experimental|Option to request non-medically actionable incidental information (after receiving education about them)
89493247|NCT04793880|Active Comparator|Medication checklist|Participants with chronic heart failure with reduced ejection fraction (HFrEF) having a clinic visit at a site randomized to the medication checklist without cost information.
89493248|NCT04788667|Experimental|Experimental Group|A health education programme using a telerehabilitation platform
89493249|NCT04788667|Active Comparator|Control Group|General recommendations using a telerehabilitation platform
89493250|NCT04778397|Experimental|Magrolimab + Azacitidine|Participants will receive an escalating dose of magrolimab and a fixed dose of azacitidine.
89493251|NCT04778397|Active Comparator|Control Arm: Venetoclax + Azacitidine|Participants who are appropriate for non-intensive therapy will receive an escalating dose of venetoclax and a fixed dose of azacitidine.
88954135|NCT01969370|No Intervention|Control|No option to request non-medically actionable incidental information
88954136|NCT01969383|Experimental|heated pool|After selection, all volunteers will be asked to attend two exercise protocols performed on the ground and in the heated pool and the minimum interval of 24 hours between each protocol. Data collection will be performed only with the dominant member of each volunteer.
88954137|NCT01969396|Experimental|SonoBiopsy Catheter|
89493252|NCT04778397|Active Comparator|Control Arm: 7+3 Chemotherapy|Participants who are appropriate for intensive therapy will receive 7+3 chemotherapy: 7 day treatment with cytarabine and 3 day treatment with daunorubicin or idarubicin during induction and high-dose cytarabine and steroidal eye drops during consolidation.
89493253|NCT04776278|Experimental|Brief Alcohol Intervention (BAI) + Substance Free Activity Session (SFAS)|Participants first receive a 50-minute standard brief motivational intervention designed to reduce alcohol use. A week later, they will receive the Substance-free activity session (SFAS), a 50-minute counseling session designed to increase the salience of the individual's goals, to highlight the connection between their current patterns of behavior (including drinking and substance-free activities) and the attainment of these goals, and to increase future orientation and engagement in enjoyable and goal-directed activities that are inconsistent with substance use (even if the participant has no desire to change their use).
89493254|NCT04776278|Experimental|Relaxation Training (RT) + Substance Free Activity Session (SFAS)|Participants will complete a relaxation training session that will include a clinician leading them through a diaphragmatic breathing exercise, a progressive muscle relaxation protocol, and then a brief breath-counting (mindfulness) exercise. A week later, the participant will receive the SFAS, a 50-minute counseling session designed to increase the salience of the individual's goals, to highlight the connection between their current patterns of behavior (including drinking and substance-free activities) and the attainment of these goals, and to increase future orientation and engagement in enjoyable and goal-directed activities that are inconsistent with substance use (even if the participant has no desire to change their use).
89493255|NCT04776278|Active Comparator|Education Control|This minimal contact control condition will include a brief (2-3 minute) discussion where the research assistant (RA) who completed the assessment session will describe the educational handout. This condition is meant to approximate a public health-level approach to providing referral information and some of the content included in the BAI+SFAS condition but without any of the personalized information or motivational interviewing. Participants will receive information on risks associated with alcohol/drug misuse, strategies for reducing alcohol problems, managing stress, and goal-setting. The handout will also include links to hotlines, websites, and apps related to these domains. This condition will not include booster contact
89493256|NCT04753346||Mild Disease|Symptomatic patients meeting the case definition for COVID-19 without evidence of viral pneumonia or hypoxia.
89493257|NCT04753346||Pneumonia|Patients with clinical signs of pneumonia (fever, cough, dyspnoea, fast breathing) but no signs of severe pneumonia, including SpO2 ≥ 90% on room air
89493258|NCT04753346||Severe Pneumonia|Patients with clinical signs of pneumonia (fever, cough, dyspnoea,fast breathing) plus one of the following: respiratory rate > 30 breaths/min; severe respiratory distress; or SpO2 < 90% on room air.
89493259|NCT04753346||Critical Disease|Patients have one of the following: acute respiratory distress syndrome; sepsis; or septic shock.
89493260|NCT04733599||Adults with pain due to brachial plexus avulsion injury|Adult patients with history of brachial plexus avulsion injury referred for consideration of neuromodulation using high frequency neurostimulation will be considered.
89493261|NCT04682405|Experimental|Uproleselan + Standard of Care Melphalan|"On the evening of Day -3, patients will receive dose #1 of uproleselan~On the following morning of Day -2 (12 +/- 2 hours from prior dose), patients will receive dose #2 of uproleselan~On the evening of Day -2 (12 +/- 2 hours from prior dose), patients will receive dose #3 of uproleselan~On Day -2 following completion of dose #3 of uproleselan, the patient will be administered the conditioning dose of melphalan (200mg/m^2) as per institutional practice.~On the following morning of Day -1 (12 +/- 2 hours from prior dose), patients will receive dose #4 of uproleselan~On the evening of Day -1 (12 +/- 2 hours from prior dose), patients will receive dose #5 of uproleselan~On the following morning of Day 0 (12 +/- 2 hours from prior dose) patients will receive dose #6 (final dose) of uproleselan~On Day 0, 4 hours (+/- 2 hours) after the final dose of uproleselan, the patient will be infused with the HSC product. The patient will remain inpatient until engraftment"
89531502|NCT06065852||Hepatic Nuclear Factor 1B Mutation Rare Disease Group|"The HNF1B rare disease group (RDG) covers all diseases associated with mutations and deletions in this gene. These include renal developmental disorders, most commonly renal cysts. The most common problem outside the kidneys is diabetes. When diabetes and renal cysts occur together this is known as the renal cysts and diabetes (RCAD) syndrome. Other clinical features may include hyperuricaemia and gout, hypomagnesaemia, abnormal liver function tests, pancreatic exocrine deficiency and genital tract malformations.~We aim to increase clincians' awareness of these presentations, improve recognition and streamline diagnosis, particularly at a genetic level. To do this we are studying genetic information on patients with well-defined clinical features. We hold open meetings to inform and support patients and their families."
88954138|NCT01969396|Active Comparator|Endometrial biopsy catheter|
88954139|NCT01969422||observation group|observation
89022250|NCT00351143|Experimental|Subjects receiving salmeterol/fluticasone propionate: Period 1|All subjects treated with salmeterol/fluticasone propionate 50/250 µg b.i.d without any other intervention will be included in Period 1
89022251|NCT00457431|No Intervention|Control|Standard therapy as used in the hospital's ICU
89022252|NCT00457431|Active Comparator|Hypothermia|Standard therapy as used in the hospital's ICU plus Hypothermia
89493262|NCT04682405|Placebo Comparator|Placebo + Standard of Care Melphalan|"On the evening of Day -3, patients will receive dose #1 of placebo~On the following morning of Day -2 (12 +/- 2 hours from prior dose), patients will receive dose #2 of placebo On the evening of Day -2 (12 +/- 2 hours from prior dose), patients will receive dose #3 of placebo.~On Day -2 following completion of dose #3 of placebo, the patient will be administered the conditioning dose of melphalan (200mg/m^2) as per institutional practice.~On the following morning of Day -1 (12 +/- 2 hours from prior dose), patients will receive dose #4 of placebo.~On the evening of Day -1 (12 +/- 2 hours from prior dose), patients will receive dose #5 of placebo.~On the following morning of Day 0 (12 +/- 2 hours from prior dose) patients will receive dose #6 (final dose) of placebo.~On Day 0, 4 hours (+/- 2 hours) after the final dose of placebo, the patient will be infused with the HSC product. The patient will remain inpatient until engraftment"
89022253|NCT04698642|Experimental|CBL-514 180 mg, 1.2 mg/cm^2|CBL-514 will be administrated with the grid spacing of 2.5 cm^2
89493263|NCT04671940||Retrospective Cohort|"Patients who have previously had radiotherapy and then have had their local residual/recurrent disease managed with salvage TORS at the Royal Marsden Hospital will be eligible for inclusion. They will be informed of the RECUT+ study by a member of their usual care team at RMH during their routine outpatient appointments for follow up of their H&N cancer.~Potential participants will be asked to consent to provide blood/saliva sample for germline DNA and for permission for their original tumour biopsy sample and their residual/recurrent resection to undergo DNA analysis. Where patients have returned to their referring institution and are no longer under active regular follow up at RMH, a research pack will be sent to the patient via post and email. This pack will contain the Cover Letter, the Participant Information Sheet and the Informed Consent Form. It will also contain a saliva collection tube, buccal swab, blood tubes and instructions for how to provide blood/saliva samples."
89493264|NCT04671940||Prospective Cohort|Patients who have previously had radiotherapy and then are due to have their local residual/recurrent disease managed with salvage transoral robotic surgery at the Royal Marsden Hospital (RMH) will be approached prior to their salvage surgery at a routine outpatient appointment. They will be asked to consent to provide blood/saliva sample for germline DNA pre and post operatively. They will also be asked for permission for their original tumour biopsy sample and their residual/recurrent resection to undergo DNA analysis
89493265|NCT04655313|Experimental|ARQ-151 cream 0.3%|Open label study of ARQ-151 cream 0.3% applied once daily for 4 weeks
89493266|NCT04647760|Other|Active treatment|Participants will start the intervention immediately upon study enrollment.
89493267|NCT04647760|Other|Delayed treatment|Participants will start the intervention 4-months post enrollment.
89493268|NCT04643587|Experimental|CSL787 (SAD dose 1)|Inhalation by mouth of a nebulized aerosol in healthy subjects
89493269|NCT04643587|Experimental|CSL787 (SAD dose 2)|Inhalation by mouth of a nebulized aerosol in healthy subjects
89493270|NCT04643587|Experimental|CSL787 (SAD dose 3)|Inhalation by mouth of a nebulized aerosol in healthy subjects
89493271|NCT04643587|Experimental|CSL787 (SAD dose 4)|Inhalation by mouth of a nebulized aerosol in healthy subjects
89493272|NCT04643587|Experimental|CSL787 (MAD dose 1)|Inhalation by mouth of a nebulized aerosol in NCFB subjects
89493273|NCT04643587|Experimental|CSL787 (MAD dose 2)|Inhalation by mouth of a nebulized aerosol in NCFB subjects
89493274|NCT04643587|Experimental|CSL787 (MAD dose 3)|Inhalation by mouth of a nebulized aerosol in NCFB subjects
89493275|NCT04643587|Placebo Comparator|Placebo|Inhalation by mouth of a nebulized aerosol
89493276|NCT04631016|Experimental|MEDI3506|Approximately 72 participants will be randomized to receive MEDI3506
89022254|NCT04698642|Experimental|CBL-514 240 mg, 1.6 mg/cm^2|CBL-514 will be administrated with the grid spacing of 2.5 cm^2
89022255|NCT04698642|Experimental|CBL-514 300 mg, 2 mg/cm^2|CBL-514 will be administrated with the grid spacing of 2.5 cm^2
89022256|NCT00457509|Experimental|Group 1|Dose 1 with Adjuvant
89022257|NCT00457509|Experimental|Group 2|Dose 2 with adjuvant
89022258|NCT00457509|Experimental|Group 3|Dose 3 with adjuvant
89022259|NCT00457509|Experimental|Group 4|Dose 4 with adjuvant
89022260|NCT00457509|Active Comparator|Group 5|Control
89022261|NCT04714307||Symptomatic|Molecularly diagnosed SCA3/MJD Symptomatic subjects.
89022262|NCT04714307||Non-related Controls|Controls matched with symptomatic by age and educational level.
89022263|NCT04714307||At 50% risk for SCA3/MJD group|The offspring of affected individuals with SARA<3. This group will be comprised of two subpopulations: pre-symptomatic individuals and related controls. The determination will be made upon molecular diagnosis to be done in a double-blind manner.
89022264|NCT00450684|Experimental|Group A|Implantation and testing of CRT
89022265|NCT00450684|Experimental|Group B|IImplantation and testing of CRT
89204736|NCT00640614|Experimental|Sensitives|Subjects with a clinical history and positive patch test (current or previous) to any of the seven allergens. Subjects must otherwise be healthy and fulfill entry criteria.
89204737|NCT00640614|Experimental|Consecutives|Subjects who are being seen for standard allergy patch testing, that are asked to participate in the study.
89493277|NCT04631016|Placebo Comparator|Placebo|Approximately 72 participants will be randomized to receive placebo
89493278|NCT04622046|Experimental|ALXN2060|Participants will receive ALXN2060.
89493279|NCT04621006||UC group|Patients with active ulcerative colitis
89493280|NCT04613414|Experimental|Early Management|Scheduled for sleep physician appointment within 1 month of home sleep apnea test/triage
89493281|NCT04613414|No Intervention|Usual Care|Scheduled for sleep physician appointment approximately 6 months after home sleep apnea test/triage
89493282|NCT04607980|Experimental|Treatment Group A (ABP 654)|Participants will receive subcutaneous (SC) injection of ABP 654, 45 mg (baseline BW less than equal to [<=] 100 kg) or 90 mg (baseline BW greater than [>] 100 kg) at weeks 0, 4, and 16. Further from week 28 participants will receive ABP 654 (same dose) every 12 weeks (Q12W) at weeks 28 and 40 or may receive dose intensification Q8W at weeks 28, 36, and 44, depending on PASI score.
89493283|NCT04607980|Experimental|Treatment Group B (Ustekinumab - ABP 654)|Participants will receive SC injection of ustekinumab,45 mg (baseline BW <= 100 kg) or 90 mg (baseline BW > 100 kg) at weeks 0, 4, and 16. At week 28, participants will be re-randomized to continue on ustekinumab (Treatment group B1), or to receive ABP 654 (Treatment group B2) on weeks 28 and 40. Depending on PASI score, some participants may not be re-randomized and may receive dose intensification with ustekinumab Q8W at weeks 28, 36, and 44.
89493284|NCT04605146|Experimental|Tele-monitoring group|"In the experimental group, in addition to routine practice, each patient will benefit of a tele-monitoring of one year, and a long term follow-up up to 5 years to evaluate the Overall Survival and the Progression-Free Survival. Quality of life questionnaire will also be filled in at inclusion, M3 and M12.~50 patients are expected in this arm."
89493285|NCT04605146|No Intervention|Control group|"In the control group, patients will have a routine follow-up as per institutional practice, and a long term follow-up up to 5 years to evaluate the Overall Survival and the Progression-Free Survival. Quality of life questionnaire will also be filled in at inclusion, M3 and M12.~50 patients are expected in this arm."
89493286|NCT04576052||antibiotic-coating|patients who have been treated with an antibiotic-coated nail for tibia-fracture
89493287|NCT04576052||non-coated|patients who have been treated with a non-coated nail for tibia fracture
89493288|NCT04574609|No Intervention|no hypnotherapy|"A control group of patients receiving the usual management for PAC and chemotherapy sessions."
89493289|NCT04574609|Experimental|hypnotherapy|"A hypnotherapy group of patients benefiting from hypnotherapy sessions prior to PAC and chemotherapy cures in addition to the usual management."
89493290|NCT04544917|Experimental|SmartManage Group|Participants in this group will receive ten 90-minute weekly therapist delivered SmartManage group sessions via video conference. Participants will have access to the SmartManage web platform, which will also guide the live intervention sessions.
89493291|NCT04544917|Active Comparator|Educational Control Group|Participants in this group will view ten weekly control content video recorded sessions.
89493292|NCT04543279|Experimental|Part A: Fostamatinib|The starting dose of fostamatinib is 100 mg twice daily (BID). After the first cycle, if no major dose related safety issue is observed and the platelet count is less than 50K/microL, then the fostamatinib dose will be increased to 150 mg BID for the next 2 cycles; otherwise the dose may be continued at 100 mg BID.
89493293|NCT04543279|Experimental|Part B: Fostamatinib + Ruxolitinib|"After 3 cycles of fostamatinib monotherapy, all patients with a sustained platelet count ≥ 50K/microL, will continue on the current fostamatinib dose plus ruxolitinib at the recommended dose per standard prescribing guidelines for an additional 9 cycles.~Patients who do not reach platelet count of at least 50K/microL but who achieve clinical benefit per the treating provider may continue on single agent fostamatinib for up to 12 total treatment cycles. If these patients achieve a sustained platelet count of ≥ 50K/microL at any point prior to Cycle 10 Day 1, then they may be eligible to enroll in Part B of the study and continue treatment with fostamatinib and ruxolitinib for the remainder of the study."
89493294|NCT04540913|Experimental|RHA 3|"Injection of RHA 3 into into the vermillion body, vermillion border, and oral commissures of the lips (up to 3 ml with a max of 1.5 ml per lip), injected into the lip mucosa and/or mid to deep dermis as appropriate for lip augmentation.~Optional touch up treatment provided at 4 Weeks, optional retreatment at 36 or 52 Weeks."
89022266|NCT04714268||Procedures with EndoNaut|Endovascular interventions using the EndoNaut workstation. 3D image fusion is used for overlaying arterial information on top of fluoroscopic images
89493295|NCT04540913|Active Comparator|Restylane- L|"Injection of Restylane- L into into the vermillion body, vermillion border, and oral commissures of the lips (up to 3 ml with a max of 1.5 ml per lip), injected into the lip mucosa and/or mid to deep dermis as appropriate for lip augmentation.~Optional touch up treatment provided at 4 Weeks."
89493296|NCT04540133|Experimental|dexamethasone 0.5mg/5ml solution in Mucolox™ (group A)|Dexamethasone solution (0.5mg/5ml) in Mucolox™ three times a day (TID) swish and spit for 4 weeks
89493297|NCT04540133|Active Comparator|dexamethasone 0.5mg/5ml solution (Arm B)|Dexamethasone solution (0.5mg/5ml) TID swish and spit for 4 weeks
89493298|NCT04523376|Experimental|Sickle Cell Disease|Patients with Sickle Cell Disease (SCD) will be given previously established, disease-specific chemotherapy based conditioning regimens prior to hematopoietic stem cell transplantation using TCRalpha/beta and B cell depleted peripheral blood stem cells from closely matched unrelated donors.
89493299|NCT04523376|Experimental|Beta Thalassemias Major|Patients with Beta Thalassemias Major (BTM) will be given previously established, disease-specific chemotherapy based conditioning regimens prior to hematopoietic stem cell transplantation using TCRalpha/beta and B cell depleted peripheral blood stem cells from closely matched unrelated donors.
89493300|NCT04521647|Experimental|menthol flavor|Participants will receive 5% nicotine in an e-cigarette
89493301|NCT04521647|Experimental|tobacco flavor|Participants will receive 5% nicotine in an e-cigarette
89493302|NCT04520633||control level stable|severe asthma for which the control level is stable (variation in ACT score <3 between M0 and M6) contributing to the test-retest
89493303|NCT04520633||biologic initiation|introduction or modification of biotherapy at M0
89493304|NCT04515875|Experimental|Daily Engagement Meaningful Activity (DEMA)|This group will receive 7 individualized sessions, 1 face-to-face session at week 1 and via 6 bi weekly telephone sessions delivered by a trained intervener. DEMA will use the principles of problem-solving therapy and consistent with the overall goals of this intervention; and will provide autonomy support, classify needs and goals, generalize manageable solutions, engage in self-selected activities under family support, and self-evaluate failure and success or renew problem-solving as needed. Each session consists: 1) MCI dyads are guided to use the principles of problem-solving therapy to review their personalized, self-selected meaningful activities and plan next steps to continue the activity, identify and establish a plan for additional activities; and 2) the intervener and dyad discuss one of the 6 topics in the Toolkit such as introducing of the intervention and meaningful activity concepts, understanding MCI, its treatments, management, resources, and planning for the future.
89493305|NCT04515875|Placebo Comparator|Information Support (IS)|This group will attend 1 face-to-face meetings to receive an overview of what will happen in the study and an initial Alzheimer disease educational brochure from the Alzheimer's Association (AA). The face-to-face sessions will take place at the IADC Clinical Core clinic, Indiana University Center of Excellence of Women's Health clinic, or Indiana School of Nursing conference room that based on patient-caregiver dyad's preference. Then they will receive 6 bi weekly follow-up phone calls and have the opportunity to ask only questions related to the educational materials. After completing Time 4 data collection, the patient-caregiver dyads will receive DEMA Self-Management Tool kit package through mail.
89493306|NCT04494880|Experimental|Treatment Group (Marcaine 1 Breast)|Marcaine will be injected into one randomized breast and saline into the other in the treatment group.
89493307|NCT04494880|No Intervention|Control Group (Marcaine 2 Breasts)|Marcaine will be injected into both breasts as is currently the standard of care.
89493308|NCT04494633|Experimental|Intervention|Participants completed the pre-assessments, used the intervention, waited 2-4 weeks, and then completed the assessments again.
89493309|NCT04494633|No Intervention|Wait Group|Participants completed the pre-assessments, waited 2-4 weeks, and completed the assessments again.
89493310|NCT04482816|Experimental|Physiological pacing|"Lead placed in the His-Purkinje system (his or branch) in order to achieve QRS shortening and physiologic pacing. A backup lead will be implanted in the right ventricle.~If hisian pacing is not achieved (QRS is not shortened > 20% or QRS is not <130ms), the left bundle branch will be paced according to the criteria established in the literature (right branch block and intrinsic deflection <85ms).~Crossover from physiological pacing to right ventricular pacing will be allowed in the following situations: failed physiological pacing lead implantation; high thresholds (>3.5V / 1ms); no shortening of QRS (shortening <20%) or failure to meet non-selective HBP criteria or left bundle branch pacing criteria."
89493311|NCT04482816|Active Comparator|Right ventricular pacing|Lead placed in the right ventricle (conventional pacing).
89493312|NCT04477291|Experimental|Dose Escalation and Expansion|Dose Escalation and Expansion; CG-806 will be given orally in ascending doses in patients with relapsed or refractory AML or higher-risk MDS (escalation cohort), until the maximum tolerated dose or candidate recommended Phase 2 dose is reached. Followed up by up to 50 patients enrolled in the expansion cohort at the recommended dose.
89493313|NCT04456608|Experimental|Low and High n-3 PUFA|Individuals with low or high n-3 PUFA RBC concentration will be given aspirin (81 mg of aspirin once a day, for 6 days)
89493314|NCT04436978|Active Comparator|First month DAPT|"30-day DAPT (aspirin + P2Y12 inhibitor). After 30 days all patients will be treated with edoxaban and P2Y12 inhibitor.~Selection of P2Y12 inhibitor is at the discretion of the treating physician, depending on both bleeding and ischemic risk. Dosage of aspirin and P2Y12 inhibitor is according to local guidelines.~NOAC of choice will be edoxaban. Patients will be treated with the recommended dose of 60mg once daily or the reduced dose of 30mg once daily."
89493315|NCT04436978|Active Comparator|Guideline-directed therapy|"Standard guideline-directed therapy (edoxaban + P2Y12 inhibitor, aspirin limited to in-hospital use or up to 30 days in selected high-risk patients). After 30 days all patients will be treated with edoxaban and P2Y12 inhibitor.~Selection of P2Y12 inhibitor is at the discretion of the treating physician, depending on both bleeding and ischemic risk. Dosage of aspirin and P2Y12 inhibitor is according to local guidelines.~NOAC of choice will be edoxaban. Patients will be treated with the recommended dose of 60mg once daily or the reduced dose of 30mg once daily."
89493316|NCT04405349|Experimental|Combination Therapy|VB10.16 vaccinations. 11 intramuscular (i.m.) vaccinations for up to 48 weeks from first vaccination. 5 vaccinations of 3 mg VB10.16 during the first 12 weeks, followed by vaccination every 6 weeks for up to 48 weeks + Atezolizumab (1200 mg) intravenous (i.v.) infusion every 3 weeks.
89493317|NCT04401553|Experimental|First Tier Antibiotic|First tier antibiotics, cephalosporin, will be given before anesthesia induction in the subjects with a history of allergy-like event to beta-lactam
89493318|NCT04401553|Active Comparator|Second Tier Antibiotic|Second tier antibiotics, vancomycin, will be given before anesthesia induction for infection prevention in the subjects with a history of allergy-like event to beta-lactam
89022267|NCT04714268||Procedures without EndoNaut|Control group, endovascular interventions without 3D image fusion
89493319|NCT04393298|Experimental|Part A|Study participants assigned this arm will receive UCB6114 as monotherapy in escalating cohorts at pre-specified dose levels.
89493320|NCT04393298|Experimental|Part A1|Study participants will receive predefined doses of UCB6114 as monotherapy administered intravenously at pre-specified time points.
89493321|NCT04393298|Experimental|Part B|Study participants assigned to this arm will receive UCB6114 in escalating cohorts at pre-specified dose levels in combination with trifluridine/tipiracil (TFD/TPI).
89493322|NCT04393298|Experimental|Part C|Study participants assigned to this arm will receive UCB6114 in escalating cohorts at pre-specified dose levels in combination with oxaliplatin, leucovorin, and 5-fluorouracil (FOLFOX) regimen.
89493323|NCT04372875|Experimental|SHS-derived CDS|All adolescents seen in the emergency department that meet eligibility criteria will be offered the sexual health survey (SHS) during the pragmatic trial.
89493324|NCT04372875|No Intervention|Usual care|All adolescents seen in the emergency department that meet eligibility criteria prior to implementation of SHS-derived CDS.
89493325|NCT04363853|Experimental|Tocilizumab tratment|"Tocilizumab (RoActembra). Vials of 20 ml with 400 mg (20mg/ml) and 4ml with 80 mg (20mg/ml). A singe 60-minute IV infusion of 8mg/kg (maximum dose of 800 mg). Dose was not adjusted for weight more than 100 kg. After first dose, if fiver persists within 12 hours, a second dose was administrated.~A maximum of two doses was allowed."
89493326|NCT04291703|Experimental|Antithymocyte globulin (ATG)|Antithymocyte globulin (ATG) will be intravenously administered over two days, with a total of 2 infusion periods. The first infusion is given at baseline visit (day 1), the second is given the next day at baseline visit (day 2). Body weight at baseline (Day 0- admission for the ATG/placebo infusion) will be used in calculating the doses for all infusions. The first dose (0.5mg/kg) will be infused over a minimum of 4 hours, and the second dose (2mg/kg) over a minimum of 4 hours with a maximum infusion time for each infusion of 10 hours. The second dose should be given no less than 12 and no more than 30 hours from the start of the first infusion. The final prepared product is to be labeled to protect the blind. Infusions may be administered either in a hospital or outpatient setting at the investigator's or institutions discretion.
89493327|NCT04291703|Placebo Comparator|Placebo|"0.9% Sodium Chloride Injection USP (Normal saline) is to be dispensed as the placebo for this study. The placebo is to be prepared dispensing an infusion bag of 0.9% Sodium Chloride Injection USP (Normal saline) with no additives (no ATG, no premedications) and label the product to protect the blind. The placebo will also be administered over a minimum of 4 hours for the first and second doses with a maximum infusion time of 10 hours. The second dose of the placebo arm should be given no less than 12 and no more than 30 hours from the start of the first infusion. Infusions may be administered either in a hospital or outpatient setting at the investigator's or institutions discretion."
89493328|NCT04289142|Active Comparator|Dexmedetomidine Hydrochloride Group|Patients will receive a loading dose of 1.2 μg/kg dexmedetomidine prior to transfer to CVICU over 20 min immediately postoperative, followed by continuous infusion of 0.3 μg/kg/h for up to 12 hours or until patient is ready for discharge from CVICU (whichever is earlier). Any additional sedatives necessary at the discretion of ICU.
89493329|NCT04289142|No Intervention|Standard of Care Group|Standard sedation protocols will be followed at the discretion of the attending physician.
89493330|NCT04284852|Experimental|Experimental arm|Niraparib 200 or 300mg daily orally for 18 cycles unless disease progression or intolerable side effects (whichever occurs first)
89493331|NCT04277104|Experimental|Healthy intervention|Acoustic stimulation
89493332|NCT04277104|Sham Comparator|Healthy sham|No stimulation
89493333|NCT04277104|Experimental|At risk intervention|Acoustic stimulation
89493334|NCT04277104|Sham Comparator|At risk sham|No stimulation
89493335|NCT04277104|Experimental|MCI (mild cognitive impairment) intervention|Acoustic stimulation
89493336|NCT04277104|Sham Comparator|MCI (mild cognitive impairment) sham|No stimulation
89493337|NCT04262596|Experimental|Interactive Consulting System|The AI system adheres to the AHRQ SHARE approach (https://www.ahrq.gov/health-literacy/professional-training/shared-decision/tools/factsheet.html) for shared decision-making, which involves evaluating healthcare options, weighing pros and cons, and assessing potential risks while allowing patients to express their preferences.
89493338|NCT04262596|Active Comparator|Traditional decision aid brochure|A traditional patient decision aid brochure that includes provide standard general information, quantitative risk information on the possible outcomes of cataract surgery and value clarification exercise.
89493339|NCT04257110|Other|Part 1: Dose-escalation|Eight doses levels have been selected for evaluation in the Part 1 of the study. Dose escalation decisions will be determined based on toxicities observed during the first cycle ( 21 days or 28 days).
89493340|NCT04257110|Experimental|Part 2: Cohort 1|Breast Cancer with HER2 overexpressing or positive
89493341|NCT04257110|Experimental|Part 2: Cohort 2|Breast Cancer with HER2 low expressing
89493342|NCT04257110|Experimental|Part 2 Cohort 3|Gastric Cancer or gastroesophageal junction cancer with HER2 overexpressing or positive
89493343|NCT04257110|Experimental|Part 2 Cohort 4|Solid Tumors other than Breast Cancer and Gastric Cancer with HER2 overexpressing or positive
89493344|NCT04243005|Active Comparator|Conventional surgery|Aim of gross total resection (i.e. removal of contrast enhancing tumor) according to institutional practice. No limit in use of technical adjuncts in this arm.
89493345|NCT04243005|Experimental|Supramarginal surgery|Aim of supramarginal resection, where a margin of at least 10 mm is considered feasible prior to surgery. The resection is guided by the T2 volume (i.e. zone of edema) where removal of as much as possible of this zone (or beyond) is attempted as long as considered safe
89493346|NCT04236180|Active Comparator|Intervention Group|Patients enrolled in the Specialised Paediatric Palliative Care (SPPC) programme at the University Children's Hospital Zurich.
89493347|NCT04236180|No Intervention|Comparison Group|Patients treated at the Children's Hospital Aarau, University Children's Hospital Basel, and the University Hospital Inselspital Bern.
89493348|NCT04233801|Experimental|Empagliflozin 10 mg|"1 table of 10 milligrams (mg) of Empagliflozin was administered orally once daily for a treatment period of 24 weeks.~Before the first dose of randomised drug, all participants went through a 2-week open label placebo run-in period, taking Placebo tablets orally once daily."
89493349|NCT04233801|Experimental|Empagliflozin 25 mg|"1 table of 25 milligrams (mg) of Empagliflozin was administered orally once daily for a treatment period of 24 weeks.~Before the first dose of randomised drug, all participants went through a 2-week open label placebo run-in period, taking Placebo tablets orally once daily."
89493350|NCT04233801|Placebo Comparator|Placebo|"Matching placebo was administered orally once daily for a treatment period of 24 weeks.~Before the first dose of randomised drug, all participants went through a 2-week open label placebo run-in period, taking Placebo tablets orally once daily."
89493351|NCT04227899|Experimental|Esprit BTK|Participants who receives Esprit BTK device will be included in this arm
89493352|NCT04227899|Active Comparator|Percutaneous Transluminal Angioplasty (PTA)|Participants who receives PTA treatment will be included in this arm
89493353|NCT04198012|Experimental|The HemoCare™ Hemodialysis System|The HemoCare™ Hemodialysis System is intended for hemodialysis treatment, including short daily and nocturnal hemodialysis, of renal failure patients. The HemoCare™ Hemodialysis System is intended for use in chronic dialysis facilities, self-care dialysis facilities, or the home setting. All treatments must be prescribed by a physician and administered by a trained operator. Treatments must be performed under the supervision or assistance of a medical professional or a care partner who has been trained and deemed competent in the use of the device by the prescribing physician.
89493354|NCT04184843|Experimental|iWalk Toolkit|"Intervention period: 5 months~Intervention:~A toolkit consisting of 3 components: an educational guide, a smartphone app, and an educational video.~Access to a clinical expert by email or phone"
89493355|NCT04130659|Experimental|MARIAL® and PPI; Follow-up period: MARIAL® alone|"Period 1, open comparative phase: MARIAL® and PPI administered from day 1 to day 28.~Period 2, open non comparative follow up: MARIAL® alone administered from day 29 to month 6."
89493356|NCT04130659|Active Comparator|PPI alone; Follow-up period: MARIAL® alone|"Period 1, open comparative phase: PPI alone administered from day 1 to day 28.~Period 2, open non comparative follow up: MARIAL® alone administered from day 29 to month 6."
89493357|NCT04123847|Experimental|Stand, Step and Voluntary Training|
89493358|NCT04117100||Endoscopic mucosal resection (EMR)|It has become the standard treatment for superficial tumors of the gastrointestinal tract, either flat or sessile: precancerous lesions and superficial cancers with no or low ganglionic risk. The pre-injection of physiological serum detaches the lesion from the deep plane and allows, with great security, the resection of the mucosa, muscularis mucosae with part of the submucosa, whatever the size and location of the lesion. Compared to other techniques, it allows a histological analysis which dictates the subsequent conduct and the possible need for a complementary surgery.
89204738|NCT02550912|Active Comparator|Vitamin D group|Patients will receive vitamin D drug with generic name: V drops manufactured by Medical Union Pharmaceuticals, Egypt Dosage form: liquid drops Dosage, frequency, and Duration:1000 international units per day for 3 months then 1000 international units per 25 pounds per day for another 3 months.
89493359|NCT04117100||Endoscopic mucosal dissection (ESD)|This technique uses submucosal injection and special knives to make a peri-lesional circumferential incision, followed by dissection through the submucosal sub-lesion.
89493360|NCT04117100||Radio Frequency Ablation (RFA) and Argon Plasma Ablation (APC)|This is a mucosal thermo-destruction technique. It uses a generator that delivers a sinusoidal current of high frequency to a probe covered with bipolar electrodes in tight network ensuring a uniform diffusion of the thermal effect. The tissue penetration is superficial on 1mm, intended to eradicate the epithelium up to the muscularis mucosae. Circumferential or focal probes are used as a function of the length of the segment to be treated.
89493361|NCT04117100||Per Oral Endoscopic Myotomy (POEM)|"This technique allows a myotomy on the 8 cm of the lower esophagus extended on the gastric side of the cardia, totally endoscopically, after having approached and tunneled the esophageal submucosa.~Less invasive, it gradually replaces the pneumatic dilatation and surgical myotomy of Heller.~It requires a general anesthesia, an expert operator and a trained nursing team, ESD instruments, carbone dioxide insufflation."
89493362|NCT04098146||Mandibular Reconstruction|Patients undergoing segmental mandibular defect reconstruction. The decision of one stage or two stage reconstruction is done according to the patient and treating surgeon preferences following the local standard of care
89493363|NCT04097730|Placebo Comparator|Standard Therapy|Participants in this arm will receive topical 0.5% moxifloxacin plus topical placebo plus sham corneal cross-linking.
89493364|NCT04097730|Experimental|Early Steroids|Participants in this arm will receive topical 0.5% moxifloxacin plus topical steroids plus sham corneal cross-linking.
89493365|NCT04097730|Experimental|Cross-Linking plus Early Steroids|Participants in this group will receive topical 0.5% moxifloxacin plus topical steroids plus corneal cross-linking.
88954140|NCT01969461|Experimental|Healthy Choices: MET CHW Clinic|The 4-session Motivational Enhancement Therapy (MET) intervention will address alcohol use and HIV medication (ART) adherence. Sessions will be delivered in the CLINIC by a CHW (outreach worker, etc) already providing services in the clinic. The intervention is based on Motivational Interviewing (MI) techniques, building motivation for change by eliciting and reinforcing change talk.
88954141|NCT01969461|Active Comparator|Healthy Choices: MET CHW Home|The 4-session Motivational Enhancement Therapy (MET) intervention will address alcohol use and HIV medication (ART) adherence. Sessions will be delivered in the HOME by a CHW (outreach worker, etc) already providing services in the clinic. The intervention is based on Motivational Interviewing (MI) techniques, building motivation for change by eliciting and reinforcing change talk.
88954142|NCT01969474|Experimental|Cannabis|Treatment with a Cannabis capsule
88954143|NCT01969474|Placebo Comparator|Placebo|Placebo
88954144|NCT01969487|Experimental|Preoperative warm-up on simulator|Trainees perform standard practice tasks programmed into a robotic surgical simulator immediately before the surgery.
88954145|NCT01969487|No Intervention|No preoperative warm-up|
88954146|NCT01969513|Experimental|INTERVENTION ARM|Patients meeting the inclusion criteria will be randomly assigned to the experimental group. They will receive Epley's manoeuvre plus betahistine 8mg three times a day until they no longer have symptoms. The Epley's manoeuvre will be performed only on the first visit.
88954147|NCT01969513|Sham Comparator|CONTROL GROUP|Patients meeting the inclusion criteria will be randomly assigned to the control group. These patients will receive sham manoeuvre (simulated Epley manoeuvre) plus betahistine 8mg three times a day until they no longer have symptoms. Placebo manoeuvre is performed with the patient lying down over the affected side for 5 minutes as it is described in similar studies.
88954148|NCT01969526|Experimental|Multifactorial Intervention|Intervention consists in three different actions on frailty dimensions, applied to each subject in the intervention group, in groups of 15 participants: rehabilitative therapy plus intake of hyperproteic shakes, memory workshop and review of the medication.
88954149|NCT01969526|No Intervention|No intervention|Usual care
88954150|NCT01969552||Thyroid testing|Adult subjects presenting for thyroid testing or treatment
88954151|NCT01969591|Experimental|fast-track surgery|Patients with colorectal cancer will undergo laparoscopic colorectal resection, and will be divided into two groups. Protocols for fast-track group includes skipping preoperative mechanical bowel preparation, early restoration of diet and early postoperative ambulation.
88954152|NCT01969591|Other|convontional postoperative care|Patients with colorectal cancer will undergo laparoscopic colorectal resection, and will be divided into two groups. Protocols for fast-track group includes skipping preoperative mechanical bowel preparation, early restoration of diet and early postoperative ambulation.
88954153|NCT01969604|Experimental|Motivational lifestyle counselling|This arm will include 1) Three individual motivational counselling sessions including handouts of four key messages regarding reduction of daily sitting time in combination with 2) Individual Short Text Message (SMS) reminders.
88954154|NCT01969604|No Intervention|Control Group|A control group will be encouraged to maintain their usual lifestyle during the 16-week intervention period.
88954155|NCT01969617|Experimental|Nalmefene 18 mg, then placebo|18 mg nalmefene corresponds to 20 mg nalmefene hydrochloride
88954156|NCT01969617|Placebo Comparator|Placebo, then Nalmefene 18 mg|18 mg nalmefene corresponds to 20 mg nalmefene hydrochloride
88954157|NCT01969630|Active Comparator|PEB|PEB angioplasty plus provisional nitinol stent implantation
88954158|NCT01969630|Experimental|PES|Systematic PES angioplasty
88954159|NCT01969656|Placebo Comparator|Placebo|
89493366|NCT04069897|Experimental|Botox injections towards SPG|Botulinum Toxin type A injections
88954160|NCT01969656|Active Comparator|Calcitriol|
88954161|NCT01969656|Experimental|50 ng 2MD|
88954162|NCT01969656|Experimental|110 ng 2MD|
88954163|NCT01969656|Experimental|170 ng 2MD|
88954164|NCT01969656|Experimental|220 ng 2MD|
88954165|NCT01969656|Experimental|440 ng 2MD|
88954166|NCT01969669|Experimental|Arm A (ABT-199 and ketoconazole)|
88954167|NCT01969682|Experimental|Arm A (ABT-199 and rifampin)|
88954168|NCT01969695|Experimental|ABT-199|ABT-199 monotherapy
88954169|NCT01969734|Experimental|Endobronchial valves|All subjects will have endobronchial valves inserted into the target lobe of the lung with the aim of complete lobar exclusion.
88954170|NCT01969760|No Intervention|Wait-list control|Wait-list control. No intervention delivered until post follow-up assessment. Upon completion of the follow-up, the family was offered the full intervention.
89493367|NCT04069897|Placebo Comparator|Controls|Placebo injections
89493368|NCT04069156|Placebo Comparator|Placebo Arm|LVAD Patients on the placebo arm will be given placebo medication
89493369|NCT04069156|Active Comparator|Active Arm|LVAD Patients on the active arm will be given 100mg Aspirin
89493370|NCT04059042|Experimental|Music|"The investigators will manipulate the audio environment the participant experiences 10 minutes before and throughout pain threshold testing (~1 hour). All participants will have one testing session with silence (testing as usual control). On the other testing session, participants will hear music.~The musical selections will be professional recordings of instrumental Classical music selected by the researcher. All participants will hear the same pieces in the same order. Instrumentation ranges from piano solo to full orchestra, but they are without lyrics or heavy percussion. Pitch ranges across the pieces, but is standard across participants and not controlled by either the participant or the researcher. Tempo for all of the pieces is slow (~60 beats per minute). The pieces are in either major keys or minor keys, but all consist primarily of consonant harmonies and sustained melodic phrases. Participants will control the volume to their individual comfort level."
89493371|NCT04059042|Placebo Comparator|Nature Sounds|"The investigators will manipulate the audio environment the participant experiences 10 minutes before and throughout pain threshold testing (~1 hour). All participants will have one testing session with silence (testing as usual control). On the other testing session, participants will hear nature sounds.~Professional recordings of nature sounds selected by the researcher without added music will be used as the active placebo control condition. All participants will hear the same recording. This active control condition will allow for non-musical analgesic effects, such as distraction, to be controlled in the experimental design. Participants will control the volume to their individual comfort level."
89493372|NCT04033328|Experimental|Dose Escalation|ORIC-101 dosed orally, once per day in combination with enzalutamide (160 mg) of each 28-day cycle.
89493373|NCT04033328|Experimental|Dose Expansion|RP2D dose
89493374|NCT04033003|Experimental|Group ANC|Intervention groups consist of up to 14 women of similar gestation age (10 to 20 weeks) for nine meetings. The first meeting is an individual meeting with the midwife and the standard history and physical exam as well as lab tests are completed. Group meetings are held once a month until 28 weeks of pregnancy, then every 2 weeks until 34 weeks of pregnancy, and the remaining group meetings are once a week. Prior to the start of each group, blood pressure, weight, and a urinalysis are measured for each woman.
89493375|NCT04033003|No Intervention|Stand ANC|Individual standard antenatal care delivered at health facilities in Ghana
89493376|NCT04019015|Experimental|Kcentra|"A single dose of Kcentra based on estimated body weight~2000 U for patients with an estimated body weight ≤ 75kg~3000 U for patients with an estimated body weight > 75kg"
89493377|NCT04019015|Placebo Comparator|Placebo|A single infusion of volume matched placebo solution (Normal Saline)
89493378|NCT04013555|Experimental|N-acetylcysteine & Tryptophan|N-acetylcysteine 140 mg/kg up to a maximum of 15 g. Thirty minutes after N-acetylcysteine administration participants will receive Tryptophan, 6 grams.
89493379|NCT04013555|Placebo Comparator|Placebo & Tryptophan|Placebo 140 mg/kg up to a maximum of 15 g. Thirty minutes after placebo administration participants will receive Tryptophan, 6 grams.
89493380|NCT03980314|Active Comparator|Arm A (Process C)|
89493381|NCT03980314|Experimental|Arm B (Process D)|
89493382|NCT03979781|Experimental|Treatment Group|Intervention group
89493383|NCT03979781|Active Comparator|Control Group|Standard of Care group
89493384|NCT03976843|Experimental|1/18F-DCFPyL PET/CT + radical prostatectomy|18F-DCFPyL PET/CT with radical prostatectomy and lymphadenectomy
88954171|NCT01969760|Experimental|Healthy Families DC Program|Healthy Families DC Program
88954172|NCT01969773|Experimental|Botulinum toxin A|Patients will be randomly assigned to receive intravesical injection of 100U of BoNT-A (BOTOX, Allergan, Irvine, CA, USA)
88954173|NCT01969773|Placebo Comparator|Control arm-Normal saline instillation|Patients will be randomly assigned to receive intravesical injection of injection with normal saline.
88954174|NCT01969864|Experimental|HRSA Video Intervention|5-minute video on organ donation from U.S. Department of Health and Human Services
88954175|NCT01969864|Experimental|PI Video Intervention|5-minute video on organ donation created in part by the principal investigator.
89493385|NCT03967470|Placebo Comparator|Placebo arm|Placebo spray used during one month
89493386|NCT03967470|Active Comparator|Treatment arm|Bacteria spray used during one month
89493387|NCT03958630|Experimental|PET scan|Healthy and Patients
89493388|NCT03956680|Experimental|Part 1A Group 1: BMS-986301 Monotherapy Intramuscular (IM)|
89493389|NCT03956680|Experimental|Part 1A Group 2: BMS-986301 Monotherapy Intratumoral (I-TUMOR) Sub-study|
89493390|NCT03956680|Experimental|Part 1A Group 3: BMS-986301 Monotherapy Intravenous (IV) Sub-study|
89493391|NCT03956680|Experimental|Part 1B Group 4: Systemic BMS-986301 + Nivolumab + Ipilimumab|
89493392|NCT03956680|Experimental|Part 1B Group 5: I-TUMOR BMS-986301 + Nivolumab + Ipilimumab|
89493393|NCT03940560|Experimental|Duramesh Suturable Mesh|Use of Duramesh Suturable Mesh for internal load bearing closures
89493394|NCT03928314|Experimental|Dose Escalation (Part I)|ORIC-101 dosed orally, once per day, for 5 or 7 days/week in combination with nab-paclitaxel (75 or 100 mg/m2 on Days 1, 8, and 15) of each 28-day cycle.
89493395|NCT03928314|Experimental|Dose Expansion (Part II)|RP2D dose
89493396|NCT03925987|Experimental|Exposure therapy|Participants complete 10 weekly sessions of a group-based exposure therapy class for anxiety disorders.
89493397|NCT03924869|Experimental|SBRT+Pembolizumab|Participants receive SBRT once every 3 days for 3, 4, 5, or 8 fractions (dependent on tumor type/location; 45-70 Gray [Gy] total) over approximately 2 weeks PLUS pembrolizumab 200 mg via intravenous (IV) infusion once every 3 weeks for up to 17 cycles (up to approximately 1 year). Each cycle is 21 days.
89493398|NCT03924869|Placebo Comparator|SBRT+Placebo|Participants receive SBRT once every 3 days for 3, 4, 5, or 8 fractions (dependent on tumor type/location; 45-70 Gy total) over approximately 2 weeks PLUS placebo (normal saline solution) via IV infusion once every 3 weeks for up to 17 cycles (up to approximately 1 year). Each cycle is 21 days.
89493399|NCT03913078|Active Comparator|Group Fitness|Subjects will be offered several sessions per week of a traditional group fitness program led by a trained group leader.
89493400|NCT03913078|Active Comparator|PlayFit|Subjects will be offered several sessions per week of a modified sports fitness program, led by a trained group leader.
89493401|NCT03908788|Experimental|Intplex test|In vitro diagnostic device
89493402|NCT03893682|Experimental|Dose Escalation and Expansion|CG-806 will be given orally in ascending doses in patients with relapsed or refractory CLL/SLL or Non-Hodgkin's Lymphomas (escalation cohort), until the maximum tolerated dose or recommended dose is reached. Followed by up to 100 patients enrolled in the expansion cohort at the recommended dose.
89493403|NCT03869970|Active Comparator|Rest|Discharge instructions focused on 24 - 48 hours of rest then symptom guided activity, Fitbit monitored.
89493404|NCT03869970|Active Comparator|mHealth|"Use of the resilience application on a smart phone to assess daily symptoms over 14 days and follow a self directed, symptom guided return to physical activity. Also Fitbit monitored."
89493405|NCT03869970|Active Comparator|Activity|Low intensity activity regardless of symptoms using their Fitbit to measure said activity with goals (eg. 10,000 steps/ day.
89493406|NCT03869970|Active Comparator|Both Activity and mHealth|"This group will receive both interventions and utilize the SuperBetter app. Interventions will be integrated by having research assistants support the subject to set and physical activity goals and milestones to the subject's pre-programmed general resilience goals in the SuperBetter© app (e.g. take a 30 min walk, march in place for 5 minutes, increase my step count by 2000 today, achieve 10,000 steps today)."
89493407|NCT03860168|Other|PICU Up! pre- and post-implementation|Each unit will begin in the baseline, usual care phase and then be randomized to implement the PICU Up! program during a set time period, followed by the post-implementation phase.
89493408|NCT03854058||OHS or elevated OHS-risk (stages 0-IV)|"stage 0: OHS-risk (OSA / no hypercapnia)~stage I: obesity associated hypoventilation (intermittent hypercapnia during sleep, arterial carbon dioxide partial pressure (PaCO2) or transcutaneous carbon dioxide partial pressure (PtcCO2) morning ~ evening), bicarbonate < 27 mmol/L awake)~stage II: obesity associated hypoventilation (intermittent hypercapnia during sleep, PaCO2 or PtcCO2 morning > evening, bicarbonate ≥ 27 mmol/L awake)~stage III: OHS (hypercapnia, carbon dioxide partial pressure (PCO2) > 45 mmHg awake)~stage IV: OHS with end organ damage (hypercapnia , PCO2 > 45 mmHg awake, cardiometabolic comorbidities)~diagnostic tests: magnetic phrenic nerve stimulation, diaphragmatic ultrasound"
89493409|NCT03816891|Experimental|Phase 2a - Vixarelimab 360 mg SC QW|Vixarelimab 720 mg loading dose followed by 360 mg weekly for 8 weeks (Protocol Version 3) or 16 weeks (Protocol Version 2)
89493410|NCT03816891|Placebo Comparator|Phase 2a - Placebo SC QW|Placebo loading dose followed by placebo weekly for 8 weeks (Protocol Version 3) or 16 weeks (Protocol Version 2)
89493411|NCT03816891|Experimental|Phase 2b - Vixarelimab 540 mg SC Q4W (DBL)|Vixarelimab 540 mg SC, every 4 weeks for 16 weeks during Double Blind Period
89493412|NCT03816891|Experimental|Phase 2b - Vixarelimab 360 mg SC, Q4W (DBL)|Vixarelimab 360 mg SC, every 4 weeks for 16 weeks during Double Blind Period
89493413|NCT03816891|Experimental|Phase 2b - Vixarelimab 120 mg SC, Q4W (DBL)|Vixarelimab 120 mg SC, every 4 weeks for 16 weeks during Double Blind Period
89493414|NCT03816891|Placebo Comparator|Phase 2b - Placebo SC, Q4W (DBL)|Placebo SC, every 4 weeks for 16 weeks during Double Blind Period
88954176|NCT01969864|Placebo Comparator|CDC Health Website Intervention|This control intervention will include text from the CDC website on health and wellness.
88954177|NCT01969877|Experimental|Arm 1|Radiotherapy with a dose of 68.0 Gy in 34 fractions, and cetuximab with a loading dose of 400 mg/m2 one week before start of radiotherapy, then 250 mg/m2 weekly during radiotherapy (tumor stage 1-4).
88954178|NCT01969877|Experimental|Arm 2|Radiotherapy with a dose of 73.1 Gy in 34 fractions, and cetuximab with a loading dose of 400 mg/m2 one week before start of radiotherapy, then 250 mg/m2 weekly during radiotherapy (tumor stage 3-4).
88954179|NCT01969877|Experimental|Arm 3|Radiotherapy with a dose of 68.0 Gy in 34 fractions, and cisplatin weekly with a dose of 40 mg/m2 (tumor stage 1-4).
88954180|NCT01969877|Experimental|Arm 4|Radiotherapy with a dose of 73.1 Gy in 34 fractions, and cisplatin weekly with a dose of 40 mg/m2 (tumor stage 3-4).
88954181|NCT01969890|Experimental|G-CSF administration|Granulocyte Colony-Stimulating Factor (G-CSF) administration - 5 microg/kg subcutaneous every 12 hours for 6 days
88954182|NCT01969890|No Intervention|standard therapy|Standard therapy
88954183|NCT01969903|Experimental|No dexmedetomidine injected|Control group in which will be used only lidocaine for brachial plexus block
88954184|NCT01969903|Experimental|0.3 microgs/kg of dexmedetomidine|Experimental group, in which 0.3 microgs/kg dexmedetomidine will be added to lidocaine for brachial plexus block
88954185|NCT01969903|Experimental|0.6 microgs/kg of dexmedeomidine|Experimental group, in which 0.6 microgs/kg dexmedetomidine will be added to lidocaine for brachial plexus block
88954186|NCT01969929|Active Comparator|20G|20G vitrectomy with scleral and conjunctival sutures for closure
88954187|NCT01969929|Active Comparator|23G|23G transconjunctival sutureless vitrectomy
88954188|NCT01969942|Experimental|allogeneic stem cell transplantation Plan A|Subjects will receive the vaccine, Busulfan and Melphalan.
88954189|NCT01969942|Experimental|allogeneic stem cell transplantation Plan B|If subject have already received a stem cell transplant using Busulfan and Melphalan, they will receive Clysophosohamide and Fludarabine.
88954190|NCT01969955|Experimental|nanoparticle albumin-bound paclitaxel|Nanoparticle albumin-bound paclitaxel is given at 130 mg/m2 intravenously on day 1 and 8, every 21 days.
89493415|NCT03816891|Experimental|Phase 2b - Vixarelimab 360 mg SC, Q2W (OLE)|Vixarelimab 360 mg SC, every 2 weeks for 36 weeks during Open Label Extension
89493416|NCT03800121||Localized sarcoma with neoadjuvant chemotherapy|"In total, several blood tests specific to the EXOSARC study will be necessary:~A first blood test of 7 mL during the initial assessment (inclusion)~Then four blood samples of 32mL distributed over 6 months"
89493417|NCT03800121||Metastatic or locally advanced sarcoma|"In total, several blood tests specific to the EXOSARC study will be necessary :~A first blood of 7 mL during the initial assessment (inclusion)~Then three blood samples of 32 mL distribuated over 3 months"
89493418|NCT03740113|Experimental|Kids SipSmartER|Kids SIPsmartER is a 12 session, 6-month program with an integrated two-way short service message (SMS) strategy to engage caregivers in SSB role modeling and supporting home SSB environment changes
89493419|NCT03740113|No Intervention|Control|Control arm receives no intervention
89493420|NCT03736993|Other|Additional blood sampling|non-small cell lung cancer (NSCLC)
89493421|NCT03719924|Experimental|arm A: ONIVYDE|ONIVYDE ONIVYDE will be administered first, followed by folinic acid or L-folinic acid and then 5-FU at D1 and D14 ONIVYDE: 80 mg/m² intravenous over 90 minutes Folinic acid: 400 mg/m² intravenous over 30 minutes or L-folinic acid (racemic form L) 200 mg/m² over 30 minutes 5-FU: 2400 mg/m² over 46 hours
89493422|NCT03719924|Active Comparator|Arm B: TAXOL|TAXOL Premedication consists of corticosteroids, H1 antihistamines and H2 antagonists during 30 minutes at time 1 hour before chemotherapy One cycle every 28 days (D1=D28) 80 mg/m2 IV over 60 minutes at D1, D8 and D15
89493423|NCT03713879|Experimental|indomethacin|rectal indomethacin 100 mg to be administered before or after ERCP
89493424|NCT03713879|Experimental|pancreatic stenting|"a PD stent to be inserted during ERCP (a 3 to 5 cm 5Fr single pigtail pancreatic duct stent without inner flap is used, the stent is inserted after deep cannulation of pancreatic duct with a .025 or .035 wire)"
89493425|NCT03713879|Experimental|indomethacin plus pancreatic stenting|"[rectal indomethacin 100 mg to be administered before or after ERCP] plus [a PD stent to be inserted during ERCP (a 3 to 5 cm 5Fr single pigtail pancreatic duct stent without inner flap is used, the stent is inserted after deep cannulation of pancreatic duct with a .025 or .035 wire]"
89493426|NCT03713775|Experimental|Meal Replacement Weight Loss Programme|The study intervention will be the referral to a commercial provider (CP) offering a Meal Replacement Weight Loss Programme with behavioural support. Briefly, participants will be referred to a nominated CP local counsellor who will set regular appointments during a period of 32-to-36 weeks to provide behavioural support, weight monitoring, and deliver formula meals. All counsellors delivering the programme will receive, beyond their routine training and accreditation, specific information related to this study before being allocated patients. The programme conventionally includes the 3 phases (meal replacement phase, transition phase, and weight maintenance phase) but the Consultant will have full discretion to modify and tailor this programme to suit each individual participant.
89493427|NCT03713775|Active Comparator|Usual Care|Participants randomised to the control group will receive best usual care, consisting of a one-off face-to-face consultation on weight loss with a nurse at baseline (~15 min at the John Radcliffe Hospital, Oxford) together with supporting written information (i.e. a copy of the booklet 'Facts not fads - Your simple guide to healthy weight loss.')
89493428|NCT03687359||Participants with atopic dermatitis (AD)|Participants receive AD therapy as part of their usual care as determined by their physician independent of decision to enroll in the study.
89493429|NCT03679598|Active Comparator|Alvelestat (MPH966)|Alvelestat (MPH966) 120mg (4 30mg tablets) twice daily by mouth for 12 weeks
89493430|NCT03679598|Placebo Comparator|Placebo|4 Placebo tablets twice daily by mouth for 12 weeks
89493431|NCT03635788|Experimental|Arm A: LA ART|In Step 1, participants will receive SOC oral ART regimen for up to 24 weeks. In Step 2, participants will receive oral RPV once daily and oral CAB once daily for 4 weeks (optional), followed by a RPV-LA loading dose and a CAB-LA loading dose, followed in 4 weeks by an RPV-LA maintenance dose and a CAB-LA maintenance dose every 4 weeks for 44 weeks. In Step 3, participants will receive a RPV-LA maintenance dose and a CAB-LA maintenance dose every 4 weeks until the end of Step 2. In Step 4, eligible participants will be followed until they complete 52 weeks on locally sourced oral ART.
89493432|NCT03635788|Active Comparator|Arm B: SOC Oral ART|In Step 1, participants will receive SOC oral ART regimen for up to 24 weeks. In Step 2, participants will continue SOC oral ART regimen for 52 weeks. In Step 3, participants will receive oral RPV once daily and oral CAB once daily for 4 weeks (optional), followed by a RPV-LA loading dose and a CAB-LA loading dose, followed in 4 weeks by an RPV-LA maintenance dose and CAB-LA maintenance dose every 4 weeks until the end of Step 3. In Step 4, eligible participants will be followed until they complete 52 weeks on locally sourced oral ART.
89204739|NCT02550912|Placebo Comparator|Placebo group|Patients will receive glucose syrup same taste and color as vitamin D3 drops with same dosage regimen to vitamin D group.
89204740|NCT00999700|Experimental|ARM A|Induction chemotherapy: TCF (Vermorken, N Eng J Med 2007) Definitive treatment: RT + C-mab (Bonner, N Eng J Med 2006)
89493433|NCT03597620|Experimental|Nonsystemic Therapy + Herbal Anti-Inflammatory Treatment (HAT1)|Patients who received HAT1 and were not on systemic treatment at time of enrollment. Metaderm cream will be applied topically twice a day to all active lesions. The metaderm scalp spray will be applied daily to the affected areas on the scalp.
89493434|NCT03597620|Experimental|Systemic Therapy + Herbal Anti-Inflammatory Treatment (HAT1)|Patients who received HAT1 and were on systemic treatment at time of enrollment. Metaderm cream will be applied topically twice a day to all active lesions. The metaderm scalp spray will be applied daily to the affected areas on the scalp.
89493435|NCT03562494|Experimental|VY-AADC02 (NBIb-1817)|Single administration of up to 3.6 x 10^12 vector genomes (vg) of VY-AADC02
89493436|NCT03562494|Placebo Comparator|Sham (Placebo) Surgery|Sham surgical procedure
88954191|NCT01969981||PICC placement|
89493437|NCT03560323|Active Comparator|Group I Beta-Hydroxy-Butyrate|Administration of beta-hydroxy-butyrate at 0.4 mg/kg.min for 20 minutes and then at a constant rate of 0.2 mg/kg.min until study end
88954192|NCT01969994|Experimental|Controlled dietary background & (-)-[2-14C]epicatechin intake|
89493438|NCT03560323|Active Comparator|Group II Beta-Hydroxy-Butyrate|Administration of beta-hydroxy-butyrate at 1.5 mg/kg.min for 20 minutes and then at a constant rate of 0.75 mg/kg.min until study end
89493439|NCT03560323|Active Comparator|Group III Beta-Hydroxy-Butyrate|Administration of beta-hydroxy-butyrate at 4.0 mg/kg.min for 20 minutes and then at a constant rate of 2.0 mg/kg.min until study end
88954193|NCT01970020|Experimental|JNJ-38518168|
88954194|NCT01970033|Placebo Comparator|Placebo|
89493440|NCT03532412||HF+CSA+PB|Systolic heart failure with predominant central sleep apnea and periodic breathing
88954195|NCT01970033|Experimental|SP2086 50 mg b.i.d|
88954196|NCT01970033|Experimental|SP2086 100 mg q.d.|
88954197|NCT01970046|Placebo Comparator|Placebo/Metformin|
88954198|NCT01970046|Experimental|SP2086 (50mg b.i.d)/Metformin|
88954199|NCT01970046|Experimental|SP2086 (50mg q.d.)/Metformin|
88954200|NCT01970059|Experimental|Extended-Release Carvedilol Sulfate|18-72mg/d,po
88954201|NCT01970059|Active Comparator|Sustained-release Metoprolol Succinate|47.5-190mg/d,po
88954202|NCT01970072|Experimental|1.Remimazolam Tosylate|Single IV bolus of Remimazolam Tosylate over 1 minute at 0.01 mg/kg body weight
89493441|NCT03531463|Active Comparator|Operative treatment|"Operative treatment of the displaced proximal humeral fracture with a reversed total shoulder prothesis (Delta prosthesis) using a stadardized deltopectoral approach, bone block grafting and thread cerclages of the tubercles.~Rehabilitation with standardized physiotherapy guideline and self exercise protocol"
89493442|NCT03531463|No Intervention|Non-Operative treatment|Rehabilitation with standardized physiotherapy guideline and self exercise protocol
89493443|NCT03529565||Ancillary-Correlative (biospecimen collection)|Participants undergo collection of blood samples for histamine level analysis via ELISA.
89493444|NCT03495180|Experimental|Standard EEG or SSEP|the intensity of an experimental pain stimulus and perceived (self-rating, subjective) pain intensity.
89493445|NCT03475212|Experimental|Virus specific T cell lines (VSTs) against three viruses|The study will evaluate whether partially-HLA matched allogeneic multivirus-specific VSTs, activated using overlapping peptide libraries spanning immunogenic antigens from CMV, adenovirus and EBV, will be safe and produce anti-viral effects in immunodeficient recipients infected with one of more of the targeted viruses that are persistent despite conventional anti-viral therapy.
89493446|NCT03426748|Active Comparator|Low dose rate brachytherapy|Device: Radiation. Low dose rate prostate brachytherapy is delivered under anesthesia in a single 1.5-2 hour procedure as an out-patient. The men return 4 weeks later for detailed imaging to assess implant quality.
89493447|NCT03426748|Experimental|High dose rate brachytherapy|"Device: Radiation. High dose rate prostate brachytherapy is delivered in 2 procedures, 2 weeks apart, also under anesthesia, but no follow-up imaging visit is required.~HDR brachytherapy is also accomplished as an out-patient."
89493448|NCT03415854|Experimental|Paricalcitol (Zemplar)|Participants will be treated with the regimen according to the study protocol. Participants will complete 3 cycles (cycle is 21 days) and then will be evaluated for CA19-9 normalization and undergo imaging to determine response, if any.
89493449|NCT03404505|Experimental|Infant Achievements|Families randomized to the IA condition will receive 17 in-home sessions. These include a one-time start up session followed by twice-weekly visits in which they will be coached on how to implement the IA strategies. Families will receive a set of developmentally appropriate toys.
89493450|NCT03404505|Experimental|Caregiver Education|In this condition, parents will receive 17 sessions with a trained study team member focused on promoting child development and well-being. Sessions include a one-time start-up visit followed by one in-home visit and one phone contact per week. Families will receive a set of developmentally appropriate toys.
89493451|NCT03397966|Experimental|BNP, then placebo|At Study Visit 1, subjects will receive an IV infusion of recombinant human b-type natriuretic peptide (BNP (1-32), nesiritide) for 240 minutes. After a washout period of at least 2 weeks, subjects then present for Study Visit 2, where they will receive an IV infusion of placebo (control, normal saline) for 240 minutes.
89493452|NCT03397966|Experimental|Placebo, then BNP|At Study Visit 1, subjects will receive an IV infusion of placebo (control, normal saline) for 240 minutes. After a washout period of at least 2 weeks, subjects then present for Study Visit 2, where they will receive an IV infusion of recombinant human b-type natriuretic peptide (BNP (1-32), nesiritide) for 240 minutes.
88954203|NCT01970072|Experimental|2.Remimazolam Tosylate|Single IV bolus of Remimazolam Tosylate over 1 minute at 0.02 mg/kg body weight
89493453|NCT03374657|Experimental|CPK Dose 1 (lowest dose)|CPK850, one subretinal injection to the study eye
89493454|NCT03374657|Experimental|CPK Dose 2 (next lowest dose)|CPK850, one subretinal injection to the study eye
88954204|NCT01970072|Experimental|3.Remimazolam Tosylate|Single IV bolus of Remimazolam Tosylate over 1 minute at 0.05 mg/kg body weight
88954205|NCT01970072|Experimental|4.Remimazolam Tosylate|Single IV bolus of Remimazolam Tosylate over 1 minute at 0.075 mg/kg body weight
88954206|NCT01970072|Experimental|5.Remimazolam Tosylate|Single IV bolus of Remimazolam Tosylate over 1 minute at 0.1 mg/kg body weight
88954207|NCT01970072|Experimental|6.Remimazolam Tosylate|Single IV bolus of Remimazolam Tosylate over 1 minute at 0.15 mg/kg body weight
88954208|NCT01970072|Experimental|7.Remimazolam Tosylate|Single IV bolus of Remimazolam Tosylate over 1 minute at 0.2 mg/kg body weight
88954209|NCT01970072|Experimental|8.Remimazolam Tosylate|Single IV bolus of Remimazolam Tosylate over 1 minute at 0.25 mg/kg body weight
88954210|NCT01970072|Experimental|9.Remimazolam Tosylate|Single IV bolus of Remimazolam Tosylate over 1 minute at 0.3mg/kg body weight
88954211|NCT01970072|Experimental|10.Remimazolam Tosylate|Single IV bolus of Remimazolam Tosylate over 1 minute at 0.35 mg/kg body weight
88954212|NCT01970072|Active Comparator|11.Midazolam|Single IV bolus of Midazolam over 1 minute at 0.075 mg/kg body weight
88954213|NCT01970098|Experimental|KPS-0373|
88954214|NCT01970098|Placebo Comparator|Placebo|
88954215|NCT01970111|Experimental|KPS-0373|
88954216|NCT01970124|Experimental|KPS-0373|
88954217|NCT01970137|Experimental|KPS-0373|
88954218|NCT01970150|Experimental|1|In this intervention patients receive 5 days a week for 4 weeks of rTMS treatment with real coil
88954219|NCT01970163|Experimental|DermACELL|DermACELL acellular dermal matrix will be used to treat subjects diagnosed with an ulcer of the lower extremity (diabetic foot ulcer or venous stasis ulcer).
89022268|NCT00457782|Experimental|I|Intravenous KW-2478 (ascending dose cohorts)
89022269|NCT00351806|Experimental|Chinese herbal medicine|
89022270|NCT00351806|Placebo Comparator|placebo|
89022271|NCT00457938|Other|"Low fat diet is the drug"|Diet 10% fat versus 35% fat
89022272|NCT00458016|Experimental|1|
89022273|NCT00458016|Experimental|2|
89493455|NCT03374657|Experimental|CPK Dose 3 (third lowest dose)|CPK850, one subretinal injection to the study eye
89493456|NCT03374657|Experimental|CPK Dose 4 (highest dose)|CPK850, one subretinal injection to the study eye
89493457|NCT03260920|Experimental|Low Dose|
89493458|NCT03260920|Experimental|Medium Dose|
89493459|NCT03260920|Experimental|High Dose|
89493460|NCT03248063|Active Comparator|Cloxacillin|Intravenous treatment by cloxacillin, 25 to 50 mg/kg every 4 or 6 hours, without doing less than the minimum daily dose of 8 g/day and without exceeding the maximum daily dose of 12 g/day, administered as a 60-minutes infusion.
89493461|NCT03248063|Experimental|Cefazolin|Intravenous treatment by cefazolin, 25 to 50 mg/kg every 8 hours (without exceeding the maximum daily dose of 6 g/day), administered as a 30-minutes infusion.
89493462|NCT03225196||Samples|We seek to measure a 665 exRNAs spanning a variety of classes in plasma from 4095 young to middle-aged adult participants in the Third Generation cohort of the FHS
89493463|NCT03221257|Placebo Comparator|Placebo (Plac) + Mycophenolate (MMF)|Participants will receive Placebo (Plac) as add-on to a background therapy of Mycophenolate Mofetil (MMF).
89493464|NCT03221257|Experimental|Pirfenidone (PFD) + Mycophenolate (MMF)|Participants will receive Pirfenidone (PFD) as add-on to a background therapy of Mycophenolate Mofetil (MMF).
89493465|NCT03182465|Other|the predictive value of ProCalcitonin|Patients with solid tumors admitted at the emergency care presenting a febrile neutropenia due to chemotherapy
89493466|NCT02981173|Active Comparator|Psilocybin High Dose|
89493467|NCT02981173|Active Comparator|Psilocybin Low Dose|
89493468|NCT02981173|Placebo Comparator|Placebo|
89493469|NCT02980341|Experimental|Dose Escalation Part|Participants receive U3-1402 from 1.6 mg/kg to 9.6 mg/kg, administered via intravenous (IV) solution at 3-week intervals.
89493470|NCT02980341|Experimental|Dose Finding Part|Participants receive 1 of 5 different U3-1402 dosing regimens, administered via IV solution at 2 or 3-week intervals at doses at or lower than those studied in the Dose Escalation Part.
89022274|NCT00458016|Experimental|3|
89022275|NCT00458016|Experimental|4|
89022276|NCT00458016|Placebo Comparator|5|
89022277|NCT00351884|Experimental|vildagliptin am|
89022278|NCT00351884|Experimental|vildagliptin pm|
89022279|NCT00351884|Placebo Comparator|placebo|
89022280|NCT00351962|Experimental|Schedule I (10 fractions)|Subjects will receive a total of 10 stereotactic radiation treatments, given over 3 weeks.
89022281|NCT00351962|Experimental|Schedule II (4 fractions)|Subjects will receive a total of 4 stereotactic radiation treatments, given over 2 weeks.
89204741|NCT00999700|Active Comparator|ARM B|RT + Cddp (RTOG, Adelstein, J Clin Oncol 2003)
89493471|NCT02980341|Experimental|Dose Expansion Part|Participants with HER3 high, HER2 negative, HR positive status receive 4.8 mg/kg or 6.4 mg/kg of U3-1402 administered via intravenous (IV) solution at 3-week intervals. Participants with HER3 low, HER2 negative, HR positive status receive 6.4 mg/kg of U3-1402 administered via intravenous (IV) solution at 3-week intervals. Participants with HER3 high, HER2 negative, HR negative status receive 6.4 mg/kg of U3-1402 administration via intravenous (IV) solution at 3-week intervals.
89493472|NCT02978326|Experimental|Part A: SAGE-217 15/20 mg Oral Solution|Participants received SAGE-217, 15 milligrams (mg), oral solution, twice daily (BID) for first 2 days followed by SAGE-217, 15 or 20 mg, oral solution, BID, starting on Day 3 for up to 14 days as tolerated.
89493473|NCT02978326|Placebo Comparator|Part B: Placebo|Participants received SAGE-217 matching placebo, capsules, orally, once daily, for up to 14 days.
89493474|NCT02978326|Experimental|Part B: SAGE 217 30 mg Capsules|Participants received SAGE-217, 30 mg, capsules, orally, once daily, for up to 14 days.
89493475|NCT02967172|Experimental|Peri-incisional injection|"A single, 25 cc multimodal analgesic cocktail will be injected following completion of ankle fracture fixation/instrumentation while the patient remains under general anesthesia and prior to skin closure. The injection will be administered as such:~20 mL injected into the peri-incisional soft tissues in a circumferential fashion~5mL injected into the ankle joint This cocktail includes 200 mg of 0.8% ropivacaine, 0.6 mg of epinephrine, 5 mg of morphine sulfate, and sodium chloride solution. All infiltrations will be completed with a blunt trochar to minimize the risk of intravascular injection.~Interventions:~Drug: Ropivacaine Drug: Epinephrine Drug: Morphine Drug: 0.9% sodium chloride solution Following surgery, patients in the treatment and non-treatment groups will both be provided with the same intravenous (patient-controlled analgesia) and oral pain medications scheduled per needed."
89022282|NCT04698798|Experimental|Skeletal muscle wasting|investigating acute skeletal muscle wasting in patients infected with SARS-CoV-2 and admitted to the ICU
89022283|NCT00352196|Experimental|Magnetic Resonance Spectroscopy|Subjects will receive a baseline MRS prior to and within 7 day of completing 12 weeks of standard treatment with.
89022284|NCT00352196|Other|NO-MRS|Subjects will receive 12 weeks of standard treatment of risperidone 0.25 to 11 mg per day, or early termination. Dose titration will based on response and tolerability.
89022285|NCT00450879|Experimental|Treatment (pazopanib hydrochloride)|Patients receive pazopanib hydrochloride PO QD for 12-20 days in the absence of disease progression or unacceptable toxicity. Patients then undergo surgical resection of tumor between days 13 and 21 (24 hours after completion of pazopanib hydrochloride).
89022286|NCT00352313|Experimental|Phase I|Patients receive ATN-161 IV over 10 minutes 3 times weekly in weeks 1-6 and carboplatin IV over 20 minutes in week 3 during course 1. Beginning in course 2, patients receive carboplatin IV over 20 minutes in week 1 and ATN-161 IV over 10 minutes 3 times weekly in weeks 1-4. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.
89022287|NCT00352313|Experimental|Phase II|Patients receive carboplatin IV in week 1 and ATN-161 IV, at the MTD determined in phase I, 3 times weekly in weeks 1-4. Treatment repeats every 4 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.
89022288|NCT00450957|Experimental|Arm I (high-dose lycopene)|Participants receive high-dose oral lycopene once or twice a day for 14 days. After 2 weeks of a lycopene-free period, participants crossover and receive high-dose lycopene at the alternative daily schedule (once or twice a day) for 14 days.
89493476|NCT02967172|No Intervention|Control|Ankle fracture fixation/instrumentation will be completed per the standard of care. No peri-incisional injection will be completed.
89493477|NCT02916316||Chemo immunotherapy|All patients enrolled in the study will have to be treated with a chemo immunotherapy scheme R-CHOP with doxorubicin, with doxorubicin analogue or non pegylated liposomal anthracycline (R-COMP; Sec. 648 DM) administered every 21 days for 6 cycles. In unfavourable patients (stage II-IV) are allowed 2 additional cycles of rituximab at the end of the 6 cycles of R-CHOP.
89493478|NCT02879864|Experimental|Light therapy|Light therapy takes place in the patient's home the day following receipt of the equipment and for at least 7 days before the start of chemotherapy and according to current recommendations: daily exposure to a high intensity light (10,000 lux) in the morning at a time to be adapted to the patient according to his chronotype), for 30 minutes. Light therapy begins immediately after receipt of the luminometer. The total duration of daily outpatient therapy program is 6 months. A set of questionnaires evaluation of fatigue and quality of life will be given to the patient at the inclusion visit and at weeks 12 and 24. They will complete the same day or the day before, and / or before any chemotherapy. A follow-up visit will be performed 1 month after the end of therapy (week 28).
89493479|NCT02879864|Active Comparator|usual care|usual care in oncology: The patient will be taken care of according to local chemotherapy in routine care and the recommendations. A set of questionnaires evaluation of fatigue and quality of life will be given to the patient at baseline and at weeks 12 and 24. They will complete the same day or the day before, and / or chemotherapy before . A follow-up visit will be performed 1 month after the last visit (week 28). A set of questionnaires evaluation of fatigue and quality of life will be given to the patient and will complete the same day or the day before
89493480|NCT02864108||Those with trisomy 21|People aged 6 months to 89 years old who have some form of trisomy 21.
89493481|NCT02864108||Controls|People aged 6 months to 89 years old who do not have trisomy 21. These persons can be related to someone with some form of trisomy 21 but do not have to be related.
89493482|NCT02853214|Experimental|Identification of genetic factors in dysglobulinemia cases|
89493483|NCT02834403|Experimental|L-NMMA 7.5 mg/kg and Docetaxel 75 mg/m2|Phase Ib: L-NMMA and docetaxel will be given for 6 21-day cycles. L-NMMA at doses of 7.5 mg/kg (starting dose) will be administered IV on Days 1-5. Docetaxel will be administered at 75 mg/m2 as an IV 15 min after L-NMMA infusion Day 1.
89493484|NCT02834403|Experimental|L-NMMA 10 mg/kg and Docetaxel 75 mg/m2|Phase Ib: L-NMMA and docetaxel will be given for 6 21-day cycles. L-NMMA at doses of 10 mg/kg will be administered IV on Days 1-5. Docetaxel will be administered at 75 mg/m2 as an IV 15 min after L-NMMA infusion Day 1.
89493485|NCT02834403|Experimental|L-NMMA 12.5 mg/kg and Docetaxel 75 mg/m2|Phase Ib: L-NMMA and docetaxel will be given for 6 21-day cycles. L-NMMA at doses of 12.5 mg/kg will be administered IV on Days 1-5. Docetaxel will be administered at 75 mg/m2 as an IV 15 min after L-NMMA infusion Day 1.
89493486|NCT02834403|Experimental|L-NMMA 15 mg/kg and Docetaxel 75 mg/m2|Phase Ib: L-NMMA and docetaxel will be given for 6 21-day cycles. L-NMMA at doses of 15 mg/kg will be administered IV on Days 1-5. Docetaxel will be administered at 75 mg/m2 as an IV 15 min after L-NMMA infusion Day 1.
89493487|NCT02834403|Experimental|L-NMMA 17.5 mg/kg and Docetaxel 100 mg/m2|Phase Ib: L-NMMA and docetaxel will be given for 6 21-day cycles. L-NMMA at doses of 17.5 mg/kg will be administered IV on Days 1-5. Docetaxel will be administered at 100 mg/m2 as an IV 15 min after L-NMMA infusion Day 1.
89022289|NCT00450957|Experimental|Arm II (low-dose lycopene)|Participants receive low-dose oral lycopene once or twice a day for 14 days. After 2 weeks of a lycopene-free period, participants crossover and receive low-dose lycopene at the alternative daily schedule (once or twice a day) for 14 days
89022290|NCT00352391||Vanguard Study|Patients with Head and Neck or Non-Small Cell Lung Cancer who are Current or Former Smokers.
89022291|NCT03275844||Group 1|Children with congenital heart disease
89493488|NCT02834403|Experimental|L-NMMA 20 mg/kg and Docetaxel 100 mg/m2|Phase Ib: L-NMMA and docetaxel will be given for 6 21-day cycles. L-NMMA at doses of 20 mg/kg will be administered IV on Days 1-5. Docetaxel will be administered at 100 mg/m2 as an IV 15 min after L-NMMA infusion Day 1.
89493489|NCT02834403|Experimental|Phase II: RP2D determined in the Phase Ib|Phase II: L-NMMA starting dose will be the RP2D determined in the Phase Ib portion of the study.
89493490|NCT02682511|Experimental|Patients with dcSSc|Patients with dcSSc will be randomized to receive either oral ifetroban or oral placebo daily for 365 days
88954220|NCT01970163|Placebo Comparator|Conventional care dressings|Currently accepted standard of care wound management including Conventional care dressings will be utilized in subjects with a diagnosis of either diabetic foot ulcer or venous stasis ulcer.
88954221|NCT01970163|Active Comparator|GraftJacket|GraftJacket acellular dermal matrix will be used in those subjects diagnosed with a diabetic foot ulcer.
88954222|NCT01970189||Primary Immune Thrombocytopaenia|Recently-diagnosed (i.e. < 6 months) primary ITP adult patients (≥ 18 years) characterized by platelet counts less than 100x109/L as defined by the International Working Group.
88954223|NCT01970202|Active Comparator|40mg Enoxaparin|Patients with obesity undergoing laparoscopic sleeve gastrectomy, will receive 40mg Enoxaparin per day for 3 days after surgery by subcutaneous administration.
88954224|NCT01970202|Active Comparator|60mg Enoxaparin|Patients with obesity undergoing laparoscopic sleeve gastrectomy, will receive 60mg Enoxaparin per day for 3 days after surgery by subcutaneous administration.
88954225|NCT01970202|Other|Control|no treatment
88954226|NCT01970215|Placebo Comparator|Group 1|TA-8995 0mg (placebo) & placebo statin
88954227|NCT01970215|Experimental|Group 2|TA-8995 1mg & placebo statin
88954228|NCT01970215|Experimental|Group 3|TA-8995 2.5mg & placebo statin
88954229|NCT01970215|Experimental|Group 4|TA-8995 5mg & placebo statin
88954230|NCT01970215|Experimental|Group 5|TA-8995 10mg & placebo statin
88954231|NCT01970215|Active Comparator|Group 6|TA-8995 0mg (placebo) & atorvastatin 20mg
88954232|NCT01970215|Active Comparator|Group 7|TA-8995 10mg & atorvastatin 20mg
88954233|NCT01970215|Active Comparator|Group 8|TA-8995 0mg (placebo) & rosuvastatin 10mg
88954234|NCT01970215|Active Comparator|Group 9|TA-8995 10mg & rosuvastatin 10mg
88954235|NCT01970228|Active Comparator|Adverse reaction to metal debris|68Ga-citrate and 19F-FDG PET/CT imaging of hip replacement patients with adverse tissue reactions to metal debris
88954236|NCT01970228|Active Comparator|Periprosthetic joint infection|68Ga-citrate and 19F-FDG PET/CT imaging of hip replacement patients with periprosthetic joint infection
88954237|NCT01970228|Active Comparator|Aseptic mechanical implant loosening|68Ga-citrate and 19F-FDG PET/CT imaging of patients with aseptic mechanical loosening of hip prosthesis
89204742|NCT00818298|Experimental|1|ziprasidone
89493491|NCT02682511|Experimental|Patients with SSc-PAH|Patients with SSc-PAH will be randomized to receive either oral ifetroban or oral placebo daily for 365 days
89493492|NCT02620852|Active Comparator|Annual Arm|Women in this arm will receive Athena standard of care mammography screening, including annual mammograms. They will complete a health questionnaire and receive screening advice based on a basic risk assessment.
89493493|NCT02620852|Experimental|Risk-Based Arm|Women in this arm will receive risk-based screening, where risk is calculated based on a model including personal history, family history, and genetic testing. All women in the risk-based arm complete a health questionnaire, provide a saliva sample for genetic testing, and receive screening advice based on a comprehensive risk assessment. Women in this arm will be tested for a panel of 9 genes related to breast cancer risk as well as a panel of SNPs, which can further modify risk. Women will be assigned a screening start date, screening stop date, and screening frequency.
89493494|NCT02576795|Experimental|valoctocogene roxaparvovec|Single administration of valoctocogene roxaparvovec at escalating doses.
89493495|NCT02541435||conventional radiotherapy|450 breast cancer patients treated with conventional radiotherapy with or without anthracyclines and/or trastuzumab during 2007-2012
89493496|NCT02541435||breath controlled radiotherapy|350 breast cancer patients treated with laser assisted breath controlled radiotherapy with or without anthracyclines and/or trastuzumab during 2015-2017
89493497|NCT02541435||controls|per participating patient 2 age-matched female controls from the HUNT-3 population (total 800)
89493498|NCT02456974||amoxicillin-clavulanate|Patients receiving amoxicillin-clavulanate as part of routine clinical care.
89493499|NCT02456974||piperacilline-tazobactam|Patients receiving piperacilline-tazobactam as part of routine clinical care.
89493500|NCT02456974||vancomycin|Patients receiving vancomycin as part of routine clinical care.
89493501|NCT02456974||teicoplanin|Patients receiving teicoplanin as part of routine clinical care.
89493502|NCT02456974||meropenem|Patients receiving meropenem as part of routine clinical care.
89493503|NCT02456974||ciprofloxacin|Patients receiving ciprofloxacin as part of routine clinical care.
89493504|NCT02456974||amikacin|Patients receiving amikcain as part of routine clinical care.
89493505|NCT02414477|Experimental|Smokeless tobacco study product|Smokeless tobacco product spiked with deuterated NNN.
89493506|NCT02411656|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab 200mg IV over approximately 30 minutes on day 1. Cycles repeat every 21 days for 8 cycles and then pembrolizumab 400mg IV every 42 days for total up to 24 months in the absence of disease progression or unacceptable toxicity
89493507|NCT02392455||A|
89493508|NCT02300961|Experimental|Cognitive rehabilitation arm|Cognitive rehabilitation program
89493509|NCT02225171||Physicians|15 physicians each will be interviewed from the specialties of reproductive endocrinology and obstetrics/gynecology.
89493510|NCT02091245|Experimental|KPT-330|KPT-330 will be administered twice a week on Days 1 and 3 for four weeks. Starting dose 30 mg/m2.In the dose-escalation cohort, three patients will initially be enrolled at each dose level and will be monitored for a DLT during the 28-day treatment cycle before dose escalation may occur.
89493511|NCT02060188|Experimental|Nivolumab Monotherapy|
89022292|NCT03275844||Group 2|Control healthy subjects
89022293|NCT00352469|Placebo Comparator|2|Subjects will be randomized to receive either Seroquel SR or placebo
89493512|NCT02060188|Experimental|Nivolumab + Ipilimumab|
89493513|NCT02060188|Experimental|Nivolumab + Ipilimumab Cohort C3|
89493514|NCT02060188|Experimental|Nivolumab + Ipilimumab + Cobimetinib Cohort C4|
89493515|NCT02060188|Experimental|Nivolumab + BMS-986016 Cohort C5|
89493516|NCT02060188|Experimental|Nivolumab + Daratumumab Cohort C6|
89204743|NCT00821574|Experimental|1|Fluvastatin: daily 80 mg, oral
89204744|NCT00821574|Experimental|2|Valsartan
89204745|NCT00821574|Experimental|3|Hydrochlorothiazide
89204746|NCT00995800|Active Comparator|Fluticasone propionate / Formoterol fumarate|
89204747|NCT00995800|Placebo Comparator|Fluticasone propionate / Formoterol fumarate placebo|
89204748|NCT00993850|Other|Bipolar disorder education|Psychoeducation
89204749|NCT00993850|Other|Cognitive behavioral therapy|Cognitive behavioral therapy for insomnia
89204750|NCT00816192|Active Comparator|1|"The externally irrigated-tip catheter is an open system in which saline is continuously infused and empties into the blood pool. For the externally irrigated-tip catheter, RF energy delivery settings were: power ≤ 35 watts and temperature ≤ 43°C with a variable flow-rate to obtain a temperature around 40°C."
89493517|NCT02027818|Experimental|Indocyanine Green|study of the correlation between fluorescence and margins of the tumours after iv injection of Indocyanine Green
89493518|NCT02003950|Other|Chocolate pre-restriction|
89493519|NCT02003950|Other|Chocolate Baseline|
89493520|NCT02003950|Other|Chocolate post-restriction|
89493521|NCT02003950|Other|Salty Snacks|
89493522|NCT02003950|Other|Sweet Non-Chocolate Snacks|
89493523|NCT02003950|Other|Dried Fruit|
89493524|NCT01966731|Experimental|Hydroxyurea|After patient enrollment, a two-month pre-hydroxyurea evaluation phase will be used to perform baseline evaluations including nutritional and infectious assessments, and to provide supplements or treatments as deemed necessary. After the pre-hydroxyurea evaluation and supplementation phase, hydroxyurea dosing will be administered as a single daily dose, using capsules provided as a monthly supply in 200mg, 300mg, 400mg, or 500mg sizes.
89493525|NCT01958307|Experimental|Intervention|Lifestyle intervention
89493526|NCT01958307|No Intervention|No intervention|Standard prenatal care, short information leaflet about healthy lifestyle in pregnancy
89493527|NCT01946074|Experimental|Monotherapy|ABT-165 will be administered at escalating dose levels in 28-day dosing cycles (2 doses per cycle). Additional subjects will be enrolled in an expansion cohort that will further evaluate ABT-165
89493528|NCT01946074|Experimental|Cohort A|ABT-165 plus paclitaxel
89493529|NCT01946074|Experimental|Cohort B|ABT-165 plus FOLFIRI
89493530|NCT01946074|Experimental|Cohort C|ABT-165 plus ABBV-181
89493531|NCT01946074|Experimental|Cohort D|ABT-165 plus ABBV-181 plus paclitaxel
89493532|NCT01813968|Experimental|Ischemic postconditioning|"Ischemic postconditioning via the cardioplegia line starting with 2 min of reperfusion followed by 2 min of ischemia x 3"
89493533|NCT01813968|No Intervention|Control|Standard operating technique
89493534|NCT01791556|No Intervention|Standard of Care|clinical (World Health Organization staging) and immunological (CD4 count) monitoring every 6 months with confirmatory or targeted viral load monitoring based upon Kenya Ministry of Health and World Health Organization guidelines
89493535|NCT01791556|Experimental|HIV-1 viral load testing|viral load in addition to clinical (World Health Organization staging) and immunological (CD4 count) monitoring every 6 months
89493536|NCT01736059|Experimental|Stem cell treated|
89493537|NCT01484730||Vascular Occlusion|Multi-Spectral and Laser Speckle Imaging
89493538|NCT01397851|Experimental|Treatment: Insecticide-treated net|Smallholder farmers in the treatment group are informed that they won a raffle, and receive a free insecticide-treated net
89493539|NCT01397851|No Intervention|Control|Smallholder farmers in the control group are informed that they had a chance to win an insecticide-treated mosquito net in a raffle, but did not end up winning
89493540|NCT01254864|Experimental|Abiraterone Acetate + Prednisone (AP)|Abiraterone Acetate at 1000 mg orally each day, given in combination with 5 mg of Prednisone orally twice daily.
89493541|NCT01254864|Experimental|Group 1: AP + Sunitinib|AP (Abiraterone Acetate + Prednisone) Plus Sunitinib; Randomized from AP group to receive Sunitinib if disease worsens. Assignment to crossover group AP + Dasatinib with further disease progression.
89493542|NCT01254864|Experimental|Group 2: AP + Dasatinib|AP (Abiraterone Acetate + Prednisone) Plus Dasatinib; Randomized from AP group to receive Dasatinib if disease worsens. Assignment to crossover group AP + Sunitinib with further disease progression.
89493543|NCT01166893||Burn wound|Modulated Imaging and Laser Speckle Imaging
89493544|NCT01070212|Experimental|soft gum|. Participants will either chew nothing or chew one of the two gum varieties (flavorless soft or hard) at a constant rate (determined by a metronome) for 15 minutes while sipping apple juice through a straw. Appetite will be measured continuously via a slide potentiometer attached to a 100mm gLMS scale. The juice will provide 10% of the participants estimated daily energy requirement (i.e., equal to 1-2 servings of most commercial snacks). It will also contain 10g of lactulose (a soluble, non-absorbable carbohydrate used to assess gastric transit time via analyses of breath hydrogen) and acetaminophen (a marker for gastric emptying).
89493545|NCT01070212|Experimental|firm gum|. Participants will either chew nothing or chew one of the two gum varieties (flavorless soft or hard) at a constant rate (determined by a metronome) for 15 minutes while sipping apple juice through a straw. Appetite will be measured continuously via a slide potentiometer attached to a 100mm gLMS scale. The juice will provide 10% of the participants estimated daily energy requirement (i.e., equal to 1-2 servings of most commercial snacks). It will also contain 10g of lactulose (a soluble, non-absorbable carbohydrate used to assess gastric transit time via analyses of breath hydrogen) and acetaminophen (a marker for gastric emptying).
89493546|NCT01070212|Experimental|no gum|. Participants will either chew nothing or chew one of the two gum varieties (flavorless soft or hard) at a constant rate (determined by a metronome) for 15 minutes while sipping apple juice through a straw. Appetite will be measured continuously via a slide potentiometer attached to a 100mm gLMS scale. The juice will provide 10% of the participants estimated daily energy requirement (i.e., equal to 1-2 servings of most commercial snacks). It will also contain 10g of lactulose (a soluble, non-absorbable carbohydrate used to assess gastric transit time via analyses of breath hydrogen) and acetaminophen (a marker for gastric emptying).
89493547|NCT00968266|Experimental|Group intervention|"In short, the intervention consists of two group sessions moderated by a pharmacist. During these sessions, patients' self-perceived needs to take medication ('necessity beliefs'), concerns about taking medication ('concern beliefs'), and practical barriers are discussed. To explore a patient's individual ambivalence regarding his/her beliefs and barriers, the pharmacist uses Motivational Interviewing techniques. In between the sessions, participants make a homework assignment about their own beliefs and barriers, and eight weeks after the second session, a follow-up call to the individual patients is made by the pharmacist.~Patients in the experimental arm also receive a brochure about the DMARDs they currently use (see: control arm)"
89493548|NCT00968266|Active Comparator|Control arm: usual care|In the control arm, patients receive a brochure about the DMARDs they are currently using.
89493549|NCT00868283|Experimental|Cerebrolysin|
89493550|NCT00868283|Placebo Comparator|0.9% Saline Solution|
89493551|NCT00641238||Early stage NSCLC|Early stage non-small cell lung cancer
89493552|NCT00289068||Phacoemulsification Sleeve 2.2mm|Phacoemulsification Sleeve setting 2.2 mm Procedure/Surgery: Phacoemulsification Sleeves surgery
89493553|NCT00289068||Phacoemulsification Sleeve 2.8mm|Phacoemulsification Sleeve setting 2.8 mm Procedure/Surgery: Phacoemulsification Sleeves surgery
89493554|NCT00289068||Phacoemulsification Sleeve 3.0mm|Phacoemulsification Sleeve setting 3.0 mm Procedure/Surgery: Phacoemulsification Sleeves surgery
89493555|NCT04817306||Cancer Arm|Participants with new diagnosis of cancer, from whom blood samples will be collected
89493556|NCT04817306||Benign Diseases Arm|Participants with benign diseases corresponding to the tumor types in the Cancer Arm, from whom blood samples will be collected
89493557|NCT04817306||Non-tumor (Healthy) Arm|Participants without known presence of malignancies or benign diseases, from whom blood samples will be collected
89493558|NCT02121977|Active Comparator|Elevate Anterior and Apical|Prolapse repair with mesh
89493559|NCT02121977|Active Comparator|Native Tissue Repair|Prolapse repair with sutures
89493560|NCT02125175|Experimental|Hypofractionated IMRT boost Radiotherapy|
89493561|NCT04817150|Experimental|3D-laparoscopy|patients who underwent 3D laparoscopic ventral rectopexy
89493562|NCT04817150|Active Comparator|2D-laparoscopy|patients who underwent conventional 2D laparoscopic ventral rectopexy
89493563|NCT02127047|Experimental|Sitagliptin|Patients receive Sitagliptin (100mg/d) without further intervention
89493564|NCT02127047|Experimental|Sitagliptin and exercise|Patients receive sitagliptin (100mg/d) and follow a physical training intervention program
89022294|NCT00352703|Experimental|Kepivance (palifermin) 60 μg/kg/day IV|60 μg/kg/day IV for 3 consecutive days before the conditioning regimen and 3 consecutive days after the peripheral blood stem cell transplantation.
89022295|NCT00465855|Active Comparator|Hyperbaric Oxygen (HBO2) - 3 sessions|Subjects undergo 3 hyperbaric oxygen sessions within 24 hours following carbon monoxide poisoning.
89022296|NCT00465855|Sham Comparator|Hyperbaric Oxygen (HBO2) - 1 session|Subjects undergo 1 hyperbaric oxygen session and then 2 sham chamber sessions within 24 hours of carbon monoxide poisoning.
89493565|NCT04811690|Experimental|claim and imagery|control condition (status quo) showing a front-of-package (FOP) vitamin C claim and fruit imagery on all fruit-flavored drinks.
89493566|NCT04811690|Experimental|imagery only|FOP fruit imagery on all fruit-flavored drinks, no vitamin C claim on drinks high in added sugars (>=20 %DV)
89493567|NCT04811690|Experimental|claim only|FOP vitamin C claim on all fruit-flavored drinks, no fruit imagery on drinks high in added sugars
89493568|NCT04811690|Experimental|no claim or imagery|No FOP vitamin C claim or fruit imagery on drinks high in added sugars
89493569|NCT04811690|Experimental|claim, imagery, and % juice disclosure|FOP fruit imagery, vitamin C claim, and % juice disclosure on all fruit-flavored drinks
89493570|NCT04811690|Experimental|claim, imagery, and added sugar warning|FOP fruit imagery and vitamin C claim on all fruit-flavored drinks; added sugar warning on drinks high in added sugar
89493571|NCT04811690|Experimental|claim, imagery, and added sugar warning with teaspoons of added sugar disclosure|FOP fruit imagery and vitamin C claim on all fruit-flavored drinks; added sugar warning with teaspoons of added sugar disclosure on drinks high in added sugar
89493572|NCT02122055|Experimental|Propofol/Dexmedetomidine|"Propofol is started with dosage of 0.3 mg/kg/h, observe the patient's response, increase 0.3 mg/kg/h propofol every 10 minutes until target sedation level is obtained(Riker Sedation Agitation Score(SAS) 3-4),then 0.3-3 mg/kg/h propofol is maintained.~After the screen of the weaning is passed, change to Dexmedetomidine sedation, the dose is 0.2-0.7 mg/kg/h and continuously pumped, increase the dose 0.1-0.2 mg/kg/h every 30 minutes, titrate to Riker Sedation Agitation Score(SAS) 3-4，the maximum dose is 1 mg/kg/h maintained，and prepare for weaning."
89493573|NCT02122055|Experimental|Midazolam/Dexmedetomidine|"Midazolam 2 mg is slowly titrated to Riker Sedation Agitation Score(SAS) 3-4 every 10 minutes, then Midazolam 0.02-0.1 mg/kg/h is maintained.~After the screen of the weaning is passed, change to Dexmedetomidine sedation, the dose is 0.2-0.7 mg/kg/h and continuously pumped, increase the dose 0.1-0.2 mg/kg/h every 30 minutes, titrate to Riker Sedation Agitation Score(SAS) 3-4，the maximum dose is 1 mg/kg/h maintained，and prepare for weaning."
89493574|NCT04801628|Active Comparator|Active Tecar|"Transfer Electrode Capacitive and Resistive (TECAR) Therapy (radio frequency therapy; INDIBA, Spain) will be used. In CET mode, heat transfer is concentrated on the skin and superficial muscles, which are tissue with high electrolytes, while the RET mode focuses heat transfer on bones, tendons, joints, and deep muscles. In this study, both CET and RET modes will be applied to the participant' quadriceps for 15-20 minutes at stable frequency of 448 KHz. According to the manufacturer's guidelines for safety, the CET mode will be first implemented for 5 minutes. Then will be continued in RET mode using for the rest of the treatment. Participants will be asked to lie down comfortably, and treatment will be beginning.~The intensity of the current will be set at the level of comfort between 0%-100%, averaging about 40%. TECAR therapy will be applied by a physical therapist for all participants."
89493575|NCT04801628|Placebo Comparator|Placebo Tecar|the same procedure as in active Tecar but the device not provide any radio frequency
89493576|NCT04801082|Active Comparator|EUS-CPB|Endoscopic Ultrasound Guided Coeliac Plexus Block
89493577|NCT04801082|Active Comparator|EUS-CPA|Endoscopic Ultrasound Guided Coeliac Plexus Radiofrequency Ablation
89493578|NCT02127203||Chronic Periodontitis group (ChP)|20 patients aged > 45 years and have presence of ≥2 non-adjacent sites per quadrant that were not first molars or incisors, with probing depth (PD) ≥5 mm, which bleed on gentle probing. The demonstrated radiographic bone loss ≥30% of the root length, patient with poor oral hygiene, the amount of accumulated plaque commensurate with the amount of clinical attachment level (CAL)
89493579|NCT02127203||Resistant Control group (R)|20 age-sex matched patients who are > 45 years exhibit no signs of periodontal disease as determined by the absence of the evidence of interproximal (CAL ≤ 1mm), PD > 3 mm at any site, whole-mouth bleeding scores <10% and have no clinical signs of gingival inflammation .
89493580|NCT02127203||Aggressive Periodontitis group (AgP)|20 patients who are aged < 35 years and diagnosed with rapid attachment loss with periodontal pocket depth (PD) > 4 mm around at least three teeth other than the first molars and incisors. Rapid bone destruction (>50%bone loss at diseased sites). Weak relationship between dental plaque and the severity of gingival inflammation.
89022297|NCT00352742|Experimental|1|ATN-224 + bortezomib
89022298|NCT00352820||Interview + Questionnaire|
89022299|NCT00352859|Experimental|Arm 1|
89022300|NCT00352859|Experimental|Arm 2|
89022301|NCT00105183|Active Comparator|EZ-2053|Anti-human-T-lymphocyte Immune Globulin, Rabbit (EZ-2053)
89022302|NCT00105183|Placebo Comparator|Placebo|USP 0.9% sodium chloride solution
89022303|NCT00105183|Active Comparator|EZ-2053 5mg/kg|Anti-human-T-Lymphocyte Immune Globulin, Rabbit
89022304|NCT00466089|Experimental|1|RT + Tarceva
89022305|NCT00466089|No Intervention|2|RT
89022306|NCT00466245|Experimental|A|Previously vaccinated for smallpox, 1x10-8 dose
89022307|NCT00466245|Experimental|B|Smallpox vaccine naive, 1x10-8 dose
89493581|NCT02127203||Young Control group (YC)|20 age- and sex matched patients who are < 35 years and exhibit no signs of periodontal disease.
89493582|NCT04816994|Experimental|High dose cannabis oil|Single-dose 20.0 mg tetrahydrocannabinol + 20 mg cannabidiol, Sub-linguistic.
89493583|NCT04816994|Experimental|Low dose cannabis oil|Single-dose 10 mg tetrahydrocannabinol + 10 mg cannabidiol, Sub-linguistic.
89493584|NCT04816994|Placebo Comparator|Control|Single-dose Olive oil that is similar in appearance and taste to cannabis oil
89493585|NCT02125409|Experimental|Group 1|Group 1, individuals will be treated with ASA for 1 week; then blood and tissue samples (during the screening colonoscopy) will be collected at from 6-7 h after the last dose of ASA.
89493586|NCT02125409|Experimental|Group 2|Group 2, individuals will be treated with ASA for 1 week; then blood and tissue samples (during the screening colonoscopy) will be collected at 24 hours after the last dose.
89493587|NCT02125487|Active Comparator|Low-Fidelity Simulation|Teaching using traditional method
89493588|NCT02125487|Experimental|Hybrid Simulation|Teaching using Hybrid Simulation of breast examination
89493589|NCT04811768|Experimental|Bony wall group|In the bony wall group, following piezosurgery the retrieved bony wall was repositioned.
89493590|NCT04811768|Experimental|Collagen membrane group|In the collagen membrane group, the lateral window was created by rotary instruments, covered via a native collagen membrane (collprotect, botiss biomaterials GmbH, Zossen, Germany).
89493591|NCT02122133||PC 400|Patients treated with the PC 400 according to the IFU
89493592|NCT02122133||Conventional Embolic Coils|These are any approved embolic coils on the market used as part of the standard of care for treating intracranial aneurysms.
89493593|NCT04816838|Experimental|N/A(Single Arm)|
89493594|NCT04816448|Experimental|Studygroup|cervical mobilization (Headache SNAG) with baseline treatment (Hot pack for 10 minutes, TENS 10 minutes, Neck isometrics and stretching).
89493595|NCT04816448|Active Comparator|Control Group|Sub-occipital myofascial release with baseline treatment (Hot pack for 10 minutes, TENS for 10 minutes, Neck isometrics and stretching
89493596|NCT04811612|Experimental|Infants sampled for warmed and unwarmed heel stick glucose measurements|This single study arm will be samples for blood glucose measurement using both a warmed and unwarmed heel.
89493597|NCT02788175|Experimental|HIV-infected Adults on cART|HIV-infected Adults (age 18 - 65) on CART with suppressed viremia
89493598|NCT04811456||MIS-C|"Cases fulfilling following criteria:~fever ≥3 days~at least two of the following:~rash or bilateral conjunctivitis or mucocutaneous inflammation signs~hypotension~features of myocardial dysfunction, pericarditis, or coronary artery abnormality, based on echocardiographic findings or elevated B-type natriuretic peptide (BNP)/N-terminal-pro-BNP (NT-proBNP) or troponin~evidence of coagulopathy~acute gastrointestinal problems~elevated inflammatory markers AND~no other apparent microbial cause~evidence of COVID-19 (positive real-time polymerase chain reaction, antigen test or serology), or personal history of COVID-19 or contact with a proven COVID-19 case"
89493599|NCT03551171|Experimental|ZL-2306 (niraparib)|Subjects will be randomised into 100mg, 200mg, 300mg dose group at the first day of the first cycle.
89493600|NCT02787083|Experimental|Mirabegron|These patients will receive mirabegron 50mg tablets daily for 12 weeks.
89493601|NCT02787083|Placebo Comparator|Placebo|These patients will receive placebo tablets daily for 12 weeks.
89493602|NCT04800848||Mask/No Mask|"The group will perform both situations in a randomized cross-over design:~1. Scholars will perform the fitness test with the use of a N95/FFP2 face mask~2. Scholars will perform the fitness test without the use of a N95/FFP2 face mask"
89493603|NCT02122211|Experimental|Betaine supplement|Will use powdered betaine (BetaPower, Dupont Nutrition) that is commercially available for food uses. This powder will be delivered as capsules containing 0.5 gram of powdered betaine which will be administered as eleven capsules twice per day (6 in the morning, 5 in the evening) for a daily total of 6 grams of betaine.
89493604|NCT04800926|Experimental|Xavier wheelchair controller|Surface electromyography control of wheelchair
89493605|NCT02125565|Experimental|Local Anaesthesia|These subjects received an injection of lidocaine 1% 2ml subcutaneously prior to arterial puncture
89493606|NCT02125565|No Intervention|No Local Anaesthesia|Patients underwent arterial puncture directly with NO prior anaesthesia
89493607|NCT04800380|No Intervention|Routine training|Nursing students in the control group will receive training in routine metric and drug dose calculation in virtual environment.
89493608|NCT04800380|Experimental|Edpuzzle application|Students in the intervention group will watch the routine metric and drug dose calculation training in virtual environment, as well as interactive videos prepared by the first researcher and uploaded to the Edpuzzle application.
89493609|NCT02122289|Experimental|Application of Smartphone|Weekly questionnaire on Smartphone
89493610|NCT02122289|Placebo Comparator|No application Smartphone|No Weekly questionnaire on Smartphone
89493611|NCT02125643|Active Comparator|Caffeine Pill|The caffeine will be administered.
88954238|NCT01970267|Active Comparator|Laser Treated|Laser will direct the laser at vitreous opacities. The power of the laser will be adjusted from 0.3-12 millijoules (mJ) with the end point being laser induced optical breakdown and the production of a small gas bubble 50% of the time. The treatment will attempt to reduced or eliminate symptomatic floaters in the visual axis. Each treatment session will be limited to 300 laser applications. Participants will be retreated based on continued symptoms for up to 5 sessions
88954239|NCT01970267|Sham Comparator|Not Treated|
88954240|NCT01970280|Active Comparator|Enoxaparin|Following a first AV graft thrombosis and successful thrombolysis with angioplasty, patients on chronic hemodialysis will be randomized to s.c Enoxaparin (Clexane) 0.5 mg/1kg of body weight per day or control group (not on Clexane).
88954241|NCT01970280|No Intervention|Observation|
88954242|NCT01970293|Other|Introduction to AA volunteer|
88954243|NCT01970293|No Intervention|AA materials offered|
88954244|NCT01970319||Diabetic with nephropathy|
89493612|NCT02125643|Placebo Comparator|Placebo/Flour Pill|The flour will be administered.
89493613|NCT04811144|Experimental|Cavity group|The 35 participants accepted Er:YAG laser treatment for dental cavity. Each participant was collected their data including history records, affected range check, X-ray&photo, treatment, pain index check, return visit check after two weeks by researchers.
89493614|NCT04811144|Experimental|Sensitive Teeth group|The 35 participants accepted Er:YAG laser treatment for sensitive teeth. Each participant was collected their data including history records, sensitive check, X-ray&photo, treatment, pain index and effectiveness check, return visit check after two weeks by researchers.
89493615|NCT04811144|Experimental|Abnormal Frenum Attachment group|The 35 participants accepted Er:YAG laser treatment for Abnormal Frenum Attachment. Each participant was collected their data including history records, abnormal position check, photo, cutting, pain index check, return visit check after three, five and seven days. by researchers.
89022308|NCT00466245|Experimental|C|Previous smallpox vaccination, 1x10-7 dose
89493616|NCT04811144|Experimental|Peri-implantitis intervention group|The 12 participants accepted Er:YAG laser treatment for Peri-implantitis. Each participant was collected their data including History records, measure periodontal pocket depth, anaerobes collect, X-ray, photo, CT, treatment, pain index check, return visit check after one week, two weeks, four weeks and three months, and six month check the effectiveness and collect anaerobes during every return visit. In the last return visit, X-ray and CT would be included
89493617|NCT04811144|No Intervention|Peri-implantitis control group|The 12 participants accepted mechanical debridement for Peri-implantitis. Each participant was collected their data including History records, measure periodontal pocket depth, anaerobes collect, X-ray, photo, CT, treatment, pain index check, return visit check after one week, two weeks, four weeks and three months, and six month check the effectiveness and collect anaerobes during every return visit. In the last return visit, X-ray and CT would be included
89493618|NCT02122367|Experimental|stroke volume variation, pleth variability index|"stroke volume variation: recorded using the FloTrac/Vigileo system (Edwards Lifesciences)~pleth variability index: recorded using the Masimo Radical-7 monitor (Masimo Corporation, Irvine, CA, USA)"
89493619|NCT04797806|Experimental|combination therapy|Anlotinib Combined With Icotinib
89493620|NCT04797806|Other|monotherapy|Icotinib
89493621|NCT02122523|Experimental|SLN identification with NIR-dye-subserosa injection|Near-Infrared (NIR) dye Indocyanin Green (ICG) to identify nodes with a newly developed NIR laparoscope. The investigators compared two different injection techniques; subserosal and submucosal injection.
89493622|NCT02122523|Active Comparator|SLN identification with NIR-dye-submucosal injection|Near-Infrared (NIR) dye Indocyanin Green (ICG) to identify nodes with a newly developed NIR laparoscope. The investigators compared two different injection techniques; subserosal and submucosal injection.
89493623|NCT04811378|Active Comparator|HaemoCer|
89493624|NCT04811378|No Intervention|No HaemoCer|
89493625|NCT03551483|Experimental|ArtontheBrain|ArtontheBrain application for about 30 to 45 minutes twice per week, over 6 weeks.
89493626|NCT03551483|Active Comparator|Seniors Online Victoria|Senior Online Victoria games for about 30 to 45 minutes twice per week, over 6 weeks (https://www.seniorsonline.vic.gov.au/services-information/games), after which they will participate in the ArtontheBrain intervention.
89493627|NCT03551483|Other|Waitlist Control|The waitlist control group will no treatment for 6 weeks, after which they will six weeks of the ArtontheBrain intervention.
89493628|NCT04811222|Experimental|Ga-DOTATATE PET/MRI scan|Patients with abdominal aortic aneurysm will undergo Ga-DOTATATE PET/MRI scan
89493629|NCT02127359||Lung/Colon Adenocarcinomas|Metastatic lung and colon adenocarcinomas
89493630|NCT02127437|Experimental|A - treated group|
89493631|NCT02127437|Placebo Comparator|B - control group|
89022309|NCT00466245|Experimental|D|Smallpox vaccine naive, 1x10-7 dose
89493632|NCT04797494|No Intervention|Control Group|No acrylic Removable Appliance (RA) was prescribed for patients prior to restorative treatment of generalized severe tooth wear.
89022310|NCT00466245|Experimental|E|Previous smallpox vaccination, 1x10-6 dose
89022311|NCT00466245|Experimental|F|Smallpox vaccine naive, 1x10-6 dose
89022312|NCT00466245|Experimental|G|Previous smallpox vaccination, placebo dose
89022313|NCT00466245|Experimental|H|Smallpox vaccine naive, placebo dose
89022314|NCT00353015|Experimental|Irinotecan plus Cisplatin|Irinotecan 65 mg/m2 and Cisplatin 25 mg/m2 intravenous (IV) days 1, 8 of a 21-day cycle
89493633|NCT04797494|Experimental|Experimental Group|A acrylic Removable Appliance (RA) was prescribed for patients prior to restorative treatment of generalized severe tooth wear. Patients were asked to wear the RA 3 weeks prior to restorative treatment for 24h per day, except for when eating.
89493634|NCT02127515|Experimental|Non Invasive Prenatal Testing|Blood sample
89493635|NCT02127515|Active Comparator|Invasive Prenatal Testing|CVS or amniocentesis
89493636|NCT04799678||Participants|Current user of the Smart Asthma app
89493637|NCT04799600||Acute Renal Failure in ICU|COVID-19 Patients with Acute Renal Failure in ICU
89493638|NCT04799444||Adult patients with complications post COVID-19|
89493639|NCT04799444||Children with complications post COVID-19|
89493640|NCT02122601|Other|LBSA0103|single arm , LBSA0103 only
89493641|NCT04799366||MC|MC patients with either dominant (Thomsens) or recessive (Becker) myotonia.
89493642|NCT04799366||Healthy Controls|Healthy controls age- and gender matched.
89493643|NCT02127593|Experimental|First NGM/EE (Wet Process), then NGM/EE (Dry Process)|Participants will receive 1 tablet (formulated by wet process) containing norgestimate 250 microgram (mcg) and ethinyl estradiol 35 mcg, orally on Day 1 of Period 1, followed by 1 tablet (formulated by dry process) containing norgestimate 250 mcg and ethinyl estradiol 35 mcg, orally on Day 1 of Period 2, wherein Period 1 and Period 2 are separated by a wash out period of at least 10 days.
89204751|NCT00816192|Experimental|2|"For the internally irrigated tip catheter (reference catheter), radiofrequency (RF) energy delivery settings will be: power ≤ 35 watts, temperature ≤ 47◦C and a fixed flow rate of 0.6 ml/s.~The advantage of the Chili thermo-cooled tip system is that no saline solution leaves the catheter system and flows into the patient."
89204752|NCT00999778|Active Comparator|Caregiver Education Intervention|10 1:1,one hour sessions weekly for 10 weeks with parent and interventionist. Behavioral education strategies will be targeted
89204753|NCT00999778|Active Comparator|Caregiver-Mediated Intervention|One hour 1:1 with parent, child and interventionist, each week, for 10 weeks social communication and joint engagement strategies will be targeted
89204754|NCT00821652|Other|Dose-esclation|Part I represents a dose-escalation part with topical resiquimod in an open-label fashion.
89204755|NCT00821652|Experimental|2|Part II: Eligible patients will be randomized to receive a subcutaneous vaccination of 100µg NY-ESO-1 protein emulsified in 1.25mL Montanide ISA®-51 VG (day 1) followed by topical placebo gel (Arm A) or topical resiquimod gel (Arm B) on days 1, 3 and 5; or resiquimod dosing regimen established in Part I.
89204756|NCT00761657|Experimental|Roxadustat 0.7 mg/kg BIW|Participants will receive roxadustat 0.7 mg/kg BIW orally with doses administered at least 68 hours apart for 29 days.
89493644|NCT02127593|Experimental|First NGM/EE (Dry Process), then NGM/EE (Wet Process)|Participants will receive 1 tablet (formulated by dry process) containing norgestimate 250 mcg and ethinyl estradiol 35 mcg, orally on Day 1 of Period 1, followed by 1 tablet (formulated by wet process) containing norgestimate 250 mcg and ethinyl estradiol 35 mcg, orally on Day 1 of Period 2, wherein Period 1 and Period 2 are separated by a wash out period of at least 10 days.
89204757|NCT00761657|Experimental|Roxadustat 0.7 mg/kg TIW|Participants will receive roxadustat 0.7 mg/kg TIW orally with doses administered at least 46 hours apart for 26 days.
89204758|NCT00761657|Experimental|Roxadustat 1.0 mg/kg BIW|Participants will receive roxadustat 1.0 mg/kg BIW orally with doses administered at least 72 hours apart for 29 days.
89204759|NCT00761657|Experimental|Roxadustat 1.0 mg/kg TIW|Participants will receive roxadustat 1.0 mg/kg TIW orally with doses administered at least 48 hours apart for 26 days.
89204760|NCT00761657|Experimental|Roxadustat 1.5 mg/kg BIW|Participants will receive roxadustat 1.5 mg/kg BIW orally with doses administered at least 68 hours apart for 29 days.
89204761|NCT00761657|Experimental|Roxadustat 1.5 mg/kg TIW|Participants will receive roxadustat 1.5 mg/kg TIW orally with doses administered at least 46 hours apart for 26 days.
89204762|NCT00761657|Experimental|Roxadustat 2.0 mg/kg BIW|Participants will receive roxadustat 2.0 mg/kg BIW orally with doses administered at least 68 hours apart for 29 days.
89204763|NCT00761657|Experimental|Roxadustat 2.0 mg/kg TIW|Participants will receive roxadustat 2.0 mg/kg TIW orally with doses administered at least 46 hours apart for 26 days.
89204764|NCT00761657|Placebo Comparator|Placebo|Participants will receive placebo orally, matching to the roxadustat dose, number of days per week, and duration.
89204765|NCT00816270|Experimental|1|Experimental operatory wound closure with liquid bandage (Johnson & Johnson, Skillman, NJ, USA).
89204766|NCT00999856|Active Comparator|Cohort 1|In the Cohort 1 an uncoated Insert and the photometer version 1 is used. Twelve trial subjects are appointed into 4 subgroups. The difference between these subgroups is the wearing time of the insert.
89204767|NCT00999856|Active Comparator|Cohort 2|Cohort 2 consists of 12 trial subjects who are appointed to 2 subgroups. One group will wear the insert for a minimum of 12 month and the other group for a minimum duration of 18 month. In Cohort 2 an improved insert is used. The photometer will be the same than in cohort 1.
89204768|NCT00999856|Active Comparator|Cohort 3|Cohort 3 only differs in the used photometer from cohort 2.
89204769|NCT00999856|Active Comparator|Cohort 4|Twelve trial subjects are appointed to two subgroups that differ in the minimum wearing duration of the insert (12 month and 18 month). In Cohort 4 a new insert will be tested together with a better photometer.
89204770|NCT00999856|Active Comparator|Cohort 5|The difference between Cohort 5 and Cohort 4 is that the best tested insert and the best evaluated photometer will be used.
89204771|NCT00319501|Placebo Comparator|Placebo|During the Double-blind Period, participants received a single, age- and weight-appropriate dose of placebo solution as a deep intramuscular injection in the mid to outer thigh. Drug was administered by a caregiver using a spring-driven, pressure-activated, prefilled autoinjector at the onset of an episode of acute repetitive seizures (ARS).
89204772|NCT00319501|Experimental|Diazepam|During the Double-blind Period, participants received a single, age- and weight-appropriate dose of diazepam solution, ranging from 0.2 to 0.5 mg/kg, as a deep intramuscular injection in the mid to outer thigh. Additional doses were permissible during the Open-label Period. Drug was administered by a caregiver using a spring-driven, pressure-activated, prefilled autoinjector at the onset of an episode of ARS.
89204773|NCT00818532||1|Measurement device
89204774|NCT00994006|Active Comparator|Magnesium oxide tables|Subjects will be instructed to take Magnox 520 qd
89204775|NCT00994006|Active Comparator|Magnesium citrate tablets|Subjects will be instructed to take magnesium diasporal tablets t.i.d.
89204776|NCT00818610|Experimental|Monotherapy|
89204777|NCT00818610|Active Comparator|Bi-therapy|
89204778|NCT02551302|Other|PLIF|The control group will receive a monosegmental posterior lumbar spine fusion with an intervertebral cage (PLIF).
89204779|NCT02551302|Other|Hybrid system (PLIF + flexible pedicle screw system above the|The intervention group will receive a hybrid system with a PLIF and a flexible pedicle screw system above the fusion.
89204780|NCT00995878|Active Comparator|Focused Ultrasound (MRgFUS)|
89204781|NCT00995878|Active Comparator|Uterine Artery Embolization (UAE)|
89204782|NCT00761579|Experimental|Paliperidone|Paliperidone oral tablet was administered once daily at a starting dose of either 3 milligram (mg), 6 mg or 9 mg for 48 weeks, wherein recommended dose was 6 mg and dose range was 3 to 12 mg per day.
89493645|NCT04810832|Experimental|Whole group|"The whole group undergo the two phases of the study:~1/ They listen successively the 3 oddball paradigms in the department of neurophysiology : P3 own-name recorded by listening to a smiling voice P3 own-name recorded by listening to a neutral voice P3 own-name recorded by listening to a rough voice~2/ They listen successively the same 3 oddball paradigms in the neurosurgical department, during their intractable epilepsy presurgical evaluation : P3 own-name recorded by listening to a smiling voice P3 own-name recorded by listening to a neutral voice P3 own-name recorded by listening to a rough voice"
89204783|NCT01000090||Acromegaly patients, somatostain analogues|
89493646|NCT02125799|Experimental|Accelerated HF-rTMS|Twice daily rTMS sessions involving 10 Hz in 75 trains of 4 seconds duration, with 26 seconds intertrain intervals (6,000 pulses per day) at 120% of the resting motor threshold.
89493647|NCT04812158|Active Comparator|Control group|participants in the control group receive gold standard physiotherapy intervention 5 times a week for 6 weeks
89493648|NCT04812158|Experimental|Experimental group|3 min video-aided mindful deep breathing (VAMDB) or visual guiding on deep breathing with 6 deep breath per minute along with standard physiotherapy (SP) protocol and the control group was given standard physiotherapy (SP) protocol 5 times a week for 6 weeks
89493649|NCT04812158|No Intervention|Healthy control|Active healthy participants who engaged in regular collegial sports
89493650|NCT02122679|Active Comparator|Study group|Receive tranexamic acid in operating room.
89493651|NCT02122679|Placebo Comparator|Placebo group|Receive placebo in the operating room
89493652|NCT02127671|Experimental|IDEAL intervention|Individual cardiovascular risk reduction counseling, coordination with primary care providers to ensure appropriate management of risk factors, and collaboration with mental health staff and social supports. All participants will be offered group exercise classes, and programs will be provided with instruction to provide more healthy meals.
89493653|NCT02127671|Other|Control|All participants will be offered group exercise classes, and programs will be provided with instruction to provide more healthy meals.
89493654|NCT04810754|Experimental|Daratumumab subcutaneous|open label daratumumab s.c., unblinded
89493655|NCT02122757|Placebo Comparator|Sham Anodal Cefaly tDCS|2 mA placebo anodal tDCS (the direct current is delivered just for 30 seconds) is applied over the visual cortex for 20 minutes, everyday for 2 months, in 15 patients
89493656|NCT02122757|Active Comparator|Anodal Cefaly tDCS|2 mA anodal tDCS is delivered over the visual cortex, for 20 minutes, everyday for 2 months, in 15 patients.
89493657|NCT04810286|Experimental|Experimental Group|3D-print myofunctional appliance
89493658|NCT04810286|Active Comparator|Control Group|Prefabricated myfunctional appliance
89493659|NCT02127749|Experimental|Control|Subjects are not pretreated with antibiotics Subjects receive 2 ng/kg endotoxin intravenously
89493660|NCT02127749|Experimental|Antibiotics|Subjects are pretreated with broad-spectrum antibiotics: Vancomycin, Metronidazole, Ciprofloxacin Subjects receive 2 ng/kg endotoxin intravenously
89493661|NCT02125955|Experimental|Prebiotic fiber|The intervention group will consume an 8 gram dose of prebiotic fiber one time per day approximately 30 minutes prior to their evening meal.
89493662|NCT02125955|Placebo Comparator|Placebo|The placebo group will consume an isocaloric dose of placebo (maltodextrin; 3.3 grams) one time per day approximately 30 minutes prior to their evening meal.
89204784|NCT01000090||Acromegaly patients, surgery|
89204785|NCT00994084|Active Comparator|Lifestyle modification|This arm receives the intervention program that includes structured physical activities and nutrition and behavior lessons
89204786|NCT00994084|Placebo Comparator|Control|This arm receives no intervention
89493663|NCT04810442|Experimental|Nap Group|This group will be involved with taking a nap in between the two scanning procedures.
89493664|NCT04810442|No Intervention|No-Nap Group|This group will not be taking a nap in between the two scanning procedures, and instead will be silently watching a film for the 45 minute period.
89493665|NCT02126033|Experimental|celiac disease|
89493666|NCT04797338|Active Comparator|GnRHa treatment based luteal support|Patients will initiate intranasal treatment with Nafarelin inhaler: 200 micrograms twice daily (a total of 400 micrograms/d; Synarel, Pfizer) on the evening after oocyte retrieval which will be continued up to the bHCG blood test, 12 days post embryo transfer. In cases with positive serum hCG results, the treatment will be stopped.
89493667|NCT04797338|Active Comparator|Estrogen and progesterone supplementation|Patients will start treatment with a combination of oral estrogen (Estrofem or Progynova 4 mg twice daily), vaginal progesterone (vaginal Utrogestan 200mg or Endometrin 100 mg three times daily) and intramuscular injection of progesterone retard 250 mg once every five days. The treatment will start at the day of the oocyte retrieval up to the bHCG blood test, 12 days post embryo transfer. In cases with positive serum hCG results, the treatment will be continued up to 9+0 weeks of pregnancy.
89493668|NCT05272865|Active Comparator|Dronabinol 5mg/mL|Drug: Dronabinol (SYNDROS) Oral solution of SYNDROS (5 mg/mL)
89493669|NCT05272865|Experimental|THC F1|Drug: THC Oral solution of THC (5 mg/mL)
89493670|NCT05272865|Experimental|THC F2|Drug: THC:CBG Oral solution of THC (5 mg/mL) & CBG (5 mg/mL)
89493671|NCT05272865|Experimental|THC F3|Drug: THC:CBC Oral solution of THC (5 mg/mL) & CBC (5 mg/mL)
88954245|NCT01970319||Diabetics without nephropathy|
88954246|NCT01970358|Experimental|Personalized NeoAntigen Cancer Vaccine|"- NeoVax (peptides + poly-ICLC)~Poly-ICLC: 4 x 0.5 mg (total dose 2 mg) given on days Days 1, 4, 8, 15, 22, 78, and 162~Peptides: 4 x 300 mcg per peptide given on days Days 1, 4, 8, 15, 22, 78, and 162"
88954247|NCT01970384|Experimental|Transcranial direct current stimulation|20 Minutes of transcranial direct current stimulation (20 min, 1 mA) administered over the contralesional cortical swallow motor area once daily over 4 consecutive days. In case of a brainstem stroke stimulation will be applied over the cortical swallow motor area of the right hemisphere.
88954248|NCT01970384|Sham Comparator|Sham stimulation|20 Minutes of sham transcranial direct current stimulation (20 min, no current applied) administered over the contralesional cortical swallow motor area once daily over 4 consecutive days. In case of a brainstem stroke sham stimulation will be applied over the cortical swallow motor area of the right hemisphere.
88954249|NCT01970423|Other|CRT|After randomization and polysomnography the CRT will get activated. After 3-5 months cross over to conventional right ventricular stimulation.
89022315|NCT00353249|Experimental|1|Participants will receive adapted cognitive behavioral therapy treatment
89022316|NCT00353249|No Intervention|2|Participants will receive no treatment for the course of the study; they will be offered courtesy PTSD 5 weeks after the experimental intervention.
89022317|NCT03272256|Experimental|IM156, Dose escalation|
89493672|NCT04810676|Experimental|Sequence 1|"Peroid 1: CKD-501, D745, D150 -PO~Peroid 2: CKD-383- PO"
89493673|NCT04810676|Experimental|Sequence 2|"Peroid 1: CKD-383- PO~Peroid 2: CKD-501, D745, D150 -PO"
89493674|NCT03552107||Observational Group - Lorcaserin Treated|The group in this study will be all patients who initiated therapy with Lorcaserin during the review period.
89493675|NCT04798976||CDSS (MedicBK) Analysis|
89022318|NCT03272100||test side ( horizontal flap)|Horizontal incision was realised in alveolar mucosa, in order to obtain the exposure of the lateral wall of the maxillary sinus, thus accessing the sinus cavity
89022319|NCT03272100||control side ( standard flap)|Trapezoidal flap was realised, using a crestal incision and two deep vertical incisions extended in the fornix to expose the lateral wall of the maxillary sinus
89493676|NCT04798976||Core Laboratory Analysis|
89493677|NCT04797182|Experimental|blank control|No intervention aiming at preventing thrombocytopenia will be taken after first cycle. Avatrombopag as salvage treatment will be administered to patients suffering from thrombocytopenia with nadir platelet count < 50 × 109/L at a dose of 60mg/day until there is drug-withdrawal indication.
89493678|NCT04797182|Experimental|primary prevention|"As the primary prevention of thrombocytopenia induced by cytarabine-based chemotherapy, Avatrombopag will be administered at a dose of 60mg/day on days -3~-1 and 3~9, for a total of 10 doses. On the condition that patients have platelet counts <50 × 10 9 /L before next cycle, Avatrombopag will be administered at a dose of 60mg/day until there is drug-withdrawal indications. Platelet transfusions were administered to patients when the platelet count was less than 10×109 /L.~Drug-withdrawal indications:~PLT ≥ 100×109/L during salvage treatment or platelet count increases by 50×109/L, comparing with baseline level.~When platelet count is higher than 400×109/L during this study, researchers determine whether avatrombopag is discontinued"
89493679|NCT02787863|Experimental|COPD with Prevenar-13 (1)|33 patients with COPD. Standard therapy with Prevenar-13.
89493680|NCT02787863|Experimental|Asthma with Prevenar 13 (2)|34 patients with asthma. Standard therapy with Prevenar 13.
89493681|NCT02787863|Experimental|COPD with Pneumo-23 (3)|25 patients with COPD. Standard therapy with Pneumo-23.
89493682|NCT02787863|Experimental|Asthma with Pneumo-23 (4)|25 patients with asthma. Standard therapy with Pneumo-23.
89493683|NCT02787863|Experimental|COPD with Pneumo-23/Prevenar-13 (5)|32 patients with COPD. Standard therapy, vaccinated with pneumococcal polysaccharide vaccine/pneumococcal conjugate vaccine (PPV23/PCV13).
89493684|NCT02787863|Experimental|Asthma with Pneumo-23/Prevenar-13 (6)|18 patients with Asthma. Standard therapy, vaccinated with PPV23/PCV13.
89493685|NCT02787863|Experimental|COPD with Prevenar-13/Pneumo-23 (7)|25 patients with COPD. Standard therapy, vaccinated with PCV13/PPV23.
89493686|NCT02787863|Experimental|Asthma with Prevenar-13/Pneumo-23 (8)|27 patients with Asthma. Standard therapy, vaccinated with PCV13/PPV23.
89493687|NCT04809818|Experimental|Part A - LT3001 Drug Product|Multiple doses of LT3001 administered by intravenous infusion
89493688|NCT04809818|Placebo Comparator|Part A - Placebo|Multiple doses of Placebo administered by intravenous infusion
89493689|NCT04809818|Experimental|Part B - LT3001 and Aspirin|Multiple doses of LT3001 and Aspirin administered
89493690|NCT04809818|Experimental|Part B - LT3001 and Clopidogrel|Multiple doses of LT3001 and Clopidogrel administered
89493691|NCT04809818|Experimental|Part B - LT3001 and Apixaban|Multiple doses of LT3001 and Apixaban administered
89493692|NCT04809818|Experimental|Part B - LT3001 and Dabigatran|Multiple doses of LT3001 and Dabigatran administered
89493693|NCT04797416|Active Comparator|1-hour group|The time between the activation of the sensor and the storage of the first blood glucose value is 1 hour.
89022320|NCT00353405|Experimental|1|Participants receiving social skills training and mass media messages
89022321|NCT00353405|Experimental|2|Participants receiving social skills training and no mass media messages
89022322|NCT00353405|Experimental|3|Participants receiving mass media messages and no social skills training
89493694|NCT04797416|Experimental|6-hour group|The time between the activation of the sensor and the storage of the first blood glucose value is 6 hours.
89493695|NCT04797416|Experimental|12-hour group|The time between the activation of the sensor and the storage of the first blood glucose value is 12 hours.
89493696|NCT02126111|Active Comparator|DEPIGOID phleum|The active treatment arm receive active phleum pollen immunotherapy (Depigoid 100% phleum). Depigmented and polymerized allergen extract of Phleum pollen for subcutaneous injection.
89493697|NCT02126111|Placebo Comparator|DEPIGOID Placebo & DEPIGOID Phleum|"This arm receive DEPIGOID Placebo during the first year, and DEPIGOID Phleum during the second year of study.~DEPIGOID Placebo contains the same composition as in the active DEPIGOID Phleum with the only difference being the exclusion of the phleum pollen allergen extract."
89493698|NCT04796480|Active Comparator|YOGURT|Group 1 children were given home made plain yogurt in treatment of acute diarrhea
89493699|NCT04796480|Active Comparator|LACTOSE FREE FORMULA MILK|Group 2 children were given lactose free formula milk in treatment of acute diarrhea
89493700|NCT02127827|Experimental|investigational device off|
89493701|NCT02127905|Other|CD34+ selected cells|use of unrelated bone marrow or peripheral blood for hematopoietic stem cell transplantation with CD34+ selected cells
89493702|NCT04798742|Experimental|Gait performance preop vs postop|Pre and postop
89493703|NCT04798742|Experimental|Gait performance postop vs controls|Postop vs controls
89493704|NCT04796402|Active Comparator|Control|Standard of care
89493705|NCT04796402|Experimental|Intervention|Administration of Bamlanivimab
89493706|NCT02127983|Experimental|Early intervention|Early intervention arm engaging informal providers Received the intervention early in the first 12 months
89493707|NCT02127983|Active Comparator|Delayed intervention|Delayed intervention arm, engaging informal providers Received the intervention after one year
89493708|NCT04798508|Other|Whole group|"The whole group listen successively the 3 paradigms :~P3 own-name recorded by listening to a smiling voice~P3 own-name recorded by listening to a neutral voice~P3 own-name recorded by listening to a rough voice"
89493709|NCT03551093|Experimental|Study Population|The ISS is intended to deliver electrical stimulation to the nerves within the greater palatine canal and pterygopalatine fossa.
89493710|NCT02126189||Head and neck cancer|All patients presenting to the Head and Neck Cancer Clinic at the Princess Alexandra Hospital, Brisbane, Australia are invited to participate.
89493711|NCT04809428||vNOTES Salpingectomy|Elective bilateral salpingectomy by vaginal Natural Orifice Transluminal Endoscopic Surgery approach
89493712|NCT04809428||LS Salpingectomy|Elective bilateral salpingectomy by conventional laparoscopy
89493713|NCT02126267|Experimental|Full mouth disinfection - FMD|n = 10: Procedures for scaling and root planing were performed in a single stage (24 hours) divided into two sessions (60 min per session) on two consecutive days
89493714|NCT02126267|Experimental|FMD + chlorhexidine (FMD-CX)|n = 15: Same as FMD with the inclusion of chlorhexidine in office (application of chlorhexidine (CX) (1%) gel in pockets after scaling, brushing tongue for 1 min. with CX (1%) gel and mouthwash at the beginning and end of each session with CX 0.2% for 30 seconds (with the form of a gargle in the last 10 seconds)). In addition, use was made of homemade CX 0.2% for 60 days after the scaling in a single phase.
89493715|NCT02126267|Experimental|FMD + azithromycin (FMD-AZ)|n = 15: Same as with the FMD include the use of azithromycin (500 mg) once daily for 3 consecutive days. Medication was started the same day as the end of the scaling.
89493716|NCT02126267|Experimental|Scaling and root planing (SRP)|(n = 13): scaling procedures were performed per quadrant (30 min. per quadrant) at weekly intervals between sessions;
89493717|NCT02126267|Experimental|SRP + azithromycin (SRP-AZ)|n = 11: Same as scaling and root planing group (SRP) with inclusion of the use of azithromycin (500 mg) once daily for 3 consecutive days. Medication was started the same day as the end of the last scaling hemi-arch;
89493718|NCT02126267|Experimental|SRP + chlorhexidine (SRP-CX)|n = 13 : Same as group scaling and root planing (SRP) with the inclusion of home use of CX 0.2% for 60 consecutive days after the end of the first session of scaling
89493719|NCT02131103|Active Comparator|Early ( < 24hr)|Early percutaneous coronary intervention means performed coronary intervention between 3-24 hours after successful fibrinolytic therapy.
89493720|NCT02131103|Active Comparator|Delay ( > 24 hours)|Delay percutaneous coronary intervention means received coronary intervention >24 hours to 2 weeks after successfully fibrinolytic therapy.
89493721|NCT02131103|Active Comparator|Early|"We randomized the patients into two groups early (≤ 24 hours) and delay group (> 24 hours) All patients received fibrinolysis, aspirin 300 mg and clopidogrel (300 mg for participants 75 years of age or younger or 75 mg for participants older than 75 years of age). Patients older than 75 years of age did not receive enoxaparin.~Patients will be randomly assigned to either the group that received routine early PCI (hereinafter termed the early-PCI group) or the group that received standard treatment (PCI performed after 24-72 hours of successfully fibrinolysis). Randomized will perform within 24 hours after successful fibrinolytic therapy. PCI will be performed when persistent occlusion or substantial stenosis of the infarct-related artery (either stenosis of 70% or more of the diameter of the artery or stenosis of 50-70% with thrombus, ulceration, or spontaneous dissection) was present. In case of multivessel disease, only culprit lesion will be correct."
89493722|NCT04796090||Adolescents with genital warts (Study Group)|The Study group included adolescents who was diagnosed as positive for genital warts during the examination.
89493723|NCT04796090||Healthy adolescents (Control Group)|The Control group was composed of healthy adolescents who admitted for only contraceptive counselling.
89493724|NCT02126345||MASTER SL|
89493725|NCT02126423||1st intravitreal injection|Conjunctival and nasopharyngeal swabs are obtained from each treatment-naive patient receiving their 1st intravitreal injection
89493726|NCT02126423||>20 intravitreal injections|Conjunctival and nasopharyngeal swabs are obtained from each patient with >20 intravitreal injection therapies.
89493727|NCT02128061|Active Comparator|R-miniCHOP|"All patients will be treated with R-miniCHOP at a three-weeks interval for 6 cycles CYCLOPHOSPHAMIDE IV: 400 mg/m² Day 1 (D1) DOXORUBICINE IV : 25 mg/m² D1 VINCRISTINE IV : 1 mg Total Dose (TD) D1 PREDNISONE PO : 40 mg/m² D1 to D5 RITUXIMAB SC* : 1400 mg TD D1~*The first cycle of rituximab is delivered by IV at the dose of 375 mg/m2"
89493728|NCT02128061|Experimental|R2-miniCHOP|"All patients will be treated with R2-miniCHOP at a three-weeks interval for 6 cycles CYCLOPHOSPHAMIDE IV: 400 mg/m² D1 - DOXORUBICINE IV : 25 mg/m² D1 - VINCRISTINE IV : 1 mg TD D1 - PREDNISONE PO : 40 mg/m² D1 to D5 - RITUXIMAB SC* : 1400 mg TD D1 LENALIDOMIDE PO** :10 mg TD D1 to D14~*The first cycle of rituximab is delivered by IV at the dose of 375 mg/m2"
89493729|NCT05615558|Experimental|Animal|Arm of the study consuming a high-protein diet from animal sources.
89493730|NCT05615558|Experimental|Non-animal|Arm of the study consuming a high-protein diet from non-animal sources.
89022323|NCT00353405|Experimental|4|Participants receiving no social skills training and no mass media messages
89493731|NCT02128295|Experimental|Primiparous mothers|Mother who are primiparous
89493732|NCT02128295|Experimental|Multiparous mothers|Mothers who are multiparous
89493733|NCT04795778||Patients with breast cancer|Breast cancer patients with or without breast cancer surgery, with or without mastectomy, with or without lymphedema
89493734|NCT04795778||Control group|Healty individuals with no disease
89022324|NCT00466518|Experimental|1|
89493735|NCT03551015|Experimental|Intervention|The intervention arm will have outpatient review at 3 weeks and start 8 sessions of cardiac rehabilitation from 4 weeks, after hospital discharge following CABG.
89493736|NCT03551015|No Intervention|Control|This arm will have outpatient review 6 weeks after hospital discharge and start 8 sessions of cardiac rehabilitation from 8 weeks.
89493737|NCT02131181||Delirium|Patients with delirium and patients without delirium
89493738|NCT02252393|Experimental|Arm I (RARC with IUD)|Patients undergo RARC with IUD.
89493739|NCT02252393|Experimental|Arm II (RARC with EUD)|Patients undergo RARC with EUD.
89493740|NCT02596958||Bevacizumab|Patients will receive six 3-weeks cycle of IV bevacizumab along with platinum-based chemotherapy, followed by maintenance therapy of bevacizumab until progression (approximately 7 months).
89493741|NCT03550625||Routine Colonoscopy Cohort|Photographies of polyps for creation of computer program
88954250|NCT01970423|Other|Right Ventricular Stimulation|After randomization and polysomnography the conventional right ventricular stimulation will get activated. After 3-5 months cross over to CRT activation.
88954251|NCT01970436|Experimental|Remote Prenatal Care|Remote Prenatal Care using a combination of in-person and telemedicine prenatal care visits.
88954252|NCT01970436|No Intervention|Usual Prenatal Care|Usual, in-person prenatal care.
88954253|NCT01970449|Experimental|Group 1: study vaccines with Nat-B env insert|Participants in this arm will receive DNA Nat-B env vaccine injections on Day 0 and Day 28 followed by NYVAC Nat-B env vaccine injections on Day 84 and Day 164.
88954254|NCT01970449|Placebo Comparator|Group 1: placebo vaccines with Nat-B env insert|Participants in this arm will receive placebo injections of DNA Nat-B env vaccine on Day 0 and Day 28 followed by placebo injections for NYVAC Nat-B env vaccine on Day 84 and Day 164.
88954255|NCT01970449|Experimental|Group 2: study vaccines with CON-S env insert|Participants in this arm will receive DNA CON-S env vaccine injections on Day 0 and Day 28 followed by NYVAC CON-S env vaccine injections on Day 84 and Day 164.
88954256|NCT01970449|Placebo Comparator|Group 2: placebo vaccines with CON-S env insert|Participants in this arm will receive placebo injections of DNA CON-S env vaccine on Day 0 and Day 28 followed by placebo injections for NYVAC CON-S env vaccine on Day 84 and Day 164.
88954257|NCT01970449|Experimental|Group 3: study vaccines with Mosaic env insert|Participants in this arm will receive DNA Mosaic env vaccine injections on Day 0 and Day 28 followed by NYVAC Mosaic env vaccine injections on Day 84 and Day 164.
88954258|NCT01970449|Placebo Comparator|Group 3: placebo vaccines with Mosaic env insert|Participants in this arm will receive placebo injections of DNA Mosaic env vaccine on Day 0 and Day 28 followed by placebo injections for NYVAC Mosaic env vaccine on Day 84 and Day 164.
88954259|NCT01970514|Experimental|ARO Spinal System|ARO Spinal System
88954260|NCT01970553|Experimental|lurbinectedin (PM01183) / gemcitabine|"Patients will consecutively receive the following on Days 1 and 8 q3wk (three weeks = one treatment cycle):~- Gemcitabine: intravenous infusion of 800 mg/m2/day over 30 minutes,~immediately followed by:~- PM01183: intravenous infusion over one hour at a starting dose of 2.5 mg/day, flat dose (FD), both on Days 1 and 8 every 3 weeks"
88954261|NCT01970566|Experimental|IE-MCR|Intense Exercise/Moderate Calorie Restriction
88954262|NCT01970566|Active Comparator|TP-CBT|Topiramate-Phentermine plus cognitive behavioral therapy
88954263|NCT01970566|Active Comparator|CBT|cognitive behavioral therapy
88954264|NCT01970579|Experimental|Paclitaxel coated balloon|
88954265|NCT01970579|Active Comparator|uncoated PTA catheter|
88954266|NCT01970605||Patients with PAOD or aneurysms|"Patients~in Fontaine class > IIa,~in need of aneurysm repair,~with defined cardiovascular risk factors or~graft infections.~Surgical reconstruction with defined Silver Graft vascular prosthesis."
88954267|NCT01970618|Experimental|Part A: single dose escalation (healthy subjects)|
88954268|NCT01970618|Experimental|Part B: 7 day repeat dose (healthy subjects)|
88954269|NCT01970618|Experimental|Part C: 14 day repeat dose (COPD patients)|
88954270|NCT01970631|No Intervention|Usual Care|Participants randomized to the Usual Care group will receive the current standard post-operative TKR care.
88954271|NCT01970631|Active Comparator|Motivational Interviewing (MI)|Participants randomized to the MI Intervention group will receive up to 14 telephone calls from a Health Educator for 9 months post-TKR.
88954272|NCT01970631|Active Comparator|Financial Incentives (FI)|Participants randomized to the FI Intervention group will receive financial incentives for completing physical activity logs weekly/bi-weekly and achieving pre-specified physical activity goals over the course of the study.
88954273|NCT01970631|Active Comparator|Motivational Inverterviewing (MI) + Financial Incentives (FI)|Participants randomized to the FI + MI Intervention group will receive financial incentives for completing physical activity logs weekly/bi-weekly and achieving pre-specified physical activity goals as well as receive up to 14 telephone calls from a Health Educator for 9 months post-TKR.
88954274|NCT01970644||Brain metastases (>= 4)|Patients with pathologically proven solid tumour malignancy who have >=4 brain metastases will be treated with gamma knife radiosurgery.
88954275|NCT01970657||HP802-247 in prior study|Observational safety follow up study, no treatment specified
88954276|NCT01970657||Vehicle Control in prior study|Observational safety follow up study, no treatment specified
88954277|NCT01970683|Experimental|VSL #3|probiotics given orally BID
88954278|NCT01970683|Other|placebo|Near-identically appearing placebo
88954279|NCT01970696||Ovarian Stromal Tumors|
88954280|NCT01970696||Testicular Stromal Tumors|
88954281|NCT01970696||Ovarian Small Cell Carcinoma|
88954282|NCT01970748|Placebo Comparator|Propranolol|Propranolol 10mg BID initially and titrate dosage every week to achieve 25% drop of heart rate (keep heart rate>55 or systemic blood pressure>90mmHg)
88954283|NCT01970748|Active Comparator|Esophageal variceal ligation|Esophageal variceal ligation every 3-4 weeks to achieve variceal eradication under endoscopy. After eradication, follow-up endoscopy every 3 months and variceal ligation again if recurrence.
88954284|NCT01970761||scar, Fat Graft, Visual Analogue Scale|patients received autologous fat grafting in scar areas
88954285|NCT01970774|Experimental|MTM and PGx|Participants attend two MTM sessions and have PGx testing
88954286|NCT01970800|Experimental|Growth hormone, injections|Growth hormone injection 0.3mg/kg/week dailY
88954287|NCT01970813|Active Comparator|Study group|acupuncture and bee venom acupuncture point injection
89022325|NCT00458094|Experimental|1|Participants will receive the peer-supported physical activity intervention
89022326|NCT00458094|Active Comparator|2|Participants will receive physical activity without peer support
89022327|NCT04714580|Experimental|Animal Fun Group|Baseline assessment with MABC-2; Animal Fun activity with a certified trainer (physiotherapist) for one month, three times a week, for 30 minutes; one-month follow-up assessment with MABC-2.
89022328|NCT04714580|No Intervention|Control Group|Baseline assessment with MABC-2; normal curricular activity at school with the teachers; one-month follow-up assessment with MABC-2.
89022329|NCT00353561|Active Comparator|1, Boric acid|600 mg vaginal pessaries for 14 days
89022330|NCT00353561|Other|2, Fluconazole|
89022331|NCT00353639||IBD subjects|Subjects with Inflammatory Bowell Disease
89022332|NCT02959736||National Rehabilitation Hospital Dublin|Music Therapy (MATADOC)
89022333|NCT02959736||Spectrum|Music Therapy (MATADOC)
89493742|NCT02128373|Active Comparator|Arm I (usual care)|Participants receive usual care (care from physician, physician nurse, and social worker) for 5 weeks. During the week 5 office visit, distance caregivers are not present. In the pre-physician interview patients will verbally complete the FACT, POMS-B, Tension-Anxiety subscale, Distress Thermometer. Distance caregivers will verbally complete the POMS-B, Tension-Anxiety subscale, and Distress Thermometer
89493743|NCT02128373|Experimental|Arm II (usual care with CLOSER intervention)|Participants receive usual care (care from physician, physician nurse, and social worker) for 5 weeks. During the week 5 office visit, distance caregivers will use a computer-assisted intervention to be present electronically with video and audio feed to provide psychosocial support. In the pre-physician interview patients will verbally complete the FACT, POMS-B, Tension-Anxiety subscale, Distress Thermometer. Distance caregivers will verbally complete the POMS-B, Tension-Anxiety subscale, and Distress Thermometer. Up to 96 hours after the week 5 visit, patients and caregivers will be interviewed about their experience during the intervention
89493744|NCT04764422|Placebo Comparator|Placebo|0.9% Normal Saline for injection
89493745|NCT04764422|Active Comparator|NDV-HXP-S 1 µg|35 subjects age 18-59 will receive NDV-HXP-S 1 µg study vacine administered 0.5 mL IM
89493746|NCT04764422|Active Comparator|NDV-HXP-S 3 µg|35 subjects age 18-59 will receive NDV-HXP-S 3 µg study vacine administered 0.5 mL IM
89493747|NCT04764422|Active Comparator|NDV-HXP-S 10 µg|35 subjects age 18-59 will receive NDV-HXP-S 10 µg study vacine administered 0.5 mL IM
89493748|NCT04764422|Active Comparator|NDV-HXP-S 1 µg + CpG1018 1.5 mg|35 subjects age 18-59 will receive NDV-HXP-S 1 µg + CpG1018 1.5 mg study vacine administered 0.5 mL IM
89493749|NCT04764422|Active Comparator|NDV-HXP-S 3 µg + CpG1018 1.5 mg|35 subjects age 18-59 will receive NDV-HXP-S 3 µg + CpG1018 1.5 mg study vacine administered 0.5 mL IM
89022334|NCT02959736||Royal Hospital for Neuro-disability London|Music Therapy (MATADOC)
89022335|NCT00466674|Experimental|Allogenic Transplant|
89022336|NCT00353717|Experimental|1|
89022337|NCT00466791|Active Comparator|Methylphenidate Transdermal System|Transdermal patch, 27.5mg, 41.3mg, 55mg, and 82.5mg, daily for 11 weeks
89022338|NCT00466791|Placebo Comparator|Placebo|Transdermal patch, 0mg, daily for 11 weeks
89022339|NCT00458289|No Intervention|1|P-containing meal alone
89022340|NCT00458289|Active Comparator|2|P-containing meal AND single 1 g oral dose of chewed lanthanum carbonate
89022341|NCT00458289|Active Comparator|3|P-containing meal and single 1 g oral dose of lanthanum carbonate crushed into a fine powder
89022342|NCT00458367||001|Open label risperidone long acting injectable intramuscular injections every 2 weeks for 26 weeks flexible dose 25 to 50 mg
89022343|NCT00354185|Experimental|Treatment (tanespimycin, belinostat)|"Patients receive 17-AAG IV over 2 hours on days 1, 4, 8, and 11 and PXD101 IV over 30 minutes on days 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of 17-AAG and PDX101 until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Up to 12 patients are treated at the MTD.~Patients undergo blood collection on days 1 and 4 of course 1 for pharmacokinetic studies."
89022344|NCT00458445|Experimental|SPD465 then Placebo|
89022345|NCT00458445|Experimental|Placebo then SPD465|
89022346|NCT00354263|Placebo Comparator|A|PBS injected alone in step 1 or mixed with Aggripal in step 2
89022347|NCT00354263|Experimental|B|
89022348|NCT04714229|Experimental|EuMCV4|Healthy adults received 0.5mL single intramuscular dose on Day 0.
89022349|NCT04714229|Active Comparator|Menveo|Healthy adults received 0.5mL single intramuscular dose on Day 0.
89022350|NCT04714502||Infants enrolled in AAMBI1|
89022351|NCT00467064|Experimental|Arthritis self-management workshop|Comparison of two-week, lay led, scripted self-management workshop emphasizing action planning, problem-solving, and content specific to arthritis.
89022352|NCT00467064|Other|Delayed treatment control|After 4 month delay, participants in Control Group receive Experimental intervention.
89022353|NCT00458562||HIV+, <CIN2|HIV positive women without CIN2-3 or worse
89022354|NCT00458562||HIV-, no >=CIN3 biopsy, HR HPV+|HIV negative women without biopsy-proven CIN3 or worse, and with high risk HPV infection
89022355|NCT00458562||HIV-, <=CIN1, HPV- at screening|HIV negative women who are <= CIN1 and HPV negative at screening
89022356|NCT00354419|Experimental|Arm I|See Detailed Description
89022357|NCT02273856||Treatment naïve patients with CLL|
89022358|NCT02273856||Treatment naïve patients with iNHL|
89022359|NCT02273856||Relapsed/refractory patients with CLL|
89022360|NCT02273856||Relapsed/refractory patients with iNHL|
89022361|NCT00458679|Experimental|Vaccine|autologous B-CLL vaccine expressing CD40L and IL2
89493750|NCT02126501|No Intervention|Sudden wean|When ready Nasal Continuous Positive Airway Pressure (NCPAP) will be removed from the neonate
89493751|NCT02126501|Active Comparator|Gradual pressure wean|NCPAP will be removed by gradually decreasing pressure over 24 hours once the weaning is decided
89493752|NCT04794998||"Recommended schedule cohort"|COVID-19 patients who have applied the proposed treatment recommendation algorithm at the onset of or within few days from the beginning of symptoms.
89204787|NCT04100525|Active Comparator|Standard Care|Participant received neuropsychological testing, report detailing cognitive strengths and weaknesses, tailored recommendations to address areas of weakness (including psychological and/or physical symptoms impacting work productivity). Participant received a copy of this report in the mail and a call from the psychologist to go over test findings and recommendations.
89493753|NCT04794998||"control cohort"|COVID-19 patients enrolled in the ORIGIN study of the Istituto di Ricerche Farmacologiche Mario Negri IRCCS, and treated at home by their family doctors with drug regimens other than those proposed in the recommendations
89493754|NCT04808726|Other|Control Group|standard breastfeeding education and counseling service to another group
89493755|NCT04808648|Experimental|Itraconazole and SH-1028|In the itraconazole study, patients received single-dose SH-1028 200 mg on Days 1 and 12 and itraconazole(200 mg twice daily) on Days 8-14 orally.
89493756|NCT04808648|Experimental|Rifampicin and SH-1028|In the rifampicin study, patients received SH-1028 200mg once daily on Days 1 and 14 and rifampicin 600 mg once daily on Days 8-16
89493757|NCT03550547|Experimental|7 educational workshops|"Intervention: 7 educational workshops in addition to spa therapy :~Knowledge of the pathology ; Educational physical activity ( 2 workshops); Dietary; Management of pain, fatigue and the medical treatments; Articular hygiene and ergonomics; Technical assistance, an adaptation of the living condition"
89493758|NCT03550547|Active Comparator|spa therapy|Approved Spa therapy
89493759|NCT04808804||DM|Patients With Type 2 Diabetes Mellitus without any signs of diabetic retinopathy or with mild non proliferative diabetic retinopathy
89493760|NCT04808804||Healthy|healthy controls
89493761|NCT02131337|Other|Contact force lesions|
89493762|NCT02126657|Other|Single Arm|Single arm study - pre and post peel assessment
89493763|NCT04786418|Active Comparator|Control group|Participants will be given standard advice about healthy eating, physical activity and management of weight during the study visit, in line with current NHS practice. There will be a total of 9 study visits for this group.
89493764|NCT04786418|Experimental|Low-calorie diet intervention group|Participants will received a special diet involving 25 regular visits and intensive management. Participants will be given a supply of especially formulated soups and shakes, a special diet in a form of powder that need to be mixed with 200 ml water.
89493765|NCT03551405||Intensity accuracy|"The difference of the HU values in corresponding ROIs in the two image sets will be compared with zero using one sample t-test.~In addition, we will also use these patient cases to test the computational efficiency of our algorithm. Based on our preliminary study, it is expected that the computation time will be 5~10 sec per phase. The reconstruction time will be recorded in these patient cases and will be assessed."
89493766|NCT04786496|Experimental|ITP+SA Wise intervention (Incremental Theory of Personality Intervention with Self-affirmations)|Wise intervention (based on ITP and SA) consisting on several tasks to be completed individually. 30 minutes
89493767|NCT04786496|Experimental|ITP Wise intervention (Incremental Theory of Personality Intervention)|Wise intervention (based on ITP) consisting on several tasks to be completed individually. 30 minutes
89493768|NCT04786496|Other|Control Intervention|Educational intervention (about heritage conservation) consisting on several tasks to be completed individually. 30 minutes
89493769|NCT04795310|Experimental|Pulsed Dye Laser|PDL (Vbeam perfecta, 595 nm, Candela Corporation, Wayland, MA) was used with energy dosages of 9-11J/cm2, pulse durations of 10ms/20ms, and 7 or 10 mm handpieces with dynamic cooling device (DCD)
89493770|NCT04795310|Active Comparator|Intense Pulsed Light|Vascular wavelength bands of 530-650nm and 900-1200nm
89493771|NCT03551327|Experimental|Intervention plus information|Participants in this arm will receive 6 telephone therapy sessions and 1 booster session. Participants will be followed up at 4 months and 6 months.
88954288|NCT01970813|Sham Comparator|Control group|sham acupuncture and normal saline injections
88954289|NCT01970813|No Intervention|Waiting group|no additional intervention
88954290|NCT01970826|Experimental|Sterilized Clean Full-Mouth|"The operatory room will be prepared with clean instruments but with no aseptic preparation.~Full-mouth dental implants placement will be made, Clean technique involves meticulous hand-washing, maintaining a clean environment by preparing a clean field, using clean gloves and sterile instruments, and preventing direct contamination of materials and supplies.~There is contact between : non-sterile material in any change procedures and contact between sterile instruments or materials and any non-sterile surface or product.~It will be evaluated the duration of surgery."
88954291|NCT01970826|Active Comparator|Sterilized Aseptic Full-Mouth|"The operatory room will be prepared with sterilized aseptic clean instruments. Full-mouth dental implants placement will be performed and involves meticulous hand washing, use of a sterile field, use of sterile gloves for application of a sterile dressing, and use of sterile instruments and fluid only. Involves the use of only sterile instruments and materials in dressing.~There is no contact between : non-sterile material in any change procedures and contact between sterile instruments or materials and any non-sterile surface or products.~It will be evaluated the duration of surgery."
89493772|NCT03551327|Other|Information only|Participants in this arm will receive information only. Participants will be followed up at 4 months and 6 months.
89493773|NCT02128451|Active Comparator|Meperdine group|15ml 0.5% bupivacaine,25 mg of meperdine and 1 ml of clonidine will be injected epidurally in meperdine Group.
89493774|NCT02128451|Active Comparator|Fentanyl group|15ml 0.5% bupivacaine, 25 micrograms of fentanyl and 1 ml of clonidine will be injected epidurally in fentanyl Group
89493775|NCT04291040|Experimental|Decision Aid|
89493776|NCT04291040|Active Comparator|Routine Care|
89493777|NCT02128529||Chronic obstructive pulmonary disease|Patients with chronic obstructive pulmonary disease will undergo a single visit with the collection of data from his/her records.
89493778|NCT02131571||HIV patients older than 50 years|HIV infected patients older than 50 years in current follow up
89493779|NCT04808336|Active Comparator|PRP injection group|Group 1: thirty patients were injected in the facet joint capsule with a series of three ultrasound-guided PRP injections at four-week intervals,
89493780|NCT04808336|Active Comparator|surgical group..|Group 2: thirty patients underwent surgery
89022362|NCT00354458|Placebo Comparator|1|
89022363|NCT00354458|Experimental|2|
89022364|NCT00354536|Active Comparator|albiglutide|albiglutide injection
89022365|NCT00354536|Placebo Comparator|albiglutide placebo|placebo injection
89022366|NCT00467220|No Intervention|Control|Subjects will follow all study tasks but will not be required to follow a calorie-restricted meal plan.
89022367|NCT00467220|Other|Alternate Day Fasting Arm|Subjects in this arm will be asked to alternate between one day of eating as they wish versus one day on a calorie-restricted meal plan. Subjects will follow this alternating meal plan for 3 months.
89022368|NCT00467220|Other|Calorie Restriction|Subjects in this arm will be asked to follow a calorie-restricted meal plan, daily, for three months.
89022369|NCT00425711|Experimental|DUI Court Participants|Individuals enrolled in the DUI Court treatment site will be recruited for the 13 week open-label trial of acamprosate.
89022370|NCT03274011|Experimental|Apatinib Treatment|Apatinib for Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
89022371|NCT00425906|Experimental|Nicotine inhaler|
89022372|NCT00425906|Placebo Comparator|Placebo inhaler|
89022373|NCT00467376|Experimental|1|Administration of Insulin Glulisine
89022374|NCT00467376|Active Comparator|2|Administration of Lispro
89022375|NCT00426023|Experimental|1|this group of patients is treated with the experimental drug (Cyclosporine A 0,05% eye drops) 2 times daily
89022376|NCT00426023|Active Comparator|2|
89022377|NCT00467454|Active Comparator|1|Naltrexone
89022378|NCT00467454|Placebo Comparator|2|Placebo
89022379|NCT00426101|Experimental|Etoposide, Dexamethasone, Cyclosporin A plus IT MTX & Steroids|"As compared to the HLH-94 treatment, the main changes are that~Cyclosporin A is administered from day 1 and~Intrathecal steroids are added to the intrathecal methotrexate.~Drugs, dosage, frequency and duration are described in the paragraph Interventions below."
89022380|NCT00426140|Experimental|EPO906|
89022381|NCT00467493|Experimental|Anastrozole - A|Treatment for 26 consecutive days
89022382|NCT00467493|Experimental|Anastrozole -B|Treatment for 7 consecutive days early in menstrual cycle
89022383|NCT00467493|Experimental|Anastrozoe - C|Treatment for 7 consecutive days mid follicular phase
89022384|NCT00467493|Experimental|Anastrozole - D|Treatment for 7 consecutive days - mid cycle
89022385|NCT00467493|Experimental|Anastrozole - E|Treatment for 7 consecutive days - luteal
89022386|NCT00467493|Placebo Comparator|Anastrozole - F|Treatment with placebo for 26 consecutive days
89022387|NCT00458874|Experimental|Receive CIMT Results (R-CIMT)|This group will receive visual feedback of their CIMT results on a weekly basis.
89022388|NCT00458874|No Intervention|Withhold CIMT Results (W-CIMT)|The W-CIMT group will not receive their CIMT results until the end of their study participation.
89022389|NCT00426218|Experimental|1|ACZ885
89022390|NCT01059617|Experimental|Flulaval/Arepanrix Group|subjects received Flulaval vaccine on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.
89022391|NCT01059617|Experimental|Flulaval/Unadjuvanted Arepanrix Group|subjects received Flulaval vaccine on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.
89022392|NCT01059617|Experimental|Placebo/Arepanrix Group|subjects received a saline placebo on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.
89022393|NCT01059617|Experimental|Placebo/Unadjuvanted Arepanrix Group|subjects received a saline placebo on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.
89022394|NCT03271944|Other|Single group 30 post menopause females.|
89493781|NCT02128607|Active Comparator|Real SNAG|A real sustained natural apophyseal glide (SNAG / Mulligan technique) applied on the lumbar spine from a sitting position, and in a trunk flexion direction with the use of the belt.
89493782|NCT02128607|Placebo Comparator|Sham SNAG|A sham (placebo) sustained natural apophyseal glide (SNAG / Mulligan technique) applied on the lumbar spine from a sitting position, and in a trunk flexion direction with the use of the belt.
89493783|NCT04808102|Experimental|IER serious game|A serious game training interpersonal emotion regulation strategies.
89493784|NCT04808102|Sham Comparator|control game|A control puzzle game without psychoeducational content.
89493785|NCT01367249|Experimental|Bromfenac Ophthalmic Solution|Bromfenac ophthalmic solution 0.07% one drop into study eye, once daily (QD) starting the day before cataract surgery and continued for 14 days post surgery for a total of 16 days.
89022395|NCT03273933|Active Comparator|10 children with DragONE only|
89493786|NCT01367249|Placebo Comparator|Placebo|One drop of placebo into study eye, once daily (QD) starting the day before cataract surgery and continued for 14 days post surgery for a total of 16 days.
89493787|NCT04795154|No Intervention|Pre-test group|pregnant women> 20 weeks who had blood pressure level which was 130/80 mmHg to 140/90 mmHg without treatment.
89493788|NCT04795154|Experimental|Post-test group|pregnant women > 20 weeks who had blood pressure level which was 130/80 mmHg to 140/90 mmHg got yoga exercise, and post group was got yoga exercise was 30 minutes every 2 weeks for two months (4 times treatment). Yoga exercises technique used stretching and posture exercises (asanas) combined with deep breathing (pranayama) and meditation, to unify body, mind, and spirit (Babbar S, Parks-Savage AC, Chauhan SP, 2012).
89493789|NCT02131727|Experimental|Hand Hygiene Improvement Intervention|Hand Hygiene Improvement Intervention: Participants receive a 4 minute training video about actions to take to reduce risk of respiratory and GI infections that includes hand hygiene practices, along with educational posters and hand hygiene supplies.
89493790|NCT02131727|Placebo Comparator|Ask Me 3|Participants in the control group received a 4 minute training video about the Ask Me 3 program for clearer communication with health care providers, a brochure, and a key chain containing principles for clear communication with health care providers.
89493791|NCT02128685|Active Comparator|Dydrogesterone|Patients allocated to the dydrogesterone group will receive oral dydrogesterone 40mg stat, followed by 10mg orally three times a day, and placebo will be used in the control group accordingly. Patients will be followed up with weekly pelvic ultrasound till 12 completed weeks of gestation or 1 week after the bleeding stopped, whichever is longer.
89493792|NCT02128685|Placebo Comparator|Placebo pill|Patients allocated to the dydrogesterone group will receive oral dydrogesterone 40mg stat, followed by 10mg orally three times a day, and placebo will be used in the control group accordingly. Patients will be followed up with weekly pelvic ultrasound till 12 completed weeks of gestation or 1 week after the bleeding stopped, whichever is longer.
89493793|NCT04808024|Experimental|Players of amateur football leagues|The players of amateur football leagues who will receive SelfMyofascial Release intervention
89493794|NCT04808024|No Intervention|Control group|The players of amateur football leagues who will receive no intervention
89493795|NCT02131883|Experimental|Group-Cognitive Behavioral Therapy|Group-Cognitive Behavioral Therapy for 7 patients and 2 therapists, 3 hours sessions a week in 12 weeks and a 3 hours booster session 12 weeks after
89493796|NCT02131883|Other|Wait-List with treatment as usual|Wait-List with treatment as usual waiting in 9 months for the intervention with group-CBT
89022396|NCT03273933|Experimental|10 children with DragONE and SmartOne|
89493797|NCT02252315|Active Comparator|Written Education|
89493798|NCT02252315|Active Comparator|Verbal Education|
89493799|NCT02252627||Group 1|Healthy volunteers
89493800|NCT04807790|Experimental|Telerehabilitation based structured home program group|"The structured home program will consist of activities determined by the family members according to the functional level of the child and the activities he / she can not do, and which are determined according to the goals specific to the child. In order to ensure that the structured home program created can be implemented by the family, a 1 hour family training will be provided.~After the structured home program training, a 45-minute video interview will be held with one of the family members (mother-father-caregiver) once a week, in order to check by the physiotherapist whether the home program is implemented correctly. Video interviews will be the telerehabilitation part of the study."
89022397|NCT00459030|Experimental|Print Communication|Cancer screening educational information mailed to patient's home one time after signing consent.
89022398|NCT00459030|Experimental|Electronic communication|Cancer screening educational information delivered via a password protected internet site.
89022399|NCT00459030|Active Comparator|No Health Communication|No additional cancer screening education information sent to patient.
89022400|NCT04705337|Experimental|Levosimendan|administration of levosimendan
89022401|NCT04705337|Placebo Comparator|Placebo|administration of placebo
89022402|NCT00426257|Experimental|1|Secondary debulking surgery with hyperthermic intraperitoneal chemotherapy
89022403|NCT00426257|Active Comparator|2|Secondary debulking surgery
89022404|NCT00467571|Experimental|I|Drug: lansoprazole, clarithromycin, amoxycillin
89022405|NCT00467688|No Intervention|A,1|Real time access to current measured glucose values; hyperglycemic or hypoglycemic alerts
89022406|NCT00467688|No Intervention|A,2|Retrospective analysis of glucose values
89022407|NCT03271905|Experimental|Pressure-controled-ventilation (PCV)|Nebulization during mechanical ventilation on a pressure controled ventilation mode.
88954292|NCT01970826|Experimental|Sterilized Clean Single|"The operatory room will be prepared with clean instruments but with no aseptic preparation.~Single dental implants placement will be made, Clean technique involves meticulous hand-washing, maintaining a clean environment by preparing a clean field, using clean gloves and sterile instruments, and preventing direct contamination of materials and supplies.~There is contact between : non-sterile material in any change procedures and contact between sterile instruments or materials and any non-sterile surface or products.~It will be evaluated the duration of surgery."
89493801|NCT04807790|No Intervention|Routine physiotherapy and rehabilitation group|Routine physiotherapy and rehabilitation practices, consist of activities organized by physiotherapists as one or two sessions per week according to the functional levels of children with CP. Routine physiotherapy and rehabilitation applications include increasing postural control, gaining motor development steps, strengthening training, balance training, long-term stretching training, manual therapy, hydrotherapy, hippotherapy and neurodevelopmental therapy approaches.
89493802|NCT02135939|Active Comparator|American Heart Association diet|Participants randomized into this arm will follow an American Heart Association diet plan for 8 weeks.
89493803|NCT02135939|Experimental|Whole-food plant-based vegan diet|Participants randomized into this arm will be asked to follow a whole-food plant-based vegan diet plan for 8 weeks.
89493804|NCT02131961|Experimental|Study arm|Collagenase ointment topical application, once daily for 14 days, modified Contact Cast System, applied at days 0,3, and 7.
89493805|NCT02136017||Changchun biologial's vaccine|Changchun Biological's vaccine group is the population injected with this vaccine.
89493806|NCT02136095|Experimental|IFC-group|The investigators included patients undergoing laparoscopic cholecystectomy by a single surgeon between September and December 2013 at a single centre university department with unrestricted referral of patients. The included patients represented all patients undergoing laparoscopic cholecystectomy by one surgeon during the study period. All patients underwent intra-operative fluorescent cholangiography (IFC) with concomitant angiography, according to a standardized protocol, during their laparoscopic cholecystectomy.
88954293|NCT01970826|Active Comparator|Sterilized Aseptic Single|"The operatory room will be prepared with clean instruments but with no aseptic preparation.~Single dental implants placement will be made, Clean technique involves meticulous hand-washing, maintaining a clean environment by preparing a clean field, using clean gloves and sterile instruments, and preventing direct contamination of materials and supplies.~There is contact between : non-sterile material in any change procedures and contact between sterile instruments or materials and any non-sterile surface or product.~It will be evaluated the duration of surgery."
88954294|NCT01970826|Experimental|Sterilized Clean - Partial|"The operatory room will be prepared with clean instruments but with no aseptic preparation.~One or more dental implants will be made for partial rehabilitation, Clean technique involves meticulous hand-washing, maintaining a clean environment by preparing a clean field, using clean gloves and sterile instruments, and preventing direct contamination of materials and supplies.~There is contact between : non-sterile material in any change procedures and contact between sterile instruments or materials and any non-sterile surface or product.~It will be evaluated the duration of surgery."
88954295|NCT01970826|Active Comparator|Sterilized Aseptic - Partial|"The operatory room will be prepared with clean instruments but with no aseptic preparation.~One or more dental implants will be made for partial rehabilitation, Clean technique involves meticulous hand-washing, maintaining a clean environment by preparing a clean field, using clean gloves and sterile instruments, and preventing direct contamination of materials and supplies.~There is contact between : non-sterile material in any change procedures and contact between sterile instruments or materials and any non-sterile surface or product.~It will be evaluated the duration of surgery."
89493807|NCT02128841|Experimental|All patients|CATHAR is a prospective, open-label, pilot, phase 2 study with independent evaluation of all outcomes. The trial is based on a Bayesian design by incorporating historical information for the control group for all analyses.
89493808|NCT02132039|Active Comparator|12-step sitting Tai Chi Chuan|The intervention is a simplified Tai Chi Chuan exercise, which consists of 12 steps, including weight shifting in different sitting positions, trunk and upper limb movements, and alternate thigh lift in a smooth and coordinated manner.
89493809|NCT02132039|Placebo Comparator|Control|We provide participants in the control group with a level of social contact equivalent to the intervention group, which comprises structured conversations on topic other than physical activity.
89493810|NCT03550859|Experimental|Duowell Tab. 40/10mg|Telmisartan/Rosuvastatin 40/10mg qd for 48 weeks
89493811|NCT03550859|Active Comparator|Micardis Tab. 40mg|Telmisartan 40mg qd for 48 weeks
89493812|NCT03550781|Experimental|Anti-inflammatory treatment group|Prednisone and/or cyclophosphamide
89493813|NCT03550781|No Intervention|Control group|No intervention
88954296|NCT01970839|Other|Tourniquet, pain, nerve injury, sensory nerve function|
88954297|NCT01970852|Experimental|Standard tablet computer|Patient will receive tablet computer within 18 hours of admission and will continue to have access to it for the rest of his/her stay. Tablet has typical applications including access to the internet and entertainment.
88954298|NCT01970852|No Intervention|Usual Care|Patients will receive usual care and will answer surveys during the usual time-frame specified.
88954299|NCT01970852|Experimental|Enhanced tablet computer|Patients will receive a tablet computer within 18 hours of admission. Tablet will give access to a personalized inpatient personal health record portal. Will also provide access to standard tablet applications (e.g. video calling, streaming movies, etc.)
88954300|NCT01970891|Experimental|Freezing of Gait amelioration|Effect of neuromuscular stimulation device will be assessed on Freezing of Gait amelioration
89022408|NCT03271905|Experimental|PCV and high PEEP|Nebulization during mechanical ventilation on a pressure controled ventilation mode and PEEP = 15 cmH2O.
89493814|NCT02136173|Experimental|sequential balloons|effect of weight loss by applying sequential balloons
89493815|NCT02260583|Experimental|extracorporeal CO2 removal device|"the patients will be enroll to start a one shot session of extracorporeal CO2 removal. The patient will be connected to the device via a double lumen catheter inserted in the femoral vein An ECCO2R device based on a modified continuous venovenous hemofiltration system will be used. Blood flow is driven by a roller nonocclusive pump (0-450 mL/min) through a polypropylene oxygenator ; priming volume, 100 mL; contact surface area, 1.35 m2; maximum blood flow rate, 7 L/min) that is connected to a fresh gas flow source delivering 100% oxygen at a constant rate of 8 L/min. Exiting the oxygenator, blood is driven to a hemofilter."
89493816|NCT02136251||shoulder replacement|Subjects who had shoulder replacement surgery at The University of Nebraska and The Nebraska Medical Center at least 5 or more years ago and autologous bone graft around the anchor-peg glenoid prosthesis was used.
89493817|NCT02260661|Experimental|Part A|AZD8835 single agent dose escalation
89493818|NCT02260661|Experimental|Part B|Following the single agent dose escalation (Part A), additional patients with mutations in the PIK3CA gene will be enrolled to a single agent dose expansion phase at the MTD or recommended phase II dose (RP2D) at the selected dose schedule (as appropriate) to explore further the safety, tolerability, pharmacokinetics and biological activity at the selected dose (Part B). Part B will include patients with ER+/HER2 negative breast cancer whose tumours have a mutation of the PIK3CA gene and patients with any solid tumours which have a mutation of the PIK3CA gene.
89493819|NCT02260661|Experimental|Part C|AZD8835 in combination with fulvestrant dose escalation
89493820|NCT02260661|Experimental|Part D|Following the combination dose escalation segment of the study (Part C), additional postmenopausal patients with ER+/HER negative breast cancer and mutations of the PIK3CA gene will be enrolled to a AZD8835 and fulvestrant combination dose expansion phase at the maximum tolerated dose (MTD) or recommended phase II dose (RP2D) (as appropriate) to explore further the safety, tolerability, pharmacokinetics and biological activity at the selected dose (Part D).
89493821|NCT02136329|Experimental|Sildenafil|All subjects in groups 1-6 will receive SIldenafil but in escalating doses.
89493822|NCT02136407||Blood donors|N=540
89493823|NCT02136407||Thrombocyte donors|N=75
89493824|NCT02129153|Experimental|LIFT (Parent information)|"LIFT (Parent information): during their child's 7th and 8th grade years research staff will 1. communicate with parents about their child's academic and behavioral performance in school, roughly twice-monthly 2. invite parents to participate in a 2-hour parent support session to help teach parents to communicate better with their child and support better academic and behavioral performance in school~students take a baseline survey then 3 surveys (one/year)~parents take a baseline survey then 2 surveys (one/year)"
89493825|NCT02129153|No Intervention|Usual care group|"Usual care control group/No Intervention consists of neither communication of academic information to parents nor invitation to parent support sessions.~students take a baseline survey then 3 surveys (one/year)~parents take a baseline survey then 2 surveys (one/year)"
89493826|NCT02129231|Placebo Comparator|placebo|calcined magnesia 100 mg tablets once a day for 16 weeks
89493827|NCT02129231|Active Comparator|ezetimibe/simvastatin|ezetimibe/simvastatin 10/20 mg tablets once a day for 16 weeks
89493828|NCT02129231|Active Comparator|rosuvastatin|rosuvastatin 20 mg tablets once a day for 16 weeks
89493829|NCT02136485|Experimental|MBSR|8 weekly sessions each lasting 2.5 hours
89493830|NCT02136485|Other|Control|Control arm - waiting list control, once the intervention group has completed MBSR the control group will be invited to participate in MBSR
89493831|NCT02136563||Darbepoetin alfa|
89493832|NCT03550079|Experimental|three screws fixation|femoral neck fractures were fixed with three converted screws
89493833|NCT03550079|Experimental|four screws fixation|femoral neck fractures were fixed with four screws
89022409|NCT03271905|Experimental|Pressure suport ventilation (PSV)|Nebulization during mechanical ventilation on a pressure suport ventilation mode.
89493834|NCT03550001|Experimental|Injection CNP before NAT|Inject carbon nanoparticle as a lymph node tracer before the patient receive neoadjuvant therapy.
89493835|NCT03550001|No Intervention|No injection|Do not inject carbon nanoparticle during the treatment.
89493836|NCT02132273|Experimental|Educational Story|Participants receiving this intervention will have access to the educational story as they prepare for the overnight sleep study.
89493837|NCT02132273|No Intervention|Typical Preparation|Participants will receive traditional materials, directions, what to bring list, only. They will not recieve access to educational story
89493838|NCT02136641|Active Comparator|Midazolam|1. Sedation with Midazolam 0.03 mg / kg, Intravenous, administered as a single dose. Was given to those patients randomly assigned to this group, who were scheduled for procedures previously defined in the inclusion criteria.
89493839|NCT02136641|Experimental|Midazolam+Fentanyl Combination|2. Sedation with Midazolam 0.015 mg / Kg + Fentanyl 0.8mcg/kg, Intravenous, administered as a single dose. Was given to those patients randomly assigned to this group, who were scheduled for procedures previously defined in the inclusion criteria.
89493840|NCT02136641|Experimental|Midazolam+Ketamine Combination|3. Sedation with Midazolam 0,015 mg / Kg + ketamine 0.25 mg / kg, Intravenous, administered as a single dose. Was given to those patients randomly assigned to this group, who were scheduled for procedures previously defined in the inclusion criteria.
88954301|NCT01970904|Experimental|200 mg BID|Dual-therapy with a response-guided treatment duration with Alisporivir 200 mg twice daily (BID) and Ribavirin (RBV) for 12 or 24 weeks (Treatment period 1). Patients who were considered treatment failures were to be treated with peg-IFNα2a/RBV 800 mg daily for 24 weeks in Treatment period 2 (Roll-over treatment arm).
88954302|NCT01970904|Experimental|300 mg BID|Dual-therapy with a response-guided treatment duration with Alisporivir 300mg BID and RBV for 12 or 24 weeks (Treatment period 1). Patients who were considered treatment failures were to be treated with peg-IFNα2a/RBV 800 mg daily for 24 weeks in Treatment period 2 (Roll-over treatment arm).
89493841|NCT02136719|Active Comparator|Group A|bimanual uterine compression immediately after delivery of placenta for 5 minutes in 260 women
89493842|NCT02136719|No Intervention|Group B|no intervention (260 women).
89493843|NCT02129309|Experimental|Systemic Apelin infusion|"Study 2a - Haemodynamic studies to investigate the response to systemic infusions of 3 apelin agonists in healthy volunteers~Study 2b - Haemodynamic studies to investigate the response to 3 apelin agonists in COPD patients with elevated pulmonary artery pressures"
89493844|NCT02129309|Experimental|Apelin infusion - forearm|"Study 1a - A validation dose study of 3 apelin agonists using forearm plethysmography to evaluate changes in forearm blood flow: performed in healthy volunteers and COPD patients with elevated pulmonary artery pressures.~Study 1b- A validation dose study of apelin receptor antagonist using forearm plethysmography to evaluate changes in forearm blood flow, in healthy volunteers and COPD patients with elevated pulmonary artery pressures."
89493845|NCT02132351||Hepatologists|Doctors working as hepatologists
89493846|NCT03550703|Experimental|Single arm receiving V3-Myoma|A single oral pill of V3-Myoma therapeutic vaccine containing pooled antigens circulating in peripheral blood and within myoma tissues
89493847|NCT02786927|Experimental|ELLIPTA - HANDIHALER; HANDIHALER Questionnaire Version 1|Subjects will be dispensed the ELLIPTA inhaler at Visit 1 to use during the first period (once daily for 5-9 days), and the HANDIHALER inhaler at Visit 2 to use during the second period (once daily for 5-9 days). At Visit 3, subjects will complete Version 1 of the inhaler preference questionnaire.
89493848|NCT02786927|Experimental|ELLIPTA - HANDIHALER; Questionnaire Version 2|Subjects will be dispensed the ELLIPTA inhaler at Visit 1 to use during the first period (once daily for 5-9 days), and the HANDIHALER inhaler at Visit 2 to use during the second period (once daily for 5-9 days). At Visit 3, subjects will complete Version 2 of the inhaler preference questionnaire.
89493849|NCT02786927|Experimental|HANDIHALER - ELLIPTA; Questionnaire Version 1|Subjects will be dispensed the HANDIHALER inhaler at Visit 1 to use during the first period (once daily for 5-9 days), and the ELLIPTA inhaler at Visit 2 to use during the second period (once daily for 5-9 days). At Visit 3, subjects will complete Version 1 of the inhaler preference questionnaire.
89493850|NCT02786927|Experimental|HANDIHALER - ELLIPTA; Questionnaire Version 2|Subjects will be dispensed the HANDIHALER inhaler at Visit 1 to use during the first period (once daily for 5-9 days), and the ELLIPTA inhaler at Visit 2 to use during the second period (once daily for 5-9 days). At Visit 3, subjects will complete Version 2 of the inhaler preference questionnaire.
89493851|NCT03549689|Experimental|Switch|Dolutegravir (DTG) 50MG/ lamivuidne (3TC) 300MG FIXED_DOSE COMBINATION (FDC) DAILY at randomization for 96 weeks
89493852|NCT03549689|Active Comparator|Continuation|Continue current tenofovir alafenamide (TAF)-containing ART regimen from weeks 0 to 96.
89493853|NCT02132429|Experimental|AMG 333|Subjects will receive a single oral dose of AMG 333 daily for 14 days.
88954303|NCT01970904|Experimental|400 mg BID|Dual-therapy with a response-guided treatment duration with Alisporivir 400 mg BID and RBV for 12 or 24 weeks (Treatment period 1). Patients who were considered treatment failures were to be treated with peg-IFNα2a/RBV 800 mg daily for 24 weeks in Treatment period 2 (Roll-over treatment arm).
88954304|NCT01970917|Other|Healthy volunteers right eye|The medical device will be randomly assigned to the right or left eye on the study day (randomization 1:1) whereas the fellow eye will receive placebo.
88954305|NCT01970917|Other|Healthy volunteers left eye|The medical device will be randomly assigned to the right or left eye on the study day (randomization 1:1) whereas the fellow eye will receive placebo.
88954306|NCT01970930||PV or ET|subject who has polycythemia vera or essential thrombocythemia
88954307|NCT01970969||Cardiac arrhythmia symptoms|All subjects enrolled in the study will have an iRhythm Zio patch placed and a blood sample obtained.
88954308|NCT01971021|Active Comparator|PICC-line|PICC line insertion.
88954309|NCT01971021|Active Comparator|PORT|Subcutaneous venous port insertion
88954310|NCT01971034|Experimental|Paclitaxel and Metformin|
88954311|NCT01971047|Active Comparator|Group 1-Regular Insulin|Intravenous Regular Insulin will be administered for a preoperative Blood glucose of greater than 180.
88954312|NCT01971047|Active Comparator|Group 2-Humalog|Subcutaneous Humalog will be administered for a preoperative Blood glucose of greater than 180
88954313|NCT01971060|Experimental|V-Loc suture|Laparoscopic surgery utilizing V-Loc suture
89493854|NCT02132429|Placebo Comparator|Placebo|Subjects will receive a single oral dose of placebo daily for 14 days.
89493855|NCT02129699|Other|None, standard chemotherapy only|"4 - 6 cycles of standard chemotherapy + best supportive care including any bone protective agent except denosumab.~Standard chemotherapy consis of a combination of platinum-based doublet agents plus gemcitabine or pemetrexed."
89493856|NCT02129699|Experimental|Standard chemotherapy + Denosumab|"4 - 6 cycles of standard chemotherapy + denosumab 120 mg, administered subcutaneously every 3-4 weeks until unacceptable toxicity, patient refusal, or patient's death. Denosumab should be administered on day 1 of each cycle, before or after the administration of chemotherapy. After stop of first-line chemotherapy, denosumab must be continued life-long, regardless of tumour progression and concomitantly with subsequent lines of systemic treatment, as long as tolerable for the patient.~Standard chemotherapy consis of a combination of platinum-based doublet agents plus gemcitabine or pemetrexed."
89022410|NCT00459225|Active Comparator|1|The parent/guardian will be educated on the iron study and provided the opportunity to ask questions. If the parent/guardian chooses to participate in the study, the parent/guardian will give informed consent for the patient to be placed in either Group I or Group II, based upon guardian/parents' choice for participation in the iron arm of the study. Group I will be randomized in a 1:1 ratio in this open label trial to either receive or not receive iron. Group II will not receive iron but will be a participant in the study and follow the course of the non-iron randomized patients.
89022411|NCT00459225|No Intervention|2|Group II will not receive iron but will be a participant in the study and follow the course of the non-iron randomized patients.
89022412|NCT00426413||1|Obese AA subjects with DKA or severe hyperglycemia
89493857|NCT03549923|Experimental|Simultaneous CRRT group|CRRT is initiated simultaneously (not late than 24 hours from the initiation of ECMO treatment), regardless of presentation of conventional indication of CRRT. CRRT lasts for 12 hours or more is recommended.The physician can decide when to withdraw CRRT based on the patient's condition.
89493858|NCT03549923|Experimental|Conventional-indication CRRT group|CRRT is not initiated unless conventional indication of CRRT is presented. The conventional indication of CRRT is as follow: KDIGO stage 3 AKI and one of the following criteria is met: severe hyperkalemia (> 6.5 mmol/L), metabolic acidosis (pH < 7.2), pulmonary edema, blood urea nitrogen level >112 mg/dL, or oliguria (urine output < 200 mL/12 h) for more than 72 hours.
89493859|NCT03549923|Experimental|Esmolol group|Patients will receive a continuous esmolol infusion in addition to routine management. The esmolol infusion commences at 25 mg/h and increases by 25 mg/h every 20-minute until the maximal tolerate dosage is reached or the heart rate reduced to 75±5 bpm, or an upper dose limit of 2000 mg/h is reached. Continue infusing esmolol to maintain the heart rate threshold or at the discretion of the physician until either ICU discharge or death. Oral beta-blockers should be considered before the withdrawal of esmolol.
89493860|NCT03549923|Experimental|Control group|All beta-blockers, including esmolol, should not be used during ICU treatment, unless the doctor thinks there's a strong indication.
89493861|NCT02132585||Sjogren|Sjogren Patients evaluated with Speckle tracking echocardiography
89493862|NCT02132585||Control|Controls Speckle tracking echocardiography
89493863|NCT02136875|Experimental|Double dose of Advair for AECOPD|Double dose of Salmeterol + Fluticasone Propionate (Advair) Self-administered prescription Self-management education on the use of a self-administered prescription
89493864|NCT02132663|Experimental|Infant formula containing an alternate source of DHA|
89493865|NCT02132663|Active Comparator|Marketed routine infant formula|
89493866|NCT05212493|Active Comparator|Seach CBD:THC 20:1 cannabis oil|cannabis oil containing CBD:THC ratio of 20:1. plant material is grown by Seach LTD and oil manufactured by Nextar Pharma LTD.
89022413|NCT00426413||2|obese nondiabetic subjects, age 19-65.
89493867|NCT05212493|Active Comparator|Candoc CBD:THC 20:1 cannabis oil|cannabis oil containing CBD:THC ratio of 20:1. plant material is grown by Candoc LTD and oil manufactured by Panaxia LTD.
89493868|NCT02136953|Experimental|Exercise|12-weeks of structured, individual aerobic exercise, 3 times a week, increasing from 15-30 minutes to 30-40 minutes per session.
89493869|NCT02136953|Active Comparator|Cognitive Behavioural Therapy (CBT)|12-weeks of manual-based group CBT, 2 hours per week, 8 participants per group.
89493870|NCT02136953|Experimental|Exercise and CBT|Combined 12-week Exercise program and CBT.
89493871|NCT02136953|No Intervention|Waitlist Condition|12-week waitlist control condition, after which participants will have the chance to receive CBT group treatment.
89493872|NCT02129933|Experimental|Tracer bevacizumab-IRDye800CW|"Two days prior to the fluorescence endoscopy procedure (with the near infrared fluorescence endoscopy platform), all patients will receive the fluorescent tracer bevacizumab-IRDye800CW intravenously.~*amendement June 2015: topical administration of bevacizumab-800CW"
89493873|NCT02132819|Placebo Comparator|Feeding During Transfusion|The feeding process will be continued during the transfusion
89022414|NCT00426413||3|Any subjects with recurrent DKA. Recurrent DKA is defined as more than one admission to Grady Memorial Hospital.
89022415|NCT00459264|Active Comparator|1|Folic Acid
89022416|NCT00459264|Placebo Comparator|2|Matching placebo for folic acid
89022417|NCT00467727|Experimental|1|Phase Contrast Mammography Exam
89022418|NCT00426491|Active Comparator|A|Four 200 ug tablets of Misoprostol
89022419|NCT00426491|Placebo Comparator|B|
89493874|NCT02132819|Active Comparator|witholding feeds|At least 2 feeds before the transfusion, 2 feeds after the transfusion and feeds during the transfusion are withholded
89493875|NCT02132897|Other|TR (Test - Reference)|Sequence : Auration CR 400 Single Dose/Tegretol CR 400 Single Dose
89493876|NCT02132897|Other|RT (Reference - Test)|Sequence: Tegretol CR 400 Single Dose/Auration CR 400 Single Dose
89493877|NCT02130011|No Intervention|without feeding/fluid instructicon|Ten patients treated with preoperative chemoradiotherapy without feeding/fluid instructions
89493878|NCT02130011|Experimental|with feeding/fluid instructions|Ten patients treated with preoperative chemoradiotherapy with feeding/fluid instructions
89493879|NCT02132975|Experimental|With motorised probe handler|The surgeon use the motorised probe handler to do the biopsy
89493880|NCT02132975|Experimental|Without motorised probe handler|The surgeon do the biopsy as he usually do.
89022420|NCT03273777|Experimental|Drawing of an incision line|An incision line of 14 cm will be drawn using a conventional surgical ruler and pen before skin incision.
89022421|NCT03273777|No Intervention|No drawing of an incision line|Skin incision will be carried out without previous drawing of an incision line.
89022422|NCT00426530|Experimental|RAD001 Daily Schedule|5mg or 10mg
89022423|NCT00426530|Experimental|RAD001 Weekly Schedule|30mg
89204788|NCT04100525|Experimental|Experimental Treatment|Participant received neuropsychological testing, report detailing cognitive strengths and weaknesses, tailored recommendations to address areas of weakness (including psychological and/or physical symptoms impacting work productivity). Participant then receives in-person feedback (and a copy of the report at this visit) and two calls from a care-coordinator research nurse at approximately 1 and 6 months post feedback, who asks participant whether they completed recommendations and assist participant in completing recommendations where possible (i.e., help find a provider, explanation of importance of completing recommendations, etc).
89204789|NCT01000168|Experimental|Treadmill therapy|"Patients assigned to the Treadmill therapy group received daily 30 minutes specific walking training on treadmill with body weight support alternatively overground, and 30 minutes functional training, treated by a physiotherapist."
89493881|NCT02252471|Experimental|Choices-Teen Intervention|A three session intervention with two counseling sessions with a master's level therapist and a counseling session with a physician. The counseling with the master's level therapist utilizes a motivational interviewing approach to encourage changes in alcohol use, contraceptive use, smoking and HIV risk behaviors. This part of the intervention (a) provides norms-based-but personalized-feedback; (b) encourages participating in the smoking cessation program; (c) increases motivation to change each of the target behaviors; (d) decreases temptation to engage in risk behaviors; (e) increases confidence to avoid risk behaviors; and (f) develops a personalized, tailored change plan. The physician session provides individualized contraception and HIV risk reduction counseling.
89493882|NCT02252549|Active Comparator|A|SPIES+WLI assisted TURB
89493883|NCT02252549|Active Comparator|B|WLI assisted TURB
89493884|NCT02137031|Experimental|Mini Link REAL-Time Transmitter|
89493885|NCT02133053||Ectoin Group|Ectoin Allergy Nasal Spray (Medical Device, drug-like)
89493886|NCT02133053||Beclomethasone Group|Beclomethasone nasal spray
89493887|NCT02137109||natalizumab|Natalizumab will not be provided as a part of this study. Participants will receive natalizumab per the local label specifications.
89493888|NCT02130089|Other|All patients|Intensive tailored education
89493889|NCT02130167|Experimental|0.01% Atropine|
89493890|NCT02130167|Active Comparator|0.05% Atropine|
89493891|NCT02133209|Active Comparator|Stress Management for Headaches|This intervention involves a standardized stress management for headaches (SMH) group intervention that focuses on stress and general stress management skills for managing migraine headaches.
89493892|NCT02133209|Active Comparator|Mindfulness Based Stress Reduction|Intervention involves a standardized mindfulness-based stress reduction (MBSR) group intervention following the guidelines originally conceived and developed by the Center for Mindfulness in Medicine, Health Care and Society at the University of Massachusetts. The intervention also included an extended period of training in addition to the usual 8 weeks.
89022424|NCT00459420|Placebo Comparator|Placebo|
89022425|NCT00459420|Experimental|Caffeine|
89022426|NCT00467883|Experimental|amphotericin B|Treatment with high dosage of amphotericin B liposomal 10 mg/kg/day during 4 weeks
89022427|NCT00426608|Experimental|Session 1|Subjects will be randomized to receive Dose 1 of Metyrapone 0.04 gram per kilogram (g/kg) and Dose 2 of AEBCD sequence. In AEBCD sequence A is placebo, E Alprazolam, B GSK6561679 10 milligram (mg), C GSK6561679 50 mg and D GSK6561679 400 mg. Wash-out period will be of 7 days.
89022428|NCT00426608|Experimental|Session 2|Subjects will be randomized to receive Dose 1 of Metyrapone 0.04 g/kg and Dose 2 of BACED sequence. In BACED sequence B is GSK6561679 10 mg, A placebo, C GSK6561679 50 mg, E Alprazolam, and D GSK6561679 400 mg. Wash-out period will be of 7 days.
89022429|NCT00426608|Experimental|Session 3|Subjects will be randomized to receive Dose 1 of Metyrapone 0.04 g/kg and Dose 2 of CBEAD sequence. In CBEAD sequence C is GSK6561679 50 mg, B GSK6561679 10 mg, E Alprazolam, A placebo, and D GSK6561679 400 mg. Wash-out period will be of 7 days.
89493893|NCT02130245|Active Comparator|Early cholecystectomy|Laparoscopic cholecystectomy well be done after the immediate admission
89022430|NCT00426608|Experimental|Session 4|Subjects will be randomized to receive Dose 1 of Metyrapone 0.04 g/kg and Dose 2 of ECABD sequence. In ECABD sequence E is Alprazolam, C is GSK6561679 50 mg, A placebo, B GSK6561679 10 mg and D GSK6561679 400 mg. Wash-out period will be of 7 days.
89022431|NCT00426608|Experimental|Session 5|Subjects will be randomized to receive Dose 1 of Metyrapone 0.04 g/kg and Dose 2 of GSK561679 400 mg and alprazopam placebo. Wash-out period will be of 7 days.
89022432|NCT00426647|Experimental|Buprenorphine|Norspan transdermal patch
89022433|NCT00426647|Active Comparator|Tramadol|Tramadol SR tablets
89022434|NCT00468078|Experimental|A|Parkinson's disease
89022435|NCT00468078|Active Comparator|B|ET+Normal
89022436|NCT00468156|Active Comparator|1|written materials only
89022437|NCT00468156|Experimental|2|written materials plus asked to form implementation intentions
89022438|NCT00468156|Experimental|3|same as arm 2 plus telephone support
89493894|NCT02130245|Active Comparator|Delayed cholecystectomy|Laparoscopic cholecystectomy after a period of conservative treatment
89493895|NCT02130323|Active Comparator|Loop Electrosurgical Excision Procedure|Excision of the cervical transformation zone by way of the loop electrosurgical excision procedure (LEEP) or cold knife conization (CKC).
89493896|NCT02130323|Experimental|Imiquimod|Imiquimod 12.5mg intravaginally once weekly for 16 weeks
89493897|NCT03549611|Experimental|Multimodel Drug Regimen|"The patients randomized to this arm will receive the following multimodal oral drug regimen administered shortly before induction of general anesthesia~Tylenol, 975mg (3 tabs)~800mg Gabapentin~400mg Celecoxib~10mg Oxycodone"
89493898|NCT03549611|Active Comparator|Acetaminophen Only|"The patients randomized to this arm will receive oral acetaminophen only administered shortly before induction of general anesthesia~1. Tylenol, 975mg (3 tabs)"
89493899|NCT02253017||Children operated on for cataract|
89493900|NCT02133287|Experimental|AVI® Arsenic trioxide drug eluting stent|Study group: Arsenic trioxide drug eluting stent delivery system (AVI®)
89493901|NCT02133287|Active Comparator|Firebird2® sirolimus eluting stent system|Control group: sirolimus eluting cobalt-chromium alloy stent system(Firebird 2®)
88954314|NCT01971073|Experimental|bilateral Anodal-L/R Cathodal-R/L tDCS|"bilateral Anodal-left and cathodal-right tDCS over DLPFC or bilateral Anodal-right and cathodal-left tDCS over DLPFC.~Intervention: Device: transcranial direct current stimulation"
89493902|NCT02137187|Experimental|Drug therapy|Control Arm: optimized drug therapy (plus implantable defibrillator (ICD) according to guidelines)
89493903|NCT02137187|Active Comparator|Device: AV junction ablation & CRT|AV junction ablation + CRT (CRT-P or CRT-D according to guidelines) + optimized drug therapy
89493904|NCT02130401|Experimental|TNM (thermoneuromodulation device)|A standardized active thermal neuromodulation waveform will be used for all patients. The device is non-invasive and does not use electrical stimulation.
88954315|NCT01971073|Sham Comparator|Sham tDCS|Sham tDCS
88954316|NCT01971099|Placebo Comparator|Placebo|patients will use placebo for 120 days
88954317|NCT01971099|Experimental|Tribulus Terrestris|patients will use Tribulus terrestris (750 mg/day) during 120 days
88954318|NCT01971112|Experimental|Multivitamins and minerals|Experimental: X: Multivitamins and minerals (MVM) Arm X: 1X US-RDA of vitamins A, D,E,B6,B12, folate, copper and iron plus 500 mg vitamin C, and 14 mg of Zinc
88954319|NCT01971112|Placebo Comparator|Placebo|
88954320|NCT01971138||Surgical site infection registration|Is there a routine for SSI registration
88954321|NCT01971151|Experimental|Exposure with safety-seeking behavior|Patients receive exposure therapy. In the current condition, exposure is offered while patients are allowed to use their own safety-seeking behaviors (i.e., behavior believed to be necessary to prevent a feared catastrophe).
88954322|NCT01971151|Experimental|Exposure without safety-seeking behavior|Patients receive exposure therapy.In the current condition, exposure is offered while patients are instructed to omit their safety-seeking behavior.
88954323|NCT01971151|Active Comparator|Exposure therapy only|Patients receive exposure therapy. In the current condition, exposure is offered while patients do not receive any specific instructions about what to do with their safety-seeking behavior.
88954324|NCT01971164|Experimental|Dose 1 JTZ-951 or Placebo|Tablets, 1 dose per day for 15 days
88954325|NCT01971164|Experimental|Dose 2 JTZ-951 or Placebo|Tablets, 1 dose per day for 15 days
89493905|NCT02130479|Experimental|Contingency Management-Family Engagement|The Contingency Management-Family Engagement or CM-FAM model integrates behavioral (e.g., drug testing linked with consequences) and cognitive behavioral (e.g., functional analyses of drug use, self-management and drug refusal skills training) strategies based on the Community Reinforcement Approach with effective family engagement strategies used in Multisystemic Therapy.
89493906|NCT02130479|Active Comparator|Treatment as Usual|Standard community-based substance abuse treatment services.
89493907|NCT02137265|Active Comparator|Clomiphene citrate|Clomiphene citrate 50 mg daily during 4-6 months
89493908|NCT02137265|Placebo Comparator|Placebo|Placebo (1 pill daily) during 4-6 months
89493909|NCT02133365|Active Comparator|Mindfulness and Interoceptive Exposure|Atrial fibrillation patients will receive 4-5 manualized, individualized sessions of Mindfulness and Interoceptive Exposure.
89493910|NCT02133365|No Intervention|Medical care as usual|Atrial fibrillation patients will receive medical and cardiac care as usual.
89493911|NCT02133443|Active Comparator|Pressure Support Ventilation|Device: PSV - pressure support ventilation
89493912|NCT02133443|Active Comparator|Neurally Adjusted Ventilatory Assist|Device: Partial ventilator support with partial ventilation mode (NAVA)
89493913|NCT02592434|Experimental|CP-690,550|Treatment arm: Tofacitinib tablets or solution, according to subjects' body weights
89493914|NCT02592434|Placebo Comparator|Placebo|Control arm: matching placebo tablets or solution for tofacitinib
89493915|NCT02130713|Active Comparator|Group A, antibiotics|Prulifloxacin 600 mg
89493916|NCT02130713|Active Comparator|Group B, antibiotics plus nutraceuticals|Prulifoxacin plus Serenoa repens 320 mg, Lactobacillus Sporogens 200 mg, Arbutin 100 mg
89493917|NCT02133599|Other|Iohexol|All patients will receive two Iohexol clearance tests, 5 mL each time before cycle 1 and 4 of HDMTX
89493918|NCT02130791|Experimental|PSD then TSD|baseline sleep, five nights sleep restriction, four nights recovery sleep, one night total sleep deprivation, one night recovery sleep
89493919|NCT02130791|Experimental|TSD then PSD|baseline sleep, one night total sleep deprivation, four nights recovery sleep, five nights sleep restriction, one night recovery sleep
89493920|NCT02137421|Experimental|CAD, Metabolic syndrome .|"Arm1:coronary artery disease with metabolic syndrome . Intervention:Resveratrol (3, 4´, 5 trihydroxystilbene), 50 micromolar,12hour treatment .~Each experiment repeats three times ."
89493921|NCT02137421|Experimental|Healthy subjects .|"Arm2:healthy subjects Intervention:Resveratrol (3, 4´, 5 trihydroxystilbene), 50 micromolar,12hour treatment .~Each experiment repeats three times ."
89493922|NCT02260739|Other|chronic myelomonocytic leukemia|Three cohorts will be investigated: ET (essential thrombocythemia), IMF and secondary MF (myelofibrosis) and CMML (chronic myelomonocytic leukemia)
89493923|NCT02260739|Other|essential thrombocytemia|Three cohorts will be investigated: ET (essential thrombocythemia), IMF and secondary MF (myelofibrosis) and CMML (chronic myelomonocytic leukemia)
89493924|NCT02260739|Other|myelofibrosis|Three cohorts will be investigated: ET (essential thrombocythemia), IMF and secondary MF (myelofibrosis) and CMML (chronic myelomonocytic leukemia)
89493925|NCT02137577|Experimental|DEB catheter|use DEB catheter(trade name: Lotus/Tulip) to treat the stenosis or occlusion in below popliteal artery of experimental arm
89493926|NCT02137577|Active Comparator|common PTA balloon catheter|use common PTA balloon catheter(trade name:Amphirion Deep) to treat stenosis or occlusion in below popliteal artery of control group
89493927|NCT02133677|Experimental|temozolomide+WBRT|temozolomide: TMZ 200 mg p.o. q.d. x 5 days per week x 3 weeks WBRT:30 Gy in 15 fractions (2 Gy per fraction, 5 fractions per week)
89493928|NCT02137733|Active Comparator|Bisoprolol group|Daily oral administration of bisoprolol 0.625 mg tablet once a day should be given (Step 1). If tolerability is confirmed by an investigator, the dose should be increased to 1.25 mg (bisoprolol 0.625 mg, 2 tablets; or bisoprolol 2.5 mg, half tablet; once daily) (Step 2). In the same manner, the doses should be increased to 2.5 mg (bisoprolol 2.5 mg, 1 tablet; or bisoprolol 5 mg, half tablet; once daily, Step 3), to 3.75 mg (bisoprolol 2.5 mg, 1.5 tablets once daily, Step 4), and to 5 mg (bisoprolol 2.5 mg, 2 tablets; or bisoprolol 5 mg, 1 tablet; once daily, Step 5).
89493929|NCT02137733|Active Comparator|Carvedilol group|Daily oral administration of carvedilol 1.25 mg, 1 tablet twice a day (after breakfast and supper) should be given (Step 1). If tolerability is confirmed by an investigator after administering 2.5 mg/day of carvedilol, the dose should be increased to 5 mg (carvedilol 2.5 mg, 1 tablet twice daily) (Step 2). In the same manner, the dose should be increased to 10 mg (carvedilol 2.5 mg, 2 tablets twice daily, Step 3), to 15 mg (carvedilol 2.5 mg, 3 tablets twice daily, Step 4), and to 20 mg (carvedilol 10 mg, 1 tablet twice daily, Step 5).
89493930|NCT02137811||Patients that received MICK assay|Patients with pathological diagnoses of cancer or leukemia who have had a MiCK assay (CorrectChemo) test performed
89493931|NCT02252705||Incident patients|Patients with less than three months from diagnosis to start of the Registry or those who have been diagnosed during the recruitment period.
89493932|NCT02252705||Prevalent patients|Patients who have been diagnosed with more than three months from diagnosis to start of the Registry.
89493933|NCT04371458|Experimental|Intraoperative providone-iodine lavage|Intraoperative providone-iodine lavage during resection
89493934|NCT02137889|Experimental|Arm 1- relapsed/refractory CLL patients|Patients with relapsed/refractory CLL with two or three prior treatment regimens
89493935|NCT02137889|Experimental|Arm 2 - rituximab or ofatumumab refractory CLL patients|Patients with relapsed/refractory CLL with four or more prior treatment regimens
89493936|NCT04794452|Active Comparator|Battery operated toothbrush|battery operated toothbrush
89493937|NCT04794452|Active Comparator|Manual toothbrush|Manual toothbrush
89493938|NCT02133755|Other|Bromocriptine mesylate (Cycloset)|Cycloset 1.6 to 3.2 mg daily for 3 months
88954326|NCT01971164|Experimental|Dose 3 JTZ-951 or Placebo|Tablets, 1 dose per day for 15 days
88954327|NCT01971164|Experimental|Dose 4 JTZ-951 or Placebo|Tablets, 1 dose per day for 15 days
88954328|NCT01971177|Experimental|Femtosecond laser cataract surgery|"Laser group: a pre-fragmentation of the ocular lens will be performed by VICTUS femtosecond laser lens fragmentation procedure."
89493939|NCT02130869|Experimental|Group A: Neuroblastoma|"All participants first receive standard of care high-dose chemotherapy specific to their tumor type. Group A participants receive busulfan, melphalan, CD133+ selected autologous stem cell infusion, hu14.18K322A, IL-2, haploidentical natural killer cell infusion, G-CSF, and GM-CSF.~Cells for infusion are prepared using the CliniMACS System."
89493940|NCT02130869|Experimental|Group B: Lymphoma|"All participants first receive standard of care high-dose chemotherapy specific to their tumor type. Group B participants receive bendamustine, etoposide (or etoposide phosphate), cytarabine, melphalan, CD133+ selected autologous stem cell infusion, IL-2, haploidentical natural killer cell infusion, G-CSF, and GM-CSF.~Cells for infusion are prepared using the CliniMACS System."
89493941|NCT02130869|Experimental|Group C: High-Risk Tumors|"All participants first receive standard of care high-dose chemotherapy specific to their tumor type. Group C participants receive melphalan, etoposide (or etoposide phosphate), carboplatin, CD133+ selected autologous stem cell infusion, IL-2, haploidentical natural killer cell infusion, G-CSF, and GM-CSF.~Cells for infusion are prepared using the CliniMACS System."
89493942|NCT04785404|Experimental|primary skin closure|in this group, skin wound will be primarily closed
89493943|NCT04785404|No Intervention|secondary skin closure|skin will be left open to heal by secondary intention
88954329|NCT01971177|Active Comparator|Manual cataract surgery|"Manual: manual group acts as a control group where the lens fragmentation are performed manually without femtosecond laser assisted lens fragmentation"
89493944|NCT02130947|Experimental|Exercise Intervention Arm|The exercise intervention will consist of a combination of aerobic (cardiovascular exercise) and strength training (emphasis of the intervention) 3 times per week for 12 weeks with each session lasting ~1.5 hours.
89493945|NCT02130947|No Intervention|Non-Exercise Control Arm|Participants in the Non-Exercise Control Arm will not exercise for 12 weeks.
89493946|NCT04785248|No Intervention|Controlled group|the routine preoperative disinfection method
89493947|NCT04785248|Experimental|Three-step disinfection|new developed method of preoperative disinfection
89493948|NCT02133833|Experimental|Quantum Spectrum Radiation Emitter|five pieces of Quantum Spectrum Radiation Emitter will be placed on the affected shoulder daily for three weeks.
89493949|NCT02137967|Experimental|NaOCl pulpotomy|Use 2.5% NaOCl as pulpotomy medication
89493950|NCT02137967|Active Comparator|FC pulpotomy|Use 20% Formocresol as pulpotomy medicament
88954330|NCT01971190|Sham Comparator|Sham injection|Sham injection at baseline, at 1 month, and at 2 month
88954331|NCT01971190|Active Comparator|Intravitreal Aflibercept injection|2mg intravitreal Aflibercept(Eylea) injection at baseline, at 1 month, and at 2 month
89204790|NCT01000168|Active Comparator|Conventional walking therapy|Patients assigned to the comparative conventional walking therapy group received daily 30 minutes specific traditional walking training overground and 30 minutes functional training, treated by a physiotherapist.
89493951|NCT04785170|Experimental|amino acid|"Dose: 1000 mg/day (500 mg/Capsule) Regimen: One capsule after breakfast & one capsule after dinner to be taken with a glass of water.~Duration: 14 Days"
89493952|NCT02133911|No Intervention|Controls|
89493953|NCT02133911|Experimental|Ranolazine|Initial dose is 375 mg bid. After 2 - 4 weeks the dose is increased to 500 mg bid and after another 2-4 weeks to 750 mg bid. In case of side effects the dose of the drug is to be decreased to the highest dose that the patient is still able to tolerate.
88954332|NCT01971216|No Intervention|Control|Breastfeeding mothers who are not randomised to relaxation intervention
88954333|NCT01971216|Experimental|Relaxation|Breastfeeding mothers randomised to use relaxation tape at 2 weeks post-partum
88954334|NCT01971229|Sham Comparator|Carbohydrate|Patients in this arm will drink a 425 mL 100% clear apple juice (carbohydrate 50 g, 700 mOsmol). 1.5 g of acetaminophen will be dissolved in the beverage for determination of gastric emptying.
88954335|NCT01971229|Active Comparator|Whey Protein|Patients in this arm will drink a 330 mL Boost fruit flavoured clear beverage (whey protein 12.2 g, carbohydrate 50 g, 700 mOsmol).1.5 g of acetaminophen will be dissolved in the beverage for determination of gastric emptying.
88954336|NCT01971242|Active Comparator|Exenatide|Bydureon- 2mg administered subcutaneously once weekly
88954337|NCT01971242|Placebo Comparator|Placebo|Placebo, 2mg administered subcutaneously once weekly
88954338|NCT01971268||Platform-Switch Group|T3 dental implant, with platform-switch dental implant platform concept, measure marginal bone loss
88954339|NCT01971268||Platform-Matched Group|T3 dental implant, platform-matched dental implant platform concept, measure marginal bone loss
88954340|NCT01971281|Experimental|TTFilelds + gemcitabine|Patients will be treated continuously with the NovoTTF-100L device, in addition to Gemcitabine.
88954341|NCT01971281|Experimental|TTFields + gemcitabine+ nab-paclitaxel|Patients will be treated continuously with the NovoTTF-100L device, in addition to Gemcitabine plus nab-paclitaxel
88954342|NCT01971294||Systemic sclerosis|Adult suffering from systemic sclerosis included in the EUSTAR network of Brescia (I), Geneva (CH), Padova (I) and Paris (F).
89493954|NCT02133989|Experimental|Ticlopidine+Ginko biloba|Switch to ticlopidine + ginko biloba
89493955|NCT02133989|Active Comparator|Clopidogrel|Keep clopidogrel
89022439|NCT00426725|Experimental|A|This group uses the EasyLabour device according to the protocol
89204791|NCT01000246|Experimental|influenza vaccine day 4|influenza vaccine day 4 of chemotherapy
89204792|NCT01000246|Experimental|influenza vaccine day 16|influenza vaccine day 16 of chemotherapy
89204793|NCT01000246|Active Comparator|influenza vaccine|influenza vaccine in patients with heartfailure
89204794|NCT00627042|Experimental|Ramucirumab (IMC-1121B)|
89493956|NCT02138045|Placebo Comparator|Placebo treatment|"Placebo solution will be slowly titrated to maximum tolerable dose in order to minimize potential side-effects, hence treatment will follow:~First and second week: 0.6 mg/day; Third and fourth week: 1.2 mg/day and Fifth and to sixth week: 1.8 mg/day."
89493957|NCT02138045|Active Comparator|Liraglutide treatment|"Liraglutide will be slowly titrated to maximum tolerable dose in order to minimize potential side-effects, hence treatment will follow:~First and second week: 0.6 mg/day; Third and fourth week: 1.2 mg/day and Fifth and to sixth week: 1.8 mg/day."
89493958|NCT02138123|Experimental|IOL-shell technique|In this group, before the emulsification of the last nuclear fragment, cohesive viscoelastic material was injected below the nuclear fragment and a foldable IOL was implanted into the well inflated capsular bag posterior to the nuclear fragment. The remaining last piece of nuclear fragment was then emulsified and removed within the capsular bag.
88954343|NCT01971307|Experimental|SGE-PsyScan|The SGE-PsyScan is an internet application to which the General Practitioner (GP) refers the patient, which includes the distress screener, the 4-Dimensional Symptom Questionnaire (4DSQ) and a series of additional questions for differentiating between stress, depressive, anxious and somatization symptoms. Based on the 4DSQ patients and GPs receive advices for possible treatments.
88954344|NCT01971307|No Intervention|Usual care|Usual care for persons with psychosocial symptoms and disorders in Dutch primary care includes all usual care procedures; preventive, screening, diagnostic, (non-)pharmacological or therapeutic procedures which are routinely used in everyday care.
88954345|NCT01971320|Experimental|active stimulation|"sensitive electrical stimulation applied during meals with Urostim I for 6 weeks~Urostim I stimulation will be done during meals for 6 weeks"
88954346|NCT01971320|Placebo Comparator|fake stimulation|"Urostim I stimulation will be done during meals for 6 weeks~Fake sensitive electrical stimulation applied during meals with modified Urostim I who not deliver stimulation for 6 weeks"
88954347|NCT01971333||Liver transplantation|"Compare intraoperative change of dynamic parameters after fluid loading:~pulse pressure variation~stroke volume variation~plethysmographic variation index"
88954348|NCT01971359||Retrospective|
89022440|NCT00426725|No Intervention|Control|
89022441|NCT01059344|Experimental|Mesalamin|4.8g Mesalamin (800mg tablet)
89493959|NCT02138123|Active Comparator|Conventional procedure|In this group, a Sensar IOL (AMO Laboratories) was implanted in the capsular bag with the injector system after the lens material was completely removed. The nuclear fragmentation was performed using the Phaco-chop technique, which was then followed by ultrasound emulsification of the nuclear fragments piece by piece. Due to lack of cortical shell within the capsular bag, special care was taken to carry out the emulsification of the last nuclear fragment at a relatively more anterior anatomical position between the iris plan and the anterior chamber.
89493960|NCT02134067|Experimental|TAS-119|"TAS-119 tablets, oral, dose-escalating, 28-day cycle.~Paclitaxel (90mg/m2) is administered IV in combination with TAS-119 in each of the arms."
89493961|NCT02253329|Active Comparator|Treatment during the day|Neuromuscular electrical stimulation after a protein bolus, performed during the day
89022442|NCT01059344|Placebo Comparator|Placebo|4.8g Placebo to Mesalamin (800 mg tablet)
89022443|NCT00459654|Experimental|Radium-223 dichloride (Xofigo, BAY88-8223)|Each subject receives local filed external beam radiotherapy (EBR) and repeated injections of the investigational drug radium-223 (EBR+Radium-223)
89022444|NCT00459654|Placebo Comparator|Saline|Each subject receives local filed external beam radiotherapy (EBR) and repeated injections of saline (EBR+placebo)
89204795|NCT00319111|Experimental|Bosentan|Open label bosentan treatment
89493962|NCT02253329|Active Comparator|Treatment prior to sleep|Protein ingestion directly after one-legged NMES, directly prior to sleep
89493963|NCT05614154|Active Comparator|Povidone-iodine Group|The care of patients with central venous catheters will be done with Povidone iodine as long as they stay in the intensive care unit
89493964|NCT05614154|Experimental|hypochlorous active substance|The care of patients with central venous catheters will be done with antiseptic with hypochlorous active substance as long as they stay in the intensive care unit.
89493965|NCT04794140|Experimental|one pass group|We use the endoscopic ultrasound-guided fine-needle biopsy (EUS-FNB) wet suction technique to procure the specimens, and use the sample obtained from a single pass for primary cell culture. EUS-FNB wet suction technique refer from Tong T, et al. J Gastroenterol Hepatol. 2020;10.1111/jgh.15371.
89493966|NCT04794140|Experimental|two passes group|We use the endoscopic ultrasound-guided fine-needle biopsy (EUS-FNB) wet suction technique to procure the specimens, and use the sample obtained from two passes for primary cell culture. EUS-FNB wet suction technique refer from Tong T, et al. J Gastroenterol Hepatol. 2020;10.1111/jgh.15371.
89493967|NCT04091126|Experimental|Cohort 1: belantamab mafodotin 1.9 mg/kg Q3/4W + VRd/Rd|Participants will receive 1.9 milligram /kilogram (mg/kg) Q3W dose of belantamab mafodotin on Day 1 of every cycle for the first 8 cycles in combination with VRd and Q4W dose in combination with Rd from cycle 9 onwards.
89493968|NCT04091126|Experimental|Cohort 2: belantamab mafodotin 1.4 mg/kg Q6/8W + VRd/Rd|Participants will receive 1.4 mg/kg Q6W dose of belantamab mafodotin on Day 1 of every other cycle for the first 8 cycles in combination with VRd and Q8W dose in combination with Rd from cycle 9 onwards.
89493969|NCT04091126|Experimental|Cohort 3: belantamab mafodotin 1.9 mg/kg Q6/8W + VRd/Rd|Participants will receive 1.9 mg/kg Q6W dose of belantamab mafodotin on Day 1 of every other cycle for the first 8 cycles in combination with VRd and Q8W dose in combination with Rd from cycle 9 onwards.
89493970|NCT04091126|Experimental|Cohort 4: belantamab mafodotin 1.0 mg/kg Q3/4W + VRd/Rd|Participants will receive 1.0 mg/kg Q3W dose of belantamab mafodotin on Day 1 of every cycle for the first 8 cycles in combination with VRd and Q4W dose in combination with Rd from cycle 9 onwards.
89493971|NCT04091126|Experimental|Cohort 5: belantamab mafodotin 1.4 mg/kg Q3/4W + VRd/Rd|Participants will receive 1.4 mg/kg Q3W dose of belantamab mafodotin on Day 1 of every cycle for the first 8 cycles in combination with VRd and Q4W dose in combination with Rd from cycle 9 onwards.
89493972|NCT04091126|Experimental|Cohort 6: belantamab mafodotin 1.4mg/kg cycle 1, 1.0 mg/kg Q9/12W Cycle 4+VRd/Rd|Based on emerging data from Cohort 2-5, participants will receive 1.4 mg/kg dose of belantamab mafodotin on Day 1 of cycle 1, followed by 1.0 mg/kg dose on Day 1 of every third cycle from cycle 4 onwards, in combination with VRd for the first 8 cycles and in combination with Rd from cycle 9 onwards.
89493973|NCT04091126|Experimental|Cohort 7: belantamab mafodotin 1.9 mg/kg Cycle 1, 1.4 mg/kg Q9/12W Cycle 4+VRd/Rd|Based on emerging data from Cohort 2-5, participants will receive 1.9 mg/kg dose of belantamab mafodotin of cycle 1, followed by 1.4 mg/kg on Day 1 of every third cycle from cycle 4 in combination with VRd for the first 8 cycles and in combination with Rd from cycle 9 onwards.
89493974|NCT04091126|Experimental|Cohort 8a : belantamab mafodotin 1.9 mg/kg Cycle 1,4; 1.4 mg/kg Q9/12W from Cycle 7 +VRd/Rd|Based on emerging data from Cohort 6-7, participants will receive 1.9 mg/kg dose of belantamab mafodotin on Day 1 of cycle 1 and cycle 4, followed by 1.4 mg/kg on Day 1 of every third cycle from cycle 7 onwards, in combination with VRd for the first 8 cycles and in combination with Rd from cycle 9 onwards.
89493975|NCT04091126|Experimental|Cohort 8b: belantamab mafodotin 1.4 mg/kg Cycle 1,3; 1.0 mg/kg Q9/12W from Cycle 6 +VRd/Rd|Based on emerging data from Cohort 6-7, participants will receive 1.4 mg/kg IV dose of belantamab mafodotin on Day 1 of cycle 1 and cycle 3, then 1.0 mg/kg on Day 1 of every third cycle from cycle 6 in combination with VRd for the first 8 cycles and in combination with Rd from cycle 9 onwards.
89493976|NCT04091126|Experimental|Cohort 8c: belantamab mafodotin 1.0 mg/kg Cycle 1,5;1.0 mg/kg Q9/12W from Cycle 9 +VRd/Rd|Based on emerging data from Cohort 6-7, participants will receive 1.0 mg/kg IV dose of belantamab mafodotin on Day 1 of cycle 1 and cycle 5, then 1.0 mg/kg on day 1 of every third cycle from cycle 9 in combination with VRd for the first 8 cycles and in combination with Rd from cycle 9 onwards.
89493977|NCT04785014|Experimental|aspiration group|In the aspirated group, the popliteal fossa areas were sterilized and BC content was aspirated from the popliteal fossa percutaneously under USG guidance with a 21-gauge needle (Figure 1). If the BC was septal, aspiration was performed from several different levels of the cyst so that the cyst content could be completely emptied.Additionally, the participants in both groups were trained on how to perform exercises and were also recommended to practice cold treatment for 15 min both in the morning and evening for 2 weeks.
89493978|NCT04785014|Active Comparator|control group|no aspiration was performed in the control group. Additionally, the participants in both groups were trained on how to perform exercises and were also recommended to practice cold treatment for 15 min both in the morning and evening for 2 weeks.
89493979|NCT02785913|Experimental|Arm I (GDC-0032)|Patients receive taselisib PO daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89493980|NCT04793672||Patients with malignant tumors and healthy people|Tongue images, coating on the tongue and clinical data of patients with malignant tumors and healthy people will be collected.
89493981|NCT04784468||Covid-19|Covid-19 patients
89493982|NCT04784468||Influenza|Influenza patients
88954349|NCT01971398|Experimental|Positive Brochure|"Women receive a positive FASD education brochure with positive images and are asked to read this brochure in the presence of a data collector."
88954350|NCT01971398|Experimental|Negative Brochure|"Women receive a negative FASD education brochure with negative, vivid images and are asked to read this brochure in the presence of a data collector."
88954351|NCT01971398|Active Comparator|A general women's health brochure|Women receive a brochure on general aspects of women's health and pregnancy that is available in the Russian language and are asked to read this brochure in the presence of a data collector.
88954352|NCT01971411||Community dwelling elderly black females|
88954353|NCT01971424|Experimental|Mg oxide|Participants were supplemented for 12-weeks with 300 mg of daily oral magnesium oxide.
88954354|NCT01971424|No Intervention|Controls|The control group was educated by a trained dietician to follow a healthy diet.
88954355|NCT01971437|Experimental|Cystodistension & Cystoscopy Arm|This is the Arm receiving cystodistension and cystoscopy due to refractory OAB.
88954356|NCT01971437|Placebo Comparator|Cystoscopy Arm|This is the arm that receives cystoscopy only in women with refractory OAB.
88954357|NCT01971450||Iloprost|The patients with pulmonary hypertension with inhaled treatment with Ventavis according to routine practice meeting the criteria of inclusion.
88954358|NCT01971502|Experimental|BI 1060469 single rising dose part|single rising doses given as tablet
88954359|NCT01971502|Experimental|BI 1060469 food effect part|given as tablet fasted and fed
88954360|NCT01971515|Experimental|MSC2363318A|
88954361|NCT01971515|Experimental|MSC2363318A plus Trastuzumab|
88954362|NCT01971515|Experimental|MSC2363318A plus Tamoxifen|
88954369|NCT01971541|Experimental|Mindfulness-Based Stress Reduction (MBSR)|An 8-week program designed to teach mindfulness skills
88954370|NCT01971541|Active Comparator|Cognitive Processing Therapy|A group-administered PTSD treatment program.
88954371|NCT01971606|Experimental|Rosuvastatin group|Rosuvastatin group
88954372|NCT01971606|Placebo Comparator|Placebo group|Placebo group
88954373|NCT01971619||SACS cohort|patients with acute myocardial infarction at Severance hospital
88954374|NCT01971632|Active Comparator|Oxycodone/Naloxone|
88954375|NCT01971632|Placebo Comparator|Placebo oxycodone/naloxone|
88954376|NCT01971658|Active Comparator|VELCADE (BORTEZOMIB) THALIDOMIDE DEXAMETHASONE (VTD)|"Arm A:~Induction therapy 4 cycles of VTD (21 days) Thalidomide® 100 mg/day Per Os Day1 to Day21 Velcade® 1.3 mg/m²/day Subcutaneous Day1, 4, 8 and 11 Dexamethasone 40 mg/day Per Os Day 1 to 4 and Day 9 to 12~Systematic stem cell harvest after cycle 3 Mobilization: Cyclophosphamide and one week after the last dose of Thalidomide, stem cells have to be harvested"
89022445|NCT00468468|Experimental|CHESS Condition|Subjects who receive the CHESS (Comprehensive Health Enhancement Support System)
89493983|NCT04784468||Cotrol|Control group
88954377|NCT01971658|Active Comparator|VELCADE (BORTEZOMIB) CYCLOPHOSPHAMIDE DEXAMETHASONE (VCD)|"For arm B:~Induction therapy : 4 cycles of VCD (21 days)~Cyclophosphamide 500 mg/m²/day, Per Os Day 1, 8, 15~Velcade® and Dexamethasone identical treatment to Arm A~Systematic stem cell harvest after cycle 3 Mobilization: Cyclophosphamide and two weeks after the last dose of Cyclophosphamide, stem cells have to be harvested"
88954378|NCT01971671||Chinese lactating mother|no intervention.
88954379|NCT01971684||Refractory Pediatric ITP Patients|Pediatric ITP patients, ages 1-18, starting a new second line ITP therapy, defined as not IVIG, steroids, anti-D, or aminocaproic acid.
88954380|NCT01971710|Other|Community Leader Engagement|Trained formal and informal community leaders conducting community dialogues and advocacy, and developing community action plans
88954381|NCT01971710|Other|Community Days|Community gatherings involving participatory dialogue, guided discussion, and the provision of education and selected health services.
89493984|NCT04085900||Screening cohort|30-69 years old healthy participants in Zhongshan and Wuzhou.
88954382|NCT01971710|Other|Community Peer Groups|Pregnant women attend 4 weekly peer-led classes in community peer groups. Men attending 4 peer-led education sessions in community peer groups
88954383|NCT01971736||1064nm laser, laxity|split-face single-blind randomized placebo-controlled trial evaluating improvement in facial skin laxity of the side of the face with placebo versus laser
88954384|NCT01971749||Unprotected left main coronary artery stenosis patients|
88954385|NCT01971762||Patients diagnosed bacteremia by S. aureus|
88954386|NCT01971775|Active Comparator|Ultrasonically Activated Shear|Dissection and lymphovascular sealing with Ultrasonically Activated Shears
88954387|NCT01971775|Active Comparator|Conventional Monopolar Electrocautery|Dissection and lymphovascular sealing with Conventional Monopolar Electrocautery
88954388|NCT01971788|Experimental|Prolonged bivalirudin infusion|Bivalirudin infusion is prolonged after the end of primary PCI
88954389|NCT01971788|Active Comparator|Intra-procedural bivalirudin infusion|Bivalirudin infusion is stopped at the end of primary PCI
88954390|NCT01971801|Active Comparator|Vitamin D|Vitamin D3, 50,000 IU, weekly
88954391|NCT01971801|Placebo Comparator|Placebo|Placebo comparator, weekly
88954392|NCT01971814|Experimental|Early infliximab monitoring group.|A consecutive sample of patients hospitalized with severe ulcerative colitis who are eligible to receive infliximab at 10mg/kg IV.
88954393|NCT01971827|No Intervention|Control|No intervention
88954394|NCT01971827|Experimental|MOVI-KIDS Program|Intervention group
88954395|NCT01971840|Experimental|MOVI-KIDS Program|Intervention group
88954396|NCT01971840|No Intervention|Control|No intervention
88954397|NCT01971879|Sham Comparator|Control|
88954398|NCT01971879|Active Comparator|Remote preconditioning|
88954399|NCT01971892|Experimental|Non invasive ventilation (NIV)|Experimental arm = non invasive ventilation (NIV) which associated pressure support ventilation (PSV: 5 to 15 cmH2O) and positive end expiratory pressure (PEEP: 5 to 10 cmH2O) NIV will intermittently delivered to the patients for at least six hours (cumulative tme of all trials which lasted at least 30 min) during the first 24h after the initiation of treatment. Between each NIV period, the patient will received supplemental oxygen through facial mask to achieve an oxygen saturation level above 94%.
88954400|NCT01971892|Active Comparator|standard oxygen therapy with facial mask|Patients assigned to standard medical therapy will received supplemental oxygen via a facial Venturi mask at a rate of up to 15 liters per minute with in order to maintain peripheral oxygen saturation above 94%.
89493985|NCT04784156||All study patients|"All study patients will be in one group.~Interventions:~Procedure: Subtalar (Talocalcaneal) arthrodesis Device: DynaNail Mini"
89493986|NCT04793594||Tele- Assessment Group|Balance Assessment
89493987|NCT04793594||Face To Face (Clinic) Group|Balance Assessment
89204796|NCT00994396|Placebo Comparator|Placebo pill|Placebo soft gel pills (soy bean oil encapsulated in soft gel comprised of gelatin, glycerin and water) twice per day for 6 mos
89204797|NCT00994396|Experimental|Vitamin D|4000 IU vitamin D3 (cholecalciferol) per day for 6 months.
88954401|NCT01971905||Oben label|There is no intervention on this descriptive study
88954402|NCT01971918|Experimental|early switch|"early switch of monoclonal antibodies anti-TNF~anti drug antibodies dosage"
88954403|NCT01971918|Experimental|therapeutic intensification|"therapeutic intensification of monoclonal antibodies anti-TNF~anti drug antibodies dosage"
88954404|NCT01971931||Patients undergoing TKR.|
89204798|NCT00818688||1|Patients eligible for enrolment were all consecutive patients aged 18 years or over, with a symptomatic ST of the lower limbs at least 5 cm long on compression ultrasonography. Patients who had undergone surgery under general or loco-regional anaesthesia in the previous 10 days, those in whom ST had occurred after sclerotherapy within the previous 30 days and those whose follow-up was not considered to be feasible were ineligible.
89204799|NCT00818688||2|Patients eligible for enrolment were all consecutive patients aged 18 years or over, with a symptomatic ST of the lower limbs at least 5 cm long on compression ultrasonography. Patients who had undergone surgery under general or loco-regional anaesthesia in the previous 10 days, those in whom ST had occurred after sclerotherapy within the previous 30 days and those whose follow-up was not considered to be feasible were ineligible.
89204800|NCT03978013|Experimental|Pomegranate|
88954405|NCT01971944||Patients achieving steady state concentrations of carvedilol|Patients achieving steady state concentrations of carvedilol who receive a trial of dobutamine followed by milrinone.
88954406|NCT01971944||Patients achieving steady state concentrations of metoprolol|Patients achieving steady state concentrations of metoprolol who receive a trial of dobutamine followed by milrinone.
88954407|NCT01971944||Patients not receiving beta blocker|Patients not receiving beta blocker who receive a trial of dobutamine followed by milrinone.
89204801|NCT03978013|Active Comparator|Apple|
88954408|NCT01971983|Experimental|HVLA|The subjects allocated to this group will receive a 'High-velocity, low-amplitude (HVLA) technique over the lumbar spine.
88954409|NCT01971983|Experimental|ME|Subjects allocated to this group will receive a muscle energy (ME) technique.
89022446|NCT00468468|Experimental|Mentor Condition|Subjects who receive access to a Human Cancer Mentor only
89493988|NCT05613998|Experimental|GR1. GPR intervention|Patients who will receive the GRP treatment protocol
89493989|NCT05613998|Experimental|GR2. Non-specific Aerobic exercice intervention|Patients who will receive the non-specific aerobic exercise treatment protocol
89493990|NCT05613998|No Intervention|GR3. No physiotherapy intervention|Patients who will not receive physiotherapy treatment
89493991|NCT03962114|Experimental|Intervention group|treatment with vitamin B3
89493992|NCT04346186||Hospital Staff in the Capital Region of Denmark|
89493993|NCT04346186||Healthy volunteer blood donors|
89493994|NCT03720158|Experimental|Omega 3 Group|Five mL of an Omega-3 highly concentrated substance (containing 2.25 g of EPA and 1.08 g of DHA) will be added daily to the standard enteral diet during the entire radiotherapy treatment period (from 5-7 weeks)
89493995|NCT03720158|Placebo Comparator|Placebo or Control Group|Five mL of pigmented and flavored corn oil will be added daily to the standard enteral diet during the entire radiotherapy treatment period (from 5-7 weeks)
89493996|NCT05473052|Experimental|Preoperative home-based exercise training|Patients received usual care plus a preoperative home-based exercise program consisting of aerobic and resistance exercise. In addition, a physical therapist carried out weekly telephone supervision with all participants
89493997|NCT05579405||Acute Ischemic Stroke|Ischemic stroke within 24 hours of onset and modified Rankin Scale 0 to 2
89493998|NCT05579405||Transient ischemic attack|Transient ischemic attack without MRI positivity within 7 days of onset
89493999|NCT05579405||Patient Control|Contemporary patients with neurological symptoms required for differentiation from ischemic stroke or transient ischemic attack
89494000|NCT05472896|Experimental|cTACE with TP21|In experimental groups, the dosage of dicycloplatin (TP21) was based on the body surface area (550 mg/m2) according to previous research. If grade III or above myelosuppression was observed, an adjusted dose of 450 mg/m2 was then considered, or the patient was removed from the group at the investigator's discretion.The volume ratio of lipiodol to dicycloplatin aqueous solution was 1:1.The volume of lipiodol used was calculated by the size and vascularity of the tumor, within 20 mL. Standardized gelatin sponge particles of 150-350 μm or 350-560 μm in diameter were injected following embolization with ethiodized oil-chemoembolic emulsion.
89494001|NCT05472896|Active Comparator|cTACE with epirubicin|the dosage of epirubicin was determined according to the tumor size, and the maximum dose was limited to 40 mg. The volume ratio of lipiodol to epirubicin aqueous solution was 2:1. The volume of lipiodol used was calculated by the size and vascularity of the tumor, within 20 mL. Standardized gelatin sponge particles of 150-350 μm or 350-560 μm in diameter were injected following embolization with ethiodized oil-chemoembolic emulsion.
89494002|NCT05579171|Experimental|Left Side Treatment with picosecond 755nm Alexandrite laser|Subjects will have their left side of face treated with picosecond 755nm Alexandrite laser then will undergo full face radiofrequency microneedling.
89494003|NCT05579171|Experimental|Right Side Treatment with Picosecond 755NM Alexandrite laser|Subjects will have their right side of face treated with picosecond 755nm Alexandrite laser then will undergo full face radiofrequency microneedling.
89494004|NCT04793048|Active Comparator|Active group received an active device and a scaling and root planing (SRP) at baseline|
89494005|NCT04793048|Sham Comparator|Sham group received a sham device and a scaling and root planing (SRP) at baseline|
89494006|NCT02138201||control|individuals with normal bladder function
89494007|NCT02138201||neurogenic bladder|individuals suffering from neurogenic lower urinary tract dysfunction
89494008|NCT05472428|Experimental|Autologous BMMNC transplantation|- Autologous bone marrow mononuclear cell transplantation 2 intrathecal administrations of autologous bone marrow mononuclear cells at baseline and 6 months afterward
89204802|NCT00996112||Historical|
89204803|NCT00996112||Prospective|
89204804|NCT04000984|Experimental|Mindfulness-Based Intervention|Participants in this arm will complete baseline and follow-up visits (approximately 3-months after) and Mid-intervention safety checks. They will attend the in the Mindfulness-Based Training program that will meet weekly for 8 weeks. Each session will last approximately one-and-a-half hours.
89204805|NCT04000984|Active Comparator|Cognitive Rehabilitation Training|Participants in this arm will complete baseline and follow-up visits (approximately 3-months after) and Mid-intervention safety checks. They will attend the Cognitive Rehabilitation program that will meet weekly for 8 weeks. Each session will last one-and-a-half hours.
89204806|NCT04000984|No Intervention|Treatment As Usual|Participants in the Treatment As Usual group were only required to attend baseline and follow-up visits (approximately 3-months after) and Mid-intervention safety checks. Participants in this group will not receive an intervention for the duration of the study. They received treatment as usual which is 6 months to 1-year follow up visits with their attending neurologist of psychologist.
89204807|NCT00816426|Other|1|Dosing 2 hours before surgery. -Rifampicin (RIF) will be dosed orally at 600mg or 50mg for subjects under 50kg of bodyweight;-Isoniazid (INH) will be dosed orally at 300mg;-Pyrazinamide (PZA) will be dosed orally at 1.5g;-Moxifloxacin (MXF) will be dosed orally at 400mg;-Kanamycin (KM) will be dosed intramuscularly at 1g or 750mg for subjects under 50kg of body weight
89204808|NCT00816426|Other|2|Dosing 4 hours before surgery. -Rifampicin (RIF) will be dosed orally at 600mg or 50mg for subjects under 50kg of bodyweight;-Isoniazid (INH) will be dosed orally at 300mg;-Pyrazinamide (PZA) will be dosed orally at 1.5g;-Moxifloxacin (MXF) will be dosed orally at 400mg;-Kanamycin (KM) will be dosed intramuscularly at 1g or 750mg for subjects under 50kg of body weight
89204809|NCT00816426|Other|3|Dosing 8 hours before surgery. -Rifampicin (RIF) will be dosed orally at 600mg or 50mg for subjects under 50kg of bodyweight;-Isoniazid (INH) will be dosed orally at 300mg;-Pyrazinamide (PZA) will be dosed orally at 1.5g;-Moxifloxacin (MXF) will be dosed orally at 400mg;-Kanamycin (KM) will be dosed intramuscularly at 1g or 750mg for subjects under 50kg of body weight
89204810|NCT00816426|Other|4|Dosing 12 hours before surgery. -Rifampicin (RIF) will be dosed orally at 600mg or 50mg for subjects under 50kg of bodyweight;-Isoniazid (INH) will be dosed orally at 300mg;-Pyrazinamide (PZA) will be dosed orally at 1.5g;-Moxifloxacin (MXF) will be dosed orally at 400mg;-Kanamycin (KM) will be dosed intramuscularly at 1g or 750mg for subjects under 50kg of body weight
89204811|NCT00816426|Other|5|Dosing 24 hours before surgery. -Rifampicin (RIF) will be dosed orally at 600mg or 50mg for subjects under 50kg of bodyweight;-Isoniazid (INH) will be dosed orally at 300mg;-Pyrazinamide (PZA) will be dosed orally at 1.5g;-Moxifloxacin (MXF) will be dosed orally at 400mg;-Kanamycin (KM) will be dosed intramuscularly at 1g or 750mg for subjects under 50kg of body weight
89204812|NCT00996190|Active Comparator|Phenylephrine Intermittent Bolus|Bolus syringe will contain 120 micrograms/mL of phenylephrine. Infusion solution bag will contain placebo (saline solution).
89204813|NCT00996190|Active Comparator|Phenylephrine Continuous Infusion|Infusion solution bag will contain 120 micrograms/mL of phenylephrine. Bolus syringe will contain placebo (saline solution).
89204814|NCT00996268|Experimental|Part A|Three groups of sixteen healthy subjects will be randomized to single doses of 3 different formulations of GSK2212836.
89204815|NCT00996268|Experimental|Part B|Four cohorts of at least 10 subjects will participate in a 2-week repeat dose period with 4 dose levels (based on data obtained in Part A) of the GSK2212836 test formulations or placebo.
89204816|NCT00816504|Experimental|1|Galactose
89204817|NCT01000402|Other|Psychopharmacotherapy|No specific arms; Treatment decision based on available guidelines
89204818|NCT00640224|Active Comparator|Rosiglitazone|Treatment naive overweight adolescent females with PCOS treated with Rosiglitazone
88954410|NCT01971983|Sham Comparator|Sham group|"The individuals allocated to this group received an intervention of the sham. The sample of this group will consist of subjects with history of dysfunctions of the lumbar spine."
88954411|NCT01971996||Lumbar spine surgical patients|Patients undergoing lumbar spine surgery in the prone position
89204819|NCT00640224|Active Comparator|Drospirenone/ethinyl estradiol|Treatment naive overweight adolescent females with PCOS treated with Drospirenone/ethinyl estradiol
89204820|NCT00640224|No Intervention|Overweight/Obese without PCOS|Overweight adolescent females without PCOS to use as comparison of normal developmental changes. *No participants were enrolled in this Arm.
89204821|NCT00640224|No Intervention|Lean without PCOS|Lean healthy girls without PCOS to serve as controls for the cardiovascular markers. *No participants were enrolled in this Arm.
89022447|NCT00468468|Experimental|CHESS + Mentor|Subjects who receive the CHESS system plus a Human Cancer Mentor
88954412|NCT01972009||Subjects without pulmonary hypertension|Patients with normal pulmonary pressures will be recruited amongst patients who are on the waiting list awaiting routine cardiac catheterisation for the investigation of shortness of breath and chest pain.
88954413|NCT01972009||Subjects with pulmonary hypertension|Patients with pulmonary hypertension will be recruited from the National Pulmonary Hypertension Service who are awaiting right and left heart catheterisation studies as part of their routine diagnostic work-up.
88954414|NCT01972022|Experimental|EES SYNERGY™|coronary artery lesions treated with Bioabsorbable Polymer EES
88954415|NCT01972022|Active Comparator|ZES, RESOLUTE Integrity™|coronary artery lesions treated with ZES, RESOLUTE Integrity™ stent system
88954416|NCT01972048|Active Comparator|Control group|Participants in the control group will receive the mailed print brochure about breast cancer screening and community resources.
88954417|NCT01972048|Experimental|Intervention group|Participants will receive the mMammogram intervention.
88954418|NCT01972087|No Intervention|Control|Participants randomized to the control arm receive no telephone simulation training.
88954419|NCT01972087|Experimental|Simulation Training|Participants randomized to the intervention arm receive telephone simulation training.
88954420|NCT01972100|Active Comparator|Low-level laser therapy (LLLT)|Use of low-level laser therapy (LLLT) to induce a muscle fatigue resistance in intense exercises
88954421|NCT01972100|Active Comparator|Placebo low-level laser therapy (Placebo)|Use of low-level laser therapy (LLLT) placebo to induce a muscle fatigue resistance
88954422|NCT01972113|Placebo Comparator|Placebo-Control|The placebo-control group will take one placebo softgel capsules every day for 8 weeks.
88954423|NCT01972113|Active Comparator|Low-Dose Vitamin K2 (45 mcg/d)|The low-dose vitamin K2 group will take one 45-mcg vitamin K2 softgel capsule and one placebo softgel capsule every day for 8 weeks.
89204822|NCT02550990|Active Comparator|Cognitive training group|One 60-min session of cognitive training. Before and after the treatment, a total of 2 evaluations were conducted, including clinical assessments and blood test (each 18c.c.). A saliva sample (2 mL) will only be collected once from each subject. A follow-up assessment of clinical outcomes will be conducted at six month after the end of the course of treatment.
89494009|NCT03596918||Supportive care (vincristine sulfate, bleomycin sulfate)|Patients receive vincristine sulfate IV over 1-2 minutes and bleomycin sulfate IV over 10 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
89494010|NCT02261051||Non-concurrent control group|"A group of advanced cancer patients who received care at our Center before implementation of the LCCM model. They will receive current standard of care.~This current study is to collect data on the control group only. After system redesign, we will open an intervention arm study to collect data after implementation of the new care model (about 18-24 months from start of control phase)."
89494011|NCT04793438|Experimental|Intervention group|Motive-specific intervention; three appointments within two weeks, 30-45 minutes per session.
89494012|NCT04793438|Active Comparator|Control group|Supportive conversations; three appointments within two weeks; 30-45 minutes per session.
89494013|NCT02134145||Self Selected Investors|A self selected crowdfunding backers from teh Scanadu Scout Crowdfunding campaign.
89494014|NCT05472350|Experimental|Breztri Aerosphere Group|Participants will receive Breztri Aerosphere twice a day from 3 days before surgery to 14 days after surgery
89494015|NCT05472350|Placebo Comparator|Placebo Group|Participants will receive 0.9% normal saline twice a day from 3 days before surgery to 14 days after surgery
89494016|NCT02134223|Experimental|dialectical behavior therapy|Primary intervention group: receiving one year of dialectical behavior therapy
89494017|NCT02134223|Placebo Comparator|treatment as usual|Comparison group: receiving one year of treatment as usual
89494018|NCT02134223|No Intervention|Receiving no treatment at all|Healthy control group
88954424|NCT01972113|Active Comparator|High-Dose Vitamin K2 (90 mcg/d)|The high-dose vitamin K2 group will take one 90-mcg vitamin K2 softgel capsules every day for 8 weeks.
88954425|NCT01972126||AMI patients with LVEF 36% - 50%|Acute myocardial infarction patients with left ventricular ejection fraction between 36% and 50%
88954426|NCT01972165|Experimental|Group I|Mini-incision carpal tunnel release group
89022448|NCT00468468|No Intervention|Internet Only|Subjects receive routine care and nothing else
89494019|NCT02138435||VSD-patients|Patients who had VSD closure between 1990 and 1995. They will be tested by a MRI exercise test and a gas-exchange exercise test measuring cardiac output.
89494020|NCT02138435||Control|A group of healthy control subjects. They will be tested by a MRI exercise test and a gas-exchange exercise test measuring cardiac output.
89494021|NCT02134379||Heart Failure|Subjects have implanted Medtronic device and a primary diagnosis of left ventricular systolic dysfunction
89494022|NCT02138513|Experimental|Online MBCT|
89494023|NCT02138513|Experimental|group MBCT|
88954427|NCT01972165|Active Comparator|Group II|Endoscopic carpal tunnel release group
88954428|NCT01972191||Group 1|Group 1 : Bare eye marking group
88954429|NCT01972191||Group 2|Group 2 : Pendulum attached marker group
88954430|NCT01972191||Group 3|Group 3 : Horizontal slit beam assisted marker group
88954431|NCT01972230|Experimental|Bilanced group|"Sevofluorane adjusted to obtain an Et-Sevo of 1.8-2%, for all the time of the surgical procedure.~Remifentanyl TCI adjusted according to protocol to maintain the range of 1-3 ng / ml."
88954432|NCT01972230|Active Comparator|TCI group|Propofol 3-4 mg / ml and remifentanyl 1-3 ng / ml according to protocol TCI
88954433|NCT01972256||Previous transsacral fusion|Subject candidates are those who had required a transsacral fusion at L4-L5-S1 where these were the only lumbar levels treated for pseudoarthrosis, spinal stenosis, spondylolisthesis, or degenerative disc disease (DDD).
88954434|NCT01972256||Previous transforaminal lumbar interbody fusion|Subject candidates are those who had required transforaminal lumbar interbody fusion at L4-L5-S1 where these were the only lumbar levels treated for pseudoarthrosis, spinal stenosis, spondylolisthesis, or degenerative disc disease (DDD).
89494024|NCT02138513|No Intervention|Treatment as usual|3 months waiting list, subsequent assignment to group or online MBCT
89494025|NCT04792814||MAT-RAP group|MAT and RAP
89494026|NCT04792814||historical group|standard procedure
89494027|NCT03548831||MLH|Minilaparotomy Hysterectomy
89494028|NCT03548831||LAVH|Laparoscopic Assisted Vaginal Hysterectomy
89494029|NCT02134457|Experimental|Ranibizumab 0.12 mg|"20 µl of the 6 mg/ml ranibizumab concentration will be applied intravitreally. After an initial response the same dose as in the first injection can be re-applied after at least four weeks post injection.~A maximum number of 3 regular re-injections can be applied."
88954435|NCT01972269|Active Comparator|bupivacaine-fentanyl 4|Test dose: 3mL of 0.125% bupivacaine-fentanyl 5mcg/mL. Loading dose: 4mL of 0.125% bupivacaine-fentanyl 5mcg/mL.
88954436|NCT01972269|Active Comparator|bupivacaine-fentanyl 6|Test dose: 3mL of 0.125% bupivacaine-fentanyl 5mcg/mL. Loading dose: 6mL of 0.125% bupivacaine-fentanyl 5mcg/mL.
88954437|NCT01972269|Active Comparator|bupivacaine-fentanyl 8|Test dose: 3mL of 0.125% bupivacaine-fentanyl 5mcg/mL. Loading dose: 8mL of 0.125% bupivacaine-fentanyl 5mcg/mL.
88954438|NCT01972269|Active Comparator|bupivacaine-fentanyl 10|Test dose: 3mL of 0.125% bupivacaine-fentanyl 5mcg/mL. Loading dose: 10mL of 0.125% bupivacaine-fentanyl 5mcg/mL.
88954439|NCT01972269|Active Comparator|bupivacaine-fentanyl 12|Test dose: 3mL of 0.125% bupivacaine-fentanyl 5mcg/mL. Loading dose: 12mL of 0.125% bupivacaine-fentanyl 5mcg/mL.
89494030|NCT02134457|Experimental|Ranibizumab 0.20 mg|"20 µl of the 10 mg/ml ranibizumab concentration will be applied intravitreally. After an initial response the same dose as in the first injection can be re-applied after at least four weeks post injection.~A maximum number of 3 re-injections can be applied."
89494031|NCT02138591|Experimental|Vitamin D3|"Vitamin D3 (cholecalciferol) 50,000 IU by mouth daily for each of the five days prior to surgery.~Blood draw pre-operatively Blood draw post-operative Day 1 Blood draw post-operative Day 2"
89494032|NCT02138591|Placebo Comparator|Placebo pill|Placebo pill by mouth daily for each of the five days prior to surgery. Blood draw pre-operatively Blood draw post-operative Day 1 Blood draw post-operative Day 2
89494033|NCT05613920|Experimental|diet management program based on the nudge strategy|The intervention group will receive a diet management program based on the nudge strategy
89494034|NCT05613920|No Intervention|routine dietary management program|The control group will receive a routine dietary management program
89494035|NCT02134535||laboratory specimens|cervical biopsies vaginal biopsies blood
89494036|NCT05471882||Single neuromuscular blocking agent dose|Patients receiving a single dose of neuromuscular blocking agent
89494037|NCT05471882||Incremental doses of neuromuscular blocking agents|Patients receiving repetitive doses of neuromuscular blocking agents
89494038|NCT05471882||Pharmacological reversal|Patients receiving pharmacological reversal of neuromuscular block
89494039|NCT03548753||Patients with Agatston score > 399|"Coronary computed tomography angiography with FFR-CT~Invasive coronary angiography with FFR"
89494040|NCT05471804|Placebo Comparator|Placebo control|An inert tablet with the same physical appearance as the experimental intervention tablet
89494041|NCT05471804|Experimental|Zembrin|25 mg per day of Sceletium tortuosum extract (Zembrin®)
89494042|NCT02134613|Experimental|anti-TNF-alpha scintigraphy|99mTc-anti-TNF-alpha Scintigraphy will be compared with MRI results, analysed and discussed by physicians who are in charge of the patients.
89494043|NCT04792736||Survivors|Patients discharged alive from intensive care unit
89494044|NCT04792736||non survivors|Patients who succumbed during their ICU stay
89494045|NCT05578625||Myeloma|This study includes a total of 60 multiple myeloma patients, and peripheral blood will be collected at newly diagnosed, remission after 4 cycles of therapy, and, relapse stage.
89494046|NCT02134691|Experimental|Prolonged Exposure|Behavioral: Prolonged Exposure (PE) PE is a 16 week, 90 minute culturally informed treatment program.
89494047|NCT02134691|Active Comparator|Applied Relaxation|Behavioral: Applied Relaxation (AR) AR is a 16 week, 90 minute treatment program.
89494048|NCT02590562||RA patients treated with routine clinical practice|Describe in routine clinical practice the treatment patterns of usage of biological DMARDs in patients suffering from RA including frequency of monotherapy, biological DMARDs usage status (types, dosage), concomitant DMARDs usage information (type and dosage)
89494049|NCT05578469||posterior chamber intraocular lens(IOL) implantation with a Cionni capsular tension ring (CTR)|
89494050|NCT05578469||sutured scleral fixation of posterior chamber IOL/ posterior chamber IOL and CTR|
89494051|NCT02138903||ZEEP and tubing-spontaneous ventilation|Prospective clinical study in ICU with ventilated patients eligible to weaning trials of mechanical ventilation (ZEEP and tubing-spontaneous ventilation) comparing hemodynamic and cardiac effects evaluated by trans-thoracic echocardiography.
89494052|NCT02138903||trans-thoracic echocardiography|Prospective clinical study in ICU with ventilated patients eligible to weaning trials of mechanical ventilation (ZEEP and tubing-spontaneous ventilation) comparing hemodynamic and cardiac effects evaluated by trans-thoracic echocardiography.
89494053|NCT02138981|Active Comparator|Immediate Resection|patients received immediate surgical hepatic resection
89494054|NCT02138981|Experimental|Chemoembolization and Response-Dependent Resection|patients underwent transarterial chemoembolization (TACE) as initial treatments, and only patients who showed good response were subjected to surgical resection.
89494055|NCT02134769|No Intervention|Control|No use of Bionecteur; handling according to institutional guideline
89494056|NCT02134769|Active Comparator|Bionecteur|Use of Bionecteur; handling according to institutional guideline
89494057|NCT05613686|Experimental|contralateral 1Hz+ipsilateral iTBS 1|Patients received contralateral 1 Hz and ipsilateral iTBS with protocol 1
89494058|NCT05613686|Experimental|contralateral 1Hz+ipsilateral iTBS 2|Patients received contralateral 1 Hz and ipsilateral iTBS with protocol 2
88954440|NCT01972269|Active Comparator|bupivacaine-fentanyl 14|Test dose: 3mL of 0.125% bupivacaine-fentanyl 5mcg/mL. Loading dose: 14mL of 0.125% bupivacaine-fentanyl 5mcg/mL.
88954441|NCT01972269|Active Comparator|bupivacaine-fentanyl 16|Test dose: 3mL of 0.125% bupivacaine-fentanyl 5mcg/mL. Loading dose: 16mL of 0.125% bupivacaine-fentanyl 5mcg/mL.
88954442|NCT01972269|Active Comparator|lidocaine 4|Test dose: 3mL of 2% lidocaine. Loading dose: 4mL of 0.125% bupivacaine-fentanyl 5mcg/mL.
88954443|NCT01972269|Active Comparator|lidocaine 6|Test dose: 3mL of 2% lidocaine. Loading dose: 6mL of 0.125% bupivacaine-fentanyl 5mcg/mL.
88954444|NCT01972269|Active Comparator|lidocaine 8|Test dose: 3mL of 2% lidocaine. Loading dose: 8mL of 0.125% bupivacaine-fentanyl 5mcg/mL.
89022449|NCT00459771|Placebo Comparator|Placebo|Placebo
89494059|NCT05613686|Active Comparator|contralateral 1Hz|Patients received contralateral 1 Hz and ipsilateral sham iTBS
89494060|NCT05578391|Experimental|Convalescent plasma|
89494061|NCT05578391|No Intervention|Conventional treatment|
89494062|NCT02253407|Experimental|Disposable syringe jet injector|Subjects in this arm will be given a single subcutaneous 0.5 mL dose of Serum Institute of India Ltd.'s MMR vaccine (Brand name: Tresivac) via Disposable Syringe Jet Injector (Brand Name:Stratis) of Pharmajet Inc.
89494063|NCT02253407|Active Comparator|Needle-Syringe|Subjects in this arm will be given a single subcutaneous 0.5 mL dose of Serum Institute of India Ltd.'s MMR vaccine (Brand name: Tresivac) via conventional needle and Syringe
89494064|NCT03549767|Experimental|Springfusor|Women in this group will have their loading dose (4 gm of 50% Magnesium sulphate in 10 ml syringe administered over 20 minutes) and maintenance therapy (4 gm of 50% Magnesium sulphate in 10 ml syringe administered over 4 hours through an IV infusion administered using a Springfusor pump.. The 4 gm maintenance dose will be repeated every 4 hours for 24 hours.
89494065|NCT03549767|Active Comparator|Standard of care|The control group will have Magnesium sulphate administered using the Pritchard regimen, which involves administration of loading dose of 4 gm of 20% Magnesium sulphate IV over 15-20 minutes, immediately followed by 10 gm of 50% Magnesium sulphate IM (5gm on each buttock). The maintenance dose of 5 gm of 50% Magnesium sulphate IM every 4 hourly in alternate buttocks continued for 24 hours
89494066|NCT04090190|Other|standard of care anticholinergic treatment|Women presenting to the Urogynecology clinic with urgency urinary incontinence symptoms will receive standard of care anticholinergic treatment and will have their urinary microbiome evaluated before and after treatment
89494067|NCT05578313||• Group 1 (study group)|IBD patients prescribed cannabis as treatment of their bowel disease.
89494068|NCT05578313||• Group 2 (Control group)|One hundred healthy patients who do not use cannabis and are not eligible or not interested to commence this intervention.
89494069|NCT05578313||• Group 3 (control group)|Up to 100 IBD patient who experience pain and do not use cannabis
89494070|NCT05578313||• Group 4 (control group)|Up to 100 IBD patient who do not experience pain and do not use cannabis
89494071|NCT05578313||• Group 5 (Cannabis responders group)|up to 100 IBD patients previously prescribed cannabis and were identified to have positive effect on their disease
89494072|NCT05471570|Active Comparator|anodal tDCS|20 minutes of one mA anodal High-Definition tDCS (HD-tDCS) over right IFG combined with 40 minutes of naming therapy for five consecutive days in week 1
89494073|NCT05471570|Sham Comparator|sham tDCS|20-minutes sham HD-tDCS with 40-minutes therapy of naming therapy for five consecutive days in week 1
88954445|NCT01972269|Active Comparator|lidocaine 10|Test dose: 3mL of 2% lidocaine. Loading dose: 10mL of 0.125% bupivacaine-fentanyl 5mcg/mL.
88954446|NCT01972269|Active Comparator|lidocaine 12|Test dose: 3mL of 2% lidocaine. Loading dose: 12mL of 0.125% bupivacaine-fentanyl 5mcg/mL.
88954447|NCT01972269|Active Comparator|lidocaine 14|Test dose: 3mL of 2% lidocaine. Loading dose: 14mL of 0.125% bupivacaine-fentanyl 5mcg/mL
89494074|NCT04792034|Experimental|Active|Active: FDA Approved Golprelto (Cocaine Hydrochloride Topical Solution)
89494075|NCT02253095|Experimental|Multiple Intervention Arm|single dose albendazole, two weeks of zinc, 24 weeks of multiple micronutrients
89494076|NCT02253095|Placebo Comparator|Placebo|three placebos
89494077|NCT02134847|Experimental|Intervention cohort|This cohort will work on the SCS intervention schedule
89494078|NCT02134847|No Intervention|Control cohort|This group will work on a traditional schedule
88954448|NCT01972269|Active Comparator|lidocaine 16|Test dose: 3mL of 2% lidocaine. Loading dose: 16mL of 0.125% bupivacaine-fentanyl 5mcg/mL
88954449|NCT01972321|Experimental|Technology supported supervision|The technology supported supervision intervention will support the CHWs in providing quality case management for the under-fives who suffer from diarrhea, pneumonia and malaria through unlimited communication with their health facility supervisors and colleagues through closed-user-groups. It will enhance timely reporting of patient data and targeted support supervision on the CHWs who need support from their supervisors. With the CHWs receiving the above support and feedback messages, this will potentially increase CHW motivation, performance and retention. Data reported by CHWs can be used by the district planners to forecasting of medicine procurements and react to drug stock-outs or unusual data trends (e.g. disease outbreaks).
88954450|NCT01972321|Experimental|Community supported supervision|The community supported supervision intervention will set up village health clubs with the aim to improve child health through a community led forum with the CHW as the main focus point. Village health club meetings will provide a forum where CHWs and community members who are part of the club can work together to identify child health and CHW challenges. They will use village networks, knowledge, creativity and other assets.
88954451|NCT01972321|Active Comparator|Control arm|The CHWs in the control arm will be receiving the standard Ministry of Health designed package to integrated community case management support and supervision.
88954452|NCT01972334|Experimental|FMT or fecal microbial transplant|intervention is fecal microbial transplant done through endoscopy, subjects will be randomized 1:1 to receive either FMT or placebo
88954453|NCT01972334|Placebo Comparator|placebo|1:1 randomization to FMT versus placebo (which is saline or salt water)
88954454|NCT01972360||Diagnosis|Group 3: 99mTCSPECT plus stress echocardiography
88954455|NCT01972360||group 1 : diagnosis|Group 1: 99mTcSPECT plus CMR
88954456|NCT01972360||Group 2: diagnosis|Group 2: 99mTcSPECT plus CT
88954457|NCT01972373|Experimental|NIR endoscopy with Bevacizumab-IRDye800CW|In this non-randomized, non-blinded, prospective, feasibility study, bevacizumab-IRDye800CW will be administered to a total of 30 patients with proven locally advanced rectal cancer.
89494079|NCT03549455|Experimental|Exposure Therapy and Self Distancing|All subjects will have 2 introduction sessions and then receive Exposure therapy with Self-Distancing (2 weeks) following Exposure therapy without Self-Distancing (2 weeks) followed by 2 more weeks of Exposure therapy with Self-Distancing.
89494080|NCT05578157||Group 1|Age 55 - 60 years
89494081|NCT05578157||Group 2|Age 60 - 65 years
89494082|NCT05578157||Group 3|Age 65 - 70 years
89494083|NCT03767465||PembroHIV|HIV-infected subjects with advanced melanoma or other oncological conditions in which the use of immunological checkpoint inhibitors is clinically indicated
89494084|NCT02135003|Experimental|Buddy arm, Standard of care arm|"Standard of care: Patients enrolled for pre-ART care received general health education, clinical monitoring, CD4 testing and other clinically indicated investigations, treatment of opportunistic infections, and cotrimoxazole prophylaxis.~Patient-selected Care buddy intervention: In addition to standard of care, pre-ART patients randomized to this arm were requested to choose a care buddy who was aware of the patient's HIV infection and resided in the same household or in close proximity. buddies attended at least two HIV health education. Information on HIV, and the importance of adhering to scheduled clinic visits and to prescribed medications will be emphasized. Buddies were requested to remind participants to take their prophylactic treatments, and remind them of clinic appointments"
89494085|NCT02139059|Active Comparator|initial urinary drainage|initial urinary drainage to stabilize renal functions before ureteroscopy
89494086|NCT02139059|Active Comparator|direct ureteroscopy|direct ureteroscopy without initial urinary drainage
89494087|NCT03283982|Active Comparator|Robotic IPOM|Robotic Ventral Hernia Repair with IPOM: The da Vinci® Surgical System robotic platform (Intuitive Surgical, Inc.) will be used to perform a minimally invasive ventral hernia repair with intraperitoneal mesh placement.
89494088|NCT03283982|Active Comparator|Laparoscopic IPOM|Laparoscopic Ventral Hernia Repair with IPOM: The standard laparoscopic platform will be used to perform a minimally invasive ventral hernia repair with intraperitoneal mesh placement.
89494089|NCT02135081||Single Ventricle|"Subjects will be single ventricle patients who will be prospectively recruited when they are at the first stage of Fontan reconstruction; they will be followed throughout all 3 stages with cerebral blood flow measurements and brain MRIs.~Additional single ventricle patients who will not participate in the study for all 3 stages but who may participate for one of two. For example, patients who completed their Stage I and hemi Fontan/bidirectional Glenn operations before this study began will be recruited before Fontan stage completion. Also, patients whose Stage I and hemi Fontan/bidirectional Glenn surgeries will be completed during the study, but who will not complete all 3 surgical stages before this project ends. Cerebral blood flow measurements and brain MRIs will be completed after each surgical stage which occurs during study participation."
89494090|NCT02135081||Normal Control Group|Children likely to have a normal brain MRI will be asked to participate. After the brain MRI is obtained as part of routine clinical care, and a normal brain scan is confirmed, measurement of cerebral blood flow using velocity mapping in the jugular veins and the aorta will be performed. This will add approximately 10 minutes to the scan but no extra sedation medications will be administered to obtain this data.
89494091|NCT04791332|Experimental|Single Dose Cohort: Cohort 1 and 2|Participants will receive a single oral dose of JNJ-67953964 or a matching placebo on Day 1.
89494092|NCT04791332|Experimental|Multiple Dose Cohort: Cohort 3|Participants will receive multiple oral dose of JNJ-67953964 once daily or a matching placebo up to Day 14.
89494093|NCT04791410||Experimental group|patients who met the inclusion criteria were treated with RVLM decompression at the same time of facial nerve decompression.
89494094|NCT04791410||control group|Patients who met the inclusion criteria were followed up for 3 months before surgery
89494095|NCT04791020|Active Comparator|Lidocaine + paracervical blockade|5 minutes previous to endouterine manual aspiration, 5mL of lidocaine gel was applied plus standard paracervical blockade.
89494096|NCT04791020|Experimental|Lidocaine|5 minutes previous to endouterine manual aspiration, 5mL of lidocaine gel was applied.
89494097|NCT02531906|Experimental|Arm I (gabapentin)|"Patients receive gabapentin PO TID for up to 7 weeks during radiotherapy.~All patients may continue to receive treatment for pain throughout their course of chemoradiation therapy (and up to 24 months following CRT if continuing on a pain regimen)."
89494098|NCT02531906|Experimental|Arm II (gabapentin, methadone, oxycodone)|"Patients receive gabapentin PO TID, methadone hydrochloride PO BID, and oxycodone hydrochloride PO Q8H PRN for up to 7 weeks during radiotherapy.~All patients may continue to receive treatment for pain throughout their course of chemoradiation therapy (and up to 24 months following CRT if continuing on a pain regimen)."
89494099|NCT02783729|Experimental|Lemborexant 5 milligrams (mg)|Participants will receive one lemborexant 5 mg tablet and one zolpidem-matched placebo tablet each night
89494100|NCT02783729|Experimental|Lemborexant 10 mg|Participants will receive one lemborexant 10 mg tablet and one zolpidem-matched placebo tablet each night
89494101|NCT02783729|Active Comparator|Zolpidem tartrate|Participants will receive one zolpidem 6.25 mg tablet and one lemborexant-matched placebo tablet each night
89494102|NCT02783729|Placebo Comparator|Placebo|Participants will receive one zolpidem-matched placebo tablet and one lemborexant-matched placebo tablet each night
89494103|NCT02443766||Healthy Subjects|Healthy subjects will attend the weeklong meditation retreat.
89494104|NCT04790942|Experimental|berberine hydrochloride group|the berberine hydrochloride group (BBR) take berberine hydrochloride tablets
89494105|NCT04790942|Placebo Comparator|lifestyle intervention group|Lifestyle intervention group (CON) refers to healthy lifestyle education
88954458|NCT01972386||Spectrum Image Analysis|
88954459|NCT01972399|Experimental|Laser|A laser will be used to clean out the area around the diseased implant to try to regain bone.
88954460|NCT01972399|Active Comparator|Mechanical|Mechanical debridement will be used to clean out the area around the diseased implant to try to regain bone.
88954461|NCT01972412|Other|Telephone support|Intervention type: Telephone support for four months.
88954462|NCT01972425|Experimental|Biomarker-based diagnostic|Analyse sample on arrival
88954463|NCT01972425|No Intervention|Routine use of antibiotics|Do not analyse the sample on arrival
88954464|NCT01972451|Placebo Comparator|Colonoscopy without enhanced dye|no enhanced dye
88954465|NCT01972451|Active Comparator|Colonoscopy with enhanced dye|enhanced dye
88954466|NCT01972477|Experimental|DLBS1449, 1x75 mg|DLBS1449 softcapsule 1x75 mg daily, taken every day along the study period.
88954467|NCT01972477|Experimental|DLBS1449, 1x150 mg|DLBS1449 softcapsule 1x150 mg (2 softcapsules 75 mg) daily, taken every day along the study period
88954468|NCT01972477|Placebo Comparator|Placebo|Placebo once daily, taken every day along the study period
88954469|NCT01972490|Experimental|ARM A|patients received avastin in combination with mFOLFOX6
88954470|NCT01972490|Active Comparator|ARM B|Patients received mFOLFOX6 alone
89494106|NCT04791098|Experimental|Stronger pre-transplant check-up|routine patient management + specific infectious diseases consultation
89494107|NCT04791098|No Intervention|Standard pre-transplant check-up|routine patient management + letter sent to nephrologist
89494108|NCT04344080|Active Comparator|CytoSorb-Therapy|Therapy of COVID-19 with need for extracorporeal circulation (continuous renal replacement therapy or extracorporeal membrane oxygenation) using standard of care in Addition with hemoadsorption using CytoSorb-Adsorber
89494109|NCT04344080|No Intervention|Standard of care|Therapy of COVID-19 with need for extracorporeal circulation (continuous renal replacement therapy or extracorporeal membrane oxygenation) using standard of care
89494110|NCT02324504|Experimental|Placement with C3 Wave Tip System|Subjects will have their central catheters placed with the addition of the FDA approved C3 Wave ECG-Based PICC Tip Confirmation System to the standard institution protocol. The system will assist with location of the catheter tip in real-time, during the procedure.
89494111|NCT02227940|Experimental|Arm 1 (ceritinib MTD then with gemcitabine alone)|"Dose Escalation Cohort 1: Patients with advanced solid tumors for whom gemcitabine hydrochloride-based therapy is clinically appropriate receive ceritinib PO (QD on days 1-28 and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Expansion Cohort 1E: Once the MTD of ceritinib has been determined, an additional 10 patients with ALK-positive advanced solid tumors who previously progressed on gemcitabine hydrochloride-based therapy receive ceritinib and gemcitabine hydrochloride as in the dose escalation cohort 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
89494112|NCT02227940|Experimental|Arm 2 (ceritinib MTD then with gemcitabine and nab-paclitaxel)|"Dose Escalation Cohort 2: Patients with advanced pancreatic cancer receive ceritinib PO QD on days 1-28, gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15, and paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Expansion Cohort 2E: Once the MTD of ceritinib has been determined, patients with ALK-positive advanced solid tumors receive ceritinib, gemcitabine hydrochloride, and paclitaxel albumin-stabilized nanoparticle formulation as in the dose escalation cohort 2. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
89494113|NCT02227940|Experimental|Arm 3 (ceritinib MTD then with gemcitabine and cisplatin)|"Dose Escalation Cohort 3: Patients with advanced solid tumors for whom gemcitabine hydrochloride and cisplatin-based therapy is clinically appropriate receive ceritinib PO QD on days 1-28, gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, and cisplatin IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Expansion Cohort 3E: Once the MTD of ceritinib has been determined, an additional 10 patients with ALK-positive advanced solid tumors receive ceritinib, gemcitabine hydrochloride, and cisplatin as in the dose escalation cohort 3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity."
89494114|NCT02135159|Experimental|TDM1 concommitant with RT|T-DM1 (First injection day 1) followed by brain sequential RT (start day D3), second injection T-DM1 day 22.
89494115|NCT02135159|Experimental|TDM1 during and after RT|Brain sequential RT (start day 1) followed by T-DM1 (First injection day 15), second injection T-DM1 day 36.
89494116|NCT02135159|Experimental|RT before TDM1|Brain sequential RT (start day 1) followed by T-DM1 (First injection day 22), second injection T-DM1 day 43.
89494117|NCT02135159|Experimental|TDM1 before RT|T-DM1 (First injection day 1) followed by brain sequential and concomitant RT (start day D18), second injection T-DM1 day 22.
89494118|NCT02072486|Experimental|Treatment (sorafenib tosylate)|Patients receive sorafenib tosylate PO BID. Treatment continues in the absence of disease progression or unacceptable toxicity.
89494119|NCT03548441||Surgery|Exposed
89494120|NCT03548441||Non-surgical management|Non-exposed
89494121|NCT03548363|Active Comparator|Gingest High|200 mg/d Gingest (powdered extract obtained from Ginger rhizomes) for 4-weeks
89494122|NCT03548363|Active Comparator|Gingest low|100 mg/d Gingest (powdered extract obtained from Ginger rhizomes) + 100 mg maltodextrin for 4-weeks
89494123|NCT03548363|Placebo Comparator|Placebo|200 mg/d maltodextrin for 4-weeks
88954471|NCT01972503|Experimental|ARM A|Patients with stage II or stage III colorectal cancer (CRC) were randomly assigned to two arms. In ARM A, patients accepted intraoperative intraportal infusion of 5-FU 1g and oxaliplatin 100mg + curative resection+mFOLFOX6.
88954472|NCT01972503|Active Comparator|ARM B|Patients with stage II or stage III colorectal cancer (CRC) were randomly assigned to two arms. In arm B, patients accepted curative resection + mFOLFOX6 alone.
88954473|NCT01972542|Active Comparator|Type 2 DM|"Intervention : Oral fat tolerance test~well or moderately controlled type 2 diabetes mellitus (HbA1c < 10%) No dipeptidyl peptidase-4 -inhibitor, Glucagon-like peptide-1 agonist, thiazolidinediones"
88954474|NCT01972542|Active Comparator|Prediabetes|"Intervention : Oral fat tolerance test~Glucose 140-199 mg/dL after 75g oral glucose tolerance test HbA1c 5.7-6.4%"
88954475|NCT01972542|Sham Comparator|Normal glucose tolerance|"Intervention : Oral fat tolerance test~No impaired fasting glucose and impaired glucose tolerance"
89022450|NCT00459771|Active Comparator|Candesartan|Candasartan
89022451|NCT01058369|Experimental|Deferasirox|
88954476|NCT01972555|Experimental|Minimally invasive aortic valve replacement|Minimally invasive AVR with either ministernotomy or anterior right-sided minithoracotomy will be performed according to current standard of care practices. Transthoracic echocardiography will be performed preoperatively and at day 1, 4, and 40.
88954477|NCT01972555|Active Comparator|Conventional aortic valve replacement|Conventional AVR through a standard median sternotomy will be performed according to current standard of care practices. Transthoracic echocardiography will be performed preoperatively and at day 1, 4, and 40.
89494124|NCT00988364|Active Comparator|Ezetimibe|Randomly chosen participants will receive ezetimibe 10mg daily for 3 months.
89494125|NCT00988364|Active Comparator|Simvastatin|Randomly chosen participants will receive Simvastatin 20mg daily for 3 months.
89494126|NCT00988364|Active Comparator|Vytorin|Randomly chosen participants will receive Vytorin 20/10mg daily for 3 months.
89494127|NCT00988364|Placebo Comparator|Placebo|Randomly chosen participants will receive Placebo tab 1 daily for 3 months.
89494128|NCT05578001|Experimental|Pilocarpine|1 drop of Pilocarpine 1% instill in the eye
89494129|NCT05577923|Experimental|T-sunflower group|Patients will be treated with Trastuzumab, Pyrotinib, Dalpiciclib plus Fulvestrant.
89494130|NCT04790708|Experimental|Midgut NETs|75 patients affected by non-functional and functional NETs arising from: stomach, duodenum, jejunum, ileum, colon and rectum.
89494131|NCT04790708|Experimental|Pancreatic NETs|75 patients affected by non-functional and functional NETs arising from Pancreas.
89494132|NCT04790708|Experimental|Bronchial NETs|25 patients affected by non-functional and functional Bronchial NETs.
89494133|NCT04790708|Experimental|Sympathetic-Adrenergic axis NEts|25 patients affected by non-functional and functional: Pheochromocytoma, Paraganglioma and Neuroblastoma
89494134|NCT04790708|Experimental|Other Nets|25 patients affected by non-functional and functional NETs arising from Skin, Thyroid (medullary thyroid and anaplastic cancer) and Parathyroids.
89204823|NCT02550990|Active Comparator|Aerobic exercise training group|One 60-min session of aerobic exercise training. Before and after the treatment, a total of 2 evaluations were conducted, including clinical assessments and blood test (each 18c.c.). A saliva sample (2 mL) will only be collected once from each subject. A follow-up assessment of clinical outcomes will be conducted at six month after the end of the course of treatment.
89494135|NCT04790708|Experimental|Cancers of Unknown Primary Origin (CUP) NETs|25 patients affected by non-functional and functional unknown primary NETs
89494136|NCT05577689||All patients|There is only one arm in the trial
89494137|NCT05577611|Experimental|Basic chemotherapy + UCB transplantation|
88954478|NCT01972581|Experimental|Reaction Time Training|
88954479|NCT01972581|No Intervention|Control|
88954480|NCT01972594|No Intervention|Control group.|Natural progession based on Step count is recorded with a pedometer for 12 weeks.
88954481|NCT01972594|Experimental|Targeted protocol with Pedometer|A step based targeted protocol is given along with a pedometer for 12 weeks post surgery.
88954482|NCT01972607|No Intervention|CONTROL|This group will receive the same treatment of the experimental group after the test-retest measurements.
88954483|NCT01972607|Experimental|EXERCISE|This group will receive the treatment with aerobic exercise training
88954484|NCT01972620|Active Comparator|Multi-modal analgesia|Thirty-one patients were enrolled in this arm. Standard analgesia according to institutional standard and 50:50 mixture of normal saline (8 ml) and 0.5% Bupivacaine was prepared within a 20 ml syringe (Total volume = 16 ml; Final concentration = 0.25%). Following delivery of the gallbladder specimen 8 ml of 0.25% bupivacaine solution was sprayed onto the cystic plate (gallbladder fossa) with a spinal needle advanced under direct laparoscopic vision via a 5mm right subcostal laparoscopic port. The anesthetic solution was sprayed at an operating distance from the cystic plate of ~ 2 cm. Following evacuation of the pneumoperitoneum, the remaining 8 ml of 0.25% Bupivacaine was infiltrated subcutaneously at each of the 4 laparoscopic port sites (2 ml per port site) prior sutured closure.
89204824|NCT02550990|Experimental|Sequential training group|"One 30-min session of aerobic exercise training + one 30-min session of cognitive training.~Before and after the treatment, a total of 2 evaluations were conducted, including clinical assessments and blood test (each 18c.c.). A saliva sample (2 mL) will only be collected once from each subject. A follow-up assessment of clinical outcomes will be conducted at six month after the end of the course of treatment."
89494138|NCT05475314|Experimental|ReFerm(R); fermented oat gruel|ReFerm® is manufactured by the fermentation of an oat gruel with L. plantarum 299v. The product is tested for pH and colony-forming units (CFU) of Enterobacteriaceae, yeasts/moulds, and L. plantarum 299v. The pH must be < 4.0, the CFU of Enterobacteriaceae and yeasts/moulds must be < 100/mL, and the CFU for L. plantarum 299v must be > 10E+08 immediately after completion of fermentation. The energy content of 100 mL ReFerm® is 58 kcal (240 kJ), from 1.6 g protein, 9.8 g carbohydrate, and 0.9 g fat. Each ReFerm® package contained 250 ml
88954485|NCT01972620|No Intervention|Control|Thirty-two patients were enrolled in this arm. They received standard analgesia according to institutional standard of practice consisted of non-narcotic analgesia with narcotic analgesic rescue after laparoscopic cholecystectomy.
88954486|NCT01972633|Active Comparator|1470nm Laser|Patient with varicose vein treated with 1470nm Laser (Biolitec)
88954487|NCT01972633|Active Comparator|VNUS Closure Fast|Patient with varicose vein treated with VNUS Closure Fast (Radiofrequency System)
89494139|NCT05475314|Placebo Comparator|Thick-it(R); thickened water|Thick-it ® mildly thick, Kent Precision Foods Group, Inc.; commercially available) was chosen as a placebo to mimic the viscosity. This product contains artesian mineral water and ≤ 2% xanthan gum, calcium chloride, malic acid, potassium benzoate, potassium sorbate (to preserve freshness), sodium hexametaphosphate, and disodium EDTA. The energy content of 237 mL Thick-it ® (one package) was 5 kcal (21 kJ) from 0 g protein, 1 g carbohydrate, and 0 g fat
89494140|NCT04426604|Experimental|Light induced fluorescence intraoral camera|
89022452|NCT04705103||initial|
89022453|NCT04705103||relapse|
89022454|NCT04705103||inactive|
89494141|NCT04426604|Experimental|Laser-induced fluorescence device|
89494142|NCT04426604|Active Comparator|Visual-tactile assessment method according to FDI criteria|
89494143|NCT05224856|Experimental|CT-P63 and CT-P66|
89494144|NCT05224856|Placebo Comparator|Placebo|
89204825|NCT03742804|Experimental|G100 injections|All patients will receive 6 intratumoral G100 injections alone over 5 weeks. There will be a 4-week break for restaging. Patients will receive another 6 doses of G100 with either topical nitrogen mustard for 2 days before each dose or local radiotherapy (2 Gy daily x 2 days) prior to G100 to the injected lesion to assess the response to combination therapy. After the first 4 doses, nitrogen mustard is optional and can be omitted at the discretion of the investigator.
89204826|NCT00822042||1|Patients with corticotherapy lasting more than 3 months
89204827|NCT00822198|Experimental|plantar vibration|Subject will use Juvent plantar vibration device daily in the home or office for six months.
89494145|NCT02139293|Experimental|auricular vagus nerve stimulation|"Study participants (healthy) are treated with auricular vagus nerve stimulation using five needle electrodes connected to an electrical stimulation device (PrimeStim). After acclimatization the stimulation is turned on for 20 minutes followed by 20 minutes of paused stimulation, 20 minutes of stimulation, and 10 minutes paused stimulation. This intervention is repeated on four consecutive days, whereas at each intervention only one of the four stimulation points (and one fixed reference point) is stimulated. Needle electrodes are applied at each study visit.~Stimulation points in the auricle are stimulated in random order. One stimulation pattern is tested. Stimulation amplitudes are adjusted with respect to a distinct but comfortable sensation at the auricle.~During the described protocol various biosignals are continuously recorded, including ECG, respiration, blood perfusion, oxygen saturation, transcutaneous oxygen tension, blood pressure and skin temperature."
89494146|NCT05615168|Experimental|AcumenIQ - HPI guided hemodynamic optimization|HPI guided hypotension prediction alarms... Interventions based on SVV (fluid), dp/dt (inotropes), EAdyn (pressors)
89494147|NCT05615168|Active Comparator|Flotrac - conventional GDT guided hemodynamic optimization|GDT guided hemodynamic optimization - MAP > 65 mmHg, CI ≥ 2.4 l/min/m2, SVI ≥ 30 ml/beat/m2 and SVRI 1700-2400 dyn·s·cm-5/m2
89204828|NCT01000792|Experimental|Levocetirizine|Levo 5 mg o.d.
89204829|NCT02550756|Experimental|0.2 mg of CNTX-4975|CNTX-4975 will be provided at a capsaicin concentration of 2.0 mg/ml and will be diluted to final concentration using sterile water and 30% PEG 300. Dose volume 1.0 mL-2.0 mL will be used at the discretion of the investigator. Capsaicin concentration will be 0.1 to 0.2 mg/ml
89494148|NCT02139371|Experimental|64Cu-DOTA-AE105 PET|One injection of 64-Cu-DOTA-AE105 (app. 200 Mbq IV) followed by 3 PET scans 1,3 and 24 hours post injection
89494149|NCT04790552|Active Comparator|Fast Group|Subjects will be asked to consume a standardized ready-to-eat dinner meal before 5 pm on day 1. Subjects will fast overnight for approximately 19 hours.
89494150|NCT04790552|Experimental|Night Bar Group|Subjects will be asked to consume a standardized ready-to-eat dinner meal before 5 pm on day 1. Subjects will consume a Fast Bar 3 hours after the dinner and then fast overnight. Subjects will fast overnight for approximately 15 hours and then consume a Fast Bar with coffee on day 2.
89204830|NCT02550756|Experimental|0.6 mg of CNTX-4975|CNTX-4975 will be provided at a capsaicin concentration of 2.0 mg/ml and will be diluted to final concentration using sterile water and 30% PEG 300. Dose volume 1.0 mL-2.0 mL will be used at the discretion of the investigator. Capsaicin concentration will be 0.3 to 0.6 mg/ml
89494151|NCT04790552|Experimental|Bar + Coffee Group|Subjects will be asked to consume a standardized ready-to-eat dinner meal before 5 pm on day 1. Subjects will fast overnight for approximately 15 hours and then consume a Fast Bar with coffee on day 2.
89494152|NCT04790552|Experimental|Bar + Tea Group|Subjects will be asked to consume a standardized ready-to-eat dinner meal before 5 pm on day 1. Subjects will fast overnight for approximately 15 hours and then consume a Fast Bar with tea on day 2.
89494153|NCT02139449||ICD/CRT registry|ICD / CRTregistry in Severance or Ewha Womans University Medical Center
89494154|NCT04790006|Experimental|TG103|TG103 will be administered via subcutaneous injection once weekly in subjects with type 2 diabetes.
89204831|NCT01000870|Experimental|Access MNI-513 and PET Imaging|
89204832|NCT01000948|Experimental|ZD4054|The study had only one arm: intervention
89204833|NCT01001026|Other|1|Adults: One doses of H1N12009 vaccine
89204834|NCT01001026|Other|2|Children: Two doses of H1N12009 vaccine given 3 weeks apart
89204835|NCT01001182||Non interventional|Patients with RA diagnosis receiving any treatment for RA (DMARDS or biologics)
89204836|NCT01001260||No Aspirin Treatment|
89204837|NCT01001260||81 mg Aspirin Treatment|
89204838|NCT01001260||325 mg Aspirin|
89204839|NCT00996424|Experimental|Acetylcysteine|Inhalation with N-Acetylcysteine
89204840|NCT00996424|Placebo Comparator|normal saline|Inhalation with normal saline solution
89494155|NCT04790006|Placebo Comparator|Placebo|Placebo will be administered via subcutaneous injection once weekly in subjects with type 2 diabetes.
89494156|NCT02784431|Experimental|Contour Neurovascular System placement|Treatment of intracranial aneurysm with the Contour Neurovascular System device.
89494157|NCT02590406|Active Comparator|Beach chair (BC) and ZEEP|Table Position: Beach chair, Inclination of the upper part of the table at 25 degrees, breaking at the patient's hips ZEEP: 3 minutes pre-oxygenation with tidal volumes, FiO2 100%, mouth piece used as a ventilatory interface
89494158|NCT02590406|Experimental|Reverse Trendelenburg and NIPPV|"Table Position: Reverse Trendelenburg, Inclination of the whole table at 25 degrees from an horizontal plane, head up.~NIPPV: 3 minutes of pre-oxygenation with 8 cm H2O positive pressure and 10 cm H2O PEEP. Trigger set at 1,5 L/min, mouth piece is used as a ventilatory interface"
89494159|NCT02135237|Active Comparator|Control Group|Standard Care
89494160|NCT02135237|Experimental|Experimental Group|Standard Care plus Prize Contingency Management for Alcohol Abstinence
89204841|NCT00994474|Active Comparator|Fractional carbon dioxide laser treatment|
89204842|NCT00994474|Active Comparator|Fractional Er:YAG laser treatment|
89204843|NCT05220280|No Intervention|Local standard of care|
89204844|NCT05220280|Experimental|Imatinib + local standard of care|
89204845|NCT05220280|Experimental|Infliximab + local standard of care|
89494161|NCT02139683|Experimental|HIFU treatment|HIFU treatment in patient diagnosed with fibroadenoma
89494162|NCT05577377|Experimental|OM intervention|
89494163|NCT05614934|Active Comparator|S3|Standard clarithromycin triple
89494164|NCT05614934|Experimental|V3|Vonoprazan triple
89494165|NCT05614934|Experimental|V2|Vonoprazan dual
88954488|NCT01972646||Adult patients (≥ 18 years) with uncomplicated cellulitis|Adult patients (≥ 18 years) whose chief complaint was consistent with a skin or soft tissue infection (key words included cellulitis, abscess, infection, insect bite, ulcer, or rash) were screened for eligibility by ED staff or trained research assistants and invited to participate in this study once an emergency physician confirmed a cellulitis infection.
88954489|NCT01972672|Experimental|Icaritin|Icaritin 600 mg orally, twice daily for a total daily dose of 1200 mg
88954490|NCT01972685|Other|Cryo vs Transbronchial vs VATS biopsy|Each patient will be brought to the operating room and will undergo transbronchial, cryoprobe and VATS biopsy of the lung.
88954491|NCT01972698|Experimental|Self-directed and simulation-assisted training|
88954492|NCT01972698|Active Comparator|Traditional apprenticeship training|
89204846|NCT00318643|Experimental|Cohort 1: MMC plus Chemophase 20,000 U|Participants will receive 40 milligrams (mg) MMC intravesically on Day 1 of Week 1 followed by a combination of 40 mg MMC and 20,000 U Chemophase intravesically once weekly from Weeks 2 through 6.
89204847|NCT00318643|Experimental|Cohort 2: MMC plus Chemophase 60,000 U|Participants will receive 40 mg MMC intravesically on Day 1 of Week 1 followed by a combination of 40 mg MMC and 60,000 U Chemophase intravesically once weekly from Weeks 2 through 6.
89204848|NCT00318643|Experimental|Cohort 3: MMC plus Chemophase 200,000 U|Participants will receive 40 mg MMC intravesically on Day 1 of Week 1 followed by a combination of 40 mg MMC and 200,000 U Chemophase intravesically once weekly from Weeks 2 through 6.
89204849|NCT00318643|Experimental|Cohort 4: MMC plus Chemophase 400,000 U|Participants will receive 40 mg MMC intravesically on Day 1 of Week 1 followed by a combination of 40 mg MMC and 400,000 U Chemophase intravesically once weekly from Weeks 2 through 6.
89204850|NCT00318643|Experimental|Cohort 5: MMC plus Chemophase 800,000 U|Participants will receive 40 mg MMC intravesically on Day 1 of Week 1 followed by a combination of 40 mg MMC and 800,000 U Chemophase intravesically once weekly from Weeks 2 through 6.
89204851|NCT00996814|Experimental|Proactive Ethics Intervention|These patients have an ethics consultant involved in their care beginning on the fifth day of treatment in the ICU
89204852|NCT00996814|No Intervention|Usual Care|These patients receive usual care in the ICU.
89204853|NCT01001650|Experimental|Group 1|4 doses of 7,500 PfSPZ/immunization.
89204854|NCT01001650|Experimental|Group 2|4 doses of 30,000 PfSPZ/immunization
89204855|NCT01001650|Experimental|Group 3|4 doses of 135,000 PfSPZ/immunization
89204856|NCT01001650|Experimental|Group 4|4 or 6 doses of 135,000 PfSPZ/immunization.
89204857|NCT01001728|Active Comparator|Prone Position|Patients will lie on their fronts on an in-house designed board comprising an arm positioning device registerable to the couch-top, together with a styrofoam/ memory foam mattress. The ipsilateral breast will drop through an aperture in the mattress. The distance from the nipple to the superior, inferior and lateral aspects of the aperture will be recorded along with the distance of the nipple from the couch-top. Arms will be extended as far as possible above the head and the position of the arm immobilisation handles recorded. The head will be turned to the contralateral side. The contralateral breast will be pulled laterally such that it is as flat as possible beneath the patient. Measurements will be taken in order to relate the position of the bi-lateral tattoos to the orthogonal lasers. A fourth tattoo will be marked on the patient's back in line with the A-P laser. The position will be reproduced at treatment using measurements from the tattoo to the laser.
89204858|NCT01001728|Active Comparator|Supine position|For the supine position, patients will be positioned on a customized supine breast board co-registerable to the couch-top to CT and the treatment machines. Arms will be placed above the head in supports. Arm and head position will be recorded along with the angle of the board (which is adjusted such that the sternum is parallel to the couch-top). Tattoos will be marked bi-laterally and medially in a defined relationship to orthogonal lasers. The position will be reproduced at treatment using the above measurements, tattoos and lasers.
89204859|NCT00318565|Experimental|Navistar ThermoCool Catheter|
89204860|NCT00994552|Active Comparator|Pressure support ventilation|Pressure support ventilation
89204861|NCT00994552|Active Comparator|Pressure control ventilation|Pressure control ventilation
89204862|NCT01001884|Experimental|counseling|caregiver psychoeducational consultation program (CPCP)
89204863|NCT03983083|Experimental|Intervention|Aspects of the HEALED intervention are based on various components of successful interventions for breast cancer survivors and older adults, NCI funding priorities, CPS-3 survivor preferences discussed in prior focus groups and survivorship research from other cohorts. As such, HEALED participants will receive monthly motivational e-mails, based on prior studies of the most effective delivery time intervals for interventions involving cancer survivors, with links to a web-based platform which will provide: physical activity information (largely consisting of publicly available evidence-based resources), at-home exercise demonstrations/videos for survivors of all fitness levels, personal survivor stories, physical activity/sitting recommendations (based on National Guidelines and ACS guidelines for survivors), positive messaging, a space for SMART goal setting, a platform for physical activity tracking, a discussion board, etc.
89204864|NCT03983083|No Intervention|Wait-list control|"Wait-listed control group will be instructed to continue behavior as-usual. They will receive access to the HEALED website at the end of the 12-week intervention period."
89204865|NCT01325389|Experimental|Myo+Mel|Patients are treated with 2g of myo + 3mg of melatonin daily
89204866|NCT01325389|Placebo Comparator|Placebo|
89204867|NCT00994630||BP I patients manic phase|
89204868|NCT01001962|Active Comparator|Metformin|527 Patients treated with Metformin 850x2mg titrated to 1000x2mg Daily oral
89204869|NCT01001962|Active Comparator|Empagliflozin|527 Patients treated with empagliflozin 10mg titrated to 25 mg Daily oral
89204870|NCT01002040|Active Comparator|One Dose Influenza vaccine|Arepanrix H1N1 Influenza vaccine (one dose)
88954493|NCT01972711|Experimental|SEP-363856|Single-dose SEP-363856 50 mg
88954494|NCT01972711|Active Comparator|Amisulpride|Single-dose Amisulpride 400 mg.
88954495|NCT01972711|Placebo Comparator|Placebo|Matched placebo
88954496|NCT01972737|Experimental|Ad5-hGCC-PADRE Vaccine|Active vaccine
88954497|NCT01972750|Experimental|Dovitinib|IMP: Dovitinib (TKI258) Manufacturer: Novartis Dose: 500 mg/day Mode of application: orally Duration of treatment: 5 days / week (5 days on / 2 days off) of a 28-days cycle until progression of disease
88954498|NCT01972763|Active Comparator|Ranibizumab 1 mg|Subjects will receive Ranibizumab 0.5 mg for 3 doses and then be separated into 2 arms based on initial response. In this Arm (Arm 1), patients will receive 1 mg of Ranibizumab monthly for the remainder of the study, if persistent or worse subretinal fluid with or without intraretinal cysts on SD-OCT is present.
89204871|NCT01002040|Active Comparator|Two Doses Influenza vaccine|Arepanrix H1N1 Influenza vaccine (2 doses, 3 weeks apart)
89494166|NCT05475158||Dementia|"Patients with Alzheimer disease dementia (ADD) fulfilled the NIA-AA core clinical criteria for probable ADD and Aβ positive according to ATN classification scheme.~Aβ positive refers to Aβ pathology (CSF Aβ1-42 < 631.8 pg/ml or positive amyloid deposits on 18F-flutemetamol PET by visual inspection)."
89494167|NCT05475158||MCI (Mild cognitive impairment)|Patients with mild cognitive impairment (MCI) met the Petersen's criteria.
89494168|NCT05475158||CU (Cognitively unimpaired control)|CU consisted of cognitively unimpaired subjects whose cognition (as defined by the Seoul Neuropsychological Screening Battery (SNSB)) was within normal limits.
89494169|NCT05475158||Aβ positive|Aβ positive refers to Aβ pathology (CSF Aβ1-42 < 631.8 pg/ml or positive amyloid deposits on 18F-flutemetamol PET by visual inspection).
89494170|NCT05475158||Aβ negative|Aβ negative was within normal limits.
89494171|NCT02135393|Experimental|13C5-folic acid or 13C5-6S-5-FormylTHF|Physiological 500 nmol (220 µg folic acid equivalent) dose of dietary supplement 13C5-folic acid or 13C5-6S-5-FormylTHF given to subjects with in situ transjugular intrahepatic portosystemic stent at the time of routine venography patency check followed by regular portal venous sampling for 85 minutes at pre determined intervals and then physiological 500 nmol dose of 13C-6S-5-FormylTHF or 13C5-folic acid respectively at the next annual routine venography patency check followed by portal venous sampling for 85 minutes
89494172|NCT04426448|Experimental|Intervention group|Participants will receive the BREATHE intervention for three weeks
89494173|NCT04426448|No Intervention|Control group|The participants will receive treatment as usual
89494174|NCT02139761|Active Comparator|l-tetrahydropalmatine (l-THP)|Subjects will be dosed 30 mg BID (2 capsules total a day, total of 60mg/day), matching placebo or l-THP) (total 60 mg daily). The half-life of l-THP is about 10 hours, so subjects will reach steady state in about 2-3 days. The l-THP will be prepared at the University of Maryland School of Pharmacy to Chemistry under Good Manufacturing Practice (GMP) and standards. The identical placebo and active capsules will be manufactured and sent to the Maryland Psychiatric Research Center Pharmacy, where they will be stored, randomized and dispensed. Medication will be transported by the study staff to the participant once dispensing occurs.
89494175|NCT02139761|Placebo Comparator|Placebo|Subjects will be dosed 30 mg BID (2 capsules total a day, total of 60mg/day), matching placebo or l-THP) (total 60 mg daily). The half-life of l-THP is about 10 hours, so subjects will reach steady state in about 2-3 days. The l-THP will be prepared at the University of Maryland School of Pharmacy to Chemistry under Good Manufacturing Practice (GMP) and standards. The identical placebo and active capsules will be manufactured and sent to the Maryland Psychiatric Research Center Pharmacy, where they will be stored, randomized and dispensed. Medication will be transported by the study staff to the participant once dispensing occurs.
89494176|NCT04426370||Case|100 rheumatoid arthritis patients (age from 20 to 70 years)
89494177|NCT04426370||Control|95 healthy volunteer
89494178|NCT02139839|Placebo Comparator|Gelatin pill first|
89494179|NCT02139839|Experimental|Lactobacillus capsules first|
89494180|NCT05150600|Experimental|Group Inverse Ratio Ventilation (IRV)|The inspiratory to expiratory (I:E) ratio in this group will be 2:1 with the maximum inspiratory time (Ti) of 1.3 seconds
89204872|NCT03978169||General anaesthesia with orotracheal intubation|surgery patients under general anaesthesia with orotracheal intubation
89494181|NCT05150600|No Intervention|Group Conventional Ratio Ventilation (CRV)|The inspiratory to expiratory (I:E) ratio in this group will be 1:2 with the minimum inspiratory time (Ti) of 0.4 seconds
89494182|NCT04790084||Healthy-Myopia-CSC|Cross-sectional study, no intervention, only collecting OCT,OCTA images and other eye parameters of patients.
89494183|NCT02139917|Experimental|Transitional Palliative Care|"Transitional palliative care include:-~telephone follow up for early identification of signs and symptoms~home visit for spiritual support"
89494184|NCT02139917|No Intervention|Customary care|"Customary care receive care :-~hospital based medical follow up~general nursing assessment and advice"
89494185|NCT05144438||Pregnant women or woman in desire for conception|Towseek test : hair taking different questionnaires : environmental questionnaire, compliance questionnaire
88954499|NCT01972763|Active Comparator|Ranibizumab 0.5 mg|Subjects will receive Ranibizumab 0.5 mg for 3 doses and then be separated into 2 arms based on initial response. In this Arm (Arm 2), patients will receive 0.5 mg of Ranibizumab monthly for the remainder of the study, if complete resolution of subretinal fluid on SD-OCT is present.
88954500|NCT01972828|Experimental|PRELOAD DEPENDENCE|in this arm, fluid loading is administered with an algorithm using preload dependence indexes (variation in cardiac output in response to passive leg raising).
88954501|NCT01972828|Active Comparator|CONTROL|
88954502|NCT01972880|Experimental|tablet-1|
88954503|NCT01972880|Active Comparator|tablet-2|
89204873|NCT03978169||General anaesthesia with laryngeal mask|surgery patient under general anaesthesia with laryngeal mask
89204874|NCT03978169||Spinal anaesthesia|surgery's patients under Spinal anaesthesia
89204875|NCT00304915|Experimental|Arm 1: Collaborative Care Intervention|HIV patients were screened for depression and the screener results were available to HIV clinicians. Depressed HIV patients received collaborative care intervention.
89204876|NCT00304915|No Intervention|Arm 2: Usual Care|HIV patients were screened for depression and the screener results were available to HIV clinicians. Depressed HIV patients received usual care.
89204877|NCT05206786|Experimental|Control group. Conventional preventive work out|
89204878|NCT05206786|Experimental|Intervention group. Gluteus maximus strengthening specific program|
89204879|NCT03980197|Experimental|Intervention|Active surveillance test and preemptive isolation is performed. If MDRO is isolated in surveillance test, contact precaution is needed.
89494186|NCT05577143||Case group|All consecutive patients from participating centers with an abnormal colonoscopy (presence of mucosal lesions at endoscopy), with histological confirmation of colorectal cancer. These will be patients with one or more histologically confirmed adenocarcinomatous lesions (CRC+) located in the colonic frame or rectum, with or without synchronous liver metastases.
89494187|NCT05577143||Control group|All consecutive patients between 50 and 75 years of age for whom colonoscopy will be normal (no mucosal lesions). In this situation, histological examination is not performed.
89494188|NCT05577143||Polyp group|All consecutive patients for whom colonoscopy shows mucosal lesions that will be classified as polyps after histological examination.
89494189|NCT02135471|Experimental|acellular dermal matrix graft|
89494190|NCT02135471|Experimental|enamel matrix derivative|
89494191|NCT03762941||Elderly patients acutely admitted|Elderly patients (aged ≥ 65 year) admitted to emergency departments at the Hospital of Southern Jutland or Odense University
89494192|NCT05614778||Treatment group|Zoledronic Acid inj. 5mg/100mL
88954504|NCT01972893|Experimental|ZYD1|Tablet ZYD1 5 to 50 mg subcutaneously Once a day (OD) or BID depending upon the pharmacokinetic profile obtained in Plan I (Single dose study)
88954505|NCT01972893|Placebo Comparator|Placebo|Tablet Placebo 5 to 50 mg subcutaneously OD or BID depending upon the pharmacokinetic profile obtained in Plan I (Single dose study)
88954506|NCT01972906|Experimental|Moxibustion treatment group|Apply traditional acupuncture to prevent the dysmenorrhea according to traditional Chinese medicine theory
88954507|NCT01972906|Active Comparator|Medicine control group|Ibuprofen Sustained Release Capsules will be penetrated for dysmenorrhea
88954508|NCT01972945|Experimental|Vaginoscopy|Vaginoscopy, otherwise known as the 'no touch' technique, describes a technique where the hysteroscope is guided into the uterus without the need for potentially painful vaginal instrumentation i.e. passage of a vaginal speculum to separate the vaginal walls, cleansing of the cervix and sometimes application of traumatic forceps to the ectocervix in order to stabilise it.
89494193|NCT02139995|Experimental|Transfusion trigger based on WCTS-CP|Determination of whether a patient need red blood cells transfusion or which hemoglobin level should be maintained is based on WCTS-CP
89494194|NCT02139995|Active Comparator|Transfusion trigger based on experience|Determination of whether a patient need red blood cell transfusion or which hemoglobin level should be maintained is base on the physician's experience
89494195|NCT05614700|Active Comparator|High dose-rate brachytherapy|Two HDR-BT treatment schedules, either a single fraction 19Gy treatment or 27Gy in 2 fractions approximately 2 weeks apart will be used to be decided by treating centre.
89494196|NCT05614700|Experimental|Ultra-hypofractionated external beam radiotherapy|Patients will receive 5 fractions of 7.25Gy per fraction which will be delivered alternate days over no more than 2 weeks to provide a total dose of 36.25Gy.
88954509|NCT01972945|Active Comparator|Standard Hysteroscopy|Traditional hysteroscopy consists of introducing speculum and grasping of the cervix to provide counter traction to allow instrumentation of the uterus. Introducing a speculum also allows the cervix to be cleaned with sterilising fluid.
88954510|NCT01972958|Experimental|comprehensive care|comprehensive assessment, physical activity training, community resources referral, health education, health promotion activity.
88954511|NCT01972958|No Intervention|usual care|control group with usual care
88954512|NCT01972971|Other|pharmacist care|
88954513|NCT01972984|Experimental|Anastrozole|All qualifying women will receive anastrozole at the usual dose of 1mg daily for 2-6 weeks leading up to their surgery
88954514|NCT01972997|Experimental|SENSIMED Triggerfish|There is only 1 arm in the study. SENSIMED Trigerfish lens sensors with different base curves are placed on subjects in random and double-blinded manner in sequential sessions.
88954515|NCT01973010|Experimental|Massage|To treat low back pain with massage
88954516|NCT01973010|Active Comparator|Ibuprofen|Medicine control group
88954517|NCT01973023||Chronic spastic stroke patients|Chronic spastic stroke patients treated regularly with botulinum toxin injection in lower limb muscles
89494197|NCT02252783|Experimental|BFPET|BFPET will be administered as a single intravenous injection of up to 2 mCi (74 MBq) at rest and a single intravenous injection of up to 8mCi (296 MBq) following a stress protocol. Total amount not to exceed 10mCi (370 MBq).
89494198|NCT05474924|Experimental|Budesonide Intrapolyp injection|"patients are to receive Endoscopic Intrapolyp steroid injection weekly for 5 weeks, using the following technique, where 2 nasal packs soaked in xylometazoline hydrochloride 0.1%  Otrivin adult nasal drops applied one pack in each nostril for 5 minutes before injection, then using the 0° nasal endoscopy patients receive intrapolyp budesonide injection by 0.5 mg/ml budesonide respules commercially available as Pulmicort ampules 1 ml for each nostril using 1 cc 28 gauge needle sterile syringe, where injections carefully distributed amongst visible polyps avoiding visible vessels, No local anesthesia will be used before injections, patients come back to the clinic weekly to complete a series of 5 injections."
88954518|NCT01973075||premature ovarian Insufficiency|4ml whole blood sample is going to collect from premature ovarian Insufficiency group for the assessment of genetic abnormalities
88954519|NCT01973075||healthy control group|4 ml of whole blood is going to taken from healthy control group
88954520|NCT01973088||non-urate calculus|
88954521|NCT01973088||non-calculus|
88954522|NCT01973088||urate calculus|
88954523|NCT01973101|Experimental|Chemo-induction|Cisplatin plus Gemcitabine for 3 cycles followed by Cisplatin, radiotherapy and brachytherapy
89494199|NCT05474924|Active Comparator|budesonide wash|"patients will be instructed to perform budesonide nasal wash, through a 250 ml squeeze bottle filled with saline, 0.5 mg/ml budesonide Pulmicort ampule added to the solution and half the amount used for each nostril, patients gurgle with antiseptic solution to minimize the risk of oral candidiasis, patients carry out the wash twice daily for one month duration"
89494200|NCT05474924|Active Comparator|Oral steroid|patients receive oral prednisolone 1 mg/kg/d tapering it by 5 mg/day for 2 weeks, patients will be prescribed omeprazole 20mg protective against gastrointestinal effects of steroid
88954524|NCT01973101|Active Comparator|Chemoradiotherapy|Cisplatin, radiotherapy and brachytherapy
88954525|NCT01973114|Experimental|Group 1|One intratympanic injection of latanoprost (Day1)
88954526|NCT01973114|Placebo Comparator|Group 2|One intratympanic injection of placebo
88954527|NCT01973114|Experimental|Group 3|Three intratympanic injections of latanoprost (Day 1, 2 and 3)
88954528|NCT01973114|Placebo Comparator|Group 4|Three intratympanic injections of placebo (Day 1, 2 and 3)
88954529|NCT01973127|Experimental|Verum rTMS|"n=15. After detoxification of alcohol (maximum 4 days) rTMS treatment will start : 20 sessions (5 times during 4 weeks)of verum rTMS on the right dorsolateral prefrontal cortex.~Measurements of all objectives at baseline and 2,4,8 and 12 weeks after start treatment."
88954530|NCT01973127|Sham Comparator|Sham TMS|"n=15. After detoxification of alcohol (maximum 4 days) rTMS treatment will start : 20 sessions (5 times during 4 weeks)of sham rTMS on the right dorsolateral prefrontal cortex.~Measurements of all objectives at basleine and 2,4,8 and 12 weeks after start treatment."
88954531|NCT01973140|Other|Tolvaptan and Hypertonic saline infusion|Tolvaptan 60 mg or 30 mg tablet by mouth for the first part of the study. A week later, infusion of hypertonic saline.
89494201|NCT02135549|Experimental|SugarDown 4 grams|SugarDown 4 gram dose in tablet form, before meals, daily for one week
89494202|NCT02135549|Experimental|SugarDown 8 grams|SugarDown 8 gram dose in tablet form, before meals, daily for one week
89494203|NCT02135549|Placebo Comparator|Placebo|Placebo dose in tablet form, before meals, daily for one week
89494204|NCT04789772|Experimental|Laser acupuncture group|Laser acupuncture group receive laser acupuncture treatment with cognitive behavioral therapy.
89494205|NCT05576987|Experimental|intervention group|Experimental group will be selected from the branches 3rd and 4th grade. 3 branches will be selected for the experimental group. Branches will be determined by drawing. In order not to interfere with the education of students during the training, the groups will be designated as class branches.
89494206|NCT05576987|No Intervention|control group|"Control group will be selected from the branches 3rd and 4th grade. 3 branches for the control group. Branches will be determined by drawing. In order not to interfere with the education of students during the training, the groups will be designated as class branches.~After the training of the experimental group is completed and the final data are obtained, a 40-minute training will be given to the control group about prevention from school accidents. This training was planned so that the control group would not be devoided of the intervention."
89494207|NCT04789460||COVID-19 patients in hospital|All patients aged 18 years and over, positive for SARS-CoV-2 PCR test and / or Covid-19 treatment with signs of Covid-19 disease on CT in two tertier hospital in Istanbul
89494208|NCT02135627|Experimental|Control group|Current standard endoscopic therapy such as epinephrine injection, sclerotherapy, mechanical (endoclip). contact electrocautery/thermal, and non-contact electrocalcautery (APC) ± radiation therapy, angioembolization, and/or surgery.
89494209|NCT02135627|Active Comparator|TC-325|TC-325 monotherapy on initial endoscopy ± radiation therapy, angioembolization, and/or surgery.
89494210|NCT05576909|Experimental|Donafenib|"Donafenib combine with TACE for downstaging treatment;~Donafenib for adjuvant therapy."
88954532|NCT01973244|Experimental|NNC0195-0092 (somapacitan)|
88954533|NCT01973244|Active Comparator|Norditropin®|
88954534|NCT01973257|Experimental|select from the option menu|select from the option menu
88954535|NCT01973270|Experimental|Targeted Cognitive Training - TCT|Neuroadaptive cognitive training
88954536|NCT01973270|Experimental|General Cognitive Exercises (GCE)|Neuroadaptive cognitive training
88954537|NCT01973270|No Intervention|Treatment as Usual|Treatment as Usual
88954538|NCT01973296|Experimental|ED to home care transition|The ED to home care transition intervention is a 4-week program that uses a Area Agency on Aging coach to conduct a home visit and three follow up phone calls to help patients develop the skills needed for self-management and to communicate with healthcare providers.
88954539|NCT01973296|Other|Usual Care|Patients randomized to usual care will receive verbal and written discharge instructions from the treating emergency department physician and nurse as is the standard of care.
89494211|NCT02252861||Left Atrial Appendage Closure|Patients with atrial fibrillation and counter-indication to anticoagulant therapy referred for percutaneous Left Atrial Appendage Closure in routine care
89494212|NCT02135783|Experimental|Decompressive Craniectomy|Decompressive Craniectomy afte Hematoma Removal in Patients with Intracerebral Hemorrhage
89494213|NCT02135783|Active Comparator|non-Decompressive Craniectomy|non-Decompressive Craniectomy afte Hematoma Removal in Patients with Intracerebral Hemorrhage
89494214|NCT05614622|No Intervention|Control|Control group receives standard post-operative treatment, which includes self-instillation of Ofloxacin and Dexamethasone eye drops with tapering down from q.i.d for the 1st week to once daily in the 4th week
89494215|NCT05614622|Experimental|Study|The study group receives standard post-operative treatment same as the control group. And additional treatment of a short-acting mydriatic agent (Cyclopentolate Hydrochloride 1.0% eye drops) t.i.d for 4 weeks (to operate eye alone)
89494216|NCT03548129|Active Comparator|Fosfomycin group (FG)|"Pre-treatment Urine culture will be done then all patients will receive empirical 3 gm oral phosphomycin fosfomycin will be taken by mouth on an empty stomach i.e. 2-3 hours after meals preferably in the evening before bed time after emptying the bladder.~The contents of 1 packet of Monuril will be dissolved in a glass of water or another non-alcoholic drink and drink immediately. Do not mix with hot water. Do not take fosfomycin in its dry form.~Response to treatment will be assessed by post-treatment urine culture."
89494217|NCT03548129|Active Comparator|Culture specific group (CG):|"Pre-treatment Urine culture and antimicrobial sensitivity testing will be done then all patients will receive oral culture specific antibiotic therapy in the form of five days regimen.~Response to treatment will be assessed by post-treatment urine culture."
89494218|NCT02140073|Experimental|omeprazole+domperidone SR|patients with GERD receive omeprazole 20mg + domperidone SR 30mg , 2 capsules in the morning
89494219|NCT02140073|Active Comparator|omeprazole|omeprazole 40mg in the morning
89494220|NCT04788290||Single group(No interventional)|Other Name: Observational Rabone D®, Once daily administered per the locally approved product information
89494221|NCT03549377||Rested|Based on Pittsburgh Sleep Quality Index, participants scoring in the top 10-20% will be assigned to the rested group and will experience deception as part of the delayed gratification task
89494222|NCT03549377||Sleep-deprived|Based on Pittsburgh Sleep Quality Index, participants scoring in the bottom 10-20% will be assigned to the sleep-deprived group and will experience deception as part of the delayed gratification task
89494223|NCT05474612|Experimental|kinesiology taping with conventional therapy|"Patients in group A is treated with conventional treatment (include stretching exercises of SCM, Scaleni and upper fibers of trapezius followed by strengthening (isometrics) of Neck flexors (SCM, rectus capitis, anterior and longus capitis) and then with kinesiology taping.~Two pieces of the tape cutted in a Y-shape. Applied on deep cervical extensors and upper fibers of trapezius."
89494224|NCT05474612|Active Comparator|Instrument Assisted Soft Tissue Mobilization with Conventional therapy|"Patients in group B is treated with conventional treatment (stretching exercises of SCM, Scaleni and upper fibers of trapezius followed by strengthening (isometrics) of Neck flexors (SCM, rectus capitis, anterior and longus capitis) and then with Instrument Assisted soft tissue mobilization technique.~IASTM using tools over the length of targeted muscles (SCM, descending fiber of trapezius, suboccipitalis muscles) in a multidirectional stroking fashion applied to the skin at 30°- 60° for 5 minutes."
89494225|NCT02140229|Active Comparator|Usual care|Usual care and follow-up every 3 months
89494226|NCT02140229|Experimental|US-driven therapy|Clinical evaluation according to DAS28 + US every 3 months
89494227|NCT02140229|Active Comparator|ACR/EULAR remission criteria-driven therapy|Clinical evaluation according to DAS28 + ACR/EULAR remission criteria every 3 months
89494228|NCT05575973|Experimental|mitoxantrone hydrochloride liposome|Patients with relapsed and refractory diffuse large B-cell lymphoma (DLBCL) will receive sequentially mitoxantrone hydrochloride liposome in combination with rituximab and lenalidomide for up to 6 cycles (28 days per cycle).
89494229|NCT05474222|Experimental|Horizon Eagle Fatherhood Programming - classroom instruction|The intervention (the Horizon Eagle Fatherhood Programming) is an intensive 40-hour classroom-based program taught by project staff. This instruction addresses topics such as Fatherhood Development, Relationship Enhancement, and Financial Literacy, and features the 24/7 Dad curriculum as part of the instruction. Intervention participants and control participants will have an opportunity to participate in case management services and workforce training.
89494230|NCT05474222|No Intervention|Control|The control group does not receive any part of the classroom instruction that the intervention group receives. Like the intervention group, however, the control group does have access to case management and workforce training.
89494231|NCT03547895|Active Comparator|cases|"patients with decompensated cirrhosis~treated with Sofosbuvir 400 mg (Sovaldi) + Daclatasvir 60mg (Daklinza) + Ribavirin 200 mg (Rebetol)"
89494232|NCT03547895|Placebo Comparator|control group|the control group treated with liver support including silymarin 140 + phytomenadione 10 mg + lasilactone 50 mg + albumin infusion
88954540|NCT01973309|Experimental|Vantictumab combined with paclitaxel|Drug: vantictumab combined with paclitaxel - administered intravenously
88954541|NCT01973322|Experimental|arm 1: DC Vaccine + RT|three daily doses of 8 Gy up to 12 Gy delivered to one non-index metastatic field between vaccine doses 1 and 2 (optional to one additional field between vaccine doses 7 and 8) utilizing IMRT-IMAT techniques
88954542|NCT01973322|Experimental|arm 2: DC Vaccine + IFN-alfa|daily 3 MU subcutaneous IFN-alfa for 7 days before leukapheresis (day -15 to -9, and for 7 days before any other additional leukapheresis)
88954543|NCT01973322|Experimental|arm 3: both arm 1 and 2 + RT|both 1 and 2 external immunostimulant conditions (Intradermal Autologous Dendritic Cell Vaccine + 3 single boosts of RT + IFN-alfa, 3 MU daily for 7 days before leukapheresis)
88954544|NCT01973322|Experimental|arm 4: DC Vaccine|neither 1 or 2 external immunostimulant conditions (only Intradermal Autologous Dendritic Cell Vaccine)
88954545|NCT01973361|Experimental|Ultrasound debridement|Participants receiving ultrasound assisted debridement in addition to best practice wound care.
88954546|NCT01973361|Active Comparator|Best Practice wound care|Participants receiving best practice wound care alone
88954547|NCT01973374|No Intervention|Routine Care|
88954548|NCT01973374|Experimental|Text Message Intervention|The text message intervention group receives usual prenatal and diabetic care in addition to two text messages per week throughout the pregnancy and a reminder text message prior to the postpartum visit. The text message intervention group also fills out a survey about the intervention after delivery.
88954549|NCT01973400|Experimental|Tocotrienol|200 mg, twice a day, 12 months
88954550|NCT01973400|Placebo Comparator|Placebo|200 mg, twice a day, 12 months
88954551|NCT01973426||Children with limited control of their thumb|Children afflicted by hemiplegic stroke or hemiplegic cerebral palsy who have lost the ability to actively (and accurately) control the thumb.
88954552|NCT01973465|Experimental|Fecal Microbiota Therapy|
89022455|NCT03271788|Experimental|stroke patients and caregivers|Stroke patients will conduct two phases ( A-Phase: regular occupational therapy; B-Phase occupational therapy with additional mindfulness) Caregivers of the patients will conduct the MBSR Course (Mindfulness) together with their relatives (Phase B). In Phase A they will not receive any treatment.
89022456|NCT01057433|Experimental|Pitavastatin|Healthy adult subjects
89022457|NCT01057394|Active Comparator|Radiofrequency Ablation|PVI using RF ablation
89022458|NCT01057394|Experimental|Visually Guided Ablation|PVI using visually guided ablation with an endoscopic ablation system
89494233|NCT01359254|Experimental|Conditioning Regimen I|Arm I contains fludarabine, melphalan, and antithymocyte globulin (ATG)
89494234|NCT01359254|Experimental|Conditioning Regimen II|Arm II contains fludarabine, busulfan, antithymocyte globulin (ATG), and total body irradiation (TBI).
89494235|NCT05474144|Experimental|Verum|Patients received probiotic supplement SmartProbio C, one capsule twice a day - mornings and evenings before meal - for a period of 2 weeks.
89494236|NCT05474144|Placebo Comparator|Placebo|Patients received placebo consisting of purified maltodextrin, one capsule twice a day - mornings and evenings before meal - for a period of 2 weeks.
89494237|NCT05575739||Male factor|Couples that have just the male factor as cause of infertility
89494238|NCT05575739||Other causes of infertility|diminished ovarian reserve polycystic ovarian syndrome unexplained infertility tubal factor
89494239|NCT05035862|Experimental|Infusion of γMSCs|Escalating doses Dose escalation design with two dose levels. The low dose level involves a single intravenous infusion of γMSCs at 2x106 cells/kg. The high dose level involves a single intravenous infusion of γMSCs at 5x106 cells/kg.
89494240|NCT05575661||Postprandial hypotension group|Patients who have a fall in systolic blood pressure of >20 mm Hg, or a decrease to ≤90 mm Hg when preprandial systolic blood pressure is ≥100 mm Hg within 2 hours of the lunch
89494241|NCT05575661||No postprandial hypotension group|Patients who do not meet the postprandial hypotension criteria within 2 hours of the lunch
89494242|NCT05033210|Other|Control Group|The control group will receive Psychological First Aid (PFA) and Care as Usual (CAU)
89494243|NCT05033210|Experimental|Treatment Group|The treatment group will receive the stepped-care program consisting of Doing What Matters (DWM) (step 1) and Problem Management Plus (PM+) (step 2), in addition to Psychological First Aid (PFA) and care as usual (CAU). Step 2 will only be provided if the participant still has elevated levels of psychological distress (K10 > 15.9) at 2 weeks after DWM, i.e. during the second quantitative assessment at 2 weeks after DWM.
89494244|NCT02140307|Experimental|Meditation training, group format|"The course Relaxation Response-based Mental Health Promotion (publicly referred to as Open and Calm) is given in group format.~The intervention entails 9 courses (1 per week of 2.5 hrs), a course book (120 pages), audio support (6 guided meditative practices), access to a webpage with additional information, and the possibility of two personal sessions with the intervention instructor (a certified psychologist)."
88954553|NCT01973478|Experimental|DBS|"The medical device includes:~Either a pacemaker ACTIVA PC (Ref 37601) two-channel (Medtronic USA) or two pacemakers Activa SC (Ref 37603) to a channel (Medtronic USA)~Two DBS electrodes with four contacts (type Medtronic DBS 3389). Patients will be operated with the usual stereotactic surgical procedure.~The target is the Accumbens nucleus.~The two electrodes are implanted in a single session under local anaesthesia or intermittent sedation (propofol parenteral without intubation early intervention). Day 0 is defined by the surgery.~The DBS is on during 6 months (between Month 1 and Month 7). Stimulation will also be on after Month 7."
88954554|NCT01973478|Sham Comparator|SHAM|"The medical device includes:~Either a pacemaker ACTIVA PC (Ref 37601) two-channel (Medtronic USA) or two pacemakers Activa SC (Ref 37603) to a channel (Medtronic USA)~Two DBS electrodes with four contacts (type Medtronic DBS 3389). Patients will be operated with the usual stereotactic surgical procedure.~The target is the Accumbens nucleus.~The two electrodes are implanted in a single session under local anaesthesia or intermittent sedation (propofol parenteral without intubation early intervention). Day 0 is defined by the surgery.~The DBS is off during 6 months (between Month 1 and Month 7). Possibility to active the stimulation after Month 7."
88954555|NCT01973504|Experimental|MP4OX 500-mL|500-mL dose of MP4OX
88954556|NCT01973504|Experimental|MP4OX 750-mL|750-mL dose of MP4OX
88954557|NCT01973504|Sham Comparator|Control|Standard crystalloid Keep Vein Open (KVO) infusion
88954558|NCT01973517||Relapsing Remitting MS|Patients with relapsing remitting multiple sclerosis will be imaged under high-field (7T) MRI prior to and following administration of gadolinium-based contrast (0.1 mmol/kg IV). Afterwards, they will be administered Feraheme 5mg/kg IV via slow push, and they will return 24 hours or later after pharmaceutical administration for post-Feraheme MR imaging.
89022459|NCT01058642|Experimental|ADL5747|ADL5747 150 milligrams (mg) administered orally as 1 ADL5747 150-mg capsule and 1 placebo capsule twice daily (BID) for 14 days during 1 of 2 Treatment Periods.
89022460|NCT01058642|Placebo Comparator|Placebo|"Placebo: two placebo capsules administered orally BID for 14 days during 1 of 2 Treatment Periods.~Participants were also administered placebo orally BID during a 14-day washout period that took place between Treatment Period 1 and Treatment Period 2."
89022461|NCT01058642|Active Comparator|Pregabalin|Pregabalin administered orally as a dose of 1 pregabalin 75-mg capsule and 1 placebo capsule BID for the first 3 days, increased to a dose of 1 pregabalin 150-mg capsule and 1 placebo capsule BID for the last 11 days of 1 of 2 fourteen-day Treatment Periods, followed by a dose of 1 pregabalin 75-mg capsule and 1 placebo capsule BID for 3 days as a taper period.
89022462|NCT00426881|Experimental|1|Twice weekly resistance training for 52 weeks.
89022463|NCT00426881|Experimental|2|Once weekly resistance training for 52 weeks.
89022464|NCT00426881|Experimental|3|Twice weekly balance and tone training for 52 weeks.
89022465|NCT03271437|Experimental|PC-trained therapists|
89022466|NCT03271437|Experimental|EMDR-trained therapists|
89022467|NCT03271710|Experimental|Peripheral balloon angioplasty|Peripheral vascular percutaneous transluminal angioplasty (PTA) and capture and removal of embolic material during angioplasty for the femoral, iliac, popliteal and profunda arteries with the Vanguard IEP Peripheral Balloon Angioplasty System with Integrated Embolic Protection
89494245|NCT02140307|Active Comparator|Meditation training, individual format|"The course Relaxation Response-based Mental Health Promotion (Open and Calm) is given by the same instructor as for group formats using precisely the same material and methods, but in about 6-9 (as to each persons' individual needs and preferences) face-to-face meetings."
89494246|NCT02140307|No Intervention|Wait-list control|This arm is an inactive wait-list control.
89494247|NCT02973269|Experimental|daxibotulinumtoxinA (DAXI) for injection|DAXI for injection
88954559|NCT01973530|Active Comparator|adductor canal block|Continuous adductor canal block and single shot posterior tibial nerve block under ultrasound guidance and using nerve stimulating needle (bolus: 0.5% Ropivacaine 10-15ml with dexamethasone 4mg ;with single shot posterior tibial nerve block (8-10ml 0.5% ropivacaine)
89494248|NCT02973269|Placebo Comparator|Placebo|Placebo Intramuscular injection
89494249|NCT03549221|Experimental|MAC with adrenaline|the multimodal anesthetic cocktail (MAC) consisted of 100 mg Levobupivacaine (0.5%, 20 mL) 30 mg ketorolac (1 ml) and 0.6 mg 1:1000 epinephrine (0.6 ml). They were mixed with a 0.9% normal saline solution to a total volume of 100 ml.
88954560|NCT01973530|Other|continuous femoral nerve block|Femoral nerve catheter inserted under ultrasound guidance using nerve stimulating needle administering ropivacaine bolus 10-15ml and infusing 0.2% ropivacaine at 4-6ml/h; plus a single shot posterior tibial nerve block under ultrasound guidance and use of nerve stimulating needle
88954561|NCT01973543|Experimental|VY-AADC01 Dose 1|7.5 x 10^11 vector genomes of VY-AADC01; Single dose, neurosurgically infused, bilaterally into the striatum.
88954562|NCT01973543|Experimental|VY-AADC01 Dose 2|1.5 x 10^12 vector genomes of VY-AADC01; Single dose, neurosurgically infused, bilaterally into the striatum.
89022468|NCT00427076|Experimental|A|Cotrimoxazole
89494250|NCT03549221|No Intervention|MAC without adrenaline|the multimodal anesthetic cocktail (MAC) consisted of 100 mg Levobupivacaine (0.5%, 20 mL) and 30 mg ketorolac (1 ml). They were mixed with a 0.9% normal saline solution to a total volume of 100 ml.
89494251|NCT05185505|Experimental|Atezolizumab + Bevacizumab|Patients will receive transarterial chemoembolization (TACE) every 3 months, with a maximum of 4 treatments, plus atezolizumab combined with bevacizumab.
89494252|NCT01667432||Peginterferon alfa-2a|Participants received peginterferon alfa-2a (PEGASYS®) 180 µg subcutaneously in the abdomen or thigh once weekly for 12 weeks.
89494253|NCT02140385|Active Comparator|Abdominoplasty-Scarpa's fascia preservation|Scarpa's fascia preservation Lymphoscintigraphy 3D imaging Abdominal ultrasound
89494254|NCT02140385|Active Comparator|Abdominoplasty-Scarpa's fascia ablation|Scarpa's fascia ablation Lymphoscintigraphy 3D imaging Abdominal ultrasound
89494255|NCT05614466|Experimental|Patients living with hepatitis B|Patients living with hepatitis B will be managed at the GP clinic using the Simply B e-support package
89494256|NCT05575271|Experimental|Vagus nerve stimulation|The stimulator will be activated 2 weeks after the operation and continue for 24 weeks. The initial parameters of the program is set as: current 0.20mA, pulse width 500us, frequency 20Hz, stimulation time 30s, interval time 5min. A dynamic program control will be started at a speed of 0.20 mA, and the stimulation intensity will be controlled with the range of 0.4- 0.8mA.
89494257|NCT05575271|Sham Comparator|Sham stimulation|2 weeks after the operation, the stimulator will be turned off for 12 weeks. Then the stimulator will be turned on for 12 weeks. The initial parameters of the program is set as: current 0.20mA, pulse width 500us, frequency 20Hz, stimulation time 30s, interval time 5min. A dynamic program control will be started at a speed of 0.20 mA, and the stimulation intensity will be controlled with the range of 0.4- 0.8mA.
89494258|NCT05575115||Peer Comparison|Providers from the BEARI trial who received the Peer Comparison intervention.
89494259|NCT05575115||Control|Providers from the BEARI trial who did not receive the Peer Comparison intervention.
89494260|NCT04750460|Experimental|Teriparatide group (11 patients)|Dialysis-dependent patients underwent total parathyroidectomy with autotransplantation of parathyroid tissue, who will receive subcutaneous injections ot recombinant parathyroid hormone (Teriparatide) after surgery in addition to the standard local protocol for hypocalcemia treatment.
89494261|NCT04750460|No Intervention|Control group (9 patients)|Dialysis-dependent patients underwent total parathyroidectomy with autotransplantation of parathyroid tissue, receiving standard local protocol for hypocalcemia treatment (2 micrograms of alphacalcidol plus 4 grams of oral calcium daily).
89494262|NCT04966364|Active Comparator|patients with hypotension prediction index guided|Patients receiving hypotension prediction index guided. In this group, they will be alerted when the index exceeded 85 (range 0 to 100) indicating the later occurrence of MAP< 65mmHg for at least minutes and a treatment protocol based on advanced hemodynamic parameters recommended vasopressor or inotrope, fluid administration, or observation.
89494263|NCT04966364|Other|patients without hypotension prediction index gudied|Patients will receive usual care during the operation without hypotension prediction index alerted.
89494264|NCT04426526|Experimental|Biceps circumference reduction|This arm will evaluate the clinical efficacy and safety of the high power magnet system for toning and strengthening of biceps brachii.
89494265|NCT04426526|Experimental|Triceps circumference reduction|This arm will evaluate the clinical efficacy and safety of the high power magnet system for toning and strengthening of triceps brachii.
89494266|NCT04426526|Experimental|Lower limb circumference reduction|This arm will evaluate the clinical efficacy and safety of the high power magnet system for toning and strengthening of muscles in lower limbs.
88954563|NCT01973543|Experimental|VY-AADC01 Dose 3|4.7x 10^12 vector genomes of VY-AADC01; Single dose, neurosurgically infused, bilaterally into the striatum.
88954564|NCT01973556|Experimental|Pharmacist-Physician Collaborative Medication Management|Pharmacist-Physician Collaborative Medication Management
88954565|NCT01973556|No Intervention|Usual Care|
88954566|NCT01973647|Experimental|Cognitive Behavioral Therapy (CBT-I)|Six weekly sessions of Cognitive Behavioral Therapy for Insomnia
88954567|NCT01973647|Experimental|CBT-I + COPD-ED|Six weekly sessions of Cognitive Behavioral Therapy for Insomnia plus COPD Education
88954568|NCT01973647|Experimental|COPD Education (COPD-ED)|Six weekly sessions of COPD education
88954569|NCT01973647|Placebo Comparator|Attention Control (AC)|Six weekly sessions of non-sleep, non-COPD health education
88954570|NCT01973660|Experimental|Dual HER2 blockade|For a total of 18 weeks, HR-negative patients will be given dual blockade consisting of daily lapatinib at 1000 mg and trastuzumab at a loading dose of 8 mg/kg, followed by 6 mg/kg every 3 weeks.
88954571|NCT01973660|Experimental|Dual HER2 blockade plus endocrine therapy|For a total of 18 weeks, HR-positive patients will be given letrozole (2.5 mg daily) or tamoxifen (20 mg daily) with concurrent dual blockade consisting of daily lapatinib at 1000 mg and trastuzumab at a loading dose of 8 mg/kg, followed by 6 mg/kg every 3 weeks.
88954572|NCT01973673|Active Comparator|Bone health educational materials|Bone health written educational materials, Bone health prescription,verbal counselling
89494267|NCT04426526|Experimental|Oblique muscles toning|This arm will evaluate the clinical efficacy and safety of the high power magnet system for toning and strengthening of oblique muscles.
89494268|NCT04788212|Experimental|GBAT|10-week behavioral activation treatment group.
89494269|NCT01563107|Experimental|High Salt Diet|POTS and healthy controls will be randomly assigned the order of dietary sodium levels. All procedures are performed at both levels. The high sodium diet will provide 300 milliequivalents (mEq) sodium/day.
89494270|NCT01563107|Experimental|Low Salt Diet|POTS and healthy controls will be randomly assigned the order of dietary sodium levels. All procedures are performed at both levels. The low sodium diet will provide 10 mEq sodium/day.
89494271|NCT04787900|Experimental|iPhone measurement application|For the measurement, the participant was asked to lie on his side and flex the knee to 90 degrees. The examiner stabilized the patient from the pelvis with one hand, and with the other hand brought the flexed leg of the participant to abduction and extension. The Examiner 3 recorded the result by placing the device to be measured on the lateral projection of the midpoint of the femur.
89494272|NCT04787900|Active Comparator|Bubble inclinometer|measurement will be done by the same method. For the measurement, the participant was asked to lie on his side and flex the knee to 90 degrees. The examiner stabilized the patient from the pelvis with one hand, and with the other hand brought the flexed leg of the participant to abduction and extension. The Examiner 3 recorded the result by placing the device to be measured on the lateral projection of the midpoint of the femur.
89494273|NCT04788056|Experimental|Bupivacaine|PSPB catheters will be placed with 60mL of 0.2% bupivacaine and continue to infuse bupivacaine 0.125% at 10mL/hr through the catheter
89494274|NCT04788056|Placebo Comparator|Saline|PSPB catheters will be placed with 60mL of saline and continue to infuse saline through the catheters.
89494275|NCT05574803|Experimental|Active tDCS|The experimental group will receive 20 minutes of anodal HD-tDCS for five sessions, combined with 20 minutes of behavioural therapy.
89494276|NCT05574803|Sham Comparator|Sham tDCS|The control group will only receive one minute of anodal HD-tDCS stimulation which aims to create a similar sensation on the scalp as those in the experimental group, with 20 minutes of behavioural therapy.
89494277|NCT05614310||Development Group 1 (N = 10) (Development Phase)|Development group participants (N = 10) will undergo 1 magnetic resonance imaging (MRI) sessions. Before and after their MRI scan participants will be given a pinprick blood sugar test.
89494278|NCT05614310||Patients (N = 20) (Clinical Phase)|"Patients (N = 20) will attend 2 visits up to 1 week apart. Patients will be asked to have a no-sugar diet and take no exercise for 24 hours before each visit and to avoid eating 6 hours before scan.~Visit 1: Patients will undergo a positron emission tomography (PET) assessment. Before and after their PET assessment patients will be given a pinprick blood sugar test. PET assessment:~Visit 2: Patients will undergo MRI assessment. Before and after their MRI scan patients will be given a pinprick blood sugar test. Healthy controls will complete cognitive assessments."
89494279|NCT05614310||Healthy Controls (N = 20) (Clinical Phase)|"Healthy controls (N = 20) will attend 2 visits up to 1 week apart. Healthy controls will be age matched (+/- 3 years) and sex matched to the patient group. Healthy controls will be asked to have a no-sugar diet and take no exercise for 24 hours before each visit and to avoid eating 6 hours before scan.~Visit 1: Healthy Controls will undergo a positron emission tomography (PET) assessment. Before and after their PET assessment patients will be given a pinprick blood sugar test. PET assessment:~Visit 2: Healthy Controls will undergo MRI assessment. Before and after their MRI scan patients will be given a pinprick blood sugar test. Healthy controls will complete cognitive assessments."
89494280|NCT05614310||Development Group 2 (N = 10) (Development Phase)|To investigate the repeatability of MRI assessment, 10 development phase healthy volunteers will be recruited to undergo two repeated study assessments. The second visit will be between 7 and 14 days after their first visit. The second repeated study assessment will follow the same procedure as the first visit, consisting of blood glucose assessment and MRI assessment. Participants will be advised to fast from mid-night and avoid eating breakfast.
89494281|NCT03549065|Active Comparator|20 min active tDCS, and 20 min active rTMS|Applying active tDCS AND active TMS will reduce cue induced craving and opioid use, more than sham TMS AND sham tDCS and also either active TMS OR active tDCS alone. We will apply 10 daily sessions of brain stimulation (1 hour total treatment time). This is composed of 20 minutes active tDCS (anode on F3 EEG positioning and cathode on contra shoulder), followed by 4000 pulses of real rTMS (10Hz over left Dorsolateral Prefrontal Cortex(DLPFC) for 20 minutes at 120%MT). There will be 10 minutes rest between each module. We will test for cue-induced craving scores using VAS and urine drug screens for opioid abuse in comparison to the control group of sham TMS AND sham tDCS and the groups with only active tDCS OR active TMS.
89494282|NCT03549065|Active Comparator|20 min sham tDCS, and 20 min active rTMS|Applying sham tDCS AND active TMS will reduce cue induced craving and opioid use, more than will sham TMS AND sham tDCS. We will apply 10 daily sessions of brain stimulation (1 hour total treatment time). This is composed of with 20 minutes sham tDCS (anode on F3 EEG positioning and cathode on contra shoulder), and 4000 pulses of real rTMS with (10Hz over left DLPFC for 20 minutes at 120%MT. There will be 10 minutes rest between each module. We will test for cue-induced craving scores using VAS and urine drug screens for opioid abuse in comparison to the control group of sham TMS AND sham tDCS.
89204880|NCT03980197|Active Comparator|Control|No active surveillance test and preemptive isolation performed. Only standard precaution is needed, and if clinical isolates reveals MDRO, start contact precaution.
88954573|NCT01973673|No Intervention|Usual care|Usual clinical care to be provided by oncologists.
88954574|NCT01973686|Experimental|Vigorous intensity LTPA|Leisure time physical activity (LTPA): Exercise intensity: 70% of maximal oxygen uptake (VO2 max); Energy expenditure: Females: 1600 kcal/week; Males: 2100 kcal/week
89022469|NCT00427076|Active Comparator|B|Vancomycin
89204881|NCT00997048|Experimental|Laying open|
89204882|NCT00997048|Active Comparator|Sinus excision|
89204883|NCT02532829||GROUP NS-A|Healthy Participants: No known disease, no previous surgery, HbA1c<5.7%, BMI<25 kg/m2 (n=30). Blood sample analysis (Blood samples will be taken for the analysis of GLP-1, Peptide YY, glucose and insulin before and 30-60-120 minutes after Oral Mixed Meal Tolerance Test).
89022470|NCT00460083|Active Comparator|Elidel(r)|
89204884|NCT02532829||GROUP NS-B|Obese, type 2 diabetic: Type 2 diabetes diagnosis longer than 3 years; BMI>30 kg/m2 (n=30). Blood sample analysis (Blood samples will be taken for the analysis of GLP-1, Peptide YY, glucose and insulin before and 30-60-120 minutes after Oral Mixed Meal Tolerance Test).
88954575|NCT01973686|Experimental|Moderate intensity LTPA|Leisure time physical activity (LTPA): Exercise intensity: 50% VO2 max; Energy expenditure: Females: 1600 kcal/week; Males: 2100 kcal/week
89204885|NCT02532829||GROUP NS-C|Non-obese, type 2 diabetic: Type 2 diabetes diagnosis longer than 3 years; BMI<30 kg/m2 (n=30). Blood sample analysis (Blood samples will be taken for the analysis of GLP-1, Peptide YY, glucose and insulin before and 30-60-120 minutes after Oral Mixed Meal Tolerance Test).
89204886|NCT02532829||GROUP NS-D|Obese non-diabetic: HbA1c<5.7%, No signs and history of T2D, and BMI>30 kg/m2 (n=30). Blood sample analysis (Blood samples will be taken for the analysis of GLP-1, Peptide YY, glucose and insulin before and 30-60-120 minutes after Oral Mixed Meal Tolerance Test).
89204887|NCT02532829||Group SG|Type 2 Diabetic participants who underwent a sleeve gastrectomy, performed more than 6 months ago, but within the last 2 years, with steady weight profile. Blood sample analysis (Blood samples will be taken for the analysis of GLP-1, Peptide YY, glucose and insulin before and 30-60-120 minutes after Oral Mixed Meal Tolerance Test).
89204888|NCT02532829||Group MGB|Type 2 Diabetic participants who underwent a mini-gastric bypass, performed more than 6 months ago, but within the last 2 years, with steady weight profile. Blood sample analysis (Blood samples will be taken for the analysis of GLP-1, Peptide YY, glucose and insulin before and 30-60-120 minutes after Oral Mixed Meal Tolerance Test).
89204889|NCT02532829||Group IT|Type 2 Diabetic participants who underwent a sleeve gastrectomy with ileal transposition, performed more than 6 months ago, but within the last 2 years, with steady weight profile. Blood sample analysis (Blood samples will be taken for the analysis of GLP-1, Peptide YY, glucose and insulin before and 30-60-120 minutes after Oral Mixed Meal Tolerance Test).
89204890|NCT02532829||Group TB|Type 2 Diabetic participants who underwent a sleeve gastrectomy with transit bipartition, performed more than 6 months ago, but within the last 2 years, with steady weight profile. Blood sample analysis (Blood samples will be taken for the analysis of GLP-1, Peptide YY, glucose and insulin before and 30-60-120 minutes after Oral Mixed Meal Tolerance Test).
89204891|NCT01002196|Experimental|stimulus fading procedures|
89204892|NCT01002196|Active Comparator|guidance of defocused communication|
89204893|NCT01066429|No Intervention|Poor prognosis DLBCL|Newly diagnosed patients with DLBCL and an age-adjusted IPI 2-3
89204894|NCT01002274|Experimental|MCS-2|2 soft-gel capsules Qd for 40 weeks
89204895|NCT03978247|Experimental|NASHMIR group|Validation of the NASHMIR Test
89204896|NCT05200390|Experimental|Continuous Glucose Monitor|Adult patients with Type 2 Diabetes on any anti-diabetic regimen utilizing continuous glucose monitors for 3 months
89204897|NCT01066507||Breast cancer|Slides containing breast cancer paraffin embedded tissue sections.
89204898|NCT00994786|Experimental|pregabalin|
89204899|NCT00994786|Placebo Comparator|Placebo|
89204900|NCT01002430|Experimental|Gene therapy|
89204901|NCT01002430|No Intervention|Control|Control patients will have electroanatomic mapping procedure but no gene injections.
89204902|NCT01002586|Experimental|Wii-Fit arm|Half hour daily, five days a week, for 8 weeks
89204903|NCT01002586|Active Comparator|Walking arm|Half hour daily, five days a week, for 8 weeks
89204904|NCT01002664|Active Comparator|MCS-2|Drug Name: MCS-2 Dosage: 2 soft-gel capsules Frequency: Qd per day after dinner Duration: 12 weeks
89204905|NCT01002664|Placebo Comparator|Placebo|Drug Name: MCS-2 placebo Dosage: 2 soft-gel capsules Frequency: Qd per day after dinner Duration: 12 weeks
89204906|NCT00997282|Experimental|OPC-262 2.5 mg|orally administered once daily for 24 weeks
89204907|NCT00997282|Experimental|OPC-262 5 mg|orally administered once daily for 24 weeks
89204908|NCT00997282|Placebo Comparator|Placebo|orally administered once daily for 24 weeks
89204909|NCT00997360|Experimental|1|PKI-179
89204910|NCT00995098|Experimental|Early enteral nutrition|Twenty patient will be enrolled into this arm. Enteral nutrition administration will start within 24 hours after admission through naso-jejunal tube and continue for 7 days after admission.Naso-jejunal tube will be set up by endoscopy.
89204911|NCT00995098|Active Comparator|Control: Parenteral Nutrition|Twenty patient will be enrolled into this arm. PN administration will start within 24 hours after admission and continue for 7 days after admission.Parenteral nutrition will be administered through subclavian central venous catheter.
89204912|NCT01002898|Experimental|lopinavir/ritonavir|
89204913|NCT01003054|Experimental|Autologous Transplantation|Busulfan 130 mg/m^2 intravenous (IV) every 24 hours Days -7 to -4; Cyclophosphamide 60 mg/kg over 4 hours Day -3 and -2; Imatinib Mesylate Starting dose 100 mg/day, and Autologous Stem Cell Transplantation on Day 0.
88954576|NCT01973686|No Intervention|Control|Receives no intervention
88954577|NCT01973699|Placebo Comparator|With Epinephrine|Patients undergoing shoulder arthroscopy with epinephrine in their irrigation as standardly performed
88954578|NCT01973699|Experimental|Without Epinephrine|Patients undergoing shoulder arthroscopy without epinephrine in their irrigation fluid as typically done
88954579|NCT01973712|Experimental|Locked Compression Plating|A direct lateral approach to the distal femur will be employed utilizing minimally invasive and indirect reduction techniques. After fracture reduction is achieved with the use of intra-operative fluoroscopy, a locking plate will be provisionally implanted. Following confirmation of placement, definitive fixation will follow with multiple locking screws in the distal fragment and bicortical screw fixation proximally. A standard layered closure will follow
89022471|NCT00460083|Experimental|Epiceram(r)|
89204914|NCT01003132|No Intervention|Treatment As Usual|Treatment as usual as determined by the clinical team responsible for the individual's care
88954580|NCT01973712|Experimental|Retrograde Intramedullary Nailing (RIMN)|The previous midline knee incision will be employed to access to the knee joint, allowing exposure of the femoral start point via the open box in the femoral component. Following reaming of the canal, an appropriately sized retrograde nail will be inserted. Intra-operative fluoroscopy will be used to confirm reduction. Both proximal and distal locking screws will be used to transfix the nail. A standard layered closure will follow.
88954581|NCT01973751|No Intervention|Healthy controls|Healthy controls who will be studied at baseline and serve as a control group for the bronchoscopy, induced sputum and peripheral blood collection.
88954582|NCT01973751|Active Comparator|Asthmatics (treatment)|Steroid-naïve asthma, randomized to inhaled budesonide, 2 puffs (200mcg) twice a day for 8 weeks. These subjects will undergo bronchoscopy and induced sputum collection at baseline, undergo pulmonary function testing and peripheral blood collection at baseline, 4 and 8 weeks after treatment with inhaled corticosteroids.
88954583|NCT01973751|No Intervention|Asthmatics (no treatment)|Steroid-naïve asthmatics randomized to no treatment for 8 weeks. These subjects will undergo bronchoscopy and induced sputum collection at baseline, undergo pulmonary function testing and peripheral blood collection at baseline, 4 and 8 weeks of no treatment.
88954584|NCT01973764|Other|Ultrasound guided arm|
88954585|NCT01973764|Other|Landmark-based arm|
89204915|NCT01003132|Active Comparator|Acceptance and Commitment Therapy|Up to 10 sessions of Acceptance and Commitment Therapy plus treatment as usual
89204916|NCT01004068|Experimental|SET-diet plus clomiphene|Structured exercise program plus hypocaloric diet for two months and received one-cycle of clomiphene citrate for one cycle
89204917|NCT01004068|Active Comparator|Clomiphene citrate|One month of observation followed by one-cycle of clomiphene citrate therapy
89204918|NCT01004068|Experimental|SET plus diet|Lifestyle modifications for two months.
89494283|NCT03549065|Active Comparator|20 min active tDCS, and 20 min sham rTMS|Applying active tDCS AND sham TMS will reduce cue induced craving and opioid use, more than will sham TMS AND sham tDCS. We will apply 10 daily sessions of brain stimulation (1 hour total treatment time). This is composed of with 20 minutes active tDCS (anode on F3 EEG positioning and cathode on contra shoulder), and 4000 pulses of sham rTMS with (10Hz over left DLPFC for 20 minutes at 120%MT. There will be 10 minutes rest between each module. We will test for cue-induced craving scores using VAS and urine drug screens for opioid abuse in comparison to the control group of sham TMS AND sham tDCS.
89494284|NCT03549065|Sham Comparator|20 min sham tDCS, and 20 min sham rTMS|Applying sham tDCS AND sham TMS will not reduce cue induced craving and opioid use. We will apply 10 sessions of one hour of brain stimulation. We will apply 10 daily sessions of brain stimulation (1 hour total treatment time). This is composed of with 20 minutes sham tDCS (anode on F3 EEG positioning and cathode on contra shoulder), and 4000 pulses of sham rTMS with (10Hz over left DLPFC for 20 minutes at 120%MT. There will be 10 minutes rest between each module. We will test for cue-induced craving scores using VAS and urine drug screens for opioid abuse in comparison to the control group of sham TMS AND sham tDCS.
89494285|NCT04787432|Experimental|Intervention|"Experimental: SAFRAPP Intervention~Participants in this group will receive a 6-week SAFRAPP intervention, comprising of laughter yoga, health education and case management. SAFRAPP will be conducted on social media (Facebook and WhatsApp)."
89494286|NCT04787432|No Intervention|Control Grup|The control group will not receive any intervention during the study. Participants in the control group will take the same program after the study is completed.
89494287|NCT04787588||Hospitalized patients|100 patients hospitalized with Covid-19, and 100 hospitalized controls without Covid-19
89494288|NCT04787588||Mild/Moderate asthma and health controls|20 asthmatic patients, 10 patients with asthma and allergic rhinitis, and 5 healthy controls.
89494289|NCT04722614|Active Comparator|Control group|Mechanically ventilated patients who will be subjected to the routine unit intervention for agitation
89494290|NCT04722614|Experimental|Music group|Mechanically ventilated patients who will listen to classic music
89494291|NCT04722614|Experimental|Essential oil group|Mechanically ventilated patients who will inhale bergamot oil
89494292|NCT03547817|Experimental|Optimal negative pulse pressure regime|The equipment for physiological measurements will be attached to the patient, and the foot will then be placed in the pressure chamber of the intermittent negative pressure device. The device induces pulses of 10 sec negative pressure, and 7 sec of atmospheric pressure. Pressure levels of 0 mmHg, -10 mmHg, -20 mmHg, -40 mmHg and -60 mmHg will be tested, with washout periods of 5 minutes between the different pressure levels. The order of the different negative pressure levels will be randomized to avoid causal interference.
89494293|NCT04787120||Individuals with arterial abdominopelvic bleeding|Arterial abdominopelvic bleeding or imminent risk of bleeding
89494294|NCT05614232||Positive group|chest radiographs with the specific target radiologic findings (Atelectasis, Calcification, Cardiomegaly, Consolidation, Fibrosis, Mediastinal Widening, Nodule/Mass, Pleural Effusion, Pneumoperitoneum, Pneumothorax)
89494295|NCT05614232||Negative group|chest radiographs with no target radiologic findings
89494296|NCT04787276|Experimental|E.coli Nissle 1917|probiotic, oral, for the first 4 days, 1 capsule, and then 2 capsules per day for 1 month treatment
89494297|NCT04787276|Active Comparator|Lactulose|will receive 30-60 ml of lactulose in 2 or 3 divided doses so that patient passed 2-3 semisoft stools per day, 1 months of treatment
88954586|NCT01973790|Experimental|Z-338|100mg TID
88954587|NCT01973816|Experimental|Medical treatment|The patients received triptoreline and add back therapy by estradiol during 6 months, followed by daily intake of cyproterone acetate and add back therapy during 18 months.
88954588|NCT01973816|Active Comparator|Surgical|The patients are managed by rectal surgery (depending on the surgeon choice: rectal shaving, rectal disc excision or colorectal resection) followed by the prevention of recurrences by daily intake of cyproterone acetate and add back therapy during 18 months.
88954589|NCT01973829|Other|Baseline arm|baseline data (50 patients or 3 months per center)
88954590|NCT01973842|Active Comparator|0.2 mg triptorelin|0.2 mg triptorelin compared with 0.1 mg triptorelin and 0.4 mg triptorelin
89494298|NCT04787276|Active Comparator|Rifaximin|rifaximin, oral, 500 mg BID, 1 months of treatment
89494299|NCT04686734||SARS-CoV-2 positive|
89494300|NCT04686734||SARS-CoV-2 negative|
89494301|NCT01564979|Experimental|preseptal|
89494302|NCT01564979|Experimental|pretarsal|
89494303|NCT02140541||Blood eosinophil count ≤ 400/µl|
89494304|NCT02140541||Blood eosinophil count > 400/µl|
89494305|NCT05613140||Cohort 1 - Adult HFrEF patients|adult HFrEF patients who newly initiated sacubitril/valsartan
89494306|NCT05613140||Cohort 2 - Adult CHF patients|adult CHF patients who newly initiated sacubitril/valsartan
89494307|NCT02253719||HIV positive women|500 HIV women will be recruited from the hospital's current patient base as well as the community
89494308|NCT02253719||HIV negative women|500 HIV women will be recruited from the hospital's current patient base as well as the community
89494309|NCT02140619|Active Comparator|multiple health education interventions|The group will receive health education manuals and Digital Video Disc (DVD) during hospitalization and regular text message during 1 year after discharge.
89494310|NCT02140619|Placebo Comparator|conventional health education|The second group will receive conventional health education during hospitalization except health education manuals, text message and Digital Video Disc (DVD)
89494311|NCT04786886|Experimental|Virtual Reality Visual Field Group|Participants in this group will have virtual reality visual field testing during standard of care follow-up visit.
89494312|NCT02260973|Active Comparator|Omega-3|re esterified TG omega-3
89494313|NCT02260973|Placebo Comparator|Safflower Oil|vegetable oil
89494314|NCT03548909||ED Setting|An acute HF population enrolled at EDs. Testing of clinical samples will be performed with the VITROS Immunodiagnostic Products NT-proBNP II assay.
89494315|NCT03548909||Outpatient Setting|A non-acute population enrolled at outpatient centers.Testing of clinical samples will be performed with the VITROS Immunodiagnostic Products NT-proBNP II assay.
89494316|NCT03547505|Experimental|R-Pilot®|"R-Pilot® was operated by an endomotor (VDW Silver, Munich, Germany) at Reciproc All setting."
89494317|NCT03547505|Experimental|ProGlider®|ProGlider® was operated by an endodontic motor (X-Smart, Dentsply Sirona, Ballaigues, Switzerland) with 16:1 contra angle at the suggested settings (300 rpm on display, 5 Ncm).
89494318|NCT03547505|Experimental|Manual preparation|"In the manual glide path group, glide path creation was performed with stainless steel #08, 10, 15 K-files used with push and pull motion. Instruments were used with a motion in which the instrument proceeds apically quarterly to the point of resistance, then is pulled out for debris removal. The procedure was repeated with each file until the working length was achieved and confirmed with an electronic apex locator (Root ZX Mini, Morita Corp., Kyoto, Japan)."
89494319|NCT04335578|Experimental|Zampilimab Cohorts|Participants will be randomized to receive zampilimab (UCB7858).
89494320|NCT04335578|Placebo Comparator|Placebo|Participants randomized to this arm will receive matching Placebo.
89494321|NCT05279183|Active Comparator|Erythritol|20 volunteers receive erythritol dissolved in 300 mL tap water as oral preloads (3 times 100mL). The dosage will be calculated based on the participants ratings of the sweetness intensity (matched sweetness to 10 % sucrose).
89494322|NCT05279183|Active Comparator|Sucrose|20 volunteers receive 30g sucrose dissolved in 300 mL tap water as oral preloads (3 times 100mL).
89494323|NCT05279183|Active Comparator|Sucralose|20 volunteers receive sucralose dissolved in 300 mL tap water as oral preloads (3 times 100mL). The dosage will be calculated based on the participants ratings of the sweetness intensity (matched sweetness to 10 % sucrose).
89494324|NCT05568485|Experimental|Telerehabilitation|Telerehabilitation was applied to the group with rheumatism
89494325|NCT05143346|Other|Group A|Group A will include 168 patients and will be intubated by the use of video stylet.
89494326|NCT05143346|Other|Group B|Group B will include 168 patients and will intubated by the use of video laryngoscope
89494327|NCT05567003|Other|Patients with benign biliary strictures|Patients with benign biliary strictures with current or prior biliary obstruction, who would otherwise receive standard treatment with long-term biliary tube drainage.
89494328|NCT04462952|Experimental|Adavosertib (AZD1775) monotherapy|Dose escalation of adavosertib monotherapy for patients with advanced solid tumours
89494329|NCT04462952|Experimental|Adavosertib (AZD1775) in combination with gemcitabine|Dose escalation of adavosertib in combination with gemcitabine for patients with advanced solid tumours
89494330|NCT05263427|Experimental|TOCONAUTE and gold standard : cardiotocograph|
89494331|NCT05563259||Groups/Cohorts Interventions Control|patients with steatosis < 5%
89494332|NCT05563259||non-NASH|patients with steatosis ≥ 5% and did not achieve the criteria for NASH
89494333|NCT05563259||NASH|patients with NAFLD Activity Score (NAS) ≥ 5
89494334|NCT02253485||telbivudine treated entire pregnancy|mothers in this group were treated with antiviral therapy during entire pregnancy for hepatitis, and their infants receive standard immunoprophylaxis for preventing MTCT of HBV.
89494335|NCT02253485||telbivudine treated in late pregnancy|mothers with high serum HBV DNA load were treated with antiviral therapy in late pregnancy, and their infants receive standard immunoprophylaxis for preventing MTCT of HBV.
88954591|NCT01973842|Active Comparator|0.1 mg triptorelin|0.1 mg triptorelin compared with 0.2 mg triptorelin and 0.4 mg triptorelin
89204919|NCT03687970|Experimental|Group A: Painful CIPN Group|-Performed at baseline: NPSI, BPI, HADS, Spontaneous pain at baseline on 0-10 Numerical Rating Scale (NRS), QST, CPM, and DLss
88954592|NCT01973842|Active Comparator|0.4 mg triptorelin|0.4 mg triptorelin compared with 0.1 mg triptorelin and 0.2 mg triptorelin
88954593|NCT01973855|Experimental|TCM and Western Medicine|TCM and Western Medicine:First Infectious diseases soup recipe,every time a dose,Two times a day;Ribavirin 10-15mg per kg every time Western Medicine：Ribavirin 10-15mg per kg every time
88954594|NCT01973855|Placebo Comparator|Western Medicine|Western Medicine：Ribavirin 10-15mg per kg every time
88954595|NCT01973868|Experimental|Regorafenib|"Regorafenib will be administered once daily on Days 1-21 of each 28-day Cycle (3 weeks on / 1 week off). The starting dose of regorafenib is 120 mg q.d., if this is tolerable in combination with cetuximab the dose will be escalated to 160 mg q.d.; if it is not tolerated the dose will be de-escalated to 80 mg q.d.~Subjects will receive an initial i.v. infusion of cetuximab (loading dose of 400 mg/ m2 BSA) on Pre-cycle Day -7.~The treatment of regorafenib in combination with cetuximab maintenance dose (250 mg/m2 BSA) starts on Cycle 1 Day 1.~Cetuximab infusions will be given in a once-weekly dosing-regimen as approved."
89204920|NCT03687970|Active Comparator|Group B: Control Group|-Performed at baseline: NPSI, BPI, HADS, Spontaneous pain at baseline on 0-10 Numerical Rating Scale (NRS), QST, CPM, and DLss
89204921|NCT01004224|Experimental|BGJ398|
89204922|NCT01003366|Experimental|bevel down|approaching the IJV with the needle bevel facing down
89204923|NCT01003366|Active Comparator|bevel up|approaching the IJV with the needle bevel facing up
89494336|NCT02253485||HBV DNA positive control|infants in this group born to mother with high serum HBV DNA load and receive standard immunoprophylaxis or additional HBIG injection at 1 month after birth for preventing MTCT of HBV.
89494337|NCT02253485||HBV DNA negative control|infants in this group born to a HBsAg positive and serum HBV DNA negative mothers and receive standard immunoprophylaxis for preventing MTCT of HBV
89494338|NCT02253563|Experimental|Resistance Training|Group performing resistance training.
89494339|NCT02253563|Experimental|Balance Training|Group performing balance training.
89494340|NCT05131256|Experimental|patients suffering from obesity with BED|
89494341|NCT05131256|Active Comparator|patients suffering from obesity without BED|
89494342|NCT05131256|Active Comparator|healthy participants|
89494343|NCT02253641|Active Comparator|Standard Weight Loss Intervention|"Participants will take part in a 14 session weight loss/healthy lifestyle intervention. Sessions will be 2 hours in length and will occur weekly for month 1 then bi-weekly for months 2 - 6. The core lifestyle curriculum content for both groups will come from the previously IRB-approved Weight Wise intervention developed by Samuel-Hodge et al. (Samuel-Hodge, Carmen D., et al. Randomized Trial of a Behavioral Weight Loss Intervention for Low?income Women: The Weight Wise Program. Obesity 17.10 (2009): 1891-1899). The only modifications to the content (other than some general formatting) will be the combining of sessions 3 and 4 and sessions 6 and 7. These changes will allow us to fit the original 16-session curriculum into the 14-session format of our intervention."
89494344|NCT02253641|Experimental|Stress-Focused Weight Loss Intervention|Participants will take part in a 14 session weight loss/healthy lifestyle intervention. Sessions will be 2 hours in length and will occur weekly for month 1 then bi-weekly for months 2 - 6. The core lifestyle curriculum content for both groups will come from the previously IRB-approved Weight Wise intervention developed by Samuel-Hodge et al.. The participants in this arm will receive all of the content that the comparison group receives (just moderately condensed to allow time for additional components) plus a stress-reduction intervention woven into each of the sessions. The stress-reduction content aims to reduce stress by helping participants: (1) identifying and reducing exposure (to the degree possible) of current stressors, (2) change their perceptions of current stressors and (3) use healthier stress-coping techniques (e.g. yoga, meditation, etc.)
89494345|NCT05612516|Active Comparator|Hydrogen peroxide 9.5% bleaching using a tray with reservoir.|". Alginate impressions of maxillary dental arches of patients will be taken to obtain casts and produce the customized trays.~Reservoirs 1.5 mm thick will be created on the facial surfaces of anterior teeth, including the first premolars in the arches, applying a light-cured resin on the casts. The resin layer thickness will be standardized using a thickness gauge (1.5 mm thickness). Then, customized trays will be fabricated with 1.5 mm-thick vinyl acetate sheets using the thermoforming process. Trays will be precisely trimmed completely involving tooth surface (1.5 mm incisal or occlusal to gingival margin), and the adaptation will be verified on the casts. The trays will be placed over teeth to verify the adaptation in the patients' mouth."
89494346|NCT05612516|Active Comparator|Hydrogen peroxide 9.5% bleaching using a tray without reservoir.|Alginate impressions of maxillary dental arches of patients will be taken to obtain casts to produce the customized trays. Then, customized trays will be fabricated with no space for reservoir, with 0.9 mm-thick vinyl acetate sheets using the thermoforming process applying a light-cured resin on the casts. Trays will be precisely trimmed completely involving tooth surface (1 mm incisal or occlusal to gingival margin), and the adaptation will be verified on the casts. The trays will be placed over teeth to verify the adaptation in the participants' mouths.
89494347|NCT05558072|Experimental|Group 1|Newborn
89494348|NCT05558072|Experimental|Group 2|adolescent
89494349|NCT05557994|Active Comparator|Blood clotting|Blood clotting protocol for pulp regeneration of mature teeth
89494350|NCT05557994|Experimental|Disinfection technique|Compare different disinfection technique
89494351|NCT02589626|Experimental|empagliflozin 10 mg|empagliflozin 10 mg tablet and placebo matching empagliflozin 25 mg tablet
89494352|NCT02589626|Experimental|empagliflozin 25 mg|empagliflozin 25 mg tablet and placebo matching empagliflozin 10 mg tablet
89494353|NCT04816175|Experimental|Treatment Intervention|All children will receive 3-5 weeks of intensive neuromotor Acquire therapy, an operant conditioning, play based therapy that maximizes therapeutic movements, attention, and engagement.
88954596|NCT01973894||Midazolam|"Patients will be enrolled within 24h from the beginning of continuous Midazolam perfusion.~Blood and urine sampling will follow this schedule:~24h: blood (3ml)~48h: blood (3ml) and urine~End of infusion: blood (3ml)~6h after end of infusion: blood (3ml) and urine.~Blood samples will be centrifuged for 10 minutes at 3300rpm, then supernatant will be placed into test tubes and stored at -20°C; urine samples will be freeze at -20°C as well.~Then all frozen samples will be analyzed to get Midazolam concentrations."
89204924|NCT01004302|Sham Comparator|Sham surgery|
89204925|NCT01004302|Active Comparator|Active radiosurgery|
89204926|NCT01003444|Experimental|Cohort 1|Muscle biopsy in healthy volunteers
89494354|NCT04976036|Experimental|Nintedanib|nintedanib 150 mg once a day for 2 weeks, then twice a day for 14 weeks
89494355|NCT04976036|Placebo Comparator|Placebo|placebo 150 mg once a day for 2 weeks, then twice a day for 14 weeks
89494356|NCT05557916|Active Comparator|Standard rehab group|This group will follow the clinics standard rehab protocol, wherein they have a knee orthosis for six weeks, with flexion limited to 0-30 degress week 0-2, 0-60 degrees week 2-4 and 0-90 degrees week 4-6. Crouching is not permitted week 6-12.
89494357|NCT05557916|Active Comparator|Accelerated rehab group|accelerated rehab group, wherein they are permitted to perform range of motion training within their comfort zone. Running is permitted after 8 weeks, contact sports 4 months postoperatively
89494358|NCT05557682||clinical performance|restoration of caries primary molars using two different restorative materials
89494359|NCT05557682||psychological impact|evaluation of colour of restoration on the satisfaction of the children and impact on their hygiene
89494360|NCT05557604|No Intervention|arm 1|SBRT alone 38 GY in 4 fractions
89494361|NCT05557604|Experimental|arm 2|SBRT along with short course (6 months) androgen deprivation (STAD)
89494362|NCT05292716|Experimental|MitraClip + Optimal medical therapy|Patients randomized to this arm will receive percutaneous treatment of secondary mitral regurgitation by MitraClip system and Optimal medical therapy (OMT) for heart failure
89494363|NCT05292716|No Intervention|Optimal medical therapy|Patients randomized to this arm will receive only Optimal medical therapy (OMT) for heart failure
89494364|NCT05612282||G1a - women|The G1a group consisted of women with obesity, in whom no additional components of the metabolic syndrome were found (n =16)
88954597|NCT01973907|No Intervention|Usual Care Resuscitation Strategy|Decisions regarding the IV/IO administration of isotonic fluid boluses and/or the initiation and escalation of vasoactive medication infusions are left to the discretion of the treating physician and medical team. We ask that vasoactive medications not be initiated until at least 60 mL/kg (3 litres for children ≥ 50 kg) of isotonic fluid bolus therapy has been administered. The treating physician and medical team are advised to follow ACCM guidelines for the resuscitation of neonatal and pediatric septic shock and to target ACCM recommended therapeutic endpoints.
88954598|NCT01973907|Experimental|Fluid Sparing Resuscitation Strategy|The treating physician and medical team are advised to follow the assigned Fluid Sparing Resuscitation Strategy to guide decisions regarding the IV/IO administration of further isotonic fluid boluses, and the timing of initiation and escalation of vasoactive medication infusions to target the therapeutic endpoints recommended in the ACCM guidelines for the resuscitation of neonatal and pediatric septic shock.
88954599|NCT01973920|Experimental|Oshadi Icp|Oshadi Icp oral insulin,
88954600|NCT01973933|Experimental|Metformin and Pyrimethamine|Metformin 750mg(D1), Metformin 500mg(D2)/Metformin 750mg+Pyrimethamine 50mg(D7), Metformin 500mg+Pyrimethamine 50mg(D8)
88954601|NCT01973946|No Intervention|Usual Care|Patients in the usual care group called the automated monitoring system daily to report presence, severity, and distress for 11 common symptoms. The attentional control group received equivalent contact time with the automated system including identical voice and assessment questions. Patients did not hear self-care messages during the call and the data were not available for clinical action by the study nurse practitioner. Patients were told on every phone call to call their oncology providers if they had concerns about their symptoms which is usual care for symptom follow up in oncology.
88954602|NCT01973946|Experimental|Symptom Alert and Coaching|"Patients in the Symptom Alert and Coaching arm called the automated monitoring system daily to report presence, severity, and distress on 11 symptoms. The system provided automated self care coaching based on the symptoms reported and automatically generated alerts to the study NP if symptoms exceeded preset thresholds. Two thresholds were set: a simple alert when severity or distress was 4 or greater on a 10 point scale and trend alerts based on a pattern of moderate severity over several days.~The alerts went into a case management site. The study NP logged into the system daily and responded to the alerts within 24 hours by calling patients to further assess the symptoms and to intensify symptom treatment using evidence based guidelines."
88954603|NCT01974011|Experimental|Dorsal penile nerve block according to Dalens' technique|Two injections at the dorsum penis according to Dalens' technique.
88954604|NCT01974011|Active Comparator|DPNB with additional infiltration of the ventromedial penis|"Modified procedure:~Two injections at the dorsum penis according to Dalens' technique plus on subcutaneous injection in the ventral midline of the penis at the transition between the penis and the scrotum."
88954605|NCT01974024|Experimental|Methylprednisolone|Dexamethasone was replaced with methylprednisolone as an antiemetic.
88954606|NCT01974024|Active Comparator|Dexamethasone|Dexamethasone was re-administered in the cycle.
88954607|NCT01974037|Active Comparator|Capsaicin_effect subgroup 1|The volunteers allocated to the arm will perform neuroimaging detection with buccal administration of water with capsaicin.
88954608|NCT01974037|Experimental|Capsaicin_effect subgroup 2|The volunteers allocated to the arm will perform neuroimaging detection with buccal administration of 100 mmol/L NaCl with capsaicin.
88954609|NCT01974037|Experimental|Capsaicin_effect subgroup 3|The volunteers allocated to the arm will perform neuroimaging detection with buccal administration of 150 mmol/L NaCl with capsaicin.
89204927|NCT01004380|Experimental|Farletuzumab|2.5 mg/kg once weekly administered i.v. during the Combination treatment period and 7.5 mg/kg Q3W administered i.v. during the Maintenance period
89204928|NCT01003522|Other|Treatment Arm A|Stenting of central lesion and subsequent standard palliative treatment and dyspnoea symptom control
89204929|NCT01003522|Other|Treatment Arm B|Standard palliative treatment and standard dyspnoea symptom control.
89204930|NCT01004458|Active Comparator|Early treatment group|The experimental group receiving CBT
89204931|NCT01004458|No Intervention|Waiting list group|The waiting list group served as referents during the trial
89204932|NCT01003600||Questionnaire|This study is a cross-sectional survey study to be administered to adults who completed treatment for nonmetastatic colorectal cancer at MSKCC or at Queens Cancer Center (QCC) at Queens Hospital between 6 months and 2 years ago and have no evidence of disease at the time of study enrollment.
89204933|NCT01004536|No Intervention|no treatment|The other half of cesarean section wound that is to be left untreated.
89204934|NCT01004536|Experimental|silicone gel|Randomly-designated half of cesarean section wound that is to be subject to application ot silicone gel
89204935|NCT01003678|Experimental|Level 1|1 mg daily for 5 consecutive days followed by 23 days off drug
89204936|NCT01003756|Experimental|Knee Intervention|Patients undergoing Total Knee Replacement. Exercise 8-10 weeks preoperatively
89204937|NCT01003756|No Intervention|Knee Control|Patients undergoing Total Knee Replacement. Receives standard instructions
89204938|NCT01003756|Experimental|Hip Intervention|Patient undergoing Total Hip Replacement. Exercise 8-10 weeks preoperatively
89204939|NCT01003756|No Intervention|Hip Control|Patients undergoing Total Hip Replacement. Receives standard instructions
89204940|NCT04000204|Experimental|HYAJOINT Plus|
89204941|NCT04000204|Active Comparator|Durolane|
89204942|NCT01003834|Placebo Comparator|Control|Screening only
89204943|NCT01003834|Active Comparator|Assessment|Screening plus assessment
89204944|NCT01003834|Experimental|Computer Intervention|Screening, assessment, and computer-delivered intervention
89204945|NCT01003834|Active Comparator|Therapist Intervention|Screening, Assessment, and therapist-delivered intervention
89204946|NCT04000126|Active Comparator|Control C|This group will be given induction anesthesia agents in standard doses (fentanyl 3mcg/kg, propofol 2mg/ kg, rocuronium 0,6mg/kg)
89204947|NCT04000126|Experimental|Lignocaine group L|This group will be given additionally 1.5 mg/kg lidocaine/ 100ml 0,9% NaCl iv 10min before intubation
89204948|NCT04000126|Placebo Comparator|Placebo P|This group will be given additionally 100 ml 0,9% NaCl iv 10 min before intubation
89204949|NCT01004926|Experimental|Echelon|
89204950|NCT01008826|Experimental|glucoraphanin-rich broccoli extract|
89204951|NCT01008826|Experimental|sulforaphane-rich broccoli extract|
89204952|NCT01005004|Experimental|HuCNS-SC cells|Intracerebral implantation of HuCNS-SC via direct injection during surgery
89204953|NCT01005082|Experimental|Low salt diet plus water therapy|
89204954|NCT01005082|Active Comparator|water therapy alone|
89204955|NCT01008982|Experimental|single arm|
89204956|NCT03999736|Experimental|Treatment|"14 sessions x 30 minutes of 2mA transcranial direct current stimulation to the dorsolateral prefrontal cortex.~10 x sessions over the course of the initial two weeks (e.g. 5 x per week with flexibility).~4 x sessions over the course of a two week maintenance treatment."
89204957|NCT01005160|Experimental|CKD501|
89204958|NCT03878758|Experimental|BD Nano™ PRO pen needle vs 33G Artsana Insupen Extr3me|Subjects are to perform 2 pairs of injections. Each Pair consists of BD Nano™ PRO pen needle vs Artsana Insupen Extr3me 4mm x 33G x 2
89494365|NCT05612282||G1b - men|The G1b group consisted of men with obesity, in whom no additional components of the metabolic syndrome were founds (n =6)
88954610|NCT01974037|No Intervention|Capsaicin_effect subgroup 4|The volunteers allocated to the arm will perform neuroimaging detection with buccal administration of 200 mmol/L NaCl.
88954611|NCT01974037|No Intervention|Salt_effect subgroup 1|The volunteers allocated to the arm will perform neuroimaging detection with buccal administration of water.
88954612|NCT01974037|Experimental|Salt_effect subgroup 2|The volunteers allocated to the arm will perform neuroimaging detection with buccal administration of 100 mmol/L NaCl.
88954613|NCT01974037|Experimental|Salt_effect subgroup 3|The volunteers allocated to the arm will perform neuroimaging detection with buccal administration of 150 mmol/L NaCl.
88954614|NCT01974037|Experimental|Salt_effect subgroup 4|The volunteers allocated to the arm will perform neuroimaging detection with buccal administration of 200 mmol/L NaCl.
88954615|NCT01974063||A. Nonsmokers|Subjects have smoked <100 cigarettes or <10 shisha pipes per lifetime and whose urine nicotine <2 ng/mL and/or urine cotinine <5 ng/mL, at entry into the study.
89494366|NCT05612282||G2a - women|The G2a group consisted of women with obesity, in whom only one additional component of the metabolic syndrome was found (e.g. triglycerides ≥ 150 mg/dl, HDL cholesterol in women < 50 mg/dl, and in men < 40 mg/dl, or glycaemia ≥ 100 mg/dl), but it was not a disease previously diagnosed and treated (n=19)
89494367|NCT05612282||G2b - men|The G2a group consisted of men with obesity, in whom only one additional component of the metabolic syndrome was found (e.g. triglycerides ≥ 150 mg/dl, HDL cholesterol in women < 50 mg/dl, and in men < 40 mg/dl, or glycaemia ≥ 100 mg/dl), but it was not a disease previously diagnosed and treated (n=11)
89494368|NCT05612282||G3a - women|Group G3a consisted of women who met the full criteria for diagnosing the metabolic syndrome (n=24)
89494369|NCT05612282||G3b - men|Group G3a consisted of men who met the full criteria for diagnosing the metabolic syndrome (n=15)
89494370|NCT05556278||Intervention|An electroneurography and an ultrasound study will be performed to patients with clinical suspicion of CTS and fulfilling the inclusion/exclusion criteria.
89022472|NCT00427310|Experimental|Arm 1: Postoperative 5 FU + sodium heparin|Continuous portal vein infusion with 5 FU 600 mg/m2 + 5000 units sodium heparin per day given for a total of 7 consecutive days.
89022473|NCT00427310|Active Comparator|Arm 2: Postoperative observation|
89022474|NCT00468741|No Intervention|1|subjects receive internet access and computer
89022475|NCT00468741|Experimental|2|CHESS informational services only
89022476|NCT00468741|Experimental|3|CHESS social support and informational services
89022477|NCT00468741|Experimental|4|Full CHESS
89022478|NCT00427388|Experimental|Treatment|500 mg of methylprednisolone divided into two intravenous doses of 250 mg each, one during anesthetic induction and the other on CPB initiation
89022479|NCT00427388|Placebo Comparator|Placebo|500 mg of matching placebo (normal saline solution) divided into two intravenous doses of 250 mg each, one during anesthetic induction and the other on CPB initiation
89022480|NCT01056653|Experimental|Group A Teal|Standard Dose - Two intervention home visits (at 4 and 6 months of age)
89022481|NCT01056653|Experimental|Group B Purple|High Dose - Four intervention home visits (at 4, 5, 6, and 7 months of age)
89022482|NCT01056653|Sham Comparator|Group C Yellow|Comparison Group - One home visit, information only (at 4 months of age)
89022483|NCT01056536|Experimental|Structured intervention + free condoms|The subjects will receive a structured intervention on STI's and will be offered free condoms
89022484|NCT01056536|Active Comparator|Free condoms|Subjects will be offered free condoms at the end of the pre-travel consultation
89022485|NCT01056536|No Intervention|No intervention|The topic of STI's will not be actively discussed during the pretravel consultation
89022486|NCT04704947|Experimental|nonselective beta blocker group|Twenty patients with osteoporosis and hypertension on the same treatment as control group in addition to propranolol (Inderal®) 10 mg once daily titrated as patient's response.
89022487|NCT04704947|Experimental|cardio-selective beta blocker group|Twenty patients with osteoporosis and hypertension on the same treatment as control group in addition to bisoprolol (Concor®) 5 mg once daily titrated as patient's response.
89022488|NCT04704947|Placebo Comparator|Control group|Ten patient with osteoporosis on alendronate sodium 70 mg (Fosamax®) once/week, vitamin D3 1 mcg once daily and calcium supplement 500 mg once daily.
89022489|NCT04705142|Experimental|MgSO4|"MgSO4~1st dose within 6 hours of life @250mg/kg,2nd after 24 hours of life @250mg/kg, 3rd after 48 hours of life @250mg/kg.~Monitoring and Protective measures:~Before and during administration of MgSO4, B.P, Capillary refill time, Heart rate and respiratory rate will be assessed closely i-e on 10 minutes interval, infusion of MgSO4 will be give over 30 minutes and baby will be monitored every 15 minutes interval after completion of infusion as well for 1 hour."
89022490|NCT04705064||AI_AKI|Adults patients undergoing non-cardiac surgery
89022491|NCT00460161|Active Comparator|1|true acupuncture
89022492|NCT00460161|Placebo Comparator|2|placebo/sham acupuncture
89022493|NCT00468897|Experimental|Treatment Arm AB|A will be a single tablet RSG XR 8 milligram (mg) manufactured in Harlow administered in the fasted state and B will be a single tablet RSG XR 8 mg manufactured in Crawley administered in the fasted state. In Arm AB subject will receive A regimen in Period 1 and B regimen in Period 2.There will be wash-out period of 5 days between doses.
89494371|NCT05611814|Sham Comparator|Sham treatment|The sham maneuver treatment addressed soft tissue tension, restriction of motion, and tenderness of the lower thoracic and lumbar regions.
89494372|NCT05611814|Experimental|Experimental Osteopathic Manipulative Treatment|The sham maneuver treatment addressed soft tissue tension, restriction of motion, and tenderness of the cervical region (targeted anatomical structures).
89494373|NCT05556122|Experimental|intercostal nerve block at the incision|General anesthesia and intercostal nerve block were performed.The drug for intercostal nerve block was 0.33% ropivacaine +2.333mg compound betamethasone (1.667mg betamethasone dipropionate + 0.667mg betamethasone sodium phosphate) to 15ml
89494374|NCT05556122|Active Comparator|lateral intercostal nerve block at costal angle|General anesthesia and intercostal nerve block were performed.The drug for intercostal nerve block was 0.33% ropivacaine +2.333mg compound betamethasone (1.667mg betamethasone dipropionate + 0.667mg betamethasone sodium phosphate) to 15ml
89494375|NCT04880720||COVID-19 Patients|
89022494|NCT00468897|Experimental|Treatment Arm BA|A will be a single tablet RSG XR 8 mg manufactured in Harlow administered in the fasted state and B will be a single tablet RSG XR 8 mg manufactured in Crawley administered in the fasted state. In Arm BA subject will receive B regimen in Period 1 and A regimen in Period 2. There will be wash-out period of 5 days between doses.
89022495|NCT00427583|Experimental|STI571|
89022496|NCT00468936|No Intervention|1|Usual medications (Cellcept)
89022497|NCT00468936|Active Comparator|2|Patients taking Myfortic
89022498|NCT00427739||CCT exam|
89022499|NCT00460356||Ancillary-Correlative (glycoprotein and glycan profiling)|Primary and metastatic tumor specimens are collected during lymphadenectomy and used for tissue microarray analysis, mutational analysis of T-synthase and Cosmc, immunohistochemical staining of Tn antigen and sialyl Tn antigen, and customized gene expression array analysis of 400 genes associated with glycobiology. Pre-lymphadenectomy blood is collected from patients at baseline for customized glycan array analysis of 300 carbohydrates.
89022500|NCT00428012|Experimental|QOLT|Quality of Life Therapy (QOLT) 8 weekly individual counseling sessions
89494376|NCT04880720||Rheumatoid Arthritis Patients|
89494377|NCT04880720||Healthy Comparator|
89494378|NCT05555966|Experimental|Tailor-made CRT delivery|Device placement based on Electrical Activation Mapping result
89494379|NCT04865198||Patients with Autism Spectrum Disorder (ASD)|Patients diagnosed with ASD in a child psychiatry clinic.
89494380|NCT04865198||Patients with High Functioning Autism (HFA)|Patients diagnosed with ASD in a child psychiatry clinic and with an IQ above 70.
89494381|NCT04865198||Healty control|Healthy volunteers who are in the age range compatible with the patient groups.
89494382|NCT05555810|Active Comparator|Suture ligation of cystic duct and artery|The investigators will ligate cystic duct and artery by traditional sutures during laparoscopic cholecystectomy .
89494383|NCT05555810|Active Comparator|Application of clips|The investigators will put a clips on the cystic duct and artery during laparoscopic cholecystectomy.
89494384|NCT04842734|Experimental|Physical exercise and computerized cognitive stimulation|"Supervised Physical Exercise Program (SPEP) sessions will be performed simultaneously online together with the physiotherapist and the patient. Participants will be able to do the exercises together with their caregivers if needed.~The Computerized Cognitive Stimulation Program (CCSP) (Beynex) will be planned for 12 weeks, 5 days a week, approximately 10 minutes, for a total of 40 sessions.~Fisrtly, the use of CCSP will be demonstrated to the patients. Then, it will be given as home program. While the patients play the games in CCSP via their smartphones, their caregivers will be informed in detail about accompanying the patients if they need it. The follow-up of cognitive stimulation will be made with the person accompanying the patient over the phone.~Individuals will be evaluated by a physiotherapist who will perform the assessment at pre-treatment, post-treatment (12th week) and follow-up period (24th week)."
89022501|NCT00428012|Active Comparator|ST|Supportive Therapy (ST) 8 weekly individual counseling sessions
89494385|NCT04842734|Experimental|physical exercise|"SPEP sessions will be demonstrated to individuals by a 6-year-experienced physiotherapist via videoconference (Zoom Inc.) and the exercises will be performed simultaneously online together with the physiotherapist and the patient. Participants will be able to do the exercises together with their caregivers if needed.~Individuals will be evaluated by a physiotherapist who will perform the assessment at pre-treatment, post-treatment (12th week) and follow-up period (24th week)."
89494386|NCT04842734|No Intervention|control|"The individuals included in this group will be informed that they should continue their normal daily life activities.~Individuals will be evaluated by a physiotherapist who will perform the assessment at pre-treatment, post-treatment (12th week) and follow-up period (24th week)."
89494387|NCT04817228|Experimental|EX-02 Gel|The powder of EX-02 (8.1 g in each unit) should be reconstituted with 20 g sterile water for injection (WFI) to obtain 5% EX-02. EX-02 5% gel will be topically applied on a wound surface of up to 80 cm2 for 24±3 hours, up to 8 consecutive applications
89022502|NCT00428012|No Intervention|Standard Care|
89022503|NCT00469131|Active Comparator|1 Drug:|tacrolimus + steroid
89022504|NCT00469131|Active Comparator|2 Drug:|tacrolimus + mycophenolate mofetil
89022505|NCT00428051||All eligible patients|
88954616|NCT01974063||B.Current cigarette smokers|Defined by self-report and urine nicotine >30 ng/mL and/or urine cotinine >50 ng/ml.
88954617|NCT01974063||C. Current shisha smokers|Defined by self-report of smoking >4 pipes/wk and carboxyhemoglobin >2.5.
89494388|NCT05555498|Experimental|Intervention group: VR-glasses added to standard care of conscious sedation|For the intervention group, Virtual Reality glasses will be administered on top of standard pain and anxiety management. Standard pain and management consists of conscious sedation, where benzodiazepines and opioids are administrered. In addition, participants are asked to complete 4 questionnaires on different times : immediately before, immediately after and three days after oocyte retrieval. In case of ongoing pregnancy, women are asked to complete a questionnaire approximately a month after their expected date of delivery.
89494389|NCT05555498|No Intervention|standard care consisting of conscious sedation|The control group will receive standard pain- and anxiety management during oocyte retrieval in IVF/ICSI treatment, consisting of opioids combined with benzodiazepines. This will result in a conscious sedated state. In addition, participants are asked to complete 4 questionnaires on different times : immediately before, immediately after and three days after oocyte retrieval. In case of ongoing pregnancy, women are asked to complete a questionnaire approximately a month after their expected date of delivery.
89494390|NCT05549882||HFNC success group|
89494391|NCT05549882||HFNC failure group|HFNC failure was defined as the subsequent need for invasive MV.
89494392|NCT05549804|Experimental|Dose Escalation|KL340399 weekly on Days 1, 8 and 15 on repeated 21-day cycles in escalating doses.
89494393|NCT05549570|Experimental|Reference group|Thirty minutes after the start of the breakfast, a single dose of the Reference formulation was administered with approximately 240 mL of water at ambient temperature
89494394|NCT05549570|Experimental|Test group|Thirty minutes after the start of the breakfast, a single dose of the Test formulation was administered with approximately 240 mL of water at ambient temperature
89494395|NCT05549492|Experimental|Group B|Candidates received 20 ml of 0.25% ropivacaine for TAP block
89494396|NCT05549492|Experimental|Group RB|Candidates received 20 ml of 0.25% ropivacaine and 300 μg of buprenorphine, respectively, for the TAP block.
89494397|NCT04331132|Placebo Comparator|Conventional diuretic group|The conventional furosemide treatment will follow the modified 2019 Position Statement from the ESC Heart Failure Association
89494398|NCT04331132|Active Comparator|Vasopressin-2 antagonist group|Tolvaptan 15mg once daily for 2 days will be added-on the furosemide strategy based on the modified 2019 Position Statement from the ESC Heart Failure Association
89494399|NCT05555420|Active Comparator|SRP only|
89494400|NCT05555420|Experimental|SRP+Laser|
89494401|NCT05549336||PD-1-treated tumor patients|Tumor patients who are initiating receive chemotherapy that includes PD-1 inhibitors.
89494402|NCT05549336||non-PD-1-treated tumor patients|Tumor patients who are initiating receive chemotherapy that not includes PD-1 inhibitors.
89494403|NCT05554952|Active Comparator|Group 1|Indirect pulp capping with MTA
89494404|NCT05554952|Active Comparator|Group 2|Pulpotomy with MTA
88954618|NCT01974063||D. smokers willing to quit|Defined by self-report and urine nicotine >30 ng/ml and/or urine cotinine >50 ng/ml. Subjects must be a current smoker willing to stop smoking. Subjects will stop smoking after the baseline bronchoscopy, and switch to taking a smoking cessation medication called varenicline. We will provide subjects with the smoking cessation medication as part of this study. They will also receive phone calls to help with smoking cessation counseling.
89022506|NCT02956356|Placebo Comparator|Control treatment + oral glucose|Control treatment as preload and then an oral glucose load of 75g enriched with C13 sodium acetate (for determination of gastric emptying rates)
89022507|NCT02956356|Active Comparator|SATIOSTAT treatment + oral glucose|SATIOSTAT treatment as preload and then an oral glucose load of 75g enriched with C13 sodium acetate (for determination of gastric emptying rates)
89022508|NCT02956356|Placebo Comparator|Control treatment + meal intake|Control treatment as preload followed by a test meal
89022509|NCT02956356|Active Comparator|SATIOSTAT treatment + meal intake|SATIOSTAT treatment as preload followed by a test meal
89022510|NCT00428129|Experimental|1|
89022511|NCT03271515|No Intervention|conventional therapy|patients accept conventional radioactive and chemical therapy.
89494405|NCT04753034|Experimental|TER-101|BID (twice daily) application
89494406|NCT04753034|Placebo Comparator|Vehicle|Vehicle ointment, BID (twice daily) application
89494407|NCT05611190|Other|Usual Care|Participants randomized to usual care will be evaluated according to institutional standard practice. The investigators will review clinical data and results of the diagnostic tests to recommend a treatment strategy, according to the institution's standard practice.
89494408|NCT05611190|Experimental|CT-FFR|Participants randomized to a CT-FFR strategy will be assigned to non-invasive CT-FFR evaluation. The investigators will review the results CT-FFR, and will recommend a further ICA test if CT-FFR≤0.8. The investigators will review the results of all available diagnostic tests, including CT-FFR and ICA, and will recommend a treatment strategy accordingly.
89494409|NCT05554718|Experimental|App condition|All participants will receive access to the developed social anxiety disorder (SAD) treatment app for 12 weeks.
89494410|NCT05554718|Experimental|App with accompanying therapy sessions|In addition to being able to use the app to treat social anxiety over a 12-week period, participants will receive a total of 8 video therapy sessions based on cognitive behavioral therapy to accompany their use of the app.
89494411|NCT05554718|No Intervention|Waitlist control condition|Delayed use of the mobile application after 12 weeks.
89494412|NCT05549024|Experimental|68Ga-RM26-RGD and 18F-FDG PET/ CT scan|Within 2 week, each patient underwent PET/CT scan after intravenous administration of 68Ga-RM26-RGD and 18F-FDG, respectively.
89494413|NCT05549024|Experimental|68Ga-RM26-RGD and 68Ga-RM26 PET/ CT scan|Within 2 week, each patient underwent PET/CT scan after intravenous administration of 68Ga-RM26-RGD and 68Ga-RM26, respectively.
89494414|NCT05549024|Experimental|68Ga-RM26-RGD and 68Ga-RGD PET/ CT scan|Within 2 week, each patient underwent PET/CT scan after intravenous administration of 68Ga-RM26-RGD and 68Ga-RGD, respectively.
89494415|NCT04666844||Survey|Clinicians will be asked to provide responses to the two surprise questions for each of their PD patients.
89494416|NCT05548868|Experimental|Experimental Arm|Patients will receive standard dietary counselling and use of E4W mobile app
89494417|NCT05548868|Active Comparator|Control Arm|Patients will receive standard dietary counselling. No use of E4W.
89494418|NCT05548790|Experimental|Group 1|Group 1: patients were given information via silent video with subtitle (5-minute)
89494419|NCT05548790|Experimental|Group 2|Group 2: patients were given information via video with background audio (5-minute 34-second)
89494420|NCT05548790|Experimental|Group 3|Group 3: patients were given written information brochure
89494421|NCT05548790|Experimental|Group 4|Group 4: patients were given information verbally
89494422|NCT01666730|Experimental|Treatment (metformin hydrochloride, FOLFOX)|Patients receive metformin hydrochloride PO BID on days 1-14 and FOLFOX therapy comprising leucovorin calcium IV over 120 minutes, fluorouracil IV continuously over 46 hours, and oxaliplatin IV over 120 minutes on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
89494423|NCT05700188||Resectable|Patients with resectable pancreatic cancer
89494424|NCT05700188||Borderline resectable|Patients with borderline resectable pancreatic cancer
89494425|NCT05700188||Locally advanced|Patients with locally advanced unresectable pancreatic cancer
89494426|NCT05700188||Metastatic|Patients with metastatic pancreatic cancer
89494427|NCT05554484|Experimental|AMI-DC|Infusion of AMI-DC + Guideline directed optimal medical therapy
89494428|NCT05554484|No Intervention|Standard treatment|Control, Guideline directed optimal medical therapy
89494429|NCT05554250||Obese patients|The population of the study consisted of individuals who applied to the Diet Polyclinic of a hospital, and the sample consisted of 500 individuals who applied to the Diet Polyclinic and met the research criteria.
89494430|NCT04426136||1. WLE group|patients in this group receiving WLE merely
89494431|NCT04426136||2. other method group|patients in this group receiving any other surgical procedures except WLE
89494432|NCT04434560|No Intervention|Standard of Care (no neoadjuvant immunotherapy)|Patients will proceed to surgical resection with no nivolumab/ipilimumab given prior to surgery.
89494433|NCT04434560|Experimental|Neoadjuvant Immunotherapy|Patients will receive a single dose of neoadjuvant nivolumab and ipilimumab 7 days (± 3 days) prior to surgical resection.
89494434|NCT05700656|Experimental|Galunisertib plus capecitabine|Galunisertib 150 mg BID for 14 days in a 28-day cycle plus capecitabine 1000 mg/m2 BID for 14 days in a 28-day cycle
89494435|NCT05548478|Active Comparator|TransEpi single step PRK|
89494436|NCT05548478|Active Comparator|alcohol assisted PRK|
89494437|NCT05548400||Criticaly ill patients who remained on invasive mechanical ventilation for at least 48 hours.|Criticaly ill patients who remained on invasive mechanical ventilation for at least 48 hours, and dietary followed up after ventilator withdrawal.
89494438|NCT00103285|Experimental|Group 0 Induction Therapy|All patients receive cytarabine intrathecally (IT) on day 1; vincristine IV on days 1, 8, 15, and 22; dexamethasone IV or orally (PO) twice daily (BID) on days 1-28; pegaspargase intramuscularly (IM) (may give IV over 1 to 2 hours) on day 4, 5, or 6; and methotrexate IT on days 8 and 29 (and days 15 and 22 for patients with CNS3 disease). Patients with Down syndrome (DS) receive leucovorin calcium PO at 48 and 60 hours after each dose of methotrexate IT. Patients are assessed for response on day 29. Patients with M1 bone marrow AND minimal residual disease (MRD) < 0.1% OR MRD >= 0.1% and < 1% proceed to therapy in part II. Patients with M2 bone marrow OR M1 bone marrow AND MRD >= 1% proceed to extended induction therapy. Patients with M3 bone marrow are removed from the study.
89494439|NCT00103285|Active Comparator|Group 1-SR-low ALL, Arm I (combination chemotherapy)|Patients receive standard consolidation therapy, standard interim maintenance therapy, and standard delayed intensification (DI) therapy, followed by maintenance therapy. Therapies are given by mouth, injection, and infusion for up to 2 or 3 years
89494440|NCT00103285|Experimental|Group 1-SR-low ALL, arm II (combination chemotherapy)|Patients receive experimental consolidation therapy, experimental interim maintenance therapy, and standard DI therapy, followed by maintenance therapy. Therapies are given by mouth, injection, and infusion for up to 2 or 3 years.
89494441|NCT00103285|Active Comparator|Group 2-SR-avg ALL, arm I (combination chemotherapy)|Patients receive standard consolidation therapy, standard interim maintenance therapy, and standard DI therapy as in group 1, arm I, followed by maintenance therapy. Therapies are given by mouth, injection, and infusion for up to 2 or 3 years.
89494442|NCT00103285|Experimental|Group 2-SR-avg ALL, arm II (combination chemotherapy)|Patients receive standard consolidation therapy, augmented interim maintenance therapy, augmented DI therapy, followed by maintenance therapy. Therapies are given by mouth, injection, and infusion for up to 2 or 3 years.
89494443|NCT00103285|Active Comparator|Group 2-SR-avg ALL, arm III (combination chemotherapy)|Patients receive intensified consolidation therapy, standard interim maintenance therapy, and standard DI therapy, followed by maintenance therapy. Therapies are given by mouth, injection, and infusion for up to 2 or 3 years.
89494444|NCT00103285|Active Comparator|Group 2-SR-avg ALL, arm IV (combination chemotherapy)|Patients receive intensified consolidation therapy, augmented interim maintenance therapy, and augmented DI therapy, followed by maintenance therapy. Therapies are given by mouth, injection, and infusion for up to 2 or 3 years.
89494445|NCT00103285|Experimental|Group 3-SR-high ALL, combination chemotherapy|Patients receive intensified consolidation therapy, augmented interim maintenance therapy (2 courses), and augmented DI therapy (2 courses), followed by maintenance therapy. Therapies are given by mouth, injection, and infusion for up to 2 or 3 years.
89494446|NCT02155075|Experimental|Arm 1|"Testing phase (Phase II) Arm 1 - 180 participant will be enrolled for this arm. Participants will be enrolled to undergo MIRA device imaging. Following the MIRA device imaging procedure, the optimized risk model will assign a binary result to the participant.~All participants will recive standart of care, participants with negative screening exams and a positive MIRA device imaging result will additionally undergo MRI."
89494447|NCT02155075|Experimental|Arm 2|Testing phase (Phase II) Arm 2 - 150 participant will be enrolled for this arm. Participants will be enrolled to undergo MIRA device imaging. Following the MIRA device imaging procedure all participants in arm 2 will be following standard of care, MIRA device imaging will NOT change their clinical path.
89494448|NCT03541915|Experimental|Mg group|20mg/kg of magnesium sulfate will be infused after induction of anesthesia. And magnesium sulfated will be continuously infused at a rate of 15mg/kg/h during the operation.
89204959|NCT03878758|Experimental|BD Nano™ PRO pen needle vs 34G Artsana Insupen Extr3me|Subjects are to perform 2 pairs of injections. Each pair consists of Nano™ PRO pen needle vs Artsana Insupen Extr3me 3.5mm x 34G x 2
89204960|NCT03878758|Experimental|BD Nano™ PRO pen needle vs Simple Diagnostics Comfort EZ™|Subjects are to perform 2 pairs of injections. Each pair consists of BD Nano™ PRO pen needle vs Simple Diagnostics Comfort EZ™ 4mm x 33G x 2
89204961|NCT03878602|Active Comparator|Control Group|Newborns will be subjected to umbilical cord immediate clamping
89204962|NCT03878602|Experimental|Study Group|Newborns will be subjected to umbilical cord delayed clamping
89204963|NCT01005238|Active Comparator|telbivudine|patients in this arm will continue to take telbivudine
89204964|NCT01005238|Experimental|lamivudine|patients in this arm will take lamivudine
89494449|NCT03541915|Placebo Comparator|Control group|Same volume of normal saline will be infused after induction of anesthesia. And the same volume of normal saline will be continuously infused at a same rate of magnesium during the operation.
89494450|NCT03541837|Other|peri operative analgesia|Post operative regional analgesia by Erector Spinae bilateral catheters with infusion of ropivacaine
89494451|NCT02155153|Experimental|Sugar Free Chewing Gum|All patients receiving sugar free gum
89494452|NCT02155153|No Intervention|Control|Patients receiving no intervention
89494453|NCT02783573|Experimental|Lanabecestat 20 milligrams (mg)|Participants received Lanabecestat 20 mg film-coated tablets orally once daily until week 156.
89494454|NCT02783573|Experimental|Lanabecestat 50 mg|Participants received Lanabecestat 50 mg film-coated tablets orally once daily until week 156.
89494455|NCT02783573|Experimental|Placebo/ Lanabecestat 20 mg|Placebo given orally once daily for 78 weeks and then 20 mg of lanabecestat given orally once daily until week 156.
89022512|NCT03271515|Experimental|anti-CD19 anti-CD20 Bispecific CAR-T|patients accept transfusion of anti-CD19 anti-CD20 Bispecific CAR-T cells.
89204965|NCT01009216|Experimental|ABT-384|
89204966|NCT01005394||Navigated TMS|single arm study where all subjects will be studied using the Navigated TMS device
89204967|NCT01005472|Experimental|sunitinib malate, temozolomide|
89204968|NCT03742726|Experimental|Smart Matrix scaffold|Smart Matrix dermal replacement scaffold
89204969|NCT01005550|Experimental|6 mg of ropivacaine|6 mg of ropivacaine are used for the spinal anaesthesia
89204970|NCT01005550|Experimental|8 mg of ropivacaine|8 mg of ropivacaine are used for the spinal anaesthesia
89204971|NCT01005550|Experimental|10 mg of ropivacaine|10 mg of ropivacaine are used for the spinal anaesthesia
89204972|NCT01005550|Experimental|12 mg of ropivacaine|12 mg of ropivacaine are used for the spinal anaesthesia
89204973|NCT03999580|Experimental|Experimental Arm:|"Experimental: Vitamin D3 3000 or 4000 UI/day then 2,000 UI/day~3000 UI or 4,000 UI/day as induction therapy (according to weight) for 4 weeks then 2,000 UI/day as maintenance therapy for 48 weeks.~The administration of vitamin D will be considered as an adjunct to conventional therapy (corticosteroids, exclusive enteral nutrition or immunosuppressive agents (ISA)."
89494456|NCT02783573|Experimental|Placebo/ Lanabecestat 50 mg|Placebo given orally once daily for 78 weeks and then 50 mg of lanabecestat given orally once daily until week 156.
89494457|NCT02157961||General Practitioner / Family Physician in German Primary care|
89494458|NCT02157961||Medical Specialists|Working in the ambulatory setting
89494459|NCT02158117|Experimental|nasal naloxone|8 and 16 mg/ml, comparator 1 mg/ml. Three daily occasions with at least 3 days washout between treatment (min 8 days).
89494460|NCT02160067|Experimental|Treatment A|Second generation patch BTDS 12.6mg
89494461|NCT02160067|Experimental|Treatment B|Second generation patch BTDS 3.15mg
89494462|NCT02160067|Active Comparator|Treatment C|First generation patch BuTrans 20mg
89494463|NCT02160067|Active Comparator|Treatment D|First generation patch BuTrans 5mg
89494464|NCT03541603|Experimental|Levosimendan 2.5mg/mL Injectable Solution|0.075 - 0.1µg/kg/min for 24 hrs (weekly)
89494465|NCT03541603|Placebo Comparator|Matching Placebo|0.075 - 0.1µg/kg/min for 24 hrs (weekly)
89494466|NCT02155387||Coronary artery bypass graft surgery|with cardiopulmonary bypass
89494467|NCT02155387||Pulmonary metastasectomy by thoracotomy|with one lung ventilation
89494468|NCT02155387||Minimal invasive mitral valve surgery|with cardiopulmonary bypass and one lung ventilation
89494469|NCT02160223|Experimental|Sugammadex|Group S patients will receive 2 mg kg -1 sugammadex at the end of surgery
89494470|NCT02160223|Active Comparator|Neostigmine|Group N patients will receive 50 µg kg-1 neostigmine and 05 mg atropin at the end of surgery
89494471|NCT04809701|Experimental|Configuration A first|Subjects receive the test of Configuration A first and Configuration B second.
89494472|NCT04809701|Experimental|Configuration B first|Subjects receive the test of Configuration B first and Configuration A second.
89494473|NCT02163031|Active Comparator|right radial approach|devices used in the coronary angiography by right radial approach
89022513|NCT00428168|Experimental|Betahistine 24 mg|
89494474|NCT02163031|Active Comparator|left radial approach|devices used in the coronary angiography by left radial approach
89022514|NCT00428168|Placebo Comparator|Placebo|
89022515|NCT00428285|Experimental|Single Arm|
89022516|NCT00428402||Focus Group|Participant is a 4th-8th grade student in select schools from Bastrop Independent School District (BISD).
89022517|NCT00469170|Experimental|A|vaginal ring first 12 weeks & observational safety last 12 weeks
89022518|NCT00469170|Experimental|B|observational safety first 12 weeks & vaginal ring last 12 weeks
89494475|NCT05537987|Experimental|ICP-723|
89494476|NCT02158351||Simple steatosis|We will run a cross-sectional observational study including two groups of human subjects: patients with simple steatosis (SS) or non-alcoholic steatohepatitis (NASH). Grouping in patients SS or NASH will be performed based on the histological diagnosis of the type of NAFLD obtained at operation (sleeve gastrectomy or cholecystectomy). BMI will be considered as a confounding variable to be statistically analyzed. Main hypothesis: GM can lead to liver inflammation in patients with liver fat accumulation.
89494477|NCT02158351||Non-alcoholic steato-hepatitis|We will run a cross-sectional observational study including two groups of human subjects: patients with simple steatosis (SS) or non-alcoholic steatohepatitis (NASH). Grouping in patients SS or NASH will be performed based on the histological diagnosis of the type of NAFLD obtained at operation (sleeve gastrectomy or cholecystectomy). BMI will be considered as a confounding variable to be statistically analyzed. Main hypothesis: GM can lead to liver inflammation in patients with liver fat accumulation.
89494478|NCT05258825|Experimental|Intravenous Iron Infusion Arm|If the patient is found to have iron deficiency anemia, the patient will receive IV iron preoperatively. Patients that agree to be enrolled in the study will be scheduled for the IV iron dose approximately 3-4 weeks prior to surgery. A single IV dose of 1000 mg of Monoferric will be administered. This will be administered at the Brigham and Women's Hospital infusion center and coordinated with the Hematology team.
89494479|NCT02158429|Active Comparator|3 Dimensional ultrasound|an additional 5-10 minutes of ultrasound using three dimensional technique
89494480|NCT02158429|Active Comparator|2 dimensional|an additional 5-10 minutes of ultrasound using standard two-dimensional technique
89494481|NCT02160301|Experimental|Multimodal pain control|Oxycodone 5-15mg PO q4hrs prn pre- and post-op, Acetaminophen 1000mg IV once pre-op, Acetaminophen 1000mg PO q8hrs pre-op and x2 weeks post op, prn thereafter, Gabapentin 100mg/200mg PO a8hrs pre-op and x2 weeks post op, Dexamethasone 8mg IV once intra-op, Celecoxib 400mg PO once pre-op.
89494482|NCT02160301|Active Comparator|Standard pain control|Oxycodone 5-15mg PO q4hrs prn, Acetaminophen 1000mg PO q8hrs prn.
89494483|NCT05531981||initial surgical treatment group|"After the patients were enrolled in the study according to the criteria, they were given standard treatment. The patients were followed up every 3~6 months within 2 years after treatment and every 6~12 months from 3 to 5 years after treatment, including general and gynecological physical examination, cervical or vaginal cytology test, HPV typing test, SCC, CA125, and imaging examination such as CT or MRI if necessary.~Peripheral blood samples were collected to detect HPV E7 ctDNA before treatment, 2 weeks after surgery, (1 month after adjuvent radiotherapy if available) and at 6, 12, 18, 24, 30, and 36 months of follow-up."
89022519|NCT00428480|Experimental|1|Daily reinforcement of walking speed
89022520|NCT00428480|Active Comparator|2|No reinforcement of walking speed
89022521|NCT00460473|Experimental|Dexmedetomidine|
89022522|NCT00460473|Placebo Comparator|Placebo (PBO)|
89022523|NCT00428519|Placebo Comparator|1|
89022524|NCT00428519|Active Comparator|2|
89022525|NCT00428519|Active Comparator|3|
89022526|NCT00428558|Active Comparator|2|A Phase 3 Trial of Systematic versus Response-adapted Timed-SEQUENTIAL Induction in Patients with Core Binding Factor (CBF) Acute Myeloid Leukemia (AML)
89022527|NCT00428558|Experimental|1|BRAS INDUCTION SEQUENTIAL
89022528|NCT00460512|Experimental|Paliperidone Extended Release (ER)|
89022529|NCT01056380|Active Comparator|Nitazoxanide|
89022530|NCT01056380|Placebo Comparator|Placebo|
89022531|NCT00460590|Experimental|1|12 adults with prior BCG
89022532|NCT00460590|Experimental|2|12 adults without prior BCG
89022533|NCT00460590|Experimental|3|12 Adolescents
89022534|NCT01055834|Experimental|Eszopiclone 3 mg tablet|
89022535|NCT01055834|Experimental|Eszopiclone 1 mg tablet|
89022536|NCT00469326|Active Comparator|atorvastatin|atorvastatin pre-treatment group (80mg atorvastatin two days before PCI)
89022537|NCT00469326|No Intervention|control|PCI without atorvastatin pretreatment
89022538|NCT01055639|Active Comparator|In-person ACT|8 individual in-person sessions of Acceptance and Commitment Therapy (ACT). ACT is a psychotherapy intervention comprised of meditation, goal-setting, and behavior change.
89494484|NCT05531981||initial concurrent chemoradiotherapy group|"After the patients were enrolled in the study according to the criteria, they were given standard treatment. The patients were followed up every 3~6 months within 2 years after treatment and every 6~12 months from 3 to 5 years after treatment, including general and gynecological physical examination, cervical or vaginal cytology test, HPV typing test, SCC, CA125, and imaging examination such as CT or MRI if necessary.~Peripheral blood samples were collected to detect HPV E7 ctDNA before treatment, 1 month after radiotherapy and at 6, 12, 18, 24, 30, and 36 months of follow-up."
89204974|NCT03999580|Active Comparator|Control Arm:|"Active Comparator: Vitamin D3 600 UI/day then 600 UI/day~600 UI/day as induction therapy for 4 weeks, then 600 UI/day as maintenance therapy for 48 weeks.~The administration of vitamin D will be considered as an adjunct to conventional therapy (corticosteroids, exclusive enteral nutrition or immunosuppressive agents (ISA))."
89204975|NCT00768755|Experimental|I|Axitinib (continuous) + Pemetrexed(500mg/m2)/Cisplatin(75mg/m2) x max 6 cycles followed by axitinib maintenance
89494485|NCT02160379||post Roux-en-Y-gastric bypass|Formerly obese females 1-5 years after gastric bypass
89494486|NCT02160379||matched controls|non-operated females age-and weight-matched to post Roux-en-Y-gastric bypass subjects
89494487|NCT02160379||healthy young controls|non overweight (BMI between 19 and 25 kg/m2) healthy females
89494488|NCT02160457|Experimental|Intervention with IGA|Individually tailored interdisciplinary intervention based on measures performed as part of the Cerebral Palsy follow-Up Program and other clinical examinations AND instrumented gait analysis (IGA)
89494489|NCT02160457|No Intervention|Intervention without IGA|'Care as usual' - Individually tailored interdisciplinary interventions based on measures performed as part of the Cerebral Palsy follow-Up Program and other clinical examinations BUT NOT (IGA).
88954619|NCT01974063||E. Smokers switching to E-cigarettes|Defined by self-report and urine nicotine >30 ng/ml and/or urine cotinine >50 ng/ml. Must be willing to switch from tobacco cigarettes to electronic cigarettes. The switch will occur after the baseline bronchoscopy. The nicotine dose that will be given to each subject will be determined by the study physician based on the urine smoking metabolite test. It will be adjusted depending on whether the subject is a light smoker or heavy smoker (Light smoker defined as having either a urine nicotine value from 2ng/ml-1000ng/ml or a urine cotinine value from 5ng/ml-1000ng/ml. Heavy smoker is defined as having either a urine nicotine or cotinine value of over 1000ng/ml.) We will provide the subjects with the electronic cigarettes to use as part of this study.
88954620|NCT01974076|Active Comparator|Active tDCS|
88954621|NCT01974076|Sham Comparator|Sham tDCS|
88954622|NCT01974115|Active Comparator|Radial extracorporeal shock wave therapy|All patients were treated with radial extracorporeal shock waves using the Swiss Dolorclast (Electro Medical Systems S.A., Nyon, Switzerland) and the Power+ handpiece with the 36-mm applicator. Patients were treated unilaterally with two weekly treatments for four weeks on a randomly selected leg (left or right), totaling eight treatments on the selected side. After the application of coupling gel, treatment was performed at 3.5 to 4 bar, with 15,000 impulses per session, and applied at 15 Hz. Impulses were applied homogeneously over the posterior thigh and buttock area. One patient was treated on both legs, with each leg considered an independent treatment.
88954623|NCT01974154||Cohort I|A. Healthy nonsmokers B. Healthy smokers C. Healthy smokers/quit smoking D. COPD smokers E. COPD smokers/ quit smoking
88954624|NCT01974154||Cohort II|A. Smokers with normal spirometry and normal DLCO B. Smokers, normal spirometry, low DLCO
88954625|NCT01974167|Experimental|Eldecalcitol group|Eldecalcitol 0.75 microgram once daily orally
88954626|NCT01974167|Active Comparator|Alfacalcidol group|Alfacalcidol 1 microgram once daily orally
89494490|NCT02160613|Other|Open flap for periodontitis patients|Open flap debridement
89494491|NCT03541759|Active Comparator|Hydromorphone|Hydromorphone Hcl 4 milligram (mg) Tab 2 times after surgery as basic medication. Hydromorphone Hcl 2.6mg maximum 2 per 24h when numeric rating scale (NRS) > 5.
89494492|NCT03541759|Active Comparator|Piritramide|Piritramide 15mg s.c. 2 times after surgery as basic medication. Piritramide 7.5mg s.c. maximum 2 per 24h when numeric rating scale (NRS) > 5.
89494493|NCT04064021|Experimental|Acupuncture|Acupuncture 12 sessions over 6 week to be given to pateints
89494494|NCT05149235|Active Comparator|early mobilization group|this group will perform early mobilization exercises using a cycle ergometer.
89494495|NCT05149235|Experimental|game tech group|this group will use physio adventure device instead of a cycle ergometer
89494496|NCT05149235|Placebo Comparator|placebo group|this group is placebo control and will receive routine respiratory physiotherapy
89494497|NCT01666652|Experimental|TDENV-PIV alum4|4 µg TDENV-PIV with Alum adjuvant; 0.5 mL intramuscular injection at 0 and 28 days
89494498|NCT01666652|Experimental|TDENV-PIV AS01E1|1 µg TDENV-PIV with AS01E1 adjuvant; 0.5 mL intramuscular injection at 0 and 28 days
89494499|NCT01666652|Experimental|TDENV-PIV AS03B1|1 µg TDENV-PIV with AS03B1 adjuvant; 0.5 mL intramuscular injection at 0 and 28 days
89494500|NCT01666652|Placebo Comparator|Placebo|Phosphate buffered saline; 0.5 mL intramuscular injection at 0 and 28 days
89494501|NCT01666652|Experimental|TDENV-PIV alum1|1 µg TDENV-PIV with Alum adjuvant; 0.5 mL intramuscular injection at 0 and 28 days
89494502|NCT03545789|Experimental|[18F]MNI-958|To measure blood metabolites of [18F]MNI-958 and perform kinetic modeling to assess its ability to measure tau protein in brain using the tracer plasma concentration or a reference region as indirect input.
89494503|NCT05548322|Experimental|Study of tactile afferent responses to natural surfaces|
89494504|NCT05548322|Experimental|Modulation of touch according to the emotional state|
89494505|NCT05548322|Experimental|Effect of temperature on tactile sensitivity|
89494506|NCT05548322|Experimental|Origin of wetness perception|
89494507|NCT05548322|Experimental|Aging and tactile sensitivity|
89494508|NCT05548322|Experimental|Tactile perceptions induced by the stimulation of single sensory fibers|
89494509|NCT05548322|Experimental|Study of tactile feedback after amputation|
89494510|NCT04428086|Experimental|Assess PK effects of Apatinib on Rosuvastatin|Participant will be administered a single oral dose of rosuvastatin 10 milligram (mg) on Day 1 and Day 7 and Apatinib at a dose of 250 mg once daily from Day 4 until Day 9.
89494511|NCT04428086|Experimental|Assess PK effects of Apatinib on Metformin|Participant will be administered a single oral dose of metformin 500 milligram (mg) on Day 1 and Day 6 and Apatinib at a dose of 250 mg once daily from Day 3 until Day 7.
89494512|NCT05548166||Pediatric Patients|Pediatric patients with celiac disease.
89494513|NCT05548166||Caregivers and parents|Caregivers and parents of pediatric patients with celiac disease
89494514|NCT05548166||Experts|Group of experts in pediatric celiac disease to provide feedback on scale development.
89494515|NCT03929549|Experimental|RCMP titration|Remotely Controlled Mandibular Positioner
89494516|NCT04355858|Experimental|NF1 mutated|If a patient were NF1 mutated, she would receive SHR7390(MEK1/2 inhibitor) and Faminitib.
89494517|NCT04355858|Experimental|gBRCA mutated|If a patient were gBRCA mutated, she would receive SHR3162 (PARP inhibitor)and SHR6390(CDK4/6 inhibitor) .
89494518|NCT04355858|Experimental|HER2 activated mutated|If a patient were HER2 activated mutated and had not previously used capecitabine, she would receive Pyrotinib and Capecitabine , while if the patient have previously used capecitabine, she would only use pyrotinib as a single agent.
89494519|NCT04355858|Experimental|PDGFRb mutated|If a patient were PDGFRb mutated, she would receive Faminitib.
89022539|NCT01055639|Experimental|Telehealth ACT|8 individual telehealth sessions of Acceptance and Commitment Therapy (ACT). Sessions were delivered via videoconferencing system. ACT is a psychotherapy intervention comprised of meditation, goal-setting, and behavior change.
89022540|NCT00460668|Experimental|Pulmonary rehabilitation post-thoracotomy|Pulmonary rehabilitation post-thoracotomy
89022541|NCT00460668|No Intervention|Control|Control
89022542|NCT04704713|Experimental|Afamelanotide|Afamelanotide implants were administered on Days 0 and 60. Patients returned to the clinic on Day 120 for the final visit.
89204976|NCT00768755|Experimental|II|Axitinib (modified) + Pemetrexed(500mg/m2)/Cisplatin(75mg/m2) x max 6 cycles followed by axitinib maintenance
89494520|NCT04355858|Experimental|CD8 ≥10%|In the arm which IHC showed CD8 ≥10%, this arm will be subdivided into 6 sub-arms, in which Arm 5A-4D, we choose the patients who had CDK4/6 inhibitor before while in Arm 5E, we choose the patients who secondarily resistant to adjuvant endocrine therapy , and in Arm 5FF, we choose the patients who is in stage IV without precious treatment or sensitively recurrence. A patient would receive SHR1210(PD-1 antibody) ,nab-paclitaxel and Faminitib in Arm-5A. A patient would receive SHR1210(PD-1 antibody) and VEGF inhibitor in Arm-5B. A patient would receive SHR1701(PD-L1/TGF-βRII inhibitor) in Arm-5C. A patient would receive SHR1701(PD-L1/TGF-βRII inhibitor) and SHR6390(CDK4/6 inhibitor) in Arm-5D. A patient would receive SHR1210(PD-1 antibody) and SHR6390(CDK4/6 inhibitor) and SERD in Arm-5E. A patient would receive SHR1210(PD-1 antibody) and SHR6390(CDK4/6 inhibitor) and AI in Arm-5F.
89494521|NCT04355858|Experimental|PAM pathway mutated|If a patient had any PAM pathway mutation, she would receive Everolimus(mTOR inhibitor) combined with nab-paclitaxel.
89494522|NCT04355858|Experimental|AR≥10%|If a patient's IHC showed AR≥10% , she would receive SHR2554(EZH2 inhibitor) and SHR3680(AR inhibitor).
89494523|NCT04355858|Experimental|Epigenetic Cohort|In this cohort, a patient would receive SHR2554(EZH2 inhibitor) and SHR3162 (PARP inhibitor).
89494524|NCT04355858|Experimental|Combined Immunity Cohort|In this cohort, a patient would receive SHR6390(CDK4/6 inhibitor) combined with SHR1701(anti-PD-L1/TGF-βRII bifunctional fusion protein) .
89494525|NCT03917225|Experimental|MIN-102|MIN-102 (5-[[4-[2-[5-(1-Hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]-2,4-thiazolidinedione hydrochloride (1:1)). Dosing is once daily at approximately the same time each morning throughout the entire treatment phase (48 weeks).
89494526|NCT03917225|Placebo Comparator|Placebo|Matches MIN-102 visually and by taste. Dosing is once daily at approximately the same time each morning throughout the entire treatment phase (48 weeks).
89494527|NCT05548088|Experimental|LILRB4 STAR-T cells|LILRB4 STAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of STAR-T cells, subjects receive fludarabine at dose 25-30mg/m2/day and cyclophosphamide treatment at dose 250-300mg/m2 for 3 days and take a rest for 2 days before infusion. STAR-T cells will be intravenously infused with a escalated dose of 1E6#3E6#6E6#1E7 cells/kg.
89494528|NCT03913013|Experimental|FFT with MCC App (FFT-MCC)|Youth in this study arm will receive 12 sessions of FFT (psychoeducation, communication skills training, and problem-solving skills training) with their parents and siblings. They and their parents will make regular mobile app ratings of mood, sleep, family functioning, stress, and perceived criticism. Children and parents will call into a voice-activated phone system and be asked to speak freely for 3-5 minutes about their health and family functioning. They will be guided through 12 lesson plans in which they practice skills such as active listening or identifying prodromal signs of episodes, paralleling what they are learning in sessions. The clinician will be able to set a weekly skill training assignment and observe the family's practice of the skill between sessions. They will adapt session content accordingly.
89494529|NCT03913013|Active Comparator|FFT with App Assessments only (FFT-Assess)|Youth in this condition will receive the same 12 sessions of FFT, but the app will be limited to daily and weekly assessments of their mood, sleep, stress, and family functioning. The app will not provide the skill training offered in the FFT-MCC condition.
89494530|NCT05700500|Experimental|shockwave therapy|The calcification will be located by ultrasound and the energy will be applied in the precise place. 3 sessions will be carried out as follows: 1, 2, 3 weeks This procedure will be carried out by a single experienced Physical and Rehabilitation medical doctor
89022543|NCT04704713|Placebo Comparator|Placebo|Placebo implants were administered on Days 0 and 60. Patients returned to the clinic on Day 120 for the final visit.
89494531|NCT05700500|Experimental|Ultrasound-Guided Barbotage|The calcification will be located by ultrasound. By injecting serum at high pressure, it is intended to wash away the calcification. A subacromial inyection will be associated with this procedure. A maximum of 3 Ultrasound-Guided Barbotage will be performed with an interval of 6 weeks between each puncture. This procedure will be performed by two experienced radiologists
89494532|NCT05700500|Experimental|us guided subacromial injections|An US guided subacromial injection (1 cc of corticostheroid ) and anesthetic (2 cc of mepivacaine) will be performed. The periodicity will be one infiltration every 8-10 weeks, being able to carry out a maximum of 3 per year.
89494533|NCT03894995|No Intervention|Part 1. Focus group discussions on ventilation preferences|Participant's perceived benefits/detriments of having ventilation options in the household and their opinions on the behavior change material developed to encourage increased household ventilation will be explored using 6-9 focus group discussions with 10-12 participants each.
89494534|NCT03894995|No Intervention|Part 2. PM 2.5 pilot|Indoor, outdoor, and personal particulate matter concentrations among ten mother-child pairs and their homes will be monitored.
89494535|NCT03894995|Experimental|Part 3. Intervention|Households will participate in a baseline survey and a Beck-DeGroot-Marshak auction to establish willingness-to-pay for ventilation. If the household wins, or if it is decided to install ventilation in all intervention households, the household will receive installation of a ventilating mechanism.
89494536|NCT03894995|No Intervention|Part 3. Control|For 12 month after intervention, the air exchange rate will be measured in all control households.
89494537|NCT03894995|No Intervention|Part 4. Spillover|Households that neighbor enrolled study households will be surveyed and asked whether they, on their own, chose to install a window. If they did install a window, they will be asked how much they paid.
89494538|NCT05553782|Experimental|IMD PLACEMENT + SURGICAL RESECTION + ADJUVANT TREATMENT ARM|"Newly diagnosed, localized ACC salivary cancers undergoing surgical resection~Interventional radiology guided IMD placement~Planned oncologic resection with IMD retrieval 3-5 days after placement~Standard of care adjuvant treatment~Tumor specimen analysis for local drug response and molecular analysis"
89494539|NCT03890627||Thoracic bio-reactance measurement of cardiac output|
89494540|NCT05553626|Experimental|LBBP Treatment|Patients were performed left bundle branch pacing by a single/dual chamber pacemaker or dual chamber ICD device
89494541|NCT05553626|Active Comparator|BVP Treatment|Patients were performed bi-ventricular pacing by a CRT/CRTD device
89494542|NCT05553548|Experimental|biologically oriented alveolar ridge preservation (BARP) group|for alveolar ridge preservation using demineralized bovine bone graft layer in the most coronal part of the extracted tooth socket
88954627|NCT01974193|Experimental|Floseal|application of floseal to one side of pelvis after pelvic lymphadenectomy
88954628|NCT01974193|No Intervention|Control|counter-site of pelvis; no intervention after pelvic lymphadenectomy
88954629|NCT01974219||Healthy nonsmokers|Healthy nonsmokers
88954630|NCT01974219||Healthy smokers|Healthy smokers
88954631|NCT01974219||COPD smokers|COPD smokers
88954632|NCT01974232||Romiplostim group|
88954633|NCT01974232||Eltrombopag group|
88954634|NCT01974258|Experimental|Dose-expansion: onartuzumab + cobimetinib|
89204977|NCT00768755|Active Comparator|III|pemetrexed and cisplatin
89494543|NCT05553548|Active Comparator|bone graft (entire apico-coronal extension)|alveolar ridge preservation using demineralized bovine bone graft on the entire apico-coronal extension.
89494544|NCT05610956|Placebo Comparator|placebo group|Patients will receive conventional treatment only (corticosteroids +immune suppressive +amino salicylic acid) for 4 months.
89494545|NCT05610956|Experimental|empagliflozin group|Patients will receive conventional treatment (corticosteroids +immune suppressive + aminosalicylic acid) and empagliflozin (0.4 - 0.5mg/kg/day) orally (maximum dose 25mg per day)for 4months.
88954635|NCT01974258|Experimental|Dose-expansion: onartuzumab + vemurafenib|
88954636|NCT01974258|Experimental|Dose-expansion: onartuzumab + vemurafenib + cobimetinib|
88954637|NCT01974258|Experimental|Dose-finding: onartuzumab + vemurafenib + cobimetinib|
88954638|NCT01974271||Cohort|
88954639|NCT01974297|Active Comparator|Atorvastatin 20mg, monotherapy|Atorvastatin 20mg/day PO for 12weeks
88954640|NCT01974297|Experimental|Atorvastatin 10mg, Fenofibric acid 135mg|Atorvastatin 10mg, Fenofibric acid 135mg per day PO for 12weeks
88954641|NCT01974310|Active Comparator|Face-down positioning|Patients advised face-down positioning after surgery for macular hole.
88954642|NCT01974310|Experimental|Non-face-down positioning|Patients advised non-face-down positioning after surgery for macular hole.
88954643|NCT01974336|Experimental|UDCA+placebo group|15-30mg/kg/d UDCA for 2 months + placebo for 2 months
88954644|NCT01974336|Experimental|placebo+UDCA|placebo for 2 months+15-30mg/kg/d UDCA for 2 months
88954645|NCT01974349|Experimental|selumetinib 75mg (oral capsule fasted)|Volunteers will recieve selumetinib 75mg administered by mouth, as a capsule, in a fasted state.
89204978|NCT00768755|Experimental|IV|Axitinib interrupted before each chemo cycle (Pemetrexed(500mg/m2)/Cisplatin(75mg/m2) x max 6 cycles followed by axitinib maintenance
89022544|NCT02957513|Experimental|Text Messaging (TM)|The TM intervention will use an extensive text message library focused on 3 key behavioral areas (diet, exercise, and medication adherence). The TM intervention will incorporate supportive cognitive behavioral strategies such as goal setting, positive reinforcement, self-talk and dealing with barriers to change. Messages will encourage social interaction (social support, problem-solving, and feedback), self-monitoring of diet and exercise, diet modification, physical activity advice and prompting and basic self- regulatory skills. Messages will be tailored based on participant demographics, health literacy, and preferences.
89022545|NCT02957513|Experimental|Health Coaching (HC)|The HC intervention will place emphasis on the coach establishing rapport with the participant and assessing and establishing their initial goals using motivational interviewing, HC program goals, plans for future individual sessions. A written copy of personal health goals will be given to patients at the end of the first session. Coaches will aim to meet with participants for individual HC sessions bi-monthly the first 2-3 months followed by monthly for 8 - 9 months to provide information and support regarding health habits focusing sessions on areas related to patient-identified health goals, needs, and barriers to change. Sessions can occur in person or by phone based on patient preference.
89204979|NCT00768755|Active Comparator|V|pemetrexed and cisplatin
89204980|NCT05734222|Active Comparator|Control Group|The control group is retrospective. It will include patients who have been operated on for POVG in the surgical department No. 1 of the KPH during the last 3 years (25-35) and 5-10 patients who will be operated on within the next 6-8 months.
89494546|NCT00109733|Experimental|Standard dose group|0.005 mg/kg/day recombinant human growth hormone (r-hGH) for 30 days then increasing, with the Investigator's approval, to 0.010 mg/kg/day from Day 31 to Week 24.
89494547|NCT00109733|Experimental|High dose group|0.010 mg/kg/day recombinant human growth hormone for 14 days with the opportunity to dose escalate, with the Investigator's approval, on Day 15 to 0.02 mg/kg/day and Day 29 to 0.03 mg/kg/day.
89204981|NCT05734222|Experimental|Established group|The established group - patients who will be operated on in the surgical department No. 1 of the KPH over the next 1.5 - 2 years, using the developed techniques.
89204982|NCT01005628||001|bortezomib Injection into a vein 1.3 mg/m2 twice a week for 21 days
89204983|NCT01005784|Active Comparator|fixed|
89494548|NCT05699876|Experimental|Melatonin|
89494549|NCT05699876|Active Comparator|Gabapentin|
89494550|NCT05610878|Experimental|Cultured ASCs enrichment fat grafting|Fat graft will be supplemented with naïve ASCs
89494551|NCT05610878|Experimental|Curcumin-preconditioned ASCs enrichment fat grafting|Fat graft will be augmented with curcumin preconditioned ASCs
89494552|NCT05610878|Active Comparator|conventional fat grafting|Fat graft will not be supplemented with ex-vivo expanded ASCs
89494553|NCT02706405|Experimental|Group I (JCAR014, durvalumab) Early - Dose Level 2|"Patients receive JCAR014 IV over 20-30 minutes on day 0 and durvalumab IV over 60 minutes on day 21 (may occur as early as day 7) and then every 4 weeks for up to 10 doses in the absence of disease progression or unacceptable toxicity.~Group 1 - early: start durvalumab no earlier than 7 days after JCAR014.~Group 1 Dose Level 2 is 750 mg Durvalumab, up to 2 x 106/kg CAR T cells"
89494554|NCT02706405|Experimental|Group I (JCAR014, durvalumab) Late- Dose Level 1|"Patients receive JCAR014 IV over 20-30 minutes on day 0 and durvalumab IV over 60 minutes on day 21 (may occur as early as day 7) and then every 4 weeks for up to 10 doses in the absence of disease progression or unacceptable toxicity.~Group 1 - late: start durvalumab no earlier than 21 days after JCAR014~Group 1 Dose Level 1 is 225 mg Durvalumab, up to 2 x 106/kg CAR T cells~."
89494555|NCT02706405|Experimental|Group I (JCAR014, durvalumab) Late - Dose Level 2|"Patients receive JCAR014 IV over 20-30 minutes on day 0 and durvalumab IV over 60 minutes on day 21 (may occur as early as day 7) and then every 4 weeks for up to 10 doses in the absence of disease progression or unacceptable toxicity.~Group 1 - late: start durvalumab no earlier than 21 days after JCAR014~Group 1 Dose Level 2 is 750 mg Durvalumab, up to 2 x 106/kg CAR T cells"
89494556|NCT02706405|Experimental|Group II (durvalumab, JCAR014) - Dose Level 1|"Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.~Group 2 Dose Level 1 is 7.5 mg Durvalumab, up to 2 x 106/kg CAR T cells"
89494557|NCT02706405|Experimental|Group II (durvalumab, JCAR014) - Dose Level 2|"Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.~Group 2 Dose Level 2 is 22.5 mg Durvalumab, up to 2 x 106/kg CAR T cells"
89494558|NCT02706405|Experimental|Group II (durvalumab, JCAR014) - Dose Level 3|"Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.~Group 2 Dose Level 3 is 75 mg Durvalumab, up to 2 x 106/kg CAR T cells"
89494559|NCT02706405|Experimental|Group II (durvalumab, JCAR014) - Dose Level 4|"Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.~Group 2 Dose Level 4 is 225 mg Durvalumab, up to 2 x 106/kg CAR T cells"
89494560|NCT02706405|Experimental|Group II (durvalumab, JCAR014) - Dose Level 5|"Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.~Group 2 Dose Level 5 is 750 mg Durvalumab, up to 2 x 106/kg CAR T cells"
89494561|NCT04857359|Experimental|Dipraglurant TID|
89494562|NCT04857359|Placebo Comparator|Placebo TID|
88954646|NCT01974349|Experimental|selumetinib 75mg (oral capusle fed)|Volunteers will receive selumetinib 75mg administered by mouth, as a capsule, in a fed state.
88954647|NCT01974375|Experimental|micafungin|micafungin sodium IV (Mycamine®)
88954648|NCT01974375|Active Comparator|Fluconazole|Fluconazole IV (use same brand in each hospital)
88954649|NCT01974388|Active Comparator|LSG started 2 cm from the pylorus|laparoscopic sleeve gastrectomy starting 2 cm from the pylorus
88954650|NCT01974388|Active Comparator|LSG started 6 cm from pylorus|LSG started 6 cm from pylorus
89494563|NCT02761993|Active Comparator|Group 1|Group 1 received ST266 treatment daily on Days 1 through 5, 8 through 12, 22, and 30, and then monthly for 7 months (Days 60, 90, 120, 150, 180, 210, and 240).
89494564|NCT02761993|Active Comparator|Group 2|Group 2 received ST266 treatment 2x/week (with at least 1 day between treatments) for the first 3 months, and then monthly for 5 months (Days 120, 150, 180, 210, and 240).
89494565|NCT02761993|Placebo Comparator|Group 3|Group 3 received commercially available sterile saline (0.9% sodium chloride) according to the same schedule as Group 1.
89494566|NCT05547776|Experimental|Arms and Interventions|"Mindfulness App Use~Participants will have the opportunity to use the mindfulness app for four weeks."
89494567|NCT04425980|Experimental|Modified Constraint-Induced Movement Therapy (test treatments)|A list of fine and motor activities consisted of the functional tasks or play activities such as school-education and sports activities, manipulative games, arts, and crafts, etc. to elicit the maximum capacity of the more affected upper limb was created according to the procedure of modified constraint-induced movement therapy (Gordon et al., 2005) and Bimanual training. In addition, specific activities were also chosen in terms of deficit of interest, participant preference (on the condition of having potential effects on hand skills) and parent/guardian, or their teacher's request. In case of activities requiring both hand use, such as stabilizing paper during the painting or holding the bricks of lego on the ground, the treating physiotherapist undertook a role as a dominant hand
89494568|NCT04425980|Active Comparator|Bimanual training|For the Bimanual training, skilled, repetitive, and structured bimanual activities (part or whole task practice) were used to promote bimanual hand use and improve movement deficits determined before the intervention. All targeted deficits of interest were addressed within the context of the selected activity. Specifically, symmetrical bilateral movements were utilized to augment neural input from both sides. Also, meaningful activities such as buttoning and zipping-up trousers, etc. were used to ensure a transition from structured setting to real-life activities
89494569|NCT05114759|Experimental|SHR-A2009 for Injection will be administrated per dose level in which the patients are assigned.|
89494570|NCT05553158|Active Comparator|Pelvic Vein Embolization (PVE)|Patients will have their pelvic veins embolized in accordance with their personalised treatment plan, based on their trans-vaginal ultrasound scan. These patients form the control group.
89494571|NCT05553158|Experimental|Compression Therapy|Patients will wear compression pants (with leg compression if patients also have symptomatic leg varicose veins).
89494572|NCT04193150||Reassessment Cohort|"150 invited participants in active treatment with high-dose inhaled corticosteroids plus second controller as per NICE guidelines, without active treatment from a pulmonologist.~Intervention includes:~Extensive pulmonary and allergy assessments. Questionnaires, FeNO-measurement, Skin prick-test, Spirometry, Blood sampling, Body Plethysmography and Diffusion capacity measurement, Bronchial challenge test, Induced sputum.~Treatment optimization As per GINA and Nordic Severe Asthma Network guidelines. Treatment can either be stepped up (e.g. added biological treatment), stepped down or held constant.~Treatment is then monitored with regard to symptoms and socioeconomical parameteres such as sick leave over a 12 month period using questionnaires and official databases."
89494573|NCT04193150||Control Cohort|"400 invited participants in active treatment with high-dose inhaled corticosteroids plus second controller as per NICE guidelines, without active treatment from a pulmonologist.~The control cohort is followed for 12 months using questionnaires and official databases with regard to disease control and socioeconomic parameteres such as sick leave."
89494574|NCT02425839|Experimental|Experimental group|"ultrasound exam by Supersonic Shear Imaging® technique~EMG examination by electromyograph Keypoint system."
88954651|NCT01974401|Active Comparator|water jet irrigator|patients used supra-gingival irrigators as an oral health measure
88954652|NCT01974401|No Intervention|control group|patients in this group received routine oral health care protocols.
88954653|NCT01974414|Active Comparator|cedar honey|The two study groups were provided with standard treatment(dexamethasone and Fluconazole).The Case group(A) received cedar honey, 20 ml 3 times daily by swish and swallow technique, in addition to the standard treatment .
88954654|NCT01974414|No Intervention|control group|the control group (B) only received standard treatment(Dexametazone and Fluconazole).
88954655|NCT01974453||Right transradial|Procedures performed through right transradial approach
88954656|NCT01974453||Left transradial|Procedures performed through left transradial approach
89204984|NCT01005784|Experimental|flexible|
89494575|NCT03546257||EUS|group using conventional WLE and EUS
89494576|NCT03546257||ME-NBI|group using WLE and ME-NBI.
89494577|NCT05553002|Experimental|Deneroll cervical extension traction|The study group will receive 3-point bending cervical extension traction following the protocol of Deed Harrison . The duration of each session will start at approximately three minutes and increased one minute per session until reaching the goal of 20 minutes per session
89494578|NCT05553002|Active Comparator|Traditional treatment|The participants will receive hot packs (15 minutes) and TENS therapy to control pain and eliminate the causal role of muscle spasms and/or tightness in changing the posture parameters.
89494579|NCT02423421|Active Comparator|Treatment group|The treatment group will have faecal microbiota transplantation performed using stool from a healthy human donor
89494580|NCT02423421|Placebo Comparator|Placebo group|The placebo group will have autologous faecal microbiota transplantation performed.
89494581|NCT03183219|Experimental|Group A|In this group, the patients will receive under CT Cryosurgery or IRE surgery to control the local tumor.
89494582|NCT03183219|Experimental|Group B|In this group, the patients will receive multiple high-activity γδ T cell immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
89494583|NCT03183219|Experimental|Group C|In this group, the patients will receive multiple high-activity γδ T cell immunotherapies and Cryosurgery or IRE surgery
89494584|NCT03545711|Experimental|Anlotinib plus Irinotecan|
89494585|NCT05552846|Experimental|experimental group|chemo-immunotherapy followed by thoracic radiotherapy and PD-1/PD-L1 maintenance therapy
89494586|NCT03546959|Experimental|Lycra sleeve after botulinum toxin|8 hours a day lycra sleeve wear plus rehabilitation (for five days a week for three weeks) after botulinum toxin injection for post-stroke spasticity
89494587|NCT03546959|Active Comparator|Rehabilitation after botulinum toxin|Rehabilitation (five days a week for three weeks) after botulinum toxin injection for post-stroke spasticity
89494588|NCT04164836|No Intervention|control group|nose selection will be done by random table
89494589|NCT04164836|Experimental|rhinoscope group|nose selection will be done by rhinoscopy
89494590|NCT03791645|Experimental|SKY Intervention|Participants in the intervention group will get to participate in the SKY program, for 5 days with each day session taking 3 hours/day. SKY program involves a) specific breathing exercises and social interaction with other participants in the program. Following completion of the program, another set of questionnaires will be administered to collect information regarding stress, mood, and opioid use. After completion of the 5 day SKY program, participants will practice SKY every day at home for 30 days. They will also need to attend 4 weekly group sessions during this period and each session is expected to last 1 hour. At the end of the 30 day period, another set of questionnaires will be administered to collect information regarding stress, mood, and opioid use.
89494591|NCT03791645|No Intervention|Usual treatment|Participants assigned to the control group will not have access to the SKY program but will continue with usual care. They will also complete questions after 5 days and again after 30 days.
89494592|NCT05552768|Active Comparator|Bone level-driven placement (BL Group)|Implants will be placed at the bone level, they will receive a 1.5-2 mm long CONNECT abutment.
89494593|NCT05552768|Experimental|Biological width-driven placement guidelines (BW Group)|Implants will be placed 4 mm below the mucosal margin using a 2-3 mm long CONNECT abutment.
89494594|NCT01569659|Active Comparator|Standard dose of lurasidone|
89494595|NCT01569659|Experimental|High dose of lurasidone|
89494596|NCT02423187||Arm 1|Participants with combination therapy (rabeprazole and low-dose aspirin)
89494597|NCT04111406|Other|Current practice|Epidural insertion and epidural drug administration depend on anesthetist in charge
89494598|NCT04111406|Experimental|Protocol based|Epidural insertion and epidural drug administration depend on anesthetist in research team using protocol based
88954657|NCT01974453||Femoral|Procedures performed through transfemoral approach
88954658|NCT01974466|Active Comparator|Goal A|"controled fluid therapy: 5~10ml/kg/hr fulfillment of two or more of four criteria:~heart rate <120 beats/min,~mean arterial blood pressure 65-85 mm Hg,~urine output ≥1 ml/kg /h~Hematocrit ≤35%."
88954659|NCT01974466|Other|Goal B|"controled fluid therapy: 5~10ml/kg/hr fulfillment of all of the following criteria:~1 central venous pressure8-12 mmHg , 2.mean arterial pressure 65-85 mm Hg, 3. urine output ≥0.5 ml/kg/h 4. ScvO2 ≤70%"
88954660|NCT01974479|Experimental|anti-CD19 redirected NK cells|This is a single arm study. Intravenous Infusion of activated NK cells bearing anti-CD19-BB-zeta receptors at cell dose of 0.5 - 5 x 10^7 CD56+ cells/kg, and up to 1 x 10^8 CD56+ cells/Kg
88954661|NCT01974492|Active Comparator|Upper leg vein|Upper leg vein harvesting
88954662|NCT01974492|Active Comparator|Lower leg vein|Lower leg vein harvesting
89494599|NCT03183453|Experimental|Neuropsychological treatment|The tested treatment is a combination of neuropsychological rehabilitation procedures: learning, episodic memory recall after a delay, selective attention, inhibition of predominant responses and awareness of deficits.
89494600|NCT03183453|No Intervention|Non-confabulators control group|Non-confabulators (brain injured patients but without confabulations) in this control group only performed the pre- and post-measurements without treatment.
89494601|NCT03183453|No Intervention|Healthy control group|Healthy participants in this control group only performed the pre- and post-measurements without treatment.
89494602|NCT05547308|Experimental|Prosthetic device|All subjects will receive the 3D myoelectric prosthetic device
89494603|NCT02253953|Experimental|D1|
89494604|NCT02253953|Experimental|D2|
89494605|NCT02253953|Experimental|D3|
89494606|NCT02253953|Experimental|D4|
89494607|NCT02253953|Experimental|D5|
89494608|NCT02253953|Experimental|D6|
89494609|NCT02253953|Experimental|D7|
89494610|NCT02253953|Experimental|D8|
89494611|NCT02253953|Experimental|D10|
89494612|NCT02253953|Placebo Comparator|Placebo|for D3 - D10
89494613|NCT05547230||teachers|4 basic components will be examined posture analysis body awareness work motivation quality of life
89494614|NCT03546803||Cohort A|Head and Neck Patients; Photon or Proton Treatment with product
88954663|NCT01974505|Experimental|intubation using optiscope|The investigators are novice on optiscope. They will perform intubation using optiscope to patients scheduled elective surgery.
88954664|NCT01974518|Active Comparator|Rituximab|Inj Rituximab 1 gram IV given on day 0 and day 15
89494615|NCT03546803||Cohort B|Hair/skin fold areas (Axilla, Groin, Perineum); Photon or Proton Treatment with product
89494616|NCT03546803||Cohort C|Misc. (per Rad Onc Physician); Photon or Proton Therapy with routine skin care
89494617|NCT02422953|Experimental|Intervention|Wheat Soya Blend, Wawa Mum, Micronutrient Powders, Behavior change and preventive health massages
89494618|NCT02422953|No Intervention|Control|Control group will receive routine public and private health services available in the area.
89494619|NCT02766283||Iodinated contrast agents|children age 0-3 years (inclusive), who underwent a iodine contrast enhanced radiological examination.
89494620|NCT05547152|Experimental|Experimental arm|patients benefiting from rehabilitation associated with virtual reality
89494621|NCT05547152|Active Comparator|Control arm|patients benefiting from rehabilitation without virtual reality
89494622|NCT04597541|Experimental|1|AK112
89494623|NCT03182985|Experimental|Time Restricted Feeding|Patients will reduce daily oral intake to 10 hours per day
88954665|NCT01974518|Active Comparator|Combination of Rituximab and Cyclophosphamide IV|IV Rituximab 1gram on day 0 and 15 750 mg IV cyclophosphamide in 250 ml of NS over 2-3 hr on day 1 and day 16
88954666|NCT01974544|Experimental|Best medical treatment|Fifty obese patients with kidney damage or high risk of kidney damage secondary to T2DM will will be treated using the American Diabetes Association protocol. Also this arm will be treated like: General interventions for all groups: blood presure, General interventions for all groups: dysilipidemia and General interventions for all groups: lifestyle establishes.
89494624|NCT03118089|Experimental|Biscuit style oral nutritional supplement treatment|Participants will take the biscuit style oral nutritional supplement at an intervention level equivalent to their current oral nutritional supplement prescription
89494625|NCT03118089|No Intervention|Standard Care|Participants will remain on their current oral nutritional supplement
89494626|NCT03106935|Active Comparator|Obstet Gynecol,SecondSoochowU|Levothyroxine is an orodispersible tablet.For the LT4 treatment group, 50μg LT4 (Merck Serono, Geneva,Switzerland) was administered every morning from the first day of diagnosed as subclinical hypothyroidism and continued up to the day of serum β-HCG measurement.If pregnancy was confirmed, levothyroxine dose need to increase 25-30% and adjusted according to the pregnancy specific reference range ( T1 0.1-2.5mIU/L,T2 0.2-3.0mIU/L, T3 0.3-3.0mIU/L) .
89494627|NCT03106935|No Intervention|reproductive center,SecondSoochowU|For the control group ,women with subclinical hypothyroidism are not given any drugs .
89494628|NCT03106857|Placebo Comparator|Group A|Physical activity, a low caloric diet, and the routine standard care for constipation
89494629|NCT03106857|No Intervention|Group B|No intervention
89494630|NCT02422407||Subgroup 1|Healthy Volunteers - subset of which 10 will receive salivary gland biopsy.
89494631|NCT02422407||Subgroup 2|Diagnosis of pSS based on the criteria of the American-European Consensus Criteria for Sjögren's Syndrome (AECCSS) with positive biopsy result.
89204985|NCT05734144|Active Comparator|"Laparo-endoscopic rendezvous technique"|the first group was treated by a single-step procedure combining LC and IOES
89494632|NCT02422407||Subgroup 3|Diagnosis of pSS based on the criteria of the American-European Consensus Criteria for Sjögren's Syndrome (AECCSS) with negative biopsy result.
89494633|NCT02422407||Subgroup 4|Presenting with sicca but not satisfying the criteria of the AECCSS for diagnosis of pSS.
89494634|NCT03985904|Experimental|Art Therapy|Participants will attend art therapy group sessions for three months in a designated museum.
89494635|NCT03107169|Active Comparator|Vancomycin|Patients in this arm received vancomycin 250mg every 6 hrs for 10-14 days
89494636|NCT03107169|Experimental|FMT-FURM|Patients in this arm receive FMT-FURM
89494637|NCT05552300|Experimental|Superselective adrenal arterial embolization|"Selectively injects ethanol into adrenal artery to ablate part of the adrenal gland~Interventions:~Procedure: superselective adrenal arterial embolization Drug: traditional triple antihypertensive treatment"
89494638|NCT05552300|Active Comparator|Traditional triple antihypertensive treatment|No intervention, but treated with traditional triple antihypertensive treatment
89494639|NCT02425683|Experimental|Regorafenib|Regorafenib 120 or 160 mg by mouth every day for the first 21 days of each 28-day cycle. If the dose is tolerated during the first 2 cycles in the 120 mg group, in Cycle 3 the 120 mg dose will be increased to 160 mg by mouth each day for the first 21 days of each 28-day cycle for 4 more cycles for a total of 6 cycles or 6 months of therapy.
89494640|NCT02425683|No Intervention|Standard of Care (No Treatment)|No study drug (which is the standard care for Stage IIIC colorectal cancer patients after they've received FOLFOX chemotherapy).
89494641|NCT05547074||The training cohort|To develop the prognostic model, 302 cases of postoperative PDAC were included in the final analysis and divided into the training and validation cohort by stratified sampling with 7:3 ratio (The training cohort: n=212; The validation cohort: n=90).
89494642|NCT05547074||The validation cohort|To develop the prognostic model, 302 cases of postoperative PDAC were included in the final analysis and divided into the training and validation cohort by stratified sampling with 7:3 ratio (The training cohort: n=212; The validation cohort: n=90).
88954667|NCT01974544|Experimental|gastric bypass surgery|Fifty obese patients with kidney damage or high risk of kidney damage secondary to T2DM will undergo gastric bypass surgery, in the conventional procedure. Also this arm will be treated like: General interventions for all groups: blood presure, General interventions for all groups: dysilipidemia and General interventions for all groups: lifestyle establishes.
88954668|NCT01974544|Experimental|sleeve gastrectomy|Fifty obese patients with kidney damage or high risk of kidney damage secondary to T2DM will undergo sleeve gastrectomy surgery, in the conventional procedure. Also this arm will be treated like: General interventions for all groups: blood presure, General interventions for all groups: dysilipidemia and General interventions for all groups: lifestyle establishes.
88954669|NCT01974570|Experimental|Marealis refined peptide concentrate|Participants are provided in double blinded fashion to Marealis refined peptide concentrate
88954670|NCT01974570|Placebo Comparator|Placebo|Participants are provided in double blinded fashion to Placebo
88954671|NCT01974583||the treatment group A|The people in treatment group were regrafted with thin split-thickness skin graft
88954672|NCT01974583||the control group B|The group B covered with the occlusive hydrocellular dressing (Allevyn Adhesive, Smith & Nephew)
88954673|NCT01974583||the control group C|Group C were covered with paraffin gauze
88954674|NCT01974596|Experimental|Probiotic Lactobacillus reuteri Vs Placebo|patients with full arch with dental implant received a tablet of Lactobacillus reuteri every day during 28 days, and after a wash-up, the same patients receive a tablet of placebo every day during 28 days
88954675|NCT01974622|Experimental|Visudyne|Visudyne half fluence- 1 treatment with the possibility of a second treatment.
88954676|NCT01974648|Active Comparator|propofol|In control group, propofol concentrations will start at 4 μg ml-1, with 0,5 μg ml-1 as the step size, with the coadministration of saline.
88954677|NCT01974648|Experimental|propofol and remifentanil|In propofol-remifentanil group, propofol + remifentanil at a target-controlled infusion 5 ng/mL will be coadministered.
88954678|NCT01974661|Experimental|COMBIG-DC|COMBIG-DC (allogeneic dendritic cells) Cancer Vaccine 3 vaccinations: 5, 10 or 20 million cells per injection
88954679|NCT01974674|Experimental|Allogeneic transplantation of intrahepatic islet|Allogeneic transplantation of intrahepatic islet number required for insulin independence of obtaining, with a threshold dose of 9,000 IEQ/kg body weight of the recipient and a maximum sequence number of 3 infusions. The patient will receive after transplantation immunosuppressive therapy with Thymoglobulin for induction, Prograf and Cellcept, both of which are given throughout the duration of the study
88954680|NCT01974726|Other|affected, intact tympanic membranes|History of middle-ear disease, ears with no holes/perforations/patent tympanostomy tubes in eardrum
88954681|NCT01974726|Other|affected, non-intact tympanic membranes|History of middle-ear disease, ears with hole/perforation/patent tympanostomy tube in eardrum
88954682|NCT01974726|Other|controls, intact tympanic membranes|No history of middle-ear disease, ears with no hole/perforation/patent tympanostomy tube in eardrum
88954683|NCT01974726|Other|controls, non-intact tympanic membranes|No history of middle-ear disease, ears with hole/perforation/patent tympanostomy tube in eardrum
88954684|NCT01974739|Active Comparator|hydrochloorthiazide|once a day 25 mg
88954685|NCT01974739|Placebo Comparator|placebo|once a day placebo
88954686|NCT01974778|Experimental|Active|Meal
88954687|NCT01974778|Placebo Comparator|Control|Water
88954688|NCT01974791|Experimental|GET Living Treatment|
88954689|NCT01974830||Adult Alpha-1 Patients|Adult Alpha-1 patients receiving augmentation therapy in the home through Coram
88954690|NCT01974843||Group BT|Bupivacaine-tramadol (BT) group received a caudal injection of bupivacaine 0.25% plus tramadol 2 mg/kg
88954691|NCT01974843||Group LT|Levobupivacaine-tramadol (LT) group received a caudal injection of levobupivacaine 0.25% plus tramadol 2 mg/kg, resulting in a total volume of 1 ml/kg.
88954692|NCT01974869||Inflammatory bowel diseases-1|Treatment with anti-tumor necrosis factor alpha agents
88954693|NCT01974869||Inflammatory bowel diseases-2|Controls
89494643|NCT02425917|Experimental|geko|
89204986|NCT05734144|Other|POES followed by LC|the second (control) group was treated by 2-stage (sequential treatment) POES followed by LC.
89204987|NCT01005862|Experimental|PF-04360365|
89204988|NCT01005862|Placebo Comparator|Placebo|single dose administered intravenously
89494644|NCT02425917|Active Comparator|ipc-calf|intermittent pneumatic compression of the calf
89494645|NCT02425527|Experimental|The rehabilitation gaming|The rehabilitation gaming group (n=30) will use an internet browser-based digital brain training program CogniFit (https://www.cognifit.com), with a selection of about 33 games.The participants will use the rehabilitation gaming for at least 30 min per day over a period of 8 weeks.
89494646|NCT02425527|Active Comparator|The entertaining gaming|The entertaining gaming group (n = 30) will use commercial digital games with Sony Playstation 3 (PS3) consoles, played with wireless Sony DualShock gamepad controllers. The participants will be guided to play the console for at least 30 min per day over a period of 8 weeks
89494647|NCT02425527|No Intervention|"Do-nothing"|"The passive control group Do-nothing group (n = 30) will not have gaming activities organized by the project."
89494648|NCT03985202|Experimental|Structured Exercise Programme|"An initial 45 min exercise counselling incorporating behaviour modification techniques.~Participants will be offered three sessions per week of aerobic interval exercise on a cycle ergometer over nine weeks. Exercise programmes will be tailored to each patient, taking previous level of activity, mobility and any barriers to exercise into consideration.~Following this:~Participants will be encouraged to comply with current physical activity recommendations: 150 min of moderate intensity aerobic exercise per week (brisk walking / cycling). They will also be sign posted to local exercise facilities."
89494649|NCT02425605|Experimental|CCRT-sorafenib group|
89494650|NCT03117465|Experimental|the experimental group|Stroke hemiplegia patients are randomly assigned to the experimental group (scalp acupuncture + low frequency repetitive transcranial magnetic stimulation + routine rehabilitation treatment). All patients in the day of inpatient and the fourteenth day received DTI magnetic resonance examination twice to study the change in white matter fiber microstructure.
89494651|NCT03117465|Other|the control group|Stroke hemiplegia patients are randomly assigned to the control group (scalp acupuncture + routine rehabilitation treatment). All patients in the day of inpatient and the fourteenth day received DTI magnetic resonance examination twice to study the change in white matter fiber microstructure.
89494652|NCT03978806|Active Comparator|peer navigator|The first PN visit will take place within 1-2 weeks of consent. Each of the 5 subsequent PN visits will take place every 1-2 weeks. We expect patients to complete the intervention within 2-3 months of consent. The function of the initial visit is to establish trust and ensure a more personal approach with participants. The community-based PN intervention is grounded in core Latino values (e.g. trust, personalized relationships). The core elements of the PN intervention include patient motivational interviewing as well as patient activation, empowerment (e.g. help with scheduling of healthcare appointments and re-scheduling of missed HD sessions), education (e.g. education of ESKD and need for renal replacement therapy), and social challenges (e.g. access to resources for transportation, benefits, immigration issues). The duration, individuals present during the visit, and content discussed will be documented in the visit form.
89494653|NCT03978806|Placebo Comparator|Control Arm (standard of care)|Standard of care
89494654|NCT02422563|Experimental|Arm A: NACT+radical hysterectomy|Arm A includes patients for dose dense chemotherapy using TP (paclitaxel, carboplatin) or TIP (cisplatin, paclitaxel, ifosfamide) weekly for six cycles. Radical hysterectomy is performed after the 6th week + lymphadenectomy
89494655|NCT02422563|Other|Arm B: Chemoradiation|Arm B includes patients undergoing primary cisplatin based chemo-radiation
89494656|NCT04330118||20 patients with DRESS syndrome|
89494657|NCT04330118||20 patients with drug induced MPE with eosinophilia|patients with drug induced maculopapular exanthema (MPE) with eosinophilia
89494658|NCT04330118||20 patients with drug induced MPE without eosinophilia|
89494659|NCT04330118||20 Healthy subjects|
89494660|NCT03545633|Experimental|Treatment Group|Treatment with the investigational device - High Intensity Focused ElectroMagnetic System
89494661|NCT03185403|Active Comparator|continous paravertebral block|"echoguided thoracic continous paravertebral block was placed before the surgery.~A bolus of 5 ml of ropivacaine 0.2% and 10µg of Sufentanil was injected in the catheter at the end of the abdominal time. A continuous infusion of ropivacaine 0.2% at 4ml/h was then initiated at the thoracic time. Postoperative patient-controlled analgesia consisted on an infusion of ropivacaine 0.2% at 6ml/h and a permitted bolus of 4ml every 15min as required."
89494662|NCT03185403|Active Comparator|continous Thoracic epidural block|thoracic epidural catheter was inserted before the surgery. A bolus of 5 ml of ropivacaine 0.2% and 10µg of Sufentanil was injected in the catheter at the end of the abdominal time. A continuous infusion of ropivacaine 0.2% at 4ml/h was then initiated at the thoracic time. Postoperative patient-controlled analgesia consisted on an infusion of ropivacaine 0.2% at 6ml/h and a permitted bolus of 4ml every 15min as required.
89204989|NCT01005940|Experimental|Mandibular advancement device|Subject is evaluated when receiving intervention with mandibular advancement device.
89204990|NCT01005940|No Intervention|No mandibular advancement device|Subject is evaluated when not receiving treatment with mandibular advancement device.
89204991|NCT01006096|Experimental|Erlotinib|
89204992|NCT01006096|Placebo Comparator|Placebo tablets|
89204993|NCT01006174|Experimental|A|Subjects will be assigned to consume 3 grams soybean oil, 8 grams canola oil, and 20 grams butter that is added to a salad.
89204994|NCT01006174|Experimental|B|Subjects will be assigned to consume 8 grams soybean oil, 20 grams canola oil, and 3 grams butter that is added to a salad.
89204995|NCT01006174|Experimental|C|Subjects will be assigned to consume 20 grams soybean oil, 3 grams canola oil, and 8 grams butter that is added to a salad.
89204996|NCT01006330||Elderly medical inpatients|
89204997|NCT05733442|Active Comparator|Treatment as Usual (TAU)|The TAU condition will entail the current CNHS MAT program for OUD.
89204998|NCT05733442|Experimental|CHaRRM-CN|The CHaRRM-CN condition comprises changes and additions to TAU codesigned with a community advisory board and taking into account suggestions from MAT patients and community members impacted by OUD with the goal of improving MAT retention in culturally aligned and community-driven ways.
89204999|NCT01006408|Active Comparator|Low Level Laser|Low Level Laser twice a week for 8 weeks
89205000|NCT01006408|Sham Comparator|Placebo and Low Level Laser|Placebo twice a week for 4 weeks then crossover to Low Level Laser twice a week for 4 weeks
89205001|NCT01006486|Experimental|Anticoagulation clinic|Anticoagulation clinic, including all procedures related to a standardized use of coumarins.
89205002|NCT01006486|Active Comparator|Standard care|Standard use of coumarins, as prescribed by their physicians.
89205003|NCT01006642||Healthy controls|Asymptomatic individuals admitted for health surveillance or patients for follow up after polypectomy.
89205004|NCT01006642||Functional dyspepsia-EPS|Functional dyspepsia-EPS(epigastric pain syndrome) Patients admitted to outpatient department with symptoms meeting ROME III criteria
89205005|NCT01006642||Functional dyspepsia-PDS|Functional dyspepsia-PDS(postprandial distress syndrome) Patients admitted to outpatient department with symptoms meeting ROME III criteria
89205006|NCT01006720||Sgx 0.25|Sugammadex group: Different doses of sugammadex for reversal of shallow neuromuscular blockade
89205007|NCT01006720||Sgx 0.5|Sugammadex group: Different doses of sugammadex for reversal of shallow neuromuscular blockade
89205008|NCT01006720||Sgx 0.75|Sugammadex group: Different doses of sugammadex for reversal of shallow neuromuscular blockade
89205009|NCT01006720||Sgx 1.0|Sugammadex group: Different doses of sugammadex for reversal of shallow neuromuscular blockade
89205010|NCT01006720||Sgx 1.25|Sugammadex group: Different doses of sugammadex for reversal of shallow neuromuscular blockade
89205011|NCT01006720||Neo 10|Neostigmine group: Different doses of neostigmine for reversal of shallow neuromuscular blockade
89205012|NCT01006720||Neo 25|Neostigmine group: Different doses of neostigmine for reversal of shallow neuromuscular blockade
89205013|NCT01006720||Neo 40|Neostigmine group: Different doses of neostigmine for reversal of shallow neuromuscular blockade
89205014|NCT01006720||Neo 55|Neostigmine group: Different doses of neostigmine for reversal of shallow neuromuscular blockade
89205015|NCT01006720||Neo 70|Neostigmine group: Different doses of neostigmine for reversal of shallow neuromuscular blockade
89205016|NCT01006720||Saline|Saline group: Saline as placebo
89205017|NCT05733052|Experimental|Polyester suture arm|A No 3 polyester suture will be inserted into the external urethral ligament, into the uurethral part of pubourethral ligament and into the pubic part of the pubourethral lgament then will be tied, but not tightly. The interventions will be carried on either side of the urethra that will be opened up by an 2.5 cm incision in the periurethral sulci.
89205018|NCT01006876|Active Comparator|Study Arm|Patients receive continuous Coumadin therapy throughout the study.
89205019|NCT01006876|Active Comparator|Control Arm|Patients discontinue Coumadin 3-4 days prior to ablation and replace it with heparin until the end of the procedure and bridge low molecular weight heparin (LMWH) with Coumadin 48-72 hours after ablation.
89205020|NCT05043220|Experimental|Telemedicine|Telemonitoring via PPG (photoplethysmography) and PROM (patient reported outcome monitoring) via app
89205021|NCT01006954|Active Comparator|Flare Up|Flare up protocol in poor responders for IVF/ICSI
89205022|NCT01006954|Experimental|Microdose GnRh|Microflare protocol in poor responders for IVF/ICSI
89205023|NCT05732818|Experimental|Lumbar Disc Nucleus Replacement following discectomy|All patients meeting all inclusion criteria and no exclusion criteria will be considered for nucleus replacement surgery following a review by the Medical Advisory Board.
89205024|NCT01007188|Active Comparator|1.5PD|average American diet plus 1.5 oz per day almonds
89205025|NCT01007188|Other|Base|average American diet without almonds
89205026|NCT01007188|Active Comparator|3.0PD|average American diet plus 3.0 oz per day almonds
89205027|NCT05035576|Active Comparator|400 mg OPN-019|
89205028|NCT05035576|No Intervention|Standard of Care (SOC)|
89205029|NCT03882424|Experimental|TRS003|Proposed biosimilar of bevacizumab，Intravenous administration
89205030|NCT03882424|Active Comparator|China-approved Bevacizumab|Intravenous administration
89205031|NCT03882424|Active Comparator|US-licensed Avastin|Intravenous administration
89205032|NCT05732662|Experimental|SBRT combined with PD-1/CTLA-4 dual antibody|
89205033|NCT03879772|Experimental|MFNS 25 mcg QD|Mometasone furoate nasal spray 12.5 mcg/spray was administered intranasally, one spray per nostril in the morning (upon awakening), daily for 4 weeks. A matching placebo nasal spray was administered intranasally (1 spray per nostril) in the evening. Chlorpheniramine maleate syrup 2 mg/5 mL was to be used for relief of intolerable SAR symptoms.
89494663|NCT02422485|Experimental|Salsalate|All participants will be administered 2,250 mg daily [1,500 mg every day before noon (every AM) and 750 mg every night at bedtime (every HS)] for 6 months.
89494664|NCT05551910|Experimental|Analgesia and sedation with esmketamine combined with propofol|
89494665|NCT05551910|Other|Remifentanil combined with propofol for analgesia and sedation|
89494666|NCT03608423|Experimental|Surgical treatment|Minimally-invasive endoscopy-guided surgery or hematoma aspiration, additional to standard medical treatment.
89494667|NCT03608423|No Intervention|Standard medical management|Standard medical treatment (treatment of bloodpressure, admission to stroke unit and supportive care, surgical treatment if necessary in case of deterioration)
89494668|NCT02430753|Experimental|IRE Group|irreversible electroporation for Lung Neoplasms accompanied by Respiratory Function Insufficiency
89494669|NCT02430753|No Intervention|Control|The patients without treatment
89494670|NCT05551676|Active Comparator|Transforaminal group|Transforaminal steroid injection will be applied, 30 patients
88954694|NCT01974882|Experimental|Cryotherapy|Patients in the cryotherapy study group will have ice packs placed on their abdominal wound for the first hour following surgery.
88954695|NCT01974882|No Intervention|Control|No adjunctive therapy following abdominal surgery.
88954696|NCT01974908|Experimental|Ventricular Tachycardia (VT)|Patients with VT will undergo a clinically indicated ablation of their VT
88954697|NCT01974921|Experimental|Bronchial thermoplasty|ALAIR Catheter. Radiofrequency system.
88954698|NCT01974934|Experimental|Desvenlafaxine Succinate|
88954699|NCT01974947||Infertile men|Man partner of an infertile couple. Blood sample, sperm sample and clinical examens will be done at the day of the inclusion
89494671|NCT05551676|Active Comparator|Lateral parasagittal group|Lateral parasagittal steroid injection will be applied, 30 patients
89494672|NCT02430675|Experimental|Group A|irreversible electroporation for Unresectable Laryngeal Neoplasms
88954700|NCT01974973|Experimental|Stem cell|autologous bone marrow mononuclear cell transplantation
88954701|NCT01974986|Placebo Comparator|Placebo|Water with flavoring and non-nutritive sweetener.
88954702|NCT01974986|Experimental|High-Na low-CHO beverage|Beverage containing sodium concentration of 40 to 50 mEq/L and carbohydrate concentration between 310 and 350 mmol/L.
88954703|NCT01974986|Experimental|Low-Na high-CHO beverage|Beverage containing sodium concentration of 15 to 25 mEq/L and carbohydrate concentration between 120 and 160 mmol/L.
88954704|NCT01975012|Experimental|Cohort 1: 6 to less than 12 years of age|Participants in this arm will be at least 6 but younger than 12 years of age; they will receive the study drug RPV together with 2 other NRTIs.
88954705|NCT01975012|Experimental|Cohort 2: 2 to less than 6 years of age|Participants in this arm will be at least 2 but younger than 6 years of age; they will receive the study drug RPV together with 2 other NRTIs.
88954706|NCT01975025|Experimental|All study participants|Short daily dialysis for 2 weeks
88954707|NCT01975038||A convenience sample|The characteristics of the sample will be monitored to assure that each category of skin type (I- VI) is accrued in sufficient size to support analysis. In addition, the sample will have equal representation from 4 ethnic groups within each skin type category: African American, Asian, Hispanic, or non-Hispanic White. Participants will self-identify as being Asian, Black, Hispanic Black, Hispanic White, or non-Hispanic White.
88954708|NCT01975051|Experimental|Miltefosine|Tablet Miltefosine 100 mg daily in two divided doses for 12 weeks.
89205034|NCT03879772|Experimental|MFNS 100 mcg QD|Mometasone furoate nasal spray 50 mcg/spray was administered intranasally, one spray per nostril in the morning (upon awakening), daily for 4 weeks. A matching placebo nasal spray was administered intranasally (1 spray per nostril) in the evening. Chlorpheniramine maleate syrup 2 mg/5 mL was to be used for relief of intolerable SAR symptoms.
89205035|NCT03879772|Experimental|MFNS 200 mcg QD|Mometasone furoate nasal spray 100 mcg/spray was administered intranasally, one spray per nostril in the morning (upon awakening), daily for 4 weeks. A matching placebo nasal spray was administered intranasally (1 spray per nostril) in the evening. Chlorpheniramine maleate syrup 2 mg/5 mL was to be used for relief of intolerable SAR symptoms.
89205036|NCT03879772|Active Comparator|BDP 84 mcg BID|Beclomethasone dipropionate nasal spray 42 mcg/spray was administered intranasally, one spray per nostril in the morning (upon awakening) and in the evening, daily for 4 weeks. Chlorpheniramine maleate syrup 2 mg/5 mL was to be used for relief of intolerable SAR symptoms.
88954709|NCT01975077|Experimental|A- 4mg QD|arm A- fruquintinib 4mg once daily, p.o.,continuous;given in 28-days cycles until disease progress, intolerable toxicity or patients withdrawal of consent
88954710|NCT01975077|Experimental|B- 5mg once daily, 3wks on/1wk off|arm B-fruquintinb 5mg once daily,p.o.,3 weeks on/1 week off, given in 28-day cycles until disease progress,intolerable toxicity or patients withdrawal of consent
88954711|NCT01975103|Experimental|Topcon Endpoint management|Active laser treatment
89205037|NCT03879772|Placebo Comparator|Placebo|Matching placebo nasal spray was administered intranasally, one spray per nostril in the morning (upon awakening) and in the evening, daily for 4 weeks. Chlorpheniramine maleate syrup 2 mg/5 mL was to be used for relief of intolerable SAR symptoms.
89205038|NCT01007266|Other|Group A|Buddy Group - Individuals with type 2 diabetes receive conventional diabetes treatment and are assigned a patient partner (Buddy)
89205039|NCT01007266|Active Comparator|Group B|Individuals receive conventional treatment for type 2 diabetes
89205040|NCT05027620|Experimental|Home training|Participants train 3 times weekly in their home environment with help of a digital training app, over a 10-week period.
89205041|NCT01007344|Active Comparator|flaxseed|2 muffins and 1 slice of bread for a total of 30g flaxseed per day
89205042|NCT01007344|Placebo Comparator|whole wheat flour|2 muffins and 1 slice of bread containing whole wheat flour per day
89205043|NCT01007422||Supportive Care|
89205044|NCT01007500|Experimental|Group Dexamethasone|
89205045|NCT01007500|Active Comparator|Group Ondansetron|
89205046|NCT05725252|Experimental|NVP-2203|After fasting (except water) for at least 10 hours before dosing, oral administration of investigational product once daily on Period 1(or Period 2)
89205047|NCT05725252|Active Comparator|NVP-2203-R|After fasting (except water) for at least 10 hours before dosing, oral administration of investigational product once daily on Period 1(or Period 2)
89205048|NCT00642954|Experimental|Level 1: Vorinostat 300 mg + lenalidomide 10 mg|Participants will receive vorinostat 300 mg orally once-daily (QD) on Days 1-7 and Days 15-21; lenalidomide 10 mg orally QD on Days 1-21 and dexamethasone 40 mg orally QD on Days 1, 8, 15 and 22 of each 28-day cycle for up to 8 cycles. Qualified participants who don't have disease progression can continue treatment after 8 cycles at the same dose and schedule, until progressive disease or unacceptable toxicity.
88954712|NCT01975103|Sham Comparator|Control|Powerless (sham) laser treatment
88954713|NCT01975116|Experimental|Treatment: p28|Pts receive azurin-derived cell-penetrating peptide p28 IV over 15 min 3x/week for 4 wks. Tx repeats every 6 weeks for up to 10 courses in the absence of disease progression or unacceptable toxicity.
88954714|NCT01975129|Experimental|Vagitocin (Oxytocin)|
89205049|NCT00642954|Experimental|Level 2: Vorinostat 400 mg + lenalidomide 10 mg|Participants will receive vorinostat 400 mg orally QD on Days 1-7 and Days 15-21; lenalidomide 10 mg orally QD on Days 1-21 and dexamethasone 40 mg orally QD on Days 1, 8, 15 and 22 of each 28-day cycle for up to 8 cycles. Qualified participants who don't have disease progression can continue treatment after 8 cycles at the same dose and schedule, until progressive disease or unacceptable toxicity.
89205050|NCT00642954|Experimental|Level 3: Vorinostat 400 mg + lenalidomide 15 mg|Participants will receive vorinostat 400 mg orally QD on Days 1-7 and Days 15-21; lenalidomide 15 mg orally QD on Days 1-21 and dexamethasone 40 mg orally QD on Days 1, 8, 15 and 22 of each 28-day cycle for up to 8 cycles. Qualified participants who don't have disease progression can continue treatment after 8 cycles at the same dose and schedule, until progressive disease or unacceptable toxicity.
89205051|NCT00642954|Experimental|Level 4: Vorinostat 400 mg + lenalidomide 20 mg|Participants will receive vorinostat 400 mg orally QD on Days 1-7 and Days 15-21; lenalidomide 20 mg orally QD on Days 1-21 and dexamethasone 40 mg orally QD on Days 1, 8, 15 and 22 of each 28-day cycle for up to 8 cycles. Qualified participants who don't have disease progression can continue treatment after 8 cycles at the same dose and schedule, until progressive disease or unacceptable toxicity.
89205052|NCT00642954|Experimental|Level 5: Vorinostat 400 mg + lenalidomide 25 mg|Participants will receive vorinostat 400 mg orally QD on Days 1-7 and Days 15-21; lenalidomide 25 mg orally QD on Days 1-21 and dexamethasone 40 mg orally QD on Days 1, 8, 15 and 22 of each 28-day cycle for up to 8 cycles. Qualified participants who don't have disease progression can continue treatment after 8 cycles at the same dose and schedule, until progressive disease or unacceptable toxicity.
89205053|NCT01007734||1|
89205054|NCT00822276||ADEH+ participants colonized with MSSA|
89205055|NCT00822276||ADEH+ participants colonized with MRSA|
89205056|NCT00822276||Uncolonized ADEH+ participants|
89205057|NCT00822276||ADEH- participants colonized with MSSA|
89205058|NCT00822276||ADEH- participants colonized with MRSA|
89205059|NCT00822276||Uncolonized ADEH- subjects|
88954715|NCT01975142|Experimental|TDM-1|
88954716|NCT01975155||Celiac|patients with celiac disease filling the questionnaire and undergoing urinary test
88954717|NCT01975155||healthy controls|healthy patients filling the questionnaire and undergoing urinary test
88954718|NCT01975168|Experimental|Group 1|arrange laser acupuncture intervention for 12 weeks, then cross over to sham laser acupuncture intervention for 12 weeks
88954719|NCT01975168|Sham Comparator|Group 2|arrange sham laser acupuncture for 12 weeks, then cross over to laser acupuncture for 12 weeks
88954720|NCT01975194|Experimental|Rosuvastatin|Patients that receive rosuvastatin
89494673|NCT02430675|No Intervention|Control|The patients without treatment
89494674|NCT05039567|Experimental|optimal heart team group|Heart teams in this group will be established according to the optimal heart team protocol. Each team consists of two interventional cardiologists and two cardiac surgeons. Team members will be trained systematically before the heart team meeting.
89494675|NCT05039567|No Intervention|conventional heart team group|Heart teams in this group will be established according to the basic elements recommended by guidelines. Each team consists of an interventional cardiologist, a cardiac surgeon, and a non-interventional cardiologist. No team training will be held before the heart team meeting.
89494676|NCT05699720|Experimental|Magnesium Sulphate|Conventional treatment and 250mg of MgSO4 through nebulizer four times a day. 1 vial of injection MgSO4 was taken which contains 1gm of MgSO4 (each vial contains 10ml). It was divided into 4 equal parts, each contained 250mg MgSO4 i.e., 2.5 ml solution, which were used for nebulization 4 times a day.
89494677|NCT05699720|No Intervention|Conventional|conventional treatment in the form of oxygen inhalation, anti-cholinergic and beta-2 agonist nebulization, intravenous steroids, as well as intravenous antibiotics.
89494678|NCT02421471||Ingenol mebutate treatment cohort|Patients who are prescribed ingenol mebutate gel for the first time by investigator's medical judgment.
89494679|NCT04578509||Salicov|Ambulatory adults or children requiring screening for SARS-CoV-2 by nasopharyngeal swab
89494680|NCT04578509||SalicovII (ancillary study)|Ancillar study : Children and teachers / staff from middle and high schools in Ile de France Saliva samples is collected as part of care. Only a self-rated questionnaire is collected.
89494681|NCT05546762|Experimental|Antiseptic irrigation arm|250 ml solution of 2% povidone-iodine (i.e. 50 ml betadine in 200 ml saline) will be attached to the chest tube via a giving set and a 3-way tap and irrigated into the pleural space with gravity. The chest tube will be clamped for 10-20 minutes after irrigation and then will be unclamped and left to drain freely. The first dose will be applied 24-48 hours after tube insertion. This will be repeated every 12 hours for a total of four to six applications.
89494682|NCT05546762|Active Comparator|Saline irrigation arm|250 ml solution of normal saline will be attached to the chest tube via a giving set and a 3-way tap and irrigated into the pleural space with gravity. The chest tube will be clamped for 10-20 minutes after irrigation and then will be unclamped and left to drain freely. The first dose will be applied 24-48 hours after tube insertion. This will be repeated every 12 hours for a total of four to six applications.
89494683|NCT02421549|Active Comparator|Interrogation with unpaired remote monitoring transmitter|Interrogation with unpaired remote monitoring transmitter Interrogation with an unpaired remote monitoring transmitter for devices that are compatible.
89205060|NCT00822276||Non-atopic uncolonized S. aureus participants|
89205061|NCT00816660|Experimental|1|
89205062|NCT00816660|Active Comparator|2|
88954721|NCT01975207|No Intervention|Group 1|"Patients will have information collected on their quality of life (QOL) at baseline (EuroQual 5-item measure - EQ-5D). Patients will be followed up at week 12 for a repeated measure of QOL and a score on the depression rating scale being used in this study (Patient Health Questionnaire-9 item version - PHQ-9). Individuals will also be asked on their health care access frequency (HCAF) at baseline and follow up."
88954722|NCT01975207|Experimental|Group 2|"Group #2. Screening for depression followed by treatment as usual: Patients will complete baseline measurements of their score on the PHQ-9, self-reported HCAF and QOL (EQ-5D) score.~The PHQ-9 score will be given to the clinic staff who will then follow up with treatment as usual. Patients will be followed up at week 12 for self-reported HCAF,PHQ-9 and QOL scores."
88954723|NCT01975207|Experimental|Group 3|Group #3 is Internet intervention: At baseline patients will complete QOL (EQ-5D), PHQ-9 scores, and self-reported HCAF. Those who score 10 or more on the PHQ-9 will be offered a guided internet-based intervention for the treatment of depression by the study staff. Patients will be followed up at week 12 for self-reported HCAF, PHQ-9 and QOL scores.
88954724|NCT01975207|Experimental|Group 4|Depression Treatment Pathway: At baseline patients will complete PHQ-9, QOL (EQ-5D) scores, and self-reported HCAF. Those who score 10 or more on the PHQ-9 will be offered the specific treatment as determined by the Depression Pathway by the clinic physician. Whenever possible, this pathway will be integrated into the local clinic's electronic medical record system, for ease of administration by the clinic. Patients will be followed up at week 12 for self-reported HCAF, PHQ-9 and QOL (EQ-5D) scores.
88954725|NCT01975259||Cystic Fibrosis|"Adult patients with confirmed cystic fibrosis who are clinically stable. Interventions:~Oral Glucose Tolerance test (75g 2-hour) Modified Oral Glucose Tolerance Test (50g 4-hours) Matched isoglycemic clamp Hyperglycemic clamp with concurrent GLP-1 infusion Hyperglycemic Clamp with concurrent GIP infusion Hyperglycemic clamp with placebo infusion Liquid Meal Test (Carbohydrate-rich) Continuous Glucose Monitoring"
88954726|NCT01975259||Controls|"Adult Non-CF subjects matched for age and body mass index with normal glucose tolerance.~Oral Glucose Tolerance test (75g 2-hour) Modified Oral Glucose Tolerance Test (50g 4-hours) Matched isoglycemic clamp Hyperglycemic clamp with concurrent GLP-1 infusion Hyperglycemic Clamp with concurrent GIP infusion Hyperglycemic clamp with placebo infusion Liquid Meal Test (Carbohydrate-rich)"
88954727|NCT01975311|Experimental|Lumbopelvic Manipulation|Participants in this group will receive lumboplevic manipulation twice within a week.
89205063|NCT00819000||Treated MS Subjects|Subjects who are treated with Glatiramer Acetate or Interferon (IFN)-β and receive their therapy from one of the participating Specialty Pharmacies
89205064|NCT00640146|Experimental|MNTX|Participants will receive methylnaltrexone (MNTX) 12 milligrams (mg) subcutaneously (SC) once daily for up to 4 or 7 days, depending upon the protocol version under which each participant is enrolled.
89205065|NCT00640146|Placebo Comparator|Placebo|Participants will receive placebo matching to MNTX SC once daily for up to 4 or 7 days, depending upon the protocol version under which each participant is enrolled.
89205066|NCT00819078|Active Comparator|Bupropion Sr|40 adolescent patients
89205067|NCT00819078|Placebo Comparator|Placebo (sugar pill)|40 adolescent patients will receive placebo
89205068|NCT00822432||1|
89205069|NCT01008046|Experimental|combined N-acetyl cysteine - CC|N-acetyl cysteine(1.8 g orally daily)for 5-6 weeks from the 1st day of spontaneous or induced menstruation followed by 100 mg CC for 5 days from day 3 of spontaneous or induced menstruation. With persistent anovulation,CC increased by 50 mg for the next cycle. Treatment continued for three successive cycles
89494684|NCT02421549|No Intervention|Interrogation with Programmer|Interrogation with programmer Interrogation with programmer according to usual standard of care
89494685|NCT05546684|Experimental|foot bath|Individuals who apply to the urology service for TURP or TURM will be informed about the study 1 day before the surgery, and the questions in the patient introduction form will be asked to the patients who declared that they agreed to participate in the study in written and verbal form. On the morning of the surgery, the RCSQ will be applied to the patients to determine the preoperative sleep quality, and the Patient follow-up form will be applied to determine the confounding factors that may affect the sleep. The patient's feet will be kept in the footbath device for ten minutes. After the foot bath, the patient's feet will be completely dried with a towel and the existing socks and anti-embolic socks will be put on again. On the morning of the 1st postoperative day, the patient will be asked the questions in the RCSQ and the follow-up form, and the data collection process of the study will be terminated.
89494686|NCT05546684|No Intervention|Control Group|After informing the individuals who applied to the urology service for TURP or TURM about the study, the researcher will receive their informed consent in written form. The information required for the study of the patients in the control group 1 day before the operation will be recorded in the Patient Information Form by the service nurse. On the morning of the surgery, the RCSQ will be applied to the patients to determine the preoperative sleep quality and the Patient follow-up form will be applied to determine the confounding factors that may affect sleep. In the morning of the first day after the surgery, the RCSQ will be applied to the patients to determine the sleep quality on the postoperative day 0, and the Patient follow-up form will be applied to determine other possible factors that may affect sleep, and the data collection process of the study will be terminated. No foot bath application will be in question for the patients in the control group.
89494687|NCT02422719|Experimental|Radotinib|Radotinib treatement single arm
89494688|NCT05026775|Experimental|Initial Medication Adherence (IMA) intervention|General practitioners (GP) will apply the IMA intervention to all patients receiving a new prescription for treatment of cardiovascular disease or diabetes. Following the IMA intervention, nurses and community pharmacists will offer information support in line with the information provided by the GP.
89494689|NCT05026775|Active Comparator|Usual care|Patients will receive the usual care when being prescribed a new prescription for treatment of cardiovascular disease or diabetes. Nurses and community pharmacists will be asked to also provide usual care to those patients.
89494690|NCT02422329|Experimental|Educational Video|Participants complete self-administered numerical rating scale (NRS) constipation questionnaire at baseline. Participants watch a 3-minute educational video describing symptoms of constipation and importance of regular bowel movements. Participants then complete three self-administered questionnaires, post-educational material, Modified Rome III questionnaire, and Overall satisfaction of the educational material.
89494691|NCT02422329|Experimental|Fact Sheet|Participants complete self-administered numerical rating scale (NRS) constipation questionnaire at baseline. Participants read educational material describing symptoms of constipation and importance of regular bowel movements. Participants then complete three self-administered questionnaires, post-educational material, Modified Rome III questionnaire, and Overall satisfaction of the educational material.
89494692|NCT05551598|Experimental|Mitoxantrone Hydrochloride Liposome Injection 8 mg/m^2 group|
89494693|NCT05551598|Experimental|Mitoxantrone Hydrochloride Liposome Injection 12 mg/m^2 group|
89494694|NCT05551598|Placebo Comparator|Placebo Injection every 12 weeks (Q12W).|
89494695|NCT02421315|Experimental|Participants With Obsessive-compulsive Disorder (OCD)|Children and adolescents who meet DSM-IV diagnostic criteria for OCD and had clinically significant obsessive-compulsive symptoms (CY-BOCS score>15). Comorbid anxiety disorders, but no other lifetime psychiatric diagnoses, were permitted in the OCD group as long as OCD was the primary diagnosis. Participants were unmedicated and had not received a full course of CBT with exposure and response prevention for OCD prior to their participation in the study. Following baseline assessment and scan, patients with OCD underwent a course of manualized treatment of CBT with E/RP adapted for pediatric OCD delivered by a licensed clinical psychologist or advanced supervised graduate student in clinical psychology at the NYSPI.
89494696|NCT02421315|No Intervention|Healthy Control (HC) Participants|Healthy control (HC) participants matched on age and sex with the OCD group. HC participants had no lifetime psychiatric disorders. HC participants were assessed and scanned at baseline and again after 12-16 weeks.
88954728|NCT01975311|Placebo Comparator|Passive lumbar spine flexion and extension|Participants in this group will receive passive lumbar spine flexion and extension for 1 min twice within a week.
88954729|NCT01975324|Experimental|dalfampridine (ampyra)|Dalfampridine (ampyra) 10mgs twice a day (b.i.d.)for two weeks
88954730|NCT01975324|Placebo Comparator|Placebo|placebo (sugar Pill) twice a day (b.i.d.)for two weeks
88954731|NCT01975337|Experimental|End stage renal disease participants|End stage renal disease (ESRD) participants received a single 400 mg (2 x 200 mg capsules) oral dose of alisporivir with food at any time during the 2 hours after completion of hemodialysis on Day 1.
88954732|NCT01975337|Active Comparator|Matched healthy participants|Healthy participants (matched to those with end stage renal disease by sex, age, weight, and smoking status), received a single 400 mg (2 x 200 mg capsules) oral dose of alisporivir with food on Day 1.
88954733|NCT01975350||Colistimethate sodium inhalation|"Colistimethate sodium inhalation for patients with ventilator-associated tracheobronchitis, pneumonia or lower respiratory tract colonization by multidrug resistant Gram-negative bacteria.~Additional intravenous colistimethate sodium for patients with ventilator-associated pneumonia"
88954734|NCT01975350||saline inhalation|saline inhalation for patients with ventilator-associated tracheobronchitis, pneumonia or lower respiratory tract colonization by multidrug resistant Gram-negative bacteria.
88954735|NCT01975363|Experimental|Arm I (lower dose curcumin)|Participants receive 50 mg dose curcumin PO BID for 3 months. Biomarker analyses of breast adipose tissue and plasma samples will be obtained at baseline and 3 months. Breast adipose tissue samples will be obtained via fine needle aspiration. Plasma samples from the baseline blood draw will be assessed for curcumin and also stored at -80°C for biomarker analysis. Assessment of dietary intake by food frequency questionnaires and 24 hour dietary recalls will be used to assess usual dietary habits. All participants will complete a daily log on the date and time of NEC administration, potential adverse events, and medications.
89205070|NCT01008046|Active Comparator|combined metformin-CC|Patients received metformin HCl (1500 mg daily) for 5-6 weeks from the 1st day of spontaneous or induced menstruation, followed by 100 mg CC for 5 days starting from day 3 of spontaneous or induced menstruation. With persistent anovulation,CC increased by 50 mg for the next cycle. Treatment continued for three successive cycles.
89205071|NCT00819312|Active Comparator|Arm 1|
89205072|NCT01008124|Experimental|Liberatory Maneuver|Liberatory Maneuver
89205073|NCT01008124|Placebo Comparator|Placebo Maneuver|Placebo Maneuver
89205074|NCT05006560|Experimental|Usual care rehabilitation and aftercare|Participants receive the standard inpatient pulmonary rehabilitation followed by an internet based 12-week rehabilitation aftercare program.
89205075|NCT05006560|Experimental|Rehabilitation and aftercare (aligned)|"Participants receive the standard inpatient pulmonary rehabilitation followed by an internet based 12-week rehabilitation aftercare program.~During rehabilitation, participants already get familiarized with components of the after care program."
89205076|NCT05005624||Validation group 1 (VG-1)|20 participants with binocular Uncorrected Near Visual Acuity (UNVA) 0.1 logMAR (Snellen 20/25)
89205077|NCT05005624||Validation group 2 (VG-2)|20 participants with binocular Uncorrected Near Visual Acuity (UNVA) 0.4 logMAR (Snellen 20/50)
89205078|NCT05005624||Validation group 3 (VG-3)|20 participants with binocular Uncorrected Near Visual Acuity (UNVA) 0.7 logMAR (Snellen 20/100)
89205079|NCT00317473|Experimental|FMP1/AS02A Malaria vaccine 10ug|Subject vaccinated with 10 ug of FMP1/AS02A on days 0, 29 and 57
89205080|NCT00317473|Experimental|FMP1/AS02A Malaria vaccine 25 ug|Subject vaccinated with 25 ug of FMP1/AS02A on days 14, 42, and 70
89205081|NCT00317473|Experimental|FMP1/AS02A Malaria vaccine 50 ug|Subject vaccinated with 50 ug of FMP1/AS02A on days 28, 56 and 84
89205082|NCT00317473|Active Comparator|Imovax Rabies Vaccine|Subject vaccinated with Imovax Rabies Vaccine on corresponding FMP1/AS021 vaccination days
89205083|NCT00530218|Experimental|All Study Participants|Ganciclovir IV 5 mg/kg/bid x 7 days followed by Ganciclovir Oral 1000 mg tid 7 days per week x 5 weeks
89205084|NCT00761267|Experimental|Anidulafungin IV|All subjects meeting screening criteria will receive IV anidulafungin.
89205085|NCT03982303|Experimental|Hemay102 at the dosage of 5mg/m2|Hemay102 will be administered to patients through i.v. drip for 4hrs at the dosage of 5mg/m2.
89205086|NCT03982303|Experimental|Hemay102 at the dosage of 10mg/m2|Hemay102 will be administered to patients through i.v. drip for 4hrs at the dosage of 10mg/m2.
89205087|NCT03982303|Experimental|Hemay102 at the dosage of 20mg/m2|Hemay102 will be administered to patients through i.v. drip for 4hrs at the dosage of 20mg/m2.
89205088|NCT03982303|Experimental|Hemay102 at the dosage of 40mg/m2|Hemay102 will be administered to patients through i.v. drip for 4hrs at the dosage of 40mg/m2.
89205089|NCT03982303|Experimental|Hemay102 at the dosage of 60mg/m2|Hemay102 will be administered to patients through i.v. drip for 4hrs at the dosage of 60mg/m2.
89494697|NCT02422251|Experimental|Mobile high congruency bearing|Device B Braun Columbus total knee system using a rotating platform tibia and high congruency mobile bearing.
89494698|NCT02422251|Experimental|Fixed high congruency bearing|Device B Braun Columbus total knee system using a fixed tibial platform and high congruency bearing.
89494699|NCT02422251|Experimental|Fixed low congruency bearing|Device B Braun Columbus total knee system using a fixed tibial platform and low congruency bearing.
89494700|NCT02422251|No Intervention|Control|Healthy control group
88954736|NCT01975363|Experimental|Arm II (higher dose curcumin)|Participants receive 100 mg dose curcumin PO BID for 3 months. Biomarker analyses of breast adipose tissue and plasma samples will be obtained at baseline and 3 months. Breast adipose tissue samples will be obtained via fine needle aspiration. Plasma samples from the baseline blood draw will be assessed for curcumin and also stored at -80°C for biomarker analysis. Asssessment of dietary intake by food frequency questionnaires and 24 hour dietary recalls will be used to assess usual dietary habits. All participants will complete a daily log on the date and time of NEC administration, potential adverse events, and medications.
88954737|NCT01975415||Experienced Meditators|Self-identified participants who confirm to having a regular meditation practice for at least 3 months and practiced at least 70 minutes per week.
88954738|NCT01975415||Novice meditators|Self-identified participant who confirm to either having never seriously tried meditation, or who have not meditated more than once a week for at least 3 months
88954739|NCT01975441|Active Comparator|standard treatment|Diethylcarbamazine 6 mg/kg + Albendazole 400 mg administered annually (at 0, 12, and 24 months).
88954740|NCT01975441|Experimental|DEC 6 mg/kg + Alb 400 mg x 1|Diethylcarbamazine 6 mg/kg + Albendazole 400 mg given once
88954741|NCT01975441|Experimental|DEC + ALB + IVM|Diethylcarbamazine 6 mg/kg + Albendazole 400 mg + Ivermectin 200 µg/kg administered once only at the beginning of the RCT (0 month)
88954742|NCT01975454|Active Comparator|chemotherapy|Patients receive chemotherapy until disease progression or unacceptable toxicity
88954743|NCT01975454|Experimental|Herbal therapy plus chemotherapy|Patients receive herbal therapy plus chemotherapy until disease progression or unacceptable toxicity
88954744|NCT01975480|Experimental|Desvenlafaxine|At the screening visit those who are eligible will enter a randomized trial with Pristiq (desvenlafaxine) 50 to 100 mg. The study will begin with a single week of Pristiq (desvenlafaxine) 50mg. Subsequently, tablets will be administered in a flexible dose fashion and patients will be followed up weekly (biweekly after week 8) and at the investigators discretion. After the first week the patients' dosage will be increased up to a maximum of 100 mg daily. This dose will remain fixed after 8 weeks of treatment until week 16.
88954745|NCT01975493||Amoxicillin|"Group subdivided into age categories:~Preterm newborn infants Term newborn infants (0-27 days) Infants and toddlers (1 month to 23 months) Children (2 - 11 years) Adolescents (12 - 16 years)"
88954746|NCT01975493||Ampicillin|"Group subdivided into age categories:~Preterm newborn infants Term newborn infants (0-27 days) Infants and toddlers (1 month to 23 months)"
88954747|NCT01975493||Benzylpenicillin|"Group subdivided into age categories:~Preterm newborn infants Term newborn infants (0-27 days) Infants and toddlers (1 month to 23 months) Children (2 - 11 years) Adolescents (12 - 16 years)"
88954748|NCT01975493||Co-amoxiclav|"Group subdivided into age categories:~Preterm newborn infants Term newborn infants (0-27 days) Infants and toddlers (1 month to 23 months) Children (2 - 11 years) Adolescents (12 - 16 years)"
88954749|NCT01975493||Flucloxacillin|"Group subdivided into age categories:~Preterm newborn infants Term newborn infants (0-27 days) Infants and toddlers (1 month to 23 months) Children (2 - 11 years) Adolescents (12 - 16 years)"
88954750|NCT01975493||Piperacillin/tazobactam|"Group subdivided into age categories:~Preterm newborn infants Term newborn infants (0-27 days) Infants and toddlers (1 month to 23 months) Children (2 - 11 years) Adolescents (12 - 16 years)"
88954751|NCT01975506||head start practitioners|
88954752|NCT01975545|Active Comparator|Fluor varnish|Fluor dental varnish (Fluor Protector, Ivoclar Vivadent, Principality of Liechtenstein)
88954753|NCT01975545|Experimental|Fluor varnish with nanoparticles|Fluor dental varnish (Fluor Protector, Ivoclar Vivadent, Principality of Liechtenstein) plus 25% 50 nm silver nanoparticles.
88954754|NCT01975558||Control group A|Control group. The group will undergo blood, urine, sebum, and saliva sampling.
88954755|NCT01975558||Breast cancer B|Breast cancer (60 Gy). The group will undergo blood, urine, sebum, and saliva sampling within the irradiation field.
88954756|NCT01975558||Breast cancer C|Breast cancer (60 Gy). The group will undergo blood, urine, sebum, and saliva sampling outside of the irradiation field, e.g. at the arm.
88954757|NCT01975584|Experimental|Trier Social Stress Test|Participants will participate in a standardized role play (Trier Social Stress Test ). A role play is pretending to be in a certain situation. A research staff member will describe the role play, during which teh participant will act out a scene. Participants will be asked to imagine that they are in a certain role with several other research team members who will also participate in the role play. Participants will also be asked to do some math problems without using paper or pencil.
88954758|NCT01975623|Experimental|Intervention Group|Pulmonary artery Energy Sealing with HARMONIC ACE+ Shears (HS) ex-vivo
88954759|NCT01975636|Experimental|E2609|Single oral 100 mg +/- 10 mg E2609 with a level of radioactive exposure consistent with the Radioactive Drug Research Committee allowance
88954760|NCT01975649|Experimental|Tribulus Terrestris|patients will use Tribulus terrestris (750 mg/day) during 120 days
88954761|NCT01975649|Placebo Comparator|Placebo|patients will use placebo for 120 days
88954762|NCT01975662|Experimental|Daptomycin|"Daptomycin will be dosed intravenously at 6-8mg/kg every 24 hours.~Patients with uncomplicated bacteremia will receive a dose of 6mg/kg every 24 hours. Patients with suspected complicated bacteremia or endocarditis, or receipt of at least two doses of vancomycin in the last 90 days (apart from vancomycin received for their current MRSA bacteremia) will receive a dose of 8mg/kg every 24 hours.~In patients with a creatinine clearance less than 30ml/min, or on intermittent or continuous hemodialysis, daptomycin will be dosed at 6-8mg/kg every 48 hours. The same criteria as above applies as to whether they receive 6mg/kg or 8mg/kg every 48hours. Daptomycin will be administered after hemodialysis in patients undergoing intermittent hemodialysis."
88954763|NCT01975662|Active Comparator|Vancomycin|Vancomycin will be dosed at 15mg/kg every 12 hours with appropriate dose adjustments by a pharmacist in patients with a creatinine clearance less than 50 ml/min, so as to achieve a vancomycin trough level of 15-20ug/ml.
89494701|NCT02421081|Active Comparator|having arteriel cut|30 patients who refer to Erciyes University emergency department because of wrist laceration with radial and/or ulnar artery incision,will be presenting to the study.All patient's flow rate will be evaluated by Doppler ultrasonography before surgery,as well as the healthy side and side of the cuts.Then 5 ml of blood samples will be taken from the systemic circulation,flowcytometric analysis of serum CD34,CD133 and CD309 levels to be measured.Then after patients received surgery,under a microscope using microsurgical techniques and polyamide suture will be held vascular repair.Patients will be assessed by Doppler ultrasonography again 4 weeks after surgery;flow velocity and vessel diameter will be measured at the anastomoses line and patient will be divided to 4 groups. Among these groups serum CD34,CD133,CD309 levels and distribution of lymphoid cells measured by immunohistochemistry; The relationship between the anastomosis opening will be evaluated statistically.
89494702|NCT02421081|Active Comparator|having tendon cut|10 patients having similar age and sex with first group, who refer to Erciyes University emergency department because of wrist laceration without radial or ulnar artery cutting,will be taken to compare with first group.All patient's flow rate will be evaluated by Doppler ultrasonography before surgery,as well as the healthy side and side of the cuts.Then 5 ml of blood samples will be taken from the systemic circulation,flowcytometric analysis of serum CD34,CD133 and CD309 levels to be measured.Then after patients received surgery to repair tendons and/or nerves. Among these groups serum CD34,CD133,CD309 levels and distribution of lymphoid cells measured by immunohistochemistry; and will compare with first group.
89494703|NCT02421081|No Intervention|healthy control|10 healty having similar age and sex with first group,controls who accept to give blood to determine normal range of serum CD34,CD133 and CD 309 will be taken to compare with first group.All patient's flow rate will be evaluated by Doppler ultrasonography.Then 5 ml of blood samples will be taken from the systemic circulation,flowcytometric analysis of serum CD34,CD133 and CD309 levels to be measured.
89494704|NCT03758222|Experimental|Arm-1: Device implantation for 1 month|Treatment group receives intervention with the XFLO Expander System implantation for 1 month, and then retrieved.
89494705|NCT03758222|Experimental|Arm-2: Device implantation for 6 months|Treatment group receives intervention with the XFLO Expander System implantation for 6 months, and then retrieved.
89494706|NCT03758222|Experimental|Arm-3: Device implantation for 12 months|Treatment group receives intervention with the XFLO Expander System implantation for 12 months, and then retrieved.
89494707|NCT03179007|Experimental|Anti-CTLA-4/PD-1 expressing MUC1-CAR-T|This study have only one arm that is anti-CTLA-4/PD-1 expressing MUC1-CAR-T group. All patients with advanced solid tumor will take part in the screening, who matching all the conditions will be chosen for the treatment using CTLA-4 and PD-1 antibodies expressing MUC1-targeted CAR-T cells. New CAR-T cells are cultured from PBMC and returned to the patients by venous transfusion.
89494708|NCT02421237|Experimental|Experimental condition|Narrative enhancement and cognitive therapy (NECT) groups. Structured psychoeducational and skills-training groups focused on self-stigma and its impact on people with schizophrenia
89494709|NCT02421237|Active Comparator|Control condition|Supportive group therapy groups. Unstructured supportive groups not focused on self-stigma.
89494710|NCT05551442||In control group A,|In control group A, we adopted the conventional lateral position
89494711|NCT05551442||control group B|control group B adopted the lumbar bridge cushion lateral position
89494712|NCT05551442||observation group C|observation group C adopted the modified javelin lateral position
89494713|NCT03185793|Placebo Comparator|Placebo|placebo for 5 weeks
89494714|NCT03185793|Experimental|2.5mg SHR4640|SHR4640 for 5 weeks
89494715|NCT03185793|Experimental|5mg SHR4640|SHR4640 for 5 weeks
89494716|NCT03185793|Experimental|10mg SHR4640|SHR4640 for 5 weeks
89494717|NCT03185793|Active Comparator|50mg benzbromarone|Benzbromarone for 5 weeks
89494718|NCT03185637||Gastroschisis|All patients presenting primarily to the institution with gastroschisis during the data collection period will be included in the study.
89494719|NCT03185637||Anorectal malformation|All patients presenting primarily to the institution with anorectal malformation during the data collection period will be included in the study.
89494720|NCT03185637||Appendicitis|All patients under 16-years of age presenting primarily to the institution with appendicitis during the data collection period will be included in the study.
89494721|NCT03185637||Intussusception|All patients under 16-years of age presenting primarily to the institution with intussusception during the data collection period will be included in the study.
89494722|NCT03185637||Inguinal hernia|All patients under 16-years of age undergoing surgery for an inguinal hernia at the institution during the data collection period will be included in the study.
89494723|NCT03660488|Active Comparator|Benzathine Penicillin G|"Patients of the Penicillin Group will receive the standard of care treatment. This is one intramuscular injection of 2.4 million units Benzathine Penicillin G. The group will consist of 50 patients."
89494724|NCT03660488|Experimental|Cefixime Group|"Patients of the Cefixime Group will receive Cefixime 400 mg, per os, one tablet, two times per day, for ten consecutive days. The study team will provide the medication.~The group will consist of 50 patients."
89022546|NCT02957513|Active Comparator|Enhanced Usual Care (EC)|"All participants in all 3 study arms (TM, HC, and EC) will receive enhanced usual care. Usual care in the participating practices will be supplemented through the following key EC resources:~A. Patient-focused Resources including: 1) MODEL Program Toolkit, and 2) low literacy diabetes educational materials.~B. Availability of diabetes support services including: 1) peer group support sessions, 2) diabetes education, 3) MyDiabetesCenter.org resources, and 4) Diabetes Coalition education hub resources.~C. Practice-focused components including: 1) practice training/continuing medical education, and 2) reporting of diabetes performance measures."
89494725|NCT03185091|Other|rapid ventricular pacing|Safety of rapid ventricular pacing during neurosurgical procedures
89494726|NCT02421003|Experimental|Patients|Patients undergoing heart surgery
89022547|NCT00460707|Experimental|Cohort 1|All subjects in Cohort 1 will receive ketoconazole 400 milligrams (mg) once daily on Day 1 to 9 and oral casopitant 150 mg on Day 4 and 50 mg on Day 5 and Day 6 of treatment period 1. After a washout period of 21 days, subjects will be administered oral casopitant 150 mg on Day 1 and 50 mg on Day 2 and Day 3 of treatment period 2.
89022548|NCT00460707|Placebo Comparator|Cohort 2, Group A|Subjects will receive placebo once daily on Day 1 to Day 3 in treatment period 1. Subjects will receive ketoconazole 400 mg once daily on Day 1 to Day 9 and oral placebo once daily on Days 4, 5 and 6 in treatment period 2. There will be a 14-day washout period between treatment periods 1 and 2.
89022549|NCT00460707|Experimental|Cohort 2, Group B|In treatment period 1, subjects will receive oral casopitant 150 mg on Day 1 and 50 mg on Days 2 and 3. In treatment period 2, they will be administered ketoconazole 400 mg once daily on Day 1 to Day 9 and oral casopitant 150 mg on Day 4 and 50 mg on Days 5 and 6. There will be a 14-day washout period between treatment periods 1 and 2.
89022550|NCT01055132|Other|Etafilcon A toric contact lens/Nelfilcon A toric|Etafilcon A toric contact lens first, then nelfilcon A toric second
89022551|NCT01055132|Other|Nelfilcon A toric/ Etafilcon A toric|Nelfilcon A toric contact lens first, then etafilcon A toric toric second
89022552|NCT01054976|Experimental|Galantamine|
89022553|NCT00469443|Experimental|1|FOLFIRI/Avastin
89022554|NCT00469443|Experimental|2|XELIRI/Avastin
89022555|NCT00428831||1|Patients with respiratory illnesses.
89022556|NCT00428870|Experimental|Arthroscopic acromioplasty|Arthroscopic acromioplasty
89022557|NCT00428870|Placebo Comparator|Sham surgery|Shoulder arthroscopy without active treatment and subacromial arthroscopy without bursectomy, decompression or other active interventions
89494727|NCT03185247|Experimental|Group Intervention|10-week parent-child multi-family group
89494728|NCT02422017|Experimental|Timolol|Patients will receive one drop of timolol every 6cm ² every other day for twelve weeks in combination with dressings and compression.
89494729|NCT02422017|Other|Control|Local care treatment only (dressing and compression applied every other day)
89494730|NCT02761915|Other|Dose Level 1|Patients in Dose Level 1 will receive 1x10^7 1RG-CART/m^2 intravenously (IV) on Day 0.
89494731|NCT02761915|Other|Dose Level 2|Patients in Dose Level 2 will receive 300 mg/m^2/day of cyclophosphamide for four days (Days -4 to -1) followed by 1x10^7 1RG-CART/m^2 IV on Day 0.
89494732|NCT02761915|Other|Dose Level 3|Patients in Dose Level 3 will receive 300 mg/m^2/day of cyclophosphamide for four days (Days -7 to -4) and 25 mg/m^2/day of fludarabine for five days (Days -8 to -4), followed by 1x10^7 1RG-CART/m^2 IV on Day 0.
89494733|NCT02761915|Other|Dose Level 4|Patients in Dose Level 4 will receive 300 mg/m^2/day of cyclophosphamide for four days (Days -7 to -4) and 25 mg/m^2/day of fludarabine for five days (Days -8 to -4), followed by 1x10^8 1RG-CART/m^2 IV on Day 0.
89494734|NCT02761915|Other|Dose Level 5|If the required level of 1RG-CART survival is not reached, a further cohort of patients (Dose Level 5) will receive 300 mg/m^2/day of cyclophosphamide for four days (Days -7 to -4) and 25 mg/m^2/day of fludarabine for five days (Days -8 to -4), followed by 5-10x10^8 1RG-CART/m^2 IV which could be be split over two days (Day 0 and Day 1).
89494735|NCT02761915|Other|Patients who underwent leukapheresis but did not proceed to receive any IMP|Patients who were enrolled and underwent leukapheresis but who did not receive any IMP.
89494736|NCT02706327|Experimental|CAD/CAM|8-week follow-up with CAD/CAM insole and home based exercise program
89494737|NCT02706327|Experimental|Semi-custom|8-week follow-up with semi-custom insole and home based exercise program
89494738|NCT02706327|Placebo Comparator|Control|8-week follow-up with placebo insole and home based exercise program
89494739|NCT03619148|Other|High-Flow Humidified Nasal Oxygen - TOE participants|High-Flow Humidified Nasal Oxygen - standard care
89494740|NCT03619148|Active Comparator|High-Flow Humidified Nasal Oxygen|High-Flow Humidified Nasal Oxygen - staff volunteers
89494741|NCT02422095||Pancreatic fluid collections|Patients with pancreatic fluid collections undergoing endoscopy-based (EUS-guided) interventions
89205090|NCT03982303|Experimental|Hemay102 at the dosage of 90mg/m2|Hemay102 will be administered to patients through i.v. drip for 4hrs at the dosage of 90mg/m2.
89494742|NCT02422095||Pancreatic cysts|Patients with pancreatic cysts undergoing EUS examination and possible EUS-guided sampling of cystic fluid.
89205091|NCT03982303|Experimental|Hemay102 at the dosage of 120mg/m2|Hemay102 will be administered to patients through i.v. drip for 4hrs at the dosage of 120mg/m2.
89494743|NCT03464084|Other|bright light placebo|
89494744|NCT03464084|Other|bright light melatonin|
89205092|NCT04099979||Psoriasis patients|Patients who have been diagnosed with Psoriasis
89494745|NCT03464084|Other|dim light|
89494746|NCT05551208|Experimental|maintenance treatment|after 4-9 cycles chemotherapy containing platinum and bevacizumab, fluzopanib and bevacizumab were used for maintenance treatment
89494747|NCT02161003|Experimental|Stem Cells Isolation|"Stem cell isolation technique and Stem Cells Injection Technique The method of isolation of MSC from bone marrow will be carried out using the Ficoll-Paque technique for the isolation of mononucleated cells followed by the separation of MSC by adherence to plastic. Finally, the cells will be resuspended and counted using a hemocytometer.~Mononucleated cells will be cultured and incubated at 37°C in an atmosphere of 95% relative humidity and 5% CO2."
88954764|NCT01975688|Experimental|Sativex: pre-treatment (Grade 0)|The PKs of a single dose of Sativex are investigated in subjects with mucositis of Radiation Therapy Oncology Group (RTOG) Grade 0 (i.e. at baseline, pre-induction of mucositis).
88954765|NCT01975688|Experimental|Sativex: mild mucositis (Grade 1)|The PKs of a single dose of Sativex are investigated in the same subjects when their mucositis is RTOG is Grade 1 (mild).
88954766|NCT01975688|Experimental|Sativex: moderate mucositis (Grade 2)|The PKs of a single dose of Sativex are investigated in the same subjects when their mucositis is RTOG is Grade 2 (moderate).
88954767|NCT01975688|Experimental|Sativex: severe mucositis (Grade 3)|The PKs of a single dose of Sativex are investigated in the same subjects when their mucositis is RTOG is Grade 3 (severe).
88954768|NCT01975714|Experimental|Latanoprost (Period I) + Bimatoprost (Period II)|"Preservative-free latanoprost 0.005% Unit Dose (LUDPF) (Monoprost) eye drops will be administered every day at 21:00 for the first 3 months.~After the follow-up visit, patient will start Preservative-free bimatoprost 0.03% Unit Dose (BUDPF) eye drops every day at 21:00 for the last 3 months."
88954769|NCT01975714|Experimental|Bimatoprost (Period I) and Latanoprost (Period II)|"Preservative-free bimatoprost 0.03% Unit Dose (LUDPF) (Monoprost) eye drops will be administered every day at 21:00 for the first 3 months.~After the follow-up visit, patient will start Preservative-free latanoprost 0.005% Unit Dose (BUDPF) eye drops every day at 21:00 for the last 3 months."
88954770|NCT01975727|Placebo Comparator|Injection of Placebo|Intravenous Saline 0.9% 10 ml
88954771|NCT01975727|Active Comparator|Dexamethasone 3 mg|Intravenous Dexamethasone 3mg diluted in saline 0.9% up to 10 ml
88954772|NCT01975727|Active Comparator|Dexamethasone 6 mg|Intravenous Dexamethasone 6mg diluted in saline 0.9% up to 10 ml
88954773|NCT01975727|Active Comparator|Dexamethasone 12 mg|Intravenous Dexamethasone 12mg diluted in saline 0.9% up to 10 ml
88954774|NCT01975740|Experimental|Manual diaphragm release technique|
88954775|NCT01975740|Other|Sham manual diaphragm release technique|
88954776|NCT01975753|Active Comparator|Intravenous morphine|one bolus of intravenous morphine
88954777|NCT01975753|Experimental|nebulized morphine|"one nebulized bolus of morphine"
88954778|NCT01975753|Active Comparator|fentanyl|"one nebulized bolus of fentanyl"
88954779|NCT01975766|Experimental|Ketogenic diet|Ketogenic diet designed to sustain ketone levels through treatment.
88954780|NCT01975779|Experimental|Cohort A1: Lu AE58054 or placebo|
88954781|NCT01975779|Experimental|Cohort A2: Lu AE58054 or placebo|
88954782|NCT01975779|Experimental|Cohort B1: Lu AE58054|
88954783|NCT01975792||Preterm Admits|Women who are admitted for preterm labor observation and management
88954784|NCT01975805|Experimental|Chlorhexidine Gluconate|Use of Chlorhexidine Gluconate as skin disinfectant for cesarean section.
88954785|NCT01975805|Experimental|Povidone Iodine|Use of Povidone Iodine as skin disinfectant for cesarean section.
88954786|NCT01975844|Experimental|Individualized Anemia Mangement Protocol|"Single arm study, therefore all patients will participate in the following:~Phase 1 (1-3 months): Develop individualized patient models and Anemia Management Protocols (AMP) while patients are receiving standard medical care.~Phase 2 (9 months): Individualized AMP study period. Phase 3 (9 months): Follow up period: return to standard-care AMP ."
88954787|NCT01975857|Experimental|Mind-Body Bridging Program|The Mind-Body Bridging Program (MBBP) is an awareness training program (ATP) to help individuals improve their health condition and attain a state of well-being. Bridging is the primary technique that facilitates the healing process, by bringing one back to the present moment to experience thoughts, emotions and physical sensations. Bridging aims to reduce the impact of negative thought patterns that contribute to stress in the body.
88954788|NCT01975857|Active Comparator|Supportive Education|Supportive Education program will provide educational lectures on disability, sleep hygiene, and current research on depression and non-directive, supportive discussions about these topics.
88954789|NCT01975870|Experimental|intervention group|use of application on smartphone for lifestyle counseling
88954790|NCT01975870|No Intervention|control group|no use of application on smartphone
88954791|NCT01975883||Spine surgical patients|Sequential patients scheduled for spine surgery, including degenerative, deformative, tumoral and traumatologic indications are eligible to participate. Exclusion criteria are the following : infection or history of infection of surgical site, past medical history of diabetes mellitus, defined as chronic glucose intolerance either insulin-dependent or non insulin-dependent at the time of operation, and patients with preoperative random BG levels greater than 126 mg/dl considering they could also represent undiagnosed diabetes
88954792|NCT01975896|Experimental|Meditation|The intervention's curriculum will include: 1) the body scan; 2) training in the awareness of the sensations of breathing; 3) training in directing the attention to simple activities of daily life; 4) practice of 'open awareness' in which students will be instructed to just notice which events (physical sensation, sound, visual object, thought) their attention is spontaneously drawn to from moment to moment; 5) mindful movement (standing and walking exercises); and 6) mindful eating. In addition to the weekly training session, students will practice mindfulness techniques for 15 minutes daily in class with the health education teacher and for an additional 15 minutes daily on their own
88954793|NCT01975896|No Intervention|Health Education|The health education curriculum will be informed by: 1) the dietary and PA didactic units and materials developed as part of our school based trial, adapted for adolescents from the Diabetes Prevention Program (DPP) and 2) the standard curricula for school-based health education programs with particular attention to the unique needs of adolescents:increasing fruits and vegetables, reducing sugar sweetened drinks, and decreasing foods high in fat, unhealthy carbohydrates, and calories. The PA component will be based on current recommendations of engaging in at least 1 hour of moderate-to-vigorous physical activity (MVPA) most days of the week, building PA into the teen's lifestyle,and reducing sedentary behavior.
89022558|NCT00428870|Active Comparator|Conservative treatment|Standardized exercise rehabilitation (supervised by physiotherapist)
89538034|NCT03196063|Experimental|Modified protocol|"Patients allocated in this group will receive treatment based on a protocol published in a clinical practice guide, with modifications to make the protocol more pragmatic. Thus, the use of mechanotherapy devices will be replaced by free weight exercises, so that the protocol can be performed in environments that do not offer this type of machinery. This protocol is composed of four exercise stages, being the first three stages performed in the presence of the physiotherapist, and will last eight weeks with approximately 24 face-to-face sessions.~Both groups will receive a protocol with complementary isotonic exercises, focusing on the strengthening of gluteus maximus, gluteus medius, hamstrings and calves."
89538035|NCT03291977|Experimental|Fluorescein sodique FAURE|Fluorescein (Fluorescéine sodique FAURE) will be given intravenously during the induction of the anesthesia
89538036|NCT03291977|Active Comparator|White-light surgery|"In the control arm, the surgery will be performed under classical conditions (so-called  white-light  surgery)."
89538037|NCT02448979|Active Comparator|Left thoracotomy|Esophagectomy through left side transthoracic approach, with esophagogastric anastomosis above aortic arch and two-field lymphadenectomy (thoracic and abdominal lymph node)
89538038|NCT02448979|Active Comparator|Right thoracotomy|Esophagectomy through right side transthoracic approach, with esophagogastric anastomosis above azygos vain arch or on the top of chest cavity and two-field lymphadenectomy (thoracic and abdominal lymph node)
88954794|NCT01975961|Experimental|FDC YH16410|"Drug: Test treatment: FDC YH16410 (Telmisartan 80mg/ Rosuvastatin 20mg).~Subjects will receive single oral dose of 1 tablet of FDC containing Telmisartan 80mg and Rosuvastatin 20mg in fasted state"
88954795|NCT01975961|Active Comparator|Co-administration|"Drug: Reference Treatment: Co-administration(Telmisartan 80mg and Rosuvastatin 20mg).~Subjects will receive 1 x Telmisartan 80mg with 1 x Rosuvastatin 20mg tablet administered orally in fasted state as a single dose"
88954796|NCT01975987|Experimental|Intubation with the Bonfils fiberscope|"Characteristics of patients will be assessed before induction of general anesthesia~Glottic visualization will be evaluated by direct laryngoscopy.~The endotracheal tube will be loaded onto the scope~Intubation will be performed with the Bonfils fiberscope with the patient in supine position with head and neck in neutral position~Bonfils fiberscope will be inserted from the right side of the patient's mouth, alongside the molars and advanced underneath the epiglottis. With the tip of the Bonfils in satisfactory position, the endotracheal tube will be advanced into the trachea using gentle rotary motions. The scope will then be removed.~Accurate positioning of the endotracheal tube will be confirmed by capnography and lung auscultation."
88954797|NCT01976000||Group A|the surgeons were able to view 3D reconstructions before and during surgery
88954798|NCT01976000||Group B|the surgeons were only able to view 3D reconstructions after the surgery
88954799|NCT01976013|Other|Coaguchek|infants will receive sequential coagulation checks
89022559|NCT00469482|Active Comparator|Sedation, RASS Targeted|Patient sedation utilizing standard of care methods (RASS Targeted)
89022560|NCT00469482|Active Comparator|Sedation,RASS Targeted plus BIS Monitoring|Providing patient sedation utilizing standard of care methods (RASS) plus BIS monitoring.
89022561|NCT00428909|Other|Drug-Drug interaction|
89022562|NCT02956941|Experimental|BCC on Essential Nutrition and Hygiene Actions (ENHAs)|Intervention group will be received 12 months on nutrition behavior change communication using two modes (lecture, and posters).
89205093|NCT00303667|Experimental|SCT w/Donor Natural Killer Cells - short schema|Patients with high risk myeloid malignancies undergoing allogeneic hematopoietic stem cell transplantation, receiving fludarabine phosphate (daily dose of 40mg/m^2), cyclophosphamide (administered on Day -15 only), cyclosporin A, total body irradiation, natural killer cells, aldesleukin, and thymoglobulin.
89538039|NCT03287609|Active Comparator|Evolocumab|Evolocumab 140 mg/mL, pre-filled auto-injector pen, 3 injections at day 1 and week 4
89538040|NCT03287609|Placebo Comparator|Placebo|Placebo, pre-filled auto-injector pen, 3 injections at day 1 and week 4
89538041|NCT02448745|No Intervention|Control|21 clusters composed of one or more villages with a total number of 30 to 70 children under 5 years old. Routine distribution of long-lasting insecticidal nets is the only malaria control intervention.
89538042|NCT02448745|Experimental|Intervention|21 clusters composed of one or more villages with a total of 30 to 70 children under 5 years old. Routine distribution of long-lasting insecticidal nets is available and in addition insecticide treated wall lining is installed in all sleeping areas with homeowner consent. All 4 walls and the ceiling are covered with lining.
89494748|NCT05551130|Active Comparator|Equia Group|Equia system bulk fill glass hybrid material
89494749|NCT05551130|Active Comparator|Charisma Group|Charisma Smart universal composite resin
89494750|NCT02764333|Experimental|vaccine|Patients will receive an intradermal (ID) injection of TPIV200 (500 μg per peptide) and GM-CSF (125 μg per peptide) on Day 1 of cycles 1-6. They will also receive intravenous (IV) injections of durvalumab (750mg) on Days 1 and 15 of cycles 1-12. Radiologic tumor assessment will be repeated every 12 weeks (or 3 cycles) during and after treatment, until time of progression. Treatment will continue until progression, intolerance, withdrawal, study completion, or study termination.
89494751|NCT02158741|No Intervention|Usual Primary Care|Usual Primary Care will be received by half the participants during the course of the Study
89494752|NCT02158741|Active Comparator|Home Visits and educational support|Intervention comprised of Home Visits and group educational sessions. Home Visits and will be conducted by Diabetes Education staff in lieu of usual care conducted at the Diabetes clinic. Lifestyle support and educational will be offered in the form of monthly Diabetes Wellness Days offered in the community where nutrition, exercise and support will be given to help improve self-management of diabetes.
89494753|NCT02705625|Experimental|MIV-711:1|MIV-711 for a total of 26 w
89494754|NCT02705625|Experimental|MIV-711:2|MIV-711 for a total of 26 w
89494755|NCT02705625|Placebo Comparator|Placebo|Placebo for a total of 26 w
89494756|NCT02163109||Critically-ill patients|Adult patients requiring intubation and mechanical ventilation on an intensive care unit, predicted to require a further 48 hours of artificial ventilation
89494757|NCT05550974||LC|laparoscopic surgery using conventional laparoscopic instruments
89538043|NCT03287531|Experimental|conventional therapy (group I)|"Exercise therapy.~For muscles around TMJ :~Masetter Lateral Pterygoid Medial Pterygoid Temporalis Digastric~Pulsed ultrasound at 0.3 to 0.6 watts per sq cm over the lateral poles of the temporomandibular joint condyles with a small sound head for 2 to 3 minutes per side"
89022563|NCT02956941|No Intervention|Control cluster|Control group will receive routine dietary practices.
89022564|NCT00460902|Experimental|Deep TMS stimulation|
89022565|NCT00460902|Experimental|DTMS with positive cognitive-emotional provocation|
89022566|NCT00460902|Experimental|DTMS with negative cognitive-emotional provocation|
89205094|NCT00303667|Experimental|SCT w/Donor Natural Killer Cells - extended schema|Patients with high risk myeloid malignancies undergoing allogeneic hematopoietic stem cell transplantation, receiving fludarabine phosphate (daily dose of 35mg/m^2), cyclophosphamide (administered on Days -15 and -16), cyclosporin A, total body irradiation, natural killer cells, aldesleukin, and thymoglobulin.
89494758|NCT05550974||LW|Using wristed laparoscopic instruments (Artisential Maryland dissector, Artisential Fenestrated gasper)
89494759|NCT05550974||RC|Conventional robotic surgery
89494760|NCT05550974||RSS|Use of singlesite system for reduced port robotic surgery
89494761|NCT05550974||RSP|Use of da Vinci SP system for reduced port robotic surgery
89494762|NCT05550974||RRI|A new surgical robot Revo-i developed by Meerae company in Korea
89494763|NCT02161081|Experimental|Myocardial CT perfusion (21-second)|A total of 60 symptomatic patients will be randomized to dynamic CT perfusion protocol with 21-second scan duration.
89494764|NCT02161081|Active Comparator|Myocardial CT perfusion (30-second)|A total of 60 symptomatic patients will be randomized to dynamic CT perfusion protocol with 30-second scan duration.
89494765|NCT02422173|Experimental|Anodal tDCS|Participants in the acute post-stroke stage will receive anodal transcranial direct current stimulation
89494766|NCT02422173|Experimental|Cathodal tDCS|Participants in the acute post-stroke stage will receive cathodal transcranial direct current stimulation
89494767|NCT02422173|Experimental|Bilateral tDCS|Participants in the acute post-stroke stage will receive bilateral transcranial direct current stimulation
89494768|NCT02422173|Sham Comparator|Sham tDCS|Participants in the acute post-stroke stage will receive sham transcranial direct current stimulation
89494769|NCT05546216|Experimental|Experimental group|"Patients in the intervention group CAG exit Written informed consent was obtained from the patients for the study. Pretest data of the patients were collected at 0 hour using the Patient Information Form, Visual Analog Scale, State Anxiety Scale and Immobility Comfort Scale. After informing the patient with hemodynamics, at the 0th hour, a 36x33x10 cm gel-containing silicone pad was placed in the lumbar cavity of the patient to fill the patient's anatomical lumbar cavity, and CAG output was supported. The patient was in the supine position 30 degrees elevated when measured with the visual aid. Patients lie in the same position for 4 hours. Back pain of the patients was evaluated again with the Visual Analog Scale at the 2nd hour. At the 4th hour, the posttest data of the patients were collected with the Visual Analogue Scale, the State Anxiety Scale and the Immobility Comfort Scale."
89494770|NCT05546216|No Intervention|control group|"After the patients in the control group were placed in the supine position on the CAG exit, they were monitored, their vital signs were evaluated, and the necessary information of the patient was collected with the Patient Information Form, Visual Analog Scale, State Anxiety Scale and Immobilization comfort scale at the 0th hour of CAG exit. The patient was in a routine supine position without back support for 4 hours and received standard nursing care. After the . position was given, back pain was evaluated again at the 2nd hour and 4th hour using the Visual Analogue Scale. Anxiety and comfort levels were evaluated with the State Anxiety Scale and Immobilization Comfort Scale at the 0th minute before the position and at the 4th hour after the position ."
89494771|NCT02161159||Patients With Urinary Incontinence Due to iOAB|Patients with urinary incontinence due to iOAB treated with BOTOX® in accordance with physician standard practice.
89494772|NCT02421861|Experimental|Anxiety Management (AM)|
89494773|NCT02421861|Placebo Comparator|Usual Care (UC)|
89494774|NCT05546138||Type 1 diabetes without known peripheral neuropathy|"People with type 1 diabetes without known peripheral neuropathy with limited diabetes duration"
89494775|NCT02160925|Experimental|Preoperative 99mTc-Sestamibi SPECT/CT|
89494776|NCT02421783||NCWS patients|Consecutive adult patients with an irritable bowel syndrome (IBS)-like clinical presentation, according to Rome II criteria, and a definitive diagnosis of NCWS.
89494777|NCT02421783||CD patients|Sex- and age-matched subjects with CD, diagnosed according to standard criteria during the same study period and enrolled as first control group
89494778|NCT02421783||IBS patients|Sex- and age-matched subjects with IBS unrelated to NCWS or other food 'intolerance', diagnosed according to standard criteria during the same study period and enrolled as second control group
89494779|NCT02161237|Experimental|standard dose group|Oral
89494780|NCT02161237|Experimental|optimized dose group|Oral
89494781|NCT03326336|Other|Cohort|3 dose escalation cohorts (low, medium and high dose) with 3 subjects per cohort followed by an extension cohort at the highest-well tolerated dose with 3 to 9 subjects.
89494782|NCT03116607|No Intervention|Control|The control group will receive the usual hospital care. In addition, an interview that allows the characterization of the sample and the measurement of variables such as adherence, problems related to medication and user satisfaction.
89538044|NCT03287531|Experimental|low level laser therapy (groupII)|LLLT with the appropriate parameters (904 nm, 8 j/cm2, 250mw) for duration of 20 min with repletion of three treatment sessions per week.
89538045|NCT03195907||PPT group|Those participated in pulmonary rehabilitation program
88954800|NCT01976026|Experimental|Endovascular treatment with flow diversion|"Endovascular treatment with flow diversion, including standard management of thrombo-embolic risk. The goal of the treatment procedure is (as usual) to prevent rebleeding, while keeping treatment-related risks as low as possible.~This trial permits the interventionist or surgeon to use any device, technique or drug judged important to the safety and success of the endovascular or surgical procedure, at his/her discretion at any time during the procedure. It is imperative that the allocated procedure is conducted in the safest possible manner. The interventionist or surgeon may switch to an alternative BST or cross-over to the alternative treatment group, if it is in the best interest of the patient."
88954801|NCT01976026|Active Comparator|Best standard therapy|"May be any of the following:~Conservative management when no surgical or endovascular treatment is considered possible or reasonable~Conventional endovascular options including coiling with or without high-porosity stenting, and stent-in stent techniques~Parent vessel occlusion, with or without bypass~Surgical clipping or clip-wrapping (including parent vessel occlusion as a salvage procedure).~Choice of best option is based on the location, anatomy, and particular circumstances, before randomization for this patient's aneurysm.~This trial permits the interventionist or surgeon to use any device, technique or drug judged important to the safety and success of the endovascular or surgical procedure, at his/her discretion at any time during the procedure. The interventionist or surgeon may switch to an alternative BST or cross-over to the alternative treatment group, if it is in the best interest of the patient."
89494783|NCT03116607|Experimental|Intervened|"The intervention group will receive a Pharmaceutical Intervention Program during their stay in the Service and discharge.~In addition, an interview that allows the characterization of the sample and the measurement of variables such as adherence, problems related to medication and user satisfaction.~patient education/ recommendations to the health team"
89494784|NCT02161315||Observation group|Steroid Aromatase Inhibitors
89494785|NCT02161315||Control group|Non-Steroid Aromatase Inhibitor
89494786|NCT02430597|Experimental|IRE Group|irreversible electroporation for Unresectable Hilus Pulmonis Neoplasms
89494787|NCT02430597|No Intervention|Control|The patients without treatment
89494788|NCT03173066|Experimental|Single Arm|Patients with a clinical concern for pulmonary embolus but not able to receive iodinated contrast will be enrolled. Ferumoxytol will be administered as a contrast agent in coordination with magnetic resonance angiography to identify patency of the cardiopulmonary vasculature.
89494789|NCT03540823|Experimental|Patients with rheumatic diseases|Patients with diagnosis of adult and juvenile systemic lupus erythematosus (SLE and JSLE) and Sjogren syndrome (SSp)
89494790|NCT03540823|Other|Healthy controls|Healthy children and adults
88954802|NCT01976039|Other|RRC|rhinopharyngeal retrograde clearance (RRC) isolated: First patient sits in a chair. Second: patient inhales air deeply and exhales making noise and vibration in the upper airway to facilitate swalling. Third patients finishes with another deep inhalation. This technique is new, simple to use and with no cost. No need of any material or equipment.
88954803|NCT01976039|Experimental|RRC+S|retrograde rhinopharyngeal retrograde clearance combined with saline instillation (RRC+S): patient sits in a chair and inhaled air and make noise and vibrate the upper airway at the same instills saline into the nare to facilitate nose washing and swalling. This technique is new, simple to use and with low cost (only saline).
88954804|NCT01976052||Obstructive sleep apnea patients|Patients with obstructive sleep apnea that has not received CPAP treatment
88954805|NCT01976052||Matched volunteers with non OSA|Matched volunteers without OSA. Matched in respect to age and BMI
88954806|NCT01976052||Matched normal controls with normal BMI|Volunteers that are matched according to age but has a normal BMI
88954807|NCT01976078||Midazolam/Ranitidine/Esomeprazole|All enrolled subjects will have a study pharmacokinetic visit where they will be given the above cocktail of drugs along with their clinically indicated voriconazole dose, followed by blood sampling over the next 12 hours.
89494791|NCT02421627|Experimental|Moxibustion group|Receiving moxibustion treatment
89494792|NCT02421627|Sham Comparator|Sham moxibustion group|Receiving sham moxibustion.
89494793|NCT05546060|Experimental|Venetoclax Combined With Dexamethasone and Etoposide|Patients who met the inclusion criteria will receive venetoclax combined with dexamethasone and etoposide for 8 weeks.
89494794|NCT02161393|Experimental|Physical Activity Intervention|12 week home-based walking programme consisting of weekly physical activity consultations and a pedometer-driven walking programme
88954808|NCT01976117|Experimental|enose|
88954809|NCT01976130|Experimental|bronchoscopy|Procedure
88954810|NCT01976143|Experimental|NKTR-102|A single 90 minute IV infusion of 220 mg/m2 NKTR-102
89494795|NCT02161393|Active Comparator|Pulmonary Rehabilitation Programme|6-week supervised outpatient programme consisting of twice-weekly exercise sessions and once-weekly education sessions.
89494796|NCT02416869|Active Comparator|Intramuscular application|Intramuscular application of 4mg Dexamethasone
89494797|NCT02416869|Experimental|Submucosal application|Submucosal application of 4mg Dexamethasone
89494798|NCT02416869|Active Comparator|4mg Dexamethasone submucosal|4mg Dexamethasone submucosal application
89494799|NCT02416869|Experimental|8mg Dexamethasone submucosal|8mg Dexamethasone submucosal application
89494800|NCT02416869|Active Comparator|4mg Dexamethasone postoperative|4mg Dexamethasone postoperative application
89494801|NCT02416869|Experimental|4mg Dexamethasone preoperative|4mg Dexamethasone postoperative application
88954811|NCT01976156|Experimental|Phopsholean dietary supplement|Subjects in the Phospholean group will receive six capsules of PhosphoLean orally daily (total of 180 mg of NOPE and 120 mg of EGCG), ); two capsules consumed one hour before lunch, two capsules one hour prior to dinner, and two capsules two hours after dinner.
88954812|NCT01976156|Placebo Comparator|Placebo (rice flour) group|The control (placebo) group will receive a placebo (identical in appearance, but containing 100 mg of rice flour per capsule).
88954813|NCT01976195|Experimental|Thalidomide plus HD-Dexmamethasone|Thalidomide 150mg per day, 15 consecutive days Dexamethasone 40 mg per day, 4 consecutive days
89494802|NCT02163265|Experimental|Surgery|Patients suffering from Pectus excavatum and Pectus carinatum will be surgically treated
89494803|NCT03107013|Experimental|[14C]-BTD-001|
89494804|NCT02161471||Aortic coarctation|Patients after repair of coarctation of the aorta
89494805|NCT02161471||Tetralogy of Fallot|Patients after repair of tetralogy of Fallot
89494806|NCT02161471||TGA atrial switch|Patients with transposition of the great arteries after atrial switch (Senning procedure)
89494807|NCT02161471||TGA arterial switch|Patients with transposition of the great arteries after arterial switch operation
89494808|NCT02161471||Normal|Normal controls
89494809|NCT02410395|Active Comparator|Conventional technique|Closure of the uterotomy with a conventional two-layer technique
89494810|NCT02410395|Experimental|Modified technique|Closure of the uterotomy with a modified two-layer technique
89494811|NCT03731299||Stroke|Individuals suffered from a haemorrhagic or ischaemic stroke. Diagnosis has to be confirmed on the basis of CT or MRI imaging.
89494812|NCT03731299||Healthy adults|Healthy individuals without any neurological or orthopaedic disorder that could influence motor performance and balance
89494813|NCT03178929|Experimental|S-Adenosyl Methionine Treatment|"Patients will be treated with S-Adenosyl Methionine treatment after radical treatment.~2000mg, po"
89494814|NCT03178929|No Intervention|control group|Patients will be treated without S-Adenosyl Methionine treatment after radical treatment.
89494815|NCT02161861|Experimental|group cFEE|"The group cFEE will be similarly inseminated with 100000/ml motile spermatozoa and will be supplemented with cFEE 100µM during 18 hours.~The cFEE will increase the fusiogenic capacities of a gamete,"
89494816|NCT02161861|No Intervention|untreated group|control group
89494817|NCT02416557|Experimental|Group P|Patients using positive end-expiratory pressure (PEEP) of 10 cmH2O (centimeter of water) intraoperatively
89494818|NCT02416557|No Intervention|Group C|Patients using no positive end-expiratory pressure (zero PEEP) intraoperatively
89494819|NCT02588612|Experimental|letetresgene autoleucel (GSK3377794)|Eligible participants will be leukapheresed to manufacture engineered T-cells. Participants will then receive letetresgene autoleucel (GSK3377794), as a single intravenous (IV) infusion after completing lymphodepleting chemotherapy.
89494820|NCT02416479|Experimental|SystemCHANGE|SystemCHANGE supports patient-designed, interventionist-guided, small experiments to: 1) assess individual systems (including important others who shape medication taking) and the system's impact on medication taking and propose individual system solutions to improve MA, 2) implement the proposed individual systems' solutions to improve MA, 3) track MA data, and 4) evaluate MA data.
89494821|NCT02416479|Active Comparator|Patient-education attention-control|The 6-month Patient education attention-control (AC) intervention includes 6 transplant educational materials, covering healthy post-transplant behavior, developed by the International Transplant Nurses Society. The RA calls Pps at 1, 2, 3, 4, 5 and 6 months to review the brochure information and answer any questions about it.
89494822|NCT03540979|Active Comparator|Estrogen|Endometrial preparation: Estrogen supplements (Estradiol 6mg/d) will be started at the 2nd-3rd day of the cycle. First US scan will be performed after 10 days. If necessary, adjusting the estradiol doses will be performed according to the physician decision. After achieving trilinear endometrial thickness ≥8mm progesterone supplements (Endometrin 100mg*3/d) will be administrated. Embryo transfer will be performed after completing 5 days of progesterone supplements (at the 6th day after starting the progesterone supplements).
89494823|NCT03540979|Experimental|Letrozole|Women in the Letrozole arm will be treated with Aromatase inhibitors ( Letrozole; 2.5 mg per day) starting at the 3rd day of the cycle for 5 days. US scan,and blood work for serum Estradiol (E2) and progesterone (P) will initially be examined 3-5 days after the last Letrozole pill. Following US scans and serum E2+P will be performed according to the treating physician decision. When US scan demonstrate trilaminar endometrium ≥8 mm and the dominant follicle will be ≥18mm, hCG will be administrated ( recommbinant hCG - Ovitrelle 250 mcg) and 3 days later vaginal Endometrin 100mg*3/d will be started. Single vitrified-warmed blastocyst transfer will be performed after completing 4 days of the progesterone supplements (7 days from hCG administration).
89494824|NCT02416401|Experimental|Experimental Treatment|Computerized plasticity-based adaptive cognitive training requiring a total maximum of 36 treatment sessions, 4-5 times weekly, one hour each session.
89494825|NCT02416401|Active Comparator|Active Comparator|Commercially available computerized training requiring a total maximum of 36 treatment sessions, 4-5 times weekly, one hour each session.
88954814|NCT01976195|Active Comparator|Dexamethasone|Dexamethasone 40 mg per day, 4 consecutive days
89494826|NCT02158819|No Intervention|TKA with standard instrumentation|This arm consists of the Genesis II Total knee implant system or the Legion Primary total knee system with standard instrumentation
89494827|NCT02158819|Active Comparator|Total knee arthroplasty with Visionaire|This arm will consist of the Genesis II Total Knee Implant System or Legion Primary Total Knee System with the Visionaire patient-matched instrumentation
89494828|NCT03174873|Other|Laparoscopy for unexplained infertile couples|
89494829|NCT02946788|Experimental|BPX-01 1%|BPX-01 1% minocycline topical gel
89494830|NCT02946788|Experimental|BPX-01 2%|BPX-01 2% minocycline topical gel
89538046|NCT03195907||Control group|Those served as control group
89494831|NCT02420925|Experimental|Celiac Plexus Block|There is one treatment arm who undergoes celiac plexus block.
89494832|NCT02158897|No Intervention|Control|Participants will consume their normal diet. Body weight and physiological change at two time points (approximately 2-3 months apart) will be examined. The participants will be crossed over to the diet group.
89494833|NCT02158897|Experimental|Prolon Diet|Participants will be provided with a 5-day supply of fasting-mimicking diet, including energy bars, soups, drink packets and dietary supplements. Participants will diet for 3 cycles. Each one-month cycle consists of 5 days of dieting with a calorie intake estimated at 600-1200 calories per day. The rest of the month participants will eat normally. After 3 cycles, participants will be examined again after consuming their normal diet after 2-3 months.
89494834|NCT05550740|Experimental|RLRL therapy|In addition to SVS, participants will be treated with RLRL twice a school day.
89494835|NCT02159131|Experimental|OC containing levonorgestrel and ethinyl estradiol + GSK126574|Eligible subjects will enter a run-in-period of 21 days (may extend to 49 days) to stabilize on OC containing levonorgestrel and ethinyl estradiol in order to synchronize the menstrual cycles of multiple subjects. Subjects completing run-in-period will enter Treatment period 1 and will be dosed OC once daily on Days 1 to 10. At day 11 subjects will enter Treatment period 2 and will be dosed with OC containing levonorgestrel and ethinyl estradiol + 744 once daily on Day 12 to 19. Subjects completing Treatment period 2 will have 7 OC free days (Day 22 to 28) during which withdrawal menses should occur. Subjects will then be followed up for 7 to 14 days (Day 28 to 35/49).
89494836|NCT02420769||Threatened abortion|Pregnant patients > 8 weeks gestation coming to the ANC clinic with mild vaginal bleeding but healthy viable intrauterine pregnancy. Vaginal color doppler for uterine artery and corpus luteum together with serum progesterone and CA125 will be assessed.
89494837|NCT05550506||Duloxetine Group|Patients who use duloxetine at least 3 months for chronic pain or fibromyalgia
89494838|NCT05550506||Healthy Group|Age and sex matched 51 healthy individuals
89494839|NCT02159209||Drug Induced Renal Injury (DIRI)|This is a prospective observational cohort study of patients who have developed acute kidney injury Stage 2 or a glomerular disorder following exposure to specific drugs that have been associated with DIRI.
89494840|NCT03178695|Experimental|Treatment Group|PRP is freshly isolated from patients with diminished ovarian reserve as determined by at least one prior IVF cycle canceled for poor follicular recruitment response, or estimated by serum AMH and/or FSH, no menses for ≥1 year. Immediately following substrate isolation and activation with calcium gluconate, approximately 5 mL of autologous PRP is injected into each ovary under direct transvaginal sonogram guidance. AMH, FSH, and serum estradiol data will be recorded at 2wk intervals post-PRP and compared to baseline (pre-PRP) values.
89494841|NCT03178695|No Intervention|Comparison Group|Data collected from all patients in the Treatment Group will be compared to a dataset compiled from 25 - 50 women of similar age having received like treatment via IVF and gonadotropin stimulation for positive fertility outcomes in past clinical work at the Center for Advanced Genetics, as a comparison model and substitute control group. The purpose of this comparison will be to determine overall efficacy of the Inovium Ovarian Rejuvenation Treatment as separated from the standard efficacy rates of CAG-established IVF processes and gonadotropins used in the trial.
89494842|NCT05545982|Experimental|Intubation with Miller approach|"Posttest group: Patient receive intubation with conventional video laryngoscope with Miller approach.~Pretest group: Patient receive intubation with conventional video laryngoscope with Macintosh approach."
89494843|NCT02162017|Experimental|The lying flat intervention|Patients in lying flat intervention to be nursed lying flat (0°) immediately after diagnosis of acute stroke is made and to remain in this position for 24 hours
89494844|NCT02162017|Active Comparator|The sitting-up intervention|Patients in the sitting up intervention to be nursed with their head elevated (≥30°) by raising the head of the bed (or with extra pillows or wedge) immediately after the diagnosis of acute stroke is made, and to remain in this position for the next 24 hours
88954815|NCT01976208|Experimental|Omalizumab|During the 4~6-week Run-in phase, the dosage of budesonide inhaled powder(BUD) was prescribed and optimized to maintain asthma control according to Global Initiative for Asthma(GINA, 2008) guidelines. During the following treatment phase, patients continued to receive optimized BUD and Omalizumab for 28 weeks, administered by subcutaneous injection every 2 weeks or 4 weeks. The dosage of Omalizumab received was based on body weight and serum IgE.
88954816|NCT01976208|Placebo Comparator|placebo|During the 4~6-week Run-in phase, the dosage of budesonide inhaled powder(BUD) was prescribed and optimized to maintain asthma control according to Global Initiative for Asthma(GINA, 2008) guidelines. During the treatment phase, patients continued to receive placebo and optimized BUD for 28 weeks, administered by subcutaneous injection every 2 weeks or 4 weeks.
88954817|NCT01976221||Prioritization|Team-based multifaceted interactive training
88954818|NCT01976234|Active Comparator|Fresh group|Fresh group will receive RBC stored for less than 14 days
88954819|NCT01976234|Active Comparator|Old group|Old group will receive RBC stored for 14 days or more
89494845|NCT02416323|No Intervention|Usual Care|Community therapist delivers routine care to participant child with no training in AIM HI.
89494846|NCT02416323|Other|AIM HI Training|Therapist enrolls in AIM HI training
89494847|NCT05545904|Experimental|Intervention arm|Participants randomized to the intervention arm will undergo a substance use screening and brief intervention delivered by the peer-mentors. Screening will be performed using the ASSIST-Y (28). The brief intervention will be delivered in a single session (20-30 minutes) using the FRAMES model i.e.(i) providing feedback on screening results (ii) ensuring responsibility on the part of the adolescents (iii) giving clear advice to stop/cut down (iv) giving menu of options (alternative healthy behaviors to engage in) (v) expressing empathy, and (vi) encouraging self-efficacy (15). The BI will be delivered for the highest scoring substance or the one the adolescent identifies as the most problematic.
88954820|NCT01976325|No Intervention|Standard Care|This arm will receive no intervention; only standard medical care.
88954821|NCT01976325|Experimental|Decision Aid + Standard Care|This group will receive the intervention (the Ottawa Malaria Decision Aid), in addition to standard medical care.
89494848|NCT05545904|Placebo Comparator|Control arm|Participants assigned to the control arm will participate in a substance use education intervention. This intervention will entail review of material in the NACADA substance use education manual for adolescents, and will be followed by a question and answer session. The manual contains summarized and simple information on the harms and myths related to alcohol, tobacco, cannabis, prescription medication and khat use, substances. This education intervention will be delivered over a single 20-30 minute session by a counselor stationed at Rafiki clinic.
89494849|NCT03174951|Experimental|Treatment group|IVIg group
89494850|NCT03174951|No Intervention|control group|Patients who do not receive any treatment despite a history of Recurrent Pregnancy Loss problem as controls
89494851|NCT02163343||No treatment|
88954822|NCT01976351||Barrett's esophagus|Patients were eligible for the study if they were scheduled for endoscopic examination at the National Taiwan University Hospital and its Yun-Lin branch, because of a BE, with or without a previous history of dysplasia. Exclusion criteria included patients who are younger than 20 years of age or patients with esophageal or cardiac varices or pregnant women.
89494852|NCT05700968||patients diagnosed with cardiac disease|
89494853|NCT03174795|Experimental|RO7079901 and Meropenem|Participants will receive RO7079901 and meropenem. The duration of study drug treatment will be determined by the investigator after evaluation of the participant's response to study drug treatment. Participants should receive a minimum treatment period of 3 days and up to 14 days of intravenous (IV) study drug treatment.
89494854|NCT02163655|Placebo Comparator|PLACEBO|PLACEBO: placebo, oral, every 24 hours for maximum 5 days
89494855|NCT02163655|Experimental|FUROSEMIDE|FUROSEMIDE: 20mg furosemide, oral, every 24 hours for maximum 5 days
89494856|NCT02162095||Chronic obstructive pulmonary disease|Approximately 100 participants with documented chronic obstructive pulmonary disease (post-bronchodilator Forced expiratory volume in 1 second (FEV1)/Forced vital capacity (FVC) < 0.7).
89494857|NCT02162095||Control|Approximately 100 participants with exclusion of chronic obstructive pulmonary disease (post-bronchodilator Forced expiratory volume in 1 second (FEV1)/Forced vital capacity (FVC) > 0.7).
89494858|NCT02410083|Experimental|Clopirin 1|Clopirin single-administration. Before this clinical trial Clopidogrel/Aspirin co-administration.
89494859|NCT02410083|Active Comparator|Clopidogrel/Aspirin co-administration 1|Clopidogrel-aspirin co-administration. Before this clinical trialClopidogrel/Aspirin co-administration.
89494860|NCT02410083|Experimental|Clopirin 2|Clopirin single-administration. Before this clinical trial Aspirin single-administration.
89494861|NCT02410083|Active Comparator|Clopidogrel/Aspirin co-administration 2|Clopidogrel-aspirin-co-administration. Before this clinical trial Aspirin single-administration.
89494862|NCT02162173|Experimental|Endoscopy|All patients underwent the same endoscopy.
88954823|NCT01976377||Stage I, II, III, IV HNSCC|Stage I, II, III, IV HNSCC reveive treatment in NTUH
88954824|NCT01976403|Experimental|Pain booklet|
88954825|NCT01976403|No Intervention|standard care|
89494863|NCT02416245|Experimental|Test beverage powder|Test beverage powder is fortified with micronutrients and Bacopa monnieri extract. Each sachet contains 32g of treatmemt product and 6g dairy whitener. Entire content of the sachet will be stirred with 180mL of potable lukewarm water, and given orally twice daily
89494864|NCT02416245|Placebo Comparator|Control beverage powder|Control beverage powder is the non-fortified isocaloric powder i.e. without micronutrients and Bacopa Monnieri extract. Each sachet contains 32g of placebo product and 6g dairy whitener. Entire content of the sachet will be stirred with 180mL of potable lukewarm water, and given orally twice daily
89494865|NCT02716376|Experimental|Otovent®|Otovent® is a special designed balloon that is blown up through the nose, also referred to as auto-inflation of the eustachian tube. The patients use the Otovent® 5 times a day.
89494866|NCT02716376|No Intervention|No treatment|Observation: No treatment.
89494867|NCT02416167|Active Comparator|FYU-981 High dose|Drug: FYU-981 High dose, (Oral daily dosing for 8 week-maintenance period) Subjects randomized to the FYU-981 High dose arm receive active drug, FYU-981 High dose.
89494868|NCT02416167|Active Comparator|FYU-981 High middle dose|Drug: FYU-981 High middle dose, (Oral daily dosing for 8 week-maintenance period) Subjects randomized to the FYU-981 High middle dose arm receive active drug, FYU-981 High middle dose.
89494869|NCT02416167|Active Comparator|FYU-981 Middle dose|FYU-981 Middle dose, (Oral daily dosing for 8 week-maintenance period) Subjects randomized to the FYU-981 Middle dose arm receive active drug, FYU-981 Middle dose.
89494870|NCT02416167|Active Comparator|FYU-981 Low dose|Drug: FYU-981 Low dose, (Oral daily dosing for 8 week-maintenance period) Subjects randomized to the FYU-981 Low dose arm receive active drug, FYU-981 Low dose.
89494871|NCT02416167|Placebo Comparator|Placebo|Drug: Placebo, (Oral daily dosing for 12 weeks) Subjects randomized to the placebo arm receive placebo.
89494872|NCT05550350|Experimental|DEXYCU|DEXYCU, 103.4 mcg/mcl dexamethasone: equivalent dexamethasone dose: 517 mcg
89494873|NCT05550350|Placebo Comparator|Placebo|Placebo/vehicle, 0 mcg/mcl dexamethasone: equivalent dexamethasone dose: 0 mcg
89494874|NCT02166619|Experimental|tDCS + physical therapy|Firstly, patients will undergo electrophysiological evaluation: motor evoked potential, motor threshold and silent period in both hemispheres. After those procedures, bihemispheric tDCS will be applied with duration of 20 minutes, intensity of 2 mA where anodal electrode will be on the affected hemisphere and the cathodal electrode, on the non-affected hemisphere. After tDCS, patients will be submitted to 40 minutes of physical therapy protocol. Experimental sessions will be repeated five times per week to complete 10 sessions.
88954826|NCT01976429|Other|asymptomatic on flight/dive|individuals who experience no middle-ear problems on flying or diving
88954827|NCT01976429|Other|symptomatic on flying/diving|individuals who have experienced middle-ear problems on flying or diving
88954828|NCT01976468||SCC metastasis|organ transplant recipients
88954829|NCT01976481|Experimental|Sunbed|sunbed exposure
88954830|NCT01976481|No Intervention|Observation|only observation of subjects recruited after randomization
89494875|NCT02166619|Sham Comparator|Sham tDCS + physical therapy|Firstly, patients will undergo electrophysiological evaluation: motor evoked potential, motor threshold and silent period in both hemispheres. After those procedures, bihemispheric sham tDCS will be applied. Anodal electrode will be on the affected hemisphere and the cathodal electrode, on the non-affected hemisphere. Sham tDCS will be performed by ramping current flow for the first 10 seconds of stimulation, but switching the stimulator off after 30 seconds. After bihemispheric sham tDCS, patients will be submitted to 40 minutes of physical therapy protocol. Experimental sessions will be repeated five times per week to complete 10 sessions.
89494876|NCT02416089|Experimental|Tampostat|Tampostat™ is a self-regulating, low cost, pressure based emergency obstetric device designed specifically for use in low-resource settings. It has 6 parts: probe, condom, O ring, nerve centre, tube and bulb pump. It offers significant benefits over the current model by simplifying the insertion process, reducing the need for constant monitoring, eliminating leakage and the need for sterile saline, and using a pressure-based mechanism to apply consistent pressure to all women regardless of uterus size.Women who develop PPH even after applying AMTSL at the hospital or women who visit the hospital with PPH within 24 hours after delivery will be managed by Tampostat for the intervention arm or by the condom catheter tamponade in the control arm(172 patients in each arm)
89494877|NCT02416089|Active Comparator|Condom catheter tamponade|Condom catheter tamponade have been used by medical professionals for several years in the management of atonic (primary) PPH. In this approach, Sterile rubber catheter fitted with a condom as a tamponade balloon device and using normal saline to inflate the condom.
89494878|NCT02420535|Experimental|Immediately Receive Tool|Caregiver/Care Recipient Dyad will be randomly assigned to immediately receive the WeCareAdvisor Tool for 4 weeks.
89494879|NCT02420535|Active Comparator|One Month Delay|Caregiver/Care Recipient Dyad will be randomly assigned to a 4 week delay (usual care activities only) before receiving the WeCareAdvisor Tool for 4 weeks.
89494880|NCT02163889||Candida Positive Patients|Symptomatic adult patients, confirmed via blood culture with species identification to be positive for Candida
89494881|NCT02420457||Back pain receiving epidural injection|Patients who have chronic back pain and are scheduled for an epidural injection to treat this pain will be receive a transforaminal epidural steroid injection as determined by routine care provider
89494882|NCT02166853|Experimental|conventional group|"a conventional group, in which intravenous sedation with midazolam will be administered"
88954831|NCT01976494|Experimental|domestic PCA equipment|Patient controlled analgesia by the domestic PCA equipment
89494883|NCT02166853|Experimental|sevoflurane group|"a sevoflurane group, in which patients will inhale sevoflurane during a 48 hour-period, through dedicated devices"
89494884|NCT02704689|Experimental|AccuLIF|
89494885|NCT02162251||E2020|
89494886|NCT02164045|Experimental|BMS-663068- Fasted|BMS-663068 tablet twice a day by mouth on specified days
89494887|NCT02164045|Experimental|BMS-663068- Fed|BMS-663068 tablet twice a day by mouth on specified days
89494888|NCT02704143|Experimental|Combination of Cyberknife with S-1|Patients with locally advanced pancreatic cancer meeting all inclusion criteria will receive combination of Cyberknife with S-1.
89494889|NCT02586506|Experimental|Placebo ELLIPTA inhaler|Subjects will be provided the ELLIPTA inhaler, which is a molded plastic two-sided inhaler that holds two individual blister strips containing either lactose or a blend of lactose and magnesium stearate. Subjects will continue to use regular COPD medications throughout the study as per protocol.
89494890|NCT05550116|Active Comparator|Icon resin infiltration material|Smooth surface resin infiltration comprises three steps for resin infiltration; Icon etch, Icon dry, and Icon infiltrant
89494891|NCT05550116|Experimental|PRG Barrier Coat|fluoride-releasing coating material containing surface reaction-type pre-reacted glass-ionomer (S-PRG) fillers
89494892|NCT05550116|Experimental|Permaseal composite resin sealant|Permaseal unfilled composite resin sealants
89494893|NCT05550116|Experimental|Optiguard|Optiguard unfilled composite resin sealant
89494894|NCT02410005|Active Comparator|Losartan alone|In the losartan alone group, subjects are prescribed: losartan 50mg twice daily.
89494895|NCT02410005|Experimental|Losartan and Calcitriol|In the losartan plus calcitriol group, subjects are prescribed: losartan 50mg twice daily and calcitriol 0.25mcg daily.
89494896|NCT02166931|Placebo Comparator|placebo|placebo with the same color, order, taste as BRAND'S® Essence of Chicken , 70cc daily for 2weeks
89494897|NCT02166931|Experimental|Chicken Essence|BRAND'S® Chicken Essence 70cc, daily for 2 weeks
89494898|NCT02420145|Experimental|Yoga|This group will participate in 12 weeks of yoga
89494899|NCT02420145|No Intervention|Waitlist|No intervention
89494900|NCT02410239|Experimental|Mesenchymal Stem Cell|Third party donor Mesenchymal Stem Cells (MSC) will be administered via intrathecal administration at the assigned dose on days 0, 7 and 14. Dose escalation will be guided by a fast track design. One patient is entered per dose level until a DLT is experienced. At that point, two additional patients will be enrolled at the same dose level. Dose levels will be 2.5 x 10e6 MSC/kg per dose, 5 x 10e6 MSC/kg per dose or 7.5 x 10e6 MSC/kg per dose.
89494901|NCT02255617|Experimental|Fecal Microbiota Transplant|Single arm open label FMT administered at Week 0 by colonoscopy and at Weeks 1-4 by enema
89494902|NCT05543330|Experimental|Experimental group|Pleural drainage and M701 infusion
89494903|NCT05543330|Sham Comparator|Control group|Pleural drainage only or plus chemotherapy as investigator's choice.
89494904|NCT03174561|Other|Inuline, Choline and Silymarin + Diet|"Patients diagnosed with Irritable bowel syndrome who will follow diet restrictions together with a dietary supplement.~Intervention: Dietary Supplement, a combination of Inuline, Silymarin and Choline The dose: 1 sachet first 7 days and 1 sachet x 2 times daily for the next 21 days"
89494905|NCT03174561|Other|Diet restriction|Patients diagnosed with Irritable bowel syndrome who will follow diet restrictions for 28 days. After the first month the patients are crossed between groups.
89494906|NCT02164123|Experimental|Spinal mobilization|20 subjects will be randomized to this arm. A postero-anterior (PA) mobilization, to the fourth thoracic vertebra will be applied, for 3 sets of one minute. The subject will be comfortable prone lying.
88954832|NCT01976494|Active Comparator|imported PCA equipment|Patient controlled analgesia by imported PCA equipment
89205095|NCT01066741|Experimental|Homeodent®|Mouthwash with Homeodent® is started on the first day of irradiation, then continued until the end of the irradiation period or until occurrence of grade ≥3 mucositis. In case of grade ≥3 mucositis, patients are instructed to mouthwash with Sodium Bicarbonate solution until complete disappearance of mucositis or until the end of irradiation.
89494907|NCT02164123|Active Comparator|Spinal Mobilization II|20 subjects will be randomized to this arm. A postero-anterior (PA) mobilization, to the fourth thoracic vertebra will be applied, for 3 sets of one minute, but in this case, the subject will be seated, in a position that influence the sympathetic trunk, at the thorax.
89494908|NCT02164123|Placebo Comparator|Placebo|20 subjects will be randomized to this arm. Only manual contact will be applied, without any oscillation. The subject will be comfortable prone lying. The intervention time is the same of the other arms.
89494909|NCT02420301|Experimental|Exercises on real points|Self administered exercises were done in real treatment points
89494910|NCT02420301|Placebo Comparator|Exercises on false points|Self administered exercises were done in false treatment points
89494911|NCT05545592|Experimental|Low oestrogen|The patients take orally estradiol tablets 2 mg (Femoston) q.d. during the HRT-FET cycles
89494912|NCT05545592|No Intervention|Regular oestrogen|The patients take orally estradiol tablets 2 mg (Femoston) t.i.d. during the HRT-FET cycles
89494913|NCT02167087|Experimental|Sentinel node mapping|Sentinel node mapping with indocyanine green injected orally and anally to the tumor.
89494914|NCT05545436|Experimental|Camrelizumab + SOX (oxaliplatin + Teggio) /XELOX (oxaliplatin + capecitabine )|Camrelizumab + SOX / XELOX
89494915|NCT03174639|Experimental|Inverted and free ILM insertion|Both inverted and free ILM flaps were inserted into the macular hole
89494916|NCT02164279||Progressor (ND)|Group of patients with an albuminuria > 100mg/L, by Urinary sample collection
89494917|NCT02164279||Non-Progressor (non-ND)|Group of patients without an albuminuria > 100mg/L, by Urinary sample collection
89494918|NCT05545358||Amputees with phantom pain|Adult patients who have been amputated for more than 2 years and have chronic phantom pain
89494919|NCT05545358||Amputees without phantom pain|Adult patients who have been amputated for more than 2 years and do not have chronic phantom pain
89494920|NCT05545358||Healthy participants|Healthy adult participants with no neurological history
89494921|NCT02167165||Digoxin and AF|Patients consulting the emergency deprtment (ED) for AF and receiving Digoxin treatment
89494922|NCT05545124|Experimental|Donafenib+Tislelizumab|Donafenib+Tislelizumab
89494923|NCT02409849|No Intervention|control group|
89494924|NCT02409849|Experimental|Octreotide LAR treatment|The patients with unresectable or metastatic GEP or esophageal NEC who got CR/PR/SD after chemotherapy with IP or EP regimen qualified with the inclusion criteria are enrolled. All the patients enrolled in our study will be randomly assigned to receive octreotide LAR (group A) as maintenance treatment or follow up (group B) to disease progression.
89494925|NCT02162407|Experimental|Insulin detemir 60 pmol/kg/min|Subjects will be randomised to one of six treatment sequences (the 3 test drugs given at 3 different trial days 7-28 days apart in randomised order)
89494926|NCT02162407|Experimental|Insulin detemir 120 pmol/kg/min|Subjects will be randomised to one of six treatment sequences (the 3 test drugs given at 3 different trial days 7-28 days apart in randomised order)
89494927|NCT02162407|Active Comparator|Human insulin 6 pmol/kg/min|Subjects will be randomised to one of six treatment sequences (the 3 test drugs given at 3 different trial days 7-28 days apart in randomised order)
89494928|NCT02409693||Myringotomy with tube insertion|Patients who received surgically inserted ear tubes.
89494929|NCT02162485|Experimental|Salmeterol/fluticasone Easyhaler|Single dose of Salmeterol/fluticasone Easyhaler
89494930|NCT02162485|Experimental|Salmeterol/fluticasone Easyhaler with charcoal|Single dose of Salmeterol/fluticasone Easyhaler with concomitant charcoal administration (Carbomix granules)
89494931|NCT02162485|Active Comparator|Seretide Diskus|Single dose of Seretide Diskus
89494932|NCT02162485|Active Comparator|Seretide Diskus with charcoal|Single dose of Seretide Diskus with concomitant charcoal administration (Carbomix granules)
89494933|NCT02415777|Experimental|udca003|udca003
89494934|NCT02415777|Placebo Comparator|placebo|placebo of udca003
89494935|NCT02409771|Experimental|Intervention arm|Bilateral implantation with PRECIZON Presbyopic intraocular lens
89494936|NCT05543018|Active Comparator|Silicon oil group|Patients diagnosed with retinal detachment and undergone vitrectomy operation with silicon oil tamponade.
89494937|NCT05543018|Active Comparator|Air tamponade|Patients diagnosed with retinal detachment and undergone vitrectomy operation with air tamponade.
89494938|NCT05543018|Active Comparator|Non-expansile gas|Patients diagnosed with retinal detachment and undergone vitrectomy operation with non-expansile gas tamponade (sulfur hexafluoride).
89494939|NCT02409615|Active Comparator|Hypnosis Group|Hypnosis Group: fifteen participants will receive Hypnosis therapy in addition to the standard postoperative pain management protocol
89494940|NCT02409615|Active Comparator|Healing Touch Group|Healing Touch Group: fifteen participants will receive Healing Touch therapy in addition to the standard postoperative pain management protocol
89494941|NCT02409615|No Intervention|Control Group|Control Group will receive standard postoperative pain management protocol
89494942|NCT03178539|Active Comparator|diclofenac|patients will receive intra-operative diclofenac sodium at dose of 0.3 mg/kg intravenously then will continue postoperatively on the same drug received intra-operative.
89494943|NCT03178539|Active Comparator|ketorolac|patients will receive intra-operative ketorolac tromethamine at dose of 0.5 mg/kg intravenously then will continue postoperatively on the same drug received intra-operative.
89531757|NCT05527587|Experimental|Nature Connections Group|Participants will be screened to confirm their eligibility to partake in the study. Participants who meet the study criteria will then be invited to participate in the nature connections intervention. At the start of the intervention, mid-intervention and post intervention, participants will be invited to participate in assessments of their behaviour and mood symptoms, cognition, quality of life, caregiver burden and stress levels using different measures and questionnaires at the University of Calgary. Participants will be provided with a visit passport to record a log of activities completed during the park visits.
89494944|NCT03178305|Experimental|Intervention|"Besides the behavior change programme (Do Something Different)~All patients will receive: Fitbit, Beddit, Care-portal, Do CHANGE app (including dietary habits picture taking), CookiT (smart spatula that monitors cooking behavior)~patients with heart failure will, in addition to the above mentioned, be offered a weight scale, blood pressure monitor, and FluiT (smart cup to measure fluid intake).~Patients with hypertension will also be offered a bloodpressure monitor.~Data from these devices will be gathered and visible for patients (in patient portal) and for their health care provider (health care provider portal). In case of negative results the patient will be contacted by their health care provider (usually the cardiologist).~Once every week the patients will be contacted to discuss their progress and will be given feedback about their dietary intake."
89494945|NCT03178305|No Intervention|Care as usual|Patients in this arm will receive care as usual with no restrictions.
89494946|NCT03174717|Experimental|Music intervention|LTC residents will participate in an individualized music performance with a musician
89494947|NCT03178461|No Intervention|Room temperature parenteral fluids|"This group will receive IV room temperature fluids, which is the standard of care.~The composition of the fluids given will be normal saline with 5% dextrose."
89494948|NCT03178461|Experimental|Body temperature parenteral fluids|"This group will receive IV warmed fluids, body temperature, which is the experimental intervention.~The composition of the fluids given will be normal saline with 5% dextrose."
89494949|NCT05558930|Experimental|iTBS stimulation|Participants receive iTBS stimulation of bilateral cerebellar one session per day for 5 consecutive days.
89494950|NCT05558930|Sham Comparator|sham stimulation|Participants receive sham stimulation of bilateral cerebellar one session per day for 5 consecutive days.
89494951|NCT03178227|Experimental|Intervention|The intervention is a school-based intervention involving photoaging of the students selfies which takes 45 minutes total.
89494952|NCT03178227|No Intervention|Control|No intervention.
89494953|NCT03174483|Experimental|hypertonic saline|nasal spray will be used twice daily
89494954|NCT03174483|Active Comparator|fluticasone|nasal spray will be used once daily
89494955|NCT05542784||Patients with choledocholithiasis secondary to choledocholithiasis undergoing LERV surgery|
89494956|NCT05542784||Patients with choledocholithiasis secondary to choledocholithiasis undergoing PreERCP+LC surgery|
89494957|NCT02419833|Experimental|Immediate invasive intervention|Invasive coronary angiography followed by either percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) surgery as soon as possible and/or within 2 hours of admission
89494958|NCT02419833|Active Comparator|Delayed invasive intervention|Invasive coronary angiography followed by either percutaneous coronary intervention (PCI) and/or coronary artery bypass graft (CABG) surgery during the hospitalization and within 2-72 hours of admission
88954833|NCT01976520|Experimental|Oncoquest-CLL vaccine treatment|Patients receive Oncoquest-CLL vaccine subcutaneously on Day 1 and 15, and then monthly for 3 months in the absence of disease progression or unacceptable toxicity.
89494959|NCT04320914|Experimental|High Intensity LASER Therapy group (HILT)|Fourty patients with chronic KOA in HILT group will receive Class IV LASER therapy. A Class IV LASER emits power more than 500 mW .
89494960|NCT04320914|Active Comparator|Ibuprofen gel phonophoresis (IGP) group|Patients with chronic KOA in IGP group will administered with continuous ultrasound set at a frequency of 1 MHz and an intensity of 1 W/cm2 was applied on a circular basis
89494961|NCT02415543|Active Comparator|GROUP A|Group A will undergo SIL-TEP inguinal hernia repair with a single port LESS (12 to 15 mm paraumbilical)
89494962|NCT02415543|Active Comparator|GROUP B|Group B will undergo laparoscopic TEP inguinal hernia repair with 3 ports (10 mm , and 2 ports of 5 mm )
89494963|NCT05544812||experimental|"Patients in this group had previously received the following treatment regimens:~Oxaliplatin :130 mg/m2, D1, Q3W; Capecitabine :1000mg/m2, bid q2w Sintilimab for injection :200mg, D1, Q3W Bevacizumab :7.5mg/kg, D1, Q3W or cetuximab :500 mg/m, D1, Q2W"
89494964|NCT02415699|Experimental|DC-CIK Immunotherapy Plus Chemotherapy|Stage III Colon Cancer patients after radical operation and adjuvant chemotherapy will receive 12 cycles of DC-CIK therapy in this group
89494965|NCT02415699|Active Comparator|Chemotherapy Alone|Stage III Colon Cancer patients after radical operation and adjuvant chemotherapy alone.
89494966|NCT05544656|Experimental|Tolperisone|Tolperisone 3 times 150 mg daily, i.e. a daily dose of 450 mg. Treatment lasts for 14 days
89494967|NCT05544656|Placebo Comparator|Placebo|Matching placebo 3 times daily. Treatment lasts for 14 days
89494968|NCT03116451|Experimental|Foot Health Promoting Program|The experimental group will receive an electronic intervention (Foot Health Promotion Program, FHPP) for 8 weeks consisting of foot self-care guidance (skin and nail self-care), foot exercises, foot stretching and professional footwear guidance. Each topic includes lectures (delivered via Adobe Presenter) and self-directed learning where participant will go through a list of links to websites and watch videos about foot self-care. In addition, the learning will be evaluated using four individual tasks related to foot self-care.
89494969|NCT03116451|No Intervention|Comparison group|The comparison group will not receive any instructions or guidance for foot self-care but participant in the comparison group will complete the same measurement points than experimental group. After the study, the comparison group will also receive the same intervention than experimental group (if effective).
89494970|NCT05542472|No Intervention|Control group|No intervention will perform on the caregivers in the control group. The patients will continue to receive care under public services.
89531758|NCT05519241|Experimental|Phase I dose-escalation and expansion cohort|There are three doses at the dose escalation stage: Dose level I: paclitaxel (PTX) 25 mg or 0.5 mg/ml; Dose Level II: PTX 50 mg or 1.0 mg/ml; Dose Level III: PTX 75 mg or 1.5 mg/ml. At the expansion cohort, up to 12 patients will be recruited and treated with PPM at the PTX dose of 50 mg or 1.0 mg/ml to determine the efficacy.
89494971|NCT05542472|Experimental|Interventional group|"A Family Support Program Based on the Nurse-Led Case Management Model will create for the caregivers in the intervention group. The nurse-led case management model is made up of five basic nursing activities.~First Nursing Activity: Determining individuals who can benefit from the case management model Second Nursing Activity: Establishing individuals' problems and care needs Third Nursing Activity: Planning nursing activities to meet the determined needs Fourth Nursing Activity: Implementing nursing activities Fifth Nursing Activity: Regular review, monitoring and assessment of nursing activities"
89494972|NCT02409537|Active Comparator|non cholesterolemic individuals|Individuals with normal cholesterol levels will consume red wine for 1 month. There will be 1 month of wash out period. After 1 month of wash out period resveratrol will be consumed for 1 month and finally after 1 month wash out period placebo will be administered for 1 month.
88954834|NCT01976533||Advanced therapy, Heart-lung transplantation, dead|
88954835|NCT01976546||airway|Patients with one or more predictors of diffucult airway
88954836|NCT01976559|Experimental|Hydrocephalus / Shunt Malfunction|Patients between the ages of 18-80 years with suspected hydrocephalus, shunt malfunction, or disorders of CSF circulation who are recommended by their doctor based on standard clinical criteria to undergo CSF infusion testing. The interventions include tympanic membrane displacement (TMD) and DPOAE.
88954837|NCT01976598||Spinal Cord Stimulation: Sub-Sensory|Patients implanted with a Boston Scientific Spinal Cord Stimulation System for the treatment of chronic back and/or leg pain using Sub-Sensory Stimulation.
88954838|NCT01976611||BOTOX®|Patients who receive botulinum toxin Type A (BOTOX®) treatment for chronic migraine as per local standard of care in clinical practice.
89494973|NCT02409537|Active Comparator|Asymptomatic Hypercholesterolemics|individuals with high levels of cholesterol with no cardiovascular disease Those individuals will consume red wine for 1 month. There will be 1 month of wash out period. After 1 month of wash out period resveratrol will be consumed for 1 month and finally after 1 month wash out period placebo will be administered for 1 month.
89494974|NCT05558540|Experimental|Implantation with spinal cord stimulator|Women participating in the trial will receive a spinal cord stimulator (SCS). Women will first undergo a trial implantation period of 14 days. When the trial period is considered successfull (at least 50 percent reported pain reduction) women will receive definitive placement of the SCS. Normal lead placement( bilateral TH8-12) and different stimulation types will be used (FAST, subthresholdand/orCombination). When participating in the trial, women will be asked to complete a set of questionnaires on several occasions, i.e. at baseline, 3 months after implantation, 6 months after implantation and 12 months after implantation.
89494975|NCT03177993|Experimental|IDA 1|"ivermectin, diethylcarbamazine and albendazole Day 0,~permethrin Day 0 if excluded from ivermectin~Details of dosing:~ivermectin: 200 mcg/kg oral~diethylcarbazine: 6mg/kg oral~albendazole 400mg oral~permethrin 5% cream topical: apply to whole body and wash o after 4hrs when less than 2 months; apply to whole body and wash off after 8hrs when 2 months and older."
89494976|NCT03177993|Experimental|IDA 2|"ivermectin, diethylcarbamazine and albendazole Day 0, ivermectin Day 8~permethrin Day 0 and Day 8 if excluded from ivermectin~Details of dosing:~ivermectin: 200 mcg/kg oral~diethylcarbazine: 6mg/kg oral~albendazole 400mg oral~permethrin 5% cream topical: apply to whole body and wash o after 4hrs when less than 2 months; apply to whole body and wash off after 8hrs when 2 months and older."
89494977|NCT03177993|Active Comparator|DA|"diethylcarbamazine and albendazole Day 0~permethrin Day 8 if scabies present in participant or household member~Details of dosing:~diethylcarbazine: 6mg/kg oral~albendazole 400mg oral~permethrin 5% cream topical: apply to whole body and wash off after 4hrs when less than 2 months; apply to whole body and wash o after 8hrs when 2 months and older."
89494978|NCT05544578|Experimental|Intervention Group|This is a phase 1 feasibility study via a cluster randomized controlled trial.
89494979|NCT05544578|No Intervention|Control Group|The control group will receive the Korean version of the 2-page Prepared New York: Disaster and Emergency Preparation pocket guide (NYC Emergency Management, n.d.) after data collection has been completed.
89494980|NCT02167009|Experimental|Prostate Artery Embolization|Embospheres microspheres
89494981|NCT02409381|Experimental|Motore|Curcuma longa complexed with phosphatidylcholine - 250 mg (Motore®), two (02) capsules orally every twelve (12) hours
89494982|NCT02409381|Active Comparator|Alivium|Ibuprofen 600 mg (Alivium®), one (01) coated tablet orally, every six (06) hours.
89494983|NCT05544422|Other|Study Group|The Timed Up & Go Test and 30-second Chair-Stand Tests with conventional and tele-assessment methods will be applied to the participants included in the study.
89494984|NCT02415231|Experimental|humor|humor group will watch humor video for 20 minutes
89494985|NCT02415231|No Intervention|control non humor|control group did not watch humor, they sat quietly for 20 minutes.
89494986|NCT05698862|Active Comparator|Probiotic|Probiotic supplement (Lactobacillus brevis)
89494987|NCT05698862|Placebo Comparator|Placebo|Placebo (maltodextrin)
89494988|NCT02408991|Experimental|AA and Neopogen|Patient undergoes treatment with Art-assist device and Neupogen
88954839|NCT01976637|Experimental|no compression|no compression stockings worn during a 3 weeks period
88954840|NCT01976637|Active Comparator|compression stockings|compression stockings class II (23-32 mm Hg) worn during the day for up to 3 weeks
88954841|NCT01976676|Experimental|5-methyltetrahydrofolate|1 mg 5-methyltetrahydrofolate per day
88954842|NCT01976676|Active Comparator|folic acid|1 mg Folic acid per day
89022567|NCT04704206|Active Comparator|Active Interactive Media Group|"AIMG children will perform active activities on the interactive tablet media. The games and applications that will be used during this intervention were selected through a search in the online application store compatible with the tablet used during the intervention (Google Play). The search term used was games for children aged 2 to 3 years and they were analyzed for the following criteria: (1) interactivity: critical thinking, active participation, decision making; (2) learning: activities that stimulate cognitive development, fine motor, receptive language, expressive and social-emotional language (see table 1 to view activities); (3) suitability: age, period of development, multiple domains and (4) results: challenging activity, not frustrating, providing feedback"
89022568|NCT04704206|Active Comparator|Passive Interactive Media Group|PIMG children will go to the intervention room where they will use interactive tablet media in passive activities, such as: watching videos and children's stories that they often watch at home. This survey will be possible thanks to the questionnaire on the Use of Interactive Media where parents will list which drawings, stories and videos children use to watch.
89022569|NCT06189729|Other|Cluster 1|Participants will receive text reminders at Month 0 only. They will receive an HIV self-test at Months 3, 6, 9 and 12, upon submission of the self-test result.
89494989|NCT05558306|Other|Treatment protocol|All patients were treated according to the treatment protocol with cast for minimally displaced fractures and surgery for displaced fractures.
89494990|NCT02419677|Other|RFA alone|Patients undergo radiofrequency ablation alone.
89494991|NCT02419677|Experimental|RFA+CIK|Autologous cytokine-induced killer cells were transfer via venous one week after RFA.
89494992|NCT04425590|Experimental|Experimental Group|standard therapy consists of aspirin 100 mg once daily, atorvastatin 20 mg once daily, vitamin B12 100 mg three times daily and DLBS1033 3 times daily (experimental group).
89494993|NCT04425590|Active Comparator|Control Group|standard therapy consists of aspirin 100 mg once daily, atorvastatin 20 mg once daily, vitamin B12 100 mg three times daily
89494994|NCT02419599|Experimental|Group A|The group who will receive high energy density, low volume oral nutritional supplement, to be taken for 4 weeks (28 days)
89494995|NCT02419599|Active Comparator|Group B|The group who will receive the standard energy density oral nutritional supplement, to be taken for 4 weeks (28 days)
89494996|NCT02419911|Other|FloShield|FloShield Air Laparoscopic Cleaning and Defogging System used during laparoscopic surgery
89022570|NCT06189729|Other|Cluster 2|Participants will receive text reminders at Months 0 and 3. They will receive an HIV self-test at Months 6, 9 and 12, upon submission of the self-test result.
89022571|NCT06189729|Other|Cluster 3|Participants will receive text reminders at Months 0, 3 and 6. They will receive an HIV self-test at Months 9 and 12, upon submission of the self-test result.
89022572|NCT06189690|Experimental|rTMS 5 Hz group|Two-session/day 5-Hz rTMS will be administered by two week (weekdays) with a 30-minutes inter-session interval. A total of 20 sessions will be administered. Then two sessions per week along 12 weeks will be administered as maintenance phase. Parameters are considered as follow: 10 s. train, 10 s. inter-train interval, 2500 pulses per session at 100% of motor threshold (MT).
89022573|NCT06189690|Sham Comparator|Sham group|Two-session/day sham 5-Hz rTMS will be administered by two week (weekdays) with a 30-minutes inter-session interval. A total of 20 sessions will be administered. Then two sessions per week along 12 weeks will be administered as maintenance phase. Parameters are considered as follow: 10 s. train, 10 s. inter-train interval, 2500 pulses per session at 100% of motor threshold (MT).
89494997|NCT02419911|Other|Clearify|Clearify Visualization System used during laparoscopic surgery
89494998|NCT02409069|Experimental|Transcutaneous vagus nerve stimulation (Nemos®, Cerbomed GmbH)|Stimulation of the ramus auricularis of the vagus nerve (ear)
89494999|NCT02409069|Sham Comparator|Sham stimulation (Nemos®, Cerbomed GmbH)|Stimulation of the earlobe
89495000|NCT02409069|No Intervention|No stimulation|No stimulation
89495001|NCT00707889|Active Comparator|A|Open-label to Bevacizumab plus mFOLFOX6
89495002|NCT00707889|Active Comparator|B|Open-label to High-dose ABT-869 arm plus mFOLFOX6
89495003|NCT00707889|Active Comparator|C|Open-label to low-dose ABT-869 arm plus mFOLFOX6
89495004|NCT00109031|Active Comparator|Palifermin 60 µg/kg for 3 days|Palifermin 60 µg/kg plus placebo to match the total volume equivalent to a 180 µg/kg dose on the 3 days prior to fractionated total body irradiation (fTBI) and palifermin 60 µg/kg on Days 0, 1 and 2 after peripheral blood progenitor cell transplantation (PBPC). Participants also received conditioning therapy with fTBI and cyclophosphamide/etoposide prior to PBPC transplantation on Day 0.
89495005|NCT00109031|Experimental|Palifermin 180 μg/kg on Day -1|Palifermin 180 μg/kg on Day -1 and matched placebo on Days -2 and -3 prior to fTBI, and palifermin 60 μg/kg on Days 0, 1, and 2 after PBPC. Participants also received conditioning therapy with fTBI and cyclophosphamide/etoposide prior to PBPC transplantation on Day 0.
89495006|NCT00109031|Experimental|Palifermin 180 μg/kg on Day -2|Palifermin 180 μg/kg on Day -2 and placebo on Days -1 and -3 prior to fTBI, and palifermin 60 μg/kg on Days 0, 1, and 2 after PBPC. Participants also received conditioning therapy with fTBI and cyclophosphamide/etoposide prior to PBPC transplantation on Day 0.
89495007|NCT00109031|Experimental|Palifermin 180 μg/kg on Day -3|Palifermin 180 μg/kg on Day -3 and placebo on Days -1 and -2 prior to fTBI, and palifermin 60 μg/kg on Days 0, 1, and 2 after PBPC. Participants also received conditioning therapy with fTBI and cyclophosphamide/etoposide prior to PBPC transplantation on Day 0.
89495008|NCT02419443|Placebo Comparator|Placebo|Patients randomized to the placebo-group were administered placebo-pills orally one hour prior to surgery, then three times a day for a maximum of 6 total doses.
89495009|NCT02419443|Active Comparator|Gabapentin|Patients randomized to the gabapentin-group were administered 300 mg orally one hour prior to surgery, then three times a day for a maximum of 6 total dose.
89495010|NCT05535608|Experimental|SRW Cel system|"Cel1, Cel2, Cel3~Patients will take all three supplements once daily. Patients will take 2 capsules of each supplement in the morning with food."
89495011|NCT05535530|No Intervention|Control group|Passive PSIO will be used
89495012|NCT05535530|Experimental|Experimental|Active PSIO will be used
89495013|NCT02415465|Active Comparator|Combined Spinal Epidural|Spinal Intraoperative Anesthesia with standard Epidural (0.1% bupivacaine with fentanyl 5 mcg/mL running at 6mL/hr with 1mL q15 bolus) with standard post-operative analgesics.
89495014|NCT02415465|Active Comparator|General+Continuous Adductor Canal Block|General Intraoperative Anesthesia with standard post-operative Continuous Adductor Canal Block (0.2% ropivacaine running at 6-8mL/hr) with standard post-operative analgesics.
89495015|NCT02415465|Active Comparator|Spinal+Continuous Adductor Canal Block|Spinal Intraoperative Anesthesia with standard post-operative Continuous Adductor Canal Block (0.2% ropivacaine running at 6-8mL/hr) with standard post-operative analgesics.
89495016|NCT05542082|Experimental|Single Arm|CHILLS Procedure
89495017|NCT05699096||eye surgery ,Vitreoretinal Surgery and Related Ocular Inflammation|
89495018|NCT03521999|Active Comparator|AboutFace|Veterans in the AboutFACe arm will receive access to an online peer-to-peer digital storytelling resource for Veterans with PTSD
89495019|NCT03521999|Placebo Comparator|Enhanced Usual Care (eUC)|Veterans in the Enhanced Usual Care (eUC) arm will receive an education brochure for PTSD
89495020|NCT05698082|Experimental|Test group-stained by FOS antibody|Sixty colorectal cancer tissue sections were included. The tissue was cut to 5 μm thick and placed on a glass slide for staining. Endogenous peroxidase activity was inhibited and blocked by deparaffin, rehydration, and treatment with 5% bovine serum albumin for 30 min at 37 ° C. The treated sections were incubated with anti-FOS (promab 30360) overnight at 4 ° C and washed three times with PBS. After that, it was required to incubate with secondary anti-peroxidation sunflower for 30 min at 37 ° C. After washing three times with PBS, the images were developed in diamine benzidine and micrographs were obtained under a light microscope.
89495021|NCT02409225|Experimental|Home Monitoring|Remote monitoring od ICD/CRT-D function and patient condition. Device: HM provided by St Jude Medical, Biotronik or Medtronic.
89495022|NCT02409225|Active Comparator|HM option not active.|Regular visits in outpatient clinic. Device: no HM
89495023|NCT02408913|Experimental|Group 2|MVA-EbolaZ 1x10(8) PFU
89495024|NCT02408913|Experimental|Group 3|cAd3-EBO 2x10(11) PU followed by MVAEbolaZ 1x10(8) PFU at 8 weeks
89495025|NCT02408913|Experimental|Group1|MVA-EbolaZ 1x10(7) PFU
89495026|NCT02408913|Experimental|Groups 4 to 7|MVA-EbolaZ 1x10(8) PFU administered in VRC 208 to participants who received cAd3-EBO or cAd3-EBOZ in VRC 207.
89495027|NCT05542004|No Intervention|Control|No letter
89495028|NCT05542004|Experimental|Standard Letter|This group will receive a standard letter on the benefits of influenza vaccination without behavioral economic enhancement
89495029|NCT05542004|Experimental|Priming & Hot State Activation - 1 reminder|The standard letter sent out two times instead of once
89495030|NCT05542004|Experimental|Depersonalized Letter|The standard letter without the recipient's name
89495031|NCT05542004|Experimental|Gain-Framing/Context|Text added to the standard letter employing the specified behavioral economic principle
89495032|NCT05542004|Experimental|Loss-Framing/Context|Text added to the standard letter employing the specified behavioral economic principle
89495033|NCT05542004|Experimental|Collective Goal|Text added to the standard letter employing the specified behavioral economic principle
89495034|NCT05542004|Experimental|Active Choice/Implementation Intention Prompt|Text added to the standard letter employing the specified behavioral economic principle
89495035|NCT05542004|Experimental|Cardiovascular Gain Frame|Text added to the standard letter employing the specified behavioral economic principle
89495036|NCT05542004|Experimental|Expert Authority|Text added to the standard letter employing the specified behavioral economic principle
89495037|NCT02414919||HERC|Women who had an insertion of HERC (Mirena IUD, ParaGard IUD, Implanon or Nexplanon)
89495038|NCT05005559|Experimental|Vaccine candidate|
89495039|NCT05005559|Placebo Comparator|Saline placebo|
89495040|NCT05535452|Placebo Comparator|Group control|Patients will receive applications with the LED board turned off without light activation. Applications will be performed within 1 hour after radiotherapy, three times a week, by a trained team, consisting of physical therapists and physical therapy students, and the application time will be the same as in the intervention group. Women will be instructed to maintain specific home exercises for the upper limbs, which are part of the routine of the physiotherapy sector since the first postoperative day at the HCIII/INCA, in addition to their usual physical activities.
89495041|NCT05535452|Experimental|Intervention group|At the beginning of radiotherapy treatment, all HCIII/INCA patients are instructed by the nursing team in this sector to use the DNA® ointment provided at the institution and to take proper skin care. Patients identified by the nursing staff with some degree of radiodermatitis undergo treatment with silver sulfadiazine and, if necessary, radiotherapy can be interrupted so that the skin regenerates.
89495042|NCT02419053||Pre-checklist|Surgical interventions performed for children before the introduction of the surgical safety checklist in Ontario, from October 2008 to September 2009.
89495043|NCT02419053||Post-checklist|Surgical interventions performed for children after the introduction of the surgical safety checklist in Ontario, from October 2010 to September 2011.
89495044|NCT05543954|Experimental|68Ga-FAPI-RGD and 18F-FDG PET/ CT scan|Within 2 week, each patient underwent PET/CT scan after intravenous administration of 68Ga-FAPI-RGD and 18F-FDG, respectively.
89495045|NCT05543954|Experimental|68Ga-FAPI-RGD and 68Ga-FAPI PET/ CT scan|Within 2 week, each patient underwent PET/CT scan after intravenous administration of 68Ga-FAPI-RGD and 68Ga-FAPI, respectively.
89495046|NCT05543954|Experimental|68Ga-FAPI-RGD and 68Ga-RGD PET/ CT scan|Within 2 week, each patient underwent PET/CT scan after intravenous administration of 68Ga-FAPI-RGD and 68Ga-RGD, respectively.
89495047|NCT02419131|Experimental|Behavioral Headache Therapy|A standard, manualized behavioral intervention for primary headache disorders
89495048|NCT02419131|Experimental|Cognitive Processing Therapy|A gold-standard treatment for PTSD, called Cognitive Processing Therapy
89495049|NCT02419131|Active Comparator|Treatment as Usual|Treatment as usual, receiving standard care for PTHA
89495050|NCT02419209|Experimental|Individualised Homeopathic Remedy|A single individualised homeopathic remedy will be administered to each participant in the form of medicated sucrose pillules. The potency, dosage and frequency of administration will be individualised for each participant in accordance with the laws that govern homeopathic prescribing.
89495051|NCT02408679||All subjects|300 eligible subjects will perform a blood sampling for a dosage of serum vitamin D and will fill up a study questionnaire during one visit.
89531759|NCT05514093||App users|As this is a single cohort study, there is only one group consisting of the Beyond Silence app users.
89495052|NCT05698004|Active Comparator|Group-1: prone positioning + standard treatment|Patients randomized to the intervention group will be subjected to awake prone positioning. The target duration of prone positioning is 8 h/d to 10 h/d with 2 to 3 breaks (1-2 hours each), if needed. Daily prone positioning sessions will be protocolized to continue until 1 of the following stopping criteria is met: a relative improvement in the FIO2 requirement by 40% from the baseline value that sustained for 24 hours; endotracheal intubation; or discharge from the ICU. The treating team will supervise patients who could move themselves during the prone positioning process and assist the patients with positioning as required.
89495053|NCT05698004|No Intervention|Group-2: Standard treatment only|Patients randomized to the control group, and their treating team, will be informed of their group assignment. Nurses instruct patients not to position themselves in the prone position.
89495054|NCT04486781|Experimental|Combination Therapy|All study participants will receive Pembrolizumab + sEphB4-HSA through a needle in a vein in their arm for an hour in an outpatient clinic. Pembrolizumab will be given at Day 1 of each 3 week cycle. The study drug (sEphB4-HSA) will be given at Day 1, 8, and 15 of each 3 week cycle.
89495055|NCT02408601|Active Comparator|Group 1|"split mouth study. one side of the arch that is the lower left permanent 1st molar will be receiving resin based sealants.~Application of the resin sealants as per the standard instructions of the manufacturer~Helioseal -F ( Resin based sealant)~isolate the tooth surface~etch the fissure anatomy with 37% phosphoric acid for 20 seconds~wash the tooth surface and dry it. No salivary contamination is accepted~using a syringe based system, apply the sealant onto the fissures, do not overfill the fissures, run an explorer along the fissures to avoid any air entrapment.~light cure the sealant~check for high points and the occlusion"
89495056|NCT02408601|Experimental|Group 2|"split mouth study. one side of the arch that is the lower right permanent 1st molar will be receiving ART sealants.~Application of the ART sealants as per the standard instructions of the manufacturer~isolate the tooth surface~condition the fissure anatomy using a GC conditioner for 10 seconds~wash the conditioner by using a cotton pellet for a couple of times, do not use a three way syringe.~dry the tooth surface~mix the GIC according to the standard powder: liquid ratio~place the mix onto the fissures using a plastic spatula~apply pressure on the occlusal surface with a gloved index finger( the gloved index finger must be coated with petroleum jelly)~apply pressure for 10-15 sec and withdraw the finger in a sideways motion~scrap out the excess material~check for the high points and the occlusion~apply petroleum jelly onto the GIC mix~advice patient not to eat or drink for 30 minutes."
89495057|NCT05541692|Other|Efficacy of a sleep hygiene toolkit in ARU|Pre/post of intervention group (no control)
89495058|NCT05543798|Experimental|Non-Randomized|All subjects with ventricular tachycardia associated with ischemic cardiomyopathy will undergo catheter ablation using the Vision-MR Ablation Catheter 2.0
89495059|NCT02408835|Active Comparator|PICO™|Use of PICO™ system negative pressure wound therapy device on surgical wound for up to seven days.
89495060|NCT02408835|No Intervention|Conventional wound care|Usual wound dressings will be used as comparison group.
89495061|NCT04467359|Experimental|The experimental group|ERAS intervention group
89495062|NCT04467359|Placebo Comparator|The control group|Sports medicine rehabilitation nursing group
89495063|NCT02418975|Experimental|Very low-calorie protein-based diet|Patients will receive a homemade very low-calorie (~5 kcal/kg of ideal body weight /day) protein-based formula (milk proteins; 1.2 g per kilogram of ideal body weight) for 4 weeks by a polyurethane nasogastric feeding tube.
89495064|NCT02418975|Active Comparator|Hypocaloric diet|Patients will receive a commercial balanced enteral formula (~20 kcal/kg of ideal body weight /day; protein content, 1.0 g per kilogram of ideal body weight) for 4 weeks by a polyurethane nasogastric feeding tube.
89495065|NCT05543486|Experimental|Levitation 2 Tri-Compartment Offloader (TCO) knee brace|Participants in this group are sized and fitted for a Levitation 2 TCO brace and instructed to wear the brace on their affected limb for a total of 3 or more hours per day for 3 months.
89495066|NCT05543486|Active Comparator|Knee sleeve|Participants are provided with a off-the-shelf knee sleeve and instructed to wear the sleeve on their affected limb for a total of 3 or more hours per day for 3 months.
89495067|NCT05543486|No Intervention|Standard of Care Self-Management|Control group practicing conservative self-management of knee osteoarthritis without using a knee device (e.g., hard brace or sleeve) for 3 months.
89495068|NCT05089565||Sarcoidosis, not on treatment|Sarcoidosis patients, 18 years of age or older, not currently being treated with immunosuppressive medications
89022574|NCT06189690|No Intervention|no rTMS control group|The patients on this group will receive any rTMS intervention. The purpose of this gruop is to compare all clinical, cognitive variables and BDNF levels under conditions of no cocaine/crack consumption, i.e., controlled environments, without rTMS.
89495069|NCT05089565||Sarcoidosis, on treatment|Sarcoidosis patients, 18 years of age or older, currently being treated with immunosuppressive medications
89495070|NCT05089565||Healthy controls|Healthy individuals, matched for age and sex with those in the two sarcoidosis cohorts
89495071|NCT05543408|Experimental|EXERCISE|
89495072|NCT05543408|No Intervention|CONTROL|
89495073|NCT02414997|Experimental|RIPC group|Surround left upper limb with cuff, inflate cuff to 200 mmHg and maintain 5 minutes, than deflate to 0 mmHg. Change to right upper limb and repeat the procedure described above. Change back to left upper limb and repeat the same procedure. Perform once a day ( Thus 15 minutes a day).
89495074|NCT02414997|Sham Comparator|Sham RIPC group|Surround left upper limb with cuff, inflate cuff to 20 mmHg and maintain 5 minutes, than deflate to 0 mmHg. Change to right upper limb and repeat the procedure described above. Change back to left upper limb and repeat the same procedure. Perform once a day ( Thus 15 minutes a day).
89495075|NCT05697926||Experiment|The excess tumor tissue from patients following surgical resection will be collected for further analysis.
89495076|NCT03174171|Experimental|Intervention|Everolimus 0.75 mg b.i.d. orally for 14 days.
89495077|NCT05541302||1-20 TMS sessions|PHQ 9 ratings during this treatment period
89495078|NCT05541302||21 - 29 TMS sessions|PHQ 9 ratings during this treatment period
89495079|NCT05541302||30 TMS Sessions|PHQ 9 ratings during this treatment period
89495080|NCT05541302||31-36 TMS Sessions|PHQ 9 ratings during this treatment period
89495081|NCT05541302||extended treatment 36 and beyond|PHQ 9 ratings during this treatment period
89495082|NCT02418663|Other|Postoperative elective surgical patients|Patients undergoing major elective thoracic and abdominal, the latter group including upper gastrointestinal, esophageal, and colorectal procedures. In this group FR will predicted by administering a fluid challenge of 250 ml of Lactated Ringer's solution and measuring SV with the ccNexfin
89495083|NCT03116373|Active Comparator|maxilla fixing then mandible fixing|The tracheal tube is first fixed on the maxilla. After the measures of the outcomes, its site of fixation is changed for the mandible for the outcome measurement in the second site of fixation.
89495084|NCT03116373|Active Comparator|mandible fixing then maxilla fixing|The tracheal tube is first fixed on the mandible. After the measures of the outcomes, its site of fixation is changed for the maxilla for the outcome measurement in the second site of fixation.
89495085|NCT03174249|Experimental|Exposure therapy|Graded exposure therapy in vivo in combination with methods targeting cortical reorganisation.
89495086|NCT02418741|Experimental|Degree of neck flextion|Two degrees of neck flexion were achieved using a 4 cm or 8 cm height of pillow
89495087|NCT02418507|Active Comparator|Proprietary Probiotic Blend|A proprietary probiotic blend: Lactobacillus acidophilus, Bifidobacterium lactis, Bifidobacterium longum, and Bifidobacterium bifidum at 56.75 mg
89022575|NCT06189651|Experimental|Wrist splint treatment|The same type of wrist splint was given
89022576|NCT06189651|Experimental|Wrist splint treatment+ %5 dextrose injection|The same type of wrist splint was given and 5% dextrose injection using USG-guided nerve hydrodissection method was applied
89022577|NCT06189638|Experimental|Antimicrobial Peptide PL-5 Topical Spray: 1 mg/g (1‰)|Eligible subjects will be randomized (1:1:1) to receive twice a day, 14 days treatment of Antimicrobial Peptide PL-5 Topical Spray (1‰)
89022578|NCT06189638|Experimental|Antimicrobial Peptide PL-5 Topical Spray:2 mg/g (2‰)|Eligible subjects will be randomized (1:1:1) to receive twice a day, 14 days treatment of Antimicrobial Peptide PL-5 Topical Spray (2‰)
89022579|NCT06189638|Placebo Comparator|Topical placebo (vehicle)|Eligible subjects will be randomized (1:1:1) to receive twice a day, 14 days treatment of Antimicrobial Placebo of Antimicrobial Peptide PL-5 Topical Spray (vehicle).
89022580|NCT06189586|Active Comparator|Nebulized inhalation group|2 mg budesonide suspension for inhalation, nebulized inhalation for minutes,administered 4 times a day for 5 consecutive days.
89022581|NCT06189586|Active Comparator|Intravenous hormone group|40mg sodium methylprednisolone succinate for injection(dissolved in 0.9% saline or5% glucose injection 50ml), intravenous infusion for 30 minutes, once a day for 5 consecutive days.
89022582|NCT06189573|Other|Quadriceps Tendon graft|Patients with ACL reconstruction with the use of quadriceps tendon graft
89022583|NCT06189573|Other|Bone Patellar Tendon Bone Graft|Patients with ACL reconstruction with the use of bone patellar tendon bone graft
89022584|NCT06189547||Without prior cancer|
89495088|NCT02418507|Placebo Comparator|Placebo|The placebo is administered to randomized healthy participants
89495089|NCT05696210||High transfusion rate group|patients requiring Veno-arterial extracorporeal membrane oxygenation for medical or post cardiotomy cardiogenic shock and with a blood transfusion rate greater than or equal to 7 red blood cells.
89495090|NCT05696210||Low transfusion rate group|patients who required Veno-arterial extracorporeal membrane oxygenation for medical or post cardiotomy cardiogenic shock and with a blood transfusion rate strictly below 7 red blood cells.
89495091|NCT02414763|No Intervention|Care as Usual|Participants will receive usual care services provided to suicide attempt survivors, including inpatient psychiatry, outpatient psychotherapy, and case management.
89495092|NCT02414763|Experimental|Teachable Moment Brief Intervention|The brief intervention consists of engaging the patient in conversation regarding suicidal ambivalence (desire to live vs. desire to die), collaborative discovery of primary and secondary drivers of suicidality, functional analysis of the suicidal ideation and behaviors, and crisis response planning. Participants will also receive usual care services provided to suicide attempt survivors, including inpatient psychiatry, outpatient psychotherapy, and case management.
89495093|NCT03174093|Experimental|MATCh AFib|Participants assigned to the intervention group will have the support of the MATCh AFib application during the consultations with their physician and receive individual text messaging targeting knowledge about atrial fibrillation, medication adherence and monitoring during months 1-3.
89495094|NCT03174093|No Intervention|Standard Care|Participants assigned to the control group will complete measures at each time point and maintain care as usual (i.e., medical treatment, INR monitoring and consultations with their physician without mHealth support)
89022585|NCT06189547||With prior colorectal cancer history|
89495095|NCT05592470||PATEINTS|51 patients newly diagnosed with acute lymphoblastic leukemia
89495096|NCT05592470||controls|51 normal persons
89495097|NCT02414529|Placebo Comparator|Placebo group|"Placebo group B: single blinded to patients, receive 6 capsule PO (placebo) at once.~Subjects are blinded then they will crossover groups"
89495098|NCT02414529|Active Comparator|Treatment group|"Group A will receive 6 capsules (50.000 units/each) of vitamin D2(ergocalciferol) at once.~Subjects are blinded then they will crossover groups."
89495099|NCT05541068|Active Comparator|Guided by bioimpedance analysis|These patients were discharged when dry-weight was achieved according to BIA measurements if there was none clinical condition which justified the hospitalization.
89495100|NCT05541068|Active Comparator|Control arm|In those patients, BIA parameters were not known by the physician responsible. These patients were discharged when they achieved the euvolemic state based in the criteria of their physician
89495101|NCT02418273|Experimental|Denosumab|These subjects will receive two sequential doses of denosumab
89495102|NCT02418273|No Intervention|No drug intervention|These subjects do not receive denosumab
89495103|NCT02418429|Active Comparator|waxy maize starch|pancake test meal - waxy maize starch
89495104|NCT02418429|Active Comparator|waxy maize starch and whey protein|pancake test meal - waxy maize starch and whey protein
89495105|NCT02418429|Active Comparator|resistant starch|pancake test meal - resistant starch
89495106|NCT02418429|Active Comparator|resistant starch and whey protein|pancake test meal - resistant starch and whey protein
89495107|NCT03724526|Experimental|Intervention-Text messaging|Participates will receive regular 6 text messages per week for 12 months. They will receive one general education about diabetes and CVD messages, one glucose control message, one blood pressure control message, one healthy eating message, one medication adherence message and one physical activity message per week. Each message will be sent on 6 of 7 randomly selected weekdays and arrived at random times the day during working hours.
89495108|NCT03724526|No Intervention|Control|Participates in control group will not receive text messages.
89495109|NCT03174015|Experimental|Intervention|"Landlords on selected plots will receive the Bauleni Secret intervention. Landlords and selected tenants will be surveyed in baseline/end-line data collection."
89495110|NCT03174015|No Intervention|Control|Landlords and selected tenants will be surveyed in baseline/end-line data collection only.
89495111|NCT02414685|Experimental|intravenous chemotherapy|"TIP regimen:~Paclitaxel 250 mg/ m2 iv on day 1~Ifosfamide 1,2 g/ m2/ day iv x 5 days~Cisplatin 20 mg/ m2/ day iv x 5 days"
89495112|NCT04425824|Experimental|Toripalimab combine with Rituximab|"Experimental: Toripalimab combine with Rituximab~Induction period:~Toripalimab 240mg administered intravenously (IV) on Day 1 of each 21-day cycle for 6 cycles.~Rituximab 375mg/m² administered intravenously (IV) on Day 1 of each 21-day cycle for 6 cycles.~Maintenance:~Toripalimab 240mg administered intravenously (IV) and Rituximab 375mg/m² on Day 1 of each 56-day cycle for 6 cycles."
89495113|NCT02408367||Exercise|30 minutes of active training at 75% of the Maximum heart rate achieved in a cardiopulmonary exercise test
89495114|NCT02408367||Relaxation|30 Minutes of passive relaxation
89022586|NCT06189547||With prior prostate cancer history|
89022587|NCT06189547||With prior breast cancer history|
89022588|NCT06189547||With prior uterine cancer history|
89022589|NCT06189547||With prior bladder cancer history|
89022590|NCT06189547||With prior skin cancer history|
89022591|NCT06189547||With prior lung cancer history|
89022592|NCT06189547||With prior kidney cancer history|
89022593|NCT06189547||With prior thyroid cancer history|
89495115|NCT02414451|Experimental|Propranolol arm|"Propranolol will be administered via oral capsule(s) daily for a period of 10 weeks, involving gradual titration up from 40mg to 100mg and subsequent tapering off of the drug. The titration/tapering schedule will be as follows:~Week 1: 40 mg propranolol (1 capsule, nightly) Week 2: 80 mg propranolol (2 40mg capsules, morning & night) Weeks 3 - 8: 100 mg propranolol (3 capsules, 40 mg/morning, 20mg/afternoon, & 40mg/night) Week 9: 60 mg propranolol (2 capsules, 40 mg/morning & 20mg/night) Week 10: 20 mg propranolol (1 capsule, nightly) Week 11: no capsules"
89022594|NCT06189547||With prior stomach cancer history|
89022595|NCT06189534|Experimental|Arms of the study|Experimental group : participants in experimental group will receive 8-10 sessions of intervention in overall the course of study.
89495116|NCT02414451|Placebo Comparator|Placebo arm|"Placebo will be administered via lactose-filled oral capsule(s) daily for a period of 10 weeks. The schedule of placebo administration will be as follows:~Week 1: 1 capsule, nightly Week 2: 2 capsules, morning & night Weeks 3 - 8: 3 capsules, morning, afternoon, & night Week 9: 2 capsules, morning & night Week 10: 1 capsule, nightly Week 11: no capsules"
89495117|NCT02418117|Experimental|Stereolitographic template's accuracy|Evaluating the accuracy of stereolitographic template comparing the final implant insertion to the planned implant position at coronal and apical level
89495118|NCT02408289|Placebo Comparator|Lo-Flav|Low-flavonoid cocoa powder with 0 mg of procyanidins and 0 mg epicatechin per kg of body weight will be consumed as a beverage
89022596|NCT06189534|No Intervention|Control group|Control group: participants in control group will not receive any sessions of intervention.
89022597|NCT06189521|Active Comparator|Extracorporeal shock wave group|"Patients were randomized into three groups by a physiotherapist with sealed envelopes. The researchers were blinded to the patient's groups. The same physiotherapy program was applied to all groups. The physiotherapy program consisted of hot packs and TENS for 10 minutes and stretching and eccentric strengthening exercises were given to all groups. All exercises were done under the supervision of the same physiotherapist.~In addition to the ten-day of physiotherapy program, in the first group one day for a week a total of 3 sessions of ESWT was applied at 1.8 bar, 10.0 Hz, 2000 beats (Elmed Vibrolith Ortho)."
89022598|NCT06189521|Active Comparator|ultrasound group|In addition to the ten-day of physiotherapy program, in the second group, ten days of ultrasound applied at 1.5 watt/cm2, continuous mode to the painful area for 5 minutes, 5 days a week for two weeks (Chattanooga Intelect Advanced).
89495119|NCT02408289|Active Comparator|Hi-Flav|Cocoa powder with 3.8 mg procyanidins per kg of body weight and 0.6 mg Epicatechin per kg of body weight will be consumed as a beverage.
89495120|NCT02408289|Active Comparator|Epicatechin|Low-flavonoid cocoa powder plus 1 mg epicatechin per kg of body weight will be consumed as a beverage.
89495121|NCT02408289|Active Comparator|Procyanidins|Low-flavonoid cocoa powder plus 3.7 mg procyanidins per kg of body weight will be consumed as a beverage.
89495122|NCT02417883|Experimental|Furosemide Stress Test|Furosemide stress test will be perform to patients scheduled for kidney bipsy. The test consist in 1.5 miligrams per kilogram of weight of intravenous furosemide administration, along with urinary output follow up and measurement for 6 hours. The urinary output will be replaced intravenously with normal saline to avoid dehydration and/or hypotension.
89495123|NCT03173859|Experimental|Rotational|Abiraterone acetate 1000mg qD and prednisone 5mg bid administered orally starting on Day 1 of Cycle 1 for 3 cycles, followed by apalutamide 240mg qD orally for 3 cycles. The duration of each cycle is 28 days
88954843|NCT01976689||Patients with New-onset Diabetes|New-onset diabetes after transplantation was defined as a fasting plasma glucose (FPG) level ≥ 126 mg/dL (7 mmol/L) or symptoms of diabetes plus casual plasma glucose concentrations ≥200 mg/dL (11.1 mmol/L), confirmed by repeat testing on a different day. According to these criteria, 63 patients were diagnosed as NODAT between years 2007-2010 but after the exclusion criteria of our study 57 patients with and 102 patients without NODAT were included in the study.
88954844|NCT01976689||Patients without NODAT|New-onset diabetes after transplantation was defined as a fasting plasma glucose (FPG) level ≥ 126 mg/dL (7 mmol/L) or symptoms of diabetes plus casual plasma glucose concentrations ≥200 mg/dL (11.1 mmol/L), confirmed by repeat testing on a different day. According to these criteria, 63 patients were diagnosed as NODAT between years 2007-2010 but after the exclusion criteria of our study 57 patients with and 102 patients without NODAT were included in the study.
88954845|NCT01976702|Experimental|Enhanced Behavioral Skills Training|The Enhanced Behavioral Skills Training (E-BST) will include four 90-minute group sessions and two 60-minute individual sessions regarding HIV prevention and diminishing risk behavior, enhancing communication skills, improving the use of support services, and enhancing the use of resources in their community.
88954846|NCT01976702|Active Comparator|Health Promotion Comparison|The Health Promotion Comparison (HPC)condition will receive one video-based HIV prevention session, 3 video-based 90-minute group sessions and an additional 2 60-minute sessions with discussions on relevant topics unrelated to HIV.
88954847|NCT01976767||Cohort A|Adults: severe asthmatics on high dose ICS and / or OCS
88954848|NCT01976767||Cohort B|Adults: current smokers or ex-smokers, severe asthmatics on high dose ICS and / or OCS
88954849|NCT01976767||Cohort C|Adults: non-smokers, mild to moderate asthmatics on regular inhaled corticosteroids (ICS)
88954850|NCT01976767||Cohort D|Adults: healthy volunteers, non-smokers, non-asthmatic with pre bronchodilator FEV1 > 80% predicted
88954851|NCT01976780|Active Comparator|AS/MQ|Treatment of P.falciparum mono-infection with 4 mg/kg of Artesunate daily for three days followed by 25mg/kg of Mefloquine split over two days.
88954852|NCT01976780|Active Comparator|AL|Treatment of P. falciparum mono-infection with Artemether Lumefantrine administered at the standard dosage according to pre-defined weight bands (5-14 kg: 1 tablet; 15-24 kg: 2 tablets; 25-34 kg: 3 tablets; and > 34 kg: 4 tablets) given twice a day for 3 days.
88954853|NCT01976793||patients with major depression|Inpatients and outpatients diagnosed with an episode of major depression relating to RDD (ICD-10, Version 2010) during the period from January 1, 2012 till September 30, 2013. Initially treated with antidepressant monotherapy, using a flexible dosage regimen if required, for at least 2 week
89495124|NCT03173859|Active Comparator|Sequential|Abiraterone acetate 1000mg qD and prednisone 5mg bid administered orally starting on Day 1 of Cycle 1 until disease progression, followed by apalutamide 240mg qD orally until second disease progression.
89495125|NCT04482465|Other|pilot study 1 arm|50 subjects with no AMD or early AMD, aged over 55, at moderate-to-high risk for AMD based on a simplified AMD risk assessment scale score > or = 10, not taking vitamin D or trace nutriënt containing supplements
89495126|NCT01664624|Experimental|Roflumilast + alogliptin|Roflumilast 500 μg, tablets, orally and alogliptin 25 mg, tablets, orally, once a day for 11 days.
89495127|NCT01664624|Experimental|Alogliptin alone|Placebo to roflumilast, tablets, orally and alogliptin, 25 mg, tablets, orally, once a day for 11 days.
89495128|NCT01664624|Experimental|Roflumilast alone|Roflumilast 500 μg, tablets, orally and placebo to alogliptin, tablets, orally, once a day, for 11 days.
89495129|NCT01664624|Active Comparator|Exenatide|Exenatide 5 μg subcutaneous injection twice a day for 11 days.
89495130|NCT02414061|Experimental|Breakfast - Carbohydrate + Whey Protein|Addition of whey protein isolate (20 g dissolved in flavoured water) to breakfast meal composition
89495131|NCT02414061|Placebo Comparator|Breakfast - Carbohydrate|Only flavoured water consumed with breakfast meal
89495132|NCT02414061|No Intervention|No Breakfast|Only water consumed at breakfast time point
89495133|NCT05079399||Healthy Control|
89495134|NCT05079399||Diabetes but no retinopathy|
89495135|NCT05079399||Mild non proliferative diabetic retinopathy|
89495136|NCT05079399||Moderate non proliferative diabetic retinopathy|
89495137|NCT05079399||Severe non proliferative diabetic retinopathy|
89495138|NCT05079399||Proliferative diabetic retinopathy|
89495139|NCT03173781|Experimental|droxidopa|"Droxidopa will be supplied in 100 and 200 mg pill sizes. The subject should administer the three doses 4 hours apart with the last dose prior to 4:00 pm (example: 8:00 am, 12:00 pm, and 4:00 pm). The proposed dosing is 100mg TID at baseline, then titrate slowly up to 600 mg TID. During titration, droxidopa or placebo, initiated at 100 mg TID was titrated upward in 100-mg TID increments every 48 hours until the subject:~Reaches the maximum permitted dosage of 600 mg TID;~Has a systolic blood pressure≥160mmHg or diastolic blood pressure ≥100mmHg after 10 minutes supine on 3 consecutive measurements; or~Experiences intolerable adverse events (AEs)."
89495140|NCT03173781|Placebo Comparator|placebo|sugar pill
89495141|NCT05540912|Experimental|Sequence 1|Period 1: D064+D701 Period 2: Test1 Period 3: Test2
89495142|NCT05540912|Experimental|Sequence 2|Period 1: Test2 Period 2: D064+D701 Period 3: Test1
89495143|NCT05540912|Experimental|Sequence 3|Period 1: Test1 Period 2: Test2 Period 3: D064+D701
89495144|NCT05540912|Experimental|Sequence 4|Period 1: Test2 Period 2: Test1 Period 3: D064+D701
89495145|NCT05540912|Experimental|Sequence 5|Period 1: Test1 Period 2: D064+D701 Period 3: Test2
89495146|NCT05540912|Experimental|Sequence 6|Period 1: D064+D701 Period 2: Test2 Period 3: Test1
89495147|NCT02408133|No Intervention|Control|The control group will be accompanied according to the service routine.
89495148|NCT02408133|Experimental|Exercise|The group will be instructed to perform home exercises autonomously for range of motion and muscular fitness
89495149|NCT05540834|Experimental|VET guided tPA administration + standard care|Actilyse (tPA) will be administered as a 2-hour bolus then low dose infusion over 24 hours (safety and dose-finding stage) and 72 hours (randomised stage). Regular monitoring of the coagulation status and lysis time using VET will enable increases or decreases/cessation of the dose. Prophylactic low molecular weight heparin will continue throughout.
89495150|NCT05540834|No Intervention|Standard care|Patients will receive standard care for their condition including prophylactic low molecular weight heparin. Coagulation status and lysis time monitoring with VET will occur at the same times as the experimental arm.
89495151|NCT05696132|Experimental|Decolonization|Nasal decolonization with betadin gel
89495152|NCT02407899|Experimental|Metformin (and insulin) + saxagliptin|Patients who have diagnosed LADA are assigned to receive Saxagliptin tablets 5mg/d and Metformin 1.5g/d (and insulin at individual dose) for 104-week.
89495153|NCT02407899|Experimental|Metformin(insulin)+saxagliptin +vitamin D3|Patients who have diagnosed LADA are assigned to receive Saxagliptin tablets 5 mg/d, vitamin D drop 2000IU/d, Metformin 1.5g/d (and insulin at individual dose) for 104-week.
89495154|NCT02407899|Active Comparator|Metformin (and insulin)|Patients who have diagnosed LADA are assigned to receive Metformin 1.5g/d(and insulin at individual dose) for 104-week.
88954854|NCT01976832|Experimental|Music with movement|Participants in the intervention group will receive the intervention delivered by their family member according to the validated 8-weeks music with movement (MWM) intervention protocol.
88954855|NCT01976832|Active Comparator|Social interaction|"The control group will receive a protocol for social interaction as the control condition, where caregivers were asked to discuss up to date news with PWeD.~The design of the control condition will be highly similar to the MWM protocol in terms of the frequency and duration of the sessions, the number of people involved, and the total intervention period."
88954856|NCT01976858|Experimental|PEX168 50 microgram|PEX168 50 microgram qw sc. and the medication continued for 8 weeks
88954857|NCT01976858|Experimental|PEX168 100 microgram|PEX168 100 microgram qw sc. and the medication continued for 8 weeks
88954858|NCT01976858|Experimental|PEX168 200 microgram|PEX168 200 microgram qw sc. and the medication continued for 8 weeks
89495155|NCT05592080||pcos|
89495156|NCT05592080||non-pcos|
89495157|NCT02417493|Experimental|Simulation of Epinephrine Self-Injection|The patient will self-inject an empty syringe into his/her thigh simulating a self-injection of epinephrine during a routine outpatient visit to the allergist.
89495158|NCT02417493|No Intervention|Control Group|The patient will be encouraged to speak to their physician about self-injection, but will not undergo the self-injection protocol during a routine outpatient visit to the allergist.
89495159|NCT05540600|Experimental|Digoxin group|Patients will receive digoxin 0.25 mg once daily for a duration of 4 weeks
89495160|NCT05540600|Experimental|beta blocker group|Patients will receive bisoprolol 2.5 mg or 5 m twice a day for a duration of 4 weeks. The choice of dose will depend on blood pressure (BP): If systolic BP ≥ 150 mmHG, the patient will have bisoprolol 5 mg x 2 per day, If systolic BP < 150 mmHG, the patient will have bisoprolol 2.5 mg x 2 per day
89531760|NCT05489913|Experimental|Web based Cardiac Rehabilitation program and follow-up telephone|"The website was created under the name of Cardiac Rehabilitation Support Program. The language of the website is Turkish. Designed for computer, tablet and mobile phone use. Patients must be registered to access the website. After creating a six-digit password during registration, they log in to the website with their e-mail address and this password. The password is determined specifically for the patient. There is a welcome text on the home page of the website. The main headings in the menu section; trainings, disease management questions, questionnaires, ask questions to the researcher."
88954859|NCT01976858|Experimental|PEX168 300 microgram|PEX168 300 microgram qw sc. and the medication continued for 8 weeks
88954860|NCT01976858|Placebo Comparator|Placebo|Placebo qw sc. and the medication continued for 12 weeks
88954861|NCT01976884||Severe sepsis|Patients with severe sepsis
88954862|NCT01976884||Infectious kidney stone|Patients with sepsis after PCNL for infectious kidney stone
88954863|NCT01976884||Tumor|Patients with pancreatic cancer
88954864|NCT01976884||Volunteer|
88954865|NCT01976897||The study population|"Only one group is included. See inclusion/exclusion criteria.~Intervention: Knee flexion measurement 1~Intervention: Knee flexion measurement 2~Intervention: Heel - interface pressure measurements"
88954866|NCT01976910|Experimental|4-DM-CHOC-PEN|"DM-CHOC-PEN is an intervention and will be dosed @ 39 mg/M2,escalated in 1-patient cohorts at 40% dosage.~At the 1st DLT - expand to 3-6 patient cohorts/dose with escalations at 33% increments.~The MTD will be where 2 DLTs are noted and the study is discontinued."
88954867|NCT01976923|Active Comparator|Study arm|Intravitreal bevacizumab Small-gauge pars plana vitrectomy
88954868|NCT01976923|Sham Comparator|Control arm|Small-gauge pars plana vitrectomy
89495161|NCT03373448|Active Comparator|Labrida BioClean|Labrida BioClean- chitosan device.The brush bristles of the test device (Labrida BioClean® LABRIDA AS, Oslo Norway) are made of the biopolymer chitosan. Any debris left from the chitosan bristles is completely biocompatible and will dissolve or be resorbed thus not causing harm to the tissues surrounding the implant. Chitosan is made from chitin derived from shell of marine crustaceans such as shrimp and crab, however chemically modified and thus not even considered to be animally derived. Chitosan has been approved for use in e.g., surgical bandages, as a haemostatic agent and as dietary supplement used in a wide range of nutritional and health products. Chitosan has also been documented to be non-allergenic and it has been suggested that chitosan has anti-inflammatory properties.
89495162|NCT03373448|Other|Titanium curettes|Peri-implant pockets will be debrided with titanium curettes.
89495163|NCT02417649|Experimental|Ismigen|Treatment over 3 successive months. One sublingual tablet every day on the first ten days of each month, followed by twenty days of rest.
89495164|NCT02417649|Placebo Comparator|Placebo|Treatment over 3 successive months. One sublingual tablet every day on the first ten days of each month, followed by twenty days of rest.
89495165|NCT03173625|Experimental|AC-076 sc administration - single ascending dose|On Day 1, 48 subjects will receive AC-076 at different single dose levels in a sequential manner and in a maximum of 6 dose levels, starting from 1 mg. Subjects will be followed by an observation period of 48 h. Each dose level will be investigated in a new group of 8 healthy male subjects (6 on active drug and 2 on placebo)
89205096|NCT01066741|Active Comparator|1.4 % Sodium Bicarbonate solution|"Mouthwash with sodium bicarbonate is started on the first day of irradiation, then continued until the end of the irradiation period. In case of grade ≥3 mucositis, mouthwash is continued until complete disappearance of the mucositis or until the end of irradiation.~In both arms, after the end of irradiation, patients can receive treatment with Sodium Bicarbonate solution until complete disappearance of the mucositis."
89495166|NCT03173625|Placebo Comparator|Placebo|For each AC-076 dose level tested, 2 healthy male subjects will receive matching placebo in the same condition
89495167|NCT02417571|Experimental|ABPM group|"Ambulatory blood pressure monitoring (ABPM) performed at 3, 6 months after randomization; adjusting drugs/doses based on ABPM results.~Target BP: daytime ABP < 135/85 mm Hg according to British NICE clinical guideline 127."
89495168|NCT02417571|No Intervention|Office BP group|"Conventional BP management using office BP according to KDIGO guideline on BP management.~Target BP: <140/90 mm Hg."
89495169|NCT03177837|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m
89495170|NCT03177837|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m.
89495171|NCT05696054||SBP group|Patients diagnosed as spontaneous bacterial peritonitis based on ascitic fluid study.
89495172|NCT05696054||non-SBP group|Patients without spontaneous bacterial peritonitis based on ascitic fluid study
89495173|NCT02414295|Experimental|Mesenchymal stem cell injection|Bone marrow Mesenchymal stem cell injection in the testicular tubules and testicular artery
89495174|NCT05591768|Experimental|MBA group monopolar radiofrequency group.|Inferomedial, superomedial, and superolateral GN branches of the patients were identified with ultrasonography, and a 22 Gauge, 10 cm radiofrequency (RF) cannula with a 10 mm active tip was advanced to the targeted nerves under fluoroscopy guidance. The location of the RF cannula was visualized by anteriorposterior and lateral images. Sensory stimulation was applied at 50 Hz to determine the nerve position. Since the sensory stimulation threshold must be < 0.6 V, nerve position was tested with the absence of fasciculation in the relevant area of the lower extremity upon 2.0 V stimulation at 2 Hz.
89495175|NCT05591768|Experimental|BFA group bipolar radiofrequency group|similar technique will be used to insert the canula, except that, instead of one cannula two cannulae (approximately 10 mm apart) apart) will be inserted and no manipulation of cannulae was done to stimulate the target nerve as done in MRFA Target areas were similar to monopolar technique Each nerve will be ablated for 90 s in both the groups. All procedures were done by one pain physician who had more then 10 years' experience of radiofrequency procedures
89495176|NCT02414373|Experimental|Ropivacaine|Ropivacaine 2mg/ml (ROPIVACAIN Sintetica 2 mg/ml ™, Sintetica-Bioren, Couvet, Schweiz)
88954869|NCT01976936|Experimental|High Dose Lovastatin|High dose lovastatin (640 mg daily for three days) will be administered orally
89495177|NCT02414373|Active Comparator|Bupivacaine|Bupivicaine 1.25mg/ml (BUPIVACAIN Sintetica 0.125 % ™ (Bupivacain 1,25 mg/ml), Sintetica-Bioren, Couvet, Schweiz)
89495178|NCT04320290|Experimental|Treatment with Direct Acting Antiviral for HCV|8 weeks of treatment with HCV Direct Acting Antiviral tablet
89495179|NCT03173235||Infertile women|Women which desire to have children but are probable infertile between 18 and 45 year old
89495180|NCT03173235||healthy women|Healthy women without systemic diseases in the age of 18 to 45 years
89495181|NCT05697692|Placebo Comparator|Placebo|Saline 0.9%
89495182|NCT05697692|Active Comparator|Heparin sodium|70 international units (IU)/kg Heparin sodium
89531761|NCT05489913|No Intervention|Standard care|patients received their training before discharge from the hospital and no intervention was made for 12 weeks.
88954870|NCT01976936|Active Comparator|Low Dose Lovastatin|Lovastatin 80 mg daily for three days will be administered orally to patients who were taking statin therapy at the time of enrolment
88954871|NCT01976936|Placebo Comparator|Placebo|Placebo will be administered orally to patients who were NOT taking statin therapy at the time of enrolment
89205097|NCT00761189|Experimental|Paliperidone|Paliperidone extended-release (ER) tablet will be administered orally in dose range of 3 to 12 milligram (mg) per day for 12 weeks as per Investigator's discretion.
89206303|NCT04092959|Experimental|Control group|A total of 240 hypertensive subjects aged 40-69 years (including 126 patients complicated with diabetes) will be included in a few communities in Beijing, and will be divided into 3 groups according to the individual wishes of the subjects: walking group(n=80, including 42 patients complicated with diabetes), Chinese square dancing group(n=80, including 42 patients complicated with diabetes) and control group(n=80, including 42 patients complicated with diabetes).
89206304|NCT00827580|Experimental|Eniluracil|
88954872|NCT01976949|Active Comparator|Social-networking intervention|Individuals interested in participating in the study will be randomized to receive access to a 12-week internet-based treatment group. Subjects assigned to the treatment group will have access to a group discussion board, a structured 12-week coping-skills training course, professional facilitation of the group, a real-time chat board, and personal profiles established by other group members. Subjects will be asked to complete online self-report measures of distress, mood disturbance, and quality of life at baseline and again after participation in the 12-week group.
88954873|NCT01976949|Active Comparator|Control group|12 week wait-list control subjects will be able to join a group after they complete the 12-week assessment and will be asked to complete a 24-week assessment in order to measure change over time. Subjects will have access to a group discussion board, a structured 12-week coping-skills training course, professional facilitation of the group, a real-time chat board, and personal profiles established by other group members. Subjects will be asked to complete online self-report measures of distress, mood disturbance, and quality of life at baseline and again after participation in the 12-week group.
88954874|NCT01977001||Primary Headache|Treatment with MigraineBoxTM
88954875|NCT01977014||Patient with LenusPro pump|
88954876|NCT01977027|Other|Stroke & age-matched Controls|"Alternate Hand Training or Affected Hand Training:~40 patients with stroke and 40 control subjects will participate over 7 visits. After completion of informed consent, subjects will undergo clinical assessments (Visit 1) which will involve testing for kinesthetic, visual, tactile and motor impairments and upper limb function. Visit 2, subjects will undergo no contrast MRI to identify lesion location. Healthy controls will not be imaged.~Visits 3-7 will involve psychophysical experiments to test adaptation with short-term Alternate Hand Training and Affected Hand Training. During 5 visits the subjects will grasp and lift an instrumented grip device of different weights, textures and shapes while data is being collected via surface electrodes from, upper arm and back muscles."
88954877|NCT01977027|Other|Phase 2 - Stroke ONLY|"Alternate Hand Training or Affected Hand Training:~Subjects will be randomized into two groups one receiving Alternate Hand Training and the other receiving Affected Hand Training. The groups will be matched by age, gender, handedness, side of lesion, extent of motor impairment and lesion location. They will complete 17 Study visits.~Visits 1 and 2 will involve clinical assessments and MRI. Visit 3. Pre-intervention assessments involving grasping and lifting objects of different weights, textures and shapes while fingertip forces, finger and arm movements. Muscle activity and performance is measured.~Visits 4-15. Subjects will participate in 12 training visits for 1 hour a day, twice a week for 6 weeks.~Visits 16-17. Recovery of hand function will be measured by repeating the pre-intervention clinical and grasping assessments (in 2 visits) immediately after 6-weeks of training, and another 6 weeks later."
88954878|NCT01977053|No Intervention|A: Standard medical care|Arm A: standard supervision and medical care during an adjuvant chemotherapy treatment in France
88954879|NCT01977053|Experimental|B: telephonic monitoring|Arm B: telephonic monitoring during inter-treatment intervals + personalized medical care.
88954880|NCT01977066|Experimental|Six months supervised exercise training|
88954881|NCT01977066|Experimental|Six months home-based exercise training|
88954882|NCT01977066|No Intervention|Control group|
88954883|NCT01977079|Other|Premature birth|"At the end of the study patients will be divided into two groups: Premature delivery versus No premature delivery. Prematurity is defined as a birth before 37.~In each group, the procalcitonin rate be estimated with a confidence interval of 95% and compared from a logistic regression."
88954884|NCT01977079|Other|Not premature birth|"At the end of the study patients will be divided into two groups: Premature delivery versus No premature delivery. Prematurity is defined as a birth before 37.~In each group, the procalcitonin rate be estimated with a confidence interval of 95% and compared from a logistic regression."
88954885|NCT01977105|Experimental|Pilot Intervention Group|Mothers who are screened and determined to be eligible for this single-group pilot study will be enrolled along with their infants in the Grow Together peer group intervention.
88954886|NCT01977118|Experimental|Group B [streptokinase]|50000U of injection streptokinase dissolved in 100ml of normal saline instilled in to the pancreatic and/or peripancreatic collections via the percutaneous catheters and clamped for 2 hours. After release of clamp, cavity will be irrigated with 100-500ml of normal saline. This procedure will be done thrice daily for five days
88954887|NCT01977118|Placebo Comparator|Group A [placebo]|100 ml of normal saline will be instilled through percutaneous catheters in the pancreatic and/or peripancreatic collections and clamped for 2 hours. After release of clamp, cavity will be irrigated with 100-500ml of saline. This procedure will be performed thrice daily for five days
88954888|NCT01977131|Experimental|stromal cells modified HGF|
88954889|NCT01977157||bioimpedance measurements while trinking alcohol|Bioimpedance spectroscopy (BIS) measurements on 12 healthy subjects were performed while they were drinking alkohol until reaching a BAC of 0.8 ‰.
88954890|NCT01977170|Experimental|Hib/PRP-T vaccine|"One dose, correspond to 0.5 ml, composed of:~PRP-T 10ug NaCl 0.85%~Frequency: 1 injection"
88954891|NCT01977196|Experimental|DTP/HepatitisB/Hib vaccine|Purified diphteria toxoid Purified tetanus toxoid Inactivated Bordetella pertussis HbsAg PRP-TT Aluminum phosphate Natrium Chloride Thimerosal
88954892|NCT01977209|Experimental|Arm A|Docetaxel 75mg/m2/iv over 90min and cisplatin 75mg/m2/iv over 90min on day 1. Gossypol 20mg from day 1 to day 14. repeat Q 3weeks. Four cycles.
89495183|NCT02702193|Experimental|SET-R/Healthy Home|SET is a manualized, strength-based,directive and process-oriented family-ecosystemic intervention based on Brief Strategic Family Therapy. Healthy Home is an adaptation of SET to be delivered by nurses as an enhanced, family-strengthening, home-health intervention. Healthy Home is delivered in addition to the usual substance abuse or mental health outpatient services received by the mothers.
89495184|NCT02702193|No Intervention|TAU|Treatment as usual - the usual outpatient substance abuse or mental health services received by the mothers with no additional services provided by the study team.
89495185|NCT02761057|Experimental|Arm I (sunitinib malate)|Patients receive sunitinib malate PO on days 1-28. Cycles repeat every 42 days in the absence of disease progression or unacceptable toxicity.
89495186|NCT02761057|Experimental|Arm II (cabozantinib s-malate)|Patients receive cabozantinib s-malate PO on days 1-42. Cycles repeat every 42 days in the absence of disease progression or unacceptable toxicity.
89495187|NCT02761057|Experimental|Arm III (crizotinib closed to accrual 12/5/18)|"Patients receive crizotinib PO BID on days 1-42. Cycles repeat every 42 days in the absence of disease progression or unacceptable toxicity.~At the time of prespecified interim analysis, crizotinib showed a HR for PFS greater than 1 compared with that of sunitinib. The DSMC subsequently recommended that accrual be stopped for this group, and this recommendation was accepted by the NCI."
89495188|NCT02761057|Experimental|Arm IV (savolitinib closed to accrual 12/5/18)|"Patients receive savolitinib PO on days 1-42. Cycles repeat every 42 days in the absence of disease progression or unacceptable toxicity.~At the time of prespecified interim analysis, savolitinib showed a HR for PFS greater than 1 compared with that of sunitinib. The DSMC subsequently recommended that accrual be stopped for this group, and this recommendation was accepted by the NCI."
89495189|NCT02414217|Experimental|In-Person Diabetes Numeracy Education|"Participants randomized to the in-person education group attended four group classes, each addressing a specific set of diabetes self-care skills (i.e., understanding and using blood glucose numbers, counting carbohydrates, taking medications at the right dose and time). So that each class included a stable group of 8 and 16 participants, we ran classes in cohorts of 8-16 people. A participant always attended classes with his/her cohort."
89205098|NCT01064869|Experimental|Psycho-educational intervention|"A nurse-led programme of intervention will be devised. Patients will attend weekly for a period of 12 weeks. It will have two stages incorporating:~1. Structured interview to identify demographic information and individual reasons for non-adherence and assessment of readiness to change behaviour~This will be followed by an individualised package incorporating:~A structured asthma education programme, to address any gaps in asthma knowledge or requests for information~Motivational interviewing based on stages of change model to encourage change and adherence~Psychological therapy involving (a) relaxation therapy (b) cognitive behavioural techniques looking at negative and catastrophic thoughts and (c) panic cycle adapted to respiratory patients"
89495190|NCT02414217|Experimental|Online Diabetes Numeracy Education|Participants randomized to the online education group attended a single session, at which he/she completed a computerized education module that addressed understanding blood sugar values and using them to examine the impact of food, exercise, and medicines on blood sugar.
89495191|NCT02414217|No Intervention|Control|Participants were given written educational materials about diabetes.
89495192|NCT02417181|No Intervention|General Practitioners Care|Usual medical care provided by a general practitioner at the out-of-hours primary care service
89495193|NCT02417181|Experimental|Physician Assistants Care|Medical care provided by the Physician Assistant at the out-of-hours primary care service
89495194|NCT03173391|Experimental|HMS5552|75mg BID
89495195|NCT03173391|Placebo Comparator|Placebo|BID
89495196|NCT02413983||CI (conventional incision)|The living liver donors underwent hepatectomy using right subcostal incision with a midline extension (conventional incision)
89205099|NCT01064869|No Intervention|usual care|Standard asthma management
89205100|NCT01062295|Experimental|Siesta-System|Use of Siesta-System
89495197|NCT02413983||MI (midline incision)|The living liver donors underwent hepatectomy using upper midline incision (10cm) without laparoscopic assistance
89495198|NCT02413983||TI (transverse incision)|The living liver donors underwent hepatectomy using transverse incision with laparosocpic assistance
89495199|NCT03172923|Active Comparator|sliding hip screw|fixation of fracture with a sliding hip screw
89495200|NCT03172923|Experimental|intramedullary nail|fixation of the fracture with an intramedullary nail
89495201|NCT03177915|Active Comparator|Hyalase|injection of Hyalase + 10 cc saline injection nearby median nerve as hydro-dissection
89495202|NCT03177915|Active Comparator|Saline|Injection 10 cc saline injection as a median nerve hydro-dissection
89495203|NCT03173157|Experimental|Value Feedback Arm|A weekly email will be sent to all inpatient, resident-staffed cardiology teams outlining best use practices from AHA/ACC statements on trans-thoracic echoacardiography and data feedback on in-hospital charges, running 13 week average usage and previous week usage of full and limited trans thoracic echocardiograms
89495204|NCT02413905||Senegal|Stool samples on Children with and without severe acute malnutrition in Senegal recruited in 3 locations (Dakar, Dielmo and Ndiop)
88954893|NCT01977209|Placebo Comparator|Arm B|Docetaxel 75mg/m2/iv over 90min and cisplatin 75mg/m2/iv over 90min on day 1. Placebo from day 1 to day 14. repeat Q 3weeks. Four cycles.
89495205|NCT02413905||Niger|Stool samples Children with and without severe acute malnutrition in Niger recruited in Niamey
89495206|NCT03176355|Other|Chronic dacryocystitis patients|
89495207|NCT02407821|Active Comparator|Escitalopram|
89495208|NCT02407821|Placebo Comparator|Placebo|
89495209|NCT02167243|Experimental|Reinforcement for performing BG testing|Subjects will receive reinforcement for BG testing. The intervention will reinforce subjects for conducting Self Monitoring of Blood Glucose (SMBG), with escalating reinforcers provided when subjects achieved sustained periods of testing at least 4 times/day at appropriate intervals.
89495210|NCT02167243|Active Comparator|No reinforcement for BG testing|Subjects will receive standard of care without reinforcement for Self Monitoring Blood Glucose
89495211|NCT02408055|Experimental|Radiolabelled TA-8995|
89495212|NCT02164357||EVT|Patients receiving endovascular treatment (EVT) within 4.5 hours after onset because intravenous thrombolytic therapy (IVT) is contraindicated
89495213|NCT02164357||IVT + EVT|Patients receiving intravenous thrombolytic therapy (IVT) followed by endovascular treatment (EVT) within 4.5 hours after onset
89495214|NCT02164357||IVT (intravenous thrombolytic therapy)|Patients that will received IVT only within 4.5 hours after onset
89495215|NCT03177213||pemphigus vulgaris patients|20 pemphigus vulgaris patients will be included in the study, either newly diagnosed or recurrent. Patients will be recruited on admission from Dermatology department and Outpatient Clinic, Assiut University Hospitals
89495216|NCT03177213||Healthy controls|10 healthy age and sex matched subjects will be included as controls.
89495217|NCT03540745|Experimental|TES Treatment|Where subject is randomized to TES.
89495218|NCT03540745|Placebo Comparator|TES-SHAM Treatment|Where subject is randomized to a SHAM condition
89495219|NCT02407665|Experimental|Tai Chi|Participants who practice Tai Chi 2X/week for 12-weeks
89495220|NCT02407665|No Intervention|Healthy Control|24 healthy controls
89495221|NCT03540667||Single group study|The study population will include patients presenting for primary elective unilateral total hip and knee arthroplasty.
89495222|NCT02417337|Active Comparator|Group I|paracetamol 1000mg
89495223|NCT02417337|Experimental|Group II|ibuprofen 600mg + paracetamol 1000mg,
89495224|NCT02417337|Experimental|Group III|Mefenamic acid 500mg + Paracetamol 1000mg
88954894|NCT01977248|Experimental|SMART therapy|The Sensorimotor Affect Relationship-based Therapy (SMART) program is an interdisciplinary program that teaches children ages 2-12.5 the fundamental skills necessary to build and maintain relationships. Sessions last for 12 weeks at a time and address skills such as: tolerance for sitting and structure, joint attention, eye contact, transitions between activities, participation in group activities, communication skills, and play skills.
88954895|NCT01977261|Experimental|Opening-wedge HTO|Opening-wedge high tibial osteotomy fixated with a Puddu-plate
88954896|NCT01977261|Active Comparator|Closing-wedge HTO|Closing-wedge high tibial osteotomy fixated with 2 staples
89495225|NCT02417337|Experimental|Group IV|Diclofenac K 50mg + paracetamol 1000 mg
89495226|NCT02417337|Placebo Comparator|Group V|No medication
89495227|NCT02164435|Other|Renal Denervation|
89495228|NCT02417025|Experimental|PE-HBT|Prolonged Exposure via home-based telehealth (i.e., completed using videoconferencing technology)
89205101|NCT01062295|Active Comparator|Standard headrest|Use of standard headrest
89205102|NCT00529516|Experimental|FluAS25 Group|Subjects aged 65 years and above, who had received one dose of GlaxoSmithKline (GSK) Biologicals' AS25 adjuvanted influenza vaccine (GSK576389A) in study NCT00377585, received one dose of GlaxoSmithKline (GSK) Biologicals' AS25 adjuvanted influenza vaccine (GSK576389A) in the current study.
89205103|NCT00529516|Active Comparator|Fluarix ≥ 65 years age Group|Subjects aged 65 years and above, who had received one dose of Fluarix™ vaccine in study NCT00377585, received one dose of Fluarix™ vaccine in the current study.
89495229|NCT02417025|Active Comparator|PE-SD|Prolonged Exposure via standard delivery (i.e., completed in person at the therapist's office)
89495230|NCT02167321|Active Comparator|Arm A|"Arm A; standard neoadjuvant chemoradiotherapy group~fluoropyrimidine based concurrent chemoradiotherapy-> TME -> adjuvant chemotherapy (Low risk: fluoropyrimidine-based chemotherapy, High risk: FOLFOX)"
89495231|NCT02167321|Experimental|Arm B|"Arm B : adjuvant FOLFOX group~Total mesorectal excision (TME) --> 12 cycles of FOLFOX every 2 weeks (or Total mesorectal excision (TME) --> Concurrent chemoradiotherapy + 12 cycles of FOLFOX every 2 weeks)"
89495232|NCT03176589|Sham Comparator|sham PEP|3 cycles of 10 deep inspiration and expiration in a sham tube without expiratory resistance
89495233|NCT03176589|Active Comparator|PEP|3 cycles of 10 deep inspiration followed by expiration with positive expiratory pressure (PEP) device or PEP bottle of 10-15 cm of water pressure
89495234|NCT03176589|Experimental|deep breathing maneuvers|3 cycled of 10 deep breathing maneuvers without PEP or sham PEP
89495235|NCT02162641||SCC of the anus|
89495236|NCT02407743||Surgical patients' clinical progression|Patients undergoing non-ambulatory surgery will be asked questions and complete surveys in an effort to characterize postoperative pain experience profiles. A blood sample will be obtained for genetic markers exploring a variety of pain-related genes.
89495237|NCT04733833|Experimental|Arm 1|VB-201 + standard of care
89495238|NCT04733833|Active Comparator|Arm 2|Standard of care
89495239|NCT02416635||Control|Use Flow cytometry (FCM) and RT-PCR to test peripheral blood mononuclear cells(PBMCs) from healthy volunteer.
89495240|NCT02416635||Cryosurgery group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received cryosurgery only, 1 day before and 2 days after the cryosurgery.
89495241|NCT02416635||DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received DC-CIK treatment only, 1 day before and 2 days after the DC-CIK treatment.
89495242|NCT02416635||Cryosurgery with DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients received cryosurgery and DC-CIK treatment both, 1 day before and 2 days after the cryosurgery with DC-CIK treatment.
89495243|NCT02162797|Experimental|Placebo supplementation|Intervention Group B: Patients who will orally receive a placebo for 3 months.
89205104|NCT00529516|Active Comparator|Fluarix 18-40 years age Group|Subjects aged between 18 and 40 years, who had received one dose of Fluarix™ vaccine in study NCT00377585, received one dose of Fluarix™ vaccine in the current study.
89495244|NCT02162797|Experimental|zinc supplementation|Intervention group A. Patients who will orally receive zinc for 3 months.
89495245|NCT02413749||Stable PsA response to treatment|Individuals with psoriatic arthritis who are being treated standard of care with a stable DMARD or a biologic
89495246|NCT02413749||PsA inadequate response to DMARD|Individuals with psoriatic arthritis who have had an inadequate response to a DMARD and are being treated standard of care with a biologic.
89495247|NCT02407587|Experimental|unilateral cochlear implants|"Study Group~PET scans for the mature patients with unilateral cochlear implants and preserved hearing~4 states and each state will be repeated 3 times Cochlear implant only Residual hearing only Combination of implant and residual hearing No auditory stimulation"
89495248|NCT02407587|No Intervention|Healthy volunteers|4 states and each state will be repeated 3 times Auditory stimulation Left ear only Auditory stimulation right ear only Binaural auditory stimulation Silence
89495249|NCT02162875|Experimental|MDA once a year|Community wide treatment (CWT) once a year for four years with single dose praziquantel 40mg/kg
89495250|NCT02162875|Experimental|MDA 2nd year CWT follwed by 2 years SBT|Treatment with praziquantel as arm 1 given by two years of community wide treatment (CWT) followed by two years of school-based treatment (SBT)
89495251|NCT02162875|Experimental|Praziquantel every second year CWT|Treatment with praziquantel given every second year as CWT
89495252|NCT02162875|Experimental|MDA once a year SBT|Treatment with praziquantel as above given as 4 years of SBT
89495253|NCT02162875|Experimental|MDA given for 2 years as SBT|Treatment with praziquantel as above given for 2 years as SBT followed by 2 years without MDA
89495254|NCT02162875|Experimental|MDA as SBT 1year and 1 year without MDA|Treatment with praziquantel given as one years of SBT alternating with one year without treatment
89205105|NCT01008436|Active Comparator|Control|Traditional best-practice surgical hemostasis
89495255|NCT02413671|Other|Lupin Protein|Subjects received a test meal rich in carbohydrates and supplemented with lupin protein.
89495256|NCT02413671|Other|Whey Protein|Subjects received a test meal rich in carbohydrates and supplemented with whey protein.
89495257|NCT02413671|Other|Reference|Subjects received a test meal rich in carbohydrates not supplemented with any protein.
89495258|NCT02167399||smart phone inclinometer|For the smart phone analysis we will be using the tilt meter application which is a digital inclinometer application available on the I phone. The phone will be placed in the vertical position utilizing the bubble level feature of the application. The application will be set to display measurements to the closest tenth of the degree, set to log measurements every 0.2 seconds. The subject will stand with knee extended to 0 degrees and quadriceps muscle activated and upper extremity support on opposite side of stance limb. The phone will be placed in the vertical position on the anterior portion of the middle third of the subject's thigh attached using double sided adhesive tape. Being placed as close as possible to level when attached to the anterior thigh with subject in single limb stance with a reading of less than 1 deg as minimum for correct set-up prior to testing. Immediately prior to testing recording will be initiated logging measurements for later assessment.
89495259|NCT02167399||2-D video analysis|two dimensional video analysis by first placing markers on the subject at the midpoint of the femoral condyles, midpoint of the ankle malleoli, and the proximal thigh along a line from the anterior superior iliac spine (ASIS) to the knee marker. Testing will take place in front of a digital video camera with tape on the floor to give a reference point for the subject being tested. Participants will be tested twice on day 1 and then again 5-9 days later. Subjects will be allowed 2-3 practice trials prior to each test in order to allow the subject to feel comfortable with each test. Following the practice trials the subject will perform 3 trials of each test on bilateral lower extremities. This set up was consistent with the set up by Munro et al.
89495260|NCT02407353|Experimental|PF-06648671 High dose group|subjects receive a single oral dose of PF-06648671 at 300 mg
89495261|NCT02407353|Experimental|PF-06648671 Low dose group|Subjects receive a single oral dose of PF-06648671 lower than 300 mg dose
89495262|NCT02407353|Placebo Comparator|Placebo group|Subjects receive matching placebo
89495263|NCT02407353|Experimental|PF-06648671 Low dose group (2)|Optional arm. Subjects receive a single oral dose of PF-06648671 at second lower dose if 300 mg dose is not repeated in cohort 2
88954897|NCT01977274|Experimental|gynecological cancer|blood and tumor samples
89205106|NCT01008436|Experimental|Omni-stat Celox|Administration of 6 gr of Omni-stat Celox intraoperatively at the time of Hemostasis
89205107|NCT00316693|Experimental|Cervarix Group|Subjects received 3 doses of GSK Biologicals HPV-16/18 vaccine (Cervarix™) according to a 0, 1, 6-month schedule.
89205108|NCT00316693|Active Comparator|Aimmugen Group|Subjects received 3 doses of Aimmugen™ (Hepatitis A [HAV] vaccine) according to a 0, 1, 6-month schedule.
89205109|NCT05099692||CHD patients participating in the cardiac rehabilitation|
89205110|NCT01008592||Group 1|Subjects with chronic idiopathic urticaria exhibiting dermatographism.
89495264|NCT03726385||Group I|Group I: The control group. Participants in this group received only NDT based upper extremity rehabilitation. Number of the participants were 19.
89495265|NCT03726385||Group II|Group II: The study group. Participants in this group received NDT based upper extremity rehabilitation + Cogniboard® Light Trainer training. Number of the participants were 19.
89495266|NCT03177447|Other|Summative evaluation trial of ENABLE CHF-PC|Single arm summative evaluation study was selected for several reasons: 1) to continue to determine recruitment feasibility; 2) retention- our prior work has demonstrated fairly equal dropouts in the intervention and control conditions, hence we believe we will be able to judge retention in a single arm design; 3) using a small randomized controlled trial (RCT) for power estimates runs a high risk of either overestimating or underestimating treatment effects; and 4) most importantly, the primary purpose of this study is to determine intervention efficacy. Therefore delivering the intervention to the maximum number of participants given the limitations of 2-year pilot funding allows the investigators to obtain the maximal input and experience with the intervention that is needed to achieve the study's Aim 1.
89495267|NCT03177135|Experimental|AmnioSense diagnostic pantyliner|AmnioSense diagnostic pantyliner of amniotic fluid compared with standard clinical diagnosis methods
89495268|NCT02167555|Active Comparator|Wild Bluberries|Active Comparator
89495269|NCT02167555|Placebo Comparator|Placebo|Placebo Comparator
89495270|NCT03177057|Experimental|Arm I (self-monitoring)|ARM I (SELF-MONITORING): Patients complete tanning and sun protection usage entries daily for 14 days.
89495271|NCT03177057|Experimental|Arm II (text messages)|ARM II (TEXT MESSAGES): Patients receive individualized text messages based on baseline assessment of tanning motives (appearance, enjoyment, social) daily for 14 days.
89495272|NCT03177057|Experimental|Arm III (self-monitoring, text messages)|ARM III (COMBINED GROUP): Patients complete tanning and sun protection usage entries and also receive individualized text messages daily for 14 days.
89495273|NCT03177057|Sham Comparator|Arm IV (questionnaire administration)|ARM IV (CONTROL GROUP): Patients complete study assessments.
89495274|NCT02164747||Control group before telemedicine|Residents of nursing homes without telemedicine before implementation of telemedicine in nursing homes with telemedicine
89495275|NCT02164747||Control group after telemedicine|Residents of nursing homes without telemedicine after implementation of telemedicine in nursing homes with telemedicine
89495276|NCT02164747||Exposed group, before telemedicine|Residents of nursing homes with telemedicine prior implementation of telemedicine
89495277|NCT02164747||Exposed group, after telemedicine|Residents of nursing homes with telemedicine after implementation of telemedicine
89495278|NCT03176901|Experimental|Mindfulness-Based Stress Reduction|8 week manualized, standardized mindfulness-based stress reduction program taught by a certified Mindfulness-Based Stress Reduction instructor
89495279|NCT03176901|Active Comparator|Health Enhancement Program|8 week manualized, standardized health enhancement program, taught by a certified health education specialist
89495280|NCT03176745||healthy controls|"no history of pulmonary disease~absence of symptoms, smoking history < 10 pack years~normal lung function testing"
89495281|NCT03176745||chronic obstructive pulmonary disease|"clinical history and/or specialist diagnosis of COPD and risk factor(s)~persistent bronchial obstruction and/or hyperinflation and/or radiological sign of emphysema, each without alternative explanation~dyspnea, cough and/or sputum production"
89495282|NCT03176745||bronchial asthma|"clinical history and/or specialist diagnosis of bronchial asthma~respiratory symptoms compatible with asthma varying over time~variable and/or reversible obstructive ventilation disorder and/or airway hyperresponsiveness~exclusion of alternative explanation"
89495283|NCT03176745||sarcoidosis|"clinical history and/or specialist diagnosis of sarcoidosis~lymphocytic alveolitis and CD4/CD8 > 3.5 in bronchoalveolar lavage and/or noncaseating epithelioid granuloma~exclusion of alternative explanation"
88954898|NCT01977287||Functional Electrical Stimulation|The Functional Electrical Stimulation (FES) group will be asked to use their clinically prescribed FES unit (either ODFS III or Pace) to the dorsiflexors to treat foot drop for a period of 12 weeks.
88954899|NCT01977287||Ankle Foot Orthosis|The people in the Ankle Foot Orthosis group (AFO) will be asked to use their clinically prescribed AFO to treat drop foot for a period of 12 weeks.
88954900|NCT01977300|Placebo Comparator|Mood stabilizer & Placebo|Patients will receive lithium or valproate plus placebo for 52 weeks (risperidone or olanzapine tapering will begin on the day of randomization with discontinuation of the drug within 2 weeks).
88954901|NCT01977300|Experimental|"'24 week  arm"|Continuation of the lithium or valproate plus risperidone or olanzapine for 24 weeks followed by mood stabilizer plus placebo for another 28 weeks. Dosages: 1 to 6 mg of risperidone, 5 to 20 mg olanzapine.
88954902|NCT01977300|Active Comparator|"52 week arm"|Continuation of the atypical antipsychotic, risperidone or olanzapine, plus lithium or valproate for 52 weeks.
88954903|NCT01977313||All study participants|All study participants
88954904|NCT01977326|Experimental|counseling intervention|Each woman recruited into the intervention arm will undergo 6 sessions of basic counselling by lay-health workers
88954905|NCT01977326|Active Comparator|Enhanced usual care|usual antenatal care with additional 3 - 4 monthly phone calls.
89495284|NCT03176667|Experimental|ESP for VATS|Erector Spinae plane (ESP) block
89495285|NCT03176667|Active Comparator|ICB for VATS|Intercostal block (ICB)
89495286|NCT02167633|Active Comparator|Decompression surgery plus fractionated radiotherapy|
89495287|NCT02167633|Experimental|Radiosurgery|Patients treated with radiosurgery/SBRT will receive a prescribed dose of 16 Gy in one fraction to cover as large a fraction as possible the defined target volume
89495288|NCT02416947|Placebo Comparator|0g SCF|Subjects will consume 0 g of SCF in two equal doses as a muffin and a drink, daily for 50 days.
89495289|NCT02416947|Active Comparator|10 g SCF|Subjects will consume 10 g of SCF in two equal doses as a muffin and a drink, daily for 50 days.
89495290|NCT02416947|Active Comparator|20g SCF|Subjects will consume 20 g of SCF in two equal doses as a muffin and a drink, daily for 50 days.
89495291|NCT02413281|Experimental|ALKS 5461 Dose 1|Sublingual tablets
89495292|NCT02413281|Experimental|ALKS 5461 Dose 2|Sublingual tablets
89495293|NCT02413281|Experimental|ALKS 5461 Dose 3|Sublingual tablets
89495294|NCT02413281|Active Comparator|Buprenorphine Dose 1|Sublingual tablets
89495295|NCT02413281|Active Comparator|Buprenorphine Dose 2|Sublingual tablets
89495296|NCT02413281|Placebo Comparator|Placebo|Sublingual tablets
89495297|NCT02170909|Experimental|BIBR 1048 MS low dose|
89495298|NCT02170909|Experimental|BIBR 1048 MS medium dose|
89495299|NCT02170909|Experimental|BIBR 1048 MS high dose|
89495300|NCT02164825|Experimental|Single-shot nerve block|Efficacy compared to epidural
89495301|NCT02164825|Active Comparator|Continuous epidural|Continuous epidural perfusion
89495302|NCT03176511|Experimental|MOB+DTBC Group|A Matter of Balance plus Dual-Task Balance Challenge Group. Standardized MOB classes twice/week for 4 weeks, plus 15 minutes of DTBC each class. Each class is 2 hours 15 minutes.
89495303|NCT03176511|Active Comparator|MOB Group|A Matter of Balance Group. Standardized MOB classes twice/week for 4 weeks, plus 15 minutes of social time each class. Each class is 2 hours 15 minutes.
89495304|NCT02170987|Experimental|Dabigatran etexilate low|
89495305|NCT02170987|Experimental|Dabigatran etexilate high|
89495306|NCT02170987|Placebo Comparator|Placebo to dabigatran etexilate|
89495307|NCT02170987|Active Comparator|Moxifloxacin|
89495308|NCT03176121|Experimental|Oxycodone treatment|"Patients will take either control-released oxycodone (OxyContin® 10mg and 20mg) or immediate-released oxycodone (OxyNorm® 5mg) or both for initial dose and used it to titrate his/her background dose.~After regular time assessment of the pain score (NRS), if the pain control is inadequate (NRS ≥ 4), a total daily dose in 24hrs will be summed up for the next dose titration until reach a stable dose (as defined as total daily dose is fixed for at least two weeks)."
89495309|NCT02261155|Other|Hypnosis|hypnotic induction followed by relaxation and pleasant imagery
89495310|NCT02171143|Experimental|ASP2409 Dose Escalation|
89495311|NCT02171143|Placebo Comparator|Placebo Dose Escalation|
89495312|NCT03176199|Experimental|Control-released oxycodone|Control-released oxycodone Q12H, initial daily dose is 20 mg + immediate-released oxycodone for PRN
89495313|NCT03176199|Active Comparator|Immediate-released oxycodone|Immediate-released oxycodone Q6H, initial daily dose is 20mg + immediate-released oxycodone for PRN
89495314|NCT05697614|Experimental|intervention|valproic acid 15 - 60 mg/kg body weight/day, divided into 2 dosages/day for 12 weeks ; carbamazepine 10 - 30 mg/kg body weight/day, divided into 2 dosages/day for 12 weeks ; phenytoin 5-7 mg/kg body weight/day, divided into 2 dosages/day for 12 weeks
88954906|NCT01977339|Experimental|Liposome Bupivacaine|Single injection femoral nerve block of 10 cc of 266 mg liposome bupivacaine with 10 cc of normal saline
89495315|NCT05697614|Active Comparator|control|lamotrigine 0.2 mg/kg body weight/day, divided into 2 dosages/day for 12 weeks ; clobazam 0.1 - 0.8 body weight/day, divided into 2 dosages/day for 12 weeks ; oxcarbazepine10 - 30 mg/kg body weight/day, divided into 2 dosages/day for 12 weeks
89495316|NCT03539185|Active Comparator|Airtraq|Awake tracheal intubation using airtraq videolaryngoscope.
89495317|NCT03539185|Active Comparator|Fiberoptic|Awake nasotracheal tracheal intubation using flexible fiberoptic bronchoscope.
89495318|NCT02407275|Other|biological sample|Genomic & culturomic analyses
89495319|NCT02171221|Experimental|Oral DFP-11207|DFP-11207: daily oral dosing, 28 day treatment cycle
89495320|NCT02413515|Experimental|Arm 1|Single arm study,the eligible subjects will receive Nifedipine GITS 60mg for 8 weeks
89495321|NCT02167789|No Intervention|PhD|
89495322|NCT02413437|Experimental|CEUS guided biopsy|Biopsy was operated under contrast-enhanced ultrasound-guided
89495323|NCT02413437|Other|US guided biopsy|Biopsy was operated under conventional ultrasound-guided
89495324|NCT03194906|Active Comparator|Memantine|Beginning at least two weeks prior to radiation therapy, participants receive memantine. Treatment continues for 12 weeks with periodic cognitive assessments and lab work.
89495325|NCT03194906|Placebo Comparator|Placebo|Beginning at least two weeks prior to radiation therapy, participants receive a placebo. Treatment and assessment are identical to the memantine group.
88954907|NCT01977339|Active Comparator|Bupivacaine|Single shot femoral nerve block with 20cc of 0.25% bupivacaine
88954908|NCT01977365|Experimental|Growth promotion based on child centered approach|
89495326|NCT03540589|Experimental|Video distraction|A video will be available as soon as the child is randomized to this group, thus enabling the child to become more involved with distraction. A tablet will be delivered to the parents in the reception room to be viewed by the child before entering the vaccine room. After entering the room, the parents will keep the child entertained with the videos. There will be several videos, and it may be optional for the parents to choose according to their preferences.
89495327|NCT03540589|Experimental|Vibration device|Buzzy® specific vibration device will be placed by the professional or caregiver at the application site, 15 to 45 seconds before the procedure.
89495328|NCT03540589|Experimental|Distraction plus vibration|Combination of the two interventions described above
89495329|NCT03540589|No Intervention|Usual care|The vaccine will be carried out according to the routine of the Vaccine Center. Lidocaine plus prilocaine, non-nutritive sucking or breastfeeding may be used.
89495330|NCT03171987|Experimental|Lidocaine patch|Lidocaine patch local application 1 piece per day for 28 days at back pain area.
89495331|NCT03171987|Active Comparator|Flurbiprofen patch|Flurbiprofen patch local application 1 piece per day for 28 days at back pain area.
89495332|NCT02164903||Imatinib|Patients in first line treatment with imatinib for no more than 3 years.
89495333|NCT02164903||Dasatinib|Patients in first line treatment with dasatinib for no more than 3 years.
89495334|NCT03172065|Other|control group|will receive 3.5 ml (17.5 mg) hyperbaric Bupivacaine + 0.5 ml saline
89495335|NCT03172065|Other|Dexmedetomidine group|will receive 3.5 ml (17.5 mg) hyperbaric Bupivacaine + 0.5 ml dexmedetomidine (0.5 mic)
88954909|NCT01977365|No Intervention|Control|
88954910|NCT01977378|Experimental|Sustained-Release Desvenlafaxine Hydrochloride|50-100mg/d
88954911|NCT01977378|Active Comparator|Sustained-Release Venlafaxine Hydrochloride|75-225mg/d
88954912|NCT01977430|Experimental|Diuretics arm|The diuretic arm's patients will receive combined thiazide-furosemide therapy for 1 month: 20 mg of furosemide three times daily and 50 mg of hydrochlorothiazide twice daily
89495336|NCT06110650|Experimental|surufatinib|surufatinib 300mg orally, once a day, every 21 days for one cycle, treatment until disease progression or intolerance
89495337|NCT06110611|Experimental|dental implant and a screw-retained implant-supported zirconia restoration|patients which were treated 5 years ago with a dental implant and a screw-retained implant-supported zirconia restoration
89495338|NCT06110585|Experimental|Experimental: rTMS Treatment|20 sessions of TMS using the intermittent theta burst stimulation (iTBS) protocol
89495339|NCT06110585|Sham Comparator|Sham Comparator: Sham Treatment|20 sham sessions using a placebo procedure with the TMS equipment.
89495340|NCT06110546|Experimental|Methadone group|
89495341|NCT06110546|Active Comparator|Non-Methadone group|
89495342|NCT06110494|Experimental|Iron oxide nanoparticles treatment Ferumoxytol/H2O2|After access preparation with sterile burs and sterile saline irrigation and working length determination as part of routine root canal treatment, and after obtaining a pre-treatment bacteriological samples, 2 mL of a mixture of Ferumoxytol (6mg/mL)/H2O2(3%) was introduced into the canal. Canals were instrumented with 15/0.04, 20/0.04, and 25/0.04 rotary files using 2 mL of treatment solution after each file with a total of 8 mL of solution used and a total contact time of 10 minutes.
89495343|NCT06110494|Active Comparator|Sodium Hypochlorite (NaOCl)|After access preparation with sterile burs and sterile saline irrigation and working length determination as part of routine root canal treatment, and after obtaining a pre-treatment bacteriological samples, 2 mL of 3% NaOCl was introduced into the canal. Canals were instrumented with 15/0.04, 20/0.04, and 25/0.04 rotary files using 2 mL of solution after each file with a total of 8 mL of treatment solution used and a total contact time of 10 minutes.
89495344|NCT06110494|Placebo Comparator|Saline (NaCl)|After access preparation with sterile burs and sterile saline irrigation and working length determination as part of routine root canal treatment, and after obtaining a pre-treatment bacteriological samples, 2 mL of 0.89% NaCl was introduced into the canal. Canals were instrumented with 15/0.04, 20/0.04, and 25/0.04 rotary files using 2 mL of treatment solution after each file with a total of 8 mL of solution used and a total contact time of 10 minutes.
89495345|NCT06110468|Experimental|Intervention, CoreDISTParticpation|"Week 1-2: a)Videos for PwMS and employers on MS, possible work adaptations, physical activity (PA) and function. b)A meeting between PwMS and a work-consultant (WC). They will decide if the PwMS should discuss the work situation with their employer or if the WC and/or other professionals are needed. c)A clinical assessment with a trained MS-OP-PT to explore possibilities for optimalisation of movement.~Week 3-8: a)A clinical assessment with the mPT building on previous assessment. Goal-setting for function and PA. b)CoreDIST-training in groups, 6 weeks, 1/week. indoors and 1/week outdoors. Independent training 1/week, CoreDISTvideos. c)A follow up meeting regarding work, evaluation of goals with mPT. New goal setting for week 10-15 Week 10-15, Self-administered, digitally supported home training: a)CoreDIST-videos 3x10 min/week b)Training of own choice including elements of high intensity and balance 2x30 minutes per week. c)Week 15: Evaluation of goals regarding work and PA"
89495346|NCT06110468|No Intervention|Control, usual care|Usual care (control group): These participants will continue with their regular routines and will be encouraged to obtain the national and MS-specific recommendation of 150-300 minutes of moderate physical activity or 75 minutes of high intensity physical activity per week or a combination of these, stay employed, continue medical treatment and seek any health care required, including physiotherapy.
89531762|NCT05484011|Experimental|Part A|Patients will have regularly scheduled study visits on days 1, 8, and 15 of each cycle. On Day 1 patients will receive odetiglucan and CDX-1140. On Days 8 & 15 only odetiglucan. Additional study visits may be required during some cycles for safety, efficacy, and translational assessments. Patients will dose to confirmed progression, a safety event or other administrative reason requiring discontinuation; all patients are allowed to dose up to 2 years (patients continuing to derive benefit may stay on treatment longer following consultation between Investigator and Sponsor). Following discontinuation patients will be followed up to 1 year.
88954913|NCT01977430|No Intervention|Control Arm|
88954914|NCT01977235|Experimental|Arm A|Irinotecan 90mg/m2/iv over 90min and cisplatin 30mg/m2/iv over 60min on day 1 and 8, repeat Q 3weeks. Four cycles.
88954915|NCT01977235|Active Comparator|Arm B|Irinotecan 65mg/m2/iv over 90min and cisplatin 30mg/m2/iv over 60min on day 1 and 8, repeat Q 3weeks. Four cycles.
88954916|NCT01977443|Active Comparator|APD-209 Eye drops|APD-209 Eye drops
88954917|NCT01977443|Placebo Comparator|APD-209 Placebo Eye drops|APD-209 Placebo Eye drops
88954918|NCT01977469|Experimental|Low intensity resistance training|Low intensity resistance training + aerobic training
88954919|NCT01977469|Experimental|High intensity resistance training|High intensity resistance training + aerobic training
88954920|NCT01977495|Active Comparator|Opt-in Enrollment|Opt-in enrollment: patient will be sent a recruitment letter, in which they must call the study team to take part in the study. During that call, the study team will schedule the participant for an intake visit.
88954921|NCT01977495|Active Comparator|Opt-out enrollment|Opt-out enrollment: patient will be sent a letter communicating to them that they have been enrolled into a research program at their doctor's office. After 10 days, the study team will contact the opt-out participants to schedule an intake visit.
88954922|NCT01977508||haemodialysis vascular access using ePTFE grafts|
88954923|NCT01977521|Experimental|Treatment|transcranial direct current stimulation (2mA)
88954924|NCT01977521|Sham Comparator|Sham|Sham stimulation
88954925|NCT01977534||Absorb BVS|Subjects receiving Absorb BVS
88954926|NCT01977586|Experimental|Metastatic renal cell carcinoma|Patients with clear cell renal cell carcinoma treated with anti-angiogenic therapies
88954927|NCT01977664||oocyte maturation failure|no intervention
88954928|NCT01977703|Active Comparator|Traditional ICD Programming|ICD will be set to pre-LVAD settings post LVAD implant.
88954929|NCT01977703|Experimental|Ultra Conservative ICD Programming|ICD will be set to ultra conservative settings post LVAD implant.
88954930|NCT01977716||Incident peritoneal dialysis patients|Patients with chronic kidney disease incident to peritoneal dialysis treatment
88954931|NCT01977742|Active Comparator|Initiate with SEP but without RTTE|Initiate supervised exercise (SEP) program but without rest-exercise transition training (RTTE)to improve cardiac vagal tone at same time; will stop RTTE after 8 weeks.
88954932|NCT01977742|Active Comparator|Initiate with RETT and SEP|"Supervised exercise program (aerobic, strength and flexibility exercises) and a specific sudden rest-exercise training protocol, three times a week. After 8 weeks, the sudden rest-exercise training protocol will be discontinued.~The cardiac vagal index will be measured at every 8 weeks."
88954933|NCT01977755|Active Comparator|danegapetide high dose|7,5 mg bolus injection, followed by 22,5 mg infused over 6 hours
88954934|NCT01977755|Active Comparator|danegaptide low dose|2,5 mg bolus injection, followed by 7,5 mg infused over 6 hours
88954935|NCT01977755|Placebo Comparator|Placebo|bolus injection, followed by infused over 6 hours
88954936|NCT01977768|Experimental|V7: Heat-inactivated M. vaccae pill|Daily pill of V7 together with standard tuberculosis therapy
88954937|NCT01977768|Placebo Comparator|Placebo pill|one pill of placebo pill once per day together with standard of care TB drugs
88954938|NCT01977807|Experimental|Myopia|Myopia Lasik treatment of virgin eyes.
88954939|NCT01977807|Experimental|Hyperopia|Hyperopia Lasik treatment of virgin eyes.
88954940|NCT01977833|Experimental|High Calorie Breakfast (BTdiet)|High Calorie Breakfast (BTdiet): The subject will consume High caloric breakfast, average lunch and reduced in calories dinner (BTdiet)
88954941|NCT01977833|Active Comparator|High Calorie Dinner (DTdiet)|High Calorie Dinner (DTdiet): The subject will consume High caloric dinner, average lunch and reduced in calories breakfast (DTdiet)
88954942|NCT01977859|Placebo Comparator|Saline|Saline infusion
89495347|NCT06110455|Experimental|Neuromuscular Exercise Training (NMT)|"The 8-week exercise intervention program consists of group sessions of Neuromuscular training supervised by a physical therapist 3 times per week. Patients will be taught and familiarized with the proper way to do the exercises on a separate day prior to the start of their actual rehabilitation program.~Each session consists of a 5 minute submaximal warm-up followed by 25 minutes of NMT.~Every 2 weeks, there will be a progression that will be achieved by increasing the difficulty level of each exercise. We will take under consideration the individuality each patient has on how much progression is needed every two weeks and it will be done by maintaining a proper quality of performance, minimal exertion and control of the movement. Participants will be given special equipment including sliders and elastic tubing"
89495348|NCT06110455|Experimental|Progressive Resistance Training (PRT)|"The 8-week exercise intervention program consists of group sessions of progressive resistance training supervised by a physical therapist 3 times per week. Patients will be taught and familiarized with the proper way to do the exercises on a separate day prior to the start of their actual rehabilitation program.~Each session consists of a 5 minute submaximal warm-up followed by 25 minutes of PRT, targeting hip and knee muscles, such as hip abductors, knee flexors and extensors. The exercise intensity will be monitored by the physical therapist, as determined by the patients' ability to complete 3 sets of 8-12 repetitions for a given exercise and a Borg Rating of Perceived Exertion (RPE) of 6-8.~Every 2 weeks, progression will be achieved by changing the resistance based on VAS and RPE, with an elastic tubing"
89495349|NCT06110429|Experimental|lactate sodium|100 mL of Sodium lactate (Osmolality 2560 mOsm/L) in 15 mins of administration via a central venous catheter
89495350|NCT06110429|Active Comparator|Hypertonic Saline solution|single infusion of 100 mL of 7.5% saline (osmolarity, 2560 mOsm/L) (HSS group)in 15 mins of administration via a central venous catheter
89495351|NCT06110416|Other|Aromatherapy|
89495352|NCT06110403|Experimental|Experimental group|Symptomatic COPD patients in stable condition treated with BGF 160 (Trixéo Aerosphere®), a combination of budesonide, formoterol and glycopyrronium in a metered dose inhaler, taken twice a day
89495353|NCT06110390|Experimental|High Flow Nasal Oxygen|HFNO device
89495354|NCT06110390|Experimental|Non-invasive ventilation|Non-invasive ventilation via tight-fitting facemask
89495355|NCT06110390|Active Comparator|Standard Oxygen therapy|Facemask oxygen is the default device used
89495356|NCT06110364|Experimental|Low-Level Tragus Stimulation|The Low-Level Tragus Stimulation will be done with TENS.
89495357|NCT06110364|Experimental|Heart Rate Variability- Biofeedback|Heart Rate Variability-Biofeedback will be done with a phone application. Practice sessions are at least 10-15 minutes twice a daily.
89495358|NCT06110364|Active Comparator|Conventional Medical Therapy|Subjects without beta blockers will be initiated on a usual/standard care medication of beta blockers to determine the efficacy of this standard medication therapy for Premature Ventricular Contraction suppression.
89495359|NCT06110338|Experimental|IBI355 dose 1|IBI355 0.3mg/kg and placebo will be given to the subjects (3:2)
89495360|NCT06110338|Experimental|IBI355 dose 4|IBI355 7.5mg/kg and placebo will be given to the subjects (6:2)
89495361|NCT06110338|Experimental|IBI355 dose 6|IBI355 25mg/kg and placebo will be given to the subjects (6:2)
89495362|NCT06110338|Experimental|IBI355 dose 7|IBI355 35mg/kg and placebo will be given to the subjects (6:2)
89495363|NCT06110338|Experimental|IBI355 dose 2|IBI355 1mg/kg and placebo will be given to the subjects (6:2)
88954943|NCT01977859|Active Comparator|Nesiritide 1.0|Nesiritide infused for 90 minute, initially at 0.5 pmol/kg/min and doubled every 15 minutes to achieve a target infusion rate of 1.0 pmol/kg/min, followed by a steady state infusion at the target rate for an additional 150 minutes (4 hours total).
89495364|NCT06110338|Experimental|IBI355 dose 3|IBI355 3mg/kg and placebo will be given to the subjects (6:2)
89495365|NCT06110338|Experimental|IBI355 dose 5|IBI355 15mg/kg and placebo will be given to the subjects (6:2)
89022599|NCT06189521|Active Comparator|dexamethasone iontophoresis group|In addition to the ten-day of physiotherapy program, in the third group ten days of dexamethasone iontophoresis therapy was applied. 10 days for 10 minutes. 0,1% dexamethasone ophthalmic pomade was applied to the anodal electrode and placed on the lateral epicondyle and 0.1-0.2 milliampere/cm2 galvanic current was applied in each session (ES-522; ITO Physiotherapy and Rehabilitation).
89022600|NCT06189495|Experimental|GenSci048|1. Dosage: 300 mg.2. Duration of administration: All subjects received one dose of Genakumab injection every 4 weeks according to their group.The dose was injected subcutaneously.3. Course of administration: Phase I subjects were treated with Genakumab injection until the end of the study or the occurrence of the drug.Tolerable toxicity or investigator-assessed efficacy (whichever occurs first); The phase 2 randomized double-blind treatment period was 24 weeks, with a total of 6 administration times. After the randomized double-blind treatment period, an open-label treatment period was entered, and all subjects will receive Genakumab injection 300 mg Q4W until the end of the study or the occurrence of intolerable toxicity or poor efficacy assessed by the investigators (whichever occurs first).4. Administration method: subcutaneous injection; The injection site is the abdomen (3 cm away from the navel
89022601|NCT06189495|Placebo Comparator|GenSci048 placebo|".1. Dosage: 300 mg.2. Duration of administration: All subjects received one dose of placebo every 4 weeks according to their group The dose was injected subcutaneously.3. Course of administration: Phase I subjects were treated with placebo until the end of the study or the occurrence of the drug.Tolerable toxicity or investigator-assessed efficacy (whichever occurs first); The phase 2 randomized double-blind treatment period was 24 weeks, with a total of 6 administration times. After the randomized double-blind treatment period, an open-label treatment period was entered, and all subjects will receive placebo 300 mg Q4W until the end of the study or the occurrence of intolerable toxicity or poor efficacy assessed by the investigators (whichever occurs first).~4. Administration method: subcutaneous injection; The injection site is the abdomen (3 cm away from the navel)"
89022602|NCT06189456|Experimental|Group A|Patients with diagnosis of moderate to severe dry eye syndrome will start a 60 days treatment period with BLUgel A free (2 drops per eye, 3 times a day, bilaterally)
89205111|NCT01062373|Active Comparator|TG-DHA|TG-DHA: lactating mothers and their newborn with mothers supplemented with Triglyceride enriched in docosahexaenoic acid
89495366|NCT06110312|Experimental|intervention group|In EU NAVIGATE, participants in the intervention group will receive a navigation intervention (also called NavCare-EU), alongside any usual care. Navcare-EU is a person- and family-centered navigation intervention, aimed at supporting older people with cancer throughout the care and illness continuum, via the involvement of a patient/family navigator. Navigators focus on connecting clients to social supports, both formal and informal, advocating for clients in meeting their quality-of-life goals, resourcing by identifying needs and negotiating access to meeting those needs, and engaging clients in what is most meaningful to them. Navigators are selected, trained, and mentored volunteers or professionals. NavCare-EU is based on the existing and successfully tested Nav-CARE(c) intervention from Canada.
89495367|NCT06110312|No Intervention|control group|Participants in the control group will receive what is usual care in each of the participating countries for 24 weeks (primary trial outcome). After 24 weeks, they will also receive the navigation intervention (NavCare-EU) (fast-track RCT).
89495368|NCT06110299|Experimental|patients with obstructed ureters|
89495369|NCT06110286||Mechanical photorefractive keratectomy|Laser photorefractive keratecyomy by Ex500 excimer laser after mannual removal of corneal epithelium
89495370|NCT06110286||Stream light trans-PRK|Laser photorefractive keratectomy by Ex500 excimer laser after removal of corneal epithelium by stream-light laser technique
89495371|NCT06110260|Experimental|AstraGin|"The 1st round: Before each study day, all subjects took a 50 mg AstraGin capsule at 9 p.m. and began fasting for 12 hours, except for a small amount of water the night before the experiment. On each study day, all subjects collected their first blood sample at 9 a.m. from the median cubital vein using the indwelling catheter method. After the first blood collection, all subjects took 50 mg AstraGin and 35 g of whey protein with 250 mL water.~Additional blood samples were collected at 0, 15, 30, 45, 60, 90, 120, 150, and 180 min to analyze the plasma concentration of amino acids.~The washout period is seven days, during which the subjects maintain a stable lifestyle and dietary habits.~The 2nd round: All subjects take a 50 mg AstraGin capsule and conduct the procedure (same as the 1st round)"
89531763|NCT05484011|Experimental|Part B|Patients will have regularly scheduled study visits on day 1 of each cycle. On Day 1 patients will receive odetiglucan and CDA-1140. Additional study visits may be required during some cycles for safety, efficacy, and translational assessments. Patients will dose to confirmed progression, a safety event or other administrative reason requiring discontinuation; all patients are allowed to dose up to 2 years (patients continuing to derive benefit may stay on treatment longer following consultation between Investigator and Sponsor). Following discontinuation patients will be followed up to 1 year.
89531764|NCT05471271|Other|[18AlF]-RESCA-IL2 PET imaging|
89205112|NCT01062373|No Intervention|Control|Control: lactating mothers and their newborn with no supplementation given to the mother
89538047|NCT03291821|Experimental|DuoStim|Two controlled ovarian stimulation within the same menstrual cycle using human menopausal gonadotropin 225 IU/day subcutaneously, GnRH antagonist in a dose of 0.25 mg/day subcutaneously and 0.2 mg of GnRH analog to induce oocyte maturation. It will be followed by ovarian puncture, oocyte isolation, intracytoplasmic sperm injection and trophectoderm biopsy at the blastocyst stage. Preimplantation genetic test and MitoScore will be performed in all the embryos prior to the embryo transfer. At this step embryos will be frozen to wait for the results. Chromossomally normal embryos will be thawed and transferred to the uterus in a deferred cycle. A pregnancy test will be performed when appropriate.
89538048|NCT03291821|Active Comparator|Conventional Stimulation|Two controlled ovarian stimulation in different menstrual cycles using human menopausal gonadotropin 225 IU/day subcutaneously, GnRH antagonist in a dose of 0.25 mg/day subcutaneously and 0.2 mg of GnRH analog to induce oocyte maturation. It will be followed by ovarian puncture, oocyte isolation, intracytoplasmic sperm injection and trophectoderm biopsy at the blastocyst stage. Preimplantation genetic test and MitoScore will be performed in all the embryos prior to the embryo transfer. At this step embryos will be frozen to wait for the results. Chromossomally normal embryos will be thawed and transferred to the uterus in a deferred cycle. A pregnancy test will be performed when appropriate.
89538049|NCT02445937|No Intervention|Control|The control group will receive usual care, in which the frequency and content of physician-family communication is determined by the clinical team according to their usual practice. No study ICU has a protocolized approach to family communication and instead clinicians determine the timing and frequency of communication with families. All sites have palliative care services.
89538050|NCT02445937|Experimental|Behavioral: The PARTNER II Intervention|"The PARTNER intervention is a multifaceted intervention delivered by a trained PARTNER Champion who has undergone 16 hours of intense communication training, with audit and feedback, quarterly booster training, and expert implementation support. Additionally, there is academic detailing of ICU physicians and ICU bedside nurses to augment the intervention. The PARTNER Intervention deploys three strategies to improve: 1) the timeliness and frequency of clinician-family communication, 2) the emotional and decision support provided to families and 3) the appropriate involvement of palliative care specialists."
89538051|NCT03287141|Sham Comparator|First intervention|The subjects did a shuttle walk test without any previous intervention.
89538052|NCT03287141|Experimental|Second intervention|Subjects underwent 30 minutes of noninvasive ventilation (CPAP) and then re-performed the shuttle walk test.
89538053|NCT03287141|Experimental|Third intervention|Subjects underwent 30 minutes of noninvasive ventilation (Bi-pap) and then re-performed the shuttle walk test.
89538054|NCT03291353|Experimental|AML Patients|pembrolizumab 200 mg given IV once every three weeks
89538055|NCT03195751||Manual Goniometer measurements|Measurements of shoulder range of motion using manual goniometer
89538056|NCT03195751||Software development kit measurements|Measurements of shoulder range of motion using a proprietary SDK
89538057|NCT03286985||General ICU patients|No intervention is associated with inclusion to the study (observational study). Included will be all patients admitted to general ICU with ICU stay >72 hours, having deep venous thrombosis prophylaxis appropriate to clinical setting and following the recent guidelines. All study participants will undergo repeated noninvasive ultrasound testing for deep venous thrombosis, which is normal part of the routine care in our ICU.
89538058|NCT03286907|Experimental|Online videos|Participants will watch two online videos, complete a self-administered online tutorial, and receive reminders at Month 1, 2, 4, 6 & 8
89538059|NCT03286907|Experimental|Online videos and MI|Participants will watch two online videos, complete a self-administered online tutorial, received motivational interviewing (MI), and receive reminders at Month 1, 2, 4, 6 & 8
89538060|NCT03286907|Active Comparator|Control group|Participants will receive online messages about mental health problems and stress reduction exercises
89538061|NCT03195985|Experimental|Mindfulness-based Intervention|Mindfulness intervention of 4 weeks
89538062|NCT03195985|Active Comparator|"Age Well psycho-education course"|4-week active control condition
89538063|NCT02460185|No Intervention|Control|Without maternal physical exercise practice
89538064|NCT02460185|Active Comparator|Study Group|Behavioral: 30 minutes of walking, 3 times a week at 4 Km/h. Induction of labor was performed at 41 weeks.
88954944|NCT01977859|Active Comparator|Nesiritide 2.0|Nesiritide infused for 90 minute, initially at 0.5 pmol/kg/min and doubled every 15 minutes to achieve a target infusion rate of 2.0 pmol/kg/min, followed by a steady state infusion at the target rate for an additional 150 minutes (4 hours total).
89538065|NCT02448433|Other|Phototherapy|
88954945|NCT01977859|Active Comparator|Nesiritide 4.0|Nesiritide infused for 90 minute, initially at 0.5 pmol/kg/min and doubled every 15 minutes to achieve a target infusion rate of 4.0 pmol/kg/min, followed by a steady state infusion at the target rate for an additional 150 minutes (4 hours total).
88954946|NCT01977859|Active Comparator|Nesiritide 8.0|Nesiritide infused for 90 minute, initially at 0.5 pmol/kg/min and doubled every 15 minutes to achieve a target infusion rate of 8.0 pmol/kg/min, followed by a steady state infusion at the target rate for an additional 150 minutes (4 hours total).
88954947|NCT01977872|Experimental|A worksite activity-diet intervention|A 12 month intensive program that includes individual sessions, interactive group sessions and online activities.
88954948|NCT01977872|No Intervention|Motiva Program|The Motiva Program is the internal corporate wellness program offered to all BCBSIL employees.
88954949|NCT01977885|Experimental|High Protien Diet + Exercise|All participants will participate in both interventions (High Protein Diet and Exercise).
89205113|NCT01062373|Experimental|GPL-DHA|GPL-DHA: lactating mothers and their newborn with mothers supplemented with Glycerophospholipid enriched in docosahexaenoic acid
89205114|NCT00316303|Experimental|1|Participants will receive screening, testing, immunization, and risk reduction. Screening and testing will take place at study entry, immunization will occur at entry and after 3 and 6 months, and risk reduction will take place at study entry and after 3 and 6 months.
88954950|NCT01977911|Experimental|Tissue engineered airway construct|"Stem cell based tissue engineered partial laryngeal implants:~The final experimental product is a highly tested, recellularised, stem cells based tissue engineered product (airway construct) for operative partial laryngeal implantation into patients with severe laryngotracheal stenosis"
88954951|NCT01977924|Experimental|polyphenols|600 mg polyphenols (grape extract)
88954952|NCT01977924|Placebo Comparator|Placebo|microcrystalline cellulose
88954953|NCT01977963||Agranulocytosis|
88954954|NCT01977976|Experimental|Endometrial Aspirate (EA) group|Endometrial aspirate by pipelle
89495372|NCT06110260|Placebo Comparator|Placebo|"The 1st round: Before each study day, all subjects took a 50 mg placebo (maltodextrin) capsule at 9 p.m. and began fasting for 12 hours, except for a small amount of water the night before the experiment. On each study day, all subjects collected their first blood sample at 9 a.m. from the median cubital vein using the indwelling catheter method. After the first blood collection, all subjects took 50 mg placebo and 35 g of whey protein with 250 mL water.~Additional blood samples were collected at 0, 15, 30, 45, 60, 90, 120, 150, and 180 min to analyze the plasma concentration of amino acids.~The washout period is seven days, during which the subjects maintain a stable lifestyle and dietary habits.~The 2nd round: All subjects take a 50 mg Placebo capsule and conduct the procedure (same as the 1st round)"
89495373|NCT06110234|Experimental|Episodic Specificity Induction|In each of the six training sessions, participants practice the ESI first under supervision and then unsupervised (self-administered). Self-administration is performed on a laptop. During each practice of the ESI, participants perform a detailed recall of a new 1-minute video clip of a complex scene - a skit of the famous English comedian Mr. Bean. Each session lasts for 90 minutes.
89495374|NCT06110234|Active Comparator|Associative Memory|In each of the six training sessions, participants recall pairs of words and pictures (e.g., names of women and rings). These pairs are presented successively after a fictitious scenario is presented to motivate memorization. There are 12 scenarios, each with 5 different word/picture pairs. Simple additions and subtractions separate the encoding phase from the recall phase. This training is adapted from Bellander et al, (2017). A general knowledge quiz is also administered at the end of the session. The training is performed on a laptop. Each session lasts for 90 minutes.
89495375|NCT06110221||Periodontitis|This group consisted of patients with generalized stage III periodontitis, who had interproximal CAL≥5 mm and PD≥6 mm as well as radiographical bone loss extending to the mid-third of the root or beyond at 30% of the teeth or more. CAL was not caused by trauma-related gingival recession, dental caries extending into the cervical areas of the teeth, endodontic lesions draining through the marginal periodontium, and the distal bone loss in adjacent second molars due to extractions of third molars. They showed no more than four teeth loss due to periodontitis.
89495376|NCT06110221||Gingivitis|This group demonstrated no detectable interproximal CAL or radiographical bone loss. PD was ≤3 mm and BOP (%) was ≥30% in the entire mouth.
89495377|NCT06110221||Periodontal health|This healthy control group had an intact periodontium without detectable CAL and radiographical bone loss. PD was ≤3 mm and BOP (%) was <10% in the entire mouth.
89495378|NCT06110208|Experimental|AML subjects|This study is a single-center clinical study. The main purpose is an IIT clinical trial to evaluate the safety and preliminary efficacy of CLL1 and CD38 dual CAR-T injection in r/r AML subjects . The included population was patients with relapsed and refractory acute myeloid leukemia (r/r AML) .
88954955|NCT01977976|No Intervention|Control group|No intervention prior to scheduled IVF
88954956|NCT01977989|No Intervention|No Vancomycin Powder|Patients who only receive IV Vancomycion prior to surgery. No Vancomycin powder is administered.
88954957|NCT01977989|Active Comparator|Vancomycin Powder|Patients who receive Vancomycin powder in the surgical site following surgery.
88954958|NCT01978002||Group 1 (Clinic Patients)|Women who have documented urinary status from surveys completed.
88954959|NCT01978002||Group 2 (Community Sample)|Women who have a clinical diagnosis of IC/BPS or OAB, and who have undergone urodynamic testing within the preceding 6 months as part of their routine clinical care.
88954960|NCT01978015|Experimental|latanoprost and timolol maleate fixed combination|Latanoprost 0.005% and timolol maleate 0,5% fixed combination was dropped once daily at 8 p.m. for 6 months
88954961|NCT01978015|Experimental|bimatoprost and timolol maleate fixed combination|bimatoprost 0.03% and timolol maleate 0,5% fixed combination was dropped once daily at 8 p.m. for 6 months
88954962|NCT01978015|Placebo Comparator|dextran and hypromellose|A control group of patients with POAG and pseudophakic after trabeculectomy without medication. These patients received a lubricant drop twice daily at 8 a.m. and 8 p.m. for 6 months
88954963|NCT01978015|Experimental|travoprost and timolol maleate fixed combination|Travoprost 0.004% and timolol maleate 0,5% fixed combination was dropped once daily at 8 p.m. for 6 months
88954964|NCT01978028|Active Comparator|ferric carboxymaltose|ferric carboxymaltose
88954965|NCT01978028|Placebo Comparator|placebo|placebo
88954966|NCT01978041|Experimental|Meal prepared with non fluoridated water (<0.1 ppm F)|
88954967|NCT01978041|Experimental|Meal prepared with fluoridated water (1 ppm F)|
88954968|NCT01978041|Experimental|Non fluoridated water (<0.1 ppm F)|
88954969|NCT01978041|Experimental|Fluoridated water (1 ppm F)|
88954970|NCT01978041|Experimental|Pilot study: Meal providing a fluoride dose of 60 ug F/kg|
88954971|NCT01978041|Experimental|Pilot study: Meal providing a fluoride dose of 120 ug F/kg|
88954972|NCT01978054|Experimental|Dissemination|Dissemination of public health knowledge: Participating states will help develop and choose 3-5 dissemination strategies they prefer for their state health department chronic disease units to receive. Dissemination strategies may include multi-day in-person training workshops, electronic information exchange modalities, and information on ways to enhance organizational climates favorable to evidence-based chronic disease prevention.
88954973|NCT01978054|No Intervention|Comparison|Comparison state health department chronic disease units will be provided links to preexisting sources of public health evidence-based information such as the Community Guide, Cancer Control P.L.A.N.E.T. (Plan, Link, Act, Network, with Evidence-based Tools), and NCI Research to Reality.
88954974|NCT01978067||transvaginal resection of Uterine Scar|transvaginal resection of Uterine Scar From Previous Cesarean Delivery
88954975|NCT01978080|Experimental|Tremor reports provided|Kinesia HomeView utilized to monitor tremor at home and reports provided to treating clinician
89495379|NCT06110195|Experimental|Escalation Group Dose Level -1|"Participants assigned to this cohort will receive xevinapant 50 mg for 2 out of every 3 weeks (Daily on days 1-14 of a 21-day cycle). They will also receive carboplatin and paclitaxel weekly for 7 doses with radiation (chemoRT).~An additional 3 cycles of xevinapant will be given after completion of chemoRT."
89495380|NCT06110195|Experimental|Escalation Group Dose Level 0|"Participants assigned to this cohort will receive xevinapant 100 mg for 2 out of every 3 weeks (Daily on days 1-14 of a 21-day cycle). They will also receive carboplatin and paclitaxel weekly for 7 doses with radiation (chemoRT).~An additional 3 cycles of xevinapant will be given after completion of chemoRT."
89495381|NCT06110195|Experimental|Escalation Group Dose Level 1|"Participants assigned to this cohort will receive xevinapant 150 mg for 2 out of every 3 weeks (Daily on days 1-14 of a 21-day cycle). They will also receive carboplatin and paclitaxel weekly for 7 doses with radiation (chemoRT).~An additional 3 cycles of xevinapant will be given after completion of chemoRT."
89495382|NCT06110195|Experimental|Escalation Group Dose Level 2|"Participants assigned to this cohort will receive xevinapant 200 mg for 2 out of every 3 weeks (Daily on days 1-14 of a 21-day cycle). They will also receive carboplatin and paclitaxel weekly for 7 doses with radiation (chemoRT).~An additional 3 cycles of xevinapant will be given after completion of chemoRT."
89495383|NCT06110195|Experimental|Dose Expansion|"Participants assigned to this cohort will receive xevinapant at the dose found during escalation phase of study for 2 out of every 3 weeks (Daily on days 1-14 of a 21-day cycle). They will also receive carboplatin and paclitaxel weekly for 7 doses with radiation (chemoRT).~An additional 3 cycles of xevinapant will be given after completion of chemoRT."
89495384|NCT06110182||enteral nutrition|children who received enteral nutritional support during treatment
89495385|NCT06110182||parenteral nutrition|children who received parenteral nutritional support during treatment
89495386|NCT06110104|Experimental|control group|they recieve Routine physiotherapy program comprises a combination of closed kinetic chain and open kinetic chain exercises, including straight leg raising, isometric quadriceps, isometric hip adduction, terminal knee extension, semi-squat, and leg press for 6 weeks.
88954976|NCT01978080|Active Comparator|Tremor reports not provided|Kinesia HomeView utilized to monitor tremor at home and reports not provided to treating clinician
89495387|NCT06110104|Experimental|Retro-walking group|they recieve routine physiotherapy and Retro-walking program which is about 10 min of supervised retro walking training 3 days a week for 6 weeks at their comfortable walking speed . The participants will be instructed to gradually increase their walking time up to 30 min over the 6-week period.
89495388|NCT06110104|Experimental|whole body vibration group|they recieve routine physiotherapy and whole body vibration which is 3 days per week for 6 weeks. During the training, the participants will perform static squat training barefoot on the platform with bent knees (30° and 60°). The distance between the feet was consistent with the shoulders. the duration time, sets and total time will be increased progressively over the 6-week.
89495389|NCT06110078|Experimental|Group 1|Daily oral acetazolamide mouth rinse
88954977|NCT01978106||a WTR corneal astigmatism group|Corneal astigmatism was defined as WTR when the steep corneal cylinder axis was within 30 degrees of the horizontal axis.
88954978|NCT01978106||an ATR corneal astigmatism group|Corneal astigmatism was defined as ATR when the cylinder axis was within 30 degrees of the vertical axis.
89022603|NCT06189456|Experimental|Group B|Patients with diagnosis of mild dry eye syndrome will start a 60 days treatment period with BLUyal A free (2 drops per eye, 3 times a day, bilaterally).
89495390|NCT06110078|Experimental|Group 2|Twice daily oral acetazolamide mouth rinse
89495391|NCT06110078|Placebo Comparator|Group 3|Placebo mouth wash daily
89495392|NCT06110078|Placebo Comparator|Group 4|Twice daily placebo mouth wash
89495393|NCT06110065||Cohort 1|
89495394|NCT06110039|Experimental|Group 1: Cervicothoracic junction mobilization with arm movement along with baseline treatment|
89495395|NCT06110039|Experimental|Group 2: upper thoracic manipulation woth baseline treatment|
89495396|NCT06110026|Experimental|Brunkow exercise program|Brunkow program includes Push up and stabilization against the wrists and heels,brunkow- from plank to a standing position ,plank from lying on the stomach to a sitting in a tilted position, Turning from the back to the position on all four
89495397|NCT06110026|Experimental|Lumbar stabilization exercises|lumbar stabilization exercises protocol includes Diaphragmatic breathing and abdominal bracing, bridging, side plank on knees, bird dog
89495398|NCT06110013||A|Patients on invasive mechanical ventilation
89495399|NCT06110013||B|Patients on Non invasive mechanical ventilation
89495400|NCT06110013||C|Patients Not on mechanical ventilation
89495401|NCT06110000|Experimental|pragmatic set of interventions|"The pragmatic set included 6 interventions as follows.~Pragmatic posterior capsular stretch (PPCS)~Serratus anterior stretch (SAS)~Rotator cuff facilitation (RCF)~Acromioclavicular joint mobilization~Pectoralis minor stretch~Thoracic manipulation"
89495402|NCT06110000|Placebo Comparator|scapular strengthening exercises|"Scapular strengthening exercises will be individualised focusing on Serratus anterior, trapezius, Levator scapulae, Rhomboids.~Serratus anterior;~Dynamic hug~Scaption with external rotation~Diagonal PNF (shoulder flexion, horizontal flexion, external rotation),~Trapezius - Upper trapezius:~Unilateral shoulder shrug,~Rowing,~Forward shoulder flexion,~Shoulder abduction in scapular plane above 120 degrees.~Middle trapezius:~Prone shoulder horizontal abduction~Scaption, horizontal abduction with external rotation~Lower trapezius:~Unilateral scapular retraction,~Prone bilateral shoulder external rotation at 90 degrees of abduction,~Prone shoulder abduction.~Levator Scapulae:~Horizontal abduction with shrug,~Horizontal abduction with ER,~Prone shoulder extension.~Rhomboids:~ER at 90° of abduction,~ER at 0° of abduction,~Horizontal abduction,~Shoulder extension,"
89495403|NCT06109948|Experimental|Part A Single Dose (active)|Subjects will receive 1 single IV dose of ABX1100 on Day 1.
89495404|NCT06109948|Placebo Comparator|Part A Single Dose (placebo)|Subjects will receive 1 single IV dose of placebo on Day 1.
89495405|NCT06109948|Experimental|Part B Multi-dose (active)|Subjects will receive 1 IV dose of ABX1100 on Day 1 and Day 29 each.
89495406|NCT06109948|Placebo Comparator|Part B Multi-dose (placebo)|Subjects will receive 1 IV dose of placebo on Day 1 and Day 29 each.
89495407|NCT06109935||Children with GHD|Participants will be treated with commercially available Sogroya® according to routine clinical practice at the discretion of the treating physician. Administration will be according to the approved product labelling. The decision to treat a participant with Sogroya® is made at the treating physician's discretion before and independently from the decision to include the patient in this study.
89495408|NCT06109857||Observational|Patients undergo blood and urine sample collection and have their medical records reviewed while on study.
89495409|NCT06109805||Gastric cancer group|Patients diagnosed with gastric cancer, including early gastric cancer and advanced gastric cancer
89495410|NCT06109805||Non-gastric cancer group|Patients diagnosed with benign gastric diseases or healthy controls
89495411|NCT06109792|Active Comparator|• Group I|Ten overdentures with locator retentive caps and blue inserts were picked up by the indirect method.
89495412|NCT06109792|Active Comparator|• Group II|Ten overdentures with locator retentive caps and pink inserts were picked up by the indirect method.
89495413|NCT06109792|Active Comparator|Group III|Ten overdentures with locator retentive caps and blue inserts were picked up by the direct method.
89495414|NCT06109792|Active Comparator|Group IV|Ten overdentures with locator retentive caps and pink inserts were picked up by the direct method.
89495415|NCT06109766|Experimental|Promoting First Relationships Home Visiting|"PFR-HV is a 10-week home-based parenting support program that promotes parental sensitivity and reduce the risk of maltreatment. PFR uses a curriculum, each week consisting of a theme for discussion and an activity. Sessions includes at least two handouts, one with new content and one titled Thoughts for the Week, which asks parents to think about a topic discussed in the session and apply it to their relationship with their child. On alternating weeks, the provider video records the parent-child dyad playing for 10 minutes. The following week the parent and provider view the video recording, and the provider guides the parent to reflect on their observation of the play. When the parent is sensitive to the child's needs, the provider acknowledges that with positive instructive comments. When there is tension between child and parent, the provider pauses the video and asks reflective questions, which allows parents to reconsider the meaning behind their child's behavior."
89205115|NCT00316303|Placebo Comparator|2|Participants will receive enhanced treatment as usual.
89205116|NCT01008670||Device Implant Recipients|Patients undergoing CRT implantation, or candidates for future CRT devices currently undergoing ICD or pacemaker implantation.
89495416|NCT06109766|Experimental|Promoting First Relationships Telehealth|"PFR-T is a 10-week telehealth parenting support program. PFR-T retains all of the core content features of PFR-HV: use of parent-child interaction during play as a way to reflect on the child's social and emotional needs, use of handouts and exercises to deepen the learning, and thoughts for the week. The parent-child video observations will be completed online over Zoom. The provider will mail the handouts to participants before starting PFR-T and send handouts by email as a backup. To discuss the handouts, the provider will use share screen. During five of the weekly sessions, the provider uses the record feature of Zoom to record playtime between parent and child. At the next visit, the PFR-T provider will use share screen to playback the video to offer positive instructive and reflective feedback and facilitate discussion. As is typical in PFR, the provider will be able to pause or rewind the recording as needed."
89495417|NCT06109766|No Intervention|Control, Resource Condition|For families randomized to the control group, they will not receive any intervention in the 3 month timeframe between the first two research visits. The research coordinator will maintain contact with the families in this group, and they will be emailed a resource packet with some information about services or programs that might be helpful for them based on the area they reside.
89495418|NCT06109753||Robotically Assisted Laparoscopy|Surgeons perform robot-assisted laparoscopic surgery
89495419|NCT06109753||Conventional Laparoscopy|Surgeons perform conventional laparoscopic surgery
89495420|NCT06109740|Experimental|Lactobacillus GG|Probiotic nutritional supplement
89495421|NCT06109740|Placebo Comparator|Placebo capsule|Matching placebo capsule
89495422|NCT06109727|Experimental|Intervention|In the intervention group, the anodic stimulations will start after a ramp period of 30 s, followed by 20 min at 2 mili ampere and will end with a ramp of 30 s.
88954979|NCT01978132|Active Comparator|Primary hyperaldosteronism|"patients with primary hyperaldosteronism will be subjected to the intervention forearm ischemia and reperfusion (20 minutes of forearm ischemia and 20 minutes of reperfusion).~Primary endpoint is the reduction in brachial FMD by forearm ischemia-reperfusion, as a measure of endothelial ischemia-reperfusion injury"
89205117|NCT01062529|Experimental|somatostatin|
89495423|NCT06109727|Placebo Comparator|Placebo|In the simulated configuration, the ramp of 30 s will be immediately followed by the ramp of 30 s and without any current (Sham Group)
89205118|NCT00760877|Experimental|Nilotinib|Participants received Nilotinib 400 mg orally twice daily (bid) for 48 months.
89205119|NCT00760877|Active Comparator|Imatinib|Participants received Imatinib 400 mg or 600 mg once daily (qd) (based on the participant's dose prior to randomization) for 48 months.
89495424|NCT06109714|Experimental|ACUMEN guided resuscitation protocol|Fluid resuscitation and hemodynamic management will be guided by ACUMEN based off a protocol.
89495425|NCT06109714|No Intervention|Standard of care resuscitation|Fluid resuscitation will be guided by standard monitors (urine output, blood loss, transesophageal echocardiography).
89495426|NCT06109688|Experimental|Bovine lactoferrin|Sachets with bovine lactoferrin at a dosage of 100 mg/day for a period of 4 weeks.
89495427|NCT06109688|Placebo Comparator|Placebo|Matched sachets with maltodextrin for a period of 4 weeks.
89495428|NCT06109675|Experimental|Education group|
89495429|NCT06109675|No Intervention|Control group|
89495430|NCT06109649|Experimental|Afamelanotide and NB-UVB Light|
89495431|NCT06109649|Other|NB-UVB Light|
89495432|NCT06109636||Normal group|
89495433|NCT06109623||SUI group|Female patients diagnosed with stress urinary incontinence in our hospital, who met the inclusion and exclusion criteria, and received six sex hormone tests.
89495434|NCT06109623||control group|Patients with non-stress urinary incontinence
89495435|NCT06109610|Experimental|Intervention group|Taking Behavioral Therapy
89495436|NCT06109610|No Intervention|Control group|Do not taking Behavioral Therapy
89495437|NCT06109584|Active Comparator|CVC location with Rx|After placement of the CVC we will perform the X-ray and subsequent verification of the correct location. Simultaneously, a stopwatch will be started to calculate the time interval until the interpretation of the X-ray by the anesthesiologist.
89495438|NCT06109584|Active Comparator|CVC location with echocardiography|Cardiac ultrasound will be performed to visualize the correct position of the CVC tip, and the time until the interpretation of the ultrasound results will also be monitored.
89495439|NCT06109545||Women with suspicion of ovarian malignancy|Women with suspicion of ovarian malignancy depending on ultrasound, CT, MRI and CA 125
89495440|NCT06109519|Active Comparator|Group I|patients who would be delivered a mandibular implant overdenture using conventional locator attachments.
89495441|NCT06109519|Active Comparator|Group II (study)|patients who would be delivered mandibular implant overdenture using Locator RTX attachments
89495442|NCT06109493|Experimental|ACT group|8 individual weekly sessions which included ACT methods
89495443|NCT06109493|No Intervention|Waiting list|Participants assigned to Waiting List arm waited for 5 months before receiving treatment
89495444|NCT06109428|Experimental|Treatment Group 1 Cohort 2|HTX-011 + MMA regimen
89495445|NCT06109428|Active Comparator|Treatment Group 2 Cohort 2|Bupivacaine HCl + MMA regimen
89495446|NCT06109415|Experimental|Treatment Group 1 Cohort 1|HTX-011 + multimodal analgesic (MMA) regimen
89495447|NCT06109415|Active Comparator|Treatment Group 2 Cohort 1|Bupivacaine HCl + MMA regimen
89495448|NCT06109389|Experimental|infusion of saline|infusion saline for 4 successive weeks once weekly over 45 min
89495449|NCT06109389|Active Comparator|lidocaine infusion|infusion of lidocaine 3 mg per kg for 2 successive weeks then 4 mg per kg for 2 successive weeks
89495450|NCT06109376|Experimental|Hypothermia|Patients in Hypothermia group received hypothermia combined with endovascular thrombectomy.
89495451|NCT06109376|Active Comparator|Control|Patients in Control group received endovascular thrombectomy alone.
89495452|NCT06109363|Experimental|Stepped-care CBT-I group|"A total of 3 steps of CBT-I intervention will be provided, with the objectives to increase the awareness of sleep health, increase sleep literacy, establish good sleep hygiene and treat insomnia.~Step 1: self-help digital CBT-I program; Step 2: guided CBT-I program; Step 3: individualized consultation."
89495453|NCT06109363|No Intervention|Control group|Participants in the control group remain unexposed to the stepped-care CBT-I intervention.
89495454|NCT06109350|Experimental|Supporting play exploration and early development intervention|Preterm infants will receive supporting play exploration and early developmental intervention till 3 months of corrected age.
89495455|NCT06109350|Active Comparator|Standard care|Preterm infants will receive standard care mostly including health education till 3 months of corrected age.
89495456|NCT06109324|Experimental|Robotic Rehabilitation|
89495457|NCT06109324|Active Comparator|Conventional treatment|
89495458|NCT06109298|Experimental|First study group|Before performing intravenous intervention, cold spray was applied for 5 seconds at a distance of 15 cm to an area of approximately 5 cm2 at the site of the procedure. After tourniquet fixation and subsequent skin disinfection for 60 seconds, the nurse researcher performed intravenous administration.
89495459|NCT06109298|Experimental|Second study group|Before the intravenous intervention, refrigerated gel ice was applied for 5 minutes at 2 cm above the area to be treated. After that, the nurse removed the gel ice from the procedure area, a tourniquet was applied, and skin disinfection was performed for 60 seconds. The nurse researcher performed intravenous administration.
89495460|NCT06109298|No Intervention|Control group|No pharmacologic or nonpharmacologic application was performed. The researcher performed intravenous access after skin disinfection by the nurse.
89495461|NCT06109285|Experimental|Reader Study|Vascular Severity Score Provided on second reading
89495462|NCT06109259|Experimental|DWJ1567|DWJ1567
89495463|NCT06109259|Active Comparator|DWC202312|DWC202312
89495464|NCT06109220|Experimental|Stage of arthritis|Patients with unilateral or bilateral knee degenerative inflammation (KOA) with Kellgren-lawrence rating of level 3 or lower
89495465|NCT06109207|Experimental|ESCC:Camrelizumab+Dalpiciclib(100mg) 3 patients|"Camrelizumab will be given at at a dose of 200 mg intravenously every three weeks on day 1 of a planned 21-day cycle, and two doses before surgery~Dalpiciclib will be given at a dose of 100 mg every day orally with three weeks on and one week off. Four weeks is a cycle and it will be given for two cycles.~For dalpiciclib, there is 2 dose levels, 100mg qd and 150 mg qd, and if no patients experience DLT on 100mg level, 150mg level will be administered."
89531765|NCT05440331||Experimental group|Experimental group with training after randomization immediately
89531766|NCT05440331||Control group with delayed training|Control group with training: the training will delayed from time of randomization
89205120|NCT03977545|Other|Newborn with risk of neonatal opioid abstinence syndrome|The newborns will have actigraphy during 30 minutes and Lipsitz scoring system twice a day during 7 days
89495466|NCT06109207|Experimental|ESCC:Camrelizumab+Dalpiciclib(150mg) 3 patients|"Camrelizumab will be given at at a dose of 200 mg intravenously every three weeks on day 1 of a planned 21-day cycle, and two doses before surgery~Dalpiciclib will be given at a dose of 150 mg every day orally with three weeks on and one week off. Four weeks is a cycle and it will be given for two cycles.~For dalpiciclib, there is 2 dose levels, 100mg qd and 150 mg qd, and if no patients experience DLT on the 100mg level, the 150mg level will be administered."
89495467|NCT06109207|Experimental|HNSCC:Camrelizumab+Dalpiciclib(100mg) 3 patients|"Camrelizumab will be given at at a dose of 200 mg intravenously every three weeks on day 1 of a planned 21-day cycle, and two doses before surgery~Dalpiciclib will be given at a dose of 100 mg every day orally with three weeks on and one week off. Four weeks is a cycle and it will be given for two cycles.~For dalpiciclib, there is 2 dose levels, 100mg qd and 150 mg qd, and if no patients experience DLT on 100mg level, 150mg level will be administered."
89495468|NCT06109207|Experimental|HNSCC:Camrelizumab+Dalpiciclib(150mg) 3 patients|"Camrelizumab will be given at at a dose of 200 mg intravenously every three weeks on day 1 of a planned 21-day cycle, and two doses before surgery~Dalpiciclib will be given at a dose of 150 mg every day orally with three weeks on and one week off. Four weeks is a cycle and it will be given for two cycles.~For dalpiciclib, there is 2 dose levels, 100mg qd and 150 mg qd, and if no patients experience DLT on 100mg level, 150mg level will be administered."
89495469|NCT06109103|Experimental|Group 1|Telerehabilitation-based physiotherapy program + telerehabilitation-based motor imagery training Telerehabilitation-based physiotherapy program; Eight (8) weeks, three (3) sessions per week, 40 minutes, using an image-based rehabilitation system, by connecting volunteers with a physiotherapist online in their home environment. Telerehabilitation-based motor imagery training will only be applied to the treatment group by the same physiotherapist for 15-20 minutes in addition to the physiotherapy training, three (3) sessions per week for eight (8) weeks.
89495470|NCT06109103|Active Comparator|Group 2|"Telerehabilitation-based physiotherapy program~Telerehabilitation-based physiotherapy program; Eight (8) weeks, three (3) sessions per week, 40 minutes, using an image-based rehabilitation system, by connecting volunteers with a physiotherapist online in their home environment."
89495471|NCT06109103|No Intervention|Healthy children group|No intervention will be applied.
89495472|NCT06109090||Adopted children|"Patients included in the study must meet the following inclusion criteria:~Signing the informed consent~Age between 6 and 10 years~Adopted after the first year of life~The exclusion criteria for this study are:~Comorbidity with other pathologies~Children adopted from birth~Cognitive impairment (IQ<85)"
89495473|NCT06109077|Experimental|Levator ani release|Participants will receive levator ani release exercise
89495474|NCT06109077|Experimental|Post isometric relaxion|Participants will receive post isometric relaxion exercise
89495475|NCT06109064|Experimental|chemotherapy+Unrelated Umbilical Cord Blood microtransplantation|"Intermittent infusion of HLA mismatched or incompletely matched granulocyte colony-stimulating factor (G-CSF) mobilized peripheral blood stem cells (G-PBSC) during routine chemotherapy without the use of immunosuppressants, abbreviated as microtransplantation"
89495476|NCT06109051||EndeavorOTC Users|All users who subscribe to EndeavorOTC for any duration
89495477|NCT06108986|Experimental|tabata training|Group A will perform tabata that includes squats, push up, side jump, medicine ball pass, commando dance, plank, skip rope, burpees. three sessions per week for six weeks.
89495478|NCT06108986|Experimental|plyometric training|Group B will perform plyometric training that includes squats, ankle hopes, jumps in a place, lunges, shuffling, stair jump exercises. three sets of eight reps, three sessions per week for six weeks.
89495479|NCT06108973||Normal Patients|Normal patients without any Lung Pathology for General Anesthesia
89495480|NCT06108973||COPD patients|Established Chronic Obstructive Pulmonary Disease for General Anesthesia
89531767|NCT05440331||Control group without training|Control group without training
89538066|NCT02460341|Experimental|ondansetron-8|Single dose of 8 mg ondansetron (crossover with single dose of placebo)
89538067|NCT02460341|Experimental|ondansetron-16|Single dose of 16 mg ondansetron (crossover with single dose of placebo)
89205121|NCT03977545|Other|Eutrophic term newborn|The newborns will have actigraphy during 30 minutes and Lipsitz scoring system twice a day during 2 days
89495481|NCT06108960|Experimental|Proprioceptive neuromuscular facilitation|The patients will be positioned in supine lying and then contract relax will be performed on affected side of pelvis first in D1 pattern (anterior elevation and posterior depression) 3 times with 10 sec contractions and 5 sec relaxations in 1 set. Then in D2 pattern (posterior elevation and anterior depression) 3 times with 10 sec contractions and 5 sec relaxations in 1 set. 3 set of each diagonal pattern to be performed in 1 treatment session alternatively. Treatment will be given for a period of 4 days a week for 8 weeks
89495482|NCT06108960|Experimental|Pelvic stabilization exercises|All participants will receive training programs for the eight levels of training from static to dynamic conditions. The practiced therapy method will first taught by a physical therapist with a verbal explanation and visual aids (such as photographs) in each group. The therapist will supervise all stages of the exercise therapy to ensure the patients correctly performed the exercises. The supervised exercise intervention will be conducted 3 days a week for 8 weeks.
89022604|NCT06189443|No Intervention|Traditional lifestyle changes and kegel exercise recommended group|Patients with stress urinary incontinence will be given a brochure that will be prepared similar to the brochure given to the Intervention group.
89495483|NCT06108934|Experimental|Intervention group|Insignia hip stem study group
89495484|NCT06108921|Experimental|xylitol|In the xylitol group, 5% xylitol solutions were first prepared by mixing two packs of 10 mg xylitol powder with 400 mL of sterile water in the container of the irrigator. Nasal irrigation was performed by using a Sanvic SH903 pulsatile irrigator (Yun-Wang Industrial Co., Tainan, Taiwan). When irrigating the nose, patients irrigated both of their nasal cavities each with 200 mL of solutions once a day. Patients performed nasal irrigations for 2 months.
89495485|NCT06108921|Placebo Comparator|saline|In the saline group, the normal saline solution was prepared by mixing 2 packs of 1.8 mg salt powder with 400 mL of sterile water in the container of the irrigator. Nasal irrigation was performed by using a Sanvic SH903 pulsatile irrigator (Yun-Wang Industrial Co., Tainan, Taiwan). When irrigating the nose, patients irrigated both of their nasal cavities each with 200 mL of solutions once a day. Patients performed nasal irrigations for 2 months.
89495486|NCT06108908||Intervention Group|"Patients (compliance rate <80%) received active contact to remind on regular use of medication.~The intervention is engaged in caring aspect behavior. None of regular asthma treatment is altered between groups."
89495487|NCT06108908||Control|Patients were not informed regardless to their compliance rate.
89495488|NCT06108882|Experimental|Manual Ischemic Compression with Strain Counter Strain technique|Participants in this group will receive Manual Ischemic Compression with Strain Counter Strain technique.
89495489|NCT06108882|Active Comparator|Manual Ischemic Compression|Participants in this group will receive only Manual Ischemic Compression
89495490|NCT06108869|Experimental|1|6 Week ABT intervention as described.
89495491|NCT06108869|Experimental|2|6 Week ABT intervention as described.
89495492|NCT06108869|Experimental|3|6 Week ABT intervention as described.
89495493|NCT06108869|Experimental|4|6 Week ABT intervention as described.
89495494|NCT06108869|Experimental|5|6 Week ABT intervention as described.
89495495|NCT06108869|Active Comparator|6|Delayed intervention group
89495496|NCT06108869|Active Comparator|7|Delayed intervention group
89495497|NCT06108869|Active Comparator|8|Delayed intervention group
89495498|NCT06108869|Active Comparator|9|Delayed intervention group
89495499|NCT06108869|Active Comparator|10|Delayed intervention group
89495500|NCT06108869|Experimental|11|ABT intervention as described
89495501|NCT06108869|Experimental|12|ABT intervention as described
89495502|NCT06108869|Experimental|13|ABT intervention as described
89495503|NCT06108869|Experimental|14|ABT intervention as described
89495504|NCT06108869|Experimental|15|ABT intervention as described
89022605|NCT06189443|Active Comparator|Group administered to individual telemedicine|A brochure containing incontinence patient information will be prepared and given, web-based training will be implemented, and informative/reminder messages will be sent via short messages every day.
89205122|NCT03977545|Other|Term newborn with low birth weight|The newborns will have actigraphy during 30 minutes and Lipsitz scoring system twice a day during 2 days
89495505|NCT06108869|Active Comparator|16|Delayed Control group
89495506|NCT06108869|Active Comparator|17|Delayed Control group
89495507|NCT06108869|Active Comparator|18|Delayed Control group
89495508|NCT06108869|Active Comparator|19|Delayed Control group
89495509|NCT06108869|Active Comparator|20|Delayed Control group
89495510|NCT06108843|Experimental|Myofascial arm pull technique and Active Release Technique|Participant will receive both Myofascial arm pull and active release technique along with Ultrasound therapy.
89495511|NCT06108843|Active Comparator|Myofascial arm pull technique|Participant will receive Myofascial arm pull along with ultrasound therapy.
89495512|NCT06108804|Experimental|mulligan pain release phenomenon with tapping.|Participants in group A will receive mulligan pain release phenomenon with tapping.
89495513|NCT06108804|Active Comparator|mulligan pain release phenomenon|Participants in group B will receive mulligan pain release phenomenon
89495514|NCT06108791|Active Comparator|HIGH FIO2|will include 50 patients: each one will receive intraoperatively a high concentration of oxygen (80% oxygen + 20% air), following extubation, high-concentration oxygen supplementation will be maintained and given through non-rebreathing face mask with a reservoir at 10 L/min for 2 h.
89495515|NCT06108791|Placebo Comparator|LOW FIO2|will include 50 patients: each one will receive intraoperatively standard concentration oxygen (33% oxygen + 66% air) followed by oxygen supplementation through the standard Venturi face mask of 30%
89495516|NCT06108726|Experimental|envafolimab plus chemotherapy|Local injection of Envafolimab 5mg/kg plus platinum-based chemotherapy under fiberoptic bronchoscopy, Q2W.
89495517|NCT06108713|Experimental|Addition of juggling|Group taking part in juggling exercise protocol in a crossover regimen.
89495518|NCT06108713|No Intervention|Without addition of juggling|Group not taking part in juggling exercise protocol in a crossover regimen.
89495519|NCT06108661|Experimental|Group A|"Treatment protocol given to both groups will be carried out for 3 sessions per week for 2 weeks.~It will comprise of hot pack for 10 minutes in prone position. Stretching protocol for shortened muscles. Frequency would be: 3 times per week (alternatively) for 1st week and 2nd week.~ELDOA. As per the tolerance of the patient. (Max hold time=60sec) For 2 weeks (alternatively)."
89495520|NCT06108661|Active Comparator|Group B|"Treatment protocol given to both groups will be carried out for 3 sessions per week for 2 weeks.~It will comprise of hot pack for 10 minutes. Stretching protocol for shortened muscles. Frequency would be: 3 times per week (alternatively) for 1st week and 2nd week.~Slump Stretching: Slump stretching will be performed with the patient in the long sitting position with the patient's feet against the wall to assure the ankle remained in 0 degree dorsiflexion. The therapist will apply over pressure to the cervical spine flexion to the point where the patient's symptoms will be reproduced. The position will be held for 30 s. A total of 5 repetitions will be completed"
89495521|NCT06108648|Experimental|Lavender oil|"Lavender chest wrap:~Before the first application pour 10-15 ml of lavender essential oil 10% evenly on the cotton cloth. Put the soaked cotton in the plastic bag, close it and put it to heat in two heating pads (2-5 minutes) so that the oil is distributed on all the fabric. Place the cotton cloth around the patient's chest. Cover the cotton cloth with a woolen fabric that is 2 cm larger than the cotton cloth."
89495522|NCT06108648|Active Comparator|Control|Standard care: supportive measures according to national standards.
89495523|NCT06108635|Active Comparator|Group A|McKenzie exercises with moist heat therapy will be given as intervention to experimental group. 2 sets of 5 reps will be given then progressed to 3 sets of 10 repetitions .Participants will be given Hot pack for 15 minutes.
89495524|NCT06108635|Experimental|Group B|The patients will be given Maitland mobilization (central glide on effected cervical spinous process) with McKenzie exercises. Grade i and ii mobilizations will be given in week 1 and then progressed to grade iii and iv in week 2. The total time duration will be 25-30 minutes. Participants will be given Hot pack for 15 minutes.
89495525|NCT06108583|Experimental|Experimental group|"The experimental group received intervention with TEAlimento program. The intervention combines parent training in both group and individual sessions, as well as group sessions with children.~The program is made up of 12 sessions, focuses on parent training and uses video-modeling. Additionally, a post-group individual session is conducted three months after the intervention. Sessions are held weekly, combining group (1.5 h) with individual (1 h) sessions. During group sessions, caregivers attend a parent training session, which is focused on teaching strategies based on the principles of behavior intervention and specific techniques related to eating. Simultaneously, children attend a group session in a separate room to target sensory issues and receive oral-facial stimulation. Individual sessions are held only with caregivers in order to individualize strategies to target the needs of each child. Each group includes from 3 to 5 participants."
89495526|NCT06108583|No Intervention|Control group|"The control group included participants in a waiting list. These families completed questionnaires at baseline and three months later (same time points as the experimental group), but they did not receive intervention during this period.~Intervention was provided afterwards, but data after participating in the program was not included in this study."
89495527|NCT06108557|Active Comparator|control group|Group I (Control group): which will include 20 healthy volunteers who will be selected based on their clinical examination, recent clinical history, and age and sex matching to the case group.This control group will be the basic profile for the studied group.
89495528|NCT06108557|Active Comparator|case group|Group II (Case group): which will include 70 cases, including both genders who will be admitted to Sohag University Hospital with acute organophosphate poisoning .
89495529|NCT06108531||pancreatic patients|Cases will be the patients with newly-diagnosed pancreatic.
89495530|NCT06108531||The controls|Controls will be selected from patients with pancreatitis from the same hospital as the case, matched by gender, race and age (1:1).
89495531|NCT06108518|Placebo Comparator|Control group|Group1 (Placebo group; n=35) which will receive the standard treatment for RA plus placebo tablet for 3 months.
89495532|NCT06108518|Active Comparator|Treatment group|Group 2 (Carvedilol group; n=35) which will receive the standard treatment for RA plus carvedilol 12.5mg once a day for 2 days; this is increased to 25 mg once a day or 12.5 mg twice a day for 3 months.
89495533|NCT06108505|Experimental|Lacticaseibacillus with oats|This group of subjects receives the Lacticaseibacillus with oats.
89495534|NCT06108505|Placebo Comparator|Plain oats|This group of subjects receives plain oats.
89495535|NCT06108453|Experimental|Methotrexate|
89495536|NCT06108453|Experimental|Methotrexate + Rifampicin|Methotrexate + Rifampicin
89495537|NCT06108414|Experimental|Low-dose rivaroxaban|15mg q.d. rivaroxaban for 2 years after randomization. The dose should be reduced in the following special conditions: 1. Creatinine clearance <50 mL/min; 2. Body weight ≤60kg; 3. Age ≥80 years old. In the low-dose group, the dose was reduced from the usual 15mg q.d. to 10mg q.d. .
89495538|NCT06108414|Active Comparator|Standard-dose rivaroxaban|20mg q.d. rivaroxaban for 2 years after randomization. The dose should be reduced in the following special conditions: 1. Creatinine clearance <50 mL/min; 2. Body weight ≤60kg; 3. Age ≥80 years old. In the standard-dose group, the dose was reduced from the 20mg q.d. to 15mg q.d. .
89495539|NCT06108401|Experimental|Goat milk formula-fed group|79 participants
89495540|NCT06108401|Placebo Comparator|Cow milk formula-fed group|79 participants
89495541|NCT06108362|Experimental|experimental group|Continuous terlipressin infusion，Use a syringe to dilute to 50ml Infusion speed is 2ug/kg*h, From the beginning to the end of the surgery.
89495542|NCT06108362|Placebo Comparator|control group|Continuous normal saline infusion，Use a syringe to draw 50ml Infusion speed is 4ml/h, From the beginning to the end of the surgery.
89495543|NCT06108349|Experimental|Cannabidiol|Participants will receive 5mL syringe with Cannabidiol (Investigational drug) in it.
89495544|NCT06108349|No Intervention|Placebo|Participants will receive 5mL syringe with Shea Butter cream (Placebo) in it.
89495545|NCT06107647|Experimental|GRUP DA|Patients who will be given low-flow anesthesia during the operation and will be heated with an active air blower heater.
89495546|NCT06107647|Experimental|GRUP YA|Patients who will be given high current anesthesia during the operation and will be heated with an active air blower heater.
89495547|NCT06107647|Experimental|GRUP DR|Patients who will be given low-flow anesthesia during the operation and will be heated with a resistive heater
89495548|NCT06107647|Experimental|GRUP YR|Patients who will be treated with high-flow anesthesia and heated with a resistive heater during the operation
89495549|NCT06107569|Experimental|Promicrobioma|MIcrobiote tranplant
89495550|NCT06107569|Active Comparator|Antibiotic (metronidazole or vancomycin)|Antibiotic commonly used for treatment of CDI, including oral vancomycin or metronidazol)
89495551|NCT06107504|Experimental|Intervention group|After the EST and stone extraction, we will randomly assign the patients to either a control or an intervention group. After EST, if immediate bleeding occurs, we will apply standard endoscopic therapy by either local injection of diluted epinephrine or heater probe coagulation. After then, we will spray 2g of sucralfate powder and 1g of tranexamic acid powder through a duodenoscope precisely on the EST wound in the intervention group.
89495552|NCT06107504|No Intervention|Control group|After the EST and stone extraction, we will randomly assign the patients to either a control or an intervention group. After EST, if immediate bleeding occurs, we will apply standard endoscopic therapy by either local injection of diluted epinephrine or heater probe coagulation.
89495553|NCT06106763|Experimental|Mandala group|Mandala coloring page
89495554|NCT06106763|No Intervention|Control group|Routine maintenance will be applied
89022606|NCT06189430|Experimental|Yoga Group|Individuals in the yoga group of the study had 10 minutes of meditation, 10 minutes of warm-up, and 40 minutes of vinyasa yoga practice, 2 days a week face-to-face and 1 day online, for a total of 12 weeks.Yoga practice was standardized throughout the study to avoid the risk of intervention variability. The basic structure of each yoga session is meditation, breathing exercises (pranayama), and after a warm-up, yoga practice includes asanas (postures) for strength, balance and mobility, and finally ends with relaxation.
89205123|NCT03977545|Other|Eutrophic premature newborn|The newborns will have actigraphy during 30 minutes and Lipsitz scoring system twice a day during 2 days
89495555|NCT06105619|Experimental|PLB1001|Subjects will receive 300mg of PLB1001 twice daily in cycles of 4 weeks duration until death or adverse event(AE) leading to discontinuation
89495556|NCT06105619|Active Comparator|Temozolomide or Cisplatin combined with etoposide|"Investigators can choose one of two treatments~Dose density of temozolomide：100-150mg/m2/d,day 1 to 7 and day 15 to 22 of each 28-day cycle~Cisplatin combined with etoposide：Cisplatin,80-100mg/m2/3 days,28 days/cycle.etoposide, 100mg/m2/d,3 days,28 days/cycle"
89495557|NCT06105463|Experimental|Women with Multiple Sclerosis|Women diagnosed with Multiple Sclerosis by a certified neurologist
89495558|NCT06105463|Active Comparator|Women without Multiple Sclerosis|Women not diagnosed with multiple sclerosis
89495559|NCT06105060|Active Comparator|Group 1 (Rosuvastatin group):|40 patients will receive Crestor (Rosuvastatin 20mg/day orally for 3 months).
89495560|NCT06105060|Active Comparator|Group 2 (N-acetyl cysteine group (NAC):|40 patients will receive high dose of NATURAL TRUTH'S NAC cap 2400 mg /day for 3 months.
89495561|NCT06105060|Active Comparator|"Group 3 Two separate drugs (N-acetyl cysteine and Rosuvastatin group):"|"40 patients will receive NAC dose 2400 mg and Rosuvastatin 20mg /day for 3 months."
89495562|NCT06105060|Placebo Comparator|Group 4 (Control group):|40 patients will receive Vitamin E 400 mg twice daily for 3 months.
89495563|NCT06104865|Experimental|Tinnitus Sound Therapy|Resound Tinnitus Application, different sounds will be presented over a six months period of time on the speaker of the mobile handset in the background for 30 mins twice a day at least, loudness near but less than the tinnitus intensity itself.
89495564|NCT06104410|Active Comparator|Arm A (standard fractionated dose): Groups A-B|Arm A contains of 2 groups. Group A: Total dose of 6 Gy in 4 single fractions of 1.5 Gy applied twice weekly (most commonly used regimen, considered standard arm in this trial) Group B: Total dose of 3 Gy in 2 single fractions of 1.5 Gy applied twice weekly
89495565|NCT06104410|Experimental|Arm B (experimental single dose): Groups C-F|Arm B contains of four groups. Group C: Total dose of 0.5 Gy in 1 single fractions of 0.5 Gy Group D: Total dose of 1 Gy in 1 single fractions of 1 Gy Group E: Total dose of 1.5 Gy in 1 single fractions of 1.5 Gy Group F: Total dose of 2 Gy in 1 single fractions of 2 Gy
89495566|NCT06104098|Other|One dose daily for 7 consequtive days (dose acc to IFU)|Open user study with Vernivia once daily for 7 consequtive days. Dosage according to IFU/Instructions For Use.
89495567|NCT06103682|Experimental|Ablative local therapy|Stereotactic ablative radiotherapy (SABR) or interventional radiology (IR) ablation therapy
89206305|NCT00827658|Active Comparator|Hypothenar Palm block|Hypothenar Palmar block group. Local anesthetic is placed at this location in this study group. The same local composition (Intervention) is used for both study groups. The trial is a comparison of location not the Intervention.
89495568|NCT06103396|Experimental|Autologuos MSCs transplantation in nonunion defects|Autologuos MSCs harvested and cultured in osteogenic medium are seeded on collagen scaffold, and mixed with autologous rich plasma clot. The MSCs construct (MSCs/Col/PRP clot), is implanted in the nonunion defect.
89495569|NCT06103396|Experimental|Allogeneic MSCs transplantation in nonunion defects|Allogeneic MSCs harvested and cultured in osteogenic medium are seeded on collagen scaffold, and mixed with autologous rich plasma clot. The MSCs construct (MSCs/Col/PRP clot), is implanted in the nonunion defect.
89495570|NCT06102577|Experimental|1gr. Vitamine C|Take 1g. of vitamin C at the end of an osteopathic manual treatment
89495571|NCT06102577|Placebo Comparator|1gr.Placebo|Take 1g. of placebo at the end of an osteopathic manual treatment
89495572|NCT06102577|Sham Comparator|control group|control
89495573|NCT06101992|Active Comparator|Mesoglycan|According to randomization, patients will take mesoglycan mg 50 (heparan sulphate 47.5%, dermathan sulphate 35.5%, chondroitin sulfate 8.5%,slow heparin 8.5%, excipients: lactose monohydrate, corn starch, croscarmellose sodium, magnesium stearate, gelatin, titanium dioxide, erythrosine) 4 capsules/day for 5 days and 2 capsules/day for 35 days
89495574|NCT06101992|Placebo Comparator|Placebo|According to randomization, patients will take placebo (lactose monohydrate, corn starch, croscarmellose sodium, magnesium stearate) 4 capsules/day for 5 days and 2 capsules/day for 35 days
89495575|NCT06101862|Active Comparator|Coronary computed tomography angiography + team-based interventional triage|
89495576|NCT06101862|Other|Conventional invasive coronary angiography|
89495577|NCT06101277|Experimental|Ablative local therapy|Stereotactic ablative radiotherapy (SABR) or interventional radiology (IR) ablation therapy
89495578|NCT06101147|Experimental|Vitamin D group|
89495579|NCT06101147|Placebo Comparator|Placebo group|
89495580|NCT06095128|Experimental|Vedolizumab 300 mg + Tofacitinib 10 mg|Participants will receive Vedolizumab 300 mg , intravenous (IV) infusion, at Week 0, Week 2 and Week 6 along with Tofacitinib 10 mg, tablets, orally, twice daily from Week 0 to Week 8. Participants with clinical response at Week 8 will transition to receive vedolizumab 300 mg IV infusion every 8 weeks (Q8W) through Week 46.
89495581|NCT06093048|Active Comparator|group A|patients with obstructive jaundice equal or older than 65 years old
89495582|NCT06093048|Active Comparator|group B|patients with obstructive jaundice younger than 65 years old
89495583|NCT06087380|Experimental|Arms and Interventions|The experimental group A total of 32 patients to undergo auricular acupuncture interventional
89495584|NCT06087380|Other|No Intervention: Control group:|The control group total 30 patients No interventions implemented
89495585|NCT06082778|Experimental|Increased fermented food intake|Participants take part in a n-of-1 design. They are first required to consume their habitual diet, for one week, followed by a period of dietary advice, for two weeks.
89495586|NCT06079970|Experimental|nCLE arm|Diagnostic bronchoscopy is done according to institutional practice with the addition of nCLE
89495587|NCT06079970|Active Comparator|Control arm|Diagnostic bronchoscopy is done according to institutional practice without the addition of nCLE
89495588|NCT06074692|Experimental|Bone arm|Bone tumor subgroup (bone arm) includes high-grade osteosarcoma, chondrosarcoma, undifferentiated bone sarcoma and other rare bone sarcomas with complex genomic features..
89495589|NCT06074692|Experimental|Soft tissue arm|Soft tissue sarcoma subgroup (soft tissue arm) includes leiomyosarcoma, pleomorphic rhabdomyosarcoma, angiosarcoma, fibrosarcoma, epithelioid sarcoma, malignant peripheral nerve sheath tumor(MPNST) and other rare soft tissue sarcomas with complex genomic features.
89495590|NCT06074692|Experimental|UPS/DDLPS arm|Immune hot tumor subgroup (UPS/DDLPS arm) includes undifferentiated pleomorphic sarcoma (UPS), dedifferentiated liposarcoma (DDLPS).
89495591|NCT06070233|Sham Comparator|Sham Treatment|No intervention but can crossover after 6 months
89495592|NCT06070233|Active Comparator|SRS Treatment|
89495593|NCT06069193|Experimental|Experimental: Touch Intervention|This group receives professional touch techniques, such as procedural touch.
89495594|NCT06069193|Experimental|Experimental: Control|This group does not receive professional touch techniques and serves as the control for comparison.
89495595|NCT06068322|Experimental|Supramaximal high-intensity interval training (Supramaximal HIIT)|Each HIIT session consists of 10 repeated 6-seconds regulated high intensity cycling sprints against an individualized load set to reach a supramaximal exercise intensity (i.e. power output is higher than power output at maximum oxygen uptake). Session duration for HIIT is initially 20 min, including warm-up (5 min) and cool-down (5 min). The protocol enables controlled and systematic adjustments of training intensity by means of standardized criteria.
89495596|NCT06068322|Active Comparator|Moderate-intensity continuous training (MICT)|Each MICT session will consist of aerobic training regulated against an individualized load set to reach a moderate submaximal exercise intensity (i.e. power output is lower than power output at maximum oxygen uptake). Session duration for MICT is initially 30 min, including warm-up (5 min) and cool-down (5 min). The protocol enables controlled and systematic adjustments of training intensity by means of standardized criteria.
89495597|NCT06068322|No Intervention|Usual care|The passive control group will receive usual care alone and a standardized phone call every three months including assessments of health status (CAT), disease specific quality of life (CRQ) and questions on symptoms of exacerbations. We will match the participants in the standard care group to those randomized to HIIT or MICT by age, sex, disease severity, educational level, and physical activity.
89495598|NCT06067165|Experimental|POET feeling|POET will include six guided digital treatment modules for the youth, and six modules for the parents administered over the course of six weeks.
89495599|NCT06067165|Active Comparator|Supportive treatment|The active control will be supportive treatment. It includes six guided digital treatment modules for the youth, and six modules for the parents administered over the course of six weeks.
89495600|NCT06065020|Experimental|Intervention group|VIDACTIVA program
89495601|NCT06065020|Active Comparator|Control group|Standard Care
89495602|NCT06061653|Experimental|IPT plus HD-tDCS|
89495603|NCT06061653|Sham Comparator|IPT plus sham HD-tDCS|
89495604|NCT06061159|Experimental|1-3years old|single intravenous bolus remimazolam about 5min before general anesthesia induction
89495605|NCT06061159|Experimental|3-6years old|single intravenous bolus remimazolam about 5min before general anesthesia induction
89495606|NCT06061159|Experimental|6-12years old|single intravenous bolus remimazolam about 5min before general anesthesia induction
89495607|NCT06050850||Aim 1a: Adapting the NOURISH-ALL Intervention for Families of Youth with ALL (Year 1)|The purpose of Aim 1a is to adapt the NOURISH-T intervention to meet the specific needs of families during the early phases of ALL treatment. To achieve this goal, the study will initiate a three-step intervention adaptation process that includes (1) initial integration of cognitive behavioral therapy (CBT) and family systems frameworks, (2) formative assessment with families of youth with ALL, and (3) formative assessment with multidisciplinary experts.
89495608|NCT06050850||Aim 1b: Iteratively Refining the NOURISH-ALL Intervention (Year 2)|"The purpose of Aim 1b is to adaptively refine NOURISH-ALL through sequential testing with individual families during the early phases of ALL treatment, with the goal of optimizing feasibility and acceptability from the family perspective. In line with the ORBIT model, the study will utilize an adaptive approach, similar to the commonly known PDSA cycle, to maximize responsivity to individual patient/family feedback. Participants will receive NOURISH-ALL and provide feedback throughout the intervention (i.e., after each session and upon intervention completion), which will be iteratively analyzed and incorporated to improve intervention delivery for the next family"
89531768|NCT05436132|Experimental|VR/AR group|Home care workers (HCW)HCWs in the VR/AR group received 2.5 hours of VR and AR training. VR offered learners the standard oral care procedures under different physical and oral health conditions in elderly people and AR simulation training for the manual Bass brushing technique.
89495609|NCT06050850||Aim 2: Pilot Single-Arm Trial of NOURISH-ALL Focused on Participant Engagement (Years 3-5)|Pilot testing key components of engagement is critical to optimizing design and methodology of fully powered efficacy trials. The purpose of Aim 2 is to pilot a single-arm trial of the finalized NOURISH-ALL intervention in a sample of families of youth in the early phases of ALL treatment to assess recruitment, retention, and dose received. Results will directly inform the design of the fully powered randomized control trial to test intervention efficacy (R01 application to be submitted in Year 4).
89495610|NCT06047405|Active Comparator|Average Volume-Assured Pressure Support (AVAPS)|Average Volume-Assured Pressure Support (AVAPS) setting on the noninvasive ventilator. The exact AVAPS setting will be titrated by the clinical team involved directly in the patient's care based on patient comfort and clinical response.
89022607|NCT06189430|Active Comparator|Control Group|In order to better understand the effectiveness of Vinyasa yoga, individuals in the control group will perform moderate-intensity standard exercise (50-70% MHR: maximum pulse rate) for the same duration and at the same hours.
89022608|NCT06189417|Experimental|Intervention Group|A total of 280 study participants are allocated to intervention group
89495611|NCT06047405|Active Comparator|Bilevel Positive Airway Pressure Spontaneous Timed (BIPAP S/T)|Bilevel Positive Airway Pressure Spontaneous Timed (BIPAP S/T) setting on the noninvasive ventilator. The exact BIPAP S/T setting will be titrated by the clinical team involved directly in the patient's care based on patient comfort and clinical response.
89495612|NCT06046976|Active Comparator|Healthy|
89495613|NCT06046976|Experimental|Diabetes mellitus type 2|
89495614|NCT06045078|Experimental|Lavender-Peppermint Aromatherapy Group|This is the interventional group. Participants in this group will receive aromatherapy tabs in the scent of lavender-peppermint. Tabs will be worn on a badge for a total of 72 hours, and participants will replace the aroma tabs every 12 hours.
89495615|NCT06045078|Placebo Comparator|Almond-oil Aromatherapy Group|This is the placebo group. Participants in this group will receive aromatherapy tabs in the scent of almond oil. Tabs will worn on a badge for a total of 72 hours, and participants will replace the aroma tabs every 12 hours.
89495616|NCT06043830|Experimental|Placebo followed by acetazolamide|"Subjects will start with a 1-week PLACEBO regimen Day 1-7: Placebo (matching Acetazolamide) nightly~After a 2 week wash-out period, subjects will then cross-over to a 1-week ACETAZOLAMIDE regimen:~Day 1-7: Acetazolamide 500 mg nightly"
89495617|NCT06043830|Experimental|Acetazolamide followed by placebo|"Subjects will start with a 1-week ACETAZOLAMIDE regimen Day 1-7: Acetazolamide 500 mg nightly~After a 2 week wash-out period, subjects will then cross-over to a 1-week PLACEBO regimen:~Day 1-7: Placebo (matching Acetazolamide) nightly"
89495618|NCT06042946||iscm_resection|-Adult patients admitted to one of the participating centres and treated for ISCM between 2017 and 2023 by resection of the ISCM with or without adjuvant radiotherapy
89495619|NCT06042946||iscm_radiotherapy|-Adult patients admitted to one of the participating centres and treated for ISCM between 2017 and 2023 by radiotherapy without resection of the ISCM
89495620|NCT06040918|Experimental|Healthy Subjects|Subjects will be scheduled for first apheresis collection on study Day 1. All subjects will receive N-803 at a fixed dose of 1 mg by subcutaneous (SC) injection 4 to 5 days prior to the second apheresis collection. The study day for N-803 administration will be determined based on the planned date of the second apheresis collection.
89495621|NCT06038318|Experimental|PRISM Program Mobile App|"Participants will be randomized to app-only group and will complete:~Baseline questionnaire.~mPRISM App self guided modules~3 month questionnaire.~mPRISM App self guided modules until final survey at 6 months and end of participation."
89495622|NCT06038318|Active Comparator|PRISM Program Video Coach|"Participants will be randomized to video group and will complete:~Baseline questionnaire.~PRISM sessions.~3 month questionnaire with re-randomization to either app-only or text groups or referral to specialty psychosocial support.~After re-randomization, participants will complete PRISM sessions until final survey at 6 months and end of participation."
89495623|NCT06038318|Active Comparator|PRISM Program Text Coach|"Participants will be randomized to text group and will complete:~Baseline questionnaire.~PRISM sessions.~3 month questionnaire with re-randomization to app-only, text, or video groups.~After re-randomization, participants will complete PRISM sessions until final survey at 6 months and end of participation."
89495624|NCT06037382|Experimental|MoodTriggers App|"Mood Triggers provides personalized feedback on individuals' maintenance factors (i.e., triggers) of their anxiety and depressive symptoms based on the theory that such feedback will lead to symptom reduction. Mood Triggers delivers ultra-brief interventions (less than 2 minutes long) where participants view videos which introduce an important skill to treat their anxiety and depressive."
89495625|NCT06032585||Patients with parkinsonism|Parkinsonism incl. tremor, parkinsons, atypical parkinsons
89495626|NCT06032104|Experimental|Bean smoothie then usual diet|Participants first receive 2 weeks of adding bean smoothie to usual diet before colonoscopy. After a washout period of 4 weeks after colonoscopy, they receive usual diet for 2 weeks
88954980|NCT01978132|Placebo Comparator|Primary hypertension|"Patients with primary hypertension (PHA excluded)will be subjected to 20 minutes of forearm ischemia and 20 minutes of reperfusion.~Primary endpoint is the reduction in brachial FMD by forearm ischemia-reperfusion, as a measure of endothelial ischemia-reperfusion injury"
88954981|NCT01978158|Experimental|Hypoxia|Subjects will be breathing an individualized mix of nitrogen and room air titrated to an oxygen saturation of 80-85%.
88954982|NCT01978158|Experimental|Hyperoxia|Subjects will be breathing 100% of oxygen
88954983|NCT01978158|Active Comparator|Normoxia|Subjects wil be breathing room air (21%)
88954984|NCT01978171||breast cancer patients|Postmenopausal women with estrogen receptor (ER) positive advanced breast cancer whose disease is refractory to non steroidal aromatase inhibitors, and are eligible for treatment with exemestane and everolimus.
88954985|NCT01978210|Experimental|Wireless Moisture Pager|Parent(s) of subjects will participate in training and follow-up sessions in a manualized toilet training intervention for their child that incorporates use of a wireless moisture pager.
88954986|NCT01978210|Active Comparator|Standard Behavioral Treatment|Parent(s) of subjects will participate in training and follow-up sessions in a toilet training intervention for their child that incorporates use of the Autism Treatment Network's Toilet Training Tool Kit. The Tool Kit is a publication widely available to parents and clinicians that is designed to serve as an aid in the toilet training of children with autism. In this study, it is being used as a standard treatment control.
88954987|NCT01978223||Cases|Children hospitalised for SGE, aged 12 weeks to < 5 years at the time of hospital admission/ED stay and whose stool samples test positive for RV by enzyme linked immunosorbent assay (ELISA) at a GSK designated laboratory.
88954988|NCT01978223||Controls|Children hospitalised for SGE, aged 12 weeks to < 5 years at the time of hospital admission/ ED stay, whose stool samples test negative for RV by enzyme linked immunosorbent assay at a GSK designated laboratory and who will be matched to the cases by date of birth and the hospital of admission/ ED stay.
88954989|NCT01978249|Experimental|Chemotherapy first without primary tumor resection|Patients will receive chemotherapy first without primary tumor resection.
88954990|NCT01978249|Active Comparator|Primary tumor resection followed by chemotherapy|Patients will receive primary tumor resection followed by chemotherapy.
88954991|NCT01978275|Experimental|stimulating catheters group|Lumbar plexus block performed through stimulating catheter
88954992|NCT01978275|Active Comparator|nonstimulating catheters|lumbar plexus block through nonstimulating catheters
88954993|NCT01978301|Active Comparator|Triamcinolone acetonide|Subjects will receive three intra-lesional injections of triamcinolone acetonide in their qualifying keloid(s), at 2-3 weeks intervals, according to their assigned treatment sequence
88954994|NCT01978301|Placebo Comparator|Placebo|Subjects will receive three intra-lesional injections of placebo in their qualifying keloid(s), at 2-3 weeks intervals, according to their assigned treatment sequence.
89495627|NCT06032104|Experimental|Usual diet then bean smoothie|Participants first receive 2 weeks of usual diet before colonoscopy. After a washout period of 4 weeks after colonoscopy, they then add bean smoothie to usual diet for 2 weeks
89495628|NCT06026345||Treatment Arm|Patients enrolled and treated with the Affera Platform
88954995|NCT01978301|No Intervention|No treatment|Keloid(s) assigned 'No Treatment' will not receive any treatment.
88954996|NCT01978327|Experimental|GSK2647544|The planned repeat doses of GSK2647544 are 80 mg bid, 200 mg bid, and 350 mg bid
88954997|NCT01978327|Placebo Comparator|Placebo|Matching placebo
88954998|NCT01978327|Experimental|simvastatin|for drug-drug interaction
88954999|NCT01978327|Experimental|simvastatin co-dosed with GSK2647544|for drug-drug interaction
88955000|NCT01978340||sleeplab|Sleep Lab examined, usualy with some obesity or sleeping disorders.
88955001|NCT01978353|Experimental|Memory Training|Participants receive memory training to facilitate learning and memory of face-name associations
89495629|NCT06014996|Experimental|Pulsed Field Ablation|PVI using the PFA system (Insight Medtech).
88955002|NCT01978353|Active Comparator|Psychoeducation|Participants receive information about memory functioning and aging
88955003|NCT01978392|Experimental|Self-management group workshops|Self-management group workshops: Participants randomized to the intervention arm will be asked to participate in group workshop sessions (10 hours total) led by a specially trained facilitator and provided over a span of approximately 2-3 months.
88955004|NCT01978392|No Intervention|No treament (wait-list control)|Wait-list control: Participants randomized to the control arm will receive no intervention during the one-year period of data collection, but they will be invited to attend a full-day Saturday workshop after all study data collection is complete). The intent of the full-day workshop will be to provide the same self-management information as in the intervention arm, but on a delayed basis and in a more condensed format.
89495630|NCT06014996|Active Comparator|Radiofrequency Ablation|PVI using the RFA system ((Biosense Webster).
89495631|NCT06008015|Experimental|BR1015|
89495632|NCT06008015|Active Comparator|BR1015-1 + BR1015-2|
89495633|NCT06004609|Experimental|Treatment group (low-level laser therapy with conventional physical therapy)|Low-level laser therapy two to three times a week, 10 minutes each time, totally 24 times, for 8 to 10 weeks. Along with conventional physical therapy, two to three times a week, for 12 to 14 weeks.
89538068|NCT02460341|Experimental|ondansetron-24|Single dose of 24 mg ondansetron (crossover with single dose of placebo)
89495634|NCT06004609|Active Comparator|Conventional group (conventional physical therapy only)|Conventional physical therapy, two to three times a week, for 12 to 14 weeks.
89495635|NCT06003829|Experimental|Treatment A|
89495636|NCT06003829|Experimental|Treatment B|
89495637|NCT06003829|Other|Treatment C|Comparator
89495638|NCT06003829|Experimental|Treatment D|
89495639|NCT06003829|Experimental|Treatment E|
89495640|NCT06003829|Experimental|Treatment F|
89495641|NCT05999292|Other|68Ga-R8760 Dose Selection (Part 1)|
89495642|NCT05999292|Other|68Ga-R8760 Expansion Cohort (Part 2)|
89495643|NCT05993975|Active Comparator|BUPIPURE|"Hyperbaric Bupivacaine 0.5% (1.5 ml/7.5 mg) to be given intrathecally~Total volume 1.5 mL"
89495644|NCT05993975|Experimental|BUPI-DEX|"Hyperbaric Bupivacaine 0.5% (1.2 ml/6 mg)+Dexmedetomidine (0.3 mL) 3 microgram intrathecally.~Total volume 1.5 mL"
89495645|NCT05993013|No Intervention|Conventional exercise|Normally physiotherapist-recommended, tailored strength and balance exercises. These exercises are given in printed handouts and demonstrated by our physiotherapist with the patients during their initial clinic visit. Exercise is recommended to be done at least 3 times per week.
89495646|NCT05993013|Experimental|Game-based exercise|Strength and balance exercises using the LudoFit game-based exercise software. Participants will be registered on the platform. Exercise is recommended to be done at least 3 times per week.
89495647|NCT05991713|Experimental|Modifying Exploration|Individuals will be asked on certain days to increase their levels of exploration, and some days be asked to decrease their levels of exploration. Participants will do this for up to six months.
89495648|NCT05981417|Experimental|Supervised exercise|Exercise sessions will beguided by a physiotherapist.
89495649|NCT05981417|Active Comparator|Home exercise|Exercise sessions will be perfomed at home.
89495650|NCT05981040|Active Comparator|Arm 1|ZYIL1 capsules 25 mg for oral administration + matching placebo of 50 mg ZYIL1 capsule
89495651|NCT05981040|Active Comparator|Arm 2|ZYIL1 capsules 50 mg for oral administration + matching placebo of 25 mg ZYIL1 capsule
89495652|NCT05981040|Active Comparator|Arm 3|ZYIL1 capsules 25 mg for oral administration + ZYIL1 capsules 50 mg for oral administration
89495653|NCT05981040|Placebo Comparator|Arm 4|Matching placebo of 25 mg ZYIL1 capsule + Matching placebo of 50 mg ZYIL1 capsule
89495654|NCT05977140|Experimental|SAD Cohort 1A|first single-dose level
89495655|NCT05977140|Experimental|SAD Cohort 1B|second single-dose level
89495656|NCT05977140|Experimental|SAD Cohort 1C|third single-dose level; food-effect cohort
89495657|NCT05977140|Experimental|SAD Cohort 1D|fourth single-dose level
89495658|NCT05977140|Experimental|MAD Cohort 2A|first multiple-dose level
89495659|NCT05977140|Experimental|MAD Cohort 2B|second multiple-dose level
89495660|NCT05977140|Experimental|MAD Cohort 2C|third multiple-dose level
89495661|NCT05976971|Other|Patients with REM Sleep Behaviour Disorder|
89495662|NCT05976971|Other|Healthy volunteers|
89495663|NCT05966025|Experimental|control group|• control group Weight reduction and life style modification(modification in diet like decrease lipids intak).pateints will recieve their conventional therapy
89495664|NCT05966025|Experimental|interventions: drug itopride|• itopride group Weight reduction and life style modification and receive (itopride) 100 mg once dialy for 24 weeks plus their conventional therapy
89495665|NCT05965531|Experimental|Neoadjuvant chemo-radiotherapy with TAS-102|The patients in this group will all receive neoadjuvant treatment consisting of intensity-modulated radiotherapy and concurrent Trifluridine/Tipiracil (TAS-102). Then the ones evaluated to have a possibility of R0 resection will receive radical surgery, followed by 6 cycles of adjuvant XELOX (capecitabine plus oxaliplatin) chemotherapy.
89495666|NCT05960942|Experimental|propofol-esketamine|
89495667|NCT05960942|Active Comparator|propofol-sufentanil|
89495668|NCT05959005||Early GA lesions|Non-interventional
89495669|NCT05957042|Experimental|Contrast Enhanced Ultrasound (with Lumason)|
89495670|NCT05951946|Active Comparator|Treatment 1(T1)|BR3006-1 + BR3006-2 administered in combination once daily for 7 days.
89495671|NCT05951946|Active Comparator|Treatment 2(T2)|BR3006-3 administered alone once daily for 7 days.
89495672|NCT05951946|Experimental|Treatment 3(T3)|BR3006-1 + BR3006-2 + BR3006-3 administered in combination once daily for 7 days.
89538069|NCT02460107|Placebo Comparator|Normal saline|Normal saline
89205124|NCT00302731|Active Comparator|1 equine estrogens m-progesteroneacetate|Menopausal women in first seven years of menopause randomized to arm 1 receive conjugated equine estrogens 0.45 mg combined with medroxyprogesteroneacetate 1.5 mg placed in a placebo capsule to disguise contents from participant and study team. Drug dosed daily for 1 year. Screening FSH and PAP. Baseline mammogram, bone density, pelvic ultrasound, EKG, blood work for cholesterol panel (surrogate marker for cardiovascular disease), BUN/Creatinine. Repeated at 12 months. Safety check at 6 months includes BUN/creatinine, EKG, cholesterol panel, estradiol, progesterone levels.
89205125|NCT00302731|Experimental|2 estradiol estriol progesterone|Menopausal women in first seven years of menopause randomized to arm 2 estradiol .5mg, estriol 2.0mg, progesterone 100mg dosed orally / day placed in a placebo capsule to disguise contents from participant and study team. Drug dosed daily for 1 year. Screening FSH and PAP. Baseline mammogram, bone density, pelvic ultrasound, EKG, blood work for cholesterol panel (surrogate marker for cardiovascular disease), BUN/Creatinine. Repeated at 12 months. Safety check at 6 months includes BUN/creatinine, EKG, cholesterol panel, estradiol, progesterone levels.
89495673|NCT05931627|No Intervention|Control|Patients undergoing patellar bone-tendon-bone autograft ACL reconstruction with a tourniquet used for the duration of the case.
89495674|NCT05931627|Active Comparator|Treatment/Intervention|Patients undergoing ACL reconstruction with a tourniquet used only during patellar bone-tendon-bone autograft harvest, for a maximum of 20 minutes.
89495675|NCT05925114|Experimental|Dose Level 1: S-309309|Participants will receive S-309309 (low dose) once daily for 24 weeks
89495676|NCT05925114|Experimental|Dose Level 2: S-309309|Participants will receive S-309309 (middle dose) once daily for 24 weeks
89495677|NCT05925114|Experimental|Dose Level 3: S-309309|Participants will receive S-309309 (high dose) once daily for 24 weeks
89495678|NCT05925114|Placebo Comparator|Placebo|Participants will receive placebo once daily for 24 weeks
89531769|NCT05436132|Placebo Comparator|Control group|The home care workers in the control group received 2.5 hours of traditional teaching methods for oral care.
89531770|NCT05404919|Other|Recipient of Hepatitis B NAT+ Donor|All subjects will then be treated with Hepatitis B Immune Globulin and entecavir, tenofovir disoproxil, or tenofovir alafenamide (choice of specific drug to be based on long-term cost, clinical response, and renal function)
89531771|NCT05401110|Experimental|Osimertinib with Carotuximab|
89538070|NCT02460107|Active Comparator|Botulinum toxin type A 50U|Botulinum toxin 50U
89538071|NCT02460107|Active Comparator|Botulinum toxin type A 100U|Botulinum toxin 100U
88955005|NCT01978405|Experimental|alpha-lipoic acid group|Alpha lipoic acid 600 mg in 0.9% sodium chloride 250 ml was given before and after contrast agent was administrated.
88955006|NCT01978405|Placebo Comparator|Placebo intervention group|Only 0.9% sodium chloride 250 ml was given for this group.
88955007|NCT01978418|Placebo Comparator|Placebo|Placebo is administered once, at 30-60 minutes of age
88955008|NCT01978418|Active Comparator|Intervention|Salbutamol 0,4 mg inhalation, given once at 30-60 minutes of age
88955009|NCT01978444|Experimental|laparoscopic D2 lymphadenectomy plus CME|Laparoscopic D2 lymphadenectomy plus CME will be performed for the treatment of patients assigned to this group.
89495679|NCT05922462|Experimental|Greek yogurt intervention group (GY)|Participants in the GY group will be instructed by a registered dietician to consume 2 servings/day (preferably morning and night) of 175 g GY (0% MF, flavoured, 130 calories, 17 g protein, 225 g calcium; e.g., OIKOS High Protein GY) for a total of 16 weeks. For their convenience, the athletes will be provided with appropriate scoops to measure out 175 g of GY per serving of the larger 650 g commercially available, pre-packaged containers. Although it is recommended to consume the two servings morning and night, to increase ecological validity and strengthen the feasibility of the intervention, the timing of the servings will be flexible to facilitate the training and competition routines. For the same reasons, the athletes will be able to choose the flavour of their GY.
89495680|NCT05922462|Experimental|Whey protein intervention group (WP)|Participants in the WP group will follow a similar consumption schedule but will be instructed by the RD to consume two servings/day (preferably morning and night) each of 2/3 of a scoop of commercially available WP powder (flavoured, ~29 g, 120 calories, 19 g protein, 112.5 g calcium; e.g., PURE Whey Protein, Walmart) for a total of 16 weeks. The WP scoop will be dissolved in water (e.g., 1 g of WP isolate to 10 mL of water, as recommended by the manufacturer). This protein dose is similar to the previous dose in young swimmers and comparable to other studies in adults. Athletes will be provided with appropriately marked scoops (corresponding to 2/3 of the manufacturer scoop) to measure their single servings. Each athlete will receive two large containers (2 x 907 g = 1814 g per week) at the beginning of each week, which will be enough to cover the two daily servings of 29 g (i.e., 58 g/day).
89495681|NCT05920759|Placebo Comparator|Normal sleep|Participants will sleep for 7-9 hours the night prior to the study visit.
89495682|NCT05920759|Experimental|Restricted sleep|Participants will restrict sleep to four hours the night prior to the study visit.
89495683|NCT05917782|Experimental|Test drug (T1): CBP-201 injection (pre-filled syringe, 150 mg/1 mL)|Strength: pre-filled syringe, 150 mg/1 mL
89495684|NCT05917782|Experimental|Test drug (T2): CBP-201 injection (pre-filled syringe, 300 mg/2 mL)|Strength: pre-filled syringe, 300 mg/2 mL
89495685|NCT05917782|Active Comparator|Reference drug (R): CBP-201 injection (vial, 150 mg/1 mL)|Strength: vial, 150 mg/1 mL
89495686|NCT05912959|Experimental|photo biostimulation group|"this group will receive a photo bio stimulation (LASER) session consisting of 3 sessions using the LASER device (VECTRA GENISYS, INTELLECT LEGEND XT, Chattanooga, USA). The following parameters will be used; Power output: 300 mv, Wavelength: 820 nm, Contact area: 0.495; Powr density: 0.606 mW/ cm2, Treatment time per point: 13 seconds, Number of points are three: (GB34, LR3, LIV 3).~in addition to the LASER, this group will receive a standard physiotherapy program designed by an experienced pediatric physical therapist"
89495687|NCT05912959|Active Comparator|standard physiotherapy group|This group will receive a standard physiotherapy program designed by an experienced pediatric physical therapist
89495688|NCT05908344|Experimental|Activated Sleep Pad controller|Treatment dosing is under participant control, by physical proximity/orientation to the Sleep Pad pad portion of the Sleep Pad system, and by a manually operated power button on an activated bedside controller portion of the Sleep Pad system. Dosing is pre-set at a stable level across all participants. Dosing occurs throughout a participant's typical nocturnal sleep period, nightly, unless manually paused by the participant.
88955010|NCT01978444|Active Comparator|laparoscopic D2 lymphadenectomy|Laparoscopic D2 lymphadenectomy will be performed for the treatment of patients assigned to this group.
88955011|NCT01978457|Experimental|cocaine hydrochloride|cocaine hydrochloride
88955012|NCT01978457|Experimental|propranolol|propranolol
88955013|NCT01978457|Placebo Comparator|placebo|placebo
88955014|NCT01978470|Experimental|Active|Trigeminal nerve stimulation
88955015|NCT01978483|Other|DPCP alone (Cohort 1)|Diphenylcyclopropenone sensitization patches applied for 48hours. Diphenylcyclopropenone elicitation patches applied for 48hours.
88955016|NCT01978483|Experimental|UVB and denosumab group (Cohort 2)|Denosumab 60mg subcutaneous injection once. Broadband UVB exposure once. Diphenylcyclopropenone sensitization patches applied for 48hours. Diphenylcyclopropenone elicitation patches applied for 48hours.
88955017|NCT01978483|Placebo Comparator|UVB and placebo group (Cohort 2)|Normal saline 1mL subcutaneous injection once. Broadband UVB exposure once. Diphenylcyclopropenone sensitization patches applied for 48hours. Diphenylcyclopropenone elicitation patches applied for 48hours.
88955018|NCT01978496|Placebo Comparator|Placebo|
88955019|NCT01978496|Experimental|Eletriptan 20 mg|
88955020|NCT01978496|Experimental|Eletriptan 40 mg|
89538072|NCT03192553|Experimental|Double Gloving Procedure|Participants will doff PPE using a double gloving procedure after coating with Glogerm fluorescent dye +/- staphylococcus epidermidis
89538073|NCT03192553|Experimental|Intensified Hand Hygiene Procedure|Participants will doff PPE using an intensified hand hygiene procedure after coating with Glogerm fluorescent dye +/- staphylococcus epidermidis
89538074|NCT03192553|Experimental|One-Step Procedure|Participants will doff PPE using a one-step procedure after coating with Glogerm fluorescent dye +/- staphylococcus epidermidis
89538075|NCT03192553|Other|CDC Procedure (Control)|Participants will doff PPE following the CDC procedure after coating with Glogerm fluorescent dye +/- staphylococcus epidermidis
89538076|NCT02448511|Experimental|Ozone|this group received local application of ozone gas in addition to conventional treatment.
89538077|NCT02448511|Sham Comparator|Placebo|This group received sham treatment in addition to conventional treatment
89538078|NCT03286673|Experimental|calcium phosphate|Pentacalcium hydroxy-triphosphate (Ca5(PO4)3OH) was incorporated in wholemeal and crispy wafer bread in order to achieve a additional calcium intake of 1000 mg/d.
89538079|NCT03286673|Experimental|Tricalcium Phosphate|β-tricalcium phosphate (Ca3(PO4)2) as incorporated in wholemeal and crispy wafer bread in order to achieve a additional calcium intake of 1000 mg/d.
89538080|NCT03286673|Experimental|Calcium carbonate|Calcium carbonate (CaCO3) was incorporated in wholemeal and crispy wafer bread in order to achieve a additional calcium intake of 1000 mg/d.
89538081|NCT03286673|Active Comparator|Placebo|Wholemeal and crispy wafer bread without additional calcium additive.
89538082|NCT04483843||CPE patients|All patients prehospitally treated for cardiogenic pulmonary edema in the pre-hospital emergency setting in the Central Bohemian region, Czech Republic.
89538083|NCT04233593|Experimental|LPS Challenge|Subjects will undergo one 120-minute [11C]PBR28 PET scan before and one scan 3-hours after LPS administration (1.0ng/kg; IV).
89538084|NCT04233593|No Intervention|LPS Follow-up|Subjects will undergo one 120-minute [11C]PBR28 PET scan 24+ hours after LPS.
89538085|NCT02448589|Experimental|TAS-119 Monotherapy|"Dose Escalation:~A Monotherapy Dose-Escalation Phase Performed in Approximately 5 Dose Levels (3 to 12 Patients Per Dose Level) to Determine the MTD for TAS-119 Given Orally (PO), Twice-Daily (BID) in a 28-Day Treatment Cycle; and:~Dose Expansion:~A Monotherapy Expansion Phase in Which Approximately 40 Additional Patients will be Enrolled to Further Evaluate the Recommended Phase II Dose (RP2D)"
89538086|NCT03286595|Experimental|Early Psychosis (EP)|EP participants will be individuals who are either a) at clinical high risk (CHR) for developing psychosis and/or bipolar disorder, or b) First Episode Psychosis (FEP) participants meeting criteria for schizophreniform disorder, schizophrenia, schizoaffective disorder or another psychotic, non-schizophrenia diagnosis including those with bipolar disorder.
89538087|NCT03286595|Experimental|Clinicians|Clinicians/treatment team members who are providing treatment services to the EP participants at one of the three early psychosis clinics.
89538088|NCT03194425|Experimental|OAB|Patients with overactive bladder on sacral neuromodulation.
89538089|NCT03194425|Experimental|NOUR|Patients with non-obstructive urinary retention on sacral neuromodulation.
88955021|NCT01978496|Experimental|Eletriptan 80 mg|
88955022|NCT01978522|Experimental|NICOLA Participants|All participants enrolled in the NICOLA cohort
89538090|NCT03283163|Experimental|Chronic Pain//PTSD group|This group will receive baseline and endpoint maximum load exercise testing which will inform their individualized exercise prescription (based on a progressive methodology) of aerobic exercise training aimed at meeting specific heart rate ranges over time (increasing up to 80% of maximum HRR between the midpoint and endpoint (6-12 weeks).
89538091|NCT03283163|Active Comparator|Trauma-exposed healthy control group|This group will receive baseline and endpoint maximum load exercise testing which will inform their individualized exercise prescription (based on a progressive methodology) of aerobic exercise training aimed at meeting specific heart rate ranges over time (increasing up to 80% of maximum HRR between the midpoint and endpoint (6-12 weeks).
89538092|NCT03286517|Experimental|Tanner Stage I|A 1ml blood sample was obtained for 30 minutes pre and 120 minutes post-kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany) injection periods at 30 min intervals (-30, 0, 30, 60, 90, 120). The dose was 9.5 µg/BW.
89538093|NCT03286517|Experimental|Tanner Stage II|A 1ml blood sample was obtained for 30 minutes pre and 120 minutes post-kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany) injection periods at 30 min intervals (-30, 0, 30, 60, 90, 120). The dose was 11.50 µg/BW.
88955023|NCT01978548|Experimental|JNJ-54861911 10 mg|From Day 1 to Day 28 inclusive, patients will self-administer once daily study drug (JNJ-54861911 or placebo) with a glass of non-carbonated water (approximately 200 mL).
88955024|NCT01978548|Experimental|JNJ-54861911 50 mg|
88955025|NCT01978548|Placebo Comparator|Placebo|Patients will receive matching placebo.
88955026|NCT01978561|Experimental|Follow-Up after dosing with NT100 Dose 1|Follow-Up after dosing with NT100 Dose 1
88955027|NCT01978561|Experimental|Follow-Up after dosing with NT100 Dose 2|Follow-Up after dosing with NT100 Dose 2
88955028|NCT01978561|Placebo Comparator|Follow-Up after dosing with Placebo|Follow-Up after dosing with Placebo
88955029|NCT01978574|Active Comparator|Documentary videos|In the placebo control condition, participants watch daily videos.
88955030|NCT01978574|Experimental|Intellectual Enrichment|Daily activities that encourage intellectual enrichment, including games, reading/writing, and hobby activities.
88955031|NCT01978587|Experimental|Dose 1 JTZ-951|Tablets, 1 dose on Day 1 before hemodialysis
88955032|NCT01978587|Experimental|Dose 2 JTZ-951|Tablets, 1 dose on Day 8 after hemodialysis
88955033|NCT01978613|Experimental|Oral B (DC)|Escalation design. Planned end dose level is 5 mg alternative dosing condition (fasting for 30 minutes post-dosing)
88955034|NCT01978613|Experimental|Oral D|Escalation design. Planned end dose level is 20 mg standard dosing condition (fasting for 120 minutes post-dosing)
88955035|NCT01978613|Experimental|Oral C|Escalation design. Planned end dose level is 10 mg standard dosing condition (fasting for 120 minutes post-dosing)
89495689|NCT05908344|Sham Comparator|Deactivated Sleep Pad controller|Use of the Sleep Pad system is consistent with the Experimental arm, excepting that a deactivated bedside controller portion of the Sleep Pad system is used.
89495690|NCT05906238|Experimental|STEREOBES|This arm will follow a program developed specifically for this project. It will include specific workshops on obesity stigma issues which are not part of the standard program.
89495691|NCT05906238|Active Comparator|CONTROL|"This arm will follow the standard therapeutic patient education program proposed by La Vie La Santé."
89495692|NCT05885282|Active Comparator|Control Exercise Group|Lumbar spinal stabilization exercises will be given. Lumbar spinal stabilization exercises; diaphragmatic breathing, and contraction of the transversus abdominis and multifidus muscles will be taught in the supine position. Activation of these muscles will be studied in different positions (prone, crawling, sitting, and sitting on different surfaces). The focus will be on increasing kinesthetic awareness. It will be desirable to ensure and maintain the activation of these muscles during subsequent exercises. Exercises will be continued according to the patient's functional status and individual needs. Advancement of exercises; extremity movements on dynamic surfaces, narrowing of support surfaces, reciprocal movements, increasing the number of resistance and repetitions. The duration of a session will be 40 minutes.
89495693|NCT05885282|Active Comparator|Paraspinal Vibration Group|In addition to lumbar spinal stabilization exercises, LV will be applied to the cervical and lumbar paraspinal muscles. Spinal stabilization exercises will be as in the control group. The duration of a session will be 50 minutes, with spinal stabilization exercises 40 minutes and LV 10 minutes.LV will be applied before the exercises. LV will be applied to the cervical paraspinal muscles for a total of 5 minutes (2.5 minutes on the right side, 2.5 minutes on the left side) while the patients are in a sitting position. LV will be applied to the lumbar paraspinal muscles for a total of 5 minutes (2.5 minutes on the right side, 2.5 minutes on the left side) while the patients are lying in the prone position. LV application will be made with Vibrasens © device and vibration frequency 80 Hz amplitude 1 mm will be selected.
89495694|NCT05885282|Active Comparator|Gastrosoleus Muscle Complex Vibration Group|In addition to lumbar spinal stabilization exercises, LV will be applied to the gastrosoleus muscle complex. Spinal stabilization exercises will be as in the other 2 groups. The duration of a session will be 50 minutes, with spinal stabilization exercises 40 minutes and LV 10 minutes.LV application will be applied sequentially, bilaterally, to the gastrosoleus complex. LV will be applied before the exercises. LV will be applied for a total of 10 minutes (5 minutes each on the right and left) while the patients are lying in the prone position. LV application will be made with Vibrasens © device and vibration frequency 80 Hz amplitude 1 mm will be selected.
89495695|NCT05881707|Experimental|Sequence 1|"Period 1: D064, D702 - A single oral dose of 2 tablets~Period 2: CKD-828 - A single oral dose of 1 tablet~Period 3: D064, D702 - A single oral dose of 2 tablets~Period 4: CKD-828 - A single oral dose of 1 tablet"
89495696|NCT05881707|Experimental|Sequence 2|"Period 1: CKD-828 - A single oral dose of 1 tablet~Period 2: D064, D702 - A single oral dose of 2 tablets~Period 3: CKD-828 - A single oral dose of 1 tablet~Period 4: D064, D702 - A single oral dose of 2 tablets"
89495697|NCT05866523|Active Comparator|Standard of Care Historic Control|Control group will get treatment as usual, which consists of medical care by primary admitting service
89495698|NCT05866523|Active Comparator|Team based inpatient ARTAS|Eligible patients after the study consent process will receive Antiretroviral Treatment Access Study (ARTAS) intervention by social-worker and a medical consultation by an infectious disease physician
89495699|NCT05866484||TESA-ICSI|Compare ICSI outcomes with high Sperm DNA fragmentation undergoing TESA (testicular sperm extraction)
89495700|NCT05866484||Zymot-ICSI|Compare ICSI outcomes with high Sperm DNA fragmentation using microfluidic sperm separation device (Zymot)
88955036|NCT01978613|Experimental|Oral B|Escalation design. Planned end dose level is 5 mg standard dosing condition (fasting for 120 minutes post-dosing)
88955037|NCT01978613|Experimental|Oral A|Escalation design. Planned end dose level is 2.5 mg standard dosing condition (fasting for 120 minutes post-dosing)
88955038|NCT01978626|Experimental|Smart phone Apps|"1st year: Electronic sleep diary module: an app with electronic sleep diary and message reminder~2nd year: Social persuasion system module: an app of smart phone that encourages participants with each others~3rd year: Tai-chi module: a multi-media oriented app that helps participants practice Tai-Chi"
88955039|NCT01978626|Active Comparator|Control|"1st year: traditional paper-pencil diary~2nd year: no social persuasion is given beyond sessions~3rd year: Tai-chi teaching by Digital Video Disc only"
88955040|NCT01978652|Experimental|Peginterferon Beta-1a administered to Japanese participants|A single dose of Peginterferon Beta-1a 125 μg subcutaneous (SC) injection administered by pre-filled syringe
88955041|NCT01978652|Experimental|Peginterferon Beta-1a administered to Caucasian participants|A single dose of Peginterferon Beta-1a 125 μg subcutaneous (SC) injection administered by pre-filled syringe
88955042|NCT01978665|Placebo Comparator|prednisone and Solumedrol|placebo arm versus prednisone
88955043|NCT01978665|Placebo Comparator|solumedrol|placebo versus solu medrol
88955044|NCT01978665|Other|placebo|measurement of fitness
88955045|NCT01978678||Pulmicort|ICS and LABA - based on ACQ and FeNO
89205126|NCT00302731|Experimental|4 estradiol progesterone|Menopausal women in first seven years of menopause randomized to arm 4 estradiol 0.5 mg, progesterone 100 mg dosed orally / day placed in a placebo capsule to disguise contents from participant and study team. Drug dosed daily for 1 year. Screening FSH and PAP. Baseline mammogram, bone density, pelvic ultrasound, EKG, blood work for cholesterol panel (surrogate marker for cardiovascular disease), BUN/Creatinine. Repeated at 12 months. Safety check at 6 months includes BUN/creatinine, EKG, cholesterol panel, estradiol, progesterone levels.
88955046|NCT01978691|Active Comparator|Probiotic|Bifidobacterium animalis ssp. lactis 420 (10^10 colony-forming units (CFU)/day in 12 g of microcrystalline cellulose), once per day for six months in a sachet mixed into a smoothie drink
89205127|NCT00302731|Experimental|3 estriol progesterone|Menopausal women in first seven years of menopause randomized to arm 3 estriol 2.5mg, progesterone 100mg dosed orally / day placed in a placebo capsule to disguise contents from participant and study team. Drug dosed daily for 1 year. Screening FSH and PAP. Baseline mammogram, bone density, pelvic ultrasound, EKG, blood work for cholesterol panel (surrogate marker for cardiovascular disease), BUN/Creatinine. Repeated at 12 months. Safety check at 6 months includes BUN/creatinine, EKG, cholesterol panel, estradiol, progesterone levels.
89205128|NCT00780143|Experimental|Arm 1|Plitidepsin in combination with Cytarabine
89205129|NCT01581229|Experimental|NPPV|
89205130|NCT01581229|Active Comparator|Control|
89205131|NCT01007968|Experimental|HDACi|
89205132|NCT03999034|Experimental|Patients|experimental, cognitive test, no treatment investigated. 140 patients (90 relasping remitting and 50 progressive multiple sclerosis)
89205133|NCT03999034|Experimental|Healthy controls|experimental, cognitive test, no treatment investigated. 400 healthy controls divided into 20 groups, due to gender, age (5 classes: 18-33, 34-43, 44-54, 55-64, and more than 65 years old), and level of education (graduated or not).
89205134|NCT01065025|Experimental|4SC-205|
89205135|NCT00779909|Placebo Comparator|1- Placebo|placebo capsule once per day
89205136|NCT00779909|Experimental|2- Vitamin D3, 500 IU|vitamin D3, 500 IU capsule once per day
89205137|NCT00779909|Experimental|3- Vitamin D3, 2500 IU|vitamin D3, 2500 IU capsule once per day
89205138|NCT00779909|Experimental|4- Vitamin D3, 5000 IU|vitamin D3, 5000 IU capsule once per day
89205139|NCT01065103|Experimental|FFR measurement|
89205140|NCT04273685|Experimental|Intervention Condition|Cognitive remediation training, cognitive behavioural therapy, social recovery therapy
89205141|NCT04273685|Active Comparator|Control Condition|Treatment as usual (TAU),non-directive counselling
89205142|NCT00302107|Active Comparator|Arm 1|Mirtazapine
89205143|NCT00302107|Placebo Comparator|Arm 2|Placebo
89205144|NCT02602301|Active Comparator|1|group A that included 109 women in whom labour was augmented by IV infusion of oxytocin using isotonic saline 0.9%,
89205145|NCT02602301|Active Comparator|2|group B that included 109 women in whom labour was augmented by IV infusion of oxytocin using glucose 5% .
89205146|NCT02602301|Placebo Comparator|3|Group C in which 109 women continued their labour course without any further augmentation.
88955047|NCT01978691|Active Comparator|Prebiotic|Polydextrose, 12 g once per day for six months in a sachet mixed into a smoothie drink
88955048|NCT01978691|Active Comparator|Synbiotic|B. lactis 420 (10^10 CFU/day) in 12 g of polydextrose, once per day for six months in a sachet to be mixed into a smoothie drink
88955049|NCT01978691|Placebo Comparator|Control|12 g of microcrystalline cellulose once per day for six months in a sachet to be mixed into a smoothie drink
88955050|NCT01978704|Experimental|Glycaemic load|
89205147|NCT04097483|Experimental|Telephone Intervention Group|Nurse-led, telephone-based, and psychoeducational intervention, centered on motivational interviewing and cognitive behavioural therapy for adherence and depression.
89205148|NCT04097483|No Intervention|Control group|Control group with treatment as usual (TAU).
89205149|NCT04925206|Experimental|ET-01|
89205150|NCT00760487|Experimental|AcrySof Toric IOL|AcrySof Toric Intraocular Lens (IOL)
89205151|NCT00316225|Experimental|Pemetrexed|Pemetrexed 500 mg/m^2 intravenous (IV) every 21 days for 6 cycles
89205152|NCT04097405|Active Comparator|D-0120 Dose Ascending Cohorts 1-4|D-0120 dose daily for up to 7 days.
89205153|NCT04097405|Placebo Comparator|Placebo Dose Ascending Cohorts 1-4|Placebo dose daily for up to 7 days
89205154|NCT04097405|Experimental|D-0120/Uric Acid Lowering Agent Cohort 6|D-0120 in combination with a uric acid lowering agent for up to 7 days of combination therapy
89205155|NCT01062607||1|Patients diagnosed with Bipolar Disorder I or II (DSM-IV-TR) at any phase of the disorder with at least one mood event during the 12 months before the study start.
89205156|NCT01062607||2|Patients diagnosed with Bipolar Disorder I or II (DSM-IV-TR) at any phase of the disorder with at least one mood event during the 12 months before the study start receiving Seroquel extended release at some point during the retrospective period .
89205157|NCT00586703|Experimental|NK-CD56|NK Cell infusion using CD56 monoclonal antibody following nonmyeloablative SCT from mismatched donors
89205158|NCT04988152|Experimental|Part 1 Sotrovimab intravenous infusion, single dose|
89205159|NCT04988152|Placebo Comparator|Part 1 Volume-matched placebo, intravenous infusion|
89205160|NCT04988152|Experimental|Part 2 Sotrovimab intramuscular injection, single dose|
89205161|NCT04988152|Placebo Comparator|Part 2 Volume-matched placebo, intramuscular injection|
88955051|NCT01978704|Active Comparator|Carbohydrates content|
88955052|NCT01978717|Experimental|general anesthesia & epidural anesthesia|26 patients received general anesthesia combined with epidural anesthesia for surgery, and patient-controlled epidural analgesia for 2 days after surgery
88955053|NCT01978717|Experimental|general anesthesia|27 patients received general anesthesia for surgery, and patient-controlled intravenous analgesia for 2 days after surgery
88955054|NCT01978730|Experimental|high dose group of SaiLuoTong capsule|take three pills (180 mg) of SaiLuoTong capsule each time, twice a day, 0.5 hours after breakfast and dinner, taking with lukewarm water.
88955055|NCT01978730|Experimental|low dose group of SaiLuoTong capsule|take two pills (120 mg) of SaiLuoTong capsule plus one pill of placebo (analog SaiLuoTong capsule) each time, twice a day, 0.5 hours after breakfast and dinner, taking with lukewarm water.
88955056|NCT01978730|Placebo Comparator|the control group|The control group is randomly divided into two groups by 1:1. During the first 26 weeks, all subjects will take three pills of placebo each time, twice a day. During the last 26 weeks, the subjects in the placebo group will take two pills of SaiLuoTong plus one pill of placebo or three pills of SaiLuoTong each time, twice a day.
88955057|NCT01978756||Outpatient clinic|All patients treated for breast cancer with curative intent in MAASTRO clinic in 2002-2003 who are still alive, who respond to our invitation letter and are willing to participate to visit the outpatient clinic. These patients will be sent a questionnaire with both basic and more detailed questions on their disease-status and on quality of life related outcome. In addition they will be asked to come to MAASTRO clinic for a more detailed evaluation of late side effects of the treatment. Patients are seen by a physician or a physician assistant at the outpatient clinic.
88955058|NCT01978769||Preadolescents with ADHD|preadolescents with prior diagnosis of ADHD and without any other psychiatric or neurological diagnosis.
88955059|NCT01978769||Preadolescents with out any diagnosis|Preadolescents with out any diagnosis
88955060|NCT01978782|Active Comparator|raltegravir alone|raltegravir 400 mg BID for 5 days
88955061|NCT01978782|Active Comparator|citalopram alone|citalopram 10 mg QD for 3 days, followed by citalopram 20 mg QD for 13-14 days
88955062|NCT01978782|Experimental|raltegravir + citalopram|raltegravir 500 mg BID and citalopram 20 mg QD for 5 days
88955063|NCT01978795|Experimental|Brain 101 website|Brain 101: The Concussion Play book is a web-based, stand-alone guide for school leaders on effective policies and practices in concussion management. The website offers a school-wide approach to preventing and managing sports concussion, including a) training for educators, athletics staff, students, and parents; b) guidelines for creating a concussion management team; and c) information on strategies for supporting students in the classroom following concussion.
88955064|NCT01978795|Active Comparator|Control|
88955065|NCT01978821|Experimental|stem cell|autologous bone marrow mononuclear cell transplantation
88955066|NCT01978860|Experimental|NovaCross, CTO|assess the safety and technical feasibility, deployment and withdrawal characteristics of the NovaCross™ micro-catheter during an interventional coronary angioplasty procedure and evaluating the CTO penetration rate.
88955067|NCT01978873|Experimental|Arm A:|"Cabazitaxel 25 mg / m² / day on day 1 every 3 weeks continued if the patient has stable disease or responding to up to 10 cycles. Cabazitaxel will be administered in combination with oral prednisone or prednisolone (Prednisolon 10mg 1x1)~Hormones will be initiated in conjunction with the last cycle of chemotherapy. Consists of the administration of a luteinizing hormone-releasing hormone (LHRH) agonist + antiandrogens for 30 days OR surgical castration OR complete androgen blockade (CAB) by LHRH agonist + antiandrogen device. G-CSF treatment according to ASCO guidelines is recommended."
89538094|NCT03286517|Experimental|Tanner Stage III|A 1ml blood sample was obtained for 30 minutes pre and 120 minutes post-kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany) injection periods at 30 min intervals (-30, 0, 30, 60, 90, 120). The dose was 12.67 µg/BW.
89538095|NCT03286517|Experimental|Tanner Stage IV|A 1ml blood sample was obtained for 30 minutes pre and 120 minutes post-kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany) injection periods at 30 min intervals (-30, 0, 30, 60, 90, 120). The dose was 15.11 µg/BW.
89538096|NCT03286517|Experimental|Tanner stage V|A 1ml blood sample was obtained for 30 minutes pre and 120 minutes post-kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany) injection periods at 30 min intervals (-30, 0, 30, 60, 90, 120). The dose was 20.5 µg/BW.
89538097|NCT03286517|Experimental|Adult Group|A 1ml blood sample was obtained for 30 minutes pre and 120 minutes post-kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany) injection periods at 30 min intervals (-30, 0, 30, 60, 90, 120). The dose was 1 µg/kg.
89538098|NCT02445703|Experimental|Group 1 (HAV + HAV)|"Intervention: Inactivated Hepatitis A vaccine (HAV);~Subjects in this group each received 2 doses of inactivated HAV with a 6-month interval (day 0, month 6);~Route of administration: intramuscular injection in deltoid region;"
89205162|NCT04854148||Experimental|Each participant will perform a Smartphone movement health assessment and a series of 12 gold standard tests under the supervision of a licensed physical therapist or other research study staff
89205163|NCT00586625|Experimental|Bepreve|bepotastine besilate ophthalmic solution 1.5%
89205164|NCT00586625|Placebo Comparator|Placebo|vehicle
89538099|NCT02445703|Experimental|Group 2 (HAV + HABV)|"Intervention: Inactivated Hepatitis A vaccine (HAV) and Combined hepatitis A and hepatitis B vaccine (HABV);~Subjects in this group each received 1 dose of inactivated HAV at day 0, and 1 dose of HABV at month 6.~Route of administration: intramuscular injection in deltoid region;"
89538100|NCT02445703|Experimental|Group 3 (HABV + HABV)|"Intervention: Combined hepatitis A and hepatitis B vaccine (HABV);~Subjects in this group each received 2 doses of HABV with a 6-month interval (day 0, month 6);~Route of administration: intramuscular injection in deltoid region;"
89538101|NCT02448355|Experimental|Patient undergoing carotid endarterectomy|"All patients undergoing carotid endarterectomy in Shaare Zedek Medical Center Visual acuity measurement (Snellen) SS-OCT (DRI-Atlantis, Topcon) 3-dimensional scanning protocol with 3 μm axial resolution and a speed of 100,000 A-scans per second. 256 B-scans to be taken on an area of 12 × 9 μm.~On pre-op visit (Monday)~Day 1 post-surgery~Discharge day~Week 1 post-surgery~Month 1 post-surgery"
89538102|NCT04484545||Alive or Dead with COVID-19 diagnosis|Patients selected in phase 1 of study according to Health Protection Scotland criteria for diagnosis of COVID-19 infection Patients selected for phase 2 (validation phase) by PCR result
89538103|NCT03286205|Active Comparator|Weekly Dosage|weekly dose of 100mg
89538104|NCT03286205|Active Comparator|3 week dosage|every 3 week dosage.
89538105|NCT02448277|Experimental|Macintosh Laryngoscope|experimental Macintosh Laryngoscope group: laryngoscope is used to assist for nasotracheal intubation.
89205165|NCT03999502|Experimental|Intervention|The procedure will be performed under general anesthesia with tracheal intubation. Endomina will be introduced into the stomach over a guidewire and then fixed to the endoscope. The procedure will include at least one suture of the gastric cardia to tighten it. Patients will be kept overnight after the procedure.
89022609|NCT06189417|No Intervention|control group|A total of 280 study participants are allocated to control group
89538106|NCT02448277|Experimental|Pentax Airway scope|experimental Pentax Airway scope group:Pentax Airway scope is used to assist for nasotracheal intubation.
89538107|NCT02448277|Experimental|Glidescope|experimental Glidescope group:Glidescope is used to assist nasotracheal tube into trachea
89538108|NCT03286127||PCU (unit)|Those patients who received specialised palliative care on a palliative care unit.(palliative care unit)
89538109|NCT03286127||IPCC (hospital)|"Those patients admitted to a regular hospital ward who received specialised palliative care from an inpatient palliative care consultation team.~(inpatient palliative care consultation team)"
89538110|NCT03286127||OPCC (outpatient)|Those patients who received specialised palliative care at home from an outpatient palliative care consultation team. (outpatient palliative care consultation team)
89538111|NCT02444377|Experimental|High-intensity interval -2min|5 bouts of 2 min cycling at varying intensities of VO2peak (80-100%) with 1 min recovery.
89538112|NCT02444377|Experimental|High-intensity interval -1min|10 bouts of 1 min cycling at 90% of VO2peak with 1 min rest periods
89538113|NCT02444377|No Intervention|Control|No exercise
89538114|NCT03286049||Healthy children (HC)|10 healthy children
88955068|NCT01978873|Active Comparator|Arm B:|-Hormone: LHRH agonist antiandrogens for 30 days + OR surgical castration OR CAB complete androgen blockade by LHRH agonist + antiandrogen device.
88955069|NCT01978886||Patient with diabetes|Patients who have been diagnoses with diabetes.
88955070|NCT01978886||Patients without diabetes|Patients who have not previous been diagnosed with diabetes.
89538115|NCT03286049||Children with non allergic rhinitis (NAR)|10 children with non allergic rhinitis
89538116|NCT03286049||Rhinitis children, perennial allergy (PAR)|10 rhinitis children, sensitized to perennial allergens
89538117|NCT03286049||Rhinitis children, seasonal allergy, outside season (OSR)|10 rhinitis children sensitized to seasonal allergens, observed outside the allergen season
89538118|NCT03286049||Rhinitis children, seasonal allergy, within season (WSR)|10 rhinitis children sensitized to seasonal allergens, observed during the allergen season
89538119|NCT03194659|No Intervention|Placebo|Administration of the deuterated choline chloride will take place in a grape juice cocktail solution. For individuals in the placebo arm of the trial, no additional choline chloride will be added to the cocktail.
88955071|NCT01978899|Active Comparator|Immediate Weight Loss Program Group|"Immediate Weight Loss Program Group~The weight loss Program Group will include weekly in-person sessions comprised of dietary counseling and increased physical activity. Patients will also be provided with exercise and dietary goals each week to implement at home.~Assessments will occur at baseline (pre-randomization), at the end of the 16-week intervention or control period and at 32 weeks."
89205166|NCT00636168|Active Comparator|A|
89495701|NCT05866016|Experimental|Skill birth attendants who trained on new modular training package|"Maternal and child health service providers (skilled birth attendants) will be trained using modular training that covers both theory and practical sessions on midwifery skills.~Auxiliary nurse midwives should complete modules 1, 2, and 3 whereas nurses will get modules 1, 2, 3, and 4.~The training will be implemented in National Health Training Center-accredited training sites/ hospitals."
89495702|NCT05866016|Active Comparator|Skill birth attendants who trained on existing standard training package|"Maternal and child health service providers (auxiliary nurse midwives and nurses) get training based on the existing standard skilled birth attendant training curriculum of Nepal. This is a two-month-long integrated skill birth attendant package implemented in National Health Training Center-accredited training sites.~The midwifery competencies of these service providers will be assessed and compared with the competencies of experimental groups."
89495703|NCT05865392|Experimental|Move physical activity support program|Participants receive the Move physical activity support program over 12 weeks.
89495704|NCT05835908||Patient who contacted the Emergency Call Center and were referred to an Unscheduled Care Center|
89495705|NCT05833958|Experimental|GMRx-4 IR polypill in the morning and metformin Immediate Release (IR)175mg at night|One GMRx-4 IR polypill capsule (metformin IR 175mg + dapagliflozin 2.5mg + sitagliptin 17.5mg) in the morning and one metformin IR 175mg capsule at night. Capsules are taken with, or just after, food, and swallowed whole with water. Capsules will be taken at, or as close as possible to, the same time of morning (GMRx-4 IR) and the same time of evening (metformin 175mg) each day for 16 weeks.
89495706|NCT05833958|Active Comparator|Metformin IR 500mg in the morning and at night|One metformin IR 500mg capsule in the morning and at night. Capsules are taken with, or just after, food, and swallowed whole with water. Capsules will be taken at, or as close as possible to, the same time of morning and the same time of evening each day for 16 weeks.
89495707|NCT05830071|Experimental|Single therapeutic dose of CHF5993 (BDP/FF/GB)|Dose: BDP/FF/GB 100/6/12.5 μg, single dose inhalation via pressurized metered dose inhaler (2 puffs from 1 BDP/FF/GB 100/6/12.5 μg pMDI + 2 puffs from 3 placebo pMDI)
89495708|NCT05830071|Experimental|Single supra-therapeutic dose of CHF5993 (BDP/FF/GB)|Dose: BDP/FF/GB 800/48/100 μg single dose inhalation, via pressurized metered dose inhaler (8 puffs from 4 BDP/FF/GB 100/6/12.5 μg pMDI)
89495709|NCT05830071|Experimental|Single supra-therapeutic dose CHF5259 (GB)|Dose: GB 100 μg single dose inhalation, via pressurized metered dose inhaler (8 puffs from 4 GB 12.5 μg pMDI)
89495710|NCT05830071|Placebo Comparator|Single dose Placebo|Dose: placebo single dose inhalation, via pressurized metered dose inhaler 8 puffs from 4 CHF5993 placebo pMDI
89495711|NCT05830071|Active Comparator|Moxifloxacin|Dose: moxifloxacin 400 mg single dose, for oral use - open label treatment (1 tablet of moxifloxacin 400 mg PO)
89495712|NCT05828836|Placebo Comparator|placebo|
89495713|NCT05828836|Active Comparator|allopurinol|
89495714|NCT05821075|Active Comparator|Prednisolone|
89495715|NCT05821075|Active Comparator|Cerebrolysin|
89495716|NCT05821075|Active Comparator|Prednisolone and Cerebrolysin|
89495717|NCT05815485|Experimental|Phase 2 azeliragon|
89495718|NCT05815485|Placebo Comparator|Phase 2 placebo|
89495719|NCT05815485|Experimental|Phase 3 azeliragon|
89495720|NCT05815485|Placebo Comparator|Phase 3 placebo|
89495721|NCT05814172||Death by 1 y|patients who dieded within 1-year after discharge due to hip fracture surgery
89495722|NCT05814172||Alive at 1 y|patients who survived 1-year after discharge due to hip fracture surgery
89495723|NCT05789758||Nusinersen Treated Participants|Pregnant participants with SMA who are exposed to nusinersen during the relevant window defined as 14 months prior to the first day of the participant's last menstrual period before conception, 14.5 months before conception and anytime during pregnancy and are enrolled in the registries, International Spinal Muscular Atrophy Registry (ISMAR) and SMArtCARE will be followed prospectively up to 3 months post-delivery, the infants will be followed up to 2 years post-delivery and the available data is collected retrospectively.
89495724|NCT05785325|Experimental|RC48-ADC plus Bevacizumab|Administer RC48-ADC intravenously in combination with bevacizumab 5mg/kg once every two weeks. Medication must be discontinued until disease progression, intolerable toxicity, informed consent is withdrawn, or investigator judgment is made.
89205167|NCT00636168|Placebo Comparator|B|
89495725|NCT05784597|Experimental|Cohort A|3 female + 3 male patients with a primary tumor only
89495726|NCT05784597|Experimental|Cohort B|Patients with a primary tumor and/or advanced/metastatic disease with a quantifiable number of lesions
89495727|NCT05765513|Experimental|35kDa hyaluronan fragment HA35 injection|The investigator injected 35kDa hyaluronan fragment HA35 into the periodontal pocket in a single dose of 100 mg.The distribution of injection amount was determined by the location of gingival inflammation.
89495728|NCT05758402|Other|EARP group|EARP group
89495729|NCT05758402|Active Comparator|Routine practice groups|Routine practice groups
89495730|NCT05737056||Children diagnosed with rheumatoid purpura at the pediatric emergency department|Children diagnosed with rheumatoid purpura from admission to the pediatric emergency department up to two years of follow-up by general practitioners after hospital discharge.
89495731|NCT05736588|No Intervention|Usual care|
89495732|NCT05736588|Experimental|Elimisha HPV|Elimisha HPV is a multi-level stigma-responsive cervical cancer prevention service delivery model that incorporates stigma-responsive education, peer navigation and a patient-centered delivery strategy, addressing drivers while mitigating harms from stigma.
89495733|NCT05727137|Experimental|Single shot adductor canal block|
89495734|NCT05727137|Active Comparator|Continuous adductor canal block|
89495735|NCT05725265|Experimental|Large-area low-level laser therapy|Large-area low-level laser therapy(Venusure) was administered at proximal forearm, upper arm and axillary region of affected side. The wavelength was 980±15nm, average dose was 10-40nm/cm2 and maximal output was 1000mW. Total treatment duration was 30 min and frequency was 3 sessions/week for 4 weeks.
89495736|NCT05725265|Placebo Comparator|Conventional low-level laser therapy|Conventional low-level laser therapy was administrated on antecubital fossa and the axilla of affected side. The wavelength was 808nm and maximal output was 60 mW. Total treatment duration was 30 min and frequency was 3 sessions/week for 4 weeks.
89495737|NCT05719831|Experimental|H-VA-dual-10|"10 days(vonoprazan fumarate tablets 20 mg/time, 2 times/day, oral~+Amoxicillin 750mg/ time, 4 times/day, oral)"
89495738|NCT05719831|Experimental|L-VA-dual-10|"10 days(vonoprazan fumarate tablets 20 mg/time, 2 times/day, oral~+Amoxicillin 1000mg/ time, 2 times/day, oral)"
89495739|NCT05719831|Active Comparator|H-VA-dual-14|"14 days(vonoprazan fumarate tablets 20 mg/time, 2 times/day, oral~+Amoxicillin 750mg/ time, 4 times/day, oral)"
89495740|NCT05704400|Experimental|single arm|
89495741|NCT05698550|Experimental|EZTG group|
89495742|NCT05698550|Placebo Comparator|Control group|
89495743|NCT05686421|Experimental|Device C (OD-OS), then Device N (OD-OS)|"Participants will be randomized to receive 1 macular scan on each eye and 1 optic nerve head (ONH) scan on each eye from two devices: device C, a standard conventional device with no attachment; and device N, the standard conventional device with the invention (comfortable chin and forehead rest that can be adjusted to fit each individual's size) attached to the device.~Participants will first be imaged using device C starting with the right eye (OD), then left eye (OS). They will then be imaged using device N, starting with OD, then OS."
89495744|NCT05686421|Experimental|Device C (OS-OD), then Device N (OS-OD)|"Participants will be randomized to receive 1 macular scan on each eye and 1 optic nerve head (ONH) scan on each eye from two devices: device C, a standard conventional device with no attachment; and device N, the standard conventional device with the invention (comfortable chin and forehead rest that can be adjusted to fit each individual's size) attached to the device.~Participants will first be imaged using device C starting with the left eye (OS), then right eye (OD). They will then be imaged using device N, starting with OS, then OD."
89495745|NCT05686421|Experimental|Device N (OD-OS), then Device C (OD-OS)|"Participants will be randomized to receive 1 macular scan on each eye and 1 optic nerve head (ONH) scan on each eye from two devices: device N, a standard conventional device with the invention (comfortable chin and forehead rest that can be adjusted to fit each individual's size) attached to the device; and device C, the standard conventional device with no attachment.~Participants will first be imaged using device N starting with the right eye (OD), then left eye (OS). They will then be imaged using device C, starting with OD, then OS."
89495746|NCT05686421|Experimental|Device N (OS-OD), then Device C (OS-OD)|"Participants will be randomized to receive 1 macular scan on each eye and 1 optic nerve head (ONH) scan on each eye from two devices: device N, a standard conventional device with the invention (comfortable chin and forehead rest that can be adjusted to fit each individual's size) attached to the device; and device C, the standard conventional device with no attachment.~Participants will first be imaged using device N starting with the left eye (OS), then right eye (OD). They will then be imaged using device C, starting with OS, then OD."
89495747|NCT05684367|Experimental|Center-Based Walking Exercise|Subjects will be randomly assigned to receive a center-based walking exercise intervention 3 days per week for the duration of the study.
89495748|NCT05684367|Experimental|Home-Based Walking Exercise|Subjects will be randomly assigned to walk for exercise in their community five days/week.
89495749|NCT05673837||Type 1 Diabetes|111 persons with Type 1 Diabetes since childhood
89495750|NCT05673837||Controls|37 persons without diabetes
89495751|NCT05663502||Observational (biospecimen collection)|Patients undergo collection of fresh blood and/or tumor tissue samples
89495752|NCT05662137|No Intervention|Control group|"At the beginning of the study, data collection tools Personal Information Form, Expression of Emotions Scale, Toronto Alexithymia Scale, Positive and Negative Syndrome Scale will be applied to the control group.~No intervention will be made in the control group. Measurement tools will be applied for the posttest. Emotional Expression Scale, Toronto Alexithymia Scale and Positive and Negative Syndrome Scale will be reapplied 1 month after the last session."
89495753|NCT05662137|Experimental|Experimental group|"Emotion recognition and expression program is aimed to be carried out in 8-week sessions for schizophrenia patients included in the experimental group. Personal Information Form, Expression of Emotions Scale, Toronto Alexithymia Scale, Positive and Negative Syndrome Scale will be applied to the experiment. The principal investigator will lead the structured group sessions as the group leader.~The principal investigator will lead the structured group sessions as the group leader.~Each group is planned to be 60-90 minutes. Before sessions, participants are taken from their previous session's emotions so far. Homework is discussed by providing recall of the topic from the previous session, and then the current topic is moved on. At the end of each session, a general summary and evaluation is made. After the sessions in the research, measurement tools will be applied for the posttest. It will be reapplied 1 month after the last session."
89495754|NCT05660941|Experimental|Ultrarapid-acting Lispro|ultrarapid-acting lispro delivered by hybrid closed loop system.
88955072|NCT01978899|Active Comparator|Delayed Weight Loss Program Group|The Delayed Weight Loss Program Group will take part in the weight loss intervention after the 16-week control period. Assessments will occur at baseline (pre-randomization), at the end of the 16-week intervention or control period and at 32 weeks
88955073|NCT01978925|Experimental|Pharmaceutical care|In the ED, immediately after discharge, participants randomized to the pharmaceutical care group will receive intervention coordinated by the study pharmacist.
88955074|NCT01978925|No Intervention|Usual care|In addition to counseling provided by a physician and by the nursing staff during their stay in the ED (usual care), patients randomized to the control group will receive the same printed material information on hypertension and/or diabetes medications and lifestyle interventions in order to keep patients masked.
88955075|NCT01978951|Experimental|Integrated Chronic Kidney Disease care|standard guidelines of CKD treatment + Integrated CKD care consisting of multidisciplinary team care and home visit by community care network
88955076|NCT01978951|Active Comparator|Conventional CKD care|standard guidelines of CKD treatment
88955077|NCT01978964|Experimental|ONT-10 Vaccine|
88955078|NCT01978977||Avastin regimens|Patients who are going to receive chemotherapy plus Avastin (bevacizumab)
88955079|NCT01978990||Diabetes Management System , blood glucose|
89205168|NCT04098263|Active Comparator|Part B: Cohort 1|300 mg PO TID given as a single 300-mg capsule of LMN-101 orally three times daily for 28 days
89495755|NCT05660941|Active Comparator|Insulin Lispro|Insulin lispro delivered by hybrid closed loop system.
89495756|NCT05643248|Experimental|Cohort 1|The planned doses are 15 mg for the sentinel subject in cohort 1 and 35 mg for the remaining 2 subjects in cohort 1
89495757|NCT05643248|Experimental|Cohort 2|The planned dose for all 3 subjects in cohort 2 is 70 mg.
89495758|NCT05643248|Experimental|Cohort 3|The planned dose for all 3 subjects in the optional cohort 3 is 100 mg.
89495759|NCT05642806|Experimental|Mepolizumab|Mepolizumab (100 mg) subcutaneously every 4 weeks
89495760|NCT05642806|Placebo Comparator|Placebo|Placebo 100 mg subcutaneously every 4 weeks
89495761|NCT05638555||Lactated Ringer's (LR) solution|
89495762|NCT05638555||Normal Saline (NS)|
89495763|NCT05629546|Experimental|Arm 1: Autologous: Memory-like natural killer cells + nivolumab + relatilimab|"Subjects enrolled into arm 1 will receive autologous ML NK cells on Day 0.~Relatlimab/nivolumab will be initiated at day 29 and continue every 28 days for 11 cycles, or until unacceptable toxicity, or progression, whichever is earlier."
89495764|NCT05629546|Experimental|Arm 2: Allogeneic: Memory-like natural killer cells + nivolumab + relatilimab|"Subjects with a haploidentical donor will enroll into arm 2, where ML NK cells sourced from the haploidentical allogenic donor will be activated.~Subjects will receive the IV infusion of ML NK cells on Day 0.~Relatlimab/nivolumab will be initiated at day 29 and continue every 28 days for 11 cycles, or until unacceptable toxicity, or progression, whichever is earlier."
89495765|NCT05629546|No Intervention|Allogeneic Donors|
89495766|NCT05629143|Other|Intermittent deprescribing strategy|Classical approach for deprescribing of PPI based on Belgian Guidelines. In this study arm, the patients will keep the intake of their PPI but will decrease the use of PPI using a scheme where the PPI dose in reduced intermittently for one month. After one month in the intermittent deprescribing scheme, the patients will stop the use of PPI.
89495767|NCT05629143|Other|On-demand deprescribing strategy|In this study arm, the patients will keep the intake of their PPI but will decrease the use of PPI in an on-demand bases for one month. The patient will only take the PPI when strictly needed because of symptoms. After one month in the on-demand PPI use, the patients will stop the use of PPI.
89495768|NCT05629143|Other|Replacement of PPI with alginate therapy|In this study arm, the patient will stop the intake of the PPI band replace it with the use of an alginate for one month. After one month, the patient will stop the use of alginates.
89495769|NCT05624866|Active Comparator|Dexmeditomidine group|injection of 1 microgram/kg dexmeditomidine + 10 cc saline injection nearby median nerve as hydro-dissection
89495770|NCT05624866|Active Comparator|Triamcinolone group|injection of 40 mg triamcinolone + 10 cc saline injection nearby median nerve as hydro-dissection
89495771|NCT05613361|Experimental|Group 1|patients in this group will receive loading dose of colistin intravenously of 9 MIU followed by maintenance doses of 4.5 MIU given every 12 hours.
89495772|NCT05613361|Active Comparator|Group 2|patients in this group will receive loading dose of colistin intravenously of 9 MIU followed by maintenance doses of 4.5 MIU given every 12 hours and curcumin will be administered as orally or through nasogastric tube at a dose of 2 capsules every 6 hours (1 gm/6 hour)
89495773|NCT05598359|Experimental|TA-65|TA-65 (250 U) taken once per day
88955080|NCT01979042||patients with stones|80 men and women with a normal creatinine for the past year that present in the ER with renal colic and a stone in their ureter according to imaging
88955081|NCT01979042||patients without stones|20 men and women that presented in our department for elective surgery that is not related to stones or bladder outlet obstruction
88955082|NCT01979055|Experimental|Self-regulation intervention|6 session educational intervention (3 telephone, 3 In-person), led by a health educator
88955083|NCT01979055|Placebo Comparator|Control group|3 telephone calls to assess any additional questions regarding asthma
89495774|NCT05598359|Placebo Comparator|Placebo|Placebo taken once per day
89495775|NCT05591092||Observational (I-123, planar imaging, SPECT/CT scan)|Patients receive iodine-123 PO and then undergo planar imaging and a SPECT/CT scan on study.
89495776|NCT05589727||Patients with VAP - ANVISA criteria|Patients notified with Ventilator-Associated Pneumonia (VAP) when using the current ANVISA criteria.
89495777|NCT05589727||Patients with VAP - NHSN criteria|Patients notified with Ventilator-Associated Pneumonia (VAP) when using the Ventilator-Associated Events (VAE) criteria defined by the NHSN.
89495778|NCT05579665|Experimental|Platelet-rich Plasma (PRP)|Platelet-rich plasma administered 5 times as an intra-articular injection under ultrasound guidance as a series of one weekly injections to the affected knee. 1 weekly injections are of leukocyte poor, buffer/additive free, singe spin, platelet-rich plasma averaging 3mL in volume.
89531772|NCT05395936|Experimental|Intraoperative Data Collection Arm|Participants scheduled for mastectomy with or without breast reconstruction during the course of their breast surgery treatment will have breast skin temperatures taken using a myocardial probe in different anatomical breast areas at multiple time points during the surgery.
89495779|NCT05579665|Experimental|Conditioned Medium From Umbilical Cord Mesenchymal Stem Cell Culture (MSCs) Secretome|Conditioned Medium From Umbilical Cord Mesenchymal Stem Cell Culture (MSCs) Secretome administered 5 times as an intra-articular injection under ultrasound guidance as a series of one weekly injections to the affected knee. 1 weekly injections are Conditioned Medium From Umbilical Cord Mesenchymal Stem Cell Culture (MSCs) Secretome averaging 2 mL in volume.
89495780|NCT05579665|Experimental|Hyaluronic Acid (HA)|Hyaluronic Acid administered 5 times as an intra-articular injection under ultrasound guidance as a series of one weekly injections to the affected knee. 1 weekly injections are of low molecular weight hyaluronan in a 2mL injection.
89495781|NCT05571280|Active Comparator|Standard Intervention (CONTROL Arm)|"The Standard package includes a series of actions carried out by the Community and Health Development Agents (ADECOS), who improves access to primary health care practices and promotes well-being behaviors at community levels. ADECOS has the potential to facilitate improvements in the health state and quality of life in rural communities. Activities performed by ADECOS can be grouped into two blocks:~Health awareness-raising, and promotion activities at the community level (against malnutrition and promoting adequate nutrition).~Preventive community activities involving the promotion of treatment against malnutrition at the community level and direct referral to local health facilities when necessary."
89495782|NCT05571280|Experimental|Standard Intervention plus nutritional supplementation (CONTROL+NUT Arm)|"In addition to the services performed by the ADECOS, it is included a supply of complementary food rations (individual + family) at the relative level, being:~One individual portion composed by nutritional lipid supplements in small quantities (SQ-LNS)~One complementary family portion composed by local foods."
89495783|NCT05571280|Experimental|Standard Intervention plus money transfers (CONTROL+TM Arm)|In addition to the services performed by the ADECOS, it will be delivered a total of 14,000.00 Kz per month and per relative with 4 or more people living in the same household by the end of the study. It will be delivered a total of 11,000.00 Kz per month and per relative with 3 or fewer people living in the same household by the end of the study. The monetary value will be delivered in cash with unconditional format, and it will not be determined by the investigator team the use and the destination of said amount and nothing will be requested in return.
89495784|NCT05559359|Experimental|Lebrikizumab (Cohort 1)|"Participants who are 6 years to <18 years of age, 12 years to <18 years of age who weigh <40 kilogram (kg) or 6 years to <12 years of age (may weigh ≥40 kg) will receive a loading dose and then subsequent doses by subcutaneous (SC) injections with a topical corticosteroid (TCS).~Dosing will be based on weight."
89495785|NCT05559359|Experimental|Lebrikizumab (Cohort 2)|"Participants who are 6 months to <6 years of age, 2 years to <6 years of age or 6 months to <2 years of age will receive a loading dose of lebrikizumab and then subsequent doses by SC injections with a TCS.~Dosing will be based on weight."
89495786|NCT05559359|Placebo Comparator|Placebo|Participants will receive placebo matching lebrikizumab by SC injections with a TCS.
89495787|NCT05558098|Active Comparator|Standard of Care|Current standard of care for critically ill patients.
88955084|NCT01979081||People with chronic disease|Participants greater than or equal to 44 years of age with a chronic disease (diabetes, heart disease, stroke, hypertension, osteoporosis, osteoarthritis, rheumatoid arthritis, chronic obstructive pulmonary disease, back pain, Multiple Sclerosis, Parkinson's Disease).
88955085|NCT01979081||People without chronic disease|Participants greater than or equal to 65 years of age without a chronic disease.
88955086|NCT01979107|Experimental|Proactive action by the general practitioner|Proactive action by the general practitioner inviting to preventive health check.
88955087|NCT01979107|No Intervention|Control group|The participants will be treated as usual by the general practitioner.
88955088|NCT01979120||only 1 cohort!|All patients already got an ICD implanted which includes an algorithm for screening of sleep-disordered breathing and will be examined by an portable polygraphy monitor in order to compare the Apnea-Hypopnea-Index.
88955089|NCT01979146|Experimental|Provider Unrelieved Symptom Alert|Patients in the intervention arm called the automated monitoring system daily to report presence, severity and distress on a 1-10 scale for nine symptoms. The system immediately sent an emailed symptom alert report to their oncologist and oncology nurse if symptoms exceeded preset thresholds (moderate to severe levels). Two thresholds were set: a simple alert when severity or distress was 4 or greater on the 10 point scale and trend alerts based on a pattern of moderate severity over several days.
88955090|NCT01979146|No Intervention|Attentional Control Usual Care Group|Patients in the usual care group called the automated monitoring system daily to report presence, severity and distress (1-10 scale) on 9 symptoms and also measured symptom interference with daily activities, functional status, work attendance, and unscheduled provider visits, urgent care and emergency department visits, and unscheduled hospitalizations. The usual care group received equivalent contact time with the automated system including identical voice and assessment questions. Data were not available for clinical action and not reported to the oncology providers. On every call, usual care participants were reminded to call their oncology provider if they had symptom concerns, which is the usual practice in oncology settings to address unrelieved symptoms.
88955091|NCT01979198||fusion group|close reduction with posterior short-segment transpedicular screw fixation with posterior fusion
88955092|NCT01979198||non-fusion group|close reduction with posterior short-segment transpedicular screw fixation without posterior fusion
88955093|NCT01979224|No Intervention|treatment and routine counseling|Parents attend regular consultation and receive regular medical guidance
88955094|NCT01979237|Experimental|SPASO method, FARES method|Reduction method: SPASO method, FARES method
88955095|NCT01979250|No Intervention|Normal corneas|Normal corneas from patients that undergo cataract surgery.
88955096|NCT01979250|Other|DSAEK surgery|Corneal endothelial transplantation by Descemet's stripping automated endothelial keratoplasty (DSAEK).
88955097|NCT01979263|Active Comparator|Attention Bias Modification|Attention Bias Modification computer task
89495788|NCT05558098|Active Comparator|Standard of care plus dapagliflozin|Current standard of care for critically ill patients plus open-label dapagliflozin 10 mg per day for 14 days or until ICU discharge
89495789|NCT05556733|Experimental|Faecal Microbiota Transplantation|Subjects will receive Faecal Microbiota Transplantation
89495790|NCT05556733|No Intervention|Control|The control subjects will not receive FMT
89495791|NCT05535712|Experimental|Da Vinci SP intervnetion group|for patients who received Da Vinci SP robotic surgery
89495792|NCT05510115|Experimental|Experimental|Empagliflozin
89495793|NCT05510115|Placebo Comparator|Placebo comparator|Placebo
89495794|NCT05506371|Experimental|Az group|"Periodontitis patients, who underwent scaling and root planning (SRP) as one-stage full-mouth disinfection procedure and additionally received oral azithromycin (Health Pharmaceutical Company, Kharkiv, Ukraine) in a dose of 500 mg q.d. for 7 days, then 500 mg q.w. for the next 3 weeks"
89495795|NCT05506371|Active Comparator|SRP group|Periodontitis patients who underwent scaling and root planning (SRP) as one-stage full-mouth disinfection procedure.
89495796|NCT05506371|Other|H group|Reference group. 25 healthy volunteers who underwent only diagnostics to confirm the clinical healthy state of the gingiva
89495797|NCT05505513|Experimental|Implantation of a percutaneous Utah Slanted Electrode Arrays (pUSEAs)|The arm (s) of the patient which has been amputated. Intervention include insertion of the percutaneous Utah Slanted Electrode Arrays which will interact with nerve endings in order to gain knowledge about device feasibility and nerve stimulation.
89495798|NCT05501548|Experimental|Olaparib and Vitamin C|Olaparib will be administered at 300 mg by mouth, twice daily; ascorbate will be administered at 1 g/kg IV twice weekly at least 24 hours apart, until objective disease progression or unacceptable toxicities or patient withdrawal for other reasons.
89495799|NCT05473897|Experimental|Catalyst Cryohelmet intervention with symptomatic care|The treatment arm will receive symptomatic care (acetaminophen 1000mg and ondansetron 4mg) along with 30 minutes of head-neck cooling in the emergency department while being monitored for side effects.
89495800|NCT05473897|No Intervention|Control: symptomatic care arm|The control arm will receive symptomatic care (acetaminophen 1000mg and ondansetron 4mg). They will not wear any helmets.
89495801|NCT05464849||Resistant hypertension|Patients presenting with resistant hypertension
89495802|NCT05464849||non-resistant hypertension|Patients presenting with non-resistant hypertension
89495803|NCT05464849||normotensive subjects|control group including normotensive volunteers
89495804|NCT05455840|Experimental|Intervention|Patients with qualified criteria will be enrolled in this study
89495805|NCT05417438|Experimental|Wearable device deployment|Participants will be enrolled in the experimental trial to receive Fitbits and a smartphone app.
89495806|NCT05407233|Active Comparator|Group 1|Doesn´t reuse the syringe for insulin application
89495807|NCT05407233|Experimental|Group 2|Uses the syringe five times to insulin application
88955098|NCT01979263|Placebo Comparator|Placebo Computer Task|Placebo computer task
88955099|NCT01979289|Experimental|Computer Treatment: Active|Computerized Cognitive Remediation: Targeted to underlying cerebral networks associated with remission.
89495808|NCT05394844|Active Comparator|CGM with DM education|if you are in the intervention group you will received culturally tailored diabetes education and use a Real Time CGM device to see your glucose over 12 weeks. Both group will completed blinded CGM at the beginning of the study and at 24 weeks
89495809|NCT05394844|No Intervention|Education only|If you are in the control group your will receive culturally tailored diabetes education and wear a blinded prior to education and after education sessions complete and 24 weeks
89495810|NCT05391893|Active Comparator|Diltiazem with oral and intravenous treatment|Diltiazem 0.25mg/kg injection, give over 2 minutes, max dose 30mg. 15 minutes following Diltiazem Infusion administer oral Diltiazem 60mg IR Tablet, do not give if BP<100
89495811|NCT05391893|Placebo Comparator|traditional atrial fibrillation with rapid ventricular response|these patients will receive traditional treatments at provider discretion. To be included in teh study their initial heart rate must also be over 125, and they must receive at least one intravenous medication for atrial fibrillation with rapid ventricular response. This will be a heterogenous group of patients receiving digoxin, amiodarone, various beta-blockers, and intravenous diltiazem without oral diltiazem.
89495812|NCT05384132|Experimental|Scaling and Root Planing (SRP) + Livfresh Dental Gel (LDG)|SRP at Baseline with use of LDG (test dentifrice) for twice daily brushing between study visits.
89495813|NCT05384132|Active Comparator|Scaling and Root Planing (SRP) + standard fluoride dentifrice|SRP at Baseline with use of standard fluoride dentifrice (control dentifrice) for twice daily brushing between study visits.
89495814|NCT05381766|Experimental|Study Group|Low-income Chinese American immigrant families with a focus on adults 18+ years in Brooklyn will participate in a culturally adapted systems -level program for improving diet.
89495815|NCT05373173|Experimental|Tele-assessment + In-person assessment|All families will receive an in-person tele-assessment appointment and an in-person evaluation.
89495816|NCT05373082||Patients with hereditary spastic Paraplegia|Patients with hereditary spastic Paraplegia
89495817|NCT05367336|No Intervention|Control|not receiving any narcotics
89495818|NCT05367336|Experimental|Morphine|the second group will be those receiving morphine
89495819|NCT05367336|Experimental|Fentanyl|the 3rd group will be those receiving fentanyl
89495820|NCT05359133|Active Comparator|Tetrodotoxin for injection|30 µg, 1 ml SC injection in the thigh or abdomen, twice daily for 4 Days
89495821|NCT05359133|Placebo Comparator|Placebo|1.0 mL of placebo, SC injection in the thigh or abdomen, twice daily for 4 Days
89495822|NCT05356637|Other|Intervention Group Receiving Fastseal|
89495823|NCT05353595|Experimental|insect protein|0.38g insect protein / kg body mass with vanilla flavouring is provided. In the morning the participant is weighed and based on this weight an independent researcher prepares the protein drink.
89495824|NCT05353595|Placebo Comparator|placebo|participants receive the same amount of water (based on body weight) with vanilla flavouring. this drink is also prepared by an independent researcher.
89495825|NCT05351502|Experimental|Cohort 1|Subjects will receive 25,000 ppm NO
89495826|NCT05351502|Experimental|Cohort 2|Subjects will receive 50,000 ppm NO
89495827|NCT05351502|Experimental|Cohort 3|Subjects will receive 100,000 ppm NO
89495828|NCT05351502|Experimental|RP2D Expansion|Subjects will receive the RP2D dose of NO
89495829|NCT05337423|Experimental|Group 1|Moisturizing cream indicated and provided by the hospital (with urea) + LED treatment.
89495830|NCT05337423|Sham Comparator|Group 2|Moisturizing cream indicated and provided by the hospital (with urea) + LED sham treatment.
89495831|NCT05297461|Experimental|Medication Review|The intervention group will receive medication review intervention which includes reviewing older adults' medications and identifying any drug-related problems.
89495832|NCT05297461|No Intervention|Standard Care|The standard care includes the current existing care provided to patients in the community pharmacy.
89495833|NCT05289024||MABT utilizers|Chronic pain patients receiving MABT in an interdisciplinary clinic as part of their standard of care.
89495834|NCT05280223|Active Comparator|Dexmeditomidine group|injection of 1 microgram/kg dexmedetomidine + 10 cc saline injection nearby median nerve as hydrodissection
89495835|NCT05280223|Active Comparator|Hyalase|injection of Hyalase + 10 cc saline injection nearby median nerve as hydro-dissection
89495836|NCT05248503||Nurse|Pediatric nurses taking charge of the care of patients with epidermolysis bullosa at Necker Hospital
89495837|NCT05246254||Prefrailty group|According to the frailty index(FI) and FI =0.12~0.25
89495838|NCT05246254||Frailty group|According to the frailty index(FI) and FI≥ 0.25
89495839|NCT05246254||Nonfrailty group|According to the frailty index(FI) and FI<0.12
89495840|NCT05238506|Experimental|Lidocaine|1% lidocaine intravenous bolus of 0.15 ml/kg over 5 min before induction of anesthesia followed by lidocaine infusion at 0.15 ml/kg/h intraoperatively will be administered. The infusion will be discontinued before the patients' transfer to the postanesthesia care unit.
89495841|NCT05238506|Placebo Comparator|Control|0.9% NaCl intravenous bolus of 0.15 ml/kg over 5 min before induction of anesthesia followed by 0.9% NaCl infusion at 0.15 ml/kg/h intraoperatively will be administered. The infusion will be discontinued before the patients' transfer to the postanesthesia care unit.
89495842|NCT05216991||TetraGraph monitoring on dominant hand|Patients receiving sugammadex after undergoing liver transplantation with quantitative monitoring as standard of care
89495843|NCT05216991||TetraGraph monitoring on non-dominant hand|Patients receiving sugammadex after undergoing liver transplantation with quantitative monitoring as standard of care
89495844|NCT05216796|Experimental|Low-carbohydrate diet|Participants assigned to the Low-carbohydrate diet will be instructed to limit carbohydrate intake to <30 g/d.
89495845|NCT05216796|Active Comparator|Low-calorie diet|Participants assigned to the Low-calorie diet will be instructed to reduce their energy intake to match the LoCHO block (we are predicting ~1200 kcal/d for women and ~1500 kcal/d for men, following current recommendations for treatment of NAFLD).
89495846|NCT05216328|Active Comparator|Macrogol/electrolytes|"Macrogol/electrolytes is started at a dose of 1 sachet once a day orally, based on the current guideline 'Diagnosis and treatment of pain in patients with cancer' (www.pallialine.nl). The dose of macrogol/electrolytes may be increased to 2 sachets a day during the study period.~The effect of laxatives will be judged after 14 days."
89495847|NCT05216328|Active Comparator|Magnesium hydroxide|Magnesium hydroxide is started at a dose of 724 mg three times a day orally, based on the current guideline 'Diagnosis and treatment of pain in patients with cancer' (www.pallialine.nl). The dose of magnesium hydroxide may be increased to 1448 mg three times a day during the study period. The effect of laxatives will be judged after 14 days.
89495848|NCT05214144||evaluating sources of physical function (PF)|evaluate 4 distinct modalities of sources of PF (PRO, ClinRo, PerfO and wearable device data) on Hugo Health platform in breast cancer and lymphoma patients undergoing cytotoxic chemotherapy.
89495849|NCT05208099||Patients with Hidradenitis suppurativa|
89495850|NCT05208099||Controls (coming for abdominoplasty)|
89495851|NCT05203302|Experimental|Late Adult Cochlear Implant (LateAdultCI)|Post-lingually implanted adults, 18+ years
89495852|NCT05203302|Experimental|Early Child Cochlear Implant (EarlyChildCI)|Early implanted children, ages 7-17 years
89495853|NCT05203302|Experimental|Early Adult Cochlear Implant (EarlyAdultCI)|Early implanted adults, ages 18 to 35 years
89022610|NCT06189404|Experimental|Cohort 1 (Periods 1-3), Cohort 2 (Periods 1-4)|Period 1: Single oral dose of theophylline (Day 1); Period 2: Once-daily oral doses of tigulixostat (Days 6 to 10); Period 3: Once-daily oral doses of tigulixostat (Days 11 to 13) and a single oral dose of theophylline (Day 11); Period 4: Single oral dose of tigulixostat (Day 19)
89205169|NCT04098263|Active Comparator|Part B: Cohort 2|1000 mg PO TID given as two 500-mg capsules of LMN-101 orally three times daily for 28 days
89022611|NCT06189352|Experimental|Intervention group|The infants will follow a feeding protocol with detailed nutritional needs, and individual supportive care interventions for enhancing oral feeding development. Parents will get counseling sessions for supporting this strategy. The protocol will follow the infant until discharge.
89205170|NCT04098263|Active Comparator|Part B: Cohort 3|3000 mg PO TID given as six 500-mg capsules of LMN-101 orally three times daily for 28 days
89205171|NCT04098263|Other|Part A|3000 mg PO single dose given as six 500-mg capsules of LMN-101 orally
89205172|NCT04102631|Experimental|exposed group|patients will receive colonoscopy with assistance of Endo.Angel
89495854|NCT05203302|Experimental|Cochlear Implant (CI)|CI children, ages 7-17 years, with aided residual hearing (bimodal/contralateral, electric+acoustic/ipsilateral)
89495855|NCT05203302|Active Comparator|Normal Hearing Children (NHC)|Ages 7-17 years, Control Group
89495856|NCT05203302|Active Comparator|Normal Hearing Adults (NHA)|18+ years, Control Group
89495857|NCT05190913|Experimental|Initiative group I|In the active phase of labor, perineal massage will be performed with the device at an interval of one hour.
89495858|NCT05190913|Experimental|Initiative group II|During the active phase of labor, manual perineal massage will be performed with an interval of one hour.
89495859|NCT05177991|Active Comparator|Liposomal Bupivacaine (Exparel)|The bilateral TAP block will be performed by the department of anesthesia under ultrasound guidance using 20cc of local anesthetic per side. Additional local anesthetic will be supplied by the surgeon at the incision sites.
89495860|NCT05177991|Active Comparator|Bupivacaine (Marcaine)|The bilateral TAP block will be performed by the department of anesthesia under ultrasound guidance using 20cc of local anesthetic per side. Additional local anesthetic will be supplied by the surgeon at the incision sites.
89495861|NCT05168319|Experimental|pcTBS|pcTBS was administered to the left M1 at 80% resting motor threshold (RMT), consisting of a burst of 3 pulses given at 50 Hz repeated every 5 Hz. A total of 1,200 pulses were delivered with the TMS coil positioned in a posterior-anterior (PA) direction parallel to the midline.
89495862|NCT05168319|Active Comparator|10HZ rTMS|The rTMS protocol included 15 trains of 10-second stimulation given at 10 Hz to the left M1 at 80% resting motor threshold (RMT), with the inter-train interval being set to 50 seconds (1500 pulses)
89495863|NCT05168319|Sham Comparator|Sham|The Sham stimulation was delivered using the same protocol, with the coil being orientated at 90° to the scalp so that the magnetic field would be delivered away from the scal
89495864|NCT05161000|Experimental|Oral Nutritional Supplement (ONS) Group|Two servings per day in addition to dietary counseling
89495865|NCT05161000|Other|Control Group|dietary counseling
89205173|NCT04102631|Sham Comparator|non-exposed group|patients will receive colonoscopy without assistance of Endo.Angel
89205174|NCT00759941|Experimental|Xalatan + Azopt|Xalatan dosed once a day at 10 pm, with Azopt dosed three times a day at 8 AM, 2 PM, and 10:05 PM as an adjunctive therapy for 3 months.
89495866|NCT05159856||Prospective cohort study (observational)|400 children/adolescents, aged 6-18 years, with type 1 diabetes for more than 12 months
89495867|NCT05141877|Experimental|Propofol Group|The propofol group was both induced and maintained at an effect-site concentration (Ce) of 2.0-4.0 mcg/mL by a target-controlled infusion (TCI) system.
89495868|NCT05141877|Experimental|Sevoflurane group|The sevoflurane group was maintained via sevoflurane vaporizer between 1% and 3% (target minimum alveolar concentration of 0.7-1.3).
89495869|NCT05128578|Experimental|LEAP Intervention Arm|"Enrolled patients will participate in 12 weekly sessions led by a health coach to learn self-pain management tools and skills. In addition to 6 individual sessions and 6 optional group sessions, participants will complete activities from the LEAP workbook (provided after enrollment), as tracking is a key component of most pain-self management interventions and is intended to address self-regulation. All patients can continue to use other pain management strategies (usual care) in order to mimic real-life conditions."
89495870|NCT05120622|Experimental|Tremelimumab|Patients who will receive local cystoscopic injection of tremelimumab into the bladder wall in combination with systemic administration of durvalumab
89495871|NCT05112120||Single centre single arm observational cohort|Olumiant (4mg) will be administered in line with standard of care guidance. This is the standard dose in line with license for use in active moderate to severe RA. A dose adjustment from 4mg to 2mg is permitted during the study depending on side-effects
89495872|NCT05100147|Experimental|Group 1|The uterotomy suture technique is continous, double layer suturing, in which the first layer is continuous and unlocked involving all uterine layers and a second, continuous non-locking imbrictating layer is applied over the first suture.
89495873|NCT05100147|Experimental|Group 2|The uterotomy suture technique is continous, double layer suturing, in which the first layer is continuous and unlocked not including decidua and a second, continuous non-locking imbrictating layer is applied over the first suture.
89495874|NCT05100147|Experimental|Group 3|The uterotomy suture technique is continous ,double layer with the first layer unlocked, excluding the decidua and including the deep part of the myometrium, and the second layer unlocked including the remaining part of the myometrium.
89495875|NCT05099666|Experimental|Lurbinectedin + Doxorubicin Phase I|"The phase 1b trial will follow a standard 3+3 design. Upon determination of the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of lurbinectedin plus doxorubicin. A treatment cycle will be defined as 21 consecutive days. Treatment will be administered on an outpatient basis~Lurbinectedin~Doxorubicin"
89495876|NCT05099666|Experimental|Lurbinectedin + Doxorubicin at RP2D|"The randomized two arm phase 2 trial will begin following the determination of the RP2D for lurbinectedin and doxorubicin.~Participants will be randomized 1:1 to enroll to either Arm 1 or Arm 2~Participants enrolled to Arm 1 will receive Lurbinectedin with Doxorubicin at the RP2D defined during the phase 1b portion of the trial."
89495877|NCT05099666|Active Comparator|Doxorubicin Monotherapy|"The randomized two arm phase 2 trial will begin following the determination of the RP2D for lurbinectedin and doxorubicin.~Participants will be randomized 1:1 to enroll to either Arm 1 or Arm 2~Participants enrolled to Arm 2 will receive Doxorubicin at the standard dose of 75 mg/m2"
89495878|NCT05092763|Experimental|FIT4SURGERY Intervention|The Fit4Surgery intervention consists of the FitBit Inspire HR device, the Fit4Surgery mobile app, and weekly coaching calls.
89495879|NCT05092763|Active Comparator|Healthy Lifestyle Control|The Healthy Lifestyle Control group engages in their usual activities and receives education about physical activity and a healthy lifestyle for ovarian cancer patients. They receive weekly check in calls.
89495880|NCT05090124|Experimental|anti-TNF treatment|"Adalimumab 40mg, will be administered as a subcutaneous injection once fortnightly on four occasions. No dose adjustments are permitted. The actual Adalimumab product selected at site will be dictated by what is used in standard care.~The single-use, pre-filled syringe will be removed from storage at 2-8oC at least 30 minutes prior to administration to allow the contents to come to room temperature. The pre-filled syringe will be visually inspected for discolouration and particulates as per the product Summary of Product Characteristics.To facilitate maintenance of the blind, the pre-filled syringe (PFS) presentation will be used. The pen presentation will not be used."
89495881|NCT05090124|Placebo Comparator|Placebo|Sodium chloride 0.9% for injection will be used as a placebo to adalimumab. An equal volume will be drawn up into a suitable sized syringe and labelled in accordance with standard practice at site. The dose will be administered as a subcutaneous injection once fortnightly on four occasions. No dose adjustments are permitted. Prior to administration, the prepared placebo syringe will be visually inspected for discolouration and particulate matter prior to administration.
89495882|NCT05086263|No Intervention|Standard of Care (No VR) Randomization|Participants would take the same questionnaires as the VR interventional group except the RT questionnaire. Then they will proceed with their MRI.
89495883|NCT05086263|Experimental|VR Randomization|The virtual reality MRI training will be conducted immediately after completion of the questionnaires in a distraction free room. The training explains the procedure to the viewer and addresses common questions that individuals often have regarding an MRI. Using audio/visual cues and biofeedback training is aimed to mimic the experience of the MRI with real audio recordings of image acquisition, in order to adequately train the view to stay still in an MRI procedure. The research subject will continue with their regularly scheduled MRI. The modified Yale Preoperative Anxiety Scale (mYPAS) is an observational measure and will be completed by research staff.
89495884|NCT05085730|Experimental|Treatment|All subjects will receive 4 separate treatments with the InMode Morpheus8 System.
89495885|NCT05084716|Experimental|Intervention|At the intervention site during healthcare facility outreach events, PrEP initiators will be offered guidance on selecting an adherence supporter during PrEP initiation. All outreach event attendees at the events will be offered the opportunity to attend the intervention workshops. Check-in reminder calls will be conducted systematically with PrEP users.
89495886|NCT05084716|No Intervention|Control|At the control site, healthcare facility staff will continue to provide PrEP according to the standard of care.
89495887|NCT05069961|Active Comparator|ESPB Group|20ml Ropivacaine is injected near the nerves in the back and then continued using an infusion pump.
89495888|NCT05069961|Active Comparator|TEA Group|5ml Bupivacaine is injected into the space around the spinal cord and then continued using an infusion pump.
89495889|NCT05056038|Active Comparator|Lateral Quadratus Lumborum Block|After the premedication with ketamine and midazolam will be performed, the patient will be brought to the operation room. After the induction with thiopental 5mg/kg, fentanyl 1mcg/kg, rocuronium 0.6mg/kg, patients will be intubated. The maintenance of the anesthesia will be provided with sevoflurane. 0.4 ml/kg %0.25 bupivacaine will be used as a local anesthetic agent in both groups and the local anesthetic agent will be administrated with ultrasound at the anterolateral border of quadratus lumborum muscle with 18, 20 or 22 Gauge IV Cannula (Bıçakçılar Cooperation, Istanbul, Turkey) according to age and body weight.
89495890|NCT05056038|Active Comparator|Posterior Quadratus Lumborum Block|After the premedication with ketamine and midazolam will be performed, the patient will be brought to the operation room. After the induction with thiopental 5mg/kg, fentanyl 1mcg/kg, rocuronium 0.6mg/kg, patients will be intubated. The maintenance of the anesthesia will be provided with sevoflurane. 0.4 ml/kg %0.25 bupivacaine will be used as a local anesthetic agent in both groups and the local anesthetic agent will be administrated with ultrasound at the posterior border of quadratus lumborum muscle with 18, 20 or 22 Gauge IV Cannula (Bıçakçılar Cooperation, Istanbul, Turkey) according to age and body weight.
89495891|NCT05055011||Observational (survey, medical record review)|Parents complete survey over 20 minutes. Patients' medical records are reviewed.
89495892|NCT05048862||Neuromuscular disorder|Patients age at least 20 years, and have been diagnosed as neuromuscular disorders by the neurologist. Patients who are unable to read the questionnaire, fail to accept all the examinations, and refuse to provide inform consent are excluded from this study.
89495893|NCT05048862||Normal group|The normal group (age at least 20 years) who had no neurological symptoms or signs were also recruited. The neurological examination performed by the board neurologist must be normal in the normal group.
89495894|NCT05036577|Experimental|ORMD (Orelabrutinib, Rituximab, Methotrexate and Dexamethasone)|Patients were treated for 6-8 cycles of induction therapy with 21 days per cycle, receiving rituximab (375mg/m2 on day 1), dexamethasone (10-15mg on d1-d4), MTX (d2, 3.5g/m2 or 5g/m2), and orelabrutinib (once daily, after MTX clearance, 150mg/d, or 200mg/d), followed by orelabrutinib maintenance up to one year among CR/CRu patients or until disease progression, intolerable toxicity, death, informed consent withdrawal or lost of follow up (whichever occurs first). The primary objective was to determine the maximum tolerated dose (MTD) of the combination of orelabrutinib and MTX with R and D and investigate the safety and tolerability of this regimen using Bayesian Optimal Interval (BOIN) waterfall design to determine rule of dose escalation and movement among dose combination matrix to identify MTD contour.
89495895|NCT05024097|Experimental|Radiation therapy and etrumadenant (AB928)|Enrolled patients will receive Radiation therapy of 25 Gy in 5 fractions along with etrumadenant 150mg oral drug taken once daily. this will then be followed by 9 cycles of FOLFOX in combination of etrumadenant and zimberelimab investigational drugs.
89495896|NCT05017116|Experimental|Part A，single dose group|Subjects will receive single dose RBD1016/placebo on D1 combined with antiviral drugs during the study period.
89495897|NCT05017116|Experimental|Part B, multiple dose group|Subjects will receive two doses of RBD1016/placebo on D1 and D29 combined with antiviral drugs during the study period.
89495898|NCT05015881|Active Comparator|Ketone ester + echocardiogram + PET FDG scanning visit.|"Subjects will drink single dose of ketone ester 1.9 kcal/kg + echocardiogram + PET scanning visit. Dietary Supplement: Ketone Ester (R)-3-hydroxybutyl (R)-3-hydroxybutyrate (R)-3-hydroxybutyrate (commercially available as DeltaG, (TdeltaS, Orlando, FL). 2-Deoxy-2-[18F] fluoro-D-glucose (FDG) Positron Emission Tomography/Computed Tomography (PET/CT) scan."
89495899|NCT05015881|Other|Echocardiogram + PET FDG scanning visit.|Subjects will complete a echocardiogram + PET scanning visit. 2-Deoxy-2-[18F] fluoro-D-glucose (FDG) Positron Emission Tomography/Computed Tomography (PET/CT) scan.
89495900|NCT04981392|Experimental|Multi-component patient and provider intervention to promote COVID-19 vaccination|
89495901|NCT04981392|No Intervention|Usual care|Patients will receive usual care
89495902|NCT04979676|Experimental|Cognitive Therapy|Experimental group subjected to active individual psychotherapy based on developing skills relating to flexibility of attention, which in turn sustains adolescents adopting a more realistic perspective on social events and acting based on external (and not only internal) social information. Assessed weekly during the intervention period on symptom change. Also assessed at pre-intervention, post-intervention (i.e., 10 to 12 weeks later), 12-weeks follow, and 24-weeks follow-up.
89495903|NCT04979676|Experimental|Compassion-focused Therapy|Experimental group subjected to active individual psychotherapy based on developing skills relating to flexibility of attention, which in turn sustains adolescents adopting a more realistic perspective on social events and acting based on external (and not only internal) social information. Assessed weekly during the intervention period on symptom change. Also assessed at pre-intervention, post-intervention (i.e., 10 to 12 weeks later), 12-weeks follow, and 24-weeks follow-up.
89495904|NCT04979676|Experimental|Acceptance and Commitment Therapy|Experimental group subjected to active individual psychotherapy based on developing skills for acceptance, defusing, and focusing on the present moments, which in turn sustain acting in social events in line with ones valued actions instead of prioritizing the avoidance of negative internal experiences). Assessed weekly during the intervention period on symptom change. Also assessed at pre-intervention, post-intervention (i.e., 10 to 12 weeks later), 12-weeks follow, and 24-weeks follow-up.
89495905|NCT04979676|Placebo Comparator|Waiting-list control|Group of participants with a main dignosis os social anxiety disorder not subjected to any psychological intervention within the current trial. Assessed at time 0, then at time 1 ten to twelve weeks after time 1, then again at time 3 twelve weeks later, and then again at time 4 another twelve weeks later (i.e., 24 weeks after time 1).
88955100|NCT01979289|Active Comparator|Computer Treatment: Control|Computerized Cognitive Remediation: Non-targeted
88955101|NCT01979302|Experimental|Depression CAREPATH|Patients receiving care from Nurses trained in depression care management
88955102|NCT01979302|Other|Usual Care|Patients under the care of nurses who were trained in depression assessment and usual care
88955103|NCT01979328|Experimental|Study arm|geko neuromuscular electrostimulation
88955104|NCT01979341|Active Comparator|Dual trigger|final oocyte maturation trigger using 6500 IU Ovitrelle (hCG) plus 0.2mg triptorelin acetate (GnRH agonist)
88955105|NCT01979341|Active Comparator|hCG trigger|final oocyte maturation trigger using 6500 IU Ovitrelle (hCG)
88955106|NCT01979341|Active Comparator|agonist trigger|final oocyte maturation trigger using 0.2mg triptorelin acetate (GnRH agonist)
88955107|NCT01979354|Active Comparator|Spinal morphine|0.15 mg spinal morphine
88955108|NCT01979354|No Intervention|Control|No spinal morphine
88955109|NCT01979380|Experimental|KD101|
88955110|NCT01979380|Placebo Comparator|placebo|
88955111|NCT01979419||cognitively normal|MRI scans, PET scans, lumbar puncture
88955112|NCT01979419||mild cognitive impairment|MRI scans, PET scans, lumbar puncture
88955113|NCT01979419||Alzheimer's Disease|MRI scans, PET scans, lumbar puncture
88955114|NCT01979419||vascular MCI|MRI scans, PET scans, lumbar puncture
88955115|NCT01979419||subcortical ischemic vascular dementia|MRI scans, PET scans, lumbar puncture
88955116|NCT01979432|Other|Cardiovascular evaluation|Measure of the index of systolic pressure Echo doppler Echography Measure of the speed of the wave of pulse and the central pressure
88955117|NCT01979458|Experimental|PSE|Patients whose distal colon is imaged using the PSE device. This is a pilot trial of 30 patients.
89495906|NCT04946396|Experimental|dexmedetomidine intravenous infusion|Patients who will receive continuous intraoperative infusion of dexmedetomidine hydrochloride (0.5 µg/kg/h).
88955118|NCT01979471|Other|Advanced care|For all the patients randomized to the advanced care group the pharmacist will complete a Comprehensive Annual Care Plan (CACP) or Standard Medication Management Assessment (SMMA)
88955119|NCT01979471|No Intervention|Usual Care|"Patients randomized to the usual care group will receive:~Usual pharmacy care with no specific interventions for 3 months~At the end of the 3 months of the usual care period, all patients will cross over to receive the advanced care outlined above for 3 months"
88955120|NCT01979484|Experimental|PPI-668 capsule followed by tablet|On day 1 two 100 mg PPI-668 capsules will be administered; on day 8 one 200 mg PPI-668 tablet will be administered
88955121|NCT01979484|Experimental|PPI-668 tablet followed by capsule|On day 1 one 200 mg PPI-668 tablet will be administered; on day 8 two 100 mg PPI-668 capsules will be administered
88955122|NCT01979497|Active Comparator|Suture with Adhesive Stripping|Buried dissolving subcuticular sutures are sued for both sides of the wound to approximate wound edges and then steri-strips for the adhesive stripped half of the scar is applied.
88955123|NCT01979497|Active Comparator|Suture without Adhesive Stripping|Buried dissolving subcuticular sutures are sued for both sides of the wound to approximate wound edges and then no closure material for the half of the scar is applied.
89495907|NCT04946396|Sham Comparator|0.9% saline solution intravenous infusion|Patients who will receive continuous infusion of 0.9% saline solution (sham group).
89495908|NCT04932135||Group Treatment|Patients with newly diagnosed hyperthyroidism due to Graves' disease, if anti thyroid drug treatment is planned.
89495909|NCT04932135||Group Surveillance|Patients suffering from Graves' disease in whom discontinuation of the anti-thyroid therapy is planned.
89495910|NCT04910750|Active Comparator|Intervention Arm 1 - Pulse oximetry and Clinical Decision Support Algorithm|Facilities in intervention arm 1 will be provided with handheld pulse oximeters and tablet-based clinical decision support algorithms, with pulse oximetry, CDSA and IMCI refresher training
89495911|NCT04910750|Active Comparator|Intervention Arm 2 - Pulse oximetry alone|Facilities in intervention arm 2 will be provided with handheld pulse oximeters and paper-based guidance (pulse oximetry job aid and IMCI chart booklet integrating pulse oximetry), with pulse oximetry and IMCI refresher training
89495912|NCT04910750|No Intervention|Control Arm - Routine Primary Health Care|Facilities in the control arm will be provided with IMCI refresher training
89495913|NCT04905134|Active Comparator|Patients evaluated using flexible nasopharyngoscope prototype device|
89495914|NCT04905134|No Intervention|Patients evaluated using standard of care nasopharyngoscope|
89495915|NCT04905134|Active Comparator|Providers using flexible nasopharyngoscope prototype device|
88955124|NCT01979510|Experimental|MK-0663B|MK-0663B (etoricoxib 90 mg immediate release [IR]/tizanidine 6 mg modified release [MR]) capsules once daily for 8 days.
88955125|NCT01979510|Experimental|DOLOCAM PLUS®|DOLOCAM PLUS® (meloxicam 7.5mg/methocarbamol 215mg) capsules once daily for 8 days.
88955126|NCT01979549||Sedation|patients underwent upper gastrointestinal endoscopy with sedation
88955127|NCT01979549||non-sedation|patients underwent upper gastrointestinal endoscopy without sedation
88955128|NCT01979562||100 runners|Male runners between 18-60 years.
89495916|NCT04892875|Experimental|Concurrent Cisplatin/Radiation Therapy + Zimberelimab (Cohort 1)|Concurrent weekly cisplatin with radiation and zimberelimab therapy followed by adjuvant zimberelimab
89495917|NCT04892875|Experimental|Concurrent Cisplatin/Radiation Therapy + Zimberelimab + Etrumadenant (Cohort 2)|Concurrent weekly cisplatin with radiation + etrumadenant + zimberelimab with adjuvant combined etrumadenant + zimberelimab
89495918|NCT04892875|Active Comparator|Concurrent Cisplatin/Radiation Therapy|Concurrent weekly cisplatin with radiation therapy control arm
89495919|NCT04886596|Experimental|RSVPreF3 Group|Participants in this group received a single dose of the RSVPreF3 OA vaccine at Day 1. Before the second vaccination participants were re-randomized into 2 groups: participants in one receiving an additional dose of RSVPreF3 OA vaccine before Season 2; participants in the other receiving a dose of placebo before Season 2.
89495920|NCT04886596|Placebo Comparator|Placebo Group|Participants in this group received 1 dose of placebo at Day 1 and received an additional dose of placebo before Season 2.
89495921|NCT04881045|Experimental|Dose Escalation (Part 1)|Participants will receive PF-07257876 at escalating dose levels.
89495922|NCT04881045|Experimental|Dose Expansion (Part 2) - Cohort 1 (NSCLC)|Participants with non-small cell lung cancer (NSCLC) will receive PF-07257876 at the recommended dose from Part 1.
89495923|NCT04881045|Experimental|Dose Expansion (Part 2) - Cohort 2 (SCCHN)|Participants with squamous cell carcinoma of the head and neck (SCCHN) will receive PF-07257876 at the recommended dose from Part 1.
89495924|NCT04864665|Experimental|Formula fed|0 - 6 months: a formula with prebiotics and milk fat (Stage 1); >6 - 12 months: a formula with prebiotics and milk fat (Stage 2); >1 - 2 years: a formula with prebiotics and milk fat (Stage 3)
89495925|NCT04839380|Experimental|Treatment Group : Ruxolitinib|ruxolitinib cream 1.5% will be applied twice daily as a thin film.
89495926|NCT04836585|No Intervention|Care As Usual|Participants in the control condition are followed by their RLS psychiatrists during the study as per usual care.
89495927|NCT04836585|Experimental|eMBC Intervention|Participants in the intervention arm are followed by their RLS psychiatrists during the study at clinically appropriate intervals with the addition of eMBC.
89495928|NCT04828980|Active Comparator|Mindfulness Virtual Reality Experience|Patients will be provided with a mindfulness VR experience for use up to 15 minutes at bedside.
88955129|NCT01979588|Placebo Comparator|Control|Providers do not have access to What's Going Around Tool but receive an instructional video explaining tool
89538120|NCT03194659|Experimental|Supplemental Choline|Administration of the deuterated choline chloride will take place in a grape juice cocktail solution. For individuals in the experimental arm of the trial, supplemental choline chloride will be added to the cocktail.
89538121|NCT03282929|Experimental|Part 1 Group 1|A single dose of 500 μg epinephrine (0.5 mL Suprarenin®) will be administered i.m. and s.c. by using a needle and a syringe in randomized order.
89538122|NCT03282929|Experimental|Part 2 group 1|300 μg epinephrine auto-injector (Emerade, Bausch and Lomb, 23 mm needle length)
89538123|NCT03282929|Experimental|Part 2 Group 2|500 μg epinephrine auto-injector (Emerade, Bausch and Lomb, 23 mm needle length)
89538124|NCT03282929|Experimental|Part 2 Group 3|300 μg epinephrine auto-injector (Fastjekt, MEDA Pharma, 16 mm needle length)
88955130|NCT01979588|Active Comparator|What's Going Around Tool|Provider has access to What's Going Around Tool. Provider also shown a video explaining how to use Tool
88955131|NCT01979601|Experimental|Patient: LGT209 0.3 mg/kg|0.3 mg/kg LGT209 intravenous administration in patients on stable doses of statins
88955132|NCT01979601|Experimental|Patient: LGT209 1 mg/kg|1 mg/kg LGT209 intravenous administration in patients on stable doses of statins
88955133|NCT01979601|Experimental|Patient: LGT209 3 mg/kg|3 mg/kg LGT209 intravenous administration in patients on stable doses of statins
88955134|NCT01979601|Experimental|Patient: LGT209 10 mg/kg|10 mg/kg LGT209 intravenous administration in patients on stable doses of statins
88955135|NCT01979601|Experimental|Patient: LGT209 20 mg/kg|20 mg/kg LGT209 intravenous administration in patients on stable doses of statins
88955136|NCT01979601|Experimental|Healthy Volunteers: LGT209 0.3 mg/kg|0.3 mg/kg LGT209 intravenous administration in healthy volunteers
88955137|NCT01979601|Experimental|Healthy Volunteers: LGT209 1 mg/kg|1 mg/kg LGT209 intravenous administration in healthy volunteers
88955138|NCT01979601|Experimental|Healthy Volunteers: LGT209 3 mg/kg|3 mg/kg LGT209 intravenous administration in healthy volunteers
88955139|NCT01979601|Experimental|Healthy Volunteers: LGT209 10 mg/kg|10 mg/kg LGT209 intravenous administration in healthy volunteers
88955140|NCT01979601|Experimental|Healthy Volunteers: 20 mg/kg|20 mg/kg LGT209 intravenous administration in healthy volunteers
88955141|NCT01979601|Placebo Comparator|Patient: Placebo|Matching intravenous placebo in patients on stable doses of statins
88955142|NCT01979601|Placebo Comparator|Healthy Volunteers: Placebo|Matching intravenous placebo in healthy volunteers
88955143|NCT01979627|Experimental|transulnar approach group|Patients in transulnar group received interventional procedure through ulnar artery
88955144|NCT01979627|Other|transradial approach group|patients in transradial group received interventional procedure through radial artery
89022612|NCT06189326|Active Comparator|non-penetrating deep sclerectomy|
89538125|NCT03282929|Experimental|Part 2 Group 4|300 μg epinephrine auto-injector (Jext, Alk-Abelló, 15 mm needle length)
89538126|NCT02445547|Experimental|UC-MSCs|UC-MSCs by peripheral intravenous infusion
89538127|NCT02445547|Active Comparator|control|received hormone maintenance therapy
89538128|NCT03285815|Experimental|Proton Therapy 60 CGE|60 CGE (3CGE X 20) for 4wks
89538129|NCT03285815|Experimental|Proton Therapy 47 CGE|47 CGE (4.7CGE X 10) for 2wks
89538130|NCT03194191|Experimental|Regular acupuncture needles|"Real acupuncture procedure The real acupuncture will be performed by means of standard stainless-steel needles (0.30-mm diameter, 30-mm length/Gauge 8 x 1.2), located bilaterally in 5 real acupoints."
89538131|NCT03194191|Sham Comparator|Sham acupuncture needles|Sham acupuncture with a no penetrating sham needle (blunt and telescopic), giving the impression of insertion but without penetrating the skin will be placed bilaterally in 5 false acupoints
89538132|NCT03282851|Experimental|MSB11456|
89538133|NCT03282851|Active Comparator|US-licensed Actemra|
88955145|NCT01979640|Experimental|39 Fr double lumen group|patients are assigned to 35 Fr, 37 Fr, 39 Fr double lumen tube group according to their left main bronchus diameter measured by preoperative chest CT, to minimize difference between main bronchus diameter and bronchial tip diameter of double lumen tube
88955146|NCT01979640|Experimental|37 Fr double lumen group|patients are assigned to 35 Fr, 37 Fr, 39 Fr double lumen tube group according to their left main bronchus diameter measured by preoperative chest CT, to minimize difference between main bronchus diameter and bronchial tip diameter of double lumen tube
88955147|NCT01979640|Experimental|35 Fr double lumen tube group|patients are assigned to 35 Fr, 37 Fr, 39 Fr double lumen tube group according to their left main bronchus diameter measured by preoperative chest CT, to minimize difference between main bronchus diameter and bronchial tip diameter of double lumen tube
88955148|NCT01979653|Experimental|dexmedetomidine alone|dexmedetomidine 0.5 mcg/kg for 10 min + normal saline (volume-matched) bolus + dexmedetomidine 0.2-0.4 mcg/kg/hr infusion
88955149|NCT01979653|Experimental|dexmedetomidine + midazolam|normal saline (volume-matched) for 10 min + midazolam 0.2 mg/kg bolus + dexmedetomidine 0.2-0.4 mcg/kg/hr infusion
88955150|NCT01979666|Experimental|study group|the patients that will get a nitrate patch
88955151|NCT01979666|Placebo Comparator|control group|the patients that will get the placebo patch
88955152|NCT01979679|Active Comparator|Lurasidone 80 mg per day|Lurasidone 80 mg per day
88955153|NCT01979679|Active Comparator|Lurasidone 120 mg per day|Lurasidone 120 mg per day
88955154|NCT01979679|Active Comparator|Lurasidone 160 mg per day|Lurasidone 160 mg per day
88955155|NCT01979692|Experimental|One arm ; CLM use in TTNB|"to determine the feasibility of using the CLM in performing TTNB of thoracic and mediastinal lesions~to obtain imaging criteria for distinguishing viable from non viable (necrotic) tissue and normal versus abnormal (inflammatory/malignant) lesions. On site rapid cytological examination (ROSE) will be the standard of biopsy quality.~the results will be compared to historic data of standard biopsies as to yield and quality of sampling"
88955156|NCT01979718|Experimental|Full term intervention|"random selection~composed of the daily standard physical treatment and 1 session per one day over two weeks with a break on Saturday and Sunday (1 session is consisted of 50 repetitions of voluntary simultaneous flexion and extension of the both knees, taking a look at the mirrored virtual reality simulating the surgeried knee."
88955157|NCT01979718|Active Comparator|Half term intervention|"random selection~composed of the daily standard physical treatment over two weeks and 1 session per one day over one weeks with a break on Saturday and Sunday (1 session is consisted of 50 repetitions of voluntary simultaneous flexion and extension of the both knees, taking a look at the mirrored virtual reality stimmulating the surgeried knee )"
88955158|NCT01979731|Experimental|Job rotation|The intervention group will perform rotation function, switching between tasks with low, moderate and high ergonomic risk and different requests for ergonomic body region added to ergonomic guidelines.
88955159|NCT01979731|Active Comparator|Guidelines Ergonomics|Manual material handling Orientation posture Orientation furniture Orientation in general
88955160|NCT01979744|Experimental|Resolute Integrity - IVUS|Resolute Integrity - IVUS arm
88955161|NCT01979744|Active Comparator|Resolute Integrity - Angio|Resolute Integrity - Angio arm
88955162|NCT01979744|Active Comparator|Promus - Angio|Promus - Angio arm
88955163|NCT01979744|Active Comparator|Promus - IVUS|Promus - IVUS arm
88955164|NCT01979757|Active Comparator|Centrifugation|Patients recieved fatgraft processed by Centrifugation
88955165|NCT01979757|Active Comparator|Puregraft|Patients recieved fatgraft processed by Puregraft
88955166|NCT01979783||LBP|group of subjects with low back pain
88955167|NCT01979783||nonLBP|group without low back pain
88955168|NCT01979809|Sham Comparator|Arm 1|Untailored control website designed to support increase in fruit and vegetables with no age targeting used in previously funded MENU Choices study
88955169|NCT01979809|Active Comparator|Arm 2|MENU GenY age-targeted and tailored interactive website including 8 information sessions over 4 months, and options to visit over 185 recipes, videos, 4 bloggers, and information articles on dietary change topics
88955170|NCT01979809|Active Comparator|Arm 3|"Web intervention that is age targeted and tailored, identical to Arm 2, with the addition of personalized e-coaching support via email."
88955171|NCT01979822||PH patients with LenusPro pump|"Patient Inclusion Criteria:~Patient aged ≥ 18 years;~diagnosed with Pulmonary Arterial Hypertension (WHO) Category Group 1~Patient is in stable clinical condition and~the previous specific PH medication has been retained unchanged during the past 3 weeks"
88955172|NCT01979848||MRI Mapping Group|After Subjects arrive at the MRI facility, subjects will fill out a medical questionnaire that will be used to determine whether a MRI study can be performed. The investigators will determine whether there are any problems that make the subject not suitable for participating in this study.
88955173|NCT01979861|Experimental|vapor endometrial ablation|endometrial ablation using the AEGEA Vapor System
88955174|NCT01979874|Experimental|Pro-Omega|High-dose, short-duration dietary omega-3 fatty acids supplementation; 325mg of EPA and 225mg of DHA per capsule. 4.4gm/day x 3 months (Nordic Naturals, Watsonville, CA, USA)
89495929|NCT04828980|Active Comparator|Gaming Virtual Reality Experience|Patients will be provided with an active gaming VR experience for use up to 15 minutes at bedside.
89495930|NCT04828109|Active Comparator|VR and Fitbit|Daily VR use every 3 hours up to 30 minutes at a time and Fitbit daily step goal of 2,000 steps
89495931|NCT04828109|Active Comparator|VR Only|Daily VR only. Daily VR use every 3 hours up to 30 minutes at a time.
89495932|NCT04828109|Active Comparator|Fitbit Only|Fitbit daily step goal of 2,000 steps.
89495933|NCT04828109|No Intervention|Control|Standard of care
89495934|NCT04818866||Patients hospitalized for Covid-19|
89495935|NCT04817826|Experimental|Cohort 1|"Pre-operative treatment with tremelimumab 300 mg single administration (day 1) and durvalumab 1500 mg Q4W for 3 cycles (day 1, 29 and 57).~Patients in Cohort 1 will undergo standard gastrectomy with D2 lymphadenectomy and then they will be followed by an active follow-up every 12 weeks for two years and then a standard follow-up every six months until the end of the fifth year from surgery."
89495936|NCT04817826|Experimental|Cohort 2|"Pre-operative treatment with tremelimumab 300 mg single administration (day 1) and durvalumab 1500 mg Q4W for 3 cycles (day 1, 29 and 57).~In Cohort 2, patients with no evidence of complete clinical response will undergo standard gastrectomy with D2 lymphadenectomy and then they will be followed up. Patients with complete clinical response will undergo a non-operative management (NOM) with an active follow-up phase every 12 weeks for two years, followed by standard follow-up every six months until the end of the fifth year. At any time during follow-up, in case of clinical suspicion or confirmation of residual gastric cancer, patients will undergo standard surgery according to the clinical practice at their Centre."
89495937|NCT04798248|Experimental|Momentary Affect Regulation - Safer Sex Intervention|Momentary Affect Regulation - Safer Sex Intervention (MARSSI) is the treatment condition. MARSSI aims to enhance an individual's motivation to change risk behaviors, provides skills to address depression's effects on behavior, and prompts and reinforces healthy affect regulation, cognitive behavioral skill use, and behavior change in daily life.
89495938|NCT04798248|Sham Comparator|Podcast Health Group|The Podcast Health Group is the control counterfactual condition.
89495939|NCT04794842|Active Comparator|Tetracaine|Patients will be positioned in supine position at this time 0.5% tetracaine drops will be used to fill the ear canal. Tetracaine will then be allowed to stay in place for approximately 10 to 15 minutes with the patient's head positioned with affected ear up. After this, using an operative microscope the drops will be removed from the ear canal with suction.
89495940|NCT04794842|Active Comparator|Phenol|Patients will be positioned in supine position and tympanic membrane visualized with operative microscope. Phenol applicator will be used to topically apply 90% phenol to the injection site (posterior/Inferior aspect of tympanic membrane).
89022613|NCT06189326|Active Comparator|primary combined trabeculotomy-trabeculectomy|
89022614|NCT06189287||Participants|Patient of legal age agreeing to answer an anonymous questionnaire on their knowledge of clinical research given at the anesthesia consultation for scheduled surgery
89022615|NCT06189274|Experimental|Anatomy-Based Electrode Selection|For individuals in the anatomy-based electrode (ABE) group, magnetic resolution imaging (MRI) or computed tomography (CT) scans will be evaluated by MED-EL Canada employees. Based on these results, an appropriate electrode array will be selected.
89205175|NCT00759941|Active Comparator|Xalatan + Placebo|Xalatan dosed once a day at 10 pm, with placebo dosed three times a day at 8 AM, 2 PM, and 10:05 PM concomitantly for 3 months.
89205176|NCT00915863|Active Comparator|Billroth-II-type|Billroth-II-type reconstruction after pancreaticoduodenectomy
89205177|NCT00915863|Experimental|Isolated Roux-en-Y|Isolated Roux-en-Y type reconstruction after pancreaticoduodenectomy
89205178|NCT00528424|Experimental|AA4500 0.58 mg|
89205179|NCT00315445|Placebo Comparator|Placebo|Placebo oxycodone (OXY)/acetaminophen (APAP) tablets and placebo transdermal patch (TDS) 5, 10, or 20
89205180|NCT00315445|Active Comparator|OXY/APAP|5 mg oxycodone/325 mg acetaminophen tablets
89205181|NCT00315445|Experimental|BTDS|Buprenorphine transdermal patch 5, 10, or 20 mcg/hour
89205182|NCT03687736|Other|AbobotulinumtoxinA|Open-label
89205183|NCT04861324|No Intervention|Prenatal Care/Nutrition Education|Standard prenatal care with primary care physician with USDA-based federal guidelines
89205184|NCT04861324|Experimental|Fruit/veggie + postprandial physical activity|Nutrition education on increasing fruit and vegetable consumption and physical education on increasing postprandial physical activity for the duration from GDM diagnosis till delivery
89205185|NCT04857580|Experimental|CTS device|
89205186|NCT04857580|No Intervention|Control|
89205187|NCT00779675||Infliximab 5 mg/kg|
89205188|NCT03980119|Experimental|HITSystem 3.0 Intervention|All HIV-positive children and their caregivers attending health facilities randomized to the HITSystem intervention arm will be monitored by the HITSystem. In the event that the child misses an appointment or a scheduled laboratory test, or the child's laboratory results suggest ART treatment failure, an automated SMS text message and alert will be generated in the HITSystem that will notify the child's health care provider. The child's caregiver will also receive a text message asking them to return to the clinic with the child. If the child is 16 years of age and considered an independent adolescent without a caregiver, the same process will be implemented, with the text messages being sent directly to the child. If the child's caregiver, or the independent adolescent, does not have a mobile phone, the health care provider will notify the community health worker (CHW) to trace the individual and visit them in their home.
89205189|NCT03980119|No Intervention|Control|All HIV-positive children and their caregivers attending health facilities randomized to the Control arm will receive HIV/AIDS standard of care.
89205190|NCT01066975||young and fit|5 healthy subjects, age lower than 30 yrs and high physical fitness
89205191|NCT04097093||Study 62005-STBSG patients treated with imatinib > 10 years|
89205192|NCT04097171|Experimental|High Carbohydrate Diet|Participants will consume a high carbohydrate diet (65-75% of total energy intake). Protein intake will be standardized at 15% of total energy intake.
89205193|NCT04097171|Experimental|Ketogenic Diet|Participants will consume a low carbohydrate diet (<5-10% of total energy intake). Protein intake will be standardized at 15% of total energy intake.
89205194|NCT00759863|Experimental|Lifezig|Subjects watch personalized reminiscence video channels developed by program staff with the help of family members/caregivers (using the LifeZig system)
89205195|NCT00759863|No Intervention|Usual Care|Subjects follow routine activities applied by nurses or caregivers, such as traditional reminiscence, crafts, singing, recreational activities, and other activities.
89205196|NCT03998722|Experimental|Vagivital|Vagivital once Daily for 12 weeks
89205197|NCT04102943|Experimental|Tacrolimus1|Tacrolimus tablet Orally, twice a day in the morning and night After first dose 0.1mg/kg, check the blood concentration of tacrolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 7~12ng/ml for 0 to 3months and then at 5~8ng/ml for 3 to 6months of study treatment.
89205198|NCT04102943|Active Comparator|Tacrolimus2|Tacrolimus Cap Orally, twice a day in the morning and night After first dose 0.1mg/kg, check the blood concentration of tacrolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 7~12ng/ml for 0 to 3months and then at 5~8ng/ml for 3 to 6months of study treatment.
89205199|NCT00759785|Experimental|ER-positive Luminal B|Single dose of dalotuzumab 20 mg/kg infused intravenously over 60-120 minutes.
89205200|NCT00759785|Experimental|Triple Negative|Single dose of dalotuzumab 20 mg/kg infused intravenously over 60-120 minutes.
89205201|NCT00300781|Experimental|Neratinib 240 mg, with prior trastuzumab|Neratinib administered with 80 mg capsules and 40 mg coated tablets taken orally in prescribed dose of 240 mg daily, as long as tolerated and disease does not worsen.
89205202|NCT00300781|Experimental|Neratinib 240 mg, no prior trastuzumab|Neratinib administered with 80 mg capsules and 40 mg coated tablets taken orally in prescribed dose of 240 mg daily, as long as tolerated and disease does not worsen.
89206306|NCT00827658|Active Comparator|Volar Wrist Block|Volar Wrist block group. Local anesthetic is placed at this location in this study group. The same local composition (Intervention) is used for both study groups. The trial is a comparison of location not the Intervention.
89538134|NCT03282851|Active Comparator|EU-approved RoActemra|
89495941|NCT04794647|Experimental|cervical mobilization|'Rotation mobilization' was applied to the symptomatic segment / segments after the detailed evaluation (symptom localization tests, cervical region safety tests, joint play tests, pain provocation/alleviation tests) in accordance with the Kaltenborn-Evjenth system in cervical region. Five series of 45-s mobilizations were performed with 15 s of rest. Each patient received 6 treatment sessions over a period of 3 week.
88955175|NCT01979874|Placebo Comparator|Placebo|Pro-Omega Placebo soybean capsules (Nordic Naturals, Watsonville, CA, USA); 4.4gm/day x 3 months
89495942|NCT04794647|Placebo Comparator|placebo mobilization|Placebo mobilization was applied to the cervical region in the same position and the same grip with the mobilization group. The physiotherapist put her hand on a randomly selected faset without any pushing or pulling, The duration of placebo mobilization was the same as the duration of the other group. Each patient received 6 treatment sessions over a period of 3 week.
88955176|NCT01979887||Non-MGD Participants|Participants without MGD who have meibum expressed as per protocol. No investigational drug is administered in this study.
88955177|NCT01979887||Mild-Moderate MGD Participants|Participants with Mild-Moderate MGD who have meibum expressed as per protocol. No investigational drug is administered in this study.
88955178|NCT01979887||Severe MGD Participants|Participants with Severe MGD who have meibum expressed as per protocol. No investigational drug is administered in this study.
88955179|NCT01979900|Experimental|Vaccae|Experiment group:One vial of Vaccae diluted with 1.0ml sterile water for injection, take deep coxal muscle injection after shaking well, once every 2 weeks, 6 times totally.
88955180|NCT01979900|Placebo Comparator|Placebo|Placebo group:One vial of placebo diluted with 1.0ml sterile water for injection, take deep coxal muscle injection after shaking well, once every 2 weeks, 6 times totally
88955181|NCT01979913|Experimental|Patients with POAG or OHT|Patients with primary open angle glaucoma or ocular hypertension
89495943|NCT04788147|Experimental|Cohort I: RRFD Cohort|Cohort I seeks to identify the Recommended RefleXion FDG dose (RRFD), which is the dose of administered FDG that allows for functioning of the RefleXion system. This phase of the investigation seeks to optimize the balance between minimizing patient exposure to the radiotracer and achieving satisfactory performance of the RMRS PET subsystem for BgRT. The dose levels of 15 mCi and 20 mCi (if required) will be assessed sequentially in an escalation protocol. To determine the RRFD, a modified 3+3 design will be utilized wherein meeting the Activity Concentration threshold - not dose-limiting toxicity as is typically used - will be the relevant criteria for escalating from one dose to the next. Up to 12 participants will be enrolled in Cohort I, and will undergo one RMRS imaging session and one third-party Positron Emission Tomography (PET) /CT imaging session.
89531773|NCT05391256|Experimental|Automated flying Drone carrying an Automated external defibrillator (AED)|Totally six drone systems are setup to be deployed in suspected OHCA cases as a complement to EMS. This is a single-arm intervention evaluating referral of bystanders during 112-calls to retrieve drone delivered AEDs in suspected OHCA.
89531774|NCT05388656|Experimental|Estradiol, Then Placebo|Participants will first receive 0.1 mg/day of transdermal estradiol patch for 3 weeks. After a washout period of 3 weeks, participants will then receive transdermal placebo patch (matching transdermal estradiol 0.1 mg/day patch) for 3 weeks. Upon completion of the second intervention, all participants will receive 200 mg/day of progesterone for 10 days.
89538135|NCT02444065|Experimental|Cognitive Behavior Therapy (CBT)|In this arm, participants receive the Cognitive behavior therapy (CBT) intervention as an augmentative treatment to standard day hospital treatment as usual.
88955182|NCT01979926|Experimental|N02RS1 200mg|Combination of Broussonetia spp and Lonicera spp
88955183|NCT01979926|Experimental|N02RS1 400mg|Combination of Broussonetia spp and Lonicera spp
88955184|NCT01979926|Placebo Comparator|Placebo|Sugar pill
88955185|NCT01979965|Active Comparator|Active drug|Ranolazine therapy for three months
88955186|NCT01979965|Placebo Comparator|Sugar Pill|sugar pill therapy for three months
88955187|NCT01979978|Experimental|Healthy Buddies Curriculum|Healthy buddies curriculum delivered by older peers weekly covering three components of healthy living: Physical activity, healthy eating and a healthy body image.
88955188|NCT01979978|No Intervention|Control|This group received standard school curriculum.
88955189|NCT01979991|Experimental|CT Imaging and Reconstruction|To develop a MBIR (model-based image reconstruction) method that will improve X-ray CT lung imaging by improving image quality and reducing dose.
88955190|NCT01980004|Experimental|Dietary Education|Participants in this treatment arm will undergo dietary counseling for the prevention of kidney stone formation.
88955191|NCT01980004|Experimental|Potassium Citrate and Dietary Education|Participants in this treatment arm will undergo potassium citrate supplementation and dietary counseling for the prevention of kidney stone formation.
88955192|NCT01980030|Experimental|Romiplostim|Weekly Romiplostim for 12 weeks with intra-patient weekly dose escalation from 1µg/Kg to a maximum dose of 10 µg/Kg with a dose reduction schema in case of platelet overshoot
88955193|NCT01980043|Other|Rectal Prolapse|endoluminal rectal prolapse repair under sedation and local anesthesia using CO2 colonoscopy to fix the rectum with sutures to the abdominal wall under needlescopic control.
88955194|NCT01980069|Experimental|Neostigmine arm|Neostigmine arm
88955195|NCT01980069|Active Comparator|Sugammadex arm|Sugammadex arm
88955196|NCT01980082|Active Comparator|Cefazolin|"Cefazolin~1 gram/2 gram if body mass index > 40 - one time dose, 30-60 min prior to incision."
88955197|NCT01980082|Placebo Comparator|Placebo|1 dose of placebo - NaCl 0.9% with no drugs added to it.
88955198|NCT01980108|No Intervention|empty stomach|No fluid will be given to the patient prior to scanning.
88955199|NCT01980108|Experimental|50mL|50mL of water will be given to the patient prior to scanning
88955200|NCT01980108|Experimental|100mL|100mL of water will be given to the patient prior to scanning
88955201|NCT01980108|Experimental|200mL|200mL of water will be given to the patient prior to scanning
88955202|NCT01980108|Experimental|300mL|300mL of water will be given to the patient prior to scanning
88955203|NCT01980108|Experimental|400mL|400mL of water will be given to the patient prior to scanning
88955204|NCT01980121||Term pregnant patients|Term pregnant patients for scheduled elective cesarean section will be examined using a portable ultrasound machine to evaluate gastric contents.
88955205|NCT01980160|Active Comparator|Activated Nometex Device|Nometex Device that is activated so will be sending electrical pulses to the median nerve which will travel through afferent nerve fibers to the emetic centers of the brain. It is in these areas that the neurotransmitters modulate signals going to the stomach via the Vagus nerve. These electrical signals normalize the stomach rhythms, thereby alleviating nausea and vomiting.
88955206|NCT01980160|Sham Comparator|Unactivated Nometex Device|The Nometex device will not be activated and therefore have no effect on the nausea/vomiting associated with chemotherapy.
88955207|NCT01980173|Experimental|With Bakri balloon|"Patients randomized to this arm will be treated using the Bakri balloon.~Intervention: Bakri balloon"
88955208|NCT01980173|Active Comparator|Without Bakri balloon|"Patients randomized to this arm will receive routine care not including the Bakri Balloon.~Intervention: Routine Care"
88955209|NCT01980186||Individuals with autism|Both individuals with autism and their siblings will be evaluated with (TUS)transcranial 2D ultrasound.
88955210|NCT01980186||Siblings of individuals with autism|Non-autistic siblings with no other obvious health issues will be screened
88955211|NCT01980199|Experimental|Fexinidazole|"600mg tablets~3 tablets once a day for 4 days continued by 2 tablets once a day for 6 days"
88955212|NCT01980212||first line advanced non-small cell lung cancer|patients newly diagnosed advanced non-small cell lung cancer, and received platinum based chemotherapy in Hunan Province Tumor Hospital
88955213|NCT01980225|Experimental|Collapse|This arm includes the patients where laser-induced collapse (=artificial shrinkage) of all blastocysts is performed before vitrification
88955214|NCT01980225|No Intervention|control|This control arm includes the patients of which the blastocysts are vitrified without performing collapse
88955215|NCT01980238|Experimental|cannula ileostomy|After LAR, experimental group will accept cannula ileostomy. Operation has described in the Detailed Description.
88955216|NCT01980238|Active Comparator|loop ileostomy|After LAR, active comparator group will accept loop ileostomy. This operation is well known by colorectal surgeons.
88955217|NCT01980277|Experimental|LY2780301 + paclitaxel|"The following dose-levels will be investigated:~Continuous daily PO LY2780301 400 mg QD + weekly paclitaxel 70 mg/m²/week~Continuous daily PO LY2780301 400 mg QD + weekly paclitaxel 80 mg/m²/week~Continuous daily PO LY2780301 500 mg QD + weekly paclitaxel 80 mg/m²/week~A dose reduction could be explored:~- Continuous daily PO LY2780301 300 mg QD + weekly paclitaxel 70 mg/m²/week"
88955218|NCT01980303|Experimental|Cohort 1: Treatment A|Japanese participants will receive 1 spray of esketamine solution in each nostril (total dose: 28 mg).
88955219|NCT01980303|Experimental|Cohort 1: Treatment B|Japanese participants will receive 1 spray of esketamine solution in each nostril at time 0 and 5 minutes (total dose: 56 mg).
88955220|NCT01980303|Experimental|Cohort 1: Treatment C|Japanese participants will receive 1 spray of esketamine solution in each nostril at time 0, 5, and 10 minutes (total dose: 84 mg).
88955221|NCT01980303|Experimental|Cohort 2: Treatment A|Caucasian participants will receive 1 spray of esketamine solution in each nostril (total dose: 28 mg).
88955222|NCT01980303|Experimental|Cohort 2: Treatment B|Caucasian participants will receive 1 spray of esketamine solution in each nostril at time 0 and 5 minutes (total dose: 56 mg).
88955223|NCT01980303|Experimental|Cohort 2: Treatment C|Caucasian participants will receive 1 spray of esketamine solution in each nostril at time 0, 5 and 10 minutes (total dose: 84 mg).
88955224|NCT01980316|Experimental|Argatroban group|Argatroban in patients undergoing load 250μg/kg, followed by 15μg/kg/min continuous intravenous infusion.5 days after surgery, take 10mg intravenous infusion of speed 2/day
88955225|NCT01980316|Experimental|non-argatroban treated group|Patients in control group will receive Unfractionated heparin treatment
88955226|NCT01980329|Experimental|Maraviroc|single oral administration of 300 mg maraviroc
88955227|NCT01980368|Experimental|Group I (Tai Chi Easy)|Patients attend Tai Chi Easy class for 60 minutes once a week for 6 weeks. Patients also receive a DVD and exercise manual of Tai Chi Easy exercises and are encouraged to practice at home for 30 minutes most days per week for 6 weeks.
88955228|NCT01980368|Active Comparator|Group II (educational control)|Patients receive readings each week and attend a book club to discuss the readings for 60 minutes once a week for 6 weeks.
88955229|NCT01980394|Other|prospective cohort study|
88955230|NCT01980407|Experimental|SOL, single arm|S-1 combined with leucovorin and oxaliplatin
88955231|NCT01980420|Other|Sleeve gastrectomy|All patients will undergo sleeve gastrectomy
88955232|NCT01980433|Experimental|Active rTMS|Repetitive Transcranial Magnetic stimulation: 1 Hz rTMS, delivered to left somatosensory cortex during rest. Intervention is delivered during 20 minutes in one single session.
88955233|NCT01980433|Sham Comparator|Sham rTMS|Placebo Transcranial Magnetic stimulation delivered to left somatosensory cortex during rest. Intervention is delivered during 20 minutes in one single session.
88955234|NCT01980446|Other|1:Mismatch negativity|Presence of the mismatch negativity during the cortical auditory-evoked potential would predict a favorable outcome in comatose survivors after cardiac arrest.
88955235|NCT01980459|Experimental|Magnesium Lactate|Patients will receive 2 tablets twice a day of Magnesium Lactate for 3 months.
88955236|NCT01980472|Experimental|bevacizumab, carboplatin and paclitaxel|bevacizumab, carboplatin and paclitaxel
88955237|NCT01980498|Experimental|PecFent nasal spray|"Patients that have signed the ICF and met inclusion and exclusion criteria are randomly assigned 1:1 to receive one of the following IP-BTP treatments:~Fentanyl pectin nasal spray (FPNS)~Physician choice-Usual Care (PC-UC)"
88955238|NCT01980498|Active Comparator|Physician choice-Usual Care (PC-UC)|"Patients that have signed the ICF and met inclusion and exclusion criteria are randomly assigned 1:1 to receive one of the following IP-BTP treatments:~Fentanyl pectin nasal spray (FPNS)~Physician choice-Usual Care (PC-UC)"
89538136|NCT02444065|Active Comparator|Motivational Interviewing (MI)|In this arm, participants receive the Motivational Interviewing intervention as an augmentative treatment to standard day hospital treatment as usual.
89495944|NCT04788147|Experimental|Cohort II: Emulated Delivery Cohort|"After the RRFD is determined by Cohort I, Cohort II enrollment will start enrollment. Cohort II seeks to determine whether BgRT dose distributions generated from Limited Time Sample (LTS) RMRS PET images obtained at the time of treatment delivery are consistent with the approved BgRT plan. To achieve this objective, RMRS PET scans will be added to the SBRT workflow at timepoints representing some of the instances when the RMRS PET subsystem would be utilized during a BgRT workflow. Specifically, subjects will undergo RMRS PET collections at the time of planning, and then before the first and final fractions of their planned course of SBRT treatment.~Up to 22 participants will be enrolled in Cohort II, and will undergo three RMRS imaging sessions and one third-party Positron Emission Tomography (PET) /CT imaging session."
89495945|NCT04786262|Experimental|VX-880|
89495946|NCT04773041||Patients with DLB|Patients diagnosed with DLB enrolled from the HealthPartners Neuroscience Center.
89495947|NCT04773041||Patients with Alzheimer's disease (AD)|Patients diagnosed with AD age and sex-matched, selected from the ADNI database.
89495948|NCT04773041||Patients with normal cognition (CN)|Patients diagnosed with normal cognition age and sex-matched, selected from the ADNI database.
89495949|NCT04770155|Active Comparator|Beetroot juice (Aim 1a)|Upon arriving at the laboratory, participants will ingest 140 ml of beetroot juice containing a high (~12.8 mmol) concentration of nitrates (James White Drinks, Suffolk, UK).
89495950|NCT04770155|Placebo Comparator|Placebo (Aim 1a)|Upon arriving at the laboratory, participants will ingest 140 ml of beetroot juice containing a low concentration (~0.0055 mmol) of nitrates (James White Drinks, Suffolk, UK).
89495951|NCT04770155|Active Comparator|L-citrulline (Aim 1b)|Participants will receive pills containing 3 g of L-citrulline (Superior Labs, Park City, UT) to take twice daily for 7 days before the study visit.
89495952|NCT04770155|Placebo Comparator|Placebo (Aim 1b)|Participants will receive pills containing a placebo to take twice daily for 7 days before the study visit.
89495953|NCT04770155|Active Comparator|Sildenafil (Aim 1c)|Upon arriving at the laboratory, participants will ingest a liquid mixture containing Sildenafil (100 mg), an inhibitor of phosphodiesterase 5.
89495954|NCT04770155|Placebo Comparator|Placebo (Aim 1c)|Upon arriving at the laboratory, participants will ingest a liquid mixture containing a placebo.
89495955|NCT04770155|Active Comparator|Bosentan (Aim 2)|Upon arriving at the laboratory, participants will ingest a liquid mixture containing Bosentan (125 mg), a non-selective blocker of endothelin-1 receptors ETA and ETB.
89495956|NCT04770155|Placebo Comparator|Placebo (Aim 2)|Upon arriving at the laboratory, participants will ingest a liquid mixture containing a placebo.
89495957|NCT04757402|Active Comparator|Control arm|All eligible candidates will be receiving standard preoperative counselling as per the hospital standards and protocols. The patient will fill five-points Amsterdam Preoperative Anxiety and Information Scale (APAIS) form for anxiety evaluation and Seven-points Likert Scale form for satisfaction regarding the counselling.
89495958|NCT04757402|Experimental|NSQIP Arm|All eligible candidates will be receiving standard preoperative counselling as per the control arm PLUS the risk will be explained using the scores from the NSQIP surgical risk calculator. The anxiety and the satisfaction scores will be recorded as in the control arm.
89495959|NCT04753931|Experimental|Sensory Training in addition to Bobath Training|Exercises will be applied to the individuals participating in the study 3 days a week, 8 weeks, and 24 sessions in total. Exercises will be applied after the conventional therapy sessions.
89495960|NCT04753931|Experimental|Bobath Training|Exercises will be applied to the individuals participating in the study 3 days a week, 8 weeks, and 24 sessions in total. Exercises will be applied after the conventional therapy sessions.
89495961|NCT04753203|Experimental|A single arm study with Alpelisib plus Capecitabine|A phase lb/ll, open label, single arm study with Alpelisib plus Capecitabine in patients with PIK3CA mutant metastatic colorectal cancer
89495962|NCT04751955|Experimental|Olinvacimab plus Capecitabine|A single arm study with Olinvacimab plus Capecitabine
89495963|NCT04734080|Experimental|Dronabinol|57 subjects undergoing primary Total Knee Arthroplasty will be randomized to receive BID (2x/day) dosing of 5 mg of Dronabinol beginning on the day of surgery and with the final dose on the morning of POD (postoperative day) 2.
89495964|NCT04734080|Placebo Comparator|Placebo|57 subjects undergoing primary Total Knee Arthroplasty will be randomized to receive BID (2x/day) dosing of a non-active placebo pill beginning on the day of surgery and with the final dose on the morning of POD (postoperative day) 2.
89495965|NCT04731662|No Intervention|Control Group (8888888)|The Control group will have 8-hours time-in-bed, both weeknights and weekends.
89205203|NCT00315055|Experimental|Group 1: DTaP-IPV-Hep B-PRP-T|Participants will receive 3 vaccinations with Diphtheria (D) and tetanus (T) toxoids, acellular pertussis (2-component) (aP), recombinant Hepatitis B surface antigen (HBsAg), inactivated poliomyelitis virus (IPV), and Hemophilus influenzae type b (Hib) polysaccharide conjugated to tetanus protein (DTaP-IPV-Hep B-PRP~T); One dose each at 2, 3, and 4 months of age.
88955244|NCT06329375|No Intervention|SoC group|Standard of care (SOC)
88955245|NCT06329375|Experimental|Nutrition program (Intervention)|"Patients in the intervention group will be provided the following two resources in addition to SOC:~Enhanced access to nutritious food (twice daily meal delivery up to 90 days post-discharge).~Education at discharge and continuing outreach to enhance knowledge for better diet and food options."
89205204|NCT00315055|Active Comparator|Group 2: PENTAXIM™ and ENGERIX B® PEDIATRIC|Participants will receive 3 vaccinations with DTaP-IPV-PRP~T (PENTAXIM™ ) and recombinant Hepatitis B (ENGERIX® PEDIATRIC) vaccines. One dose each at 2, 3, and 4 months of age.
89205205|NCT00528970|Experimental|MOA-728 12 mg|Participants will receive methylnaltrexone (MOA-728) 12 mg as an IV infusion over approximately 20 minutes for approximately every 6 hours for a total of 4 doses in 24-hour period. The first dose of study drug will be administered within approximately 90 minutes after completion of the surgical procedure (defined as the time when the last skin suture or staple is placed in the participant). Dose administration will be continued for a maximum of 10 days.
88955248|NCT06329349|Experimental|Intervention|Exercise intervention
88955249|NCT06329349|No Intervention|Control|No intervention.
88955250|NCT06329336|Experimental|Preventive Behavioral Parenting Program|This preventive parenting intervention combines behavioral parenting and mindfulness-based well-being practices to support effective parenting.
89205206|NCT00528970|Experimental|MOA-728 24 mg|Participants will receive MOA-728 24 mg as an IV infusion over approximately 20 minutes for approximately every 6 hours for a total of 4 doses in 24-hour period. The first dose of study drug will be administered within approximately 90 minutes after completion of the surgical procedure (defined as the time when the last skin suture or staple is placed in the participant). Dose administration will be continued for a maximum of 10 days.
89205207|NCT00528970|Placebo Comparator|Placebo|Participants will receive placebo matching to MOA-728 as an IV infusion over approximately 20 minutes for approximately every 6 hours for a total of 4 doses in 24-hour period. The first dose of study drug will be administered within approximately 90 minutes after completion of the surgical procedure (defined as the time when the last skin suture or staple is placed in the participant). Dose administration will be continued for a maximum of 10 days.
89205208|NCT00759395|Experimental|AZD2327|AZD2327 3mg BID
89205209|NCT00759395|Placebo Comparator|Placebo|Placebo BID
89205210|NCT00293293|Active Comparator|Chemotherapy Alone|Patients receiving 6 cycles of taxane and platinum therapy for ovarian, fallopian tube or primary peritoneal cancer by their treating physician. Chemotherapy administration is not administered as part of this protocol.
88955256|NCT06329310|Experimental|aXess-E conduit|
88955257|NCT06329297||Open-heart surgery inpatients|Patients having elective open-heart surgery including coronary artery bypass grafting (CABG), aortic valve repair/replacement (AVR), mitral valve repair/replacement (MVR), or any combination of those will have a CGM monitor placed within one hour of admission for up to 7 days or upon discharge.
88955258|NCT06329297||General medical inpatients|Medical inpatients who have a Glucommander order for management of hyperglycemia will have a CGM monitor placed within 24 hours of admission for up to 7 days or upon discharge.
89538137|NCT03285737|Experimental|Whey protein supplement|Supplement will be delivered twice daily (30g per supplement) of whey protein isolate
88955260|NCT06329271|Experimental|Early-Weight bearing|Early Weight bearing was defined as starting Weight bearing within 48 h postoperatively, and WBAT referred to the adjustment of fracture site weight-bearing by pain tolerance.
88955261|NCT06329271|No Intervention|Weight-bearing restriction|Weight bearing as toleration started after 48 h postoperatively.
88955262|NCT06329258|Experimental|Deucravacitinib in combination with Enstilar|deucravacitinib in combination with Enstilar
88955263|NCT06329258|Experimental|Deucravacitinib monotherapy|monotherapy
88955264|NCT06329245||high-risk group|Subjects in the case group have one or more older siblings with ASD.
88955265|NCT06329245||low-risk group|Subjects in the controlled group do not have older siblings with ASD.
88955266|NCT06329232||Healthy subjects and Stroke, Tumor, TBI patients|Healthy subjects and Stroke, Tumor, TBI patients
88955269|NCT06329206|Experimental|GH2616 GROUP|"Dose Escalation: Dose Escalation Cohorts Subjects will be enrolled at various doses of GH2616. These Dose Escalation Cohorts will be utilized to To determine the maximum tolerated dose (MTD) and/or recommended dose for expansion(s) (RDEs) for Dose Expansion. Dose Escalation: Backfill Cohorts 2 ~ 3 dose cohorts are allowed to be backfilled.These Backfill Cohorts will be utilized to build additional data to support selection of doses and/or tumor types for further study in Dose Expansion.~Dose Expansion: Expansion Cohorts 2 ~ 3 dose cohorts are planned.Subjects with advanced solid tumors harboring TP53 mutation and whole genome duplication (WGD+) will be enrolled.These Cohorts will be utilized to to determine the recommended Phase II dose (RP2D) of GH2616 Tablet."
88955270|NCT06329193|Experimental|Training Group|The 3-week mid-season camp period loading at sea level, including daily gym and field-based exercise interventions, five days a week, will be applied to the participants in the sports club's gym and soccer field.
88955271|NCT06329167|Experimental|Daphnetin treatment group|Daphnetin capsule 150mg tid (3 capsules/time, 3 times daily) and gradient compression stockings.
88955272|NCT06329167|Active Comparator|Aescuven Forte group|Aescuven Forte oral tablet 150mg (2 capsules/time, 2 times daily) and gradient compression stockings.
89205211|NCT00293293|Experimental|Standard Chemotherapy + CAM|Patients receiving 6 cycles of taxane and platinum therapy for ovarian, fallopian tube or peritoneal cancer with additional complementary alternative medicine - CAM (healing touch, hypnosis and massage therapy). Chemotherapy administration is not administered as part of this protocol.
89205212|NCT05774613|Placebo Comparator|Placebo|beverage with physical and sensory characteristics to the treatment beverage without the bioactive compounds corresponding to the study.
89205213|NCT05774613|Experimental|Hibiscus-based drink|beverage in patent process with application number MX/a/2022/010704
89205214|NCT05774574|Experimental|CBD|1 mL hemp oil containing 60 mg/mL CBD, daily.
89205215|NCT05774574|Placebo Comparator|Placebo|1 mL hemp oil containing 0 mg/mL CBD, daily.
89205216|NCT05774561|Active Comparator|Arm A - Oropharyngeal cancer patients|In total, approx. 200 OPC cancer patients will be enrolled in the study Arm A, with both prospective and retrospective parts enrolling 100 OPC patients. The Arm A will enroll patients from the Department of Otorhinolaryngology and Head and Neck Surgery, University Hospital Olomouc. Pre-treatment primary samples of fresh or FFPE tissue samples will be collected. Liquid biopsies (gargle lavage, oropharyngeal smear, breath condensate, and blood sample) will be collected. Obtained samples will be tested by CE-IVD (device complies with European in vitro diagnostic Directive) marked HPV diagnostic test. A laboratory developed digital droplet PCR assay will be used for ct HPV DNA detection. Sampling will be performed at pre & post treatment check-ups, and every 3 months for 3 years and every 6 months for 2 years.
89205217|NCT05774561|Active Comparator|Arm B - Cervical cancer patients|Into the study Arm B will be enrolled 80 patients with CC and 120 patients with HSIL, and 80 patients will be enrolled into the retrospective part. The Arm B will enroll patients from the Department of Gynecology and Obstetrics, University Hospital Olomouc. Pre-treatment primary samples of fresh or FFPE tissue samples will be collected. Liquid biopsies (cervicovaginal swab and blood sample) will be collected. Obtained samples will be tested by CE-IVD marked HPV diagnostic test. A laboratory developed digital droplet PCR assay will be used for ct HPV DNA detection. Sampling will be performed at pre & post treatment check-ups, and every 3 months for 2 years and every 6 months for 3 years.
89205218|NCT05774535||Experimental|Patients who will undergo thyroidectomy
89205219|NCT05774522|Experimental|Suspicion of sleep apnea syndrome|All patients, consulting Bichat sleep center for suspected sleep apnea syndrome
89205220|NCT05774457|Experimental|Traditional intervention|Participants will receive traditional training in voice, in a standard clinical environment.
89205221|NCT05774457|Experimental|Virtual reality intervention|Participants will receive voice training under virtual reality conditions.
89205222|NCT05774418||vaccinated|Healthcare workers (aged ≥18 years) working at hospital sites who could provide written informed consent and who will complete the immunization program with the administration of the second dose after approximately 21 days from the first dose at the FPG
89205223|NCT05774418||unvaccinated|unvaccinated health workers
89205224|NCT05774379|Experimental|virtual reality and fatigue education|watching the application by wearing virtual glasses for 3 days and Providing training on fatigue to all children (1 session, average 45 minutes) (using role-play, exercise, games, coloring books and activity materials)
89205225|NCT05774379|Experimental|fatigue education|Providing training on fatigue to all children (1 session, average 45 minutes) (using role-play, exercise, games, coloring books and activity materials)
89205226|NCT05774275|Experimental|Treatment Arm|"There will be 52 patients with high-risk localized extremity and trunk soft tissue sarcoma recruited.~In safety lead-in phase (phase Ib): using 3+3 design, patients will receive 4 cycles of Doxil or doxorubicin hydrochloride, sintilimab and radiotherapy.~In phase II: Doxil in RP2D, sintilimab and radiotherapy will be applied as before."
89205227|NCT05774171||Cancer patients with SARS-CoV-2 vaccination|Cancer patients with SARS-CoV-2 vaccination
89205228|NCT05774171||Cancer patients without SARS-CoV-2 vaccination|Cancer patients without SARS-CoV-2 vaccination
89205229|NCT05774158||Adult Congenital Heart Diseases|
89205230|NCT05774106|Experimental|Participatory Action Research (PAR).|"Two circular spirals following Kemmis & Mctaggart PAR principles. Each spiral includes the following stages: planning, action, observation and reflection.~Four discussions groups and two reflective diaries will be carried out in total.~Note: the PAR process will be conducted only with case managers."
89205231|NCT05774106|No Intervention|Regular Practice|The other group will continue working as usual in their daily practice.
89205232|NCT05774093||COVID-19 Antibody Group 1|Participants will be divided into positive group and negative group according to the baseline of COVID-19 antibody titer.Group 1 is for those COVID-19 antibody are positive.
89205233|NCT05774093||COVID-19 Antibody Group 2|Participants will be divided into positive group and negative group according to the baseline of COVID-19 antibody titer.Group 1 is for those COVID-19 antibody are negative.
89205234|NCT05774028|Experimental|P-GEMD group|Pegaspargase Combined With Gemcitabine, Etoposide, Liposomal Mitoxantrone Hydrochloride and Dexamethasone (P-GEMD) regimen
89205235|NCT05773937|Experimental|9MW2821|
89205236|NCT05773924|Other|Trilift system treatment arm|Single arm with Before & After photos, triLift treatment protocol study design.
89205237|NCT05773911|Experimental|Test|Curettes+ Ultrasonic scalers supragingivally and a chitosan brush in oscillating handpiece subgingivally with adjunct 4% chitosan gel (pH 3.48).
89205238|NCT05773911|Active Comparator|Control|Curettes+ Ultrasonic scalers supragingivally and a chitosan brush in oscillating handpiece subgingivally
89205239|NCT05773898||person close to the deceased|Relatives will be invited to participate in two semi-structured research interviews in the form of a storytelling interview with an interviewer. All interviews will be conducted after obtaining the participants' non-objection. The interviews will be recorded and, once transcribed, will be analysed.
89205240|NCT05773885|Experimental|Experimental Group (EG)|The Experimental Group (EG) will carry out 30 sessions (3-5 days/week, for 6-10 weeks) of motor, speech, and cognitive rehabilitation exercises using the VRRS Tablet home TR system (Khymeia srl, Noventa Padovana, Italy).
89495966|NCT04731662|Experimental|Stable Short Sleep (8866666)|The short sleep group will have 6-hours time-in-bed on weeknights and 8-hours time-in-bed on weekends.
89495967|NCT04731662|Experimental|Variable short sleep group (8884846)|The short sleep group time in-bed will vary across weeknights but will maintain the same amount of total time-in bed as the stable short sleep (8866666).
89495968|NCT04723186|Experimental|Monotherapy of MT1002, 3 doses via intravenous (IV) + infusion|Three doses of MT1002 (IV loading + continuous IV infusion) will be sequentially tested. The first dose level is 0.90 mg/kg initial loading dose (bolus intravenous injection) + 1.8 mg/kg/h (infusion) for 4 hours. The second dose level will be based on the results from the first cohort (If the dose is escalated, then the second dose level is 1.2 mg/kg initial loading dose (bolus intravenous injection) + 2.3 mg/kg/h (infusion) for 4 hours; if the dose is de-escalated, then the second dose level is 0.6 mg/kg initial loading dose (bolus intravenous injection) + 1.2 mg/kg/h (infusion) for 4 hours). The third dose will be determined based on the results from the first 2 cohorts.
89495969|NCT04709276|Experimental|Neuroendocrine Prostate Cancer (NEPC) or Aggressive Variant Prostate Cancer (AVPC)|"Subjects with neuroendocrine prostate cancer (NEPC) or aggressive variant prostate cancer (AVPC) will receive a combination of nivolumab, ipilimumab, carboplatin and cabazitaxel for up to 10 cycles of 21 days each. After carboplatin and cabazitaxel are discontinued, a combination of nivolumab and ipilimumab will be administered.~Nivolumab will be administered intravenously at a dose of 360 mg every 3 weeks.~Ipilimumab will be administered intravenously at a dose of 1 mg/kg every 6 weeks.~Carboplatin will be administered intravenously at a dose of AUC 4 mg/ml per minute.~Cabazitaxel will be administered intravenously at a dose of 20 or 25 mg/m2."
89495970|NCT04706533||Covid-19|Patients with confirmed SARS-CoV-2 infection presenting specifically for Covid-19
88955273|NCT06329154|Experimental|extracorporeal shock wave therapy group|The experimental group received extracorporeal shock wave therapy combined with conventional rehabilitation therapy. Conventional rehabilitation therapy includes medium frequency electricity, ultrasound, ultrashort wave, laser, wax therapy, etc.
89495971|NCT04696731|Experimental|ALLO-647, ALLO-316|
89495972|NCT04681339||Pneumonia with antibiotics|Children with non-severe community acquired pneumonia and fever: managed with antibiotics
89495973|NCT04681339||Pneumonia without antibiotics|Children with non-severe community acquired pneumonia and fever: managed without antibiotics
89495974|NCT04645719|Placebo Comparator|Lactate ringer group|Patients will receive only general anesthesia
89495975|NCT04645719|Active Comparator|Real weight group|Patients who will receive general anesthesia and magnesium sulfate infused at a dose of 15 mg.kg-1.h-1 based on the actual body weight
89495976|NCT04645719|Active Comparator|Corrected ideal weight group|Patients who will receive general anesthesia and magnesium sulfate infused at a dose of 15 mg.kg-1.h-1 based on the corrected ideal weight
89495977|NCT04626882|Active Comparator|Staged in-hospital CR (complete revascularization)|Non-infarct related artery (IRA) will be revascularized in other day (during hospitalization) after PCI for IRA. Non-IRA lesion which have equal or more than 70% diameter stenosis by visual estimation will be revascularized without FFR evaluation. Non-IRA lesion with diameter stenosis 50-70% by visual estimation will be evaluated using FFR device. In case of FFR value more than 0.8, non-IRA lesion wll be deferred without PCI. If FFR value was equal or less than 0.8, non-IRA lesion will be revascularized.
89495978|NCT04626882|Experimental|Immediate CR (complete revascularization)|Non-infarct related artery (IRA) will be revascularized immediately after PCI for IRA (during primary PCI). Non-IRA lesion which have equal or more than 70% diameter stenosis by visual estimation will be revascularized without FFR evaluation. Non-IRA lesion with diameter stenosis 50-70% by visual estimation will be evaluated using FFR device. In case of FFR value more than 0.8, non-IRA lesion wll be deferred without PCI. If FFR value was equal or less than 0.8, non-IRA lesion will be revascularized.
89495979|NCT04621604|Experimental|Patients|
89495980|NCT04601324|Active Comparator|Dymista (Azelastine hydrochloride and fluticasone propionate)|Participants will receive standard of care, which includes twice daily MP-AzeFlu nasal spray (formulation of 137 mg of azelastine hydrochloride and 50 mcg of fluticasone propionate per spray) separated by 12 hours.
89495981|NCT04601324|Experimental|Fluticasone Propionate and Rupatadine|Participants will administer fluticasone propionate nasal spray once daily (2 sprays in each nostril, 50 mcg fluticasone propionate per spray)and 1 tablet of Rupatadine (10mg) once daily in the morning.
89495982|NCT04596800|Experimental|Prehabilitation + Enhanced Recovery After Surgery|Patients allocated to the intervention group will undergo prehabilitation protocol (nutrition + exercise + psychological counselling), with individualized monitoring by the multidisciplinary team.
89495983|NCT04596800|Active Comparator|Enhanced Recovery After Surgery|Patients allocated to the control group will not undergo any pre-surgical intervention, except for preoperative counselling, already implicated in ERAS®.
88955274|NCT06329154|Active Comparator|control group|The control group received conventional rehabilitation therapy. Conventional rehabilitation therapy includes medium frequency electricity, ultrasound, ultrashort wave, laser, wax therapy, etc.
88955275|NCT06329141|Experimental|Vutiglabridin 400 mg Multiple Dose|Multiple oral dosing of vutiglabridin 400 mg for 24 weeks
88955276|NCT06329141|Experimental|Vutiglabridin 800 mg Multiple Dose|Multiple oral dosing of vutiglabridin 800 mg for 24 weeks
88955277|NCT06329141|Placebo Comparator|Placebo|Multiple oral dosing of placebo
88955278|NCT06329128|Experimental|Study Group|This group will get manuel therapy that combinated electroterapy and hm programme (exercise).
88955279|NCT06329128|Active Comparator|Control Group|This group will get traditional therapy (electrotherapy and exercise)
88955280|NCT06329115|Experimental|Exercise Group|This group will get aerobic exercise programme and respiratory exercise
88955284|NCT06329089||Recurrent ipsilateral breast cancer|Recurrent ipsilateral breast cancer refers to the return of breast cancer in the same breast where it originally developed or was treated.
88955285|NCT06329076|Experimental|Losartan group|Drug:Losartan
88955286|NCT06329076|Placebo Comparator|Placebo group|Drug: Placebo
88955287|NCT06329063|Experimental|Vasopressin group|Drug: Vasopressin (20IU)
88955288|NCT06329063|Placebo Comparator|Placebo group|Drug: Placebo
88955289|NCT06329050|Experimental|Losartan group|Losartan tablet(50 mg)
88955290|NCT06329050|Placebo Comparator|Placebo group|Placebo tablet
88955291|NCT06329037|Experimental|Vasopressin group|Vasopressin (20IU)
88955292|NCT06329037|Placebo Comparator|Placebo group|Placebo
89495984|NCT04585165||Risk of HIV acquisition|Individuals reporting behavioral risk of HIV acquisition.
89495985|NCT04576871|Experimental|Heavily Exposed|
89495986|NCT04576871|Experimental|Moderately Exposed|
89022616|NCT06189274|Active Comparator|Standard of Care Electrode Selection|The comparison in this study will be to current standard of care, which is to select a single electrode length for most patients, in this case the FLEX28 electrode, which is 28 mm long.
89022617|NCT06189261||Patients with stage 1/2 malignant melanoma|During the study, two intervention consultations will take place 1 and 3 months after the initial clinical team meeting, where each participant's case will be discussed. At the start of each intervention consultation, patients will be asked to complete the intervention questionnaire. The recorded information will be passed to their nurse specialist, who will identify the participant's needs and offer tailored advice and support to meet these needs. Throughout the study, participants will also be asked to complete a set of questionnaires in the clinic (months 1 and 3) or at home (months 2 and 4) to explore potential effects of the intervention.
89495987|NCT04575935|Experimental|Arm A (MIS, standard of care chemotherapy)|Patients undergo MIS within 6 weeks after last cycle of standard of care neoadjuvant chemotherapy. If during MIS the surgeon thinks complete gross resection can only be accomplished by performing an open procedure, patients may undergo laparotomy instead. Within 6 weeks after surgery, patients receive standard of care chemotherapy.
89495988|NCT04575935|Active Comparator|Arm B (laparotomy, standard of care chemotherapy)|Patients undergo laparotomy within 6 weeks after last cycle of standard of care neoadjuvant chemotherapy. Within 6 weeks after surgery, patients receive standard of care chemotherapy.
89022620|NCT06189235|No Intervention|System development: Validation for patients|No intervention. The patients will receive one time of MRI and three times of ultrasound evaluation on the injured area, each evaluaitons will be done by two to three days interval.
89022621|NCT06189235|No Intervention|System development: Building dataset from healthy subjects|No intervention. The healthy subjects will receive one time of ultrasound evaluation on the dominant hand, the different part and different axis in dominant hand will be assessed in types of images or films for building the dataset.
89022622|NCT06189235|No Intervention|System application: Understanding the recovery patterns in patients|No intervention. The patients will receive three times of ultrasound evaluation on the injured area and hand function assessments, each evaluaitons will be done by two weeks interval.
89495989|NCT04570878|Experimental|SC TAP|Bilateral subcostal transverse abdominis plane block will be performed using 0.25% ropivacaine (0.5mL/kg for each side, MAX 20mL for each side) under ultrasound-guidance at the end of surgery.
89495990|NCT04570878|Active Comparator|Control|No regional block is provided at the end of surgery.
89495991|NCT04561739|Experimental|Drug-coated balloon|
89495992|NCT04561739|Active Comparator|Drug-eluting stent|
89495993|NCT04550845|Experimental|Prostate Cancer Genetic Literacy Application (PCGLA) Educational Video.|Focus group discussions about the PCGLA educational video post-study. Focus group audiotapes will be transcribed verbatim, and then entered into the qualitative data software package, NVivo 14. A data dictionary will be created for each technical term to establish acceptable and unacceptable responses. Trained coders will evaluate comprehension of the technical terms independently and then resolve disagreement by consensus.
89495994|NCT04550845|Experimental|Prostate Cancer Genetic Literacy Application (PCGLA) Educational Video plus Communication Coaching.|"Focus group discussions about the PCGLA educational plus nurse-navigated, tailored, prostate cancer education and communication coaching post-study.~Focus group audiotapes will be transcribed verbatim, and then entered into the qualitative data software package, NVivo 14. A data dictionary will be created for each technical term to establish acceptable and unacceptable responses. Trained coders will evaluate comprehension of the technical terms independently and then resolve disagreement by consensus. post-study. Focus group audiotapes will be transcribed verbatim, and then entered into the qualitative data software package, NVivo 14. A data dictionary will be created for each technical term to establish acceptable and unacceptable responses. Trained coders will evaluate comprehension of the technical terms independently and then resolve disagreement by consensus."
89495995|NCT04547439|Active Comparator|Control|Placebo
89495996|NCT04547439|Active Comparator|Melatonin|Melatonin
89495997|NCT04519476|Experimental|Selinexor/Lenalidomide/Steroids|All subjects enrolled will receive: 1) selinexor, PO, at 60 mg once weekly on days 1-28 of a 28-day cycle, 2) lenalidomide, PO, 10 mg daily on days 1-21 of 28-days cycle and 3) methylprednisolone at the same dose and schedule as the last lenalidomide-containing regimen if it contained steroids. If patient's qualifying lenalidomide-containing regimen contained different type of steroid (e.g. prednisone, dexamethasone, etc.) then patient on this study will receive methylprednisolone at the equivalent dose and schedule.
89495998|NCT04508049|Other|Early identification of fibrosis.|A pilot study to test the ability of qMT to quantify fibrosis in the post-stenotic human kidney, in comparison to innovative biomarkers of renal dysfunction and tissue damage. We will pursue the Specific Aim that qMT in stenotic human kidneys is feasible and reproducible.
89495999|NCT04498234|Experimental|GROUP(A) (CONTROL GROUP)|Patients will receive standard regimen of anesthesia .
89022623|NCT06189235|Experimental|System application: Biofeedback training|"The program last for one month. In this program, the patients receive traditional rehabilitation protocol assigned from original hospital or therapist. Also, ultrasound evaluation and hand function assessment will be performed at pre-test, one follow-up test and post-test, which will be done with two weeks interval.~For this biofeedback training group, the therapist and patients will be asked to use the hint recommanded by modular system to assist the rehabilitation excepting the traditional routine at least two times a week."
89496000|NCT04498234|Experimental|Group B|Patients will receive 0.25% bupivacaine (20 ml ) into interfascial plane below erector spinae muscle at level of T4.
89496001|NCT04498234|Experimental|Group C|Patients will receive (0.3 ml /kg ) 0.25% bubivicaine divided equially at each level of T2 , T4 and T6 at thoracic paravertebral space .
89496002|NCT04476758||Fungal Infection Group|Have had a fungal species isolated from sputum and/or BAL culture on >= 2 separate occasions in the 18 months preceding study visit and do not have a diagnosis of ABPA (N=10).
89496003|NCT04476758||Control Group|Have never previously isolated fungus from sputum, BAL, or OP swab (N=10).
89496004|NCT04476758||ABPA Group|"Previous diagnosis of ABPA as defined by CFF guidelines, regardless of the amount of fungal infection or history thereof.~• ABPA Minimum diagnostic criteria per CFF: Acute or subacute deterioration, total serum IgE > 500 IU per mL, immediate cutaneous reactivity to Aspergillus or in vitro IgE antibody to A. fumigatus, and either a new or recent chest imaging change that has not responded to antibiotics and standard physiotherapy OR precipitin to A. fumigatus or IgG antibody to A. fumigatus1 (N=5). Culture positive sputum is not required for ABPA diagnosis and is not taken into account for the diagnosis per CFF guidelines."
89496005|NCT04471207|Experimental|Intelligent Biometrics - Prolonged Exposure (Therapist Guided).|"In the therapist-guided group, Study Therapists will virtually accompany patients during IVEs and use actionable biometric and subjective data during in vivo exposures (IVEs) (galvanic skin response [GSR], heart rate [HR], and subjective units of distress [SUDS]) to modify the assignments in real-time.~All participants receive at least 10 sessions of prolonged exposure therapy for posttraumatic stress disorder."
89496006|NCT04471207|Active Comparator|Intelligent Biometrics - Prolonged Exposure (Record Only).|"In the record-only group, passive data collection will be utilized to collect and store biometric and behavioral data for future offline analyses to investigate predictors of outcome.~All participants receive at least 10 sessions of prolonged exposure therapy for posttraumatic stress disorder."
89496007|NCT04451707||non-cholera Vibrio infection|Patients diagnosed with non-cholera Vibrio infection in Western France from 2000 to 2019
89496008|NCT04446351|Experimental|Participants receiving GSK6097608 monotherapy (Arm A)|Participants will be administered an intravenous (IV) infusion of GSK6097608 every 3 weeks as monotherapy in escalating doses.
89496009|NCT04446351|Experimental|Participants receiving GSK6097608 plus dostarlimab (Arm B)|Participants will be administered IV infusion of GSK6097608 every 3 weeks in escalating doses followed by dostarlimab.
89496010|NCT04446351|Experimental|Participants receiving dostarlimab monotherapy (Arm D)|Participants will be administered an IV infusion of dostarlimab monotherapy (1 cohort will receive dostarlimab every 3 weeks and 1 cohort will receive dostarlimab every 6 weeks).
89496011|NCT04446351|Experimental|Participants receiving dostarlimab plus belrestotug (Arm E)|Participants will be administered IV infusions of dostarlimab followed by belrestotug, every 3 weeks.
89496012|NCT04446351|Experimental|Participants receiving dostarlimab plus belrestotug plus GSK6097608 (Arm F)|Participants will be administered an IV infusion of dostarlimab followed by belrestotug followed by GSK6097608 every 3 weeks.
89496013|NCT04446351|Experimental|Participants receiving dostarlimab plus cobolimab (Arm G)|Participants will be administered an IV infusion of cobolimab followed by dostarlimab
89496014|NCT04418232|Experimental|Alianza Latina|The main components of Alianza Latina are 1) providing primary care providers with education, training and tools for timely dementia diagnosis and optimal treatment and 2) providing Latino dementia patients with enhanced chronic care through bilingual Health Navigators.
89538138|NCT03285737|Active Comparator|Collagen peptide supplement|Supplement will be delivered twice daily (30g per supplement) of hydrolyzed collagen peptides.
89538139|NCT03285659|Experimental|Intervention: INDI Implementation|Primary care centres which will implement the collaborative (INDI) care model for depression
89496015|NCT04417725||Chronic kidney disease|Adult patients (≥18 years of age) with CKD were identified in Alberta during the case ascertainment period (April 1, 2010, to March 31, 2019), based on a validated algorithm incorporating ICD-9-CM/ICD-10-CA coding, estimated glomerular filtration rate, and albuminuria laboratory tests. This is a non-interventional, observational study, and thus, no intervention was administered.
89496016|NCT04417725||Type 2 diabetes mellitus|Adult patients with T2DM were identified in Alberta during the case ascertainment period (April 1, 2010 to March 31, 2018), based on a validated algorithm incorporating ICD-9-CM and ICD-10-CA codes. This is a non-interventional, observational study, and thus, no intervention was administered.
89496017|NCT04417725||Comorbid type 2 diabetes mellitus and chronic kidney disease|The derived T2DM cohort was used to identify patients with comorbid T2DM/CKD (stages 1-3) during the same case ascertainment period (April 1, 2010 to May 31, 2018). The study cohort included T2DM patients with comorbid CKD (stages 1-3) identified in Alberta within the two years prior or after their T2DM index date, using the T2DM index date as the index date for this cohort. This is a non-interventional, observational study, and thus, no intervention was administered.
89496018|NCT04410224|Experimental|ASN004 ascending doses|Patients will receive escalating doses of ASN004 to identify the best dose for further study.
89496019|NCT04405024|Other|Hepatitis C testing|"If the patient is included in the study, HCV serology (2 x 5 ml tubes) will be taken at the time of admission as part of the routine entry assessment.~These two tubes will be used for HCV screening. The patient is informed of the HCV serology result during hospitalization by an investigator."
89496020|NCT04381663||conservative treatment|In study A this group will be treated conservatively (stenosis). Study B is a single centre longitudinal study where the same patient groups will be followed up during the course of their treatment
89496021|NCT04381663||surgical treatment (stenosis and myelopathy).|In study A this group that will be treated surgically (stenosis and myelopathy). Study B is a single centre longitudinal study where the same patient groups will be followed up during the course of their treatment
89496022|NCT04367233|Active Comparator|Placebo group|General anesthesia with fentanyl, propofol and remifentanyl
89496023|NCT04367233|Experimental|Transverse block group|At the end of general anesthesia with fentanyl, propofol and remifentanil, the patient will receive transverse plan block, with ropivacaine 0,25% 0,2 ml/kg.
89496024|NCT04367233|Experimental|Quadratus lumborum group|At the end of general anesthesia with fentanyl, propofol and remifentanil, the patient will receive quadratus lumborum block with ropivacaine 0,25% 0,2 ml/kg.
89496025|NCT04363164|Experimental|Arm A: Enzalutamide|Patients randomized to Arm A will receive continuous therapy with standard dose Enzalutamide (160 mg oral daily).
89496026|NCT04363164|Experimental|Arm B: Sequential Testosterone and Enzalutamide|Patients in Arm B will receive intramuscular injection with testosterone cypionate (T) at a dose of 400 mg every 28 days x 2 (i.e. cycle 1). On Day 1 of cycle 2, patients will stop testosterone and begin enzalutamide 160 mg po q day for 56 days. Each cycle is 56 days. On Day 1 of cycle 3, patient will not take enzalutamide and will again receive injection of testosterone. Patients will continue to alternate one cycle of testosterone (2 injections) with one cycle of 56 days of enzalutamide.
89496027|NCT04363164|Experimental|Arm C: Variable Sequential Testosterone and Enzalutamide|Patients in Arm C will receive intramuscular injection with testosterone cypionate (T) at a dose of 400 mg every 28 days x 2 injections per cycle. Each cycle is 56 days. Patients with PSA progression will stop T injection and begin Enzalutamide. Patients on T with initial PSA decline will remain on high dose T for additional cycles of 2 injections until PSA progression occurs (≥25% increase in PSA from PSA nadir on current BAT cycle). These patients will then be started on Enzalutamide. Patients with PSA progression will stop Enzalutamide and will restart injections of T with 2 injections/cycle. Patients on enzalutamide with initial PSA decline after one 56-day cycle will continue on Enzalutamide until PSA progression occurs (≥25% increase in PSA from PSA nadir on current Enzalutamide cycle). These cycles of switching between T and Enza with onset of PSA progression will continue until clinical and/or radiographic progression occurs.
89496028|NCT04356040|Experimental|Main Study|
89496029|NCT04356040|Experimental|High Standard Power Sub-Study|
89496030|NCT04349631|Experimental|HB-adMSCs|Five IV infusions of autologous, adipose-derived mesenchymal stem cells. Baseline laboratory data will be collected prior to first infusion; follow-up data will be compared against baseline according to the following schedule: safety lab follow ups at weeks 6, 14, 26; inflammatory marker follow ups at weeks 6, 14, 26; SF-36 and PHQ-9 Questionnaires at weeks 2, 6, 10, 14, 18, 22, 26.
89496031|NCT04331873|Experimental|Ultrasound|An ultrasound will be obtained to evaluate placement of the gastrostomy tube prior to obtaining the standard contrast injection
89496032|NCT04331236|Experimental|Patient and Caregiver Intervention|Patient and Caregivers receive both cognitive behavioral intervention and yoga interventions each week, for 7 weeks.
89496033|NCT04320966||Acquired Anemia|Otherwise healthy individuals with hemoglobin below 10.5 g/dl or hematocrit below 32
89496034|NCT04320966||Control|Age and sex matched individuals with hemoglobin in the upper quartile of normal
89496035|NCT04288258|Experimental|Treatment|Health and Wellness Program
89496036|NCT04279392|Active Comparator|Active Infusion|At 6 weeks post surgery, 5 mg of zoledronic acid in 100 ml of saline will be infused intravenously over a 15 minute time period.
89496037|NCT04279392|Placebo Comparator|Non-active Infusion|At 6 weeks post surgery, 100 ml of saline will be infused intravenously over a 15 minute time period.
89538140|NCT03285659|No Intervention|Control: no INDI implementation|Primary care centres in which the collaborative care strategy INDI will not be implemented, but will be compared in terms of their clinical practice towards depression
89496038|NCT04257955||Pancreatic cancer|"Outpatients seen at the Gastroenterology, Pancreatic Surgery and Oncology Clinics of the Pancreas Translational and Clinical Research Centre, IRCCS San Raffaele, Milan (Italy) will be considered includable if:~Adult patients (≥18 years);~Of Italian mother tongue;~Have a histologic diagnosis of PDAC obtained during the 4 weeks before the visit~The visit is the first visit after completion of diagnostic procedures and is set to communicate the diagnosis and treatment strategies~Give full, written informed consent~The following exclusion criteria will be applied:~PDAC recurrence after previous diagnosis and treatment~poor performance status (ECOG ≥ 3);"
89538141|NCT03190603|Experimental|Celecoxib arm|Axial Spondyloarthritis patients who takes celecoxib 400mg for day
89205241|NCT05773885|Active Comparator|Control Group (CG)|The Control Group (CG) will carry out 30 sessions (3-5 days/week, for 6-10 weeks) of conventional rehabilitation treatments (including physiotherapy, occupational therapy, speech therapy, psychotherapy) without the use of any technological devices.
89205242|NCT05773859|Experimental|XP-DC vaccinations|Patients in this arm will receive XP-DC vaccination in addition to standard-of-care treatment.
89205243|NCT05773833|Experimental|"Go Healthy Intervention Group"|"Go Healthy program"
89205244|NCT05773833|No Intervention|Wait-list Control Group|"Monetary compensation equal in value to the Go Healthy program"
89205245|NCT05773807|Experimental|BIS group|In the BIS group, the anesthesiologist set the TCI parameters according to the patient's height, weight, gender and age. The initial plasma target concentration was set to 1.5ug/ml, and the target concentration would be increased or decreased 0.5ug/ml every two minutes to maintain the BIS value at 45-60.
89205246|NCT05773807|Placebo Comparator|OAAS/S group|In the OAAS/S group, the anesthesiologist set the TCI parameters according to the patient's height, weight, gender and age. The initial plasma target concentration was set to 1.5ug/ml, and the target concentration would be increased or decreased 0.5ug/ml every two minutes maintain the OAA/S value at 1 point.
89205247|NCT05773781|Active Comparator|PuraBond®|Surgery with PuraBond® application to surgical field.
89205248|NCT05773781|No Intervention|No PuraBond®|Surgery without PuraBond® application to surgical field.
89205249|NCT05773729|Experimental|BD211 Adult Single-Dose group|Route of Administrate: infusion intravenously. Dosage form: injection solution. Dose: 5×10*6 cells /kg ~ 10×10*6 cells /kg. Frequency of administration: One dosing intravenously. Intervention: Single dose of BD211 for adults
89205250|NCT05773716|Experimental|Electroacupuncture plus pelvic floor muscle training|Participants in this arm will receive pelvic floor muscle training using unified standards, and electroacupuncture therapy for 6 weeks.
89205251|NCT05773716|Sham Comparator|Sham electroacupuncture plus pelvic floor muscle training|Participants in this arm will receive pelvic floor muscle training using the same approach as that in experimental group, and sham electroacupuncture for 6 weeks.
89205252|NCT05773690|Experimental|Movement Quality group|movement quality training based on mobility, stability and motor control exercises
89205253|NCT05773690|Experimental|Conventional resistance training group|traditional strength training exercises
89205254|NCT05773625|Other|Test group of app|All participants will first use the app one week without receiving just-in-time notifications. Their movement patterns are collected through GPS. In the second week, they will receive just-in-time notifications based on their chosen goal. Participants will act as their own control group.
89496039|NCT04225130|Experimental|Written Exposure Therapy -for Suicide|Written Exposure Therapy-for Suicide (WET-S) consists of 5 treatment sessions. Each session includes a written exposure exercise. It also includes CRP. Participants assigned to WET-S will complete the CRP prior to beginning their writing in session 1. Patient use of the CRP since the previous session will be briefly reviewed at the start of each WET-S session to manage safety and problem solve fluctuations in risk during treatment.
89496040|NCT04225130|Active Comparator|Treatment as Usual|The TAU condition consists of daily contact and patient centered care by the acute psychiatric inpatient unit provider team. TAU includes initial stabilization, nurse case management, medication management, psychoeducation groups, and discharge planning. Patients engage with the provider team daily.
89496041|NCT04204408|Experimental|Single dose (part 1) Mim8|Blinded. Single doses in healthy volunteers. Dose escalation. In each of the 6 cohorts, 6 participants will receive Mim8.
89496042|NCT04204408|Placebo Comparator|Single dose (part 1) placebo|Blinded. Single doses in healthy volunteers. In each of the 6 cohorts, 2 participants will receive placebo.
88955293|NCT06329024|Experimental|rehabilitation treatment+ Myofascial Release group|Study lasts 21 days for each patient. All patients are given rehabilitation treatment.The experimental group was given the Myofascial Release Therapy, five days a week, once a day, for 30-60 minutes each time.
89496043|NCT04204408|Experimental|Multiple dose (part 2)|Open-label. There will be 4 cohorts receiving once-weekly doses (part 2 cohorts 1, 2, 3 and 5) and one cohort receiving once-monthly doses (part 2 cohort 4). Participants will continue into the part 2 extension on the same treatment regimen.
89496044|NCT04165460|Experimental|"A Intervention"|Psychoeducation, Relaxation, Cognitive Reestructuring and Problem Solving
89496045|NCT04165460|Active Comparator|"B Intervention"|Psychoeducation, Relaxation
89496046|NCT04156347|Experimental|Phase I Open Label Study|Phase I Single Arm
89496047|NCT04141514|Experimental|intervention group|therapeutic fasting
89496048|NCT04141514|No Intervention|control group|usual alimentation
89496049|NCT04115514|Experimental|Treatment Arm|Liothyronine Sodium (T3+0.9% sodium chloride) modified formulation specifically for airway instillation.
89496050|NCT04115514|Other|Control arm|Standard of Care
89496051|NCT04105868|Experimental|Neurofeedback|Participants will receive feedback about their attention to negative distractors during each trial using activity from their brain waves, which will help them reduce their attention to distractors.
89496052|NCT04097002|Experimental|Phase I, Part A, Cohort 1|"Single dose-escalation of ORCA-010, Dose Cohort 1: 1x10*11 viral particles.~Single dose of ORCA-010 will be administered for the first subject only and all relevant safety data for this subject will be reviewed by the DSMB prior to enrolling additional subjects.~After the DSMB review, subjects will be enrolled in groups of three (including the first subject) and assessed for safety and Dose-Limiting Toxicity (DLT) after a single dose of ORCA-010.~Group of 3 subjects.~Dose will be escalated to the next cohort based on safety and toxicity results from the 3 treated subjects to determine the Maximum Tolerated Dose, if not determined by this cohort."
89496053|NCT04097002|Experimental|Phase I, Part A, Cohort 2|"Single dose-escalation of ORCA-010, Dose Cohort 2: 5x10*11 viral particles.~Group of 3 subjects.~Dose will be escalated to the next cohort based on safety and toxicity results from the 3 treated subjects to determine the Maximum Tolerated Dose, if not determined by this cohort."
89496054|NCT04097002|Experimental|Phase I, Part A, Cohort 3|"Single dose-escalation of ORCA-010, Dose Cohort 3: 1.5x10*12 viral particles.~Group of 3 subjects.~Dose will be considered as the Maximum Tolerated Dose based on safety and toxicity results from the 3 treated subjects."
89496055|NCT04097002|Experimental|Phase IIa, Part B, Cohort 4|"Two dose administration of ORCA-010 seperated by 2 weeks, Dose Cohort 4: The Maximum Tolerated Dose depending on Phase I/ Part A results.~Group of 12 subjects."
89496056|NCT04095091||Control Group|"Healthy volunteers will be asked to complete a single imaging session that will include acquiring simultaneous 4D ultrasound and 4D MRI scan.~A substudy including patients undergoing radiotherapy for malignancies of the abdomen and pelvis. They will also be asked to complete a single imaging session that will include acquiring simultaneous 4D ultrasound and 4D MRI scan."
89496057|NCT04095091||Patient Group|Patients receiving radiotherapy for malignancies of the abdomen and pelvis will be asked to complete two research visits lasting approximately one hour. Each visit will include a 30 minute combined 4D ultrasound and 4D MRI scan.
88955294|NCT06329024|Active Comparator|rehabilitation treatment group|Study lasts 21 days for each patient. All patients are given rehabilitation treatment, five days a week, once a day, for 30-60 minutes each time.
88955295|NCT06329011|Experimental|Comprehensive rehabilitation+Intermittent Oro-esophageal Tube+Transcranial stimulation|The patients are randomly assigned to either the experimental group or the placebo group. All patients receive routine rehabilitation therapy and swallowing rehabilitation training, along with enteral nutrition support using Intermittent Oro-esophageal Tube. In addition to these interventions, patients in the experimental group receive transcranial direct current stimulation, while the instruments used for patients in the placebo group only illuminate an indicator light without any actual effect.
88955296|NCT06329011|Placebo Comparator|Comprehensive rehabilitation+Intermittent Oro-esophageal Tube|The patients are randomly assigned to either the experimental group or the placebo group. All patients receive routine rehabilitation therapy and swallowing rehabilitation training, along with enteral nutrition support using Intermittent Oro-esophageal Tube. In addition to these interventions, patients in the experimental group receive transcranial direct current stimulation, while the instruments used for patients in the placebo group only illuminate an indicator light without any actual effect.
88955297|NCT06328998|Experimental|Routine rehabilitation treatment+Intra-articular Injection|The patients receive a 15-day treatment and are required to stay in the hospital during this period. Patients in the experimental group are given routine rehabilitation treatment and intra-articular injections. Lidocaine is used as the injected medication at a dose of 2ml, administered once every 5 days for a total of three injections.
88955298|NCT06328998|Active Comparator|Routine rehabilitation treatment|The patients receive a 15-day treatment and are required to stay in the hospital during this period. Patients are given routine rehabilitation treatment.
89496058|NCT04083456|Experimental|Walking Biobehavioral Intervention (EXP)|The EXP group will receive biobehavioral training that is integrated into the conventional outpatient training component and is delivered over 5 months. There will be 10 biobehavioral sessions, 1 of which will be a combined biobehavioral/conventional outpatient session and the other 9 being telehealth sessions.
89496059|NCT04083456|Active Comparator|Attention Control (CTL)|The CTL group intervention will include the same conventional outpatient training (10 sessions) as the EXP group and receive the same computer tablets with telehealth software as the EXP group (week 3 of prosthetic training).
89496060|NCT04078061|Active Comparator|MABA|
89496061|NCT04078061|Active Comparator|EIBI|
89496062|NCT04053517||Observational (questionnaire administration)|Patients complete questionnaires about financial state and quality of life over 15 minutes. Patients' medical chart is also reviewed.
89496063|NCT04044534|Experimental|Intranasal insulin|Subjects in this arm will receive 40 IU of intranasal insulin twice a day (80 IU per day).
89496064|NCT04044534|Experimental|Placebo|Subjects in this arm will receive placebo.
89496065|NCT04039464|Active Comparator|Monotherapy with Sildenafil Group|mono-therapy: first-line monotherapy (sildenafil alone) - in pediatric subjects with PAH.
89496066|NCT04039464|Active Comparator|Duo Therapy with Sildenafil + Bosentan Group|duo-therapy: compare two treatment strategies - first-line combination therapy (sildenafil and bosentan)
89496067|NCT03989141|Experimental|Repeated cannulation Buttonhole|The intervention group (I): repeated needling into the same site in the AVF with sharp needles (4-6 pieces) at each dialysis (1-3 dialyses) creating a buttonhole tunnel track where cannulation with a blunt needle is possible.
89496068|NCT03989141|Active Comparator|Single cannulation Buttonhole|The control group (C): needling into the same site in the AVF with 1 sharp needle at each dialysis (6-12 dialyses) creating a buttonhole tunnel track, where cannulation with a blunt needle is possible. .
89496069|NCT03974139|Experimental|Obese patients|Patients with body mass index >30
89496070|NCT03968822|Experimental|Intralipid 20% IV Bolus|"This is 1 out of the 2 study visits. The patient will receive 6 injections (3 in each thigh). The 6 injections are:~lidocaine 1%~lidocaine 2%~bupivacaine 0.5%~bupivacaine 0.25%~saline~no injection~Each test solution will be injected over 5 seconds through a 27G needle and tuberculin syringe at a 30 degree angle.~The patient will also receive an intravenous bolus in the arm of Intralipid 20%.~Participant will be blindfolded for these activities so they will not know what they received during the visit."
89531775|NCT05388656|Experimental|Placebo, Then Estradiol|Participants will first receive transdermal placebo patch (matching transdermal estradiol 0.1 mg/day patch) for 3 weeks. After a washout period of 3 weeks, participants will then receive 0.1 mg/day of transdermal estradiol patch for 3 weeks. Upon completion of the second intervention, all participants will receive 200 mg/day of progesterone for 10 days.
88955299|NCT06328985|Experimental|Rehabilitation therapy+Intermittent Oro-esophageal Tube Feeding|Both groups of patients were provided with routine treatments, including pharmacological treatment, rehabilitation therapy.Based on this, the patients in the observation group were given enteral nutrition support with Intermittent Oro-esophageal Tube Feeding (Medical Device No. 20010234, developed by the Swallowing Disorders Research Institute of Zhengzhou University).
88955300|NCT06328985|Active Comparator|Rehabilitation therapy+Nasogastric tube feeding|Both groups of patients were provided with routine treatments, including pharmacological treatment, rehabilitation therapy. The patients in the control group were provided nutrition support with Nasogastric tube feeding , while the feeding process strictly followed the relevant guideline
88955301|NCT06328972|Experimental|Intermittent Oro-Esophageal Tube Feeding+ systemic therapy|All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy, to promote the development of motor and cognitive function, as well as to improve intellectual development. Besides, swallowing function training was also provided, including direct training, indirect training, and compensatory training.Within 4 hours of admission, the observation group were required to undergo nasogastric tube removal and initiated Intermittent Oro-Esophageal Tube Feeding for nutrition support.
89496071|NCT03968822|Placebo Comparator|Saline|"This is 2 out of the 2 study visits. The patient will receive 6 injections (3 in each thigh). The 6 injections are:~lidocaine 1%~lidocaine 2%~bupivacaine 0.5%~bupivacaine 0.25%~saline~no injection~Each test solution will be injected over 5 seconds through a 27G needle and tuberculin syringe at a 30 degree angle.~The patient will also receive an intravenous bolus in the arm of Saline.~Participant will be blindfolded for these activities so they will not know what they received during the visit."
89496072|NCT03961204|Other|Cohort A|The participants previously enrolled in parent studies CLARITY (NCT00213135), CLARITY-EXT (NCT00641537), ORACLE (NCT00725985) and had received Cladribine tablet and Placebo were invited up to 2 visit for follow-up/data collection.
89496073|NCT03946800|Experimental|MEDI1191 escalation in combination with durvalumab|MEDI1191 escalation in sequential and concurrent combination with durvalumab
89496074|NCT03946800|Experimental|MEDI1191 expansion in combination with durvalumab|MEDI1191 expansion in concurrent combination with durvalumab
89496075|NCT03935971|Experimental|Subjects with Allergic Contact Dermatitis|Dupilumab 600 mg/4 mL subcutaneously once, then 300 mg/2 mL every 2 weeks for 10 weeks
89496076|NCT03932136|Active Comparator|SFN group|The intervention duration with SFN tablet is 52 consecutive weeks. The dosage is six active tablets (411 μmol GR) per day.
89496077|NCT03932136|Placebo Comparator|Placebo group|The intervention duration with placebo tablet is 52 consecutive weeks. The placebo group will be given six placebo tablets per day.
89496078|NCT03918057|Experimental|Cognitive-Behavioural Therapy Group|Participants receive 5 in-person weekly 1.5-hour sessions of cognitive-behavioural therapy for insomnia (CBT-I) for pregnant women, supervised by a registered, licensed clinical psychologist.
89496079|NCT03918057|Active Comparator|Treatment as Usual Group|Participants receive usual obstetric care and are placed on a wait-list until six months postpartum. All activities or efforts participants make to treat or improve their sleep on their own is recorded and coded. After the final assessment six months postpartum, participants have the option of receiving 1.5-hour sessions (for a total of 5 session) of cognitive-behavioural therapy for insomnia (CBT-I) for pregnant women, supervised by a registered, licensed clinical psychologist.
89496080|NCT03841019|Experimental|magnetic seizure therapy|12 treatment sessions of MST, three times per week.
89496081|NCT03841019|Active Comparator|electroconvulsive therapy|12 treatment sessions of ECT, three times per week.
89496082|NCT03816007|Experimental|Yoga and Mantram Repetition|An existing yoga intervention designed for persons with chronic pain will be augmented with training in mantram repetition. The intervention meets 1x weekly for 75 minutes for 12 weeks, and includes a home practice component.
89496083|NCT03816007|Active Comparator|Relaxation/Health Education|A relaxation intervention used previously as a comparator intervention will be delivered by a health educator.
89496084|NCT03804229|Experimental|active group|Take two pills (100 mg each) of Butylphthalide soft capsule each time, three times a day, 0.5 hours before meal, taking with lukewarm water.
89496085|NCT03804229|Placebo Comparator|control group|Take two pills of placebo soft capsule each time, three times a day, 0.5 hours before meal, taking with lukewarm water.
89496086|NCT03797326|Experimental|Pembrolizumab + Lenvatinib (Arm 1)|Participants receive pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W) plus lenvatinib 20 mg via oral capsule once a day (QD). Pembrolizumab will be administered for up to 35 cycles (up to 2 years). Lenvatinib will be administered until progressive disease or unacceptable toxicity (up to at least 2 years).
89496087|NCT03797326|Experimental|Lenvatinib Monotherapy (Arm 2)|Participants receive lenvatinib 24 mg via oral capsule QD, to be administered until progressive disease or unacceptable toxicity (up to at least 2 years).
89496088|NCT03781700|Experimental|Prednisolone|Prednisolone
89496089|NCT03781700|Placebo Comparator|Placebo|Placebo oral tablet
89496090|NCT03771417|Experimental|Resistance Exercise|Exercise Intervention: Participants will be asked to complete supervised resistance exercise 2 days per week.
89496091|NCT03771417|Experimental|RE plus Low Intensity Physical Activity|Exercise Intervention: Participants will be asked to complete supervised resistance exercise 2 days per week and regular unsupervised low intensity physical activity breaks in sedentary time 5 days per week [6x10 min breaks/d at 2 metabolic equivalents (METS) or ~30-40% peak oxygen consumption (VO2 peak), ~500 kcal/wk above resting metabolism].
89496092|NCT03771417|Active Comparator|RE plus Moderate IntensityExercise|Exercise Intervention: Participants will be asked to complete supervised RE 2 days per week and supervised calorically matched moderate intensity physical activity 3 days per week (50 min/session at 4 METS (~60-75% VO2 peak), ~500 kcal/week above resting metabolism).
89496093|NCT03749018|Experimental|Treatment (nivolumab, DA-REPOCH)|Patients receive rituximab IV and nivolumab IV over 60 minutes on day 1. Patients also receive etoposide, vincristine sulfate and doxorubicin hydrochloride IV continuously over 96 hours, cyclophosphamide IV bolus, and prednisone PO on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. After course 6, patients receive nivolumab IV over 60 minutes on day 1 every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
89496094|NCT03712449|Experimental|BELKYRA Treatment|"BELKYRA was injected into the subcutaneous fat for maximum of 6 treatments, 1 month apart from Month 0 to Month 5. Maximum dose did not exceed 100 milligrams (mg) [10 milliliters (mL)] in a single treatment.~SkinMedica products: (Facial Cleanser, TNS Essential Serum®, Rejuvenative Moisturizer, Optional: Total Defense + Repair Broad Spectrum Sunscreen SPF34), applied daily from Month 6 to Month 11.~Facial filler injectable treatment (JUVÉDERM VOLBELLA with Lidocaine and/or JUVÉDERM VOLIFT with Lidocaine and/or JUVÉDERM VOLUMA with Lidocaine and/or JUVÉDERM VOLITE with Lidocaine) from Month 6 to Month 8. The volume of filler injected at initial and touch-up treatments was determined by the investigator.~BOTOX Cosmetic 20 units (U) to glabellar lines and/or 2-6 U injected bilaterally to crow's feet lines and/or 24 U total injected to forehead lines at Month 9 and Month 10."
89496095|NCT03712449|Experimental|Non-BELKYRA Treatment|"Participants who did not receive BELKYRA.~SkinMedica products: (Facial Cleanser, TNS Essential Serum®, Rejuvenative Moisturizer, Optional: Total Defense + Repair Broad Spectrum Sunscreen SPF34), applied daily from Month 0 to Month 5.~Facial filler injectable treatment (JUVÉDERM VOLBELLA with Lidocaine and/or JUVÉDERM VOLIFT with Lidocaine and/or JUVÉDERM VOLUMA with Lidocaine and/or JUVÉDERM VOLITE with Lidocaine) from Month 0 to Month 2. The volume of filler injected at initial and touch-up treatments was determined by the investigator.~BOTOX Cosmetic 20 units (U) to glabellar lines and/or 2-6 U injected bilaterally to crow's feet lines and/or 24 U total injected to forehead lines at Month 3 and Month 4."
89496096|NCT03671226|Experimental|Supportive Care (questionnaire)|Patients and their caregivers complete a questionnaire over 15 minutes either in person or over the phone within 3 days after their supportive care center visit.
89496097|NCT03649178|Other|low salt diet|low-sodium diet (50mmol/24hours x 8 weeks ) Subjects will choose a rotation of low-sodium meals from a predetermined list from a commercial vendor (Mom's Meals) that will be used to provide 2 meals (lunch and dinner)/day that the vendor will deliver at approximately 7 day intervals. Staff of the Vanderbilt Diet,Body Composition, and Human Metabolism Core determine breakfast and snacks appropriate for theHS andLS diets and provide instructions to subjects.
89496098|NCT03649178|Other|high salt diet|high-sodium diet (200mmol/24hours x 8weeks) Subjects will choose a rotation of low-sodium meals from a predetermined list from a commercial vendor (Mom's Meals) that will be used to provide 2 meals (lunch and dinner)/day that the vendor will deliver at approximately 7 day intervals. Staff of the Vanderbilt Diet,Body Composition, and Human Metabolism Core determine breakfast and snacks appropriate for theHS andLS diets and provide instructions to subjects.
88955302|NCT06328972|Active Comparator|systemic therapy+Persistent Nasogastric Tube Feeding|All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy, to promote the development of motor and cognitive function, as well as to improve intellectual development. Besides, swallowing function training was also provided, including direct training, indirect training, and compensatory training.The control group was given nutrition support with persistent nasogastric tube feeding , of which the tube passed through the nasal cavity into the stomach.
89022624|NCT06189235|No Intervention|System application: Traditional training|The program last for one month. In this program, the patients receive traditional rehabilitation protocol assigned from original hospital or therapist. Also, ultrasound evaluation and hand function assessment will be performed at pre-test, one follow-up test and post-test, which will be done with two weeks interval.
89496099|NCT03637400|Experimental|Trimethoprim/sulfamethoxazole (TMP-SMX)|TMP-SMX will be dosed as follows: for adults, 160/800 mg administered as two single strength (SS) over-encapsulated tablets (equivalent to one double strength (DS) tablet) twice daily. As dosages of these medications may be lower in children with lower body weight (<40 kg), we will use weight based liquid medications for children < 40 kg (TMP/SMX dosed based on 8-10 mg/kg of TMP daily, divided into two daily doses) for those children who are under 40 kg in weight. As dosages of these medications are higher in persons with high body weight (>100 kg), we will use TMP/SMX 160/800 mg administered as four single strength (SS) over-encapsulated tablets (equivalent to two double strength (DS) tablet) twice daily.
89496100|NCT03637400|Experimental|Doxycycline (DOXY)|DOXY will be dosed as follows: for adults, two 50 mg tabs (100 mg total) given twice daily. As dosages of these medications may be lower in children with lower body weight (<40 kg), we will use weight based liquid medications for children < 40 kg (DOXY 2.2 mg/kg twice daily) for those children who are under 40 kg in weight. The doxycycline dose will remain the same for persons with high body weight (>100 kg) and four additional placebo tabs will be given to subjects > 100 kg randomized to doxycycline.
89496101|NCT03620539|No Intervention|Control|Participants randomized to the control condition will be asked to maintain their normal daily habits.
89496102|NCT03620539|Experimental|Sauna|The sauna intervention will consist of 20 to 30 minute sauna bathing sessions within a dry Finnish sauna, performed 4 times per week.
89496103|NCT03619655|Experimental|"Cohort A - SPECT CT and NaF PET"|Intervention 1: SPECT CT Intervention 2: NaF PET
89496104|NCT03619655|Experimental|"Cohort B - SPECT CT and 18F-DCFPyL PET/CT"|Intervention 1: SPECT CT Intervention 2: 18F-DCFPyL PET/CT
89496105|NCT03619655|Experimental|"Cohort C - SPECT CT and WB-MRI"|Intervention 1: SPECT CT Intervention 2: WB-MRI
89496106|NCT03615222||SERVE assessment only|Eligible veterans will complete 4 assessments over a two year period of time.
89496107|NCT03607552||Phase 1: Pilot Study Phase|Optimize DWI sequences to maximize spatial resolution, reduce distortion, and increase lesion contrast.
89496108|NCT03607552||Phase 2: Development Phase|Develop interpretation tools to optimize diagnostic performance for detecting cx on DWI.
89496109|NCT03607552||Phase 3: Reader Performance Phase|Test the performance of the optimized DWI approach for detecting clinically and mammographically-occult cancer in women with dense breasts.
89496110|NCT03586453|Experimental|Osimertinib|Osimertinib: Oral, once a day, dosage determined per protocol
89496111|NCT03583255|Experimental|Arm I (dexamethasone, exercise)|Patients receive dexamethasone PO BID for 7 days. Patients also complete resistance training and moderate intensity walking at home for minimum 5 days per week over 4 weeks.
89496112|NCT03583255|Active Comparator|Arm II (placebo, exercise)|Patients receive placebo PO BID for 7 days. Patients also complete resistance training and moderate intensity walking as in Arm I.
89496113|NCT03546101||Department of Kidney Medicine|Primarily transplant recipients undergoing monitoring for EBV and patients suspected for having PTLD.
89496114|NCT03546101||Department of Hematology|Patients diagnosed with PTLD and other kinds of lymphoma. Patients undergoing hematopoietic stem cell transplantation and patients with hemophagocytosis.
89496115|NCT03546101||Department of pediatrics|Children undergoing transplantation. Children diagnosed with hemophagocytic lymphohistiocytosis.
89496116|NCT03523559||Interstitial Cystitis|
89496117|NCT03523559||normal|
88955303|NCT06328959|Experimental|IOE group|IOE groups were given systematic therapy according to the routine treatment plan for PRS for 4 weeks. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
89496118|NCT03505424|Active Comparator|Group 1: Standard of Care|Parents of infants born from April -mid-August 2018 (Group 1)
89496119|NCT03505424|Active Comparator|Group 2: NICU2HOME app|Parents of infants born from mid-August 2018- January 2019 (Group 2)
89496120|NCT03505424|Active Comparator|Group 3: SMART NICU2HOME app|Parents of infants born from February- June 2019 (Group 3)
89496121|NCT03502603|Active Comparator|Cerebral neurological illness (CNI) participants|Identified from the department of Rehabilitation, Psychiatry, and Medicine and referred to the research staff via in-person communication, email or staff message
89496122|NCT03502603|Active Comparator|Non-CNI participants|Identified from the department of Rehabilitation, Psychiatry, and Medicine and referred to the research staff via in-person communication, email or staff message
89496123|NCT03409432|Experimental|Treatment (brentuximab vedotin, lenalidomide)|Patients receive brentuximab vedotin IV over 30 minutes on day 1 and lenalidomide PO QD on day 1-21. Treatment repeats every 21 days for up to 16 courses in the absence of disease progression or unacceptable toxicity.
89496124|NCT03407833||Obese, surgery|Obese subjects recruited from the Center for Surgical Weight loss who are undergoing weight loss surgery as part of their standard of care. Tissue biopsies, blood, and fecal swabs will be collected at surgical visits.
89205255|NCT05773612|Other|Rock Steady Boxing classes|The Rock Steady Boxing classes are 60-90 minutes in duration twice a week and include the following 4 components: (1) active warm up (2) functional mobility exercises (3) whole body strengthening exercises and (4) non-contact boxing exercises.
89205256|NCT05773560|Experimental|Patients receiving rehabilitation with virtual reality.|Single Group Assignment Patients after a major amputation would received at least 10 days of rehabilitation with the assistance of virtual reality. Before the operation, patients consent, life quality, pain score and motivation score were be evaluated. The rehabiliation with virtual reality started on the second postoperative day. The pain score would be evaluated everyday before and after the rebilitation. On the fifth and tenth day, motivation, life quality and functional index would be carried out again as the evaluation of the outcome of training.
89205257|NCT05773547||Professional|Two investigators who have performed over 200 MSOT measurements.
89205258|NCT05773547||Trainee-personal teaching|Trainees are defined as who haven't performed any MSOT measurement. In this cohort, one trainee received a personal teaching from one professional.
89496125|NCT03407833||Obese, nonsurgery|Obese subjects recruited from the Vanderbilt Endoscopy Clinic who are undergoing upper endoscopy or colonoscopy as part of their standard of care. Tissue biopsies, blood, and fecal swabs will be collected at day of procedure.
89496126|NCT03407833||Lean control|Lean control subjects recruited from the Vanderbilt Endoscopy Clinic who are undergoing upper endoscopy or colonoscopy as part of their standard of care. Tissue biopsies, blood, and fecal swabs will be collected at day of procedure.
89496127|NCT03407833||Liver transplant|Lean or obese subjects who are undergoing liver transplantation as part of their standard of care. Excised liver tissue will be collected the day of procedure.
89496128|NCT03374826|Experimental|Dedicated axillary hybrid PET-MRI axilla|
89496129|NCT03343483|Experimental|Volunteering|Structured social volunteering program providing peer companionship to frail, homebound older adults for at least 16 hours per month for 12 months.
89496130|NCT03343483|Active Comparator|Life Review|Self-guided program of life review for 12 months.
89496131|NCT03323476|Experimental|Discontinuation of maintenance treatment|
89496132|NCT03323476|Active Comparator|Maintenance of immunosuppressive treatment|
89496133|NCT03315312|Active Comparator|Fissure sealant|
89496134|NCT03315312|Experimental|Fluoride varnish|
89496135|NCT03304691||Bandiagara, Mali|Children of both sexes between 6 months and 10 years of age.
89496136|NCT03304691||Yirimadio, Bamako, Mali|Children and adults of both sexes 6 months and older.
89496137|NCT03289325|Experimental|DEX group|The active drug (dexmedetomidine hydrochloride for injection) will be administered during a period from before anesthesia induction until the end of mechanical ventilation after surgery.
89496138|NCT03289325|Placebo Comparator|CTRL group|The placebo drug (normal saline, or 0.9% sodium chloride for injection) will be administered in the same rate and volume for a same duration as that in the DEX group.
89205259|NCT05773547||Trainee-video|Trainees are defined as who haven't performed any MSOT measurement. In this cohort, one trainee received instruction from video.
89205260|NCT05773547||Trainee-instruction in paperform|Trainees are defined as who haven't performed any MSOT measurement. In this cohort, one trainee received instruction in paperform.
89496139|NCT03204123|Active Comparator|Ga-HBED-iPSMA PET with CT or MRI|Participants will have a PET scan with Ga-HBED-iPSMA. PET may be combined with CT or MRI at the discretion of the referring clinician.
89496140|NCT03204123|Active Comparator|Ga-HBED-iPSMA PET with MRI|Participants will have a PET scan with Ga-HBED-iPSMA and will be combined with MRI. If PET/MR imaging is not available, PET/CT imaging may be substituted. This arm will be closed to accrual and these patients will be analyzed separately.
89496141|NCT03197454|Experimental|Experimental Treatment|Computerized plasticity-based adaptive cognitive training requiring a total maximum of 50 treatment sessions, up to 5 sessions per week, 42 minutes per session.
89496142|NCT03197454|Active Comparator|Active Comparator|Commercially available computerized training requiring a total maximum of 50 treatment sessions, up to 5 sessions per week, 42 minutes per session.
89496143|NCT03190954|Placebo Comparator|[11C]NNC-112|[11C]NNC-112 PET scan obtained without any drug intervention to measure dopamine D1 receptors. Blind N/A
89496144|NCT03190954|Active Comparator|[11C]raclopride plus drug|Methylphenidate 60 mg. po will be given 60 minutes prior to [11C]raclopride scan to measure striatal dopamine release. MRI scan to follow end of PET scan. Subject blind as to drug administration.
89496145|NCT03190954|Placebo Comparator|[11C]raclopride plus placebo|Placebo (po) will be given 60 minutes prior to [11C]raclopride scan to measure baseline dopamine D2 receptors. MRI scan to follow end of PET scan. Subject blind as to drug administration.
89496146|NCT03150433|Experimental|Behavioral symptom management|Five sessions working one-on-one with a study interventionist, either in person or by telephone. Includes monitoring of the individual's sleep pattern, feedback and goals for improving sleep and pain management, and addressing cognitive and emotional strategies for managing sleep and pain.
89496147|NCT03150433|Other|Sickle cell disease management|Five sessions working one-on-one with a study interventionist, either in person or by telephone. Includes monitoring of the individual's sleep pattern, information about sickle cell disease and its management, and information about improving sleep and managing pain.
89205261|NCT05773534||healthy group|"Multispectral Optoacoustic Tomography (MSOT) of the Musculus triceps surae of one leg in healthy volunteers~Physical assessment: Pulse status / Color-Coded Duplex Sonography / Ankle-Brachial Index / 6-minute walk test (6MWT) / Continued heel raises for at least 30s"
89496148|NCT03146442|Active Comparator|Normal Protein (NP) Breakfast|The participants in the NP Breakfast group will be provided with NP Breakfasts to consume, at home, between 6:00-9:00 am each day over the 6-month intervention. The energy content of the breakfast meals will be standardized to 350 kcal. The energy content of the breakfast meals is ~18% of daily energy intake estimated from the energy expenditure equations specific for adolescents ages 13-19y. The NP breakfasts will be 11% protein (10g protein), 63% CHO, and 26% fat. The types of protein incorporated within the NP and HP meals will include a combination of animal (egg, dairy, animal tissue) and plant-based proteins (soy, pea, gluten). An 8-d breakfast rotation will occur throughout the 6 months.
89496149|NCT03146442|Experimental|High Protein (HP) Breakfast|The participants in the HP Breakfast group will be provided with HP Breakfasts to consume, at home, between 6:00-9:00 am each day over the 6-month intervention. The energy content of the breakfast meals will be standardized to 350 kcal. The energy content of the breakfast meals is ~18% of daily energy intake estimated from the energy expenditure equations specific for adolescents ages 13-19y. The HP breakfasts will be 34% protein (30g protein), 40% CHO, and 26% fat. The types of protein incorporated within the HP and HP meals will include a combination of animal (egg, dairy, animal tissue) and plant-based proteins (soy, pea, gluten). An 8-d breakfast rotation will occur throughout the 6 months.
89496150|NCT03146442|Placebo Comparator|Breakfast Skipping (BS)|The participants in the BS group will continue to skip breakfast each day over the 6-month intervention. They will have nothing to eat or drink (besides water) until 11 am.
89496151|NCT03122717|Experimental|Gefitinib + Osimertinib|"Gerfitinib will administered orally at a pre determine dose daily~Osimertinib will administered orally at a pre determine dose daily"
89496152|NCT03104972|Experimental|tDCS - placebo|tDCS-placebo (sham) group to receive either transcranial direct stimulation (tDCS) or matching placebo (sham( during 5 following days (one session each day). After a one week break, there will be a crossover between the control group and the sham group: those we received tDCS in the 1st week will get sham, while those who received sham in the 1st week will received tDCS at the 3rd week.
89496153|NCT03104972|Experimental|tRNS - placebo|trans cranial random stimulation (tRNS)-sham group, who will receive the same type of intervention with the same intervals as above but with tRNS instead of tDCS.
89496154|NCT03104972|Experimental|tDCS-tRNS|tDCS-tRNS group. Here the same intervention as above will be provided with the same intervals, but real tDCS and real tRNS will be provided in a counterbalanced fashion. This would allow to compare the different treatment in a within-subject design, as well as to compare the effect of those to sham stimulation in the first two groups in a between-subject design.
89496155|NCT03035409|Experimental|Supportive Care (anamorelin, physical activity, counseling)|Patients receive anamorelin hydrochloride PO QD and undergo physical activity consisting of resistance exercises and a home walking program. Treatment continues for up to 6 weeks in the absence of disease progression or unacceptable toxicity. Patients also undergo nutritional counseling on day 21.
89496156|NCT03006068|Experimental|Participants receiving Upadacitinib (ABT-494) Dose A|The participants in this arm will receive Upadacitinib (ABT-494) dose A.
89496157|NCT03006068|Experimental|Participants receiving Upadacitinib (ABT-494) Dose B|The participants in this arm will receive Upadacitinib (ABT-494) dose B.
89496158|NCT03006068|Experimental|Participants receiving Upadacitinib (ABT-494) Dose C|The participants in this arm will receive Upadacitinib (ABT-494) dose C.
89496159|NCT03006068|Experimental|Participants receiving Placebo|The participants in this arm will receive placebo until study is unblinded.
89496160|NCT03006068|Experimental|Participants receiving Upadacitinib (ABT-494) Dose A or Dose B|The participants in this arm will receive Upadacitinib (ABT-494) dose A or dose B.
89496161|NCT02965703|Experimental|Arm I (aspirin)|Patients receive aspirin PO daily for 12 weeks in the absence of unacceptable toxicity. Patients also undergo collection of blood, urine, stool, rectal swab samples, and rectal biopsies throughout the trial.
89496162|NCT02965703|Experimental|Arm II (aspirin, placebo)|Patients receive aspirin PO daily at weeks 1-3 and 7-9 and placebo PO daily at weeks 4-6 and 10-12 in the absence of unacceptable toxicity. Patients also undergo collection of blood, urine, stool, rectal swab samples, and rectal biopsies throughout the trial.
89496163|NCT02965703|Placebo Comparator|Arm III (placebo)|Patients receive placebo PO daily for 12 weeks in the absence of unacceptable toxicity. Patients also undergo collection of blood, urine, stool, rectal swab samples, and rectal biopsies throughout the trial.
89496164|NCT02943915|Experimental|Group 1: Ekso GT Rehabilitation Therapy|Participants in this group receive Ekso GT (gait training) PT therapy intervention 3 times per week for 12 weeks (36 sessions). Intervention: Ekso GT Rehabilitation therapy
89496165|NCT02943915|Active Comparator|Group 2: Active controls - BWSTT Therapy|Participants in this group receive a matched number of sessions of standard gait training using body-weight supported treadmill training and overground training. Intervention: Body Weight Supported Treadmill Training
89496166|NCT02943915|No Intervention|Group 3: Passive controls|Participants in this group continue with normal daily activities over 12 weeks.
89496167|NCT02824185|Experimental|FCH-PET/MRI|FCH-PET/MRI exam performed in addition to the usual examinations for monitoring hepatocellular carcinoma.
89496168|NCT02795442|Experimental|Even protein|Menu to provide 90 g of protein per day in an even distribution of 30 g at each meal.
89496169|NCT02795442|Experimental|Skewed protein|Menu to provide 90 g of protein per day in a skewed distribution of 10 g at breakfast, 15 g at lunch and 65 g at dinner.
89496170|NCT02772003|Experimental|Treatment (INO-8000, INO-9012, EP)|Patients receive INO-8000 IM and DNA plasmid encoding interleukin-12 INO-9012 IM (dose levels 2-4) followed by EP at day 0 and at weeks 4, 12, and 24.
89496171|NCT02763384|Experimental|Arm 1: BL-8040 and Nelarabine|"Cycle 1: BL-8040 subcutaneous daily from Day 1 to Day 6 and nelarabine intravenously over 2 hours on Days 2, 4, and 6~Cycles 2-4: BL-8040 subcutaneous daily from Day 1 to Day 5 and nelarabine intravenously over 2 hours on Days 1, 3, and 5~Treatment may be repeated every 21 days for up to 4 cycles"
89496172|NCT02708394|Experimental|olanzapine|Atypical antipsychotic
89496173|NCT02708394|Placebo Comparator|placebo|Placebo comparator
89496174|NCT02662062|Experimental|Pembrolizumab|Pembrolizumab to be administered via IV 200mg 3 weekly commenced concurrently with chemoradiotherapy, and continuing until 12 week cystoscopy.
89496175|NCT02649855|Experimental|Arm A/Sequential Docetaxel followed by PROSTVAC|Standard androgen deprivation therapy (ADT) followed by sequential docetaxel + prostvac
89496176|NCT02649855|Experimental|Arm B/ Combined Docetaxel with PROSTVAC|Standard androgen deprivation therapy (ADT) followed by combined docetaxel + prostvac
89022625|NCT06189222|Experimental|virtual reality glasses|The sample of the research, which was carried out as a randomized controlled experimental study, consisted of 102 children, including 51 in the control group and 51 in the study group, who were aged between 7 and 12 and were on treatment in the emergency department. Research data were collected using a Descriptive Data Form for Children and the Children's Emotional Manifestation Scale. During the data collection phase, first, the Descriptive Data Form for Children was filled out for the control and study groups. No intervention was applied to the control group. After the tourniquet was tied in the study group, the children started watching a video of their choice through virtual reality glasses. When the process was completed, the video was stopped. During this period, the child was evaluated using the Children's Emotional Manifestation Scale.
89022626|NCT06189222|No Intervention|standard care|Intervention during intravenous catheter insertion to the child
89022627|NCT06189196|Experimental|Group A|BLOW BOTTLE
89022628|NCT06189196|Experimental|Group B|ACBT
89022629|NCT06189157|Experimental|Dose Level 0|Phase I: DL 0: 0,1x10e6 MB-CART19.1 cells Dose finding algorithm will start at dose level 1, with dose level 0 as a rescue dose.
89496177|NCT02649855|Experimental|Arm C/ PROSTVAC Prior to Docetaxel|Standard androgen deprivation therapy (ADT) followed by prostvac, then docetaxel. No ADT for less than 28 days, prostvac prior to docetaxel.
89496178|NCT02619682|Experimental|Treatment (ixazomib citrate and lenalidomide)|Within 30-120 days after finishing autologous transplant, patients receive ixazomib citrate PO on days 1, 8 and 15. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients then receive lenalidomide PO QD on days 1-28. Treatment repeats for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients will continue to alternate between ixazomib citrate and lenalidomide every 2 courses for up to 24 months in the absence of disease progression or unacceptable toxicity.
89022630|NCT06189157|Experimental|Dose Level 1|Phase I: DL 1: 0,5x10e6 MB-CART19.1 cells Patients will be treated in cohorts of 3. If no DLT is determined, the dose can be escalated.
89496179|NCT02613507|Experimental|Arm A: Nivolumab|Nivolumab Intravenous infusion specified dose on specified days
89496180|NCT02613507|Active Comparator|Arm B: Docetaxel|Docetaxel Intravenous infusion specified dose on specified days
89496181|NCT02592382|Experimental|Xylitol spray|Xylitol nasal spray ( Xlear ltd which contains 10% of Xylitiol) given 3 times a day (one puff for each nostril) for three months period.
89022631|NCT06189157|Experimental|Dose Level 2|Phase I: DL 2: 1,0x10e6 MB-CART19.1 cells At the highest dose level 3 additional patients will be treated.
89022632|NCT06189157|Experimental|Phase II - Recommended dose MB-CART19.1|Phase II will evaluate the efficacy and safety in patients treated with the recommended dose
89022633|NCT06189144|Experimental|experimental arm|SLS irritation model and Treatment
89022634|NCT06189144|Placebo Comparator|placebo comparator|SLS irritation model and No Treatment
89496182|NCT02539407||Anti-infectives|"Anti-infectives of the following : β-lactam antibiotics, Aminoglycosides, Glycopeptides, Fluoroquinolone, Daptomycin, Rifampin, Trimethoprim, Sulfamethoxazole, Clarithromycin, Fungal, Antiviral~Pharmacokinetics"
89496183|NCT02538510|Experimental|Treatment (vorinostat, pembrolizumab)|Patients receive vorinostat PO QD or via PEG on days 1-5 and pembrolizumab IV over 30 minutes on day 1. Courses repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
89496184|NCT02521285|Experimental|Arm A (aspirin)|Patients receive aspirin PO QD for 12 months.
89496185|NCT02521285|Placebo Comparator|Arm B (placebo)|Patients receive placebo PO QD for 12 months.
89496186|NCT02436226|Active Comparator|Clomiphene citrate-HCG group|Women will receive clomiphene citrate and human chorionic gonadotropin (HCG)
89496187|NCT02436226|Active Comparator|Clomiphene citrate group|Women will receive clomiphene citrate alone
89496188|NCT02421380|Experimental|Hyperpolarized Pyruvate MRI Reproducibility|This is a reproducibility study of hyperpolarized [1-13C] pyruvate MRI in patients with solid tumors. A total of 100 patients will be enrolled, 50 of whom will be imaged using 1D MR spectroscopy and the other 50 with 3D imaging sequence.
89496189|NCT02419040|Experimental|Barbotage|Ultrasound guided needling, lavage and steroid/lidocain injection (20 mg Triamcinolon/9 ml Lidocain 1%) Ultrasound guided lidocain injection (10 ml Lidocain 1%, sham group) and home exercises
89496190|NCT02419040|Active Comparator|Corticosteroid injection|Ultrasound guided steroid/lidocain injection (20 mg Triamcinolon/9 ml Lidocain 1%) and home exercises
89496191|NCT02419040|Sham Comparator|Lidocain injection (sham)|Ultrasound guided lidocain injection (10 ml Lidocain 1%, sham group) and home exercises
89496192|NCT02407171|Experimental|Non Small Cell Lung Cancer, Phase I|Dose escalation cohort for patients with Non Small Cell Lung Cancer (NSCLC). The starting dose will be 3000 cGy in 5 fractions; there will be one dose escalation cohort (3000 cGy in 3 fractions), and if necessary one dose de-escalation cohort (1000 cGy in a single fraction). If there is dose-limiting toxicity at the lowest cohort, that arm will be closed and SBRT to that site will be discontinued.
89496193|NCT02407171|Experimental|Non-Lung, Phase I|Dose escalation cohort for non lung cancer patients. The starting dose will be 3000 cGy in 5 fractions; there will be one dose escalation cohort (3000 cGy in 3 fractions), and if necessary one dose de-escalation cohort (1000 cGy in a single fraction). If there is dose-limiting toxicity at the lowest cohort, that arm will be closed and SBRT to that site will be discontinued.
89022635|NCT06189131|Experimental|Group 1: Acutely admitted surgical patients with no planned surgery|This cohort of individuals will be those admitted to the EGS department with a surgical pathology but who have not undergone surgery during the admission and by the end of data collection (7 days) (e.g. pancreatitis, conservative management intra-abdominal pathology). The rationale behind recruiting this cohort of patients is to assess the admission V02Max and how unwell patients are during their admission by correlating this result to their NEWS score, blood results and any evidence of clinical deterioration. This cohort of patients will help us understand whether V02Max correlates with patient's clinical conditions and outcomes.
89022636|NCT06189131|Experimental|Group 2: Acutely admitted surgical patients who have undergone an emergency procedure|Pre and post-operative Ventriject V02Max values will be taken in this group of patients to assess whether pre-operative V02Max correlates with pre-operative PPOSSUM, NELA scores and post-operative outcomes. This group of participants will answer whether acute V02Max is reflective of operative outcomes and whether it correlates with current methods of risk stratification (PPOSSUM, NELA, ASA) and post-operative outcome scores (Clavien-Dindo classification). This group is important as it will help establish whether V02Max measurements in the acute setting for operative risk stratification is feasible.
89022637|NCT06189118|Experimental|Online Mindfulness based Cognitive Therapy|The intervention will consist of 8 online weekly sessions (90-min each) of Mindfulness based Cognitive Therapy, plus daily home practice.
89022638|NCT06189118|Active Comparator|Online Health Education Program|The active control will consist of 8 online weekly sessions (90-min each) of Health Education Program, plus daily home practice.
89022639|NCT06189105|Experimental|experimental arm|"Use of facial serum with~niacinamide, plant-based collagen and~peptides on randomized site on forehead"
89022640|NCT06189105|Placebo Comparator|placebo comparator|"No treatment (usual~skincare rutine)"
89022641|NCT06189092||Performed electrosclerotherapy|All patients who performed electrosclerotherapy in the treatment of vascular malformations
89496194|NCT02407171|Experimental|Melanoma Expansion Cohort|Phase 2a expansion cohort for patients with melanoma. Patients will be treated at the maximum tolerated dose discovered in phase I.
89496195|NCT02407171|Experimental|Non Small Cell Lung Cancer Expansion Cohort|Phase 2a expansion cohort for patients with NSCLC. Patients will be treated at the maximum tolerated dose discovered in phase I.
89496196|NCT02381535|Experimental|Treatment (onalespib, cisplatin, IMRT)|Patient receive onalespib IV over 1 hour on days -7, 3, 10, 24, 31, and 38 and cisplatin IV over 1 hour on days 1, 8, 15, 22, 29, 36 and 43. Patients also undergo IMRT QD, 5 days a week over 7 weeks for a total of 35 fractions. Treatment continues in the absence of disease progression or unacceptable toxicity.
89496197|NCT02358083|No Intervention|Arm 1. HPV + Control + Control|HPV is target vaccine. No message regarding relative safety of vaccine; Provider provides brief routine recommendation for vaccination.
89022642|NCT06189053||Cohort 1: Post-vaccine Myocarditis (PVM)|Cohort 1 will include participants with a myocarditis event diagnosis or service date within 30 days on/after a SPIKEVAX vaccination and participants with at least 1 dose of SPIKEVAX in the 7 days prior to and including the index date.
89022643|NCT06189053||Cohort 2: All Other Myocarditis|Cohort 2 will include participants with no evidence of SPIKEVAX and no evidence of other vaccines targeting SARS CoV-2 within 30 days on/after a SPIKEVAX vaccination.
89022644|NCT06189040|Active Comparator|BNT162b2 regular schedule|day 0: intramuscular administration of BNT162b2 (30µg) day 28: intramuscular administration of BNT162b2 (30µg)
89022645|NCT06189040|Experimental|BNT162b2 + mRNA-1273 schedule|day 0: intramuscular administration of BNT162b2 (30µg) day 28: intramuscular administration of mRNA-1273 (100µg)
89022646|NCT06189040|Experimental|BNT162b2 + ChAdOx1-S schedule|day 0: intramuscular administration of BNT162b2 (30µg) day 28: intramuscular administration of ChAdOx1-S [recombinant] (not less than 2.5x10^8 infectious units)
89496198|NCT02358083|Experimental|Arm 2. HPV + Control + Strong|HPV is target vaccine; No message regarding relative safety of vaccine; Provider provides strong recommendation for vaccination.
89496199|NCT02358083|Experimental|Arm 3. HPV + Control + Disclosure|HPV is target vaccine; No message regarding relative safety of vaccine; Provider provides strong recommendation for vaccination and personal disclosure regarding own child's vaccination history.
89496200|NCT02358083|Experimental|Arm 4. HPV + Safety + Control|HPV is target vaccine; Provider provides message about relative safety of vaccination compared to other common daily activities; Provider provides brief routine recommendation for vaccination.
89496201|NCT02358083|Experimental|Arm 5. HPV + Safety + Strong|HPV is target vaccine; Provider provides message about relative safety of vaccination compared to other common daily activities; Provider provides strong recommendation for vaccination.
89496202|NCT02358083|Experimental|Arm 6. HPV + Safety + Disclosure|HPV is target vaccine; Provider provides message about relative safety of vaccination compared to other common daily activities; Provider provides strong recommendation for vaccination and personal disclosure regarding own child's vaccination history.
89496203|NCT02358083|No Intervention|Arm 7. Flu + Control + Control|Flu is target vaccine. No message regarding relative safety of vaccine; Provider provides brief routine recommendation for vaccination.
89496204|NCT02358083|Experimental|Arm 8. Flu + Control + Strong|Flu is target vaccine; No message regarding relative safety of vaccine; Provider provides strong recommendation for vaccination.
89496205|NCT02358083|Experimental|Arm 9. Flu + Control + Disclosure|Flu is target vaccine; No message regarding relative safety of vaccine; Provider provides strong recommendation for vaccination and personal disclosure regarding own child's vaccination history.
89496206|NCT02358083|Experimental|Arm 10. Flu + Safety + Control|Flu is target vaccine; Provider provides message about relative safety of vaccination compared to other common daily activities; Provider provides brief routine recommendation for vaccination.
89496207|NCT02358083|Experimental|Arm 11. Flu + Safety + Strong|Flu is target vaccine; Provider provides message about relative safety of vaccination compared to other common daily activities; Provider provides strong recommendation for vaccination.
89531776|NCT05381623|Experimental|Simplified suture-less approach|Infiltration of local anesthetic (articaine 4% 1:100.000 epinephrine) around the harvesting site and attendance for the establishment of a competent coagulum.
89022647|NCT06189040|Experimental|BNT162b2 low dose schedule|day 0: intramuscular administration of BNT162b2 (20µg) day 28: intramuscular administration of BNT162b2 (20µg)
89496208|NCT02358083|Experimental|Arm 12. Flu + Safety + Disclosure|Flu is target vaccine; Provider provides message about relative safety of vaccination compared to other common daily activities; Provider provides strong recommendation for vaccination and personal disclosure regarding own child's vaccination history.
89496209|NCT02331134|Other|Melanoma, head and neck|10 μg/kg/day of Filgrastim will be given subcutaneously for 4 days
89496210|NCT02303171|Active Comparator|Enoxaparin group|Women will be subjected to anticoagulant therapy by Enoxaparin throughout pregnancy
89496211|NCT02303171|Active Comparator|Warfarin group|Women will be subjected to anticoagulant therapy by Enoxaparin in the first trimester then Warfarin after the first trimester
89496212|NCT02243605|Experimental|Treatment (cabozantinib s-malate)|Patients receive cabozantinib s-malate PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89496213|NCT02243592||Ancillary-Correlative (molecular profiling)|Previously collected tissue samples are analyzed via whole exome sequencing and/or targeted NGS assay deep sequencing. Cases for which sufficient nucleic acid amounts are available will undergo additional analyses including whole genome sequencing, mRNA-sequencing, miRNA sequencing, promoter methylation analysis, and SNP analysis.
89496214|NCT02217735|Experimental|Writing Intervention - Expressive Arm|Participants are asked to write about the most traumatic or stressful experience of their entire lives in three, 20 minute writing sessions.
89496215|NCT02217735|Active Comparator|Writing Intervention - Neutral Arm|Participants are asked to write about what they did the day before, refraining from including emotional details.
89496216|NCT02170103|Experimental|Ultrasound and microbubbles|Patients who provide emergent consent will be randomized to either conventional therapy for a heart attack, or conventional therapy and ultrasound with microbubbles. The ultrasound will be applied both before and after emergent heart catheterization, in order to break up the blood clots that are not only in the artery supplying the heart muscle, but also in the small branches (capillaries) that are fed by this artery.
89022648|NCT06189040|Experimental|BNT162b2 long-interval schedule|day 0: intramuscular administration of BNT162b2 (30µg) day 84: intramuscular administration of BNT162b2 (30µg)
89496217|NCT02170103|Other|Standard of care|Emergent PCI/antithrombotic/antiplatelet therapy with Echocardiogram to assess Left Ventricular Ejection Fraction (LVEF) and Aspirin, Plavix, or Direct Thrombin Inhibitor.
89496218|NCT02135042|Active Comparator|Arm I (chemoradiation, cisplatin, fluorouracil)|Patients receive PF regimen comprising cisplatin IV over 60-120 minutes and fluorouracil IV over 96 hours continuously beginning at least 4 weeks after completion of IMRT. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity.
89496219|NCT02135042|Experimental|Arm II (chemoradiation, gemcitabine hydrochloride, paclitaxel)|Patients receive GT regimen comprising paclitaxel IV over 1 hour and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 at least 4 weeks after completion of IMRT. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
89496220|NCT02135042|Active Comparator|Arm III (chemoradiation, cisplatin, fluorouracil)|Patients receive PF regimen as in Arm I of Phase II.
89496221|NCT02135042|Experimental|Arm IV (chemoradiation, observation)|Patients undergo clinical observation.
89496222|NCT02013479|Experimental|SelenoPRECISE|SelenoPRECISE
89496223|NCT02013479|Placebo Comparator|Placebo|Placebo
89496224|NCT01693601|Experimental|Panobinostat and Ruxolitinib|Combination of Panobinostat and Ruxolitinib
89496225|NCT01671982|Experimental|Tenofovir-containing HAART|
89496226|NCT01668186||Patients diagnosed with a peroxisomal disorder|Collection of medical records and images (ultrasounds, X-rays, MRIs, CT scans, ophthalmic images), Next-generation panel, Drug screening, and Consultation
89496227|NCT01650311||Healthy controls|Healthy control group will include participants consenting prior to colorectal cancer screening.
89496228|NCT01650311||CD patient groups|The patient groups will include patients with clinical diagnosis of CD.
89496229|NCT01650311||UC patient group|The patient groups will include patients with clinical diagnosis of UC.
89496230|NCT01408511|Experimental|Arm 1|
89496231|NCT01376622||Chronically Transfusion Patients|Patients with transfusion dependent anemia (excluding sickle cell disease), ages 2-25, on Deferasirox chelation therapy, to be monitored over 2 years.
89496232|NCT01376622||Controls|Normal controls, ages 2-25, with no known brain abnormality or endocrine dysfunction.
89496233|NCT01363635||severe sepsis|severe sepsis/septic shock, organ failure, ICU death
89496234|NCT01284348|Experimental|Sotatercept 15 mg|Participants will receive sotatercept 15 mg by subcutaneous (SC) injection once every 42 days, up to four doses.
89496235|NCT01284348|Experimental|Sotatercept 30 mg|Participants will receive sotatercept 30 mg by SC injection once every 42 days, up to four doses.
89496236|NCT01099644|Experimental|131 I-8H9|This is a phase I study of 131I-8H9 for patients with DSRCT and other 8H9-reactive solid tumors metastatic to the peritoneum.
89496237|NCT00488241|Active Comparator|1|Topically applied daily for 2 weeks
89496238|NCT00201526||Study group|RCT
89496239|NCT00201526||Control group|RCT
89496240|NCT00082706|Experimental|5-FU, Leucovorin, Gemcitabine + Cisplatin|5-FU continuous infusion over Days 1 - 5; Leucovorin once a day as a short infusion on Days 1 - 5; Cisplatin infusion over a few hours (usually 2-4 hours) once a day on Days 1 - 5; Gemcitabine infusion over 30 minutes on Days 1 & 5 only.
89496241|NCT03172143|Active Comparator|Mesenteric sparing ileocolic resection|Ileocolic resection without removal of the lymph nodes in the mesentery.
89496242|NCT03172143|Active Comparator|High ligation ileocolic resection|Ileocolic resection with removal of lymph nodes in the mesentery
89496243|NCT02168023|Experimental|DACC impregnated dressing|Patients undergoing elective or emergency caesarean section with DACC impregnated dressing Sorbact Surgical Dressing ® (ABIGO Medical AB, Sweden) placed over post-caesarean wound after skin closure, the dressing will be removed after the first 48 hours postoperatively
89496244|NCT02168023|Active Comparator|Standard surgical dressing|Patients undergoing elective or emergency caesarean section with standard surgical dressing placed over post-caesarean wound after skin closure, the dressing will be removed after the first 48 hours postoperatively
89496245|NCT02406963|Active Comparator|TTC|Current standard of care- a telephone call with the NP in the event of a post-operative concern where advice/interventions/reassurance is provided based on information provided by family
89496246|NCT02406963|Experimental|PEC|Experimental arm, the standard telephone call with the NP and the addition of a digital photograph of the surgical site for assessment prior to the administration of advice
89496247|NCT02171299|Experimental|intervetional group (local anaesthetic)|intraoperative wound infiltration with ropivacaine 10%.
89496248|NCT02171299|No Intervention|control (no local anesthetic)|no infiltration of the wound with local anaesthetic
89496249|NCT02165059||Study Group|Patients undergoing surgical full thickness biopsy of the stomach and/or proximal jejunum for the clinical evaluation of GI neuromuscular disorder.
89496250|NCT02165059||Control Group|"Patient undergoing esophagectomy, sleeve gastrectomy for obesity, Roux-en-Y gastric bypass, Whipple surgery, transplant surgery.~Patients who are organ donors and undergoing surgery are also part of the control group."
89496251|NCT02171377|Experimental|Group 2 : quadricipital electrical stimulation|stimulation in addition to rehabilitation (30 min bilateral quadricipital electrical stimulation pd, 5 days per week, 8 weeks)
89496252|NCT02171377|Active Comparator|Group 1 : Pulmonary rehabilitation|Pulmonary rehabilitation 3 to 5 times per week, 8 weeks
89496253|NCT03171831|Experimental|Haploidentical HSCT|"Procedure: Haploidentical hematopoietic stem cell transplantation from a related donor (partially matched sibling, father or mother).~Conditioning: Busulfan （4 mg/kg/day,4 days） + Cyclophosphamide （50 mg/kg/day,4 days）+ Fludarabine （50 mg/m2/day,3 days）~GVHD Prophylaxis：Mycophenolate mofetil（0.25g/day）+ Tacrolimus（0.03mg/kg/day）+ Methotrexate（15mg/m2 on day +1,10mg/m2 on day +3,+6,+11）+ Thymoglobulin（2.5 mg/kg/day,4 days）+Basiliximab（10mg on day 0 and +4）"
89496254|NCT02171455|Experimental|Dabigatran etexilate low dose|
89496255|NCT02171455|Experimental|Dabigatran etexilate medium dose|
89496256|NCT02171455|Experimental|Dabigatran etexilate high dose|
89496257|NCT03171753|Experimental|Music therapy|Listening prerecorded music through an individual headset for 30 min in before the induction of anesthesia
88955304|NCT06328959|Active Comparator|PNG group|PNG groups were given systematic therapy according to the routine treatment plan for PRS for 4 weeks. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
88955305|NCT06328946|Experimental|Intermittent Oro-esophageal Tube Feeding+Basic treatment|"The patients were provided with 1) basic treatment including intracranial pressure reduction, anti-infection therapy, blood pressure and blood glucose control.~For the observation group, the nasogastric tube was removed, and Intermittent oro-esophageal tube feeding was initiated for nutrition support within 4 hours after completing the admission assessment, following the standard Intermittent oro-esophageal tube feeding procedure."
88955306|NCT06328946|Active Comparator|Nasogastric Tube Feeding+Basic treatment|"The patients were provided with 1) basic treatment including intracranial pressure reduction, anti-infection therapy, blood pressure and blood glucose control.~Patients in the control group were provided with nutrition support by the indwelling nasogastric tube. The entire feeding process strictly followed the standardized procedure for nasogastric feeding."
88955307|NCT06328933|Experimental|Intermittent Oro-esophageal Tube Feeding+comprehensive rehabilitation therapy|"Assigned randomly before the treatment, all patients were provided with comprehensive rehabilitation therapy as follows:~Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training.~The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure. The feeding content was formulated by the nutritionists based on the condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups"
89022649|NCT06189040|Experimental|BNT162b2 intradermal schedule|day 0: intradermal administration of BNT162b2 (6µg) day 28: intradermal administration of BNT162b2 (6µg)
89022650|NCT06189040|Active Comparator|mRNA-1273 regular schedule|day 0: intramuscular administration of mRNA-1273 (100µg) day 28: intramuscular administration of mRNA-1273 (100µg)
89022651|NCT06189040|Experimental|mRNA-1273 low dose schedule|day 0: intramuscular administration of mRNA-1273 (50µg) day 28: intramuscular administration of mRNA-1273 (50µg)
89022652|NCT06189027|Active Comparator|MDMA Assisted Psychotherapy|A longitudinal course of psychotherapy with administration of MDMA on two occasions to assist with the psychotherapeutic process
89022653|NCT06189027|Placebo Comparator|Placebo Assisted Psychotherapy|A longitudinal course of psychotherapy with administration of placebo on two occasions to assist with the psychotherapeutic process
89022654|NCT06189001|Experimental|Oxytocin|Intravenous oxytocin 0.2 IU/minute for 300 minutes Approx. 500 ml
89022655|NCT06189001|Other|Placebo|intravenous saline (0.9% NaCl) infusion for 300 minutes Approx. 500 ml
89205262|NCT05773534||Patients with PAD in Fontaine stage II|"Multispectral Optoacoustic Tomography (MSOT) of the Musculus triceps surae of the affected leg in PAD patients in Fontaine stage II (intermittent claudication)~Physical assessment: Pulse status / Color-Coded Duplex Sonography / Ankle-Brachial Index / 6-minute walk test (6MWT) / Continued heel raises for at least 30s"
89205263|NCT05773508||Group with video-regulation and using of the emergency kit|Use of video regulation and/or emergency kit → addressing modified by the use of one or the other
89496258|NCT03171753|Active Comparator|Control|patients wear headphones for 30 minuts without any sound
89496259|NCT02255851||Treatment Group|TAVR + SENTINEL (Cerebral Protection System)
89496260|NCT02406417|Experimental|Investigation for pituitary dysfunction|Further investigation for pituitary dysfunction by blood tests, dynamic function tests and pituitary imaging e.g. CT Scan with contrast. Patients identified as being at high risk of having pituitary dysfunction based on preliminary blood tests will have further tests added. If these results point to a likely pituitary dysfunction, the patient will be referred to the Endocrine team for further investigations including dynamic function tests and/or imaging.
89496261|NCT02171533|Experimental|Fixed sequence|Treatments will be given in a fixed sequence
89496262|NCT02171533|Experimental|Crossover|Treatments will be given in randomized sequences
89496263|NCT04482543|Active Comparator|Intra-silicone oil injection of 250 µg methotrexate|
89496264|NCT04482543|No Intervention|No intra-silicone oil injection of methotrexate|
89496265|NCT02406807|Experimental|HVLA manipulation|Osteopathic high velocity, and low amplitude spinal lumbar manipulation
89496266|NCT02406807|Sham Comparator|Sham Spinal lumbar manipulation|Just position in the side lying and not performed the high velocity and low amplitude
89496267|NCT02413125|Experimental|ChitoRino irrigation solution|The study participants will be provided a NeilMed irrigation bottle and instructed to administer 1 packet of ChitoRhino irrigation solution (premixed from manufacturer containing sea salt, Chitosan, and sodium bicarbonate). An informational sheet regarding care and cleaning of the irrigation bottle will be provided during the initial visit. Participants will be instructed to complete up to three nasal saline irrigations daily for 1 month and keep a log to determine compliance. After 1 month of use, the irrigation bottle will be returned at a second study visit.
89496268|NCT02413125|Experimental|Normal saline solution|The study participants will be provided a NeilMed irrigation bottle and instructed to administer nasal saline (250mL of 0.9% sodium chloride) irrigation solution. An informational sheet regarding care and cleaning of the irrigation bottle will be provided during the initial visit. Participants will be instructed to complete up to three nasal saline irrigations daily for 1 month and keep a log to determine compliance. After 1 month of use, the irrigation bottle will be returned at a second study visit.
89496269|NCT02406339|No Intervention|Control|Are not subject to any intervention.
89496270|NCT02406339|Experimental|Electrotherapy|The athletes will be submitted to NMES of bilateral quadriceps. The stimulation will be held in order to induce the move flexion / extension involuntary knee in extension machine, with resistance of 30% of maximum voluntary strength.
89496271|NCT02406339|Experimental|Electrotherapy + Vascular Occlusion|The same as in Electrotherapy group, athletes are subjected to NMES associated total vascular occlusion of the members below the level of the groin.
89496272|NCT03172845|Experimental|Vulnerable plaque|Thin-cap fibro atheroma (TCFA) was defined as a lipid-rich plaque with the thinnest fibrous cap thickness<65um. Plaque rupture was identified by the presence of fibrous cap discontinuity with a clear cavity formation inside the plaque. Plaque erosion is characterized by luminal thrombus and absence of the endothelium or without evidence of fibrous cap disruption. Fibro calcific plaque contains OCT evidence of fibrous tissue along with calcium that appears as a signal-poor or heterogeneous region with a sharply delineated border which is applied to larger calcifications. Calcified nodule is characterized as a signal or multiple regions of calcium protruding into the lumen, superficial calcification accompanied by substantive calcium proximal and or distal to the lesion. Thrombus is defined as a mass attached to luminal surface or floating within the lumen. It is seen as a protrusion inside the lumen of the artery with signal attenuation.
89496273|NCT03172845|Active Comparator|Without any vulnerable plaqueStable plaque|patient with bifurcation lesion undergoing baseline coronary angiography and baseline OCT.
89022656|NCT06188962|Other|3-8 week baseline wait period followed by CBT-informed school-based counselling|All participants undergo a baseline wait period but are randomized to different baseline lengths (3-8 weeks)
89022657|NCT06188936|Other|Work Package 1: Survey for clinicians and scientists|Online survey of UK clinicians' and scientists' views on home semen analysis tests, including whether a randomised trial is needed to compare them to standard care, and their willingness to recruit to such a trial.
89022658|NCT06188936|Other|Work package 2: Survey for patients|Sample size: 100 patients. Survey of patients' views prior to undergoing routine laboratory semen analysis, including awareness of home testing.
89496274|NCT02406183|Experimental|Treatment (SBRT, Ipilimumab)|"Drug: Ipilimumab Dosage: Ipilimumab will be administered intravenously at 3 mg/kg every 3 weeks for 4 cycles,~Radiation: Stereotactic Body Radiotherapy Radiation therapy 24 Grays in 8 Grays fractions, Radiation therapy 30 Grays in 10 Grays fractions, Radiation therapy 36 Grays in 12 Grays fractions"
89496275|NCT02412969|Active Comparator|Lumbar Epidural|Control group will have standard of care Lumbar Epidural
89022659|NCT06188936|Experimental|Work package 3: Home testing with ExSeed home semen analysis test and post-test survey|Sample size: 25 patients. Assessment of patients' ability to complete home semen testing with the ExSeed® test, opinions on ease of test use, and views after undergoing both laboratory semen analysis and home testing. Results from the ExSeed® test will be compared to the participant's laboratory semen analysis result to assess the accuracy of the home test.
89496276|NCT02412969|Experimental|Dural Puncture Epidural|Will receive Dural Puncture Epidural
89496277|NCT05539820|Experimental|Reiki group|PIF-I and STAS were administered to the Reiki group through an online questionnaire. After the pretests of the students were completed, between 14-17 June 2022, the distant reiki application was made under the guidance of a researcher with a Usui Reiki Master &Teacher degree and by the researchers with Reiki -II or Reiki-III degrees. The application was carried out for 20 minutes on four consecutive days. Before the final exams (19 June 2022), the posttests (PIF-II and STAS) were applied to the students through an online questionnaire.
89496278|NCT05539820|No Intervention|Control Group|PIF-I and STAS were administered to the control group through an online questionnaire. Then before the final exams on 19 June 2022, the posttests (PIF-II and STAS) were applied to the students through an online questionnaire.
89496279|NCT02412891|Active Comparator|Patients receive active UroShield device|Patients receive active UroShield device
89496280|NCT02412891|Sham Comparator|Patients receive inactive UroShield device|Patients receive inactive UroShield device
89496281|NCT04723472|Active Comparator|Classic bismuth quadruple treatment group|
89496282|NCT04723472|Experimental|Cefuroxime containing bismuth quadruple treatment group|
89496283|NCT03176043|Experimental|Thirst Driven infusion|Subjects who are self administering fluid will be instructed when (at any point in the experiment) they are experiencing thirst to request a fluid bolus with an electronic trigger. In response to this trigger the researcher will then deliver a 200ml bolus of IV fluid. After delivery of the fluid bolus, a lockout period is set for 15mins within which the researcher will not deliver another bolus in response to the trigger.
89496284|NCT03176043|Active Comparator|NICE infusion|Subjects receiving standard fluid maintenance will receive a baseline infusion rate of 30 mL/kg/24hr (1.25 mL/kg/hr). In addition to this a 500 mL bolus will be delivered if any of the following clinical signs, indicating hypovolaemia, are observed on regular examination: low peripheral perfusion, heart rate >90 /min, systolic BP <100 mmHg, respiratory rate >20, peripheral capillary refill >2sec. A maximum of 2000 mL of fluid will be delivered by additional boluses.
89496285|NCT04425668|Active Comparator|Control Group|
89496286|NCT04425668|Experimental|Academic detailing intervention|
89496287|NCT02406105|Experimental|Radiosurgical thalamotomy|Cyber Knife based functional radiosurgical thalamotomy, photons 6MV, single dose 70-110 Gy
89496288|NCT03172767||Preterm Preschoolers|Preterm children who haven't attend school.
89022660|NCT06188923|Active Comparator|Pregnenolone|Pregnenolone 250 mg BID x 14 DAYS, followed by Pregnenolone 500 mg BID x 14 DAYS, followed by Pregnenolone 1000 mg BID x thereafter for the remainder of the 8-week trial.
89022661|NCT06188923|Placebo Comparator|Placebo|Same as active comparator, except placebo dispensed
89022662|NCT06188897|Experimental|Experimental group|The experimental group did the intervention, which consisted of self-stretching of the masticatory muscles. This stretch consisted of introducing three knuckles of the non-dominant hand between the incisors for two minutes while sitting
89022663|NCT06188897|Placebo Comparator|Control group|The control group was asked to introduce only two knuckles in the oral cavity and perform a mandibular occlusion, an intervention that serves as a simulated stretch in said group.
89022664|NCT06188871|Experimental|Dupilumab|Two injections of 300mg dupilumab, subcutaneous 14 days apart
89496289|NCT03172767||Term Preschoolers|Term children who haven't attend school.
89496290|NCT02412813|Active Comparator|LEGION OXINIUM femoral component|
89496291|NCT02412813|Active Comparator|LEGION Cobalt Chrome femoral components|
89496292|NCT02013128|Experimental|Ublituximab + ibrutinib|Ublituximab: IV infusion dose Days 1, 8 and 15 followed by maintenance infusions Ibrutinib: Fixed oral daily dose
89496293|NCT04482075|Other|SEGMENTAL STABILISATION TRAINING (SST)|Segmental Stabilisation Training is an established treatment technique for chronic low back pain
89496294|NCT05591378|Experimental|core stability exercises|improve balance and muscle strengthening
89496295|NCT05591378|Experimental|otago exercises|improve balance and quality of life
89496296|NCT02405949||T2D 40%EWL|15 pacients who had type 2 diabetes before bariatric surgery and presented with less than 40% of the excess weight loss after 12 month from surgery.
89496297|NCT02405949||nonT2D40%EWL|15 pacients without type 2 diabetes before bariatric surgery and presented with less than 40% of the excess weight loss after 12 month from surgery.
89022665|NCT06188845|Experimental|KT group|Participants in the KT group were applied I-shaped Kinesio tape to the wrist extensor and pronator teres of the hemiplegic forearm for 2 days. Throughout the 2-day experiment, all participants received regular conventional rehabilitation.
89205264|NCT05773508||Group without video-regulation and using of the emergency kit|no video-regulation and no use of the emergency kit → addressing patients according to the standard of care
89205265|NCT05773443||Ambroxol: Digital biomarkers|Oral ambroxol medication, from day 1 to study end (at 60 mg TID (day 1-7), 120 mg TID (day 8- 14), 315 mg BID (day 15-21), 315 mg TID (day 22-28) and 420 mg TID (day 29-550))
89022666|NCT06188845|No Intervention|CT group|Participants in the CT group did not receive tape intervention but received regular conventional therapy.
89022667|NCT06188819||Cryopreserved arterial allograft|Aortic infection treated by cryopreserved arterial allograft
89205266|NCT05773443||Placebo: Digital biomarkers|Oral placebo medication, from day 1 to study end (at 60 mg TID (day 1-7), 120 mg TID (day 8- 14), 315 mg BID (day 15-21), 315 mg TID (day 22-28) and 420 mg TID (day 29-550)).
89205267|NCT05773443||Caregivers|Primary family caregivers to participants
89496298|NCT02405949||T2D75%EWL|35 pacients who had type 2 diabetes befor bariatric surgery and presented with more than 75% of the excess weight loss after 12 month from surgery.
89496299|NCT02405949||nonT2D75%EWL|35 pacients without type 2 diabetes befor bariatric surgery and who presented with more than 75% of the excess weight loss after 12 month from surgery.
89496300|NCT02405559|Experimental|Lymphatic occlusion pressure lower limb|injection of 100µg Indocyanine Green in the first interdigital space and application of increasing pressure around the leg to visualize at which pressure lymph flow is interrupted.
89496301|NCT03116061||Multimorbidity cohort|The study population included a random sample of multimorbid patients (according to the EGPRN definition of multimorbidity). Patients were selected by 19 FPs in their offices in the county of Finistere (in north-west France) from July 2014 to December 2014. Randomization was achieved by including the first four multimorbid patients (according to the inclusion criteria) encountered during their second working day of each week. As patients were booking their appointments with the practice without the FPs' clearance, the FPs were not able to select them
89496302|NCT05539664|Experimental|experimental Group|The test group will use the investigational medical device Hydrogen-Oxygen Generator with Nebulizer (Shanghai Asclepius Meditec Co., Ltd.) + basic treatment (the investigator provides corresponding symptomatic support treatment based on the condition of the patients)
89022668|NCT06188819||Rolled pericardium patch|Aortic infection treated by Pericardium patch rolled
89496303|NCT05539664|Active Comparator|Control Group|The control group will use the hospital routine oxygen supply equipment (wall oxygen or cylinder oxygen) + basic treatment
89496304|NCT02405637|Experimental|SAFE group|simulated amniotic fluid 20cc/kg/day enterally divided according to number of feds (syringe for every fed). This amount provides enteral 4.5μg rhG-CSF / kg/day and enteral 88IU rhEPO / kg/day.
89496305|NCT02405637|Placebo Comparator|placebo|distilled water 2.5 ml/kg every 3 hours enterally
89496306|NCT04425512|Active Comparator|Thyroid Malignancy|Thyroidectomy
89496307|NCT04425512|Sham Comparator|Benign Thyroidal Goitor|Thyroidectomy
89496308|NCT04425512|Other|Control Group|Selective lichtenstein procedure for inguinal hernia
89496309|NCT03116295|Experimental|Group 1 - 25 mg OPC|In Group 1, subjects will receive randomly in Period 1 and 2, either a single 25 mg dose of OPC [AF] or a single 25 mg dose of OPC [NF]. Treatments will be administered in the fasting state, the subjects having fasted for at least 10 hours
89496310|NCT03116295|Experimental|Group 2 - 50 mg OPC|In Group 2, subjects will receive randomly on Period 1 and 2, either a single 50 mg dose of OPC [AF], or a single 50 mg dose of OPC [NF]. Treatments will be administered in the fasting state, the subjects having fasted for at least 10 hours
89496311|NCT00548756|Experimental|Whole Brain Radiation Therapy|Whole Brain Radiation Therapy
89496312|NCT00548756|Other|Observation|Observation
89496313|NCT05586542|Active Comparator|Standard of Care (SOC)|"Wash and sharps debride the target diabetic foot ulcer to remove all non-viable tissue, callus, epibole at wound edges, slough, and debris (at the physician's discretion). The wound margins should be excised to healthy bleeding tissue.~Wash the wound once more with saline to remove remaining debris and confirm hemostasis is achieved, as needed.~Measure wound after debridement.~Place soft silicone contact layer dressing to cover over the wound, secured with adhesive strips.~Cover the contact layer with a hydroconductive wound dressing secured with kerlix gauze and adhesive tape.~Apply the Foot Defender® boot."
89496314|NCT05586542|Experimental|Plasma Film|"Wash and sharps debride the target diabetic foot ulcer to remove all non-viable tissue, callus, epibole at wound edges, slough, and debris (at the physician's discretion). The wound margins should be excised to healthy bleeding tissue.~Wash the wound once more with saline to remove remaining debris and confirm hemostasis is achieved, as needed.~Measure wound after debridement.~Place an appropriately sized piece of Plasma Film onto the wound bed. The test agent should be cut to fit the interior of the wound with minimal overlap onto healthy skin.~Place soft silicone contact layer dressing to cover over the wound, secured with adhesive strips.~Cover the contact layer with a hydroconductive wound dressing secured with kerlix gauze and adhesive tape.~Apply the Foot Defender® boot."
89531777|NCT05381623|Active Comparator|Conventional approach|Application of hemostatic sponges over the donor site and placement of tooth-suspended compressive sutures over the area.
89531778|NCT05378971|Experimental|experimental group|Primary MM patients started maintenance therapy after 3 months of ASCT or after maximum efficacy was achieved with induction and consolidation therapy. All patients will receive pomalidomide 1 mg daily on days 1 through 21 of each 28-day cycle.
89205268|NCT05773430|Experimental|Targeted Neurocognitive Training|BrainHQ (POSIT Science Inc.) computerized cognitive training modules will be used as in our other studies; but these will focus on the two cognitive domains in which the participants exhibited the worst performance at baseline. Twenty hours or training will administer to each participant target these two cognitive domains (10 hours each). These programs have gaming components that encourage adherence. BrainHQ cognitive training products are tested and endorsed by the scientific community. A meta-analysis of computerized cognitive training in older adults found optimal therapeutic effects occurred when training sessions last at most 60 minutes and are administered 1-3 times per week - dosage parameters already incorporated in our study. This self-administered program uses touch-screen technology with tablets which allows computer novices to engage with the training exercises.
89496315|NCT05586542|Experimental|DERMASEAL|"Wash and sharps debride the target diabetic foot ulcer to remove all non-viable tissue, callus, epibole at wound edges, slough, and debris (at the physician's discretion). The wound margins should be excised to healthy bleeding tissue.~Wash the wound once more with saline to remove remaining debris and confirm hemostasis is achieved, as needed.~Measure wound after debridement.~Place an appropriately sized piece of DERMASEAL onto the wound bed. The test agent should be cut to fit the interior of the wound with minimal overlap onto healthy skin.~Place soft silicone contact layer dressing to cover over the wound, secured with adhesive strips.~Cover the contact layer with a hydroconductive wound dressing secured with kerlix gauze and adhesive tape.~Apply the Foot Defender® boot."
89496316|NCT02405715|Placebo Comparator|Placebo Spray And Interpersonal Psychotherapy|Participants will receive 6 sprays of a placebo nasal spray prior to the beginning of each session of interpersonal psychotherapy (16 sessions in total).
89496317|NCT02405715|Experimental|Oxytocin Spray And Interpersonal Psychotherapy|Participants will receive 6 sprays of a oxytocin nasal spray prior to the beginning of each session of interpersonal psychotherapy (16 sessions in total). Each spray will contain 4IU of oxytocin, for a total dose of 24IU.
89496318|NCT03171519|Active Comparator|Exercise|
89496319|NCT03171519|Experimental|Exercise + acupuncture|
89496320|NCT04482387|Other|subjects recruited to visual acuity testing|All recruited subjects will have the intervention (Digivis visual acuity self-testing) and the standard clinical visual acuity assessment in clinic.
89496321|NCT02412423|Experimental|treatment group|post-transplantation cyclophosphamide
89496322|NCT05679206||Preeclampsia and obstetric Antiphospholipid Syndrome|Women in this group wil be followed during 3 years. Echocardiography images, 24-hour ambulatory blood pressure monitoring will be collected.
89496323|NCT05679206||Preeclampsia without obstetric Antiphospholipid Syndrome|Women in this group wil be followed during 3 years. Echocardiography images, 24-hour ambulatory blood pressure monitoring will be collected.
89496324|NCT02412345|Experimental|Extracorporeal Shockwave therapy|Extracorporeal shockwave therapy at the penis. 6 sessions.
89205269|NCT05773430|No Intervention|No-Contact Control Group|These participants will not receive any intervention.
89205270|NCT05773417||Low Flow|0.5 L/minute
89205271|NCT05773417||High Flow|4 L/minute
89205272|NCT05773235||Patients with intracerebral hemorrhage|Patients with symptomatic intracranial hemorrhage (defined as non-traumatic intracerebral hemorrhage or convexity, non-aneurysmal subarachnoid hemorrhage) enrolled in the PRO-SVD study
89205273|NCT05773235||Healthy controls|Clinically healthy persons of at least 55 years of age
89496325|NCT02412345|Sham Comparator|Sham treatment|Extracorporal shockwave therapy with a placebo probe. 6 sessions
89496326|NCT05679128|Active Comparator|palpation|digital palpation used to identify the cricothyroid membrane
89496327|NCT05679128|Experimental|ultrasonography|Ultrasonography used to identify the cricothyroid membrane
89496328|NCT03172611|Experimental|Plant-based diet|A defined, plant-based diet was prescribed for 4 weeks.
89496329|NCT05679050|Experimental|AG Regimen Followed by FOLFIRINOX Regimen|AG Regimen Followed by FOLFIRINOX Regimen
89496330|NCT02412267|Experimental|O-ICE|"O-ICE:~Ofatumumab 1000mg intravenous (IV) infusion on Day 1 and Day 8 of cycle 1 of the salvage chemotherapy, and thereafter on Day 1 of each cycle; Ifosfamide 1667 mg/m2 IV infusion over 2 hours on days 1,2,3 of each cycle; Carboplatin 5 x ((25 + Creatinine clearance (CrCl)) IV in 250 ml Normal Saline over 1 hour on day 1 of each cycle; Etoposide 100mg/m2/day IV infusion day 1,2,3 over 45 to 60 minutes of each cycle."
89496331|NCT05539586|Experimental|Tecar group|
89496332|NCT05539586|Sham Comparator|Sham Group|
89496333|NCT03171675||Preterm/Chronic Periodontitis|Included ten female patients who underwent spontaneous preterm birth and were diagnosed with chronic periodontitis upon clinical examination
89496334|NCT03171675||Preterm/Healthy Periodontium|Included ten female patients who underwent spontaneous preterm birth and who had a healthy periodontium upon clinical examination
89205274|NCT05773183||OBS1 [Observational Cohort 1]|20 Eugonadal Healthy men 20 Men with Testosterone Deficiency not currently on Testosterone replacement therapy
89205275|NCT05773183||IC1 [Interventional Cohort 1]|20 Men with Testosterone Deficiency progressed from OBS1 6 months post initiation of testosterone replacement therapy
89205276|NCT05773183||IC2 [Interventional Cohort 2]|20 men with prostate cancer planned for GnRH analogue therapy
89205277|NCT05773144|Sham Comparator|Attention control|Static stretching
89205278|NCT05773144|Experimental|75 min/wk aerobic exercise|Aerobic exercise at a dose of 75 minutes per week
89205279|NCT05773144|Experimental|150 min/wk aerobic exercise|Aerobic exercise at a dose of 150 minutes per week
89205280|NCT05773144|Experimental|225 min/wk aerobic exercise|Aerobic exercise at a dose of 225 minutes per week
89205281|NCT05773144|Experimental|300 min/wk aerobic exercise|Aerobic exercise at a dose of 300 minutes per week
89205282|NCT05773131|Experimental|VR collaborative visualization group|In this intervention system, the stimulation materials, communication interface, collaboration tasks, and immersive 360-degree scenario will be played inside a commercially available head-mounted display on the patient side, as well as these materials will be played in the smartphone on the family members' side.
89205283|NCT05773131|No Intervention|Standard ICU Care|Patients will be treated with standard ICU care and not receive VR stimulation.
89205284|NCT05773027|Experimental|Sexual Assault and Alcohol Feedback and Education (SAFE)|SAFE includes a motivational interviewing session addressing alcohol use and risk for sexual aggression, a workshop addressing alcohol use and sexual aggression, and a booster session review.
89205285|NCT05773027|Active Comparator|Mindfulness-Based Control Condition|The program includes the same amount of contacts as SAFE, including an individual session focused on mindfulness and stress, a group session, and a booster session review.
89205286|NCT05772975|Experimental|E-PRF|After the impacted mandibular third molar has been surgically removed E-PRF is placed in the dentoalveolar defect and the wound is primarily closed.
89205287|NCT05772975|Experimental|H-PRF|After the impacted mandibular third molar has been surgically removed H-PRF is placed in the dentoalveolar defect PRF made with horizontal centrifuge and the wound is primarily closed.
89205288|NCT05772975|No Intervention|CONTROL|After the impacted mandibular third molar has been surgically removed, the wound is primarily closed.
89205289|NCT05772936|Experimental|single arm non-randomized|all enrolled subjects will participate in the perturbation-induced step training, 1 or 6 sessions about 1-1.5 hour (30-90 trials) each session.
89205290|NCT05772923|Experimental|Contact x-ray brachytherapy|Contact x-ray brachytherapy will be given applied after randomisation with a maximum interval of 14 weeks after finishing the neoadjuvant (chemo)radiation. Contact x-ray brachytherapy consists of three fractions of 30Gy per fraction applied to the tumour, with a 2 week interval between each boost. Response evaluation takes place every 3 months thereafter. Patients in whom a clinical complete response is detected during follow-up are offered a watch-and-wait approach; patients in whom an incomplete response or disease progression is noted, completion or salvage TME-surgery is advised.
89205291|NCT05772923|Experimental|Extending the waiting interval, with or without local excision|The waiting interval will be extended with 6-8 more weeks after the first response evaluation, followed by a second (or third in case of ongoing response) re-assessment. Patients with a clinical complete response at the time of the second (or third) response evaluation will be offered a watch-and-wait approach without any surgical treatment. Patients with a remaining small lesion will be offered transanal local excision. Depending on the final pathological staging after local excision, patients are categorized as low-risk or high-risk, and will be offered a watch-and-wait strategy or completion TME-surgery, respectively.
89205292|NCT05772884|Experimental|Supervised Exercise Intervention|Participants will be asked to complete 3 walking sessions per week for 12 weeks. We will ask them to complete at least 1 of these sessions in-person on-site and they will be given the option to complete up to 2 walking sessions per week off-site. Exercise training on-site will be performed on an indoor walking path, 50 min/session (plus 5 min. for each warm-up and cool down).
89205293|NCT05771571|Placebo Comparator|Control|The meal contained mashed potatoes, homogenized with refined olive oil.
89205294|NCT05771571|Other|Interventional|The meal contained mashed potatoes, homogenized with the functional olive oil, enhanced with orange peel extract
89205295|NCT05771519|Experimental|HIV disclosure intervention|"Participants assigned to the intervention group will likely participate in the following:~Sexual health education~Cognitive behavioral therapy strategies~Problem-solving skills building~Motivational interviewing~Developing a personalized HIV disclosure plan~Communication skills building~Role-playing disclosure strategies Procedures in both arms will encompass 3-5 individual sessions lasting 30-60 minutes over 2-3 months. There may also be a booster session at approximately the six-month timepoint."
89205296|NCT05771519|No Intervention|Control|Participants assigned to the control group will likely participate in educational topics related to healthy living for men living with HIV. Procedures in both arms will encompass 3-5 individual sessions lasting 30-60 minutes over 2-3 months. There may also be a booster session at approximately the six-month timepoint.
89205297|NCT05771467||Trauma Group|Non-Trauma Eye After Open-Globe Injury
89205298|NCT05771467||Control Group|Age-, sex-matched healthy volunteers
89496335|NCT03171675||Term/Chronic Periodontitis|Included ten female patients who underwent spontaneous normal term birth and were diagnosed with chronic periodontitis upon clinical examination
89496336|NCT03171675||Term/Healthy Periodontium|Included ten female patients who underwent spontaneous normal term birth and who had a healthy periodontium upon clinical examination (Armitage1999)
89496337|NCT05539508||Primary open-angle glaucoma (POAG) group|
89496338|NCT05539508||Age-matched normally sighted control group|
89496339|NCT03171597|Other|conventional western medicine|Patients in this group will be treated by conventional western medicine, including anti-platelet drugss，lipid regulating drugs, coronary vasodilator, etc.
89496340|NCT03171597|Experimental|Qi deficiency and blood stasis|Patients in this group will be treated by Shuanghe Decoction at the base of conventional western medicine.
89496341|NCT03171597|Experimental|Qi stagnation and blood stasis|Patients in this group will be treated by Xuefu Zhuyu Decoction at the base of conventional western medicine.
89496342|NCT03171597|Experimental|Phlegm and blood stasis|Patients in this group will be treated by Gualou Xiebai Banxia Decoction & Danshen Decoction at the base of conventional western medicine.
89496343|NCT05698394|Experimental|Esketamine group|For women in this group, study drug (esketamine 0.2 mg/kg in 20 ml normal saline) will be infused at a rate of 30 ml/h (infusion finished in 40 minutes) after giving birth.
89496344|NCT05698394|Placebo Comparator|placebo group|For women in this group, study drug (20 ml normal saline) will be infused at a rate of 30 ml/h (infusion finished in 40 minutes) after giving birth.
89496345|NCT03171363|Experimental|Gaze-contingent feedback|Participants will receive gaze-contingent feedback according to their viewing patterns
89496346|NCT05539274||cervical cancer group, control group|
89496347|NCT03171285||Less than 35 years old|Clinical and laboratory evaluations
89496348|NCT03171285||Greater than or equal to 35 years|Clinical and laboratory evaluations
89496349|NCT05539118|Experimental|Recombinant human interferon α1b + toripalimab + anlotinib hydrochloride|Recombinant human interferon α1b administered 600μg every other day. Toripalimab administered 240mg intravenously every three weeks. Anlotinib hydrochloride given 12mg or 10mg or 8mg orally (Daily for two weeks continuously, followed by one week of rest). A recommended phase II dose (RP2D) of anlotinib hydrochloride will be determined.
89496350|NCT03171441||Controls|eutrophic children
89496351|NCT03171441||Overweight|Overweight children
89496352|NCT03171441||Obese|Obese children
89496353|NCT02405793|Experimental|Meloxicam low dose test capsule|Meloxicam SoluMatrix Capsules - low dose QD
89496354|NCT02405793|Experimental|Meloxicam high dose test capsule|Meloxicam SoluMatrix Capsules - high dose QD
89496355|NCT02405793|Active Comparator|Meloxicam tablets|Meloxicam Tablets QD
89496356|NCT05579912||Esophagogastric Surgery Patients|Patients who underwent esophageal and gastric resections requiring an anastomosis from January 2001 to March 2019
89496357|NCT02405481|No Intervention|Wait List Control|
89496358|NCT02405481|Experimental|SEPA III Intervention|SEPA brings together two important theoretical perspectives that will be effective and sustainable for HIV/AIDS prevention among Hispanic women in an inner city environment. The content and learning strategies of SEPA are based on the social cognitive theory and of HIV/AIDS prevention that prior research has shown to be the most effective in increasing HIV/AIDS prevention behaviors, modified to take into account the special needs of Hispanic women related to gender inequality and cultural values and practices. SEPA's conceptual framework integrates the Social Cognitive Model of behavioral change with Freire's Pedagogy of the Oppressed that guides the delivery and contextual tailoring.
89496359|NCT05575622||Patients with hepatocellular carcinoma receiving immunotherapy|
89496360|NCT00702741|Experimental|A|Chondrogen (low dose)
89496361|NCT00702741|Experimental|B|Chondrogen (high dose)
89496362|NCT00702741|Placebo Comparator|C|Hyaluronan
89496363|NCT05695664|Experimental|Ibuprofen|patient received 800 mg of Ibuprofen IV
89496364|NCT05695664|Experimental|Ketorolac|Patients received Keterolac 30 mg IV
89496365|NCT02412189|No Intervention|control|Ordinary anesthesia, mean arterial pressure allowed to decrease to 60 mmHg. If it is lower the patients will receive a norepinephrine infusion in order to raise the mean arterial pressure to 60 mmHg.
89496366|NCT02412189|Active Comparator|Maintained blood pressure|Ordinary anaesthesia and maintained preanesthetic blood pressure by norepinephrine infusion
89496367|NCT05695586|Experimental|Mindful Self-Compassion (MSC) training|Participants in the MSC group will be trained in the standard 8-week Mindfulness Self-Compassion (MSC) protocol (Germer and Neff, 2013a, b; Germer and Neff, 2019). Once participants have completed the 8-week MSC training they will enter a 12-month phase of regular supervised practice, in which they will continue to perform MSC exercises on a guided basis. Supervised practice will be provided on a weekly basis.
89496368|NCT05695586|Experimental|Mindfulness Based Stress Reduction (MBSR) training|Participants in the MBSR group will receive the standard 8-week Mindfulness-Based Stress Reduction (Stahl & Goldstein, 2010). Once participants have completed the 8-week MBSR training they will enter a 12-month phase of regular supervised practice, in which they will continue to perform MBSR exercises on a guided basis. Supervised practice will be provided on a weekly basis.
89496369|NCT05695586|No Intervention|Control group|The waitlist CG will comprise subjects with no MBSR/MSC related practice, who will not receive the MSC or MBSR training. However, subjects in the CG will be waitlisted to receive a MBSR or MSC training once the present project will be finished.
89496370|NCT02411955|Experimental|Tazarotene Cream 0.1%|Tazarotene Cream 0.1% (Taro Pharmaceuticals Inc.)
89496371|NCT02411955|Active Comparator|Tazorac®|Tazorac® (tazarotene cream 0.1%) (Allergan LLC)
89496372|NCT02411955|Placebo Comparator|Placebo|Placebo (Vehicle of the test product) (Taro Pharmaceuticals Inc.)
89496373|NCT03175887|Experimental|Intervention Arm|Participants will receive TMS. They will be randomized to either the left dorsolateral prefrontal cortex or the medial prefrontal cortex.
89496374|NCT03175887|Other|Treatment Arm|"After the experimental arm, if a patient was randomized to the medial prefrontal cortex during the experimental arm and it did not work for them, they have the option of returning for a session of TMS to the FDA-approved dorsolateral prefrontal cortex.~If they were assigned to the dorsolateral prefrontal cortex, they are not eligible to return for another set of treatment."
89496375|NCT03172533|Active Comparator|verum group|approved oral contraceptive: ethinyl estradiol 0.03mg and dienogest 2mg (combination drug) daily intake over 10 weeks
89496376|NCT03172533|Placebo Comparator|placebo group|placebo
89496377|NCT05678894|Experimental|femoro-acetabular impingement|symptomatic patients with femoro-acetabular impingement
89022669|NCT06188806|Active Comparator|PROXİMAL ADDUKTOR CANAL BLOCK GROUP|Patients are placed in the supine position and a high-frequency linear probe is inserted for a cross-sectional image of the groin and thigh. The femoral nerve is identified in the short axis near the inguinal crease and the ultrasound transducer is placed caudally beyond the femoral triangle. The location of the proximal block is determined where the superficial femoral artery passes under the medial border of the sartorius muscle (usually 8-12 cm distal to the inguinal crease). Using the in-plane technique, a 100 mm peripheral nerve block needle is advanced until the tip of the needle passes the sartorius muscle and enters the adductor canal from the lateral side of the superficial femoral artery, and 20 mL 0.375% Bupivacaine is administered. To verify block success, sensory function is assessed by pinprick testing along the saphenous nerve distribution by comparing the pinprick sensation to the unaffected limb.
89022670|NCT06188806|Active Comparator|DİSTAL ADDUKTOR CANAL BLOCK GROUP|Patients are placed in the supine position, the mid-thigh point is determined as half the distance between the groin crease and the top of the patella. After the mid-thigh mark is marked with a sterile marking pen, the ultrasound transducer is positioned for a transverse view of the adductor canal into the mid-thigh. Under USG imaging, the femoral artery and saphenous nerve are identified. The distal position is determined where the USG probe moves away from the sartorius muscle of the femoral artery and proceeds deep into the adductor hiatus, and a 100 mm block needle passes the sartorius muscle with an in plane technique and 20 mL 0.375% Bupivacaine is administered to the lateral side of the femoral artery and saphenous nerve.
89022671|NCT06188806|Sham Comparator|CONTROL GROUP|No nerve block procedure is applied to patients.
89022672|NCT06188780||victims of DFSA|Every patients presenting at the sexual assault care centre with a suspicion of drug-assisted sexual assault
89022673|NCT06188767|Experimental|Testosterone|Participants are randomized to a single injection of 1000 mg testosterone undecanoate
89022674|NCT06188767|Placebo Comparator|Placebo|Participants are randomized to a single placebo injection
89022675|NCT06188754|Experimental|Time Restricted Eating (TRE) for 8 weeks|Participants will receive an intro to TRE and then throughout 8 weeks they will receive brief blogs several times per week with optional weekly coaching sessions. TRE involves restricting the window of eating to 10 hours/ day. To do so, people typically avoid eating in the first 1-2 hours after they wake up and in the 2-4 before sleep. Those with an eating window > 14 hours will be asked to restrict their eating to 12 hours in the first week, then 10 hours in week 2. To select the time period, the investigators will ask Ss to review baseline logs to consider sleep, eating, family meals and social commitment schedules. The investigators will review any special energy demands, such as exercise. During the eating window, no restrictions are placed on the type or quantity of food consumed. The investigators will instruct participants to follow their habitual diet within their 10-hour eating window and to aim to consume the same number of calories per day as they did at baseline.
89022676|NCT06188754|Active Comparator|Mediterranean diet for 8 weeks|"Participants will receive a several page introduction to the Mediterranean diet, and then will receive support throughout the 8 week intervention to follow this food plan, including brief blogs that will be sent several times per week, and optional weekly coaching sessions.~The Mediterranean Diet is a plan for healthy eating based on how people eat in the 16 countries that border the Mediterranean Sea. Individuals will be encouraged to consume vegetables (6 servings/day), fruits (2-4 servings/day), whole grains (daily), legumes (3-4 times per week), nuts (.5 oz per day), and oily fish (2 servings/week). Participants will be encouraged to choose lean meats and other sources of protein over red meat and processed meats. Sweets, refined cereals, alcohol, and wine or alcohol will be labelled as extras, and participants will be encouraged to limit consumption of extras."
89022677|NCT06188702|Experimental|Dose Escalation|
89022678|NCT06188689|Experimental|Pacing|Separate ventricular and atrial pacing trains will be administered at different cycle lengths and the ventricular repolarization response on the first sinus beat following the subsequent pause will be evaluated.
89022679|NCT06188676|Active Comparator|A|Active Comparator: Arm A (DA-EPOCH-R) Patients receive prednisone or prednisolone on days 1-5 and rituximab IV or rituximab and hyaluronidase human SC over 5 minutes on day 1 or 5. Patients also receive etoposide phosphate, doxorubicin hydrochloride, and vincristine sulfate IV over 96 hours on days 1-4 and cyclophosphamide IV over 30-60 minutes on day 5. Beginning 24-72 hours after completing cyclophosphamide, patients receive filgrastim or pegylated filgrastim SC daily until ANC is >= 500/uL after the expected nadir. Treatment repeats every 21 days for up to 6 cycles (5 if the patient had 1 prior cycle of treatment) in the absence of disease progression or unacceptable toxicity. Patients also undergo FDG-PET/CT on study. When СR is achieved according to PET / CT after 4 cycles of chemotherapy, 2 randomization is performed, a total of 4 or 6 chemotherapy courses
89022680|NCT06188676|Experimental|B|(DA-EPOCH-R, nivolumab) Patients receive treatment as in Arm A. Patients also receive nivolumab 40 mg IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 6 cycles (5 if the patient had 1 prior cycle of treatment) in the absence of disease progression or unacceptable toxicity. Patients also undergo FDG-PET/CT on study. When СR is achieved according to PET / CT after 4 cycles of chemotherapy, 2 randomization is performed, a total of 4 or 6 chemotherapy courses.
89022681|NCT06188650|Experimental|experimental group|
89022682|NCT06188637|Experimental|Open- label ozanimod|All patients will receive open-label ozanimod
89022683|NCT06188611|Experimental|Huazhi Rougan granule|Take with boiling water ,3 times a day, for 24 weeks;
89022684|NCT06188611|Placebo Comparator|Placebo granule|Take with boiling water ,3 times a day, for 24 weeks;
89022685|NCT06188546|Placebo Comparator|Group 0|Will receive no drugs for pruritis prophylaxis
89496378|NCT05678894|Other|Healthy volunteers|Healthy volunteers
89496379|NCT02405247||NSCLC without T790M mutation|NSCLC patients who have failed first line TKI treatment (defined radiological documentation of disease progression during treatment for advanced or metastatic NSCLC with an approved EGFR-TKI e.g. gefitinib, afatinib or erlotinib) and are screened for the AURA3 study and determined to be lacking the T790M mutation as determined using the AURA3 designated central laboratory using the cobas® EGFR Mutation Test (Roche Molecular Systems).
89496380|NCT02405403|Experimental|amyotrophic lateral sclerosis (ALS)|[18F]DPA-714 PET
89496381|NCT05488574|Experimental|Deep breathing with Yoga positioning|subjects participating in breathing and moving meditation program. 12 minutes daily of deep breathing and yoga positioning first 30 days, then continuation of breathing and positioning and self-directed, mentored, behavior modification activities the second 30 days.
89205299|NCT05769894||Fracture neck of femur|"Trauma and Orthopaedics wards and the Emergency department will be screened for new admissions with fractured neck of femur proven by X-ray on admission, thereby identifying 20 participants according to eligibility criteria.~Suitable patients will be approached about the study and given an information sheet. Later, when they have had enough time to consider, they will be enrolled if they are happy to provide written informed consent.~Blood samples will be taken on the ward on admission, 24, 48 and 72 hours from admission and at 1 month.~Blood will be collected in 4 tubes on each occasion. (1 x2ml 3.2% sodium citrate vacutainer, 1 x 6ml lithium heparin vacutainer. 2 x 5ml SST tubes for Inflammatory markers.) A detailed description of this is laid out below."
89496382|NCT05488574|No Intervention|Control|No changes in lifestyle or activities over the 60 day period.
89496383|NCT05678816|Experimental|BREATHER GROUP|"1)respiratory muscle training for inspiratory and expiratory muscles by the breather device 2)physiotherapy prgramme for stroke rehabilitation which include:~Passive stretching exercise, strengthening exercise.~Postural control and balance exercise from different positions as quadruped, kneeling, sitting and standing.~Gait training."
89496384|NCT05678816|Other|CONTROL|"physiotherapy prgramme for stroke rehabilitation which include:~Passive stretching exercise, strengthening exercise.~Postural control and balance exercise from different positions as quadruped, kneeling, sitting and standing.~Gait training."
89496385|NCT02701413|Experimental|ApexM Device|The ApexM Device (InControl Medical) is a cylindrical inflatable instrument with electrodes on the dorsal and ventral sides. It is a battery operated, non-implanted device which will be inserted into the vagina and will stimulate the pelvic floor muscles. This device has been shown to be safe and effective for clinical use. Stimulation will alternate between 13 and 50Hz. The initial intensity will be set by the clinician at the patient's initial visit and will be increased in a standard fashion over the duration of the trial.
89496386|NCT02701413|Sham Comparator|Sham Device|The ApexM Device will be identical in every way but the electrical stimulation will be disabled. The device will still turn on and inflate to fit the contours of the vagina.
89496387|NCT02412033|Active Comparator|Misoprostol group|Going to receive 400 µg misoprostol vaginally 3 hours before IUD insertion.
89496388|NCT02412033|Placebo Comparator|Placebo group|Going to receive placebo.
89496389|NCT05538494|Experimental|BFR group|Training is applied to this group using low-load exercises with restriction of blood flow.
89496390|NCT05538494|Active Comparator|High load group|A program will be applied to this group of exercise with high loads as a method of treatment
89496391|NCT04481685|Active Comparator|ATI-450|Treated with 50 mg dose of ATI-450, orally, twice daily for 14 days
89496392|NCT04481685|Placebo Comparator|Placebo|Treated with matched placebo, orally, twice daily for 14 days
89496393|NCT02401971|Experimental|Arm A (thalidomide+CPT-11)|Patients will receive CPT-11 180 mg/m^2 ivgtt ,over 90 minutes on day 1, every 21 days for one cycle, four cycles ,and oral thalidomide 100 mg/d qn. Maintenance therapy with thalidomide in the same dose is performed until disease progression.
89496394|NCT02401971|Experimental|Arm B (CPT-11)|Patients will receive CPT-11 180 mg/m^2 ivgtt ,over 90 minutes on day 1, every 21 days for one cycle, four cycles.
89496395|NCT05538416||Open PLIF|Patients undergoing conventional open posterior lumbar interbody fusion (PLIF) surgery. A long midline skin incision (10-15 cm) is made, after which the paravertebral muscles are detached from the midline and retracted laterally in order to expose the facet joints and pedicle entry point. After the pedicle screws are positioned, the disc will be removed bilaterally and packed with autogenous bone chips, followed by bilateral placement of polyetheretherketone (PEEK) PLIF cages.
89496396|NCT05538416||CBT-PLIF|Patient undergoing minimal access PLIF surgery with cortical bone trajectory (CBT-PLIF). The CBT-PLIF uses more medialized entry points, closer to the spinal process. Due to the medial approach of this technique, a smaller incision is needed and the need to retract muscles laterally is minimalized.
89496397|NCT05538416||MI-PLIF|Patients undergoing minimal invasive PLIF surgery. A small midline incision (3-5 cm) will be made to perform mini-open decompression and placement of bilateral PEEK PLIF cages. In addition, two small paramedian incisions will be made on both sides for percutaneous pedicle screw fixation.
89496398|NCT00701883|Placebo Comparator|Placebo/Placebo|
89205300|NCT05769894||Patients > 70 years age admitted with chest infection|"The Emergency department, Acute Medical Unit and medical wards will be screened for eligible participants whose primary diagnosis is chest infection (Acute bronchitis or Pneumonia). Aiming to recruit 20 participants.~Acute Bronchitis is a lower respiratory tract infection causing inflammation in the bronchial airways It is a clinical diagnosis characterised by a cough with no evidence of pneumonia. The chest X-ray can be normal.~Pneumonia is an infection of the lung tissue in which the air sacs in the lungs become filled with microorganisms, fluid and inflammatory cells, affecting the function of the lungs. 39 Patients will be selected according to symptoms, clinical diagnosis +/- Chest X-ray findings (Pneumonia only)."
89205301|NCT05769894||Healthy volunteers following COVID booster|Aiming to recruit 20 participants due to have a COVID vaccine at Southampton General Hospital. We are aiming to recruit 20 healthy volunteers meeting the criteria as per study eligibility.
89496399|NCT00701883|Experimental|MBX-8025 50 mg/Placebo|
89496400|NCT00701883|Experimental|MBX-8025 100 mg/Placebo|
89496401|NCT00701883|Active Comparator|Placebo/Atorvastatin 20 mg|
89496402|NCT00701883|Experimental|MBX-8025 50 mg/Atorvastatin 20 mg|
89496403|NCT00701883|Experimental|MBX-8025 100 mg/Atorvastatin 20 mg|
89496404|NCT05678738|Experimental|Acute and Chronic Exercise-Heat Stress|All participants (male and female) will be exposed to repeated bouts of exercise-heat stress.
89496405|NCT05678738|Active Comparator|Exercise-Heat Stress + Antioxidant Berry Supplementation|All participants (male and female) will be exposed to repeated bouts of exercise-heat stress. Participants who opt-in may be randomly assigned to receive bioactive (antioxidant berry supplement) ingredient in addition to repeated bouts of exercise-heat stress.
89496406|NCT05678738|Placebo Comparator|Exercise-Heat Stress + Placebo (Non-juice) Supplementation|All participants (male and female) will be exposed to repeated bouts of exercise-heat stress. Participants who opt-in may be randomly assigned to receive placebo (non-juice) ingredient in addition to repeated bouts of exercise-heat stress.
89496407|NCT02401659||naïve with CareLink|patients with a first implant of an implanted cardiac device naïve in CareLink or patients with a refill who have not used CareLink until the implant
89205302|NCT05769894||Patient admitted with AMI within 6 weeks of inflammatory condition|Screening will include patients admitted with Type 1 or Type 2 MI or myocardial injury, as defined by the 4th Universal Definition, if they are within 6 weeks of one of the inflammatory conditions listed above.40 Suitable patients will be approached about the study and given an information sheet.
88955308|NCT06328933|Active Comparator|Nasogastric Tube Feeding+comprehensive rehabilitation therapy|"Assigned randomly before the treatment, all patients were provided with comprehensive rehabilitation therapy as follows:~Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training.~Besides, the control group was given enteral nutritional support with Nasogastric Tube according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements."
88955309|NCT06328920|Experimental|Intermittent Oro-esophageal Tube Feeding|The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure. The feeding content was formulated by the nutritionists based on the condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups
88955310|NCT06328920|Active Comparator|Nasogastric Tube Feeding|The control group was given enteral nutritional support with Nasogastric Tube Feeding according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient's cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time.
89205303|NCT05769894||AMI secondary to stent thrombosis|"Eligible patients will have been admitted with definite stent thrombosis according to the Academic Research Consortium definition. 41 Stent thrombosis is a complete occlusion of the artery secondary to thrombus inside the stent. ARC (Academic research consortium) has identified stent thrombosis detected by angiography as Definite stent thrombosis (ST). They also categorised stent thrombosis as early (up to 30 days from deployment), or late (30 days to 12 months from deployment).~Suitable patients will be approached about the study and given an information sheet."
89205304|NCT05769296||Concussed|Diagnosis of concussion
89496408|NCT02401659||users of CareLink|patients with an implanted cardiac device who have used CareLink for more than one year
88955311|NCT06328907|Experimental|comprehensive rehabilitation therapy+Intermittent Oro-esophageal Tube Feeding|"Assigned randomly before the treatment, all patients were provided with comprehensive rehabilitation therapy.~The group is given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure. The feeding content was formulated by the nutritionists based on the condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups"
89022686|NCT06188546|Active Comparator|Group 1|Will receive 1ml of propofol 10 mg/ml
89022687|NCT06188546|Active Comparator|Group 2|Will receive 2 ml of propofol 10mg/ml
89022688|NCT06188546|Active Comparator|Group 3|Will receive 3 ml of propofol 10mg/ml
89205305|NCT05769296||Controls|Athletes with no concussion within the preceding year
89205306|NCT05768893|Experimental|Group 1: Combined Er:YAG laser and long-pulsed Nd:YAG laser group|This group included 120 wart lesions, treated with Er:YAG laser followed by LP Nd:YAG laser after 1-2 minutes. Cryo 6 (Zimmer Medizin Systems) was used to cool the lesions before, during and after applying the Nd:YAG laser.
89205307|NCT05768893|Active Comparator|Group 2: Er:YAG laser group.|This group included 120 wart lesions, treated with Er:YAG laser only.
89205308|NCT05767866|Experimental|Part 1: Dose Escalation Component|In dose-escalation phase, previously treated patients with EGFR T790M mutation were enrolled. YK-029A was given at doses of 50, 100, 150, 200 to 250 mg/day (3+3 design).
89205309|NCT05767866|Experimental|Part 2: Expansion Cohort 1|In dose-escalation phase, previously treated patients with EGFR T790M mutation were enrolled. YK-029A was given at doses of 50mg/day and who have no active, measurable central nervous system (CNS) metastases.
89205310|NCT05767866|Experimental|Part 2: Expansion Cohort 2|In dose-escalation phase, previously treated patients with EGFR T790M mutation were enrolled. YK-029A was given at doses of 100mg/day and who have no active, measurable central nervous system (CNS) metastases.
89205311|NCT05767866|Experimental|Part 2: Expansion Cohort 3|In dose-escalation phase, previously treated patients with EGFR T790M mutation were enrolled. YK-029A was given at doses of 150mg/day and who have no active, measurable central nervous system (CNS) metastases.
89205312|NCT05767866|Experimental|Part 3: ExTension Cohort 4|In dose-extension phase, previously treated patients with EGFR exon 20ins mutation were enrolled. YK-029A was given at doses of 150mg/day and who have no active, measurable central nervous system (CNS) metastases.
89205313|NCT05767866|Experimental|Part 3: ExTension Cohort 5|In dose-extension phase, previously treated patients with EGFR exon 20ins mutation were enrolled. YK-029A was given at doses of 200mg/day and who have no active, measurable central nervous system (CNS) metastases.
89205314|NCT05767866|Experimental|Part 3: ExTension Cohort 6|In dose-extension phase, previously untreated patients with EGFR exon 20ins mutation were enrolled. YK-029A was given at doses of 200mg/day and who have no active, measurable central nervous system (CNS) metastases.
89496409|NCT03175653|Experimental|Arm A - Oxycodone Pill A|Participants in this study arm will receive a prescription for a lower number oxycodone (oxycodone A) pills for post-cesarean pain control.
89496410|NCT03175653|Active Comparator|Arm B - Oxycodone Pill B|Participants in this study arm will receive a prescription for a higher number of oxycodone (oxycodone B) pills for post-cesarean pain control.
89496411|NCT02401737|Experimental|NVR 3-778|NVR 3-778 in varying doses of capsules by mouth for 28 days
89496412|NCT02401737|Placebo Comparator|Placebo for NVR 3-778|Placebo for NVR 3-778 in varying doses of capsules by mouth for 28 days
89496413|NCT02401737|Experimental|NVR 3-778 and Pegasys|NVR 3-778 and Pegasys in combination in a yet to be determined dose by mouth and subcutaneous injection for 28 days
89205315|NCT05767866|Experimental|Part 3: ExTension Cohort 7|In dose-extension phase, previously treated patients with EGFR rare mutation （G719X、L861Q、S768I etal.)were enrolled. YK-029A was given at doses of 150mg/day and who have no active, measurable central nervous system (CNS) metastases.
89496414|NCT02401737|Active Comparator|Pegasys|Pegasys alone in a yet to be determined dose by subcutaneous injection for 28 days
89496415|NCT02401581|Experimental|rate of early removal of the catheter|In our study, we propose to evaluate the failure rate of an early removal of the catheter 3 hours post-operative after a PVP procedure with GL 180 W/XPS in selected patients on general anesthesia or spinal anesthesia for limiting autonomic effects on the bladder and ensure fastest possible recovery of voiding .
89496416|NCT05678504||Application Group|"Filling out the pre-initiative volunteering form and sociodemographic data~Preparation of the individual for the transaction~Monitoring the vein with a vein imaging device and operating a stopwatch~Implementation of the initiative~Stopping the stopwatch at the end of the process~Application of VAS Pain and VAS satisfaction Scale"
89496417|NCT05678504||Control Group|"Filling out the pre-initiative volunteering form and sociodemographic data~Preparation of the individual for the transaction~Starting routine blood collection and starting the stopwatch~Implementation of the initiative~Stopping the stopwatch at the end of the process~Application of VAS Pain and VAS satisfaction Scale"
89496418|NCT03175497|Experimental|Telatinib mesylate treatment arm|"Open label, single arm trial. For the 1st phase: three cohorts, and each with 3-6 solid tumor patients who will be treated with telatinib at predetermined dose: 600 mg bid, 900 mg bid, or 1200 mg bid, respectively.~For the 2nd phase, one cohort with 12 GC patients who will be treated with telatinib at 900 mg bid"
89496419|NCT03175341|Experimental|Vitamin C Supplement|"Ascorbic Acid (AA) with neoadjuvant chemotherapy. Participants received an initial loading dose of 1,5 g Ascorbic Acid (i.v in 100 ml sterile water) on Day 1 followed by 0,75g Ascorbic Acid (i.v in 100 ml sterile water) on Day 2-4 at each chemotherapy cycle and concomitant neoadjuvant chemotherapy regimens administered at the choice of treating physician.~Ascorbic Acid is administered intravenously before neoadjuvant therapy in D1"
89496420|NCT03175341|Active Comparator|Placebo|"Placebos (normal saline (0.9%) with neoadjuvant chemotherapy. 100 ml normal saline 0.9% (placebo) will be administered (i.v) by the same scheme as Ascorbic Acid on Day 1 and respectively Day 2-4 at each chemotherapy cycle.~Concomitant neoadjuvant chemotherapy regimens administered at the choice of treating physician."
89496421|NCT05538026|Active Comparator|standard care group|mesalazine (Pentasa) at a daily dose of 3 g (2 g orally + 1 g rectally)
89496422|NCT05538026|Experimental|Fecal transplantation|Fecal transplantation of fresh prepared feces from healthy donor. Application by colonoscope in proximal half of colon.
89496423|NCT02401425|Active Comparator|letrozole|Women will receive three tablets of letrozole(FemaraR, NOVARTIS) as a single dose, each tablet 2.5 mg (total dose 7.5 mg per day) for two days at home and will be told to bring back the empty packs. The third dose will be given on admission to hospital on day three and will be followed by 4 tablets of vaginal misoprostol (200 mcg) (MisotacR,SIGMA)soaked with saline every three hours up to maximum 2 doses.
89496424|NCT02401425|Placebo Comparator|placebo|Women will receive three tablets of placebo as a single dose, for two days at home and will be told to bring back the empty packs. The third dose will be given on admission to hospital on day three and will be followed by 4 tablets of vaginal misoprostol (200 mcg) (MisotacR,SIGMA)soaked with saline every three hours up to maximum 2 doses.
89496425|NCT05537870|Active Comparator|cancer navigator care|experimental group: case manager care combined cancer nurse navigator care
89496426|NCT05537870|Placebo Comparator|case manager care|control group: only case manager care(usual care)
89496427|NCT02401269|Experimental|Aspirin|Aspirin 325mg daily
89496428|NCT02401269|Placebo Comparator|Placebo|Placebo
89496429|NCT02168179|Experimental|Supportive Care (KeraStat Skin Therapy)|Patients apply KeraStat Skin Therapy topically BID during radiation therapy.
89496430|NCT04480905|Sham Comparator|Sham tape group|in supine, full knee extension position, apply the sham tape from the anterior inferior iliac crest to the middle of the lower leg
89496431|NCT04480905|Experimental|Dynamic tape group|in supine, full knee extension position, apply the dynamic tape from the anterior inferior iliac crest to the middle of the lower leg
89496432|NCT02168257|Experimental|RAM Cannula CPAP|CPAP provided by RAM Cannula
89496433|NCT02168257|Active Comparator|Binasal Prong CPAP|CPAP provided by binasal prong
89496434|NCT04480827|Experimental|Part 1: Mild Hepatic Impairment (Cohort A)|8 mild hepatic impaired subjects
89496435|NCT04480827|Experimental|Part 1: Moderate Hepatic Impairment (Cohort B)|8 moderate hepatic impaired subjects
89496436|NCT04480827|Experimental|Part 1: Severe Hepatic Impairment (Cohort C)|8 severe hepatic impaired subjects
89496437|NCT04480827|Experimental|Part 1: Healthy Volunteers (Cohort D)|up to 24 matched healthy volunteers
89496438|NCT04480827|Experimental|Part 2: Hepatic Impairment cohort|up to 8 hepatic impaired subjects (mild, moderate or severe)
89496439|NCT04480827|Experimental|Part 2: Healthy Volunteers cohort|up to 8 matched healthy volunteers
89496440|NCT02582684|Experimental|Arm 1: DTG 50 mg + 3TC 300 mg|Dolutegravir 50mg and Lamivudine 300mg, orally daily
89496441|NCT02400957|Experimental|Silver nanoparticles|Half of the mouth was applied silver nanoparticles. Allocation was randomized.
89496442|NCT02400957|Experimental|Placebo|Half of the mouth was applied placebo. Allocation was randomized.
89205316|NCT05767866|Experimental|Part 3: ExTension Cohort 8|In dose-extension phase, previously treated patients with EGFR rare mutation （G719X、L861Q、S768I etal.)were enrolled. YK-029A was given at doses of 200mg/day and who have no active, measurable central nervous system (CNS) metastases.
89205317|NCT05767866|Experimental|Part 3: ExTension Cohort 9|In dose-extension phase, previously untreated patients with EGFR exon 20ins mutation were enrolled. YK-029A was given at doses of 150mgBID and who have no active, measurable central nervous system (CNS) metastases.
89205318|NCT05766995|Experimental|Manual toothbrush and water flosser with standard jet tip|Brush with a standard ADA manual toothbrush twice daily followed by water flossing once in the evening
89205319|NCT05766995|Experimental|Manual toothbrush and water flosser with targeted jet tip|Brush with a standard ADA manual toothbrush twice daily followed by water flossing once in the evening
89205320|NCT05766995|Active Comparator|Manual toothbrush and dental floss|Brush with a standard ADA manual toothbrush twice daily followed by dental flossing once in the evening
89205321|NCT05765942||Implant surgery for harvesting healthy implant tissue (group HP)|the preoperative mucosal thickness will be measured clinically using a periodontal probe. A crestal incision will be performed, and a full-thickness flap will be elevated. Following the osteotomy, one or more implants measuring 4.5 or 5.0 mm in diameter will be placed. The implant platform will be positioned 0.5 mm below the bone level. A narrow-diameter healing abutment designed specifically for this study will be screwed in at 20 N, and flaps will be repositioned and sutured to obtain optimal adaptation of the mucosa to the titanium abutment. Healthy tissue samples will be harvested after 2 months of healing. Before the surgery, a guide pin will be connected to each healing abutment, attached to a circular punch 5 mm wide and with a cutting edge, which screwed apically around the abutment. Hence, a 1.5 mm thick collar of peri-implant soft tissue will be harvested Then, a new 4.5-5.0 mm-wide smooth-surfaced healing abutment will be connected to the implant directly.
88955312|NCT06328907|Active Comparator|comprehensive rehabilitation therapy+Nasogastric Tube Feeding|Assigned randomly before the treatment, all patients were provided with comprehensive rehabilitation therapy.Besides, this group is given enteral nutritional support with Nasogastric Tube according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements.
88955313|NCT06328894|Experimental|comprehensive rehabilitation therapy+Intermittent Oro-esophageal Tube Feeding|"Assigned randomly before the treatment, all patients were provided with comprehensive rehabilitation therapy as follows:~Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training.~The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure. The feeding content was formulated by the nutritionists based on the condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups"
89205322|NCT05765942||Implant surgery for harvesting peri-implantitis tissue (group PP)|In each patient, at least one implant site demonstrating signs of peri-implantitis will be selected for biopsy. The site will be anesthetized and two parallel incisions, about 3mm apart, will be made with a 15C scalpel blade through the soft tissue until bone contact would be achieved. The 2 incisions will be connected with a perpendicular incision that will be placed at a distance of 4 mm from the proximal surface of the implant. The biopsies, including the entire supra-crestal soft tissue portion of the diseased site, will be carefully retrieved
89205323|NCT05743335|Experimental|Investigational product|Patients randomized to this arm will be given the investigational product (JCXH-221).
89205324|NCT05743335|Placebo Comparator|Placebo|Patients randomized to this arm will be given a placebo vaccine.
89205325|NCT05743335|Active Comparator|Active Comparator|Patients randomized to this arm will be given an active FDA approved COVID-19 Vaccine (Pfizer, Moderna, etc.).
89205326|NCT05739513|Other|Patients with COVID-19|blood sampling for miRNA analysis
89205327|NCT05739513|Other|Patients without COVID-19|blood sampling for miRNA analysis
89538142|NCT02459639||Anthroposophic integrative care|"Inclusion criteria are: Pain patients with a primary diagnosis corresponding to ICD-10 M79, or long-term pain for a period of over 3 months in neck/shoulders and/or low back, or generalised pain, fluency in Swedish and allowing for co-morbidity/ multiple secondary diagnoses.~The exclusion criteria are: psychotic illness, schizophrenia, bipolar disorder, substance dependency problems, and cancer."
89538143|NCT02459639||Multimodal pain rehabilitation|"Inclusion criteria are: Pain patients with a primary diagnosis corresponding to ICD-10 M79, or long-term pain for a period of over 3 months in neck/shoulders and/or low back, or generalised pain, fluency in Swedish and allowing for co-morbidity/ multiple secondary diagnoses.~The exclusion criteria are: psychotic illness, schizophrenia, bipolar disorder, substance dependency problems, and cancer."
89022689|NCT06188507|Experimental|Part 1: Cohort 1-GSK4347859 or Placebo|Participants in Part 1 Cohort 1 will receive a single dose level of GSK4347859 dose level 1 or placebo in treatment period 1, followed by GSK4347859 dose levels 2 and 3 or placebo in 3- period dose escalation design. Additionally, there will be an optional 4th treatment period with dose level 4. Followed by a wash out period of at least 7 days between each dose.
89022690|NCT06188507|Experimental|Part 1: Cohort 2-GSK4347859 or Placebo|Participants in Part 1 Cohort 2 will receive a single dose level of GSK4347859 dose level 5 or placebo in treatment period 1, followed by GSK4347859 dose levels 6 and 7 or placebo in 3- period dose escalation design. Additionally, there will be an optional 4th treatment period with dose level 8. Followed by a wash out period of at least 7 days between each dose.
89022691|NCT06188507|Experimental|Part 2: Cohort 3-GSK4347859 or Placebo|Participants in Part 2 Cohort 3 will receive 14 days of repeat doses of GSK4347859 dose level A or placebo.
89022692|NCT06188507|Experimental|Part 2: Cohort 4-GSK4347859 or Placebo|Participants in Part 2 Cohort 4 will receive 14 days of repeat doses of GSK4347859 dose level B or placebo.
89022693|NCT06188507|Experimental|Part 2: Cohort 5-GSK4347859 or Placebo|Participants in Part 2 Cohort 5 will receive 14 days of repeat doses of GSK4347859 dose level C or placebo.
89022694|NCT06188468|Experimental|68Ga-THP-Trop2 VHH|Each subject receives a single intravenous injection of 68Ga-THP-Trop2 VHH and undergoes PET/CT imaging within the specified time.
89205328|NCT05737147||100 adult patients of both genders scheduled for cardiac surgery|100 adult patients of both genders scheduled for cardiac surgery with CPB for either coronary artery bypass grafting (CABG), aortic valve replacement (AVR), mitral valve replacement (MVR) or CABG + AVR.
89496443|NCT02411877|Active Comparator|Normothermia|As part of standard of care, an interventional reperfusion procedure will be performed on all subjects using the Trevo Pro Retriever (Stryker), after which normothermia will attempt to keep core body temp between 38 and 36.5 degrees centigrade.
89496444|NCT02411877|Experimental|Mild hypothermia|As part of standard of care, an interventional reperfusion procedure will be performed on all subjects using the Trevo Pro Retriever (Stryker). Subjects will also have a catheter placed in the femoral vein (Zoll Thermogard XP technology with the Quattro catheter) and temperature brought to 33 degrees centigrade as quickly as possible. They will stay in mild hypothermia for 12 hours, and then be rewarmed very slowly.
89496445|NCT04721288|Experimental|Intervention Group|1 year of tailored communication with transplant care team through Reboot application in addition to standard of care communication system.
89496446|NCT04721288|Sham Comparator|Standard of Care Group|1 year of generic communication through Reboot application with communication with transplant care team through standard of care communication system.
89496447|NCT02401191|Experimental|FEX60/PE10|Internal use of FEX60/PE10 combination tablet will be administered twice daily (1 tablet per intake) for 2 weeks
89496448|NCT04714970|Experimental|iTBS stimulation|The participants randomized into experimental group will receive iTBS stimulation of dlPFC 5 times a day, with 1h interval between two stimulations, and for 5 continuous days.
89496449|NCT04714970|Sham Comparator|Sham stimulation|The participants randomized intoSham group will receive Sham stimulation, as the coil vertical to the brain surface, 5 times a day, with 1h interval between two stimulations, and for 5 continuous days.
89496450|NCT04892901||c-ESPB group|Postoperative analgesia ensured by continuous ultrasound-guided ESPB performed at the end of surgery.
89496451|NCT04892901||c-SAPB group|Postoperative analgesia ensured by continuous SAPB performed by surgeons at the end of surgery.
89496452|NCT04892901||ICNB-group|"Postoperative analgesia ensured by one-shot ICNB + continuous intravenous administration of tramadol by elastomeric pump."
89496453|NCT03169491|Experimental|Therapeutic|Continuous positive airway pressure (CPAP) with automatic pressure from 4 to 15 cmH2O every night for one week, afterwards use of CPAP at the P90 of pressure determinated during automatic use for one week, via oronasal interface.
89496454|NCT03169491|Sham Comparator|Suboptimal|Continuous positive airway pressure (CPAP) every night for two weeks at fixed pressure of 4 cmH2O, via oronasal interface.
89496455|NCT03169491|Other|Severe OSAS|Continuous positive airway pressure (CPAP) with automatic pressure from 4 to 15 cmH2O every night for one week, afterwards use of CPAP at the P90 of pressure determinated during automatic use for one week, via oronasal interface.
89496456|NCT02411721|Experimental|Animal assisted intervention|The Effects of Dog Intervention on Anxiety Levels in Children. The experimental group will receive standard training on the imaging process by the MRI technician plus intervention activity with a dog
89496457|NCT02411721|No Intervention|control group|The control group will receive the standard training on the imaging process by the MRI technician.
89022695|NCT06188455|Experimental|Fuzuloparib With Apatinib Mesylate Tablets|
89022696|NCT06188442|Active Comparator|DoxyODPrEP|Participants in the DoxyODPrEP arm would be instructed to take two doxycycline hyclate 100mg capsules orally 2-24 hours before sex, and one 100mg capsule each 24 and 48 hours after loading dose. If they have sex within 48 hours after the loading dose, they would be asked to continue a daily 100mg until two days after the last sex.
89496458|NCT03115437|Experimental|Hard cushioned running shoes|Running shoes with cushioned properties among the hardest of the market benchmark (Stiffness: +/- 90 N/mm)
89496459|NCT03115437|Experimental|Soft cushioned running shoes|Running shoes with cushioned properties among the softest of the market benchmark (Stiffness: +/- 57 N/mm)
89022697|NCT06188442|Active Comparator|DoxyPEP|Participants in the DoxyPEP arm would be instructed to take two doxycycline hyclate 100mg capsules orally within 24 hours and up to 72 hours after each sex.
89022698|NCT06188429||Experimental Group|Children with ASD
89022699|NCT06188429||Control Group|Normal Children
89022700|NCT06188416||Cases with CAI|Cases that reported previous experience of chronic ankle instability
89022701|NCT06188416||Cases without CAI|Cases that did not report any previous experience of chronic ankle instability
89205329|NCT05736796|Other|General cervical Exercise|Students of this group will perform general exercises of the cervical region to strengthen the Muscles.
89205330|NCT05736796|Experimental|Lumber Extension Excersie|Lumber Extension Excersie will be done to prevent the lumber straighten.
89205331|NCT05732298|Experimental|active treatment|intermittent theta burst stimulation
89205332|NCT05732298|No Intervention|waiting list|patients waiting for intervention
89205333|NCT05732051|Active Comparator|Treatment Arm|The patients randomised into this arm of the trial will receive 500 mg Nicotinamide Riboside b.i.d. The duration of blinded therapy will depend on the duration of anthracycline therapy, and will for some patients last for 3 months, others for 6 months.
89205334|NCT05732051|Placebo Comparator|Placebo Control Arm|The patients randomised into this arm of the trial will receive a matching placebo b.i.d. The duration of treatment is equivalent to the description in the treatment arm.
89496460|NCT03169569|Experimental|Hemostatic powder group (Endo-clot™ group)|Patients who will undergo ESD with Endo-clot™ (EndoClot Plus, Unc., Santa Clara, CA, USA) after hemostasis on the post-resection ulcer using conventional method and removal of specimen.
89496461|NCT03169569|Active Comparator|Hemostatic forceps Only (Coagrasper®, Olympus, Japan) group|For patients in the control group, hemostasis with conventional method (electrical coagulation and/or clip, Coagrasper®, Olympus, Japan) will be done.
89022702|NCT06188403|Active Comparator|(group one) will be treated with custom titanium plates and guide to reposition the maxilla|7 patients are included in this arm. Le Fort I osteotomy using CAD CAM surgical guide and 3Dcustomized plate are placed to reposition the maxilla according to the virtual surgical planning.
89022703|NCT06188403|Active Comparator|(group 2) will be treated with prebent titanium plates|7 patients are included in this arm. le fort 1 osteotomy using surgical guide and pre-bent stock titanium plates are used after their adaptation on the model of postoperative plan.
89022704|NCT06188390|Experimental|Hyaluronic acid group|Hyaluronic acidwas injected under ultrasound guidance around wrist median nerve
89205335|NCT05731479|Experimental|Diathermy + exercise group|Application of diathermy and a therapeutic exercise protocol.
89205336|NCT05731479|Placebo Comparator|Diathermy placebo + exercise group|Application of the diathermy device without energy emission and a therapeutic exercise protocol.
89205337|NCT05717088|Experimental|Oral sucrose + soother group (group A)|"Group A: Infants will receive oral sucrose (24%) followed by a soother 2 minutes before the procedure LUS scan. The dose will be 0.2 mL, 0.5 mL and 1 mL for infants with current weight < 1500g, 1500-2500g, and > 2500g respectively."
89205338|NCT05717088|No Intervention|Soother alone group (group B)|Group B (control group): infants will receive a soother 2 minutes before LUS scan.
89205339|NCT05715099|Active Comparator|mild-moderate ulcerative colitis for low dose|2 low dose (25 mg \dose) per day N= 20
89205340|NCT05715099|Active Comparator|mild-moderate ulcerative colitis for high dose|2 high dose (50 mg \dose) per day N=20
89205341|NCT05715099|Active Comparator|healthy subjects for low dose|2 low dose (25 mg \dose) per day N= 10
89205342|NCT05715099|Active Comparator|healthy subjects for high dose|2 high dose (50 mg \dose) per day N=10
89205343|NCT05715099|Placebo Comparator|mild-moderate ulcerative colitis for placebo|2 dose placebo per day N=20
89205344|NCT05715099|Placebo Comparator|healthy subjects for placebo|2 dose placebo per day N=10
89205345|NCT05708716|Experimental|Diet and Cognitive Training|The arm will follow a modified ketogenic diet using an exogenous ketogenic formula (KetoCal) and use the online cognitive training program Lumosity at time of enrollment on the study.
89205346|NCT05708716|Active Comparator|WaitList Control|The arm will only use the online cognitive training program Lumosity 3 months after enrollment in the study.
89205347|NCT05707195|Experimental|Experimental:children hospitalized in pediatric intensive care unit|All parents of children aged 0 to 18 who have been hospitalized in the pediatric intensive care unit over a period of 24 months will be offered the study.
89205348|NCT05685771|Other|Auditory stimulation first|This study group receives auditory stimulation in the first intervention week (second week of trial) and sham stimulation in the second intervention week (fourth week of trial).
89205349|NCT05685771|Other|Sham stimulation first|This study group receives sham stimulation in the first intervention week (second week of trial) and auditory stimulation in the second intervention week (fourth week of trial).
89205350|NCT05681637|Experimental|Hypoxia|Volunteers sequentially inhale three hypoxic gas mixtures each for 2.5 minute. Every measurement will begin with a two-minute stabilization phase, during which the physiological values of the volunteer will be checked. During the experiment, non-invasive SpO2 measurements will be performed continuously on the individual fingers of volunteer hands throughout the experiment.
89531779|NCT05378880|Experimental|Intervention clusters|Intervention bundle consisting of 3 components introduced over 12 months: one to improve antibiotic use targeting health centres and medicine stores and two targeting the general population: one to increase community health literacy and one to improve water, hygiene and sanitation practices.
89022705|NCT06188390|Active Comparator|Dextrose group|Dextrose was injected under ultrasound guidance around wrist median nerve
89205351|NCT05667922||Remission|
89205352|NCT05667922||Non-remission|
89205353|NCT05667909||Remission|
89205354|NCT05667909||Non-remission|
89205355|NCT05667896||Remission|
89205356|NCT05667896||Non-remission|
89205357|NCT05667883||Remission|
89205358|NCT05667883||Non-remission|
89205359|NCT05667805|Active Comparator|Liberal substitution of human prothrombin complex and/or platelet concentrates|If INR < 1,5: 10 I.E. human prothrombin complex/kg bodyweigt/0,5 INR AND/OR If platelets < 50 G/l: ((50 G/l - measured thrombocyte concentration G/l) x total blood volume) platelet concentrate
89496462|NCT03170037|Active Comparator|Standard V-E ventilation technique|After induction of anesthesia subject will be ventilated using the standard V-E ventilation technique. Ventilation will be carried out using pressure mode ventilation at respiratory rate of 10 breaths per minute, I:E ratio of 1:2, peak inspiratory pressure of 20cmH2O and no PEEP. If the subjects can be adequately ventilated, as defined by perceivable chest movement and end tidal CO2 during the first three breaths, ventilation will continue for total ten breaths.
89022706|NCT06188351|Experimental|Three-Dimensional Navigation Atrial Septal Puncture|Atrial septal puncture will be performed using a three-dimensional navigation intracardiac guidance kit
89496463|NCT03170037|Experimental|Reversal V-E ventilation technique|After induction of anesthesia subject will be ventilated using the reversal V-E ventilation technique. Ventilation will be carried out using pressure mode ventilation at respiratory rate of 10 breaths per minute, I:E ratio of 1:2, peak inspiratory pressure of 20cmH2O and no PEEP. If the subjects can be adequately ventilated, as defined by perceivable chest movement and end tidal CO2 during the first three breaths, ventilation will continue for total ten breaths.
89496464|NCT02585960|Experimental|Pharmacokinetic (PK) evaluation of BAX 855|Participants will first undergo an initial pharmacokinetic (PK) assessment. Following the PK assessment participants will be randomized to one of 2 dosing regimens.
89022707|NCT06188351|Active Comparator|Conventional Atrial Septal Puncture|Atrial septal puncture will be performed using trational atrial septal puncture kit using traditional method.
89022708|NCT06188338|Active Comparator|Formulation containing MLYAAT-1002® Composition|After the 1064nm fractional picosecond laser treatment, daily use of the formulation for 56 days: apply one pump of the formulation to the treated side of the face in the morning and evening, respectively.
89205360|NCT05667805|Experimental|Restrictive substitution of human prothrombin complex and/or thrombocytes|No substitution of blood products described in the Active Comparator group.
89496465|NCT02585960|Experimental|FVIII trough target 1-3%|Standard treatment arm - PK-guided dosing schedule to achieve a Factor VIII (FVIII) trough of 1-3%
89496466|NCT02585960|Experimental|FVIII trough target 8-12%|Intensified treatment arm - PK-guided dosing schedule to achieve a Factor VIII (FVIII) trough of 8-12%
89531780|NCT05378880|No Intervention|Control clusters|
89531781|NCT05377957||Brachytherapy|Uveal melanoma patients treated with Ruthenium-106 plaque brachytherapy
89531782|NCT05377957||Proton therapy|Uveal melanoma patients treated with proton therapy
89496467|NCT03169413||cases|Fifty diabetic children diagnosed under the age of one year subjected to genetic analysis to study human leucocytic antigen haplotype class two (DR-DQ) and detection of mutations in the potassium channel, inwardly rectifying subfamily J member 11 gene encoding the Kir6.2 subunit of adenosine triphosphate sensitive potassium channel also possible risk factors associated with the disease.
89022709|NCT06188338|Placebo Comparator|Blank formulation without MLYAAT-1002® Composition|After the 1064nm fractional picosecond laser treatment, daily use of the blank formulation for 56 days: apply one pump of the blank formulation to the control side of the face in the morning and evening, respectively.
89022710|NCT06188325|Experimental|Group 1|CYP2D6 Extensive metabolizers - dose 1, 2 and 3 of eliglustat
89022711|NCT06188325|Experimental|Group 2|CYP2D6 Poor metabolizers - dose 1, 2 and 3 of eliglustat
89496468|NCT03169413||control one|Twenty five diabetic children diagnosed after the age of one year subjected to genetic study to study human leucocytic antigen and possible of presence of gene mutation of the potassium channel, inwardly rectifying subfamily J member 11 gene encoding the Kir6.2 subunit of adenosine triphosphate sensitive potassium channel and possible risk factors associated with disease .
89496469|NCT03169413||control two|Twenty five healthy children matched by age subjected to genetic study to study human leucocytic antigen and possible of presence of gene mutation of the potassium channel, inwardly rectifying subfamily J member 11 gene encoding the Kir6.2 subunit of adenosine triphosphate sensitive potassium channel and exposure to similar risk factors associated with disease .
89496470|NCT03169335|Experimental|Experimental group|QL1101 + paclitaxel/carboplatin:subjects are given 15 mg/kg QL1101 on Day 1 of each cycle with every 3 weeks as a cycle, respectively combined with paclitaxel/carboplatin for 6 cycles (at least 4 cycles).
89496471|NCT03169335|Active Comparator|Control group|Avastin® + paclitaxel/carboplatin:subjects are given 15 mg/kg Avastin® on Day 1 of each cycle with every 3 weeks as a cycle, respectively combined with paclitaxel/carboplatin for 6 cycles (at least 4 cycles).
89496472|NCT03169179|Experimental|Fitbit and Bupa Boost app|Fitbit Charge 2™ wearable physical activity monitor and Bupa Boost health and wellbeing smartphone app. 12 weeks initial use (individual goal-setting in weeks 1-6 then social features of the app in weeks 7-12) followed by a further five months of optional use (as desired by the participant).
89496473|NCT02401113|Experimental|UA group|UA group who takes Ursolic acid of Loquat Extract , 500 mg/ day during 12 weeks for treatment of muscle function improvement with relatively health adults
89496474|NCT02401113|Placebo Comparator|placebo group|placebo group who takes a placebo, 500 mg/day for 12 weeks
89496475|NCT03106623|Experimental|ONO-8577 Arm|Oral administration of ONO-8577 once a daily for 4 weeks
89496476|NCT03106623|Active Comparator|Active Comparator Arm|Oral administration of solifenacin succinate and mirabegron once a daily for 4 weeks
89496477|NCT03106623|Placebo Comparator|Placebo Arm|Oral administration of Placebo once a daily for 4 weeks
89496478|NCT02411175|Experimental|20% Ethanol|20% ethanol will be medicated with the individualised homeopathic remedy as determined by the researcher and administered as drops. The potency, dose and frequency of the medicated 20% ethanol drops will be determined for each prescription, in accordance with the laws that govern homeopathic prescribing.
89496479|NCT03169023|Experimental|Arm 1: ScaleDown (only first 16 patients)|"Baseline quality of life and image surveys~Weigh themselves every day on the provided Wi-Fi Scale~Personalized feedback with text message comes as soon as participants step on the scale~At the 6 month time period, quality of life and body image surveys will be completed and in-office anthropometric assessments will be completed~At the end of 6 months, the participants will also receive the Enhanced Usual Care Packet which provides printed material from the American Cancer Society Website~Only 16 participants were in this arm because ScaleDown went out of business~At 12 month follow-up weight will be abstracted from medical record"
89531783|NCT05377957||Enucleation|Uveal melanoma patients treated with enucleation
89531784|NCT05377437|Experimental|Participants|Participants of the study
89022712|NCT06188299|No Intervention|Liberal Group Therapy|Liberal Fluid Therapy was administered to this group. Fluid restrictions were not used.
89496480|NCT03169023|Active Comparator|Arm 2: Enhanced Usual Care|"Baseline quality of life and image surveys~Brief in-person counseling session by a research assistant using the Enhanced Usual Care Handouts from the American Cancer Society website which provides guidelines on healthy eating and exercise~At the 6 month time period quality of life and body image surveys will be completed and in-office anthropometric assessments will be completed~At 12 month follow-up weight will be abstracted from medical record"
89496481|NCT03169023|Experimental|Arm 3: iOTA|"Baseline quality of life and image surveys~Weigh themselves everyday using the provided Balance High Accuracy Digital Body Fat Scale~Health coach will meet one-on-one with each participant (in-person or phone) to review health risk assessment and to choose 3 behavior goals related to healthy eating and physical activity at enrollment, 3 months, and 6 months~Self-monitoring via SMS text messaging. Weekly check-ins by text providing data about weight and goals~At the 6 month time period quality of life and body image surveys will be completed and in-office anthropometric assessments will be completed~At the end of 6 months, the participants will also receive the Enhanced Usual Care Packet which provides printed material from the American Cancer Society Website~At 12 month follow-up weight will be abstracted from medical record"
89496482|NCT05678426|Experimental|Smoking cessation|Smoking cessation encompasses three guided smoking cessation group therapy sessions (6-12 participants per session) followed by smoking cessation (occuring in the second session) for 6 months. Participants receive an optional exercise programme and motivational coaching over the duration of the study.
89496483|NCT05678426|Experimental|Diet intervention (intermittent fasting)|The dietary intervention encompasses induction (1 month) and maintenance (5 months) of a 16:8 intermittent fasting regime (time restricted eating to 8 h a day, fasting for remaining 16 h). During the introductory month, participants will only maintain a 14:10 intermittent fasting regime. Participants are randomized to receive a ketogenic supplement, medium-chain triglyceride fiber, to use daily. Participants receive an optional exercise programme and motivational coaching over the duration of the study.
89496484|NCT02411331|Experimental|Experimental group|90 patients will receive 10 injections of ethanol lock solution in implantable venous access port during the first 10 days of the study.
89496485|NCT02411331|Other|control group|90 patients will receive 10 injections of vancomycin lock solution in implantable venous access port during the first 10 days of the study
89496486|NCT02411097|Experimental|femoral nerve block|femoral nerve block will be administered before or after the surgery
89496487|NCT02411019||Observational group|Subjects in the period less than 24 weeks after the final administration of GX-188E
89496488|NCT02168335|Experimental|Treatment group|"OrasaltsTM~1 level scoop of OrasaltsTM will be dissolved in warm water. Participants will rinse and gargle the mouth for 30 seconds, then expel and not swallow the mixture, twice daily"
89496489|NCT02168335|Placebo Comparator|Control group|"Sea salt~1 level scoop of sea salt will be dissolved in warm water. Participants will rinse and gargle the mouth for 30 seconds, then expel and not swallow the mixture, twice daily"
89496490|NCT05151926|Experimental|Full weight-bearing|Full immediate weight-bearing postoperatively
89496491|NCT05151926|Active Comparator|Partial-weight bearing|Partial weight-bearing for the first 6 weeks postoperatively.
89538144|NCT03282773|Experimental|Deferred stent implantation|Drug-eluting stents are implanted 4-10 days after primary angiography and restoration of blood flow in left main coroanry artery in a secondary PCI
88955314|NCT06328894|Active Comparator|comprehensive rehabilitation therapy+Nasogastric Tube Feeding|"Assigned randomly before the treatment, all patients were provided with comprehensive rehabilitation therapy as follows:~Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training.~Besides, the control group was given enteral nutritional support with Nasogastric Tube according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements."
88955315|NCT06328881|Experimental|Intermittent Oro-esophageal Tube+Comprehensive rehabilitation training|"Assigned by the random number table. During the treatment, all patients were provided with comprehensive rehabilitation therapy as follows:~Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training.~The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube Feeding"
88955316|NCT06328881|Active Comparator|Comprehensive rehabilitation training+Nasogastric tube|"Assigned by the random number table. During the treatment, all patients were provided with comprehensive rehabilitation therapy as follows:~Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training.~Besides, the control group was given enteral nutritional support with Nasogastric Tube Feeding according to the relevant guidelines."
88955317|NCT06328868|Experimental|Intermittent Oral-esophageal Tube Feeding+comprehensive rehabilitation therapy|During the 15-day treatment, both groups of patients are hospitalized, while conventional care and enteral nutrition support are provided to the two groups. Specifically, conventional care includes health education, dietary adjustments, nasopharyngeal hygiene, management of risk factors (blood pressure and lipid control, etc.), exercise rehabilitation, and psychological support. The frequency and content of these interventions are arranged based on the patients; health condition. The observation group receives Intermittent Oro-esophageal Tube Feeding for enteral nutrition support
88955318|NCT06328868|Active Comparator|Nasogastric Tube Feeding+comprehensive rehabilitation therapy|During the 15-day treatment, both groups of patients are hospitalized, while conventional care and enteral nutrition support are provided to the two groups. Specifically, conventional care includes health education, dietary adjustments, nasopharyngeal hygiene, management of risk factors (blood pressure and lipid control, etc.), exercise rehabilitation, and psychological support. The frequency and content of these interventions are arranged based on the patients; health condition.The control group receives nasogastric tube for enteral nutrition support
88955319|NCT06328855|Experimental|Intermittent Oro-esophageal Tube Feeding+comprehensive rehabilitation therapy|Study lasts 15 days for each patient. The patients were given comprehensive rehabilitation therapy. The observation group was provided the support of enteral nutrition by Intermittent Oro-esophageal Tube Feeding.
88955320|NCT06328855|Active Comparator|comprehensive rehabilitation therapy+Nasogastric Tube Feeding|Study lasts 15 days for each patient. The patients were given comprehensive rehabilitation. The observation group was provided the support of enteral nutrition by Nasogastric Tube Feeding.
88955321|NCT06328842|Active Comparator|Nasogastric Tube Feeding|the control group was given enteral nutritional support with nasogastric tube according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation.
88955322|NCT06328842|Experimental|Intermittent Oro-esophageal Tube Feeding|the group was given enteral nutritional support with Intermittent Oro-esophageal Tube Feeding according to the relevant guidelines.
88955323|NCT06328829|Experimental|Conventional Care+Intermittent Oral-esophageal Tube Feeding|During the 15-day treatment, both groups of patients are hospitalized, while conventional care and enteral nutrition support are provided to the two groups. The observation group receives Intermittent Oral-esophageal Tube Feeding for enteral nutrition support
88955324|NCT06328829|Active Comparator|Conventional Care+Nasogastric tube|During the 15-day treatment, both groups of patients are hospitalized, while conventional care and enteral nutrition support are provided to the two groups. The control group receives Nasogastric Tube Feeding for enteral nutrition support
88955325|NCT06328816|Experimental|routine rehabilitation treatment+Computer-assisted Cognitive Function Training|In this study, each patient received a continuous 15-day treatment. During the treatment, both groups of patients received routine rehabilitation treatment. The experimental group additionally underwent computer-assisted cognitive training, which generated training content of corresponding difficulty based on the patient's cognitive impairment assessment results. The training was conducted seven days a week, once a day, for a duration of 30-45 minutes per session.
88955326|NCT06328816|Active Comparator|routine rehabilitation treatment|In this study, each patient received a continuous 15-day treatment. During the treatment, both groups of patients received routine rehabilitation treatment.The control group was given conventional cognitive training.
88955327|NCT06328803|Experimental|Rehabilitation training+Active Breathing Exercises|"Assigned by the random number table. During the treatment, all patients were provided with comprehensive rehabilitation therapy as follows:~Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Based on this, this group was given Active Breathing Exercises"
89538145|NCT03282773|Active Comparator|Immediate stent implantation|Drug-eluting stents are implanted immediately after primary angiography and restoration of blood flow in left main coroanry artery
89538146|NCT02445469|Other|Parkinson's disease|MRI exam of the brain
89538147|NCT02445469|Other|Multiple System Atrophy|MRI exam of the brain
89538148|NCT02445469|Other|Progressive Supranuclear Palsy|MRI exam of the brain
88955328|NCT06328803|Active Comparator|Rehabilitation training|"Assigned by the random number table. During the treatment, all patients were provided with comprehensive rehabilitation therapy as follows:~Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training."
89496492|NCT02699463|Active Comparator|Continous Positive Airway Pressure|Participants in this group will use CPAP therapy, nightly, for the 3 month duration of the trial
89496493|NCT02699463|Placebo Comparator|Control Group|Participants will receive standard care (Sleep hygiene counseling) during the study.
89496494|NCT05537480|Other|Normal GCT|Women with GCT <140mg/dl
89496495|NCT05537480|Other|Abnormal GCT|Women with GCT >=140mg/dl
89496496|NCT00100789|Experimental|gemcitabine paclitaxel combination|
89496497|NCT02410863|Experimental|Cohort A (BRAFi naïve)|Dabrafenib (BRAFi) and trametinib (MEKi) will be administered orally at their recommended doses for combination therapy of 150 mg twice daily (BID) and 2 mg daily.
89496498|NCT02410863|Experimental|Cohort B (BRAFi / MEKi rechallenge)|Dabrafenib (BRAFi) and trametinib (MEKi) will be administered orally at their recommended doses for combination therapy of 150 mg twice daily (BID) and 2 mg daily
89496499|NCT05537324|Experimental|Brazil nut|50g Brazil nuts
89496500|NCT05537324|Other|Coconut|46g Coconut flakes
89496501|NCT03168945|Active Comparator|Novel diagnostics arm|The intervention is to screen a sputum specimen collected on a participant with suspected TB in the community at the point-of-contact in a mobile van using an on-site GeneXpert MTB/RIF machine
89496502|NCT03168945|Placebo Comparator|Routine screening arm|The control arm is to send a sputum specimen collected on a participant with suspected TB at the mobile van for routine smear microscopy at a laboratory
89205361|NCT05660460|Other|Socially vulnerable individuals in contact with a mobile clinic|After obtaining informed consent, a project nurse in the mobile clinic reviews the online-questionnaire with the participant and performs a lung function examination requiring the individual to blow into a plastic tube. If the participant is identified as having obstructive reduction of lung function, they are offered a referral and patient support to a local pulmonary medicine department or GP for further investigation - regardless of whether or not they have a diagnosed or undiagnosed lung disease. In addition, participants are questioned about their motivation for smoking cessation and are informed of the options for this (in hospital and/or referral to the municipality).
89496503|NCT05678192|Other|Transdermal MHT|The group includes women 45-59 years old, with menopausal symptoms. The choice of transdermal MHT was based on personal history (chronic diseases of the gastrointestinal tract, high blood pressure, etc.), family history (stroke, thromboembolism in relatives, etc.), and patient preferences. Used estradiol hemihydrate 0.6 mg 2 protective pumps. The progesterone component of MHT includes micronized progesterone 100 mg or 200 mg, depending on the MHT regimen (continuous or cyclic). Blood sampling to determine the immune status is carried out before the start of therapy after 3 months.
89496504|NCT05678192|Other|Oral MHT|"The group includes women 45-59 years old, with menopausal symptoms. Examination before the appointment of MHT can be carried out according to clinical recommendations. The choice of transdermal MHT was based on the history (chronic diseases of the gastrointestinal tract, high blood pressure, etc.), family history (stroke, thromboembolism in relatives, etc.), the patient's preferences.Drugs used in this group include:~Dydrogesterone 5 mg + Estradiol 1 mg or Dydrogesterone 10 mg + Estradiol 1 mg, depending on the MHT regimen. Blood sampling to determine the immune status is performed before the start of therapy and after 3 months"
89496505|NCT00708123|Active Comparator|Sodium Fluoride (NaF) toothpaste[1350 parts per million(ppm)F]|Participants to brush their natural teeth twice daily with a full ribbon of NaF toothpaste (1350 ppm F as NaF) for one timed minute, after removing their partial denture from their mouth.
89022713|NCT06188299|Other|Targeted Fluid Therapy|Targeted (restrictive) Fluid therapy was administered to this group. Fluids were given according to targeted blood pressure levels and aimed to avoid from fluid overload.
89496506|NCT00708123|Experimental|NaF/Carbopol toothpaste (1400 ppm F)|Participants to brush their natural teeth twice daily with a full ribbon of NaF and 0.5% carbopol toothpaste (1450 ppm F as NaF) for one timed minute, after removing their partial denture from their mouth.
89496507|NCT00708123|Active Comparator|NaMFP/NaF toothpaste (1450 ppm F)|Participants to brush their natural teeth twice daily with a full ribbon of NaMFPand NaF toothpaste (1450 ppm F - 1000 ppm F as NaMFP and 450 ppm F as NaF) for one timed minute, after removing their partial denture from their mouth.
89496508|NCT00708123|Active Comparator|NaF toothpaste (250 ppm F)|Participants to brush their natural teeth twice daily with a full ribbon of NaF toothpaste (250 ppm F as NaF) for one timed minute, after removing their partial denture from their mouth.
89496509|NCT00708123|Placebo Comparator|Placebo toothpaste (0 ppm F)|Participants to brush their natural teeth twice daily with a full ribbon of fluoride free toothpaste (0 ppm F) for one timed minute, after removing their partial denture from their mouth.
89496510|NCT03168789|Experimental|Tension Tamer (TT)|Breathing Awareness Mediation delivered by smartphone app.
89538149|NCT02445469|Other|Vascular parkinsonism|MRI exam of the brain
89538150|NCT02445469|Other|Healthy volunteers|MRI exam of the brain
88955334|NCT06328764|Experimental|CS-101|Autologous CD34+ hematopoietic stem cell suspension modified by in vitro base editing technique
89022714|NCT06188273||Myosteatotic Group|The group of patients was diagnosed with myosteatosis through CT imaging assessment before transplantation.
89022715|NCT06188273||Non-myosteatotic Group|The group of patients was diagnosed without myosteatosis through CT imaging assessment before transplantation.
89022716|NCT06188273||The Group with Severe Muscle Loss|The group of patients, through the comparison of CT images before and after transplantation, was diagnosed with significant muscle loss.
89022717|NCT06188273||The Group without Severe Muscle Loss|The group of patients, through the comparison of CT images before and after transplantation, was diagnosed without significant muscle loss.
89022718|NCT06188221|Experimental|Corticosteroid with Lidocaine|"The group with the lidocaine will get a combined injection with a steroid and lidocaine. The dosages depend on the disease. The steroid dosage will be the same as for the group without lidocaine.~Trigger finger/De Quervain's tenosynovitis/Tendonitis: 20mg kenalog (0.5mL of kenalog 40mg/mL suspension) + 5mg lidocaine (0,5mL 10mg/mL lidocaine solution)~Carpal tunnel injections: 6mg betamethasone (1mL of betamethasone 6mg/mL suspension) + 20mg lidocaine (2mL 10mg/mL lidocaine solution)~CMC/Basal joint arthritis: 3mg betamethasone (0.5mL of betamethasone 6mg/mL suspension) + 5mg lidocaine (0,5mL 10mg/mL lidocaine solution)"
89022719|NCT06188221|Active Comparator|Corticosteroid without Lidocaine|"The group without the lidocaine will get an injection with only steroids. The steroid dosage depends on the disease and will be the same as for the group with the lidocaine:~Trigger finger/De Quervain's tenosynovitis/Tendonitis: 20mg kenalog (0,5mL of kenalog 40mg/mL suspension)~Carpal tunnel injections: 6mg betamethasone (1mL of betamethasone 6mg/mL suspension)~CMC/Basal joint arthritis: 3mg betamethasone (0,5mL of betamethasone 6mg/mL suspension)"
89496511|NCT03168789|Active Comparator|Lifestyle education program (SPCTL)|Healthy lifestyle education provided by text messages and links to media. Runkeeper app to log physical activity.
89496512|NCT05677958|Active Comparator|Test group|125 mL Fortimel/Nutridrink Compact Protein
89496513|NCT05677958|No Intervention|Control group|
89496514|NCT02410785|Active Comparator|Medical device polyglucosamine|2 times daily 2 tablets with the two main meals with the highest fat content. Participants follow the German guideline with a hypo-caloric (-500 kcal daily) lifestyle and increased physical activity.
89496515|NCT02410785|Placebo Comparator|Placebo|2 times daily 2 tablets with the two main meals with the highest fat content. Participants follow the German guideline with a hypo-caloric (-500 kcal daily) lifestyle and increased physical activity.
89496516|NCT02410941|Experimental|Decision-support for MTBI|Clinical decision support will be provided on ordering CT scans for patients suspected to have Minor Traumatic Brain Injury (MTBI) to treating physicians randomized into this group. This arm will also serve as a control for the PE group.
89496517|NCT02410941|Experimental|Decision-support for PE|Clinical decision support will be provided on ordering CT scans for patients suspected to have Pulmonary Embolism (PE) to treating physicians randomized into this group. This arm will also serve as a control for the MTBI group.
89496518|NCT03168633|Experimental|patients receiving emails|"Diagnosed DM2 patients who meet inclusion criteria. the patients will receive emails containing information about DM2 as a method of reminding patients of the importance of adjusting post diagnosis life-style changes.~web-based DM2 information pages"
89496519|NCT05536934|Experimental|Arginase inhibition|Endothelium dependent and -independent vasodilatation before and after 120min intra-arterial administration of arginase the inhibitor N-omega-hydroxy-nor-l-arginine (nor-NOHA) is started and is maintained for 120 min at a rate of 0.1 mg/min
89496520|NCT02400879|Active Comparator|Remifentanil|For anesthesia maintenance, TCI-remifentanil (fixed Cp of 20 ng/ml) and TCI-propofol (variable Ce < 2.0 µg/ml) for maintaining BIS 40-60
89496521|NCT02400879|Placebo Comparator|sevoflurane and sufentanil|TCI-sufentnail (Cp of 0.4-0.8 ng/ml) and sevoflurane (< 1.5 MAC) for maintaining 80-120 % of preoperative value and BIS < 60
89496522|NCT05034692|Experimental|Overlap group|Total laparoscopic with intracorporeal anastomosis by overlap method
89496523|NCT05034692|Active Comparator|Traditional group|Laparoscopic-assisted colectomy with extracorporeal anastomosis
89496524|NCT03175107|Experimental|PD_patients|Patients with Parkinson disease or Parkinsonism (characteristic symptoms such as rigidity, extrapyramidal symptoms), with functional disorders in upper extremities and minor problems at daily activities, with the level 2-3 in the Hoehn and Yahr Scale. They will perform exergaming at home for up to 4 weeks.
89022720|NCT06188208|Experimental|Dose Escalation: VVD-130850 Single Agent|Participants will receive ascending doses of VVD-130850, orally, once daily in 21-day treatment cycles during the dose escalation phase.
89205362|NCT05660174||Patient with a digestive surgery procedure|
89205363|NCT05660174||Patient with a vascular surgery procedure|
89538151|NCT03285503|Experimental|400 mg group|Aripiprazole IM depot 400mg will be administered every four weeks for 20 weeks after drug switch / steady dose of oral aripiprazole tablets (each subject will receive 5 intramuscular injections totally).
89022721|NCT06188208|Experimental|Dose Escalation: VVD-130850 + Pembrolizumab Combination Therapy|Participants will receive ascending doses of VVD-130850, orally, once daily, along with pembrolizumab intravenous (IV) infusion, every 3 weeks (Q3W) in 21-day treatment cycles during the dose escalation phase.
89022722|NCT06188208|Experimental|Dose Expansion: VVD-130850 Single Agent|Participants will receive VVD-130850 at recommended dose for expansion (RDE), orally, once daily in 21-day treatment cycles during the dose expansion phase.
89022723|NCT06188208|Experimental|Dose Expansion: VVD-130850 + Pembrolizumab Combination Therapy|Participants will receive VVD-130850 at RDE orally, once daily along with pembrolizumab IV infusion, Q3W in 21-day treatment cycles during the dose expansion phase.
89022724|NCT06188195|Experimental|the experimental group|For pregnant women with a probability greater than 80% in the prediction model of NARDS, those who agreed to ACS intervention were included in the experimental group
89496525|NCT04133480|Experimental|GWP42003-P|For the first 7 days of the treatment period, participants are to take GWP42003-P at a dose of 5 milligrams per kilogram per day (mg/kg/day), administered as 2 equally divided doses (i.e., 2.5 mg/kg in the morning and 2.5 mg/kg in the evening). On Day 8, participants are to increase the dose to 10 mg/kg/day, administered as 2 equally divided doses (i.e., 5 mg/kg in the morning and 5 mg/kg in the evening). The 10 mg/kg/day dose should be maintained for the remainder of the treatment period; however, per labeling, investigators may increase the dose to a maximum of 20 mg/kg/day if clinically warranted by titrating an additional 5 mg/kg/day each week until reaching the maximum dose. GWP42003-P will be taken b.i.d. (morning and evening).
89496526|NCT02400645|Active Comparator|Group A: pre-incisional bupivacaine|Intervention: Pre-incisional wound infiltration with bupivacaine plain 0.25%. Ketorolac 30mg IV will be given following surgical procedure.
89496527|NCT02400645|Active Comparator|Group B: laparoscope to place TAP block|Intervention: laparoscope to place TAP block with liposomal bupivacaine and bupivacaine plain 0.25%. Ketorolac 30 mg IV will be given following surgical procedure.
89496528|NCT02165215|Experimental|Open-Label Induction Phase: Etrolizumab|All participants will receive treatment with open-label etrolizumab 105 milligrams (mg) subcutaneous (SC) injection once every 4 weeks (Q4W) up to Week 10.
89496529|NCT02165215|Experimental|Double-Blind Maintenance Phase: Etrolizumab|Participants who achieved a clinical response at Week 10 during the induction phase and randomized to this arm for the double-blind maintenance phase will receive etrolizumab 105 mg SC injection Q4W from Week 12 up to Week 62.
89496530|NCT02165215|Placebo Comparator|Double-Blind Maintenance Phase: Placebo|Participants who achieved a clinical response at Week 10 during the induction phase and randomized to this arm for the double-blind maintenance phase will receive placebo (matched to etrolizumab) SC injection Q4W from Week 12 up to Week 62.
89496531|NCT02400801|Active Comparator|oral oestroprogestogen pre-treatment|preparation with oral oestroprogestogens prior to downregulation in an assisted reproductive technology treatment (ART) cycle
89496532|NCT02400801|Experimental|gonadotropin-releasing hormone (GnRH) pre-treatment|preparation with gonadotropin-releasing hormone (GnRH) analogues prior to downregulation in an assisted reproductive technology treatment (ART) cycle
89496533|NCT05677802|Experimental|Health Services Research (stress management therapy)|Patients receive biobehavioral stress reduction intervention while on study. Patients undergo blood specimen collection at baseline and follow up and have their medical records reviewed.
89496534|NCT03175185||Parents of children with ADHD|100 parents of 50 children who were diagnosed with ADHD and
89496535|NCT03175185||Parent of children without ADHD|100 parents of 50 children who are ADHD free as a control group
89496536|NCT05677724||Group 1|HBV DNA(>20000IU/mL)
89022725|NCT06188195|No Intervention|the control group|For pregnant women with a probability greater than 80% in the prediction model of NARDS, those who did not agree with ACS intervention were included in the control group
89496537|NCT05677724||Group 2|HBV DNA(>2000IU/mL)
89022726|NCT06188169|Experimental|Group A = C-PCV received conventional pressure-controlled ventilation|Inspiratory pressure will be adjusted to achieve an expired tidal volume of 7 ml/Kg; the respiratory rate will be adjusted to achieve an end ETCO2 at 32-35 mmHg, inspiratory to expiratory ratio at 1:2, PEEP at 4 cm H2O, and FiO2 at 0.5. No further adjustment in IP will be made throughout the surgery. LUS will be performed at the same fixed four-time interval as Group-B. Anesthesiologist will not do any interventions to the atelectatic areas in this group.
89022727|NCT06188169|Active Comparator|Group B = US-PCV: received ultrasound-guided pressure-controlled ventilation|Initial IP will be ten cmH2O, PEEP 4 cmH2O with a 0.5 inspired oxygen fraction, and RR 12 breaths/min. Then under ultrasound guidance, a stepwise increase in inspiratory pressure from 10 cmH2O by 2 cmH2O increments every 5 min until the atelectasis disappeared on ultrasound (progression from lung collapse to B lines to normal lung image). The IP will be fixed at this level, and RR will be adjusted to maintain an EtCO2 at 32-35 mmHg. The maximum airway pressure will be limited to 35 cmH2O.
89022728|NCT06188156|Active Comparator|Thoracic Epidural Block(Group 1)|About 33 Patients will receive thoracic epidural block with an injection of a single shot of 15ml of 0.25% bupivacaine between T4 and T5 vertebrae.
89022729|NCT06188156|Active Comparator|Ultrasound Guided Sserratus Anterior Plane Block (Group 2)|About 33 Patients will receive Ultrasound Guided Sserratus Anterior Plane Block( SAPB) with an injection of 30 ml bupivacaine 0.25% .
89022730|NCT06188156|Active Comparator|Ultrasound Guided Pectoral Nerve Block (Group 3)|About 33 Patients will receive Ultrasound Guided Pectoral Nerve Block ( PECS II) with an injection of 20 ml bupivacaine 0.25% of pectoral-minor above the Serratus anterior muscle.
89496538|NCT05677724||Group 3|HBV DNA(10-2000IU/mL)
89496539|NCT05677724||Group 4|HBV DNA(=<10IU/mL)
89496540|NCT05677724||Group 5|HBV DNA(0 IU/mL)
89496541|NCT02400177|Experimental|Emotion regulation training|This is a 4 sessions group workshop and 1 session individual pre-screening about parental emotion regulation and emotion co-regulation. In this study the facilitators will give information about efficient strategies to regulate parent emotions and their children's emotions.
89496542|NCT02400177|No Intervention|Control group|"In this condition we will take all the measurement before and after the waiting list period.~This group will go through the workshop after the measurements will be taken."
89496543|NCT03175029|Experimental|TAC-302|
89496544|NCT03175029|Placebo Comparator|Placebo|
89496545|NCT02400411|Experimental|Wheat bread|Bread-based meal
89496546|NCT02400411|Experimental|Wheat bread with margarine and ham|Bread-based meal
89496547|NCT02400411|Experimental|Wheat bread with margarine, ham and soup|Bread-based meal
89496548|NCT02400411|Experimental|Rye bread|Bread-based meal
89496549|NCT02400411|Experimental|Rye bread with margarine and ham|Bread-based meal
89496550|NCT02400411|Experimental|Rye bread with margarine, ham and soup|Bread-based meal
89496551|NCT02168569|Active Comparator|Cohort 1|5 sites, namely Manhiça, Dondo, Montepuez, Tete and Chokwe
89496552|NCT02168569|Active Comparator|Cohort 2|3 sites, namely Montepuez, Dondo and Chokwe
89496553|NCT03175263||Patients with chronic migraine|Patients with chronic migraine refractory to conventional treatments
89496554|NCT02165293|Experimental|RO7033877|
89496555|NCT05536622|Experimental|Infrared imaging of affected tibia|All eligible children will have infrared imaging undertaken of both affected limb and unaffected limb simultaneously.
89496556|NCT02171689|Experimental|BIBW 2992 MA2|
89496557|NCT05536544|Other|IBDMED-ISR|Patients with newly diagnosed CD in Israel
89496558|NCT05536544|Other|IBDMED-IND|Patients with newly diagnosed CD in India
89496559|NCT02396901|Experimental|GDT group|Patients randomized to the GDT Group will care from a protective strategy with the suspension of angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) 48 hours before surgery and receive hydration with lactated Ringer's solution at the rate of 1 mL/kg/h in the night before the surgery until the surgical procedure and perioperative hemodynamic therapy.
89496560|NCT02396901|Placebo Comparator|Control group|Patients randomized to the control group will be treated in accordance with the care in the institution's routine.
89496561|NCT02165371|Experimental|Sinovuyo Caring Families Programme|12-week group-based parenting program (Sinovuyo Caring Family Programme) delivered in weekly 3 hour sessions. Program is manualized.
89496562|NCT02165371|No Intervention|No intervention|Control group receives not intervention
89496563|NCT02171767|Experimental|BIBW 2992 MA2 - single rising dose|
89496564|NCT02400021|Experimental|Prometrium|Prometrium (progesterone capsules) intervention
89496565|NCT02400021|No Intervention|No treatment|no treatment arm
89496566|NCT04757246|Other|Cohort 1|Stable outpatients without implantable devices
89496567|NCT04757246|Other|Cohort 2|Stable outpatients with Boston Scientific pacemakers or defibrillators with Heart Logic capability
89496568|NCT04757246|Other|Cohort 3|Stable outpatients with implantable CardioMEMS devices
89496569|NCT02255539|Experimental|CPAP Nasal Mask|Geelong Prototype Mask
89496570|NCT02396667||pregnant women with macrosomia|Pregnant wo.en between 37 and 42 weeks with fetal macrosomia as suspected by clinical estimation and 2D ultrasound.
89496571|NCT02171923||Remitted depressed patients|Formerly depressed patients in remission for 6 months or more
89496572|NCT02171923||healthy controls|healthy subjects with no history of mental disorders
89496573|NCT02396589|Active Comparator|Education Group|Participants in the Education group receive five 90 minute tailored stroke education sessions in the home.
89496574|NCT02396589|Experimental|Home Modifications Group|Participants in the treatment group receive a home assessment and home modifications tailored to functional abilities (pre discharge) and then five 90 minute occupational therapy treatment sessions at home (post discharge) to improve functional abilities and community participation.
89496575|NCT02165449|Experimental|Ketamine|
89496576|NCT02400099|Active Comparator|High-protein low calorie diet (HPLC)|900 Kcal; Protein 90 g (39%); CHO 75 g (30%); Lipid 32 g (31%)
89496577|NCT02400099|Placebo Comparator|Control low calorie diet (CLC)|900 Kcal; Protein. 50 g (22%); CHO 119 g (48%); Lipid 31 g (30%)
89496578|NCT05536466|Experimental|doravirine treatment|patients stable on doravirine and candidate for bariatric surgery
89496579|NCT02168647|Experimental|Behavioral Lifestyle counseling|Intervention group participants will take part in behavioral lifestyle counseling provided by a Registered Dietitian Nutritionist from week 14 of gestation through childbirth.
89496580|NCT02168647|Active Comparator|Control|Participants in the control arm will receive no form of lifestyle intervention.
89496581|NCT02399865|Experimental|YSBNT Group|Six 50 minute YSBNT sessions (delivered by a trained YSBNT practitioner) for over a maximum period of 12 weeks
89496582|NCT02399865|No Intervention|Treatment as Usual Group|Usual care delivered by treatment-as-usual practitioners
89496583|NCT02168725|Experimental|briciclib|The starting dose of briciclib in the Escalation Stage will be 17 mg/week, with subsequent dose escalation levels of 35 mg, 70 mg, 140 mg, 280 mg, 560 mg, and 1120 mg. The dose of briciclib in the RPTD Confirmation Stage will be the dose as determined during the escalation stage. At each dose level, briciclib will be administered as a 2-hour intravenous infusion, once-a-week per 3-week cycles.
89496584|NCT02399787||infertile patients|Infertile patients with more than 5 oocytes retrieved and no endometriosis
89496585|NCT02172001|Experimental|Iron isomaltoside 1000|Iron isomaltoside 1000. Dose: 1000 mg, 1500 mg or 2000 mg
89022731|NCT06188143|No Intervention|Control group|No medication before hysteroscopic procedure
89022732|NCT06188143|Experimental|Ibuprofen-Paracetamol|Ibuprofen 40mg and Paracetamol 500mg per oral, single dose each, before hysteroscopic procedure 30minutes
89022733|NCT06188130|Experimental|active rTMS|Participants recevied 20 Hz high frequency repetetive TMS during 20 minutes and a total of 1200 stimuli for 15 sessions. The patient received robotic therapy for lower extremity just after each active TMS sessions
89022734|NCT06188130|Sham Comparator|sham rTMS|Participants recevied sham TMS during 20 minutes and a total of 1200 sham stimuli for 15 sessions with sham coil. The patient received robotic therapy for lower extremity just after each sham TMS sessions
89022735|NCT06188130|Experimental|active tDCS|Participants recevied 2 mA anodal transcranial direct current stimulation 20 minutes for 15 sessions. The patient received robotic therapy for lower extremity just after each active tDCS sessions
89022736|NCT06188130|Sham Comparator|sham tDCS|Participants recevied sham stimulation. The patient received robotic therapy for upper extremity just after each sham tDCS sessions
89496586|NCT02172001|Placebo Comparator|Placebo (NaCl 0,9%)|Sodium Chloride. Dose: 100 ml or 5 ml
89496587|NCT02165527|Experimental|x-ray with iXDA scan|Tota body scan taken by the Lunar iXDA. During the scan, subject will be asked to lay on their back. Following the Lunar iDXA scan, the computer of the Luna iXDA will calculate bone length. The calculation of bone length will be compared to a calculation from the subject's conventional x-ray to determine accuracy.
89496588|NCT05535998||Combined therapy group (TACE-HAIC combined with TKIs and PD-1 inhibitors)|Patients recieve combined with TKIs and PD-1 inhibitors
89496589|NCT05535998||TACE alone group|TACE alone
89496590|NCT02255695|No Intervention|Control group|Control group
89496591|NCT02255695|Experimental|School-based exercise program|School-based exercise program
89496592|NCT03540199|Experimental|Cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
89496593|NCT03540199|Active Comparator|Cryotherapy & Activated CIK and bispecific antibody|the maximum tumor length≥2cm, use cryotherapy. the maximum tumor length<2 cm,Biological/Vaccine:Activated CIK and bispecific antibody CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
89022737|NCT06188104|Experimental|TCA plus acetic acid 1|No lesion group,
89022738|NCT06188104|No Intervention|Acetic acid 1|No lesion group, Applying acetic acid which normally used during colposcopic examination at transformation zone during colposcopic examination
89022739|NCT06188104|Experimental|TCA plus acetic acid 2|Having lesion with normal pathologic examination
89022740|NCT06188104|No Intervention|Acetic acid 2|Having lesion with normal pathologic examination, Applying acetic acid which normally used during colposcopic examination at transformation zone and lesion during colposcopic examination
89022741|NCT06188104|Experimental|TCA plus acetic acid 3|Having lesion with low-grade abnomality on pathologic examination,
89022742|NCT06188104|No Intervention|Acetic acid 3|Having lesion with low-grade abnomality on pathologic examination, Applying acetic acid which normally used during colposcopic examination at transformation zone and lesion during colposcopic examination
89022743|NCT06188091|Active Comparator|Intervention with active exercises for knee joint 2 times a day|Intervention group A does 1 active exercise to improve flexion and 1 active exercise to improve extension 2 times a day, 18 days in a row
89022744|NCT06188091|Active Comparator|Intervention with active exercises for knee joint 8 times a day|Intervention group B does 1 active exercise to improve flexion and 1 active exercise to improve extension 8 times a day, 18 days in a row
89022745|NCT06188052|Active Comparator|Group (A), tranexamic acid IV|tranexamic acid will be given 1 hr preoperatively as 1mg/kg intravenously
89022746|NCT06188052|Active Comparator|Group (B), topical tranexamic acid|topical tranexamic acid will be given as an irrigation by 40 ml of tranexamic acid 2mg/kg dissolved in 200ml to the surgical site every 1 hour for the first 5 hours .
89022747|NCT06188052|Placebo Comparator|Group (C), control group.|Saline will be given intravenously instead of tranexamic acid And irrigation with Saline instead of tranexamic acid
89022748|NCT06188013||proliferative diabetic retinopathy|Age ≥18 years old；patients diagnosed with PDR by FFA
89496594|NCT03540199|No Intervention|Conventional therapy|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
89496595|NCT04313582|Experimental|SmartPrompt|
89496596|NCT03540043|Placebo Comparator|Placebo|Administration of Placebo
89496597|NCT03540043|Experimental|PUR0110 (Thykamine) 0.05%|Administration of PUR0110 (Thykamine) 0.05%
89496598|NCT03540043|Experimental|PUR0110 (Thykamine) 0.10%|Administration of PUR0110 (Thykamine) 0.10%
89496599|NCT03540043|Experimental|PUR0110 (Thykamine) 0.25%|Administration of PUR0110 (Thykamine) 0.25%
89496600|NCT02172079|Experimental|Real mobilization-with-movement (MWM)|For the MWM group, an accessory posterior-lateral gliding movement in the humeral head combined with a movement of active shoulder flexion will be applied. One hand will be placed over the scapula posteriorly while the thenar eminence of the other hand will be placed over the anterior aspect of the head of the humerus
89496601|NCT02172079|Sham Comparator|Sham mobilization-with-movement (MWM)|The sham condition will replicate the treatment condition except for the hand positioning. The therapist locates one hand over the belly of the pectoralis major muscle and the other over scapula without applying any pressure. The patient will be asked to move the arm in a similar manner as in the MWM group
89496602|NCT02261233|Experimental|Immediate treatment|This arm receives osteopathic manipulative treatment shortly after enrollment
89496603|NCT02261233|Experimental|Delayed treatment|This arm receives osteopathic manipulative treatment approximately 4 weeks after enrollment
89022749|NCT06188013||non-proliferative diabetic retinopathy|Age ≥18 years old；patients diagnosed with NPDR by FFA
89496604|NCT02261311||Quality of Life, tissue collection|All participants will complete the GAD-7 and Cancer Locus of Control Scale - Course of Illness Subscale questionnaires and additional tissue will be collected at the time of the diagnostic biopsy.
89496605|NCT05694962|Experimental|Treatment group|supportive care and standard of care drug therapies (i.e., glucocorticosteroids, Paxlovid, etc.) plus 1.5Gy single treatment of whole-lung radiation therapy
89022750|NCT06188013||diabetes mellitus without retinopathy|Age ≥18 years old；patients diagnosed with Diabetes Mellitus；patients weren't diagnosed with diabetic retinopathy
89022751|NCT06188013||health control|Age ≥18 years old；patients weren't diagnosed with Diabetes Mellitus
89022752|NCT06188000|Experimental|Extra Virgin Olive Oil|The patients was given a capsule contained extra virgin olive oil 15 milliliters twice a day.
89538152|NCT03282617|Experimental|locally recurrent or metastatic nasopharyngeal cancer|This cohort consists of patients with metastatic or locally recurrent NPC who have received systemic concurrent chemotherapy and have a favourable response of stable disease, partial or complete response. As up to 30% of these patients will suffer from relapse within 5 months of completion of chemotherapy, following definitive treatment, y, and treatment with CD137L-DC-EBV-VAX may activate T cell response against the tumor and prolong time to progression.
89538153|NCT03282617|Experimental|stage 4 locally advanced nasopharyngeal cancer|This cohort consists of patients with stage 4 locally advanced patients (N2 and N3 disease, and/or T4 disease) who are treated definitely with chemoradiation with curative intent, but who have a high risk of distant relapse. Treatment with CD137L-DC-EBV-VAX may activate antitumor T cell responses and prolong time to relapse.
89022753|NCT06188000|Active Comparator|Olive Oil|The patients was given a capsule contained olive oil 15 milliliters twice a day.
89022754|NCT06188000|Placebo Comparator|Placebo|The patients was given an empty capsule twice a day.
89538154|NCT02439931|Experimental|Remote psychosocial intervention|10 sessions of remotely delivered psychoeducation and support
89538155|NCT03285347|Experimental|Brain+ Evolution|"Intervention: Training with computer-based programme Brain+ Evolution for 8 weeks, receiving follow-ups every second week.~Computer-based cognitive training."
89022755|NCT06187987||FlowTriever|Acute PE patients treated with the FlowTriever device
89022756|NCT06187987||Intravenous Thrombolysis|Acute PE patients treated with intravenous thrombolysis
89022757|NCT06187974||Study group|stroke patients
89022758|NCT06187974||Control group|healthy volunteers
89538156|NCT03285347|Experimental|Scientific Brain Training PRO|"Intervention: Training with computer-based programme Scientific Brain Training PRO for 8 weeks, receiving follow-ups every second week.~Computer-based cognitive training."
89538157|NCT03285347|No Intervention|Control group|This Group receives no intervention except for the same amount of follow-ups as the two training Groups. This is done to ensure that an effect of training is not aqtually due to the follow-up's with a professional.
89538158|NCT03282539||LAMS|EUS-guided transmural drainage of pancreatic fluid collections with lumen apposing metal stents.
89538159|NCT03282539||LAMS + pigtail|EUS-guided transmural drainage of pancreatic fluid collections with lumen apposing metal stents and a coaxial double pigtail stent
89538160|NCT02443909|Active Comparator|first group|Patients undergoing Retrograde Intrarenal Surgery with 20w Holmium laser device who have 2-3 cm kidney stones
89538161|NCT02443909|Active Comparator|second group|Patients undergoing Retrograde Intrarenal Surgery with 30w Holmium laser device(working over 20w power) who have 2-3 cm kidney stones
89022759|NCT06187961|Experimental|HAIC-len-cado|Patients with advanced hepatocellular carcinoma who was initially evaluated unsuitable for the radical therapy and received combined HAIC plus lenvatinib (Len) and cadonilimab as conversion therapy for downstaging.
89022760|NCT06187948|Experimental|1. group that watches an informative video|All participants in the intervention group watches an informative video on recruitment. This video describes in detail the expected external cephalic version process.
89022761|NCT06187948|No Intervention|2. group that does not watch an informative video|this group do not watch an informative video before recruitment
89022762|NCT06187935||pulmonary nodule group|Patients with pulmonary nodules less than 3cm on CT imaging.
89022763|NCT06187922|Active Comparator|Pregabalin group|this group of patient will receive cap pregabalin 75mg as premedication and will continue as twice daily dose for 72 hrs.
89022764|NCT06187922|Sham Comparator|Control group|This group of patient will not receive cap pregabalin but it will receive standard medical care as routine
89022765|NCT06187909|Active Comparator|PECS II block group|First group 44 patients
89022766|NCT06187909|Active Comparator|MTP block group|Second group 44 patients
89022767|NCT06187896|Experimental|Remimazolam|In this group, participants are sedated with remimazolam and remifentanil.
89022768|NCT06187896|Active Comparator|propofol|In this group, participants are sedated with propofol and remifentanil.
89022769|NCT06187883||1|patients treated with PRFT
89022770|NCT06187844|Experimental|Children with impalpable tests|For children with impalpable tests before and under anesthesia and by laparoscopy, cord structures could be seen entering the inguinal canal, inguinal exploration will be done.
89022771|NCT06187818||experience group 1|Take 4 total glucosides of crocin tablets (Ruiyang Pharmaceutical Co., Ltd.) 3 times a day for 8 days (the day before chemotherapy) during each chemotherapy.Previous history of heart disease.
89022772|NCT06187818||experience group 2|Take 4 total glucosides of crocin tablets (Ruiyang Pharmaceutical Co., Ltd.) 3 times a day for 8 days (the day before chemotherapy) during each chemotherapy.No previous heart disease.
89022773|NCT06187818||Control group 1|Did not take crocine tablets during chemotherapy.Previous history of heart disease.
89022774|NCT06187818||Control group 2|Did not take crocine tablets during chemotherapy.No previous heart disease.
89022775|NCT06187779|Experimental|Segmental thickness measurement|This population's lower segment will be measured.
89496606|NCT05694962|No Intervention|Control group|supportive care and standard of care drug therapies (i.e., glucocorticosteroids, Paxlovid, etc.)
89496607|NCT02165917|Placebo Comparator|Excision only|Laparoscopic excision of endometriotic lesions followed by 3 month of GnRH-Analogue administration
89496608|NCT02165917|Active Comparator|Excision plus hyaluronic acid gel|Standard Laparoscopic excision of endometriotic lesions plus application of 10 cc of a hyaluronic acid gel (Hyalobarrier® ), followed by 3 month of GnRH-analogue administration
89496609|NCT05696756|Experimental|Brief Clinician Motivational Support|Participants will learn to use the EMMA app through a personalized web-based training platform with brief weekly motivational support from a clinician.
88955335|NCT06328751|Experimental|Case Group|The case group will watch a 7-minute immersive virtual reality video of mindfulness meditation with image and sound in the office of the Oncology Control Center Foundation (FCECON), using Samsung® gear VR virtual reality glasses and Samsung® smart watch.
88955336|NCT06328751|Active Comparator|Active Control Group|The active control group will watch a 7-minute mindfulness meditation video presented via cell phone with image and sound in the office of the Oncology Control Center Foundation (FCECON), using a Samsung® smart watch.
88955337|NCT06328751|Active Comparator|Passive Control Group|The passive control group will perform meditation breathing exercises based on instructions and through an audio played from the health professional for 4 minutes in the office of the Oncology Control Center Foundation (FCECON), using a Samsung® smart watch.
89205364|NCT05657288|Experimental|Hypoxia|Volunteers sequentially inhale three hypoxic gas mixtures each for 2.5 minute. Every measurement will begin with a two-minute stabilization phase, during which the physiological values of the volunteer will be checked. During the whole experiment, non-invasive SpO2 measurements will be performed on the middle finger and on the wrist of left hand.
89496610|NCT05696756|Active Comparator|Technology Support Only|Participants will learn to use the EMMA app through a personalized web-based training platform with technical support and reminders as needed.
89496611|NCT03539107|Experimental|Spontaneous void|Subjects will not have retrograde fill of bladder, rather will be required to void 150 mL spontaneously prior to discharge.
89496612|NCT03539107|Active Comparator|Retrograde bladder fill|Subjects will have their bladder retrograde filled with 300mL of fluid prior to a voiding trial.
89496613|NCT02168881|Active Comparator|misoprostol|oral misoprostol in solution 25 microgram every 2 hours
89496614|NCT02168881|Active Comparator|dinoprostone|3 mgs dinoprostone vaginally every six hours
89496615|NCT02165995|Experimental|Navigated Transcranial Magnetic Stimulation (nTMS)|Participant assessed by nTMS system before surgery, then again at 1, 3, 6, and 12 months following surgery. Motor mapping and speech mapping performed at these visits. This should take about 1½-2 hours to complete.
89496616|NCT02168959|Active Comparator|Femoral nerve block|bupivacaine
89496617|NCT02168959|No Intervention|No femoral nerve block|No block
89496618|NCT02169037|Experimental|FIRM ablation|These patients will be treated by ablation of patient-specific rotors and focal sources (FIRM) alone.
89496619|NCT02169037|Active Comparator|Conventional AF ablation with PVI|These patients will treated by conventional AF ablation by pulmonary vein isolation (PVI) alone.
89496620|NCT05450822||Healthy Controls|Healthy volunteers with no pre-existing or current psychiatric, neurological or server somatic illness.
89496621|NCT05450822||Cohort I|Patients who have a history of only one epileptic seizure.
89496622|NCT05450822||Cohort II|Patients who are newly diagnosed with epilepsy.
89205365|NCT05656053||Patients undergoing glioma removal surgery|Patients will undergo magnetic resonance examination before surgery, followed by rapid ultrasound acquisition of the tumor section by the surgeon during surgery and the resection of the tumor tissue for cryopreservation. After surgery, the tissue sample will be used for genetic sequencing and mass spectrometry to obtain molecular information. The data involved in the overall surgical procedure will be saved and used in this observational study.
89205366|NCT05651542|Experimental|Comprehensive Self-Management|The 8 week intervention is delivered online with a brief weekly check-in with a registered nurse.
89205367|NCT05651542|Other|Usual care group|The control group will receive standard care without the comprehensive self-management intervention.
89496623|NCT05450822||Cohort III|Patients who are newly diagnosed with epilepsy and have an epileptogenic lesion on MRI concordant with seizure semiology and/or EEG.
89496624|NCT02172157|Experimental|BI 1744 CL i.v. (intravenous) infusion|
89496625|NCT02172157|Active Comparator|BI 1744 CL Oral solution|
89496626|NCT02166151|Experimental|Omalizumab|Omalizimab 150 mg S.C. once a month for consecutive 3 months
89496627|NCT02172235|Active Comparator|Pioglitazone|
89496628|NCT02172235|Experimental|Pioglitazone + BI 10773 low|
89496629|NCT02172235|Experimental|Pioglitazone + BI 10773 medium|
89496630|NCT02172235|Experimental|Pioglitazone + BI 10773 high|
89496631|NCT02172235|Experimental|Pioglitazone low + BI 10773 medium|
89496632|NCT02172235|Experimental|Pioglitazone + BI 10773 1 hour after Pioglitazone|
89496633|NCT05689346|Experimental|study group|study group will receive high tone power therapy
89496634|NCT05689346|Active Comparator|control group|children in the contol group will recieve traditional treatment for improving balance.
89496635|NCT02169193|Experimental|99mTc-Rhenium Sulfide Nanocolloid|99mTc-Rhenium Sulfide Nanocolloid
89496636|NCT02166229|Experimental|Divalproex sodium|Divalproex sodium will be initiated at 125 mg twice daily and increased monthly to a maximum dose of 500 mg twice daily.
89531785|NCT05364632|Experimental|Behavioral Intervention|Participants will undergo an eight-week behavioral intervention protocol (once a week) aimed at increasing the level of physical activity, consisting of a brief educational program: brief education for asthma and benefits of physical activity and behavioral intervention based on Social Cognitive Theory and the Theory of Stages of Behavior Change.
89496637|NCT04474964|Experimental|Low Dose Craniospinal Irradiation|WNT subgroup medulloblastoma patients accrued in the study will be treated with Low-dose Craniospinal Irradiation (18Gy/10fx) plus focal conformal tumor-bed boost (36Gy/20fx) for total primary-site dose of 54Gy/30fx over 6-weeks. Followed by adjuvant multi-agent systemic chemotherapy which will be initiated 4-6 weeks after completion of radiotherapy provided the ANC >1500 and platelet count >1,00,000. A total of 6 cycles of alternating chemotherapy every 4-weekly will be planned as per our standard practice using CET protocol.
89496638|NCT04410926|Placebo Comparator|control group|"Corrective exercises The experimental and control groups performed a designed strengthening exercises included short-foot exercise, toes-spread-out exercise, toes-extension exercise and toe-curls for 60 minutes. Each exercise was performed for 30 repetitions holding each repetition for 5 seconds (about three minutes).~Neuromuscular electrical stimulation The control group received placebo NMES with no current stimulation. In another words, the current intensity was set at 0mA while standing on both feet for 30 minutes."
89496639|NCT04410926|Experimental|intervention group|"Corrective exercises The experimental and control groups performed a designed strengthening exercises included short-foot exercise, toes-spread-out exercise, toes-extension exercise and toe-curls for 60 minutes. Each exercise was performed for 30 repetitions holding each repetition for 5 seconds (about three minutes).~Neuromuscular electrical stimulation~The experimental group received NMES aiming to reinforce the planter intrinsic foot muscles. High-voltage pulsed current was set at frequency of 85 Hz with 5 seconds contraction time and 12 seconds rest time while the ramp-up and ramp-down time were 0.3 and 0.7 respectively. The current intensity was adjusted based on the individual tolerance without reporting pain or discomfort while standing on both feet. The stimulation time lasted each session for 30 minutes."
89496640|NCT04375514|Experimental|ARO-ENaC|ARO-ENaC Inhalation
89496641|NCT04375514|Placebo Comparator|Placebo|Sterile normal saline (0.9% NaCl)
89496642|NCT05677178||survival group|Patients who survived 2 months after treatment.
89496643|NCT05677178||death group|Patients who died 2 months after treatment.
89496644|NCT05677022|Experimental|Adapted motor activity|
89538162|NCT02443909|Active Comparator|third group|Patients undergoing Retrograde Intrarenal Surgery with 30w Holmium laser device(working under 20w power) who have 2-3 cm kidney ston
89496645|NCT05696600|Experimental|Thick periodontal phenotype|Scaling and root planing and open flap debridement in patients with stage II and stage III periodontitis
89496646|NCT05696600|Active Comparator|Thin periodontal phenotype|Scaling and root planing and open flap debridement in patients with stage II and stage III periodontitis
89205369|NCT05607498|Experimental|EMB-07-Patients with solid tumor|Patients with solid tumor will receive intravenous infusions of EMB-07 weekly (QW). Dose escalation will continue until the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) is reached or all planned doses are administered.
89205370|NCT05607498|Experimental|EMB07-Patients with lymphoma|Patients with lymphoma will receive intravenous infusions of EMB-07 weekly (QW). Dose escalation will continue until the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) is reached or all planned doses are administered.
89496647|NCT05696522|Experimental|Treatment arm|Treatment with stereotactic ablative radiotherapy
89205371|NCT05603416|Active Comparator|Benegut|Dietary Supplement: Perilla frutescens extract
89205372|NCT05603416|Placebo Comparator|Placebo|Dietary Supplement: Placebo, no active ingredient
89205373|NCT05573243|Experimental|Etch-and-rinse|G2 Bond Universal bonded to NCCL using etch-and-rinse technique
89022776|NCT06187779|No Intervention|Segmental thickness no measurement|No measurements of lower segment.
89205374|NCT05573243|Experimental|Selective enamel etching|G2 Bond Universal bonded to NCCL using selective enamel etching technique
89205375|NCT05573243|Experimental|self-etch|G2 Bond Universal bonded to NCCL using self-etch technique
89205376|NCT05554978|Experimental|Landiolol|initial dose: 20mg target dose: repeated dose (20mg) possible, max. 40mg (total)
89205377|NCT05554978|Placebo Comparator|Placebo|Sodium Chlorid 0,9%
89205378|NCT05538273||Minimal invasive surgery|removal of urinary catheter postoperatively
89205379|NCT05538273||Laparotomy|removal of urinary catheter postoperatively
89205380|NCT05538273||Simple surgery|removal of urinary catheter postoperatively
89205381|NCT05538273||Radical surgery|removal of urinary catheter postoperatively
89538163|NCT03285191||Subjects participating in the CE interview|Thirty subjects (comprised of n=15 csDMARD-IR and n=15 bDMARD-IR) will participate in the CE interview.
89538164|NCT03285191||Subjects participating in interview and real-time data capture|Ten of the thirty CE interview participants will be offered the opportunity to participate in the real-time data capture App substudy.
89538165|NCT02439697|Experimental|Darbepoetin alfa (NESP®) same dose|Patients on stable low dose Aranesp® (darbepoetin alfa manufactured by Amgen®) (on 20mcg preparations or on 40mcg every 2 weeks or less) will be converted to the same dose of NESP® (darbepoetin alfa manufactured by Kirin®)
89205382|NCT05516212|Active Comparator|CAFMONO supplementation|The experimental procedure for each participant assume random blind acute ingestion of CAFMONO in individual dose providing 3mg/kg BM of CAF at one of the study visits, which will be separated from other study visits with 7-days wash-out. The preparation will be provided in the form of powder and the individual doses of CAFMONO will be dissolved in 200 mL of water. The test preparation will be ingested within up to 5 minutes. The ingestion will take place 60 minutes before the test exercise.
89205383|NCT05516212|Active Comparator|CAFMIPS_1 supplementation|The experimental procedure for each participant assume random blind acute ingestion of CAFMIPS_1 in individual dose providing 3mg/kg BM of CAF at one of the study visits, which will be separated from other study visits with 7-days wash-out. The preparation will be provided in the form of powder and the individual doses of CAFMIPS_1 will be dissolved in 200 mL of water. The test preparation will be ingested within up to 5 minutes. The ingestion will take place 60 minutes before the test exercise.
89496648|NCT05674214||birth weight-discordant group|the birth weight difference within twins is greater than 20%
89496649|NCT05674214||the birth weight-concordant group|the birth weight difference within twins is less than or equal to 20%
89496650|NCT02757625|Experimental|DA-9501|A single vial contains an injection solution with 2 mL of dexmedetomidine hydrochloride solution (100 µg/mL as dexmedetomidine) dissolved in physiological saline
89496651|NCT04231058|Experimental|Transcutaneous Electrical Nerve Stimulation (TENS)|15 experimental subjects treated withTENS and Pulmonary Rehabilitation
89496652|NCT04231058|No Intervention|Rehabilitation|15 experimental subjects treated with Pulmonary Rehabilitation only
89496653|NCT04112186|Experimental|Behavioral group therapy 1|8-weeks of group therapy
89496654|NCT04112186|Active Comparator|Behavioral group therapy 2|8-weeks of group therapy
89496655|NCT05693324|Active Comparator|1 Minority stress|"Intervention starts with the minority stress module, followed by worry and then compassion.~Modules are given with a trans-affirmative stance, based on the minority stress model. The minority stress module contains psychoeducation on minority stress and minority joy as well as behavioral interventions. The worry module contains cognitive interventions. The compassion module targets internalized transphobia and is based on compassion-focused therapy."
89496656|NCT05693324|Active Comparator|2 Minority stress|"Intervention starts with minority stress module, followed by compassion and then worry.~Modules are given with a trans-affirmative stance, based on the minority stress model. The minority stress module contains psychoeducation on minority stress and minority joy as well as behavioral interventions. The worry module contains cognitive interventions. The compassion module targets internalized transphobia and is based on compassion-focused therapy."
89496657|NCT05693324|Active Comparator|3 Worry|"Intervention starts with worry module, followed by minority stress and then compassion.~Modules are given with a trans-affirmative stance, based on the minority stress model. The minority stress module contains psychoeducation on minority stress and minority joy as well as behavioral interventions. The worry module contains cognitive interventions. The compassion module targets internalized transphobia and is based on compassion-focused therapy."
89496658|NCT05693324|Active Comparator|4 Worry|"Intervention starts with worry module, followed by compassion and then minority stress.~Modules are given with a trans-affirmative stance, based on the minority stress model. The minority stress module contains psychoeducation on minority stress and minority joy as well as behavioral interventions. The worry module contains cognitive interventions. The compassion module targets internalized transphobia and is based on compassion-focused therapy."
89496659|NCT05693324|Active Comparator|5 Compassion|"Intervention starts with compassion module, followed by minority stress and then worry.~Modules are given with a trans-affirmative stance, based on the minority stress model. The minority stress module contains psychoeducation on minority stress and minority joy as well as behavioral interventions. The worry module contains cognitive interventions. The compassion module targets internalized transphobia and is based on compassion-focused therapy."
89496660|NCT05693324|Active Comparator|6 Compassion|"Intervention starts with compassion, followed by worry and then minority stress.~Modules are given with a trans-affirmative stance, based on the minority stress model. The minority stress module contains psychoeducation on minority stress and minority joy as well as behavioral interventions. The worry module contains cognitive interventions. The compassion module targets internalized transphobia and is based on compassion-focused therapy."
89496661|NCT02256007|Active Comparator|Standardized Assessments|"Standardized Assessments (paper and pencil tests) to be given to each participant. The standardized assessments will be completed in paper and pencil format. These tests include:~Line Bisection Test~Patient Reported Outcomes~Trial Making A and B~Usability Questionnaire"
89496662|NCT02256007|Experimental|Videogame Assessments|"Videogame assessments will be performed by each participant using videogames. The videogame assessments will be performed using videogames on a tabletop platform with touchscreen which includes:~Line Crossing~Patient Reported Outcomes~Trial Making A & B-Asteroid Adventure Game~Usability Questionnaire"
89496663|NCT05692232|Experimental|Group 1|Thirty participants randomly allocated to group 1. All the participants received a pressure biofeedback guided deep cervical flexor muscle strength training along wth conventional intervention.
89496664|NCT05692232|Active Comparator|Group 2|Thirty participants randomly allocated to group 2. All the participants received a manual therapy along wth conventional intervention.
89496665|NCT05691920|Active Comparator|Block group|Patients will be subjected to bilateral external oblique intercostal plane and pectointercostal plane blocks
89496666|NCT05691920|Active Comparator|Opioid group|Patients will be subjected to fentanyl infusion at a rate of 1μg/kg/h
89022777|NCT06187766||University Students|University students will be categorized with Bergen Social Media Addiction Scale.
89496667|NCT02172313|Experimental|Fed conditions|Fasting for 10 hours overnight followed by a high-fat, high-calorie meal, after the meal dosing of the tablet with 240 mL of water and a post-dose fasting period of 4 hours
89496668|NCT02172313|Experimental|Fasting conditions|Fasting for 10 hours overnight followed by dosing of the tablet with 240 mL of water and a post-dose fasting period of 4 hours
89496669|NCT02172313|Experimental|Reference dosing condition|Fasting for 6 hours overnight followed by dosing of the tablet with 120 mL of water and a post-dose fasting period of 30 min
89496670|NCT03539965||Single-arm cohort|Initially, patients will be analyzed in a single group. After determining the status of the biomarkers, the patient sample will be divided into specific groups for comparative purposes.
89022778|NCT06187753||Children with Eosinophilic Esophagitis|Children with Eosinophilic Esophagitis The first group will consist 30 children with definite EoE diagnoses who were between ages 3 and 10 years. The Sensory Profile will used to evaluate sensory processing. This questionnaire will be completed by parents who record a child's responses to sensory events in daily life.
89022779|NCT06187753||Children with Typically Developing|Typically Developing Children The second group will consist of 30 children with typically developing who were between ages 3 and 10 years. The Sensory Profile will used to evaluate sensory processing. This questionnaire will be completed by parents who record a child's responses to sensory events in daily life.
89022780|NCT06187727|Experimental|henagliflozein group|Patients in henagliflozein group was given henagliflozein once a day for 6 months after myocardial infarction.
89022781|NCT06187727|No Intervention|Placebo group|Patients in placebo group was given palcebo once a day for 6 months after myocardial infarction.
89022782|NCT06187714||0.25ml/sec|
89022783|NCT06187714||0.5ml/sec dose|
89496671|NCT03539809|Experimental|BCAA Ratio|Different Branched-chain amino acid (BCAA) ratios will be tested. BCAA are comprised of 3 different amino acids (leucine, isoleucine and valine). The ratios among these 3 amino acids will be tested at 6 different ratios. Each intervention will be for 8hours.
89496672|NCT05650346|Active Comparator|Control Group ( Deep Cervical Training )|
89022784|NCT06187662|Experimental|Default Bias|This intervention consists of a checklist to guide blood culture decisions, that a clinician in a site randomized to Arm A will be asked to consult and complete prior to ordering or not ordering a blood culture; as the relevant clinical scenario occurs.
89022785|NCT06187662|Experimental|Loss Aversion|"This intervention consists of targeted messaging and education that the primary study team will create and ask the Arm B sites to deliver to the PICU clinicians, which focuses on the importance of diagnostic stewardship and the current evidence for the benefit/low risk nature of the stewardship program to date.~Sites in this arm will also receive a checklist to guide blood culture decisions, that clinicians at sites will be asked to consult and complete prior to ordering or not ordering a blood culture."
89022786|NCT06187623||Home based Group|"15 patients in the home-based group and their parents will be informed about the treatment program. Exercise training will be given to individuals by a physiotherapist trained in ISST- International Schroth 3-Dimensional Scoliosis Therapy.~Individuals in this group will be included in an exercise program 1 day a week (8 sessions) accompanied by a physiotherapist for 8 weeks. Each exercise session will last 50 minutes. Patients will be asked to do the given home exercises on the remaining 6 days of the week."
89022787|NCT06187623||Clinic based Group|"15 patients and their parents in the clinic-based group will be informed about the treatment program. Exercise training will be given to individuals by a physiotherapist trained in ISST- International Schroth 3-Dimensional Scoliosis Therapy.~Individuals in this group will be included in an exercise program 3 days a week (24 sessions) with a physiotherapist for 8 weeks. Each exercise session will last 50 minutes. Patients will be asked to do the given home exercises on the remaining 4 days of the week."
89022788|NCT06187610|Experimental|Educational intervention group|
89022789|NCT06187610|No Intervention|Control group|
89022790|NCT06187584|Active Comparator|Control Group (opioid group)|Hydrocodone/acetaminophen 0.15mg/kg PO q6 hours PRN with ibuprofen 10mg/kg PO q6 hours PRN
89205384|NCT05516212|Active Comparator|CAFMIPS_2 supplementation|The experimental procedure for each participant assume random blind acute ingestion of CAFMIPS_2 in individual dose providing 3mg/kg BM of CAF at one of the study visits, which will be separated from other study visits with 7-days wash-out. The preparation will be provided in the form of powder and the individual doses of CAFMIPS_2 will be dissolved in 200 mL of water. The test preparation will be ingested within up to 5 minutes. The ingestion will take place 60 minutes before the test exercise.
89496673|NCT05650346|Experimental|Experimental group I (Deep cervical training + Upper cervical mobilization group)|
89496674|NCT05650346|Experimental|Experimental group II (Deep cervical training + Upper thoracic mobilization group)|
89022791|NCT06187584|Experimental|Experimental Group (nonopioid group):|Acetaminophen 15mg/kg PO q6 hours with ibuprofen 10mg/kg PO q6 hours
89022792|NCT06187571|Experimental|MWM Group|This group received treatment with the Mulligan technique.
89496675|NCT02174809|Experimental|5As|Physicians' use of the 5As tool to discuss gestational weight gain with their pregnant patients
89496676|NCT02174809|Active Comparator|Usual care|Usual care by physicians in addressing gestational weight gain with their pregnant patients
89496677|NCT05696366|Active Comparator|sotagliflozin 200 mg|"Each participant will receive 12-week insulin-adjunctive treatment with both: (1) SGLTi (sotagliflozin 200 mg PO each day) + Placebo and (2) SGLTi + GRA (volagidemab 35 mg subcutaneously each week), in a random-order, cross-over design with a 14-week washout period between treatment periods.~Sotagliflozin is a dual sodium-glucose co-transporter-1 and sodium-glucose co-transporter-2 (SGLT1/2) inhibitor."
89022793|NCT06187571|Active Comparator|CT Group|This group received treatment with the conventional therapy.
89496678|NCT05696366|Active Comparator|volagidemab 35 mg|"Each participant will receive 12-week insulin-adjunctive treatment with both: (1) SGLTi (sotagliflozin 200 mg PO each day) + Placebo and (2) SGLTi + GRA (volagidemab 35 mg subcutaneously each week), in a random-order, cross-over design with a 14-week washout period between treatment periods.~Volagidemab is a human monoclonal antibody glucagon receptor antagonist (GRA)."
89496679|NCT05696366|Placebo Comparator|Placebo|Each participant will receive 12-week insulin-adjunctive treatment with both: (1) SGLTi (sotagliflozin 200 mg PO each day) + Placebo and (2) SGLTi + GRA (volagidemab 35 mg subcutaneously each week), in a random-order, cross-over design with a 14-week washout period between treatment periods.
89496680|NCT05696288|Experimental|Arm A: investigational device (Respiratory Gas Delivery System)|Patients ventilated with the Optiflow™ system, a nasal high flow oxygenation system (NHFO) while undergoing a panendoscopy
89496681|NCT05696288|Active Comparator|Arm B: standard nasal oxygenation device|Patients ventilated according to the standard technique while undergoing a panendoscopy
89496682|NCT02169583|Experimental|Part A (Cohort 1)|Approximately 8 subjects (6 Active, 2 Placebo) will be randomized to receive single escalating IV doses i.e.10 milligrams (mg), 25 mg and 100 mg, plus one oral 100 mg dose (on the last occasion) of GSK1325756 or matching placebo, with a 7-days washout between doses. Dose escalations will be based on review of PK and safety data from preceding dose level. The projected doses for each group are subject to modification based upon PK and safety data from preceding cohorts. Pharmacokinetic parameters will be reviewed from at least 4 active subjects from preceding dose before dose escalating to the next dose level. The maximum dose administered will be 100 mg. Additional subjects/Cohorts may be enrolled.
89496683|NCT02169583|Experimental|Part B (Cohorts 2 and 3)|Approximately 8 subjects (6 Active, 2 Placebo) per cohort will be randomized to receive escalating repeated IV doses of GSK1325756 or matching placebo (Cohort 2: 25 mg, Cohort 3: 50 mg) for 5 days. Repeated (BID) doses of GSK1325756 will begin the morning of Day 1 and continue through the morning of Day 5 (9 total doses). Dose escalations will be based on review of PK and safety data from preceding dose level. The projected doses for each group are subject to modification based upon PK and safety data from preceding cohorts. Pharmacokinetic parameters will be reviewed from at least 4 active subjects from preceding dose before dose escalating to the next dose level. The maximum dose administered will be 50 mg BID. Additional subjects/Cohorts may be enrolled.
89496684|NCT02169661|Experimental|Burger and Beetroot Study|
89496685|NCT02172391|Experimental|Tiotropium|Tiotropium inhalation powder capsules 18 mcg, one capsule once daily for 28 days
89496686|NCT02172391|Placebo Comparator|Placebo|Placebo inhalation powder capsules, one capsule once daily for 28 days
89496687|NCT05606120||CL TRAUMA implanted patients|Patients who underwent hip arthroplasty with CL TRAUMA cemented femoral stem from 2017 to 2020.
89496688|NCT02172469|Experimental|Tiotropium & Placebo|
89496689|NCT02172469|Active Comparator|Atrovent & Placebo|
89496690|NCT02172547||COPD patients who stopped smoking during treatment|
89496691|NCT02174887|Experimental|Nab-paclitaxel + Gemcitabine|Gemcitabine 1 g/m² IV infusion over 30 minutes at D1-D8-D15 every 28 days in combination with Nab-paclitaxel 125 mg/m² IV infusion over 30 minutes at D1-D8-D15 every 28 days The patients will receive 2 cycles of treatment every 28 days
89496692|NCT05173376|Experimental|Larger portions|the main meal component (lunch/dinner) served to participants in the laboratory, reflecting 100% portion. All other foods are identical across conditions (e.g. sides, seconds, breakfast, dessert, snacks).
89496693|NCT05173376|Experimental|Smaller portions|the main meal component (lunch/dinner) served to participants in the laboratory, reflecting 66% portion (i.e. reduced portion size). All other foods are identical across conditions (e.g. sides, seconds, breakfast, dessert, snacks).
89496694|NCT04373564|Experimental|Linear GBCAs|Adult participants, who were scheduled for repeated enhanced magnetic resonance imaging (MRI), receive a linear gadoliniumbased contrast agent (GBCA, i.e. Eovist/ Primovist, MultiHance or Omniscan) prior to MRI. Each participant will receive the same GBCA throughout the study.
89496695|NCT04373564|Experimental|Macrocyclic GBCAs|Adult participants, who were scheduled for repeated enhanced magnetic resonance imaging (MRI), receive a macrocyclic gadolinium-based contrast agent (GBCA, i.e. Gadavist/ Gadovist, Dotarem, Magnescope or ProHance) prior to MRI. Each participant will receive the same GBCA throughout the study.
89496696|NCT04373564|Other|No GBCA (Control arm)|Adult participants who were never exposed to any gadolinium-based contrast agent and matching the population characteristics of the two GBCA arms. They will not receive any gadolinium-based contrast agent over the study course, but may undergo clinically indicated imaging (e.g. unenhanced magnetic resonance imaging (MRI), unenhanced or enhanced computed tomography, ultrasound and/or X-ray).
89496697|NCT02169817|Experimental|Enterogermina + Enterolyte|2 vials of Enterogermina per day for 5 days and Enterolyte according to investigator´s recommendation
89496698|NCT02174965|Experimental|MiniHip (Corin U.K.)|MiniHip (Corin U.K.) femoral component
89496699|NCT02174965|Active Comparator|Metafix (Corin, U.K)|Metafix (Corin, U.K) conventional cementless stem
89496700|NCT05142319|Active Comparator|Homologous mRNA booster vaccine|BNT162b2 + BNT162b2 + BNT162b2 or mRNA-1273 + mRNA-1273 + mRNA-1273
89496701|NCT05142319|Experimental|Heterologous mRNA booster vaccine|BNT162b2 + BNT162b2 + mRNA-1273 or mRNA-1273 + mRNA-1273 + BNT162b2
89496702|NCT05142319|Experimental|Non-mRNA booster vaccine A|BNT162b2 + BNT162b2 + vaccine A or mRNA-1273 + mRNA-1273 + vaccine A
89496703|NCT05142319|Experimental|Non-mRNA booster vaccine B|BNT162b2 + BNT162b2 + vaccine B or mRNA-1273 + mRNA-1273 + vaccine B
89496704|NCT05142319|Experimental|Non-mRNA booster vaccine C|BNT162b2 + BNT162b2 + vaccine C or mRNA-1273 + mRNA-1273 + vaccine C
89496705|NCT02169973|Experimental|Part A|3 to 5 participants will undergo Positron Emission Tomography (PET)/computed tomography scan after administration of 11C-MK-3168 on Day 1.
89496706|NCT02169973|Experimental|Part B|3 to 12 participants will undergo PET scan after administration of 11C-MK-3168 on Day 1. Participants will receive 2 single doses of JNJ-42165279: 100 mg on Days 1 and up to 250 mg on Day 8. Participants will undergo PET scans after 1 hour of each administration of JNJ-42165279 on Days 1 and 8, with 11C-MK-3168 administration.
89496707|NCT02169973|Experimental|Part C|4 to 8 participants will undergo PET scan after administration of 11C-MK-3168 on Day 1. Participants will receive once daily dose of JNJ-42165279 (up to 100 mg) from Day 1 to Day 7. Participants will undergo PET scans after 24 hour of administration of JNJ-42165279 on Days 1 and 7, with 11C-MK-3168 administration.
89496708|NCT04373174|Active Comparator|Group E|Thoracic Epidural block + Regional oximetry probe will be placed in the frontal area of the head
89496709|NCT04373174|Sham Comparator|Group P|Regional oximetry probe will be placed in the frontal area of the head
89496710|NCT02172703|Other|Non-invasive ICP measurement|non-invasive ICP measurement with NON-INVASIVE ICP ABSOLUTE VALUE METER (carried out simultainusly with standard invasive ICP measurement catheter and probes)
89496711|NCT04298528|Experimental|dronabinol|Patient will be directed to take 2.5mg of Study Drug 2 times a day for 4 weeks. Patient is blinded as to whether or not this is Dronabinol.
89496712|NCT04298528|Placebo Comparator|placebo|Patient will be directed to take 2.5mg of Study Drug 2 times a day for 4 weeks. Patient is blinded as to whether or not this is Dronabinol.
89496713|NCT02170129|Active Comparator|100% AAB|Surgical procedures were performed according to a lateral approach technique at the edentulous region distal to the position of the first premolar. A mucoperiosteal buccal flap was elevated, exposing the lateral bony wall of the sinus antrum. A round diamond bur, 2 mm in diameter, was used to outline the demarcation of the lateral window, which was removed, thus completely exposing the underlying Schneiderian membrane. The membrane was separated from the housing bone, and a tension-free reflection exposing the sinus walls was achieved by gently pushing it away using a large flat curette (Kramer-Nevins, Hu-Friedy, Chicago, IL). The established voids were then filled with 100% AAB (Bio-Oss) followed by sealing the open lateral window by the placement of a collagen membrane (Bio Gide) and primary soft tissue closure using Vicryl 4.0 sutures (Vicryl, Ethicon J&J International, Sint-Stevens-Woluwe, Belgium).
89496714|NCT02170129|Active Comparator|50% AAB plus 50% autologous bone|Surgical procedures were performed according to a lateral approach technique at the edentulous region distal to the position of the first premolar. A mucoperiosteal buccal flap was elevated, exposing the lateral bony wall of the sinus antrum. A round diamond bur, 2 mm in diameter, was used to outline the demarcation of the lateral window, which was removed, thus completely exposing the underlying Schneiderian membrane. The membrane was separated from the housing bone, and a tension-free reflection exposing the sinus walls was achieved by gently pushing it away using a large flat curette (Kramer-Nevins, Hu-Friedy, Chicago, IL). The established voids were then filled with 50% AAB (Bio-Oss) plus 50% autologous bone harvested locally with a bone scraper followed by sealing the open lateral window by the placement of a collagen membrane (Bio Gide) and primary soft tissue closure using Vicryl 4.0 sutures (Vicryl, Ethicon J&J International, Sint-Stevens-Woluwe, Belgium).
89496715|NCT02175043|Experimental|the operation to add in CFAE to conventional liner ablation|The group of positive control is the operation to add in CFAE to conventional liner ablation in persistent atrial fibrillation patients
89496716|NCT02175043|Active Comparator|only doing conventional liner ablation|The group of negative is the operation to only doing conventional liner ablation with persistent atrial fibrillation
89496717|NCT02581202||HIV-1 infected participants|HIV-1-infected participants on any triple highly active antiretroviral therapy (HAART) with plasma HIV-1 ribonucleic acid (RNA) level < 50 copies/mL for at least 6 months (two consequently plasma HIV-1 RNA levels) transferred as medically appropriate to lopinavir with ritonavir plus lamivudine (LPV/r+3TC) as decided by the physician in the routine clinical settings. Or HIV-1 infected participants who were switched on the dual therapy (LPV/r+3TC) no more than 60 days prior to enrollment.
89496718|NCT02758171|Experimental|Empagliflozin+Linagliptin FDC|One tablet fix dose combination (FDC)
89022794|NCT06187558||Pelvic Organ Suspension Patients|This group comprises patients who have undergone multiport or single-port access laparoscopic surgery (SPAL) at the Tertiary referral University Hospital of Cagliari, Italy. These patients suffer from benign (like endometriosis, pelvic prolapse) or malignant (like endometrial cancer) gynecological diseases. During their surgery, they have experienced at least one instance of the described pelvic organ suspension technique using an adjustable tension suture tied to a Foley catheter fragment for organ suspension.
89496719|NCT02758171|Active Comparator|Empagliflozin+Linagliptin single tablets|
89496720|NCT05662826|Experimental|Avatar-based Social Physical Activity|Group classes with virtual reality exercise games, talking, acting, and painting activities
89496721|NCT02170285|Experimental|Interventional tDCS|The primary intervention will be cathodal (inhibitory) tDCS (see below).
89496722|NCT02170285|Sham Comparator|Sham tDCS|Sham subjects will undergo exactly the same tDCS protocol as outlined above. This includes the initial stimulation sequence, generating the initial transient scalp sensations identical to the treatment group. The stimulator will be programmed by the technologist to automatically ramp down to off over 30 seconds after 120 seconds of stimulation.
89205385|NCT05516212|Placebo Comparator|Placebo treatment|The experimental procedure for each participant assume random blind acute ingestion of placebo (PLA) at one of the study visits, which will be separated from other study visits with 7-days wash-out. The PLA preparation will be provided in the form of powder and dissolved in 200 mL of water. PLA will be ingested within up to 5 minutes. The ingestion will take place 60 minutes before the test exercise.
89496723|NCT05141396|Experimental|Intervention - Telehealth- enabled support plus usual audit and feedback for SAT/SBT adherence|Usual audit and feedback + telehealth-enabled support
89496724|NCT05141396|Active Comparator|Control - Usual audit/feedback for SAT/SBT adherence only|Usual audit and feedback
89496725|NCT04268420|Active Comparator|"Part A - Low Dose"|"Part A vaccinees in the low dose arm will receive the lower dosing (20 μg FMP013 per 0.5 mL ALFQ) approximately 2 weeks prior to each vaccination. Vaccination to be delivered on 0,1,2 month."
89496726|NCT04268420|Active Comparator|"Part A - High Dose"|"Part A vaccinees in the high dose arm will receive the lower dosing (40 μg FMP013 per 1.0 mL ALFQ) approximately 2 weeks prior to each vaccination.~Vaccination to be delivered on 0,1,2 month."
89496727|NCT04268420|Active Comparator|"Part B - Standard Dose"|"Part B vaccinees in the high dose arm will receive the lower dosing (40 μg FMP013 per 1.0 mL ALFQ) approximately 2 weeks prior to each vaccination.~Vaccination to be delivered on 4,5,6 month."
89496728|NCT04268420|Active Comparator|"Part B - Delayed Dose"|"Part B vaccinees in the high dose arm will receive the lower dosing (40 μg FMP013 per 1.0 mL ALFQ) approximately 2 weeks prior to each vaccination.~Vaccination to be delivered on 0,1,6 month."
89496729|NCT04268420|Active Comparator|"Part B - Delayed Fractional Dose"|"Part B vaccinees in the high dose arm will receive the lower dosing (40 μg FMP013 per 1.0 mL ALFQ) approximately 2 weeks prior to each vaccination.~Vaccination to be delivered on 0,1,6 month."
89496730|NCT04268420|No Intervention|Control|Up to 6 subjects will be enrolled (defined as receiving malaria challenge) later in the trial to serve as challenge controls. Additional subjects may be recruited as alternates to ensure that 6 control subjects undergo the challenge. Any alternates not challenged will be released from the study at day of challenge.
89496731|NCT02172781|Experimental|Ipratropium - unit dose vial|
89496732|NCT02172781|Experimental|Tiotropium - inhalation capsule - low dose|
89496733|NCT02172781|Placebo Comparator|Placebo matching tiotropium - inhalation capsule|
89496734|NCT02172781|Placebo Comparator|Placebo matching to ipratropium - unit dose vial|
89496735|NCT02172781|Experimental|Tiotropium - inhalation capsule - high dose|
89496736|NCT05572346||Home-based telerehabilitation group|"For each subject, the treatment will lasts 8 weeks. The intervention will include both endurance and resistance exercises as prescribed by the pneumologist at the time of the hospital discharge.~The intervention will be delivered and monitored through a digital app with appropriate sensors."
89496737|NCT02172859|Active Comparator|lumiVida™|lumiVida™ (2 x 0.5 g sachets to be dissolved in 150ml water/ day): First dose 2h after breakfast and second dose 60-90min before bed-time for 19 days.
89496738|NCT02172859|Placebo Comparator|Placebo|Placebo (2 x 0.5 g sachets of casein hydrolysate to be dissolved in 150ml water/ day): First dose 2h after breakfast and second dose 60-90min before bed-time for 19 days
89496739|NCT02172937|Experimental|Decidual Stromal Cells as last line treatment|Patients with therapy-refractory GVHD and on calcineurin inhibitor and high dose corticosteroids without any signs of improvement will be given DSCs to evaluate a possible effect. DSCs will be thawed from the freezer in plasma.
89496740|NCT02172937|Active Comparator|Decidual Stromal Cells|Patients with therapy-refractory GVHD and on calcineurin inhibitor and high dose corticosteroids will be given DSCs as early as possible at one or more occasions at weekly intervals dependent on clinical response. DSCs will be thawed from the freezer in plasma.
89496741|NCT02173015|No Intervention|Low Fall Risk|"Individuals who have a functional reach greater than 8 and a unipedal stance time greater than 5 s."
89496742|NCT02173015|No Intervention|High Fall Risk, No Training|"Individuals who have a functional reach of 8 or less OR a unipedal stance time of 5 s or less, but do not qualify for compensatory step training due to health concerns."
89496743|NCT02173015|Experimental|High Fall Risk, Training|"Individuals who have a functional reach of 8 or less OR a unipedal stance time of 5 s or less, and qualify for compensatory step training."
89496744|NCT02173093|Experimental|Treatment (IL-2, GM-CSF, GD2Bi-aATC)|Patients receive IL-2 SC daily on days -2 to 35, GM-CSF SC twice weekly x 5 weeks, and GD2Bi-aATC IV over 30 minutes twice weekly x 4 weeks for a total of 8 infusions. Laboratory evaluations of immune responses are obtained prior and after immunotherapy.
89496745|NCT02170441||Patients at risk for drug-resistant TB|No intervention
89496746|NCT05142085|Experimental|Efficacy of nano-PSO on motor and non-motors symptoms of Parkinson´s disease.|"It is the clinical trial itself where more than 140 subjects will be included:~84 under active treatment and 56 under placebo"
89496747|NCT05142085|Experimental|Effect of nano-PSO on molecular images of PD patients|In this group, the study implicates performing a multitracer PET-scan before treatment, and at 6 months, to 25 subjects in the clinical trial : 15 under active treatment and 10 in the placebo group.
89496748|NCT03538483|Active Comparator|ultrasound guided serratus plane block|Ultrasound Guided Serratus Plane Block 30 ml %0.25 Bupivacaine
89496749|NCT03538483|Active Comparator|ultrasound guided erector spinae plane block|Ultrasound Guided Erector Spinae Plane Block 20 ml %0.25 Bupivacaine
89496750|NCT02173171||Previously treated with T-VEC|Received at least 1 dose of talimogene laherparepvec on Amgen or BioVEX-sponsored clinical trial
89496751|NCT02175355|Experimental|Low dose of Micardis®|
89496752|NCT02175355|Experimental|Medium dose of Micardis®|
89496753|NCT02175355|Experimental|High dose of Micardis®|
89496754|NCT02175355|Active Comparator|Hydrochlorothiazide|
89022795|NCT06187545|Active Comparator|Control group|5-hour period in which patients will continue to be routinely sedated in the critical care unit
89022796|NCT06187545|Experimental|Experimental group|5-hour period in which patients will be sedated through the closed-loop system
89496755|NCT02175355|Placebo Comparator|Placebo|
89496756|NCT03538327|Experimental|Silybin|50 Caucasian never-treated hypertensive outpatients, 27 males and 23 women, age range 42-60 years (mean+SD=52+7), showing normal glucose tolerance but 1-h post load plasma glucose >155 mg/dl, during the OGTT.
89496757|NCT02170597|Experimental|BIBR 1018 MS HPMC capsule fasted|
89496758|NCT02170597|Experimental|BIBR 1048 MS HPMC capsule after high fat meal|
89496759|NCT02170597|Active Comparator|BIBR 1048 MS gelatine capsule fasted|
89496760|NCT02170675|Experimental|Dabigatran etexilate + Ketoconazole|"Period 1 - Dabigatran etexilate~Period 2 - Dabigatran etexilate and single dose of 400 mg Ketoconazole on Day 8 and 9~Period 3 - Dabigatran etexilate and multiple doses of 400 mg Ketoconazole on Day 10 to 16"
89496761|NCT02175433|Experimental|Dose Escalation of AGS67E 0.05 mg/kg Without GF|Participants will receive 0.05 milligram per kilogram (mg/kg) AGS67E without growth factor (GF) by intravenous infusion once every three weeks.
89496762|NCT02175433|Experimental|Dose Escalation of AGS67E 0.1 mg/kg Without GF|Participants will receive 0.1 mg/kg AGS67E without GF by intravenous infusion once every three weeks.
89496763|NCT02175433|Experimental|Dose Escalation of AGS67E 0.3 mg/kg Without GF|Participants will receive 0.3 mg/kg AGS67E without GF by intravenous infusion once every three weeks.
89496764|NCT02175433|Experimental|Dose Escalation of AGS67E 0.6 mg/kg Without GF|Participants will receive 0.6 mg/kg AGS67E without GF by intravenous infusion once every three weeks.
89496765|NCT02175433|Experimental|Dose Escalation of AGS67E 0.9 mg/kg Without GF|Participants will receive 0.9 mg/kg AGS67E without GF by intravenous infusion once every three weeks.
89496766|NCT02175433|Experimental|Dose Escalation of AGS67E 1.2 mg/kg Without GF|Participants will receive 1.2 mg/kg AGS67E without GF by intravenous infusion once every three weeks.
89496767|NCT02175433|Experimental|Dose Expansion of AGS67E 0.9 mg/kg Without GF|Participants will receive 0.9 mg/kg AGS67E without GF by intravenous infusion once every three weeks.
89496768|NCT02175433|Experimental|Dose Escalation of AGS67E 1.2 mg/kg With GF|Participants will receive 1.2 mg/kg AGS67E with GF by intravenous infusion once every three weeks.
89496769|NCT02175433|Experimental|Dose Escalation of AGS67E 1.5 mg/kg With GF|Participants will receive 1.5 mg/kg AGS67E with GF by intravenous infusion once every three weeks.
89496770|NCT02175433|Experimental|Dose Escalation of AGS67E 1.8 mg/kg With GF|Participants will receive 1.8 mg/kg AGS67E with GF by intravenous infusion once every three weeks.
89496771|NCT02175433|Experimental|Dose Expansion of AGS67E 1.5 mg/kg With GF|Participants will receive 1.5 mg/kg AGS67E with GF by intravenous infusion once every three weeks.
89496772|NCT04154150|Experimental|Ketamine + Cognitive Training|
89496773|NCT04154150|Sham Comparator|Ketamine + Sham Training|
89496774|NCT02173249|Experimental|AC 170 0.24%|
89496775|NCT02256085|Sham Comparator|Sham rTMS|"Daily rTMS with Sham coil~30 minutes of 1Hz rTMS, 5 days per week, for 6 weeks with Sham (placebo) coil"
89496776|NCT02256085|Experimental|Active rTMS|"Daily rTMS with Active coil~30 minutes of 1Hz rTMS, 5 days per week, for 6 weeks with active coil"
89496777|NCT02256085|Experimental|Open Active rTMS|"Open Label Daily rTMS with Active coil~30 minutes of 1Hz rTMS, 5 days per week, for 6 weeks with active coil"
89496778|NCT02173327|Other|Continuously Helm CPAP|Continuously helm CPAP for 6 hours
89496779|NCT02173327|Other|Intermittent Mask CPAP|Intermittent Mask CPAP for 10minuttes every 2 hours in a 18 hours period postoperative.
89496780|NCT02170753|Experimental|Regional manual therapy|The experimental group will receive regional thoracic, pelvic, and hip manual therapy and a standard physical therapy approach including motor control exercise and local lumbar spine manual therapy
89496781|NCT02170753|Active Comparator|Standard physical therapy|The control group will receive standard physical therapy including motor control exercise and local lumbar spine manual therapy.
89496782|NCT02170831|Experimental|BIBR 1048 MS low dose|
89496783|NCT02170831|Experimental|BIBR 1048 MS medium dose 1|
89496784|NCT02170831|Experimental|BIBR 1048 MS medium dose 2|
89496785|NCT02170831|Experimental|BIBR 1048 MS high dose|
89496786|NCT02170831|Placebo Comparator|BIBR 1048 Placebo|
89496787|NCT04141670|Experimental|Low dose group|Experimental: Low dose group Group of three participants who are treated with a low dose of S48168 (ARM210) for 28 days.
89496788|NCT04141670|Experimental|High dose group|Experimental: High dose group Group of seven participants who are treated with a high dose of S48168 (ARM210) for 28 days.
89496789|NCT03539263|Experimental|Group 1|the subjects are treated with probiotics: Bifihappy
89496790|NCT03539263|Placebo Comparator|Group 2|the subjects are treated with a placebo
89496791|NCT00028340||1/Breast Cancer and High-Risk Patients|Pre- or postmenopausal women who have or have previously had invasive or noninvasive breast cancer of epithelial origin, or women without breast cancer but at an increased risk of breast cancer.
89496792|NCT00028340||2/Normal Volunteers|Pre- or postmenopausal women who are not at an increased risk for breast cancer.
89496793|NCT03538249|Experimental|Aerobic training|Patients follow an alternating aerobic training using a treadmill at an intensity of 60% of maximum heart rate, 3 mn and 3 mn working off an alternative way.To ensure progressive overload appropriate, we adjust moderate intensity aerobic exercise every two weeks with an overall 5% increase in heart rate.
89496794|NCT03538249|Experimental|Inspiratory muscle training|The inspiratory muscle training involves a high intensity endurance training to 60% of PI, max. We recalculate the individual SPImax and PImax in each training session. Patients use the driving tool inspiratory muscle.
89496795|NCT03538249|Experimental|Resistance training|The resistance should be measured on 1 RM (Repetition Maximum) for each muscle group. The exercises are performed in three sets of ten repetitions of exercises at 60% of 1RM intensity recalculated every two weeks training.
89496796|NCT03538249|No Intervention|Control|The control group patients were allocated to a non-training time period, during which they were told to continue their life as before enrollment.
89496797|NCT03538249|Experimental|Aerobic and Inspiratory training|Note that the Aerobic and Inspiratory group participant undergone same protocols of inspiratory and aerobic training stated above, with almost a 5 minutes rest in between.
89496798|NCT03538249|Experimental|Combined|Note that the Aerobic, Inspiratory and resistance group participant undergone same protocols of inspiratory and aerobic training stated above, with almost a 5 minutes rest in between.
89496799|NCT04978064|Experimental|Intervention group|Behavioral e-health psychological counselling
89496800|NCT04978064|Other|Control group|Usual care (delayed behavioral e-health psychological counselling)
89496801|NCT02175511|Experimental|Cloud-based home BP monitoring|170 were assigned to the experimental group
89496802|NCT02175511|No Intervention|Traditional Care|212 patients were assigned to the traditional care group (paper-based data)
89496803|NCT02173483|Other|Quadriceps graft|Proximally from patella the Quadriceps graft is harvested and used as a knew anterior cruciate ligament after rupture.
89496804|NCT02173483|Other|Hamstrings Graft|The Hamstrings graft is harvested and used as a knew anterior cruciate ligament after rupture.
89496805|NCT05653076|Placebo Comparator|Placebo|Microcrystalline cellulose
89496806|NCT05653076|Experimental|Hibiscus sabdariffa extract|520 mg of Hibiscus sabdariffa extract
89496807|NCT02173561|Experimental|Group Cognitive Processing Therapy-Cognitive Only|
89496808|NCT02173561|Experimental|Individual Cognitive Processing Therapy-Cognitive Only|
89496809|NCT02178319|Active Comparator|open group|the patients under go the open esophagogastric devascularization and splenectomy
89496810|NCT02178319|Experimental|laparoscopic group|the patients under go the laparoscopic esophagogastric devascularization and splenectomy
89496811|NCT02175589|Other|Study group|Colchicine Cessation in FMF patients with one MEFV mutation
89496812|NCT02175589|No Intervention|Control group|The control group includes FMF patients that will be kept on a daily colchicine treatment
89496813|NCT05438186||Liraglutide|Participants with obesity who received initial prescription of Saxenda® (liragltuide 3.0 milligrams (mg) once daily) and maintained treatment with Saxenda® for at least 16 weeks, without treatment break, following the initial prescription for weight management.
89496814|NCT02178397|Experimental|EXPERIMENTAL ARM B|"INDUCTION chemotherapy: 4 cycles of~pemetrexed with cisplatin or carboplatin~or gemcitabine with cisplatin or carboplatin in combination with erlotinib~THEN, for responders and for patients with stable disease :MAINTENANCE chemotherapy by Pemetrexed in combination with erlotinib"
89496815|NCT02178397|Active Comparator|STANDARD ARM A|"INDUCTION chemotherapy: 4 cycles of~pemetrexed with cisplatin or carboplatin~or gemcitabine with cisplatin or carboplatin~THEN, for responders and for patients with stable disease :MAINTENANCE chemotherapy by Pemetrexed"
89496816|NCT04072016|Experimental|Beacon Aqueous Microshunt|
89496817|NCT02173639|Experimental|BI 1356/metformin|
89496818|NCT02173639|Experimental|BI 1356 + Metformin|
89496819|NCT05534906||Small HCC with Cirrhosis|200 patients diagnosed with small HCC (as defined in Eligibility Criteria) and cirrhosis
89496820|NCT05534906||Small HCC without Cirrhosis|50 patients diagnosed with small HCC (as defined in Eligibility Criteria) but without cirrhosis
89496821|NCT05534906||Imaging Subgroup|In a subgroup of patients (N=80, around 64 patients with HCC with liver cirrhosis and around 16 patients with HCC without liver cirrhosis), additional magnetic resonance liver imaging & elastography will be performed
89496822|NCT02175667|Experimental|Global Postural Reeducation|Participants receiving GPR treatment during 45 minutes to stretch muscular chains
89496823|NCT02175667|No Intervention|Control|Participants not receiving GPR treatment
89496824|NCT02173717|Experimental|Dabigatran etexilate|"Four treatments of 150 mg Dabigatran etexilate (single oral administration) in a fixed sequence.~Single oral administration of dabigatran etexilate on Day 1;~Oral administration of 600 mg rifampicin q.d. in the evening for 7 days (Days 2 to 8) followed by an oral morning dose of dabigatran etexilate on Day 9;~Single oral administration of dabigatran etexilate on Day 16, after 7 days of rifampicin washout;~Single oral administration of dabigatran etexilate on Day 23, after 14 days of rifampicin washout"
89496825|NCT04926194|Experimental|Patient with MDS/MPN|DSCs will be given 1 × 10^6 cells per kilogram of participant's body weight intravenously, administered once per week up to a maximum of six weeks depending on the clinical response.
89496826|NCT04067648|Experimental|S1 group|Sufentanil 0.3 μg/kg was intravenously given during anesthesia induction
89496827|NCT04067648|Experimental|S2 group|Sufentanil 0.4 μg/kg was intravenously given during anesthesia induction
89496828|NCT04067648|Experimental|S3 group|Sufentanil 0.5 μg/kg was intravenously given during anesthesia induction
89496829|NCT02173795|Experimental|Berodual® Respimat® - Berodual® MA HFA|"randomized sequence~Berodual® Respimat® (20 µg ipratropium bromide + 50 µg fenoterol hydrobromide per actuation for 49 days)~Berodual® MA HFA (20 µg ipratropium bromide + 50 µg fenoterol hydrobromide per puff for 49 days)"
89496830|NCT02175901|Experimental|Amoxicillin/metronidazole|Amoxicillin/metronidazole-based quadruple therapy for 14 days: Lansoprazole 30mg bid, Bismuth Potassium Citrate 220mg bid, amoxicillin 1000mg bid, Metronidazole 400mg qid
89496831|NCT02175901|Active Comparator|Amoxicillin/clarithromycin|Amoxicillin/clarithromycin-based quadruple therapy for 14 days: Lansoprazole 30mg bid, Bismuth Potassium Citrate 220mg bid, Amoxicillin 1000mg bid, Clarithromycin 500mg bid
89496832|NCT02178631|Experimental|Deprexis|Online self-help
89496833|NCT02178631|Active Comparator|CAU|Care as usual
89496834|NCT02173873|Experimental|one injection of ziv aflibercept intravitreal route|Intervention: Inject 0.05 ml of zaltrap into the vitreous of blind eyes with various diseases (AMD, CRVO) and monitor vision and OCT 1 day and 1 week after injection
89496835|NCT02176057|Experimental|Antibiotic|Azithromycin, suspension (liquid), 1 gram, one-time dose
89496836|NCT02176057|No Intervention|Observation|
89496837|NCT02173951|Active Comparator|arm 1 iron chelation|Active Comparator arm : iron chelation Included 32 thalassemia major patients with low serum ferritin (≥500) . They will receive low dose Deferiprone( DFP )on 50 mg/kg/d.
89496838|NCT02173951|Placebo Comparator|arm 2 blood transfusion|Placebo Comparator arm: blood transfusion only Included 32 thalassemia patients with low serum ferritin (≥500). They receive blood transfusion with no chelation. Patients will start deferiprone 75 mg/kg/d when reaching Primary end point which is elevation of SF to around 1000 ng/ml or more or Tsat > 90 % and or LPI > 0.6
89496839|NCT02174029||Ventilation- mandatory mode only|those patient ventilator days during which they had only received a mandatory mode of ventilation
89496840|NCT02174029||Ventilation- voluntary mode only|Those patient days on a mechanical ventilator who have not received prior mandatory ventilation during this episode of mechanical ventilation.
89496841|NCT02174029||voluntary with preceding mandatory|Those patient ventilator days where the patient had at least one prior day of mandatory mechanical ventilation during this episode of respiratory support.
89496842|NCT01664078|Experimental|InCraft® - AAA stent graft system|Intervention: Endovascular AAA repair using the InCraft device
89496843|NCT03537625|Experimental|Green tea|Green tea extract 2 gram per day
89496844|NCT03537625|Experimental|Fermented green tea|Fermented green tea extract 2 gram per day
89496845|NCT03537625|Placebo Comparator|Placebo|Placebo
89496846|NCT02176135|Experimental|Dose escalation|Auranofin 3 to 6 mg/day oral administration for 12 weeks
89496847|NCT02176213|Experimental|Pomalidomide, Cyclophosphamide, Dexamethasone|Three oral drugs will be given in 28-day cycles: Pomalidomide 4 mg daily x 21 days; cyclophosphamide 50 mg BID x 21 days; and dexamethasone 40 mg weekly x 3 (20 mg weekly if the patient aged ≥ 75 years old)
89496848|NCT03537547|Experimental|GeneSight Psychotropic test|Participants randomized to have their study clinician have access to their pharmacogenetic report (provided through the GeneSight Psychotropic tool) in order to make treatment decisions for the first 12 weeks. At Visit 5, Week 12, participants will receive a copy of their pharmacogenetics report and clinicians will continue to be able to use the results to guide treatment options for an additional 12 weeks.
89496849|NCT03537547|Active Comparator|Treatment As Usual|Participants randomized to treatment as usual will receive treatment from study clinicians who do not have access to the participant's report for the first 12 weeks. At Visit 5, Week 12, participants will receive a copy of their pharmacogenetics report and clinicians will be unblinded to be able to use the results to guide treatment options for an additional 12 weeks.
89496850|NCT04771364||Standard care|"Patients aged >65 years old scheduled for hip fracture between January 1st 2017 and December 31th 2019.~Standard anesthesiology cares were performed, as usual in our hospital institution."
89496851|NCT04771364||ASAP cohort|"Patients aged >65 years old scheduled for hip fracture between January 1st 2020 and December 31th 2022.~Standard anesthesiology cares were performed, as usual in our hospital institution, but the investigator focused the attention on these cares' adaptation: early geriatrician's advice, prefer locoregional anesthesia techniques where possible, early surgical therapy and medical adaptation on chronic therapy."
89496852|NCT02174107|Experimental|Arm A|Percutaneous vertebroplasty
89496853|NCT02174107|Experimental|Arm B|External radiotherapy
89496854|NCT05425160|Experimental|Progressive lower limb activities (Chair rise and Step ups)|Chair rise and Step ups Exercises
89496855|NCT05425160|Active Comparator|Standard aerobic exercise i.e. low intensity walking|aerobic exercise i.e. low intensity walking
89496856|NCT02174185||bladder cancer, conduit diversion|new patients with bladder cancer scheduled for radical cystectomy and subsequent conduit diversion
89496857|NCT02174185||bladder cancer, orthotopic neobladder|new patients with bladder cancer scheduled for radical cystectomy and subsequent orthotopic neobladder
89496858|NCT04305002|Experimental|Exenatide|
89496859|NCT04305002|Placebo Comparator|Placebo|
89496860|NCT03367403|Experimental|Donanemab Monotherapy (Donanemab-M)|Participants received 700 milligram (mg) donanemab intravenously (IV) every 4 weeks (Q4W) x 3 doses, then 1400 mg donanemab IV Q4W for up to 72 weeks.
89496861|NCT03367403|Placebo Comparator|Placebo|Participants received placebo IV Q4W for up to 72 weeks.
89496862|NCT03367403|Experimental|Donanemab in Combination With LY3202626 (Donanemab-C)|"Participants received 700 mg donanemab IV Q4W x 3 doses, then 1400 mg donanemab IV Q4W in combination with 12 mg of LY3202626 orally for up to 72 weeks.~As per protocol amendment (d) approved on Oct 9, 2018, donanemab in combination with LY3202626 (donanemab-C) arm discontinued as there was a low probability of identifying a statistically significant effect of 12mg of LY3202626 slowing cognitive decline."
89496863|NCT04743596||Sarcoidosis group|Consecutive patients with clinical and radiological (CT scan) suspect of sarcoidosis as assessed by a respiratory physician.
89496864|NCT04680728||patient|Patient admitted to intensive care for less than 24 hours.
89496865|NCT03297905|Experimental|Complementary and Integrative Therapies|Chiropractic, Acupuncture, Yoga, Biofeedback (if indicated), and Foam roller instruction
89496866|NCT03297905|Active Comparator|Standard Rehabilitative Care|Cognitive Behavioral Therapy (CBT) 60-minute orientation, CBT psychoeducation group, and Physical therapy/occupational therapy
89496867|NCT02577146|Experimental|Study ultrasound|Study ultrasound with ureteral jet assessment will be obtained after CT diagnosis of ureteral calculus is made. Ureteral jet data will be documented and patients will be followed prospectively for 42 days for spontaneous stone passage or need for surgical intervention.
89496868|NCT02253797|Experimental|TPV/r followed by 14C-radiolabeled TPV|Tipranavir/Ritonavir dosed to steady state followed by single-dose 14C-radiolabeled tipranavir co-administered with Tipranavir/Ritonavir
89496869|NCT03285971|Experimental|CPP Alert Group|Device: Electronic CPP pager alert anesthesia providers will receive a pager alert when CPP decreases below 60 mmHg (median value over 5-minute epochs)
89496870|NCT03285971|No Intervention|Control|This arm will not receive the automated pager alerts.
89496871|NCT02254109|Experimental|BEA 2180 BR - rising dose|
89496872|NCT02254109|Placebo Comparator|Placebo|
89496873|NCT04445753|Experimental|Tai Chi program|Individuals in the intervention group will perform a 12-week Tai Chi exercise in company with a researcher.Following the warm-up movements (Qi-gong), the training protocol of the Tai Chi movements, which includes the 10-form Yang style, will continue for 12 weeks, with two sessions per week determined by the researchers.The first and second weeks of the exercise protocol will include introducing the Tai Chi philosophy and teaching 10 forms of Yang style to patients. For 12 weeks, individuals will practice 10 forms of Tai Chi exercises with a researcher in each session. Each session will be planned as one hour.
89496874|NCT04445753|Other|Control group|Individuals in the control group will be trained on heart failure. The only attempt to be made to the control group will be education.
89496875|NCT02253875|Experimental|TPV + RTV + Omeprazole|
89496876|NCT04408157|Experimental|Self-management booklet|Self-management booklet: developed drawing on existing evidence and work conducted by researchers at the Health Psychology section at KCL, tailored to the current circumstances in response to the COVID-19 pandemic.
89205386|NCT05509959|Placebo Comparator|Control Arm|Women assigned to the control arm (n=180) will receive one 60-minute group session facilitated by the licensed clinical therapist (LCT) on self-care and well-being as it relates to HIV, interpersonal violence, trauma, adverse mental health, and substance use. During this session, women will be provided with resources to HIV care, interpersonal violence, trauma, mental health, and substance use, through a static website created for Women SHINE. The content will include: 1) names and locations of clinics and organizations, services provided, and contact information; 2) links to support websites and hotlines and 3) testimonials from WLHA.
89496877|NCT04408157|No Intervention|Education only (waiting-list)|Participants allocated to the waiting-list control arm will receive a link via email to educational materials related to COVID produced by King's College London for an online event and will be provided with the self-management booklet after completing the T2 assessment and qualitative interview. The topics covered in the online event are the same as the ones included in the self-management booklet, without structured guidance and behaviour change techniques to facilitate behaviour change.
89496878|NCT03819140|Active Comparator|Continuous OCP Therapy|Participants randomly assigned to this arm will receive 8 packs of a 21 day oral contraceptive pills (OCP) called Yasmin (3 mg Drospirenone/0.03 mg Ethinyl estradiol) which comes in a formulation of 21 days of active hormone and 7 days of sugar pills. In this arm, participants will only be expected to take active hormone pills (colored pills) for the 6 months straight without stopping or taking the sugar pills in each pack.
89496879|NCT03819140|Active Comparator|Cyclical OCP Therapy|Participants randomly assigned to this arm will receive 6 packs of a 21 day oral contraceptive pill (OCP) called Yasmin (3 mg Drospirenone/0.03 mg Ethinyl estradiol) which has 21 days of active hormone and 7 days of sugar pills. Participants will take one pill daily for 6 months and be expected to take the sugar pills at the end of each monthly pack prior to starting a new pack.
89496880|NCT04406831||New Unresectable Pancreatic Cancer|Individuals with biopsy-proven adenocarcinoma of the pancreas, classified as locally advanced or metastatic disease
89496881|NCT04406831||Control|Healthy individuals without cancer diagnoses to provide reference microRNA
89496882|NCT05534360||Tenecteplase|All consecutive patients with an arterial acute ischemic stroke treated with intravenous thrombolysis with tenecteplase.
89496883|NCT04606238|No Intervention|Group without DA|adult patients with incurable, stage IV disease (Prostate-, Breast-, Pancreatic-, Stomach- and Colorectal cancer) in an advanced treatment stage.
89496884|NCT04606238|Other|Group with DA|adult patients with incurable, stage IV disease (Prostate-, Breast-, Pancreatic-, Stomach- and Colorectal cancer) in an advanced treatment stage.
89496885|NCT04597268|Experimental|dexmedetomidine|IV dexmedetomidine
89496886|NCT04597268|Experimental|ketamine|IV ketamine
89496887|NCT04597268|Active Comparator|Midazolam|IV midazolam
88955351|NCT06328725|Active Comparator|Phase 1 - Cohort 1|EN001 5.0x10^5 cells/kg
88955352|NCT06328725|Active Comparator|Phase 1 - Cohort 2|EN001 2.5x10^6 cells/kg
88955353|NCT06328725|Placebo Comparator|Phase 2 - Experimental Group|The recommended phase 2 dose (RP2D) of EN001
88955354|NCT06328725|Placebo Comparator|Phase 2 - Control Group|EN001 placebo
88955355|NCT06328712|Active Comparator|Cohort 1|EN001 1.25×10^6 cells/kg
88955356|NCT06328712|Active Comparator|Cohort 2|EN001 2.5×10^6 cells/kg
89538166|NCT02439697|Experimental|Extended dosing Darbepoetin alfa (NESP®)|Patients on stable dose of Aranesp® (darbepoetin alfa manufactured by Amgen®) will be converted to higher dose preparation of NESP® (darbepoetin alfa manufactured by Kirin®) 40 or 120 mcg preparations) with extended dosing intervals. The total dose of Darbepoetin alpha remains the same.
88955359|NCT06328686|Experimental|Arm A (IV L-arginine, WBRT)|Patients receive L-arginine IV over 10-20 minutes followed by WBRT approximately 1 hour later for up to 10 days of treatment over 2 weeks in the absence of disease progression or unacceptable toxicity. Patients also undergo CT at screening, undergo collection of blood samples and spectroscopy on study, and undergo MRI at screening and follow up.
88955360|NCT06328686|Experimental|Arm B (oral L-arginine, WBRT)|Patients receive L-arginine PO followed by WBRT approximately 1 hour later for up to 10 days of treatment over 2 weeks in the absence of disease progression or unacceptable toxicity. Patients also undergo CT at screening, undergo collection of blood samples and spectroscopy on study, and undergo MRI at screening and follow up.
89496888|NCT04395443|Experimental|patients admitted to emergency department|the intervention is the medication reconciliation
89496889|NCT03545555|Experimental|Kale Powder|"5 capsules with kale preparation kale powder per day for 8 weeks"
89496890|NCT03545555|Experimental|Kale Extract|"5 capsules with kale preparation kale extract per day for 8 weeks"
89496891|NCT03545555|Experimental|Flavonoid Extract|"5 capsules with kale preparation flavonoid extract (from kale) per day for 8 weeks"
89496892|NCT03545555|Placebo Comparator|Placebo|"5 capsules with placebo per day for 8 weeks"
89496893|NCT04698980|Other|participants selected according to their G6PD activity|"50 subjects with severe deficit G6PD activity (<30% of the median in the general population, ie 3.6U / g Hb), adults or children two years and over.~50 subjects with intermediate G6PD activity (30-80%), adults.~50 subjects with normal G6PD activity (> 80% ie> 9.6U / g Hb), adults."
89496894|NCT04578548|Experimental|DB Period: GLPG2737|GLPG2737 will be administered orally once daily with food for 52 weeks.
89496895|NCT04578548|Placebo Comparator|DB Period: Placebo|Matching placebo will be administered orally once daily with food for 52 weeks.
89496896|NCT04578548|Experimental|OLE Period: GLPG2737|Participants completing the DB period (GLPG2737 and placebo arm) will enter an OLE period of 52 weeks where GLPG2737 will be administered orally once daily.
89496897|NCT04976543|Experimental|NWS group|nadroparin calcium injection subcutaneously every 12 hours for 1 month and switched to warfarin orally for 5 months
89496898|NCT04976543|No Intervention|control group|no anticoagulation therapy
89496899|NCT04565756|Experimental|Dose Escalation Cohort 1|Each subject will receive a low-dose 0.5 mg/mL (0.05%) of EXN407 or placebo twice a day in 14 doses over a 7 day period.
89496900|NCT04565756|Experimental|Dose Escalation Cohort 2|Each subject will receive a mid-dose 1 mg/mL (0.1%) of EXN407 or placebo twice a day in 14 doses over a 7 day period.
89496901|NCT04565756|Experimental|Dose Escalation Cohort 3|Each subject will receive a high-dose 1.5 mg/mL (0.15%) of EXN407 or placebo twice a day in 14 doses over a 7 day period.
89496902|NCT04565756|Experimental|Dose Expansion Cohort|The highest well-tolerated dose of EXN407 will be evaluated where subjects will receive EXN407 at the selected dose or placebo twice a day for up to 84 days resulting in a total of 168 doses
89496903|NCT03232541|Other|Standard care (A)|Standard care (A) with neutral communication (A1) or positive communication (A2)
89496904|NCT03232541|Placebo Comparator|Sham acupuncture (B)|Standard nausea treatment plus Sham acupuncture (B) with neutral communication (B1) or positive communication (B2)
89496905|NCT03232541|Experimental|Genuine acupuncture (C)|Standard nausea treatment plus Genuine acupuncture (C) with neutral communication (C1) or positive communication (C2)
89496906|NCT04373759||Unexpected in-intensive care unit cardiac arrest patients|ICUCA Patients admitted in intensive care unit for a confirmed COVID-19 and presenting an unexpected in-intensive care unit cardiac arrest
89496907|NCT04373759||In-hospital cardiac arrest patients|IHCA Patients admitted in intensive care unit for an in-hospital cardiac arrest with a confirmed Covid-19
89496908|NCT04373759||Out-of-hospital cardiac arrest|OHCA Patients admitted in intensive care unit for an out-hospital cardiac arrest with a confirmed Covid-19
89496909|NCT03546725|Experimental|Leg with compression stocking|Leg wearing compression stocking during the flight
89496910|NCT03546725|No Intervention|Leg without compression stocking|Leg not wearing compression stocking during the flight
89496911|NCT05534048|Experimental|PTX-COVID19-B|
89496912|NCT05534048|Active Comparator|Comirnaty®|
89496913|NCT04951037|Experimental|Fully Asynchronous Online Savvy Program|Family caregivers of PLWD taking part in a fully asynchronous online caregiver education program.
89496914|NCT04691492|Experimental|Friends-Based Motivational Interview (FMI) Group|Will participate in the Friends-Based Motivational Interview (FMI) program.
89496915|NCT04691492|No Intervention|Wait List Control|The Wait List Control group will also be offered to participate in the Friends-Based Motivational Interview Program but at a deferred date (12 weeks later).
89496916|NCT02924441|Experimental|Right Breast Lidocaine and calming music|Group 1 - right breast lidocaine & calming music
89496917|NCT02924441|Experimental|Right Breast Lidocaine and no music|Group 2 - right breast lidocaine & no calming music
89496918|NCT02924441|Experimental|Left Breast Lidocaine and calming music|Group 3 - left breast lidocaine & calming music
89496919|NCT02924441|Experimental|Left Breast Lidocaine and no music|Group 4 - left breast lidocaine & no calming music
89496920|NCT04527224|Experimental|AstroStem-V|AstroStem-V which consists of three syringes and each syringe contains 1.0 x 10^8 cells / 3mL of saline with 30% human serum
89496921|NCT04933877|Active Comparator|Serratus Anterior Plan block|The SAPB was performed in the operative room (OR) after anesthesia induction using the same ultrasound machine (SonoSite) and linear ultrasound transducer 8- 12 Hz. The patient was positioned in a lateral position with the operative side up and arm flexed forward; then, a linear ultrasound transducer was placed in a sagittal plane over the mid-clavicular line of the thoracic cage. Then, moving inferior-lateral direction till the fifth rib was identified in the mid-axillary line. The following structures were recognized: the rib, pleura, teres major muscle (superior), latissimus dorsi muscle (superficial and posterior), and serratus muscles muscle (deep and inferior). Under complete sterile conditions, a 22-gauge echogenic needle was introduced in-plane with respect to the ultrasound probe targeting the plane deep to the serratus anterior muscle. Then, 0.4 ml/kg of 0.25% bupivacaine was injected with continuous ultrasound guidance.
89496922|NCT04933877|Active Comparator|Erector spinae plane block|Patients in Group ESPB receive US erector spinae plane block by injecting 0.4ml/kg (bupivacaine 0.25%). Under strict aseptic precautions, The T3 spinous process is located by palpating and counting down from the C7 spinous process. A high-frequency 12 MHz linear ultrasound transducer is placed in a longitudinal orientation 3 cm lateral to the T3 spinous process corresponding to the T2 transverse process. Three muscles; trapezius (uppermost), rhomboids major (middle), and erector spinae (lowermost) will be identified superior to the hyperechoic transverse process.Using an in-plane approach a 22 G needle is inserted in caudal-cephalad direction until the tip is deep to erector spinae muscle. Correct needle tip location is confirmed by injecting 3 mL of normal saline and visualizing the linear LA spread (i.e., hydrodissection) in the fascial plane between the erector spinae muscle and the transverse process. Then, bupivacaine is injected, and visualizing the fascial plane.
89496923|NCT04235699|Experimental|Ketogenic Diet|This arm will be provided food to induce a state of nutritional ketosis in each person as defined as blood [3-OHB] ≥0.5 mM.
89496924|NCT04235699|Experimental|Low-fat mixed Diet|This arm will be provided food consisting of ~25% fat, and the remaining calories from carbohydrate (~55% after accounting for protein at ~20%).
89496925|NCT03545945|Experimental|Study arm|Patients having office diagnostic hysteroscopy and endometrial biopsy
89496926|NCT03545945|Other|Control arm|Patients having only endometrial biopsy
89496927|NCT03752801||Script Review Parents/Caregivers|will have script reviewed and evaluated by parents/caregivers in groups of 5 up to 40 participants until 4/5 parents/caregivers demonstrate that script is understandable and acceptable.
89496928|NCT03752801||Video Review Parents/Caregivers|review and evaluation of the developed educational videos by parents/caregivers up to 20 parents who have not participated in the script review
89496929|NCT02784977||Obstructive Sleep Apnea (OSA)|Patients with apnea hypopnea index of at least 5 events per hour. Intervention with positive airway pressure, or intraoral device, or uvuloplasty, or conservative treatment.
89496930|NCT02784977||No-OSA|Patients with apnea hypopnea index less than 5 events per hour. No intervention.
89496931|NCT03545399|Experimental|Ulva Lactuca|The subject is given a capsule containing a concentrated fraction of freeze-dried and crushed hydrosoluble extract of seaweeds. The dose tested of extract of seaweeds is of 6.45mg per kg weight. The daily dose is 3 capsules per day for subjects weighing between 50 and 70kg, 4 capsules per day for subjects weighing between 70 and 90kg and 5 capsules per day for subjects weighing between 90 and 110kg. The duration of the treatment is 12 weeks.
89496932|NCT03545399|Placebo Comparator|Placebo|The subject is given a capsule looking alike that of the active product but containing no extract of seaweeds.The duration of the treatment is 12 weeks.
89022797|NCT06187519|Experimental|Uric Acid and Metabolite Monitor System (UR+AIMS) skin patch|15 patients with gout will be invited to participate in a standardized meal at the UCLA Human Nutrition Center and a 7-day community follow up for the measurement of uric acid (and other metabolites) using our Uric Acid and Metabolite Monitor System (UR+AIMS) skin patch.
89022798|NCT06187506|Experimental|RC48+BCG|Disitamab Vedotin (2.0 mg/kg, administered intravenously every three weeks); BCG therapy: Induction therapy, i.e., intravesical therapy once a week for 6 weeks. maintenance therapy, i.e., one course of maintenance therapy at three, six and twelve months after surgery, each course once a week for 3 weeks.
89022799|NCT06187493|Other|Efficacy of ACEi|Patients receive an ACEi medication, such as lisinopril, enalapril, or ramipril. These drugs work by blocking the production of angiotensin II, a hormone that can constrict blood vessels and raise blood pressure.
89496933|NCT00109967|Experimental|Arm I|Patients receive CCI-779 IV over 30 minutes on days 1, 8, 15, and 22. Patients also receive rituximab IV on days 1, 8, 15, and 22 of course 1 and on day 1 only of courses 3, 5, 7, 9, and 11. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. After completion of course 3, patients undergo reevaluation. Patients achieving a CR or an unconfirmed CR (CRu) receive 2 additional courses of treatment for a total of 5 courses. Patients achieving a PR or stable disease continue study treatment as outlined above for up to 12 courses. Patients achieving a PR or stable disease who subsequently achieve a CR or CRu between courses 3 and 10 receive 2 additional courses of treatment.
89496934|NCT02579096|Active Comparator|Allopurinol / Sham Comparator (Febuxostat)|Patients will be titrated up to the dose that will lower to target uric acid levels. A placebo resembling Febuxostat will be given with allopurinol
89496935|NCT02579096|Active Comparator|Febuxostat / Sham Comparator (Allopurinol)|Febuxostat will be titrated up to the dose that will lower to target uric acid levels. A placebo resembling Allopurinol will be given with Febuxostat
89496936|NCT04904003|Experimental|Experienced LLA - intervention|Experienced lower-limb amputees that complete a 4-week semi-structured individualized rehabilitation regime with extensive testing before and after the intervention.
89496937|NCT04904003|Experimental|Experienced LLA - controls|Experienced lower-limb amputees that will be tested with a 4-week interval. No intervention. This group will be matched to the group of experienced lower-limb amputees.
89496938|NCT04904003|Experimental|New LLA learning to use prosthesis|New lower-limb amputees that complete a 8-11 weeks semi-structured individualized rehabilitation regime with extensive testing before and after the intervention.
89496939|NCT02578940|Experimental|Single arm|Single intravenous administration of 18F-Fluciclovine for PET Scan
89496940|NCT02578862|Experimental|Total Intravenous|Intravenous propofol for maintenance of anesthesia
89496941|NCT02578862|Active Comparator|Inhaled Anesthetic|Inhaled volatile anesthetic for maintenance of anesthesia
89496942|NCT02578706|Active Comparator|Aspirin and placebo|At week 0, participants will be administered aspirin 81mg (one tablet) and placebo for clopidogrel 75 mg (one tablet) once daily. At week 24, participants will stop both study product tablets.
89496943|NCT02578706|Active Comparator|Clopidogrel and placebo|At week 0, participants will be administered clopidogrel 75 mg (one tablet) and placebo for aspirin 81 mg (one tablet) once daily. At week 24, participants will stop both study product tablets.
89496944|NCT02578706|Placebo Comparator|Placebos only|At week 0, participants will be administered placebo for aspirin 81 mg (one tablet) and placebo for clopidogrel 75mg (one tablet) once daily. At week 24, participants will stop both study product tablets.
89496945|NCT05533736|Experimental|Community based strategy to follow-up pactientes with Cutaneous Leishmaniasis|Patients with cutaneous leishmaniasis are followed with the Guaral+ST app by Community Health Leaders. This intervention was not randomized
89496946|NCT05533736|No Intervention|Control group: Standard of care|Control group: Standard of Care: Registers historical patients with cutaneous leishmaniasis is followed in the health facility by physicians according to national guidelines.
89496947|NCT05533424|Active Comparator|Group quadratus lumborum|the patient will be positioned supine with lateral tilt , and the transducer was placed at the level of the anterior superior iliac spine and moved cranially until the three abdominal wall muscles were clearly identified. The external oblique muscle was followed posterolaterally until its posterior border was visualized . The probe was tilted down to identify a bright hyperechoic line that represented the middle layer of the thoracolumbar fascia. The needle will be inserted in plane from anterolateral to posteromedial. The needle tip was placed between the thoracolumbar fascia and the QL muscle, and after negative aspiration, the correct position of the needle was proved by injection of 5 mL of normal saline to confirm the space with a hypoechoic image and hydrodissection. An injection of 20 mL of 0.25% bupivacaine was applied
89496948|NCT05533424|Active Comparator|Group transversus abdominis plane|the probe will located between the iliac crest and the lower costal margin in the anterior axillary line at the level of umbilicus, and the layers of abdominal wall were identified (external oblique, internal oblique, and transverse abdominis muscles). In-plane technique was used and the tip of the needle was inserted between the internal oblique and transverse abdominis muscles. After negative aspiration (to exclude intravascular injection), 20 mL of 0.25% bupivacaine was injected. The same technique will be performed on the other side
89496949|NCT03455504|Experimental|Cohort 1|FLAI + V400 mg
89022800|NCT06187493|Other|Efficacy of SGLT2i|Patients receive an SGLT2i medication, such as dapagliflozin, empagliflozin, or canagliflozin. These drugs work by preventing the kidneys from reabsorbing glucose from the urine, leading to lower blood sugar levels and potentially reducing the risk of kidney damage.
89496950|NCT03455504|Experimental|Cohort 2|FLAI + V600 mg
89496951|NCT04475666|Active Comparator|Replenish protein group|The subjects randomized to this group will receive the standard amount of proteins (maximum 1.2 g/kg/day) from the primary polymeric formula AND supplemental protein at 1.2 g/kg/day
89022801|NCT06187480||group 1|underwent total parathyroidectomy
89022802|NCT06187480||group 2|underwent subtotal parathyroidectomy
89022803|NCT06187454|Experimental|Active tDCS|
89022804|NCT06187454|Sham Comparator|Sham tDCS|
89022805|NCT06187441|No Intervention|Arm A|A continuous therapy arm - continuation of therapy with Dara-Rd until PD
89022806|NCT06187441|Experimental|Arm B|treatment free interval arm - discontinuation of therapy with Dara-Rd, which will be resumed at biochemical progression and given until PD
89022807|NCT06187376|Experimental|Chinese Herbal Medicine (CHM) herbal tincture|Chinese herbal tincture
89022808|NCT06187376|Placebo Comparator|Placebo|Matching placebo tincture.
89022809|NCT06187350||Screened women in Region Östergötland, Sweden|All screened women in Region Östergötland, Sweden.
89022810|NCT06187337|Experimental|Early maxillary expansion|"The subjects in the experimental group will be treated with a maxillary expansion appliance with bands on the second deciduous molars and arms to the deciduous canines. The screw gives a expansion of 0,20 millimeter per activation. The arms are bonded to the deciduous canines with light curing composite and the bands are cemented with glassionomer cement.~The subject are instructed to activate the appliance once a day (1/4 turn) for 2 weeks and thereafter every second day until adequate space for the lateral incisors is obtained.During the expansion the subjects will be asked to complete a questionnaire on pain and discomfort.~The subjects will be recalled for follow-up visits after 24 months (T1), 36 months (T2), 48 months (T3) and when all permanent premolars are erupted (T4).~At T4 the subjects are asked to fill out the Psychosocial Impact of Dental Aesthetics Questionnaire (PIDAQ).~The subjects need for further treatment will be evaluated and initiated at T4."
89022811|NCT06187337|No Intervention|Control group|"The control group is not going to receive any treatment under the observation period.~The subjects will be recalled for follow-up visits with photographs (4 extraoral photos and 5 intraoral photos) and study models (digital or cast) after 24 months (T1), 36 months (T2), 48 months (T3) and when all permanent premolars are erupted (T4).~At T4 the subjects are asked to fill out the Psychosocial Impact of Dental Aesthetics Questionnaire (PIDAQ) to evaluate their oral health related quality of life.~The subjects need for further treatment will be evaluated and initiated at T4."
89022812|NCT06187324|Experimental|periopaper|periopaper used to collect GCF
89022813|NCT06187272|No Intervention|Group one with no music|Graduate students with no music
89496952|NCT04475666|Active Comparator|Standard protein group|The subjects randomized to this group will receive standard prescription without supplemental proteins (maximum1.2 g/kg/day) from the primary polymeric formula. No supplemental protein will be allowed
89496953|NCT00108953|Experimental|Sorafenib + Doxorubicin|"Sorafenib + Doxorubicin -- combination therapy: Sorafenib (Nexavar, BAY43-9006) 200 mg tablets by mouth (orally) twice daily + doxorubicin 60 mg/m2 intravenous infusion every 21 days for 6 cycles (18 weeks)"
89496954|NCT00108953|Active Comparator|Placebo + Doxorubicin|"Placebo + Doxorubicin -- monotherapy: Sorafenib (Nexavar, BAY43-9006) matching placebo tablets by mouth (orally) twice daily + doxorubicin 60 mg/m2 intravenous infusion every 21 days for 6 cycles (18 weeks)"
89496955|NCT04810520||Point-of-care ultrasound with tele-supervision|Point-of-care ultrasound of critically ill patients (acute dyspnoea, circulatory failure, trauma) will be performed with tele-supervision.
89496956|NCT04810520||Point-of-care ultrasound without tele-supervision|Point-of-care ultrasound of critically ill patients (acute dyspnoea, circulatory failure, trauma) will be performed without tele-supervision.
89496957|NCT02741531|Experimental|Intervention|Patients in this group will have their bladder filled with 150 cubic centimeters (cc) of saline solution prior to being moved to the PACU.
89496958|NCT02741531|No Intervention|Control|patients in this group will have their bladders drained completely prior to being moved to the PACU as is the current standard of care.
89496959|NCT03545867|Experimental|Seated control (CON)|Participants remain seated in their habitual wheel chair for ~45 min (duration of exercise performed in other arms). Following the intervention they are fed.
89496960|NCT03545867|Experimental|Circuit resistance training (CRT)|Participants complete upper extremity resistance maneuvers (lifts) interspersed with low-load/high-speed arm cycling for a combined 30 repetitions of 6 lifts and ~20 min of arm cycling. During this time energy expenditure is measured via open-circuit indirect calorimetry. Following the intervention they are fed.
89496961|NCT03545867|Experimental|Moderate intensity continuous (MICT)|Participants complete continous arm cycling at a steady-state power output (intensity) matched to the energy expenditure (kcal/min) and duration of exercise (min) response during CRT. Following the intervention they are fed.
89496962|NCT03545867|Experimental|High intensity interval training (HIIT)|"Participants complete interval arm cycling at power output that varies between 2 min active and two min recovery periods. This interval exercise is matched to the total energy expenditure (accumulated kcals) response during CRT. Following the intervention they are fed."
89496963|NCT04205435|Experimental|β-globin restored autologous HSC|each subject will accept one dose of β-globin restored autologous hematopoietic stem cells
89496964|NCT05361044|Other|Donnor of liver grafts|Blood samples And liver biopsy taken from the donnor
89022814|NCT06187272|Experimental|Group Two with music|Graduate students listening to music
89205387|NCT05509959|Experimental|Women SHINE|Women SHINE consists of a four-month intervention that includes video-based one-on-one peer navigation and 7 weekly psycho-education support group sessions co-facilitated by a licensed clinical therapist (LCT) and peer navigator (PN). 180 women will be enrolled in the Women SHINE intervention and will remain in their assigned psycho-education support group sessions with the same members over the course of the intervention.
89205388|NCT05508243|Experimental|Experimental|
89496965|NCT05130281|Experimental|Social Support|Participants receive treatment with the Maya app in conjunction with social support incentives for 6 weeks.
89496966|NCT05130281|Experimental|Gain Framed|Participants receive treatment with the Maya app in conjunction with gain-framed incentives for 6 weeks.
89496967|NCT05130281|Experimental|Loss Framed|Participants receive treatment with the Maya app in conjunction with loss-framed incentives for 6 weeks.
89496968|NCT02732873|Experimental|FibroFix|
89496969|NCT05532956||Individual semi-structured interview|A semi-structured individual interview lasting a maximum of 1.5 hour ,conducted by a psychologist, remotely (telephone, videoconference) or at home
89496970|NCT05532956||Collective interview|Group interviews lasting a maximum of 2 hours will consolidate the information obtained during individual interviews
89022815|NCT06187246|Experimental|Avatar-based Intervention Group|Treatment was based on the CBT approach and previous literature about FOD. It consisted of 12 weekly online individual sessions, which were administered once a week (total duration = 3 months) and lasted about 60 minutes each.
89496971|NCT02578316|Experimental|Lenvatinib 24 mg|Participants with advanced solid tumors or lymphomas, who are unsuitable for, or had failed, existing therapies.
89022816|NCT06187246|Active Comparator|Minimal support control group|It consisted in individual informative talks, during which they were provided with information about female orgasm (e.g., what is an orgasm, neuronal orgasm, factors that may influence consecution, sexual response), masturbatory techniques (e.g., key elements to achieve pleasure, anatomy of the female genitalia, pleasure areas) and techniques to focus attention on one's body (i.e., an important factor to pleasure). Participants received three individual sessions once a month, and had a duration of one hour.
89022817|NCT06187233|Experimental|binaural music group|The music group listened to music containing binaural beats during the colonoscopy
89022818|NCT06187233|No Intervention|control|The control group had headphones without sound during the procedure.
89022819|NCT06187220||Therapeutic Plasma Exchange (PEX)|Patients receiving in addition to Standard Medical Therapy (SMT) at least one treatment with Therapeutic Plasma Exchange (PEX)
89022820|NCT06187220||Standard Medical Therapy (SMT)|Patients receiving only Standard Medical Therapy (SMT) of Amanita Toxin associated acute liver failure, including intensive care support (invasive ventilation, vasopressors, renal replacement therapy), silibinin and n-acetylcystein. Included in this group are also patients receiving albumine dialysis or other extracorporeal liver assist therapies excluding therapeutic plasma exchange.
89022821|NCT06187142|Experimental|Intervention Group (Group PCS, subgroup PCS-1+PCS-2+PCS-3)|Personalized Chat Support (PCS) + Multi-component Optional Support (MOS) + 5A's / 5R's advice + health warning leaflet +Self-help booklet
89022822|NCT06187142|Experimental|Control Group (Group GCS, subgroup GCS-1+GCS-2+GCS-3)|Group Chat Support (GCS) + Personalized Chat Support (PCS) + 5A's / 5R's advice + health warning leaflet +Self-help booklet
89022823|NCT06187116|Experimental|Physiotherapist led orthopaedic triage|Patients who are randomised to PT led triage will be scheduled for a consultation with a physiotherapist (PT) at a rehabilitation clinic in primary care in the Region Västra Götaland.
89022824|NCT06187116|Active Comparator|Usual care|Patients who are randomised to usual care will be sceduled according to standard procedure for an orthopaedic surgeon (OS) consultation at the orthopaedic department of a hospital in the Region Västra Götaland.
89496972|NCT05532878||Study group|stable PD patients with non-valvular AF
89022825|NCT06187103|Experimental|HyperSight Imaging arm|Subjects are imaged with the new HyperSight CBCT imaging system.
89496973|NCT05532644||Patients receiving cholinesterase inhibitors|
89496974|NCT05532644||Patients receiving memantine|
89496975|NCT05532644||Healthy people|
89496976|NCT05502614|Experimental|Treatment|
89022826|NCT06187090|Experimental|PEA Arm|
89022827|NCT06187051||Patient presenting a type 1A endoleak after EVAR treated by relining with FEVAR|
89022828|NCT06187051||Patient presenting a type 1A endoleak after EVAR treated by explantation of the EVAR|
89022829|NCT06187012||Hypertensive pregnancy|
89022830|NCT06186986|Experimental|Part 1|In Part 1 of this side study a minimum of 5 eligible patients will undergo 89Zr-brentuximab-PET scans at 3 different time points (1, 4 and 7 days after tracer injection) either without (2 patients) or with preceding administration of 10 mg (3 patients) or more (n patients) of unlabeled brentuximab.
89022831|NCT06186986|Experimental|Part 2|In Part 2 of this side study the optimized imaging schedule from Part 1 will be used to investigate biodistribution and tumor uptake of 89Zr-brentuximab in 15 patients and correlate imaging data to baseline sCD30 serum levels, CD30 IHC and CD30 Gene Expression Profiling (GEP).
89022832|NCT06186973||No maternal epidural labor analgesia|Term infants monitored with cardiotocography with ST-segment analysis (STAN) during labour: No maternal epidural labor analgesia
89022833|NCT06186973||With maternal epidural labor analgesia|Term infants monitored with cardiotocography with ST-segment analysis (STAN) during labour: With maternal epidural labor analgesia
89205389|NCT05505019|Experimental|Parkinson's Disease with apathy - Music-listening|"Participants in this arm will receive a YouTube account app to use. Prior to the start of the intervention, a research team member will guide participants in this group in constructing a playlist of music that they find rewarding or motivating."
89205390|NCT05505019|Experimental|Parkinson's Disease with apathy - Podcast-listening|"Participants in this arm will receive a YouTube account app to use. Prior to the start of the intervention, a research team member will guide participants in this group in choosing a podcast that they find rewarding or motivating."
89205391|NCT05494346|Other|Arm A: Patients with peak nasal flow performed|This arm is made up of major patients. Nasal flow point measurements will be performed at D0 and D3.
89496977|NCT04405388|Other|Spermidine first|First treatment period (8 weeks) will be 4 mg spermidine per day orally. Afterwards 4 weeks of wash-out followed by 8 weeks of placebo treatment.
89496978|NCT04405388|Other|Placebo first|First treatment period (8 weeks) will be placebo. Afterwards 4 weeks of wash-out followed by 8 weeks of 4 mg spermidine per day orally.
89496979|NCT05332340|Experimental|Healthy Patients|Healthy patients receiving topical application of BZ371A
89496980|NCT05495360|Experimental|Arm 1|twice daily serving of the study product
89205392|NCT05494346|No Intervention|Arm B: No peak nasal flow|This arm is made up of minor patients. Unlike arm A, nasal flow measurements will not be performed at D0 and D3.
89205393|NCT05481931||Safety Population|The safety population will consist of all patients who receive at least one treatment of NUCEIVA.
89205394|NCT05481931||Botulinum Toxin Naïve|Sub-population of patients that have never been treated with botulinum toxin
89205395|NCT05481931||Botulinum Toxin Exposed|Sub-population of patients that have previously been treated with botulinum toxin
89205396|NCT05476289||A|children who received partially hydrolyzed formula containing synbiotics in the first 17 weeks of life in the Dragon study.
89205397|NCT05476289||B|children who received standard infant formula containing prebiotics in the first 17 weeks of life in the Dragon study.
89205398|NCT05476289||C|children who received full breastfeeding in the first 17 weeks of life in the Dragon study.
89205399|NCT05466630|Other|participant|All eligible participants will undergo 5 serological field tests for HAT and a malaria test. Those testing positive in at least 1 serological field test will undergo parasitology to confirm HAT and immunological and molecular laboratory tests
89205400|NCT05462132|Experimental|Cohort 1|"HV subjects receive doses 3 × 10^11 live cells of SYNB1353 and 30 mg/kg of methionine.~Subjects will receive a single dose of SYNB1353 on the first day of dosing (Day 1), on Days 2 and 3 subjects will receive up to 2 doses of IMP (BID), and on Days 4 to 7 subjects will receive up to 3 doses of IMP (TID).~A methionine loading study will be performed on Day -1 and Day 7 after an overnight fast. A dose of methionine of 30 mg/kg will be evaluated."
89205401|NCT05462132|Experimental|Cohort 2|"HV subjects receive doses 3 × 10^11 live cells of SYNB1353 and up to 100 mg/kg of methionine.~Subjects will receive a single dose of SYNB1353 on the first day of dosing (Day 1), on Days 2 and 3 subjects will receive up to 2 doses of IMP (BID), and on Days 4 to 7 subjects will receive up to 3 doses of IMP (TID).~A methionine loading study will be performed on Day -1 and Day 7 after an overnight fast. A dose of methionine of up to 100 mg/kg will be evaluated."
89205402|NCT05462132|Experimental|Cohort 3|"HV subjects receive doses 6 × 10^11 live cells of SYNB1353 and 30 mg/kg of methionine.~Subjects will receive a single dose of SYNB1353 on the first day of dosing (Day 1), on Days 2 and 3 subjects will receive up to 2 doses of IMP (BID), and on Days 4 to 7 subjects will receive up to 3 doses of IMP (TID).~A methionine loading study will be performed on Day -1 and Day 7 after an overnight fast. A dose of methionine of 30 mg/kg will be evaluated."
89205403|NCT05462132|Experimental|Cohort 4|"HV subjects receive doses 6 × 10^11 live cells of SYNB1353 and up to 100 mg/kg of methionine.~Subjects will receive a single dose of SYNB1353 on the first day of dosing (Day 1), on Days 2 and 3 subjects will receive up to 2 doses of IMP (BID), and on Days 4 to 7 subjects will receive up to 3 doses of IMP (TID).~A methionine loading study will be performed on Day -1 and Day 7 after an overnight fast. A dose of methionine of up to 100 mg/kg will be evaluated."
89496981|NCT05532566|Experimental|Extract Q. ilex + extract Q. robur + positive control + negative control|"There is only one treatment arm. In each subject, one drop of each of the 3 concentrations of each allergenic extract (2 extracts) will be applied in addition to the positive control (histamine 10mg/mL) and the negative control, with prick test.~Quercus ilex: 2,500, 500 and 100 μg/mL Quercus robur: 2,500, 500 and 100 μg/mL"
89531786|NCT05364632|Experimental|Aerobic Training|Participants will undergo an eight-week aerobic training protocol (twice a week) on a treadmill, each aerobic training session will consist of 45 minutes divided into 5 minutes of warm-up, 35 minutes of aerobic exercise and 5 minutes of cool-down.
89496982|NCT02576678|Experimental|Open label apremilast|"Apremilast doses of 10-mg, 20-mg or 30-mg tablets have been selected to determine the dose range in adolescents and children with moderate to severe plaque psoriasis. These pediatric dosages are expected to achieve exposures similar to those achieved in adult psoriasis and psoriatic arthritis (PsA) subjects treated with apremilast 30 mg orally twice daily (BID).~A staggered, stepwise approach by age range and weight (starting with older and heavier subjects) is considered appropriate for this first-time-in-children study. Doses for younger and lower body weight subjects will be adjusted based on safety and PK data from older and heavier subjects.~Subjects will be divided into 2 age groups with at least 16 subjects in each group. Dosing within and between groups will be staggered, based on PK data collected and on a minimum of 2 weeks of safety data."
89496983|NCT05532488|Experimental|Inulin 20 mg|Inulin 20 mg administrated orally q24h
89496984|NCT05532488|Placebo Comparator|Placebo|Matching placebo q24h
89496985|NCT04303208|Other|study group|Blood sample ( 5 ml venous blood ) will be obtained under complete aseptic conditions from all eligible participants , using serum separator tube and allow samples to clot for 30 minutes before centrifugation for 15 minutes to obtain clear serum .Separated serum will be stored at < - 20c ( avoid repeated freeze - thaw cycles) till assessment of Sirt 3 and Sirt 7 levels using Enzyme- linked immunosorbent assay (ELISA) method .
89496986|NCT04303208|Other|control group|Blood sample ( 5 ml venous blood ) will be obtained under complete aseptic conditions from all eligible participants , using serum separator tube and allow samples to clot for 30 minutes before centrifugation for 15 minutes to obtain clear serum .Separated serum will be stored at < - 20c ( avoid repeated freeze - thaw cycles) till assessment of Sirt 3 and Sirt 7 levels using Enzyme- linked immunosorbent assay (ELISA) method .
89496987|NCT02869646|Experimental|Verum acupuncture|Traditional Chinese Medicine (TCM) based acupuncture at prescribed sites
89496988|NCT02869646|Sham Comparator|Minimal needling|shallow and non-acupoint needles at same number of sites
89496989|NCT05487404|Experimental|ADX-629 Oral Tablets|
88955365|NCT06328660|Experimental|Lens 1|All participants will wear Lens 1 for 14 ± 3 days (Period 1)
88955366|NCT06328660|Experimental|Lens 2|All participants will wear Lens 2 for 14 ± 3 days (Period 2)
88955367|NCT06328647|Experimental|POC Quantra QPlus System|Perfusion team or trained (certified for POC testing) research personnel will perform hemostasis testing using the Quantra QPlus POC System, results will be interpreted by the primary anesthesia team that will decide if transfusion of blood components is necessary in the operating room and up to 12 hours after surgery in the cardiac surgery intensive care unit (ICU).
88955368|NCT06328647|Active Comparator|Routine Care|The primary anesthesia provider will determine the need for blood and blood component transfusion with or without guidance from central laboratory testing for hemostatic abnormalities in the operating room and up to 12 hours after surgery in the cardiac surgery intensive care unit (ICU).
89496990|NCT05487404|Placebo Comparator|Placebo|
89496991|NCT05532332|Experimental|Test Product (T)|subjects were administered a single hard gelatin capsule of 10 mg Fluoxetine with approximately 240 ml water after an overnight fast of 10 hours
89496992|NCT05532332|Active Comparator|Reference Product (R)|subjects were administered a single hard gelatin capsule of 10 mg Fluoxetine with approximately 240 ml water after an overnight fast of 10 hours
89496993|NCT05326802||U.S. Embryologists|U.S. embryologists of all ages, career levels, and other sociodemographic groups will be asked questions about their physical and mental health related to their occupational characteristics using the nationally validated surveys and questionnaires, and also about their working conditions in the ART/IVF laboratories using a custom occupational questionnaire and the single-item work unit grade (A-F).
89496994|NCT05323136|Experimental|Renal impairment|moderate and severe Renal impairment subjects
89496995|NCT05323136|Experimental|Healthy control|Healthy control subjects with normal renal function
89496996|NCT05480540|Experimental|Serious game|A serious game-based web application on Sterile Dressing and Surgical Instrument Preparation Training, which was prepared in accordance with the formal education curriculum and prepared as a support for formal education, will be downloaded to the mobile phones of the students in the intervention group.
89496997|NCT05480540|Active Comparator|Video|The video prepared on sterile dressing and surgical instrument preparation training will be shown to the students in the control group for 2 weeks.
89496998|NCT05532254|Experimental|Test Product (T)|subjects were administered a single tablet of 10 mg Aripiprazole with approximately 240 ml water after an overnight fast of 10 hours
89496999|NCT05532254|Active Comparator|Reference Product (R)|subjects were administered a single tablet of 10 mg Aripiprazole with approximately 240 ml water after an overnight fast of 10 hours
89497000|NCT05532176|Other|postural group|one healthy group of different age
89497001|NCT05319626|Experimental|Intervention group 1|Compression socks with Textured insoles
89497002|NCT05319626|Experimental|Intervention group 2|Compression socks with Smooth insoles
89497003|NCT05319626|Experimental|Intervention group 3|Smooth socks with Textured insoles
89497004|NCT05319626|Placebo Comparator|Control group|Smooth socks with Smooth insoles
89497005|NCT05530850|Experimental|Holistic Corrective Exercise Program|A holistic approach corrective exercise program including corrective exercises and postural perception training
89497006|NCT05530850|Experimental|Thoracic exercise program|Thoracic region focused exercise program
89497007|NCT05530850|No Intervention|control group|Individuals in the control group were asked to continue their activities of daily living.
89497008|NCT05471648|Experimental|420 mg EirGenix Pertuzumab|EirGenix Pertuzumab given intravenous with an infusion bag as a single dose of 420 mg over 60min.
89497009|NCT05471648|Active Comparator|420 mg Pertuzumab Perjeta EU Origin|EU Pertuzumab given intravenous with an infusion bag as a single dose of 420 mg over 60min.
89497010|NCT05471648|Active Comparator|420 mg Pertuzumab Perjeta US Origin|US Pertuzumab given intravenous with an infusion bag as a single dose of 420 mg over 60min.
89497011|NCT04305392|Experimental|Normal liver function|Patients will receive single dose of SHR4640
89497012|NCT04305392|Experimental|Mild Hepatic Impairment|Patients will receive single dose of SHR4640
89497013|NCT04305392|Experimental|Moderate Hepatic Impairment|Patients will receive single dose of SHR4640
89497014|NCT05532098|Active Comparator|Control group|Patients diagnosed with ADD under this group are subjected to Dry Needling
88955369|NCT06328621||Observational (survey, biospecimen, medical record, CT)|"Participants complete a survey over 40-45 minutes at baseline. Participants' medical records are also reviewed. Participants who have lung cancer but have not undergone treatment and participants not diagnosed with lung cancer (i.e., unaffected), undergo collection of blood samples at a scheduled clinical or research blood draw. Participants not diagnosed with lung cancer (i.e. unaffected), undergo a low-dose CT scan over 20 minutes."
88955370|NCT06328608|Experimental|Single Arm - Pegunigalsidase alfa (PRX-102)|"For Cohort C, PXR-102 administered every two weeks at 1.0 mg/kg is believed to be the minimum effective dose.~For Cohorts A and B, the starting dose will be 1.0 mg/kg every two weeks but it may be adjusted on the outcomes of Stage I, with the support of the Data Safety Monitoring Board."
89497015|NCT05532098|Experimental|Test group|Patients diagnosed with ADD under this group are administered with 1ml of PRP solution .
89497016|NCT00108745|Experimental|Arm I (paclitaxel poliglumex)|Patients receive polyglutamate paclitaxel IV over 10-20 minutes on day 1.Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
89497017|NCT00108745|Active Comparator|Arm II (paclitaxel)|Patients receive paclitaxel IV over 3 hours on day 1. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
89497018|NCT00108745|Other|Arm III (observation)|Patients receive no further anticancer treatment until evidence of disease progression.
89497019|NCT05532020|Experimental|Open-label DCCR|75 - 525 mg DCCR
89497020|NCT05530226|Experimental|Traditional Chinese medicine group|Traditional Chinese medicine, twice daily
89497021|NCT02098343|Experimental|Phase Ib. APR-246 (35mg/kg) + Carboplatin/PLD.|Dose escalation of APR-246.
89497022|NCT02098343|Experimental|Phase II: Arm A. APR-246 + Carboplatin/PLD.|Experimental
89497023|NCT02098343|Active Comparator|Phase II: Arm B. Carboplatin/PLD.|Active Comparator
89497024|NCT02098343|Experimental|Phase Ib. APR-246 (50mg/kg) + Carboplatin/PLD.|Dose escalation of APR-246.
89497025|NCT02098343|Experimental|Phase Ib. APR-246 (67.5mg/kg) + Carboplatin/PLD.|Dose escalation of APR-246.
89497026|NCT02176369|Experimental|vinorelbine|50 mg three times a week for a three weeks cycle
89497027|NCT02176369|No Intervention|Close observation/Best Supportive Care|Close observation/Best Supportive Care (BSC)
89497028|NCT02176603||Patients with Phenylketonuria|Patients with Phenylketonuria due to phenylalanine hydroxylase deficiency
89497029|NCT02176603||Control group|Control group of healthy volunteers
89497030|NCT02716805|Experimental|Cohort 1|"Subjects received Prevnar-13 on Day -33 ± 2 days, tremelimumab (75 mg) on Day -31, leukopheresis on ~Day -10, melphalan (200 mg/m^2) on Day -2, ASCT on Day 0, and reinfusion of PBLs and tremelimumab (75 mg) on Day 3. Late post-ASCT treatment comprised Prevnar-13 on Days 30 and 60, tremelimumab (75 mg) on Day 100 ± 10 days and Day 128 (Cycles 1 and 2), followed by up to 6 cycles of durvalumab (1500 mg) on Day 1 of Cycles 3 through 8."
89022834|NCT06186960|Experimental|Tandem Virtual Reality Experience|Tandem VR Intervention After the surveys are completed, the researchers will share a personalized library of immersive, nature-based, 360-degree VR experiences for the participant-caregiver dyads to choose from based on their VR Intake Form. Once the dyad has determined their desired Tandem VR experience from the library, the researchers will assist the dyads in donning the VR head mounted display (HMD). The researchers will ensure the safety of both dyads while using the HMDs. The researchers will then initiate the Tandem VR experience. The duration of the Tandem VR experience will be 5-15 minutes.
89022835|NCT06186947||COVID-19 group|Patients infected by SARS CoV2 before reproductive events.
89022836|NCT06186947||Control group|Patients who were not infected by SARS CoV2 before reproductive events.
89022837|NCT06186921|Experimental|Intraligamentary injection of dexamethasone|After endodontic instrumentation and placement of temporary restoration, the patients shall receive Intraligamentary injection of dexamethasone
89022838|NCT06186921|Experimental|Intraligamentary injection of diclofenac sodium|After endodontic instrumentation and placement of temporary restoration, the patients shall receive Intraligamentary injection of dexamethasone
89022839|NCT06186921|Experimental|Intraligamentary injection of 0.5% bupivacaine|After endodontic instrumentation and placement of temporary restoration, the patients shall receive Intraligamentary injection of dexamethasone
89022840|NCT06186921|Active Comparator|Intraligamentary injection of 2% lidocaine|After endodontic instrumentation and placement of temporary restoration, the patients shall receive Intraligamentary injection of dexamethasone
89022841|NCT06186908|Experimental|Healthy periodontium|The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Tubes were stored at -80ºC until the day of analysis.
89022842|NCT06186908|Experimental|Gingivitis|The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Tubes were stored at -80ºC until the day of analysis.
89022843|NCT06186908|Experimental|Periodontitis|The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Tubes were stored at -80ºC until the day of analysis.
89022844|NCT06186895|Experimental|Dexmedetomidine group|Group D, received an intravenous loading dose of DEX (1 μg/kg) over 15 minutes prior to the anesthetic induction. Following the intubation procedure, a maintenance infusion of DEX was delivered at a rate of 0.6 μg/kg/h. The infusion was discontinued upon trocars removal
89022845|NCT06186895|Active Comparator|Fentanyl group|Group F were administered fentanyl (1 μg/kg) that was given intravenously slowly over 60 seconds before induction of anesthesia as a loading dose. Following intubation, a continuous infusion of fentanyl was administered at a rate of 1μg/kg/hr. The infusion was discontinued upon the removal of the trocars.
89022846|NCT06186882|Experimental|ENVIRONMENTAL STIMULATION|
89022847|NCT06186869|Active Comparator|Aerobic Exercise and Mediterranean Diet|Subjects randomized and assigned to this intervention group will follow the low glycaemic index Mediterranean diet and simultaneously perform 180 minutes of moderate-intensity aerobic exercise per week for 4 months. Intervention type: aerobic exercise and Mediterranean diet.
89022848|NCT06186869|Active Comparator|HITT and Mediterranean Diet|Subjects randomized and assigned to this intervention group will follow the low glycaemic index Mediterranean diet and simultaneously perform 150 minutes per week of high-intensity interval exercise (HITT) in the gym for 4 months. Intervention type: HIIT and Mediterranean diet.
89022849|NCT06186869|Active Comparator|Mediterranean Diet|Subjects randomized and assigned to this intervention group will follow the low-glycaemic index Mediterranean diet for 4 months. Intervention type: Mediterranean Diet.
89022850|NCT06186856||Patients|
89022851|NCT06186843|Experimental|Plant-based diet|The group will follow a plant-based diet. Compliance will be checked with dietary questionnaires.
89497031|NCT02716805|Experimental|Cohort 2|"Subjects were to receive Prevnar-13 on Day -33 ± 2 days, tremelimumab (75 mg) on Day -31, leukopheresis on ~Day -10, melphalan (200 mg/m^2) on Day -2, ASCT on Day 0, and reinfusion of PBLs and tremelimumab (75 mg) on Day 3. Early post-ASCT treatment comprised Prevnar-13 on Days 30 and 60, tremelimumab (75 mg) on Days 30 through 40 and Day 100 ± 10 days (Cycles 1 and 2), followed by up to 6 cycles of durvalumab (1500 mg) on Day 1 of Cycles 3 through 8."
89497032|NCT02716805|Experimental|Cohort 3|"Subjects were to receive Prevnar-13 on Day -33 ± 2 days, tremelimumab (75 mg) + durvalumab (1500 mg) on Day -31, leukopheresis on ~Day -10, melphalan (200 mg/m^2) on Day -2, ASCT on Day 0, and reinfusion of PBLs and tremelimumab (75 mg) on Day 3. Late post-ASCT treatment comprised Prevnar-13 on Days 30 and 60, tremelimumab (75 mg) + durvalumab (1500 mg) on Day 100 ± 10 days and Day 128 (Cycles 1 and 2), followed by up to 6 cycles of durvalumab (1500 mg) on Day 1 of Cycles 3 through 8."
89497033|NCT02716805|Experimental|Cohort 4|"Subjects were to receive Prevnar-13 on Day -33 ± 2 days, tremelimumab (75 mg) + durvalumab (1500 mg) on Day -31, leukopheresis on ~Day -10, melphalan (200 mg/m^2) on Day -2, ASCT on Day 0, and reinfusion of PBLs and tremelimumab (75 mg) on Day 3. Early post-ASCT treatment comprised Prevnar-13 on Days 30 and 60, tremelimumab (75 mg) + durvalumab (1500 mg) on Days 30 through 40 and Day 100 ± 10 days (Cycles 1 and 2), followed by up to 6 cycles of durvalumab (1500 mg) on Day 1 of Cycles 3 through 8."
89497034|NCT02174263|Experimental|Supportive care (tocilizumab)|Patients receive tocilizumab IV over 1 hour every 2 weeks for 12 weeks (weeks 1, 3, 5, 7, 9, and 11) and then every 4 weeks for 12 weeks (weeks 13, 17, and 21).
89497035|NCT04152473|Experimental|Proglumide|Open labelled proglumide treated
89497036|NCT02174497||Control|Three day Bowel Preparation
89497037|NCT02174497||Study Arm|One day Bowel Preparation
89497038|NCT02143193|Experimental|Skin to Skin Contact|implement mother-baby Skin-to-Skin contact immediately after vaginal birth
89497039|NCT02143193|No Intervention|Standard of Care|standard care for newborn and mother immediately after vaginal birth
89497040|NCT02178865||translocation carrier|balanced translocation carriers who have undergone IVF
89497041|NCT02178943||Heart Transplant Recipients|Heart allograft recipients undergoing scheduled surveillance visits that are part of a long-term management plan.
89497042|NCT01955915||Choroidal Tumor Group|15 patients diagnosed with small posterior choroidal tumors will be considered and evaluated for enrollment into this study
89497043|NCT02581982|Experimental|Treatment (pembrolizumab, paclitaxel)|Patients receive pembrolizumab IV over 30 minutes on day 1 and paclitaxel IV over 60 minutes on day 1 and 8. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity.
89497044|NCT03537469|Experimental|CTU Mega 20 real device|A single-session of real CTU Mega 20 on the corresponding primary right-hand motor area, using the real (magnetic field = 2 Tesla; intensity = 90 J; frequency of impulses = 7Hz; duration = 15 minutes) CTU Mega 20 device. This real stimulation provided a Low Frequency-Pulsed Electromagnetic Fields (LF-PEMFs).
89497045|NCT03537469|Sham Comparator|CTU Mega 20 sham device|A single-session of sham CTU Mega 20 on the corresponding primary right-hand motor area (magnetic field = 0 Tesla; intensity = 0 J; frequency of impulses = 7Hz; duration = 15 minutes). The sham stimulation did not provide a Low Frequency-Pulsed Electromagnetic Fields (LF-PEMFs).
89497046|NCT02143271|Experimental|KHK7580|
89022852|NCT06186830||Patients with temporomandibular disorder|
89022853|NCT06186817|Active Comparator|Manual Therapy based Fascial Distortion Model|All participants were given manual therapy based on the Fascial Distortion Model in addition to conventional therapy (Rocabado's 6x6 Exercises and Patient Education). Conventional therapy was implemented as a home program for 8 weeks, while Manual Therapy was conducted for forty-five minutes once a week in a clinical setting.
89497047|NCT05141617|Experimental|Endoscopic treatment group|Patients in the endoscopic treatment group receive endoscopic variceal ligation and N-butyl-cyanoacrylate according to the type of varices.
89497048|NCT05141617|Experimental|TIPS group|Patients in the TIPS group receive transjugular intrahepatic portosystem stent-shunt.
89497049|NCT02143349|Experimental|Coleus forskohlii extract|Ingestion of 250 mg capsle (Coleus forskohlii extract) twice a day for 12 weeks
89497050|NCT02143349|Placebo Comparator|Placebo|Ingestion of 250 mg capsule (placebo) twice a day for 12 weeks
89497051|NCT02174653|Active Comparator|EPs® 7630|"Active Comparator 20 mg EPs® 7630 film-coated tablet~During the common cold free period: One film-coated tablet (20 mg) three times a day~During a common cold episode: Two film-coated tablets (1 x 20 mg and 1x placebo) three times a day (in the morning, midday and evening; total daily dose 60 mg) over the individual treatment duration of 14 consecutive days."
89497052|NCT02174653|Active Comparator|EPs(R) 7630|"Active Comparator 20 mg EPs® 7630 film-coated tablet~During the common cold free period: One film-coated tablet (20 mg) three times a day~During a common cold episode: Two film-coated tablets (2 x 20 mg = 40 mg) three times a day (in the morning, midday and evening; total daily dose 120 mg) over the individual treatment duration of 14 consecutive days."
89497053|NCT02174653|Placebo Comparator|Placebo|"During the common cold free period: One film-coated tablet (placebo) three times a day~During a common cold episode: Two film-coated tablet (placebo) three times a day (in the morning, midday and evening) over the individual treatment duration of 14 consecutive days."
89497054|NCT02143427|Experimental|Social Skills Training|Social Skills Training child-focused and subsequent social competence training which combines patient- and parent-/teacher and peer-focused interventions
89497055|NCT02143427|Active Comparator|Treatment Program with techniques to activate resources|Treatment Program with techniques to activate resources of the child and subsequent Social Skills Training child-focused
89497056|NCT02176681|Active Comparator|Insulin alone|Use the usual frequency and dose
89497057|NCT02176681|Experimental|Insulin and Vildagliptin|vildagliptin 50 mg/day during 3 months
89497058|NCT02143505|Experimental|Ca plus vit D|elemental calcium 1200mg/d plus vitamin D3 250 IU/d daily supplements for 3 years
89497059|NCT02143505|Placebo Comparator|placebo|identical-appearing placebo supplements for 3 years
89497060|NCT02179099|Experimental|BTX mixed with TC-3 Gel|Patients will be treated with a single intravesical instillation of 40 ml TC-3 gel mixed with 300U BTX
89497061|NCT02254577|Experimental|Endometrin® plus Progesterone in Oil (PIO)|Subjects in all arms will undergo the standard monitoring appointments and therapies involved in a frozen embryo transfer cycle. Patients randomized to the Endometrin® plus PIO arm will take progesterone as 2 100mg tablets of Endometrin® inserted vaginally twice daily. In addition, on the first day of Endometrin® therapy, patients randomized to this arm will take a 50mg intramuscular injection (1mL) of PIO and will repeat this injection every third day. Patients in this arm will undergo Frozen Embryo Transfer on the fifth day of Endometrin® therapy.
89497062|NCT02254577|Active Comparator|Progesterone in Oil (PIO) Alone|Subjects in all arms will undergo the standard monitoring appointments and therapies involved in a frozen embryo transfer cycle. Patients randomized to the PIO Only arm will take progesterone as a daily 50mg intramuscular injection (1mL) of PIO and will undergo Frozen Embryo Transfer on the sixth day of taking this medication.
89497063|NCT02176759|Experimental|Regular FePP|Rice (50g dry weight) fortified with 4mg regular FePP
89497064|NCT02176759|Experimental|Regular FePP with citrate added during extrusion|Rice (50g dry weight) fortified with 4mg regular FePP and citrate added during the extrusion process
89497065|NCT02176759|Experimental|Regular FePP with citrated added at consumption|Rice (50g dry weight) fortified with 4mg regular FePP and citrate shortly added before consumption
89497066|NCT02176759|Active Comparator|Ferrous sulphate|Rice (50g dry weight) fortified with 4mg ferrous sulphate
89497067|NCT02030275|Experimental|RXI-109|Treatment with RXI-109 on one side of revised scar and a placebo comparator on the other side. Treatment to begin either immediately or 2 weeks following the scar revision surgery.
89497068|NCT02030275|Placebo Comparator|Placebo|Treatment with RXI-109 on one side of revised scar and a placebo comparator on the other side. Treatment to begin either immediately or 2 weeks following the scar revision surgery.
89497069|NCT06010667||EBC|cyclophosphamide and bevacizumab in combination with Envafolimab
89497070|NCT06010667||BC|cyclophosphamide in combination with Envafolimab
89497071|NCT06010654|Experimental|Experimental Group|The general treatment of the standard treatment method and the test device that provides self-talk training based on acceptance and commitment therapy (ACT) are used concurrently for 10 weeks.
88955371|NCT06328582|Experimental|routine treatment+Acupuncture Technique for Restoring Consciousness Combined with Scalp Acupuncture|The experimental group was given routine treatment. Moreover, the experimental group will receive Acupuncture Technique for Restoring Consciousness.
88955372|NCT06328582|Active Comparator|routine treatment|The experimental group was given routine treatment.
88955373|NCT06328569|Experimental|Virtual Reality group|conventional dysphagia treatment and Virtual Reality Therapy are provided
88955374|NCT06328569|Active Comparator|conventional dysphagia treatment group|conventional dysphagia treatment is provided
88955375|NCT06328556|Experimental|Injectable Type A Botulinum Toxin|This group will be given Left cricopharyngeal muscle botulinum toxin injection, Injectable Type A Botulinum Toxin (National Medical Products Administration Approval Number S10970037) 100 unit, diluted with 1ml of 0.9% sodium chloride solution for injection and kept ready for use. Only once.
88955376|NCT06328543|Experimental|1st pruritogen|The subproject is conducted in 1 session (approx. 3 hours in total) divided into two parts. In the first part, 3 test areas (3x3 cm) will be selected on one forearm of the subject. The 3 areas will be randomly treated with 1 application of cowhage, 2 applications of cowhage (the second application will be conducted 90 seconds after the first one in the same area), and 2 applications of cowhage (the second application will be conducted 180 seconds after the first one in the same area). Itch will be monitored using a VAS (visual analog scale) for 15 min in each session. After the removal of cowhage, FLPI, alloknesis, and mechanically evoked itch will be measured.
88955377|NCT06328543|Experimental|2nd pruritogen|The second part will be conducted 20 minutes after the first part, and the procedure will be the same, but using histamine instead of cowhage. The two parts will be randomized between subjects.
88955378|NCT06328530|Experimental|1st pruritogen|"The subproject consists of 2 sessions 3 days apart. Each session consists of 3 parts.~In the first session, 3 test areas (4x4 cm) will be selected on the subject's forearms. In part 1, we will apply cowhage in one area. In part 2, we will apply cowhage in two areas on the same arm. In part 3, we will again apply cowhage in 2 areas, one on each arm. In each part, the itch intensity will be measured using a VAS (visual analog scale) for 10 min from the cowhage application. After removal of the cowhage, alloknesis and mechanically evoked itch will be measured in the area selected in part 1."
88955379|NCT06328530|Other|2nd pruritogen|The second session will take place 3 days after the first one and will follow the same procedure as session 1. However, histamine will be applied instead of cowhage. The order of the two sessions will be randomized.
88955380|NCT06328517||Patients with cirrhosis|Abdominal ultrasound, CT, or MRI showed Cirrhosis during the screening period; Fibroscan results during the screening period were> 17.5kPa.
88955381|NCT06328504|Experimental|Cashew Immunotherapy|Children with cashew allergy receiving OIT.
88955382|NCT06328504|No Intervention|Cashew avoidance|Children with cashew allergy not receiving OIT.
88955383|NCT06328491|Experimental|Erdafitinib in metastatic steroid-cell tumor of the ovary|Erdafitinib, 8 mg, orally, once daily. Dose increase to 9 mg once daily may be considered based on serum phosphate levels and tolerability.
88955384|NCT06328465|Experimental|DWB-MRI|Surveillance with diffusion whole body MRI
88955385|NCT06328439|Experimental|ANS014004|"Dosage: 1. Dose-escalation participants receive ANS014004 single dose on Day 1, if DLT does not occur within the 7-day elution period, subjects will begin multiple doses on Day 8 and receive ANS014004 QD (once daily) for a 28-day cycle. 2, Backfill, Dose Extension Subjects, who go directly to multiple dosing, will receive ANS014004 QD (once daily) for 28 days as a cycle.~Dosing Schedule: 1. Dose-escalation subjects, single dosing + multiple dosing, 35-day cycle. 2, Backfill, dose-expansion subjects, direct access to multiple dosing, 28 days to a cycle."
88955386|NCT06328426|Active Comparator|Vtamin D and omega-3.|First arm will be treated with vitamin D and omega-3.
88955387|NCT06328426|Active Comparator|vitamin D and metformin|: Second arm will be treated with vitamin D and metformin.
88955388|NCT06328426|Placebo Comparator|Placebo|Third arm will be treated with placebo.
88955389|NCT06328413|Experimental|Photobiomodulation group|Photobiomodulation application at different extra and intraoral points for 60 seconds with a wavelength of 940 nm in repeated sessions after the extraction of third molar
88955390|NCT06328413|Active Comparator|Leukocyte and platelet-rich fibrin group|Leukocyte and platelet rich fibrin ( blood product centrifuged for 12 minutes at 2700rpm) application after third molar extraction, single session.
88955391|NCT06328400|Experimental|Deuremidevir Hydrobromide for Suspension 900mg group, twice a day|9 subjects will receive Deuremidevir Hydrobromide for Suspension 900mg, orally, Q12h, 5.5 days; 3 subjects will receive Deuremidevir Hydrobromide for Suspension Placebo 900mg, orally, Q12h, 5.5 days.
88955392|NCT06328400|Experimental|Deuremidevir Hydrobromide for Suspension 900mg group, 3 times a day|9 subjects will receive Deuremidevir Hydrobromide for Suspension 900mg, orally, Q8h, 5.5 days; 3 subjects will receive Deuremidevir Hydrobromide for Suspension Placebo 900mg, orally, Q8h, 5.5 days.
88955393|NCT06328400|Experimental|Deuremidevir Hydrobromide for Suspension 1200mg group, twice a day|9 subjects will receive Deuremidevir Hydrobromide for Suspension 1200mg, orally, Q12h, 5.5 days; 3 subjects will receive Deuremidevir Hydrobromide for Suspension Placebo 1200mg, orally, Q12h, 5.5 days.
88955394|NCT06328387|Other|Sacituzumab Govitecan|Sacituzumab Govitecan (SG) is given by intervenous route, 10 mg/kg on day 1 and day 8 of 21-day treatment cycles. Patient will receive treatment until disease progression, unacceptable toxicity, or decision to withdraw its participation.
88955395|NCT06328387|Experimental|Hydroxychloroquine Combined With Sacituzumab Govitecan|"The dosage of hydroxychloroquine is determined based on the dose escalation study, and the appropriate administration method will be determined based on this result.~Sacituzumab Govitecan (SG) is given by intervenous route, 10 mg/kg on day 1 and day 8 of 21-day treatment cycles. Patient will receive treatment until disease progression, unacceptable toxicity, or decision to withdraw its participation."
88955396|NCT06328387|Other|Trastuzumab Deruxtecan|Patients will receive T-DXd at 5.4 mg/kg administered as an intravenous (IV) infusion every three-weeks (Q3W) until disease progression, unacceptable toxicity, death, or discontinuation from the study.
88955397|NCT06328387|Experimental|Hydroxychloroquine Combined With Trastuzumab Deruxtecan|"The dosage of hydroxychloroquine is determined based on the dose escalation study, and the appropriate administration method will be determined based on this result.~Patients will receive T-DXd at 5.4 mg/kg administered as an intravenous (IV) infusion every three-weeks (Q3W) until disease progression, unacceptable toxicity, death, or discontinuation from the study."
89205404|NCT05462132|Experimental|Cohort 5|"HV subjects receive doses 1 × 10^12 live cells of SYNB1353 and 30 mg/kg of methionine.~Subjects will receive a single dose of SYNB1353 on the first day of dosing (Day 1), on Days 2 and 3 subjects will receive up to 2 doses of IMP (BID), and on Days 4 to 7 subjects will receive up to 3 doses of IMP (TID).~A methionine loading study will be performed on Day -1 and Day 7 after an overnight fast. A dose of methionine of 30 mg/kg will be evaluated."
89497072|NCT06010654|No Intervention|Control Group|Treatment as usual (TAU) is a standard treatment for 10 weeks, which is the clinical trial period.
89497073|NCT06010602|Active Comparator|Quadratus lumborum block group|the patient In the lateral decubitus position, a subcostal area and above the iliac crest in the mid-axillary line, a convex ultrasound probe is placed under sterile conditions. Using an in-plane technique, the quadratus lumborum and psoas major muscles, as well as the transverse process of the L4 vertebra, are visualized. 22G, 100 mm peripheral block needle is used to perform the block. The needle is directed between the quadratus lumborum muscle and the psoas major muscle in the subfascial plane, following hydrodissection for proper needle placement. Then, 20 mL of 0.25% bupivacaine is injected slowly, aspirating every 5 cc to ensure proper spread. The injection is performed under ultrasound guidance, visualizing the local anesthetic pushing the fascia. The same procedure will be repeated for the other side.
89497074|NCT06010602|Active Comparator|İlioinguinal-İliohipogastric nerve block group|the patient in the supine position, a linear ultrasound probe is placed over the spina iliaca anterior superior (SIAS) line, drawn from SIAS to the umbilicus. The probe is used to visualize the abdominal wall muscles, focusing on the fascial plane between the transversus abdominis and internal oblique muscles, where a flattened football-like appearance is seen. The iliohypogastric nerve is observed more laterally, and the ilioinguinal nerve is seen more medially. Using an in-plane technique with 22G, 100 mm peripheral block needle, local anesthetic is injected near the SIAS, between the transversus abdominis and internal oblique muscles. Again, 20 mL of 0.25% bupivacaine is injected slowly, aspirating every 5 cc, and the injection is visualized under ultrasound guidance, ensuring proper fascial spread. The same procedure will be repeated for the other side.
89497075|NCT06010485|Active Comparator|Serial Casting|The serial casting group received intermittent serial casting once every three days for three weeks.
89497076|NCT06010485|Active Comparator|Exercise|The physical therapy group underwent three sessions per week for three weeks, consisting of stretching exercises, strengthening exercises, balance training, proprioception exercises, and walking on heels.
89497077|NCT06010485|No Intervention|Control Group|This group consists of the patients on the waitlist.
89497078|NCT06010381|Active Comparator|Muscle energy technique|This group includes 15 patients who received muscle energy technique post-surgery in addition to traditional shoulder exercise, 3 sessions/week for four weeks.
89497079|NCT06010381|Active Comparator|Maitland mobilization|This group includes 15 patients who received mobilization in addition to traditional shoulder exercise, 3 sessions/week for four weeks.
89497080|NCT06010342|Experimental|Single arm, Open label|Participants will receive TL118 capsule taken orally with (preferred) or without food, 252 mg twice daily, 28 days for a cycle.
89497081|NCT06010290||Parkinsonism patients|This group/cohort comprises clinically diagnosed as Parkinsonism, including Parkinson's disease and atypical Parkinsonism syndromes, and each participant is injected 18F-SMBT-1 (185-370Mbq) and underwent PET/CT scanning within 50-70 min after injection.
89497082|NCT06010290||Health control|Each participant is injected 18F-SMBT-1 (185-370Mbq) and underwent PET/CT scanning within 50-70 min after injection.
89497083|NCT06010277|Experimental|Folinic acid arm|Patients in the intervention-arm will receive oral folinic acid orally 4 times 45mg / day for 3 days, starting 24 hours after the administration of pemetrexed.
89497084|NCT06010277|No Intervention|No folinic acid arm|Patients will be treated according to regular care.
89497085|NCT06010264|Experimental|Kinesiotaping group|Kinesiotaping + Standard Physiotherapy Program
89497086|NCT06010264|Active Comparator|Control group|Standard Physiotherapy Program
89497087|NCT06010264|Sham Comparator|Shamtape Group|Shamtaping + Standard Physiotherapy Program
89497088|NCT06010238|Active Comparator|Visual interpretation of cardiotocography|Monitoring by visual interpretation of cardiotocography
89497089|NCT06010238|Experimental|Short term variation|Short term variation by computer software analysis
89497090|NCT06010225||ERAS group|Patients who met the inclusion criteria and consented were assigned to the ERAS group
88955400|NCT06328361|Experimental|Nonoperative management|The patients presenting with complete clinical response undergo nonoperative management (i.e. watch & wait) as surveillance for local regrowth or distant spread.
88955401|NCT06328348|Experimental|supplementation group|
88955402|NCT06328348|Placebo Comparator|placebo group|
89497091|NCT06010225||control group|Patients who met the inclusion criteria and did not consent were assigned to the ERAS group
89497092|NCT06010212|Experimental|Treatment group|Fruquintinib,Camrelizumab, Paclitaxel liposome combined with nedaplatin
88955403|NCT06328335|Experimental|Comprehensive rehabilitation training+Rise-bed Training|"Assigned by the random number table. During the treatment, all patients were provided with comprehensive rehabilitation therapy as follows:~Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
88955404|NCT06328335|Active Comparator|Comprehensive rehabilitation training|"Assigned by the random number table. During the treatment, all patients were provided with comprehensive rehabilitation therapy as follows:~Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
89497093|NCT06010134|Experimental|Control Group|Group 1 the control group received selected physical therapy program which contain strengthening exercises for upper limb and lower limb muscles, stretching exercises for elbow extensors, hand pronator, wrist extensors, knee extensors and ankle dorsiflexors, coordination and balancing exercises.
89497094|NCT06010134|Experimental|Study group|Group 2 the study group received the same physical therapy program 15 min. plus Whole Body Vibration for 15 min.
89497095|NCT06010082|Experimental|STUDY GROUP|Intervention group Group one (study group, 40 pregnant women): received Music Therapy intervention.
89497096|NCT06010082|Active Comparator|Control group|Group two(the control group, 40 pregnant women):act as a control group/ waiting list
89497097|NCT06010069||pre-frail patients|That patient group have clinical frailty scale scores 1,2 or 3 which is accepted as non-frail.
89497098|NCT06010069||frail patients|That patient group have clinical frailty scale scores 4 or 5 which is accepted as frail.
89497099|NCT06010069||very frail patients|That patient group have clinical frailty scale scores 6,7,8 or 9 which is accepted as severly frail.
89497100|NCT06010056|Experimental|Group A|PCA ketamine (Ketamine HCl, Pfizer Inc., US) 0.5 mg plus morphine 0.5 mg ml-1 (ratio 1:1) as postoperative analgesia.
89497101|NCT06010056|Active Comparator|Group B|PCA morphine (Pfizer Inc., US) 1 mg ml-1 as postoperative analgesia.
89497102|NCT06009978|Active Comparator|Additional treatment with NMES after Achilles Tendon rupture|"Neuromuscular electrical stimulation 2 times a day á 15 minutes during the week 3-8 after the Achilles Tendon rupture.~Patients will also follow ordinary standard rehabilitation for Achilles Tendon rupture"
89497103|NCT06009978|No Intervention|Control group|Patients will follow ordinary standard rehabilitation for Achilles Tendon rupture
89497104|NCT06009965|Experimental|Severe aplastic anemia group|CsA: 3-5 mg/kg/day, monitor trough concentration monthly, maintain trough concentration at 100-200 ng/ml.ATG: rabbit anti-thymocyte immunoglobulin (r-ATG) 3 mg/kg/d x 5 days or porcine anti-lymphocyte immunoglobulin ((p-ATG) 25 mg/kg/d x 5 days.TPO-RA: Heptapepto-Papa 7.5 mg qd to start. Monitor blood every 2 weeks and if ineffective, increase by 1 tablet every 2 weeks up to a maximum of 6 tablets (15mg) qd.
89497105|NCT06009965|Experimental|Non-severe aplastic anemia group|CsA: 3-5 mg/kg/day, monitor trough concentrations monthly, maintain trough concentrations at 100-200 ng/ml.TPO-RA: Start with Hetropoxyphene 7.5 mg qd, monitor blood every 2 weeks, and if ineffective, increase by 1 tablet every 2 weeks up to a maximum of 6 tablets (15 mg) qd.
89497106|NCT06009952|Experimental|Group A|•Group A will receive cryolipolysis with vegan diet,
89497107|NCT06009952|Experimental|Group B|Group B will receive cavitation with vegan diet
88955405|NCT06328309|Experimental|Rehabilitation treatment+Myofascial Release Therapy|Study lasts 21 days for each patient. All patients are given rehabilitation treatment.The experimental group was given the Myofascial Release Therapy, five days a week, once a day, for 30-60 minutes each time.
88955406|NCT06328309|Active Comparator|Rehabilitation treatment|Study lasts 21 days for each patient. All patients are given rehabilitation treatment, five days a week, once a day, for 30-60 minutes each time.
88955407|NCT06328296|Experimental|Rehabilitation treatment+Myofascial Release Therapy|Study lasts 15 days for each patient. All patients are given rehabilitation treatment.The experimental group was given the Myofascial Release Therapy, five days a week, once a day, for 30-60 minutes each time.
88955408|NCT06328296|Active Comparator|Rehabilitation treatment|Study lasts 15 days for each patient. All patients are given rehabilitation treatment, five days a week, once a day, for 30-60 minutes each time.
88955409|NCT06328283||cases group|cirrhotic patients with early hepatocellular carcinoma
89497108|NCT06009952|Experimental|Group C|Group C will receive vegan diet only.
89497109|NCT06009913|Experimental|online teaching|Teaching was done completely online
89497110|NCT06009913|Active Comparator|Conventional class room|Teaching was done completely offline in classroom
89497111|NCT06009900|Active Comparator|Non-steroidal drug (Celecoxib) group|Oral Celecoxib 200mg/time, twice a day, for three consecutive weeks.
89497112|NCT06009900|Experimental|Weak laser treatment group|Low intensity laser treatment: Both patients and doctors wear goggles during the irradiation process. Using 810nm (infrared)/658nm (red) dual wavelength output for direct skin contact point irradiation, the maximum output power is 100mW (red)/60mW (infrared). Select the treatment site based on the patient's anatomical positioning (muscle and tendon attachment points, nerve distribution aggregation points) and/or pain points, and perform spot laser irradiation. Low intensity laser treatment process: Treat once a day for 15 minutes each time, with 5 consecutive days of treatment and 2 days of rest per week. The patient received a total of 3 weeks (15 times) of low intensity laser treatment.
89497113|NCT06009887|Experimental|Experimental: İntervention Group|Motivational interviewing is a counseling approach that pays special attention to the language of change, adopts a collaborative, goal-oriented communication style and aims to strengthen personal motivation and commitment to this change, revealing and discovering the reasons for the change in one's own, in an atmosphere of acceptance and empathy.
89497114|NCT06009887|No Intervention|No Intervention: Control Group|No interventions were made for those in the control group other than routine hospital practices.
89497115|NCT06009874|Active Comparator|Dapagliflozin group|patients with MI will be treated with DAPA 10 mg once daily for three months.
89497116|NCT06009874|Placebo Comparator|Placebo group|patients with MI will be treated with a matching placebo once daily for three months.
89531787|NCT05357716||Arm A|Up to 40 patients will be enrolled in Arm A. Subjects will wear the HeartWatch and an Event Recorder for up to 72 hours. Subjects will be asked to document their activities (standing, sitting, walking, exercise, or laying down). Event recorder subjects will collect user-triggered and auto-triggered data.
88955410|NCT06328283||control group|cirrhotic patients with no hepatocellular carcinoma
89497117|NCT06009861|Experimental|Neoadjuvant Tislelizumab plus chemotherapy and adjuvant RT or Tislelizumab plus CCRT|"Neoadjuvant phase: Patients will receive neoadjuvant Tislelizumab in combination with Albumin-Bound Paclitaxel and Cisplatin Q3W for 2 cycles.~Adjuvant phase:~For High-risk group(non-R0 resection or extranodal extension (ENE) or Lymph node metastasis>5): Concurrent chemoradiotherapy followed by Tislelizumab Q3W for 14 cycles.~For the other group: intensity-modulated radiation therapy."
89497118|NCT06009848|Experimental|Cadonilimab (AK104) combined with Nab -Paclitaxel|Cadonilimab (10 mg/kg, administered on the first day of each cycle, Q3W, until there is no clinical benefit)+Nab-Paclitaxel(200 mg/m2, Q3W, 6cycles), every 3 weeks (21 days) is a treatment cycle
89497119|NCT06009835||Treatment group based on DOTr/DOTA detection result|Develop a final treatment plan based on DOTr/DOTA test results, MTB consultation expert opinions, and drug accessibility
89497120|NCT06009822||Patients with Medial Patellofemoral Ligament reconstruction|"Must have undergone unilateral medial patellofemoral ligament (MPFL) reconstruction.~At least 2 years post MPFL reconstruction surgery. Absence of patellar instability subsequent to the surgical procedure. Exclusion of patients with any orthopedic or neurological issues that might impact functionality, except for those who have undergone unilateral MPFL reconstruction."
89497121|NCT06009809||Heart Surgical Patients|Patients with cardiovascular disease, who must undergo cardiac surgery in extracorporeal circulation with continuous flow
89497122|NCT06009796|Active Comparator|Full Coverage Rapid Palatal Expansion (FCRPE) group:|Impressions were taken from the maxilla using alginate to obtain study models. In the obtained study model, a 10 mm hyrax expansion screw (Dentarum®, Germany) was placed at the midline as close to the palate as possible and parallel to the occlusal plane. The vestibular, occlusal, and palatal surfaces of all maxillary teeth are covered in acrylic, and this acrylic support extends toward the median palatal suture in the palatal region. Under pressure, the acrylic appliance was polymerized.
89497123|NCT06009796|Active Comparator|Modified McNamara Rapid Palatal Expansion (MMRPE) Group:|Impressions were taken from the maxilla using alginate to obtain study models. In the obtained study model, a 10 mm hyrax expansion screw (Dentarum®, Germany) was placed at the midline as close to the palate as possible and parallel to the occlusal plane. The vestibular, occlusal, and palatal surfaces of the posterior maxillary teeth are covered in acrylic, and this acrylic support extends toward the median palatal suture in the palatal region. Under pressure, the acrylic appliance was polymerized.
89497124|NCT06009796|Active Comparator|Miniimplant Assisted Rapid Palatal Expansion (MARPE) Group|The MARPE appliance was composed of a central expansion jackscrew (Dentarum), 4 tubes, 2 bands on the upper first molars to facilitate placement of the appliance, and 1.5-mm diameter stainless steel arms extending to the premolar teeth. Soldered stainless steel tubes (internal diameter: 2.0 mm; external diameter: 3.0 mm; length: 2.0 mm) served as guides for miniscrew placement. The size of the screws (PSM) was chosen as 1.8 mm in diameter and 11 mm in length, considering the 2 mm height of the tubes, 1 to 2 mm gap between the appliance and the palate surface, 1 to 2 mm gingiva thickness, and 5 to 6 mm length required for the bicortical placement of the screw in the bone.
89497125|NCT06009796|No Intervention|Control Group|A control group in the same age, without maxillary constriction was also added to our study.Polygraphy for respiratory evaluation, rhinomanometry for nasal airway resistance were used. Polygraphy and rhinomanometry measurements were obtained at the beginning of the follow-up and at the end of the 4-month follow-up period.
89497126|NCT06009783|Experimental|Intervention arm - ChatGPT|Patient's interested in participating in the intervention group will be provided a secure ChatGPT account. They will have the opportunity to converse with ChatGPT to ask any potential questions they may have regarding their upcoming vasectomy. Patient's will then be seen for the standard pre-vasectomy consultation.
89497127|NCT06009783|No Intervention|Control arm - no ChatGPT|No intervention - standard of care
88955411|NCT06328270|Active Comparator|Study Group|The group received a 3-week intra-articular injection of 15 mg/ml ozone.
88955412|NCT06328270|Active Comparator|Control Group|The group received a 1 ml intra-articular injection of betamethasone
89497128|NCT06009770|Experimental|Telerehabilitation|"The TR intervention for people with PD, MS, and people post-stroke will be focused on addressing impairments and functional limitations that affect activities and participation in everyday life.~Frequency: 5 weeks (4 sessions/week) of TR intervention provided according to a mixed model (3 asynchronous sessions + 1 synchronous, in-clinic session/week);~Intensity: customized according to the patient's functional abilities (system's feedback);~Time: 50 minutes/session;~Type: according to the disease, TR protocols with a digital system (for MS and PD) or robotic tool (for post-stroke)."
89497129|NCT06009770|Active Comparator|Usual Care|Conventional rehabilitation exercises at home, customized according to the disease.
89497130|NCT06009744|Sham Comparator|Vit C y zinc bajo|Parenteral nutrition + Vitamin C 100-300 mg/d y zinc 3-5 mg/d
89497131|NCT06009744|Active Comparator|Vit C and zinc alto|Parenteral nutrition + Vitamin C 1000-2000 mg/d y zinc 10-15 mg/d
89497132|NCT06009731||adult patients undergoing mechanical ventilation|
89497133|NCT06009718||Model training group|Compare the results of PCG and ECG with UCG, and conduct model training analysis
89497134|NCT06009718||Model validation group|Compare the results of PCG and ECG with UCG, and conduct model validation analysis
89497135|NCT06009692|Experimental|Upper Limb Neurodynamics Group|Upper limb Neuro-dynamics (Slider/Tensioner Technique) along with Task Oriented Training
89497136|NCT06009692|Active Comparator|Upper Limb Conventional Therapy|Stretching, Strengthening exercises along with Task Oriented Training
89497137|NCT06009679|Experimental|Intervention group|The intervention group will include patients with suspected postpartum RPOC that will receive treatment with Misoprostol, 600 microgram SL/PO/PV
89497138|NCT06009679|No Intervention|Control group|The control group will include women with suspected postpartum RPOC per ultrasound examination that will undergo conservative follow-up with ultrasound for a period of 6-12 weeks postpartum
89497139|NCT06009666||Patient Group|Both Extremities of Patients With Breast Cancer Related Lymphedema
89497140|NCT06009666||Control Group|Both Extremities of Healthy People With No History of Breast Cancer
89497141|NCT06009627|Experimental|Dalcelli+Goserelin+Exemestane|SD patients undergoing 2 cycles of preoperative treatment were randomly assigned to Group A and received darcelli, Exemestane, and Goserelin
89497142|NCT06009627|Active Comparator|Docetaxel, epirubicin hydrochloride, Cyclophosphamide|SD patients undergoing 2 cycles of preoperative treatment were randomly assigned to Group B and received TAC chemotherapy
89497143|NCT06009601||Patients aged 3-18 years who were diagnosed with pectus deformity|Pectus study forms consisting of clinical and radiological measurements of patients aged 3-18 years who applied to the outpatient clinic with chest deformity will be filled in in detail.
89497144|NCT06009588|Experimental|Self-expandable valve group|Patients using self-expandable valves
89497145|NCT06009588|Experimental|Balloon-expandable valve group|Patients using balloon-expandable valves
89497146|NCT06009575|Experimental|intervention group|
89497147|NCT06009575|Active Comparator|control group|
89497148|NCT06009536|Experimental|Resistance training protocol|Participants in this group will complete a 12-week ankle dorsiflexion resistance training protocol according to Silbernagel. It is a series of heel rise exercises with a gradual progression of load according to defined criteria, which the patient practices every day.
89497149|NCT06009536|No Intervention|Participants with healthy tendons|"Participants in this group are considered healthy based on subjective judgment followed by clinical and ultrasound examination of the Achilles tendon.~In this group, no specific treatment will be performed, only Achilles tendon will be monitored through time."
89497150|NCT06009497|Experimental|Romiplostim+CsA|"Romiplostim 10 µg/kg, subcutaneous injection, once a week, for at least 3 months. Patients with platelet count ≥50×109/L can stop using, and continue to use with platelet count < 50×109/L.~Ciclosporin 3-5mg/kg/d, adjust the dose to keep trough ciclosporin plasma concentration 100-200ng/ml. Ciclosporin should be used for at least 6 months to evaluate the efficacy. Effective patients will continue to use ciclosporin for at least 1.5 years, followed by a slow reduction."
89497151|NCT06009497|Experimental|CsA|Ciclosporin 3-5mg/kg/d, adjust the dose to keep trough ciclosporin plasma concentration 100-200ng/ml. Ciclosporin should be used for at least 6 months to evaluate the efficacy. Effective patients will continue to use ciclosporin for at least 1.5 years, followed by a slow reduction.
89497152|NCT06009471|Active Comparator|Control group|All participants were treated with routine treatment in Neurology.
89497153|NCT06009471|Experimental|Experimental group|"All participants were treated with routine treatment in Neurology and rTMS treatment.~rTMS parameters were set to stimulate the site: bilateral primary motor cortex; Stimulus frequency :5Hz; Pulse number: 1000 pulses per day, 500 on the left and 500 on the right; Stimulus intensity :90% resting threshold; Coil: 70mm round coil; Once a day, 30 minutes each time, 5 days a week for 4 weeks"
89531788|NCT05357716||Arm B|Up to 10 patients will be enrolled in Arm B.Subjects will wear the HeartWatch and Holter monitor for up to 48 hours. Subjects will be asked to document their activities (standing, sitting, walking, exercise, or laying down). Holter subjects will record diary information on their activities and any relevant symptoms.
89531789|NCT05351827|Experimental|Mild Intermittent Hypoxia|This arm of the protocol will receive mild intermittent hypoxia (8% Oxygen) with end-tidal carbon dioxide maintained 1-3 millimeters of mercury above baseline, while in the laboratory. If diagnosed with sleep apnea, participants will be treated with continuous positive airway pressure for the duration of the intervention.
88955413|NCT06328257|Experimental|Myofascial Release Training|The elderly individuals will be arranged to undergo a continuous three-week (21 days) duration of Myofascial Release Training, with weekends off and training conducted only on weekdays, two sessions per day, each lasting 15-30 minutes. Each training session will be conducted approximately one hour prior to meals. Apart from this,we require participants to only engage in daily activities and avoid strenuous and dangerous behaviors
88955414|NCT06328244|Experimental|Systematic simple swallowing training|The elderly individuals will be arranged to undergo a continuous three-week (21 days) duration of systematic simple swallowing training, with weekends off and training conducted only on weekdays, two sessions per day, each lasting 15-30 minutes. Each training session will be conducted approximately one hour prior to meals. Apart from this,we require participants to only engage in daily activities and avoid strenuous and dangerous behaviors
88955415|NCT06328231|Experimental|Systematic simple swallowing training|The elderly individuals will be arranged to undergo a continuous three-week (21 days) duration of systematic simple swallowing training, with weekends off and training conducted only on weekdays, two sessions per day, each lasting 15-30 minutes. Each training session will be conducted approximately one hour prior to meals. Apart from this,we require participants to only engage in daily activities and avoid strenuous and dangerous behaviors
88955416|NCT06328218|Experimental|Simple Gymnastics Training|The elderly individuals will be arranged to undergo a continuous three-week (21 days) duration of Simple Gymnastics Training, with weekends off and training conducted only on weekdays, two sessions per day, each lasting 30 minutes. Each training session will be conducted approximately at 9.00 a.m. Apart from this,we require participants to only engage in daily activities and avoid strenuous and dangerous behaviors
88955417|NCT06328205|Experimental|Rehabilitation therapy+Glossopharyngeal Nerve Block|The study lasts 10d for each patient. During the treatment, All the participants are provided with the rehabilitation therapy. Based on this, the patients in the experimental group are provided with Stellate Ganglion Block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g), once a day.
88955418|NCT06328205|Placebo Comparator|Rehabilitation therapy+placebo injection|The study lasts 10d for each patient. During the treatment, All the participants are provided with the rehabilitation therapy.
89497154|NCT06009458|Other|Acuity 200™ (fluoroxyfocon A) Orthokeratology Contact Lens for Overnight Wear|For the orthokeratology treatment the subjects will be instructed to wear the study lenses each night during the hours of sleep (for a minimum of 6 hours) and remove the lenses during the waking hours. The subject will be examined at 1 day, 1 week, 1 month, 3 months, 6 months, 9 months and 12 months after dispensing to evaluate the ocular physiology and the treatment effect. The target refractive error (sphere) will be plano for all subjects. All subjects enrolled at two of the investigational sites (targeted total of 40 subjects) will be evaluated for the stability of UCVA and manifest refraction throughout a single day on or following the 3 month, 6 month, or 9 month follow up visits. A post-treatment follow-up visit will be scheduled 1 month following discontinuation of the study lens. When it has been determined that no additional follow up visits are required, the subject will be discharged from the study.
89497155|NCT06009445||AKI group|"Acute kidney injury (AKI) was defined according to the Kidney Disease Improving Global Outcome (KDIGO) classification using both creatinine and urine output criteria.~The KDIGO guidelines define AKI as follows:~Increase in serum creatinine by ≥0.3 mg/dL (≥26.5 micromol/L) within 48 hours, or~Increase in serum creatinine to ≥1.5 times baseline, which is known or presumed to have occurred within the prior seven days, or~Urine volume <0.5 mL/kg/hour for six hours"
89497156|NCT06009445||Non AKI group|Patients who will no develop Acute kidney injury (AKI).
89497157|NCT06009393|Experimental|SHR-1918|
89497158|NCT06009367|Experimental|Investigated group with fascial manipulation|Participants in this group received one treatment of fascial manipulation by Stecco method
89497159|NCT06009367|No Intervention|Control group with no intervention|Participants in this group received no treatment
89497160|NCT06009250||CKD patients|CKD patient who are not DM are investigated for the presence of NAFLD
89497161|NCT06009250||normal control group|normal population are investigated to know the prevalence of NAFLD in contrast to patients with CKD.
89497162|NCT06009224|No Intervention|Conventional|Conventional ERAS program
89497163|NCT06009224|Experimental|Experimental|complete ERAS program (Conventional ERAS program + Epidural analgesia + Fluid balance)
89497164|NCT06009211||Aromatherapy|Randomized crossover research study
89497165|NCT06009198|Experimental|Advance Education with Iron Folate Supplement|"Nutrition education~WASH education~Micronutrient supplementation"
89497166|NCT06009198|No Intervention|Routine Education|Routine school education
89497167|NCT06009146||Rutherford scale < 4|
89497168|NCT06009146||Rutherford scale 4-5|
89497169|NCT06009146||Rutherford scale 6|
89497170|NCT06009042|Experimental|IVIG 20g/d|Participants will receive IVIG (intravenous immunoglobulin) 20g/d for 6 days. They also receive conventional liquid therapy and symptomatic supportive treatment.
89497171|NCT06009042|Active Comparator|IVIG 10g/d|Participants will receive IVIG (intravenous immunoglobulin) 10g/d for 6 days. They also receive conventional liquid therapy and symptomatic supportive treatment.
89497172|NCT06009029|Experimental|SBRT Combined With Zimberelimab|Patients diagnosed with locally advanced pancreatic cancer are treated with SBRT combined with Zimberelimab
89497173|NCT06008925|Experimental|Single Arm|"Part1:~VG161:~1) 1.0 × 10 ^ 8 PFU daily on Day 1 of each cycle (D1); 2)1.0 × 10 ^ 8 PFU daily for 2 consecutive days on Days 1-2 of each cycle (D1-D2); 3)1.0 × 10 ^ 8 PFU daily for 3 consecutive days on days 1-3 (D1-D3) in the first cycle; 1.0 × 10 ^ 8 PFU daily for 2 consecutive days on days 1-2 (D1-D2) in the second and subsequent cycles; Nivolumab Injection: 3 mg/kg every 2 weeks (D8, D22)~Part2:~Depends on the recommended dose in Part1"
89497174|NCT06008899|Active Comparator|ultrasound (US) assisted caudal epidural pulsed radiofrequency|
89497175|NCT06008899|No Intervention|conventional medical treatment|
89497176|NCT06008873||One group only|No intervention.
89497177|NCT06008847||Lower Gastrointestinal Symptoms|Participant aged over 18 with referred lower gastrointestinal symptoms
89497178|NCT06008769|Experimental|12 Week Manualized Cognitive-Behavioral Therapy Intervention|Participants will receive a once-per-week, 12 week manualized cognitive-behavioral therapy intervention.
89497179|NCT06008743|Experimental|All subjects|All subjects (healthy and stroke survivors) participating in the study
89497180|NCT06007157|Experimental|SGLT2i-treated patients|
89497181|NCT06007157|Active Comparator|Non SGLT2i-treated patients|
89497182|NCT06005792|Experimental|Plaque Psoriasis|
89497183|NCT06005792|Experimental|Atopic Dermatitis|
89497184|NCT06005298|No Intervention|AUDIT <8|Participants whose audit score is less than eight are assigned to this arm. AUDIT is a 10-item screening tool developed by the World Health Organization (WHO) to assess alcohol consumption, dependence, and experience of alcohol-related harm. AUDIT <8 is non-hazardous.
89497185|NCT06005298|Experimental|AUDIT >8 + SBIRT|This is an experimental arm, and AUDIT >8 is hazardous. The goal is to make connections on the impact of the SBIRT intervention on PrEP engagement and alcohol use among the participants to create a full picture of the impact of the intervention on groups exhibiting different types of alcohol use.
89497186|NCT06005298|No Intervention|AUDIT > 8 NO SBIRT|This is NOT an experimental arm, despite an AUDIT score > 8.
89497187|NCT06005142|Active Comparator|Eriomin/Placebo|Group A will receive Eriomin (250 mg/day) for 12 weeks, followed by a 2-week washout period, and then placebo (250 mg/day) for 12 weeks.
89497188|NCT06005142|Placebo Comparator|Placebo/Eriomin|Group B will receive placebo (250 mg/day) for 12 weeks, followed by a 2-week washout period, and then Eriomin (250 mg/day) for 12 weeks.
89497189|NCT06003504|Experimental|First aid training with blended learning approach|Participants follow a first aid training delivered through a blended learning approach.
88955419|NCT06328192|Experimental|Active Breathing Exercises|The elderly individuals will be arranged to undergo a continuous three-week (21 days) duration of Active Breathing Exercises, with weekends off and training conducted only on weekdays. Apart from this,we require participants to only engage in daily activities and avoid strenuous and dangerous behaviors.
89497190|NCT06003504|Active Comparator|First aid training with face-to-face approach|Participants follow a first aid training delivered through a conventional face-to-face approach.
88955420|NCT06328179|Experimental|VHEA regimen in the treatment of ND-AML and RR-AML with MLL gene abnormalities.|"Venetoclax 100 mg d1，200 mg d2，400 mg d3-14； homoharringtoine, HHT 2 mg/m2，qd，d1-7； Etoposide 0.1 g，qd，d1-5； Cytarabine 100 mg/m2，qd，d1-7~The patient meets the criteria for autologous hematopoietic stem cell transplantation (ASCT) during the treatment process, they can undergo ASCT.If the patient meets the criteria for transplantation and there is a suitable donor, they can undergo allogeneic hematopoietic stem cell transplantation (allo-HSCT)."
89497191|NCT06003504|No Intervention|Waitlist control|Participants do not receive any training
89497192|NCT06003088|Experimental|HSK7653(5mg) Sequence A(Formulation A + Formulation B)|Participants will receive a single oral dose of treatment 1: Formulation A followed by a washout period of at least 36 days from first dose of HSK7653(5mg). After the washout period, participants will receive a single oral dose of Treatment 2: HSK7653(5mg) Formulation B.
89497193|NCT06003088|Experimental|HSK7653(5mg) Sequence B(Formulation B + Formulation A)|Participants will receive a single oral dose of treatment 1: Formulation B followed by a washout period of at least 36 days from first dose of HSK7653(5mg). After the washout period, participants will receive a single oral dose of Treatment 2: HSK7653(5mg) Formulation A.
89497194|NCT06003088|Experimental|HSK7653(25mg) Sequence A(Formulation A + Formulation B)|Participants will receive a single oral dose of treatment 1: Formulation A followed by a washout period of at least 36 days from first dose of HSK7653(25mg). After the washout period, participants will receive a single oral dose of Treatment 2: HSK7653(25mg) Formulation B.
89497195|NCT06003088|Experimental|HSK7653(25mg) Sequence B(Formulation B + Formulation A)|Participants will receive a single oral dose of treatment 1: Formulation B followed by a washout period of at least 36 days from first dose of HSK7653(25mg). After the washout period, participants will receive a single oral dose of Treatment 2: HSK7653(25mg) Formulation A.
89497196|NCT06002997||Control Group|Healthy pregnant women
89497197|NCT06002997||Case Group|Pregnant women with Diabetes Mellitus Type 1
89497198|NCT06000605|Active Comparator|Fed|Exercise and passive infusions of ketones and lactate in the fed state. Participants will be fed a small meal in the middle of the protocol, also.
89497199|NCT06000605|Experimental|Fasted|Exercise and passive infusions of ketones and lactate in the fasted state. Participants will be required to fast for 72 hours prior to arriving to the lab for this testing arm.
89497200|NCT06000124|Experimental|Plyometric exercises training|High knee lifts, squat jumps, lunge cross jumps, squat jumping lunges, and squat jump twists are examples of plyometric exercises suitable for older adults.
89497201|NCT06000124|Active Comparator|Regulation exercises program|The regulated exercise program includes the use of elastic bands, Qigong, and dance et al.
89022854|NCT06186817|Active Comparator|Core Stabilization Training|All participants were given manual therapy based on the Core Stabilization Training in addition to conventional therapy (Rocabado's 6x6 Exercises and Patient Education). Conventional therapy was implemented as a home program for 8 weeks, while Core Stabilization Training was conducted for forty-five minutes once a week in a clinical setting.
89538167|NCT02439697|Experimental|Darbepoetin alfa (NESP®) 120mcg|Patients on Aranesp® 100 mcg preparation (darbepoetin alfa manufactured by Amgen®) will be switched to the NESP® (darbepoetin alfa manufactured by Kirin®)120mcg preparation with slight increase in dosing interval according to the conversion
89538168|NCT03285035||Non-operable esophageal cancer|Cryotherapy treatment
89538169|NCT02445313||Control|Normal, healthy participants
89538170|NCT02445313||AMD|Age-related Macular Degeneration participants
89538171|NCT03284645||ART Before or Early in Pregnancy|HIV positive pregnant women who started antiretroviral therapy (ART) before or early in pregnancy for prevention of mother-to-child transmission of HIV and for their own health.
89022855|NCT06186817|No Intervention|Control|No participant was given any therapy during the study.
89022856|NCT06186804|Experimental|ABSK021|Patients will be instructed to take a specified dose of ABSK021 at the same time each day.
89022857|NCT06186752|Experimental|MyIBD|Each participant randomized to the intervention arm (MyIBD) will receive an individually tailored MyIBD document within a week of a scheduled outpatient clinic visit. The MyIBD document will be prepared by the patient's usual, assigned nurse coordinator together with the study's clinical champion (a nurse practitioner in the IBD program). Participants will receive a copy of the MyIBD document with language suggesting that they use it to guide decisions about care in between appointments. Each participant's primary care provider will also receive a copy of the MyIBD document. The nurse coordinator will send reminder messages to intervention-group participants (using the electronic patient portal) to access and use their MyIBD document at 1-2 months, 3-4 months, 7-8 months, and 11-12 months after initial plan creation.
89538172|NCT03284645||ART Started Third Trimester|HIV positive pregnant women starting antiretroviral therapy (ART) during the third trimester of pregnancy for prevention of mother-to-child transmission of HIV and for their own health.
89538173|NCT03284645||ART Started Postpartum|HIV positive women starting antiretroviral therapy (ART) after delivery for prevention of mother-to-child transmission of HIV and for their own health.
89538174|NCT02445157||IPF_Reliability|Patients diagnosed with IPF according to NICE guidelines.
89538175|NCT03284567|Active Comparator|Football fitness|"Participants in the intervention group will practice soccer for 52 weeks two times weekly. A soccer instructor will be in charge of all training sessions. The training will consist of 30 min of warm-up exercises (running, dribbling, passing, shooting, balance and muscle strength exercises), followed by 2 x 15 minutes of 4-7 a-side games.~Training will take place on a natural grass pitch. In adverse weather conditions (i.e., < 5°C or heavy rain) training will be performed indoors. Participants will be told to avoid hard tackles and other actions that carry a risk of injury."
89538176|NCT03284567|No Intervention|Control group|Participants in the control group will receive verbal advice about the benefits of exercise and physical activity.
89538177|NCT03190447|Active Comparator|Conventional dressing|The conventional dressing (sterile gauzes) will be applied
89538178|NCT03190447|Experimental|Aquacel Surgical®|Postoperative sterile dressing composed by non-woven inner pad (in contact with wound) Technology Hydrofiber® formed from sodium carboxymethylcellulose
89538179|NCT03190447|Experimental|Mepilex Border post-op®|Flexible absorbent all-in-one post-op dressing, super-absorbent fibres for high and fast absorption with optimised retention.
89538180|NCT03190447|Experimental|Opsite post-op visible®|Adhesive dressing with absorbent foam in the form of a grid to visualize the wound without lifting the dressing
89538181|NCT03190447|Experimental|Urgotul ABSORB border silicona®|A soft-adherent TLC (Technology Lipido-Colloid) layer (polymers and hydrocolloid particles) combined with an absorbent polyurethane foam pad and a highly absorbent layer. A vapour permeable waterproof outer film with silicone adhesive on the edges.
89538182|NCT03284489||ICU patients|Patients with pancreatitis
89497202|NCT05999123||All Participants|Up to 150 participants will be enrolled at one or more clinical research sites in the United States. Participants will be healthy, menstruating individuals between 18 to 42 years of age who meet all eligibility criteria.
89497203|NCT05996159|Experimental|vHPSD ablation only for PVI|Pulmonary vein encirclement is achieved using contiguous applications of very high power and short duration (90 W over 4 seconds). The inter-lesion distance is set at 3-4mm for the roofs and anterior segments, and 5-6mm for other segments. If the esophageal temperature rises > 38 for segments near the esophagus, encirclement will be applied at 25 W for 15 seconds.
88955421|NCT06328166|Experimental|recombinant human fibroblast growth factor 1 (ES135)|Ultrasound-guided injection with recombinant human fibroblast growth factor 1 (ES135) between carpal tunnel and median nerve.
88955422|NCT06328166|Placebo Comparator|normal saline|Ultrasound-guided injection with normal saline between carpal tunnel and median nerve.
88955423|NCT06328153|Experimental|FSN group|Fu's subcutaneous needling (FSN) is a new type of acupuncture. Patients in the FSN Group only received FSN treatment, without other interventions such as oral drugs or topical drugs.
88955424|NCT06328153|Active Comparator|Drug Group|Celecoxib is a member of Nonsteroidal Antiinflammatory Drugs (NSAIDs) and the most commonly used treatment for knee osteoarthritis. Patients in the drug group received only oral celecoxib, no other oral or topical drugs, and no other physical therapies.
89497204|NCT05996159|Experimental|vHPSD and AI-guided ablation for PVI|"At the anterior segments, pulmonary vein encirclement is achieved through contiguous applications using AI-guided ablation (40-50 W, AI target 500, and an inter-lesion distance of 4mm).~In the other segments, pulmonary vein encirclement is achieved through contiguous applications using very high-power and short-duration techniques (90 W over 4 seconds, inter-lesion distance of 3-4mm; if the segments are near the esophagus, encirclement will be applied at 25 W for 15 seconds)."
89497205|NCT05996159|Experimental|AI-guided ablation only for PVI|Pulmonary vein encirclement is achieved through contiguous applications using AI-guided ablation (40-50 W, AI target 500 for anterior segments and 400 for other segments, with an inter-lesion distance of 4mm; if the segments are near the esophagus, encirclement will be applied at 25 W for 15 seconds)
89497206|NCT05995327||spine degenerative disease|patients with spine degenerative disease
89497207|NCT05995327||spine tumor|patients with spinal tumors
89497208|NCT05995327||spine deformity|patients with spinal deformity
89497209|NCT05995327||spine fracture|patients with spine fracture
89497210|NCT05992467|Experimental|WECARE|Participants will first complete a baseline survey online, then subscribe to the WECARE official account on their own WeChat accounts and begin receiving the 7-week interactive and personalized program. The program content includes short video clips, pictorial messages, and audio recordings. Each week, the WECARE program is focused on a theme aimed to increase participants' caregiving mastery, enhance self-care, and improve psychosocial wellbeing. Four weeks after the intervention or 11 weeks after the baseline, participants will complete a follow-up survey online.
89497211|NCT05991843|Experimental|Study cohort|"The cohort of healthy volunteers, who will breath at three different respiratory rates, as guided by normal, slowly and rapid."
89497212|NCT05988346||type 2 diabetes mellitus (T2DM) obese patients without left ventricle (LV) diastolic dysfunction.|
89497213|NCT05988346||T2DM obese patients with first degree of left ventricle (LV) diastolic dysfunction.|
89497214|NCT05988346||T2DM obese patients with second degree of left ventricle (LV) diastolic dysfunction.|
89497215|NCT05981352|Active Comparator|Mineral trioxide aggregate (positive control group)|": according to the manufacturing instructions as following:~After achieving hemostasis, Mineral trioxide aggregate powder will be mixed with saline.~Then Mineral trioxide aggregate will be placed directly on the pulp stumps."
89497216|NCT05981352|Experimental|Dehydrated amniotic membrane group|"After achieving hemostasis, a double layer of sterile processed human allograft tissue (dehydrated dual-layer dental amnion patch) will be trimmed and soaked in saline for a minute.~Dehydrated amniotic membrane will be Placed directly on the pup stumps using sterile tweezers and adjusted to the entire floor of the pulp chamber."
89497217|NCT05981352|Experimental|Hyaluronic acid group|• After achieving hemostasis, pulp stumps will be covered with a mixture of Hyaluronic acid gel and zinc oxide powder with consistency (1:1 ratio by volume) .
89497218|NCT05978752|Active Comparator|A|The patients will undergo endoscopic gel embolization of gastric fundus varices and esophageal varices ligation.
89497219|NCT05978752|Active Comparator|B|The patients will undergo endoscopic gel embolization of gastric fundus varices and sclerotherapy of esophageal varices.
89497220|NCT05978752|Experimental|C|The patients will undergo endoscopic gelatinization of gastric varices (esophageal varices were not treated).
89497221|NCT05969327|No Intervention|with out vitamin D|neonates without supplementation
89497222|NCT05969327|Experimental|Vitamin D 400 IU|neonates with 400 IU supplementation
89497223|NCT05969327|Experimental|Vitamin D 800 IU|neonates with 800 IU supplementation
89497224|NCT05958030|No Intervention|No Interventional|Participants will perform protocol-specific tasks with no device
89497225|NCT05958030|Experimental|Investigational Device Arm|GyroGlove
89497226|NCT05958030|Placebo Comparator|Placebo Arm|Placebo
89497227|NCT05957627|Experimental|Saleem's intervention|Early tenotomies and serial casting were used in Saleem's technique to reduce foot deforming forces. It involved 2 principal tenotmies and 2 accessory tenotmies. Principal tenotmies include tendo achillies and planter fascia release. 2 Accessory tenotmies include tibialis posterior and abductor hallucis. All tenotmies are done under local anesthesia.The foot is placed in a serial cast close to its natural anatomical position following tenotomies at first visit. children are evaluated after 1 week.This technique necessitates 4 to 5 casts on average. DB shoes were advised when the foot casting was finished, and a 6-month follow-up with the patient was conducted.
89022858|NCT06186752|No Intervention|Usual Care|Each participant randomized to the control group will receive usual care in the pediatric IBD program. They will be eligible to receive a MyIBD document after completing the study (12 months after enrollment).
89497228|NCT05952999||Hospital at Home Care|The population for this study includes adult patients who are acutely ill and presenting to the emergency room, and are discharged to their home for hospital-level care in the home setting. The patients in this cohort may also include those who are discharged from the hospital early, but receive hospital-level care in the home setting.
89497229|NCT05952999||Traditional Hospital Care|The population for this study includes adult patients who are acutely ill and presenting to the emergency room who elect not to be discharged, choose to be cared for in the hospital setting.
89497230|NCT05949515||Minneapolis Heart Institute|
89497231|NCT05949515||The Feinstein Institutes for Medical Research|
89497232|NCT05949515||NCH Baker Downtown Hospital|
89497233|NCT05949515||OhioHealth Research Institute|
89497234|NCT05949515||Baptist Health Baptist Hospital|
89497235|NCT05949515||St. Mary's Medical Center|
89497236|NCT05949515||Corewell Health William Beaumont University Hospital - Research Institute|
89497237|NCT05949515||University of Chicago Medicine|
89497238|NCT05945901|Experimental|HR070803|HR070803 plus oxaliplatin, 5-FU/LV, bevacizumab
89497239|NCT05945901|Placebo Comparator|HR070803 simulator|HR070803 simulator plus oxaliplatin, 5-FU/LV, bevacizumab
89497240|NCT05943548|Experimental|Omuyambi Traditional Healer (TH) Intervention|The traditional healer (TH) clusters randomized to the intervention arm will refer consented people living with HIV to a predetermined government-run HIV clinic for the provision of care. The patients that are in this arm will receive, adherence support for PLWH using a TH-tailored curriculum as an adjunct to clinic-based HIV care. These participants will also receive one-on-one counselling to improve self-efficacy, be provided social support, and will work with THs to develop individualized adherence strategies.
89205405|NCT05462132|Experimental|Cohort 6|"HV subjects receive doses 1 × 10^12 live cells of SYNB1353 and up to 100 mg/kg of methionine.~Subjects will receive a single dose of SYNB1353 on the first day of dosing (Day 1), on Days 2 and 3 subjects will receive up to 2 doses of IMP (BID), and on Days 4 to 7 subjects will receive up to 3 doses of IMP (TID).~A methionine loading study will be performed on Day -1 and Day 7 after an overnight fast. A dose of methionine of up to 100 mg/kg will be evaluated."
89205406|NCT05462132|Experimental|Cohort 7|"HV subjects receive doses less than or equal to 2 × 10^12 live cells of SYNB1353 and 30 mg/kg of methionine.~Subjects will receive a single dose of SYNB1353 on the first day of dosing (Day 1), on Days 2 and 3 subjects will receive up to 2 doses of IMP (BID), and on Days 4 to 7 subjects will receive up to 3 doses of IMP (TID).~A methionine loading study will be performed on Day -1 and Day 7 after an overnight fast. A dose of methionine of 30 mg/kg will be evaluated."
89497241|NCT05943548|Placebo Comparator|Control Arm|The traditional healer (TH) clusters randomized to the control arm will refer consented people living with HIV to a predetermined government-run clinic for the provision of care. The patients in this arm will receive no additional linkage or psychosocial support.
89497242|NCT05926609|Active Comparator|EB-PA|One capsule to be taken after breakfast once a day for 30 days
89497243|NCT05926609|Placebo Comparator|Placebo|One capsule to be taken after breakfast once a day for 30 days
89497244|NCT05923164||Breast Cancer Patients|Patients who had undergone breast cancer surgery, aged between 18-75 years-old
89497245|NCT05920642|Experimental|Intrathecal morphine administration|Study subjects randomized into this arm will be administered morphine intrathecally in the dose of dose 100 ug.
89497246|NCT05920642|Active Comparator|Parenteral administration of analgesics|Study subjects randomized into this arm will receive standard postoperative pain management (parenteral administration of analgesics).
89497247|NCT05920005|Experimental|Association of candesartan cilexetil 16mg + chlorthalidone 12.5mg + amlodipine 5mg|The participant will take, once a day, 01 tablet of the active experimental drug (association candesartan cilexetil 16mg + chlorthalidone 12.5mg + amlodipine 5mg), plus 01 placebo, both orally.
89497248|NCT05920005|Active Comparator|Exforge HCT® (valsartan 160mg + hydrochlorothiazide 12.5mg + amlodipine 5mg)|The participant will take 01 tablet of Exforge HCT® active comparator (valsartan 160mg + hydrochlorothiazide 12.5mg + amlodipine 5mg) plus 01 placebo, both orally.
89497249|NCT05918796|Active Comparator|bupivacaine|ultrasound guided quadratus lumborum perineural injection of 18 ml bupivacaine (0.25%) combined with 2 ml normal saline bilaterally.
89497250|NCT05918796|Active Comparator|bupivacaine and dexamethasone|ultrasound guided quadratus lumborum perineural injection of 18 ml bupivacaine (0.25%) combined with 2ml volume of dexamethasone (8mg) bilaterally.
89497251|NCT05916131|Experimental|Hypoglycemia Symptom Detection Training|To provide Hypoglycemia Symptom Detection Training intervention.
89497252|NCT05916131|Experimental|Education Plus|To provide Education Plus intervention.
89497253|NCT05916131|Experimental|Hypoglycemia Symptom Detection Training and Education Plus|To provide both Hypoglycemia Symptom Detection Training and Education Plus interventions simultaneously.
89497254|NCT05916131|Other|Usual Care|Continuing usual care after basic education.
89497255|NCT05899231|Experimental|Prehabilitation Group|The prehabilitation group will be provided with access to the online digital web platform which contains the weekly acceptance and commitment therapy based education videos, nutrition intervention, and exercise intervention.
89497256|NCT05899231|No Intervention|Usual Care|This group will receive standard care for LT candidates with cirrhosis and will be provided with standard online exercise, nutrition, and behavioural resources. Control participants will not receive access to the online digital platform.
89497257|NCT05899023|Experimental|Telehealth Bridge Visits|Patients in the experimental arm will receive post-emergency department telehealth bridge visits to connect ED patients with newly diagnosed diabetes to outpatient primary care.
88955425|NCT06328140||Lurasidone Treatment|"Patients with bipolar disorder or psychotic disorders for whom lurasidone is a US Food and Drug Administration (FDA)-approved treatment.~Patients will be treated with a daily dose of 40-80 mg./day for schizophrenia and 30-60 mg./day for bipolar disorder."
88955426|NCT06328140||Treatment as usual for major depression|Patients with major depression will received treatment with antidepressant treatments that are approved by the US FDA for treatment of major depression. All dosing will be required to be consistent with the FDA approved package insert.
89497258|NCT05899023|Active Comparator|Control|Patients in the control arm will receive standard of care.
89497259|NCT05853185|Experimental|Pro Root MTA®|Patients in this group will receive the pulpotomy with Pro Root MTA®.
89497260|NCT05853185|Active Comparator|EBRRM®|Patients in this group will receive the pulpotomy with Endosequence Bioceramic Root Repair Material (EBRRM)®.
89497261|NCT05851378|Experimental|Cohort 1: Hyperpolarized Carbon-13 Alpha-ketoglutarate (HP 13C-aKG)|Cohort 1 will be comprised of 10 participants with Isocitrate dehydrogenase (IDH) mutant glioma who may or may not have received prior treatment for optimizing imaging protocol. Participants will be injected with 0.67ml/kg actual body weight of 100 millimolar (mM) of α-KG solution and have a single imaging scan.
89497262|NCT05851378|Experimental|Cohort 2: Hyperpolarized Carbon-13 Alpha-ketoglutarate (HP 13C-aKG)|Cohort 2 will be comprised 30 participants with recurrent IDH mutant glioma before receiving surgical resection. Participants will be injected with 0.67ml/kg actual body weight of 100 millimolar (mM) of α-KG solution and have a single imaging scan.
89497263|NCT05846698||control group|
89497264|NCT05846698||treatment group|
89497265|NCT05838794|Active Comparator|Mckenzie exercise for neck|Participants in the McKenzie exercise for neck group will receive a six-week exercise program that includes the McKenzie exercise protocol for neck pain. The program will consist of three 30-45 minute sessions per week, for a total of 18 sessions over six weeks. The exercises will be performed under the supervision of a physiotherapist in the outpatient clinic. The McKenzie exercise protocol for neck pain involves a series of movements that aim to reduce pain and improve range of motion in the cervical spine. The exercises are tailored to each participant's individual needs and may include sustained postures, repeated movements, and mobilization techniques. Participants will be instructed to perform the exercises at home as well, as part of a home exercise program, to ensure that they are performing the exercises correctly and consistently. Participants in this group will not receive any additional stabilization exercises.
88955427|NCT06328127|Experimental|Positive Affect in the Transplantation of Hematopoietic Stem Cells (PATH)|"Participants recruited from the Dana-Farber Cancer Institute, Duke Cancer Institute, and Moffitt Cancer Center who are randomized to the intervention/experimental arm will receive the PATH intervention, which is focused on gratitude, strengths, and meaning, as well as focused exercises on goal-setting and tracking daily physical activity.~Participants will complete questionnaires (in person, over the computer or telephone, or by mail) at predetermined days per protocol."
88955428|NCT06328127|No Intervention|Usual Care|"Participants recruited from the Dana-Farber Cancer Institute, Duke Cancer Institute, and Moffitt Cancer Center who are randomized to the usual care arm will receive their usual support from the HSCT team, including all routine supportive care resources (e.g., support from social work) offered by the HSCT team.~Participants will complete questionnaires (in person, over the computer or telephone, or by mail) at predetermined days per protocol."
88955429|NCT06328114|Active Comparator|TMS to premotor cortex|Participants receive TMS at premotor cortex
88955430|NCT06328114|Active Comparator|TMS to primary somatosensory cortex|Participants received TMS sessions at primary somatosensory cortex
88955431|NCT06328114|Sham Comparator|TMS at low amplitude to primary somatosensory cortex|Participants receive TMS at a cortical target at smaller amplitude
88955432|NCT06328101||AIP_mlg|Autoimmune pancreatitis patients with cancer
88955433|NCT06328101||AIP_nomlg|Autoimmune pancreatiits patients without cancer
88955434|NCT06328101||general population|"Cancer Incidence in Five Continents Volume XI (CI5XI) registry patients used to determine expected cancer incidence and calculate SIR"
89497266|NCT05838794|Experimental|Mckenzie ex for neck + Stabilization exercise for|Participants in the McKenzie exercises for neck with cervical and scapulothoracic stabilization exercises group will receive a six-week exercise program that includes the McKenzie exercise protocol for neck pain and cervical and scapulothoracic stabilization exercises, performed under the supervision of a physiotherapist in the outpatient clinic. The program consists of three 30-45 minute sessions per week for a total of 18 sessions over six weeks. Participants will perform the McKenzie exercise protocol for neck pain first, followed by cervical and scapulothoracic stabilization exercises. Stabilization exercises aim to improve strength, endurance, and neuromuscular control of the cervical and scapulothoracic muscles. Participants will be instructed to perform the exercises at home as part of a home exercise program to ensure proper technique and consistency. This group receives both the McKenzie exercise protocol for neck pain and cervical and scapulothoracic stabilization exercises.
89497267|NCT05835271|Experimental|exoskeleton assist|A powered exoskeleton describes a wearable robot designed around the shape and function of the human body with segments and joints externally coupled to those of the user. The exoskeleton includes a belt frame, sensors that detect a user's desired movements, a computerized controller, motors and actuators, and lightweight batteries.
89497268|NCT05816798|Experimental|Photobiomodulation Intervention|"PBM therapy sessions will be performed with the Therapy EC device (DMC brand) 100mW power, which is a Low Intensity Laser Therapy. During the interventions, the patient will be allowed to choose the position that is most comfortable for him and accompanied by the physical therapist throughout the procedure. Examiner and patient will be wearing protective eyewear. Applications will occur after local asepsis of the device and skin. Patients will receive the PBM therapy described below:~Paravertebral region at levels L3 to S2:1 cm lateral to the corresponding level, on each right and left side, which are root levels that innervate the knee joint (totaling 10 paravertebral points) with 3 Joules per point (30 s) in each point~Knees bilaterally (4 points each knee): anteromedial portal; anterolateral portal; apex of patella; base of patella; with 4 J per point (40 s)"
88955435|NCT06328088||Non vegetarian diet|Non vegetarian diet
88955436|NCT06328088||Vegetarian diet|Vegetarian diet
88955437|NCT06328075||Transthyretin cardiac amyloidosis (ATTR-CM)|Patients with an ATTR-CM and undergoing a transthoracic echocardiography
88955438|NCT06328075||Controls|Patients without cardiac amyloidosis undergoing transthoracic echocardiography as part of cardiological follow-up
88955439|NCT06328062|Experimental|Mirogabalin|Participants will receive 5 mg of mirogabalin, taken as half a tablet, every day twice a day, after breakfast and dinner, for 6 weeks.
88955440|NCT06328062|Active Comparator|Pregabalin|Participants will receive 50 mg of pregabalin, taken as a tablet, every day twice a day, after breakfast and dinner, for 6 weeks.
88955441|NCT06328049|Experimental|Trilaciclib plus chemotherapy|"Patients with lung adenocarcinoma were treated with Trilaciclib (240mg/m2, d1, within 4 hours before each chemotherapy) combined with pemetrexed and carboplatin (dose according to the guideline recommendation, d1, Q3W). For squamous lung cancer, Trilaciclib (d1, 240mg/m2, 4 hours before each chemotherapy) plus paclitaxel/albumin-bound paclitaxel plus carboplatin (dose according to guideline recommendation, d1), Q3W. In the second cycle, patients were left to their own discretion with or without treaclib combination therapy."
88955442|NCT06328036|Experimental|GROUP A (neoadjuvant atezolizumab, tiragolumab)|Patients receive atezolizumab IV over 60 minutes and tiragolumab IV over 20-75 minutes and 14-19 days later, undergo surgical resection. Following surgery, patients may receive tiragolumab IV and atezolizumab IV on day 1 of each cycle. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo MRI at baseline, 24-72 hours after surgery, then every 9 weeks until progression and blood sample collection throughout the study.
88955443|NCT06328036|Experimental|GROUP B (neoadjuvant tiragolumab)|Patients receive tiragolumab IV over 20-75 minutes and 14-19 days later, undergo surgical resection. Following surgery, patients may receive tiragolumab IV and atezolizumab IV on day 1 of each cycle. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo MRI at baseline, 24-72 hours after surgery, then every 9 weeks until progression and blood sample collection throughout the study.
88955444|NCT06328036|Experimental|GROUP C (neoadjuvant atezolizumab)|Patients receive atezolizumab IV over 60 minutes and 14-19 days later, undergo surgical resection. Following surgery patients may receive atezolizumab IV on day 1 of each cycle. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo MRI at baseline, 24-72 hours after surgery, then every 9 weeks until progression and blood sample collection throughout the study.
88955445|NCT06328036|Active Comparator|GROUP D (no neoadjuvant drug)|Patients undergo surgical resection on study. Following surgery patients may receive atezolizumab IV on day 1 of each cycle. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo MRI at baseline, 24-72 hours after surgery, then every 9 weeks until progression and blood sample collection throughout the study.
89497269|NCT05816798|Placebo Comparator|Photobiomodulation Placebo|Control group research participants will receive the standard treatment described as well as placebo PBM treatment to mask the treatment. The number of points, dose and PBM application site will be the same as described in the PBM Intervention Group item, however the PBM equipment will be turned off.
89497270|NCT05806372||HDP with FGR|Evaluation of sera and ultrasound data on fetal growth and Doppler velocimetry in women with HDP and fetal growth restriction.
88955446|NCT06328010||Wound Treatment with Advanced Therapies|Only treatments with advanced therapies, post standard care (SOC) will be collected.
88955447|NCT06327997|Experimental|Fast CAR T cells|Pretreatment was given 5 days before CAR T infusion for 3 consecutive days, and CAR T cell infusion was performed on the 0th day
88955448|NCT06327958||Group 1: McGRATH-MAC Videolaryngoscope,|Cormack-Lehane (C&L) and percentage of glottic opening (POGO) scores in the airway management training of medical students.
89497271|NCT05806372||HDP without FGR|Evaluation of sera and ultrasound data on fetal growth and Doppler velocimetry in women with HDP and without fetal growth restriction.
89497272|NCT05806372||Normotensive|Evaluation of sera and ultrasound data on fetal growth and Doppler velocimetry in normotensive women.
88955449|NCT06327958||Group 2: C-MAC Videolaryngoscopy|Cormack-Lehane (C&L) and percentage of glottic opening (POGO) scores in the airway management training of medical students.
88955450|NCT06327958||Group 3: Macintosh Laryngoscope.|Cormack-Lehane (C&L) and percentage of glottic opening (POGO) scores in the airway management training of medical students.
88955451|NCT06327945|Experimental|Lung uDCD Protocol|
88955452|NCT06327932|Active Comparator|Matched control|Patients undergo Transurethral Resection of Bladder Tumors (TURBT) and receive Intravesical Chemotherapy.
88955453|NCT06327932|Experimental|HIVEC|Patients undergo Transurethral Resection of Bladder Tumors (TURBT) and Hyperthermic Intravesical Chemotherapy (HIVEC)
88955454|NCT06327919|Experimental|Intervention|"Probiotic supplementation with a weight loss program and ten one-hour online individual sessions cognitive behavioral therapy for 12 weeks.~multi-strain probiotics were used in this study. Each probiotic capsule contains Lactobacillus acidophilus, Bifidobacterium bifidum, Bifidobacterium lactis, Bifidobacterium longum, Lactobacillus reuteri, Lactobacillus rhamnosus, magnesium stearate and maltodextrin. 1.8 × 109 CFU / capsule. 2 capsules per day, for 12 weeks."
89497273|NCT05800600|Experimental|Venofer treatment|Venofer (iron-sucrose) 200mg (5 days) every week administered as an IV infusion
89497274|NCT05798559|Experimental|Intervention Group|"Sleep Training will be applied.~With the training, examples will be presented to mothers that they can apply in their daily lives.~1 month will be followed"
89497275|NCT05798559|No Intervention|Control Group|"No training will be provided~note: Sleep Training will be given after the study is completed so that the control group is not victimized."
89531790|NCT05351827|Sham Comparator|Sham|This arm of the protocol will receive sham air (21 % Oxygen) while in the laboratory. No additional gases will be employed. If diagnosed with sleep apnea, participants will be treated with continuous positive airway pressure for the duration of the intervention.
89531791|NCT05347069|Active Comparator|Aspirin|Aspirin 100 mg/day
88955455|NCT06327919|Placebo Comparator|Placebo|"Placebo supplementation with a weight loss program and ten one-hour online individual sessions cognitive behavioral therapy for 12 weeks.~The placebo capsule contains 300 mg of starch. 2 capsules per day, for 12 weeks"
89022859|NCT06186739|Experimental|home-based motor rehabilitation training participated by caregivers|The patients in this group received face-to-face learning of rehabilitation skills when they were discharged from the hospital. The main learning contents of patients are: how to carry out limb rehabilitation training at home? when to carry out rehabilitation training? and how to choose the most appropriate rehabilitation training content? Members of the rehabilitation nursing team should assist patients in setting rehabilitation goals, help patients make weekly rehabilitation plans, and distribute learning manuals and video learning materials to patients for review at home. The rehabilitation nursing team conducts online follow-up of patients every other week to assess whether patients have achieved short-term goals, adjust or add rehabilitation contents for patients, and reconfirm the intensity of home-based training of patients. answer the questions raised by the patient during the rehabilitation process at home and encourage the patient to maintain rehabilitation.
89022860|NCT06186739|Active Comparator|routine self-care group|The control group will be routinely given post-discharge health education, such as secondary prevention measures, education on medication adherence, universal guidance on the content of home care, universal rehabilitation-related education such as correct limb positioning, post-discharge precautions, and medical referral-related assistance.
89497276|NCT05788068|Experimental|Intervention Group|Participants in the intervention group will receive CBT-based digital smoking cessation intervention. The intervention is a set of smoking cessation methods based on the theoretical study of cognitive behavioral therapy for smoking cessation, and its effectiveness has been confirmed through our large sample of randomized controlled studies. This study plans to intervene smokers for 4 weeks after the start of smoking cessation.
89497277|NCT05774704|Active Comparator|Low curcumin group|
89497278|NCT05774704|Active Comparator|High curcumin group|
89497279|NCT05772351|Experimental|Experimental group|Patients of the experimental group received Detralex® 1000 mg QD for 15 days before the operation, 3000 mg starting from day 1 after the surgery for 4 days, then 2000 mg for the next 3 days and 1000 mg till day 30 after surgery
89497280|NCT05772351|No Intervention|Control group|Patients of the control group received a tablet containing starch.
89497281|NCT05745233|Experimental|Checkpoint inhibitor (nivolumab or pembrolizumab)|Patients with malignant ascites will received either nivolumab or pembrolizumab intraperitoneally.
89497282|NCT05727215|Experimental|Primary dose of inactivated (Sinovac®) vaccine|Subject who had received a complete primary dose of inactivated (Sinovac®) vaccine
89497283|NCT05725382|Experimental|NOL-guided remifentanil dosing|"Remifentanil dosing will preferentially be guided by the NOL index, but blood pressure and heart rate will be monitored and considered concurrently.~If the NOL index is > 25, remifentanil infusion will be increased.~If the NOL index is < 10 the remifentanil infusion rate will be reduced"
89497284|NCT05725382|No Intervention|Standard care remifentanil dosing|Remifentanil dosing will be administered according to standard care per institutional practice.
89497285|NCT05722288|Experimental|Arm I (time-restricted eating)|Patients undergo time-restricted eating Monday through Friday only of each week on study during standard RT or chemoRT. Patients also undergo collection of blood throughout the trial.
89497286|NCT05722288|Active Comparator|Arm II (nutritional counseling)|Patients receive nutritional counseling on study. Patients also undergo collection of blood throughout the trial.
89497287|NCT05721404|Experimental|ICO (icodextrin)|When the extracellular water /total body water (ECW/TBW) ≥ 0.40, the patients in the ICO arm will be prescribed icodextrin (Extraneal) for long night dwell to improve fluid overload till their re-measurement of ECW/TBW < 0.40.
89497288|NCT05721404|Other|CON (control)|When the extracellular water /total body water (ECW/TBW) ≥ 0.40, the patients in the CON arm will be prescribed hypertonic Dextrose solution for long night dwell to improve fluid overload till their ECW/TBW < 0.40
89497289|NCT05717270||Prospective group|Acute Achilles tendon Rupture undergoing surgical repair.
89497290|NCT05717270||comparison group|Patients group from a previous trial (NCT04263493).
89497291|NCT05710874|Experimental|CPP-ACP paste|Daily application of CPP-ACP (Casein phosphopeptide amorphous calcium phosphate) paste (Tooth Mousse®) in addition to twice daily use of conventional toothpaste.
89497292|NCT05710874|Experimental|CPP-ACPF paste|Daily application of CPP-ACPF (Casein phosphopeptide amorphous calcium phosphate in combination with fluoride) paste (MI Paste Plus®) in addition to twice daily use of conventional toothpaste..
89497293|NCT05710874|Experimental|1.25% fluoride gel|Weekly application of 1.25% fluoride gel (Elmex Medical Gel®) in addition to twice daily use of conventional toothpaste.
89497294|NCT05710874|Placebo Comparator|Conventional|Twice daily use of conventional toothpaste.
89497295|NCT05690373|Experimental|Probiotic|2B Colony Forming Unit/ day
89497296|NCT05690373|Placebo Comparator|Placebo|Equivalent placebo
89497297|NCT05684289|Experimental|Part 1: BMS-986278 + Sildenafil|
89497298|NCT05684289|Placebo Comparator|Part 1: Placebo + Sildenafil|
89497299|NCT05684289|Experimental|Part 2: BMS-986278|
89497300|NCT05684289|Placebo Comparator|Part 2: Placebo|
89497301|NCT05681962||Standard Oxygen Therapy (SOT)|Patients receiving low oxygen flow administration through nasal prongs, oxygen mask with or without reservoir, and Venturi mask.
89497302|NCT05681962||High Flow oxygen through Nasal Cannula (HFNC)|Administration of high flows (up to 60 L/min) of air/oxygen admixtures, heated (at temperatures ranging from 31 to 37°C) and fully humidified (up to 44 mg H2O/L), providing an inspired oxygen fraction ranging from 21 to 100%
89497303|NCT05681962||Continuous Positive Airway Pressure (CPAP)|application of positive end-expiratory pressure (PEEP) throughout the whole respiratory cycle by means of interfaces such as mask or helmet
89497304|NCT05681962||Non-Invasive Ventilation (NIV)|application of a PEEP by means of a mask or helmet, with an inspiratory pressure support triggered by the patient and delivered by a ventilator and through interfaces such as mask or helmet
89497305|NCT05681962||Invasive Mechanical Ventilation (iMV)|application of a ventilatory assistance in controlled or partial assisted modalities through an endotracheal or tracheostomy tube
89497306|NCT05681949|No Intervention|Participants' cases discussed in tumor conference without ADBoard|Participants' cases are discussed in tumor conference without the use of ADBoard, according to conventional practice.
89497307|NCT05681949|Experimental|Participants' cases discussed in tumor conference with ADBoard|Participants' cases will be evaluated by ADBoard directly before they are discussed in the tumor conference.
89022861|NCT06186713||Pulmonary hypertension (PH) group|The PH group comprised of patients with systolic pulmonary artery pressure (sPAP) ≥ 35mmHg measured by echocardiology.
89022862|NCT06186713||Control group|The control group included patients with systolic pulmonary artery pressure (sPAP) <35mmHg measured by echocardiology.
89022863|NCT06186674||normal|normal persons
89022864|NCT06186674||low back pain|patients with low back pain
89022865|NCT06186661|Experimental|Experimental Group|The Experimental group was applied a total of 2 hours-exercise programs consisting of 1-hour-neurophysiological exercise and 1-hour cognitive rehabilitation
89022866|NCT06186661|Active Comparator|Control Group|The Control Group was implemented only 1-hour neuropsychological exercise program.
89022867|NCT06186648|Experimental|Glofitamab + Obinutuzumab|cf Intervention
89022868|NCT06186635|Experimental|Traditional yoga group|This group will practice traditional yoga for an average of 2 hours, preferably once a week, for 12 weeks.
89022869|NCT06186635|Experimental|AI-Assisted Yoga|This group will practice AI-assisted yoga for an average of 2 hours, preferably once a week, for 12 weeks.
89022870|NCT06186609|Experimental|Experiment Arm|PD-1 inhibitor combined with radiotherapy
89022871|NCT06186596|Experimental|intervention|All subjects will receive standard-of-care intralesional injection with triamcinolone using an Injection Assistance Device (i.e., for self-administered intralesional injections) at Visit 1 (Day 1). Subjects will then submit photos via secure photographic app for asynchronous follow up on Day 2 (24-hours post-injection), Day 3 (48-hours post-injection), Day 4 (72-hours post-injection), Day 7, and Day 14.
89022872|NCT06186583|Experimental|[14C]ABSK021 Suspension|On Day 1, subjects will receive a single oral dose of approximately 50 mg ABSK021 containing approximately 100 μCi of [14C] ABSK021 in the fasted state.
89497308|NCT05677126|Active Comparator|Tralement|This study will enroll new prescribed home parenteral nutrition users, i.e. a patient enrolled in the study within six weeks of initiating first-time use of long-term home parenteral nutrition requiring trace element additives. Note: a portion of patients who meet inclusion criteria may have received parenteral nutrition in an inpatient setting before discharge home.
89497309|NCT05677126|Active Comparator|a fixed-dose trace element combination product of zinc, copper, and selenious acid|This study will enroll new prescribed home parenteral nutrition users, i.e. a patient enrolled in the study within six weeks of initiating first-time use of long-term home parenteral nutrition requiring trace element additives. Note: a portion of patients who meet inclusion criteria may have received parenteral nutrition in an inpatient setting before discharge home.
89497310|NCT05661682|Active Comparator|Tralement|This study will enroll new prescribed home parenteral nutrition users, i.e. a patient enrolled in the study within six weeks of initiating first-time use of parenteral nutrition formulation requiring trace element additives. Note: a portion of patients who meet inclusion criteria may have received parenteral nutrition in an inpatient setting before discharge home.
89497311|NCT05661682|Active Comparator|a fixed-dose trace element combination product of zinc sulfate, copper sulfate, and selenious acid|This study will enroll new prescribed home parenteral nutrition users, i.e. a patient enrolled in the study within six weeks of initiating first-time use of parenteral nutrition formulation requiring trace element additives. Note: a portion of patients who meet inclusion criteria may have received parenteral nutrition in an inpatient setting before discharge home.
89497312|NCT05659004||All participants|1 qualitative interview
89497313|NCT05655078|No Intervention|Standard of care|MPM participants who are on the standard of care watch and wait approach i.e. immediate treatment not suitable. Participants will have follow-up for 2 years (3 monthly in year 1, 4 monthly in year 2).
89022873|NCT06186570|Experimental|Online-Based Self-Help Intervention|The online-based self-help intervention is implemented as a six-week self-help intervention that is primarily based on Metacognitive Training (MKT), Mindfulness-Based Group Therapy (MBGT), and elements of cognitive behavioural therapy. It is conducted online and includes worksheets, audio, and interactive files. Participants work themselves through the intervention, based on their own needs and speed. All participants are allowed to continue parallel implemented standard scheduled treatment (TAU; for a description of TAU, see the section below).
89022874|NCT06186570|No Intervention|Waitlist-Control Group|The waitlist control group will not receive any additional intervention but is allowed to continue standard scheduled treatment (WL-TAU). This includes various forms of psychotherapeutic, pharmacologic, psychosocial, online, and other self-help interventions, either carried out individually or within a group. After study completion, participants in the waitlist-control group will equally receive the online-based self-help intervention.
89022875|NCT06186531|Experimental|PhytoSERM|Active intervention group
89022876|NCT06186531|Placebo Comparator|Placebo group|Control group
89022877|NCT06186518|Other|Control group|
89022878|NCT06186518|Experimental|PİKSEÇ group|
89022879|NCT06186505|Experimental|Phase 1a|Phase 1a will be undertaken in 10 healthy volunteers to assess the effects of the AirGlove device on lower limb arterial flow, tissue perfusion, and product usability following a single session. Measurements will be taken just prior to device application, and then again at the time of device removal.
89205407|NCT05462132|Experimental|Cohort 8|"HV subjects receive doses less than or equal to 2 × 10^12 live cells of SYNB1353 and up to 100 mg/kg of methionine.~Subjects will receive a single dose of SYNB1353 on the first day of dosing (Day 1), on Days 2 and 3 subjects will receive up to 2 doses of IMP (BID), and on Days 4 to 7 subjects will receive up to 3 doses of IMP (TID).~A methionine loading study will be performed on Day -1 and Day 7 after an overnight fast. A dose of methionine of up to 100 mg/kg will be evaluated."
89497314|NCT05655078|Experimental|Proton beam therapy|MPM participants to receive 5 weeks of proton beam therapy to the hemithorax. Following completion of treatment participants will have follow-up at the referring centre for 2 years (3 monthly in year 1, 4 monthly in year 2).
89497315|NCT05642507|Experimental|Active (AC01) Microtablets|Escalating doses of AC01
89022880|NCT06186505|Experimental|Phase 1b|Phase 1b will be undertaken in 20 PAD patients with intermittent claudication to assess the effects of the AirGlove device on lower limb arterial flow, tissue perfusion, quality of life and product usability both in a single session, and following a 12-week trial of heat therapy. Measurements will be taken just prior to device application, and then again at the time of device removal at the start of the trial, and again at week 12 (in line with the recommended duration of SET).
89497316|NCT05642507|Placebo Comparator|Placebo Microtablets|Matching placebo tablets
88955456|NCT06327893||Aquatic rescue|Patients treated by the Danish EMS following an aquatic rescue performed by lay or professional rescuers are identified from the Danish PEMR using the Danish Drowning Formula (DDF) and extensive manual validation.
88955457|NCT06327880|Experimental|PF-07054894|
88955458|NCT06327880|Placebo Comparator|Placebo|
88955459|NCT06327867|Active Comparator|Direct Laryngoscopy|All participants who are intubated from Direct laryngoscopy is enrolled in this arm.
88955460|NCT06327867|Experimental|Video Laryngoscopy|All participants who are intubated from Video laryngoscopy is enrolled in this arm.
88955461|NCT06327841|Experimental|sesame oil|8 weeks oil pulling with sesame oil 15ml 15min every morning
89497317|NCT05607147|Other|SARS-CoV-2 testing|There is only one arm in this study- the study is a non-randomized pilot. All the subjects will be tested for SARS CoV 2 viral Antigen and antibody to the virus as described.
89497318|NCT05604989|Experimental|Neovascular AMD patients with anti-VEGF treatment, oral probiotics supplement|"Neovascular AMD patients will be allocated. Regular intravitreal anti-VEGF injection treatment will be done. At the baseline and 6 months, the investigators will collect stool, saliva, and blood samples for microbiome analysis.~Oral probiotics (The Perfect Probiotics®) supplement will be given to the participants for 6 months."
89497319|NCT05604989|Sham Comparator|neovascular AMD patients with anti-VEGF treatment, no oral probiotics supplement|"Neovascular AMD patients will be allocated. Regular intravitreal anti-VEGF injection treatment will be done. At the baseline and 6 months, the investigators will collect stool, saliva, and blood samples for microbiome analysis.~No Oral probiotics (The Perfect Probiotics®) supplement in this group."
89497320|NCT05604989|No Intervention|Control patients, no oral probiotics supplement|"Healthy, no retinal disease patients will be allocated. At the baseline and 6 months, the investigators will collect stool, saliva, and blood samples for microbiome analysis.~No Oral probiotics (The Perfect Probiotics®) supplement in this group."
89497321|NCT05580406|No Intervention|Usual Care|Participants assigned to usual care will not receive outreach messages (online or via telephone) by study staff.
89497322|NCT05580406|Experimental|Outreach Messaging|Participants in the outreach messaging arm will receive messages via online secure message system (embedded within the health care record) and/or telephone.
89497323|NCT05579964|Experimental|DEX Group|Priming Dexmedetomidine 0.5 mcg/kg, Infusion Dexmedetomidine 0.25 mcg/kg/hour
89497324|NCT05579964|Placebo Comparator|Control Group|NaCl 0.9% with adjusted amount and rate same as the DEX group
89497325|NCT05567770|Active Comparator|Cohort 1|
89497326|NCT05567770|Active Comparator|Cohort 2|
89497327|NCT05550337|Experimental|Test: Trifarotene Cream, 0.005%|Trifarotene Cream, 0.005%, Apply to the affected areas of the face once daily for 84 days.
89497328|NCT05550337|Active Comparator|AKLIEF®|AKLIEF® (Trifarotene Cream, 0.005%), Apply to the affected areas of the face once daily for 84 days.
89497329|NCT05550337|Placebo Comparator|Vehicle Product|Vehicle of the Test Product, Cream, Apply to the affected areas of the face once daily for 84 days.
89497330|NCT05549180|Active Comparator|Patients received DTG/3TC + BIC/FTC/TAF placebo|DTG 50 mg/3TC 300 mg 1 tablet per day + BIC 50 mg/ FTC 200 mg/ TAF 25 mg placebo 1 tablet per day
89497331|NCT05549180|Experimental|Patients received BIC/FTC/TAF + DTG/3TC placebo|BIC 50 mg/ FTC 200 mg/ TAF 25 mg per day + DTG 50 mg/3TC 300 mg placebo1 tablet per day
89497332|NCT05544084|Experimental|Adapted Patient Navigation Program|Adaptation of a patient navigation approach to effect change in cervical cancer screening uptake in Kedougou and Dakar, Senegal. Conduct a stepped-wedge randomized pragmatic trial in three districts in the Kedougou Region and three districts in Dakar to evaluate the impact of The Adapted Program. In order to conduct this trial, investigators will deploy The Adapted Program and evaluate the impact of The Adapted Program on screening uptake and time to treatment initiation (for those with abnormal screening results) within the various contexts across clusters. Investigators will also explore the effect of The Adapted Program on intrapersonal- and community-level barriers. Finally, evaluate the implementation outcomes of The Adapted Program within the context of these rural and urban districts, whereby clusters serve as their own controls as they cross over from the control to intervention group.
89497333|NCT05544084|No Intervention|Control|Standard of care
89497334|NCT05523505|Sham Comparator|Sham stimulation|Participants receiving sham stimulation.
89497335|NCT05523505|Experimental|Reading and Language Network (RLN)|Participants receiving real stimulation to the left angular gyrus and left temporal pole.
89497336|NCT05523505|Experimental|Cognitive Control Network (CCN)|Participants receiving real stimulation to the bilateral dorsolateral prefrontal cortices.
89497337|NCT05523505|Experimental|RLN and CCN|Participants receiving real stimulation to the left dorsolateral prefrontal cortex and left angular gyrus.
89497338|NCT05518825|Experimental|Fortimel/Nutridrink Compact Protein|Twice daily serving of the study product
89497339|NCT05514119|Experimental|Recipients of DCD liver transplants|Subjects that have undergone transplant of a liver donation after circulatory death (DCD) in the last 21-35 days will receive a 12 week fenofibrate (Lofibra) for a duration of 12 weeks
89497340|NCT05500573|Experimental|Sperm sorting|Selection of gender specific spermatozoa using a multilayer density gradient
88955462|NCT06327841|Other|distilled water|8 weeks rinsing with distilled water 15ml 15min every morning
88955463|NCT06327828|Experimental|Semi-automated computer-aided treatment|
89531792|NCT05347069|Active Comparator|No Aspirin|No Aspirin
89531793|NCT05344716|Experimental|Laser|Intraurethral and vaginal laser treatment
89531794|NCT05338086|Experimental|MB09-MB09|Subjects randomised into MB09-MB09 group will receive MB09 (60 mg in 1 mL) SC injection every 6 months.
88955464|NCT06327828|Active Comparator|Usual care|
88955465|NCT06327815|Active Comparator|Co-administered Dual Therapy|Dapagliflozin tablets and Metformin HCl extended-release tablets
88955466|NCT06327815|Experimental|FDC Regimen of Dapagliflozin/Metformin XR|Xigduo (Dapagliflozin and Metformin hydrochloride extended-release) tablets
89022881|NCT06186505|Experimental|Phase 1c|Phase 1c will be undertaken in 10 PAD patients with critical limb ischaemia Rutherford stage 4 (rest pain). Lower limb arterial flow, tissue perfusion, pain scores, quality of life, and product usability will be assessed both in a single session and following a 2-12 week trial of heat therapy.
89531795|NCT05338086|Active Comparator|Prolia-MB09|Subjects randomised into Prolia- MB09 group will receive Prolia® (60 mg in 1 mL) SC injection every 6 months.
89497341|NCT05474534|Experimental|Treatment Group|Mothers in the treatment group will complete pre- and post-treatment self-report surveys assessing trauma symptoms, mental health, parenting attitudes and behaviors, and infant crying patterns and socioemotional development. Mothers in the treatment group will be provided with a wearable neurofeedback device called the MUSE 2, to use at home for 4-6 10-minute sessions per week, over the course of 3 months. Mothers in the treatment group will complete weekly virtual surveys assessing emotional and behavioral self-regulation capacities (e.g., anger control, etc.) throughout the 3 month duration of this study phase. Mothers in the treatment group will also answer additional weekly questions about intervention uptake (i.e., no. of sessions completed in the past week) and feasibility (i.e.,barriers to treatment uptake, ease of use of the device, etc.).
89497342|NCT05474534|No Intervention|Wait-list Control Group|Mothers in the wait-list control group will complete pre- and post-treatment self-report surveys assessing trauma symptoms, mental health, parenting attitudes and behaviors, and infant crying patterns and socioemotional development. Mothers in the wait-list control group will complete weekly virtual surveys assessing emotional and behavioral self-regulation capacities (e.g., anger control, etc.) throughout the 3 month duration of this study phase.
89497343|NCT05416229|Experimental|Psilocybin-assisted therapy|45 patients will receive a single administration of 25mg psilocybin given in a protocol of psychological support before, during and after dosing.
89497344|NCT05416229|Placebo Comparator|Placebo-assisted therapy|45 patients will receive a single administration of placebo (lactose) given in a protocol of psychological support before, during and after dosing.
89497345|NCT05414877|Experimental|Ephedrine|receive ephedrine (configured concentration 2 mg/mL). The individualized blood pressure control target was a 20% increase in baseline blood pressure, and the target blood pressure value was used as the basis for adjusting the dosing or pumping rate.
89497346|NCT05414877|Experimental|Phenylephrine|receive intravenous infusion of phenylephrine (configured concentration 0.1 mg/mL) The individualized blood pressure control target was a 20% increase in baseline blood pressure, and the target blood pressure value was used as the basis for adjusting the dosing or pumping rate.
89497347|NCT05414877|Experimental|norepinephrine|intravenous infusion of norepinephrine (configured concentration of 6 μg/ml).The individualized blood pressure control target was a 20% increase in baseline blood pressure, and the target blood pressure value was used as the basis for adjusting the dosing or pumping rate.
89497348|NCT05413876||Men with classical Fabry disease|
89497349|NCT05413876||Women with classical Fabry disease|
89497350|NCT05413876||Men with non-classical Fabry disease|
89497351|NCT05413876||Healthy controls|Age-, Sex-, BMI-matched controls
89497352|NCT05408390|Experimental|Low physical and energy density|
89497353|NCT05408390|Experimental|High physical and low energy density|
89497354|NCT05408390|Experimental|Low physical and high energy density|
89497355|NCT05408390|Experimental|High physical and energy density|
89497356|NCT05389696|Experimental|Part1. Group1. MIT-001 SC 10mg|Single subcutaneous administration of 10mg MIT-001 or placebo
89497357|NCT05389696|Experimental|Part1. Group2. MIT-001 SC 20mg|Single subcutaneous administration of 20mg MIT-001 or placebo
89497358|NCT05389696|Experimental|Part1. Group3. MIT-001 SC 40mg and IV 40mg|Single subcutaneous administration of 40mg MIT-001 or placebo and then signle intravenous administration of 40mg MIT-001 or placebo
89497359|NCT05389696|Experimental|Part2. Group1: MIT-001 SC 20mg|Multiple subcutaneous administration of 20mg MIT-001/day or placebo for 7days
89497360|NCT05389696|Experimental|Part2. Group2: MIT-001 SC 40mg|Multiple subcutaneous administration of 40mg MIT-001/day or placebo for 7days
89497361|NCT05387863|Experimental|Decision Aid (DA) Web Tool|
89497362|NCT05387863|Active Comparator|Institutional Pamphlet|
89497363|NCT05386602||Prior trial patients|In stage III, patients who have been on an experimental cancer medicine trial for less than six weeks will complete a draft PREM-ECM (less than six weeks), the EORTC PATSATC33 and HAD questionnaires at entry to the PREM study (baseline/time point 1 (T1)). Approximately 50 patients will be asked to repeat the draft of the PREM-ECM (less than six weeks) approximately one week later at time point 2 (T2). In stage IV, the PREM-ECM will be administered alone.
89497364|NCT05386602||On trial patients|In stage III, patients who have been on an experimental cancer medicine trial for more than six weeks will complete a draft PREM-ECM (more than six weeks), the EORTC PATSATC33 and HAD questionnaires at entry to the PREM study (baseline/time point 1 (T1)). Approximately 50 patients will be asked to repeat the draft of the PREM-ECM (more than six weeks) approximately one week later at time point 2 (T2). In stage IV, the PREM-ECM will be administered alone.
89497365|NCT05386602||Carers of patients|In stage III, carers of patients recruited on an experimental cancer medicine trial will be asked to complete a draft PREM-ECM-carers, the Adult Carer Quality of Life Questionnaire (AC-QOL), the EQ5D-5L, and the Hospital Anxiety and Depression Scale (HADS) at entry to the PREM study (baseline/time point 1 (T1)). Approximately 50 carers will be asked to repeat the draft of the PREM-ECM-carers approximately one week later at time point 2 (T2). In Stage IV, the PREM-ECM-carer will be administered alone.
89497366|NCT05383846|Experimental|Experimental: Narrative Exposure Therapy|This is a multiple baseline single case series design which focuses on assessing the posited exposure and autobiographical memory integration components of Narrative Exposure Therapy; no comparator will be included.
89497367|NCT05382819|Experimental|Part 1A Single Ascending Dose (SAD) - Active|Increasing dose of FRTX-02 Capsules will be administered to healthy volunteers.
88955467|NCT06327789||Multiple Sclerosis|Patients who were 18-50 years old, diagnosed with RRMS by a experienced neurologist, and with an EDSS score ≤ 3 were included in this study. Patients with orthopedic or sensory additional problems in the lower extremity, who had an interventional procedure in the last six months, and had an attack in the last three months were excluded from the study.
89497368|NCT05382819|Placebo Comparator|Part 1A Single Ascending Dose (SAD) - Placebo|Matching placebo will be administered to healthy volunteers.
89497369|NCT05382819|Experimental|Part 1B Multiple Ascending Dose (MAD) - Active|Increasing dose of FRTX-02 Capsules will be administered to healthy volunteers.
89497370|NCT05382819|Placebo Comparator|Part 1B Multiple Ascending Dose (MAD) - Placebo|Matching placebo will be administered to healthy volunteers.
89497371|NCT05382819|Experimental|Part 2 Subjects with Moderate to Severe Atopic Dermatitis (AD) - Active|FRTX-02 Capsules will be administered daily for 28 days to subjects with atopic dermatitis.
88955468|NCT06327776||MILD TBI Diagnostic and long term prognostic study|1000 patients suffering mild Traumatic Brain Injury
89497372|NCT05382819|Placebo Comparator|Part 2 Subjects with Moderate to Severe Atopic Dermatitis (AD) - Placebo|Matching placebo will be administered daily for 28 days to healthy volunteers.
89497373|NCT05359900|Experimental|Pain neuroscience education|Pain neuroscience education group. One-off, 70 minute duration session delivered by Dr Cormac Ryan.
89497374|NCT05359900|Active Comparator|Red flag education|Red flags education group. One-off 70 minute duration session delivered by Dr Cormac Ryan.
89497375|NCT05356546||Participants with a previous TYRX™ Absorbable Antibacterial Envelope implant|Participants who previously underwent a transvenous CIED implantation with the market released TYRX™ Absorbable Antibacterial Envelope, used for approved indications per country/region, and are returning for a CIED replacement procedure at least 12 months from the prior CIED implantation will be evaluated in this study.
89497376|NCT05348447|Experimental|Cryoanalgesia with standard of care pain control|subjects will receive standard of care pain control + cryoanalgesia in the intercostal spaces during routine surgery
89497377|NCT05348447|Active Comparator|Standard of care pain control|subjects will receive standard of care pain control only
89497378|NCT05345327|Experimental|Dapagliflozin 10mg|1x over-encapsulated Dapagliflozin 10mg tablet and 2x Metformin placebo tablets, taken orally once daily for 2 years
89497379|NCT05345327|Active Comparator|Metformin XR 2000mg|2x Metformin XR 1000mg tablets and 1x over-encapsulated Dapagliflozin placebo, taken orally once daily for 2 years
89497380|NCT05327257|Experimental|iTBS rTMS Left Dorsolateral Prefrontal Cortex (DLPFC) then Vertex|Subjects will receive 10 consecutive days of daily single session of iTBS rTMS for 3.5 minutes per day over the DLPFC in the first treatment period, complete a washout period of 4 weeks then receive 1 session of iTBS rTMS for 3.5 minutes daily over the vertex for 10 consecutive days.
89497381|NCT05327257|Experimental|iTBS rTMS Lateral Parietal Cortex (LPC) then Vertex|Subjects will receive 10 consecutive days of daily single session of iTBS rTMS for 3.5 minutes per day over the LPC in the first treatment period, complete a washout period of 4 weeks then receive 1 session of iTBS rTMS for 3.5 minutes daily over the vertex for 10 consecutive days.
89497382|NCT05327257|Experimental|iTBS rTMS Vertex then Left Dorsolateral Prefrontal Cortex (DLPFC)|Subjects will receive 1 session of iTBS rTMS for 3.5 minutes daily over the vertex for 10 consecutive days in the first treatment period, complete a washout period of 4 weeks then receive 10 consecutive days of daily single session of iTBS rTMS for 3.5 minutes per day over the DLPFC.
89497383|NCT05327257|Experimental|iTBS rTMS Vertex then Lateral Parietal Cortex (LPC)|Subjects will receive 1 session of iTBS rTMS for 3.5 minutes daily over the vertex for 10 consecutive days in the first treatment period, complete a washout period of 4 weeks then receive 10 consecutive days of daily single session of iTBS rTMS for 3.5 minutes per day over the LPC.
89497384|NCT05327257|Sham Comparator|iTBS rTMS Vertex only|Cognitively normal and healthy controls will receive 1 session of iTBS rTMS for 3.5 minutes daily over the vertex for 10 consecutive days. The vertex serves as a control as there are no functional improvements in cognition with stimulation of the vertex region.
89497385|NCT05325450|Experimental|Training A|Training A in Unilaterally postlingually-deafened adult cochlear implanted candidates
89497386|NCT05325450|Experimental|Training B|Training B in Unilaterally postlingually-deafened adult cochlear implanted candidates
89497387|NCT05325450|Active Comparator|Control|Training in bilaterally postlingually-deafened adult cochlear implanted candidates
89497388|NCT05315505|Experimental|Maintenance|"Participants will undergo an initial home-based pulmonary rehabilitation program for eight weeks.~At the end of the eight weeks, the participants will be randomly assigned into two groups, one receiving the maintenance pulmonary rehabilitation program and the other receiving the usual care.~The maintenance arm will receive home visits for supervised physical exercise and progressively alternated with phone calls to motivation and feedback"
89497389|NCT05315505|Active Comparator|control|"Participants will undergo an initial home-based pulmonary rehabilitation program for eight weeks.~At the end of the eight weeks, the participants will be randomly assigned into two groups, one receiving the maintenance pulmonary rehabilitation program and the other receiving the usual care.~The control group will have access to the usual follow."
89497390|NCT05309018||Patients|
88955469|NCT06327763|No Intervention|inguinal hernioplasty with ilioinguinal nerve preservation|
88955470|NCT06327763|Experimental|inguinal hernioplasty with ilioinguinal nerve section|
88955471|NCT06327750|Active Comparator|Hemodialysis (DNa=PNa)|High-flux hemodialysis with expected diffusive zero sodium balance (DNa=PNa)
88955472|NCT06327750|Active Comparator|Hemodialysis (DNa<PNa)|High-flux hemodialysis with expected diffusive sodium efflux (DNa<PNa, difference: 3 mmol/L)
88955473|NCT06327750|Active Comparator|Hemodialysis after isolated ultrafiltration (DNa=PNa)|High-flux hemodialysis after isolated ultrafiltration with expected zero sodium balance (DNa=PNa)
88955474|NCT06327750|Active Comparator|High volume hemodiafiltration (DNa=PNa)|High volume hemodiafiltration with expected diffusive zero sodium balance (DNa=PNa)
88955475|NCT06327750|Active Comparator|High volume hemodiafiltration (DNa<PNa)|High volume hemodiafiltration with expected diffusive sodium efflux (DNa<PNa, difference: 3 mmol/L)
88955476|NCT06327711|Active Comparator|CHO Blend|Group will consume a ready to feed CHO blend beverage
89022882|NCT06186492|Experimental|Experimental WVE-006 (Dose A) or placebo|
89022883|NCT06186492|Experimental|Experimental WVE-006 (Dose B) or placebo|
89022884|NCT06186492|Experimental|Experimental WVE-006 (Dose C) or placebo|
89497391|NCT05309018||medical staff|
89497392|NCT05305287|Experimental|NAFL TZD|T2D with non-alcoholic fatty liver (NAFL), treated with pioglitazone
89497393|NCT05305287|Placebo Comparator|NAFL Placebo|T2D with non-alcoholic fatty liver (NAFL), treated with placebo
89497394|NCT05305287|Experimental|NASH TZD|T2D with non-alcoholic steatohepatitis (NASH), treated with pioglitazone
89497395|NCT05305287|Placebo Comparator|NASH Placebo|T2D with non-alcoholic steatohepatitis (NASH), treated with placebo
89497396|NCT05305235|Experimental|RISE Guide|"The RISE (RCT for Innovating Stress-related eHealth) Guide is based on CAST, an anxiety sensitivity intervention effective in reducing anxiety sensitivity, posttraumatic stress, depression, and anxiety. RISE Guide delivers psychoeducation and cognitive-behavioral therapy principles in an interactive, audio-visual format discussing the stress response, myth-busting cognitive distortions related to stress, and facilitating safe exposure to feared sensations. Participants then complete a validated cognitive bias modification (CBM-I) for interpretation biases related to anxiety sensitivity. Finally, intervention principles are reinforced using ecological momentary intervention (EMI), in which surveys and personalized reminders are delivered based on symptoms reported during ecological momentary assessments (EMAs)~RISE Guide delivered by smartphone via Qualtrics and is completed in ~45 minutes over 2 weeks, with EMI weeks 1-7 post-assault."
89531796|NCT05338086|Active Comparator|Prolia-Prolia|Subjects randomised into Prolia-Prolia group will receive Prolia® (60 mg in 1 mL) SC injection every 6 months.
89531797|NCT05337917||Case|Injury to digital nerve: thumb, digit II radial side, digit V ulnar side
89022885|NCT06186492|Experimental|Experimental WVE-006 (Dose D) or placebo|
89022886|NCT06186492|Experimental|Experimental WVE-006 (Dose E) or placebo|
89022887|NCT06186492|Experimental|Experimental WVE-006 (Dose F) or placebo|
89022888|NCT06186492|Experimental|Experimental WVE-006 (Dose G) or placebo|
89022889|NCT06186479|Experimental|Verum|
89022890|NCT06186479|Placebo Comparator|Placebo|
89022891|NCT06186440|Experimental|Experimental|Cisplatin 20mg/m2 Cisplatin days 1-5 plus Temozolomide 150-200mg/m2 days 1-5
89022892|NCT06186440|Active Comparator|Temozolomide|Temozolomide 150-200mg/m2 days 1-5
89022893|NCT06186388|Other|Pathology|Subjects with glaucoma-affected eyes
89022894|NCT06186388|Other|Normal|Subjects with healthy eyes
89022895|NCT06186375||Patients' study|Patient with planned biotherapy
89022896|NCT06186349||non-significant hyperbilirubinemia|including 500 cases of non-significant hyperbilirubinemia ( TSB / TCB < 205umol / L )
89022897|NCT06186349||significant hyperbilirubinemia|500 cases of significant hyperbilirubinemia ( 205umol / L ≤ TSB / TCB < 342umol / L )
89022898|NCT06186349||severe hyperbilirubinemia|500 cases of severe hyperbilirubinemia ( TSB / TCB ≥ 342umol / L )
89022899|NCT06186349||Extremely severe hyperbilirubinemia|500 cases ( TSB / TCB ≥ 428umol / L )
89022900|NCT06186336||DL-Based Vulnerable Plaque Detection and Assessment Tool|"Enrolled subjects will receive a clinically indicated CCTA and ICA with OCT within 10 days. At least two qualified CCTA radiologists will independently review and annotate the coronary plaques in the CCTA using their local post-processing tools. At least two trained OCT readers will review and annotate the coronary plaques in the ICA/OCT using their local post-processing tools.~The original de-identified CCTA data will be inputted into the Vulnerable Plaque Detection and Assessment Tool. The tool will perform the automatic identification of the plaque location and characteristics. These results will be compared to assess the algorithm's performance."
89531798|NCT05337917||Control|Injury to digital nerve: digit II ulnarside, dig III, dig IV dig V radial side.
89497397|NCT05305235|Active Comparator|Relaxation Control|Breathe2Relax is a mobile application that instructs users on diaphragmatic breathing, a coping tool in which slow breathing through the diaphragm reduces anxiety. Participants in the control condition will download Breathe2Relax to their smartphones and receive short message service (SMS) reminders to engage with the app. The control intervention is expected to reduce symptoms, but not as much as the cognitive-behavioral therapy strategies taught in RISE Guide.
89497398|NCT05283564|Other|Administration of Percussive ventilation breathhold (PVB) technique in healthy volunteers|The healthy patient will execute the Percussive ventilation breathhold technique
89497399|NCT05283564|Other|Administration of the PVB-SABR in lung cancer patients|Lung cancer patients will execute a PV breathhold and a verification cone-beam CT scan.
89497400|NCT05213000|Experimental|Exercise post-immunization|After the initial mRNA-based COVID-19 vaccine is received, a supervised 90 minute light to moderate exercise session will take place.
89497401|NCT05213000|No Intervention|Daily routine as usual (control)|After the initial mRNA-based COVID-19 vaccine is received, participants will be asked to go about their daily routine as usual, but avoid exercise for that day.
89497402|NCT05207267|Experimental|testing arm|ventilated with different VT using an EIT monitor (PulmoVista® 500, Dräger, Lübeck, Germany)
89497403|NCT05188677|Experimental|Group 1a (primary series: Comirnaty)|participants will receive one dose of SCB-2019 vaccine on Day 1
89497404|NCT05188677|Active Comparator|Group 1b (primary series: Comirnaty)|participants will receive one dose of Comirnaty vaccine on Day 1
89497405|NCT05188677|Experimental|Group 2a (primary series: Vaxzevria)|participants will receive one dose of SCB-2019 vaccine on Day 1
89497406|NCT05188677|Active Comparator|Group 2b (primary series: Vaxzevria)|participants will receive one dose of Vaxzevria vaccine on Day 1
89497407|NCT05188677|Experimental|Group 3a (primary series: CoronaVac)|participants will receive one dose of SCB-2019 vaccine on Day 1
89497408|NCT05188677|Active Comparator|Group 3b (primary series: CoronaVac)|participants will receive one dose of CoronaVac vaccine on Day 1
89497409|NCT05188677|Experimental|Group 4a (primary series and booster dose CoronaVac)|participants will receive one dose of SCB-2019 vaccine on Day 1
89497410|NCT05188677|Active Comparator|Group 4b (primary series and booster dose CoronaVac)|participants will receive one dose of CoronaVac on Day 1;
89497411|NCT05188677|Experimental|Group 4c (primary series and booster dose CoronaVac)|participants will receive a half dose of SCB-2019 vaccine on Day 1
89497412|NCT05188677|Experimental|Group 5a (primary series: CoronaVac)|participants will receive a dose of 2-vial presentation of SCB-2019 vaccine
89497413|NCT05188677|Experimental|Group 5b (primary series: CoronaVac)|participants will receive a dose of 3-vial presentation of SCB-2019 vaccine
89497414|NCT05170009|Active Comparator|Active and standard of care|Active Baloxavir Marboxil and standard of care Oseltamivir
89497415|NCT05170009|Placebo Comparator|Placebo and standard of care|Placebo-matched Baloxavir Marboxil and standard of care Oseltamivir
89497416|NCT05168085|Experimental|Intervention group|One chicken egg per day
89497417|NCT05168085|No Intervention|Control group|True control
89497418|NCT05159427|Experimental|G.I Intubation|Single dose of Glipizide (5 mg modified-release tablet) and Rifaximin (200 mg tablet) administered with 200 mL of 14% glucose solution in water + 1 mg of the stable isotope Glipizide (13C6-Glipizide) with 40 ml of 14% glucose solution in water. A 'Stable isotope' means a heavier version of the drug that is not radioactive.
89497419|NCT05159427|Experimental|SmartPill®|Single dose of Glipizide (5 mg modified-release tablet), Rifaximin (200 mg tablet) and SmartPill® administered with 200 mL of 14% glucose solution in water + 1 mg of the stable isotope Glipizide (13C6-Glipizide) with 40 ml of 14% glucose solution in water.
89497420|NCT05157958|Experimental|ALLO-ASC-SHEET|"Allogeneic mesenchymal stem cells~Dressing for Dystrophic Epidermolysis Bullosa wound"
89497421|NCT05157958|Active Comparator|Conventional Therapy|"Hydrogel Sheet~Matching control"
89497422|NCT05155891|Experimental|Embosphere Microspheres group|Participants in this group who are undergoing standard of care (SOC) prostate artery embolization (PAE) for treatment of their symptomatic benign prostatic hyperplasia (BPH) will receive Embosphere Microspheres during scheduled SOC PAE surgery.
89497423|NCT05155891|Active Comparator|HoLEP Group|Participants in this group who are undergoing SOC PAE for treatment of their symptomatic benign prostatic hyperplasia (BPH) will receive SOC Holmium laser enucleation of prostate (HoLEP).
89497424|NCT05145582|Experimental|Unguided, Transdiagnostic ICBT Tailored for PSP|An 8-week, unguided, transdiagnostic ICBT program tailored specifically for public safety personnel and designed to treat depression, anxiety, and PTSD.
89497425|NCT05145582|Experimental|Unguided, Transdiagnostic ICBT Tailored for PSP + Online Discussion Forum|An 8-week, unguided, transdiagnostic ICBT program tailored specifically for public safety personnel and designed to treat depression, anxiety, and PTSD plus a built-in online discussion forum.
89497426|NCT05134935|Active Comparator|OKL|
89497427|NCT05134935|Experimental|DIMS|
89497428|NCT05132699|Active Comparator|Cannabidiol (CBD)|Epidiolex oral solution 500mg (5ml) per day
89497429|NCT05132699|Placebo Comparator|Placebo|Placebo oral solution 5ml per day
89497430|NCT05129878|Experimental|Test group 1|patients with PCOS on combined oral contraceptives (COCs) having gingivitis will receive scaling and oral hygiene instructions (OHI)
89497431|NCT05129878|Experimental|Test group 2|patients with PCOS on combined oral contraceptives (COCs) having gingivitis will receive oral hygiene instructions only
89497432|NCT05129878|Active Comparator|Control Group|Systemically Healthy (age and BMI matched) females with gingivitis will receive with OHI and scaling.
89497433|NCT05125991|Experimental|Prepectoral reconstruction|Prepectoral breast reconstruction with Braxon dermal matrix
89497434|NCT05125991|Active Comparator|Submuscular reconstruction|Submuscolar breast reconstruction
89497435|NCT05125679|Experimental|Guselkumab|Participants will receive guselkumab 100 milligrams (mg) by subcutaneous injection at Weeks 0, 4, 12, 20 and 28.
89497436|NCT05107115|Experimental|Rilzabrutinib dose A|dose A
89497437|NCT05107115|Experimental|Rilzabrutinib dose B|dose B
89497438|NCT05107115|Experimental|Rilzabrutinib dose C|dose C
89497439|NCT05107115|Placebo Comparator|Placebo|Matching placebo
89497440|NCT05103449|No Intervention|Control Group (No Video Coaching)|Control Group (No Video Coaching)
89497441|NCT05103449|Experimental|Experimental Group (Video Coaching)|Video-based coaching group
89497442|NCT05091476|Experimental|Eyes treated with the OPTiC System|Eyes that OPTiC System treatment has been completed
89497443|NCT05091476|No Intervention|Fellow Eye|Contralateral comparator
89497444|NCT05086757|Experimental|Trauma Resilience and Recovery Program (TRRP)|Enrollment in TRRP which includes 3 major steps: (1) in-hospital education, brief risk reduction session, and tracking patients' emotional recovery via an automated text-messaging system, (2) conducting a 30-day screen via telephone to identify patients who are good candidates for psychological treatment, and (3) providing referral to formal mental health services, if needed.
89497445|NCT05086757|Active Comparator|Enhanced Usual Care|Receive brief education about mental health after traumatic injury, educational materials about mental health recovery, and local referral information to assist treatment-seeking patients in seeking care
89497446|NCT05067764|Experimental|Aponeurectomy with grafting|The experimental group evaluates the aponeurectomy associated with adipose tissue grafting.
89497447|NCT05067764|Active Comparator|Aponeurectomy alone|The control group evaluates the aponeurectomy alone.
89497448|NCT05044299|Active Comparator|Isoped mobilization with resistance load|Use of Isoped with movement at 3 levels of resistance load: zero, low, high, each condition lasts 3 minutes at 9 minutes total work
89497449|NCT05044299|Active Comparator|Isoped mobilization without resistance load|Use of Isoped with movement at zero resistance load lasts 9 minutes of work
89497450|NCT05033665|Active Comparator|Euhydrated|Afternoon urine osmolality < 800 mmol/kg or urine specific gravity < 1.020.
89497451|NCT05033665|Experimental|Underhydrated|Afternoon urine osmolality ≥ 800 mmol/kg or urine specific gravity ≥ 1.020.
89497452|NCT05026983|Experimental|Treatment (encorafenib, binimetinib)|Patients receive encorafenib PO QD and binimetinib PO BID on day 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89497453|NCT04995809||EPRIMM study participants|No intervention: Questionnaires, food diaries and stool sample.
88955477|NCT06327711|Experimental|CHO Blend plus AN100|Group will consume a ready to feed CHO plus AN100 beverage
89022901|NCT06186297|Experimental|Cranberry extract|
89497454|NCT04993079|Experimental|Clotild®|Subjects presenting an acute ischemic stroke due to M1 or middle cerebral artery (MCA) bifurcation occlusion, eligible for Endovascular Thrombectomy (EVT) based on neuro-interventionist and/or neurologist investigators' opinion will be eligible. Twenty (20) patients will be initially enrolled. Up to 42 patients will be enrolled following an analysis of the data of the first 20 enrolled patients by a data safety monitoring board (DSMB) and its' recommendation to proceed with the study. Clots will be retrieved and analysed in a group of participants for which Clotild® is used as neurovascular guidewire.
89497455|NCT04981132|Experimental|Education+Exercise Group|Group 1: Patients will have 15 minutes of pain neuroscience education (PNE) and 30 minutes of progressive therapeutic exercise training (PTE) with the telerehabilitation method.
89497456|NCT04981132|Experimental|Exercise group|Group 2: Patients will have 45 minutes of progressive therapeutic exercise training (PTE) with the telerehabilitation method.
89497457|NCT04981132|No Intervention|Control Group|Group 3: Participants will be taken for the waiting list after evaluation with the telerehabilitation method.
89497458|NCT04919629|Experimental|Cohort 2B-1 (pegcetacoplan, pembrolizumab)|
88955478|NCT06327698|Experimental|Combination+ Anlotinib|Cadonilimab (AK104) (10 mg/kg, Q3W, administered on the frst day of each cycle, Q3W, until there is no clinical beneft) + anlotinib (8 mg, QD, 2 weeks off for 1 week)
89205408|NCT05458622|Other|Stable or quiescent SLE|"Patients included in this study will undergo one assessment at the time of recruitment and at the time of the end of study (time of a flare or at least 24 months after inclusion)~The following information will be collected :~General data: date of flare.~Disease activity: BILAG; SLEDAI-2K; PhGA (0-3); PGA (0-10); LLDAS; DORIS ; CLASI for mucocutaneous involvement; 44 joint assessment; proteinuria (UPCR); serum creatinine and eGFR for lupus nephritis.~Organ damage: SLICC/ACR Damage Index.~Kidney histopathology~HRQoL: EQ-5D-5L; FACIT-F; Medical Outcomes Study 36-item Short Form health survey (SF-36); Epworth Sleepiness scale (ESS); Lupus-QoL.~Start day and current dose for current treatments~Biological samples which will be obtained twice, at baseline and at the time of the first flare documented over 24 months, or at month 24 if no flare has been documented:~Blood~Urine~Stool~Saliva~Tissue samples for organ-specific manifestations"
89205409|NCT05450224|Other|Telehealth Massed Imaginal Exposure Therapy|
89205410|NCT05446051|Experimental|Experimental Group|New patients and take the TRAEs Questionnaire on week.
89205411|NCT05446051|No Intervention|Control group|Control Group：Old patients and usual care.
88955483|NCT06327646|Active Comparator|IFA-180 (Blister)|
88955484|NCT06327646|Experimental|MMS-180 (Blister)|
88955485|NCT06327646|Experimental|MMS-180 (Bottle)|
89205412|NCT05441267|Active Comparator|Oral semaglutide|14mg daily (option to reduce to 7mg daily)
89205413|NCT05441267|Placebo Comparator|Placebo|
88955488|NCT06327620|Experimental|Daivobet Ointment|Daivobet Ointment Arm: Patients in this arm will be asked to topically apply Daivobet ointment three times daily for four weeks
88955489|NCT06327620|Active Comparator|Topical steroids|Patients in this arm will be asked to topically apply a steroid ointment three times daily for four weeks.
88955490|NCT06327607||Control group|Standard iter of treatment for breast cancer
88955491|NCT06327607||Experimental group|Psychosexuological intervention
88955492|NCT06327594||Lung cancer patients with sarcopenia|
88955493|NCT06327594||Lung cancer patients without sarcopenia|
88955494|NCT06327581|Experimental|lactic acid group|· First group (A): 11 AA patients will be treated with MN combined with lactic acid solution 1%. Lactic acid solution 88% concentration PH (6.84), diluted with distilled water to have a final concentration of 1%
88955495|NCT06327581|Experimental|vitamin d3|· Second group (B): 11 AA patients will be treated with MN combined with topical application of vitamin D3 (an aqueous preparation of cholecalciferol (Devarol® ampoule 200 000 IU/2 ml, Memphis, Egypt) (2.5 mg/ ml), The maximum total amount of vitamin D3 injected into a patient in every session will be 2.5 mg (1 ml)
88955496|NCT06327581|Experimental|triamcinolone acetonide group|· Third group (C): 11 AA patients will be treated with MN combined with triamcinolone acetonide injectable suspension (Epirelefan®, 40mg/ ml, Eipico, Egypt) (10 mg/ml) will be used in a dose of 0.1 ml/cm2 area
88955497|NCT06327581|Experimental|saline|· Fourth group (D): 11 AA patients will be treated with MN combined with normal saline 0.9%
89205414|NCT05438888||Warfarin cohort (Reference)|Patients with NVAF treated with warfarin
89205415|NCT05438888||Apixaban cohort|Patients with NVAF treated with apixaban
88955500|NCT06327555|Other|the traditional rehabilitation group|The traditional rehabilitation group takes a face-to-face approach, with therapists providing outpatient rehabilitation instruction twice a week for six weeks.
88955501|NCT06327555|Experimental|the remote rehabilitation group|The remote rehabilitation group uses software and sensors to provide remote postoperative rehabilitation guidance.
89205416|NCT05430074|Other|HM Cast|
89205417|NCT05430074|Other|Fibreglass Cast|
89205418|NCT05424406|Experimental|Active light condition|Timed bright light exposure will be delivered in a controlled laboratory setting (10,000 lux) designed to delay the DLMO to 4 am or later. This would shift the circadian nadir (e.g., the period of maximal sleepiness) into the typical daytime sleep period after the nightshift (i.e., circadian nadir at ~10am). Bright light will be delivered in a controlled lab environment using a full spectrum light-box with UV filter (Sunbox Sunray II) to achieve a robust reduction of circadian misalignment. The light schedule will be tailored to each individual nightshift worker, determined by: 1) their baseline circadian phase, and 2) the human phase response curve adjusted to the individual's baseline circadian phase.
89205419|NCT05424406|Active Comparator|Control light condition|Shift workers randomized to the control condition will receive less intense light that still has a perceptible alerting effect (100 photopic lux). However, light will occur during a portion of the phase response curve with minimal phase shifts.
89205420|NCT05424406|Experimental|Cognitive Behavioral Therapy (CBT) condition|The CBT condition will probe sleep reactivity using validated CBT strategies over 6 sessions in accordance with the two-factor theory of emotion. Behavioral strategies will be used to reduce physiological arousal (e.g., relaxation training, breathing) and to strengthen behavioral cues for sleep (e.g., sleep hygiene and sleep scheduling). Sleep times will be scheduled to align with the reduced circadian misalignment (compromised phase position, i.e., maintaining a slightly delayed sleep period on offwork days). Cognitive strategies will identify stressors (e.g., dysfunctional beliefs about sleep) and intervene on worry and rumination with cognitive reappraisal and active coping. Sessions will be conducted by a trained behavioral sleep medicine provider via telemedicine to increase accessibility.
89205421|NCT05424406|Active Comparator|Sleep education control condition|"This condition will use an established sleep education control protocol modified for nightshift workers based on the Plain Language about Shiftwork published by the National Institute for Occupational Safety and Health (NIOSH). Sleep duration recommendations will be equivalent to the CBT group (8 hours of sleep opportunity) to ensure that outcomes are not confounded by time in bed. Materials in the sleep education control condition will be separated into weekly electronic materials monitored for engagement and completion."
89205422|NCT05423327|Other|Single Blood Draw|
89205423|NCT05411731|Active Comparator|Conventional physical therapy treatment|Patients in this group will receive conventional physical therapy i.e. stretching, strengthening exercises, Aeroplan positioning
89205424|NCT05411731|Experimental|Constraint induced movement therapy|patients of this group will receive the same treatment along with constraint induced movement therapy
89497459|NCT04919629|Experimental|Cohort 2B-2 (pegcetacoplan, pembrolizumab, bevacizumab)|
89022902|NCT06186297|Active Comparator|Baseline|
89022903|NCT06186271||E4/DRSP|"E4/DRSP: estetrol/drospirenone~new users (starters and restarters with at least two months break)"
89022904|NCT06186271||EE/DRSP|"EE/DRSP: ethinyl estradiol/drospirenone~new users (starters and restarters with at least two months break)"
89022905|NCT06186271||EE/LNG and EE/NETA and EE/NGM|"EE/LNG: ethinyl estradiol/levonorgestrel~EE/NETA: ethinyl estradiol/norethisterone/norethindrone acetate~EE/NGM: ethinyl estradiol/norgestimate~new users (starters and restarters with at least two months break)"
89497460|NCT04919629|Experimental|Cohort 2B-3 (bevacizumab)|
89497461|NCT04879017|Experimental|FHD-286 dose escalation and expansion|Up to approximately 125 patients will be enrolled in dose escalation and expansion
89022906|NCT06186232|Other|patient with horizontally deficient ridge in ethetic maxilary zone need (GBR) and implant placement|a group of patients with with horizontally deficient ridge in esthetic maxillary zone will undergo ridge augmentation with guided bone regeneration (GBR) technique using polymethylmethacrylate (PMMA) polymer as membrane.
89022907|NCT06186219|Experimental|Rituximab|Rituximab 1000 mg will be administered at week -6 and week -4 via intravenous infusion over the duration of 5 hours prior to the Pegloticase (Standard-of-Care) treatment.
89497462|NCT04838925|Experimental|Mobile Neurofeedback|Participants engage in the use of a mobile neurofeedback intervention, which involves using a mobile app paired with an EEG headset, to achieve a calm, relaxed state. Participants will be instructed to use the intervention at a minimum of 10 minutes a day, 4 times a week for a total of 12 weeks.
89497463|NCT04832568||Delirium is determined by CAM or CAM-ICU score|
89022908|NCT06186167||High-Risk Cardiac Device Recipients|Participants in this cohort are individuals undergoing clinically indicated cardiac device implantation, such as pacemakers, ICDs, ILRs, or CRT-D/Ps. During the standard implantation procedure, chest wall fat tissue typically excised to create space for the device is collected for histopathological analysis to identify amyloid deposits. This study involves no additional intervention beyond the routine clinical care received by the patients.
89022909|NCT06185894|Placebo Comparator|conservation without the use of a tourniquet|surgical conservation of placenta accreta spectrum cases with Kasr alainy conservative management technique, without the use of a tourniquet
89022910|NCT06185894|Active Comparator|conservation with the use of a tourniquet|surgical conservation of placenta accreta spectrum cases with Kasr alainy conservative management technique, with the use of a uterovesical tourniquet before fetal extraction
89022911|NCT06185647||All infants visiting the Emergency department from october 2023 to february 2024|Extraction from medical and nursing records data on the previous administration of nirsevimab and determin whether a bronchiolitis diagnosis was given in the pediatric emergency department This information was inserted systematically in the PED records on October 31st, 2023
89022912|NCT06185647||All infants having the diagnosis of bronchiolitis|All patients visiting the PED for bronchiolitis. Comparison of those who received previously nirsevimab and those who did not.
89022913|NCT06185439|Experimental|Experimental: Study group|In this study, the study group was provided with prenatal pilates-assisted childbirth preparation training and follow-up, in addition to the usual care provided by health professionals.
89497464|NCT04832568||No delirium is determined by CAM or CAM-ICU score|
89497465|NCT04830514|Experimental|Recommended dietary allowance (RDA) for protein|(RDA; 0.8g/kg/day) Protein intakes will be structured within two meals per day. A 2-day dietary lead-in will precede each dietary intervention. Study duration per subject will last about two weeks.
89497466|NCT04830514|Experimental|Habitual protein intake consistent with population level norms|(NHANES; 1.0g/kg/day) Protein intakes will be structured within two meals per day. A 2-day dietary lead-in will precede each dietary intervention. Study duration per subject will last about two weeks.
89497467|NCT04830514|Experimental|Optimal protein intake (OPI)|(OPI; 1.5g/kg/day) Protein intakes will be structured within two meals per day. A 2-day dietary lead-in will precede each dietary intervention. Study duration per subject will last about two weeks.
89497468|NCT04827927|Experimental|INTELLiVENT-ASV|Use of INTELLiVENT-ASV during 3 hours with 30 minutes wash-out time before.
89497469|NCT04827927|Active Comparator|Conventional Ventilation|Use of conventional ventilation during 3 hours with 30 minutes wash-out time before.
89497470|NCT04785157||severe COVID-19 patients with delirium|i) SARS-CoV-2 quasispecies detection and associated serology testing profiles description (peripheral blood and cerebrospinal fluid - CSF) ii) systemic and central immune response characterization, associated to the assessment of CNS damage biomarkers (peripheral blood and CSF) iii) in vivo brain PET-TSPO acquisitions (Positon Emission Tomography using a radioligand that targets the Translocator Protein, which is upregulated in activated microglia) iv) structural/functional brain MRI assessment (PWI/DWI mismatch imaging, quantification of gray and white matter microstructural integrity, DTI, functional connectivity) v) multi-domains neurocognitive assessment.
89497471|NCT04785027|Other|PSORI-CM01 group|"Expanded Allogeneic Adipose-derived multipotent mesenchymal stem cells(AD-MSCs) will be administered by intravenous drip at a dose of 2×10 ^ 6 cells/kg at week 0, week 2, week 4, week 6, week 8 with a total of 5 times.~PSORI-CM01 formula will be orally administrated once a day for 12 weeks excpet the day for the infusion of AD-MSCs."
89497472|NCT04785027|Experimental|Gu Ben Hua Yu group|"Expanded Allogeneic Adipose-derived multipotent mesenchymal stem cells(AD-MSCs) will be administered by intravenous drip at a dose of 2×10 ^ 6 cells/kg at week 0, week 2, week 4, week 6, week 8 with a total of 5 times.~Gu Ben Hua Yu formula will be orally administrated once a day for 12 weeks excpet the day for the infusion of AD-MSCs."
89497473|NCT04784182|Experimental|Synbiotic supplement group|Daily consumption of pills containing prebiotics and probiotics
89497474|NCT04784182|Placebo Comparator|Placebo group|Daily consumption of pills containing maltodextrin
89497475|NCT04724694|Experimental|Brief CBT for Chronic Pain and treatment as usual|Participants will receive Brief CBT-CP in addition to usual primary care treatment. Brief CBT-CP is a manualized protocol that includes six, 30-minute sessions over the course of 6-12 weeks. Session one focuses on foundational pain education and the development of treatment goals. Session two emphasizes balanced engagement in physical activity and pleasurable events. Session three emphasizes skills training for easily implemented relaxation techniques. Sessions four and five focus on recognizing and modifying unhelpful thoughts that negatively impact pain. Session six focuses on relapse prevention and independent implementation of CBT-CP skills following treatment.
89205425|NCT05392504|Experimental|Core stability exercise|"The core stability training consist of three phases. The first and second phases each will last for three weeks in total, and the third phase will take place in four weeks. Each training session will begin with 10 minutes of warm-up exercises and finish with 10 minutes of cool-down exercises; both warm-up and cool-down exercises includes breathing and stretching exercises. The number of repetitions will be adjusted according to the participant's exercise tolerance.~During the first week of each phase, the number of repetitions of each exercise will be 7-10, and this will progress to 10-15 based on the patient's physical tolerance."
89497476|NCT04724694|Other|Treatment as usual only|Participants assigned to treatment as usual will receive standard medical care from their primary care provider including pain medications, brief advice (e.g., use of relative rest, application of heat or ice, other self-care strategies), or referral to pain-related adjunctive interventions (e.g., physical therapy), as indicated.
89497477|NCT04717804|Active Comparator|AIP (Average Intensity Projection) CT (Computed Tomagraphy)|An image taken over a longer time of the lungs (average intensity projection of 4DCT) will be compared with breathing during treatment.
89497478|NCT04717804|Placebo Comparator|FB (Free-Breathing) CT|A snapshot of breathing (free-breathing traditional CT) will be used to compare with breathing during treatment.
89497479|NCT04705207|Experimental|reflexology massage|foot reflexology massage
89497480|NCT04705207|Placebo Comparator|sham massage|traditional foot massage
89497481|NCT04701307|Experimental|Treatment (niraparib, dostarlimab)|Patients receive niraparib PO QD on days 1-21 of cycles 1-4, and on days 1-42 of subsequent cycles. Patients also receive dostarlimab IV over 30 minutes on day 1. Cycles repeat every 21 days for cycles 1-4 and every 42 days for subsequent cycles in the absence of disease progression or unacceptable toxicity.
89497482|NCT04693208|Experimental|Laser|Laser light will be applied to the surgery site after tonsils excision.
89497483|NCT04693208|No Intervention|Standard care|
89497484|NCT04683731|Active Comparator|Group 1|Patients view decision aid without personalized message and whose providers do not receive the personalized message.
89497485|NCT04683731|Experimental|Group 2|Patients view decision aid with personalized message and whose providers do not receive the personalized message.
89497486|NCT04683731|Experimental|Group 3|Patient view decision aid without the personalized message and whose providers receive the personalized message.
89497487|NCT04683731|Experimental|Group 4|Patients view decision aid with the personalized message and whose providers receive the personalized message.
89497488|NCT04675567|Active Comparator|Safety-Net Intervention|
89497489|NCT04675567|No Intervention|Treatment as Usual|
89497490|NCT04673461|Experimental|STA363 containing 90 mg (60 mg/mL) lactic acid|"STA363 containing 90 mg (60 mg/mL) lactic acid will be injected into the center of up to two intervertebral discs. Patients with two discs appropriate for treatment will be treated at both affected levels by two separate injections.~Each patient will have 5 visits to study site and 1 telephone call. The patient's total time in the study will be approximately 61 weeks (~15 months) including an 8-week screening period."
89497491|NCT04673461|Experimental|STA363 containing 180 mg (120 mg/mL) lactic acid|"STA363 containing 180 mg (120 mg/mL) lactic acid will be injected into the center of up to two intervertebral discs. Patients with two discs appropriate for treatment will be treated at both affected levels by two separate injections.~Each patient will have 5 visits to study site and 1 telephone call. The patient's total time in the study will be approximately 61 weeks (~15 months) including an 8-week screening period."
88955512|NCT06327490|Experimental|ICG-guided manual lymphatic drainage|
88955513|NCT06327490|Active Comparator|Traditional manual lymphatic drainage|
88955514|NCT06327477|Experimental|Treatment (P-SFRT, IG-IMRT)|Patients undergo P-SFRT over 1 fraction and then undergo IG-IMRT over 25-28 fractions for 35 to 42 days. Patients undergo surgical resection 21 to 35 days after radiation therapy. Patients undergo blood sample collection during screening and on study. Patients also undergo biopsy during screening and CT on study and on follow up.
88955515|NCT06327464|Other|Ketone supplement condition first|
88955516|NCT06327464|Other|Ketone supplement condition second|
88955517|NCT06327451|Experimental|Atorvastatin administrating group|According to the clinical standard dose of lipid-lowering drugs, the subjects were enrolled in this study. After 2 weeks of glioma surgery, one tablet of liptor was taken orally every night on the basis of STUPP protocol.
88955518|NCT06327438|Experimental|Group (A)|(n=20) received complex decongestive therapy only
88955519|NCT06327438|Experimental|Group (B)|(n=20) received cryotherapy and complex decongestive therapy
88955520|NCT06327438|Experimental|Group (C)|(n=20) received kinesio taping and complex decongestive therapy
88955521|NCT06327425|Experimental|Patients with atrial tachycardia|Patients with atrial tachycardia will receive dynamic ECG, MCG and cardiac electrophysiologic examinations.
89497492|NCT04673461|Placebo Comparator|Placebo|"Placebo will be injected into the center of up to two intervertebral discs. Patients with two discs appropriate for treatment will be treated at both affected levels by two separate injections.~Each patient will have 5 visits to study site and 1 telephone call. The patient's total time in the study will be approximately 61 weeks (~15 months) including an 8-week screening period."
89497493|NCT04673175|Experimental|Ceftolozane-Tazobactam|Participants receive ceftolozane-tazobactam by injection directly into the vein (intravenously, IV) every 8 hours for 10-14 days.
89497494|NCT04666649|Experimental|Cohort 400mg of Venetoclax, 500 IU/m ² of Pegcrisantaspase|The subject will take 400mg of Venetoclax every day as a pill by mouth and a dose of 500 IU/m ² of Pegcrisantaspase in an IV every 14 days ( per cycle)
89497495|NCT04666649|Experimental|Cohort 400mg of Venetoclax, 750 IU/m ² of Pegcrisantaspase|The subject will take 400mg of Venetoclax every day as a pill by mouth and a dose of 750 IU/m ² of Pegcrisantaspase in an IV every 14 days ( per cycle)
89497496|NCT04666649|Experimental|Cohort 400mg of Venetoclax, 1000 IU/m² of Pegcrisantaspase|The subject will take 400mg of Venetoclax every day as a pill by mouth and a dose of 1000 IU/m² of Pegcrisantaspase in an IV every 14 days ( per cycle)
89497497|NCT04666649|Experimental|Cohort 600mg Venetoclax, 1000 IU/m ² of Pegcrisantaspase|The subject will take 600mg of Venetoclax every day as a pill by mouth and a dose of 1000 IU/m ² of Pegcrisantaspase in an IV every 14 days ( Per cycle)
89497498|NCT04661774|Other|Sham massage before reflexology massage (RP)|Sham massage (MS) comparator will be realised before RP.
89497499|NCT04661774|Other|Reflexology massage (RP) before Sham massage|RP will be realized before Sham massage.
89497500|NCT04649541|Active Comparator|Single intravenous doses of MRX-8|Single escalating doses of MRX-8
89497501|NCT04649541|Placebo Comparator|Single intravenous doses of placebo|Single intravenous doses of placebo to match MRX-8
89497502|NCT04649541|Active Comparator|Multiple intravenous doses of MRX-8 for 7 days|Multiple ascending intravenous doses of MRX-8 every 12 hours for 7 days.
89497503|NCT04649541|Placebo Comparator|Multiple intravenous doses of placebo for 7 days|Multiple intravenous doses of placebo every 12 hours for 7 days to match MRX-8.
89497504|NCT04649541|Active Comparator|Multiple intravenous doses of MRX-8 for 14 days|Multiple ascending intravenous doses of MRX-8 every 12 hours for 14 days.
89497505|NCT04649541|Placebo Comparator|Multiple intravenous doses of placebo for 14 days|Multiple intravenous doses of placebo every 12 hours for 14 days to match MRX-8.
89497506|NCT04577456|Experimental|Active|Reinfusion of chyme using the Insides System for subjects with Type II intestinal failure dependent on PN
89497507|NCT04577456|No Intervention|Control|Standard of care therapies in accordance with ASPEN and ESPEN treatment guidelines
89497508|NCT04564378||Mild Fuchs Dystrophy|
89497509|NCT04564378||Severe Fuchs Dystrophy|
89497510|NCT04549896|Experimental|CT scan|CT scan with a last generation 256 slice machine of occluded coronary artery before CTO PCI
89497511|NCT04549896|Active Comparator|Control|No CT scan before CTO PCI
89497512|NCT04547959|Experimental|C-CURVE Titane|According the routine practice of the investigator surgeon, the interbody cage C-CURVE in Titane is used
89497513|NCT04534725|Experimental|prophylaxis|"This study arm (arm 1) is evaluating the effect of interferon-alpha on the incidence of COVID-19 infection in cancer patients with no COVID-19 infection or no known COVID-19 positive contacts.~Participants in this study arm are randomly allocated (by chance) to one of two groups. One group will receive daily interferon-alpha intranasal spray for 3 months while the other group will receive a daily placebo intranasal spray for 3 months.~Participants will be followed during the 3-month treatment for incidence of COVID-19 and other respiratory infections."
89497514|NCT04534725|Experimental|Post-Exposure Prophylaxis|"This study arm (arm 2) is evaluating the effect of interferon-alpha on the incidence of COVID-19 infection in cancer patients with confirmed exposure to COVID-19 virus.~Participants in this study arm are randomly allocated (by chance) to one of two groups. One group will receive daily interferon-alpha intranasal spray for 7 days (at a higher dose than arm 1) while the other group will receive a daily placebo intranasal spray for 7 days~Participants will be followed for 28 days for incidence of COVID-19 and other respiratory infections."
89497515|NCT04534725|Experimental|Moderate COVID-19 infection|"This study arm (arm 3) is evaluating the effect of Selinexor on the incidence of COVID-19 infection in cancer patients with moderate COVID-19 infection.~Participants in this study arm are randomly allocated (by chance) to one of two groups. One group will receive oral Selinexor 3 times a week for 2 weeks while the other group will receive oral placebo 3 times a week for 2 weeks~Participants will be followed for 60 days to assess effectiveness and safety."
89497516|NCT04534725|Experimental|Severe COVID-19 infection|"This study arm (arm 4) is evaluating the effect of Lenzilumab on the treatment of COVID-19 infection in cancer patients with severe COVID-19 infection.~Participants in this study arm are randomly allocated (by chance) to one of two groups. One group will receive intravenous Lenzilumab over 24 hours while the other group will receive placebo intravenously over 24 hours.~Participants will be followed for 60 days to assess effectiveness and safety."
89497517|NCT04497805|Experimental|ALLO-ASC-SHEET|ALLO-ASC-SHEET Hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells
89497518|NCT04497805|Placebo Comparator|Hydrogel SHEET(Vehicle control)|Vehicle Control Hydrogel sheet without allogenic adipose-derived mesenchymal stem cells
89497519|NCT04463498|Experimental|n=15, Sleep-school 8 weeks|Patients receive treatment as usual in the psychiatric clinic combined with participation in the sleep school. They have already been given education on sleep regulation and sleep hygiene advice in the first meeting with the sleep-school facilitator.
89497520|NCT04463498|Experimental|n=15, Sleep-school 8 weeks and additive bb-glasses|Patients receive treatment as usual in the psychiatric clinic combined with participation in the sleep school and additive treatment with bb-glasses. They have already been given education on sleep regulation and sleep hygiene advice in the first meeting with the sleep-school facilitator.
88955522|NCT06327425|Experimental|Patients with atrial flutter|Patients with atrial flutter will receive dynamic ECG, MCG and cardiac electrophysiologic examinations.
89497521|NCT04463498|Active Comparator|n=30 8-week wait list for sleep-school|Patients receive treatment as usual in the psychiatric clinic while they wait for participation in the sleep school. They have already been given education on sleep regulation and sleep hygiene advice in the first meeting with the sleep-school facilitator.
89497522|NCT04443751|Experimental|SHR-1702 monotherapy|SHR-1702 monotherapy, given intravenously (IV); dose escalation and dose expansion.
88955525|NCT06327399|Active Comparator|Group A|patients will receive Dexmedetomidine infusion dose of 1 mcg/kg over 10 min.
88955526|NCT06327399|Active Comparator|Group B|patients will receive Dexmedetomidine bolus dose of 0.3 mcg/kg over 60 seconds.
89022914|NCT06185439|No Intervention|Control group|The control group was in the usual care.
89497523|NCT04385433|Experimental|EXPERIMENTAL GROUP|RADIOTHERAPY + PRAVASTATIN
89497524|NCT04385433|Placebo Comparator|CONTROL GROUP|RADIOTHERAPY + PLACEBO
89497525|NCT04362111|Experimental|Anakinra Group|The active treatment group will receive anakinra 100 mg subcutaneously every 6 hours for period of 10 days. For subjects meeting complete response criteria at 5 days, dosing will be decreased to 100 mg twice daily for the remaining 5 days.
89497526|NCT04362111|Placebo Comparator|Control Group|The control group will receive normal saline placebo subcutaneously every 6 hours for period of 10 days. For subjects meeting complete response criteria at 5 days, dosing will be decreased to twice daily for the remaining 5 days.
89497527|NCT04357964||obese and lean individuals|obese and lean individuals
89497528|NCT04318132|Experimental|NIDEK Mirante Comparison - Normal|Subjects without any current ocular pathology other than cataract in either eye
89497529|NCT04318132|Experimental|NIDEK Mirante Comparison - Retina|Subjects diagnosed with retinal pathology
89497530|NCT04318132|Experimental|NIDEK Mirante Comparison - Glaucoma|Subjects who have been diagnosed with glaucoma
89497531|NCT04318132|Experimental|NIDEK Mirante Comparison - Corneal disease|Subjects with corneal pathologies
89497532|NCT04293094|Experimental|Dose Exploration Phase|Participants will receive AMG 650 in 1 of 3 alternative schedules. The maximum tolerated dose (MTD) of each schedule will be estimated using isotonic regression (Ji et al, 2010). The Recommended Phase 2 Dose (RP2D) may be identified based on emerging safety, efficacy, and pharmacodynamics (PD) data prior to reaching an MTD.
89497533|NCT04293094|Experimental|Dose Expansion Phase Group 1: TNBC|Participants with locally advanced or metastatic triple negative breast cancer (TNBC), will be administered with the preliminary RP2D identified from the dose exploration part of the study.
89497534|NCT04293094|Experimental|Dose Expansion Phase Group 2: HGSOC|Participants with locally advanced or metastatic high grade serous ovarian cancer (HGSOC), will be administered with the preliminary RP2D identified from the dose exploration part of the study.
89497535|NCT04284761|Experimental|Biolen|Biolen bicalutamide implant. Single implantation. In situ until prostatectomy
89497536|NCT04275024|Experimental|Experimental group|"AD-MSCs: adipose-derived multipotent mesenchymal stem cells intravenous injection at a dose of 2 million cells/kg of body weight at week 0, week 2, week 4, week 6, week 8 with a duration for treatment for 12 weeks.~The basic treatment is oral PSORI-CM01 Granule plus calcipotriol ointment (Dovonex;LEO Laboratories Ltd, Ireland) for topical use twice daily for 12 weeks."
89497537|NCT04271254|Experimental|PET/MR|Each patient will undergo one combined PET/MR scan prior to surgery. The PET/MR scans are for research purposes and not part of the patient's standard of care.
89497538|NCT04259255||Edaravone (Radicava®/Radicava ORS®)|During an estimated 12-month period, eligible participants who are prescribed Edaravone within the approved indication will be invited to participate in the study.
89497539|NCT04226326|Other|Subjects with Chronic Total Occlusion (CTO)|All subjects in this study have been scheduled for a clinically-indicated cardiac catheterization.
89497540|NCT04216732||Observational (questionnaire, blood pressure)|"AIM I & II: Patients complete questionnaires over 10-40 minutes 2-4 times per year about health and how finances and quality of life effect experience with disease.~AIM III: Patients complete a questionnaire over 2 minutes and undergo blood pressure measurements every day for up to 12 weeks."
89497541|NCT04146935|Experimental|Patients with XLH|Patients will receive Burosumab monthly at visits 1,2 and 3 subcutaneously at a dose of 1.0 mg/kg. Dose may be adjusted as needed.
89497542|NCT04018677|Experimental|Beta Testing|For the beta testing, input will be provided by cancer patient/survivor, caregivers, and clinicians. TOGETHER app will be downloaded on smart phone. Subjects will be asked to answer questions and/or perform activities on his/her smartphone device. Project information will include responses to surveys and giving additional feedback on app user experience.
89497543|NCT04018677|Experimental|Usability testing|For the usability testing, caregivers will be the primary type of stakeholder providing input. TOGETHER app will be downloaded on smart phone. Subjects will be asked to answer questions and/or perform activities on his/her smartphone device. Project information will include responses to surveys and giving additional feedback on app user experience.
89497544|NCT04011345|Other|Folic Acid Supplement [Phase 1]|Phase 1: Folic acid supplement (1 mg per day) for 12 weeks; Phase 2: Wash-out period (no supplement or placebo) for 12 weeks; Phase 3: Placebo for 12 weeks
89497545|NCT04011345|Other|Placebo [Phase 1]|Phase 1: Placebo for 12 weeks; Phase 2: Wash-out period (no supplement or placebo) for 12 weeks; Phase 3: Folic acid supplement (1 mg per day) for 12 weeks
89497546|NCT04007848|Experimental|Cobimetinib|Experimental group : 36 histiocytoses's patients without or with BRAF V600E will be randomised in cobimetinib group
89497547|NCT04007848|Placebo Comparator|Placebo|Control group : 18 histiocytoses's patients without or with BRAF V600E will be randomised in the placebo group
89497548|NCT03996109|Experimental|Aim2Be|Youth-parent dyads randomized to Aim2Be
89497549|NCT03996109|Active Comparator|BnLt|Youth-parent dyads randomized to BnLt
89497550|NCT03970837|Experimental|GSK3196165 90mg + csDMARD (Global Cohort)|Participants in Global Cohort received GSK3196165 90 mg subcutaneous (SC) injection once weekly for 52 weeks in combination with conventional synthetic disease-modifying antirheumatic drugs (csDMARD).
88955527|NCT06327386||After neoadjuvant therapy for gastric cancer|a) Diagnosed primary gastric adenocarcinoma patients (cT2N+non-surgical treatment, cT3NanyMany and above staging); b) Staging of MRI enhanced examination before neoadjuvant therapy; c) Restaging of preoperative 18F-FAPI and 18F-FDG PET/MRI examination; d) Postoperative resection was performed after neoadjuvant therapy, with postoperative pathology, regression grading, and related immunohistochemistry; e) Patient age ≥ 18 years old; f) The patient voluntarily participates and signs an informed consent form.
88955528|NCT06327373|Placebo Comparator|Room air|Participants will receive no supplemental oxygen.
88955529|NCT06327373|Experimental|Supplemental oxygen (0.5 liters per minute)|Participants will receive supplemental oxygen by oxygen concentrator delivered by nasal cannula at 0.5 liters per minute.
88955530|NCT06327373|Experimental|Supplemental oxygen (3 liters per minute)|Participants will receive supplemental oxygen by oxygen concentrator delivered by nasal cannula at 3 liters per minute.
89205426|NCT05392504|Active Comparator|Scroth's program|The Schroth program include exercises for rotational breathing, spinal elongation, de-flexion, stretching, de-rotation, and strengthening, and these exercises are performed to improve the curvature, muscle strength, and endurance of postural muscles. During the Schroth exercises, rice bags, foam blocks, a stool, and long sticks will be used to adjust the posture and give passive support. The intensity of the Schroth exercises will gradually increased depending on the patient's improvement in exercise performance by decreasing the amount or degree of passive support, changing the patient's position, and adjusting the sets and repetitions of exercises
89497551|NCT03970837|Experimental|GSK3196165 150mg + csDMARD (Global Cohort)|Participants in Global Cohort received GSK3196165 150 mg subcutaneous (SC) injection once weekly for 52 weeks in combination with csDMARD.
89497552|NCT03970837|Active Comparator|Tofacitinib 5mg + csDMARD (Global Cohort)|Participants in Global Cohort received Tofacitinib 5mg capsule, orally, twice daily (BID) in combination with csDMARD plus placebo injection weekly to maintain the blind for 52 weeks.
88955534|NCT06327347|Active Comparator|ARTIS SYMBIOSE|25 patients will be implanted bilaterally with Artis Symbiose IOLs (Cristalens Industrie, France) . The device is CE-marked and used according to the intended purpose.
88955535|NCT06327347|Active Comparator|PANOPTIX|25 patients will be implanted bilaterally with AcrySof IQ PanOptix IOLs (Alcon, Switzerland).The device is CE-marked and used according to the intended purpose.
89497553|NCT03970837|Placebo Comparator|Placebo + csDMARD and GSK3196165 90mg + csDMARD (Global Cohort)|Participants in Global Cohort received Placebo weekly SC injection in combination with csDMARD for 12 weeks. At week 12, participants were switched from placebo to GSK3196165 90 mg, SC injection, once weekly in combination with csDMARD until 52 weeks.
89497554|NCT03970837|Placebo Comparator|Placebo +csDMARD and GSK3196165 150mg +csDMARD (Global Cohort)|Participants in Global Cohort received Placebo weekly SC injection in combination with csDMARD for 12 weeks. At week 12, participants were switched from placebo to GSK3196165 150 mg, SC injection, once weekly in combination with csDMARD until 52 weeks.
88955536|NCT06327321|Experimental|Drug group|Following central randomization, patients will be assigned to receive either deucravacitinib 12mg daily (QD) or a placebo daily (QD) for a duration of 24 weeks. At the end of this period, patients will be re-randomized to receive either deucravacitinib 12mg QD alone or deucravacitinib 12mg QD + twice weekly narrowband UVB treatment twice weekly for an additional 24 weeks.
88955537|NCT06327321|Placebo Comparator|Placebo group|Following central randomization, patients will be assigned to receive either deucravacitinib 12mg daily (QD) or a placebo daily (QD) for a duration of 24 weeks. At the end of this period, patients will be re-randomized to receive either deucravacitinib 12mg QD alone or deucravacitinib 12mg QD + twice weekly narrowband UVB treatment twice weekly for an additional 24 weeks.
89497555|NCT03970837|Placebo Comparator|Placebo +csDMARD and Tofacitinib 5mg +csDMARD (Global Cohort)|Participants in Global Cohort received Placebo capsule BID in combination with csDMARD for 12 weeks. At week 12, participants were switched from placebo capsule to Tofacitinib 5mg, capsule, orally, BID in combination with csDMARD plus placebo injection to maintain the blind for 52 weeks.
89497556|NCT03970837|Experimental|GSK3196165 90mg + csDMARD (Asia Cohort)|Participants in Asia Cohort received GSK3196165 90 mg subcutaneous (SC) injection once weekly for 52 weeks in combination with csDMARD.
89497557|NCT03970837|Experimental|GSK3196165 150mg + csDMARD (Asia Cohort)|Participants in Asia Cohort received GSK3196165 150 mg subcutaneous (SC) injection once weekly for 52 weeks in combination with csDMARD.
89497558|NCT03970837|Active Comparator|Tofacitinib 5mg + csDMARD (Asia Cohort)|Participants in Asia Cohort received Tofacitinib 5mg capsule, orally, twice daily (BID) in combination with csDMARD plus placebo injection weekly to maintain the blind for 52 weeks.
89497559|NCT03970837|Placebo Comparator|Placebo + csDMARD and GSK3196165 90mg + csDMARD (Asia Cohort)|Participants in Asia Cohort received Placebo weekly SC injection in combination with csDMARD for 12 weeks. At week 12, participants were switched from placebo to GSK3196165 90 mg, SC injection, once weekly in combination with csDMARD until 52 weeks.
89497560|NCT03970837|Placebo Comparator|Placebo + csDMARD and GSK3196165 150mg + csDMARD (Asia Cohort)|Participants in Asia Cohort received Placebo weekly SC injection in combination with csDMARD for 12 weeks. At week 12, participants were switched from placebo to GSK3196165 150 mg, SC injection, once weekly in combination with csDMARD until 52 weeks.
89497561|NCT03970837|Placebo Comparator|Placebo + csDMARD and Tofacitinib 5mg + csDMARD (Asia Cohort)|Participants in Asia Cohort received Placebo capsule BID in combination with csDMARD for 12 weeks. At week 12, participants were switched from placebo capsule to Tofacitinib 5mg, capsule, orally, BID in combination with csDMARD plus placebo injection to maintain the blind for 52 weeks.
89531799|NCT05329961|Experimental|Single Arm|HPV 9-valent human papillomavirus vaccine (Gardasil 9) - 0.5mL intramuscular dose - 2 doses (Month 0, 12)
88955539|NCT06327295|Experimental|ATB1651-102 Cohort 1|The planned ATB1651 dose of 3% solution to each infected toenail once daily for 12 weeks (follow up for 24 weeks) Twenty-five participants are expected to enroll per cohort.
88955540|NCT06327295|Experimental|ATB1651-102 Cohort 2|The planned ATB1651 dose of 3% solution to each infected toenail once daily for 20 weeks follow up for 16 weeks) Twenty-five participants are expected to enroll per cohort.
89022915|NCT06185426|Placebo Comparator|Healthy Control Group (HCG)|Seven rats will be included randomly in this group. No surgical/medical approach will be applied.
89022916|NCT06185426|Active Comparator|Damaged Control Group (DCG):|Facial nerve injury will be created on the right facial nerve. No surgical/medical approach will be applied.
89022917|NCT06185426|Experimental|Laser Group (LG)|Facial nerve injury will be created on the right facial nerve. LLLT (Low-Intensity et al.) willl be applied 3 times a week for 4 weeks postoperatively, at 830 nm with an optical power output of 30 mW, an energy density of 4 J/cm2, an irradiation area of 0.116 cm2 and an exposure time of 16 s per spot.
89497562|NCT03945357|Active Comparator|Saline Irrigation|Normal saline is to be placed into the dissected retromuscular space AFTER placement and fixation of mesh. This should fill the cavity completely to the level of the skin. Irrigant is to be left to stand for a total of three minutes and then evacuated. Additional irrigation with saline PRIOR to the randomization is permitted at the surgeons' discretion for hemostasis with no requirement for duration. Additional saline irrigation of the subcutaneous space after fascia closure should be performed prior to skin closure.
89497563|NCT03945357|Active Comparator|Antibiotic Irrigation|Antibiotic solution is prepared consisting of 240 mg gentamicin and 600 mg clindamycin in 500 ml saline to ensure proper concentration. This solution should be placed into the dissected retromuscular space AFTER placement and fixation of mesh. This should fill the cavity completely to the level of the skin. Irrigant is to be left to stand for a total of three minutes and then evacuated. Additional irrigation with saline PRIOR to the randomization is permitted at the surgeons' discretion for hemostasis with no requirement for duration. Additional antibiotic irrigation of the subcutaneous space after fascia closure should be performed prior to skin closure. This second irrigation is not timed.
89497564|NCT03938636|Experimental|Subjects free of inflammatory disease|Arm 1 includes inflammatory-disease-free HCs. Arm 1 was designed to evaluate image/re-image consistency (repeatability and stability) of joint-specific and global TUVs across a variety of image acquisition intervals and to collect normative HC data.
89497565|NCT03938636|Experimental|RA subjects on stable therapy|Arm 2 includes clinically-diagnosed RA subjects on stable treatment. Arm 2 was designed to evaluate image/re-image and test re-test (i.e., repeated dose) consistency of joint-specific and global TUVs across a variety of image acquisition intervals.
89497566|NCT03938636|Experimental|RA subjects who are candidates for initiation of a new anti-TNFα therapy|Arm 3 includes clinically-diagnosed RA subjects on stable treatment who are candidates for initiation of, or change to, new anti-TNFα therapy. Arm 3 was designed to assess the efficacy of global TUVs, obtained before and after initiation of a new anti-TNFα therapy, to predict future clinical responsiveness to the new therapy.
89497567|NCT03928509||Estrie CIUSSS|Subjects from the Estrie's Integrated Health and Social Services Centre
89497568|NCT03928509||Saguenay-Lac-Saint-Jean CIUSSS|Subjects from the Saguenay-Lac-Saint-Jean's Integrated Health and Social Services Centres
89497569|NCT03927885|Experimental|Arm I (open labeled placebo)|Patients receive open labeled placebo PO BID for 4 weeks in the absence of disease progression.
89497570|NCT03927885|Active Comparator|Arm II (waiting list, open labeled placebo)|Patients are assigned to a waiting list during week 1. Beginning in week 2, patients receive open labeled placebo PO BID for 3 weeks in the absence of disease progression.
89497571|NCT03900962|Experimental|Slow-speed strength training|The slow-speed strength training group performed the concentric phase of each resistance exercise over two seconds, paused at full extension/flexion for one second, and then performed the eccentric phase for two seconds.
89497572|NCT03900962|Experimental|High-speed power training|During the first three weeks of training, the high-speed power training group completed the concentric phase of each resistance exercise over two seconds, paused at full extension/flexion for one second, and then performed the eccentric phase for two seconds. Thereafter, this group completed the concentric phase of five resistance exercises (squat, press-up, incline chest press, seated row and push-press) as fast as possible whilst still taking two seconds to complete the eccentric phase.
89497573|NCT03896009|Experimental|AXS-07|Taken once upon a qualifying migraine
89497574|NCT03896009|Active Comparator|Meloxicam|Taken once upon a qualifying migraine
89497575|NCT03896009|Active Comparator|Rizatriptan|Taken once upon a qualifying migraine
89497576|NCT03896009|Placebo Comparator|Placebo|Taken once upon a qualifying migraine
89497577|NCT03875781|Experimental|A: Modified Folfirinox|"Experimental : preoperative chemotherapy:~Modified FOLFIRINOX regimen comprised oxaliplatin 85mg/m2 + irinotecan 180mg/m2 + Folinic acid 400 mg/m2 at day1, then 5-FU given as a continuous infusion over 46h every two weeks. Six cycles are planned preoperatively."
89497578|NCT03875781|Active Comparator|B: Modified Folfirinox followed by Radiochemotherapy|Active comparator: preoperative chemotherapy : Modified FOLFIRINOX regimen comprised oxaliplatin 85mg/m2 + irinotecan 180mg/m2 + Folinic acid 400 mg/m2 at day1, then 5-FU given as a continuous infusion over 46h every two weeks. Six cycles are planned preoperatively FOLLOWED BY Preoperative radiochemotherapy with concurrent capecitabine 825 mg/m2/12h 5 days/week and intensity modulated radiation therapy using a simultaneous integrated boost technique with 45 Gy in 25 fractions in pelvic volume and 50 Gy in 25 fractions to the tumor
89497579|NCT03859492|Experimental|Intermediate or high-risk breast cancer subjects|Subjects with a negative mammogram who are intermediate or high-risk for breast cancer will get supplemental screening with contrast enhanced digital mammography (CEDM)
89497580|NCT03836716|Experimental|Arimoclomol|248 mg arimoclomol base (equivalent to 400 mg arimoclomol citrate) 3 times daily
89497581|NCT03754465|Experimental|ALLO-ASC-DFU|Experimental: ALLO-ASC-DFU Hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells
89497582|NCT03754465|Placebo Comparator|Hydrogel SHEET(Vehicle control)|Placebo Comparator: Vehicle Control Hydrogel sheet without allogenic adipose-derived mesenchymal stem cells
89497583|NCT03744975|Placebo Comparator|Placebos|Control Intervention will be 1 Placebo Capsule given orally, one time
89022918|NCT06185426|Experimental|Steroid group (SG)|Facial nerve injury will be created on the right facial nerve. Intraperitoneal methylprednisolone (1mg/kg/day) will be administered every day for 1 week postoperatively.
89022919|NCT06185426|Experimental|Laser+Steroid Group (LSG):|Facial nerve injury will be created on the right facial nerve. Laser and steroid treatment will be applied in combination.
89497584|NCT03744975|Active Comparator|LCZ 696|1st Experimental Arm will be 1 capsule of LCZ 696 given orally, one time
89497585|NCT03702556|Active Comparator|Mastectomy without breast reconstruction|Functional MRI scan of the somatosensory cortex while the breast skin is stimulated by piezo-stimulators.
89497586|NCT03702556|Active Comparator|Breast reconstruction with nerve|Functional MRI scan of the somatosensory cortex while the breast skin is stimulated by piezo-stimulators.
89497587|NCT03702556|Active Comparator|Breast reconstruction without nerve|Functional MRI scan of the somatosensory cortex while the breast skin is stimulated by piezo-stimulators.
89497588|NCT03691519|Placebo Comparator|Placebo|"During the 18 months placebo-controlled period, participants will ask to consume 3 identical 1g vegetarian control capsules (containing a 1:1 ratio of corn oil and soy oil) per day. During the following 18-month open-label extension period, placebo subjects are switched to active treatment.~36 months consisting of a 18-month placebo-controlled period followed by a 18-month open-label extension period wherein all participants will receive active treatment"
89497589|NCT03691519|Experimental|Omega-3 treatment|During the entire length of the study (that is, both the placebo-controlled and open-label extension periods), participants in the intervention (Omega-3 treatment) arm will ask to consume 3- 1g softgel vegetarian capsules of DHA-O per day as a single dose for 36 months; each 1g capsule of DHA-0 providing 324 mg DHA and 185 mg EPA (total daily DHA+EPA dose = 1.53 g/day).
89497590|NCT03686215|Experimental|Device Intervention: LUM Imaging System used during surgery|The LUM Imaging Device will be used to look inside the lumpectomy cavity to see if the dye indicates any areas that may contain residual tumor. If the imaging identifies that there may be cancer cells remaining in the lumpectomy cavity, the surgeon will remove an additional piece of tissue. This process will be continued until a negative reading from the device is obtained or a maximum of 2 shaves of additional tissue has been removed. Patients in this arm will receive the study drug, LUM015.
89497591|NCT03686215|No Intervention|Standard of Care Arm|The LUM Imaging Device will not be used to guide additional tissue removal. Patients in this arm will receive the study drug, LUM015.
89497592|NCT03665077|Experimental|Participants|Patients with breast cancer who have completed all their primary treatments (surgery±radiation therapy) and are scheduled to start their adjuvant hormonal therapy.
89497593|NCT03653013|Active Comparator|Control Group|Usual standard of care from their diabetes care team
89497594|NCT03653013|Experimental|Neuropsychological Consultation Group|Children will be administered a number of neuropsychological tests. Children and parents in Group 2 will also complete a pediatric quality of life scale (PedsQL, Generic Scale and Diabetes Module), diabetes related family conflict scale (DFCS-R) to assess quality of life and family stress at the start of the study, as well as the self-report form of the BRIEF-2 if they are over age 11. Parents will also undergo a brief literacy and numeracy screening using the Wide Range Achievement Test, complete a parent report assessing their children's executive functioning skills at the start of the study (BRIEF-2) and they will fill out the Family Impact Module.
88955541|NCT06327295|Experimental|ATB1651-102 Cohort 3|"The planned ATB1651 dose of 3% solution to each infected toenail twice daily for 12weeks follow up for 24 weeks).~Twenty-five participants are expected to enroll per cohort."
89497595|NCT03633799|Experimental|VeraCept|VeraCept™ Intrauterine Contraceptive
89497596|NCT03612804|No Intervention|Unstructured care|Providers in this arm will continue to provide care as usual during lung cancer screening, with no intervention from the study team.
89497597|NCT03612804|Experimental|Proactive care|Providers in this arm will receive guidance from the study team about offering lung cancer screening patients proactive cessation care, including cessation medications and behavioral telephone counseling.
89497598|NCT03606174|Experimental|Cohort 1|Patients previously treated with checkpoint inhibitor and platinum-based chemotherapy. Nivolumab over 30 min IV infusion (240 mg IV every 2 weeks or 480 mg every 4 weeks) and sitravatinib 120 mg orally once per day continuously in 28-day cycles.
89497599|NCT03606174|Experimental|Cohort 2|Patients previously treated with checkpoint inhibitor, but ineligible for platinum-based chemotherapy. Nivolumab over 30 min IV infusion (240 mg IV every 2 weeks or 480 mg every 4 weeks) and sitravatinib 120 mg orally once per day continuously in 28-day cycles.
89497600|NCT03606174|Experimental|Cohort 3|Patients previously treated with selected immunotherapies and platinum-based chemotherapy. Nivolumab over 30 min IV infusion (240 mg IV every 2 weeks or 480 mg every 4 weeks) and sitravatinib 120 mg orally once per day continuously in 28-day cycles.
89497601|NCT03606174|Experimental|Cohort 4|Patients previously treated with with selected immunotherapies, but ineligible for platinum-based chemotherapy. Nivolumab over 30 min IV infusion (240 mg IV every 2 weeks or 480 mg every 4 weeks) and sitravatinib 120 mg orally once per day continuously in 28-day cycles.
89497602|NCT03606174|Experimental|Cohort 5|Patients previously treated with platinum-based chemotherapy, but never treated with checkpoint inhibitor. Nivolumab over 30 min IV infusion (240 mg IV every 2 weeks or 480 mg every 4 weeks) and sitravatinib 120 mg orally once per day continuously in 28-day cycles.
89497603|NCT03606174|Experimental|Cohort 6|Patients ineligible for treatment with platinum-based chemotherapy and never treated with checkpoint inhibitor. Nivolumab over 30 min IV infusion (240 mg IV every 2 weeks or 480 mg every 4 weeks) and sitravatinib 120 mg orally once per day continuously in 28-day cycles.
89497604|NCT03606174|Experimental|Cohort 7|Patients previously treated with antibody-drug conjugate, checkpoint inhibitor and platinum-based chemotherapy. Nivolumab over 30 min IV infusion (240 mg IV every 2 weeks or 480 mg every 4 weeks) and sitravatinib 120 mg orally once per day continuously in 28-day cycles.
88955542|NCT06327295|Experimental|ATB1651-102 Cohort 4|"The planned ATB1651 dose of 5% solution to each infected toenail once daily for 12weeks follow up for 24 weeks).~Twenty-five participants are expected to enroll per cohort."
88955543|NCT06327295|Placebo Comparator|Placebo|"Matching placebo to the IP per cohort.~Five participants are expected to be enrolled per cohort."
88955544|NCT06327282||Intervention group|Anesthesia nurses carried out pain-related knowledge education.
88955545|NCT06327282||Blank group|Patients who did not receive any knowledge education.
89205427|NCT05377541||PENG block|To perform the PENG block, the patient will be placed in the supine position and with the convex transducer in a transverse plane over the anteroinferior iliac spine, the probe will be aligned with the iliopectineal eminence of the pubic ramus rotating about 45º medially.
89497605|NCT03606174|Experimental|Cohort 8|Patients previously treated with antibody-drug conjugate and checkpoint inhibitor, but ineligible for platinum-based chemotherapy. Nivolumab over 30 min IV infusion (240 mg IV every 2 weeks or 480 mg every 4 weeks) and sitravatinib 120 mg orally once per day continuously in 28-day cycles.
89205428|NCT05377541||Fascia iliaca compartment block|To perform the iliac fascia block, the patient is placed in the supine position and with the linear transducer placed at the junction of the middle third with the lateral third of the inguinal ligament, the needle is inserted through the fascia lata and the iliac fascia.
89205429|NCT05377112|Experimental|SYNB8802v1|Dose ramp to 1 × 1011 QD and then dose ramp to 3 × 1011 TID SYNB8802v1 live cells
89205430|NCT05377112|Placebo Comparator|Placebo|Placebo will be administered during the dose ramp such that all subjects receive IMP dosing TID
89205431|NCT05354362|Experimental|ATG-010 and ATG-008|ATG-010 and ATG-008 should be taken 6 hours apart on a PK sampling day
89205432|NCT05351736|Experimental|Recent-onset schizophrenia|Patients diagnosed with schizophrenia with onset in the last 5 years that will be started on lurasidone or that have been on treatment with lurasidone for less than two weeks at the time of enrollment.
89205433|NCT05343065|Experimental|CGM insulin bolus calculator arm|Participants will use the CGM insulin bolus calculator arm
89205434|NCT05337098|Active Comparator|Aspartame|Controlled feeding study. Dosage of aspartame will follow 50% of the acceptable daily intake (equivalent to 25 mg/kg for aspartame). This amount represents 1,500 mg/day of aspartame for a 60 kg adult.
89205435|NCT05337098|Active Comparator|Sucralose|Controlled feeding study. Dosage of sucralose will follow 50% of the acceptable daily intake (equivalent to 2.5 mg/kg for sucralose). This amount represents 150 mg/day of sucralose for a 60 kg adult.
89205436|NCT05337098|Sham Comparator|No NNS|Controlled feeding study with no non-nutritive sweeteners.
89205437|NCT05335928|Experimental|Abatacept plus standard of care|Abatacept (10 mg/kg) will be administered IV after randomization, again at 24 hours after first study drug treatment, at 14 days after first study drug treatment and an optional 4th dose at 28 days.
89205438|NCT05335928|Placebo Comparator|Placebo plus standard of care|Placebo will be administered at the same intervals.
89205439|NCT05286957|Experimental|MRD-guided adjuvant tislelizumab and chemotherapy|"MRD+: Tislelizumab 200mg Q3W + chemotherapy 1-4 cycles and followed by Tislelizumab 200mg Q3W Up to 16 cycles or until PD or intolerable toxicity or withdrawal~MRD-: Adjuvant chemotherapy and surveillance the MRD status, the patient will receive treatment for MRD+ patient when MRD detected,"
89497606|NCT03606174|Experimental|Cohort 9|Patients previously treated with checkpoint inhibitor and platinum-based chemotherapy. There are 2 parts to this Cohort - a lead-in dose escalation portion and a dose expansion portion. In the dose escalation portion, treatment with up to 3 dose levels of sitravatinib in combination with up to 2 dose levels of pembrolizumab and enfortumab combination regimen to determine the recommended doses to be used in the combination treatment regimen and those doses will be further studied in the dose expansion portion. Pembrolizumab 200 mg over 30 min IV infusion every 3 weeks, sitravatinib orally once per day continuously in 21-day cycles (at 35 mg, 50 mg, 70 mg, or 100 mg) and enfortumab vedotin over 30 min IV infusion on Day 1 and Day 8 in 21-day cycles (at 1 mg/kg or 1.25 mg/kg).
89497607|NCT03581357|Active Comparator|Control/Waitlist (Anxiety Group)|Subjects assigned to this arm will not be offered access to the mobile app during the first 8 weeks of their participation. Subjects will be asked to begin using the app eight weeks after randomization. Subjects assigned to this arm will complete a questionnaire at three times points: the beginning after the subject has signed the informed consent form, at the 8 week time point (just before subject begins using the mobile app) and 16 week time point.
89497608|NCT03581357|Active Comparator|Mindfulness App (Anxiety Group)|Subjects assigned to this arm will receive mindfulness meditation instructions for 8 consecutive weeks following randomization to this arm. The mobile app contains 14 sessions that subject can participate in at their own pace. Subjects are asked to try and practice mindfulness meditation daily, for a total time of 2 hours per week. Subjects assigned to this arm will complete a questionnaire at three times points: the beginning after the subject has signed the informed consent form, at the 8 week and 16 week time points.
89497609|NCT03581357|Active Comparator|Control/Waitlist (Neuropathy Group)|Subjects assigned to this arm will not be offered access to the mobile app during the first 8 weeks of their participation. Subjects will be asked to begin using the app eight weeks after randomization. Subjects assigned to this arm will complete a questionnaire at three times points: the beginning after the subject has signed the informed consent form, at the 8 week time point (just before subject begins using the mobile app) and 16 week time point.
89497610|NCT03581357|Active Comparator|Mindfulness App (Neuropathy Group)|Subjects assigned to this arm will receive mindfulness meditation instructions for 8 consecutive weeks following randomization to this arm. The mobile app contains 14 sessions that subject can participate in at their own pace. Subjects are asked to try and practice mindfulness meditation daily, for a total time of 2 hours per week. Subjects assigned to this arm will complete a questionnaire at three times points: the beginning after the subject has signed the informed consent form, at the 8 week and 16 week time points.
89497611|NCT03523143|Experimental|Early-screen Group|The early screening group will be screened by a 75g 2-hour oral glucose tolerance test (OGTT) at 18-20 weeks of gestational age (GA). The time of early screening and intervention will be 6-8 weeks earlier than that of standard screening and intervention.
89497612|NCT03523143|Active Comparator|Standard-screen Group|The standard screening group will be screened by a 75g 2-hour oral glucose tolerance test (OGTT) at 24-28 weeks of gestational age (GA). The time of standard screening and intervention will be 6-8 weeks later than that of early screening and intervention.
89531800|NCT05322174|Experimental|Baby Sleep|Those randomized to this intervention group will receive an interactive online intervention focused on promoting infant sleep. This will include membership in a private Facebook group with support provided in the group, including weekly resources in the form of videos and tip sheets. To supplement this, they will also receive items meant to help with sleep (ex. sleep sack, baby sleep book).
89538183|NCT03189979|Experimental|Club Fit|Intervention includes exposure to physical activity and healthy eating intervention policy implementation, staff training, a challenge/self-monitoring program for healthy behaviors, a peer-coaching program for healthy behaviors, and a social marketing campaign.
89538184|NCT02445001|Experimental|ICG loaded erythrocytes|Ability to directly visualize erythrocyte dynamics within the retinal and choroidal microcirculations would facilitate focused investigations into the relationships between vasomotion (i.e., pulsatile erythrocyte movement through capillaries) and oxygen distribution to localized tissue regions.
89538185|NCT03284255|Experimental|study group|in this group the subject will accept the treatment of BioheartRapamycin Drug-Eluting Bioresorbable Coronary Stent System
89538186|NCT03284255|Active Comparator|control group|in this group the subject will accept the treatment of Drug Eluting Stent of Abbott's XIENCE PRIME™ or XIENCE V®
89538187|NCT03194113|Active Comparator|Trauma-Focused Treatment|Weekly sessions of prolonged exposure
89538188|NCT03194113|Active Comparator|Emotion Regulation Treatment|weekly sessions of emotion regulation and skills training.
89538189|NCT03194113|Active Comparator|Intensive Trauma-Focused Treatment|prolonged exposure, 3 sessions per week
89538190|NCT03284177|Experimental|C13-CAC|
89538191|NCT02439619|Experimental|Feasibility Trial|
89538192|NCT03192709|Experimental|A|Sildenafil vaginal suppositories users
89538193|NCT03192709|Placebo Comparator|B|Daily vaginal placebo users with HMG administration
89538194|NCT03192709|Placebo Comparator|C|Daily vaginal placebo users with HMG administration day until the day of oocyte retrieval.
89538195|NCT02443753|Experimental|Device|Subjects who receive the device
89538196|NCT02443987|Experimental|Received intravenous fluids|The patient will receive 500ml of 0.9% NaCl fluid intravenously during the operation.
89538197|NCT02443987|No Intervention|Control Arm|The patient will receive no intravenous fluid as per current routine protocol
89538198|NCT02459873|Experimental|Computer games to assess change in executive function skills|Children in Intervention group get to train using executive function games at more difficult levels.
89538199|NCT02459873|Active Comparator|Easy games as active comparators for executive function skills|Children in Non-intervention group get to play executive function games at an easy level.
89538200|NCT02444923|Experimental|Scleral rigid gas permeable contact lenses|The experimental intervention is the Scleral Rigid Gas Permeable contact lens (SRGPcl), Zenlens™. These lenses are designed to bridge the cornea and fit in alignment with the sclera, thus avoiding any detrimental effects associated with corneal contact.
89538201|NCT02444923|Placebo Comparator|Corneal rigid gas permeable contact lenses|The control intervention is the RoseK2™ Corneal Rigid Gas Permeable contact lens (CRGPcl). Corneal lenses are considered the gold standard in the management of the visual disability due to keratoconus and other related irregular cornea disorders.
89538202|NCT03283943|Experimental|Durvalumab and focal radiotherapy|Durvalumab 1500 mg IV every 28 days, and 2 fractions of focal sensitizing radiation with cycles 1 and 2 of treatment.
89538203|NCT02443597||obese pregnant women|"With the use of trans-abdominal ultrasound, the following measurements will be recorded:~Fetal nuchal translucency thickness.~Nasal bone.~Fetal facio-maxillary angle.~The flow across the tricuspid valve as normal or regurgitated.~A-wave in the ductus venosus as normal or reversed."
89538204|NCT02443597||lean pregnant women|"With the use of trans-abdominal ultrasound, the following measurements will be recorded:~Fetal nuchal translucency thickness.~Nasal bone.~Fetal facio-maxillary angle.~The flow across the tricuspid valve as normal or regurgitated.~A-wave in the ductus venosus as normal or reversed."
89538205|NCT03283865|Experimental|Ultrasound|"The attending anesthesiologist will perform or instruct the placement of a caudal block according to their standard of practice. At the time of administration of local anesthetic into the caudal space, the study collaborator (SC) will ultrasound the caudal space keeping the provider placing the block blinded to the imaging. The provider placing the block will inject 0.5mL of saline. The provider will then be asked to state if they are correctly in the caudal space or not. If the provider feels they are not in the caudal space, they will re-do the procedure. If the provider fails to identify incorrect location and this is noted by ultrasound, the SC will inform the provider to re-do the procedure.~All study participants will have ultrasound used for caudal block."
89538206|NCT03108053|Active Comparator|Guidewire used|Patients whose semirigid ureteroscopy procedure is conducted with the use of safety guidewire
89538207|NCT03108053|Experimental|No guide wire used|Patients whose semirigid ureteroscopy procedure is conducted without the use of safety guidewire
89538208|NCT02710045|Active Comparator|MV at 9 months|"Measles Vaccine at 9 months of age. Measles Vaccine at 18 months of age. All vaccines given as per normal Gambia schedule until 9 months of age, including third dose of diphtheria-tetanus-whole cell pertussis (DTP3), hepatitis B vaccine (HBV) and oral polio vaccine (OPV) at four months of age.~At 9 months of age given a single standard intramuscular (i.m.) dose of measles vaccine (MV) (Edmonston Zagreb strain, Serum Institute of India Ltd., Pune, India) into the deltoid. Yellow fever vaccine (YF) and OPV administered at 11 months of age. Given a standard MV challenge at 18 months of age."
89538209|NCT02710045|Active Comparator|DTP + MV at 9 months|Measles Vaccine at 9 months of age. DTP Vaccine at 9 months of age. Measles Vaccine at 18 months of age. DTP3 dose withheld and given HBV and OPV at four months of age. At 9 months of age given a single standard intramuscular (i.m.) dose of measles vaccine (MV) (Edmonston Zagreb strain, Serum Institute of India Ltd., Pune, India) into the deltoid, and i.m. DTP (Serum Institute of India Ltd.) in the thigh. Yellow fever vaccine (YF) and OPV administered at 11 months of age. Given a standard MV challenge at 18 months of age.
89538210|NCT02710045|Active Comparator|DTP at 9 months|DTP Vaccine at 9 months of age. Measles Vaccine at 18 months of age. DTP3 dose withheld and given HBV and OPV at four months of age. At 9 months of age given i.m. DTP (Serum Institute of India Ltd.) in the thigh. MV, OPV and YF administered at 11 months of age. Given a standard MV challenge at 18 months of age.
89538211|NCT03283631|Experimental|EGFRvIII-CARs|Gamma-retroviral MSGV1 139 scFv EGFRvIII CAR gene-modified T cells
89205440|NCT05286957|Active Comparator|Non MRD-guided adjuvant tislelizumab and chemotherapy|patients in non MRD-guided arm receive adjuvant tislelizumab and chemotherapy
89538212|NCT04483375|Experimental|anti-SARS-CoV-2 monoclonal antibody(SCTA01)|SCTA01: single dose on Day0
89205441|NCT05282108||Carcemia group|The cohort treated with Carcemia
89205442|NCT05282108||Glivec Group|The cohort treated with Glivec
89538213|NCT04483375|Placebo Comparator|Placebo|Placebo: single dose on Day0
89538214|NCT03283475|No Intervention|control group|"- Control group will include 60 adult individuals between 18 and 35 years old who have body mass index (BMI) between 19 and 25, not complaining of any thigh contour deformities or skin redundancy with no history of body weight fluctuations. This group will be divided into two subgroups, 30 males and 30 females.~The following measurements will be recorded :- Weight, height, thigh length, hip circumference, maximum buttocks circumference, upper thigh, middle thigh and lower thigh circumferences."
89538215|NCT03283475|Active Comparator|patient group|"- Patient group will include 30 patients suffering from thigh lipodystrophy and contour deformities who will undergo surgical intervention after their assessment.~After assessment, one of the following techniques will be selected:-~Liposuction only.~thigh lift.~Liposuction assisted thigh lift."
89538216|NCT02444767|Experimental|13mg Bimatoprost Insert|Subjects in this arm have 13mg Bimatoprost Ocular Inserts placed in both eyes for 7 days.
89497613|NCT03450707|Experimental|Thiamine|Patients randomized to the thiamine arm will receive thiamine 500mg in 100mL of normal saline intravenously every 12 hours for 5 doses. Patients will be connected to a noninvasive monitor for measurement of global oxygen consumption (VO2) for at least 48 hours or until extubated, whichever comes first. Blood will be drawn at 0,6,12,24,72 and 168 hours for measurement of lactate, thiamine level, pyruvate dehydrogenase, NSE, S100 and other markers of organ injury. CPC-E score will be assessed prior to hospital discharge and at 30 and 90 days to evaluate differences in neurologic and functional impairment.
89205443|NCT05275751|Placebo Comparator|Hot injection without TRP-channel inhibition|Pain induced by an increasingly hot intradermal injection up to 52°C over 2 minutes.
89497614|NCT03450707|Placebo Comparator|Placebo|Patients randomized to placebo will receive 100mL normal saline intravenously every 12 hours for 5 doses. All other aspects of the protocol will be the same as in the experimental arm. Patients will be connected to a noninvasive monitor for measurement of global oxygen consumption (VO2) for at least 48 hours or until extubated, whichever comes first. Blood will be drawn at 0,6,12,24,72 and 168 hours for measurement of lactate, thiamine level, pyruvate dehydrogenase, NSE, S100 and other markers of organ injury. CPC-E score will be assessed prior to hospital discharge and at 30 and 90 days to evaluate differences in neurologic and functional impairment.
89497615|NCT03392311|Experimental|AD-MSCs plus Calcipotriol ointment group|AD-MSCs（adipose-derived multipotent mesenchymal stem cells ） intravenous injection at a dose of 2 million cells/kg at week 0, week 2, week 4, week 6, week 8 with a duration for treatment for 12 weeks. The topical treatment in the study was calcipotriol ointment(Dovonex;LEO Laboratories Ltd, Ireland) twice daily for 12 weeks.
89497616|NCT03350464|Experimental|Pain in PD Arm|This arm will receive a total 10 sessions of TMS stimulation over 10 weeks. Pre and post intervention scales will be performed on week one and week 10.
89497617|NCT03337009|Experimental|Naloxone Navigator|"Targeted, web-based animated video (Naloxone Navigator [NN]):~This arm is a web-based intervention targeted to patients receiving chronic opioid therapy identified in the electronic health record. Participants in this arm have access to naloxone under standing orders from the pharmacy or with a prescription from their providers."
89497618|NCT03337009|No Intervention|Usual Care|Participants in the usual care arm will receive usual care from their health plan, pharmacy and clinicians. As part of usual care, participants can access naloxone through physician prescription or standing orders.
89497619|NCT03334656|Experimental|Biological Dressing|"It is a cellularized dressing of 100 cm² composed of fetal skin cells associated to a bovine collagen matrix:~Fetal skin cells were obtained from a single fetal skin sample and consist in two clinical grade banks of keratinocytes (reference BKF07 K CB1) and fibroblasts (reference BKF07 WCB F d P3) produced at the UTCG. These two clinical grade cells banks were fully characterized and secure.~The matrix is a customized type I calf collagen produced by the company Symatese. Symatese's collagen is in compliance with the European requirements"
89497620|NCT03334656|Active Comparator|Paraffin Gauze Dressing|"It is a low-adherent, sterile paraffin Tulle Gras dressing made from open weave gauze. The gauze has interlocking threads which minimize fraying when the dressing is cut to shape. JELONET® dressings are non-medicated and are used as a primary wound contact layer with paraffin present to reduce the adherence of the product to the surface of a granulating wound.~JELONET® is a product of Smith-Nephew, it has the CE-mark (n°0086) and the class of this medical device is IIa.~The features of this dressing are: Soft paraffin base, Sterile leno weave presentation, Comprehensive size range."
89497621|NCT03322865|Experimental|One Arm|Obinutuzumab i.v.
89497622|NCT03305874||Study Group|Prospectively, inpatients undergoing percutaneous coronary intervention (PCI) will be consented, and the computer-based contrast induced nephropathy (CBCIN) risk score will be calculated and displayed to the operator, along with suggested standard CIN-avoidance strategies during the PCI. Following the PCI, serum creatinine will be measured as per treating physician, but those who undergo at least two consecutive daily serum creatinine measurements starting the day after the procedure will be included in the study. These patients will be called 6 months and 12 months post-procedure to determine mortality and re-hospitalization status.
89022920|NCT06185179|Experimental|Metformin|Metformin pills will be given orally and daily during the 2-week recovery period following single leg immobilization Metformin will be titrated up to a dose 2g/day. 1g dose (two 500 mg pills) will be taken in the morning and a 1g dose will be taken in the evening. This will take place over each day for 14 days during the recovery period.
89022921|NCT06185179|Placebo Comparator|Placebo|Placebo pills will be given orally and daily during the 2-week recovery period following single leg immobilization. Two pills will be taken in the morning and two pills will be taken in the evening. This will take place over each day for 14 days during the recovery period.
89022922|NCT06185140|Experimental|Intervention group|Cardiac rehabilitation program
89022923|NCT06185140|Active Comparator|Control group|These patients will complete the program from their home through the TELEA platform that belongs to SERGAS. They go to the hospital once at the beginning of the program to learn the program with the Physiotherapist and once again after a month. The program will be carried out twice a week for their home. Patients will be monitored during physical exercise with Garmin® heart rate monitors. Patients will download heart rate and Borg scale data after each session and can establish contact through the TELEA platform with the nursing staff of the Cardiac RHB Unit at all times.
89022924|NCT06185010|Experimental|One Resistance Training Set (Single Session)|The participants will perform one resistance training session with one set.
89022925|NCT06185010|Experimental|Three Resistance Training Sets (Single Session)|The participants will perform one resistance training session with three sets.
89022926|NCT06185010|Experimental|One Resistance Training Set (8 Weeks)|The participants will perform eight weeks of resistance training (two sessions per week, separated by 72 hours of rest) with one set.
89022927|NCT06185010|Experimental|Three Resistance Training Sets (8 Weeks)|The participants will perform eight weeks of resistance training (two sessions per week, separated by 72 hours of rest) with three sets.
89022928|NCT06185010|Experimental|Control (8 Weeks)|The participants will not perform any form of physical exercise during the intervention period of eight weeks.
89022929|NCT06184672|Experimental|intervention group|the principal investigator will apply the dry needling technique to those allocated to the experimental group on the latent trigger points diagnosed on the selection phase. They will receive just one session following Hongs protocol.
89497623|NCT03305874||Comparator Group|Retrospectively, inpatients who underwent PCI and had at least two consecutive daily serum creatinine measurements will be selected. These patients will then be matched to the prospective patients, and matched by age and gender. Baseline CBCIN score will be calculated and other demographic and outcomes information will be obtained from medical records review.
89497624|NCT03296527|Experimental|Follitropin delta|Recombinant follicle-stimulating hormone (rFSH). Follitropin delta for subcutaneous injection
89497625|NCT03296527|Active Comparator|Gonal-F|rFSH. Follitropin alfa for subcutaneous injection
89497626|NCT03267498|Experimental|Nivolumab + chemoradiation|Patients receive nivolumab IV over 60 minutes on day 1 of courses 1-5 and 7-12. Treatment repeats every 14 days for 11 courses in the absence of disease progression or unacceptable toxicity. Beginning at course 2, patients undergo radiation therapy QD 5 days per week and receive cisplatin IV over 30-60 minutes on day 1. Treatment repeats every 7 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
89022930|NCT06184672|No Intervention|control group|Subjects in the control group will be asked to wait on the intervention couch for a similar time the ones who received the treatment.
89497627|NCT03241771|Experimental|Naloxone Navigator 1.0|Participants randomized to the Naloxone Navigator 1.0 arm will receive a link to the web-based resource. They will also receive usual care from their health plan, pharmacy and physicians. As part of usual care, participants will have access to naloxone through standing orders (i.e., they can request it without a prescription under their usual pharmacy benefit).
89497628|NCT03241771|No Intervention|Usual Care|Participants in the usual care arm will receive usual care from their health plan, pharmacy and physicians. As part of usual care, participants will have access to naloxone through standing orders (i.e., they can request it without a prescription under their usual pharmacy benefit).
89497629|NCT03228680|Experimental|Follitropin delta|FE 999049 was administered as single daily subcutaneous injections in the abdomen. Participants randomized to FE 999049 had their individual dose determined on the basis of their anti-Müllerian hormone (AMH) level at screening and their body weight at randomization. The daily FE 999049 dose was fixed throughout the stimulation period. The minimum allowed daily FE 999049 dose was 6 μg and maximum allowed daily dose was 12 μg. Dosing continued until the criterion for triggering of final follicular maturation was met. Participants could be treated for a maximum of 20 days.
89497630|NCT03228680|Active Comparator|Follitropin beta|FOLLISTIM was administered as single daily subcutaneous injections in the abdomen. The starting dose of FOLLISTIM was 150 IU and fixed for the first five stimulation days, after which it could be adjusted by 75 IU based on the individual response. The maximum allowed daily dose was 375 IU. Dosing continued until the criterion for triggering of final follicular maturation was met. Participants could be treated for a maximum of 20 days.
89497631|NCT03194542|Experimental|Luspatercept in subjects with MPN-associated myelofibrosis|Subjects across each of the cohorts (Cohort 1, Cohort 2, Cohort 3A, and Cohort 3B) will receive luspatercept.
89497632|NCT03188094||South Asians with Prediabetes|
89022931|NCT06184542|Experimental|Intervention (Children aged 6 years, one-dose)|Diphtheria-Tetanus-acellular Pertussis Component Combined Vaccine in Children aged 6 years on Day 0
89022932|NCT06184542|Active Comparator|DT Control (Children aged 6 years, one-dose)|Diphtheria-Tetanus Combined Vaccine in Children aged 6 years on Day 0
88821671|NCT02992782|Active Comparator|Standard Care|Standard care Intervention: including a home program of therapeutic (decongestive) exercise, which will include active, non-resistive motion of the involved limb. Participants will perform the exercise once daily for about 10 minutes and will be required to wear their compression sleeve for at least 12 hours per day, each day of the week. After 24 weeks, they will be given the opportunity to take part in the decongestive progressive resistance exercise program and will be provided with an adjustable compression garment to use during exercise.
89497633|NCT03160079|Experimental|Blinatumomab + Pembrolizumab|"Drug: blinatumomab Cycle 1 Blinatumomab Day 1-7 Continuous IV infusion for 28 days (9 mcg/day) Blinatumomab Day 8-28 Continuous IV infusion for 28 days (28 mcg/day)~Cycle 2-5 Blinatumomab Day 1-28 Continuous IV infusion for 28 days (28 mcg/day)~Cycle length 42 days~Other Names:~Blincyto~Drug: pembrolizumab Cycle 1 Pembrolizumab Day 15 and 36 IV infusion over 30 minutes (200mg)~Cycle 2-5 Pembrolizumab Day 15 and 36 IV infusion over 30 minutes (200mg)~Other Names:~Keytruda~MK-3475"
89497634|NCT03101917|Experimental|Visual assessment of electrode insertion|This arm will include the first 6 participants. In this group, a cut will be made near the eardrum and it will be lifted up so the surgeon can see the electrode as it goes into the cochlea.
89497635|NCT03101917|Experimental|Camera assessment of electrode insertion|This arm will include the next 6 participants. In this group, a tube with a camera will be inserted past the ear drum, by making a small hole in the ear drum, to see the electrode as it goes into the cochlea.
89497636|NCT03098628|Active Comparator|V - PCV10 vaccine, 0+1|PCV10, 0+1 schedule. PCV vaccine at 12 months of age
89497637|NCT03098628|Active Comparator|W - PCV13 vaccine, 0+1|PCV13 in 0+1 schedule. PCV vaccine at 12 months of age
89497638|NCT03098628|Active Comparator|X - PCV10 vaccine, 1+1|PCV10, 1+1 schedule. PCV vaccine given at 2 and 12 months of age
89497639|NCT03098628|Active Comparator|Y - PCV13 vaccine, 1+1|PCV13, 1+1 schedule. PCV vaccine at 2 and 12 months of age
89497640|NCT03098628|Other|Z - Control|Control group. PCV vaccine given at end of study (24 months)
89497641|NCT03083808|Experimental|Pembrolizumab 200mg IV every 21 days|Patients who have been treated with a PD-1 or PD-L1 inhibitor and experienced a PFS of ≥3 months will be enrolled within 6 weeks of last dose of PD-1 or PD-L1 inhibitor. On Day 1 of each 3-week cycle, subjects will first receive pembrolizumab at a dose of 200mg IV every three weeks in combination with chemotherapy. Partner chemotherapy will be either gemcitabine 1000mg/m^2 IV D1 and D8 every three weeks, docetaxel 75mg/m^2 IV D1 every three weeks, or pemetrexed 500mg/m^2 IV D1 every 3 weeks (pemetrexed for non-squamous histologies only). Subjects will continue to receive this combination until progression or intolerable toxicity.
89497642|NCT03047330|Experimental|Sleep fragmentation - active|Participants after 3 nights of experimentally-fragmented sleep
89497643|NCT03047330|No Intervention|Sleep fragmentation - control|Participants after 2 nights of unfragmented sleep
89497644|NCT03047330|Experimental|Estradiol withdrawal - active|Participants after experimentally-induced hypo-estradiol
89497645|NCT03047330|No Intervention|Estradiol withdrawal - control|Participants during high-estradiol phase of menstrual cycle
89497646|NCT03005951|Experimental|Lean males|This is a randomized, two-period, cross over design with the intervention of consuming breakfast versus fasting for breakfast to study the effects on hormone responses and cognitive function using CTET in lean and obese male adolescents. These two study groups will be randomized to one of two orders:: (A,B) or (B,A) where A = Yes breakfast and B=No breakfast
89497647|NCT03005951|Experimental|Obese males|This is a randomized, two-period, cross over design with the intervention of consuming breakfast versus fasting for breakfast to study the effects on hormone responses and cognitive function using CTET in lean and obese male adolescents. These two study groups will be randomized to one of two orders:: (A,B) or (B,A) where A = Yes breakfast and B=No breakfast
89497648|NCT02981407|Active Comparator|Liberal Transfusion Strategy|Red blood cell transfusion - One unit of packed red cells is transfused following randomization followed by enough red blood cell units to raise the hemoglobin concentration above 10 g/dL any time the hemoglobin concentration is detected to be below 10g/dL during the hospitalization for up to 30 days.
89497649|NCT02981407|Active Comparator|Restrictive Transfusion Strategy|Permitted to receive a red blood cell transfusion if the blood count is below 8 g/dL and the physician believes it is in the patient's best interest. A transfusion will be strongly recommended if the blood count drops to less than 7 g/dL. If the patient has symptoms of angina (e.g., chest discomfort described as pressure or heaviness) that do not go away with medication, a blood transfusion will be ordered regardless of the blood count.
89497650|NCT02960737|Experimental|Intervention group|Intensive training with oral neuromuscular training using an oral device (intervention group) and routine care with compensatory swallowing training under 3 months with start 12 (±3) weeks after stroke onset.
89497651|NCT02960737|No Intervention|Control group|Routine care with compensatory swallowing training under 3 months with starting 12 (±3) weeks after stroke onset.
89497652|NCT02860481|Other|first cohort : first 100 patients|first cohort : first 100 patients 10 patients with ovarian and/or endometrial cancer 10 patients with colorectal cancer 10 patients with head and neck cancer 10 patients with uveal melanoma 40 patients with invasive breast cancer 10 patients with breast ductal carcinoma in situ 10 patients with other tumor type
89497653|NCT02860481|Other|second cohort : 100 patients|Patients with breast cancer of with ovarian and/or endometrial cancer
89497654|NCT02764918||Children|
89497655|NCT02764918||Mothers|
89497656|NCT02608216|Experimental|FLT PET/CT|All subjects will receive an [18F]FLT PET/CT scan.
89497657|NCT02493530|Experimental|Escalation and expansion|TGR1202 and Ruxolitinib combination
89497658|NCT02415816|Experimental|Participants|All patients who consent to participate in this protocol. They will have diffusion weighted magnetic resonance imaging performed at several time points.
89497659|NCT02328014|Experimental|Dose Escalation and Expansion|"The acalabrutinib dose will be fixed and the ACP-319 dose will be escalated in each of three cohorts, and each cohort will take both study drugs by mouth, twice per day (BID) at approximately 12 hour intervals.~Expansion groups of up to 12 subjects for Germinal center B-cell (GCB) DLBCL and Non-GCB DLBCL to take a fixed dose of acalabrutinib and ACP-319. Each disease group will take both study drugs by mouth, twice per day (BID) at approximately 12 hour intervals."
89497660|NCT02316652|No Intervention|Healthy sites|Healthy sites with no inflammation; observational only
88955546|NCT06327269|Active Comparator|A new generation of targeted therapies and adjuvant therapy after LDLT.|The proton therapy or yttrium 90 as a more aggressive down-staging therapy may contribute to change tumor behavior. Lenvatinib is applied to adjuvant therapy after LDLT.
89497661|NCT02316652|Placebo Comparator|Scaling and root planing sites|Inflamed pocket receiving mechanical instrumentation
89497662|NCT02316652|Active Comparator|Scaling and root planing with solution|Inflamed pocket receiving mechanical instrumentation with sodium hypochlorite solution
89497663|NCT02213926|Experimental|ACP-196 (acalabrutinib) Regimen 1|ACP-196 (acalabrutinib) Regimen 1
89497664|NCT02125786|Experimental|Stratum 1: Local Failure|"Participants exhibit an initial pattern of failure that is local (disease confined to primary site). Treatment is surgery and a second course of focal irradiation. The total dose for the second course of irradiation will be 54Gy.~Participants may receive one or both: Photon therapy or proton therapy.~Participants receive ^1^8F-fluorodeoxyglucose and ^1^1C-methionine to aid in tumor visualization."
88955547|NCT06327269|Active Comparator|prolong the recurrence-free survival to high risk of HCC after LDLT|Lenvatinib which is applied to adjuvant therapy after LDLT may prolong the recurrence-free survival
88955552|NCT06327243|Experimental|Kineso taping group|
88955553|NCT06327243|Sham Comparator|Sham group|
88955554|NCT06327230|No Intervention|"Non-TEA group"|After enrollment, the subjects are given standard treatment, including continuous monitoring of vital signs, pain control with intravenous non-steroidal anti-inflammatory drugs (such as ibuprofen) and intravenous opioids (such as tramadol), goal-directed intravenous fluid resuscitation, correction of electrolyte and metabolic disturbances, nutritional support, use of antibiotics and sedatives as needed, necessary mechanical ventilation, continuous renal replacement therapy (CRRT) and other organ support therapies as needed.
89497665|NCT02125786|Experimental|Stratum 2: Metastatic Failure|"Participants exhibit an initial pattern of failure that is metastatic (neuraxis metastatic disease without equivocal evidence of local failure). Treatment is surgery and craniospinal irradiation. Craniospinal irradiation (36-39.6Gy) will include focal boost treatment of metastatic sites (54-59.4Gy) depending on location, extent of resection and target volume.~Participants may receive one or both: Photon therapy or proton therapy.~Participants receive ^1^8F-fluorodeoxyglucose and ^1^1C-methionine to aid in tumor visualization."
88955555|NCT06327230|Experimental|TEA group|Patient in lateral position, standard disinfection, puncture point selected at T7-T9 level, local anesthesia to pierce skin. Direct/lateral needle approach cautiously, confirm entry into epidural space with disappearance of resistance and negative pressure. Insert epidural catheter 3-5cm towards head, secure firmly. Test dose with 3mL 1% lidocaine injection to confirm epidural anesthesia efficacy and safety. Epidural infusion of 0.15% ropivacaine (250mL) + fentanyl (2.5mg) via patient-controlled pump at 5mL/h with bolus option. Adjust infusion rate 1-3mL/h based on pain needs.
89497666|NCT02125786|Experimental|Stratum 3: Local and Metastatic Failure|"Participants exhibit an initial pattern of failure that is both local and metastatic (neuraxis metastatic disease with equivocal evidence of local failure). Treatment is surgery and craniospinal irradiation.~Participants may receive one or both: Photon therapy or proton therapy.~Participants receive ^1^8F-fluorodeoxyglucose and ^1^1C-methionine to aid in tumor visualization."
89497667|NCT02125786|Experimental|Stratum 4: Local Failure|"Local Failure Participants exhibit an initial pattern of failure that is local (disease confined to primary site). Age is >36 months at time of enrollment to <21 years. Tumor shows presence of 1q gain. Treatment is optional craniospinal irradiation.~Participants may receive one or both: Photon therapy or proton therapy.~Participants receive ^1^8F-fluorodeoxyglucose and ^1^1C-methionine to aid in tumor visualization."
88955556|NCT06327217||Hip arthroscopy 5-10jr|
88955557|NCT06327204|Active Comparator|Group I|patient received one session / week
88955558|NCT06327204|Active Comparator|group II|patient received two session / week
88955559|NCT06327204|Active Comparator|Group III|Patient received three session / week
89497668|NCT02107963|Experimental|Arm 1|Dose escalation of anti-GD2 CAR T cells
89497669|NCT02107963|Experimental|Arm 2|Dose expansion of anti-GD2 CAR T cells
89497670|NCT01990040||Teduglutide treated|SBS participants who have been treated with teduglutide.
89497671|NCT01990040||Non-teduglutide treated|SBS participants who have not been treated with teduglutide.
89497672|NCT01928589|Active Comparator|PBI|270 cGy (centigray) x 15
89497673|NCT01928589|Experimental|PBI with chemotherapy|270 cGy (centigray) x 15 concurrent with chemotherapy of the treating medical oncologist's choice
89497674|NCT01892085|Experimental|Early initiation|Initiation of breast milk expression <1 hour following delivery.
89497675|NCT01892085|Experimental|Intermediate expression|Initiation of milk expression 1-<3 hours following delivery.
89497676|NCT01892085|Other|Late initiation|Initiation of milk expression >3-6 hours following delivery.
89497677|NCT01718275||Non-operative Group|Patients and caregivers who agree to receive non-operative management with antibiotics alone
89497678|NCT01718275||Surgery Group|Patients and caregivers who decide to undergo appendectomy that permit us to track their standard treatment course
89497679|NCT00815880|Experimental|Implantable Counterpulsation Therapy|The primary study population will include 20 patients enrolled and implanted with C-Pulse. This expansion protocol will allow up to 40 patients to be enrolled and implanted. Patients that meet eligibility will be enrolled and implanted into the treatment arm of the study. These patients will receive the C-Pulse System Implant as intervention therapy. There is not a control arm in this feasibility study.
89497680|NCT00265798|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89497681|NCT03748901||Full analysis set|Patients with recurrent or metastatic RCC who have initiated first line treatment between 1 January 2010 and 31 December 2015, with representative FFPE of nephrectomy surgical specimen which are suitable for assessment of PD-L1 expression
89497682|NCT03538171|Active Comparator|ARM Entinostat+Exemestane|Patients receive Exemestane orally (PO) once daily (QD) on days 1-28 and Entinostat PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89022933|NCT06184542|Experimental|Intervention (Toddlers aged 18-24 months, one-dose)|Diphtheria-Tetanus-acellular Pertussis Component Combined Vaccine in toddlers aged 18-24 months on Day 0
89497683|NCT03538171|Placebo Comparator|ARM Placebo+Exemestane|Patients receive Exemestane as in Arm A and placebo PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89497684|NCT02143661||Critically ill patients in the newly designed ICU rooms|Critically ill patients treated in one of the newly designed ICU rooms.
89497685|NCT02143661||Critically ill patients in the conventional ICU rooms|Critically ill patients treated in one of the conventional rooms on the same ICU.
89497686|NCT02256241||The role of RING ubiquitin ligases in osteogenic progenitors|Bone marrow (BM) will be collected from healthy patients undergoing orthopedic surgery. BM will be collected from disposable tissue that is removed during the normal sequence of the surgery.
89497687|NCT02256241||The role of RING ubiquitin ligases in musculoskeletal cancer|Collection of connective tissue from patients with tumors of musculoskeletal origin - a part of the resected tumor specimens.
89497688|NCT02143739||Newly diagnosed asthma patients|The patient population will be outpatients, men or women, ≥18 years of age, Newly diagnosed asthma patients who are not on inhaled gluococorticosteroid within 3 months.The patient population should not have COPD(chronic obstructive pulmonary diseases) history, or asthma exacerbation.
89497689|NCT02176915|Experimental|Group program|8-session group weight loss program and 4 follow-up phone counseling sessions
89497690|NCT02176915|Active Comparator|Print Materials|8 weekly mailings of print materials covering weight loss topics through US mail.
89497691|NCT05529836|Experimental|electroacupuncture(EA) group|The participants in EA group will receive acupuncture with PSD at bilateral Hegu (LI4), bilateral Quchi (LU5), bilateral Xuehai (SP10) and bilateral San Yinjiao (SP6). After skin disinfection, followed at an angle of 90°, acupuncture needles were inserted approximately 50 to 60 mm into the skin. When achieving qi, connect the four pairs of electrodes, two each on bilateral Quchi (LI4) and Hegu (LI11), two each on bilateral Xuehai (SP10) and San Yinjiao (SP6), and they are all ipsilateral to one another. The duration of the electroacupuncture stimulation is 30 minutes, and the current intensity ranges from 1 to 5 mA with a continuous wave of 20 Hz. For two weeks straight, the participants will have three therapy sessions each week (preferably every other day), for a total of six sessions.
89497692|NCT05529836|Sham Comparator|sham electroacupuncture(SEA) group|Participants in the SEA group will receive sham electroacupuncture with PSD, but not energizing the electropuncture device. Procedures, electrode placements, and other treatment settings are the same as in the EA group but with no electricity output only.
89497693|NCT05529836|Placebo Comparator|sham acupuncture(SAC) group|Participants in the SAC group will receive sham acupuncture with PSD and PSN on sham acupoints (the non-meridian and non-acupuncture points). Procedures, electrode placements, and other treatment settings are the same as in the EA group but with no skin penetration, electricity output, or needle manipulation for achieving qi.
89497694|NCT02030197|Active Comparator|CRISP program|educational and socialization program
89497695|NCT02030197|Placebo Comparator|Control Group|no treatment control group
89497696|NCT05312216|Experimental|Durvalumab plus Lenvatinib|"Durvalumab is a human IgG1 κ monoclonal antibody that inhibits binding of PD-L1 to its receptors PD-1 and CD80.~Lenvatinib is a multi- kinase inhibitor of VEGF receptors 1 to 3, FGF receptors 1 to 4, PDGFRa, RET, and KIT."
89497697|NCT02256319|Experimental|Dexmedetomidine recording|Recording registered through the deep brain stimulation electrodes with dexmedetomidine at 0.2 μg/kg/h.
89497698|NCT02256319|Active Comparator|Propofol recording|Recording registered through the deep brain stimulation electrodes with propofol at plasmatic levels of 0.5, 1, 1.5, 2, 2.5 μg/mL.
89497699|NCT02256319|No Intervention|Basal recording|Recording registered through the deep brain stimulation electrodes with no sedation .
89497700|NCT04510285|Experimental|Trastuzumab and Pembrolizumab|"Trastuzumab will be administered on an every 3 week dosing schedule, with initial loading dose of 8 mg/kg as a 90 minute infusion, followed by trastuzumab 6 mg/kg every 3 weeks.~The planned dose of pembrolizumab for this study is 200 mg every 3 weeks."
89497701|NCT05450432|Other|Ketamine and Esketamine Treatment|All study subjects will receive intravenous (IV) ketamine and intranasal (IN) esketamine treatment.
89497702|NCT02179255|Experimental|Human Growth Hormone|1.9 mg (5.7 units) daily injection of Recombinant Human Growth Hormone (HGH) for at least 6 weeks (42 days) plus FSH 450 to 600 units per day administered subcutaneous (SQ) daily dose adjusted based on the patients response starting on day 2 of the 28 day menstrual cycle and continued until Ovulation trigger
89497703|NCT02179255|Active Comparator|Follicle Stimulating Hormone|FSH 450 to 600 units per day administered SQ daily dose adjusted based on the patients response starting on day 2 of the 28 day menstrual cycle and continued until Ovulation trigger
89497704|NCT05529680|Experimental|Scapular mobilization and strengthening exercise|"Group A (study group):~This group included 20 patients with shoulder dysfunction post-mastectomy who received scapular mobilization and strengthening exercise in addition to their conventional physical therapy program in form of joint mobilization, posterior capsule stretching and range of motion exercise (ROM)."
89497705|NCT05529680|Active Comparator|Conventional physical therapy program|This group included 20 patients with shoulder dysfunction who received conventional physical therapy programs in form of joint mobilization, posterior capsule stretching, and range of motion exercise (ROM).
89497706|NCT04425044||AiM Covid|Self Monitoring of symptoms in AiM Covid App
89497707|NCT02182063|Experimental|BIBF 1120 low dose|
89497708|NCT02182063|Experimental|BIBF 1120 high dose|
89497709|NCT05444816|Experimental|Personalised Neurofeedback training at home|All patients will perform personalised neurofeedback training at home with the device Brainhero 2019, type 201
89497710|NCT02182141|Experimental|BIBF 1120|
89497711|NCT04425278|Active Comparator|Real Stimulation|The Real Stimulation of tDCS lasted 20 mins.Behavior and ERPs dataset should be acquired before the first tDCS session and after the last tDCS session.
89538217|NCT02459717|Experimental|Probiotics and prebiotic|fermented milk (125 grams), containing multiple probiotics strains and prebiotic fiber
89205444|NCT05275751|Experimental|Hot injection with TRPA1-inhibition|Pain is induced by an increasingly hot intradermal injection up to 52°C over 2 minutes, while TRPA1 is blocked pharmacologically by an antagonist dissolved in the hot fluid (synthetic interstitial fluid). The antagonist(s) have sufficient concentration to reliably block the channel. The total dose is in the range of a microdose trial.
89205445|NCT05275751|Experimental|Hot injection with TRPV1-inhibition|Pain is induced by an increasingly hot intradermal injection up to 52°C over 2 minutes, while TRPV1 is blocked pharmacologically by an antagonist dissolved in the hot fluid (synthetic interstitial fluid). The antagonist(s) have sufficient concentration to reliably block the channel. The total dose is in the range of a microdose trial.
88955563|NCT06327139|Active Comparator|Arm One: Conventional 5 point closed face immobilisation mask.|Participants will be immobilized using the standard of care immobilization for patients receiving radical radiation therapy to the head and neck which is a five point closed face mask. The thermoplastic mask immobilizes the patients head, neck and shoulders fully. Participants randomized to this group will not be monitored using intra fraction surface guided monitoring.
88955564|NCT06327139|Experimental|Arm Two: 5 point open face immobilization mask|Participants will be immobilized using the 5 point open face immobilization mask. The thermoplastic mask immobilizes the participants head, neck and shoulders however the mask does not cover the patients anterior portion of the participants face or chest Participants randomized to this group will be monitored using intra fraction surface guided monitoring.
88955565|NCT06327139|Experimental|Arm Three: 3 point open face immobilization mask|Participants will be immobilized using the 3 point open face immobilization mask. The thermoplastic mask immobilizes the patients head only and does not cover the participants face. Participants randomized to this group will be monitored using intra fraction surface guided monitoring.
89538218|NCT02459717|Placebo Comparator|Placebo|pasteurized fermented milk (125 grams) without prebiotics
89538219|NCT02439541|Experimental|UCMSC group|Patients in this arm received umbilical cord MSCs by intracoronary injection
88955568|NCT06327113|No Intervention|Control Group (Standard Wound Care)|The 'control' group will receive wound care treatment in accordance to standard of care procedures. The 'control' group will not receive study intervention.
88955569|NCT06327113|Experimental|Treatment Group (Tumescent Antibiotic Injection)|The 'treatment' group will receive wound care treatment in accordance to standard of care procedures along with the study intervention, a one-time tumescent antibiotic injection (TAI).
88955570|NCT06327100|Experimental|Group 1|Participants have already been receiving ruxolitinib for at least 3 months and are not responding well to ruxolitinib or have low blood cell counts, participants will be assigned to Group 1. In Group 1, participants will receive tasquinimod alone.
88955571|NCT06327100|Experimental|Group 2|Participants cannot tolerate JAK inhibitors, if the disease has come back after or has not responded to JAK inhibitor treatment, or if participants are not eligible to receive JAK inhibitors, you will be assigned to Group 2. In Group 2, participants will receive tasquinimod and ruxolitinib.
88955572|NCT06327074|No Intervention|Control Group|Sites in the control condition will be asked to complete appropriate/relevant surveys and interviews with minor modifications as needed and use the same Electronic Health Record Data Abstraction process.
88955573|NCT06327074|Experimental|Experimental Group|Sites randomized to use the EA-LCS materials will be given password-protected access to the program/toolkit web portal and encouraged to use any materials that fit the normal flow of clinic procedures. Materials available include both staff-facing and LCS candidate-facing materials.
89205446|NCT05275751|Experimental|Hot injection with TRPM3-inhibition|Pain is induced by an increasingly hot intradermal injection up to 52°C over 2 minutes, while TRPM3 is blocked pharmacologically by an antagonist dissolved in the hot fluid (synthetic interstitial fluid). The antagonist(s) have sufficient concentration to reliably block the channel. The total dose is in the range of a microdose trial.
89538220|NCT02439541|No Intervention|Control group|Patients in this arm did not receive any intervention.
88955576|NCT06327048|No Intervention|Control group|Routine rehabilitation nursing
88955577|NCT06327048|Experimental|Intervention group|On the basis of routine rehabilitation nursing, individual cognitive rehabilitation training based on Remind strategy was given
89538221|NCT03282149|Experimental|Dose 1|Lowest trial dose of XT-150
89538222|NCT03282149|Experimental|Dose 2|Second, escalating dose of XT-150
89538223|NCT03282149|Experimental|Dose 3|Third, escalating dose of XT-150
89538224|NCT03282149|Placebo Comparator|Saline placebo|2 of 8 participants in each cohort will randomly be assigned to placebo
89497712|NCT04425278|Sham Comparator|Sham Stimulation|The Sham Stimulation of tDCS lasted 20 minutes with no current. In particular, the current went up for the first 30 seconds and went down for the last 30 seconds.Behavior and ERPs dataset should be acquired before the first tDCS session and after the last tDCS session.
89497713|NCT04425278|No Intervention|Control|Behavior and ERPs dataset should be acquired before and after 14 days.
89497714|NCT02176993||Application of surface cooling|Surface cooling during 60 minutes.
89497715|NCT02182219|Experimental|BIBF 1120|
89497716|NCT05303480|Active Comparator|Chlormethine gel|Chlormethine gel 0.016% in 60mg tube, topical home administration from day 0 to day 155.
89497717|NCT05303480|No Intervention|Healthy volunteers|Healthy volunteer cohort (observational)
89497718|NCT02177149|Active Comparator|Standard of Care|DBS using standard of care.
89497719|NCT02177149|Experimental|DBS Clinical Support System|DBS using Clinical Support System.
89497720|NCT02182297|Experimental|BI 201335 NA in single rising doses|
89497721|NCT02182297|Placebo Comparator|Placebo|
89497722|NCT02182375|Experimental|BI 201335 NA|"400 mg raltegravir (bid) from day 1-14 and once on day 15;~240 mg BI 201335 NA (bid) from day 7-14 with a loading dose of 480 mg in the morning of day 6 and once on day 15"
89497723|NCT02179411|Active Comparator|healthy volunteers|healthy volunteers
89497724|NCT02179411|Active Comparator|renal transplant recipients|renal transplant recipients
89497725|NCT02179411|Active Comparator|renal transplant recipients grave|renal transplant recipients grave
89497726|NCT02179567|Experimental|Doc/Bev|Docetaxel/Bevacizumab
89497727|NCT02182453|Experimental|BI 10773 - single rising dose|
89497728|NCT02182453|Placebo Comparator|Placebo|
89497729|NCT02576054|Experimental|V501|0.5 mL intramuscular injection on Day 1, Month 2, and Month 6
89497730|NCT02182531|Experimental|Epinastine and Pseudoephedrine combination|
89497731|NCT02182531|Active Comparator|Epinastine|
88955578|NCT06327022|Experimental|Social media-based electronic bibliotherapy|Eight weekly sessions of social media-based electronic bibliotherapy
88955579|NCT06327022|Other|Usual care|Routine services provided by community centers
88955580|NCT06327009||fasting|100 patients who decided to fast the month of ramadan.
89022934|NCT06184542|Active Comparator|DTaP Control (Toddlers aged 18-24 months, one-dose)|Diphtheria-Tetanus-acellular Pertussis Vaccine in toddlers aged 18-24 months on Day 0
89497732|NCT02182531|Active Comparator|Pseudoephedrine|
89497733|NCT03537313|No Intervention|Control-douching group|No preoperative vagina douching
89497734|NCT03537313|No Intervention|Control-painting group|No intra-operative vagina painting
89497735|NCT03537313|Experimental|Vaginal douching group|Preoperative vaginal douches with povidone-iodine solution
89497736|NCT03537313|Experimental|Vaginal painting group|Intra-operative vaginal painting with povidone-iodine solution
89497737|NCT05531474|Active Comparator|Medical Weight Management|MWM corresponds to standard medical practice for weight loss that is available at the local participating centre, and thus reflects the local standard of care. MWM will typically consist of dietary, lifestyle and/or behavioral modification counseling, which may include nutritional counseling, safe weight management and/or making healthy lifestyle changes. MWM may also include the implementation of a low caloric diet, which may comprise the use of adjuvant meal replacements and/or anti-obesity mediations at the discretion of the treating physician and according to local practice guidelines.
89497738|NCT05531474|Experimental|Bariatric Surgery|The bariatric surgery procedures performed in BRAVE include either gastric bypass, sleeve gastrectomy, or duodenal switch, performed at the discretion of the surgeon and according to local practice standards. Sleeve gastrectomy will be performed as a stand-alone procedure, but may also be performed as part of a planned duodenal switch. Gastric banding is not permitted. Patients may receive a low fat, high protein meal replacement preceding surgery to reduce the size of the liver. Perioperative use of aspirin, thienopyridines (clopidogrel, ticagrelor or prasugrel), and anti-thrombotic therapy (compression stockings and subcutaneous heparin) should follow local guidelines and will be left at the discretion of the individual surgeons. .
89497739|NCT03537235|Experimental|Libramed|3 tablets of Libramed 2 twice a day 15 minutes before meals for 3 months.
89497740|NCT03537235|Placebo Comparator|Placebo|3 tablets of Placebo 2 twice a day 15 minutes before meals for 3 months.
89497741|NCT02177305|Experimental|Tiotropium dose group 1|0.02 mcg tiotropium solution
89497742|NCT02177305|Experimental|Tiotropium dose group 2|0.04 mcg tiotropium solution
89497743|NCT02177305|Experimental|Tiotropium dose group 3|0.08 mcg tiotropium solution
89497744|NCT02177305|Experimental|Tiotropium dose group 4|0.16 mcg tiotropium solution
89497745|NCT02177305|Experimental|Tiotropium dose group 5|0.28 mcg tiotropium solution
89497746|NCT02177305|Experimental|Tiotropium dose group 6|0.40 mcg tiotropium solution
89497747|NCT05531396|Active Comparator|Health Education|
89497748|NCT05531396|Experimental|Agility Training Group|
89497749|NCT02182609|Experimental|99mTc-rhAnnexin V-128|
89497750|NCT05529368|Experimental|conventional exercise group|Participants in the conventional exercise group attended an 8-week conventional exercise program, which consisted of the track, field, ball games et al. If the participant chooses to run, the mileage shall be more than 4km and the pace shall be within 10min. The conventional exercise treatment was performed 3 times a week, 1 hour each time.
89497751|NCT05529368|Experimental|tai chi exercise group|Participants in the tai chi exercise group attended an 8-week Yang-style 24-form tai chi training program and tai chi (8 trigrams 5 steps) which was the tai chi style most commonly adopted and studied in the literature. The tai chi exercise treatment was performed 3 times a week, 1 hour each time.
89497752|NCT05529368|No Intervention|control group|Participants in the control group received no intervention and keep their eating and living habits.
89497753|NCT02182765|Experimental|Nevirapine|"Part I: Study days 15-43~Part II: Study day 44 to end of trial"
88955581|NCT06326996|Experimental|Post-CABG patients with Thiamine Treatment Intervention.|Assess cognition and evaluate blood thiamine, lactate, and inflammatory marker levels in patients receiving thiamine intervention treatment within 5 days (baseline) and one month after CABG.
88955582|NCT06326996|Placebo Comparator|Post-CABG patients without Thiamine Treatment Intervention.|Assess cognition and evaluate blood thiamine, lactate, and inflammatory marker levels in patients receiving placebo treatment within 5 days (baseline) and one month after CABG.
88955583|NCT06326983|Experimental|Opioid-Sparing Anesthetic Plan|For their tonsil surgery, subjects will receive Dexmedetomidine (1mcg/kg bolus given intravenously at induction of anesthesia) and Acetaminophen (12.5mg/kg with a maximum dose of 1 gram given intravenously at induction of anesthesia). Ketorolac 0.5mg/kg with a max dose of 30mg given intravenously at the end of surgery. No opioids will be given during the procedure.
88955584|NCT06326983|Active Comparator|Opioid Anesthetic Plan|For their tonsil surgery, subjects will receive Morphine (0.1mg/kg given intravenously at induction of anesthesia) and Acetaminophen (12.5mg/kg with a maximum dose of 1 gram given intravenously at induction of anesthesia). Ketorolac 0.5mg/kg with a max dose of 30mg intravenously at the end of surgery.
89497754|NCT02182765|Active Comparator|Amprenavir|"Part I: Study days 0 to 43~Part II: Study day 44 to end of trial"
89497755|NCT02182765|Active Comparator|Abacavir|"Part I: Study days 0 to 43~Part II Study day 44 to end of trial"
88955585|NCT06326957|Experimental|SELF-BREATHE (Intervention)|SELF-BREATHE + usual NHS care (Intervention)
88955586|NCT06326957|No Intervention|Usual NHS care (Control)|Participants randomised to the control group continue with usual NHS care, as was available to them prior to entry into the trial
88955587|NCT06326892||Natural Orifice Specimen Extraction (NOSE)|Patients with low rectal cancer who underwent rectal resection with Natural Orifice Specimen Extraction (NOSE)
89497756|NCT02177383|Experimental|Docosahexaenoic acid|1 liter/day of one experimental beverage (containing 0.2% olive oil + 0.6% DHA-S Martek) provides 1.14 g DHA/daily
89497757|NCT02177383|Placebo Comparator|Olive oil|1 liter/day of placebo beverage (containing 0.8% olive oil)
89497758|NCT03536689|Experimental|Upright maternal position change|The participant will be measured by ultrasonograhy for amniotic fluid index in supine position before maternal position change, then she will do the upright position for 5 minute. After 5 minute of upright position , she will lie down in supine position and she will be measured by ultrasonograhy for amniotic fluid index after upright position.
89497759|NCT03536689|Experimental|Left lateral decubitus maternal position change|the participant will be measured by ultrasonograhy for amniotic fluid index in supine position before maternal position change, then she will do the left lateral decubitus position for 5 minutes. After 5 minutes of left lateral decubitus position , she will lie down in supine position and she will be measured by ultrasonograhy for amniotic fluid index after left lateral decubitus position.
89497760|NCT02179645|Experimental|GRC 27864|Test Treatment GRC 27864
89497761|NCT02179645|Active Comparator|Celecoxib|Active Comparator Treatment
89497762|NCT02179645|Placebo Comparator|Placebo|Placebo Treatment
88955588|NCT06326892||Controls|Patients with low rectal cancer who underwent rectal resection with traditional specimen extraction
88955589|NCT06326879||Early Onset Colorectal Cancer (EOCRC)|Patients aged less or equal to 49 years old at the time of colorectal cancer diagnosis
88955590|NCT06326879||Late Onset Colorectal Cancer (LOCRC)|Patients aged more or equal to 50 years old at the time of colorectal cancer diagnosis
88955591|NCT06326398|No Intervention|Control group|The control group will perform stoma care using the low-reality simulation (stoma model) method.
88955592|NCT06326398|Experimental|Experimental group|Students in the experimental group will perform stoma care using high-reality simulation (3D printing and moulage) method.
88955593|NCT06326385||intracerebral hemorrhage|
88955594|NCT06326333|Other|Combined parasternal block and serratus anterior plane block|"In the parasternal block application, the needle will be advanced under the pectoralis major muscle and above the intercostal muscle with the ultrasound-guided in-plane technique. 7.5 ml of 0.25% bupivacaine will be injected into this area per each level, at the level of the second and fourth intercostal space.~Then, in the serratus anterior plane block application, in the anterior axillary line, the needle will be advanced under the serratus anterior muscle, above the sixth rib, with the in-plane technique under ultrasound guidance. 10 ml of 0.25% bupivacaine will be injected into this area.~The application will be applied bilaterally."
89022935|NCT06184542|Active Comparator|PENTAXIM Control (Toddlers aged 18-24 months, one-dose)|PENTAXIM (DTaP-IPV-Hib) Vaccine in toddlers aged 18-24 months on Day 0
89022936|NCT06184542|Experimental|Intervention (Infants aged 3 months, three-dose)|Diphtheria-Tetanus-acellular Pertussis Component Combined Vaccine in infants aged 3 months on an M3-M4-M5 immunization schedule
89497763|NCT03537157|Experimental|Rifaximin delayed release tablets|Two 400 mg tablets twice a day (total daily dose 1600 mg) for 26 weeks
89497764|NCT03537157|Placebo Comparator|Placebo|Two placebo tablets twice a day for 26 weeks
89497765|NCT01606202|Experimental|GW-1000-02|Active treatment.
89497766|NCT01606202|Placebo Comparator|Placebo|Placebo control.
89497767|NCT05282030|Experimental|Severe Renal Impairment (RI) group (Part A only)|Single dose of tolebrutinib (SAR442168) will be administered on Day 1 under fed condition
89497768|NCT05282030|Experimental|Normal Renal Function group (Part A and B)|Single dose of tolebrutinib (SAR442168) will be administered on Day 1 under fed condition
89497769|NCT05282030|Experimental|Moderate RI group (Part B only conditional)|Single dose of tolebrutinib (SAR442168) will be administered on Day 1 under fed condition
89497770|NCT01493960|Experimental|Cobitolimod|2 doses 4 weeks apart
89497771|NCT01493960|Placebo Comparator|Placebo|2 doses 4 weeks apart
89497772|NCT03537079|Placebo Comparator|normoxia conditioning|exercise training in normoxia and rest conditioning in normoxia
89497773|NCT03537079|Active Comparator|exercise hypoxia|exercise training in hypoxia and rest conditioning in normoxia
89497774|NCT03537079|Active Comparator|rest hypoxia|exercise training in normoxia and rest conditioning in hypoxia
89497775|NCT02179723|Experimental|Leukosan Adhesive|Leukosan Adhesive applied to one wound (left or right)
89497776|NCT02179723|Active Comparator|Transcutaneous suture|Transcutaneous suture applied to second wound (left or right)
88955595|NCT06326320|Other|Combined serratus anterior plane block|Following the visualization of the anatomical structures, the nerve block needle will be advanced via the in-plane technique beneath the serratus anterior muscles until the interfascial space was reached. After hydrodissection with 2 ml normal saline, 20 ml 0.25% bupivacaine will be injected into the area. Then, with the same needle, will be returned 1-2 cm from the deep serratus anterior area to superficial serratus anterior area above the serratus anterior muscle and will be injected 2 ml normal saline for hydrodissection. Finally 20ml of 0.25% bupivacaine will be injected for superficial serratus anterior block into the interfacial area.
89497777|NCT02179879||Video validation group|This will include video taping of experts (defined as one who has performed more than 500 labor epidurals in preceding 5 year period) and novices (defined as one who has done less than 50 epidurals in preceeding 2 years) perfoming labor epidural
89497778|NCT05524922||Neurodegenerative disorders associated with sleep disorders|
89497779|NCT02179957||CT and FFR|Coronary stenoses which have been analysed with both CT and FFR
89497780|NCT02180035|Experimental|Symbiotic & Nutritional intervention|Symbiotic (dietary fibers + probiotic bacteria) 6g sachet twice daily for 6 months, dietary prescription and nutritional counseling
89497781|NCT02180035|Placebo Comparator|Maltodextrin & Nutritional intervention|Maltodextrin (placebo for symbiotic) 6g sachet twice daily for 6 months, dietary intervention and nutritional counseling.
89497782|NCT05531240|Experimental|PAE|Prostate Artery Embolization (PAE)
89497783|NCT05531240|Active Comparator|TURP|Transurethral Prostate Resection (TURP)
89497784|NCT02180113|Other|Fibroscan®|Fibroscan® is an active non implantable medical device using ultrasound. It has been designed to measure liver stiffness in a painless, rapid and non invasive manner. It is a diagnostic aid tool. In this study, Spleen Stiffness Measurement will be assessed using a dedicated FibroScan® device which has been developed specifically to assess spleen stiffness.
89497785|NCT05524844||Control|Non-BE controls undergoing endoscopy for any indication who are on stable dose Proton Pump Inhibitors for the past month.
89497786|NCT05524844||Barrett's Esophagus|Patients scheduled for upper endoscopy for clinical purposes, with a history of histologically confirmed Barrett's esophagus (2 cm length); 40 with no history of dysplasia, and 40 with high grade dysplasia or esophageal adenocarcinoma.
89497787|NCT02180191||Obesity|27 obese individuals (20 men and 7 women with mean BMI: 39.98±5.56 kg/m2)
89497788|NCT02180191||Diabetes|26 patients with newly diagnosed type 2 diabetes (18 men and 8 women with mean BMI: 28.63±5.08 kg/m2)
89497789|NCT02180191||Control|Healthy control subjects (22 men and 6 women with mean BMI: 23.02±1.70 kg/m2)
89497790|NCT02180269|Experimental|Cohort A|Single oral dose of either JNJ-54861911, 25 milligram (mg) tablet or matched placebo tablet on Day 1.
89497791|NCT02180269|Experimental|Cohort B|Single oral dose of either JNJ-54861911, 50 mg (2*25 mg tablets) or matched placebo tablets on Day 1.
89497792|NCT02180269|Experimental|Cohort C|Single oral dose of either JNJ-54861911, 100 mg (4*25 mg tablets) or matched placebo tablets on Day 1.
89497793|NCT05531162|Other|Microgravity condition|a group of parabolic flyers exposed to micro and partial gravity
89497794|NCT03536611|Experimental|dabigatran|dabigatran etexilate 110 mg bid + aspirin 100 mg qd + clopidogrel 75 mg qd for 1 month followed by dabigatran 110mg bid + clopidogrel 75mg/d for at least 5 months
89497795|NCT03536611|Active Comparator|warfarin|warfarin (according to clinical routine monitoring of INR, maintain the therapeutic range at 2.0-3.0) + aspirin 100 mg qd + clopidogrel 75 mg qd for 1 month followed by warfarin + clopidogrel 75mg/d for at least 5 months
89497796|NCT02630459|Placebo Comparator|Double Blind Treatment Phase (DBTP): Placebo|Participants received placebo by subcutaneous injection on day 1 and at weeks 4, 8, 12, 16, and 20 in the double-blind treatment phase.
88955596|NCT06325904|Active Comparator|1|"This group included 30 adult patients with stage I/II pleural empyema who operated initially by VATS.~All patients were subjected to the following:~1. Full history taking. 2.Full clinical examination. 3-Routine Laboratory investigations and Pleural fluid sample analysis. 4- Radiological investigations: Chest X-ray , CT chest.~All patients will be managed by general anesthesia using double lumen endoteracheal tube to achieve single lung ventilation.~All patients were positioned in lateral decubitus position.~Single port skin incisions was made to pass the port through which the camera head and instruments were introduced into the chest .~One chest tubes ws inserted as drains."
89022937|NCT06184542|Active Comparator|DTaP Control (Infants aged 3 months, three-dose)|Diphtheria-Tetanus-acellular Pertussis Vaccine in infants aged 3 months on an M3-M4-M5 immunization schedule
89497797|NCT02630459|Experimental|DBTP: Erenumab 28 mg QM|Participants received erenumab 28 mg by subcutaneous injection on day 1 and at weeks 4, 8, 12, 16, and 20 in the double-blind treatment phase.
89497798|NCT02630459|Experimental|DBTP: Erenumab 70 mg QM|Participants received erenumab 70 mg by subcutaneous injection on day 1 and at weeks 4, 8, 12, 16, and 20 in the double-blind treatment phase.
89497799|NCT02630459|Experimental|DBTP: Erenumab 140 mg QM|Participants received erenumab 140 mg by subcutaneous injection on day 1 and at weeks 4, 8, 12, 16, and 20 in the double-blind treatment phase.
89497800|NCT02630459|Experimental|Open-Label Treatment Phase (OLTP): Erenumab 70-140 mg QM|Participants received an erenumab dose of 70 and/or 140 mg QM SC (depending on the participant's visit completion status after Institutional Review Board [IRB] approval of Protocol Amendment 2) in the OLTP for a total of 76 weeks.
89497801|NCT02630459|Experimental|CHU Sub-Study: Two 70 mg/mL AI/pens|A subset of participants in the OLTP randomized to self administer erenumab via two 70 mg/mL autoinjector (AI)/pens on day 29 and day 57 of the CHU Sub-Study
89497802|NCT02630459|Experimental|CHU Sub-Study: One 140 mg/mL AI/pen|A subset of participants in the OLTP randomized to self administer erenumab via one 140 mg/mL AI/pen on day 29 and day 57 of the CHU Sub-Study
89497803|NCT05528354|Experimental|VEN and DEC based conditioning regimen followed with post-HSCT DEC maintenance therapy|
89497804|NCT03536533|Experimental|Exergame|The Senso is a training system (dividat, Schindellegi, Switzerland) for improving physical and cognitive function was used as exergame. With foot pushes participants triggered on a pressure-sensitive plate. The Senso game was projected with a beamer at white wall. To promote head movement during training the direction of the beamer was vertical tilted (± 15°) and horizontal turned (90°) with a remote controlled power panner.
89497805|NCT02183077|Experimental|Meloxicam gel|
89497806|NCT02183077|Active Comparator|Meloxicam tablet|
89497807|NCT02183155|Experimental|Meloxicam - low|
89497808|NCT02183155|Experimental|Meloxicam - medium|
89497809|NCT02183155|Experimental|Meloxicam - high|
89497810|NCT02183155|Placebo Comparator|Placebo|
89497811|NCT02183155|Active Comparator|Extended-release indomethacin|
89497812|NCT02183233|Experimental|Eschscholtzia Californica|
89497813|NCT02183233|Placebo Comparator|Eschscholtzia Californica Placebo|
89497814|NCT02177461|Experimental|Telmisartan|
89497815|NCT02177461|Active Comparator|Enalapril|
89497816|NCT02177461|Experimental|Telmisartan + clonidine TTS1|
89497817|NCT02177461|Active Comparator|Enalapril + clonidine TTS1|
89497818|NCT03545243|Other|Pantoprazole 40mg in healthy volunteers|Peroral Pantoprazole 40mg once daily for 4 weeks
89497819|NCT03545243|Other|Pantoprazole 40mg in functional dyspepsia|Peroral Pantoprazole 40mg once daily for 4 weeks
89497820|NCT03545243|Other|PPI-withdrawal in functional dyspepsia|no PPI for 8 weeks
89497821|NCT02183311|Experimental|BI 1356 BS - single rising dose|
89497822|NCT02183311|Experimental|BI 1356 BS - multiple rising dose|
89497823|NCT02183311|Active Comparator|Placebo|
89497824|NCT05518526|Experimental|L-Annamycin|
89497825|NCT01464593|Experimental|Thermodox|Thermodox 50 mg/m2 intravenous infusion over 30 minutes starting 15 minutes before thermal ablation.
89497826|NCT02183389|Experimental|Treatment B: BI 1356 and Warfarin|BI 1356 for 12 days combined with a single dose of warfarin on day 6
89497827|NCT02183389|Active Comparator|Treatment A: Warfarin|Warfarin as single dose
89022938|NCT06184542|Active Comparator|PENTAXIM Control (Infants aged 3 months, three-dose)|PENTAXIM (DTaP-IPV-Hib) Vaccine infants aged 3 months on an M3-M4-M5 immunization schedule
89497828|NCT05518448|Experimental|Ketone|Ketone monester (beta-hydroxybutyrate (β-OHB)
89497829|NCT05518448|Placebo Comparator|Placebo|Non-caloric placebo
89497830|NCT02180347||Multifocal contact lenses|Coopervision Proclear Multifocal
89497831|NCT02180347||Single vision contact lenses|Coopervision Proclear Sphere
89497832|NCT02143817|No Intervention|Control|This arm involves not making any change to the subject's lifestyle at the moment of the start of the intervention and for 8 wk.
89497833|NCT02143817|Experimental|Whole body vibration training plus L-citrulline|Lower-body exercise training on a vibration platform combined with L-citrulline supplemetation (6 grams/day)
89497834|NCT02143817|Experimental|Whole body vibration training & placebo|Lower-body exercise training on a vibration platform combined with placebo supplementation (6 grams/day)
89497835|NCT02143817|Experimental|L-citrulline supplementation|(6g per day)containing L-citrulline
89497836|NCT05528276|Active Comparator|standard Tubularized incised plate urethroplasty (sTIPU)|
89497837|NCT05528276|Active Comparator|Preputial inlay graft urethroplasty (PIGU)|
89497838|NCT02177539|Active Comparator|Cyclopentolate|
89497839|NCT02177539|Experimental|Cyclopentolate+tropicamide+phenylephrine|
89497840|NCT05524376||sepsis group|
89497841|NCT05524376||control group|
89497842|NCT06220357|Experimental|Group A (5 mg/mL)|This group received 5 mg/mL of ICG or 100% in terms of concentration. The 1 mL of the ICG solution was taken using a 3 mL syringe
89497843|NCT06220357|Active Comparator|Group B (2,5 mg/mL)|This group received 2,5 mg/mL of ICG or 50% in terms of concentration. The 0.5 mL of the ICG solution was mixed with 0.5 mL of distilled water using a 1 cc syringe
89497844|NCT06220357|Active Comparator|Group C (0,5 mg/mL)|This group received 0,5 mg/mL of ICG or 10% in terms of concentration. The 0.1 mL of the ICG solution was mixed with 0.9 mL of distilled water using a 1 cc syringe
89497845|NCT06220331||Elder patients diagnosed with cataract|Patients that diagnosed with cataract and had implantation with Hanita Intensity IOL or Intensity Toric Lenses in the clinic participating in the study.
89497846|NCT06220305||Pulmonary Nodule Group|patient conform pulmonary nodules on CT images
89497847|NCT06220279|Active Comparator|Arm 1, oral diclofenac|Two doses of 50mg oral diclofenac 12 hours apart was administered to this arm
89497848|NCT06220279|Active Comparator|Arm 2, rectal diclofenac|100mg diclofenac was administered rectally to this arm
89497849|NCT06220253|Other|Vaginal Hysterectomy by bipolar coagulation technique|The surgery will take place according to the canonical times of vaginal hysterectomy, after incision of the portio, detachment of the bladder-vaginal fascia and vaginal rectum, opening of the anterior and posterior peritoneum, taking, section and ligament of the ligaments uterus-sacral ligaments, and subsequent coagulation by bipolar instrument of the other structures of the uterus and their section, in particular of the uterine arteries, tubes, uterine-ovarian ligaments and round ligament bilaterally.
89497850|NCT06220253|Other|Vaginal hysterectomy by traditional technique with reabsorbable stitches|The surgery will take place according to the canonical times of vaginal hysterectomy, after incision of the port, detachment of the bladder-vaginal fascia and vaginal rectum, opening of the anterior and posterior peritoneum, taking and suturing with absorbable threads of all the support structures of the uterus, in particular uterus-sacral ligaments, uterine arteries, tubes, uterine-ovarian ligaments and round ligament bilaterally.
89497851|NCT06220240|Active Comparator|Modified Training Group|It is a training program that will be carried out under the supervision of a physiotherapist. There will be 3-minute breaks between sets. A training program will be applied to the athletes based on revising the training program they use in their routine with eccentric contractions.
89497852|NCT06220240|Active Comparator|Routine Training Group|The training program that the athlete uses in her normal routine will be implemented under the supervision of a physiotherapist.
89497853|NCT06220227||embryologist freezing the embryo|
89497854|NCT06220227||embryologist thawing the embryo|
89497855|NCT06220175|Experimental|Strepsils Intensiv Arm|"Patient will take one pill of Strepsils Intensiv containing 8.75mg flurbiprofen 10 to 15 minutes before endoscopy.~The patient will not have pharyngeal topical xilocaine spray before upper GI endoscopy."
89497856|NCT06220175|Active Comparator|Xilocaine Spray Arm|The patient will have pharyngeal topical xilocaine spray before upper GI endoscopy, 5 puffs in two applications immediately before examination.
89497857|NCT06220149||Post polypectomy cohort|
89497858|NCT06220123|Experimental|Investigational product arm|
89497859|NCT06220123|Active Comparator|Positive control arm|
89497860|NCT06220097|Experimental|Effective of MHL injection-containing bridging regimens with CD19 CAR-T|After enrollment, all subjects will receive a combination regimen of mitoxantrone hydrochloride liposomal injection within 28 days to 7 days before CAR-T infusions will be included, including but not limited to the R-MINE regimen (mitoxantrone hydrochloride liposomal injection combined with rituximab, mesna, ifosfamide and etoposide), G-MINE regimen (mitoxantrone hydrochloride liposomal injection combined with obinutuzumab, mesna, ifosfamide and etoposide), MAE scheme (mitoxantrone hydrochloride liposomal injection combined with cytarabine, etoposide), etc.
89497861|NCT06220084|Experimental|Live DfPD®|Eight weeks intervention of two 60min live dance classes per week plus their usual care
89497862|NCT06220084|Experimental|Remote DfPD®|Eight weeks intervention of two 60min online-via zoom platform dance classes per week plus their usual care
89497863|NCT06220084|No Intervention|Control|Non-interventional group in which participants receive their usual care only
89497864|NCT06220058|Experimental|Group Bites|"Closure of the midline laparotomy using the small bites technique"
89497865|NCT06220058|Experimental|Group Mesh|"Closure of the midline laparotomy using the small bites technique adding a suprapubic polypropylene mesh."
89497866|NCT06220045|Experimental|Polyvinylidene fluoride mesh|"In all patients, surgery will be performed according to their individual pathology. Once midline laparotomy closure is initiated, randomization will be conducted, and patients will be assigned to one of the two groups.~PVDF Group (Polyvinylidene Fluoride Mesh): Midline laparotomy closure using the small bites technique associated with a prophylactic suprafascial polyvinylidene fluoride mesh"
89497867|NCT06220045|Experimental|Prophylactic polypropylene mesh|"In all patients, surgery will be performed according to their individual pathology. Once midline laparotomy closure is initiated, randomization will be conducted, and patients will be assigned to one of the two groups.~PP Group (Polypropylene Mesh): Midline laparotomy closure using the small bites technique associated with a prophylactic suprafascial polypropylene mesh."
89497868|NCT06220019||TCM cohort|"The main syndromes of discharged CAP patients included in the traditional Chinese medicine queue are Qi deficiency phlegm dampness syndrome and Qi yin deficiency phlegm heat syndrome, mainly referring to the 2011 edition of the Diagnosis Standards for Traditional Chinese Medicine Syndrome of Community Acquired Pneumonia issued by the Pulmonary Disease Professional Committee of the Internal Medicine Branch of the Chinese Society of Traditional Chinese Medicine. The exposure factors are the use of modified formulas for tonifying the lungs, strengthening the spleen, and resolving phlegm, or modified formulas for tonifying qi, nourishing yin, and clearing the lungs. Patients with other syndrome types can truthfully record their syndrome types and use traditional Chinese medicine prescriptions."
89497869|NCT06220019||Non TCM queue|CAP patients discharged within 7 days who meet the inclusion and exclusion criteria, and those who do not meet the traditional Chinese medicine queue.
89497870|NCT06220006|Experimental|Pulsed Field Ablation|Pulmonary vein isolation using the Farapulse Pulsed Field Ablation System (Boston Scientific)
89497871|NCT06220006|Active Comparator|Cryoballoon Ablation|Pulmonary vein isolation using the Medtronic Cryoballoon Ablation System
89497872|NCT06219993||RKPE group|"Firstly, the Exploring hepatic subcapsular spider-like telangiectasis (HSST) sign at the surface of the liver, and indocyanine green (ICG) cholangiography were observed to confirm the BA diagnosis by Da Vinci robot.~The Roux-en-Y jejunojejunostomy reconstruction was fashioned extracorporeally through the umbilical incision.~With Da Vinci robotic electric scissors help, the fibrous plate was horizontally cut from the middle of the portal plate and transected from to the left and to the right sides which was the Glissonian systems enter the liver parenchyma until see the bile outflow by verified by ICG. The opening of microbile ducts and abundant bile outflow were clearly visible under 10× camera of Da Vinci robot.~Last, an end-to-side hepaticojejunostomy was conducted with one-layer continuous 5-0 PDS sutures posteriorly and anteriorly. A drainage tube was left under the liver, and the incision was closed."
89531801|NCT05322174|Active Comparator|Baby Care|The active control condition will parallel the intervention, but will be focused on general baby care and not sleep. Participants will be added to a private Facebook group in which general baby care information will be shared (e.g., bathing, play) and will receive items to help with general baby care (e.g., baby care kit with items such as nail clippers and comb; general baby care book). Topics related to sleep and feeding will not be highlighted in this group.
89022939|NCT06184542|Experimental|Intervention (Infants aged 2 months, three-dose, 2-3-4)|Diphtheria-Tetanus-acellular Pertussis Component Combined Vaccine in infants aged 2 months on an M2-M3-M4 immunization schedule
89022940|NCT06184542|Experimental|Intervention (Infants aged 2 months, three-dose, 2-4-6)|Diphtheria-Tetanus-acellular Pertussis Component Combined Vaccine in infants aged 2 months on an M2-M4-M6 immunization schedule
89022941|NCT06184542|Active Comparator|PENTAXIM Control (Infants aged 2 months, three-dose)|PENTAXIM (DTaP-IPV-Hib) Vaccine infants aged 2 months on an M2-M3-M4 immunization schedule
89022942|NCT06184295|Experimental|TBI - Intervention Group|The participants will receive 10 customized robotic balance training sessions to improve balance using the Hunova robotic device. Each session will last for up to 1.5 hours. The training may include standing or sitting on the robotic balance platform and performing the following tasks: maintaining balance when the platform becomes unstable or moving in various directions, or in an inclination; these tasks may be performed as instructed with eyes open or eyes closed condition; move in different directions to reach targets with my hands; stand on one leg or heel to toe and maintain balance; perform head or torso rotation while standing or sitting. All training will be performed with an overhead harness and a spotter will be present at all times.
89022943|NCT06184295|No Intervention|TBI - Non Intervention Group|Participants will receive no intervention
89022944|NCT06184295|No Intervention|Participants without disability group|Participants will receive no intervention
89022945|NCT06184282|Experimental|MEBO group|MEBO (Julphar®, Ras Al Khaimah, United Arab Emirates) was applied using sterile plastic brush daily and the patients were recalled at 2, 5 and 10 days for evaluating the healing of the ulcer.
89205447|NCT05275751|Experimental|Hot injection with TRPA1- and TRPV1-inhibition|Pain is induced by an increasingly hot intradermal injection up to 52°C over 2 minutes, while TRPA1 and TRPV1 are blocked pharmacologically by an antagonist dissolved in the hot fluid (synthetic interstitial fluid). The antagonist(s) have sufficient concentration to reliably block the channel. The total dose is in the range of a microdose trial.
89205448|NCT05275751|Experimental|Hot injection with TRPA1- and TRPM3-inhibition|Pain is induced by an increasingly hot intradermal injection up to 52°C over 2 minutes, while TRPA1 and TRPM3 are blocked pharmacologically by an antagonist dissolved in the hot fluid (synthetic interstitial fluid). The antagonist(s) have sufficient concentration to reliably block the channel. The total dose is in the range of a microdose trial.
89497873|NCT06219993||OKPE group|"The Exploring hepatic subcapsular spider-like telangiectasis (HSST) sign at the surface of the liver, cholangiography were observed to confirm the BA diagnosis by conventional open surgery.~The Roux-en-Y jejunojejunostomy reconstruction by hand-sewn anastomosis.~Dissecting forceps and electric scissors were applied to dissociate the atresia bile ducts and lymph nodes in portal hepatis. Exposed the hepatic artery and portal vein. All portal vein tributaries that drain into the fibrous cone were coagulated by bipolar coagulation to expose the portal plate for resection. With scissors help, the fibrous cone of the hilar region was transected from left to right (the level of transection depends on adequate bile outflow).~Last, an end-to-side hepaticojejunostomy was conducted with one-layer interrupt 5-0 PDS sutures posteriorly and anteriorly. A drainage tube was left under the liver, and the incision was closed."
89497874|NCT06219967|Experimental|Activated charcoal with cola|
89497875|NCT06219967|Active Comparator|Activated charcoal|
89497876|NCT06219928|Active Comparator|Control Group|After intubation, saline infusion will be started. The control group will also be infused with the same volume of saline..
89497877|NCT06219928|Active Comparator|Ketamin Group|After intubation, the patient will be started on ketamine infusion at a low dose of 0.25mg/kg/hour.
89497878|NCT06219928|Active Comparator|Dexmedetomidine Group|After intubation, the patient will be infused at a low dose of 1 mg/kg dexmedetomidine for the first 10 minutes, then 0.5 mg/kg/hour
89497879|NCT06219889|Active Comparator|Hourly Neurochecks|Patients will be awakened hourly for their examinations
89497880|NCT06219889|Experimental|Every-Other-Hour Neurochecks|Patients will be awakened every other hour for their examinations
89497881|NCT06219876|Active Comparator|Control|wrist splints of an appropriate size in a neutral position for at least 8 hours at night for 3 months
89497882|NCT06219876|Active Comparator|Low Level Laser Treatment|"wrist splints of an appropriate size in a neutral position for at least 8 hours at night for 3 months~received an additional LLLT"
89497883|NCT06219876|Active Comparator|High Intensity Laser Treatment|"wrist splints of an appropriate size in a neutral position for at least 8 hours at night for 3 months~received an additional HILT"
89497884|NCT06219863|Experimental|Body weight supported harness|Harness is set up in families' homes for one month. Caregivers re asked to use the harness with their infant for 30 min/day, 5 times a week.
89497885|NCT06219850||HIIT+Diet|High-Intensity Interval Training (HIIT) and Nutritional education
89497886|NCT06219850||MICT+Diet|Moderate-Intensity Continuous Training (MICT) and Nutritional education
89497887|NCT06219850||HIIT+NoDiet|High-Intensity Interval Training (HIIT) without Nutritional education. The HIIT training consisted of 3 sessions per week in a cycle ergometer, with 1-2 days off between sessions, during a total of 12 weeks under the supervision of a personal trainer. HIIT program consisted of 10 series of 1 min duration at 90% of peak power output, with 60 seconds of rest between sets (estimated total time of the session: 25 minutes).
89497888|NCT06219850||MICT+NoDiet|Moderate-Intensity Continuous Training (MICT) without Nutritional education. The MICT training consisted of 3 sessions per week in a cycle ergometer during 50 min at moderate intensity, with 1-2 days off between sessions, during a total of 12 weeks under the supervision of a personal trainer.
89497889|NCT06219850||Diet+NoExercise|Nutritional education without Exercise. The education intervention consisted of individual nutritional counselling. The nutritional education program was conducted every 2 weeks for 12 consecutive weeks, with 20-min counselling sessions by an experienced nutritionist. Participants were provided with an introduction (in an easy-to-understand manner) regarding the association between T2DM, gut microbiome and dietary habits. Firstly, the diet of the patient should be analysed, to determine which aspects can be improved, such as, total calories intake, amount and types of carbohydrates (highlighting the relevance of fibre), etc. Moreover, some suggestions about the combination of foods and culinary technical in order to manage the glycaemic index of foods were provided.
89497890|NCT06219850||Control group|Neither exercise nor nutritional education
88955597|NCT06325904|Placebo Comparator|2|"This group included 30 adult patients with stage I/II pleural empyema who underwent conventional tube thoracotomy.~All patients were subjected to the following:~1. Full history taking. 2.Full clinical examination. 3-Routine Laboratory investigations and Pleural fluid sample analysis. 4- Radiological investigations: Chest X-ray , CT chest.~The patient is placed in a supine position.~The intercostals pace is opened .~Chest tube is inserted in proper position regarding the site of fluid collection."
88955598|NCT06325852|Experimental|Phase 1|5 to 10 patients with tremor already treated with VIM-DBS but not doing well because of early or late loss of benefits will be recruited by the PI over a 6 months period. If interested, the potential participants will be screened, informed, and consented by a research coordinator. Before the replacement of their IPG (implantable pulse generator), a baseline measurement will be performed.
88955599|NCT06325852|Experimental|Phase 2|Ten patients with ET needing DBS-VIM surgery will be recruited and will receive Boston Scientific Genus IPG bilaterally connected to Boston Scientific Cartesia™ 8-contact Directional Leads. The programming will be done in four different settings/periods during the course of 8 months.
88955600|NCT06325787|Active Comparator|lobectomy|thyroid lobectomy, is recommended as first-line treatment for papillary thyroid micraocarcinima
88955601|NCT06325787|Experimental|image-guided thermal ablation|radiofrequency ablation or microwave ablation
89205449|NCT05275751|Experimental|Hot injection with TRPM3- and TRPV1-inhibition|Pain is induced by an increasingly hot intradermal injection up to 52°C over 2 minutes, while TRPM3 and TRPV1 are blocked pharmacologically by an antagonist dissolved in the hot fluid (synthetic interstitial fluid). The antagonist(s) have sufficient concentration to reliably block the channel. The total dose is in the range of a microdose trial.
89497891|NCT06219837|Active Comparator|bupivacaine group|the patient in this arm will receive 20 ml of 0.25% bupivacaine injection by ultrasound guided transversalis fascia block for inguinal herniorraphy
88955606|NCT06325579|Experimental|Dysphagia patients using VR|"Day 1: Consent taken 5mins. Baseline period wearing strain gauge 5mins, it´d pick up and measure the patient's swallow movements while at rest not using the VR. IVR trial 25mins, the headset will be refitted and instructions to use two different games for up to 10 minutes with a 5-minute break in between. The SALT Assistant would be closely guide and monitor the participant. The experience will be concluded for the day if the participant shows sign of or indicates discomfort.~Days 2-4 (30-35mins) same proceed as above, minus the test experience (Baseline period (5 mins) and IVR trial (25 mins).~Day 5 (40-45mins) final day of the trial and after take part in a short semi-structured interview (10mins) in person and audio recorded by the SALT Assistant. SALT Assistant post-trial interview (25-40mins) online audio recorded by a member of the research team ."
88955607|NCT06324526||People undergoing bariatric surgery|People under going primary bariatric surgery between 1st June 2017 and 23rd November 2022 with complete health-related quality of life records (EQ-5D) with one pre-operative and at least one follow-up record within 1 year of surgery.
88955608|NCT06324409|Active Comparator|Reminder telephone call|A reminder telephone call with information on colorectal cancer screening in the language of origin (Urdu or Somali) in addition to the reminder letter in Norwegian (usual care)
88955609|NCT06324409|No Intervention|Comparison|The reminder letter in Norwegian (usual care) only
88955610|NCT06324344|Active Comparator|Intervention Group|"The intervention group will be undergoing Transcutaneous Electrical Nerve Stimulation (TENS) therapy on a daily basis with a high-dose TENS device for 8 weeks.~The high-dose TENS device elicits 1 hour of TENS per session. Subjects are instructed to complete at least 3 sessions per day. To deliver TENS, a band strap with hydrogel pads will be placed around the calf muscle of one lower-extremity alternating to the other side on a weekly basis."
88955611|NCT06324344|Placebo Comparator|Placebo Group|"The placebo group will be undergoing Transcutaneous Electrical Nerve Stimulation (TENS) therapy on a daily basis with a low-dose TENS device for 8 weeks.~The low-dose TENS device is identical to the high-dose TENS device in all respects except that it delivers 6 minutes of TENS therapy per session (10% out of 60 minutes). Subjects are instructed to complete at least 3 sessions per day. To deliver TENS, a band strap with hydrogel pads will be placed around the calf muscle of one lower-extremity alternating to the other side on a weekly basis."
88955612|NCT06324123||Patients with neuropathic pain|Patients with acute or chronic neuropathic pain
88955613|NCT06323603||1. Textile industry workers|Workers from the textile industry, that manufactures non-wovens fibers
88955614|NCT06323603||2. Plastic Recycling Workers|Workers involved in recycling and waste management of plastic
88955615|NCT06323603||3. Controls|Control group that will match the characteristics of grup 1 and 2
88955616|NCT06323551|Experimental|Mother's Smell|In the study group that will be made to smell the mother's scent; The mother of each baby whose heel blood will be taken will be given a specially made cover made of 100% cotton yarn, sterilized the day before, and the mother will be asked to put the cover on her bare skin (on her bare skin) after the shower and to keep the cover on the mother's chest for one night (8 hours). one). It will be placed 15 cm away from the baby and smelled 5 minutes before and 5 minutes after the heel prick attempt (1,4). The baby's pain score will be evaluated by the observing nurse according to the NIPS pain scale 5 minutes before, during and 5 minutes after the procedure.
88955617|NCT06323551|Experimental|Mother's Breast Milk Smell|In the study group that will be made to smell the scent of breast milk, the procedures for the scent of the mother will be carried out in the same way, and 20 drops of each baby's own mother's milk will be dropped onto the diaper (4). The cover, which has the scent of breast milk, will be placed 15 cm away from the baby and allowed to smell it from 5 minutes before to 5 minutes after the heel prick blood collection attempt. The baby's pain score will be evaluated by the observing nurse according to the NIPS pain scale 5 minutes before, during and 5 minutes after the procedure.
88955618|NCT06323551|No Intervention|Control|Routine care will be provided to the control group and no intervention will be applied.
88955619|NCT06323499||Induced atypical atrial flutter|Sinus rhythm when starting the procedure, so atypical atrial flutter had to be induced.
88955620|NCT06323499||Ongoing atrial flutter|Atypical atrial flutter was already ongoing when starting the procedure.
88955622|NCT06322264||Pediatric patients|Pediatric patients between the ages of 4 and 12 undergoing conventional X-ray examinations.
88955623|NCT06322264||Parents|Parents of the included pediatric patients between the ages of 4 and 12 undergoing conventional X-ray examinations.
88955624|NCT06322264||Radiographers|Radiographers who examine the included pediatric patients between the ages of 4 and 12 undergoing conventional X-ray examinations.
88955625|NCT06322134||Fatal drowning|Drowning incidents where the patient dies within 30 days after the incident as a consequence of the submersion or immersion injury
89497892|NCT06219837|Placebo Comparator|20 ml of 0.9% normal saline solution|he patient in this arm will receive 20 ml of 0.9% normal saline solution by ultrasound guided transversalis fascia block for inguinal herniorraphy
89497893|NCT06219811|Experimental|Mandibular implant-retained overdenture reinforced with a Co-Cr framework|The patient received a mandibular implant-retained acrylic overdenture reinforced with a Co-Cr framework. The framework is manufactured by milling polymethylmethacrylate (PMMA) and then the PMMA undergo conventional casting to produce cobalt chromium (Co-Cr) framework. The framework included in the overdenture by conventional processing technique.
89497894|NCT06219811|Active Comparator|Mandibular implant-retained overdenture reinforced with a PEKK framework|The patient received a mandibular implant-retained acrylic overdenture reinforced with a Polyetherketoneketone (PEKK) framework. The framework is manufactured by milling PEKK the framework included in the overdenture by conventional processing technique.
89497895|NCT06219798||Name of Arm 1: Study group|Description: Full participation (medical + dietitian+ specialist nurse)
89497896|NCT06219798||Name of Arm 2: Control 1|Description: Partial participation (medical+ dietitian OR specialist nurse)
89497897|NCT06219798||Name of Arm 3: Control 2|Description: No participation (medical visit only)
89497898|NCT06219785|Active Comparator|Active|"Patient lies down with legs extended.~In order to get a proper transmission, a drop of silicone oil is applied on the anatomical stand-off before putting the ring.~Connect the headpiece to the ring.~Apply ultrasound gel for proper energy transmission on the shaft of the penis~1500 shocks to the lateral penile shaft (distal, mid, and proximal penile shaft), 500 impulses in each area, for a total of 1500 shocks along the penis~Duration of the procedure: approximately 30 minutes"
89497899|NCT06219785|Sham Comparator|Control|"Patient lies down with legs extended.~In order to get a proper transmission, a drop of silicone oil is applied on the anatomical stand-off before putting the ring.~Connect the headpiece to the ring.~Apply ultrasound gel for proper energy transmission on the shaft of the penis~1500 shocks to the lateral penile shaft (distal, mid, and proximal penile shaft), 500 impulses in each area, for a total of 1500 shocks along the penis~Duration of the procedure: approximately 30 minutes"
89497900|NCT06219746|No Intervention|Control arm|Subjects undergo bone scintigraphy and whole body CT
89497901|NCT06219746|Experimental|Experimental arm|Subjects undergo bone scintigraphy, whole body CT, 99mTc-MIP-1404 SPECT/CT, and 18F- PSMA-1007 PET/CT
89497902|NCT06219733|Experimental|Vactosertib and imatinib combination|Vactosertib 200 mg PO BID 5 days on / 2 days off in combination with imatinib 400 mg PO QD daily
89497903|NCT06219733|Active Comparator|Imatinib alone|Imatinib 400 mg PO QD daily
89497904|NCT06219707|Experimental|Electro-Acupuncture group|Disposable acupuncture needles (0.30 mm in diameter and 25-40 mm in length) are inserted at a depth of 10-30 mm obliquely into scalp acupuncture points (Baihui, Toulinqi) or straightly into body acupuncture points (Taichong, Zhangmen, Sanyinjiao, Zhongwan, Guanyuan, Tianshu, Zusanli). Electroacupuncture will be applied to the abdominal points at fast and dispersed waves through electric needle stimulator (ES-160 6-Channel Programmable Electro-acupuncture) for 30 min. The intensity is adjusted to a level at which patients feel comfortable. The alternating stimulation is believed to produce maximal biochemical responses in the brain [1].
89497905|NCT06219707|Sham Comparator|Sham-Acupuncture group|Disposable acupuncture needles (0.30 mm in diameter and 25-40 mm in length) are inserted (actual penetration of the skin) at the same way as in the acupuncture group but on sham-acupuncture points (Sham-Baihui, Sham-Toulinqi, Sham-Taichong, Sham-Zhangmen, Sham-Sanyinjiao, Sham-Zhongwan, Sham-Guanyuan, Sham-Tianshu, Sham-Zusanli. The sham points aren't acupuncture points nor located on meridians [2].
89497906|NCT06219655|Active Comparator|Extended symathectomy|
89497907|NCT06219655|Active Comparator|limited sympathectomy|
89497908|NCT06219642|Experimental|VR mindfulness intervention|The intervention consists of a total of 10 sessions each lasting 30 minutes. In each session, we fit participants with the VR headset with a smartphone running the Sites for VR app. The phone, placed in the viewing compartment of the headset, shows a nature scene of the participant's choosing. Once participants have acclimated to the scene and understand how to look around the VR scene (by moving their heads in different directions), we will read a mindfulness script with a guided body scan and instructions to engage participants through experiencing the virtual reality nature scene with all senses.
89497909|NCT06219642|No Intervention|Phone call check-in|Investigators will call patients every week and ask how they are doing.
89497910|NCT06219616|Other|BKV immune monitoring|"In this prospective cohort, the included kidney transplant recipients will receive regular post-transplantation care, including routine therapeutic drug monitoring of tacrolimus and screening for BK viremia. No extra medications beyond the standard of care will be given to the patients in this study.~Whole blood will be drawn from kidney transplant recipients on day 30, day 180, and at the time of BK viremia. PBMCs will be separated and incubated with BK viral peptides.~PBMCs will be stained for surface marker of activated T cells and intracellular cytokines 4. Phenotypic features of T cells will be analyzed under flow cytometry and correlated with the occurrence of BKV infection and immunosuppressive medications."
89497911|NCT06219603||excellent|participants who answered on > 80 % of the questioned correctly
89497912|NCT06219603||good|participants who answered on 61 - 80 % of the questioned correctly
89497913|NCT06219603||average|participants who answered on 41 - 60 % of the questioned correctly
89497914|NCT06219603||bad|participants who answered on 21 - 40 % of the questioned correctly
89205450|NCT05275751|Experimental|Hot injection with TRPA1-, TRPV1 and TRPM3-inhibition|Pain is induced by an increasingly hot intradermal injection up to 52°C over 2 minutes, while TRPA1, TRPV1 and TRPM3 are blocked pharmacologically by an antagonist dissolved in the hot fluid (synthetic interstitial fluid). The antagonist(s) have sufficient concentration to reliably block the channel. The total dose is in the range of a microdose trial.
88955626|NCT06322134||Non-fatal drowning|Drowning incidents where the patient survive to 30 days after the submersion or immersion injury.
89497915|NCT06219603||very bad|participants who answered on <=20 % of the questioned correctly
89497916|NCT06219590|Active Comparator|Study group (A)|"40 patients with type 2 diabetes mellitus clinically proved peripheral neuropathy.~Both groups were received conventional medical treatment and healthy diet.~Group A was received iontophoresis by acetylcholine with (15) min for three sessions per week for four weeks."
89497917|NCT06219590|Sham Comparator|Control group (B)|"40 patients with asymptomatic type 2 diabetes mellitus, both groups were selected from south valley university hospitals.~Both groups were received conventional medical treatment and healthy diet.~Group (B) was received shame iontophoresis with (15) min for three sessions per week for four weeks."
89497918|NCT06219564|Active Comparator|Total placenta previa (t-PP) patients who underwent placental MRI (p-MRI).|"The study compares clinical factors and p-MRI findings between two surgical procedures: Caesarean Section (C/S) and Peripartum Total Abdominal Hysterectomy (p-TAH). The study analyzes both univariate and multivariate associations with surgical procedures.~This arm presents the results of a study assessing risk factors affecting peripartum hysterectomy in placenta previa patients, focusing on the impact of MRI screening. Peripartum hysterectomy (p-TAH) refers to the surgical removal of the uterus around the time of childbirth.~The arm does not explicitly mention specific interventions to be administered. However, it provides information on clinical and p-MRI factors that might influence the surgical procedure (C/S or p-TAH) choice in placenta previa patients. The interventions, if any, would likely be based on assessing these risk factors and involve decisions on the type of surgery, additional procedures, or use of certain medical interventions based on the patient's condition."
89497919|NCT06219564|Active Comparator|Total placenta previa (t-PP) patients who did not undergo placental MRI (p-MRI).|"The study compares clinical factors without p-MRI between two surgical procedures: Cesarean Section (C/S) and Peripartum Total Abdominal Hysterectomy (p-TAH). The study analyzes both univariate and multivariate associations with surgical procedures.~This arm presents the results of a study assessing risk factors affecting peripartum hysterectomy (p-TAH) in placenta previa patients, focusing on the impact of clinical factors.~The arm does not explicitly mention specific interventions to be administered. However, it provides information on clinical factors that might influence the surgical procedure (C/S or p-TAH) choice in placenta previa patients. The interventions, if any, would likely be based on assessing these risk factors and involve decisions on the type of surgery, additional procedures, or use of certain medical interventions based on the patient's condition."
89497920|NCT06219551|Active Comparator|Usual care|Usual care arm, smoker patients with rheumatologist diseases will be implemented brief smoking cessation interventions and referred to quit lines or smoking cessation services and also directly contacted to get an appointment from the cessation clinic.
89497921|NCT06219551|Experimental|Intervention|The intervention arm, smoker patients with rheumatologist diseases will be implemented brief tobacco cessation interventions and directly contacted to get an appointment from cessation clinic and will be send periodically motivational and informative text messages regarding tobacco cessation via WhatsApp.
89497922|NCT06219525|Active Comparator|Higher dose of enteral zinc|higher dose of zinc sulfate 10 mg/day; each 1 mL contains 10 mg of elemental zinc (osmolality 450 Osm/kg H2O).
89497923|NCT06219525|Placebo Comparator|Standard dose of enteral zinc|standard dose of zinc sulfate 1 mg/day; each 1 mL contains 1 mg of elemental zinc (osmolality 45 Osm/kg H2O).
89497924|NCT06219512|Experimental|CPET exercise prescription group|Formulate exercise prescription of cardiopulmonary exercise test (CPET) according to the principle of FITT [frequency, intensity, time and type]
89497925|NCT06219512|Experimental|6MWT exercise prescription group|Exercise prescription is set according to the recommendation of the Chinese expert consensus on the application of clinical norms of six-minute walking test
89497926|NCT06219512|Active Comparator|Regular exercise group|Carry out regular exercise as usual
89497927|NCT06219499|Placebo Comparator|Placebo|
89497928|NCT06219499|Experimental|ONC-841|
89497929|NCT06219486|No Intervention|Placebo|Usual care
89497930|NCT06219486|Experimental|Intervention|Use of D-dimer to guide care of the patient
89497931|NCT06219473|Experimental|Fascia Lata (Study group)|It includes eight patients seeking for implant placement in the upper anterior areas and implants will be placed with the application of fascia lata allograft membrane.
89497932|NCT06219473|Experimental|PRF (Study group)|It includes eight patients seeking for implant placement in the upper anterior area and implants will be placed with the application of PRF.
89497933|NCT06219473|Active Comparator|Connective tissue Graft(Control group)|It includes eight patients seeking for single implant placement at the upper anterior area and those patients will be received their implants with subepithelial connective tissue graft.
89497934|NCT06219460|Experimental|Cuffed face amsk|Ventilation using cuffed face mask
89497935|NCT06219460|Experimental|Uncuffed face mask|Ventilation using uncuffed face mask
88955627|NCT06321926|Experimental|Intervention group|Participants in the intervention group use the ActiveWaiting App for one week.
88955628|NCT06321926|Other|Waitlist control group|Participants in the waitlist control group go through a one-week control period without any intervention first, before they are using the app for one week.
88955629|NCT06321588||retrospective cohort|patients with a diagnosis of new-onset neurocognitive disorders (major and minor) with onset within the previous 24 months
89497936|NCT06219447|Experimental|Experimental group|Children will be immediately trained through the TABLET TOSCANA technologies (VRRS Home Tablet or Medico Amico Kids APP) for a cycle of 3 months.
89497937|NCT06219447|No Intervention|Waitlist group|Children will continue standard care for 3 months and after that they will be guaranteed to be enrolled for the next 3-month cycle through the TABLET TOSCANA technologies (VRRS Home Tablet or Medico Amico Kids APP).
88955630|NCT06321588||prospective cohort|patients with a diagnosis of new-onset neurocognitive disorders (major and minor) with onset within the previous 24 months
89497938|NCT06219434|Experimental|Supportive care (mindfulness program)|Patients participate in a mindfulness program composed of topics that include mindfulness of breathing and the body scan, mindful eating, mindful activity, mindfulness in daily life, expanding the field of awareness, and maintaining a flexible mindfulness practice weekly over 2.5 hours for 8 weeks. Patients also undergo blood sample collection and fMRI on the study.
89497939|NCT06219421||Patients|
89497940|NCT06219421||Controls|
89497941|NCT06219395||Iron deficiency anaemia|Persons 18-85 years with Iron deficiency anaemia referred for gastroscopy and colonoscopy
89497942|NCT06219382||Neurorehabilitation ecosystem (NEST)|Patients will use Nest apart from the regular neurorehabilitation treatment
89497943|NCT06219343|Experimental|Transcervical non-invasive vagus nerve stimulation group|Patient will be treated with non-invasive electrical stimulation of the left vagus nerve in the neck. After routine induction of atrioventricular reentrant tachycardia prior to radiofrequency ablation, the electrode patch was placed on the patient's left cervical vagal body surface localization, i.e., between the sternocleidomastoid muscle and the trachea where the left common carotid artery pulsation could be palpated, and resuscitation was performed using non-invasive electrical stimulation.
89497944|NCT06219330||Group I (control group)|15 Healthy participants without any oral lesions
89497945|NCT06219330||Group II:|15 Patients having atrophic/erosive oral lichen planus (OLP). Group III: 15 Patients having oral leukoplakia
89497946|NCT06219330||Group III:|15 Patients having oral leukoplakia
89497947|NCT06219317|Experimental|Cemiplimab|Cemiplimab IV 350 mg every 3 weeks for up to 12 months or until progression or discontinuation
89497948|NCT06219317|Placebo Comparator|Placebo|Placebo (saline solution) IV every 3 weeks for up to 12 months or until progression or discontinuation
89497949|NCT06219304|Experimental|Multimodal functional training|Multimodal training to reduce fatigue and to improve balance and strength
89497950|NCT06219304|Active Comparator|Usual care|Rehabilitative intervention to improve balance and mobility
89497951|NCT06219265|Experimental|Experimental group 1: people with SMD receiving dance therapy|Intervention group of people with SMD (n=26) who receive a 20-session dance therapy program for 10 weeks with 2 sessions per week in which they work for 1 hour on memory, attention and executive functions through dance and movement, ending with 10 minutes of Mindfulness.
89497952|NCT06219265|No Intervention|Control group: people with SMD who do not receive any intervention|This group of 21 persons with SMD will not receive any intervention.
89497953|NCT06219239|Experimental|KL003 cell injection Drug Product|Traditional myeloablative conditioning regimen consists of Busulfan, which may increase the risk of irreversible pulmonary fibrosis, VOD, and infertility due to potential serious toxicity. In this study, we intend to use genetic hematopoietic stem cells (lentivirus transduction) transfusion with no conditioning regimen, which could avoid toxicity due to chemotherapy drugs.
89497954|NCT06219213|Experimental|Group A: Cream of formulation A|Daily application of glyceryl Eicosapentaenoate serum and glyceryl Eicosapentaenoate cream of formulation A on both targeted skin area. The skin areas must be clean and dry. Subjects may proceed with additional product applications if needed. However, for each additional application, both targeted areas must be treated with the Serum and the cream. Subjects must proceed with at least one application of products each day for 14 consecutive days.
89497955|NCT06219213|Experimental|Group B: Cream of formulation B|Daily application of glyceryl Eicosapentaenoate serum and glyceryl Eicosapentaenoate cream of formulation B on both targeted skin area. The skin areas must be clean and dry. Subjects may proceed with additional product applications if needed. However, for each additional application, both targeted areas must be treated with the Serum and the cream. Subjects must proceed with at least one application of products each day for 14 consecutive days.
88955631|NCT06321562|Experimental|Group 1: TimoD implant-Dose 1 (low dose)|Participants in the Group 1 will receive a low dose of TimoD implant in the study eye on Day 1.
88955632|NCT06321562|Experimental|Group 2: TimoD implant-Dose 2 (intermediate dose)|Participants in Group 2 will receive an intermediate dose of TimoD implant in the study eye on Day 1 if all participants in Group 1 have completed a 4-week treatment period with the lowest dose of TimoD implant, providing there are no safety issues in Group 1.
88955633|NCT06321562|Experimental|Group3: TimoD implant-Dose 3 (high dose)|Participants in Group 3 will receive a high dose of TimoD implant in the study eye on Day 1 if all participants in Group 2 have completed a 4-week treatment period with the intermediate dose, providing there are no safety issues in Group 2.
88955634|NCT06321289|Experimental|Allogeneic TRAC locus-inserted CD19-targeting STAR T cells|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide (FC regimen) will be administered followed by investigational treatment, allogeneic targeting CD19 synthetic T-cell receptor antigen receptor T cells.
89538225|NCT02444689|Experimental|Electronic Media Application|Participants will receive an age-appropriate behavioral intervention designed to promote weight loss, improved diet quality, and exercise.
89538226|NCT02444689|Active Comparator|Control|Participants will receive standard of care education and feedback on how to implement a heart healthy lifestyle to promote weight loss, improved diet quality and exercise.
88955638|NCT06319365|Experimental|yoga group|the yoga practice of the group should be completed at the end of 12 weeks. Participants should be encouraged to practice at home 3 days a week for 3 months. An example of yoga practices in the research for women should be shared as a video.
88955639|NCT06319365|No Intervention|control group|The control group should be continue standard hypertension treatment
88955640|NCT06319352|Experimental|Active UroShield|Active UroShield Device
88955641|NCT06319352|Sham Comparator|Sham UroShield|Inactive UroShield device
88955642|NCT06318533|Experimental|anti-CD19 CAR NK cells|
88955643|NCT06318169|Experimental|Pegozafermin Regimen 1|
88955644|NCT06318169|Experimental|Pegozafermin Regimen 2|
88955645|NCT06318169|Placebo Comparator|Placebo|Matched Placebo will be administered in Regimens 1 and 2.
88955646|NCT06318117||Rice infant formula started before age of 6 months|"After inclusion (V1), infants will return for a V2 visit at 12 months (± 30 days) of age (according to the child's regular appointment calendar). No visit is imposed by the protocol.~Anthropometric data from visits to the pediatrician carried out between V1 and V2 will be collected from medical records, as well as the date of cessation of RIF, if applicable.~Retrospective data will be collected from medical files (anthropometric data, medical and feeding history) and from parents' and investigator's recall."
88955647|NCT06318117||Rice infant formula started after age of 6 months|"After inclusion (V1), infants will return for a V2 visit at 12 months (± 30 days) of age (according to the child's regular appointment calendar). No visit is imposed by the protocol.~Anthropometric data from visits to the pediatrician carried out between V1 and V2 will be collected from medical records, as well as the date of cessation of RIF, if applicable.~Retrospective data will be collected from medical files (anthropometric data, medical and feeding history) and from parents' and investigator's recall."
88955648|NCT06317675|Experimental|Osteopathic manipulative treatment (OMT)|Participants will receive four OMTs at week 1, 2, 4 and 8. Joint mobilization techniques for ribs, cervical and dorsal spine, as well as visceral treatment, soft-tissue release on diaphragm and abdominal wall will be used.
89497956|NCT06219213|Experimental|Group C: Cream of formulation C|Daily application of glyceryl Eicosapentaenoate serum and glyceryl Eicosapentaenoate cream of formulation C on both targeted skin area. The skin areas must be clean and dry. Subjects may proceed with additional product applications if needed. However, for each additional application, both targeted areas must be treated with the Serum and the cream. Subjects must proceed with at least one application of products each day for 14 consecutive days.
89497957|NCT06219161|Active Comparator|Test product (NAD3)|344 mg microcrystalline cellulose,156 mg of a proprietary blend of Wasabia japonica (freeze-dried rhizome) cultivar, standardized to NLT 12,000 ppm isothiocyanates, 97.0% Theacrine, Copper Nicotinic Acid chelated complex (17-20% Copper by ICP-Mass spectroscopy) per capsule
89497958|NCT06219161|Placebo Comparator|Placebo|500 mg of foodgrade mass, and color-matched microcrystalline cellulose per capsule
89497959|NCT06219096|Experimental|The new ICG & HSA injection Group (experimental group)|After ligation of the targeted hepatic segmental portal vein, a novel ICG protocol is used (0.5mg ICG powder is added to 20mL normal saline containing 500mg human albumin, shaken and allowed to stand for more than 5 minutes to form a stable complex, with final concentrations of ICG 0.025mg/mL and human albumin 25mg/mL). This ICG-albumin conjugate solution is then administered intravenously at a rate of 1mL/min. The infusion is stopped when sufficient fluorescence enhancement is observed in the negative-staining liver regions.
89497960|NCT06219096|Active Comparator|The guideline-recommended ICG injection Group (active comparator group)|After ligation of the targeted hepatic segmental portal vein, 2.5mg of ICG (concentration 2.5mg/mL) is administered intravenously as a bolus injection.
89497961|NCT06219070|Experimental|Experimental group|The experimental group will undergo 60 minutes of Core Training.
89497962|NCT06219070|No Intervention|Control group|The control group will follow the curriculum standards set by the Sports University.
89497963|NCT06219057|Experimental|Intervention|"Group of adolescents living in residential youth care. Participants selection will take as inclusion criteria: age (between 14 and 18 years old) and being placed in residential care at least for 1-month (allowing for an adjustment period); as exclusion criteria: a) cognitive impairment; b) psychotic symptoms; d) remaining in residential care less than 9-months, considering the study's length. They will be asked to fill in the self-report protocol at 3 different time points (baseline, post-test and 6-month follow-up).~Intervention comprises the psychological intervention program The Wise Adolescent, twenty individual psychotherapeutic sessions based on Compassion Focused Therapy."
89497964|NCT06219057|No Intervention|Care as Usual|"Group of adolescents living in residential youth care. Participants selection will take as inclusion criteria: age (between 14 and 18 years old) and being placed in residential care at least for 1-month (allowing for an adjustment period); as exclusion criteria: a) cognitive impairment; b) psychotic symptoms; d) remaining in residential care less than 9-months, considering the study's length. They will be asked to fill in the self-report protocol at 3 different time points (baseline, post-test and 6-month follow-up).~Participants in the control group will receive care as usual (TAU). There will be no restrictions on the care that can be provided and it may comprise no treatment or, instead, referral to a variety of health care professionals (e.g. psychologist, psychiatrist) with diverse dosage. TAU will be recorded in terms of timing and nature of any intervention received."
89497965|NCT06219044|Experimental|symptomatic ovarian endometrioma|patients aged between 18 and 40 years with clinical and/or ultrasound diagnosis of symptomatic ovarian endometrioma
89497966|NCT06218992||Study group|Type 2 diabetic patients
89497967|NCT06218992||Control group|Age- and sex-matched subjects without DM
89497968|NCT06218979|Placebo Comparator|Control phase|Study drug dose (1 mg risperidone) and 250 ml of water at 8:00 a.m., and 250 ml of water at 8:30 a.m.
89497969|NCT06218979|Active Comparator|Tea phase|Study drug dose (1 mg risperidone) and 250 ml of tea at 8:00 a.m., and 250 ml of tea at 8:30 a.m.
89497970|NCT06218979|Active Comparator|Cola beverage phase|Study drug dose (1 mg risperidone) and 250 ml cola drink at 8:00 a.m., and 250 ml cola beverage at 8:30 a.m.
89497971|NCT06218966|Experimental|study group with INCAT|study group with patients receiving intracochlear steroid treatment with the intracochlear catheter INCAT prior to application of the cochlear implant electrode array
89497972|NCT06218940|Experimental|HY1272|HY1272 IV weekly
89497973|NCT06218927||Autologous hematopoietic stem cell transplantation (AHSCT)|Patients who underwent autologous hematopoietic stem cell transplantation (AHSCT).
89497974|NCT06218927||Disease-modifying therapy|Patients who undergo disease-modifying therapy - standard treatment.
89497975|NCT06218888|Experimental|Tislelizumab combined with fruquintinib and Chidamide|The treatment option for the chidamide + tislelizumab +fruquibtinib is 200 mg of tislelizumab IV Drip Q3W, 30 mg of chidamide PO BIW, and fruquibtinib 3mg PO Q3W until loss of clinical benefit or development of intolerable toxicity
89497976|NCT06218875||GORE® EXCLUDER® Conformable AAA Endoprosthesis (EXCC Device)|Patients treated with the EXCC Device
89497977|NCT06218875||GORE® EXCLUDER® Iliac Branch Endoprosthesis (IBE Device)|Patients treated with the IBE Device
89497978|NCT06218862||Sivelestat sodium|Sivelestat sodium was administered through a 24-hour continuous intravenous infusion at a rate of 0.2 mg/kg/h, for a maximum duration of 14 days.
89497979|NCT06218862||Control|Not use Sivelestat sodium
89497980|NCT06218810|Experimental|single arm|This study includes only on experimental arm
89497981|NCT06218784|Experimental|iN1011-N17 HCl Suspension (Part 1)|"Oral, Preformulation Suspension, b.i.d, Multiple Ascending Dose (Day 1~ Day7)~Part 1:~Participants will receive either iN1011-N17 or placebo in a 3:1 ratio. From Day 1 to Day 6, participants will receive iN1011-N17 or placebo b.i.d in the morning and in the evening, with approximately 12 hours between the 2 daily doses, and receive the last dose on Day 7 in the morning."
89497982|NCT06218784|Experimental|iN1011-N17 HCl Capsule (Part 1)|"Oral, Nano Suspension Powder Capsule, b.i.d, Multiple Ascending Dose (Day 1~ Day7)~Part 1:~Participants will receive either iN1011-N17 or placebo in a 3:1 ratio. From Day 1 to Day 6, participants will receive iN1011-N17 or placebo b.i.d in the morning and in the evening, with approximately 12 hours between the 2 daily doses, and receive the last dose on Day 7 in the morning."
89497983|NCT06218784|Placebo Comparator|Placebo Capsule (Part 1)|"Oral, Placebo capsule, b.i.d, Multiple Ascending Dose (Day 1~ Day7)~Part 1:~Participants will receive either iN1011-N17 or placebo in a 3:1 ratio. From Day 1 to Day 6, participants will receive iN1011-N17 or placebo b.i.d in the morning and in the evening, with approximately 12 hours between the 2 daily doses, and receive the last dose on Day 7 in the morning."
89497984|NCT06218784|Experimental|iN1011-N17 HCl Capsule (Part 2)|"Oral, Nano Suspension Powder Capsule, Single dose~Part 2:~2-period, randomized, open-label, crossover bioavailability part. Participants will receive a single oral dose of each study treatment (HCl salt and Mesylate salt), one during each of the 2 inpatient periods, in a randomized sequence of administration. There will be a minimum washout period of 5 days between each dose of study treatment."
89497985|NCT06218784|Active Comparator|iN1011-N17 Mesylate Capsule (Part 2)|"Oral, AA10 Capsule, Single dose~Part 2:~2-period, randomized, open-label, crossover bioavailability part. Participants will receive a single oral dose of each study treatment (HCl salt and Mesylate salt), one during each of the 2 inpatient periods, in a randomized sequence of administration. There will be a minimum washout period of 5 days between each dose of study treatment."
89497986|NCT06218784|Experimental|iN1011-N17 HCl Capsule (Part 3)|"Oral, Nano Suspension Powder Capsule, b.i.d, Multiple dose (Day 1~ Day7)~Part 3:~2 cohorts with up to 8 healthy volunteers and 8 PHN patients who will be randomized in a ratio of 3:1 to receive iN1011-N17 or placebo.~Each participant in both cohorts will receive oral doses of iN1011-N17/ placebo b.i.d from Day 1 to Day 13, with approximately 12 hours between the 2 daily doses, and receive the last dose on Day 14 in the morning."
89497987|NCT06218784|Placebo Comparator|iN1011-N17 Mesylate Capsule (Part 3)|"Oral, AA10 Capsule, b.i.d, Multiple dose (Day 1~ Day14)~Part 3:~2 cohorts with up to 8 healthy volunteers and 8 PHN patients who will be randomized in a ratio of 3:1 to receive iN1011-N17 or placebo.~Each participant in both cohorts will receive oral doses of iN1011-N17/ placebo b.i.d from Day 1 to Day 13, with approximately 12 hours between the 2 daily doses, and receive the last dose on Day 14 in the morning."
88955649|NCT06317675|Active Comparator|OMT + breathing exercises.|This group will receive OMTs and five breathing exercises to perform daily at home. A recorded video of the exercises will be provided to participants in this group.
88955650|NCT06317675|No Intervention|Control|Usual care group (PPI or reflux suppressant)
88955651|NCT06316856|Experimental|Autologous CD5 CAR T-cells|After a lymphodepleting regimen, the patients will receive autologous CD5 CAR T-cell infusion.
88955652|NCT06316856|Experimental|Prior stem-cell transplantation (SCT) donor-derived CD5 CAR T-cells|After a lymphodepleting regimen, the patients will receive prior SCT donor-derived CD5 CAR T-cell infusion.
88955653|NCT06316856|Experimental|Newly matched donor-derived CD5 CAR T-cells|After a lymphodepleting regimen, the patients will receive newly matched donor-derived CD5 CAR T-cell infusion.
88955654|NCT06316427|Experimental|Arm-1|Autologous CD7 CAR T-cell treatment
88955655|NCT06316427|Experimental|Arm-2|Prior-HSCT donor-derived CD7 CAR T-cell treatment
88955656|NCT06316427|Experimental|Arm-3|New donor-derived CD7 CAR T-cell treatment
89022946|NCT06184282|Active Comparator|Control Group|Lidocaine gel was applied using sterile plastic brush daily and the patients were recalled at 2, 5 and 10 days for evaluating the healing of the ulcer.
89022947|NCT06184217|Experimental|Experimental group (MSPE programme group).|Experimental (MSPE group). The experimental group received the Mindful Sport Performance Enhancement programme (MSPE), with some changes and adaptations taking into account the characteristics and needs of the Para-athletes and the overall aim of the study. Such as reducing the session time (2h), including staff and support material, extending the pre-session time (35-40 min), and incorporating the dynamics of emotions and Mindful Yoga into the floor of the MBSR programme [2].
89022948|NCT06184217|Active Comparator|Control group (relaxation group).|Control group. Control group. Athletes with physical disabilities participating in the home were provided with a guide to body awareness-based relaxation training guidelines [3].
89022949|NCT06184152||CEUS/aMRI|
89205451|NCT05275751|Experimental|Hot injection with TRPA1-, TRPM3- and chloride channel inhibition|Pain is induced by an increasingly hot intradermal injection up to 52°C over 2 minutes, while TRPA1, TRPM3 and a chloride channel are blocked pharmacologically by an antagonist dissolved in the hot fluid (synthetic interstitial fluid). The antagonist(s) have sufficient concentration to reliably block the channel. The total dose is in the range of a microdose trial.
89205452|NCT05275751|Experimental|Hot injection with TRPV1-, TRPM3- and chloride channel inhibition|Pain is induced by an increasingly hot intradermal injection up to 52°C over 2 minutes, while TRPV1, TRPM3 and a chloride channel are blocked pharmacologically by an antagonist dissolved in the hot fluid (synthetic interstitial fluid). The antagonist(s) have sufficient concentration to reliably block the channel. The total dose is in the range of a microdose trial.
89205453|NCT05275751|Experimental|Hot injection with TRPA1- and chloride channel inhibition|Pain is induced by an increasingly hot intradermal injection up to 52°C over 2 minutes, while TRPA1 and a chloride channel are blocked pharmacologically by an antagonist dissolved in the hot fluid (synthetic interstitial fluid). The antagonist(s) have sufficient concentration to reliably block the channel. The total dose is in the range of a microdose trial.
89497988|NCT06218784|Experimental|Placebo Capsule (Part 3)|"Oral, Placebo capsule, b.i.d, Multiple dose (Day 1~ Day14)~Part 3:~2 cohorts with up to 8 healthy volunteers and 8 PHN patients who will be randomized in a ratio of 3:1 to receive iN1011-N17 or placebo.~Each participant in both cohorts will receive oral doses of iN1011-N17/ placebo b.i.d from Day 1 to Day 13, with approximately 12 hours between the 2 daily doses, and receive the last dose on Day 14 in the morning."
89497989|NCT06218771|Experimental|TQB3454 Tablets|TQB3454 Tablets, orally administered, 28 days as a treatment cycle.
89497990|NCT06218680|Experimental|group P|Receive 0.5 mg/kg of propofol intravenously at end of sevoflurane anesthesia
89497991|NCT06218680|Placebo Comparator|group S|Receive saline intravenously at end of sevoflurane anesthesia
89497992|NCT06218667|Experimental|Copanlisib in Combination With Degarelix|"Phase 1b: The starting Dose level 1 will be 45 mg with the intent of dose escalating to the standard dose of 60 mg approved for heme malignancy. In the event of > =2 DLT at Dose level 1 (45 mg) the study will be terminated. If >= 2 DLT in patients at Dose level 2 (60 mg), Dose level 1 (45 mg) will be the RP2D if <= 1 DLT out of 6 patients at this dose.~Phase 2: Patients may dose reduce at the discretion of the investigator to the lowest dose of 45 mg. Participants who do not tolerate the copanlisib dose of 45 mg must discontinue study treatment permanently."
89497993|NCT06218641|Active Comparator|CP- Conventional protocol|A group of patients a group of patients to whom attachments will be bonded at the beginning of the first aligner.
89497994|NCT06218641|Experimental|DP - delayed protocol|A group of patients to whom attachments will be bonded at the beginning of the third aligner, approximately one month after the start of orthodontic treatment.
89205454|NCT05275751|Experimental|Hot injection with TRPV1- and chloride channel inhibition|Pain is induced by an increasingly hot intradermal injection up to 52°C over 2 minutes, while TRPV1 and a chloride channel are blocked pharmacologically by an antagonist dissolved in the hot fluid (synthetic interstitial fluid). The antagonist(s) have sufficient concentration to reliably block the channel. The total dose is in the range of a microdose trial.
89497995|NCT06218589|Experimental|Velacur Ultrasound|Patients 2 to 20 years of age with suspicion of MASLD or presenting to liver clinic for evaluation of liver disease, including possible MASLD receiving a Velacur ultrasound.
89497996|NCT06218576||acute cerebral and/or cerebellar CMI|Patients with acute cerebral and/or cerebellar CMI
89497997|NCT06218550|Placebo Comparator|Oral Placebo|A brownie containing no experimental drugs will be eaten by study participants
89497998|NCT06218550|Experimental|Oral administration of 30mg ∆8-THC|A brownie infused with 30mg ∆8-THC will be eaten by study participants
89022950|NCT06184113|Experimental|Intervention Arm|Patients randomised to the intervention arm will receive an open-label dose adjusted apixaban twice a day. The treatment will be continued for three months. After the tree-month treatment period apixaban will be stopped and acetylsalicylic acid will be started.
89022951|NCT06184113|Active Comparator|Control Arm|Patients assigned to the control arm will receive an open-label low dose acetylsalicylic acid indefinitely.
89497999|NCT06218550|Experimental|Oral administration of 60mg ∆8-THC|A brownie infused with 60mg ∆8-THC will be eaten by study participants
89498000|NCT06218550|Experimental|Oral administration of 30mg ∆9-THC|A brownie infused with 30mg ∆9-THC will be eaten by study participants
89498001|NCT06218550|Placebo Comparator|Administration of vaporized Placebo|"Participants will inhale ambient air through a handheld vaporizer (minimum 15 puffs)"
89498002|NCT06218550|Experimental|Administration of vaporized 30mg ∆8-THC|"Participants will inhale 30mg ∆8-THC using a handheld vaporizer (minimum 15 puffs)"
89205455|NCT05275751|Experimental|Hot injection with TRPV1-, TRPA1, TRPM3- and chloride channel inhibition|Pain is induced by an increasingly hot intradermal injection up to 52°C over 2 minutes, while TRPV1, TRPA1, TRPM3 and a chloride channel are blocked pharmacologically by an antagonist dissolved in the hot fluid (synthetic interstitial fluid). The antagonist(s) have sufficient concentration to reliably block the channel. The total dose is in the range of a microdose trial.
89498003|NCT06218550|Experimental|Administration of vaporized 60mg ∆8-THC|"Participants will inhale 60mg ∆8-THC using a handheld vaporizer (minimum 15 puffs)"
89498004|NCT06218550|Experimental|Administration of vaporized 30mg ∆9-THC|"Participants will inhale 30mg ∆9-THC using a handheld vaporizer (minimum 15 puffs)"
89498005|NCT06218524|Placebo Comparator|TMZ single|Single oral Temozolomide
89498006|NCT06218524|Experimental|TMZ and Haloperidol|Oral Temozolomide and Haloperidol
89498007|NCT06218498|Experimental|ablative fractional 2940-nm erbium yttrium aluminum garnet (Er: YAG) laser|
89498008|NCT06218498|Experimental|non-ablative fractional 1565nm|
89498009|NCT06218498|Active Comparator|5% minoxidil|
89498010|NCT06218485|Experimental|Experimental group|The percutaneous coronary intervention will be performed by intravascular ultrasound (IVUS)-guided strategy after angiography-derived FFR-based decision-making.
89498011|NCT06218485|Active Comparator|Control group|The percutaneous coronary intervention will be performed by fractional flow reserve (FFR)-guided strategy.
89498012|NCT06218459|Experimental|Oldpain2go®|This is a concept of dealing with a client in a way that uses their conscious mind to alter their unconscious automated programs (chronic pain) that are troubling them.
89498013|NCT06218459|Placebo Comparator|Jacobson's progressive relaxation|Jacobson's progressive relaxation is used in a range of conditions to relieve muscle tension and stress as part of self-management.
89498014|NCT06218446||Patients|
89498015|NCT06218446||Care team|
89498016|NCT06218433|Experimental|Screening arm|Invitation to participate in urothelial cancer screening and questionnaires
89498017|NCT06218420|Other|Patients with hepatocellular carcinoma enlisted for a liver transplant and eligible for SBRT|All patients enrolled in the trial and responding to inclusion/exclusion criteria will receive SBRT (a high-precision technique allowing to deliver a precise high dose irradiation on moving intrahepatic lesions).
88955658|NCT06312202||Fatal drowning|This group of patients experienced a drowning incident defined as the process of experiencing respiratory impairment from submersion or immersion in liquid and died within 30 days after the incident as a consequence of the submersion injury.
89205456|NCT05275751|Experimental|Hot injection with TRPM3- and chloride channel inhibition|Pain is induced by an increasingly hot intradermal injection up to 52°C over 2 minutes, while TRPM3 and a chloride channel are blocked pharmacologically by an antagonist dissolved in the hot fluid (synthetic interstitial fluid). The antagonist(s) have sufficient concentration to reliably block the channel. The total dose is in the range of a microdose trial.
89498018|NCT06218407|Experimental|Computerized Chemosensory-Based Orbitofrontal Cortex Training (CBOT) short-burst paradigm|CBOT consists of repetitive cycles of olfactory stimulation and tasks daily for 14 days.
88955659|NCT06312202||Non-fatal drowning|This group of patients experienced a drowning incident defined as the process of experiencing respiratory impairment from submersion or immersion in liquid and survived until 30 days after the incident.
88955660|NCT06311188|Experimental|ITR Healing Intervention|This is a single arm nonrandomized test of the culturally adapted ITR healing intervention.
88955661|NCT06310525||Fatal drowning|Drowning incidents where the patient died within 30 days after the incident as a consequence of the submersion injury
89498019|NCT06218407|Experimental|Computerized Chemosensory-Based Orbitofrontal Cortex Training (CBOT) long-burst paradigm|CBOT consists of repetitive cycles of olfactory stimulation and tasks daily for 14 days.
89498020|NCT06218407|Experimental|CBOT plus (CBOT + beta caryophyllene [BCP])|CBOT device enhanced with BCP
89498021|NCT06218407|Sham Comparator|Computerized Chemosensory-Based Orbitofrontal Cortex Training (CBOT)|CBOT device without BCP enhancement as control for BCP
89498022|NCT06218394|Experimental|microneedling|
89498023|NCT06218394|Experimental|autologous concentrated growth factor|
89498024|NCT06218394|Active Comparator|5% minoxidil|
88955662|NCT06310525||Non-fatal drowning|Drowning incidents where the patient survived to 30 days
89498025|NCT06218342|Experimental|Henagliflozin|Participants in this group will receive a combination of lifestyle intervention, background medication, and Henagliflozin. The choice of hypoglycemic drugs within the background medication is restricted to either one, two, or three among metformin, DPP-4 inhibitors, alpha-glucosidase inhibitors, or secretagogues.
89498026|NCT06218342|Other|Control|Participants in this group will receive lifestyle intervention and background medication. The choice of hypoglycemic drugs within the background medication is restricted to either one, two, or three among metformin, DPP-4 inhibitors, alpha-glucosidase inhibitors, or secretagogues.
89498027|NCT06218316|Experimental|Botox for spasticity|Botox for spasticity in lower limbs in cerebral palsy children
89498028|NCT06218316|Experimental|transcranial magnetic stimulation for spasticity|transcranial magnetic stimulation for spasticity in cerebral palsy children
89498029|NCT06218316|Experimental|Botox combined with transcranial magnetic stimulation for spasticity|Botox combined with transcranial magnetic stimulation for spasticity in cerebral palsy children
89498030|NCT06218277|Experimental|ASTAR|Use of the early AST results for guidance of the antimicrobial therapy
89498031|NCT06218264|Active Comparator|FullAA|Amino acid drink containing all amino acids
89498032|NCT06218264|Active Comparator|NoBCAA|Amino acid drink containing all amino acids except for BCAAs.
89022952|NCT06184061|No Intervention|Control Group|Placebo will be given to this group (100ml, contain same carbohydrate amount as herbal supplement)
89498033|NCT06218199|Active Comparator|Diuretic protocol|"If asymptomatic at time of HeartLogic(HL) alert, will add or increase diuretic based on current medications.~If currently taking ≤ 20 mg. furosemide, begin furosemide 40mg orally daily until recovery from alert or re-alert. If currently taking ≥ 40mg furosemide begin torsemide 20 mg orally daily or bumetanide 1 mg orally daily. If patient unable to obtain torsemide or bumetanide double furosemide daily dose (maximum 480mg daily).~If currently taking ≥ 20mg torsemide or ≥ 1mg bumetanide, double daily dose. Recheck HeartLogic index 7 days following initiation of diuretic protocol. If patient recovers from alert consider reducing dose or stopping diuretic. If HeartLogic index is lower but still in alert continue current diuretic dose. If HeartLogic index is the same or higher double diuretic dose and/or add metolazone 2.5mg for 1-2 days."
89498034|NCT06218199|Active Comparator|Afterload reduction protocol|"If asymptomatic at time of HL alert, increase afterload reduction drugs based on current medications.~If on Sacubitril/valsartan, double the dose. If on maximum Sacubitril/valsartan, add Hydralazine 10mg and Isordil10 mg both three times a day. If on Angiotensin Receptor Blocker (ARB) at low dose (less than or equal to Valsartan 160mg daily or equivalent) then stop ARB and start sacubitril/valsartan 24-26mg twice a day. If on ARB at high dose (greater than Valsartan 160mg daily or equivalent) then immediately stop ARB and start Sacubitril/valsartan 49-51mg twice a day. If on Angiotensin-converting enzyme (ACE) inhibitor at low dose (less than or equal to 10mg daily or equivalent) then immediately stop ACE inhibitor and start Sacubitril/valsartan 24-26mg twice a day after 48hours. If on ACE inhibitor at high dose (greater than Enalapril 10mg daily or equivalent) stop ACE inhibitor and start Sacubitril/valsartan 49-51mg twice a day after 48hours. Cut diuretic in half for all."
89498035|NCT06218199|No Intervention|Observation protocol|Standard therapy offered until development of symptoms of heart failure decompensation occurs. Patients will be monitored until out of alert and at 30, 60, and 90 days.
89498036|NCT06218186|Experimental|Medical Device: Wesper Lab (Single Arm)|Participants already undergoing a prescribed polysomnography (PSG) sleep study for the diagnosis of sleep apnea will be asked to simultaneously wear Wesper Lab, a home sleep test device.
89498037|NCT06218173||Early LA group|The group that received LA at the induction of the sedation
89498038|NCT06218173||Late LA group|The group that received LA at the end of the sedation
89498039|NCT06218160|Experimental|Hydromorphone combined with ropivacaine|The posterior quadrat block was performed by adding 1mg hydromorphone to 0.375% ropivacaine in a total of 30ml.
89498040|NCT06218160|Active Comparator|ropivacaine|A mixture of 0.375% ropivacaine for a total of 30ml was performed for posterior quadrate block.
89498041|NCT06218147|No Intervention|Standard care group|Participants in this group will meet with their CHW for 8 sessions (almost weekly from weeks 14 to 27 gestation) and then 4 sessions (almost biweekly from weeks 28-35 gestation) to match the contact provided in dietary-lifestyle behavioral intervention group. Sessions will be held in person, with videoconferencing and phone call options available when in person is not possible. In these brief check-in sessions, the CHW will be focused on maintaining regular contact, connecting participants to community resources, checking in about any new or ongoing medical issues described by participant during each session visit, and providing overall general information about diabetes management when indicated. CGM will be blinded for both groups.
89498042|NCT06218147|Experimental|Nutrition-behavior lifestyle program group|"Participants in this group meet with their CHWs for 8 sessions (almost weekly from weeks 14 to 27 gestation) and then 4 sessions (almost biweekly from weeks 28-35 gestation). Sessions are held in person, with videoconferencing and phone call options available when in person is not possible. CGM wear is blinded in both groups. The topics for each session are:~Welcome and Understanding Diabetes in Pregnancy~Understanding Food Groups & Setting Goals~Understanding Carbohydrate Types & Portions~Reading Nutrition Labels & Understanding Added Sugar~Exercise in Pregnancy & Carbohydrate Counting~Grocery Shopping & Using SNAP or WIC Benefits~Managing Stress - Communal Coping as a Family~Getting Ready for Baby & My Family Plan~How to Receive Social Support~Making Choices at Restaurants & Social Eating Settings~Learning Empowered Communication with Providers~Maintaining Changes & Staying Motivated"
89498043|NCT06218134|Experimental|human Wharton's jelly-derived mesenchymal stem cells (EN001)|"human Wharton's jelly-derived mesenchymal stem cells (EN001) dose of administration: 2.5x106 cells/kg~method of adminstration: one-time, intravenous administration"
89498044|NCT06218095|Experimental|Experimental|"3rd grade midwifery students experimental group Diagnostic Information Form and Thromboembolism Information Form were applied before the theory training.~Pregnancy and postpartum thromboembolism theory training was given,~st application: Deep vein thrombosis management scenario during pregnancy A high-validity simulation scenario was implemented. Student Satisfaction and Self-Confidence Scale in Learning after the application, Simulation Design Scale implemented~nd application: It will be done after 2 weeks. Postpartum Embolism Management Scenario was implemented Student Satisfaction and Self-Confidence Scale in Learning after the application, Simulation Design Scale will be applied. Thromboembolism Information Form - Posttest Done After 2 Weeks After 2 months, Thromboembolism Information Form - Persistence Test was performed."
89498045|NCT06218095|No Intervention|control group|"3rd grade midwifery students Control group Diagnostic Information Form and Thromboembolism Information Form were applied before the theory training.~Thromboembolism Information Form-Posttest was applied 1 month later. After the Last Test, Thromboembolism Information Form - Persistence Test was applied 2 months later."
89022953|NCT06184061|Active Comparator|Interventional Group|Herbal Supplement will be given to this group (100ml, Herbal Supplement)
89022954|NCT06183619||Pulmonary vein isolation plus superior vena cava isolation|
89022955|NCT06183619||Pulmonary vein isolation|
89022956|NCT06183177|Experimental|Exercise + WBV Group|
89022957|NCT06183177|Active Comparator|Exercise Group|
89022958|NCT06183177|No Intervention|Control Group|
89022959|NCT06183138||Sick Neonatal Cohort|Infants and their parents enrolled through Neonatal Intensive Care Unit of member hospitals who are un-randomized to receive genomic sequencing. Results disclosure sessions will include a discussion of: family history report, results from standard newborn screening, any potentially medically relevant findings from the baby&#39;s medical history/physical exam, and the results of the genomic sequencing report.
89022960|NCT06182267|Experimental|Group I|toothpaste containing 8% L-arginine
89022961|NCT06182267|Active Comparator|Group II|toothpaste containing 0.24% sodium fluoride
89498046|NCT06218069|Active Comparator|Site EKUT (Tuebingen)|"Patients will receive a single subcutaneous administration of the immunotherapy sasanlimab in a fixed dose of 300 mg in a neo-adjuvant setting, followed by curative-intended surgery.~Patients will also receive a radiolabeled imaging tracer [89Zr]Zr-crefmirlimab berdoxam that entails two intravenous administrations of a fixed dose of 1.5 mg protein dose labelled with activity dose 37 MBq Zirconium-89; one at baseline and one at 2 weeks after sasanlimab injection."
89498047|NCT06218069|Active Comparator|Site Radboudumc (Nijmegen)|"Patients will receive a single subcutaneous administration of the immunotherapy sasanlimab in a fixed dose of 300 mg in a neo-adjuvant setting, and 3 days of non-ablative dose radiation therapy starting with sasanlimab injection. This is followed by curative-intended surgery.~Patients will also receive a radiolabeled imaging tracer [89Zr]Zr-crefmirlimab berdoxam that entails two intravenous administrations of a fixed dose of 1.5 mg protein dose labelled with activity dose 37 MBq Zirconium-89; one at baseline and one at 2 weeks after sasanlimab injection."
89498048|NCT06218056|Active Comparator|Cannabidiol (CBD) 400 mg or 800 mg|Sixty participants who meet all eligibility criteria will be randomized to receive CBD (ATL5; Ananda Scientific) at a dose of 400 mg or 800 mg.
89498049|NCT06218056|Placebo Comparator|Placebo|Sixty participants who meet all eligibility criteria will be randomized to receive placebo.
89498050|NCT06218043|Other|Iodine intake intervention balance experiment|Replace subjects' iodized salt with non-iodized salt.
89498051|NCT06218017|Experimental|HFNO first|This study follows a crossover design employing a randomized controlled methodology. Patients undergoing gastrointestinal endoscopy and receiving deep sedation were monitored using electronic tracheal sound auscultation. Within this group, patients first underwent a 10-minute session of high-flow nasal oxygen (50 L/min) followed by the utilization of the standard low-flow nasal oxygen (4 L/min). Electronic tracheal sound recordings were obtained during both the high-flow and low-flow nasal oxygen administrations. The aim is to develop an algorithm capable of mitigating the noise generated specifically by the high-flow nasal oxygen.
89498052|NCT06218017|Active Comparator|HFNO later|This study follows a crossover design employing a randomized controlled methodology. Patients undergoing gastrointestinal endoscopy and receiving deep sedation were monitored using electronic tracheal sound auscultation. Within this group, patients first underwent a 10-minute session of standard low-flow nasal oxygen (4 L/min) followed by the utilization of the high-flow nasal oxygen (50 L/min). Electronic tracheal sound recordings were obtained during both the high-flow and low-flow nasal oxygen administrations. The aim is to develop an algorithm capable of mitigating the noise generated specifically by the high-flow nasal oxygen
89498053|NCT06218004|Experimental|Group A: Neoadjuvant treatment group|envafolimab: 150 mg once every 1 week for 8 doses subcutaneously on day 1 Chemotherapy: nab-paclitaxel + cisplatin/carboplatin 3 cycles; Albumin paclitaxel 260 mg/m2, cisplatin 75 mg/m2 divided into 3 days, carboplatin AUC 5 applied on the first day.
89498054|NCT06218004|Experimental|Group B: Conversion therapy group|envafolimab: 150 mg once every 1 week for 8 doses subcutaneously on day 1 Chemotherapy: nab-paclitaxel + cisplatin/carboplatin 3 cycles; Albumin paclitaxel 260 mg/m2, cisplatin 75 mg/m2 divided into 3 days, carboplatin AUC 5 applied on the first day.
89498055|NCT06217991|Experimental|PTST anastomose group after proximal gastrectomy|"Standard procedure: Patient placed in a supine position and proximal gastrectomy performed under general anesthesia.~Lymph node dissection~Cut the esophagus~Gymnosis of gastric curvature greater and gastric curvature lesser~The specimen removed from the stomach(5cm away)~Preparation of serosa-muscle flap: Mark two straight lines, A and B, about 3cm long, with methylene blue on the anterior wall of the stomach about 2cm and 6cm from the gastric stump. The electrocoagulation and cutting power of the electrotome were adjusted to 10 watts, and the serosa-muscle layer of the gastric wall was cut along the marked line with the electrotome. With the help of the assistant, the surgeon separated the gastric parietal serosa-muscle layer from the submucosa along line B to line A. When the dissociation reached the middle point of the tunnel, it should be dissociated along line A to line B, completely dissociated the gastric parietal serosa-muscle layer from the submucosa."
89498056|NCT06217952|Active Comparator|SPL84|
89498057|NCT06217952|Placebo Comparator|Placebo|
89498058|NCT06217939|Experimental|Early hydrocortisone|After randomization, low-dose hydrocortisone will be administered as soon as possible
89498059|NCT06217939|Placebo Comparator|Standard care|Low-dose hydrocortisone will be given when indicated according to the current Surviving Sepsis Campaign Guidelines
89498060|NCT06217926|No Intervention|Control Group|"During the pretest of the study, firstly, the 3rd year students of the Faculty of Health Sciences will be informed about the purpose of the study, that their participation in the study is based on the principle of voluntariness, that they can leave the study at any time, and that the study results will be used only for scientific purposes. Then, data collection tools will be applied to students who volunteer to participate in the research.~During the posttest implementation of the study (one week before the final exams), the Personal Information Form, Attitude Scale Towards Artificial Intelligence and Westside Exam Anxiety Scale will be re-administered to the 3rd and 4th year students of the Faculty of Health Sciences."
88955663|NCT06309368|Active Comparator|Primary Closure with 0.1% Betaine/0.1% Polyhexanide Wound Irrigation|The ostomy wound will be irrigated with 0.1% Betaine/0.1% Polyhexanide wound irrigation, then closed completely with sutures.
88955664|NCT06309368|Active Comparator|Secondary Closure with Pursestring|The ostomy wound will be partially closed using the Pursestring method.
88955665|NCT06306300|No Intervention|Study I|Study I is a population-based cross-sectional screening study (n=30,000 individuals) using rapid tests to determine the prevalence of HCV infection in people attending a Basic Health Care Unit.
88955666|NCT06306300|No Intervention|Substudy I|The sub-study associated with Study I is a cross-sectional study to assess the usability of a self-test for the detection of HCV antibodies in oral fluid (n=1,500 participants included in Study I).
89022962|NCT06181825|Experimental|COMET-BA|COMET-BA (Common Elements Toolbox- Behavioral Activation) includes 4 online weekly modules which focus on elements of behavioral activation, including positive activity scheduling, avoidance reduction, values, and change plans.
89498061|NCT06217926|Experimental|Experimental Group|"During the pretest of the study, firstly, the 4th year students of the Faculty of Health Then, data collection tools will be applied to students who volunteer to participate in the research.~Educational content; ChatGPT and Google Bard training for senior students of the Faculty of Health Sciences who volunteered to participate in the study was provided by Dr. Lecturer It will be given by member Yasemin Özyer Güvener. After the training is completed, students will be asked to use generative artificial intelligence for educational purposes.~During the posttest implementation of the study (one week before the final exams), the Personal Information Form, Attitude Scale Towards Artificial Intelligence and Westside Exam Anxiety Scale will be re-administered to the 3rd and 4th year students of the Faculty of Health Sciences."
89498062|NCT06217913|No Intervention|control group|routine delivery examination group
89498063|NCT06217913|Experimental|intervention group|routine delivery examination group + use of wearable blood pressure monitoring device group
89498064|NCT06217900||Case arm|Participants with newly diagnosed cancer of lung, breast, digestive tract, urinary tract and etc.
89498065|NCT06217900||Control arm|Participants without a cancer diagnosis after routine cancer screening tests.
89498066|NCT06217887|Experimental|loxenatide Group|loxenatide will be initiated and maintained at 0.2mg once weekly until the completion of the study. Meanwhile, all patients will also continue on their existing dose and regimen of metformin throughout the study. Visits at 4-week intervals will be performed to evaluate the safety of drugs. Metformin dose can be reduced in response to hypoglycaemia, but loxenatide could not be adjusted. If the plasma glucose still not achieve the target at the maximum dose, the maximum dose will be maintained until the completion of the study.
89498067|NCT06217887|Experimental|Gliclazide Group|Gliclazide will be initiated and maintained at 30mg/ day every morning until the completion of the study. Meanwhile, all patients will also continue on their existing dose and regimen of metformin throughout the study. Visits at 4-week intervals will be performed to evaluate the safety of drugs. Metformin dose can be reduced in response to hypoglycaemia, but Gliclazide could not be adjusted. If the plasma glucose still not achieve the target at the maximum dose, the maximum dose will be maintained until the completion of the study.
89498068|NCT06217874||Observational|Patients undergo blood sample collection, tumor biopsy (during clinically scheduled biopsy), and have their medical records reviewed on study.
89498069|NCT06217861|Experimental|VGM-R02b|VGM-R02b is an adeno-associated viral vector 9 delivering human Glutaryl-CoA Dehydrogenase (GCDH) gene.
89498070|NCT06217848|Experimental|Patients diagnosed with a hypothalamic tumor.|
89498071|NCT06217835|Experimental|Plantilla 0,5 cm|A template with the dimensions indicated is introduced to the user and he/she walks for 1 minute.
89498072|NCT06217835|Experimental|Plantilla 1 cm|A template with the dimensions indicated is introduced to the user and he/she walks for 1 minute.
89498073|NCT06217835|Experimental|Plantilla 1,5 cm|A template with the dimensions indicated is introduced to the user and he/she walks for 1 minute.
89498074|NCT06217809|Experimental|EmpowHer|The intervention curriculum is designed to address sexual activity, abstinence, and adulthood preparation topics.
89498075|NCT06217783|Experimental|Group A|Participants will receive a catheter that is up to 1.75 inches long based on what the nurse thinks is best for you.
89498076|NCT06217783|Experimental|Group B|Participants will receive a catheter that is either 1.75 or 2.5 inches long based on what the nurse thinks is best for you.
89498077|NCT06217692|Experimental|experimental group|experimental group
89498078|NCT06217692|No Intervention|control group|control group
89022963|NCT06181825|No Intervention|Waitlist Control|Thoss assigned to the waitlist control condition will complete weekly surveys but will not have access to the COMET-BA materials until the data collection period is over.
89022964|NCT06180824|No Intervention|normal saline|Insulin will be diluted with normal saline crystalloid fluid in 50mls syringe and tubing (same product manufacturer). Blood glucose level will be taken from arterial line at presentation or prior to start insulin and checked using glucometer. Then, at 2 hour and 6 hours after initiation of treatment.
89022965|NCT06180824|Active Comparator|gelafundin|Insulin will be diluted with gelafundin colloid fluid in 50mls syringe and tubing (same product manufacturer). Blood glucose level will be taken from arterial line at presentation or prior to start insulin and checked using glucometer. Then, at 2 hour and 6 hours after initiation of treatment.
89022966|NCT06180161|Experimental|intervention grou[|Behavioral: multidomain intervention Dosage: a 2-hour session once a week for 12 weeks. Each multidomain intervention session includes 1 hour of combined physical (balance, strength and aerobic exercises) and cognitive (attention, memory, calculation, visual-spatial ability, processing speed and executive function) training and 1 hour of risk factor prevention and management strategies (nutrition, chronic disease management, oral health, fall prevention and transportation safety, psychosocial factors and sleep).
89022967|NCT06180161|No Intervention|control group|Waiting for 12 weeks (waiting-list control group)
89022968|NCT06179082|Active Comparator|Group A|received Botox then threads
89498079|NCT06217549|Experimental|healthy participants|healthy, physically active people will be included the study.
89498080|NCT06217276|Active Comparator|COPD Group|
89498081|NCT06217276|Active Comparator|Healthy Group|
89498082|NCT06217159|Sham Comparator|Poikilocapnia|Room air-breathing
89498083|NCT06217159|Experimental|Normocapnia|Breathing air mixture with slightly elevated CO2 to maintain PetCO2 to resting baseline levels
89498084|NCT06217146|Experimental|MediCane's balanced T3:C3 medical cannabis oil|
89498085|NCT06217146|Placebo Comparator|Placebo|
89498086|NCT06216808|Experimental|Laparoscopic Renal Denervation|"Intervention:~Device: HyperQure Renal Denervation System"
89498087|NCT06216652|Active Comparator|downhill walking|All participants received a conventional physiotherapy program. In addition to this program, the first group performed downhill walking exercise on the treadmill
89498088|NCT06216652|Active Comparator|uphill walking|All participants received a conventional physiotherapy program. In addition to this program, the second group performed uphill walking exercise on the treadmill
89498089|NCT06216652|Active Comparator|walking with no incline|All participants received a conventional physiotherapy program. In addition to this program, the third group performed walking with no incline exercise on the treadmill
89022969|NCT06179082|Active Comparator|Group B|received threads insertion only
89498090|NCT06216600|Experimental|WE RISE Intervention|Participants will undergo WE RISE intervention: twice a week for 8 week combination delivery of acceptance and commitment therapy + exercise + social suppot.
89498091|NCT06216600|Active Comparator|Control|Participants will receive standard of care which would be referrals to local opportunites for therapy, exercise and social support.
89498092|NCT06216600|Experimental|Observational|Observational study of participants undergoing WE RISE adapted for sustainability.
89498093|NCT06216405|Experimental|AI-aided colonoscopy|Experimental arm : patients receive a colonoscopy using GI Genius™ intelligent endoscopy system (Medtronic Inc., Minneapolis, Minnesota, USA)
89498094|NCT06216405|Active Comparator|Standard colonoscopy|Control arm :The artificial intelligence is not activated during the colonoscopy exam,the patient receive a standard high definition colonoscopy
89498095|NCT06216366|Placebo Comparator|Control|Sterile normal saline 0.9% IV immediately prior to hyperbaric chamber exposure, and immediately after exposure
89498096|NCT06216366|Active Comparator|rhu-pGSN pre-exposure|rhu-pGSN 24 mg/kg IV immediately prior to hyperbaric chamber exposure, and sterile normal saline 0.9% IV immediately after exposure
89498097|NCT06216366|Active Comparator|rhu-pGSN post-exposure|Sterile normal saline 0.9% IV immediately prior to hyperbaric chamber exposure, and rhu-pGSN 24 mg/kg IV immediately after exposure
89498098|NCT06215690||Pregnant Women with Fetal Growth Restriction|Fetuses with fetal growth restriction according to Delphi consensus criteria between 32-37 weeks of gestation
89498099|NCT06215690||Healthy Pregnancies|Normally developing fetuses between 32-37 weeks of gestation
89498100|NCT06215599||Medical doctors|Medical doctors that specialize in ENT and also mostly work in otology
89498101|NCT06215599||audiologist|Health professionals that specialüze in Audiology
89498102|NCT06215196|Experimental|Semaglutide with Active Fiber Supplement Group|
89498103|NCT06215196|Placebo Comparator|Placebo group|
89498104|NCT06214871|Experimental|Single Arm|
89498105|NCT06214780||Type 1 diabetes patients|Adult patients treated with advanced hybrid closed-loop in Castilla-La Mancha during summer 2023.
89498106|NCT06214273|Active Comparator|Ibuprofen oral gel and miconazole oral gel|One group will receive conventional oral therapy composed of topical ibuprofen oral gel as an anti-inflammatory and analgesic and topical miconazole as an anti-fungal oral gel.
89498107|NCT06214273|Experimental|low-level diode laser diode laser|The second group will receive a diode laser with a wave length range of 800-980 nm and power less than 500 ml.
89498108|NCT06214273|Experimental|Chamomile|The third group will receive chamomile 3% mucoadhesive gel.
89498109|NCT06214130|Experimental|Test|Orfiril long 500 mg (sodium valproate) prolonged-release minitablets
89022970|NCT06179030||Group 1|switched from bevacizumab to ranibizumab 0.5
89498110|NCT06214130|Active Comparator|Reference|Ergenyl chrono 500 mg (valproic acid) prolonged -release tablets
89498111|NCT06213636|Experimental|Experimental: Treatment (CD19/CD22-CAR T cells, chemotherapy)|Patients will be administered fludarabine phosphate intravenously (IV) over a 30-minute period on days -4 to -2. Additionally, cyclophosphamide will be administered intravenously (IV) over 60 minutes on day -2. Subsequently, patients will receive CD19/CD22-CAR T cells intravenously (IV) over a duration of 10-20 minutes on day 0. Patients who exhibit positive responses to the initial dose of CD19/CD22-CAR T cells, do not experience unacceptable side effects, and have a sufficient quantity of cells available may be eligible to receive 2 or 3 additional doses of CD19/CD22-CAR T cells.
89498112|NCT06212102|Experimental|Progestin primed ovarian stimulation group|"HMG ( 300IU) was used during the follicular phase of ovarian stimulation (FPS) and during the luteal phase of ovarian stimulation (LPS). Progestin (dydrogesterone) 30 mg/day was used to prevent premature LH surge during the FPS and LPS.~In subsequent cycle, frozen embryo transfer was done"
89498113|NCT06212102|Active Comparator|GnRH antagonist group|"HMG ( 300IU) was used during the follicular phase of ovarian stimulation (FPS) and during the luteal phase of ovarian stimulation (LPS). Flexible GnRH antagonist protocol (Cetrorelix acetate) (0.2 mg) was used to prevent premature LH surge during the FPS and LPS.~In subsequent cycle, frozen embryo transfer was done"
89498114|NCT06212089|Experimental|TR-012001|Single dose of TR-012001
89498115|NCT06212089|Other|Placebo|Single dose of placebo
89498116|NCT06210828|Experimental|Telerehabilitation Group|A telerehabilitation group participates in two weekly exercise sessions over a 12-week period at home. These sessions, led by a physical therapist through two-way communication, focus on lower extremity strengthening and balance exercises. In addition to the guided sessions, participants are encouraged to perform self-directed exercises one day per week.
89498117|NCT06210828|Active Comparator|Control Group|"Receive fall prevention exercise brochure that includes instructions on how to perform the exercises, the recommended repetition and number of sets.~Participants are suggested to perform self-directed exercises three day per week."
89498118|NCT06210685|Experimental|ACES Device|Implantation of the ACES device for treatment of aseptic pleural effusion
89498119|NCT06210386|Experimental|Helmet noninvasive ventilation|1-hour treatment with helmet noninvasive ventilation (PEEP 12 cmH2O + pressure support 10 cmH2O).
89022971|NCT06179030||Group 2|switched from bevacizumab to dexamethasone implant
89022972|NCT06178367|Experimental|Topical 0,1% low molecular weight (7 kDa) hyaluronic acid|Participants receive moisturizer containing 0,1% low molecular weight (7 kDa) hyaluronic acid on 7 cm x 7 cm area on the right or left leg based on the randomization, twice a day for 1 month
89022973|NCT06178367|Active Comparator|Topical 0,1% high molecular weight (7 kDa) hyaluronic acid|Participants receive moisturizer containing 0,1% high molecular weight (7 kDa) hyaluronic acid on 7 cm x 7 cm area on the right or left leg based on the randomization, twice a day for 1 month
89498120|NCT06210386|Active Comparator|Facemask noninvasive ventilation (facemask settings)|1-hour treatment with facemask noninvasive ventilation (PEEP 5 cmH2O + pressure support 10 cmH2O).
89498121|NCT06210386|Active Comparator|Facemask noninvasive ventilation (helmet settings)|1-hour treatment with facemask noninvasive ventilation (PEEP 12 cmH2O + pressure support 10 cmH2O).
89498122|NCT06209554|Experimental|control group|Eight patients to be treated with only Scaling and root planning .
89498123|NCT06209554|Experimental|erythritol group|Eight patients to be treated with erythritol air polishing as an adjunct to Scaling and root planning .
89498124|NCT06209554|Experimental|laser group|Eight patients to be treated with dioad laser as an adjunct to Scaling and root planning .
89498125|NCT06208488|Experimental|Gefurulimab PFS-SD|Participants will be administered gefurulimab as a single dose of 600 mg by PFS-SD on the abdomen, thigh, or upper arm.
89498126|NCT06208488|Experimental|Gefurulimab AI|Participants will be administered gefurulimab as a single dose of 600 mg by AI on the abdomen, thigh, or upper arm.
89498127|NCT06207175|Experimental|Nonavalent HPV study vaccine|"Study vaccine: Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli) (Hereinafter referred to as Nonavalent HPV study vaccine)~Provided by: Beijing Health Guard Biotechnology, Inc.~Dosage: 0.5 mL per dose~Appearance: White, cloudy liquid suspension~Dosage form: 0.5-mL suspension for injection as a prefilled syringe~Route of administration: Intramuscular injection into the lateral deltoid muscle of the upper arm~Vaccination schedule in this study：3 injections on a 0, 2, 6-month schedule."
89498128|NCT06207175|Active Comparator|GARDASIL® 9|"Control vaccine: GARDASIL® 9~Manufacturer: Merck Sharp and Dohme Corp (MSD).~Dosage: 0.5 mL per dose~Appearance: After thorough agitation, GARDASIL® 9 is a white cloudy liquid~Dosage form: 0.5-mL suspension for injection as a prefilled syringe~Route of administration: Intramuscular injection into the lateral deltoid muscle of the upper arm~Vaccination schedule：3 injections on a 0, 2, 6-month schedule."
89498129|NCT06206850|Experimental|neoadjuvant osimertinib|Osimertinib 80 mg QD
89498130|NCT06205316|Experimental|Group I (SBRT)|Patients undergo SBRT over 15-20 minutes every other day for a total of 5 treatments over 1-2 weeks in the absence of disease progression or unacceptable toxicity. Patients may receive androgen deprivation therapy for up to 18 months, as clinically indicated. Patients undergo bone scan and PET at screening and treatment failure, and undergo MRI and blood sample collection throughout the study.
89498131|NCT06205316|Experimental|Group II (Hypofractionated radiation therapy)|Patients undergo hypofractionated radiation therapy over 15-20 minutes once per day for a total of 20 treatments over 4-6 weeks in the absence of disease progression or unacceptable toxicity. Patients may receive androgen deprivation therapy for up to 18 months, as clinically indicated. Patients undergo bone scan and PET at screening and treatment failure, and undergo MRI and blood sample collection throughout the study.
89498132|NCT06201403||COPD Group|Patients diagnosed with COPD at Istanbul Yedikule Chest Diseases and Thoracic Surgery Training and Research Hospital
89498133|NCT06201403||Healthy Group|Healthy individuals without any chronic or acute disease
89498134|NCT06201299|Experimental|Chair-based Exercise Group|Exercises will be performed with chair support.
89498135|NCT06201299|Experimental|Standard Exercise Group|Exercises will be performed using theraband.
89498136|NCT06201182|Experimental|FMT rectal enema|Patients will receive FMT via rectal enema and placebo capsules.
89498137|NCT06201182|Experimental|Encapsulated FMT|Patients will receive FMT capsules and placebo via rectal enema.
89498138|NCT06201182|Placebo Comparator|Placebo|Patients will receive placebo capsules and placebo via rectal enema.
89498139|NCT06201143|Experimental|BREATHING EXERCISE AND MOBILIZATION TRAINING GROUP|"Breathing exercise and mobilization training will be given in the patient&#39;s room during the preoperative period. Each training is planned to last approximately 20 minutes. Respiratory and mobilization training for patients during training techniques will be taught in practice, they will be shown how to mark the breathing exercise and mobilization tracking chart, and their questions will be answered.~Individuals in this group will be given breathing exercise and mobilization training. VAS form will be filled in at the 10th, 24th, 48th and 72nd hours of postpartum. The patient&#39;s total mobilization time and the number of breathing exercises will be recorded. The postpartum comfort scale will be filled in at the 10th and 72nd hours."
89498140|NCT06201143|Experimental|KINESIOLOGICAL TAPING + BREATHING EXERCISE AND MOBILIZATION TRAINING GROUP|Participants in this group will be given kinesiology taping, breathing exercise and mobilization training. Kinesiological taping will be done at the 10th hour postoperatively. The VAS form will be filled out at the 10th, 24th, 48th and 72nd postoperative hour. The patient&#39;s total mobilization time and the number of breathing exercises will be recorded. The postpartum comfort scale will be filled in at the 10th and 72nd hours.
89498141|NCT06201143|No Intervention|CONTROL GROUP|No intervention will be made to individuals participating in this group. The VAS form will be filled out at the 10th, 24th, 48th and 72nd postoperative hour. The patient&#39;s total mobilization time and the number of breathing exercises will be recorded. The postpartum comfort scale will be filled in at the 10th and 72nd hours.
89498142|NCT06200714||IPF patients|Clinical management of interstitial lung diseases (IPF) or other progressive pulmonary fibrosis (PPF) patients who experienced nintedanib-associated diarrhoea
89498143|NCT06197620|Experimental|Thread Embedding Acupuncture and Standard Therapy|The patients are pre-operative laparoscopic living donor nephrectomy patients that receive standard analgetic drug treatment according to post-operative kidney donor transplant protocol and receive thread embedding acupuncture. All patients are also given standard therapy after surgery in the form of intravenous Paracetamol 1000 mg, 3 times a day.
89498144|NCT06197269|Experimental|Short duration antibiotic|antibiotic therapy will be stopped at the time of randomization i.e. 72 hrs after starting treatment
89498145|NCT06197269|Active Comparator|Standard duration antibiotic|Antibiotics will be continued for 5-7 days more, 72 hrs after starting treatment.
89498146|NCT06196749|Experimental|Modified ultrasound-guided dynamic needle tip positioning technique group|Perform distal radial arterial cannulation using modified ultrasound-guided dynamic needle tip positioning technique
89498147|NCT06196749|Active Comparator|Palpation group|Perform radial arterial cannulation under palpation guidance
89498148|NCT06195332|Active Comparator|open TAR|Open transversus abdominis release procedure will be use as combine open procedure Rives-Stoppa hernia repair in combination with bilateral transversus abdominis release with retromuscular mesh placement
89498149|NCT06195332|Active Comparator|endoscopic TAR|Endoscopic transversus abdominis release procedure will be use as combine minimally invasive Rives-Stoppa hernia repair in combination with bilateral transversus abdominis release via endoscopic technique with retromuscular mesh placement
89498150|NCT06190769||Observation study - cross-sectional survey.|"sample size of monks will be 400 subjects of both genders (monks and nuns) randomly selected from different monasteries, Participants aged from 24 years old and above thought monastic years. As:~(1-3) years novice or probationary~(4-10) years of monasticism~more than 10 years of monasticism"
89498151|NCT06187194|Experimental|Enlarged tonsil(s) mass will be reduced by ENTire IRE System.|The bi-polar IRE System locally applies short, high-voltage (HV) pulses, increasing the permeability of tissue cells, creating non-thermal irreversible electroporation (NTIRE). The energy is transferred via bipolar forceps and causes irreversible cell membrane perforation and apoptosis. This results in tissue reduction within 2-4 weeks after treatment.
89498152|NCT06186401|Experimental|Cohort 1: Starting Dose (5 x 10^7 CAR+ cells)|Participants with newly diagnosed EGFRvIII+ GBM with unmethylated MGMT promotor status will undergo leukapheresis for manufacturing of E-SYNC T cells at least 2 weeks after completion of tnon-interventional, standard of care radiation therapy. Participants receive cyclophosphamide IV and fludarabine IV on days -5, -4, and -3 and then receive E-SYNC T cells IV on day 0. Participants will receive a single infusion of drug product (DP) (5 x 10^7 CAR+ T cells) and be monitored for safety, presence of and possible synNotch > CAR-T priming of the DP in the peripheral blood.
89498153|NCT06186401|Experimental|Cohort 1: Dose-escalation (1.5 x 10^8 CAR+ cells)|If there are no dose-limiting toxicities in the starting dose cohort, participants with newly diagnosed EGFRvIII+ GBM with unmethylated MGMT promotor status will undergo leukapheresis for manufacturing of E-SYNC T cells at least 2 weeks after completion of tnon-interventional, standard of care radiation therapy. Participants receive cyclophosphamide IV and fludarabine IV on days -5, -4, and -3 and then receive E-SYNC T cells IV on day 0. Participants will receive a single infusion of drug product (DP) (1.5 x 10^8 CAR+ T cells) and be monitored for safety, presence of and possible synNotch > CAR-T priming of the DP in the peripheral blood.
89498154|NCT06186401|Experimental|Cohort 2: Tissue analysis cohort|Participants with EGFRvIII+ glioblastoma recurrence after initial non-investigational, chemoradiation who need surgery will have the EGFRvIII H-scored based on digital image analysis of EGFRvIII immunohistochemistry (IHC) slides, with the score denoting both extent of and intensity of positive staining. Participants with an H-score of >=250 will undergo leukapheresis for manufacturing of E-SYNC T cells at the maximum tolerated dose, or recommended dose based on results from cohort 1 more than 2 weeks after completion of their non-investigational, standard of care radiation therapy. Participants will receive a single infusion of drug product (DP) on day 0 and will be admitted to the hospital for surgical resection (non-investigational) between days 14 and 28, and monitored for safety, presence of and possible synNotch > CAR-T priming of the DP in the peripheral blood, and anti-tumor response of E-SYNC T cells.
89498155|NCT06185075|Active Comparator|Straight transmucosal contour|Implant crown will be designed with a straight transmucosal contour
89498156|NCT06185075|Active Comparator|Concave transmucosal contour|Implant crown will be designed with a concave transmucosal contour
89498157|NCT06179264|Experimental|Treatment|Following random assignment to the condition after completing baseline assessment, participants will be instructed to complete the ACT Guide for Chronic Health Conditions program over the next 6 weeks.
89498158|NCT06179264|No Intervention|Waitlist Control|Following random assignment to the condition after completing baseline assessment, participants will be instructed to wait to receive the intervention after a period of 10 weeks (this accounts for the 6 weeks that treatment condition participants are given to complete the program, plus the 4 interim between post-assessment and follow-up.
89498159|NCT06178380|Active Comparator|standard rehabilitation|rehabilitation of knee osteoarthritis patients using standard techniques of massage, stretching, muscle strengthening and balance work
89498160|NCT06178380|Experimental|instrumental rehabilitation|rehabilitation of knee osteoarthritis patients using isokinetic, posturograph and antigravity treadmill
89022974|NCT06178367|Placebo Comparator|Vehicle|Participants receive vehicle on 7 cm x 7 cm area on the right or left leg based on the randomization, twice a day for 1 month.
89022975|NCT06175962|Experimental|Experimental Group|"At the beginning of the research, the Introductory Information Form, the Attitudes Towards Menopause Scale (MITÖ), and the Spirituality Index Well-Being Scale will be applied to the experimental group. Later, menopause health education will be given to women within the scope of the menopause adaptation program prepared based on Meleis's transition theory. Then, the women will be taught the baduanjin exercise for 4 weeks by the researcher who has a Qigong practitioner certificate. All training will be held online. After making sure that the women have learned the baduanjin exercise, they will be asked to do the baduanjin exercises at home 3 times a week for 8 weeks.~During this process, counseling services will be provided and women will be followed. The study will be completed in 14 weeks, after which posttest data will be collected."
89022976|NCT06175962|No Intervention|Control Group|"At the beginning of the research, the Introductory Information Form, Attitudes Towards Menopause Scale (MITÖ), and Spirituality Index Scale will be applied to the control group.~No intervention will be made to the control group."
89022977|NCT06174402|Experimental|Fenofibrate-ursodesoxycholic acid（UDCA）|Fenofibrate 200 mg/day and UDCA 13-15mg/kg/day for 12 months
89022978|NCT06174402|Placebo Comparator|Placebo-UDCA|1 tablet/ day and UDCA 13-15mg/kg/day for 12 months
89498161|NCT06177600|Other|Deferred Access|Deferred access participants will be given usual care and gain access to the digital app at 6 months. Usual care consists of access to published resources and community support organizations, if available. The list of resources will include contact information for a suicide prevention hotline.
89498162|NCT06177600|Experimental|Immediate Access|Immediate access participants will have access to a digital app, plus usual care, after enrollment and the deployment of the app. Usual care consists of access to published resources and community support organizations, if available. The list of resources will include contact information for a suicide prevention hotline.
89498163|NCT06175923||MDS patients|"Adult patients with myelodysplastic syndrome or suspected myelodysplastic syndrome according to the criteria defined by the World Health Organization:~one or more cytopenias,~and/or dysplasia of one or more lines,~and/or bone marrow blastosis~and/or sideroblasts in medullary crowns~and/or genetic/cytogenetic abnormalities characteristic of MDS.~Whatever the R-IPSS stage (Revised International Prognostic Scoring System)~No history of cytotoxic treatment (hydroxycarbamide, azacytidine)"
89498164|NCT06175923||AML patients|Adult patients with suspected de novo acute myeloid leukemia at initial management
89498165|NCT06171035|Active Comparator|Traditional model group|Received a regular learning
89498166|NCT06171035|Experimental|3D-printed high-fidelity craniofacial manikin model presention group|Received a regular learning plus 3D printing model
89498167|NCT06169410|Experimental|ramucirumab combined with lobaplatin, S-1 and nab-paclitaxel|Patients will be given ramucirumab (8mg/kg), lobaplatin (30 mg/m2) and nab-paclitaxel (100mg/m2) by intravenous drip on the first day of each cycle, 3 weeks a cycle, together with oral S-1 (patients with a body surface area less than 1.25 m2, will give 40 mg each time; patients with a body surface area between 1.25 and 1.5 m2; will give 50 mg each time; patients with a body surface area greater than 1.5 m2, will give 60 mg each time), 2 weeks on and 1 week off.
89498168|NCT06169410|Active Comparator|lobaplatin combined with S-1 and nab-paclitaxel|Patients will be given lobaplatin (30 mg/m2) and nab-paclitaxel (100mg/m2) by intravenous drip on the first day of each cycle, 3 weeks a cycle, together with oral S-1 (patients with a body surface area less than 1.25 m2, will give 40 mg each time; patients with a body surface area between 1.25 and 1.5 m2; will give 50 mg each time; patients with a body surface area greater than 1.5 m2, will give 60 mg each time), 2 weeks on and 1 week off.
89498169|NCT06168929|Experimental|Treatment group A|
89498170|NCT06168929|Experimental|Treatment group B|
89498171|NCT06168396|Active Comparator|Baseline (Without Somatosensation Device)|Participants will perform all outcome measures without wearing the somatosensation device.
89498172|NCT06168396|Experimental|With Somatosensation Device|Participants will perform all outcome measures while wearing the somatosensation device.
89498173|NCT06167434|Experimental|Single Arm|Insertable Cardiac Monitor Implant.
89498174|NCT06167343|Experimental|Semitendinosus tendon graft|"Surgical reconstruction of primary ACL rupture with autograft harvested from the semitendinosus tendon (ST).~The ST graft is harvested through a 4-5 cm incision at the pes anserinus. The semitendinosus is identified and harvested. The tendon is prepared and folded to a four-stranded graft with a total diameter of 8-11 mm.~The femoral tunnel is placed anatomically central in the native footprint of the ACL. The tibia tunnel is also placed anatomically; the center of the tunnel being medially between the eminential spines at the level of the posterior margin of the anterior horn of the lateral meniscus.~The quadrupled ST graft is fixed proximally with the RIGIDLOOP® adjustable cortical system (DePuy Synthes) and distally with the RIGIDLOOP® XL adjustable cortical system."
89531802|NCT05316571|Active Comparator|One 5-Minute Walking Bout Each Hour|"A 4-hour sedentary behavior bout, during which the participant remains seated while watching a non-stimulatory documentary.~The interruption strategy includes breaking up the 4-hour sitting bout with one 5-minute light intensity walking bout each hour. Each participant will be re-randomized to any of the non-completed arms after completion of the initial 4-hour sitting bout and interruption strategy until all arms have been completed."
89022979|NCT06172673||Community dwelling participants|Individuals between the ages of 19 and 45 in South Korea.
89022980|NCT06171854|Experimental|cabozantinib|60 mg once daily. Route: per os Cycle: 28 days
89022981|NCT06168539|Active Comparator|Standard|A regular standard dialysis is performed and held as active comparator for analysis
89022982|NCT06168539|Experimental|Emboless|"Emboless tubing set is part of the extracorporeal venous bloodline instead of the venous chamber by Fresenius (see standard above).~For more information see reference Jonsson et al 2023- mentioned in references."
89022983|NCT06168383|Experimental|Double-blind 80 mg Daily|Patients take double-blind HSK31679 80 mg for 52 weeks
89022984|NCT06168383|Experimental|Double-blind 160 mg Daily|Patients take double-blind HSK31679 160 mg for 52 weeks
89022985|NCT06168383|Placebo Comparator|Placebo|Patients take double-blind placebo for 52 weeks
89022986|NCT06168019||Influenza & COVID-19 Obstetric and Perinatal Epidemiology (ICOPE)|Pregnant women in their first trimester of pregnancy who present to the outpatient antenatal care clinic at Government Medical College Hospital in Nagpur, India.
89022987|NCT06166485|Active Comparator|1st group babies where the head is washed first and then the whole body|The effects of washing the head first and then the whole body on the physiological parameters (oxygen level, pulse, body temperature, calming time, stress level) of the first group babies will be examined.
89022988|NCT06166485|Active Comparator|2nd group babies, where the whole body is washed first and the head is washed last.|The effects on the physiological parameters (oxygen level, pulse, body temperature, calming time, stress level) of the second group of babies, where the whole body is washed first and the head last, will be examined.
89022989|NCT06165900|Experimental|adebrelimab plus stereotactic radiotherapy and chemotherapy|
89498175|NCT06167343|Experimental|Quadriceps tendon graft|"Surgical reconstruction of primary ACL rupture with autograft harvested from the quadriceps tendon (QT) without bone block.~The QT graft is harvested through a 4-5 cm incision at the upper pole of the patella. A graft sized 10-12 mm in with and app. 6 mm in depth is harvested from the middle part of the tendon.~The femoral tunnel is placed anatomically central in the native footprint of the ACL. The tibia tunnel is also placed anatomically; the center of the tunnel being medially between the eminential spines at the level of the posterior margin of the anterior horn of the lateral meniscus.~The QT graft is fixed proximally with the RIGIDLOOP® adjustable cortical system (DePuy Synthes) and distally with the RIGIDLOOP® XL adjustable cortical system"
89498176|NCT06163924||PCa receiving ADT|prostate cancer patients receiving androgen deprivation therapy
89498177|NCT06155435|Experimental|experimental group|"Firstly, the Pregnant Information Form, Traumatic Birth Perception Scale and Vaginal Birth Self-Efficacy Scale forms will be applied.Solution-oriented approach training; It is indicated for pregnant women one by one and in the form of at least 4 entries. A recording will take approximately 30-35 minutes.15-21 days after the solution-oriented approach training is completed the traumatic birth perception and vaginal birth self-efficacy scale form will be applied again.The traumatic birth perception form will be applied again 15-21 days after birth. The woman's birth type will be learned and recorded.~40 pregnant women will be followed in the experimental group."
89498178|NCT06155435|No Intervention|control group|Firstly, the Pregnant Information Form, Traumatic Birth Perception Scale and Vaginal Birth Self-Efficacy Scale forms will be applied. will be no intervention on the pregnant women in the control group, and the 15-21st week after the prenatal care given to the pregnant women by the Ministry of Health is completed. Traumatic birth perception and vaginal birth self-efficacy scale form will be filled in on these days. The traumatic birth perception form will be applied again 15-21 days after birth. The woman's birth type will be learned and recorded. 40 pregnant women will be followed in the control group.
89498179|NCT06142773|Experimental|Group 1: tidal volume delivered at 6 ml/kg for 3-5 minutes, followed by 12ml/kg for 3-5 minutes|"The clinical MRI examination will be obtained before commencing with the study protocol. The study protocol will commence once the scheduled MRI scan is finished. The study-related procedures will add 10 minutes after the scheduled MRI scans are finished with two different tidal volumes with maintaining isocapnia and isooxia.~Study procedure: tidal volume delivered at 6 ml/kg for 5 minutes, followed by 12ml/kg for 5 minutes"
89498180|NCT06142773|Active Comparator|Group 2: tidal volume delivered at 12 ml/kg for 3-5 minutes, followed by 6ml/kg for 3-5 minutes|"The clinical MRI examination will be obtained before commencing with the study protocol. The study protocol will commence once the scheduled MRI scan is finished. The study-related procedures will add 10 minutes after the scheduled MRI scans are finished with two different tidal volumes with maintaining isocapnia and isooxia.~Study procedure: tidal volume delivered at 12 ml/kg for 5 minutes, followed by 6ml/kg for 5 minutes"
89498181|NCT06138106|Experimental|Natural Product Supplement|The participant will consume a dose of hydrolyzed collagen (20g) supplemented with vitamin C (100 mg), epicatechin (75 mg), vitamin E (350 iU) and stevia extract (225 mg).
89498182|NCT06138106|Placebo Comparator|Placebo|The participant will consume a dose of hydrolyzed collagen (20g) supplemented with vitamin C (100 mg) and sweetener.
89498183|NCT06131632|Experimental|Breast conserving surgery|
89498184|NCT06131632|Active Comparator|Radical modified mastectomy|
89498185|NCT06129097|Experimental|Thyme honey mouthwash|"Thyme honey will be applied as oral rinse.~Based on this protocol, patients will have oral rinses (20 ml of thyme honey diluted in 100 ml of purified water) 3 times per day.~Patients will be instructed to perform thyme honey rinses in the oral mucosa.~Patients will be instructed not to swallow the thyme honey oral rinse."
89498186|NCT06129097|Placebo Comparator|Saline mouthwash|Patients in the control arm followed the same protocol with normal saline rinses.
89498187|NCT06128265|Experimental|Sleep Extension|Participants that are in the sleep extension group will have their time in bed extended by 2 hours. This can include going to bed earlier and/or waking up later.
89498188|NCT06128265|Experimental|Sleep Regularity|Participants in the sleep regularity group will have consistent bedtimes (within 30min).
89498189|NCT06124261||MASLD and PCOS hyperandrogenism|Patients with MASLD and PCOS with the phenotype of hyperandrogenism
89498190|NCT06124261||MASLD and PCOS non-hyperandrogenism|Patients with MASLD and PCOS with the phenotype of non-hyperandrogenism
89022990|NCT06165900|Active Comparator|adebrelimab plus nab-paclitaxel + carboplatin|
89022991|NCT06165575|Experimental|Press needle and medication|
89022992|NCT06165575|Sham Comparator|Sham press needle and medication|
89022993|NCT06165471|Experimental|Blended learning group|The Intervention group will adopt the mode of online and offline blended learning based on the Chaoxing mobile application (Chaoxing app). The researchers will create surgical nursing practice courses on the Chaoxing app, and the experimental group will be subjected to 2 months of online and offline blended teaching intervention using the Chaoxing app.
89022994|NCT06165471|Active Comparator|Traditional teaching group|The control group will adopt the traditional face-to-face teaching method for the surgical nursing practice course. The teacher will demonstrate the process, and the students will practice. The teacher demonstrates each step, and the students practice each step.
89022995|NCT06163287|Experimental|Supplement|One tablet of hydrogen-rich supplement before breakfast and dinner
89022996|NCT06163287|Placebo Comparator|Placebo|One tablet of hydrogen-free supplement before breakfast and dinner
89022997|NCT06160895|Experimental|TQ-A3334 tablets (once a day)|TQ-A3334 tablets, administered once a day.
89022998|NCT06160895|Placebo Comparator|TQ-A3334 placebo tablets (once a day)|TQ-A3334 placebo tablets, administered once a day.
88955667|NCT06306300|Active Comparator|Study II - Specialist|"HCV standard-of-care treatment; control arm. Participants randomized for the Standard-of-Care HCV treatment arm will be referred for the usual treatment of hepatitis C by specialists (hepatologists and/or infectious disease specialists) at a tertiary center [INI/FIOCRUZ or Hospital Universitário Clementino Fraga Filho (HUCFF/UFRJ)]. Participants will be treated with the pan-genotypic therapeutic regimen single-pill daily, at a fixed dose and duration: sofosbuvir/velpatasvir 400/100 mg (Epclusa, Gilead Sciences, USA) 1 tablet orally per day for 12 weeks."
89022999|NCT06160895|Experimental|TQ-A3334 tablets (every other day)|TQ-A3334 tablets, administered once every other day.
89023000|NCT06160895|Placebo Comparator|TQ-A3334 placebo tablets (every other day)|TQ-A3334 placebo tablets, administered once every other day.
89023001|NCT06160895|Experimental|TQ-A3334 tablets (every three days)|TQ-A3334 tablets, administered once every three days.
89023002|NCT06160895|Placebo Comparator|TQ-A3334 placebo tablets (every three days)|TQ-A3334 placebo tablets, administered once every three days.
89023003|NCT06156644|Other|PFA strategy|PFA will be performed based on a specific protocol
89023004|NCT06154278|Experimental|Imdusiran (AB-729)|Participants receive subcutaneous injections of 60mg, one injection every 8 weeks for 4 doses.
89023005|NCT06153264|Experimental|Control Group|Upper extremity strengthening exercises will be applied 10 repetitions a day, 3 days a week for 6 weeks.
89023006|NCT06153264|Experimental|Study Group|Upper extremity neurodynamic mobilization exercises and upper extremity strengthening exercises will be applied 10 repetitions a day, 3 days a week for 6 weeks.
89023007|NCT06152328|Active Comparator|VR group|During the exercise, games will be selected from the movements that focus on upper extremity function and require the use of both extremities. These functions will be to grasp the object with both hands, to throw the object, and to provide the object's rotation by revealing the hand's supination-pronation movement. During these movements, the image of the healthy side will be mirrored to the affected side. Before each exercise, what kind of movement requested from the patient will be shown in the VR environment.
89498191|NCT06124261||MASLD and no-PCOS|Patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and no PCOS
89023008|NCT06152328|Active Comparator|Control group|In addition to mirror therapy, Bobath therapy, walking exercises, upper extremity active exercises, proprioceptive neuromuscular facilitation techniques, which are traditional physical therapy and rehabilitation methods, will be applied to the control group. In addition, a virtual environment monitoring session will be conducted in non-interactive virtual environments for 10 minutes after their treatment.
89023009|NCT06151717||Observational|Patients have their medical records reviewed on study.
89023010|NCT06150144|Experimental|Patients with intralesional 5-fluorouracil.|
89023011|NCT06150144|Active Comparator|Patients with Surgery|
89023012|NCT06148337|Experimental|low-dose uESM|This arm will receive a treatment protocol consisting of enough capsules to provide a daily dose of two capsules containing one 300 mg capsule of uESM + 1 dummy capsule of psyllium husk fiber.
89023013|NCT06148337|Experimental|high-dose uESM|This arm will receive a treatment protocol consisting of enough capsules to provide a daily dose of two capsules containing two 300 mg capsules of uESM.
89023014|NCT06148337|Placebo Comparator|Placebo|This arm will receive a treatment protocol consisting of enough capsules to provide a daily dose of two capsules containing psyllium husk fiber.
89023015|NCT06147336|Experimental|V-LAP™ System|Heart failure subjects - Percutaneous implantation of the V-LAP™ implant by right heart catheterization (RHC) approach and daily LAP measurements at home and will be trained on the use of the device for self-management.
89023016|NCT06146088|Experimental|Batch 1 (6-35 months old, 2 doses)|Inactivated Enterovirus 71 Vaccine (human diploid cell) in children aged 6-35 months old on Day 0 and Day 30 approved by the National Institute for Food and Drug Control
89023017|NCT06146088|Experimental|Batch 2 (6-35 months old, 2 doses)|Inactivated Enterovirus 71 Vaccine (human diploid cell) in children aged 6-35 months old on Day 0 and Day 30 approved by the National Institute for Food and Drug Control
89023018|NCT06146088|Experimental|Batch 3 (6-35 months old, 2 doses)|Inactivated Enterovirus 71 Vaccine (human diploid cell) in children aged 6-35 months old on Day 0 and Day 30 approved by the National Institute for Food and Drug Control
89023019|NCT06144762|Experimental|Blood sample and tissue sample|Blood sample and tissue sample
89023020|NCT06144385|Experimental|CAR-GPC3 T cells|The safety and efficacy of JWATM204 will be evaluated in a Bayesian Optimal Interval Design (BOIN) dose escalation approach. 3 CAR-T dose levels will be tested in this study: 1×10^8, 3×10^8, 10×10^8, and 30×10^8 CAR-T cells will be explored.
89023021|NCT06144099|Active Comparator|fresh frozen plasma|according to the Thromboelastography (TEG) test, CK r-time prolongation, fresh frozen plasma transfusion (FFP) is performed
89023022|NCT06144099|Experimental|prothrombin complex concentrate|according to the Thromboelastography (TEG) test, CK r-time prolongation,prothrombin complex concentrate (PCC) administration
89023023|NCT06141460|Experimental|RRG001 Dose1|Frequency of administration: one time injection.
89023024|NCT06141460|Experimental|RRG001 Dose2|Frequency of administration: one time injection.
89023025|NCT06141460|Experimental|RRG001 Dose3|Frequency of administration: one time injection.
89023026|NCT06141460|Experimental|RRG001 Dose4|Frequency of administration: one time injection.
89023027|NCT06140966|Experimental|Study Treatment|"Pretrial induction chemotherapy (if required): bortezomib, cyclophosphamid, dexamethasone (VCD).~Induction Chemotherapy: Daratumumab, Carfilzomib,Lenalidomide, Dexamethasone, CisPlatin, epirubicin, Cyclophosphamide and Etoposide (Dara-KRd-PACE).~Autologous Stem Cell Transplant (ASCT) : Melphalan, ASCT.~Consolidation: Daratumumab, Carfilzomib, Lenalidomide, Dexamethasone (Dara-KRd).~Maintenance: Daratumumab, Carfilzomib, and Dexamethasone (Dara-Kd)."
89531803|NCT05316571|Active Comparator|One 15-Minute Standing Bout Each Hour|"A 4-hour sedentary behavior bout, during which the participant remains seated while watching a non-stimulatory documentary.~The interruption strategy includes breaking up the 4-hour sitting bout with one 15-minute standing bout each hour. Each participant will be re-randomized to any of the non-completed arms after completion of the initial 4-hour sitting bout and interruption strategy until all arms have been completed."
88955668|NCT06306300|Active Comparator|Study II - Non Specialist|"Decentralized hepatitis C treatment (DS HCV treatment; experimental arm).Participants randomized for the Decentralized-and-Simplified HCV treatment (DS HCV treatment) arm will be referred for simplified treatment of chronic hepatitis C at the Primary Health Care unit where participants were included in Study I and are registered for care. The treatment will be conducted by a non-specialist physician (general practitioner or family doctor) after training provided by a specialist (hepatologist) on the treatment of patients with hepatitis C using DAAs. Participants will be treated with a pan-genotypic therapeutic regimen, a fixed-dose, single-pill daily: sofosbuvir/velpatasvir 400/100 mg (Epclusa, Gilead Sciences, USA), 1 tablet orally per day for 12 weeks."
88955669|NCT06305767|Experimental|Pembrolizumab + V940|Participants receive 200 mg of pembrolizumab via intravenous (IV) infusion on Day 1 of every 6-week cycle for up to 9 cycles, plus 1 mg of V940 via intramuscular (IM) injection once available every 3 weeks up to a total of 9 doses. V940 doses may begin as soon as Day 22 of Cycle 1. The total duration of treatment is up to approximately 13 months.
88955670|NCT06305767|Active Comparator|Pembrolizumab + Placebo|Participants receive pembrolizumab 200 mg via IV infusion on Day 1 of each 6-week cycle for up to 9 cycles. Placebo will be administered every 3 weeks up to a total of 9 doses. The total duration of treatment is up to approximately 13 months.
89498192|NCT06123845|Experimental|CPAP 8|Upon arrival of the infant on the neonatal resuscitation trolley, start the normal standard procedures required by international protocols (e.g., drying, temperature control measures, placement of pulse-oximeter sensor to the right hand or wrist, etc.). Immediately start CPAP application with mask and T-piece: the CPAP level will be set at 8 cmH2O. Perform gentle tactile stimulation if the child is not breathing in appropriately. Place the pulse-oximeter sensor on the right hand then connect it to the oxymeter previously turned on. Assess breathing and HR for 30 seconds. Perform the next step of the flow-chart of resuscitation in the delivery room according to the Neonatal Resuscitation Program guidelines. If positive pressure ventilation (PPV) is required (in case of persistent bradycardia or apnea), maintain PEEP at 8 cm H2O and an initial PIP of 25 cm H2O. The CPAP level will be reduced to 6 cm H2O after 15 minutes of life, then the recording will be discontinued.
89498193|NCT06123845|Active Comparator|CPAP 5|Upon arrival of the infant on the neonatal resuscitation trolley, start the normal standard procedures required by international protocols (e.g., drying, temperature control measures, placement of pulse-oximeter sensor to the right hand or wrist, etc.). Immediately start CPAP application with mask and T-piece: the CPAP level will be set at 5 cmH2O. Perform gentle tactile stimulation if the child is not breathing in appropriately. Place the pulse-oximeter sensor on the right hand then connect it to the oxymeter previously turned on. Assess breathing and HR for 30 seconds. Perform the next step of the flow-chart of resuscitation in the delivery room according to the Neonatal Resuscitation Program guidelines. If positive pressure ventilation (PPV) is required (in case of persistent bradycardia or apnea), maintain PEEP at 5 cm H2O and an initial PIP of 25 cm H2O. The CPAP level will be raised to 6 cm H2O after 15 minutes of life, then the recording will be discontinued.
89498194|NCT06123117|Experimental|Daycare: STALL|Local ropivacaine infiltration + laparoscopically controlled TAP (transversus abdominis plane block). Daycare patients.
89498195|NCT06123117|Active Comparator|Daycare: local only|Local ropivacaine infiltration only. Daycare patients.
89498196|NCT06123117|Experimental|In-patient: STALL|Local ropivacaine infiltration + laparoscopically controlled TAP. In-patient surgery.
89498197|NCT06123117|Active Comparator|In-patient: local only|Local ropivacaine infiltration only. In-patient surgery.
89498198|NCT06123117|Experimental|Emergency: STALL|Local ropivacaine infiltration + laparoscopically controlled TAP. Emergency patients.
89498199|NCT06123117|Active Comparator|Emergency: local only|Local ropivacaine infiltration only. Emergency patients.
89498200|NCT06122922|Other|Patients with Stable Pulmonary Arterial Hypertension|Stable on current treatment regimen and not planning to undergo initiation of new therapy for at least 3 months Intervention: Drug: 129Xe Hyperpolarized
89498201|NCT06120816|Experimental|Nitric Oxide Releasing Mouthwash|Nitric Oxide Releasing Mouthwash (NORM) liquid producing NO at 266 ppm*min in 20mL
89498202|NCT06119464|No Intervention|Unexposed to intervention (control period)|This is the time period of the study where hospital clusters are not receiving the intervention
89498203|NCT06119464|Experimental|Exposed to intervention (intervention period)|This is the time period of the study where hospital clusters are receiving the multimodal intervention.
89498204|NCT06115785|Experimental|Cognitive Stimulation Therapy|Cognitive Stimulation Therapy In the 2nd, 3rd, 4th, 6th, 7th and 8th weeks, IPT implementation twice a week, as two themes, for 7 weeks, with each session of 45 minutes.
89498205|NCT06115785|No Intervention|CST nonpharmacological intervention|CST nonpharmacological intervention Individuals in the control group will be given two sessions in the 2nd week, and they will continue their daily lives in the following weeks.
89498206|NCT06109974||Participants with high risk of COPD|no intervention
89531804|NCT05316571|Active Comparator|One 5-Minute Walking Bout and One 15-Minute Standing Bout Each Hour|"A 4-hour sedentary behavior bout, during which the participant remains seated while watching a non-stimulatory documentary.~The interruption strategy includes breaking up the 4-hour sitting bout with one 5-minute light intensity walking bout and one 15-minute standing bout each hour. Each participant will be re-randomized to any of the non-completed arms after completion of the initial 4-hour sitting bout and interruption strategy until all arms have been completed."
89205457|NCT05275751|Experimental|Hot injection with TRPV1-, TRPA1, and chloride channel inhibition|Pain is induced by an increasingly hot intradermal injection up to 52°C over 2 minutes, while TRPV1, TRPA1, and a chloride channel are blocked pharmacologically by an antagonist dissolved in the hot fluid (synthetic interstitial fluid). The antagonist(s) have sufficient concentration to reliably block the channel. The total dose is in the range of a microdose trial.
88955673|NCT06301737|Experimental|comprehensive rehabilitation+stellate ganglion block|Patients enrolled are firstly numbered for privacy with software and divided into the observation group and the control group with. Additionally, the staffs involved in assessment would not participate in the intervention of the study. The treatment lasts 10 days.
88955674|NCT06301737|Placebo Comparator|comprehensive rehabilitation+placebo|Patients enrolled are firstly numbered for privacy with software and divided into the observation group and the control group with. Additionally, the staffs involved in assessment would not participate in the intervention of the study. The treatment lasts 10 days.
89498207|NCT06104202||Care professionals suffering from burn out|The group of care professionals suffering from burnout will be made up of care professionals who have been admitted to an outpatient facility at the Clinique Mon Repos. Attached to the clinic, this facility is specifically dedicated to them (day care unit). Around 100 care professionals suffering from burnout have already been assessed using the Maslach Burnout Inventory, Young Schema Questionnaire Short form, Montgomery-Asberg depression rating Scale and White Bear Suppression Inventory, with a view to adapting therapeutic interventions as part of their day-to-day care. These participants will be contacted by telephone by the investigator, who will inform them about the study if they meet the eligibility criteria.
89498208|NCT06104202||Care professionals without burn out|The study will also include a group of healthcare professionals not suffering from burnout, who will be informed about the study by investigating physicians from the occupational medicine department. During a regular occupational medicine consultation, the investigator will check the eligibility criteria, collect Maslach Burnout Inventory and Montgomery-Asberg depression rating Scale data as in normal practice, and inform eligible patients about the study.
89498209|NCT06104202||Non-care professionals in a state of burn out|Lastly, the study will include a group of non-medical professionals in a state of burnout who will be seen in consultation by an occupational medicine investigator, or who will consult and be monitored by an investigator at the Clinic. For those who are seen by an occupational health physician, the investigator will check the eligibility criteria, collect the Maslach Burnout Inventory and Montgomery-Asberg depression rating Scale data as in normal practice, and inform the eligible patients about the study.
89498210|NCT06103604||in-patients requiring temperature monitoring|The patient at any age whose core temperature is monitored during hospitalisation
89498211|NCT06101511|Experimental|Individualized high PEEP strategy with recruitment maneuvers|The intervention is intraoperative ventilation using the available ventilator with individualized high positive end-expiratory pressure (PEEP) titrated to the lowest driving pressure (ΔP) with recruitment maneuvers (RMs). After abdominal insufflation, patients randomized to the individualized high PEEP with RMs group will receive a RM followed by a 'decremental PEEP trial'. This is followed by a second RM after which PEEP is set at the level indicated by the decremental PEEP trial.
89498212|NCT06101511|No Intervention|Standard low PEEP strategy without recruitment maneuvers|Patients randomized to the standard low PEEP group will receive 5 cm H2O PEEP for the complete duration of general anesthesia. They will neither receive one of the planned RMs nor a decremental PEEP trial.
89498213|NCT06098365|Experimental|Cervical Stabilization Exercise Group|After applying traditional treatment for 40 minutes to the cases in Group A, additional segmental cervical stabilization exercises (20 minutes) will be applied.
89498214|NCT06098365|Other|Cervical Isometric Exercise Group|After applying traditional treatment for 40 minutes to the cases in Group B, additional cervical isometric exercises (20 minutes) will be applied.
89498215|NCT06096038|Experimental|Chimeric Antigen Receptors|blood will be collected to prepare the iC9.CAR-CSPG4 T cells. Disease-fighting T cells will be isolated and modified to prepare the iC9.CAR-CSPG4 T cells. In part 2, the iC9.CAR-CSPG4 T cells are given by infusion after completion of lymphodepletion chemotherapy.
89498216|NCT06092814|Active Comparator|real-tACS|The active stimulation will consist of an alternating current delivered in the alpha frequency band with a peak-to-peak intensity of 4 milliamps (mA) for 20 minutes. Participants will complete sentence completion and verb generation task during stimulation.
89498217|NCT06092814|Placebo Comparator|sham-tACS|"Sham stimulation involves the delivery of 60 seconds of the actual stimulation waveform (ramp up) which is then gradually reduced to 0 milliamps (mA) (ramp down). Participants will complete sentence completion and verb generation task during stimulation."
89498218|NCT06090227|Experimental|Metformin + Standard of Care|Administration of daily oral extended-release Metformin 500 mg tablets with standard of care for 6 months.
89498219|NCT06090227|Placebo Comparator|Placebo + Standard of Care|Administration of daily placebo tablets with standard of care for 6 months.
89498220|NCT06086444|Placebo Comparator|Placebo|Normal saline for intravenous administration.
89498221|NCT06086444|Active Comparator|Tranexamic acid|Tranexamic Acid for intravenous administration.
89498222|NCT06086431|Placebo Comparator|Placebo|0.2% ropivacaine for erector spinae plane block
89498223|NCT06086431|Active Comparator|Dexamethasone|0.2% ropivacaine + 0.1mg/kg Dexamethasone for erector spinae plane block
89498224|NCT06086431|Active Comparator|Dexmedetomidine|0.2% ropivacaine + 0.1ug/kg Dexmedetomidine for erector spinal plane block
89498225|NCT06086418|Placebo Comparator|placebo|0.2% ropivacaine for popliteal nerve block
89498226|NCT06086418|Active Comparator|0.1mg/kg Dexamethasone|0.1mg/kg dexamethasone added to 0.2% ropivacaine for popliteal nerve block
88821709|NCT02590822|Experimental|Total Dietary Replacement|"Group receives a total meal replacement diet from Cambridge Weight Plan containing 810 kcal/day (40% protein, 50% carbohydrate, 10% fat). The diet will be stopped, and a maintenance diet re-introduced once 50% excess body weight has been lost, or by 12 weeks, whichever comes first.~The TDR will be undertaken alongside health behaviour coaching and relapse prevention contact & current medications will need to be adjusted initially and throughout the study."
89498227|NCT06086418|Active Comparator|0,05mg/kg dexamethasone|0.05mg/kg dexamethasone added to 0.2% ropivacaine for popliteal nerve block
89498228|NCT06086392|Active Comparator|Placebo|0.2% ropivacaine for supraclavicular brachial plexus block
88821710|NCT02590822|Experimental|Supervised Exercise|"The exercise group will attend thrice weekly 60minute supervised exercise sessions at the Leicester-Loughborough Diet, Lifestyle and Physical Activity (LLP) BRU or at the Leicester Diabetes Centre. An initial assessment of cardiorespiratory fitness will be performed (VO2 max) to allow design of a tailored exercise programme.~Current medication will need to be adjusted initially and throughout the study."
89498229|NCT06086392|Active Comparator|0.1mg/kg Dexamethasone|0,1mg/kg dexamethasone added to 0.2% ropivacaine for supraclavicular brachial plexus block
89498230|NCT06086392|Active Comparator|0,05mg/kg dexamethasone|0,05mg/kg dexamethasone added to 0.2% ropivacaine for supraclavicular brachial plexus block
89498231|NCT06083298|Placebo Comparator|control group|patients will be operated under general anesthesia
89498232|NCT06083298|Active Comparator|MCP group|patients will receive MCP block followed by general anesthesia
89498233|NCT06083298|Active Comparator|ISP group|patients will receive ISP block followed by general anesthesia
89498234|NCT06071299|Experimental|FCC model|Participants will receive family-focused care.
89498235|NCT06071299|Active Comparator|CCC model|Participants will receive the usual child-focused care.
89498236|NCT06069999|Experimental|TR Bedside Telerehabilitation|"Participants will be assigned 45-minutes of therapy training exercises each day for 7 days a week up to 4 weeks or until discharge.~Participants will use the HandyMotion device to interact with the telerehabilitation program displayed on the TV set in the patient room."
89498237|NCT06064214|Experimental|block|33 patients will receive bilateral u/s guided intermediate cervical plexus block with general anesthesia
89498238|NCT06064214|Active Comparator|morphine|33 patients will receive morphine in a dose of 0.1-0.2 mg/kg to maintain intraoperative analgesia
89498239|NCT06059599|Experimental|active informed consent|The experimental group will be prepared for the surgery through the new information tools, a video will be administered with information about the various surgical possibilities, graphics and animations in order to direct the patient toward a more informed choice. Next, an interview with the surgeon will be arranged for the patient and care givers to be listened to and guided through the use of 3D-printed models into the best decision for the individual case (Shared Decision Making - SDM). Having decided on the surgery, patients with similar surgical programs will be guided in educational programs to reinforce information, understanding and long-term retention of the concepts learned. The course will conclude with a second interview with the surgeon and the signing of the standard informed consent.
89498240|NCT06059599|No Intervention|Traditional informed consent|The control group of patients will be informed about the surgery according to standard practices. As per standard practice, the patient will meet with the physician before surgery for an explanatory interview and subsequent signing of informed consent.
89498241|NCT06055972|Experimental|Letter Recipients with Coronary Calcium Score/Educational Materials|Patients randomized to the CAC-based educational intervention will receive an educational letter within 8 weeks of CT examination.
89498242|NCT06055972|No Intervention|Non-Letter Recipients (Control)|Patients in the control group will not receive any letter in the mail with their coronary calcium score and educational materials.
89498243|NCT06051409|Experimental|Olverembatinib|Olverembatinib in combination with chemotherapy
89498244|NCT06051409|Active Comparator|Imatinib|Imatinib in combination with chemotherapy
89498245|NCT06050291|Experimental|FDC Tablet Fed + Fast|Participants will receive a single Obicetrapib/Ezetimibe, 10 mg/10 mg FDC Tablet in a fed condition on Day 1 of treatment followed by a single Obicetrapib/Ezetimibe, 10 mg/10 mg FDC Table in a fasted condition after, at a minimum, a 56 day washout.
89498246|NCT06050291|Experimental|FDC Tablet Fast + Fed|Participants will receive a single Obicetrapib/Ezetimibe, 10 mg/10 mg FDC Tablet in a fasted condition on Day 1 of treatment followed by a single Obicetrapib/Ezetimibe, 10 mg/10 mg FDC Table in a fed condition after, at a minimum, a 56 day washout.
89498247|NCT06048302|Active Comparator|Active Comparitor: Subjects with Moderate Hepatic Impairment|8 patients with hepatic impairment of moderate Child Pugh Category
89498248|NCT06048302|Other|Active Comparator: Healthy Subjects|Healthy volunteers will be matched with impaired hepatic function patients
89498249|NCT06043492|Experimental|High Intensity Interval Training|The participants will perform an acute bout of high intensity interval training
89498250|NCT06043492|Experimental|Coninuous Running|The participants will perform an acute bout of continuous running
89498251|NCT06043492|Other|Control Trial|The participants will not perform any endurance exercise protocol
89498252|NCT06039501|Experimental|Family Perspective Program|"Families of critically ill patients will receive a program designed to enhance equitable communication and emotional support.~Questionnaires will be completed by primary surrogate decision makers, ICU support counselors, and ICU care team members (physicians, nurses, social workers). Meetings between families and ICU support counselors will be audio recorded (optional). Meetings between families and ICU care teams will be audio recorded (optional). Interviews with participants will be completed (optional)."
89498253|NCT06039501|No Intervention|Usual Care|"Families of critically ill patients will receive usual care, which involves regular and routine meetings between families and the ICU care team.~Questionnaires will be completed by primary surrogate decision makers and ICU care team members (physicians, nurses, social workers). Meetings between families and ICU care teams will be audio recorded (optional). Interviews with participants will be completed (optional)."
89498254|NCT06034652||Prospective Analysis of Minimally Invasive Surgical Approach (i.e., laparoscopic or robotic)|Collection of performance data for twenty-one subjects having prior minimally invasive surgical approach for ventral hernia repair (i.e., laparoscopic or robotic) from the previous T-GENVIH-002 study last data collection time-point (1-yr post-op) to present (prospective analysis), not previously reported.
89498255|NCT06034067|Experimental|Osseodensification (test) group|Implant site preparation will be completed using osseodensification technique where tapered multifluted burs (Densah Burs; Versah, MI, USA) will be used as per manufacturer's instructions.
89498256|NCT06034067|Active Comparator|Standard (control) group|Implant site preparation will be completed using conventional drilling protocol technique where standardized drills provided by Straumann (Straumann®, Institute Straumann AG, Basel, Switzerland)) will be used as per manufacturer's instructions.
89498257|NCT06033222|Experimental|750 mg castor oil treatment group|Subjects will take ricinoleic acid daily on an empty stomach in the morning 30 minutes before breakfast for a total of 4 days
89498258|NCT06033222|Experimental|1500 mg castor oil treatment group|Subjects will take ricinoleic acid daily on an empty stomach in the morning 30 minutes before breakfast for a total of 4 days
89498259|NCT06033222|Experimental|3000 mg castor oil treatment group|Subjects will take ricinoleic acid daily on an empty stomach in the morning 30 minutes before breakfast for a total of 4 days
89498260|NCT06033222|Placebo Comparator|Placebo group|Subjects will take placebo daily on an empty stomach in the morning 30 minutes before breakfast for a total of 4 days
89498261|NCT06029322|Active Comparator|Collagen membrane|BioGide Compressed® 13x25 mm, Geistlich Pharma AG, Wolhusen, Switzerland
89498262|NCT06029322|Experimental|collagen matrix|Mucograft Seal®, Geistlich Pharma AG, Wolhusen, Switzerland
89498263|NCT06021613|Experimental|Case-crossover|"Participants will be randomized in two-day blocks to consume then avoid cannabis (Start: On Cannabis) or avoid then consume cannabis (Start: Off Cannabis). Using an case-crossover strategy delivered by the NIH-funded, UCSF-run Eureka platform utilizing a mobile smartphone-based application, or the Mosio text messaging software for clinical research, participants will receive instructions and answer questions to help researchers and physicians understand the relationship between inhaled cannabis and heart rhythm."
89498264|NCT06018987|Experimental|Cohort 1: Treatment Group|Participants will receive subdermal injection of HAC20L to the nasolabial folds on Day 1 followed by an optional touch-up treatment on Day 30 if applicable. Participants will then be eligible to receive optional repeat treatment at Month 12 if applicable.
89498265|NCT06018987|Other|Cohort 1: Control Group|Participants will not receive treatment for 6 months and then will be offered an optional delayed treatment of HAC 20L after completion of of Month 6 visit with an optional touch-up treatment offered 30 days after delayed treatment.
89498266|NCT06018987|Experimental|Cohort 2: Treatment Group|Participants will receive subdermal injection of HAC20L to the nasolabial folds on Day 1 followed by an optional touch-up treatment on Day 30 if applicable. Participants will then be eligible to receive optional repeat treatment at Month 12 if applicable.
88955675|NCT06291363|Experimental|Esmolol|"In the Esmolol group, intravenous esmolol will be given as a bolus (0.5mg.kg-1) over 5 minutes, and will be started simultaneously to the remifentanil initiation.~Once the bolus of esmolol is over, a perfusion of 20 mcg.kg-1.min-1 will be programmed and maintained until the end of the surgery and completion of skin sutures"
88955676|NCT06291363|Placebo Comparator|Standard of care|"In the standard of care group, intravenous saline bolus, equivalent to an esmolol bolus (0.5mg.kg-1) will be given over 5 minutes, and will be started simultaneously to the remifentanil initiation.~Once the bolus of saline is over, a saline perfusion equivalent to an esmolol infusion of 20 mcg.kg-1.min-1 will be programmed and maintained until the end of the surgery and completion of skin sutures"
89498267|NCT06018987|Other|Cohort 2: Control Group|Participants will not receive treatment for 6 months and then will be offered an optional delayed treatment of HAC 20L after completion of of Month 6 visit with an optional touch-up treatment offered 30 days after delayed treatment.
89498268|NCT06013839|Experimental|TXA127 SC 0.5mg/kg/day|TXA127 (talfirastide) 0.5mg/kg/day given via subcutaneous injection for 6 months
89498269|NCT06010901|Experimental|TQB2618 injection+Penpulimab injection +Anlotinib hydrochloride capsules|TQB2618 injection combined with Penpulimab injection and Anlotinib hydrochloride capsules, 3 weeks as a treatment cycle.
89498270|NCT06010901|Experimental|TQB2618 injection+Penpulimab injection|TQB2618 injection combined with Penpulimab injection, 3 weeks as a treatment cycle.
89498271|NCT06010901|Experimental|TQB2618 injection|TQB2618 injection, 3 weeks as a treatment cycle.
89538227|NCT02444845||Study Population|Hypertensive and diabetic patients who meet eligibility criteria will be enrolled and evaluated for the presence of anemia secondary to CKD. The first visit will capture medical history including risk factors for CKD; laboratory assessments will be performed at the second and third visits to evaluate glomerular filtration rate (eGFR) and anemia profile, respectively. Participants who are not diagnosted with CKD based upon the second visit will not return for the third visit.
89538228|NCT03281993||CPAP-AT|After 2 hours from I-AT was performed the alternative AT by CPAP ventilation mode. Before CPAP-AT and 10 minutes after blood samples for arterial blood gases (ABG) were collected. If the investigators observe rapid desaturation defined as a decline in O2 saturation below 85%, CPAP-AT was aborterd.
89538229|NCT03281915||high inguinal approch|Patients undergoing high inguinal varicocelectomy with normal pre operative semen parameters, post operative semen analysis parameters will be recorded
89538230|NCT03281915||subinguinal approch|Patients undergoing subinguinal varicocelectomy with normal pre operative semen parameters, post operative semen analysis parameters will be recorded
89538231|NCT02443285|Active Comparator|Cefotaxime|cefotaxime 2gm every 12 hours daily for 5 days
89538232|NCT02443285|Active Comparator|Ceftriaxone|ceftriaxone 2 gm every 24 hours for 5 days.
88955677|NCT06287801|Experimental|Annual Wellness Visits (AWV)|Randomized Vanderbilt Health Affiliated Network (VHAN) practice to AWV and assess impact on the population deemed by study algorithm as high-risk and recruit 50 participants from the VHAN primary care clinical practice (n=50/practice) to complete surveys prior to the intervention and 6 months later.
88955678|NCT06287801|Experimental|Annual Wellness Visits + Geriatric Resources and Assessment for the Care of Elders (AWV + GRACE)|Randomized Vanderbilt Health Affiliated Network (VHAN) practice to AWV + GRACE and assess impact on the population deemed by study algorithm as high-risk and recruit 50 participants from the VHAN primary care clinical practice (n=50/practice) to complete surveys prior to the intervention and 6 months later.
88955679|NCT06286735|Active Comparator|Intervention|60 capsules of 500 mg of powdered cinnamomum bark (cinnamomum verum; 40% polyphenols) each. Participants in this group will be instructed to consume two capsules per day, one after lunch and the other after dinner for 3 months.
88955680|NCT06286735|Placebo Comparator|Placebo|60 capsules with 500 mg of corn starch each. Participants in this group will be instructed to consume two capsules per day, one after lunch and the other after dinner for 3 months.
89205458|NCT05275751|Experimental|Hot injection with chloride channel inhibition|Pain is induced by an increasingly hot intradermal injection up to 52°C over 2 minutes, while a chloride channel is blocked pharmacologically by an antagonist dissolved in the hot fluid (synthetic interstitial fluid). The antagonist(s) have sufficient concentration to reliably block the channel. The total dose is in the range of a microdose trial.
89205459|NCT05268133|Experimental|Aronia|An aronia melanocarpa extract. Study volunteers will receive a daily oral dose of 160 mg AME for 6 weeks.
89205460|NCT05268133|Placebo Comparator|Control|Cellulose. Study volunteers will receive a daily oral dose of 160 mg cellulose for 6 weeks.
89205461|NCT05262725|Experimental|Values-based Behavioral Activation (BA)|
89538233|NCT02445079||HIV infected|HIV infected sub-group
89538234|NCT02445079||HIV uninfected|HIV uninfected sub-group, age and gender matched to the HIV-infected group
89538235|NCT03284099|Experimental|intervention|ACEIs or ARBs will be switch to be taken before bedtime
89538236|NCT03284099|Active Comparator|control|ACEIs or ARBs will be taken in the morning as usual
89538237|NCT03281837|Experimental|Group 1: Hymovis plus Physical Exercise Program (PEP)|Intra-articular (IA) Hyaluronan (HA) (Hymovis 24mg/3mL) combined with Physical Exercise program (PEP)
89538238|NCT03281837|Other|Group 2: Physical Exercise Program (PEP) alone alone|Specified designed Physical Exercise Program (PEP) not combined with any other intervention
89538239|NCT03281837|Other|Group 3: Cross-Over group|Patients who were randomized to receive only Physical Exercise Program (PEP) alone and do not respond after 3 months to this intervention will have the opportunity to cross-over to receive 2 intra-articular weekly injections, each injection given 1 week apart, of Hymovis.
89538240|NCT02459405|Experimental|NIR anastomotic perfusion assessment|"Patient will have their anastomosis assessed after they receive 7.5 to 9 mg of Indocyanine green intravenously (at a concentration of 2.5mg/ml).~The microvascularisation assessment will be performed using a near infrared device(Pinpoint device), allowing to increase reality.~This procedure will be repeated twice during the surgery, the first time before and the second time after the anastomosis has been done."
89538241|NCT03193879||COPD group|COPD patients
89538242|NCT03193879||Asthma group|Asthma patients
89538243|NCT03193879||Health group|Healthy volunteers
89538244|NCT02439073|Experimental|early initiated rehabilitation|A supervised 12-week rehabilitation program, initiated two weeks post surgery, containing 24 group-based exercise sessions, three individual counseling sessions, and three group-based lessons in health-promoting behavior. If the participants have special needs in terms of smoking cessation, nutritional counseling or patient education, this is offered too.
89538245|NCT02439073|Active Comparator|late initiated rehabilitation|A supervised 12-week rehabilitation program, initiated 14 weeks post surgery, containing 24 group-based exercise sessions, three individual counseling sessions, and three group-based lessons in health-promoting behavior. If the participants have special needs in terms of smoking cessation, nutritional counseling or patient education, this is offered too.
89538246|NCT03190135|Experimental|BOKS: 2 day per week|
89538247|NCT03190135|Experimental|BOKS: 3 day per week|
89205462|NCT05255276|Active Comparator|Group 1 Treatment A|A single-dose administration of sitravatinib malate 50 mg on Day 1. Day 12, a single dose of sitravatinib malate 50 mg will be will be followed by a 72-hour PK sample collection period. Subjects will be discharged from the CRU on Day 4 after collection of 72-hour postdose PK sample and completion of all required study procedures.
89498272|NCT06005935||Participants with Lewy body dementia|50 women and 50 men with a clinical diagnosis of Lewy body dementia (Parkinson's disease dementia or dementia with Lewy bodies) will be included. If assistance is needed to complete the survey, care partners can help, however, they cannot answer the questions on the participant's behalf without the participant's contribution.
89498273|NCT06005935||Controls|50 women and 50 men with normal cognition and without Parkinson's disease will be included. Normal cognition will be determined using a screening questionnaire in the beginning of the survey to determine eligibility.
89498274|NCT06004895|Experimental|Actual IPL and LLLT|IPL and LLLT will be administered using the Espansione Group Ltd Eye-light unit. Five pulses of IPL will be administered along the lower lid region of the eye after the Pult meiboscore and Fitzpatrick skin grading has been entered into the unit. LLLT consisting of a wearable facial mask with red LEDs is then administered for 15 minutes.
89498275|NCT06004895|Sham Comparator|Sham IPL and LLLT|Sham IPL will be administered by placing a separate empty IPL cartridge on the lower eyelid regions of the patient's other eye while a working IPL cartridge (Espansione Group Ltd Eye-light unit) simulates a light pulse pointed away from the patient's face, after entering the Pult meiboscore and Fitzpatrick skin grading into the unit. Five simulated pulses will be administered. LLLT consisting of a wearable facial mask with red LEDs is then administered for 15 minutes.
89498276|NCT06004674|Experimental|Enoxaparin Group|Participants in the enoxaparin group will be asked to take a dose of the enoxaparin once a day (40 mg daily) daily from 12 0/7 weeks and/or start of enrollment (whichever is later), and continue until 36 weeks gestational age, after which enoxaparin will be discontinued.
89498277|NCT06004674|No Intervention|Control Group|Participants in this group will have standard care as usual, with no additional medications.
89498278|NCT06004362|Experimental|Complementary and Integrative Medicine online intervention, routine care and book|
89498279|NCT06004362|Active Comparator|Routine care and book|
89531805|NCT05316571|Active Comparator|Uninterrupted Sitting|"A 4-hour sedentary behavior bout, during which the participant remains seated while watching a non-stimulatory documentary.~This uninterrupted sedentary bout will serve as a control. Each participant will be re-randomized to any of the non-completed arms after completion of the initial 4-hour sitting bout and interruption strategy until all arms have been completed."
89205463|NCT05255276|Active Comparator|Group 1 Treatment B|On Days 9 to 11, itraconazole 200 mg will be administered QD in the morning. On Day 12, a single dose of sitravatinib malate 50 mg will be coadministered with itraconazole. Itraconazole QD dosing will continue on Days 13 to 18 to maintain steady state during the PK sample collection period.
89205464|NCT05255276|Active Comparator|Group 2 Treatment A|A single-dose administration of sitravatinib malate 100 mg on Day 1 will be followed by a 72-hour PK sample collection period. Subjects will be discharged from the CRU on Day 4 after collection of 72-hour postdose PK sample and completion of all required study procedures.
88955691|NCT06280196|Experimental|BAT3306|25 mg/mL concentrate for solution for infusion.200 mg on Day 1 of each 21-day cycle
88955692|NCT06280196|Active Comparator|EU-Keytruda® arm|25 mg/mL concentrate for solution for infusion.200 mg on Day 1 of each 21-day cycle
88955693|NCT06280196|Active Comparator|US-Keytruda® arm|25 mg/mL concentrate for solution for infusion. 200 mg on Day 1 of each 21-day cycle
88955694|NCT06276725|Experimental|Writing Wrongs|Writing Wrongs is an adaptation of expressive writing, a prolonged exposure practice targeting symptoms resulting from stressful life events. Writing Wrongs is specifically tailored to microaggressions experienced by minoritized students at predominantly White institutions. The intervention includes three 20-minute writing sessions occurring on three consecutive days. The Writing Wrongs writing activity asks participants to reflect on the facts and feelings associated with a microaggression they experienced.
88955695|NCT06276725|No Intervention|Assessment Control|The Assessment Control is administered the same measures during the same number of sessions as the Writing Wrongs condition without receiving the Writing Wrongs writing activity. The participants assigned to this arm of the study will receive the Writing Wrongs intervention following the completion of the study.
88955696|NCT06276023|Experimental|Mindful and Self-Compassionate Care Program (MASC)|"The intervention arm will be comprised of:~Six Virtual Group Sessions. The sessions will teach mindfulness, self-compassion and behavioral management skills.~At Home Practice. After each group session, participants will have the opportunity to integrate the practices learned into their everyday life."
88955697|NCT06276023|Active Comparator|Health Education Program (HEP)|"The control arm will be comprised of:~Six Virtual Group Sessions. The sessions will discuss caregiver stress, sleep hygiene, nutrition, and ways to stay physically active as a caregiver.~At Home Practice. After each group session, participants will have the opportunity to complete journal exercises that encourage them to integrate the health information that they learn into their daily lives."
88955698|NCT06275282|Experimental|Regenerative Peripheral Nerve Interface (RPNI)|Participants will have regenerative peripheral nerve interfaces (RPNIs) created on nerves in their residual thighs. During either the same surgery or a separate surgery, electrodes will be implanted into these RPNIs.
89498280|NCT05994911|Experimental|Mindfulness Training adolescent|An 8-week interview will be conducted with the individuals in the experimental group in the research in which the mindfulness training psychiatric nursing approach is applied. The control group will continue their routine school life. Individuals in the experimental group will be trained as a group and initiatives will be implemented in line with the goals of the individuals and the objectives of the research.
89498281|NCT05994911|No Intervention|Mindfulness|Individuals in the control group will continue their school life.
89498282|NCT05994495|Experimental|ARM A Molecular test|"Patients randomized to Arm A will be subjected to a microbiological test (either swabs or urine testing by NAAT). After having obtained the result of the molecular test, patients will be prescribed a targeted treatment"
89023028|NCT06139107|Experimental|Combined Pre-Operative Therapy with Abemaciclib, Letrozole, and Radiation in HR+/HER2- Breast Cancer|"Part A:~28-day treatment cycle based on abemaciclib~Abemaciclib 150mg BID (twice a day).~Letrozole 2.5mg daily and Abemaciclib 150mg twice a day for three cycles prior to undergoing radiation therapy.~On-treatment biopsy conducted between cycle 3, day 16, and cycle 4, day 1.~This occurs two weeks prior to transitioning to Part B.~Dose Level 0 150mg Twice daily with at least 6 hours between doses Dose Level 1 100mg Twice daily with at least 6 hours between doses Dose Level 2 50mg Twice daily with at least 6 hours between doses~Part B:~Continue treatment from Part A, 28-day cycle based on abemaciclib.~Abemaciclib 150mg BID (twice a day) with letrozole 2.5mg daily.~Part B focuses on the administration of radiation therapy following the three cycles of combined abemaciclib and letrozole.~Targeted radiation treatment.~Part C:~Two cycles of abemaciclib, 150mg twice a day.~Letrozole 2.5mg daily.~Part D:~Surgery"
89498283|NCT05994495|Active Comparator|ARM B Clinical Syndromic Approach|"Patients randomized to Arm B will be subjected to a molecular test, but they will be treated according to the current guidelines and the best practice using the clinical syndromic approach. So, patients randomized to Arm B and their physician also will be blinded to the results of the molecular test"
89498284|NCT05990660|Experimental|Treatment|
89498285|NCT05986539||Breastfeeding dyad|Women, and their infants, that intend to exclusively breastfeed or begin using formula as supplemental to breastmilk throughout the study.
89498286|NCT05986539||Formula feeding dyads|Women, and their infants, that intend to exclusively use formula from 6-18 weeks of life, the duration of the study,
89498287|NCT05982015|Experimental|Intervention group|Remote ischemic conditioning (RIC) -200mmHg and best medical management
89498288|NCT05982015|Sham Comparator|Sham group|Remote ischemic conditioning (RIC) -60mmHg and best medical management
89498289|NCT05978973|Experimental|elemental diet|subjects will be using the elemental diet packets daily. Subjects who are positive for excessive methane (i.e. methane level>10 ppm) will be required to complete a single daily fasting methane measurement (SMM) for the duration of the 14 days.
89498290|NCT05977920|Other|Only one Arm|s. description
89498291|NCT05977751|Experimental|FemBloc|Investigational device and procedure
89498292|NCT05975632|Experimental|Potassium measurement|Calibration Phase : 1 visit (duration 1 day) for subjects not on dialysis and hemodialysis patients Comparaison Phase : 1 visit (diration 1 day) for hemodialysis patients Comparaison Phase : 2 visits (diration 1 day) for subjects not on dialysis
89498293|NCT05974384|Placebo Comparator|No Music|Intervention without music
89498294|NCT05974384|Active Comparator|Music|Intervention while listening to music
89498295|NCT05973825|Experimental|Immuno-virological evaluation of persons living with HIV|Leucapheresis will be performed in HIV positive people making white blood cells available for in depth virological and immunological evaluation
89498296|NCT05972278|Placebo Comparator|Obicetrapib placebo|identical matching placebo
89498297|NCT05972278|Experimental|Obicetrapib 10 mg|10 mg tablets
89498298|NCT05967910||Early esophageal cancer patients with chronic psychological stress|
89498299|NCT05967910||Early esophageal cancer patients without chronic psychological stress|
89498300|NCT05967910||Advanced esophageal cancer patients with chronic psychological stress|
89498301|NCT05967910||Advanced esophageal cancer patients without chronic psychological stress|
89498302|NCT05966597|Experimental|Written persuasive leaflet|Participants will receive a written persuasive leaflet in addition to the standard referral leaflet.
89498303|NCT05966597|Sham Comparator|Standard referral leaflet|Participants will receive a standard referral leaflet.
89498304|NCT05966519||TKA with ROSA Knee|Total Knee Arthroplasty (TKA) is conducted using with robotic surgical assistant (ROSA) system
89498305|NCT05957965|Active Comparator|Conventional exercise training group|30 patients will receive conventional physical therapy training only which consist of strengthening, proprioceptive exercises.
88821711|NCT02561507||American College of Surgeons members|Survey participants
89023031|NCT06136455|Experimental|Arm 1: Brush / Listerine Clinical Solutions Teeth Strength|After brushing for 1 timed minute, participants will rinse full strength for 1 minute with Listerine Clinical Solutions Teeth Strength mouthwash.
89023032|NCT06136455|Experimental|Arm 2: Brush / Listerine Total Care Zero|After brushing for 1 timed minute, participants will rinse full strength for 1 minute with Listerine Total Care Zero mouthwash.
89498306|NCT05957965|Experimental|Wii Fit rehabilitation training group|30 patients Wii Fit group will receive Wii Fit rehabilitation training and the same conventional exercise training (strengthening, proprioceptive exercises)
89498307|NCT05957159|Experimental|Alcohol Use Disorder population completing Detoxification|Subjects will be asked to complete both 90 minute [11C]CFN and 90 minute [11C]PKAB PET Imaging after 1-3 days of a detoxification program.
89498308|NCT05957159|Experimental|Healthy Control population|Subjects will be asked to complete both a 90 minute [11C]CFN and a 90 minute [11C]PKAB PET Imaging.
89531806|NCT05301673||Adults with ADHD|
89538248|NCT03190135|No Intervention|Non-BOKS|
89498309|NCT05954832|Experimental|Echocardiography|Patients participating in this study will undergo routine anesthetic and perioperative care with the addition of an echocardiography and Clearsight BP measurement.
89498310|NCT05951452||ENDO +|Patients with endometriosis diagnosed by Magnetic Resonance Imaging (MRI) or laparoscopy
89498311|NCT05951452||ENDO -|Patients without endometriosis diagnosed by laparoscopy
89498312|NCT05945069|Experimental|TriLift|Combination of Dynamic Muscle Stimulation and Radiofrequency
89498313|NCT05944497||ISBPB group|Interscalene brachial plexus block involving the C5 to C8 nerve roots
89498314|NCT05944354||Low Back Pain|Subjects with Low Back Pain
89498315|NCT05944354||Neck Pain|Subjects with Neck Pain
89498316|NCT05944354||Control|Subjects with healthy spines, who have no neck or low back pain
89498317|NCT05944354||Operational Air Crew|Subjects that are in training aircrew program
89498318|NCT05940870||Nerivio treatment for migraine prevention|Patients with migraine who recieved the Nerivio device for migraine prevention therapy
89498319|NCT05938387|Experimental|Dose escalation: CVGBM Dose Level -1|Dose Level -1 represents a dose that may be evaluated if dose level 1 is poorly tolerated. No dose de-escalation below this level is planned for this study. If the dose level -1 is poorly tolerated, the study will be terminated.
89498320|NCT05938387|Experimental|Dose escalation: CVGBM Dose Level 1|
89498321|NCT05938387|Experimental|Dose escalation: CVGBM Dose Level 2|
89498322|NCT05938387|Experimental|Dose escalation: CVGBM Dose Level 3|
89498323|NCT05938387|Experimental|Dose escalation: CVGBM Dose Level 4|
89498324|NCT05938387|Experimental|Dose expansion|After completion of the dose-escalation part and safety data review by the DSMB, approximately 20 patients will be enrolled at the selected Recommended Dose for Expansion (RDE) to generate more data on safety, tolerability and immunogenicity.
89498325|NCT05936580|Experimental|Nuwiq|All patients receiving Nuwiq (recombinant FVIII). Nuwiq will be administered intravenously in accordance with the relevant prescribing information. Treatment will be repeated as necessary every 8-24 hours until adequate wound healing, then - if required - for at least another 7 days to maintain FVIII plasma levels of 30-60 IU/dL.
89498326|NCT05928403||medial pivot|Return to sport rate for patients with a Medial Pivot knee prosthesis
89498327|NCT05928403||medial bearing|Return to sport rate for patients with a Medial Bearing knee prosthesis
89498328|NCT05928403||cruciate retaining|Return to sport rate for patients with a Cruciate Retaining prosthesis
89498329|NCT05925478|Experimental|Treatment arm|
89498330|NCT05924594|Experimental|Experimental: 6.25mg CTx-1301 (Dexmethylphenidate tablet)|All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg. The starting dose for all subjects at Day 0 is 6.25mg. Each subject is expected to be on their optimal dose for 2 sequential weeks prior to the randomization phase. Subjects will be randomized (1:1) to their optimal dose or placebo in the 7-day, double-blind, randomization phase.
89498331|NCT05924594|Experimental|Experimental: 12.5mg CTx-1301 (Dexmethylphenidate tablet)|All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg. The starting dose for all subjects at Day 0 is 6.25mg. Each subject is expected to be on their optimal dose for 2 sequential weeks prior to the randomization phase. Subjects will be randomized (1:1) to their optimal dose or placebo in the 7-day, double-blind, randomization phase.
88955701|NCT06274021|Experimental|Transcutaneous spinal stimulation in combination of baclofen/tizanidine/placebo|"Each participant will receive five distinct interventions:~Transcutaneous spinal stimulation at 100 Hz for 30 minutes with a placebo~Transcutaneous spinal stimulation at 50 Hz for 30 minutes with a placebo~Transcutaneous spinal stimulation at 50 Hz for 30 minutes with a single-dose baclofen~Transcutaneous spinal stimulation at 50 Hz for 30 minutes with a single-dose tizanidine~Transcutaneous spinal stimulation (sham) for 30 minutes with a placebo"
88955702|NCT06273618|Active Comparator|Immediate|ECP participants who receive access to the Micro-Learning intervention immediately upon completing the Core Training.
88955703|NCT06273618|Active Comparator|3-month|ECP participants who receive access to the Micro-Learning intervention 3 months after upon completing the Core Training.
89498332|NCT05924594|Experimental|Experimental: 18.75mg CTx-1301 (Dexmethylphenidate tablet)|All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg. The starting dose for all subjects at Day 0 is 6.25mg. Each subject is expected to be on their optimal dose for 2 sequential weeks prior to the randomization phase. Subjects will be randomized (1:1) to their optimal dose or placebo in the 7-day, double-blind, randomization phase.
89498333|NCT05924594|Experimental|Experimental: 25.0mg CTx-1301 (Dexmethylphenidate tablet)|All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg. The starting dose for all subjects at Day 0 is 6.25mg. Each subject is expected to be on their optimal dose for 2 sequential weeks prior to the randomization phase. Subjects will be randomized (1:1) to their optimal dose or placebo in the 7-day, double-blind, randomization phase.
89498334|NCT05924594|Experimental|Experimental: 31.25mg CTx-1301 (Dexmethylphenidate tablet)|All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg. The starting dose for all subjects at Day 0 is 6.25mg. Each subject is expected to be on their optimal dose for 2 sequential weeks prior to the randomization phase. Subjects will be randomized (1:1) to their optimal dose or placebo in the 7-day, double-blind, randomization phase.
89498335|NCT05924594|Experimental|Experimental: 37.5mg CTx-1301 (Dexmethylphenidate tablet)|All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg. The starting dose for all subjects at Day 0 is 6.25mg. Each subject is expected to be on their optimal dose for 2 sequential weeks prior to the randomization phase. Subjects will be randomized (1:1) to their optimal dose or placebo in the 7-day, double-blind, randomization phase.
89498336|NCT05924594|Placebo Comparator|Placebo Comparator: Placebo|Subjects will be randomized (1:1) to their optimal dose or placebo in the 7-day, double-blind, randomization phase.
89498337|NCT05916586|Experimental|Prednisone + usual care|Prednisone tablets, 40 mg once a day orally, for 7 days plus usual treatment for acute heart failure
89023033|NCT06136455|Experimental|Arm 3: Brush / Listerine Cool Mint Zero|After brushing for 1 timed minute, participants will rinse full strength for 30 seconds with Listerine Cool Mint Zero mouthwash.
89023034|NCT06136455|Other|Arm 4: Brush / Water (Negative Control)|After brushing for 1 timed minute, participants will rinse with for 1 minute with tap water.
89498338|NCT05916586|No Intervention|Usual care|Usual treatment for acute heart failure
89498339|NCT05910970|Experimental|Adjuvant tislelizumab plus lenvatinib|Patients at high-risk of hepatocellular carcinoma recurrence after curative resection or ablation will receive adjuvant tislelizumab plus lenvatinib treatment for six months, HCC recurrence, or unacceptable adverse events.
89023037|NCT06133699|Experimental|SLNB|
89023038|NCT06131788|Active Comparator|Intervention Arm|"The intervention among people who inject drugs (PWID) from the intervention arm consist in : i) educational hand washing training (fingertips first model), ii) supply of single use alcohol-based hand rub (called MONO-RUB).~Only staff from the 11 harm reduction (HR) centres in the intervention arm will be trained in the educational hand-washing intervention."
89023039|NCT06131788|No Intervention|Control Arm|The 11 control arm HR centres will be the placebo group. People who inject drugs (PWID) in this group will receive standard HR services, including to reduce abscesses if necessary. MONO-RUBs will not be made available in these HR centres during the intervention period.
89023040|NCT06129890|Other|M1 - DLPFC|"Initial primary motor cortex stimulation (M1) followed by cortex prefrontal cortex (DLPFC) :~rTMS of M1, washout, rTMS of DLPFC"
89023041|NCT06129890|Other|DLPFC - M1|"Initial cortex prefrontal cortex (DLPFC) stimulation followed by primary motor cortex stimulation (M1) :~rTMS of DLPFC, washout, rTMS of M1"
89023042|NCT06129175|Experimental|Neuroncell-EX|Umbilical cord-derived mesenchymal stem cells
89023043|NCT06129175|Placebo Comparator|Control|Normal saline
89023044|NCT06129058|Experimental|tDCS|active tDCS
89023045|NCT06129058|Sham Comparator|Sham|sham tDCS
89023046|NCT06128304|Active Comparator|Core Implementation Strategies|"Core Implementation Strategies~Ongoing consultation~Educational meetings~Strengthen referral system~Prepare patients to be active participants"
89023047|NCT06128304|Experimental|Core+ Enhanced Implementation Strategies|"Includes all of the Core implementation strategies and adds:~5. Community engagement using Health Beginning Initiative Model~6. Smart Cards to facilitate patient engagement"
89023048|NCT06128239|Experimental|Two-Way Caring Contacts Texts (CC2)|"In addition to receiving enhanced usual care as described below, a series of 25 standardized outgoing Caring Contacts text messages will be sent to participants randomized to the CC2 intervention arm through our online texting platform. To remind participants that they can respond, the outgoing texts will periodically invite replies in a non-demanding way, e.g., Hope you're doing well this week, Anna. Feel free to text me back if you feel like it, I'm here for you. Responses to CC2 participant replies will be unscripted and individually tailored."
89023049|NCT06128239|Experimental|One-Way Caring Contacts Texts (CC1)|"In addition to receiving enhanced usual care as described below, CC1 participants will be sent 25 caring texts, such as Even though know we do not personally know each other, we truly value your wellbeing and are thinking of you. If you'd like to connect with someone, feel free to call or text 988 anytime - their team would be happy to hear from you. CC1 participants will not be able to reply to the texts and the online texting platform will block incoming messages. This will be clearly communicated to CC1 participants during the informed consent process and they will be asked to sign off on understanding this and other key points before enrolling in the study."
89023050|NCT06128239|No Intervention|Enhanced Usual Care (UC)|Participants randomized to the UC arm will receive best available usual care from the health system, such as standardized clinical assessments, the safety planning intervention or other intervention(s), appropriate referrals and/or medication management through a system wide electronic health record system-assisted suicide care clinical workflow. Usual care will vary based on patient clinical needs, availability of providers/staff, and provider clinical judgment. Following study enrollment, all participants will be given a list of resources, offered a warm hand-off to 988, and encouragement to call or text 988 as needed. During the baseline survey, participants will have the opportunity to opt into a call from the follow-up team to develop or revise a safety plan.
89023051|NCT06127823|Experimental|Intensive dietary care group|Women randomised to the intensive dietary intervention group will receive one initial dietary counselling consultation (60 min), and two mandatory follow-up consultations (2 x 30 min) with a dietitian. In addition, participants in this group will be offered 1-2 follow-up consultations (1-2 x 15-30 min) if needed.
89023052|NCT06127823|Active Comparator|Standard dietary care group|Women randomised to the standard dietary care group will receive one dietary counselling consultation (60 min) according to the initial dietary counselling described without any follow-up consultations with a dietitian. Participants are encouraged to follow their dietary plan until delivery.
89023053|NCT06126562|Experimental|Lanifibranor 800 mg|"In Part A, lanifibranor 800 mg is given as a single dose (followed by 14 days follow-up).~In Part B, lanifibranor 800 mg is given once daily for 7 consecutive days (followed by 7 days follow-up)."
89023054|NCT06126562|Experimental|Lanifibranor 120 mg|"In Part A, lanifibranor 1200 mg is given as a single dose (followed by 14 days follow-up).~In Part B, lanifibranor 1200 mg is given once daily for 7 consecutive days (followed by 7 days follow-up)."
89023055|NCT06119165|No Intervention|Control|Participants will conduct online shopping tasks without any environmental nudges. This includes no labels, peer comparison messages, or suggested product swaps.
89023056|NCT06119165|Experimental|Environmental|Participants in the experimental arm will shop and receive environmental nudges in the form of labels, peer comparisons messages, and suggested product swaps.
89498340|NCT05910970|Active Comparator|Adjuvant tislelizumab|Patients at high-risk of hepatocellular carcinoma recurrence after curative resection or ablation will receive adjuvant tislelizumab treatment for six months, HCC recurrence, or unacceptable adverse events.
89023057|NCT06117969|Experimental|Tibolone|take Tibolone 1.25mg/day orally for 8 weeks
89498341|NCT05906732|Experimental|Part 1: Arm A: 500 μg of Dofetilide BID in combination with dose-escalating LQT-1213 TID, orally|Dofetilide 500 μg BID (2 × 250 μg capsules), orally (Days 1-8) and LQT-1213 3 times a day (TID) low dose (Days 3 and 4), mid dose (Days 5 and 6), and high dose (not to exceed 0.747 mg/kg TID, daily dose 2.24 mg/kg/day) on Days 7 and 8. The specific doses will be determined before administration of the first dose of LQT-1213, but the high dose will not exceed 0.747 mg/kg TID or 2.24 mg/kg/day. Only 1 dose of dofetilide and LQT-1213 will be administered on Day 8.
88955704|NCT06273618|Active Comparator|6-month|ECP participants who receive access to the Micro-Learning intervention 6 months after upon completing the Core Training.
89498342|NCT05906732|Placebo Comparator|Part 1: Arm B: 500 μg of Dofetilide BID in combination with placebo|Dofetilide 500 μg BID (2 × 250 μg capsules), orally (Days 1-8) and placebo matched to LQT-1213 TID (Days 3-8). Only 1 dose of dofetilide and placebo matched to LQT-1213 will be administered on Day 8.
89498343|NCT05906732|Experimental|Part 2: TID dosing of LQT-1213|LQT-1213 2.24 mg/kg/day TID (at time 0, 8 and 16 hours) on Days 2-4, with a final single morning dose on Day 4 at time 0, though these time points may be adjusted based upon emerging data.
89498344|NCT05906732|Other|Part 2: TID dosing of Placebo|Placebo matched to LQT-1213 (Day 1)TID
89498345|NCT05906511|Active Comparator|Dronabinol 5mg|Dronabinol 5 mg
89498346|NCT05906511|Placebo Comparator|Dronabinol 10mg|Dronabinol 10 mg
89498347|NCT05906511|Active Comparator|Vaporized THC 2mg|Vaporized THC 2mg
89498348|NCT05906511|Active Comparator|Vaporized THC 4mg|Vaporized THC 4 mg
89498349|NCT05906511|Placebo Comparator|Placebo|Masked oral placebo or vaporized saline
89498350|NCT05904847|Experimental|Intervention|
89498351|NCT05904847|No Intervention|Control|
89498352|NCT05898841|Experimental|Dolutegravir (DTG) 50 mg/day + Rilpivirine (RPV) 25mg per day|Dolutegravir (DTG) 50 mg/day + Rilpivirine (RPV) 25mg per day. They may be administered in combination as 50/25 mg/day tablets (Juluca 50/25) or separately as Dolutegravir 50 mg/d tablets together with Rilpivirine 25 mg/d tablets (Tivicay 50 + Edurant 25)
89498353|NCT05898841|Experimental|TDF 245 mg /day or TAF 25 mg /day + FTC 200 mg /day + RPV 25 mg / day|Tenofovir disoproxil fumarate (TDF) 245 mg per day or Tenofovir alafenamide (TAF) 25 mg per day + Emtricitabina (FTC) 200 mg/d + Rilpivirina (RPV) 25 mg/d. They may be administered as single tablets (EVIPLERA 200 mg/25 mg/245 mg) or in combination forms where one tablet contains TDF/TAF and FTC and another RPV tablet (TDF/FTC + Edurant 25 or Descovy 25/200 + Edurant 25)
89498354|NCT05898841|Active Comparator|Continue with their previous treatment. Any previous HAART does not contain RILPIVIRINE.|Patients who are randomised to this treatment arm will continue with the HAART they were receiving prior to signing the informed consent. As in arms 1 and 2, a change in the form of HAART administration (from a combined to a separate form and vice versa) will be allowed as long as the HAART components are respected.
89498355|NCT05897216|Experimental|Sequence A|Period 1: CKD-383 (A single oral dose of 1 tablets under fed condition) Period 2: CKD-501, D745, D150, D029 (A single oral dose of 4 tablets under fed condition)
88955705|NCT06273618|Active Comparator|9-month|ECP participants who receive access to the Micro-Learning intervention 9 months after upon completing the Core Training.
88955706|NCT06273618|Active Comparator|Non-ECPs|Non-ECP participants
88955707|NCT06272058|Experimental|Avenciguat (BI 685509) severe hepatic impairment (Child-Pugh C)|
88955708|NCT06272058|Experimental|Avenciguat (BI 685509) normal hepatic function|
89205465|NCT05255276|Active Comparator|Group 2 Treatment B|On Days 9 to 15, rifampin 600 mg will be administered QD in the morning. On Day 16, a single dose of sitravatinib malate 100 mg will be coadministered with rifampin followed by a 72 hour PK sample collection period. Rifampin QD dosing will continue on Days 17 to 22 to maintain steady state during the PK sample collection period.
89205466|NCT05252858|Experimental|nCAP + ERAS|Participants will have the nCAP Signal Relief Patch and complete Enhanced Recovery After Surgery (ERAS) standard of care. After surgery, the subjects randomized to the intervention group will have the nCAP Signal Relief patch applied to their surgical dressing by a trained researcher in the immediate Post Anesthesia Care Unit (PACU).
89498356|NCT05897216|Experimental|Sequence B|Period 1: CKD-501, D745, D150, D029 (A single oral dose of 3 tablets under fed condition) Period 2: CKD-383 (A single oral dose of 2 tablets under fed condition)
89498357|NCT05879029|Experimental|experimental group|Jinsang Liyan Capsule: oral, 0.4g/ capsule, 4 capsules, twice a day, for 8 weeks; Rabeprazole enteric-coated tablets: taken orally before breakfast, 10mg/ tablet, 2 tablets at a time, once a day, for 8 weeks;
89498358|NCT05879029|Placebo Comparator|control group|Jinsang Liyan Capsule placebo: oral, 0.4g/ capsule, 4 capsules, twice a day, for 8 weeks; Rabeprazole enteric-coated tablets: taken orally before breakfast, 10mg/ tablet, 2 tablets at a time, once a day, for 8 weeks;
89498359|NCT05878353|Experimental|Subgingival instrumentation plus local doxycycline|Gentle debridement plus local doxycycline administered 2 weeks prior to periodontal regeneration.
89531807|NCT05301673||Partner, family member or close friend of the individuals with ADHD|
88955716|NCT06269484|Placebo Comparator|Treatment Group 1|Participants will receive once daily dose of placebo matching zibotentan capsule + placebo matching dapagliflozin tablet for 6 weeks
88955717|NCT06269484|Experimental|Treatment Group 2|Participants will receive once daily zibotentan capsule + placebo matching dapagliflozin tablet for 6 weeks
88955718|NCT06269484|Experimental|Treatment Group 3|Participants will receive once daily zibotentan capsule + dapagliflozin tablet 10 mg for 6 weeks
89023058|NCT06117969|Experimental|Xiangshao granules|take Xiangshao granules orally 3 times a day, 4g each time
89023059|NCT06117969|Experimental|Tibolone plus Xiangshao granules|take Tibolone 1.25mg/day and Xiangshao granules 3 times a day, 4g each time orally for 8 weeks
89023060|NCT06116708|Experimental|22 Healthy Volunteers|Each of the 22 volunteers will participate in a trial with both of the seat cushions. The test order is randomized.
89023061|NCT06113887|Experimental|intervention group 1 in which psychoeducation based on acceptance and commitment therapy was applied|Personal Information Form, Psychological Flexibility Scale and Barratt Impulsivity Scale -11 Short Form (BIS-11-SF) pre-tests will be applied. After the pre-test, acceptance and stability-based psychoeducation consisting of 8 modules will be implemented once a week as a single module. Each session of the acceptance and stability therapy-based psychoeducation, which will last 8 weeks in total, will be implemented for 45-60 minutes. Immediately after the training sessions are completed, the post-test; Psychological Flexibility Scale and Barratt Impulsivity Scale -11 Short Form (BIS-11-SF) will be administered. A follow-up test will be administered one month after the post-test, i.e. in the 12th week.
89498360|NCT05878353|Active Comparator|Subgingival instrumentation alone|Gentle debridement alone performed 2 weeks prior to periodontal regeneration.
89498361|NCT05863104|Experimental|Glycopyrronium Bromide (GPB) Cream|Formulation containing Glycopyrronium Bromide (GPB) for topical application
89498362|NCT05858996|Experimental|Pain-CPG-EIT|The four components of the PAIN-CPG-EIT are provided by a research nurse facilitator working with the champion(s) and stakeholder team. Following the first stakeholder team meeting, the research nurse facilitator works 8 hours weekly during months one and two and then for four hours weekly months three to 12 to implement: Component I: Stakeholder team meeting and goal setting; Component II: Education of the staff; Component III: Mentoring and motivating the staff to address pain using the Pain Management CPG ; and Component IV: Ongoing monitoring of pain management in the community based on the Pain Management CPG.
89498363|NCT05858996|Active Comparator|Pain-CPG-Education Only|Communities randomized to education only will be provided with staff education using our developed Powerpoint for Component II of the PAIN-CPG-EIT intervention in 30 minute sessions as is currently done in usual practice. They will also be given access to an online copy of the Pain Management CPG. The education will be provided in the preferred format (e.g., face-to-face; webinar).
89498364|NCT05855135|Experimental|CCM-D Implant|The subject is implanted with the CCM-D device.
89498365|NCT05848843|Experimental|Dose Confirmation Cohort|
89498366|NCT05848843|Experimental|Dose Expansion Cohort|
89498367|NCT05846516|Experimental|Cohort A|
89498368|NCT05846516|Experimental|Cohort B|
89498369|NCT05846516|Experimental|Cohort C Treatment|
89498370|NCT05846516|No Intervention|Cohort C Observational|
89498371|NCT05839873||Treatment Group|Single Arm Group to receive ablation.
89498372|NCT05836259|Experimental|Cohort 1|Dose for Cohort 1 will be 3E13 vg/kg
89498373|NCT05836259|Experimental|Cohort 2|Dose for Cohort 2 will be 6E13 vg/kg
89498374|NCT05832879|Experimental|OUD Telehealth Platform|Participants will be assigned to receive the OUD Telehealth Platform, which will be delivered remotely by research staff.
89498375|NCT05832658|Experimental|EMG-Biofeedback|Mendelsohn maneuver and effortful swallow exercise will be applied through game-based emg-biofeedback to patients with post-stroke dysphagia.
89498376|NCT05832658|Active Comparator|Classic Therapy|Mendelsohn maneuver and effortful swallow exercise with only verbal feedback will be applied to patients with post-stroke dysphagia.
89498377|NCT05828810|Active Comparator|Chlorhexidine gluconate-alcohol solution|"Chlorhexidine gluconate-alcohol solution is a type of solution that has antiseptic properties, which means it helps to eliminate harmful bacteria on the skin at the time of surgery, and therefore, reduce the risk of infection.~For participants in this arm, their surgeons will use chlorhexidine-based skin preparation solutions at the time of surgery to sterilize the surgical area."
89498378|NCT05828810|Active Comparator|Povidone-iodine solution|"Povidone-iodine solution is a type of solution that has antiseptic properties, which means it helps to eliminate harmful bacteria on the skin at the time of surgery, and therefore, reduce the risk of infection.~For participants in this arm, their surgeons will use iodine-based skin preparation solutions at the time of surgery to sterilize the surgical area."
89498379|NCT05821985|Other|The Study group|The patients within the study group will receive intraarticular TMJ and masseteric Trigger point injection of a solution that contains (0.75 ml. 12.5% Dextrose solution, 0.75 ml. Saline solution, and 1.5 ml. Lidocaine).
89498380|NCT05821985|Other|The Control group|Patients in the control group will receive intraarticular TMJ and masseteric Trigger point dry needle insertion without injecting any solution.
89498381|NCT05816759|Experimental|Sequence A|Period 1: CKD-383 (A single oral dose of 1 tablet under fed condition) Period 2: CKD-501, D744, D150 (A single oral dose of 3 tablets under fed condition)
89498382|NCT05816759|Experimental|Sequence B|Period 1: CKD-501, D744, D150 (A single oral dose of 3 tablets under fed condition) Period 2: CKD-383 (A single oral dose of 1 tablet under fed condition)
89498383|NCT05811676|Experimental|study group|Intravenous administration of 10 mL (1 g of tranexamic acid) diluted in 40 ml of normal saline, over 10 minutes after umbilical-cord clamping, the routine prophylactic uterotonic administration
89498384|NCT05811676|Placebo Comparator|control group|Intravenous administration of 10 mL placebo (0.9% sodium chloride), diluted in 40 ml of normal saline, over 10 minutes after umbilical-cord clamping, the routine prophylactic uterotonic administration
89498385|NCT05806749|Experimental|Immune tolerance in mismatched kidney transplant recipient|"Our goal is to establish this regimen as a novel, safe and effective approach for induction of transplant tolerance in HLA single haplotype-matched related and HLA mismatched unrelated recipients of combined Hematopoietic Stem Cell Transplant(HSCT)/ Kidney Transplant (KT). Patients will undergo conditioning with rATG and TLI, followed by infusion of hematopoeitic stem cells from the same donor, a triple immunosuppressive regimen, and receive belumosudil following the kidney transplant. Immunosuppression taper will be stopped and/or immunosuppression will be resumed for any of the following conditions:~(1) loss of chimerism 2) clinical or pathological evidence of acute rejection and (3) clinical or pathological evidence of graft vs host disease."
89498386|NCT05802797|Experimental|Algae Oil Fortified Soymilk|Subjects will drink 12 ounces of 0.4% algae oil-fortified soymilk
89023062|NCT06113887|No Intervention|Control group 1|Personal Information Form, Psychological Flexibility Scale and Barratt Impulsivity Scale -11 Short Form (BIS-11-SF) pre-tests will be applied. After the pre-test is administered, post-test will be administered in the 8th week and follow-up tests will be administered in the 12th week without any intervention.
89023063|NCT06113887|Experimental|Intervention group 2 in which psychoeducation based on acceptance and commitment therapy was applied|Personal Information Form, Psychological Flexibility Scale and Barratt Impulsivity Scale -11 Short Form (BIS-11-SF) pre-tests will be applied. After the pre-test, acceptance and stability-based psychoeducation consisting of 8 modules will be implemented once a week as a single module. Each session of the acceptance and stability therapy-based psychoeducation, which will last 8 weeks in total, will be implemented for 45-60 minutes. Immediately after the training sessions are completed, the post-test; Psychological Flexibility Scale and Barratt Impulsivity Scale -11 Short Form (BIS-11-SF) will be administered. A follow-up test will be administered one month after the post-test, i.e. in the 12th week.
89498387|NCT05802797|Active Comparator|Algae Oil Supplements|Subjects will take 2 commercial algae oil capsules.
89498388|NCT05800353|Experimental|early treatment group|Participants in the early treatment group will receive a YAG laser vitreolysis immediately and a sham laser treatment three months later.
89498389|NCT05800353|Experimental|delayed treatment group|Participants in the delayed treatment group will receive a sham laser treatment immediately and a YAG laser vitreolysis three months late.
89498390|NCT05799625|No Intervention|Usual Care|Eligible smokers randomized to usual care will receive an educational brochure for the University of Ottawa Heart Institute's Ottawa Model for Smoking Cessation (OMSC) Community Program. The brochure will include information about the OMSC Community Program and how to register for it to receive assistance to quit smoking.
89498391|NCT05799625|Experimental|Intervention|Eligible smokers randomized to the intervention group will be asked to download the StepOne smartphone application onto their smartphone via the Apple Store or Google Play Store. They will be provided with a unique ID and unique code, which will enable them to log into the StepOne smartphone application to begin the 14-day program. Users will interact with the application in the morning and evening; the exact time of the engagement is selected by the participant and ideally at a time that maximizes the likelihood of engaging with the activity. The application incorporates interactive educational material, daily reminders, gamification, and models of habit formation to engage users. As with any other smartphone application, users can turn off notifications if they choose to do so. New content and activities will be shared daily.
89498392|NCT05796336|Experimental|Passive lip taping|Will receive passive baby feeding plate and conventional steri strip
89498393|NCT05796336|Experimental|Custom-made tape|will receive passive baby feeding plate and custom-made tape (Steri Srip and orthodontic elastics)
89498394|NCT05795244|Experimental|Experimental|
89498395|NCT05794516|Experimental|ZB004|
89498396|NCT05794516|Placebo Comparator|Placebo|
89498397|NCT05793918|Experimental|Percutaneous Electrolysis and neuromodulation.|The intervention for this group consisted of Therapeutic Percutaneous Electrolysis and neuromodulation. Patient received once week for four weeks associated with eccentric exercises device at home.
89498398|NCT05793918|Active Comparator|Control group|"The multimodal physical therapy program includes 10 sessions of:~Ultrasound pulsatil therapy (US) for 10 minutes , transcutaneous electric nerve stimulation (TENS) for 20 minutes ans associated with eccentric exercises device at home."
89498399|NCT05786326|Experimental|multiholes fully covered metaalic stents group|Insertion of multiholes fully covered self-expandable metallic stents in the biliary tree through Endoscopic retrogrades cholangiopancreatography (ERCP)patients with malignant biliary obstruction.
89498400|NCT05786326|Active Comparator|parially covered metallic stents group|Insertion of partially covered metallic stents in patients with malignant biliary obstruction.
89498401|NCT05786326|Active Comparator|unocoered metaalic stents group|Insertion of uncovered metallic stents in patients with malignant biliary obstruction.
89498402|NCT05785286||Subject with male LUTS|Male subjects who have been bothered by male LUTS for at least 4 weeks and are still able to pass urine on their own without the need of assistance or urethral catheterization.
89498403|NCT05785286||Subject who is waiting for their transurethral ablative prostate surgery|Male subjects who are waiting for BPH surgery and are still able to pass urine on their own without the need of assistance or urethral catheterization.
89498404|NCT05784428|Active Comparator|Multiple fraction SABR (Arm 1)|Participants randomized to this arm will receive multiple fraction SABR
89498405|NCT05784428|Experimental|Single fraction SABR (Arm 2)|Participants randomized to this arm will receive single fraction SABR
89498406|NCT05784428|Active Comparator|Patient-reported outcome (PRO) collection : QoL reporting alone (Arm A)|Participants will complete the EuroQoL-5Dimensions-5levels (EQ-5D-5L) and Functional Assessment of Cancer Therapy-General (FACT-G) prior to each scheduled follow-up (FU).
89498407|NCT05784428|Experimental|QoL reporting and healthcare provider (HCP) intervention guided by symptom screen (Arm B)|"Patients complete EQ-5D-5L and FACT-G prior to each scheduled FU~Patient complete online adaptive symptom screen with HCP intervention, prior to each scheduled appointment"
89498408|NCT05775458||Adult neurosurgical patients|Adult neurosurgical patients with a brain lesion suspected for GBM, candidate to gross total tumor resection (GTR), followed by radiotherapy and chemotherapy (concomitant and adjuvant).
89498409|NCT05773586|Experimental|Single Ascending Dose (SAD) cohorts in Healthy Subjects (Part A)|Subjects will be randomized to receive a single dose of APG-5918 or placebo.
89498410|NCT05773586|Experimental|Multiple Ascending Dose (MAD) cohorts in Anemic Patients (Part B)|Subjects will be randomized to receive once daily APG-5918 or placebo for 28 days.
89498411|NCT05761756|Active Comparator|Sleep Deprivation|Effect of sleep deprivation on HCVR and arterial PCO2 during submersed rest and exercise at 98 fsw. Ten subjects will be tested before and after 24 hours of sleep deprivation. The order of sleep deprivation vs. control will be randomized. Measurements at 98 fsw will be obtained at rest and during 10 minutes of moderate exercise in thermoneutral (29-30°C) water.
89205467|NCT05252858|Active Comparator|ERAS alone|Participants randomized into the control group will receive complete Enhanced Recovery After Surgery (ERAS) standard of care and no nCAP patch.
89531808|NCT05285371|Placebo Comparator|CONT Group|CONT group will receive standard traditional intravenous fluid of D50.45% NaCl + 20 mEq/L KCl at 2/3 maintenance rate.
88955719|NCT06269198|No Intervention|Control arm|Blinded data collection by the WARD-CSS without vital signs and active alerts displayed to the ward staff
88955720|NCT06269198|Experimental|Intervention arm|Monitoring by the WARD-CSS including vital signs and active alerts relayed to the nurses' smartphones during hospitalization
88955721|NCT06267846|Experimental|NBI-1070770: Low Dose|Participants will receive low-dose NBI-1070770.
89205468|NCT05246579||Patients with short cervix|Patients with a short cervix identified on transvaginal ultrasound <30 mm
89205469|NCT05246579||Patients with a history of spontaneous preterm birth|Patients with a history of spontaneous preterm birth (<34 weeks)
89205470|NCT05246579||Patients with symptoms of preterm birth|Patients with preterm premature rupture of membranes or </=2 cm dilated before 34 weeks gestation.
89205471|NCT05246579||Control/Nulliparous|Nulliparous patients
89205472|NCT05243199|Experimental|Sacubitril/Valsartan|The initial dose of 50mg Qd was increased to 50mg Bid after 1 week and maintained to 100mg Bid after 2 weeks if the patient could tolerate it
88955722|NCT06267846|Experimental|NBI-1070770: Medium Dose|Participants will receive medium-dose NBI-1070770.
88955723|NCT06267846|Experimental|NBI-1070770: High Dose|Participants will receive high-dose NBI-1070770.
88955724|NCT06267846|Placebo Comparator|Placebo|Participants will receive matching placebo.
89205473|NCT05243199|Active Comparator|Irbesartan|the maximum tolerated dose of irbesartan was administered
89205474|NCT05229211||New Onset Atrial Fibrillation|Patients admitted to an adult intensive care unit for more than 24 hours who develop new onset atrial fibrillation during their ICU admission will be included. After discharge from ICU patients will undergo continuous ECG monitoring via VitalConnect patch for 14 days or until hospital discharge, whichever is shortest. They will undergo a further 7 days of continuous ECG monitoring via VitalConnect patch as an outpatient at 3 months post hospital discharge.
89205475|NCT05227716|Experimental|Magnesium sulphate|"Administration of intravenous MgSO4 as an adjunct to anesthesia.~Dose: 30 mg / kg of MgSO4 IV 15 minutes before induction of anesthesia and 10 mg / kg / h in continuous IV infusion during the operation"
89205476|NCT05227716|Placebo Comparator|Placebo|"Administration of intravenous physiological solution (NaCl 0.9%) as a complement to anesthesia.~Dose: equivalent to that administered in the MgSO4 group"
89205477|NCT05218343|No Intervention|Control|No change in default dose or frequency selected for the eight targeted drugs
89205478|NCT05218343|Experimental|Intervention|The first option a prescriber sees when prescribing any of eight high-risk drugs for elderly hospitalized patients will be modified; the first frequency option a prescriber sees will be modified as well. Providers retain the ability to prescribe any dose or frequency.
89205479|NCT05217433|Experimental|Investigational product|The investigational product is a capsule containing 100mg of the active ingredient oleuropein and will be provided once daily in the form of a 250mg olive leaf extract (i.e. 100mg of oleuropein per day) product for the duration of the intervention period (36 days).
89205480|NCT05217433|Placebo Comparator|Control arm|The control will be a placebo capsule containing 336 mg of cellulose microcrystalline, matching the investigational product appearance.
89498412|NCT05761756|Experimental|Caffeine|Effect of caffeine and methylphenidate on HCVR and arterial PCO2 during submersed rest and exercise at 98 fsw. Twenty subjects will be similarly sleep-deprived, tested as above and then re-tested tested following oral administration of administration of either oral caffeine (N=10) or methylphenidate (N=10). Pre-dive caffeine will be administered 500 mg orally [59]. Pre-dive methylphenidate will be administered as a single dose of 5 mg [60]. The order of drug administration vs. control will be randomized. Measurements at 98 fsw will be obtained at rest and during 10 minutes of moderate exercise in thermoneutral (29-30°C) water. fNIRS will be used to assess cerebral oxygenation and regional blood volume.
89498413|NCT05761756|Experimental|Methylphenidate|Effect of caffeine and methylphenidate on HCVR and arterial PCO2 during submersed rest and exercise at 98 fsw. Twenty subjects will be similarly sleep-deprived, tested as above and then re-tested tested following oral administration of administration of either oral caffeine (N=10) or methylphenidate (N=10). Pre-dive caffeine will be administered 500 mg orally [59]. Pre-dive methylphenidate will be administered as a single dose of 5 mg [60]. The order of drug administration vs. control will be randomized. Measurements at 98 fsw will be obtained at rest and during 10 minutes of moderate exercise in thermoneutral (29-30°C) water. fNIRS will be used to assess cerebral oxygenation and regional blood volume.
89531809|NCT05285371|Experimental|BOL Group|BOL group will receive intravenous boluses of Lactated Ringer's three times daily at 2/3 maintenance rate.
88955725|NCT06265584|Experimental|phase II single arm study of 2 step ATG dosing in prevention of aGVHD|The primary outcome for the study is GRFS rate at one-year post transplant. GRFS will be estimated using Kaplan Meier method The reported GRFS with recent phase III trial of PTCY/tac/MMF in transplant from matched related and unrelated donors at 1 year follow up was 52%. We hypothesize that with 2 step ATG/Tac/Mini MTX regimen, we can achieve a one year GRFS of 69%.
88955726|NCT06264440|Experimental|Period 1|Participants will receive a single oral dose of BIIB122, while fasting, followed by a washout period.
88955727|NCT06264440|Experimental|Period 2|Participants will receive PPI pretreatment (rabeprazole) once daily (QD), followed by a single oral dose of BIIB122 while fasting, followed by a washout period.
88955728|NCT06264440|Experimental|Period 3|Participants will receive PPI pretreatment (rabeprazole) QD, followed by a single oral dose of BIIB122 while fed, followed by a washout period.
89205481|NCT05195996|Active Comparator|beta blocker|Will be given Propranolol 1mg in 10 ml distilled water intravenous every 6 hours for 48 hours
89205482|NCT05195996|Placebo Comparator|placebo|Will be given normal saline 10 ml every 6 hours for 48 hours
88821712|NCT02515474|Active Comparator|LCBDE group (single step)|Choledocholithiasis patient, after Laparoscopic Cholecystectomy (LC) to remove the gallbladder, Laparoscopic Common Bile Duct Exploration (LCBDE) was performed for removing the bile duct stone(s) in laparoscopy. Choledochoscope detection or cholangiograms should be chosen as a method of obtain stone clearance. T-tube was acceptable if needed.
88955729|NCT06263244|Experimental|Ziltivekimab|15 mg ziltivekimab subcutaneously once per month for 5 months
88955730|NCT06263244|Placebo Comparator|Placebo|Placebo, subcutaneously, once per month for 5 months
88955731|NCT06262191|Experimental|Study group|Participants will walk with the new AFO, their own AFOs, and no AFOs.
89205483|NCT05195359|Active Comparator|Allocation to Sleep Improvement App|Participants will be instructed to engage with the Dein Schlaf. Dein Tag. smartphone app, log their behaviors in-app, and track their sleep daily for the duration of the study (12 weeks). Participants will be instructed to start the sleep tracking device via their iOS device before lying down in bed and turning off the lights to go to sleep. In the morning, participants will turn off the sleep tracking device as soon as they wake up and decide to leave the bed. At the three time points (baseline, 6 weeks, and 12 weeks), participants will be instructed to complete online assessments on self-reported sleep quality, health perception, psychosocial factors and sleep-permissive behaviors (i.e., preventative health)
89531810|NCT05284110|Experimental|Walking breaks (WALK)|During this session, participants will be requested to remain seated during 4 hours, but the sitting will be interrupted every 30 min with a 3-min light-intensity walking.
89531811|NCT05284110|No Intervention|Prolonged sitting (SIT)|During this session, participants be requested to remain seated during 4 uninterrupted hours (excepted for visiting the toilet) in a comfortable chair
89531812|NCT05274217|Experimental|Immediate group|Study participants in the immediate group will be randomly assigned to start the intervention immediately at the beginning of the fall trimester.
88955736|NCT06251986||ofatumumab|Subcutaneous ofatumumab in a real-world setting
88955737|NCT06250283|Experimental|Resveratrol|Dietary Supplement: Resveratrol (500 mg) + 500 mg calcium and 400 IU vitamin D3
88955738|NCT06250283|Placebo Comparator|Placebo|Dietary Supplement: Placebo (500 mg) + 500 mg calcium and 400 IU vitamin D3
89531813|NCT05274217|Experimental|Waitlist group|Study participants in the waitlist group will be randomly assigned to start the intervention at the beginning of the winter trimester.
88955740|NCT06245915|Experimental|AB-2100|Patients receive fludarabine and cyclophosphamide intravenously on days -5 to -3. Patients receive a single dose of AB-2100 intravenously on day 0.
88955741|NCT06243198|Experimental|Lebrikizumab|
88955742|NCT06243198|Placebo Comparator|Placebo|
88955743|NCT06241313|Placebo Comparator|Sequence 1|Participants will receive both atogepant and placebo to treat qualifying migraines.
88955744|NCT06241313|Experimental|Sequence 2|Participants will receive both atogepant and placebo to treat qualifying migraines.
88955745|NCT06241313|Experimental|Sequence 3|Participants will receive both atogepant and placebo to treat qualifying migraines.
88955746|NCT06241313|Experimental|Sequence 4|Participants will receive both atogepant and placebo to treat qualifying migraines.
88955747|NCT06240741|Experimental|[68Ga]Ga-DOTA-TATE|All eligible participants will receive [68Ga]Ga-DOTA-TATE via intravenous injection at a dose of 2 MBq/kg (0.054 mCi/kg) of body weight up to a maximum total dose of 200 MBq (5.4 mCi)
89531814|NCT05268120|Active Comparator|A|doxycycline 200 mg q.d. - rifampicin 600mg b.i.d.
89531815|NCT05268120|Active Comparator|B|trimethoprim 200mg b.i.d. - rifampicin 600mg b.i.d.
89531816|NCT05258890|Experimental|Social Network Counseling|The index patient and influential social network members will meet via Zoom 3 times over the course of 3 months with a clinical research nurse for teamwork counseling and blood pressure education.
89531817|NCT05258890|Active Comparator|Individual Counseling|The index patient will meet via Zoom 3 times over the course of 3 months with a clinical research nurse for blood pressure education.
89531818|NCT05258279|Experimental|Pemetrexed+Carboplatin+Pembrolizumab+Lenvatinib|Participants receive carboplatin Area Under Curve 5 mg/mL/min (AUC5) via intravenous (IV) infusion on Day 1 of each 3-week cycle (Q3W) for 4 cycles PLUS pemetrexed 500 mg/m^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS lenvatinib via oral capsule once daily for up to 2 years.
89531819|NCT05245331|Active Comparator|High-volume TAI|This group will be instructed on High-volume TAI to be perform daily or every 2 days for 2 months. After 15 days of wash-out they will switch to Low-TAI treatment for 2 months.
89531820|NCT05245331|Active Comparator|Low volume - TAI|This group will be instructed on Low-volume TAI to be perform daily or every 2 days for 2 months. After 15 days of wash-out they will switch to the Low-TAI treatment for 2 months.
89531821|NCT05237362|Experimental|Intervention|Receives the Saga Stories health promotion talk as well as take-home material
89531822|NCT05237362|No Intervention|Control|Receives standard health promotion talk
89531823|NCT05220189||Hematuria patients aged ≥40|Device: EarlyTect Bladder Cancer test, PENK methylation assay by LTE (Linear Target Enrichment)-qMSP (quantitative methylation-specific real time PCR)
89531824|NCT05207059|Experimental|Study Arm|The intervention will comprise four modules, namely the HELMS Journey, HELMS Model, HELMS Lifestyle and HELMS Community. The HELMS Journey will provide anticipatory guidance for both HELMS and routine clinic visits. The HELMS Model will deliver the 4S ('Screening', 'Size', 'Supplementation' and 'Specific case management') care plan, detailed below. The HELMS Lifestyle will provide lifestyle support in terms of healthy eating through the 6P tool ('Portion', 'Proportion', 'Pleasure', 'Phase', Physicality', 'Psychology'), physical activity, sleep and mental well-being. Finally, the HELMS Connection will provide community support and improve engagement with the program.
89531825|NCT05204732|Experimental|Experimental group|"Speech training: 4 times 1 hour of intonation training for 4 weeks~Standard voice assessment (voice recording, VAS, questionnaire(s)) (1 premeasurement and 2 postmeasurements)"
89531826|NCT05204732|Sham Comparator|Control group|"Speech training: : 4 times 1 hour sham therapy (info sessions + active intervention non-verbal communication) during 4 weeks + 4 times 1 hour intonation training during 4 weeks~Standard voice assessment (voice recording, VAS, questionnaire(s)) (1 premeasurement and 3 postmeasurements)"
89531827|NCT05195697||Mild acute pancreatitis|Patients treated with mild acute pancreatitis during the study period
88955748|NCT06240195||patients with metastatic triple-negative breast cancer treated with sacituzumab govitecan|The availability of at least one tumor tissue sample to be transferred to the coordinating center will be essential for enrollment in the study. For patients for whom a new sampling is scheduled biopsy of the tumor (primary or metastasis) as per clinical practice, the feasibility of the development will be assessed tumor organoids and the execution of single-cell sequencing on tumor tissue. In these cases, the order of priority in dividing the sampled tissue will be: sufficient quota to carry out the histological examination that will have to be carried out naturally confirm the diagnosis of triple-negative breast cancer. Quota to be prepared as a fresh preparation for the two experiments of feasibility indicated above; quota to be considered as a second sample, to be analyzed at the end of the study.
88955749|NCT06239064||Participants suspected to genetic obesity|Participants suspected to genetic obesity
89205484|NCT05195359|No Intervention|Allocation to Waitlist Control Group|At the three time points (baseline, 6 weeks, and 12 weeks) participants assigned to the wait-list control group will be instructed to complete online assessments on self-reported sleep quality, health perception, psychosocial factors and sleep-permissive behaviors (i.e., preventative health)
89205485|NCT05192876||Data Base of Patient Records 2000-2025|Analysis of outcomes and adverse events
89498414|NCT05761756|Experimental|Carbon Dioxide Exposure|Effect of simulated chronic CO2 exposure on HCVR and arterial PCO2 during submersed rest and exercise at 98 fsw. Ten subjects will be studied before and after induction of metabolic alkalosis as described above with daily oral administration of sodium bicarbonate. Oral bicarbonate to simulate hypercapnia exposure will seek to increase serum bicarbonate to 30 mM/L via daily oral intake of 6 teaspoons of NaHCO3 for five days. Subsequently, blood will be drawn and intake adjusted as necessary [61]. The order of alkalization vs. control will be randomized. Measurements at 98 fsw will be obtained at rest and during 10 minutes of moderate exercise in thermoneutral (29-30°C) water.
89498415|NCT05758389|Experimental|immunotherapy combined with chemotherapy|
89498416|NCT05758142|Placebo Comparator|Placebo|Participants randomized to the placebo arm will receive 1, 2, or 3 inert placebo tablets twice daily (i.e., 2, 4, or 6 tablets per day) for 12 weeks.
89498417|NCT05758142|Active Comparator|Potassium Chloride 30 mmol per day|Participants randomized to the 30 mmol per day group will receive 1 potassium chloride tablet (15 mmol strength) twice daily (i.e., 2 tablets per day) for 12 weeks.
89498418|NCT05758142|Active Comparator|Potassium Chloride 60 mmol per day|Participants randomized to the 60 mmol per day group will receive 2 potassium chloride tablets (15 mmol strength) twice daily (i.e., 4 tablets per day) for 12 weeks.
89498419|NCT05758142|Active Comparator|Potassium Chloride 90 mmol per day|Participants randomized to the 90 mmol per day group will receive 3 potassium chloride tablets (15 mmol strength) twice daily (i.e., 6 tablets per day) for 12 weeks.
89498420|NCT05756140||Patients Group|Geriatric patients in the postoperative period hospitalized in surgical wards
89498421|NCT05755932|Experimental|Treatment A: HFO MDI|Test arm, 6 inhalations BID for 7 days
89498422|NCT05755932|Active Comparator|Treatment B: HFA MDI|Reference arm, 6 inhalations BID for 7 days
89498423|NCT05750862|Other|Intervention arm|Study with one single arm. All participants will receive two interventions that will be compared to each other.
89498424|NCT05749861|Experimental|Sequence 1|"Period 1: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition~Period 2: CKD-348(5) - A single oral dose of 1 tablet under fasting condition~Period 3: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition~Period 4: CKD-348(5) - A single oral dose of 1 tablet under fasting condition"
89498425|NCT05749861|Experimental|Sequence 2|"Period 1: CKD-348(5) - A single oral dose of 1 tablet under fasting condition~Period 2: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition~Period 3: CKD-348(5) - A single oral dose of 1 tablet under fasting condition~Period 4: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition"
89498426|NCT05741385|Experimental|Group 1: Healthy participants|Every participant receives a cocktail of Caffeine, Warfarin sodium, Omeprazole, Metoprolol, Midazolam.
89498427|NCT05741385|Experimental|Group 2: F4 Child-Turcotte-Pugh class A (Child-Pugh A) participants (compensated)|"Every participant receives a cocktail of Caffeine, Warfarin sodium, Omeprazole, Metoprolol, Midazolam.~Compensated=without any disease symptoms"
89498428|NCT05741385|Experimental|Group 3: F4 Child-Turcotte-Pugh class B (Child-Pugh B) participants (decompensated)|"Every participant receives a cocktail of Caffeine, Warfarin sodium, Omeprazole, Metoprolol, Midazolam.~Decompensated= with disease symptoms like aszites, variceal bleeding, hepatic encephalopathy, hepato-renal syndrome"
89498429|NCT05740709||AKI patients|Patients who suffered from AKI whilst in ICU and are awaiting discharge from hospital
89498430|NCT05737563|Experimental|Experimental|PD-1 Antibody Combined With mXELIRI
89498431|NCT05737563|Active Comparator|Control|mXELIRI
89498432|NCT05733936|Experimental|criterion-based rehabilitation protocol|It's a three phases rehabilitation protocol with a goal-based progression which include a three criterion based postoperative phases: (1) impairment phase, (2) sport-specific training phase and (3) return to play phase. Patients can start with the next phase only if specific goals of the previous phase are achieved
89498433|NCT05733936|Active Comparator|accelerated rehabilitation protocol|It's a four phases rehabilitation protocol mainly based on the remodeling process of the graft., emphasizing full passive knee extension, immediate weight bearing as tolerated and functional exercises
89498434|NCT05727696|Active Comparator|radial shortening|
89498435|NCT05727696|Active Comparator|capitate shortening|
89498436|NCT05716529|Experimental|accelerated rehabilitation protocol|It's a four phases rehabilitation protocol mainly based on the remodeling process of the graft., emphasizing full passive knee extension, immediate weight bearing as tolerated and functional exercises
89498437|NCT05716529|Active Comparator|conventional physical therapy program|Current conventional protocols were based mainly on biological tissue healing time frames. These protocols emphasize pain reduction, full passive knee extension, quadriceps strength training, immediate motion, immediate par¬tial weight bearing (only if there is a correct gait pattern without any complications), and functional exercises
89498438|NCT05715268|Experimental|WeB and pelvic floor physical therapy group|This group will receive standard PFPT as well as WeB device for 12 weeks, and MS-symptom (including bladder bother) related questionnaires at baseline, 12 weeks and 6 months post intervention. Participants will also be provided with a remote activity monitor to use during the study.
89498439|NCT05715268|Active Comparator|Control pelvic floor physical therapy group|"This group will receive standard PFPT for 12 weeks. MS-symptom (including bladder bother) related questionnaires at baseline, 12 weeks and 6 months after the last PFPT visit.~Patients will be invited to use WeB devices after this time."
89498440|NCT05711823|Experimental|Aprepitant in combination with granisetron and dexamethasone|Patients with unresectable hepatocellular carcinoma will receive aprepitant in combination with granisetron and dexamethasone during the therapeutic process of hepatic arterial infusion chemotherapy.
89498441|NCT05711823|Active Comparator|granisetron and dexamethasone|Patients with unresectable hepatocellular carcinoma will receive granisetron and dexamethasone during the therapeutic process of hepatic arterial infusion chemotherapy.
89498442|NCT05706506|Experimental|Tirzepatide|Participants will receive tirzepatide subcutaneously (SC).
89498443|NCT05703828||chronic ankle sprain group|
89498444|NCT05703828||health subjects group|
89498445|NCT05700890||Implementation Team|"The Implementation Group will complete two surveys at the beginning of the study, then at five different points during the HPC Toolkit's use, and again three months post-intervention. The surveys are the Safe Surgery Checklist Culture Survey and the SSC Use and Attitudes Survey and a series of user experience surveys.~They will also do interviews pre- and post-HPC toolkit, and we will observe the Implementation Team's meetings as they work through the toolkit."
89498446|NCT05700890||OR Team|The OR members will complete the same pre- and post-intervention surveys (Safe Surgery Checklist Culture Survey and the SSC Use and Attitudes Survey) and do interviews before and after the IT has worked through the HPC toolkit.
89498447|NCT05700890||Surgical Patients|Surgical patients will be invited to participate in focus groups on their experiences from the time they enter the hospital on the day of their surgery to the moment they are put under anaesthesia.
89498448|NCT05695443|Experimental|Motivational Interviewing|Prisoners in this group are subjected to a MI-based conversation lasting up to 30 minutes aiming at improving oral health and oral health related behavior
89498449|NCT05695443|No Intervention|Control group|Prisoners in this group do not receive the MI-based intervention
89498450|NCT05695248|Experimental|Cohort 1 - Single Dose|Participants will receive 1 dose of STAR-0215.
89498451|NCT05695248|Experimental|Cohort 2 - Multiple Dose|Participants will receive 2 doses of STAR-0215 administered 3 months apart.
89498452|NCT05695248|Experimental|Cohort 3 - Multiple Dose|Participants will receive 2 doses of STAR-0215 administered 1 month apart.
89498453|NCT05674968|Experimental|Managing Challenging Behaviors in ADHD|This is a 7-session behavioral parent training delivered to children ages 3-7 referred to the study after an initial ADHD diagnosis or when challenging behaviors are identified by their medical provider.
89498454|NCT05674968|No Intervention|Wait List|Families assigned to the wait list will complete measures at baseline, 14 weeks, and 24 weeks. After 24 weeks they will be offered the experimental treatment.
89498455|NCT05664958|Experimental|ESP Block|Standard of care analgesic regimen with ESP Block
89498456|NCT05664958|No Intervention|Control|Standard of care analgesic regimen
89498457|NCT05660785|Experimental|CsA + Herombopag|Herombopag combined with cyclosporine
89498458|NCT05655130|Experimental|Test Group|Test Group will receive 10mg intravenous dexamethasone at the time of incision, administered by the assigned anesthesiologist. Post-surgery, Test Group patients will be prescribed a 6-day oral methylprednisolone taper course.
89498459|NCT05655130|Other|Control Group|Standard of care with no placebo
89498460|NCT05642897|Experimental|Mind|The Mind programme is an ACT, mindfulness and compassion intervention for women with breast cancer. It will include 8 weekly group sessions, with the duration of 120 minutes each, and will be delivered at the Radiotherapy Service of the CHUC or through an online platform. All participants will continue on receiving the recommended medical treatment for their clinical diagnosis.
89498461|NCT05642897|Active Comparator|Support group|A support group intervention, with 8 weekly 90-120-minute sessions, will be delivered to the active control group at the Radiotherapy Service of the CHUC or through an online platform. All participants will continue on receiving the recommended medical treatment for their clinical diagnosis.
89498462|NCT05642832|Experimental|Throughflow|Throughflow is a novel system that reduces anatomical dead space by providing a constant flow of fresh gas (i.e., gas that is free of CO2) during inspiration in patients receiving invasive mechanical ventilation. By clearing the CO2 that normally remains in the upper airway after exhalation (anatomical dead space), TF can dramatically reduce anatomical dead space without the need to increase the delivered VT, making it a safe strategy in terms of lung protection. This reduction in dead space reduces the ventilatory demands of the patients, reducing respiratory drive.
89498463|NCT05637801|Experimental|Active|Treatment Group: Subjects are treated with the Active Sensory Stimulation System at home for 60 minutes daily for up to12 months.
89498464|NCT05637801|Sham Comparator|Control|Control Group: Subjects are treated with a Sham Sensory Stimulation System at home for 60 minutes daily for up to 12 months.
89498465|NCT05635929|Experimental|Acute group (Phase 1)|Patients during radiotherapy
89498466|NCT05635929|Experimental|Chronic group (Phase 2)|Patients 6 months after oncological treatment is finished
89498467|NCT05625217|Experimental|Total-body PET scan|All participants are asked to complete two study scan visits. First visit occurs before treatment and the second visit occurs 12 +/- 2 weeks after treatment. Each visit will involve a single injection of FDG, followed by three PET/CT scans that will start immediately following injection, at about 2 hours post-injection and at 5 hours post-injection, respectively and last about 60 minutes, 20 minutes and 20 minutes, respectively.
89498468|NCT05623163|Experimental|EndoZip System|"The Nitinotes EndoZip system is designed to allow for the creation of multiple internal gastric segmentation (up to 5) in the stomach by using an endoscopic approach. The system allows the forming of wall-to-wall longitudinal attachments of the anterior and posterior stomach walls, creating multiple strictures within.~Creation of this segmentation may significantly reduce gastric volume, may affect gastric motility and consequently, reduce weight."
89498469|NCT05616910|Experimental|Group A|Subjects will receive iNO for 4 hours, followed by standard respiratory support (SRS) for 4 hours. This pattern will be reversed the next day (SRS then iNO). on the following day, the pattern will be reversed back to iNO for 4 hours and SRS for 4 hrs.
89531828|NCT05195697||Moderate acute pancreatitis|Patients treated with moderate acute pancreatitis during the study period
88955752|NCT06237517|Experimental|Progressive acclimation of healthy individuals with Idiopathic Chilblains|Throughout the experiment, the participants remained seated in a sitting position. The trial began with the chamber's temperature at 22-24°C and 40-50% (relative humidity) for 20 minutes. After this period, the temperature within the chamber dropped by 4 degrees every 20 minutes. After 80 minutes, the temperature was maintained at 10°C and 40-50% (relative humidity) for 15 minutes, and an occlusion foot test for 15 minutes, and an occlusion foot test (5 minutes ''baseline'' phase, 5 minutes ''occlusion'' phase, and 5 minutes ''release'' phase) was performed to observe any hemodynamic changes in the foot. Participants provided blood and urine samples before and following the trial.
89205486|NCT05190939|Active Comparator|no-dye/saline|Subjects assigned to the no-dye/saline group will have cystoscopy performed using saline as the bladder distending media and will not utilize any intravenous dye
89205487|NCT05190939|Experimental|dye/saline|Subjects assigned to the dye/saline group will have cystoscopy performed using saline as the bladder distending media and will utilize intravenous dye (methylene blue or fluorescein) as a ureteral jet visualization aid
88955753|NCT06237517|Experimental|Progressive acclimation of healthy individuals with Idiopathic Chilblains (Rewarming Phase)|Throughout the experiment, the participants remained seated in a sitting position. The trial began with the chamber's temperature at 22-24 °C and 40-50% relative humidity for 20 minutes. After this period, the temperature within the chamber dropped by 4 degrees every 20 minutes. After 80 minutes (the chamber's temperature was 10°C and 40-50%), a radiator heater was placed in front of the participants to increase the temperature of their extremities. Simultaneously, the investigators increased the temperature of the chamber to 22-24 °C and 40-55% relative humidity, and the participants remained in the same sitting position for 20 minutes. Following this period, an occlusion foot test was performed to observe any hemodynamic changes in the foot. The test consisted of a 5-minute ''baseline'' phase, a 5-minute ''occlusion'' phase, and a 5-minute ''release'' phase. Before and after the trial, participants provided blood and urine samples.
88955754|NCT06237517|Active Comparator|Progressive acclimation of healthy individuals without Idiopathic Chilblains|Throughout the experiment, the participants remained seated in a sitting position. The trial began with the chamber's temperature at 22-24°C and 40-50% (relative humidity) for 20 minutes. After this period, the temperature within the chamber dropped by 4 degrees every 20 minutes. After 80 minutes, the temperature was maintained at 10°C and 40-50% (relative humidity) for 15 minutes, and an occlusion foot test for 15 minutes, and an occlusion foot test (5 minutes ''baseline'' phase, 5 minutes ''occlusion'' phase, and 5 minutes ''release'' phase) was performed to observe any hemodynamic changes in the foot. Participants provided blood and urine samples before and following the trial.
89205488|NCT05190939|Experimental|no-dye/water|Subjects assigned to the no-dye/water group will have cystoscopy performed using water as the bladder distending media and will not utilize any intravenous dye
89205489|NCT05190939|Experimental|dye/water|Subjects assigned to the dye/water group will have cystoscopy performed using water as the bladder distending media and will utilize intravenous dye (methylene blue or fluorescein) as a ureteral jet visualization aid
89205490|NCT05187858|Experimental|LNP3794|Participants will receive LNP3794 orally once daily at different doses in 28 day cycles on a continuous basis
89205491|NCT05184231||Patient cohort|
89205492|NCT05184231||Physician cohort|
89205493|NCT05172752|Other|Citizen Science Training|Study participants in this condition will participate in training and in-home sampling for disinfection by-products.
89205494|NCT05172752|Other|Stakeholder Consultation Core Membership|Study participants in this condition will participate in quarterly meetings and deliberative activities of the project's Stakeholder Consultation Core.
89205495|NCT05124158||Patients with a diagnosis of COVID-19|"A directed psychiatric evaluation will be carried out and 1 evaluation instrument will be applied: Global Tool for the Evaluation of Mental Health in Primary Care (GMHAT / PC).~The Global Mental Health Assessment Tool / Primary Care (GMHAT / PC) is a computerized, semi-structured clinical interview tool developed to assess and identify mental health problems. The main diagnosis derives from the use of a hierarchical model based on ICD-10. The diagnostic program takes into account the severity of symptoms (moderate to severe). It also generates alternative diagnoses and comorbidity states based on the presence of symptoms of other disorders. In addition, it includes a suicide risk assessment."
89205496|NCT05120089|Experimental|muscle energy technique|Muscle energy technique is an associate degree of osteopathic manipulation methodology. The muscles of patients were used, on request, to type a singular controlled position, in a very specific direction, and against a distinctly executed therapist-applied counterforce. Muscle energy technique could be a post-isometric relaxation, because it reduces the tone of a muscle or cluster of muscle after a brief period following an isometric contraction. The result of post-isometric relaxation is mediated by receptive input from Golgi connective tissue organ (GTO) that has associate degree repressive result on the antagonist muscles mediated by the muscle spindle receptive. The technique will be applied for three month (3 session/week)
89205497|NCT05120089|Experimental|myofacial release|The technique will be applied for three month (3 session/week). All participants underwent ipsilateral side bending in a side-lying position, with the goals being de-rotation and scoliosis reduction.
89205498|NCT05110326|Experimental|ERGON Technique Group|Patients in this group will receive ERGON Technique along with conventional therapy
89205499|NCT05110326|Experimental|Proprioceptive Neuromuscular Facilitation(PNF) stretching Group|Patients in this group will receive Proprioceptive Neuromuscular Facilitation (PNF) stretching along with conventional therapy
89205500|NCT05109884|Other|newly diagnosed very high risk locally advanced and/or oligometastatic prostate cancer|
89205501|NCT05109884|Other|metastatic, castration resistant prostate cancer|
89205502|NCT05109884|Other|newly diagnosed prostate cancer with planned radical prostatectomy|
89205503|NCT05109884|Other|primary bladder cancer with planned radical cystectomy|
89205504|NCT05101564|Experimental|IC1:Alpelisib in combination with Tamoxifen|Integrative subtype IC1, Treatment (14 days, - 2 or + 7 days): Take assigned alpelisib pills, 300 mg (two 150 mg tablets) with food, once daily by mouth. Tamoxifen pills, 20 mg once daily by mouth
89205505|NCT05101564|Active Comparator|IC1:Tamoxifen|Integrative subtype 1, Treatment (14 days, -2 to +7 days): Take assigned tamoxifen pills, 20 mg once daily by mouth
89205506|NCT05101564|Experimental|IC2:Zotatifin in combination with Fulvestrant|Integrative subtype 2, Treatment (14 days, - 2 to +7 days). Zotatifin (calculated by weight, 0.10 mg/kg) should be administered as a 60-minute IV infusion on Days 1. A total of 500 mg Fulvestrant should be administered intramuscularly as two 5mL injection on Day 1.
89205507|NCT05101564|Active Comparator|IC2:Fulvestrant|Integrative subtype 2, Treatment (14 days, - 2 to +7 days) A total of 500 mg Fulvestrant should be administered intramuscularly as two 5mL injection on Day 1.
89205508|NCT05101564|Experimental|IC3:Zotatifin in combination with Fulvestrant|Integrative subtype 3, Treatment (14 days, - 2 to +7 days). Zotatifin (calculated by weight, 0.10 mg/kg) should be administered as a 60-minute IV infusion on Days 1. A total of 500 mg Fulvestrant should be administered intramuscularly as two 5mL injection on Day 1.
89205509|NCT05101564|Active Comparator|IC3:Fulvestrant|Integrative subtype 3, Treatment (14 days, - 2 to +7 days) A total of 500 mg Fulvestrant should be administered intramuscularly as two 5mL injection on Day 1. on Day 1.
89205510|NCT05101564|Experimental|IC4:Zotatifin in combination with Fulvestrant|Integrative subtype 4, Treatment (14 days, - 2 to +7 days). Zotatifin (calculated by weight, 0.10 mg/kg) should be administered as a 60-minute IV infusion on Days 1. A total of 500 mg Fulvestrant should be administered intramuscularly as two 5mL injection on Day 1.
89205511|NCT05101564|Active Comparator|IC4:Fulvestrant|Integrative subtype 4, Treatment (14 days, - 2 to +7 days) A total of 500 mg Fulvestrant should be administered intramuscularly as two 5mL injection on Day 1..
89205512|NCT05101564|Experimental|IC6:Zotatifin in combination with Fulvestrant|Integrative subtype 6, Treatment (14 days, - 2 to +7 days). Zotatifin (calculated by weight, 0.10 mg/kg) should be administered as a 60-minute IV infusion on Days 1. A total of 500 mg Fulvestrant should be administered intramuscularly as two 5mL injection on Day 1.
89205513|NCT05101564|Active Comparator|IC6:Fulvestrant|Integrative subtype 6, Treatment (14 days, - 2 to +7 days) A total of 500 mg Fulvestrant should be administered intramuscularly as two 5mL injection on Day 1.
89205514|NCT05101564|Experimental|IC7:Zotatifin in combination with Fulvestrant|Integrative subtype 7, Treatment (14 days, - 2 to +7 days). Zotatifin (calculated by weight, 0.10 mg/kg) should be administered as a 60-minute IV infusion on Days 1. A total of 500 mg Fulvestrant should be administered intramuscularly as two 5mL injection on Day 1.
89205515|NCT05101564|Active Comparator|IC7:Fulvestrant|Integrative subtype 7, Treatment (14 days, - 2 to +7 days) A total of 500 mg Fulvestrant should be administered intramuscularly as two 5mL injection on Day 1.
88821713|NCT02515474|Active Comparator|ERCP group (sequential step)|Choledocholithiasis patient, Endoscopic Retrograde cholangiopancreatography (ERCP) was performed for removing the bile duct stone(s) in endoscopy prior to Laparoscopic Cholecystectomy (LC). Sphincterotomy (EST) and Endoscopic papillary balloon dilatation (EPBD) can be chosen accordingly. The laparoscopic cholecystectomy was subsequently performed as soon as technically feasible following the ERCP in one month.
89205516|NCT05101564|Experimental|IC8:Zotatifin in combination with Fulvestrant|Integrative subtype 8, Treatment (14 days, - 2 to +7 days). Zotatifin (calculated by weight, 0.10 mg/kg) should be administered as a 60-minute IV infusion on Days 1. A total of 500 mg Fulvestrant should be administered intramuscularly as two 5mL injection on Day 1.
89205517|NCT05101564|Active Comparator|IC8:Fulvestrant|Integrative subtype 8, Treatment (14 days, - 2 to +7 days) A total of 500 mg Fulvestrant should be administered intramuscularly as two 5mL injection on Day 1.
89205518|NCT05061316|Experimental|Nutrition intervention group|Participants will receive Nestlé Impact Advanced Recovery Immunonutrition two times daily for 5 days leading up to the date of surgery. Nestlé Impact Advanced Recovery will be administered either orally or through a feeding tube.
89205519|NCT05058963|Experimental|Mantram repetition program|Weekly 90 minute virtual group therapy sessions for 8 weeks run by two faciliators and will consist of 5-8 participants.
89205520|NCT05036993|Experimental|Intervention|Coaching
89205521|NCT05036993|Experimental|Control|Control, Coaching later
89205522|NCT05022290|Experimental|Single-syringe technique|Patients in this arm will receive adenosine in a single syringe, diluted with normal saline up to 20 ml. The dosage of adenosine is according to the recommendation of ACLS guidelines, which recommended 6 mg as the first dose and 12 mg as the subsequent dose if SVT can not be terminated by the first dose.
89205523|NCT05022290|Active Comparator|Double-synring technique|Patients in this arm will receive adenosine using a double syringe, the first syringe contains only adenosine and the second syringe contains only normal saline 20 ml. Both syringes are connected to each other, and to the patient's IV portal with a stopcock. The administration must be done by two nurses one after another, adenosine syringe is injected first, then follow by normal saline. The dosage of adenosine is according to the recommendation of ACLS guidelines, which recommended 6 mg as the first dose and 12 mg as the subsequent dose if SVT can not be terminated by the first dose.
89205524|NCT05010525|Experimental|ATG-016-20mg|20 mg QD×5/ week as the initial dose in the Dose Escalation Phase, with a treatment cycle of 21 days,1-5/week will be the initial dose of this study
89205525|NCT05010525|Experimental|ATG-016-35mg|35 mg QD×5/ week as the initial dose in the Dose Escalation Phase, with a treatment cycle of 21 days,1-5/week will be the initial dose of this study
89205526|NCT05010525|Experimental|ATG-016-50mg|50 mg QD×5/ week as the initial dose in the Dose Escalation Phase, with a treatment cycle of 21 days,1-5/week will be the initial dose of this study
89205527|NCT05010525|Experimental|ATG-016-65mg|65 mg QD×5/ week as the initial dose in the Dose Escalation Phase, with a treatment cycle of 21 days,1-5/week will be the initial dose of this study
89205528|NCT05005741|Experimental|Beinaglutide|
89205529|NCT05005741|Active Comparator|Dulaglutide|
89498470|NCT05616910|Experimental|Group B|Subjects will receive iNO for 4 hours, followed by standard respiratory support (SRS) for 4 hours. This pattern will be reversed the next day (SRS then iNO). on the following day, the pattern will be reversed back to iNO for 4 hours and SRS for 4 hrs.
89498471|NCT05592990|Experimental|NGI226|single peritendon injection
89498472|NCT05592990|Placebo Comparator|Placebo|single peritendon injection
89498473|NCT05591014|Experimental|Software Tutorial|Participants will be asked to interpret a series of ROTEM studies before and after a tutorial on a novel ROTEM interpretation software.
89498474|NCT05585528|Other|Type of management, surgical or functional, after rupture of the anterior cruciate ligament|Patients will choose the type of management, surgical or functional, after rupture of the anterior cruciate ligament.
89023064|NCT06113887|No Intervention|Control group 2|Personal Information Form, Psychological Flexibility Scale and Barratt Impulsivity Scale -11 Short Form (BIS-11-SF) pre-tests will be applied. After the pre-test is administered, post-test will be administered in the 8th week and follow-up tests will be administered in the 12th week without any intervention.
89023065|NCT06113887|Experimental|Intervention group 3 in which psychoeducation based on acceptance and commitment therapy was applied|Personal Information Form, Psychological Flexibility Scale and Barratt Impulsivity Scale -11 Short Form (BIS-11-SF) pre-tests will be applied. After the pre-test, acceptance and stability-based psychoeducation consisting of 8 modules will be implemented once a week as a single module. Each session of the acceptance and stability therapy-based psychoeducation, which will last 8 weeks in total, will be implemented for 45-60 minutes. Immediately after the training sessions are completed, the post-test; Psychological Flexibility Scale and Barratt Impulsivity Scale -11 Short Form (BIS-11-SF) will be administered. A follow-up test will be administered one month after the post-test, i.e. in the 12th week.
89023066|NCT06113887|No Intervention|Control group 3|Personal Information Form, Psychological Flexibility Scale and Barratt Impulsivity Scale -11 Short Form (BIS-11-SF) pre-tests will be applied. After the pre-test is administered, post-test will be administered in the 8th week and follow-up tests will be administered in the 12th week without any intervention.
89498475|NCT05584111|Experimental|Dose Level 1|30mg capsules, daily administration for 3 week (21 day) cycles
89498476|NCT05584111|Experimental|Dose Level 2|30mg capsules, MWF administration for 3 week (21 day) cycles
89498477|NCT05584111|Experimental|Dose Level 3|100mg capsules, MWF administration for 3 week (21 day) cycles
89498478|NCT05584111|Experimental|Dose Level 4|30mg and 100mg capsules, M-MWF administration for 3 week (21 day) cycles
89498479|NCT05584111|Experimental|Dose Level 5|30mg and 100mg capsules, M-MWF administration for 3 week (21 day) cycles
89498480|NCT05572632|Experimental|COPD Wellness|This arm, COPD Wellness gives low-intensity exercise component with pulmonary rehabilitation for individuals with moderate-to-severe COPD. COPD Wellness is a program that was built from the Better Breathing Program, that is a part of San Francisco Health Network (SFHN) standard care for COPD.
89498481|NCT05572632|Active Comparator|Usual Care|This includes access to comprehensive primary care services. Participants randomized to the usual care arm will be offered referral to the Better Breathing Program that is part of SFHN standard care for COPD. This program consists of an evidence-based curriculum that improves disease knowledge and management skills but has no effect on symptoms or functional status. At end of study enrollment, usual care participants will be offered the COPD Wellness intervention.
89498482|NCT05572632|Experimental|COPD Wellness Plus+|This arm includes COPD Wellness Plus+. This arm is built from COPD Wellness with the addition of Health Advocates (i.e. Plus+). This intervention seeks to understand the effects of addressing social needs on overall health and wellness through Zuckerberg San Francisco General Hospital's (ZSFG) Health Advocate (HA) program; participation and engagement with the HA's will serve as an adherence strategy.
89498483|NCT05571072|Active Comparator|Standard Opioid Prescription|Patients will be given a prescription for opioid pain medication to use for acute postoperative pain as would be typical for the attending surgeon performing the surgery.
89498484|NCT05571072|Experimental|Opioid Calculator Prescription|Patients will be a given a prescription for opioid pain medication based on the opioid calculator.
89498485|NCT05570994|Experimental|177Lu HTK03170 Phase I/II|"Phase I, the administered activity will be 1.1 GBq ± 10% as an intravenous infusion over a time of 10 to 30 minutes. Initial Activity (IA) escalation will only occur on the initial dosimetry IA, with an increase of 30% over the initial IA (used for dosimetry) at each subsequent level ( 1.65 GBq, 2.5 GBq, 3.7 GBq) in up to 12 participants. Personalized dosimetry will be calculated for each subject.~Phase II, subjects will be treated with an initial IA of 177Lu-HTK03170 at the MTIA as determined during Phase I or 13.7 GBq whichever is lower. Treatment is administered as an intravenous infusion over a time of 10 - 30 minutes. Personalized dosimetry will be calculated for each subject so that subsequent treatments will be estimated to remain within the absorbed cumulative dose limits of 28Gy and 35Gy for kidneys and salivary glands, adjusted iteratively over the 4 remaining treatment cycles separated by 8 weeks. Up to 32 subjects will be enrolled to continue efficacy evaluation."
89498486|NCT05552118|Experimental|Cochlear™ Remote care|Is composed of Cochlear™ Remote Check and Cochlear™ Remote Assist.
89498487|NCT05552118|Active Comparator|Standard of care|Routine In-clinic care
89498488|NCT05549947|Experimental|Treatment group A：SHR-1819|
89498489|NCT05549947|Experimental|Treatment group B：SHR-1819|
89023067|NCT06113887|Experimental|Intervention group 4 in which psychoeducation based on acceptance and commitment therapy was applied|Personal Information Form, Psychological Flexibility Scale and Barratt Impulsivity Scale -11 Short Form (BIS-11-SF) pre-tests will be applied. After the pre-test, acceptance and stability-based psychoeducation consisting of 8 modules will be implemented once a week as a single module. Each session of the acceptance and stability therapy-based psychoeducation, which will last 8 weeks in total, will be implemented for 45-60 minutes. Immediately after the training sessions are completed, the post-test; Psychological Flexibility Scale and Barratt Impulsivity Scale -11 Short Form (BIS-11-SF) will be administered. A follow-up test will be administered one month after the post-test, i.e. in the 12th week.
89023068|NCT06113887|No Intervention|Control group 4|Personal Information Form, Psychological Flexibility Scale and Barratt Impulsivity Scale -11 Short Form (BIS-11-SF) pre-tests will be applied. After the pre-test is administered, post-test will be administered in the 8th week and follow-up tests will be administered in the 12th week without any intervention.
89498490|NCT05549947|Experimental|Treatment group C：SHR-1819|
89498491|NCT05549947|Placebo Comparator|Treatment group D：placebo|
89498492|NCT05543278|Experimental|Amiodarone Arm|In addition to the regular care provided to cardiac surgery patients, those in the Amiodarone Arm will also receive the amiodarone regimen.
89498493|NCT05543278|No Intervention|Standard of Care Arm|Patients randomized to the Standard of Care Arm will receive the regular care provided to cardiac surgery patients.
89498494|NCT05539716|No Intervention|No Intervention (Aim 1) Group|Participants in this group will not receive an intervention and will only undergo several testing procedures conducted within 3 to 4 weeks to assess OSA severity.
89531829|NCT05195697||Severe acute pancreatitis|Patients treated with severe acute pancreatitis during the study period
89023069|NCT06113887|Experimental|Intervention group 5 in which psychoeducation based on acceptance and commitment therapy was applied|Personal Information Form, Psychological Flexibility Scale and Barratt Impulsivity Scale -11 Short Form (BIS-11-SF) pre-tests will be applied. After the pre-test, acceptance and stability-based psychoeducation consisting of 8 modules will be implemented once a week as a single module. Each session of the acceptance and stability therapy-based psychoeducation, which will last 8 weeks in total, will be implemented for 45-60 minutes. Immediately after the training sessions are completed, the post-test; Psychological Flexibility Scale and Barratt Impulsivity Scale -11 Short Form (BIS-11-SF) will be administered. A follow-up test will be administered one month after the post-test, i.e. in the 12th week.
89023070|NCT06113887|No Intervention|Control group 5|Personal Information Form, Psychological Flexibility Scale and Barratt Impulsivity Scale -11 Short Form (BIS-11-SF) pre-tests will be applied. After the pre-test is administered, post-test will be administered in the 8th week and follow-up tests will be administered in the 12th week without any intervention.
89023071|NCT06113887|Experimental|Intervention group 6 in which psychoeducation based on acceptance and commitment therapy was applied|Personal Information Form, Psychological Flexibility Scale and Barratt Impulsivity Scale -11 Short Form (BIS-11-SF) pre-tests will be applied. After the pre-test, acceptance and stability-based psychoeducation consisting of 8 modules will be implemented once a week as a single module. Each session of the acceptance and stability therapy-based psychoeducation, which will last 8 weeks in total, will be implemented for 45-60 minutes. Immediately after the training sessions are completed, the post-test; Psychological Flexibility Scale and Barratt Impulsivity Scale -11 Short Form (BIS-11-SF) will be administered. A follow-up test will be administered one month after the post-test, i.e. in the 12th week.
89498495|NCT05539716|Experimental|PAP Therapy and Lifestyle Intervention (Aim 2) Group|Participants in the Aim 1 Group found to have moderate to severe OSA (defined as having a Apnea-Hypopnea Index (AHI) of 15.0 events/hour or more) randomized to this arm will receive the PAP therapy and Lifestyle Intervention for 12 weeks.
89498496|NCT05539716|Experimental|Lifestyle Intervention Only (Aim 2) Group|Participants in the Aim 1 Group found to have moderate to severe OSA (defined as having a Apnea-Hypopnea Index (AHI) of 15.0 events/hour or more) randomized to this arm will receive only the Lifestyle Intervention for 12 weeks.
89498497|NCT05535088|Experimental|Virtual reality|Virtual reality
89498498|NCT05533060||TBI group|patients with traumatic brain injury (TBI) treated surgically
89498499|NCT05533060||RN group|relatively normal (RN) participants including patients with other brain diseases, for example, gliomas, meningiomas, and schwannomas, treated surgically
89498500|NCT05532319|Experimental|HAIC sequential TAE combined with lenvatinib and tislelizumab|The aim of this phase II trial is to evaluate the safety and efficacy of hepatic arterial infusion chemotherapy (HAIC) sequential transarterial embolization combined with lenvatinib and tislelizumab in patients with unresectable hepatocellular carcinoma (HCC), and to explore the optimal benefit population.
89023072|NCT06113887|No Intervention|Control group 6|Personal Information Form, Psychological Flexibility Scale and Barratt Impulsivity Scale -11 Short Form (BIS-11-SF) pre-tests will be applied. After the pre-test is administered, post-test will be administered in the 8th week and follow-up tests will be administered in the 12th week without any intervention.
89023073|NCT06111040|Other|Caregiver-child dyads|A cohort of 375 caregivers and 375 children aged 4-5 years at baseline will be recruited and followed longitudinally for 18 months.
89023074|NCT06110793|Experimental|Lenvatinib, Pembrolizumab, and Fulvestrant|This is an open-label phase Ib/II trial of lenvatinib (20mg orally PO daily) plus pembrolizumab (400mg IV Q6W) plus fulvestrant (500mg IM Q4W) in patients with unresectable, locally advanced/metastatic ER+/HER2- breast cancer.
89023075|NCT06108479|Experimental|DF6215 Dose Escalation|Dose escalation cohorts of DF6215 in sequential ascending order.
89023076|NCT06108479|Experimental|DF6215 Safety/PK/PD|Expansion cohorts of DF6215 in multiple dose levels after evaluation for safety in the DF6215 Dose Escalation arm. Additional Pharmacokinetic (PK) and Pharmacodynamic (PD) samples included in this arm.
89023077|NCT06108479|Experimental|DF6215 Expansion in Advanced Melanoma|Expansion cohort enrolling 20 patients with advanced melanoma who have progressed after an anti-PD-1 containing regimen using the dose selected for Phase 1b identified in the DF6215 Dose Escalation arm.
89023078|NCT06100653|Experimental|BCG for therapeutic use clinical trial group|Ten patients with non-muscular invasive bladder cancer ≥14 days after surgery were included.
89023079|NCT06097676|Placebo Comparator|Placebo|- Single oral dose
89023080|NCT06097676|Active Comparator|Alprazolam 2 mg|"Single oral dose~Drug: Alprazolam 2 mg capsule"
89023081|NCT06097676|Experimental|GE-IR 200 mg|"Single oral dose~Drug: GE-IR 200 mg capsule"
89023082|NCT06097676|Experimental|GE-IR 450 mg|"Single oral dose~Drug: GE-IR 450 mg capsule"
89023083|NCT06097676|Experimental|GE-IR 700 mg|"Single oral dose~Drug: GE-IR 700 mg capsule"
89023084|NCT06089239|Active Comparator|High Intensity Coaching|"In Quarter 1, high intensity initiation coaching will consist of a four-hour orientation session that will include:~comprehensive information on behavior and organizational change theory,~suggested approaches, and~in-depth training on behavioral and organization-focused change techniques to stimulate implementation efforts.~Commencing in Quarter 2, high intensity sustainability coaching will consist of:~weekly virtual follow up sessions for the first month, followed by private monthly coaching follow up sessions via a virtual format.~Access to additional monthly web-based, synchronous office hours for group discussion on progress and customized troubleshooting to assist in navigating barriers.~Sites will also have access to on call assistance with coaches to assist with navigating challenges in real time."
89205530|NCT05002829|Experimental|Restricted Post-Operative Antibiotics Group|"Participants undergoing standard of care (SOC) with simple appendicitis will not receive post-operative antibiotics.~Participants undergoing standard of care with complicated (gangrenous or perforated) appendicitis will receive up to 24 hours of SOC post-operative antibiotics."
89498501|NCT05528302|Experimental|Tech-CBT intervention|Participants allocated to the Tech-CBT intervention group will attend six telehealth videoconferencing sessions - 1 session per week over 6 weeks. Each session will last between 60 to 90 minutes and will be facilitated by a trained therapist. During each session, the participant will learn and practice different psychotherapy techniques. The participant will be encouraged to practice these skills between sessions with the technology provided, either on their own or with the help of their support person.
89023085|NCT06089239|Sham Comparator|Low Intensity Coaching|"In Quarter 1, low intensity initiation coaching will be conducted. It will consist of:~initial two-hour orientation session with introductory content on behavior change and organizational change theory and techniques,~an overview of implementation phases, and~selection of tailored de-implementation strategies for that site based on readiness for change, focus group data and local resources.~Implementation coaches will provide the Fuld Toolkit for the site with suggestions for assigning strategies, local leaders, and development of timelines for de-implementation.~Coaches will instruct site Team Leaders to establish the primary mechanism for sharing baseline and trended data in real time."
89023086|NCT06088030|Experimental|Arsenic trioxide combined chemotherapy|Patients with p53-mutated pediatric cancer should initially undergo the corresponding first-line chemotherapy regimen. If the patient is evaluated as PD/SD, arsenic trioxide (ATO) will be administered in conjunction with previous conventional chemotherapy on the third day of each treatment cycle.
89023087|NCT06085339|Experimental|Social Media Intervention|In addition to receiving usual care, participants enrolled in the social media arm will receive diabetes education and support over the course of 6 months by following the study team's Instagram page and engaging with the study team and other adolescent participants on Instagram.
89023088|NCT06085339|No Intervention|Usual Care|Usual care reflects the standard treatment currently provided to adolescents living with type 1 diabetes. Every adolescent with diabetes is cared for by a team of diabetes specialists which includes a provider (MD, Physician Assistant and/or Nurse Practitioner), registered nurse, nutritionist and social worker. Adolescents with type 1 diabetes are seen by their multidisciplinary team approximately every 3 months. In addition, they have access to their multidisciplinary care team via telephone and/or MyChart communication as often as is necessary between clinic visits.
89023089|NCT06084195|Experimental|Single arm|single arm
89023090|NCT06080906|Experimental|Tolldlers (7-71 months old, two-dose)|Inactivated Rotavirus vaccine (Vero cell) in toddlers aged 7-71 months old on Day 0, 28
89023091|NCT06080906|Experimental|Infants (2-6 months old, three-dose)|Inactivated Rotavirus vaccine (Vero cell) in infants aged 2-6 months old on Day 0, 28, 56
89023092|NCT06080906|Placebo Comparator|Placebo in Tolldlers (7-71 months old, two-dose)|Two doses of placebo at the vaccination schedule of Day 0, 28
89023093|NCT06080906|Placebo Comparator|Placebo in Infants (2-6 months old, three-dose)|Three doses of placebo at the vaccination schedule of Day 0, 28, 56
89023094|NCT06074627|Placebo Comparator|Placebo Control 1|Energy Product Form 1 - control
89023095|NCT06074627|Experimental|Active Product 1.1|Energy Product Form 1 - active product 1
89023096|NCT06074627|Experimental|Active Product 1.2|Energy Product Form 1 - active product 2
89023097|NCT06074627|Experimental|Active Product 1.3|Energy Product Form 1 - active product 3
89023098|NCT06072794|Experimental|Treatment Arm|
89023099|NCT06068959|Experimental|Photobiomodulation|Photobiomodulation using a LED cluster
89023100|NCT06068959|Placebo Comparator|Placebo Photobiomodulation|Placebo Photobiomodulation with the equipment turned off
89023101|NCT06065527|Active Comparator|Enhanced usual care and Map Our Life|Participants will be introduced to Map Our Life, by research staff. In accordance to the Preparation for Future Care Model, PYL: (1) introduces users to long-term care (LTC) related choices (care expectation); (2) assesses the unique caregiving needs of the care recipient (awareness); (3) educates the users on locally and nationally available home-based resources (information gathering); (4) makes choices about LTC preferences (decision-making), and (5) shares those choices with others (concrete planning).This process is associated with informed and value-based decisions that fit the preferences of the care recipient and increased well-being according to the theory of proactive coping, which states that preparation for future stressors improves the ability to cope in real-time.
89023102|NCT06065527|Placebo Comparator|Enhanced usual care and Attention Control|"In this arm, caregivers will be referred to a website containing information from Disability and Health Information for Family Caregivers. The content in the attention control is from CDC-sponsored websites that promote healthy activities and behaviors targeting people with disabilities and their family caregivers. Additionally, the content leads users to CDC-sponsored Caregiving webpages which assist families in developing care plans. All content is available in English and Spanish."
89023103|NCT06062173||Adherent perirenal fat group|The surgeon considers perirenal fat to be adherent.
89023104|NCT06062173||Non-adherent perirenal fat group|Perirenal fat is considered nonadherent by surgeons.
89205531|NCT05002829|Active Comparator|Liberal Post-Operative Antibiotics Group|"Participants undergoing standard of care with simple appendicitis will receive 24 hours of post-operative SOC antibiotics~Participants undergoing standard of care with complicated (gangrenous or perforated) appendicitis will receive 4 days of post-operative SOC antibiotics."
89498502|NCT05528302|No Intervention|Control|Participants allocated to the Control group will receive usual care (i.e., no treatment for anxiety) and a mid-point check-in phone call/video call/email (depending on their preference) from the study team approximately 3 weeks after completing the initial questionnaires. This mid-point check-in is to identify whether there have been any changes to their usual care.
89023105|NCT06057571|Experimental|TT-00420 (tinengotinib) Tablet Monotherapy|TT-00420 (tinengotinib) tablets will be administered once daily in 21-day cycles with initial dosage of 10 mg QD.
89023106|NCT06056245||Study group|Patients with chronic kidney disease (CKD) over 18 years old undergoing surgery using general anesthesia with subsequent use of intravenous patient-controlled analgesia (IV-PCA) of methadone.
89023107|NCT06054256|Experimental|Group CBT-I|The group CBT-I will receive 6-session group-based CBT-I.
89023108|NCT06054256|Experimental|App-based CBT-I|The app-based CBT-I group will receive 6-session CBT-I via smartphone.
89205532|NCT04974216|Experimental|R-Lena-Tafa|"12 cycles of 28 days. From C1 to C6 : rituximab + tafasitamab + lenalidomide and from C7 to C12: tafasitamab and lenalidomide~Patients with Progressive Disease or Stable Disease after 3 cycles should start a conventional chemotherapy (rituximab + cyclophosphamide + adriamycine + vincristine + prednisone R-miniCHOP) at Investigator's discretion according to local practices"
89205533|NCT04972552|Active Comparator|Watermelon Diet & Coenzyme Q10|800-1200 mg of coenzyme Q10 daily plus diet high in watermelon
89205534|NCT04972552|Active Comparator|Usual Diet & Coenzyme Q10|800-1200 mg of coenzyme Q10 daily plus no watermelon in diet
89205535|NCT04972552|Placebo Comparator|Watermelon Diet & Placebo|Placebo pill plus diet high in watermelon
89023109|NCT06054256|Sham Comparator|Health-related psychoeducation control|The control group will receive group-based health-related psychoeducation, a format that has been adopted in the previous research, in order to provide the credibility of the intervention to the participants, and to control for the potential effects of attention and nonspecific components, e.g., receiving health-related information, expectations of benefit. It will also consist of 6 weekly sessions which contain education on healthy diet, exercise habits, sleep hygiene and self-care specific to pregnancy, but will not include any active therapeutic components of CBT-I.
89205536|NCT04972552|Placebo Comparator|Usual Diet & Placebo|Placebo pill plus no watermelon in diet
89205537|NCT04955925||Sevoflurane group|Anesthesia is maintained with sevoflurane during the surgery.
89205538|NCT04955925||Propofol group|Anesthesia is maintained with total venous anesthesia using propofol during the surgery.
89205539|NCT04947865|Experimental|Post-stroke Stiff-Knee Gait Participants|Individuals with post-stroke Stiff-Knee gait
89205540|NCT04947865|Experimental|Healthy Individuals|Healthy Individuals
89205541|NCT04934332|Experimental|Newly hospitalized patients|Patients admitted for the first time to a post intensive care rehabilitation unit after severe neurological trauma.
89205542|NCT04924699|Experimental|MRG002|MRG002 will be administrated via intravenous infusion of 2.6 mg/kg once on Day 1 of every 3 weeks (21-day cycle).
89205543|NCT04924699|Active Comparator|Trastuzumab Emtansine for Injection|Trastuzumab Emtansine for Injection will be administrated via intravenous infusion of 3.6 mg/kg once on Day 1 of every 3 weeks (21-day cycle).
89538249|NCT03281759|Active Comparator|Active Coil Helmet|The patients will undergo 18 sessions (627 nm, 70 mW/cm2, 10 J/cm2) at four points of the frontal and parietal region for 30 s each, totaling 120 s three times per week for 6 weeks, lasting 30 minutes of transcranial LED stimulation.
89538250|NCT03281759|Placebo Comparator|Inactive Coil Helmet|The patients assigned to this group will undergo 18 sessions of transcranial LED but with an inactive coil, which will not generate LED emissions.
89205546|NCT04907539|Experimental|Arm A: RXC004 monotherapy|"Patients will receive RXC004 (2 mg once daily [QD], orally).~Patients in Arm A may crossover to Arm B treatment if they have progressive disease on the first Response Evaluation Criteria in Solid Tumours, (RECIST) scan (if Arm B is open at the time of progression)."
89205547|NCT04907539|Experimental|Arm B: RXC004 + nivolumab|"Patients will receive RXC004 (1.5 mg QD, orally) in combination with nivolumab (480 mg every 4 weeks [q4w], intravenous [IV] infusion).~Arm B will be opened once a RP2D for RXC004 in combination with nivolumab is established in the phase I dose escalation study (NCT03447470). RXC004 dose to be used in combination with nivolumab will be based on data from the phase 1 study (NCT03447470)."
89205548|NCT04907097|Other|MOF/placebo|During period 1 (4 weeks) participants will receive monomeric and oligomeric flavanols and during period 2 (4 weeks) placebo. Wash out period between two interventions will be 4 weeks. The daily dose of monomeric and oligomeric flavanols will be 200 mg (2 capsules once a day) and for placebo (2 capsules once a day).
89205549|NCT04907097|Other|Placebo/MOF|During period 1 (4 weeks) participants will receive placebo and during period 2 (4 weeks) monomeric and oligomeric flavanols. The wash out period between two interventions will be 4 weeks. The daily dose of placebo will be 2 capsules once a day and for monomeric and oligomeric flavanols 200 mg (2 capsules once a day).
89205550|NCT04894682||Vaccinated Case|Pulmonary nodules/lung cancer patients who have been vaccinated against the SARS-CoV-2 (with any type/brand of vaccine)
89205551|NCT04894682||Vaccinated Healthy Control|Healthy people who have been vaccinated against the SARS-CoV-2 (with any type/brand of vaccine)
89205552|NCT04894682||Unvaccinated Case|Pulmonary nodules/lung cancer patients who are not vaccinated against the SARS-CoV-2
89205553|NCT04885205|Experimental|CBT-I Initial Group|The CBT-I Initial Group will start the CBT-I intervention immediately following baseline assessments. After re-assessment 1, participants in the CBT-I Initial Group will continue with typical activities while the WL group will receive the CBT-I intervention. After re-assessment 2, both groups continue typical activities. All participants will complete a third re-assessment 21 weeks after starting the study.
89205554|NCT04885205|Active Comparator|Wait List Group|The WL will wait 6 weeks before starting the CBT-I intervention. After re-assessment 1, participants in the CBT-I Initial Group will continue with typical activities while the WL group will receive the CBT-I intervention. After re-assessment 2, both groups continue typical activities. All participants will complete a third re-assessment 21 weeks after starting the study.
89205555|NCT04884087|Experimental|EMA, 3x/day, fixed incentive|Ecological Momentary Assessment (EMA; Metricwire). Participants randomized to this group will be sent prompts through the EMA app to complete brief EMA survey at 3 random times per day. Participants randomized to this group will earn a fixed bonus/incentive based on completion of the EMA surveys (50-74%=$3; 75-89%=$5; ≥90%=$10) each week.
89531830|NCT05195697||Acute gastrointestinal bleeding|Patients treated with acute gastrointestinal bleeding during the study period
89023110|NCT06052176|Placebo Comparator|Placebo|Saline given at the same volume as the albumin on visits the patients are assigned to it
89023111|NCT06052176|Active Comparator|Albumin|IV Albumin at 1.5g/kg ideal body weight
89023112|NCT06041048|Active Comparator|Modafinil|Single oral dose (200 mg) of medication versus placebo given to healthy control subjects
89023113|NCT06041048|Placebo Comparator|Placebo|Oral placebo
89205556|NCT04884087|Experimental|EMA, 6x/day, fixed incentive|Ecological Momentary Assessment (EMA; Metricwire). Participants randomized to this group will be sent prompts through the EMA app to complete brief EMA survey at 6 random times per day. Participants randomized to this group will earn a fixed bonus/incentive based on completion of the EMA surveys (50-74%=$3; 75-89%=$5; ≥90%=$10) each week.
89531831|NCT05195697||Perforated ulcer|Patients treated with perforated ulcer during the study period
89531832|NCT05195697||Older than 70 years|Patients older than 70 years
89531833|NCT05195697||Less than 70 years|Patients younger than 70 years
89531834|NCT05195697||Prothrombotic medications|Patients on prothrombotic medications
89531835|NCT05195697||Frail patients|Patients with increased frailty score
89531836|NCT05195697||Reintervention group|Patients in need of reintervention
89538251|NCT03193957|Experimental|SB4|SB4 (etanercept) 50 mg/mL
88821714|NCT02500849|Experimental|Cohort 1:|target busulfan AUC levels: 8,000 µM*min (+/- 1,000)
89023114|NCT06030141|Experimental|nigella sativa oil application group|"Peripheral venous catheter is applied under aseptic conditions. In order to easily see whether phlebitis occurs in the catheter area, the area where the catheter is inserted is covered with a Tegaderm transparent film cover and the catheter is fixed. Determine the distal peripheral venous catheter (3.2 cm length from the entry point for catheter 20) An area of 10 cm will be determined from the distal of the catheter. Nigella sativa oil is dripped 5 drops on a 10 cm area.~The dripped oil is applied without massaging, Nigella Sativa oil will be applied to the patients in the application group before the start of amiodarone infusion and at 6-hour intervals. The patients in all groups will be evaluated with the GIFTS scale for phlebitis every hour for the first 25 hours from the time of opening the catheter, and every 6 hours for the next 48 hours."
89023115|NCT06030141|Experimental|Sesame oil application group|"Peripheral venous catheter is applied under aseptic conditions. In order to easily see whether phlebitis occurs in the catheter area, the area where the catheter is inserted is covered with a Tegaderm transparent film cover and the catheter is fixed. Determine the distal peripheral venous catheter (3.2 cm length from the entry point for catheter 20) An area of 10 cm will be determined from the distal of the catheter. Sesame oil is dripped 5 drops on a 10 cm area.~The dripped oil is applied without massaging, The dripped oil is applied without massaging, Sesame oil will be applied to the patients in the application group before the start of amiodarone infusion and at 6-hour intervals. The patients in all groups will be evaluated with the GIFTS scale for phlebitis every hour for the first 25 hours from the time of opening the catheter, and every 6 hours for the next 48 hours."
89498503|NCT05523947|Experimental|YH32367|"Dose Escalation Part: 8 Cohorts (Dose level: 0.3, 0.75, 1.5, 3, 6, 12, 20, and 30 mg/kg). In Dose Escalation part, patients are assigned to receive YH32367 at a starting dose of 0.3 mg/kg and the dose being escalated/de-escalated in adjacent dose cohorts will be 0.75, 1.5, 3, 6, 12, 20, and 30 mg/kg.~Dose Expansion Part: 2 Cohorts (Cohort 1: Breast cancer, Cohort 2: Gastric cancer). Dose Expansion part will consist of multiple cohorts in patients who were treated with three or more prior lines of therapy including at least one trastuzumab-based regimen, HER2-positive, locally advanced or metastatic breast cancer(Cohort 1); in patients who were treated with two or more prior lines of therapy including at least one trastuzumab-based regimen, HER2-positive, locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma(Cohort 2)."
89498504|NCT05519345|Experimental|Operant Conditioning|Motor evoked responses will be elicited along with operant conditioning training for about 2 weeks
89498505|NCT05519345|Experimental|Control|Motor evoked responses will be elicited without operant conditioning training for about 2 weeks
89498506|NCT05517616|Experimental|[14C]APG-2575|To investigate the absorption properties, as well as to evaluate the mass balance and elucidate the pathways of biotransformation after a single oral dose of 400mg, 200μCi [14C] APG-2575 to healthy subjects.
89498507|NCT05516862|Experimental|Group 1|Script followed by Dragons Acupuncture (external Dragons points with patient prone for 15 minutes followed by internal Dragons points with patient supine for 15 minutes).
89498508|NCT05516862|Sham Comparator|Group 2|Script followed by Dragons sham acupressure placed at the Dragons points (external Dragons points with patient prone for 15 minutes followed by internal Dragons points with patient supine for 15 minutes).
89498509|NCT05516862|Placebo Comparator|Group 3|Script followed by Acupuncturist lightly touching Dragons points (external Dragons points with patient prone for 15 minutes followed by internal Dragons points with patient supine for 15 minutes).
89498510|NCT05512598|Experimental|HB0034|Recombinant Humanized Anti-IL-36R Monoclonal antibody
89498511|NCT05510284|Active Comparator|Doula Coordinated-Care Arm|Postpartum care will be doula-coordinated. The doula will meet with the mother at least once a week during their infant's NICU stay, with a minimum of 3 meetings. Participants will be given the option of seeing the study nurse midwife or their own provider. If the participant opts to see the nurse midwife, they can meet in a private office located in the NICU. The doula, as typical of the doula role, will coordinate any needed community services in the transition to home.
89498512|NCT05510284|No Intervention|Standard Postpartum Care Arm|In this arm participants will receive usual postpartum care. They will be discharged from the hospital while their baby is still in the NICU and a plan will be made to for follow-up with their provider as an outpatient at some point in the next 6 weeks. The study coordinator will provide the participant with a community postpartum resources list.
89498513|NCT05509842|Experimental|Open label treatment|All subjects then will receive open-label treatment (Tx) for six days within an fourteen-day span (Visits 3-8). Briefly, a newer form of rTMS called intermittent theta burst stimulation (iTBS) will be used that mimics endogenous theta rhythms, which can improve induction of synaptic long-term potentiation and influence functional connectivity. A 10-min iTBS sessions will be applied to the basal ganglia-cerebellar-cortical network immediately after the subject has primed and activated the network by performing a precision force tracking task for up to 10 min. The subject will undergo 5 sessions of the force task and stimulation per day, with each session separated by 40 min.
89498514|NCT05495464|Experimental|Acalabrutinib and Rituximab (Part 1)|Participants may receive acalabrutinib and rituximab for up to 12 cycles. Each cycle is 28 days.
89498515|NCT05495464|Experimental|Brexucabtagene Autoleucel (Part 2)|Participants will have a procedure called leukapheresis to collect enough T cells.
89498516|NCT05471375||Stroke|For this cohort, individuals who have experienced a stroke will be asked to complete a variety of movement related rehabilitation assessments with wearable sensors and audio/video recording.
89498517|NCT05471375||Parkinsons Disease|For this cohort, individuals who have been diagnosed with Parkinsons Disease will be asked to complete a variety of movement related rehabilitation assessments with wearable sensors and audio/video recording.
89498518|NCT05471375||Lower Limb Amputation|For this cohort, individuals who have experienced a lower limb amputation will be asked to complete a variety of movement related rehabilitation assessments with wearable sensors and audio/video recording.
89498519|NCT05471375||Healthy Control|For this cohort, individuals who have no significant neurologic or orthopedic injuries will be asked to complete a variety of movement related rehabilitation assessments with wearable sensors and audio/video recording.
89531837|NCT05182606|Experimental|Implementation bundle|"Participating clinics will experience integration of the Implementation Bundle into their practices."
88821715|NCT02500849|Experimental|Cohort 2:|busulfan AUC levels: 12,000 µM*min (+/- 1,000)
89498520|NCT05468736|Experimental|Originally Randomized to Vaccine, Immediate Booster Group|2 doses of 5 μg SARS-CoV-2 rS + 50 μg Matrix-M1 adjuvant (co-formulated), 1 dose each on Days 0 and 21 in Initial Vaccination Period.One dose of 5 μg SARS-CoV-2 rS + 50 μg Matrix-M1 adjuvant (co-formulated) on Day 201 in the Booster Vaccination Period.
89498521|NCT05468736|Experimental|Originally Randomized to Vaccine, Delayed Booster Group|2 doses of 5 μg SARS-CoV-2 rS + 50 μg Matrix-M1 adjuvant (co-formulated), 1 dose each on Days 0 and 21 in the Initial Vaccination Period. 1 dose of 5 μg SARS-CoV-2 rS + 50 μg Matrix-M1 adjuvant (co-formulated) on Day 201 or Day 229 and 1 dose of Placebo (Saline) on Day 201 or Day 229 in the Booster Vaccination Period.
89498522|NCT05468736|Experimental|Originally Randomized to Placebo|2 doses of Placebo (Saline),1 dose each on Days 0 and 21 in the Initial Vaccination Period. 2 doses of 5 μg SARS-CoV-2 rS + 50 μg Matrix-M1 adjuvant (co-formulated) 1 dose each on Day 201 and Day 229 in Open-Label Crossover Vaccination Period. One dose of 5 μg SARS-CoV-2 rS + 50 μg Matrix-M1 adjuvant (co-formulated) on Day 409 in the Booster Vaccination Period.
89498523|NCT05462990|Experimental|QUC398|QUC398 150 mg/mL, solution for s.c. injection (1 mL). 2 injections will be applied per dose to complete the 300 mg
89498524|NCT05462990|Placebo Comparator|Placebo|Placebo 0 mg/mL, solution for s.c. injection (1 mL). 2 injections will be applied per dose to ensure blinding
89498525|NCT05452109|Experimental|Blood Flow Restriction + Classical Training|
89498526|NCT05452109|Experimental|Classical Training Alone|
89498527|NCT05450146|Experimental|Partner in Balance (intervention group)|"Informal caregivers assigned to the intervention group will receive the 8-week online selfmanagement program Partner in Balance (Boots, 2018)."
89498528|NCT05450146|No Intervention|Usual/standard care (control group)|"Participants in the comparison condition will continue to receive the care as usual.~The control group will be shared with another collaborating study from the 'Vrije Universiteit of Amsterdam'), which has the same goals, applies the same inclusion criteria, applies the same study procedures, and obtains the same outcomes. This implies that the data of the participants recruited for the control group for this study will be shared with the collaborating study."
89498529|NCT05446155||Patients with a suspected primary melanoma or equivocal pigmented skin tumour|Patients, 18 years or older, in dermatological outpatient routine care in Helsingborg, Lund or Malmö Hospitals. Patients are planned for surgical excision for an equivocal pigmented skin lesion that could be a primary melanoma or a differential diagnosis of melanoma. Imaging of tumours will be applied before surgery. Blood samples are taken before surgery. Tumour/normal skin biopsies will be taken and snap-frozen (-80°C) immediately after surgery. A baseline questionnaire about skin cancer risk factors, co-morbidities, phenotypic factors, diets, smoking, alcohol and quality of life will be given to the patient before surgery.
89498530|NCT05446155||Patients with secondary melanoma (metastatic disease)|Patients, 18 years or older, in surgical or oncological routine care in Helsingborg, Lund, Malmö or Kristianstad Hospitals. Patients are planned for surgical excision or cytological diagnostics (needle aspiration) of metastatic melanoma. Imaging of tumours will be applied before surgery. Blood samples are taken before surgery. Tumour biopsies will be taken and snap-frozen (-80°C) immediately after surgery. A baseline questionnaire about skin cancer risk factors, co-morbidities, phenotypic factors, diets, smoking, alcohol and quality of life will be given to the patient before surgery.
89498531|NCT05445804|Experimental|Within-Subjects Dose Conditions|All participants will receive the same drug conditions, but the order in which the participants receive the drug conditions will be counterbalanced across participants. Thus, comparisons of the drug conditions on outcome measures will be compared within-subjects (e.g., between drug and placebo) and not between arms.
89498532|NCT05445804|Experimental|Additional Within-Subjects Dose Conditions|All participants will receive the same drug conditions, but the order in which the participants receive the drug conditions will be counterbalanced across participants. Thus, comparisons of the drug conditions on outcome measures will be compared within-subjects (e.g., between drug and placebo) and not between arms.
89498533|NCT05443451|Experimental|Transperineal Microwave needle ablation for symptomatic BPH|
89498534|NCT05435196|Experimental|Experimental|"Get the training in with high-intensity interval exercise. Will be applied through 10 sets of 60 seconds. The first 30 seconds will consist of going up and down a step 15 cm high, immediately 30 seconds of squats as fast as possible with 90° knee flexion. The recovery period between each set will be 60 seconds, with a low-intensity activity (light walking). Based on high-intensity exercise, we must achieve an effort greater than 85% of the maximum frequency, using the heart rate meter and its equivalences with the Perceived Effort Scale (RPE).~Receive a multimodal training that will consist of: resistance exercises for the main muscle groups of the extremities. In the plan, lumbopelvic, scapulothoracic and craniocervical neuromuscular efficiency exercises will also be included."
89498535|NCT05435196|Active Comparator|Control|Get the training in with high-intensity interval exercise. Will be applied through 10 sets of 60 seconds. The first 30 seconds will consist of going up and down a step 15 cm high, immediately 30 seconds of squats as fast as possible with 90° knee flexion. The recovery period between each set will be 60 seconds, with a low-intensity activity (light walking). Based on high-intensity exercise, we must achieve an effort greater than 85% of the maximum frequency, using the heart rate meter and its equivalences with the Perceived Effort Scale (RPE).
89498536|NCT05434156|Experimental|Cohort 1 (Part 1)|A single 10-minute intravenous infusion of 0.25 mg ELE-101 or placebo (randomized as 6 active and 2 placebo)
89498537|NCT05434156|Experimental|Cohort 2 (Part 1)|A single 10-minute intravenous infusion of 0.75 mg ELE-101 or placebo (randomized as 6 active and 2 placebo)
89498538|NCT05434156|Experimental|Cohort 3 (Part 1)|A single 10-minute intravenous infusion of 2.0 mg ELE-101 or placebo (randomized as 6 active and 2 placebo)
89498539|NCT05434156|Experimental|Cohort 4 (Part 1)|A single TBD minute intravenous infusion of TBD mg ELE-101 or placebo (randomized as 6 active and 2 placebo)
89498540|NCT05434156|Experimental|Cohort 5 (Part 1)|A single TBD minute intravenous infusion of TBD mg ELE-101 or placebo (randomized as 6 active and 2 placebo)
89205557|NCT04884087|Experimental|EMA, 3x/day, prize-based incentive|"Ecological Momentary Assessment (EMA; Metricwire). Participants randomized to this group will be sent prompts through the EMA app to complete brief EMA survey at 3 random times per day. Participants randomized to this group will be rewarded for high survey completion with increasing numbers of draws for prizes depending on their level of response each week (50-74%=1 draw, 75-89%=2 draws, ≥90%=3 draws)."
89498541|NCT05434156|Experimental|Cohort 6 (Part 2)|A single TBD minute intravenous infusion of TBD mg ELE-101
89498542|NCT05432388|Experimental|remibrutinib low dose|remibrutinib oral tablet
89498543|NCT05432388|Experimental|remibrutinib medium dose|remibrutinib oral tablet
89498544|NCT05432388|Experimental|remibrutinib high dose|remibrutinib oral tablet
89498545|NCT05432388|Experimental|placebo 3 week / remibrutinib low dose 1 week|placebo oral tablet/ remibrutinib oral tablet
89498546|NCT05432388|Placebo Comparator|placebo|oral tablet
89498547|NCT05432375|Experimental|Tinostamustine|Infusion delivered over 60 minutes
89498548|NCT05429489|Experimental|Bilevel erector spinae plane block|Bilevel erector spinae block at 3rd and 5th thoracic vertebral levels
89498549|NCT05429489|Experimental|Single level erector spinae plane block|single level erector spinae plane block at 5th thoracic vertebral levels
89498550|NCT05429489|Active Comparator|Intravenous morphine|Intravenous morphine 0.1 mg/ kg
89498551|NCT05429125|Active Comparator|Endotracheal Tube with Stylet|Patients randomised to Endotracheal Tube with Stylet will be intubated with a Videolaryngoscopy and with an endotracheal tube + stylet.
89498552|NCT05429125|Active Comparator|Flexible Tip Bougie|Patients randomised to Flexible Tip Bougie will be intubated with a Videolaryngoscopy and with a Flexible Tip Bougie.
89498553|NCT05428995|Active Comparator|C-MAC videolaryngoscope|Patients with anticipated difficult airway will be awake intubated with a C-MAC videolaryngoscopy. Spontaneous breathing will be preserved, and the same protocol of sedation plus upper airways topical anesthesia will be applied in both groups.
89498554|NCT05428995|Active Comparator|Airtraq videolaryngoscope|Patients with anticipated difficult airway will be awake intubated with a Airtraq videolaryngoscopy. Spontaneous breathing will be preserved, and the same protocol of sedation plus upper airways topical anesthesia will be applied in both groups.
89498555|NCT05427370|Experimental|Revascularization by PCI|Revascularization will be attempted on/for significant lesions in major coronary vessels/side branches as planned by the local Heart Team, with the general recommendation of stenotic/occluded vessels with diameter >2.0 mm for PCI. The Heart Team consists of a minimum of one heart failure cardiologist, one interventional cardiologist and one cardiac surgeon.
89498556|NCT05427370|Experimental|Revascularization by CABG|Revascularization will be attempted on/for significant lesions in major coronary vessels/side branches as planned by the local Heart Team, with the general recommendation of stenotic/occluded vessels with diameter >1.5 mm for CABG. The Heart Team consists of a minimum of one heart failure cardiologist, one interventional cardiologist and one cardiac surgeon
89498557|NCT05425745|Placebo Comparator|Placebo|one placebo tablet once daily
89498558|NCT05425745|Experimental|Obicetrapib 10 mg|one 10 mg Obicetrapib tablet once daily
89498559|NCT05413369|Experimental|iGlarLixi|iGlarLixi (insulin glargine/lixisenatide) will be self-administered subcutaneously once daily in the morning in the hour (0 to 60 minutes) before the first meal on top of metformin ± SGLT-2 inhibitor for 24 weeks
89498560|NCT05413369|Active Comparator|IDegAsp|IDegAsp will be self-administered subcutaneously once daily prior to the largest meal of the day according to the locally approved label on top of metformin ± SGLT-2 inhibitor for 24 weeks
89498561|NCT05411133|Experimental|Phase 1a: Dose Escalation|
89498562|NCT05411133|Experimental|Phase 1b: Low dose Cabotamig (ARB202)|
89498563|NCT05411133|Experimental|Phase 1b: High dose Cabotamig (ARB202)|
89498564|NCT05411133|Experimental|Phase 1b: Low dose Cabotamig (ARB202) + Immune Checkpoint Inhibitor|
89498565|NCT05411133|Experimental|Phase 1b: High dose Cabotamig (ARB202) + Immune Checkpoint Inhibitor|
89498566|NCT05411107|Experimental|Arm I (iloprost)|Patients receive Iloprost PO BID for a 180 days in the absence of unacceptable toxicity. Patients undergo bronchoscopy with biopsies and brushings at day 180.
89498567|NCT05411107|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID for a 180 days in the absence of unacceptable toxicity. Patients undergo bronchoscopy with biopsies and brushings at day 180.
89498568|NCT05393258|Experimental|Arm 1: temporally-modulated pulsed radiotherapy (TMPRT)|Patients receive TMPRT daily as 10 pulses of 0.2 Gy each with a 3-minute interval between pulses (effective dose rate = 0.0667 Gy/min) to a total dose of 54 Gy at 2 Gy per day. Treatment continues for a total of 27 fractions in the absence of disease progression or unacceptable toxicity.
89498569|NCT05387265|Experimental|CX-904|
89498570|NCT05385055||Cigarette|Current cigarette smokers
89498571|NCT05385055||THS|THS users with a minimum of 2 years of THS use
89498572|NCT05385055||SA|Former cigarette smokers with minimum of 2 years of smoking abstinence
89498573|NCT05379829|Experimental|Ziltivekimab 15 mg|Participants will receive ziltivekimab at weeks 0, 4 and 8.
89498574|NCT05379829|Placebo Comparator|Placebo|Participants will receive placebo at weeks 0, 4 and 8.
89498575|NCT05376800|Experimental|Phase 0 Part: BI 907828 (Brigimadlin)|
89498576|NCT05376800|Experimental|Phase Ia Part: BI 907828 (Brigimadlin)|
89498577|NCT05373758|Experimental|Standard of Care|In Uganda, participants will receive management per Uganda Ministry of Health (MOH) guidelines. A reflex genotypic resistance test (GRT) is performed by MOH for individuals with a second viral load >1,000 while on TLD. Participants will continue enhanced adherence counseling (EAC) and TLD while awaiting the GRT result. Participants will have an additional Week 24 visit for specimen collection. Participants will return for a visit after GRT results are received and a treatment decision has been made by the regional switch committee. In South Africa, participants will receive management per South Africa Department of Health guidelines. At enrollment, participants will undergo EAC and continue on TLD. At Week 24, participants will undergo repeat viral load testing. If viral load >1,000, the participant will continue TLD and EAC. If resuppressed, participants will be maintained on TLD. All participants will undergo plasma HIV-1 RNA viral load testing at Week 48.
89538252|NCT03281681|Experimental|VAL-083, Dianhydrogalactitol|VAL-083 given by intravenous infusion with a starting dose of 60 mg/m2 once weekly. If this regimen is well tolerated for at least three sequential weekly treatments the patient's dose may be escalated to 67 mg/m2 i.v. If the 67 mg/m2 dose is well tolerated for at least three sequential weekly treatments the patient's dose may be escalated to 75 mg/m2 i.v. once weekly for the remainder of the study. Dosing will be conducted once per week for a total of 16 weeks.
89023116|NCT06030141|No Intervention|control group|Peripheral venous catheter is applied under aseptic conditions. In order to easily see whether phlebitis occurs in the catheter area, the area where the catheter is inserted is covered with a Tegaderm transparent film cover and the catheter is fixed. No oil application will be made. The patients in all groups will be evaluated with the GIFTS scale for phlebitis every hour for the first 25 hours from the time of opening the catheter, and every 6 hours for the next 48 hours.
89023117|NCT06025292|Active Comparator|High Quality Protein Intake -Pork|Meal patterns will mimic a standard American diet (50% carbohydrate, 15% protein, 35% fat), providing an isonitrogenous 0.8 g/kg/d protein, and meeting individual estimated daily energy requirements. We have chosen 0.8 g/kg/d as it is the recommend dietary allowance for protein in the US. This arm's protein source will be from lean pork.
89023118|NCT06025292|Active Comparator|Low Quality Protein Intake- Plant|Meal patterns will mimic a standard American diet (50% carbohydrate, 15% protein, 35% fat), providing an isonitrogenous 0.8 g/kg/d protein, and meeting individual estimated daily energy requirements. We have chosen 0.8 g/kg/d as it is the recommend dietary allowance for protein in the US. This arm's protein source will be from plant based protein (ie impossible burger, black bean burger, soy, etc).
89023119|NCT06020274|Experimental|iCF-PWR Program|Parents are encouraged to review the program along with their child and then children are encouraged to complete the program 1-2 additional times (or as many times as they like). It is suggested that modules be completed at a rate of 1-2 per week, with program completion ranging from 3-6 weeks. Additional mental health resources are provided at the end of the program.
89023120|NCT06020274|No Intervention|Standard Care|Participants will continue to receive their usual standard care related to CF (i.e., accessing services through their local health authority and CF clinic). Following the proposed maximum program completion time-frame (i.e., 6 weeks) and follow-up time period (i.e., 3 months), those in the standard care groups will be provided access to iCF-PWR.
89498578|NCT05373758|Experimental|Individualized Care|Participants will undergo routine EAC, point-of-care urine tenofovir (TFV) testing, and genotypic resistance testing (GRT) at enrollment. Participants will return when GRT results are available for a treatment decision. Side effects and tolerance will also be assessed. All information will be used to make an optimal treatment recommendation with participant input. Participants will have an additional study visit at Week 24 and will continue to have routine care visits, adherence counseling by the clinic, and viral load monitoring at intervals determined by the clinic per national guidelines. Participants will undergo plasma HIV-1 RNA viral load testing at Week 48.
89498579|NCT05373758|Experimental|Immediate Switch|Participants will undergo routine EAC and a switch from TLD to PI-based second-line ART at the enrollment visit (Week 0). Participants will have an additional study visit at Week 24. Participants will continue to have routine care visits and viral load monitoring at intervals determined by the clinic per national guidelines. At study completion, participants will undergo plasma HIV-1 RNA viral load testing at Week 48.
89498580|NCT05371587|Active Comparator|A - Standard resistance training prescription|"Standard resistance training prescription: participants will perform three sessions per week comprised of six resistance training exercises - horizontal leg press, lat-pulldown, knee extension, chest press, leg curls and shoulder press. They will perform 3 sets of 10 repetitions using 65% percent of the maximal load that can be lifted once according to a one repetition maximum (1RM) test. Their progression model will be as follows:~Weeks 1-3 65%1RM; Weeks 4-6 70%1RM; 1RM reassessment at week 6; Weeks 7-9 70% of the updated 1RM; Weeks 10-12 75%1RM.~Prior to beginning of the program four visits will take place:~Laboratory visit for measuring physiological and anthropometric outcomes (see outcomes section)~1RM testing~Endurance and maximal voluntary contraction testing + introduction with the exercise program~A second introduction session with the exercise program"
89498581|NCT05371587|Experimental|B- Autonomy and perceptions approach to resistance training (APART)|"Participants will perform 3 sessions/week of the same exercises. They will perform 3 sets of each exercise, self-select the load they lift in each set and perform repetitions aiming to reach a level of effort of 7-8 on a 0-10 rating of perceived effort scale (RPE) at the end of the set. Their progression model will be as follows: Weeks 1-3 RPE 7/10; Weeks 4-12 RPE 8/10. The selected RPE score of 7 and then 8 out of 10 has been shown to lead to increases in maximal strength in previous research. Prior to beginning of the program four visits will take place:~Laboratory visit (similar to standard).~1RM testing where the principles of perceived effort will be introduced.~Endurance and maximal voluntary contraction testing + introduction with the exercise program. Participants will practice how to self-select the load they prefer and then perform repetitions leading to the target RPE score.~A second introduction session with the exercise program and the RPE construct."
89498582|NCT05362994|Active Comparator|Plain old balloon (POB) arm|"Balloon catheter used in the POB arm will be the Medtronic Euphora Rapid Exchange Balloon Dilatation Catheter, with diameters from 1.5 mm to 4.0 mm, and length from 6 to 30 mm,"
89498583|NCT05362994|Experimental|Drug-eluting balloon (DEB) arm|The Selution SLR™ sirolimus-eluting balloon catheter system comprises of a semi-compliant polyamide balloon catheter with low tip profile coated with sirolimus drug (concentration: 1.00 μg/mm2 of balloon surface). Selution sustained limus release (SLR™) sirolimus-eluting balloon provides controlled and 90-day sustained release of sirolimus given its MicroReservoir technology made from biodegradable polymer intermixed with sirolimus. The balloon platform is the percutaneous transluminal coronary angioplasty (PTCA) rapid exchange catheter, with diameters from 2.0 to 4.5 mm and length from 15 to 30 mm.
89498584|NCT05358470|Experimental|Exercise therapy and adapted physical activity-based intervention|The intervention in the experimental group (EG) consists of a exercise therapy and adapted physical activity program based on racket sports. The immediate EG will receive sixteen, twice a week, one-hour sessions of group-based, racket sports specific fundamental movement skills training. All sessions will be guided and supervised by a physiotherapist and delivered in groups of 5 participants to promote exchange and conviviality and to optimize the rates of participation and compliance.
89498585|NCT05358470|No Intervention|Usual care|Participants in the CG receive conventional management with general physical activity recommendation.
89538253|NCT03281603|Experimental|CAD/CAM complete denture|"First intervention: Constructing complete denture by CAD/CAM technology utilizing milling technique.~Second intervention:Constructing complete denture CAD/CAM technology utilizing 3D printing technique"
89538254|NCT03281603|Active Comparator|Conventional complete denture|Constructing complete denture by conventional technique of denture processing
89498586|NCT05354557|Experimental|Single prior autoHCT with melphalan|"Participants have not experienced disease progression since initiation of initial systemic anti-myeloma therapy, are within 12 months of frontline autoHCT with~>/=140mg/m2 of melphalan, initiated lenalidomide maintenance at least 6 months ago, and have a very good partial response (VGPR) or less at time of enrollment. Cohort 1 will be initiated after evaluation of preliminary efficacy and safety data from Cohort 2."
89498587|NCT05354557|Experimental|2 to 3 prior lines of systemic anti-myeloma therapy +/- prior autoHCT|Participants have already received lenalidomide maintenance after a prior line of treatment, underwent a salvage autoHCT within the prior 2-6 months as consolidation therapy for relapsed disease after 2 to 3 prior therapies
89498588|NCT05342753|Experimental|Restylane Kysse|Hyaluronic Acid
89498589|NCT05342467|Active Comparator|Gemeprost|Gemeprost 1 mg inserted 3 hourly for maximum of 5 doses in 24 hours.
89498590|NCT05342467|Active Comparator|Dinoprostone|Dinoprostone 3 mg inserted 4 hourly for maximum of 3 doses in 24 hours.
89498591|NCT05329155|Experimental|Administration of Heparin in ER|Administration of Heparin (100U/Kg body weight) with loading dose of DAPT (Aspirin 300mg and Ticagrelor 180mg) at first medical contact for STEMI patients intended to perform PPCI.
89498592|NCT05329155|Active Comparator|Administration of Heparin in Cathlab|Administration of Heparin (100U/Kg body weight) in Cathlab after insertion of artery sheath catheter.
89498593|NCT05326620||localized RCC|all patients with localized RCC
89498594|NCT05326620||metastatic RCC|all patients with metastatic RCC, synchronous or metachronous
89498595|NCT05326204||1 hour|Blood glucose monitoring comprises of 1 hour post meal
89498596|NCT05326204||2 hours|Blood glucose monitoring comprises of 2 hours post meal
89498597|NCT05318534|Experimental|GL-0719|"Dose level cohorts randomized in a 3:1 ratio to GL-0719 or placebo treatment, respectively.~The study will comprise a single-dose, sequential-group design.~Single Ascending IV Dose Cohorts~Cohort 1: 4 subjects~Cohort 2: 8 subjects~Cohort 3: 8 subjects~Cohort 4: 8 subjects~Cohort 5: 8 subjects~Subcutaneous Injection Cohort~Cohort 6: 8 subjects~Cohort 7: 8 subjects~Cohort 8 (Patient Arm): Up to 6 subjects with Cold Agglutinin Disease (CAD); Placebo is not applicable."
89498598|NCT05318534|Placebo Comparator|Placebo|"Dose level cohorts randomized in a 3:1 ratio to GL-0719 or placebo treatment, respectively.~The study will comprise a single-dose, sequential-group design.~Single Ascending IV Dose Cohorts~Cohort 1: 4 subjects~Cohort 2: 8 subjects~Cohort 3: 8 subjects~Cohort 4: 8 subjects~Cohort 5: 8 subjects~Subcutaneous Injection Cohort~Cohort 6: 8 subjects~Cohort 7: 8 subjects"
89498599|NCT05311072||PEA cohort|patients with CTEPH receiving PEA
89498600|NCT05311072||BPA cohort|patients with CTEPH receiving BPA
89498601|NCT05311072||Pulmonary arterial hypertension (PAH)-specific medication|CTEPH patients without PEA or BPA, treatment with any PAH-specific medication, i.e. endothelin receptor antagonists, phosphodiesterase type 5 inhibitors, soluble guanylate cyclase stimulators, drugs acting on the prostanoid pathway and prostaglandin I2 receptor agonists
89498602|NCT05306600||Breast cancer|300 patients with locally advanced HER2-positive breast cancer who underwent neoadjuvant therapy followed by breast surgery.
89498603|NCT05306600||Prostate cancer|250 patients with metastatic prostate cancer
89498604|NCT05298722|Other|Study arm|Imaging with CT-scan and MRI-DWI and peripheral blood samples for liquid biopsy
89498605|NCT05295030|Active Comparator|Breast Milk-Fed Group|The infants will be breastfed during the study.
89498606|NCT05295030|Experimental|Breast Milk Simulated Formula Group|Kieember Infant formula, Ruibuen®: Infants will be fed Kieember infant formula(Phase I) from baseline (about 0-14 days) to 12 weeks old.
89498607|NCT05295030|Experimental|Traditional Formula Group|Yashili Infant formula, Ruibuen®: Infants will be fed Yashili infant formula (Phase I) from baseline (about 0-14 days) to 12 weeks old.
89498608|NCT05286762|Active Comparator|18.75 mg CTx-1301 (dexmethylphenidate tablet)|Subjects who are randomized to active drug (18.75 mg of CTx-1301) will be titrated (increased) weekly up to their assigned fixed dose. The starting dose at Day 0 is 12.5 mg; at week 1 they will be increased to their assigned dose of 18.75 mg. Subjects will remain on this assigned fixed dose for the remainder of the randomized study period.
89498609|NCT05286762|Active Comparator|25 mg CTx-1301 (dexmethylphenidate tablet)|Subjects who are randomized to active drug (25 mg of CTx-1301) will be titrated (increased) weekly up to their assigned fixed dose. The starting dose at Day 0 is 12.5 mg; at week 1 they will be increased to 18.75 mg; at week 2 they will be increased to their assigned dose of 25 mg. Subjects will remain on this assigned fixed dose for the remainder of the randomized study period.
89498610|NCT05286762|Active Comparator|37.5 mg CTx-1301 (dexmethylphenidate tablet)|Subjects who are randomized to active drug (37.5 mg of CTx-1301) will be titrated (increased) weekly up to their assigned fixed dose. The starting dose at Day 0 is 12.5 mg; at week 1 they will be increased to 18.75 mg; at week 2 they will be increased to 25 mg; at week 3 they will be increased to their assigned dose of 37.5 mg. Subjects will remain on this assigned fixed dose for the remainder of the randomized study period.
89498611|NCT05286762|Placebo Comparator|Placebo|Subjects randomized to placebo will be on placebo for the full 5 weeks of the study.
89498612|NCT05283577|Experimental|Treatment Arm|Each participant will attend a total of 10 treatment visits (one visit per week), over the course of 10 weeks. Each EA session will be approximately 1 hour. Participants in the treatment arm will receive EA at 13 standardized acu-points that were chosen for their therapeutic effects.
89498613|NCT05283577|Sham Comparator|Control Arm|Each participant in the control arm will attend a total of 10 treatment visits (one visit per week), over the course of 10 weeks. Participants in the control arm will receive electrical stimulation at non-disease related acu-points for approximately 1 hour per session.
88821716|NCT02477826|Experimental|Arm A: Nivolumab|Nivolumab intravenously (IV) as specified
88821717|NCT02477826|Experimental|Arm B: Nivolumab + Ipilimumab|Nivolumab + Ipilimumab IV as specified
88821718|NCT02477826|Experimental|Arm C: Nivolumab + Platinum doublet chemotherapy|Nivolumab + Platinum doublet chemotherapy (IV) dose as specified
88821719|NCT02477826|Experimental|Arm D: Platinum doublet chemotherapy|Chemotherapy administered on specified days of IV chemotherapy
89498614|NCT05280704|Other|V1 Lidocaine, D2 Saline|Will undergo volar technique 1st with 4 mL of 1% lidocaine and then dorsal technique 2nd with 4 mL of 0.9% sterile saline. This is a 1-time dose.
89538255|NCT02439151|Experimental|New Strategy|New Strategy: use transpulmonary pressure guide new lung ventilation strategy in ECMO for severe ARDS patients
88821720|NCT02444286||standard care group|optimal standard of care therapy
89023121|NCT06019975||Autoimmune Encephalitis patients|Patients with autoimmune encephalitis admitted to the centers, who underwent a brain FDG-PET during the course of their disease trajectory.
89498615|NCT05280704|Other|V1 Saline, D2 Lidocaine|Will undergo volar technique 1st with 4 mL of 0.9% sterile saline and then dorsal technique 2nd with 4 mL of 1% lidocaine. This is a 1-time dose.
89498616|NCT05280704|Other|D1 Lidocaine, V2 Saline|Will undergo dorsal technique first with 4 mL of 1% lidocaine and then volar technique second with 0.9% sterile saline. This is a 1-time dose.
89498617|NCT05280704|Other|D1 Saline, V2 Lidocaine|Will undergo dorsal technique 1st with 4 mL of 0.9% sterile saline and then volar technique 2nd with 4 mL of 1% lidocaine. This is a 1-time dose.
89498618|NCT05279131|Experimental|Tirbanibulin (Klisyri®)|Participants will apply tirbanibulin ointment 1% once daily for 5 days beginning Day 1. Participants will be evaluated for safety, tolerability, and the presence of Actinic Keratosis (AK) lesions in the treatment field (TF) until completion of the response assessment period at Day 57.
89498619|NCT05275374|Experimental|Part 1 - XP-102 Dose Escalation|XP-102
89498620|NCT05275374|Experimental|Part 2 - XP-102 + Trametinib Dose Escalation|XP-102 plus Trametinib
89498621|NCT05275374|Experimental|Part 3 - XP-102 + Trametinib Dose Expansion|XP-102 plus Trametinib
89498622|NCT05269706|Experimental|Standard Meal|Participants taking a standard meal.
89498623|NCT05269706|Experimental|High Fat Meal|Participants taking a high fat meal.
89498624|NCT05254457|No Intervention|Observation Only Group|
89498625|NCT05254457|Experimental|Treated or Retreated Group|
89498626|NCT05251233|Placebo Comparator|Placebo|-Visually equivalent placebo once daily from postoperative day 1 and continued for 10 doses or until the day of discharge (whichever is earlier).
89498627|NCT05251233|Active Comparator|Proton pump inhibitor|-Pantoprazole once daily from postoperative day 1 and continued for 10 doses or until the day of discharge (whichever is earlier).
89498628|NCT05250011||Single-cohort|Patients initiated on dapagliflozin according to the approved indication for heart failure with reduced ejection fraction (HFrEF) and current medical practice
89498629|NCT05242965|Experimental|Arm I (STEMVAC, sargramostim)|Patients receive STEMVAC ID and sargramostim ID on day 14 of the 21-day maintenance therapy cycle for a series of 3 vaccines doses and a booster vaccine 9 weeks after third vaccine dose.
89498630|NCT05242965|Active Comparator|Arm II (sargramostim)|Patients receive sargramostim ID on day 14 of the 21-day maintenance therapy cycle for a series of 3 vaccines doses and a booster vaccine 9 weeks after third vaccine dose.
89498631|NCT05241288|Experimental|Albuterol eMDPI DS (ProAir® Digihaler®)|This arm will receive the intervention of the Albuterol eMDPI DS for three months.
89498632|NCT05239169|Experimental|A: Cape+Durva+Treme|Capecitabine + Durvalumab + Tremelimumab
89498633|NCT05239169|Active Comparator|B: Durva+Treme|Durvalumab + Tremelimumab
88821721|NCT02444286||device group|Follow-up of MitraClip device implantation plus optimal standard of care therapy
88821722|NCT02408406|Experimental|Arm I (PatientCareAnywhere program system)|Patients are encouraged to use the PatientCareAnywhere program at least once weekly either in the clinic or at home. Patients receive reminder emails after 1 week of inactivity. If patients indicate they are experiencing moderate to severe symptoms, an alert message is sent to at least 1 member of the patient's support team along with a list of expected response times.
89023122|NCT06016348||Good outcome|mRS of 0-3; mRS of 0-2
89498634|NCT05238831|Experimental|Treatment (SMMART-ACT)|Administered in monotherapy or in combination with other targeted agents or immunotherapies, chemotherapies, or radiation. Combination treatment plans may include a two-week monotherapy lead-in, followed by a combination treatment regimen. Each ACT study intervention must have an established RP2D determined in a prior clinical trial. Participants undergo a Pre-Treatment Biopsy, plus an On-Treatment Biopsy after two weeks on first dose of study drug(s) and prior to starting Cycle 2, regardless of regimen. Participants continue to receive study agent(s) after the On-Treatment Biopsy, according to the biopsy results and the results of ongoing safety and clinical assessments. Treatment cycles repeat every 21 to 28 days in the absence of disease progression or unacceptable toxicity. Cycles are determined based on the study agent(s). Upon disease progression, participants are given the option to undergo an additional biopsy.
89498635|NCT05230433|Experimental|High-fat Metabolic Challenge|Participants will consume a high-fat agent one time, at the second study visit.
89498636|NCT05226390|Experimental|1 x 107 IU/dose MVA-SARS-2-ST|All Participants will receive a single booster dose of 1 x 107 IU MVA-SARS-2-ST in 0.5 mL as inhalation (total inhaled volume 0.5 mL)
89498637|NCT05224908|Experimental|pregnant women with a breech fetus|pregnant women with a breech fetus performing standing and sitting EOS pelvimetry
89498638|NCT05223036|Experimental|Arm I (OCA)|Patients receive OCA PO QD for 6 months in the absence of unacceptable toxicity. Patients also undergo GI endoscopy with biopsy and collection of blood samples at screening and on study.
89498639|NCT05223036|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD for 6 months in the absence of unacceptable toxicity. Patients also undergo GI endoscopy with biopsy and collection of blood samples at screening and on study.
89498640|NCT05214989|Experimental|Tailored intervention|Tailored intervention designed to address individual barriers to cardiac rehabilitation participation
89498641|NCT05208840|Experimental|LMCE-positive|LMCE-positive participants enrolled in the study will receive therapy with ocrelizumab for 2 years.
89498642|NCT05208840|Experimental|LMCE-negative|LMCE-negative participants enrolled in the study will receive therapy with ocrelizumab for 2 years.
89498643|NCT05198154||Advanced NSCLC patients with long-term benefit after first-line immunotherapy|For patients with advanced NSCLC who have long-term benefit (PFS 12 months) after first-line immunotherapy
89498644|NCT05189977|Active Comparator|Sertraline alone at steady state|To assess the hemodynamic changes associated with the effects of a single dose of prazosin or propranolol in the presence of brexpiprazole + sertraline at steady state compared with a single dose of prazosin or propranolol in the presence of sertraline alone at steady state.
89498645|NCT05189977|Active Comparator|Sertraline + brexpiprazole at steady state|To assess the hemodynamic changes associated with the effects of a single dose of prazosin or propranolol in the presence of brexpiprazole + sertraline at steady state compared with a single dose of prazosin or propranolol in the presence of sertraline alone at steady state.
89498646|NCT05189535|Experimental|pentoxifylline 400 mg|Patients will receive paclitaxel 80 mg/m2 once per week for 12 weeks and pentoxifylline 400 mg twice daily for the paclitaxel treatment period.
89498647|NCT05189535|Placebo Comparator|Placebo|Patients will receive paclitaxel 80 mg/m2 once per week for 12 weeks and placebo twice daily for the paclitaxel treatment period..
89498648|NCT05186012|Experimental|Arm A (Single agent)|
89498649|NCT05186012|Experimental|Arm B (combo)|
89498650|NCT05183828|Experimental|Treatment (letrozole)|Patients receive letrozole PO QD for 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of saliva samples. If tumor resection occurs before or after day 22, letrozole administration must occur for a minimum of 14 days and a maximum of 70 days of total treatment.
89498651|NCT05178407|Experimental|Multiple micronutrient-fortified bouillon cube|"10-gram shrimp-flavoured bouillon cube, fortified with 6 micronutrients~Enrolled participants will receive a household bouillon ration for use in daily cooking (ad lib). Bouillon rations will be replenished every 2 weeks for the study duration of 38 weeks (non-pregnant, non-lactating women 15-49 y and children 2-5 y) or 12 weeks (lactating women 15-49 y and 4-18 mo postpartum)."
89498652|NCT05178407|Placebo Comparator|Control bouillon cube (iodine only)|"10-gram shrimp-flavoured bouillon cube, fortified with iodine~Enrolled participants will receive a household bouillon ration for use in daily cooking (ad lib). Bouillon rations will be replenished every 2 weeks for the study duration of 38 weeks (non-pregnant, non-lactating women 15-49 y and children 2-5 y) or 12 weeks (lactating women 15-49 y and 4-18 mo postpartum)."
89498653|NCT05176444|Experimental|Music therapy intervention|Music therapy
89498654|NCT05176444|No Intervention|Control group - standard care|Standard care for residents with cognitive impairment. Staff will not receive music therapy training.
89498655|NCT05172960|Experimental|TAVR - Main Cohort|Subjects will undergo transcatheter aortic valve replacement (TAVR)
89498656|NCT05172960|Experimental|TAVR - Bicuspid Registry|Subjects with bicuspid aortic valve morphology will undergo TAVR
89498657|NCT05163912|Experimental|Intervention|Virtual home intervention
89498658|NCT05163587|Placebo Comparator|Control|control group will be provided with the commercially available whole-wheat flour for their consumption during the study period.
89498659|NCT05163587|Experimental|Intervention|intervention group will be provided with low GI composite flour for their chapatis during study period and they will be instructed to consume at least 4 chapatis each day.
89498660|NCT05150405|Experimental|QLF31907|single arm with QLF31907 treatment
89498661|NCT05147467|Experimental|APG-2575 single agent in Relapse/Refractory CLL/SLL|APG-2575 orally once daily at 600mg dose levels, every 28 days as a cycle.
89498662|NCT05142358|Active Comparator|left-sided breast cancer|Participants will come in for their regularly scheduled radiation planning and treatment. Participants will undergo three scans (with and without DIBH (i.e., free-breathing), with CPAP). Participants will also use the CPAP device before the CT scan, for which they will be educated and trained.
89498663|NCT05142358|Active Comparator|Lung SBRT|Participants will come in for their regularly scheduled radiation planning and treatment. Participants will undergo three scans (with and without DIBH (i.e., free-breathing), with CPAP). Participants will also use the CPAP device before the CT scan, for which they will be educated and trained.
89498664|NCT05136495|Experimental|Caffeinated coffee|Drink caffeinated coffee one morning and drink decaffeinated coffee the other morning
89498665|NCT05136495|Experimental|Decaffeinated coffee|Drink decaffeinated coffee one morning and drink caffeinated coffee the other morning
89498666|NCT05119881|Experimental|MT+tDCS|The participants will receive mirror therapy combined with real transcranial direct current stimulation.
89498667|NCT05119881|Active Comparator|MT+sham tDCS|The participants will receive mirror therapy combined with sham transcranial direct current stimulation.
89498668|NCT05119881|Active Comparator|sham MT + tDCS|The participants will receive sham mirror therapy combined with real transcranial direct current stimulation.
89498669|NCT05113017||SBRT group|Patients with residual lung nodules are treated with SBRT
89498670|NCT05108337|Experimental|Scpb group|Superficial cervical plexus block group
89498671|NCT05108337|Sham Comparator|Control group|Saline group
89498672|NCT05100472|Experimental|Hormone Therapy and Radiation|Patients enrolled in this study will receive ADT for 6 months which will consist of bicalutamide 50 mg PO daily starting approximately 1-2 weeks before leuprolide 22.5mg injected every 3 months. The HDR prostate brachytherapy procedure will be performed approximately 3 months after starting ADT to allow for potential radiosensitization and cytoreduction. Approximately 4 weeks after the HDR boost, patients will receive image-guided, intensity-modulated, hypofractionated radiation therapy targeting the prostate, seminal vesicles and pelvic lymph nodes to a dose of 25 Gy in 5 fractions delivered daily.
89498673|NCT05095883||healthy|Children in this group will be healthy category according to CDC chart which ranged from BMI-for-age 5th to 85th percentiles
89498674|NCT05095883||overweight|Children in this group will be overweight category according to CDC chart which ranged from BMI-for-age 85th to 95th percentiles
89498675|NCT05095883||obese|Children in this group will be obese category according to CDC chart which ranged from BMI-for-age > 95th percentiles
89498676|NCT05095883||underweight|Children in this group will be underweight category according to CDC chart ranged from BMI-for-age < 5th percentiles
89023123|NCT06016348||Unfavorable outcomes|mRS of 4-6
89023124|NCT06014008|No Intervention|No Intervention group|Not taking test product
89498677|NCT05090943||Quality of life questionnaires|
89023125|NCT06014008|Experimental|Test product consumption group|Participants will take one bottle (80 ml) of Yakult® drink daily for a period of 4 weeks. Yakult is a branded probiotic drink with 8x10^9 CFU Lacticaseibacillus paracasei strain Shirota. Subsequently, a two-week follow-up period will follow.
89205558|NCT04884087|Experimental|EMA, 6x/day, prized-based incentive|"Ecological Momentary Assessment (EMA; Metricwire). Participants randomized to this group will be sent prompts through the EMA app to complete brief EMA survey at 6 random times per day. Participants randomized to this group will be rewarded for high survey completion with increasing numbers of draws for prizes depending on their level of response each week (50-74%=1 draw, 75-89%=2 draws, ≥90%=3 draws)."
89205559|NCT04864639|Experimental|Transition of Care|Experimental: 32 participants will be discharged to a newly developed discharge/transition of care model.
89205560|NCT04830397|Experimental|QLS-101 0.5%|
89205561|NCT04830397|Experimental|QLS-101 1%|
89498678|NCT05079100|Active Comparator|group of intervention (counseling)|the group will receive the contraception counseling
89498679|NCT05079100|No Intervention|group of control (no counseling)|this group will not receive any counseling
89498680|NCT05075408|Experimental|Nemolizumab 30 mg|
89498681|NCT05075408|Experimental|Nemolizumab 60 mg|
89498682|NCT05075408|Placebo Comparator|Placebo|
89498683|NCT05074511||healthy|Children in this group will be healthy category according to CDC (Centers for Disease Control and Prevention) growth chart which ranged from BMI-for-age 5th to 85th percentiles
89498684|NCT05074511||overweight|Children in this group will be overweight category according to CDC (Centers for Disease Control and Prevention) growth chart which ranged from BMI-for-age 85th to 95th percentiles .
89498685|NCT05074511||obese|Children in this group will be obese category according to CDC chart which ranged from BMI-for-age > 95th percentiles
89498686|NCT05074511||underweight|Children in this group will be underweight category according to CDC chart ranged from BMI-for-age < 5th percentiles
89498687|NCT05067348|Experimental|Tocilizumab|Participants will receive tocilizumab administered intravenously (IV) on weeks 1,5,9 and 13 of the randomized controlled period.
89498688|NCT05067348|Placebo Comparator|Placebo|Participants will receive placebo administered intravenously (IV) on weeks 1,5,9 and 13 of the randomized controlled period.
89498689|NCT05062837|Experimental|Hepatectomy Combined With Camrelizumab and Apatinib|Patients with CNLC IIIb hepatocellular carcinoma will receive hepatectomy. Two to four weeks later, they will receive camrelizumab and apatinib treatments.
89498690|NCT05061004|Experimental|Treatment|Treatment of symptomatic patients with mitral valve disease (including mitral regurgitation, mitral stenosis and mixed mitral valve disease) with the Cephea Mitral Valve System
89498691|NCT05057234|Experimental|Simultaneous - FoundationOne liquid CDx|Patients undergoing FoundationOne liquid CDx while tissued-based NGS panel is in progress or reported within 4 weeks of enrollment
89498692|NCT05057234|Experimental|Simultaneous - no additional testing|Patients undergoing no additional testing while tissue-based NGS panel is in progress or reported within 4 weeks of enrolment
89498693|NCT05057234|Experimental|Sequential - FoundationOne liquid CDx|Patients undergoing FoundationOne liquid CDx if standard tissue based NGS oncopanel testing identifies no somatic tier 1 variant of strong clinical significance
89498694|NCT05056272||PCOS GROUP|
89498695|NCT05056272||Non PCOS group|
89498696|NCT05047978|Active Comparator|A routine cow's milk-based infant formula|A routine cow's milk-based infant formula
89498697|NCT05047978|Experimental|A partially hydrolyzed cow's milk protein (PHP) infant formula|A partially hydrolyzed cow's milk protein (PHP) infant formula
89498698|NCT05038137|Experimental|Time restricted feeding|daily eating period of 8 hours, before 8 PM
89498699|NCT05038137|Active Comparator|Control|daily eating period ≥ 12 hours
89498700|NCT05036304|Active Comparator|Aerobic Exercise Indoors|Each session will consist of 10 min of warm-up, 40 min of aerobic exercise, and 10 min of cool-down. Aerobic exercise will be progressive and of moderate intensity. During training, each participant will wear a heart rate monitor and will be asked to work initially at approximately 45% of his/her target heart rate (i.e., heart rate reserve (HRR)) and gradually progress to reach the target of 70% of HRR over the 12-week study period. Participants will also subjectively monitor workout intensity using the 20-point Borg's Rating of Perceived Exertion. Participants will walk or jog on treadmills or cycle on stationary bikes in the Exercise Prescription Suite of the Centre for Hip Health and Mobility.
89498701|NCT05036304|Experimental|Aerobic Exercise Outdoors|Each session will consist of 10 min of warm-up, 40 min of aerobic exercise, and 10 min of cool-down. Aerobic exercise will be progressive and of moderate intensity. During training, each participant will wear a heart rate monitor and will be asked to work initially at approximately 45% of his/her target heart rate (i.e., heart rate reserve (HRR)) and gradually progress to reach the target of 70% of HRR over the 12-week study period. Participants will also subjectively monitor workout intensity using the 20-point Borg's Rating of Perceived Exertion. participants will walk or jog pre-determined routes in trails of an urban forest (Pacific Spirit Park).
89205562|NCT04830397|Experimental|QLS-101 2%|
89205563|NCT04830397|Active Comparator|Timolol Maleate 0.5% preservative free ophthalmic solution|
89205564|NCT04821960|Active Comparator|Conventional Mindfulness Program|Routine mindfulness lessons and activities.
89498702|NCT05035628|Experimental|Cardiopulmonary exercise training group|Cardiopulmonary exercise intervention will include aerobic exercise, resistance and respiratory exercises, three sessions per week for 2 months
89498703|NCT05035628|No Intervention|control group|Control group with no intervention.
89498704|NCT05028517|Experimental|FMF Connect Intervention + Coaching|Participants receive the FMF Connect mobile health app plus text-based coaching to support continued use of the app and individualized goal setting.
89498705|NCT05028517|Experimental|FMF Connect Intervention (no coaching)|Participants receive the FMF Connect mobile health app. They do not receive coaching.
89498706|NCT05028517|No Intervention|Waitlist comparison group|Participants receive the FMF Connect mobile health app at the conclusion of the study.
89498707|NCT05018208||Arm 1 (wearable device[s], smartphone app)|Patients undergoing CAR-T therapy use the Biofourmis wearable device(s) and smartphone app to answer a series of questions about health and neurologic symptoms a few times a day for 5 weeks.
89498708|NCT05018208||Arm 2 (wearable device[s], smartphone app, questionnaires)|Patients undergoing radiation therapy (RT) for head and neck, lung, or gastrointestinal cancers use the Biofourmis wearable device(s) for 90 days after completion of RT. Patients also use the smartphone app to answer a series of questions about health and neurologic symptoms before start of RT, after completion of RT, 3 months after completion of RT, and 1 year after completion of RT. In addition, patients complete weekly questionnaires regarding side effects and tolerance of the device.
89498709|NCT05013138|Active Comparator|Standard of Care Arm|During the study period, standard of care providers will continue to provide standard of care treatment(s); however, families receiving care from the standard of care providers will complete all study surveys. Instead of ACEs training, standard of care providers will undergo training on study procedures including obtaining survey instruments from caregivers and proper storage of survey instruments. This training will stress the importance of not reviewing caregiver ACE scores and minimizing possible treatment contamination. However, standard of care providers will still be able to provide resources to the families as part of standard of care.
89498710|NCT05013138|Experimental|Intervention Arm|Intervention providers will undergo training for ACEs screening and discussion. Eligible families will be enrolled into the study at the intake of their child's 4-month, 6-month, 9-month, 15-month, or 18-month well child check. Caregivers will complete the intake surveys including demographics, caregiver ACEs, resilience, warmth, PTSD, and depression. The providers will lead a discussion regarding the impact of caregiver ACEs. Patients will be contacted 1-week, 6-months, and 18-months following their enrollment to obtain repeat measures of the survey instruments. At the 18-month time point, the electronic medical record (EMR) will be queried to obtain outcome measures.
89498711|NCT05012683|No Intervention|No Prosthesis|Baseline outcome measurements will be performed without a prosthesis
89498712|NCT05012683|Experimental|Prosthesis|Outcome measurements will be performed after the subject has been fit with a prosthesis at 3 different points in time: immediately post-fitting, ~30 days post-fitting, and ~60 days post-fitting
89498713|NCT05012098|Experimental|1/Arm 1|Treatment with Bintrafusp alfa
89498714|NCT04996030|Experimental|Single-Dose PK Module: Sequence 1|Participants will receive IV ATO in a fasted state on Day 1, SY-2101 in a fed state on Day 8, and SY-210 in a fasted state on Day 15 during Weeks 6, 7, and 8 of any consolidation cycle being received as part of SOC treatment consolidation cycle.
89498715|NCT04996030|Experimental|Single-Dose PK Module: Sequence 2|Participants will receive IV ATO in a fasted state on Day 1, SY-2101 in a fasted state on Day 8, and SY-2101 in a fed state on Day 15 during Weeks 6, 7, and 8 of any consolidation cycle being received as part of SOC treatment consolidation cycle.
89498716|NCT04996030|Experimental|Single-Dose PK Comparability Module|Participants will receive two single-dose treatments of SY-2101, with separated from one another by approximately 1 week and separated from any preceding IV ATO dose by at least 72 hours.
89498717|NCT04996030|Experimental|Multiple-Dose IV Module|Participants will receive IV ATO, once daily (QD), 5 days/week for 28 days as a part of at least one cycle (Weeks 1 through 4) of SOC treatment consolidation.
89498718|NCT04996030|Experimental|Multiple-Dose Oral Module|Participants will receive SY-2101, QD, 5 days/week for 28 days as a part of one cycle (Cycle 4; Weeks 1 through 4) of SOC treatment consolidation.
89498719|NCT04990141||Cases group|Women recruited between 9 and 14 gestational weeks diagnosed with preeclampsia or other complication at the end of pregnancy
89498720|NCT04990141||Control group|Women recruited between 9 and 14 gestational weeks without diagnosis of preeclampsia or other complication at the end of the pregnancy
89498721|NCT04988633|Experimental|Intervention CFG App|Online healthy lifestyle education through an App. The intervention will consist of viewing educational videos on diet and exercise through an App.
89498722|NCT04988633|Experimental|Control Group|Standard tips for healthy lifestyles that are carried out in regular Primary Care practice.
89498723|NCT04982133|Active Comparator|Fortification adjusted according to urea|Fortification adjusted according to urea with FM 85 at 4% and oligopeptides. In this arm, fortification at 4% is started, and according to plasma urea control every 15 days the fortification is modified.
89498724|NCT04982133|Experimental|Individualized fortification according to the nutritional characteristics of breast milk|"Individualized fortification according to the nutritional characteristics of the mother's own milk or pasteurized milk taken by the premature infant.~In this arm, fortification is adjusted based on the macronutrient analysis of breast milk or donated twice weekly."
89498725|NCT04978519|Experimental|Cryotherapy|Cryotherapy achieves a temperature averaging -40°C. Through the transperineal insertion of treatment probes, it exerts its effect through freezing of tissue and vascular injury, leading to destruction of cancer tissue.
89498726|NCT04972721||Questionnaire survey|Participants of the SELECT trial (EX9536-4388 ) are invited to transition to SELECT-LIFE (follow-up study) when SELECT ends.
89498727|NCT04970355|Experimental|Erenumab|Double-Blind Treatment Phase: Participants receive erenumab 280 mg subcutaneous (SC) injections (loading dose, week 0) followed by erenumab 140 mg s.c. in week 4.
89498728|NCT04970355|Placebo Comparator|Placebo|Double-Blind Treatment Phase: Participants receive placebo subcutaneous (SC) injections in week 0 and week 4.
89498729|NCT04956341|Experimental|Standard treatment from PCM or Mental Health or both + auricular acupuncture|
89498730|NCT04956341|Placebo Comparator|Standard treatment from Primary Care Manager (PCM) or Mental Health or both|
89498731|NCT04950660|Active Comparator|Caffeine arm|Experimental Group: patient group (n = 34) receiving a 100 mg dose of caffeine (1/2 of a 200mg tablet to be taken whole or crushed), taken twice daily. This will be an adjuvant to their standard pain control.
89498732|NCT04950660|Placebo Comparator|Placebo arm|Control group: patient group (n = 34) receiving placebo compounded to look similar to the caffeine treatment, taken twice daily. This will be an adjuvant to their standard pain control.
89498733|NCT04949100|Experimental|Microcurrent|
89498734|NCT04949100|Placebo Comparator|Placebo|
89498735|NCT04947917|Experimental|Lymph Node SpotTM Tattoo|"Spot™ ink tattooing will be administered once prior to surgery.~Initial test set of participants with previous sampled lymph nodes positive for metastasis will have SpotTM ink administered at time of standard of care pre-surgery radioseed localization.~A feasibility set of participants will have SpotTM ink administered at time standard of care lymph nodes sampling."
89498736|NCT04936581||Open Total Mesorectal Excision|Patients undergoing open low anterior resection
89498737|NCT04936581||Laparoscopic Total Mesorectal Excision|Patients undergoing laparoscopic low anterior resection
89498738|NCT04936581||Robotic Total Mesorectal Excision|Patients undergoing robotic low anterior resection
89498739|NCT04936581||Transanal Total Mesorectal Excision|Patients undergoing transanal Total Mesorectal Excision (taTME)
89498740|NCT04934540||Patients undergoing ERBT|Patients who are diagnosed with bladder tumors and planning for ERBT.
89498741|NCT04931134|Experimental|Active stimulation|"Active or sham TNS treatment will be performed at the patients' home for approximately 8 hours per night 7 days a week for 8 consecutive weeks.~Trigeminal nerve stimulation will occur by placement of electrodes (1.25 silver electrodes Bio-Flex BF4, Biotens/Vermed, Buffalo, NY, USA) bilaterally on the V1 branches of the trigeminal nerve (CNV) located on the forehead. Current will be generated from the EMS 7500 stimulator (TENS Products, Inc., Granby, CO) (Class II medical device) and will be set to a level that is clearly perceptible by each patient (i.e. tingling sensation) but not uncomfortable or painful. Current level will be determined for each patient at baseline and will likely be between 4-6 mA. Active stimulation will occur at 120 Hz with a 250 µs pulse width and with a duty cycle of 30 seconds on to 30 seconds off."
89498742|NCT04931134|Sham Comparator|Sham stimulation|"Active or sham TNS treatment will be performed at the patients' home for approximately 8 hours per night 7 days a week for 8 consecutive weeks.~Sham stimulation will occur by placement of electrodes (1.25 silver electrodes Bio-Flex BF4, Biotens/Vermed, Buffalo, NY, USA) bilaterally on the V1 branches of the trigeminal nerve (CNV) located on the forehead. Current will be generated from the EMS 7500 stimulator (TENS Products, Inc., Granby, CO) (Class II medical device) and will be set to a level that is clearly perceptible by each patient (i.e. tingling sensation) but not uncomfortable or painful. Current level will be determined for each patient at baseline and will likely be between 4-6 mA. Sham stimulation will use the same parameters of active stimulation, but after 60 seconds the stimulator will turn off."
89498743|NCT04928339|Experimental|PIFB intervention|bilateral PIFB with a mixture of standard 0.25% bupivacaine (15 mL) and 133 mg liposomal bupivacaine (10mL)
89498744|NCT04928339|Sham Comparator|Saline Control|bilateral PIFB with 25 mL saline only
89498745|NCT04926636|No Intervention|Standard Mobile App|This group will be supplied with Novidan DTC hearing aids and documentation following standard of care as a control. They will be provided with the mobile application allowing for the monitoring of data for study analysis and personal control of their hearing aids, but not Health and Wellness Coaching features.
89498746|NCT04926636|Experimental|Enhanced Mobile App with Health Coaching|This group will also be supplied with the Novidan DTC hearings aids and documentation, same as the control group, but will be supplied the enhanced mobile application that allows for participation in health coaching features. They will be assigned to a health coach and will have coaching sessions scheduled.
89498747|NCT04924660|Experimental|TXA127 (4/20/2022 Arm Closed to Accrual)|An investigational peptide agonist of Mas receptors.
89498748|NCT04924660|Experimental|TRV027 (4/20/2022 Arm Closed to Accrual)|An investigational peptide biased agonist of the AT1 receptor.
89498749|NCT04924660|Placebo Comparator|Placebo|"NaCl 0.9% infused to match the duration of the agent for TXA127, TRV027, and APN01.~Orange film-coated, plain, bioconvex tablets for fostamatinib.~For the purposes of interim and final analyses, the route and frequency of placebo will be ignored, and all placebo participants will be pooled together as a single group. In comparing an active drug versus placebo, only those placebo participants that were eligible for the active drug will be included."
89498750|NCT04924660|Experimental|Fostamatinib|An investigational oral spleen tyrosine kinase inhibitor.
89498751|NCT04919057|Experimental|Robotic perineal radical prostatectomy|The patient is laid in the exaggerated lithotomy and 15 degree Trendelenburg position. An incision is made between both ischial tuberosities. Perineal dissection is performed till the apex of the prostate is seen. Subcutaneous tissue laying under the incision borders is dissected deeply over the superficial perineal fascia to place the GelPOINT®.Once the robotic system is docked, dissection of prostate is started.
89498752|NCT04912765|Experimental|Neoantigen Dendritic Cell Vaccine and Nivolumab|"NA DC vaccine every 2 weeks at a dose of 3-5 million cells.~Adjuvant nivolumab every 2 weeks at 240mg when given concurrently with the vaccine; every 4 weeks at 480mg after vaccine treatment is completed for a total duration of 1 year."
89498753|NCT04905888|Experimental|Hyperbaric oxygen therapy|Treatment with hyperbaric oxygen
89498754|NCT04905888|No Intervention|Control|Control, no treatment.
89498755|NCT04898543|Experimental|Cohort 1: Subjects newly diagnosed no prior therapy or prior first line treatment|Cohort 1: Subjects with either newly diagnosed solid tumors who have not received prior therapy or subjects who have received prior first line treatment. Cohort 1 may subsequently enroll in cohort 2 part B if they have progressive disease after ≥ 2 prior therapies or if they have progressive disease within 12 months of receiving neoadjuvant or adjuvant chemotherapy and meet the inclusion criteria for cohort 2 part B.
89498756|NCT04898543|Experimental|Cohort 2: Subjects with relapsed/refractory (r/r) solid tumors|Cohort 2: Subjects with relapsed/refractory (r/r) solid tumors who have progressive disease after receiving ≥ 2 prior therapies or not a candidate for therapy of proven efficacy for their disease.
89498757|NCT04883658|Experimental|Sequence 1|"Period 1: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition~Period 2: CKD-348(2) - A single oral dose of 1 tablet under fasting condition~Period 3: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition~Period 4: CKD-348(2) - A single oral dose of 1 tablet under fasting condition"
89498758|NCT04883658|Experimental|Sequence 2|"Period 1: CKD-348(2) - A single oral dose of 1 tablet under fasting condition~Period 2: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition~Period 3: CKD-348(2) - A single oral dose of 1 tablet under fasting condition~Period 4: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition"
89498759|NCT04869982|Experimental|RZV Group|Participants randomized to the RZV Group receive 1 dose of RZV at Day 1 and 1 dose at Month 2 and are followed up until the study end.
89498760|NCT04869982|Placebo Comparator|Placebo Group|Participants randomized to the Placebo Group receive 1 dose of placebo at Day 1 and 1 dose at Month 2 and are followed up until the study end.
89498761|NCT04857632|Experimental|Statins group|
89498762|NCT04857632|No Intervention|Control group|
89498763|NCT04846803|Experimental|Patients prophylatic treated with ABU|Patients with prophylactic bladder flushing with an ABU strain.
89498764|NCT04846803|Placebo Comparator|Patients control group|The control group with bladder flushing with saline solution.
89498765|NCT04846101|Experimental|Anterior restorations using single shade OMNICHROMA composite|Anterior class III and Class IV cavities will be restored using single shade composite material according to standard protocols of etching, bonding and composite placement.
89498766|NCT04846101|Active Comparator|Anterior restorations using multi-shade composite|Shade selection for the tooth will be performed prior to the placement of the restoration. Anterior class III and Class IV cavities will be restored using multi-shade composite material according to standard protocols of etching, bonding and composite placement.
89498767|NCT04835506|Experimental|proactive infliximab optimization|proactive infliximab optimization using a pharmacokinetic dashboard
89498768|NCT04835506|Experimental|standard of care infliximab dosing|standard of care infliximab dosing
89498769|NCT04832685|Active Comparator|Active LIFUP|All participants will receive active modulation of the posterior cingulate cortex (PCC) during Visit 3 or 4 (order counterbalanced).
89498770|NCT04832685|Sham Comparator|Sham LIFUP|All participants will receive sham modulation of the posterior cingulate cortex (PCC) during Visit 3 or 4 (order counterbalanced).
89498771|NCT04827251|Other|Caffeinated coffee|Patients will be instructed to abstain from caffeinated beverages during 22 days. After this period, they will consume caffeinated coffee during 28 days, followed by decaffeinated coffee during more 28 days.
89498772|NCT04827251|Other|Decaffeinated coffee|Patients will be instructed to abstain from caffeinated beverages during 22 days. After this period, they will consume decaffeinated coffee during 28 days, followed by caffeinated coffee during more 28 days.
89498773|NCT04825041||Infertilite women|Subjected to three successive hysteroscopic tests
89498774|NCT04821635|Experimental|Rower|Single group of 35 traumatic paraplegic patients meeting the inclusion criteria will benefit from the FES-ROW protocol during 9 months
89498775|NCT04785521||BM patients|Adult patients carrying new diagnosed BM confirmed by MRI
89498776|NCT04785521||No BM patients|Adult patients carrying extracranial tumor without BM as confirmed by MRI
89498777|NCT04785521||Benign lesion patients|Adult patients carrying intracranial extra-axial tumor as as confirmed by MRI
89498778|NCT04785196|Experimental|APG-115+Toripalimab|
89498779|NCT04779645|Experimental|GRA (REMD-477) Group|Once weekly, subcutaneous injection of 70mg REMD-477 (in 1 mL solution) for up to 12 weeks.
89498780|NCT04779645|Placebo Comparator|Placebo Group|Once weekly, subcutaneous injection of 1mL saline solution for up to 12 weeks.
89205565|NCT04821960|Experimental|Tailored Mindfulness Program for Fear of Memory Loss|Tailored mindfulness lessons and activities for fear of memory loss.
89498781|NCT04760717|Experimental|Spironolactone|Participants randomized to the Spironolactone arm will be receiving Spironolactone in addition to their normal routine blood pressure treatment.
89498782|NCT04760717|No Intervention|Standard Care|Participants randomized to the Standard care arm will be receiving their normal routine blood pressure treatment.
89498783|NCT04743960|Experimental|Nighttime cycled parenteral feeds followed by daytime cycled parenteral feeds|Patients will follow nighttime feeding regimen for one week, and then advance their feeds (approximately 12 hours earlier) to daytime feeding regimen for one week.
89498784|NCT04733352|Experimental|proximal acupoints of knees|GB34, SP9, and EX-LE2
89498785|NCT04733352|Experimental|distal acupoints of knees|LI11, HT3, and TE10
89498786|NCT04731545|Active Comparator|thin buccal bone|
89498787|NCT04731545|Active Comparator|thick buccal bone|
89498788|NCT04731480|Active Comparator|CLADS group|Propofol administration rate will be controlled by a feedback loop facilitated by BIS monitoring using the closed-loop anaesthesia delivery system (CLADS). A BIS value of 50 will be used as the target point for induction and maintenance of anesthesia.
89498789|NCT04731480|Active Comparator|Marsh model group|The target-controlled infusion (TCI) pump will be programmed to marsh model with the target plasma site concentration of 3-µg/ml. The plasma concentration will be altered to maintain a target BIS of 50 during induction and maintenance of anesthesia
89498790|NCT04731480|Active Comparator|Schnider model group|The TCI-pump will be programmed to will be programmed to Schnider model with the target effect site concentration of 3-µg/ml. The effect-site concentration will be altered to maintain a target BIS of 50 during induction and maintenance of anesthesia.
89498791|NCT04731480|Active Comparator|Manual group|Propofol administration will be controlled manually using an intravenous infusion pump to maintain a target BIS of 50 during induction and maintenance of anesthesia.
89498792|NCT04725643||Implant Group|Adults who are choosing to get a replacement Nexplanon and agree to track and report their bleeding patterns for one month before replacement and 3 months after.
89498793|NCT04722770||Pediatric patients with possible ear infections|Pediatric patients presenting with otitis media (acute otitis media or otitis media with effusion) will be imaged with the PhotoniCare OtoSight.
89498794|NCT04720209|Experimental|Circuit-style aerobic and resistance Exercise(CARE)|"This research study involves exercise. Participants in this study will be assigned to one of 2 exercise groups, undergo three (voluntary) biopsies of fat tissue, and participate in 7 testing visits and 48 exercise training visits. Participation is expected to last 12 months.~-16 weeks of circuit-style aerobic and resistance exercise"
89498795|NCT04720209|Experimental|Traditional Aerobic Resistance Exercise (TARE)|"This research study involves exercise. Participants in this study will be assigned to one of 2 exercise groups, undergo three (voluntary) biopsies of fat tissue, and participate in 7 testing visits and 48 exercise training visits. Participation is expected to last 12 months~- 16 weeks of traditional aerobic and resistance exercise"
89538256|NCT02439151|Other|Conventional Strategy|Conventional Strategy: use conventional ventilation strategy (ELSO guide ventilation strategy) in ECMO for severe ARDS patients
89205566|NCT04818762||Preterm neonates with infection|Preterm neonates (30+0 - 36+6 weeks of gestation) with clinical and laboratory signs of early onset infection (within 72 hours after birth).
89205567|NCT04818762||Preterm neonates without infection|Preterm neonates (30+0 - 36+6 weeks of gestation) without clinical and laboratory signs of early onset infection (within 72 hours after birth).
89205568|NCT04818762||Term neonates with infection|Preterm neonates (30+0 - 36+6 weeks of gestation) with clinical and laboratory signs of early onset infection (within 72 hours after birth).
89498796|NCT04720209|Active Comparator|Home-Based Stretching|"Attention Control for 16 weeks home-based stretching~-structured home-based stretching program, participants will be asked to maintain their current activity level for the 4-month study duration, and will be offered the CARE program upon study completion"
88955755|NCT06237517|Active Comparator|Progressive acclimation of healthy individuals without Idiopathic Chilblains (Rewarming Phase)|Throughout the experiment, the participants remained seated in a sitting position. The trial began with the chamber's temperature at 22-24 °C and 40-50% relative humidity for 20 minutes. After this period, the temperature within the chamber dropped by 4 degrees every 20 minutes. After 80 minutes (the chamber's temperature was 10°C and 40-50%), a radiator heater was placed placed in front of the participants to raise the temperature of their extremities. Simultaneously, the investigators increased the chamber temperature to 22-24 °C and 40-55% relative humidity, and the participants remained in the same sitting position for 20 minutes. Following this period, an occlusion foot test was performed to observe any hemodynamic changes in the foot. The test consisted of a 5-minute ''baseline'' phase, a 5-minute ''occlusion'' phase, and a 5-minute ''release'' phase. Before and after the trial, participants provided blood and urine samples.
88955756|NCT06237517|Experimental|Thermoneutral environment healthy participants with Idiopathic Chilblains (Baseline)|Throughout the experiment, the participants remained seated in a sitting position. The trial began with the chamber's temperature at 22-24°C and 40-50% (relative humidity) for 20 minutes. After 20 minutes, the temperature was maintained at 22°C and 40-50% (relative humidity) for 15 minutes, and an occlusion foot test was conducted (5 minutes ''baseline'' phase, 5 minutes ''occlusion'' phase, and 5 minutes ''release'' phase), to observe any hemodynamic changes in the foot.
88955757|NCT06237517|Active Comparator|Thermoneutral environment healthy participants without Idiopathic Chilblains (Baseline)|Throughout the experiment, the participants remained seated in a sitting position. The trial began with the chamber's temperature at 22-24°C and 40-50% (relative humidity) for 20 minutes. After 20 minutes, the temperature was maintained at 22°C and 40-50% (relative humidity) for 15 minutes, and an occlusion foot test was conducted (5 minutes ''baseline'' phase, 5 minutes ''occlusion'' phase and 5 minutes ''release'' phase), to observe any hemodynamic changes in the foot.
89205569|NCT04818762||Term neonates without infection|Preterm neonates (30+0 - 36+6 weeks of gestation) without clinical and laboratory signs of early onset infection (within 72 hours after birth).
89205570|NCT04804891|Experimental|Cell Therapy|Patients will receive an infusion containing 1x106/kg CD34+ cells. No more than 104 CD34+ T cells per kg recipient weight will be included in the infusion. Cadaveric donor CD34 cell infusion will occur at any time between post-operative day 11 to day 13 following transplantation.
89498797|NCT04711161|Experimental|Part 1 (Phase 1a): Single Arm, Open Label (GRN-300 single-agent)|Part 1 of the study will determine the safety of continuous twice a day oral dosing of GRN-300, with each cycle consisting of 28 days of treatment. The number of administered cycles will depend on the tolerability of each dose level and the severity and occurrence of side effects and DLTs. The maximal tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of GRN-300 as a single agent will be determined. The overall duration of Part 1 will be approximately 24-36 months, depending on the rate of enrollment and the number of subjects enrolled.
89498798|NCT04711161|Experimental|Part 2 (Phase 1b): Single Arm, Open Label (GRN-300 plus paclitaxel)|"The study will determine the safety of continuous twice a day oral dosing of GRN-300, with each cycle consisting of 28 days of treatment, in combination with intravenously administered paclitaxel weekly x 3 during each 28-day cycle. The number of administered cycles will depend on the tolerability of each dose level and the severity and occurrence of side effects and DLTs. The maximal tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of GRN-300 in combination with paclitaxel will be determined. The overall duration of Part 2 will be approximately 12-18 months, depending on the rate of enrollment and the number of subjects enrolled. Part 2 will commence following determination of the MTD and RP2D of single-agent GRN-300 in Part 1.~Overall duration of the study will be approximately 36-48 months, depending on the rate of enrollment and number of subjects enrolled."
89498799|NCT04707651|Experimental|Lifestyle intervention|Nutrition advices and formula diet
89498800|NCT04700696|Experimental|EPIC Participants|EPIC participants are 1) matched with trained peer recovery supporters with lived experience related to child welfare and substance EPIC participants are also incentivized to participate in 2) family treatment drug court (FTDC), with medications for opioid use disorders (MOUD); and 3) home-based parenting supports based on the Nurturing Parenting Program.
88955764|NCT06223048|Experimental|AMDX-2011P 50 mg|AMDX2011P mg 50 (2ml) single bolus injection intravenous for diagnostic review
88955765|NCT06223048|Experimental|AMDX-2011P 100 mg|AMDX2011P 100mg (4ml) single bolus injection intravenous for diagnostic review
88955766|NCT06222593|Experimental|Bicalutamide in combination with Sunitinib|Bicalutamide 50mg once a day (QD) in combination with sunitinib 37.5mg, 25mg or 50mg QD (2 weeks ON, 1 week OFF). Four or more 21 day-long cycles.
89498801|NCT04700696|Active Comparator|Ohio Sobriety Treatment And Reducing Trauma (START) participants|Adapted from the evidence-based national START model (Sobriety Treatment and Recovery Teams) this intervention matches child welfare parents in need of addiction services to caseworker and family peer mentor (FPM) dyads for intensive case management services.
89498802|NCT04700696|No Intervention|Treatment as usual (TAU)|Treatment as usual includes home visits by the assigned caseworker, referrals to SUD assessment/treatment, family group decision making, and (non-incentivized) referral to FTDC.
89498803|NCT04698746|Active Comparator|Ultrasound guided pericapsular nerve group block|Injection of 15 ml 0.5% bupivacaine + 2 mg dexamethasone + 14.5 ml isotonic saline mixture between iliopubic eminentia and psoas tendon under ultrasound guidance
89498804|NCT04698746|Active Comparator|Intra-articular local anesthetic injection|At the end of the surgical case, a total of 10 ml 0.5% bupivacaine + 2 mg dexamethasone + 9.5 ml isotonic saline injection intra-articularly.
89498805|NCT04692597|Experimental|Group 1 (LLLT)|"Group 1: Low level laser therapy (LLLT) using Phoenix Thera-lase device (74 Watts, 1275 nm wavelength) for 6 minutes affected per hand.~The protocol for each group will involve one minute of LLLT over each of the following treatment zones: dorsal fingers and thumb, dorsal metacarpals, dorsal wrist, palmar fingers and thumb, palmar metacarpals, palmar wrist for a total of 6 minutes affected on each hand. The LLLT device will be held approximately 12 inches from the skin surface."
89538257|NCT02443363||Patients After Kidney Transplantation|A total of 300 consecutive patients admitted to routine visit in Transplant Centre with functioning graft longer than 3 months to 10 years
89023126|NCT06012084|Experimental|iCF-PWR Intervention|"Internet-delivered Cystic Fibrosis Mental Health Prevention, Wellness, and Resource (iCF-PWR) program is comprised of five text/voice-delivered, animated, interactive modules. The pathways are comprised of the same modules that take approximately 15 to 20 minutes to complete. Modules are comprised of web pages and/or screens with numerous illustrations and interactive components. Written module content will be presented verbally as well as in text format.~The program modules include: (1) What is CF? (i.e., physiological explanation of CF, prevalence rate); (2) How does my sibling with CF stay healthy? (i.e., review of medication, nutrition, physiotherapy treatment, and why treatment is important); (3) How does CF affect me?; (4) Mental health awareness (i.e., introduction to cognitive behaviour model of emotions-thoughts, feelings, bodily sensations, and behaviours); and (5) Strategies (i.e., ways to challenge unhelpful thoughts, talking about emotions, relaxation)."
89498806|NCT04692597|Sham Comparator|Group 2 (LLLT Sham)|"Group 2: Sham LLLT using the Phoenix Thera-lase device with the guide light on but without emitting laser photons for 6 minutes affected per hand.~The protocol for each group will involve one minute of sham LLLT over each of the following treatment zones: dorsal fingers and thumb, dorsal metacarpals, dorsal wrist, palmar fingers and thumb, palmar metacarpals, palmar wrist for a total of 6 minutes affected on each hand. The LLLT device will be held approximately 12 inches from the skin surface."
89498807|NCT04685876|Active Comparator|liposomal bupivacaine|40 ml of plain bupivacaine 0.25% will be mixed with 20 ml liposomal bupivacaine and 20 ml of saline. 20 ml of the mix will be injected at each location of the 4-quadrant TAP block.
89498808|NCT04685876|Active Comparator|plain bupivacaine|50 ml of plain bupivacaine 0.5% will be combined with 30 ml of normal saline making a total of 80 ml. 20 ml will be injected at each location of the 4-quadrant TAP block.
89498809|NCT04685876|Placebo Comparator|Normal Saline|patients will receive total of 80 ml of normal saline, injected 20 ml in each of the four-quadrant sites.
89498810|NCT04684615||AmBiGen|Individuals who are enrolled in AmBiGen over the last 3 years
89498811|NCT04669678|Experimental|Group 1 DOR + ETG|100mg DOR-containing ART [oral tablet taken daily] + 68mg ETG implant (follow up for 30 weeks)
89498812|NCT04669678|Experimental|Group 2 DOR + IM DMPA|100mg DOR-containing ART [oral tablet taken daily] + 150mg IM DMPA (follow up for 18 weeks)
89498813|NCT04669678|Experimental|Group 3 DOR + SC MPA|100mg DOR-containing ART [oral tablet taken daily] + 104mg SC MPA (follow up for 18 weeks)
89498814|NCT04669678|Experimental|Group 4 DOR + IUD|100mg DOR-containing ART [oral tablet taken daily] + 1 non-hormonal IUD device (follow up for 30 weeks)
89498815|NCT04669678|Active Comparator|Group 5 DTG + DMPA|50mg DTG-containing ART [oral tablet taken daily] + 150mg IM DMPA DMPA administered at enrolment (follow up for 18 weeks)
89498816|NCT04660370|Experimental|Sequence 1|"Period 1: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition~Period 2: CKD-348- A single oral dose of 1 tablet under fasting condition~Period 3: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition~Period 4: CKD-348- A single oral dose of 1 tablet under fasting condition"
89498817|NCT04660370|Experimental|Sequence 2|"Period 1: CKD-348- A single oral dose of 1 tablet under fasting condition~Period 2: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition~Period 3: CKD-348- A single oral dose of 1 tablet under fasting condition~Period 4: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition"
89498818|NCT04656600|Experimental|Cerezyme® / Imiglucerase|Cerezyme® (imiglucerase for injection) is administered by intravenous infusion, 60 U/kg once every 2 weeks.
89498819|NCT04654234||Total-body PET/CT (uExplorer)|Patients with locally advanced NSCLC will receive total-body PET/CT (uExplorer) scans before, during and after the treatment
89498820|NCT04638517|Active Comparator|Danazol|800mg daily in two divided doses orally for 12 months. In subjects who have difficulty tolerating danazol / placebo, the dose will be reduced by 200mg/day and side effects will be reassessed. If symptoms related to the study drug persist, subsequent 200mg/day dose reductions will be allowed until a tolerated dose is achieved. Background antifibrotic therapy is allowed.
89498821|NCT04638517|Placebo Comparator|Placebo|Matching placebo capsules.
89498822|NCT04638400|Active Comparator|Simvastatin|Obese subjects with elevated cholesterol
89498823|NCT04638400|Active Comparator|Ezetimibe|Obese subjects with elevated cholesterol
89498824|NCT04598165|Experimental|Interactive two-way SMS dialogue|Participants will receive automated SMS messages with prompts to reply. They will have the ability to both respond to and initiate SMS dialogue. Trained Study Nurses will monitor and respond to participant messages.
89498825|NCT04598165|No Intervention|No SMS Control|Control receiving standard of care.
89498826|NCT04596150|Experimental|ARM A - CX-2009 Monotherapy, HR-positive/HER2-negative|CX-2009 Monotherapy in advanced, metastatic Hormone Receptor (HR)-positive / Human Epidermal growth factor Receptor 2 (HER2)-negative breast cancer
89498827|NCT04596150|Experimental|ARM B - CX-2009 Monotherapy, TNBC|CX-2009 Monotherapy in advanced, metastatic Triple-Negative Breast Cancer (TNBC)
89498828|NCT04596150|Experimental|ARM C - CX-2009 Combination therapy, TNBC|CX-2009 and CX-072 Combination therapy in advanced, metastatic TNBC
89498829|NCT04595994|Experimental|Selinexor + Gemcitabine|"Dose escalation levels (Phase I):~All included patients will take both drugs:~Selinexor weekly (given on days 1,8 and 15 of each cycle) will be dispensed at different dose levels: dose level 1:60 mg, dose level 2: 60 mg, dose level 3: 60 mg, and dose level 4: 80 mg).~Gemcitabine weekly (given on days 1, 8 of each cycle) will be administered at different dose levels: (dose level 1:1000 mg/m2 (30 min), dose level 2:1000 mg/m2 (10 mg/m2/min), dose level 3:1200 mg/m2 (10 mg/m2/min) and dose level 4: 1200 mg/m2 (10 mg/m2/min)).~Selinexor: tablet (20 mg tablets) Oral use.~Gemcitabine: Concentrate for solution for infusion. Intravenous use."
89498830|NCT04591314|Experimental|Neurofeedback participants|All the participants studied.
89498831|NCT04581421|Experimental|High Carb first|
89498832|NCT04581421|Experimental|Low Carb first|
89498833|NCT04573387|Active Comparator|Fixed-time drainage|Drainage will be removed after 48 hours.
89498834|NCT04573387|Experimental|Exhaustive drainage|Drainage will be removed when postoperative hematoma volume is minimized with repeated urokinase injection into hematoma cavity through catheter.
89498835|NCT04567914||Adolescent idiopathic scoliosis|Ultrasonographic measurements were performed of bilaterally abdominal muscle thickness of AIS patients diagnosed by a specialist. Spirometry evaluation was performed by the investigator
89023127|NCT06011876|Experimental|Single-session testing days|Participants will complete three separate single-session testing days. Baseline testing will be performed, then on each day, participants will receive AIH, AIHH, and sham AIH in random order. Post-testing will occur after each intervention.
89023128|NCT06011876|Experimental|Respiratory strength training blocks|Participants will complete three separate respiratory strength training blocks. In each block, participants will receive 5 days of AIH, 5 days of AIHH, and 5 days of sham AIH in random order, followed by respiratory strength training. Each block will include 5 days of intervention and training, and post-testing 1, 3, and 7 days after intervention and training has concluded.
89023129|NCT06009614|Placebo Comparator|Placebo Control 1|GI Health Product Form 1 - control
89023130|NCT06009614|Experimental|Active Product 1.1|GI Health Product Form 1 - active product 1
89023131|NCT06009614|Placebo Comparator|Placebo Control 2|GI Health Product Form 2 - control
89023132|NCT06009614|Experimental|Active Product 2.1|GI Health Product Form 2 - active product 1
89023133|NCT06009614|Experimental|Active Product 2.2|GI Health Product Form 2 - active product 2
89023134|NCT06009614|Placebo Comparator|Placebo Control 3|GI Health Product Form 3 - control
89023135|NCT06009614|Experimental|Active Product 3.1|GI Health Product Form 3 - active product 1
89023136|NCT06005480|Experimental|Block upper extremity (arm)|Upper extremity with a nerve block
89023137|NCT06005480|No Intervention|Control upper extremity (arm)|Upper extremity without a nerve block
89023138|NCT06003218|Experimental|Dexmedetomidine-esketamine combined with oxycodone|Dexmedetomidine-esketamine combination will be infused in addition to oxycodone; the target is to maintain a Richmond Agitation and Sedation Scale between -2 and -1 during surgery.
89023139|NCT06003218|Active Comparator|Remifentanil combined with oxycodone|Remifentanil will be infused in addition to oxycodone; the target is to maintain a Richmond Agitation and Sedation Scale between -2 and -1 during surgery.
89023140|NCT06002607||Short course of antibiotics|Patients assigned to a 48-hour course of antibiotics. As the current standard of care, the antibiotics used in this treatment are Clindamycin, Vancomycin, Piperacillin-Tazobactam; these antibiotics may be administered combined or individually, based on individualized patient treatment. The specific choice of antibiotic therapy will not be dictated by the study protocol but by the attending surgeon taking care of the patient
89023141|NCT06002607||Long course of antibiotics|Patients assigned to a 7 day course of antibiotics. As the current standard of care, the antibiotics used in this treatment are Clindamycin, Vancomycin, Piperacillin-Tazobactam; these antibiotics may be administered combined or individually, based on individualized patient treatment. The specific choice of antibiotic therapy will not be dictated by the study protocol but by the attending surgeon taking care of the patient
89023142|NCT05999305|Experimental|The intervention group|The conventional class and an escape room game will be implemented for the intervention.
89023143|NCT05999305|Active Comparator|The comparison group|The conventional class and a case-based learning will be implemented for the comparison
89023144|NCT05987956|Experimental|Alectinib - Usual|"Usual ALECENSA - Alectinib~Chemotherapy (NDC...01)~Usual ALECENSA - alectinib hydrochloride capsule 600 mg orally twice daily~Usual Approach Group (NDC...01)~ALECENSA - alectinib hydrochloride capsule -- 600 mg orally twice daily"
89023145|NCT05987956|Experimental|Alectinib - Study|"Study ALECENSA - Alectinib~Chemotherapy (NDC...86)~Study ALECENSA - alectinib hydrochloride capsule 600 mg orally twice daily~Study Approach Group (NDC...86)~ALECENSA - alectinib hydrochloride capsule -- 600 mg orally twice daily"
89023146|NCT05981235|Experimental|AZD6422|It is anti-CLDN18.2 CAR-T cell therapy and the study consists of two parts: dose escalation (part 1) and dose expansion (part 2)
89023147|NCT05981118|Active Comparator|Betamethasone dipropionate 0.05%|The betamethasone dipropionate 0.05% cream group will be treated with betamethasone dipropionate 0.05% cream once daily on both legs until clear or up to 12 weeks.
89023148|NCT05981118|Active Comparator|Tapinarof|The tapinarof group will be treated with 1% tapinarof cream applied once daily to both legs until clear or up to 12 weeks.
89023149|NCT05973448|Other|Lighting Sequence 1: CCLL|"In this arm, the participant will receive the control lighting condition (C) for the first two quarters (180 days) and then crossover to the novel lighting condition (L) for the last two quarters (180 days).~Q1 - Control lighting Q2 - Control lighting Q3 - Novel lighting Q4 - Novel lighting"
89023150|NCT05973448|Other|Lighting Sequence 2: CLLC|"In this arm, the participant will receive the control lighting condition (C) for the first quarter (90 days) and then crossover to the novel lighting condition (L) for the next two quarters (180 days) and finally crossover again to the control condition (C) for the last quarter (90 days).~Q1 - Control lighting Q2 - Novel lighting Q3 - Novel lighting Q4 - Control lighting"
89023151|NCT05973448|Other|Lighting Sequence 3: LCCL|"In this arm, the participant will receive the novel lighting condition (L) for the first quarter (90 days) and then crossover to the control lighting condition (C) for the next two quarters (180 days) and finally crossover again to the novel condition (L) for the last quarter (90 days).~Q1 - Novel lighting Q2 - Control lighting Q3 - Control lighting Q4 - Novel lighting"
89023152|NCT05973448|Other|Lighting Sequence 4: LLCC|"In this arm, the participant will receive the novel lighting condition (L) for the first two quarters (180 days) and then crossover to the control lighting condition (C) for the last two quarters (180 days).~Q1 - Novel lighting Q2 - Novel lighting Q3 - Control lighting Q4 - Control lighting"
89023153|NCT05961410|Experimental|Eltrombopag|ESHAP + Eltrombopag as peripheral blood stem cell mobilization
89023154|NCT05956769|Active Comparator|Empirical 2: TXA administration|Tranexamic acid administration, regardless of the result of TEG6.
89023155|NCT05956769|Experimental|Goal-directed 1: Placebo administration|Normal saline administration, according to the result of TEG6. . Placebo administration, at LY30 < 3% or MA > 54 mm in CRT of TEG6
89023156|NCT05956769|Experimental|Goal-directed 2: TXA administration|Tranexamic acid administration, according to the result of TEG6. Placebo discard, at LY30> 3% or MA<54 mm in CRT of TEG6
89023157|NCT05943977|Experimental|130 mg MB-102 DMID, then 130 mg MB 102-OMID|Participants will receive a single 130 mg dose of the MB-102 Domestic Manufactured Investigational Drug (DMID), and blood and urine samples will be collected per protocol. There will be a 5-day washout period between treatments, and then participants will receive a single 130 mg dose of the MB-102 Overseas Manufactured Investigational Drug (OMID). Blood and urine samples will be collected per protocol
89023158|NCT05943977|Experimental|130 mg MB-102 OMID, then 130 mg MB 102-DMID|Participants will receive a single 130 mg dose of the MB-102 Overseas Manufactured Investigational Drug (OMID), and blood and urine samples will be collected per protocol. There will be a 5-day washout period between treatments, and then participants will receive a single 130 mg dose of the MB-102 Domestic Manufactured Investigational Drug (DMID). Blood and urine samples will be collected per protocol.
89023159|NCT05943977|Experimental|Participants with eGFR ≥ 70 mL/min/1.73 m^2|130 mg of the MB-102 Domestic Manufactured Investigational Drug (DMID) will be administered to participants with estimated glomerular filtration rate (eGFR) eGFR ≥ 70 mL/min/1.73 m^2, and fluorescence measured using the MediBeacon Transdermal GFR Measurement System
89023160|NCT05943977|Experimental|Participants with eGFR < 70 mL/min/1.73 m^2|130 mg of the MB-102 Domestic Manufactured Investigational Drug (DMID)will be administered to participants with estimated glomerular filtration rate (eGFR) eGFR < 70 mL/min/1.73 m^2, and fluorescence measured using the MediBeacon Transdermal GFR Measurement System
89498836|NCT04567914||Adolescent healthy individuals|Healthy adolescents aged 10-18 were selected. Ultrasonographic measurements were performed of bilaterally abdominal muscle thickness. Spirometry evaluation was performed by the investigator.
89498837|NCT04542382|Experimental|Placebo and Rosuvastatin|Subjects will be dosed with placebo tablet and Rosuvastatin 10mg tablet
89498838|NCT04542382|Experimental|Eltrombopag and Rosuvastatin|Subjects will be dosed with Eltrombopag 75mg tablet and Rosuvastatin 10mg tablet
89498839|NCT04531956|No Intervention|Before group|In the before group (BG) GPs will execute care as usual in the decision-making process for a diagnostic trajectory for memory complaints.
89498840|NCT04531956|Active Comparator|After group|In the after group (AG), a patient decision aid will be added to the decision-making process provided by the GP.
89498841|NCT04529070|Experimental|Intervention + Standard of care|Nightmare Rescripting and Rehearsal: a 10 minute intervention for Primary Care plus Sleep Hygiene handout.
89498842|NCT04529070|Active Comparator|Standard of care|Standard of Care Sleep Hygiene handout alone.
89498843|NCT04528693|Experimental|Intervention|40 women with insulin resistance aged 25-45, BMI 18,5-29,9 will perform, for a period of 3 months, 3 times a week, strength training, interspersed with bouts of endurance exercise carried out on circuit machines integrated with the Milon computer software.
89498844|NCT04528693|No Intervention|Control|40 women with insulin resistance aged 25-45, BMI 18,5-29,9 will be asked to maintain their current level of physical activity and their diet for a period of 3 months.
89498845|NCT04527185|Experimental|Endotoxin|Endotoxin (0.4ng/kg i.v.) will be administered one time during the laboratory session.
89498846|NCT04527185|Placebo Comparator|Placebo|Administered one time during the laboratory session.
89498847|NCT04507074|Experimental|Patients With Obesity|40 subjects aged 35-60 with simple obesity (BMI ≥ 30 kg / m2) and chronic low back pain.
89498848|NCT04507074|Active Comparator|Normal-Weight Patients|20 subjects aged 35-60 with normal body weight (BMI ≤ 24.9 and ≥ 18.5 kg/m2) suffering from chronic low back pain.
89498849|NCT04504500|No Intervention|Observation phase|Routine practice assessment
89498850|NCT04504500|Active Comparator|Intervention phase|Clinical practice assessment after the application of the trial's educational, behavioral and organizational interventions
89498851|NCT04475250|Experimental|Tetragraph|
89498852|NCT04474808|Experimental|L-arginine-containing foot cream|The participants apply one foot (randomized assignment) with the L-arginine-containing foot cream twice a day (morning and evening) over a period of six weeks.
89498853|NCT04474808|Active Comparator|Urea-containing foot cream|The participants apply one foot (randomized assignment) with the Urea-containing foot cream twice a day (morning and evening) over a period of six weeks.
89498854|NCT04465487|Experimental|Dose Escalation|REGN6569 lead-in, then combo therapy
89498855|NCT04465487|Experimental|Dose Expansion|Randomized 1:1 between cohorts Cohort 1: Concurrent start of REGN6569 + cemiplimab Cohort 2: REGN6569 lead-in, then combo therapy
89498856|NCT04464876|Experimental|Treatment|SATURN TA TMVR Device implanted
89498857|NCT04462770|Experimental|Active arm with EPX-100 (Clemizole HCl)|EPX-100 oral solution
89498858|NCT04462770|Placebo Comparator|Placebo arm|Color- and taste-matched placebo oral solution dosed to match the active arm.
89498859|NCT04440592|Experimental|MT-7117|Oral tablet of MT-7117 once a day.
89498860|NCT04440592|Placebo Comparator|Placebo|Oral tablet of placebo once a day.
89498861|NCT04440033|Experimental|Parkinson's Disease group|Patients with stage 3 idiopathic Parkinson's Disease
89498862|NCT04440033|Active Comparator|Healthy control group|Age and sex-matched healthy adults
89498863|NCT04434040|Experimental|Atezolizumab and Sacituzumab govitecan|"Patients will receive the following treatment:~Atezolizumab and Sacituzumab govitecan treatment will continue for 6 cycles (18 total weeks).~Atezolizumab intravenously (IV) at a pre-determined dose on day 1 in a 21-day cycle~Sacituzumab govitecan: intravenously (IV) at a pre-determined dose on days 1 and 8 in a 21-day cycle"
89498864|NCT04397133|Experimental|intervention 1|in this group patients will get 4 week of inspiratory muscle training exercise 30 minutes every weekday ( 15 minutes of two session in each day)
89498865|NCT04397133|Experimental|intervention 2|in this group patients will get 8 week of inspiratory muscle training exercise 30 minutes every weekday ( 15 minutes of two session in each day)
89498866|NCT04397133|Sham Comparator|control group|this group will get sham intervention with 0 to 5 cmH2O resistance
89498867|NCT04385940|Experimental|High dose vitamin D|Ddrops® products,Vitamin D3, 50,000 IU, Oral
89205571|NCT04804891|No Intervention|Control|Patients who do not consent to receive donor CD34 cell infusion or whose donor family declines consent for research use of donor bone marrow will receive their usual standard of care.
89205572|NCT04802590|Experimental|Arm A|Ibrutinib (+ CD20Ab)
89498868|NCT04385940|Active Comparator|Low dose vitamin D|Vitamin D3 1000IU
89498869|NCT04379635|Experimental|Neoadjuvant chemotherapy + Neoadjuvant/Adjuvant Tislelizumab|Tislelizumab + cisplatin/carboplatin + paclitaxel or Pemetrexed Disodium
89498870|NCT04379635|Placebo Comparator|Neoadjuvant chemotherapy + Neoadjuvant/Adjuvant Placebo|Placebo + cisplatin/carboplatin + paclitaxel or Pemetrexed Disodium
89498871|NCT04363944|Experimental|mRehab|Use of mRehab in a home program completing unilateral and bilateral activities. Participants are able to complete unilateral activities with their paretic arm/hand
89498872|NCT04363944|Experimental|mRehab completing all activities bilaterally|Use of mRehab in a home program completing unilateral and bilateral activities. Participantsare can only complete intended unilateral activities using both hands
89498873|NCT04361487||Horizontal Cleavage Meniscal Tear|Participants with horizontal cleavage meniscal tears
89498874|NCT04361487||Complex Meniscal Tear|Participants with complex meniscal tears
89498875|NCT04354103|Experimental|patients with Tourette's syndrome|Atomoxetine in Patients With Tourette's Syndrome
89498876|NCT04343079|Experimental|braeast cancer|breast cancer patients
89498877|NCT04342585|Active Comparator|Vaginal progestogen|200mg of vaginal progestogen will be inserted before bedtime every day from time of recruitment until 34 weeks gestation.
89498878|NCT04342585|Active Comparator|Vaginal pessary|Vaginal pessary with an internal diameter size of 32 or 35 mm will be inserted at the time of recruitment and kept until 34 weeks gestation.
89498879|NCT04342260|Experimental|Active Monitoring|Clinicians will receive symptom alerts if the survey suggests increased or worsening symptoms.
89498880|NCT04342260|Active Comparator|Passive Monitoring|Clinicians will not receive any symptom alerts.
89498881|NCT04339777|Active Comparator|Arm A|Low Intensity, Intermediate Intensity and High Intensity Conditioning with or without alemtuzumab
89498882|NCT04339777|Active Comparator|Arm B|Intermediate Intensity Conditioning with or without Alemtuzumab
89498883|NCT04335110|Other|Intervention|Care Partners and Persons with Dementia. Up to 40 Care Partners and their 40 care-recipients with ADRD will participate in this study. The primary focus of this study is on Care Partners, however, we will gather subjective and objective data on participants with Alzheimer's Disease and Related Dementias (ADRD) to assess the effect of the intervention on Care Partner affective responses to caregiving and quality of life for both. STELLA participants will be recruited from the existing cohort of patients, and their Care Partners, who are enrolled in the Oregon Roybal Center for CAre Support Translational Research Advantaged by Integrating Technology) ORCASTRAIT Life Laboratory (OSLL).
89498884|NCT04329962|Experimental|Group I (blueberry extract, blueberry powder)|Participants undergo a washout on days -7 to -1 and then consume blueberry extract confection on day 0. Participants undergo a second washout on days 1-7 and then consume blueberry powder confection on day 8.
89498885|NCT04329962|Experimental|Group II (blueberry powder, blueberry extract)|Participants undergo a washout on days -7 to -1 and then consume blueberry powder confection on day 0. Participants undergo a second washout on days 1-7 and then consume blueberry extract confection on day 8.
89498886|NCT04323839||Pregnant Women|Women who are currently pregnant and are suspected or diagnosed COVID-19 positive.
89498887|NCT04323839||Post-partum women|Women who have been pregnant in the past 6 weeks and are suspected or diagnosed COVID-19 positive.
89498888|NCT04304079|Experimental|ARssist system|The surgery will follow the same steps of a standard robotic assisted radical prostatectomy procedure, with the addition of the ARssist system used by the patient side surgeon.
89498889|NCT04278924|Placebo Comparator|Part A: Double Blind, Placebo|TAK-079 placebo-matching injection subcutaneously (SC) once weekly (QW) for 8 weeks.
89498890|NCT04278924|Experimental|Part A: Double Blind, TAK-079 Dose 1|TAK-079 Dose 1, SC injection QW for 8 weeks.
89498891|NCT04278924|Experimental|Part A: Double Blind, TAK-079 Dose 2|TAK-079 Dose 2, SC injection QW for 8 weeks.
89498892|NCT04278924|Experimental|Part A: Open-label Extension (OLE) Phase, TAK-079 Dose 1|Participants who received placebo in double-blind Part A and opt to receive further treatment will be randomized to receive TAK-079 Dose 1, SC injection QW for 8 weeks in OLE Phase of Part A.
89498893|NCT04278924|Experimental|Part A: OLE Phase, TAK-079 Dose 2|Participants who received placebo in double-blind Part A and opt to receive further treatment will be randomized to receive TAK-079 Dose 2, SC injection QW for 8 weeks in OLE Phase of Part A.
89498894|NCT04278924|Placebo Comparator|Part B: Double Blind, Placebo|TAK-079 placebo-matching injection SC, QW for 8 weeks.
89498895|NCT04278924|Experimental|Part B: Double Blind, TAK-079 Dose 3|TAK-079 Dose 3, SC injection QW for 8 weeks.
89498896|NCT04278924|Experimental|Part B: OLE Phase, TAK-079 Dose 3|Participants who received placebo in double-blind Part B and opt to receive further treatment will receive TAK-079 Dose 3, SC injection QW for 8 weeks in OLE Phase of Part B.
89498897|NCT04251091|Experimental|ReWalk Soft Exosuit|During this study, we will explore which timing: early timing (10-20%), mid timing (50%) and late timing (90%) may be optimal for an individual and then carry out an 18 session training protocol.
89023161|NCT05931601|Experimental|Intervention|"Peripheral noradrenaline will be infused at rates of 0.05-0.15 mcg/kg/min for up to 24 hours after randomization in the ED until shock control is achieved.~If shock control cannot be achieved, patients will be transferred to the ICU for further treatment of their condition but without further trial intervention.~Weaning of intervention will be completed during the 24 hours, and if possible, terminated.~If termination of treatment is not achievable within 24 hours, participants will be transferred to the ICU."
89023162|NCT05931601|No Intervention|Control|No ED administered noradrenaline. Standard care of hypotension and shock in the Danish ED's are fluid therapy and if not possible to achieve shock control, they are transferred to the ICU for administration of vasopressors if they are eligible for ICU admittance.
89023163|NCT05930093|Placebo Comparator|Placebo|Placebo without active ingredient
89023164|NCT05930093|Active Comparator|2 cap.LivPhcD/per day|515mg/LivPhcD cap. 2 cap./per day
89498898|NCT04248244|Experimental|Early Palliative Care Integration|12 months of PC with concurrent standard treatment for MM, QOL assessments
89498899|NCT04245423|Active Comparator|Augmented Usual Care (AUC)|If not already waivered, PCPs will be trained and waivered to treat OUD with medications. Almost all practices have hired mental health clinicians, equivalent to the care managers in the investigators' collaborative care model, to treat mild and moderate depression and anxiety. These clinicians typically are licensed clinical social workers; a few are nurses or psychologists. No care managers have received systematic training in treating patients with OUD. The clinicians will retain their role and continue to treat and monitor patients with mental health conditions in these practices. Other than that, the research team will provide no support to the PCP or practice staff. However, an addiction psychiatrist is available for consultation for OUD. Patients are informed that the primary care practice provides both OUD and mental health treatment and are referred back to their provider for referral or to schedule care. A list of available community resources are available to the patient.
89498900|NCT04245423|Experimental|Collaborative Care (CC)|"CC condition includes the following elements:~Personnel trained to assist with scheduling, reminders and referrals;~PCP trained and waivered to provide evidence-based pharmacotherapy for OUD;~Addictions psychiatrist with collaborative care expertise to provide treatment consultation and supervision in both OUD and mental health issues;~A care manager trained in evidence-based interventions for individuals with OUD and psychiatric disorders, who provides care in the primary care practice as part of the collaborative care team;~Measurement-guided care and treat-to-target practices, using validated measures of substance use, depression, anxiety as well as measures of adherence and side effects;~Electronic and in-person systematic communication regarding patient care among team members, facilitated by the electronic health record; and~Shared patient-provider decision making."
89498901|NCT04245423|Experimental|Collaborative Care + Certified Recovery Specialist (CC+)|In addition to the collaborative care model described above, patients in the CC+ condition will have access to a Certified Recovery Specialist (CRS) to assist with treatment engagement and retention. A CRS is a person in the community who is in recovery and may share similar experiences and barriers that participants have faced. They will work with participants as a peer to help them coordinate information and needs with their providers. The CRS will take participants to their PCP appointments and any other appointments that they may have to help them engage and stay in care to remain healthy. They will also provide education and help participants work on their recovery goals. They will identify and support linkages to community resources and help participants identify barriers to full participation in their recovery and develop strategies to overcome those barriers.
89498902|NCT04227717||Thoracic, lumbar and sacral spine lesions|Participants will have thoracic, lumbar and sacral spine lesions
89498903|NCT04226690|Experimental|Active Dose 1|Participants will receive the most tolerable CBD/THC dose with repeated dosing for 7 days. On day 1 and 6/7 of the 7-day dosing, subjects will complete laboratory sessions.
89498904|NCT04226690|Placebo Comparator|Matching Placebo|Participants will receive a placebo with repeated dosing for 7 days. On day 1 and 6/7 of the 7-day dosing, subjects will complete laboratory sessions.
89498905|NCT04226690|Experimental|Active Dose 2|Participants will receive the second most tolerable CBD/THC dose with repeated dosing for 7 days. On day 1 and 6/7 of the 7-day dosing, subjects will complete laboratory sessions
89498906|NCT04221477|Experimental|Obinutuzumab|"Participants will be randomized into 2 groups. Group 1 will receive obinutuzumab 1000 mg IV at baseline and Weeks 2, 24, 26, 50, and 52 plus MMF and oral prednisone. Group 2 receive obinutuzumab 1000 mg IV at baseline and Weeks 2, 24, 26, and 52 plus MMF and oral prednisone. Group 2 participants will receive a placebo infusion at their Week 50 visit.~Participants with an adequate response at Week 76 will continue receiving blinded obinutuzumab infusions every 6 months starting at Week 80.~Participants without an adequate response at Week 76 may be eligible for open-label obinutuzumab starting at Week 80."
89498907|NCT04221477|Placebo Comparator|Placebo|"Placebo participants will receive obinutuzumab matched placebo at baseline and Weeks 2, 24, 26, 50, and 52 plus MMF and oral prednisone.~Participants with an adequate response at Week 76 will continue receiving blinded obinutuzumab infusions every 6 months starting at Week 80.~Participants without an adequate response at Week 76 may be eligible for open-label obinutuzumab starting at Week 80."
89498908|NCT04221178||MRD-Negative Participants|
89498909|NCT04219670||Patient Group|Individuals diagnosed with stroke admitted to the Shirley Ryan AbilityLab (inpatient), or individuals in the community who had a stroke (chronic)
89498910|NCT04219670||Healthy Control Group|Individuals without any known significant health problems
89498911|NCT04183205|Placebo Comparator|Placebo only arm|For individuals who are placebo responders during the 2 week placebo lead in phase, they will remain on placebo for the duration of the study (i.e., the 12 weeks where the placebo non-responders are taking sertraline).
89498912|NCT04183205|Active Comparator|Sertraline arm|After the 2-week placebo lead-in phase, placebo-non responders will receive sertraline 25 mg daily for 2 weeks. Thereafter, sertraline will be increased flexibly by 25 to 50 mg per day (at a rate no higher than 50 mg per week) to achieve a total daily dose of 50 to 200 mg, based on clinical response and tolerability, with a maximum dose of 200 mg/d. Subjects unable to tolerate higher doses may be dropped back to the previous dose and remain at that dose for the remainder of the study.
89023165|NCT05930093|Active Comparator|4 cap.LivPhcD/per day|515mg/LivPhcD cap. 4 cap./per day, BID
89023166|NCT05930093|Active Comparator|6 cap.LivPhcD/per day|515mg/LivPhcD cap. 6 cap./per day, TID
89498913|NCT04157686|Experimental|Placebo/MT10109L Dose 1|The participant pool in this arm are from the MT10109L-001 lead-in study, who received Placebo in period 1 and MT10109L Dose 1 in period 2. Eligible participants from this study continue receiving Dose 1 in the open-label MT10109L-004 study
89498914|NCT04157686|Experimental|Placebo/MT10109L Dose 2|The participant pool in this arm are from the MT10109L-002 lead-in study, who received Placebo in period 1 and MT10109L Dose 2 in period 2. Eligible participants from this study continue receiving Dose 2 in the open-label MT10109L-004 study.
89023167|NCT05929885|Experimental|Low Dose OXIRI (LD-OXIRI)|Low Dose OXIRI (LD-OXIRI) regimen comprises Metronomic Oxaliplatin (O) and Metronomic Capecitabine (xeloda; X) in combination with UGT1A1-directed dosing of Irinotecan (IRI).
89498915|NCT04157686|Experimental|Placebo/MT10109L Dose 1 + Dose 2|The participant pool in this arm are from the MT10109L-005 and MT10109L-006 lead-in studies, who received Placebo in periods 1 & 2. Eligible participants from this study receives Dose 1 into the GL area and Dose 2 into the LCL area in the open-label MT10109L-004 study.
89498916|NCT04157686|Experimental|MT10109L Dose 1/Dose 1|The participant pool in this arm are from the MT10109L-001 lead-in study, who received MT10109L Dose 1 each in period 1 and period 2. Eligible participants from this study continue receiving Dose 1 in the open-label MT10109L-004 study.
89498917|NCT04157686|Experimental|MT10109L Dose 2/Dose 2|The participant pool in this arm are from the MT10109L-002 lead-in study, who received MT10109L Dose 2 each in period 1 and period 2. Eligible participants from this study continue receiving Dose 2 in the open-label MT10109L-004 study.
89498918|NCT04157686|Experimental|MT10109L Dose 1/Dose 1+2|The participant pool in this arm are from the from MT10109L-005 lead-in study, who received MT10109L Dose 1 in periods 1 and 2. Eligible participants from this study receives Dose 1 into the GL area and Dose 2 into the LCL area in the open-label MT10109L-004 study.
89498919|NCT04157686|Experimental|MT10109L Dose 2/Dose 1+2|The participant pool in this arm are from the MT10109L-006 lead-in study, who received MT10109L Dose 2 in periods 1 and 2. Eligible participants from this study receives Dose 1 into the GL area and Dose 2 into the LCL area in the open-label MT10109L-004 study.
89498920|NCT04157686|Experimental|MT10109L Dose 1+2/Dose 1+2|The participant pool in this arm are from the MT10109L-005 and MT10109L-006 lead-in studies, who received MT10109L Dose 1 into GL and Dose 2 into LCL in periods 1 & 2. Eligible participants from this study receives Dose 1 into the GL area and Dose 2 into the LCL area in the open-label MT10109L-004 study.
89498921|NCT04156620|Experimental|Secukinumab|Secukinumab intravenous (i.v.) regimen
89498922|NCT04156620|Placebo Comparator|Placebo|Placebo intravenous (i.v.) regimen
89498923|NCT04146714|Experimental|Substance use screening|Participants complete a substance use questionnaire (=intervention).
89498924|NCT04146714|Active Comparator|Physical activity screening|Participants complete a physical activity questionnaire (=control).
89498925|NCT04138706|Placebo Comparator|Control: Placebo|Following a 14-day initial vancomycin treatment (125mg QID x14 days), the participant will receive a placebo for an additional 14 days (twice a day x 7 days, then once a day for 7 days).
89498926|NCT04138706|Active Comparator|Intervention: Extended vancomycin regimen|Following a 14-day initial vancomycin treatment (125mg QID x14 days), the participant will receive active vancomycin for an additional 14 days (125mg twice a day x 7 days, then 125mg once a day for 7 days).
89498927|NCT04136171|Experimental|Eplontersen|Eplontersen by subcutaneous injection once every 4 weeks
89498928|NCT04136171|Placebo Comparator|Placebo|Eplontersen-matching placebo by subcutaneous injection once every 4 weeks
89498929|NCT04102774|Experimental|myAIRVO2|Patients will receive a myAIRVO2 at home over-night with humidifier on top of standard therapy for bronchiectasis according to international guidelines (ERS 2017).
89498930|NCT04102774|No Intervention|Control|Patients will receive standard therapy for bronchiectasis according to international guidelines (ERS 2017).
89498931|NCT04098718|Other|PO open label prednisolone (in low blood eosinophils)|Standard care Prednisolone 30mg given daily for 5 days to treat an exacerbation.
89498932|NCT04098718|Experimental|Benralizumab SC + PO placebo|Benralizumab as a single 100mg sub cut injection and oral placebo tablet daily for 5 days
89498933|NCT04098718|Experimental|Benralizumab SC + PO prednisolone|Benralizumab as a single 100mg sub cut injection and oral prednisolone 30mg daily for 5 days
89498934|NCT04098718|Active Comparator|Placebo SC + PO prednisolone|Placebo sub cut injection and oral prednisolone 30mg daily for 5 days.
89498935|NCT04081246|Experimental|Modified en bloc resection|For patients undergoing modified en bloc resection, piecemeal resection of the exophytic part of the bladder tumour will be performed, followed by en bloc resection of the tumour base.
89498936|NCT04060082||Persons Diagnosed|Individuals with a diagnosis of bvFTD.
89498937|NCT04060082||Persons At Risk|Individuals with a known genetic risk factor for bvFTD: people with genetic testing that identified a disease-causing change in a gene that is known to cause bvFTD, such as in C9ORF72, MAPT, GRN, VCP, TARDBP, CHMP2B, or another gene that has been identified as causing FTD in the family
89498938|NCT04043689|Active Comparator|tACS stimulation of the right frontal region|Active tACS stimulation of the right frontal region (around the right FEF, EEG electrode FC2) at a high-beta frequency (30 Hz) with the goal of visibly training EEG recordings, frontal oscillatory activity and right fronto-parietal synchrony (FEF-IPS, or between FC2 and P4 electrodes) in the high-beta band (~ 30 Hz) which facilitates attentional orientation and visual perception in the two visual hemi-fields, but more particularly the targets present on the blind field of vision.
89498939|NCT04043689|Active Comparator|tACS stimulation of the occipito-parietal region|Active tACS stimulation of the occipito-parietal posterior contralesional region(around the right IPS, EEG electrode P4), at an alpha frequency (10 Hz) which will induce on the EEG recordings an oscillatory drive in the alpha band ( ~ 10Hz) and an increase in synchrony at this frequency band on the stimulated posterior occipital and parietal lobe (EEG electrodes P4 and 02), but also, by transcallosal push-and-pull phenomena, a desynchronization effect of the contralateral posterior occipital and parietal area (EEG electrodes P3 and 01), which will facilitate attention orientation and target detection in the blind visual field of view.
89023168|NCT05929378|Experimental|3-point fixation group|Lightweight Mesh Fixation with 3-point Fixation. First fixation is in cooper ligament. Second fixation is in the back of rectus abdominis. Third fixation is in the later of tractus iliopubicus.
89498940|NCT04043689|Sham Comparator|TACS stimulation of the right frontal (FEF)|. Condition TACS stimulation of the right frontal (FEF) at a high-beta frequency (30 Hz) for half of the patients and unilateral occipital cortex (right / left) at an alfa frequency (10 Hz) for the other half . This condition will control the possible placebo effects of tACS stimulation and the potential effects of visual field enhancement with repetition of perimetry tests. This condition will also verify the lack of changes in cerebral rhythm activity in the case of an application without effective electrical current.
89498941|NCT04024696|Experimental|Dosing Cohorts|Three (3) dose cohorts are pre-set to include 40 mg BID, 60 mg BID and 80 mg BID,respectively.The pre-set dose group is subject to change during the study and the actual dosage increment is determined by the Data safety Monitoring Committee (DSMC).
89498942|NCT04020978|Other|Patients with GUC|Each patient with GUC will first undergo an X-ray CT scan for attenuation correction purpose. After that, 10 mCi 18F-Fludeoxyglucose (18F-FDG) will be injected into the patient through the IV in a period of 10 seconds. The PET scan commences 10 seconds before the FDG injection and lasts for 60 minutes. After the PET scan, the patient gets off the scanner. One blood sample (10cc) will be drawn using a butterfly method with the time recorded.
89498943|NCT04018456|Experimental|Biodentine|Intervention group: application of biodentine as pulp space barrier during regenerative endodontic treatment.
89498944|NCT04018456|Active Comparator|White MTA|Control group: application of White MTA as pulp space barrier during regenerative endodontic treatment.
89498945|NCT04018053|Experimental|18F-fluciclovine|"18F-fluciclovine will be administered via slow push over 10 seconds through a peripheral intravenous line~Immediately after the injection of the radiopharmaceutical, dynamic PET/CT images of the pelvis will be obtained for 15 minutes~Subsequently, PET/CT images will be obtained from the pelvis to the base of skull."
89498946|NCT04010786|Experimental|Active treatment NNC0247-0829|Up to 6 single dose cohorts are planned with 10 subjects in each; 8 will receive active treatment. Up to 2 multiple dose cohorts are planned with 12 subjects in each; 8 will receive active treatment
89498947|NCT04010786|Placebo Comparator|Placebo|In each of the 6 single dose cohorts, 2 subjects will receive placebo. In the 2 multiple dose cohorts, 4 subjects will receive placebo
89498948|NCT03994029|Experimental|Polyphenol supplementation|120mg per day of powder polyphenol for 60 days
89498949|NCT03994029|Placebo Comparator|Placebo|1 tab PO QD per day of placebo for 60 days
89498950|NCT03950336|Other|"Prebiotics + Low n-6 PUFA Diet"|A combination of beta-fructans (12g/day) and a diet with reduced intake of n-6 PUFAs and higher intake of n-3 PUFAs.
89498951|NCT03950336|Other|"Placebo + Control Diet."|A combination of maltodextrin (5g/day) and a control diet following the guidelines of Canada's Food Guide.
89498952|NCT03945240|Experimental|Group 1 (Pinnacle, lower dosimetry parameters)|Utilize the Pinnacle Series Laser by Aspen Laser Systems to apply LLLT
89498953|NCT03945240|Experimental|Group 2 (Pinnacle, higher dosimetry parameters)|Utilize the Pinnacle Series Laser by Aspen Laser Systems to apply LLLT
89498954|NCT03945240|Experimental|Group 3 (Phoenix)|Utilizing the Phoenix Thera-Lase by Phoenix Thera-Lase Systems, we will apply LLT.
89498955|NCT03940352|Experimental|treatment arm1: HDM201+MBG453|Phase Ib (escalation)
89498956|NCT03940352|Experimental|treatment arm2: HDM201+venetoclax|Phase Ib (escalation)
89498957|NCT03938415|Experimental|Acupuncture|Acupuncture
88955770|NCT06214559|Experimental|Serum VERRUPRO|To be applied twice a day
89498958|NCT03938415|Active Comparator|Standardized pre-procedure medications|The clinic standardized pre-procedure medications alone
89498959|NCT03936153|Experimental|Abexinostat 80 mg bis in die (BID)|Abexinostat 80 mg BID
89498960|NCT03935750|Experimental|BPTB + LET|Patients will undergo anterior cruciate ligament reconstruction (ACLR) using a bone patellar bone tendon (BPTB) autograft with lateral extra-articular tenodesis (LET).
89498961|NCT03935750|Active Comparator|BPTB alone|Patients will undergo ACLR using a BPTB autograft without LET.
88955771|NCT06213090||Autism|Children with autism will be followed in regards to their clinical management.
88955772|NCT06213090||Mitochondrial Encephalopathy|Children with Mitochondrial Encephalopathy will be followed in regards to their clinical management.
88955773|NCT06213090||Down Syndrome|Children with Down Syndrome will be followed in regards to their clinical management.
88955774|NCT06213090||Cerebral Folate Deficiency|Children with Cerebral Folate Deficiency will be followed in regards to their clinical management.
88955775|NCT06213090||PANS|Children with PANS will be followed in regards to their clinical management.
88955776|NCT06213090||PANDAS|Children with PANDAS will be followed in regards to their clinical management.
88955777|NCT06213090||Epilepsy|Children with Epilepsy will be followed in regards to their clinical management.
89498962|NCT03935750|Experimental|QT + LET|Patients will undergo ACLR using a quadriceps tendon (QT) autograft with LET.
89498963|NCT03935750|Active Comparator|QT alone|Patients will undergo ACLR using a QT autograft without LET.
89023169|NCT05929378|Active Comparator|1-point fixation group|Lightweight Mesh Fixation with 1-point Fixation in the back of rectus abdominis.
89023170|NCT05918978|Experimental|Efgartigimod|Receive efgartigimod IV 10mg/kg infusions during a treatment period of 48 weeks
89498964|NCT03934567|Experimental|Abexinostat 80 mg bis in die (BID)|Experimental: Abexinostat 80 mg BID
89498965|NCT03931941|Experimental|Active|RBX2660 is an enema of a microbiota suspension
89498966|NCT03893929||Chinese patients with clinical suspicious of prostate cancer|To identify potential new blood and urine markers for the diagnosis, risk stratification and prognosis prediction for prostate cancer in Chinese population.
89498967|NCT03880435|Experimental|Hyalobarrier® gel endo|Application of Hyalobarrier® gel endo immediate after the complete hysteroscopic removal of the polyp, myoma, adhesion, uterine septum or retained products of conception + application of sterile ultrasound gel into the vagina (to blind all trial participants, fertility physicians and gynaecologists doing second-look hysteroscopy)
89498968|NCT03880435|No Intervention|No Hyalobarrier® gel endo|No application of Hyalobarrier® gel endo after the hysteroscopic removal of the polyp, myoma, adhesion, uterine septum or retained products of conception + application of sterile ultrasound gel into the vagina (to blind all trial participants, fertility physicians and gynaecologists doing second- or third-look hysteroscopy)
89205573|NCT04802590|Experimental|Arm B|Ibrutinib + Venetoclax (+CD20Ab)
89205574|NCT04797260|Experimental|Gene therapy|In this arm, 10 patients will be included for gene therarpy
89205575|NCT04776993|Experimental|Methimazole|Antithyroid drugs (at individualized dosage) for 72 weeks and a cumulative dose of 4.5 g of methylprednisolone divided into 12 weekly infusions
89498969|NCT03877809|Experimental|Open label trial|Sirolimus 0.5 mg tablets
89498970|NCT03862781|Other|Intra-corporeal|Right Hemicolectomy
89498971|NCT03862781|Other|Extra-corporeal|Right Hemicolectomy
89498972|NCT03834688|Experimental|Induction|Venetoclax, bendamustine and rituximab as induction therapy for 6 cycles of 28 days.
89498973|NCT03808961|Active Comparator|Group 1 ? Niacin Arm|Oral 100 mg fixed dose twice daily x 18-months (200 mg total / day) with assessments @ baseline, 6 month, 12 month and 18 months
89498974|NCT03808961|Active Comparator|Group 2 ? Niacinamide Arm|Oral 100 mg fixed dose twice daily (200 mg total / day) x 18-months with assessments @ baseline, 6 month, 12 month and 18 months
89498975|NCT03808961|Placebo Comparator|Group 3 ? Placebo Wait-listed Arm|Oral placebo twice daily x 18- months with assessments @ baseline, 6 month, 12 month and 18 months
89498976|NCT03765736||Screening (genetic testing)|Patients submit blood samples for genetic testing.
89498977|NCT03760406|Experimental|Severe essential tremor treated by DBS|
89498978|NCT03740724|Experimental|FCX-013 + veledimex|Following the injection of FCX-013, subjects will initiate a 14-day course of veledimex to be taken orally daily
89205576|NCT04776993|Active Comparator|Thyroid ablation|Radioiodine therapy or total thyroidectomy (according to ultrasound thyroid volume) and a cumulative dose of 4.5 g of methylprednisolone divided into 12 weekly infusions
89205577|NCT04771663|Experimental|Hypoxic|In this phase, participants inhale the hypoxic mixture for five minutes.
89205578|NCT04771663|Experimental|Hypoxic and Hypercapnic|In this phase, participants inhale the hypoxic and hypercapnic mixture for five minutes.
89498979|NCT03716245|Experimental|supraclavicular lymph node dissection and raidiotherapy|breast cancer patients with supraclavicular lymph node metastasis receive supraclavicular lymph node dissection and supraclavicular area radiotherapy
89205579|NCT04766138|Experimental|Fecobionics studies|Single-arm study
89205580|NCT04753658||Pediatric Neuroblastoma Patients Treated with Lorlatinib|
89205581|NCT04752891|Experimental|AOM diagnosis with app|
89498980|NCT03716245|Active Comparator|supraclavicular area radiotherapy|breast cancer patients with supraclavicular lymph node metastasis receive supraclavicular area radiotherapy
89498981|NCT03704818|Experimental|Dapagliflozin 5mg|
89498982|NCT03704818|Experimental|Placebo|
89498983|NCT03703778||bilateral orchidectomy|Patients with advanced prostate cancer who receive surgical androgen deprivation therapy - bilateral orchidectomy
89498984|NCT03703778||GnRH agonist|Patients with advanced prostate cancer who receive medical androgen deprivation therapy - GnRH agonist
89498985|NCT03703778||GnRH antagonist|Patients with advanced prostate cancer who receive medical androgen deprivation therapy - GnRH antagonist
89498986|NCT03640208|Experimental|Complete colorectal screening|11 step process divided into three phases: 1. Community Outreach Event; 2. Data Collection; 3. Navigation and Program Monitoring
89538258|NCT03281447|Experimental|Nurse navigation|Coherent navigation and support from a family-centred viewpoint throughout the cancer trajectory, despite the individual patient's affiliation to any department.
89538259|NCT03281447|Active Comparator|Current care coordination|Department-specific coordination and answers to questions from a patient-centred viewpoint.
89538260|NCT02444611|Active Comparator|Group 1|BCG vaccine, 0,05ml intradermally at birth
89023171|NCT05918029|Experimental|Potassium Citrate|Potassium Citrate extended-release tablets 30 mEq twice daily (1 mEq/kg/day divided into two doses for children to a maximum dose of 30 mEq twice daily).
89023172|NCT05918029|Placebo Comparator|Placebo|Placebo capsules identical to the active capsules.
89023173|NCT05917548|Experimental|Tele-education|The tele-education group will receive the same intervention as the comparison group with an educational reinforcement mediated by teledentistry. This intervention consists of 4 educational videos, designed for the elderly, promoting correct toothbrushing and flossing, detection, and prevention of dental caries, periodontal disease, and oral cancer. These four videos were sent via WhatsApp.
89538261|NCT02444611|Active Comparator|Group 2|BCG vaccine, 0,05ml intradermally at birth Hepatitis B vaccine, 5 micrograms, intramuscularly at birth
89023174|NCT05917548|Active Comparator|Comparison|The comparison group receive a medical-dental-geriatric diagnosis and face-to-face standardized education via powerpoint presentation and use of dental models for the promotion of correct toothbrushing and flossing, detection, and prevention of dental caries, periodontal disease, and oral cancer.
89023175|NCT05908383|Experimental|GMDTC for injection|The subjects assigned to the treatment group will receive once medication at 8:00 am on the second day after admission.
89023176|NCT05908383|Placebo Comparator|Normal saline group|The subjects assigned to the placebo group will receive once medication at 8:00 am on the second day after admission.
89023177|NCT05901909|No Intervention|stroke home care patient|Before applying the education program based on the Precede-Proceed Model to 70 individuals who care for stroke home care patients, the evaluation of the patients will be made with home visits. After the training is given to the caregivers, the first evaluation will be made at the 8th week in order to determine the change in patient results after the training is completed. In the 16th week after the completion of the training, a final evaluation will be made with home visits to determine the change in patient results.
89023178|NCT05901909|Experimental|Individuals caring for stroke home care patients|Before the training program based on the Precede-Proceed Model is applied to the 70 individuals who care for stroke home care patients, the evaluation of the caregivers will be made in the hospital meeting room. After the training is given to the caregivers, the first evaluation will be made at the 8th week in order to determine the changes in their caregiving reactions and social support perceptions after the training is completed. In the 16th week after the completion of the training, a final evaluation will be made in the hospital meeting room in order to determine the changes in caregiver reactions and social support perceptions.
89023179|NCT05896592|Experimental|Group 1|Group 1 will undergo EPS, ECVS, CNA with continuation of PM therapy and ILR implantation. Two months later pacing rate, will be assessed. In addition, there will be a non-invasive assessment of the effectiveness of CNA. After another month, EPS and ECVS will be performed and a re-CNA if the ECVS does not show full parasympathetic denervation of the heart. The pacemaker will be set to VVI or AAI 30/min. One month after the second invasive procedure, the pacing rate will be assessed. Patients with zero percentage of PM stimulation will be set to ODO/OVO/OAO-stimulation off mode. Patients will be monitored for the next 12 months. During the next 4 visits repeated every 3 months, patients in this group will undergo non-invasive assessment of the effectiveness of CNA and symptoms of bradycardia. At the 7th visit, patients in this group will be qualified to discontinue of the cardiac pacing treatment, with possible qualification for TLE.
89023180|NCT05896592|Experimental|Group 2|Group 2 will undergo EPS and ECVS with continuation of PM therapy, ILR implantation, without CNA. Two months later pacing rate, will be assessed. After another month, EPS, ECVS and CNA will be made. The pacemaker will be set to VVI or AAI 30/min. One month after the second invasive procedure, patients in this group will have their pacing rate assessed. Patients with zero percentage of PM stimulation will be set to ODO/OVO/OAO-stimulation off mode. Patients will be monitored for the next 12 months. During next 4 visits repeated every 3 months, patients in this group will undergo a non-invasive assessment of the effectiveness of CNA and symptoms of bradycardia. At the 7th visit, the qualification for discontinuation of cardiac pacing treatment will take place, with possible qualification for TLE.
89023181|NCT05896592|Active Comparator|Group 3|Group 3 patients will only be observed for the duration of the study. The observation period will be 18 months. At subsequent visits 1, 3, 4, 6, 9, 12, 15 months after randomization, they will be assessed for the presence of MAS, paraMAS and assessment of the percentage of stimulation.
89538262|NCT02444611|Active Comparator|Group 3|Hepatitis B vaccine, 5 micrograms, intramuscularly at birth
89538263|NCT02444611|No Intervention|Group 4|No birth vaccines
89023182|NCT05893940|Experimental|LIMS vibration Therapy, DEXA Scan - Cohort 1|Patients undergo LIMS vibration therapy over 10 minutes on study. Patients also undergo DEXA scan at follow up and may optionally undergo blood sample collection and questionnaire at baseline and follow up
89023183|NCT05893940|Experimental|LIMS vibration therapy - Cohort II|Patients undergo LIMS vibration therapy over 10-minutes BID for 14 days on study. Patients also undergo blood sample collection throughout the trial.
89023184|NCT05893758||PFO subjects|Patients with a confirmed diagnosis of Patent Foramen Ovale (PFO) which is associated with TIA or cryptogenic stroke, and implanted with the investigational device.
89538264|NCT03545477|Experimental|Novel treatment, curved-walking training|It consists of 20 sessions of training (three times a week for seven weeks) composed by standard physical therapy and a novel approach to locomotion rehabilitation based on curved-walking training. Each session lasts about 90 minutes.
89538265|NCT03545477|Active Comparator|Usual care|It consists of 20 sessions of training (three times a week for seven weeks) of standard physical therapy and conventional straight-walking training. Each session lasts about 90 minutes.
89538266|NCT02438917||Hepatitis C|Patients who are about to begin HCV treatment
89538267|NCT03281213||Female|
89538268|NCT03281213||Male|
89538269|NCT02438761|Experimental|PF-05212384|150 mg Intra-venous every week
89538270|NCT03536429|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
89538271|NCT03536429|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
89538272|NCT02438683|Placebo Comparator|1 Placebo|2 x single doses (1x resting conditions, 1 x exercise conditions)
89538273|NCT02438683|Experimental|2 BI 409306|2 x single doses (1 x resting conditions, 1 x exercise conditions)
89538274|NCT02438683|Experimental|3 BI 409306|2 x single doses (1 x resting conditions, 1 x exercise conditions)
89023185|NCT05872282|Experimental|ZIPPER aortic arch stentgraft system|
89023186|NCT05868629||dabrafenib plus trametinib|patients treated with dabrafenib and trametinib
89023187|NCT05864560||AAA Subjects|Patient diagnosed with Abdominal Aortic Aneurysm, who needs endovascular aortic repair.
89023188|NCT05859477|Experimental|Nivolumab in combination with chemotherapy|Nivolumab 360 mg with CAPOX (capecitabine and oxaliplatin) every 3 weeks
89023189|NCT05857397||Patients treated within the EAPs with niraparib for ovarian cancer|This is an observational study; patients will not be exposed to clinical interventions different from those belonging to the standard of care.
89023190|NCT05855200|Experimental|Dostarlimab|Participants will receive Dostarlimab pre and post surgery
89023191|NCT05855200|Active Comparator|Standard of Care (SOC)|Participants will receive SOC (FOLFOX/CAPEOX) or undergo expectant observation post surgery.
89023192|NCT05851924|Experimental|NALIRIFOX + AD-XRT and capecitabine|Patients will receive neoadjuvant chemotherapy for 4 months. Patients will undergo a CT scan at 8 weeks and 16 weeks after the start of neoadjuvant chemotherapy to assess treatment response. Patients without disease progression will then undergo AD-XRT for 15 to 25 fractions (3 to 5 weeks). Patient's whose disease is deemed resectable based on their re-evaluating imaging, will be recommended surgical intervention with consideration for laparotomy or laparoscopy if deemed appropriate at multidiscplinary cancer conference review.
89023193|NCT05851183|Active Comparator|Therapeutic lifestyle change|Therapeutic lifestyle change only
89538275|NCT02444455|Experimental|UCMSC group|Human umbilical cord MSCs are administrated to patients by intravenous infusion
89023194|NCT05851183|Experimental|Therapeutic lifestyle change plus Vitis Vinifera extract therapy|Therapeutic lifestyle change plus Vitis Vinifera extract medication therapy
89205582|NCT04752891|Other|AOM diagnosis without app|
89538276|NCT03281135|Other|HPV testing|This is an experimental arm for the primary outcome, 'adherence to the procedures'. In this group self sampling will be done using the Evalyn brush for HPV testing.
89538277|NCT03281135|No Intervention|Standard care: VIA screening|Control Arm, in which women's are invited to cervical cancer screening as per standard Ethiopian cervical cancer prevention and control guideline. Uptake of screening in this group will be compared with the HPV testing arm group to test for significant differences in adherence.
89538278|NCT03193645||Degarelix|
89538279|NCT03280979|Experimental|study group1|In the rescue regimen , we administer MTX in an eight-day treatment regimen consisting of four administrations of MTX given at 1 mg/kg I.M. every other day with folinic acid 0.1 mg/kg I.M,. given on intervening days.
89538280|NCT03280979|Experimental|study group2|In the high dose MTX protocol, the patients will receive 100 mg/m2 intravenous (IV) MTX bolus followed by 200 mg/m2IV MTX infused over 12 hours followed by folinic acid
89538281|NCT02714153|Experimental|Bridge Occlusion Balloon|Bridge Balloon catheter is designed to be used for temporary vessel occlusion of the superior vena cava in applications including perioperative occlusion and emergency control of hemorrhage associated with vascular tears that may occur during lead extraction procedures.
89538282|NCT02438527|Experimental|Chest Compressions Only|"After recruitment and consenting, volunteers in the chest compressions only arm will receive a chart with a description of Basic Life Support without mouth to mouth ventilations. The participants will be asked to perform Cardiopulmonary Resuscitation according to the chart for a period of 5minutes on a manikin in a simulated cardiac arrest scenario."
89538283|NCT02438527|Experimental|Standard CPR|"After recruitment and consenting, volunteers in the standard CPR arm will receive a chart with a description of Basic Life Support. The participants will be asked to perform Cardiopulmonary Resuscitation according to the chart (including the initial check, chest compressions and mouth to mouth ventilations) for a period of 5minutes on a manikin in a simulated cardiac arrest scenario."
89538284|NCT03192085|Other|SITA FAST then SITA STANDARD|SITA FAST and SITA STANDARD
89538285|NCT03192085|Active Comparator|SITA STANDARD then SITA FAST|SITA FAST and SITA STANDARD
89538286|NCT03280901|Experimental|Standard HD|HD with constant temperature of 37°C, MRI scans of the heart, kidneys and brain during HD sessions
89538287|NCT03280901|Experimental|Thermocontrolled HD|HD applying the Blood Temperature Monitor (BTM), MRI scans of the heart, kidneys and brain during HD sessions
89538288|NCT03270839|Active Comparator|Responsive to Scopolamine (Active)|Scopolamine administration - subject will take 1 tablet per os (Kwells, Hyoscine Hydrobromide 0.3mg, 1*day )
89538289|NCT03270839|Placebo Comparator|Responsive to Scopolamine (Placebo)|Placebo administration - subject will take 1 tablet per os (Placebo Oral Tablet, no active substance in the tablet)
89538290|NCT03270839|Active Comparator|Non-responsive to Scopolamine (Active)|Scopolamine administration - subject will take 1 tablet per os (Kwells, Hyoscine Hydrobromide 0.3mg, 1*day )
89538291|NCT03270839|Placebo Comparator|Non-responsive to Scopolamine (Placebo)|Placebo administration - subject will take 1 tablet per os (Placebo Oral Tablet, no active substance in the tablet)
89538292|NCT03270839|Active Comparator|Responsive to Meclizine (Active)|Meclizine administration - subject will take 1 tablet per os (Bonine 25Mg Chewable Tablet, Meclizine Hydrochloride 25mg, 1*day )
89538293|NCT03270839|Placebo Comparator|Responsive to Meclizine (Placebo)|Placebo administration - subject will take 1 tablet per os (Placebo Oral Tablet, no active substance in the tablet)
89538294|NCT03270839|Active Comparator|Non-responsive to Meclizine (Active)|Meclizine administration - subject will take 1 tablet per os (Bonine 25Mg Chewable Tablet, Meclizine Hydrochloride 25mg, 1*day )
89538295|NCT03270839|Placebo Comparator|Non-responsive to Meclizine (Placebo)|Placebo administration - subject will take 1 tablet per os (Placebo Oral Tablet, no active substance in the tablet)
89538296|NCT02458547|Experimental|Group D|General anesthesia with desflurane
89538297|NCT02458547|Active Comparator|Group P|General anesthesia with propofol total intravenous anesthesia
89538298|NCT02458547|Active Comparator|Group S|Spinal anesthesia with 0.5% bupivacaine
89023195|NCT05844267|Experimental|Booster Breaks group (led breaks)|Participants will engage in active breaks led by a professional, where they will perform various exercises based on the guidelines provided by the Chilean safety association (ACHS). These breaks will have an average duration of 14-16 minutes per day and will take place from Monday to Friday for a period of 12 weeks.
89538299|NCT02459561|Experimental|EndoBarrier Arm|The EndoBarrier Gastrointestinal Liner device received CE Mark for 12 months implant duration on 11 December 2009 and is a single use, minimally invasive device, used to achieve weight loss and improve Type 2 Diabetes status in subjects who are obese. The intent of the EndoBarrier Gastrointestinal Liner is to mimic portions of the standard Roux-en-Y bypass procedure. The device consists of 3 components: the implant, the delivery system, and the removal system. At study visit 4, after eight hours fasting, 80 subjects will arrive to the pre- assessment unit as part of the theatres at St. Mary's Hospital or Southampton Hospital and receive the EndoBarrier TM Gastrointestinal Liner as part of the EndoBarrier Arm Intervention.
89023196|NCT05844267|Experimental|Computer Prompts group (unled breaks)|"Active breaks will be guided by an application called Ponte de Pie por tu Salud, designed by the Chilean Ministry of Health which will be installed on the participants' computers. The application will be configured to generate breaks every hour for a duration of 2 minutes for 8 hours, ensuring that an average of 14-16 minutes of active breaks are accumulated throughout the day."
89023197|NCT05844267|No Intervention|Control|The group will participate in evaluations pre-post but not interventions. We will recommend continuing with their usual routine.
89023198|NCT05841290|Experimental|Group (1) Resin Based Sealer intervention|evaluate the incidence and intensity of post-operative pain after obturation using resin based sealers.
89023199|NCT05841290|Experimental|Group (2) Silicone Based Sealer intervention|evaluate the incidence and intensity of post-operative pain after obturation using sillicon based sealers.
89538300|NCT02459561|Other|Medical Therapy Arm|"The standard medical therapy arm will be carried out in accordance with the guidelines of the American Diabetes Association. These guidelines have been chosen as they are applicable to an International audience and thus would adhere to the current best worldwide practice that would still be likely to be relevant when the results are published following study completion.~Diabetes reviews appointments with a Diabetologist/Endocrinologist will be performed with the control arm patients at visits 2, 4, 6, 7, 9, 11, 12, 13 and 15.~At study visit 4, 80 subjects will arrive at Mary's Hospital or Southampton Hospital and receive the best Medical Care and dietary advice as part of the Medical Therapy Arm Interventions."
89498987|NCT03637543|Experimental|PD-L1 Positive|-Nivolumab will be given on day 1 of a 28-day cycle intravenously
89498988|NCT03637543|Experimental|PD-L1 Negative|-Nivolumab will be given on day 1 of a 28-day cycle intravenously
89498989|NCT03621189|Active Comparator|Active-Active|"Participants received the real intervention of TBS (iTBS 1200) over the posterior superior temporal sulcus for 8 weeks (2 days/week).~*iTBS = intermittent theta burst stimulation"
89498990|NCT03621189|Sham Comparator|Sham-Active|"Participants received the sham intervention of TBS (coil tilted one-wing 90° off the head) over the posterior superior temporal sulcus for 4 weeks (2 days/week) and then received the real intervention of TBS (iTBS 1200) over the posterior superior temporal sulcus for 4 weeks (2 days/week).~*iTBS = intermittent theta burst stimulation"
89498991|NCT03616860|Experimental|Focused Ultrasound (FUS) BBB Disruption|The Exablate Model 4000 Type 2 system is intended for use as a tool to induce localized and temporary blood-brain barrier disruption in patients with glioblastoma undergoing standard of care chemotherapy.
89498992|NCT03604302|Experimental|Functional Magnetic Resonance Imaging (fMRI)|The interventions for this study are non-invasive. For patients, routine pre-operative MRI that includes task based fMRI and perfusion data acquisition will be performed on a 3T scanner. Patients who participate in this study, will have approximately 5 minutes added to their scan time for the below described breath holding fMRI (BH fMRI) paradigm, which will be done for research purposes. For healthy volunteers, participation will involve having a high resolution anatomical MRI done with the same paradigms which patients will have, listed below. the total scanner time will be approximately 25 minutes, and the scan will not be billed to the healthy volunteer.
89498993|NCT03600441|Experimental|Abexinostat|"Abexinostat tablets will be administered orally at 80 mg (4 × 20 mg tablets) BID (twice a day) 4 hours apart for 7 days in a one week on, one week off schedule (on Days 1 to 7 and Days 15 to 21 of each 28-day cycle)."
89498994|NCT03594136|Experimental|Telemetric intracranial pressure implant|A telemetric intracranial pressure monitoring sensor is inserted into the brain parenchyma at the end of an uncomplicated surgery for an unruptured aneurysm
89498995|NCT03592472|Experimental|Pazopanib plus abexinostat|Randomized patients will receive a combination of pazopanib plus abexinostat. The patients will receive pazopanib by mouth (p.o.) daily on Days 1 to 28 of each treatment cycle and will receive abexinostat p.o twice daily (BID) on Days 1 to 4, 8 to 11, and 15 to 18 of every 28-day cycle, 2 doses 4 hours apart. Patients will be instructed to take their once- daily oral dose of pazopanib and BID oral dose of abexinostat at the same time each day.
89498996|NCT03592472|Placebo Comparator|Pazopanib plus placebo|Randomized patients will receive a combination of pazopanib plus abexinostat matching placebo. The patients will receive pazopanib by mouth (p.o.) daily on Days 1 to 28 of each treatment cycle and will receive abexinostat matching placebo p.o BID on Days 1 to 4, 8 to 11, and 15 to 18 of every 28-day cycle, 2 doses 4 hours apart. Patients will be instructed to take their once- daily oral dose of pazopanib and BID oral dose of placebo at the same time each day.
89498997|NCT03583528||PET/CT Diagnostic Imaging|Each subject will have two PET/CT scans, one using 68Ga-DOTATOC and the other using 18F-FDG. The 68Ga-DOTATOC radioactive tracer is manufactured for this study under a Clinical Trial Application filed with Health Canada. 18F-FDG is considered standard care and has been approved by Health Canada.
89498998|NCT03582891|Other|Parkinson's Disease STN Target|Parkinson's disease patients implanted in STN
89498999|NCT03582891|Other|Parkinson's disease patients GP Target|Parkinson's disease patients implanted in Globus Pallidus
89499000|NCT03582891|Other|Dystonia patients|Isolated dystonia patients
89499001|NCT03574012|Active Comparator|Control Group (general health information, fitness tracker)|Participants receive general information about physical activity and diet, and access to Fitbit and Healthwatch.
89499002|NCT03574012|Experimental|Intervention Group (individualized information, tracker)|Participants receive individualized goal-setting and coaching in relation to physical activity and diet, supplemented with peer support through the study's social media platform, over 4 months. They also have access to mHealth apps including Fitbit and Healthwatch that provide feedback on physical activity and diet.
89499003|NCT03551964|Experimental|Cangrelor therapy|Initiation of iv Cangrelor immediately upon arrival of the patient to the cardiac catheterization laboratory and after randomization into the study.
89499004|NCT03551964|Active Comparator|Ticagrelor therapy|Initial dose Ticagrelor immediately upon arrival of the patient to the cardiac catheterization laboratory and after randomization into the study. In patients with a disorder of consciousness, initial dose of Ticagrelor will be administered immediately after nasogastric tube insertion.
89499005|NCT03543813|Experimental|CX-2029 Escalation|Dose Escalation and Determination
89499006|NCT03543813|Experimental|CX-2029 Biomarker|Characterization of CX-2029 in the tumor microenvironment in subjects with select tumor types
89499007|NCT03543813|Experimental|CX-2029 Expansion|Evaluate antitumor activity of CX-2029
89499008|NCT03532971||allogeneic hematopoietic-cell transplantation patients|Prospective HCT cohort of patients undergoing allogeneic HCT at DFCI
89499009|NCT03527537|Active Comparator|20% cutoff group|Treatment intervention will be initiated with insulin if 20% cutoff of abnormal values is reached. Medication dosages will depend on the physician's discretion.
89499010|NCT03527537|Active Comparator|40% cutoff group|Treatment intervention will be initiated with insulin if 40% cutoff of abnormal values is reached. Medication dosages will depend on the physician's discretion.
89499011|NCT03520790|Experimental|Gemcitabine + Nab-paclitaxel + Placebo|"Gemcitabine and Nab-paclitaxel is administered intravenously 3 times/cycle.~Placebo is administered orally on a daily basis"
89499012|NCT03520790|Experimental|Gemcitabine + Nab-paclitaxel + Paricalcitol IV|"Gemcitabine + Nab-paclitaxel is administered intravenously 3 times/cycle.~Paricalcitol is administered intravenously once weekly."
89499013|NCT03520790|Experimental|Gemcitabine + Nab-paclitaxel + Paricalcitol oral|"Gemcitabine + Nab-paclitaxel is administered intravenously 3 times/cycle.~Paricalcitol is administered orally on a daily basis"
89499014|NCT03511391|Experimental|Experimental arm|"Stereotactic body radiotherapy concurrent with checkpoint inhibitor treatment:~Nivolumab or Pembrolizumab or Atezolizumab + SBRT"
89499015|NCT03511391|Active Comparator|Control arm|"Checkpoint inhibitor treatment only:~Nivolumab or Pembrolizumab or Atezolizumab monotherapy"
89499016|NCT03486834|Experimental|V160 3-Dose Regimen|Participants received 3 doses of vaccine V160 (100 Units/0.5 mL dose with Merck aluminum phosphate adjuvant [MAPA], 4°C stable formulation) administered by intramuscular (IM) injection on Day 1, Month 2, and Month 6.
89499017|NCT03486834|Experimental|V160 2-Dose Regimen|Participants received 2 doses of vaccine V160 (100 Units/0.5 mL dose with MAPA, 4°C stable formulation) administered IM on Day 1 and Month 6 and a placebo-saline solution at Month 2.
89499018|NCT03486834|Placebo Comparator|Placebo|Participants received placebo (saline solution) by IM injection on Day 1, Month 2, and Month 6.
89499019|NCT03482167|Placebo Comparator|Placebo|placebo
89499020|NCT03482167|Experimental|Nicotinamide Riboside|Niagen® (ChromaDex, Inc.) 500 mg, twice daily
89499021|NCT03356145|Experimental|12 mL arm|"Intervention:~Syringe loaded with 12 mL of 1% lidocaine (120 mg); 22-gauge spinal needle~2 mL injected at the tenaculum site, either 6 or 12 o'clock superficially into the cervix~The tenaculum is immediately placed at the previously injected site~The remaining 10 mL are slowly injected into the cervicovaginal junction in two equal aliquots at 4 and 8 o'clock; the injection is continuous from superficial to deep (3 cm) to superficial (injecting with insertion and withdrawal)~No wait time between injection and dilator insertion"
89499022|NCT03356145|Active Comparator|20 mL arm|"Intervention:~Syringe loaded with 20 mL of 1% lidocaine (120 mg); 22-gauge spinal needle~2 mL injected at the tenaculum site, either 6 or 12 o'clock superficially into the cervix~The tenaculum is immediately placed at the previously injected site~The remaining 18 mL are slowly injected into the cervicovaginal junction in two equal aliquots at 4 and 8 o'clock; the injection is continuous from superficial to deep (3 cm) to superficial (injecting with insertion and withdrawal)~No wait time between injection and dilator insertion"
89499023|NCT03344835||Prostate Cancer|Patients diagnosed with prostate cancer
89499024|NCT03312738|Experimental|Everolimus + Exemestane|Participants received everolimus as a continuous oral daily dose of 10 mg and exemestane as a continuous oral daily dose of 25 mg
89499025|NCT03312738|Active Comparator|Placebo + Exemestane|Participants received placebo as a continuous oral daily dose and exemestane as a continuous oral daily dose of 25 mg
89538301|NCT02458625|Active Comparator|Iron sucrose 500 mg|One treatment arm will receive a single dose of I.V iron sucrose 500 mg.
89538302|NCT02458625|Active Comparator|Iron sucrose 500 mg+60 mg Iron bisglycinate|Second treatment arm will receive a single dose of I.V iron sucrose 500 mg and oral treatment with 60 mg Iron bisglycinate for 6 weeks after giving birth.
89499026|NCT03297359|Experimental|Weight adjusted dalteparin|"Participants will receive a daily subcutaneous injection of weight-adjusted dalteparin (See Table below) at a dose of approx. 200 IU/kg beginning on the day of enrolment and for a one month.~91 to 95 kg: 18,000 IU daily ( or 1 prefilled syringe of 18,000 IU) 96 to 105 kg: 20,000 IU daily ( or 2 prefilled syringes of 10,000 IU) 106 to 120 kg: 22,500 IU daily ( or 2 pre-filled syringes (10,000 and 12,500 IU)) 121 to 130 kg: 25,000 IU daily ( or 2 prefilled syringes of 12,500 IU) 131 to 145 kg: 27,500 IU daily ( or 2 pre-filled syringes (12,500 and 15,000 IU)) 146 to 150 kg: 30,000 IU daily ( or 2 prefilled syringes of 15,000 IU)~≥ 151 kg: 33,000 IU daily ( or 2 prefilled syringes (15,000 and 18,000 IU))"
89499027|NCT03284866|Experimental|Arm I, recombinant HPV 9-valent vaccine|Patients receive Recombinant Human Papillomavirus Nonavalent Vaccine (Gardasil 9) IM at baseline, 4, and 26 weeks in the absence of disease progression or unacceptable toxicity, with sample collection for Laboratory Biomarker Analysis.
89499028|NCT03284866|Placebo Comparator|Arm II, saline|Patients receive saline placebo vaccine IM at baseline, 4, and 26 weeks, with sample collection for Laboratory Biomarker Analysis.
89499029|NCT03268954|Experimental|Azacitidine 75 mg/m^2|Azacitidine 75 milligram per square meter (mg/m^2) intravenous (IV) or subcutaneous (SC) injection on Days 1 to 5, Days 8 and 9, in 28-day treatment cycles until disease progression or unacceptable toxicity or up to approximately 42 months.
89499030|NCT03268954|Experimental|Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2|Azacitidine 75 mg/m^2 IV or SC injection on Days 1 to 5, Days 8 and 9 and pevonedistat 20 mg/m^2 IV infusion, on Days 1, 3, and 5 in 28-day treatment cycles until disease progression or unacceptable toxicity or up to approximately 42 months.
89499031|NCT03242382|Experimental|Palbocilib|Palbociclib will be administered orally at a dose of 125 mg once a day for 21 consecutive days followed by 7 rest days to comprise a complete cycle of 28 days.
89499032|NCT03204513|Experimental|Vanderbilt Powered Knee-Ankle Prosthesis|"Upon screening and enrollment participants return for up to 8 prosthetic fitting sessions and up to 12 physical therapy training sessions using the Vanderbilt Powered Knee-Ankle (PKA) Prosthesis. Once training is complete participants will return for up to 6 post-training assessment sessions using the Vanderbilt Powered Knee-Ankle (PKA) Prosthesis. The device participants begin with will be randomly selected but there will be an equal opportunity to train with both devices. In between training, there will be an 8 week wash out period to allow normalization to use of the device, reducing carryover effects. After wash-out period protocol will be repeated with second device."
89531838|NCT05174624||FAMILY Cohort|This Cohort was part of a prospective population-based study in 2007, consisting of 46,001 participants in Hong Kong. It was the first large-scale programme to understand the determinants of physical, mental, and social wellbeing in Hong Kong. The Cohort has an excellent (99.8%) coverage of the neighbourhoods in Hong Kong and represents roughly 1% of all households, which enables detailed studies linking the social environment to physical and mental health.
88955778|NCT06213090||ADHD|Children with ADHD will be followed in regards to their clinical management.
88955779|NCT06213090||Dyslexia and other learning disabilities|Children with Dyslexia and other learning disabilities will be followed in regards to their clinical management.
88955780|NCT06213090||Other Neurodevelopmental Disorders|Children with Other Neurodevelopmental Disorders will be followed in regards to their clinical management.
88955781|NCT06212583|Active Comparator|Androgen deprivation therapy + Stereotactic ablative radiation|
89499033|NCT03204513|Active Comparator|Microprocessor (MP) Knee Prosthesis|"Upon screening and enrollment participants return for up to 8 prosthetic fitting sessions and up to 12 physical therapy training sessions using their own Microprocessor (MP) Knee Prosthesis. Once training is complete participants will return for up to 6 post-training assessment sessions using the Microprocessor (MP) Knee Prosthesis. The device participants begin with will be randomly selected but there will be an equal opportunity to train with both devices. In between training, there will be an 8 week wash out period to allow normalization to use of the device, reducing carryover effects. After wash-out period protocol will be repeated with second device."
89499034|NCT03196232|Experimental|Treatment (epacadostat, pembrolizumab)|Participants receive oral epacadostat BID on Days 1 to 21 and pembrolizumab IV over 30 minutes on Day 1, with cycles repeating every 21 days for up to 24 months, in the absence of disease progression or unacceptable toxicity.
89499035|NCT03181256||Screening|Patients are followed up at 1, 2, 3, 4, and 5 years and undergo collection of sputum, nasal epithelium, buccal epithelium, blood, and urine samples. Patients also undergo pulmonary function tests, chest CT, and review of medical records
89499036|NCT03122899|Other|SIJ fusion with iFuse 3D with 6 mo CT|These subjects will get pelvic CT at 6 months post-operatively.
89499037|NCT03122899|Other|SIJ fusion with iFuse 3D with 12 mo CT|These subjects will get pelvic CT at 12 months post-operatively.
89499038|NCT03120624|Experimental|Arm A (VSV-hIFNbeta-NIS, TFB-PET, biopsy)|Patients receive VSV-hIFNbeta-NIS IV over 60-90 minutes on day 1. After 2 days, patients receive technetium Tc-99m sodium pertechnetate IV, and about 30 minutes later, receive fluorine F18 tetrafluoroborate IV and undergo TFB-PET imaging. If previous imaging data are positive, patients receive technetium Tc-99m sodium pertechnetate IV and fluorine F18 tetrafluoroborate IV and undergo another TFB-PET imaging between 7-10 days and on 15 days if needed after VSV-hIFNbeta-NIS infusion. Biopsy of accessible NIS image-positive tumors may occur after any imaging. Patients also undergo CT throughout the study. Patients also undergo mouth rinse, buccal swab and urine on study and blood sample collection throughout the study. Biopsy of accessible NIS image-positive tumors may occur after any imaging. Patients also undergo image-guided biopsy of accessible tumor on day 29.
89499039|NCT03120624|Experimental|Arm B (ruxolitinib, VSV-hIFNbeta-NIS, SPECT/CT,TFB-PET,biopsy)|Patients receive ruxolitinib phosphate PO BID on days -3 to 9. Patients also receive VSV-hIFNbeta-NIS IV over 60-90 minutes on day 1. After 2 days, patients receive technetium Tc-99m sodium pertechnetate IV, and about 30 minutes later, receive fluorine F18 tetrafluoroborate IV and undergo TFB-PET imaging. If previous imaging data are positive, patients receive technetium Tc-99m sodium pertechnetate IV and undergo fluorine F18 tetrafluoroborate IV and undergo another TFB-PET imaging between 7-10 days and on 15 days if needed after VSV-hIFNbeta-NIS infusion. Patients also undergo CT throughout the study. Biopsy of accessible NIS image-positive tumors may occur after any imaging. Patients also undergo image-guided biopsy of accessible tumor on day 29. Patients also undergo mouth rinse, buccal swab and urine on study and blood sample collection throughout the study.
89499040|NCT03117933|Active Comparator|A: Paclitaxel|Paclitaxel, IV weekly, 80mg/m2; until progression
89499041|NCT03117933|Experimental|B: Olaparib|Olaparib, oral, 300mg twice daily; until progression
89499042|NCT03117933|Experimental|C: Olaparib and Cediranib|Olaparib, oral, 300mg twice daily and Cediranib, tablet, 20mg once daily; until progression
89499043|NCT03115840||Adults (≥18 years old) with critical illness|
89499044|NCT03114527|Experimental|Dedifferentiated Liposarcoma Arm|Patients receive ribociclib orally at 300mg/day for 21 days of each 28 day cycle and everolimus 2.5mg orally on a continuous 28 day cycle.
89499045|NCT03114527|Experimental|Leiomyosarcoma Arm|Patients receive ribociclib orally at 300mg/day for 21 days of each 28 day cycle and everolimus 2.5mg orally on a continuous 28 day cycle.
89499046|NCT03113513|Active Comparator|McCall culdoplasty|The McCall culdoplasty will be performed in a modified version as described by McCall in 1957. Specifically, two long acting bioresorbable sutures are put through the specific anatomic landmarks.
89531839|NCT05171244|Experimental|Experimental group|
89531840|NCT05171244|Sham Comparator|Control group|
88955782|NCT06212583|Active Comparator|Androgen deprivation therapy + Stereotactic ablative radiation + niraparib/abiraterone acetate|
88955783|NCT06209749|Experimental|Intervention group|"Sensory-based intervention module will be given for three sessions a week for 12 weeks (30 minutes per session).~Usual school activities will be given four days a week for 12 weeks (6 hours per day)"
88955784|NCT06209749|No Intervention|Control group|Usual school activities will be given four days a week for 12 weeks (6 hours per day)
88955785|NCT06206733|Experimental|Group A|Treatment with intravenous infusion of ASKB589 on day 1 of each cycle. The infusion duration should be at least 3 hours, and can be shortened or extended in subsequent cycles as appropriate according to the patient's tolerability. Interruption or slow down of intravenous infusion is allowed to manage toxicity. Dosing is continued every cycle until participants meet the criteria of treatment discontinuation.
88955786|NCT06206733|Placebo Comparator|Group B|Treatment with intravenous infusion of placebo on day 1 of each cycle. The infusion duration should be at least 3 hours, and can be shortened or extended in subsequent cycles as appropriate according to the patient's tolerability. Interruption or slow down of intravenous infusion is allowed to manage toxicity. Dosing is continued every cycle until participants meet the criteria for treatment discontinuation.
89499047|NCT03113513|Active Comparator|Sacrospinous ligament fixation|The SLF technique will be performed as described by Richter et al (Amreich, 1951). Two long acting bioresorbable sutures are passed through the right sacrospinous ligament and then fixed to the vaginal cuff.
89499048|NCT03094663|Active Comparator|Peri-Articular Injections only|"Combined spinal epidural anesthetic with 1.5% Mepivacaine (60mg)~Injection prior to cementation~bupivacaine 0.5% with epinephrine 30cc;~methylprednisolone, 40 mg/ml, 1 ml~cefazolin, 500 mg in 10 ml~normal saline, 22cc~Superficial injection prior to closure.~20cc 0.25% bupivacaine~2 mg IV dexamethasone."
89499049|NCT03094663|Experimental|Peri-Articular Injections, Adductor Canal Block, and IPACK|"Combined spinal epidural anesthetic with 1.5% Mepivacaine (60mg)~Injection prior to cementation~bupivacaine 0.25% with epinephrine 30cc;~methylprednisolone, 40 mg/ml, 1 ml~cefazolin, 500 mg in 10 ml~normal saline, 22cc~Superficial injection prior to closure.~a. 20cc 0.25% bupivacaine~Adductor canal block technique (supine position, post IV sedation)~a. Mid-thigh injection of 15 cc of bupivacaine 0.25% with 2 mg of PF Dexamethasone~IPACK technique (supine position) a. 25 cc 0.25% bupivacaine"
89499050|NCT03022032|Experimental|Comparing Steps Collected by Accelerometer (HOPE)|"10 patients will be enrolled in stage 1 to refine the HOPE App intervention~All participants will receive :~HOPE App~The Fitbit Zip~The Fitbit Charge 2 The amount of step collected by each device will be compared. This will allow the team to identify which wearable accelerometer to use in stage 2"
89499051|NCT03022032|Other|Usual care (HOPE)|"Stage 2 will consist of arm 2-5 and will enroll 100 randomized patients.~Usual care~The app will also collect passive data from the smartphone"
89499052|NCT03022032|Experimental|Wearable accelerometer (HOPE)|"Participants will be asked to wear the Fitbit~The Hope App will measure daily steps~The app will also collect passive data from the smartphone"
89499053|NCT03022032|Experimental|Refined smartphone app (HOPE)|"Participants will be prompted to answer questions about their quality of life and physical health daily~The HOPE App will present tailored advice to improve symptoms if one or more low-risk toxicities are reported. If the symptoms are determined to be high-risk, the App will prompt the patient to call their clinician.~The app will also collect passive data from the smartphone"
89499054|NCT03022032|Experimental|Refined smartphone app and accelerometer (HOPE)|"Participants will be prompted to answer questions about their quality of life and physical health daily~The HOPE App will present tailored advice to improve symptoms if one or more low-risk toxicities are reported. If the symptoms are determined to be high-risk, the App will prompt the patient to call their clinician.~Participants will be asked to wear the Fitbit~-The Hope App will measure daily steps The app will also collect passive data from the smartphone"
89499055|NCT03022032|Experimental|SMART Study Arm|"Two smartphone apps and a wearable accelerometer (Fitbit) in 30 patients with gynecologic cancers receiving chemotherapy at two NCI Community Oncology sites.~The SMART intervention refers to the combination of both smartphone apps (SMART app and Beiwe app) and the accelerometer (Fitbit).~The SMART app is the technology that is actively collecting symptom reporting information from patients (e.g. patients are receiving surveys, recording their symptoms daily, and receiving tailored symptom management materials on their phone in response).~The Beiwe app is the technology involved in the passive data collection of participants' symptoms (GPS and accelerometer data) without their involvement."
89499056|NCT02966145||PSP & CBD|Observational study of participants with a diagnosis of Progressive Supranuclear Palsy or Corticobasal Degeneration (also called Corticobasal Syndrome or Cortical-basal Ganglionic Degeneration).
89499057|NCT02966145||o/vPSP|Observational study of participants with a diagnosis of an oligosymptomatic or variant Progressive Supranuclear Palsy syndrome.
89531841|NCT05142267|Other|Adults with chronic non-cancer low back pain|
88955787|NCT06206408|Experimental|Fezolinetant low dose|Participants will receive low dose of fezolinetant and placebo once daily for 12 weeks.
88955788|NCT06206408|Experimental|Fezolinetant high dose|Participants will receive high dose of fezolinetant and placebo once daily for 12 weeks.
88955789|NCT06206408|Placebo Comparator|Placebo|Participants will receive matching placebo once daily for 12 weeks.
88955790|NCT06204510|No Intervention|control group|
88955791|NCT06204510|Experimental|study group|
89499058|NCT02966145||Normal Volunteers|Observational study of participants with no known diagnosis of a neurological or neurodegenerative condition, and no known history of memory complaints.
88955792|NCT06204302||Darolutamide|Participants with nmPC previously untreated with novel ARIs or abiraterone acetate and received Darolutamide as initial treatment.
89499059|NCT02902211|Experimental|Ankle foot orthosis|Patients will wear an off-the-shelf, carbon composite AFO that is adjusted for them for three months. The patients will be asked to wear the AFO at all times except when they are in bed or showering/bathing. The instructions given to the patients about walking will be to follow the instructions from their doctor regarding risk factor management and exercise.
89499060|NCT02902211|Active Comparator|Control|Patients will be asked to follow the instructions from their doctor regarding risk factor management and exercise for three months.
89499061|NCT02855593||Physicians|Physicians who perform acupuncture
89499062|NCT02855593||Patients|Patients who have received acupuncture treatment in the past
89499063|NCT02851706||First cohort Patients (Person with the disease)|Patients with tumors of the central nervous system (CNS) who appear to be probable candidates for future protocol entry, have disease manifestations that are of unique scientific interest, importance, and/or educational value, or who have understudied tumors with unknown or unclear natural history. Patients with known genetic syndromes at high risk of developing CNS cancers will also be evaluated.
89499064|NCT02851706||Second cohort Caregivers (Informants)|Caregivers will be defined as anyone who patients identify as an unpaid close friend or family member who knows them well and who is involved with their day-to-day care.
89499065|NCT02792270|Experimental|Caloric Restriction Diet|"Patients will meet with the Registered Dietitian to discuss calorie, protein, and fluid needs.The dietitian will calculate calorie needs.~Calorie needs will be reduced by 30%.~Protein needs will be estimated based on 0.8g/kg BW and then reduced by 70%.~Dietitian will educate participants on electrolytes and fluid intake based on the reduced food intake."
89499066|NCT02792270|No Intervention|Normal Diet|Participant will follow a normal diet.
89499067|NCT02763345|Active Comparator|Paper-based CCM (Standard Care)|Children are assessed and treated according to the WHO and UNICEFs paper-based Community Case Management decision aid for Malawi for a minimum of 2 and a maximum of 7-weeks. Clinical assessment is guided by the paper-based 'Sick Child Form' presented in English, and clinical data is recorded by Health Surveillance Assistants manually in the Village Clinic Register.
89499068|NCT02763345|Experimental|SL eCCM App + paper CCM|Health Surveillance Assistants use the Supporting LIFE electronic Community Case Management App (SL eCCM App) deployed on a smartphone and replicating paper-based CCM guidelines to assess and treat children in conjunction with standard care, for a minimum of 2-weeks and maximum of 7-weeks. Clinical data is recorded in both the SL eCCM App and Village Clinic Register.
88955793|NCT06204302||Enzalutamide|Participants with nmPC previously untreated with novel ARIs or abiraterone acetate and received Enzalutamide as initial treatment.
88955794|NCT06204302||Apalutamide|Participants with nmPC previously untreated with novel ARIs or abiraterone acetate and received Apalutamide as initial treatment.
88955795|NCT06204250|Experimental|Part 1 Single Ascending Dose: Cohorts 1 to 5|Participants will receive GS1-144 5 mg, 15 mg, 30 mg, 60 mg and 90 mg tablets once on Day 1 in their respective Cohort in Part 1. 2 participants will receive placebo in each cohort.
88955796|NCT06204250|Experimental|Part 2 Multiple Ascending Dose: Cohorts 1 to 3|Participants will receive GS1-144 15 mg, 30 mg and 60 mg tablets once on Day 1 in their respective Cohort in Part 2. 2 participants will receive placebo in each cohort.
89205583|NCT04741932|No Intervention|Care as usual|
88955800|NCT06203054|Experimental|Penditure™ LAA Exclusion System|Penditure™ LAA Exclusion System
88955801|NCT06202716|Experimental|Cadonilimab plus CapeOX chemotherapy|Efficacy of cadonilimab plus CapeOX as first-line treatment in advanced GC/GEJC with high TMEscore.
89499069|NCT02663622|Experimental|Efprezimod alfa 240 mg|Efprezimod alfa in 240 mg as intravenous (IV) infusion at Day -1 + Tacrolimus (begin on day -3. IV [0.03 mg/kg/day] or PO [0.045 mg/kg/dose] dosing is permitted) + Methotrexate (given intravenously at a dose of 15 mg/square meter/dose once daily on Day 1 after HCT, and at a dose of 10 mg/square meter/dose on days 3, 6, and 11 after HCT)
89499070|NCT02663622|Experimental|Efprezimod alfa 480 mg|Efprezimod alfa in 480 mg as intravenous (IV) infusion at Day -1 + Tacrolimus (begin on day -3. IV [0.03 mg/kg/day] or PO [0.045 mg/kg/dose] dosing is permitted) + Methotrexate (given intravenously at a dose of 15 mg/square meter/dose once daily on Day 1 after HCT, and at a dose of 10 mg/square meter/dose on days 3, 6, and 11 after HCT)
88955802|NCT06199323|Experimental|routine treatment+swallowing rehabilitation training+acupuncture therapy|The experimental group was given routine treatment and swallowing rehabilitation training. Moreover, the experimental group was given acupuncture therapy.
89499071|NCT02663622|Experimental|Efprezimod alfa 960 mg|Efprezimod alfa (480 mg (day -1), 240 mg (day +14) and 240 mg (day +28)) + Tacrolimus (begin on day -3. IV [0.03 mg/kg/day] or PO [0.045 mg/kg/dose] dosing is permitted) + Methotrexate (given intravenously at a dose of 15 mg/square meter/dose once daily on Day 1 after HCT, and at a dose of 10 mg/square meter/dose on days 3, 6, and 11 after HCT)
89499072|NCT02663622|Placebo Comparator|Placebo|Placebo to efprezimod alfa (saline IV injection solution) on day -1 or days -1, 14, and 28 + Tacrolimus (begin on day -3. IV [0.03 mg/kg/day] or PO [0.045 mg/kg/dose] dosing is permitted) + Methotrexate (given intravenously at a dose of 15 mg/square meter/dose once daily on Day 1 after HCT, and at a dose of 10 mg/square meter/dose on days 3, 6, and 11 after HCT)
89499073|NCT02650271|Experimental|Entecavir|Patients will be received entecavir (10 mg/d) after 3 days of liver resection.
89499074|NCT02650271|Active Comparator|Tenofovir|Patients will be received tenofovir (1#/d) after 3 days of liver resection.
89499075|NCT02649387|Experimental|Treatment (ibrutinib)|"Patients receive ibrutinib PO QD on days 1-28. Treatment repeats every 4 weeks* for up to 36 courses in the absence of disease progression or unacceptable toxicity.~Note: *The last course may last up to 56 days to accommodate the study drug discontinuation visit."
89499076|NCT02649153|Experimental|smoked plum|Patients will receive smoked plum (3 piece each time, three times per day) starting in the first day after resection until flatus.
89499077|NCT02649153|Active Comparator|gum chewing|Patients will receive gum chewing (three times per day) in the first day after resection until flatus.
89499078|NCT02649153|No Intervention|empty control|This group patients will not receive gum chewing or smoked plum.
89499079|NCT02637713|Experimental|Radiofrequency Energy to the Lower Esophageal Sphincter (LES)|All patients that have undergone sleeve gastrectomy as treatment for obesity that have developed severe reflux symptoms will be treated with Stretta (FDA approved device for the management of GERD) and evaluated prospectively for resolution/improvement of reflux symptoms.
89499080|NCT02564172|Experimental|CMS group|Conus medullaris stimulation with pentapolar surgical lead plus optimal medical management.
89499081|NCT02564172|Active Comparator|OMM group|Optimal medical management alone.
89499082|NCT02553473|Active Comparator|Doxycycline for 6 weeks|Doxycycline 200 mg once daily for six weeks
89499083|NCT02553473|Placebo Comparator|Doxycycline for 2 weeks + placebo|Doxycycline 200 mg once daily for two weeks + placebo for four weeks.
89499084|NCT02550366||CMR|Subjects with no contraindication to magnetic resonance imaging, who will undergo cardiac MRI scanning.
89499085|NCT02520713||Genetic testing and GAIN report|All enrolled patients will submit specimens for sequencing and analysis.
89499086|NCT02470507||AKI with SIRS|Patients with AKI stage II or III and systemic inflammation without sepsis
89499087|NCT02470507||AKI without SIRS|Patients with AKI stage II or III and no systemic inflammation
89499088|NCT02470507||SIRS without AKI|Patients with systemic inflammation and normal renal function
89499089|NCT02470507||No SIRS and no AKI|Patients after major surgery who do not have an infection, SIRS or AKI
89499090|NCT02461615||Registry Participants|All participants who participate in the National PAP Registry will be put into this cohort and observed over approximately 5 years.
89499091|NCT02410850||University of Montreal|Patients from University of Montreal in Canada
89499092|NCT02410850||University of Antwerp|Patients from University of Antwerp in Belgium.
89499093|NCT02410850||University of Sydney|Patients from University of Sydney in Australia.
89499094|NCT02410850||Angers University Hospital|Patients from Angers University Hospital in France.
89499095|NCT02410850||University of Gronigen|Patients from University of Gronigen in Netherlands.
89499096|NCT02410850||Kaiser Permanente|Patients from Kaiser Permanente from USA.
89499097|NCT02410850||Stanford University|Patients from Stanford University from USA.
89499098|NCT02410850||Laval University|Patients from Laval University in Canada.
89499099|NCT02410850||Cambridge University|Patients from Cambridge University in UK.
89499100|NCT02410850||Kyushu University|Patients from Kyushu University in Japan
89499101|NCT02410850||Japan Somnology Center|Patients from Japan Somnology Center in Japan.
89499102|NCT02410850||Uniformed Services University|Patients from the Uniformed Services University in USA.
89499103|NCT02410850||University of British Columbia|Patients from the University of British Columbia in Canada.
89499104|NCT02398747|Experimental|AZD2014 50mg, 125mg, 25mg and 50mg intermittent BD|50mg BD continuous dosing, 125mg BD intermittent dosing, 25 mg and 50mg intermittent dosing with weekly Paclitaxel
89499105|NCT02384473|Experimental|Real-time CEUS and SWE|Patients undergo real-time CEUS and SWE at baseline, 6 weeks after initiation of neoadjuvant therapy, and 9 weeks after initiation of neoadjuvant therapy (prior to surgery).
88955803|NCT06199323|Active Comparator|routine treatment+swallowing rehabilitation training|The control group was given routine treatment and swallowing rehabilitation training.
88955804|NCT06196203|Experimental|AK117 (dose 1) in combination with azacitidine|Subjects receive AK117 (dose 1) intravenously, in combination with azacitidine (75 mg/m2, D1-7, Q4W) subcutaneously
88955805|NCT06196203|Experimental|AK117 (dose 2) in combination with azacitidine|Subjects receive AK117 (dose 2) intravenously, in combination with azacitidine (75 mg/m2, D1-7, Q4W) subcutaneously
88955806|NCT06196203|Placebo Comparator|Placebo in combination with azacitidine|Subjects receive placebo intravenously, in combination with azacitidine (75 mg/m2, D1-7, Q4W) subcutaneously
89499106|NCT02230501|Experimental|moderate diet regimen|"Week 1-4: replacement of breakfast and dinner with 1g PRMR /kg normal weight (=height in cm-100), a protein-rich lunch was allowed Week 5-12: replacement of dinner~For this arm a local subgroup (n=55) and a nation-wide subgroup (n=100) is planned."
89499107|NCT02230501|Experimental|stringent diet regimen|"Week 1: replacement of 3 main meals by 1g PRMR / kg normal weight (=height in cm - 100) Week 2-4: replacement of breakfast and dinner, a protein-rich lunch was allowed Week 5-12: replacement of dinner~For this arm a local subgroup (n=55) and a nation-wide subgroup (n=100) is planned."
89499108|NCT02169310|Experimental|1|up to 40 adult TBI patients between the ages of 18 and 60
89499109|NCT02169310|Active Comparator|2|up to 40 adult healthy volunteers between the ages of 18 and 60
89499110|NCT02091999|Experimental|Part A enfortumab vedotin Dose Escalation (Dose Levels 1-4)|All subjects will receive a single 30 minute intravenous (IV) infusion of enfortumab vedotin once weekly for the first 3 weeks of every 4 week cycle (i.e., on Days 1, 8 and 15).
89499111|NCT02091999|Experimental|Part B enfortumab vedotin Renal Insufficiency Expansion|Subjects will receive a single 30 minute IV infusion of enfortumab vedotin at a dose level below and escalated up to the preliminary RP2D once weekly for 3 weeks of every 4 weeks (i.e., on Days 1, 8 and 15) until disease progression, intolerability of the investigational product or consent withdrawal. A cycle is 4 weeks.
89499112|NCT02091999|Experimental|Part B enfortumab vedotin NSCLC Expansion|Subjects will receive a single 30 minute IV infusion of enfortumab vedotin at the preliminary RP2D once weekly for 3 weeks of every 4 weeks (i.e., on Days 1, 8 and 15) until disease progression, intolerability of the investigational product or consent withdrawal. A cycle is 4 weeks.
89499113|NCT02091999|Experimental|Part B enfortumab vedotin Ovarian Cancer Expansion|Subjects will receive a single 30 minute IV infusion of enfortumab vedotin at the preliminary RP2D once weekly for 3 weeks of every 4 weeks (i.e., on Days 1, 8 and 15) until disease progression, intolerability of the investigational product or consent withdrawal. A cycle is 4 weeks.
89499114|NCT02091999|Experimental|Part C enfortumab vedotin CPI Treated Expansion|Subjects will receive a single 30 minute IV infusion of enfortumab vedotin at the preliminary RP2D once weekly for 3 weeks of every 4 weeks (i.e., on Days 1, 8 and 15). A cycle is 4 weeks. Subjects will continue treatment until disease progression, intolerability of enfortumab vedotin, Investigator decision or consent withdrawal.
89499115|NCT02014675||SD01 ICD lead|
89499116|NCT01961869|Experimental|Arm I (Fast release BRB confection 4g)|Participants receive one fast release BRB confection (4g) PO 4-6 hours apart thrice daily (TID) for 2 weeks.
89499117|NCT01961869|Experimental|Arm II (Fast release BRB confection 8g)|Participants receive two fast release BRB confection (8g) PO 4-6 hours apart TID for 2 weeks.
89499118|NCT01961869|Experimental|Arm III (Intermed release BRBconfection 4g)|Participants receive one intermediate release BRB confection (4g) PO 4-6 hours apart TID for 2 weeks.
89499119|NCT01961869|Experimental|Arm IV (Intermed release BRBconfection 8g)|Participants receive two intermediate release BRB confection (8g) PO 4-6 hours apart TID for 2 weeks.
89499120|NCT01961869|Experimental|Arm V (Prolong release BRB confection 4g)|Participants receive one prolonged release BRB confection (4g) PO 4-6 hours apart TID for 2 weeks.
89499121|NCT01961869|Experimental|Arm VI (Prolong release BRB confection 8g)|Participants receive two prolonged release BRB confection (8g) PO 4-6 hours apart TID for 2 weeks.
89499122|NCT01804452||Subjects with a diagnosis of PSP or CBD|
89499123|NCT01783288|Other|All participants|"All participants will be administered all procedures as described previously.~Interventions:~Autonomic Function Testing, Posture Study ,Measurement of Total Blood Volume ,Exercise Capacity Test"
89499124|NCT01780142||asthmatics|Subjects with confirmed diagnosis of asthma without other lung disease followed for collection of clinical data &amp; specimens
89499125|NCT01780142||non-asthmatic healthy volunteers|Healthy volunteers in whom asthma has been ruled out and without other lung disease followed for comparison to asthmatics
89499126|NCT01722240|Active Comparator|Liraglutide 1.8mg|Daily Injection
89499127|NCT01722240|Placebo Comparator|Placebo|Daily Injection
89499128|NCT01697397||Patients with and without FGIDs/IBS|Patients with functional gastro-intestinal disorders (FGIDs) undergo recording of myoelectric signals before, during, and after a meal. In addition, patients without FGIDs undergo recording of myoelectric signals before, during, and after a meal.
89499129|NCT01651208|Experimental|Motivational interviewing (MINT)|The MINT intervention will consist of 4 to 7 telephone encounters between a nurse trained in Motivational interviewing and a minority subject who recently received a coronary stent. All subjects in the MINT arm will be contacted every 3 months to complete 4 encounters. MINT is a well-known, scientifically tested behavioral counseling strategy developed as an amalgamation of principles drawn from several theoretical paradigms, the most important of which are Self-Determination Theory, Patient-Centeredness, Self-Efficacy theory, and the Stages of Change model.
89499130|NCT01651208|Active Comparator|Mailed DVD|A DVD that re-enforces an adequate behavior regarding adherence to anti-platelet will be compared to a MINT intervention. The DVD will also address many questions and concerns patients have after stent placement. The intervention is based on role theory and the effects of vicarious learning via electronic media with respect to Cardiovascular behaviors.
89499131|NCT01524549||WT for CYP2J2*7 and heterozygous for EPHX2 K55R|SNP
89499132|NCT01524549||WT for CYP2J2*7 and homozygous for EPHX2 K55R|SNP
89499133|NCT01524549||WT for EPHX2 K55R and heterozygous for CYP2J2*7|SNP
89499134|NCT01524549||WT for EPHX2 K55R and homozygous for CYP2J2*7|SNP
89499135|NCT01524549||WT for EPHX2 K55R and WT for CYP2J2*7|SNP
89499136|NCT01524211|Experimental|Single Treatment Arm|All subjects enrolled will receive endovascular treatment with the investigational Zenith t-Branch Endovascular Graft.
89499137|NCT01442896||Primary Open Angle Glaucoma|"• Group A (diagnosis of primary open-angle glaucoma or pseudo-exfoliative glaucoma) - subjects with documented disease progression in the past and high IOP (IOP above target), disc hemorrhage, family history of glaucoma-related vision loss or thin central cornea (<510um),~Progression is confirmed with repeatable abnormal standard automated perimetry (SAP) or progressive glaucomatous optic neuropathy~For patients that have had previous glaucoma surgery, they can be included if they have had documented glaucomatous progression post-surgery~Best corrected visual acuity of 20/40 or better at enrollment"
89538303|NCT04978155||Echo group|All the patients (n=90) who had an AVF creation with preoperative venous identification by the surgeon at CHU de TOULOUSE (echo group).
89499138|NCT01442896||Healthy Individuals|"• Group B (healthy controls)- healthy subjects without any ophthalmic disease and an IOP < 22mmHg~o Normal appearing optic disc and no evidence of optic disc damage"
89499139|NCT01190787|Experimental|VMP|"INDUCTION Velcade will be given as subcutaneous (SC) injection. Each cycle will be repeated every 28 days.~Melphalan will be given orally. Each cycle will be repeated every 28 days. Prednisone will be given orally.Each cycle will be repeated every 28 days. MAINTENANCE Velcade will be given a SC injection. Each cycle will be repeated every 28 days."
89499140|NCT01190787|Experimental|VCP|"INDUCTION Velcade will be given as subcutaneous (SC) injection. Each cycle will be repeated every 28 days.~Cyclophosphamide will be given orally. Each cycle will be repeated every 28 days.~Prednisone will be given orally.Each cycle will be repeated every 28 days. MAINTENANCE Velcade will be given a SC injection. Each cycle will be repeated every 28 days."
89499141|NCT01190787|Experimental|VP|"INDUCTION Velcade will be given as subcutaneous (SC) injection. Each cycle will be repeated every 28 days.~Prednisone will be given orally.Each cycle will be repeated every 28 days. MAINTENANCE Velcade will be given a SC injection. Each cycle will be repeated every 28 days."
89499142|NCT01107717|Experimental|Triple Therapy|initiation a combination of metformin (1000 mg), pioglitazone (15 mg) and exenatide (5 microgram bid) at the time diabetes is diagnosed
89499143|NCT01107717|Active Comparator|conventional therapy|sequential addition of metformin, glyburide and basal insulin
89499144|NCT00978458|Active Comparator|Arm I|Patients undergo 3-dimensional conformal or intensity-modulated radiotherapy once daily 5 days a week for 5½ weeks (28 fractions).
89499145|NCT00978458|Experimental|Arm II|Patients undergo radiotherapy as in arm I and receive concurrent oral temozolomide once daily for 5½ weeks. Beginning 28 days after completion of chemoradiotherapy, patients receive oral temozolomide alone once daily on days 1-5. Treatment with temozolomide repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.
89499146|NCT00882895|Experimental|Allogeneic Transplant|"TLI - 80 cGy on days -14, -11, -10, -9, -8, -7, -4, -3, -2, -1~Anti-thymocyte globulin (ATG) 1.5 mg/kg on days -11, -10, -8, -7~Solumedrol - 1 mg/kg on days -11, -10, -9, -8, -7~Tacrolimus - beginning on day -3 with starting dose of 0.3 mg/kg PO BID. Will be continued per institutional guidelines.~Stem cell infusion - day 0~Mycophenolate mofetil (MMF) - beginning on day 0 with dose of 15 mg/kg PO (5-10 hours after transplant)"
89499147|NCT00819546|Other|Only one arm on this study.|
89499148|NCT00794352||Healthy Volunteer|Healthy patients with NO inflammatory and/or demyelinating/dysmyelinating diseases of the CN
89499149|NCT00794352||Patient Cohort|Patients who present with CNS white matter injury (including inflammatory and/or demyelinating/dysmyelinating diseases of the CNS)
89499150|NCT00776412||HIV negative|Healthy Volunteer cohort
89499151|NCT00776412||HIV positive INR|HIV positive INR cohort
89499152|NCT00776412||HIV positive Standard|HIV positive Standard cohort
89499153|NCT00730678||All Participants|All participants enrolled on this study will have blood drawn for genetic testing.
89499154|NCT00588029||1|breast cancer patients
89499155|NCT00588029||2|control subjects without breast cancer
89499156|NCT00548236|Experimental|1|Immediate participation in a 16-week exercise program
89499157|NCT00548236|No Intervention|2|Control population; will receive exercise plan after 16-week control period
89499158|NCT00368615||1|Subjects ages 18-85 years old with biopsy proven melanoma. Peripheral blood will be collected from adults ages 18-85 years old. These samples will then be used for PCR analysis and to generate melanoma-specific T cell clones. If the participant requires a palliative resection of a melanoma tumor(s) then tissue from the tumor will be used to characterize the melanoma's interaction with the immune system and to generate melanoma-specific cell lines. T cell clones isolated from participant's peripheral blood will then be assayed for in-vitro responsiveness to these cell lines. All experiments will be conducted in-vitro.
89499159|NCT00368615||2|Age-matched controls (no evidence of melanoma)
89499160|NCT00060775||Non-Targets|Characterized by temperament - no behavioral inhibition
89499161|NCT00060775||Parents|Parents of children enrolled in the study
89499162|NCT00060775||Targets|Characterized by temperament - high/low behavioral inhibition
89499163|NCT00001254||Patients|Patients will Zollinger-Ellison Syndrome
89499164|NCT05528042|Other|N/A, only one arm|All the patients that would like to participate and those where the inclusion criteria are past, are available to make the test. No drugs are administered.
88955807|NCT06195189|Experimental|Sunvozertinib combined with chemotherapy (Pemetrexed +platinum)|Sunvozertinib 200mg Quaquedie (QD) combined with chemotherapy (Pemetrexed +platinum)
89538304|NCT04978155||Control|All the patients (n=93) who had a native AVF placed during the year 2019 without having received immediate preoperative ultrasound and therefore there was no alteration in the surgical project in relation to that planned at the time of the consultation
88955808|NCT06194461||AZD5851|Follow-up for up to 15 years of subjects who received AZD5851 in study NCT06084884
88955809|NCT06194461||AZD0754|Follow-up for up to 15 years of subjects who received AZD0754 in study NCT06267729
89205584|NCT04741932|Experimental|Intervention|
88955812|NCT06186414|Experimental|Dose escalation-mono|BCG-unresponsive high-risk NMIBC, receiving SIM0237 monotherapy intravesically. Induction period (QW for 6 weeks) + a 3-week maintenance course or a 6-week re-induction course at Month 3 + maintenance treatment (QW for 3 weeks) at Months 6, 9, 12, and 18 + optional maintenance treatment at Months 24, 30, and 36.
88955813|NCT06186414|Experimental|Dose escalation-combo|BCG-unresponsive high-risk NMIBC, receiving SIM0237 and BCG intravesically. Induction period (QW for 6 weeks) + a 3-week maintenance course or a 6-week re-induction course at Month 3 + maintenance treatment (QW for 3 weeks) at Months 6, 9, 12, and 18 + optional maintenance treatment at Months 24, 30, and 36.
88955814|NCT06186414|Experimental|Dose expansion-Cohort 1|BCG-unresponsive CIS, receiving SIM0237 monotherapy intravesically. Induction period (QW for 6 weeks) + a 3-week maintenance course or a 6-week re-induction course at Month 3 + maintenance treatment (QW for 3 weeks) at Months 6, 9, 12, and 18 + optional maintenance treatment at Months 24, 30, and 36.
88955815|NCT06186414|Experimental|Dose expansion-Cohort 2|BCG-unresponsive CIS, receiving SIM0237 and BCG intravesically. Induction period (QW for 6 weeks) + a 3-week maintenance course or a 6-week re-induction course at Month 3 + maintenance treatment (QW for 3 weeks) at Months 6, 9, 12, and 18 + optional maintenance treatment at Months 24, 30, and 36.
89023212|NCT05837910|Placebo Comparator|Placebo Control 1|Calm Product Form 1 - control
89023213|NCT05837910|Experimental|Active Product 1.1|Calm Product Form 1 - active product 1
89023214|NCT05837910|Experimental|Active Product 1.2|Calm Product Form 1 - active product 2
89023215|NCT05837910|Experimental|Active Product 1.3|Calm Product Form 1 - active product 3
89023216|NCT05837910|Placebo Comparator|Placebo Control 2|Calm Product Form 2 - control
89499165|NCT05518292|Active Comparator|rhomboid intercostal block|Ultrasound guided RIB will apply with 10-12 MHz linear ultrasound transducer, in plane technique. Patients will placed in the sitting position. 22G spinal needle needle will be inserted to plane between the rhomboid muscle and intercostal muscles over the T5-6 ribs 2 cm to 3 cm medially from the medial border of the scapula. 20 ml of bupivacaine 0.25% will inject into the fascial plane.
89499166|NCT05518292|Active Comparator|serratus anterior plane block|Patients will placed in the lateral position with the diseased side up. A 10-12 MHz linear ultrasound transducer is placed over the mid-clavicular region of the thoracic cage in a sagittal plane. The fifth rib is identified in the mid-axillary line. The following muscles are identified easily overlying the fifth rib: the latissimus dorsi (superficial and posterior), teres major (superior) and serratus muscle (deep and inferior). As an extra-reference point, the thoracodorsal artery is used to aid the identification of the plane superficial to the serratus muscle. The needle (22G spinal needle) will be introduced in-plane with respect to the ultrasound probe targeting the plane superficial to the serratus muscle. Under continuous ultrasound guidance, 20 ml of bupivacaine 0.25% will inject.
89499167|NCT05524142||Atrial fibrillation|Patients with atrial fibrillation underwent radiofrequency ablation.
89499168|NCT05524142||Control|Patients underwent electrophysiological examination alone and were confirmed no arrhythmia.
89499169|NCT05518136|Experimental|Recovery group|Recovery group was given home-based rehab exercise periodically supervised by cellphone APP. Left ventricular ejection fractions (LVEF), the rate of increase in heart rate (rHRI), and the rate of recovery heart rate (rHRR) were measured for representing cardiopulmonary capacity. The Alberta test and Neuro-intelligence Scale were used to evaluate their motor developmental outcomes.
89499170|NCT05518136|No Intervention|Control group|General post-operative care for control group. Left ventricular ejection fractions (LVEF), the rate of increase in heart rate (rHRI), and the rate of recovery heart rate (rHRR) were measured for representing cardiopulmonary capacity. The Alberta test and Neuro-intelligence Scale were used to evaluate their motor developmental outcomes.
89499171|NCT05518058|Experimental|Control group|
89499172|NCT05518058|Experimental|Study group|
89499173|NCT05517824|Active Comparator|Post-treatment|After a single treatment using a microinsulated needle RF device
89499174|NCT05517824|No Intervention|Pre-treatment (Baseline)|
89499175|NCT04425356|Experimental|Intervention Group|This group will receive the LifeXT program
89499176|NCT04425356|No Intervention|Control Group|Wait-list control group that receives the LifeXT program after the conclusion of the study
89499177|NCT05527496||Patients with Helicobacter pylori infection|Patients with H. pylori infection identified by testing for H. pylori.
89499178|NCT05527496||Patients not infected with Helicobacter pylori|Patients without H. pylori infection identified by H. pylori testing.
89499179|NCT04141904|Experimental|Tofacitinib|Tofacitinib 5mg capsule twice a day for 7-10 days
89499180|NCT04141904|Placebo Comparator|Placebo|Placebo capsule twice a day for 7-10 days
89499181|NCT04622462||Oral Mucosal Biopsies With or Without Evidence of Epithelial Dysplasia|"No evidence of dysplasia~Mild dysplasia~Moderate dysplasia~Severe dysplasia"
89499182|NCT02144051|Experimental|AZD5312|"AZD5312 will be given intravenously (IV) as an infusion, over one hour. For the purpose of planning, each 4 week period (28 days) will be called a Cycle. AZD5312 will initially be administered 4 times within the first 11 days, (on Days [1, 4, 8 and 11]± 2), with no dosing on sequential days. Patients will receive weekly treatments on Days 15 and 22 to complete Cycle~1. During the subsequent cycles, patients will receive weekly treatment on Days 1, 8, 15 and 22 (±2)."
89499183|NCT04605848|Experimental|BAT group|"Patients will be divided in two groups for statistical analysis:~patients with detectable BAT by PET-CT (BAT+)~patients with no detectable BAT by PET-CT (BAT-)"
89023217|NCT05837910|Experimental|Active Product 2.1|Calm Product Form 2 - active product 1
89023218|NCT05837910|Placebo Comparator|Placebo Control 3|Calm Product Form 3 - control
89023219|NCT05837910|Experimental|Active Product 3.1|Calm Product Form 3 - active product 1
89023220|NCT05837910|Placebo Comparator|Placebo Control 4|Calm Product Form 4 - control
89023221|NCT05837910|Experimental|Active Product 4.1|Calm Product Form 4 - active product 1
89023222|NCT05837481|Experimental|Meditation Group|Two sessions of guided meditation on the day of surgery, both to occur before the start of surgery
89023223|NCT05837481|No Intervention|Control Group|Standard of care, which does not involve any meditation programs
89023224|NCT05830058|Experimental|ARM I: (standard care SBRT)|Patients undergo 5 SBRT treatments every other day on study. Patients also undergo CT or PET/CT and blood collection throughout study.
89023225|NCT05830058|Experimental|ARM II: (PET guided SBRT)|ARM II: Patients undergo 3 SBRT treatments every other day week 1, undergo PET/CT and replanning one month post SBRT, then undergo 2 additional treatments with SIB on study. Patients also undergo CT or PET/CT and blood collection throughout study.
89023226|NCT05829343||Robotic surgery group|Patients with diverticular disease resected with a robotic approach.
89023227|NCT05829343||Laparoscopic surgery group|Patients with diverticular disease resected with a laparoscopic approach.
89023228|NCT05826847|Sham Comparator|Control Group|ARDS patients at spontaneous breathing onset on pressure support ventilation mode in supine position at 45º degrees, performed under standard PEEP according to ARDSNet strategy and individualized PEEP applied in random order.
89205585|NCT04679961||Experimental|"Epidermal inflammations, including eczematous diseases and psoriasis~Epidermal tumors, including benign tumors and malignant tumors~Pigmented diseases, including hypopigmentation and hyperpigmentation"
89205586|NCT04679961||Control|Healthy skin
89499184|NCT05517746|Experimental|Group 1|Participants received BAY2395840 dose A as tablets under diet 1 conditions (Period 1). After the safety assessment for Period 1 and a washout period of at least 14 days participants were re-dosed with the same BAY2395840 dose A1 as oral solution under diet 1 conditions (Period 2)
89499185|NCT05517746|Experimental|Group 2|Participants received BAY2395840 dose C as tablets under diet 1 conditions.
89499186|NCT05517746|Experimental|Group 3|Participants received BAY2395840 dose E as tablets under diet 1 conditions.
89499187|NCT05517746|Experimental|Group 4|Participants received BAY2395840 dose H as tablets under diet 1 conditions
89499188|NCT05517746|Experimental|Group 5|Participants received BAY2395840 dose B as tablets on Day 1 after diet 2, on Days 2 to 7 under diet 1 conditions
89499189|NCT05517746|Experimental|Group 6|Participants received BAY2395840 dose C as tablets on Day 1 after diet 2, on Days 2 to 7 under diet 1 conditions
89499190|NCT05517746|Experimental|Group 7|Participants received BAY2395840 dose I as tablets under diet 1 conditions
89499191|NCT05517746|Experimental|Group 8|Participants received BAY2395840 dose G as tablets on Day 1, followed by 3 BAY395840 doses of dose F as tablets on Days 2 to 4 and subsequently 7 further BAY395840 doses of dose G as tablets on Days 5 to 11 under diet 1 conditions
89499192|NCT05517746|Placebo Comparator|Placebo matching Group 1|Participants received a dose of placebo as tablets under diet 1 conditions (Period 1). After the safety assessment for Period 1 and a washout period of at least 14 days participants were re-dosed with a single dose of placebo as oral solution under under diet 1 conditions (Period 2)
89499193|NCT05517746|Placebo Comparator|Placebo matching Group 2 to 4 and Group 7|Participants received a dose of Placebo as tablets under diet 1 conditions
89499194|NCT05517746|Placebo Comparator|Placebo matching Group 5 and 6|Participants received Placebo as tablets on Day 1 after diet 2, on Days 2 to 7 under diet 1 conditions
89499195|NCT05517746|Placebo Comparator|Placebo matching Group 8|Participants received a dose of Placebo as tablets on Day 1, followed by 3 doses of Placebo as tablets on Days 2 to 4 and subsequently 7 further doses of Placebo as tablets on Days 5 to 11 under diet 1 conditions.
89499196|NCT05527340|Experimental|iberdomide + dexamethasone (IBERDEX)|"IBERDEX~Iberdomide on days 1 to 21 at 1.6 mg, every 4 weeks, orally (PO).~Dexamethasone will be given on days 1, 8, 15, and 22 at 40 mg (patients aged ≥ 75 years: 20 mg), every 4 weeks, PO."
89499197|NCT05527340|Experimental|iberdomide + daratumumab + dexamethasone (IBERDARADEX)|"IBERDARADEX~Iberdomide on days 1 to 21 at 1.6 mg, every 4 weeks, PO.~Dexamethasone will be given on days 1, 8, 15, and 22 at 40 mg (patients aged ≥ 75 years: 20 mg), every 4 weeks, PO.~Daratumumab will be given at 1800 mg, every 4 weeks, subcutaneously (SC). Cycles 1 and 2 (C1 and C2): Days 1, 8, 15, and 22 C3-6: Days 1 and 15 From C7 onwards: Day 1 of each cycle Cycles will be of 4 weeks of duration (28 days)."
89499198|NCT05523752|Other|Proseal Laryngeal Mask|
89499199|NCT05523752|Other|Classic Laryngeal Mask|
89499200|NCT05523752|Other|I-gel|
89499201|NCT05523752|Other|Suprema Laryngeal Mask|
89499202|NCT02572388|Active Comparator|Group 1|10µg of R21 mixed with 50µg of Matrix-M on days 0, 28, and 56.
89499203|NCT02572388|Active Comparator|Group 2|50µg of R21 on days 0, 28, and 56.
89499204|NCT02572388|Active Comparator|Group 3|50µg of R21 mixed with 50µg of Matrix-M on days 0, 28, and 56.
89499205|NCT02572388|Active Comparator|Group 4|2µg of R21 mixed with 50µg of Matrix-M
89205587|NCT04669249|Experimental|PROCare|Technology-enabled, reward-based recovery platform
89499206|NCT05523518|Experimental|The Buzzy® group|From one minute before the location of the catheter and until the end of the procedure, the researchers will place the Buzzy® device approximately 5cm above the area where the procedure will take place, with its wings under it. The gel in its wings will have been previously frozen solid in a refrigerator. In this way, vibration and cold will be applied, and immediately afterwards, vein entry will be performed. (For the children's safety, a piece of thin sterile gauze will be placed on the area in order to prevent direct contact between the ice wings and the skin.)
89499207|NCT05523518|Experimental|the AccuVein® group|In this group, the veins in the area where the entry is to be performed will be visualized with the AccuVein® infrared vein visualization device, and the standard catheter implementation will be performed in the vein which is decided on for entry.
89499208|NCT05523518|No Intervention|The control group|With the pediatric patients in the control group, no intervention will be performed before or during the procedure, and routine IV catheterization will be carried out without the use of any device.
89499209|NCT05517512||Gestational Hypertension|
89499210|NCT05517512||Pre Eclampsia|
89499211|NCT05517512||Control|
89499212|NCT05162924|Experimental|Spinal manipulation|Group receiving 12 sessions of spinal manipulative therapy in the lumbar area
89499213|NCT05162924|Placebo Comparator|Placebo|Group receiving 12 sessions of placebo spinal manipulative therapy in the lumbar area
89205588|NCT04669249|No Intervention|Control|Treatment-as-Usual
89205589|NCT04667702||Patient Focused Interviews|
89205590|NCT04667702||Caregiver Focused Interviews|
89205591|NCT04667702||Healthcare Provider Focused Interviews|
89499214|NCT05162924|No Intervention|Healthy controls|A healthy control population will receive no treatment during the same time period (4 weeks) to measure the same physiological variables and their evolution.
89499215|NCT05527106|Experimental|Citicoline|Cebrolux 800 is a food supplement based on citicoline (163 mg) that also contains vitamin A, E, C and B6.
89023229|NCT05826847|Experimental|Prone Positioning|ARDS patients at spontaneous breathing onset on pressure support ventilation mode in prone position, performed under standard PEEP according to ARDSNet strategy and individualized PEEP applied in random order.
89023230|NCT05826847|Experimental|Thoracoabdominal Binding|ARDS patients at spontaneous breathing onset on pressure support ventilation mode in supine position at 45º degrees using thoracoabdominal binding with the binder's upper edge above the costal margin, performed under standard PEEP according to ARDSNet strategy and individualized PEEP applied in random order.
89023231|NCT05825963|Experimental|PEHM/CHM|In this arm, participants received psyllium-enriched hamburger meatballs first, then after the washout period, they received classic hamburger meatballs.
89023232|NCT05825963|Experimental|CHM/PEHM|In this arm, participants received classic hamburger meatballs first, then after the washout period, they received psyllium-enriched hamburger meatballs.
89499216|NCT05527106|Experimental|Docosahexaenoic Acid (DHA)|Brudypio 1.5g is a food supplement based on Omega-3 fatty acid in the form of triglycerides (DHA 70% [350 mg], EPA 8.5%, DPA 6%) that also contains vitamins (A, B1, B2, B3, B6, B9, B12, C, E), carotenoids ( lutein, zeaxanthin, lycopene), glutathione, coenzyme Q10 and minerals (Zn, Se, Cu, Mn).
89499217|NCT05527106|Experimental|Citicoline and Docosahexaenoic Acid (DHA)|Cebrolux 800 and Brudypio 1.5g (see above).
89499218|NCT05527106|Experimental|Vitamin C|Vitamin C.
89499219|NCT05517434|Experimental|For STUDY 1 (ARM A): Bone Marrow Aspirate Concentrate (BMAC)|This group will undergo a bone marrow aspiration and receive an ultrasound guided intra-articular injection of BMAC (a single dose of concentrated cell suspension of 9 mL or less)
89499220|NCT05517434|Placebo Comparator|For STUDY 1 (ARM C): Saline Injection|This group will undergo a bone marrow aspiration and receive an ultrasound guided intra-articular injection of saline solution (9 mL)
89499221|NCT05517434|Experimental|For STUDY 2 (ARM B): Lipoaspirate + Leukocyte-Poor Platelet-Rich Plasma (LAC + LP-PRP)|This group will undergo a blood collection/lipoaspiration and receive an ultrasound guided intra-articular injection of LAC (a single dose of concentrated cell suspension of 9 mL or less) followed by LP-PRP (a single dose of concentrated cell suspension of 2 mL or less)
89499222|NCT05517434|Placebo Comparator|For STUDY 2 (ARM D): Saline Injection|This group will undergo a blood collection/lipoaspiration and receive ultrasound guided intra-articular injections of saline solution (9 mL followed by 2 mL)
89499223|NCT05517356|Experimental|Malperfusion Cohort|"Patients presenting to hospital with ATAAD meeting criteria for malperfusion syndrome which includes both components:~Radiographic findings reveal occlusion of the corresponding arteries (including either coronary artery, either carotid artery, celiac trunk, superior mesenteric artery or either iliac artery).~Clinical features of end organ ischemia (abnormal left ventricular wall motion, disorder of consciousness or paralysis, abdominal pain, distended abdomen, pulselessness, loss of sensory or motor function of the lower extremities) OR Laboratory findings suggestive of end organ ischemia (elevated troponin, elevated creatine kinase, lactic acidosis, elevated myoglobin)."
89499224|NCT05523128|Experimental|ZS802|Single intravenous (i.v.) infusion of ZS802 Intervention: Gene Therapy / Gene Transfer
89499225|NCT05526794||Group 1|General anesthesia or sedation
89499226|NCT05526794||Group 2|Central Block (Spinal and Epidural Anesthesia
89499227|NCT05526794||Group 3|Peripheral Block [Erector Spina Plane Block (ESPB), and Paravertebral Block (PVB)
89499228|NCT05523050|Other|active enterostomy|active enterostomy before serious complications
89499229|NCT05522894|Experimental|Cohort A|AK104 alone
89499230|NCT05522894|Experimental|Cohort B|AK104 in combination with chemotherapy
89499231|NCT05526638|Experimental|New/ recurrent mycosis fungoides patients|New' Recurrent mycosis fungoides treatment will receive be assessed for both serum and tissue levels of IL-15 and IL-15 Rα prior to and after treatment with phototherapy
89499232|NCT05522816|Experimental|KX01 0.01% in stage I|Six patients in the stage 1 will receive KX01 0.01% (0.1 mg/g) for 2 weeks, followed by 1-week wash-out, another 2-week treatment, and then 2-week follow-up.
89499233|NCT05522816|Placebo Comparator|Placebo in stage 1|Two patients in the stage 1 will receive placebo treatment for 2 weeks, followed by 1-week wash-out, another 2-week treatment, and then 2-week follow-up.
89499234|NCT05522816|Experimental|KX01 0.1% in stage 2|Six patients in the stage 2 will receive KX01 0.1% (1.0 mg/g) for 4 weeks, followed by 2-week follow-up.
89499235|NCT05522816|Placebo Comparator|Placebo in stage 2|Two patients in the stage 2 will receive placebo treatment for 4 weeks, followed by 2-week follow-up.
89499236|NCT05522816|Experimental|KX01 1% for 5 days in stage 3|Six patients in stage 3 will receive 1% KX01 (10 mg/g) once daily for consecutive 5 days and then receive post-treatment follow-up on Day 6, 15 and 29.
89499237|NCT05522816|Experimental|KX01 1% for consecutive 5 days and 2 days rest for 1 cycle, and repeat up to 4 cycles in stage 4|Six patients in stage 4 will be treated with daily KX01 1% (10 mg/g) ointment for consecutive 5 days and 2 days rest for 1 cycle, and repeat up to 4 cycles. And post-treatment follow-up visits will be conducted 14 days (Follow-up visit 1) and 28 days (Follow-up visit 2) after the end of cycle 4 treatment.
89499238|NCT05010746|Experimental|MV replacement with Innovalve MR system|MV replacement with Innovalve MR system
89499239|NCT05154500|Experimental|Biofortified Potato with iron or zinc ('A')|Women volunteers will consume biofortified ('A') for one day in zinc study, and 10 days in iron study Zinc study and a local non-fortified Peruanita potato variety ('B') in a randomized order (either A-B or B-A). The potatoes have significantly different (p<0.001) content of iron or zinc, but no significant differences in vitamin C or phenolics (p>0.05). Based on this study design, every woman is her own control.
89499240|NCT05154500|Placebo Comparator|Non Biofortified potato with iron or zinc ('B')|Women volunteers will consume no biofortified ('B') for one day in zinc study, and 10 days in iron study
89499241|NCT05153954||Colorectal cancer patients|Patients who can be treated with either PME or TME and receive a primary anastomosis during surgery.
89499242|NCT02573870|Experimental|Batefenterol + Fluticasone Furoate|Subjects will self-administer batefenterol/fluticasone furoate 300/100 micrograms inhalation powder once daily for 42 days. Albuterol will be provided from screening to Day 42, to use as needed for symptom relief.
89205592|NCT04660162|Experimental|Arm-1: Laser speckle contrast imaging|(Perimed AB, Järfälla, Sweden)
89205593|NCT04660162|Experimental|Arm-2: Laser Doppler perfusion imaging|(Moor Instruments, Devon, UK)
89023233|NCT05825469|Experimental|Nutrition Algorithm (NACHO)|"Study procedures will be conducted as follows:~Development of nutrition algorithm by dietitian panel participants with oncology clinician consultation via convened group meetings.~Refinement of draft algorithms through feedback from participants and Family Advisory Council (PFAC) members.~Baseline questionnaires for participants.~Semi-structured interviews and/or focus groups with participants to evaluate algorithm usability and acceptability.~Participant questionnaires."
89023234|NCT05823480|Experimental|Treatment (magrolimab, azacitidine)|Patients undergo allo HCT per standard of care. Patients then receive magrolimab IV and azacitidine IV on study. Patients undergo ECHO or MUGA during screening and blood sample collection and bone marrow biopsy and aspirate throughout the study.
89499243|NCT02573870|Placebo Comparator|Placebo|Subjects will self-administer matching placebo inhalation powder once daily for 42 days. Albuterol will be provided from screening to Day 42, to use as needed for symptom relief.
89499244|NCT02572076|Experimental|Motus Cleansing System (MCS)|The MCS enables colon cleansing during standard colonoscopy using a standard colonoscope. The cleansing device, which is attached to the tip of the colonoscope and is connected to an external workstation, generates fluid jets within the colon thus dissolving the feces into small parts. The fecal matter & fluids are drained through the evacuation pipe of the cleansing device into a collecting reservoir.
89499245|NCT04995458|Experimental|Composite-ceramic|To assess the clinical performance and survival of posterior composite-ceramic implant-supported crowns
89499246|NCT04995458|Active Comparator|Monolithic zirconia|To assess the clinical performance and survival of posterior monolitihic zirconia implant-supported crowns
89499247|NCT02571452|Experimental|Brief Behavioral Treatment for Insomnia|Participants will receive 4 weeks of Brief Behavioral Treatment for Insomnia (BBTI). BBTI consists of two in-person sessions, with the two other sessions conducted via telephone. BBTI emphasizes behavioral elements of insomnia treatment. Treatment begins with sleep education and discussion of the biological rhythms that influence sleep cycles. Next, a series of interventions are employed that are derived from sleep restriction and stimulus control techniques.
89499248|NCT02571452|Active Comparator|Progressive Muscle Relaxation|Participants will receive 4 weeks of progressive muscle relaxation training (PMRT). PMRT consists of two in-person and two phone sessions. Treatment begins with training on muscle tensing and relaxing, and advances to progressively more efficient tensing-relaxing and passive relaxation exercises. Sessions are employed that teach techniques and problem-solve barriers to the use of PMRT.
89499249|NCT05526170||Patients with previously diagnosed paroxysmal or persistent atrial fibrillation|Patients with previously diagnosed paroxysmal or persistent atrial fibrillation who are in sinus rhythm at inclusion time. During trial period subjects will be monitored for different atrial arrhythmias and divided into the following subgroups: atrial fibrillation, atrial flutter, atrial tachycardia, premature atrial contractions (bigeminy, trigeminy, couplets), multiple atrial arrhythmias and no arrhythmia detected.
89499250|NCT05522348|Experimental|Stability of a two piece PSI deign in splintless maxillary orthognathic surgery|A two piece fixation device will be used connecting the nasomaxillary and the zygomaticomaxillary buttresses on both sides
89499251|NCT05522348|Active Comparator|Stability of a one piece PSI deign in splintless maxillary orthognathic surgery|A one piece fixation device will be used extending from one zygomaticomaxillary buttress to the nasomaxillary area then just below the anterior nasal spine then to the same buttresses on the other side
89499252|NCT05525936||Critically-ill patients|"Patients admitted to intensive care unit~inserted with a central venous catheter in the superior vena cava territory or a pulmonary arterial catheter for their management, and requiring one or both of the following:~invasive ventilation, and/or~catecholamine infusion."
89499253|NCT05148026|Active Comparator|Anticoagulation sequence 1 (UFH+ RCA)|UFH+ RCA first
89499254|NCT05148026|Active Comparator|Anticoagulation sequence 2 (UFH)|UFH first
89499255|NCT05516420||Patients with first abdominal surgery in Scotland between 2009 and 2011|Patients with first abdominal surgery in Scotland between 2009 and 2011
89499256|NCT04991714|Experimental|Sucrose|10% solution in water
89499257|NCT04991714|Experimental|Sucrose + Reb M|10% sucrose + 60 mg/L Rebaudioside M
89499258|NCT04991714|Experimental|Sucrose + Lactisole|10% sucrose + 30 mg/ L Lactisole
89499259|NCT04991714|Experimental|Sucrose + Reb M + Lactisole|10% sucrose + 60 mg/L Rebaudioside M + 30 mg/ L Lactisole
89499260|NCT05522270|Experimental|revitalization by concentrated growth factor|modified platelet concentrate
89499261|NCT05522270|Active Comparator|revitalization by platelet rich fibrin|platelet concentrate
89499262|NCT05522192|Experimental|Venetoclax-Mitoxantrone liposome|"Phase I~Mitoxantrone liposome~Level 1: 24mg/m^2, ivgtt, d1;~Level 2: 30mg/m^2, ivgtt, d1;~Level 3: 36mg/m^2, ivgtt, d1;~Venetoclax: 100mg po d1, 200mg po d2, 400mg po d3-28.~Every 4 weeks is a cycle, a total of 2 cycles, the first cycle to observe DLT.~Phase II~Mitoxantrone liposome: RP2D~Venetoclax: 100mg po d1, 200mg po d2, 400mg po d3-28.~28 days is a cycle, and a maximum of 6 cycles can be carried out. If the patient achieves CR, CRi or PR, if the patient can tolerate it, it will be used for 6 cycles; if the patient is suitable for transplantation, it can also enter the transplantation path; If the patient was evaluated as NR (no response) after 2 cycles, he could withdraw from the study."
89499263|NCT05522114|Experimental|Patient specific guided injection|Patients treated with HA injection in TMJ using PSG and the accuracy evaluated using MSCT.
89023235|NCT05823012|Experimental|XP-8121|XP-8121 100 to 1500 μg subcutaneous injection
89023236|NCT05819372|Experimental|finite arm|
89499264|NCT05516186|Experimental|Scapular-focused exercise protocol supported by real-time EMGBF|The scapular-focused exercise protocol followed the protocol described by dos Santos et al. (2021). The protocol uses sequential stages of motor relearning (cognitive, associative, and autonomous) as a framework, while promoting the integration of local and global muscle function in weekly sessions divided into three phases. The main purpose of the protocol is to increase scapular neuromuscular activity and control.
89499265|NCT05516186|Experimental|Scapular-focused exercise protocol without EMGBF|The same protocol described above was applied without EMGBF
89499266|NCT05516186|Other|Control therapy group|The control therapy group underwent conservative physical therapy, which included both manual and exercise therapy
89499267|NCT04624490|Experimental|Hyperpolarized 129Xe|Administration of hyperpolarized xenon during MRI (up to 1L doses) to develop imaging methods and assess pulmonary function in adults.
89499268|NCT05525702|Experimental|VR Stimulation|Patients wear head-mounted displays and experience high immersive virtual environments for treatment.
89499269|NCT05525702|No Intervention|Standard ICU Care|Patients will be treated with standard ICU care and not receive VR stimulation.
89499270|NCT05525624|Experimental|Experimental|"TRAMPRE is an acronym that defines multimodal interventions discharge training. TRAMPRE will be applied to the participants in line with the Preterm Baby Care Guide at the discharge stage. Weekly telephone follow-up will be carried out for 12 weeks after discharge. Applications to be made to the initiative group are given below. Phone Follow-up/Interview: During the first 12 weeks following the discharge of the preterm baby, parents will be interviewed by phone at least once a week."
89499271|NCT05525624|Active Comparator|Control Group|Participants in this group will be included in the routine neonatal clinic discharge training of the hospital where the research was conducted and no intervention will be applied.
89499272|NCT05516030|Experimental|HIFT for People with MRD|12-week, thrice weekly HIFT intervention for adults with MRD at a local facility that currently hosts HIFT for people with disability and, thus, is conducive to the training needs of individuals with MRD. We will provide financial support for 12-week membership costs, transportation, and participant compensation for completing pre- and post-intervention assessments. Baseline and post-intervention testing will include assessments of weight, body composition, flexibility, and strength, in addition to quality of life, sense of community, self-determination, sleep, and life satisfaction. Each participant will also have energy expenditure assessed during two, randomly selected HIFT sessions during the 12-wk intervention.
89499273|NCT04296812|Experimental|Injeti Self-Love Model|"Psychoeducational intervention focusing improving self-esteem and increasing self-awareness.~The session will start with discussion on healthy relationships, self-esteem.~A white board will be used in group format and regular 8.5 by 11 paper during individual session to illustrate the Self-Love model and the characteristics and traits that are effected by self-love and lack of self-love.~At the end of illustration and discussion there will be handout of the self-love intervention.~The session will end by answering questions and emphasizing the importance of having self-awareness of traits that promote low-self-esteem, and finally, strategies to promote and maintain self-esteem."
89499274|NCT05521724|Experimental|exercise group|"The exercise protocol includes balance training and resistance training for all major muscle groups. The program will be performed twice a week.~Squat~Step up~Step-up sideways~Upright row~Chest presS~Biceps curl In balance exercises; It will start with static balance exercises and progress to dynamic balance exercises and will be applied 2 days a week for a minimum of 15 minutes.~Tandem stance~Semitandem stance~Standing exercises on one leg will be performed first with eyes open and then with eyes closed.~As dynamic balance exercises;~Just tip toe walking~Don't just walk on heels~Tandem walking is selected."
89499275|NCT05521724|Active Comparator|control group|No intervention will be made to the control group during the study.
89499276|NCT05525234|Experimental|Thalidomide group|Thalidomide tablets, 50mg/day, increase or decrease dose according to itch score. The maximum dose is 100mg/day.
89499277|NCT05525234|Placebo Comparator|Placebo group|Palacebo tablets, 50mg/day, increase or decrease dose according to itch score. The maximum dose is 100mg/day.
89499278|NCT02574260|Experimental|Talimogene Laherparepvec|Participants received talimogene laherparepvec 10⁸ plaque forming units (PFU)/mL (up to 4 mL depending on tumor size) administered intratumorally every 2 weeks, on Day 1 and Day 15 of 28-day cycles until discontinuation criteria were met.
89499279|NCT05521490|Other|Usual Care Control|Children allocated to the control group will continue with their usual curriculum, which includes the stipulated 30 minutes of daily physical activity.
89499280|NCT05521490|Experimental|Physical Activity Enhanced Curriculum|Children allocated to the intervention group will receive enhanced physical fitness and healthy lifestyle education and a physical activity enhanced curriculum during their school year.
89499281|NCT04295330|Experimental|Lidocaine group|at the end of the induction of general anesthesia, a bolus injection of lidocaine 1.5 mg/kg, calculated using the patient's ideal body weight and given as an infusion over 10 minutes, followed by a continuous infusion of lidocaine at 1.5 mg/kg per hour for the whole surgical procedure and will be discontinued at the end of surgery.
89499282|NCT04295330|Placebo Comparator|placebo group|the same volume of normal saline will be administered during anesthesia.
89531842|NCT05142111|Experimental|Sexual therapy|In the sessions a series of questions will be proposed to the subject, who will be free to answer or not, being able to express questions in turn. The sessions will last about 45 minutes, and will be held once a week, for a total of 6 sessions.
89023237|NCT05817084|Active Comparator|12 patients with varus knee malalignment and acl deficiency under went acl reconstruction and hto|anterior cruciate ligament reconstruction and medial opening wedge high tibial osteotomy in the same session
89023238|NCT05817084|Active Comparator|12 patients with varus knee malalignment and acl deficiency underwent acl reconstruction|anterior cruciate ligament reconstruction alone.
89499283|NCT05525156|Experimental|Aspirin arm|In addition to their antiretroviral regimen, participants self administer blister packaged enteric coated tablet of 75 mg aspirin (Cardisprin 75, Cosmos, Nairobi, Kenya) for 24 weeks at a dose of one tablet per day at evening times swallowed wholly with a glass of clean drinking water, preferably after a meal. All adults initiating antiretroviral therapy are prescribed the default combination of tenofovir (TDF) +lamivudine (3TC)+dolutegravir (DTG). Those with contraindications are alternatively prescribed abacavir+3TC+DTG or TDF +3TC+efavirenz and in special situations zidovudine+3TC+DTG
89499284|NCT05525156|Placebo Comparator|Placebo arm|In addition to their antiretroviral regimen, participants self administer blister packaged placebo (Cardisprin 75, Cosmos, Nairobi, Kenya) for 24 weeks at a dose of one tablet per day at evening times swallowed wholly with a glass of clean drinking water, preferably after a meal. The placebo has colour, shape and size similar to aspirin
89499285|NCT05521334|Experimental|Adult Glaucomatous patients with refractory glaucoma|Adult glaucomatous patients with uncontrolled intraocular pressure despite maximal tolerated medical treatment
89023239|NCT05816850||Patients enrolled|Patient affected by advanced Follicular Lymphoma treated with immunochemotherapy in the FIL_FOLL12 trial
89023240|NCT05816057|Experimental|semaglutide injection|Semaglutide 0.25 mg、0.5 mg、1.0mg
89023241|NCT05816057|Active Comparator|ozempic®|Ozempic® 0.25 mg、0.5 mg、1.0mg
89023242|NCT05807594|Experimental|HMZ 2.0 Intervention Group|HMZ 2.0 will be delivered by a registered dietitian in weekly didactic, one-on-one discussions in remote synchronous format (e.g., Zoom). If a subject has internet connectivity issues, she will be able to participate in the remote sessions from an onsite location (e.g., laboratory space on the Penn State University Park campus, clinical space at Hershey campus or Geisinger). All intervention women will receive the baseline intervention delivered as a maximum of 24 weekly modules (depending on gestational age at enrollment) which includes: Education and Counseling (GWG/PA/EI/sedentary behaviors/sleep behaviors/stress management, etc.), Goal-Setting and Action Plans (guided and self-selected PA/EI goals including recipe and workout booklet use), Self-Monitoring (wearing/using mHealth tools to monitor GWG/PA/EI/sleep), and Featured Evidence and Fetal Growth Facts (evidence-based studies and baby growth fun facts shared with women about how mom's health impacts her baby).
89023243|NCT05807594|Active Comparator|Attention Control Group|All women will receive prenatal care offered by recruitment sites with routine provider visits, prenatal counseling, brief discussions on healthy prenatal behaviors, and clinical oversight of health (e.g., monitor glucose levels if diagnosed with gestational diabetes during the study period). Women randomized to the attention control group will complete the same measurement procedures as the intervention group. To match the HMZ intervention group, women will receive weekly, remote-delivered education content (60 min/session) on preparing for labor/delivery and benefits of behavioral pain management strategies (e.g., mindfulness-based relaxation, imagery, music, massage, deep-breathing) to regulate pain after childbirth with non-pharmacological approaches. Content is drawn from evidence-based guidelines and materials designed by Dr. Downs and her team for a Patient-Provider Toolbox to reduce opioid-related pain management use after childbirth.
89205594|NCT04570553|Experimental|V-care uterine manipulator|Patients in the V-care uterine manipulator arm will undergo standard staging surgery utilizing a V-care uterine manipulator in the standard fashion
89205595|NCT04570553|Active Comparator|Sponge stick|Patients in the sponge stick arm will undergo standard staging surgery utilizing a non-invasive sponge stick for cervical delineation.
89205596|NCT04546516||HYAcorp Lips|HYAcorp Lips is indicated for the restoration of volume and contour of the lips.
89205597|NCT04546516||HYAcorp Face|HYAcorp Face is indicated for volume replacement (filling of folds), medium to deep folds, nasolabial folds, cheek area, glabella. It is not intended for injection to the periorbital region (eyelid, crow's feet, circles under the eyes).
89205598|NCT04546152||HYAPROF® SOFT|HYAPROF® SOFT is indicated for volume replacement (filling of folds), fine to medium folds, lip augmentation, periorbital region.
89205599|NCT04546152||HYAPROF® BALANCE|HYAPROF® BALANCE is indicated for volume replacement (filling of folds), deep folds, nasolabial folds, cheek area, glabella folds. It is not intended for injection to the periorbital region (eyelid, crow's feet, circles under the eyes).
89205600|NCT04545944|Experimental|Midazolam single doses / Vonoprazan multiple doses|Single oral doses of 2 mg of midazolam syrup on Day 1 and Day 9 and twice daily (BID) doses of 20 mg vonoprazan oral tablets on Days 2 through 10
89205601|NCT04529928|Experimental|Implanted|Subjects successfully implanted with the Carillon Mitral Contour System
89023244|NCT05806346|Active Comparator|Empirical 1: TXA and Placebo administration|"Tranexamic acid administration, regardless of the result of rotational thromboelastometry.~Placebo administration, at LI60 < 85 % or A10< 40 mm in EXTEM of rotational thromboelastometry"
89499286|NCT05512442|Experimental|record the centric relation using the gothic tracing method|the vertical dimension of occlusion (VDO) were were determineded through facial appearance observation,thus,the patients were trained to execute bordering protrusive, retrusive and bilateral lateral-protrusive movements wearing the intraoral apparatus and a Gothic Arch Tracing was made, the apex of the Gothic Arch Tracing was defined as the gothic arch position.
89499287|NCT05512442|Experimental|record the centric relation using the neuromuscular method|the participant were subjected to a low-frequency transcutaneous electrical nerve stimulation (TENS) using the J5 Myotronics for 45 minutes,With the help of TENS, complete relaxation of the muscles were achieved and the mandibular musculature was induced to guide the mandible in the physiologic position,thus using K7 to track the physical mandibular positon which was defined as the neuromuscular position.
89499288|NCT05512286|Experimental|Preoperative radiotherapy|Radiotherapy followed by mastectomy and DIEP flap reconstruction
89499289|NCT05512286|Active Comparator|Postmastectomy radiotherapy|Radiotherapy after mastectomy and DIEP flap reconstruction
89499290|NCT02570126|Experimental|VAR_HSA_F Group|2 doses of Varilrix HSA-free vaccine, one at Visit 1 (Day 0) and the other at Visit 2 (Day 42), will be given to the subjects in this group. The vaccine will be administered subcutaneously in the triceps region of the left arm
89499291|NCT02570126|Active Comparator|VAR Group|2 doses of Varilrix™ vaccine, one at Visit 1 (Day 0) and the other at Visit 2 (Day 42), will be given to the subjects in this group. The vaccine will be administered subcutaneously in the triceps region of the left arm
89499292|NCT04903184|Experimental|Group RUTI|Participants will receive two dose of RUTI® vaccine at the baseline visit and after 2 weeks +/- 3 days, which will be administered subcutaneously in the deltoid region at a dose of 25 µg of fragmented, purified and liposomed heat-inactivated Mycobacterium tuberculosis bacilli in an injection volume of 0.3 mL.
89499293|NCT04903184|Placebo Comparator|Group Placebo|Participants will receive two dose of physiological serum will be administered subcutaneously in the deltoid region at the baseline visit and after 2 weeks +/- 3 days.
89499294|NCT05512130|Experimental|Empagliflozin / Placebo|Participants randomized to this arm will receive 25 mg of empagliflozin daily for 2 weeks followed placebo daily for 2 weeks
89499295|NCT05512130|Experimental|Placebo / Empagliflozin|Participants randomized to this arm will receive placebo daily for 2 weeks followed by 25 mg of empagliflozin daily for 2 weeks
89499296|NCT05512052|Experimental|Hannah Cervical Cup (2 mm)|
89499297|NCT05512052|Experimental|Hannah Cervical Cup (4 mm)|
89499298|NCT05512052|Experimental|Hannah Cervical Cup (6 mm)|
89499299|NCT02180425||Healthy Group|The subjects in this group do not have a history of acne.
89499300|NCT02180425||Acne Group, Topical Retinoid|These subjects have been prescribed a topical retinoid for their acne. They will participate in the study for a period of 1 month.
89499301|NCT02180425||Acne Group, Isotretinoin|These subjects have been prescribed isotretinoin for their acne. They will participate in the study for a period of 5-6 months.
89499302|NCT02183467|Experimental|BI 1356, low dose|
89499303|NCT02183467|Experimental|BI 1356, high dose|
89499304|NCT02183467|Placebo Comparator|Placebo|
89499305|NCT02183467|Active Comparator|Moxifloxacin|
89499306|NCT02183545|Experimental|BI 1060469|single rising doses given as tablet
89499307|NCT02183545|Placebo Comparator|Placebo|given as tablet (matching placebo of BI 1060469)
89499308|NCT02755831|Experimental|Sleep Study + CPAP group|Pregnant women in early pregnancy may be randomized to this arm and be assigned Sleep study + CPAP treatment
89499309|NCT02755831|Other|Standard Prenatal Care group|Pregnant women in early pregnancy may be randomized to this arm and will receive standard prenatal care without CPAP treatment.
89499310|NCT05515484|Experimental|Prone position with airbags|
89023245|NCT05806346|Active Comparator|Empirical 2: TXA administration|"Tranexamic acid administration, regardless of the result of rotational thromboelastometry.~Placebo discard, at LI60 ≥ 85% or A10 ≥ 40 mm in EXTEM of rotational thromboelastometry"
89023246|NCT05806346|Experimental|Goal-directed 1: Placebo administration|"Placebo administration, regardless of the result of rotational thromboelastometry.~Tranexamic acid administration at LI60 < 85 % or A10 < 40 mm in EXTEM of rotational thromboelastometry"
89023247|NCT05806346|Experimental|Goal-directed 2: TXA and Placebo administration|"Placebo administration, regardless of the result of rotational thromboelastometry.~Tranexamic acid discard at LI60 ≥ 85% or A10 ≥ 40 mm in EXTEM of rotational thromboelastometry"
89023248|NCT05801614|Other|Low Carb diet|Participants will have acces to a plattform with recepies containing 30 g carbohydrate / day during the first three months and thereafter recepies containing 80 g carbohydrate/ day during the remaining 12 months
89023249|NCT05801614|Other|Low Calori diet|Participants will be asked to by low caloric diet replacement containing 850 kCal/day during the first 3 months, aiming for a weight loss of 10 kg during and thereafter will have access to recepies containing less calorie for weight maintenance during the remaining 12 months
89023250|NCT05797519|Experimental|VDyne System Treatment Arm|
89023251|NCT05796687|Experimental|My Future Self Intervention|My Future Self - 5 group sessions; 1 hour each over 5 weeks; content includes: health education around abstinence and contraception methods, and consideration of goals of parenthood and family planning in their adult future; future plans, discussion of healthy intimate partner relationships/
89023252|NCT05796687|No Intervention|Control|Youth will continue to receive any services that they would normally receive around health education.
89205602|NCT04520763|Experimental|Respiratory Muscle Exercises|Two respiratory muscle exercises
89499311|NCT05515484|Active Comparator|prone position standard of care|
89499312|NCT05521100|Experimental|Proglide group|Vascular Sutures for Transvenous Cardiac Interventions Using Proglide
89499313|NCT05521100|Active Comparator|figure eight stitch|Vascular Sutures for Transvenous Cardiac Intervention Using Conventional Figure-8 Sutures
89023253|NCT05792696|Experimental|PPI guided strategies|The decision making for prevention and treatment of hypotension was PPI guided to maintain the PPI between 1 and 3.
89499314|NCT05511974|Other|obstructive sleep apnea patients|Group I : consist of sixty-three patients having OSA. Group II : consist of sixty-three non-OSA patients.
89499315|NCT02180503|Experimental|BI 1356 BS - low dose|
89499316|NCT02180503|Experimental|BI 1356 BS - high dose|
89499317|NCT05511896|Experimental|Intermittent trunk flexion|60-min intermittent trunk flexion protocol.
89499318|NCT02177851|Experimental|Single oral iron supplement per day (120 mg)|Single oral iron dose of 120 mg per day for 3 consecutive days
89499319|NCT02177851|Active Comparator|B.i.d. oral iron supplement (2x 60 mg)|Two oral iron doses of 60 mg per day (morning + afternoon) for 3 consecutive days
89499320|NCT05075876|Experimental|Group 1 (SP-01-K)|Application of SP-01 manufactured by Site K (SP-01-K) for 6 days followed by washout period for 21 days followed by application of SP-01 manufactured by Site A (SP-01-A) for 6 days
89499321|NCT05075876|Active Comparator|Group 2 (SP-01-A)|Application of SP-01 manufactured by Site A (SP-01-A) for 6 days followed by washout period for 21 days followed by application of SP-01 manufactured by Site K (SP-01-K) for 6 days
89499322|NCT02180581|Experimental|Probiotic (2 * 10^9 cfu/d)|Daily intake of bifidobacterium animalis ssp. Lactis (BB12) and Lactobacillus Rhamnosus GG (LGG) in a dosage of 10^9 cfu/day of each strain. The probiotics are provided as powder in a sachet, and can be added to food or drink
89499323|NCT02180581|Placebo Comparator|Placebo|provided as powder in a sachet, and can be added to food or drink
89499324|NCT02180737|Experimental|Dexmeditomedine|Dexmedetomidine will be initiated at 0.6 mcg/kg/hr and titrated to achieve desired clinical effect with doses ranging from 0.2 to 1 mcg/kg/hr.
89499325|NCT05520944||Retrospective Data Collection|
89499326|NCT02183623|Experimental|BI 1356 BS and Simvastatin|
89499327|NCT05511740|No Intervention|Morning Radiation|
89499328|NCT05511740|Active Comparator|Afternoon Radiation|
89023254|NCT05792696|Other|conventional strategies|The decision making for prevention and treatment of hypotension dependent on the experience of anesthesiologist.
89499329|NCT02183701|Experimental|Telmisartan|4 weeks placebo run-in, 6-weeks fixed dose period
89499330|NCT02183701|Active Comparator|Losartan + Hydrochlorothiazide|4 weeks placebo run-in, 6-weeks fixed dose period (Losartan 50 mg / HCTZ 12.5 mg)
89499331|NCT05511662||routine follow-up|The patients were instructed to come to the hospital for routine follow-up at 1, 3, 6, and 12 months after the operation. If necessary, the investigators contacted the patients by phone for symptom follow-up and instructed them to come to the hospital for relevant examinations (eg: EKG, Holter, echocardiography, etc.)
89499332|NCT05511662||PRO follow-up|On the basis of the routine follow-up group, interactive follow-up was conducted through the chronic disease follow-up system, including the APP for regular follow-up (bound to sign the informed consent form, and the account of the patient and his immediate family who can be familiar with the WeChat applet), SMS reminders, and doctors when necessary. Wechat/platform communication and exchange, inappropriate ECG data upload and other multi-dimensional follow-up, at the same time assisting the ECG integrated follow-up platform for ECG data management and medication guidance.
89499333|NCT05141851|Active Comparator|Implants with 0,7mm threads|Placement of Implants with 0,7mm threads
89499334|NCT05141851|Active Comparator|Implants with 0,3mm threads|Placement of Implants with 0,3mm threads
89499335|NCT03537859|Experimental|Augmented Reality (AR)|Books with augmented reality plus an electronic tablet.
89023255|NCT05784181|Other|patients prostatic volume more than 80 gm turp by bipolar resection|pt with 80gm prostate size underwent bipolar resection
89023256|NCT05784181|Other|patients prostatic volume more than 80 gm turp by Laser enaculation by holmium: YAG laser|pt with 80gm prostate size underwent Laser enaculation by holmium: YAG laser
89023257|NCT05782361|Experimental|Part A- Escalation|"The safety run-in part of the study will enrol 6-12 patients. Tepotinib will be given to patients daily for three weeks. After thee weeks, patients will be given pembrolizumab immunotherapy on a 21-day cycle along side tepotinib daily.~Dose de-escalation of Tepotinib only will be performed in in Part A.. Should dose level 1 (500mg OD) be deemed non-tolerable by the SRC then a single dose de-escalation to dose level -1 (250mg OD) may be performed. Alternative dosing schedules may be explored. Recruitment into Part A will be staggered such that at least 7 days elapse between treatment of the 1st and 2nd patient of each dose level. In the dose confirmation phase, the study will first evaluate the dose level 1 with 3 patients, expanding to a maximum of 6 evaluable patients. If needed, a maximum of 6 patients will be evaluate in the dose level -1."
89205603|NCT04520763|No Intervention|Control|The control intervention consists of quiet sitting for 15 min
89205604|NCT04503395|Experimental|ESAR|Endovascular Aneurysm Repair + Heli-FX EndoAnchors
89499336|NCT03537859|Other|Non Augmented Reality (NoAR)|Conventional children book. No electronic device will be given to children.
89499337|NCT05511506|Other|first-eye group|
89499338|NCT05511506|Other|second-eye group|
89499339|NCT02183779|Experimental|Reynaud|patients with reynaud phenomena
89499340|NCT02183779|Experimental|Healthy|Healthy volunteers
89499341|NCT02183857|Other|Ultrasound|Patients in group Ultrasound will have their femoral arterial lines inserted under the guidance of US. The Ultrasound equipment used is a SonoSite 180 PLUS with an L25/10- to 5-MHz linear array transducer (SonoSite, Inc., Bothell, WA)
89499342|NCT02183857|Other|Landmark|No Device is used. Patients in group Landmark will have their femoral line inserted using the blinded, external landmark-guided technique. After localization of the femoral artery by identifying the pulse in the femoral triangle immediately distal to the inguinal ligament.
89499343|NCT02183935|No Intervention|Lifestyle counseling, metformin|Age, gender and BMI matched controls will be managed by lifestyle counseling and metformin if indicated.
89499344|NCT02183935|Active Comparator|Duodeno - jejunal liner|Duodeno-jejunal liner (Endobarrier) will be implanted for the duration of 12 months. During this time subjects will be regularly monitored for investigated parameters. In addition, subjects will be carefully monitored upon device removal for additional 12 months.
89499345|NCT02180815||ReVENT implanted group|
89023258|NCT05782361|Experimental|Part B- Expansion|The expansion part of the study will enrol 13-26 patients with NSCLC and MET exon 14 skipping mutations. The combination of tepotinib and pembrolizumab will be tested throughout this part of the study. The first cycle will test the safety run-in of tepotinib followed by the introduction of combination with pembrolizumab from cycle 2 onwards.
89499346|NCT02256397|Active Comparator|Standard comprehensive care|Standard comprehensive care at High Risk Children's Clinic
89205605|NCT04503395|Active Comparator|FEVAR|Fenestrated EndoVascular Aneurysm Repair
89499347|NCT02256397|Experimental|Enhanced comprehensive care|"standard comprehensive care at the High Risk Children's Clinic enhaced with new technologies:~If between 2 and 5 years old--> will receive Home-centered comprehensive care with the propeller~5 and above--> will receive home-centered comprehensive care with propeller and PIKO"
89499348|NCT02573246|Experimental|Cognitive Restructuring+rTMS (left)|Participants in this arm will be administered the neuromodulation enhanced cognitive restructuring intervention over the left side of the brain and will partake in short term and long term follow up testing.
89499349|NCT02573246|Sham Comparator|Cognitive Restructuring + sham rTMS|Participants in this arm will receive cognitive restructuring alone as an active intervention and will partake in short term and long term follow up testing.
89499350|NCT02573246|Experimental|Cognitive Restructuring+rTMS (right)|Participants in this arm will be administered the neuromodulation enhanced cognitive restructuring intervention over the right side of the brain and will partake in short term and long term follow up testing.
89499351|NCT02256475|Experimental|Adolescents Dose Group 1|Fixed dose of NBI-98854 administered once daily at 0800 for 14 days.
89499352|NCT02256475|Experimental|Adolescents Dose Group 2|Fixed dose of NBI-98854 administered once daily at 0800 for 14 days. Dosing will not commence until all safety and PK results from the adolescent dose group 1 have been reviewed to ensure there are no safety concerns and that maximum tolerated dose (MTD) has not been reached.
89499353|NCT02256475|Experimental|Adolescents Dose Group 3|Fixed dose of NBI-98854 administered once daily at 0800 for 14 days. Dosing will not commence until all safety and PK results from the adolescent dose group 2 have been reviewed to ensure there are no safety concerns and that MTD has not been reached.
89499354|NCT02256475|Experimental|Children Dose Group 1|Fixed dose of NBI-98854 administered once daily at 0800 for 14 days. Dosing will not commence until all safety and PK results from the adolescent dose group 1 have been reviewed to ensure there are no safety concerns and that MTD has not been reached.
89499355|NCT02256475|Experimental|Children Dose Group 2|Fixed dose of NBI-98854 administered once daily at 0800 for 14 days. Dosing will not commence until all safety and PK results from the children dose group 1 have been reviewed to ensure there are no safety concerns and that MTD has not been reached.
89499356|NCT02256475|Experimental|Children Dose Group 3|Fixed dose of NBI-98854 administered once daily at 0800 for 14 days. Dosing will not commence until all safety and PK results from the children dose group 2 have been reviewed to ensure there are no safety concerns and that MTD has not been reached.
89499357|NCT05141773|Experimental|Computed adenoma detection system (CADe) and Endocuff|CADe system can detect in the screen suspicion areas of adenomatous polyps. This is an additional help for the endoscopist for the detection of lesions. Endocuff increases the colonic surface examinated
89499358|NCT05141773|Active Comparator|Control group (Endocuff)|Endocuff increases the colonic surface examinated
89499359|NCT02177929|Experimental|adapted canoeing, handbike, conventional physiotherapy|Individuals are divided into three groups: one group adapted canoeing, one group of handbike and one grup of conventional physiotherapy.
89499360|NCT04293302||Brain abnormality|Newborn who had any gestational brain sonographic abnormality
89499361|NCT04293302||No brain abnormality|Newborn who did not have any gestational brain sonographic abnormality
89499362|NCT03537781|Experimental|Food label available, hungry state|foods will be displayed with food labels present and when participants had nothing to eat
89023259|NCT05773040|Experimental|Part 1 (dose escalation)|Part 1, the dose of JV-213 participants receive will depend on when you join this study. Up to 3 dose levels of JV-213 will be tested. About 3-6 participants will be enrolled at each dose level. The first group of participants will receive the lowest dose level of JV-213. Each new group will receive a higher dose of JV-213 than the group before it, if no intolerable side effects were seen. This will continue until the highest tolerable dose of JV-213 is found.
89023260|NCT05773040|Experimental|Part 2 (dose expansion)|Participants will receive JV-213 at the recommended dose that was found in Part 1.
89023261|NCT05772065|Active Comparator|CDC/NTCA guidelines only|The control group will have a link to US guidelines only and use it as a resource to answer the case vignettes.
89023262|NCT05772065|Experimental|LTBI ASSIST and CDC/NTCA guidelines|The intervention group will have a link to both US guidelines, and the LTBI-ASSIST tool as resources to answer the case vignettes.
89023263|NCT05770921|Experimental|Non-randomized|All subjects will be ablated using the Pulsed Field Ablation Device and Force Sensing Pulsed Field Ablation Catheter in the management of their Paroxysmal Supraventricular Tachycardia
89499363|NCT03537781|Experimental|food label available, satiated|foods will be displayed with food labels present and when participants had already eaten breaksfast
89499364|NCT03537781|Experimental|food label unavailable, hungry state|foods will be displayed without food labels present and when participants had nothing to eat
89499365|NCT03537781|Experimental|food label unavailable, satiated|foods will be displayed without food labels present and when participants had already eaten breakfast
89499366|NCT02180971|Experimental|Positive CAG with EG test|A positive finding for coronary angiography with an ergonovine provocation test is defined as transient, total, or sub-total occlusion (>90% stenosis) with signs/symptoms of myocardial ischemia (chest pain and ischemic ECG change).
89499367|NCT02180971|Experimental|Negative CAG with EG test|Negative test: less than 70% luminal narrowing, without chest pain or ST-segment changes after ergonovine coronary injection
89499368|NCT04292912|Experimental|Participants receiving GSK2798745|
89499369|NCT02184091|Experimental|Nevirapine|Single dose administration
89499370|NCT02184247|Experimental|anhydrous theophylline, 350 mg|
89499371|NCT02184247|Active Comparator|anhydrous theophylline, 300 mg|
89499372|NCT04292756|Active Comparator|Triamcinolone Acetonide 40 mg|Arm 1
89499373|NCT04292756|Active Comparator|Triamcinolone Acetonide 4 mg|Arm 2
89023264|NCT05768711|Experimental|Azacidine+Venetoclax|"Azacitidine will be administered subcutaneously at the standard dose of 75 mg/m²/d either on days 1-7 or using a 5-2-2 schedule of the 28 day-cycles.~Patiens will be exposed to Venetoclax during the first 7 or 14 days of the 28 day-cycles (number of days of Venetoclax determined during the safety run-in phase).~At cycle 1, Venetoclax will be given orally with 3-day ramp-up, at 100 mg on day 1, 200 mg on day 2 and 400 mg on days 3 to 7 or 14 of the cycle.~At all subsequent cycles, Venetoclax will be given orally at 400 mg on days 1 to 7 or 14 of the cycle.~Treatment duration will be 24 months."
89023265|NCT05760924|Active Comparator|Cardiac Resynchronization Therapy with Biventricular Pacing|Patients who are non-responders to biventricular cardiac resynchronization therapy (CRT) with indications to CRT devices with defibrillator function (CRT-D) or CRT-D leads replacement. CRT-D or CRT-D leads replacement will be performed in this group of patients.
89499374|NCT03537703|Experimental|Active tDCS + Auditory Training|Cathodal tDCS plus concurrent active auditory training exercise
89023266|NCT05760924|Experimental|Cardiac Resynchronization Therapy with Left Bundle Branch Pacing|Patients who are non-responders to biventricular cardiac resynchronization therapy (CRT) with indications to CRT devices with defibrillator function (CRT-D) or CRT-D leads replacement. CRT-D or CRT-D leads replacement with the new lead implantation to the left bundle branch and inactivation of conventional right and left ventricular pacing will be performed in this group of patients.
89499375|NCT03537703|Active Comparator|Active tDCS + Control Condition|Cathodal tDCS plus concurrent control condition
89499376|NCT03537703|Active Comparator|Sham tDCS + Auditory Training|Sham tDCS plus concurrent active auditory training exercise
89499377|NCT05520632||Children without autism spectrum disorder|Children without autism spectrum disorder undergoing BAEP
89499378|NCT05520632||Children with autism spectrum disorder|Children with autism spectrum disorder undergoing BAEP
89023267|NCT05760924|Experimental|Cardiac Resynchronization Therapy with Combined Left Bundle Branch and Left Ventricular Pacing|Patients who are non-responders to biventricular cardiac resynchronization therapy (CRT) with indications to CRT devices with defibrillator function (CRT-D) or CRT-D leads replacement. CRT-D or CRT-D leads replacement with the new lead implantation to the left bundle branch and inactivation of conventional right ventricular pacing will be performed in this group of patients.
89023268|NCT05759338|Experimental|Intervention|Using the Revian Red All LED cap 10 minutes each day for 6 months
89023269|NCT05758168|No Intervention|Layered Closure|A cutaneous layer of sutures will be placed on one side of wound, as is standard of care.
89023270|NCT05758168|Experimental|Layered Closure with Tie-Over Bolster Dressing|The other side of wound will have a cutaneous layer of sutures with the addition of a bolster dressing.
89023271|NCT05756621||Dual anti-glutamate therapy (DUAL)|"Patients who received ketamine as a continuous i.v. for 3 days (induction dose 1.5-3 mg/kg, followed by maintenance dose 2-10 mg/kg/h; dose adjustment according to EEG target of ketamine pattern) + oral perampanel via nasogastric tube for 5 days (12 mg if weight > 60 kg; 9 mg if weight 50-60 kg; 6 mg if weight < 50 kg), followed by gradual dose reduction according to clinical evolution."
89023272|NCT05756621||Control (OTHERS)|Patients who received any antiseizure and anesthetic therapy according to usual clinical practice, excluding the two anti-glutamate drugs ketamine and perampanel.
89023273|NCT05755347||Single Arm|Subjects with metastatic breast carcinoma have been receiving treatment at the study center and responding to survey questionnaires.
89023274|NCT05734729|Experimental|Pleural Arm|Patient's maximum volume is 1 litre per hour, not to exceed total 4 litres over 4 hours
89023275|NCT05734729|Experimental|Ascites arm|Patient's maximum volume is 3 litre per hour, not to exceed total 15 litres over 5 hours
89023276|NCT05728333|Experimental|Tirofiban|Tirofiban will be administrated intravenously before endovascular thrombectomy.
89023277|NCT05728333|Active Comparator|Alteplase|Alteplase will be administrated intravenously before endovascular thrombectomy.
89023278|NCT05727072|Experimental|LY3848575 IV|Single ascending doses of LY3848575 administered intravenously (IV).
89023279|NCT05727072|Placebo Comparator|Placebo IV|Placebo administered IV.
89023280|NCT05727072|Experimental|LY3848575 SC|Multiple doses of LY3848575 administered subcutaneously (SC).
89023281|NCT05727072|Placebo Comparator|Placebo SC|Placebo administered SC.
89023282|NCT05723562|Experimental|Dostarlimab monotherapy|
89023283|NCT05720520|Experimental|Mobile Application Group|Participants will use mobile application
89023284|NCT05720520|No Intervention|Control Group|Participants only will take traditional education method
89023285|NCT05719363|Experimental|POC ON|6MWT with Inogen Rove 6 POC turned ON
89023286|NCT05719363|Sham Comparator|POC OFF|6MWT with Inogen Rove 6 POC turned OFF
89023287|NCT05719285|Active Comparator|1: Single-Dose Antibiotic Prophylaxis|Patients will receive one dose of antibiotic prior to bladder onabotulinumtoxinA injection.
89023288|NCT05719285|Active Comparator|2: Multi-Dose Antibiotic Prophylaxis|Patients will receive one dose of antibiotic prior to bladder onabotulinumtoxinA injection. The same antibiotic will be continued for 3 days of total antibiotic administration with additional doses prescribed to the patient's pharmacy.
89023289|NCT05712720|Experimental|Group 1 - 50 mg RZ402|
89023290|NCT05712720|Experimental|Group 2 - 200 mg RZ402|
89023291|NCT05712720|Experimental|Group 3 - 400 mg RZ402|
89023292|NCT05712720|Placebo Comparator|Group 4 - Placebo|
89023293|NCT05708144|Experimental|Indocyanine green-Sacituzumab govitecan-hziy (ICG-SG)|The fresh excision breast cancer tissues were completely soaked in the ICG-SG incubation solution for about 10 minutes, followed by 5 minutes of rinsing with PBS buffer and drying with the use of absorbent paper. Then fluorescence imaging was performed with the DPM NIR-II system. And the result was analyzed to identify the tumor area and distinguish the tumor boundary.
89023294|NCT05698407|Experimental|Dexmedetomidine|loading dose of 0.45 microgram/ml dexmedetomidine plus 0.09% ropivacaine, maintenance dose of 0.36 microgram/ml dexmedetomidine plus 0.07% ropivacaine
89499379|NCT02178085|Experimental|Flow imaging|Glaucoma patients and healthy subjects who will undergo ocular flow imaging
89499380|NCT04597502|Placebo Comparator|Oral Placebo, Topical Placebo|Oral Placebo, Topical Placebo on both forearms and dorsal hands
89499381|NCT04597502|Experimental|Oral Placebo, Topical TC|Oral Placebo, Topical TC on both forearms and dorsal hands
89499382|NCT04597502|Experimental|Oral TC, Topical Placebo|Oral TC, Topical Placebo on both forearms and dorsal hands
89023295|NCT05698407|Active Comparator|Sufentanil|loading dose of 0.45 microgram/ml sufentanil plus 0.09% ropivacaine, maintenance dose of 0.36 microgram/ml sufentanil plus 0.07% ropivacaine
89499383|NCT04597502|Experimental|Oral TC, Topical TC|Oral TC, Topical TC on both forearms and dorsal hands
89499384|NCT02030353|Experimental|Self-regulation plus activity monitoring|Participants will receive an individual in-person session, digital smart scale, access to a website to view tracking information, weekly lessons, tailored feedback, and activity monitoring.
89499385|NCT02030353|Experimental|Self-regulation|Participants will receive an individual in-person session, digital smart scale, access to a website to view tracking information, weekly lessons, and tailored feedback.
89499386|NCT02030353|No Intervention|Delayed intervention control|Participants will receive an individual in-person session and a digital smart scale, and a modified version of the self-regulation intervention after the 6-month assessment.
89499387|NCT02184325|Experimental|Kiddi® Pharmaton Fizz, effervescent tablets|with reduced amount of minerals
89499388|NCT02184325|Active Comparator|Kiddi® Pharmaton Fizz, effervescent tablets: marketed formula|
89499389|NCT02184325|Active Comparator|Comparator product|in the form of a product that is a market leader
89499390|NCT05515172|Experimental|Intervention group|Mindfulness-based intervention is composed of micropractices, cohesion groups, affirmations, and journaling. This was administered via a webpage designed for this intervention.
89499391|NCT03537001||Penthrox|Administration of Penthrox at the beginning of the management of the traumatized adult patient
89499392|NCT03536299|Active Comparator|Single-Task Gait|The Single-Task Gait group will be provided with gait training without the Dual-Task cognitive tasks.
89499393|NCT03536299|Experimental|Dual-Task Gait|The Dual-Task Gait group will be provided with gait training AND secondary cognitive tasks during gait training.
89499394|NCT02181205|Experimental|placebo|sphenopalatine ganglion block performed with normal saline as the placebo
89499395|NCT02181205|Active Comparator|bupivacaine|sphenopalatine ganglion block performed with bupivacaine
89499396|NCT05515016|Other|A surgical technique for double chin treatment and chin advancement|the same surgical technique was performed on 10 participants with their consent. Subplatysmal fat, of the submental region, was dissected from the subcutaneous plan and the platysma muscle, then elevated as a flap to be plicated and turned, then fixed on the muscular layer of the chin. This technique provides both double chin treatment and chin advancement. It improves the profile of the face.
89023296|NCT05697939||Adolescent Idiopathic Scoliosis|Reproducibility group
89023297|NCT05691790|Active Comparator|Control Group|Participants who are allocated to the control group will receive a pamphlet about recommendation for influenza vaccines, pneumococcal vaccines, and COVID-19 vaccines (if appropriate) for older people using information from Hong Kong Department of Health. This group will receive six control telephone care visits over six weeks. We will purposively balance the characteristics of the student helpers who do the control telephone visits and the patient activation interviews. Each control telephone care visit will be around 5-10 min during which the student helper will give general guidelines about dietary health and exercise for older people. The control messages are mainly educational and designed using information derived from the websites of Hong Kong Department of Health. In the last telephone care visit, the interviewer will give a summary for how to live a healthy lifestyle and a reminder of taking the recommended vaccinations for older people shown in the pamphlet.
89499397|NCT02181283|Active Comparator|W+W|Web-delivered alcohol/prescribed drug misuse brief intervention with Web booster sessions (W+W).
89499398|NCT02181283|Active Comparator|W+P|Web-delivered brief intervention with Peer-delivered booster sessions (W+P).
89499399|NCT02181283|No Intervention|Enhanced Usual Care|Enhanced usual care.
89499400|NCT02184481|Experimental|Working memory training|Participants executed the training for three weeks, three times a week, half an hour per session. The training was a game in which the participant was a person who had to become strong to fight with a fantasy figure. The person could become stronger when giving the right answers in eight different working memory tasks. The level adapted to the working memory capacity of the participant.
89499401|NCT02184481|Placebo Comparator|Placebo training|Participants executed the training for three weeks, three times a week, half an hour per session. The training was a game in which the participant was a person who had to become strong to fight with a fantasy figure. The person could become stronger when giving the right answers in eight different working memory tasks. The level in the placebo condition was easy and did not adapt to the working memory capacity of the participant.
89499402|NCT05520242|No Intervention|Control|No animation
89499403|NCT05520242|Experimental|General animation movie|Participants randomized to receive the general animation video
89499404|NCT05520242|Experimental|Men aged 16-24 years|Participants randomized to receive the animation targeted men aged 16-24 years
89499405|NCT05520242|Experimental|Women aged 75 years or older|Participants randomized to receive the animation targeted women aged 75 years or older
89499406|NCT05520242|Experimental|Ethnic minorities|Participants randomized to receive the animation targeted ethnic minorities
89499407|NCT02184559|Experimental|TAP block|
89499408|NCT02184559|Active Comparator|infiltration continues|
89499409|NCT02185651|Active Comparator|Zavesca® 100 mg|"3 study participants are given Zavesca® prescription 100 mg for administration before ERT infusion. Week 0 infusion is completed at study site, with blood collection for anti-GAA antibody level before, during and after the ERT infusion. A punch muscle biopsy is completed the day after ERT infusion with pre-medication Zavesca®. Health Survey is completed.~Week 2, 4, and 6 ERT infusion with pre-medication are completed at local/home infusion center. Travel to site for week 7 study visit includes physical exam, blood collection and punch muscle biopsy. Health survey is completed."
89205606|NCT04455724|Experimental|Negative Pressure Incisional Wound Therapy|A PREVENA™ PEEL & PLACE™ system kit will be applied to the surgical wound and assembled in the operating room following closure by primary intent. The system will be set for a negative pressure of -125mmHg. The dressing will be left in place for 7 days post-operation, during which the patient may be discharged from hospital. The dressing will only be removed or changed if the treating physician has suspicion of one of the complications included in the primary composite outcome or is planning re-intervention on the surgical site.
89205607|NCT04455724|Active Comparator|Standard sterile dressing|A sterile island dressing will be applied to the surgical wound in the operating room following closure by primary intent, which will be removed on post-operative day 2 and left open to air unless there is ongoing discharge.
89499410|NCT02185651|Active Comparator|Zavesca® 300 mg|"3 study participants are given Zavesca® prescription 300 mg for administration before ERT infusion. Week 0 infusion is completed at study site, with blood collection for anti-GAA antibody level before, during and after the ERT infusion. A punch muscle biopsy is completed the day after ERT infusion with pre-medication Zavesca®. Health Survey is completed.~Week 2, 4, and 6 ERT infusion with pre-medication are completed at local/home infusion center. Travel to site for week 7 study visit includes physical exam, blood collection and punch muscle biopsy. Health survey is completed."
89499411|NCT02181361||hirudin plus aspirin|14 days after stroke onset, patients in the hirudin plus aspirin group received natural hirudin 0.75g, three times a day and aspirin 100mg, once daily.
89499412|NCT02181361||Warfarin|14 days after stroke onset, patients in warfarin group were given an initial dose of 1.25mg of warfarin,once daily. 3 days later, INR of patients was checked every three days and the dose of warfarin was adjusted until reach the target range of 2 to 3. Since then INR monitoring was performed at 1, 2, 3, 6, 9, 12 months after stroke onset, targeting an INR between 2 and 3 and the dose of warfarin was adjusted accordingly.
89499413|NCT05520164|No Intervention|Control Group|Routine heel blood was taken from the control group. At the same time, the behaviors of newborns were recorded on camera throughout the procedure. At the end of the study, the camera recording was watched and scored by two midwives who had training in the Neonatal Pain Scale.
89499414|NCT05520164|Experimental|Experimental Group|The newborns in the experimental group listened to the recorded heart sounds of their mothers for 1 minute before the heel blood procedure, during the procedure and for 1 minute after the procedure. At the same time, the behaviors of newborns were recorded on camera throughout the procedure. At the end of the study, the camera recording was monitored and scored by two midwives trained in the Neonatal Pain Scale.
89499415|NCT05060276|Experimental|STI-3258|Intravenous infusion to be given with prophylaxis for infusion reactions, evaluating up to five dose cohorts including: 8 mg/kg, 12 mg/kg, 16 mg/kg, 20 mg/kg, and 24 mg/kg.
89499416|NCT02181439|Other|Right irradiated sector|"The low-energy laser (LLLT Low Level Laser Therapy) SIROLaser Advance: laser diode (970nm) is applied twice at day 0 and at M1. For each patient, randomized in this arm, only the right maxillary canine is actually irradiated. Irradiation is performed by scanning an area from the mesial surface of the maxillary canine to the distal surface of the maxillary first molar in the sagittal direction and the cement enamel junction (CEJ) to the bottom of the vestibule in the vertical direction as well in buccally as in Palatine.~The same procedure will be applied to the left non-irradiated area, the only difference being that the laser will not be activated (placebo, laser inactive). Indeed, only the beam director will be lit and a beep start and end will be heard by the patient. In addition, the practitioner evaluating obtention or not of the class I will not know either which area has been irradiated or not."
89499417|NCT02181439|Other|Left irradiated sector|"The low-energy laser (LLLT Low Level Laser Therapy) SIROLaser Advance: laser diode (970nm) is applied twice at day 0 and at M1. For each patient, randomized in this arm, only the left maxillary canine is actually irradiated. Irradiation is performed by scanning an area from the mesial surface of the maxillary canine to the distal surface of the maxillary first molar in the sagittal direction and the cement enamel junction (CEJ) to the bottom of the vestibule in the vertical direction as well in buccally as in Palatine.~The same procedure will be applied to the right non-irradiated area, the only difference being that the laser will not be activated (placebo, laser inactive). Indeed, only the beam director will be lit and a beep start and end will be heard by the patient. In addition, the practitioner evaluating obtention or not of the class I will not know either which area has been irradiated or not."
89499418|NCT05511194|Experimental|Experimental Group|Experimental Group: scheduled nausea and vomiting prophylaxis the first postoperative 24 hours, start liquid diet 8 hours postoperative, if tolerated, advance to a soft diet in the next shift, double IV antibiotic scheme (ceftriaxone, metronidazole) for at least 3 days and change to oral route upon discharge to complete 10 days of antibiotics, discharge upon accomplish discharge criteria (at least 3 days with IV antibiotic scheme, tolerance to feeding, tolerance to postoperative pain and 24 hours without the presence of fever).
89499419|NCT05511194|Other|Control Group|Control Group: use of antiemetic only in case of nausea or vomiting, start of liquid diet when presenting intestinal transit data (channeling of gases or presence of evacuation), if they tolerate advancing to a soft diet in the next shift, triple IV antibiotic regimen (ampicillin, amikacin, metronidazole) for at least 5 days and change to oral route upon discharge to complete 10 days of antibiotics, discharge upon accomplish discharge criteria (at least 5 days with IV antibiotic regimen, tolerance to feeding, tolerance to postoperative pain and 24 hours without the presence of fever).
89499420|NCT02184637|Experimental|Cohort 1- TQ w/DHA+PQP|Tafenoquine (TQ) will be co-administered with Dihydroartemisinin + Piperaquine tetraphosphate (DHA+PQP) on Day 1. DHA+PQP alone will be administered at 24 hours (h) (Day 2) and 48 h (Day 3) post first dose administration.
89499421|NCT02184637|Experimental|Cohort 2 - TQ w/AL|Tafenoquine co-administered with Artemether + Lumefantrine (AL) on Day 1. AL alone will be administered at 8h (Day 1), 24h and 36h (Day 2), 48h and 60 h (Day 3) post first dose administration.
89499422|NCT02184637|Experimental|Cohort 3 - DHA+PQP alone|Dihydroartemisinin + Piperaquine tetraphosphate (DHA+PQP) will be administered on Day 1 and at 24 hours (Day 2) and 48 hours (Day 3) post first dose administration
88955816|NCT06186414|Experimental|Dose expansion-Cohort 3|BCG-unresponsive high-risk Ta or T1, receiving SIM0237 and BCG intravesically. Induction period (QW for 6 weeks) + a 3-week maintenance course or a 6-week re-induction course at Month 3 + maintenance treatment (QW for 3 weeks) at Months 6, 9, 12, and 18 + optional maintenance treatment at Months 24, 30, and 36.
89023298|NCT05691790|Experimental|Intervention Group|"Intervention development and delivery The interventions will involve deliver a booklet designed based on MMA and six telephone interviews for patient activation.~Design of booklet for older people's preventive care: The booklet will be framed as one series of Positive aging via preventive care-vaccination. According to MMA, the booklet will be aimed to translate expert knowledge into information that can fit to older people's mental models (e.g., misperceptions and knowledge deficits revealed in our previous qualitative studies) regarding vaccinations to facilitate cognitive process of the information.~Patient activation sections: We will design six telephone-based patient activation sections with accommodation for older people's mental models and decision-making preference. The motivation interviewing (MI) techniques will be incorporated into the design of patient activation sections."
89023299|NCT05690087|Experimental|Lidocaine group|Intravenous lidocaine 2% bolus of 1.5 mg/kg over 5 min before induction of anesthesia followed by lidocaine infusion at 1.5 mg/kg/h intraoperatively until desufflation.
89023300|NCT05690087|Placebo Comparator|Control group|Intravenous sodium chloride 0.9% solution volume matched in bolus and infusion.
89023301|NCT05681143|Active Comparator|Crisis Prevention Arm|
89499423|NCT02184637|Experimental|Cohort 4 - AL alone|Artemether + Lumefantrine will be administered on Day 1 and 8h, 24 and 36h (Day 2), 48h and 60 h(Day 3) post first dose administration
89499424|NCT02184637|Experimental|Cohort 5 - TQ alone|A single dose of Tafenoquine will be administered on Day 1
89499425|NCT05510960||General surgery residents|39 participants
89499426|NCT05510960||Urology residents|14 participants
89499427|NCT05510960||Pediatric surgery residents|7 participants
89499428|NCT02184715|Active Comparator|Virtual reality video game|Participants received rehabilitation treatment and additional virtual reality system (30 minutes of interactive virtual reality system play, two times per week, in eight sessions over a 4-week span) for 1 month, followed by rehabilitation treatment for 1 month
89499429|NCT02184715|Placebo Comparator|Virtual reality system|received rehabilitation treatment for 1 month, followed by rehabilitation treatment and additional virtual reality system (30 minutes of interactive video game play, two times per week, in eight sessions over a 4-week span) during the one month of intervention period.
89499430|NCT05514704|Active Comparator|Synchronous Telerehabilitation Group|Synchronous Telerehabilitation Group will receive exercise therapy via video conference.
89499431|NCT05514704|Experimental|Asynchronous Telerehabilitation Group|Asynchronous Telerehabilitation Group will receive exercise therapy via mobile application.
89499432|NCT02185807|Active Comparator|video-assisted group|The video assistance patients watch a video in Cantonese or Mandarin explaining the surgery procedure and its risks, benefits and alternatives before discussion with their physicians, and receive face- to face discussion with their physicians as well.
89499433|NCT02185807|Placebo Comparator|control group|The control patients receive verbal information and discussion from their physicians.
89499434|NCT05514392||Receiving Single Leg Cycling Ergometer Training|First of all, an initial warm-up will be done with 40 watts of exercise intensity for 3 minutes. Exercise will be started with 80 watts of exercise intensity and will be increased by 40 watts every 3 minutes. Cycling cadence will be determined as a pedaling speed of 80 revolutions per minute and patients will be asked to keep their dominant leg on the pedal and keep their non-dominant leg on the ground. The exercise protocol will consist of 2 sets as 15 minutes of exercise + 1 minute of break + 15 minutes of exercise. During the exercise, the heart rate and oxygen saturation of the participants will be monitored by finger pulse oximetry. EMG measurements were taken at the beginning and end of the ergometer training.
89499435|NCT05514392||Receiving Double Leg Cycling Ergometer Training|First, a 3-minute initial warm-up will be done with an exercise intensity of 40 watts. The workout will begin with an exercise intensity of 80 watts and increase by 40 watts every 3 minutes. Cycling cadence will be determined as a pedaling rate of 80 revolutions per minute and patients will be asked to pedal with both legs. The exercise protocol will consist of 2 sets of 15 minutes of exercise + 1 minute of break + 15 minutes of exercise. During the exercise, the heart rate and oxygen saturation of the participants will be monitored by finger pulse oximetry. EMG measurements were taken at the beginning and end of the ergometer training.
89499436|NCT05126095||Trial cohort|"CBCT: before radiotherapy and once a week during radiotherapy~Body weight: before radiotherapy and once a week during radiotherapy~The Patient-Generated Subjective Global Assessment (PG-SGA): before radiotherapy, 1st week, 3rd week and the last week during radiotherapy."
89499437|NCT02030431|Active Comparator|Cancellous screws|Patients in this group are having osteosynthesis with three screws
89499438|NCT02030431|Active Comparator|Dynaloc|Patients in this group are having osteosynthesis with Dynaloc (three screws fixed in a small plate)
89499439|NCT02184793|Other|EMD (Inclinomax) then usual care|"EMD (electronic monitoring device) : recording the head of bed inclination degree with digital display and alarm on for 24h.~Usual care : recording the head of bed inclination degree with masked digital display and alarm off for 24h."
89499440|NCT02184793|Other|usual care then EMD (Inclinomax)|"Usual care : recording the head of bed inclination degree with masked digital display and alarm off for 24h.~EMD (electronic monitoring device) : recording the head of bed inclination degree with digital display and alarm on for 24h."
89499441|NCT05514314|Experimental|Icotinib|Icotinib oral 125mg tid for 2 years
89499442|NCT04870424|Experimental|Colchicine|
89499443|NCT04870424|Placebo Comparator|Placebo|
89499444|NCT03536845|Active Comparator|400 IU|
89499445|NCT03536845|Active Comparator|1000 IU|
89023302|NCT05681143|Placebo Comparator|Control|
89205608|NCT04409925|Experimental|rhDNase1 (Pulmozyme, Roche/Genentech)|Single Arm: rhDNase1 (Pulmozyme, Roche/Genentech) 2.5 mg inhaled nebulisations BID, for a maximum of 14 consecutive days.
89499446|NCT02256709|Experimental|single rising dose BIBP 5371 CL|
89499447|NCT02256709|Experimental|BIBP 5371 CL tablet high dose|to be compared with same daily dose level from single rising dose arm
89499448|NCT02256709|Experimental|BIBP 5371 CL tablet low dose|to be compared with same daily dose level from single rising dose arm
89499449|NCT02256709|Placebo Comparator|Placebo drinking solution|
89499450|NCT02256709|Experimental|BIBP 5371 CL drinking solution|
89499451|NCT02256709|Experimental|BIBP 5371 CL tablet high dose with food|
89499452|NCT02256709|Experimental|BIBP 5371 CL tablet low dose with food|
89499453|NCT02256709|Placebo Comparator|Placebo tablet|
89499454|NCT05510804|Experimental|ALISA (therapist-assisted digital self-help intervention)|structured app-based self-help programme with scheduled therapist assistance
89499455|NCT05510804|Active Comparator|TAU (supportive therapist contacts)|low-frequency supportive therapist contacts
89499456|NCT02185885|Experimental|Increased bloodpressure during CPB|The cardiopulmonary bypass (CPB) procedure is conducted according to department guidelines with the modification that MAP is kept between 70 and 80 mm Hg. This is achieved by refract intravenous doses of phenylephrine to a total maximum of 2.0 mg, and after that continuous intravenous infusion of norepinephrine up to 0.4 μg/kg/min if necessary.
89499457|NCT02185885|No Intervention|Regular bloodpressure during CPB|The cardiopulmonary bypass (CPB) procedure is conducted in accordance with departmental guidelines, where MAP is sought to be ≥ 45 mm Hg. This is achieved by refract intravenous doses of phenylephrine to a total maximum of 2.0 mg, and after that continuous intravenous infusion of norepinephrine up to 0.4 μg/kg/min if necessary.
89499458|NCT05519852|Experimental|Pilates group|this pilates group (20 patients) will be trained 30 minutes of pilates (before it there will be warm up period and after it there will be cooldown period , each will be 5 minutes). the pilates will be repeated five sessions per the week for 3 months
89499459|NCT05519852|No Intervention|control group|The patients will not receive training (20 patients)
89499460|NCT02181907|Experimental|UH-AC 62 XX tablet|
89499461|NCT02181907|Active Comparator|UH-AC 62 XX capsule|
89499462|NCT02181985|Active Comparator|TNK-tPA + heparin|
89499463|NCT02181985|Experimental|TNK-tPA + enoxaparin|
89499464|NCT02181985|Experimental|TNK-tPA + abciximab + heparin|
89499465|NCT05514080|Other|Insulin alone closed-loop|
89499466|NCT02184871||intrahepatic cholangiocarcinoma|Patients committed to surgery and stratified according to exposure to different risk factors for ICC, basing on modified ReNaM questionnaire.
89499467|NCT02184949||Primary Sample|All percutaneous coronary intervention patients who meet the primary eligibility criteria for this study.
89499468|NCT02184949||Subsample|Patients drawn from the main sample who specifically underwent a primary percutaneous coronary intervention procedure.
89499469|NCT02185027||complications and compliance with GIHP recommendations|Description at 1 month post-intervention of an potential event
89023305|NCT05676112||Nintedanib new users|
89023306|NCT05676112||Pirfenidone new users|
89023307|NCT05676112||no drug-treated users|subjects who did not receive nintedanib, pirfenidone
89023308|NCT05674396|Experimental|Traditional Palliation|Participant will be randomized to standard radiation
89023309|NCT05674396|Experimental|Stereotactic body radiotherapy (SBRT)|Participants will be randomized to receive (SBRT) Stereotactic body radiotherapy.
89023310|NCT05674188|Experimental|Augmented Reality Enhanced Simulation (Treatment group)|Participants will experience augmented simulations with a holographic mixed-reality setting based on different workplace scenarios such as medical error and workplace harassment via Augmented Reality (AR) headset.
89023311|NCT05674188|No Intervention|Traditional In Situ Simulation (Control group)|Participants will experience in-person simulations of different workplace scenarios such as medical error and workplace harassment
89023312|NCT05672368|Experimental|Device feasibility (da Vinci SP1098 robotic system)|Patients undergo surgery using the da Vinci SP1098 robotic system on study.
89205609|NCT04394325|Experimental|Group A) Intervention group|Group A) an intervention group (n=80) who will receive the standard care and information (oral and written) + the digital information tool.
89205610|NCT04394325|No Intervention|Group B) Control group|Group B) a control group (n=80) who will receive standard care and information (oral and written).
89205611|NCT04393285|Experimental|Abemaciclib and Letrozole|Study treatment will consist of abemaciclib 150mg orally twice a day and letrozole 2.5mg orally once a day.
89499470|NCT05510648|Active Comparator|High-intensity laser therapy|A total of 15 sessions of hotpack, TENS and exercise program will be applied to the patients for three weeks, 5 days a week, 1 session a day. The hotpack, which is used as a superficial heater, is applied to the knee area for 30 minutes, wrapped in two layers of towels. As analgesic current, conventional TENS is applied to the knee area for 30 minutes with 4 electrodes at 80 Hz frequency, 200 ms current duration. Flow intensity is adjusted according to the patient's tolerance, and the current intensity is increased as the patient's sense of current decreased in the following periods. HILT is applied in analgesic mode for 3 sessions every other day in the first week, and 6 sessions every other day in the biostimulant mode for the next two weeks, for a total of 9 sessions for three weeks.
89499471|NCT05510648|Sham Comparator|Sham high-intensity laser therapy|Hotpack, TENS and exercise program applications will be applied to the patients in the same way as in the HILT group, 5 days a week, 1 session a day, a total of 15 sessions for three weeks. HILT is administered as a placebo for three weeks, 3 sessions a week, every other day, for a total of 9 sessions.
89499472|NCT05519618||Participants|Patient planned to receive debulking or en bloc resection of vertebral tumor.
89499473|NCT02030509||New diagnosed patients of head and neck cancer|New diagnosed patients of head and neck cancer
89499474|NCT02030509||Old diagnosed head and neck cancer patients|
89499475|NCT05510570||control|healthy child
89499476|NCT05510570||experimental|patients with language disorder
89499477|NCT02185963|Experimental|Rosuvastatin|Rosuvastatin will be started in type 2 DM and having 1 or more cardiovascular risk factors
89023313|NCT05668650|Active Comparator|Medical Reference Product|"Keytruda® will be administered as monotherapy, on Day 1 of every 3-week cycle (21 days), during the Main Study Period (6 cycles) unless there is disease progression, intolerance to the study drug, or treatment discontinuation for other reason, whichever occurs first.~Those subjects with clinical benefit from treatment (CR, PR, and SD) as per the investigator's discretion, will be allowed to continue receiving treatment with MB12/Keytruda® in the Extended Study Period, according to the arm initially assigned, every 3 weeks, for a maximum of 52 weeks from the first infusion or until evidence of disease progression, intolerance to the study drug, or treatment discontinuation for other reason, whichever occurs first."
89023314|NCT05668650|Experimental|Investigational Product|"MB12 will be administered as monotherapy, on Day 1 of every 3-week cycle (21 days), during the Main Study Period (6 cycles) unless there is disease progression, intolerance to the study drug, or treatment discontinuation for other reason, whichever occurs first.~Those subjects with clinical benefit from treatment (CR, PR, and SD) as per the investigator's discretion, will be allowed to continue receiving treatment with MB12/Keytruda® in the Extended Study Period, according to the arm initially assigned, every 3 weeks, for a maximum of 52 weeks from the first infusion or until evidence of disease progression, intolerance to the study drug, or treatment discontinuation for other reason, whichever occurs first."
89499478|NCT02570750||Group 1: smokers patients group|smokers (more than 10 cigarettes per day)
89499479|NCT02570750||Group 2 : non-smokers patients group|Smoking status will be classified as current and never/former. Former smokers will be defined as those who had stopped smoking at least 1 year before being interviewed for this study
89023315|NCT05657808|Placebo Comparator|Placebo Control 1|Rest Product Form 1 - control
89023316|NCT05657808|Placebo Comparator|Placebo Control 2|Rest Product Form 2 - control
89023317|NCT05657808|Experimental|Active Product 1.1|Rest Product Form 1 - active product 1
89023318|NCT05657808|Experimental|Active Product 1.2|Rest Product Form 1 - active product 2
89023319|NCT05657808|Experimental|Active Product 2.1|Rest Product Form 2 - active product 1
89023320|NCT05657808|Experimental|Active Product 2.2|Rest Product Form 2 - active product 2
89023321|NCT05657808|Placebo Comparator|Placebo Control 3|Rest Product Form 3 - control
89205612|NCT04374799|Active Comparator|Low dose heparin|heparin (25 IU/Kg -maximal dose 3,000 IU)
89499480|NCT02186041||De-Novo patients|Patients tested and de novo implanted with Interstim®. These patients will be followed-up for 5 years after the implant visit.
89499481|NCT02186041||Device replacement|Patients implanted with Interstim® for a device replacement. These patients will be followed-up for 5 years after the implant visit.
89499482|NCT02186041||Not-implanted patients|Patients who are tested and are not implanted with the Interstim® system. The data of the follow up of the test will be captured up to one year after the end-test visit
89499483|NCT02186119|Experimental|abicipar pegol 2 mg (group A)|Abicipar pegol 2 mg administered to the study eye by intravitreal injection at day 1, weeks 4, 8, and 20, followed by a sham procedure at weeks 12, 16, and 24.
89499484|NCT02186119|Experimental|abicipar pegol 2 mg (group B)|Abicipar pegol 2 mg administered to the study eye by intravitreal injection at day 1, weeks 4, 8, 16, and 24, followed by a sham procedure at weeks 12 and 20.
89499485|NCT02186119|Experimental|abicipar pegol 1 mg|Abicipar pegol 1 mg administered to the study eye by intravitreal injection at day 1, weeks 4, 8, 16, and 24, followed by a sham procedure at weeks 12 and 20.
89499486|NCT02186119|Active Comparator|ranibizumab|Ranibizumab (Lucentis®) administered to the study eye by intravitreal injection every 4 weeks from day 1 through week 24.
89499487|NCT02185261|Experimental|interferon Alfa-2b group|Acute leukemia patients who are minimal residual disease positive after hematopoietic stem cell transplantation receive interferon Alfa-2b
89499488|NCT02186197||Shock and/or Respiratory Failure|
89499489|NCT02573012|Experimental|Tocilizumab+prednisone (constant dose)|Participants will receive tocilizumab at a dose of 162 milligram (mg) once a week subcutaneously; and prednisone at a dose of 5 milligram per day (mg/day) or matching placebo orally for 24 weeks.
89499490|NCT02573012|Experimental|Tocilizumab+prednisone (tapering dose)|Participants will receive tocilizumab at a dose of 162 milligram (mg) once a week subcutaneously; and prednisone at a dose of 5 milligram per day (mg/day) with 1 mg decrements every 4 weeks or matching placebo orally for 24 weeks.
89023322|NCT05657808|Experimental|Active Product 3.1|Rest Product Form 3 - active product 1
89023323|NCT05657808|Placebo Comparator|Placebo Control 4|Rest Product Form 4 - control
89023324|NCT05657808|Experimental|Active Product 4.1|Rest Product Form 4 - active product 1
89023325|NCT05657808|Experimental|Active Product 4.2|Rest Product Form 4 - active product 2
89023326|NCT05657808|Experimental|Active Product 4.3|Rest Product Form 4 - active product 3
89023327|NCT05657743|Experimental|DaRT Seeds|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds
89023328|NCT05656599||Letermovir Group|HSCT recipients who received letermovir prophylaxis
89023329|NCT05656599||Preemptive therapy Group|HSCT recipients who received PCR-guided preemptive therapy
89023330|NCT05652725|Placebo Comparator|Placebo Control 1|Clarity Product Form 1 - control
89023331|NCT05652725|Placebo Comparator|Placebo Control 2|Clarity Product Form 2 - control
89023332|NCT05652725|Placebo Comparator|Placebo Control 3|Clarity Product Form 3 - control
89023333|NCT05652725|Placebo Comparator|Placebo Control 4|Clarity Product Form 4 - control
89205613|NCT04374799|Active Comparator|High dose heparin|heparin 50 IU/kg -maximal dose 5,000 IU
89499491|NCT02185495|Experimental|High-risk individuals|"The elder and heavy smokers, which are high-risk individuals for early lung cancer. These subjects will be examined using Observer nodule detection and  Computer-aided nodule detection."
89499492|NCT03536377|Experimental|very low calorie liquid diet|Phase 1: Caloric restriction Phase 2: Solid diet Phase 3: Transition to independence
89499493|NCT05121727|Active Comparator|Erector Spinae Plane Block|After the linear ultrasound (US) probe will be placed 2-3 cm lateral to the T5 spinous process, 20 ml of 0.25% bupivacaine hydrochloride will be injected into the interfacial space below the erector spinae muscle, above the transverse process.
88955817|NCT06186323||congenital muscular torticollis|"40 children diagnosed with congenital muscular torticollis, aged 0-15 months, with parental consent, without any vision or hearing problems, will be included in the study. Children with chromosomal anomalies, serious congenital problems and whose parents do not volunteer to participate will not be included in the study.~During the evaluations, the demographic characteristics of the babies (gender, gestational age, birth weight, parental information, mother's pregnancy type, pregnancy history, Apgar score) will be recorded from the file and by interviewing the family. Photographs will be taken to ensure an objective evaluation. The Affordances in the Home Environment for Motor Development-Infant Scale will be used to explore and evaluate the home environment. It was planned to use the Test of Sensory Functions in Infants to evaluate the sensory development of babies. It is planned to use Peabody Motor Development Scale-2 to evaluate motor development."
89023334|NCT05652725|Experimental|Active Product 1.1|Clarity Product Form 1 - active product 1
89499494|NCT05121727|Active Comparator|Deep and Superficial Serratus Anterior Plane Block|In patients who are planned to have combined deep and superficial serratus anterior plane block, following the visualization of the anatomical structures, the nerve block needle will be advanced via the in-plane technique beneath the serratus anterior muscles until the interfascial space was reached. After hydrodissection with 2 ml normal saline, 10 ml 0.25% bupivacaine will be injected into the area. Then, with the same needle, will be returned 1-2 cm from the deep serratus anteror area to superficial serratus anteror area above the serratus anterior muscle and will be injected 2 ml normal saline for hydrodissection. Finally 10 ml of 0.25% bupivacaine will be injected for superficial serratus anetrior block into the interfacial area.
89499495|NCT05513690|Experimental|Amnioinfusion at room temperature (intervention arm)|Routine amnioinfusion will be administered via an intrauterine catheter inserted through the cervix. Normal saline at room temperature will be infused per hospital protocol at a rate of 600 milliliters/hour for the first hour followed by 180 milliliters/hour. A plastic applicator will be used to introduce a flexible disposable general-purpose temperature probe into the uterus. The probe will be guided to the contralateral side of the uterus from the intrauterine pressure catheter. Intrauterine temperature will then be measured by DataThermII continuous temperature monitor. This monitor has accuracy of 0.1 °C and will store temperature measurements every 10 minutes until delivery. The temperature data will be downloaded into a computer software. The DataThermII has been previously used in prior research to measure intrauterine temperature.
89499496|NCT05513690|No Intervention|Standard of care (control arm)|Women in this group will have the temperature probe placed and temperate measured as described in experimental arm. They will otherwise receive current standard of care (i.e. no amnioinfusion).
89499497|NCT02190331|Experimental|Interventional program|The training protocol is constituted by 4 strengthening exercises (Side Lying External Rotation, Prone Horizontal Abduction with External Rotation, Y to I exercise and Chin Tuck) and 3 stretching exercises(one- Sided Unilateral Self Stretch Exercise, one-sided Unilateral Self Stretch Exercise, Static Sternocleidomastoid Stretch and Static Levator Scapulae Stretch
89499498|NCT02190331|Active Comparator|Control group|The control group will only participate in the Physical Education classes
89499499|NCT02190409|Experimental|Test, Control|Test: Minimum two tapered implants (Ankylosis, Dentsply Friadent) were placed to each patient. After surgical preparation of implant sockets, PRF that was prepared preoperatively was placed randomly to one of the sockets (PRF+). Acellular plasma portion of PRF was used to wet the implant placed into the PRF-coated socket Control: Other socket was selected as a control group (No Platelet Rich Fibrin used): In the control group no extra intervention used and the conventional procedure was done. Thus the readings of the experimental arm compared with this control.
89499500|NCT05510414|Experimental|PCI group|intervention based on psychological capital model
89499501|NCT05510414|No Intervention|Control group|routine psychological counseling
89499502|NCT02190487||TAS group|patients who had thoracic aortic surgery due to dissection
89499503|NCT04128176|Experimental|Rituximab combined with Omalizumab|All patients will receive daily doxycycline, nicotinamide, and high-potency topical steroids. Additionally, all patients will receive rituximab combined with omalizumab.
89499504|NCT02186275|Experimental|Vitamin D3 3000 or 4000 UI/day then 2,000 UI/day|"3000 UI or 4,000 UI/day as induction therapy (according to weight) for 4 weeks then 2,000 UIday as maintenance therapy for 48 weeks.~The administration of vitamin D will be considered as an adjunct to conventional therapy (corticosteroids, exclusive enteral nutrition or immunosuppressive agents (ISA))."
89499505|NCT02186275|Active Comparator|Vitamin D3 800 UI/day then 800 UI/day|800 UI/day as induction therapy for 4 weeks, then 800 UI/day as maintenance therapy for 48 weeks. The administration of vitamin D will be considered as an adjunct to conventional therapy (corticosteroids, exclusive enteral nutrition or immunosuppressive agents (ISA)).
89499506|NCT05519306|Experimental|Mental Practice Patients|Patients with upper extremity hemiparesis following a stroke.
89499507|NCT05519306|No Intervention|Occupational Therapists|Licensed, full-time, or part-time occupational therapists currently working in the inpatient rehabilitation unit of Adventist Healthcare Rehabilitation
89499508|NCT02186353|Experimental|Intact/minimally processed whole grains|Partial feeding study
89499509|NCT02186353|Experimental|Highly processed whole grains|Partial feeding study
89499510|NCT02186353|Active Comparator|Refined grains|Partial feeding study
89499511|NCT02190565|Placebo Comparator|Placebo|Placebo consisting of two sham multivitamin and mineral tablets and two capsules of oil
89205614|NCT04374799|Placebo Comparator|Placebo|Normal saline 0.9%.
89205615|NCT04373382|Experimental|Peer Resilience Champion Support|The clusters that receive this intervention will receive support from a Peer Resilience Champion.
89499512|NCT02190565|Active Comparator|Food supplement|Food supplement consisting of fish oil (omega 3 fatty acids DHA and EPA) and multivitamin and mineral tablets with extra iron and folic acid
89499513|NCT05510336|Active Comparator|Study group|Concentric needle technique TMJ arthrocentesis using lactated ringer solution to help reduce inflammatory mediators and anterior disc discplacement with reduction
89499514|NCT05510336|Active Comparator|Control group|Double needle technique TMJ arthrocentesis using lactated ringer solution to help reduce inflammatory mediators and anterior disc discplacement with reduction
89023335|NCT05652725|Experimental|Active Product 2.1|Clarity Product Form 2 - active product 1
89023336|NCT05652725|Experimental|Active Product 3.1|Clarity Product Form 3 - active product 1
89499515|NCT02185573|No Intervention|Conventional Technique|Multi-layer filling technique
89023337|NCT05652725|Experimental|Active Product 4.1|Clarity Product Form 4 - active product 1
89023338|NCT05652725|Experimental|Active Product 4.2|Clarity Product Form 4 - active product 2
89023339|NCT05652725|Experimental|Active Product 4.3|Clarity Product Form 4 - active product 3
89023340|NCT05652725|Placebo Comparator|Placebo Control 5|Clarity Product Form 5 - control
89023341|NCT05652725|Experimental|Active Product 5.1|Clarity Product Form 5 - active product 1
89499516|NCT02185573|Active Comparator|Bulk fill technique|Bulk fill technique
89499517|NCT02185573|Experimental|SonicFill technique|SonicFill technique
89499518|NCT05510258|Experimental|experimental group|core-stability exercises therapy given with conventional therapy
89499519|NCT05510258|Other|control group|only conventional therapy given
89499520|NCT05117281|Active Comparator|spinal group|Plain, isobaric levobupivacaine(0.25%) 0.25 mg/kg
89499521|NCT05117281|Active Comparator|caudal group|Plain, isobaric levobupivacaine (0.25%) 1 ml/kg
89499522|NCT04424810|Experimental|Video group|Patients selected to be in the intervention group will be asked to watch a high-quality, physician created video describing their condition and the operative treatment they are about to undergo.
89499523|NCT04424810|Placebo Comparator|Control group|Patients selected to be in the control group will not be asked to watch a video prior to surgery.
89499524|NCT02186431|Experimental|history of corneal infiltrative events|To quantify and compare baseline tear proteins and ocular response in contact lens wearers with a history of corneal infiltrative events
89499525|NCT02186431|Active Comparator|without a history of corneal infiltrative events|To quantify and compare baseline tear proteins and ocular response in contact lens wearers without a history of corneal infiltrative events.
89499526|NCT02190643|Experimental|Adherence condition|Brief smoking cessation counseling session (based on 5 A's approach) that includes a module focused on improving adherence to using the nicotine patch, plus 8-week supply of nicotine patches.
89499527|NCT02190643|Active Comparator|Standard condition|Brief smoking cessation counseling session (based on 5 A's approach) that does not include a module focused on improving nicotine patch adherence, plus 8-week supply of nicotine patches.
89499528|NCT02186743|Experimental|Intervention Diet|Personalized dietary advice based on a commercially available blood test. Participants will be instructed to avoid eating selected foods for the duration of the intervention period (4 weeks). Some foods will be acceptable to consume every four days in rotation diet fashion.
89499529|NCT02186743|Active Comparator|Active control diet|Personalized dietary advice based on a commercially available blood test. Participants will be instructed to avoid eating selected foods for the duration of the intervention period (4 weeks). Some foods will be acceptable to consume every four days in rotation diet fashion.
89499530|NCT02190799|Experimental|Convalescent plasma|Enrolled patients will receive 2 units of the convalescent plasma after meeting the eligibility criteria
89499531|NCT04411706|Experimental|Sintilimab+Apatinib+Capecitabine|=Drug: Sintilimab（i.v）+apatinib（p.o）+capecitabine（p.o）
89499532|NCT02190877||Cohort 1: Subjects taking diuretic medication|All subjects will be in the same group, Cohort 1
89499533|NCT05518994|Experimental|Cohort 1|Subjects with ctDNA-level-relapse Astrocytoma before clinical relapse, determined according to the dynamics of TISF ctDNA.
89499534|NCT05518994|Experimental|Cohort 2|Subjects with clinical-relapse Astrocytoma, determined according to the response assessment in neuro-oncology (RANO) criteria for gliomas.
89499535|NCT05518994|No Intervention|Cohort 3|Subjects without ctDNA-level-relapse and clinical-relapse Astrocytoma.
89499536|NCT02256943|Active Comparator|Amitriptyline first, Placebo second|Amitriptyline first, Placebo second
89023342|NCT05652725|Experimental|Active Product 5.2|Clarity Product Form 5 - active product 2
89023343|NCT05642078|Experimental|Investigational Vaccine(Low dose group)|Quadrivalent influenza vaccine(Split Virion),Inactivated，Produced by Anhui Zhifei Longcom Biopharmceutical Co., Ltd.；0.25mL/branch, each contains 7.5 μg H1N1, H3N2, B(V), B(Y) hemagglutinin.Subjects were vaccinated with one dose of vaccine on day 0 and day 28 respectively.
89023344|NCT05642078|Experimental|Investigational Vaccine(High dose group)|Quadrivalent influenza vaccine(Split Virion),Inactivated，Produced by Anhui Zhifei Longcom Biopharmceutical Co., Ltd.；0.5mL/branch, each contains 15 μg H1N1, H3N2, B(V), B(Y) hemagglutinin.Subjects were vaccinated with one dose of vaccine on day 0 and day 28 respectively.
89023345|NCT05642078|Active Comparator|Active compared Vaccine|Influenza Vaccine(Split Virion),Inactivated Quadrivalent,Produced by Hualan Biological Vaccine Co., Ltd.;0.25mL/branch,each contains 7.5 μg H1N1, H3N2, B(V), B(Y) hemagglutinin.Subjects were vaccinated with one dose of vaccine on day 0 and day 28 respectively.
89205616|NCT04373382|No Intervention|No Peer Resilience Champion Support|The clusters in this arm of the study will not receive the Peer Resilience Champion support until they cross-over into the Peer Resilience Champion support arm.
89499537|NCT02256943|Active Comparator|Placebo first, Amitriptyline second|Placebo first, Amitriptyline second
89531843|NCT05142111|Active Comparator|Mindfulness|"During the mindfulness treatment the subjects will be subjected to sessions in which they will be invited to relax, to become aware of the present moment, of their body, through exercises that involve breathing, attention, and visualization of the body.~The sessions will last about 45 minutes, and will be held once a week, for a total of 6 sessions."
89531844|NCT05136885|Experimental|SLS-005|SLS-005 is administered via infusion once weekly for 24 weeks.
89531845|NCT05136885|Placebo Comparator|Matching Placebo|Matching placebo is administered via infusion once weekly for 24 weeks.
89499538|NCT05518916|Experimental|Yakson Method Group|"The mother is informed about the benefits of the Yakson method.~Yakson method is taught practically to the mother. Education continues until the researcher is sure that the mother has done the method correctly. The mother starts the application 10 minutes before the heel lancing is done and continues for another 5 minutes after the heel lancing is done. During the application, the baby is recorded with the camera. Just before starting the Yakson method (initial assessment), at 10 minutes of the Yakson method (just before the heel lancing), during the heel lancing while the Yakson method is in progress, and 5 minutes after the procedure (just before the end of the tender touch), the newborn's pain and physiological parameters are evaluated. Evaluation results are recorded in the application observation form."
89023346|NCT05641246|Active Comparator|Control Arm|"Standard of care Urea-based cream (CARBAMIDE®) will be applied to hands and feet 2-3 times daily for 14 days starting from the first dose and cycle of Capecitabine (XELODA ®).~Each Capecitabine (XELODA ®) cycle lasts for 21 days.~Capecitabine (XELODA ®) dose :2g/m2 daily divided into 2 doses after breakfast and dinner for 14 days followed by 7 days Capecitabine free.~Capecitabine (XELODA ®) dose will be modified according to treatment related side effects (26).~This regimen will be repeated at each cycle of Capecitabine (XELODA ®) and lasts for 6 cycles (18 weeks) and preventive measures of Hand-foot syndrome will be applied (Avoid mechanical stress"
89023347|NCT05641246|Active Comparator|Intervention Arm|"Standard of care Urea-based cream (CARBAMIDE®) will be applied to hands and feet twice daily for 14 days starting from the first dose and cycle of Capecitabine (XELODA ®).~Each Capecitabine (XELODA ®) cycle lasts for 21 days.~Capecitabine (XELODA ®) dose: 2g/m2 daily divided into 2 doses after breakfast and dinner for 14 days followed by 7 days Capecitabine free.~Capecitabine (XELODA ®) dose will be modified according to treatment related side effects (26).~This regimen will be repeated at each cycle of Capecitabine (XELODA ®) and lasts for 6 cycles (18 weeks) and preventive measures of Hand-foot syndrome will be applied (Avoid mechanical stress Plus~Topical diclofenac (VOLTAREN®) Emulgel 1% 2-4g (2g = 4 fingertip Units (FTU)) twice daily 2 hours away from Urea-based cream (CARBAMIDE®) for 14 days starting from the first cycle and dose of Capecitabine.~This regimen will be repeated at each cycle of Capecitabine (XELODA ®) and lasts for 6 cycles (18 weeks)."
89023348|NCT05639569||Patients with Descending Thoracic Aneurysm (DTA) or Type B Aortic Dissection (TBAD)|"All patients who signed informed consent and are used with Ankura™ TAA Stent Graft Systems will undergo follow-up (FU) evaluations as per local hospital standards and corresponding IFU which is expected to be at the following time points post-implant:~Before discharge, 30days after the procudure, 3-6 months after the Procedure, 12 months after the procedure, 24 months after the procedure, 36 months after the procedure"
89499539|NCT05518916|Experimental|Swaddling Group|"Parents are informed about the research and verbal consent is obtained.~Written consent is obtained with an informed consent form.~The Mother-Baby Information Form is filled.~Babies are fed 1 hour before blood collection.~And researher swaddling the baby"
89499540|NCT05518916|No Intervention|Control Group|"Parents are informed about the research and verbal consent is obtained.~Written consent is obtained with an informed consent form.~The Mother-Baby Information Form is filled.~Babies are fed 1 hour before blood collection.~Before starting the heel lancing, a pulse oximeter probe will be attached to the baby's left big toe.~Blood is taken from the right heel of the foot.~During the application, the baby is recorded with the camera.~Evaluation results are recorded in the application observation form."
89023349|NCT05633407|Experimental|Efgartigimod|Receive efgartigimod IV 10mg/kg during weekly infusions during a treatment period of 24 weeks
89023350|NCT05633407|Placebo Comparator|Placebo|Receive a matching placebo during weekly infusions during a treatment period of 24 weeks
89499541|NCT02193607|Active Comparator|No TVT-O|Improved reconstruction pelvic surgery
89499542|NCT02193607|Experimental|Combined surgery group|Improved reconstruction pelvic surgery TVT-O procedure
89499543|NCT05510102|Experimental|Treatment group|Subjects will have full remote monitoring data access throughout the entirety of the study (6 months).
89023351|NCT05632718|Experimental|Resistance group|16 weeks of resistance exercise-training.
89205617|NCT04373382|Experimental|Enriched Feedback|This arm of the study encompasses individuals who will receive feedback from the survey that will hopefully help provoke self-reflection.
89499544|NCT05510102|Active Comparator|Control group|Subjects will be blinded to remote monitoring data for the first 3 months of the study followed by an unblinding and full access to remote monitoring data at the 3 month mark (continued for the remainder of the study).
89499545|NCT02186899|Active Comparator|General Anesthesia Femoral continuous|General anesthesia plus continuous femoral nerve block
89499546|NCT02186899|Active Comparator|General anesthesia Femoral bolus|General anesthesia plus single shot femoral nerve block
89499547|NCT02186899|Active Comparator|Femoral Sciatic Obturator Nerve block|Ultrasound guided femoral plus sciatic plus obturator nerve block
89499548|NCT05510024|Experimental|Radiofrequency ablation of bilateral inferior turbinate followed by subcutaneous Immunotherapy|Radiofrequency ablation of bilateral inferior turbinate followed by subcutaneous Immunotherapy will be conducted in participants with severe house dust mite-sensitized allergic rhinitis.
89499549|NCT05510024|Active Comparator|Subcutaneous Immunotherapy (SCIT)|Allergen-specific subcutaneous Immunotherapy will be conducted in participants with severe house dust mite-sensitized allergic rhinitis.
89499550|NCT02190955||NEPTUNE contact registry patients|Patients and caregivers will be recruited from the Nephrotic Syndrome Study Network (NEPTUNE) Patient Contact Registry. Over 1000 patients and caregivers are members of the registry and have already provided permission to be contacted for future research studies. Analysis of the one-time online questionnaire will be done in collaboration with investigators from the NEPTUNE Consortium.
89499551|NCT05513222|Experimental|flipped autograft|
89023352|NCT05632718|Experimental|Endurance group|16 weeks of endurance exercise-training.
89023353|NCT05632718|No Intervention|Control group|Does not enrole in exercise-training programme.
89023354|NCT05626569|Experimental|PD-1 combined with SBRT for metastatic lesions|Participants will receive anti-PD1 and SBRT to the metastatic lesions which are amenable to the delivery of SBRT after 4~6 cycles of systemic chemotherapy and anti-PD-1. SBRT for the metastatic lesions shall be conducted within two months after the completion of systemic therapy. The prescription of SBRT is determined by the investigator and the BED is required to over 50Gy.
89023355|NCT05624372||Investigator|Child and Adolescent Psychiatrists, Speech Therapists
89205618|NCT04373382|No Intervention|Express Feedback|This arm of the study encompasses individuals who will not receive feedback from the survey.
89205619|NCT04367857||Prior Positive polymerase chain reaction (PCR) and Recovered|Prior Positive PCR result, fully recovered, back at work and symptom free for greater than or equal than 14 days.
89205620|NCT04367857||Never tested, history of COVID-19 Symptoms and Recovered|Never tested and history of COVID-19 symptoms and symptom-free for more than 14 days
89499552|NCT02030665|Active Comparator|Standardized MET plus CB (SMET-CB)|Motivational Enhancement plus Cognitive-Behavioral treatment
89499553|NCT02030665|Experimental|SMET+ CM (SMET-CB-CM)|Motivational Enhancement plus CB treatment plus contingency management
89499554|NCT02030665|Experimental|Individualized Assessment & Treatment (IATP)|Individualized Assessment and Treatment Program; Cognitive-Behavioral Treatment based on in-depth field monitoring of patient behavior
89499555|NCT02030665|Experimental|IATP + CM (IATP-CM).|Individualized Assessment and Treatment plus Contingency Management
89499556|NCT05512988|Experimental|Experimental|MSCs Participants will receive HUC-MSCs
89499557|NCT05512988|Placebo Comparator|Comparator|Comparator participants will receive saline solution
89499558|NCT02186977|Active Comparator|Intramuscular group|These subjects will receive one intramuscular injection of 1.0cc HBVAXPRO 10mcgr/ml (Sanofi Pasteur-MSD) with syringe and needle in the deltoid region.
89499559|NCT02186977|Experimental|Intradermal group (Mantoux)|These subjects will receive one intradermal injection with mantoux technique in the forearm. 0.1cc of HBVAXPRO 40mcgr/ml (Sanofi Pasteur-MSD) will be injected.
89499560|NCT02186977|Experimental|Intradermal group (VAX-ID) A|These subjects will receive one intradermal injection with the newly developed intradermal injection device VAX-ID in the forearm. 0.1cc of HBVAXPRO 40mcgr/ml (Sanofi Pasteur MSD) will be injected.
89499561|NCT02186977|Experimental|Intradermal group (VAX-ID) B|These subjects will receive two intradermal injections with two newly developed intradermal injection devices VAX-ID in both forearms each 0.1cc of HBVAXPRO 40mcgr/ml (Sanofi Pasteur MSD) will be injected.
89499562|NCT05512832||ISR|Patient developed in-stent restenosis 9-24 months after stenting
89499563|NCT05512832||no ISR|Patients were free of in-stent restenosis 9-24 months after stenting
89499564|NCT02752633|Experimental|Study subjects|Following a 7 day washout period all patients receive allopurinol (400 mg/day) as a single daily dose for 2 weeks. Following another 7 day washout period all participants receive febuxostat, 80 mg/day as a single daily dose, for 2 weeks.
89499565|NCT02191189|Active Comparator|Treatment A, p.o.|50 mg Nevirapine administered orally in 100 mL water
89499566|NCT02191189|Experimental|Treatment B, ascending colon|50 mg Nevirapine administered to the ascending colon via Enterion™ capsule
89499567|NCT02191189|Experimental|Treatment C, jejunum|50 mg Nevirapine administered to the jejunum via Enterion™ capsule
89499568|NCT02191189|Experimental|Treatment D, ileum|50 mg Nevirapine administered to the ileum via Enterion™ capsule
89499569|NCT02191189|Experimental|Treatment E, descending colon|50 mg Nevirapine administered to the descending colon via Enterion™ capsule
89499570|NCT02187133|Experimental|Treatment|Patients receive carfilzomib IV over 30 minutes twice weekly on days 1, 2, 8, 9, 15, and 16 or weekly on days 2, 9, and 16; bendamustine hydrochloride IV over 60 minutes on days 1 and 2; and rituximab IV over 30-90 minutes on day 9 (course 1 only) and day 1 (subsequent courses). Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
89499571|NCT04411862|Experimental|Intervention Group|50 Participants with NAFLD that receive lifestyle modification by Clinical Pharmacist plus Phosphatidylcholine two soft capsules 3 times daily(2.1 g per day) for 6 month
89499572|NCT04411862|Active Comparator|Control Group|50 Participants with NAFLD that receive only lifestyle modification by Clinical Pharmacist
89499573|NCT02187211|Experimental|Minocycline Low Dose|Participants in this arm will receive a low dose (200mg/day) of Minocycline for 10 days
89205621|NCT04367857||Never tested and current COVID-19 Symptoms|Never tested and current COVID-19 Symptoms (e.g. referred by a provider or clinic)
89205622|NCT04367857||Never tested and asymptomatic|Never tested and asymptomatic for COVID-19 symptoms, including asymptomatic health care worker
89205623|NCT04343586|Experimental|Adult treatment arm|Adults enrolled in the study will receive treatment (blue light phototherapy) on one area of their body affected by psoriasis or Grover's disease. The treatment area (restricted by size of the device) will be compared to untreated areas affected by disease on the same patient.
89499574|NCT02187211|Experimental|Minocycline High Dose|Participants in this arm will receive a high dose (400mg/day) of Minocycline for 10 days
89499575|NCT02187211|Placebo Comparator|Placebo|Participants in this arm will receive the Placebo for 10 days
89499576|NCT02752087|Experimental|U-193 LY900014 Test|LY900014 test dose administered via subcutaneous (SC) injection
89499577|NCT02752087|Active Comparator|U-95 LY900014 Reference|LY900014 reference dose administered via SC injection
89023356|NCT05624372||Participant|Kids aged 4-18 diagnosed with ADHD
89023357|NCT05620888|Experimental|Tailored messages (TM)|"Participants assigned to this arm receive a daily tailored message on the benefits of taking at least 7000 steps daily. Tailoring concerns change-related expectations, risk perception, planning, retention capacity, resilience, and coping skills and is based on the responses provided by participants at baseline evaluation.~In addition, they receive a daily request to declare the number of steps taken (walking self-monitoring).In particular, every evening, the mobile application sends a message to the participants requesting to enter the number of steps taken during the day in a dedicated app section."
89205624|NCT04333238|Active Comparator|Standard template|Usual outpatient progress note with standard Subjective Objective Assessment Plan (SOAP) format
89023358|NCT05620888|Experimental|Non tailored messages (NTM)|"Participants assigned to this arm receive a daily non-tailored message on the emotional benefits of taking at least 7000 steps daily.~In addition, they receive a daily request to declare the number of steps taken (walking self-monitoring). In particular, every evening, the mobile application sends a message to the participants requesting to enter the number of steps taken during the day in a dedicated app section."
89023359|NCT05620888|No Intervention|No messages (NM)|Participants assigned to this arm receive a daily request to declare the number of steps taken (walking self-monitoring). In particular, every evening, the mobile application sends a message to the participants requesting to enter the number of steps taken during the day in a dedicated app section.
89499578|NCT02187289|Active Comparator|Standard care|Weeks 1-12, Standard Care only (Compression Sleeve, daytime wear)
89499579|NCT02187289|Experimental|Standard Care plus Night-time Compression Bandages|Weeks 1 - 12, Daytime compression sleeve plus night-time compression by self-administered or assisted multi-layered Compression Bandages.
89499580|NCT02187289|Experimental|Standard Care Plus Night-time Compression System Garment|Weeks 1 - 12, Standard care (day-time sleeve) plus night-time use of a custom-made Night-time Compression System Garment
89499581|NCT02191345|No Intervention|10 minute break|Participants asked to take a 10 minute break as usual 3 times per week for 4 weeks
89499582|NCT02191345|Experimental|Guided Imagery|Participants listen to one of 6 pre-recorded guided imagery tracks 3 times per week for 4 weeks
89499583|NCT04766996|Experimental|Prospective cases undergoing non-opioid drug regimen|Prospective study participants undergoing unilateral total hip replacement surgery and non-opioid drug regimen perioperatively
89499584|NCT04766996|No Intervention|Retrospective control underwent opioid drug regimen|Retrospective controls that underwent unilateral total hip replacement surgery and used opioid drug regimen perioperatively
89499585|NCT04766996|No Intervention|Professional Staff|Staff that participate in the implementation of the opioid free surgical protocol will be completing team assessment surveys seeking their opinion about interprofessional teamwork and communication.
89499586|NCT04621747|Experimental|Study group|healthy volunteers aged 18-35, balanced sex ratio, all of them undergoing the same battery of psychophysical explorations.
89499587|NCT02191423|Experimental|postpartum depression|"Women suffering from postpartum depression, assessed by fMRI and then treated by dyadic psychotherapy~All participants will undergo two functional brain scans at the Tel Aviv Medical Center. The two scans will take place one week apart, one scan will include administration of oxytocin (24IU) and the other will include the use of placebo (the order in which the two different treatments is applied will be random).~All women in this group participate in 8-weeks of dyadic psychotherapy (DP) at the outpatient Psychiatric Department, Tel-Aviv Medical Center.~A final end-of-study clinical evaluation, will be conducted at the end of 8 weeks. The evaluation will include a psychiatric evaluation, the MADRS, and a physical examination, the mother-infant interaction will be videotaped, and the YIPTA, BDI, EPDS & STAI will be administered. Salivary OXT samples will be collected from the mother and from the infant and infants will undergo a developmental assessment."
89499588|NCT02191423|Other|normal controls|"Normal control women not suffering from postpartum depression assessed by fMRI~All participants will undergo two functional brain scans at the Tel Aviv Medical Center. The two scans will take place one week apart, one scan will include administration of oxytocin (24IU) and the other will include the use of placebo (the order in which the two different treatments is applied will be random).~A final end-of-study clinical evaluation, will be conducted at the end of 8 weeks. The evaluation will include a psychiatric evaluation, the MADRS, and a physical examination, the mother-infant interaction will be videotaped, and the YIPTA, BDI, EPDS & STAI will be administered. Salivary OXT samples will be collected from the mother and from the infant and infants will undergo a developmental assessment."
89499589|NCT05509946|Experimental|Single dose of celecoxib 400 mg and pregabalin 150 mg|Single dose of celecoxib 400 mg and pregabalin 150 mg administered an hour before surgery
89499590|NCT05509946|Active Comparator|Repeated dose of celecoxib 200 mg and pregabalin 75 mg|Repeated dose of celecoxib 200 mg twice a day and pregabalin 75 mg twice a day administered starting from 3 days before surgery
89499591|NCT05509946|Placebo Comparator|Placebo|Placebo
89499592|NCT04304209|Experimental|Cohort A|After 4 cycles of neoadjuvant sintilimab treatment, the patients and doctors could choose one of the following treatments: (1) surgery, followed by 4 cycles of adjuvant sintilimab with or without Capeox chemotherapy; (2) another 4 cycles of sintilimab, followed by radical surgery or observation (only for patients with clinical complete response).
89499593|NCT04304209|Experimental|Cohort B-arm 1|After four cycles of neoadjuvant Sintilimab, Capeox and radiotherapy, the patients and doctors could choose one of the following treatments: (1) curative surgery and four cycles of adjuvant Capeox chemotherapy;(2)four cycles of Capeox chemotherapy then observation (only for patients with clinical complete response after neoadjuvant therapy)
89023360|NCT05619926|Experimental|Consecutive doses of low-dose of STSP-0601|
89499594|NCT04304209|Active Comparator|Cohort B-arm 2|After four cycles of neoadjuvant Capeox chemotherapy and radiotherapy, the patients and doctors could choose one of the following treatments: (1) curative surgery and four cycles of adjuvant Capeox chemotherapy;(2)four cycles of Capeox chemotherapy then observation (only for patients with clinical complete response after neoadjuvant therapy)
89499595|NCT05509868|Experimental|PBK_L1704 0.35mg|
89499596|NCT05509868|Experimental|PBK_L1704 0.5mg|
89023361|NCT05619926|Experimental|Consecutive doses of high-dose of STSP-0601|
89023362|NCT05618145||PSC population residing in Italy|All PSC patients living in Italy and aged at least 17 years can be included in the database.
89499597|NCT05509868|Placebo Comparator|Placebo|
89499598|NCT02187367|Experimental|EGF Vaccine|Patients in this arm will receive a low dose of cyclophosphamide and the recombinant human rEGF-P64K/Montanide ISA 51
89023363|NCT05609565|Active Comparator|Group 1|
89023364|NCT05609565|Active Comparator|Group 2|
89023365|NCT05608902||DOCTOBA cohort|Patients > 18 years of age with suspected basal cell carcinoma requiring biopsy or skin resection in the dermatology department
89023366|NCT05607108|Experimental|ZEN003694|All patients enrolled on the study will undergo treatment with ZEN003694 60mg po qd on a 5 days on/2 days off schedule in an every 21-day cycle. All assessments, including drug dosing, have a window of +/- 7 days unless otherwise noted.
89499599|NCT02187367|No Intervention|Best Supportive Care|Patients in this arm will receive best supportive care
89499600|NCT02563028|Experimental|SightSaver Visual Stimulator|A SightSaver Visual Stimulator mask will be applied during surgery. Baseline VEPs will be recorded prior to prone positioning. At the end of surgery, after supine positioning, the SightSaver Visual Stimulator mask will be removed and discarded.
89499601|NCT02187445|Experimental|Budesonide inhalation suspension|To determine the acceptability of budesonide inhalation suspension (BIS) 0.5 QD for 6 months for children with SCD that develop ACS between 1 and 4 years of age (n=10).
89499602|NCT02191501|Experimental|Pyloric restriction|Endoscopic method of pyloric restriction in order to decrease gastric emptying. The hypothesis is that this will cause and early and prolonged satiety which will inturn lead to decreased food consumption and lead to weight loss.
89499603|NCT05502848|Experimental|AD patients treated with ICBT|
89499604|NCT05502848|No Intervention|AD patients receiving regular treatment|
89499605|NCT05502848|No Intervention|Healthy Controls|
89499606|NCT02187523|Experimental|Telmisartan/HCTZ FDC|
89499607|NCT02187523|Active Comparator|Telmisartan and HCTZ individual tablets|
89499608|NCT02187679|Experimental|Abobotulinum toxin A|Abobotulinum toxin A Injection
89499609|NCT05507606|Experimental|Osimertinib+Bevacizumab+Carboplatin and Pemetrexed|Bevacizumab, 7.5mg/kg, d1; Pemetrexed, 500mg/m2, d1; Carboplatin AUC5, d1; Osimertinib 80mg/d , d1-21; Q3W/cycle induction therapy for 4 cycle. Then Carboplatin was stopped after 4 cycles, and Osimertinib combined with Bevacizumab and Pemetrexed were given for maintenance treatment every 3 weeks for 2 years. After that, the maintenance treatment of Osimertinib was continued.
89499610|NCT02191657|Experimental|Cohort 1|Subjects in this arm were asymptomatic HIV-infected individuals who received a dose of 33 mg/kg deferiprone three times a day for a total daily dosage of 99 mg/kg
89499611|NCT02191657|Experimental|Cohort 2|Subjects in this arm were healthy volunteers who received a dose of 50 mg/kg deferiprone three times a day for a total daily dosage of 150 mg/kg
88955818|NCT06186141|Active Comparator|Intravenous (IV) Morphine Patient controlled analgesia (PCA)|Morphine PCA IV 20mcg/kg bolus to a maximum of 1mg with a 5-minute lockout- as per current RCH Children's Pain Management Service (CPMS) dosing and use.
88955819|NCT06186141|Active Comparator|IV Oxycodone PCA|Oxycodone PCA IV 20mcg/kg bolus to a maximum of 1mg with a 5-minute lockout- as per current RCH Children's Pain Management Service (CPMS) dosing and use.
88955820|NCT06185985|Experimental|Open-Label Treatment|SPN-812 (200mg to 600mg once daily) for up to 14 weeks
89499612|NCT02191657|Experimental|Cohort 3|Subjects in this arm were asymptomatic HIV-infected individuals who received a dose of 50 mg/kg deferiprone three times a day for a total daily dosage of 150 mg/kg.
89499613|NCT05509556||patients with calcaneal spur on the lateral radiograph of the foot|The group in which talocalcaneal angle measurement was performed in patients with calcaneal spurs on the lateral radiograph of the foot.
89499614|NCT05509556||patients without calcaneal spur on lateral radiograph of the foot|The group in which talocalcaneal angle measurement was performed in patients without calcaneal spur on the lateral radiograph of the foot.
89499615|NCT02191735||Troponin I|Subjects who have undergone a routine test order of Troponin for suspected Acute Coronary Syndrome / Myocardial Infarction (ACS/MI). Waste sample blood will then be tested on the RAMP 200 and the RAMP Reader for comparison.
89499616|NCT02191735||Myoglobin|Subjects who have undergone a routine test order of Troponin for suspected Acute Coronary Syndrome / Myocardial Infarction (ACS/MI) and who have a RAMP Myoglobin test result that is within the test reportable range. Waste sample blood will then be tested on the RAMP 200 and the RAMP Reader for comparison.
89499617|NCT02191735||CK-MB|Subjects who have undergone a routine test order of Troponin for suspected Acute Coronary Syndrome / Myocardial Infarction (ACS/MI) and who have a RAMP CK-MB test result that is within the test reportable range. Waste sample blood will then be tested on the RAMP 200 and the RAMP Reader for comparison.
89499618|NCT02191735||NT-proBNP|Subjects who have undergone a routine test order of NT-proBNP or BNP for suspected Heart Failure (HF). Waste sample blood will then be tested on the RAMP 200 and the RAMP Reader for comparison.
89499619|NCT04585256|Active Comparator|Trendelenburg|Women positioned in the trendelenburg position during external cephalic version.
89499620|NCT04585256|No Intervention|Control|Women positioned on their back during external cephalic version.
89499621|NCT02191813|Experimental|Seresis®|
89499622|NCT02191813|Placebo Comparator|Placebo|
89499623|NCT02191891|Experimental|BI 836845 + afatinib|BI 836845 low or high dose (weekly IV infusion), afatinib 30mg or 40mg (once daily oral dosing)
89499624|NCT05502536|Experimental|Intervention group|traditional rehabilitation programs with additional individualized fairytales class
89499625|NCT05502536|No Intervention|Control group|traditional rehabilitation programs without additional individualized fairytales class
89499626|NCT05507372|Experimental|Dopamine Receptor Modulator|Pimozide 1mg Oral
89499627|NCT05507372|Placebo Comparator|Placebo|Placebo Oral
89499628|NCT02193685||Subjects with HAEC|There is no intervention involvement. The clinical data and biologic specimens collected during the study will serve as an invaluable resource for a wide spectrum of clinical and translational ancillary studies directly related to the aims and goals of the study.
89499629|NCT02193685||Subjects without HAEC|A subgroup of children who have Hirschsprung Disease may or may not develop enterocolitis; therefore we will be identifying the bio-markers in children with or without associated enterocolitis.
89499630|NCT02193763|Experimental|90 days and under--Interventional|Neonates aged 90 days and under randomized to ultrasound assisted lumbar puncture
89499631|NCT02193763|No Intervention|90 days and under--control|Neonates aged 90 days and under randomized to lumbar puncture using the anatomical landmark approach
89499632|NCT02193763|Experimental|Over 90 days--Interventional|Neonates aged over 90 days randomized to ultrasound assisted lumbar puncture
89499633|NCT02193763|No Intervention|Over 90 days--Control|Neonates aged over 90 days randomized to lumbar puncture using the anatomical landmark approach
89499634|NCT04571047||Colorectal cancer patients|Patients diagnosed with colonrectal cancer between 2008-2016
89499635|NCT02191969|No Intervention|Control|This group will be receiving adjuvant chemotherapy for colorectal cancer. They will not participate in the Walk With Ease program. They will be followed up using standard of care.
89499636|NCT02191969|Experimental|Intervention|"This group will be receiving adjuvant chemotherapy for colorectal cancer. They will participate in the Walk With Ease (WWE) program during the course of their chemotherapy treatment. They will be requested to initiate the WWE starting on Day 1 of adjuvant chemotherapy. Participants are asked to walk at a safe and comfortable pace, increasing their minutes per day at a rate they can sustain, with the ultimate goal of 30 minutes/day for at least 5 days/week. They are asked to maintain a daily walking log that is provided to them, entering total minutes per day.~Participants will be asked to do the walking program independently (self-directed, not in a formal group with an instructor) throughout chemotherapy."
89499637|NCT02192047|Experimental|palm olein margarine|8 weeks
89499638|NCT02192047|Experimental|IE palm olein margarine|8 weeks
89499639|NCT02192047|Experimental|IE soybean oil-based margarine|8 weeks
89499640|NCT02192125|Experimental|REWIRE-System|The training system consists of a so-called Tymoplate® (Tyromotion, Austria), a medical device class 1 with CE certification and approval by the FDA for use in neurorehabilitation after stroke. The Tymoplate® is connected to a computer and allows by means of a base plate with integrated pressure sensors and custom-developed training software different postural biofeedback exercise.
89499641|NCT02192203|Experimental|Diclofenac + Menthol Gel|1% diclofenac, 3% menthol
89499642|NCT02192203|Active Comparator|Diclofenac Only Gel|1% diclofenac, 0.09% menthol
89499643|NCT02192203|Active Comparator|Menthol Only Gel|3% menthol
89499644|NCT02192203|Placebo Comparator|Placebo Only Gel|0.09% menthol
89499645|NCT02192281|Experimental|Playworks|Playworks was implemented during the entire school year, and outcome measures were collected in spring of the school year.
89499646|NCT02192281|No Intervention|Control|Playworks was not implemented at these schools.
89499647|NCT02192437|Experimental|Methionine restricted diet|Intervention will be a Sulfur amino acid restricted diet (methionine). Control diet for 4 weeks followed by a washout for 3-4 weeks, then a methionine restricted diet (70%) for 4 weeks, followed by 3-4 weeks washout period and then a methionine restricted diet (90%) for 4 weeks.
89499648|NCT02192437|Experimental|Methionine and cysteine restricted diet|Intervention will be a Sulfur amino acid restricted diet (methionine and cysteine). Control diet for 4 weeks followed by a washout for 3-4 weeks then a methionine and cysteine restricted diet (50%) followed by 3-4 weeks washout period and then a methionine and cysteine restricted diet (65%) for 4 weeks.
89499649|NCT02193919||cohort 1 placebo + UVB|cohort 1 placebo + UVB
89499650|NCT02193919||South Beach Diet + UVB|South Beach DIet + UVB
89499651|NCT02193919||Ornish Diet + UVB|Ornish Diet + UVB
89499652|NCT02187757|Experimental|PreLipid|Study Dietary Supplement (PreLipid 600 mg capsules) will be given to subjects twice daily 30 mins before food for 90days along with lifestyle modification.
89499653|NCT02187757|Placebo Comparator|Placebo 600 mg capsules|Placebo was given to patients twice daily 30 mins before food for 90 days along with lifestyle modification program.
89499654|NCT02192515|Experimental|APD356 10 mg|Subjects will be randomized to APD356 10 mg group (6 subjects) or placebo group (2 subjects) to receive single dose of study drug.
89499655|NCT02192515|Experimental|APD356 20 mg|Subjects will be randomized to APD356 20 mg group (6 subjects) or placebo group (2 subjects) to receive single dose of study drug.
89499656|NCT02192515|Experimental|APD356 XR-20 mg|Subjects will be randomized to APD356 XR-20 mg group (6 subjects) or placebo group (2 subjects) to receive single dose of study drug on Day 1 and multiple doses of study drug on Day 8-14 once daily before breakfast.
89499657|NCT02192515|Experimental|APD356 10 mg and APD356 XR-20mg (orange tablet)|"Subjects will be randomized to Sequence A (8 subjects) or Sequence B (8 subjects) to receive study drug in the sequence shown below.~Sequence A: 10 mg tablet, 2 doses (12 hours apart) => XR-20 mg orange tablet, single dose => XR-20 mg orange tablet, q. d., multiple doses (fasted) => XR-20 mg orange tablet, q. d., multiple dose (fed)~Sequence B: XR-20 mg orange tablet, single dose => 10 mg tablet, 2 doses (12 hours apart) => XR-20 mg orange tablet, q. d., multiple dose (fed) => XR-20 mg orange tablet, q. d., multiple doses (fasted)"
89499658|NCT02257021|Experimental|Tipranavir and high dose of ritonavir plus BILR 355 BS|
89499659|NCT02257021|Experimental|BILR 355 BS with low dose of ritonavir|
89499660|NCT02187835||schizophrenia|patients with a diagnosis of schizohrenia
89499661|NCT02187835||control|healthy control group
89499662|NCT02187913|Experimental|Resistant starch|The test snack bar consumed has the resistant starch
89499663|NCT02187913|Experimental|Control|The control bar uses maltodextrin rather than the resistant starch.
89499664|NCT03536065|Active Comparator|Pre-Intervention|Current practice (unchanged)
89499665|NCT03536065|Experimental|Post-Intervention|Reduction of opioid prescription based on Pre-Intervention data, implementation of a discharge sheet and nursing education.
89499666|NCT02192593|Experimental|Computer CBT|A 10-session computerized cognitive-behavioral therapy intervention
89499667|NCT02192593|No Intervention|Usual Care|
89499668|NCT03535441||voluteer group|No treatment, only blood sample collection
89499669|NCT03535441||hemorrhagic shock group|HS was defined as out-of-hospital systolic blood pressure (SBP) of 70 mmHg or less or SBP ranging 71 to 90 mmHg with a heart rate of 108 beats/min or more. Exclusion criteria were pregnancy, <15 years old, more than 2,000 mL of intravenous fluids or blood before enrollment, hypothermia, drowning, asphyxia, burns, isolated penetrating head injury, time of call received by dispatch to study intervention longer than 4 h, known prisoners, and transfer from another hospital
89499670|NCT04547491|Other|GDT group|Cardiac optimization with goal-directed therapy, liberal use of vasopressor agents.
89499671|NCT04547491|Experimental|HPI group|Hemodynamic management HPI-based, protocol-based use of fluids, vasopressors and inotropes.
89499672|NCT02193997|Experimental|Fiber 1|Fiber bar containing inulin as fiber soucre taken once daily for 4 weeks
89499673|NCT02193997|Experimental|Fiber 2|Fiber bar containing soluble corn as fiber soucre taken once daily for 4 weeks
89499674|NCT02193997|Placebo Comparator|Placebo|Bar with low fiber content (placebo) once daily for 4 weeks
89499675|NCT02192749|Experimental|Umbilical cord mesenchymal stem cells|
89499676|NCT03535987||Observational|To determine the feasibility of using myocardial PET imaging
89499677|NCT02192827|Experimental|Single Dose Dexamethasone|0.6 mg/kg of Dexamethasone Sodium Phosphate Injection 10mg/1ml given with equivalent volume of cherry syrup given orally once
89499678|NCT02192827|Experimental|Two Dose Dexamethasone|0.6 mg/kg of Dexamethasone Sodium Phosphate Injection 10mg/1ml given with equivalent volume of cherry syrup given orally once in the Emergency Department (ED), followed by another dose of dexamethasone at home, which will be prescribed from the ED. The second dose will be the same dosage, but will be prescribed and may be pill or liquid form.
89499679|NCT02188225|Experimental|Acupuncture|12 sessions of acupuncture / 3 sessions weekly/ 20 minutes each session
89499680|NCT02188225|Active Comparator|fluoxetine|10 mg daily
89499681|NCT04535089|Active Comparator|dexmedetomdine|IV bolus dose of 0.5ug/kg dexmedetomidine diluted in 10ml saline 1% over 15 minutes followed by continuous infusion of 0.5ug/kg/h
89499682|NCT04535089|Active Comparator|lidocaine|IV bolus dose of 1mg/kg lidocaine 1% over 15 minutes followed by continuous infusion of 1.5mg/kg/h
89499683|NCT02192983||chemotherapy regimen|those with XELOX regimen and those with EOX regimen
89499684|NCT02188537|Experimental|Nelfinavir, Bortezomib, Dexamethasone|"The trial is designed as an add-on therapy, where nelfinavir is added to the approved bortezomib-containing therapy. Bortezomib and dexamethasone background treatment will be given in the Swissmedic-approved dose and schedule and according to international therapeutic standard."
89499685|NCT02193061|Active Comparator|ROTA 1|two doses of monovalent vaccine Rotarix followed by one dose of sterile water
89499686|NCT02193061|Active Comparator|ROTA 2|three doses of pentavalent vaccine RotaTeq
89499687|NCT02193061|Active Comparator|ROTA 3|one dose of monovalent Rotarix vaccine followed by two doses of pentavalent vaccine Rotateq
89499688|NCT02193061|Active Comparator|ROTA 4|one dose of pentavalent RotaTeq vaccine followed by two doses of monovalent vaccine Rotarix
89205625|NCT04333238|Experimental|New template|The assessment and plan section is placed in the beginning, subjective data grouped into the assessment section, and elements not related to the current presentation were deemphasized
89499689|NCT02193061|Active Comparator|ROTA 5|two doses of pentavalent vaccine RotaTeq followed by a dose of monovalent vaccine Rotarix
89499690|NCT02193061|Active Comparator|ROTA 6|one dose of pentavalent vaccine RotaTeq followed by a dose of monovalent vaccine Rotarix and a dose of pentavalent vaccine RotaTeq
89499691|NCT02193061|Active Comparator|ROTA 7|a dose of monovalent vaccine Rotarix followed by a dose of pentavalent vaccine and a dose of monovalent vaccine Rotarix
89499692|NCT03535051|Experimental|Treatment A|Combination treatment of fractional carbon dioxide laser monthly sessions and topical tacrolimus 0.03% daily application (Tacrolimus Oint 0.03%)
89499693|NCT03535051|Active Comparator|Treatment B|Monotherapy with only topical tacrolimus 0.03% daily intervention: Tacrolimus Oint 0.03%
89499694|NCT02188615|Experimental|experimental group|Neo-adjuvant Chemoradiotherapy followed by Mckeown MIE
89499695|NCT02188615|Active Comparator|Radical Chemoradiotherapy|only Radical Chemoradiotherapy
89499696|NCT02188615|Active Comparator|Mckeown MIE|only Mckeown MIE
89499697|NCT02188693||Gemcitabine, Experimental|Gemcitabine 1250 mg/m2, IV on day 1 of 21 day cycle,with a follow up for every 12 weeks until disease progression or the date of first documented death from any cause
89499698|NCT02188693||Observational|Observation for every 12 weeks until disease progression or the date of first documented death from any cause
89205626|NCT04298723|Experimental|Left Atrial Appendage Occlusion|Percutaneous closure of the LAA by use of CE-mark approved LAA occlusion device Watchman / Watchman FLX
89205627|NCT04298723|No Intervention|Best medical therapy for anticoagulation|Standard of care (according to current guidelines)
89205628|NCT04288947|Other|Usual Care|Training of midwives on 4 respectful maternal care modules.
89205629|NCT04288570|Active Comparator|Bone socket formation with a punch|suture anchor socket creation with punch
89205630|NCT04288570|Active Comparator|Bone socket formation with a drill|suture anchor socket creation with drill
89205631|NCT04266275|Experimental|Curcumin Arm|Participants in this arm will use 2000 mg of intravaginal curcumin once a week for 20 weeks
89205632|NCT04266275|Placebo Comparator|Placebo Arm|Participants in this arm will use 2000 mg of intravaginal placebo once a week for 20 weeks
89205633|NCT04245449|Experimental|e learning+therapy (TEAACH)|TEAACH-Training to Empower Activity-dependent plasticity-based Arm-use habits in the Community and at Home
89205634|NCT04194359|Experimental|Sintilimab (IBI308) plus Bevacizumab, Oxaliplatin and Capecitabine|Sintilimab (IBI308)：200MG, once every three weeks; Bevacizumab:7.5mg/kg, once every three weeks; oxplatin: 135 mg per square meter body surface, once every three weeks; Capecitabine : Capecitabine 1 gram per square meter body surface area, from the first day to the 14th day
89205635|NCT04144725||Suspected coronary artery disease|Patients hospitalized for suspected acute coronary syndrome who are referred to CCTA or patients referred to CCTA from outpatient clinics for evaluation of stable coronary artery disease.
89205636|NCT04066907|Experimental|Integrated Disease Management|Physicians randomized to intervention will attend a training session on the program standards and details of the IDM. Following the initial baseline interview a heart failure educator (HFE) will meet with subjects to obtain a detailed history of their HF, provide education, self-care management strategies (medication adherence, symptoms monitoring, dietary adherence, fluid restriction, exercise, weight management, smoking cessation) and review immunization status. A self-management action plan will be developed with the study physician and HFE to enable monitoring and management of HF by the participant.
89205637|NCT04066907|No Intervention|Usual Care|Subjects will receive HF care as usually provided by their physician as advised or as needed. Study commitments for the control group include the initial interview, the expected time allotment for this initial visit is 1 hour. Telephone follow-up will occur at 3 months and 9 months to collect exacerbation data and maintain contact with participant. At 6 months and 12 months telephone follow-up will be conducted by the research assistant and the questionnaires will be completed.
89205638|NCT04053491|Experimental|Axillary block group|Initial bolus will be given and then a perinervous catheter will be inserted by the axillary approach.
89205639|NCT04053491|Experimental|Infraclavicular block group|Initial bolus will be given and then a perinervous catheter will be inserted by the infraclavicular approach.
89205640|NCT04041232|Experimental|PBA treatment of ATF6-/- Achromatopsia|Patients will be monitored at the baseline visit, followed by a second and third visit that will be 1 and 3 months after the initial visit. Patients will complete a standard visual functioning questionnaire and undergo a complete ophthalmic evaluation at each visit. Other visual assessments will consist of color vision testing, contrast sensitivity, retinal imaging, and macular sensitivity testing using microperimetry. Full-field electroretinogram will also be performed at the baseline visit and after 1 and 3 months of PBA use. If improvement in retinal function is observed, an additional ophthalmic evaluation will be conducted after 6 months of PBA use. A blood draw will be performed at each visit to test for any indications of adverse effects from drug use.
89205641|NCT04038541|Other|Prebiotic/ Probiotic|These subjects will be assigned to first receive prebiotics (Prebiotin Prebiotic Fiber Stick Pac) for 6 weeks. Then after a 6 week wash-out period, subjects will take probiotics (Visbiome®) for 6 weeks (followed again by a 6 week washout period).
89205642|NCT04038541|Other|Probiotic/ Prebiotic|These subjects will be assigned to first receive probiotics (Visbiome®) for 6 weeks. Then after a 6 week wash-out period, subjects will take (Prebiotin Prebiotic Fiber Stick) for 6 weeks (followed again by a 6 week washout period).
89205643|NCT04037501|Experimental|Intervention|
89205644|NCT04037501|No Intervention|care as usual|
89205645|NCT04030000|Other|Paclitaxel/Carboplatin and radiation|"Paclitaxel 135 mg/m2 over 3 hrs on day 1 Carboplatin IP (AUC= 6.0) on day 1 Paclitaxel 60 mg/m2 IP on Day 8 Repeat q 21 days x 6 cycles~Pelvic 6MV Photon Beam Energy, or IMRT where appropriate 1.8 Gy Dose/FX Total Dose 45 Gy~High Dose Radiation (HDR) x 3, or IMRT where appropriate 5 Gy to 0.5cm Depth from the Vaginal Cylinder Surface Total Dose 15 Gy"
89205646|NCT03983161|Experimental|Fedratinib in moderate hepatic impairment subjects|A single oral dose of 300 mg of fedratinib will be given to subjects with moderate hepatic impairment
89499699|NCT02030743|Active Comparator|Visual training|Training in visual attention
88955821|NCT06183931|Experimental|ALXN2220|Participants will receive weight-based dose of ALXN2220 via intravenous (IV) infusion every 4 weeks (q4w) for at least 24 months up to a maximum of 48 months.
89499700|NCT02030743|Placebo Comparator|Usual activity|Usual activity
89499701|NCT02188771|Experimental|RegenoGel SP 2ml|"RegenoGel-SP is a new viscosupplement intended for the intra-articular treatment of OA.~Following signing the Informed Consent form (Visit 1), subjects who conform to the inclusion criteria will be evaluated for vital signs, blood hematology, chemistry, INR, aPTT and ECG, and will be subjected to a 30-40ml blood withdrawal that will be used for the production of autologous RegenoGel-SP. Subjects randomized to receive RegenoGel-SP will receive a single, intra-articular injection (Visit 2)."
89499702|NCT02188927|Experimental|Implementation of ANL|"Intervention: Procedure : Implementation of routine Advanced Notification Letter included in Standard Invitation procedure~Advanced Notification Letter will be implemented in invitation procedure and send two weeks before Standard Invitation (Standard Invitation will be send six weeks before planned screening colonoscopy)"
89499703|NCT02188927|Active Comparator|No included ANL|Intervention: Behavioral : No included Advanced Notification Letter Sending Standard Invitation six weeks before planned screening colonoscopy
89499704|NCT02194075|Active Comparator|Fluvoxamine+Methylphenidate Hydrochloride|"Fluvoxamine: tablet, 100mg-300mg/d, were treated with a course of 8 weeks.~Methylphenidate Hydrochloride: tablet, 18mg-36mg/d, were treated with a course of 8 weeks."
89499705|NCT02194075|Placebo Comparator|Fluvoxamine+sugar pill|"Fluvoxamine: tablet, 100mg-300mg/d, were treated with a course of 8 weeks.~sugar pill: tablet, 1-2 tablets/d, were treated with a course of 8 weeks."
89499706|NCT02030587|Experimental|Radiofrequency Ablation|Radiofrequency Ablation
89499707|NCT02030587|Active Comparator|Laparoscopic Adrenalectomy|Laparoscopic Adrenalectomy
89499708|NCT03535285|Experimental|Surgical modification side|Periodontal ligament distraction without the oblique cuts but with apical horizontal cut
89499709|NCT03535285|Active Comparator|Conventional surgery|Periodontal ligament distraction
89499710|NCT02189005|Experimental|PreCrea|Study dietary supplement (Precrea 600 mg capsules) will be given to subjects twice daily 30 mins before food for 90 days along with life style modification program.
89499711|NCT02189005|Placebo Comparator|Placebo 600 mg capsules|Placebo was given to patients twice daily 30 mins before food for 90 days along with lifestyle modification program.
89499712|NCT02189083|Experimental|High dose TSD|Subjects in this arm receive high dose (217 g/day) TSD for 16 weeks.
89499713|NCT02189083|Active Comparator|Low dose TSD|Subjects in this arm receive low dose (69 g/day) TSD for 16 weeks.
89499714|NCT02256787|Experimental|BILB 1941 ZW - single rising dose|Single rising dose part
89499715|NCT02256787|Placebo Comparator|Placebo|Single rising dose part
89499716|NCT02256787|Experimental|BILB 1941 ZW - tablet - fasted|Relative bioavailability: The oral solution fasted should be compared with the solid form fasted and after a standardized breakfast
89499717|NCT02256787|Experimental|BILB 1941 ZW - solution|Relative bioavailability: The oral solution fasted should be compared with the solid form fasted and after a standardized breakfast
89499718|NCT02256787|Experimental|BILB 1941 ZW - tablet - fed|Relative bioavailability: The oral solution fasted should be compared with the solid form fasted and after a standardized breakfast
89499719|NCT02193217|Experimental|MT-1303-Low|MT-1303-Low dose
89499720|NCT02193217|Experimental|MT-1303-High|MT-1303-High dose
89499721|NCT02193217|Active Comparator|Fingolimod|Fingolimod
88955822|NCT06183931|Placebo Comparator|Placebo|Participants will receive placebo via IV infusion q4w for at least 24 months up to a maximum of 48 months.
89499722|NCT02193217|Placebo Comparator|Placebo|Placebo
89499723|NCT03534973|Active Comparator|Caffeine intake|Caffeine is given orally prior to cataract surgery
89499724|NCT03534973|Sham Comparator|No caffeine intake|Caffeine is not given orally prior to cataract surgery
89499725|NCT03535207|Experimental|high dose chemoradiotherapy|all eligible patients receive intensity-modulated radiotherapy 50 Gy in 25 fractions over 5 weeks and concurrent paclitaxel and cisplatin once weekly for 5 weeks，followed by hyperfractionated intensity-modulated radiotherapy boost to gross tumor volume concurrent with the same chemotherapy
89499726|NCT02189239|Active Comparator|Zeller Entspannung film coated tablets|Relaxing film coated tablets, 570 mg (Zeller Entspannung Filmtabletten), 3x1 tablet per day for the first three days (morning, midday, evening), at day four 2x1 tablet (morning, midday) preferably during meals with a glass of water.
89499727|NCT02189239|Placebo Comparator|Placebo tablets|Placebo medication is identical in presentation, color and shape, 3x1 tablet per day for the first three days (morning, midday, evening), at day four 2x1 tablet (morning, midday) during meals with a glass of water.
89499728|NCT02189239|Sham Comparator|No Treatment|No medication intake.
89499729|NCT04728061|Experimental|Single Ascending Dose|
89499730|NCT04728061|Experimental|Multiple Ascending Dose|
89499731|NCT03534895|Placebo Comparator|PC1|5mL normal saline intravenous, single-administration, as pre-medication
89499732|NCT03534895|Experimental|PC2|midazolam 0.02mg/Kg in 5mL normal saline, intravenous, single-administration, as pre-medication
88955823|NCT06182410|Experimental|Supportive Care (defibrotide)|Participants receive defibrotide IV over 2 hours every six hours on days -8 to +21 during the first and second rounds of Hematopoietic stem-cell transplantation (HSCT).
88955824|NCT06181240|Experimental|Bolt IVL System|Lithotripsy is a medical procedure that uses shock waves to modify intravascular calcium.
89205647|NCT03983161|Experimental|Fedratinib in severe hepatic impairment subjects|A single dose of 200 mg of fedratinib will be given to subjects with severe hepatic impairment
89205648|NCT03983161|Experimental|Fedratinib in healthy vs moderate hepatic impairment subjects|A single oral dose of 300 mg of fedratinib will be given to healthy subjects with normal hepatic function.
89499733|NCT03534895|Experimental|PC3|midazolam 0.06mg/Kg in 5mL normal saline, intravenous, single-administration, as pre-medication
89499734|NCT03535753|Experimental|Decitabine and R-GDP|ALL patients will be treated with Decitabine and R-GDP
89499735|NCT02189395|Experimental|NPH and regular insuline group|For the group receiving NPH and regular 2/3 and 1/3 formula will be followed. If Nil per os (NPO), patient will receive NPH twice daily but AM dose will equal to PM dose. Regular insulin given along with NPH will be held while patient is NPO. A correctional dose of regular insulin will be given for any blood glucose >180 mg/dL. If subjects were not eating, they could also receive correctional doses of regular insulin. Correctional insulin could be given four times daily with meals or at bedtime.
88955825|NCT06170814||external odak|Exercise will be done for approximately 40 minutes, 3 days a week for 6 weeks. Ramps, obstacle jumping, stairs and tracks will be built to improve walking and balance functions. During exercises, attention is directed to movement and an environmental stimulus in the external focus of attention.
88955826|NCT06170814||internal focus|Exercise will be done for approximately 40 minutes, 3 days a week for 6 weeks. Ramps, obstacle jumping, stairs, and tracks will be built to improve walking and balance functions. In internal focus during exercises, attention is directed directly to body movements.
89499736|NCT02189395|Active Comparator|glargine and humalog group|Half of the total insulin dose will be given as glargine once daily, either in the AM or in the PM, depending on when the patient was enrolled. The other half of the total daily insulin dose was given as humalog; doses were divided equally between breakfast, lunch, and dinner. An additional correctional dose of humalog will be given for any blood glucose >180 mg/dL. If subjects were not eating, they received glargine once daily and could also receive correctional doses of humalog. Correctional humalog could be given four times daily with meals or at bedtime.
89499737|NCT02193373|Active Comparator|Sub-Occipital Release|Osteopathic Manual Medicine
89499738|NCT02193373|Active Comparator|Rib-Raising|Osteopathic Manual Medicine
89499739|NCT02193373|Active Comparator|Stellate Ganglion Release|Osteopathic Manual Medicine
89499740|NCT02193373|Active Comparator|All techniques|Osteopathic Manual Medicine
89499741|NCT02193373|Sham Comparator|All Techniques-S|Sham Osteopathic Manual Medicine
89499742|NCT02193373|Sham Comparator|Sub-Occipital Release-S|Sham Osteopathic Manual Medicine
89499743|NCT02193373|Sham Comparator|Rib-Raising-S|Sham Osteopathic Manual Medicine
89499744|NCT02193373|Sham Comparator|Stellate Ganglion Release -S|Sham Osteopathic Manual Medicine
89499745|NCT02189551|Active Comparator|Lokomat Pro|gait robot established on the market
89499746|NCT02189551|Experimental|Lokomat Pro FreeD|gait robot based on the Lokomat Pro with changes in guidance of the hip, approved for the Swiss market
89499747|NCT04674631||Case group 1|52 patients with score of 12 or more on Leeds assessment of neuropathic symptoms and signs (LANSS) questionnaire will be included in the neuropathic pain group.
89499748|NCT04674631||Case group 2|46 patients with scores less than 12 on LANSS will be included in the group without neuropathic pain.
89499749|NCT02194153||Metalyse|Metalyse weight-adjusted
89499750|NCT04435873||Mail Survey Participants|Approximately 1200 home patients will receive mail surveys. Of these, one thousand and twenty (1,020) patients will be asked to complete the survey once. One hundred and eighty (180) patients will be asked to complete the survey twice.
89499751|NCT04435873||Telephone Survey Participants|Three hundred (300) home patients will be surveyed by phone. Of those, one hundred and twenty will be asked to complete the survey once. One hundred and eighty patients will be asked to complete the phone surveys on two separate occasions.
89499752|NCT02189707|Experimental|Probiotic Bifidobacterium 1x1010 cfu|One capsule of study product, mixed with provided yogurt, will be consumed once a day.
89499753|NCT02189707|Experimental|Probiotic Bifidobacterium 1x109 cfu|One capsule of study product, mixed with provided yogurt, will be consumed once a day.
89499754|NCT02189707|Placebo Comparator|Placebo powder in capsules|One capsule of study product, mixed with provided yogurt, will be consumed once a day.
89499755|NCT02194231|Experimental|Trabectedin|Patients will receive trabectedin treatment
89499756|NCT02562482|Experimental|Group 1: VRC-CHKVLP059-00-VP 20 mcg|Group 1 subjects were randomized to receive two intramuscular (IM) injections of CHIKV VLP vaccine (VRC-CHKVLP059-00-VP) at Day 0 and Day 28 (+14 days) at a dose of 20 micrograms (mcg).
89499757|NCT02562482|Placebo Comparator|Group 2: Placebo (VRC-PBSPLA043-00-VP)|Group 2 subjects were randomized to receive two intramuscular (IM) injections of Phosphate Buffered Saline (VRC-PBSPLA043-00-VP) placebo at Day 0 and Day 28 (+14 days).
89205649|NCT03983161|Experimental|Fedratinib in healthy vs severe hepatic impairment subjects|A single oral dose of 200 mg of fedratinib will be given to healthy subjects with normal hepatic function.
89205650|NCT03965676|Other|Adult patients with a tophaceous gout|Adult patients with a tophaceous gout but no urate-lowering treatment or treatment but target not reached (target = uricemia < 360µmol/L).
89499758|NCT02193451|Experimental|Urodynamics|Invasive urodynamic cystometry including pressure flow studies, along with usual diagnostics in male LUTS
89499759|NCT02193451|Active Comparator|Usual care|Usual diagnostics in male LUTS; flow rate test, symptom score and bladder diary
89499760|NCT02189785||Healthy Controls|Healthy men and women ages 18-25 years
89499761|NCT02190019|Active Comparator|transcranial magnetic stimulator|Neurostar repetitive transcranial magnetic stimulator. The active procedure will stimulate at 120% motor threshold for 4 seconds at a frequency of 10 Hz, with an inter-train interval of 26 seconds for a total of 3,000 pulses. 10 treatment sessions are given over a two week period.
89499762|NCT02190019|Sham Comparator|Sham coil treatment|Neurostar repetitive transcranial magnetic stimulator. 10 treatments identical in duration will be administered over a two week period.
89499763|NCT02933671|Experimental|Suprainguinal Fascia Iliaca (SIFI) block|A nerve block technique using a numbing medication called ropivacaine.
89499764|NCT02933671|Placebo Comparator|Sham group|The same nerve block technique as above, however using an inactive solution of salt water.
89499765|NCT05509478|Experimental|Lenvatinib+PD-1 inhibitors|Participants received lenvatinib capsules 8 mg , orally, once daily (QD) PD-1 inhibitors in this study include, but not limited to, Pembrolizumab, nivolumab, sintilimab, toripalimab, etc. The usage and dosage refer to label information or other clinical study
89499766|NCT05507294|Experimental|SCC244：Fasting+High-fat meal+Low-fat meal|Participants will receive a single oral dose of Glumetinib tablet in fasting condition on Day 1 of treatment period 1 followed by a single oral dose of Glumetinib tablet in fed condition(High-fat meal) on Day 1 of treatment period 2.Then，Participants will receive a single oral dose of Glumetinib tablet in fed condition （Low-fat meal）on Day 1 of treatment period 3. The time interval between two adjacent dosages was at least 14 days.
89538305|NCT03270449|Experimental|Multidisciplinary intervention|The 10-week intervention will include twice weekly 1-2 hours sessions with multiple professional team members to undergo education and exercise sessions. The multidisciplinary team will consist of a rheumatologist, rheumatology nurse, dietitian, physiotherapist, a trained exercise therapist, a physiologist who specializes in pain management, a psychiatrist and a mental health clinician. All intervention team members have expertise in working with individuals with chronic pain conditions. General disease information, current best practices and techniques such as self-pain management, pacing, sleep hygiene, approach to a healthy lifestyle and weight loss will be discussed. The total number of hours for the 10 week intervention is 31 hours.
89538306|NCT03270449|No Intervention|Usual care|Usual care involves being referred to the local rheumatologist involved in the study. The rheumatologist and the rheumatology nurse will see the control group patients during a one hour one on one consultation appointment. During that time the patient's history will be taken, physical exam performed and investigations analyzed. If a diagnosis of fibromyalgia is confirmed, the rheumatologist and nurse will counsel the patient and provide resources for self directed management. Unless there is a concern of an alternative diagnosis, follow up will not be arranged.
89538307|NCT04970043|Experimental|Camrelizumab+ pemetrexed + platinum|
89538308|NCT03280745|Active Comparator|7.3% NaCl (intervention)|At admission to the ICU patients will receive 5ml/kg body weight of 7.3% NaCl NaCl by infusion pump over 60 minutes.
89538309|NCT03280745|Active Comparator|0.9% NaCl (comparator)|At admission to the ICU patients will receive 5ml/kg body weight of 0.9% NaCl by infusion pump over 60 minutes.
89538310|NCT04977921|Experimental|Elsiever clinical skill platform|
89538311|NCT03270371|Experimental|MCO Dialysis|Theranova Dialyzer
89538312|NCT03270371|Active Comparator|Standard High Flux Dialysis|Standard High Flux Dialyzer
89538313|NCT03107741|No Intervention|Passive Control|Subjects in this group will not receive any intervention.
89499767|NCT05507294|Experimental|SCC244：Fasting+Low-fat meal+High-fat meal|Participants will receive a single oral dose of Glumetinib tablet in fasting condition on Day 1 of treatment period 1 followed by a single oral dose of Glumetinib tablet in fed condition(Low-fat meal) on Day 1 of treatment period 2.Then，Participants will receive a single oral dose of Glumetinib tablet in fed condition （High-fat meal）on Day 1 of treatment period 3. The time interval between two adjacent dosages was at least 14 days.
88955829|NCT06168266|Active Comparator|Control group|Undergoing conventional treatment
88955830|NCT06168266|Experimental|Intervention Group: eccentric cycling exercise|Received eccentric cycling exercise
88955831|NCT06163274|Experimental|Sequence: Placebo Intravaginal Ring A followed by Placebo Intravaginal Ring B|Placebo Intravaginal Ring A will be inserted and used for 28 days, Ring A will be removed and followed by no intravaginal ring use for 7-21 days. Then Placebo Intravaginal Ring B will be inserted and used for 28 days.
88955832|NCT06163274|Experimental|Sequence: Placebo Intravaginal Ring B followed by Placebo Intravaginal Ring A|Placebo Intravaginal Ring B will be inserted and used for 28 days, Ring B will be removed and followed by no intravaginal ring use for 7-21 days. Then Placebo Intravaginal Ring A will be inserted and used for 28 days.
89205651|NCT03957590|Experimental|Tislelizumab + chemoradiotherapy|Tislelizumab once every 3-week cycle (Q3W) + paclitaxel on Day 1 of every cycle, for a total of 2 cycles + cisplatin on Day 1 to 3 of every cycle (3 weeks), for a total of 2 cycles + Radiotherapy
89205652|NCT03957590|Placebo Comparator|Placebo combined + chemoradiotherapy|Placebo once every 3-week cycle (Q3W) + paclitaxel on Day 1 of every cycle, for a total of 2 cycles + cisplatin on Day 1 to 3 of every cycle (3 weeks), for a total of 2 cycles + Radiotherapy
89205653|NCT03887221|Experimental|Safinamide 50mg|The subjects will receive 50mg safinamide on Day 1 of Period 1 and on Days 8 to 14 in period 2.
89205654|NCT03887221|Experimental|Safinamide 100mg|The subjects will receive 100mg safinamide on Day 1 of Period 1 and on Days 8 to 14 in period 2.
89499768|NCT05507294|Experimental|SCC244：High-fat meal+Fasting+Low-fat meal|Participants will receive a single oral dose of Glumetinib tablet in fed condition（High-fat meal） on Day 1 of treatment period 1 followed by a single oral dose of Glumetinib tablet in fasting condition on Day 1 of treatment period 2.Then，Participants will receive a single oral dose of Glumetinib tablet in fed condition(Low-fat meal) on Day 1 of treatment period 3. The time interval between two adjacent dosages was at least 14 days.
89538314|NCT03107741|Placebo Comparator|Conventional Exercise|Subjects in this group will receive three 1-hour conventional exercise training sections per week for 12 weeks
88955839|NCT06161506|Experimental|1/Elidah Device|Elidah device application.
89538315|NCT03107741|Active Comparator|Tai Chi|Subjects in this group will receive three 1-hour tai chi training sections per week for 12 weeks
89538316|NCT04977843|Experimental|E-BAL|E-BAL carried out within 48 hours
89538317|NCT04977843|No Intervention|Conservative/Control|Standard of care management
89538318|NCT03107975|Experimental|Cell Therapy|intrathecal injection of human amniotic epithelial cells
89538319|NCT04977219||Prism Adaptation Training;|Patients who received prism adaptation training for treatment of spatial neglect during their inpatient rehabilitation admission
89538320|NCT04977219||Standard Care|Patients who received standard treatment of spatial neglect during their admission
89538321|NCT03107819||Pediatric patients undergoing EGD|Subjects ages 2-18 years undergoing upper endoscopy (EGD) will submit a blood and urine specimen for plasma and urine metabolomics profiling.
89538322|NCT04969809|Experimental|Patients on diet|We will invite approximately 50 adult patients with PKU who were or are still being managed in the PPB clinic of the Pediatric Clinic of the University Medical Center Ljubljana. It is estimated that half of the patients still fully or at least partially follow the dietary treatment.
89538323|NCT04969809|Experimental|patients without diet|Half of the patients have abandoned the diet treatment and mostly no longer come for outpatient examinations.
89538324|NCT04432233|Experimental|Intravenous therapy|Subjected enrolled will receive (a) a 10-day intravenous triple therapy containing esomeprazole 40 mg thrice a day, metronidazole 500 mg twice a day and levofloxacin 500 mg once a day and (b) esomeprazole 20 mg twice a day taken orally for 8 weeks.
89538325|NCT03269903|Experimental|Patients|Patients with malignant dysphagia treated with the HILZO stent
89499769|NCT05507294|Experimental|SCC244：High-fat meal+Low-fat meal+Fasting|Participants will receive a single oral dose of Glumetinib tablet in fed condition（High-fat meal） on Day 1 of treatment period 1 followed by a single oral dose of Glumetinib tablet in fed condition（Low-fat meal） on Day 1 of treatment period 2.Then，Participants will receive a single oral dose of Glumetinib tablet in fasting condition on Day 1 of treatment period 3. The time interval between two adjacent dosages was at least 14 days.
89499770|NCT05507294|Experimental|SCC244：Low-fat meal+Fasting+ High-fat meal|Participants will receive a single oral dose of Glumetinib tablet in fed condition（Low-fat meal） on Day 1 of treatment period 1 followed by a single oral dose of Glumetinib tablet in fasting condition on Day 1 of treatment period 2.Then，Participants will receive a single oral dose of Glumetinib tablet in fed condition(High-fat meal) on Day 1 of treatment period 3. The time interval between two adjacent dosages was at least 14 days.
88955842|NCT06158126||Prospective safety cohort of time and type of PrEP initiation|The cohort will include pregnant women assessed as being at substantial risk for HIV acquisition and eligible for PrEP per Malawi national PrEP guidelines at Bwaila District Hospital. All women meeting eligibility criteria will be consented and offered PrEP (if not already taking it). Women will have access to either CAB-LA or oral PrEP and will be given an opportunity to choose one option. We will group our women according to use of oral PrEP (FTC/TDF or TDF/3TC) versus injectable PrEP (CAB-LA), and according to PrEP use before or after pregnancy diagnosis and follow up in those groups. All women will be registered into the PrEP Pregnancy Registry as part of routine care.
88955843|NCT06153355|Experimental|LY3839840 (Part A)|Single ascending dose of LY3839840 administered orally.
88955844|NCT06153355|Experimental|LY3839840 (Part B)|Multiple ascending dose of LY3839840 administered orally.
88955845|NCT06153355|Experimental|LY3839840 (Part C)|Single and multiple dose of LY3839840 administered orally in Chinese participants.
88955846|NCT06153355|Experimental|LY3839840 (Part D)|Multiple ascending dose of LY3839840 administered orally in Japanese participants.
88955847|NCT06153355|Placebo Comparator|Placebo|Placebo administered orally.
88955848|NCT06150820|Other|Participants with Late-Onset Pompe Disease|Adolescent or adult participants with LOPD.
88955849|NCT06150287|Active Comparator|Probiotics Group|Participants will receive one probiotics capsule daily for six months immediately after the onset of post-surgical non-infectious diarrhea.
88955850|NCT06150287|Placebo Comparator|Placebo Group|Participants will receive one placebo capsule daily for six months immediately after the onset of post-surgical non-infectious diarrhea.
89531846|NCT05128929|Experimental|Experimental Treatment Oral Hymecromone (H01)|Treatment will be initiated. Participants will be administered 800 mg of oral H01 two times a day (total dose: 1600 mg/day). Participants will continue to be on treatment for 24 weeks and will be monitored with assessments.
88955851|NCT06149845|Experimental|Pulpotomy|Participants diagnosed with symptomatic irreversible pulpitis in vital primary molars will receive the pulpotomy treatment intervention
88955854|NCT06147895|Experimental|Group 1|CVI-HBV-002 1 mL Intramuscular injection at Baseline, Week 4, Week 8 / total 3 doses
88955855|NCT06147895|Experimental|Group 2|CVI-HBV-002 1 mL Intramuscular injection at Baseline, Week 4, Week 24 / total 3 doses
88955856|NCT06146972|Experimental|RF positive group|Iguratimod (25mg per tablet) 25mg twice daily plus tofacitinib (5mg per tablet) 5mg twice daily for 24 weeks.
88955857|NCT06146972|Experimental|RF negative group|Iguratimod (25mg per tablet) 25mg twice daily plus tofacitinib (5mg per tablet) 5mg twice daily for 24 weeks.
89538326|NCT04977609|Experimental|VR+MUSIC|Upper limb repetitive training activities through the imitation of movements (i.e., unscrew the cap of a bottle, pour water into a glass, drink water from a glass, sugaring coffee, placing an object in a box) synchronized with a musical accompaniment (i.e., a selection of classical music pieces). Participants will wear a VR headset (Gear VR, Samsung) through which they will observe egocentric 180° 3D videoclips shot from a first-person perspective, as if the patient himself was performing the movement, while listening to music.
89538327|NCT04977609|Experimental|VR|Upper limb repetitive training activities through imitation of movements, without any musical accompaniment. Participants will wear a VR headset through which they will observe egocentric 180° 3D silent videoclips.
89023367|NCT05605730|Active Comparator|Traditional exercise management|"Prone back extension.~Shoulder external rotation starting in 45° of internal rotation, with the arm by the side and the elbow flexed to 90 °.~Shoulder internal rotation starting in 45 ° of external rotation, with the arm by the side and the elbow flexed to 90 °..~Shoulder abduction (scapular plane) through a 0- to 60-° with the elbow flexed 90 ° and the shoulder in neutral rotation.~Shoulder flexion (sagittal plane) through a 0- to 60-°starting with the elbow flexed 90 ° and the shoulder in neutral rotation and punching forward, simultaneously extending the elbow and flexing the shoulder.~Internal rotation towel stretch: Subjects will be instructed to sit or stand while holding a towel with the affected arm behind the back and to use the other arm to pull the affected arm up the back."
89023368|NCT05605730|Experimental|Maitland mobilization for thoracic spine|This group will receive the previously mentioned exercises protocol targeting shoulder joint in addition to Maitland mobilization for thoracic spine.
89538328|NCT04977609|Active Comparator|TAU|Treatment as usual (TAU). Patients will be engaged in upper limb repetitive training activities through traditional physiotherapy rehabilitation.
89538329|NCT03269747|Active Comparator|Prednisone|Prednisone 40 mg daily for 7 days
89538330|NCT03269747|Placebo Comparator|Placebo|Placebo daily for 7 days
89538331|NCT04977531||6 months less|Stroke onset less than 6 months
89538332|NCT04977531||6 months to 2 years|Stroke onset between 6 months and 2 years
89538333|NCT04977531||over 2 years|Stroke onset over 2 years
89538334|NCT04976985|Experimental|Interventional Group receiving Osteopathic Manipulative Therapy (OMT)|70 patients with chronic migraine who consent to OMT will receive four standardized osteopathic manipulative treatment protocol over the course of twelve weeks at week 0,2,6,10. MIDAS and HIT-6 Questionnaires will be obtained at time of consent prior to first treatment and again at the conclusion of treatment period of twelve weeks.
89538335|NCT04976985|Other|Control Group with Standard of Care|70 patients with the diagnosis of migraine headache who are receiving the standard of care medications will complete a MIDAS and HIT-6 questionnaire at week 0 and week 12. A new prophylactic medication may be started at time of initial questionnaires and the patient can be on up to two prophylactic medications, with no changes during the 12 week period.
89023369|NCT05605730|Experimental|Mulligan thoracic sustained natural apophyseal glide (SNAGS)|Treatment would be administered at the vertebral level revealed during the evaluation of thoracic SNAG.
89538336|NCT02459483|Experimental|Nurse phone call|a nurse will interview patients by phone every 14 +/- 2 days for 6 months
89538337|NCT02459483|No Intervention|Control Group|Common practice
89538338|NCT03269513|Experimental|Intervention group|"Adolescent Obesity~The exercise program, nutritional counseling and oral health will last for five to three months and will be held in the gym and rooms of the University of Santa Cruz do Sul (UNISC).~The sessions will last two hours (one hour of physical exercise and the second time divided into nutritional counseling, postural, psychological and oral) with a frequency of three times a week."
89538339|NCT03269513|No Intervention|Control group|
89538340|NCT04369469|Experimental|Group 1 - Ravulizumab + BSC|
89538341|NCT04369469|Other|Group 2 - BSC alone|
89538342|NCT03269591|Active Comparator|Pulsed electromagnetic field|magnetic therapy device which generate frequency from 5-100 Hz and intensity from 1 to 60 Gauss. Group (A) received 20 min 3 times per week for three month with strength 60 gauss and frequency 50 Hz
89538343|NCT03269591|Experimental|diclofenac tablets|(50 mg) few hours at the onset of menstruation for 3 months
89538344|NCT03269591|Other|Visual analogue scale|was used to determine the pain intensity level. Pain assessed before and after treatment procedure (3 month)
89538345|NCT03269591|Other|Progesterone blood level|Sample of blood was taken to detect the level of progesterone.
89499771|NCT05507294|Experimental|SCC244：Low-fat meal +High-fat meal +Fasting|Participants will receive a single oral dose of Glumetinib tablet in fed condition（Low-fat meal） on Day 1 of treatment period 1 followed by a single oral dose of Glumetinib tablet in fed condition（High-fat meal） on Day 1 of treatment period 2.Then，Participants will receive a single oral dose of Glumetinib tablet in fasting condition on Day 1 of treatment period 3. The time interval between two adjacent dosages was at least 14 days.
89499772|NCT02194309|Experimental|Telmisartan low + amlodipine|
89499773|NCT02194309|Experimental|Telmisartan high + amlodipine|
89499774|NCT02257255|Active Comparator|Pfannenstiel cesarean section|Women in 36 to 40 weeks of pregnancy undergoing first cesarean section by Pfannenstiel technique. Pain assessment on postoperative hours 6, 12 and 24.
89499775|NCT02257255|Experimental|Misgav-Ladach cesarean section|Women in 36 to 40 weeks of pregnancy undergoing first cesarean section by minimally invasive technique. Pain assessment on postoperative hours 6, 12 and 24.
89499776|NCT02568254|Active Comparator|Lens 1/ Lens 2/ Lens 3|Each subject will be randomly assigned to one of six unique sequences. Subjects randomized to this sequence will first wear Lens 1 (etafilcon A), then wear Lens 2 (nelfilcon A) second and then wear Lens 3 (nesofilcon A) third.
89499777|NCT02568254|Active Comparator|Lens 1 / Lens 3 / Lens 2|Each subject will be randomly assigned to one of six unique sequences. Subjects randomized to this sequence will first wear Lens 1 (etafilcon A), then wear Lens 3 (nesofilcon A) second and then wear Lens 2 (nelfilcon A) third.
89499778|NCT02568254|Active Comparator|Lens 2/ Lens 3/ Lens 1|Each subject will be randomly assigned to one of six unique sequences. Subjects randomized to this sequence will first wear Lens 2 (nelfilcon A), then wear Lens 3 (nesofilcon A) second and then wear Lens 1 (etafilcon A) third .
89499779|NCT02568254|Active Comparator|Lens 2 / Lens 1/ Lens 3|Each subject will be randomly assigned to one of six unique sequences. Subjects randomized to this sequence will first wear Lens 2 (nelfilcon A), then wear Lens 1 (etafilcon A) second and then wear Lens 3 (nesofilcon A) third. Each lens type will be worn for approximately 2 weeks (12 +/- 2 days).
89499780|NCT02568254|Active Comparator|Lens 3 / Lens 1 / Lens 2|Each subject will be randomly assigned to one of six unique sequences. Subjects randomized to this sequence will first wear Lens 3 (nesofilcon A), then wear Lens 1 (etafilcon A) second and then wear Lens 3 (nelfilcon A) third.
89499781|NCT02568254|Active Comparator|Lens 3 / Lens 2 / Lens 1|Each subject will be randomly assigned to one of six unique sequences. Subjects randomized to this sequence will first wear Lens 3 (nesofilcon A), then wear Lens 2 (nelfilcon A) second and then wear Lens 3 (etafilcon A) third.
89499782|NCT02197117|Active Comparator|Remote ischemic conditioning|Standard blood pressure cuff placed on upper arm and inflated to 200 mmHg. The cuff is left inflated at this level for 5 minutes and then rapidly deflated to 0 mmHg left deflated for 5 minutes0 this cycle is repeated 4 times in total.
89499783|NCT02197117|Sham Comparator|Control|Standard blood pressure cuff placed on upper arm and left un-inflated for 40 minutes, and then cuff is removed.
89499784|NCT04392505|Experimental|The whole study population|All patients will receive durvalumab for up to 1 months after standard treatment With chemoradiotherapy.
89499785|NCT05502458|Active Comparator|propofol|propofol（50ml,1g）,Intravenous propofol infusion was slowly pushed until loss of consciousness, and anesthesia was maintained at 4-8 mg/kg/h
89499786|NCT05502458|Active Comparator|desflurane|In the general anesthesia group with desflurane( 240ml), intravenous propofol infusion was slowly pushed until consciousness disappeared, and then anesthesia was maintained with 4-6% desflurane
89499787|NCT02197195|Experimental|Chocolate Milk Beverage|Chocolate milk beverage and sitting quietly
89499788|NCT02197195|Experimental|Chocolate Milk Beverage and Exercise|Chocolate milk beverage and exercising
89499789|NCT02197195|Experimental|Fruit Drink Beverage|Fruit drink beverage and sitting quietly
89499790|NCT02197195|Experimental|Fruit Drink Beverage and Exercise|Fruit drink beverage and exercising
89499791|NCT05507060|Active Comparator|Vibrating MESH nebulizer|Medication will be applied with Vibrating MESH nebulizer
89499792|NCT05507060|Active Comparator|Jet nebulizers|Medication will be applied with Jet nebulizers
89538346|NCT03269591|Other|Menstrual symptom questionnaire|to assess symptoms of dysmenorrhea.
89538347|NCT03989609|Experimental|Dexmedetomidine Group|patients will receive dexmedetomidine as sedative
89538348|NCT03989609|Active Comparator|Midazolam|patients will receive midazolam as sedative
89538349|NCT03988205|Experimental|Intervention|The study intervention is the application of a prescribed outpatient care model including a nurse teacher educational program and quality of life surveys for both subjects and caregivers. Induction therapy and medical follow up are performed without prophylactic admission to an inpatient facility. Subjects will also receive CPX-351 according to FDA approval, to subjects who meet medical and logistical criteria for study enrollment.
89023373|NCT05598320|Experimental|TransCon CNP|Once weekly double-blinded treatment with SC injection of 100 µg/kg of TransCon CNP for 52 weeks
89023374|NCT05598320|Placebo Comparator|Placebo for TransCon CNP|Once weekly double-blinded treatment with SC injection of 100 µg/kg of Placebo for TransCon CNP for 52 weeks
89023375|NCT05596747|Experimental|LY3209590|LY3209590 administered subcutaneously (SC).
89023376|NCT05596747|Active Comparator|Insulin glargine|Insulin glargine administered SC.
89499793|NCT03534037|Experimental|Febuxostat 40mg|Febuxostat 40mg orally per day
89499794|NCT03534037|Active Comparator|Benzbromarone 50mg|Benzbromarone 50mg orally per day
89023377|NCT05596162|Experimental|Blood Flow Restriction Group|"Patient specific tourniquet settings to achieve 80% occlusion.~Weight- 20% of 1 rep max, 4 sets 30-15-15-15 reps with 30 second rests between sets~Exercises: The first phase will focus on active and passive range of motion of the ankle as well as non-weighted concentric exercises. Phase two will progress with gastrocnemius and soleus stretches along with body weight and light resistance band concentric and eccentric exercises focusing on posterior, anterior and lateral muscle groups of the lower limb. Phase three will introduce weighted, dynamic and proprioceptive exercises."
89023378|NCT05596162|Active Comparator|Non-Blood Flow Restriction Group|This group will perform the same exercises for the same volume without the use of BFR.
89499795|NCT03534037|Other|Control|Dietary control only
89499796|NCT02197429|Experimental|Acupuncture|Acupuncture
89499797|NCT02197429|No Intervention|Wait-list Control|Wait-list Control
89499798|NCT03533959||alirocumab therapy group|patients with 10mg daily rosuvastatin and alirocumab at least 75mg every 2 weaks
89538350|NCT03280355|Experimental|Singing Training|Singing Training as training activity in Pulmonary Rehabilitation: 10 weeks, twice a week for 1 1/2 hour, leading to a total of 20 sessions.
89538351|NCT03280355|Active Comparator|Physical Training|Physical Training as training activity in Pulmonary Rehabilitation: 10 weeks, twice a week for 1 1/2 hour, leading to a total of 20 sessions.
89499799|NCT03533959||standard statin therapy group|patient with 10mg daily rosuvastatin and never use alirocumab or other PCSK-9 inhibitor
89499800|NCT05502380|Active Comparator|Standard prophylaxis arm|"The standard prophylaxis consists of one to three intravenous doses of cefuroxime 1.5 g intravenously; or cefuroxim 3g if obesity > 120 kg or a BMI > 35 kg/m2; or vancomycin 1 g or clindamycin 600 mg in case of intolerance to cephalosporins~In patients alrady under current therapuetic antibiotic therapy, continuation of that therapuetic antibiotic regimen"
89499801|NCT05502380|Experimental|Innovative prophylaxis arm|Additional single-shot perioperative antibiotic prophylaxis with Broad-spectrum prophylaxis: vancomycin 1 g & gentamicin 5 mg/kg.
89499802|NCT02194543||HD 3D|The patients received surgeries with HD 3D on their left eyes.
89499803|NCT02194543||Conventional|The patients received surgeries with conventional method on the other eye.
89499804|NCT02030899|Active Comparator|Cage|Cage filled with autologous bone
89499805|NCT02030899|Other|Plate|Plate augmentation after iliac bone graft
89023382|NCT05580237||Severe aortic valve stenosis|
89023383|NCT05571644|Experimental|mFOLFOXIRI+Cadonilimab|Patients will receive neoadjuvant treatment with mFOLFOXIRI plus cadonilimab for 6 cycles before surgey
89023384|NCT05571644|Active Comparator|mFOLFOX6|Patients will receive neoadjuvant mFOLFOX6 chemotherapy every two weeks for 6 cycles before surgery.
89023385|NCT05571644|Active Comparator|mFOLFOXIRI|Patients will receive neoadjuvant mFOLFOXIRI chemotherapy every two weeks for 6 cycles before surgery.
89023386|NCT05558501|Experimental|Mild Intermittent Hypoxia (MIH)|This arm of the protocol will receive mild intermittent hypoxia (8% oxygen) with end-tidal carbon dioxide maintained 2 millimeters of mercury above baseline, while in the laboratory.
89023387|NCT05558501|Sham Comparator|Sham Mild Intermittent Hypoxia (Sham MIH)|This arm of the protocol will receive sham MIH (the equivalent of room air), while in the laboratory.
89023388|NCT05552794||Good outcome|Good outcome was defined as cerebral performance category (CPC): 1-2
89023389|NCT05552794||Poor outcome|Poor outcome was defined as cerebral performance category (CPC): 3-5
89499806|NCT02196025|Experimental|Transcranial magnetic stimulation|Patients will receive sequential bilateral bifrontal low frequency TMS stimulation daily on weekdays for three weeks. In addition, a Pittsburgh Sleep Quality Index (PSQI), Insomnia severity rating index, Montgomery Asberg Depression Rating Scale, and a sleep diary will be kept.
89499807|NCT02567708|Experimental|GSK2269557 and Placebo|Each subject will complete two treatment periods: GSK2269557 1000 mcg in one treatment period, and matching placebo in the other treatment period. Each treatment will be administered once daily for 28 days (+/- 2 days) via the DISKUS DPI. The treatment periods will be separated by a washout of at least 4 weeks.
89499808|NCT02196103|Experimental|Expectant management|
89499809|NCT02196337||Women of reproductive age|Age: 18-44 years
89499810|NCT02196337||Pregnant women|Age: 18-44 years
89499811|NCT02196337||Lactating women|Age: 18-44 years
89499812|NCT02196337||Young infants|Age: younger than 6 months
89499813|NCT02196337||Toddlers|Age: between 6 and 24 months
89499814|NCT02196337||School-aged children|Age: 6-12 years
89499815|NCT04283383|Experimental|Intervention training|A structured training process oriented to the clinical practice of the family physician, Primary Care Clinical Ultrasound Classroom (AECAP) will be carried out, and the improvement of knowledge and skills will be evaluated, as well as the improvement of quality of care based on clinical indicators.
89499816|NCT04283383|No Intervention|control|
89499817|NCT05509244|Active Comparator|control group|acetaminophen 1g iv dripping
89499818|NCT05509244|Experimental|experimental group|the combination of acetaminophen 1g and ibuprofen 300mg iv dripping
89531847|NCT05128929|Placebo Comparator|Placebo|Participants randomized to placebo will receive oral tablet placebo (inactive ingredients) two times a day. Participants will continue to be on placebo for 24 weeks and will be monitored with assessments.
89499819|NCT05502068|Experimental|Vitamin D 25 (OH) 12000 IU, Sublingual sprayable microemulsion|Vitamin D in the form of a sublingual sprayable microemulsion (4000 IU) will be given three times daily after breakfast, lunch, and dinner (daily dose 12,000 IU) to patients with blood vitamin D levels below 30 ng/ml for 5-day intervention
89499820|NCT05502068|Placebo Comparator|Placebo|Placebo will be given to the control group. It will be administrated sublingually, with one spray three times per day for 5 days of the study period
89499821|NCT02194777|Experimental|BIBN 4096 BS - in single rising doses|
89499822|NCT02194777|Placebo Comparator|Placebo|
89499823|NCT02197507|Experimental|RA patients|
89499824|NCT05506904|Experimental|Extubation Advisor|Wave form data from participants' spontaneous breathing trials (SBT) will be analyzed using Extubation Advisor (EA) to generate an EA report that provides clinical decision support regarding extubation.
89499825|NCT05506904|No Intervention|Standard of Care Arm|Participants will undergo SBTs as directed by clinicians. The EA device will not be used.
89499826|NCT02197585|Experimental|Glue|Mesh fixation with glue
89499827|NCT02197585|Active Comparator|Suture|Mesh fixation with suture
89499828|NCT02030977|Active Comparator|Resveratrol|"Active Comparator: Resveratrol~1 Resveratrol capsules for 12 weeks"
89499829|NCT02030977|Placebo Comparator|Placebo|one capsule per day
89499830|NCT02194855|Experimental|laparoscopic operation on rocuronium|according different surgical type, all patients were divided into 2 groups: the laparoscopic surgery group and open surgery group.Each group were randomly assigned to the rocuronium group and cisatracurium group.
89499831|NCT02194855|Experimental|laparoscopic operation on cisatracurium|according different surgical type, all patients were divided into 2 groups: the laparoscopic surgery group and open surgery group.Each group were randomly assigned to the rocuronium group and cisatracurium group.
89499832|NCT02194855|Experimental|conventional open surgery on rocuronium|according different surgical type, all patients were divided into 2 groups: the laparoscopic surgery group and open surgery group.Each group were randomly assigned to the rocuronium group and cisatracurium group.
89499833|NCT02194855|Experimental|conventional open surgery on cisatracurium|according different surgical type, all patients were divided into 2 groups: the laparoscopic surgery group and open surgery group.Each group were randomly assigned to the rocuronium group and cisatracurium group.
89499834|NCT03534661|Placebo Comparator|Teduglutide + Normal Saline|Teguglutide + (L-NMMA control)
89499835|NCT03534661|Active Comparator|Teduglutide + L-NMMA|Tedulgutide + L-NMMA
89499836|NCT03534661|Placebo Comparator|Placebo + L-NMMA|(Teduglutide control) + L-NMMA
88955860|NCT06144177|Active Comparator|Darkened room and star projector with parental presence|Subjects assigned to this arm, when in the operating room prior to the start of induction, the room will be darkened, and a star projector that lights up the ceiling and walls will be turned on. They will also have a parent in the room with them during induction of anesthesia.
88955861|NCT06144177|Active Comparator|Preoperative midazolam 0.5 mg/kg po and parental presence|Subjects assigned to this arm will be given midazolam by mouth preoperatively, and will have a parent in the room with them during induction of anesthesia.
88955862|NCT06144177|Active Comparator|Parental presence alone|Subjects assigned to this arm will have a parent in the room with them during induction of anesthesia.
89499837|NCT02562716|Experimental|Arm I (mFOLFIRINOX, surgery)|Patients receive oxaliplatin IV over 2 hours and irinotecan hydrochloride IV over 90 minutes on days 1 and 15. Patients also receive 5-fluorouracil IV over 46 hours on days 1-3 and 15-17. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity. Patients achieving stable disease or better undergo pancreatectomy 4-8 weeks after completion of first 3 courses of treatment. Within 4-8 weeks following pancreatectomy, patients receive an additional 3 courses of oxaliplatin, irinotecan hydrochloride, and fluorouracil treatment in the absence of disease progression or unacceptable toxicity.
89499838|NCT02562716|Experimental|Arm II (gemcitabine, nab-paclitaxel, and surgery)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity. Patients achieving stable disease or better undergo pancreatectomy 4-8 weeks after completion of first 3 courses of treatment. Within 4-8 weeks following pancreatectomy, patients receive an additional 3 courses of paclitaxel albumin-stabilized nanoparticle formulation and gemcitabine hydrochloride treatment in the absence of disease progression or unacceptable toxicity.
89499839|NCT04286347|Experimental|HCV, HBV, HIV testing|All patient ≥ 18 years-old with a next planned surgery in Lariboisiere Hospital, Paris, France, able to give written informed consent for testing will be proposed to be tested for HIV and HCV if no previous testing found in the medical record and will be proposed to be tested for HBV if the patient belong to a high-risk group: high prevalence area (Asia, sub-Saharan Africa, French Indies, East and South Europe, North-Africa, Middle-East, India, Pakistan, South-America), IVDU, prisoners, unprotected sexual intercourses.
89499840|NCT02197663|Experimental|Acupuncture|The total course of the acupuncture contains 24times(about 3 months). The acupoints are fixed and located over head and limbs.
89499841|NCT02197663|Sham Comparator|sham acupuncture|The total course of the acupuncture contains 24times(about 3 months). The acupoints are fixed and 1cm away from meridian and no acupoints over head were chosen.
89499842|NCT05509088|Experimental|high flow nasal cannula|will receive oxygen through high flow nasal cannula
89499843|NCT05509088|No Intervention|oxygen mask|will receive oxygen through oxygen mask
89499844|NCT02031211|Placebo Comparator|Placebo|0.4 ml/kg of normal saline will be administered subcutaneously.
88955863|NCT06142461|Experimental|1: Intradermal needle-free injection|Fractional dose (2 x 0.1 mL injections) intradermal administration of Gardasil® using PharmaJet Tropis® Needle-Free Injection System.
88955864|NCT06142461|Experimental|2: Intramuscular needle-free injection|Full dose (0.5 mL injection) intramuscular administration of Gardasil® using PharmaJet Stratis® Needle-Free Injection System
88955865|NCT06142461|Active Comparator|3: Needle and syringe|Full dose (0.5 mL injection) intramuscular administration of Gardasil® using needle and syringe
88955866|NCT06139328|Experimental|BI 765845 very low dose group|
88955867|NCT06139328|Experimental|BI 765845 low dose group|
89023390|NCT05545137|Experimental|Pivmecillinam hydrochloride tablets treatment group|"participants received Pivmecillinam Hydrochloride Tablets + Fosfomycin Tromethamine Granules Simulant.~Pivmecillinam Hydrochloride Tablets:oral,One tablets each time,3 times a day for five days.~Fosfomycin Tromethamine Granules Simulant :oral, 1 pack, only once for the entire course of treatment"
89023391|NCT05545137|Active Comparator|Fosfomycin Tromethamine Granules treatment group|"participants received Fosfomycin Tromethamine Granules + Pivmecillinam Hydrochloride Tablets Simulant~Fosfomycin Tromethamine Granules:oral, 1 pack, only once for the entire course of treatment.~Pivmecillinam Hydrochloride Tablets Simulant :oral,One tablets each time,3 times a day for five days."
89023392|NCT05543915|Experimental|Group with tDCS-MRI|Participants will have a cognitive assessment, an optional gait assessment, and a 1-hour MRI brain scan combined with 20 minutes of simultaneous tDCS. Participants may also complete the MRI on a separate visit.
89023393|NCT05543915|No Intervention|Group without tDCS- MRI|Participants will have include a cognitive assessment and an optional gait assessment
89023394|NCT05539027|Active Comparator|Group 1 (Treatment group)|
89023395|NCT05539027|Active Comparator|Group 2 (Control group)|
89023396|NCT05537246||GROUP HT|In the preoperative evaluation, after arterial blood pressure measurement was made 3 times; Hypertension group was defined as the patients who did not use drugs that are effective on the cardiovascular system, whose SBP value was higher than 140 mmHg, or those who were diagnosed with hypertension and were using drugs with a SBP value higher than 140 mmHg.
89023397|NCT05537246||GROUP NORMO|As a result of 3 measurements and medical histories of the cases, those who did not use drugs effective on the cardiovascular system and whose SBP value was lower than 140 mmHg were called the normotensive group.
89023398|NCT05531097|Experimental|HSK31679|
89023399|NCT05531097|Placebo Comparator|Placebo|
89023400|NCT05522075|Experimental|Exercise Group|Binge drinkers who have been assigned to exercise group will receive baseline assessment, 8-week exercise training plus alcohol abstinence intervention, and post-intervention assessment.
89499845|NCT02031211|Experimental|Etanercept|Patient will receive 0.4 mg/kg of Etanercept subcutaneously twice weekly.
89499846|NCT02195089|Experimental|BLS_ILB_E710c 500mg|"Drug: BLS_ILB_E710c 500mg~Dosage and duration: 2 capsules per day for 20 days (week 1,2,4 & 8)"
89499847|NCT02195089|Experimental|BLS_ILS_E710c 1000mg|"Drug: BLS_ILS_E710c 1000mg~Dosage and duration: 4 capsules per day for 20 days (week 1,2,4 & 8)"
89499848|NCT02195089|Experimental|BLS_ILS_E710c 1500mg|"Drug: BLS_ILS_E710c 1500mg~Dosage and duration: 6 capsules per day for 20 days (week 1,2,4 & 8)"
89499849|NCT05509010||Retrospective|4000 patients who were clinically evaluated by CTCA from 1 Jan 2007 to 31 Oct 2017.
89499850|NCT05509010||Prospective|4000 patients who are clinically evaluated by CTCA.
89499851|NCT02031289|Active Comparator|Anemia|Hb < 120 g/L in women, Hb < 130 g/L in men Erythropoietin/Ferric carboxymaltose/Vitamin B12/Folic Acid
89499852|NCT02031289|Active Comparator|Iron deficiency|ferritin < 100 µg/l Erythropoietin/Ferric carboxymaltose/Vitamin B12/Folic Acid
89499853|NCT02031289|No Intervention|Natural comparison group|Patients without anemia or iron deficiency will be observed and the same postoperative measurements performed
89499854|NCT02197741||opiate without bolus|continuous opiate administration without bolus application
89499855|NCT02197741||opiate with bolus|continuous opiate administration with additional bolus application
89499856|NCT02196493|Experimental|Azithromycin|250mg azithromycin three times weekly for 12 weeks
89499857|NCT02197819|Experimental|External Rotation Brace|Shoulder placed in an external rotation brace for 4 weeks
89499858|NCT02197819|Active Comparator|Traditional Sling|Patient placed in traditional sling
89499859|NCT02196571|Experimental|Exercise and lifestyle change|Women in the experimental group will be included in structured exercise programme two times per week with duration of 50 minutes.Participants will start with training sessions right after they are diagnosed with GDM and they will exercise until the end of the pregnancy or occurence of contraindications. Programme will consist of aerobic exercises (20 minutes), resistance exercises (20 minutes), plevic floor, stretching and relaxation exercises (10 minutes). Women in control group will receive standard antenatal care.
89499860|NCT02196571|No Intervention|Control|Standard antenatal care
89499861|NCT02195167|Experimental|Dasotraline|"Dasotraline 1 mg, 2 mg, 4 mg, 8 mg, 12 mg, 16 mg, 20 mg, 24 mg, 28 mg, 32 mg once daily. The planned dose for the first cohort is 1mg. There will be no more than a 2-fold increase in dose increase in dose between consecutive dose cohorts up to 8 mg, and dose cohorts beyond the 8 mg level will increment no more than 4mg. The maximum dose will not exceed 32mg. The language should precede the text that is currently there"
89499862|NCT05506592|Active Comparator|Selenium disulfide shampoo|
89499863|NCT05506592|Placebo Comparator|placebo shampoo|
89499864|NCT03533881|Active Comparator|Arom Digest Slim and nutritional changes|Subjects take collagen and follow minimal nutritional changes.
89499865|NCT03533881|Active Comparator|Nutritional changes|Subjects only follow minimal nutritional changes
89499866|NCT02195245|No Intervention|Control|Control - Observational (non interventional) data is collected from current state of the art absorber devices.
89499867|NCT02195245|Experimental|memsorb|New CO2 filter - data is collected using the new CO2 absorber.
89499868|NCT02196727||Patients undergoing Bascom operation|
89531848|NCT05121246|Experimental|MB05 (Proposed palivizumab biosimilar)|Sterile vial 100mg/1ml, single-dose 3mg/kg administered as intramuscular injection on day 1.
89499869|NCT02257411|Active Comparator|Ear-sized based and weight based formula|the sizes of the PLMA determined with the ear-based compared with the sizes according to the manufacturer's weight-based formula
89499870|NCT02195323|Experimental|MSC recipient|The patients with CKD who underwent intravenous injection of MSC.
89499871|NCT02197975|Experimental|PT010 Dose 1|PT010 Dose 1; Budesonide, Glycopyrrolate, and Formoterol Fumarate (BGF) Inhalation Aerosol. Administered as 2 inhalations.
88955868|NCT06139328|Experimental|BI 765845 medium dose group|
88955869|NCT06139328|Experimental|BI 765845 high dose group|
88955870|NCT06139328|Placebo Comparator|Placebo group|
88955871|NCT06135324||Prevalence of Cognitive impairment and impaired manual dexterity|Determine the prevalence of both cognitive impairment and impaired manual dexterity in stable out-patients with COPD
88955872|NCT06135324||Assess relationship of impairments with patient errors using pMDI, SMI, and/or DPIs|assess the relationships of cognitive impairment and impaired manual dexterity with patient errors using their prescribed, current pMDIs, SMIs, and/or DPIs.
88955873|NCT06132893|Experimental|BHV-7000 25 mg|
88955874|NCT06132893|Experimental|BHV-7000 50 mg|
88955875|NCT06132893|Placebo Comparator|Placebo|
89499872|NCT02197975|Experimental|PT010 Dose 2|PT010 Dose 2; Budesonide, Glycopyrrolate, and Formoterol Fumarate (BGF) Inhalation Aerosol. Administered as 2 inhalations.
89499873|NCT02197975|Placebo Comparator|Placebo MDI|Placebo MDI. Administered as 2 inhalations
89499874|NCT03533803|Active Comparator|Group A (Indomethacin)|All patient had long stimulation protocol and IVF/ICSI. After mock embryo transfer women with any degree of difficulty will receive Indomethacin 100Mg Suppository 1-2 hours before embryo transfer.
89499875|NCT03533803|Placebo Comparator|Group B (Control)|All patient had long stimulation protocol and IVF/ICSI. After mock embryo transfer women with any degree of difficulty will not receive any medications before embryo transfer.
89499876|NCT02195401||Sleeping in a cleanroom|Each child and his or her parent slept in a cleanroom for two weeks. Within 24 hours pre and post this two week experience blood and hair samples were taken from the children and the parents filled out rating scales.
89499877|NCT02198053||Ticagrelor2|Ticagrelor with a loading dose of 180mg followed by 90 mg twice per day
89538352|NCT03280277|Experimental|Diagnostic (ferumoxytol-enhanced MRI)|Patients receive ferumoxytol IV over 15 minutes and then after 24-36 hours undergo ferumoxytol-enhanced MRI before start of neoadjuvant therapy and within 4 weeks before surgery.
89499878|NCT02198053||Ticagrelor1|Ticagrelor with a dose of 90mg followed by 90 mg twice per day .
89499879|NCT02198209|Other|single arm|"Liraglutide (Victoza)~acute study: one injection of 0.6 mg s.c. before IVGTT~chronic study: 6 weeks of daily liraglutide administration (1 week at 0.6 mg, 1 week at 1.2 mg, 4 weeks at 1.8 mg, s.c)."
89499880|NCT02031055|Experimental|TAS-102 with light tracer dose of [14C]FTD|
89499881|NCT02031055|Experimental|TAS-102 with light tracer dose of [14C]TPI|
89499882|NCT02198287|Experimental|BIIX 1 XX, rising doses|
89499883|NCT02198287|Placebo Comparator|Placebo|
89499884|NCT03534115|Placebo Comparator|Placebo|Placebo was prepared by using the same solution containing buffers that were used in the preparation of NAC solution, except it did not contain NAC
89499885|NCT03534115|Experimental|Experimental Arm|solution containing NAC with buffers
89499886|NCT02195557||Synvisc®|
89499887|NCT02195635|Experimental|Period 1|Single oral dose of 500 mg telotristat etiprate on Day 1
88955880|NCT06125808|Experimental|1050 mg HRO350|1050 mg HRO350 daily given as 3 capsules of HRO350 (350 mg) in the morning and 3 capsules of placebo in the evening. Total of 6 capsules daily.
88955881|NCT06125808|Experimental|2100 mg HRO350|2100 mg HRO350 daily given as 3 capsules of HRO350 in the morning and 3 capsules of HRO350 in the evening. Total of 6 capsules daily.
88955882|NCT06125808|Placebo Comparator|Placebo|Placebo given as 3 capsules of placebo in the morning and 3 capsules of placebo in the evening, Total of 6 capsules daily.
88955883|NCT06125522|Experimental|ARV-471 in combination with Samuraciclib|ARV-471 administered orally QD continuously and Samuraciclib administered orally QD continuously on 28-day cycles
89499888|NCT02195635|Other|Period 2|Subcutaneous injections of 200 µg octreotide acetate three times daily with a single oral dose of 500 mg telotristat etiprate on Day 6
89499889|NCT03534505|Experimental|Ketorolac injections|Patients will undergo herniorrhaphy with Lichtenstein Tension-Free Repair technique. After abdominal sheath will be closed by Vicryl No.0, Patients who are the Ketorolac group will receive local infiltration in abdominal sheath layer with Ketorolac 30 mg in normal saline 10ml. And then skin closure will be done by nylon 3-0.
89499890|NCT03534505|Active Comparator|bupivacaine|Patients will undergo herniorrhaphy with Lichtenstein Tension-Free Repair technique. After abdominal sheath will be closed by Vicryl No.0, Patients who are the bupivacaine group will receive local infiltration in abdominal sheath layer with 0.5% bupivacaine 10 ml. And then skin closure will be done by nylon 3-0.
89499891|NCT02198365||Group 2|Group 1: normal pap smear Group 2: cervical neoplasia
89499892|NCT02195791|Active Comparator|Pioglitazone|
89499893|NCT02195791|Placebo Comparator|Placebo|
89499894|NCT02196805|Experimental|1|
89499895|NCT02196805|Experimental|2|
89499896|NCT02196883|Active Comparator|MRI Pathology|
89499897|NCT02196883|Active Comparator|Physical Exam Pathology|
89499898|NCT02198443|Active Comparator|Tenofovir+emtricitabine|
89499899|NCT02198443|Experimental|Elvitegravir/cobicistat/emtricitabine/Tenofovir-Disoproxil|
89499900|NCT02201095|No Intervention|Normal care|Normal care - no active warming
89499901|NCT02201095|Active Comparator|Forced air warming|Underbody forced air warming blanket
89499902|NCT02201095|Active Comparator|Conduction warming mattress|Underbody conduction warming mattress
89499903|NCT02201173|Experimental|Locomotor Training|
89499904|NCT02198521||Bilateral Carpal Tunnel Syndrome (CTS)|
89499905|NCT02257645||Euforvac-Hib vaccine|
89499906|NCT05262049|Experimental|intermittent compression-decompression with glides|Patients in this group will be given only intermittent compression and decompression with glides. Traction (decompression applied at knee joint with anteroposterior glide followed by compression for about 6 minutes (30 glides, 10 seconds compression and vice versa), for the duration of 4 weeks (3 days a week, alternate days)
89499907|NCT05262049|Experimental|Conventional Physical Therapy|"In this group conventional therapy will be given according to below mentioned protocol for 4 weeks (3 days a week, alternate days).~Hot pack /TENS for 10 minutes~Stretching: Hamstring(10x) and calf (10x)~Strengthening of periarticular muscles especially the quadriceps (straight leg raising, pillow squeeze-isometric and dynamic)"
89499908|NCT05262049|Experimental|conventional physical therapy and intermittent compression-decompression with glides|Patients in this group will receive the combination of conventional physical therapy andintermittent compression and decompression with glides, for 4 weeks (3 days a week, alternate days).
89499909|NCT03533179|Experimental|Esmolol-placebo+glucagon 1 placebo (A)|"Physiologic saline - esmolol dummy (10 mg esmolol/ml) is administered as a loading dose at baseline (time= -15 minutes) (corresponding to 0.125 ml/kg/min of saline). Continuous infusion (0.05-0.075 ml/kg/min) of saline is then administered until T=30 minutes.~+ Physiologic saline - glucagon dummy bolus 50 ml at time=0."
89499910|NCT03533179|Experimental|Esmolol+glucagon 1 placebo (B)|"Esmolol intravenous solution (10 mg/ml esmolol hydrochloride) is administered as a loading dose (1.25 mg/kg/min esmolol) at baseline (time= -15 minutes). Continuous infusion (500-750 micrograms/kg/min) of esmolol/placebo is then administered until T=30 minutes.~+ Physiologic saline - glucagon dummy bolus (50 ml) at time=0."
89499911|NCT03533179|Experimental|Esmolol+glucagon 1 (C)|"Esmolol intravenous solution (10 mg/ml esmolol hydrochloride) is administered as a loading dose (1.25 mg/kg/min esmolol) at baseline (time= -15 minutes). Continuous infusion (500-750 micrograms/kg/min) of esmolol/placebo is then administered until T=30 minutes.~+Glukagon 1 (50 μg/kg bolus - over 1-3 min from time=0 min in 50 ml isotonic fluid)"
89499912|NCT03533179|Experimental|Esmolol-placebo+glucagon 2 (D)|"Physiologic saline - esmolol dummy (10 mg esmolol/ml) is administered as a loading dose at baseline (time= -15 minutes) (corresponding to 0.125 ml/kg/min of saline). Continuous infusion (0.05-0.075 ml/kg/min) of saline is then administered until T=30 minutes.~+Glukagon 2 (50 μg/kg bolus - over 30 min in 50 ml isotonic fluid from time=0 min)"
89499913|NCT03533179|Experimental|Esmolol-placebo+glucagon 1 (E)|"Physiologic saline - esmolol dummy (10 mg esmolol/ml) is administered as a loading dose at baseline (time= -15 minutes) (corresponding to 0.125 ml/kg/min of saline). Continuous infusion (0.05-0.075 ml/kg/min) of saline is then administered until T=30 minutes.~+ Glukagon 1 (50 μg/kg bolus - over 1-3 min from time=0 min in 50 ml isotonic fluid)"
89499914|NCT02198599|Experimental|Mobility-enhancing-nursing intervention|A 30 day mobility enhancing-nursing intervention for patients with Multiple Scerosis and stroke to expand kinaesthetic competence in order to increase compensation of limitations, improve functionality, and quality of life
89499915|NCT02198599|No Intervention|Standard usual rehabilitation care|Participants in the control group will receive usual care, which is based on the principles of rehabilitation nursing. Based on patients functional ability (EBI data) the nursing process is used to determine objectives and interventions. The main focus is on providing a therapeutic environment and supporting and advancing abilities to perform the Activities of Daily Living, support mobility and kinesthetic perception.
89499916|NCT02206321||Navigation total knee arthroplasty|Navigation total knee arthroplasty
89499917|NCT02206321||Conventional total knee arthroplasty|Conventional total knee arthroplasty
89531849|NCT05121246|Active Comparator|EU-Synagis®|Sterile vial 100mg/1ml, single-dose 3mg/kg administered as intramuscular injection on day 1
89531850|NCT05121246|Active Comparator|US-Synagis®|Sterile vial 100mg/1ml, single-dose 3mg/kg administered as intramuscular injection on day 1
89499918|NCT02201407||CHB Participants Treated With Peginterferon alfa-2a|As this is an observational study, treatment schedule will be at the clinician's discretion in accordance with local labeling and not directed by the protocol. Participants with CHB who are receiving peginterferon alfa-2a treatment according to standard of care, current summary of product characteristics, and in line with the local labeling will be followed for the duration of treatment with peginterferon alfa-2a (48 weeks) and up to 24 weeks after peginterferon alfa-2a treatment (72 weeks in total).
89499919|NCT05261971|No Intervention|Medical therapy|One non-steroidal anti-inflammatory drug (400mg etodolac) and one muscle relaxant drug (4 mg thiocolchicoside) were prescribed to the patients in this group.
89499920|NCT05261971|Active Comparator|Hard Splint Therapy|The patients in this group were asked to use a hard splint delivered to them to use at night.
89499921|NCT05261971|Active Comparator|Soft Splint Therapy|The patients in this group were asked to use a soft splint delivered to them to use at night.
89499922|NCT02201485|Active Comparator|PTA in combination with stent-placement|In this group, the patients will undergo percutaneous balloon angioplasty with or without stent-placement angioplasty in combination with stent-placement.
89499923|NCT02201485|Active Comparator|PTA alone|In this group, the patients will undergo percutaneous balloon angioplasty alone. The patients will transfer to the stent placement in the following cases: 1) reocclusion with thrombosis; and 2) at least 2 reocclusion events.
89499924|NCT02201563|Experimental|Minocycline|oral Minocycline 100 mg twice a day for 3 months.
89499925|NCT02198677|Experimental|AP|Anterior to posterior pressures 5x10 seconds per set with 10 seconds rest between each set
89499926|NCT02198677|Experimental|Lateral glides|Lateral glides 5x10 seconds per set with 10 seconds rest between each set
89499927|NCT02206477|Experimental|DMSO treatment group|The treatment group will be exposed to DMSO according to our built protocol. On the seventh post-operative day, the patient will be guided to set 10 cc of DMSO soaked gauze compresses on the breast, twice a day for 20 minutes, for the term of 6 weeks. This treatment will be holed for 24 hours on tissue expander inflation dates. A repeated course of compresses will be taken after adjuvant radiotherapy, starting 24 hours after the last therapy.
89499928|NCT02206477|Placebo Comparator|the control group|The control group will be treated with the same post-operative protocol, but with 0.9% saline instead of DMSO. On the seventh post-operative day, the patient will be guided to set 10 cc 0.9% saline soaked gauze compresses on the breast, twice a day for 20 minutes, for the term of 6 weeks. This treatment will be holed for 24 hours on tissue expander inflation dates. A repeated course of compresses will be taken after adjuvant radiotherapy, starting 24 hours after the last therapy.
89538353|NCT03269357|Other|Intervention|"Clinics randomized to intervention will provide structured LARC centered counselling"
89499929|NCT02201641|Experimental|calcium silicate cement (Biodentine™)|calcium silicate cement (Biodentine™) used for indirect pulp capping of teeth with deep carious lesions and inflammed pulps.
89499930|NCT02201641|Experimental|Cone Beam computed tomography (CBCT)|CBCT scans are taken to assess the efficacy of this method in detecting the presence of early peri-radicular lesions.
89499931|NCT02201641|Active Comparator|Periapical radiographs|Periapical radiographs are taken as a control to detect the presence of early peri-radicular lesions.
89499932|NCT02201641|Active Comparator|Glass ionomer cement ( Fuji IX™)|Glass ionomer cement ( Fuji IX™) used for indirect pulp capping of teeth with deep carious lesions and inflammed pulps.
89499933|NCT02201719||Hysterectomy Adenomyosis|Adenomyosis present
89499934|NCT02201719||Hysterectomy no adenomyosis|Adenomyosis not present
89499935|NCT02206555|Experimental|Treatment group (TRUVADA)|Homosexual men and heterosexual men and women at high risk of HIV infection
89499936|NCT02201797|Experimental|DCE and DWI MRI|MRI SCAN 1 and MRI SCAN 2 must be completed no less than 2 calendar days (to ensure 24 hours for clearance of gadolinium) and no greater than 14 days apart, and both must be completed prior to new treatment initiation. The same MRI unit and configuration must be used for MRI SCAN 1 and MRI SCAN 2.
89499937|NCT02201875||Healthy subjects|male, aged 18-65 moderately trained healthy, no treatment
89499938|NCT02201875||obstructive sleep apneas|patients with apnea/hypopnea index > 15 BMI < 30 Age < 50 yrs
89499939|NCT02201875||cardiac failure|NYHA class I to III ejection fraction < 40% age < 65 yrs BMI < 30
89499940|NCT03533647||entire cohort (observational)|none (observational study)
89499941|NCT02198755|Active Comparator|High Resolution Ultrasound|High Resolution Ultrasonography (HRUS) with a Hitachi-Aloka Noblus Scanner
89499942|NCT02198755|Active Comparator|Magnetic Resonance Imaging (MRI)|Magnetic Resonance Imaging (MRI)
89499943|NCT02206633||Elderly, assisted living residents|Hydration Monitor ultrasound measurements
89499944|NCT02206711|Experimental|Single oral dose of [14C] BMS 955176|A single 180 mg oral dose of [14C] BMS-955176 containing approximately 80 microcurie of total radioactivity.
89499945|NCT02206711|Experimental|Nasoduodenal (ND) Tube Cohort|A single dose of [14C] BMS 955176 on Day 1 with ND placement 1 hour post dose to facilitate continuous bile collection though 8 hours post dose.
89499946|NCT02202187|Experimental|GSK2140944|Dose range 100mg to 3000mg single dose
89499947|NCT02202187|Placebo Comparator|Matching Placebo|Placebo
89499948|NCT02206789|Active Comparator|penetrating keratoplasty|"each arm will have two groups A and B.. Only on topical steroids(prednisolone acetate1%) group A On topical steroids + 2% cyclosporine Group B . Methodology of drug administration In both agroups 1. Schedule of topical steroid administration : 6 times for 2 weeks; 5 times for 2 weeks; 4 times for a month; 3 times for a month, and, subsequently twice-a-day until 1 year is completed . Topical steroids will be withdrawn at the end of ine year.Systemic steroids may be administered in the initial 2 weeks at the discretion of the investigators.~3. Patients randomized to receive 2% cyclosporine will receive the same 3 times a day for 2years~."
89538354|NCT03269357|No Intervention|Routine counselling|Clinics randomized to routine counselling
89538355|NCT03280199|Other|Type of simulator - 1|"VR simulator with physical mannequin and probe.~PLEASE NOTE THAT THE INTERVENTIONS BEING COMPARED ARE DIFFERENT TYPES OF SIMULATORS - NOT A DRUG!"
89499949|NCT02206789|Active Comparator|therapeutic keratoplasty|"each arm will have two groups A and B.. Only on topical steroids(prednisolone acetate1%) group A On topical steroids + 2% cyclosporine Group B . Methodology of drug administration In both agroups 1. Schedule of topical steroid administration : 6 times for 2 weeks; 5 times for 2 weeks; 4 times for a month; 3 times for a month, and, subsequently twice-a-day until 1 year is completed . Topical steroids will be withdrawn at the end of ine year.Systemic steroids may be administered in the initial 2 weeks at the discretion of the investigators. (For all patients with fungal keratitis topical steroids will be administered only after 2 weeks post keratoplasty.) Until then diclofenac sodium0.1% may be used 3. Patients randomized to receive 2% cyclosporine will receive the same 3 times a day for 2years~."
88955884|NCT06124716|Experimental|Enhanced COACH|Enhanced blood pressure management recommendations that use cognitive and behavioral science to increase the likelihood of self-management goal setting to lower blood pressure. The CDS tool allows participant access to BP visualizations, reminders, and affectively tailored messaging about blood pressure management.
88955885|NCT06124716|Active Comparator|Usual Care COACH|Equivalent of usual care delivered through the CDS tool: Blood pressure management with basic information, reduced reminders, and no affective alerts.
89205655|NCT03863808|Experimental|Cognitive Behavioural Therapy|"Following assessment a one on one session will be given comprising education cognitively targeting false ideas and beliefs on the nature of pain, differentiating nociception due to a painful stimulus and the transition of such a stimulus to a centrally sensitized experience due to misinformation, maladaptive behaviour and fear avoidance. Upon completion of the session assessment using the NPQ will be done to assess the understanding of the patient and further address any shortcomings in future exercise sessions.~Another SEMG recording of the Flexion Relaxation phenomenon will be upon completion of the educational session and a SEMG biofeedback session will begin to help the patient regain their sense of control over their body and function.~After the SEMG biofeedback session a graded exposure exercise program of strengthening and functional training starting from the least feared movements to the most over 10 sessions over 5 weeks."
89205656|NCT03863808|Active Comparator|Strengthening and Core Stability|"Following assessment 12 sessions over 6 weeks will start, focusing on strengthening exercises of the transversus abdominis and lumbar multifidus muscles (Angela Searle, 2015).~Exercises will be graduated according to the patient pain tolerance."
89499950|NCT02202265|Active Comparator|Control diet (standard dietary)|Patients will receive a control diet based on standard dietary guidelines
89499951|NCT02202265|Experimental|Olive oil (30ml a day)|Patients will receive a control diet based on standard dietary guidelines + 30ml of olive oil a day
89499952|NCT02202265|Experimental|Nuts (30g a day)|Patients will receive a control diet based on standard dietary guidelines plus 30g of nuts a day
89499953|NCT03892369|Experimental|Alcohol|The participant receive 0.5 g ethanol per kg body weight over 10 minutes. Subsequently blood samples are taken frequently the next ten hours.
89499954|NCT02206867|Experimental|LBAL|Developed by LG Life Sciences
89499955|NCT02206867|Active Comparator|Humira®|Abbvie
89499956|NCT02202343|Experimental|School-based health and nutrition education|
89499957|NCT03533101|Experimental|Tocilizumab 4 mg/kg|Tocilizumab 4 mg/kg IV single dose day -1 prior to haploidentical transplantation
89499958|NCT03533101|Active Comparator|Tocilizumab 8 mg/kg|Tocilizumab 8 mg/kg IV single dose day -1 prior to haploidentical transplantation
89499959|NCT02751931|Experimental|Children (3 to < 12 Years)|Participants aged 3 to < 12 years received initial dose of 25 milligram (mg) of mirabegron orally once daily based on weight (pediatric equivalent dose of 25 mg (milligram) [PED25]) on day 1. At weeks 2, 4 or 8, participant's were up-titrated to the pediatric equivalent dose of 50 mg in adults [PED50], orally once daily based on the given dose titration criteria. Following week 24, participants stayed on their individual dose level until week 52 end-of-study (EOS) or end-of-treatment (EOT).
89499960|NCT02751931|Experimental|Adolescents (12 to < 18 Years)|Participants aged 12 to < 18 years received initial dose of 25 mg of mirabegron orally once daily based on weight [PED25] on day 1. At weeks 2, 4 or 8, participant's were up-titrated to the pediatric equivalent dose of 50 mg in adults [PED50] orally once daily based on the given dose titration criteria. Following week 24, participants stayed on their individual dose level until week 52 EOS or EOT.
89499961|NCT02561156|Experimental|Part 1 Cohort 1: TAK-653 0.3 mg|TAK-653 0.3 milligram (mg), tablet, orally, once on Day 1 or TAK-653 placebo-matching tablet, orally, once on Day 1. TAK-653 or placebo will be administered after an overnight fast of approximately at least 10 hours.
89499962|NCT02561156|Experimental|Part 1 Cohort 2: TAK-653 1.0 mg|TAK-653 1.0 mg, tablet, orally, once on Day 1 or TAK-653 placebo-matching tablet, orally, once on Day 1. TAK-653 or placebo will be administered after an overnight fast of approximately at least 10 hours.
89499963|NCT02561156|Experimental|Part 1 Cohort 3: TAK-653 3.0 mg|TAK-653 3.0 mg, tablet, orally, once on Day 1 or TAK-653 placebo-matching tablet, orally, once on Day 1. TAK-653 or placebo will be administered after an overnight fast of approximately at least 10 hours.
89538356|NCT03280199|Other|Type of simulator - 2|"VR simulator with virtual mannequin / abdomen~PLEASE NOTE THAT THE INTERVENTIONS BEING COMPARED ARE DIFFERENT TYPES OF SIMULATORS - NOT A DRUG!"
89205657|NCT03859648|Experimental|Bone Conduction Implant|All subjects will be implanted with the bone conduction implant.
89205658|NCT03852875|Experimental|Education|Patients in the experimental arm will receive a 1-on-1 education session to review the their CR participation. As part of the discussion about their CR participation, these patients will also receive feedback on their intake exercise stress test.
89205659|NCT03852875|Sham Comparator|Control|Patients in the Control arm will receive a 1-on-1 education session to review the their CR participation. As part of the discussion about their CR participation, these patients will NOT receive feedback on their intake exercise stress test.
89205660|NCT03760588|Experimental|Sacubitril/valsartan|Sacubitril/valsartan (target dose 97/103 mg b.i.d.) and matching placebo will be provided orally in a 1:1 parallel fashion stratified by study site and for planned treatment with trastuzumab. Dose titration will be performed as follows: Sacubitril/valsartan 24/26 mg b.i.d. will be administered for 2-4 weeks and provided blood pressure > 100 mmHg, no symptoms of hypotension or other side effects or adverse events (AE), followed by sacubitril/valsartan 49/51 mg b.i.d. for 2-4 weeks. Provided blood pressure > 100 mmHg, no symptoms of hypotension or other side effects or AE a further uptitration to sacubitril/valsartan 97/103 mg b.i.d. will be performed.
89205661|NCT03760588|Placebo Comparator|Placebo|Matched to the comparator.
88955898|NCT06107205|Active Comparator|TTYP01|Healthy subjects were administered 1 single oral dose of 90 mg TTYP01 (3 tablets of the test drugs, test formulation T)
88955899|NCT06107205|Active Comparator|Radicava|Healthy subjects were administered 1 injection of 60 mg Radicava (reference drug R1, intravenous infusion of 60 mg administered over 60 minutes)
88955900|NCT06107205|Active Comparator|Radicava ORS|Healthy subjects were administered 1 single oral dose of 105 mg/5 mL Radicava ORS (reference drug R2)
89499964|NCT02561156|Experimental|Part 1 Cohort 4: TAK-653 5.0 mg|TAK-653 5.0 mg, tablet, orally, once on Day 1 or TAK-653 placebo-matching tablet, orally, once on Day 1. TAK-653 or placebo will be administered after an overnight fast of approximately at least 10 hours.
89499965|NCT02561156|Experimental|Part 1 Cohort 5: TAK-653 9.0 mg|TAK-653 9.0 mg, tablet, orally, once on Day 1 or TAK-653 placebo-matching tablet, orally, once on Day 1. TAK-653 or placebo will be administered after an overnight fast of approximately at least 10 hours.
89499966|NCT02561156|Experimental|Part 1 Cohort 6: TAK- 653 18 mg|TAK-653 18 mg, tablet, orally, once on Day 1 or TAK-653 placebo-matching tablet, orally, once on Day 1. TAK-653 or placebo will be administered after an overnight fast of approximately at least 10 hours. Dose escalation to be decided (TBD) based on safety, tolerability, and available PK and pharmacodynamics (PD) data from previous cohorts.
89499967|NCT02561156|Experimental|Part 1 Additional Cohorts: TAK- 653 Placebo|TAK-653 placebo-matching tablet, orally, once on Day 1. TAK-653 or placebo will be administered after an overnight fast of approximately at least 10 hours. Dose escalation TBD based on safety, tolerability, and available PK and PD data from previous cohorts.
89499968|NCT02561156|Experimental|Part 2 Cohort 1: TAK-653 0.3 mg|TAK-653 0.3 mg, tablet, orally, once on Day 1, and once daily (QD) from Days 6 to 18 or placebo-matching tablet, orally, once on Day 1 and QD from Days 6 to 18.
89499969|NCT02561156|Experimental|Part 2 Cohort 2: TAK-653 1.0 mg|TAK-653 1.0 mg, tablet, orally, once on Day 1, and QD from Days 6 to 18 or placebo-matching tablet, orally, once on Day 1 and QD from Days 6 to 18.
89499970|NCT02561156|Experimental|Part 2 Cohort 3: TAK-653 3.0 mg|TAK-653 3.0 mg, tablet, orally, once on Day 1, and QD from Days 6 to 18 or placebo-matching tablet, orally, once on Day 1 and QD from Days 6 to 18.
89499971|NCT02561156|Experimental|Part 2 Cohort 4: TAK-653 6 mg|TAK-653 6 mg, tablet, orally, once on Day 1, and QD from Days 6 to 18 or placebo-matching tablet, orally, once on Day 1 and QD from Days 6 to 18. Dose escalation TBD based on safety, tolerability, and available PK and PD data from previous cohorts.
89499972|NCT02561156|Experimental|Part 2 Cohort 5: TAK-653 9 mg|TAK-653 9 mg, tablet, orally, once on Day 1, and QD from Days 6 to 18 or placebo-matching tablet, orally, once on Day 1 and QD from Days 6 to 18. Dose escalation TBD based on safety, tolerability, and available PK and PD data from previous cohorts.
89499973|NCT02561156|Experimental|Part 2 Additional Cohorts: TAK-653 Placebo|TAK-653 placebo-matching tablet, orally, once on Day 1 and QD from Days 6 to 18. Dose escalation TBD based on safety, tolerability, and available PK and PD data from previous cohorts.
89499974|NCT02207023|No Intervention|Memory Training Program|Participants will participate in 7 memory training coaching sessions (two in the first month) over a 6 month period. The coaching sessions will be administered by phone.
89499975|NCT02207023|Experimental|Healthy Lifestyle Training Program|Participants will participate in 7 lifestyle coaching sessions (two in the first month) over a 6 month period. The coaching sessions will be administered by phone.
89538357|NCT03280199|Other|Type of image acquisition - 3|"US images are acquired through real US volumes from patients~PLEASE NOTE THAT THE INTERVENTIONS BEING COMPARED ARE DIFFERENT TYPES OF SIMULATORS - NOT A DRUG!"
89538358|NCT03280199|Other|Type of image acquisition - 4|"US images are acquired through computer-generated images.~PLEASE NOTE THAT THE INTERVENTIONS BEING COMPARED ARE DIFFERENT TYPES OF SIMULATORS - NOT A DRUG!"
89538359|NCT03269123|Other|A device to relieve Blepharospasm|The pressure device known as Pressop1 is the intervention which is attached to the spectacles and worn for 2 weeks prior to retreatment with Botulinum Toxin injections to assess its effectiveness in controlling eyelid spasms.
89538360|NCT03280043||Cases|Women who underwent reduction mammoplasty and then developed a hematoma which required return to the operating room for evacuation.
89538361|NCT03280043||Controls|Women who had uncomplicated reduction mammoplasty.
89538362|NCT03269201||Parkinson;s Disease|Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis. Additionally patients will be rated using MoCA, FAB, Verbal Fluency, - Beck Depression Inventory, PDQ-39, PD sleep scale (PDSS), MDS-UPDRS.SF-EMG and KinesiaOne and motion sensor assessment for tremor.
89538363|NCT03269201||Essential tremor|Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis.Additionally patients will be rated using mmse/ MoCA, Verbal Fluency, essential tremor rating assessment scale (TETRAS) clinical rating scale for tremor (CRST).SF-EMG and KinesiaOne and motion sensor assessment writing and drawing on digitizer, for tremor.
89538364|NCT03269201||Multiple system atrophy|Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis. Additionally patients will be rated using MoCA, FAB, Verbal Fluency, - Beck Depression Inventory, PDQ-39, PD sleep scale (PDSS), MDS-UPDRS.SF-EMG and KinesiaOne and motion sensor assessment for tremor.
89538365|NCT03269201||Normal Pressure Hydrocephalus|Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis. Additionally patients will be rated using MoCA, FAB, Verbal Fluency, - TIMED UP AND GO TASK (INSTRUMENTAL)
88955901|NCT06106308|Experimental|Onvansertib 20mg + Standard of Care|Participants will receive 20 mg of onvansertib on Days 1 to 5 and Days 15 to 19 of each 28-day treatment cycle + FOLFIRI/BEV on Day 1 and Day 15 of each 28-day treatment cycle.
88955902|NCT06106308|Experimental|Onvansertib 30 mg + Standard of Care (SOC)|Participants will receive 30 mg of onvansertib + on Days 1 to 5 and Days 15 to 19 of each 28-day treatment cycle + FOLFIRI on Day 1 and Day 15 of each 28-day treatment cycle.
88955903|NCT06106308|Active Comparator|Standard of Care (SOC)|Participants will receive FOLFIRI/Bev on Day 1 and Day 15 of each 28-day treatment cycle.
89499976|NCT02202421|Active Comparator|T-ABA Parent Training Only|Participants in the T-ABA Parent Training Only group will be given Targeted Applied Behavior Analysis (T-ABA) Intervention with five weeks of parent group training and five weeks of parent-therapists one-on-one sessions. They will also be offered eight one hour individual therapist-child applied behavior analysis sessions at the conclusion of the study if desired.
89499977|NCT02202421|Experimental|T-ABA Parent Group + Individual Therapy|Participants in the T-ABA Parent Group plus Individual Therapy group will be given Targeted Applied Behavior Analysis (T-ABA) Intervention with five weeks of parent group training and five weeks of parent-therapists one-on-one sessions. They will also be offered eight one-hour individual therapist-child applied behavior analysis therapy sessions concurrent with the parent group and parent-therapist sessions.
89499978|NCT02207101|Active Comparator|E-OJ-01 (OXYJUN)|E-OJ-01 (OXYJUN). Dose: 01 capsule to be taken orally daily after lunch.
89499979|NCT02207101|Placebo Comparator|Placebo|Matching placebo capsules [for E-OJ-01 (OXYJUN)] composed of microcrystalline cellulose. Dose: 01 capsule to be taken orally daily after lunch.
89499980|NCT02198989|Experimental|peer support and yoga music therapy|"Patients in the group will receive peer support and yoga music therapy before bed.~Patients in the group will received the group education courses and clinical medical therapy."
89499981|NCT02198989|No Intervention|Control group|Patients in the group will received the group education courses and clinical medical therapy.
89499982|NCT05261581|Experimental|Intervention|Patients that will get ESPB, NSAID and exercise programme
89499983|NCT05261581|Active Comparator|Control|Patients that will only get NSAID and exercise programme
89499984|NCT02207179|No Intervention|Single Arm|LumaScan Image Guided Surgery
89499985|NCT02199223|Experimental|panitumumab + regorafenib|
89499986|NCT02202733|Other|Cooking|A skill-based cooking intervention for caretakers of an overweight/obese child aged 3-10 years.
89499987|NCT02207335|Experimental|Gemcitabine，Capecitabine|Gemcitabine: 1250 mg/m2, ivgtt, 30mins, D1,8 Capecitabine: 1250 mg/m2, PO, Q12h, D1-14
89499988|NCT02207335|Active Comparator|Gemcitabine, Carboplatin|Gemcitabine: 1250 mg/m2, ivgtt,30mins, D1,8 Carboplatin: AUC 2, ivgtt, 60mins, D1,8
89499989|NCT02202811|Experimental|Obstructive Sleep Apnea|Forced Desynchrony, OSA
89499990|NCT02202811|Placebo Comparator|Control|Forced Desynchrony, Control
89499991|NCT03533023|Experimental|TRE + SOC|Time Restricted Eating + Standard of Care
89499992|NCT03533023|Other|SOC|Standard of Care
89499993|NCT02561078|Experimental|Human regular U-500 insulin administered by CSII|Human regular U-500 insulin administered by CSII and titrated based on blood glucose readings for 26 weeks with a 2-week MDI lead-in.
89499994|NCT02561078|Active Comparator|Human regular U-500 insulin administered by MDI|Human regular U-500 insulin administered subcutaneously (SC) by MDI three times a day and titrated based on blood glucose readings for 26 weeks.
89499995|NCT04058197|Experimental|Active|Deferoxamine (DFO) Intradermal Delivery Patch (DIDP), 45mg DFO daily, up to 12 weeks
89499996|NCT04058197|Placebo Comparator|Placebo|Placebo
89499997|NCT02207881|Placebo Comparator|placebo|placebo gel, 25mg, 3 times up to 10 days
89499998|NCT02207881|Experimental|VDO gel|VDO gel 25mg, 3 times a day up to 10 days
89499999|NCT03533569||Osteoarthritis|Participants with an established diagnosis of knee osteoarthritis
89500000|NCT03533569||Rheumatoid arthritis|Participants with an established diagnosis of rheumatoid arthritis
89500001|NCT03533569||Spondyloarthritis or psoriatic arthritis|Participants with an established diagnosis of spondyloarthritis or psoriatic arthritis
89500002|NCT03533569||Case controls|Participants with no arthritis or knee pain as controls
89500003|NCT02202967|Active Comparator|Misoprostol|Misoprostol
89500004|NCT02202967|Placebo Comparator|Placebo|Placebo
89500005|NCT02203045|Active Comparator|Tourniquet|All lower extremities will be exsanguinated by elevation for 2 minutes. For lower extremities in the tourniquet group (TQT), a pneumatic tourniquet will be inflated according to standard practice (>200 mmHg). For the NOTQT group, the tourniquet will only be inflated during component cementation. In both groups, tourniquet will be deflated after bone cement has set. In both groups, electrocautery will be used as needed throughout the procedure.
88955904|NCT06106308|Experimental|Onvansertib 20 mg + Standard of Care|Participants will receive 20 mg of onvansertib on Days 1 to 5 and Days 15 to 19 of each 28-day treatment cycle + FOLFOX on Day 1 and Day 15 of each 28-day treatment cycle.
88955905|NCT06106308|Experimental|Onvansertib 30 mg + Standard of Care|Participants will receive 30 mg onvansertib on Days 1 to 5 and Days 15 to 19 of each 28-day treatment cycle + FOLFOX on Day 1 and Day 15 of each 28-day treatment cycle.
88955906|NCT06106308|Active Comparator|Standard of Care|Participants will receive FOLFOX/Bev on Day 1 and Day 15 of each 28-day treatment cycle.
88955907|NCT06104280|Experimental|MOUD therapy methadone|50 methadone participants
88955908|NCT06104280|Experimental|MOUD therapy buprenorphine|50 buprenorphine participants
88955909|NCT06104280|Experimental|MOUD therapy extended-release naltrexone|50 extended-release naltrexone (XR-NTX) participants
89500006|NCT02203045|Experimental|Non- tourniquet|All lower extremities will be exsanguinated by elevation for 2 minutes. For lower extremities in the tourniquet group (TQT), a pneumatic tourniquet will be inflated according to standard practice (>200 mmHg). For the NOTQT group, the tourniquet will only be inflated during component cementation. In both groups, tourniquet will be deflated after bone cement has set. In both groups, electrocautery will be used as needed throughout the procedure.
89500007|NCT04545164|No Intervention|Usual Care|Participants in the usual care arm will receive no specific trial intervention. Usual care includes tests routinely available at Zomba Central Hospital, including (but not limited to) conventional (plain film) chest X-ray, urine Alere LAM and sputum Xpert Mtb/Rif on treating clinician request.
88955910|NCT06104280|Other|Non-opioid using controls|non-opioid using controls
88955911|NCT06104254|No Intervention|control group|The patient who assign to control group, they will give standard ward care before surgery and we measure their pain beliefs and pain level. After operation we will asses their pain beliefs and pain level. the last measure will be carried out after 30 days operation.
88955912|NCT06104254|Experimental|experimental group|The patient who assign to experimental group, we will measure their pain beliefs and pain level before surgery. After that a researcher will give an education before operation to these patients about pain, potential pain and pain management after surgery. we will asses these patients pain beliefs and pain level after surgery and 30 days later again.
89205662|NCT03729778|Active Comparator|HIV+|One time administration of Prevnar-13 vaccine to HIV+ participants
88955914|NCT06103656|Experimental|Active Comparator::Chinese Herbal Medication|"Interventions:~- Drug: Chinese Herbal Medication (E-B-FAHF-2), dose level was determined using the subject's weight at the screening visit (>20-30 kg = 5 capsules daily, >30-70 kg = 8 capsules daily, and >70 kg = 10 capsules daily)"
89205663|NCT03729778|Active Comparator|HIV Negative Controls|One time administration of Prevnar-13 vaccine to HIV Negative Control participants
89500008|NCT04545164|Experimental|DCXR-CAD and FujiLAM and usual care|Participants randomized to the intervention arm will receive TB screening using DCXR-CAD and urine FujiLAM. The CAD score and FujLAM results will be appended into their medical notes for treating clinicians to see. If patients have a CAD score above a pre-determined threshold the study team will attempt to collect sputum for Xpert Mtb/Rif. Chest X-ray images will be available for clinicians to view. This is in addition to usual care (detailed above).
89500009|NCT04545164|Other|Diagnostic cohort|Patients in the observational enhanced diagnostic arm will receive an enhanced package of diagnostics. This is a smaller arm (1 in 9 of all clusters) and is observational only - participants in this arm do not contribute to trial outcomes.
89500010|NCT03532945|Experimental|Bioactive Glass-Ceramic Spacer|The one-level Posterior Lumbar Interbody Fusion(PLIF) surgery will be carried out with Novomax, which is the bioactive glass ceramic intervertebral spacer.
89500011|NCT03532945|Active Comparator|Titanium cage|The one-level Posterior Lumbar Interbody Fusion(PLIF) surgery will be carried out with titanium cage.
89500012|NCT05506514|Experimental|Hot|1h per day of water immersion at 42ºC for 11 days
89500013|NCT05506514|Sham Comparator|Temperate|30min per day of water immersion at 32ºC for 11 days
89500014|NCT05506514|Experimental|Cold|15min per day of water immersion at 15ºC for 11 days
89500015|NCT05977803|Other|Radiation therapy|Patient treated for metastatic cerebral lung cancer who has been treated with external beam radiotherapy such as in toto brain irradiation or stereotactic radiosurgery followed in the thoracic oncology department of Bichat Hospital.
89500016|NCT05977777|Experimental|Patients|Patients affected by focal pancreatic lesions
89500017|NCT05977764|Experimental|lesion target|CEUS on lesion target
89500018|NCT05977647|Active Comparator|Tamsulosin|Patients with lower ureteric stone will be randomized through permuted block randomization equally into two group. 120 patients will be on tamsulosin 0.4 mg once daily, therapy will be given for a maximum of 4 weeks.
89500019|NCT05977647|Active Comparator|Silodosin|Patients with lower ureteric stone will be randomized through permuted block randomization equally into two group. 120 patients will be on Silodosin 8 mg once daily. Therapy will be given for a maximum of 4 weeks.
89500020|NCT05977608|Experimental|Group 1|Participants will be asked to participate in the reminiscence program during the first 6 weeks of the study.
89500021|NCT05977608|Experimental|Group 2|Participants will be asked to participate in the reminiscence program during the second 6 weeks of the study.
89500022|NCT05977569|Experimental|Prolonged Fasting|All participants are asked to act as their own control prior to being asked to undergo 3 days of fasting.
89500023|NCT05977491|No Intervention|Standard treatment|Patients are treated by the health care practitioner according to local protocol. This protocol corresponds to the syndromic approach without laboratory or microscopic testing. This may or may not include inspection and examination of the vulva, vagina, cervix and lower abdomen.
89500024|NCT05977491|Active Comparator|POCT based treatment|"The health care practitioner is informed about the POCT results for CT and NG (positive or negative). In addition, if the pH is within the normal level (4.5 and below). If it is higher, he will receive the outcome of the whiff test (positive or negative).~Examination of the patient is performed according to the discretion of the health care practitioner."
89500025|NCT05977491|Active Comparator|POCT based treatment PLUS|"Same as in POCT based treatment PLUS:~Patients are given a short educational leaflet and 10 min audio-recording about physiological and abnormal vaginal discharge and about problems associated with unnecessary use of antibiotics.~All women complete a questionnaire prior to examination, including a screening tool for anxiety and depression and domestic violence. If they screen positive, the health care practitioner will be informed, in addition to the POCT result."
89500026|NCT05977478|Experimental|SPECTRA IMDx™.|During endoscopy, the endoscopist will first locate the precancerous/cancerous gastric lesions using HD-WLE. Upon location of the lesion, the endoscopist will use the SPECTRA IMDx™ probe to capture the Raman spectra from the lesion and its adjacent normal mucosa.
89500027|NCT05977452||patients with PICC placement|
88955915|NCT06103656|Placebo Comparator|Placebo Comparator: Placebo|"Interventions:~Drug: Placebo. Placebo capsules were identical in appearance but contained corn starch~Drug: Omalizumab. Omalizumab was dosed as per the product insert~Drug: Multi OIT. An initial rush dose to a maximum of 250 mg of protein of each allergen (total 270 mg of protein) and up-dosing every 2 weeks until the maintenance dose of 1000mg was reached."
88955916|NCT06099704||Participants with msAD|Canadian msAD participants (ages 6+) who receive Dupixent for msAD according to the Canadian-country specific prescribing information (in accordance with the Canadian Dupixent Product Monograph)
89205664|NCT03718260|Experimental|Cohort 1|Men who are node positive or who have persistently detectable PSA after initial radical prostatectomy will be restaged with [18F]-DCFPyL PET/ CT scan (PSMA PET)
89205665|NCT03718260|Experimental|Cohort 2|Men with biochemical failure after initial prostatectomy will be restaged with [18F]-DCFPyL PET/ CT scan (PSMA PET)
89205666|NCT03718260|Experimental|Cohort 3|Men with biochemical failure after initial radical prostatectomy and salvage radiotherapy will be restaged with [18F]-DCFPyL PET/ CT scan (PSMA PET)
89205667|NCT03718260|Experimental|Cohort 4|Men with biochemical failure after initial radical prostatectomy with or without adjuvant/ salvage radiotherapy who are currently on salvage hormone therapy will be restaged with [18F]-DCFPyL PET/ CT scan (PSMA PET)
89500028|NCT05977426|Experimental|Reiki|"A sociodemographic questionnaire including questions about age, last menstrual period, education level and income level, Menopause Rating Scale (MRS), Beck Depression Inventory (BDI) were utilized for the collection of research data. And a question investigating the level of being affected by menopause complaints. The question investigating the level of being affected by menopause is: At which level do menopause complaints affect you?. Women answered this question on a scale of 0 (very little/very slightly) to 10 (extreme/very much). Data were collected from women who applied to the FHC for general healthcare services after receiving service. Women in the experimental group received Reiki once a week for four weeks. No initiative was applied to the pregnant women in the control group. Each session lasted 30-40 minutes. Four weeks after the data collection tools used in the research were filled in as a pre-test, post-test data were obtained with the same measurement tools."
89500029|NCT05977426|No Intervention|Routine checks|The researchers applied no initiative to the control group, and the women in the control group solely had the routine checks. The women in the control group filled out all pretest forms(A sociodemographic questionnaire including questions about age, last menstrual period, education level and income level, Menopause Rating Scale (MRS), Beck Depression Inventory (BDI)). The post-test forms (MRS, BDI) were re-administered 4 weeks later to women who did not receive any intervention.
88955923|NCT06095505|Experimental|Alisertib|50 mg of alisertib PO BID on days 1-7 of each 21-day cycle
89500030|NCT05977413|Experimental|Notification of CAC|"For patients randomized to the notification of CAC arm (NC), primary clinicians will be notified that with the assistance of a deep-learning algorithm, one of their patients was found to have a CAC score >100 AU. The notification will include an image taken from the CT scan with CAC clearly marked. The notification will also include American Heart Association/American College of Cardiology 2a recommendation to initiate lipid lowering therapy (usually statin) given the presence of moderate-severe CAC.~Patients randomized to notification will receive messages (via EHR portal-based messages, text, or US postal mail) with notification of CAC presence on their LDCT, images showing the presence of CAC from their previous chest CT clearly marked, the recommendation to discuss statin or other lipid-lowering therapy with their clinician, and a link to a patient-friendly website about CAC and risk factor control. There will be reminder messages sent at 3 weeks and 12 months."
89500031|NCT05977413|Other|Usual Care|Patients randomized to Usual Care will receive usual medical care provided by their clinician informed by widely publicized clinical practice guidelines.
88955926|NCT06088290|Experimental|Phase IIb (& Phase III if selected), Doxorubicin (dose A) + Lurbinectedin (dose B)|Participants will receive doxorubicin and lurbinectedin intravenously every three weeks (q3wk) on day 1 of each treatment cycle (treatment cycle = three weeks).
88955927|NCT06088290|Experimental|Phase IIb (& Phase III if selected), Doxorubicin (dose C) + Lurbinectedin (dose D)|Participants will receive doxorubicin intravenously q3wk on day 1 of each treatment cycle (treatment cycle = three weeks).
88955928|NCT06088290|Active Comparator|Phase IIb & Phase III, Doxorubicin|Participants will receive doxorubicin intravenously q3wk on day 1 of each treatment cycle (treatment cycle = three weeks).
88955929|NCT06085482|Experimental|LY3502970 + [14C]-LY3502970|Single dose of LY3502970 administered orally followed by single dose of [¹⁴C]-LY3502970 administered intravenously (IV)
88955930|NCT06083987|Active Comparator|Control Group - No Interventions|Arm 1 will have not be given any of the interventions and will be a control group.
88955931|NCT06083987|Experimental|Intervention 1 - Intersectionality and Identity|Arm 2 will be given access to intervention 1. It will have video and text content focused on identity and intersectionality.
88955932|NCT06083987|Experimental|Interventions 1 and 2 - Intersectionality and Identity/Confidentiality and Privacy|Arm 3 will be given access to with the video and text content focused on intersectionality and confidentiality
88955933|NCT06083987|Experimental|Interventions 1, 2, and 3 - Intersectionality/Confidentiality/Educational Tools|Arm 4 will be given access to with the video and text content focused on intersectionality, confidentiality, and education about identity
88955934|NCT06083987|Experimental|Interventions 1, 2, and 4 - Intersectionality/Confidentiality/Finding Affirming Care|Arm 5 will be given access to interventions 1, 2, and 4, with the video and text content focused on intersectionality, confidentiality, and determining if caregivers are affirming
88955935|NCT06083987|Experimental|Interventions 1, 2, 3 and 4 - Intersectionality/Confidentiality/Educational Tools/Affirming Care|Arm 6 will be given access to all 4 interventions, with the video and text content focused on intersectionality, confidentiality, education about identity, and determining if caregivers are affirming
88955936|NCT06083987|Experimental|Interventions 1 and 3 - Intersectionality and Identity/Educational Tools|Arm 7 will be given access to interventions 1 and 3, with the video and text content focused on intersectionality and education about identity
88955937|NCT06083987|Experimental|Interventions 1, 3, and 4 - Intersectionality and Identity/Educational Tools/Finding Affirming Care|Arm 8 will be given access to interventions 1, 3, and 4, with the video and text content focused on intersectionality, education about identity and determining if caregivers are affirming.
88955938|NCT06083987|Experimental|Interventions 1 and 4 - Intersectionality and Identity/Finding Affirming Care|Arm 9 will be given access to interventions 1 and 4, with the video and text content focused on intersectionality and determining if caregivers are affirming.
88955939|NCT06083987|Experimental|Intervention 2 - Confidentiality and Privacy|Arm 10 will be given access to intervention 2, with the video and text content focused on confidentiality
88955940|NCT06083987|Experimental|Interventions 2 and 3 - Confidentiality and Privacy/Educational Tools|Arm 11 will be given access to interventions 2, and 3. Video and text content will focus on confidentiality and education about identity.
88955941|NCT06083987|Experimental|Interventions 2, 3 and 4 - Confidentiality and Privacy/Educational Tools/Finding Affirming Care|Arm 12 will be given access to interventions 2, 3, and 4. Video and text content will focus on confidentiality, education about identity, and determine if caregivers are affirming.
88955942|NCT06083987|Experimental|Interventions 2 and 4 - Confidentiality and Privacy/Finding Affirming Care|Arm 13 will be given access to interventions 1, 3, and 4. Video and text content will focus on confidentiality and determining if caregivers are affirming.
88955943|NCT06083987|Experimental|Intervention 3 - Educational Tools|Arm 14 will be given access to intervention 3. Video and text content will focus on education about identity
88955944|NCT06083987|Experimental|Interventions 3 and 4 - Educational Tools/Finding Affirming Care|Arm 15 will be given access to interventions 3 and 4. Video and text content will focus on educational tools about identity and determining if caregivers are affirming.
88955945|NCT06083987|Experimental|Intervention 4 - Finding Affirming Care|Arm 16 will be given access to intervention 4, with video and text content focusing on determining if caregivers are affirming.
88955946|NCT06082960|Experimental|Part A: GS-9911 Monotherapy Dose Escalation|Participants will receive escalating doses of GS-9911 monotherapy.
88955947|NCT06082960|Experimental|Part B: GS-9911 Monotherapy Dose Expansion|Participants will receive GS-9911 monotherapy at the recommended dose for expansion (RDE) determined in Part A.
88955948|NCT06082960|Experimental|Part C: Dose Escalation: GS-9911 + Anti-PD-1 Monoclonal Antibody|Participants will receive escalating doses of GS-9911 in combination with an anti-PD-1 monoclonal antibody (zimberelimab).
89500032|NCT05977400|Active Comparator|Very preterm infants that receive empiric antibiotic treatment in the first 48 hours of life|Neonates in this group will have been enrolled and randomized into the NANO trial and received a blinded 48 hour course of empiric antibiotic treatment.
89500033|NCT05977400|Placebo Comparator|Very preterm infants that do not receive empiric antibiotic treatment in the first 48 hours of life|Neonates in this group will have been enrolled and randomized into the NANO trial and received a blinded 48 hour course of placebo.
89500034|NCT05977374|Experimental|elliptical training group.|In this group, Ultrasound 1MHz, 1.5W/cm2 7 mins, knee isometrics, and open chain activities. static stretching of the lower limbs will be given 10 reps each and held for 10 secs. 5 mins of warm-up activity on elliptical training will be given prior to the treatment group. then 3 mins of training with a set pace of 120 strides/min will start, then after 7 weeks, the timings will be increased to 5 mins. The base check-up will be conducted during 7 weeks and at the end of 12 weeks.
89500035|NCT05977374|Other|Conventional treatment group|Static stretching of the lower limbs as mentioned above, Ultrasound 1MHz 1.5W/cm2 7min, knee isometrics, open chain activities, anterior-posterior Maitland knee mobilizations grade 1 and 2, and home care plan.
89500036|NCT05977309|Experimental|Effect of Topical Ozone on The Healing Diabetic Foot Ulcer|The topical ozone therapy group received standard wound care with modern dressings every three days for thirty days.
89500037|NCT05977309|Placebo Comparator|Effect of Standart Wound Care on The Healing Diabetic Foot Ulcer|The placebo group received standard wound care with modern dressings thrice weekly for thirty days.
89500038|NCT05977296|Experimental|OSA patients|The experimental group in this study consisted of individuals who were assigned to the CPAP (Continuous Positive Airway Pressure) intervention. Participants in the experimental group were instructed to wear a CPAP device during their sleep.
89500039|NCT05977296|No Intervention|Usual group|In the control group, participants received standard or routine nursing care without any specific interventions(CPAP) or modifications. The standard nursing care provided to the participants followed established protocols and guidelines commonly practiced in general healthcare settings.
89500040|NCT05977257||Non Interventional long term safety follow up|Non Interventional long term safety follow up
89500041|NCT05977244|Experimental|HGI+palm olein|1 portion of HGI(high glycemic index) fried rice, fried with palm olein will be served together with 250 milliliter of plain water.
89500042|NCT05977244|Experimental|HGI+soy bean oil|1 portion of HGI (high glycemic index) fried rice, fried with soybean oil will be served together with 250 milliliter of plain water.
88955949|NCT06082960|Experimental|Part D: Dose Expansion: GS-9911 + Anti-PD-1 Monoclonal Antibody|Participants will receive GS-9911 at RDE determined in Part C in combination with an anti-PD-1 monoclonal antibody (zimberelimab).
89023401|NCT05522075|Active Comparator|Non-exercise Group|Binge drinkers who have been assigned to non-exercise group will receive baseline assessment, 8-week alcohol abstinence intervention, and post-intervention assessment.
89538366|NCT03269201||DYSTONIA-focal, generalized and others|"Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis. Additionally patients will be rated using MoCA, FAB, Verbal Fluency, - Beck Depression Inventory, Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis. Additionally patients will be rated using MoCA, FAB, Verbal Fluency, - Beck Depression Inventory, PDQ-39, PD sleep scale (PDSS), MDS-UPDRS.SF-EMG and KinesiaOne and motion sensor assessment for tremor.Fahn-Marsden Evaluation Scale for Dystonia~.SF-EMG and KinesiaOne and motion sensor assessment , writing and drawing on digitizer,for dystonia"
89538367|NCT03269201||Cerebellar ataxia|Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis. Additionally patients will be rated using MoCA, FAB, Verbal Fluency,Scale for the assessment and rating of ataxia (SARA), International Cooperative Ataxia Rating Scale . TIMED UP AND GO TASK (INSTRUMENTAL)
89538368|NCT03269201||Progressive supranuclear palsy|Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis. Additionally patients will be rated using MoCA, FAB, Verbal Fluency, - Beck Depression Inventory, PDQ-39, PD sleep scale (PDSS), MDS-UPDRS.SF-EMG and KinesiaOne and motion sensor assessment for tremor.
89538369|NCT03269201||Corticobasal degeneration|Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis. Additionally patients will be rated using MoCA, FAB, Verbal Fluency, - Beck Depression Inventory, PDQ-39, PD sleep scale (PDSS), MDS-UPDRS.SF-EMG and KinesiaOne and motion sensor assessment for tremor.
89538370|NCT03269201||Dementia with Lewy Bodies|Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis. Additionally patients will be rated using MoCA, FAB, Verbal Fluency, - Beck Depression Inventory, PDQ-39, PD sleep scale (PDSS), MDS-UPDRS.SF-EMG and KinesiaOne and motion sensor assessment for tremor.
89538371|NCT03278795|Active Comparator|PSV mode|PSV weaning group
89538372|NCT03278795|Experimental|VSV mode|VSV weaning group
89538373|NCT03269045|Other|Treatment with ORL-1B.|Pediatric patients with biotinidase deficiency.
89538374|NCT03269279|Experimental|Medical abortion arm|200mg of Mifepristone and repeat doses of 400mcg of misoprostol every 3 hours administered for medical abortion in 2nd trimester
89538375|NCT03278483|Active Comparator|Isoniazid|Diabetic patients with a positive TST of >10mm, will be randomly assigned to receive treatment with isoniazid 300mg Oral Tablet daily plus pyridoxine 50mg daily for six months
88955952|NCT06080828|Experimental|study group (SG)|they will receive treatment with 20 minutes of neuromodulation of the posterior tibial nerve of both lower limbs using Physio Go-lite electrical stimulation device (made by ASTAR, ver 1.0.2 in Poland). Using TENS current in the device, the positive electrode will be placed posterior to the medial ankle malleolus, and the negative electrode will placed ten centimeters away on the leg along the tibial nerve path. The TENS current parameters will be 200 micro second pulse width, 10 Hz frequency, and intensity according to participant tolerance ranging between (10 - 50 mA) that increased gradually until visible movement in the big toe or fanning of toes will be noticed. The therapy sessions will be given three times a week, every other day, for a total of twelve sessions. Alos, they will receive leaflet with information for home instructions on how to properly walk, sleep, maintain good posture, and deal with activities of daily living.
89538376|NCT03278483|Active Comparator|Rifampin|Diabetic patients with a positive TST of >10mm, who wil be randomly assigned to receive treatment with rifampin 600mg Oral Tablets daily for three months
89538377|NCT03277937|Experimental|Patients with gastric varices|Patients above 18 years old with gastric varices (GV) on the initial standard diagnostic upper endoscopy will be enrolled and treated using angiography in EUS-injection of coils + CYA. GV will be classified according to Sarin and Kumar classification. Only gastro-esophageal varices type II (GOV II) (fundal varices communicating with esophageal varices) and isolated gastric varices type I (IGV I) (fundal varices within a few centimeters of the gastric cardia) will be included. Gastro-esophageal varices type I (GOV I) will be excluded. Patients with active bleeding and history of previous bleeding due to GV (secondary prophylaxis) will be included as well as patients with high-risk GV suitable for primary prophylaxis according to Baveno VI consensus. T
89538378|NCT03268733|Experimental|Treatment group|45 PCOS patients will receive 5 mg folic acid
89538379|NCT03268733|No Intervention|control group|45 PCOS patients will receive no folic acid
89538380|NCT03268889|Experimental|treatment group|In this arm, patients would be given the regimen composed of Chidamide, Cyclophosphamide, epirubicin, Vincristine and Prednisone.
89538381|NCT03268967|Active Comparator|Structured Admission procedure|After implementation of a structured admission procedure to all ICU patients inspired by principles of Crisis Resource Management, Closed loop communication, action cards, and staff simulation training
89538382|NCT03268967|No Intervention|Standard Care|Randomly admission procedure to all ICU patients based on the clinicians' evaluation prior implementation of the intervention.
89538383|NCT03277391|Active Comparator|Serratus anterior plane block|Deep serratus anterior plane block
89538384|NCT03277391|Active Comparator|patient-controlled analgesia|patient-controlled analgesia: pump containing morphine (1mg/ml) and dehydrobenzperidol (50 mcg/ml).
89538385|NCT02458391|Experimental|Treatment 2x/wk|Participants will receive standard of care complete decongestive therapy 2x/wk for 4 weeks.
89538386|NCT02458391|Experimental|Treatment 4x/wk|Participants will receive standard of care complete decongestive therapy 4x/wk for 4 weeks.
88955953|NCT06080828|Placebo Comparator|control group (CG)|They will receive placebo neuromodulation of the posterior tibial nerve in both lower limbs, much as those in the research group. Alos, they will receive leaflet with information for home instructions on how to properly walk, sleep, maintain good posture, and deal with activities of daily living.
89500043|NCT05977244|Experimental|LGI+palm olein|1 portion of LGI (low glycemic index) fried rice, fried with palm olein will be served together with 250 milliliter of plain water.
89500044|NCT05977244|Experimental|LGI+soy bean oil|1 portion of LGI (low glycemic index) fried rice, fried with soybean oil will be served together with 250 milliliter of plain water.
88955955|NCT06063421|Active Comparator|Nicotine Replacement Therapy (NRT)|The arm will comprise participants that receive NRT. The NRT used will be combination therapy; transdermal Nicotine patches will be combined with faster-acting oral products like gum or lozenges. The strength of nicotine patches will be from 7 to 21 mg, and for gum or lozenges, the strength will be 1-4 mg. Usage will be in the form of a daily nicotine patch and ad libitum use of the faster-acting lozenge to curb nicotine cravings. Participants will be provided with a 12-week supply of NRT.
89500045|NCT05977231||Bladder training (BT)|Data obtained before and after the training.
89500046|NCT05977231||biofeedback-assisted pelvic floor muscle training (bPFMT)|Data obtained before and after the training.
89500047|NCT05977231||intra-vaginal electric stimulation (iVES)|Data obtained before and after the training.
89500048|NCT05977231||BT+bPFMT|Data obtained before and after the training.
89500049|NCT05977231||BT+iVES|Data obtained before and after the training.
89500050|NCT05977231||bPFMT+iVES|Data obtained before and after the training.
89500051|NCT05977218|Experimental|Intervention|Access to the 'DiabetesSwitch' filter of the FoodSwitch app when food shopping during 26 weeks.
89500052|NCT05977218|No Intervention|Control|Access to written dietary advice during 26 weeks.
89500053|NCT05977205||Type 1 Diabetes|280 patients with type 1 diabetes
89500054|NCT05977205||Type 2 Diabetes|155 patients with type 2 diabetes
89500055|NCT05977205||Type 1 Diabetes with Islet or Pancreas Transplantation|23 patients with islet transplantation, 7 with pancreas transplantation, 27 with simultaneous pancreas-kidney transplantation
89500056|NCT05977166|Active Comparator|hyperbaric oxygen therapy ,breathing exercise,medical treatment|Hyperbaric oxygen treatment HBO treatment was given daily in the morning on 21 consecutive days. (HBOT) treatment is a procedure performed inside a pressured chamber (the Hyperbaric Chamber). The patient is place inside the chamber exposure to 100% oxygen at 2 ATA with 5 min air breaks every 20 min. Each session consisted of 60 min. Measurements will be taken in the morning before entering, the first and last session.
89531851|NCT05081934|Active Comparator|Treatment as usual, TAU|TAU: Interventions and treatments usually offered and delivered in institutional care. For example, Motivational Interviewing, MI, Cognitive Behavioral Therapy, CBT, Aggression Replacement Therapy, ART or Acceptance and Commitment Therapy, ACT. Further specification of TAU will be made in collaboration with the institutions included in the trial.
89205668|NCT03718260|Experimental|Cohort 5|Men who have prior PSMA directed treatment for oligometastatic disease, such as lesion directed therapy (e.g. stereotactic radiosurgery) or systemic therapy (e.g. hormone therapy or chemotherapy) with subsequent biochemical failure will be restaged with [18F]-DCFPyL PET/ CT scan (PSMA PET)
89205669|NCT03718260|Experimental|Cohort 6|Men with biochemical failure after primary radiation therapy (external beam, brachytherapy or combinations together with or without hormone therapy) will be restaged with [18F]-DCFPyL PET/ CT scan (PSMA PET)
89205670|NCT03718260|Experimental|Cohort 7|[18F]-DCFPyL as a problem-solving tool in patients with prostate cancer when confirmation of the site of disease and/or disease extent may impact clinical management. Patients in this cohort require approval from an independent adjudication by Cancer Care Ontario.
89205671|NCT03621982|Experimental|Part 1: Dose Escalation, ADCT-301 Monotherapy|In Part 1 (dose escalation) patients will receive escalating doses of ADCT-301 as monotherapy.
89205672|NCT03621982|Experimental|Part 1: Dose Escalation, ADCT-301 Combination Therapy|In Part 1 (dose escalation) patients will receive escalating doses of ADCT-301 in combination with pembrolizamab as combination therapy.
89205673|NCT03621982|Experimental|Part 2: Dose expansion, ADCT-301 Combination Therapy|"In Part 2 (dose expansion), patients will receive ADCT-301 in combination with pembrolizamab as combination therapy at the dose identified in Part 1 (dose escalation). Patients will be split into two groups:~Group 1: One of the indications identified in Part 1, for which at least 1 response (PR [partial response] or CR [complete response]) was seen.~Group 2: A basket group of patients with advanced/metastatic solid tumors and microsatellite instability/deficient MisMatch Repair (MSI-H/dMMR) status, who have received prior regimen containing a PD-1/PD-L1 inhibitor, for which the best response was CR, PR, or SD (stable disease) ≥4 months, and then progressed while continuing on the PD-1/PD-L1 inhibitor-based regimen."
89205674|NCT03612648|Experimental|TRI-APBI|"Brachytherapy TRI-APBI the PTV is prescribed 7.5 Gy x three fractions given over two to three days OR~External beam TRI-APBI the PTV is prescribed 8.5 Gy x three fractions given over two to three days"
89205675|NCT03608163|No Intervention|No intervention (Susceptibility to HAAF evaluation)|Susceptibility to HAAF evaluation: No intervention medication will be given during episodes of hypoglycemia.
89205676|NCT03608163|Experimental|Naloxone|Naloxone evaluation: Intranasal naloxone (4 mg NARCAN Nasal Spray) via a nostril twice during the first hypoglycemia episode; once at the start of insulin administration and again after one hour. Intranasal naloxone (4 mg NARCAN Nasal Spray) will again be given via a nostril twice during the second period of hypoglycemia; once at the start of insulin administration and again after one hour.
89205677|NCT03608163|Placebo Comparator|Placebo (for Naloxone)|Naloxone evaluation: Placebo (for naloxone) nasal spray via a nostril twice during the first hypoglycemia episode; once at the start of insulin administration and again after one hour. Placebo (for naloxone) nasal spray will again be given via a nostril twice during the second period of hypoglycemia; once at the start of insulin administration and again after one hour.
89205678|NCT03608163|Experimental|Naloxone + diazoxide|Naloxone/Diazoxide evaluation: Up to 7 mg/kg oral diazoxide 3 hours before the first hypoglycemic episode. Intranasal naloxone (4 mg NARCAN Nasal Spray) via a nostril twice during the first hypoglycemia episode; once at the start of insulin administration and again after one hour. Intranasal naloxone (4 mg NARCAN Nasal Spray) will again be given via a nostril twice during the second period of hypoglycemia; once at the start of insulin administration and again after one hour.
89205679|NCT03608163|Active Comparator|Diazoxide + placebo (for naloxone)|Naloxone/Diazoxide evaluation: Up to 7 mg/kg oral diazoxide 3 hours before the first hypoglycemic episode. Placebo (for naloxone) nasal spray via a nostril twice during the first hypoglycemia episode; once at the start of insulin administration and again after one hour. Placebo (for naloxone) nasal spray will again be given via a nostril twice during the second period of hypoglycemia; once at the start of insulin administration and again after one hour.
89205680|NCT03608163|Active Comparator|Naloxone + placebo (for diazoxide)|Naloxone/Diazoxide evaluation: Oral placebo (for diazoxide) 3 hours before the first hypoglycemic episode. Intranasal naloxone (4 mg NARCAN Nasal Spray) via a nostril twice during the first hypoglycemia episode; once at the start of insulin administration and again after one hour. Intranasal naloxone (4 mg NARCAN Nasal Spray) will again be given via a nostril twice during the second period of hypoglycemia; once at the start of insulin administration and again after one hour.
89205681|NCT03608163|Placebo Comparator|Placebo (for naloxone) + placebo (for diazoxide)|Naloxone/Diazoxide evaluation: Oral placebo (for diazoxide) 3 hours before the first hypoglycemic episode. Placebo (for naloxone) nasal spray via a nostril twice during the first hypoglycemia episode; once at the start of insulin administration and again after one hour. Placebo (for naloxone) nasal spray will again be given via a nostril twice during the second period of hypoglycemia; once at the start of insulin administration and again after one hour.
89205682|NCT03604445|Experimental|BI 905677 0.05 mg/kg|0.05 milligrams (mg) per kilogram (kg) solution for infusion BI 905677 were administered intravenously on Day 1 of each 3-week treatment cycle. Patients may continue on treatment for unlimited cycles, until disease progression or other criteria for stopping treatment are met.
89205683|NCT03604445|Experimental|BI 905677 0.1 mg/kg|0.1 milligrams (mg) per kilogram (kg) solution for infusion BI 905677 were administered intravenously on Day 1 of each 3-week treatment cycle. Patients may continue on treatment for unlimited cycles, until disease progression or other criteria for stopping treatment are met.
89205684|NCT03604445|Experimental|BI 905677 0.2 mg/kg|0.2 milligrams (mg) per kilogram (kg) solution for infusion BI 905677 were administered intravenously on Day 1 of each 3-week treatment cycle. Patients may continue on treatment for unlimited cycles, until disease progression or other criteria for stopping treatment are met.
89205685|NCT03604445|Experimental|BI 905677 0.4 mg/kg|0.4 milligrams (mg) per kilogram (kg) solution for infusion BI 905677 were administered intravenously on Day 1 of each 3-week treatment cycle. Patients may continue on treatment for unlimited cycles, until disease progression or other criteria for stopping treatment are met.
89205686|NCT03604445|Experimental|BI 905677 0.8 mg/kg|0.8 milligrams (mg) per kilogram (kg) solution for infusion BI 905677 were administered intravenously on Day 1 of each 3-week treatment cycle. Patients may continue on treatment for unlimited cycles, until disease progression or other criteria for stopping treatment are met.
89538387|NCT03277001|Active Comparator|Enoxaparin|AECOPD patients meeting the eligibility criterion by GOLD2017 in hospitalization Padua score > 4
88955956|NCT06063421|Experimental|Electronic Cigarettes (EC)|Participants randomised to the EC group will be supplied with an EC starter kit. The kit will consist of a personal vaping device with an integrated battery. Three commonly used flavours of e-liquid (tobacco, menthol, and fruit flavours) will be provided. All e-liquids will have a nicotine concentration of 18-20 mg/ml. EC will be provided for a total of 12 weeks.
89500057|NCT05977166|Active Comparator|breathing exercise and medical treatment|"breathing exercise completely each session of three repetitions initially. Every repetition consisted of one round of intervention 10-15 times followed by a brief rest (normal breathing) of <1 min (one repetition). Such 3 repetitions were given initially & advanced till 10 repetitions (one session) by last day of the week. In this manner participants practised 3 sessions twice a day, for a total duration of about 10-20 min every day.Vitamin D: The recommended dietary dose of vitamin D is 600 IU each day .~Vitamine C: The recommended dietary dose 200 mg/day vitamin C. Anticoagulation drugs (blood thinners), doctors usually prescribe low-molecular-weight heparin (enoxaparin) (30 mg), each given subcutaneously every 12 hours"
89500058|NCT05977153|Active Comparator|Group 1: ARDSNet|Participants will receive standard ARDSNet low-stretch PEEP (positive end-expiratory pressure) protocol.
89500059|NCT05977153|Experimental|Group 2: Individualized PEEP (positive end expiratory pressure) Strategy|Participants will receive individualized PEEP (positive end-expiratory pressure).
89500060|NCT05977101|Experimental|MY-586 SARS-CoV-2 Neutralizing Antibody nasal spray|Specifications: 5mg/mL, 5mL/ bottle; Provided by Chongqing Mingdao Haoyue Biotechnology Co., LTD
89500061|NCT05977101|Placebo Comparator|MY-586 SARS-CoV-2 Neutralization Antibody nasal excipient|Specifications: 0mg/mL, 5mL/ bottle; Provided by Chongqing Mingdao Haoyue Biotechnology Co., LTD
89500062|NCT05977075|Experimental|"ApisMela/Unstuck Group"|Six children belonging to the experimental group. ApisMela training teaches to focus on the purpose of the task, check that you understand it, and make explicit the procedures to be implemented. Being a crossover clinical trial, the group ending with the ApisMela protocol continues with the Ustuck protocol.
89500063|NCT05977075|Experimental|"Unstuck/ApisMela Group"|Six children belonging to the experimental group. Unstuck protocol teaches people to be more flexible, skillful in planning and goal-oriented. Being a crossover clinical trial, the group ending with the Unstuck protocol continues with the ApisMela protocol.
89500064|NCT05977062|Other|Coaching arm|
89500065|NCT05976997|Experimental|Duvelisib-Chidamide|Patients with newly diagnosed PTCL were treated with a combination of Duvelisib and Chidamide. The dose of Duvelisib was 25mg twice a day. Every 4 weeks (28 days) is a cycle with a total of 2 cycles.
89500066|NCT05976932||treatment group|After enrollment, patients will receive standard treatment (pegylated liposomal doxorubicin) and follow-up strategy. Peripheral blood samples will be collected from all patients before treatment and 3 weeks after the first cycle of treatment，If necessary, Peripheral blood samples also be collected after 2 cycles of treatment.
89500067|NCT05976906|Experimental|CNK-UT cells therapy|"Dose Escalation： Cohort A：Intravenous injection of CNK-UT cells directly. Cohort B：Intravenous injection of CNK-UT cells after preconditioning by fludarabine and cyclophosphamide.~Indications Expansion:~Intravenous injection of CNK-UT cells according to the results of dose escalation."
89500068|NCT05976893|Experimental|the PCSK9 inhibitor plus statin therapy|Patients with very high risk of ASCVD and cancer are treated with moderate intensity statin daily and evolocumab (420 mg) every 4 weeks throughout the study period.
89500069|NCT05976893|Other|the statin alone therapy|Patients with very high risk of ASCVD and cancer are treated with moderate intensity statin daily throughout the study period.
89500070|NCT05976802|Experimental|High dose budesonide rectal foam|
89500071|NCT05976802|Experimental|Low dose budesonide rectal foam|
89500072|NCT05976802|Placebo Comparator|Matching placebo rectal foam|
89500073|NCT05976789|Experimental|HAT-Online Counseling|In Aim 1, the investigators will provide remote counseling for four weeks to 60 participants and compare results to baseline. All participants will be in a wait list control for four weeks before the counseling begins.
89500074|NCT05976789|Experimental|Sound therapy|In Aim 2, the investigators will randomize the 60 participants to receive intervention using one of the two sound therapy approaches. Group 1: Listening to bothersome sounds or Group 2: Listening to low-level background noise.
89500075|NCT05976776|Experimental|Experimental group|The Childbirth and Parenthood Preparation Education program
89500076|NCT05976776|No Intervention|Control group|No intervention
89500077|NCT05976737|Experimental|Fasting state|In this trial, 32 healthy subjects are planned to be enrolled in fasting. According to the randomization table, subjects will be randomly assigned to one of the two groups (Group A: TRTR, Group B: RTRT). The washout period (dosing interval) between doses will be at least 5 days. After fasting for at least 10 hours, subjects were given either the test formulation (T) Entacapone, Levodopa and Carbidopa Tablets (II) or the reference formulation (R) Entacapone,Levodopa and Carbidopa Tablets (II) in 240 milliliter (mL) of warm water. 1 tablet 100mg/25mg/200mg orally per cycle.
89500078|NCT05976737|Experimental|Fed state|In this trial, 36 healthy subjects are planned to be enrolled in postprandial. According to the randomization table, subjects will be randomly assigned to one of the two groups (Group A: TRTR, Group B: RTRT). The washout period (dosing interval) between doses will be at least 5 days. After fasting for at least 10 hours, subjects were given a high-fat, high-calorie meal 30 minutes prior to dosing, which was completed within 30 minutes. 30 minutes after the start of the meal, the test formulation (T) Entacapone,Levodopa and Carbidopa Tablets (II) or the reference formulation (R)Entacapone,Levodopa and Carbidopa Tablets (II) were administered in 240 milliliter of warm water. Take 1 tablet 100mg/25mg/200mg orally per cycle.
89500079|NCT05976672|No Intervention|Treatment as usual|Participants will receive standard of care treatment as usual and will receive no contact from a peer recover support specialist (PRSS intervention) when data anomalies are detected by machine learning algorithms.
89500080|NCT05976672|Experimental|PRSS intervention|Participants receiving PRSS intervention will be contacted by the PRSS who will be blinded (not knowing whether an alert was caused by data anomaly or a random generation), and will contact the participant by phone and assess the need for assistance. PRSS will follow-up with the participant to assist participant if needed (once after the initial alert and then a second follow-up).
89538388|NCT03277001|Experimental|Rivaroxaban|AECOPD patients meeting the eligibility criterion by GOLD2017 in hospitalization Padua score > 4
89500081|NCT05976659|Experimental|tDCS prefrontal cortex + tASC angular gyrus in MDD in the context of AD|Participants will undergo 20 sessions of home-based tDCS over the prefrontal cortex and tACS over the left angular gyrus.These sessions will take place five times a week for four weeks, with one daily stimulation session of no more than 20 minutes. The participant's home will be the setting for the completion of the brain stimulation intervention, which will be delivered by trained caregivers/study companions/administrators.
89205687|NCT03604445|Experimental|BI 905677 1.6 mg/kg|1.6 milligrams (mg) per kilogram (kg) solution for infusion BI 905677 were administered intravenously on Day 1 of each 3-week treatment cycle. Patients may continue on treatment for unlimited cycles, until disease progression or other criteria for stopping treatment are met.
89205688|NCT03604445|Experimental|BI 905677 2.4 mg/kg|2.4 milligrams (mg) per kilogram (kg) solution for infusion BI 905677 were administered intravenously on Day 1 of each 3-week treatment cycle. Patients may continue on treatment for unlimited cycles, until disease progression or other criteria for stopping treatment are met.
89205689|NCT03604445|Experimental|BI 905677 2.8 mg/kg|2.8 milligrams (mg) per kilogram (kg) solution for infusion BI 905677 were administered intravenously on Day 1 of each 3-week treatment cycle. Patients may continue on treatment for unlimited cycles, until disease progression or other criteria for stopping treatment are met.
89205690|NCT03604445|Experimental|BI 905677 3.6 mg/kg|3.6 milligrams (mg) per kilogram (kg) solution for infusion BI 905677 were administered intravenously on Day 1 of each 3-week treatment cycle. Patients may continue on treatment for unlimited cycles, until disease progression or other criteria for stopping treatment are met.
89205691|NCT03573700|Experimental|SJCAR19 Therapy|"Patients in both the Phase I and Phase II portion of the study will receive lymphodepleting chemotherapy (unless determined by PI that lymphodepletion is not necessary), followed by a single infusion of the patient-derived SJCAR19 cellular product. The most commonly used lymphodepleting chemotherapy regimen will consist of the agents: Fludarabine and Cyclophosphamide. They will also receive Mesna. Dosing of SJCAR19 on the Phase I study will follow a dose escalation schema, with dose changes based on dose-limiting toxicities. In the Phase II study, SJCAR19 dosing with follow the maximum tolerated dose, as determined in the Phase I portion.~Cells for infusion are prepared using the CliniMACS System."
89205692|NCT03567837|Active Comparator|Obese Metabolically Healthy|Intervention: Oral challenge of Fructose+Glucose Beverage 1:1, 3g/kg
89205693|NCT03567837|Experimental|Obese Pre-diabetes|Intervention: Oral challenge of Fructose+Glucose Beverage 1:1, 3g/kg
89205694|NCT03539848|Experimental|Subjects with mTBI|Individuals who come to the emergency department or urgent/acute care facility with an mTBI will undergo testing with the I-PAS Goggles.
89205695|NCT03539848|Active Comparator|Subjects with minor injuries|Individuals who come to the emergency department or urgent/acute care facility with minor injuries (such as ankle sprains or knee sprains) will undergo testing with the I-PAS Goggles.
89205696|NCT03530371|Experimental|Dexmedetomidine Hydrochloride|sedation of patients to perform auditory test
89205697|NCT03489122|Experimental|Iyengar yoga and coherent breathing|The yoga intervention consists of Iyengar yoga method and coherent breathing sessions for 90 minutes twice a week or a maximum of 24 interventions over the 12 week intervention.
89205698|NCT03489122|Active Comparator|Walking|The walking intervention consists of walking sessions at 2.5 miles an hour on a flat surface for 60 minutes twice a week or a maximum of 24 interventions over the 12 week intervention.
89205699|NCT03456934|Experimental|Experimental Group|Modified infant formula given from 3 to 12 months of age, as per standard requirement.
89205700|NCT03456934|Active Comparator|Control Group|Standard infant formula given from 3 to 12 months of age, as per standard requirement.
89205701|NCT03456934|No Intervention|Breast-fed Reference Group|Non-randomized infants who are predominantly breast-fed at time of enrollment.
89205702|NCT03433417|Experimental|Treatment Side|One truSculpt treatment
89205703|NCT03433417|No Intervention|Control Side|Untreated contralateral control
89205704|NCT03418649|Experimental|Experimental|Eplerenone 50 Mg Tab
89205705|NCT03418649|Placebo Comparator|Control|Placebo Oral Tablet
89205706|NCT03327441|Experimental|Almonds|
89205707|NCT03327441|Active Comparator|Omelette|
89205708|NCT03326141|Active Comparator|Otago+PAM+Health / Wellness topics|"Condition 1:~Otago Exercise Program adapted for delivery to small groups; a physical activity monitor such as a Fitbit (PAM); and, information about health and wellness (8) topics guided by content in the National Institute on Aging (NIA) and Centers for Disease Control and Prevention websites."
89205709|NCT03326141|Experimental|Otago + PAM + Interpersonal strategies|"Condition 2:~Otago Exercise Program adapted for delivery to small groups; a PAM (e.g.,Fitbit); 5 Interpersonal behavior change strategies; and, information about health and wellness topics (1) guided by content in the National Institute on Aging (NIA) and Centers for Disease Control and Prevention websites."
89205710|NCT03326141|Experimental|Otago, PAM, Intrapersonal strategies|"Condition 3:~Otago Exercise Program adapted for delivery to small groups; a PAM (e.g.,Fitbit); 5 Intrapersonal behavior change strategies; and, health and wellness topics (1) guided by content in the National Institute on Aging (NIA) and Centers for Disease Control and Prevention websites."
89205711|NCT03326141|Experimental|Otago,PAM, Inter+Intra strategies|"Condition 4:~Otago Exercise Program adapted for delivery to small groups; a PAM (e.g., Fitbit); 5 Interpersonal behavior change strategies; and, 5 Intrapersonal behavior change strategies"
89205712|NCT03315832|Experimental|Valsartan|The active treatment is valsartan, an orally active, potent, and specific angiotensin II receptor antagonist. The treatment will be initiated (80 mg, daily) at 5±4 days following aortic valve intervention. The dose will be increased at 160 mg daily 13±2 days after aortic valve intervention and, if well tolerated, for the remaining period of the study.
89500082|NCT05976568|Experimental|Arm 1|QL1706 in combination with bevacizumab and chemotherapy
89500083|NCT05976568|Experimental|Arm 2|QL1706 in combination with bevacizumab
89500084|NCT05976568|Experimental|Arm 3|QL1706 in combination with chemotherapy
89500085|NCT05976568|Active Comparator|Arm 4|Sintilimab in combination with bevacizumab
89500086|NCT05976516||pirffmann 2 grade|
89500087|NCT05976516||pirffmann 3 grade|
89500088|NCT05976516||pirffmann 4 grade|
89500089|NCT05976516||pirffmann 5 grade|
89500090|NCT05976503|Experimental|Tunodafil Hydrochloride plus alcohol|Participants received 100 mg Tunodafil Hydrochloride Tablets plus 0.5 g/kg alcohol.
89500091|NCT05976503|Experimental|Placebo plus alcohol|Participants received placebo plus 0.5 g/kg alcohol.
89023402|NCT05522075|No Intervention|Alcohol abstainer/moderate drinker group|Alcohol abstainer/moderate drinker will complete baseline assessment only and will not receive any intervention.
89500092|NCT05976503|Experimental|Tunodafil Hydrochloride|Participants received 100mg Tunodafil Hydrochloride Tablets.
89500093|NCT05976438|Other|Open label arm 1|Participants will be randomised to AB sequence of drugs A: 1 to 2 weeks of Amlodipine 5mg followed by 6 to 7 weeks of Amlodipine 10mg B: Approximately 8 weeks of 25mg Chlortalidone
89500094|NCT05976438|Other|Open label arm 2|Participants will be randomised to BA sequence of drugs B: Approximately 8 weeks of 25mg Chlortalidone A: 1 to 2 weeks of Amlodipine 5mg followed by 6 to 7 weeks of Amlodipine 10mg
89500095|NCT05976425|Experimental|Blood pressure readings|Using the data acquisition software provided, a reading for the subject will be started. The tool will automatically record the pre invasive blood pressure readings, then take the NIBP measurement with the device under test, and it will follow up with a post invasive blood pressure reading.
89500096|NCT05976386|Experimental|New dupilumab product|A single subcutaneous injection on Day 1
89500097|NCT05976386|Active Comparator|Current dupilumab product|A single subcutaneous injection on Day 1
89500098|NCT05976373|Active Comparator|Dupilumab drug product 1|A single subcutaneous injection on Day 1
89500099|NCT05976373|Experimental|Dupilumab drug product 2|A single subcutaneous injection on Day 1
89500100|NCT05976360|Active Comparator|Dupilumab drug product 1|A single subcutaneous injection on Day 1
89500101|NCT05976360|Experimental|Dupilumab drug product 2|A single subcutaneous injection on Day 1
89500102|NCT05976282|Experimental|FIT Group|Participants aged 40-65 years will receive the self-administered FIT test by mail including instructions for obtaining and returning their stool specimens. Participants will be in this group for up to 6 months.
89500103|NCT05976282|Experimental|Septin9 Test Group|Participants aged 50-65 years who declined the initial offer of FIT, will complete a 10-15 minute questionnaire about their personal health, quality of life, and health-related to colorectal cancer including screening history and smoking. Participants will be in this group for up to 6 months.
89500104|NCT05976269|Experimental|Bilateral Patellofemoral Pain with Fear of Movement|The first group will consist of 20 subjects presenting with bilateral chronic anterior knee pain and high fear of movement with scores on Tampa Kinesiophobia Scale (fear of movement) greater than 37.
89500105|NCT05976269|Experimental|Bilateral Patellofemoral Pain with Low Fear of Movement|The second group with consist of 20 subjects with bilateral chronic anterior knee pain and low fear of movement between ages of 18 and 40 years old.
89500106|NCT05976269|Active Comparator|Healthy controls without knee pain|The third group will consist of healthy controls without knee pain between 18 and 40 years old.
89500107|NCT05976256|Active Comparator|Kinesiotape|Patients receives the additional treatment with kinesiotaping (and also standard treament)
89500108|NCT05976256|Sham Comparator|sham tape|patient receives an additional treatment with sham tape (without elastic features) (and also standard treatment)
89500109|NCT05976256|No Intervention|control group|patient receives the standard treamtment without additional tape treatment
89500110|NCT05976191|Experimental|experimental group|Patients whose blood glucose is measured intravenously and from the fingertip
89500111|NCT05976191|No Intervention|control group|Patients with fingertip blood glucose measurement
89500112|NCT05976152|Experimental|dl-3-butylphthalide|Routine treatment and dl-3-butylphthalide
89500113|NCT05976152|Placebo Comparator|dl-3-butylphthalide Placebo|Routine treatment and dl-3-butylphthalide Placebo
89500114|NCT05976126||High environmental pollution group (HIGH)|subjects living in area characterized by high environmental pollution, as defined by Pizzolante et al. [Development of a municipality index of environmental pressure in Campania, Italy. Future Sci. OA 7(7), FSO720 (2021).]
89500115|NCT05976126||Medium environmental pollution group (MEDIUM)|subjects living in area characterized by medium environmental pollution, as defined by Pizzolante et al. [Development of a municipality index of environmental pressure in Campania, Italy. Future Sci. OA 7(7), FSO720 (2021).]
89500116|NCT05976126||Low environmental pollution group (LOW)|subjects living in area characterized by low environmental pollution, as defined by Pizzolante et al. [Development of a municipality index of environmental pressure in Campania, Italy. Future Sci. OA 7(7), FSO720 (2021).]
89500117|NCT05976113||Patients with multiple classifier endometrial cancer|Endometrial cancer patients who have two or more molecular features
89500118|NCT05976100|Experimental|Group 1 (15 volunteers)|"Single use:~Single 200-mg oral dose of NIOCH-14"
89500119|NCT05976100|Experimental|Group 2 (15 volunteers)|"Single use:~Single 600-mg oral dose of NIOCH-14"
89205713|NCT03315832|Placebo Comparator|Placebo Oral Tablet|The comparative treatment will be a placebo; tablets of valsartan and placebo have a similar appearance and administration mode. Patient in the control group will receive a placebo using the same protocol as the valsartan group.
89023403|NCT05511246|Active Comparator|Control|Endocardial radiofrequency ablation of ventricular tachycardia
89023404|NCT05511246|Experimental|Venous ethanol|Endocardial radiofrequency ablation of ventricular tachycardia combined with venous ethanol ablation of the tachycardia substrate
89205714|NCT03292601|Experimental|Feedback Group|Patients in the Feedback Group will receive their brace-wear (Cinch Smart Strap) compliance data via the Wellinks phone application (Cinch Mobile App). Patients will also receive their brace-wear compliance information at their standard of care follow-up visits.
89205715|NCT03122652|Experimental|Terifunomide|
89205716|NCT03122652|Placebo Comparator|Placebo|
89205717|NCT03028779|Experimental|Fast-track total hip or knee arthroplasty|Be able to return patient home on the same day of a total hip or knee surgery.
89205718|NCT03011268|Experimental|Anti TNF discontinuation|Discontinuation of anti-TNF treatment (Infliximab, Adalimumab, Golimumab)
89205719|NCT03011268|Active Comparator|Anti TNF continuation|Continuation of anti-TNF treatment (Infliximab, Adalimumab, Golimumab)
89205720|NCT02956031||HIV pos|those who serologically tested positive for HIV
89205721|NCT02956031||HIV neg|those who serologically tested negative for HIV
89205722|NCT02956031||HIV unk|those with no available serological test for HIV
89205723|NCT02945774|Experimental|(18F)-FEPPA|
89205724|NCT02944578|Experimental|Curcumin Arm|Participants in this arm will use 2000 mg of intravaginal curcumin once a week for 12 weeks.
89205725|NCT02944578|Placebo Comparator|Placebo Arm|Participants in this arm will use 2000 mg of a placebo once a week for 12 weeks.
89205726|NCT02943291|Experimental|4x4 minutes interval training|4x4 minutes high intensity interval training with 4 minute intervals
89205727|NCT02943291|Experimental|10x1 minute interval training|10x1 minute high intensity interval training with 1 minute intervals
89205728|NCT02893943|Active Comparator|Probiotics|1 capsule per day containing probiotics
89205729|NCT02893943|Placebo Comparator|Placebo|1 capsule per day without probiotics
89205730|NCT02889523|Experimental|DLBCL cohort|"RCHOP + tazemetostat:~- RCHOP: rituximab (IV, 375 mg/m², day 1), Prednisolone (PO, 40 mg/m² in the morning, day 1 to day 5), doxorubicine (IV, 50 mg/m², day 1), cyclophosphamide (IV, 750 mg/m², day 1), vincristine (IV, 1.4 mg/m², day 1): Phase I : 8 cycles, every 21 days Phase II : 6 cycles, every 21 days~Rituximab (IV, 375 mg/m², day 1) Phase II : 2 cycles, every 21 days~Tazemetostat: PO, doses according to dose cohorts for phase I, and at RP2D for phase II: continuous: Cycle 1: 2 to 21 BID, Cycle 2-8: 1 to 21 BID"
89205731|NCT02889523|Experimental|FL cohort|"RCHOP + tazemetostat:~Induction~RCHOP: rituximab (IV, 375 mg/m², day 1), Prednisolone (PO, 40 mg/m² in the morning, day 1 to day 5), doxorubicine (IV, 50 mg/m², day 1), cyclophosphamide (IV, 750 mg/m², day 1), vincristine (IV, 1.4 mg/m², day 1):~6 cycles, every 21 days~Rituximab (IV, 375 mg/m², day 1) Phase II : 2 cycles, every 21 days~Tazemetostat: PO, RP2D, continuous: Cycle 1: 2 to 21 BID, Cycle 2-8: 1 to 21 BID~Maintenance~Tazemetostat : 6 months (every 8 weeks)~Rituximab : 24 months (every 8 weeks)"
89205732|NCT02782741|Experimental|avalglucosidase alfa (GZ402666)|Administered intravenously every 2 weeks
89205733|NCT02782741|Active Comparator|alglucosidase alfa (GZ419829)|Administered intravenously every 2 weeks
89205734|NCT02771626|Experimental|Telaglenastat 600 mg + Standard Dose Nivolumab|Telaglenastat 600 mg in combination with standard dose nivolumab in participants with advanced/metastatic clear cell renal cell carcinoma (ccRCC), melanoma, and non-small cell lung cancer (NSCLC).
89205735|NCT02771626|Experimental|Telaglenastat 800 mg + Standard Dose Nivolumab: ccRCC Naïve to Checkpoint Inhibitors|Telaglenastat 800 mg/standard dose nivolumab combination in participants with advanced/metastatic ccRCC who have previously received at least one tyrosine kinase inhibitor (TKI) but are treatment naïve to checkpoint modulators programmed death-1/programmed death ligand-1 (PD-1/PD-L1), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), or any other agent that specifically targets a T-cell checkpoint or co-stimulation pathway.
89205736|NCT02771626|Experimental|Telaglenastat 800 mg + Standard Dose Nivolumab: ccRCC Recently Treated With Nivolumab|Telaglenastat 800 mg/standard dose nivolumab combination in participants with advanced/metastatic ccRCC who received nivolumab in most recent treatment line that had documented radiological disease progression OR are currently receiving nivolumab with stable disease for at least 24 weeks.
89205737|NCT02771626|Experimental|Telaglenastat 800 mg + Standard Dose Nivolumab: ccRCC With Prior PD-1 Therapy|Telaglenastat 800 mg/standard dose nivolumab combination in participants with advanced/metastatic ccRCC that had documented radiological disease progression while receiving an anti-PD-1/PD-L1 therapy in any prior line of therapy.
89205738|NCT02771626|Experimental|Telaglenastat 800 mg + Standard Dose Nivolumab: Melanoma With Prior PD-1 Therapy|Telaglenastat 800 mg/standard dose nivolumab combination in participants with unresectable or metastatic melanoma that had documented radiological disease progression while receiving an anti-PD-1 therapy in their most recent line of therapy.
89205739|NCT02771626|Experimental|Telaglenastat 800 mg + Standard Dose Nivolumab: NSCLC With Prior PD-1 Therapy|Telaglenastat 800 mg/standard dose nivolumab combination in participants with NSCLC that does not harbor an activating mutation in the epidermal growth factor receptor (EGFR) oncogene and who received nivolumab in most recent treatment line and had documented radiological disease progression OR are currently receiving nivolumab with Stable Disease for at least 24 weeks.
89500120|NCT05976100|Experimental|Group 3 (15 volunteers)|"Single use:~Single 1200-mg oral dose of NIOCH-14 (on the same day in the morning 600 mg and in the evening 600 mg)"
89500121|NCT05976100|Experimental|Group 4 (15 volunteers)|"Multiple application:~Daily 200-mg oral dose of NIOCH-14 once a day for 6 days"
89500122|NCT05976100|Experimental|Group 5 (15 volunteers)|"Multiple application:~Daily 600-mg oral dose of NIOCH-14 once a day for 6 days"
89500123|NCT05976100|Experimental|Group 6 (15 volunteers)|"Multiple application:~Daily 600-mg oral dose of NIOCH-14 twice a day for 6 days"
89500124|NCT05976087|Experimental|Experimental group|
89500125|NCT05976074|Experimental|Wearable device for tremor assessment|Subjects already implanted with a deep brain stimulation (DBS) system for therapy for essential tremor wear an Apple Watch and complete tremor assessment tasks detailed through the BrainRISE app four times a day for two weeks.
89500126|NCT05976061||Low risk patients|Low risk actinic keratosis patients referred by the general practitioner and diagnosed as actinic keratosis by the dermatologist in 2018 and 2019.
89500127|NCT05976061||High risk patients|High risk actinic keratosis patients referred by the general practitioner and diagnosed as actinic keratosis by the dermatologist in 2018 and 2019.
89500128|NCT05975996|Experimental|Experiemental|ALG/CsA(Cyclosporine) + eltrombopag + moderate-dose cyclophosphamide
89500129|NCT05975944|Experimental|dose-escalation part of phase Ib clinical trial|Dose level 1: Selinexor 40mg PO QW, Olaparib 150mg PO BID; Dose level 2: Selinexor 60mg PO QW, Olaparib 150mg PO BID; Dose level 3: Selinexor 80mg PO QW, Olaparib 150mg PO BID.
89500130|NCT05975931||"Cohort 1 (new insertions cohort)"|Subjects who have had Aspire SR® implanted as their first VNS model.
89500131|NCT05975931||"Cohort 2 (battery change cohort)"|Subjects who have had their VNS battery changed from a previous model to Aspire SR®.
89500132|NCT05975918|Experimental|Motivational İnterview|The participants in the experimental group will be informed about the study through pre-interviews and data (Caregiver Identifying Characteristics Form, Patient Identifying Characteristics Form, Depression, Anxiety and Stress Scale (DASS-21), Coping Attitudes Assessment Scale) will be collected through pre-tests. A motivational interview intervention consisting of a total of 6 interviews will be conducted.Then, data will be collected with posttest (Caregiver Descriptive Characteristics Form, Patient Descriptive Characteristics Form, Depression Anxiety and Stress Scale (DASS-21), Coping Attitudes Assessment Scale).
89500133|NCT05975918|Other|Control|Participants in the control group will be informed about the study through pre-interviews and data (Caregiver Identifying Characteristics Form, Patient Identifying Characteristics Form, Depression, Anxiety and Stress Scale (DASS-21), Coping Attitudes Assessment Scale) will be collected through pre-tests. 2 hours of training on coping with stress and problem solving skills will be provided. Then, data will be collected with posttest (Caregiver Descriptive Characteristics Form, Patient Descriptive Characteristics Form, Depression Anxiety and Stress Scale (DASS-21), Coping Attitudes Assessment Scale).
89500134|NCT05975892|Experimental|Allogeneic MSCs transplantation in periodontal disease|Allogeneic MSC harvested and cultured in osteogenic medium are seeded on collagen scaffold, mixed with autologous platelet rich plasma clot. The MSCs construct (MSCs/Coll/PRP clot) is implanted in the bone defect.
89500135|NCT05975879|Active Comparator|ARTNEO|1 capsule 1 time per day for 6 months
89500136|NCT05975879|Placebo Comparator|Placebo|1 capsule 1 time per day for 6 months
89500137|NCT05975866|Experimental|The group receiving anti-inflammatory diet with curcumin supplement|Implementation of an anti-inflammatory diet along with the daily consumption of three 500 mg curcumin capsules along with the main meals of breakfast, lunch, and dinner.
89500138|NCT05975866|Placebo Comparator|Group receiving anti-inflammatory regimen with curcumin placebo|Implementation of an anti-inflammatory diet along with the daily consumption of three 500 mg placebo capsules of curcumin (microcrystalline cellulose) and the main meals of breakfast, lunch, and dinner.
89500139|NCT05975853|Experimental|Binaural beat music group (BBM group)|20 minutes of music thrice a week (Monday, Wednesday, and Friday) for two weeks (total of 12 times)
89500140|NCT05975853|Sham Comparator|Control group|20 minutes of music thrice a week (Monday, Wednesday, and Friday) for two weeks (total of 12 times)
89500141|NCT05975827|Experimental|Sterile Wound Care Liquid Dressing|
89500142|NCT05975827|No Intervention|Control|
89500143|NCT05975814|Experimental|concave abutment vs. straight abutment|After implant is placed a randomization will determine if the implant receives a straight or a concave abutment. If a patient requires 2 implants, one of them will be straight and the other will be concave. A patient can therefore have both abutments.
89500144|NCT05975801|Experimental|Dry Cupping Therapy Group|In addition to the conventional treatment, moving cup application was applied for 10 minutes twice a week. During the treatment, the patients were placed in a side-lying position with the affected side on top. Liquid petroleum jelly was applied on the skin and negative pressure was created with a manual pump, allowing the cup to be slid on the skin. Care was taken to ensure that the negative pressure would not cause increased pain and would allow the cup to slide. Deltoid, Trapeze, Supraspinatus, Infraspinatus, Pectoral muscles were applied in the origo insertion direction for a total of 10 minutes.
89500145|NCT05975801|Other|Conservative Treatment Group|The patients in the control group received a conservative treatment program including hotpack (20 min), transcutaneous electrical nerve stimulation(TENS) (COMPEX Rehab 400 - 20 min), ultrasound (Chattanooga Ultrasound - 1 megahertz, 1.5 W/cm², 5 min) for 4 weeks, 5 days a week, and wand, Codman, stretching and strengthening exercises were applied.Stretching exercises were added to the treatment for the shoulder girdle and scapular region muscles, while strengthening exercises were added to the treatment by increasing the resistance at the pain limit. In addition, the home exercise program was taught to be 10 repetitions 2 times a day.
88955960|NCT06053749||Pregnancies exposed to IFNB only|With dispensed IFNB, no other MS disease modifying drugs (MSDMDs) during the pre-pregnancy period or during pregnancy
89500146|NCT05975762|Active Comparator|intervention group|surgical fixation group
89500147|NCT05975762|No Intervention|control group|conservation group
89500148|NCT05975736|Experimental|Blocked Trials|There are four conditions in the experiment. Each condition will be presented in a separate block of 100 trials.
89500149|NCT05975736|Experimental|Mixed Trials|There are four conditions in the experiment. All condition will be presented, randomly mixed in a single block of 400 trials (with breaks every 100 trials).
89500150|NCT05975723|Experimental|MIND diet intervention|Participants in the MIND diet group will receive an education program on a localized MIND diet for 1-year, and will be routinely followed up and given advice on other healthy lifestyles.
89500151|NCT05975723|Active Comparator|Control group|Participants in the control group will be routinely followed up and given general advice on healthy lifestyle.
89500152|NCT05975645|Experimental|TQB2618 injection +Penpulimab injection+ Anlotinib Hydrochloride Capsules|Intravenous infusion of TQB2618 Injection 1200mg and Penpulimab Injection 200mg on 1st day, combining with Anlotinib capsules 10mg given orally in fasting conditions once daily in each 21-day cycle. (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
89500153|NCT05975567||Diseased cadaveric coronary arteries from individuals with sudden cardiac death|Cadaveric coronary artery segments (5-15 mm) will be excised at necropsy (post mortem) from 10 individuals with SCD likely to have advanced coronary atherosclerosis.
89500154|NCT05975567||Aspirated thrombotic specimens from patients with ST-elevated myocardial infarction|Thrombotic samples will be aspirated from 30 patients with STEMI admitted to the Hippokrateion Hospital of Thessaloniki, Greece and undergoing primary PCI and routine thrombus aspiration per standardized procedures.
89500155|NCT05975567||Calcific aortic valves surgically resected from patients with calcific aortic valve disease|Calcific aortic valves will be surgically removed from 30 patients with CAVD undergoing cardiac surgery for aortic valve replacement.
89500156|NCT05975528|Experimental|SGLT2 inhibitor user|
89500157|NCT05975528|Active Comparator|Glimepiride user|
89500158|NCT05975502||Pregnant women with positive syphilis serology|Pregnant women with blood TPHA/TPPA ≥ 80
89500159|NCT05975502||Children born with positive syphilis serology|Children born from mothers with syphilis during pregnancy and / or with blood TPHA/TPPA ≥ 80 at birth
89500160|NCT05974124|Experimental|Group A|Povidone-Iodine 0.66%
89500161|NCT05974124|Experimental|Group B|Chlorhexidine 0.02%
89500162|NCT05973968||surufatinib|Surufatinib 300mg QD, po, every 4 weeks as a course of treatment, continuous administration until PD, death or intolerable toxicity
89500163|NCT05973799|Experimental|Fasting|Subjects will remain fasted prior to insulin-induced hypoglycemia.
89500164|NCT05973799|Experimental|Feeding|Subjects will eat a normal breakfast and lunch prior to insulin-induced hypoglycemia.
89500165|NCT05972200|Experimental|HD-tDCS V5/MT, HD-tDCS V1, Sham|"Active HD-tDCS over V5/MT~Active HD-tDCS over V1~Sham HD-tDCS over V5/MT or V1"
89500166|NCT05972200|Experimental|HD-tDCS V5/MT, Sham, HD-tDCS V1|"Active HD-tDCS over V5/MT~Sham HD-tDCS over V5/MT or V1~Active HD-tDCS over V1"
89500167|NCT05972200|Experimental|HD-tDCS V1, HD-tDCS V5/MT, Sham|"Active HD-tDCS over V1~Active HD-tDCS over V5/MT~Sham HD-tDCS over V5/MT or V1"
89500168|NCT05972200|Experimental|HD-tDCS V1, Sham, HD-tDCS V5/MT|"Active HD-tDCS over V1~Sham HD-tDCS over V5/MT or V1~Active HD-tDCS over V5/MT"
88955961|NCT06053749||Pregnancies unexposed to IFNB nor other MSDMDs|No dispensed IFNB nor any other MSDMDs during the pre-pregnancy period nor any time during pregnancy
89500169|NCT05972200|Experimental|Sham, HD-tDCS V5/MT, HD-tDCS V1|"Sham HD-tDCS over V5/MT or V1~Active HD-tDCS over V5/MT~Active HD-tDCS over V1"
89500170|NCT05972200|Experimental|Sham, HD-tDCS V1, HD-tDCS V5/MT|"Sham HD-tDCS over V5/MT or V1~Active HD-tDCS over V1~Active HD-tDCS over V5/MT"
88955962|NCT06053749||Pregnancies exposed to IFNB (regardless of other MSDMDs)|With dispensed IFNB, regardless of other MS disease modifying drugs (MSDMDs) during the pre-pregnancy period or during pregnancy
89500171|NCT05970458||Ethioperm|All patients with a permanent ostomy visiting the stoma center in Addis Abeba
89500172|NCT05970458||EthioTemp|All patients waiting for ostomy reversal at Tikur Anbessa Specialized Hospital
89500173|NCT05970458||SweSto|All patients visiting the stoma clinic at South General Hospital
89500174|NCT05969054|Experimental|Group A: lacosamide|Subjects who were randomly divided into group A took lacosamide for 6 months during treatment (initial dose was 50mg bid, maintained for one week and then increased to 100mg bid and maintained at this dose)
88955963|NCT06053749||Pregnancies unexposed to IFNB (regardless of other MSDMDs)|"No dispensed IFNB during the pre-pregnancy period nor any time during pregnancy, regardless of other MSDMDs~Outcomes:"
89205740|NCT02616302|Experimental|Weight ≤30 kg: Dexlansoprazole 15 mg|Dexlansoprazole 15 mg, capsules, once, daily, for 12 weeks. Participants weigh ≤30 kg.
89205741|NCT02616302|Experimental|Weight ≤30 kg: Dexlansoprazole 30 mg|Dexlansoprazole 30 mg, capsules, once, daily, for 12 weeks. Participants weigh ≤30 kg.
89205742|NCT02616302|Experimental|Weight >30 kg: Dexlansoprazole 30 mg|Dexlansoprazole 30 mg, capsules, once, daily, for 12 weeks. Participants weigh >30 kg.
88955967|NCT06044935|Experimental|Men with overweight or obesity|To investigate whether NR supplementation augments the sleeping energy expenditure and fat oxidation rate during the ketogenic diet in men and women with overweight and obesity
88955968|NCT06044935|Experimental|MODY2 Patients|To measure changes in sleeping energy expenditure and fat oxidation rate after transitioning from a baseline diet to an isocaloric ketogenic diet similar to our previous study in men
88955969|NCT06044935|Experimental|Women with overweight or obesity|To investigate whether NR supplementation augments the sleeping energy expenditure and fat oxidation rate during the ketogenic diet in men and women with overweight and obesity
89500175|NCT05969054|Experimental|Group B: levetiracetam|Subjects randomly divided into group B took levetiracetam for 6 months during treatment (initial dose was 250mg bid, maintained for one week and then increased to 500mg bid and maintained at this dose).
89500176|NCT05957107|Experimental|Injection of recombinant humanized monoclonal antibody against interleukin-6 receptor4mg/kg|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 4mg/kg as the low dose group.
89500177|NCT05957107|Experimental|Injection of recombinant humanized monoclonal antibody against interleukin-6 receptor6mg/kg|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 6mg/kg as the middle dose group.
89500178|NCT05957107|Experimental|placebo control|placebo control
89500179|NCT05957107|Experimental|Tocilizumab Injection8mg/kg|Tocilizumab Injection8mg/kg
89500180|NCT05953233|Experimental|Active HEPA cleaner|Active HEPA cleaners will be placed in classrooms throughout the school year
89500181|NCT05953233|Placebo Comparator|Sham HEPA cleaner|Sham HEPA cleaners will be placed in classrooms throughout the school year
89500182|NCT05943327|Experimental|Part A: Multiple Doses of Lu AG06474 or Placebo|Participants will receive multiple oral doses of Lu AG06474 or placebo.
89500183|NCT05943327|Experimental|Part B: Single Doses of Lu AG06474|Participants will receive single oral doses of Lu AG06474.
89500184|NCT05938413|Experimental|Intervention or CHAMPS|Wise App that delivers medication adherence reminders and community health worker sessions
89500185|NCT05938413|No Intervention|Control|Standard of care
89500186|NCT05932082|Experimental|myomectomy group|The study group received IVF after myomectomy.
89500187|NCT05932082|Placebo Comparator|control group|The control group was directed to IVF after the routine evaluation, probably including diagnostic laparoscopy.
89500188|NCT05926635||Exoskeleton group|sessions of rehabilitation with the ATLAS 2030 exoskeleton twice per week as part of their of their routine rehabilitation
89500189|NCT05926635||Control group|The children included in the control group will continue receiving their usual conventional therapy
89500190|NCT05919342|No Intervention|Routine care arm|Patients in this arm will undergo routine care. They will be managed and followed up as per routine clinical care. They will be remotely monitored for HF events by follow up through electronic records and routinely collected data.
88955970|NCT06044454||Service deployment|Intervention Chest X-ray received - care team (standard of care) CT scan - care team (standard of care)
89205743|NCT02616302|Experimental|Weight >30 kg: Dexlansoprazole 60 mg|Dexlansoprazole 60 mg, capsules, once, daily, for 12 weeks. Participants weigh >30 kg.
89205744|NCT02515370|Experimental|Friends for Life Circles (FLC)|The intervention will include formation of peer support groups of eight to ten women in the community with incorporation of income generating activities to improve maternal adherence to clinic appointments and life long antiretroviral therapy
89205745|NCT02515370|No Intervention|Standard of Care (SOC)|Normal standard of care and follow up. The standard care provided in the clinic will be provided for the control arem
89205746|NCT02469753|Experimental|Patients treated with anti-TNF and continuous daily NSAIDs|
89205747|NCT02469753|Active Comparator|Patients treated with anti-TNF and NSAIDs on demand|
89500191|NCT05919342|Experimental|Investigational arm|Patients in this arm will have a blood sample performed for measurement of N-terminal prohormone of B-type natriuretic peptide (NT-proBNP). Patients with an elevated Roche NT-proBNP (≥125 pg/mL) will undergo a transthoracic echocardiogram, clinical examination for signs of HF, HF symptom assessment, an ECG). Patients will undergo echocardiography with a CE-marked, FDA-approved handheld point of care (POC) EchoNous echocardiogram device in all countries. The US2.ai algorithm (which is also CE-marked and FDA-approved) will generate an AI-automated echocardiogram report.
89500192|NCT05918081||Adolescent Basketball Players|Adolescent male basketball players registered in a local basketball academy will form the universe of the research.
89500193|NCT05910957||Non-depressed controls|Subjects without depression will fill out questionnaires about their general health and wellbeing, quality of life, mental health, emotional health, suicide risk, support system, and childhood experiences. Smartwatch data will also be collected to monitor step count, sleep quality, heart rate (resting and active), and activity rates.
88955978|NCT06040086|Experimental|Tozorakimab|Dosing subcutaneously tozorakimab
88955979|NCT06040086|Placebo Comparator|Placebo|Dosing subcutaneously with equivalent volume to tozorakimab
88955980|NCT06039826|Experimental|LY3437943 + Combined Oral Contraceptive (COC)|The COC ethinyl estradiol and drospirenone administered orally in combination with LY3437943 administered subcutaneously (SC).
88955981|NCT06029283|Placebo Comparator|Placebo arm of non-dietary nitrate gum|Placebo gum with no dietary nitrate
88955982|NCT06029283|Experimental|Test arm of dietary nitrate containing gum|Functional gum with dietary nitrate
88955983|NCT06029270|Active Comparator|Arm I (Nivolumab)|Patients receive nivolumab IV over 30 minutes. Cycles repeat every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo CT or MRI on study. Patients also undergo PET/CT or bone scan as clinically indicated.
88955984|NCT06029270|Experimental|Arm II (Nivolumab, relatlimab)|Patients receive nivolumab IV over 30 minutes and relatlimab IV over 30-90 minutes. Cycles repeat every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo CT or MRI on study. Patients also undergo PET/CT or bone scan as clinically indicated.
88955985|NCT06029270|Experimental|Induction therapy (Platinum-gemcitabine-nivolumab)|Patients receive nivolumab IV over 30 minutes, cisplatin IV or carboplatin IV over 30-60 minutes on day 1 of each cycle and gemcitabine IV over 30 minutes on days 1 and 8 of each cycle. Cycles repeat every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT or MRI and blood sample collection during screening and on study.
88955986|NCT06028230|Experimental|SAR444656|Participants will receive SAR444656 orally
88955987|NCT06028230|Placebo Comparator|Placebo|Participants will receive placebo orally
88955988|NCT06024304|Active Comparator|Trigen InterTan|Patients in this arm will be implanted with the cephalomedullary nail Trigen InterTan manufactured by Smith & Nephew.
88955989|NCT06024304|Active Comparator|Synthes TFNA|Patients in this arm will be implanted with the single-screw device TFNA manufactured by DePuy Synthes.
88955990|NCT06021353|Experimental|UV fs-Laser|First surgical eye randomly assigned to the UV fs-Laser with the second surgical eye (fellow eye) assigned to the IR fs-Laser for the purpose of corneal flap creation during LASIK surgery
88955991|NCT06021353|Active Comparator|IR fs-Laser|First surgical eye randomly assigned to the IR fs-Laser with the second surgical eye (fellow eye) assigned to the UV fs-Laser for the purpose of corneal flap creation during LASIK surgery
89500194|NCT05910957||Antidepressant-treated adults|Subjects diagnosed with depression will fill out questionnaires about their general health and wellbeing, quality of life, mental health, emotional health, suicide risk, support system, and childhood experiences. Smartwatch data will also be collected to monitor step count, sleep quality, heart rate (resting and active), and activity rates.
88955992|NCT06021236|Experimental|mindfulness-based intervention and routine care|mindfulness-based intervention including: breathing awareness, body scanning, mindful yoga, mindful eating, and loving-kindness meditation. From the time when the patients signed up to be the first to receive the cardiac device surgery schedule, the experimental group that met the including criteria, in addition to following the routine care of the hospital, was involved in teaching the above mindfulness skills, and Osaka continued to follow the regular care.
88955993|NCT06021236|Other|The control group received the CIED procedure routine care|From the time when the patients signed up to be the first to receive the cardiac device surgery schedule, the control group that met the including criteria take routine care of the hospital.
89205748|NCT02366598|Experimental|20g Hemp protein shake|Hemp protein shake, 20 grams, given once at beginning of acute trial
89205749|NCT02366598|Experimental|40 g hemp protein shake|Hemp protein shake, 40 grams, given once, at beginning of acute trial
89205750|NCT02366598|Active Comparator|20 g Soybean protein shake|Soybean protein shake, 20 grams, given once, at beginning of acute trial
89500195|NCT05909488|Experimental|EYESTEM 001-X|1.8 ml cell preparations are suspended in Conditioned Media (CM) until it reaches a 2 ml volume of cell suspension. Umbilical Cord Mesenchymal Stem Cell (UC-MSC) suspension will be injected into the peribulbar.
89500196|NCT05909488|Experimental|EYESTEM 001-XF|1.8 ml cell preparations are suspended in Conditioned Media (CM) until it reaches a 2 ml volume of cell suspension. Umbilical Cord Mesenchymal Stem Cell (UC-MSC) suspension will be injected into the peribulbar.
89500197|NCT05888857|Experimental|Cohort A: patients with TLS+ IO-naïve solid tumors|Participants with TLS+ IO-naïve solid tumors will be treated by MEDI5752
89500198|NCT05888857|Experimental|Cohort B: patients with TLS+ PD1/PDL1-experienced solid tumors|Participants with TLS+ PD1/PDL1-experienced solid tumors will be treated by MEDI5752
89500199|NCT05887583|Experimental|Intervention|The Rising New York Road Runners program: A School-based physical education curriculum with family engagement component.
89500200|NCT05887583|No Intervention|Control|Standard school operating procedures
89500201|NCT05881538|Experimental|Exercise group|"16 weeks of a High Intensity Interval Training exercise program conducted telematically with real time supervision twice a week.~The exercise program consists of a circuit of exercises aiming to achieve a target heart rate for each fitness level."
89500202|NCT05881538|No Intervention|Control group|Routine physician recommendations for physical activity.
89538389|NCT03268577||Prevention (diet and activity tracking)|Patients complete the ASA24 about foods, cooking methods, and other aspects of diet every 2 months for up to 6 times, and complete ACT24 about activities and time reporting every 2 months for up to 6 times. Patients also complete DHQ-II questionnaires at the beginning and end of the study about the frequency and portion sizes of foods consumed over the past 12 months, provide a 7-day food checklist twice with the DHQ-II, and provide a 4-day food record twice, once every 6 months. Physical activity monitors are worn to measure movement at different intensity levels and sitting or standing periods, twice during the study with 6 months between each time they are worn.
89538390|NCT03268655|Experimental|Ginger extract|Ginger extract, 2000 mg daily for 6 weeks, followed by 6 week washout.
89538391|NCT03268655|Experimental|Placebo|Placebo, daily for 6 weeks, followed by 6 week washout.
89538392|NCT02459249|Experimental|Healthy Lifestyle|A physician and a nutritionist will be give recommendations for diet and exercise emphasizing the importance of a healthy lifestyle (suggesting moderate-intensity activity at least 150 minutes/week and to eat less sodium, fat, sugar, portions and calories). Verbal and written individualized recommendations from trained professionals (nutritionists, and physician) will be provided. Monthly sessions of at least 30 minutes covering diet, exercise, and behavior modifications were held. The first was a one-to-one meeting and was followed by group sessions based on behavioral counseling
89538393|NCT02459249|Placebo Comparator|Treatment of Mexican Health Minister|General and unspecific recommendations of diet and physical activity for the metabolic syndrome treatment, given for a physician
89538394|NCT02458859|Active Comparator|PICO|PICO Negative Pressure Wound Therapy (NPWT) system
89538395|NCT02458859|No Intervention|Standard care|Standard care
89538396|NCT02458001|Experimental|SAFFRON stepped care|3 level intervention: level 1:Self help booklet level 2: CNS delivered intervention level 3: psychologist delivered intervention
89538397|NCT02458001|No Intervention|enhanced treatment as usual (ETU)|level 1 intervention: self help booklet Non study trained CNS will offer assessment, advice, vaginal dilator training where appropriate, arrange topical oestrogens or other creams
89538398|NCT03268187|Experimental|Self-Alert Training|Biofeedback-based Self-Alert Training Vigilance Task Questionnaires accessing apathy, fatigue, depression, sleep quality, sleep behavior
89205751|NCT02366598|Experimental|40 g Soybean protein shake|Soybean protein shake, 40 grams, given once, at beginning of acute trial
88955999|NCT06014866||LBBA INGEVITY+ Pacing|Patients indicated for anti-bradycardia pacing that have been implanted with an INGEVITY+ lead in the LBBA.
88956000|NCT06013241|Experimental|Brensocatib 40 mg|Participants will receive brensocatib 40 mg tablet, orally, QD for 24 weeks along with mometasone furoate nasal spray (MFNS) by nasal route as background therapy at a stable dose according to the Investigator's discretion and local guidance.
88956001|NCT06013241|Experimental|Brensocatib 10 mg|Participants will receive brensocatib 10 mg tablet, orally, QD for 24 weeks along with MFNS by nasal route as background therapy at a stable dose according to the Investigator's discretion and local guidance.
88956002|NCT06013241|Placebo Comparator|Placebo|Participants will receive a brensocatib-matching placebo tablet, orally, QD for 24 weeks along with MFNS by nasal route as background therapy at a stable dose according to the Investigator's discretion and local guidance.
89205752|NCT02366598|Placebo Comparator|Control shake|non-protein control shake, given once, at beginning of acute trial
88956003|NCT06010914||mHSPC patients to treat with darolutamide in combination with docetaxel and ADT|Patients over the age of 18 years with a diagnosis of mHSPC and for whom a decision to treat with darolutamide in combination with docetaxel and ADT has been made by the treating physician before study enrollment.
88956004|NCT06010472|Experimental|anti-CD19 CAR NK cells|To evaluate the safety and effectiveness of anti-CD19 CAR NK cells (KN5501) in patients with moderate to severe refractory SLE. All subjects will receive fludarabine/cyclophosphamide lymphodepletion followed by anti-CD19 CAR NK cells infusion on Day 0, 7, and 14.
89023405|NCT05498948|Experimental|Probiotic mixture|Dietary Supplements: Probiotic mixture supplementation The Probiotic mixture supplementation contains Lactobacillus acidophilus, Lactobacillus lactis, and Streptococcus lactis.
89023406|NCT05498948|Placebo Comparator|Placebo|Dietary Supplement: Placebo The placebo product will be orally take.
89023407|NCT05498935||CPB time ≥ 90 minutes|No intervention, regular therapy
89205753|NCT02314988|Active Comparator|Intervention|Subjects will receive tranexamic acid on the surgical wound.
89538399|NCT03268187|Active Comparator|Relaxation Training|Biofeedback-based Relaxation Training Vigilance Task Questionnaires accessing apathy, fatigue, depression, sleep quality, sleep behavior
89538400|NCT03272711|Experimental|Vortioxetine plus cognitive training|Vortioxetine (10 mg) plus cognitive training 5 times weekly for 30 minutes a day
89538401|NCT03272711|Placebo Comparator|Placebo plus cognitive training|Placebo plus cognitive training 5 times weekly for 30 minutes a day
89205754|NCT02314988|Placebo Comparator|Placebo control|Subjects will receive placebo (saline solution) on the surgical wound.
89205755|NCT02256904|Experimental|Anatomical|67 subjects will be randomized to receive an Anatomical TKA with the My knee instruments and a GMK sphere device.
89538402|NCT03267719|Experimental|laser therapy|Erbium-laser therapy will be applied
89500203|NCT05869474|Experimental|I125-AG|Participants will receive the implantation of radioactive seeds under EUS guide. 48h after implantation, chemotherapy with Gemcitabine 1000mg/m2 plus albumin paclitaxel 125mg/m2 given on days 1 and 8 of each 21-day cycle will be conducted.
89500204|NCT05869474|Active Comparator|AG|Participants receive chemotherapy alone. Gemcitabine 1000mg/m2 plus albumin paclitaxel 125mg/m2 given on days 1 and 8 of each 21-day cycle.
89500205|NCT05866536|Experimental|Bacillus Calmette-Guérin|2 BCG vaccinations spaced 4 weeks apart at the beginning of the trial
89500206|NCT05866536|Placebo Comparator|Saline Injection|2 placebo injections spaced 4 weeks apart at the beginning of the trial
89500207|NCT05847309|Active Comparator|Early extubation|Patients randomized to early extubation, will be extubated < 6 hours after endovascular treatment under general anesthesia.
89500208|NCT05847309|Experimental|Delayed extubation|Patients randomized to delayed extubation, will be extubated 6-12 hours after endovascular treatment under general anesthesia.
89500209|NCT05831644|Experimental|Treatment arm 1|A single dose of C21 at visit 2 followed by a single dose of placebo at visit 3.
89500210|NCT05831644|Experimental|Treatment arm 2|A single dose of placebo at visit 2 followed by a single dose C21 at visit 3.
89500211|NCT05811312||Cohort 1-individuals who are na�ve to SCS|Individuals with chronic neuropathic pain who are na�ve to SCS and were selected for SCS trial period as part of their clinical care will participate in two study visits: before the beginning of the SCS trial and the end of the trial period. Data collection will be consistent across all data collection timepoints (T1 - T3) and include rs-fNIRS/EEG and clinical pain measures.
89500212|NCT05811312||Cohort 2-individuals with effective implanted SCS 6 months|Cohort 2: Participants with effective implanted SCS 6 months will participate in three study visits conducted 24-48 hours apart. Data will be collected during SCS use and following an SCS washout period. Data collection will be consistent across all data collection timepoints(T1-T4) and include rs-fNIRS/EEG and clinical pain measures. Both cohorts will receive paresthesia based SCS.
89500213|NCT05793593|Active Comparator|Colorectal Cancer (CRC) education alone|All participants will be educated, on a simplified clinical and medical background of CRC; causes and risk factors for CRC; eligibility criteria for screening; lifestyle modifications to lower risk of developing CRC; screening methods for CRC, including FIT and colonoscopy; addressing myths and misconceptions about CRC; and information about resources for low-cost and no-cost screening, screening for the uninsured and screening for those without legal immigration documentation. Participants will also be educated on elements of fecal immunochemical testing (detects signs of cancer in the stool, can be done at home and sent to a laboratory for analysis, needs to be done yearly to ensure maximal effectiveness for cancer screening). Follow-up Assessment at 8 months complete follow-up form and assist in completion of peer outreach tracker Provide reminders to encourage participants to encourage peers to get FIT tested.
89500214|NCT05793593|Experimental|FITx3 intervention and CRC education|Provide CRC education, SN education, handouts and text message/social media posts example library. Monthly Telephone Support Provide any additional support to index participants for peer FIT testing, assist in completion of peer outreach tracker. Biweekly Text Messages. Follow-up Assessment (month 8 after intervention) Complete follow-up form and assist in completion of peer outreach tracker Provide reminders to encourage participants to encourage peers to get FIT tested.
89500215|NCT05790525|Other|Both gastric and oral Helicobacter pylori are positive|
89500216|NCT05790525|Other|Positive for Helicobacter pylori for gastric and negative for Helicobacter pylori for oral cavity|
89500217|NCT05790512||Both gastric and oral Helicobacter pylori are negative|
89500218|NCT05790512||Negative for Helicobacter pylori for gastric and positive for Helicobacter pylori for oral cavity|
89500219|NCT05790512||Positive for Helicobacter pylori for gastric and negative for Helicobacter pylori for oral cavity|
89500220|NCT05790512||Both gastric and oral Helicobacter pylori are positive|
89500221|NCT05780671||Oxygen receiving group|patients diagnosed as headcahe related to migraine without aura who received supplemental oxygen together with the standart theraphy
89500222|NCT05780671||standart group|patients diagnosed as headcahe related to migraine without aura who received standart theraphy only.
89500223|NCT05777265|Experimental|Training Group|CT will be applied to the participants, taking into account the recommendations of the American College of Sports Medicine (ACSM), 3 days a week, an average of 40 minutes a day, for a total of 16 weeks
89500224|NCT05777252|Experimental|Training Group|Circuit training will be applied to the participants for a total of 16 weeks, with an average of 40 minutes a day, 3 days a week, taking into account the recommendations of the American College of Sports Medicine (ACSM).
89500225|NCT05763732|No Intervention|Pre RAS|"After a 10-minute washout period, participants will receive the participants' optimized stimulation.~The participants will undergo assessments to measure gait parameters and patterns during stimulation ON and OFF (Pre-RAS) using the 10-meter walk (during a 2-minute walk) and MDS-UPDRS-III rating scale.~Electrophysiological activity (e.g., local field potentials, LFPs) will be collected before assessments."
89500226|NCT05763732|Experimental|During RAS|"The participants will walk to the metronome beats for four minutes (2 minutes for the same beats as baseline cadence and 2 minutes for 10% faster than baseline cadence) (RAS), and the participants' gait parameters will be recorded.~Electrophysiological activity (e.g., local field potentials, LFPs) will be collected."
89500227|NCT05763732|No Intervention|Post RAS|The same assessment as the Pre-RAS will be conducted (Post-RAS).
89538403|NCT03267797|Experimental|Treatment group|Peripheral blood mononuclear cells (PBMCs) were administered into the uterine cavity of RIF patients in this group.
89538404|NCT03267797|Placebo Comparator|Control group|Phosphate buffer saline (PBS) as placebo was injected into the uterine cavity of RIF patients in this group.
89023408|NCT05498935||CPB time < 90 minutes|No intervention, regular therapy
89205756|NCT02256904|Active Comparator|Mechanical|67 subjects will be randomized to receive a Mechanical TKA with the My knee instruments and the GMK sphere device.
89023409|NCT05495815|Active Comparator|6 months of SAT|TJA DAIR, followed by 6 weeks of IV antibiotics then 6 months of oral suppressive antibiotic therapy
89205757|NCT02190500|Active Comparator|Mobile Stroke Unit Management|Acute ischemic stroke patients treated in the Mobile Stroke Unit
89205758|NCT02190500|No Intervention|Standard Management|Acute ischemic stroke patients receiving standard management
89205759|NCT02174055||Cancer Patients|This protocol aims to design, develop and pilot test a psychometric assessment for depression in older cancer patients. The study is divided in three phases. In Phase 1, approximately 15 depressed patients (as determined clinically) and approximately 15 non-depressed patients will undergo individual interviews. In Phase 2, the team will use the themes and subthemes obtained in Phase 1 to write a set of indicators into questionnaire form. In Phase 3, the newly developed questionnaire will be given to a sample of approximately 150 cancer patients who meet the eligibility criteria. Survey results obtained from this sample of 150 patients will be used to assess internal consistency, conduct item analysis, and determine the unique content of the proposed instrument.
89205760|NCT02091583|Placebo Comparator|Butter, sunflower and safflower oil|The oil (50g/day) is given in muffin and cookies made with refined wheat flour (3 g/day)daily for 4 weeks.
89205761|NCT02091583|Active Comparator|High Oleic Canola Oil and DHA (HOCO-DHA)|The oil (50g/day) is given in muffin and cookies made with refined wheat flour (3 g/day) daily for 4 weeks.
89205762|NCT02091583|Active Comparator|Barley Beta-glucan|The Barley beta-glucan (3 g/day) is given in muffin and cookies made with a combination of butter, sunflower and safflower oil (50 g/day) daily for 4 weeks.
89205763|NCT02091583|Active Comparator|HOCO-DHA and Barley beta-glucan|The oil and beta-glucan (50g and 3g/day, respectively) is given in muffin and cookies daily for 4 weeks.
89205764|NCT02032953|Experimental|Insulin, Travasol (35%) postop|Insulin (hyperinsulinemic-normoglycemic clamp) with Travasol (amino acid supplementation) given from start of surgery to 6 hours after, at an amount of 35% of patient's energy expenditure as measured before surgery, .
89205765|NCT02032953|Experimental|Insulin, Travasol (20%) postop|Insulin (hyperinsulinemic-normoglycemic clamp) with Travasol (amino acid infusion), given from start of surgery to 6 hours after, at an amount of 20% of patient's energy expenditure as measured before surgery.
89205766|NCT02032953|Placebo Comparator|Insulin, no protein after surgery|Insulin (hyperinsulinemic-normoglycemic clamp, an insulin infusion between 2 and 5 microunits/kg with glucose at a variable rated titrated to maintain normoglycemia, blood glucose 4-6 mmol/L) with no protein supplementation from start of surgery to 6 hours after.
89205767|NCT02029833|Experimental|Regular Canola Oil|60% oleic acid
89205768|NCT02029833|Experimental|High Oleic Canola Oil|70% oleic acid
89205769|NCT02029833|Active Comparator|Western Type Diet - Common Dietary Oils|Ghee, Safflower oil, Coconut oil, & flax oil
89205770|NCT01850355|Experimental|Buspirone|Buspirone administered in tablets twice daily titrated to a maximum daily dose of 60mg for 8 weeks.
89205771|NCT01582776|Experimental|Lenalidomide and GA101|Ga101 and lenalidomide
89205772|NCT01524822||Artillery personnel|exposure to a significant number of concussive evolutions, specifically, exposure to 400 or more within a career, will be considered experienced by the investigators.
89205773|NCT01524822||Breachers|exposure to a significant number of breaching blasts, specifically, exposure to 400 breaching blasts or more within a career, will be considered experienced by the investigators
89205774|NCT01524822||Companions|The criterion is met by a person who has both some historical knowledge of the participant and routine interactions outside a work environment.
89205775|NCT01524822||Unexposed|People not exposed to repeated blasts
89205776|NCT01464164|Experimental|Sotatercept|Sotatercept to be given as a subcutaneous injection once a month for 4 consecutive months, using a dose escalation scale among 3 cohorts. *Protocol Amendment: Two additional cohorts will be given Sotatercept 0.75mg/kg and 1 mg/kg as a subcutaneous injection once every 3 weeks.
89205777|NCT01464164|Experimental|Sotatercept with prednisone boost|Protocol Amendment: Two additional cohorts will be given Sotatercept 0.75mg/kg and 1 mg/kg as a subcutaneous injection once every 3 weeks along with a prednisone boost of 1 mg/kg daily for 3 weeks (max of 60 mg).
89205778|NCT01156428||Control Subjects (normal volunteers)|"Control kidney specimens will be obtained from donor transplant kidneys or nephrectomy specimens performed on patients undergoing nephrectomy for the clinical indication of an identified renal mass.~In the case of donor transplant kidneys, the renal biopsy will be conducted during the act of living donor nephrectomy and transplantation.~In the case of renal mass nephrectomies, representative normal tissue will be obtained from the nephrectomized kidney at a site distant from the renal mass."
89205779|NCT01156428||Renal Disease Subjects|Patients who require a renal biopsy based upon clinical indications such as proteinuria, hematuria, acute renal failure (ARF) of unclear etiology, chronic kidney disease of unclear etiology, nephrotic syndrome, nephritic syndrome, suspected lupus nephritis or any other medically warranted indication for a biopsy.
89205780|NCT00602459|Active Comparator|Arm A (rituximab, fludarabine phosphate)|Participants receive induction therapy (every 28 days for up to 6 cycles) of: Patients receive rituximab IV over 1-4 hours on days 1 (50 mg/m^2), 3 (325 mg/m^2), and 5 (375 mg/m^2) of course 1 and on day 1 (375 mg/m^2) of all subsequent courses. Patients also receive fludarabine phosphate 25 mg/m^2/day IV over 30 minutes or PO on days 1-5.
89205781|NCT00602459|Experimental|Arm B (rituximab, fludarabine phosphate, lenalidomide)|Participants receive induction therapy (every 28 days for up to 6 cycles) of: rituximab IV over 1-4 hours on days 1 (50 mg/m^2), 3 (325 mg/m^2), and 5 (375 mg/m^2) of course 1 and on day 1 (375 mg/m^2) of all subsequent courses. Patients also receive fludarabine phosphate 25 mg/m^2/day IV over 30 minutes or PO on days 1-5. Participants without progression receive consolidation therapy lenalidomide 5mg/day cycle 1, 10 mg/day cycles 2-6 PO QD on days 1-21 of 28 day cycle.
89023410|NCT05495815|Active Comparator|12 months of SAT|TJA DAIR, followed by 6 weeks of IV antibiotics then 12 months of oral suppressive antibiotic therapy
89023411|NCT05495815|Active Comparator|Indefinite SAT|TJA DAIR, followed by 6 weeks of IV antibiotics then indefinite oral suppressive antibiotic therapy
89023412|NCT05492175|Experimental|proximal-prioritized robotic practice plus kinetic exergaming group|60 minutes per day, 3 days per week for 6 weeks
89538405|NCT03267953|Experimental|First stage: Self-directed My Health CheckUp|Participants randomized to this group will be sent an e-mail invitation by the research team to register to the website. Once registered, participants will receive a second e-mail that will provide brief instructions on getting started and invite them to use the website for 12 weeks ad libitum. No additional contact will be provided thereafter by research team.
89205782|NCT00602459|Experimental|Arm C (rituximab, fludarabine phosphate, cyclophosphamide)|Participants receive induction therapy (every 28 days for up to 6 cycles) of: rituximab IV over 4 hours on days 1 (50mg/m^2) and 3 (325 mg/m^2) of course 1 and on day 1 (500 mg/m^2) of all subsequent courses. Patients then receive fludarabine phosphate (age < 70: 25 mg/m^2/day; age >= 70: 20 mg/m^2/day) IV piggyback over 30 minutes or PO (32 mg/m^2/day) followed by cyclophosphamide (age < 70: 250 mg/m^2/day; age >= 70: 150 mg/m^2/day) IV piggyback over 30 minutes on days 1-3.
89205783|NCT00602459|Experimental|Arm D (rituximab, fludarabine, cyclophosphamide, lenalidomide)|Patients receive the first course of induction therapy as in Arm A or B before being re-assigned to Arm D. Beginning in course 2, patients receive rituximab IV (500 mg/m^2) on day 1 and fludarabine phosphate (age < 70: 25 mg/m^2/day; age >= 70: 20 mg/m^2/day) IV piggyback over 30 minutes or PO (32 mg/m^2/day) and cyclophosphamide IV (age < 70: 250 mg/m^2/day; age >= 70: 150 mg/m^2/day) piggyback over 30 minutes on days 1-3. Participants without progression receive consolidation therapy: lenalidomide 5mg/day cycle 1, 10 mg/day cycles 2-6PO QD on days 1-21 of 28 day cycle.
89205784|NCT00591175||1|Standard Care
89205785|NCT00591175||2|Standard Care with Hygienist Counseling
89205786|NCT00591175||3|Standard Care with Hygienist Counseling & Personalized Risk Communication
89205787|NCT00199043|Experimental|Only 1 arm|
89205788|NCT00006177||Adult bipolar patients|Adult bipolar patients
89205789|NCT00006177||Adult Extended Relatives of BD probands|Adult Extended Relatives of BD probands
89205790|NCT00006177||Bipolar Children and Youth|Bipolar Children and Youth
89205791|NCT00006177||Child/Adolescent Extended Relatives of BD probands|Child/Adolescent Extended Relatives of BD probands
89205792|NCT00006177||Children with ADHD only (controls)|Children with ADHD only (controls)
89205793|NCT00006177||First degree relatives of BD patients|First degree relatives of BD patients
89205794|NCT00006177||Healthy volunteer adults (parents or not)|Healthy volunteer adults (parents or not)
89205795|NCT00006177||Healthy volunteer children and youth|Healthy volunteer children and youth
89205796|NCT02601989|Experimental|Tadalafil|Per oral intake of tadalafil 20 mg o.d. for six weeks
89205797|NCT02601989|Placebo Comparator|Placebo|Per oral intake of placebo
89205798|NCT01067053|Experimental|bevacizumab, capecitabine, oxaliplatin|"6 cycles (3 weeks each one) of:~bevacizumab: 7,5 mg/kg (iv), 1st day of each cycle.~capecitabine: 1000 mg/m2 bid, oral. Days: 1-14 every three weeks.~oxaliplatin: 130/mg/m2(iv),1st day of each cycle.~After the first 6 cycles of treatment, continuing only with bevacizumab and capecitabine"
89205799|NCT04097015|Experimental|Treatment|The treatment or intervention is the use of NI-ES using a signal generator, Alpha-Stim M, with an Ocular Interface connected to one channel and a Spinal Interface to the other channel. The treatment is done at home for 40 minutes at a time, twice a day. The upper lids of the closed eyes are treated for 10 minutes and the lower lids of the closed eyes are treated for 10 minutes, alternated throughout the treatment time. The Spinal Interface is placed above the SCI for 40 minutes. The entire procedure is repeated for another 40 minutes for a second time. The participant will treat himself at home.
89205800|NCT01067131|Experimental|PEV7C1, intravaginal|Vaccine containing virosomes intravaginally applied
89205801|NCT01067131|Placebo Comparator|PEV7C9, placebo, intravaginal|Placebo vaccine (excipient only) intravaginally applied
89205802|NCT01067131|Experimental|PEV7B2, intramuscular low dose|Intramuscular vaccine low dose of antigen
89205803|NCT01067131|Experimental|PEV7B1, intramuscular high dose|Intramuscular vaccine, high dose of antigen
89023413|NCT05492175|Active Comparator|distal-prioritized robotic practice plus kinetic exergaming group|60 minutes per day, 3 days per week for 6 weeks
89023414|NCT05492175|Active Comparator|robotic practice plus conventional therapy group|60 minutes per day, 3 days per week for 6 weeks
89205804|NCT02601287|Experimental|BOTOX® 100U|Botulinum Toxin Type A 100U into the detrusor muscle on Day 1 in patients with Overactive Bladder
89205805|NCT02601287|Experimental|BOTOX® 200U|Botulinum Toxin Type A 200U into the detrusor muscle on Day 1 in patients with Neurogenic Detrusor Overactivity
89205806|NCT01067365|Experimental|12.5 mg Androxal|12.5 mg Androxal daily
89205807|NCT01067365|Experimental|25 mg Androxal|25 mg Androxal daily
89205808|NCT00568776|Placebo Comparator|1|
89205809|NCT00568776|Active Comparator|2|
89205810|NCT00568776|Active Comparator|3|
89205811|NCT00568776|Active Comparator|4|
89205812|NCT00758771||Cystic Fibrosis|People who have been diagnosed with cystic fibrosis
89205813|NCT00758771||Healthy|People who do not have cystic fibrosis and who do not have any other lung conditions
89205814|NCT04021511|No Intervention|Phase A|The first one (Phase A) will occur in the emergency department with the application of OAR only by the physicians (without changing the standard of care) during 4 weeks
89205815|NCT04021511|Experimental|Phase B|The second one (Phase B) will occur after the Phase A. Nurses will apply OAR according to the protocol. This phase will also lasts 4 weeks.
89205816|NCT01067443|Experimental|Amb+SSG|AmBisome® one dose of 10mg/kg body weight (IV) on day 1 followed by 10 days of SSG at 20mg/kg body weight (IV/IM) from days 2-11
89205817|NCT01067443|Experimental|Amb+Milt|AmBisome® one dose of 10mg/kg body weight (IV) on day 1 followed by 10 days Miltefosine at 2.5mg/kg body weight (oral) from days 2-11
89205818|NCT01067443|Experimental|Milt|Monotherapy course of Miltefosine at 2.5mg/kg body weight (oral) from days 1-28
89205819|NCT01065259|Experimental|OROS MPH|the group treated by OROS MPH
89205820|NCT01065259|Active Comparator|atomoxetine|the group treated by atomoxetine
89205821|NCT01065259|No Intervention|control|the normal control with no intervention
89205822|NCT00822666|Active Comparator|1|patients homozygous for the 2C19*1 genetic variant
89500228|NCT05752331|Experimental|Physical activity behavioural modification|The 8-week PA behavioural modification intervention will focus on engaging participants in ADL and lowering sedentary time. Each participant will receive one semi-structured motivational interview at baseline to discuss favourite activities and barriers and facilitators to PA. Participants will produce an individualised action plan following the interview that will be followed throughout the intervention to allow an individualised approach to take place. Participants will then be provided with a low-cost pedometer and PA diary to self-monitor and record daily PA. The PA diary will provide examples of various activities that can be done in and around the house, with an emphasis placed on simple, effective movements to reduce sedentary time. Following this, a researcher will conduct weekly virtual meetings with the participant to discuss the past weeks PA levels and provide future individualised goals to promote ADL.
89500229|NCT05752331|No Intervention|Usual Care|All participants will be notified of the government 'your Covid recovery' programme (usual care) which provides details and support on managing long term symptoms of Covid-19.
89500230|NCT05740501||Observational (biospecimen collection, chart review)|Patients undergo collection of blood samples and have medical records reviewed on study.
89500231|NCT05667285||BIOTRONIK Orsiro Sirolimus-Eluting Coronary Stent System|Subject only implanted with BIOTRONIK Orsiro Sirolimus-Eluting Coronary Stent System in stent implantation operation.
89500232|NCT05660954|Experimental|Cabozantinib, 60 mg|Patients with advanced radioactive-iodine refractory DTC who progressed to previous TKIs (including but not limited to lenvatinib or sunitinib). Patients will have not received previously cabozantinib, selective small-molecule BRAF kinase inhibitors, immune checkpoint inhibitor therapy, or systemic chemotherapy regimens.
89500233|NCT05642780|Experimental|cohort A|subjects will receive SKB264 in combination with pembrolizumab by intravenous administration
89500234|NCT05642780|Experimental|cohort B|subjects will receive SKB264 in combination with pembrolizumab by intravenous administration
89500235|NCT05642780|Experimental|cohort C|subjects will receive SKB264 in combination with pembrolizumab by intravenous administration
89500236|NCT05642780|Experimental|cohort D|subjects will receive SKB264 in combination with pembrolizumab by intravenous administration
89500237|NCT05642741||Hypoparathyroidism after total thyroidectomy|Adult patients definitive post-thyroidectomy HoPT defined by a parathyroid hormone (PTH) concentration ≤ 25 pg/mL more than 6 months after the operation and who require treatment with vitamin D and/or calcium supplementation. Each patient will complete a questionnaire twice (3 weeks apart +/- 7 days). The questionnaire, which evaluates the severity of clinical symptoms related to HoPT and their impact on quality of life, is adapted to this pathology.
89500238|NCT05640063|Experimental|Intervention Arm|Provision of Enhanced Delivery and Newborn Kits (CMWs and LHW program will continue to function as usual)
89500239|NCT05640063|No Intervention|Control Arm|Standard Delivery Kits alone (CMWs and LHW program will continue to function as usual)
89500240|NCT05640050|Experimental|Audit Implementation with Community Engagement|This feasibility and implementation research implementing in secondary level care hospitals (Tehsil Head Quarters THQ) at Matiari district of Sindh Province, Pakistan. The audit committees will be established in three THQs including management, specialist, medical officer, and community representatives from catchment area.The implementation phases follow the standard World Health Organization (WHO) audit system. The initial step includes identifying death cases for review and subsequently collecting the detailed information on the near miss and adverse event history. A mixed methods data analysis will include both quantitative components, such as identification of trends in rates and causes of death and geographic location, and qualitative components, such as analysis of modifiable factors. A monthly monitoring cycle will be set up within the implementing facilities to ensure effective implementation of the audit systems.
89500241|NCT05629117|Experimental|Personalized Diabetes Text Messaging (DB-TEXT) combined with Peer Support Education Group|Patients who are assigned to the DB-TEXT+PSE group will receive personalized short text message services twice weekly at approximately noon on Monday and Thursday for three months (12 weeks). Additionally they will receive peer support education weekly during three month.
89500242|NCT05629117|Active Comparator|Personalized Diabetes Text Messaging (DB-TEXT) Group|The participants in the Personalized DB-TEXT group will receive the personalized short text message twice weekly at approximately noon on Monday and Thursday for three months (12 weeks).
89500243|NCT05629117|No Intervention|Control Group|Health education related to diabetes management will be provided to the control group once a month during three months
89500244|NCT05627635|Experimental|Phase I (3B-FOLFOX)|Patients receive FOLFOX, bevacizumab, balstilimab, and botensilimab IV on study. Patients undergo an x-ray, CT scan, PET scan, and/or MRI throughout the trial. Patients also undergo blood sample collection during screening and on study.
89023415|NCT05486065|Experimental|Semaglutide 2 mg|Participants will receive once-weekly semaglutide 2 mg subcutaneous (s.c.) injection.
89205823|NCT00822666|Experimental|2|carriers of the 2C19*2 genetic variant (homozygous or heterozygous)
89205824|NCT00816816|Other|1|All patients will receive docetaxel 75 mg/m2 on day 1; cisplatin 75 mg/m2 on day 1; and a continuous fluorouracil infusion at 500 mg/m2/d on days 1 through 5. Cycles are repeated every 21 days for a total of three cycles. Patients then will receive definitive radiotherapy with 3D-CRT or IMRT, and cisplatin (40mg/m2) weekly during external radiotherapy.
89500245|NCT05627635|Experimental|Phase II, Arm I (3B-FOLFOX)|Patients receive FOLFOX, bevacizumab and balstilimab IV with botensilimab IV at a lower dose on study. Patients undergo an x-ray, CT scan, PET scan, and/or MRI throughout the trial. Patients also undergo blood sample collection during screening and on study.
89500246|NCT05627635|Experimental|Phase II, Arm II (3B-FOLFOX)|Patients receive FOLFOX, bevacizumab and balstilimab IV with botensilimab IV at a higher dose on study. Patients undergo an x-ray, CT scan, PET scan, and/or MRI throughout the trial. Patients also undergo blood sample collection during screening and on study.
89500247|NCT05609890|Experimental|Active intervention|A formulation made of natural components. Each sachet contains saffron, tea extract, lemon balm and valerian.
89500248|NCT05609890|Placebo Comparator|Placebo|Placebo sachet will contain inert excipient.
89500249|NCT05602376|Experimental|U=U testing messaging scripts|Aim 1: Human-centred designed, behavioural nudge theory informed U=U messaging intervention to improve HIV testing uptake by men
89500250|NCT05602376|Experimental|U=U adherence messaging scripts|Aim 2: Human-centred designed, behavioural nudge theory informed U=U messaging intervention to improve ART adherence, HIV viral suppression and retention in care
89500251|NCT05602376|No Intervention|Standard of Care (SoC) messaging|"Aim 1: SoC messaging scripts will be used to both invite men for CB-HTS and to refer those that test HIV-positive for DoH clinic-based ART initiation~Aim 2: SoC messaging as part of ART initiation counselling, and as part of their HIV care and treatment program"
89500252|NCT05593978|Experimental|Culinary Medicine|Those in this group will receive culinary medicine, which includes cooking videos and educational videos to help educate on ways to increase protein intake through lean ground beef.
89500253|NCT05593978|Other|Control|This group will only receive recipes containing lean ground beef to help increase protein intake.
89500254|NCT05590598|Experimental|Group 1: Azelastine + Mometasone, nasal spray|Participants will receive test product Azelastine + Mometasone, nasal spray, 140 mcg + 50 mcg/dose (Sandoz d.d., Slovenia), one actuation in each nostril twice daily, morning and evening (recommended interval between administrations is approximately 12 hours), for 14 consecutive days.
89500255|NCT05590598|Active Comparator|Group 2: Momat Rhino Advance, nasal dosed spray|Participants will receive reference product Momat Rhino Advance, nasal dosed spray, 140 mcg + 50 mcg mcg/dose (Glenmark Pharmaceuticals Limited., India), one actuation in each nostril twice daily, morning and evening (recommended interval between administrations is approximately 12 hours), for 14 consecutive days.
89500256|NCT05589857|Experimental|Group 1 (Spellbound)|Participants will play SpellBound using the iPad's standard camera, which will show you your hospital room and the decal/stickers s as they appear in the real world.
89500257|NCT05589857|Experimental|Group 2 (Spellbound)|Participants will play the game using augmented reality.
89500258|NCT05588804|Experimental|Group 1: Broncho-munal®|Participants will receive the study drug Broncho-munal®, capsules, 7 mg (Sandoz dd, Slovenia), 1 capsule per day in the morning on an empty stomach, 30 minutes before meals, for 10 consecutive days
89500259|NCT05588804|Placebo Comparator|Group 2: Placebo|Participants will receive a placebo, 1 capsule per day in the morning on an empty stomach, 30 minutes before meals, for 10 consecutive days
89500260|NCT05582551|Experimental|Patients: Highlighting Patients at Risk for Sensory Screening (HPARSS)|"The primary oncology team will utilize the HPARSS to identify patients who are at risk for sensory deficits based on prior treatment. The HPARSS will constitute a file of that will contain eligible patients based upon their past treatment and their corresponding risk for a particular sensory deficit based upon that treatment. The patient and parent/guardian will be approached to participate in the study.~Sensory deficit screening will be completed in the clinic and any screening results that indicate the need for referral for diagnostic testing or therapy will be scheduled by the primary treatment team staff."
89500261|NCT05582551|No Intervention|Providers: Highlighting Patients at Risk for Sensory Screening (HPARSS)|-Providers will complete a survey regarding their views of the HPARSS. The Acceptability of Intervention Measure has 4 questions and the Feasibility of Intervention Measure has 4 questions.
89500262|NCT05554705|Experimental|experimental|standard of care + lifestyle intervention
89500263|NCT05554705|No Intervention|control|no intervention (control group)
89500264|NCT05526053|No Intervention|Standard|"SBT: PSV 8 cmH2O, PEEP 0 cmH2O for 30 minutes and, when successful, followed by extubation with continuous suctioning.~Patients included in the ultrasound nested study:~Diaphragm and intercostal thickness and thickening fraction at the beginning and the end of the SBT.~Modified LUS at the beginning of the SBT, at the end of the SBT and after extubation if successful SBT."
89500265|NCT05526053|Experimental|Lung Volume Preservation|"SBT: PSV 8 cmH2O, PEEP 5 cmH2O for 30 minutes and, when successful, followed by direct extubation without suctioning and connected to the ventilator with PEEP 5 cmH2O.~Patients included in the ultrasound part:~Diaphragm and intercostal thickness and thickening fraction at the beginning and the end of the SBT.~Modified LUS at the beginning of the SBT, at the end of SBT and after extubation if successful SBT."
89500266|NCT05507775|Experimental|Treatment with digoxin|This arm will consist of 10 patients with radioiodine refractory non-medullary thyroid carcinoma. All participants will be treated according to the same protocol.
89500267|NCT05497154|Experimental|Training Arm|
89500268|NCT05495945|Experimental|Dorsolateral prefrontal cortex (DLPFC)|
89500269|NCT05495945|Experimental|Anterior insula cortex (AIC)|
89500270|NCT05495945|Experimental|Central thalamus (CT)|
89500271|NCT05495945|Active Comparator|Sham control|
89538406|NCT03267953|Experimental|First stage: Minimally guided My Health CheckUp.|This group will also be invited to use the 12-week Internet-based stress management program, but they will additionally receive support via weekly telephone calls from a lay coach.
88956005|NCT06008808|Experimental|Phase I: Ruxolitinib|"Ruxolitinib at 5 mg twice per day (BID) beginning on Day -3 and continuing until Day 180 followed by a taper (duration of taper depends on dose of ruxolitinib at Day 180). Once a patient's counts have reached ANC > 1.5 K/cumm, hemoglobin > 9.0 g/dL, and platelets > 50 K/cumm, ruxolitinib dosing will escalate to 10 mg BID.~Ruxolitinib starting dose for patients receiving fluconazole will be 5 mg QD. Patients who remain on fluconazole and meet the target recovery criteria below can increase ruxolitinib dosing to 5 mg BID and subsequently 10 mg BID."
89500272|NCT05483582|Active Comparator|classical electrical stimulation protocol (control group)|"Apply 2-channel electrical stimulation device with protocol 1.~It will simultaneously stimulate bilateral suprahyoid, bilateral thyrohyoid muscle with 2-channel electrical stimulation device.~Basic intervention involves 600-900 minutes of electrical stimulation for 2 weeks. (based on 60 minutes per 1 time, applied 10 times(+5 times, within 1 week))~With the consent of the patient, an additional evaluation is performed after additional 2 weeks of intervention, which is use as an exploratory indicator.~After application of the device, we evaluate videofluoroscopic swallowing study(VFSS) for evaluation of swallowing function.~In addition, we evaluate clinical questionnaires(FOIS, MDADI, Likert scale), nutritional status assessments(MNA-SF), and oral intake assessments.~Also, we measure tongue strength through IOPI and body composition changes through Inbody."
89500273|NCT05483582|Experimental|revised sequential activation protocol (experimental group)|"Apply 4-channel electrical stimulation device with protocol 2.~It sequentially stimulates bilateral suprahyoid muscle(ch 1, ch 2), bilateral thyrohyoid muscle(ch 3), bilateral sternothyroid muscle(ch 4) with 4-channel electrical stimulation device.~Basic intervention involves 600-900 minutes of electrical stimulation for 2 weeks. (based on 60 minutes per 1 time, applied 10 times(+5 times, within 1 week))~With the consent of the patient, an additional evaluation is performed after additional 2 weeks of intervention, which is use as an exploratory indicator.~After application of the device, we evaluate videofluoroscopic swallowing study(VFSS) for evaluation of swallowing function.~In addition, we evaluate clinical questionnaires(FOIS, MDADI, Likert scale), nutritional status assessments(MNA-SF), and oral intake assessments.~Also, we measure tongue strength through IOPI and body composition changes through Inbody."
89500274|NCT05474625|Active Comparator|Exercise Group|Only exercises
89500275|NCT05474625|Active Comparator|High Intensity Laser Therapy(HILT) Group|Exercises+HILT
89500276|NCT05474625|Active Comparator|Conventional Physiotherapy Group|Exercise+Hotpack+Transcutaneous nerve stimulation (TENS)+Ultrasound
89500277|NCT05466383|Active Comparator|recommend exercise - perference exercise|
89500278|NCT05466383|Active Comparator|recommend exercise - perference brace|
89500279|NCT05466383|No Intervention|recommend exercise - perference observation|
89500280|NCT05466383|Active Comparator|recommend brace - perference brace|
89500281|NCT05466383|Active Comparator|recommend brace - perference exercise|
89500282|NCT05466383|No Intervention|recommend brace - perference observation|
89500283|NCT05441592|Experimental|Irrigation that contains tranexamic acid (TXA)|
89500284|NCT05441592|Other|No additional irrigation usual care|
89500285|NCT05438199|Experimental|apparatus use|"All participants will use the apparatus following the same procedures. They will weigh themselves on a scale located in the bathroom, use the apparatus with or without hats (hats refer to a plastic container used to catch stool/urine that needs to be placed between the toilet rim and the toilet seat and discarded after each use) and weigh themselves after using the toilet."
89500286|NCT05437419|Experimental|Cohort 1|The patient will receive Dose A of TCK-276 or matching placebo orally from Day 1 to Day 7 (once daily (QD) under fed conditions).
89500287|NCT05437419|Experimental|Cohort 2|The patient will receive Dose B of TCK-276 or matching placebo orally from Day 1 to Day 7 (once daily (QD) under fed conditions).
89500288|NCT05437419|Experimental|Cohort 3|The patient will receive Dose C of TCK-276 or matching placebo orally from Day 1 to Day 7 (once daily (QD) under fed conditions).
89500289|NCT05437419|Experimental|Cohort 4|The patient will receive Dose D of TCK-276 or matching placebo orally from Day 1 to Day 7 (once daily (QD) under fed conditions).
89023416|NCT05486065|Placebo Comparator|Semaglutide placebo 2 mg|Participants will receive once-weekly semaglutide placebo 2 mg s.c. injection.
89023417|NCT05486065|Experimental|Semaglutide 8 mg|Participants will receive once-weekly semaglutide 8 mg s.c. injection.
88956006|NCT06008808|Experimental|Expansion Phase: Ruxolitinib|"Ruxolitinib at 5 mg twice per day (BID) beginning on Day -3 and continuing until Day 180 followed by a taper (duration of taper depends on dose of ruxolitinib at Day 180). Once a patient's counts have reached ANC > 1.5 K/cumm, hemoglobin > 9.0 g/dL, and platelets > 50 K/cumm, ruxolitinib dosing will escalate to 10 mg BID.~Ruxolitinib starting dose for patients receiving fluconazole will be 5 mg QD. Patients who remain on fluconazole and meet the target recovery criteria below can increase ruxolitinib dosing to 5 mg BID and subsequently 10 mg BID."
88956007|NCT06006702|Experimental|Bioavailability Tablet vs Capsule Formulation|TYRA-300-B01 single oral dose of tablet or capsule crossover followed by twice-daily tablet dosing
88956008|NCT06006702|Experimental|Food Effect Tablet Formulation|TYRA-300-B01 single oral dose of tablet in the fed and fasted state
88956009|NCT06006702|Experimental|Pharmacokinetic Tablet Formulation|TYRA-300-B01 single oral dose
88956010|NCT06006702|Experimental|Pharmacokinetic Mini-Tablet Formulation|TYRA-300-B01 multiple-dose mini-tablet formulation
88956011|NCT06004245|Experimental|Part I: RO7589831 Dose Escalation|
88956012|NCT06004245|Experimental|Part II: RO7589831 Dose Expansion|
89500290|NCT05414968|Experimental|Pilot Feasibility Arm|Each participant will receive the same 45-minute intervention on 10 days spread over no more than 14 days total. At the end of each session, pain will be assessed on scales such as the Defense and Veterans Pain Rating Scale (DVPRS) to establish the safety and feasibility of the proposed intervention.
88956014|NCT06002503|Experimental|1: Intramuscular|Route (device): Intramuscular (PharmaJet Stratis Needle-free Injection System) Vaccine dose schedule (week): 0, 4, 8 Saline dose schedule (week): 26
88956015|NCT06002503|Experimental|2: Intramuscular|Route (device): Intramuscular (PharmaJet Stratis Needle-free Injection System) Vaccine dose schedule (week): 0, 8, 26 Saline dose schedule (week): 4
88956016|NCT06002503|Experimental|3: Intradermal|Route (device): Intradermal (PharmaJet Tropis Needle-free Injection System) Vaccine dose schedule (week): 0, 4, 8 Saline dose schedule (week): 26
88956017|NCT06002503|Experimental|4: Intradermal|Route (device): Intradermal (PharmaJet Tropis Needle-free Injection System) Vaccine dose schedule (week): 0, 8, 26 Saline dose schedule (week): 4
89500291|NCT05406505|Experimental|Dapagliflozine 10mg|
89500292|NCT05406505|Placebo Comparator|Placebo|
89500293|NCT05399875|Experimental|Augmented reality virtual ruler|Patient's in this arm will have their physician use an augmented reality virtual ruler to measure catheter length during catheter placement.
89500294|NCT05398094|Experimental|Experimental: Induction treatment + Post-Induction Phase|"Patients enrolled in the study will receive AMG510 (Sotorasib) 960mg once daily for 2 cycles (Q4W) in the induction phase and AMG510 (Sotorasib) 960 mg once daily (Q4W) in the treatment postinduction phase.~Treatment post-induction phase only for patients with SD, PR or CR after induction treatment. This treatment will be administered until progression disease (PD), unacceptable toxicity, patient or physician's decision to discontinue or death."
89500295|NCT05352451|Experimental|Intervention Arm - coaching sessions|Intervention group, will be asked to complete the surveys before and after attending coaching sessions. The two interviews each lasting for about one hour and will be done in-person or through video-conferencing meeting (depending on which is more convenient for you) with a study team member
89500296|NCT05352451|Active Comparator|Control Arm - interview|"Will be asked to complete the same surveys at appropriate time after meeting with the research assistant. Be asked to complete brief questionnaire about the understanding of the illness.~All individual interviews, patient and caregiver coaching, and caregiver support sessions will be audio recorded. The recorders are password protected and the audio files will be saved securely. Only authorized study team members can access the recordings to evaluate how well the answers to survey questions are logged and how well the coaching/support content is delivered by the study team member."
89500297|NCT05351866|Experimental|SparkRx|5-week CBT-based mobile intervention for adolescents with depressive symptoms
89500298|NCT05351866|Active Comparator|Educational Control|5-week mobile control with education about depression
89500299|NCT05331183|Experimental|ELX/TEZ/IVA|Participants will receive ELX/TEZ/IVA in the morning and IVA in the evening.
89500300|NCT05324137|Experimental|Group 1: 55mg Q2W|CM326 55 mg or matched placebo, every 2 weeks, subcutaneous (SC)
89500301|NCT05324137|Experimental|Group 2: 110mg Q2W|CM326 110 mg or matched placebo, every 2 weeks, subcutaneous (SC)
89500302|NCT05324137|Experimental|Group 3: 220mg Q2W|CM326 220 mg or matched placebo, every 2 weeks, subcutaneous (SC)
89500303|NCT05324137|Experimental|Group 4: 220mg Q4W|CM326 220mg or matched placebo, every 4 weeks, subcutaneous (SC)
89500304|NCT05324137|Experimental|Group 5: CM326 220 mg Q2W|CM326 220 mg, every 2 weeks, subcutaneous (SC)
89500305|NCT05317832|Active Comparator|Web-based physical activity intervention (WI) program|Participants in the WI arm will take part in the WI program (weeks 3 to 16). After the WI program is completed in week 16, the participants will transition to the physical activity sustainability phase which will include participants having continued access to the information provided during the WI program (weeks 17 to 24).
89500306|NCT05317832|Experimental|Web-based physical activity intervention (WI) program + just-in-time adaptive intervention (JITAI)|Participants in the WI + JITAI arm will take part in the WI program (weeks 3 to 16). After the WI program is completed in week 16, the participants will transition to the physical activity sustainability phase which will include participants having continued access to the information provided during the WI program (weeks 17 to 24). In addition, participants will have access to the JITAI that will provide just-in-time feedback and physical activity recommendations (weeks 3 to 24). The type of the feedback and recommendation messages in the WI + JITAI arm will be delivered using micro-randomization, which involves random selection of intervention components at each possible time of delivery.
89500307|NCT05284058|Experimental|Cardiac Magnetic Resonance Imaging|All patients who are candidates for surgical mitral valve repair through minimally-invasive access according to the standard of care will be considered for inclusion in this clinical study. All patients will undergo cardiac Magnetic Resonance Imaging (MRI) exam before the surgery, as well as at 3 months follow-up.
89500308|NCT05253365|Experimental|Memory Support System participants|
89500309|NCT05251116|Other|only one Arm is included in this study|This is a non-randomized, single arm study. All subjects will use the System. Results from the System will be compared to reference instrument.
89205825|NCT00816894|Experimental|D-serine arm|6 week fixed dose phase with D-serine 1500 mg/day to be increased starting from week two to 3000 mg/day followed by a 4 week flexible dose phase allowing for two 500 mg/day dose changes.
89205826|NCT00816894|Active Comparator|Olanzapine arm|6 week fixed dose phase with Olanzapine 15 mg/day to be increased starting from week two to 30 mg/day followed by a 4 week flexible dose phase allowing for two 5 mg/day dose changes.
89205827|NCT00922350|Experimental|heliox|The patients in this group underwent nebulization with heliox carried by the trunk erect
89023418|NCT05486065|Placebo Comparator|Semaglutide placebo 8 mg|Participants will receive once-weekly semaglutide placebo 8 mg s.c. injection.
89500310|NCT05226676|Experimental|Real rTMS group|Repetitive TMS at 20Hz frequency over the M1 will be performed for five consecutive days for 2 weeks (using 90% of the resting motor threshold/total of 500 pulses). The rTMS will be applied through a figure-8 coil connected to a magnetic stimulator, which provides a biphasic pulse. This protocol was developed in accordance with the guidelines for the safe use of rTMS.
89500311|NCT05226676|Sham Comparator|Sham group|Sham stimulation will be performed for five consecutive days for 2 weeks (using 90% of the resting motor threshold/total of 500 pulses). For the sham stimulation a sham coil will be used.
89500312|NCT05225233|Experimental|Active tDCS with Cognitive Training|Participants will receive active tDCS stimulation with their cognitive training during a one-hour session each day which includes 20 minutes of stimulation at the beginning of a 46-minute task training session. Ten sessions will be completed over three weeks.
89500313|NCT05225233|Sham Comparator|Sham tDCS with Cognitive Training|Participants will receive 10 sessions of cognitive training concurrent with sham tDCS. For sham tDCS, electrodes are placed at the same locations as for active tDCS, but current is ramped up for the initial 30 seconds, then immediately ramped back down. This method mimics the initial physical sensation of stimulation, but there is no active current for the remainder of the session.
89500314|NCT05215236|Experimental|Opiate Sparing|Standard icing and elevation therapy Acetaminophen 1000 milligrams by mouth every 8 hours for five days then as needed every 8 hours for pain control Gabapentin 100 milligrams by mouth three times per day for 14 days Celecoxib 100 milligrams by mouth two times per day for 5 days Esomeprazole 20 milligrams by mouth once per day for 14 days Promethazine 12.5 milligrams by mouth every 8 hours as needed for nausea or vomiting Docusate 100 milligrams by mouth two times per day while taking oxycodone Oxycodone 5 milligrams by mouth every 6 hours as needed for pain control unresponsive to other medications
89500315|NCT05215236|Active Comparator|Opiate Based|Standard icing and elevation therapy Oxycodone 5-10 milligrams by mouth every 4 to 6 hours as needed for pain control Acetaminophen 1000 milligrams by mouth every 8 hours as needed for pain control Promethazine 12.5 milligrams by mouth every 8 hours as needed for nausea or vomiting Docusate 100 milligrams by mouth two times per day while taking oxycodone
89500316|NCT05210920|Experimental|Regular Nail Polish|Participants will have regular nail polish applied to one fingernail of their dominant hand
89500317|NCT05210920|Experimental|Gel Nail Polish|Participants will have gel nail polish applied to one fingernail of their dominant hand
89500318|NCT05210920|No Intervention|Bare Nail|Participants will have one fingernail of their dominant hand left bare for comparison
89500319|NCT05182229|Active Comparator|Clinic-Based Lymphedema Therapy|
89500320|NCT05182229|Active Comparator|Home-Based (a hybrid model) Lymphedema Therapy|
89500321|NCT05179941|Experimental|patients requiring a shoulder arthroplasty|Patients will be administered Food and Drug Administration (FDA) approved Indocyanine green (ICG) through intravenous injection and imaged by a FDA approved surgical fluorescence imaging device. Both ICG fluorescence and the imaging system have been used for routine clinical practice for many years. ICG fluorescence imaging utilizes intravenously injected ICG, which is a fluorescent dye that is FDA approved for clinical use, illuminated with near-infrared light. The ICG dye is indirectly activated and the dynamic fluorescence due to meniscal perfusion can be captured by an FDA approved imaging system.
89500322|NCT05170178|Experimental|Women with parental experience caring for infants|Women parent of a child under 2 years old
89205828|NCT00922350|Experimental|heliox+posture|The patients in this group carried out the mist carried by heliox and the trunk tilted forward
89205829|NCT00922350|Experimental|oxygen+posture|The patients in this group carried out the mist carried by oxygen and the trunk tilted forward
89205830|NCT00922350|Active Comparator|oxygen|The patients in this group carried out the mist carried by the oxygen and the trunk upright
89500323|NCT05170178|Experimental|Men with parental experience caring for infants|Men parent of a child under 2 years old
89500324|NCT05170178|Experimental|Women with professional experience in caring for infants|Women in daily contact with infants in professional circle (e.g., nannies, pediatricians, midwives, maternity nurses) without dependent children under 2 years old
89500325|NCT05165901|Experimental|Nociceptive pain|patients with joint pain (knee and shoulder), myofascial pain syndrome
89500326|NCT05165901|Experimental|Neuropathic pain|patients with postherpetic neuralgia, peripheral nerve injury (CRPS type II, brachial plexopathy, nerve entrapment syndrome)
89500327|NCT05165901|Experimental|Mixed pain|patients with spine or SIJ origin back and buttock pain or neck pain and SPINE-origin back pain과 neck pain, SIJ-origin back and buttock pain
89500328|NCT05160558|Experimental|Cohort 1: BIIB132 Dose 1 or Matching Placebo|Participants will be randomized to receive BIIB132 Dose 1 or matching placebo, intrathecally (IT), every 4 weeks (Q4W), up to Day 85.
89500329|NCT05160558|Experimental|Cohort 2: BIIB132 Dose 2 or Matching Placebo|Participants will be randomized to receive BIIB132 Dose 2 or matching placebo, IT, Q4W, up to Day 85.
89500330|NCT05160558|Experimental|Cohort 3: BIIB132 Dose 3 or Matching Placebo|Participants will be randomized to receive BIIB132 Dose 3 or matching placebo, IT, Q4W, up to Day 85.
89500331|NCT05160558|Experimental|Cohort 4: BIIB132 Dose 4 or Matching Placebo|Participants will be randomized to receive BIIB132 Dose 4 or matching placebo, IT, Q4W, up to Day 85.
89500332|NCT05160558|Experimental|Cohort 5: BIIB132 Dose 5 or Matching Placebo|Participants will be randomized to receive BIIB132 Dose 5 or matching placebo, IT, either Q4W or every 12 weeks (Q12W), up to Day 85 or every 8 weeks (Q8W) up to Day 57.
89205831|NCT00635154|Experimental|Anakinra with/without Dexamethasone|"Anakinra was given alone for 6 months at which time response was assessed.~If participants achieved a minor response or better they continued on Anakinra alone until disease progression.~If participants achieved stable disease, they added low dose Dexamethasone to Anakinra until progression.~If at any time a participant progresses, they were administered high dose Dexamethasone with Anakinra."
89500333|NCT05157971|Experimental|Treatment (venetoclax, C10403 regimen)|See Detailed Description
89500334|NCT05143203||Staff trained in October 2021|22 nursing staff will follow two days of Self-Hypnosis training in October 2021
89500335|NCT05143203||Staff trained in May 2021|22 nursing staff will follow two days of Self-Hypnosis training in May 2021
89500336|NCT05143203||Control staff without training|22 nursing staff will not follow any training
89500337|NCT05142215|Active Comparator|Percutaneous coronary intervention|Percutaneous coronary intervention (PCI) for chronic total occlusion (CTO).
89500338|NCT05142215|Placebo Comparator|Placebo percutaneous coronary intervention|Placebo procedure for chronic total occlusion (CTO).
89500339|NCT05141643|Experimental|Participants with pancreatic ductal adenocarcinoma (PDAC)|Participants will have histologically-confirmed pancreatic ductal adenocarcinoma (PDAC). The experimental design of this study is to perform a single [18F]-FAC PET scan prior to the administration of chemotherapy with an optional second [18F]-FAC PET scan procedure during SOC treatment to observe changes in tumor uptake and biodistribution. Patients will be offered a second [18F]-FAC PET scan procedure during their SOC treatment. This second scan will be optional.
89500340|NCT05138991|Experimental|Screening (echo, CMR, Tonometry-based system)|Patients undergo a one time assessment of cardiac function by echo, CMR, and the Tonometry-based system system in the clinic over 4-6 hours, and will be asked to perform their home-based measurements within 1-5 days of the clinical assessment, allowing us to directly compare measurements obtained by survivors to those by research personnel. Patients also complete questionnaires at baseline.
89500341|NCT05129280|Experimental|Part I: Single Participant Cohort (SPC) Dose Escalation|In Part I, RO7444973 is administered intravenously (IV) every 3 weeks (Q3W) at a fixed dose in a single participant per dose level.
89500342|NCT05129280|Experimental|Part II: Multiple Participant Cohort (MPC) Dose Escalation|In Part II, RO7444973 is administered IV Q3W at a fixed dose in multiple participants per dose level. Step-up dosing may also be explored.
89500343|NCT05129280|Experimental|Part III: Recommended Phase 2 Dose (RP2D) Expansion|Based on emerging data from Part II, an RP2D and dosing regimen will be further investigated in Part III.
89500344|NCT05106725||Neurological patients|This cohort will include patients having been diagnosed with a neurological condition.
89500345|NCT05106725||Control|This cohort will include patients who have not been diagnosed with a neurological disorder.
89500346|NCT05095506|Experimental|eHeatlh Intervention Arm|The intervention platform is an interactive, web-based self-management program comprised of computer-adaptive tests (CATs) to assess depression, anxiety, and resilience and multimedia-assisted components. Participants will access the system once a week for 6 weeks, complete the symptom monitoring CATs, receive score reports, and watch a system-assigned self-management strategy video (which is selected by the system based on the participant's current level of depression/anxiety symptoms).
89500347|NCT05095506|Active Comparator|Active Control Arm|The active control condition is a static web-based program which also includes computer-adaptive tests (CATs) to assess depression, anxiety, and resilience, but does not provide score reports and plays a predetermined educational video (related to health promotion after SCI) each week. Participants will access the system once a week for 6 weeks, complete the symptom monitoring CATs and watch the educational video.
89500348|NCT05023252|Experimental|mobile application|Participants use a mobile application on their smartphone
89538407|NCT03267953|Experimental|Second stage: High intensity Motivational Interviewing (MI)|After 6 weeks, response to the first stage programs will be assessed and only the non-responders will be randomized a second time to (a) continue with the first stage programs or (b) High-intensity MI. In addition to continued access to My Health CheckUp, participants in this group will also be supported with 6 weekly, telephone-based MI sessions.
89023419|NCT05486065|Experimental|Semaglutide 16 mg|Participants will receive once-weekly semaglutide 16 mg s.c. injection.
89500349|NCT05010005|Experimental|Ruxolitinib and Duvelisib|Ruxolitinib 20mg BID plus Duvelisib 25mg, 50mg, or 75mg BID. Patients will be instructed to take duvelisib and ruxolitinib by mouth every 12 hours, the same time each day, +/- 2 hours. Duvelisib and ruxolitinib will be provided via the institutional investigational pharmacy. The researchers will utilize a dose-escalation standard 3+3 design in which we evaluate 3 doses of duvelisib (25mg BID, 50mg BID, and 75mg BID) in combination with ruxolitinib 20mg BID. A minus-1 dose level of duvelisib (15mg BID) can be used if de-escalation is needed. The cohort expansion phase will have two treatment groups JAK/STAT activation or mutation present or JAK/STAT activation or mutation absent or unknown. Upon discussion with PI, the treating physician may increase dose up to 20 mg of ruxotlinib and/or 25 mg of duvelisib when deemed clinically favorable.
89500350|NCT04972968|Experimental|ABBV-154 Dose A|Participants in this group will receive dose A of ABBV-154 subcutaneously (SC) every other week (eow) for 52 weeks. In addition, participants will receive a glucocorticoid oral tablet taper.
89500351|NCT04972968|Experimental|ABBV-154 Dose B|Participants in this group will receive dose B of ABBV-154 SC eow for 52 weeks. In addition, participants will receive a glucocorticoid oral tablet taper.
89500352|NCT04972968|Experimental|ABBV-154 Dose C|Participants in this group will receive dose C of ABBV-154 SC eow for 52 weeks. In addition, participants will receive a glucocorticoid oral tablet taper.
89500353|NCT04972968|Placebo Comparator|Placebo|Participants will receive placebo SC eow for 52 weeks. In addition, participants will receive a glucocorticoid oral tablet taper.
89500354|NCT04972097|Experimental|IRE Treatment Arm|All patients enrolled in this trial will receive IRE treatment with the NanoKnife System
89500355|NCT04963400||Patients with low disease severity|Hospitalized patients without a diagnosed or suspected cardiac disease and with an acute medical condition of low severity (e.g. patients with retinal detachment)
89500356|NCT04963400||Patients with medium disease severity|Hospitalized patients without a diagnosed or suspected cardiac disease and with an acute medical condition of medium severity (e.g. patients with an uncomplicated acute pancreatitis oder an acute exacerbation of a chronic inflammatory bowel disease)
89500357|NCT04963400||Patients with high disease severity|Hospitalized patients without a diagnosed or suspected cardiac disease and with an acute medical condition of high severity (e.g. patients with a proximal femoral fracture)
89500358|NCT04954625|Experimental|Autologous Blood Patch|
89500359|NCT04954625|Active Comparator|Standard of Care (Per physician)|
89500360|NCT04953806|Experimental|Step-CBT|Participants will complete Step-CBT, an integrative 10-week physical activity and cognitive behavioral therapy (CBT) intervention, delivered by a licensed clinical psychologist. Sessions will take place once per week for 60 minutes using VA Video Connect. Each session will include core components 1) Reviewing physical activity goals, prescribing new step count goal, and problem-solving barriers and 2) The weekly CBT intervention module.
89500361|NCT04953806|No Intervention|Usual care|Participants are assigned to wait-list control
89500362|NCT04951700||Schizophrenia|Women and men, all races and ethnicities, aged 18-65 years, meeting diagnostic DSM-5 criteria for schizophrenia or schizoaffective disorder.
88956022|NCT05985954|Experimental|BRAF Expansion Cohort|1 of these 2 doses will be selected as the recommended dose of ulixertinib that can be given in combination with cetuximab and encorafenib.
89500363|NCT04951700||Healthy Controls|Women and men, all races and ethnicities, aged 18-75 years, without personal history of lifetime psychiatric disorders, or a family history of psychotic disorders in 1st- or 2nd-degree relatives.
89500364|NCT04945785||control|Before switch Advagraf to Envarsus
89500365|NCT04945785||case|After switch Advagraf to Envarsus
88956023|NCT05985954|Experimental|Cohort A|1 of these 2 doses will be selected as the recommended dose of ulixertinib that can be given in combination with cetuximab alone.
88956024|NCT05983991|Experimental|Subject with a germline GATA2 mutation (Interventional prospective cohort)|
89500366|NCT04928651||Clonidine|Preterm infants (< gw 37+0) who are in need for analgesic or sedative medication will receive treatment with clonidine according to an algorithm based on pain and sedative scoring results
89500367|NCT04923672|No Intervention|Control group|Participants will be asked to wear an Apple watch through about 30 days after surgery and will be asked to maintain their current activity level.
89538408|NCT03268031||Glaucoma patients|Glaucoma patients will take visual field test and OCT imaging of optic nerve area. All of these data will be collected as source of machine learning.
89500368|NCT04923672|Active Comparator|Moderate continuous training group|"Apple watch and a smartphone application~Increase activity to 5 days a week, 40 minutes a day of continuous moderate intensity exercise prior to surgery."
89500369|NCT04923672|Active Comparator|High intensity interval training group|"Apple watch and a smartphone application~Increase activity to 5 days a week, 40 minutes a day of intervals of high and moderate intensity exercise prior to surgery."
89500370|NCT04922762|Experimental|Moderate Intensity, Normal Volume Exercise Training|Participants will complete study 1 (HM20020955-1) and then 10 weeks of moderate intensity, normal volume exercise training
89500371|NCT04922762|Experimental|High Intensity, Normal Volume Exercise Training|Participants will complete study 1 (HM20020955-1) and then 10 weeks of high intensity, normal volume exercise training
89500372|NCT04922762|Experimental|Moderate Intensity, High Volume Exercise Training|Participants will complete study 1 (HM20020955-1) and then 10 weeks of moderate intensity, high volume exercise training
89500373|NCT04916340|Experimental|Muscular Strength|Participants will complete study 1 (HM20020955-1) and then 10 weeks of resistance training for muscular strength
89500374|NCT04916340|Experimental|Muscular fitness|Participants will complete study 1 (HM20020955-1) and then 10 weeks of resistance training for muscular fitness
89500375|NCT04916327|Experimental|Antioxidant then Placebo|Subjects will ingest an antioxidant cocktail prior to their second visit and a placebo prior to third second visit
89500376|NCT04916327|Experimental|Placebo then Antioxidant|Subjects will ingest a placebo prior to their second visit and an antioxidant cocktail prior to their third visit.
89500377|NCT04881448|Experimental|Patients with chronic kidney disease - overall population|Patients with chronic kidney disease (CKD), including patients with non-diabetic chronic kidney disease (non-DKD) and diabetic kidney disease (DKD). Participants in this study did not receive any medication or study drug.
89500378|NCT04875364|Experimental|Early PAP Start|After two initial baseline overnight studies, and two experimental overnight studies during which subjects will receive Eszopiclone (2mg before bedtime) or oxygen (4L/min via nasal cannula for the duration of the time in bed) in random order, subjects will be set up with a loaner CPAP for 8 weeks to initiate therapy right away.
89500379|NCT04875364|Experimental|Usual PAP Start|After two initial baseline overnight studies, and two experimental overnight studies during which subjects will receive Eszopiclone (2mg before bedtime) or oxygen (4L/min via nasal cannula for the duration of the time in bed) in random order, subjects will remain untreated until they are set up with their clinically prescribed CPAP (typically takes about 8 weeks).
89500380|NCT04858022|Experimental|Visual Acoustic Biofeedback for RSE via Telepractice-Treatment|"Condition1: Treatment-first~Children with RSE and typical perception will be allocated to a randomized controlled trial measuring the efficacy of online visual-acoustic biofeedback treatment. Ten children with RSE will receive 10 weeks of visual-acoustic biofeedback training via video call."
89500381|NCT04858022|Experimental|Visual Acoustic Biofeedback for RSE via Telepractice-Wait|"Condition 2: Waitlist-first~Following the initial evaluation, 10 children with RSE will be allocated to a 10 week no treatment condition."
89500382|NCT04848116|Experimental|Cohort 1|Nivolumab (240 mg) + HuMax/BMS-986253 (2400 mg) will be administered as an IV infusion.
89500383|NCT04848116|Experimental|Cohort 2|Nivolumab (240 mg) + HuMax/BMS-986253 (3600 mg) will be administered as an IV infusion.
89500384|NCT04846829|Placebo Comparator|Placebo infusion|Placebo comparator to active study drug
89500385|NCT04846829|Active Comparator|intravenous citalopram hydrochloride (CIT)|A single 40 mg dose of CIT diluted in 60 cc normal saline will be delivered intravenously under double-blind conditions via pump over a 40-minute period.
89500386|NCT04846829|Experimental|intermittent Theta Burst Stimulation|"10 sessions of treatment with cTBS to right DLPFC~TBS consists of three TMS pulses given at 50 Hz, with this triplet repeated at a frequency of 5 Hz (every 200 ms).~iTBS paradigm of a 2 s train repeated every 10 seconds"
89500387|NCT04846829|Experimental|continuous Theta Burst Stimulation|"10 sessions of treatment with iTBS to left or cTBS to right DLPFC~TBS consists of three TMS pulses given at 50 Hz, with this triplet repeated at a frequency of 5 Hz (every 200 ms).~1800 pulses of cTBS will be delivered"
89500388|NCT04837989|Experimental|Diabetes Body Project|Participants randomized to the experimental condition will receive virtual Diabetes Body Project groups immediately.
89500389|NCT04837989|Active Comparator|Educational|Participants randomized to the control condition will receive an education brochure and will be offered the Diabetes Body Project after 6 months.
89500390|NCT04835935||subject who developed atopic disease|
89500391|NCT04835935||subject who did not develop atopic disease|
89500392|NCT04825704|Active Comparator|Bupivacaine|Topical administration of bupivacaine via gauze swab in the tonsillar fossae after removal of throat tonsils.
89500393|NCT04825704|Placebo Comparator|Sodium chloride|Topical administration of 0,9% sodium chloride via gauze swab in the tonsillar fossae after removal of throat tonsils.
89500394|NCT04815083|Placebo Comparator|Standard of Care Arm|Patients in this arm will receive the placebo orally approximately 3 hrs prior to anesthesia followed by standard of care BCS. Fluorescence imaging will be performed on tissue specimens resected prior to completion of standard of care resection. Fluorescence-guided resection will not be performed in patients in this arm.
89500395|NCT04815083|Experimental|PD G 506 A + Fluorescence-Guided Resection Arm|Patients in this arm will receive PD G 506 A orally approximately 3 hrs prior to anesthesia followed by standard of care BCS. Fluorescence imaging will be performed on tissue specimens resected prior to completion of standard of care resection. Fluorescence imaging performed after SoC BCS is complete will guide the resection of additional tissue.
89500396|NCT04798469|Experimental|Testosterone|Intramuscular injections of testosterone undecanoate 750 mg.
89500397|NCT04798469|Placebo Comparator|Placebo|Intramuscular injections of placebo.
89538409|NCT03268031||Non-glaucoma participants|Non-glaucoma participants will take visual field test and OCT imaging of optic nerve area. All of these data will be collected as source of machine learning.
88956029|NCT05980598|Experimental|TransCon TLR7/8 Agonist in combination with pembrolizumab|Participants receive 2 cycles, once every 3 weeks of TransCon TLR7/8 Agonist intratumoral (IT) injection in combination with pembrolizumab as a 30-minute intravenous (IV) infusion
88956030|NCT05980598|Experimental|TransCon TLR7/8 Agonist in combination with TransCon IL-2 β/γ|Participants receive 2 cycles, once every 3 weeks of TransCon TLR7/8 Agonist (IT injection) in combination with TransCon IL-2 β/γ as a 30-minute IV infusion
89500398|NCT04792697|Experimental|Advance/Extend Manipulation|"For ~2 weeks, Advance/Extend participants will advance bedtime and regularize wake time. The first night of the manipulation will be conducted in the lab under tightly-controlled experimental conditions. Participants will then go home and for the next 12 days will be instructed to:~Sleep scheduling-- advance bedtime by 1.5 hours ( + sleep duration)~Decrease evening blue light exposure via blue blocker goggles (2 hrs before bed)~Increase morning bright light exposure via bright light goggles (30 min after rise)~Monitor sleep, mood, and substance use via smartphone-based platform and wrist actigraph"
89500399|NCT04792697|Active Comparator|Control|Control participants will complete the baseline laboratory study, then maintain their habitual sleep schedules over the next 13 days at home, with no instruction on sleep timing or light exposure. Control participants will complete smartphone-and text-based assessments, thereby controlling for effort.
89500400|NCT04782102|Experimental|SOPHIE Intervention|SOPHIE is an online-intervention aiming to reduce social anxiety in adolescents. SOPHIE has 8 modules, one module per week, which lasts about 60 minutes. SOPHIE includes elements of evidence-based psychotherapeutic interventions to reduce social anxiety and of an existing online-intervention for adults with social anxiety adopted to the needs of adolescents. The intervention consists of psychoeducation (how social anxieties arise), application examples (e.g. setting up a personal anxiety cycle or anxiety pyramid, imagination exercise: journey to a safe place), and contains weekly tasks for which regular repetition in everyday life is important (e.g. progressive muscle relaxation, observing anxiety in everyday life, exposures in various situations). At the end of each module, a short quiz allows participants to recall and consolidate what they have learned. The content is presented in video inputs, short explanatory texts, application tasks and quizzes.
89500401|NCT04782102|No Intervention|Care-as-usual|Care-As-Usual: all other kinds of interventions are allowed and will be recorded using the Client Sociodemographic and Service Receipt Inventory (Chisholm et al., 2000; Roick et al., 2001)
89500402|NCT04758000|Experimental|Metformin|"Metformin will be administrated according with patients body mass index (BMI). The study is divided into 2 groups.~Group 1: Localized osteosarcoma that have presented a response ≤ 60% to the pre-operatory chemotherapy).~Group 2: Osteosarcoma and Ewing sarcoma patients with complete remission after the first relapse."
89500403|NCT04756141|Experimental|CGM Use|Determine CGM accuracy when compared with POC (point of care) glucometers.
89500404|NCT04735289||GROUP 1 - 215 Patients and 430 Control cases (1:2)|"Patients of >= 12 years old (pediatric and adults) with new diagnosis of osteosarcoma and Ewing sarcoma will be included~Localized and metastatic~Male and female~Control cases matched by age, sex and italian geographic area"
89500405|NCT04735289||GROUP 2 - Pilot Phase :55 Patients and 110 Control cases (1:2)|"Patients of >= 12 years old (pediatric and adults) with new diagnosis of osteosarcoma and Ewing sarcoma will be included Localized and metastatic Male and female~Control cases matched by age, sex, and geographic area"
89500406|NCT04721145|Experimental|Dexcom G6 Continuous Glucose Monitor|Children with type 1 diabetes will wear a continuous glucose monitor (CGM) for 10 days.
89500407|NCT04691141|Experimental|ATG-016|5 mg QD×Days 1-5/week will be the initial dose of this study.
89500408|NCT04688320|Experimental|Recombinant nonimmunogenic staphylokinase|lyophilisate for preparation of a solution for intravenous administration, 5 mg (745,000 IU) complete with a solvent. 15 mg (2,235,000 IU) - 3 vials, intravenously as a quick single bolus injection for 10-15 seconds, regardless of body weight.
89500409|NCT04688320|Experimental|Alteplase|Alteplase® is administered in accordance with the instructions for use for pulmonary embolism( 10 mg bolus and 90 mg as IV infusion over 2 hours, maximum 100 mg). In patients weighing less than 65 kg, the total dose should not exceed 1.5 mg / kg.
89500410|NCT04684576|Experimental|Explorer Mini First (AB Arm)|Children randomized into this arm will first trial a Permobil Explorer Mini powered mobility device over an 8-week intervention period, then trial a modified ride-on car over a second 8-week intervention period in their home and community environments.
89500411|NCT04684576|Active Comparator|Modified Ride On Car First (BA Arm)|Children randomized into this arm will first trial a modified ride-on car over an 8-week intervention period, then trial a Permobil Explorer Mini powered mobility device over a second 8-week intervention period in their home and community environments.
89500412|NCT04661072||Patients with Congenital Uterine Anomalies (CUA)|The rates of renal, breast, uterine, ovarian and vaginal cancers in women who have been diagnosed with a CUA will be studies
89500413|NCT04659616|Experimental|Treatment (cytarabine, daunorubicin, pemigatinib)|"INDUCTION: Patients receive cytarabine IV on days 1-7, daunorubicin IV on days 1-3, and pemigatinib PO QD on days 8-21 in the absence of disease progression or unacceptable toxicity. Patients with hematologic count recovery (assessed between days 25-42) after induction proceed to consolidation therapy. Patients undergo ECHO during screening and as clinically indicated on study. Patients undergo blood sample collection and bone marrow aspirate and biopsy during screening and cycle 11 day 21 on study.~CONSOLIDATION: Patients receive high dose cytarabine IV BID on days 1, 3, and 5, and pemigatinib PO QD on days 8-21. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression of unacceptable toxicity. Patients undergo ECHO as clinically indicated and blood sample collection and bone marrow biopsy and aspirate at the end of consolidation."
89500414|NCT04645927|Placebo Comparator|Placebo control beverage group|The placebo will be provided in the same unmarked plain packages and contain the same constituents, but without flax (control packages contain oat fiber and milk). For 180 days (6 months) participants will consume 2 servings of 330 ml of placebo beverage (i.e. normal fiber beverage; control) per day.
89500415|NCT04645927|Experimental|Experimental flax beverage group|Flax beverage (30 gr daily, oral) is presented in liquid form in plain unmarked packages. For 180 days (6 months) participants will consume 2 servings of 330 ml of flax beverage (treatment group; 30 gms flax/day beverage) per day.
89500416|NCT04627870|Experimental|DCB group|use drug (paclitaxel) coated balloon to treat intracranial in-stent restenosis
89500417|NCT04627870|Active Comparator|PTA group|use PTA balloon to treat intracranial in-stent restenosis
89500418|NCT04625101|Experimental|NBI-827104|NBI-827104 administered orally for 13 weeks.
89500419|NCT04625101|Placebo Comparator|Placebo|Placebo administered orally for 13 weeks.
89500420|NCT04586699|Experimental|Medi1TMS|rTMS theta-burst protocol paired with a consistent attention-to-breath task
89500421|NCT04586699|Active Comparator|Medi2TMS|rTMS theta-burst protocol paired with an intermittent deep breathing task
89500422|NCT04564742|Experimental|Dapagliflozin|Patients will be randomized 1:1 to either dapagliflozin or placebo
89500423|NCT04564742|Placebo Comparator|Placebo|Placebo matching dapagliflozin
89500424|NCT04562649|Experimental|Intervention|Wise App that delivers medication adherence reminders and community health worker sessions
89500425|NCT04562649|No Intervention|Control|Standard of care
89500426|NCT04508790|Experimental|Treatment (leflunomide, pomalidomide, dexamethasone)|Patients receive leflunomide PO on days 1-28, pomalidomide PO on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89500427|NCT04492566|Experimental|AID Evaluation|"After completing a 1-2 week CGM run-in period, subjects will complete a 48-60 hour closed-loop (CL) session in a supervised outpatient environment with medical staff present.~For subjects who wish to continue use of the system, they will be offered the option of continuing use of the system at home in an extension phase, for the rest of their pregnancy."
89500428|NCT04490603|No Intervention|Conventional group|Drug is injected to epidural space for a total of 50 minutes. The drug injection is provided in the same way as the conventional method of injecting drugs in Seoul National University Hospital Pain Center.
89500429|NCT04490603|Experimental|VR group|Drug is injected to epidural space for a total of 50 minutes. The drug injection is provided with virtual reality experience. Conditions are the same in both arms except for virtual reality experience.
89500430|NCT04469881|Experimental|Virtual Reality|Wear VR glasses and watch movies during surgery
89500431|NCT04468633|Active Comparator|Baerveldt 350 implant|
89500432|NCT04468633|Active Comparator|Ahmed ClearPath 350 implant|
89500433|NCT04466787|Experimental|Spectral Photon Counting Computed Tomography (SPCCT)|The randomized SPCCT patient will have this CT scan and an MRI before surgery. The plaque carotid will be collected for histological analysis
89500434|NCT04466787|Active Comparator|Dual Energy CT (DECT)|The randomized DECT patient will have this CT scan and an MRI before surgery. The plaque carotid will be collected for histological analysis
89500435|NCT04452162|Other|Salivary Gland Tumor|
89500436|NCT04424290|Experimental|SRD part: BI 764524|SRD part: BI 764524
89500437|NCT04424290|Sham Comparator|MRD part: Sham control of BI 764524|MRD part: Sham control of BI 764524
89500438|NCT04424290|Experimental|MRD part: BI 764524|MRD part: BI 764524
89500439|NCT04393389||non-CLI group|Rutherford Clinical Category (RCC) 2-3
89500440|NCT04393389||CLI group|critical limb ischemia，Rutherford Clinical Category (RCC) 4-6
89500441|NCT04378244|Experimental|DeltaRex-G|"Escalating doses of DeltaRex-G i.v daily for 7 days as follows:~Dose Level I: 3-6 patients will receive 1 x 10e11 cfu/dose Dose Level II: 3-6 patients will receive 2 x 10e11 cfu/ dose Dose Level III: 3-6 patients will receive 3 x 10e11 cfu/dose"
89500442|NCT04298346||Case|
89500443|NCT04298346||Control|
89500444|NCT04281472|Experimental|efgartigimod PH20 SC|patients receiving efgartigimod PH20 SC in both stage A as stage B
89500445|NCT04281472|Placebo Comparator|Placebo|patients receiving efgartigimod PH20 SC during stage A and receiving placebo in stage B
89500446|NCT04280718|Experimental|efgartigimod PH20 SC|Patients treated with efgartigimod PH20 SC
89500447|NCT04275310|Experimental|Microeconomic intervention|
89500448|NCT04275310|No Intervention|Waitlisted control|
89500449|NCT04273061|Experimental|Breast Cohort|Cohort of participants whose primary tumour type is breast.
89500450|NCT04273061|Experimental|Lung Cohort|Cohort of participants whose primary tumour type is lung.
89500451|NCT04273061|Experimental|GI Cohort|Cohort of participants whose primary tumour type is gastrointestinal (including pancreas and hepatobiliary).
89500452|NCT04273061|Experimental|GU Cohort|Cohort of participants whose primary tumour type is genitourinary.
89500453|NCT04273061|Experimental|Gyne Cohort|Cohort of participants whose primary tumour type is gynecological.
89500454|NCT04273061|Experimental|Sarcoma Cohort|Cohort of participants whose primary tumour type is sarcoma.
89500455|NCT04273061|Experimental|Primary Unknown Cohort|Cohort of participants whose primary tumour type is unknown.
89500456|NCT04273061|Experimental|Other Cohort|Cohort of participants whose primary tumour type is not classified as one of the other study arms. This cohort includes participants with cancers from the head and neck, skin, or rare cancers.
89500457|NCT04268992|Experimental|Long-term exercise|Supervised exercise training three times a week for three months.
89500458|NCT04268992|No Intervention|Usual care|Patients are not offered supervised exercise.
89500459|NCT04217525||Spinal Disorders|This group includes patients with any spinal deformity or disorder coming in for treatment.
89500460|NCT04217525||Spinal Tumors|This group includes patients with spinal tumors or metastasis of the spine, coming in for treatment.
89500461|NCT04157231|No Intervention|Usual Care|Usual care to be provided to patients as per hospital guidelines for 3 months
89500462|NCT04157231|Other|Intervention arm|"The intervention consists of training and education of the site staff about the treatment protocol for the different components of the management plan will be provided on two occasions. This intervention will run for 3 months.~Refresher training will be given monthly during the intervention."
89500463|NCT04157088|Experimental|Participants treated with darolutamide|
89500464|NCT04157088|Experimental|Participants treated with enzalutamide|
89500465|NCT04149860|Experimental|Part A: Lu AF87908 or Placebo|Participants in Cohorts A1 to A6 will receive a single dose of either Lu AF87908 or matching placebo at specific dose levels on Day 1.
89500466|NCT04149860|Experimental|Part B: Lu AF87908 or Placebo|Participants in Cohorts B1 to B3 will receive a single dose of either Lu AF87908 or matching placebo at specific dose levels on Day 1.
89500467|NCT04149860|Experimental|Part C: Lu AF87908 or Placebo|Participants in Cohorts C1 and C4 will receive a single dose of either Lu AF87908 or matching placebo at specific dose levels on Day 1.
89500468|NCT04140266|Experimental|Group A: Dapivirine (DPV) Vaginal Ring (VR)-004|Mothers will use one DPV VR continuously for approximately one month, replacing the DPV VR each month for approximately three months.
89500469|NCT04140266|Experimental|Group B: Truvada Tablet|Mothers will take one Truvada oral tablet daily for approximately three months.
89500470|NCT04133363|Experimental|Ridge preservation using L-PRF/ FDBA Layered|Atraumatic tooth extraction following by socket grafting using L-PRF/FDBA layered technique
89500471|NCT04133363|Experimental|Ridge preservation using L-PRF/ FDBA|Atraumatic tooth extraction following by socket grafting using L-PRF/FDBA
89500472|NCT04133363|Experimental|Ridge preservation using L-PRF|Atraumatic tooth extraction following by socket grafting using L-PRF alone
89500473|NCT04120415|Experimental|Vaccine and Vedolizumab infusion|"Vaccine:~The vaccine is MVA HIV-B which is a solution of HIV MVA vectors in S08 buffer (10mM Tris/hydrochloride (Tris/HCl), Saccharose 5% (w/v), 10mM Sodium Glutamate (Na Glu), 50mM Sodium Chloride (NaCl), water PPI, pH 8.0).~Vedolizumab infusion (Entyvio):~Vedolizumab (300mg) is administered as an intravenous infusion (255 ml)."
89500474|NCT04120415|Experimental|Placebo vaccine and Vedolizumab infusion|"Placebo vaccine:~The placebo for MVA HIV-B to be used in this trial is a solution composed of S08 buffer (as for the MVA vaccine).~Vedolizumab infusion (Entyvio):~Vedolizumab (300mg) is administered as an intravenous infusion (255 ml)"
89500475|NCT04120415|Placebo Comparator|Placebo vaccine and placebo infusion|"Placebo vaccine:~The placebo for MVA HIV-B to be used in this trial is a solution composed of S08 buffer (as for the MVA vaccine).~Placebo infusion:~Sodium Chloride (NaCl) 0.9% administered as an intravenous infusion (255ml)"
89500476|NCT04093570|Experimental|Main Extension Study: ASTX727|The recommended starting dose is the fixed-dose combination (FDC) tablet, containing 100 mg cedazuridine and 35 mg decitabine, once daily, Days 1 through 5 in 28-day cycles. Participants should receive ASTX727 at the same dose they received in the last cycle of their parent study; if an adjustment from that dose is required, a different total cycle dose may be employed, as guided by the dose adjustment guidelines in the parent study protocol.
89500477|NCT04093570|Experimental|Substudy Arm A: ASTX727 With High-Calorie/High-Fat Breakfast Meal on Day 4|"Participants will receive ASTX727 once daily on Days 1 through 5 in a 28-day cycle (Cycle 1). Participants will fast for at least 2 hours before and 2 hours after dosing on Days 1, 3, 5 and for at least 10 hours before and 4 hours after dosing on Day 2. Participants will receive a high-calorie/high-fat breakfast meal after an overnight fast of at least 10 hours before dosing on Day 4 and will continue to fast for at least 4 hours post-dose.~Participants will continue treatment with ASTX727 in Cycle 2 onwards in the ASTX727-06 study at the Investigator's discretion, where they will continue to receive ASTX727 unless there is occurrence of disease progression requiring alternative therapy, unacceptable toxicity, noncompliance, a decision to discontinue treatment, or if the participant withdraws from the study."
89500478|NCT04093570|Experimental|Substudy Arm B: ASTX727 With Low-Calorie/Low-Fat Breakfast Meal on Day 4|"Participants will receive ASTX727 once daily on Days 1 through 5 in a 28-day cycle (Cycle 1). Participants will fast for at least 2 hours before and 2 hours after dosing on Days 1, 3, 5 and for at least 10 hours before and 4 hours after dosing on Day 2. Participants will receive low-calorie/low-fat breakfast meal after an overnight fast of at least 10 hours before dosing on Day 4 and will continue to fast for at least 4 hours post-dose.~Participants will continue treatment with ASTX727 in Cycle 2 onwards in the ASTX727-06 study at the Investigator's discretion, where they will continue to receive ASTX727 unless there is occurrence of disease progression requiring alternative therapy, unacceptable toxicity, noncompliance, a decision to discontinue treatment, or if the participant withdraws from the study."
89500479|NCT04054453|No Intervention|Pre-intervention|Baseline data on neonatal encephalopathy and epilepsy before the introduction of the care bundle
89500480|NCT04054453|Experimental|Post-intervention|Baseline data on neonatal encephalopathy and epilepsy after the introduction of the care bundle
89500481|NCT03977870||patients with Venous thromboembolism (VTE)|
89500482|NCT03977532|Experimental|patients with sickle cell disease|
89500483|NCT03971461|Experimental|Lutathera|
89500484|NCT03961854|Active Comparator|Probiotic Group|The probiotic group will receive a daily capsule with Lactobacillus johnsonii N6.2 1x109 CFUs. Participants will consume one capsule (treatment or placebo) daily for 24 weeks.
89500485|NCT03961854|Placebo Comparator|Placebo Group|The placebo group will receive a capsule daily with dried skim milk (vehicle of the probiotic). Participants will consume one capsule (treatment or placebo) daily for 24 weeks.
89538410|NCT03267875|Experimental|single arm|Patients after aneurysm in the aorta, Men and women aged 18-100 (not including special populations), who are able to read understand and sign a written consent to participate in the research
89205832|NCT00778895|Experimental|Fluviral F1 Group|Subjects 6 months to 3 years of age received if primed, 1 dose of formulation 1 of Fluviral vaccine at Day 0 and if unprimed, 2 doses of formulation 1 of Fluviral vaccine at Day 0 and approximately Day 28. The vaccine was administered intramuscularly in the anterolateral part of the thigh (if the subject was less than 12 months) or in the deltoid region of the arm.
89205833|NCT00778895|Experimental|Fluviral F2 Group|Subjects 6 months to 3 years of age received if primed, 1 dose of formulation 2 of Fluviral vaccine at Day 0 and if unprimed, 2 doses of formulation 1 of Fluviral vaccine at Day 0 and approximately Day 28. The vaccine was administered intramuscularly in the anterolateral part of the thigh (if the subject was less than 12 months) or in the deltoid region of the arm.
89205834|NCT00778895|Active Comparator|Vaxigrip Group|Subjects 6 months to 3 years of age received if primed, 1 dose of Vaxigrip vaccine at Day 0 and if unprimed, 2 doses of Vaxigrip vaccine at Day 0 and approximately Day 28. The vaccine was administered intramuscularly in the anterolateral part of the thigh (if the subject was less than 12 months) or in the deltoid region of the arm.
89205835|NCT02550678|Experimental|Cohort 1|Study Participants will receive ASN-002 at a dose 5X 10(10) vp, weekly injection in tumor nodules for 3 weeks.
89205836|NCT02550678|Experimental|Cohort 2|Study Participants will receive ASN-002 at a dose of 1.5X 10(11) vp weekly injection in tumor nodules for 3 weeks
89205837|NCT02550678|Experimental|Cohort 4|Study Participants will receive ASN- 002 at a dose of 3.0X 10(11) vp weekly injections in tumor nodules for 3 weeks.
89205838|NCT02550678|Experimental|Cohort 5|Study Participants will receive ASN- 002 at a dose of 2.25X 10(11) vp weekly injections in tumor nodules for 3 weeks.
89205839|NCT02550678|Experimental|Combination Cohorts|Study Participants will receive ASN- 002 at either dose of Cohorts II, IV or V in combination with a low dose 5-FU (1mg/2.5 mg/5mg/10mg or 25mg) weekly injections in tumor nodules for 3 weeks.
89205840|NCT00293215|Experimental|Cohort 1 (1.0 mg/m^2)|Subjects received 111-In-CMD-193 on Day 1 of Cycle 1. Subjects received CMD-193 at a dose of 1.0 mg/m^2 on Day 1 of subsequent 21-day cycles.
89205841|NCT00293215|Experimental|Cohort 2 (2.6 mg/m^2)|Subjects received 111-In-CMD-193 on Day 1 of Cycle 1. Subjects received CMD-193 at a dose of 2.6 mg/m^2 on Day 1 of subsequent 21-day cycles.
89205842|NCT00822744|Experimental|SSR411298 10 mg|SSR411298 10 mg, one capsule once daily for 8 weeks
89205843|NCT00822744|Experimental|SSR411298 50 mg|SSR411298 50 mg, one capsule once daily for 8 weeks
89205844|NCT00822744|Experimental|SSR411298 200 mg|SSR411298 200 mg, one capsule once daily for 8 weeks
89205845|NCT00822744|Active Comparator|Escitalopram 10 mg|Escitalopram 10 mg, one capsule once daily for 8 weeks
89205846|NCT00822744|Placebo Comparator|Placebo|Placebo (for SSR411298), one capsule once daily for 8 weeks
89205847|NCT04102787|Experimental|experimental group|Experimental group who received the Cardiac educational program and will be applied for Coronary Artery Disease patients, and measure the level of knowledge and satisfaction in pre and post test.
89205848|NCT04102787|No Intervention|control group|Control group who received the usual care and measure the level of knowledge and satisfaction in pre and post test.
89205849|NCT01065337|No Intervention|control group|patients received standard of care wound treatment according guideline of the American Diabetes Association (ADA)
89205850|NCT01065337|Active Comparator|bone marrow stem cells intraarterial|bone marrow stem cells administered intraarterial
89205851|NCT01065337|Active Comparator|tissue repair cells intramuscular|expanded bone marrow cells enriched in CD90+ mesenchymal stem cells administered intramuscular
89205852|NCT01065337|Active Comparator|tissue repair cells intraarterial|expanded bone marrow cells enriched in CD90+ mesenchymal stem cells administered intraarterial
89205853|NCT01065337|Active Comparator|bone marrow stem cells intramuscular|bone marrow stem cells administered intramuscular
88956031|NCT05980598|Active Comparator|Pembrolizumab|Participants receive 2 cycles, once every 3 weeks of pembrolizumab alone as a 30-minute IV infusion
89205854|NCT00819468|Experimental|Participants with Moderate Hepatic Impairment|Participants with moderate hepatic impairment (Child-Pugh score of 7-9) will receive 20 mg of teduglutide.
89205855|NCT00819468|Active Comparator|Healthy Volunteers|Healthy volunteers with normal hepatic function matched to hepatic impaired participants by age, gender, BMI, and renal function as measured by creatinine will receive 20 mg of teduglutide.
89205856|NCT04102553|Experimental|F-18-PSMA-1007|Patients will receive F-18-PSMA-1007 PET/CT first, followed by F-18-Fluorocholine PET/CT.
89205857|NCT04102553|Active Comparator|F-18-Fluorocholine|Patients will receive F-18-Fluorocholine PET/CT first, followed by F-18-PSMA-1007 PET/CT.
89205858|NCT01067599|Active Comparator|Low nicotine|Conventional smokeless tobacco product with 1) NNN plus NNK of <2 μg/gram and nicotine levels of >5 mg/g wet weight
89205859|NCT01067599|Active Comparator|Medium nicotine|Conventional smokeless tobacco product with ) NNN plus NNK of <2 μg/gram and nicotine levels of 3-5 mg/g wet weight.
89205860|NCT01067599|Active Comparator|High nicotine|Conventional smokeless tobacco product with NNN plus NNK of <2 μg/gram and nicotine levels of <3 mg/g wet weight
89205861|NCT00822822||A|Health History Process
89205862|NCT02601131||AML, ALL and MDS|Patients receiving intensive chemotherapy with diagnoses of acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL) or myelodysplastic syndromes (MDS).
89205863|NCT02601131||Autologous stem cell transplantation|Patients undergoing autologous stem cell transplantation
89205864|NCT02601131||Allogeneic stem cell transplantation|Patients undergoing allogeneic stem cell transplantation including both myeloablative conditioning (MAC) and the reduced-intensity conditioning (RIC)
89538411|NCT05075447|Experimental|ADHD group|Child diagnosed with ADHD
89538412|NCT05075447|No Intervention|control group|Children without any diagnosis
89500486|NCT03954678|Experimental|Exercise Group|Participants randomized to the activity intervention will aim for taking 10,000 steps per day and completing strength training exercises three times per week.
89500487|NCT03954678|Active Comparator|Nutrition Group|Participants randomized to the nutrition intervention will consume a liquid over-the-counter nutrition supplement two times per day.
89500488|NCT03939520|Experimental|Combined therapy|
89500489|NCT03939520|Active Comparator|Switch monotherapy|
89500490|NCT03939520|Other|Control group|
89500491|NCT03926143|Experimental|Cancer patients|Adult patients with solid cancer who received anetumab-ravtansine treatment in a completed Bayer study
89500492|NCT03876262|Experimental|Annual Moxidectin|Moxidectin 8mg per oral, administered annually for 24 months
89205865|NCT02601131||Platelet transfusion prophylaxis|Patients receiving platelet transfusion prophylaxis before the intervention, such as insertion of a central venous catheter or lumbar puncture
89205866|NCT02601131||Control|Patients with AML, ALL or MDS that have low PLC (10-20 billion/L) and is not relevant for platelet transfusion. Samples taken in the same manner as in the other groups. Control is needed to rule out other causes of variation of the PLC than the platelet transfusion and thereby strengthen the causality between a given transfusion and increased PLC.
89205867|NCT01065415||control group|routine staging work-up with chest CT, PET/CT, and brain MRI
89205868|NCT01065415||study group|routine staging work-up plus whole body MRI for Coregistered MRI/PET
89500493|NCT03876262|Experimental|Biannual Moxidectin|Moxidectin 8mg per oral, administered biannually for 24 months
89500494|NCT03876262|Active Comparator|Annual Ivermectin|Ivermectin (approximately) 150 micrograms/kg per oral, administered annually for 24 months
88956038|NCT05970172|Experimental|Roxadustat|Participants will receive roxadustat orally (or via gastric tube as an aqueous dispersion, if necessary) 3 times per week. The 24-week treatment period is defined as 4 weeks of fixed dose treatment followed by 20 weeks of dose titration(s). Dose titrations will be based on hemoglobin (Hb) monitoring. Participants in the study may receive roxadustat treatment for up to 52 weeks.
88956039|NCT05969002||Adult|Participants >/=18 years old with relapsed/refractory B cell ALL proceeding to CAR therapy at the NIH
88956040|NCT05969002||Pediatric|Participants <18 proceeding to CAR therapy at the NIH with a clinical indication for FDG PET-CT prior to CAR infusion
88956041|NCT05968859|Active Comparator|Aerobic Training|Subjects with PAH will be enrolled to complete baseline study assessments, be randomized to undergo aerobic training for 12 weeks, and then repeat study assessments.
88956042|NCT05968859|Experimental|Leg Training|Subjects with PAH will be enrolled to complete baseline study assessments, be randomized to undergo leg training for 12 weeks, and then repeat study assessments.
88956043|NCT05968859|No Intervention|Healthy Controls|Healthy controls will be enrolled to complete the baseline study assessments for generation of normal reference values for comparison. Healthy controls will not undergo randomized exercise training interventions or repeat assessments.
89500495|NCT03876262|Experimental|Biannual Ivermectin|Ivermectin (approximately) 150 micrograms/kg per oral, administered biannually for 24 months
89500496|NCT03867682|Experimental|Phase I and Phase II|"Lintuzumab-Ac225 administered on Day 5 of each cycle for four cycles (unless in the 0.5 μCi/kg or 0.25 μCi/kg cohorts, where there is a potential for an additional four cycles, pending PI and Medical Monitor review).~Venetoclax taken on Days 1-21 of each cycle for up to 12 cycles.~Each cycle is 28 days, with a potential to expand to 42 days to allow for full hematologic recovery."
89500497|NCT03846505|Experimental|Oxytocin|"A 40-IU dose of oxytocin will be self-administered 30 minutes prior to the start of each weekly ABCT session.~All participants will receive 12 weekly, 90-minute ABCT therapy sessions delivered by trained Masters or Doctoral-level clinicians consistent with the published manual."
89538413|NCT05075447|Experimental|ADHD+ODD/CD group|Child diagnosed with ADHD+ODD/CD
89538414|NCT05075525|Experimental|High Intensity Laser Therapy Group|Patients underwent High Intensity Laser Therapy (HILT) and exercise for 10 sessions
89538415|NCT05075525|Experimental|Ultrasound and Transcutaneous Electrical Nerve Stimulation Group|Patients will be treated by transcutaneous electrical nerve stimulation(TENS), ultrasound (US) and exercise for 10 sessions
89538416|NCT05075525|Experimental|Ultrasound and Interferential Current Stimulation Group|Patients will be treated with ultrasound (US) ,interferential current stimulation and exercise for 10 sessions
88956048|NCT05965830||Study cohort|The study population consists of clinically stable infants or pediatric patients up to 12 months of age admitted to the PICU.
88956049|NCT05964855|Experimental|Unilateral Subject Group|Foot-ankle devices will be given to this group to evaluate and compare the devices.
88956050|NCT05960773|Experimental|1/ Arm 1|Decitabine/cedazuridine (35 mg decitabine and 100 mg cedazuridine; PO QD)
89023420|NCT05486065|Placebo Comparator|Semaglutide placebo 16 mg|Participants will receive once-weekly semaglutide placebo 16 mg s.c. injection.
89023421|NCT05483595|Other|ZFXN group|Subjects actually testing ZFXN
89500498|NCT03846505|Placebo Comparator|Placebo|"A placebo will be self-administered 30 minutes prior to the start of each weekly ABCT session.~All participants will receive 12 weekly, 90-minute ABCT therapy sessions delivered by trained Masters or Doctoral-level clinicians consistent with the published manual."
89500499|NCT03825692|Experimental|Zhizhu Kuanzhong Capsule|Zhizhu Kuanzhong Capsule Arm is Zhizhu Kuanzhong Capsule, Specification: 0.43 g/granule; Manufacturer: Lonch Group, Shuangren Pharmaceutical Co., Ltd. ; Approval number: NMPA approval number: GUOYAOZHUNZI Z20020003; Dosage and administration: 3 capsules at a time, 3 times a day, taken orally 10-15 min before meals
89500500|NCT03825692|Placebo Comparator|Zhizhu Kuanzhong Placebo Capsule|Zhizhu Kuanzhong Placebo Capsule Arm is Zhizhu Kuanzhong Capsule Mimics composed of microcrystalline cellulose, mannitol and magnesium stearate, which used for filling agent and lubricant respectively; Specification: 0.43 g/granule; Manufacturer: Lonch Group, Shuangren Pharmaceutical Co., Ltd.; Dosage and administration: Be identical with the investigational drug.
89500501|NCT03821324|Other|Intervention|Device: Venus Viva
89205869|NCT00778817|Experimental|Arm II (Mitotane + IMC-A12)|Patients receive mitotane as in arm I and anti-IGF-1R recombinant monoclonal antibody IMC-A12 IV over 1 hour once every 2 weeks in the absence of disease progression or unacceptable toxicity.
89205870|NCT00293059|Experimental|Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027)|A blister card consists of 28 pills taken orally once a day for 28 days (one cycle): 2 days of 3 mg estradiol valerate (EV); 5 days of 2 mg EV + 2 mg dienogest (DNG); 17 days of 2 mg EV + 3 mg DNG; 2 days of 1 mg EV; 2 days of placebo
89500502|NCT03768570|No Intervention|Surveillance|
89500503|NCT03768570|Active Comparator|Durvalumab|
89500504|NCT03713411|No Intervention|No-catheter|after semirigid or flexible ureteroscopy + double J stent placement for ureteral or kidney stones, patients in whom a urethral catheter wasn't placed
89500505|NCT03713411|Active Comparator|Catheter|urethral catheter placement after semirigid or flexible ureteroscopy + double J stent placement for ureteral or kidney stones
89500506|NCT03673644||Primary Open-Angle Glaucoma|"Two following two questionnaires will be administered:~Life Space Questionnaire: This 9-item questionnaire is interested in finding out how much a person gets out and about and the spatial extent of the person's typical life space, i.e., what is the usual range of places in which the person engages in activities within the designated time frame.~Low Luminance Questionnaire: This 32-item questionnaire is interested in finding out problems that involve vision under different lighting conditions or feelings that people have about your vision under different lighting conditions."
89500507|NCT03617445|Active Comparator|FMT oral capsules/ oral vancomycin placebo|FMT plus placebo vancomycin
89500508|NCT03617445|Active Comparator|Placebo FMT capsules/ Active oral vancomycin|Vancomycin plus FMT enema placebo
88956053|NCT05959018|Sham Comparator|Non-impregnated CVC - Arrow Three-Lumen Central Venous Catheter|Control group who receives non-impregnated CVC - Arrow Three-Lumen Central Venous Catheter
88956054|NCT05959018|Experimental|Antimicrobial-impregnated CVC - Arrowg+ard Blue Plus® Three-Lumen Central Venous Catheter|Group who receives antimicrobial-impregnated CVC - Arrowg+ard Blue Plus® Three-Lumen Central Venous Catheter
88956055|NCT05957367|Experimental|Dose Escalation (Part 1, Module A)|DCC-3116 tablets in escalating dose cohorts in 28-day cycles will be administered in combination with encorafenib once daily (QD) and cetuximab once every 2 weeks (Q2W).
88956056|NCT05957367|Experimental|Expansion (Part 2, Module A)|DCC-3116 tablets will be administered in combination with encorafenib and cetuximab in 28-day cycles to evaluate preliminary efficacy in participants with 2nd- or 3rd-line BRAF V600E mutated colorectal cancer (CRC).
88956057|NCT05957367|Experimental|Dose Escalation (Part 1, Module B)|DCC-3116 tablets in escalating dose cohorts in 28-day cycles will be administered in combination with ripretinib once daily (QD).
88956058|NCT05957367|Experimental|Expansion (Part 2, Module B)|DCC-3116 tablets will be administered in combination with ripretinib in 28-day cycles to evaluate preliminary efficacy in participants with 2nd-line advanced gastrointestinal stromal tumor (GIST).
89500509|NCT03512301|Experimental|CAMCI Baseline Only|Computerized and paper-pencil neuropsychological tests, baseline
89500510|NCT03512301|Experimental|CAMCI Baseline + Follow-Up|Computerized and paper-pencil neuropsychological tests, Baseline + Follow-Up
89500511|NCT03421652|Experimental|Treatment (nivolumab, radiation therapy)|Given IV
89500512|NCT03416933|Experimental|Biological|
89500513|NCT03409770|No Intervention|Usual care|Usual care (normothermia) arm
89500514|NCT03409770|Experimental|Therapeutic hypothermia - 48 h|Whole body cooling (33 to 34 C) for 48 hours
89500515|NCT03409770|Experimental|Therapeutic hypothermia - 72 h|Whole body cooling (33 to 34 C) for 72 hours
89500516|NCT03318263|Other|experimental|
89500517|NCT03254576||Children at high-risk for obesity|Healthy-weight children (5th-75thBMI%) with two overweight/obese parents (BMI>25)
89500518|NCT03254576||Children at low-risk for obesity|Healthy-weight children (5th-75thBMI%) with two healthy-weight parents (BMI = 18-24.9)
89500519|NCT03218241|Experimental|PRT0064445 Dose 1|Dose 1 versus Placebo
89500520|NCT03218241|Experimental|PRT064445 Dose 2|Dose 2 versus Placebo
89023422|NCT05483595|Other|Placebo group|Subjects actually testing placebo
89205871|NCT00293059|Placebo Comparator|Placebo|Matching placebo to be taken orally daily
89500521|NCT03218241|Experimental|PRT064445 Dose 3|Dose 3 versus Placebo
89500522|NCT03218241|Experimental|PRT064445 Dose 4|Dose 4 versus Placebo
89500523|NCT03218241|Experimental|PRT064445 Dose 5|Dose 5 versus Placebo
89500524|NCT03215524|Experimental|ARM A|"Daratumumab, Cyclophosphamide, Dexamethasone, Pomalidomide~Daratumumab, IV, at 16 mg/kg, or Daratumumab, SC, at 1800 mg on days 1, 8, 15 and 22 for Cycles 1 and 2, on Days 1 and 15 for Cycles 3-6, and Day 1 of each cycle for Cycle 7 and beyond for each 28-day cycle.~Cyclophosphamide, orally, at 400 mg on Days 1, 8, 15 of each 28-day cycle for 24 cycles.~Dexamethasone, orally, at 20 mg on day of daratumumab administration (pre-daratumumab) and 20 mg on the following day. On weeks without daratumumab administration, 40 mg dexamethasone weekly.~Pomalidomide, orally, at 4 mg on Days 1- 21 of each 28-day cycle."
89500525|NCT03215524|Experimental|ARM B|"Daratumumab, Cyclophosphamide, Dexamethasone, Pomalidomide~Daratumumab, IV, at 16 mg/kg, or Daratumumab, SC, at 1800 mg on days 1, 8, 15 and 22 for Cycles 1 and 2, on Days 1 and 15 for Cycles 3-6, and Day 1 of each cycle for Cycle 7 and beyond for each 28-day cycle.~Cyclophosphamide, orally, at 400 mg on Days 1, 8 and 15 of each 28-day cycle for 24 cycles.~Dexamethasone,orally, at 20 mg on day of daratumumab administration (pre-daratumumab) and 20 mg on the following day. On weeks without daratumumab administration,40mg dexamethasone weekly.~Pomalidomide, orally, added at first progression at 4 mg on Days 1- 21 of each 28-day cycle."
89500526|NCT03045029||Oral treprostinil|Sustained-release oral tablets for three times daily (TID) administration in prostacyclin naive and prostacyclin transition patients
89500527|NCT03018080|Experimental|Arm A (Phased Pembrolizumab Regimen)|Paclitaxel will be given as an IV infusion over 60 minutes, on days 1 and 8 every 21 (+/- 3) days during Cycles 1 and 2. No pembrolizumab will be given during Cycles 1 and 2. Starting with cycle 3 and subsequent cycles, pembrolizumab will be given as an IV infusion over 30 minutes before paclitaxel on day 1 every 21 (+/- 3) days.
89500528|NCT03018080|Experimental|Arm B (Concurrent Pembrolizumab Regimen)|Pembrolizumab will be given as an IV infusion on day 1 before paclitaxel every 21 (+/- 3) days. Paclitaxel will be given as an IV infusion over 60 minutes, on days 1 and 8 every 21 (+/- 3) days.
88956059|NCT05954910||Cohort 1|Unfit/frail participants with DLBCL who are untreated before the administration of polatuzumab and who have started receiving polatuzumab at physician's discretion in accordance with local clinical practice and/or labeling will be observed for safety and efficacy until death, withdrawal of consent, loss to follow-up or end of study whichever occurs first (up to approximately 3 years).
88956060|NCT05954910||Cohort 2|Participants with DLBCL who can not be classified into unfit/frail but are untreated before the administration of polatuzumab and who have started receiving polatuzumab at physician's discretion in accordance with local clinical practice and/or labeling will be observed for safety and efficacy until death, withdrawal of consent, loss to follow-up or end of study whichever occurs first (up to approximately 3 years).
88956061|NCT05954910||Cohort 3|Participants with relapsed or refractory (R/R) DLBCL who have started receiving polatuzumab at physician's discretion in accordance with local clinical practice and/or labeling will be observed for safety and efficacy until death, withdrawal of consent, loss to follow-up or end of study whichever occurs first (up to approximately 3 years).
89205872|NCT00756275|Active Comparator|Nicotine Replacement + PLA pill|Nicotine replacement treatment patch plus matched placebo pill
88956063|NCT05948566|Placebo Comparator|Placebo|Placebo
88956064|NCT05948566|Experimental|Dose 1 TS23|low dose
88956065|NCT05948566|Experimental|Dose 2 TS23|next higher dose
88956066|NCT05948566|Experimental|Dose 3 TS23|next higher dose
88956067|NCT05948566|Experimental|Dose 4 TS23|highest dose
88956068|NCT05938270|Other|Saruparib (AZD5305) only|Participant will receive Saruparib (AZD5305) once daily for 21 days (+ up to 7 days) unless unacceptable toxicity or withdrawal of consent. Following the 21 days of study treatment, participants should undergo radical prostatectomy on Day 22 (+ up to 7 days)
88956069|NCT05938270|Other|Saruparib (AZD5305) + Darolutamide|Participant will receive Saruparib (AZD5305) once daily + darolutamide twice daily for 21 days (+ up to 7 days) unless unacceptable toxicity or withdrawal of consent. Following the 21 days of study treatment, participants should undergo radical prostatectomy on Day 22 (+ up to 7 days).
88956070|NCT05938270|Other|No Treatment|No study treatment is to be taken by the participants in this arm. Radical prostatectomy should be performed as per local practice
88956071|NCT05938270|Other|Darolutamide Only|Participant will receive darolutamide twice daily for 21 days (+ up to 7 days) unless unacceptable toxicity or withdrawal of consent. Following the 21 days of study treatment, participants should undergo radical prostatectomy on Day 22 (+ up to 7 days).
88956072|NCT05935215|Experimental|iptacopan 200 mg b.i.d.|open label arm of iptacopan 200 mg b.i.d.
88956073|NCT05933200|Experimental|Triheptanoin|Participants will be given prescriptions for Triheptanoin in mL/day, which will be divided into approximately 4 administrations per day, with precise instructions for administration. Triheptanoin will be titrated up to the first 6 weeks of the study. After titration, the dose is to remain stable for the remainder of the Double-blind Treatment Period.
88956074|NCT05933200|Active Comparator|MCT|Participants will be given prescriptions for MCT in mL/day, which will be divided into approximately 4 administrations per day, with precise instructions for administration. MCT will be titrated up to the first 6 weeks of the study. After titration, the dose is to remain stable for the remainder of the Double-blind Treatment Period.
88956075|NCT05925673|No Intervention|Standard of Care|Participants will follow standard practice protocols at the Roth McFarlane Hand and Upper Limb Centre in London.
88956076|NCT05925673|Experimental|Mirror Therapy|Participants will engage in a home based mirror therapy intervention from 3 to 6 weeks post-fracture.
88956077|NCT05925673|Experimental|Neuromuscular Stimulation (NMES)|Participants will engage in a home based neuromuscular stimulation intervention from 3 to 6 weeks post-fracture.
88956078|NCT05925673|Experimental|Mirror Therapy + NMES|Participants will engage in a home based combined mirror therapy + neuromuscular stimulation intervention from 3 to 6 weeks post-fracture.
89205873|NCT00756275|Active Comparator|Varenicline + PLA patch|Varenicline plus matched placebo patches containing no nicotine
89205874|NCT02601053|Active Comparator|Dull (boring) movie|Participants will be exposed to a dull (i.e. boring) movie followed by a scary (i.e. horrifying) movie.
89205875|NCT02601053|Experimental|Scary (horrifying) movie|Participants will be exposed to a scary (i.e. horrifying) movie followed by a to a dull (i.e. boring) movie.
89205876|NCT01065493|Experimental|Software Assisted Lifestyle Counseling|
89500529|NCT02869802||Biopsy Cohort|"Participants will undergo a tumour biopsy at baseline and an optional tumour biopsy at disease progression.~Participants will undergo serial collection of plasma and serum samples."
89500530|NCT02869802||Archival Cohort|"Genomic analyses will be performed on participants' archival tumour samples.~Participants will undergo serial collection of plasma and serum samples."
89500531|NCT02799641|Placebo Comparator|Control|Control arm receives ibuprofen, placebo pill, and placebo injection.
89500532|NCT02799641|Experimental|Treatment|Treatment arm receives ibuprofen, diazepam pill, and lidocaine injection.
89500533|NCT02782546|Experimental|Recipient|"Standard of care reduced conditioning regimen on Day -1~Graft cell infusion on Day 0~Post-transplant cyclophosphamide on Days +3 and +4~GvHD prophylaxis with tacrolimus and mycophenolate mofetil (MMF) will start on Day +5. MMF will continue till Day +35 and tacrolimus till Day +180 in the absence of GvHD~G-CSF will start on Day +7 and will continue until neutrophil engraftment as per institutional guidelines~The cytokine-induced memory like natural killer (CIML NK) cells will be infused on Day +7 without a filter or pump, slowly by gravity over at least 15 minutes.~ALT-803 will start approximately 4 hours after the CIML NK cell infusion. ALT-803 will be administered subcutaneously at a dose of 10 mcg/kg subcutaneously beginning Day +7 (on the day of CIML NK cell infusion) and then every 21 days for a total of 4 doses"
89500534|NCT02782546|Experimental|Donor|"Donors will receive subcutaneous G-CSF from Day -4 till Day 0 and undergo 20L apheresis per institutional guidelines.~Two consecutive days for collection are allowed in case of the target CD34+ cell dose being less than the target 4 x106/kg-bw from the first day of collection.~On Day +6 (one day before the planned CIML NK cell infusion), peripheral blood mononuclear cells will be collected by a single standard 20-L apheresis over 4-5 hours from the same haploidentical related donor that provided the HCT graft."
89500535|NCT02781090|Experimental|Positively Smoke Free on the Web (PSFW+)|"Participants were assigned to the multimodal PSFW+ interactive web-based behavioral intervention hosted within an online social network.~PSFW+: PSFW+ is an intensive eight session motivational/educational web-program, based on social cognitive theory, designed to promote cessation among HIV-infected smokers. It included a professionally administered social network/online support community.~Nicotine polacrilex: All participants were offered a 3-month supply of nicotine patches"
89500536|NCT02781090|Placebo Comparator|American Heart Association Getting Healthy (AHA)|"Participants were assigned to the AHA Getting Healthy web-based control intervention program (the AHA later changed in name from Getting Healthy to My Life's Check, Life's Simple 7~AHA: The AHA Getting Healthy website is an attention-matched, health-promoting, seven-module website developed by the American Heart Association to encourage healthy behaviors in the general population~Nicotine polacrilex: All participants were offered a 3-month supply of nicotine patches"
88956081|NCT05908786|Experimental|Atezo + Bev|Participants in the atezolizumab plus bevacizumab (Atezo + Bev) arm will receive up to three cycles of treatment until surgery or unacceptable toxicity, whichever occurs first.
88956082|NCT05908786|Experimental|Atezo + Bev +Tira|Participants in the atezolizumab plus bevacizumab plus tiragolumab (Atezo + Bev +Tira) arm will receive up to three cycles of treatment until surgery or unacceptable toxicity, whichever occurs first.
88956083|NCT05908786|Experimental|Tobe + Bev|Participants in the Tobemstomig + Bev arm will receive up to three cycles of treatment until surgery or unacceptable toxicity, whichever occurs first.
89205877|NCT01065493|Active Comparator|Lifestyle Counseling|Status quo smoking cessation counseling.
89205878|NCT00758459|Experimental|1|
88956086|NCT05900505|Experimental|Intervention Group|Participants in the intervention group will be referred to a social navigator to address their identified social needs.
88956087|NCT05900505|No Intervention|Control Group|Participants in the control group will be referred to a social worker, as per standard care.
89205879|NCT00758459|Placebo Comparator|2|
89205880|NCT03977389||Population of the study|"Patient undergoing total wrist denervation between January 1995 and December 2013 at Brest CHRU, performed by the same senior surgeon.~Total wrist denervation is a routine procedure in orthopedic surgery for wrist arthritis."
88956090|NCT05897242|Experimental|Arm I (Act on Vaping app)|Participants receive supportive messages and use the ACT on Vaping smartphone app. They also receive incentivized text message check-ins assessing their vaping status.
89205881|NCT05460143||Dementia with Lewy Bodies|These subjects should meet the criteria for dementia with Lewy Bodies (McKeith et al. (2005). Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium. Neurology. 65:1863-72.).
89500537|NCT02774291|Experimental|Treatment (mTCR, aldesleukin)|Patients receive standard cyclophosphamide IV over 1 hour on days -7 to -6 and fludarabine phosphate via IVPB over 30 minutes on days -5 to -1 followed by anti-ESO (cancer/test antigen) mTCR-transduced autologous peripheral blood lymphocytes IV over 20-30 minutes on day 0 and aldesleukin IV over 15 minutes approximately every 8 hours on days 0-4. Patients also receive filgrastim SC on days 1-4.
89500538|NCT02734771|Experimental|BV+mini-R-CHP|Brentuximab vedotin 1.8 mg/kg IV day 1 for six cycles Rituximab 375 mg/m2 IV day 1 for six cycles Cyclophosphamide 400 mg/m2 IV day 1for six cycles Doxorubicin 25 mg/m2 IV day 1 for six cycles Prednisone 40 mg/m1 PO days 1-5 for six cycles
89500539|NCT02719977|Experimental|CX-5461|CX5461 as intravenous infusion on day 1 and day 8 every 4 weeks. A day 1 every 3 weeks schedule may be used if the day 1 and day 8 every 4 weeks schedule is not tolerable
89538417|NCT05075369|No Intervention|baseline Intraocular pressure|The participants will have their intraocular pressure measured with Goldmann Application Tonometry immediately prior to beginning the water drinking test.
89205882|NCT05460143||Alzheimer's Disease|These subjects should have a clinical diagnosis of AD in accordance with the National Institute of Neurological Disorders and Stroke-Alzheimer Disease and Related Disorders criteria (McKhann, G. M., et al. 2011. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7:263-9.).
88956091|NCT05897242|Active Comparator|Arm II (Incentivized text message check-ins)|Participants receive incentivized text messages check-ins assessing their vaping status.
88956092|NCT05897190|Experimental|SARS-CoV-2 mRNA vaccine (RBMRNA-405) adult group|One dose was administered by intramuscular injection on day 1
88956093|NCT05897190|Experimental|SARS-CoV-2 mRNA vaccine (RBMRNA-405) older adult group|One dose was administered by intramuscular injection on day 1
88956094|NCT05897190|Active Comparator|CoronaVac® adult group|One dose was administered by intramuscular injection on day 1
88956095|NCT05897190|Active Comparator|CoronaVac® older adult group|One dose was administered by intramuscular injection on day 1
88956096|NCT05890027|Experimental|Phenylephrine and Eye Taping Group|Participants in this group will initially have superior visual field testing done with the upper eyelid manually taped. Then, participants will have superior visual field testing done after receiving Phenylephrine 2.5% ophthalmic solution. Participants will be in each group for up to 60 minutes.
89205883|NCT05460143||Mild Cognitive Impairment - LB|Mild Cognitive Impairment in a single or a multiple domain (Jak et al., 2009) with at least one LB symptom (MCI-LB; McKeith, I. G., et al. 2020. Research criteria for the diagnosis of prodromal dementia with Lewy bodies. Neurology. 94(17): 743-55.).
89500540|NCT02689024|Experimental|Continuous FICB with local anesthetics|"With ultrasound guidance, a Fascia Iliaca Compartment Block will be administered and a catheter left in the compartment underneath the iliac fascia. This catheter will remain in place until two days after surgery.~Initial pain treatment in the Emergency Department will be with 40 mL bupivacaine 0.25% or equipotent dosages of levobupivacaine or ropivacaine. Thereafter, until removal of the catheter, pain is treated by titrating local anesthetics according to pain scores."
89500541|NCT02689024|Active Comparator|Traditional care with systemic analgesia|"Traditional care (usual care) will be on the discretion of the treating physician or hospital protocols and will comprise of systemic opioids such as fentanyl or morphine.~Usually, these opioids are combined with several other drugs, such as: paracetamol, NSAIDs (diclofenac or ibuprofen or naproxen) or dipyrone. (Inter)national guidelines advice morphine as first line agent in elderly patients with hip fractures, as longer acting analgesics are usually required."
89500542|NCT02671448|Experimental|Homebound After Stem Cell Transplantation|The primary research outputs and measurements are the instruments/surveys, assessments, and video diaries to be completed by the patients, their caregivers and the healthcare providers during the time of the home transplantation care. Protocol-specific interventions during homebound care will continue until patient has achieved neutrophil engraftment. Post engraftment, standard of care practice will resume. Once discharged from homebound care, the patient will complete routine post-HSCT follow-up visits in the clinic setting.
89500543|NCT02658279|Experimental|Pembrolizumab (MK-3475)|Pembrolizumab 200 mg will be administered as an approximately 30 minute (-5/+10 mins) IV infusion every 3 weeks. Sites should make every effort to target infusion timing to be as close to 30 minutes as possible. Patients will be followed with DCE perfusion MRI done at baseline and every 9 weeks (+/- 7 days). Patients will be allowed to stay on treatment in spite of increase in tumor size, provided the patient has no, or manageable, new neurologic symptoms, and at the discretion of treating physician. In that situation, tumor resection should be encouraged for the distinction between tumor progression and immunologic reactions. Patients undergoing surgical resection will have tissue collected for collateral studies. All collected tissue will be stored in the Pathology Core Tissue bank at MSK.
89500544|NCT02649686|Experimental|Durvalumab plus Trastuzumab|Durvalumab q3w until PD Trastuzumab q3w x 6
89500545|NCT02619864|Experimental|AZD2014 plus temozolomide|Patients will receive single agent AZD2014 for 2 days immediately prior to surgery at a fixed dose of 125 mg bid po (i.e. on days -2, -1, and on morning of day 0 [day of surgery]). After recovery from surgery, patients will start the dose escalation (within 7-21 days after tumour resection).
89500546|NCT02602691|Active Comparator|Endomyocardial biopsy|Systematic endomyocardial biopsies performed according to a planned monitoring schedule in usual care for patients with a heart transplantation.
88956097|NCT05886491|Experimental|Phase 1: Dose Escalation of GDX012|Participants will receive GDX012 weight-based dose as intravenous (IV) infusion on Day 1 of Phase 1 after lymphodepleting chemotherapy. Three dose levels of GDX012 will be tested in Phase 1. Some participants may be eligible for a second dose.
88956098|NCT05886491|Experimental|Phase 2a: GDX012|Participants will receive GDX012 (weight-based) IV infusion at pre-selected one or two dose levels from Phase 1, on Day 1 after lymphodepleting chemotherapy. Some participants may be eligible for a second dose.
88956099|NCT05881551|Experimental|eEgg-Arm|Within the 24h interval, pain assessment is performed hourly using the NRS (during the day) and the eEgg (preferably at hourly intervals throughout the day). If necessary, additional measurements can be taken with the eEgg.
88956100|NCT05881551|Other|NRS-Arm|Patients are asked to document their current pain at hourly intervals for 24 hours (starting from the end of the intervention) according to the usual clinical routine. The first measurement is taken before the intervention.
88956101|NCT05881408|Experimental|Delandistrogene Moxeparvovec followed by Placebo|Participants will receive single IV infusion of delandistrogene moxeparvovec on Day 1. Then, participants will receive a single IV infusion of matching placebo at approximately 72 weeks.
89205884|NCT05460143||Mild Cognitive Impairment - AD|Mild Cognitive Impairment in a single or a multiple domain (Jak et al., 2009) with AD symptoms (MCI-AD; Dubois, B., et al. 2009. Early detection of Alzheimer's disease: new diagnostic criteria. Dialogues Clin Neurosci. 11(2): 135-9.).
89500547|NCT02602691|Experimental|AlloMap® test|Noninvasive gene expression profiling blood test (AlloMap®) performed instead of endomyocardial biopsies when planned in the monitoring schedule for patients with a heart transplantation.
89500548|NCT02354079|Other|genetic analysis|
89500549|NCT02144584|Placebo Comparator|Placebo plus standard of care|Participants will start taking either memantine or placebo within 24 hours after baseline testing and randomization is completed, but no later than day 8 post-symptom onset. Participants will titrate up on the dose of placebo until taking twice daily. Participants will continue for 90 days with placebo. Continue with standard of care for other treatment of stroke.
89500550|NCT02144584|Active Comparator|Memantine plus standard of care|Participants will start taking either memantine or placebo within 24 hours after baseline testing and randomization is completed, but no later than day 8 post-symptom onset. Participants will use a titration schedule starting at 7mg daily for 1 week, increasing by 7mg (1 capsule) per week until at a goal dose of 28mg daily (goal dose) as recommend by the manufacturer. Participants will continue memantine for 90 days. Continue with standard care for stroke.
89500551|NCT01846390|Experimental|romidepsin, gemcitabine, dexamethasone and cisplatin|A traditional phase I dose escalation design is proposed to assess the feasibility and tolerability of romidepsin in combination with GDP, where treatment will be escalated. Treatment will be given for 6 cycles unless there is evidence of progression prior to completion of the 6 cycles or tolerability to the regimen is not sustained.
89500552|NCT01783197|Experimental|Paclitaxel and carboplain plus selumetinib|"Cohort 1: Standard Chemotherapy (paclitaxel and carboplatin) plus selumetinib~If you are registered to Cohort 1, you will receive two commonly-used chemotherapy drugs called paclitaxel and carboplatin, plus you will be given the experimental drug selumetinib."
88956102|NCT05881408|Placebo Comparator|Placebo followed by Delandistrogene Moxeparvovec|Participants will receive matching placebo IV infusion on Day 1. Then, participants will have the opportunity to receive a single IV infusion of delandistrogene moxeparvovec at approximately 72 weeks.
89500553|NCT01783197|Experimental|pemetrexed and cisplain plus selumetinib|"Cohort 2: Standard Chemotherapy (pemetrexed and cisplatin) plus selumetinib (cohort closed)~If you are registered to Cohort 2, you will receive two commonly-used chemotherapy drugs called pemetrexed and cisplatin, plus you will be given the experimental drug selumetinib."
89500554|NCT01783197|Experimental|pemetrexed plus selumetinib|"Cohort 3: Standard Chemotherapy (pemetrexed) plus selumetinib (cohort closed)~If you are registered to Cohort 3, you will receive one commonly-used chemotherapy drug called pemetrexed, plus you will be given the experimental drug selumetinib."
88956103|NCT05880758|Active Comparator|Stable Adequate Sleep (SAS)|Participants will go to bed and wake up at the same time every night, maintaining adequate sleep duration.
89500555|NCT01765855|Experimental|Single Arm Oral Betrixaban|
89500556|NCT01708993|Active Comparator|Arm A: Pemetrexed and Reolysin (and safety run-in)|
89500557|NCT01708993|Active Comparator|Arm B: Pemetrexed|
89500558|NCT01708993|Active Comparator|Arm C: Docetaxel and Reolysin (and safety run-in)|
89500559|NCT01708993|Active Comparator|Arm D: Docetaxel|
89500560|NCT01656538|Experimental|Paclitaxel plus Reolysin|Paclitaxel given weekly on days 1, 8, 15 every 4 weeks plus reolysin days 1, 2, 8, 9, 15 and 16.
89500561|NCT01656538|Active Comparator|Paclitaxel|Paclitaxel given weekly on days 1, 8 and 15 every 4 weeks.
89500562|NCT01652144|Experimental|AT7519M|AT7519M: 27 mg/m2 IV injection, 1 hour infusion, 27 mg/m2/day twice weekly x 2 weeks every 3 weeks (days 1, 4, 8 and 11)
89500563|NCT01627054|Experimental|AT7519M|
89500564|NCT01619813|Active Comparator|Docetaxel, Reolysin and Prednisone|
89500565|NCT01619813|Active Comparator|Docetaxel and Prednisone|
89500566|NCT01591421|Experimental|BKM120 and Panitumumab|BKM120 will be given either daily starting day 1 cycle 1or 5 out of 7 days every week, depending on when patient is enrolled on the study, in combination with panitumumab given intravenously every two weeks starting day 1 cycle 1.
89500567|NCT01486368|Experimental|PF-03446962|
89500568|NCT01419834|Experimental|Humanized 3F8 Monoclonal Antibody (Hu3F8)|This phase I single arm trial assesses the toxicity of escalating doses of hu3F8.
89500569|NCT01207778||preterm ESA recipients|Former preterm infants 500-1250 grams who received erythropoietin (400 units/kg 3x/week) or darbepoetin (10 micrograms/kg 1x/week), from the first week of life through 35 weeks corrected gestation
89500570|NCT01207778||preterm controls|Former preterm infants 500-1250 grams who received placebo (sham dosing), from first week of life through 35 weeks corrected gestation
89500571|NCT01207778||term controls|Former term infants with normal delivery
89500572|NCT01184274|Experimental|SB939|
89500573|NCT01161810||Post-Burn Rehabilitation|Patients with an acute burn injury who are admitted to the hospital with anticipated length of stay of 5 days or greater
89500574|NCT01147484|Experimental|Foretinib|
88956104|NCT05880758|Experimental|ISS_Alone|Intermittent short sleep (ISS) 5 nights of 5.5 hours time in bed 2 nights of 9.5 hours time in bed with advanced bedtimes and delayed wake times
88956105|NCT05880758|Experimental|ISS_SJL|Intermittent short sleep with short jetlag (SJL) 5 nights of 5.5 hours time in bed 2 nights of 9.5 hours time in bed with constant bedtimes and delayed wake times
89205885|NCT05460143||Healthy controls|These subjects should have MMSE scores above 26, no regular memory complaints, no signs/symptoms of dementia and no unstable or significant medical illness.
89500575|NCT01145989|Experimental|AT9283|Starting dose will be 40 mg/m2/day OR 30 mg/m2/day to be confirmed at registration. IV 24 hour continuous infusion Days 1 and 8 every three weeks
89500576|NCT01140269|No Intervention|No PCR testing|Control patients will not have PCR testing. This group will have routine testing and treatment as defined by the standard of care.
89500577|NCT01140269|Experimental|PCR testing|PCR will be used in parallel with routine laboratory tests such as culture. Treatment for PCR results will be based on the standard of care. Treatment of the patient will be dependent on the physician's clinical judgment based on existing clinical information including PCR, microbiology, patient physical presentation, and other laboratory results.
89500578|NCT01138384|Experimental|Foretinib and Lapatinib|Patients will receive foretinib as a continuous oral dose, and lapatinib as a continuous oral dose. Lapatinib will commence on Day1, Cycle 1 and foretinib will commence on Day 3, Cycle 1.
89500579|NCT01112384|Experimental|SB939|
89500580|NCT01079247|Active Comparator|Liberal|Maintain hemoglobin at 10-11 g/dL
89500581|NCT01079247|Active Comparator|Restrictive|Maintain hemoglobin at 7-8 g/dL
89500582|NCT01075308|Experimental|SB939|SB939 given orally every other day 3 times a week (i.e. Monday /Wednesday /Friday, or Tuesday /Thursday / Saturday) for 3 consecutive weeks followed by one week off-dosing. A treatment cycle is 4 weeks (28 days).
89500583|NCT01068587|Active Comparator|Erlotinib|
89500584|NCT01068587|Active Comparator|Foretinib plus Erlotinib|
89500585|NCT00984113|Experimental|A-Patients with mild renal impairment|
89500586|NCT00984113|Experimental|B-Healthy subjects matched to Group A|
89500587|NCT00984113|Experimental|C-Patients with moderate renal impairment|
89500588|NCT00984113|Experimental|D-Healthy subjects matched to Group C|
89500589|NCT00984113|Experimental|E-Patients with severe renal impairment|
89500590|NCT00984113|Experimental|F-Healthy subjects matched to Group E|
89500591|NCT00917072|Experimental|Didactic|Group #1: will have a focused, interactive power point lecture on the background, content and guidelines for a good handoff (focus on a standardized electronic hand-off tool). They will have an exercise to complete
89500592|NCT00917072|Experimental|Didactic+Simulation|Group #2: will undergo the same power point lecture ( as in Group #1) with an additional intervention focused not only on the hand-off tool, but on a standardized hand-off process using an OSCE exercise (objective structured clinical exam). This group will be trained about the effective implementation of the hand-off tool. They will be taught how to standardize the hand-off process and will be given an opportunity to practice with their peers in the HFH simulation center.
89500593|NCT00917072|Placebo Comparator|Control|The control group received no formal handoff training other than an introduction to handoffs for all interns during orientation at the start of the academic year along with expected ward based experiential training from senior residents throughout the intern year.
88956108|NCT05872503||Cohort 1|Participants of African Ancestry with elevated serum prostate specific antigen of (Bullet)3ng/ml or positive digital rectal examination or strong family history.
88956109|NCT05867927||da Vinci Patients|Consecutive enrollment of patients with indications of interest and having a da Vinci robotic-assisted surgery
88956110|NCT05867927||Epidemiological Data Audit|Extended data collection on patients with indications of interest, eligible for a robotic-assisted surgery, but treatment choice was not a da Vinci surgery
88956111|NCT05860127|Active Comparator|Referral for Cognitive Stimulation Therapy|This group will receive a referral from their physician for CST treatment
88956112|NCT05860127|Placebo Comparator|Standard of Care|This group will receive standard of care and no CST referral.
88956113|NCT05856331|Experimental|INBRX-101 Q3W|IV every 3-weeks (Q3W) and placebo (normal saline)
88956114|NCT05856331|Experimental|INBRX-101 Q4W|IV every 4-weeks (Q4W) and placebo (normal saline)
88956115|NCT05856331|Active Comparator|Zemaira (A1PI)|60 mg/kg IV once weekly (QW) and placebo (normal saline)
88956116|NCT05849922|Experimental|SAR442970|Participants will receive SAR442970 once every two weeks (Q2W) in Period A (Day 1 to Week 16). Participants will receive SAR442970 Q2W in Period B (Up to Week 28).
89500594|NCT00869752|Experimental|Arm 1|MK-0646, a monoclonial antibody in combination with etoposide and cisplatin.
89500595|NCT00836485|Experimental|1|Ketotifen 4.0% Patch
89500596|NCT00836485|Placebo Comparator|2|Placebo Patch
89500597|NCT00836485|Active Comparator|3|Pataday(TM)
89500598|NCT00836485|Placebo Comparator|4|Placebo eye drops
89500599|NCT00770185|Experimental|Ridaforolimus|oral ridaforolimus 40 mg days 1-5 each week (once daily for 5 consecutive days every week; cycle arbitrarily defined as a 4 week period)
89500600|NCT00658593|Active Comparator|GEMCAP|Gemcitabine 1000mg/m2 IV days 1 and 8 ever 21 days; Capecitabine 650mg/m2 PO BID days 1-14 every 21 days.
89500601|NCT00658593|Active Comparator|Gemcitabine Alone|Gemcitabine 1000mg/m2 IV days 1, 8 and 15 every 28 days
88956117|NCT05849922|Placebo Comparator|Placebo|Participants will receive placebo Q2W in Period A (Day 1 to Week 16). Participants will receive SAR442970 Q2W in Period B (Up to Week 28).
89205886|NCT02600975|Active Comparator|Group 1|10µg of R21 with AS01B on days 0, 28, and 56.
89205887|NCT02600975|Active Comparator|Group 2|50µg of R21 with AS01B on days 0, 28, and 56.
88956120|NCT05848557|No Intervention|Usual care|Counseling will be provided using standard Ministry of Health (MoH) items and screening data and specimen tracking will be done using MoH registers.
88956121|NCT05848557|Experimental|mSaada platform|Counseling, specimen tracking and case management will be facilitated using mSaada.
88956122|NCT05844137|Experimental|Evidence-based care of NAFLD in T2D|Intervention content will include: 1) NAFLD education; 2) diet/lifestyle support; 3) T2D medication management; and 4) clinically-indicated liver testing and care
88956123|NCT05842031||Semi-structured interviews|Participants with penile cancer who have undergone invasive inguinal lymph node procedure will be recruited to participate in study via telephone recruitment.
88956124|NCT05829460|Experimental|Arm 1: Semaglutide + progestin|"The progestin will be delivered via the levonorgestrel-releasing IUD and it is standard of care.~Will receive injectable pens containing semaglutide and will be self-administered on a weekly basis for up to 104 weeks. Dosing will be escalated during weeks 1 through 16 (start at 0.24 mg up to 2.4 mg).~Will receive a telemedicine behavioral intervention delivered by a psychologist. At each session, patients will self-report weight, number of days they kept a food journal during the past week, average daily caloric intake for the week, number of days exercised for the week, total number of minutes of moderate physical activity, and average number of steps per day for the week"
88956125|NCT05829460|Active Comparator|Arm 2: Placebo + Progestin|"The progestin will be delivered via the levonorgestrel-releasing IUD and it is standard of care.~Will receive injectable pens containing the placebo and will be self-administered on a weekly basis for up to 104 weeks.~Will receive a telemedicine behavioral intervention delivered by a psychologist. At each session, patients will self-report weight, number of days they kept a food journal during the past week, average daily caloric intake for the week, number of days exercised for the week, total number of minutes of moderate physical activity, and average number of steps per day for the week"
88956126|NCT05827588|Experimental|AWAK PD|Wearable/Ultra-portable peritoneal dialysis device for home-use
88956127|NCT05820087|Experimental|HistoSonics Edison System|
89500602|NCT00651326|Active Comparator|Antiandrogen; LHRH; Docetaxel, Radiation Therapy|Antiandrogen (Flutamide or Bicalutamide) LHRH agonist (Eligard) Docetaxel
89500603|NCT00651326|Active Comparator|Antiandrogen; LHRH; Radiation Therapy|Antiandrogen (Flutamide or Bicalutamide) LHRH agonist (Eligard)
89500604|NCT00640471|Active Comparator|Brivanib|
89500605|NCT00640471|Active Comparator|Placebo|
89500606|NCT00526461|Experimental|PDT using HPPH|Patients receive HPPH IV over 1 hour on day 1. Patients then receive photodynamic therapy with laser light on day 3. Patients also undergo therapeutic bronchoscopy for endoscopic debridement on day 5.
89500607|NCT00516828|Experimental|Sorafenib and Cytarabine|Cytarabine: subcutaneously twice daily from day 1 - 10. Sorafenib: Days 2-28; at the dose level assigned at registration. Sorafenib will be given orally twice daily.
89500608|NCT00514085|Experimental|Recombinant human interleukin-21|
89500609|NCT00504296|Experimental|SB939|
89500610|NCT00443976|Experimental|AT9283|
89500611|NCT00428142|Experimental|Bortezomib + BCVP-R|BCVP-R - q 21 days x 4 cycles Bortezomib: 1.3 mg/m2 Days 1 & 8 Cyclophosphamide: 750 mg/m2 IV Day 1 Vincristine: 1.4 mg/m2 IV Day 1 (dose capped at 2 mg) Prednisone: 40 mg/m2 po Days 1-5 Rituximab: 375 mg/m2 IV Day 1
89500612|NCT00390117|Experimental|CDKI AT7519|AT7519M (1 hour IV) on days 1, 4, 8 and 11 every 5 weeks.
89500613|NCT00377052|Experimental|Bortezomib + Gemcitabine|
89023423|NCT05480514|Experimental|TEST/CONTROL|Eligible subjects will be randomized to the wear sequence (TEST/CONTROL) to wear the study lenses during each dispensing period (5 to 7 days) with a wash-out period (2 to 5 days) between wears.
89500614|NCT00357747|Experimental|AEG35156 plus docetaxel|
89500615|NCT00352079|Active Comparator|Intravesicle BCG|"Induction:~q weekly x 6 (cycle 1)~Maintenance:~q weekly x 3 at 3, 6, 12, 18, 24, 30, 36 months postrandomization (cycles 2 - 8)"
89500616|NCT00352079|Active Comparator|Iressa and Intravesicle BCG|"Intravesical BCG:~Induction:~q weekly x 6 (cycle 1)~Maintenance:~q weekly x 3 at 3, 6, 12, 18, 24, 30, 36 months post- 2 randomization (cycles 2 - 8)~Iressa® 250 mg PO Daily for 12 weeks starting on day 1 of each cycle of intravesical BCG therapy (cycles 1 - 8)"
89500617|NCT00346320|Experimental|Radiotherapy|3-dimensional conformal radiotherapy, 60 Gy in once daily 4 Gy fractions (Monday to Friday) over 3 weeks
89500618|NCT00265876|Experimental|AZD0530 + Gemcitabine|
89500619|NCT00258388|Active Comparator|OGX011, Docetaxel and Prednisone|
89500620|NCT00258388|Active Comparator|Docetaxel plus prednisone|
89500621|NCT00255788|Active Comparator|Arm A|Everolimus - 28 days q 4 wk
89500622|NCT00255788|Active Comparator|Arm B|Everolimus - days 1, 8, 15 and 22 q 4wks
89500623|NCT00245154|Experimental|Arm I|Patients receive oral cediranib maleate once daily in the absence of disease progression or unacceptable toxicity. Patients also receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Treatment with paclitaxel and carboplatin repeats every 21 days for 6-8 courses in the absence of disease progression or unacceptable toxicity.
89500624|NCT00245154|Active Comparator|Arm II|Patients receive oral placebo once daily in the absence of disease progression or unacceptable toxicity. Patients also receive paclitaxel and carboplatin as in arm I.
89500625|NCT00066443|Experimental|Pegfilgrastim, docetaxel and epirubicin|
89500626|NCT02203123|Other|Ultrasound, inferior vena cava, aorta, normal saline|
89500627|NCT03532867|Experimental|Healthy volunteers|"After an ophthalmic consultation, the healthy volunteers are summoned to perform the exercise test in the form of an aerobic exercise on an ergometric bicycle with 3 different intensity levels calculated on the theoretical maximum aerobic power.~The OCT examination in the EDI mode, centered on the macular and peri-papillary region, as well as the systolic and diastolic blood pressure and the heart rate.~In healthy patients performing aerobic physical exercise in the Department of Sports Medicine , the investigators will perform the following Intervention :~Examination of pressures before stopping the exercise~Examination of pressure during the exercise~Examination of pressures after stopping the exercise"
89500628|NCT02203201||Study group|NCWS patients who had showed a negative celiac disease serology and a Marsh 0-1 duodenal histology, but who had displayed a positive EmA assay in the culture medium of the duodenal biopsies (EmA-biopsy).
89500629|NCT02203201||Control group|NCWS patients with negative EmA-biopsy.
89500630|NCT02207959|Experimental|Surveillance Endoscopy|White light examination, vital-dye enhanced fluorescence examination (VFI), High Resolution Microendoscope (HRME)
89500631|NCT02208115|Experimental|Meal composition - High GI|Changing the glycaemic index of the meal consumed after exercise (High GI versus Low GI).
89500632|NCT02208115|Experimental|Meal composition - Low GI|Changing the glycaemic index of the meal consumed after exercise (High GI versus Low GI).
89500633|NCT02567552|Experimental|Prolutex|Subcutaneous progesterone
89500634|NCT02567552|Active Comparator|Prontogest|Intramuscular progesterone
89500635|NCT02208193|Experimental|healthy controls group|Healthy volunteers
89500636|NCT02208193|Experimental|Alzheimer subjects group|"Group A Alzheimer group: patients with mild to severe stages of Alzheimer's disease: subgroup A1 Alzheimer group hospitalized at the Paul Spillmann Centre (Centre Paul Spillmann, CPS) (CHU de Nancy, France); subgroup A2 Alzheimer group monitored at the Resource and Research Memory Centre (Centre Mémoire de Ressources et de Recherche, CMRR) (CHU de Nancy, France)"
89500637|NCT02203279|Experimental|Rebase II Fast|The direct chair-side relining materiel 'Rebase II Fast' will be used.
89500638|NCT02203279|Experimental|Flexacryl|The direct chair-side relining material Flexacryl will be used
89500639|NCT02203279|Experimental|Vertex|Vertex is a heat-cured resin material which is going to be used for indirect relining
89500640|NCT02199301|Experimental|BMTKT|Transplantation Conditioning for bone marrow transplantation (BMT) Kidney transplantation and BMT (BMTKT)
89500641|NCT02208427|Experimental|3M_RH|Rifapentine and Isoniazid for 3 months: weekly oral rifapentine 15 mg/kg plus isoniazid 15 mg/kg for 12 doses
89500642|NCT02208427|Active Comparator|9M_INH|Isoniazid for 9 months: daily oral isoniazid 5 mg/kg for 9 months
89500643|NCT05506202|Experimental|Intervention group|In intervention group, one extra physiotherapeutic intervention, Basic Body Awareness Therapy (BBAT), will be provided before ending each visit (on top of basic and advanced respiratory physiotherapy interventions as control group). Each BBAT last for 30-45 minutes. Therapist will verbally guide patients to perform twelve simple and soft movements, including lying, sitting, standing, walking and relational movements in a quiet and secured environment. Therapist will allow patients to explore the movement and the experience. Therapist will also guide patients in shifting focus between balance, free breathing and mental awareness Following principles in BBAT, BBAT movements will be selected for patients as home exercises.
89500644|NCT05506202|Active Comparator|Control group|Both basic and advanced respiratory physiotherapy interventions, including respiratory muscles training, breathing techniques, bronchial hygiene maintenance, assisting in non-invasive ventilation therapy and oxygen therapy titration, are provided according to assessment findings. There is an eight-week training program for both groups, therapist will provide one home visit per week and continuously for eight weeks for each patient.
89500645|NCT05508620|Experimental|Sirolimus for Injection (Albumin-bound)|Treatment with Sirolimus for Injection (Albumin-bound) will continue until disease progression, unacceptable toxicity, or other discontinuation criteria, whichever occurs first.
89500646|NCT03803605|Experimental|VRC07-523LS + Vorinostat (VOR)|Participants will receive two series of combination therapy consisting of one (1) intravenous (IV) dose of VRC-HIVMAB075-00-AB (VRC07-523LS) followed by 10 oral (PO) doses of Vorinostat (VOR) taken every 72 hours.
89500647|NCT02208505|Experimental|Dexmedetomidine|we administrate the single-dose dexmedetomidine (0.5mcg/kg) with low-dose remifentanil infusion(TCI 1 ng/ml).
89500648|NCT02208505|Active Comparator|Remifentanil|we administrate the high-dose remifentanil infusion(TCI 2 ng/ml) alone.
89500649|NCT05508386|Other|MATLAB-based interface, showing 50 EEG traces|A software environment (MATLAB) was developed, that allows the international experts to access the data set and score the traces pseudonymously. This MATLAB-based interface shows 50 EEG traces. A representative dataset was composed, consisting of definite Burst Suppression patterns (positive control), intraoperative EEG without Burst Suppression patterns (negative control), and patterns indicating different manifestations of a possible Burst Suppression-like pattern.
89500650|NCT02208583|Active Comparator|AR dependent CRPC|"Assignment to Treatment Group based on druggable gene mutations analysis:~CRPC patients without druggable gene mutations: Docetaxel & Prednisone; CRPC patients with druggable gene mutations: DP & Targeted drugs"
89500651|NCT02208583|Active Comparator|AR independent CRPC|"Assignment to Treatment Group based on druggable gene mutations analysis:~CRPC patients without druggable gene mutations: cisplatin & Etoposide; CRPC patients with druggable gene mutations: EP & Targeted drugs"
89500652|NCT05501288|Experimental|intervention group|receive oral HSBDG for 5 consecutive days
89205888|NCT00298831|Experimental|Sugammadex|Each participant received an intravenous single bolus dose of 0.6 mg/kg rocuronium. If further neuromuscular block was required after endotracheal intubation, maintenance dose(s) of 0.15 mg/kg rocuronium was administered. At least 15 minutes after the intubation dose or the last maintenance dose of rocuronium, an intravenous single bolus dose of 4.0 mg/kg MK-8616 was administered.
89500653|NCT05501288|Other|control group|receive compound pholcodine oral solution for 5 consecutive days
89500654|NCT02208739|Experimental|Nonsurgical periodontal therapy|Nonsurgical periodontal therapy was given to all patients at baseline
89500655|NCT02208739|Active Comparator|Oral hygiene instructions|Oral hygiene instructions were given to all patients at baseline
89205889|NCT02532595|Active Comparator|Group 1 manual therapy and exercise|manual therapy with soft tissue mobilization to trigger points in the gastrocnemius, soleus, and tibialis posterior; exercise including stretching, concentric and eccentric exercises to the hip, triceps surae, tibialis posterior and foot intrinsics.
88956130|NCT05810948|Experimental|efgartigimod IV|patients receiving infusions of efgartigimod
88956131|NCT05810948|Placebo Comparator|Placebo|patients receiving infusions of placebo
88956132|NCT05807750|Active Comparator|Control|Enhanced care planning only (plus $15 as compensation for participation)
88956133|NCT05807750|Experimental|Intervention|Enhanced care planning plus a one-time $300 post-discharge income supplement
89500656|NCT02203825|Experimental|CM-CS1 T-cell infusion|"The treatment will consist of a single infusion of CM-CS1 cells.~The following dose levels will be evaluated:~Cohort 1: 1x 10^6 CM-CS1 T-cells Cohort 2: 3x 10^6 CM-CS1 T-cells Cohort 3: 1x 10^7 CM-CS1 T-cells Cohort 4: 3x 10^7 CM-CS1 T-cells"
89500657|NCT02208817||Ill patients|Ill patients who require Paediatric Intensive Care or Paediatric High Dependency Care
89500658|NCT02208817||Well Controls|Matched controls who are well (PEWS<3)
89500659|NCT02208817||Parent feedback|Feedback from parents/carers of children recruited into the PRefill study
89500660|NCT02208817||Healthcare professionals feedback|Feedback from healthcare professionals who have cared for a child with the device on
89500661|NCT03532789|Experimental|herbal patch group|using herbal patch as an intervention
89500662|NCT03532789|Placebo Comparator|placebo patch group|using placebo patch as an intervention
89500663|NCT02258035||DBP/Gc1f-1f genotype|Human volunteers homozygous for the 1f-1f (fast) genotype of DBP.
89500664|NCT02258035||DBP/Gc1s-1s genotype|Human volunteers homozygous for the 1s-1s (slow) genotype of DBP.
89500665|NCT02258035||DBP/Gc 2-2 genotype|Human volunteers homozygous for the 2-2 genotype of DBP.
89500666|NCT02561000|Experimental|PZ-128 0.3 mg/kg|PZ-128, 0.3 mg/kg, in 250 cc 5% dextrose, single dose, 2-hour intravenous infusion
89500667|NCT02561000|Experimental|PZ-128 0.5 mg/kg|PZ-128, 0.5 mg/kg, in 250 cc 5% dextrose, single dose, 2-hour intravenous infusion
89500668|NCT02561000|Placebo Comparator|Placebo|Placebo, in 250 cc 5% dextrose, single dose, 2-hour intravenous infusion
89500669|NCT02258113|Other|LEA numbers, Pelli-Robson, Octopus|Comparable generally used method for measuring visual acuity, contrast sensitivity and visual field.
89500670|NCT04539080||Pre-operative transversus abdominis plane block|The group with transversus abdominis plane block before laparoscopic surgeries with a standard pain control protocol
89500671|NCT04539080||Traditional pain control group|The group with a standard pain control protocol
89500672|NCT03533491|Experimental|App Evaluation|All 60 teens in The Rewire Study will complete the first 4 modules of the Rewire app. Prior to using the app, they will complete a baseline assessment. Follow up surveys will be completed at 2 weeks and 8 weeks post-baseline.
88956134|NCT05807724|No Intervention|Current care|Current care at the ED
89023424|NCT05480514|Experimental|CONTROL/TEST|Eligible subjects will be randomized to the wear sequence (CONTROL/TEST) to wear the study lenses during each dispensing period (5 to 7 days) with a wash-out period (2 to 5 days) between wears.
89500673|NCT05501210|Experimental|WBV + PEMF Group|"Patients in WBV + PEMF and WBV only groups will be required to attend the WBV therapy session in Prince of Wales Hospital twice a week, for 8 weeks, fulfilling a total of 16 sessions. Patients in WBV + PEMF groups will receive PEMF after WBV session."
89500674|NCT05501210|No Intervention|Control Group|Subjects in control group will perform static squat, single leg squat and lunges without vibration.
89500675|NCT05501210|Active Comparator|WBV only|"Patients in WBV + PEMF and WBV only groups will be required to attend the WBV therapy session in Prince of Wales Hospital twice a week, for 8 weeks, fulfilling a total of 16 sessions. Patients in WBV groups will not receive PEMF after WBV session."
89023425|NCT05468242|Experimental|Neoadjuvant Chemotherapy Plus Tislelizumab + Bevacizumab|Patients in experimental group will receive Tislelizumab consolidation (200 mg/q3w) after the neoadjuvant chemotherapy plus Tislelizumab + Bevacizumab and concurrent chemoradiotherapy.
89500676|NCT02208895||iSTAT Study Group|Measure glucose of pleural fluid via glucometer, in the laboratory, and using the iSTAT device to see if the three methods give a similar reading or not.
89500677|NCT02208973|Experimental|PBF-680 (5 mg)|5 mg of PBF-680
89500678|NCT02208973|Experimental|PBF-680 (10 mg)|10 mg of PBF-680
89500679|NCT02208973|Experimental|PBF-680 (20 mg)|20 mg of PBF-680
89500680|NCT02208973|Experimental|PBF-680 (40 mg)|40 mg of PBF-680
89500681|NCT02208973|Experimental|PBF-680 (60 mg)|60 mg of PBF-680
89500682|NCT02208973|Placebo Comparator|Placebo|Comparator to the doses of 5, 10, 20, 40 and 60 mg. ( subjects for each dose level 6 are located to active treatment and two to placebo
89500683|NCT02199379|Experimental|Lenvatinib|Lenvatinib will be taken as a single dose of 24 mg consisting of 2 x 10 mg and 1 x 4 mg capsules. Treatment will be administered orally with 240 mL of water following a 10-hour overnight fast.
89500684|NCT03532711||Chemotherapy|FOLFOX/XELOX/FOLFIRI
89500685|NCT02209051|Active Comparator|AMNIOEXCEL|Human Amniotic Membrane Allograft
89500686|NCT02209051|Active Comparator|Standard of Care, Diabetic Foot Ulcers|Advanced wound care dressings and offloading of wound.
89500687|NCT02199457|Other|SVSS and reference devices|Vital signs will be measured on the same subject with the reference devices and with the SVSS. The subject will have blood pressure, pulse, blood oxygen, body temperature and respiration rate measured using standard equipment. The same subject will then use the investigational device which measures all vital signs at the same time, by placing the index finger on a sensor.
89500688|NCT04714112|Experimental|preoperative group|Intravenous dexamethasone (5mg) is used when ultrasound guided ISB is performed.
89500689|NCT04714112|Active Comparator|postoperative group|Ultasound guided ISB is performed before operation and intravenous dexamethasone (5mg) is used in postoperative care unit ( PACU)
89500690|NCT02199613|Experimental|Treatment simplification|Open-label darunavir 800mg in conjunction with the co-formulated tenofovir DF/FTC/cobicistat/elvitegravir (Stribild) tablet, both taken together once daily with food
89500691|NCT02209129||women at high risk for breast cancer|
89500692|NCT02209207|Active Comparator|Continuous walking training|n=10 patients with COPD Walking intensity 60 percent of 6-minute walking test speed
89500693|NCT02209207|Active Comparator|Interval walking training|n=10 patients with COPD Walking intensity 120 percent of 6-minute walking test speed for 1 minute alternating with 1 minute of rest
89500694|NCT05505812|Experimental|HS-IT101 monotherapy|1x10^9-6x10^10 in vitro expanded autologous TIL (HS-IT101) will be infused i.v. to patients with advanced breast cancer after lymphodepletion treatment with fludarabine and cyclophosphamide, and then followed by the administration of a regimen of IL-2.
89500695|NCT02209285|No Intervention|Control group|The control group will receive usual care, which is provided by the community care access centre (CCAC). Usual care may include in-home visits by regulated health care providers, personal support workers, and care coordination through the community care access centre. Case conferences may occur on an as-needed basis.
89500696|NCT02209285|Active Comparator|Self-Management Program for Older Adults with Multimorbidity|Individuals in the intervention group will receive a six-month self-management intervention consisting of three components: (1) intensive case management and community navigation; (2) a maximum of two in-home visits by the care coordinator, two in-home visits by a Registered Nurse, and three in-home visits by the Occupational therapist or Physiotherapist, and six visits by a Personal Support Worker over 6 months in addition to usual home care services; and (3) monthly interprofessional team case conferences to develop an evidence-based, patient-centred community reintegration plan.
89500697|NCT04710992|Sham Comparator|Needling Group|The needle will be inserted for 90 seconds without galvanic current.
89500698|NCT04710992|Experimental|Low intensity percutaneous electrolysis|A single impact of galvanic current will be applied with an intensity of 0.3 mA for 90 seconds.
88956135|NCT05807724|Experimental|Phone-based fall-prevention strategy|"The phone-based fall-prevention strategy is based on the CDC's Stopping Elderly Accidents Deaths & Injuries (STEADI) program (https://www.cdc.gov/steadi/index.html). The STEADI Algorithm will be the template for both fall-prevention strategies utilized in this study. In addition, the CDC Check For Safety-A Home Prevention Checklist for Older Adults pamphlet will be used.~At the time of study enrollment, the STEADI program written material will be provided and components of it will be discussed with the study subjects and caregivers, if present.~The phone-based strategy will provide the patient and caregiver easy to read materials before ED discharge and a structured phone call around 14 days post ED discharge."
88956136|NCT05807724|Experimental|Home-visit fall prevention strategy|The specific components of the home-visit fall prevention strategy are similar to the Phone-Based Fall-Prevention Strategy. The essential difference is the in-person visit by the research associate to discuss and reinforce the fall-prevention strategy.
88956137|NCT05804344|Experimental|Anodal speech motor tDCS (Anode: C5; Cathode: Fp2)|Speech motor learning task performed with the stimulation condition in the arm title.
89500699|NCT04710992|Experimental|High intensity percutaneous electrolysis|Three impacts of galvanic current will be applied with an intensity of 3 mA and a duration of 3 seconds each.
89500700|NCT05500898|Experimental|Experimental 1|
89500701|NCT05500898|Experimental|Experimental 2|
89500702|NCT05500898|Experimental|Experimental 3|
89500703|NCT02199847|Experimental|Pharmaton® Caplets|
89500704|NCT02199847|Placebo Comparator|Placebo|
89500705|NCT05507762|Experimental|Experimental|MSCs Participants will receive antiviral drug, anti-fibrotic drugs and UC-MSCs
89500706|NCT05507762|Placebo Comparator|Comparator|Comparator participants will receive antiviral drug, anti-fibrotic drugs and saline solution
89500707|NCT03533413|Active Comparator|Interventional:Combined CT-fluroscopy|Combined CT-fluroscopic radiofrequency ablation of thoracic dorsal root ganglia.
89500708|NCT03533413|Active Comparator|Interventional: standard fluroscopy|Fluroscopic radiofrequency ablation of thoracic dorsal root ganglia.
89500709|NCT05263531|Experimental|remote ischemic conditioning|Receiving remote ischemic conditioning (RIC) treatment with pressure set at 200 mmHg.
89500710|NCT05263531|Sham Comparator|placebo remote ischemic conditioning|Receiving sham RIPC treatment with pressure set at 60 mmHg
89500711|NCT05479838||ST Elevation MI|ST-segment in adjacent ≥2 leads Elevation ( ≥2 mm in precordial leads, ≥1 mm in extremity leads) or left bundle branch block, ischemic type chest pain lasting longer than 30 minutes, and two or more elevations of serum creatine kinase myocardial band and troponin levels will be used as diagnostic criteria for STEMI. Patients with ST-elevation on the ECG will be referred to as STEMI, non -STEMI with twice the troponin level despite the absence of ST elevation. Patients who do not have ST elevation on ECG and whose troponin values do not exceed the reference range, but who are diagnosed as USAP presenting with typical chest pain and undergoing coronary angiography will be included in the study.
89500712|NCT04704908||9-17y (0,1,6m)|Participants in this arm have received 60μg of HPV 16/18 bivalent vaccine according to 3 doses of HPV 16/18 bivalent vaccine
89500713|NCT04704908||9-14y (0,6m)|Participants in this arm have received 60μg of HPV 16/18 bivalent vaccine according to 2 doses of HPV 16/18 bivalent vaccine
89500714|NCT04704908||18-26y (0,1,6m)|Participants in this arm have received 60μg of HPV 16/18 bivalent vaccine according to 3 doses of HPV 16/18 bivalent vaccine
89500715|NCT05261347|Experimental|intervention|mobilisation group
89500716|NCT05261347|Sham Comparator|control|sham control group
89500717|NCT02204059|Experimental|hMAb BIWA 4|Bivatuzumab: 186 Re-labelled humanised monoclonal antibody BIWA 4
89500718|NCT02204137||Completion of Questionnaires|"Participants will complete an assessment consisting of the Falls Risk Questionnaire, a primarily self-administered geriatric assessment (GA) developed by the Cancer and Aging Research Group, a quality of life scale (FACT GOG/NTX) and the Falls Efficacy Scale-International.~Each questionnaire contains approximately 150 questions and will take between 30 minutes and one hour to complete."
89500719|NCT02204215|Experimental|electric acupuncture & conservative|Electric acupuncture therapy on four limbs 30 min each time, twice per day; or conservative treatment without electric acupuncture.
89501981|NCT04280198|Experimental|Experimental: Group 2 - Intervention|Participants will attend the same three laboratory visits as the control group. The intervention group will also participate in a 4-week intervention, which consists of the parent watching brief weekly parenting videos from the online Triple P Parenting Program and completing interactive parent-child activities from activity boxes created by our laboratory (~60 min of interactive activities/week). Participants will use their activity boxes to practice specific parenting skills from the week's parenting video. Throughout the intervention phase, participants will receive regular text messages to remind them of the week's activities and ask several questions about engagement in study activities over the past 24 hours. The intervention group will also complete an exit interview about the intervention following the post-test assessment to provide insights on fidelity and acceptability.
89501982|NCT05499260|Experimental|CB03-154 SAD 5mg|Participants will receive CB03-154 5mg orally once daily in a fasted state.
89501983|NCT05499260|Placebo Comparator|Placebo SAD 5mg|Participants will receive placebo 5mg orally once daily in a fasted state.
89501984|NCT05499260|Experimental|CB03-154 SAD 10mg|Participants will receive CB03-154 10mg orally once daily in a fasted state.
89501985|NCT05499260|Placebo Comparator|Placebo SAD 10mg|Participants will receive placebo 10mg orally once daily in a fasted state.
89501986|NCT05499260|Experimental|CB03-154 SAD 20mg|Participants will receive CB03-154 20mg orally once daily in a fasted state.
89501987|NCT05499260|Placebo Comparator|Placebo SAD 20mg|Participants will receive placebo 20mg orally once daily in a fasted state.
89501988|NCT05499260|Experimental|CB03-154 SAD 40mg|Participants will receive CB03-154 40mg orally once daily in a fasted state.
89501989|NCT05499260|Placebo Comparator|Placebo SAD 40mg|Participants will receive placebo 40mg orally once daily in a fasted state
89501990|NCT05499260|Experimental|CB03-154 SAD 60mg|Participants will receive CB03-154 60mg orally once daily in a fasted state.
89500720|NCT02199925|Experimental|Gammaplex 5% IGIV|Gammaplex 5% IGIV administered intravenously
88956138|NCT05804344|Active Comparator|Cathodal speech motor tDCS (Anode: Fp2; Cathode: C5)|Speech motor learning task performed with the stimulation condition in the arm title.
89500721|NCT02200003|Experimental|Attention Bias Modification|640 Trials (20 minutes) four times over four weeks
89500722|NCT02200003|Sham Comparator|Sham Attention bias modification|640 Trials (20 minutes) four times over four weeks
89500723|NCT03338647|Active Comparator|TACE|Transarterial chemoembolization with drug eluted beads or doxorubicin/lipiodol
89500724|NCT03338647|Experimental|SBRT|Stereotactic radiation therapy with risk adapted dose prescription
89500725|NCT02209675|Other|patients with elevated liver enzymes|Patients with elevated liver enzymes and/or hyperbilirubinemia post transplantation for hepatitis C virus related disease will have liver biopsy
89500726|NCT02200081|Experimental|MGN1703|MGN1703, solution in Dulbecco's Phosphate-Buffered Saline (DPBS), 2 mL of 60 mg/4 mL (15 mg/mL), administered SC at 2 application sites twice weekly
89500727|NCT02200081|Other|Standard of care|Continous first line therapy
89500728|NCT05500742|Active Comparator|Coenzyme Q10 + Selenium|Coenzyme Q10 100 mg bid + Selenium 100 mcg with the evening meal
89500729|NCT05500742|Active Comparator|Resveratrol + TA-65|Resveratrol 350 mg bid + TA-65 MD 100 U with the evening meal
89500730|NCT05500742|Placebo Comparator|Placebo|Placebo-1 bid + Placebo-2 with the evening meal
89500731|NCT03533335|Active Comparator|Chlorhexidine spray|0.2% chlorhexidine oral spray, once daily
89500732|NCT03533335|Experimental|Chlorine Dioxide spray|0.1% pH-balanced chlorine dioxide oral spray, once daily
89500733|NCT03533335|Placebo Comparator|Sterile water spray|Placebo
89500734|NCT05505188|Other|Population|no arm, single cohort follow-up
89500735|NCT02200159||dexmedetomidine|
89500736|NCT05500664|Active Comparator|Lavender|three drops of the designated lavender will be placed on a 2-inch by 2-inch impermeable, backed gauze pad and patient was asked to inhale deeply for 5 minutes
89500737|NCT05500664|No Intervention|Control|
89500738|NCT05263219|Experimental|Transarterial chemoembolization with drug-eluting beads plus hepatic arterial infusion chemotherapy|Patients will receive the combination treatment of DEB-TACE and HAIC.
89500739|NCT05263219|Active Comparator|Hepatic arterial infusion chemotherapy|Patients will receive HAIC treatment alone.
89500740|NCT05504954|Experimental|IMARA-SA intervention arm|Participants randomized to the IMARA-SA arm will receive the IMARA-SA intervention (i.e., the intervention group).
89500741|NCT05504954|Experimental|Health promotion control arm|Participants randomized to the health promotion control arm will receive the health promotion intervention (i.e., the control group).
89500742|NCT02204527|Experimental|vitamin D3|supplementation of 100.000 IU of vitamin D3
89500743|NCT02204527|Placebo Comparator|Placebo pill|Placebo
89500744|NCT02209753|Experimental|BIRB 796 BS, low dose|
89500745|NCT02209753|Experimental|BIRB 796 BS, medium dose 1|
89500746|NCT02209753|Experimental|BIRB 796 BS, medium dose 2|
89500747|NCT02209753|Experimental|BIRB 796 BS, high dose|
88956139|NCT05804344|Active Comparator|Anodal IFG tDCS (Anode: F3; Cathode: Fp2)|Speech motor learning task performed with the stimulation condition in the arm title.
88956140|NCT05804344|Active Comparator|Cathodal IFG tDCS (Cathode: F3; Anode: Fp2)|Speech motor learning task performed with the stimulation condition in the arm title.
89500748|NCT02209753|Placebo Comparator|Placebo|
89500749|NCT05500352|Experimental|Cardiovascular effects of slowly declining plasma glucose in type 1 diabetes|
89500750|NCT05500352|Experimental|Cardiovascular effects of rapidly declining plasma glucose in type 1 diabetes|
89500751|NCT05500352|Experimental|Cardiovascular effects of rebound hyperglycemia in type 1 diabetes|
89500752|NCT05500352|Experimental|Cardiovascular effects of rebound euglycemia in type 1 diabetes|
89500753|NCT05500352|Experimental|Cardiovascular effects of hypoglycemia in type 1 diabetes|
89500754|NCT05500352|Experimental|Cardiovascular effects of hypoglycemia in type 2 diabetes|
89500755|NCT05500352|Experimental|Cardiovascular effects of hypoglycemia in healthy controls|
89500756|NCT05500352|Experimental|Cardiovascular effects of hyperglycemia in type 2 diabetes|
89500757|NCT05500352|Experimental|Cardiovascular effects of hyperglycemia in healthy controls|
89500758|NCT02204605|No Intervention|Control|Visits are not videotaped
89500759|NCT02204605|Experimental|Videoed Patients|Patients will have their visit videotaped.
89500760|NCT02200237|Placebo Comparator|Placebo|Phosphate Buffer Saline with adjuvant aluminium phosphate
89500761|NCT02200237|Experimental|EV71 with adjuvant aluminium phosphate|Inactive whole monovalent EV71 virion vaccine formulated with phosphate-buffered saline based adjuvanted aluminium phosphate 150 μg/0.5ml
89500762|NCT02209831|Experimental|BIBR 796 BS + pantoprazole|
88956141|NCT05804344|Sham Comparator|Sham tDCS|Speech motor learning task performed with the stimulation condition in the arm title.
89500763|NCT02209831|Active Comparator|BIBR 796 BS without pantoprazole|
89500764|NCT01663532|Experimental|Aripiprazole IM Depot|Aripiprazole IM Depot 400 mg, with allowed decrease to 300 mg for safety and return to 400 mg for efficacy if needed, every four weeks for 12 weeks
89500765|NCT01663532|Placebo Comparator|Placebo|Matching placebo
89500766|NCT02200315|Experimental|No Antimicrobial prophylaxis|No use of antimicrobial prophylaxis during surgery
89500767|NCT02200393|Experimental|Abdominal FES|Participants in the Abdominal Functional Electrical Stimulation (AFES) group will receive AFES 5 times per week (20 to 40 mins per day), on four alternate weeks.
89500768|NCT02200471|Experimental|VeinViewer|VeinViewer will be used in conjunction with routine cosmetic dermatology procedures. Patients and physicians will complete questionnaires.
89500769|NCT02200549|Experimental|Control group|Neither cycle training nor inspiratory muscle training.
89500770|NCT02200549|Experimental|Cycle training group|A 30-minute cycling training session is performed 3 days a week using calibrated cycle ergometer.
89500771|NCT02200549|Experimental|Combined group|A 30-minute Combined training session is performed 3 days a week using calibrated cycle ergometer and threshold loading device.
89500772|NCT02204839|Experimental|Basal dose reduction|Total daily basal (Glargine, Lantus, Sanofi-Aventis, or Detemir, Levemir, Novo Nordisk) reduction of 20% versus normal basal dose.
89500773|NCT04576754|Experimental|WB001|
89500774|NCT04576754|Sham Comparator|Comparison Condition|
89500775|NCT02204995|Active Comparator|Trapeziectomy with LRTI|Trapeziectomy with Ligament Reconstruction and Tendon Interposition
89500776|NCT02204995|Active Comparator|Trapeziectomy|Trapeziectomy
89500777|NCT02205073|Placebo Comparator|Dosing Period 1|
89500778|NCT02205073|Active Comparator|Dosing Period 2|
89500779|NCT02205073|Experimental|Dosing Period 3|
89500780|NCT02209909|Experimental|aspirin continuation|Intervention : Low-dose aspirin (< 100mg/day) is used before OPCAB surgery in the aspirin continuation group.
89500781|NCT02209909|Experimental|aspirin discontinuation|Intervention: Low-dose aspirin is stopped more than 4 days before OPCAB surgery in the aspirin discontinuation group.
89500782|NCT02200783|Active Comparator|Radial|Cardiac catheterization and coronary angioplasty performed via standard radial artery technique.
89500783|NCT02200783|Active Comparator|Femoral|Cardiac catheterization and coronary angioplasty performed via standard femoral artery technique.
88956142|NCT05803499|Experimental|Targeted Intervention for Sleep and Bereavement (Targeted CBT-I)|This intervention consists of 6, 50-60-minute online individual sessions delivered via video conference. Content will include a CBT-I based program adapted to the specific needs of spousally bereaved individuals.
89500784|NCT02200783|Experimental|TripTable|Cardiac catheterization and coronary angioplasty performed with standard transradial technique plus using the TRIPTable device.
89500785|NCT04502420||Abdominal surgery|People who to be operated in the abdomen are investigated before and after surgery.
89500786|NCT02209987|Experimental|GS-5745 SC|Participants will receive a single dose of GS-5745 by SC injection.
89500787|NCT02209987|Experimental|GS-5745 IV|Participants will receive a single dose of GS-5745 by IV infusion.
89500788|NCT02205151|Other|Treatment AB|"Treatment A (1 day) → wash-out(14days) → Treatment B (1 day)~Treatment A : Fimasartanm and Amlodipine~Treatment B : Fimasartan/Amlodipine combination"
89500789|NCT02205151|Other|Treatment BA|"Treatment B (1 day) → wash-out(14days) → Treatment A (1 day)~Treatment A : Fimasartanm and Amlodipine~Treatment B : Fimasartan/Amlodipine combination"
89500790|NCT05500118||communication without PADs|We use traditional communication ways to discuss the conditions with patients.
89500791|NCT05500118||communication with PADs|The committee, composed of designers, doctors, nurses and patients, bases on guidelines and evidence-based medicine to make a tool. And we use this tool to discuss the conditions with patients.
88956143|NCT05803499|Placebo Comparator|Information-Only Control|The information-only control consists of 1, 50-60-minute online individual session delivered via video conference. Content will provide basic psychoeducation about sleep and aging.
88956144|NCT05797246|Experimental|Arm 1|Bevacizumab treatment course
89500792|NCT02257801|Experimental|Nutritional beverage fortified with 6mg lutein/day|
89500793|NCT02257801|Experimental|Nutritional beverage fortified with 12mg lutein/day|
89500794|NCT02257801|Placebo Comparator|Nutritional beverage fortified with 0mg lutein/day|
89500795|NCT04664192||Lung transplant Recipients|Biobank registry for Lung transplant recipients
89500796|NCT02257879||Sequence A|water - GFJ - supplement
89500797|NCT02257879||Sequence B|GFJ - supplement - water
89500798|NCT02257879||Sequence C|supplement - water - GFJ
89500799|NCT04488224|Experimental|Patients receiving CBCT Image Guidance during treatment|"On two separate occasions, CBCT images will be acquired while participants are rotated 360° about the horizontal axis on the Nano-X Patient Rotation System. The rotation will take approximately 72 seconds to complete. Psychometrically validated questionnaires will be completed by the participant before and after each Nano-X CBCT session.~Participants in this arm undergo conventional CBCT for image guidance during standard of care (SOC) radiotherapy treatment. These participants do not require an additional conventional CBCT as the SOC conventional CBCT images are used to benchmark the experimental Nano-X CBCT scans for evaluation of the primary outcome measure."
89500800|NCT04488224|Experimental|Patients not receiving CBCT Image Guidance during treatment|"On two separate occasions, CBCT images will be acquired while participants are rotated 360° about the horizontal axis on the Nano-X Patient Rotation System. The rotation will take approximately 72 seconds to complete. Psychometrically validated questionnaires will be completed by the participant before and after each Nano-X CBCT session.~Participants in this arm do not undergo conventional CBCT for image guidance during standard of care (SOC) radiotherapy treatment. As such these participants will receive an additional conventional CBCT scan on standard equipment which used to benchmark the experimental NAno-X CBCT scans for evaluation of the primary outcome measure."
89500801|NCT05262985|Other|Treatment with Durvalumab+|Comparison of standard treatment verses the addition of Durvalomab to the standard protocol.
89500802|NCT05069636|Experimental|Lymphatic OMM plus Moderna COVID-19 Vaccine regimen|Patients receive OMM treatments that will include thoracic inlet and outlet myofascial release, pectoral traction myofascial release, and Miller Thoracic Lymphatic Pump technique plus the Moderna COVID-19 Vaccine regimen.
89500803|NCT05069636|Sham Comparator|Light Touch plus Moderna COVID-19 Vaccine regimen|Patients receive a series of light touch techniques plus the Moderna COVID-19 Vaccine regimen.
89500804|NCT02211001|Experimental|Pilates Group|The individuals were treated with Mat Pilates Method.
89500805|NCT02211001|Experimental|Segmented Dynamic Exercises Group|The individual were treated with ball exercises.
89500806|NCT02211001|Experimental|Global Postural Reeducation Group|The individuals were treated with postures of Souchard Method.
89500807|NCT02212717|Active Comparator|EUS-guided gallbladder drainage|
89500808|NCT02212717|Active Comparator|Percutaneous cholecystomy|
89500809|NCT05504720|Experimental|Pembrolizumab Trastuzumab|Single arm with pembrolizumab (200 mg flat dose over 30 min IV) on day 1, 22 and 43 plus trastuzumab (loading dose 8 mg/kg IV over 90 min at day 1 and maintenance dose 6 mg/kg IV over 30 min) on day 22 and 43 plus FLOT in four 2-week treatment cycles prior to undergoing surgery. Following surgery, patients will receive four further 2-week cycles of pembrolizumab+trastuzumab + FLOT followed by pembrolizumab (200 mg flat dose) and trastuzumab (6 mg/kg) alone for up to 11 further cycles (Q3W).
89500810|NCT02205229||Patients receiving a topical compounded medication|
89500811|NCT05499884|Experimental|Experimental group|
89500812|NCT02205385|Active Comparator|Traditional Traction Neurectomy|"Patients will be randomized to either the current standard of care surgical treatment for neuromas (traction neurectomy) or the experimental intervention (targeted reinnervation). This arm involves the use of the current standard of care surgical treatment.~Patients will undergo the same pre-operative evaluation, anesthesia, and dissection to identify the painful residual limb neuroma(s). In the active comparator arm, gentle traction will be applied to the nerve while excising the neuroma (traction neurectomy) allowing the nerve to retract more proximally. It may be buried in healthy muscle to further pad the nerve ending. The intention is to place the inevitable recurrent end-neuroma away from superficial locations in which it is likely to become mechanically irritated."
89500813|NCT02205385|Experimental|Targeted Muscle Reinnervation|"Patients will be randomized to either the current standard of care surgical treatment for neuromas (traction neurectomy) or the experimental intervention (targeted reinnervation). This arm involves the use of the experimental surgical treatment.~Patients will undergo the same pre-operative evaluation, anesthesia, and dissection to identify the painful residual limb neuroma(s). Targeted muscle reinnervation involves transfer of residual nerves to otherwise redundant target muscles. Native motor innervation of the target muscle is cut, and the residual nerves-after excision of end-neuromas-are coapted to the motor end point of the motor nerve, close to its point of entry into the muscle."
89500814|NCT04476992|Active Comparator|NO High Concentration|Nitric oxide will be delivered twice a day with a non-rebreathing system that allows a safe administration of Nitric Oxide gas at high concentrations limiting the amount of NO2 delivered to the patient.
89500815|NCT04476992|Experimental|NO High Concentration + Continuous Low Concentration|"Nitric oxide will be delivered twice a day with a non-rebreathing system that allows a safe administration of Nitric Oxide gas at high concentrations limiting the amount of NO2 delivered to the patient.~This arm will receive in addition a continuous low flow of Nitric Oxide at 20 ppm among the high concentration treatments."
89500816|NCT05217511|Experimental|NMSE Group|Neuromuscular Electrical Stimulation(NMES) group received consecutive daily sessions of electrical stimulation at specific points starting on the first day of randomization.The subjects also receive conventional physical therapy, which included gross motor therapy and respiratory therapy twice a day every day during their stay in the ICU.
89500817|NCT05217511|No Intervention|CPT group|The subjects only receive conventional physical therapy, which included gross motor therapy and respiratory therapy twice a day every day during their stay in the ICU.
89500818|NCT05499806||Acquired Brain Injury Patients|Questionnaire and, if the requirements are met, a neuropsychological assessment.
88956145|NCT05789173|Experimental|Baseline (control)|Each CYP2B6 normal metabolizer (NM) (*1/*1), intermediate metabolizer (IM) (*1/*6), and poor metabolizer (PM) (*6/*6, *6/*18, or *18/*18) group will receive a single dose of methadone (10 mg) and a single dose of tizanidine (4 mg) orally simultaneously at baseline (control).
88956146|NCT05789173|Experimental|Efavirenz (treatment)|Each CYP2B6 normal metabolizer (NM) (*1/*1), intermediate metabolizer (IM) (*1/*6), and poor metabolizer (PM) (*6/*6, *6/*18, or *18/*18) group will be administered a single dose of methadone (10 mg) and a single dose of tizanidine (4 mg) orally simultaneously after 16-day oral treatment with 600 mg/day efavirez
88956147|NCT05786521|Experimental|Semaglutide and lifestyle intervention|Participants will meet with a dietician throughout the study to discuss lifestyle counseling based on recommendation in the diabetes prevention program. They will also be given semaglutide for 20 weeks.
88956148|NCT05786521|Active Comparator|Lifestyle intervention|Participants will meet with a dietician throughout the study to discuss lifestyle counseling based on recommendation in the diabetes prevention program
89500819|NCT05499806||Healthy volunteers|Questionnaire and, if the requirements are met, a neuropsychological assessment.
89500820|NCT02220595|Experimental|Carotid stenting|Carotid artery stenting for treatment of carotid artery stenosis
89500821|NCT02220595|Active Comparator|Carotid endarterectomy|Carotid artery endarterectomy for treatment of carotid artery stenosis
89500822|NCT05237557|Experimental|Interventional group|
89500823|NCT05237557|No Intervention|Control group|
89500824|NCT05504564||Control group|healthy child
89500825|NCT05504564||Experimental group|parents with language disorder
89500826|NCT02220673|Experimental|BHT 0.1%|
89500827|NCT02220673|Experimental|BHT 0.5%|
89500828|NCT02220673|Placebo Comparator|Placebo for RMT-B|
89500829|NCT02220673|Placebo Comparator|Placebo for HFA-MDI|
89500830|NCT02220751|Placebo Comparator|chronic periodontitis|Non-surgical periodontal therapy.
89500831|NCT02220751|Active Comparator|Chronic periodontitis + type 2 diabetes|Non-surgical periodontal therapy + systemic doxycycline non-surgical periodontal therapy was associated with systemic doxycycline 100 mg/day, for two weeks after an initial dose of 200 mg, started on the day before first scaling and root planning session.
89500832|NCT02220751|No Intervention|Control|Periodontal- and systemically healthy patients were included as control group.
89500833|NCT02205463|Experimental|KD019|Patients with HER2+ metastatic or unresectable adenocarcinoma of the esophagus, gastroesophageal junction or stomach will receive trastuzumab and mFOLFOX-6 in combination with KD019 to evaluate the safety, toxicity and MTD of this regimen. There will be four dose cohorts for KD019. KD019 will be administered orally continuously daily on a 28 day cycle. Trastuzumab and mFOLFOX-6 will be administered as infusions every 2 weeks at standard doses without escalation. The sequence on the days when all agents are administered will be KD019 followed by trastuzumab and mFOLFOX-6.
89500834|NCT04858178|Experimental|Individuals with spinal cord injury|
89500835|NCT04858178|Experimental|Individuals without spinal cord injury|
88956149|NCT05784662|Experimental|Social Workers Addressing Firearm Risk|The Social workers Addressing Firearm Risk (SAFR) intervention is fully-online intervention that contains four modules. Each module includes interviews with experts, didactic content, handouts, and brief quizzes to check learning (required by New York State for continuing education credit).
88956150|NCT05784662|No Intervention|Control|Wait list control. Will receive access to SAFR intervention at conclusion of the study.
89500836|NCT02205541|Experimental|Eculizumab|"300mg concentrate for solution for infusion. According to the patient body weight, there will be 3 to 5 injections administered in IV infusion at D0, D7, D14, D21 and D28.~Eculizumab (ECZ) will be administrated intravenously as a 30-minute injection."
88956156|NCT05780762|Experimental|IMPACT program - experimental group|patients followed for one or more stabilized chronic pathologies and benefiting from usual care with an Advanced Practice Nurse AND benefiting from the IMPACT program, which combines management at 3 levels: (1) co-definition of the health situation, (2) co-planning of care and co-actions, and (3) co-assessment with the patient and his or her care team, and incorporates evidence-based measurement tools.
89500837|NCT02205541|Placebo Comparator|Placebo|"Infusion of a solution with 5% glucose. The administration scheme will be the same as the Eculizumab arm : there will be 3 to 5 injections at D0, D7, D14, D21 and D28.~Placebo will be administrated intravenously as a 30-minute injection."
89500838|NCT03256435|Experimental|Treatment Arm|RAMP PrEP initiation, adherence, and retention intervention package as well as standard of care (access to a financial advocate and clinical staff to support, facilitate, and assist in linkage to the established PrEP clinic at Open Arms and to facilitate initiation of, and obtaining, PrEP medications)
89500839|NCT03256435|No Intervention|Control Arm|Standard of care (access to a financial advocate and clinical staff to support, facilitate, and assist in linkage to the established PrEP clinic at Open Arms and to facilitate initiation of, and obtaining, PrEP medications)
89500840|NCT05499494|Experimental|injectable composite|The material will be applied according to manufacturer instructions. BEAUTIFIL Flow Plus X will be applied directly into the cavity and create the shape desired in layers not exceeding 2 mm, and light cured for 20 seconds.
89500841|NCT05499494|Active Comparator|Nanohybrid resin composite|The nanohybrid resin composite will be applied to the the cavity using the conventional incremental technique according to manufacturer instructions.
89500842|NCT05193799|Experimental|Investigational device#1 = Kolmi® Op-AirTM KALM|
89500843|NCT05193799|Experimental|Investigational device#2 = Kolmi® Op-Air OneTM|
89500844|NCT05193799|Experimental|Investigatonal device#3 = Kolmi® Op Air-Pro® Oxygen|
89500845|NCT02213965||Vasofix® Safety|Peripheral IV catheter Vasofix® Safety
89500846|NCT02213965||Introcan Safety®|Peripheral IV catheter Introcan Safety® IV catheter
89500847|NCT02205619|Experimental|Ultrasonic instrumentation|Prior to extraction, the teeth (N = 12) were randomly included into ultrasonic instrumentation (Air Flow Master Piezon®, EMS SA, Nyon - Swiss) treatment group
89500848|NCT02205619|Experimental|Hand instrumentation|Prior to extraction, the teeth (N = 12) were randomly included into hand curette (Gracey curettes, American Eagle, Missoula, MT, USA) treatment group hand instrumentation (Gracey curettes 5/6, 11/12, 13/14 American Eagle, Missoula, MT, USA)
89500849|NCT02205619|Experimental|subgingival airpolishing with glycine|"Prior to extraction, the teeth (N = 12) were randomly included into air-polishing (Air Flow Master Piezon®, EMS SA, Nyon - Swiss) with the glycine powder (Air-flow® Powder Perio, EMS) treatment group.~subgingival airpolishing with glycine(Air-flow® Powder Perio, EMS SA, Nyon, Swiss)"
89500850|NCT02205619|Experimental|ultrasonic following airpolishing|Prior to extraction, the teeth (N = 12) were randomly included into ultrasonic following airpolishing ( Air Flow Master Piezon®, EMS SA, Nyon, Swiss) (Air-flow® Powder Perio, EMS SA, Nyon, Swiss) with the glycine powder treatment group
89501991|NCT05499260|Placebo Comparator|Placebo SAD 60mg|Participants will receive placebo 60mg orally once daily in a fasted state.
89501992|NCT05499260|Experimental|CB03-154 FE|Participants will receive CB03-154 orally once daily in a fed state.
89501993|NCT05499260|Experimental|CB03-154 MAD 10mg|Participants will receive CB03-154 10mg orally once daily in a fasted state, for 14 consecutive days.
89500851|NCT02214823|Experimental|FES-Cycling|"Timeframe: Within 72 hours of ICU admission. Program: Standard care physiotherapy AND up to one hour of supine cycling daily using a cycle ergometer (RT300 supine model Restorative Therapies, Ltd or Letto 300.) attached to a six channel stimulator (SAGE) and 2 additional RT50 wireless stimulator channels.~One leg will undergo cycling alone without the electrodes turned on (sham) and the other leg will undergo cycling and muscle stimulation. Electrodes will be placed on all major lower limb muscles. Intervention will be provided individually and supervised by a physiotherapist in ICU only. Duration /Intensity: Up to 1 hour at least 5 times a week for 28 days or ICU discharge, if 20 sessions have not occurred at this time, intervention will continue until this is achieved. Intensity of muscle stimulation will be delivered at a level able to cause visible muscle contractions, confirmed by palpation.~A subgroup of 10 individuals will be involved in biomarker analyses."
89500852|NCT02214823|Active Comparator|Standard Care|"Both groups will receive usual medical and nursing care in the ICU and ward. Both groups (control and intervention) will receive standard care physiotherapy including respiratory and rehabilitation with mobilisation activities such as sitting out of bed, marching on the spot, and mobility training.~A subgroup of 10 individuals will be involved in biomarker analyses. This will involve collection of muscle biopsy, blood and urine analyses at baseline and ICU discharge."
89500853|NCT05504330||Patient Group|Asymptomatic intracranial stenosis patients who receive standard medical treatment without stenting
89500854|NCT05504330||Healthy Control|Healthy control are free from intracranial stenosis
89500855|NCT02220829|Active Comparator|Preventive administration of Rapaflo|Rapaflo treatment will start on day one of radiation therapy (early administration- before symptoms onset) and continue for a total duration of 6 months: 8 mg daily during 4 months and 8 mg every other day for 2 months.
89500856|NCT02220829|Other|Standard care|Administration of alpha-blocker Rapaflo at the onset of symptomatic urinary problems caused by radiation therapy. 8 mg of Rapaflo is administered daily until disappearance of symptoms.
89500857|NCT02525939|Active Comparator|Dalcetrapib|"Participants received dalcetrapib 600 mg (two 300 mg tablets) orally once daily.~dalcetrapib: Cholesterol Ester Transfer Protein inhibitor, 300 mg tablets"
89500858|NCT02525939|Placebo Comparator|Placebo|"Participants received dalcetrapib placebo tablets matching dalcetrapib orally once daily.~Placebo: dalcetrapib matching placebo tablets"
89500859|NCT02215213|Active Comparator|Intervention Group|Arm 1 is receiving vitamin D supplementation in 2000 IU/day ,
89500860|NCT02215213|Active Comparator|Arm 2 intervention group|Arm 2 is receiving vitamin D supplementation in 4000/IU per day
89500861|NCT02215213|Active Comparator|Arm 3 control group|Arm 3 is receiving vitamin D supplementation in 400 IU/day
89500862|NCT05504174||Ovarian cancer group|Patients pathologically diagnosed with ovarian cancer
89500863|NCT05504174||Control group|Patients with benign or borderline adnexal mass
89500864|NCT02258269|Experimental|SQ|Patients with rheumatoid arthritis exercise square dance
89500865|NCT02258269|Sham Comparator|Control|Patients with rheumatoid arthritis listen to accompany music of square dance at home
89500866|NCT02215291||Patients undergoing EGD or esophagoscopy|The cohort includes patients undergoing EGD or esophagoscopy for initial diagnosis or initial staging and mapping, surveillance of non-treated disease, and treatment (initial or ongoing) or post-treatment surveillance
89500867|NCT02205697|Experimental|Implementation intention|The entire cohort will be asked to create an implementation intention to increase their intake of fruit and vegetables over the study period.
89500868|NCT02215525|Experimental|UVA and Herbal|Twenty four daily one hour sessions using Extra-corporeal electro-magnetic irradiation device combined with Herbal Food Supplement Selenium containing tables as an Anti Oxidant (Tablet A) starting 10 days before the radiation sessions and to continue for 24 weeks
89500869|NCT02215525|Experimental|Herbal|Chronic HCV patients, non complicated will be treated by Herbal tablets only . 500 mg twice tablets every 6 hours daily for 6 months.
89500870|NCT02217241|Experimental|Intervention|Students in the intervention group participated in a one-hour interactive, small-group handoff workshop facilitated by a study investigator. The workshop focused on the importance of specific handoff skills to patient safety.
89500871|NCT02217241|No Intervention|Control|
89500872|NCT02205775|Placebo Comparator|twice placebo before PCI|
89500873|NCT02205775|Experimental|atorvastatin 80 + 40 mg pre PCI|
89500874|NCT02205775|Experimental|rosuvastatin 40 + 40 mg before PCI|
89500875|NCT02205775|Experimental|rosuvastatin 5 + ezetimibe 10 mg twice before PCI|
89500876|NCT02205853|Other|The patient-directed (PD) strategy|A single-faceted patient-directed (PD) strategy that will embed the change at patient level.
89500877|NCT02205853|Other|The multi-faceted (MF) strategy|A multi-faceted (MF) strategy that will embed the change at the patient, professional and organizational levels.
89500878|NCT02258347|Experimental|Single arm|
89500879|NCT02258425|Experimental|FEM-CARE|Six specialized nurse case managed and health education sessions and coach-facilitated mentoring
89500880|NCT02258425|Active Comparator|Health Promotion|One brief basic health education session and coach-facilitated mentoring
89500881|NCT02217787|Other|fasted condition|
89500882|NCT02217787|Other|fed condition|
89023426|NCT05468242|Active Comparator|Neoadjuvant Chemotherapy Plus Tislelizumab|Patients in this group will receive Tislelizumab consolidation (200 mg/q3w) after the neoadjuvant chemotherapy plus Tislelizumab and concurrent chemoradiotherapy.
89023427|NCT05467800|Experimental|Canakinumab|Canakinumab will be given by subcutaneous injection (SC) injection at a starting dose of 200 mg (one 150 mg/mL syringe and one 50 mg/0.5 mL syringe) every 3 weeks.
89500883|NCT05262283||2019-2020 season|Injuries in the first 26 games of 2019-2020
89500884|NCT05262283||2020-2021 season|Injuries in the first 26 games of 2020-2021 in the new post-COVID season
89500885|NCT02144129|Experimental|active WB-EMS|2 sessions/week with 20 min of active WB-EMS application
89500886|NCT02144129|Experimental|Passive WB-EMS|2 sessions/week with 20 min of passive WB-EMS application in a resting supine position
89500887|NCT02144129|No Intervention|Inactive Control Group|sedentary non-training control group
89500888|NCT02218411|Experimental|Exercise|Exercises routine based on the Otago exercise programme
89501994|NCT05499260|Placebo Comparator|Placebo MAD 10mg|Participants will receive placebo 10mg orally once daily in a fasted state, for 14 consecutive days.
89500889|NCT02219269||Medically complex contraception users|Cohort includes women of reproductive age with diverse medical conditions (listed in inclusion criteria) who are referred to Family Planning felowship-trained physicians, seeking contraception counseling and administration.
89500890|NCT02205931|Experimental|Ketogenic diet|8 week trial of the ketogenic diet (KD) therapy. Children allocated to KD therapy will have their diets individually calculated by a paediatric dietitian with consideration of daily calorie requirements, adequate protein intake for growth and vitamin and mineral supplementation. All diets will be implemented according to a classical KD protocol, i.e. based on a ratio of fat to carbohydrate and protein that will usually be between 2:1 and 4:1.
89500891|NCT02205931|Active Comparator|Antiepileptic drug therapy|The control intervention will be drug therapy with the most appropriate further antiepileptic drug (AED) for a particular child, depending on their presenting seizures and syndrome and previous drugs used, and chosen by the expert clinician responsible for management of the patient's epilepsy according to a standardised manual (consensus document) written following the initial workshop of the paediatric neurologists from all the trial centres.
89500892|NCT02221063|Active Comparator|low [thiamin] fortified fish sauce|Fish sauce will contain 2 mg thiamin hydrochloride / mL fish sauce + iron (as NaFeEDTA)
89500893|NCT02221063|Active Comparator|higher [thiamin] fortified fish sauce|Fish sauce will contain 8 mg thiamin hydrochloride / mL fish sauce + iron (as NaFeEDTA)
89500894|NCT02221063|Placebo Comparator|Placebo fish sauce|Fish sauce will contain only iron (as NaFeEDTA), no thiamin
89500895|NCT04281212||CTO|Period of 1 month in the participating centers, during which all the patients with CTO and responding to all selection criteria may be included in the study, in order to describe which therapeutic choices have been chosen for this type of patient.
89500896|NCT04281212||CTO with attempted angioplasty|Period of 2 months in the participating centers, during which all the patients for whom an angioplasty has been attempted after a CTO, and responding to all selection criteria, may be included in the study, in order to evaluate the success of the procedure
89500897|NCT05262127|Active Comparator|Flash Version of EMDR|Flash methods (e.g. positive engaging focus) are used in addition to the standard EMDR techniques conveyed by video viewed online
89500898|NCT05262127|Active Comparator|EMDR - alone|Use of standard EMDR techniques conveyed by video online
89500899|NCT05236309||JGF (Jing-Guan-Fang): Traditional Chinese Medicine Decoction|JGF group: 100ml JGF decoction per day at least 1 week
89500900|NCT05236309||NO JGF|NO JGF group: None use traditional Chinese medicine(JGF)
89500901|NCT05564078||Subjects with Eosinophilic Asthma|
89500902|NCT05564078||Subjects without Asthma|
89023428|NCT05455541||Hospitalized patients with an indication for POCUS examination|Patient with an accepted indication for point of care echo study that are clinical stable.
89023429|NCT05454709|Experimental|Dasiglucagon|Dasiglucagon 1mg/ml solution for subcutaneous injection. Size and frequency of dosing will be determined by the AP algorithm. Duration: 3 days.
89023430|NCT05454709|Active Comparator|GlucaGen|Glucagon 1mg/ml solution for subcutaneous injection. Size and frequency of dosing will be determined by the AP algorithm. Duration: 3 days.
89500903|NCT02220049|Experimental|Velcade|Dose level Dose(mg/m²) d1-5, d8-12, d15-19 Cohort -2 Velcade 0.3 mg/m² Cohort -1 Velcade 0.4 mg/m² Cohort 1 Velcade 0.5 mg/m² Cohort 2 Velcade 0.6 mg/m² Cohort 3 Velcade 0.7 mg/m² Cohort 4 Velcade 0.8 mg/m² Cohort 5 Velcade 0.9 mg/m² Cohort 6 Velcade 1.0 mg/m² Cohort 7 Velcade 1.1 mg/m²
89500904|NCT01351805|Experimental|Fish Oil|Subjects will receive marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).
89500905|NCT01351805|Experimental|Vitamin D|Subjects will receive vitamin D3 (cholecalciferol) 2000 IU a day.
89500906|NCT01351805|Placebo Comparator|placebo|Subjects will receive placebo pill.
89500907|NCT01351805|Experimental|Vitamin D and Fish Oil|Subjects will receive marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).
89500908|NCT02206009|Experimental|Collagen membrane|First, the recipient site is prepared, and the collagen membrane hydrated. The collagen membrane is sutured firmly against the prepared vascular bed with a long-lasting suture material. The subject is requested to minimize the amount of manipulation to the area to maintain graft stability.
89500909|NCT05563922|Experimental|Neoadjuvant concurrent Chemoradiotherapy plus consolidation chemotherapy followed by TEM|All the patients will receive neoadjuvant chemoradiotherapy ( CapOx + radiotherapy) for 2 cycles, one week after chemoradiotherapy, the first evaluation including MRI, colonoscopy, digital rectal examination and serum CEA will be conducted. Patients without tumor progression will continue 4 cycles of chemotherapy （CapOx） until next imaging and serum assessment. After the second assessment, for patients with tumor regression and suitable for TEM will receive local resection otherwise TME. Following treatment strategy will be made base on the final pathology evaluation after surgery, patients with good pathological response (ypT 0-1 without neural vascular invasion) will enter into the follow-up period, otherwise TME will be operated.
89500910|NCT02206165|Experimental|Candesartan 8mg + Amlodipine 5mg|Candesartan 8mg + Amlodipine 5mg, po, q.d.
89500911|NCT02206165|Experimental|Candesartan 8mg + Amlodipine 10mg|Candesartan 8mg + Amlodipine 10mg, po, q.d.
89500912|NCT02206165|Experimental|Candesartan 16mg + Amlodipine 5mg|Candesartan 16mg + Amlodipine 5mg, po, q.d.
89500913|NCT02206165|Experimental|Candesartan 16mg + Amlodipine 10mg|Candesartan 16mg + Amlodipine 10mg, po, q.d.
89023431|NCT05454189|Active Comparator|4-week IPD Flushing Schedule|IPD standard maintenance flushes and port assessments every 4 weeks.
89023432|NCT05454189|Experimental|12-week IPD Flushing Schedule|IPD standard maintenance flushes and port assessments every 12 weeks.
89500914|NCT02206165|Active Comparator|Candesartan 8mg|Candesartan 8mg, po, q.d.
89500915|NCT02206165|Active Comparator|Candesartan 16mg|Candesartan 16mg, po, q.d.
89500916|NCT02206165|Active Comparator|Amlodipine 5mg|Amlodipine 5mg, po, q.d.
89500917|NCT02206165|Active Comparator|Amlodipine 10mg|Amlodipine 10mg, po, q.d.
89023433|NCT05454176|Experimental|Libre 2|"Half of patients will be randomized to wear an unblinded FreeStyle Libre 2 CGM for 12 months. Sensor glucose data will be continuously available to patients and their providers.~Primary outcome measurement occurs at 6 months."
89500918|NCT05503784|Experimental|Bite Deodorant|All 38 participants apply BITE deodorant daily for four weeks.
89500919|NCT02697591|Experimental|Phase 1: 20.0 Milligram Per Kilograms (mg/kg) Every 2 Weeks (Q2W)|Participants received IV infusion of study drug at a dose of 20.0 mg/kg every Q2W starting on Day 1 of each cycle for up to 15 months.
89023434|NCT05454176|Placebo Comparator|SMBG levels 3x/daily (standard diabetes management)|Half of subjects will be given sufficient test strips to test 3x per day for the first 6 months of the study, as is usual clinical practice. They wear a blinded FreeStyle Libre Pro CGM monthly during this time-the blinded device is simply to collect study data, the data will not be available to the patient or their provider for clinical use. They will use the 3x daily SMBG data for insulin adjustment, as per usual standard of care. For the final 6 months (7-12), this group will switch to unblinded CGM patients and providers will have full access to CGM data.
89500920|NCT02697591|Experimental|Phase 1: 0.03 mg/kg Q2W|Participants received intravenous (IV) infusion of study drug at a dose of 0.03 mg/kg every Q2W starting on Day 1 of each cycle for up to 15 months.
89500921|NCT02697591|Experimental|Phase 1: 0.1 mg/kg Q2W|Participants received IV infusion of study drug at a dose of 0.1 mg/kg every Q2W starting on Day 1 of each cycle for up to 15 months.
89500922|NCT02697591|Experimental|Phase 1: 0.3 mg/kg Q2W|Participants received IV infusion of study drug at a dose of 0.3 mg/kg every Q2W starting on Day 1 of each cycle for up to 15 months.
89023435|NCT05447650|Experimental|i-Lumen AMD Active|Active transpalpebral microcurrent stimulation therapy
89023436|NCT05447650|Sham Comparator|i-Lumen AMD Sham|Sham transpalpebral microcurrent stimulation therapy
89500923|NCT02697591|Experimental|Phase 1: 1.0 mg/kg Q2W|Participants received IV infusion of study drug at a dose of 1.0 mg/kg every Q2W starting on Day 1 of each cycle for up to 15 months.
89500924|NCT02697591|Experimental|Phase 1: 3.0 mg/kg Q2W|Participants received IV infusion of study drug at a dose of 3.0 mg/kg every Q2W starting on Day 1 of each cycle for up to 15 months.
89500925|NCT02697591|Experimental|Phase 1: 5.0 mg/kg Q2W|Participants received IV infusion of study drug at a dose of 5.0 mg/kg every Q2W starting on Day 1 of each cycle for up to 15 months.
89500926|NCT02697591|Experimental|Phase 1: 10.0 mg/kg Q2W|Participants received IV infusion of study drug at a dose of 10.0 mg/kg every Q2W starting on Day 1 of each cycle for up to 15 months.
89500927|NCT02697591|Experimental|Phase 1: 400 mg/kg Every 4 Weeks (Q4W)|Participants received IV infusion of study drug at a dose of 400 mg/kg every Q2W starting on Day 1 of each cycle for up to 15 months.
89205890|NCT02532595|Experimental|Group 2 TDN, manual therapy and exercise|trigger point dry needling (TDN) to trigger points in the gastrocnemius, soleus and tibialis posterior; manual therapy with soft tissue mobilization to trigger points in the gastrocnemius, soleus, and tibialis posterior; exercise including stretching, concentric and eccentric exercises to the hip, triceps surae, tibialis posterior and foot intrinsics.
89205891|NCT00758069|Placebo Comparator|1|Placebo
89205892|NCT00758069|Experimental|2|Sitagliptin 100 mg
89205893|NCT00758069|Experimental|3|Sitagliptin 50 mg
89205894|NCT01067677|Experimental|Metoclopramide|rescue emetic therapy
89205895|NCT01067677|Experimental|Ondansetron|Rescue emetic therapy
89205896|NCT01067677|Experimental|Diphenhydramine|Rescue emetic therapy
89205897|NCT01067677|Placebo Comparator|Saline|Placebo
89205898|NCT03979651|Experimental|Patients with NRAS Melanoma (Dose 1)|Patients with NRAS Melanoma receiving the 1st dose of the treatment (400 milligrams)
89205899|NCT03979651|Experimental|Patients with NRAS Melanoma (Dose 2)|Patients with NRAS Melanoma receiving the 2nd dose of the treatment (800 milligrams)
89205900|NCT03979651|Experimental|Patients with NRAS Melanoma (Dose 3)|Patients with NRAS Melanoma receiving the 3rd dose of the treatment (600 milligrams twice a day)
89205901|NCT02600741||Study group 1|Caregivers randomized to this group will receive up to 16 sessions of study-provided caregiver psycho-education and skills training sessions they are able to attend within a 6-month period. Each patient will be paired with a caregiver and patients will continue their routine antipsychotic treatments prescribed by their treating physician.
89205902|NCT02600741||Study group 2|Caregivers randomized to this group will receive whatever caregiver support that is customarily available at the study site, if any. Each patient will be paired with a caregiver and patients will continue their routine antipsychotic treatments prescribed by their treating physician.
89205903|NCT03979573|Other|Intervention Arm|"PSA testing~Multiparametric MRI (mp-MRI)~Radiomics~MR-guided biopsy (MR-guided and systematic US-guided)~Molecular Markers (Histological analysis of biopsy cores)"
89205904|NCT01325545||Cryptogenic stroke|Patients with stroke of unknown cause after comprehensive conventional evaluation
89205905|NCT01325545||Stroke of known cause|Patients with stroke of known cause determined by comprehensive conventional evaluation
89205906|NCT01067755||Bronchoscopy, lung neoplasm|Patients who have been recommended for bronchoscopy for the purpose of obtaining a biopsy sample of a central or peripheral pulmonary lesion, diagnosing mediastinal or hilar lymphadenopathy or for lung fiducial placement.
89205907|NCT01065649|Experimental|Nortriptyline|20 NERD patients will be treated with nortriptyline 10 mg a day in the first 7 days and 25 mg a day in the following 14 days
89205908|NCT01065649|Placebo Comparator|Placebo|Placebo arm
89205909|NCT01062685||Shock Cohort|"The SHOCK cohort will meet the American College of Chest physicians/Society of Critical Care Medicine criteria for septic shock, specifically:~1) Suspected infection~2) Any two of four criteria of systemic inflammatory response:~a. Temperature > 100.4° or < 96.8° F~b. Heart rate > 90 beats/minute~c. Respiratory rate > 20 breaths/min. or PaCO2 < 32 mm Hg~d. WBC >12,000 or < 4000 cells/µL or > 10% bands~3) Hypotension despite adequate fluid resuscitation:~a. SBP < 90 mm Hg after 20cc/kg crystalloid"
89500928|NCT02697591|Experimental|Phase 2: 300 mg/kg Q2W|Participants received IV infusion of study drug at a dose of 300 mg/kg every Q2W starting on Day 1 of each cycle for up to 15 months.
89500929|NCT02220127|Experimental|8 mm collimator|GKR with a single shot of the 8 mm collimator
89205910|NCT01062685||Sepsis cohort|"The SEPSIS cohort will to meet:~1) Suspected infection~2) Any two of four criteria of systemic inflammatory response:~a. Temperature > 100.4° or < 96.8° F~b. Heart rate > 90 beats/minute~c. Respiratory rate > 20 breaths/min. or PaCO2 < 32 mm Hg~d. WBC >12,000 or < 4000 cells/µL or > 10% bands~3) Absence of refractory hypotension"
89205911|NCT01062685||Non-Infected controls|The third cohort will be comprised of uninfected ED control patients who met the criteria of no suspected infection, no SIRS criteria met and no evidence of hypoperfusion that are age and sex matched on a 1:1 basis with the shock cohort.
89205912|NCT01065727|Experimental|mitoxantrone followed by immunomodulator|
89205913|NCT01065727|Active Comparator|natalizumab|
89205914|NCT01067833|Placebo Comparator|Placebo|Placebo
89205915|NCT01067833|Experimental|Dose 1|K201
89205916|NCT01067833|Experimental|Dose 2|K201
89205917|NCT01067833|Experimental|Dose 3|K201
89205918|NCT01065805|Experimental|1|18F-FLT PET
89205919|NCT01067911|Active Comparator|1|In this study subjects will consume test meals containing vegetable oils (soy) and butter
89205920|NCT01067911|Active Comparator|2|In this study subjects will consume test meals containing vegetable oils (flaxseed) and butter
89205921|NCT01067911|Active Comparator|3|In this study subjects will consume test meals containing vegetable oils (high oleic safflower) and butter
89205922|NCT01067911|Active Comparator|4|In this study subjects will consume test meals containing vegetable oils (canola) and butter
89205923|NCT00311623|Active Comparator|Control group|"Men >18years old with prostate cancer clinical stages T1c to T3, no metastases, Gleason sum of 7-10, multiple positive diagnostic cores, Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, candidates for radical prostatectomy.~Receive no intervention on Days 1-14. Surgery performed on Day 15."
89205924|NCT00311623|Experimental|Low-dose Rapamycin (3mg)|"Men >18years old with prostate cancer clinical stages T1c to T3, no metastases, Gleason sum of 7-10, multiple positive diagnostic cores, Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, candidates for radical prostatectomy.~Must have adequate hepatic, renal and bone marrow function, no allergy to rapamycins, avoid medications interfering with rapamycin metabolism, no active infection, no prior therapies for prostate cancer.~Will receive rapamycin 3mg (Wyeth Pharmaceuticals, 1mg tablets) oral (PO) once daily on Days 1-14 with the last dose given on the morning before surgery (Day 15)."
89500930|NCT02220127|Experimental|4 mm collimator|GKR with a single shot of the 4 mm collimator
89501995|NCT05499260|Experimental|CB03-154 MAD 20mg|Participants will receive CB03-154 20mg orally once daily in a fasted state, for 14 consecutive days.
89501996|NCT05499260|Placebo Comparator|Placebo MAD 20mg|Participants will receive placebo 20mg orally once daily in a fasted state, for 14 consecutive days.
89500931|NCT04350398|Experimental|Hippotherapy treated group|"During the initial week of intervention, sessions will be mainly carried on horseback. We will use the movement of the horse: (i) to allow patient re-appropriating her body and find harmony; (ii) to initiate rehabilitation of movements (shoulder, neck, upper extremity, whole body), gesture and femininity. The goal is to reconstruct a harmonic body image both in the private and public sphere, through different techniques. A few walking sessions may be needed to reinforce some landmarks.~During the short stages the work will be mainly done by walking alongside the horse. These reinforcement periods act like a trampoline, necessary to have a new momentum providing the opportunity to take a step back from the everyday, to regenerate somehow. The reaction time is generally optimized considering the imprint done during the initial long stage. One of the main themes that come up during this period is fear (relapse, the future, not achieving the goals, pain, relationship issues, etc.)."
89500932|NCT04350398|Placebo Comparator|Conventional therapy treated group|Patients in the control group are followed by dedicated personnel of the Montpellier Institut du Sein. This personalized care pathway after/during the cancer treatment takes into consideration all aspects of the disease, allowing to coordinate the intervention of the professionals that the patient might need in order to better preserve her quality of life while answering questions about cancer, prevention, treatments, or life after illness. The MIS mobilizes a chain of skills and support by providing patients: radiologists, pathologists, surgeons, oncologists, and radiation therapists, nuclear doctors, physiotherapists, cardiologists, psychologists, psychiatrists, nurses, social workers, nutritionists, dieticians, onco-geneticists, osteopaths, homeopaths, acupuncturists, sexologists, addictologists, algologists, and vascular physicians.
89500933|NCT02206243||Embozene|Patients receiving Embozene microspheres
89500934|NCT02254187|Experimental|Salmeterol capsule via Handihaler - low|
89500935|NCT02254187|Experimental|Salmeterol capsule via Handihaler - high|
89500936|NCT02254187|Active Comparator|Salmeterol via Serevent® Diskus®|
89500937|NCT02258191|Active Comparator|NIV treatment with telemonitoring|telemonitoring is used to manage NIV treatment
89500938|NCT02258191|Sham Comparator|NIV treatment with sham telemonitoring|sham telemonitoring (data not used for NIV management)
89500939|NCT05563610|Experimental|Oral Challenge|Patients will be screened for high vs. low risk of penicillin allergy. Low risk patients will be randomized to oral amoxicillin 500 mg challenge.
89500940|NCT05563610|No Intervention|No Oral Challenge|Patients will be screened for high vs. low risk of penicillin allergy. Low risk patients will be randomized to no oral amoxicillin 500 mg challenge..
89500941|NCT03545087|Experimental|Lanabecestat Control|Lanabecestat administered orally to participants with normal renal function
89500942|NCT03545087|Experimental|Lanabecestat Severe Renal Impairment|Lanabecestat administered orally to participants with severe renal impairment, not on dialysis
89500943|NCT02224807|Active Comparator|Progressive Resistance Training (PRT) and a healthy diet|PRT will be done with resistance bands; participants will receive instruction on three resistance band exercises (triceps, biceps, and shoulder overhead) from an American College of Sports Medicine (ACSM) certified exercise specialist. Participants also will receive dietary counseling from a registered dietitian on correcting nutrient deficiencies that are detected during analysis of their 2-day dietary recalls.
89500944|NCT02224807|Experimental|PRT and a healthy diet, plus weight loss|This arm will receive all components of the active comparator arm, plus counseling to achieve a weight loss of 1.5-2 pounds/week. Participants will be trained on how to achieve this caloric deficit through both dietary restriction and increased physical activity. Weight loss will be promoted via a healthy, nutritionally adequate diet consistent with American Cancer Society guidelines. Protein levels will be based on 0.8 g/kg body weight. The distribution of food groups will be customized for preferences. An exercise program will be tailored taking into account kcal expenditure for various activities at a specific body weight; expenditures of 200-400 kcal/day will serve as a goal. Aerobic training of large muscles (legs) will be emphasized to achieve a greater kcal deficit; ramping of intensity and volume over time will be pursued as per the ACSM guidelines. Participants will train once weekly while supervised by an exercise physiologist and daily at home.
89500945|NCT05563532||anxious group|Children with a score ≥4 on the venham picture test were included.
89500946|NCT05563532||non-anxious group|Children with a score <4 on the venham picture test were included.
89500947|NCT03545009|Experimental|Beetroot Juice|
89500948|NCT03545009|Active Comparator|Beetroot Juice no Nitrate|
89500949|NCT03545009|Active Comparator|Sodium Nitrate|
89500950|NCT03545009|No Intervention|Control|
89501997|NCT05499260|Experimental|CB03-154 MAD 40mg|Participants will receive CB03-154 40mg orally once daily in a fasted state, for 14 consecutive days.
89501998|NCT05499260|Placebo Comparator|Placebo MAD 40mg|Participants will receive placebo 40mg orally once daily in a fasted state, for 14 consecutive days.
89501999|NCT02744833|Experimental|GMI-1271|
89023438|NCT05431088|Active Comparator|Part A|"Initially, participants will be randomized 1:1 to 100 mg and 150 mg daily. Upon review of the 150 mg safety data from at least 6 participants, there will be 1:1:1 randomization: 100 mg, 150 mg, and up to 200 mg.~Participants will then receive maintenance once daily doses through Week 12."
89023439|NCT05431088|Placebo Comparator|Part B|Following the selection of the optimal safe and effective dose from Part A of the study, Part B of the study will assess the efficacy and safety of 48 weeks of the optimal dose, compared to placebo
89023440|NCT05431088|Experimental|Part C|100 mg dose in cohort C1, dose level for cohorts C2 to C4 to be determined based on emerging data
89023441|NCT05430477||Cohort 1 Biopsy|Subjects recruited to Cohort I will include patients who are scheduled to undergo oral lesion biopsy as well as patients who are determined to need a biopsy at the time of visual examination, which often occurs in-clinic. Cohort I will consist of 125 oral lesion biopsy patients total. Prior to the start of enrollment in this Cohort, up to 5 additional subjects will be enrolled to optimize the data acquisition process.
88956157|NCT05780762|Sham Comparator|Usal care : control group|patients followed for one or several stabilized chronic pathology(ies) and benefiting from a usual management with a Nurse in Advanced Practice.
89500951|NCT02224885|Other|addition of nCLE to help target biopsy|The patient, scheduled for a liver or lung CT-guided percutaneous biopsy or ablation will undergo a probe-based confocal laser endomicroscopy procedure after the imaging procedure. The objectives of this study are to demonstrate the technical feasibility and safety of doing endomicroscopic imaging during interventional radiology procedure and determine whether it is technically feasible to obtain images from Cellvizio during an interventional radiology procedure.
89500952|NCT02697435|Experimental|Patient-Centered Care|Patient-centered care will be directed by geriatricians who have been trained to assess and treat 11 conditions that commonly affect chronic low back pain.
89500953|NCT02697435|Placebo Comparator|Imaging-Directed Care|Imaging-Directed Care will allow patients to follow-up their initial imaging with whatever course they (and/or their doctor) chose, should they chose to follow any course at all.
89500954|NCT02031445|Placebo Comparator|Placebo|BID
89500955|NCT02031445|Experimental|MRX-6|BID
89500956|NCT02399553|Experimental|Soccer 2G|Soccer players who trained in second generation artificial turf
89500957|NCT02399553|Experimental|Soccer 3G|Soccer players who trained in third generation artificial turf
89500958|NCT02399553|Experimental|Soccer NG|Soccer players who trained in natural grass
89500959|NCT02399553|Experimental|Soccer NON-NG|Soccer players who trained in non-natural grass
89500960|NCT02399553|No Intervention|Control group|
89500961|NCT02174861|Experimental|Erenumab|Participants received erenumab 70 mg once a month (QM) or 140 mg QM by subcutaneous injection for up to 52 weeks.
89500962|NCT02221297|Experimental|Supplement product with plant stanol ester|
89500963|NCT02221297|Placebo Comparator|Placebo supplement product|
89500964|NCT02399631|Experimental|ERAS group|early recovery program with no preoperative mechanical bowel preparation, early diet initiation, and prevention of postoperative ileus after elective laparoscopic colon cancer surgery
89500965|NCT02399631|No Intervention|Congrol group|Traditional, conventional perioperative treatment
89500966|NCT02221375|Experimental|BHT low|
89500967|NCT02221375|Experimental|BHT medium|
89500968|NCT02221375|Experimental|BHT high|
89500969|NCT02221375|Experimental|BI 54903 XX low|
89500970|NCT02221375|Experimental|BI 54903 XX medium 1|
89500971|NCT02221375|Experimental|BI 54903 XX medium 2|
89500972|NCT02221375|Experimental|BI 54903 XX high|
89500973|NCT02221375|Experimental|BI 54903 XX medium single dose|
89500974|NCT02221375|Active Comparator|Ciclesonide|
89500975|NCT02399709|Experimental|simvastatin|oral administration, capsule of 20mg.
89500976|NCT02399709|Placebo Comparator|microcrystalline cellulose|oral administration, capsule of 20mg
89500977|NCT02220361|Placebo Comparator|placebo group|received 20 ml intravenous physiological saline
89500978|NCT02220361|Experimental|low dose dexmedetomidine group|received 0.5μgkg-1 intravenous dexmedetomidine (Jiang Su Heng Rui Medicine Co. Ltd, Jiangsu Province, China) diluted to 20ml with physiological saline
89500979|NCT02220361|Experimental|hemabate+high dose dexmedetomidine group|received 1μgkg-1 intravenous dexmedetomidine (Jiang Su Heng Rui Medicine Co. Ltd, Jiangsu Province, China) diluted to 20ml with physiological saline
88956158|NCT05778071|Experimental|eneboparatide|Starting dose of 20 mcg; Administered once daily by subcutaneous injection
89500980|NCT02144207|Active Comparator|Glidescope: Unrestricted View|Unrestricted view of the larynx.
89500981|NCT02144207|Active Comparator|Glidescope: Restricted View|Restricted view of the larynx.
89500982|NCT02220439||Case: non-rotavirus seroconverters|Infants not demonstrating seroconversion to rotavirus vaccination, as measured anti-RV Immunoglobulin A < 20 U/ml
89500983|NCT02220439||Control: rotavirus seroconverters|Infants demonstrating seroconversion to rotavirus vaccination, as measured by anti-rotavirus Immunoglobulin A > 20 U/ml
89500984|NCT05175001|Placebo Comparator|Group R|The patient is placed in lateral decubitus position with the operative side facing up, and the thoracic paravertebral nerve block will be performed under ultrasound. We select T4-5,T6-7and T8-9 intervertebral spaces for puncture.A 30-mL bolus of a solution of 0.33% ropivacaine in saline was administered under real-time ultrasound monitoring
88956159|NCT05778071|Placebo Comparator|Placebo|Administered once daily by subcutaneous injection
89500985|NCT05175001|Experimental|Group RD|The patient is placed in lateral decubitus position with the operative side facing up, and the thoracic paravertebral nerve block will be performed under ultrasound. We select T4-5,T6-7and T8-9 intervertebral spaces for puncture.A 30-mL bolus of a solution of 0.33% ropivacaine plus 4.67mg Diprospan in saline was administered under real-time ultrasound monitoring
89500986|NCT02224963|Experimental|Preventive Problem-Solving Training|Preventive Problem-solving Training is an adaptation of Problem-Solving Therapy that builds problem-solving skills and then focuses these skills on potential future problems. It aims to reduce avoidance of contemplation of future needs and enhance gathering information, decision-making, and concrete planning about future needs.
89500987|NCT02224963|Active Comparator|Life and Health Review|Life and Health Review is an Enhanced Attention Control that provides classes and resource information modules, just as in intervention. It differs from the intervention in that we conduct an 8-session life and health review with subjects, in which they recount life experiences from childhood to the present.
89500988|NCT02254343|Experimental|proximal robot-assisted therapy|treatment programs will target to shoulder and elbow portions of upper extremity via the InMotion2 robotic system
89500989|NCT02254343|Experimental|distal robot-assisted therapy|the InMotion3 robot system will be used to execute treatment programs focus on wrist movements. It includes three degrees of freedom to allow wrist flexion/extension, abduction/adduction, and pronation/supination.
89500990|NCT02254343|Active Comparator|individualized intensive therapy|individualized occupational therapy which is dose-match to robot-assisted therapy, based on task-oriented principle.
89500991|NCT02220517|Experimental|A: MR-guided in-bore prostate biopsy|Patients of arm A receive a targeted MR-guided in-bore prostate biopsy. From each prostate lesion defined in the diagnostic multiparametric MRI two targeted biopsy cores will be taken.
89500992|NCT02220517|Experimental|B: MRI/US fusion-guided prostate biopsy|Patients of arm B receive a targeted MRI/US fusion-guided prostate biopsy. From each prostate lesion defined in the diagnostic multiparametric MRI two targeted biopsy cores will be taken. Immediately after targeted biopsy patients undergo additional systematic TRUS-guided biopsy (12 biopsy cores)
89500993|NCT02231047|Experimental|64N Nutraceutical|Powdered 64N Nutraceutical 40 mg/kg/day mixed in 12 ounces of a culturally appropriate warm drink for 1 week (7 days).
89500994|NCT02231047|Sham Comparator|No 64N Nutraceutical|Culturally appropriate 12 ounce warm drink daily for 1 week (7 days).
89500995|NCT00140855|Experimental|ipilimumab|Three doses of ipilimumab, 3 mg/kg, were administered by intravenous infusion at 3-week intervals. A 6-week observation period followed the final dose.
89500996|NCT00700635|Experimental|Menactra® Group 1|Participants aged 2 to < 4 years
89500997|NCT00700635|Experimental|Menactra® Group 2|Participants aged 4 to < 6 years
89500998|NCT00700635|Active Comparator|Menactra® Group 3|Participants aged 6 to < 11 years
89500999|NCT02225197|Experimental|CyberKnife Radiosurgery|
89501000|NCT02399397|Active Comparator|Control group|Adult patients(18-50 years old) ASA I-II without sepsis submitted to small to medium sized surgery under general anesthesia are being recruited. All patients are being induced with individualized doses of rocuronium, midazolam, propofol and fentanyl. Serial blood sampling are being collected up to 6 h after administration of the drug for pharmacokinetic study. Neuromuscular blockade is being monitored by stimulation of the adductor muscle of the thumb on the ulnar nerve through the train of four monitoring (TOF) at the same time as blood sampling. All patients are being submitted to blood testing for liver and renal function (creatinine, urea, albumin, aspartate aminotransferase and alanine aminotransferase).
89501001|NCT02399397|Experimental|Sepsis group|Adult patients (18-50 years old) ASAII and III with sepsis, systemic inflammatory response syndrome or septic shock submitted to small to medium sized surgery under general anesthesia are being recruited. All patients are being induced with individualized doses of rocuronium, midazolam, propofol and fentanyl. Serial blood sampling are being collected up to 6 h after administration of the drug for pharmacokinetic study. Neuromuscular blockade is being monitored by stimulation of the adductor muscle of the thumb on the ulnar nerve through the train of four monitoring (TOF) at the same time as blood sampling. All patients are being submitted to blood testing for liver and renal function (creatinine, urea, albumin, aspartate aminotransferase and alanine aminotransferase).
89501002|NCT02399397|Experimental|Elderly group|Elderly patients (> 65 years old) ASA I-II without sepsis submitted to small to medium sized surgery under general anesthesia are being recruited. All patients are being induced with individualized doses of rocuronium, midazolam, propofol and fentanyl. Serial blood sampling are being collected up to 6 h after administration of the drug for pharmacokinetic study. Neuromuscular blockade is being monitored by stimulation of the adductor muscle of the thumb on the ulnar nerve through the train of four monitoring (TOF) at the same time as blood sampling. All patients are being submitted to blood testing for liver and renal function (creatinine, urea, albumin, aspartate aminotransferase and alanine aminotransferase).
89501003|NCT02221453|Other|Triamcinolone Acetonide Treatment|Triamcinolone Acetonide Injectable Suspension 40 mg/mL intravitreal injection
89501004|NCT03106545|Experimental|Single mixture LB & bupivacaine|A single mixture of liposome bupivacaine 1.3% (5 mL) + bupivacaine 0.5% (2.5 mL) injected into the distal tibial and deep peroneal nerves
89501005|NCT03106545|Active Comparator|Bupivacaine alone|Bupivacaine 0.5% (7.5 mL) injected into the distal tibial and deep peroneal nerves
89501006|NCT03106545|Sham Comparator|General anesthesia|General anesthesia
89501007|NCT02221531|Experimental|Short infusion|Carbetocin 100 microgram will be applied intravenously in a short infusion over about a minute
89501008|NCT02221531|Other|Bolus application|Carbetocin 100 microgram will be applied intravenously by bolus application over about 15 seconds
89501009|NCT02396355||All subjects|This is a single arm study. Samples from each subject will be tested with the Investigational BD FACSPresto System, the BD FACSCalibur flow cytometer, and the Sysmex hematology analyzer KX-21.
89501010|NCT02231125|Experimental|Abelmoschus manihot (AM)|Abelmoschus manihot (AM): Huangkui capsule (Jiangsu Suzhong Pharmaceutical Group Co., Ltd.), 0.5 g × 30 capsules/box. A huangkui capsule is a single plant drug extract of Flos Abelmoschus manihot.
89501011|NCT02231125|Experimental|Losartan|Losartan potassium (Hangzhou MSD Pharmaceutical Co., Ltd.), 100 mg × 7 capsules/box.
89501012|NCT02396433|Experimental|Carboplatin, eribulin, and E7449|This is a phase I/II clinical trial of the combination of carboplatin, eribulin, and E7449.
89501013|NCT03106467|Experimental|Single-port laparoscopic appendectomy|Single-port laparoscopic appendectomy is performed through single-port which is installed in umbilicus.
89501014|NCT03106467|Active Comparator|Three-port laparoscopic appendectomy|Three-port laparoscopic appendectomy is performed using conventional three-port technique which needs two additional ports outside umbilicus in addition to trans-umbilical port
89501015|NCT02399241|Experimental|Remote telemonitoring of clinical data|Bluetooth enabled nebuliser device (I-neb) providing breathing parameters and adherence data.
89501016|NCT02231203|Placebo Comparator|Placebo|2 infusions of NaCl, 2 ml/kg, one the night before operation and one the day after operation.
89501017|NCT02231203|Active Comparator|Omegaven|2 infusions of 2ml/kg, one the night before surgery and one the day after surgery
89501018|NCT03168165|No Intervention|Usual Care|Usual care, no intervention
89501019|NCT03168165|Experimental|Pain Neuroscience Education Training|The region of clinics randomized to this arm will receive PNE education, which consists of 6 weeks online training followed by an on-site training day.
89501020|NCT02231281|Experimental|cART(TDF/AZT+3TC+LPV/r)|cART(TDF/AZT+3TC+LPV/r)
89501021|NCT02231281|Experimental|CTL infusion|cART plus autologous HIV-1 specific cytotoxic T lymphocyte (CTL) infusion
89501022|NCT03168243|Experimental|High Energy High Protein Tube Feed|As study is a single arm design, all patients will be in the intervention group. The will act as their own control by means of a 3 day baseline period. All patients in the study will receive the same intervention, the high energy high protein tube feed, in quantities specified by their dietitian based on their nutritional requirements.
89023442|NCT05430477||Cohort 2 Resection|Potential study participants will be identified through Dartmouth-Hitchcock Medical Center (DHMC)'s Head and Neck Tumor Clinic, and will be patients with diagnosed or suspected cancer of the oral cavity, oropharynx, hypopharynx, or larynx who require biopsy or resection for either diagnostic or therapeutic purposes. Cohort II will be comprised of 125 patients undergoing oral cavity cancer resections. Initially, up to 5 subjects will be enrolled in addition to the 125 patients in this Cohort in order to optimize the data acquisition process.
89023443|NCT05429892|Experimental|TRTsocialmot1 arm|"Smokers will receive real-time video-based motivational counseling and home-based food delivery.~Participants will receive educational material."
89023444|NCT05429892|Active Comparator|TRTmot3 arm|"Smokers will receive real-time video-based motivational counseling only.~Participants will receive educational material."
89023445|NCT05429892|Active Comparator|TRTsocial2 arm|"Smokers will receive home-based food delivery only.~Participants will receive educational material."
89023446|NCT05419856|Experimental|4P-004 at 0.3 mg or placebo|4P-004 at 0.3 mg or placebo is administered once intraarticularly in the target knee joint
89023447|NCT05419856|Experimental|4P-004 at 1 mg or placebo|4P-004 at 1 mg or placebo is administered once intraarticularly in the target knee joint
89023448|NCT05419856|Experimental|4P-004 at 3mg or placebo|4P-004 at 3 mg or placebo is administered once intraarticularly in the target knee joint
89023449|NCT05419856|Experimental|4P-004 at 2 mg or placebo|4P-004 at 2 mg or placebo is administered once intraarticularly in the target knee joint
89023450|NCT05417165|Active Comparator|Arm A (Standard ARM- No Booster)|Patients receive PCV 20 IM at week 0. Titers will be checked 4 weeks after this dose. Booster Vaccine: None. Titers will be checked at 12 weeks and then yearly for 5 years.
89501023|NCT02221609|Experimental|Treatment based on Movement System Impairment based model|Treatment based on Movement System Impairment based classification model is composed by patient education, analysis and modification of daily living activities and prescription of specific exercises
89501024|NCT02221609|Active Comparator|General exercise|The general exercise program consists of stretching exercises of the trunk and lower limbs muscles and strengthening exercises of the trunk muscles (Hayden et al., 2005; Rainville et al., 2004).
89501025|NCT02399007|Experimental|Total Hip System made in China|Patient in this arm will be implanted with Primary Total Hip Arthroplasty Devices Manufactured in China
89501026|NCT02399007|Active Comparator|Total Hip System made outside of China|Patient in this arm will be implanted with Primary Total Hip Arthroplasty Devices Manufactured Outside of China
89501027|NCT02231359||chronic obstructive airways disease patients|
89501028|NCT02399319|Experimental|Randomized to Internal Fixator|Patient signed consent and agreed to have their treatment method randomized and the randomization system determined that their surgical intervention would be internal fixator.
89501029|NCT02399319|Experimental|Randomized to Symphyseal Plate|Patient signed consent and agreed to have their treatment method randomized and the randomization system determined that their surgical intervention would be internal plating of the symphysis.
89501030|NCT02399319|Active Comparator|Observational - Internal Fixator|Patient signed consent but did not want to randomize their procedure and the treating physician selected the internal fixator intervention based on their opinion of how best to treat the specific case.
89501031|NCT02399319|Active Comparator|Observational - Symphyseal Plate|Patient signed consent but did not want to randomize their procedure and the treating physician selected internal plating of the symphysis based on their opinion of how best to treat the specific case.
89501032|NCT02225431|Active Comparator|Standard saline infusion|All patients received standard intravenous saline hydration (0.9% sodium chloride, 1 ml/kg/h for 12 hours before and after procedure)
89501033|NCT02225431|Experimental|Double saline infusion|All patients received double dose of intravenous saline hydration (0.9% sodium chloride, 2 ml/kg/h for 12 hours before and after procedure)
89501034|NCT04711525|Experimental|Interactive Malaysian Childhood Healthy Lifestyle Program (i-MaCHeL)|The preschool children in the experimental group will be exposed to interactive classroom instruction, and their parents will be exposed to the Web-based program. In the experimental group, apart from the standard preschool health education curriculum, the preschool children will also be exposed to the interactive activities and quizzes using Web 2.0 tools, educational videos of a healthy lifestyle, sensory-based food education activities, cooking demonstrations, fun, and active games, and exercises. Whereas the parents will be exposed to Web-based healthy lifestyle educational materials, videos, and pictures sharing, quizzes, and communication through the WhatsApp and closed Facebook groups. Besides, a total of 3 messages per week will be delivered to the parents in the experimental group. The messages will be included announcing the release of a new topic, a reminder to log in to the website and read the health information, and a reminder to participate in the online activities.
89023451|NCT05417165|Experimental|Arm B (Experimental ARM-No Booster)|Patients receive PCV 20 IM at week 0 and PSV23 IM at week 8. Titers will be checked 4 weeks after the first dose and at 12 weeks (4 weeks after the second dose). Booster Vaccine: None. Annual titers will be checked for 5 years.
89501035|NCT04711525|Active Comparator|Standard health education|The children in the control group do not have exposed to the i-MaCHeL interactive classroom instruction, and their parents do not have access to the i-MaCHeL website materials. Thus, the children will be continued with standard health education only in the preschool setting, and their parents will be received Web-based health newsletters. The Web-based newsletters consist of general health information that are relevant to the preschool life stage. In ensuring that the experimental and control groups appear the same, the topics in the Web-based newsletters will have a look and feel similar nature to the experimental group condition. But still, the topics will not be included the interactive components such as videos and pictures sharing activities, quizzes, individualized feedback, and communication through WhatsApp and closed Facebook groups. Only one message (announcement of the release of a new topic) per week will be delivered to parents of the control group.
89501036|NCT02780687|Experimental|Afatinib|
89501037|NCT02231437||chronic obstructive respiratory tract disease patients|
89501038|NCT02398851|Other|TacTIC care model|Compare the 30-day readmission rate in adult patients who receive care in a trans-disciplinary chronic disease continuity of care model with integrated technology (mobile devices such as tablets, iPads and smartphones)
89501039|NCT02398851|Other|Standard of Care|Compare standard practice (patient-centered, coordinated care model without the integration of technology
89501040|NCT02225509|Other|Patients with thyroid nodules|Patients with thyroid nodules with an indication for FNA biopsy to detect thyroid cancer. These patients will undergo FNA at the time of first visit and also when considered necessary by the clinician during the course of the study.
89501041|NCT02147873|Active Comparator|azacitidine with birinapant|Azacitidine 75 mg/m2 IV on days 1-5, 8 & 9 OR days 1-7 and birinapant 13 mg/m2 IV twice a week (days 1 & 4) for 3 out of 4 weeks
89501042|NCT02147873|Placebo Comparator|Azacitidine and placebo|Azacitidine 75mg/m2 IV days 1-5, 8 & 9 OR days 1-7 and placebo IV twice a week (days 1 & 4) for 3 out of 4 weeks
89501043|NCT02398929|Other|Bisoprolol 2.5 mg|Bisoprolol 2.5 mg will be given once daily following run-in placebo for 2 weeks
89501044|NCT02259049|Active Comparator|L-Tyrosine|We will administer 1,000 mg of L-tyrosine BID for 24 hours and record BP and HR.
89501045|NCT02259049|Placebo Comparator|Sugar Pill|We will administer a sugar pill BID for 24 hours and record BP and HR.
89501046|NCT02396121|Experimental|Interventional|Administration of 1 bottle of an oral nutritional supplement, Renutryl® Booster (600 kcal), during 28 days.
89501047|NCT02221765|Experimental|Arm 1|"Visit 1 - sham visit: placebo 0.9% (w/v) saline single-dose, administered subcutaneously.~Visit: 2 - placebo 0.9% (w/v) saline single-dose, administered subcutaneously.~Visit 3 - single dose of PP 1420, administered subcutaneously. Dose levels: 8, 16, 32, 64 mg."
89501048|NCT02221765|Experimental|Arm 2|"Visit 1 - sham visit: placebo 0.9% (w/v) saline single-dose, administered subcutaneously.~Visit: 2 - single dose of PP 1420, administered subcutaneously. Dose levels: 8, 16, 32, 64 mg.~Visit 3 - placebo 0.9% (w/v) saline single-dose, administered subcutaneously."
89501049|NCT02398695||Caries Free|Participants who do not have caries (cavities) will have oral samples collected.
89501050|NCT02398695||Caries Active|Participants who do have caries (cavities) will have oral samples collected.
89501051|NCT05069129|Experimental|Subject last vaccination time is within 4-6 months（sequential clinical trial group）|Subject have been vaccinated with two doses of Inactivated COVID-19 vaccine (Vero cell).The last vaccination time is within 4-6 months
89501052|NCT05069129|Experimental|Subject last vaccination time is within 7-9 months（sequential clinical trial group）|Subject have been vaccinated with two doses of Inactivated COVID-19 vaccine (Vero cell).The last vaccination time is within 91-180 days 7-9 months
89501053|NCT05069129|Experimental|Subject last vaccination time more than 9 months（sequential clinical trial group）|Subject have been vaccinated with two doses of Inactivated COVID-19 vaccine (Vero cell).The last vaccination time more than 9 months
89501054|NCT05069129|Experimental|Safety Observation Group|Subject have been vaccinated with three doses of Recombinant COVID-19 Vaccine (CHO Cells,NVSI-06-08) on 0，30，60 days
89501055|NCT02398461|Experimental|rHIgM22|Patients will be enrolled sequentially in 2 separate cohorts, representing escalating dose levels. Each dose cohort will comprise 15 subjects, randomly assigned to receive either rHIgM22 (n=10) or placebo (n=5).
89501056|NCT02398461|Placebo Comparator|Placebo|Patients will be enrolled sequentially in 2 separate cohorts, representing escalating dose levels. Each dose cohort will comprise 15 subjects, randomly assigned to receive either rHIgM22 (n=10) or placebo (n=5).
89501057|NCT02259127|Active Comparator|SOC arm|SOC for ODYSSEY A is defined as a PI or non nucleoside transcriptase inhibitors + 2 or 3 nucleoside transcriptase inhibitor SOC for ODYSSEY B is defined as a PI or non nucleoside transcriptase inhibitor+ 2 nucleoside transcriptase inhibitors
89501058|NCT02259127|Experimental|DTG arm|DTG + 2 nucleoside transcriptase inhibitors
89501059|NCT03544073|Placebo Comparator|Saline Solution for Injection|This arm will receive a one-time subcutaneous injection of 0.4mL normal saline solution at the time of embryo transfer. This arm will continue to receive all the same treatments that everyone routinely receives for the IVF cycle, e.g. estrogen and progesterone supplements.
89501060|NCT03544073|Experimental|Leuprolide Acetate|This arm will receive a one-time subcutaneous injection of 0.4U (0.2mg=0.4mL) Leuprolide acetate at the time of embryo transfer. This arm will continue to receive all the same routine treatments for the IVF cycle, e.g. estrogen and progesterone supplements.
89501061|NCT02395887||Intervational|Patients with back or neck pain who are a candidates for operational intervention.
89501062|NCT02395887||Control|Men or women who haven't seek for spine surgery consultation.
89501063|NCT02140697|Experimental|Hippophae rhamnoides L. Leaf Extract|Hippophae rhamnoides L. Leaf Extract 3g/day
89501064|NCT02140697|Placebo Comparator|Placebo|Placebo 3g/day
89501065|NCT02398383|Experimental|CF with Normal Glucose Tolerance|Individuals with CF without cystic fibrosis related diabetes
89501066|NCT02398383|Experimental|Cystic Fibrosis Related Diabetes|Individuals with cystic fibrosis and cystic fibrosis related diabetes
88956166|NCT05761535||neurological disease patients|150 patients with Alzheimer's disease (AD) and Parkinson's disease (PD) for MRI and PET examinations and laboratory medicine
88956167|NCT05761535||healthy subjects|Healthy subjects
88956168|NCT05761327|Active Comparator|Mediterranean Diet|The individuals in this group will be given a nutrition model in accordance with the Mediterranean Nutrition Program under the supervision of a dietitian for 8 weeks. Individuals will be informed about the Mediterranean diet, their questions will be answered, the current food consumption record will be examined by the dietitian and they will be asked to follow the nutrition program prepared in the most appropriate way (by considering energy, nutrient requirements and nutritional habits). Every 15 days, the nutrition program will be updated with the meetings to be made by the dietitian and the patient, and the applicability of the program will be checked through daily communication.
89501067|NCT02398383|Active Comparator|Control|Age matched control subjects
88956169|NCT05761327|Experimental|Curcumin Supplementation|In addition to the Mediterranean Diet program in the 1st group for individuals in this group; 800 mg of curcumin supplement (VeNatura Curcumin Supplementary Food, Vefa, Istanbul, Turkey) will be given as 1 capsule each in the morning and evening meals.
89501068|NCT02398305|Active Comparator|TR Band accelerated|Diminishing air pressure in the TR Band using accelerated protocol
89501069|NCT02398305|Other|TR band standard|Diminishing air pressure in the TR band according to standard care
89501070|NCT02259205|Experimental|Enriched Yogurt|150 g yogurt enriched with approximately 0.5 g bioactive lipids extract from olive oil mill provided daily for 8 weeks
89501071|NCT02259205|Placebo Comparator|Plain Yogurt|150 g not enriched yogurt provided daily for 8 weeks
89501072|NCT02259205|No Intervention|Control|No yogurt consumption
89501073|NCT03168087||0% dilution|Blood specimen which was diluted with 0% level using a plasmalyte-148 solution
89501074|NCT03168087||20% dilution|Blood specimen which was diluted with 20% level using a plasmalyte-148 solution
89501075|NCT03168087||40% dilution|Blood specimen which was diluted with 40% level using a plasmalyte-148 solution
89501076|NCT03168087||60% dilution|Blood specimen which was diluted with 60% level using a plasmalyte-148 solution
89501077|NCT02221921|Experimental|MicroPort's Transcatheter Aortic Valve and Delivery System|single arm with intervention that percutaneous implantation of the MicroPort's Transcatheter Aortic Valve and Delivery System
89501078|NCT03168009|Experimental|Bariatric Surgery|Patients will undergo either Omega Loop Gastric Bypass or Sleeve Gastrectomy. The decision which type of surgery will be performed, will by made by the surgeon and the patient based on clinical considerations and the patient's wishes.
89501079|NCT05138887|Placebo Comparator|placebo group|The placebo group was administered a vitamin tablet (Centrum) orally, once a day
89501080|NCT05138887|Experimental|experimental group 1|The experimental group 1 was administered BH4 orally, with a dose of 2mg/kg.d (If the drug dose is within the range of 51-150mg, the drug dose will be 100mg), once per day
89501081|NCT05138887|Experimental|experimental group 2|The experimental group 2 was administered BH4 orally, with a dose of 5 mg/kg.d (If the drug dose is within the range of 151-250mg, the drug dose will be 200mg, two times a day; If the drug dose is within the range of 251-350mg, the drug dose will be 300mg, three times a day)
89501082|NCT02231593||Acromegalic patients|
89501083|NCT02698371|Active Comparator|FBDC-SE (G1; Control)|Futurabond DC (single dose blister) will be applied as thickness to the enamel/dentine and rub into the tooth surface for 20s; FBDC drying layer for at least 5s with an air syringe; This adhesive layer will be light-cured with a light emitting diode unit (LED light), with an intensity of 1000mW/cm2, during 20s.
89501084|NCT02698371|Active Comparator|FBDC-SE-EE (G2; Control )|Etch with 36% phosphoric acid, during 30s in enamel structures. Remove the 36% phosphoric acid with water during 1 minute. The remove of water excess will be done with weak air spray, not to dry the dentine completely. The dentine surface must slightly remain wet. Application of Futurabond DC (FBDC) as self-etch mode simultaneously in dentin and enamel, and the light-cured (LED light; 1000mW/cm2), during 20s.
89501085|NCT02698371|Other|FBU-ER (G3)|FuturabondU® (FBU) apply in enamel and dentin as etch-and-rinse (ER) mode. Etching of the dental hard tissue phosphoric acid (15s in dentin and 30s in enamel) and then rinse with water for 1 min. Dry off excess moisture with a gentle stream of air. Activating FBU SingleDose. FBU adhesive will be homogeneously applied to all cavity surfaces and rub in for 20s using the Single Tim; This adhesive layer will be light-cured with a light emitting diode unit, with an intensity of 1000mW/cm2 during 20s.
89501086|NCT02698371|Other|FBU-SE (G4)|FuturabondU® (FBU) apply in enamel and dentin as SE mode. Activating FBU SingleDose. FBU adhesive will be homogeneously apply to all cavity surfaces and rub in for 20 s using the Single Tim; Dry off the adhesive layer with dry, oil-free air for at least 5 s in order to remove any solvents. This adhesive layer will be light-cured with a light emitting diode unit (LED light), with an intensity of 1000mW/cm2, during 20 seconds.
89501087|NCT02698371|Other|ADU-ER (G5)|Adhese®Universal (ADU) apply by etch-and-rinse (ER) mode. Etching of the dental hard tissue phosphoric acid (15 seconds in dentin and 30 seconds in enamel); Etch agent rinse with water for 1 minute. Dry off excess moisture with a gentle stream of air. Keep dentin dry, do not over dry; Adhesive ADU will be scrubbed into the tooth surface (enamel and dentin) for at least 20 seconds. Adhesive will be dispersed with compressed air until a glossy, immobile film layer results.Light-curing for 10 s with a light emitting diode unit (LED light), with an intensity of 1000mW/cm2 for 20s.
89501088|NCT02698371|Other|ADU-SE (G6)|Adhese®Universal (ADU)apply by self-etch (SE) mode. Starting with the enamel, thoroughly coat the tooth surfaces (enamel and dentin) to be treated with ADU; Adhesive will be scrubbed into the tooth surface for at least 20 seconds. Adhesive will be dispersed with compressed air until a glossy, immobile film layer results.Light-curing for 20 s with a light emitting diode unit (LED light), with an intensity of 1000mW/cm2.
89501089|NCT02781311|Experimental|Setipiprant|Setipiprant 1000 mg (2 X 500 mg) tablets, orally, BID at 12-hour intervals for 24 weeks.
89501090|NCT02781311|Placebo Comparator|Placebo|Two placebo tablets BID at 12-hour intervals for 24 weeks.
89501091|NCT02781311|Active Comparator|Finasteride|Finasteride 1 mg tablet, orally, once daily for 24 weeks.
89501092|NCT02225821|Active Comparator|antibiotic prophylaxis|a single gift of 1000 mg cefazolin in 10 cc of NaCl 0.9% (intervention group)
89501093|NCT02225821|Placebo Comparator|No antibiotic prophylaxis|a single gift of 10 cc NaCl 0.9%, given in the same manner (control group).
89501094|NCT02140853||MDR group|patients of MDR pathogen infection
88956170|NCT05761327|Experimental|Resveratrol Supplementation|In addition to the Mediterranean Diet in the 1st group for individuals in this group; 250 mg resveratrol supplement (VeNatura Resveratrol Supplementary Food, Vefa, Istanbul, Turkey) will be given as 1 capsule each in the morning and evening meals.
88956171|NCT05760365|Active Comparator|Slide-based presention group|Received a regular learning
88956172|NCT05760365|Experimental|3D-printed presention group|Received a regular learning plus 3D printing model
88956173|NCT05756036||Renal transplant recipients|All incident renal transplant recipients after the commencement of the study
89501095|NCT02140853||non-MDR group|patients of non-MDR pathogen infection
89501096|NCT02225899||Subjects with Cystic Fibrosis|Cross-sectional, observational study
89501097|NCT02225899||healthy volunteers|Cross-sectional, observational study
89501098|NCT02225899||Subjects with CF in a vitamin D study|This is a longitudinal observational study in subjects enrolled in a high-dose vitamin D study. The investigator (Jessica Alvarez) does not assign the intervention to the subjects of the study.
89501099|NCT02231671|Experimental|Part 1: Absolute Bioavilability|Part 1 of this study is an absolute bioavailability study where the IV (intravenous) microtracer dose of ALS-008112 is administered 15-30 minutes after the oral dose to determine the bioavailability of the oral dose compared to the IV dose. The maximum microtracer IV dose administered in Part 1 of this study will not exceed a single dose of 100 μg [14C]-ALS-008112 containing NMT (not more than) 37.0 kBq (1000 nCi) 14C. Based upon previous clinical observations, it is anticipated that the single oral dose and IV microdose to be utilised in Part 1 will provide acceptable PK data and will be safe and well tolerated.
89501100|NCT02231671|Experimental|Part 2: Mass Balance|Part 2 of this study is an absorption, metabolism and excretion study, for which a single 375 mg [14C]-ALS-008176 (containing NMT 6.85 MBq (megabecquerel) (185 μCi) 14C) dose has been selected for evaluation based upon data from prior studies. Based upon previous clinical observations, it is anticipated that the dose to be utilised in Part 2 will provide acceptable PK data, will be safe and well tolerated and is within the therapeutic range.
89501101|NCT02144441|Experimental|Patient self-administered insulin|The study's only arm
89501102|NCT02225977||Gilenya treated - 1 month|Patient's taking continuous oral Gilenya at prescribed dose for 1 month.
89501103|NCT02225977||Gilenya treated - 3 months|Patient's taking continuous oral Gilenya at prescribed dose for 3 months.
89501104|NCT02225977||Gilenya treated - 6 months|Patient's taking continuous oral Gilenya at prescribed dose for 6 months.
89501105|NCT02225977||Gilenya treated - 12 months|Patient's taking continuous oral Gilenya at prescribed dose for 12 months.
89501106|NCT02225977||Gilenya qualified - untreated|Patient's qualifying to start treatment with oral Gilenya at prescribed dose but still as yet untreated.
89501107|NCT03543995||Enuresis nocturna|Patients aged 6 to 15 years with at least one night-time wetting weekly
89501108|NCT03543995||Normal population|Patients who were admitted to the urology clinic with a complaint of abdominal or lateral pain, who had no NE and had a direct abdominal x-ray examination
89501109|NCT02148029|Active Comparator|Control|Standard care: anticoagulation, compression & ad-lib ambulation
89501110|NCT02148029|Experimental|Exercise|Standard care + Interventional Exercise therapy
89502000|NCT02744833|Active Comparator|Enoxaparin Sodium (Lovenox®)|
89502001|NCT02234635|Other|monofocal IOLs group|monofocal IOLs group were implantation with Tecnis® ZCB00
88956174|NCT05746507|Experimental|Night Respite Care|18 overnight night respite care sessions over six weeks with parental skills provided through teachable moments before and after respite care supports
88956175|NCT05744375|Experimental|Trastuzumab deruxtecan (T-DXd)|"All patients enrolled will be treated with trastuzumab deruxtecan (T-DXd) 5.4 mg/kg IV every 3 weeks (± 3 days).~The subject's weight at baseline will be used to calculate the initial dose. If during the course of treatment the subject's weight changes by ± 10% of the baseline weight, the subject's dose will be recalculated based on the subject's updated weight.~Patients will receive T-DXd until unacceptable toxicity, progressive disease (PD), informed consent withdrawal, or other discontinuation criterion is met."
88956176|NCT05744336|Experimental|Group 1 Immersive Virtual Reality (VR)|Participants in Group 1 Immersive Virtual Reality (VR) will wear the device covering their eyes. The viewing experience will include calming nature sounds for between 15-20 minutes before their planned plain clinic procedure.
89501111|NCT02226055||Arterial stiffness: CKDu patients|Cohort of 50 patients with CKD of unknown aetiology Inclusion and exclusion criteria below Measure of arterial stiffness using pulse wave velocity technology Assessment of BMI, central and brachial blood pressure, arterial stiffness and 'arterial age' will be made and fed back to the patient. this information will be given in a 'results sheet' that the participant will be encouraged to give to their Gp for further treatments required.
89501112|NCT02226055||Arterial stiffness: CKD known cause|Cohort of 50 patients with CKD of known cause Inclusion and exclusion criteria below Measure of arterial stiffness using pulse wave velocity technology Assessment of BMI, central and brachial blood pressure, arterial stiffness and 'arterial age' will be made and fed back to the patient. this information will be given in a 'results sheet' that the participant will be encouraged to give to their Gp for further treatments required.
89501113|NCT02226055||Arterial Stiffness: Healthy Sri Lankan volunteers|Cohort of 50 participants who are healthy Sri Lankan volunteers Inclusion and exclusion criteria below Measure of arterial stiffness using pulse wave velocity technology Assessment of BMI, central and brachial blood pressure, arterial stiffness and 'arterial age' will be made and fed back to the patient. this information will be given in a 'results sheet' that the participant will be encouraged to give to their Gp for further treatments required.
89501114|NCT02226055||2nd aim: 250 CKDu patients for investigation of aetiology|"To recruit a cohort of up to 250 CKDu patients from specific CKDu clinics in Anuradhapura and Padavi-Sri Pura for detailed history, basic anthropometric tests, and further analysis of serum, and urine. Analysis for biomarkers of kidney damage, proteomics, exosomes, and DNA adducts will be used to seek information that may complement already collected data and help refine aetiological hypotheses.~Inclusion and Exclusion criteria as per CKDu cases in cohort 1"
89501115|NCT02810197|Experimental|Exposed group|Psychopathological assessment Neuropsychological assessment Functional magnetic resonance imaging (fMRI)
89501116|NCT02810197|Experimental|unexposed group|Psychopathological assessment Neuropsychological assessment Functional magnetic resonance imaging (fMRI)
89501117|NCT02141009|Other|Prevnar 13|Prevnar 13, 1 administration of 1 single dose (0.5mL)
89501118|NCT02231827|Experimental|Gait analysis|
89501119|NCT02564198|Experimental|Ramucirumab|"(Part A-Non-CNS Solid Tumors) Escalating doses of 8 milligrams per kilogram (mg/kg) or 12 mg/kg Ramucirumab administered as an intravenous infusion every 2 weeks (Q2W) with 3 doses per 42 day cycle.~(Part B-CNS Tumors) Participants received 12 mg/kg Ramucirumab as an intravenous injection Q2W with 3 doses per cycle."
89501120|NCT02148185|Experimental|MT-1303|
89501121|NCT02398539|Active Comparator|Group 1|Silver nitrate treatment will include weekly applications in the pediatric surgery office by a clinician.
89501122|NCT02398539|Active Comparator|Group 2|Triamcinolone cream, 0.5% applied three times per day by the patient's caregiver.
89501123|NCT02226133|Experimental|Exclusion of Left Atrial Appendage|Left Atrial Appendage (LAA) occlusion, using the LAAx, Inc. TigerPaw® System II (delivery system and implant/Fastener) using VATS techniques,
89501124|NCT02144753|Experimental|NTX-1|NTX-1 (18 g)
89501125|NCT02144753|Active Comparator|Psyllium|psyllium (15 g)
89501126|NCT02231905|Experimental|BI-Sifrol®|Tablets were administrated after switching from prior treatment of dopamine agonist (talipexole), treatment period consisted of an ascending period and a maintenance period, total duration was 4 to 12 weeks.
89501127|NCT02398071|Experimental|PEP interventon|Participants performed 6 PEP breaths using a water pressure threshold device (BreatheMAX) with expiratory load set at 5 cmH2O
89501128|NCT02398071|Sham Comparator|Sham intervention|Participants performed 6 PEP breaths using a water pressure threshold device (BreatheMAX) with expiratory load set at 0 cmH2O
89501129|NCT05563376|Other|TCPC completed|All patients after TCPC completion
89501130|NCT02231983||Severe Combined Immunodeficiency|Case histories were analyzed to grasp important characteristics of the diseases. Distribution of lymphocyte subsets from peripheral blood were examined by flow cytometry. Amplify and identify exons from gene IL-2RG by PCR and agarose gel electrophoresis, and then followed by gene sequencing.
89501131|NCT03544463|Experimental|Treated|iNAP® Sleep Therapy System Treatment Intervention
89501132|NCT03544463|No Intervention|Baseline/Control|Self-controlled, pre-treatment baseline condition
88956177|NCT05744336|Placebo Comparator|Group 2 control group|Group 2 control group has no preprocedural intervention. Standard clinic waiting conditions for 15-20 minutes before their planned pain clinic procedure.
88956178|NCT05738850|Experimental|Part 1: ABBV-932|Participants will receive ABBV-932 on Day 1 and followed for 30 days.
88956179|NCT05738850|Placebo Comparator|Part 1: Placebo|Participants will receive placebo on Day 1 and followed for 30 days.
89501133|NCT02698293|Experimental|Cohort 1|"5-aminolevulinic acid hydrochloride (Gliolan), orally, 40 mg/kg administered approximately 4-6 hours before light administration. There will be two levels of light dose: 50 and 100 J/cm2. Vitamin D3 (cholecalciferol) supplementation (10,000 IU daily) will be provided from 3 days prior through 14 weeks after light delivery for PDT.~Total duration of drug product administration (including any open-label lead-in, if applicable).~Vitamin D3 (cholecalciferol) supplementation (10,000 IU daily) will be provided from 3 days prior through 14 weeks after light delivery for PDT.~None This is a phase I dose escalation study, with two levels of light dose. The design is cohorts of 3s. Light at 50 Joules and Light at 100 joules There are pre-defined DLTs."
89501134|NCT02698293|Experimental|Cohort 2|"5-aminolevulinic acid hydrochloride (Gliolan), orally, 40 mg/kg administered approximately 4-6 hours before light administration. There will be two levels of light dose: 50 and 100 J/cm2. Vitamin D3 (cholecalciferol) supplementation (10,000 IU daily) will be provided from 3 days prior through 14 weeks after light delivery for PDT Total duration of drug product administration (including any open-label lead-in, if applicable).~Vitamin D3 (cholecalciferol) supplementation (10,000 IU daily) will be provided from 3 days prior through 14 weeks after light delivery for PDT.~None This is a phase I dose escalation study, with two levels of light dose. The design is cohorts of 3s. Light at 50 Joules and Light at 100 joules There are pre-defined DLTs."
89501135|NCT02698293|Experimental|Cohort 3|"5-aminolevulinic acid hydrochloride (Gliolan), orally, 40 mg/kg administered approximately 4-6 hours before light administration. There will be two levels of light dose: 50 and 100 J/cm2. Vitamin D3 (cholecalciferol) supplementation (10,000 IU daily) will be provided from 3 days prior through 14 weeks after light delivery for PDT Total duration of drug product administration (including any open-label lead-in, if applicable).~Vitamin D3 (cholecalciferol) supplementation (10,000 IU daily) will be provided from 3 days prior through 14 weeks after light delivery for PDT.~None This is a phase I dose escalation study, with two levels of light dose. The design is cohorts of 3s. Light at 50 Joules and Light at 100 joules There are pre-defined DLTs."
88956180|NCT05738850|Experimental|Part 2: Sequence 1|Participants will receive ABBV-932 on Day 1 in Period 1 under fasting conditions and followed for 30 days. Participants will receive ABBV-932 with food on Day 1 in Period 2 and followed for 30 days.
89501136|NCT02258737|Experimental|transitional case management|
89501137|NCT02258737|Active Comparator|standard care|
89501138|NCT03543917|Experimental|New Medication Combination|Intervention: Combination Product: Perfusion with New Combination Medication Intravenous administration of Actovegin, vitamins B1, B6, B12, C, oxytocin/dexamethasone, calcium gluconate, etc in 250 ml normal saline administered during approximately 2 hours
89501139|NCT02226211|Experimental|air-Q group|
89501140|NCT02226211|Experimental|aura-i group|
89501141|NCT02141165|Experimental|Primary.|Diagnosis, autoCPAP, follow up.
89501142|NCT02141165|Active Comparator|Hospital|Diagnosis, autoCPAP, follow up
89501143|NCT02395809|Active Comparator|LIS group|Lateral internal shincterotomy: A blade knife (No 11) was inserted between internal and external sphincter. The tip of the blade was angled medially pointing just above the dentate line and IS was divided. When the knife was felt beneath the intact mucosa, it was withdrawn.
88956181|NCT05738850|Experimental|Part 2: Sequence 2|Participants will receive ABBV-932 with food on Day 1 in Period 1 and followed for 30 days. Participants will receive ABBV-932 on Day 1 in Period 2 under fasting conditions and followed for 30 days.
89501144|NCT02395809|Active Comparator|TENS group|Posterior tibial nerve stimulation by transcutaneous electrical nerve stimulation by through a stimulating TENS unit.
89501145|NCT02226289|Experimental|bevacizumab-containing|bevacizumab with the latest received cytotoxic regimen
89501146|NCT04624646|Active Comparator|Conventional Holter Monitoring Group|Holter monitoring is performed for 24 hours each at 1, 3, and 12 months after the diagnosis of stroke, and if atrial fibrillation is detected, the antiplatelet drug is changed to an anticoagulant.
89501147|NCT04624646|Experimental|Discontinuous Monitoring Group|Discontinuous ECG monitoring by finger contact is performed 3 times every day for 12 months after a stroke diagnosis. If atrial fibrillation is detected, the antiplatelet drug is changed to an anticoagulant.
89501148|NCT04624646|Experimental|Single-lead Continuous Patch Group|Continuous 72 hours of ECG monitoring by a single-lead patch is performed at a week and 1, 3, 6, 12 months after a stroke diagnosis. If atrial fibrillation is detected, the antiplatelet drug is changed to an anticoagulant.
89502002|NCT02234635|Active Comparator|Diffractive multifocal IOLs group|Diffractive multifocal IOLs group were implantation with Tecnis® ZMB00
89502003|NCT04065386|Active Comparator|Active taVNS|"Patients will receive 5 days of transcutaneous auricular vagal nerve stimulation (taVNS) bilaterally, at the cymba conchae, the active localization.~It will be preceded and followed by a clinical assessment (Coma Recovery Scale- Revised) and a neurophysiological assessment (128/256 channels EEG and electrocardiograph) the first and last day of stimulation."
88956182|NCT05738850|Experimental|Part 3: Japanese Participants: ABBV-932|Japanese participants will receive ABBV-932 on Day 1 in Period 1 and followed for 30 days.
88956183|NCT05738850|Placebo Comparator|Part 3: Japanese Participants: Placebo|Japanese participants will receive placebo on Day 1 in Period 1 and followed for 30 days.
88956184|NCT05738850|Experimental|Part 3: Han-Chinese Participants: ABBV-932|Han-Chinese participants will receive placebo on Day 1 in Period 1 and followed for 30 days.
88956185|NCT05736211|Experimental|Phase 2 intervention|In this arm the study will implement an organization-level Youth Engagement prevention strategy by systematically incorporating Youth Engagement into prevention efforts in a community setting.
88956186|NCT05736211|No Intervention|Phase 2 control|This arm will receive no intervention. Control group organizations will continue their normal prevention strategy without the inclusion of a Youth Engagement component
88956187|NCT05733546|Experimental|25 mg COMP360 Psilocybin|25 mg COMP360 Psilocybin
88956188|NCT05733546|Experimental|10 mg COMP360 Psilocybin|10 mg COMP360 Psilocybin
88956189|NCT05733546|Active Comparator|1 mg COMP360 Psilocybin|1 mg COMP360 Psilocybin
88956190|NCT05729178||Pediatric acute lymphoblastic leukemia patients|pediatric patients of 1-16 years old affected by acute lymphoblastic leukemia
89501149|NCT02148341|Experimental|Community of Practice Facilitation|Medical Centers assigned to this arm will recieive the communtiy of practice facilitation. In this process we will contact existing members of the community of practice (called the Heart Failure Network) at the facility as well as attempt to identify new providers and other staff at the facility with an interest in improving heart failure care. The facilitation includes: describing the national H2H program, providing talking points and strategies for local providers to obtain support from their local facility to initiate local projects related to H2H, providing a forum for successful sites to describe how they initiated projects to sites yet to initiate projects.
89501150|NCT02148341|Experimental|Usual Care|Medical centers in this arm will hear of H2H through usual routs (calls with facilty Directors and Chiefs of staff).
89501151|NCT04480593|Active Comparator|Control|standard care.
88956191|NCT05729178||healthy subjects|cord blood from healthy donors that cannot be used for clinical purposes
88956192|NCT05726851|Experimental|Part A, Cohort 1: E2025 Dose 1 or Placebo|Participants will receive E2025 Dose 1 or E2025 matching placebo (normal saline) administered as an IV infusion on Day 1.
89501152|NCT04480593|Experimental|EPP-AF 400mg/day|Green propolis extract (EPP-AF) at a dose of 400mg / day in addition to the standard treatment.
89501153|NCT04480593|Experimental|EPP-AF 800mg/day|Green propolis extract (EPP-AF) at a dose of 800mg / day in addition to the standard treatment.
89501154|NCT05079217|Experimental|Experimental Group|600 participants will receive one dose of booster vaccination with high-dosage inactivated SARS-CoV-2 vaccine .
89501155|NCT05079217|Active Comparator|Control Group|600 participants will receive one dose of booster vaccination with medium-dosage inactivated SARS-CoV-2 vaccine .
89501156|NCT02398149||PwMS receiving care at the Mandell Center|
89501157|NCT02141243|Experimental|Group A|"All participants will receive both the lingual frenotomy and sham procedure. Group A infants will receive lingual frenotomy for intervention #1 and a sham procedure for intervention #2. Newborns that continue to have difficulty with breastfeeding after both interventions will undergo intervention #3, a labial frenotomy.~Lingual frenotomy: tongue will be elevated, expose frenulum with a grooved director or 2 cotton tipped applicators, and then incise frenulum tissue with a straight scissor.~Sham/placebo procedure: infant brought into a procedure room and kept there for as long as the average experimental procedure would take (~5 minutes).~Maxillary labial frenotomy: 0.1 ml of 1% lidocaine will be injected into the area, upper lip lifted, frenum stretched, and a laser, (iLaseTM 940 ± 15 nm) or scissors, will be used to release its attachment to the level of the periosteum."
89501158|NCT02141243|Experimental|Group B|"All participating infants will receive both the lingual frenotomy and sham procedure. Group B infants will receive the sham procedure for intervention #1 and a lingual frenotomy for intervention #2. Newborns that continue to have difficulty with breastfeeding after both interventions will undergo intervention #3, a labial frenotomy.~Sham/placebo procedure: infant brought into a procedure room and kept there for as long as the average experimental procedure would take (~5 minutes).~Lingual frenotomy: tongue will be elevated, expose frenulum with a grooved director or 2 cotton tipped applicators, and then incise frenulum tissue with a straight scissor.~Maxillary labial frenotomy: 0.1 ml of 1% lidocaine will be injected into the area, upper lip lifted, frenum stretched, and an iLaseTM 940 ± 15 nm laser used to release its attachment to the level of the periosteum."
88956193|NCT05726851|Experimental|Part A, Cohort 2: E2025 Dose 2 or Placebo|Participants will receive E2025 Dose 2 or E2025 matching placebo (normal saline) administered as an IV infusion on Day 1.
88956194|NCT05726851|Experimental|Part A, Cohort 3: E2025 Dose 3 or Placebo|Participants will receive E2025 Dose 3 or E2025 matching placebo (normal saline) administered as an IV infusion on Day 1.
89205925|NCT00311623|Experimental|High-dose Rapamycin (6mg)|"Men >18years old with prostate cancer clinical stages T1c to T3, no metastases, Gleason sum of 7-10, multiple positive diagnostic cores, Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, candidates for radical prostatectomy.~Must have adequate hepatic, renal and bone marrow function, no allergy to rapamycins, avoid medications interfering with rapamycin metabolism, no active infection, no prior therapies for prostate cancer.~Will receive rapamycin 6mg (Wyeth Pharmaceuticals, 2mg tablets) oral (PO) once daily on Days 1-14 with the last dose given on the morning before surgery (Day 15)."
89205926|NCT01067989|Experimental|intervention|same treatment for all patients
88956195|NCT05726851|Experimental|Part A, Cohort 4: E2025 Dose 4 or Placebo|Participants will receive E2025 Dose 4 or E2025 matching placebo (normal saline) administered as an IV infusion on Day 1.
88956196|NCT05726851|Experimental|Part B, Cohort 5: E2025 Dose 2|Participants will receive E2025 Dose 2 administered as an IV infusion on Day 1.
88956197|NCT05726851|Experimental|Part B, Cohort 6: E2025 Dose 3|Participants will receive E2025 Dose 3 administered as an IV infusion on Day 1.
88956198|NCT05726851|Experimental|Part B Cohort 7: E2025 Dose 4|Participants will receive E2025 Dose 4 administered as an IV infusion on Day 1.
88956201|NCT05721105||ECMO|50 Patients admitted to pediatric intensive care at the University Hospital of Nantes between January 2014 and December 2022 and supported by ECMO during their hospitalization.
88956202|NCT05721105||Control|50 patients hospitalized at the same age, during the same time period, and sharing the same diagnostic categories as the ECMO group, but the control group never had ECMO.
89501159|NCT02395731|Experimental|MIND at Home- Plus Intervention|MIND at Home-Plus is a home-based, care coordination that focuses on persons with dementia living at home and their family caregivers. Its goal is to help persons age in place safely while increasing quality of life. Delivered over 18 months, MIND-Plus systematically assesses and addresses unmet care needs of persons with dementia and their caregivers which are known to be linked to poor health and quality of life outcomes, and that put people at risk for long term care placement. The needs addressed in the MIND program cover a wide range of care domains, ranging from home and medication safety, to cognitive and behavior symptoms management, meaningful activities and legal considerations. The care team made up of a memory care coordinator, nurse, occupational therapist, and physician.
89501160|NCT05562986|Experimental|Oral irrigator group|Fifteen patients using toothbrush and oral irrigator (Aquapick, AQ-300, Aquapick Co, Ltd, Korea). All patients were told to use Modified Bass method of tooth brushing technique. PI, GI, PPD and CAL values were measured with William's probe (Hu-Fried, Chicago, IL, A.B.D) around the teeth. All clinical parameters were evaluated on each of the six regions of the teeth (mesio-buccal, mid-buccal, disto-buccal, mesio-lingual, mid-lingual, disto-lingual). GCF (gingival crevicular fluid) samples was collected one day after the clinical examination from buccal aspects of the mesial and distal surfaces at the interproximal sites for the evaluation of interleukin (IL)-1β, IL-10, matrix metalloproteinase (MMP)-1, MMP-8 mediators. Following the initial clinical records, all patients were performed full mouth instrumentation and described oral hygiene procedure according to their groups.
89501161|NCT05562986|Experimental|Interdental brush group|Fifteen patients using toothbrush and interdental brush. All patients were told to use Modified Bass method of tooth brushing technique. PI, GI, PPD and CAL values were measured with William's probe (Hu-Fried, Chicago, IL, A.B.D) around the teeth. All clinical parameters were evaluated on each of the six regions of the teeth (mesio-buccal, mid-buccal, disto-buccal, mesio-lingual, mid-lingual, disto-lingual). GCF (gingival crevicular fluid) samples was collected one day after the clinical examination from buccal aspects of the mesial and distal surfaces at the interproximal sites for the evaluation of interleukin (IL)-1β, IL-10, matrix metalloproteinase (MMP)-1, MMP-8 mediators. Following the initial clinical records, all patients were performed full mouth instrumentation and described oral hygiene procedure according to their groups.
89501162|NCT02141321|Experimental|Misoprostol|Women will receive two sub lingual tablets each containing 200 micro gram misoprostol (Misotac), receiving a total dose of 400 micro grams. Two hour later, Cu T 380A IUD (PREGNA) will be inserted.
89501163|NCT02141321|Placebo Comparator|Placebo|Women will receive two sub lingual placebo tablets which will be similar in size, color, odor and shape to the misoprostol tablets. Two hour later, Cu T 380A IUD (PREGNA) will be inserted.
89501164|NCT03965078||CMO without epiretinal membrane|Subject diagnosed with CMO within 12 weeks of cataract surgery without evidence of epiretinal membrane at the time of diagnosis.
88956209|NCT05709314|Experimental|AMDX-2011P 100 mg|AMDX2011P 100mg (4ml) single bolus injection intravenous for diagnostic review
89501165|NCT03965078||CMO with epiretinal membrane|Subject diagnosed with CMO within 12 weeks of cataract surgery with evidence of epiretinal membrane at the time of diagnosis.
88956210|NCT05702905|Active Comparator|metformin|About 25 subjects will be allocated to this group to receive metformin only, as the active comparator of semaglutide groups. Metformin used in this trial is Glucophage ( 500mg per tablet）produced by Bristol-Myers Squibb.The initial dose of metformin will be 500mg twice daily, which will be increased to 1000mg twice daily after two weeks, and then maintained until the end of treatment in total 12 weeks.
88956211|NCT05702905|Experimental|semaglutide|About 25 subjects will be allocated to this group to receive semaglutide only, as one of the experimental groups. Semaglutide used in this trial is WEGOVY (semaglutide) injection produced by Novo Nordisk. Administer WEGOVY once weekly, on the same day each week, at any time of day, with or without meals. Inject subcutaneously in the abdomen, thigh or upper arm. Initiate at 0.25 mg once weekly for 4 weeks. In 4 week intervals, increase the dose until a dose of 1.0 mg is reached, and then maintained 1.0 mg until the end of treatment in total 12 weeks..
88956212|NCT05702905|Experimental|semaglutide and metformin|About 25 subjects will be allocated to this group to receive both semaglutide and metformin, as another of the experimental groups. Metformin used in this trial is Glucophage ( 500mg per tablet）produced by Bristol-Myers Squibb.The initial dose of metformin will be 500mg twice daily, which will be increased to 1000mg twice daily after two weeks, and then maintained until the end of treatment in total 12 weeks. Semaglutide used in this trial is WEGOVY (semaglutide) injection produced by Novo Nordisk. Administer WEGOVY once weekly, on the same day each week, at any time of day, with or without meals. Inject subcutaneously in the abdomen, thigh or upper arm. Initiate at 0.25 mg once weekly for 4 weeks. In 4 week intervals, increase the dose until a dose of 1.0 mg is reached, and then maintained 1.0 mg until the end of treatment in total 12 weeks.
88956213|NCT05695898|Experimental|Phase 1b: Dose Escalation (Cohort 1)|Participants will receive 0.3 mg/kg of XmAb22841 (CTLA-4 X LAG3) in combination with 10 mg/kg of XmAb23104 (PD1 X ICOS) on days 1 & 15 of a 28 day cycles for up to 4 cycles. After Cycle 4, participants will receive 10 mg/kg of XmAb23104 (PD1 X ICOS) monotherapy up to an additional 20 cycles. Participants may receive treatments up to 24 total cycles, or until unacceptable toxicity or progressive disease; whichever comes first.
89023452|NCT05417165|Experimental|Arm C (Experimental ARM-Annual Booster)|Patients receive PCV 20 IM at week 0 and PSV23 IM at week 8. Titers will be checked 4 weeks after the first dose and at 12 weeks (4 weeks after the second dose). Booster Vaccine: PCV23 booster vaccination dose will be administered yearly for 5 years. Pre-vaccination and post-vaccination (at 4 weeks) titers will be checked each time yearly for 5 years.
89205927|NCT00528112|Experimental|LCS12|Intrauterine levonorgestrel contraceptive system (LCS), releasing levonorgestrel (LNG) 12 microg/24 h in vitro
88956214|NCT05695898|Experimental|Phase 1b: Dose Escalation (Cohort 2)|After the safety and tolerability for cohort 1 has been evaluated, participants will receive 1 mg/kg of XmAb22841 (CTLA-4 X LAG3) in combination with 10 mg/kg of XmAb23104 (PD1 X ICOS) on days 1 & 15 of a 28 day cycles for up to 4 cycles. After Cycle 4, participants will receive 10 mg/kg of XmAb23104 (PD1 X ICOS) monotherapy up to an additional 20 cycles. Participants may receive treatments up to 24 total cycles, or until unacceptable toxicity or progressive disease; whichever comes first.
89538418|NCT05075369|Active Comparator|Change in Intraocular pressure with Water drinking test|The participants will undergo the water drinking test as previously described, i.e. after drinking 800 mls of water over a 5 minute period, the intraocular pressure will be measured immediately after completion of ingestion, followed by intraocular pressure measurements every 15 minutes for 60 minutes, using etc Goldmann apllantion tonometer.
89501166|NCT02141477|Experimental|Omacetaxine + Decitabine|"Phase I and Phase II Omacetaxine Dose: 1.25 mg/m2 subcutaneously every 12 hours on Days 1 - 3 of a 28 day cycle.~Phase I Starting Decitabine Dose: 20 mg/m2 by vein on Days 1 - 5 of a 28 day cycle.~Phase II Starting Decitabine Dose: Maximum tolerated dose from Phase I."
89501167|NCT02397993||FNA, blood collection|blood collection prior to fine needle aspiration Endoscopic ultrasonography-guided fine needle aspiration of the pancreas blood collection after to fine needle aspiration
89501168|NCT02232139|No Intervention|Standard therapy group|Participant who will not receive midazolam for pharmacological anxiolytic premedication before general surgery
89501169|NCT02232139|Experimental|Midazolam group|Participant who will receive midazolam for pharmacological anxiolytic premedication before general surgery
89501170|NCT02148497|Other|Dry Eye Disease or Sjogren's Disease|Capturing images of the tear surface using the multi-colored Placido disk
89501171|NCT02148497|Other|Control|Capturing images of the tear surface using the multi-colored Placido disk
89501172|NCT02397681|Experimental|Experimental|
89501173|NCT02226445||ADHD medication and psychosocial counseling|
89501174|NCT02148575|Experimental|Self-Management Group|"Managing Cancer Care: A Personal Guide (MCC) is a set of magazine-format, printed modules that includes information about key self-management topics, worksheets, conversation starters, and targeted links to local and internet resources, among other features."
89501175|NCT02148575|Active Comparator|Symptom Management Group|Participants in the Symptom Management Group will be given a symptom management toolkit that provides information on the most commonly experienced symptoms and side effects of cancer treatment, including fatigue, nausea, and sleep problems, among others. Each chapter includes information on when and why the symptom may occur, how the symptom can be managed, and when to call a provider.
89501176|NCT02232217|Experimental|Cognitive Behavior Therapy Sleep|Children in this arm will receive instructions on the use of 'coping thoughts.' Common elements across the CBTcs sessions include reviewing progress, setting goals for change, problem solving to address challenges/barriers, and reinforcing progress
89501177|NCT02232217|Active Comparator|Education Control|Children in this arm will receive sleep and dietary education, as well as general coping strategies and controls for staff attention and seasonal effects that could influence changes in sleep and health outcomes.
89501178|NCT03543761|Sham Comparator|A|Sham group
89501179|NCT03543761|Active Comparator|B|LiST active treatment group
89501180|NCT03543761|Active Comparator|C|LiST active treatment group
89501181|NCT02226601|Active Comparator|Aprepitant|"Aprepitant~40 mg IV pre-operatively~40 mg PO post-op day #1~40 mg PO post-op day #2"
89501182|NCT02226601|Placebo Comparator|Placebo|"electrolyte (0.9% NaCl) infusion) pre-operatively~capsule without medication on post-op day #1~capsule without medication on post-op day #2"
89501183|NCT03168477|Experimental|dry needling and spinal manipulation|
89501184|NCT03168477|Active Comparator|mobilization, exercise, modalities|
89501185|NCT02148653|Experimental|Multifunctional diet (MFD)|Subjects eat a diet designed according to the Nordic Nutrition Recommendations with the addition of important amounts of various functional food concepts: Low GI and GI-modulating food items; Natural antioxidant-rich items, Long chain omega-3 fatty acid-rich fish; Betaglucan-rich barley and oat food/drinks; Cholesterol-modulating foods.
89501186|NCT02148653|Experimental|Control diet|Subjects eat a diet designed according to the Nordic Nutrition Recommendations but lacking the functional items included in the MFD.
89501187|NCT02232295|Active Comparator|Conventional group|Conventional group consist of Upper extremity task oriented functional exercises. Components of Task oriented training include weight bearing, supportive reactions, and reaching, grasping, holding and release activities.
89501188|NCT02232295|Experimental|Graded Motor imagery group and Conventional group|"Graded Motor imagery is a three stage process, was performed five days a week for six weeks of one hour duration. It comprises of:~Left Right discrimination training (Implicit Motor Imagery) - 2 weeks~Explicit Motor Imagery (Imagined movements) - 2 weeks~Mirror Therapy - 2 weeks"
89501189|NCT02397759|Experimental|Patients with severe SAH and vasospasm|Patients with severe SAH from ruptured aneurysm requiring the establishment of an external ventricular derivation (EVD) and presenting vasospasm
89501190|NCT02397759|Experimental|Patients with severe SAH without vasospasm|Patients with severe SAH from ruptured aneurysm requiring the establishment of an external ventricular derivation (EVD) without vasospasm
89501191|NCT02397759|Active Comparator|Patients with severe SAH without external ventricular derivati|Patients with severe severe SAH from ruptured aneurysm without necessitating a EVD subarachnoid hemorrhage
89501192|NCT05041361|Experimental|Cognitive Behavioral Therapy (CBT) and Whole-Body Hyperthermia (WBH)|Participants receive up to 4 bi-weekly whole-body hyperthermia (WBH) sessions and 8 weekly cognitive behavioral therapy (CBT) sessions. Each WBH session (including preparation and cool down) is up to approximately 3.5-4 hours, and each CBT session is approximately 50 minutes.
89501193|NCT02226679|Experimental|Algisyl-LVR device implantation|Algisyl-LVR™ employed as a method of left ventricular augmentation and restoration in patients with dilated cardiomyopathy. Algisyl-LVR™ will be injected into the myocardium under direct visualization during the surgical procedure.
89501194|NCT02397369|Experimental|Tobacco users: Self Help|Self-help intervention is defined as any manual or programme to be used by individuals to assist a quit attempt not aided by counsellors or group support.They include written materials on the health effects of tobacco, audio-or video tape or computer programmes.
89501195|NCT02397369|Experimental|Tobacco users:Telephonic counseling|Telephone counseling is a way of providing individual counseling via telephone conversation or telephone hotlines. It can be proactive or reactive.
89501196|NCT02397369|Experimental|Tobacco users:Behavioural therapy Only|Behavioural therapy includes multiple sessions of Focus Group Discussion (FGD) and individual tobacco cessation counseling sessions. The participants in this group will be given advice to quit tobacco via multisession formal cognitive-behavioural therapy as per the Tobacco Cessation Clinic (TCC) guidelines.
89501197|NCT02397369|Experimental|Tobacco users:Pharmacologic|Pharmacotherapy in the form of Nicotine Replacement Therapy based on individual need assessment to relieve withdrawal symptoms in tobacco users when trying to quit.
89501198|NCT02144909|Experimental|Partners in Care with Semi-Structured Support Group|Partners in Care with Semi-Structured Support Group: participants will receive the Partners in Care intervention followed by 6 semi-structured support groups, conducted every other week for 3 months. Half of the support groups will be conducted by professionals with diabetes specific knowledge, e.g., pharmacists, physicians, nutritionists. While the other half will be conducted by the trained diabetes self-management facilitator.
89501199|NCT02144909|No Intervention|Partners in Care Standard Follow-up|Participants will receive the Partners in Care intervention followed by monthly healthy lifestyle tips related to diabetes self-management
89501200|NCT04503811||Frail Older People|The first phase of the data collection process will include one to one interviews with up to twenty (20) frail older people. The pre-selected inclusion criteria for this category of participants include; older people (aged 65 years and over); individuals diagnosed with frailty and receiving (part of their) care services at the Day Hospital; the capacity to give free and fully informed consent; ability to use the English language, as well as judgement by the clinical staff and/or nominated manager that the potential participant can take part in an in-depth interview.
89501201|NCT04503811||Day Hospital Staff|The second phase of the data collection process will entail one to one interviews with up to ten (10) Staff at the Day Hospital. The study will include staff that routinely work with frail older people at the Day Hospital including nurses (registered and unregistered), doctors, physiotherapists, occupational therapists and therapy assistants that can give free and fully informed consent. Furthermore, the study will include both part-time and full-time staff with a minimum of six months of work experience with frail older people.
89501202|NCT02397603|Active Comparator|bupivacaine saline group|This group of patients will receive 20 ml bupivacaine plus 0.5 ml normal saline perineurally in the paravertebral catheter
89501203|NCT02397603|Active Comparator|Dexmedetomidine- bupivacaine group|This group of patients will receive 20 ml bupivacaine plus 0.5 ml (50 microgram) dexmedetomidine administered perineurally in the paravertebral catheter.
89501204|NCT04467697|Experimental|SOV2012-F1-treated|Patients treated with SOV2012-F1, starting daily dose in MRS-TU-2019EXT is 400 mg - (200 mg with morning meal and 200 mg with evening meal). Dosing is titrated up to a maximum of 600 mg SOV2012-F1 per day (300 mg in the morning and 300 mg in the evening) based on plasma T after 14 and 42 days of treatment.
89501205|NCT02395419|Active Comparator|Totaltrack|OTI with TotalTrack
89501206|NCT02395419|Active Comparator|Airtraq|OTI with Airtraq
89501207|NCT02145065|Active Comparator|Plain Balloon Angioplasty|Plain Balloon Angioplasty
89501208|NCT02145065|Experimental|microcrystalline Paclitaxel Coated Balloon (PAK)|plain balloon angioplasty followed by mcPCB dilation
89501209|NCT02226757|Experimental|Paclitaxel-trastuzumab|Paclitaxel-trastuzumab weekly
89501210|NCT02145221|Experimental|Music therapy|Music therapy post surgery
89501211|NCT02145221|No Intervention|No intervention|
89501212|NCT02232373|Sham Comparator|Normal FODMAP arm|Low FODMAP dietary advice; participants to supplement diet with oligofructose, a poorly digested carbohydrate that will restore FODMAP content to the diet.
89501213|NCT02232373|Experimental|Low FODMAP arm|Low FODMAP dietary advice; participants to supplement with maltodextrin (easily digestible carbohydrate)
89501214|NCT04616924|Experimental|RHB-204|Each capsule contains clarithromycin 158.3mg; rifabutin 40mg; clofazimine 13.3mg.
89501215|NCT04616924|Placebo Comparator|Placebo|Matching placebo will contain riboflavin, a type of B vitamin, which may discolor urine in a similar fashion as RHB-204.
89501216|NCT02141711|Experimental|Cohort 1: TAK-438 10 mg|TAK-438 10 mg tablets, orally, once, daily, for 7 days.
89501217|NCT02141711|Experimental|Cohort 2: TAK-438 20 mg|TAK-438 20 mg tablets, orally, once, daily, for 7 days.
89501218|NCT02141711|Experimental|Cohort 3: TAK-438 40 mg|TAK-438 40 mg tablets, orally, once, daily, for 7 days.
89501219|NCT02141711|Experimental|Cohort 4: TAK-438 30 mg|TAK-438 30 mg tablets, orally, once, daily, for 7 days.
89501220|NCT02141711|Placebo Comparator|Cohorts 1-4: Placebo|TAK-438 placebo-matching tablets, orally, once, daily, for 7 days.
89501221|NCT02145377|Experimental|PXVX0200 10E8 then placebo|PXVX0200 10E8 on day 0; Placebo on day 14
88956215|NCT05695898|Experimental|Phase 1b: Dose Escalation (Cohort 3)|After the safety and tolerability for cohort 2 has been evaluated, participants will receive 3 mg/kg of XmAb22841 (CTLA-4 X LAG3) in combination with 10 mg/kg of XmAb23104 (PD1 X ICOS) on days 1 & 15 of a 28 day cycles for up to 4 cycles. After Cycle 4, participants will receive 10 mg/kg of XmAb23104 (PD1 X ICOS) monotherapy up to an additional 20 cycles. Participants may receive treatments up to 24 total cycles, or until unacceptable toxicity or progressive disease; whichever comes first.
89501222|NCT02145377|Experimental|Placebo, then PXVX0200 10E8|Placebo on day 0; PXVX0200 10E8 on day 14
89501223|NCT02145377|Experimental|PXVX0200 10E9 then Placebo|PXVX0200 10E9 on day 0; Placebo on day 14
89501224|NCT02145377|Experimental|Placebo then PXVX0200 10E9|Placebo on day 0; PXVX0200 10E9 on day 14
89501225|NCT02145377|Active Comparator|Shanchol|Two doses of Shanchol, on day 0 and day 14
89501226|NCT02226913|Experimental|lidocaine & sodium bicarbonate|2% lidocaine with 1: 80,000 epinephrine buffered with 0.18 mL of 8.4% sodium bicarbonate
89501227|NCT02226913|Active Comparator|lidocaine & placebo|2% lidocaine with 1:80,000 epinephrine with 0.18 mL of sterile distilled water
89501228|NCT02254655|Experimental|Puerarin injection 400 mg|Patients were administrated with 400 mg intravenously infused puerarin injection once a day. Puerarin injection was prepared in 250 mL 0.9% sodium chloride injection before the use. The treatment course consisted of 2 weeks followed by a 15-day interval for 24 weeks. Furthermore, patients receive stable treatment with oral anti-rheumatic agents and/or non-steroidal anti-inflammatory drugs, prednisone, aspirin, statins, bone metabolism regulators and gastric mucosal protective agents on as-needed basis.
89501229|NCT02254655|Sham Comparator|Control|Patients receive routine anti-rheumatic care only. Patients receive stable treatment with oral anti-rheumatic agents and/or non-steroidal anti-inflammatory drugs, prednisone, aspirin, statins, bone metabolism regulators and gastric mucosal protective agents on as-needed basis.
89501230|NCT02226991|Experimental|TPV/RTV/EFV|tipranavir (TPV) + ritonavir (RTV) from day 1 to day 24 efavirenz (EFV) from day 10 to day 23
89501231|NCT03839576|Experimental|Computerized cognitive training|The computerized cognitive training will take place at each participant's residence. Participants will be asked to practice at least 1 session a day for 6 months, and a session lasts for 60 minutes.
89501232|NCT03839576|Experimental|Lower extremity strengthening|"This exercise will comprise stretching, muscle strengthening, and balance training at increasing difficulty levels, tailored and supervised by a physical therapist, and will take place at a subject's residence or in the neighborhood once a week for 6 months.~Each session will last 60 min."
89501233|NCT03839576|Experimental|Tai chi chuan|The 8-form Yang-style tai chi intervention will take place at a subject's residence or the neighborhood once a week for 6 months, and each session will last for 60 minutes.
89501234|NCT03839576|No Intervention|Social interaction|Immediately after the baseline assessment, the care manager will visit the subject in this group once for comparability with the other two intervention groups.
89501235|NCT03544385|Experimental|Treatment Group|
89501236|NCT03544385|Placebo Comparator|Placebo Group|
89501237|NCT03822338|Experimental|Pneumoperitoneum preconditioning group|Participant assigned to the this group will receive a treatment consisting of three cycles of 5 min insufflation (intra-abdominal pressure at 15 mmHg) and 5 min desufflation, after complete anesthesia and successfully implanting the veress.
89205928|NCT00528112|Experimental|LCS16|Intrauterine levonorgestrel contraceptive system (LCS), releasing levonorgestrel (LNG) 16 microg/24 h in vitro
89501238|NCT03822338|Sham Comparator|Control group|Participants in the control group will receive the same placement of the veress but without insufﬂation and subsequent desufﬂation.
89501239|NCT02227069|Experimental|M518101|M518101 is applied topically under occlusive patch conditions to the infrascapular area of the back, once daily for 21 consecutive days over 3 weeks
88956217|NCT05675514|Experimental|İntervention Group|The intervention group; (n=30) at the beginning of the study, after the initial evaluations (demographic information, functional movement screening test (FMS), t agility test, vertical jump test, muscle strength test, muscle viscoelasticity and star balance test) were made, twice a week for 6 weeks, pre-training myofascial release technique will be applied. Final evaluations will be made when the intervention period is over.
89501240|NCT02227069|Placebo Comparator|M518101 Vehicle|M518101 vehicle is applied topically under occlusive patch conditions to the infrascapular area of the back, once daily for 21 consecutive days over 3 weeks
89501241|NCT02227069|Active Comparator|sodium lauryl sulfate|A solution of 0.2% sodium lauryl sulfate is applied topically under occlusive patch conditions to the infrascapular area of the back once daily for 21 days over 3 weeks, will serve as a positive control.
89501242|NCT02227069|Sham Comparator|Saline|A solution of 0.9% saline is applied topically under occlusive patch conditions to the infrascapular area of the back once daily for 21 days over 3 weeks, will serve as a negative control.
89501243|NCT02148731||Comprehensive Geriatric Assessment (CGA)|Functional status, Comorbidities, Objective physical performance, Nutrition, Cognition, Depression, Social support
88956218|NCT05675514|No Intervention|Control Group|The control group; (n=30) will do their routine training for 6 weeks after initial evaluations (demographic information, FMS, t agility test, vertical jump test, muscle strength test, muscle viscoelasticity and star balance test).No action will be taken. Final evaluations will be made at the end of 6 weeks.
89205929|NCT00633594|Experimental|rituximab/bortezomib/lenalidomide|"Patients in Phase I & II to receive treatment with rituximab, bortezomib and lenalidomide in 21-day cycles up to 6 cycles.~Phase I: Cohorts of 3 patients will be enrolled at escalating dose levels to determine the maximum tolerated dose (MTD). Doses may be de-escalated if necessary.~Phase II: patients will be treated with the MTD determined in Phase I."
89205930|NCT03742648|Active Comparator|Control physiotherapy group|Basic standard medical and nursing care along with standard chest physiotherapy involving steam inhalation and nebulization for 15-20 minutes and 10-15 cycles of incentive spirometry twice daily
89501244|NCT02227225||Postoperative Delirium|
89501245|NCT02254733|Experimental|ACT + CBSST|Implementing Cognitive Behavioral Social Skills Training in an Assertive Community Treatment model
89501246|NCT02254733|Active Comparator|ACT only|Assertive Community Treatment only
89501247|NCT02227303|Other|Lifestyle counseling|
89501248|NCT02254811|Experimental|Delivery via capsule|Fecal microbiota transplant is delivered by oral capsules
89501249|NCT02254811|Experimental|Delivery via colonoscopy|Fecal microbiota transplant delivered by colonoscopy
89501250|NCT05057143|Experimental|Replacement of a defect in the chest wall with an individual implant|A patient with a tumor lesion of the chest wall undergoes СT scan with a step width of less than 1 mm, then engineers design an individual model to replace the defect. Using a 3D printer, a model is made based on the patient's anthropometric data.
89501251|NCT05057143|Active Comparator|Replacement of a defect in the chest wall with titanium plates|The use of standard titanium plates to replace the chest defect. These plates must be modeled and modified using special equipment intraoperatively, based on the characteristics of the defect after resection.
89501252|NCT05049031|Experimental|Breast cancer treated with hormone therapy|Adult patients with T1-T3, N0-N2, M0 breast cancer and referred to the Menopause Center of Toulouse Hospital for their breast cancer
89501253|NCT02141789|Experimental|Outpatient Cognitive Behavioral Psychotherapy|Outpatient Cognitive Behavioral Therapy is a well-known and frequently applied psychotherapy approach that does not need further description.
89501254|NCT02145455|Active Comparator|Mechanical alignment|Patients in this arm will have the Unity Total Knee Replacement System implanted using a surgical technique that utilizes mechanical alignment via measured resection to establish knee alignment.
89501255|NCT02145455|Active Comparator|Anatomic alignment|Patients in this arm will have the Unity Total Knee Replacement System implanted using a surgical technique that utilizes anatomic alignment via ligament balancing with the tibial cut perpendicular to the tibial anatomic axis.
89501256|NCT02222233|Experimental|BI 671800 HEA delayed release (enteric coated) tablet|
89501257|NCT02222233|Experimental|BI 671800 HEA solution released in jejunum|BI 671800 HEA solution in the Enterion® capsule released in the jejunum
89501258|NCT02222233|Experimental|BI 671800 HEA solution released in ascending colon|BI 671800 HEA solution in the Enterion® capsule released in the ascending colon
89501259|NCT02222233|Experimental|BI 671800 HEA solution released in descending colon|BI 671800 HEA solution in the Enterion® capsule released in the descending colon
89501260|NCT02222233|Experimental|BI 671800 HEA particulate released in ascending colon|BI 671800 HEA as particulate in the Enterion® capsule released in the ascending colon
89501261|NCT02145533||Group I|patient with ruptured aneurysms
89501262|NCT02145533||Group II|patients with non-ruptured aneurysms
89501263|NCT02145533||Group III|Healthy volunteers
89501264|NCT04609670|Experimental|[14C]-ALXN2050|Participants will receive [14C]-ALXN2050.
88956225|NCT05673200|Experimental|Treatment (ASTX727, paclitaxel, pembrolizumab)|Patients receive ASTX727 PO on days 1-4, paclitaxel IV over 1 hour on days 1, 8, and 15, and pembrolizumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo collection of blood samples and CT and/or MRI throughout the trial. Patients in the dose-expansion phase also undergo a tumor biopsy during screening and day 1 of the treatment cycle 2 of the study. Patients will be followed every 3 months for 2 years after treatment and then every 6 months for an additional 3 years or until death, whichever occurs first.
88956226|NCT05669794||Upadacitinib|Participants will receive upadacitinib as prescribed by their physician according to local label.
89205931|NCT03742648|Experimental|Experimental physiotherapy group|Basic standard medical and nursing care along with chest physiotherapy involving any of the deep breathing exercises as per patients ease with 5-10 repetitions each, twice daily
89501265|NCT02222311||Autistic Children|Children diagnosed with autism spectrum disorder according to the criteria of the Diagnostic Statistical Manual-V will have blood samples taken for laboratory analysis.
89501266|NCT02222311||Healthy Children|Children with no developmental or physical diseases will have blood samples taken for laboratory analysis.
89501267|NCT02222311||Children with Attention Deficit Disorder|Blood samples from children with Attention Deficit Disorder will be measured for Vitamin D and oxidative stress markers.
89501268|NCT00705783|Experimental|Aripiprazole depot|Patients received aripiprazole 300 mg or 400 mg depot intramuscularly every 28 days for 52 weeks.
89501269|NCT00705783|Placebo Comparator|Placebo depot|Patients received placebo intramuscularly every 28 days for 52 weeks.
89501270|NCT03544931|Experimental|Root Instrumentation + EMD Application|"Periodontal treatment is delivered with ultrasonic instrumentation performed with fine tips. The approach chosen is the one-stage full-mouth ultrasonic debridement in which all the treatment of diseased sites is performed within one hour.~In this group, at the end of the instrumentation enamel matrix derivatives is placed in all sites with a periodontal pocket depth deeper than 5mm."
89501271|NCT03544931|Active Comparator|Root Instrumentation|Periodontal treatment is delivered with ultrasonic instrumentation performed with fine tips. The approach chosen is the one-stage full-mouth ultrasonic debridement in which all the treatment of diseased sites is performed within one hour.
89501272|NCT02222389|Experimental|CM for alcohol|CM for alcohol
89501273|NCT02222389|Experimental|CM for drugs|CM for drugs
89501274|NCT02222389|Experimental|CM for both substances|CM for both substances
89501275|NCT02222389|Other|Non-Contingent group|No CM for either substance, the Non-Contingent (NC) group
89501276|NCT02145611|Active Comparator|vildagliptin|Vildagliptin: Dosage: 100 mg/day; Duration: 12 weeks
89501277|NCT02145611|Active Comparator|glibenclamide|Glibenclamide: Dosage: 5 mg to 20 mg; Duration: 12 weeks
89501278|NCT02222467|Experimental|Klox BioPhotonic System|Treatment with KLOX BioPhotonic System in adjunction to Standard Of Care for venous leg ulcers.
89501279|NCT02148887||SCI patients with upper limb impairment - Upper limb training|
89501280|NCT02148887||SCI patients with lower limb impairment - Lower limb training|
89501281|NCT02148887||Healthy controls - Upper limb training|
89501282|NCT02148887||Healthy controls - Lower limb training|
89501283|NCT02148887||Healthy controls - No intervention|
89501284|NCT02258503||numerical scale|Evaluation of the pain of elderly patient admitted in the emergency department by numerical scale and then taken care according to the usual practice of the emergency department.
89501285|NCT02258503||algoplus scale|Evaluation of the pain of elderly patient admitted in the emergency department by numerical scale and by Algoplus® scale then taken care according to the usual practice of the emergency department.
89501286|NCT02222545|Experimental|OMS721 low dose|Administration of OMS721 at a low dose
89501287|NCT02222545|Experimental|OMS721 medium dose|Administration of OMS721 at a medium dose
88956227|NCT05667532||Contrast Enhanced Mammography|
88956228|NCT05666804|Experimental|Personalized regimen arm|1~3 x 4-week loading injections and one 8-week injection, followed by Treat-and-extend (T&E) regimen up to Week 56
89501288|NCT02222545|Experimental|OMS721 high dose|Administration of OMS721 at a high dose
89205932|NCT00817128|Experimental|1|PEPT after randomization
89205933|NCT00817128|Experimental|2|CBO after randomization
89205934|NCT04840888|Experimental|LY3484356 (Cohort 1)|LY3484356 administered as single doses orally with (fed) or without food (fasted).
89501289|NCT04440579|Active Comparator|Standard Cystoscopy|Patients will undergo a standard of care cystoscopy
89501290|NCT04440579|Experimental|PTNS and Cystoscopy|Patients will undergo PTNS while undergoing cystoscopy
89501291|NCT04440579|Sham Comparator|Sham PTN and Cystoscopy|Patients will undergo a sham PTNS procedure while undergoing cystoscopy
89501292|NCT02222623|Active Comparator|glargine insulin|Basal glargine given once daily in the morning before breakfast plus standard hospital corrective doses of insulin aspart before meals and at bedtime.
89501293|NCT02222623|Active Comparator|NPH insulin|Basal NPH given twice daily before breakfast and at bedtime plus standard hospital corrective doses of insulin aspart before meals and at bedtime.
89501294|NCT02148965|Experimental|Lifestyle intervention|Physical Exercise / Physical Activity. Exercise intervention, three weekly sessions. Each session will last around 60 minutes and will include aerobic exercises (treadmill or stationary cycling) and strength training (with focus on major muscle groups and pregnancy-specific exercises to help alleviate low back pain and work abdominal and pelvic floor muscles to prevent urinary incontinence).
89501295|NCT02148965|No Intervention|Control Group|A group of eligible women, twice as large as the intervention group, will not receive the exercise intervention but will be followed-up equally to compare outcomes in the future.
89501296|NCT02395263|Experimental|Yuxintine 200mg per day|Yuxintine 200mg oral, once a day, 6 weeks
89501297|NCT02395263|Experimental|Yuxintine 300mg per day|Yuxintine 300mg oral, once a day, 6 weeks
89501298|NCT02395263|Experimental|Yuxintine 400mg per day|Yuxintine 400mg oral, once a day, 6 weeks
89501299|NCT02395263|Placebo Comparator|Placebo|Placebo oral, once a day, 6 weeks
89501300|NCT02222701||Replacement|Composite resins with Alpha values for the marginal adaptation criteria were used as the positive control and were made with resin composite (Filtek Supreme, 3M ESPE), eith rubber dam isolation and the adhesive system L-Pop Prompt (3M-ESPE)
89501301|NCT02222701||No treatment|Composite resin restorations (Z100, 3M ESPE) in general clinically acceptable, did not receive treatment.
88956229|NCT05666804|Active Comparator|Standard regimen arm|3 x 4-week loading injections and disease activity assessment at week 16 followed by q12w/q8w up to Week 56
89205935|NCT04840888|Experimental|LY3484356 + Omeprazole (Cohort 2)|LY3484356 administered as single dose orally on Day 1 and omeprazole administered orally as single dose on Days 5 to 8 followed by a single dose of LY3484356 co-administered with a single dose of omeprazole on Day 9 orally.
88956231|NCT05665608|Active Comparator|Optimal Medical Therapy with ICD device therapy|Patients will be treated according to Optimal Medical Therapy defined by ESC Guidelines for treatment of patients with heart failure / chronic coronary syndromes and will receive an ICD device
88956232|NCT05665608|Experimental|Optimal Medical Therapy without ICD device therapy|Patients will be treated according to Optimal Medical Therapy defined by ESC Guidelines for treatment of patients with heart failure / chronic coronary syndromes and will not receive an ICD device
89205936|NCT04840888|Experimental|LY3484356 + Itraconazole (Cohort 3)|LY3484356 administered as single dose orally on Day 1 and itraconazole administered orally as single dose on Days 5 to 9. The single dose of LY3484356 co-administered with a single dose of itraconazole on Day 10 orally followed by single dose of itraconazole administered orally on Days 11 to 16.
89205937|NCT04840888|Experimental|LY3484356 + Carbamazepine (Cohort 4)|LY3484356 administered as single dose orally on Day 1 and carbamazepine administered orally as single dose on Days 5 to 11. The single dose of LY3484356 co-administered with a single dose of carbamazepine on Day 12 orally followed by single dose of carbamazepine administered orally on Days 13 to 15.
89205938|NCT04944160||Pre Covid-19 cohort|"Children hospitalized in the Pediatric Department of the  Hôpital Femme Mère Enfant , Lyon, France with a reverse transcriptase - polymerase chain reaction (RT-PCR) positive for Respiratory Syncytial Virus (RSV) during the 2019-2020 winter epidemic"
89501302|NCT02222701||Refurbishing|For this group, The dentists finished the occlusal, lingual or facial surfaces of defective RBC restorations with the medium series of aluminum oxide disks (Sof-Lex,3M ESPE) or carbide burs (12 and 30 blades,Brasseler USA, Dental Instrumentation,Savannah, Ga.) and then polished them with afine series of aluminum oxide disks (Sof-Lex, 3M ESPE) and diamond-impregnated composite polisher (ComposiPro Diacomp, Brasseler). For restorations in which proximal surface areas were affected, the clinicians smoothed them with interproximal aluminum oxide finishing strips (Sof-Lex Finishing Strips, 3M ESPE).
88956237|NCT05662527|Experimental|Neoadjuvant pembrolizumab|Pembrolizumab
89501303|NCT02149043||Ulcerative Colitis patients|30 patients with active ulcerative colitis will be put throe thermography and colonoscopy. Their stool will be tested for fecal calprotectin and their blood for CRP and other laboratory measures.
89501304|NCT02149043||Healthy volunteers|30 healthy individuals matching sex and BMI to those of ulcerative colitis patients will be put throe thermography and have their stool tested for fecal calprotectin and their blood for CRP.
89501305|NCT02222779||Patients with Parkinson´s Disease|
89501306|NCT02222779||Patient´s with Alzheimer´s Disease|
89501307|NCT02222779||Patients with Multiple Sclerosis|
89501308|NCT02222779||Patients with any other neurodegenerative diseases|
89501309|NCT02397525|Experimental|LIPO-202|
89501310|NCT03543683||osimertinib and aspirin|Osimertinib starting at a dose of 80 mg once a day, orally with meals.The intervention is aspirin which is starting at a dose of 100 mg once a day, orally with meals.Aspirin treatment will be initiated one week before beginning TKI therapy, if possible, but TKI therapy will not be delayed for Aspirin loading. Drug: Osimertinib and Aspirin will be administered once every day. If subject has complete response, partial response, stable disease, or unacceptable toxicity.
89501311|NCT03543683||osimertinib|Osimertinib starting at a dose of 80 mg once a day, orally with meals. Drug: Osimertinib will be administered once every day. If subject has complete response, partial response, stable disease, or unacceptable toxicity.
89501312|NCT02394873|Experimental|ALLO-ASC-DFU|
89501313|NCT02222935|Experimental|Balance exercise training|Balance exercise training - thrice week, 2 weeks, 10 repetition Maximum/ set, 2 sets
89501314|NCT02222935|Active Comparator|Routine Back exercise Program|Routine Back exercise Program - 10 Repetition Maximum / set, 2 sets, three times weekly, 2 weeks
89501315|NCT02145689|Experimental|onabotulinumtoxinA Dose 1|Up to 4 treatments of onabotulinumtoxinA Dose 1 injected into muscles of the study limb on fulfillment of the retreatment criteria.
89501316|NCT02145689|Experimental|onabotulinumtoxinA Dose 2|Up to 4 treatments of onabotulinumtoxinA Dose 2 injected into muscles of the study limb on fulfillment of the retreatment criteria.
89501317|NCT02227381||Microarray / NGS test|
89501318|NCT02145767|Experimental|Progesterone|Progesterone 200mg suppository administered vaginally at bedtime until 34 completed weeks of pregnancy.
88956238|NCT05659537|Experimental|Dulaglutide|Participants will receive dulaglutide subcutaneously (SC)
89501319|NCT02145767|Placebo Comparator|Placebo|Similar appearing suppository containing vehicle alone administered vaginally at bedtime until 34 completed weeks of pregnancy.
89501320|NCT02227459|Experimental|Experimental: Arm A|Once a week dosing
89501321|NCT02227459|Experimental|Experimental: Arm B|Twice a week dosing
89501322|NCT02395029|Experimental|Injection of PMD-MSCs into the penis|Subjects will receive an initial injection of 1.0cc of Placental Matrix-Derived Mesenchymal Stem Cells (PMD-MSCs). Subjects will be eligible for re-injection at 3 months and/or 6 months as determined by the clinician based on ultrasound guided measurements of penile plaque(s) post treatment and on patient reported treatment satisfaction.
89501323|NCT02145845|Experimental|Treatment|Injectable SIS
89501324|NCT02031523|Active Comparator|Sanjie analgesic capsule|every 4 capsules , 3 times a day, on the first day of menstruation to start taking, taking three consecutive menstrual cycle.
89501325|NCT02031523|Placebo Comparator|placebo|every 4 capsules, 3 times a day, on the first day of menstruation to start taking, taking three consecutive menstrual cycle.
88956241|NCT05657197|Experimental|Intervention (exercise) group|The patients in the intervention group will follow a personalised and intensive exercise program.
88956242|NCT05657197|Other|Control group|The patients in the control group will receive usual care.
88956243|NCT05656365||Patients|Patients with periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) syndrome and other tonsil disorders.
88956244|NCT05654493|Experimental|240 Second Group|Receives 240 seconds total of MicroPulse Transscleral Laser Therapy with the revised P3 Delivery Device delivered in a total of 8 sweeps
88956245|NCT05654493|Experimental|300 Second Group|Receives 300 seconds total of MicroPulse Transscleral Laser Therapy with the revised P3 Delivery Device delivered in a total of 10 sweeps
88956246|NCT05654493|Experimental|200 Second Group|Receives 200 seconds total of MicroPulse Transscleral Laser Therapy with the revised P3 Delivery Device delivered in a total of 8 sweeps
89501326|NCT02397213|Placebo Comparator|Placebo|All components of the CicloMulsion® emulsion except ciclosporin: soybean oil (refined), triglycerides (medium-chain), egg lecithin, glycerol, oleic acid, sodium hydroxide and water for injection (=0.5 ml/kg).
89501327|NCT02397213|Active Comparator|Ciclosporin|Single dose of CicloMulsion® 5 mg/ml, 2.5 mg/kg (=0.5 ml/kg) as intravenous injection.
89501328|NCT02145923|Other|allogeneic MMSCs infusion|Subjects will undergo peripheral blood stem cell mobilisation and collection with subsequent high-dose chemotherapy. After finalization of high-dose chemotherapy subjects will receive bone marrow derived allogeneic multipotent mesenchymal stromal cells intravenous infusion two hours prior to autologous peripheral blood cells infusion.
89501329|NCT04480281|Active Comparator|Lidocaine Group|Bolus of lidocaine 1% 1.5mg/kg at the induction of general anesthesia followed by a continuous infusion of lidocaine 1% 2mg/kg/h just before surgical incision and continued until 24h after the surgery
89501330|NCT04480281|Placebo Comparator|Placebo Group|Equal bolus volume of normal saline solution at induction, and then a continuous infusion started before surgical incision and maintained up until 24h postoperatively
89501331|NCT03544775||Isolated General Anesthesia|Ontario residents, aged 18 years and older, who have undergone elective ambulatory shoulder surgery in Ontario and have not had a nerve block identified using physician billing codes.
89501332|NCT03544775||Peripheral Nerve Block|Ontario residents, aged 18 years and older, who have undergone elective ambulatory shoulder surgery in Ontario and have a nerve block identified using physician billing codes.
89501333|NCT02227537||Adolescence idiopathic scoliosis|Patients must be at least 10 years of age with a risser score of 0, 1, or 2
89501334|NCT02227615|Placebo Comparator|Sugary beverage|Sugary beverage
89501335|NCT02227615|Experimental|Mango beverage|Mango polyphenolics
89501336|NCT02149355||controls|teeth molding in subjects without congenital fourth nerve palsy
89501337|NCT02149355||congenital fourth nerve palsy|teeth molding in patients suffering from congenital fourth nerve palsy
89501338|NCT02394717|Other|Intervention|All YMCA programs will receive the Healthy Eating and Physical Activity Intervention throughout the study. All programs will receive the HEPA Strategies intervetion to assist them with achievement of the HEPA Standards.
89501339|NCT02227771||Patient with chronic total occlusion|
89501340|NCT02142101||GFR >60|5 patients with polycystic kidney disease with eGFR > 60 ml/min.
89501341|NCT02142101||GFR 15-60|5 patients with polycystic kidney disease with eGFR between 15-60 ml/min.
89501342|NCT02142101||GFR <15|5 patients with polycystic kidney disease with eGFR <15 ml/min.
89205939|NCT04944160||Post Covid-19 cohort|"Children hospitalized in the Pediatric Department of the  Hôpital Femme Mère Enfant , Lyon, France with a reverse transcriptase - polymerase chain reaction (RT-PCR) positive for Respiratory Syncytial Virus (RSV) during the 2020-2021 winter epidemic"
89205940|NCT04707976|Experimental|Navina Smart|An electronic medical device to perform transanal irrigation. Treatment period 8 weeks.
89205941|NCT04707976|Active Comparator|Standard Bowel Care|Supportive bowel care without using irrigation.
89205942|NCT00755807|Placebo Comparator|Placebo|
89501343|NCT05745831|Experimental|Women with a less active ectopic pregnancy using a therapeutic decision tool for treatment decision|Women will have a therapeutic decision tool to help medical decision making and women and doctors will have to fill a questionnaire about the tool and the decision made
88956252|NCT05649748|Experimental|Treprostinil Palmitil Inhalation Powder (TPIP)|"Participants who are not transitioning immediately from other TPIP studies:INS1009-201(NCT04791514), INS1009-202(NCT05147805) and other lead-in studies, will be given TPIP, once daily (QD), starting with 80 micrograms (μg), up-titrated to highest tolerated dose between 80 μg and 640 μg during 3-week titration period that maybe increased upto maximum dose of 1280 μg QD post initial titration, per investigator's assessment. Overall treatment period=24 months.~Participants transitioning immediately from randomized blinded lead-in TPIP study and who previously received:~TPIP- will be given placebo QD(80 μg upto achieved TPIP dose from previous study)along with achieved TPIP dose from previous study in blinded manner during 3-week titration period.~Placebo- will be given TPIP QD (80 μg up to achieved placebo dose from previous study)along with achieved placebo dose from previous study in blinded manner during 3-week titration period.Overall treatment period=24 months."
89501344|NCT02258815|Experimental|ch14.18|"A six courses regimen consisting of a 8 hour infusion (ch14.18/CHOmAb 20 mg/m² ) for five consecutive days will be administered every 4 weeks.~Interleukin 2 will be added to cycles 4-6 at days 6,8,10 (1 x 106 IU/m²/d s.c.) Participants will be premedicated with an intravenous antihistamine and ranitidine within approximately 30 minutes prior and during the infusion of the study agent Pain as an anticipated side effect is managed by a standard pain prophylaxis with Morphium hydrochloride Disease status will be evaluated after 3 and 6 courses and after 1 year."
89501345|NCT02149433|Experimental|Prednisone versus placebo|Prednisone 2mg/kg orally once a day x 7 days, 1 mg/kg orally once a day x 7 days and then 0.5 mg/kg orally once a day x 7 days
89501346|NCT02394639|Active Comparator|conventional video-EEG monitoring|conventional video-EEG monitoring with cup-electrodes and collodion
89501347|NCT02394639|Experimental|video-EEG monitoring with prototype|video-EEG monitoring of 5 hours with EEG-cap with dry electrodes
89501348|NCT02228005|Experimental|Depression|Sertraline 50- 200mg
89501349|NCT02228005|No Intervention|Comparison group (non-depressed)|No intervention
89501350|NCT02146079|Experimental|Semaglutide 0.5 mg|Dose-escalation trial
89501351|NCT02146079|Placebo Comparator|Semaglutide placebo 0.5 mg|
89501352|NCT02146079|Experimental|Semaglutide 1.0 mg|Dose-escalation trial
89501353|NCT02146079|Placebo Comparator|Semaglutide placebo 1.0 mg|
89501354|NCT02232451|Experimental|ERCP with loop tip wire|ERCP with loop tip wire is an endoscopic procedure to treat biliary disease. Wire guide cannulation with loop-tip is a new procedure to improve rate of biliary cannulation and reduce complication, as post-procedure pancreatitis.
89501355|NCT02232451|Active Comparator|ERCP for cannulation|ERCP for cannulation of CBD with traditional technique
89501356|NCT02146157|Active Comparator|herb and mineral combination product|Subjects will consume 3 herb and mineral combination product softgels daily, 1 softgel immediately before each of the 3 largest meals, throughout the 12-week supplementation period.
89501357|NCT02146157|Placebo Comparator|placebo|Subjects will consume 3 softgels daily, 1 softgel immediately before each of the 3 largest meals, throughout the 12-week supplementation period
89501358|NCT02694549|Experimental|CaveoVasc|
89501359|NCT02228083|Active Comparator|Safety of dental anesthesia|Application of local dental anesthesia with two cartridges (5,6 mL) of the lidocaine 2% with epinephrine 1:100.000 in heart failure patients in functional class III or IV.
89501360|NCT02228083|Other|Oral health profile|An oral health profile of patients with heart failure will be described based in oral clinical examination.
89501361|NCT02142179|Experimental|KARE Intervention|KARE - Knowledge about Asthma and Respiratory Education is an educational curriculum intervention organized with school staff to be applied to the intervention group. This intervention will consist of theoretical - practical weekly workshops with a targeted content for asthma and involves aspects related to anatomy and physiology of the respiratory tract, conceptualization of asthma, prevention, treatment, maintenance and retrieval; recognition and actions in periods of exacerbations and use the action plan. These workshops are suitable for the course plan of disciplines sciences, biology, chemistry, physics, history, geography, portuguese and mathematics. Those are characterized as a mandatory curriculum component and they should be developed for all students.
89501362|NCT02142179|No Intervention|A traditional curriculum education.|The control group will receive a traditional curriculum education.
89501363|NCT05745753|Experimental|Partecipants with cardiovascular disease|The research program will examine imaging and clinical biomarkers associated with plasma and cellular determinants of cardiovascular disease, taking into account the potential effects of COVID-19 infection. This will make it possible to re-evaluate the cardiovascular risk profile of subjects with cardiovascular diseases.
89501364|NCT05745753|Experimental|Partecip with cardiovascular disease and affected by COVID-19|In this arm we investigate the immune dysregulation that may play a role in the evolution of cardiovascular disease characteristics of chronic and convalescent COVID-19 participants, in this field we will perform detailed clinical cardiological and immunological phenotyping on enrolled patients.
89501365|NCT02905903|Other|Trichloroacetic Acid|Intervention-Apply 4 concentrations of TCA (20%, 25%, 30%, 35%) to the buttocks to two spots each (total of 8 lesions) and following characteristics of these lesions and comparing them to acne induced PIH during the course of the study. Comparisons will be made using Investigators Global Assessment scoring of hyperpigmentation and erythema, colorimetry, photography, and biopsies
89501366|NCT02142257||Gastric Bypass|Morbidly obese individuals who meet the criteria for and have chosen to undergo Gastric Bypass surgery.
89501367|NCT02142257||AspireAssist Aspiration Therapy|Morbidly obese individuals who meet the criteria for and have chosen to participate in Aspiration Therapy using the AspireAssist.
89501368|NCT02394483|Experimental|Cohort A active|2 mg/kg orally F901318 safety,F901318 tolerability and F901318 pharmacokinetics
89501369|NCT02394483|Placebo Comparator|Cohort A placebo|Matching placebo safety,placebo tolerability and placebo pharmacokinetics
89501370|NCT02394483|Experimental|Cohort B active|4 mg/kg orally F901318 safety,F901318 tolerability and F901318 pharmacokinetics
89501371|NCT02394483|Placebo Comparator|Cohort B placebo|Matching placebo safety,placebo tolerability and placebo pharmacokinetics
89501372|NCT02394483|Experimental|Cohort C active|6 mg/kg orally F901318 safety,F901318 tolerability and F901318 pharmacokinetics
89501373|NCT02394483|Placebo Comparator|Cohort C placebo|Matching placebo safety,placebo tolerability and placebo pharmacokinetics
89501374|NCT02394483|Experimental|Cohort D active|8 mg/kg orally F901318 safety,F901318 tolerability and F901318 pharmacokinetics
89501375|NCT02394483|Placebo Comparator|Cohort D placebo|Matching placebo safety,placebo tolerability and placebo pharmacokinetics
89501376|NCT02394483|Experimental|Cohort E active|10 mg/kg orally F901318 safety,F901318 tolerability and F901318 pharmacokinetics
89501377|NCT02394483|Placebo Comparator|Cohort E placebo|Matching placebo safety,placebo tolerability and placebo pharmacokinetics
89501378|NCT04340323|Experimental|Group A-intensive exercise group|"Dosage of intensive exercise group - 12 weeks, five times a week for 30 minutes per day; five times with education by a physiotherapist, followed by continuation at home.~PFMT with lumbopelvic stabilization. Exercise up to five times a week for up to 30 minutes per day, after initial training with a physiotherapist.~Educating probands about anatomy, physiology and pelvic floor muscle function.~Training of pelvic floor muscles in different positions.~Training of pelvic floor muscles with six stabilization exercises - activation of deep trunk muscles."
89205943|NCT00755807|Experimental|Duloxetine|
89538419|NCT05074901|Experimental|digital behavioral intervention|Digital behavioral interventions to improve mood and decrease fatigue, sleep complaints and substance usage.
89205944|NCT03998644||healthy|Subjects without colorectal disorders.
89501379|NCT04340323|Active Comparator|Group B-low-intensity exercise group|"Dosage of low-intensity exercise group - 12 weeks, twice a week for 15 minutes per day; five times with physiotherapist education, followed by continuation at home.~PFMT with lumbopelvic stabilization. Exercise up to five times a week for up to 30 minutes per day, after initial training with a physiotherapist.~Educating probands about anatomy, physiology and pelvic floor muscle function.~Training of pelvic floor muscles in different positions.~Training of pelvic floor muscles with six stabilization exercises - activation of deep trunk muscles."
89501380|NCT02149511||SCI subjects|
89501381|NCT02149511||healthy control subjects|
89501382|NCT02142335|Experimental|Rituxan/Abraxane|This is a single arm study. All patients recieve treatment.
89501383|NCT02223013|Active Comparator|BIBV 308 SE solution|
89501384|NCT02223013|Experimental|BIBV 308 SE capsule L|
89501385|NCT02223013|Experimental|BIBV 308 SE capsule S|
89501386|NCT02394249|Experimental|Sitting regime|The subjects will follow the sitting regime during four days. Each day: 14 hours sitting, 1 hour walking and 1 hour standing and 8 hours sleeping.
89501387|NCT02394249|Experimental|Sit Less regime|Subjects will follow the sit less regime during four days. Each day will consist of 9 hours sitting, 4 hours walking, 3 hours standing and 8 hours sleeping. The walking and standing will be done in a minimum of eight bouts with a time interval of >1 hour. The subjects will be instructed to walk on a slow pace, i.e. 2-3 km/h, which is comparable to walking during shopping, walking to the office etc.
88956253|NCT05649137|Experimental|Semaglutide 7.2 mg|Participants will receive once-weekly injection of semaglutide subcutaneously (s.c.) in 20 week dose escalation period with dose escalation (0.25 milligram [mg], 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg, and 7.2 mg) every fourth week. Treatment will be continued on the maintenance dose of 7.2 mg once-weekly for an additional 52 weeks until week 72.
88956254|NCT05649137|Experimental|Semaglutide 2.4 mg|Participants will receive once-weekly s.c. injection of semaglutide in 20 week dose escalation period with dose escalation (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg) every fourth week until maintenance dose of 2.4 mg of semaglutide was reached. Treatment will be continued on the maintenance dose of 2.4 mg once-weekly for an additional 52 weeks until week 72.
88956255|NCT05649137|Placebo Comparator|Placebo|Participants will receive once-weekly s.c. injection of placebo matched to semaglutide for 72 weeks.
88956256|NCT05648968|Experimental|Ianalumab low dose|Participants will receive low dose ianalumab intravenously
88956257|NCT05648968|Experimental|Ianalumab high dose|Participants will receive high dose ianalumab intravenously
88956258|NCT05648968|Placebo Comparator|Placebo|Participants will receive placebo intravenously
88956259|NCT05645458|No Intervention|Control group|Pre-tests will be applied to the caregiver before the patient is discharged, and the first data will be obtained by observing during PEG care. Then, traditional training on PEG care will be given to the patient's relatives. The tests applied after this training will be applied again. Tests and observation forms will be applied in the 1st month and 3rd month after discharge. By making home visit the participant, recording will be video-recorded so that his identity will not be seen while he is doing PEG care, and the recording will be transcribed to the observation form by 2 blinded people other than the researcher.
88956260|NCT05645458|Experimental|experimental group|In addition to maintaining the control group, the experimental group is monitored by installing the mobile application we have developed.
89205945|NCT03998644||precancerous|Subjects with risk factors that may contribute to the carcinogenesis.
89205946|NCT03998644||colorectal cancer|Patients who were identified by standard procedures to suffer with colorectal cancer.
89205947|NCT05372224|Experimental|Vitamin D 4000 IU|4000 IU of vitamin D were administrated once a day orally and calcium carbonate 1.2 g a day in a single dose.
89501388|NCT02149589|Experimental|Focal ARDS|In Focal ARDS prone position will be promote early, with low PEEP and moderate Vt.
89501389|NCT02149589|Other|non focal ARDS|In non-Focal ARDS, Recruitment maneuvers, high PEEP and low V twill be used
89501390|NCT02223091|Experimental|Consultation by a trained physician|The physicians of this group receive a free consultation training program on skills regarding consultations on complementary medicine for breast-cancer patients. The training was developed by a multi-professional team and is comprised of three parts: (1) online-training, (2) on-site-training, and (3) consultation manual. Each of the physicians will counsel 10 patients. The patients in this group therefore receive a consultation by a trained physician.
89501391|NCT02223091|Active Comparator|Consultation by an untrained physician|The physicians of the control arm receive no training. Each will counsel 10 patients. The patients in this group therefore receive a consultation by an untrained physician.
89501392|NCT02394405||valve surgery|valve plasty/replacement surgery
89501393|NCT02394405||off-pump CABG|off-pump CABG
89501394|NCT02394405||CPB-CABG|CABG with CardioPulmonal Bypass
89501395|NCT02142413||Acute Ischemic Stroke|Patients older than 18 years with an acute ischemic stroke (according to WHO criteria), stroke onset within 2 days, language: German, MRI compatibility, admission to the stroke unit at the Charité, Campus Benjamin Franklin.
89501396|NCT02394327|Active Comparator|Endoscopic nasogallbladder drainage|If GB cannulation was achieved and the wire was coiled in the GB, 5 to 7-Fr Pigtail type naso-cholecystic drainage tube (Liguory nasal biliary drainage set; Wilson-Cook Medical, Salem, NC, USA) was placed into the GB
89501397|NCT02394327|Active Comparator|Endoscopic gallbladder stenting|If GB cannulation was achieved and the wire was coiled in the GB, 7-Fr double pigtail plastic stent (Zimmon; Wilson-Cook Medical, Salem, NC, USA) was placed into the GB
89501398|NCT02228161|Experimental|Yoga exercise|Participatants will receive regular 60-minutes yoga classes twice a week for 3 months.
89501399|NCT02228161|No Intervention|Regular schedule of daily living|Participants will maintain regular schedule as usual.
89501400|NCT02228239|Experimental|Sequence 1 (ABC)|Participants will receive Treatment A (esketamine 84 milligram (mg) intranasally and 1 placebo capsule) in Period 1, Treatment B (placebo intranasally and 1 mirtazapine 30 mg capsule) in Period 2 and Treatment C (placebo intranasally and placebo capsule) in Period 3 with a washout interval of at least 6 days between treatment periods.
89501401|NCT02228239|Experimental|Sequence 2 (BCA)|Participants will receive Treatment B (placebo intranasally and 1 mirtazapine 30 mg capsule) in Period 1, Treatment C (placebo intranasally and placebo capsule) in Period 2 and Treatment A (esketamine 84 mg intranasally and 1 placebo capsule) in Period 3 with a washout interval of at least 6 days between treatment periods.
89501402|NCT02228239|Experimental|Sequence 3 (CAB)|Participants will receive Treatment C (placebo intranasally and placebo capsule) in Period 1, Treatment A (esketamine 84 mg intranasally and 1 placebo capsule) in Period 2 and Treatment B (placebo intranasally and 1 mirtazapine 30 mg capsule) in Period 3 with a washout interval of at least 6 days between treatment periods.
89501403|NCT02228239|Experimental|Sequence 4 (CBA)|Participants will receive Treatment C (placebo intranasally and placebo capsule) in Period 1, Treatment B (placebo intranasally and 1 mirtazapine 30 mg capsule) in Period 2 and Treatment A (esketamine 84 mg intranasally and 1 placebo capsule) in Period 3 with a washout interval of at least 6 days between treatment periods.
89501404|NCT02228239|Experimental|Sequence 5 (ACB)|Participants will receive Treatment A (esketamine 84 mg intranasally and 1 placebo capsule) in Period 1, Treatment C (placebo intranasally and placebo capsule) in Period 2 and Treatment B (placebo intranasally and 1 mirtazapine 30 mg capsule) in Period 3 with a washout interval of at least 6 days between treatment periods.
89501405|NCT02228239|Experimental|Sequence 6 (BAC)|Participants will receive Treatment B (placebo intranasally and 1 mirtazapine 30 mg capsule) in Period 1, Treatment A (esketamine 84 mg intranasally and 1 placebo capsule) in Period 2 and Treatment C (placebo intranasally and placebo capsule) in Period 3 with a washout interval of at least 6 days between treatment periods.
89501406|NCT03167385|Experimental|Experitmental|Continuous oral intake of Apatinib Mesylate (500mg), once a day, until progression of disease or severe adverse effect.
89501407|NCT03543527||Takayashu|
89501408|NCT03167775|Experimental|Elemene + the best supportive treatment|the patients will be treated with the Elemene Injection/Elemene Oral Emulusion in Combination with the best supportive treatment .
89501409|NCT02228317|Experimental|Telemedicine consultation|EMTs will systematically establish teleconsultation by either telephone or video with the EMDC-physician in all cases of non-critical illness
89501410|NCT02149745|Experimental|Calling the patient's name|The anesthesiologist tries to recover the patient's consciousness by calling the patient's name
89501411|NCT02149745|Experimental|Not calling the patient's name|The anesthesiologist tries to recover the patient's consciousness by giving verbal stimulus other than the patient's name
89501412|NCT02142569|Active Comparator|Chinese Red Yeast Rice (CRYR)|20 subjects with cholesterol level (200 to 240 mg/dl), ages 35-70 years of age who meet all the eligibility criteria in the screening phase of the study will be assigned to the CRYR arm of the study to evaluate the cholesterol-suppressive actions of CRYR and Tocotrienol-enriched Fraction of Palm Oil (TRF). Subjects will be asked to take 2 CRYR and 2 Sugar Pill/Placebo capsules for 12 weeks.
89501413|NCT02142569|Active Comparator|Tocotrienol-enriched Fraction of Palm Oil (TRF)|20 subjects with cholesterol level (200 to 240 mg/dl), ages 35-70 years of age who meet all the eligibility criteria in the screening phase of the study will be assigned to the TRF arm of the study to evaluate the cholesterol-suppressive actions of CRYR and Tocotrienol-enriched Fraction of Palm Oil (TRF). Subjects will be asked to take 2 TRF and 2 Sugar Pill/Placebo capsules for 12 weeks.
89501414|NCT02142569|Active Comparator|CRYR + TRF|20 subjects with cholesterol level (200 to 240 mg/dl), ages 35-70 years of age who meet all the eligibility criteria in the screening phase of the study will be assigned to the TRF + CRYR arm of the study to evaluate the cholesterol-suppressive actions of CRYR and Tocotrienol-enriched Fraction of Palm Oil (TRF). Subjects will be asked to take 2 CRYR and 2 TRF capsules for 12 weeks.
89538420|NCT05074901|No Intervention|e-diaries|Ecological momentary assessment based on e-diaries on a weekly basis to evaluate sleep/wake schedules, physical activity, substance usage and nutrition.
88956263|NCT05638334|Experimental|89Zr-S095012 tracer with S095012|
88956267|NCT05636332|Other|New electrodes|New package of electrodes
88956268|NCT05636332|Other|24-hour opened electrodes|Electrodes opened 24 hours
88956269|NCT05636332|Other|30 day opened electrodes|Electrodes opened 30 days
88956270|NCT05624749|Experimental|ianalumab s.c. monthly|ianalumab s.c. monthly
88956271|NCT05624749|Placebo Comparator|placebo s.c. monthly|placebo s.c. monthly
89205948|NCT04638322|Experimental|HIFT Group|This group receives physical training based on exercises of high intensity interval functional training.
89205949|NCT04638322|No Intervention|No intervention group|This group does not receive any treatment.
89205950|NCT04819594|Experimental|Study Group|Nurses will wear the Elequil aromatabs ® (100% pure essential oil) over a four-hour period
89205951|NCT00916019|Experimental|exercise|mild exercise training
89205952|NCT00631410|Experimental|A|
89205953|NCT00631410|Experimental|B|
89205954|NCT04097951|Experimental|Montelukast|
88956276|NCT05616650|Experimental|1/Focal SBRT|Focal SBRT to the tumor focus within the prostate, with response assessed by biopsy and imaging, including 18F-DCFPyL PET/CT.
88956277|NCT05609630|Experimental|Cohort 1 Upadacitinib|Participants will receive upadacitinib for 52 weeks.
88956278|NCT05609630|Active Comparator|Cohort 1 Tocilizumab|Participants will receive tocilizumab for 52 weeks.
88956279|NCT05609630|Experimental|Cohort 2 Upadacitinib|Participants will receive upadacitinib for 52 weeks.
88956280|NCT05608044|Experimental|Combination Botensilimab Dose 1 plus Balstilimab|Participants will receive botensilimab at dose 1 given IV and balstilimab given IV.
88956281|NCT05608044|Experimental|Combination Botensilimab Dose 2 plus Balstilimab|Participants will receive botensilimab at dose 2 given IV and balstilimab given IV.
88956282|NCT05608044|Experimental|Monotherapy Botensilimab Dose 1|Participants will receive botensilimab dose 1 given IV.
88956283|NCT05608044|Experimental|Monotherapy Botensilimab Dose 2|Participants will receive botensilimab dose 2 given IV.
88956284|NCT05608044|Active Comparator|Standard of Care|Participants will receive select standard of care as determined by the investigator.
88956285|NCT05607875|Experimental|The Grow to Recovery train-the-trainer group|Professionals of the train-the-trainer group will receive an online training and then conduct a recovery group.
88956286|NCT05607875|Other|Control group|Professionals of the control group will not receive training.
88956287|NCT05603403|Experimental|Probiatop|"Probiotic used in the reconstitution and rebalancing of the intestinal microbiota.~Association of probiotic strains containing 1 g/sachet of 1 x 109 Bifidobacterium lactis HN019, 1 x 109 Lactobacillus acidophilus, 1 x 109 Lactobacillus rhamnosus HN001 / Lacticaseibacillus rhamnosus HN001 and 1 x 109 Lactobacillus paracasei Lpc- 37 / Lacticaseibacillus paracasei Lpc-37."
88956288|NCT05603403|Placebo Comparator|Hydrolized collagen|Hydrolyzed collagen is approved by Agência Nacional de Vigilância Sanitária (ANVISA) including for use in infants (ANVISA, IN NO. 28, OF JULY 26, 2018). Its use as a placebo is convenient, as it dissolves well in water, and promotes good masking. Based on literature surveys on hydrolyzed collagen and the intestinal microbiota, it was verified that the dose used (1 g) would not promote relevant functional impact in the context of the habitual Brazilian people diet.
88956289|NCT05601128|Experimental|HIV + severe renal impairment|CAB LA + RPV LA administered to HIV virologically suppressed participants with CKD stage 4/5 (CrCl < 30 mL/min) with (n = 6) or without (n = 6) hemodialysis receiving CABENUVA monthly for 6 months followed by every 2 months for 6 months.
89205955|NCT04097951|Experimental|Bepotastine|
88956291|NCT05589181|Active Comparator|Buprenorphine Standard Dose|The standard arm will receive an induction dose of 12mg of buprenorphine (BUP) split as 8mg at time=0 and 4mg at time=30-60 min.
88956292|NCT05589181|Experimental|Buprenorphine High Dose|The experimental arm tests the safety and tolerability of 32mg of BUP split as 16mg at time=0 and 16mg at time=30-60 min as an induction dose.
88956293|NCT05585255||Acute ischemic stroke patients|Acute ischemic stroke patients with large vessel occlusion who received mechanical thrombectomy therapy and are successfully revascularized
88956294|NCT05582473|No Intervention|Wait-List Control Group|Randomized subjects will wait for a 3 month period before being assigned to the LST-LC education. This group of subjects will act as the control group.
88956295|NCT05582473|Other|Learning Skills Together-Latino Caregivers (LST-LC)|The study team convened a team of health care professionals, including nursing, occupational therapy, speech-language pathology, gerontology, nutrition, and dental hygiene, to develop a community-based education program for family caregivers.
88956298|NCT05577832|Experimental|Experimental|3 different injection techniques in Single Group design, 1 ml intramuscular injection of dodex amp 1 ml will be applied to the deltoid muscle, one technique per week, for 1 weeks(3 day). The effects of the three techniques on pain, satisfaction with hematoma, comfort and fear of injection will be compared.
88956299|NCT05570825|Experimental|Treatment (SX-682, pembrolizumab)|Patients receive SX-682 PO BID, starting 7 days prior to the start of pembrolizumab, and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 3 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity. Patients also undergo biopsy and PET/CT or CT at screening and on study and undergo MRI and collection of blood samples at screening, throughout the study, and during follow up.
88956300|NCT05570539|Active Comparator|Immediate Release formulation|IR Formulation
88956301|NCT05570539|Experimental|Extended Release formulation|ER formulation
88956302|NCT05566769|Experimental|NMOSDCopilot|Performance of digital tests and standard test in clinic at D0 and M6 Use of NMOSDCopilot at-home in between visits during 12 months
88956303|NCT05564598|Experimental|Cohort 1 Safety Run-in|The first 3 patients enrolled will receive both anti-viral medication and CMV CTLs, and treatment will be staggered every 28 days from the last dose of CMV CTLs from the prior patient.
88956304|NCT05564598|Experimental|Cohort 2 Antiviral medication + CMV CTLs|Patients will receive both anti-viral medication and CMV CTLs
88956305|NCT05564598|Active Comparator|Cohort 2 Antiviral medication only|Patients will only receive anti-viral therapy
89205956|NCT04097951|Experimental|Montelukast + Bepotastine|
89502004|NCT04065386|Placebo Comparator|Sham taVNS|"Patients will receive 5 days of transcutaneous auricular vagal nerve stimulation (taVNS) bilaterally, at the ear lobe, the sham localization.~It will be preceded and followed by a clinical assessment (Coma Recovery Scale- Revised) and a neurophysiological assessment (128/256 channels EEG and electrocardiograph) the first and last day of stimulation."
89502005|NCT04477057|Other|one arm|one arm
89501415|NCT02142569|Placebo Comparator|Sugar Pill|20 subjects with cholesterol level (200 to 240 mg/dl), ages 35-70 years of age who meet all the eligibility criteria in the screening phase of the study will be assigned to the placebo (sugar pill) arm of the study to evaluate the cholesterol-suppressive actions of CRYR and Tocotrienol-enriched Fraction of Palm Oil (TRF). Subjects will be asked to take 4 placebo tablets for 12 weeks. Additionally during a two-week run-in period, subjects will be asked to follow the American Heart Association Step 1 dietary regimen and to take a placebo capsule daily to determine their ability to comply with the diet and a pill regimen.
89205957|NCT04096469|Experimental|Motivational Interviewing|The intervention group received a guidance regarding their diet and physical activity using the motivational interviewing strategy to improve adherence to healthy behaviors. Participants received a guide with a motivational interviewing approach, which served as the basis for the interview process. The objectives in the intervention group were to consume four vegetables and two fruits a day, seven days a week, increase fiber consumption to more than 30 g daily, reduce fat consumption to no more 20% of the total energy consumed, decrease the consumption of sugary drinks and increase protein intake. Another goal was to increase the number of steps to 4,000 additional steps to those who have already walked.
89205958|NCT04096469|Active Comparator|Traditional Education|The comparison group received a guide on medical care and nutrition with a traditional educational approach. The indication was to read and learn about the health-related topics included in the booklet that was given to them. These participants were visited in the same way as the intervention group to answer questions and monitor participation throughout the intervention.
89205959|NCT00822978|Active Comparator|ACHN-490 Injection|ACHN-490 Injection in escalating doses
89205960|NCT00822978|Placebo Comparator|2|Placebo is normal saline
89205961|NCT02599883|Experimental|MulticenterRecruitment|COPD phenotypization by Low-Dose Computed Tomography
89205962|NCT03686176|Experimental|Virtual Reality Group (Study Group)|In this arm, patients will receive support from child life specialists plus may use virtual reality simulation goggles during a qualifying medical procedure.
89501416|NCT02394171|Experimental|Physical Activity|Women completed a physical activity group cohesion intervention which included six content intensive intervention sessions over a 24 week period that focused on specific group dynamics team building strategies to increase physical activity. A small team structure was used for peer problem solving and support throughout the intervention. Teams were given weekly physical activity goals, with slowly increasing weekly minutes milestones to gradually meet recommended amounts of physical activity. Sessions included brief instructions, team-based activities, and discussion with the entire group lead by a trained health educator. The intervention sessions ended with the health educator leading the teams in a brisk 15-minute walk.
89501417|NCT02394171|Active Comparator|Fruit and Vegetable|Women completed a fruit and vegetable group cohesion intervention which involved six content intensive intervention sessions over a 24 week period that focused on specific group dynamics team building strategies to increase fruit and vegetable consumption. A small team structure was used for peer problem solving and support throughout. Teams were given weekly fruit and vegetable consumption goals at each session, with slowly increasing weekly servings milestones to gradually meet recommended amounts of fruit and vegetable consumption. Sessions included brief instructions, team-based activities, and discussion with the entire group lead by a trained health educator. The intervention sessions ended with the health educator leading the teams in a fruit and vegetable taste test.
89501418|NCT02228473|Experimental|Glycopyrrolate|Glycopyrrolate will be administered as the adjuncts of neuromuscular blocker reversal agent.
89501419|NCT02228473|Active Comparator|Atropine|Atropine will be administered as the adjuncts of neuromuscular blocker reversal agent.
89502006|NCT02234791||gene mutation|
89502007|NCT02234869|Experimental|Peginterferon beta-1a|Participants will receive peginterferon beta-1a, 125 µg subcutaneously once every 2 weeks during the 6-month comparator period of the study and during the 12-month extension period.
89502008|NCT02234869|Active Comparator|Interferon-β|Participants will continue to receive their standard-of-care interferon beta treatment for the first six months. During the 12-month extension period participants will switch to receive peginterferon beta-1a, 125 µg subcutaneously once every 2 weeks.
89501420|NCT02146235|Experimental|Treatment Group - Music Therapy|The experimental group participates in once weekly group music therapy session for 6 weeks using playing of simple wind instruments, singing, and music visualization. The Music therapy session lasts 45 min. and encourages patients to use breathing techniques to achieve a relaxation response. Extructured techniques involving singing, music improvisation supports breath pattens and provides supporting coping styles. The use of wind instruments involves a focus of breathing efficiently and elongating the exhalation to prolong musical tones and transferring breath control. Music Visualization involving deep breathing techniques provides optimal mind-body connection, influences breathing rhythms through more indirect means while reducing stress, accessing altered states and encourages healing imagery.
89501421|NCT02146235|No Intervention|Standard Pulmonary Rehabilitation|"Pulmonary rehabilitation is a program to people with chronic lung diseases like COPD, emphysema, and chronic bronchitis lead full, satisfying lives and restore them to their highest functional capacity. Pulmonary rehab is aimed to improve quality of life by:~Decreasing respiratory symptoms and complications Encouraging self-management and control over daily functioning Improving physical conditioning and exercise performance Improving emotional well-being Reducing hospitalizations~Pulmonary rehab programs include:~Medical management Exercise Breathing retraining Education Emotional support Nutrition counseling"
89023455|NCT05411497|Experimental|Treatment (cyclophosphamide, MUC1-activated T-cells)|"LD CHEMOTHERAPY: Patients receive cyclophosphamide IV over 60 minutes on days -5, -4, -3.~ASCT: Patients receive MUC1-activated T-cells IV over 10 minutes to 1 hour on day 0."
89501422|NCT02228551|Other|ARC PPS|Augmented renal clearance Point prevalence study
89501423|NCT02146313|Experimental|Dose-escalation Cohort|DMUC4064A will be administered to participants at a starting dose of 1.0 milligram per kilogram (mg/kg) by IV infusion q3w and would be monitored for DLTs for 21 days after first infusion of Cycle 1 (cycle length=21 days).
89501424|NCT02146313|Experimental|Platinum-resistant Ovarian Cancer Dose-expansion Cohort|Platinum-resistant Ovarian Cancer participants will be administered with the identified RP2D during the Dose-escalation of DMUC4064A q3w IV for up to until disease progression or death, whichever occurs first.
89501425|NCT02146313|Experimental|Unresectable Pancreatic Cancer Dose-expansion Cohort|Unresectable pancreatic cancer participants will be administered with the identified RP2D during the dose-escalation of DMUC4064A q3w IV for up to until disease progression or death, whichever occurs first.
89501426|NCT02223169|Experimental|Egg albumin-derived peptide|Each participant will consume 1 sachet of Egg albumin-derived peptide (3 g) each day mixed with a fruit juice drink for 42 days.
89501427|NCT02223169|Placebo Comparator|Placebo|Participants will consume one sachet of the placebo mixed with a fruit juice drink that will appear and taste similar to the albumin derived peptide sachet.
89501428|NCT02394093|Experimental|Aspirin dry powder|500 mg Acetylsalicylic Acid (ASA) dry powder
89501429|NCT02394093|Active Comparator|Aspirin coated tablet|500 mg ASA coated tablet
89501430|NCT02394093|Active Comparator|Aspirin effervescent tablet|500 mg ASA effervescent tablet
89501431|NCT02142647|Active Comparator|meat group|Infants in this group will receive complementary foods with high protein content mainly from meat
89501432|NCT02142647|Active Comparator|dairy group|infants in this group will receive complementary foods mainly from dairy
89501433|NCT02223247|Experimental|TVB-2640|Oral TVB-2640 capsules or tablets of various dose strengths administered QD for 21 - 28 day dosing cycles, alone or in combination with certain standard chemotherapy agents
89501434|NCT03167463|Experimental|choanoplasty with flap|flap surgery
89501435|NCT02146391|Experimental|Androxal 25 mg|
89501436|NCT02223325||Elderly, acute pancreatitis|No intervention
89501437|NCT02223325||Adults <65 y, acute pancreatitis|No intervention
89502009|NCT05499104|Active Comparator|Mepilex Ag|patient will receive Mepilex Ag for their site, standard of care to be followed.
89502010|NCT05499104|Active Comparator|Xeroform|patient will receive Xeroform for their site, standard of care to be followed.
89502011|NCT05499104|Experimental|NovaDress|patient will receive NovaDress for their site, standard of care to be followed.
89023456|NCT05407805||Control Group|SCD participants not on disease modifying treatment.
89023457|NCT05407805||SCD Disease Modifying Treatment Group|SCD participants on a stable dose of a SCD disease modifying treatment regimen.
89023458|NCT05403996|Experimental|Activa-Mente (Intervention)|The active break program involves the presentation of video (4.5 min) with moderate-to-vigorous physical activities. These active breaks will be performed 6 times per day during 6 weeks.
89023459|NCT05403996|No Intervention|Control group|This group of students will not be exposed to the intervention.
89023460|NCT05403879|Experimental|cases undergoing fixation of fractured greater tuberosity|
89023461|NCT05400070|Experimental|neoadjuvant therapy|Sintilimab (200mg fixed dose) iv, d1, q3w，anlotinib 10mg, po, qd1-14, q3w combine with Chemotherapy
89023462|NCT05390177|Experimental|First health video|This video presents health information for one study condition.
89023463|NCT05390177|Active Comparator|Second health video|This video presents health information for one study condition.
89023464|NCT05388058|Experimental|Arm I (cannabidiol, placebo)|Patients apply cannabidiol cream topically to affected areas BID for 14 days. Patients then apply placebo cream topically to affected areas BID for 14 days.
89023465|NCT05388058|Experimental|Arm II (placebo, cannabidiol)|Patients apply placebo cream topically to affected areas BID for 14 days. Patients then apply cannabidiol cream topically to affected areas BID for 14 days.
89023466|NCT05379920|Experimental|Concussed Participants Group 1|High Volume Group
89023467|NCT05379920|Experimental|Concussed Participants Group 2|Low Volume Group
89023468|NCT05379920|Active Comparator|Healthy controls Group 1|High Volume Group
89023469|NCT05379920|Active Comparator|Healthy Controls Group 2|Low Volume Group
89501438|NCT03115515|Experimental|Adjustment in number of doses of thyroid hormone per week|"Patients in this group will increase pre-pregnancy thyroid hormone dose by 2 doses/week (extra dose on Wednesday and Saturday). Further dose adjustment are made every 2-4 weeks based on serum TSH, as shown below:~TSH>10mIU/L, increase by 3 doses/week~TSH 5.0-9.9mIU/L, increase by 2 doses/week~TSH 2.0-4.9mIU/L, increase by 1 dose/week~TSH 0.4-1.9mIU/L, no change~TSH<0.4mIU/L, decrease by 1 dose/week~TSH<0.1mIU/L, decrease by 2 doses/week~Thyroid hormone dose will NOT be decreased due to TSH<0.4mIU/L during the 1st trimester unless patient also has elevated circulating T4 and/or T3 levels, indicate of true hyperthyroidism."
89501439|NCT03115515|Experimental|Adjustment in micrograms per day of thyroid hormone|"Patients in this group adjust thyroid hormone dose based on Visit 1 TSH and pre-pregnancy thyroid hormone dose. Further dose adjustments are made every 2-4 weeks based on serum TSH, as shown below:~TSH>10mIU/L, increase dose by 50mcg/day if dose <125mcg/day or increase by 75mcg/day if dose >125mcg~TSH 5.0-9.9mIU/L, increase dose by 25mcg/day if dose <125mcg/day or increase by 50mcg/day if dose >125mcg~TSH 2.0-4.9mIU/L, increase dose by 12.5mcg/day if dose <125mcg/day or increase by 25mcg/day if dose >125mcg~TSH 0.4-1.9mIU/L, no change~TSH<0.4mIU/L, decrease dose by 12.5mcg/day if dose <125mcg/day or decrease by 25mcg/day if dose >125mcg/day~TSH<0.1mIU/L, decrease dose by 25mcg/day if dose <125mcg/day or decrease by 50mcg/day if dose >125mcg/day~Thyroid hormone dose will NOT be decreased due to TSH<0.4mIU/L during the 1st trimester unless patient also has elevated circulating T4 and/or T3 levels, indicate of true hyperthyroidism."
89501440|NCT02223403|Experimental|submaximal steady state exercise|90 minutes after respective beetroot juice ingestion, subjects walked on treadmill at a pre-determined steady state workload for a total of 15 minutes with oxygen consumption recorded for the last 10 minutes
89023470|NCT05379101||Transthyretin (ATTR) cardiac amyloidosis|Subjects diagnosed with ATTR cardiac amyloidosis will have CMR, TTE, and 6-minute walk
89023471|NCT05379101||Light chain amyloidosis (AL) with cardiac involvement|Subjects diagnosed with AL with cardiac involvement will have CMR, TTE, and 6-minute walk
89023472|NCT05379101||Light chain amyloidosis (AL) without cardiac involvement|Subjects diagnosed with AL without cardiac involvement will have CMR, TTE, and 6-minute walk
89023473|NCT05379101||Healthy Control|Subjects without history of cardiovascular diseases will have CMR, TTE, and 6-minute walk
89023474|NCT05370911|Experimental|Immediate Treatment|Participants randomized to this condition will receive treatment immediately, facilitated by two study staff members, and which consists of two preparatory sessions, followed by the first dosing session and two integration sessions, then the second dosing session and two integration sessions. This is followed by follow-up and long-term follow-up visits up to 12 months post-second dose.
89023475|NCT05370911|No Intervention|Waitlist Control/Delayed Treatment|Participants randomized to this condition will first enter a waitlist phase that lasts for 7 weeks, after which rater unblinding will occur, and participants will be rescreened. If participants remain eligible at this time, they will begin their treatment phase. During their treatment phase, participants in this condition will receive the same treatment as described for participants in the immediate treatment group. This is followed by follow-up and long-term follow-up visits up to 12 months post-second dose.
89023476|NCT05370287|Experimental|Glaucoma with oxygen|Primary open angle glaucoma subjects as well as pre-perimetric glaucoma suspects will be classified by clinical exam by an experienced glaucoma specialist according to the American Academy of Ophthalmology Practice Patterns. Glaucoma subjects and suspects will undergo adaptive optics (AO) imaging of several macular locations. A subset of subjects will undergo oxygen challenge intervention, which involves breathing 100% oxygen through a mask during AO imaging at pre-determined retinal vessel locations.
89023477|NCT05370287|Experimental|Healthy control with oxygen|Age-matched healthy control cohort will undergo the same AO imaging procedures as glaucoma cohort. A subset of subjects will undergo the same oxygen challenge intervention as the glaucoma cohort.
89023478|NCT05370287|Experimental|Healthy control with stimulation|Healthy control subjects will undergo AO imaging at several macular locations while flashes of visible light stimulus are delivered.
89023479|NCT05370287|Experimental|Glaucoma|Glaucoma subjects and suspects will undergo AO imaging at several macular locations without intervention.
89205963|NCT03686176|No Intervention|Active Control Group|In this arm, patients will receive standard of care with child life specialists plus distraction of the child's choosing, during a qualifying medical procedure.
89501441|NCT02223403|Experimental|six minute walk test|subjects performed six-minute walk at self-determined pace 30 minutes after treadmill exercise was performed
89501442|NCT02146469|Experimental|None varicella vaccine history|2 doses with an 3 months interval
89501443|NCT02146469|Experimental|1 year after first dose|A second dose with an 1 year interval
89501444|NCT02146469|Experimental|3 years after first dose|A second dose with an 3 year interval
89501445|NCT02146469|Experimental|5 years after first dose|A second dose with an 5 year interval
89501446|NCT02146469|Experimental|Testing group for conbined immunization|1 dose Varicella vaccine and 1 dose MMR given at the same time
89501447|NCT02146469|Placebo Comparator|Control group for conbined immunization|1 dose MMR
89501448|NCT03115593|Experimental|postmenopausal patients with metrorrhagia|"Postmenopausal patients with metrorrhagia and endometrial hypertrophy defined by an endometrium ticker than 3 mm (ultrasound result).~The threshold choice of 3 mm was chosen according to a recent review of the literature to limit the risk of false negatives for cancer."
89501449|NCT04319653|Experimental|Dynamic pelvic MRI|
89501450|NCT02142725|Experimental|LT-02|LT-02 0.8g four times daily
89501451|NCT02142725|Experimental|B: LT-02|LT-02 1.6g twice daily
89501452|NCT02142725|Placebo Comparator|Placebo|LT-02 Placebo
89501453|NCT02228629|Experimental|Typical house shoe|Subject's typical shoes worn in and around home
89501454|NCT04225273|Experimental|Investigational Arm in pivotal study- 43USSA1705|Injection with Sculptra Aesthetic reconstituted with 8ml Sterile Water for Injection
89501455|NCT02228707|Experimental|BIIB061|Participants receive BIIB061
89501456|NCT02228707|Placebo Comparator|Placebo|Participants receive matched placebo
89501457|NCT02146547|Active Comparator|aripiprazole oral|the recommended starting dose for aripiprazole is 10 or 15 mg/day with a maintenance dose of 15 mg/day administered on a once-a-day schedule without regard to meals.Aripiprazole is effective in a dose range of 10 to 30 mg/day.
89501458|NCT02146547|Active Comparator|Aripiprazole depot|"The recommended starting and maintenance dose of aripiprazole depot is 400 mg. Titration of the dose of this medicinal product is not required. It should be administered once monthly as a single injection (no sooner than 26 days after the previous injection).~After the first injection, treatment with 10 mg to 20 mg oral aripiprazole should be continued for 14 consecutive days to maintain therapeutic aripiprazole concentrations during initiation of therapy.~If there are adverse reactions with the 400 mg dosage, reduction of the dose to 300 mg once monthly should be considered."
89501459|NCT02146547|Active Comparator|Paliperidone|The recommended dose of paliperidone for the treatment of schizophrenia is 6 mg once daily, administered in the morning. Initial dose titration is not required. Some patients may benefit from lower or higher doses within the recommended range of 3 mg to 12 mg once daily. Dosage adjustment, if indicated, should occur only after clinical reassessment. When dose increases are indicated, increments of 3 mg/day are recommended and generally should occur at intervals of more than 5 days.
89501460|NCT02146547|Active Comparator|Paliperidone palmitate|The first two administrations of paliperidone palmitate (150 mg at visit 3 and 100 mg one week later) need to be administered deep into the deltoid muscle in order to attain therapeutic concentrations rapidly. No oral supplementation with paliperidone is needed. Following the second dose, monthly maintenance doses can be administered in either the deltoid or gluteal muscle. The recommended monthly maintenance dose is 75 mg, although some patients may benefit from lower doses within the recommended range of 25 to 150 mg based on individual patient tolerability and/or efficacy.
89501461|NCT02228785|Experimental|100µg dose of G17DT|Patients in this arm received a 100µg dose of G17DT via intramuscular injection.
89501462|NCT02228785|Experimental|200µg dose of G17DT|Patients in this arm received a 200 µg dose of G17DT via intramuscular injection.
89205964|NCT03686176|No Intervention|External Control (Reference Group)|No virtual reality and no child life specialists; no standardized or formal form of support.
89205965|NCT00817284|Experimental|arm I|Bevacizumab + Irinotecan and concomitant radiotherapy
89205966|NCT00817284|Experimental|Arm II|Bevacizumab and Temozolomide and concomitant radiotherapy
89205967|NCT04096235|Experimental|RAM Cannula|
89023480|NCT05370287|Experimental|Healthy control|Healthy control subjects will undergo AO imaging at several macular locations without intervention
89023481|NCT05370105||Stroke patients|80 post-stroke patients will be asked to undergo three samples of biological material (10 ml of blood): the first collection on the second day of hospitalization at IRCCS S. Maria Nascente (Milano) or at IRCCS Don Gnocchi (Florence) of Fondazioen Don Gnocchi (t0) and a second withdrawal at discharge (t1), or approximately 2 months after the first withdrawal. Where possible, a third sampling (t2 - follow up) will be performed 6 months after the event.
89205968|NCT00823056|Placebo Comparator|1|
89205969|NCT00823056|Active Comparator|2|
89205970|NCT04096157|Experimental|Isavuconazonium sulfate IV solution then capsules|Participants will first receive a single dose of isavuconazonium sulfate intravenous (IV) solution via nasogastric (NG) tube (test formulation) under fasting conditions on Day 1 of Period 1. After a washout period of 30 days, the participants then receive a single dose of isavuconazonium sulfate capsules (reference formulation) for oral administration under fasting conditions on Day 1 of Period 2.
89205971|NCT04096157|Experimental|Isavuconazonium sulfate capsules then IV solution|Participants will first receive a single dose of isavuconazonium sulfate capsules (reference formulation) for oral administration under fasting conditions on Day 1 of Period 1. After a washout period of 30 days, the participants then receive a single dose of isavuconazonium sulfate intravenous (IV) solution via nasogastric (NG) tube (test formulation) under fasting conditions on Day 1 of Period 2.
89205972|NCT00819624|Other|Interactive Voice Response System|
89205973|NCT00819624|Other|Personal Digital Assisstant|
89205974|NCT00823368||Arbaclofen followed by Placebo|
89205975|NCT00823368||Placebo followed by Arbaclofen|
89205976|NCT00755417|Experimental|G-ER 1200 mg|Gabapentin extended-release (G-ER) 1200 mg
89205977|NCT00755417|Experimental|G-ER 1800 mg|Gabapentin extended-release (G-ER) 1800 mg
89501463|NCT02228785|Experimental|500µg dose of G17DT|Patients in this arm received a 500µg dose of G17DT via intramuscular injection.
89205978|NCT00755417|Placebo Comparator|Sugar Pill|Placebo 1200 mg or 1800 mg
89205979|NCT03685708|Experimental|Chronic Lymphocytic Leukemia Patients That Are Treatment Naïve|Treatment naïve Chronic Lymphocytic Leukemia (CLL) or small lymphocytic lymphoma (SLL) patients will receive HEPLISAV-B (Hepatitis B Vaccine [Recombinant ], adjuvanted) vaccine - A series of 2 doses (0.5 ml each) will be given on a 0- and 3- month schedule via intramuscular injection.
89205980|NCT03685708|Experimental|Chronic Lymphocytic Leukemia Patients Receiving Treatment With Ibrutinib|Ibrutinib monotherapy for at least 6 months prior to administration of the first vaccine dose in patients with Chronic Lymphocytic Leukemia (CLL) or small lymphocytic lymphoma (SLL). Patients will receive HEPLISAV-B (Hepatitis B Vaccine [Recombinant ], adjuvanted) vaccine - A series of 2 doses (0.5 ml each) will be given on a 0- and 3- month schedule via intramuscular injection.
89205981|NCT03685708|Experimental|Chronic Lymphocytic Leukemia Patients Receiving Treatment With Acalabrutinib|Acalabrutinib monotherapy for at least 6 months prior to administration of the first vaccine dose in patients with Chronic Lymphocytic Leukemia (CLL) or small lymphocytic lymphoma (SLL). Patients will receive HEPLISAV-B (Hepatitis B Vaccine [Recombinant ], adjuvanted) vaccine - A series of 2 doses (0.5 ml each) will be given on a 0- and 3- month schedule via intramuscular injection.
89501464|NCT02394015||Trabectedin+ PLD|Trabectedin and Pegylated Liposomal Doxorubicin (PLD ) in the Treatment of Patients With Platinum-sensitive Recurrent Ovarian Cancer (ROC), according to SmPC.
89501465|NCT05745597||HSIL (CIN2,3) women or cervical carcinoma in situ or early invasive carcinoma confirmed by pathology|In this study, women with pathologically confirmed HSIL(CIN2, 3) or women with cervical carcinoma in situ or early invasive cancer will be included. All participants will have four follow-up visits at enrollment and at months 6, 12, and 24.
89501466|NCT04641559|Experimental|Personalized nutrition group|Intervention group that will receive personalized nutrition advice through the ALDI's catalogue during four months.
89501467|NCT04641559|Experimental|Personalized Plan group|Intervention group that will receive personalized nutrition advice through the ALDI's catalogue and behavioural change program during four months.
89501468|NCT04641559|Placebo Comparator|Control group|General recommendations but not personalization nor behavioural change advice will be implemented during four months.
89501469|NCT02142881|Experimental|Antihypertensive medication intensification|
89501470|NCT02142881|Other|Usual care|
89501471|NCT05745519||The experimental group|Aged 40-79 years old, complained of insomnia symptoms in the past month, at least three times a week, for a month, such as: difficulty falling asleep, waking up in the middle of the night, waking up unable to fall asleep, waking up in the morning and still not getting enough sleep
89501472|NCT05745519||The control group|Healthy volunteer subjects aged 40-79 without insomnia.
89501473|NCT02259283|Experimental|Achalasia|Patients (age 18-75 years old) with diagnosis of achalasia, without megaesophagus or colonic esophagus, will undergo POEM with the hybrid knife.
89501474|NCT02146625|Experimental|Dose level 1 of CJ-40002|"Single dose~8 volunteers will be administered dose level 1 of CJ-40002 or placebo comparators.(CJ-40002:placebo=6:2)"
89501475|NCT02146625|Experimental|Dose level 2 of CJ-40002|"Single dose~8 volunteers will be administered dose level 2 of CJ-40002 or placebo comparators.(CJ-40002:placebo=6:2)"
89501476|NCT02146625|Experimental|Dose level 3 of CJ-40002|"Single dose~8 volunteers will be administered dose level 3 of CJ-40002 or placebo comparators.(CJ-40002:placebo=6:2)"
89501477|NCT02146625|Experimental|Dose level 4 of CJ-40002|"Single dose~8 volunteers will be administered dose level 4 of CJ-40002 or placebo comparators.(CJ-40002:placebo=6:2)"
89501478|NCT02146625|Experimental|Dose level 5 of CJ-40002|"Single dose~8 volunteers will be administered dose level 5 of CJ-40002 or placebo comparators.(CJ-40002:placebo=6:2)"
89501479|NCT04832295|Experimental|Intervention|Photo-supported conversations about well-being, in addition to care as usual
89501480|NCT04832295|Active Comparator|Control|Care as usual
89501481|NCT02146703|Experimental|gemcitabine and S-1|
89501482|NCT04209283|Experimental|Trauma exposed women|"No Intervention: Baseline phase ('A'):~Measurements collected in a daily diary four times a day (morning, afternoon, evening and night) over one week for the primary outcome (occurrence of intrusive memories of trauma). Individual baseline phases will be used as control periods.~Experimental: Intervention phase ('B'):~A one-session intervention with a researcher including a simple cognitive task (a memory cue and 25 minutes of Tetris game-play with mental rotation) followed by instructions to engage in the task self-guided over the subsequent week. Measurements collected in a daily diary four times a day following the intervention for the primary outcome (occurrence of intrusive memories of trauma).~Intervention: Behavioral: Brief cognitive intervention"
89501483|NCT02228863|Experimental|Early Inmotion and Botox|Concomitant use of Inmotion and botulinum toxin from the baseline
89501484|NCT02228863|Active Comparator|Botox, then Inmotion|Inmotion training 4 weeks after botulinum toxin injection
89501485|NCT02228863|Active Comparator|Inmotion, then Botox|From the baseline Inmotion, then Botox injection at 4 weeks after baseline
89205982|NCT00819702|Experimental|Model Care|The Model Care approach was implemented in 7 practices, where PCPs were trained to address major risk factors for CM, including maternal depression, alcohol/substance abuse, intimate partner violence, food insecurity, harsh punishment and major stress. We taught how they can be briefly assessed and initially addressed. The initial training consisted of one 4-hour in-person session. Use of the Parent Screening Questionnaire (PSQ) was discussed, as was the importance of applying it universally during regular checkups. PCPs SEEK Parent Handouts on each targeted problem. We held 1-hour booster sessions every 6 months over the subsequent 2.5 years.
89023482|NCT05370105||Healthy Controls|The healthy controls will be volunteers recruited at Fondazione Don Gnocchi, who are not affected by neurodegenerative and cardiovascular diseases and who have not taken anti-inflammatory drugs in the week prior to recruitment.
89205983|NCT00819702|No Intervention|Standard Care|PCPs in Standard Care group served as the controls. They continued to practice as usual.
89205984|NCT03684928|Active Comparator|Comfilcon A (test)|Participants were randomized to wear either test or control contact lenses bilaterally for one month during the cross-over study.
89501486|NCT02228863|Active Comparator|Late Inmotion and Botox|No intervention, then Inmotion and Botox injection at 4 weeks from the baseline
89501487|NCT02782325|Active Comparator|Active FMT, then open label FMT|Endoscopic application of OpenBiome FMT Lower Delivery followed by 2 weeks of treatment with OpenBiome FMT Capsules G3 with follow-up at week 4, 8, 16 and 24 after inclusion. In case the study patient does not achieve clinical remission at week 4 or experiences a flare of disease on day 15-28 after start of the study he/she will be offered the possibility to participate in open label extension after at least 10 day of antibiotic therapy with an additional endoscopic FMT followed by 2 weeks of oral FMT. Follow-up will occur in open label at week 4, 8, 16 and 24 after open label FMT.
89501488|NCT02782325|Placebo Comparator|Placebo FMT, then open label FMT|Endoscopic application of Placebo FMT Lower Delivery followed by 2 weeks of treatment with Placebo FMT Capsules G3 with follow-up at week 4, 8, 16 and 24 after inclusion. In case the study patient does not achieve clinical remission at week 4 or experiences a flare of disease on day 15-28 after start of the study he/she will be offered the possibility to participate in open label extension after at least 10 day of antibiotic therapy with an additional endoscopic FMT followed by 2 weeks of oral FMT. Follow-up will occur in open label at week 4, 8, 16 and 24 after open label FMT.
89501489|NCT02693691|Experimental|CardioMEMS HF System|Subjects will collect pulmonary artery pressure measurements daily which will be used by health care professionals to adjust cardiac medications.
89501490|NCT02223481|Experimental|Terbogrel low dose|
89205985|NCT03684928|Active Comparator|Senofilcon C (control)|Participants were randomized to wear either test or control contact lenses bilaterally for one month during the cross-over study.
89205986|NCT00817440|No Intervention|Control|control: muscle and fat biopsies and basal aminoacid and glucose turnover
89205987|NCT00817440|Experimental|Exercise|1 hour ergometer cycling on 65% of Vo2max, and then the same as arm 1.
89205988|NCT00817440|Experimental|Fasting|3 days of fasting and then the same as arm 1
89205989|NCT00777803|Experimental|IncobotulinumtoxinA (Xeomin®/Bocouture®)|IncobotulinumtoxinA (Xeomin®/Bocouture®), 24 units; mode of administration: intramuscular injection.
89205990|NCT00777803|Active Comparator|OnabotulinumtoxinA (Vistabel®)|OnabotulinumtoxinA (Vistabel®), 24 units; mode of administration: intramuscular injection.
89205991|NCT00819858|Experimental|RUTF|RUTF supplement (Plumpynut®) of 500 kcal/day for 2 weeks
89205992|NCT00819858|No Intervention|control|no supplement given
89205993|NCT00819936|Experimental|2|Backward walking,
89205994|NCT00819936|Active Comparator|1|Forward walking
89501491|NCT02223481|Experimental|Terbogrel high dose|
89205995|NCT00527488|Experimental|Degarelix 16+16 mg|
89205996|NCT00527488|Experimental|Degarelix 32 mg|
89501492|NCT02223481|Placebo Comparator|Placebo|
89501493|NCT02146781|Placebo Comparator|0.80 mL Saline Placebo Cohort 1|"Healthy male and female subjects 18 to 63 years of age, who have lived in Japan and are skin test positive or negative at Screening to Japanese Red Cedar, Mountain Cedar and/or CryJ2 allergens.~Cohort # 1: Subjects will receive four 0.200 mL volume intradermal injections of saline control as a placebo control using the Biojector device.~Intervention: Saline Control via Intradermal route."
89501494|NCT02146781|Experimental|2.16 mg of CryJ2-DNA-LAMP plasmid vaccine Cohort 2|"Healthy male and female subjects 18 to 63 years of age who have lived in Japan and are skin test positive at Screening to Japanese Red Cedar, Mountain Cedar and/or CryJ2 allergens and have a history of allergic rhinitis symptoms during the Japanese Red Cedar or Mountain cedar pollen seasons.~Cohort # 2: Subjects receive four (4) injections of 0.200 mL volumes (2.7 mg/mL) for a single dose of 2.16 mg of CryJ2-DNA-LAMP plasmid vaccine; intradermally (ID) administered using the Biojector device (each dose administered by separate Biojector device injections at different skin sites. These subjects will receive the same batch vaccine used in Phase 1A and 1B~Intervention: Biological/Vaccine: CryJ2-DNA-LAMP plasmid vaccine by intradermal injection"
89501495|NCT02146781|Experimental|1.08 mg CryJ2-DNA-LAMP plasmid vaccine Cohort 3|"Healthy male and female subjects 18 to 63 years of age who have lived in Japan and are skin test positive at Screening to Japanese Red Cedar, Mountain Cedar and/or CryJ2 allergens and have a history of allergic rhinitis symptoms during the Japanese Red Cedar or Mountain cedar pollen seasons.~Cohort # 3: Subjects will receive two (2) injections of 0.200 mL (2.7 mg/mL) for a single dose intradermally (ID) for a single dose of 1.08 mg CryJ2-DNA-LAMP plasmid vaccine administered using the Biojector device, each dose administered by separate Biojector device injections at different skin sites. These subjects will receive the same batch vaccine used in Phase 1A and 1B~Intervention: Biological/Vaccine: CryJ2-DNA-LAMP plasmid vaccine by intradermal injection"
89205997|NCT00527488|Experimental|Degarelix 32+32 mg|
89205998|NCT00527488|Experimental|Degarelix 64 mg|
89205999|NCT00820014|Experimental|1|ESBA105 eye drops
89206000|NCT00820014|Placebo Comparator|2|Placebo control (vehicle)
89206001|NCT00825864|Active Comparator|1diclofenac drops treatment|four times a day for 3 months
89206002|NCT00825864|Active Comparator|2dexamethasone drops|
89206003|NCT00916799|Experimental|Oximeter arm and non-oximetry arm|
89206004|NCT00825942|Experimental|C-KAD Ophthalmic Solution|
89206005|NCT03991793||Sepsis|Severe sepsis or septic shock (2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definition Conference)
89206006|NCT03991793||Control|Absence of severe sepsis or septic shock (2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definition Conference)
89206007|NCT00823446|Experimental|Revera Wound Care|
89206008|NCT00823446|Placebo Comparator|Normal Saline|
89206009|NCT00527332|Active Comparator|A|Spinal anesthesia combined with intrathecal morphine. Spinal anesthesia applied in intervertebral space L3/L4 or L2/L3 with hyperbaric bupivacaine 20 mg and morphine 0.2 mg intrathecally. Sedation with propofol.
89206010|NCT00527332|Active Comparator|B|General anesthesia. General anesthesia induced with propofol, fentanyl and rocuronium, and maintained with propofol and oxygen in air. Rocuronium and fentanyl repeated when needed.
89501496|NCT04203667|Other|EndoRotor Resection Arm|All participants enrolled in this study will undergo treatment with the EndoRotor during colonoscopy for endoscopic mucosal resection in the colon to resect and remove tissue, not intended for biopsy, of the gastrointestinal system including post-endoscopic endoscopic mucosal resection of tissue persistence with a scarred base and residual tissue from peripheral margins following endoscopic mucosal resection.
89501497|NCT02393469|Placebo Comparator|Group phase 1|Two months of education and self-management for COPD where patients know their disease, pathophysiology, treatment, exacerbation of symptoms, and better ways pharmacological treatment education will be conducted through a system of multidisciplinary lessons with professional Physiotherapists, Psychologists, Dieticians, Pharmacists , Physical Education Professionals and Doctors
88956328|NCT05551975|Active Comparator|Control Product|Control Human Milk Fortifier added to human milk feedings
88956329|NCT05551975|Experimental|Product 1|Study Human Milk Fortifier added to human milk feedings
88956330|NCT05551975|Experimental|Product 2|Study Human Milk Fortifier added to human milk feedings
89206011|NCT00820092|Active Comparator|Xerecept 1.0|1.0 ug/kg/hr hCRF -24 hour IV infusion
89206012|NCT00820092|Active Comparator|Xerecept 2.0|2.0 ug/kg/hr-24 hour IV infusion
88956333|NCT05544929|Experimental|Single-agent KFA115|KFA115 monotherapy
88956334|NCT05544929|Experimental|KFA115 run-in (1 cycle) + pembrolizumab|1-cycle KFA115 run-in followed by addition of pembrolizumab
88956335|NCT05544929|Experimental|KFA115 + pembrolizumab|KFA115 + pembrolizumab combination given concurrently
88956336|NCT05544357|Experimental|Resistance training with short set configuration performed by normotensive postmenopausal women|Normotensive postmenopausal women performing resistance training protocol with the lowest cardiovascular stress identified in the first study of the project. It can be expected to be a short set configuration protocol
88956337|NCT05544357|Experimental|Resistance training with short set configuration performed by hypertensive postmenopausal women|Hypertensive postmenopausal women performing resistance training protocol with the lowest cardiovascular stress identified in the first study of the project. It can be expected to be a short set configuration protocol
88956338|NCT05544357|Experimental|Resistance training with long set configuration performed by normotensive postmenopausal women|Normotensive postmenopausal women performing resistance training protocol with the highest cardiovascular stress identified in the first study of the project. It can be expected to be a long set configuration protocol
89206013|NCT00820092|Active Comparator|Xerecept 3.0|3.0 ug/kg/hr-24 hour infusion
89501498|NCT02393469|Experimental|Group phase 2|Pulmonary rehabilitation for two months: The same patients enter phase 1 phase 2 performing this two months of pulmonary rehabilitation are also included new patients who participate directly in phase 2
89501499|NCT02393469|Experimental|Group phase 3|Pulmonary rehabilitation for ten months: Participate participants of phases 1 + 2 and 2, as well as new participants enter directly in phase 3
89501500|NCT02782169|Active Comparator|Pregabalin|
89501501|NCT02782169|Placebo Comparator|Placebo|
89501502|NCT02223559||right heart catheterization patients|
89501503|NCT02228941||gene mutation|
89501504|NCT02393313|Experimental|Cataract surgery toric intraocular lens|Rayner T-flex Toric IOLs (573T / 623T; Rayner Intraocular Lenses Ltd,East Sussex, United Kingdom) will be implanted in the lens capsule
89501505|NCT02146859||general anesthesia|Patient having general anesthesia
89501506|NCT04163185|Experimental|AXS-07|Taken once upon migraine
89501507|NCT04163185|Placebo Comparator|Placebo|Taken once upon migraine
89501508|NCT02393391|Active Comparator|NIBS tDCS/tACS stimulation|Each patient will undergo initial diagnosis with NIBS algorithm utilizing EEG measurements combined with TMS. Initial diagnosis will last 10 minutes in which EEG measurement will be recorded 5 minutes and then in combination with TMS for another 5 minutes with no more than 500 TMS stimuli applied to cortex at low frequency of up to 5Hz. EEG recording will be analyzed by NIBS algorithm which will propose a course of treatment with the following limitations: stimulation of 2mA (32, 33) current after 30 seconds ramp up of 0.1mA increments, 20 min for each session, twice a week
89501509|NCT02393391|Placebo Comparator|inactive electrodes|diagnosis and monitoring will be performed as in active treatment, but during treatment anodal/cathodal/alternate stimulation will begin and automatically stop after 30 seconds leaving subject with an inactive electrodes in place for the remainder of treatment duration
89501510|NCT02149901|Experimental|Pseudoephedrine + 480 ml water|Pseudoephedrine 30 mg PO 45 minutes before water 480 ml
89501511|NCT02149901|Placebo Comparator|Pseudoephedrine + 50 ml water|Pseudoephedrine 30 mg PO 45 minutes before water 50 ml
89501512|NCT02149901|Experimental|Placebo + 480 ml water (optional)|Placebo PO 45 minutes before water 480 ml
89501513|NCT02149901|Placebo Comparator|Placebo + 50 ml water (optional)|Placebo PO 45 minutes before water 50 ml
88956339|NCT05544357|Experimental|Resistance training with long set configuration performed by hypertensive postmenopausal women|Hypertensive postmenopausal women performing resistance training protocol with the highest cardiovascular stress identified in the first study of the project. It can be expected to be a long set configuration protocol
89502012|NCT05496218|Experimental|Endometriosis group|Endometriosis group are women aged 18-45 with a histologically confirmed diagnosis of endometriosis. At study entry, we will collect morning blood samples.
89023483|NCT05367999||Patients presenting with TLOC|A concurrent nested qualitative-quantitative design is used. Patients first presenting to an ED with TLOC (and witnesses) who have contributed to the quantitative part of this project will be offered participation in a qualitative interview study after completion of the iPEP during the initial study procedure. Capturing variation based on diagnosis, gender, age and participant/witness role, a purposive sample of participating participants and witnesses will be invited to semi-structured interviews in which they will be prompted to discuss their experiences of using the iPEP and their views on the accuracy in describing their peri-episodal experiences.
89023484|NCT05356403|Experimental|Difelikefalin 1 mg Oral Tablet|Patients receive oral difelikefalin 1 mg once daily
89023485|NCT05356403|Placebo Comparator|Placebo Oral Tablet|Patients receive oral placebo once daily
89501514|NCT04440267|Experimental|single arm|Patients will receive acute lymphoblastic leukemia (ALL) -based chemotherapy and are permitted to receive allogeneic hematopoietic stem cell transplantation (HSCT) in CR. Otherwise, they will finish the consolidation chemotherapy. Patients with t(9;22) will receive chemotherapy combined with tyrosine kinase inhibitors.
89023486|NCT05355415||Outer retinal disease|Subjects with outer retinal disease affecting the photoreceptor-retinal pigment epithelium complex will be classified by clinical exam by an experienced retina specialist. Outer retinal disease subjects will undergo adaptive optics (AO) imaging of several macular locations.
89023487|NCT05355415||Healthy control|Age-matched healthy control subjects will undergo the same AO imaging procedures as subjects with outer retinal diseases.
89023488|NCT05351385||Covid +|Patients SARS-CoV-2 positive.
89501515|NCT02043847|Experimental|Cohort 1Total Marrow Irradiation (TMI) 3Gy|3Gy with standard high dose melphalan prior to autologous stem cell rescue
89501516|NCT02043847|Experimental|Cohort 2 Total Marrow Irradiation (TMI) 6Gy|6Gy with standard high dose melphalan prior to autologous stem cell rescue
89501517|NCT02043847|Experimental|Cohort 3 Total Marrow Irradiation (TMI) 9Gy|9Gy with standard high dose melphalan prior to autologous stem cell rescue
89501518|NCT02143037|Active Comparator|Control Group|usual care
89501519|NCT02143037|Experimental|Experimental Group|usual care plus prize contingency management for attending treatment
89501520|NCT02564042|Experimental|GSK2894512 1% cream twice daily|Subjects will apply a thin layer of GSK2894512 1% (10 milligram per gram [mg/g]) topical cream twice daily (morning and evening) for 12 weeks, to all psoriasis lesions (except on the scalp).
89501521|NCT02564042|Experimental|GSK2894512 1% cream once daily|Subjects will apply a thin layer of GSK2894512 1% (10 mg/g) topical cream once daily (evening) for 12 weeks, to all psoriasis lesions (except on the scalp).
89501522|NCT02564042|Experimental|GSK2894512 0.5% cream twice daily|Subjects will apply a thin layer of GSK2894512 0.5% (5 mg/g) topical cream twice daily (morning and evening) for 12 weeks, to all psoriasis lesions (except on the scalp).
89501523|NCT02564042|Experimental|GSK2894512 0.5% cream once daily|Subjects will apply a thin layer of GSK2894512 0.5% (5 mg/g) topical cream once daily (evening) for 12 weeks, to all psoriasis lesions (except on the scalp).
89501524|NCT02564042|Placebo Comparator|Vehicle cream twice daily|Subjects will apply a thin layer of vehicle topical cream twice daily (morning and evening) for 12 weeks, to all psoriasis lesions (except on the scalp).
89501525|NCT02564042|Placebo Comparator|Vehicle cream once daily|Subjects will apply a thin layer of vehicle topical cream once daily (evening) for 12 weeks, to all psoriasis lesions (except on the scalp).
89501526|NCT05745051|Experimental|Evaluate the safety and effectiveness of CVA-FLOW Software Device for acute ischemic stroke|The purpose of this study is to demonstrate the effectiveness and safety of CVA-FLOW, a digital health AI based Telestroke system developed by CVAID Ltd. Company aims to assist certified medical staff to triage acute ischemic stroke patients using dedicated algorithms in order to support application for market approval for CVA-FLOW device.
89501527|NCT02149979|Experimental|Temperature Controlled Laser Soldering|Efficacy and safety of Temperature Controlled Laser Soldered wound incisions closure
89501528|NCT04156633||conventional identification methods (controls)|Patients with positive blood cultures from 2016 to 2018 receiving a conventional identification methods (controls). The conventional identification method consisted in general of an over-night subculture and subsequent identification of the bacterial pathogen using either biochemical profiling or MALDI-TOF MS.
89501529|NCT04156633||new identification method (cases)Biofire FilmArray© BCID panel|Patients with positive blood cultures from 2018 and 2019 receiving a new identification method (cases). The new identification method is the Biofire FilmArray© Blood Culture Identification (BCID) panel, a polymerase chain reaction-based method, performed directly from the positive blood culture without the need of subculture to reach single bacterial colonies. The assays allow to identify a panel of 20 most commonly Gram-positive and -negative bacteria and yeast causing blood stream infections. It also allows to determine three resistance genes (mecA, vanA/B and KPC).
89501530|NCT04156633||new identification method (cases) WGS approaches|Patients with positive blood cultures from 2018 and 2019 receiving a new identification method (cases). The new identification of positive blood cultures methods in a subset of patients is a whole genome sequencing approach. This so called shotgun metagenomic approach allows to sequence the whole genome (WGS) of pathogens and thereby potentially detect every potential pathogen and also resistance and virulence gene.
89501531|NCT02146937|Experimental|Combination therapy- bicalutamide and finasteride|3-month (90-day) course of bicalutamide 50 mg by mouth daily and finasteride 5 mg by mouth daily
89501532|NCT02229019|Experimental|Volunteer mealtime assistance|Trained volunteers will provide mealtime assistance to older hospital inpatients at one mealtime each weekday.
89501533|NCT05744895||Prospective Group- Robotic TKA Arm|Prospective TKA patient receiving total knee arthroplasty using the MAKO robotic machine
89023489|NCT05351385||Control|Patients with Pneumonia non-SARS-CoV-2 related
89023490|NCT05344573||Non-pulsatile cardiopulmonary bypass|Subjects who undergo cardiac surgery with non-pulsatile cardiopulmonary bypass
89023491|NCT05344573||Pulsatile cardiopulmonary bypass|Subjects who undergo cardiac surgery with pulsatile cardiopulmonary bypass
89206014|NCT00823524|Experimental|donor NK cell infusion|give patients donor-derived NK cells 2 to 3 weeks after HLA-haploidentical hematopoietic cell transplantation
89206015|NCT05269810|Experimental|Group 1|SA001 Low dose
89206016|NCT05269810|Experimental|Group 2|SA001 Mid dose
89501534|NCT05744895||Control- manual total Knee arthroplasty|Patients who have had a manual total knee arthroplasty
89501535|NCT02229097|Experimental|Normal then Coordinated|normal bolus during 2 weeks then coordinated bolus during 2 weeks
88956343|NCT05524792||COVID-19|no interventional study
89501536|NCT02229097|Experimental|Coordinated then Normal|coordinated bolus during 2 weeks then normal bolus during 2 weeks
89501537|NCT03166995|Experimental|Experimental group 1|Low impact aerobic exercise group. 1hour, twice a week
89501538|NCT03166995|Experimental|Experimental group 2|Postural exercises group. 1hour, twice a week
89501539|NCT03166995|No Intervention|Control propriocepcion|No exercise, just proprioceptive control.
89501540|NCT03166917|Experimental|3D printing implant|3D printing implant in bone defect
89501541|NCT03166917|Placebo Comparator|Autogenous bone grafting|autogenous bone grafting in bone defect
89501542|NCT02147015|Experimental|Personalized variable dose of glucocorticoids arm|Use of personalized variable dose of glucocorticoids according to a rating scale starting from the first day of hospitalization for 5 days, together with other necessary treatments, including antibiotics, Inhaled corticosteroid (ICS), long-acting beta2-agonist (LABA), Long-Acting Muscarinic Antagonists(LAMA), short-acting beta2-agonist (SABA), and other physical treatments.
89501543|NCT02147015|Other|Fixed dose of glucocorticoids arm|Use of fixed term of glucocorticoids (40mg) starting from the first day of hospitalization for 5 days, together with other necessary treatments, including antibiotics, ICS, LABA, LAMA, SABA, and other physical treatments.
89501544|NCT03166683|Experimental|Hemopatch|Use of hemopatch like a control of bile leakage/sealant during liver resection surgery.
89501545|NCT03166683|Active Comparator|Standard of care|Application of standards of care, may include other sealant / hemostatic devices as patches or liquid/gels, during liver resection surgery.
89501546|NCT02229175|Experimental|IVB + laser|Intravitreal bevacizumab (IVB) will be administered at baseline, month 1, and month 2, consistent with previous DME trials. Subvisible laser treatment will be administered at baseline. Patients will then undergo monthly surveillance, as they would with standard of care treatment, allowing for retreatment with monthly IVB and laser therapy every 3 months if defined retreatment criteria are met, as described below.
89501547|NCT02229175|Active Comparator|IVB only|IVB monthly at baseline, month 1, and month 2. Patients will then undergo monthly surveillance, as they would with standard of care treatment, allowing for retreatment with monthly IVB if defined retreatment criteria are met, as described below. Patients will also undergo sham laser treatment (patient will be placed in front of laser but no laser will be activated) to mask the patient to the treatment.
89501548|NCT03544697||Skin expansion and repair with flaps|The tissue expander was inserted into the scalp in 17 patients and supraclavicular area in two patients.
89501549|NCT04947007|Active Comparator|Group 1|In this group, US guided suprascapulary and axillary nerve block will be performed with 15cc+15c local anesthetic.
88956344|NCT05524792||Control I: No COVID-19|no interventional study
88956345|NCT05524792||Control II: Influenza 2018|no interventional study
88956346|NCT05524792||Control III: Historical 2018|no interventional study
88956347|NCT05514496|Experimental|Part 1: NX-019 Dose Escalation|Patients will be treated with NX-019 in multiple ascending cohorts.
88956348|NCT05514496|Experimental|Part 2: NX-019 Dose Expansion|Patients will be treated with the REDs of NX-019 as determined in Part 1.
89501550|NCT04947007|Active Comparator|Group 2|In this group, US guided suprascapulary and axillary nerve block will be performed with 10cc+10c local anesthetic.
89501551|NCT04947007|Active Comparator|Group 3|In this group, US guided suprascapulary and axillary nerve block will be performed with 5cc+5c local anesthetic.
89501552|NCT04947007|Active Comparator|Group 4|In this group, US guided suprascapulary and axillary nerve block will be performed with serum physiologic.
89501553|NCT02147171|Active Comparator|Active lutein group|44 participants taking VisionAce daily for a period of 1 year
89501554|NCT02147171|Placebo Comparator|Placebo group|44 participants taking placebo daily for a period of 1 year
89501555|NCT04104685|Experimental|FCD105 Foam|FCD105 Foam
89501556|NCT04104685|Active Comparator|3% Minocycline Foam|3% Minocycline Foam
89501557|NCT04104685|Active Comparator|0.3% Adapalene Foam|0.3% Adapalene Foam
89501558|NCT04104685|Placebo Comparator|Vehicle Foam|Vehicle Foam
89501559|NCT02147249|Experimental|erythema migrans patients treated with antibiotics|adult patients with erythema migrans will be treated with oral antibiotics
89501560|NCT02393235||unexplained infertility(n:75)|Ovarian, uterine and spiral artery pulsatility index and resistance index will measure with doppler ultrasonography in the mid-luteal phase. ( 21th day)
89501561|NCT02393235||tubal infertility(n:75)|Ovarian, uterine and spiral artery pulsatility index and resistance index will measure with doppler ultrasonography in the mid-luteal phase. ( 21th day)
89501562|NCT02393235||fertile group(n:75)|Ovarian, uterine and spiral artery pulsatility index and resistance index will measure with doppler ultrasonography in the mid-luteal phase. ( 21th day)
89501563|NCT02392845|Experimental|Combination of Docetaxel (DTX) and Epirubicin (EPI)|
89501564|NCT03166839||Region 1: Africa|Women living in and experiencing PPH in countries located in Africa.
89501565|NCT03166839||Region 2: Asia|Women living in and experiencing PPH in countries located in Africa.
89501566|NCT03166839||Region 3: Europe, NA, SA, Aus|Women living in and experiencing PPH in countries located in Africa.
89501567|NCT02229253||Degarelix|Treatment according to standard clinical practice.
89501568|NCT02393001||Dermatology patients|Patients seen in the dermatology clinic with suspicious skin lesion to be biopsied will have 4 skin swabs, 2 of the skin lesion and 2 of an area of unafflicted skin.
89501569|NCT03166293|Experimental|Immediate Group|Children will participate in intensive leg training with a physical therapist 1 hour/day, 4 days/week for 12 weeks. Children will continue to receive standard physical therapy care. Children will be followed for one year from the time of enrollment in the study.
89501570|NCT03166293|Experimental|Delay Group|Children will be monitored for 3 months with no intervention. Children will participate in intensive leg training with a physical therapist after the 3 month delay period. Training will be 1 hour/day, 4 days/week for 12 weeks. They will continue to receive standard care throughout. Children will be followed for one year from the time of enrollment in the study.
89501571|NCT03166605|No Intervention|Control|"First group: Control~Follow the current standard protocol used at Albany Medical Center that includes:~Do not drink anything for an additional 2 hours after swallowing pill cam. After which patient may drink clear liquids~Do not eat solid food until 4 hours after swallowing. After which patient may eat light that includes soup, toast.~Return to clinic (RTC) 8 hours after to remove equipment~Avoid carbonated beverages and gas forming foods for the completion of the 8-hours study period"
89501572|NCT03166605|Sham Comparator|Sham|"Receive 3 ml simethicone 20 minutes prior to capsule swallowing~Do not drink anything for an additional 2 hours after swallowing pill cam. After which patient may drink clear liquids~Do not eat solid food until 4 hours after swallowing. After which patient may eat light that includes soup, toast.~Return to clinic (RTC) 8 hours after to remove equipment~Avoid carbonated beverages and gas forming foods for the completion of the 8-hours study period."
88956349|NCT05511675|No Intervention|control group|Patients who are in the control group will receive standard clinical care and pain level and hematoma condition will be recorded. In addition usage time of the TR band will be in accordance with the manufacturer's guidelines and will be recorded with the help of a chronometer.
88956350|NCT05511675|Experimental|experimental group I|Study group I patients will have cold application twice for a twenty minute period each time. For study group I extremity pain and hematoma will be followed and the TR band will be removed after one and a half hours.
88956351|NCT05511675|Experimental|experimental group II|Study group II patients will have cold application twice for a twenty minute period each time and extremity pain and hematoma will be followed but the TR band will be removed in accordance with manufacturer's guidelines as in the control group.
89206017|NCT05269810|Experimental|Group 3|SA001 High dose
88956353|NCT05507346|Experimental|Dayspring, Non-Pneumatic Active Compression Device (NPCD)|The Dayspring, an Non-Pneumatic Active Compression Device (NPCD) Active Wearable Compression Device is an FDA cleared calibrated active gradient pressure compression garment that is segmental and programmable and applies controlled sequential pressure from the distal to proximal-end of the limb in a cyclic manner.
88956354|NCT05507346|Active Comparator|Advanced Pneumatic Compression Device (APCD)|A commercially available advanced pneumatic compression device that is FDA-cleared for the same indication for use as the Dayspring Wearable Compression Device.
88956355|NCT05505825|Experimental|AK104 once every 3 weeks and Chiauranib once a day|Subjects receive AK104 once every 3 weeks plus Chiauranib once a day until intolerable toxicity, no more clinical benefit as judged by the investigator, or completion of 24 months of treatment, or meeting other criteria for termination of treatment in the protocol, whichever occurs first.
88956356|NCT05500222|Active Comparator|Resmetirom|80 mg daily
88956357|NCT05500222|Placebo Comparator|Placebo|matching placebo daily
88956358|NCT05494658|Experimental|research group|600ml drink which contains 18g BCAA was consumed by patients 2-4h before surgery.
88956359|NCT05494658|Placebo Comparator|control group|600ml water was consumed by patients 2-4h before suegery.
89501573|NCT03166605|Experimental|Experiment|"Receive 3 ml simethicone 20 minutes prior to capsule swallowing.~Receive 3 ml simethicone 1 hours after capsule swallowing~Receive 1.5 ml simethicone 2 hours after capsule swallowing~Do not drink anything for an additional 1 hour after taking last simethicone dose. After which patient may drink clear liquids~Do not eat solid food until 4 hours after swallowing. After which patient may eat light that includes soup, toast.~Return to clinic (RTC) 8 hours after to remove equipment~Avoid carbonated beverages and gas forming foods for the completion of the 8-hours study period."
89501574|NCT03166527|Other|Open Label study|open label study using Panzyga immune globulin 10% intravenous solution with no placebo.
89501575|NCT02151383|Experimental|Serelaxin|Serelaxin was administered intravenously on top of standard therapy for acute heart failure, for a total of 48 hours.
89501576|NCT02229409|No Intervention|Control|Observation only, no behavioral intervention
89501577|NCT02229409|Experimental|Intervention|Intervention Walkadoo.
89501578|NCT03698864|Experimental|PCS499 900mg twice a day|
89501579|NCT02392533||Pre cohort group|Following 3 months of data collection (pre-cohort group), education regarding the documented intervertebral space versus the actual intervertebral space that the neuraxial anesthetic was administered will be provided to each anesthesiologist and resident. Following delivery of this information, an additional 3 months of data collection will be performed (post-cohort group) (the same as the first 3 months) to evaluate whether a practice change took place.
88956360|NCT05491226|Experimental|Pembrolizumab with Radiation Therapy and Axatilimab|
89206018|NCT05269810|Placebo Comparator|Placebo|Placebo
88956361|NCT05477524|Experimental|VLA15 Lot 1 (3-dose primary vaccination series and booster dose)|Shot in the deltoid muscle (preferable in the nondominant arm)
88956362|NCT05477524|Experimental|VLA15 Lot 2 (3-dose primary vaccination series and booster dose)|Shot in the deltoid muscle (preferable in the nondominant arm)
88956363|NCT05477524|Experimental|VLA15 Lot 3 (3-dose primary vaccination series and booster dose)|Shot in the deltoid muscle (preferable in the nondominant arm)
88956364|NCT05477524|Placebo Comparator|Placebo (3-dose primary vaccination series and booster dose)|Shot in the deltoid muscle (preferable in the nondominant arm)
89501580|NCT02392533||Post cohort group.|Following 3 months of data collection (pre-cohort group), education regarding the documented intervertebral space versus the actual intervertebral space that the neuraxial anesthetic was administered will be provided to each anesthesiologist and resident. Following delivery of this information, an additional 3 months of data collection will be performed (post-cohort group) (the same as the first 3 months) to evaluate whether a practice change took place.
89501581|NCT04043923|Experimental|Norketotifen|Norketotifen oral capsules, once daily for 5 days
89501582|NCT04043923|Placebo Comparator|Placebo|Placebo oral capsules, once daily for 5 days
89501583|NCT02147483|Active Comparator|Treatment as usual|Treatment as usual as prescribed by clinician.
89501584|NCT02147483|Experimental|Mindfulness Based Relapse Prevention|Mindfulness based relapse prevention will be provided in eight in person sessions to prevent alcohol use.
89501585|NCT02147639|Experimental|Sodium Nitrate|Patients will ingest a single oral dose of sodium nitrate (~8.4 mmol)
89501586|NCT02147639|No Intervention|Baseline|This is a baseline study visit, which will serve to assess inclusion and exclusion criteria, as well as provide untreated measurments of skeletal muscle blood flow and perfusion.
89501587|NCT02147639|Experimental|Dose-escalation trial|This is an optional study visit, where subjects will ingest twice the dose of sodium nitrate (~16.8 mmol).
89501588|NCT02147639|Placebo Comparator|Placebo-control trial|This is an optional study visit, where patients will ingest a placebo.
89501589|NCT02147639|Experimental|Increased exercise intensity|This is an optional study visit, where patients will be asked to repeat all of the blood flow assessments, but the exercise intensity will be increased.
89501590|NCT02147717|Experimental|Laser stimulation|"Laser stimulation plus opioid treatment before ETS. Low level laser acupuncture, 670 nm, 10Hz, 0,3 J per acupoint, 6 points per neonate (Zu san li, He Gu, Nei Guan) marquage CE, premio 30 laser duo de Sedatelec. Overall 3 minutes of treatment.~This sequence will be repeated 4 times during the study (1 hour before surgery and every 12 hours after surgery)"
89501591|NCT02147717|Placebo Comparator|fake laser stimulation|newborns have the same preparation procedure as the intervention to put them under the same conditions group. The laser pen is turned off, off-voltage
89501592|NCT02695719|Experimental|Lubiprostone 24 μg|Lubiprostone 24 μg, capsules, orally, twice daily, under fed conditions, for 4 weeks.
89501593|NCT02695719|Placebo Comparator|Placebo|Lubiprostone placebo-matching capsules, orally, twice daily, under fed conditions, for 4 weeks.
89501594|NCT03652454|Experimental|micro-osteoperforation|Propel device (ABD) Micro-osteoperforations were performed in the keratinized tissue. Micro-osteoperforations were 1.5 mm in diameter and 3-7 mm in depth.
89501595|NCT03652454|Other|conventional treatment|conventional fixed appliance treatment
89501596|NCT02150135|Experimental|Oncothermia group|Patients were treated with oncothermia 2 or 3 times a week. Treatment was performed for about 1 hours per each visits.
89501597|NCT03543059||exposure group|exposed to some factors
89206019|NCT04017156|Experimental|Test site (torque of <10 Ncm)|The test sites (<10 Ncm) will be over-prepared with drills of larger diameter
89206020|NCT04017156|Other|Control site (torque of ~30 Ncm)|the standard sites (~30 Ncm)will be prepared with the corresponding drills suggested by the manufacturer
89501598|NCT03543059||control group|not exposed to some factors
89206021|NCT00823602|Experimental|1|"GnRH antagonist ganirelix 0.25 mg fromm 6th ovarian stimulation"
88956367|NCT05473065|Experimental|Multiaxial Prosthetic Foot Emulator (PFE)|The multiaxial Prosthetic Foot Emulator (PFE) is a customizable robotic prosthetic foot that can mimic commercial feet to predict how prosthesis users will respond to candidate feet. Participants will walk with the PFE using three different modes (emulating three commercial feet) under different walking conditions.
88956368|NCT05473065|Active Comparator|Commercially available prosthetic feet|Participants will walk under different walking conditions using three different commercial prosthetic feet.
88956369|NCT05471544|Experimental|Sulfadoxine-Pyrimethamine + Amodiaquine (SPAQ)|Children aged 3-59 months will receive SPAQ in the intervention arm
89501599|NCT03166449|Experimental|Neomune|18 patients with traumatic brain injury were given Neomune as enteral nutrition.
89501600|NCT03166449|Active Comparator|Fresubin® HP energy|18 patients with traumatic brain injury were given Fresubin® HP energy as enteral nutrition.
89501601|NCT05498012|Placebo Comparator|Placebo group|Dental gel applied by dentist after oral hygiene (no cannabidiol). Toothpaste for daily use as needed for patients (no cannabidiol).
89501602|NCT05498012|Experimental|CBD group|Dental CBD (cannabidiol) gel applied by dentist after oral hygiene. CBD toothpaste for daily use as needed for patients.
89501603|NCT05498012|Active Comparator|Corsodyl group|Corsodyl dental gel applied by dentist after oral hygiene. Toothpaste for daily use as needed for patients (no cannabidiol).
89206022|NCT00823602|Active Comparator|2|GnRH agonist, suprefact, stimulation with a standard long protocol
89206023|NCT00820326|Active Comparator|Dolasetron|Patients will receive dolasetron at a dose of 12.5 mg / day for 4 days at J0, M1, M2 and M3
88956370|NCT05471544|No Intervention|Control|Children aged 3-59 months will not receive SPAQ in the control arm
89206024|NCT00820326|Placebo Comparator|Placebo|Patients will receive placebo everyday for 4 days at J0, M1, M2 and M3
89206025|NCT04602286|Experimental|Mindfulness meditation|"focussed attention mindfulness meditation technique taught as means to reduce pain intensity and unpleasantness."
88956373|NCT05455658|Experimental|Prevention (STEMVAC vaccine, sargramostim)|Patients receive STEMVAC vaccine with sargramostim ID every month for 3 months in the absence of disease progression or unacceptable toxicity. Patients then receive STEMVAC vaccine with sargramostim ID booster injections 3 months after the 3rd vaccination and 6 months after the 1st booster vaccination.
88956374|NCT05447689|Experimental|Integrative-Mind-Body Skills Group|Treatment group
88956375|NCT05447689|No Intervention|Control|Control group: Treatment-As-Usual (TAU) and mind-body skills reading materials.
89206026|NCT04602286|Sham Comparator|Specific sham mindfulness meditation|a training session designed to specifically match the real mindfulness training while lacking the proposed active elements of mindfulness training. Delivered as a means to elicit placebo-mediated (but not mindfulness-mediated) reductions in pain intensity and unpleasantness
89206027|NCT04602286|Sham Comparator|General sham mindfulness meditation|a training session designed to generally match focussed-attention mindfulness meditation while maintaining greater distance from proposed mindfulness mechanisms. Delivered as a means to elicit placebo-mediated (but not mindfulness-mediated) reductions in pain intensity and unpleasantness
89206028|NCT04602286|No Intervention|Book listening control|"this group completes no meditation training. They listen to a spoken excerpt from the audiobook The Natural History and Antiquities of Selborne"
88956379|NCT05445141|Experimental|Intervention|Parents included in the intervention group will be offered to participate in four meetings that are taking place during four weeks time. The focus of the meetings is on how to promote parent-infant relationship. The theoretical base is positive developmental psychology including research on attachment, parenting and co-parenting, emotional regulation, and observational learning/role models. Roleplays, video-clips, discussions, and individual reflections are used to empower families during the sessions. Parents are encouraged to try the content with their child between the sessions and will be provided a printed material.
88956380|NCT05445141|Sham Comparator|Control|Parents in the control group will via a web-based portal be able to view four pre-recorded lectures during four weeks. The lectures will be around 10 minutes long and have a content similar to the group meetings that are offered to the intervention group but more superficial and without printed material and reflection practices.
88956381|NCT05441696||Adult CHF subjects with initial high CVP|Adult subjects with congestive heart failure diagnosis who have an indicated high non-invasive estimated central venous pressure on first measurement after clinical unit admission.
88956382|NCT05441696||Adult CHF subjects with initial low CVP|Adult subjects with congestive heart failure diagnosis who have an indicated low non-invasive estimated central venous pressure on first measurement after clinical unit admission.
88956383|NCT05440409||1|Retrospective chart review of children and adults with cancer enrolled on immunotherapy treatment protocols
89206029|NCT00752609|Experimental|Peginesatide|
89206030|NCT03684304|No Intervention|Control / No Binder|Patients randomized to routine care / no abdominal binder use will not use an abdominal binder during their post operative course.
89206031|NCT03684304|Experimental|Abdominal binder|Patients randomized abdominal binder use will have an abdominal binder placed on them in the operating room once their surgery has been completed.
89206032|NCT04023539|Active Comparator|Intervention group|Daily supplement of 2 g cinnamomum zeylanicum orally (capsules) for a period of 90 days
89206033|NCT04023539|Placebo Comparator|Control group|Daily placebo capsules orally (wheat flour without any active compound) for a period of 90 days.
89206034|NCT04093583|Active Comparator|Simple suture|
89206035|NCT04093583|Experimental|PRGF-Endoret|
89206036|NCT00916097|Experimental|1|docetaxel 75mg/m2 in combination with cisplatin 75mg/m2 given every 3 weeks for 3 cycles
89206037|NCT00629772|Placebo Comparator|Placebo then infliximab|Placebo at weeks 0, 2, 6 during the first intervention period and infliximab 5mg/kg at weeks 14, 16 and 20 during second intervention period.
89206038|NCT00629772|Active Comparator|Infliximab|Infliximab 5mg/kg at weeks 0, 2, 6, 14 and 22.
89206039|NCT00526630|Active Comparator|1. MPD|Randomized to receive active Methylphenidate first. At cross-over, participants will receive placebo.
89206040|NCT00526630|Placebo Comparator|2. Placebo|Randomized to receive placebo first. At cross-over, participants will receive the active Methylphenidate.
89206041|NCT00755183|Experimental|testosterone ophthalmic solution|testosterone ophthalmic solution 0.03%
89206042|NCT00755183|Placebo Comparator|vehicle|vehicle of testosterone ophthalmic solution
89206043|NCT00823758||1|Parents of children under 8 years of age who have ever given their children an over- the-counter medication.
89206044|NCT00823758||2|Adolescents who are 13 to 20 years of age who have ever heard of over-the-counter medication.
89206045|NCT00823758||3|Adults (21 years of age or older) who have used over-the-counter medication in the past 2 years.
89206046|NCT00823758||4|Primary care physicians will be Family Practitioners or General Internist, with an active Texas license, who devote at least 50% of their time to clinical practice.
89206047|NCT00823758||5|Pharmacists holding a PharmD degree and licensure in the state of Texas and work at least half-time in a community pharmacy setting.
89206048|NCT00826332|Active Comparator|Abdominal|Transabdominal ultrasound guided embryo transfer
89206049|NCT00826332|Active Comparator|Vaginal|Transvaginal ultrasound guided embryo transfer
89206050|NCT00526162|Experimental|Implantation of Consulta CRT-D|Patients have an implant attempt with a Bi-ventricular Implantable Cardioverter Defibrillator
89206051|NCT02600195|Experimental|EPIQ sites|Use Evidence-based Practice for Improving Quality (EPIQ) method to develop and implement evidence-based practice changes to reduce hospital-acquired infection
88956386|NCT05410106|Experimental|PneuX endotracheal tube|Patients will be intubated using the PneuX endotracheal tube system
88956387|NCT05410106|Active Comparator|Standard care|Patients will be intubated using standard endotracheal tube (Taperguard, Covidien).
88956388|NCT05406908|Experimental|fractionated-dose intradermal tozinameran|10 micrograms (0.1 mL) of tozinameran administered intradermally to the deltoid area of the non-dominant arm with a sterile 30-gauge needle.
88956389|NCT05406908|Active Comparator|standard intramuscular tozinameran|30 micrograms (0.3 mL) of tozinameran administered intramuscularly to the deltoid area of the non-dominant arm with a sterile 25-gauge needle.
88956390|NCT05405660|Experimental|barzolvolimab 150 mg in patients with Symptomatic Dermographism|barzolvolimab 150 mg injection subcutaneous every 4 weeks for 20 weeks
89206052|NCT02600195|No Intervention|Control sites|Continue current practices
89206053|NCT02550600|Experimental|Intervention group|Intervention: iLA activve treatment. iLA activve treatment also requires anticoagulation with un-fractionized heparin and pre-defined PTT-goals (45s-60s depending on blood flow).
89206054|NCT02550600|Active Comparator|Control group|"Controls: standard care according to good clinical practice and recent guidelines; no extracorporeal lung assist.~For ethical reasons patients of the control group can be treated with iLA activve after fulfilling the primary endpoint criterium of an increase in SOFA ≥3 points. These cross-over patients will be analyzed as controls (intention to treat)."
89206055|NCT03875482|Experimental|Risankizumab|Subcutaneous (SC), self-administered 150 mg doses of risankizumab at Weeks 0, 4, and 16
89206056|NCT03875482|Placebo Comparator|Placebo|Subcutaneous (SC), self-administered doses of placebo solution at Weeks 0, 4, and 16
89206057|NCT04095767|Experimental|Treatment arm|The thrombectomy in eligible patients will be carried out by making use of the device under investigation.
89206058|NCT00820404|Experimental|1|BLI-489
89206059|NCT00820404|Placebo Comparator|2|Placebo
89206060|NCT02600663||acute back pain|
89206061|NCT00820482|Active Comparator|Group A|Group A: 75 UI/day of Hp-hMG (Menopur®, Ferring, Copenhaghen, Dinamarca)
89206062|NCT00820482|Experimental|Group B|75UI/day of rFSH (Gonal®, Serono, Ginebra, Suiza) + 75UI/day of rLH (Luveris®, Serono, Ginebra, Suiza)
89206063|NCT00754793|Active Comparator|1|escitalopram 10mg - 30mg daily
89206064|NCT00754793|Placebo Comparator|2|
89206065|NCT00826410|Experimental|subcutaneous drain|"Use of subcutaneus suction drain (Redon) after laparotomy"
89206066|NCT00826488|Other|observational|Observational
88956391|NCT05405660|Experimental|barzolvolimab 300 mg in patients with Symptomatic Dermographism|barzolvolimab 300 mg injection subcutaneous every 8 weeks for 20 weeks
89206067|NCT04102397|Experimental|Standard plus Vojta therapy (SVT)|The physiotherapist's hands produce the activation with no need for medication or external equipment, thus guaranteeing the patient's safety.this therapy is able to change pathological patterns to painless patterns that reduce the use of energy caused by movement difficulty. The end result is to facilitate movement without strain.
89206068|NCT04102397|Active Comparator|Standard therapy (ST)|It consists of one or more of the following procedures: transcutaneous electrical nerve stimulation (TENS), ultrasound therapy, kinesiotherapy, and cryotherapy.
89206069|NCT00826566|Active Comparator|1|500 mg caffeine capsules per day
89206070|NCT00826566|Placebo Comparator|2|500 mg placebo capsules
89206071|NCT03999190||30 subjects with schizophrenia|
89206072|NCT03999190||30 healthy controls|
89206073|NCT04093817||on pump CABG|patients under going CABG with cardiopulmonary bypass machine
89206074|NCT04093817||off pump CABG|patients under going CABG without cardiopulmonary bypass machine
89206075|NCT05245162||Participants|Study participants with breast cancer
89206076|NCT05245162||Participants partner|Study participants partner
89501604|NCT02392689|Experimental|PCT-guided|"Blood samples are taken on day 0 and day 1 of the study. Procalcitonin (PCT) is measured and used support the decision on antibiotic therapy.~PCT levels above 0.2 ng/ml: antibiotic therapy is recommended PCT levels equal/below 0.2 ng/ml: antibiotic therapy is not recommended"
89538482|NCT02457689|Active Comparator|Group 4 (Electroporation and Active)|Group 4 (Electroporation and Active) Participants will receive 1.0ml intramuscular injections of the GTU®-MultiHIV B Clade Vaccine (2mg/ml) into the upper thigh using the ICHOR TriGridTM delivery system for intramuscular (TDS-IM) delivery with electroporation. Electroporation (EP) improves the delivery of the product into muscle cells, by delivering an electrical pulse with the injection using a hand held device that is pressed against your thigh. This will cause a muscle twitch with a sharp cramp-like feeling in the thigh lasting a few seconds. Once the procedure is carried out, the muscle will feel sore for up to 72 hours. The investigator will ask volunteers not to engage in any strenuous exercise for at least 24 hours after the procedure.
89210452|NCT05277870|Experimental|Nanodropper|Microdrops of IOP-lowering medications using Nanodropper adaptor
89538483|NCT03265691|Experimental|Early hyponatremia diagnosis and treatment|The early diagnosis of hiponatremia is not a stándar procedure. In the experimental arm, hyponatremia will be diagnosed and treated early.
89538484|NCT03265691|No Intervention|No intervention|Usual pattern of work will be performed in all patients who enter in Hospital. Duration: 6 months.
89538485|NCT03265847|Experimental|Culturally-tailored Safety Planning|Women in the intervention group receive the SDA intervention with the culturally-specific DA integrated as appropriate to the target group (i.e., immigrant, refugee or indigenous).
89538486|NCT03265847|No Intervention|Usual Care|The control group receive non-DA informed usual safety planning resources modeled on national and state domestic violence online resources, but not provided with immediate and visual feedback to their level of danger or a tailored safety planning.
89538487|NCT02458157|Experimental|Forced Fluid Removal|"The experimental intervention is guided by a therapeutic goal of average negative fluid balance ≥ 1 ml/kg/h and safety variables indicating inadequate circulation (lactate ≥ 4, MAP < 50 or mottling beyond the edge of kneecaps).~The effect of fluid removal is evaluated three times daily (06:00. 14:00 and 22:00), while the safety variables are evaluated continuously. Resuscitation is started if one or more signs of inadequate circulation is present.~The first choice for fluid removal is diuretic therapy with furosemide, which is continued for a minimum of 8 hours. If the therapeutic goal (negative fluid balance ≥ 1 ml/kg/h) is not achieved and/or maintained by furosemide alone, then fluid removal with continuous renal replacement therapy (CRRT) is initiated."
89538488|NCT02458157|Active Comparator|Usual Care|Usual Care at the discretion of the treating clinicians, except for the initiation of renal replacement therapy (RRT).
89538489|NCT02457533|No Intervention|Control|Only SF-36 and CAT
89538490|NCT02457533|Active Comparator|Active|Lifestyle behavioral. Health plan, telephone support
89538491|NCT03264677|Experimental|Group 1|NTG Hydro Boost Gelee Milk Cleanser + NTG Hydro Boost Kiwi Water Gel
89538492|NCT03264677|Experimental|Group 2|NTG Hydro Boost Gelee Milk Cleanser + NTG Hydro Boost Water Gel
89538493|NCT03264677|Experimental|Group 3|NTG Hydro Boost Gelee Milk Cleanser + NTG Hydro Boost Extra Dry Emulsion
89538494|NCT03265457||patient with pseudoexfoliation syndrome|The corneal Endothelial cell count will be measured by specular microscopy
89538495|NCT03265457||Normal people at same age|
89538496|NCT03264599||occiput-spine angle > or = 126|2D trans abdominal ultrasound was done during the first stage of labor. If fetal position is occiput anterior and fetal presentation is vertex, two dimensional sagittal picture of the fetal head and upper spine was acquired and stored in the ultrasound machine. On this image, the offline measurement of the angle formed by a line tangential to the occipital bone and a line tangential to the first vertebral body of the cervical spine (occiput-spine angle > or = 126) will be performed to quantify the degree of fetal head flexion in respect to the trunk
89538497|NCT03264599||occiput-spine angle<126|2D trans abdominal ultrasound was done during the first stage of labor. If fetal position is occiput anterior and fetal presentation is vertex, two dimensional sagittal picture of the fetal head and upper spine was acquired and stored in the ultrasound machine. On this image, the offline measurement of the angle formed by a line tangential to the occipital bone and a line tangential to the first vertebral body of the cervical spine (occiput-spine angle < 126) will be performed to quantify the degree of fetal head flexion in respect to the trunk
89538498|NCT03265067|No Intervention|'Before' group|Patients who underwent primary PCI for STEMI prior to implementation of the RIC protol. These patients were not treated with the autoRIC device prior to PCI.
89538499|NCT03265067|Experimental|'After' group|Patients who underwent primary PCI for STEMI after implementation of the RIC protocol. These patients were treated with the autoRIC device prior to PCI.
89538500|NCT02458079|Experimental|Pentoxiphylline|
89210453|NCT00900744||Tamoxifen|20mg daily
89538501|NCT02458079|Active Comparator|Stool Microbiota Transplantation|
89538502|NCT03264911|Active Comparator|amoxicillin|Children will be randomized to receive, after consent to the study, an antibiotic (amoxicillin approximately 50 mg/kg/day) orally, twice a day for 6 days.
89538503|NCT03264911|Placebo Comparator|Placebo arm|Children will be randomized to receive, after consent to the study, a placebo orally, twice a day for 6 days.
89538504|NCT03264755|Active Comparator|cortical excitability in smokers|
89538505|NCT03264755|Active Comparator|cortical excitability in nonsmokers|
89538506|NCT03264521||MTurk Participants|Participants who are registered users on Amazon Mechanical Turk (crowdsourcing platform) who volunteer to take survey.
89538507|NCT03265223|No Intervention|Controls|Received 1 ml/cm normal saline (23 ml) both at intraperitoneal (=20 ml) as well as intraincisional (=3 ml) location.
89538508|NCT03265223|Active Comparator|Intraperitoneal group|Received 20 ml of 0.2% ropivacaine intraperitoneally (1 ml/cm; 16 ml along right hemi-dome, approximately equal to length of right hemi-dome of diaphragm in an average adult and 4 ml in gall bladder fossa) and 3 ml normal saline (1ml/cm of port site incision length)
89538509|NCT03265223|Active Comparator|Intraincisional group|Received 20 ml of normal saline intraperitoneally (1 ml/cm; 16 ml along right hemi-dome, approximately equal to length of right hemi-dome of diaphragm in an average adult and 4 ml in gall bladder fossa) and 3 ml 0.2% ropivacaine (1ml/cm of port site incision length)
89538510|NCT03264365|Experimental|Intervention|Relatives participated actively in the one out of three consultation conducted by trained study nurses at two months after intensive care superimposed on standard care.
89206307|NCT04094909|Experimental|Rh-endostatin + chemotherapy+Pembrolizumab|The subjects are 186, including Squamous and Non-Squamous NSCLC. Squamous NSCLC receives rh-endostatin at a dose of 15mg/m2 for 5 days and 200 mg of pembrolizumab at day 1 in each cycle, repeating every 3 weeks till to PD or unacceptable toxicities. all the patients with squamous NSCLC also receive carboplatin (5U/AUC) or cisplatin ( 75mg/m2) and [nab]-paclitaxel (100mg/m2) for the first 4 cycles. For non-squamous NSCLC, rh-endostatin at dose of 15mg/m2 for 5 days, 200 mg of pembrolizumab at day 1 and pemetrexed (500mg/m2,d1) are given in each cycle, repeating every 3 weeks till to PD or unacceptable toxicities. Non-squamous NSCLC also receive carboplatin (5U/AUC) or cisplatin ( 75mg/m2) and pemetrexed (500mg/m2,d1) for the first 4 cycles.
89206308|NCT02599571|Other|Very low nicotine content cigarettes|Reduced nicotine content cigarettes.
89538511|NCT03264365|No Intervention|Standard care|Relatives to former ICU patients, who had received standard care (SC) completed a questionnaire package at 3 and 12 months after the patient was discharged from intensive care. After enrollment were all contract handled by primary investigator.
89538512|NCT02457377|Experimental|Laparoscopic cerclage|The vesico-uterine peritoneum is opened & the urinary bladder is dissected downwards . Both needles are passed through the lower uterine tissue medial to uterine vessels on the right & left sides . Then, both needles are passed through the remaining cervical tissue medial to uterosacral ligaments towards the posterior vaginal fornix (on the right & left sides) guided by laparoscopic illumination . When the needles' blunt ends pierce the vaginal vault, the assistant pull them through the posterior vaginal fornix . After trimming of both needles, the Mersilene tape is tied tightly behind the intravaginal segment of the cervix with five knots &
89538513|NCT02457299|Active Comparator|Two Stage Esophagectomy|Ischemic gastric preconditioning performed 7-10 prior to esophagectomy
89538514|NCT02457299|Active Comparator|One Stage Esophagectomy|Esophagectomy alone
89538515|NCT03938129||Group 1|Pregnant women and their baby
89538516|NCT03264287|Experimental|3 times per week therapeutic frequency|"1.Acupuncture: GV20, LU5, LI11, LI4,GV14,BL13, ST2, BL2,ST7,ST6 and ashi point on the face.~Huatuo Brand needle (0.20*13mm) will be used for GV14, BL13, ST2, BL2, ST7, ST6 and ashi point on the face. Huatuo Brand needle (0.3*40mm) will be used for GV20, LU5, LI11 and LI4.~2.Moving capping: Du Meridian (from GV14 to GV3) as well as the first (from BL11 to BL28) and second (from BL41 to BL53) side lines of the Urinary Bladder Meridian of Foot-Taiyang.~Guoyiyan Brand cupping jar (size 4) will be used. 3.Ear point tapping: Lung (CO14), Heart (CO15), Stomach (CO4), Neifenmi (CO18), Pizhixia (AT4).~Huatuo Brand, made by the seed of Vaccaria segetalis ( Neck.)Garcke."
89538517|NCT03264287|Active Comparator|1 time per week therapeutic frequency|"The acupoints and treating procedures will be the same as the 3 times per week group. Only treating frequency is different. The treating frequency is 1 time per week.~Acupuncture: GV20, LU5, LI11, LI4,GV14,BL13, ST2, BL2,ST7,ST6 and ashi point on the face.~Moving capping: Du Meridian (from GV14 to GV3) as well as the first (from BL11 to BL28) and second (from BL41 to BL53) side lines of the Urinary Bladder Meridian of Foot-Taiyang.~Ear point tapping: Lung (CO14), Heart (CO15), Stomach (CO4), Neifenmi (CO18), Pizhixia (AT4).~Use the seed of Vaccaria segetalis ( Neck.)Garcke."
89538518|NCT02457455||Sick passangers|Passengers or cabincreew whom needed urgent medical supports during flights with completed medical records. (Aforementioned Flight Company records complaints, symptoms and diagnoses, demographic data, the mortality of those who request medical aid, whether medical treatment is performed by the cabin crew or by a medical professional on the plane, as well as those conditions which resulted in an emergency landing and dead). All ages are included.
89538519|NCT03264209|Experimental|Intervention: Case management|Case management consists confirmation of hospital visit date, checking the efficacy of intervention, adverse effect and treatment compliance
89538520|NCT03264209|No Intervention|Control: usual care|Usual care is provided with life style intervention including exercise and nutrition by printed materials.
89538521|NCT02456363|Experimental|NSAIDs(+) and sulfasalazine(+)|use TNF alpha: Adalimumab (Humira)、Etanercept (Enbrel) or Golimumab (Simponi) combine with use of NSAIDs and no sulfasalazine
89538522|NCT02456363|Experimental|NSAIDs(+) and sulfasalazine(-)|use TNF alpha: Adalimumab (Humira)、Etanercept (Enbrel) or Golimumab (Simponi) combine with use of NSAIDs and no sulfasalazine
89538523|NCT02456363|Experimental|NSAIDs(-) and sulfasalazine(+)|use TNF alpha: Adalimumab (Humira)、Etanercept (Enbrel) or Golimumab (Simponi) combine with use of sulfasalazine and no NSAIDs
89538524|NCT02456363|Experimental|NSAIDs(-) and sulfasalazine(-)|use TNF alpha: Adalimumab (Humira)、Etanercept (Enbrel) or Golimumab (Simponi) neither NSAIDs nor sulfasalazine
89538525|NCT03264443|Active Comparator|Health education|Patients will receive weekly lectures on hypertension related topics during 12 weeks.
89538526|NCT03264443|Experimental|Combined training|Patients will complete 12 weeks of combined training (aerobic + strength exercise, 3x/week) in a pragmatic setup. In order to make the interventions more similar, contents of the health education arm will also be discussed with patients receiving this intervention.
89538527|NCT03259607|Experimental|Treatment A|Nicorette Extra Mint 2 mg Gum
89538528|NCT03259607|Active Comparator|Treatment B|Nicorette Mint 2 mg Gum
89538529|NCT03259607|Experimental|Treatment C|Nicorette Extra Mint 4 mg Gum
89538530|NCT03259607|Active Comparator|Treatment D|Nicorette Mint 4 mg Gum
89538531|NCT02457143|Experimental|Letter|Patients will receive a reminder letter signed by their family physician which indicates which cancer screening tests they are overdue for and encourages them to book an appointment for screening.
89538532|NCT02457143|Experimental|Phone call|Patients will receive a phone call from a member of the practice staff. The call will inform them about which cancer screening tests they are overdue for and will encourage them to book an appointment for screening.
89206309|NCT02599571|Other|Conventional nicotine content cigarettes|Conventional nicotine content cigarettes.
89206310|NCT00296491|Active Comparator|Fluticasone Propionate/Salmeterol/Montelukast (FSC+MON)|Fluticasone propionate/salmeterol DISKUS combination product (FSC) twice daily (BID) plus vehicle placebo nasal spray once daily (QD) plus montelukast capsule 10mg (MON) QD
89206311|NCT00296491|Active Comparator|Fluticasone Propionate/Salmeterol (FSC)|FSC BID plus vehicle placebo nasal spray QD plus placebo capsule QD
89206312|NCT00296491|Active Comparator|Fluticasone Prop/Salmeterol/Flut Prop Nasal Spray (FSC+FPANS)|Fluticasone propionate/salmeterol DISKUS combination product (FSC)100/50mcg BID plus fluticasone propionate aqueous nasal spray 200mcg (FPANS) QD plus placebo capsule QD
89538533|NCT02456987|Experimental|Intervention|Patients that qualify for the intervention will receive the Samsung Gear virtual reality experiences and will participate in a brief survey about their opinions and preferences once the experiences are completed.
89206313|NCT00296491|Active Comparator|Montelukast (MON)|Placebo DISKUS BID plus vehicle placebo nasal spray QD plus MON QD
89502101|NCT04476667|Experimental|e-Psychotherapy|Participants will receive a 9-week program with CBT, mindfulness, and problem-based therapy, in addition to TAU. The content will be customized to reflect challenges faced through the COVID-19 pandemic and developed into interactive and engaging modules. All sessions and interactions will occur through Online Psychotherapy Tool (OPTT), a secure online platform. Participants will be assigned to a team of psychiatrists and social workers (SWs). The SW working with each patient will assign a pre-designed therapy module to that patient on a specific day of the week through OPTT. Participants will then be able to access the therapy content at any time throughout the week. Each module will highlight a different topic and include general information, an overview of skills, and homework that is to be completed by a specific day that week. This homework will be directly submitted through OPTT to the clinician who will provide personalized feedback to the patient.
89502102|NCT04476667|No Intervention|Treatment as Usual|The control group will receive treatment as usual during the first 9 weeks; if they still present significant symptoms (less than 50% response to treatment from baseline), they will be offered the e-psychotherapy program.
89502103|NCT05485844||Symptomatic|Individuals reporting increased back pain and/or decreased motor control function in a second questionnaire conducted a year after index pregnancy
89502104|NCT05485844||Controls|Controls reporting no change in their bodily experience between the two questionnaires
89502105|NCT04432675|Experimental|hydroxyethl starch group|10 ml/kg hydroxyethl starch as well as goal-directed fluid therapy with 3ml/kg hydroxyethl starch
89502106|NCT04432675|Active Comparator|The control group|10 ml/kg Lactated Ringer's solution as well as goal-directed fluid therapy with 3ml/kg Lactated Ringer's solution
89502107|NCT04402723|Experimental|Donafenib, 0.2g|Donafenib,0.2g,bid,Combination with Cytarabine and Daunorubicin.
89502108|NCT04402723|Experimental|Donafenib,0.3g|Donafenib,0.3g,bid,Combination with Cytarabine and Daunorubicin
89502109|NCT02262949|Experimental|LifeStent Vascular Stent|This is a single arm study and all subjects receive PTA and implantation of one Life Stent Vascular Stent.
89502110|NCT02235337|Experimental|Riboflavin|
89502111|NCT05485454|Active Comparator|Aria Health Aria Free|An Aria Free therapy session on the study lower limb.
89502112|NCT05485454|Active Comparator|Traditional PCD|A therapy session using the traditional PCD on the study lower limb.
89502113|NCT02233231|Active Comparator|Varenicline|Varenicline 0,5 mg x 1 day 1-3 Varenicline 0,5 mg x 2 day 4-6 Varenicline 2 mg x 1 day 7 to week 12
89502114|NCT02233231|Placebo Comparator|Placebo|Placebo tablets equivalent to IMP.
89502115|NCT02263027|Experimental|Vaccine, then placebo|1 injection of trivalent inactivated influenza vaccine, 0.5mL/dose, as approved for use in Canada for season of enrolment followed by 1 injection of normal saline placebo, 0.5mL/dose, 28 days later
89502116|NCT02263027|Experimental|Placebo, then vaccine|1 injection of normal saline placebo, 0.5mL/dose followed by 1 injection of trivalent inactivated influenza vaccine, 0.5mL/dose, as approved for use in Canada for season of enrolment, 28 days later
89502117|NCT05485298||retrospective analysis|A retrospective analysis of disease histories for the period from 2014 to 2021 was carried out. Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury.
89502118|NCT05485298||prospective study|Recruitment of patients for the prospective study was carried out in the period from 02.24.2022 to 05.24.2022
89502119|NCT05485220|Experimental|aerobic exercise group|the participants do aerobic training by an arm crank ergometer (Monark 881E Upper and Lower Body Ergometer)
89502120|NCT05485220|Experimental|High intensity interval training group|the participants do High intensity interval training by an arm crank ergometer (Monark 881E Upper and Lower Body Ergometer)
89502121|NCT05485220|No Intervention|control group|the participants don't do any exercises
89502122|NCT02263105|Experimental|CDDP plus Temozolomide|"Patients were treated with CDDP and TMZ. CDDP was administered iv from Day 1 to 3 with everyday dose of 30mg. TMZ was orally administered from Day 1 to 7 and Day 15 to 21, with everyday dose of 125mg/m2 (Level 2). The period of one chemotherapy cycle is 28 days. TMZ dose levels were listed in Table 1.~Table 1 TMZ dose levels Dose levels Daily TMZ dose( mg/m2/d ) TMZ dose per cycle(mg/m2)~150 2100~125 1750~100 1400~75 1050"
89502123|NCT05485064|Experimental|electroacupuncture(transcutaneous electrical acupuncture point stimulation )and remimazolam|The investigator 1 combine electroacupuncture(transcutaneous acupoint electrical stimulation ) with remimazolam to sedate patients moderately to finish gastroscopy and colonoscopy.
89502124|NCT05485064|Experimental|placebo needle and remimazolam|The investigator 1 combine placebo needle with remimazolam to sedate patients moderately to finish gastroscopy and colonoscopy.
89502125|NCT05485064|Experimental|fentanyl and remimazolam|The investigator 1 combine fentanyl with remimazolam to sedate patients moderately to finish gastroscopy and colonoscopy.
89502126|NCT05626153|Active Comparator|Routine anesthesia care|• Implementing anesthesia management according to current routine practice.
89502127|NCT05626153|Experimental|Improved anesthesia care|"Encourage regional anesthesia or combined regional-general anesthesia.~Encourage goal-directed fluid therapy, lung-protective ventilation, and active warming during surgery.~Encourage extubation in the operating room at the end of surgery.~Encourage multimodal analgesia after surgery.~Encourage strict indication for ICU admission after surgery."
89502128|NCT02553343|Experimental|QIV HD1 Group|Adults ≥ 65 years of age randomly assigned to receive an intramuscular injection of one dose of High-Dose quadrivalent influenza vaccine (formulation 1)
89502129|NCT02553343|Experimental|QIV HD2 Group|Adults ≥ 65 years of age randomly assigned to receive an intramuscular injection of one dose of High-Dose quadrivalent influenza vaccine (formulation 2)
89502130|NCT02553343|Active Comparator|TIV HD1 Group|Adults ≥ 65 years of age randomly assigned to receive an intramuscular injection of one dose of licensed High Dose trivalent influenza vaccine
89502131|NCT02553343|Active Comparator|TIV HD2 Group|Adults ≥ 65 years of age randomly assigned to receive an intramuscular injection of one dose of investigational High-Dose trivalent influenza vaccine
89502132|NCT02235415||Motens|
89538534|NCT02456987|No Intervention|Control|Age and sex matched control participants will be asked to answer a series of satisfaction questions after the study recruitment period is over. These individuals will have been inpatients during the same time as the intervention participants.
89538535|NCT03259217|Experimental|stem cell product|stem cell transplant
89538536|NCT03264053|Experimental|SOCKET SHIELD TECHNIQUE|Socket shield is the surgical removal of the frontal aspect of the badly broken root and retaining the lingual aspect so as to prevent crestal bone loss with insertion of the dental implant behind it
89538537|NCT03264053|Active Comparator|Conventional immediate implantation|Conventional immediate implantation is the surgical removal of the entire badly broken root
89538538|NCT03263819||POTS|patients with postural orthostatic tachycardia syndrome diagnosis.
89538539|NCT03263819||Healthy controls|Patients with Postural orthostatic tachycardia syndrome who has peripheral neuropathy
89538540|NCT03258983||The Diet, Cancer and Health cohort|
89538541|NCT03263975|Experimental|Exercise heat STress (EHS)|EHS - dehydration produced by sweating and fluid restriction; primary loss of body water accompanied by small loss of electrolytes (hypertonicity). Interventions include rehydration with Gatorade or Enterade oral rehydration therapies.
89538542|NCT03263975|Experimental|Lasix (LAS)|LAS - dehydration produced by Lasix (diuretic, 80 mg oral dose) administration to produce losses of body water accompanied by large losses of electrolytes (isotoncity). Interventions include rehydration with Gatorade or Enterade oral rehydration therapies.
88956559|NCT04896736|Experimental|Multisite tissue oxygenation monitoring-guided care|"Details are as follows. • Monitoring: SctO2 monitored using two probes placed on left and right forehead. SstO2 monitored using one probe placed over the forearm brachioradialis muscle on the arm not used for non-invasive blood pressure monitoring.~• Baseline: The first baseline is measured 12-48 hours before surgery, with the patient supine, awake, calm, eyes closed, and breathing room air or oxygen that is equivalent to the home oxygen rate for patients using home oxygen.~Goals: Maintain both SctO2 and SstO2 within 90-110% of the baseline level.~Trigger of intervention: SctO2/SstO2 outside of the 90-110% baseline range.~Diagnosis:~Care team: The caregivers providing SctO2/SstO2-guided care will be trained and given the opportunity to use the intervention protocol in at least 20 patients before the formal study.~Treatments: Refer to the algorithm to restore SctO2/SstO2 within 90-110% baseline range."
88956560|NCT04896736|Active Comparator|Usual care|Patients in the control group will be managed by clinical staff according to usual care. Patients in this group will be monitored using the same tissue oximeter used in the intervention group; however, the screen will be covered by an opaque cloth to prohibit the care givers seeing the monitoring data. The same baseline measurements will be performed in patients allocated to the usual care group.
89206314|NCT00747617|Active Comparator|PCOS group|Each subject will receive a dose (1, 10, 25, 100, or 250 micrograms) of recombinant human chorionic gonadotropin administered iv on 5 separate occasions.
89538543|NCT03258827|Experimental|Exercise with a towel|There are 30 old adults in this group who receives exercise program with a towel.
88956563|NCT04883749|Experimental|Acalabrutinib|Acalabrutinib will be administered up to 24 cycles (= approx. 24 months total) until progression of disease (PD) or intolerable toxicity
88956564|NCT04879849|Experimental|Combination Dose Escalation Phase: Radiation + Pembrolizumab + TAK-676|Participants will receive image-guided radiation therapy between Day -8 and Day -2. Participants will then receive pembrolizumab 200 milligram (mg), infusion, intravenously (IV), once on Day 1 of Cycle 1 and then every 3 weeks in each 21-day treatment cycle, followed by TAK-676 infusion with escalating doses (0.2 mg and above), IV, once on Days 1, 8, 15 in each 21-day treatment cycle until disease progression, intolerance to pembrolizumab or TAK-676 or withdrawal of consent, whichever occurs first.
88956565|NCT04858737|Experimental|e-predicD-Work intervention|In this arm, worker participants will receive an online personalized intervention to prevent depression based on ICTs, risk predictive algorithms and decision support systems (DSS).
88956566|NCT04858737|Active Comparator|m-Health control|In this arm, worker participants will continue receiving the usual care from their health providers. In addition, they will use an App with the same appearance as the e-predictD-Work App but it will only send weekly short messages about stress and general health that will be extracted from brochures and websites of official agencies.
88956567|NCT04853797|Active Comparator|Levcromakalim - Ivabradine|Infusion of levcromakalim (2.5 nmol minutes-1 over 20 minutes) followed by oral administration of ivabradine (15 mg orally).
88956568|NCT04853797|Placebo Comparator|Levcromakalim - Placebo|Infusion of levcromakalim (2.5 nmol minutes-1 over 20 minutes) followed by oral administration of placebo.
89538544|NCT03258827|Placebo Comparator|Home-based exercise|There are 30 old adults in this group who is suggested a home-based program focuses on walking activity at fast speed.
89538545|NCT02456129|Experimental|Vilaprisan + Itraconazole|Vilaprisan (BAY1002670)
89538546|NCT03263741|Experimental|Paclitaxel + S-1 + Oxaliplatin group|Paclitaxel: 135 mg/m2, iv, 3h, at D1 ; S-1: 40mg twice daily for patients with a body surface area (BSA) < 1.25 m2, 50mg twice daily for patients with a BSA of 1.25 m2 to < 1.5 m2, 60mg twice daily for patients with a BSA of ≥ 1.5 m2 for two weeks, and then suspend for one week; Oxaliplatin: 85 mg/m2, iv, 2h, at D1.
89538547|NCT02456207|Experimental|Experimental|SCT400:375 mg/m2, iv, one infusion
88956569|NCT04846868|Experimental|Iclepertin|
88956570|NCT04846868|Placebo Comparator|Placebo|
88956571|NCT04818268|Experimental|Adaptation to Altered Auditory Feedback|Adaptation to Altered Auditory Feedback
88956572|NCT04818268|Experimental|Auditory Sensory Memory|Auditory Sensory Memory
88956573|NCT04818268|Experimental|Somatosensory Sensory Memory|Somatosensory Sensory Memory
89538548|NCT02456207|Active Comparator|Active Comparator|Rituximab: 375 mg/m2, iv, one infusion
89538549|NCT03258749|Active Comparator|Formoterol|inhaled formoterol(4.5μg, bid)
89538550|NCT03258749|Experimental|Tiotropium|inhaled Tiotropium(18μg, qd)
89538551|NCT03258671|Experimental|Mutation+ concurrent|IMRT concurrent with EGFR-TKI on paticipants with known sensitive EGFR mutations.
89538552|NCT03258671|Experimental|Mutation+ concomitant|IMRT concomitant with EGFR-TKI on paticipants with known sensitive EGFR mutations.
89538553|NCT03263663||Chemotherapy plus targeted treatment|Patients are treated in second-line with chemotherapy plus a targeted treatment according to the resistance mechanism to cetuximab pretreatment
89538554|NCT03263663||Chemotherapy according to physician choice standard|Patients are treated in second-line with chemotherapy according to physicians choice after cetuximab pretreatment
88956574|NCT04818268|Experimental|Adaptation to Altered Auditory Feedback + cTBS to 46v|Adaptation to Altered Auditory Feedback + cTBS to 46v
88956575|NCT04818268|Experimental|Sensory Memory + cTBS to 46v|Sensory Memory + cTBS to 46v
88956576|NCT04818021|Experimental|Adaptation to Altered Auditory Feedback|Adaptation to Altered Auditory Feedback
88956577|NCT04818021|Experimental|Adaptation to Altered Auditory Feedback + Forward Skin Stretch|Adaptation to Altered Auditory Feedback + Forward Skin Stretch
88956578|NCT04818021|Experimental|Adaptation to Altered Auditory Feedback + Backward Skin Stretch|Adaptation to Altered Auditory Feedback + Backward Skin Stretch
88956579|NCT04818021|Experimental|Speech Repetition Control|Speech Repetition Control
88956580|NCT04807400|Active Comparator|Control+ BS|Participants continued to receive their background lipid lowering therapy plus behavioural support (BS).
88956581|NCT04807400|Experimental|Inclisiran|Participants continue to receive their background lipid lowering therapy, plus inclisiran for injection (delivered in an injection-only model).
88956582|NCT04807400|Experimental|Inclisiran + BS|Participants continued to receive their background lipid lowering therapy, plus inclisiran for injection, plus behavioural support.
88956583|NCT04804293|Experimental|Operative treatment (surgical decompression) for carpal tunnel syndrome|Shear wave elastography (SWE) will be used to assess the stiffness of tissue. Patients will be revaluated at 3 and 6 months post-operatively. Patient will sit done in a chair. The investigators will scan the wrist area of both arms to acquire SWE map. This imaging will be done before the treatment. We will repeat the imaging study at 3 and 6 months after the treatment. Each ultrasound imaging session will take about less than 10 min. The investigators do not expect any discomfort during the imaging.
88956584|NCT04804293|Experimental|Corticosteroid injection treatment for carpal tunnel syndrome|Shear wave elastography (SWE) will be used to assess the stiffness of tissue. Patients will be revaluated after 6 weeks following corticosteroid injection. Patient will sit done in a chair. The investigators will scan the wrist area of both arms to acquire SWE map. The investigators do not expect any discomfort during the imaging.
88956585|NCT04793412|Experimental|AHL/SSD|Children with asymmetric hearing loss or single-sided deafness
88956586|NCT04780477|Experimental|High Fiber Diet Featuring Legumes (HLD)|Participants randomized to the high fiber diet featuring legumes (HLD) will add approximately 30 grams of dietary fiber per day from legume dishes, ensuring a total intake of approximately 50 grams of dietary fiber per day.
88956587|NCT04780477|Active Comparator|Healthy American Diet Control Arm|Participants randomized to the healthy American diet control arm will receive pre-portioned meal replacement entrées with legumes replaced by lean chicken or meat.
88956588|NCT04762160|Experimental|Tazmetostat in combination with rituximab|Tazemetostat 800 mg BID is administered daily starting on Cycle 1 Day 1 (C1D1). Tazemetostat will be administered from C1D1 to the end of Cycle 24, for 24 months of therapy or until disease progression, unacceptable toxicity, or withdrawal of consent. Rituximab will be administered by either subcutaneous injection or IV infusion according to the regional product prescribing information, labeling and institutional guidelines. Rituximab will be administered at a dose of 375 mg/m2 on Day 1, 8, 15, and 22 of Cycle 1, and then on Day 1 of Cycles 3 through 6, accounting for an additional 4 doses, i.e., a total of 8 doses of rituximab in 6 cycles.
88956589|NCT04755335|Other|Early detection of PAD, assessment of the disease progression and treatment response|"The objective of this arm of the study is to evaluate the potentials of Ultrasound Perfusion imaging technique for early detection of peripheral arterial disease in patients and assess the disease progression and monitor the treatment response.~The investigators anticipate that our new cost-effective and non-invasive ultrasound perfusion technique offers a quantitative imaging of perfusion and microvessels of cuff muscle that would separate PAD from non-PAD and help early detection of PAD and would help monitoring the disease progression and treatment response."
88956590|NCT04752098|Other|premature infants and full term infants|"The study visits will be at ≥3 time points at ages: within the first 28 days after birth, 2 months, 3 months, and, if still hospitalized, at 4 months and at 6 months.~The ultrasound machine to the nursery or neonatal intensive care unit at a scheduled time.~The appropriate ultrasound probe will be placed on the infant's tibia and a miniature hydrophone near the probe. A series of ultrasound measurements will be obtained and the ultrasound data will be saved for offline processing.~The Investigators will repeat the measurement in 3 locations of the infant's tibia.~Each ultrasound measurement takes a few seconds. The complete ultrasound study will take about 15 minutes at each visit.~All procedures will be conducted in the nursery or neonatal intensive care unit to ensure infant safety.~The ultrasound measurement for full-term infants can be done in ultrasound lab."
88956591|NCT04751669|Experimental|Micronutrient dietary supplement effervescent tablet|"Tablet containing:~Retinol (Vitamin A) 700 mcg~Cholecalciferol (Vitamin D3) 10 mcg~Alpha-Tocopherol (Vitamin E) 45 mg~Ascorbic acid (vitamin C) 1000 mg~Pyridoxine (Vitamin B6) 6.5 mg~Cyanocobalamin (Vitamin B12) 9.6 mg~Folic acid 400 mg~Iron 5 mg~Zinc 10 mg~Selenium 110 mg~Copper 0.9 mg~Excipients"
88956592|NCT04751669|Placebo Comparator|Placebo dietary supplement effervescent tablet|"Effervescent tablet with only the excipients.~Sucralose 13 mg~Sodium Chloride 20 mg~Potassium Acesulfam 22.5 mg~Orange P 55 mg~Sodium Carbonate 70 mg~Betacarotene 100 mg~Malic Acid 800 mg~Citric Acid 960 mg~Sodium bicarbonate 1,000 mg~Isomalt 1,459.50 mg"
88982887|NCT03176732||Group 1: Normotensive|Categorized by 24-hr systolic BP (SBP): normotensive (< 125 mm Hg) on no BP medications
88982888|NCT03176732||Group 2: Controlled Hypertensive|Categorized by 24-hr systolic BP (SBP): controlled hypertensive (< 130 mm Hg) on BP medication(s) and/or lifestyle modification
88982889|NCT03176732||Group 3: Uncontrolled Hypertensive|Categorized by 24-hr systolic BP (SBP): uncontrolled hypertensive (≥ 130 mm Hg) on 0-2 BP medications
89538555|NCT03258515|Experimental|Cohort 1|"Participants will receive orally single dose of study drugs in the sequence of ABC.~A - AZD6094 600 mg (3X 200 mg tablet) B - Placebo C - Moxifloxacin 400 mg"
89538556|NCT03258515|Experimental|Cohort 2|"Participants will receive orally single dose of study drugs in the sequence of ACB.~A - AZD6094 600 mg (3X 200 mg tablet) B - Placebo C - Moxifloxacin 400 mg"
89538557|NCT03258515|Experimental|Cohort 3|"Participants will receive orally single dose of study drugs in the sequence of BAC.~A - AZD6094 600 mg (3X 200 mg tablet) B - Placebo C - Moxifloxacin 400 mg"
89032870|NCT02926443|Experimental|Group Program (UpEx-NTP) (Exp)|The Exp group (n =16) will partake in a 6-week group Upper Extremity Neuromuscular Training Program that consists of postural education, strength exercises, motor control exercises, and upper extremity functional tasks common for active military personnel. The UpEx-NTP program consists of 35-45 minutes of exercise, three times a week for 6 weeks (18 treatments), supervised by a physiotherapist. The program consists of 11 stations with several variations of difficulty of the same exercise per station. The exercises of each station will be performed in order of difficulty. The participant chooses one exercise to perform per station based on their current ability while respecting their pain levels at 3/10 or less.
89032871|NCT02924142|Experimental|Intervention|Mandibular removable partial denture with OT Cap attachment
89538558|NCT03258515|Experimental|Cohort 4|"Participants will receive orally single dose of study drugs in the sequence of BCA.~A - AZD6094 600 mg (3X 200 mg tablet) B - Placebo C - Moxifloxacin 400 mg"
89538559|NCT03258515|Experimental|Cohort 5|"Participants will receive orally single dose of study drugs in the sequence of CAB.~A - AZD6094 600 mg (3X 200 mg tablet) B - Placebo C - Moxifloxacin 400 mg"
89538560|NCT03258515|Experimental|Cohort 6|"Participants will receive orally single dose of study drugs in the sequence of CBA.~A - AZD6094 600 mg (3X 200 mg tablet) B - Placebo C - Moxifloxacin 400 mg"
89538561|NCT03258359|Experimental|PACTN|Open label 3+3 dose escalation phase 1 trial; 200 to 1000 mL of immunized T cells infused at 0.3, 1, and 3 x 10e7 nucleated cells/kg body weight.
89538562|NCT03263585|Active Comparator|Spinal orthosis group|Women wearing the spinal orthosis Spinomed for 6 months at least 2 hours a day.
89538563|NCT03263585|Active Comparator|Equipment training group|Women training once a week in an equipment training group led by a physiotherapist for six months.
89538564|NCT03263585|No Intervention|Control|Women in the control group get no intervention for six months.
89538565|NCT04427007|Experimental|Experimental Prosthetic Liner|Participants will test the experimental liner in combination with the active cooling socket (ICE System). Prosthetic liners and socket will be tested by walking on a treadmill.
89538566|NCT04427007|Other|Control Prosthetic Liner|Participants will test the control liner in combination with the active cooling socket (ICE System). Prosthetic liners and socket will be tested by walking on a treadmill.
89538567|NCT03788525|Experimental|Reduced recreational screen time|Reducing recreational screen-based media use for a period of 2 weeks
89538568|NCT03788525|Experimental|Timed recreational screen time|Reduced and timed recreational screen-based media use for a period of 2 weeks
89538569|NCT04977141||Under-represented minority|Non-English speaking and/or non-White
89538570|NCT04977141||Non-under-represented minority|English-speaking and/or White
89538571|NCT03258437|Experimental|DA-9401|capsules (4cap/d, 2.16 g/d) for 12 weeks.
89538572|NCT03258437|Placebo Comparator|Placebo|Placebo for 12 weeks.
89538573|NCT04976673|Experimental|photodynamic therapy side|On one side, the OLP lesion eligible for treatment was subjected to photodynamic therapy in four sessions every 2 days.Using as photosensitizer Methylen blue for 10min the lesion was irradiated with a 650 nm semiconductor laser at a dose of 120 J / cm2
89538574|NCT04976673|Active Comparator|Steroid side|on the other side The OLP on the other side was treated by daily sticking a cut-to-size carrier with 0.05% triamcinolone acetonide for 8 days
89538575|NCT03262883||Chronic Critical Illness|"The patients who is over 18 years old and staying in the critical care unit at least 8 days. Additional criterias:~Prolonged mechanical ventilation (longer than 96 hours)~Tracheostomy~Sepsis~Serious injury (burn)~Stroke (hemorhagic or ischemic)~Traumatic brain injury"
89538576|NCT04969497|Experimental|Sequence ABC|Receives interventions in the sequence, A, B, C.
89538577|NCT04969497|Experimental|Sequence CAB|Receives interventions in the sequence, C, A, B.
89538578|NCT04969497|Experimental|Sequence BCA|Receives interventions in the sequence, B, C, A.
89538579|NCT04969497|Experimental|Sequence CBA|Receives interventions in the sequence, C, B, A.
89538580|NCT04969497|Experimental|Sequence BAC|Receives interventions in the sequence, B, A, C.
89538581|NCT04969497|Experimental|Sequence ACB|Receives interventions in the sequence, A, C, B.
89538582|NCT03258047|Experimental|CAR-T treatment|In this group, patients will be treated with autologous CAR-T, and the safety and efficacy will be evaluated
89538583|NCT03258125||severe EOPE|EOPE: PE starting before 34 weeks gestation Severe PE (Blood pressure more than 160/ 110 mm Hg on 2 occasions 2 hours to 2 weeks apart and proteinuria ( 24-hour urine protein >2000 mg/d).
89538584|NCT03258125||control|Healthy Pregnant women who come for termination of pregnancy by vaginal delivery or CS between 28-34 weeks gestational age.
89538585|NCT04976751|Experimental|Electrophysiological treatment group|Two electrodes covered the two acupoints of Zhongliao and Huiyang, one electrode covered the three acupoints of Zhongji, Guanyuan and Qihai, and two skin paste electrodes covered the three acupoints of Sanyinjiao, and connected the electric stimulation therapy instrument for 30 minutes. The intensity was based on the patient's tolerance. 4 weeks before the course of treatment, the treatment was performed once a day, 3 times a week.In the last 4 weeks, 20 times were performed twice a week.Fluoroquinolones and alpha blockers were administered according to the patient's symptoms.
89538586|NCT04976751|No Intervention|Regular treatment group|Fluoroquinolones and alpha blockers were administered according to the patient's symptoms.
89538587|NCT03258203|Experimental|diet 1|diet with moderate in fat (40% energy) and protein(15%)
89538588|NCT03258203|Experimental|diet 2|diet with moderate in fat (40% energy) and protein(25%)
89538589|NCT03258203|Experimental|diet 3|diet with low in fat (20% energy) and protein(15%)
89538590|NCT03258203|Experimental|diet 4|diet with low in fat (20% energy) and protein(25%)
89538591|NCT04976829||adult (≥ 18 years) inpatients (hospitalised ≥ 48h)|
89538592|NCT02456831|Active Comparator|Control Infant Formula|Ready-to-Feed (RTF) Soy Infant Formula
89538593|NCT02456831|Experimental|Experimental Infant Formula 1|Experimental Ready-to-Feed Soy Formula
89538594|NCT02456831|Experimental|Experimental Infant Formula 2|Experimental Ready-to-Feed Soy Formula
89538595|NCT02456831|Experimental|Experimental Infant Formula 3|Experimental Ready-to-Feed Soy Formula
89538596|NCT04969029|Experimental|immunotherapy|In the immunotherapy group, the treatment regimen was Tirelizumab 200mg, intravenously infused once every 3 weeks until the end of 12 months of treatment, with a total of 17 infused times.
89206315|NCT00747617|Active Comparator|Control group|Each subject will receive a dose (1, 10, 25, 100, or 250 micrograms) of recombinant human chorionic gonadotropin administered iv on 5 separate occasions.
88956593|NCT04751370|Experimental|Treatment (nivolumab, ipilimumab, radiation therapy, TME)|Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 90 minutes on day 1. Treatment repeats every 28 days for 2 cycles. Starting at least 2 weeks but no longer than 6 weeks after completion of cycle 2 of nivolumab and ipilimumab, patients undergo short-course radiation therapy of 5 fractions daily for 1 week. Patients then continue to receive nivolumab IV over 30 minutes and ipilimumab IV over 90 minutes on day 1. Treatment repeats every 28 days for 2 cycles in the absence of disease progression or unacceptable toxicity. 8-12 weeks after completion of 4th cycle of nivolumab and ipilimumab, patients undergo TME. Patients also undergo MRI and CT prior to TME and during follow up, and undergo sigmoidoscopy prior to TME.
88956594|NCT04742231|Experimental|Cohort 1. Patients with brain lesions in non-motor areas undergoing an awake craniotomy (AC)|5 patient minimum
88956595|NCT04742231|Experimental|Cohort 2. Patients with brain lesions within or proximal to motor areas undergoing an AC|5 patient minimum
88956596|NCT04739566|Experimental|Treatment (dabrafenib, trametinib)|Patients receive dabrafenib 150 mg orally (PO) twice daily, trametinib 2mg PO once daily for 3 months
88956597|NCT04736472|Experimental|DPYD/UGT1A1 pharmacogenetic testing|"All patients will be screened for twelve single nucleotide polymorphisms (SNPs) in DPYD: DPYD*2A, *5, *6, *8, *9A, *10, *12, *13, rs2297595, rs115232898, rs67376798, HapB3.~All patients will be screened for two SNPs in UGT1A1: UGT1A1*6, *28."
88956598|NCT04731740|Experimental|Pembrolizumab + Lenvatinib|"Experimental treatment:~Lenvatinib p.o. once a day, pembrolizumab 200 mg i.v. every 21 days started 21 days after start of Lenvatinib~Duration of treatment per patient:~until the end of month 36 after registration of the last patient or disease progression or toxicity (whichever occurs first)"
88956599|NCT04731740|Experimental|Pembrolizumab + Chemotherapy|"Experimental treatment:~Investigators' choice of the Сhemotherapy, pembrolizumab 200 mg i.v. every 21 days started 21 days after the start of chemotherapy~Duration of treatment per patient:~until the end of month 36 after registration of the last patient or disease progression or toxicity (whichever occurs first)"
88956600|NCT04729179|Experimental|Cannabidiol|Participants will start with 10 mg of cannabidiol daily and the dose will be escalated every third day until the maximum dosage of 50 mg is reached (after two weeks). The participants be on the 50 mg dosage of cannabidiol for 24 weeks.
88956601|NCT04729179|Placebo Comparator|Placebo|Placebo is administered as tablets of 10 mg that are identical in appearance, taste, and smell to the Cannabidiol tablets.The participants will be on the 50 mg dosage of placebo for 24 weeks.
88956602|NCT04722250|Experimental|Medtronic Self-Expanding TAV|Subjects will be randomized on a 1:1 basis to receive TAVR with either a Medtronic SE TAV or an Edwards BE THV.
88956603|NCT04722250|Experimental|Edwards Balloon-Expandable THV|Subjects will be randomized on a 1:1 basis to receive TAVR with either a Medtronic SE TAV or an Edwards BE THV.
88956604|NCT04716634|Experimental|Tislelizumab + Fruquintinib|Participants with one of the tumors will be enrolled: GC,CRC and NSCLC
88956605|NCT04707209|Experimental|Intravitreal Sirolimus|
89502133|NCT03995017|Experimental|Safety Lead In|"Rucaparib 600 milligrams twice daily~Ramucirumab 8 milligrams per kilogram intravenous every 2 weeks~Nivolumab 480 milligrams intravenous every 4 weeks~Treatment will continue until disease progression, unacceptable toxicity or the patient desires to discontinue this therapy~One dose level decrease of Rucaparib will be planned if toxicity develops in the first 6 patients~1 cycle= 28 days"
88956607|NCT04702737|Experimental|Part 1: Dose Exploration|The maximum tolerated dose (MTD) will be estimated using isotonic regression (Ji et al, 2010). The recommended phase 2 dose (RP2D) may be identified based on emerging safety data prior to reaching an MTD.
88956608|NCT04702737|Experimental|Part 2: Dose Expansion|Participants will receive the RP2D/MTD identified in Part 1 (dose exploration) of the study.
89502134|NCT03995017|Experimental|Cohort A|"Rucaparib 600 milligrams twice daily~Ramucirumab 8 milligrams per kilogram intravenous every 2 weeks~Nivolumab 480 milligrams intravenous every 4 weeks~Treatment will continue until disease progression, unacceptable toxicity or the patient desires to discontinue this therapy~1 cycle= 28 days"
88956610|NCT04684719|Experimental|Whole Blood|Subjects will receive up to two units of whole blood as collected by local blood bank procedures and stored at 1-6 degrees Celsius initiated in the prehospital phase of care.
88956611|NCT04684719|Active Comparator|Standard Care|Subjects will receive prehospital crystalloid infusion or blood component transfusion resuscitation per site standard care for the respective Emergency Medical unit/service.
88956612|NCT04679935|Experimental|Brolucizumab 6 mg non-loading|One initial injection followed by treatment every 12 weeks.
88956613|NCT04679935|Experimental|Brolucizumab 6 mg loading|3 x 4-weekly injections followed by treatment every 12 weeks.
89502135|NCT03995017|Active Comparator|Cohort B|"Rucaparib 600 milligrams twice daily~Ramucirumab 8 milligrams per kilogram intravenous every 2 weeks~Treatment will continue until disease progression, unacceptable toxicity or the patient desires to discontinue this therapy~1 cycle= 28 days"
89502136|NCT02263183|Active Comparator|red palm olein(labelled A)|red palm olein (labelled A)
89502137|NCT02263183|Placebo Comparator|palm olein(labelled B)(control)|palm olein(labelled B)(control)
89502138|NCT02528539|Experimental|ITP (Integrative Thearpy Program)|"This ITP intervention consists of two distinct phases, Phase I, the active treatment phase and Phase II, the follow-up phase.~Phase I (Intervention phase) begins post-operatively in 4-6 weeks with a baseline visit that includes 30-minute acupuncture treatment, followed by the 30-minute self-management educational session, and the participants will return weekly for 10 weeks.~Phase II (Follow up phase) begins at month 6 and ends at month 18 from the surgery. The phase II consists of 1-hour quarterly ITP therapy at months 6, 9, 12, 15, and 18 and monthly telephone visits between ITP therapies at months 7, 8, 10, 11, 13, 14, 16, and 17. Self-management reinforcement and support will be implemented during telephone follow up visits"
89502139|NCT02558894|Experimental|MEDI4736 monotherapy|MEDI4736 via IV infusion.
89502140|NCT02558894|Experimental|tremelimumab+MEDI4736|MEDI4736+tremelimumab via IV infusion.
89502141|NCT02235571|No Intervention|Control|These subjects are receiving standard patient education
89502142|NCT02235571|Experimental|iChoose Kidney Decision Aid|These subjects receive iChoose Kidney Decision Aid along with standard patient education
89206316|NCT02599493|Experimental|Low dose|Patients will be randomly assigned to low dosage (10 mg/kg/j) rifampicin group. Rifampicin treatment will be prescribed in association with another antibiotic chosen by investigator according to the antibiogram results. Association with fluoroquinolones is the first choice combination, if it is possible. The global antibiotic treatment duration depends on the investigator's choice.
89206317|NCT02599493|Active Comparator|High dose|Patients will be randomly assigned to high dosage (20 mg/kg/j) rifampicin group. Rifampicin treatment will be prescribed in association with another antibiotic chosen by investigator according to the antibiogram results. Association with fluoroquinolones is the first choice combination, if it is possible. The global antibiotic treatment duration depends on the investigator's choice.
88956614|NCT04656223||MF/IND/GLY Breezhaler® plus Propeller Health|patients receiving MF/IND/GLY Breezhaler® plus electronic inhalation tracking sensor (Propeller Health) according to label
89206318|NCT02599415|Other|TL01 light treatment|routine treatment with a CE marked device that has been used for this disease for many years
89502143|NCT02235649|No Intervention|TAU|Treatment as usual
89502144|NCT02235649|Active Comparator|SOC+TAU|Social Cognition intervention + Treatment as Usual
88956615|NCT04656223||Other FDC therapy|patients receiving ICS+LABA+LAMA FDC therapy according to label
88956616|NCT04645966|Experimental|MenABCWY with PLP - 6 months of age|Group 1 - Participants 6 months of age vaccinated with MenABCWY on a 2+1 (2 primary vaccinations and a booster dose) schedule, and given Prophylactic Liquid Paracetamol (PLP) during primary vaccinations.
88956617|NCT04645966|Experimental|MenABCWY - 6 months of age|Group 2 - Participants 6 months of age vaccinated with MenABCWY on a 2+1 schedule
88956618|NCT04645966|Experimental|Bivalent rLP2086 (60-µg Dose) and Nimerix, with PLP or SLP - 2 months of age|Group 3 - Participants 2 months of age vaccinated with Bivalent rLP2086 (60-µg Dose) and Nimenrix on a 2+1 schedule, with PLP or Scheduled Liquid Pracetamol (SLP) during primary vaccinations.
88956619|NCT04645966|Experimental|Bivalent rLP2086 (60-µg Dose) and Nimenrix - 2 months of age|Group 4 - Participants 2 months of age vaccinated with Bivalent rLP2086 (60-mcg Dose) and Nimenrix on a 2+1 schedule
88956620|NCT04645966|Experimental|Bivalent rLP2086 (120-µg Dose) and Nimenrix, with PLP - 2 months of age|Group 5 - Participants 2 months of age vaccinated with Bivalent rLP2086 (120-µg Dose) and Nimenrix on a 2+1 schedule, and given PLP during primary vaccinations.
88956621|NCT04645966|Experimental|MenABCWY with SLP - 2 months of age|Group 7 - Participants 2 months of age vaccinated with MenABCWY on a 2+1 schedule, and given SLP during primary vaccinations.
88956622|NCT04645966|Experimental|Bexsero and Nimenrix with PLP - 2 months of age|Group 8 - Participants 2 months of age vaccinated with Bexsero and Nimenrix on a 2+1 schedule, and given PLP during primary vaccinations
88956623|NCT04645966|Experimental|Bexsero and Nimenrix - 2 months of age|Group 10 - Participants 2 months of age vaccinated with Bexsero and Nimenrix on a 2+1 schedule
88956624|NCT04645966|Experimental|MenABCWY with TLP - 2 months of age|Group 11 - Participants 2 months of age vaccinated with MenABCWY on a 2+1 schedule, with Therapeutic Liquid Paracetamol (TLP) during primary vaccinations.
89206319|NCT04092725|Experimental|Treatment A|Single oral 150-mg dose of DAB on Day 1 AM.
89206320|NCT04092725|Experimental|Treatment B|Twice daily (BID), every 12 hours (Q12H) oral doses of SCY-078 750 mg on Day 1 and Day 2; and single oral AM doses of SCY-078 750 mg on Day 3 and Day 4. On Day 3 a single 150-mg dose of DAB will be administered one hour after the AM dose of SCY-078.
89502145|NCT02235727|Experimental|GBR 900|Test treatment GBR 900
89502146|NCT02235727|Placebo Comparator|Placebo|Placebo Treatment
89502147|NCT02233387|Experimental|[18F] HX4 PET imaging|injection with [18F] HX4 and PET imaging at baseline and after 20 Gy radiotherapy
89502148|NCT02233465|Experimental|IPOM Mesh-repair parastomal hernia|Mesh-repair of para-stomal hernia. Patients with para-stomal hernia requiring surgery are offererd enrollment in the study. Preoperatively a CT-scan of the abdomen and or a 3D ultrasonography of the stoma is performed. All patients in the stydy are operated with IPOM-mesh designed for treatment of parastomal hernia.
89502149|NCT02233465|No Intervention|No mesh-repair|Patients not attending the study
89502150|NCT04251182|Placebo Comparator|Placebo|Placebo, matching T3D-959 active capsules, is pregelatinized starch NF, magnesium stearate NF, and size 0, hard gelatin, white/white, opaque, unmarked capsules. Subjects randomized to placebo will ingest three size 0 placebo capsules once per day in the morning.
89502151|NCT04251182|Experimental|15mg T3D-959|T3D-959 15 mg dose: T3D-959 is a small molecule dual nuclear receptor agonist that regulates transcription of genes, in particular those involved in glucose energy and lipid metabolism. T3D-959 is 15-times more potent for PPAR delta than for the secondary target of the drug, PPAR gamma. The 15 mg strength contains 15mg T3D-959, pregelatinized starch NF, magnesium stearate NF, and size 0, hard gelatin, white/white, opaque, unmarked capsules. Subjects will ingest one size 0, 15mg capsule and two placebo capsules once per day in the morning.
89502152|NCT04251182|Experimental|30mg T3D-959|T3D-959 30 mg dose: Subjects will ingest two size 0, 15mg capsules and one placebo capsule once per day in the morning.
89502153|NCT04251182|Experimental|45mg T3D-959|T3D-959 45 mg dose: Subjects will ingest three size 0, 15mg capsules once per day in the morning.
89502154|NCT02510599|Experimental|Solithromycin|Solithromycin 200 mg PO QD for 1 week, followed by 200 mg PO TIW for 12 weeks
89502155|NCT05572567||Rheumatoid Arthritis (RA) patients treated with biologic and nonbiologic DMARDs|to include all Japanese patients taking Tofacitinib
89502156|NCT05484986||Nursing students|
89502157|NCT02235805|Experimental|Magnesium Citrate|
89502158|NCT02235805|Placebo Comparator|Placebo|
89502159|NCT05484908|Experimental|DPMAS+LPE group|30 patients receive treatment of DPMAS, LPE, and comprehensive internal medical treatment.
89502160|NCT05484908|Active Comparator|PE group|30 patients receive treatment of PE and comprehensive internal medical treatment.
89502161|NCT02508337|Experimental|XG-102|sterile ophthalmic solution for sub-conjunctival injection
89502162|NCT02508337|Placebo Comparator|placebo|sterile ophthalmic solution for sub-conjunctival injection
89502163|NCT05484752|Experimental|Repetitive Peripheral Magnetic Stimulation|Repetitive Peripheral Magnetic Stimulation 1 session
89502164|NCT05484752|Sham Comparator|Sham Repetitive Peripheral Magnetic Stimulation|Sham Repetitive Peripheral Magnetic Stimulation 1 session
89538597|NCT04969029|No Intervention|chemotherapy|The chemotherapy regimen of the standard chemotherapy group was XELOX regimen, oxaliplatin 130mg/m2, d1, capecitabine 1000mg/m2, orally, bid (half an hour after breakfast and dinner), d1-14, every 21 days. The duration of treatment was determined according to the patient's postoperative pathological stage (3 months for T4N0/ T1-3N1 and 6 months for T4N+/ T1-3N2).
89538598|NCT04968795||Control|Participate in filling the questionnaire but NOT the meditation/wellness session (control).
89538599|NCT04968795||Wellness Group|Participate in filling the questionnaire and the meditation/wellness session
89538600|NCT03263039|Other|Treatment with pembrolizumab|Pembrolizumab will be administered at a flat dose of 200 mg as a 30 minute (-5 min/+10 min) IV infusion every 3 weeks (Q3W)
89538601|NCT03919097||Control|No atrial arrhythmia post-ablation of a flutter by radiofrequency of the isthmus of the cavotricuspid valva.
89538602|NCT03919097||Atrial fibrillation post ablation|Atrial arrhythmia (Atrial Fibrillation) post-ablation of a flutter by radiofrequency of the isthmus of the cavotricuspid valva.
89538603|NCT03919097||Flutter recidive|Recidive of the flutter after ablation.
89538604|NCT03919097||Atrial Fibrillation antecedents|Patients with atrial fibrillation after flutter ablation, with previous antecedents of atrial fibrillation.
89538605|NCT03919097||No Atrial Fibrillation antecedents|Patients with atrial fibrillation after flutter ablation, without antecedents of atrial fibrillation.
89032872|NCT02924142|No Intervention|Comparator|Mandibular removable partial denture with gingival approaching clasp assembly
89538606|NCT04976907||Perioperative patients|Patients undergoing perioperative assessment of vital signs.
89538607|NCT04432389|Experimental|ALLOB|Single injection of ALLOB at fracture site (4 ml)
89538608|NCT04432389|Placebo Comparator|placebo|Single injection of Placebo at fracture site (4 ml)
89538609|NCT03262805|Placebo Comparator|Placebo|Placebo
89538610|NCT03262805|Active Comparator|Active|Lanconone(R)
89538611|NCT03262961|Active Comparator|Intervention Group|• The intervention group will be supplied with Sildenafil Citrate (Respatio® 20mg tablets manufactured by Pharma Right Group , Egypt) according to the patient's weight by the rate of (1.5 mg/kg/day) divided into three doses per day ( every 8 hours) till termination of pregnancy.
89538612|NCT03262961|Placebo Comparator|Control Group|- The control group will be supplied with a placebo drug that has the same shape, size and color but without the active ingredient and it would also be taken in a similar way. The placebo tablet will be manufactured at the faculty of pharmacy, Assiut University.
89538613|NCT04968873|Experimental|Patients with Choledocholithiasis|Patients were managed by elective open cholecystectomy and operative exploration of the common bile duct.
89538614|NCT03257891|Experimental|Arm 1|patients with advanced Adrenocortical- Carcinoma progressing after previous chemotherapy lines will be treated with Cabazitaxel
89538615|NCT03262493|Experimental|Interventional Group|It consists of the use of the feeding tube attachment device (FTAD) to fix the enteral probe.
89538616|NCT03262493|No Intervention|Conventional Group|It consists of the fixation of the enteral probe with adhesive tape of the micropore type and plaster.
89538617|NCT03262649||Crohn's Disease Cohort|250 individuals in the Crohn's Disease Cohort
89538618|NCT03262649||ulcerative colitis cohort|108 individuals in the ulcerative colitis cohort
89538619|NCT01670097|Experimental|Dexamethasone|"Dexamethasone 8 mg (2 capsules of 4 mg) given orally twice a day for 4 days, then 4 mg given orally twice a day for 3 days. In the open label phase, patients assigned to either arm asked to take Dexamethasone 4 mg orally twice a day for 7 days. Patient to blow into spirometry machine 1 time a day to test lung function. Questionnaires completed at baseline and at day 7 and 14. It should take about 15 minutes to complete these questionnaires. Questionnaires completed at baseline and at day 7 and 14. It should take about 15 minutes to complete these questionnaires.~Participants randomized to either dexamethasone or placebo for 7 days in a blinded fashion; this will be followed by an open label phase in which patients in both arms would take dexamethasone for 7 days."
89538620|NCT01670097|Placebo Comparator|Placebo|"Two placebo capsules taken twice a day for 4 days, followed by one capsule twice a day for 3 days. Patient to blow into spirometry machine 1 time a day to test lung function. Questionnaires completed at baseline and at day 7 and 14. It should take about 15 minutes to complete these questionnaires. Questionnaires completed at baseline and at day 7 and 14. It should take about 15 minutes to complete these questionnaires.~Participants randomized to either dexamethasone or placebo for 7 days in a blinded fashion; this will be followed by an open label phase in which patients in both arms would take dexamethasone for 7 days."
89538621|NCT03257423|Active Comparator|I.v. + p.o. antibiotics (APPAC II)|Patients in this group recruited also in APPAC II trial will receive i.v. antibiotics (ertapenem 1 g twice per day) for 2 days followed by p.o. antibiotics (levofloxacin 500 mg x 1 and metronidazole 500 mg x 3) for 5 days, for a total treatment duration of 7 days. From these patients, rectal swab samples will be collected at day 0 (before treatment) and day 1 (after beginning of treatment), serum sample before treatment initiation.
89538622|NCT03257423|Active Comparator|P.o. moxifloxacin (APPAC II)|Patients in this group recruited also in APPAC II trial will receive p.o. antibiotics for a total of 7 days, moxifloxacin 400 mg once per day. From these patients, rectal swab samples of faces will be collected at two time points, day 0 (before treatment) and day 1 (after beginning of treatment), serum sample before treatment initiation.
89032873|NCT02945462|Experimental|autologous mesenchymal stem cells|"Intervention:~Autologous bone marrow derived stem cells will be injected twice intracavernously to enrolled erectile dysfunction patients"
89032874|NCT00528827|Placebo Comparator|1|
89032875|NCT00528827|Experimental|2|5 mcg
89032876|NCT00528827|Experimental|3|2.5
89032877|NCT00528827|Experimental|4|0.5
89032878|NCT02926170|Experimental|rivaroxaban|Rivaroxaban 20 mg per day
89032879|NCT02926170|Active Comparator|acenocumarol|INR adjusted dose
89032880|NCT04691765|Experimental|100 mg SC|100 mg of Kineret (anakinra) will be administered sub-subcutaneously once a day for 28 days (1 cycle) with a maximum of 7 cycles (28 weeks of treatment)
89032881|NCT04691765|Experimental|100 mg SC BID|100 mg of Kineret (anakinra) will be administered sub-subcutaneously twice a day for 28 days (1 cycle) with a maximum of 7 cycles (28 weeks of treatment)
89538623|NCT03257423|Placebo Comparator|Placebo treatment (APPAC III)|Patients in this group recruited also in APPAC III trial will receive i.v. placebo 3 times per day for 3 days followed by p.o. placebo 3 times per day for 4 additional days. From these patients rectal swab samples will be collected twice during the stay at the research hospital (time points 0 and 1 or 3 d) and three times at home (follow-up at one week, six months and one year). Serum samples are taken prior to treatment initiation and at 10 days after the treatment initiation.
89538624|NCT03257423|Other|Surgery (complicated appendicitis)|Patients in this group will undergo appendectomy and are recruited only in the MAPPAC trial. Rectal swab samples and biopsies from the removed appendix will be collected from these patients.
89538625|NCT03257423|Other|Surgery (uncomplicated appendicitis)|Patients in this group will undergo appendectomy either after refusing to participate in the APPAC II or APPAC III trials or after presenting with recurrent appendicitis after antibiotic or placebo therapy. Rectal swab samples of faces and biopsies from the removed appendix will be collected from these patients.
89538626|NCT03257423|Active Comparator|I.v. + p.o. antibiotics (APPAC III)|Patients in this group recruited also in APPAC III trial will receive i.v. antibiotics (ertapenem 1 g twice per day) for 3 days followed by p.o. antibiotics (levofloxacin 500 mg x 1 and metronidazole 500 mg x 3) for 4 days, for a total treatment duration of 7 days. From these patients rectal swab samples will be collected twice during the stay at the research hospital (time points 0 and 1 or 3 d) and three times at home (follow-up at one week, six months and one year). Serum samples are taken prior to treatment initiation and at 10 days after the treatment initiation.
89538627|NCT01670019|Experimental|Asenapine 5-20 mg daily|Asenapine will be started at 5 mg BID. The asenapine dose can be increased to 15 mg daily and then to 20 mg daily, or reduced to 5 mg daily, depending on therapeutic response and tolerability
89538628|NCT01670019|Placebo Comparator|Placebo 1-4 tablets daily|Matched, blinded placebo tablets will be administered at doses from 1-4 tablets daily depending on therapeutic response and tolerability
89538629|NCT04488341|Other|aerobic exercises in addition to diet|The study group will receive aerobic exercises in addition to diet recommendations
89538630|NCT04488341|Other|diet recommendations|control group will receive diet recommendations
89538631|NCT04976517||non-diabetes group|patients who underwent heart tranplantation without diabetes
89538632|NCT04976517||pre-transplant diabetes group|patients who underwent heart tranplantation with diabetes before the transplantation
89538633|NCT04976517||post transplant daibetes group|patients who underwent heart tranplantation without diabetes until after the transplantation
89538634|NCT03262571|Experimental|Group A|Group A includes patients undergoing lung ultrasound and physical examination.
89538635|NCT03262571|Placebo Comparator|Group B|Group B includes patients undergoing physical examination only.
89538636|NCT04976439||Age|
89538637|NCT04976439||Grade|
89538638|NCT04976439||Tumor location|
89538639|NCT04976439||Stage|
89538640|NCT04976439||Lymphovascular invasion|
89538641|NCT01669629|Experimental|Delefilcon A/ Etafilcon A|6-10 days of delefilcon A soft contact lens wear first, then 6-10 days of etafilcon A soft contact lens wear
89538642|NCT01669629|Experimental|Etafilcon A / Delefilcon A|6-10 days of etafilcon A soft contact lens wear first then 6-10 days of delefilcon A soft contact lens wear
89538643|NCT03262727|Experimental|BMS-986165 and Oral Contraceptive|Oral administration of contraceptive, then progress to combination
89538644|NCT03262025||Operated patients who survived|Patients who were discharged in index hospital admission after operative intervention
88956625|NCT04645966|Experimental|Blinded: MenABCWY and placebo with SLP or TLP - 2 months of age|Group 13 - Participants 2 months of age vaccinated with MenABCWY and placebo on a 2+1 schedule, with a determined ratio of participants given SLP or TLP during primary vaccinations.
88956626|NCT04645966|Experimental|Blinded: Bexsero and Nimenrix with PLP or TLP - 2 months of age|Group 14 - Participants 2 months of age vaccinated with Bexsero and Nimenrix on a 2+1 schedule with a determined ratio of participants given PLP or TLP during primary vaccinations.
88956627|NCT04638647|Experimental|Secukinumab s.c.|Participants will be started on 75 mg, 150 mg or 300 mg s.c. Q4W depending on what dose the participant was receiving in the parent trial (for trials with i.v. formulation the starting dose will be 300 mg s.c.). The study medication dose may be modified basedu pon clinical need, the judgement of the investigator and health authority guidelines (if applicable). For pediatric participants, the dose should not be increased beyond the maximum dose evaluated in the respective weight category in the parent protocol.
88956628|NCT04632953||Previously Treated with Triheptanoin|Patients who have been previously treated with triheptanoin in clinical studies: UX007-CL201 (NCT01886378), UX007-CL202 (NCT02214160), UX007-CL302 (2022-001539-10), Investigator Sponsored Trials (ISTs), or UX007-EAP (NCT03773770).
88956629|NCT04632953||Currently Treated with Triheptanoin|New patients enrolling into the DMP currently being treated with triheptanoin (excluding those in the previously treated with triheptanoin cohort).
88956630|NCT04632953||Triheptanoin Naïve|New patients enrolling into the DMP with no exposure to triheptanoin.
88956631|NCT04632953||Triheptanoin Naïve Transitioned to Triheptanoin|Patients already enrolled into the triheptanoin naïve cohort but transition to triheptanoin during the DMP after enrollment.
88956632|NCT04632953||Pregnant unaffected LC-FAOD carrier females|Pregnant, unaffected (women who do not have the mutations causing LC-FAOD) LC-FAOD carrier females, carrying a fetus with a diagnosis of LC-FAOD confirmed via prenatal testing.
88956633|NCT04626596|Experimental|ENG implant|Participants will have the ENG 68 mg implant inserted and in place for 36 months before enrollment. The ENG implant will remain in place for an additional 24 months.
88956634|NCT04619212|Other|Standard of Care|Standard of Care
88956635|NCT04619212|Other|new device|new device
88982890|NCT03176732||Group 4: Hypertensive|Categorized by 24-hr systolic BP (SBP): hypertensive (≥ 135 mm Hg) resistant to 3 or more BP medications ideally including a diuretic (resistant hypertension)
88982891|NCT03147430||Invasive Cancer|Invasive cancer confirmed by biopsy
89538645|NCT03262025||Operated patients who expired|Patients who expired in index hospital admission after operative intervention
89538646|NCT03262025||Non-operated patients who survived|Patients who were discharged in index hospital admission after being managed conservatively
89206321|NCT00296335|Active Comparator|Mitomycin and doxifluridine|Mitomycin-C 20mg/m2 intravenously (day 1), Doxifluridine 460-600mg/m2/day per oral (day 28-day 84)
89538647|NCT03262025||Non-operated patients who expired|Patients who expired in index hospital admission after being managed conservatively
88956636|NCT04610320|Experimental|Daratumumab-SC Injection|"Participants will receive a subcutaneous dose of Daratumumab-SC (1800 mg) weekly for 8 doses and then every other week for 2 doses.~Participants will undergo laboratory testing, including for circulating antibodies, at baseline, prior to each infusion session, and at the end of the study."
88956637|NCT04594369|Experimental|Brensocatib 10 mg|Participants will receive brensocatib 10 mg, tablets orally, once daily, for 52 weeks.
88956638|NCT04594369|Experimental|Brensocatib 25 mg|Participants will receive brensocatib 25 mg, tablets orally, once daily, for 52 weeks.
88956639|NCT04594369|Placebo Comparator|Placebo|Participants will receive a brensocatib-matching placebo, tablets orally, once daily, for 52 weeks.
88956640|NCT04584684|Placebo Comparator|0.9% NaCl Saline|Subject participants will rinse mouth one time for 60 seconds with 10 mL of Saline.
88956641|NCT04584684|Active Comparator|27% Ethanol plus essential oils|Subject participants will rinse mouth one time for 60 seconds with 10 mL 27% ethanol plus essential oils.
88956642|NCT04584684|Active Comparator|0.075% Cetylpyridinium Chloride|Subject participants will rinse mouth one time for 60 seconds with 10 mL 0.075% Cetylpyridinium Chloride.
88956643|NCT04584684|Active Comparator|1.5% w/v Hydrogen Peroxide|Subject participants will rinse mouth one time for 60 seconds with 10 mL of 1.5% w/v hydrogen peroxide rinse.
88956644|NCT04584684|Active Comparator|0.5% w/v Povidone-iodide|Subject participants will rinse mouth one time for 60 seconds with 10 mL .5% w/v povidone-iodide.
88956645|NCT04584684|Active Comparator|0.12% Chlorhexidine Gluconate|Subject participants will rinse mouth one time for 60 seconds with 10 mL of 0.12% Chlorhexidine Gluconate.
88956646|NCT04582201|Experimental|Dosage and Cohorts|"Cohort 1: 100 × 10^6 iNKT cells; Cohort 2: 300 × 10^6 iNKT cells; Cohorts 3 to 4: 1000 × 10^6 iNKT cells~Dosage Frequency and Mode of Administration: agenT-797 will be administered to hospitalized participants as a single intravenous infusion."
88956647|NCT04580927|Experimental|Randomized to breastfeeding self-efficacy enhancing intervention with nurse|Participants receiving breastfeeding self-efficacy enhancing nurse-led intervention plus postpartum standard of care consisting of postpartum medical visits with their obstetrics care provider and for cardiovascular risk assessment, routine postpartum hospital breastfeeding support, as-needed community breastfeeding support, and postpartum medical visits with their obstetrics care provider and for cardiovascular risk assessment.
88982892|NCT03147430||Benign or pre-invasive lesion|Benign or pre-invasive lesion confirmed by biopsy
89206322|NCT00296335|Experimental|Mitomycin, doxifluridine and cisplatin|Mitomycin-C 20mg/m2 intravenously (day 1), Doxifluridine 460-600mg/m2/day per oral (day 28- day 336), Cisplatin 60mg/m2 intravenously (day 28, day 56, day 84, day 112, day 140, and day 168)
89206323|NCT04094597|Placebo Comparator|placebo|saline is given orally in dose of 2 ml per day for one month
89206324|NCT04094597|Active Comparator|lacoferrin|Pravotin is given orally 100 mg per sachet dissolved in 5 ml water given for one month
89502165|NCT05557435|Experimental|Breast milk odor|Participants received breast milk odor before and during heel stick.
89502166|NCT05557435|Placebo Comparator|Placebo|Participants received placebo before and during heel stick.
89502167|NCT05484674|Experimental|One axilla will be treated with deroofing surgery and laser|One axilla will be randomly selected for treatment with deroofing surgery and laser while the other axilla will serve as a control with no treatment for each participant
89502168|NCT02263261|Other|Flex HD Pliable Perforated HADM|Single Arm
89502169|NCT02688387|Experimental|Part 1|Enrolled subjects will receive single oral dose of 4 FDCs i.e., FDC1, FDC2, FDC3 and FDC4, and reference formulations of the 2 monotherapy components taken concurrently in the fasted state. The FDC and reference formulations contains 10 mg ambrisentan and 40 mg tadalafil. Each dosing period will be separated by 7 days wash out period.
89502170|NCT02688387|Experimental|Part 2|Enrolled subjects will receive single oral dose of 4 FDCs i.e., FDC5, FDC6, FDC7 and FDC8, and reference formulations of the 2 monotherapy components taken concurrently in the fasted state. The FDCs and reference formulations contains 10 mg ambrisentan and 40mg Tadalafil. OR Subjects will receive single dose of two FDCs from Part 1 in fed and fasted state. Each dosing period will be separated by 7 days wash out period.
89502171|NCT02688387|Experimental|Part 3|Enrolled subjects will receive single oral dose of 2 FDCs from Part 2 in fed and fasted state. The FDCs contains 10 mg ambrisentan and 40 mg Tadalafil. Each dosing period will be separated by 7 days wash out period.
89502172|NCT05489900|No Intervention|0.9% Saline Infusion|The placebo group will receive 0.9% saline infusion at the same rates as the intervention group.
89502173|NCT05489900|Experimental|Dexmedetomidine Infusion|Dexmedetomidine will be used in the intervention group as follows: beginning in anesthetic induction after obtaining venous access at 1mcg/kg/h for 20 minutes, followed by 0.2 - 0.5 mcg/kg/h until the end of the surgery.
89502174|NCT02476201|Experimental|MPP ON|To activate the Multipoint Pacing (MPP) feature to ON in all patients
89502175|NCT05484362|Experimental|Glucose as reference food|Eleven healthy subjects (male: 6, female: 5) after 10-14h fast, consumed 50 g D-glucose, three times, in different weeks along with 250 mL water; and 50 g D-glucose containing 15 mg and 30 mg of Crocus Sativus tested once, in different weeks along with 250 mL water. Fingertip capillary blood glucose samples were taken at 0, 15, 30, 45, 60, 90 and 120 min postmeal. The first glucose sample was taken exactly 15 min after the beginning of the consumption of the tested beverage.
89502176|NCT05484362|Experimental|15mg of Crocus Sativus as beverage|Eleven healthy subjects (male: 6, female: 5) after 10-14h fast, consumed 50 g D-glucose, three times, in different weeks along with 250 mL water; and 50 g D-glucose containing 15 mg and 30 mg of Crocus Sativus tested once, in different weeks along with 250 mL water. Fingertip capillary blood glucose samples were taken at 0, 15, 30, 45, 60, 90 and 120 min postmeal. The first glucose sample was taken exactly 15 min after the beginning of the consumption of the tested beverage.
89502177|NCT05484362|Experimental|30mg of Crocus Sativus as beverage|Eleven healthy subjects (male: 6, female: 5) after 10-14h fast, consumed 50 g D-glucose, three times, in different weeks along with 250 mL water; and 50 g D-glucose containing 15 mg and 30 mg of Crocus Sativus tested once, in different weeks along with 250 mL water. Fingertip capillary blood glucose samples were taken at 0, 15, 30, 45, 60, 90 and 120 min postmeal. The first glucose sample was taken exactly 15 min after the beginning of the consumption of the tested beverage.
89502178|NCT05489666|Active Comparator|Treatment Group|Participants in this group will be administered an oral Vitamin D3 supplement; 5,000 IU/ day. The participants will take the supplement themselves, orally, once per day, for 8 weeks.
89502179|NCT05489666|Placebo Comparator|Control Group|Participants in this group will be administered an oral, soft-gel, lookalike placebo. The participants will take the supplement themselves, orally, once per day, for 8 weeks.
89502180|NCT04152499|Experimental|Phase I: Dose Escalation|Five dose levels have been selected for evaluation in the Phase I part of the study: 2, 4, 6, 9, and 12 mg/kg of SKB264
89502181|NCT04152499|Experimental|Phase II: Triple Negative Breast cancer|Histologically documented or cytologically , incurable, locally advanced or metastatic cancer
89502182|NCT04152499|Experimental|Phase II: Epithelial ovarian cancer|Histologically documented or cytologically , incurable, locally advanced or metastatic cancer
89502183|NCT04152499|Experimental|Phase II: Non-Small Cell Lung Cancer|Histologically documented or cytologically, incurable, locally advanced or metastatic cancer
89502184|NCT04152499|Experimental|Phase II: Gastric Adenocarcinoma or gastroesophageal junction adenocarcinoma|Histologically or cytologically documented, incurable, locally advanced or metastatic cancer
89502185|NCT04152499|Experimental|Phase II: Extensive-stage small Cell Lung Cancer|Histologically documented or cytologically, incurable, locally advanced or metastatic cancer
89502186|NCT04152499|Experimental|Phase II: HR+/ HER2- breast cancer|Histologically documented or cytologically, incurable, locally advanced or metastatic cancer
89502187|NCT04152499|Experimental|Phase II: Head and neck squamous cell carcinoma|Histologically documented or cytologically , incurable, locally advanced or metastatic cancer
89502188|NCT04152499|Experimental|Phase II: Endometrial carcinoma|Histologically documented or cytologically , incurable, locally advanced or metastatic cancer
89502189|NCT04152499|Experimental|Phase II: Urothelial carcinoma|Histologically or cytologically documented, incurable, locally advanced or metastatic cancer
89502190|NCT04152499|Experimental|Phase II:EGFR wild-type NSCLC|Histologically or cytologically documented, incurable, locally advanced or metastatic cancer
89502191|NCT05489276|Experimental|TQB2825 injection|TQB2825 injection is given intravenously every 2 weeks, and every 4 weeks (28 days) as a treatment cycle, with the longest treatment duration not exceeding 2 years.
89502192|NCT05484284|Experimental|All the patients|patients received two-stage primary total knee arthroplasty with low-dose antibiotics
89502193|NCT05484128|Experimental|Gastrus|"86 patients Gastrus sachets/chewable caps: 2x108 CFU Lactobacillus reuteri DSM 17938 + 2x108 CFU Lactobacillus reuteri ATCC PTA 6475.~Placebo sachets/chewable caps: Identical in shape, colour and taste to Gastrus capsules but without the Lactobacillus reuteri components.~Both study products are delivered in identical containers. Dosing: Two sachets/cps twice a day. Length of treatment: Gastrus or placebo will be administered for all the duration of PPI administration (8 weeks) plus two weeks after its discontinuation. A final evaluation will be performed 4 weeks after the discontinuation of both Gastrus and placebo."
89502194|NCT05484128|Placebo Comparator|Placebo|"86 patients Gastrus sachets/chewable caps: 2x108 CFU Lactobacillus reuteri DSM 17938 + 2x108 CFU Lactobacillus reuteri ATCC PTA 6475.~Placebo sachets/chewable caps: Identical in shape, colour and taste to Gastrus capsules but without the Lactobacillus reuteri components.~Both study products are delivered in identical containers. Dosing: Two sachets/cps twice a day. Length of treatment: Gastrus or placebo will be administered for all the duration of PPI administration (8 weeks) plus two weeks after its discontinuation. A final evaluation will be performed 4 weeks after the discontinuation of both Gastrus and placebo."
89502195|NCT05484050|Other|VEGF in iris tissue in primary congenital glaucoma|Estimation of VEGF grade in iris tissue in primary congenital glaucoma through Immunohistochemistry
89502196|NCT05484050|Other|VEGF in iris tissue from ocular trauma or congenital cataract|Estimation of VEGF grade in iris tissue from ocular trauma or congenital cataract through Immunohistochemistry
89502197|NCT05483894|Active Comparator|Experimental group|Atorvastatin 10mg once daily for 24 weeks
89502198|NCT05483894|Placebo Comparator|Control group|Placebo once daily for 12 weeks and then Atorvastatin 10mg once daily for 12 weeks
89502199|NCT01621243|Placebo Comparator|nab-paclitaxel, gemcitabine, placebo|"Part A: Not applicable.~Part B: nab-paclitaxel, gemcitabine, and placebo. Placebo administered daily along with nab-paclitaxel and gemcitabine administration on Day 1, Day 8, and Day 15 of each 28-day cycle."
89502200|NCT01621243|Experimental|nab-paclitaxel, gemcitabine, necuparanib|"Part A: Following a single-dose of necuparanib and a 7-day follow-up period, necuparanib was administered daily along with nab-paclitaxel and gemcitabine administration on Day 1, Day 8, and Day 15 of each 28-day cycle. Dose escalation of necuparanib proceeded by cohort in a 3+3 design.~Part B: A fixed dose of necuparanib will be administered daily along with nab-paclitaxel and gemcitabine administration on Day 1, Day 8, and Day 15 of each 28-day cycle."
89206325|NCT04093037|Experimental|Patient with dry eye disease|"Patient with dry eye disease will be included. They will have:~Time #1: LacryDiag examination without dye~Time #2: MicroInstillation Break-Up Time (MIBUT) + Oxford score~Time #3: Standard Break-Up Time (SBUT)~Time #4: Schirmer test~Satisfaction questionnaire to the patient"
89502201|NCT05483816|Experimental|Virtual Reality and Transcutaneous Electrical Nerve Stimulation|"for healthy subjects: painful stimulus induction (electrical stimulation) for patients: focus/non focus on pain~Therapy is released in presence of pain"
89502202|NCT05483816|Sham Comparator|Virtual Reality and Transcutaneous Electrical Nerve Stimulation placebo|no modulation of virtual environment and sham tens
89502203|NCT05483816|Active Comparator|Virtual Reality only|only VR delivers therapy
89502204|NCT05483816|Active Comparator|Transcutaneous Electrical Nerve Stimulation only|only TENS delivers therapy
89502205|NCT04076761|Experimental|Trifluridine/Tipiracil|FTD/TPI at 35 mg/m2 (based on BSA) that is administered in tablet form, orally, twice daily, within one hour of morning and evening meals, on days 1-5 and days 8-12 of a 28 day cycle.
89502206|NCT05494112|Experimental|Amount of Celastrol Administered|Chronic evaluation of the same doses of Celastrol to each subject over 90-day period
89502207|NCT05489198|Experimental|Centurion|Cataract surgery performed with the Centurion phacoemulsification system
89502208|NCT05489198|Experimental|Quatera 700|Cataract surgery performed with the Quatera 700 phacoemulsification system
89502209|NCT02235961|Experimental|Part 1|
89502210|NCT02235961|Experimental|Part 2|
89502211|NCT01612039|Experimental|ASP3291|
89502212|NCT01612039|Placebo Comparator|Placebo|
89502213|NCT05483738|Other|Cases and controls|Clinical assessment, blood samples, dual energy x-ray absorptiometry (DXA) scan, and assessment of bone marrow, and tetracycline labelled bone biopsy
89502214|NCT02236039|Active Comparator|Filtered air|Exposure for 2 hours to filtered air followed by a bronchoscopy 24 hours post exposure.
89502215|NCT02236039|Experimental|Diesel exhaust|Exposure for 2 hours to diesel exhaust followed by a bronchoscopy 24 hours post exposure.
89502216|NCT02688153|Active Comparator|EDWARDS INTUITY|EDWARDS INTUITY Valve System, Model 8300A
89502217|NCT02688153|Active Comparator|Stented aortic bioprostheses|Stented aortic bioprostheses
89502218|NCT05493956|Experimental|Consolidation chemoradiation|6 cycles of Chemotherapy with Gemcitabine and Cisplatin will be followed by Concurrent Chemo-radiation with capecitabine
89502219|NCT05493956|Active Comparator|Observation|6 cycles of Chemotherapy with Gemcitabine and Cisplatin will be followed by observation
89502220|NCT02236117|Experimental|Intervention: Aerobic Training|The children included in the experimental group will make 10 weeks of aerobic training. The intensity of the race will be based on individual speed obtained in the last stage completed the progressive test, known as the maximal aerobic speed (MAV) in km/h. The running speed of the exercise protocol will be minimum 80% of the MAV in the protocol of continuous training. The intermittent progressive training is n * (10*15 s) to 100% MAV, and n from 2 to 6 series between the first and tenth week. The training protocol was adapted from previously described (Mandigout et al, 2002, Gamelin et al, 2009.). Acceptance of the exercise in a pediatric population has been previously observed by pilot study.
89502221|NCT02236117|No Intervention|physical education classes|
89502222|NCT01610245|Active Comparator|Nitazoxanide|Two Nitazoxanide 300 mg tablets and one placebo capsule twice daily with food for 5 days
88956648|NCT04580927|No Intervention|Randomized to usual postpartum care|Participants receiving postpartum standard of care consisting of postpartum medical visits with their obstetrics care provider and for cardiovascular risk assessment, routine postpartum hospital breastfeeding support, as-needed community breastfeeding support, and postpartum medical visits with their obstetrics care provider and for cardiovascular risk assessment.
88956649|NCT04580927|No Intervention|Non-randomized observational arm|Participants who are not planning to breastfeed receiving postpartum standard of care consisting of postpartum medical visits with their obstetrics care provider and for cardiovascular risk assessment.
89502223|NCT01610245|Active Comparator|Oseltamivir|Two placebo tablets and one Oseltamivir 75 mg capsule twice daily with food for 5 days
89502224|NCT01610245|Active Comparator|Nitazoxanide and Oseltamivir|Two nitazoxanide 300 mg tablets and one Oseltamivir 75 mg capsule twice daily with food for 5 days
88956652|NCT04575519|Active Comparator|Control group|Standard of Care (SoC) TB treatment + placebo twice daily during first 4 weeks of TB treatment followed by placebo once daily for an additional 4 weeks.
88956653|NCT04575519|Experimental|SoC TB + ASA group|Standard of Care (SoC) TB treatment + acetylsalicylic acid 300mg twice daily during first 4 weeks of TB treatment followed by aspirin 300mg once daily for an additional 4 weeks.
89206326|NCT01065961|Active Comparator|Decadron|Subject will be given Decadron 0.2mg/kg intraoperatively. This dose will be followed by 4 mg. every 6 hours for the first 24 hours.
89502225|NCT01610245|Placebo Comparator|Placebo|Two placebo tablets and one placebo capsule with food twice daily for 5 days
88956654|NCT04575519|Experimental|SoC TB + IBU group|Standard of Care (SoC) TB treatment + ibuprofen 400mg twice daily during first 4 weeks of TB treatment followed by ibuprofen 400mg once daily for an additional 4 weeks
89206327|NCT01065961|Placebo Comparator|Saline|subject will be given a blinded dose of placebo saline intraoperatively followed by placebo doses every 6 hours for 24 hours.
89502226|NCT04138628|Experimental|ctDNA screening arm|Flat dose 1200 mg Atezolizumab every three weeks for up to 13 months
89502227|NCT03162315|No Intervention|Fresh embryo transfer|fresh embryo transfer (standard of care)
89502228|NCT03162315|Experimental|Freeze all|Vitrification of all embryos and replacement of a thawed embryo in a subsequent cycle
89502229|NCT02687919|Experimental|Modified Paleo Diet Intervention (MPDI)|Consumed a modified Paleo diet, described as nine cups of vegetables and some fruits, meat protein including organ meat, and complete abstinence from products containing gluten (wheat, barley, rye, etc.), dairy, potatoes, and legumes (beans, lentils, peanuts, soy, etc.)
89502230|NCT02687919|No Intervention|Usual Care|Typical physician recommendations for MS.
89502231|NCT02263339|Experimental|Aerobic Exercise|
89502232|NCT02263339|Active Comparator|Stretching Program|
89502233|NCT02263339|Active Comparator|Aerobic Exercise, Healthy Subjects|
89502234|NCT05489042|Experimental|Active rTMS|10 sessions of active rTMS
89502235|NCT05489042|Sham Comparator|Sham rTMS|10 sessions of sham rTMS
89502236|NCT03162237|Experimental|Porcine islets and autologous treg|Porcine islets:10000 islet equivalent（IEQ）/Kg; Treg:2x10^6/Kg
88956656|NCT04567303|Experimental|Part 1: Intravitreal Injections|Zifibancimig administered in ascending dose levels through IVT injections.
89502237|NCT03162237|Active Comparator|AutologousTreg|Autologous Treg:2x10^6/Kg
89502238|NCT02741791|Experimental|AXS-05|
89502239|NCT02741791|Active Comparator|Bupropion|
89502240|NCT05483660|Experimental|Lactobacillus plantarum|1.5×10^10 CFU probiotics and adult milk powder 15g per time , three times daily and half an hour before meal.
89206328|NCT04092881|Active Comparator|Short pulsed Nd-YAG laser treatment side|"Neodymium-Doped Yttrium Aluminum Garnet (Nd-YAG) (Fotona XP®) laser is a successful therapeutic modality and is characterized by its safe profile compared to other lasers.~Short pulsed Nd-YAG laser (Fotona XP® Accelera mode) results in a non-ablative dermal heating with intact overlying epidermis which has shown a potential for dermal collagen remodeling in histological sections."
89502241|NCT05483660|Experimental|Bacillus coagulans|1.5×10^10 CFU probiotics and adult milk powder 15g per time , three times daily and half an hour before meal.
89502242|NCT05483660|Experimental|Lactobacillus plantarum + Bacillus coagulans|1.5×10^10 CFU probiotics and adult milk powder 15g per time , three times daily and half an hour before meal.
89502243|NCT05483660|Placebo Comparator|Placebo|Adult milk powder 15 g per time, three times daily and half an hour before meal.
89502244|NCT04119518|Other|Healthy and hypertensive subjects|Subjects will be enrolled to be monitored for 24 hours via: the non-occlusive CSEM Pulse Watch, and a gold standard oscillometric device (Spacelabs OnTrak Ambulatory Blood Pressure monitor, Spacelabs Healthcare, Washington, USA) internationally validated for the 24h ABPM.
89502245|NCT05438173|Experimental|EPA + DHA Ruby-O|Subject will receive a single 1000 mg oral dose of EPA + DHA Ruby-O capsule
89502246|NCT05438173|Active Comparator|EPA + DHA Krill Oil|Subject will receive a single 1000 mg oral dose of EPA + DHA krill oil capsule
89502247|NCT05483504|Active Comparator|F61 injection|"F61 injection, specification: 150 mg/5ml/bottle, batch number: 202202002-1, produced by Wuhan Institute of Biological Products Co., Ltd.~Validity period: 24 months; Storage conditions: 2~8°C, protected from light and sealed."
89502248|NCT05483504|Placebo Comparator|F61 placebo|"F61 placebo, specification: 5 ml/bottle, produced by Wuhan Institute of Biological Products Co., Ltd.~Validity period: 24 months; Storage conditions: 2~8°C, protected from light and sealed."
89502249|NCT05493644||group A|Within 3 months of treatment failure in the course of Helicobacter pylori infection,Patients will receive esomeprazole (Nexium) 40mg po bid, bismuth potassium citrate(Lizhudele) 220mg po bid, amoxicillin1000mg po bid and tetracycline 500 mg po qid (or tetracycline 500 mg po tid) for 14d.
89502250|NCT05493644||group B|Within 3 to 6 months of treatment failure in the course of Helicobacter pylori infection,Patients will receive esomeprazole (Nexium) 40mg po bid, bismuth potassium citrate(Lizhudele) 220mg po bid, amoxicillin1000mg po bid and tetracycline 500 mg po qid (or tetracycline 500 mg po tid) for 14d.
89502251|NCT05493644||group C|Within 6 to 12 months of treatment failure in the course of Helicobacter pylori infection,Patients will receive esomeprazole (Nexium) 40mg po bid, bismuth potassium citrate(Lizhudele) 220mg po bid, amoxicillin1000mg po bid and tetracycline 500 mg po qid (or tetracycline 500 mg po tid) for 14d.
89502252|NCT05493644||group D|After 12 months of treatment failure in the course of Helicobacter pylori infection,Patients will receive esomeprazole (Nexium) 40mg po bid, bismuth potassium citrate(Lizhudele) 220mg po bid, amoxicillin1000mg po bid and tetracycline 500 mg po qid (or tetracycline 500 mg po tid) for 14d.
89502253|NCT04275518|Experimental|APG-115/APG-115+Cytarabine in Relapse/Refractory AML|
89502254|NCT04275518|Experimental|APG-115/APG-115+Aza in relapsed/progressed high risk MDS|
89502255|NCT05410171|Experimental|AI group|patients evaluated by early warning platform
89502256|NCT05410171|No Intervention|usual care group|patients not evaluated by early warning platform
89502257|NCT02263495|Active Comparator|Paclitaxel & Gemcitabine(PG)|Paclitaxel 175mg/m2 IV , Day1,every 3weeks Gemcitabine 1250mg/m2 IV ,Day1& Day8 every 3weeks
89502258|NCT02263495|Experimental|Eribulin & Gemcitabine(EG)|Eribulin 1.0 mg/m2, 2-5min iv ,Day1& Day8 every 3weeks Gemcitabine 1,000 mg/m2 ,Day1& Day8 every 3weeks
89502259|NCT02687451|Experimental|Oxymorphone HCl Open-Label Phase|Oxymorphone HCl Immediate Release Oral Liquid and Oxymorphone HCl Injection; open-label, single-dose, dose selection phase.
89502260|NCT02687451|Experimental|Oxymorphone HCl Multiple-Dose Phase|Oxymorphone HCl Immediate Release Oral Liquid and Oxymorphone HCl Injection; placebo controlled, randomized, double-blinded multiple-dose phase.
89502261|NCT02687451|Placebo Comparator|Placebo|Sodium Chloride 0.9% solution; comparator for multiple-dose phase.
89502262|NCT03908281|Experimental|Fasted Exercise|Exercise training will be performed in the fasted state (i.e., before breakfast).
89502263|NCT03908281|Active Comparator|Postprandial Exercise|Exercise will be performed in the postprandial period (i.e., after breakfast)
89502264|NCT02263573|Experimental|PEP'C-R|Subjects will benefit from one preliminary session and 18 sessions of PEP'C-R, (2 sessions per week for 9.5 weeks).
89502265|NCT02263573|Active Comparator|Control group|Subjects do not participate in the program PEP'C-R and continue their usual activities at home for 9.5 weeks.
88956657|NCT04567303|Experimental|Part 2: Port Delivery with High Dose|Zifibancimig administered at a high dose through the PD implant.
88956658|NCT04567303|Experimental|Part 2: Port Delivery with Low Dose|Zifibancimig administered at a low dose through the PD implant.
88956659|NCT04567303|Experimental|Part 3: Port Delivery with High Dose|Zifibancimig administered at a high dose through the PD implant.
88956660|NCT04567303|Experimental|Part 3: Port Delivery with Low Dose|Zifibancimig administered at a low dose through the PD implant.
88956661|NCT04567303|Active Comparator|Part 3: Port Delivery with Ranibizumab|100 milligrams/milliliter (mg/mL) of ranibizumab administered through the PD implant.
88956662|NCT04558593||active surveillance|220 participants will be included in the active surveillance group. Active surveillance is close monitoring (every 6 months the first 3 years following diagnosis and annually the following years), done per standard of care Close monitoring include: abdominal imaging (ultrasound, CT or MRI), chest X-ray or CT scan and blood tests
88956663|NCT04558593||surgery|110 participants will be included in the surgery group. Surgery is done per standard of care. The type of surgery is at the discretion of the treating physician and may include: partial resection, total resection, thermoablation.
88956664|NCT04547153|Experimental|LD-FUD (Zhen Long)|5-fluorouracil 200mg/square metre/day continuously venous infusion on days 1-21; Docetaxel 25mg/square metre, on days 1, 8 and 15; This regimen repeats every 4 weeks.
88956665|NCT04535414|Experimental|1/ Arm 1|Bethesda protocol (investigational)with confocal endomicroscopy in assigned participants
89206329|NCT04092881|Active Comparator|Fractional ablative CO2 laser treatment side|"Carbon dioxide (CO2) (Deka SmartXide DOT®) laser is one of the well-tolerated therapeutic modalities used for treatment of different skin disorders including striae alba.~CO2 laser targets mainly water content in both epidermis and dermis causing vaporization of target cells.~Fractional ablative CO2 laser creates columns of focal dermo-epidermal tissue loss known as (microablative columns) with thermal damage, hemostatic effect and incomplete coagulation of tissues. This ablation of dermal tissues (including collagen and elastin) has the potential for stimulation of new tissue formation in striae distensae."
89206330|NCT01068223|Experimental|001|A:JNJ-39758979/Placebo #1 Single oral dose of JNJ-39758979 600 mg and Placebo
89206331|NCT01068223|Placebo Comparator|002|B: JNJ-39758979 Matching Placebo /Placebo #2 A single dose of 2 different Placebos JNJ-39758979 Matching Placebo and Placebo #2
89206332|NCT01068223|Active Comparator|003|C:Cetirizine/JNJ-39758979 Matching Placebo Single oral dose of 10mg cetirizine and JNJ-39758979 Matching Placebo
89206333|NCT02600273|Active Comparator|Usual brand cigarettes|During one session, participants will smoke their usual brand cigarettes
89206334|NCT02600273|Experimental|Lower nicotine content cigarettes|During one session, participants will smoke SPECTRUM Research Cigarettes
89206335|NCT02600273|Experimental|Electronic cigarettes 1|During one session, participants will use an electronic cigarette with 0 mg/mL nicotine e-liquid
89206336|NCT02600273|Experimental|Electronic cigarettes 2|During one session, participants will use an electronic cigarette with 18 mg/mL nicotine e-liquid
89206337|NCT01069393|Active Comparator|Standard DAFNE|Usual DAFNE course taught over 5 consecutive days in one week
89206338|NCT01069393|Experimental|DAFNE 5x1 day|DAFNE course taught 1 day a week for 5 consecutive weeks
89206339|NCT01063309||Autosomal recessive CGD|Participants must have autosomal recessive CGD (p47phox, p67phox, or p22phox deficiency) as demonstrated by DHR or genetic screening.
89206340|NCT01063309||CGD carrier|Participants with confirmed as X-linked CGD carriers as demonstrated by DHR or genetic screening.
89206341|NCT01063309||Healthy Volunteer|Healthy volunteers over the age of 18, both male and female. That have not been diagnosed with CGD, Inflammatory Bowel Disease, or another primary disease of the immune system.
89206342|NCT01063309||IFN-gamma treated CGD|Participants with CGD the have been treated with Interferon gamma.
89206343|NCT01063309||Inflammatory bowel disease|Participants with Inflammatory Bowel Disease with a well-recognized granulomatous inflammation, but normal phagocyte function and ROS production. They have not been diagnosed with CGD.
89206344|NCT01063309||Other immune system disorders|Participants with other disorders such as Chediak-Higashi Syndrome, Leukocyte Adhesion Deficiency, myeloperoxidase deficiency, Hyper- IgE (Job's) Syndrome, IRAK4-deficiency, and NEMO-deficiency
89206345|NCT01063309||X-linked Chronic Granulomatous Disease (CGD)|Participants diagnosed with X-linked CGD confirmed by DHR.
89206346|NCT00747461|Experimental|Cryospray Ablation|Experimental CSA (Cryospray Ablation)
88956666|NCT04535414|Active Comparator|2/ Arm 2|Cambridge method (control) with confocal endomicroscopy in assigned participants
89206347|NCT01063387|No Intervention|Sema4c positive +Common iliac lymph nodes control|"Sema4c Positive & Radical hysterectomy +Pelvic Radiotherapy "
89206348|NCT01063387|Active Comparator|Sema4c positive +Common iliac lymph nodes Experimental|"Sema4c Positive & Radical hysterectomy+ EFI(whole pelvis + para-aortic lymph node irradiation) "
89206349|NCT01063387|No Intervention|Sema4c Positive + PAN positive control arm|"Sema4c Positive &  Radical hysterectomy+ EFI(whole pelvis + para-aortic lymph node irradiation) "
89206350|NCT01063387|Experimental|Sema4c positive+ PAN positive Experimental|Sema4c Positive & Radical hysterectomy+ EFI(whole pelvis + para-aortic lymph node irradiation+ supraclavicular lymph nodes irradiation) '
89206351|NCT01068301|Other|Second Allogeneic Transplant Procedure Recipient|"Participants with Acute Lymphoblastic Leukemia (ALL); Acute Myeloid Leukemia (AML); Myelodysplastic Syndrome (MDS); Chronic Myeloid Leukemia (CML); Juvenile Myelomonocytic Leukemia (JMML); Non-Hodgkin lymphoma (NHL) with evidence of bone marrow disease, receiving a second allogeneic transplant procedure.~Intervention: Plerixafor"
89206352|NCT04092491||1 blood sample|"1 blood sample during a consultation carried out as part of a medical follow-up:~2 PAXgene RNA tubes of 2 ml each~1 dry tube for creatinine and IgA assay~1 tube of NFs (5ml)"
89206353|NCT01068379|Experimental|Cryopexy|the cryopexy was performed by placement of a normal spherical probe under the bucklings, around the break. The number of cryo applications was limited in number of 3. Freezing was stopped at the beginning of retinal whitening.
89206354|NCT01068379|Experimental|laser photocoagulation 4 weeks after|Laser-retinopexy was performed after proper positioning the patients; laser energy was delivered by depressing a foot pedal. Short burn duration (0.1 seconds) and low (300-miliWatts) power settings were used initially, and both the burn duration and power were gradually increased as determined by observation.
89206355|NCT04866550||Connected tablet|Patients aged over 60, living at home, with heart failure and / or chronic obstructive pulmonary disease, potentially requiring care cross-border (France and Belgium).
89206356|NCT04092569|Active Comparator|Intervention group|Pre-medical consultation structured diabetes self-care education programme
89206357|NCT04092569|No Intervention|Control group|Usual care
89206358|NCT01063465|Experimental|Early weightbearing|
89206359|NCT01063465|Experimental|Control group|
89206360|NCT03873766|Active Comparator|Intrapleural fibrinolytic therapy (IPFT)|"Procedure/Surgery: Pleural Sampling~Procedure/Surgery: Pleural fluid drainage~Protocol Image #1: After chest tube is placed, imaging is obtained within 24-48 hours to assess the fluid drainage.~Other: Surgical Consultation~Intrapleural Medications (IPFT): The IPFT group will receive a total of 5-6 doses of alteplase 10mg and DNase 5 mg twice daily x 3 days. delivered through a chest tube or small bore catheter into the pleural space. The doses will be given twice a day.~Protocol Image #2: Chest X-ray PA/Lateral: The morning after intervention completion, a chest X-ray PA/lateral will be obtained~Quality of Life: Quality of life will be measured at 30 day and 90 day and 1 year clinical follow-up using the SF-36 quality of life survey and return to work questionnaires"
88956667|NCT04534010|Experimental|NACgraft patients|uni- or bilateral engraftment surgery will be performed
89502266|NCT02557646||Pegasys + Copegus|Treatment naive participants with confirmed chronic hepatitis C who are started on combined Pegasys-Copegus treatment in accordance with current guidelines and SPCs, and whose treatment has been approved by the Interferon Committee.
89502267|NCT02263651|Active Comparator|Closure with conventional technique with drainage|The skin flaps are not fixed subcutaneously but sutured at the edges, a closed suction drain is inserted under the flaps in the dead space created by the dissection at the pectoral area. The drain is stitched to the skin.
89502268|NCT02263651|Experimental|Quilting suture without drainage|In an attempt to obliterate the dead space, the skin flaps are sutured to the underlying pectoralis major with multiple parallel rows of 0/0 vicryl (or equivalent). Running sutures at periodic intervals (<2cm) are placed from the skin flaps to the underlying muscle.
89502269|NCT02679573|Experimental|Delafloxacin|IV delafloxacin with potential to switch to oral delafloxacin
89502270|NCT02679573|Active Comparator|Moxifloxacin/Linezolid|IV moxifloxacin with potential to switch to oral moxifloxacin, and potential to switch moxifloxacin to IV linezolid for confirmed MRSA
89502271|NCT02236273|Experimental|Conventional Text Message|Conventional text message reminder
89502272|NCT02236273|Experimental|Enhanced reminders|Enhanced text message reminders
89502273|NCT05493410|Experimental|TREATMENT GROUP (TG)|Pulmonary rehabilitation protocol consisting of muscle strengthening, aerobic training, and IMT using the POWERbreathe Classic Medic® device - será comparado with the CONTROL GROUP (CG), which will not undergo IMT.
89502274|NCT05493410|Active Comparator|CONTROL GROUP (CG)|Pulmonary rehabilitation protocol consisting of muscle strengthening and aerobic training.
89502275|NCT05338957|Experimental|MRG002+HX008|"MRG002 will be administrated via intravenous infusion at 1.8，,2.2, or 2.6 mg/kg , (if appropriate) once on Day 1 of every 3 weeks (21-day cycle), up to 24 months.~HX008 will be administrated via intravenous infusion at 3 mg/kg once on Day 1 of every 3 weeks (21-day- cycle), up to 24 months."
89502276|NCT05493332|Experimental|HAIC-Donafenib-Toripalimab Group|HAIC(FOLFOX)+Toripalimab+Donafenib
89502277|NCT01591447|Experimental|Solithromycin (CEM-101)|A single oral dose of 1200 mg solithromycin
89502278|NCT01591447|Experimental|Solithromycin 1000 mg|A single oral dose of 1000 mg solithromycin
89502279|NCT01578655|Experimental|Cabazitaxel plus Custirsen|cabazitaxel, prednisone, and custirsen sodium
89502280|NCT01578655|Active Comparator|Cabazitaxel|cabazitaxel and prednisone
89502281|NCT04781049|Experimental|TPLA (Trans-Perineal Laser Ablation of Prostate)|Participants who undergo Trans-Perineal Laser Ablation of Prostate
89502282|NCT04781049|Active Comparator|TURP (Trans-Urethral Resection of Prostate)|Participants who undergo the standard treatment, namely Trans-Urethral Resection of Prostate
89502283|NCT05483426|Other|Interviews|semi-directive interview
89502284|NCT03963596|Active Comparator|Ranibizumab|Arm 1
89502285|NCT03963596|Active Comparator|Aflibercept|Arm 2
89502286|NCT01577173|Experimental|A: MEHD7945A|
89502287|NCT01577173|Active Comparator|B: Cetuximab|
89502288|NCT01573351|Experimental|QUAD: Asunaprevir+Daclatasvir+Peg-interferon Alfa-2a+Ribavirin|"Asunaprevir: Capsule, Oral, 100 mg, Twice daily, 24 weeks~Daclatasvir: Tablet, Oral, 60 mg, Once daily, 24 weeks~Peg-interferon Alfa-2a: Injection, subcutaneous (SC), 180 mcg/0.5 mL, Once weekly, 24 weeks~Ribavirin: Tablet, Oral, 1000 mg/1200 mg (total daily dose), 24 weeks"
89502289|NCT03162159||cohort for model computing|patients with CAH, born between 1970 and 1993, with genetically proven CAH, available growth and bone maturation data.
89502290|NCT03162159||cohort for model validation|patients with CAH, born between 1994 and 1998, with genetically proven CAH, available growth and bone maturation data.
89502291|NCT05483348||Patients who had successful endometrial ablation|Patients included in this group experienced abnormal uterine bleeding and underwent endometrial ablation. Successful ablation was defined as not undergoing subsequent gynecological procedures such as hysterectomy for any benign indication, D&C or repeat ablation within 36 months after the endometrial ablation.
89502292|NCT05483348||Patients who had unsuccessful endometrial ablation|Patients included in this group experienced abnormal uterine bleeding and underwent endometrial ablation. Unsuccessful ablation was defined as undergoing subsequent gynecological procedures such as hysterectomy for any benign indication, D&C or repeat ablation within 36 months after the endometrial ablation.
89502293|NCT02685033|Experimental|Dalbavancin|Dalbavancin 1500 mg, intravenous (IV) administration over 30 minutes on Day 1 and Day 8. If creatinine clearance was < 30 milliliters per minute (mL/min) and participant was not receiving regular hemodialysis or peritoneal dialysis, dalbavancin dose was decreased to 1000 mg.
89502294|NCT02685033|Active Comparator|Standard of Care|Antibiotic consistent with Standard of Care (SOC), based on baseline pathogen, for 4 to 6 weeks.
89502295|NCT01559701|Experimental|PF-00345439 (oxycodone)|PF-00345439 (oxycodone)
89502296|NCT05488730|Other|shocked patient with impaired cardiac contractility|
89502297|NCT03135613|Experimental|Normal|Participants of this group are as controls.
89502298|NCT03135613|Experimental|MF|Participants of this group are patients with tumor around knee after microwave ablation with plate internal fixation.
89502299|NCT02684097|Active Comparator|Tralokinumab|Tralokinumab subcutaneous injection every two weeks for 24 weeks
89502300|NCT02684097|Placebo Comparator|Placebo|Saline subcutaneous injection every two weeks for 24 weeks.
89502301|NCT05483192|Placebo Comparator|Comparison between placebo and active treatment|"120 subjects were planned. Screening data was reviewed to determine subject eligibility. Subjects who met all inclusion criteria and none of the exclusion criteria were enrolled into the study.~The following investigational products were used:~Test product: Dichrostachys glomerata extract (Dyglomera™) at a dose of 400 mg~Control product: Placebo at a dose of 400 mg Subjects were assigned to the test group or placebo group in random order. Each subject was administered a single 400 mg dose of Dyglomera or placebo once daily, before lunch or dinner. Measurements were taken at baseline and at the beginning of each of the 5 study visits."
89502302|NCT05483192|Active Comparator|Comparison of baseline to final outcome|The effect of Dyglomera on body fat and blood parameters were compared at baseline and at the end of the intervention period.
89502303|NCT02555618|Experimental|TAK-850|A single dose of 0.5 mL TAK-850 (15 μg of hemagglutinin [HA] antigen per strain) is injected subcutaneously into the upper arm.
89502304|NCT02555618|Active Comparator|Influenza HA Vaccine|A single dose of the 0.5 mL influenza HA vaccine (15 μg of HA antigen per strain) is injected subcutaneously into the upper arm.
89206361|NCT03873766|Active Comparator|Surgery|"Procedure/Surgery: Pleural Sampling~Procedure/Surgery: Pleural fluid drainage: Chest tube placement~Protocol Image #1: Once the chest tube is placed, imaging is obtained within 24-48 hours to assess the fluid drainage.~Other: Surgical Consultation~Surgery: The surgical arm will have either open surgery or a VATS approach at the discretion of the surgeon~Protocol Image #2: Chest X-ray PA/Lateral: The morning after intervention completion (surgery or last dose of IPFT), a chest X-ray PA/lateral will be obtained~Quality of Life: Quality of life will be measured at 30 day and 90 day and 1 year clinical follow-up using the SF-36 quality of life survey and return to work questionnaires"
89206362|NCT02598479||IPTLD and nutrition therapy|Patients presenting to the Arizona Center for Advanced Medicine for the treatment of cancer using Insulin Potentiation Low Dose Chemotherapy and Nutrition Therapy
89206363|NCT01069471|Experimental|HHD O1-EPA plus adjuvant|10 ug of Shigella dysenteriae polysaccharide O1 conjugated to EPA adjuvanted to aluminium hydroxide
89206364|NCT01069471|Experimental|HHD O1-EPA|10 ug of Shigella dysenteriae polysaccharide O1 conjugated to EPA
89206365|NCT01069471|Experimental|LHD O1-EPA adjuvanted|2 ug of Shigella dysenteriae polysaccharide O1 conjugated to EPA adjuvanted to aluminium hydroxide
89206366|NCT01069471|Experimental|LHD O1-EPA|2 ug of Shigella dysenteriae polysaccharide O1 conjugated to EPA
89206367|NCT04094129|Placebo Comparator|Placebo|Subjects received two placebo sachets per day
89206368|NCT04094129|Experimental|Probiotic|Subjects received two Wismemo sachets with 1x10^10 cfu/day
89206369|NCT03683758|Experimental|FIFA11+ / Intervention Group|This group will complete the FIFA11+ warm-up three times per week for eight weeks.
89206370|NCT03683758|Active Comparator|Typical Warm-up / Control Group|This group will complete their usual warm-up three times per week for eight weeks
89206371|NCT03976921|Experimental|CCTA Strategy|CCTA will be performed with one of the latest generation scanners. A stenosis > 50% will be considered as significant from an anatomical point of view. For coronary stents, degree of intrastent restenosis will be evaluated by visual assessment of intraluminal contrast density. ISR > 50% will be considered as significant from an anatomical point of view. For CABG, each graft will be visually evaluated and scored as patent, non-significant stenosis ≤ 50%, significant stenosis > 50%, or occluded. For patients with positive CCTA results, additional stress CTP will be performed subsequently. If indicated, vasodilatation will be induced with i.v. adenosine injection or regadenoson. Static or dynamic CTP will be performed according to local practice and scanner technology available. For all patients with previous history of MI the presence of reversible ischemia will be obtained by the comparison between rest and stress perfusion.
89206372|NCT03976921|Active Comparator|Standard of care Strategy|Patients randomized to this group will be evaluated according to current clinical guidelines with the following approaches: (a) stress ECG, or imaging-based tests such as Stress Echo, Stress CMR, SPECT or PET; (b) direct referral to ICA.
89206373|NCT04092023|Other|Control group|Participants in control group will be received usual care. They will be gone through yearly DM complication screening. A screening report and information sheet on general DM management will be issued to participants. Therapeutic goals will be set and further conventional health care education intervention will be referred.
89206374|NCT04092023|Other|Intervention group|The interventions are designed to address the seven key self-management behaviours identified by the Association of American Diabetes Educations: (1) healthy eating, (2) being active, (3) monitoring, (4) taking medication, (5) problem solving, (6) reducing risk, and (7) healthy coping. In addition, the Chronic Care Model elements of self-management support and patient centered-care approach is embraced during the intervention process. The nursing care components provided to participants will be included (a) self-care management knowledge, (b) skill-based learning and problem solving, (c) participants' participation and engagement, (d) participants' in goal setting, and (e) coordinate care, involve participants to make decision.
89206375|NCT01069549||subjects with diabetic nephropathy.|"Subjects with Type 2 Diabetes. Duration of diabetes should be more than or equal to 5 years. Age between 30 and 85 years. Diabetic nephropathy as defined by ADA.~Subject must be of north Indian origin.~Type 1 diabetes and kidney disease other than diabetes nephropathy are excluded form the study."
89206376|NCT01069549||Subjects without Diabetic nephropathy.|This group of subject with similar characteristics as group 1 without any evidence of nephropathy.
89206377|NCT04767958|Experimental|Patients consulted upon by ICU, internal medicine, or cardiology for hospital admission|All patients will have both standard care and point-of-care (experimental) NP swabs performed.
89206378|NCT04767958|Experimental|patients undergoing cardiac testing/procedures|All patients will have both standard care and point-of-care (experimental) NP swabs performed.
89206379|NCT04767958|Experimental|patients awaiting surgery|All patients will have both standard care and point-of-care (experimental) NP swabs performed.
89206380|NCT04767958|Experimental|Health Care Workers|Health Care Workers who are being screened for COVID-19 will have both standard care and point-of-care NP swabs performed.
89206381|NCT02599259|Experimental|1. Monitored (M+)|Group receiving treatment as usual (TAU) and using the AiCure platform for monitoring and intervention platform on a mobile device being tested when taking their daily anticoagulation medication.
89206382|NCT02599259|No Intervention|Unmonitored (M-)|No Intervention. Group receiving TAU and not issued mobile device with the AiCure platform.
89206383|NCT00998062||1|Data from epidemiological studies performed after the year 2000 with patients between 35 and 74 years old
89206384|NCT02600039|Experimental|ELTGOL|
89206385|NCT02600039|Active Comparator|Acapella|
89206386|NCT01564810|Experimental|Arm A|patients received cetuximab in combination with chemotherapy
89502305|NCT00258427|Experimental|Marrow Isolex|Bone marrow processed using Isolex300i
89502306|NCT00258427|Experimental|USB arm|No processing
89502307|NCT00258427|Experimental|Marrow Clinimacs|Bone marrow processed using CliniMACS system
89502308|NCT00258427|Experimental|Sibling without CliniMacs|Sibling donor without the use of CliniMACS system
89502309|NCT03135457|Other|Group A|Patients will receive infusion of 300mL saline with a subsequent autologous Red Blood Cells (RBC) transfusion of 300 mL at a rate of 10mL/min
89502310|NCT03135457|Other|Group B|Patients will receive infusion of 300mL autologous RBC with a subsequent saline transfusion of 300 mL at a rate of 10mL/min
89502311|NCT05483114|Active Comparator|Polyvinylsiloxane|Accuracy of indirect bonding of self-ligating brackets made with polyvinylsiloxane transfers
89502312|NCT05483114|Active Comparator|Thermal glue|Accuracy of indirect bonding of self-ligating brackets made with thermal glue transfers
89502313|NCT02782117|Experimental|Treatment Regimen A|Treatment Regimen A will use the Luminopia device for an hour per day for 12 weeks.
89502314|NCT05488418|Experimental|Patients exposed to a potentially traumatic event|
89502315|NCT01531699|Experimental|ALT005 Ophthalmic Prep Solution|
89502316|NCT01531699|Placebo Comparator|saline control|
89502317|NCT01531699|Experimental|Comparator Product|Betadine ophthalmic prep solution
89502318|NCT02233621|Experimental|PET with [18F]-FES|PET with [18F]-FES compared to histological analysis performed at least on one biopsy done during coelioscopy.
89502319|NCT02233699|Experimental|XEN-D0501|4mg BID Days 1-13, 4mg once daily (OD) Day 14
89502320|NCT02233699|Placebo Comparator|Placebo to Match|BID Days 1-13, once daily (OD) Day 14
89502321|NCT02557100|Experimental|Treatment A|Abatacept Single Blind Treatment Period
89502322|NCT02557100|Active Comparator|Treatment B|Adalimumab Single Blind Treatment Period
89502323|NCT02557100|Active Comparator|Treatment C|Abatacept Cumulative Treatment Period
89502324|NCT02233777|Experimental|Pregabalin capsules 150 mg of Dexa Medica|Each capsule contains 150 mg pregabalin.
89502325|NCT02233777|Active Comparator|Pregabalin capsules 150 mg of Pfizer Manufacturing Deutschland|Each capsule contains 150 mg pregabalin.
89502326|NCT02236507|Other|children without anorectal disorders|All children will be investigated by 3D high resolution anorectal manometry procedure
89502327|NCT02261545|Active Comparator|n-3 Fatty Acid Supplemetation|patients with Type II Diabetes who receive 3 cap omega3, 3 times a day, for 10 weeks.
89502328|NCT02261545|Placebo Comparator|Placebo|patients with Type II Diabetes who receive 3 cap of placebo/ for 10 weeks.
89502329|NCT05171491||Indeterminate Lung Nodule|Subjects that present with indeterminate lung nodules at time of biopsy. No intervention outside of standard of care.
89502330|NCT01528111|Experimental|Low dose LX7101|Days 1-3: once daily dose in study eye (eye with highest IOP); Days 4-7: once daily dose in study eye (eye with highest IOP) and fellow eye (other eye); Days 8-14: twice daily dose in study eye (eye with highest IOP) and fellow eye (other eye)
89502331|NCT01528111|Experimental|High dose LX7101|Days 1-3: once daily dose in study eye (eye with highest IOP); Days 4-7: once daily dose in study eye (eye with highest IOP) and fellow eye (other eye); Days 8-14: twice daily dose in study eye (eye with highest IOP) and fellow eye (other eye)
89502332|NCT01528111|Placebo Comparator|LX7101 Vehicle|Days 1-3: once daily dose in study eye (eye with highest IOP); Days 4-7: once daily dose in study eye (eye with highest IOP) and fellow eye (other eye); Days 8-14: twice daily dose in study eye (eye with highest IOP) and fellow eye (other eye)
89502333|NCT02634853|Active Comparator|Tavilermide Ophthalmic Solution|1% Tavilermide Ophthalmic Solution
89502334|NCT02634853|Placebo Comparator|Vehicle Ophthalmic Solution|Placebo Ophthalmic Solution
89502335|NCT01520545|Experimental|Gablofen 3 mg/mL (baclofen Injection)|3 mg/mL Gablofen (baclofen Injection)
89502336|NCT02624947|Placebo Comparator|Treatment Group A|Formulation buffer (0.5mL injection)
89502337|NCT02624947|Active Comparator|Treatment Group|RSV F vaccine with adjuvant (0.5mL injection)
89502338|NCT05488184|Experimental|Dietary Supplement|Five different flavours of Oral Nutritional Supplement (ONS) prototypes were tested: tropical, pineapple, brownie, ham, tomato
89502339|NCT02261623||Palliation|Palliative treatment of biliary strictures produced by malignant neoplasms, no intended surgery
89502340|NCT02261623||Curative intent surgery|Palliative treatment of biliary strictures produced by malignant neoplasms, prior to curative intent surgery, with or without neoadjuvant therapy
89502341|NCT02261623||Benign biliary strictures|Treatment of benign biliary strictures
89502342|NCT02261623||Other indication|Other indication
89502343|NCT05488106|Placebo Comparator|Placebo|
89502344|NCT05488106|Active Comparator|Dose 1|
89502345|NCT05488106|Active Comparator|Dose 2|
89502346|NCT05488106|Active Comparator|Dose 3|
89502347|NCT02233933|Active Comparator|argon plasma coagulation|argon plasma coagulation of radiation proctitis
89502348|NCT02233933|Experimental|argon plasma coagulator and hemospray|treatment of radiation proctitis with argon plasma coagulator followed by application of hemospray
89502349|NCT05492318|Experimental|Givinostat, Dabigatran etexilate, Midazolam oral and IV.|"On Days 1, 6 and 17, single doses of midazolam 1 mg i.v and dabigatran etexilate 75 mg, administered 1 hour after givinostat administration.~On Days 2, 7 and 18, a single oral dose of midazolam 2.5 mg oral solution will be administered 1 hour after givinostat. From Day 4 to Day 18, givinostat 50 mg as oral suspension will be administered twice a day. On Day 19, givinostat administered once."
89502350|NCT05492318|Experimental|Givinostat and Clarithromycin|Days 1 and 8, givinostat 50 mg as oral suspension will be administered as a single dose, 1 hour after clarithromycin administration. From Day 4 to Day 10, clarithromycin 500 mg film-coated tablets will be administered twice a day.
89502351|NCT05492318|Other|Givinostat (50 mg oral suspension)|On Day 1 and Day 13, givinostat 50 mg will be administered as a single dose. From Day 5 to Day 12, givinostat 50 mg will be administered twice a day.
89502352|NCT01337635|Active Comparator|Standard dose vitamin D|Treatment with cholecalciferol 400 IU daily at home.
89502353|NCT01337635|Active Comparator|High dose vitamin D|Treatment with ergocalciferol 300,000 IU (6 capsules of 50,000 IU) as a single oral dose observed in clinic.
89023595|NCT05089695|Experimental|Helmet Noninvasive ventilation (NIV)|"Patients in helmet noninvasive ventilation group will receive continuous helmet pressure support ventilation for at least 16 hours/day in the first 2 calendar days. Dedicated helmets for noninvasive ventilation will be applied and size will be chosen according to patient's neck circumference.~Each patient will be connected to a mechanical ventilator ventilator through a bitube circuit with no humidification.~The ventilator will be set in PSV-NIV mode, with the following suggested settings [34-38]:~initial pressure support=12 cmH2O and adequate to permit a peak inspiratory flow of 100 l/min;~positive end-expiratory pressure=12 cmH2O.~FiO2 will be titrated to obtain an SpO2≥92% and ≤98%.~Inspiratory flow trigger = 2 l/min or according to the practice of each institution;~fastest pressurization time;~expiratory trigger: 10-50% of the maximum inspiratory flow, eventually modified to avoid double triggering;~maximum inspiratory time 1.2 second."
89023596|NCT05089695|Experimental|Helmet continuous airway pressure (CPAP)|"Patients in CPAP group will receive continuous helmet CPAP for at least 16 hours/day in the first 2 calendar days. Continuous CPAP without interruptions will be strongly encouraged in the first 48 hours of treatment. Dedicated helmets for noninvasive ventilation will be applied and size will be chosen according to patient's neck circumference.~Treatment will be delivered through a high-flow generator. The following settings will be applied:~Continuous air flow>45 l/min.~Bi-tube circuit with no humidification, Y-piece with heat and moisture exchanger, or active heating and humidification with humidification chamber temperature set at 31 °C, 34 °C or 37 °C according to patients' comfort.~Expiratory positive end-expiratory pressure valve set to achieve PEEP=12 cmH2O.~FiO2 will be titrated to obtain an SpO2≥92% and ≤98%."
89502354|NCT02264041|Experimental|Cilobradine, low dose plus itraconazole|Pre-study
89502355|NCT02264041|Active Comparator|Cilobradine, low dose|Pre-study
89502356|NCT02264041|Experimental|Cilobradine, high dose plus itraconazole|main study
89502357|NCT02264041|Active Comparator|Cilobradine, high dose|main study
89502358|NCT02234089||Degarelix|
89502359|NCT02234089||LHRH agonist|
89502360|NCT05488028|Experimental|Piezosurgery|Patients needing lower third molar surgery, in which the osteotomy is performed by the use of a piezo-electric instrument
89502361|NCT05488028|Experimental|Conventional bur|Patients needing lower third molar surgery, in which the osteotomy is performed by the use of a drilling bur
89502362|NCT02234167|Other|Risk behaviour and infectious diseases|.(among IDU)
89502363|NCT05492084||active group|The first - active group (100 people) included patients who had type 1 myocardial infarction (MI) (54 people) within 2 years prior to the study or the diagnosis of CAD was established according to selective coronary angiography: the presence lumen stenosis of at least two coronary arteries by 50 % or more (46 people) and an additional two (or more) cardiovascular events from the following: MI or unstable angina, emergency arterial stenting, stroke, peripheral arterial thrombosis, critical ischemia, and lower limb amputation. The combination of two or more of these cardiovascular events that occurred within two years indicated the rapid progression of atherosclerosis in these patients.
89502364|NCT05492084||comparison group|The second (comparison group) included 102 patients with confirmed coronary heart disease in a similar way (55 people had only 1 type 1 MI in the past and 45 had coronary artery disease confirmed by selective coronary angiography, respectively), in whom two years before inclusion in the study there were no cardiovascular events from the above, which indicated the spontaneous course of atherosclerosis.
89502365|NCT02261701|Experimental|Early mobilization|Intervention is early mobilization, four weeks immobilization postsurgery with collar´n cuff only.
89502366|NCT02261701|Other|Post surgery shoulder lock|Post surgery shoulder lock with abduction cushion 3 weeks and after this period collar´n cuff 3 weeks
89502367|NCT02261779|Experimental|Tretinoin & Tranylcypromine|Tretinoin started with 45mg/m2 on day 7 for one year, administered orally as soft capsules, Tranylcypromine started with 10mg/d up to a maximum dose of 60mg/d for on year, administered orally as tablets
89502368|NCT05487872|Other|Audio-guided mindfulness skills training|Participants in this group listened to a 15 mins audio track to practice mindfulness exercises
89502369|NCT05487872|Experimental|Virtual reality (VR) -based mindfulness skills training|Participants in this group completed mindfulness exercises on the VR system. The system included the same 15 mins audio track and additionally a video that displayed a 360° spherical landscape view of the sea in the afternoon
89502370|NCT02261857|Experimental|Intervention Arm|Intervention: Subjects will undergo assessment and a personalized CPAP mask device will be manufactured using patient-specific computer-aided design and 3D printing. The subject will use the personalized CPAP mask for 1 month of consistent use and post-intervention data will be collected for compare to historical control (see other arm)
89502371|NCT02261857|No Intervention|Historical Control Arm|Pre-interventional baseline data on subject OSA, CPAP compliance, and quality of life (QoL) measures will be collected to serve as historical controls.
89502372|NCT02261935|Active Comparator|Existing Home Care Nursing Practice|Home care nurses provide care based on existing home care practice
89502373|NCT02261935|Experimental|Practice Support Tool Intervention|"The practice support tool intervention will be the routine use of the Carer Support Needs Assessment Tool (CSNAT) in the practice of home care nurses (once every 4 weeks with each family caregiver) to document, monitor and address family caregiver support needs.~Update - December 22, 2016 - In some home care offices only, a study nurse will meet with family caregivers who are in the intervention group to deliver the CSNAT intervention. Information arising from the CSNAT about family caregivers' support needs will be communicated by the study nurse to the home care nurse, and incorporated by the home care nurse into the home care plan for the patient and patient's family."
89502374|NCT02556710|Experimental|AMPION™ 4 mL dose|4 mL injection of Ampion
89502375|NCT02556710|Placebo Comparator|Placebo 4 mL dose|4 mL Injection of Placebo
89032882|NCT04691765|Experimental|200 mg SC BID|200 mg of Kineret (anakinra) will be administered sub-subcutaneously twice a day for 28 days (1 cycle) with a maximum of 7 cycles (28 weeks of treatment)
89502376|NCT02262013|Active Comparator|Parents as Coaches|PAC (modeled after NIH-funded NOURISH) focuses on parenting strategies to support and facilitate their child's weight management via family-based change. Each visit includes group psychoeducation and discussion, focused on parenting strategies to facilitate healthy weight management in their child(ren). Topics include focus such as role modeling, strategies for healthy lifestyle changes, and how to be a coach to your teen.
89502377|NCT02262013|Experimental|Parent Weight Loss|In PWL parents will be given a weight loss goal of 1-2 lbs/week, as well as specific calorie and fat prescriptions, PA goals, and instructions to self-monitor key information. Parents will receive training in core behavioral weight loss strategies (e.g., goal setting, stimulus control) and techniques to help them achieve these goals and will also receive personalized feedback throughout the program.
89502378|NCT01515241|Other|Open label single arm study of CER-001|Open label single arm study of CER-001
89502379|NCT05157685|Experimental|Azithromycin oral tablet|Azithromycin 250 mg once daily morning or evening (with or without meals)
89502380|NCT05157685|Placebo Comparator|Placebo|Placebo once daily morning or evening (with or without meals)
89502381|NCT02556632|Experimental|Arm I (curcumin-based gel)|Patients apply curcumin-based gel topically TID approximately every 4-6 hours beginning on the first day of radiation therapy and continuing until 1 week after completion of radiation therapy.
89502382|NCT02556632|Experimental|Arm II (HPR Plus)|Patients apply HPR Plus™ topically TID approximately every 4-6 hours beginning on the first day of radiation therapy and continuing until 1 week after completion of radiation therapy.
89502383|NCT02556632|Placebo Comparator|Arm III (placebo gel)|Patients apply placebo gel topically TID approximately every 4-6 hours beginning on the first day of radiation therapy and continuing until 1 week after completion of radiation therapy.
89502384|NCT05135611|Experimental|4-channel Sequential NMES|"After diagnosis of sleep apnea, the registered patient group receives sufficient explanations from the researcher and uses sequential 4-channel electrical stimulation therapy at home, 5 times a week, 60 minutes each, for 8±2 weeks.~During 4-channel electrical stimulation treatment, study participants kept a treatment log including the number of applications, intensity (mA), and treatment time at home."
89502385|NCT05132803|Experimental|Main Vaccination Arm|Participants will receive the HPV 16 TA-CIN vaccine.
89502386|NCT05482490|Experimental|IFCDPprotocol|Patients subjected to the novel implant-supported fixed complete dental prostheses maintenance protocol
89502387|NCT02262091|Placebo Comparator|Placebo group|
89502388|NCT02262091|Experimental|Food fibers|
89502389|NCT02613949|Active Comparator|12-week RINCE mode 1|RINCE - active RINCE therapy involving 24 total treatment applications from NeuroPoint device at treatment mode 1
88956668|NCT04533919||Basic science (dorsal root ganglia collection)|Patients' leftover dorsal root ganglia samples are collected during standard of care surgery.
88956669|NCT04530942|Experimental|Active DBS then Sham DBS|After more than 6 months open-lable period, some patients will take DBS ON for two weeks with the optimal stimulation parameters and then take DBS OFF for two weeks.
88956670|NCT04530942|Experimental|Sham DBS then Active DBS|After more than 6 months open-lable period, some patients will take DBS OFF for two weeks and then take DBS ON for two weeks with the optimal stimulation parameters.
88956671|NCT04519619||Aflibercept (Eylea, BAY86-5321)|Decision of Eylea treatment is made by attending investigators according to the Japanese Package Insert
88956672|NCT04515238|Experimental|BZAG|"Debulking: 2 debulking cycles (q 28d) of bendamustine will be administered unless the patient has a contraindication or a debulking is not clinically indicated~Induction: 6 cycles (q 28d) of Obinutuzumab + Zanubrutinib + Venetoclax~Maintenance: max. 8 cycles (q 84d) of Obinutuzumab + Zanubrutinib + Venetoclax~Maintenance treatment will be continued until (whichever occurs first):~12 weeks (approx. 3 months) after confirmation of achievement of a CR/CRi and MRD negativity~maintenance cycle 8~progression of CLL or start of a subsequent therapy unacceptable toxicity"
88956673|NCT04501081||1|DFNA patients and their family members (affected)
89502390|NCT02613949|Active Comparator|12-week RINCE mode 2|RINCE - active RINCE therapy involving 24 total treatment applications from NeuroPoint device at treatment mode 2
89502391|NCT02613949|Sham Comparator|Sham RINCE|Sham RINCE - sham RINCE therapy involving 24 total sham applications from NeuroPoint device
88956674|NCT04501081||2|DFNA patients and their family members (unaffected)
88956675|NCT04497428|Experimental|Adaptation to Altered Sensory Feedback + cTBS to S1|Adaptation to Altered Sensory Feedback + cTBS to S1
88956676|NCT04497428|Experimental|Adaptation to Altered Sensory Feedback + cTBS to A1|Adaptation to Altered Sensory Feedback + cTBS to A1
89538648|NCT03062007|Experimental|BI-CON-02|The start dose of BI-CON-02 will be 0,3 mg/kg and it will be possible to increase gradually BI-CON-02 doses up to 0,6 mg/kg; 1,2 mg/kg; 2,4 mg/kg; 3,6 mg/kg and 4,8 mg/kg for subsequent dose cohorts. A possibility to include a new dose cohort in the study will be considered by the Data and Safety Monitoring Committee, basing on the data of BI-CON-02 safety and tolerability, received at the Visit (Week 3, Day1) in the previous dose cohort (3 weeks after - 21st day of therapy).
89538649|NCT04968561||cohort 1|"Adult patients~Admitted in the ENT and Cervico-Facial Surgery department of the Gabriel Montpied University Hospital in Clermont-Ferrand.~From November 2020 to October 2021,~Requiring endoscopic sinus surgery~With good quality imaging (CT scan and/or MRI)"
89538650|NCT03262181|Experimental|Isometric Exercise Condition|The participant will perform 5 sets of a 45-second isometric contractions at 70% of their maximum voluntary isometric contraction (MVIC). During the 45-second contraction, the participant will be provided with visual biofeedback on a computer screen (70% MVIC target line and +/- 5% error lines). The participant will be instructed to produce a level of isometric quadriceps contraction that maintains the isometric torque output line as close the target line as possible and always between the two error lines.
89538651|NCT03262181|Sham Comparator|Sham TENS Condition|"Two electrodes of the Select System TENS unit (Empi, Inc., St. Paul, MN) will be placed on either side of the patellar tendon on the test limb. The same instruction script will be used for each participant, stating, A surface electrode has been placed on either side of your patellar tendon. I will turn on the stimulation unit to emit a stimulus to your patellar tendon. This is a special sub-sensory stimulation treatment, so you will not feel anything during this period as the stimulus is set at a very low, non-detectable threshold. Please remain still during this 45-second period, letting your leg rest passively in the machine without contracting your leg muscles. After the 45-second period, the stimulation unit will be turned off and you will have a 2-minute rest period. We will repeat this same treatment/rest sequence 5 total times."
89538652|NCT04976361|Experimental|Diabetic Patients with PDR|PRP for each diabetic patient included in this study.
89023597|NCT05089695|Active Comparator|High-flow nasal oxygen|"Initial set flow will be 50-60 l/min and flows will be decreased. in case of intolerance and/or according to patients' requirements: flows≥30 L/min will be mandatory in all enrolled patients. Humidification chamber will be set at 31 °C, 34 °C or 37 °C according to patient's comfort. FiO2 will be titrated to obtain an SpO2≥92% and ≤98%.~Weaning the patient from high-flow will be considered only after 48 hours from enrolment and will be discouraged until the patients is considered for ICU discharge."
89023598|NCT05089604|Experimental|LCPT|
89023599|NCT05089604|Active Comparator|IR-TAC|
89023600|NCT05088681||Peripheral neuropathies patients|"Peripheral neuropathies patients will be assessed at baseline, after a 20 session 2-3/w program of physical therapy and at a follow up of 3 months with:~Total Neuropathy Score-clinical version (TNSc©)~Nerve conduction studies~Short Form Health Survey 36 (SF-36)~Functional Independence Measure (FIM)~postural evaluation recording during three different postural tasks (quiet standing, voluntary sway and shoulder flexion):centre of pressure (COP) displacement of force platform; surface muscle activation using electromyography (EMG) of 13 muscle on the right side of the body (tibialis anterior, soleus,gastrocnemius lateralis-medialis, biceps femoris, semitendinosus, rectus femoris, vastus lateralis and medialis, tensor fasciae latae, lumbar and thoracic erector spinae and rectus abdominis)~Six Minute Walking Test (6MWT), Mini Balance Evaluation System Test (MiniBESTest) and Timed Up and Go test (TUG)."
89023601|NCT05088681||Healthy age-matched subjects|"Healthy age-matched subjects will receive a postural evaluation recording during three different postural tasks (quiet standing, voluntary sway and shoulder flexion):~centre of pressure (COP) displacement of force platform;~surface muscle activation using electromyography (EMG) of 13 muscle on the right side of the body (tibialis anterior, soleus,gastrocnemius lateralis-medialis, biceps femoris, semitendinosus, rectus femoris, vastus lateralis and medialis, tensor fasciae latae, lumbar and thoracic erector spinae and rectus abdominis)."
89023602|NCT05087498|Experimental|ACBMNC infusion group|Those assigned to the ACBMNC group will receive intravenous autologous cord blood mononuclear cells infusion within 24 h after process. Cell dose for all patients was 2-10×107 cells per kilogram.
89023603|NCT05087498|Placebo Comparator|control group|Those in control group will receive an infusion of a placebo solution which is normal saline with the same volume per kg.
89023604|NCT05081609|Experimental|Part 1 Monotherapy Dose Escalation: TransCon IL-2 β/γ|TransCon IL-2 β/γ in escalating doses to evaluate safety/tolerability and to determine the MTD and RP2D
89023605|NCT05081609|Experimental|Part 2 Combination Dose Escalation: TransCon IL-2 β/γ with Pembrolizumab|TransCon IL-2 β/γ with Pembrolizumab in escalating doses to evaluate safety/tolerability and determine the MTD and RP2D
89023606|NCT05081609|Experimental|Part 3 Combination Dose Expansion: TransCon IL-2 β/γ with SOC Chemo|TransCon IL-2 β/γ using the RP2D with SOC Chemotherapy to evaluate safety/tolerability and anti-tumor activity of the combination
89206387|NCT01564810|Active Comparator|Arm B|Patients received chemotherapy (mFOLFOX6 or FOLFIRI) alone. mFOLFOX6 (day 1, oxaliplatin 85 mg/m², folinic acid 400 mg/m², and fluorouracil 400 mg/m² intravenous bolus, then 2400 mg/m² over 46 h continuous infusion) FOLFIRI (day 1, irinotecan 180mg/m2, folinic acid 400 mg/m², and fluorouracil 400 mg/m² intravenous bolus, then continuous infusion for 46 hours of 2400 mg/m2).
89538653|NCT03262337||Elderly Travelers|approximately 135 travelers with an age >= 60 years will be enrolled
89538654|NCT03262337||Chronic diseased travelers|approximately 225 travelers with a chronic disease will be enrolled
89538655|NCT03262337||Healthy travelers|approximately 640 healthy travelers with be enrolled
89538656|NCT04968327|Experimental|Micro-osteoperforations|
89538657|NCT04968327|Active Comparator|Canine retraction|
89538658|NCT05234645|Experimental|Younger group|Fifteen participants, between 18 and 35 years of age. Participants are not pregnant; are healthy and suffering from no chronic diseases with the potential to influence vascular function; non-smoker; sedentary (defined via the completion of the international physical activity questionnaire; IPAQ); and were not consuming regularly probiotic-containing products. Additionally, a medical questionnaire was completed to exclude anyone with overt chronic disease.
89608337|NCT01271062|Active Comparator|Non-diabetic patient before gastric bypass surgery|oral glucose tolerance test , botnia clamp, preoperative as well as 10 days postoperative and 1 year postoperative, gastric bypass surgery.
89206388|NCT04091945|Active Comparator|LT3001 Drug Product|
89206389|NCT04091945|Placebo Comparator|Placebo|
89206390|NCT04091789|Experimental|Test Article|Subjects will take Pure Femme sublingual tablets as directed, one tablet 2 days before, one tablet 1 day before, and then up to 3 tablets per day for 3 days (72 hours) during menstruation.
89206391|NCT04091711|Experimental|ReX-C intervention|Subjects use ReX-C to receive oral oncolytic medications. Adherence data, side effects and response to treatment are monitored online in real time via ReX-C cloud.
89206392|NCT00916955||Individuals with 22q11.2 deletions|Individuals confirmed with the diagnosis of velo-cardio-facial syndrome by positive FISH or CGH microarray confirming the diagnosis and deletion of 22q11.2
89206393|NCT04093895|Experimental|SRP and 3% PerioSept(r)|Scaling and root planing followed by 3% PerioSept® drug administration
89206394|NCT00522418|Experimental|VNS Therapy|VNS Therapy + Best Medical Practice
89206395|NCT00522418|Active Comparator|Best Medical Practice|Best Medical Practice
89206396|NCT00624780|Experimental|1|
89206397|NCT00624780|Active Comparator|2|
89206398|NCT00624780|Experimental|3|
89206399|NCT00624780|Placebo Comparator|4|
89206400|NCT00750893||Rotarix Group|Subjects who received 2 oral doses of Rotarix. The first dose was administered before the age of 6 weeks and the second one at least 4 weeks after, preferably before the age of 16 weeks. The 2 doses had to be given before 24 weeks of age.
89206401|NCT01564888|Placebo Comparator|Patent hemostasis|Patent hemostasis is the technique for radial artery hemostasis after transradial catheterization, with proactive attempt to maintain radial artery hemostasis and radial artery patency.
89206402|NCT01564888|Active Comparator|Ulnar artery compression|Ulnar artery compression will involve radial artery hemostasis using patent hemostasis technique and compression of ulnar artery to the point of occluding flow, in an attempt to augment radial artery flow.
89206403|NCT00753623|Active Comparator|Ramelteon first, placebo second|"In a crossover design, a subject will be first assigned to the ramelteon arm and then switched over to the placebo arm. As this is a double-blind study, neither the subject nor the study staff will know which intervention the subject is randomly assigned. The ramelteon dose is 8mg once a night.The ramelteon and placebo will be blinded by the central pharmacy.~The subject is randomly assigned to first receive either ramelteon or placebo. The first intervention will be 14 days long. There is a 7 day washout period, and then the subject is assigned to the opposite intervention. The second intervention will be 14 days long."
89206404|NCT00753623|Placebo Comparator|Placebo first, ramelteon second|"In a crossover design, a subject will be first assigned to the placebo arm and then switched over to the ramelteon arm. As this is a double-blind study, neither the subject nor the study staff will know which intervention the subject is randomly assigned. The ramelteon dose is 8mg once a night. The ramelteon and placebo will be blinded by the central pharmacy.~The subject is randomly assigned to first receive either ramelteon or placebo. The first intervention will be 14 days long. There is a 7 day washout period, and then the subject is assigned to the opposite intervention. The second intervention will be 14 days long."
89206405|NCT02599337|Experimental|sorafenib|Sorafenib is the test product.In period 1, period 2 and period 3, 12 of 36 Subjects were given Single oral dose (1 x 200 mg) sarofenib.
89206406|NCT02599337|Active Comparator|Nexavar|Nexavar is the reference product.In period 1, period 2 and period 3, 24 of 36 Subjects were given Single oral dose (1 x 200 mg) Nexavar .
89206407|NCT03855618||1 case group|Consecutive 10 post-stroke patients in intensive rehabilitation treatment with an acute event occurring no later than 15 days from admission to the SOR Neurological Foundation don Gnocchi ONLUS IRCCS; age 18-90. It is required to sign an informed consent to the patient's participation in the study or if unable to sign, of the proxy.
89206408|NCT00831636|Experimental|Open label CP-4055|Phase I: Dose escalation Phase II: Fixed dose
89206409|NCT00750737|Experimental|Posaconazole|Posaconazole 200 mg three times daily by mouth up to 6 weeks (Days 1-42)
89206410|NCT00750737|Experimental|Amphotericin B Lipid Complex (ABLC)|7.5 mg/kg of ABLC intravenously infused over 4-6 hours once per week, for up to 6 weeks (from Day 1 through Day 42)
89206411|NCT04044612|Experimental|Medial Unloader Brace|
89206412|NCT04119934||Control - None|A retrospective chart review will assess physician/NP behaviour (rates of smoking cessation counselling and prescription of smoking cessation pharmacotherapy) in the one-year pre-intervention period.
89206413|NCT04119934||Intervention - Smoking cessation infographic|Throughout the intervention period, the personalized smoking cessation infographic will be provided to physicians/NPs (for eligible patients). Chart review will be conducted for the patient's physician/NP within a three-month window of receiving the infographic to assess outcomes.
89206414|NCT04093505|Experimental|GO147_G|"GO147: Induction therapy: Gemtuzumab Ozogamicin 3mg/m² on days 1,4 and 7~_G: Consolidation & Maintenance therapy Glasdegib 100mg on days 4 to 27"
89206415|NCT04093505|Placebo Comparator|GO147_P|"GO147: Induction therapy: Gemtuzumab Ozogamicin 3mg/m² on days 1,4 and 7~_P: Consolidation & Maintenance therapy Placebo 100mg on days 4 to 27"
89206416|NCT04093505|Experimental|GO1_G|"GO1: Induction therapy: Gemtuzumab Ozogamicin 3mg/m² on day 1~_G: Consolidation & Maintenance therapy Glasdegib 100mg on days 4 to 27"
89206417|NCT04093505|Placebo Comparator|GO1_P|"GO1: Induction therapy: Gemtuzumab Ozogamicin 3mg/m² on day 1~_P: Consolidation & Maintenance therapy Placebo 100mg on days 4 to 27"
89206418|NCT00622440|Active Comparator|1|
89206419|NCT00622440|Placebo Comparator|2|
89206420|NCT04759690|Experimental|Action observation and exercise group|Action observation group consist of 30 randomly selected participants.Action observation + conventional balance exercise group
89206421|NCT04759690|Other|Exercise group|Exercise group is the control group.Consist of 30 randomly selected participants. The participants will only do the conventional balance exercise.
89206422|NCT02597777|Placebo Comparator|Side of face receiving placebo vehicle|One half of the face (left or right side) will be randomized to receive the placebo lotion. Subjects will be asked to apply a pea-sized amount of the lotion to half of the face at twice daily application for 4 weeks.
88956677|NCT04497428|Experimental|Adaptation to Altered Sensory Feedback + cTBS to M1|Adaptation to Altered Sensory Feedback + cTBS to M1
89206423|NCT02597777|Experimental|Side of face receiving AH8 lotion|One half of the face (left or right side) will be randomized to receive the 10% Acetyl Hexapeptide-8 containing (AH8) lotion. Subjects will be asked to apply a pea-size amount of the lotion to the half of the face twice daily application for 4 weeks.
89206424|NCT00831714||Group 1|
89206425|NCT00831714||Group 2|
89206426|NCT01564966||Living kidney donors|Those who donate kidneys
89206427|NCT02597699|Active Comparator|Arm 1: Sufentanil + Lidocaïne|"For patients randomized to arm 1, as in the current practice, we will inject Sufentanil intra-cordially at the dose of 1.5 μg / kg of the estimated fetal weight, then the Lidocaïne 1% bolus of 10 ml (10 mg / ml).~If 2 minutes after the start of the injection of Lidocaïne, there is no obtaining of fetal asystole, we will inject 100mg of Lidocaïne 1% in bolus of 10 ml. In the event of failure of the procedure, we will inject 10ml of KCL 10% intra-cordial if the cord is always accessible, if not intra-cardiac."
89206428|NCT02597699|Experimental|Arm 2: Remifentanil + Lidocaïne|"For patients randomized to arm 2, we will inject 30 μg of intravenous Remifentanil (Ultiva®) followed by Xylocaine 1% in a 10 ml bolus (10 mg / ml).~If 2 minutes after the start of the injection of Lidocaïne, there is no obtaining of asystole, we will inject 100 mg of Lidocaïne 1% in bolus of 10 ml. In case of failure of the procedure, we will inject 10 ml of KCL 10% intra-cordial if the cord is still accessible, if not intra-cardiac."
89206429|NCT00827736|Experimental|Botox injection|injection of 10U of BT (Botox®; Allergan, Irvine, California, USA) in the IAS on each side of the anterior midline. In addition, a placebo ointment has to be applied to the anoderm six times a day
89206430|NCT00827736|Active Comparator|ISDN ointment|application of ISDN 1% ointment 6 times a day. injection of placebo into internal anal sphincter
89206431|NCT00744653|Other|1|Patients with local-regional recurrence of breast cancer, lesion over 3 cm.
89206432|NCT00998218|Experimental|Ranolazine|Ranolazine at 1000 mg BID (or 500 mg BID if the 1000 mg dose was not tolerated) for 4 weeks
89206433|NCT00998218|Placebo Comparator|Sugar pill|Placebo comparator BID for 4 weeks.
89502392|NCT05487716||Heart failure patients (HF)|"Subjects in HF were subgrouped according to their baseline left ventricular ejection fraction obtained by 2-D echocardiography as HFrEF (LVEF<40%), HFmrEF (LVEF>=40% and <50%), and HFpEF (LVEF>50%)~Subjects underwent an additional 36 sessions of high-intensity interval training (alternating 80% and 40% peak oxygen consumption) were considered HIIT participants in each subgroup (HFrEF, HFmrEF, HFpEF). Others without exercise intervention were considered multidisciplinary disease management program (MDP) participants."
89502393|NCT02611609|Experimental|Cohort 1|Low dose MultiStem
89502394|NCT02611609|Experimental|Cohort 2|High dose MultiStem
89502395|NCT02611609|Experimental|Cohort 3|Highest safe MultiStem dose (from Cohorts 1 and 2) or Placebo
89502396|NCT05487638|Experimental|experimental Group|Training was given to the patients once a week, starting on the second day after discharge, four times in total. Increasing the level of knowledge about infection control, wound care, post-CABG care, using drugs as prescribed, hygiene, excretion (things to be done to avoid constipation), nutrition (diet and diet compliance after CABG), bleeding control, proper sleep and rest positions, deep breathing and coughing exercises, maintaining a healthy weight, what to pay attention to while taking a bath, pain management and methods of coping with pain, relaxation techniques, walking and exercise, returning to social life, reducing anxiety and depression, using elastic stockings and chest corsets, controlling Training was given on the subjects of notifying the due dates, emotional adjustment and coping methods with symptoms. After 1 month of training, at the end of the 4th week, the patients were asked to fill out the Discharge Education Satisfaction Scale and the Self-Care Strength Scale.
89502397|NCT05487638|No Intervention|Control Group|On the other hand, no intervention was made in the control group and after discharge, the personal information form, the Discharge Training Satisfaction Scale and the Self-Care Strength Scale were filled. At the end of the 4th week, the patients were asked to fill out the Discharge Education Satisfaction Scale and the Self-Care Strength Scale.
89502398|NCT02610283|Active Comparator|QPI-1002|QPI-1002 Injection, single dose
89502399|NCT02610283|Placebo Comparator|Placebo|isotonic saline
89502400|NCT05491850|Experimental|Moderate Physical Activity Group|The Experimental Group gets moderate physical activity. Elliptical will be performed at least 5 days/per week. Moderate intensity, corresponding approximately to 40-60% of Vo2max (maximal aerobic capacity) 150 min/week of exercise undertaken at moderate intensity or greater. Warm-up and Dynamic stretching is given before and static stretching is given after moderate physical activity.
89502401|NCT05491850|No Intervention|Non Specific Physical Activity Group|The Control group continues their regular medication for diabetic neuropathy.
89502402|NCT01515007|Experimental|Ciprofloxacin dispersion for inhalation|Liquid mixture of liposomally encapsulated and unencapsulated ciprofloxacin
89502403|NCT01515007|Placebo Comparator|Placebo|Liquid formulation of empty liposomes
89502404|NCT05482178|Experimental|Resistance exercise training plus hypocaloric diet|The participants received a caloric restriction of 20% of total energy estimated with Mifflin formula plus a structured, planned, and controlled resistance exercise program by a personal trained. The participant received the exercise program instructions every week and they performed by the own, and record the heart rate of each session on a paper format. All the appointment were once a month by trained nutritionists, and all the participants received a nutritional recommendation for the obesity management and a balanced food plan.
89502405|NCT05482178|Active Comparator|Hypocaloric diet|The participants received a caloric restriction of 20% of total energy estimated with Mifflin formula. All the appointment were once a month by trained nutritionists, and all the subjects received a nutritional recommendation for the obesity management and a balanced food plan.
89502406|NCT05487560||12-hour interval group (No interventional)|DAPT(Clopidogrel + Aspirin) and Esomezol Cap taken every 12 hours
89502407|NCT05487560||co-administration group (No interventional)|Taking DAPT(Clopidogrel + Aspirin) and Esomezol Cap at the same time
89502408|NCT05482100||Patients monitored with OmniGraf Testing|Subjects will have OmniGraf™ testing at study enrollment and thereafter every 3 months or at the same time as standard routine labs (minimum two per year). In addition, subjects will have OmniGraf™ testing at any time there is a workup for clinical events and referral to advanced care (transplant center, biopsy, etc)
89206434|NCT00825396|Experimental|C-KAD Ophthalmic Solution|
89206435|NCT01565044|Experimental|" AUTO  Group"|
89206436|NCT01565044|Sham Comparator|" CONTROL  Group"|
89206437|NCT03976739||chronic gastritis|patients with chronic non-atrophic gastritis and chronic atrophic gastritis according to histopathological results
89206438|NCT03976739||precancerous lesion|patients with gastric intestinal metaplasia and intraepithelial neoplasia according to histopathological results
89206439|NCT03976739||gastric cancer|patients with gastric cancer according to histopathological results
89206440|NCT04044300|Experimental|Operative|A single trans-iliac, trans-sacral screw will be inserted at the sacral one or sacral two level.
89206441|NCT04044300|Experimental|Non-operative|Continued pain management and physical therapy
89206442|NCT02598167||RRMS Population|Participants with a diagnosis of RRMS and being prescribed with a DMT for a period of at least 3 months according to standard local clinical practice will be included.
89206443|NCT00311311|Active Comparator|1|Tacrolimus + MMF + Steroids
89206444|NCT00311311|Experimental|2|Tacrolimus + MMF + Steroids with conversion from Tacrolimus to Sirolimus at 3-4 months post-transplant
89206445|NCT02599181|Experimental|WITH-Group: alcoholic skin disinfection|In the WITH-group, the skin is disinfected with an aerosolized alcoholic solution propanol-biphenol: Kodan, Schülke & Mayr, Zurich, Switzerland prior to perineural catheter removal.
89206446|NCT02599181|No Intervention|WITHOUT: no alcoholic skin desinfection|"In the WITHOUT-group, the skin is NOT disinfected prior to perineural catheter removal."
89206447|NCT04089605|Experimental|intravitreal dexamethasone implant|The eyes undergo dexamethasone intravitreal implant 0.7 mg injections at baseline and every 3 or 4 months thereafter. Dexamethasone implants are re-injected in minimal 3-month interval if macular edema persisted or recurred with CFT more than 350 μm or manifestation of apparent submacular fluid and/or intramacular cysts. If DME subside with CFT less than 350 μm without accompanying fluid and cysts, repeated injection is mandatory in maximal 4-month interval.
89206448|NCT04089605|Active Comparator|intravitreal ranibizumab|As for intravitreal ranibizumab 0.5 mg (IVR), we use OCT-guided treat-and-extend protocol for DME treatment after modifying the settings of TREX-DME study.4 The regimen include 3 monthly loading doses then extending the treatment injection interval one month more if CFT less than 350 μm without obvious submacular fluid and intramacular cysts. The injection interval shorten one month if CFT more than 350 μm or presence of obvious fluid and/or cysts. The patients are intentionally injected at most every 3 months even DME not existing.
89206449|NCT02597621||M/XDR|The M/XDR-cohort will consist of patients with a suspected infection with an M/XDR-TB strain.The suspicion will be held on behalf of molecular biological methods (i.e. GeneXpert, detection of rifampicin resistance with high probability of simultaneous isoniazid resistance). The suspected cases will be confirmed by culture (n= 20). Empirically, less than 10% of the cases have an XDR-TB
89206450|NCT02597621||Susceptible|The non M/XDR-TB cohort will consist of patients with no suspected infection with an M/XDRTB strain. The suspicion will be out ruled on behalf of molecular biological methods (i.e.GeneXpert, detection of rifampicin resistance with high probability of simultaneous isoniazid resistance). The non M/XDR-TB cases will be confirmed by culture (n= 20). Empirically, about 90% of these patients have no drug resistance against first line drugs.
89206451|NCT02597621||Healthy Controls|Healthy controls.
89206452|NCT02599025|No Intervention|Supine position|Children tested while lying down
89206453|NCT02599025|No Intervention|Standing position|Children tested while standing
88956678|NCT04497428|Experimental|Adaptation to Altered Sensory Feedback + Sham cTBS|Adaptation to Altered Sensory Feedback + Sham cTBS
89206454|NCT02599025|Experimental|Cycling supine postion|Children lying down with APT cycling system
89206455|NCT02599025|Experimental|Cycling standing postion|Children standing with Innowalk cycling system
89206456|NCT00521404|Experimental|CS-1008 + gemcitabine|CS-1008 + gemcitabine
89206457|NCT00311155|Experimental|1|"Olmesartan medoxomil oral tablets for 4 weeks followed by, if necessary:~Olmesartan medoxomil oral tablets + hydrochlorothiazide oral tablets for 8 weeks, followed by, if necessary:~Olmesartan medoxomil oral tablets + hydrochlorothiazide oral tablets + amlodipine oral tablets for 8 weeks"
89206458|NCT03977077|Experimental|Albumin binding taxol|
89206459|NCT03981679|Experimental|Biological collection|"For all the patients include in the study :~- Blood samples collected before the colonoscopy In parallel to this biological collection, standardized clinical data will be entered into a database"
89206460|NCT01068457||PTPS|Patients with pain after VATS
89206461|NCT01068457||Pain free|Patients reporting no pain late after VAT
88982893|NCT03128996|Experimental|RIC Prep Regimen & GVHD Prophylaxis|Single arm study. All patients receive the same Reduced Intensity Conditioning (RIC) regimen and GVHD prophylaxis regimen
89206462|NCT01068535||Women with Metabolic Syndrome|"Pre-menopausal women with Metabolic Syndrome~Age 35-50 and any 3 of the following:~Fasting triglycerides ≥ 150 mg/dL, Waist measurement ≥ 35 inches, HDL < 50mg/dL, Fasting glucose ≥ 100mg/dL but <126mg/dL or Blood pressure ≥ 130/85 or taking medication to treat high blood pressure."
89206463|NCT01068535||Non-Metabolic Syndrome (healthy) women|"Non-Metabolic syndrome pre-menopausal women age 35-50~Body Mass Index ≤ 25~Regular menstrual cycles (occur every 24-35 days)~Fasting glucose < 100mg/dL~HDL-C ≥ 50mg/dL~Waist measurement ≤ 35 inches~Fasting triglycerides < 150mg/dL"
89206464|NCT03981601|Active Comparator|lovastatin 40 mg with bone graft|after tooth extraction, put teh lovastatin40 mg wif bone graft wifin tooth socket
89206465|NCT03981601|Active Comparator|without drug with bone graft|after tooth extraction, put the bone graft wifin tooth socket
89206466|NCT01063543||patients with blood sample|Patients with major orthopedic surgery and prophylactic doses of fondaparinux who have 3 blood sample during their hospitalization to measure anti-Xa activity
89206467|NCT00274651|Experimental|Arm A|PXD101 1000 mg/m2 once daily for 5 days every 21 days
89023607|NCT05081609|Experimental|Part 3 Combination Dose Expansion: TransCon IL-2 β/γ with TransCon TLR7/8 Agonist|TransCon IL-2 β/γ with TransCon TLR7/8 Agonist using the RP2D to evaluate safety/tolerability and anti-tumor activity of the combination
89023608|NCT05081609|Experimental|Part 3 Monotherapy Dose Expansion: TransCon IL-2 β/γ followed by surgery|(Optional Arm): TransCon IL-2 β/γ using the RP2D followed by surgery to evaluate safety/tolerability and anti-tumor activity of the combination
89023609|NCT05081609|Experimental|Part 3 Combination Dose Expansion: TransCon IL-2 β/γ with Pembrolizumab followed by surgery|TransCon IL-2 β/γ using the RP2D with Pembrolizumab followed by surgery to evaluate safety/tolerability and anti-tumor activity of the combination
89023610|NCT05081609|Experimental|Part 3 Combination Dose Expansion:TransCon IL-2 β/γ with TransCon TLR7/8 Agonist followed by surgery|TransCon IL-2 β/γ with TransCon TLR7/8 Agonist using the RP2D followed by surgery to evaluate safety/tolerability and anti-tumor activity of the combination
89023611|NCT05081609|Experimental|Part 3 Combination Dose Expansion:TransCon IL-2 β/γ + Pembrolizumab + SOC Chemo followed by surgery|TransCon IL-2 β/γ using the RP2D with Pembrolizumab and SOC Chemotherapy followed by surgery to evaluate safety/tolerability and anti-tumor activity of the combination
89023612|NCT05081609|Experimental|Part 3 Combination Dose Expansion|TransCon IL-2 β/γ + Pembrolizumab TransCon IL-2 β/γ using the RP2D with Pembrolizumab
89023613|NCT05081609|Experimental|Part 4 Combination Dose Optimization|TransCon IL-2 β/γ + Pembrolizumab TransCon IL-2 β/γ using the RP2D in titrating doses and/or different dose frequencies with Pembrolizumab
89023614|NCT05081011|Experimental|Voice Assistant Device|Subjects have their insulin titrated by a voice assistant device for 8 weeks. The Voice Assistant Device software algorithm is used to provide daily insulin dose and titration instructions.
89023615|NCT05081011|Active Comparator|Control|Subjects have their insulin titrated via standard of care for 8 weeks. The Voice Assistant Device is limited to providing a daily reminder to take medication.
89502409|NCT02262169|Active Comparator|Treatment I|2 Omeprazole capsules 20 mg once daily and 1 placebo caplet of DLBS2411, twice daily
89023616|NCT05072964|Other|FARAPULSE Pulsed Field Ablation System|Ablation using the FARAPULSE Pulsed Field Ablation System
89538659|NCT05234645|Experimental|Older group|Fourteen participants, between 55 and 75 years of age. Participants are not pregnant; are healthy and suffering from no chronic diseases with the potential to influence vascular function; non-smoker; sedentary (defined via the completion of the international physical activity questionnaire; IPAQ); and were not consuming regularly probiotic-containing products. Additionally, a medical questionnaire was completed to exclude anyone with overt chronic disease.
89502410|NCT02262169|Experimental|Treatment II|1 DLBS2411 caplet 250 mg twice daily and 2 placebo capsules of Omeprazole once daily
89502411|NCT05491694|Experimental|HIFU+Toripalimab+Chemotherapy|High Intensity Focused Ultrasoun， followed by Toripalimab 240 mg + epirubicin 90 mg/m2 + cyclophosphamide 600 mg/m2 × 4 cycles → Toripalimab240 mg + carboplatin AUC 5 + nab-paclitaxel 260 mg/m2 IVD × 4 cycles every 3 weeks for 8 doses.
89502412|NCT05487482|Experimental|Intervention Group- Receiving intervention by educating, training and homevisit|For the intervention groups, planning will be done to provide education and training. Families will be given modules on Safety Culture in the Elderly and will also receive home visits to check and monitoring the condition of the elderly at home related to adverse events and the home environment.
89502413|NCT05487482|No Intervention|Control group|Thisi control group will only monitoring every 4 weeks by home visit. After 16 weeks, researchers will evaluate perceptions of the elderly's safety culture at home and adverse events at home
89502414|NCT03723889||PDA|Evidence of patent ductus arteriosus at echocardiography evaluation before enteral feeding introduction.
89502415|NCT03723889||noPDA|No evidence of patent ductus arteriosus at echocardiography evaluation before enteral feeding introduction.
89502416|NCT02262247||Transoral Visualization & Access|Subjects ≥ 22 yrs requiring transoral procedures
89502417|NCT01499563|Experimental|ITI-007 Low Dose|
89023618|NCT05068960|Experimental|Study group|The study group will receive an interscalene block consisting of 10 mL 0.5% bupivacaine and 10 mL of liposomal bupivacaine [133mg].
89023619|NCT05068960|Active Comparator|Control group|The control group will receive an interscalene block consisting of 20 mL of 0.5%bupivacaine alone.
89502418|NCT01499563|Experimental|ITI-007 High Dose|
89502419|NCT01499563|Placebo Comparator|Placebo|
89502420|NCT01499563|Active Comparator|Risperidone|
89023620|NCT05067972|Experimental|Monotherapy dose escalation (Part 1)|Participants will receive PF-07260437
89023621|NCT05067972|Experimental|Dose Expansion (Part 2A) - Tumor specific Arm A|Participants will receive PF-07260437
89023622|NCT05067972|Experimental|Dose Expansion (Part 2B) - Tumor specific Arm B|Participants will receive PF-07260437
89023623|NCT05067972|Experimental|Dose Expansion (Part 2C) - Tumor specific Arm C|Participants will receive PF07260437
89206468|NCT00274651|Experimental|Arm B|PXD101 1000 mg/m2 once daily for 5 days every 21 days
89206469|NCT00274261|Experimental|A|C31G vaginal gel contains 35mg (1% concentration) of C31G in 3.5 mL volume of gel
89502421|NCT05481944|Active Comparator|Patients with insulinotherapy introduction|Injected MRI
89502422|NCT05481944|Sham Comparator|Healthy volunteers|No injected MRI
89502423|NCT01491529|Experimental|AFQ056 150 mg|Patients randomized to the AFQ056 150 mg arm will receive AFQ056 oral tablets to be titrated until reaching the target dose of 150 mg twice daily.
89023624|NCT05064553||Ultrasound Surveillance Group|Subjects will undergo standard of care ultrasound surveillance imaging. Subjects with positive ultrasound are anticipated to have standard of care imaging follow-up with CT or MRI as well as other procedures as needed. Subjects with negative ultrasound will be sent for a study CT/MRI.
89023625|NCT05064553||CT/MRI Surveillance Group|Subjects will undergo standard of care CT/MRI surveillance imaging.
89023626|NCT05056402|Experimental|9-17y (0,6m)|Subjects who aged 9-17 years old would receive 2 doses of 270μg/0.5ml Recombinant HPV nonavalent (Types 6/11/16/18/31/33/45/52/58) Vaccine(E.Coli) .
89502424|NCT01491529|Experimental|AFQ056 200 mg|"Patients randomized to the AFQ056 200 mg arm will receive AFQ056 oral tablets to be titrated until reaching the target dose of 200 mg twice daily.~Patients will be randomized in two groups by amantadine status.~Group 1: Patients are not permitted to take amantadine within 2 weeks prior to the BL1 visit.~Group 2: Patients must be on a stable and well tolerated dose of amantadine for at least 4 weeks prior to BL1 and must maintain the stable dose of amantadine during the remainder of the study.)"
89023627|NCT05056402|Experimental|9-17y (0,1,6m)|Subjects who aged 9-17 years old would receive 3 doses of 270μg/0.5ml Recombinant HPV nonavalent (Types 6/11/16/18/31/33/45/52/58) Vaccine(E.Coli) .
89023628|NCT05056402|Experimental|18-26y (0,1,6m)|Subjects who aged 18-26 years old would receive 3 doses of 270μg/0.5ml Recombinant HPV nonavalent (Types 6/11/16/18/31/33/45/52/58) Vaccine(E.Coli) .
89023629|NCT05054140|Experimental|IMU-838|IMU-838 as tablet; Administration: Oral - daily
89023630|NCT05054140|Placebo Comparator|Placebo|Matching placebo as tablet; Administration: Oral - daily
89502425|NCT01491529|Placebo Comparator|Placebo|Patients randomized to the Placebo arm will receive oral AFQ056 Placebo twice daily
89023631|NCT05051059|Other|Soft tissue sarcoma of the thigh|Patients who underwent surgical resection of a deep intramuscular soft tissue sarcoma of the thigh
89023632|NCT05051059|No Intervention|Control group|A group of healthy age-matched individuals will be identified out of an available gait lab database to compare the gait pattern with tha of the patient group
89023633|NCT05051059|Other|Bone or soft tissue sarcoma of the lower extremity|Patients who underwent surgical resection of a bone or soft tissue sarcoma of the lower extremity
89023634|NCT05048394|Experimental|Standard-of-care then Semi-autonomous myoelectric control|"The standard of care myoelectric control algorithm will be implemented on a by-pass prosthetic socket with a sensorized TASKA prosthetic hand~The semi-autonomous myoelectric control algorithm will be implemented on a by-pass prosthetic socket with a sensorized TASKA prosthetic hand."
89023635|NCT05048394|Experimental|Semi-autonomous then Standard-of-care myoelectric control|"The semi-autonomous myoelectric control algorithm will be implemented on a by-pass prosthetic socket with a sensorized TASKA prosthetic hand.~The standard of care myoelectric control algorithm will be implemented on a by-pass prosthetic socket with a sensorized TASKA prosthetic hand"
89023636|NCT05047094|Experimental|DaRT seeds|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds in Combination with Standard Treatment of Pembrolizumab
89023637|NCT05043584|Experimental|(A): NIRAF-assisted surgery|Patients undergoing NIRAF-assisted total thyroidectomy
89023638|NCT05041062|Experimental|All Participants in Study Who Have Mesothelioma|Individuals in this group will receive a combination of two immunotherapy drugs (nivolumab and ipilimumab) before and after surgery to remove their cancer. There will also be a follow up period to determine how well the drugs and surgery worked to get rid of your cancer. Your overall participation in this study (including drug treatment, surgery and follow up visits) will last for roughly one and a half years. All eligible participant who enroll in the study will participate in this group.
89502426|NCT05481866|Experimental|The intervention group will be given colostrum for oropharyngeal administration|The intervention group will be given 0.2ml colostrum for oropharyngeal administration every 3 hours, which will start between the first 48 to 72 hours and continue for 5 consecutive days.
89502427|NCT05481866|Placebo Comparator|The control group will be given sterile water for oropharyngeal administration|The control group will be given sterile water for oropharyngeal administration, and the administration scheme will be the same as above.
89502428|NCT03922880|Experimental|Advanced Uveal Melanoma|
89502429|NCT02262403|Experimental|Hookworm infected|The amount, phenotype and function of Treg will be explored at several time points. Cultures with environmental antigen will be subsequently performed.
89502430|NCT02262403|Active Comparator|Non infected (hookworms) healthy subjects|All the tests done in the experimental hookworm infected group will be also done in the comparator non infected group.
89502431|NCT02264119|Experimental|Lefradafiban tablet with Pantoprazole|
89502432|NCT02264119|Active Comparator|Lefradafiban tablet without Pantoprazole|
89502433|NCT02264119|Experimental|Lefradafiban double chamber sachet with Pantoprazole|
89502434|NCT02264119|Active Comparator|Lefradafiban double chamber sachet without Pantoprazole|
89502435|NCT05481632|Experimental|Physician AI-assisted diagnosis group|
89502436|NCT05481632|Sham Comparator|Physician Independent Diagnostic Group|
89502437|NCT02262481|Active Comparator|Dydrogesterone|tocolytic + corticosteroids + Dydrogesterone 10 mg/tablet prepare in capsule, 1 cap oral every 12 hours, starting form enrollment until gestational age 37 weeks
89502438|NCT02262481|Placebo Comparator|Placebo|tocolytic + corticosteroids + Placebo prepare in capsule, 1 cap oral every 12 hours, starting form enrollment until gestational age 37 weeks
89502439|NCT02264197|Experimental|BIBX 245 CL - fed|after a light breakfast with 40 g fat
89502440|NCT02264197|Active Comparator|BIBX 245 CL - fasted|
89502441|NCT01437787|Placebo Comparator|Placebo comparator|once daily X 28 days, orally, empty stomach, approximately same time each day
89502442|NCT01437787|Experimental|SAR302503 400 mg|once daily X 28 days, orally, empty stomach, approximately same time each day
89502443|NCT01437787|Experimental|SAR302503 500 mg|once daily X 28 days, orally, empty stomach, approximately same time each day
89502444|NCT01435369|Active Comparator|CT-011 at dose level 1 (1.5 mg/kg).|
89502445|NCT01435369|Active Comparator|CT-011 at dose level 2 (6 mg/kg).|
89502446|NCT01257607|Experimental|1% MIM-D3 Ophthalmic Solution|
89502447|NCT01257607|Experimental|5% MIM-D3 Ophthalmic Solution|
89502448|NCT01257607|Placebo Comparator|Placebo Ophthalmic Solution|
89502449|NCT02264275|Experimental|Aerobic Exercise Training|An 8-week Nintendo Wii at-home dancing exergame Intervention
89502450|NCT01487083|Experimental|Pomaglumetad methionil|Pomaglumetad methionil will be administered orally. Participants entering the study will be flexibly dosed between 20 mg, 40 mg, and 80 mg twice daily.
89502451|NCT01662440|Active Comparator|R/JE - Conv|Subjects received Rabies and Japanese Encephalitis (JE) vaccines following the conventional schedule, ie, Rabies vaccination on days 1, 8, and 29, and placebo on day 4 in the right arm or leg; and JE vaccination on day 1 and 29, and placebo on day 8 in the left arm.
89502452|NCT01662440|Experimental|R/JE - Acc|Subjects received Rabies and JE vaccines following the accelerated schedule, ie, Rabies vaccination on days 1, 4, and 8, and placebo on day 29 in the right arm or leg; and JE vaccination on days 1 and 8, and placebo on day 29 in the left arm.
89502453|NCT01662440|Active Comparator|R - Conv|Subjects received Rabies vaccine following the conventional schedule, ie, Rabies vaccination on days 1, 8, and 29, and placebo on day 4 in the right arm or leg; and placebo on days 1, 8 and 29 in the left arm.
89502454|NCT01662440|Active Comparator|JE - Conv|Subjects received JE vaccine following the conventional schedule, ie, placebo on days 1, 4, 8 and 29 in the right arm or leg; and JE vaccination on days 1 and 29 and placebo injection on day 8 in the left arm.
89502455|NCT01253629|Experimental|25 mg bid AFQ056|1 capsule of 25 mg and 1 capsule of placebo per intake
89502456|NCT01253629|Experimental|50 mg bid AFQ056|2 capsules of 25 mg per intake
89502457|NCT01253629|Experimental|100 mg bid AFQ056|1 capsule of 100 mg and 1 capsule of placebo per intake
89502458|NCT01253629|Placebo Comparator|Placebo|2 capsules of placebo per intake
89502459|NCT01252693|Experimental|Ozarelix|
89502460|NCT01252693|Active Comparator|Goserelin|
89502461|NCT05481554||Common variable immunodeficiency with enteropathy|20 patients with a common variable immunodeficiency associated to enteropathy will be recruited in the study and will be compared with patients with a common variable immunodeficiency associated to enteropathy and porto-sinusoidal vascular disease
89502462|NCT05481554||Common variable immunodeficiency with enteropathy and porto-sinusoidal vascular disease|20 patients with common variable immunodeficiency associated to enteropathy and porto-sinusoidal vascular disease will be recruited in the study and will be compared with patients with a common variable immunodeficiency associated to enteropathy
89502463|NCT05486936||study arm|Eligible breast cancer patients will receive hypofractionated radiotherapy of 2.67 Gy for 16 fractions (and sequential tumor bed boost of 2.67 Gy for 4 fractions in patients with intact breast) to ipsilateral chest wall or whole breast and regional lymph regions (including supraclavicular and internal mammary lymph nodes) at the discrection of radition oncologists. The plans which pass the on-line verification will then be de-identified and transferred to RapidPlan configuration workspace for RNI model training and verification.All enrolled patients will be regularly followed up during and after RT. Acute and late toxicity will be documented as well as tumor control endpoints.
89502464|NCT01433497|Experimental|Experimental Arm A|Participants receive masitinib (4.5 mg/kg/day), given orally twice daily.
89502465|NCT01433497|Experimental|Experimental Arm B|Participants receive masitinib (4.5 mg/kg/day), given orally twice daily, with a dose escalation to 6 mg/kg/day after 3 months of treatment.
89502466|NCT01433497|Placebo Comparator|Placebo Comparator A|Participants receive placebo given orally twice daily.
89502467|NCT01433497|Placebo Comparator|Placebo Comparator B|Participants receive placebo, given orally twice daily, with a matched dose escalation after 3 months of treatment.
89502468|NCT01662362|Other|Testing Donor Specimens with ESA Chagas|Test blood donor specimens that are ABBOTT PRISM Chagas Repeatedly Reactive with ESA Chagas. Donors will be asked to return for a follow-up blood draw.
89502469|NCT05481476|Experimental|surufatinib combined with sintilimab and AG|
89502470|NCT01486849|Experimental|Dose Titration of CK-2017357 (Group 1)|Dose titration of active drug as add-on therapy to riluzole
89502471|NCT01486849|Placebo Comparator|Matching Placebo (Group 2)|Placebo as add-on therapy to riluzole
89206470|NCT00274261|Active Comparator|B|Conceptrol® Vaginal gel contains 100mg (4% concentration) of nonoxynol-9 (N-9) in 2.5 mL volume of gel.
89206471|NCT00624468|Experimental|Atacicept|
89206472|NCT00624468|Placebo Comparator|Placebo|
89502472|NCT01484119|Active Comparator|Investigational Drug|ACT-129968
89502473|NCT01484119|Placebo Comparator|Comparative Drug|matching placebo tablets and capsules
89502474|NCT01484119|Active Comparator|Reference Drug|Cetirizine
89502475|NCT05486858||LBP individuals|People who suffer from pain in the lower back area.
89502476|NCT05486858||asymptomatic individuals|People who has no low back pain in the patient history.
89502477|NCT02265055|Active Comparator|transfer early cleavage embryos (EC)|transfer early cleavage embryos
89502478|NCT02265055|Active Comparator|transfer non early cleavage embryo (NEC)|transfer non early cleavage embryos
89502479|NCT01482403|Experimental|Treatment Arm A|24 weeks of therapy with mericitabine 1000 mg twice a day (BID), boceprevir 800 mg three times daily (TID), Pegasys 180 microgram/week, and Copegus 1000/1200 mg/day (total treatment duration of 24 weeks), followed by a 24-week treatment-free follow-up period.
89502480|NCT01482403|Experimental|Treatment Arm B|24 weeks of therapy with mericitabine + boceprevir + Pegasys/Copegus followed by 24 weeks of therapy with boceprevir + Pegasys/Copegus (triple) (total treatment duration of 48 weeks), followed by a 24-week treatment-free follow-up period.
89502481|NCT01482403|Active Comparator|Treatment Arm C (Control)|4 weeks of therapy with mericitabine placebo, boceprevir placebo + Pegasys/Copegus, then 20 weeks of therapy with mericitabine placebo + boceprevir + Pegasys/Copegus, then 24 weeks of therapy with boceprevir + Pegasys/Copegus (total treatment duration of 48 weeks), followed by a 24-week treatment-free follow-up period.
88956679|NCT04472338||Screening (biospecimen collection)|Participants undergo collection of blood, urine, and/or tissue samples every 12 months, when any biopsy occurs, and if relevant, at time of curative therapy and 12 months after completion of curative therapy.
89032883|NCT04689204|Experimental|Administration of CTA30X|Dose escalation follows the standard 3+3 dose escalation design. A total of 3 dose levels are set for subjects.
89502482|NCT05486780|Experimental|Digital window|The patients who will be assigned to the experimental group will sleep on the 1st, 2nd, and 3rd beds. Experimental group patients are in the field of view of the digital window. A digital window is a tool designed by the researcher to enable patients to differentiate between day and night.
89502483|NCT05486780|No Intervention|Control group|the patients who will be assigned to the control group will sleep in the 4th, 5th, and 6th beds. Control group patients are not in the field of view of the digital window. Data collection will be completed by the researcher by completing the Day and Night Perception Form and the Richards Campbell Sleep Scale (Post-Test) on the 1st, 2nd, and 3rd days of post-op for the patients in the control group who are not in the field of view of the digital window.
89502484|NCT01481077|Experimental|Treatment A|
89502485|NCT01481077|Experimental|Treatment B|
89502486|NCT01481077|Experimental|Treatment C|
89502487|NCT02265211|Experimental|Self-Help App|Smartphone app designed to teach cognitive defusion.
89502488|NCT05481398|Experimental|Intervention group A|After the skin closed, negative pressure wound therapy will be applied.
89502489|NCT05481398|No Intervention|Control group B|After the skin is closed, the wound is covered using sterile standard guaze dressing.
89502490|NCT02268331|Experimental|Active Surveillance|"For 60 consecutive pediatric visits, patients will be asked to complete a PRE & POST form to capture adverse events (AEs) that occur up to 1 week after treatment. The PRE-treatment form will be completed prior to the start of the visit. The POST-treatment form will be completed after the treatment visit and mailed directly to the investigative team.~The providers will collect data on the treatment provided on the same 60 pediatric patients. The treatment provided is at the discretion of the doctors. If a moderate, serious, or severe AE occurs, the provider will complete the AE form with detailed information about potential risk factors and patient outcomes."
89502491|NCT02268331|Active Comparator|Passive Surveillance|"All doctors allocated to this arm will be provided with a username and password with an established chiropractic passive surveillance reporting and learning online system (CPiRLS) in the UK. If a patient safety incident occurs in their office or an adverse event (AE), the provider will complete a report on the CPiRLS website. The providers can record events that occur during the time period of 60 pediatric visits.~Treatment provided during these treatments is at the doctor's discretion."
89502492|NCT05486702|Experimental|Early Time Restricted Eating|8-hour eating period from 7 am to 3 pm with exercise
89502493|NCT05486702|Experimental|Late Time Restricted Eating|8-hour eating period from 3 pm to 11 pm with exercise
89502494|NCT05486624|No Intervention|Control group|Introductory Information Form was used in the control group on the 1st day of birth with face-to-face interviews. REEDA Scale, MAI-SF were used on the 1st, 2nd, 7th and 14th days of delivery. On the 1st day of birth, the Episiotomy Care Education Brochure and the Follow-up Form to be filled in within 14 days and to be obtained from them at the last follow-up were given. control group; It was evaluated by making a home visit on the 1st day and the 2nd day in the hospital, and on the 7th and 14th days. The records of the forms were filled by the researcher. Data collection time took approximately 15 minutes for the control group. Reiki was not applied to this group.
89502495|NCT05486624|Experimental|Intervention group|Introductory Information Form was used in the intervention group on the 1st day of birth with face-to-face interviews. REEDA Scale, MAI-SF were used on the 1st, 2nd, 7th and 14th days of delivery. On the 1st day of birth, the Episiotomy Care Education Brochure and the Follow-up Form to be filled in within 14 days and to be obtained from them at the last follow-up were given. intervention group; It was evaluated by making a home visit on the 1st day and the 2nd day in the hospital, and on the 7th and 14th days. Reiki was applied on the 1st, 2nd and 7th days of birth. In total, 3 sessions of Reiki were applied. The records of the forms were filled by the researcher. Data collection took approximately 50-55 minutes for the intervention group.
89502496|NCT02268409|Experimental|ACE-536 0.8 mg/kg once every 3 weeks SC|ACE-536 0.8 mg/kg once every 3 weeks by SC injection
89502497|NCT02268487|Experimental|Sertraline|Patients using Sertraline with any dose will be evaluated about Early Improvement
89502498|NCT02265289|Experimental|Lefradafiban with clopidogrel|"All patients received the same treatment:~Lefradafiban only (day 1-4)~Lefradafiban in combination with Clopidogrel (day 5-8)~Clopidogrel only (day 9-12)"
89502499|NCT02265445|Active Comparator|Maintaining carbapenem therapy|Intravenous therapy, Maintaining carbapenem therapy
88956680|NCT04468672|Active Comparator|Day worker|Men and women who work only day shift for at least 3 consecutive days of the week
88956681|NCT04468672|Active Comparator|Night worker|Men and women who work only night shift for at least 3 consecutive days of the week
88956682|NCT04456673|Experimental|Dupilumab|Dupilumab administered every 2 weeks
88956683|NCT04456673|Placebo Comparator|Placebo|Placebo dose administered every 2 weeks
88956684|NCT04454190||Glaucoma - Slow progressors|Rates of MD change slower than -0.50 dB/year Rates of global RNFL thickness change slower than -1.0 µm/year
88956685|NCT04454190||Glaucoma - Fast progressors|Rates of MD change faster -0.50 to -2.00 dB/year Rates of global RNFL thickness change -1.0 to -4.0 µm/year
88956686|NCT04454190||Glaucoma - Catastrophic progressors|Rates of MD change faster than -2.00 dB/year Rates of global RNFL thickness change faster than -4.0 µm/year
88956687|NCT04448886|Experimental|Sacituzumab Govitecan + Pembrolizumab|"The research study procedures include: screening for eligibility, research blood collections, at least two research biopsies, paired research stool collections, and study treatment including evaluations and follow up visits. Each Cycle =21 Days~Sacituzumab Govitecan (iv) fixed dose, administered twice per cycle~Pembrolizumab (iv) fixed dose administered once per cycle"
89206473|NCT03976687|Experimental|1: EYP001a Dose A|Dose A once daily morning dose
89502500|NCT02265445|Active Comparator|Deescalation therapy|Switch for a narrow spectrum beta-lactam active on the causative ESBL-PE. Deescalation therapy
89502501|NCT04476121|Experimental|PRF application|Patients with alveolar osteitis in which PRF application was performed.
89502502|NCT04476121|Active Comparator|Aspirin application|Patients with alveolar osteitis in which Nipas was used.
89502503|NCT05479526||Group 1|Control group will consist of 42 healthy individuals, aged between 30-60 years.
89502504|NCT05479526||Group 2|This group will consist of 42 patients with diagnosed Plantar Fasciitis, aged between 30-60 years.
89502505|NCT01234519|Experimental|Phase 1 - Cohort 1|"Determination of maximum tolerated dose (MTD) and recommended parenteral administration dosing for AEZS-108 in 4 sequential cohorts of patients (3-6 patients/cohort).~Patients will be enrolled in cohorts of 3 at a specified AEZS-108 dose beginning with 160mg/m^2. Enrollment will be suspended until all members of a cohort have been observed for dose limiting toxicities (DLT) for a period of 3 weeks (1 cycle of AEZS-108) from initial treatment with AEZS-108. Dose escalation will proceed within each cohort according to a specific scheme where DLT is defined."
89502506|NCT01234519|Experimental|Phase 1 - Cohort 2|Determination of maximum tolerated dose (MTD) and recommended parenteral administration dosing for AEZS-108 in 4 sequential cohorts of patients (3-6 patients/cohort).
89502507|NCT01234519|Experimental|Phase 1 - Cohort 3|Determination of maximum tolerated dose (MTD) and recommended parenteral administration dosing for AEZS-108 in 4 sequential cohorts of patients (3-6 patients/cohort).
89502508|NCT01234519|Experimental|Phase 1 - Cohort 4|Determination of maximum tolerated dose (MTD) and recommended parenteral administration dosing for AEZS-108 in 4 sequential cohorts of patients (3-6 patients/cohort).
89502509|NCT01234519|Experimental|Phase 2|AEZS-108 at MTD to determine efficacy in up to 40 patients.
89502510|NCT01474135|Experimental|0.25% AR-12286/ 0.004% travoprost|Fixed dose combination of 0.25% AR-12286 and 0.004% travoprost
89502511|NCT01474135|Experimental|0.5% AR-12286/ 0.004% travoprost|Fixed dose combination of 0.5% AR-12286/ 0.004% travoprost
89502512|NCT01474135|Active Comparator|0.004%Travoprost|Travatan(R) Z(travoprost ophthalmic solution)
89502513|NCT02554682|Other|Sexual Health|Parents of teens between the ages of 14 and 15 will review psychoeducational workbooks related to sexual health at a well-child visit appointment with the primary care giver (baseline); 2 weeks after baseline they will received a follow-up phone call and health coaching session to review the materials and ask questions; and then at 4 to 5 months post baseline we will collect data to assess the efficacy of the study materials.
89502514|NCT02554682|Other|Alcohol Prevention|Parents of teens between the ages of 14 and 15 will review psychoeducational workbooks related to alcohol prevention at a well-child visit appointment with the primary care giver (baseline); 2 weeks after baseline they will received a follow-up phone call and health coaching session to review the materials and ask questions; and then at 4 to 5 months post baseline we will collect data to assess the efficacy of the study materials.
89608338|NCT01271062|Active Comparator|non diabetic patients, non-bariatric abdominal surgery|oral glucose tolerance test , botnia clamp, elective laparoscopic abdominal surgery.
89608339|NCT01271062|Active Comparator|severely obese T2DM patients following a very low caloric diet|oral glucose tolerance test , botnia clamp, before as well after following a very low caloric diet. Very low caloric diet.
89608340|NCT02992912|Experimental|Cohort 1: metastatic colorectal cancer|
89608341|NCT02992912|Experimental|Cohort 2: metastatic non-small lung cancer|
89608342|NCT02992912|Experimental|Cohort 3: metastatic renal cell carcinoma|
89608343|NCT02992912|Experimental|Cohort 4: metastatic sarcoma|
89608344|NCT01276522|Experimental|Canakinumab|A 6-month open-label, single treatment arm study of canakinumab 150 or 300 mg (in case of insufficient response to 150 mg) subcutaneous injection once per month.
89608345|NCT02992444|Experimental|Cohort 5|"This is a sub-study testing the effect of real output applied under two adhesive strips on the skin after 8 hours.~There is one visit:~Two adhesive strips (standard adhesive strip and Experimental adhesive strip)are applied on the peristomal skin and allowed to sit for 8hours before being removed."
89608346|NCT01276678||Control|300 healthy controls free from any pharmacologic therapy
89206474|NCT03976687|Experimental|2: EYP001a Dose B|Dose B once daily morning dose
89206475|NCT03976687|Experimental|3: EYP001a Dose C|Dose C twice daily - first dose morning dose and second dose 3 hours post first dose
89608347|NCT01276678||Suspected CAD - Cardiac Cathetrization|subject's ≥18 years undergoing coronary angiography (inpatient cohort)or who have undergone coronary angiography within 5 years
89608348|NCT01271140|Experimental|Insulin/dextrose clamp|
89608349|NCT01271218|Placebo Comparator|Placebo|Participants ingested 2,200 mg/day of a placebo or active dietary supplement. Participants ingested three caplets in the morning and the remaining three caplets in the evening 30-minutes before a meal for 14-weeks. The supplements were prepared in caplet form and packaged in generic bottles for double blind administration. The placebo was a starch-based placebo matched for color, texture, and taste to the active supplement.
89608350|NCT01271218|Active Comparator|Active Supplement|Participants were randomly assigned to ingest in a double-blind manner caplets containing a commercially available glucosamine/chondroitin (GC) dietary supplement (Curves Joint and Connective Support™, Curves International, Waco, TX) or a suitable placebo (P). The GC supplement provided a total of 1,500 mg/d of glucosamine, 1,200 mg/d of chondroitin sulfate, 120 mg/d of niacin, 120 mg/d of sodium, 45 mg/d of zinc, 900 mg/d MSM, 300 mg/d of boswellia serrata extract, 180 mg/d of white willow bark extract, and 15 mg/d of rutin powder. Participants ingested three caplets in the morning and the remaining three caplets in the evening 30-minutes before a meal for 14-weeks.
89608351|NCT01271296|Active Comparator|Liquorice|Liquorice eq to 150 mg glycyrrhizinic acid. Results are compared to a baseline assessment without liquorice/grapefruit juice ingestion.
89608352|NCT01271296|Active Comparator|Grapefruit juice|200 ml pink grapefruit juice three times a day. Results are compared to a baseline assessment without liquorice/grapefruit juice ingestion.
89608353|NCT01271296|No Intervention|Baseline|Baseline assessment without intake of liquorice or grapefruit juice
89206476|NCT03976297|Experimental|Control Tower Intervention|For participants in the intervention arm, the results of the prediction model will be presented through a GUI interface hereby known as the Control Tower. Participants receive scores from Control Tower (0-100; higher score indicating increased need) for palliative care and are subsequently ranked from highest to lowest. Red (7 or greater) is considered high risk. The intervention will include a Control Tower operator who will interact with the inpatient palliative care consult service. The operator will monitor the Control Tower during weekday normal business hours and select daily a cohort of participants in the intervention units with the highest need of palliative care review. The final list of participants will then be sent to palliative care. The palliative care team who is on service will also assess the need for each participants, and those participants which they agree could benefit they will approach the attending clinical team to suggest a palliative care referral.
89502515|NCT02554682|No Intervention|Sexual Health & Alcohol Control Group|Parents of teens between the ages of 14 and 15 will receive their usual care at their well-child visit appointment with their primary care giver (baseline) and then at 4 to 5 months post baseline we will collect data. At the end of the post data collection, the control group will get all of the study materials from both the sexual health and alcohol prevention groups.
89502516|NCT02554682|Other|Teen Driving|Parents of teens between the ages of 16 and 17 who are planning on having the medical certification for the permit application completed and plan on taking their driving permit test in the next 8 weeks will review psychoeducational workbooks related to teen driving at a well-child visit appointment with the primary care giver (baseline); 2 weeks after baseline they will received a follow-up phone call and health coaching session to review the materials and ask questions; and then at 6 months post baseline we will collect data to assess the effectiveness of the study materials.
89502517|NCT02554682|No Intervention|Teen Driving Control|Parents of teens between the ages of 16 and 17 who are planning on having the medical certification for the permit application completed and plan on taking their driving permit test in the next 8 weeks will receive their usual care at their well-child visit appointment with their primary care giver (baseline) and then at 6 months post baseline we will collect data. At the end of the post data collection, the control group will get all of the study materials from the teen driving group.
89502518|NCT02268565|Placebo Comparator|Insomnia symptom induction/placebo|Daily intake of pill at bedtime over 2-week period prior to and during the 5-day in-hospital stay
89502519|NCT02268565|Experimental|Insomnia symptom induction/aspirin|Daily intake of pill at bedtime over 2-week period prior to and during the 5-day in-hospital stay
89502520|NCT02268643||group 1|ultrasound plus clinical breast examination
89502521|NCT01420783|Experimental|SAR302503 100 mg|once daily X 28 days
89502522|NCT01420783|Experimental|SAR302503 200 mg|once daily X 28 days
89502523|NCT01420783|Experimental|SAR302503 400 mg|once daily X 28 days
89502524|NCT01420783|Experimental|SAR302503 600 mg|once daily X 28 days
89502525|NCT02265523|No Intervention|Standard Post-op Exercise Group|The standard post-operative exercises are already currently recommended to patients. Briefly, they include deep breathing and coughing, ankle pumping, buttock contractions, and static quadriceps strengthening. These are performed on a daily basis , 2-3 times per day, 30 repetitions.
89502526|NCT02265523|Experimental|Viscus Group|The Viscus (intervention) group will complete the standard post-operative exercises and will also have access to a Viscus V1.5 cycle ergometer 24 hours per day in their recovery room to use at their leisure.
89502527|NCT05475626||Treatment Of Symptomatic Pes Planus By Sinus Tarsi Screw|Treatment Of Symptomatic Pes Planus
89502528|NCT01472887|Experimental|SAR3419|All patients will receive SAR3419 until evidence of disease progression, unacceptable toxicity, or other reasons for therapy discontinuation
89502529|NCT02268721|No Intervention|Controle Group|Patients in the control group are undergoing the same measurements and records before discharge, and at six and twelve weeks, as the intervention group. The control group receives no special treatment or care after discharge.
89502530|NCT02268721|Other|App for food delivery|"Intervention: Tablet Computer~Patients in the intervention group receives a tablet upon discharge from the hospital. The tablet contains an app, which the patients in the intervention group can use for ordering meals for delivery from the kitchen at the hospital three times a week. The app also ask the patients to register their own dietary intake, and give them feedback on their daily energy and protein intake.~Baseline measurements and records are taken at prior to discharge from the hospital, and after six and twelve weeks."
89502531|NCT05480852|Experimental|Bis-GMA Free dental resin composite|Restorative Materials
89502532|NCT05480852|Active Comparator|Bis-GMA containing dental resin composite|Restorative Materials
89502533|NCT02264509||Arterial insufficiency and HIV|Of a cohort of 206 HIV patients will be randomly selected 206 for Ankle-brachial index to identify wich suffer symptomatic or asymptomatic arterial insufficiency
89502534|NCT01466725|Experimental|Cohort 1|25 mg daily for 4 weeks (8 active/2 control)
89502535|NCT01466725|Experimental|Cohort 2|50 mg once daily for 4 weeks (8 active/2 control)
89502536|NCT01466725|Experimental|Cohort 3|100 mg daily for 6 weeks (8 active/2 control)
89502537|NCT01466725|Experimental|Cohort 4|100 mg twice daily for 6 weeks (8 active/2 control)
89502538|NCT05475548|Active Comparator|Group (A): using reversed skeletally anchored PowerScope as a fixed functional appliance.|eight patients with mild to moderate Class IΙΙ malocclusion who will be treated by pre-adjusted straight wire appliance followed by reversed skeletally anchored PowerScope as a fixed functional appliance.
89502539|NCT05475548|Active Comparator|Group (B): using dentally anchored reversed PowerScope as a fixed functional appliance|eight patients with mild to moderate Class IΙΙ malocclusion who will be treated by pre-adjusted straight wire appliance followed by dentally anchored reversed PowerScope as a fixed functional appliance
89502540|NCT04423562||Durable LVAD recipient with post implant VO2|
89502541|NCT02264587|Experimental|mosapride|mosapride 5mg by mouth, 30 minutes before meals, every times one day for 14days
88956688|NCT04448886|Experimental|Sacituzumab Govitecan|"The research study procedures include: screening for eligibility, research blood collections, at least two research biopsies, paired research stool collections, and study treatment including evaluations and follow up visits.~- Sacituzumab Govitecan (iv) fixed dose, administered twice per cycle"
88956689|NCT04448886|Experimental|Retreatment|Participants who have attained a confirmed complete response (CR) who have been treated for at least 24 weeks on protocol therapy and had at least three cycles (with pembrolizumab and sacituzumab govitecan (Arm A) or sacituzumab govitecan alone (Arm B)) beyond the date when the initial CR was declared may be eligible for additional sacituzumab govitecan and/or pembrolizumab therapy if they progress after stopping study treatment. This retreatment is termed the Second Course Phase of this study and is only available if the study remains open and the subject meets protocol-specified conditions.
88956690|NCT04438889||AML|Patients with WHO 2016 diagnosis of AML
88956691|NCT04438889||MDS|Patients with WHO 2016 diagnosis of MDS
88956692|NCT04438889||CMML|Patients with WHO 2016 diagnosis of CMML
88956693|NCT04438889||PMF|Patients with WHO 2016 diagnosis of PMF
88956694|NCT04402151|Other|Single Arm|"Patients enrolling on the protocol will undergo prostate-specific membrane antigen (PSMA) Positron Emission Tomography (PET)/Magnetic Resonance(MR) prior to start of the radiation treatment planning process. PSMA tracer is administered by IV injection and PET images are acquired.~Any patients found to have possible metastatic disease will undergo a standard of care confirmatory biopsy (if feasible) and receive treatment appropriate for their stage.~The PSMA PET/MR scan will be performed prior to initiation of androgen deprivation therapy (ADT)."
89502542|NCT02264587|Active Comparator|domperidone|domperidone 10mg by mouth, 30 minutes before meals, every times one day for 14days
89502543|NCT05475470|Experimental|group a|the group we used our new blade-finger technique
89502544|NCT05475470|Experimental|group b|the group we used Hasson's technique
89502545|NCT05475470|Experimental|group c|the group we used veress needle technique
89502546|NCT01229215|Experimental|FCFD4514S|
89502547|NCT01229215|Sham Comparator|sham|
89502548|NCT05475080||Antiplatelet|
89502549|NCT05475080||Anticoagulant|
89502550|NCT05475080||Endovascular|
89502551|NCT05475080||Surgical (endarterectomy)|
89502552|NCT01228513|Active Comparator|0.01% ointment|Lowest concentration
89502553|NCT01228513|Active Comparator|0.03% ointment|Middle concentration
89502554|NCT01228513|Active Comparator|0.1% ointment|Highest concentration
89502555|NCT01228513|Placebo Comparator|Placebo (vehicle without active)|No active ingredient
89502556|NCT04563572|Experimental|PPG Smartwatch|"The Preventicus Heartbeats algorithm ist a certified tool for detection of Atrial Fibrillation. It differentiates accurately between regular rhythm, single premature beats and the absolute arrhythmia concordant with AF. The Preventicus algorithm is device-agnostic, meaning that any wearable device capable of recording PPG-signals can be used for data collection.~CardioWatch 287 is a novel non-invasive monitoring device manufactured by the MMT company. The device monitors heart rhythm, heart rate (HR) and respiratory rate (RR) based on peripheral PPG signal.~In this arm, we will test the quality of the algorithm integrated into the smartwatch."
88982894|NCT03123978|Experimental|Treatment (niclosamide, enzalutamide)|Patients receive niclosamide PO BID and enzalutamide PO QD on weeks 1-4. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
88982895|NCT03117881|Experimental|DirectCAM|The DirectCAM arm receives the intervention content via therapists at participating clinics.
89502557|NCT04563572|Experimental|PPG Bracelet|"The Preventicus Heartbeats algorithm ist a certified tool for detection of Atrial Fibrillation. It differentiates accurately between regular rhythm, single premature beats and the absolute arrhythmia concordant with AF. The Preventicus algorithm is device-agnostic, meaning that any wearable device capable of recording PPG-signals can be used for data collection.~A PPG-sensor is also integrated into a bracelet Basler Band manufactured by the MMT company, which is a simplified multisensory device.~In this arm, we will test the quality of the algorithm integrated into the bracelet."
89502558|NCT04269434|No Intervention|Screening|In the screening arm, Ng/Ct results will be sent by the STI Laboratory to the study physicians and these participants will be treated and partner contact tracing will be done.
89502559|NCT04269434|Other|No screening|In the no screening arm, the STI Laboratory will only process the samples/report the results from the non-screening arm at the end of the study.
89502560|NCT05474300||Covid-19 ARDS patients on PCV mode|No Intervention
89502561|NCT03782402|Experimental|Cannabinoids (THC and CBD)|THC and CBD
88982896|NCT03117881|Experimental|TeleCAM|The TeleCAM arm receives the intervention content at home using pre-loaded tablets and Interactive Voice Response (IVR) system technology.
89502562|NCT03782402|Placebo Comparator|Placebo Cannabinoids|placebo cannabinoids
89538660|NCT04968171||People with newly diagnosed diabetes mellitus type 1|"People with newly diagnosed diabetes mellitus type 1 admitted to the Department of Internal Medicine and Diabetology.~Treated with intensive insulin therapy. Measurement of VO2max between 3 and 12 month after diagnosis. Further continuous observation with follow-up every year and evaluation of final end-points after 5 and 10 years."
89538661|NCT02456519||PaedQoR-15 Questionnaire|Questionnaire to be completed by all participants
89502563|NCT05478668||retrospective analysis|A retrospective analysis of disease histories for the period from 2014 to 2021 was carried out. Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury. In all patients, the assessment of anesthetic risk was carried out according to the ASA scale. The basic tool for pain intensity research was a visual analog scale. Intervals between analgesia were also studied. The study of the neuropathic component of pain was carried out using the Didier Bouhassiraa neuropathic pain diagnostic questionnaire. Study of the presence of an acute stress reaction scale The Hospital Anxiety and Depression Scale. Research on the presence of post-traumatic stress disorders was carried out using the Mississippi scale of post-traumatic stress disorders (military version). Satisfaction with treatment results was studied using the Chaban Quality of Life Scale.
89502564|NCT05478668||prospective study|"Recruitment of patients for the prospective study was carried out in the period from 02.24.2022 to 05.24.2022. Data collection was carried out during the Russian invasion of Ukraine and the offensive on Kyiv. All patients with gunshot wounds were evacuated to the stage of treatment - the National Military Medical Clinical Center Main Military Clinical Hospital. The research was conducted using the same methods as during the retrospective analysis. The exception was the study period during treatment at the military medical clinical center: here it was 14 days."
89502565|NCT00154063|Placebo Comparator|Placebo|During the Titration Phase, placebo was initiated at a dose of 1.0 mg/day for the first 2 weeks, increased to 1.5 mg/day for the next 2 weeks, and then further increased to 2.0 mg/day for 10 weeks (last 2 weeks of the Titration Phase continuing into the 8-week Maintenance Phase).
89502566|NCT00154063|Experimental|E2007|During the Titration Phase, perampanel was initiated at a dose of 1.0 mg/day for the first 2 weeks, increased to 1.5 mg/day for the next 2 weeks, and then further increased to 2.0 mg/day for 10 weeks (last 2 weeks of the Titration Phase continuing into the 8-week Maintenance Phase).
89502567|NCT02683941|Experimental|Lanreotide (Autogel formulation)|120mg every 28 days until disease progression, death, or unacceptable toxicity
89502568|NCT02683941|Placebo Comparator|Placebo|120mg every 28 days until disease progression, death, or unacceptable toxicity during the double-blind phase. The patient may enter open-label phase for treatment with Lanreotide.
89502569|NCT01463059|Placebo Comparator|Placebo every 2 weeks|Injections administered at week 0, 2, 4, 6, 8 and 10
89502570|NCT01463059|Experimental|Olokizumab 60 mg every 2 weeks|Olokizumab 60 mg injections administered at week 0, 2, 4, 6, 8 and 10
89502571|NCT01463059|Experimental|Olokizumab 60 mg every 4 weeks|Olokizumab 60 mg injection administered at week 0, 4, and 8 and Placebo injection administered at week 2, 6, and 10
89502572|NCT01463059|Experimental|Olokizumab 120 mg every 2 weeks|Olokizumab 120 mg injections administered at week 0, 2, 4, 6, 8 and 10
89502573|NCT01463059|Experimental|Olokizumab 120 mg every 4 weeks|Olokizumab 120 mg injections administered at week 0, 4 and 8 and Placebo injections at week 2, 6 and 10
89502574|NCT01463059|Experimental|Olokizumab 240 mg very 4 weeks|Olokizumab 240 mg injections administered at week 0, 4 and 8 and Placebo injections at week 2, 6 and 10
89502575|NCT01401985|Experimental|Cohort 1|5 mg TD-1211 once daily for 4 days followed by 10 mg for 14 days
89502576|NCT01401985|Experimental|Cohort 2|5 mg TD-1211 once daily for 4 days followed by 15 mg for 14 days
89502577|NCT01401985|Experimental|Cohort 3|5 mg TD-1211 once daily for 2 days followed by 10 mg for 14 days
89502578|NCT01401985|Experimental|Cohort 4|5 mg TD-1211 once daily for 2 days followed by 15 mg for 14 days
89502579|NCT01401985|Experimental|Cohort 5|2 mg TD-1211 once daily for 14 days
89502580|NCT01401985|Experimental|Cohort 6|2.5 mg TD-1211 every 6 hours for 14 days
89502581|NCT01225393|Experimental|A|
89502582|NCT01225393|Active Comparator|B|
89502583|NCT01225393|Placebo Comparator|C|
89502584|NCT02678247|Active Comparator|NU-FlexSIV Socket|The Northwestern University Flexible Sub-Ischial Vacuum Socket is a novel socket design for transfemoral amputees.
89502585|NCT02678247|Active Comparator|IC Socket|The Ischial Containment Socket is the standard of care socket design for transfemoral amputees.
89502586|NCT01225315|Experimental|Setipiprant - Dose 1|100 mg b.i.d.
89502587|NCT01225315|Experimental|Setipiprant - Dose 2|500 mg b.i.d.
89502588|NCT01225315|Experimental|Setipiprant - Dose 3|1,000 mg b.i.d
89023639|NCT05040126|Active Comparator|Arm 1 - 26 weeks of BDQ +Pa + LZD (600mg)|"26 wks. of BDQ +Pa + LZD (600mg) Bedaquiline (available as 100 mg tablets) Bedaquiline will be administered as four 100 mg tablets (400 mg) by mouth once a day for 2 weeks, followed by two 100 mg tablets (200 mg) by mouth three times a week for 24 weeks.~Linezolid: (available as 600 mg tablets) - Linezolid will be administered as one 600 mg tablet once daily in Arm1.~Pretomanid: (Available as 200 mg tablets): Pretomanid is administered as one tablet once a day for 26 weeks along with Bedaquiline and Linezolid."
89502589|NCT01225315|Placebo Comparator|Matching Placebo|Oral placebo
89502590|NCT01223911|Experimental|A|
89502591|NCT01223911|Placebo Comparator|B|
89502592|NCT01457677|Placebo Comparator|Placebo|
89502593|NCT01457677|Experimental|RO4995819 15 mg|
89502594|NCT01457677|Experimental|RO4995819 30 mg|
89502595|NCT01457677|Experimental|RO4995819 5 mg|
89502596|NCT02683785|Experimental|GSK3196165|Subjects will receive a total of 8 doses of GSK3196165 over a 12-week treatment period.
89502597|NCT02683785|Placebo Comparator|Placebo|Subjects will receive a total of 8 doses of placebo over a 12-week treatment period.
89502598|NCT02264743|Experimental|Femoston Conti 0.5mg/2.5mg|"Ultra low dose, film-coated 17β-estradiol (as hemihydrate) 0.5mg & dydrogesterone 2.5 mg~Once a day~The duration is six months.~Drug intervention: Estradiol&DydrogesteronevsOestradiol&Norethisterone acetate"
89502599|NCT02264743|Active Comparator|EVOREL® CONTI transdermal patches|"EVOREL CONTI is a transdermal self adhesive patch which is 0.1 mm in thickness and each patch releases 50mcg of oestradiol and 170mcg of norethisterone acetate over 24 hours .~The Evorel Conti patch is cut in half and applied to the lower part of the body for 3.5 days (delivering approx 25mcg of oestradiol over 24 hours ) this is replaced every 3.5 days .~The duration is six months.~Drug intervention: Estradiol&DydrogesteronevsOestradiol&Norethisterone acetate"
89502600|NCT01220947|Experimental|Group A|Danoprevir 200 mg twice a day (BID) + ritonavir 100 mg + Pegasys 180 microgram sc qw + Copegus 1000 mg or 1200 mg po daily for 24 weeks
89502601|NCT01220947|Experimental|Group B|Danoprevir 100 mg BID + ritonavir 100 mg + Pegasys 180 microgram sc qw + Copegus 1000 mg or 1200 mg po daily for 24 weeks
89502602|NCT01220947|Experimental|Group C|Danoprevir 50 mg BID + ritonavir 100 mg + Pegasys 180 microgram sc qw + Copegus 1000 mg or 1200 mg po daily for 24 weeks
89502603|NCT01220947|Experimental|Group D|Danoprevir 100 mg BID + ritonavir 100 mg + Pegasys 180 μg sc qw + Copegus 1000 mg or 1200 mg po daily for 12 weeks or 24 weeks
89502604|NCT01220947|Active Comparator|Group E|Pegasys 180 microgram sc qw + Copegus 1000 mg or 1200 mg po daily for 48 weeks
89502605|NCT02265679|Experimental|BIIL 284 BS, low dose in pediatric patients|
89502606|NCT02265679|Experimental|BIIL 284 BS, medium dose in pediatric patients|
89502607|NCT02265679|Experimental|BIIL 284 BS, high dose in pediatric patients|
89502608|NCT02265679|Experimental|BIIL 284 BS, low dose in adult patients|
89502609|NCT02265679|Experimental|BIIL 284 BS, medium dose in adult patients|
89502610|NCT02265679|Experimental|BIIL 284 BS, high dose in adult patients|
89502611|NCT02265679|Placebo Comparator|Placebo|
89502612|NCT01397227|Experimental|Cohort 1 (Low Dose)|Ad35.CS.01/Ad26.CS.01 - 1 x 10^10 vp
89502613|NCT01397227|Experimental|Cohort 2 (High Dose)|Ad35.CS.01/Ad26.CS.01 - 5 x 10^10 vp
89502614|NCT01397227|Placebo Comparator|Cohort 1 - Placebo|
89502615|NCT01397227|Placebo Comparator|Cohort 2 - Placebo|
89502616|NCT01396213|Experimental|Larazotide Acetate 0.5 mg|larazotide acetate 0.5 mg capsules TID
89502617|NCT01396213|Experimental|Larazotide Acetate 1 mg|larazotide acetate 1 mg capsules TID
89502618|NCT01396213|Experimental|Larazotide Acetate 2 mg|larazotide acetate 2 mg capsules TID
89502619|NCT01396213|Placebo Comparator|Placebo|placebo capsules TID
89502620|NCT05516433||Imipenem|Prescribing rules differ from one department to another: Imipenem is the preferred drug at Saint-Joseph Hospital.
89502621|NCT05516433||Meropenem|Prescribing rules differ from one department to another: Meropenem is the preferred carbapenem at Avicenne Hospital.
89502622|NCT01393639|Experimental|PF-04171327 1 mg QD|
89502623|NCT01393639|Experimental|PF-04171327 5 mg QD|
89502624|NCT01393639|Experimental|PF-04171327 10 mg QD|
89502625|NCT01393639|Experimental|PF-04171327 15 mg QD|
89502626|NCT01393639|Active Comparator|prednisone 5 mg QD|
89502627|NCT01393639|Active Comparator|prednisone 10 mg QD|
89502628|NCT01393639|Placebo Comparator|placebo|
89502629|NCT02265757|Experimental|No Cognitive Rehabilitation|Will receive a 10 day intervention program (over 2 weeks) consisting of Computer Brain Fitness Training, Support Group, Wellness Education and Physical Exercise.
89502630|NCT02265757|Experimental|No Computer Brain Fitness Training|Will receive a 10 day intervention program (over 2 weeks) consisting of Cognitive Rehabilitation, Support Group, Wellness Education and Physical Exercise
89502631|NCT02265757|Experimental|No Support Group|Will receive a 10 day intervention program (over 2 weeks) consisting of Cognitive Rehabilitation, Computer Brain Fitness Training, Wellness Education and Physical Exercise
89502632|NCT02265757|Experimental|No Wellness Education|Will receive a 10 day intervention program (over 2 weeks) consisting of Cognitive Rehabilitation, Computer Brain Fitness Training, Support Group, and Physical Exercise
89502633|NCT02265757|Experimental|No Physical Exercise|Will receive a 10 day intervention program (over 2 weeks) consisting of Cognitive Rehabilitation, Computer Brain Fitness Training, Support Group, and Wellness Education
89502634|NCT02265835||Cases of anastomotic airway complication|Cases of anastomotic airway complication
89502635|NCT02265835||Patients with normal anastomotic healing|Patients with normal anastomotic healing
89502636|NCT01382797|Placebo Comparator|Placebo|Capsules for oral administration
89502637|NCT01382797|Experimental|ALKS 37|Capsules for oral administration
89502638|NCT01379209|Experimental|RGI-2001 0.001 μg/kg + Standard of Care GVHD Prophylaxis|"RGI-2001 will be add to standard treatment with a calcineurin inhibitor, in combination with either methotrexate, mycophenolate mofetil, or sirolimus all at doses as per the institutional protocols~Dose escalation cohort 1 in part 1 of this study will include 2-6 patients"
89502639|NCT01379209|Experimental|RGI-2001 0.01 μg/kg + Standard of Care GVHD Prophylaxis|"RGI-2001 will be add to standard treatment with a calcineurin inhibitor, in combination with either methotrexate, mycophenolate mofetil, or sirolimus all at doses as per the institutional protocols~Cohort 2 in part 1 of this study will include 2-6 patients"
89502640|NCT01379209|Experimental|RGI-2001 0.1 μg/kg + Standard of Care GVHD Prophylaxis|"RGI-2001 will be add to standard treatment with a calcineurin inhibitor, in combination with either methotrexate, mycophenolate mofetil, or sirolimus all at doses as per the institutional protocols~Cohort 3 in part 1 of this study will include 2-6 patients"
89502641|NCT01379209|Experimental|RGI-2001 1.0 μg/kg + Standard of Care GVHD Prophylaxis|"RGI-2001 will be add to standard treatment with a calcineurin inhibitor, in combination with either methotrexate, mycophenolate mofetil, or sirolimus all at doses as per the institutional protocols~Cohort 4 in part 1 of this study will include 2-6 patients"
89502642|NCT01379209|Experimental|RGI-2001 10 μg/kg + Standard of Care GVHD Prophylaxis|"RGI-2001 will be add to standard treatment with a calcineurin inhibitor, in combination with either methotrexate, mycophenolate mofetil, or sirolimus all at doses as per the institutional protocols~Cohort 5 in part 1 of this study will include 2-6 patients"
89023640|NCT05040126|Experimental|Arm 2 - 9 weeks. of BDQ +Pa + LZD (600mg) followed by 17 wks. of BDQ +Pa+ LZD (300mg)|"9 wks. of BDQ +Pa + LZD (600mg) followed by 17 wks. of BDQ +Pa+ LZD (300mg) Bedaquiline (available as 100 mg tablets) Bedaquiline will be administered as four 100 mg tablets (400 mg) by mouth once a day for 2 weeks, followed by two 100 mg tablets (200 mg) by mouth three times a week for 24 weeks.~Linezolid: (available as 600 mg tablets) - Linezolid will be administered as one 600 mg tablet once daily in IP of Arm 2 and ½ tablet of 600 mg once daily in CP of Arm 2 .~Pretomanid: (Available as 200 mg tablets): Pretomanid is administered as one tablet once a day for 26 weeks along with Bedaquiline and Linezolid."
89502643|NCT01379209|Experimental|RGI-2001 100 μg/kg + Standard of Care GVHD Prophylaxis|"RGI-2001 will be add to standard treatment with a calcineurin inhibitor, in combination with either methotrexate, mycophenolate mofetil, or sirolimus all at doses as per the institutional protocols~Cohort 6 in part 1 of this study will include 2-6 patients"
89023641|NCT05040126|Experimental|Arm 3 -13 weeks. of BDQ +Pa + LZD (600mg) followed by 13 wks. of BDQ +Pa+ LZD (300mg)|"13 wks. of BDQ +Pa + LZD (600mg) followed by 13 wks. of BDQ +Pa+ LZD (300mg) Bedaquiline (available as 100 mg tablets) Bedaquiline will be administered as four 100 mg tablets (400 mg) by mouth once a day for 2 weeks, followed by two 100 mg tablets (200 mg) by mouth three times a week for 24 weeks.~Linezolid: (available as 600 mg tablets) - Linezolid will be administered as one 600 mg tablet once daily in IP of Arm 3 and ½ tablet of 600 mg once daily in CP of Arm 3.~Pretomanid: (Available as 200 mg tablets): Pretomanid is administered as one tablet once a day for 26 weeks along with Bedaquiline and Linezolid."
89032884|NCT04691687|No Intervention|Standard of Care (Group 1)|Patients in Group 1 received standard of care treatment per heart failure guidelines at the discretion of the primary cardiologist involved in the patient's care.
89502644|NCT01379209|Experimental|RGI-2001 250μg/kg + Standard of Care GVHD Prophylaxis|"RGI-2001 will be add to standard treatment with a calcineurin inhibitor, in combination with either methotrexate, mycophenolate mofetil, or sirolimus all at doses as per the institutional protocols~Cohort 7 in part 1 of this study will include 2-6 patients (optional)"
89502645|NCT01379209|Experimental|RGI-2001 + Standard of Care GVHD Prophylaxis|"RGI-2001 will be add to standard treatment with a calcineurin inhibitor, in combination with either methotrexate, mycophenolate mofetil, or sirolimus all at doses as per the institutional protocols~In part 2 of this study the best dose or doses determined from part 1 will be administered in up to 30 persons."
89502646|NCT01204099|Active Comparator|Docetaxel (NSCLC)|IV docetaxel administered once every three weeks as per standard of care. Treatment continues until disease progression, unacceptable toxicity or withdrawal of consent.
89502647|NCT01204099|Experimental|PX-866 (NSCLC)|Oral PX-866 administered daily at the RD in combination with IV docetaxel administered once every three weeks on a 21 day cycle. Treatment continues until disease progression, unacceptable toxicity or withdrawal of consent.
89502648|NCT01204099|Active Comparator|Docetaxel (SCCHN)|IV docetaxel administered once every three weeks as per standard of care. Treatment continues until disease progression, unacceptable toxicity or withdrawal of consent.
89502649|NCT01204099|Experimental|PX-866 (SCCHN)|Oral PX-866, administered daily at the RD in combination with IV docetaxel administered once every three weeks on a 21 day cycle. Treatment continues until disease progression, unacceptable toxicity or withdrawal of consent.
89502650|NCT01203943|Experimental|Cohort 1|• Cohort 1: CC-930 50 mg PO daily (two 25 mg capsules once per day PO) beginning on Day 1 in the AM.
89502651|NCT01203943|Experimental|Cohort 2|• Cohort 2: CC-930 100 mg PO daily (one 100 mg capsule once per day PO) beginning on Day 1 in the AM
89502652|NCT01203943|Experimental|Cohort 3|• Cohort 3: CC-930 100 mg twice daily approximately 12 hours apart (one 100 mg capsule twice per day PO) beginning on Day 1.
89502653|NCT01203943|Placebo Comparator|Placebo|Placebo
89502654|NCT01203631|Experimental|NNC 0142-0000-0002|
89502655|NCT01203631|Placebo Comparator|Placebo|
89502656|NCT01201837|Placebo Comparator|Placebo|
89502657|NCT01201837|Experimental|Low Dose|CER-001 Low Dose
89502658|NCT01201837|Experimental|Mid Dose|CER-001 Mid Dose
89502659|NCT01201837|Experimental|High Dose|CER-001 High Dose
89502660|NCT05473676|Experimental|Robotic Training Period|Participants will engage in robot assisted gait training on at least 5 days/week for at least 30 minutes each day, for a total period of 12 weeks.
89502661|NCT01192867|Experimental|RO4917838 20 milligrams (mg)|Participants, on stable antipsychotics, will receive RO4917838 orally at 20 mg once daily (QD) up to 56 weeks followed by an optional treatment extension for up to 3 years.
89502662|NCT01192867|Experimental|RO4917838 10 mg|Participants, on stable antipsychotics, will receive RO4917838 orally at 10 mg QD up to 56 weeks followed by an optional treatment extension for up to 3 years.
89538662|NCT04975971||Dextenza recepient|A Retrospective Review DEXTENZA Intracanalicular Dexamethasone (0.4 mg) Insert Prior to or Following Corneal Transplant or Cataract Surgery
89538663|NCT03256955|Other|Tof Watch SX and Tof Cuff|Patients undergoing surgery with intubation and receiving a single intubation dose of rocuronium (0.6 mg/kg) under propofol anesthesia will have monitoring of neuromuscular block with two monitors simultaneously.
89538664|NCT04968483||Study group|Patients with spine deformity undergoing surgical treatment
89538665|NCT02456441|Experimental|Intervention group|Will be obtained the evolution parasympathetic and sympathetic system 10 minutes after TENS application, through Heart Hate Variability analysis.
89538666|NCT02456441|Placebo Comparator|Placebo group|Will be obtained the evolution parasympathetic and sympathetic system 10 minutes after placebo current application, through Heart Hate Variability analysis. p. The placebo group will receive transcutaneous electric stimulation, for 30 seconds and then will gradually decrease by 15 seconds to not pass any current. This approach will aim to masking of the subject.
89538667|NCT03062163|Experimental|Resveratrol lipoic Acid|lipoic and resveratrol was loaded on the patch
89538668|NCT03062163|Experimental|Placebo|normal saline was loaded on transdermal patch
89538669|NCT02456597|Active Comparator|lidocainhydrochlorid|Lidocaine 20mg/ml, 15 ml injected perineural at the sciatic nerve
89538670|NCT02456597|Placebo Comparator|Isotonic saline|0.9% Saline Solution, 15ml injected perineural at the contralateral sciatic nerve
89538671|NCT03256877||All participants|Patients with haematuria.
89538672|NCT03061773|Experimental|Exercise group|Exercise group: physical training lasting 12 weeks, after detraining and in the end the control group receives physical training
89538673|NCT03061773|Active Comparator|Group did not exercise|Group did not exercise: conventional hospital treatment
89023642|NCT05039645|Other|Open Arm Study - All participants|"Study is open arm with no blinding or randomisation. Patients will receive standard care including frequent clinical visits, education, and preventative foot care/podiatry as required. Patients will also be given a DFS thermovisual scanner device. Patients will be instructed to use the DFS on a daily basis, at home, to record thermovisual data about the soles of their feet.~Data collected from the DFS device will be transmitted to a remote, cloud-based server for daily review using the SRI software. If a temperature difference of >2.2°C between similar points on the left and right feet is identified for 2 consecutive scans, or visible signs of skin damage are observed, the site will be notified and sent a report containing the findings. Once notified the site will contact the patient by telephone and determine the best course of action based on standard practices (e.g. offloading, attending an appointment)."
89023643|NCT05038800|Experimental|MK-0482|Participants will receive MK-0482 monotherapy administered in escalating doses as an intravenous (IV) infusion on Day 1 of each 21-day cycle for up to 35 cycles.
89023644|NCT05036343|Experimental|InPen® and CGM, then standard of care and CGM|Adolescents and young adults (13-21 years) identified with having type 1 diabetes and currently receiving insulin injections with a continuous glucose monitor (CGM) will use the InPen® and CGM for the first 90 days then switch to standard of care with traditional insulin injections and CGM for 90 days.
89023645|NCT05036343|Experimental|Standard of care and CGM, then InPen® and CGM|Adolescents and young adults (13-21 years) identified with having type 1 diabetes and currently receiving insulin injections with a continuous glucose monitor (CGM) will receive standard of care with traditional insulin injections and CGM for first 90 days then switch to the InPen® and CGM for 90 days.
89538674|NCT03261635|Active Comparator|Ranibizumab Monotherapy|All patients received monthly 0.5 mg ranibizumab intravitreal injections for 3 months, after which monthly injections were administered pro re nata
89538675|NCT03261635|Experimental|Ranibizumab + Indomethacin|All patients received monthly 0.5 mg ranibizumab intravitreal injections for 3 months, after which monthly injections were administered pro re nata. Moreover, patients also self- administered one drop of indomethacin three times a day for 12 months. All patients were followed up for 12 months.
89538676|NCT03059979|Active Comparator|Methylprednisolone 1000 mg|the methylprednisolone is dissolved in 100 cc of sodium chloride (NaCl 0.9%) by intravenous infusion in 30 minutes on three consecutive days
89538677|NCT03059979|Placebo Comparator|sodium chloride|The placebo intervention with physiologic salt solution is identical in appearance
89538678|NCT03256721|Experimental|Apatinib+docetaxel/pemetrexed|Apatinib 500mg QD PO d1-21+docetaxel(75mg/m2 IV d1)/pemetrexed(500 mg/m2 IV d1),q21d
89538679|NCT03256721|Active Comparator|docetaxel/pemetrexed|docetaxel(75mg/m2 IV d1)/pemetrexed(500 mg/m2 IV d1),q21d
89538680|NCT03061149|Experimental|Group with low-level laser treatment|"The group received low-level laser therapy (LLLT). The application of a GaAlAs infrared laser with a pencil probe (BTL 5000 Combi, United Kingdom; at 830 nm, 9J/cm2 per point, power output of 100 mW, beam diameter of 5 mm) was performed at five points along the median nerve on the palmar side of the wrist 7. The time of exposure was 10 minutes (2 minutes per point). Both the patient and the therapist wore protective glasses during every session.A total of 10 therapeutic sessions were performed during a period of two weeks (five session times per week).~Additionally, nerve and gliding exercises were administered."
89538681|NCT03061149|Active Comparator|Group with ultrasound treament|The group underwent ultrasound treatment. Ultrasound treatment was administered at a frequency of 1 MHz, intensity of 1 W/cm2 ,pulsed mode duty cycle of 1:4 and with a handhold transducer of 5 cm2 (BTL 5000 Combi, UK). The time of application was 6 minutes over the area of the carpal tunnel. Aquasonic gel was used as a couplant. A total of 10 therapeutic sessions were performed during a period of two weeks (five session times per week). Additionally, nerve and gliding exercises were administered.
89538682|NCT03256643|Experimental|Exercise|Exercise is the intervention. People be tested before the start of, and after the end of the eight (8) week exercise program.
89538683|NCT03256643|Experimental|Delayed Exercise|Delayed Exercise Group will have exercise as intervention. People be tested before the start of, and after the end of the eight (8) weeks then after exercise intervention.
89502663|NCT01192867|Placebo Comparator|Placebo|Participants, on stable antipsychotics, will receive RO4917838 matching placebo orally QD up to 56 weeks.
89502664|NCT02543294|Experimental|Anthracycline Treatment Group|Participants undergo echocardiograms with contrast done at baseline and at months 2, 4, 6, 12, 18, and 30. Electrocardiogram performed at baseline. Symptom questionnaire completed at baseline and at months 1, 2, 4, 6, 12, 18, and 30. Telephone follow-up by study staff at months 3 and 5.
89502665|NCT02543294|Experimental|Herceptin Treatment Group|Participants undergo echocardiograms with contrast done at baseline and at months 2, 4, 6, 12, 18, and 30. Electrocardiogram performed at baseline. Symptom questionnaire completed at baseline and at months 1, 2, 4, 6, 12, 18, and 30. Telephone follow-up by study staff at months 3 and 5.
89502666|NCT02543294|Experimental|Combination of Treatments Group|Participants undergo echocardiograms with contrast done at baseline and at months 2, 4, 6, 12, 18, and 30. Electrocardiogram performed at baseline. Symptom questionnaire completed at baseline and at months 1, 2, 4, 6, 12, 18, and 30. Telephone follow-up by study staff at months 3 and 5.
89502667|NCT01188187|Experimental|Custirsen, Docetaxel, Prednisone|"Three doses of 640 mg custirsen administered intravenously (IV) as a loading dose between Days -9 to -1. Custirsen, 640 mg, given IV weekly on Days 1, 8, and 15 of each 21-day cycle. Docetaxel (75 mg/M^2 via intravenous injection) on Day 1 of every 21 days plus prednisone (5 mg tablets taken by mouth) twice each day and dexamethasone (8 mg by mouth twice a day for 3 days beginning one day before docetaxel administration).~Treatment continues for 10 cycles or until unacceptable toxicity or disease progression."
89502668|NCT01188187|Active Comparator|Docetaxel, Prednisone|"Docetaxel (75 mg/M^2 via intravenous injection) on Day 1 of every 21 days plus prednisone (5 mg tablets taken by mouth) twice each day and dexamethasone (8 mg by mouth twice a day for 3 days beginning one day before docetaxel administration).~Treatment continues for 10 cycles or until unacceptable toxicity or disease progression."
89502669|NCT02268799||DC Cardioversion|Patients undergoing DC cardioversion
89502670|NCT05478356|Experimental|orthokeratology group|
89502671|NCT05478356|Active Comparator|low-dose atropine group|
89502672|NCT01186861|Experimental|Arm A: OSI-906 plus erlotinib|OSI-906 150 mg twice daily (BID) starting on Day 1; erlotinib 150 mg once daily (QD) starting on Day 1
89502673|NCT01186861|Placebo Comparator|Arm B: placebo plus erlotinib|placebo BID starting on Day 1: erlotinib 150 mg QD starting on Day 1
89502674|NCT01180465|Experimental|LIPO-102 High|
89502675|NCT01180465|Experimental|LIPO-102, Low|
89502676|NCT01180465|Placebo Comparator|LIPO-102; Placebo|
89502677|NCT01175785|Experimental|Treatment (chemo, radiation, transplant, GVHD prophylaxis)|Patients receive fludarabine phosphate IV over 1 hour on days -8 to -6 and cyclophosphamide IV on days -7 and -6. Patients undergo TBI twice daily on days -4 to -1. Patients undergo unmanipulated single- or double-unit umbilical cord blood transplantation on day 0 and receive ex vivo-expanded cord blood progenitor cells IV over 4 hours following the last unmanipulated cord blood infusion. Patients initially receive CSP IV over 1 hour beginning on day -3. CSP may be given PO when the patient can tolerate oral medications and has a normal gastrointestinal transit time. CSP is given until day 100, and may taper on day 101 if there is no graft versus host disease. Patients also receive MMF IV every 8 hours on days 0 to 7 and then may receive MMF PO beginning day 8 to 30. MMF is continued for a minimum of 30 days or until 7 days after blood counts recover whichever is later. If there is no evidence of acute GVHD and donor CD3 engraftment is at least 50% from one donor MMF may be tapered.
89502678|NCT05478044|Experimental|Ascorbic acid|Ascorbic acid IV ampoules 20% as a final flush irrigation 3ml after cleaning and shaping.
89502679|NCT05478044|Placebo Comparator|Saline|A mixture of sodium chloride and water (0.9%) as a final flush irrigation 3 ml after cleaning and shaping.
89502680|NCT01445899|Experimental|PF-04523655 (Stratum II)|Stratum II, 6 monthly injections of PF-04523655 only
89502681|NCT01445899|Experimental|PF-04523655 and ranibizumab|Stratum II, 6 monthly injections of PF-0423655 and ranibizumab administered in combination
89502682|NCT01445899|Active Comparator|ranibizumab|Stratum II, 6 monthly IVT injections of ranibizumab only
89502683|NCT01445899|Experimental|PF-04523655 (Stratum I)|Stratum I
89502684|NCT05459090||Patients with drug resistant epilepsy|All patients with drug-resistant epilepsy who undergo neurosurgical resection of the epileptic focus.
89502685|NCT04474951|Experimental|Anemia|Metastatic patients with grade 1 anemia and on treatment with anti-CDK 4/6 or PARP Inhibitors (10 patients) or on adjuvant therapy with hormonal therapy (10 patients) will be enrolled. The control of the event will be evaluated during treatment with 40 drops TID of Stinging Nettle Fluid Extract; hemoglobin levels will be assessed every 4 weeks for a maximum period of 6 months.
89502686|NCT04474951|Experimental|Fatigue|Patients on treatment with Epirubicin and Cyclophosphamide or Carboplatin and Taxane and showing fatigue not associated to anemia or with anemia grade 1 (10 patients) or associated to anemia grade 2 (10 patients) will be enrolled. The control of the event will be evaluated during treatment with 40 drops TID of Stinging Nettle Fluid Extract; the assessment of fatigue will be performed at every chemotherapy cycle, for a maximum period of 6 months.
89502687|NCT04474951|Experimental|Nausea|20 patients on treatment with Epirubicin and Cyclophosphamide or Carboplatin and Taxane and showing nausea of any grade (without vomiting) will be enrolled. The control of the event will be evaluated during treatment with 40 drops TID of Peppermint Fluid Extract, associated to antiemetic therapy prescribed as per clinical practice; the assessment of nausea will be performed at every chemotherapy cycle, for a maximum period of 6 months.
89023646|NCT05020743||Patients with ALSP|
89502688|NCT02269033|Experimental|Patient Navigated Latinas|Patient navigators provided culturally sensitive support and guidance to Latina women who presented radiologic abnormalities categorized as BI-RADS 3, 4 and 5. Patient Navigators also collected clinical information from the patients' medical charts.
89023647|NCT05020743||Patients with Prodromal ALSP|
89023648|NCT05016011|Experimental|Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs)|Patients will receive 25 x 10^6 of human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) with standard treatment.
89023649|NCT05016011|Active Comparator|Marrow cellution (standard treatment)|Patients will undergo marrow cellution surgical procedure.
89502689|NCT02269033|Active Comparator|Non Navigated Latinas|A convenience sampling approach was used to recruit non navigated Latinas. Eligibility criteria targeted self-identified Latinas at community-based health clinics, aged > 18 years with an abnormal breast screening mammogram resulting in BI-RADS 3, 4 or 5. Controls were chosen by determining eligibility consecutively backwards from the study start date.
89502690|NCT02269111|Experimental|Diagnostic (hybrid MRI)|Patients undergo hybrid 3 Tesla MRI examination that includes standard MRI sequences, DW-MRI, CEST, and combined DCE-MRI/DSC-MRI at baseline.
89502691|NCT02269189|Experimental|BIIL 284 BS, high dose in adult patients|
89502692|NCT02269189|Experimental|BIIL 284 BS, low dose in pediatric patients|
89502693|NCT02269189|Placebo Comparator|Placebo|
89502694|NCT02266069|Other|Research cluster 1: Antwerp|The first Dutch-speaking research cluster in a stepped wedge cluster design. Family doctors are implementing the Care Pathway for Primary Palliative Care and will recruit eligible patients from October 2014.
89502695|NCT02266069|Other|Research cluster 2: Mons|The first French-speaking research cluster in a stepped wedge cluster design. Family doctors are implementing the Care Pathway for Primary Palliative Care and will recruit eligible patients from November 2014.
89502696|NCT02266069|Other|Research cluster 3: Brussels|The only bilingual Dutch/French-speaking research cluster in a stepped wedge cluster design. Family doctors are implementing the Care Pathway for Primary Palliative Care and will recruit eligible patients from December 2014.
89502697|NCT02266069|Other|Research cluster 4: Limburg|The second Dutch-speaking research cluster in a stepped wedge cluster design. Family doctors will implement the Care Pathway for Primary Palliative Care and will recruit eligible patients from April 2015.
89502698|NCT02266069|Other|Research cluster 5: ?|A second French-speaking research cluster in a stepped wedge cluster design. Family doctors will implement the Care Pathway for Primary Palliative Care and will recruit eligible patients from October 2015.
89502699|NCT03649724|Placebo Comparator|Placebo|0.25 ml of sterile normal saline administered subcutaneously / 12 weeks
89502700|NCT03649724|Experimental|Leuprolide|Eligard 22.5mg administered subcutaneously / 12 weeks
89502701|NCT04474873|No Intervention|Group 1:Conventional intravenous analgesia|Conventional intravenous analgesia applied according to surgeon's preference
89502702|NCT04474873|Active Comparator|Group 2:ESPB|A 6-13 MHz linear probe was used for ultrasound-guided ESPB (Logiq e, General Electric, USA,) performed at the T11 level. The transverse process was detected by sliding the transducer 3-4 cm laterally from the midline, and after identification of the transverse process, a 20-gauge 100mm insulated echogenic needle (Vygon locoplex, France) was used
89502703|NCT04474639||with diastolic dysfunction|patients with diastolic dysfunction of the left ventricle confirmed by the results of the echocardiography (septal e' >=8, and lateral e'>=10 and left atrium <34 ml/m2) and by results of the spectral analysis of electrocardiogram (the parameters listed below will be calculated as the median of the tact-cycle: TpTe, VAT, QTc, QT / TQ, QRS_E, T_E, TP_E, BETA, BETA_S, BAD_T, QRS_D1_ons, QRS_D1_offs, QRS_D2, QRS_Ei (i = 1,2,3,4), T_Ei (i= 1,2,3,4), HFQRS, QRSw, RA, SA, TA).
89502704|NCT04474639||without diastolic dysfunction|patients without diastolic dysfunction of the left ventricle confirmed by the results of the echocardiography (septal e'<8, and lateral e'<10 and left atrium >=34 ml/m2) and by results of the spectral analysis of electrocardiogram (the parameters listed below will be calculated as the median of the tact-cycle: TpTe, VAT, QTc, QT / TQ, QRS_E, T_E, TP_E, BETA, BETA_S, BAD_T, QRS_D1_ons, QRS_D1_offs, QRS_D2, QRS_Ei (i = 1,2,3,4), T_Ei (i= 1,2,3,4), HFQRS, QRSw, RA, SA, TA).
89502705|NCT05626933|Experimental|Buccinator myomucosal flap with Furlow palatoplasty|
89502706|NCT01358695|Placebo Comparator|Placebo Comparator|
88956695|NCT04399772|Experimental|Cognitive Functional Therapy+ pathway|Treatment is performed by a CFT trained physiotherapists and a psychologist in the Pain Center. Patients receive max 10 consultations over 3 months. The first two sessions is combined with the physiotherapist and psychologist who investigates potential maintaining factors for pain and disability in the patient's everyday life. Remaining sessions are run by the physiotherapist, and the treatment is individually tailored to the needs of the individual patient, aiming to provide the patient with skills in dealing with his / her own situation via information, reflection, change of movement and training of functions and physical level. The psychologist provide extra support for 2-3 sessions to reinforce the physiotherapist work.The ethical committee made blinding conditional on a possibility of usual care after CFT+ if: the patient does not feel ready to stop treatment AND analgesic treatment is inappropriate OR the social situation is problematic OR significant psychological distress.
88956696|NCT04399772|Active Comparator|Interdisciplinary pain management pathway|"Treatment at the Interdisciplinary University Pain Center are based on elements from cognitive-behavioral therapy, Acceptance and Commitment Therapy, and Mindfulness-Based Stress Reduction programs.~Treatment can be diverse, but based on an individual assessment it consists of a combination of (1) medical treatment with a specialist pain consultant+specialist pain nurse (ie, individual adjustment of analgesics to improve effect and reduce side effects) AND (2) one or more of the following: individual consultations with a specialist pain psychologist, physiotherapist or social worker with cognitive-behavioral therapy training as well as participation in a group program with relaxation therapy, acceptance and commitment therapy or standardized mindfulness-based stress reduction programs. On average patients in the pain center receives 9-10 sessions."
88956697|NCT04396873|Other|Only one arm|All subjects receive the same tests
88982897|NCT03117881|Experimental|rDirectCAM|The rDirectCAM arm is being implemented in response to Covid-19. The rDirectCAM arm receives the intervention content delivered remotely in real-time by therapists via videoconferencing technology.
89502707|NCT01358695|Experimental|Dose 1|Dose 1
89502708|NCT01358695|Experimental|Dose 2|Dose 2
89502709|NCT01358695|Experimental|Dose 3|Dose 3
89502710|NCT01358695|Experimental|Dose 4|Dose 4
89502711|NCT01358695|Experimental|Dose 5|Dose 5
89502712|NCT02266303|Experimental|With checklist|Doctors will initiate insulin with the aid of a checklist
89502713|NCT02266303|No Intervention|Without checklist|Doctors will initiate insulin without the use of the checklist
89502714|NCT03135223|Experimental|Intervention group|Co-created, school-based intervention to promote physical activity
89502715|NCT03135223|No Intervention|Control group|
89502716|NCT01163227|Placebo Comparator|Placebo|
89502717|NCT01163227|Experimental|AQW051 Dose 1|
89502718|NCT01163227|Experimental|AQW051 Dose 2|
89210454|NCT02539758|Experimental|ocular massage|over the closed eyelids with moderate massage strength for 15 minutes. The compression of the globe was given with finger, and press for 2 seconds, then by a 2 seconds release, with a frequency of 15 presses/minute.We observed changes of anterior chamber depth before and after ocular massage by LenstarLS900,and changes of intraocular pressure before and after ocular massage by Goldmann tonometer
89210455|NCT00643760|Placebo Comparator|Placebo|Placebo
89502719|NCT01163227|Experimental|AQW051 Dose 3|
89502720|NCT02551874|Experimental|Saxagliptin/Dapagliflozin/Metformin|Oral route. Saxagliptin/Dapa adminsitered once daily for 24 weeks at a dose of 5 mg Saxagliptin and 10 mg Dapagliflozin
89502721|NCT02551874|Active Comparator|Insulin Glargine, Lantos/Metformin|Insulin glargine administered once a day with starting dose of 0.2 Unit per kg or 10 units.
89502722|NCT01162681|Experimental|A-623 high dose weekly|
89502723|NCT01162681|Experimental|A-623 low dose weekly|
89502724|NCT01162681|Experimental|A-623 high dose every 4 weeks|
89502725|NCT01162681|Placebo Comparator|Placebo|
89502726|NCT02269345|Experimental|Battlefield Acupuncture|BFA at points cingulate gyrus, thalamus, omega 2, shen-men, point zero
89502727|NCT02269345|Placebo Comparator|Standard Treatment|Standard Treatment alone
89502728|NCT03646604|Experimental|Part 1; Cohort 1|Participants, 6 to <12 years of age, will receive low dose of upadacitinib.
89502729|NCT03646604|Experimental|Part 1; Cohort 2|Participants, 6 to <12 years of age, will receive high dose of upadacitinib.
89502730|NCT03646604|Experimental|Part 1; Cohort 3|Participants, 2 to <6 years of age, will receive low dose of upadacitinib.
89502731|NCT03646604|Experimental|Part 1; Cohort 4|Participants, 2 to <6 years of age, will receive high dose of upadacitinib.
89502732|NCT03646604|Experimental|Part 2|Eligible participants who completed Part 1 will receive weight-dependant low dose of upadacitinib.
89502733|NCT02269501|Experimental|Exercise treatment|Exercise treatment
89502734|NCT02269501|No Intervention|No treatment|No treatment
89502735|NCT05477732|Placebo Comparator|Placebo group|Subjects in placebo group will treat with placebo.
89502736|NCT05477732|Experimental|Supplement group|Subjects in supplement group will treat with Bifidobacterium longum OLP-01.
89502737|NCT01354717|Active Comparator|Brand Carac|Treatment of actinic keratosis with active ingredient
89502738|NCT01354717|Active Comparator|Generic 0.5% 5-fluorouracil cream|Treatment of actinic keratosis with active ingredient
89502739|NCT01354717|Placebo Comparator|Placebo|treatment of actinic keratosis with placebo cream
89502740|NCT01072981|Experimental|HyperAcute-Pancreas Immunotherapy + Standard of Care|*Adjuvant Standard of Care Treatment (SOC) consisting of gemcitabine with or without 5FU chemoradiation + HyperAcute Immunotherapy
89502741|NCT01072981|Active Comparator|Standard of Care alone|*Adjuvant Standard of Care Treatment (SOC) consisting of gemcitabine with or without 5FU chemoradiation Alone
89502742|NCT02706626|Experimental|Cohort A: Disease progression after next generation ALK TKI|Brigatinib until progressive disease, unacceptable toxicity, withdrawal of consent. Patients enrolled regardless the number of lines of therapy
88982898|NCT03114072|Active Comparator|Blue-blocking glasses|N=30 The Blue-blocking glasses (orange-tinted), which remove more than 99% of the blue wavelengths (wavelengths within the visible spectrum shorter than 530 nm). Luminous transmittance: 50%.
88982899|NCT03114072|Active Comparator|Light grey control glasses|N=30 Partially blue blocking light grey glasses, blocking only about 50% of blue wavelengths (wavelengths within the visible spectra shorter than 530 nm). Luminous transmittance: 55%.
88982900|NCT03108586|Active Comparator|FDI - tradional group|Diagnosis and dental treatment decision based on the criteria of the International Dental Federation (FDI).
89210456|NCT00643760|Other|Pregabalin|Pregabalin 300mg/day (positive control), maintenance treatment 14 weeks
89502743|NCT02706626|Experimental|Cohort B: Disease progression after alectinib as first-line therapy|Brigatinib until progressive disease, unacceptable toxicity, withdrawal of consent. Patients enrolled after first-line alectinib
89502744|NCT02706626|Experimental|Cohort C: Disease progression after brigatinib|Brigatinib at 240 mg daily until progressive disease, unacceptable toxicity, withdrawal of consent. Patients enrolled after treatment on brigatinib at the standard dose brigatinib
89502745|NCT03347708|Experimental|High Dose IDCT|Single intradiscal injection with High Dose IDCT (9M cells).
89502746|NCT03347708|Experimental|Low Dose IDCT|Single intradiscal injection with Low Dose IDCT (3M cells).
89502747|NCT03347708|Placebo Comparator|Saline|Single intradiscal injection with saline solution.
89502748|NCT03347708|Placebo Comparator|Sodium Hyaluronate Vehicle|Single intradiscal injection with Sodium Hyaluronate Vehicle.
88982901|NCT03108586|Experimental|CARS - conservative group|Diagnosis and dental treatment decision according to CARS (Caries Associated with Restorations or Sealants) detection criteria.
88982902|NCT03089125|Active Comparator|Usual Care|Patients will receive any usual care for their dyspnea as deemed appropriate by their clinicians.
89502749|NCT02269579|Experimental|CPX-351|Study Drug CPX-351 will be given intravenously at 100u/m2 on days 1, 3 and 5 by approximately 90 minute infusion.
89502750|NCT05455970|Experimental|Rhythmic auditory stimulation (RAS) group|Physical therapy including stretching and strengthening exercise and ambulation training with rhythmic auditory stimulation.
89502751|NCT05455970|No Intervention|Conventional group|Conventional physical therapy including stretching exercise, strengthening exercise and ambulation training.
89502752|NCT01159249|Other|Open Met add-on vildagliptin|
89502753|NCT01159249|Other|Open TZD add-on vildagliptin|
89502754|NCT01159249|Other|Open α-GI add-on vildagliptin|
89502755|NCT01159249|Other|Glinides add-on vildagliptin|
89502756|NCT01156753|Experimental|CDX-011|
89502757|NCT01156753|Active Comparator|"Investigator's Choice chemotherapy"|
89502758|NCT03324464|Experimental|CET-Working Memory (WM)|Central Executive Training: Working Memory
89502759|NCT03324464|Active Comparator|CET-Behavioral Inhibition (BI)|Central Executive Training: Inhibitory Control
89502760|NCT01345045|Experimental|ABT-639|ABT-639 twice daily for 6 weeks
89502761|NCT01345045|Active Comparator|pregabalin|pregabalin starting dose twice daily for week one then titrated up to maintenance dose twice daily for duration of the study
89502762|NCT01345045|Placebo Comparator|Placebo|Placebo twice daily for 6 weeks
89502763|NCT05477654||Parkinson's disease patients|Patients with an early diagnosis of Parkinson's disease
89502764|NCT05477654||Healthy controls|Healthy controls who are age-matched
89502765|NCT05626699|Other|RT's in ICU|We will collect ventilator pressure, flow, volume, oxygen and breathing pattern data, etc, as well as arterial blood-gas exchange and hemodynamic data of adults attached to ventilators. the RRT's will treat patients as normal without the assistance of the RT Assistant for the pre-intervention phase and will be observed collecting the same data and performing patient care with the assistance of the RT Assistant during the intervention phase. The RRTs will then be given a likert scale questionnaire on the use of the RT Assistant.
89502766|NCT01344187|Experimental|riboflavin solution and KXL System|Subjects will receive riboflavin solution followed by UVA irradiation for 4 minutes
89502767|NCT01344187|Placebo Comparator|placebo solution and KXL System|Subjects will receive placebo solution followed by UVA irradiation for 4 minutes
89502768|NCT01342315|Experimental|Active|Product 33525
89502769|NCT01342315|Experimental|Placebo|Product 33525 Placebo
89502770|NCT01338883|Experimental|CVC 100 mg + Truvada|
89502771|NCT01338883|Experimental|CVC 200 mg + Truvada|
89502772|NCT01338883|Active Comparator|Sustiva + Truvada|
89502773|NCT05625919|Experimental|Sirolimus for Injection (Albumin-bound)|Sirolimus for injection (Albumin-bound) will be administered intravenously on day 1and day 8 every 21 days (a cycle).
89502774|NCT04423952||Patients with chronic otitis media|Patients aged 7 to 15 years with chronic otitis media.
89502775|NCT04423952||Controls|Minors aged 7 to 15 years, with no and no history of chronic otitis.
89502776|NCT01338805|Experimental|BGG492|hard gelatin capsule for oral administration at 50 mg TID, 100 mg TID or 150 mg TID
89502777|NCT02266537|Experimental|Tamsulosin|
89502778|NCT02266537|Experimental|Alfuzosin|
89502779|NCT02266537|Experimental|Doxazosin|
89502780|NCT02266537|Placebo Comparator|Placebo|
89502781|NCT02269735|Experimental|Part I: MK-2640 (Panel A)|Part I: Lowest dose of MK-2640 infusion (3 approximately three-hour infusions at escalating rates) and dextrose infusion for 9 hours.
89502782|NCT02269735|Experimental|Part I: MK-2640 (Panel B)|Part I: Low dose of MK-2640 infusion (3 approximately three-hour infusions at escalating rates) and dextrose infusion for 9 hours.
89502783|NCT02269735|Experimental|Part I: MK-2640 (Panel C)|Part I: Medium-low dose of MK-2640 infusion (3 approximately three-hour infusions at escalating rates) and dextrose infusion for 9 hours.
89502784|NCT02269735|Experimental|Part I: MK-2640 (Panel D)|Part I: Medium dose of MK-2640 infusion (3 approximately three-hour infusions at escalating rates) and dextrose infusion for 9 hours.
89502785|NCT02269735|Experimental|Part I: MK-2640 (Panel E)|Part I: Medium-high dose of MK-2640 infusion (3 approximately three-hour infusions at escalating rates) and dextrose infusion for 9 hours.
89502786|NCT02269735|Experimental|Part I: MK-2640 (Panel F)|Part I: High dose of MK-2640 infusion (3 approximately three-hour infusions at escalating rates) and dextrose infusion for 9 hours.
89502787|NCT02269735|Experimental|Part I: MK-2640 (Panel G)|Part 1: Highest dose of MK-2640 infusion (3 approximately three-hour infusions at escalating rates) and dextrose infusion for 9 hours.
89502788|NCT02269735|Experimental|Part II: MK-2640 followed by RHI|Part II: MK-2640 infusion and dextrose infusion for 9 hours during Period 1 of Part II followed by a 7-day wash-out period followed by RHI infusion and dextrose infusion for 9 hours during Period 2 of Part II. Insulin aspart administered approximately 10 hours before Periods 1 and 2 of Part II.
89502789|NCT02269735|Experimental|Part II: RHI followed by MK-2640|Part II: RHI infusion and dextrose infusion for 9 hours during Period 1 of Part II followed by a 7-day wash-out period followed by MK-2640 infusion and dextrose infusion for 9 hours during Period 2 of Part II. Insulin aspart administered approximately 10 hours before Periods 1 and 2 of Part II.
89502790|NCT02269735|Experimental|Part III: MK-2640 followed by RHI|Part III: MK-2640 infusion and dextrose infusion for 7 hours during Period 1 of Part III followed by a 7-day wash-out period followed by RHI infusion and dextrose infusion for 7 hours during Period 2 of Part III. Insulin aspart administered approximately 10 hours before Periods 1 and 2 of Part III.
89502791|NCT02269735|Experimental|Part III: RHI followed by MK-2640|Part III: RHI infusion and dextrose infusion for 7 hours during Period 1 of Part III followed by a 7-day wash-out period followed by MK-2640 infusion and dextrose infusion for 7 hours during Period 2 of Part III. Insulin aspart administered approximately 10 hours before Periods 1 and 2 of Part III.
89502792|NCT05477498|Experimental|Iron substitution|Iron deficiency status will be assessed at the baseline visit (Day 0) as well as after 6 weeks of iron substitution (Week 6). The study drug will be given as FCM solution (Ferinject®, Vifor Pharma AG, Villars-sur-Glâne, Switzerland) by intravenous injection. Infusions of 10 or 20 mL (which is the amount of FCM that is equivalent to 500 or 1000 mg of iron, respectively) will be administered in ≥6 minutes diluted in ≈100 mL of sterile 0.9% sodium chloride solution (NaCl) for 10 mL, or in ≥15 minutes diluted in ≈200 mL for 20 mL. Dosing will be based on screening Hb level and weight, rather than on ferritin and TSAT results. On Day 0 (baseline visit), patients with Hb ≤14 g/dL, both <70 kg and >70 kg will receive 1000 mg FCM (20 mL), whereas patients with Hb >14g/dL will receive 500 mg FCM (10 mL).
89502793|NCT05477498|Placebo Comparator|Placebo|Patients in the control group will receive a placebo solution administered as normal saline (0.9% weight/volume (w/v) NaCl) by intravenous injection as per the instructions for active treatment.
89502794|NCT05471102|Active Comparator|Study group|Cases managed by uterine lower segment resection with ligation ((suturing)) of the anterior division of the internal iliac artery (4 cm distal to the bifurcation of the common iliac artery); in addition to the bilateral uterine artery ligation at 2 levels; bilateral ligation at a level below the lower most placental part followed by bilateral uterine artery ligation at the level of the hysterotomy incision.
89502795|NCT05471102|Placebo Comparator|Control group|Cases managed by uterine lower segment resection without ligation of the anterior division of the internal iliac artery. (i.e., only bilateral ligation at a level below the lower most placental part followed by bilateral uterine artery ligation at the level of the hysterotomy incision).
89502796|NCT05477342|Experimental|İntervention 1|Experimental 1 - Board Game Group: Board game group played only board game.
89502797|NCT05477342|Experimental|İntervention 2|Experimental 2 - Tobacco Cessation Education Group: The Tobacco Cessation Education Group received only education according to the stages of change model.
89502798|NCT05477342|Experimental|İntervention 3|Experimental 3 - Combined intervention Group:Combined intervention group received both board game and tobacco cessation education.
89502799|NCT05477342|No Intervention|Control Group|No intervention was made in the control group.
89502800|NCT05231733|Experimental|SPX-101|A total of up to 27 patients will be enrolled in this study. Subjects will receive SPX-101 by IV infusion in 60-minutes（±15 minutes）on Day 1 of the first cycle (3 weeks), and will be evaluated for DLTs in 3 weeks (DLT window). After the first cycle, subjects will continue the treatment at the assigned dose level.
89502801|NCT01038739|Experimental|A|
89502802|NCT01038739|Experimental|B|
89502803|NCT01038739|Placebo Comparator|C|
89502804|NCT02269813||ET/GOOD|Endocrine therapy only.
89502805|NCT02269813||CT/POOR|Chemoendocrine therapy according to national guidelines.
89502806|NCT05231967||Atrial fibrillation recurrence|Atrial fibrillation recurrence one month after cardioversion
89502807|NCT05231967||Sinus rhythm continue|Sinus rhythm continue one month after cardioversion
89502808|NCT05487339|Active Comparator|upper lumbar ESPB group|Group where ESPB is performed at L2 with local anesthetic mixture 20 ml
89023650|NCT05013970|Other|Knee osteoarthritis|Patients with mild to moderate osteoarthritis who suffer from persistent knee pain treated with catheter-directed geniculate artery embolization
89502809|NCT05487339|Active Comparator|lower lumbar ESPB group|Group where ESPB is performed at L4 with local anesthetic mixture 20 ml
88956698|NCT04392947|Active Comparator|combined iTBS/cTBS|"Combined theta burst stimulation (TBS) of the left (intermittent TBS, iTBS) and right (continuous TBS, cTBS) dorsolateral prefrontal cortex (dlPFC; F3 and F4 according to EEG10/20 system). Each stimulation session will comprise 2 trains of 600 stimuli each applied in bursts of three pulses at 50 Hz given every 200 ms. iTBS will be applied 20 times for 2 s every 10 s. In the same session, stimulation with cTBS will be applied continuously for 40 s. Intensity of iTBS/cTBS will be standardized at 80 % of the resting motor threshold (rMT).~Additionally, patients receive an electrical co-stimulation of the forehead. One electrode is fixed to FZ and the 2nd one is either fixed to the left forehead (iTBS) or the right forehead (cTBS), rectangular aligned to the upper edge of the FZ-electrode with a distance of 0.5 cm. Intensity of the co-stimulation is applied with 50% of TBS-intensity."
88956699|NCT04392947|Sham Comparator|sham stimulation|Setup is identical to combined active iTBS/cTBS but TBS is not actively delivered
89023651|NCT05012657|Experimental|Prosthesis|Patient is temporarily fit with Point Partial partial finger prosthetic system
89502810|NCT02269891|Experimental|Nu Femme|Two capsules (500mg total) taken once daily in the morning after breakfast for 24 weeks
89502811|NCT02269891|Placebo Comparator|Placebo|Two capsules taken once daily in the morning after breakfast for 24 weeks
89502812|NCT02550938|Experimental|7 Aligner Cohort weartime 1|Seven Aligner cohort will change aligners at a designated interval Invisalign is the intervention.
89502813|NCT02550938|Experimental|7 Aligner Cohort weartime 2|Seven Aligner cohort will change aligners at a modified interval Invisalign is the intervention.
89502814|NCT02550938|Experimental|12 aligner cohort weartime 1|Twelve Aligner cohort will change aligners at a designated interval Invisalign is the intervention.
89502815|NCT02550938|Experimental|12 aligner cohort weartime 2|Twelve Aligner cohort will change aligners at a modified interval Invisalign is the intervention.
88956700|NCT04371913|Other|Radiation Therapy|Patients will be treated with the fractionation of 30 Gy in 5 fractions over 1-2 weeks, which is the accelerated fractionation scheme of choice for RT naïve patients at New York Presbyterian using External Beam Radiation Therapy (EBRT).
89210457|NCT00643760|Experimental|GEn 1200mg/day|gabapentin enacarbil 1200mg/day, maintenance treatment 14 weeks
89210458|NCT00643760|Experimental|GEn 2400mg/day|gabapentin enacarbil 2400mg/day, maintenance treatment 14 weeks
88982903|NCT03089125|Experimental|Dyspnea Intervention|"Dyspnea intervention will be administered over two sessions~Patients will receive:~Psychoeducation~Relaxation training for reducing physiological stress~Behavioral techniques for managing acute breathlessness"
89502816|NCT01336465|Experimental|rhuMAb Beta7|
89502817|NCT01336465|Placebo Comparator|placebo|
89502818|NCT03164733||<40|patients younger than 40 years
89023652|NCT05009511|Experimental|Traumatic Brain Injury (TBI)|Individuals with moderate-to-severe injury severity, defined as post-traumatic amnesia lasting more than 24hrs, loss of consciousness lasting more than 30 min, Glasgow Coma Scale (GCS) score less than 13.
89023653|NCT05009511|Experimental|Traumatic Brain Injury (TBI) with MDD|Individuals with moderate-to-severe injury severity, defined as post-traumatic amnesia lasting more than 24hrs, loss of consciousness lasting more than 30 min, Glasgow Coma Scale (GCS) score less than 13. In addition, individuals will have a diagnosis of major depressive disorder (MDD) as per DSM-5.
89023654|NCT05009511|Experimental|Major Depressive Disorder (MDD)|Individuals meeting criteria for major depressive disorder (MDD) including qualifiers 'in partial remission' or 'in full remission' if they are actively in treatment for the condition and still carry the depression diagnosis.
89502819|NCT03164733||40-60|patients younger than 60 years and not older than 40 years
89502820|NCT03164733||60-80|patients younger than 80 years and not older than 80 years
89502821|NCT03164733||>80|patients older than 80 years
89502822|NCT03161691||Ischemic Stroke|Percutaneous neurovascular treatment of acute ischemic stroke patients.
89502823|NCT05470088||Subjects with Autism Spectrum Disorders|
89502824|NCT05470088||Relatives of subjects with Autism Spectrum Disorders|
89502825|NCT05470088||Typically developing subjects|
89502826|NCT03161769||Percutaneous neurovascular treatment|Procedure: Percutaneous neurovascular treatment of intracranial aneurysms
89502827|NCT02769065|Placebo Comparator|SRD: Placebo Cohorts 1-6, 18 and 19|TAK-071 placebo-matching capsules, orally, once on Day 1 to non-Japanese healthy participants in the single-rising dose (SRD) period.
89023655|NCT05009511|Experimental|Healthy Individuals|Healthy individuals without psychiatric and neurological conditions.
89502828|NCT02769065|Experimental|SRD: Cohort 1: TAK-071 1 mg|TAK-071 1 mg, capsule, orally, once on Day 1 to non-Japanese healthy participants.
89023656|NCT05003804|Experimental|STMC-103H Part A1|Once daily dosing with one capsule of STMC-103H mixed with milk, formula, or a milk product for 28 days
89023657|NCT05003804|Placebo Comparator|Placebo Part A1|Once daily dosing with one capsule of placebo mixed with milk, formula, or a milk product for 28 days
89502829|NCT02769065|Experimental|SRD: Cohort 2: TAK-071 3 mg|TAK-071 3 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on the 24-hour post-dose safety, tolerability and pharmacokinetic (PK) data from cohort 1.
89502830|NCT02769065|Experimental|SRD: Cohort 3: TAK-071 9 mg|TAK-071 9 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK and 12-hour CSF PK data.
89502831|NCT02769065|Experimental|SRD: Cohort 4: TAK-071 20 mg|TAK-071 20 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on the 24-hour post-dose safety and tolerability data from previous cohort.
89502832|NCT02769065|Experimental|SRD: Cohort 5: TAK-071 40 mg|TAK-071 40 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 will be based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 4.
89502833|NCT02769065|Experimental|SRD: Cohort 6: TAK-071 80 mg|TAK-071 80 mg capsules, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 5
89502834|NCT02769065|Placebo Comparator|MRD: Placebo Cohorts 7-9|TAK-071 placebo-matching capsule, orally, once on Day 1 to non-Japanese healthy participants in the multiple-rising dose (MRD) period.
89502835|NCT02769065|Experimental|MRD: Cohort 7: TAK-071 3 mg|TAK-071 3 mg capsules, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety and tolerability from Cohort 4 and the 24-hour preliminary plasma PK and 12-hour CSF PK data from Cohort 3.
89502836|NCT02769065|Experimental|MRD: Cohort 8: TAK-071 9 mg|TAK-071 9 mg capsules, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants. Dose of TAK-071 was based on safety, tolerability and available PK data arising from the ongoing SRD part and previous MRD cohort.
89538684|NCT03256643|Experimental|Exercise and Enrichment|Exercise and Enrichment Group is the intervention. The group will be tested at the beginning and end of their exercise/enrichment program.
89206477|NCT03976297|No Intervention|Standard of Care|For participants who are not in an intervention period they will receive the standard of care commensurate with their clinical unit. This is feasible given that this is a pragmatic clinical trial where the investigators can easily control the communication between the control tower operator and palliative care team to prevent any contamination between clusters. In addition to the usual source of care control the investigators intentionally have calibrated the prediction model and the Control Tower review to match the average capacity of the palliative care service, knowing that that the team will still receive palliative care consults through the traditional pathway i.e. the attending care team consulting palliative care directly.
89502837|NCT02769065|Experimental|MRD: Cohort 9: TAK-071 15 mg|TAK-071 15 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to non-Japanese healthy participants. Dose of TAK-071 will be based on safety, tolerability and available PK data arising from the ongoing SRD part and previous MRD cohort.
89502838|NCT02769065|Placebo Comparator|MRD: TAK-071 Placebo Cohorts 10-12+Donepezil|TAK-071 placebo-matching capsule, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071.
89502839|NCT02769065|Experimental|MRD: Cohort 10: TAK-071 3 mg+Donepezil 5 mg|TAK-071 3 mg capsules, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 was same as the dose used in MRD Cohort 7.
89502840|NCT02769065|Experimental|MRD: Cohort 11: TAK-071 9 mg + Donepezil 5 mg|TAK-071 9 mg capsules, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 was same as the dose used in MRD Cohort 8.
89502841|NCT02769065|Experimental|MRD: Cohort 12: TAK-071 15 mg+Donepezil 5 mg|TAK-071 15 mg capsule, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 was same as the dose used in MRD Cohort 9.
89502842|NCT02769065|Experimental|MRD: Placebo Cohorts 13-15|TAK-071 placebo-matching capsule, orally, once on Day 1 to Japanese healthy participants.
89502843|NCT02769065|Experimental|MRD: Cohort 13: TAK-071 3 mg|TAK-071 3 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 was same as the dose used in MRD Cohort 7.
89502844|NCT02769065|Experimental|MRD: Cohort 14: TAK-071 9 mg|TAK-071 9 mg capsule or matching placebo, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 was same as the dose used in MRD Cohort 8.
89502845|NCT02769065|Experimental|MRD: Cohort 15: TAK-071 15 mg|TAK-071 15 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 was same as the dose used in MRD Cohort 9.
89502846|NCT02769065|Experimental|Cohort 16|
89502847|NCT02769065|Experimental|Bioavailability (BA)/Food Effect: Cohort 17 Sequence ABC|A: TAK-071 10 mg capsule, orally once on Day 1 in the fasted state in Period 1, followed by B: TAK-071 10 mg tablet, orally, once on Day 1 in the fasted state in Period 2, followed by C: TAK-071 10 mg tablet, orally, once on Day 1 in the fed state in Period 3 in non-Japanese healthy participants. There was a 21-day washout after each period.
89502848|NCT02769065|Experimental|BA/Food Effect: Cohort 17 Sequence BCA|B: TAK-071 10 mg tablet, orally, once on Day 1 in the fasted state in Period 1, followed by C: TAK-071 10 mg tablet, orally, once on Day 1 in the Fed state in Period 2, followed by A: TAK-071 10 mg capsule, orally once on Day 1 in the fasted state Period 3 in non-Japanese healthy participants. There was a 21-day washout after each period.
89502849|NCT02769065|Experimental|BA/Food Effect: Cohort 17 Sequence CAB|C: TAK-071 10 mg tablet, orally, once on Day 1 in the fed state in Period 1, followed by A: TAK-071 10 mg capsule, orally once on Day 1 in the fasted state in Period 2, followed by B: TAK-20 10 mg tablet, orally, once on Day 1 in the fasted state in Period 3 in non-Japanese healthy participants. There was a 21-day washout after each period.
89502850|NCT02769065|Experimental|SRD: Cohort 18: TAK-071 120 mg|TAK-071 120 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 6.
89502851|NCT02769065|Experimental|SRD: Cohort 19: TAK-071 160 mg|TAK-071 160 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 18.
89502852|NCT02769065|Placebo Comparator|SRD: TAK-071 Placebo+Donepezil Placebo|TAK-071 placebo-matching capsule, orally, once on Day 1 followed by donepezil placebo-matching tablet, orally on Day 2 to non-Japanese healthy participants.
89538685|NCT03061071|Experimental|Randomized to SPT First: APAP Second|Randomized to order of treatment (SPT first or APAP first) for a total of 6 weeks home use with each treatment.
89502853|NCT02769065|Placebo Comparator|SRD: TAK-071 Placebo+Donepezil|TAK-071 placebo-matching capsule, orally, once on Day 1 followed by donepezil 10 mg tablet, orally, on Day 2 to non-Japanese healthy participants.
89206478|NCT00827814|Experimental|Dutasteride|
89206479|NCT00825474|Experimental|survival rate|therapeutic effect of partial hepatectomy or TACE plus PEI for small hepatocellular carcinoma
89502854|NCT02769065|Experimental|SRD: Cohort 20: TAK-071 40 mg+Donepezil|TAK-071 40 mg capsule, orally, once on Day 1 followed by donepezil 10 mg, tablets, orally, once on Day 2 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 19.
89502855|NCT02769065|Experimental|SRD: Cohort 21: TAK-071 60 mg+Donepezil|TAK-071 60 mg capsule, orally, once on Day 1 followed by donepezil 10 mg, tablets, orally, once on Day 2 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety and tolerability data from Cohort 20.
89502856|NCT02769065|Experimental|SRD: Cohort 22: TAK-071 80 mg+Donepizil|TAK-071 80 mg capsule, orally, once on Day 1, followed by donepezil 10 mg, tablets, orally, once on Day 2 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety and tolerability data from Cohort 21.
89502857|NCT03164811|Experimental|GDFT group|The GDFT group will receive 400 ml of 12.5% carbohydrate drink after 6 pm until the bed time in the day before surgery and 200 ml in the morning of the surgery day. Acetate ringer solution will be start at 7:00. After induction PPV will be measure and fluid bolus 200 ml in 10 minutes will be given if PPV >13 before prone position. During the operation, the patient in GDFT group will receipt fluid therapy according to acceptable PPV
89502858|NCT03164811|Other|controlled group|The carbohydrate drink will not be given. Fluid, blood and blood product administration will be under attending anesthesiologist order.
89502859|NCT02681523|Experimental|Single arm study|3 x 3 weekly cycles at the recommended dose of eribulin as the ready to use solution, 1.23 mg/m2, administered intravenously over 2-5 minutes on days 1 and 8 of every 21 day cycle. This will then be followed by 9 weeks of AI treatment, to be followed again by 3 x 3 weekly cycles of eribulin and 9 weeks AI treatment. Patients will remain on treatment for up to 9 months, or until disease progression or unacceptable toxicities, whichever is sooner.
89502860|NCT02540954|Experimental|Aflibercept extended dosing|Aflibercept was administered 2mg per injection intravitreal (IVT) in the study eye in Aflibercept extended dosing. Flexible dosing interval is ≥ 8 weeks (no upper limit) based on visual and anatomic outcomes as judged by the investigator. When/if visual and anatomical outcomes indicated that the disease had re-activated, the treatment interval reverted to the last treatment interval in which the disease was inactive (ie, no signs of exudation were observed).
89502861|NCT02540954|Active Comparator|Aflibercept 2Q8 (2 mg aflibercept administered every 8 weeks)|Aflibercept was administered 2mg per injection IVT in the study eye in Aflibercept 2Q8. Fixed dosing interval is 8 weeks (±3 days), modification of the treatment interval was not allowed.
89502862|NCT05265975|Experimental|ATG-010|Enrolled patients will be treated with dosage groups. Dosage group 1:40mg/time, dosage group 2:60mg/time, dosage group 3:80mg/time; The treatment period was 28 days. The drug was administered on day 1,8 and 15 of each cycle
89502863|NCT02152241||Patients with IBD|Adult patients with IBD diagnosed during childhood
89502864|NCT03542201|Experimental|PLS|Plain abstract about the Cochrane systematic review.
89502865|NCT03542201|Experimental|Blogshot|Blogshot presentation of the results of Cochrane systematic review.
89502866|NCT03164577|Active Comparator|DARTNA|DARTNA is a culturally-adaptable therapeutic drum behavior therapy that incorporates drumming, talking circles, and uses the 12 Steps of Alcoholics Anonymous (AA)/Narcotics Anonymous (NA) program within the conceptual framework of the Northern Plains Medicine Wheel. The Northern Plains Medicine Wheel is widely utilized as a conceptual framework and integrative approach to health and wellness for AI/ANs. This intervention consists of 12 sessions provided 2 times weekly over 6 weeks.
89502867|NCT03164577|Placebo Comparator|Usual care plus|Participants randomized to usual care plus will participate in activities for approximately the same amount of time as DARTNA participants. They will engage in health and wellness education session once weekly for 6 weeks. They will also receive care for their alcohol and other drug use, This typically consists individual counseling, group therapy, and AI/AN traditional activities in their community.
89502868|NCT02151227||magnesium intake categories|comparators: categories of magnesium intake except lowest category of magnesium intake , controls: lowest category of magnesium intake
89502869|NCT04411316|Experimental|Pharmacomechanical thrombolysis plus anticoagulation|"This group of patients will receive Pharmacomechanical catheter-directed thrombolysis (PCDT) plus Anticoagulation.~PCDT will be AngioJet along with alteplase. Anticoagulation will be heparin only"
89502870|NCT04411316|Active Comparator|Anticoagulation|This group of patients will receive standard anticoagulation only. Anticoagulation will be Heparin only
89502871|NCT05245773|Experimental|30-day automated hovering + usual care|The intervention arm will get the usual post-discharge call from their practice, typically within 2 business days of discharge. In addition, they will be enrolled in the 30-day automated texting program, wherein they will receive check-in messages on a tapering schedule; they will be free to opt out at any time. They can also message into the platform at any time. Any needs identified through the platform will be escalated to their primary care practice, and they will receive a follow-up phone call from practice staff to address their needs.
89502872|NCT05245773|No Intervention|Usual care|The control arm will continue to receive the usual post-discharge call from their practice, typically within 2 business days of discharge.
89502873|NCT02151305|Experimental|Total intravenous anesthesia group|This group received propofol and remifentanil for the maintenance of general anesthesia.
89502874|NCT02151305|Experimental|Inhalation anesthesia group|This group received sevoflurane for the maintenance of general anesthesia.
89502875|NCT03164499|Active Comparator|Control group|Individual counselling on lifestyles.
89206480|NCT03976765||Hospital discharge at day 7|
89206481|NCT01068847|Experimental|1|Receives 2-4 of the drugs listed under Intervention
89206482|NCT00827892|Experimental|1|
89206483|NCT00827892|Placebo Comparator|2|
89206484|NCT00831948||Mitochondrial disease|Patients already diagnosed for mitochondrial pathology without mtDNA mutations yet detected by current diagnostic techniques
89502876|NCT03164499|Experimental|Intervention group|Individual counselling on lifestyles and additional group counselling on lifestyles.
88956703|NCT04365920|No Intervention|Re-Entry as Usual|The type and level of services provided to individuals at re-entry will vary across jails and will be carefully documented. For the most part, individuals released to the community will receive a referral to an opioid treatment provider (OTP) for treatment with MOUD, and a subset may potentially be mandated to participate in community based treatment and/or recovery programs such as recovery coaching, and/or sentenced to varying levels of probation.
88956704|NCT04365920|Experimental|Recovery Management Checkups (RMC)|In the RMC condition, participants will have access to services provided as a part of re-entry as usual. In addition, checkups will be provided on a fixed schedule that includes face-to-face monthly checkups for the initial 3 months, and quarterly for the rest of the two years. Participants will have access to referrals and services provided by the jail and linkage to an OTP as part of their usual re-entry procedures. Individuals will meet with a Linkage Manager (LM) upon study enrollment and during each quarterly checkup, during which they will complete a Brief Treatment Needs Assessment, receive motivational interviewing, linkage assistance, or a check-in on continuing care and recovery support. The priority is to engage the individual into treatment with MOUD as soon as possible at the time of release, however, if individuals express a preference for another form of SUD treatment, the LM will work with that individual to link, engage, and retain them in that form of treatment.
89502877|NCT05477030|Active Comparator|Study Group A (Intervention)|Group treated with automated insulin delivery (advanced hybrid closed-loop)
89502878|NCT05477030|Active Comparator|Study Group B (Control)|Group treated with predictive low glucose suspend (sensor augmented pump - PLGS)
89502879|NCT02152319|Experimental|KHV reporting|Clinicians will view the motor symptom severity reports and videoconference to titrate medications.
89502880|NCT02152319|Active Comparator|Standard care|Subjects in this group will still use KHV at home to minimize any placebo effects that could be attributed to using the system; however, clinicians will view the motor symptom severity reports and videoconference to titrate medications solely for the experimental subjects.
89502881|NCT03164421|Experimental|N-Acetylcysteine|N-Acetylcysteine used by clomiphene resistant pcos women
89502882|NCT03164421|Active Comparator|L-carnitine|L-carnitine used by clomiphene resistant pcos women
89502883|NCT02159339||gene-methylation|"gene-low-level of methylation: patients with early stage gastric carcinoma containing low-level of methylation change of E-cadherin,GFRA1,p16,SRF and ZNF382 CpG island.~gene-middle-level of methylation: patients with early stage gastric carcinoma containing middle-level of methylation change of E-cadherin,GFRA1,p16,SRF and ZNF382 CpG island.~gene-high-level of methylation: patients with early stage gastric carcinoma containing high-level of methylation change of E-cadherin,GFRA1,p16,SRF and ZNF382 CpG island.~gene-without of methylation: patients with early stage gastric carcinoma NOT containing methylated E-cadherin,GFRA1,p16,SRF or ZNF382 CpG island."
89502884|NCT04472702|Experimental|Subjects with knee OA using ultrasound for cRFA intervention|Knee osteoarthritis patients (Kellegren-Lawrence Scale 2-4) that have been refractory to conservative treatments and report at least 80% pain relief with diagnostic geniculate nerve blocks will be enrolled and randomized to ultrasound (N=45) cRFA treatment arm.
89502885|NCT04472702|Experimental|Subjects with knee OA using fluoroscopy for cRFA intervention|Knee osteoarthritis patients (Kellegren-Lawrence Scale 2-4) that have been refractory to conservative treatments and report at least 80% pain relief with diagnostic geniculate nerve blocks will be enrolled and randomized to fluoroscopic (N=45) cRFA treatment arm.
89502886|NCT03164343|Experimental|Pain Neuroscience Education for children|All participants within this study will receive Pain Neuroscience Education
89502887|NCT03542123|Experimental|NeuroTronik CANS Therapy® System|
89502888|NCT03164187||Diabeton MR 60|
89502889|NCT02152397|Active Comparator|Therapist-led brief intervention (TBI)|"Participants will receive therapist-led, computer-assisted intervention sessions with a therapist. The interventions are designed to address extramedical prescription opioid use and overdose risk behaviors. This includes a review of the participants' strengths, values, and goals; feedback regarding their opioid use and overdose risk behaviors; developing a discrepancy between their opioid and other drug use and ability to meet goals and values; and the formulation of a change plan for each participant."
89502890|NCT02152397|No Intervention|Enhanced usual care|Participants will receive therapist-led, computer-assisted control sessions with a therapist.
89502891|NCT05228613|Experimental|Vaccine Candidate Formula A|2 doses of vaccine candidate formula A administered with 28 days interval (0.5 mL per dose)
89502892|NCT05228613|Experimental|Vaccine Candidate Formula B|2 doses of vaccine candidate formula B administered with 28 days interval (0.5 mL per dose)
89502893|NCT05228613|Experimental|Vaccine Candidate Formula C|2 doses of vaccine candidate formula C administered with 28 days interval (0.5 mL per dose)
89502894|NCT05228613|Experimental|Vaccine Candidate Formula D|2 doses of vaccine candidate formula D administered with 28 days interval (0.5 mL per dose)
89502895|NCT05228613|Active Comparator|Active Control|2 doses of active control administered with 28 days interval (0.5 mL per dose)
89502896|NCT02156453||Total knee arthroplasty|Patients undergoing uncomplicated total knee replacement
89502897|NCT05476874|Active Comparator|Open Mini-laparotomy Group (OLG)|Distal shunt placement through open mini-laparotomy.
89502898|NCT05476874|Experimental|Abdominal Puncture Group （APG）|Distal shunt placement through abdominal puncture.
89502899|NCT02159417|Experimental|Therapeutic Education|Intensive training individual or collective teaching
89502900|NCT05221827||MIBC|Patients with clinically and pathologically confirmed diagnosis of MIBC stage II-IIIA, planned to undergo RC.
89502901|NCT03542981|Active Comparator|Interferential Current Treatment|Interferential Current group received interferential current treatment 30 minutes, 2 times a day for 5 days after the surgery.
89502902|NCT03542981|Sham Comparator|Sham Interferential Current Treatment|In the sham interferential Current treatment, no electrical stimulation was applied to the probes with the same pads for the same time.
89502903|NCT04440111|Active Comparator|Control group|One year basic life support training
89502904|NCT04440111|Sham Comparator|Experimental group|Two years basic life support training
89502905|NCT02658812|Experimental|Treatment (talimogene laherparepvec)|Patients receive talimogene laherparepvec IT on day 1. Cycles repeat every 3 weeks in cycle 1 and every 2 weeks thereafter in the absence of disease progression or unacceptable toxicity.
89502906|NCT02156531|Placebo Comparator|Attention Control Condition|3.c.14.5. Arm 1: Attention Control Condition. The minimally effective attention-control group procedure is identical to the active CBM procedure except that during the presentation of the trials where a disgusted face is present, the probe will appear with equal frequency (50-50) in the position of disgusted or neutral face. Thus, the balanced (random) presentation of the probe in this condition is not designed to explicitly train attention away from threat and toward neutral stimuli, in contrast to the active versions of CBM in Arms 2 and 3.
89502907|NCT02156531|Experimental|Arm 2: Self-administered CBM only|3.c.14.6. Arm 2: Self-Administered CBM Only. Youth assigned to this arm will receive the self-administered active CBM intervention. As described above in detail, in the 80% of CBM trials where a neutral and disgust face are both presented, the probe always replaces the neutral face. Thus, participants are trained to disengage their attention from threat. These youth do not receive Adherence Promotion telephone calls.
89502908|NCT02156531|Experimental|Arm 3: Self-administered CBM + Adherence Promotion|3.c.14.7. Arm 3: Self-Administered CBM + Adherence Promotion. Youth assigned to this arm will receive both the self-administered active CBM intervention and the telephone coach calls to deliver the Adherence Promotion (AP) procedures. AP procedures are intended to compensate for the important nonspecific 'scaffolding' provided by research staff when CBM has been traditionally delivered in laboratories. This includes technical assistance with use of the program, support/encouragement, motivational enhancement, and brainstorming solutions to barriers to regular sessions. The addition of AP to the 3rd arm of this trial attempts to recreate much of this nonspecific, yet likely important, support of in-person interventions, which we hypothesize will lead to greater participant adherence to the program and therefore better clinical outcomes.
89502909|NCT03164031|Experimental|Close-fitting orthotic shorts condition|Orthotic shorts will be made to measure for each participant, designed to provide some compression to the hips, pelvis and thighs and to provide support. Shorts will be worn during objective testing of walking ability and then taken home. Wear will be increased gradually over 5 days but then worn every day during normal daily activity.
89502910|NCT03164031|Active Comparator|Looser fitting shorts condition|Looser shorts will be made to measure for each participant, designed to look similar to the orthotic shorts but provide minimal support or compression. Shorts will be worn during objective testing of walking ability and then taken home. Wear will be increased gradually over 5 days but then worn every day during normal daily activity.
89502911|NCT02628704|Experimental|Selinexor, carfilzomib and dexamethasone|60 mg of selinexor and and 20 mg of dexamethasone will be taken twice weekly. On days coinciding with carfilzomib administration, selinexor will be given between 30 minutes and 4 hours after the end of the carfilzomib infusion.
89502912|NCT02628704|Placebo Comparator|Placebo, carfilzomib and dexamethasone|Placebo (for 60 mg of selinexor) and and 20 mg of dexamethasone will be taken twice weekly. On days coinciding with carfilzomib administration, Placebo (for 60 mg of selinexor) will be given between 30 minutes and 4 hours after the end of the carfilzomib infusion.
89502913|NCT02152475|Experimental|PDT with blue light and curcumin|PDT treatment was performed with light and curcumin.The irradiation parameters were: blue-light emitting diode (LED) illumination (455±30 nm), 400 mW of average optical power, 5 min of application, illumination area of 0.666 cm2, 600 mW/cm2 of intensity and 120 J/cm2 of fluence. The curcumin concentration of 30 mg/L was used.
89502914|NCT02152475|Active Comparator|Curcumin|The curcumin concentration of 30 mg/L was used.
89502915|NCT02152475|Active Comparator|Blue light|The irradiation parameters were: blue-light emitting diode (LED) illumination (455±30 nm), 400 mW of average optical power, 5 min of application, illumination area of 0.666 cm2, 600 mW/cm2 of intensity and 120 J/cm2 of fluence.
89502916|NCT02152553|Active Comparator|Hydrocortisone|Near-physiologic doses of Hydrocortisone are being given to subjects. The first day between 09.00 and 12.00 0,024 mg Hydrocortisone/kg per hour. The first day between 12.00 and 20.00 0,012 mg Hydrocortisone/kg per hour. The first day between 20.00 and 24.00 0,008 mg Hydrocortisone/kg per hour. The second day between 00.00 and 11.00 0,030 mg Hydrocortisone/kg per hour. Hydrocortisone infusion: 0,4 ml Solu Cortef 100 mg (50 mg/ml) added in 999,6 ml sodium chloride 0,9% solution (1 mg Solu Cortef/ 50 ml total solution volume).
89502917|NCT02152553|Placebo Comparator|Placebo|The same volume of sodium chloride 0,9% as in the other arm where Hydrocortisone is given in saline 0,9% solution. The given volume of sodium chloride will variate chronically as in Hydrocortisone arm.
88982904|NCT03037931|Active Comparator|Ferric Carboxymaltose|Ferric Carboxymaltose 2 doses intravenously of 15mg/kg to a maximum individual dose of 750mg 7 days apart and a maximum combined dose of 1500mg - repeated every 6 months as indicated by the results of iron indices.
88982905|NCT03037931|Placebo Comparator|Placebo|Normal saline 15ml - 2 doses 7 days apart repeated every 6 months.
88982906|NCT03024827|Experimental|Medical Cannabis Oil|CanniMed® 1:20
88982907|NCT03002103|Experimental|ET+P+G|
88956705|NCT04365920|Experimental|RMC-Adaptive|In the RMC-Adaptive condition, checkups will be provided based on the participant's current need for treatment and will be adapted in three ways. First, the interval between RMC-A check-ups will vary (in 1-month increments) depending upon the individual's assessed need for treatment at the prior check-up. Second, in cases where participants have 3 consecutive checkups in which they need treatment, the LM and treatment provider will discuss how to better meet the participant's needs, e.g., a different treatment provider, different type of MOUD or other types of treatment, and/or additional services. Third, if RMC-A participants are re-incarcerated at the time of their checkup, the LM will meet with the individual while incarcerated to discuss a recovery plan, which may include initiation of treatment with MOUD while incarcerated and re-linkage to an OTP upon release.
88956706|NCT04351555|Placebo Comparator|Arm 1: Placebo with platinum-based chemotherapy|Placebo plus investigator's choice of platinum-based standard of care chemotherapy (pemetrexed/carboplatin or pemetrexed/cisplatin)
88956707|NCT04351555|Experimental|Arm 2: Osimertinib with platinum-based chemotherapy|Osimertinib 80 mg QD (Dose may be reduced to 40 mg QD at the discretion of the investigator) plus investigator's choice of platinum-based standard of care chemotherapy (pemetrexed/carboplatin or pemetrexed/cisplatin)
89502918|NCT04411394||Healthy Participants|There is no intervention
89502919|NCT04411394||Anxiety Participants|There is no intervention
88956708|NCT04351555|Experimental|Arm 3: Osimertinib monotherapy|Osimertinib 80 mg QD (Dose may be reduced to 40 mg QD at the discretion of the investigator)
88956710|NCT04342429|Experimental|Prospective Study of Intensity-Modulated Proton Therapy (IMPT)|This is the first prospective study to investigate the safety and efficacy of IMPT for the treatment of SCLC. We will utilize adaptive planning throughout the radiation course. In addition, we will study the dosimetric parameters of IMPT and their correlation with treatment-related toxicities, particularly cardiac events.
89206485|NCT01070875|Active Comparator|UFH 5000 U three times per day|Study subjects will be randomized to receive unfractionated heparin 5000 U subcutaneous three times a day.
89502920|NCT03161457|Experimental|JHL1101|Each subject will receive 2 intravenous infusions of 1000 mg JHL1101: the first infusion on Baseline and the second on Day 15.
89502921|NCT03161457|Active Comparator|MabThera|Each subject will receive 2 intravenous infusions of 1000 mg MabThera: the first infusion on Baseline and the second on Day 15 (Visit 5).
89502922|NCT04468256||Cardiomyopathy|Heart Hive registered participants with self-reported cardiomyopathy
89502923|NCT04468256||Participants without Heart Disease|Heart Hive registered participants without cardiomyopathy or other heart disease.
89502924|NCT03163953|Experimental|TPAG with long break|PA coaching based on TPAG and long break or break 15 minutes for every 2 hours (TPAG with LB)
89502925|NCT03163953|Experimental|TPAG with short break|PA coaching based on TPAG and short break or break 1-2 minutes for every 1 hours (TPAG with SB)
89502926|NCT03163953|Other|Control|No intervention
89502927|NCT03161301||Group 1|IL-37 genotype 1.1
89502928|NCT03161301||Group 2|IL-37 genotype 1.2
89502929|NCT03161301||Group 3|IL-37 genotype 2.2
89502930|NCT02152709|Experimental|10µg/0.5ml hepatitis B vaccine|3 dose of 10µg/0.5ml hepatitis B vaccine made by recombinant deoxyribonudeic acid techniques in saccharomyces cereviside.Produced by Beijing Tiantan Biological Products Co., Ltd. Lot number: YHB2008063S1.
89502931|NCT02152709|Active Comparator|5µg/0.5ml hepatitis B vaccine|3 dose of 5µg/0.5ml hepatitis B vaccine made by recombinant deoxyribonudeic acid techniques in saccharomyces cereviside.Produced by Beijing Tiantan Biological Products Co., Ltd. Lot number:20080603.
89502932|NCT03164109|Experimental|GC4419 IV|
89502933|NCT03164109|Placebo Comparator|Placebo|
89502934|NCT03164109|Active Comparator|Oral moxifloxacin|
89502935|NCT02152787|Experimental|1) propofol 1.0mg/kg group|According to randomly allocated group, propofol 1.0mg/kg, propofol 0.5mg/kg or normal saline will be intravenously administered at the end of surgery
89502936|NCT02152787|Experimental|2) propofol 0.5mg/kg group|According to randomly allocated group, propofol 1.0mg/kg, propofol 0.5mg/kg or normal saline will be intravenously administered at the end of surgery
89502937|NCT02152787|Placebo Comparator|3) normal saline group|According to randomly allocated group, propofol 1.0mg/kg, propofol 0.5mg/kg or normal saline will be intravenously administered at the end of surgery
89502938|NCT00154375|Experimental|Imatinib mesylate + hydroxyurea (HU)|Imatinib was supplied as 100 mg and 400 mg tablets. Patients in the combination arm were instructed to take a daily oral imatinib dose of 600 mg (600 mg at lunch time) and a daily oral hydroxyurea (HU) dose of 1000 mg (500 mg twice daily; in the morning and at bed time). Every 6 weeks after randomization based on assessment of therapeutic response, either patients continued with above mentioned dosing regimen or switched to receive a daily dose of 800 mg imatinib with 1000 mg HU. Patients were instructed to split the intake, taking 400 mg imatinib with 500 mg HU in the morning, then the same in the evening.
89502939|NCT00154375|Active Comparator|Hydroxyurea alone|1500 mg/day of HU given as 500 mg 3 times daily. Every 6 weeks after randomization and based on assessment of therapeutic response, the patients were either switched to combination arm or continued in monotherapy arm of hydroxyurea.
89502940|NCT03163719||Patients with generalized convulsive seizure|All adult patients (aged at least 18 years old) presenting to the CHU Clermont-Ferrand adult emergencies with a strong suspicion of generalized tonic-clonic seizure beginning less than 4 hours will be included. Each eligible patient will be proposed by a doctor, to participate to the study. The emergency doctor will verify the patient's inclusion and non-inclusion criteria.
89502941|NCT03160989|Experimental|Postmenopausal and hypertensive women|The intervention will consist of a single session and after ten weeks of combined physical exercises (aerobic and resisted). All volunteers will participate in the same procedure.
89502942|NCT02765399|Experimental|Liraglutide|"Liraglutide subcutaneous injection once daily with following dose escalation:~liraglutide 0.6 mg once daily for one week; liraglutide 1.2 mg once daily for one week and thereafter liraglutide 1.8 mg once daily for 3.5 months."
89502943|NCT02765399|Placebo Comparator|Placebo|"Placebo subcutaneous injection once daily with following dose escalation:~placebo 0.1 ml once daily for one week; placebo 0.2 ml once daily for one week and thereafter placebo 0.3 ml once daily for 3.5 months."
88956712|NCT04318587|Experimental|Allosure Arm|All subjects will be in arm one and will have AlloSure blood draws at multiple time points.
88982908|NCT03002103|Active Comparator|Control|
89206486|NCT01070875|Active Comparator|UFH 5000 U two times per day|Study subjects will be randomized to receive unfractionated heparin 5000 U subcutaneous two times a day.
89502944|NCT02266693|Experimental|ICBT Group|The iCBT program consists of weekly online lessons, weekly homework assignments, regular automatic email reminders about lessons and homework, weekly contact via phone or email with a CBT therapist, and access to a large online library of written resources about depression and anxiety and application of CBT skills. The CBT therapist contacts all participants once a week to review lessons, assist patients with treatment difficulties, reinforce progress and encourage continued engagement with the program. Therapist-patient contact is limited to 10 minutes per patient per week.
89502945|NCT02266693|No Intervention|Waitlist Group|Upon completion of the 8-week study wait-list period (i.e. their study participation), the opportunity to participate in iCBT, outside the study framework will be provided.
89502946|NCT03163641|Experimental|Treatment 1|Ocular Bandage Gel
89502947|NCT03163641|Experimental|Treatment 2|Ocular Bandage Gel
89502948|NCT03163641|Active Comparator|Control Group|Artificial tears with Acuvue Oasys
89502949|NCT01037179|Experimental|AL-4943A|Olopatadine Hydrochloride Ophthalmic Solution, 0.2%, 2 drops instilled in each eye twice daily for 10 weeks
89502950|NCT05476640||National multicenter screening|NGS was performed based on conventional NBS. The relationship between NGS detected gene variation and disease occurrence was studied through follow-up.
89502951|NCT02269969|Experimental|Once daily aminoglycoside|Once daily dosing of Tobramycin
89502952|NCT02520986|Experimental|Carbon dioxide Laser ablation|Excision of genital warts using a carbon dioxide laser, ie CO2 Laser
89502953|NCT02520986|Active Comparator|Electrocoagulation|Excision of genital warts using a superficial electrical coagulation mode, ie spray coagulation
89502954|NCT03163797||Oropharyngeal cancer|A total of 160 patients with histologically proven oropharyngeal SCC subjected to chemoradiation will be enrolled. Exclusion criteria include previous head or neck malignant tumor, a second malignant tumor, distant metastasis, contraindications to MRI (renal insufficiency, cochlear implant, cardiac pacemaker placement or intracranial aneurysmal ferromagnetic clips), and serum glucose level >200 mg/dl. Before pretreatment, each enrolled patients will undergo PET/MRI and detail clinical examination, including human papillomavirus test.
89502955|NCT02266771|Active Comparator|NPWT with Instillation|Negative Pressure Wound Therapy with Instillation.
89502956|NCT02266771|Placebo Comparator|NPWT without Instillation|Negative Pressure Wound Therapy without Instillation
89502957|NCT01033357|Active Comparator|Graft, Vascular Wrap|Lifespan® ePTFE Vascular Graft and Vascular Wrap Paclitaxel-Eluting Mesh (0.9 µg/mm2 paclitaxel)
89502958|NCT01033357|Placebo Comparator|Graft|Lifespan® ePTFE Vascular Graft Only
89502959|NCT05469308|Experimental|questionary|
89502960|NCT05450666|Experimental|YOUNG GROUP|The same exercise program will be applied to both groups. Participants will be included in the exercise program for eight weeks. Athletes between the ages of 18 and 30 will be included in this group.
89502961|NCT05450666|Experimental|ADULT GROUP|The same exercise program will be applied to both groups. Participants will be included in the exercise program for eight weeks. Athletes between the ages of 30 and 60 will be included in this group.
89502962|NCT04265846||bifocal IOL group|The cataract patients who ask for bilateral phacoemulsification and bifocal IOLs implantation.
89502963|NCT04265846||mix bifocal IOL group|The cataract patients who ask for phacoemulsification and mix different bifocal IOLs implantation bilaterally
89502964|NCT04265846||trifocal IOL group|The cataract patients who ask for bilateral phacoemulsification and trifocal IOLs implantation.
89502965|NCT04265846||EDOF IOL group|The cataract patients who ask for bilateral phacoemulsification and EDOF IOLs implantation.
89502966|NCT04265846||blend vision group|The cataract patients who ask for phacoemulsification and different IOLs implantation bilaterally.
89502967|NCT04265846||monovision designed group|The cataract patients who ask for bilateral phacoemulsification and monofocal IOLs implantation with monovision designed.
89502968|NCT04265846||monofocal IOL group|The cataract patients who ask for bilateral phacoemulsification and monofocal IOLs implantation with emmetropia designed.
89502969|NCT05144685|Experimental|Experimental App + Treatment as Usual|This intervention will be for the treatment group
89502970|NCT05144685|Experimental|Other App + Treatment as Usual|This intervention will be for the control group
89502971|NCT05140863|Experimental|HSK16149 20mg BID|HSK16149 20mg, orally twice a day for 12 weeks
89502972|NCT05140863|Experimental|HSK16149 40mg BID|HSK16149 40mg, orally twice a day for 12 weeks
89502973|NCT05140863|Placebo Comparator|Placebo BID|placebo, orally twice a day for 12 weeks
89502974|NCT03232424|Experimental|NovoTTF-200A + Temozolomide Chemoradiation|NovoTTF-200A, concomitant with radiotherapy and temozolomide, as front-line therapy for glioblastoma
88956713|NCT04313608|Experimental|Arm A: Glofit-GemOx|Participants will receive up to 8 cycles of Glofit-GemOx (glofitamab in combination with gemcitabine and oxaliplatin) administered in 21-day cycles, followed by up to 4 cycles of glofitamab monotherapy. A single dose of obinutuzumab will be administered 7 days prior to the first dose of glofitamab.
88956714|NCT04313608|Experimental|Arm B: Mosun-GemOx|Participants will receive up to 8 cycles of Mosun-GemOx (mosunetuzumab in combination with gemcitabine and oxaliplatin) administered in 21-day cycles.
88956715|NCT04309552|Experimental|High Grade Glioma (HGG)|Thirty newly diagnosed treatment-naïve subjects with suspected HGG based on clinical presentation and MRI findings and undergoing surgical planning will be accrued in this study.
89502975|NCT02676765|Experimental|sublingual allergen tablets|Subjects will be administered a sublingual allergen tablet customized to their individual allergic sensitization.
89502976|NCT02676765|Placebo Comparator|Placebo|Subjects will be administered placebo sublingual tablets
89502977|NCT05476406|Experimental|äKwä Group|participants use äKwä products daily as instructed for 30 days
89502978|NCT05476406|Active Comparator|Control Group|participants use a competitor products daily as instructed for 30 days
89502979|NCT05450120|Active Comparator|Functional Rehabilitation|Functional rehabilitation protocol
89502980|NCT05450120|Experimental|NMES + Functional Rehabilitation|Functional rehabilitation protocol associated with neuromuscular electrical stimulation
89502981|NCT03163563||Easywarm|Self warming blanket to prevent perioperative hypothermia
89502982|NCT03163563||BairHugger|Forced-air warming blanket to prevent perioperative hypothermia
89502983|NCT02680041|Experimental|18F-fluciclovine PET CT|Single intravenous administration of 18F-fluciclovine PET CT.
89502984|NCT03163407|Active Comparator|Norepinephrine group|Treatment of the postspinal anesthesia hypotension by administrating 5 mcg of Norepinephrine intravenously every 3 min until normal systolic blood pressure
89502985|NCT03163407|Active Comparator|Ephedrine group|Management of the post spinal hypotension by administrating 6 mg of Ephedrine intravenously every 3 min
89502986|NCT03163485|Experimental|Dialytrode|Multimodal neuro-monitoring by dialytrode (investigational medical device)
89502987|NCT03163485|Other|Standard treatment|Either EVD and/or micro-dialysis according to standard treatment
89502988|NCT03163251|Experimental|READ-SG Cohort|Each post-graduate year (PGY) will receive the intervention of a monthly peer-facilitated small group sessions (READ-SG Sessions) based on topics that are common to residency training and based on themes regarding humanism in medicine.
89502989|NCT02547974|Experimental|GSK3277513A F1 Group|Subjects, 18 - 40 years, receiving two doses of the non adjuvanted GSK Biologicals' NTHi Mcat investigational vaccine (GSK3277513A ) containing formulation 1 (F1) of PD, PE-PilA and UspA2 during Step 1 of the study. Intramuscular injection should be done in the deltoid of the non-dominant arm. In case it is not possible to inject in the non dominant arm, an injection in the dominant arm may be performed.
89502990|NCT02547974|Experimental|GSK3277513A F2 Group|Subjects, 50 - 70 years, receiving two doses of the GSK Biologicals' NTHi-Mcat investigational vaccine(GSK3277513A) containing formulation 2 (F2) (adjuvanted) of PD, PE-PilA and UspA2 during Step 2 of the study. Intramuscular injection should be done in the deltoid of the non-dominant arm. In case it is not possible to inject in the non dominant arm, an injection in the dominant arm may be performed.
89502991|NCT02547974|Experimental|GSK3277513A F3 Group|Subjects, 50 - 70 years, receiving two doses of the GSK Biologicals' NTHi-Mcat investigational vaccine(GSK3277513A) containing formulation 3 (F3) (adjuvanted) of PD, PE-PilA and UspA2 during Step 2 of the study. Intramuscular injection should be done in the deltoid of the non-dominant arm. In case it is not possible to inject in the non dominant arm, an injection in the dominant arm may be performed.
89502992|NCT02547974|Placebo Comparator|Placebo Group|Subjects, 18 - 40 years, receiving two doses of placebo (saline solution) during Step 1 of the study and subjects, 50 - 70 years, receiving two doses of placebo (saline solution) during Step 2 of the study. Intramuscular injection should be done in the deltoid of the non-dominant arm. In case it is not possible to inject in the non dominant arm, an injection in the dominant arm may be performed.
89502993|NCT00154297|Active Comparator|Immediate Everolimus|Patients received Everolimus starting within 48 hours of kidney transplant through to the end of the study, administered orally twice a day. Dose was adjusted in order to maintain a trough level between 3-8 ng/mL.
89502994|NCT00154297|Experimental|Delayed Everolimus|Patients received Everolimus 4 weeks after kidney transplant until the end of the study, administered orally twice a day. The dose was adjusted in order to maintain a trough level between 3-8 ng/mL. Patients received mycophenolic acid until everolimus was initiated.
89502995|NCT02679729|Experimental|Part A, Dose Level 1|Subjects will inhale single doses of AZD5634 or placebo under fasted conditions and will rinse his/her mouth with approximately 100 mL (up to 240 mL) of water which must be swallowed
89502996|NCT02679729|Experimental|Part A, Dose Level 2|Subjects will inhale single doses of AZD5634 or placebo under fasted conditions and will rinse his/her mouth with approximately 100 mL (up to 240 mL) of water which must be swallowed
89502997|NCT02679729|Experimental|Part A, Dose Level 3|Subjects will inhale single doses of AZD5634 or placebo under fasted conditions and will rinse his/her mouth with approximately 100 mL (up to 240 mL) of water which must be swallowed
89502998|NCT02679729|Experimental|Part A, Dose Level 4|Subjects will inhale single doses of AZD5634 or placebo under fasted conditions and will rinse his/her mouth with approximately 100 mL (up to 240 mL) of water which must be swallowed
89502999|NCT02679729|Experimental|Part A, Dose Level 5|Subjects will inhale single doses of AZD5634 or placebo under fasted conditions and will rinse his/her mouth with approximately 100 mL (up to 240 mL) of water which must be swallowed
89503000|NCT02679729|Experimental|Part A, Dose Level 6|Subjects will inhale single doses of AZD5634 or placebo under fasted conditions and will rinse his/her mouth with approximately 100 mL (up to 240 mL) of water which must be swallowed
89503001|NCT02679729|Experimental|Part A, Dose Level 7|Subjects will inhale single doses of AZD5634 or placebo under fasted conditions and will rinse his/her mouth with approximately 100 mL (up to 240 mL) of water which must be swallowed
89503002|NCT02679729|Experimental|Part B, Dose Level 1|Subjects will receive a single dose of IV AZD5634 and after a washout period of 14 days the same subjects will receive a single dose of inhaled AZD5634
89206487|NCT04043676|Experimental|Ponatinib Treatment|Patients will be treated with 15 mg/day of ponatinib during 48 weeks. If a patient maintains MR4 throughout the 48 weeks, he/she will be eligible to start the ponatinib TFR phase. If a patient has confirmed loss of MR4 (two consecutive BCR-ABL > 0.01% IS) or loss of MMR (no confirmation needed), he/she will not be eligible for the TFR phase. Instead, he/she will restart imatinib treatment.
89503003|NCT01327183|Experimental|20 mg/kg RO4905417 before PCI|
89503004|NCT01327183|Experimental|5 mg/kg RO4905417 before PCI|
89503005|NCT01327183|Placebo Comparator|Placebo before PCI|
89206488|NCT01325935|Experimental|Short-term DAPT group|1,200 patients to be newly registered: Undergo 3-month (+ 30 days) DAPT (aspirin and clopidogrel)
89206489|NCT01325935|No Intervention|Long-term DAPT group|1,200 patients to be appropriated from E-Japan post-marketing surveillance who meet all inclusion criteria and do not fall under any exclusion criteria of the present clinical study: Undergo 12-month DAPT (aspirin and clopidogrel)
89503006|NCT05449964|Experimental|TEST GROUP|INTERVENTION: Scaling and root planning (SRP) of two contra-lateral quadrants (randomly allocated) in single sitting with ultrasonic scaler, hand scalers and curettes under local anaesthesia.
89538686|NCT03061071|Experimental|Randomized to APAP First: SPT Second|Randomized to order of treatment (APAP first or SPT first) for a total of 6 weeks home use with each treatment.
89538687|NCT03904589||Coronary Heart Disease|
89206490|NCT02549742|Experimental|Electrochemotherapy|25 patients treated with electrochemotherapy
89210459|NCT00643760|Experimental|GEn 3600mg/day|gabapentin enacarbil 3600mg/day, maintanance treatment 14 weeks
89503007|NCT05449964|Active Comparator|CONTROL GROUP|INTERVENTION: Supra-gingival scaling followed by sub-gingival scaling and root planing of two contra-lateral quadrants (randomly allocated) in two sittings with ultrasonic scaler, hand scalers and curettes under local anaesthesia.
89503008|NCT02270281|Other|Dexmedetomidine|Before dexmedetomidine infusion
89503009|NCT03163329|Experimental|TAVR group|
89503010|NCT03163329|Active Comparator|SAVR group|
89503011|NCT01033123|Experimental|BSI-201|BSI-201 in combination with gemcitabine and carboplatin.
89503012|NCT05449262|Experimental|functional resistance training GROUP A|Session of 45-60 min starting with Warm Up Exercise and stretching prior to therapy and cool-down and stretching after the training sessions
89503013|NCT05449262|Experimental|functional resistance training GROUP B|Session of 45-60 min starting with Warm Up Exercise and stretching prior to therapy and cool-down and stretching after the training sessions
89503014|NCT03163173|Experimental|Single Arm - Treatment Group|30 mg (~100 μCi) dose of [14C]GC4419 administered as an IV infusion over 15 minutes on Day 1 following an overnight fast
89503015|NCT01323205|Experimental|JNJ-40411813 (Part A)|JNJ-40411813 starting dose from 50 to 150 mg according to tolerability dose range increased stepwise from 50 mg to 150 mg capsule by mouth orally. Capsule (s) taken twice daily with a meal for 12 weeks.
89503016|NCT01323205|Experimental|JNJ-40411813 (Part B)|JNJ-40411813 starting dose from 50 to 150 mg according to tolerability dose range increased stepwise from 50 mg to 150 mg capsule by mouth orally. Capsule (s) taken twice daily with a meal for 10 weeks.
89503017|NCT01323205|Experimental|Placebo and JNJ-40411813 (Part B)|Placebo capsule (s) orally twice daily with a meal for 4 weeks followed by JNJ-40411813 according to tolerability dose range increased from 50 mg to 150 mg twice daily with a meal to 6 weeks.
89503018|NCT03162861|Experimental|the observation group|The elderly patients undergoing unilateral total hip arthroplasty will be randomized to assigned to the observation group. In the observation group, tracheal intubation will be conducted for general anesthesia after lumbar plexus-sciatic nerve block, accompanying sevoflurane inhalation for anesthesia maintenance.
89503019|NCT03162861|Experimental|the control group|The elderly patients undergoing unilateral total hip arthroplasty will be randomized to assigned to the control group. In the control group, tracheal intubation will be conducted for general anesthesia, accompanying intravenous administration of propofol for anesthesia maintenance.
89503020|NCT01322269|Experimental|HQK-1001 (30 mg/kg)|
89503021|NCT01322269|Experimental|HQK-1001 (40 mg/kg)|
89503022|NCT01322269|Experimental|HQK-1001 (50 mg/kg)|
89503023|NCT03114579|Other|Measure of the cardiac output obtained by a reference methode|
89503024|NCT03114579|Other|Measurement of cardiac output obtained by NEXFIN HD.|
89503025|NCT03114423|Experimental|Treatment As Usual + Treatment with EMDR|
89503026|NCT03114423|Sham Comparator|Treatment As Usual + Cognitive Training|
89503027|NCT02765165|Experimental|Dose-Escalation USL311, Solid Tumor, Part 1a|USL311, intravenous, once per week, starting at 60 mg/m˄2
88956720|NCT04269473|Experimental|Experimental Group|Participants in the experimental group will receive a telehealth gait retraining intervention in addition to standard physical therapy rehabilitation for running-related knee pain, which includes: an at-home exercise program, a return to running protocol, and standard physical therapy evaluations.
88956721|NCT04269473|Active Comparator|Control Group|Participants in the control group will receive standard physical therapy rehabilitation for running-related knee pain, which includes: an at-home exercise program, a return to running protocol, and standard physical therapy evaluations.
89023658|NCT05003804|Experimental|STMC-102H Part A2|Once daily dosing with one capsule of STMC-103H mixed with milk, formula, or a milk product for 28 days
89503028|NCT02765165|Experimental|Dose-Escalation USL311, Solid Tumor, Part 1b|USL311, oral, daily, starting at 40 mg
89503029|NCT02765165|Experimental|Dose-Escalation USL311 with Lomustine, Solid Tumor, Part 2|USL311, oral, daily, starting at dose as determined in Part 1b, in combination with lomustine 90 mg/m˄2, oral, once every 6 weeks
89503030|NCT02765165|Experimental|Dose-Expansion, USL311, GBM, Part 3|USL311, oral, daily, starting at dose determined in Part 1b
89503031|NCT02765165|Experimental|Dose-Expansion, USL311 with Lomustine, GBM, Part 4|USL311, oral, daily, in combination with lomustine, oral, once every 6 weeks, at dose(s) as determined in part 2
89503032|NCT02156843|Experimental|Pyridorin|Pyridorin (pyridoxamine dihydrochloride) 300 mg oral BID (twice daily, every 12 hours) Capsule
89503033|NCT02156843|Placebo Comparator|Placebo|Placebo Oral Capsule taken BID (twice daily, every 12 hours)
89503034|NCT02675907|Experimental|N1539 30mg|N1539 (Intravenous meloxicam) 30mg every 24 hours for up to 3 doses.
89503035|NCT02675907|Placebo Comparator|IV Placebo|IV Placebo every 24 hours for up to 3 doses.
89503036|NCT02156921|No Intervention|Control group|Self-guided training without app-based training (written hand-outs)
89503037|NCT02156921|Active Comparator|Intervention group|Self-guided training with app-based training
89503038|NCT02675517||Spiolto Respimat|COPD patients requiring a fixed combination therapy of two long-acting bronchodilators (LAMA + LABA) according to approved Summary of Product Characteristics (SmPC) and Global Initiative for Chronic Obstructive Lung Disease (GOLD)guidelines
89503039|NCT02152865|Active Comparator|Lupeol|Patients are supposed to apply lupeol on one side of face two times per day for 8 weeks
89503040|NCT02152865|Placebo Comparator|Control vehicle|Patients are supposed to apply vehicle control to another side of face two times per day for 8 weeks
89503041|NCT02152943|Experimental|Treatment (everolimus, letrozole, trastuzumab)|Patients receive everolimus PO QD and letrozole PO QD. Patients also receive trastuzumab IV over 30-90 minutes once every 3 weeks. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89503042|NCT02156999|Experimental|Osteoporosis|
89503043|NCT03162393||group 1|phrenic nerve transfer to musculocutaneous nerve; spinal accessory transfer to suprascapular nerve; intercostal nerve transfer to triceps branch, radial nerve and axillary nerve; contralateral C7 nerve transfer to median nerve
89503044|NCT03162393||group 2|phrenic nerve transfer to musculocutaneous nerve; spinal accessory transfer to suprascapular nerve; intercostal nerve transfer to triceps branch and radial nerve; contralateral C7 nerve transfer to median nerve
89538688|NCT04967859|Placebo Comparator|Group 1 (control):|Patients using placebo ointment at the exit site of the hemodialysis catheter
89503045|NCT03162393||group 3|spinal accessory transfer to suprascapular nerve; intercostal nerve transfer to triceps branch, radial nerve and axillary nerve; contralateral C7 nerve transfer to median nerve and musculocutaneous nerve
88982909|NCT02898207|Experimental|Dose Level 0: Olaparib 200 mg and Onalespib 20 mg/m^2|Dose Level 0 (DL0): Patients received olaparib 200 mg PO BID on days 1-7 (cycle 0). Beginning in cycle 1, patients received olaparib 200mg PO BID on days 1-28 and onalespib 20 mg/m^2 IV over 1 hour on days 1, 2, 8, 9, 15, and 16. Cycles repeated every 28 days in the absence of disease progression or unacceptable toxicity.
89503046|NCT03162393||group 4|spinal accessory transfer to suprascapular nerve; intercostal nerve transfer to triceps branch and radial nerve; contralateral C7 nerve transfer to median nerve and musculocutaneous nerve
89503047|NCT03162393||group 5|spinal accessory transfer to suprascapular nerve; intercostal nerve transfer to musculocutaneous nerve, radial nerve and axillary nerve; contralateral C7 nerve transfer to median nerve and triceps branch
89503048|NCT03162393||group 6|spinal accessory transfer to suprascapular nerve; intercostal nerve transfer to musculocutaneous nerve and radial nerve; contralateral C7 nerve transfer to median nerve and triceps branch
89503049|NCT02153021|Placebo Comparator|Lifestyle counseling|alimentation information: a nutritionist provides nutritional orientation; exercise training: 3 days by week the patients will have specific sessions of resistance training (30 minutes) and aerobic training (30 minutes); phototherapy: all patients will received application of phototherapy after exercise session. The phototherapy will be applicated in abdominal and dorsal circumference/ quadriceps and biceps femoral. In Sham group,the equipment will be off.
89503050|NCT02153021|Active Comparator|Phototherapy|"phototherapy: all patientes will received application of phototherapy after exercise session. The phototherapy will be applicated in abdominal and dorsal circumference/ quadriceps and biceps femoral.~Type Ga-Al-As Wavelength 808nm Frenquency Continue wave Optical output 100mW Spot diameter 0.6mm Power density 60W/cm2 Energy per minute 6J/point Number of Points 64points Total energy delivered 48J"
89503051|NCT02157155|Experimental|Intervention|Insulin reduction and mimic infection with LPS
89503052|NCT02157155|No Intervention|Control|Normal insulin and no LPS
89503053|NCT02157233|Experimental|Hot environment|Subjects will perform the intervention in a hot environment (33°C)
89503054|NCT02157233|Sham Comparator|Neutral environment|Subjects will perform the intervention in a neutral environment (22°C)
89503055|NCT03735719||STEMI patients|Patients with first STEMI treated with primary PCI are recruited in this study.
89503056|NCT03735719||Control group|The control group will consist of patients with risk factors for cardiovascular diseases, but without history of coronary artery disease or heart failure.
89503057|NCT02159651||1: Dermatomyositis group|patients with interstitial pneumonia associated with dermatomyositis
89503058|NCT02159651||2: Polymyositis group|patients with interstitial pneumonia associated with polymyositis
89503059|NCT04996641|Experimental|Intervention|Root canal treatment and crown restoration
89503060|NCT02764775|Experimental|Headed utilization|Use of Headpod for 6 months duration; 3 x per day for a minimum of 15 minutes each time;
89503061|NCT03160833|Experimental|HMPL-453|Two strengths of HMPL-453 tablets (25 mg and 100 mg based on the free base) will be used for clinical studies. The drug products are coated tablets, which are packaged in white induction sealed HDPE (high-density polyethylene) bottles. HMPL-453 will be administered to patients as oral tablet(s) on a daily basis, until disease progression, intolerable toxicity, or death. Dose levels are to be potentially tested in this study include 50, 100, 200, 300, 400, and 500 mg/day
89503062|NCT02159885|Experimental|Telemonitoring|In this arm, subjects will receive usual care at the sleep clinic as well as telemonitoring of their use of their automatically adjusting continuous positive airway pressure pressure (APAP) machine. They will receiving phone calls for poor adherence and/or poor efficacy of treatment.
89503063|NCT02159885|No Intervention|Usual Care|"Subjects in this arm will receive usual care for management of obstructive sleep apnea and use of automatically titrating continuous positive airway pressure."
89503064|NCT03161145||Unresectable or metastatic renal cell carcinoma (mRCC)|Medical records will be reviewed for treatment patterns and outcomes
89503065|NCT02774681|Experimental|Treatment (palbociclib)|Patients receive palbociclib PO daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with HER2 positive breast cancer may also receive trastuzumab IV over 30-90 minutes every 3 weeks.
89503066|NCT03160755||Qualitative Interviews|Adult outpatients with metabolic syndrome.
89503067|NCT03113799|Other|Single Arm study|Single Arm study In this study, the subject will act as their own control. On Day 1 of the two day study, the subject will be observed while treated on their standard EVD. On Day 2, the subject will be treated with the Smart External Drain (SED).
89503068|NCT02157311|Experimental|Four consecutive days on treatment and 3 days off|All patients will take a combination of three HIV treatment with a weekly strategy of 4 consecutive days on treatment followed by 3 days off treatment
89503069|NCT03542903|Active Comparator|Short ECT arm|In the short arm, bitemporal ECT is administered twice a week during the first 6 weeks. Afterwards, it is administered once a week during 4 weeks. After that, the patients will have one ECT every 3 weeks during 6 weeks. Lastly, patients will receive one ECT each month during 2 months.
89503070|NCT03542903|Active Comparator|Long ECT arm|In the long arm, bitemporal ECT is administered twice a week during the first 12 weeks. Afterwards, it is administered once a week during 8 weeks. After that, the patients will have one ECT every 3 weeks during 12 weeks. Lastly, patients will receive one ECT each month during 4 months.
89503071|NCT02157389|Experimental|placebo|Administration of a pharmacological placebo (sodium chloride) via transdermal application to investigate the influence on pain perception in chronic back pain patients and to investigate the influence of attitude and experience with medication on the placebo effect
89503072|NCT04784039|Active Comparator|TEE-group|
89023659|NCT05003804|Placebo Comparator|Placebo Part A2|Once daily dosing with one capsule of placebo mixed with milk, formula or a milk product for 28 days
89023660|NCT05003804|Experimental|STMC-103H Part B|Once daily dosing with one capsule of STMC-103H mixed with breastmilk, formula or a milk product for 336 days
89503073|NCT04784039|Active Comparator|DD-group|
89503074|NCT02159963|Experimental|Supervised training|8 weeks of high intensity training three times a week, once supervised. Followed by 8 weeks home based, unsupervised optional training.
89503075|NCT02159963|Experimental|Unsupervised training|"Participants have 8 weeks of non-intervention Control period, followed by 8 weeks of home based, unsupervised high intensity interval training."
89503076|NCT02547428|Experimental|CTN SR First, Then Placebo|Participants received CTN SR tablets starting at a dose of 100 or 200 milligrams (mg) on Day 1. Dose was up titrated up to 800 mg daily dose for up to 3 weeks in Period 1. The dose was decreased based on safety and tolerability based on Investigator's discretion, followed by a washout Period of 1 week followed by matching-placebo for up to 3 weeks in Period 2. The most common total daily dose (TDD) was 400 mg/day.
89503077|NCT02547428|Experimental|Placebo First, Then CTN SR|Participants received matching-placebo for up to 3 weeks in Period 1, followed by a washout Period of 1 week, followed by CTN SR tablets starting at a dose of 100 or 200 mg on Day 1. Dose was up titrated up to 800 mg daily dose for up to 3 weeks in Period 2. The dose was decreased based on safety and tolerability based on Investigator's discretion. The most common TDD was 400 mg/day.
89503078|NCT02153255||Children With Mucopolysaccharidosis Type IVa|
89503079|NCT02157467|Experimental|Arm 1: NGMN/EE + BMS-955176|"Cycle 1- Active Ortho Cyclen QD on Days 1 to 21. Inert Ortho Cyclen tablets on Days 22 to 28~Cycle 2- Active Ortho Cyclen QD alone on Days 29 to 39 (11 days), followed by concomitant administration of active Ortho Cyclen QD + BMS-955176 80 mg QD on Days 40 to 49 (10 days)"
89503080|NCT01374087|Experimental|Brachytherapy + Triptorelin 22.5 mg|Brachytherapy: Low or high dose rate. Triptorelin: A single, intramuscular injection (22.5 mg), preferably 2 months before brachytherapy.
89503081|NCT01374087|Active Comparator|Brachytherapy|Brachytherapy: Low or high dose rate.
89503082|NCT02157545||pyridostigmine|administration of rocuronium to determine its potency.
89503083|NCT02157545||control arm (no pyridostigmine)|determination of potency of rocuronium in patients not taking pyridostigmine
89503084|NCT02153333||HRV Group|Subjects who had received 2 doses of HRV vaccine in previous studies.
89503085|NCT02153333||Placebo Group|Subjects who had received 2 doses of placebo in previous studies.
89503086|NCT00152971|Experimental|Dabigatran Dose 1|low dose regimen taken once daily
89503087|NCT00152971|Experimental|Dabigatran Dose 2|high dose regimen taken once daily
89503088|NCT00152971|Active Comparator|Enoxaparin|30 mg subcutaneously twice daily
89503089|NCT02157701|Experimental|Polyherbal capsule|1 capsule taken with breakfast and 1 capsule with lunch. Capsules should be taken immediately prior to meals and not with carbonated beverages.
89503090|NCT02157701|Placebo Comparator|Placebo capsule|1 capsule taken with breakfast and 1 capsule with lunch. Capsules should be taken immediately prior to meals and not with carbonated beverages.
89503091|NCT02538614|Experimental|Phase 1b: Idelalisib + BI 836826|Participants will receive escalating dose of idelalisib at dose levels, 50 mg, 100 mg, and 150 mg + BI 836826 10 mg on Day 8, 50 mg on Day 9 and Day 15, and 100 mg on Day 22, every 2 weeks through Week 18, and every 4 weeks through Week 46. 2 dose combinations (highRP2D and lowRP2D) will be determined for further evaluations in Phase 2.
89503092|NCT02538614|Experimental|Phase 2 Idelalisib + BI 836826|Participants will be randomly assigned to receive 1 of the 2 dose combinations selected from Phase 1b.
89503093|NCT02160119||Healthy Controls|
89503094|NCT02160119||Autism Spectrum Disorders|
89503095|NCT05447078|Placebo Comparator|Placebo|inert capsules; 2 capsules given by mouth in the morning and 2 capsules given by mouth in the evening for 16 weeks duration.
88982910|NCT02898207|Experimental|Dose Level 1: Olaparib 200 mg and Onalespib 40 mg/m^2|Dose Level 1 (DL1): Patients received olaparib 200 mg PO BID on days 1-7 (cycle 0). Beginning in cycle 1, patients received olaparib 200mg PO BID on days 1-28 and onalespib 40 mg/m^2 IV over 1 hour on days 1, 2, 8, 9, 15, and 16. Cycles repeated every 28 days in the absence of disease progression or unacceptable toxicity.
89503096|NCT05447078|Experimental|Immulina TM 200 mg/day|Immulina Dietary supplementation (200 mg per capsule); 1-200 mg capsule and 1 placebo capsule given by mouth in the morning and 2 placebo capsules given by mouth in the evening for 16 weeks duration.
89503097|NCT05447078|Experimental|Immulina TM 400 mg/day|Immulina Dietary supplementation (200 mg per capsule); 1-200 mg capsule and 1 placebo capsule given by mouth in the morning and 1-200 mg capsule and 1 placebo capsule given by mouth in the evening for 16 weeks duration.
89503098|NCT05447078|Experimental|Immulina TM 800 mg/day|Immulina Dietary supplementation (200 mg per capsule); 2-200 mg capsules given by mouth in the morning and 2-200 mg capsules given by mouth in the evening for 16 weeks duration.
89503099|NCT02160197|No Intervention|No Immobilisation|No immobilisation post op, allowing patients to weight bear as tolerated.
89503100|NCT02160197|Active Comparator|Functional Bracing|Immobilise patients in Functional brace, allowing patients to weight bear as tolerated.
89503101|NCT02160197|Active Comparator|Plaster Immobilisation|Immobilise patients in plaster, allowing patients to weight bear as tolerated.
89503102|NCT04475575|Other|COVID-19 suspected|Participants where included if an oropharyngeal and nasopharyngeal swab was collected for RT-PCR and serology testing had been performed, or if participants have had a confirmed COVID-19 diagnosis in the previous days or weeks with an indication for re-testing via PCR and serology testing at the moment of inclusion
89503103|NCT03160599|Experimental|Restricted Calorie Ketogenic Diet|"Calorie restriction: The basis of dietary design is 70-85% of individual's total calories. The total calorie is based on patient's activity level and their basal metabolism values, which is obtained from indirect calorimetry or harris-benedict formula.~Treatment will consist of ketogenic diet. KD will consist of 4:1-1:1[fat]:[protein+carbohydrate].Carbohydrate is limited to 10-30 g / day.The diet will be supplemented with vitamins, calcium, phosphorus, zinc and selenium supplements to meet the requirements of US Dietary Reference Intakes (DRI) standard."
89503104|NCT02153411||8645 asthmatic patients|Men and women, 18 years of age and older. Asthmatic since at least one year before inclusion. Patient's informed consent obtained.
89503105|NCT04475341|Active Comparator|BMS without BMAC|
89503106|NCT04475341|Experimental|BMS with BMAC|
89503107|NCT03504644|Experimental|Treatment (venetoclax, vincristine liposomal)|Patients receive venetoclax PO QD on days 1-42 of course 1 and days 43-70 of course 2. Patients also receive vincristine liposomal IV weekly for 4 weeks starting on day 14 of course 1.
89503108|NCT04620135|Experimental|Netarsudil ophthalmic solution 0.02% and netarsudil ophthalmic solution vehicle|1 drop netarsudil 0.02% in the evening and 1 drop netarsudil vehicle in the morning in each eye.
89023661|NCT05003804|Placebo Comparator|Placebo Part B|Once daily dosing with one capsule of placebo mixed with breastmilk, formula or a milk product for 336 days
89503109|NCT04620135|Active Comparator|Ripasudil hydrochloride hydrate ophthalmic solution 0.4%|1 drop ripasudil twice daily in the morning and evening in each eye.
89503110|NCT02160275|Active Comparator|Open Loop|4 days patient-managed insulin pump therapy with blinded continuous glucose monitoring
89503111|NCT02160275|Experimental|Closed Loop|4 days of automated blood glucose control with the Artificial Pancreas (Inreda Diabetic BV)
89503112|NCT03126968|Experimental|Prophylactic topical epinephrine|Study participants who meet inclusion and exclusion criteria and allocated to this arm will be randomized to receive prophylactic endobronchial topical epinephrine in a blinded manner prior to performance of transbronchial lung biopsy.
89503113|NCT03126968|Placebo Comparator|Placebo|Study participants who meet inclusion and exclusion criteria and allocated to this arm will be randomized to receive prophylactic endobronchial topical placebo in the form of normal saline in a blinded manner prior to performance of transbronchial lung biopsy.
89503114|NCT05676879|Experimental|Intervention Group|Ice massage was applied to the SP6 points (SP6 point is located 3-4 fingers above the posterior malleolus bone, that is, 4 fingers above the ankle) of the pregnant women in first stage of childbirth at 4-5 cm, 6-7 cm, and 8-9 cm cervical dilatations during 3 contractions. In order to prevent direct contact of ice with the skin, ice was applied as ice cubes wrapped in gauze.
89503115|NCT05676879|No Intervention|Control Group|All the pregnant women, those in the control group, were provided with standard midwifery care.
89503116|NCT02266849|Active Comparator|Loperamide|Patients will take the drug for three days. Day 1 - uploading with the drug Day 2 - collecting output when necessary Day 3 - radiopaque marker and collection of output every two hours
89503117|NCT02266849|Placebo Comparator|Placebo|Patients will take the drug for three days. Day 1 - uploading with the drug Day 2 - collecting output when necessary Day 3 - radiopaque marker and collection of output every two hours
89503118|NCT02552966|Experimental|UESAD|Upper Esophageal Sphincter Assist Device
89503119|NCT03734783||Patients|HBsAg positive more than 6 months
89503120|NCT03734783||health control|
89503121|NCT01309945|Active Comparator|Arm 1: Duloxetine 30mg|
89503122|NCT01309945|Placebo Comparator|Arm 2: BMS-820836 placebo|
89503123|NCT01309945|Experimental|Arm 3: BMS-820836 0.5-2.0 mg/day|
89503124|NCT01309945|Active Comparator|Arm 4: Duloxetine 30mg|
89503125|NCT01309945|Placebo Comparator|Arm 5: Duloxetine placebo|
89503126|NCT02552888|Experimental|treatment|Immediate release sodium nitrite 40 mg by mouth twice per day and Isoquercetin 225 mg by mouth once per day.
89503127|NCT02552888|Placebo Comparator|Placebos|identical placebos.
89503128|NCT02153567|Placebo Comparator|Control (Placebo) group|"Identical looking placebo (once daily)~Double blinding of study medication is achieved by repacking Escitalopram 5mg and 10mg as blue and green capsules respectively.. Identical appearing placebos packed in blue and green capsules will be used for the control group."
89503129|NCT02153567|Experimental|Escitalopram|Escitalopram 5mg & 10mg daily
89503130|NCT03541967|Other|ADHEAR-PONTO|The ADHEAR system will be fitted to the patient who will take it at home for 15 days. Afterwards, the patient will come back to the clinical center and measurements will be done with the ADHEAR system. Then the patient will be fitted with the PONTO 3 SUPER POWER on softband and will take it at home for 15 days. Afterwards, the patient will come back to the clinical center and measurements will be done with the PONTO 3 SUPER POWER on softband.
89503131|NCT03541967|Other|PONTO-ADHEAR|The PONTO 3 SUPER POWER on softband will be fitted to the patient who will take it at home for 15 days. Afterwards, the patient will come back to the clinical center and measurements will be done with the PONTO 3 SUPER POWER on softband. Then the patient will be fitted with the ADHEAR system and will take it at home for 15 days. Afterwards, the patient will come back to the clinical center and measurements will be done with the ADHEAR system.
89503132|NCT01023685|Experimental|CAD106|
89503133|NCT02160431|Experimental|CBT for pediatric OCD|Participants complete standard CBT for OCD
89503134|NCT02441660|Experimental|Investigational Capsacin, Then Control Capsacin|Qutenza, Capsaicin 8% Patch will be used for 12 weeks followed by capsacin 0.025% Well Patch
89503135|NCT02441660|Experimental|Control Capsacin, Then Investigational Capsacin|Active control with low dose capsaicin 0.025% Well Patch used for 12 weeks followed by Qutenza 8% Patch
89503136|NCT02160509||- The patients who undergo ultrasonography in the ED|
89503137|NCT01303783|Experimental|Nifedipine GITS 20 mg|Subjects received 20 mg of nifedipine GITS (single tablet) monotherapy once daily for 8 weeks along with 2 placebo tablets and 1 placebo capsule
89503138|NCT01303783|Experimental|Nifedipine GITS 30 mg|Subjects received 30 mg of nifedipine GITS (single tablet) monotherapy once daily for 8 weeks along with 2 placebo tablets and 1 placebo capsule
89503139|NCT01303783|Experimental|Nifedipine GITS 60 mg|Subjects received 60 mg of nifedipine GITS (single tablet) monotherapy once daily for 8 weeks along with 2 placebo tablets and 1 placebo capsule
89503140|NCT01303783|Experimental|Candesartan cilexetil 4 mg|Subjects received 4 mg of candesartan cilexetil (single capsule) monotherapy once daily for 8 weeks along with 3 placebo tablets
89023662|NCT05003271|Experimental|Small group zoom meeting|Group one: participants were asked to follow the exercise program with a small group of peers (2 groups/6 participants each) in a Zoom meeting 3 times a week/45 min each (including 5 min before and 10 min after the meeting for free talk-chat between the participants; e.g., questions, perceptions, etc.).
89023663|NCT05003271|Experimental|YouTube pre-recorded video|Group two: participants were asked to follow the exercise program 3 times a week/30 min each while watching a pre-recorded YouTube video.
89023664|NCT04992312|Experimental|Glucagon Nasal Powder|A single dose of glucagon nasal powder administered intranasally.
89503141|NCT01303783|Experimental|Candesartan cilexetil 8 mg|Subjects received 8 mg of candesartan cilexetil (single capsule) monotherapy once daily for 8 weeks along with 3 placebo tablets
89503142|NCT01303783|Experimental|Candesartan cilexetil 16 mg|Subjects received 16 mg of candesartan cilexetil (single capsule) monotherapy once daily for 8 weeks along with 3 placebo tablets
89503143|NCT01303783|Experimental|Candesartan cilexetil 32 mg|Subjects received 32 mg of candesartan cilexetil (single capsule) monotherapy once daily for 8 weeks along with 3 placebo tablets
89503144|NCT01303783|Experimental|Nifedipine/candesartan 20/4 mg|Subjects received the combination of 20 mg of nifedipine GITS/4 mg of candesartan cilexetil once daily for 8 weeks along with 2 placebo tablets
88982911|NCT02898207|Experimental|Dose Level 2: Olaparib 300 mg and Onalespib 40 mg/m^2|Dose Level 2 (DL2): Patients received olaparib 300 mg PO BID on days 1-7 (cycle 0). Beginning in cycle 1, patients received olaparib 300 mg PO BID on days 1-28 and onalespib 40 mg/m^2 IV over 1 hour on days 1, 2, 8, 9, 15, and 16. Cycles repeated every 28 days in the absence of disease progression or unacceptable toxicity.
88982912|NCT02898207|Experimental|Dose Level 3: Olaparib 300 mg and Onalespib 80 mg/m^2|Dose Level 3 (DL3): Patients received olaparib 300 mg PO BID on days 1-7 (cycle 0). Beginning in cycle 1, patients received olaparib 300 mg PO BID on days 1-28 and onalespib 80 mg/m^2 IV over 1 hour on days 1, 2, 8, 9, 15, and 16. Cycles repeated every 28 days in the absence of disease progression or unacceptable toxicity.
89023665|NCT04987281|Experimental|Device feasibility (bronchoscopy, CT, indocyanine green)|During standard of care surgical resection, patients undergo robotic bronchoscopy and CT. Patients also receive indocyanine green via injection.
89206491|NCT00521014|Experimental|GM-CSF and Rituximab After Autologous Stem Cell Transplant|"GM-CSF: 250 mcg (flat dose) three times per week for 8 weeks, administered on alternate days. Thus, 24 doses of GM-CSF will be administered.~Rituximab: 375 mg/m2/week for 4 weeks, beginning within 3 days after the first dose of GM-CSF; rituximab. The second course of GM-CSF and rituximab will be administered approximately 22-26 weeks (day +154 to +182) after ASCT."
89206492|NCT00560235|Experimental|1|
89503145|NCT01303783|Experimental|Nifedipine/candesartan 20/8 mg|Subjects received the combination of 20 mg of nifedipine GITS/8 mg of candesartan cilexetil once daily for 8 weeks along with 2 placebo tablets
89503146|NCT01303783|Experimental|Nifedipine/candesartan 20/16 mg|Subjects received the combination of 20 mg of nifedipine GITS/16 mg of candesartan cilexetil once daily for 8 weeks along with 2 placebo tablets
89503147|NCT01303783|Experimental|Nifedipine/candesartan 30/8 mg|Subjects received the combination of 30 mg of nifedipine GITS/8 mg of candesartan cilexetil once daily for 8 weeks along with 2 placebo tablets
89503148|NCT01303783|Experimental|Nifedipine/candesartan 30/16 mg|Subjects received the combination of 30 mg of nifedipine GITS/16 mg of candesartan cilexetil once daily for 8 weeks along with 2 placebo tablets
89503149|NCT01303783|Experimental|Nifedipine/candesartan 30/32 mg|Subjects received the combination of 30 mg of nifedipine GITS/32 mg of candesartan cilexetil once daily for 8 weeks along with 2 placebo tablets
89503150|NCT01303783|Experimental|Nifedipine/candesartan 60/16 mg|Subjects received the combination of 60 mg of nifedipine GITS/16 mg of candesartan cilexetil once daily for 8 weeks along with 2 placebo tablets
89503151|NCT01303783|Experimental|Nifedipine/candesartan 60/32 mg|Subjects received the combination of 60 mg of nifedipine GITS/32 mg of candesartan cilexetil once daily for 8 weeks along with 2 placebo tablets
89503152|NCT01303783|Placebo Comparator|Placebo|Subjects received placebo (3 tablets and 1 capsule) once daily for 8 weeks
89503153|NCT02153801|Active Comparator|Low Inferior Mesenterci Artery Ligation|The opening of the peritoneum proceeds cephalad towards the duodenojejunal angle of Treitz, and the mesenteric root is incised 1 cm below the inferior margin of the pancreas. The aortomesenteric window is opened wide and the inferior mesenteric vessels are exposed. The inferior mesenteric artery (IMA) is ligated and divided at 2 cm from its origin. The inferior mesenteric vein is ligated and divided below the pancreatic margin.
89503154|NCT02153801|Other|High Inferior Mesenterci Artery Ligation|"For Low Ligation The opening of peritoneum proceeds upward and then laterally towards the sigmoid colon. Left colic artery is identified and preserved while low ligation of the inferior mesenteric artery (superior hemorrhoidal artery) is performed. Lymphadenectomy is carried on medially along the inferior mesenteric artery until 2 cm from the aorta.~For both groups dissection is then carried on windowing Toldt and Gerota fascias till the parietocolic gutter."
89503155|NCT02160587|Active Comparator|ZuraPrep|Irritation scores of the following applied to test sites will be compared: ZuraPrep, ZuraPrep without IPA, ChloraPrep, and 0.9% Physiological Saline.
89503156|NCT02153879|Experimental|Fenofibrate|Fenofibrate 145 mg/day for 12 weeks
89503157|NCT02153879|Experimental|Niacin plus Laropiprant|Niacin 2g/day plus Laropiprant for 12 weeks
89503158|NCT03541421|Experimental|Intervention|The patients administers own drugs during hospital stay.
89503159|NCT03541421|No Intervention|Control|The patients receive medications from the medicine room dispensed by a nurse (standard care). No intervention
89503160|NCT01373931|Experimental|OC + LY2216684 First, Then OC + Placebo|28-day lead-in period of Ortho Cyclen (OC; 28-day packet), followed by randomization to OC administered orally once daily for 28 days + 18 milligrams (mg) of LY2216684 administered concomitantly orally once daily for 21 days, followed by OC administered orally once daily for 28 days + placebo administered concomitantly orally once daily for 21 days.
89503161|NCT01373931|Experimental|OC + Placebo First, Then OC + LY2216684|28-day lead-in period of OC (28-day packet), followed by randomization to OC administered orally once daily for 28 days + placebo administered concomitantly orally once daily for 21 days, followed by OC administered orally once daily for 28 days + 18 mg of LY2216684 administered concomitantly orally once daily for 21 days.
89503162|NCT01147939|Experimental|Elacytarabine|
89503163|NCT01147939|Active Comparator|Investigator's Choice|
89503164|NCT02160743|Experimental|CJ-30056 20mg/500mg|fasting, fed
89503165|NCT02160743|Experimental|group 2|fed, fasting
89503166|NCT02158013|Active Comparator|Diltiazem, calcium channel blocker|Diltiazem gel 2% applied twice daily for 8 weeks
89503167|NCT02158013|Experimental|Levorag, Hibiscus plant extract|Levorag Emulgel applied twice daily for 8 weeks
89503168|NCT05676021|Experimental|intervention group|"On the second day of the COVID-19 antiviral drug treatment, the participant assigned to the intervention group was interviewed face-to-face during the home visit by providing isolation measures. In the face-to-face meeting, the COVID-19 Medication Use Brochure was given and it was stated that the participants would be video-talked about the topics included in the booklet at an appropriate time on the same day, and time was planned. In the interview, it was decided to allow the participant to tell about their antiviral drug use, to learn about their feelings, thoughts and behaviors about drug use, to reveal their feelings of indecision and anxiety about treatment, to determine their resistance to drug use, to reveal their intrinsic motivation, to support them and to change their behavior. It was intended to take action to advance the cycle of change."
89503169|NCT05676021|No Intervention|control group|After randomization, the participants in the control group continued to receive health care according to the standard COVID-19 drug treatment procedures determined by the Ministry of Health. No other intervention was performed apart from the participant standard COVID-19 drug therapy procedures in the control group.
88956725|NCT04264741|Experimental|rTMS treatment group|For rTMS treatment, we will stimulate the dorsal lateral prefrontal cortex of each patients using the iTBS pattern everyday. Treatment will lasted for 4 weeks.
88956726|NCT04264741|Sham Comparator|sham rTMS treatment group|For sham rTMS treatment, we will stimulate the dorsal lateral prefrontal cortex of each patients using the sham iTBS pattern and sham coil everyday. Treatment will lasted for 4 weeks.
88956727|NCT04235309||Total Knee Replacement Cohort|Any patients who are scheduled to undergo a total knee replacement.
88956728|NCT04224727|No Intervention|Control|Subjects are not offered a group commitment contract, individual commitment contract, or individual monetary rewards. Subjects do not receive additional information treatments.
89503170|NCT01147003|Experimental|BGG492 low dose|
89503171|NCT01147003|Placebo Comparator|Placebo|
89503172|NCT01147003|Experimental|BGG492 high dose|
89503173|NCT01023295|Placebo Comparator|Placebo|single dose
89503174|NCT01023295|Experimental|15 mg/m^2|15 mg/m^2 fosbretabulin, single dose
89503175|NCT01023295|Experimental|25 mg/m^2|25 mg/m^2 fosbretabulin, single dose
89503176|NCT01023295|Experimental|35 mg/m^2|35 mg/m^2 fosbretabulin, single dose
89503177|NCT01023295|Experimental|45 mg/m^2|45 mg/m^2 fosbretabulin, single dose
89503178|NCT05468138|Active Comparator|Adjuvant chemotherapy(SOX or XELOX )|"8 cycles of adjuvant SOX or XELOX should be performed within 8 weeks after receiving standard gastrectomy with D2 lymphadenectomy.~SOX: S-1：40~60mg bid，d1~14 q3W oxaliplatin：130mg/m2，iv drip for 2h，d1,q3W 8 cycles (6 months) XELOX: capecitabine：1000 mg/m2 ，bid, d1~14 q3W oxaliplatin：130mg/m2，iv drip for 2h，d1,q3W 8 cycles (6 months)"
89503179|NCT05468138|Experimental|Observation|After receiving standard gastrectomy with D2 lymphadenectomy, regular follow-up every 3 months alone. Abdomen/chest CT scan will be performed every 6 months after surgery.
89503180|NCT05468138|Experimental|PD-1 immunotherapy|"Adjuvant treatment with PD-1 antibody every 3 weeks(maximum 1 years) should be performed within 8 weeks after receiving standard gastrectomy with D2 lymphadenectomy.~PD-1 antibody: Sintilimab at a dose of 200 mg every 3 weeks for 16 cycles or Nivolumab at a dose of 360 mg every 3 weeks for 16 cycles"
89503181|NCT02154113|Active Comparator|Velashape II device|Controlled infrared (IR) light and conducted bipolar radiofrequency (RF) energies with mechanical manipulation.
89503182|NCT02154113|Active Comparator|Ultrashape|The UltraShape Contour I V3 uses focused ultrasound to produce localized mechanical motion within fat tissues and cells for the purpose of producing mechanical cellular membrane disruption.
89503183|NCT05620927||Type 1 diabetes|Type 1 diabetes > 10 years duration of diabetes
89503184|NCT02158325|Active Comparator|3.0-3.9 mm|pediatric cataract surgery performed with different anterior capsulorhexis sizes (3.0-3.9 mm in diameter)
89503185|NCT02158325|Experimental|4.0-5.0 mm|pediatric cataract surgery performed with different anterior capsulorhexis sizes (4.0-5.0 mm in diameter)
89503186|NCT02158325|Active Comparator|5.1-6.0 mm|pediatric cataract surgery performed with different anterior capsulorhexis sizes (5.1-6.0 mm in diameter)
89503187|NCT01140217|Experimental|Active treatment|Norethindrone Acetate Transdermal Delivery System
89503188|NCT02552732|Experimental|NHF with or without Oxygen|NHF with or without oxygen will be delivered to COPD patients using myAIRVO™ 2 for 30 days post hospital discharge
89503189|NCT02160821|Experimental|Transversus Abdominis Plane Block|Transversus Abdominis Plane Block TAPB Ultrasound guided TAPB
88956729|NCT04224727|Experimental|Group Commitment Contract + Information|Subjects are offered a group commitment contract for smoking cessation or weight loss and receive additional information treatments.
88956730|NCT04224727|Experimental|Individual Monetary Rewards + Information|Subjects are offered individual monetary rewards for smoking cessation or weight loss and receive additional information treatments.
89503190|NCT02160821|Experimental|Caudal Epidural Block|Caudal Epidural Block Caudal Block Neuraxial Block Ultrasound Guided Caudal Block
89503191|NCT01297543|Experimental|Consolidation Group A|Low dose CLT-008 (human myeloid progenitor cells)
89503192|NCT01297543|Experimental|Consolidation Group B|Intermediate dose CLT-008 (human myeloid progenitor cells)
89503193|NCT01297543|Experimental|Consolidation Group C|Intermediate dose CLT-008 (human myeloid progenitor cells), no G-CSF
89503194|NCT01297543|Experimental|Consolidation Group D|High dose CLT-008 (human myeloid progenitor cells)
89503195|NCT01297543|Active Comparator|Induction Group A1 (cytarabine 7+3)|G-CSF
89503196|NCT01297543|Experimental|Induction Group A2 (cytarabine 7+3)|Intermediate dose CLT-008 (human myeloid progenitor cells)
89503197|NCT01297543|Experimental|Induction Group A3 (cytarabine 7+3)|High dose CLT-008 (human myeloid progenitor cells)
89503198|NCT01297543|Active Comparator|Induction Group B1 (cytarabine HIDAC)|G-CSF
89503199|NCT01297543|Experimental|Induction Group B2 (cytarabine HIDAC)|Intermediate dose CLT-008 (human myeloid progenitor cells)
89503200|NCT01297543|Experimental|Induction Group B3 (cytarabine HIDAC)|High dose CLT-008 (human myeloid progenitor cells)
89503201|NCT04488068|Experimental|Magnetic Stimulation|Patients will be subjected to TPMS.
89503202|NCT04488068|No Intervention|Sham TPMS|Patients will be subjected to sham TPMS
89503203|NCT02154191|Experimental|Surgical Intervention Group|The Surgical Intervention Group will undergo the routine surgical procedures taken for patients requiring surgery for degenerative lumbar spinal stenosis.
89503204|NCT02154191|No Intervention|Non-Intervention Group (Control)|No Intervention.This group will consist of patients wait listed for surgery but further back in the queue.
89503205|NCT04439955|Experimental|CBD|At the end of the one month run-in period, all trial subjects will continue on individual Standard of case plus increasing doses of CBD during the first six weeks of the study. Dosage of CBD will start at 25 mg twice a day and will be increased once every 14 days, if no side effects are observed, to 50 mg twice a day, 100 mg twice a day and finally to 150 mg twice a day CBD respectively. Treatment will be given with food. If the 300 mg CBD dose level is deemed safe for two weeks patients will continue receiving 300 mg CBD +for an additional follow-up period of three months
88956731|NCT04224727|Experimental|Individual Commitment Contract + Information|Subjects are offered an individual commitment contract for smoking cessation or weight loss and receive additional information treatments.
88956732|NCT04224727|Experimental|Group Commitment Contract|Subjects are offered a group commitment contract for smoking cessation or weight loss and receive no additional information treatments.
88956733|NCT04224727|Experimental|Individual Monetary Rewards|Subjects are offered individual monetary rewards for smoking cessation or weight loss and receive no additional information treatments.
88956734|NCT04224727|Experimental|Individual Commitment Contract|Subjects are offered an individual commitment contract for smoking cessation or weight loss and receive no additional information treatments.
88956735|NCT04216329|Experimental|1/Experimental therapy|Selinexor with temozolomide and radiation
89538689|NCT04967859|Experimental|Group 2 (intervention)|Patient using 0.1% gentamicin ointment at the exit site of the hemodialysis catheter
89538690|NCT03261869|Experimental|Cold application|Cold applied after extraction of third molar tooth.
88956738|NCT04208113|Experimental|School teacher training /.b|"The intervention is a multi-level, multi-component complex intervention. It consists of a school teacher training programme and the .b-programme to be delivered to pupils 11-15 years in the schools.~The school teacher training programme consists of three parts: 1) the establishment of own mindfulness practice by participation in the eight week MBSR programme (2,5 hour group meeting once a week) and sustaining mindfulness with a regular formal daily practice; 2) completion of the four days .b residential course, and 3) completion of the 3x2-days seminars on relational competences and implementation issues regarding teaching .b (48 hours) The .b programme consists of well-described, weekly 40-60 minutes classroom sessions over 10 weeks. All the sessions have a specific theme, associated teachers' notes, power points and animations. The .b programme can only be delivered with fidelity by a trained .b teacher."
88956739|NCT04208113|No Intervention|Usual practice|Usual practice
88956740|NCT04199468|Experimental|Active Delta-9-THC and Placebo Ketamine|Active IV Delta-9-THC and Placebo Ketamine
88956741|NCT04199468|Experimental|Active Delta-9-THC and Active Ketamine|Active IV Delta-9-THC and Active Ketamine
88956742|NCT04199468|Experimental|Placebo Delta-9-THC and Placebo Ketamine|IV Placebo Delta-9-THC and Placebo Ketamine
88956743|NCT04199468|Experimental|Placebo Delta-9-THC and Active Ketamine|IV Placebo Delta-9-THC and Active Ketamine
88956744|NCT04195750|Experimental|Belzutifan|Participants receive 120 mg of belzutifan orally once daily (QD)
88956745|NCT04195750|Active Comparator|Everolimus|Participants receive 10 mg of Everolimus orally once daily (QD)
88956746|NCT04195347|Experimental|CM4620 Treatment|"Phase I:~Cohort 1 patients receive CM4620 IV at dose level 1 on days 1-4. Cohort 2 patients receive CM4620 IV at dose level 2 on days 1-4. Cohort 3 patients receive CM4620 IV at either dose level 1 or 2 on days 1-4~Phase II:~Patients will receive CM4620 IV on days 1-4 at the recommended Phase II dose (RP2D) as determined in Phase I."
88956747|NCT04183790|Experimental|Triple Combination Arm|Subjects will receive ELX/TEZ/IVA TC in the morning and IVA as mono tablet in the evening.
89206493|NCT00827970|Experimental|1 Screening|Individuals receiving an invitation to be tested for urogenital Chlamydia trachomatis by use of a home-obtained and mailed sample.
89206494|NCT00827970|No Intervention|2 Control|Control group receiving usual care
88956750|NCT04176497|Experimental|PMSA-PET/MRI|Patients scheduled to receive PMSA-PET/MRI scan in addition to standard of care CT scan prior to treatment
88956751|NCT04170244||Atopic Dermatitis|"Intervention is whatever Rx the URMC dermatologist thinks is best suited to the subject as part of real-world disease management in her clinic.~Ages:13-65 yrs of age, all genders, races and ethnicities~Additional 65+ age group, all genders, races and ethnicities"
88956752|NCT04170244||Healthy control|No intervention Ages:13-65 yrs of age, all genders, races and ethnicities
88956753|NCT04170244||Psoriasis|"Intervention is whatever Rx the URMC dermatologist thinks is best suited to the subject as part of real-world disease management in her clinic.~Ages:13-65 yrs of age, all genders, races and ethnicities"
88956754|NCT04157348|Experimental|Benralizumab arm|1x benralizumab SC injection + 3x placebo to mepolizumab SC injections
88956755|NCT04157348|Active Comparator|Mepolizumab arm|3x mepolizumab SC injections + 1x placebo to benralizumab SC injection
88956756|NCT04150029|Experimental|MBG453+Venetoclax +Azacitidine|Patients will receive MBG453 in combination with Venetoclax and Azacitidine
88956757|NCT04130997|Experimental|Ublituximab Infusions|"RMS301/RMS302: All participants transferring from RMS301/RMS302 who sign consent for this study will receive an initial 4-hour infusion of 150 mg ublituximab on Week 1 (Day 1) followed by a 1-hour infusion of 450 mg ublituximab 14 days later Week 3 (Day 15). Subsequent infusions of ublituximab will be administered at 450 mg for 1-hour every 24 weeks from Weeks 24 to 312.~RMS201E: All participants transferring from RMS201E who sign consent for this study will receive a 1-hour infusion of 450 mg ublituximab on Week 1 (Day 1) and subsequent infusions of ublituximab will be administered at 450 mg for 1-hour every 24 weeks from Weeks 24 to 312.~For all participants (RMS301/RMS302/RMS201E), infusion treatment will continue for 312 weeks, or until physician or participant decision to withdraw from the study."
88956758|NCT04122976||Men with nmCRPC|Men with nmCRPC for whom a decision to treat with darolutamide has been made before enrollment, and who have signed informed consent, will be eligible for the study.
88956759|NCT04106219|Experimental|LY3295668 Erbumine Escalation|LY3295668 Erbumine given orally.
89206495|NCT00828048||Pancreatic Cyst|Pancreatic Cyst
89206496|NCT00825708|Active Comparator|rTMS|rTMS session
89206497|NCT00825708|Sham Comparator|SHAM|sham session
89503206|NCT03113877||Clinical Testing for Autonomic Dysfunction|COMPASS-31 Survey completion. Autonomic Reflex Screen. Thermoregulatory Swear Test.
89206498|NCT00291577|Experimental|1|
89206499|NCT00520936|Experimental|Pemetrexed|
89206500|NCT02549430|Experimental|Arm A|Palbociclib monoterapy
89503207|NCT03541265|Experimental|Adductor block protocol|An ultrasound-guided injection of Subsartorial saphenous nerve using Exparel 266 mg (20 cc vial) via a 21-gauge 4-inch Stimuplex A needle (B. Braun Medical Inc., Melsungen, Germany) was performed at mid-thigh level with a high-frequency linear ultrasound transducer. All regional anesthesia was performed by a trained anesthesiologist. Ultrasound pictures (pre-injection and post-injection) was obtained to verify proper local anesthetic placement.
88956760|NCT04106219|Experimental|LY3295668 Erbumine + Topotecan + Cyclophosphamide Escalation|LY3295668 Erbumine given orally and topotecan and cyclophosphamide given intravenously (IV).
88956761|NCT04106219|Experimental|LY3295668 Erbumine Expansion|LY3295668 Erbumine given orally.
89503208|NCT03541265|Active Comparator|peri-articular injection|Peri-articular injection included combination of Exparel 266 mg (20 ml vial) with 20 ml of 0.5% bupivacaine, and normal saline to a total volume of 120 ml. The injection was meticulously administered prior and after cementation in the posterior capsule, posteromedial structures, the periarticular synovium, extensor apparatus, pes anserinus, anteromedial capsule, periosteum, iliotibial band, and subcutaneous plane. Injections were performed using 20-mL syringes with 22-gauge needle, minimal leakage. Visible tissue expansion was achieved.
89503209|NCT02547038|Experimental|pantoprazole+bismuth+tetra+metro|pantoprazole 40 mg twice daily, bismuth subcitrate 120 mg four times daily, and tetracycline 500 mg four times daily, and metronidazole 250 mg four times daily for 14 days
89503210|NCT02547038|Active Comparator|(panto+amox+clar+metr)+(panto+amox)|a 7-day quadruple regimen with pantoprazole 40 mg twice daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily, followed by a 7-day dual regimen with pantoprazole 40 mg twice daily and amoxicillin 1 g twice daily
89503211|NCT05620537||Gastrointestinal cancer patients cohort|
89503212|NCT02161055|Experimental|Strict control group|"Intensive insulin therapy: Keep Target blood glucose levels between 4.4-7.0 mmol/L;~Blood glucose levels were monitored and controlled using the Yale Insulin Infusion Protocol. Rapid blood glucose levels were monitored once every 2 hours."
89503213|NCT02161055|Experimental|Moderate control group|"Intensive insulin therapy: Keep target blood glucose levels between 7.1 and 10.0 mmol/L.~Blood glucose levels were monitored and controlled using the Yale Insulin Infusion Protocol. Rapid blood glucose levels were monitored once every 2 hours"
89503214|NCT02161055|Experimental|Slight control group|"Intensive insulin therapy: Keep target blood glucose levels between 10.1 and 13.0 mmol/L.~Blood glucose levels were monitored and controlled using the Yale Insulin Infusion Protocol. Rapid blood glucose levels were monitored once every 2 hours."
89503215|NCT02161055|Active Comparator|Non-intensive insulin therapy|Rapid blood glucose levels were measured once every 2 hours. When blood glucose levels were ≤ 13.0 mmol/L, no intervention was performed; When blood glucose levels were > 13.0 mmol/L, regular insulin was subcutaneously injected separately. During fasting, insulin was injected once every 8 hours. During venous or enteral nutrition infusion, insulin was infused at 30 minutes before nutrition infusion. When blood glucose levels were ≤ 13.0 mmol/L, insulin infusion was terminated.
89503216|NCT01131013|Experimental|Treatment Sequence 1|Dosing Period 1 - Placebo; Dosing Period 2 - 375 mg CK-2017357; Dosing Period 3 - 500 mg CK-2017357
89503217|NCT01131013|Experimental|Treatment Sequence 2|Dosing Period 1 - Placebo; Dosing Period 2 - 500 mg CK-2017357; Dosing Period 3 - 375 mg CK-2017357
89503218|NCT01131013|Experimental|Treatment Sequence 3|Dosing Period 1 - 375 mg CK-2017357; Dosing Period 2 - Placebo; Dosing Period 3 - 500 mg CK-2017357
89503219|NCT01131013|Experimental|Treatment Sequence 4|Dosing Period 1 - 375 mg CK-2017357; Dosing Period 2 - 500 mg CK-2017357; Dosing Period 3 - Placebo
89503220|NCT01131013|Experimental|Treatment Sequence 5|Dosing Period 1 - 500 mg CK-2017357; Dosing Period 2 - Placebo; Dosing Period 3 - 375 mg CK-2017357
89503221|NCT01131013|Experimental|Treatment Sequence 6|Dosing Period 1 - 500 mg CK-2017357; Dosing Period 2 - 375 mg CK-2017357; Dosing Period 3 - Placebo
89503222|NCT02764697|Other|H.P. Acthar Subcutaneous Gel Injection|For the current protocol we are proposing, 40 U/ml, given twice weekly x 8 weeks, followed by once weekly x 4 weeks: a total 20 doses, using the approved route, with the option to do 4 additional doses if resolution is incomplete.
89503223|NCT02266927|Active Comparator|Flovent® HFA 440µg|Flovent® HFA (fluticasone propionate) Inhalation Aerosol 440 µg
89503224|NCT02266927|Experimental|OPTINOSE™ FLUTICASONE 400µg intranasal|OPTINOSE™ FLUTICASONE, single dose of 400 µg intranasally
89503225|NCT02397668|Experimental|CorMatrix Cor TRICUSPID ECM Valve|Tricuspid valve replacement in patients for the surgical management of tricuspid valve disease, including tricuspid valve disease secondary to congenital heart disease. Enrollment will include up to 60 adults subjects and up to 18 pediatric subjects.
89503226|NCT02158481|Active Comparator|Dietary ingredients: polyphenols and carotenoids|Dietary ingredients: polyphenols and carotenoids
89503227|NCT02158481|Placebo Comparator|Placebo product|Placebo product
89503228|NCT02267005|Experimental|Treatment|patients on this arm will be treated with creapure supplements
89503229|NCT02267005|Placebo Comparator|Placebo|patients on this arm will be given a placebo glucose tablet supplement
89503230|NCT02158559|Experimental|Danhong Injection|Danhong injection 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 7 days;
89503231|NCT02158559|Placebo Comparator|Normal Saline|0.9% sodium chloride solution 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 7 days;
89503232|NCT02673489|Experimental|Daclatasvir (DCV) + Sofosbuvir (SOF) + Ribavirin (RBV)|Oral dosing of DCV 60 mg tablet once daily + SOF 400 mg tablet once daily + RBV 1000-1200 mg tablet per day (weight based) for 24 weeks.
89503233|NCT05445362|Active Comparator|Group I|Thirteen teeth were disinfected by triple antibiotic paste then revascularization was done using the standard method.
89503234|NCT05445362|Active Comparator|Group II|Thirteen teeth were Laser disinfected; revascularization was done using the standard method.
89206501|NCT02549430|Experimental|Arm B|Palbociclib + HT (Anastrozole, Letrozole, Exemestane, Fulvestrant)
89206502|NCT00828126||PET-CT Scan|
89206503|NCT00947037|Experimental|Extension|Open label extension, 1 arm
89206504|NCT03867760|Experimental|Intervention Group|Participants will use the recorded hypnosis intervention (RHI) at home for 28 days.
89206505|NCT03867760|Active Comparator|Attention Control Group|Participants will use a recorded relaxation intervention at home for 28 days.
89206506|NCT00943839|Experimental|SUVEGIL|
89503235|NCT05445362|Active Comparator|Group III|Thirteen teeth were disinfected by triple antibiotic paste then revascularization was done using the standard method followed by diode laser bio-stimulation.
89503236|NCT05611099|Experimental|Dreem + WatchPAT One|Single arm of 15 subjects wearing simultaneously the Dreem 3 + WatchPAT One devices for 3 nights, and then undergoing an end of study usability questionnaire.
89503237|NCT02772809|Other|Stroke survivors with low and moderate motor deficits|Subjects with low and moderate motor deficits will 1) complete exercises with 2 commercial (joystick and wheel) and the Theradrive haptic robot after pre assessment 2) then experience 12 therapy sessions on the Theradrive haptic robot with Adaptive Feedback. 3) Assessments pre and post therapy.
89503238|NCT01020565|Experimental|Entecavir (0.1 mg)|
89503239|NCT01020565|Experimental|Entecavir (0.5 mg)|
89503240|NCT05475938|Experimental|Analysis of painting|Pathologically confirmed children with malignant bone tumors, painting therapists to explain the requirements and purpose of painting. After the patient completes the painting, the therapist makes a targeted and individualized analysis and provides psychological counseling by reflecting the patient's psychological state through painting.
89503241|NCT05475938|Experimental|Psychological treatment|After the patient completes the painting, the therapist makes a targeted and individualized analysis and provides psychological counseling by reflecting the patient's psychological state through painting.
89503242|NCT01020097|Other|Arm I|Patients undergo fluorine F-18 EF5 positron emission tomography imaging. Scana are performed 180 minutes following injection.
89503243|NCT02154269|Experimental|G-CSF|Subjects will be randomly assigned to receive treatment with G-CSF (10mg/kg/day) for five days, during 4 cicles.
89503244|NCT02154269|Placebo Comparator|Saline|Subjects will be randomly assigned to receive saline for five days, during 4 cicles.
89503245|NCT01002235|Experimental|Cohort 1|Two divided doses of VM202 injected into the calf muscle on Day 0 and Day 14 for a total dose of 4 mg.
89503246|NCT01002235|Experimental|Cohort 2|Two divided doses of VM202 injected into the calf muscle on Day 0 and Day 14 for a total dose of 8mg.
89206507|NCT00832182|Experimental|Insulin aspart and neutral protamine Hagedorn insulin|
89503247|NCT01002235|Experimental|Cohort 3|Two divided doses of VM202 injected into the calf muscle on Day 0 and Day 14 for a total dose of 16mg.
89503248|NCT03541811||patients with hemophilia (16-45y)|not applicable (no intervention administered)
89503249|NCT03541811||peer-matched healthy control|not applicable (no intervention administered)
89503250|NCT04475965|Experimental|Group 1 20% maximal voluntary isometric contraction|Patients in group 1 received a five-series Isometric Contraction of shoulder external rotators at 20% of maximal voluntary isometric contraction. Each series of Isometric Contraction was done until exhaustion or up to a maximum of 5 minutes. Patients received five sessions of treatment during a two-week period.
89503251|NCT04475965|Active Comparator|Group 2 80% maximal voluntary isometric contraction|Patients in group 2 received a five-series Isometric Contraction of shoulder external rotators at 80% of maximal voluntary isometric contraction. Each series of Isometric Contraction was done until exhaustion or up to a maximum of 5 minutes. Patients received five sessions of treatment during a two-week period.
89503252|NCT04475887|Active Comparator|Group A|IV administration of iron-III-carboxymaltose according to iron deficit every 4 weeks.
89503253|NCT04475887|Placebo Comparator|Group B|IV administration of 1000ml 0.9% NaCl every 4 weeks.
89503254|NCT02537678|Experimental|Stepped Care TF-CBT|Stepped Care TF-CBT consist of two steps. Step One is a parent-led therapist-assisted treatment and Step Two is standard TF-CBT.
88956762|NCT04106219|Experimental|LY3295668 Erbumine + Topotecan + Cyclophosphamide Expansion|LY3295668 Erbumine given orally and topotecan and cyclophosphamide given IV.
88956763|NCT04094246|Experimental|Experimental Group|Participants in the experimental group will receive standard post-surgical rehabilitation protocol per their surgery in addition to Battlefield Acupuncture.
89206508|NCT05280171|Experimental|Teach back|Discharge information was explained by the principal investigator. It includes pictographs teach back regarding medication, exercise, diet and follow-up was given and they were asked teach back.
89206509|NCT05280171|Active Comparator|Standard of Care|Discharge information as per the standard existing routine. Than assessed the recall and patient engagement of CLD patients in general ward regarding discharge instructions by structure questionnaires for patients recall, and PAM for patient's
89206510|NCT04086316||Depression Group|Naturally cycling women with a major depressive episode, assessed by Structured Clinical Interview for DSM-5 (SCID Clinical Version)
89206511|NCT04086316||Healthy Group|Naturally cycling women without a major depressive episode, assessed by Structured Clinical Interview for DSM-5 (SCID Clinical Version)
89206512|NCT00952497|Experimental|Cisplatin, Capecitabine, Telatinib|
89206513|NCT04018716|Experimental|MTA|mineral trioxide aggregate
89206514|NCT04018716|Active Comparator|Dycal|calcium hydroxide cement
89206515|NCT00837408||Cases|Individuals with Type 2 Diabetes
89206516|NCT00837408||Controls|Individuals without Type 2 Diabetes
89503255|NCT02537678|Active Comparator|Standard TF-CBT|Standard TF-CBT consist of therapist-directly weekly in-office therapy based on the trauma-focused components of TF-CBT.
89503256|NCT02267239|Active Comparator|Essential Oils, immersion|Professional oral cleaning Plaster cast IDODS Immersion the disk with the biofilm in the essential oils antiseptic solution
89503257|NCT02267239|Active Comparator|Chlorhexidine, immersion|Professional oral cleaning Plaster cast IDODS Immersion the disk with the biofilm in the chlorhexidine antiseptic solution
89503258|NCT02267239|Other|baseline|Professional oral cleaning Plaster cast IDODS Disk in basal conditions.
89503259|NCT02267239|Active Comparator|Essential Oils, mouthwash|Professional oral cleaning Plaster cast IDODS Active mouthwash with the essential oils antiseptic solution
89206517|NCT00943995|Other|Treatment Arm|Getting Growth Hormone therapy TIW instead of nightly in the Pediatric Tanner 1 Hemodialysis population.
89206518|NCT00828282|Experimental|1|
89206519|NCT00952575|Active Comparator|polyclonal anti-D immunoglobulin|
89206520|NCT00952575|Experimental|Monoclonal anti-D immunoglobulin|
89206521|NCT04012125|Experimental|Prospective, single-arm trial|
89503260|NCT02267239|Active Comparator|Chlorhexidine, mouthwash|Professional oral cleaning Plaster cast IDODS Active mouthwash with the chlorhexidine antiseptic solution
89503261|NCT04408677|Experimental|Normative data|Ocular oxygen saturation non-invasively measured at 3 eye fundus locations in the participant's right eye
89503262|NCT04408677|Experimental|Repeatability|Ocular oxygen saturation non-invasively measured at 3 eye fundus locations in the participant's right eye. After a 15 to 30 minutes break, same measurements repeated.
89503263|NCT04408677|Experimental|Inter-eye variability|Ocular oxygen saturation non-invasively measured at 3 eye fundus locations in the participant's right eye. After a 15 to 30 minutes break, same measurements repeated in the left eye.
89503264|NCT02267395||(No-PRMSDs)|Group 1 : No Playing Related Musculoskeletal Injury
89503265|NCT02267395||(Yes-PRMSDs)|Group 2: Playing Related Musculoskeletal Injury
89503266|NCT02766023|Experimental|LACTIN-V|Subjects receive 5-day course of metronidazole gel 7.5 mg/gm daily applied vaginally. Subjects then receive LACTIN-V 2x10^9 cfu/dose applied vaginally for 5 days then twice weekly for 10 weeks. N=152
89503267|NCT02766023|Placebo Comparator|Placebo|Subjects receive 5-day course of metronidazole gel 7.5 mg/gm daily applied vaginally. Subjects then receive placebo applied vaginally for 5 days then twice weekly for 10 weeks. N=76
89503268|NCT04354935|Active Comparator|Method 1 ( iTBS)|target region: Dorsolateral Prefrontal left Fréquence : 50 Hz Intensity of the stimulation : 120% SM duration : 3 minutes Number of pulses : 600
89503269|NCT04354935|Active Comparator|Method 2 (French touch)|target region : dorsolateral prefrontal cortex right Frequency:1HZ Intensity:120% SM duration : 8 Min 30 Sec Number of plulses : 360
89503270|NCT04354935|Active Comparator|Method 3 (FDA)|target region: Dorsolateral Prefrontal left Fréquence : 10HZ Intensity of the stimulation : 120% SM duration : 37 minutes Number of pulses : 3000
89503271|NCT04354935|Active Comparator|Method 4 (ITBS VIIT)|target region: Dorsolateral Prefrontal left Fréquence : 50HZ Intensity of the stimulation : 90% SM Duration : 9 minutes Number of pulses : 1800
89503272|NCT04354935|Active Comparator|Method 5 (SNTm)|Target region: Dorsolateral Prefrontal left Fréquence : 50HZ Intensity of the stimulation : 90% SM Duration : 9 minutes Number of pulses : 1800
89503273|NCT04354935|Active Comparator|Method 6 (SNT)|Target region: Dorsolateral Prefrontal left Fréquence : 50HZ Intensity of the stimulation : 90% SM Duration : 9 minutes Number of pulses : 1800
89503274|NCT04354935|Active Comparator|Method 7 (DASH)|Target region: Dorsolateral Prefrontal left Fréquence : 10HZ Intensity of the stimulation : 120% SM Duration : 18.75 minutes Number of pulses : 3000
89503275|NCT05466500|Active Comparator|Ultrasound guided axillary block with intravenous dexamethasone|The probe will be placed parallel to the anterior axillary fold at the axilla to identify the axillary artery and to identify the hyperechoic median, ulnar, and radial nerves in relation to the axillary artery. The musculocutaneous nerve which supplies the skin of the lateral side of the forearm had to be blocked also. It is found between the biceps brachii and coracobrachialis muscles .The needle is inserted in-plane from the anterior aspect and directed toward the posterior aspect of the axillary artery. All four nerves in the axillary region will be blocked and use of intravenous dexamethasone as an adjuvant to bupivacaine for Post-operative analgesia following sensory blockade of the axillary brachial plexus in paediatrics undergoing below elbow orthopaedic surgeries.
89206522|NCT03865732|Placebo Comparator|Placebo|placebo suspension 3x's /day for 17 weeks
89206523|NCT03865732|Experimental|Ganaxolone|ganaxolone suspension (50 mg/ml) 3x's /day for 17 weeks
89206524|NCT00944151|Placebo Comparator|Single injection with Saline infused TAP catheter|Prior to surgery patient will receive single injection of 0.5% ropivacaine and a TAP catheter. Following surgery patient will be given normal saline in infusion pump, attached to catheter.
89206525|NCT00944151|Active Comparator|Single injection with Ropivicaine infused TAP catheter|Prior to surgery patient will receive single injection of 0.5% ropivacaine and a TAP catheter. Following surgery patient will be given 0.2% ropivicaine in infusion pump, attached to catheter
89206526|NCT00998452|No Intervention|MOVE!|Participants will receive the usual VA MOVE! Program. These elements include a baseline assessment, brief clinic counseling session about weight, printed targeted health information on weight management and behaviors, and opportunities to participate in group sessions at the VA site and telephone follow-up from MOVE! clinic staff.
89503276|NCT05466500|Placebo Comparator|Ultrasound guided axillary block|The probe will be placed parallel to the anterior axillary fold at the axilla to identify the axillary artery and to identifythe hyperechoic median, ulnar, and radial nervesin relation to the axillary artery. The musculocutaneous nerve which supplies the skin of the lateral side of the forearm had to be blocked also. It is found between the biceps brachii and coracobrachialis muscles .The needle is inserted in-plane from the anterior aspect and directed toward the posterior aspect of the axillary artery. All four nerves in the axillary region will be blocked
89503277|NCT05628493||The non-SALD group|The patient did not meet the SALD diagnosis during the study observation period. SALD was diagnosed when the level of serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥ 1000IU/L, or total bilirubin (TBIL) level >3mg/dL during hospitalization.
89503278|NCT05628493||The SALD group|The patient's maximum values of ALT, AST, or TBIL during hospitalization reached any of the SALD criteria.
89503279|NCT05675553|Experimental|robot-assisted rehabilitation intelligent treatment|Both groups will receive treatment as usual(TAU) provided by the clinical team, including medication, exercise, and psychotherapy. Robot-assisted intelligent rehabilitation treatment will be delivered to participants in the testing group through an addiction prevention and relapse intervention intelligent system.
89503280|NCT05675553|Other|treatment as usual|Participants in the treatment-as-usual group were offered standard treatment at the mental health hospitals, which consisted of group and/or individual therapy, as determined by the clinical team.
89503281|NCT04475107|Experimental|Arm A|Pyramax (Pyronaridine 180mg/ Artesunate 60mg)
89503282|NCT04475107|Placebo Comparator|Arm B|Placebo
88956764|NCT04094246|Active Comparator|Control Group|Participants in the control group will receive standard post-surgical rehabilitation protocol per their surgery.
88956765|NCT04085172|Experimental|Part A: Guanfacine hydrochloride (TAK-503)|Participants randomized to TAK-503 will receive initial dose of 1 milligram (mg), and up titrated with weekly incremental dose of 1 mg until an optimal dose is reached. Participants aged 6 to 12 years will receive a dose of 1 to 4 mg and aged 13 to 17 years will receive a dose of 5 to 7 mg TAK-503 oral tablet once daily (QD) for 18 weeks.
88956766|NCT04085172|Active Comparator|Part A: Atomoxetine hydrochloride|Participants who weigh less than (<) 70 kilograms (kg) at baseline will receive active Atomoxetine hydrochloride capsule orally at an initial dose of 0.5 milligram per kilogram (mg/kg) which may be increased to the target dose of 1.2 mg/kg oral capsule QD during the treatment of 18 weeks. Permitted doses of Atomoxetine hydrochloride capsule will be 10, 18, 25, 40, 60, and 80 mg QD. Participants who weigh >= 70 kg at baseline will receive Atomoxetine hydrochloride at an initial dose of 40 mg oral capsule QD which may be increased to 80 mg and then to 100 mg for 18 weeks. The total dose for participants who weigh >= 70 kg at baseline will not exceed 100 mg.
89503283|NCT02254967|Experimental|Fidaxomicin Extended Pulsed Regimen (EPFX)|Participants receive 200 mg fidaxomicin from day 1 to day 5 twice daily, followed by a 1-day gap (day 6) before starting alternate day dosing of 1 tablet of fidaxomicin 200 mg once daily from day 7 to day 25.
89503284|NCT02254967|Experimental|Vancomycin|Participants receive 125 mg vancomycin from day 1 to day 10, 4 times daily.
89503285|NCT05444036|Experimental|Ketamin-bupivacaine Group|in this method,30 patients which received 0.5 mg/kg of preservative free ketamine (i.e. 0.05ml/kg of 10mg/ml ketamine diluted up to 1ml in normal saline) plus1ml/kg of 0.25 % bupivacaine caudally, after induction of general anaesthesia
89503286|NCT05444036|Experimental|bupivacaine-saline Group|30 patients received 1ml/kg of 0.25 % bupivacaine plus 1ml of normal saline caudally of just after induction of general anaesthesia, just after induction of general anaesthesia
89503287|NCT04423640||COVID Patients|Diagnosed patients with COVID-19 by PCR
89503288|NCT05475860||Patients receiving cardiac implantable electronic device|Patients receiving cardiac implantable electronic device for any clinical indication
89206527|NCT00998452|Active Comparator|MOVE*VETS|Participants will receive the same MOVE! program as the control group plus 4 tailored newsletters on the study health behavior topics created from the baseline survey. Also 2-4 counseling calls from volunteer veteran peer counselors.
89503289|NCT02161367|Experimental|Simethicone, OVOL|Patients in the intervention arm will receive, in a blinded fashion, 160mg of simethicone orally four times a day for the first five postoperative days. Patients will be evaluated by a trained research assistant on a daily basis while in hospital. Passage of flatus, bowel movements, and postoperative pain will be evaluated at those visits. A two-week, and 30-day phone call to patients discharged from hospital will be done to assess for outcomes after discharge. Follow-up will end after the 30th postoperative day.
89503290|NCT02161367|Placebo Comparator|Oral Suspending Vehicle, Ora-Plus|Patients in the control arm will receive, in a blinded fashion, 160mg of the placebo orally four times a day for the first five postoperative days. The placebo will be prepared by pharmacy to be identical to the test drug formulation except for being pharmacologically inert. Patients will be evaluated by a trained research assistant on a daily basis while in hospital. Passage of flatus, bowel movements, and postoperative pain will be evaluated at those visits. A two-week, and 30-day phone call to patients discharged from hospital will be done to assess for outcomes after discharge. Follow-up will end after the 30th postoperative day.
89503291|NCT03542825|Active Comparator|Iron Sulphate|ferrous sulphate 150 mg iron capsule once daily for 3 consecutive months.
89503292|NCT03542825|Active Comparator|Amino acid Chelated|amino acid chelated iron capsule 15mg for 3 consecutive months.
89503293|NCT03542825|Active Comparator|Lactoferrin|lactoferrin 100 mg sachets once daily for 3 consecutive months.
89503294|NCT02161445||AHF group|patients with AHF diagnosed based on clinical, biological and echocardiographic findings. Two sub-groups of patients were identified within HF group: Patients with reduced (<45%) LVEF (HFrEF) and those with preserved (≥45%) LVEF (HFpEF).
89503295|NCT02161445||non AHF group|we included patients with acute dyspnea and for whom acute heart failure was excluded
89503296|NCT02764229|Experimental|LYC-30937-EC|LYC-30937-EC 25 mg by mouth once daily
89503297|NCT05628025||Trainees|Residents in urology or urologists with little LEP experience. Trainee group will be stratified by level of experience.
89503298|NCT05628025||Experts|Urologists with at least 5 years LEP experience.
89503299|NCT02537522|Experimental|Test/Control - Phase 1|Over visits 1 and 2, subject will wear Contact Lenses with 8.5 BC in right eye and Contact Lenses with 9.0 BC in left eye in a contralateral manner.
89503300|NCT02537522|Experimental|Control/Test - Phase 1|Over visits 1 and 2, subject will wear Contact Lenses with 9.0 BC in right eye and Contact Lenses with 8.5 BC in left eye in a contralateral manner.
89503301|NCT02537522|Experimental|Test/Control - Phase 2|During Phase 2, subjects will wear a pair of Contact Lenses with 9.0 BC at Period 1 and Contact Lenses with 8.5 BC at Period 2 in a bilateral manner.
89503302|NCT02537522|Experimental|Control/Test - Phase 2|During Phase 2, subjects will wear a pair of Contact Lenses with 8.5 BC at Period 1 and Contact Lenses with 9.0 BC at Period 2 in a bilateral manner.
89503303|NCT01001923|Experimental|REGN475/SAR164877|REGN475/SAR164877, single injection, dose depending on the participant's body weight
89503304|NCT01001923|Placebo Comparator|Placebo|Placebo (for REGN475/SAR164877), single injection
89503305|NCT02158637||Cancer patients receiving treatment|Patients receiving active treatment for cancer or initiating treatment for cancer in the next 7 days
89503306|NCT02158715||Smartphone positioning during Chest compression|
89538691|NCT03261869|No Intervention|No Cold application|Cold application is not advised after extraction of third molar tooth
89538692|NCT03256487|Experimental|Buprenorphine|"Patients will receive IV buprenorphine 0.3mg diluted to a volume of 10mL with NS in a plastic syringe administered over 3-5 minutes. At 20 minutes, the patient will be asked would you like more pain medication? If he/she answers yes, then he/she will receive a second dose of IV buprenorphine 0.3mg."
89023666|NCT04986891||subjects before first chemotherapy cycle with no neuropathy|at least 75 consecutive subjects sent for an evaluation before 1st chemotherapy cycle (TNSc score equal to 0 which means no neuropathy);
89206528|NCT00944307|Active Comparator|raltegravir alone|Subjects will receive a single dose of 400 mg raltegravir orally
89023667|NCT04986891||subjects with stable CIPN condition after chemotherapy completion|subjects sent for an evaluation due to stable CIPN condition (CIPN defined as TNSc > or = 1) after chemotherapy completion (at least 2 months off treatment).
89023668|NCT04982653|Experimental|Arm I (hepatectomy using small bites fascial closure)|Patients undergo hepatectomy as planned using small bites fascial method for abdominal wall closure.
89023669|NCT04982653|Active Comparator|Arm II (hepatectomy using conventional fascial method)|Patients undergo hepatectomy as planned using conventional fascial method for abdominal wall closure.
89503307|NCT02154503|Experimental|Microneedling|"By randomization, the side for treatment will be determined. Topical anaesthetic will be then placed onto the treatment area under occlusion for thirty minutes to one hour. This will then be removed with 70% alcohol. The area will be rolled with microneedles in two planes: coronally and sagitally. In each plane, five passes will be made. Patients will restart application of Minoxidil the following day to both sides of the lesion.~The same half of the scalp will be treated for the rest of the sessions, with topical anaesthetic applied by patient 30 minutes to an hour prior to start of treatment session. Patients will undergo microneedling on alternate weeks for a total of six treatments in 12 weeks. If there is >30% growth seen after six weeks, then the entire area will be treated."
89503308|NCT03897049|Experimental|TWC App|The intervention is a mobile app delivered sexual health promotion program designed specifically for transgender women. The mobile app will include more than 30 interactive activities including resource maps, PrEP and PEP content, and communication forums for connecting with other transgender women. The intervention/app is intended to be used regularly, approximately two times per week during the 90 day active participation period.
89206529|NCT00944307|Experimental|raltegravir plus antacid|Subjects will receive a single dose of 400mg raltegravir orally simultaneously with an antacid
89503309|NCT03897049|Active Comparator|General Health App|Participants will download a general health mobile app that contains sexual health information. The control mobile app is intended to be used regularly, approximately two times per week during the 90 day active participation period.
89503310|NCT01282255|Experimental|A|
89503311|NCT01282255|Placebo Comparator|B|
89503312|NCT02536976|Experimental|Active treatment|mirabegron
89503313|NCT02536976|Placebo Comparator|Placebo|Matching placebo
89503314|NCT02672553|Active Comparator|EDWARDS INTUITY|EDWARDS INTUITY Valve System, Model 8300A
89503315|NCT02672553|Active Comparator|Stented Aortic Bioprostheses|Stented Aortic Bioprostheses
89503316|NCT01281631|Experimental|Low dose NP001|Low drug dose
89503317|NCT01281631|Experimental|High dose NP001|High drug dose
89503318|NCT01281631|Placebo Comparator|Placebo|normal saline
89503319|NCT01270945|Experimental|CV-18C3 and standard of care|CV-18C3 and standard of care
89503320|NCT01270945|Active Comparator|standard of care|Percutaneous revascularization
89503321|NCT05526703|Experimental|Experimental Group|
89503322|NCT05526703|Active Comparator|Comparator Group|
89503323|NCT02267551|Other|Mimic dV-Trainer|
89503324|NCT02267551|Other|daVinci Skills Simulator|
89503325|NCT00992563|Experimental|AL-39324 Concentration Level A|AL-39324 ophthalmic suspension, single intravitreal injection
89503326|NCT00992563|Experimental|AL-39324 Concentration Level B|AL-39324 ophthalmic suspension, single intravitreal injection
89503327|NCT00992563|Experimental|AL-39324 Concentration Level C|AL-39324 ophthalmic suspension, single intravitreal injection
89503328|NCT00992563|Experimental|AL-39324 Concentration Level D|AL-39324 ophthalmic suspension, single intravitreal injection
89503329|NCT00992563|Experimental|AL-39324 Concentration Level E|AL-39324 ophthalmic suspension, single intravitreal injection
89503330|NCT00992563|Active Comparator|Lucentis|Ranibizumab 10 mg/mL solution, single intravitreal injection
89503331|NCT02267707|Experimental|Cohort 1 - Bilirubin level > 1.5 x ULN to 3 x ULN|4 dose levels may be given in this arm as follows: nab-paclitaxel 75 mg/m2; gemcitabine 600 mg/m2 nab-paclitaxel 100 mg/m2; gemcitabine 800 mg/m2 nab-paclitaxel 125 mg/m2; gemcitabine 800 mg/m2 nab-paclitaxel 125 mg/m2; gemcitabine 1000 mg/m2
89503332|NCT02267707|Experimental|Cohort 2 - Bilirubin level > 3 x ULN to 5 x ULN|6 dose levels may be given in this arm as follows: nab-paclitaxel 75 mg/m2 nab-paclitaxel 75 mg/m2; gemcitabine 600 mg/m2 nab-paclitaxel 100 mg/m2; gemcitabine 600 mg/m2 nab-paclitaxel 125 mg/m2; gemcitabine 600 mg/m2 nab-paclitaxel 125 mg/m2; gemcitabine 800 mg/m2 nab-paclitaxel 125 mg/m2; gemcitabine 1000 mg/m2
89023670|NCT04977154||Trainers|
89023671|NCT04973345|Experimental|Terbutaline Arm A|• Arm A: (n=6) IV bolus (0.25 mg) over 5 minutes SQ administration (0.25 mg) Participants in Part 1 Arms A and B (n=12) will be randomized to one of two treatment arms.No masking will be applied for Part 1 or for the SQ dosing in Part 2. All IV treatments in Part 2 will be masked, with exception to the unmasked study pharmacist, refer to the MOP for details.
89023672|NCT04973345|Experimental|Terbutaline Arm B|• Arm B: (n=6) SQ administration (0.25 mg) IV bolus (0.25 mg) over 5 minutes Participants in Part 1 Arms A and B (n=12) will be randomized to one of two treatment arms.No masking will be applied for Part 1 or for the SQ dosing in Part 2. All IV treatments in Part 2 will be masked, with exception to the unmasked study pharmacist, refer to the MOP for details.
89032885|NCT04691687|Placebo Comparator|IV Placebo Infusion|Patients in Group 2 received IV saline infusion (20-40 ml) concentrated by the pharmacist to minimize fluid intake.The infusions were continuous over 3 hours, biweekly over a one-month period.
89206530|NCT00520546|Experimental|1|Patients with prostate carcinoma confirmed by needle biopsy, age >50 years, planned radical prostatectomy with lymph-node dissection, fasting for >12 hours before FEC-PET and an interval between biopsy and PET >3 weeks.
89503333|NCT02267785|Experimental|Skill-Based Exercise|Participants assigned to this arm will complete the Skill-Based Exercise Intervention
89503334|NCT02267785|Experimental|Aerobic Exercise|Participants assigned to this arm will complete the Aerobic Exercise Intervention
89503335|NCT02267785|Experimental|Social Contact Group|Participants assigned to this arm will complete the Social Contact Intervention
89538693|NCT03256487|Active Comparator|Morphine|"Patients will receive IV morphine 0.1mg/kg (max dose 8mg) diluted to a volume of 10mL with NS in a plastic syringe administered over 3-5 minutes. At 20 minutes, the patient will be asked would you like more pain medication? If he/she answers yes, then he/she will receive a second dose of IV morphine 0.1mg/kg (max dose 8mg)."
89538694|NCT04968093|Other|Group sessions of mindfulness-based therapy|Education of patients followed by seven group sessions of mindfulness-based therapy
89538695|NCT03256331|Experimental|BEL-X-HG|3+3 dose escalation
89538696|NCT03256409|Experimental|Five Bar overdenture: BOD|Five systems titanium bar CARES® and synOcta® Straumann® Dental Implant System, Holding AG Inc., Basel, Switzerland (Bar overdenture: Group 1) For the manufacture of the overdentures it was used as material of choice Lucitone 199® (Dentsply International Inc. York, PA) and for the adaptation of the retention systems it was used Softreliner Tough Soft® Tocuyama Dental Corporation Inc., Japan. The working protocol for determining the BOD Ra and the adhesion of molds and yeasts and mesophyll aerobics was carried out entirely by an investigator. Patients were randomly assigned to group 1. The BOD were removed at 30 - 180 days for surface roughness evaluation (Ra:ųm) and the evaluation of the adhesion of mold and yeast and mesophyll aerobe (CFU/ml).
89538697|NCT03256409|Experimental|Five Ball Joint Overdenture: BJOD|Five systems ball joint Klockner® Implant System; Soadco Inc., Escaldes-Engordany, Andorra (Ball Joint Overdenture: Group 2) For the manufacture of the overdentures it was used as material of choice Lucitone 199® (Dentsply International Inc. York, PA) and for the adaptation of the retention systems it was used Softreliner Tough Soft® Tocuyama Dental Corporation Inc., Japan. The working protocol for determining the BJOD Ra and the adhesion of molds and yeasts and mesophyll aerobics was carried out entirely by an investigator. Patients were randomly assigned to group 2. The s BJOD were removed at 30 - 180 days for surface roughness evaluation (Ra:ųm) and the evaluation of the adhesion of mold and yeast and mesophyll aerobe (CFU/ml).
89538698|NCT03061227|Active Comparator|Intravenous glucagon|Low-dose glucagon infusion (0.5 pmol/min/kg body weight) over 150 minutes during a standardized 75 g oral glucose tolerance test
89538699|NCT03061227|Placebo Comparator|Intravenous saline|Saline infusion over 150 minutes during a standardized 75 g oral glucose tolerance test
89538700|NCT03261713|Experimental|Virtual Reality|Virtual reality training designed to train standing balance, reaching, stepping, gentle strengthening and aerobic conditioning.
89538701|NCT03261713|Active Comparator|Control|iPad apps designed to train memory, cognition, visual tracking and fine motor skills.
89538702|NCT04975659|Active Comparator|Nocebo|"We informed subjects in the N group a negative suggestion, using the following script: During the local anaesthetic injection, you are going to feel a sharp prick at your back; this is usually the painful part of the procedure"
89538703|NCT04975659|Placebo Comparator|Placebo|"We informed subjects in the P group a positive suggestion, using the following script: We will administer some local anaesthetic to numb your back; this will allow the procedure to be more comfortable and tolerable for you."
89538704|NCT04964349|Experimental|Intralesional cortisosteroid injection|Intralesional corticosteroid injection
89538705|NCT04964349|Experimental|jessener solution|topical jessener solution
89538706|NCT03256175|Experimental|Oxygen|Patient was give 15L/min of Oxygen via HFM 30 mins before and continue through out the procedure. 6 weeks post procedure, EST was arranged
89538707|NCT03256175|Placebo Comparator|Air|Patient was given Facemask without oxygen through out the procedure. 6 weeks post procedure, EST was arranged
89538708|NCT03060915|Other|Polysomnography and actigraphy|Polysomnography and actigraphy
89538709|NCT03261791|Experimental|Apatinib|Apatinib mesylate tablets 500 mg po qd.
88956767|NCT04085172|Placebo Comparator|Part A: Placebo|Participants aged 6 to 12 years will receive a dose of 1 to 4 mg tablet of placebo matched to TAK-503 and aged 13 to 17 years will receive a dose of 5 to 7 mg tablets of placebo matched to TAK-503 orally QD for 18 weeks. Participants who weigh < 70 kg at baseline will receive placebo matched to Atomoxetine hydrochloride oral capsule at an initial dose of 0.5 mg/kg which may be increased to the target dose of 1.2 mg/kg QD oral capsule during the treatment of 18 weeks. Permitted doses of placebo matched to Atomoxetine hydrochloride will be 10, 18, 25, 40, 60, and 80 mg QD and participants who weigh >= 70 kg will receive placebo matched to Atomoxetine hydrochloride at an initial dose of 40 mg QD capsule orally which may be increased to 80 mg and then to 100 mg.
88956768|NCT04085172|Experimental|Part B: Guanfacine hydrochloride (TAK-503)|Participants from Part A will roll over into Part B after 18 weeks and will receive TAK-503 at an initial dose of 1 mg, and up titrated with weekly incremental dose of 1 mg until an optimal dose is reached. Participants aged 6 to 12 years will receive a dose of 1 to 4 mg and aged 13 to 17 years will receive a dose of 5 to 7 mg TAK-503 oral tablet QD for 52 weeks of Part B.
88956769|NCT04084067|Experimental|Indocyanine green (ICG)|Participants will receive a single dose of 1.5 mg/kg of ICG intravenously over 15 minutes prior to surgery.
88956770|NCT04065399|Experimental|SNDX-5613|"Phase 1: Oral SNDX-5613; sequential cohorts of escalating dose levels of SNDX-5613 to identify the MTD and RP2D. Participants will be enrolled in 1 of 6 dose-escalation arms:~Arm A: Participants not receiving any strong CYP3A4 inhibitor/inducers or fluconazole~Arm B: Participants receiving any strong CYP3A4 inhibitors for antifungal prophylaxis~Arm C: Participants receiving SNDX-5613 and cobicistat~Arm D: Participants receiving fluconazole for antifungal prophylaxis~Arm E: Participants not receiving any weak, moderate, or strong CYP3A4 inhibitors/inducers~Arm F: Participants receiving isavuconazole for antifungal prophylaxis~Phase 2: Oral SNDX-5613; Following the determination of the RP2D in Phase 1, 3 indication-specific expansion cohorts will be enrolled as follows:~Cohort 2A: Participants with KMT2Ar ALL/MPAL~Cohort 2B: Participants with KMT2Ar AML~Cohort 2C: Participants with NPM1m AML"
88956771|NCT04047810|Experimental|Subjects with Advanced Chronic Obstructive Pulmonary Disease|Subjects diagnosed with severe or very severe COPD will be infused intravenously with Mesenchymal Stem Cells (MSC)
89206531|NCT00952887|Experimental|ACE-031|8 dosing groups
89206532|NCT00952887|Placebo Comparator|Placebo|
89206533|NCT00952965||blood pressure monitor|wrist circumference: 14cm-25cm
89538710|NCT04975113|Experimental|Exercise group|Patients were given a progressive neuromuscular exercise program that included stabilization of the knee and hip joint . Green color elastic band was used in resistant exercises. When subjects used the green color Thera-Band®, they started with an easy length and increased relative to the Omni Scale .
89538711|NCT04975113|Experimental|Exercise and Taping group|"Patients in this group received the same exercises given in the exercise group for 12 weeks. In addition to these exercises, mechanical correction tape (5cm, Kinesio Tex Gold®) was applied for the knee and foot."
89538712|NCT03256019|Active Comparator|DL user|Experienced emergency physicians who primarily used the direct laryngoscopy (DL) for endotracheal intubation during cardiopulmonary resuscitation.
89206534|NCT00952965||stethoscopy|wrist circumference: 14cm-25cm
89206535|NCT00555009|Experimental|Genotropin treatment arm|
89206536|NCT00555009|Placebo Comparator|Placebo|
89206537|NCT00998530||African American HIV+|African American women with HIV and infected with Trichomonas
88956772|NCT04038580|Sham Comparator|Prescribed Laminated Socket|In this arm, participants will wear their clinically prescribed laminated socket. This period is approximately 2 weeks.
88956773|NCT04038580|Experimental|Adjustable Sockets|In this condition, participants will be fitted with 3 different adjustable transfemoral sockets by a certified prosthetist. The order in which the sockets are fitted are randomized and the participant will spend approximately 4 weeks in each socket.
88956774|NCT04028947|No Intervention|Standard TKA|Subjects will have the standard procedure.
88956775|NCT04028947|Active Comparator|TKA with Neurectomy|Subjects will the nerve excised and protected with soft tissue.
88956776|NCT04025229|Experimental|HIIT exercise|Participants will perform HIIT exercises as instructed by the study team in the weeks prior to standard of care surgery
88956777|NCT04009005|No Intervention|Usual care|Participants will receive usual care from their treating neurologist
88956778|NCT04009005|Experimental|Therapeutic Lifestyle|Participants will be trained via videos from a three day in-person seminar that teaches the public about the use of a therapeutic diet and lifestyle to reduce multiple sclerosis related fatigue and improve quality of life.
89206538|NCT00998530||Caucasian HIV-|Caucasian women who are HIV negative and infected with Trichomonas
89206539|NCT00998530||African American HIV-|African American women who are HIV negative and are infected with Trichomonas
89206540|NCT04000516|No Intervention|Control|The control group was asked to continue their usual eating schedule and pattern.
89206541|NCT04000516|Experimental|Evening Fasters (EF)|Evening fasters were asked to not consume food after 3 pm until the next morning.
89206542|NCT04000516|Experimental|Morning Fasters (MF)|Morning fasters were asked to not consume food from the time they woke until 11 am.
89206543|NCT00944385|Experimental|ulinastatin|Administer with 30,000U /ulinastatin
89206544|NCT00944385|Placebo Comparator|C group|administer normal saline
89206545|NCT01529775|Experimental|Osseotite Certain Tapered Prevail|Osseotite Certain Tapered Prevail design with platform switching feature
89206546|NCT01529775|Active Comparator|Osseotite Certain Tapered|Osseotite Certain Tapered implant with non-platform switching design
88956779|NCT04005690|Experimental|Arm I (olaparib)|Patients receive olaparib PO BID on days 1-10 in the absence of disease progression or unacceptable toxicity. Within 12-24 hours, patients undergo biopsy or surgery.
89206547|NCT00953277|Experimental|Avance Nerve Graft|Processed Human Nerve Tissue Scaffold
88956780|NCT04005690|Experimental|Arm II (cobimetinib)|Patients receive cobimetinib PO QD on days 1-10 in the absence of disease progression or unacceptable toxicity. Within 12-24 hours, patients undergo biopsy or surgery.
88956781|NCT04005690|Experimental|Arm IV (onvansertib)|Patients receive onvansertib PO QD on days 1-10 in the absence of disease progression or unacceptable toxicity. Within 12-24 hours, patients undergo biopsy or surgery as clinically appropriate per institutional standards for management of patient's disease.
89206548|NCT00953355|Experimental|Folate|Folate plus metformin
89206549|NCT00953355|Placebo Comparator|Placebo|Placebo plus metformin
89206550|NCT00944463|Experimental|Gemcitabine+simvastatin|Gemcitabine and simvastatin
89206551|NCT00944463|Placebo Comparator|Gemcitabine+Placebo|Gemcitabine plus Placebo
89206552|NCT00956397|Active Comparator|Control Participants|
89206553|NCT00956397|Active Comparator|FD Participants|
89206554|NCT00956397|Placebo Comparator|FD (Placebo) Participants|
89206555|NCT00953433|Experimental|Endoflex tube|Use of Endoflex tube for intubation.
89206556|NCT00953433|Active Comparator|Endotracheal tube with stylet|Use of conventional endotracheal tube with a stylet for intubation.
89206557|NCT00953511|Other|genetic|
89206558|NCT00956553|Active Comparator|Cervarix|Three doses of Cervarix at month 0, 1 and 6. Blood sample at month 0, 2, 7 and 12. Optional vaginal sponge sample at month 7.
89206559|NCT00956553|Active Comparator|Gardasil|Three doses of Gardasil at month 0, 1 and 6. Blood sample at month 0, 2, 7 and 12. Optional vaginal sponge sample at month 7.
89206560|NCT00953589|Experimental|Locteron ® PANEL A|PANEL A: Locteron™ 480 µg dosed every 2 weeks in two subcutaneous injections (160 µg and 320 µg)
89206561|NCT00953589|Experimental|Locteron ® PANEL B|PANEL B: Locteron™ 480 µg dosed every two weeks in single subcutaneous injections
89206562|NCT00953589|Active Comparator|PEG-Intron® PANEL A|PEG-Intron® 1.5 µg/kg body weight weekly subcutaneous injection
89206563|NCT00953589|Active Comparator|PEG-Intron® PANEL B|PEG-Intron® 1.5 µg/kg body weight weekly subcutaneous injection
89206564|NCT04011501|Experimental|Continuous unilateral ESP block|Erector spine block and catheter placement will be performed for continuous analgesia on this group of patients undergoing minimally invasive cardiac surgery. Initially a volume of 20 ml of Levobupivacaine 0.25% will be administered and subsequently a 22G catheter will be introduced and fixed 10-12 cm from the skin. At the end of the surgery, an elastomeric pump will be installed at a flow rate of 7 ml / hr with a 1.3% Ropivacaine solution.
89206565|NCT00947739|Experimental|Cohort 1|80 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48)PO, DAILY
89206566|NCT00947739|Experimental|Cohort 2|160 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, DAILY
89206567|NCT00947739|Experimental|Cohort 3|320 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, DAILY
89206568|NCT00947739|Experimental|Cohort 4|640 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, DAILY
89206569|NCT00947739|Experimental|Cohort 5a|1280 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, DAILY
89206570|NCT00947739|Experimental|Cohort 6|2560 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, TID
89206571|NCT00947739|Experimental|Cohort 7|18 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, TID
89206572|NCT00947739|Experimental|Cohort 8|36 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, TID
89538713|NCT03256019|Active Comparator|VL user|Experienced emergency physicians who primarily used the videolaryngoscopy (VL) for endotracheal intubation during cardiopulmonary resuscitation.
89503336|NCT01373229|Experimental|Lenalidomide + Plerixafor+ Rituximab|"Lenalidomide 5mg by mouth (PO) daily beginning cycle 1 day 1.~Stage 1: increase by 2.5mg every 7 days to a maximum dose of 10mg.~Stage 2: plerixafor will be added after 28 days of 10mg dose maintenance and white blood cell count (WBC) <100.0 x 109 / L.~Dose cohorts of escalating subcutaneous (SC) thrice weekly plerixafor with continuous 10mg lenalidomide:~Cohort 1: 0.24 mg/kg~Cohort 2: 0.32 mg/kg~Cohort 3: 0.42 mg/kg~Cohort 4: 0.54 mg/kg~Stage 3: Rituximab 375mg/m2 will be added on day 1 of cycles 5-12, day 1 of combination therapy for subjects with PR.~Subjects will then continue single agent lenalidomide until disease progression."
89503337|NCT01112527|Experimental|Arm A|Patients with Glioblastoma that has returned or grown after chemotherapy or radiation treatment and who will be having a standard operation to remove the tumor.
88956782|NCT04005690|Experimental|Arm V (azenosertib)|Patients receive azenosertib PO QD on days 1-10 in the absence of disease progression or unacceptable toxicity. Within 12-24 hours, patients undergo biopsy or surgery as clinically appropriate per institutional standards for management of patient's disease.
88956783|NCT03988699|Experimental|Subject with severe tinnitus|Subjects diagnosed with severe tinnitus for at least six months, and it has not responded to conventional management will have surgical implantation of the device Tinnitus Implant System.
88956784|NCT03988595|Experimental|aerobic training 90 mins/wk|Exercise sessions will consist of individualized, walking delivered following a non-linear(i.e., exercise intensity is continually altered and progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period) dosing schedule up to 7 individual treatment sessions/wk for 6 months. Remote supervised exercise sessions will be implemented and monitored using TeleEx. General physical activity as well as exercise performed outside of the structured treatment sessions will be evaluated via continuous monitoring using MSK approved telemedicine / wireless technology.
88956785|NCT03988595|Experimental|aerobic training 150 mins/wk|Exercise sessions will consist of individualized, walking delivered following a non-linear(i.e., exercise intensity is continually altered and progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period) dosing schedule up to 7 individual treatment sessions/wk for 6 months. Remote supervised exercise sessions will be implemented and monitored using TeleEx. General physical activity as well as exercise performed outside of the structured treatment sessions will be evaluated via continuous monitoring using MSK approved telemedicine / wireless technology.
88982913|NCT02898207|Experimental|Dose Level 2a: Olaparib 200 mg and Onalespib 80 mg/m^2|Dose Level 2a (DL2a): Patients received olaparib 200 mg PO BID on days 1-7 (cycle 0). Beginning in cycle 1, patients received olaparib 200 mg PO BID on days 1-28 and onalespib 80 mg/m^2 IV over 1 hour on days 1, 2, 8, 9, 15, and 16. Cycles repeated every 28 days in the absence of disease progression or unacceptable toxicity.
89503338|NCT01112527|Experimental|Arm B|Participants with glioblastoma at first recurrence who are not surgical candidates and who have not had prior anti-VEGF therapy.
89503339|NCT01112527|Experimental|Arm C|Participants with glioblastoma who are not surgical candidates and who are at first recurrence from a therapeutic regimen containing bevacizumab.
89503340|NCT02267941||case|Diagnosis of aortic dissection was based on history and physical examination, and confirmed by imaging, visualization at surgery, and/or postmortem examination. According to the Stanford classification system, type A aortic dissection was defined as any dissection that involves the ascending aorta and type B as any that does not. Acute stage was confined to initial 14 days after symptom onset. Simple aortic aneurysm and pseudoaneurysm were excluded. Surgical and endovascular treatments were the main interventions and performed in the case group.
89503341|NCT02267941||control|As the control group, 2760 patients without AD were obtained from the hospitalized patients in the same period. Types of disease in the control group included congenital heart disease (632), coronary heart disease (467), adult valve disease (375), pulmonary artery hypertension (292), appendicitis (234), pneumonia (197), fracture (189), intestinal polyps (167), gallstone (156), esophagus cancer (51). Patients in the control group were derived from Department of Cardiovascular Surgery, Department of General Surgery, Department of Thoracic Surgery, and Department of Respiration, respectively.
89503342|NCT02671461|Experimental|BMS-986141 0.8mg|BMS-986141 0.8mg orally (tablets) and Aspirin (ASA) 75 to 162 mg orally (tablets)
89503343|NCT02671461|Experimental|BMS-986141 4.8mg|BMS-986141 4.8mg orally (tablets) and ASA 75 to 162 mg orally (tablets)
89503344|NCT02671461|Placebo Comparator|Placebo|Placebo orally (tablets) and ASA 75 to 162 mg orally (tablets)
89503345|NCT05467033|Experimental|Experimental|0,3ug/kg in 100ml 0,9% NaCl managed as intravenous infusion;
89503346|NCT05467033|Placebo Comparator|Placebo comparator|0,9% NaCl managed as intravenous infusion;
89503347|NCT04196283|Experimental|Arm 1: ABBV-368 + Tilsotolimod|Participants will be administered ABBV-368 and Tilsotolimod at various timepoints as described in the protocol.
89503348|NCT04196283|Experimental|Arm 2: ABBV-368 + Tilsotolimod + Nab-paclitaxel|Participants will be administered ABBV-368, Tilsotolimod and Nab-paclitaxel at various timepoints as described in the protocol.
89503349|NCT04196283|Experimental|Arm 3: ABBV-368 + Tilsotolimod + Nab-paclitaxel + ABBV-181|Participants will be administered ABBV-368, Tilsotolimod, Nab-paclitaxel and ABBV-181 at various timepoints as described in the protocol.
89503350|NCT02268019|Experimental|Hypospadiasis repair|
89503351|NCT02268097|Experimental|Freehand|Patellar resurfacing with freehand technique:Using freehand technique for patella preparation during total knee arthroplasty.
89503352|NCT02268097|Active Comparator|Resection guide|Patellar resurfacing with resection guide technique: Using patellar resection guide technique for patella preparation during total knee arthroplasty.
89538714|NCT04967625|Experimental|Sintilimab + Anlotinib|sintilimab 200mg, IV, d1, Q3W and anlotinib 12mg, PO, QD，d1-14, Q3W; treatment until disease progression, unacceptable toxicity, or death
89538715|NCT03261557|Experimental|CBT + SST|The treatment group will receive the intervention according to the CBSST protocol, adapted to adolescents.
89503353|NCT03114111|Active Comparator|Application of ALA|The treatment will consist of split-face comparisons of no application of aminolevulinic acid (ALA) vs ALA application to either half of the face. Prior to ALA application, the face will be swabbed for microbiome analysis. After the ALA application, the subjects will incubate with the ALA on their face per the standard PDT protocol used at UC Davis Dermatology clinic for facial PDT treatments. The side of the face being treated will remain the same during all treatments.
89503354|NCT03114111|Placebo Comparator|No Application of ALA|For the placebo, Demo Levulan Kerastick, which contains no active ingredient and is enclosed in same cardboard sleeve and cap, will be applied to the other side of the face to mimic the surface of the ALA application stick. After the placebo application, the subjects will incubate with the placebo on their face per the standard PDT protocol used at UC Davis Dermatology clinic for facial PDT treatments. The side of the face being treated will remain the same during all treatments.
89503355|NCT04475653|Active Comparator|Group coaching|Performing physical activities with Activity tracker, coaching included
89503356|NCT04475653|Active Comparator|Group Independant|Performing physical activities with Activity tracker, coaching NOT included
89503357|NCT04475653|Other|Controls|Controls from former study (see Study description)
89503358|NCT04475419|Active Comparator|Direct composite restorations|bulk-fill composite (Filtek BulkFlow, 3M Espe) will be used and covered using a nanohybrid composite, (Filtek XT, 3M Espe)
89503359|NCT04475419|Active Comparator|preformed metal crowns|preformed stainless steel crowns cemented by glass ionomer luting cement(Ketac Cem, 3M Espe)
89503360|NCT01110889|Experimental|AGO178C 0.5 mg /day|
89503361|NCT01110889|Experimental|AGO178C 1 mg / day|
89503362|NCT01110889|Placebo Comparator|Placebo|
89503363|NCT01108705|Experimental|Brivanib|
89503364|NCT01108705|Placebo Comparator|Placebo|
89503365|NCT01106989|Experimental|Heated lidocaine/tetracaine patch|Active
89503366|NCT00975091|Active Comparator|Entecavir 0.5|
89206573|NCT00947739|Experimental|Cohort 9|72 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, TID
89206574|NCT00947739|Experimental|Cohort 10|144 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, TID
89206575|NCT00947739|Experimental|Cohort 11|288 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, TID
88956786|NCT03988595|Experimental|aerobic training 225 mins/wk|Exercise sessions will consist of individualized, walking delivered following a non-linear(i.e., exercise intensity is continually altered and progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period) dosing schedule up to 7 individual treatment sessions/wk for 6 months. Remote supervised exercise sessions will be implemented and monitored using TeleEx. General physical activity as well as exercise performed outside of the structured treatment sessions will be evaluated via continuous monitoring using MSK approved telemedicine / wireless technology.
88956787|NCT03988595|Experimental|aerobic training 300 mins/week|Exercise sessions will consist of individualized, walking delivered following a non-linear(i.e., exercise intensity is continually altered and progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period) dosing schedule up to 7 individual treatment sessions/wk for 6 months. Remote supervised exercise sessions will be implemented and monitored using TeleEx. General physical activity as well as exercise performed outside of the structured treatment sessions will be evaluated via continuous monitoring using MSK approved telemedicine / wireless technology.
88956788|NCT03988595|Experimental|aerobic training 375 mins/week|Exercise sessions will consist of individualized, walking delivered following a non-linear(i.e., exercise intensity is continually altered and progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period) dosing schedule up to 7 individual treatment sessions/wk for 6 months. Remote supervised exercise sessions will be implemented and monitored using TeleEx. General physical activity as well as exercise performed outside of the structured treatment sessions will be evaluated via continuous monitoring using MSK approved telemedicine / wireless technology.
88956789|NCT03930953|Experimental|Part A: Dose Escalation|
88956790|NCT03930953|Experimental|Part B: Dose Expansion|
89503367|NCT00975091|Active Comparator|Entecavir 1.0|
89206576|NCT00947739|Experimental|Cohort 12|576 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, TID
89206577|NCT00947739|Experimental|Cohort 13|750mg/m2 PO Camptothecin-20-O-Propionate Hydrate (CZ48) PO, TID
89206578|NCT00947739|Experimental|Cohort 14|1000mg/m2 PO Camptothecin-20-O-Propionate Hydrate (CZ48) PO, TID
89206579|NCT00947739|Experimental|Cohort 5b|1280 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, TID
89206580|NCT00956787|Experimental|Treatment with AR-67|Patients will receive AR-67 at an initial dose of 7.5 mg/m2 IV over 1 hour daily for 5 days.
89206581|NCT00947817|Experimental|patient|
89206582|NCT00947817|Other|control|
89206583|NCT00947895|Active Comparator|Methylprednisolone|Intravenous (IV) methylprednisolone (Solumedrol) 1000 mg daily for 3 days.
89206584|NCT00947895|Active Comparator|ACTH|Intramuscular (IM) ACTH 80 mg/day for 5 days.
89503368|NCT05627401||Single Group Assignment|patients with sight-threatening Graves orbitopathy (GO) who underwent customized/individual multiple orbital wall decompression plus fat removal
89503369|NCT02535416|Experimental|ARC-520 Cohort 1|Single dose, intravenous administration of ARC-520 at 4.0 mg/kg 0.6 mL/min + cetirizine
89503370|NCT02535416|Experimental|ARC-520 Cohort 2A|Single dose, intravenous administration of ARC-520 at 4.0 mg/kg 0.9 mL/min + cetirizine
89503371|NCT02535416|Experimental|ARC-520 Cohort 2|Single dose, intravenous administration of ARC-520 at 4.0 mg/kg 0.75 mL/min + diphenhydramine
89503372|NCT02535416|Experimental|ARC-520 Cohort 3|Single dose, intravenous administration of ARC-520 at 4.0 mg/kg 0.9 mL/min + diphenhydramine
89503373|NCT02535416|Experimental|ARC-520 Cohort 4|Single dose, intravenous administration of ARC-520 at 4.0 mg/kg 1.2 mL/min + diphenhydramine
89503374|NCT02535416|Experimental|ARC-520 Cohort 5|Single dose, intravenous administration of ARC-520 at 4.0 mg/kg 1.5 mL/min + diphenhydramine
89503375|NCT02535416|Experimental|ARC-520 Cohort 6|Single dose, intravenous administration of ARC-520 at 4.0 mg/kg 5 minute slow bolus push + diphenhydramine
89503376|NCT02535416|Experimental|ARC-520 Cohort 7|Single dose, intravenous administration of ARC-520 at 5.0 mg/kg 0.9 mL/min + diphenhydramine
89503377|NCT02535416|Experimental|ARC-520 Cohort 8|Single dose, intravenous administration of ARC-520 at 6.0 mg/kg 0.9 mL/min + diphenhydramine
89538716|NCT03261557|Active Comparator|Psychoeducation, habits and healthy lifestyle|The control group will receive 3 modules intervention: psychoeducation, habits and healthy lifestyle.
89503378|NCT00912691|Experimental|1|CM-AT
89503379|NCT00911443|Experimental|Dacarbazine + Interferon alpha + thymosin-alpha-1 1.6 mg|Dacarbazine 800 mg/m2 IV on day 1; Interferon alpha 3MIU SC on day 11 and 18; Thymosin-alpha-1 1.6 mg SC from day 8 to 11 and from day 15 to 18 of each 28 day cycle up to 6 cycles or until progression or unacceptable toxicity develops.
89503380|NCT00911443|Experimental|Dacarbazine + Interferon alpha + Thymosin-alpha-1 3.2 mg|Dacarbazine 800 mg/m2 IV on day 1; Interferon alpha 3MIU SC on day 11 and 18; Thymosin-alpha-1 3.2 mg SC from day 8 to 11 and from day 15 to 18 of each 28 day cycle up to 6 cycles or until progression or unacceptable toxicity develops.
89503381|NCT00911443|Experimental|Dacarbazine + Interferon alpha + Thymosin-alpha-1 6.4 mg|Dacarbazine 800 mg/m2 IV on day 1; Interferon alpha 3MIU SC on day 11 and 18; Thymosin-alpha-1 6.4 mg SC from day 8 to 11 and from day 15 to 18 of each 28 day cycle up to 6 cycles or until progression or unacceptable toxicity develops.
89503382|NCT00911443|Experimental|Dacarbazine + Thymosin-alpha-1 3.2 mg|Dacarbazine 800 mg/m2 IV on day 1; Thymosin-alpha-1 3.2 mg SC from day 8 to 11 and from day 15 to 18 of each 28 day cycle up to 6 cycles or until progression or unacceptable toxicity develops.
89503383|NCT00911443|Active Comparator|Dacarbazine + Interferon alpha|Dacarbazine 800 mg/m2 IV on day 1; Interferon alpha 3MIU SC on day 11 and 18 of each 28 day cycle up to 6 cycles or until progression or unacceptable toxicity develops.
89503384|NCT03949478|Placebo Comparator|Placebo|Patients will receive placebo for at least five days prior to the first blood flow study. They will continue to receive placebo until the baseline study is obtained after the postictal study has been completed.
89503385|NCT03949478|Experimental|Ibuprofen|Patients will receive ibuprofen 400 mg by mouth three times a day (po tid) for at least five days prior to the first blood flow study. They will continue to receive ibuprofen until the baseline study is obtained after the postictal study has been completed.
89503386|NCT03949478|Experimental|Nifedipine|Patients will receive nifedipine 10 mg po tid for 2 days, then 20 mg po tid, thereafter for at least five days prior to the first blood flow study. They will continue to receive nifedipine until the baseline study is obtained after the postictal study has been completed.
89503387|NCT03856411|Experimental|Group TORIPALIMAB combined with standard chemotherapy|
89503388|NCT03856411|Placebo Comparator|Group Placebo combined with standard chemotherapy|
89503389|NCT00973141|Experimental|JNJ-42160443 1mg every 4 weeks|
89503390|NCT00973141|Experimental|JNJ-42160443 3mg every 4 weeks|
89503391|NCT00973141|Experimental|JNJ-42160443 3mg every 8 weeks|
89503392|NCT00973141|Experimental|JNJ-42160443 6mg every 8 weeks|
89503393|NCT00973141|Experimental|JNJ-42160443 10mg every 8 weeks|
89503394|NCT00973141|Placebo Comparator|Matching placebo every 4 or 8 weeks|
89503395|NCT00909649|Active Comparator|1 fibrin glue|8 ml of fibrin glue was sprayed on the surgical area with Y canula ( doubleject application system).One milliliter of fibrin glue contains 70-100 mg. fibrinogen, 10-50 u factor 8 aprotinin 3000k iu/ml, 2-9 mg fibronectin,40-120 ug plasminogen ,4 Iu/ml thrombin, 40 mmol cocl2/L (immuno AG/austrial)
89210460|NCT00904644||Salvage group|In this group patients are enrolled that have failed previous antiretroviral drug regimens and qualify for Raltegravir treatment according to the approved indication of this drug in Switzerland.
89210461|NCT00904644||Switch group|In this group, patients are enrolled which have to switch to Raltegravir due to drug toxicity or adverse events caused by other antiretroviral drugs.
89538717|NCT04975035|Experimental|Zolodine group|
89503396|NCT00909649|No Intervention|2 non fibrin glue|after good haemostasis the same sized drain was applied in axillary and breast area and incision was closed. Followed by external compression for 10 minutes in both groups. Drains were left in places until the drainage for the preceding 24 h was less than 20 ml.
89503397|NCT00971035|Experimental|A|
89503398|NCT00971035|Experimental|B|
89503399|NCT00971035|Experimental|C|
89503400|NCT00971035|Placebo Comparator|D|
89503401|NCT04787965||ONGENTYS|Opicapone 50 mg capsule once daily for 6 months
89503402|NCT00968851|Active Comparator|EVP-6124 0.3 mg|one 0.3 mg capsule every day for 84 days
89503403|NCT00968851|Active Comparator|EVP-6124 1.0 mg|one 1.0 mg capsule every day for 84 days.
89503404|NCT00968851|Placebo Comparator|Placebo|Placebo every day for 84 days
89503405|NCT02670915|Experimental|Meal-time faster-acting insulin aspart and insulin degludec|
89503406|NCT02670915|Active Comparator|Meal-time NovoRapid® (insulin aspart) and insulin degludec|
89503407|NCT02670915|Experimental|Post-meal faster-acting insulin aspart and insulin degludec|
89503408|NCT05382793|Experimental|Lactating women with assumed adequate habitual iodine intake|Women who consumed iodine-containing dietary supplements during pregnancy (≥150 μg/day). Women in this group will receive a daily oral iodine supplement providing 150 μg iodine as potassium iodide for 14 days before the study start.
89503409|NCT05382793|Experimental|Lactating mothers with assumed inadequate habitual iodine intake|Women who did not consume iodine-containing dietary supplements during pregnancy (≥150 μg/day).
89503410|NCT00907387|Active Comparator|Dose A|Dose A RT001
88956800|NCT03894215|Experimental|AGEN2034 + Placebo|AGEN2034 administered with placebo monotherapy: approximately 100 patients.
88956801|NCT03894215|Experimental|AGEN2034 + AGEN1884|AGEN2034 administered in combination with AGEN1884 (combination therapy): approximately 100 patients.
88956802|NCT03885908|Active Comparator|In-person geriatric co-management group|"In-person geriatric consults to be done via telemedicine due to the current pandemic and consideration for patient safety."
88956803|NCT03885908|Experimental|Automated geriatric co-management program group|
88956804|NCT03876769|Experimental|Single dose of CTL019|"Based on the subject's weight one of two possible dose ranges will be prepared for the subject:~Subjects ≤ 50 kg: 0.2 to 5.0 x 10(6) CAR-positive viable T cells per kg body weight~OR~Subjects > 50 kg: 0.1 to 2.5 x 10(8) CAR-positive viable T cells"
88956805|NCT03861975|Experimental|Breast Cancer-Related Lymphedema Measurements|Absolute volume of the upper extremities will be assessed using the LymphaTech Scanner and the Perometer.
88956806|NCT03858777|Active Comparator|Sarcoidosis patients without evidence of active myocarditis|A single blood draw.
88956807|NCT03858777|Experimental|Sarcoidosis patients with evidence of active myocarditis|Two blood draws 2 months apart.
88956808|NCT03858777|Active Comparator|Acute ST elevation myocardial infarction (STEMI)|Three blood draws, baseline, 6 hours and 24 hours.
88956809|NCT03858777|Placebo Comparator|Healthy controls|A single blood draw
88956810|NCT03830229||1/Germline positive mesothelioma|Individuals with mesothelioma who have a BAP1 or other DNA repair/cancer predisposition mutation regardless of CLIA confirmation
89503411|NCT00907387|Active Comparator|Dose B|Dose B RT001
89503412|NCT00907387|Placebo Comparator|Dose C|Dose C Placebo
89503413|NCT04474561|Other|Reduced sulfur diet intervention (INT)|"The INT group will receive conventional management plus a reduced sulfur diet and diet counselling by an RD. Implementation of the diet will be delivered directly by the RD and will provide each patient with an individualized plan. A reduced sulfur diet includes reducing foods, additives and beverages high in sulfate/sulfur.~The reduced sulfur diet eating plan, resources on reduced sulfur eating, and RD counselling session will be designed and reviewed by experts in nutrition, dietary design, education resources and dietary behaviour change"
89503414|NCT04474561|No Intervention|Conventional management (CM)|The CM group will receive one session with RD on reduced sulfur diet at the end of 8 weeks.CM groups will receive conventional management .
89503415|NCT00821977|Experimental|Vildagliptin Dose 1|
89503416|NCT00821977|Experimental|Vildagliptin Dose 2|
89503417|NCT00821977|Placebo Comparator|Placebo|
89503418|NCT03114267||Patient with chronic lymphocytic thyroiditis|
89503419|NCT03114267||Healthy subjects|
89503420|NCT04474327|Experimental|Intervention group|"The intervention group will receive Montelukast Sodium for 10 days in addition to the conventional antibiotic therapy regimen and other supportive measures according to the policy of neonatal units and patients' needs. Montelukast sodium will be given at a dose according to body weight (1.5 kg to 2 kg, will be given 1.5 mg; greater than 2 kg, 2 mg will be given) this dose was calculated according to ( Kim et al. (2015). Four mg of the drug will be dissolved in four ml milk and 1.5 - 2 ml milk only will be given once daily at 9 pm via an orogastric tube or by oral administration for 10 days and patients of this group will be closely observed for development of Montelukast side effects as diarrhea, colic, vomiting, fever and cough (Adelsberg et al. 2005)."
89503421|NCT04474327|No Intervention|Control group|The control group will receive antibiotics and other supportive measures according to the policy of neonatal units and patients' needs.
89503422|NCT05376787||Healthy Subjects|Subjects must be 18 years old or over, willing to shave or have shaved the sites where the neutral electrodes will be placed. Subjects also must not be pregnant, breastfeeding, have skin conditions (such as eczema, sensitivities, allergies to adhesives, sunburn).
89503423|NCT02764151|Experimental|PF-06840003|Daily Oral PF-06840003
89503424|NCT05375773|No Intervention|Control group|Participants in the Control group accept standard treatment for the management of their symptoms according to the diagnosis and treatment for novel coronavirus pneumonia (Trial Nine Edition).
89503425|NCT05375773|Experimental|PVP-I Nasal Irrigation and gargling|Participants in the intervention arm will be required to perform Nasal Irrigation and gargling 4 times daily. They will also accept standard treatment for the management of their symptoms according to the diagnosis and treatment for novel coronavirus pneumonia (Trial Nine Edition).
89503426|NCT00961675|Active Comparator|FST201|
89210462|NCT02539836|Experimental|Obesity with dietary nutrition|Obese children will be intervented by dietary nutrition based on plant fermentation extract for 2 months.
89503427|NCT00961675|Active Comparator|Ciprodex|
89503428|NCT00819169|Experimental|Part 1 Cohort 3|AMG 479 18 mg/kg IV plus AMG 655 15 mg/kg IV (day 1 of each Q3W cycle)
89503429|NCT00819169|Experimental|Part 1 Cohort 1|AMG 479 18 mg/kg IV plus AMG 655 1 mg/kg IV (day 1 of each Q3W cycle)
89503430|NCT00819169|Experimental|Part 1 Cohort 2|AMG 479 18 mg/kg IV plus AMG 655 3 mg/kg IV (day 1 of each Q3W cycle)
89503431|NCT00819169|Experimental|Part 2|AMG 479 18 mg/kg IV plus AMG 655 15 mg/kg Q3W, or the MTD, as determined in Part 1 of the study
89503432|NCT05442086|Experimental|Music and Theta Auditory Beat Stimulation|Behavioural: Listening to calm music and auditory beat stimulation Participants will listen to calm music with theta auditory beat stimulation for 24 minutes
89503433|NCT05442086|Sham Comparator|Pink Noise (control)|Behavioural: Listening to pink noise Participants listened to pink noise for 24 minutes
89503434|NCT02161601|Experimental|Correctly and incorrectly applied cricoid pressure|
89503435|NCT05221723|Experimental|Exercise Group|In this single group design, all participants will be provided with 6 months of twice weekly supervised group exercise.
89503436|NCT02161679|Experimental|IMMU-132|IMMU-132 infusion is administered
89503437|NCT02161679|Active Comparator|IMMU-132 plus Carboplatin|IMMU-132 infusion and Carboplatin infusion are administered to the participants in this arm of study.
89503438|NCT03541109|Experimental|Polypill|Polypill group will receive a fixed dose combinations of aspirin (81mg), atorvastatin (40mg), metoprolol (50 mg), and Valsartan (40 mg), prescribed once daily by moth for 34 months
89503439|NCT03541109|No Intervention|Control|The usual care arm will receive regular drug order at the time of discharge from the hospital.
89503440|NCT02545322|Experimental|Adaptive Radiotherapy|"Follow-up CT scans during week 3 and week 5 of Treatment~Image-guided adaptive Radiotherapy arm:~Follow-up CT scans are performed on a conventional CT-simulator. Deformable Image Registration between the planning-CT and the follow-up CT (fCT) is done using a dedicated Software package. Delineations for target volumes and organs at risk are transferred to the fCT based on the Deformation vector fields calculated during deformable Image registration. Volumetric changes in target volumes and organs-at-risk are assessed. The initial treatment plan is transferred to the fCT scan. Dosimetric consequences of morphologic changes are analysed with the Focus on target dose coverage for the planning target volume. Adaption and plan re-optimisation are performed."
89503441|NCT05675397|Experimental|MOM supplemented with PDM (group A)|VLBW Infants fed with mother's own milk (MOM) supplemented with preterm donor milk (PDM)
89503442|NCT05675397|Active Comparator|MOM supplemented with TDM (group B)|VLBW infants fed with mother's own milk (MOM) supplemented with term donor milk (TDM)
89210463|NCT02539836|Active Comparator|Liver fat of obese children|To investigate the accuracy of MRI in quantifying liver fat with magnetic resonance spectroscopy (MRS) as a reference.
89503443|NCT00955981|Experimental|RDEA594 200 mg qd for 28 days|
89503444|NCT00955981|Experimental|RDEA594 200 mg, 400 mg|RDEA594 200 mg qd for 7 days followed by 400 mg qd for 21 days
89503445|NCT00955981|Experimental|RDEA594 200 mg, 400 mg and 600 mg|RDEA594 200 mg qd for 7 days followed by 400 mg qd for 7 days followed by 600 mg qd for 14 days
89503446|NCT00955981|Placebo Comparator|Matching placebo|RDEA594 matching placebo qd for 28 days
89503447|NCT02154659|Other|postprandial reflux group|Esophageal pH monitoring is the current gold standard for diagnosis of gastroesophageal reflux disease. It provides direct physiologic measurement of acid in the esophagus and is the most objective method to document reflux disease, assess the severity of the disease and monitor the reflux acidity.
89503448|NCT02154659|Other|normal group|Esophageal pH monitoring is the current gold standard for diagnosis of gastroesophageal reflux disease. It provides direct physiologic measurement of acid in the esophagus and is the most objective method to document reflux disease, assess the severity of the disease and monitor the reflux acidity.
89503449|NCT04439721|Experimental|γδT|γδT,Infusion,iv,0.5×10^6-8×10^7γδT /kg,once.
89503450|NCT03541031|Experimental|Micronutrient & Fish oil|Fish oil capsule by mouth 3 capsules daily, remaining constant throughout the study and Micronutrient capsule by mouth beginning with a fixed schedule of 2 capsules twice daily and increasing monthly by 2 capsules twice daily up to a maximum of 16 capsules/day.
89503451|NCT03541031|Placebo Comparator|Olive oil & Safflower oil|Safflower oil capsule by mouth 3 capsules daily, remaining constant throughout the study and Olive oil capsule by mouth beginning with a fixed schedule of 2 capsules twice daily and increasing monthly by 2 capsules twice daily up to a maximum of 16 capsules/day.
89538718|NCT04964271||Low risk prostate cancer patients|Prostate cancer risk category is based on the definition of the European Association of Urology, namely low risk (PSA (prostate-specific antigen) <10 ng/ml, and stage T1/T2a and Gleason score 3+3).
89503452|NCT05433350|Experimental|Acoziborole|"Single dose administration~Two different formulations will be used depending on the body weight and on the step of the study:~Tablets of 320 mg dose for paediatric patients weighing 30 to 40 kg in step 1.~Granules in bottle for paediatric patients weighing 10 to 40 kg in step 2. Granules will be packed in bottles of 160 mg dose.~Initially, recruitment will be limited to paediatric patients weighing 30 to 40 kg who will receive the 320 mg tablet formulation.~Once the PK data from the first six patients have been analysed and the dosing regimen confirmed or adapted, inclusion will resume and be extended to allow enrolment of paediatric patients weighing >10 kg with the granule formulation (including for paediatric patients weighing 30 to 40 kg)."
89503453|NCT04982003|Experimental|Single Group|A single group of subjects with pretest, posttest, and one-month follow-up testing relative to 10-week drumming exercise classes
89210464|NCT04034628||Laparoscopic insertion|Individuals who undergo laparoscopic PD catheter insertion
89210465|NCT04034628||Percutaneous insertion|Individuals who undergo percutaneous PD catheter insertion by either a nephrologist or radiologist.
89503454|NCT05675241||Functional Dental Implant|An implant restored with a prothesis and in function for a minimum of one year.
89503455|NCT05465018|Experimental|Healthy volunteers|1 arm. Healthy volunteers assigned to different interventions
89503456|NCT02161835|Experimental|Training|Participants exercise 3 times a week, 30 minute, on an ergometer bike.
89503457|NCT02161835|No Intervention|Control|Participants is tested with the 4 objective myotonia test and measurements of self-assessed myotonia by the Myotonia Behavior Scale is collected.
89503458|NCT04739527|Experimental|Treatment arm|Patients receiving 4 bi-weekly vaccinations with 25E6 cells/vaccination of DCP-001, and 2 booster vaccinations with 10E6 cells/vaccination
89503459|NCT02154737|Experimental|erlotinib and gemcitabine|"Erlotinib will be administered orally on Days 2-4 and Days 16-18 of a 28-day cycle in serial cohorts with doses of 750mg, 1000mg, 1250mg, 1500mg, 1750mg, and 2000mg~Gemcitabine will be administered intravenously at 1000 mg/m2 on Days 1, 8, and 15 of a 28-day cycle."
89503460|NCT04474171|Experimental|SCI&U Intervention|The SCI&U online platform has a resource library, secure videoconferencing, and tools to support one-on-one health coaching. Health coaches are certified in motivational interviewing and have lived in the community with SCI for more than five years. In the first session, participants identify priority issues related to their health and target management of secondary conditions specific to SCI. They will work through goal setting, problem solving activities and create action plans for behaviour change, which will be securely stored. The intervention will be a maximum of 14 sessions over 6 months. Each session will cover a health-related topic (bladder, bowel, skin, pain, healthy eating, physical activity or stress, anxiety and depression) and a self-management skill topic (action planning, goal setting, problem-solving, mood management, navigating the health care system and communicating with health care providers) with an expected duration of 30 to 45 minutes.
89503461|NCT04474171|No Intervention|Waitlist Control|Usual health care and be offered the SCI&U program at the end of the 12-month follow-up period (wait-list control)
89503462|NCT02161913|Active Comparator|SCI Education Control Group|The SCIEC condition is a 16-session, highly structured educational intervention that provides information on how SCI affects the body; methods for maximizing function, coping, and living with SCI; and staying healthy with SCI. It also includes general guidelines for improving health behavior. Each SCIEC session follows the same structure, beginning with a presentation of the objectives for the current session and a brief review of material from the previous session before introducing the session's topic and presenting information on one or two key problem areas. SCIEC utilizes a traditional didactic model with information delivered by an expert SCI educator in a classroom or lecture setting.
89503463|NCT02161913|Experimental|Multi-family Group Treatment|The MFG Program uses a structured problem-solving and skills training program to provide participants with SCI and their caregivers with tools and information to improve coping and help family members to connect through positive behavioral exchanges. MFG educators are health professionals with experience in management of SCI, such as physical therapists, recreational therapists, occupational therapists, and psychologists. MFG will last for 16 sessions across 9 months.
89503464|NCT00813163|Experimental|PEP02|Liposome Irinotecan
89503465|NCT02154815||PPT|Patients with a pre-emptive kidney transplantation from deceased or living donors
89503466|NCT02154815||PDT|Patients who have experienced a pre-transplant dialysis period of less than 36 months
89503467|NCT00812383|Experimental|Bivalirudin|
89503468|NCT00812383|Active Comparator|Heparin|
89503469|NCT05430932|Experimental|Laparoscopic sleeve gastrectomy|After sleeve gastrectomy, assessment of vitamin D, calcium and parathormone levels is performed.
89503470|NCT02158871|Experimental|Contact-based mental health education|"The Beyond Silence' program is 12 hours in length: six 1.5-2 hour in-person group sessions every other week, plus five online sessions between each of the in-person sessions."
89503471|NCT02158871|Active Comparator|Mental health literacy training|"Mental Health First Aid training consists of twelve hours of standardized, module-based mental health literacy training offered in a group format. It will be offered as 2 full-day training sessions (or four half-day sessions)."
89503472|NCT00812305|Experimental|Low dose in healthy patients|
88956811|NCT03830229||2/CLIA confirmed germline mutation without mesothelioma|Individuals with a CLIA confirmed BAP1 or other DNA repair/cancer predisposition mutation who do not have a diagnosis of mesothelioma
88956812|NCT03827343||1|Retrospective chart review of children and adults with cancer enrolled on immunotherapy treatment protocols in the NCI.
88956813|NCT03816332|Experimental|Treatment (tacrolimus, prednisone, nivolumab, ipilimumab)|"Patients receive tacrolimus PO BID and prednisone PO QD. Within 28 days, patients then receive nivolumab IV over 30 minutes on day 1. Cycles repeat every 4 weeks for up to 24 cycles (96 weeks) in the absence of disease progression or unacceptable toxicity.~Patients who experience PD or patients who have experienced allograft loss at 16 weeks receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 1. Patients also receive tacrolimus PO BID and prednisone PO QD. Cycles repeat every 3 weeks for 4 cycles (12 weeks) in the absence of disease progression or unacceptable toxicity. Starting 6 weeks later, patients receive nivolumab IV over 30 minutes every 4 weeks for up to 21 cycles (84 weeks) in the absence of disease progression or unacceptable toxicity."
89503473|NCT00812305|Experimental|Low dose in hepatically impaired patients|
89023673|NCT04973345|Experimental|Terbutaline Arm C|• Arm C: (n=6) SQ (0.25 mg) IV low dose over 5 minutes IV medium dose over 5 minutes IV high dose over 5 minutes Participants in Part 2 (n=18) will be randomized to one of three treatment arms. To maintain masking the first treatment will be 0.25 mg of study drug SQ, followed by one of three IV dose regimes (low, medium, high) below, which are estimated to be 0.1 mg, 0.5 mg, 1.0 mg, but may be adjusted based on the interim analysis completed in Part 1. No masking will be applied for Part 1 or for the SQ dosing in Part 2. All IV treatments in Part 2 will be masked, with exception to the unmasked study pharmacist, refer to the MOP for details.
89503474|NCT04968197|Experimental|Stochastic Vestibular Stimulation (SVS) Condition|Subjects will perform standard clinical testing for balance and gait while wearing the Vestibular Intervention via Portable Electrical Stimulator (VIPES) system. The SVS device will be active throughout the testing at the respective current levels (i.e., 0.2mA to 1 mA at 0.2 mA increments).
89503475|NCT04968197|No Intervention|Control Condition|Subjects will perform standard clinical testing for balance and gait without SVS
89503476|NCT00901693|Experimental|AL-46383A|AL-46383A Ophthalmic Solution, 1 drop in each eye, 8 times a day for 10 days
89503477|NCT00901693|Placebo Comparator|Vehicle|AL-46383A Ophthalmic Solution Vehicle, 1 drop in each eye, 8 times a day, for 10 days
89503478|NCT05440760|Experimental|Sequence Group A|VR distraction occurring visits 1 and 2 with normal SOC therapy at visits 3 and 4.
89503479|NCT05440760|Experimental|Sequence Group B|VR distraction occurring visits 1 and 4 with normal SOC therapy at visits 2 and 3.
89503480|NCT05440760|Experimental|Sequence Group C|VR distraction occurring visits 3 and 4 with normal SOC therapy at visits 1 and 2.
89503481|NCT05440760|Experimental|Sequence Group D|VR distraction occurring visits 2 and 3 with normal SOC therapy at visits 3 and 4.
89503482|NCT04474093|Active Comparator|Zirconium-reinforced glass ceramics (ZRGC)|12 posterior single tooth crowns made from monolithic zirconium-reinforced glass ceramics(ZRGC). Restorations were evaluated prosthetic and periodontal criteria at baseline, after 6 and 12 months. While prosthetic evaluation was performed according to Modified US Public Health Service criteria; probing depth(PD), clinical attachment level(CAL), gingival bleeding time index(GBTI), gingival(GI) and periodontal index(PI) were used in periodontal evaluation.
89503483|NCT04474093|Active Comparator|Lithium disilicate glass ceramics (LGC)|Group 2: 12 posterior single tooth crowns made from monolithic lithium disilicate glass ceramics(LGC). Restorations were evaluated prosthetic and periodontal criteria at baseline, after 6 and 12 months. While prosthetic evaluation was performed according to Modified US Public Health Service criteria; probing depth(PD), clinical attachment level(CAL), gingival bleeding time index(GBTI), gingival(GI) and periodontal index(PI) were used in periodontal evaluation.
89503484|NCT04474093|Active Comparator|Resin infiltrated glass ceramics (RIGC)|12 posterior single tooth crowns made from monolithic resin infiltrated glass ceramics(RIGC). Restorations were evaluated prosthetic and periodontal criteria at baseline, after 6 and 12 months. While prosthetic evaluation was performed according to Modified US Public Health Service criteria; probing depth(PD), clinical attachment level(CAL), gingival bleeding time index(GBTI), gingival(GI) and periodontal index(PI) were used in periodontal evaluation.
89503485|NCT02154893|Experimental|Device and exercise|Device with ultrasound and laser associated with therapeutic exercise
89503486|NCT02154893|Experimental|Device|Device with ultrasound and laser
89503487|NCT02154893|Placebo Comparator|Placebo|Without any treatment
89503488|NCT05642949|Experimental|Dose Escalation - All Participants|All participants enrolled in the dose escalation part.
89503489|NCT05642949|Experimental|Dose Expansion - All Participants|All participants enrolled in the dose expansion part
89032886|NCT04691687|Experimental|IV Furosemide Infusion|The dose assignments were categorized into low dose (20 mg bolus with 20 mg/hour infusion sessions and 2 ml saline), intermediate dose (40 mg bolus with 40 mg/hour infusion sessions and 4 ml saline) and high dose (80 mg bolus with 80 mg/hour infusion sessions). The infusions were continuous over 3 hours, biweekly over a one-month period.Infusions were held at the discretion of the physician utilizing a written protocol (creatinine 25% above baseline, SBP <80 mmHg or symptoms of presyncope).
89503490|NCT05464706|Experimental|Interventional|
89503491|NCT05464706|Placebo Comparator|Control|
89503492|NCT00899977|Placebo Comparator|Placebo|Subjects may receive a single, oral dose of placebo (capsule) in one of 4 crossover periods. Also, subjects may receive placebo orally, twice daily for 14 days in the last phase of the study.
89503493|NCT00899977|Experimental|1 mg TC-5214|Subjects may receive a single, oral capsule of 1 mg TC-5214 in one of 4 crossover periods.
89503494|NCT00899977|Experimental|2 mg TC-5214|Subjects may receive a single, oral capsule of 2 mg TC-5214 in one of 4 crossover periods.
89503495|NCT00899977|Experimental|4 mg TC-5214|Subjects may receive a single, oral capsule of 4 mg TC-5214 in one of 4 crossover periods. Also, subjects may receive 4 mg TC-5214 orally, twice daily for 14 days in the last phase of the study.
89503496|NCT00899977|Experimental|8 mg TC-5214|Subjects may receive a single, oral capsule of 8 mg TC-5214 in one of 4 crossover periods.
89503497|NCT02159027|Placebo Comparator|placebo|placebo identical in appearance to maraviroc 150 and 300 mg tablets will be added to each subjects antiretroviral regimen at doses as recommended by the package insert
89503498|NCT02159027|Experimental|maraviroc|Maraviroc Tablets are available as 150 mg and 300 mg tablets. Each subject will add maraviroc to their current antiretroviral regimen with dosage based on recommendations as per maraviroc package insert
89503499|NCT02161991|Experimental|aprepitant group|Patients assigned to aprepitant group should receive aprepitant for the control of CINV, aprepitant 125 mg for day1, 80mg for day2 and day3.
89503500|NCT02161991|Placebo Comparator|placebo|Patients assigned to placebo group should receive placebo for the control of CINV compared with aprepitant group.
89503501|NCT04473859|Experimental|FSR Peptide 20 μM|Each subject will have two punch biopsies. FSR peptide will be applied to one punch biopsy. Placebo will be applied to the second punch biopsy.
89503502|NCT04473859|Experimental|FSR peptide 50 μM|Each subject will have two punch biopsies. FSR peptide will be applied to one punch biopsy. Placebo will be applied to the second punch biopsy.
89503503|NCT04473859|Experimental|FSR peptide 100 μM|Each subject will have two punch biopsies. FSR peptide will be applied to one punch biopsy. Placebo will be applied to the second punch biopsy.
89503504|NCT04473859|Experimental|FSR peptide 200 μM|Each subject will have two punch biopsies. FSR peptide will be applied to one punch biopsy. Placebo will be applied to the second punch biopsy.
89503505|NCT04473859|Placebo Comparator|Placebo only|Each subject will have two punch biopsies. Placebo will be applied to both punch biopsies.
89503506|NCT02162069|Experimental|transcatheter aortic valve replacement|Patients receive transcatheter aortic valve replacement.
89503507|NCT02154971||Patients|HIV infected for more than 10 years, aged over 40, treated with antiretroviral therapy
89503508|NCT02154971||Control|non-HIV (matched for age and gender)
89503509|NCT04473703||observation group|A total of 300 patients are expected to include in this group. And the cardiac adverse reactions related to immune checkpoint inhibitor will be observed.
89503510|NCT04473937|Experimental|Radiotherapy|"Participants must have received CAR-T infusion within the last 90 days prior to completing a study screening and enrollment process.~Participants will be enrolled within 28 days after screening is complete and radiotherapy will occur within 14 days after study enrollment.~Radiotherapy will be administered based on a dose and schedule pre-determined by the study doctor."
89503511|NCT02763215||Total|
89503512|NCT02159105||Women undergoing cesarean delivery|"FAST scan and non-invasive hemoglobin measurement~Women undergoing cesarean delivery will undergo a non-invasive hemoglobin measurement both before and after surgery. An abdominal ultrasound will be performed to establish normal levels of intra-abdominal fluid after cesarean delivery."
89503513|NCT00803413|Other|Back School|Participants received weekly sessions of 45 minutes including: 15-minute lectures about basics of spine's anatomy, ergonomics, techniques of lifting and transportation of weights and volumes, body posture in several daily tasks and situations, and spine preventive care; 30 minutes of on-place supervised exercises for posture and spine flexibility (muscle stretching, relaxation, strengthening)
89503514|NCT00803413|Other|Supervised Walking|Participants received weekly sessions of 45 minutes including: 15-minute lectures about basics of physical activity, its advantages and benefits, barriers and facilitators, types and opportunities; 30 minutes of on-place supervised walking in group
89503515|NCT00803413|Other|Back School and Walking|Participants received weekly sessions of 90 minutes including: 30-minute lectures about basics of spine's anatomy, ergonomics, techniques of lifting and transportation of weights and volumes, body posture in several daily tasks and situations, spine preventive care, and about physical activity, its advantages and benefits, barriers and facilitators, types and opportunities; 30 minutes of on-place supervised exercises for posture and spine flexibility (muscle stretching, relaxation, strengthening); 30 minutes of on-place supervised walking in group
89503516|NCT00803413|Other|Control Group|Participants received weekly sessions of 45 minutes including lectures about: stress control, healthy nutrition (2 lectures), sleep hygiene and injury prevention; beside the 2-page folder content this group received no other information about LBP, BS or walking all along the follow-up.
89503517|NCT05673213|No Intervention|Routine 15º head raised prone position (control group)|The infant was cared for, fed and treated by the primary nurse responsible for the infant between 08:30 and 08:55. No intervention was made to the preterm infant between 09:00-12:00 and the infant was allowed to rest. Preterm infants were followed for 3 hours (09:00-12:00) with routine 15º head raised prone position. Between these hours, the oxygen saturation and heart rate of the preterm infants in were counted by the researcher with a pulse oximeter device and recorded 18 times in 10 minutes. Sleep-wakefulness status was recorded by taking 15-second recordings with the Actigraphy measuring device.
89503518|NCT05673213|Experimental|Three-stair positioning pillows group|The infant was cared for, fed and treated by the primary nurse responsible for the infant between 08:30 and 08:55. No intervention was made to the preterm infant between 09:00-12:00 and the infant was allowed to rest. Preterm infants were followed for 3 hours (09:00-12:00) with three-stair positioning pillows. Between these hours, the oxygen saturation and heart rate of the preterm infants in were counted by the researcher with a pulse oximeter device and recorded 18 times in 10 minutes. Sleep-wakefulness status was recorded by taking 15-second recordings with the Actigraphy measuring device.
89503519|NCT02770547|Active Comparator|Low Heat Thermotherapy|Low heat thermotherapy will be applied to subject's leg. Subject will wear a garment through which heated water is circulated which in turn supplies low heat to the subject's leg.
89503520|NCT02770547|Experimental|High Heat Thermotherapy|High heat thermotherapy will be applied to subject's leg. Subject will wear a garment through which heated water is circulated which in turn supplies high heat to the subject's leg.
89503521|NCT00800605|Experimental|1|Vero cell-derived, trivalent, seasonal influenza vaccine
89503522|NCT00800605|Placebo Comparator|2|Phosphate-buffered saline
89503523|NCT02159261||Cohort 1|Female patients ≥ 18 years old requiring contraception.
89503524|NCT05231499||healthy volunteers|
89503525|NCT05231499||immunocompromised subjects|
89503526|NCT00890305|Experimental|CT-011 in combination with FOLFOX|"CT-011 (3 mg/kg) administered intravenously every 4 weeks for 4 weeks and every 12 weeks thereafter until disease progression or maximum tolerance.~FOLFOX (FOLFOX4 or mFOLFOX6) administered 7 days after the first administration of CT-011 and repeated every 14 days for up to 24 cycles. At the end of FOLFOX therapy, patients who have not progressed will be eligible for maintenance chemotherapy with 5-FU/leucovorin at the same dose and schedule until disease progression or study drug discontinuation."
89503527|NCT00890305|Active Comparator|FOLFOX|FOLFOX (FOLFOX-4 or mFOLFOX6) administered every 14 days for up to 24 cycles. At the end of FOLFOX therapy, patients who have not progressed will be eligible for maintenance chemotherapy with 5-FU/leucovorin at the same dose and schedule until disease progression or study drug discontinuation.
89608354|NCT01271374|Active Comparator|Hyzaar-Treatment Arm B|Weeks 1-2: Hyzaar® 50/12.5 Weeks 3-14: Hyzaar® 100/25 Weeks 15-18: Azor® 10/40+HCTZ 25 Weeks 19-20: Azor® 10/40+HCTZ 25 + spironolactone 25 once daily
89023674|NCT04973345|Experimental|Terbutaline Arm D|• Arm D: (n=6)SQ (0.25 mg) IV medium dose over 5 minutes IV high dose over 5 minutes IV low dose over 5 minutes Participants in Part 2 (n=18) will be randomized to one of three treatment arms. To maintain masking the first treatment will be 0.25 mg of study drug SQ, followed by one of three IV dose regimes (low, medium, high) below, which are estimated to be 0.1 mg, 0.5 mg, 1.0 mg, but may be adjusted based on the interim analysis completed in Part 1. No masking will be applied for Part 1 or for the SQ dosing in Part 2. All IV treatments in Part 2 will be masked, with exception to the unmasked study pharmacist, refer to the MOP for details.
89032887|NCT04110327||Claudication|Subjects presenting with claudication, identified as Rutherford category 1, 2, or 3
89503528|NCT01661972|Experimental|Phase 1: Capecitabine and Aflibercept|A standard 3+3 dose escalation format will be used. Capecitabine will start at 850mg/m2 to be given on days 1-14 and off days 15-21. If tolerated, the dose will then be escalated to 1000mg/m2 for the next cohort, given on the same schedule. The dose of aflibercept will be held constant at 6 mg/kg, given intravenously every 3 weeks.
89503529|NCT01661972|Experimental|Phase 2: Capecitabine and Aflibercept|Once the RPTD of the doublet combination has been identified, an additional 50 subjects with metastatic colorectal cancer will be added to a single, Phase 2 arm
89503530|NCT04650659||Part one of the project|83 patients with Systemic Sclerosis will perform three functional exercise tests on the same day. All 83 patients will be examined with NVC. Moreover, HRpQCT will be performed on all patients at baseline and after 1 year.
89503531|NCT04650659||Part two of the project|Half of the patients from part one of the project will be invited to repeat the three functional exercise tests approximately one week later in reverse order to determine test-retest reliability.
89503532|NCT00947557|Active Comparator|Dutogliptin|Dutogliptin
89503533|NCT00947557|Placebo Comparator|Placebo|Placebo
89503534|NCT03542747|Experimental|Time to ventilation with the iLTS|Measuring the time to ventilation (ET) based of insert the iLTS until the chest rise of the simulator in seconds
89503535|NCT03542747|Experimental|Time to ventilation with the Fastrach|Measuring time to ventilation (ET) based of insert the Fastrach until the chest rise of the simulator in seconds
89503536|NCT05464238|Active Comparator|Exercise training|
89503537|NCT05464238|Placebo Comparator|Standard treatment (waiting group)|
89503538|NCT02162225|Experimental|Beet Juice|"Volunteers will drink a single 8 ounce bottle of beet juice (Unbeetable) per day for 28 days.~On days 1,14, and 28, the juice will be drunk just prior to having blood drawn. Blood will also be drawn 1.5 hours after drinking the juice on days 1,14, and 28."
89503539|NCT02163005|Experimental|Gadolinium enhancement|Gadolinium enhancement will be performed using intravenous Dotarem[recommended dose of 0.2 mL/kg (0.1 mmol Gd/kg )]
89503540|NCT02155049|Experimental|Prostaglandin Analogues|The patients will receive a single daily drop of bimatoprost for six months.
89503541|NCT03540953|Other|Endoscopic injection of Mitomycin C|Endoscopy injection of Mitomycin C will be perform to the treatment of pharyngoesophageal stenosis refractory to endoscopic treatment with dilatation in patients with head and neck cancer
89503542|NCT00888355|Placebo Comparator|1|Placebo
89503543|NCT00888355|Experimental|2|Losartan 50 q.a.m.
89503544|NCT00888355|Experimental|3|Losartan 25 b.i.d.
89503545|NCT00888355|Experimental|4|Losartan 25 q.a.m.
89032888|NCT04110327||Critical Limb Ischemia|Subjects presenting with rest pain (Rutherford category 4) or minor tissue loss (Rutherford category 5)
89503546|NCT03542591||Participants of the VegMed congress (Berlin, April 2018)|
89503547|NCT02155127|Experimental|walking intervention|Subjects are randomized to walking/functional strength program with weekly coaching or usual care. The program is for 12 weeks. The intervention includes 3 lower extremity strengthening exercises, and progressive walking.
89503548|NCT02155127|No Intervention|usual care|these subjects receive information on walking program, however do not receive any coaching over 12 weeks
89503549|NCT00794677|Placebo Comparator|Sugar Pill|Placebo medication will be taken orally once daily in the morning on rising either during the first intervention period or the second intervention period. Single-blind ezetimibe placebo will be taken during the Run-In Period. Patients will be issued one bottle containing either active drug or placebo for each treatment period.
89503550|NCT00794677|Experimental|ezetimibe|10 mg medication will be taken orally once daily in the morning on rising either during the first intervention period or the second intervention period. Single-blind ezetimibe placebo will be taken during the Run-In Period. Patients will be issued one bottle containing either active drug or placebo for each treatment period.
89503551|NCT00792727|Experimental|Ketoprofen Patch|Treatment with experimental drug
89503552|NCT00792727|Placebo Comparator|Placebo Patch|Treatment with placebo drug
89503553|NCT00945763|Placebo Comparator|placebo|
89503554|NCT00945763|Experimental|N1539 15 mg|
89503555|NCT00945763|Experimental|N1539 30 mg|
89503556|NCT00945763|Experimental|N1539 60 mg|
89503557|NCT00945763|Active Comparator|Motrin|
89503558|NCT03135145|Active Comparator|Lite Run Gait Trainer|Participants will be using the Lite Run Gait Trainer to assist them in weightbearing and walking after SDR or SEMLS surgery.
89503559|NCT03135145|Placebo Comparator|Usual Treatments|Participants will be using current treatments used in clinical practice to assist them in weightbearing and walking after SDR or SEMLS surgery.
89503560|NCT02770391|Experimental|Apalutamide + Leuprolide Acetate|All participating patients will receive a single dose of leuprolide 7.5 mg intramuscularly (IM) in addition to Apalutamide 240 mg orally daily for four weeks prior to radical prostatectomy (RP). Treatment will be started on day (-28) ± 3 from the scheduled RP date to minimize the variability of treatment duration. Apalutamide may be continued up to and including the day before
89503561|NCT00881023|Active Comparator|1|Randomized to Microfracture
89503562|NCT00881023|Experimental|2|Randomized to Device
89503563|NCT00881023|Experimental|3|Non-randomized with lesion greater than 6cmˆ2
89503564|NCT02155205|Experimental|Telotristat etiprate|Single dose of telotristat etiprate followed by a 7-day washout.
89503565|NCT02155205|Active Comparator|Moxifloxacin|Single dose of moxifloxacin followed by a 7-day washout.
89503566|NCT02155205|Placebo Comparator|Placebo|Single dose of placebo with a 7-day washout to follow.
88811531|NCT00845000|Experimental|SCH 420814 100 mg→ SCH 420814 10 mg→Placebo|Participants were to receive their assigned experimental treatment based on randomly assigned treatment sequence at Hour 0 following an overnight withdrawal of their antiparkinsonian medications of each treatment period. The levodopa infusion was to be started at Hour 1 and was to run for 2 hours. The participants were to also receive 25 mg of carbidopa at the following times: Hours 0, 2, and 4. Treatment periods were to be separated by at least 7 days but not more than 28 days washout between each dose.
89023675|NCT04973345|Experimental|Terbutaline Arm E|• Arm E: (n=6) SQ (0.25 mg) IV high dose over 5 minutes IV low dose over 5 minutes IV medium dose over 5 minutes Participants in Part 2 (n=18) will be randomized to one of three treatment arms. To maintain masking the first treatment will be 0.25 mg of study drug SQ, followed by one of three IV dose regimes (low, medium, high) below, which are estimated to be 0.1 mg, 0.5 mg, 1.0 mg, but may be adjusted based on the interim analysis completed in Part 1. No masking will be applied for Part 1 or for the SQ dosing in Part 2. All IV treatments in Part 2 will be masked, with exception to the unmasked study pharmacist, refer to the MOP for details.
89023676|NCT04967417|Experimental|Non-squamous cell carcinoma|"4 cycles of pemetrexed 500mg/m2 + carboplatin AUC 5.0 + pembrolizumab 200mg every 3 weeks~Followed by pemetrexed 500mg/m2 + pembrolizumab 200mg every 3 weeks up to 35 cycles"
89023677|NCT04967417|Experimental|Squamous cell carcinoma|"4 cycles of paclitaxel 200mg/m2 + carboplatin AUC 6.0 + pembrolizumab 200mg every 3 weeks~Followed by pembrolizumab 200mg every 3 weeks up to 35 cycles"
89023678|NCT04963725||Participants Initiating Therapy with Ustekinumab|Data will be collected for participants in Japan who have had an inadequate response, or been intolerant to, conventional or biologic therapies. The treating physician has made the decision to initiate ustekinumab induction therapy in the routine clinical practice - either as a first or subsequent biologic therapy initiating for their moderate to severe ulcerative colitis.
89023679|NCT04963192|Experimental|OSA or COPD patients having an integrated management at home|OSA or COPD patients having an integrated management at home using connected devices, during 6 months
89503567|NCT02155361|Active Comparator|Topical Citrullus colocynthis fruit oil|Topical Citrullus colocynthis fruit oil (1%) 1 cc twice daily
89503568|NCT02155361|Placebo Comparator|Placebo (Vehicle)|Topical vehicle oil 1 cc twice daily
89503569|NCT02162303|Experimental|Colchicine|Colchicine 0.6 mg tablets,once daily, for 6 months
89503570|NCT02162303|Placebo Comparator|Placebo|Sugar,given once daily, over 6 months.To mimic active treatment.
89503571|NCT05430308|Experimental|Chlorhexidine-alcohol scrub|The surgical site selected for performing the thoracoscopy will be cleaned with 4%w/v chlorhexidine gluconate solution for 3 minutes. This will then be washed with normal saline and a sterile gauge. After drying chlorhexidine gluconate (2.5%v/v)-ethanol IP (70%v/v) will be applied and allowed to dry for 3 minutes before the incision.
89503572|NCT05430308|Active Comparator|Povidone-iodine|The surgical site selected for performing the thoracoscopy will be just cleaned with normal saline followed by 10% w/v povidone-iodine solution and would be allowed to dry for 3 minutes before the incision
89503573|NCT00877903|Experimental|Prochymal®|Participants will receive Prochymal® single intravenous (IV) infusion at a dose of 200 x 10^6 human mesenchymal stem cells (hMSC), reconstituted in 80 mL, delivered at a rate of 2 mL/min, with a maximum rate of 5.0 x 10^6 hMSC/minute, and the participants will be followed for 24 months and remain in the study for up to 60 months.
89503574|NCT00877903|Placebo Comparator|Placebo|Participants will receive Prochymal® placebo-matching single IV infusion at a dose of of 200 x 10^6 hMSC, reconstituted in 80 mL, delivered at a rate of 2 mL/min, with a maximum rate of 5.0 x 10^6 hMSC/minute, and the participants will be followed for 24 months and remain in the study for up to 60 months.
89503575|NCT00877279|Experimental|Belotero® Soft|Comparator will be given into the opposite side of the face that Belotero® Soft was administered for facial wrinkles, such as nasolabial folds.
89503576|NCT00877279|Active Comparator|CosmoDerm1|
89503577|NCT04707703|Experimental|SOC plus Isavuconazonium sulfate|SOC plus intravenous isavuconazonium sulfate 372 mg every 8 hours for 6 doses followed by 372mg once daily for up to 28 days
89503578|NCT04707703|Placebo Comparator|SOC plus Placebo|SOC plus intravenous placebo every 8 hours for 6 doses followed by once daily for up to 28 days
89503579|NCT00936871|Experimental|Part A|Lersivirine Tolerability
89503580|NCT00936871|Experimental|Part B|Thorough QTc
89503581|NCT02536508|Experimental|BGF MDI (PT010) 320/14.4/9.6 μg|Budesonide, Glycopyrronium, and Formoterol Fumarate (BGF) metered dose inhaler (MDI) (PT010, BGF MDI)
89503582|NCT02536508|Experimental|GFF MDI (PT003) 14.4/9.6 μg|Glycopyrronium and Formoterol Fumarate (GFF) metered dose inhaler (MDI) (PT003, GFF MDI)
89503583|NCT02536508|Experimental|BFF MDI (PT009) 320/9.6 μg|Budesonide and Formoterol Fumarate (BFF) metered dose inhaler (MDI) (PT009, BFF MDI)
89503584|NCT04663867|Experimental|AngioSafe Peripheral CTO Crossing System Procedure|
89503585|NCT04638361||No laryngeal mobility disorder post cardiac surgery|No Follow up, no questionnaires and no nasofibroscopic control.
89503586|NCT04638361||Laryngeal mobility disorder post cardiac surgery|During a follow-up consultation, questionnaires will be offered to assess the child's quality of life.
89503587|NCT00934921|Experimental|Ondansetron|Ondansetron HCl 8 mg Orally Disintegrating Tablet (test) dosed in first period followed by Zofran® 8 mg ODT (reference) dosed in second period
89503588|NCT00934921|Active Comparator|Zofran®|Zofran® 8 mg ODT (reference) dosed in first period followed by Ondansetron HCl 8 mg Orally Disintegrating Tablet (test) dosed in second period
89503589|NCT00930163|Experimental|1|
89503590|NCT00930163|Placebo Comparator|2|
89503591|NCT00929539|Experimental|Dose 1 JTT-130|
89503592|NCT00929539|Experimental|Dose 2 JTT-130|
89503593|NCT00929539|Experimental|Dose 3 JTT-130|
89503594|NCT00929539|Placebo Comparator|Placebo|
89503595|NCT05429450|Experimental|Methotrexate|Periocular injections of methotrexate
89023680|NCT04955301|No Intervention|Control message group|Participants will not receive the priming manipulation.
89503596|NCT05429450|Active Comparator|Triamcinolone acetonide|Periocular injections of triamcinolone acetonide
89503597|NCT00103259|Experimental|Arm I (bortezomib, irinotecan hydrochloride)|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11 and irinotecan IV over 90 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity
89503598|NCT00103259|Experimental|Arm II (bortezomib)|Patients receive bortezomib as in arm I. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Upon disease progression, patients may cross over to arm I.
89503599|NCT05437016|Experimental|HUBER rehabilitation group|centre-based and will last 6 weeks, with 4 sessions of 2 hours each per week. All the sessions will be supervised by a physiotherapist and will include: 1h of physiotherapy, 30min of balneotherapy and 30min on the HUBER platform to perform exercises
89503600|NCT05437016|Active Comparator|Standard rehabilitation group|centre-based and will last 6 weeks, with 4 sessions of 2 hours each per week. All the sessions will be supervised by a physiotherapist and will include: 1h of physiotherapy, 30min of balneotherapy and 30min of exercise on cycloergometer.
89503601|NCT02162381|Experimental|methylphenidate provided|the study group will be given a single pill containing methylphenidate 10mg to be taken 2 hours before their visual field test
89503602|NCT02162381|Active Comparator|control|control group will not be given any placebo and will perform a repeat visual field testing without any prior preparation
89503603|NCT00782431|Experimental|1|Vero cell-derived, trivalent, seasonal influenza vaccine
89503604|NCT00782431|Active Comparator|2|Licensed egg-derived, trivalent seasonal influenza vaccine
89503605|NCT02162459||whey beverage|consumption of 52 grams of whey protein supplement following resistance exercise
89608355|NCT01271374|Active Comparator|Azor-Treatment A|Weeks 1-2: Azor® 5/20 Weeks 3-14: Azor® 10/40 Weeks 15-18: Azor® 10/40+HCTZ 25 Weeks 19-20: Azor® 10/40+HCTZ 25 + spironolactone 25 once daily
89608356|NCT00710944|Experimental|Extraction Sockets|Immediate loading in extraction sockets.
89608357|NCT00710944|Experimental|Healed Ridges|Immediate loading in healed ridges.
89023681|NCT04955301|Experimental|Health benefits priming group|"Participants will be cueing with health benefits by asking to do a word-search exercise beginning with: In the following, please choose words/statements that can indicate that having a healthy and sustainable diet can have health benefits, such as..."
89503606|NCT02162459||chocolate milk beverage|consumption of chocolate flavored milk following resistance exercise
89503607|NCT02155439|Active Comparator|Triamcinolone|kortikosteroid
89503608|NCT02155439|Active Comparator|5-fluorouracil|antimitotic drug
89503609|NCT03542435|Experimental|SXC-2023|Dose Escalation
89503610|NCT03542435|Placebo Comparator|Placebo|Dose Escalation
89503611|NCT02544152|Experimental|Lubiprostone|Participants receive 8 mcg lubiprostone capsules twice daily (BID)
89503612|NCT02544152|Placebo Comparator|Placebo|Participants receive 0 mcg capsules BID
89503613|NCT02162537|Other|Arm A (standard arm)|Arm A: Initial Cerebral Radiotherapy and Chemotherapy (Cisplatin and pemetrexed with or without Bevacizumab)
89503614|NCT02162537|Other|Arm B (experimental arm)|Arm B: Chemotherapy (Cisplatin and pemetrexed with or without Bevacizumab) and Cerebral Radiotherapy if clinical or radiological progression brain
89503615|NCT02534324||High SBP+antihypertensive meds|Patients with pre-discharge systolic blood pressure at discharge < 180 mmHg
89503616|NCT02534324||Severely high SBP+antihypertensive meds|Patients with pre-discharge systolic blood pressure at discharge >= 180 mmHg
89503617|NCT02761733|Experimental|mPOWR System|Moving Patient Outcomes toward Wellness and Recovery (mPOWR) consists of an assessment questionnaire and decision support tools which map onto 6 life domains which are measured by the questionnaire.
89503618|NCT02761733|No Intervention|Control|Treatment as usual
89608358|NCT00710944|Experimental|Grafted Sites|Immediate loading of implants placed in grafted sites (four months healing after grafting).
89608359|NCT01271530|Experimental|Exercise|
89608360|NCT01271530|No Intervention|Control|
89608361|NCT01276834|Experimental|everolimus-based immunosuppression|immunosuppression with everolimus, prednisone and mycophenolate
89608362|NCT01276834|Active Comparator|standard immunosuppression|immunosuppression with tacrolimus, prednisone and mycophenolate
89608363|NCT00728260||Menactra Vaccine Recipients|"Children 2 years through 10 years of age who received Menactra vaccine within Kaiser Permanente during the study period. They served as their own controls for evaluation of acute (Days 0-30) events. Rates of events occurring during Days 0-30 following vaccination were compared to rates of events occurring during Days 31-60 following vaccination.~Six-month surveillance: For each individual receiving Menactra vaccine, the rate of an event in the 30-day follow-up period was compared with the rate of the same event in the 31-180-day follow-up period using age, sex, and seasonality as covariates in Cox regression analyses.~Menactra vaccine was administered according to routine clinical practice."
89608364|NCT01276990|Placebo Comparator|Placebo|Matching placebo in dosing regimen 1-8
89608365|NCT01276990|Experimental|BI 224436 dosing regimen 1|Dosing regimen 1
89608366|NCT01276990|Experimental|BI 224436 dosing regimen 2|Dosing regimen 2
89608367|NCT01276990|Experimental|BI 224436 dosing regimen 3|Dosing regimen 3
89608368|NCT01276990|Experimental|BI 224436 dosing regimen 4|Dosing regimen 4
89608369|NCT01276990|Experimental|BI 224436 dosing regimen 5|Dosing regimen 5
89608370|NCT01276990|Experimental|BI 224436 dosing regimen 6|Dosing regimen 6
89608371|NCT01276990|Experimental|BI 224436 dosing regimen 7|Dosing regimen 7
89608372|NCT01276990|Experimental|BI 224436 dosing regimen 8|Dosing regimen 8
89608373|NCT01277068|Active Comparator|the adjustable gastric banding|
89608374|NCT01277068|Active Comparator|the sleeve gastrectomy|
89608375|NCT01277068|Active Comparator|the gastric bypass|
89608376|NCT01271764|No Intervention|endometrial cancer|
89608377|NCT01277146|Experimental|OMP-59R5|
89608378|NCT00711022|Experimental|OsseoSpeed|
89608379|NCT00728728|Active Comparator|Arm 1: Pregnenolone|Pregnenolone
89608380|NCT00728728|Placebo Comparator|Arm 2: Placebo|Placebo
89538719|NCT04964271||High risk prostate cancer patients|Prostate cancer risk category is based on the definition of the European Association of Urology, namely high risk (PSA (prostate-specific antigen) >20 ng/ml or stage T3 or higher or biopsy Gleason score 8-10).
89538720|NCT04964271||Healthy donor|Participants who are in good health and without history of cancer disease.
89538721|NCT03255395|Experimental|Magnetic resonance-guided focused ultrasound (MRgFUS)|Ten amputees will recieve magnetic resonance-guided focused ultrasound (MRgFUS) treatment aimed to ablate neromas, which are beleived to cuase phantom / residual limb pain
89538722|NCT04967937|Experimental|Single-Group|The neuromuscular training program will consist of three 90-minute training sessions per week for 6 weeks. The 3 components of the dynamic neuromuscular training protocol utilized in this study include: (1) balance training and hip/pelvis/trunk strengthening, (2) plyometrics and dynamic movement training, and (3) resistance training. Following the completion of the training program, each subject will be re-evaluated to determine change in total, anterior-posterior, and medial-lateral single-limb stability. Two-way analysis of variance models will be used to determine differences between pre-training and post-training and between limbs.
89538723|NCT04967781||"Group Severe"|"Each enrolled patient was allocated into control group Non-severe or case group Severe as per the disease severity which was defined according to the Chinese novel coronavirus pneumonia prevention and control guideline (version 6.0), severe and critical types were grouped into case group as Severe."
89538724|NCT04967781||"Group Non-severe"|"Each enrolled patient was allocated into control group Non-severe or case group Severe as per the disease severity which was defined according to the Chinese novel coronavirus pneumonia prevention and control guideline (version 6.0), mild and moderate types were grouped into control group as Non-severe."
88956814|NCT03811002|Experimental|Arm I (etoposide, cisplatin, carboplatin, radiation therapy)|Patients receive etoposide IV on days 1-3 and cisplatin IV or carboplatin IV on day 1. Cycles repeat every 21 days for 3 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo 3D-CRT or IMRT BID for approximately 3 weeks or QD for approximately 6-7 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo blood specimen collection throughout the trial.
89538725|NCT03261245||Cas|Onset of a hypertension disorder during pregnancy
89538726|NCT03261245||Controls|No hypertension disorder during pregnancy
89538727|NCT03060603||Erythropoietin|Recombinant Human Erythropoietin, EPREX 4000 IU/0.4 ml, three times in a week, until the correction of anemia, approximately two months.
89538728|NCT03255317|Experimental|Within-participant micro-randomization|Intervention includes Reinforcers and Notifications through the app. At each available decision time, each participant is randomly assigned to either receive an engagement strategy or to not receive an engagement strategy.
89538729|NCT04431921||Lung cancer patients|Lung cancer survivors who had stable conditions and routine follow-up at Hacettepe University Oncology Hospital
89538730|NCT04431921||Healthy subjects|No health problems related or affect outcome measure parameters examined in this study.
89538731|NCT04833153|Experimental|PFP intervention|PFP 10 week continuing education intervention
89538732|NCT04833153|No Intervention|Control arm|Usual care
89538733|NCT04488107|Experimental|Dose escalation cohort of FCN-437c|"This study plans to start escalating from 50 mg QD, through 100 mg, 200 mg, 300 mg, 450 mg, to 600 mg.~Participants will receive FCN-437c in sequential 28-day cycles which are made up of monotherapy QD for 21 days followed by a 7 day rest period.~Participants must be histologically or cytologically diagnosed with ER+/ HER2- advanced breast cancer."
89608381|NCT01271842||Extra corporeal oxygenation|Survivors of ARDS due to influenza A (H1N1)2009 infection who needed an extracorporeal oxygenation at the time of infection
89608382|NCT01271842||No extracorporeal oxygenation|Survivors of ARDS due to influenza A (H1N1) 2009 infection who did not need an extracorporeal oxygenation at the time of infection
89608383|NCT04270006|Experimental|Exosomes|
89608384|NCT01271998|Experimental|healthy volunteer|healthy volunteers
89032889|NCT04110327||Critical Limb Ischemia with major tissue loss|Subjects presenting with major tissue loss (Rutherford 6)
89032890|NCT03458624||Not applicable-observational study|Not applicable-observational study
88956815|NCT03811002|Active Comparator|Arm II (etoposide, cisplatin, carboplatin, radiation therapy)|Patients receive treatment as in Arm I. Patients also receive atezolizumab IV over 30-60 minutes on day 1 or 2 of each chemotherapy cycle. Cycles repeat every 3 weeks for 17 cycles (1 year) in the absence of disease progression or unacceptable toxicity. Patients undergo blood specimen collection throughout the trial.
88956816|NCT03804944|Active Comparator|ARM 1|Focal hypo-fractionated radiation therapy 8 Gy x 3 fractions, starting day 8, every other day (M/W/F or W/F/M or F/M/W).
88956817|NCT03804944|Active Comparator|ARM 2|Focal hypo-fractionated radiation therapy - 8 Gy x 3 fractions starting day 8, every other day (M/W/F or W/F/M or F/M/W). + Pembrolizumab, on day 12 (last day of radiotherapy), infused over 200mg IV over 30 minutes and then repeated every 3 weeks until disease progression or unacceptable toxicity.
88956818|NCT03804944|Active Comparator|ARM 3|Ftl-3 ligand, self-administered by subcutaneous injections at week 1, daily, for 5 consecutive days + Focal hypo-fractionated radiation therapy - 8 Gy x 3 fractions starting day 8, (every other day (M/W/F or W/F/M or F/M/W).
88956819|NCT03804944|Active Comparator|ARM 4|Ftl-3 ligand, self administered subcutaneous injections at day 1 for 5 consecutive days+ Focal hypo-fractionated Radiation therapy starting day 8, - 8 Gy x 3 fractions, every other day (M/W/F or W/F/M or F/M/W). + Pembrolizumab, on day 12 (last day of radiotherapy), 200mg IV infused over 30 minutes then repeated every 3 weeks until disease progression or unacceptable toxicity.
88982914|NCT02898207|Experimental|Dose Level 3a: Olaparib 200 mg and Onalespib 120 mg/m^2|Dose Level 3a (DL3a): Patients received olaparib 200 mg PO BID on days 1-7 (cycle 0). Beginning in cycle 1, patients received olaparib 200 mg PO BID on days 1-28 and onalespib 120 mg/m^2 IV over 1 hour on days 1, 2, 8, 9, 15, and 16. Cycles repeated every 28 days in the absence of disease progression or unacceptable toxicity.
88982915|NCT02853474|Sham Comparator|Arm A: Chemotherapy (CT) alone|"The medical oncologists (or gastro enterologist physician) are in charge of the patient for CT administration, and for the management of symptoms related to the disease and/or the treatment, in accordance with professional practices. If needed (any time), a PC (Palliative consultation) visit could be performed.~Interventions are :~EORTC-QLQ-C30 questionnaire for the assessment of quality of life~HADS score for anxiety and depression assessment"
88982916|NCT02853474|Experimental|Arm B: CT + Early Palliative care(EPC)|"Standard oncology care as for arm A plus early PC visits.~Interventions are :~EORTC-QLQ-C30 questionnaire for the assessment of quality of life~HADS score for anxiety and depression assessment~Early palliative care visits"
88982917|NCT02825771|Experimental|Usual Care + Caring Contacts messages|Usual care services plus caring contacts messages
89503619|NCT00864175|Experimental|Treatment A - INCB007839 and Trastuzumab|"INCB007839 100 mg BID and trastuzumab~In Cycle 1, trastuzumab will be administered at a loading dose of 8 mg/kg as a 90 minute intravenous infusion on Day 8. In all subsequent 21-day cycles, trastuzumab will be administered at 6 mg/kg as a 90 minute intravenous infusion on Day 1."
89503620|NCT00864175|Experimental|Treatment B - INCB007839 and Trastuzumab|"INCB007839 200 mg BID and trastuzumab~In Cycle 1, trastuzumab will be administered at a loading dose of 8 mg/kg as a 90 minute intravenous infusion on Day 8. In all subsequent 21-day cycles, trastuzumab will be administered at 6 mg/kg as a 90 minute intravenous infusion on Day 1."
89503621|NCT00864175|Experimental|Treatment C - INCB007839 and Trastuzumab|"INCB007839 300 mg BID and trastuzumab~In Cycle 1, trastuzumab will be administered at a loading dose of 8 mg/kg as a 90 minute intravenous infusion on Day 8. In all subsequent 21-day cycles, trastuzumab will be administered at 6 mg/kg as a 90 minute intravenous infusion on Day 1."
89503622|NCT00864175|Experimental|Treatment D - INCB007839 and Docetaxel|INCB007839 300mg BID with docetaxel
89503623|NCT00861211|Experimental|Active treatment arm|
89503624|NCT00861211|Placebo Comparator|Placebo|
89503625|NCT02166593|Experimental|Pravastatin 40mg/Fenofibrate160mg|Pravastatin (40mg/day) Fenofibrate (160mg/day)
89503626|NCT02166593|Active Comparator|Atorvastatin Sodium|Atorvastatin Sodium (10mg/day)
89503627|NCT00858871|Active Comparator|Brivanib|
89503628|NCT00858871|Active Comparator|Sorafenib|
89503629|NCT02163083|No Intervention|Lymphadenectomy using standard Methods|Lymphadenectomy will be performed as a standard procedure
89503630|NCT02163083|Experimental|Lymphadenectomy using ICG|A fluorescent dye (indocyanine green) will be ultrasound-controlled preoperatively injected in the prostate. During robot-assisted radical intervention by DaVinci ® robot the lymphadenectomy is performed using the fluorescence lymphography.
89503631|NCT02162693|Experimental|Mesenchymal progenitor cells|Administrated for intra-articular use of Mesenchymal progenitor cells
89503632|NCT02162693|Active Comparator|Sodium Hyaluronate|Administrated for intra-articular use of Sodium Hyaluronate.
89503633|NCT02162927|Experimental|Potassium Nitrate (N)|This involves 1 serving (2 pills) of potassium nitrate KNO3- (N) (8 mmols NO3-). The supplementation period is six days. This pill must be taken on an empty stomach (2-3 hours after eating) and must be taken about 2-3 hours before exercise.
89503634|NCT02162927|Placebo Comparator|Potassium Chloride|This involves 1 serving (2 pills) of the nitrate-free placebo (PL) potassium chloride (8 mmol KCl) for a six-day supplementation period. This pill must be taken on an empty stomach (2-3 hours after eating) and must be taken about 2-3 hours before exercise.
89503635|NCT02166671|Experimental|HBV booster vaccination|
89503636|NCT02163161|Experimental|Treatment A|
88982918|NCT02825771|Active Comparator|Usual Care|Usual care services provided in that community following identification of suicidal ideation or behavior.
89032891|NCT04049175|Experimental|Treatment A|Administration of CHF 6532 Dose #1
89032892|NCT04049175|Experimental|Treatment B|Administration of CHF 6532 Dose #2
89032893|NCT04049175|Experimental|Treatment C|Administration of CHF 6532 Dose #3
89032894|NCT04049175|Placebo Comparator|Treatment D|Administration of CHF 6532 Placebo
89032895|NCT02926131||Infants|Infants requiring serum bilirubin (SBR) measurement seen in Wang Pha clinic (WPA) clinic.
89032896|NCT04692311|Experimental|Persons with central nervous system diseases|Persons with central nervous system diseases received additional training with i-ACT during 6 weeks. After final training, a semi-structured interview was performed. And at six weeks follow-up, a final assessment took place.
89503637|NCT02163161|Experimental|Treatment B|
89503638|NCT02163161|Experimental|Treatment C|
89503639|NCT00917293|Experimental|Pyridoxal 5'-Phosphate|Pyridoxal 5'-Phosphate, enteric-coated 2x 250mgs po bid.
89503640|NCT00917293|Placebo Comparator|Placebo|Placebo 2 pills, po bid.
89503641|NCT02166749||Subtotal abdominal hysterectomy|107 women
89503642|NCT02166749||Total abdominal hysterectomy|105 women
89503643|NCT02166827|Active Comparator|NeuroAD|NeuroAd Treatment, synchronized TMS and cognitive training stimulation
89503644|NCT02166827|Sham Comparator|Sham TMS+Cog|Sham Device, has the same appearance and sound as the real device, combined with sham cognitive exercises. Patients come for the same number of sessions, delivers no real stimulation or cognitive training.
89503645|NCT00845299|Experimental|1|Latanoprost punctal plug and use of artificial tears containing Benzalkonium Chloride
88815213|NCT00974480|Active Comparator|Combination of Redermic and Rejuva-A|Week 1, Rejuva-A cream was applied to face in the evening twice a week. Weeks 2 & 3, Rejuva-A cream was applied to the face in the evening three times a week. Weeks 4-24, Rejuva-A cream was applied to the face in the evening every other day. In cases of intolerance, returned to the previous dosage and remained there until the end of study. Redermic was applied every evening when Rejuva-A™ was not applied, as well as every morning.
89503646|NCT00845299|Experimental|2|Latanoprost punctal plug only
89503647|NCT02255591|Experimental|Shamrock|Use of the Shamrock technique to place a lumbar plexus block with injection of 20 mL 2% Lidocaine-adrenaline added gadolinium.
89503648|NCT02255591|Active Comparator|Lumbar Ultrasound Trident|Use of the Lumbar Ultrasound Trident technique to place a lumbar plexus block with injection of 20 mL 2% lidocaine-adrenaline added gadolinium.
89503649|NCT04473391|Experimental|Robot-assisted Rehabilitation|Participants will receive Functional Electrical Stimulation (FES) training with a lower extremity cycle-ergometer (MOTOmed Viva 2, Reck GmbH., Germany) and a 6-channel FES Device (TrainFES, Biomedical Devices SpA, Chile). Patients will perform lower limb exercises assisted by the device. Training involve 24 sessions, 3 sessions per week for 8 weeks, each lasting about 45 minutes.
89503650|NCT02170883|Experimental|Interactive SMS|"Intervention with interactive SMS (text messaging) by which patients are asked to disclose their level of agreement with the following statement I follow my asthma medication plan and pharmacist follow-up"
89503651|NCT02170883|Active Comparator|Usual care|Pharmacist conducted patient education, counseling and action-plan
89503652|NCT00913393|Placebo Comparator|1|Placebo IV
89503653|NCT00913393|Experimental|2|3 mg/kg FG-3019 IV
89503654|NCT00913393|Experimental|3|10 mg/kg FG-3019 IV
89503655|NCT02166983|Experimental|Arm IA (Lumosity, relaxation, compensatory strategies)|Participants complete Lumosity cognitive exercises. Lumosity cognitive exercises are online video game-based activities that are designed to practice various cognitive skills including processing speed, attention, memory and executive function. Participants complete cognitive exercises at least 20 minutes a day, 5 days a week for 6 weeks. Participants also complete relaxation exercises (guided imagery, progressive muscle relaxation, and/or autogenics) at least 10 minutes a day for 6 weeks and compensatory strategies (the use of external devices such as a notebook, day planner, or smartphone for cuing, reminding, and organizing; the use of memory strategies such as repetition, paraphrasing, and active listening; and the use of executive strategies such as self-talk for planning and attention orientation) as much as possible.
89503656|NCT02166983|Experimental|Arm IB (Active Journaling, relaxation, compensatory strategy)|Participants complete Active Journal cognitive exercises. Active Journaling requires participants to keep a written diary or journal where she discusses what her thoughts and feelings about various events with a focus on describing the meaning of the activities and experiences, particularly new things that were learned. Active Journaling is a method of practicing various cognitive skills including communication, organization, memory and executive function. Participants complete cognitive exercises at least 20 minutes a day, 5 days a week for 6 weeks. Participants also complete relaxation exercises and compensatory strategies as in Arm IA.
88815214|NCT04632641|Experimental|Perclose ProGlide Suture-Mediated Closure System (SMC) - LARGE-BORE PROCEDURES|Perclose ProGlide Suture-Mediated Closure System (SMC) will be used as closure strategy for venous access sites using sheath sizes greater than 13F.
89503657|NCT02166983|Experimental|Arm II (Lumosity only)|Participants complete Lumosity exercises as in Arm IA.
89503658|NCT04486963|Experimental|Sanhuangjingshimingwan group|Sanhuangjingshimingwan,12g/bag,1 bag,Bid.Anti VEGF injection will be injected monthly if needed.
89503659|NCT04486963|Placebo Comparator|Sanhuangjingshimingwan Placebo group|Sanhuangjingshimingwan placebo,12g/bag,1 bag,Bid.Anti VEGF injection will be injected monthly if needed.
89503660|NCT02170961||acute heart failure (AHF)|patients consulting the emergency department for dyspnea. the diagnosis of AHF was based on clinical, biological (BNP) and echocardiographic data.
89503661|NCT02170961||Non acute heart failure (NAHF)|patients consulting the emergency department for dyspnea. the diagnosis of AHF was based on clinical, biological (BNP) and echocardiographic data.
89503662|NCT03539237|Experimental|"Video-group"|"Video group: Individuals in this group receive the intervention Video demonstration of physical activity intensity levels. They watch a 3-minute-video explaining and visualizing light-, moderate-, and vigorous-intensity levels of physical activity before completing a tablet PC-supported physical activity assessment at the DZHK-examination center.The video can not be skipped."
88815215|NCT04632641|Active Comparator|Figure 8 Suture - LARGE-BORE PROCEDURES|Figure 8 suture will be used as a closure technique for venous access sites using sheath sizes greater than 13F.
88815216|NCT04538261|Sham Comparator|Control|Non-inflation of the balloon device
88815217|NCT04538261|Experimental|Intervention|Inflation of the balloon device
88815218|NCT02244983||EFAB 65|Patients presenting to the emergency department with falls, above 65 years of age. Patients History will be taken as well as a blood sample
88815219|NCT00975650|Experimental|Test 8.0, Ref 5.0, Test 14.0, Test 11.0|Treatment A: 8.0 mg Nasobol® (2 syringes), b.i.d. for 7 days; Treatment D: 5.0 mg Androderm® (Positive Control)-Patch, q.d. for 7 days; Treatment C: 14.0 mg Nasobol® (2 syringes), b.i.d. for 7 days; Treatment B: 11.0 mg Nasobol® (2 syringes), b.i.d. for 7 days;
88815220|NCT00975650|Experimental|Test 11.0, Test 8.0, Ref 5.0, Test 14.0|Treatment B: 11.0 mg Nasobol® (2 syringes), b.i.d. for 7 days; Treatment A: 8.0 mg Nasobol® (2 syringes), b.i.d. for 7 days; Treatment D: 5.0 mg Androderm® (Positive Control)-Patch, q.d. for 7 days; Treatment C: 14.0 mg Nasobol® (2 syringes), b.i.d. for 7 days
89503663|NCT03539237|No Intervention|"No video-group"|"No video group: Individuals in this group do not receive the intervention Video demonstration of physical activity intensity levels. They complete a tablet PC-supported physical activity assessment at the DZHK-examination center without receiving a 3-minute-video explaining and visualizing the different intensity levels of physical activity."
88982919|NCT02775383||Longitudinal|Participants with MDS, MDS/MPN overlap disorder, AML <30% blasts without core binding factor or acute promyelocytic leukemia, ICUS, or at risk based on select karyotypic or genetic abnormalities
88982920|NCT02775383||Cross-sectional|Participants who do not have MDS, MDS/MPN overlap disorder, or ICUS and have the baseline visit only
88982921|NCT02713126|Placebo Comparator|Placebo|Subjects will undergo cardiac exercise training and receive inhaled or oral placebo three times per day for 12 weeks while wearing an accelerometer
88982922|NCT02713126|Active Comparator|Sodium Nitrite|Subjects will undergo cardiac exercise training and receive inhaled or oral sodium nitrite three times per day for 12 weeks while wearing an accelerometer
89503664|NCT02167061|Experimental|(Part 1) DA-1229_01 → E+M|DA-1229_01 : Evogliptin/Metformin XR 5/1000mg E : Evogliptin 5 mg M : Metformin XR 1000 mg
89503665|NCT02167061|Experimental|(Part 1) E+M → DA-1229_01|DA-1229_01 : Evogliptin/Metformin XR 5/1000mg E : Evogliptin 5 mg M : Metformin XR 1000 mg
89503666|NCT02167061|Experimental|(Part 2) DA-1229_01 fast → fed|DA-1229_01 : Evogliptin/Metformin XR 5/1000mg Fast : administration on an empty stomach Fed: administration after high-fat diet
89503667|NCT02167061|Experimental|DA-1229_01 fed → fast|DA-1229_01 : Evogliptin/Metformin XR 5/1000mg Fast : administration on an empty stomach Fed: administration after high-fat diet
89503668|NCT03715465|Active Comparator|Estimated DLMO|Four weeks (28 days) of nightly melatonin 0.5 mg fast dissolve tablets timed to be administered 3 hours before estimated dim light melatonin onset.
89503669|NCT03715465|Experimental|Measured DLMO|Four weeks (28 days) of nightly melatonin 0.5 mg fast dissolve tablets timed to be administered 3 hours before measured dim light melatonin onset.
89503670|NCT02163239||10mm Cannula|Subjects that are scheduled for a robot-assisted laparoscopic single-incision surgery for cholecystectomy, benign hysterectomy or salpingo-oophorectomy under the care of the study investigator
89503671|NCT04657523|Experimental|Investigational Ultrasound Imaging for Liver Fat Quantification|
89503672|NCT00781339|Experimental|Active|
89503673|NCT02171039|Experimental|dabigatran plus atorvastatin|
89503674|NCT02171039|Active Comparator|dabigatran|
89503675|NCT02171039|Active Comparator|atorvastatin|
89503676|NCT03540407|Experimental|Oncoxin-Viusid®|will receive the Oncoxin-Viusid® (oral solution) concomitant to the onco-specific treatment.
89503677|NCT03540407|Placebo Comparator|Placebo|will receive a Placebo concomitant to the onco-specific treatment
89503678|NCT00840073|Experimental|Trandolapril|Trandolapril 4 mg Tablet (test) dosed in first period followed by Mavik® 4 mg Tablet (reference) dosed in second period
89503679|NCT00840073|Active Comparator|Mavik®|Mavik® 4 mg Tablet (reference) dosed in first period followed by Trandolapril 4 mg Tablet (test) dosed in second period
89503680|NCT02261207|Experimental|Axitinib|Axitinib will be administered at the dose of 5mg twice a day, continuously. Treatment will be continued till evidence of progression, or toxicities or patient withdrawal.
89503681|NCT02167295||Focus group|The focus groups will consist of 6 to 8 persons each (N = 32). The focus group discussions will last for about 60 to 90 minutes. The discussion topics will be based on previous literature and experience and will include reasons for betel quid chewing or for quitting, pros and cons of betel quid chewing, barriers to and facilitators of abstinence, health beliefs and experiences about betel quid chewing and other issues.
89503682|NCT02167295||In-depth interviews.|We will conduct 15 one-to-one interviews, each lasts for about 45 to 60 minutes. Participants will be interviewed by a trained interviewer using a structured interview. The interview will be designed to collect information on socio-demographic background, current and/or former betel quid use, other substance use (smoking and/or alcohol consumption), as well as other variables including usage parameters, psychosocial and environmental influences on betel quid chewing, barriers to and interest in quitting, and knowledge of adverse effects on health.
89503683|NCT02167295||Self-report questionnaire|This study is expected to enroll 30 participants who have smoking and betel nut chewing behaviors.Participants will complete 4 separate visits to CMUH, during which they will complete the same self-report questionnaire designed to measure withdrawal symptoms relating to betel quid chewing. To better measure betel quid withdrawal symptoms and to distinguish the 6 symptoms from those of smoking withdrawal, Participants will be required to attend one visit regular cigarette smoking and betel nut chewing behavior without restriction (as control), one visit after 12 hours of overnight betel quid deprivation (no cigarette deprivation), one visit after 12 hours of overnight cigarette deprivation (no betel quid deprivation), and one visit after 12 hours of both overnight betel quid and cigarette deprivation.
89503684|NCT03697447|Experimental|Endermotherapy treated scar|Endermotherapy massage treatment
88956822|NCT03779854|Experimental|Arm I (chemotherapy, naive T-cell depleted PBSC)|"CONDITIONING REGIMEN A: Patients undergo TBI BID on days -10 to -7, then receive thiotepa IV over 3 hours QD on days -6 and -5, and fludarabine IV over 30 minutes once daily on days -6 to -2.~CONDITIONING REGIMEN B: Patients undergo TBI BID on days -8 to -5, then receive fludarabine IV over 30 minutes QD on days -4 to -2, and cyclophosphamide IV over 1 hour QD on days -3 and -2.~CONDITIONING REGIMEN C: Patients receive fludarabine IV over 30 minutes QD on days -6 to -2, busulfan IV over 180 minutes QD on days -5 to -2, and undergo total body irradiation BID on day -1.~TRANSPLANT: Patients receive naive T-cell depleted PBSCs on day 0.~GVHD PROPHYLAXIS: All patients receive tacrolimus IV beginning on day -1 and methotrexate IV on days 1, 3, 6, and 11."
88956823|NCT03779854|Active Comparator|Arm II (chemotherapy, unmanipulated T cell replete BM)|"CONDITIONING REGIMEN A: Patients undergo TBI BID on days -10 to -7, then receive thiotepa IV over 3 hours QD on days -6 and -5, and fludarabine IV over 30 minutes once daily on days -6 to -2.~CONDITIONING REGIMEN B: Patients undergo TBI BID on days -8 to -5, then receive fludarabine IV over 30 minutes QD on days -4 to -2, and cyclophosphamide IV over 1 hour QD on days -3 and -2.~CONDITIONING REGIMEN C: Patients receive fludarabine IV over 30 minutes QD on days -6 to -2, busulfan IV over 180 minutes QD on days -5 to -2, and undergo total body irradiation BID on day -1.~TRANSPLANT: Patients receive unmanipulated T cell-replete BM on day 0.~GVHD PROPHYLAXIS: All patients receive tacrolimus IV beginning on day -1 and methotrexate IV on days 1, 3, 6, and 11."
88956824|NCT03763162|Experimental|Treatment (daratumumab, bortezomib, dexamethasone, ixazomib)|Patients receive daratumumab IV over 3.5-6.5 hours on days 1, 8, and 15, bortezomib SC on days 1, 4, 8, and 11, and dexamethasone IV over 15 minutes on days 1, 8, and 15 and PO on days 2, 4, 5, 9, 11, 12, and 16. Treatment repeats every 28 days for 3 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive daratumumab IV over 3.5 hours on days 1 and 15 of cycles 4-7 and day 1 of subsequent cycles, ixazomib PO on days 1, 8, and 15, and dexamethasone IV over 15 minutes or PO once weekly. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89032897|NCT04692311|Other|Occupational therapists|Occupational therapists were invited to a semi-structured interview to gather information about their professional opinion regarding i-ACT.
89503685|NCT03697447|No Intervention|Control scar|No intervention, standard of care
89503686|NCT02163473||Septic patients|Blood Draw Biological samples: The investigators will collect blood and compare the expression of HIF complex in 3 distinct ways: between patients and controls, within the same patient in a time-dependent fashion, and between different patients.
89503687|NCT02163473||Healthy Control|The investigators will collect blood and compare the expression of HIF complex in 3 distinct ways: between patients and controls, within the same patient in a time-dependent fashion, and between different patients.
89503688|NCT02167373|No Intervention|Control|
89503689|NCT02167373|Experimental|Intervention|Cogito Companion Intervention. Participants will be provided with a mobile phone application that provides feedback on their mental health. The participants' clinicians will be provided with a desktop application to review their patients' results.
89503690|NCT02163551||Spinal Cord Injury|Participants with spinal cord injury (n = 20) will be age 30-60 years with motor complete spinal cord injuries, otherwise known as American Spinal Injury Association (ASIA) classification A or B, between the levels of C3 and T12. Patients will have to be able to breathe independently without the use of a ventilator. Subjects will be divided equally into four different injury level categories. The four categories are high tetraplegia (C3 - C5), low tetraplegia (C6-C8), high paraplegia (T1-T6), and low paraplegia (T7-T12).
89503691|NCT02163551||Controls|Twenty healthy age-matched adults will also participate.
89503692|NCT00838591|Experimental|1|MN-221 given i.v. 1-hour infusion a total dose of 1200 μg (40 μg/min for 15 min [600 μg] + 13.3 μg/min for 45 min [600 μg]) as an adjunct to the standard of care for acute exacerbation of asthma.
89503693|NCT00838591|Placebo Comparator|Placebo|Placebo (Lot #CLO-095) was packaged in identical vials containing only excipients and administered as an i.v. 1-hour infusion with a regimen as described for MN-221.
89503694|NCT02163629|Experimental|psychotherapeutic intervention|"The psychotherapeutic intervention stress management is based on therapeutic, behavioral and cognitive strategies. They are active and put the patient actor of his adaptation of the heart transplantation entire process. The approached components are emotional, cognitive and behavioral (techniques of communication and problem solving)."
89503695|NCT02163629|No Intervention|Usual medical care|
89503696|NCT00838279|Experimental|Lamotrigine|Lamotrigine 2 x 25 mg Chewable Tablet (test) dosed in first period followed by Lamictal® 2 x 25 mg Chewable Tablet (reference) dosed in second period
89503697|NCT00838279|Active Comparator|Lamictal®|Lamictal® 2 x 25 mg Chewable Tablet (reference) dosed in first period followed by Lamotrigine 2 x 25 mg Chewable Tablet (test) dosed in second period
89503698|NCT02163707|Other|Psilocybin Dose 1|0.3 mg/kg (approximately 20mg/70kg)
89503699|NCT02163707|Other|Psilocybin Dose 2|0.45 mg/kg (approximately 30 mg/70 kg)
89503700|NCT02163707|Other|Psilocybin Dose 3|0.6 mg/kg (approximately 40 mg/70 kg)
89503701|NCT00772525|Experimental|Sequence 1|"placebo,1 day treatment period 1~50 mg Nerispirdine, 1 day treatment period 2~400 mg Nerispirdine, 1 day treatment period 3"
89503702|NCT00772525|Experimental|Sequence 2|"placebo,1 day treatment period 1~400 mg Nerispirdine, 1 day treatment period 2~50 mg Nerispirdine, 1 day treatment period 3"
89503703|NCT00772525|Experimental|Sequence 3|"50 mg Nerispirdine, 1 day treatment period 1~placebo, 1 day treatment period 2~400 mg Nerispirdine, 1 day treatment period 3"
89503704|NCT00772525|Experimental|Sequence 4|"50 mg Nerispirdine, 1 day treatment period 1~400 mg Nerispirdine, 1 day treatment period 2~placebo, 1 day treatment period 3"
89538734|NCT04488107|Experimental|Dose expansion cohort of FCN-437c + letrozole|"The dose expansion stage will be initiated after escalating to MTD.~Six patients will be treated with FCN-437c combined with letrozole.~DLT assessment and PK blood collection will be completed in the first 28-day cycle.~If DLT does not occur in the first three patients, 15 additional patients were enrolled to complete the expansion study of MTD group.~If one DLT occurs in the first three patients, three additional patients will be enrolled onal patients were enrolled and completed the MTD group.~Patients will be evaluated every 8 weeks until disease progression, intolerable toxicity, death, investigator's decision or patient's voluntary withdrawal from the study."
89538735|NCT04974957|Experimental|SHR-1701+BP102|
89538736|NCT02455817||Cypher|Access rate of angina including degree, post PCI up to 1 year for the Cypher stent.
89538737|NCT02455817||Taxus Express|Access rate of angina including degree, post PCI up to 1 year for the Taxus Express stent.
89538738|NCT02455817||Xience V|Access rate of angina including degree, post PCI up to 1 year for the Xience V stent.
89206585|NCT00623766|Experimental|Ipilimumab, 10 mg/kg, IV in corticosteroid-free patients|Participants who had not received corticosteroid therapy for at least 10 days before starting study drug received ipilimumab,10 mg/kg, as a 90-minute intravenous (IV) infusion every 3 weeks (Weeks 1, 4, 7, and 10) during the Induction Phase. Those eligible (patients who did not discontinue due to toxicity, did not show progression at 24 weeks, and who remained clinically stable) for the Maintenance Phase continued to receive ipilimumab, 10 mg/kg IV, every 12 weeks, beginning at Week 24.
89538739|NCT02455817||Promus Element|Access rate of angina including degree, post PCI up to 1 year for the Promus stent.
89538740|NCT02455817||Resolute|Access rate of angina including degree, post PCI up to 1 year for the Resolute stent.
89538741|NCT02455817||Bare metal stents|Access rate of angina including degree, post PCI up to 1 year for bare metal stents.
89206586|NCT00623766|Experimental|Ipilimumab, 10 mg/kg, IV in corticosteroid-dependent patients|Participants who were dependent on corticosteroid therapy received ipilimumab, 10 mg/kg, as a 90-minute intravenous (IV) infusion every 3 weeks (Weeks 1, 4, 7, and 10) during the Induction Phase. Those eligible (patients who did not discontinue due to toxicity, did not show progression at 24 weeks, and who remained clinically stable) for the Maintenance Phase continued to receive ipilimumab, 10 mg/kg IV, every 12 weeks, beginning at Week 24.
89206587|NCT00953979|Active Comparator|Sulfasalazine|Sulfasalazine is a drug in treatment RA, AS and ulcerative colonitis. In this study, Sulfasalazine is used to act as an active comparator to access the efficacy of kunxian capsule.
89538742|NCT04974723||Patients Treated with Abaloparatide|Patients who filled ≥ 1 prescription for ABL (TYMLOS) as their index medication during the identification period.
89538743|NCT04974723||Patients Treated with Teriparatide|Patients who filled ≥ 1 prescription for TPTD (Forteo) as their index medication during the identification period.
89608385|NCT00717418||1|"cyclosporine ophthalmic emulsion 0.05%~artificial tears"
89608386|NCT00717574|Active Comparator|Sevoflurane group|Sevoflurane based general anesthesia
89206588|NCT00953979|Placebo Comparator|placebo|The placebo capsule was used to be a comparator of kunxian capsule
89206589|NCT00832728|Active Comparator|ELAD|ELAD Therapy + Standard of Care
89206590|NCT00832728|Other|Standard of Care|Hospital based standard of care for acute liver failure
89206591|NCT00956865|Active Comparator|Voucher|Voucher for transportation reimbursement
89608387|NCT00717574|Active Comparator|Propofol group|Propofol based general anesthesia
89608388|NCT00718120|Experimental|Fluviral Adult Group|Subjects aged between 18 and 60 years received a single dose of Fluviral® vaccine.
89608389|NCT00718120|Experimental|Fluviral Elderly Group|Subjects aged more than 60 years received a single dose of Fluviral® vaccine.
89608390|NCT01277380||Experimental Group|
89608391|NCT01277380||Control Group|
89608392|NCT01277380||Negative control group|
89608393|NCT01277458||Non white HIV positive men who have sex with men|
89608394|NCT01277536||hospitalization >24 hours|
89608395|NCT02992054||Stimulating activities with the use of tactile tablet computer|Stimulating activities through the use of a tactile tablet computer. These tablets are linked to an internet-based service platform and offer a very easy and intuitive interaction for the user, even when this person is suffering from a moderate cognitive and/or physical impairment.
89608396|NCT02992054||Stimulating activities with usual stimulation activity program|No Stimulating activities through the use of a tactile tablet computer
89608397|NCT01277614|Experimental|Lifestyle counseling|This is a 6-month intervention in which participants with 2 or more MS components are randomly assigned to intervention or control group. Intervention comprise individual diet counseling, an exercise plan and monthly lifestyle workshops. Controls receive printed material on healthy eating and lifestyle modification.
89608398|NCT01277614|Placebo Comparator|Health Literature|
89608399|NCT01277692|Experimental|Part 1: Single Dose Escalation in Healthy Subjects|The doses currently planned are 10, 30mg, 100mg, 200mg
89608400|NCT01277692|Experimental|Part 2: Repeat Dose Escalation in Healthy Subjects|The first planned dose is currently 10mg QD and the planned maximum dose is 100mg QD
89608401|NCT01277692|Experimental|Part 3: Single Dose Escalation in HCV Infected Subjects|The planned doses for Part 3 are 5mg, 30mg, and 100 mg.
89608402|NCT00719134|Experimental|1|Maxalt administration at onset of migraine
89608403|NCT00719134|Placebo Comparator|2|
89608404|NCT00719134|Experimental|3|
89608405|NCT00719134|Placebo Comparator|4|
89608406|NCT00719134|Experimental|5|
89608407|NCT00719134|Experimental|6|
89608408|NCT04146363|Placebo Comparator|Placebo|"Induction Period (Baseline-Week 16):~Two subcutaneous (SC) injections of Placebo as a loading dose at Baseline and Week 2 followed by a single injection every 2 weeks (Q2W) from Week 4 until Week 14.~Maintenance Period (Week 16-Week 52):~Two placebo SC injections as loading dose on Week 16 and Week 18. One placebo SC injection Q2W until Week 50."
89503705|NCT00772525|Experimental|Sequence 5|"400 mg Nerispirdine, 1 day treatment period 1~placebo, 1 day treatment period 2~50 mg Nerispirdine, 1 day treatment period 3"
89503706|NCT00772525|Experimental|Sequence 6|"400 mg Nerispirdine, 1 day treatment period 1~50 mg Nerispirdine, 1 day treatment period 2~placebo, 1 day treatment period 3"
89503707|NCT02171117|No Intervention|CT-group|standard induction and consolidation chemotherapy only, without microtransplantation
89503708|NCT02171117|Experimental|MST-group|standard induction and consolidation chemotherapy with microtransplantation
89503709|NCT00769795|Experimental|Experimental|Bicalutamide 50 mg daily for 12 weeks Goserelin 10.8 mg SC once IMC-A12 10 mg/kg IV every three weeks for 12 weeks
89503710|NCT02171273|Experimental|Chronic circadian disruption|Following a baseline of adequate time in bed, study participants will spend 3 weeks on a daily jet-lag schedule (where each day is longer than 24 hours).
89503711|NCT02171273|Experimental|Chronic sleep restriction|Following a baseline of adequate time in bed, study participants will have a shortened opportunity for sleep during each 24-hour day (for three weeks).
89503712|NCT02171273|Active Comparator|Control (sleep extension)|Following a baseline of adequate time in bed, study participants will continue to have adequate time in bed and opportunity for sleep during each 24-hour day, for 3 weeks.
89503713|NCT02167607|Active Comparator|Purple Potato|Active Comparator
89503714|NCT02167607|Placebo Comparator|White Potato|Placebo Comparator
89503715|NCT02163785|Active Comparator|Supine position|Abdominoperineal resection - perineal time- in supine position
89503716|NCT02163785|Experimental|Prone position|Abdominoperineal resection - perineal time- in prone position
89503717|NCT00767299|Experimental|1|
89503718|NCT00767299|Placebo Comparator|2|
89023682|NCT04955301|Experimental|Environmental benefits priming group|"Participants will be cueing with environmental benefits by asking to do a word-search exercise beginning with: In the following, please choose words/statements that can indicate that having a healthy and sustainable diet can have environmental benefits, such as..."
89023683|NCT04955301|Experimental|Environmental and health co-benefits priming group|"Participants will be cueing with environmental and health co-benefits by asking to do a word-search exercise beginning with: In the following, please choose words/statements that can indicate that having a healthy and sustainable diet can have both benefits for health and the environment, such as..."
89023684|NCT04939662|Experimental|Olaparib+Bevacizumab to SCLC patients|"Regimen and administration:~Administration of olaparib Olaparib 300 mg bid per os every 12 hours D1-21 administered in each cycle days. One cycle consists of 21 days. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water.~Administration of bevacizumab Bevacizumab 15 mg/kg via IV administered on Day1 of each cycle. One cycle is consisted of 21 days.~The subject's body weight criterion is based on C1D1 (first dose date), and if more than 10% of BW is increased and decreased, the drug dose is changed to that BW."
89023685|NCT04935203|No Intervention|Control message group|Participants will not receive the priming manipulation.
89503719|NCT03134677|Experimental|Bupivacaine|We were performed spinal anesthesia sitting position by midline. After confirming the free flow of cerebrospinal fluid, bupivacaine was administered without aspiration.ECG recordings were performed at preoperative, 5, 15, and 30 minutes after initial anesthesia and 30 minutes post-operatively.
89503720|NCT03134677|Experimental|Sevoflurane|We were performed general anesthesia with sevoflurane. Anesthesia was maintained with 2-3% sevoflurane. ECG recordings were performed at preoperative, 5, 15, and 30 minutes after initial anesthesia and 30 minutes post-operatively.
89503721|NCT02759939|Experimental|Arm 1|
89503722|NCT02759939|Experimental|Arm 2|
89503723|NCT02759939|Experimental|Arm 3|
89503724|NCT02759939|No Intervention|Arm 4|
89503725|NCT03577483|Other|Parkinson's disease|Diagnosis of idiopathic Parkinson's disease (PD) according to criteria
89503726|NCT03577483|Other|Multiple system atrophy|Diagnosis of Multiple Atrophy System (MSA) Parkinsonian form possible or probable according to Gilman et coll 's criteria (2008)
89503727|NCT03577483|Other|Healthy volunteer|Absence of neurologic and oto-rhino-laryngologic disease
89503728|NCT02163863|Experimental|BioMimics 3D|The BioMimics 3D Stent System, delivering a self-expanding Nitinol stent with 3D helical centerline geometry.
89503729|NCT02163863|Active Comparator|Control|CR Bard LifeStent System, delivering a self-expanding Nitinol stent
89503730|NCT02163941|Experimental|Compassion Training|8 weeks of training in Cognitively-Based Compassion Training (CBCT). Classes will meet once per week for 2 hours and participants will be asked to meditate at home for 20 minute each day.
89503731|NCT03540329|Active Comparator|I-A Internal distraction|Internal osteogenesis distractor in congenital mandibular deformities in patients in growing age.
89503732|NCT03540329|Active Comparator|I-A External distraction|External osteogenesis distractor in congenital mandibular deformities in patients in growing age.
89503733|NCT03540329|Active Comparator|I-B Internal distraction|Internal osteogenesis distractor in congenital mandibular deformities in adult patients.
89503734|NCT03540329|Active Comparator|I-B External distraction|External osteogenesis distractor in congenital mandibular deformities in adult patients.
89503735|NCT03540329|Active Comparator|II-A Internal distraction|Internal osteogenesis distractor in acquired mandibular deformities in patients in growing age
89503736|NCT03540329|Active Comparator|II-A External distraction|External osteogenesis distractor in acquired mandibular deformities in patients in growing age
89503737|NCT03540329|Active Comparator|II-B Internal distraction|Internal osteogenesis distractor in acquired mandibular deformities in Adult patients.
89503738|NCT03540329|Active Comparator|II-B External distraction|External osteogenesis distractor in acquired mandibular deformities in Adult patients.
89503739|NCT00722917|Experimental|TAK-379 25 mg QD|
89503740|NCT00722917|Experimental|TAK-379 100 mg QD|
89503741|NCT00722917|Experimental|TAK-379 200 mg QD|
89503742|NCT00722917|Active Comparator|Pioglitazone 30 mg QD|
89503743|NCT00722917|Placebo Comparator|Placebo|
89503744|NCT03540797||Intensive care unit (ICU) patients with sepsis|
89503745|NCT02164097|Experimental|ODSH and ICE Chemotherapy|"Patients will receive standard doses of ICE Chemotherapy:~Ifosfamide 1800 mg/m2 mixed with Mesna 360 mg/m2 IV over 2 hours on days 1, 2, 3, 4, and 5~Carboplatin 400 mg/m2 IV over 1 hour on days 1 and 2~Etoposide 100 mg/m2 IV over 1 hour on days 1, 2, 3, 4, and 5~ODSH will be administered as a 4 mg/kg bolus 30 minutes after the first ifosfamide dose followed immediately by a continuous intravenous ODSH infusion of 0.25 mg/kg/hour for five consecutive days, on days 1-5, for a total of 120 hours of continuous ODSH infusion."
89503746|NCT00717457|Active Comparator|exenatide|
89503747|NCT00717457|Experimental|taspoglutide 10mg|
89503748|NCT00717457|Experimental|taspoglutide 10mg/20mg|
89503749|NCT02171507|Active Comparator|Dabigatran etexilate|
89503750|NCT02171507|Active Comparator|Diclofenac|
89503751|NCT02171507|Experimental|Dabigatran etexilate + diclofenac|
89503752|NCT03539159|Experimental|Allogeneic conventional sized serum eye drops|
89503753|NCT03539159|Experimental|Allogeneic micro sized serum eye drops|
89503754|NCT00758953|Experimental|1|
89503755|NCT00758953|Experimental|2|
89503756|NCT00758953|Placebo Comparator|3|
89503757|NCT00758953|Placebo Comparator|4|
89503758|NCT02167685||CMX001|Subjects who have previously participated in CMX001-301 or other CMX001 study.
89503759|NCT00758563|Placebo Comparator|A|
89503760|NCT00758563|Active Comparator|B|
89503761|NCT02171585|Experimental|Dabigatran without Clarithromycin|
89503762|NCT02171585|Experimental|Dabigatran with Clarithromycin|
89503763|NCT03540251|Active Comparator|Therapeutic auricular points treatment|Therapeutic auricular points treatment including auricular points:CO18、TF2、TF4、AT4、CO15（with complaint of sweating）or CO12(with symptom of heart palpitation)in accordance with the position of auricular points Location map of national standard(GBVT13734-2008) Both groups received a booklet with information about self-care indications, auricular points and its management, and patients can record their hot flash score each day for 12 weeks in the booklets. In addition, both group received 8 treatment sessions of sticking and pressing predefined auricular points.
89503764|NCT03540251|Sham Comparator|Placebo auricular points treatment|Placebo auricular points treatment including auricular points AH9、AH11、TG3、AT2、LO4 in accordance with the position of auricular points Location map of national standard(GBVT13734-2008) Both groups received a booklet with information about self-care indications, auricular points and its management, and patients can record their hot flash score each day for 12 weeks in the booklets.In addition, both group received 8 treatment sessions of sticking and pressing placebo auricular points treatments.
89503765|NCT03134443|Active Comparator|Experimental group|Xiyanping injection(andrographolide sulfonate) 10-20ml/d, with 0.9% normal saline 100ml-250ml diluted intravenous drip (not with other drugs in the same container mixed use), control drip speed per minute of 30-40 drops.
89503766|NCT03134443|Placebo Comparator|control group|Xiyanping injection simulation(andrographolide sulfonate simulation) 10-20ml/d, The treatment method is the same as the experimental group.
89503767|NCT02171663|Experimental|BIBW 2992|
89503768|NCT05010967|Experimental|High intensity interval training|High intensity interval training will be administered three days a week for 8 weeks. six series with 3 minutes rest period between series. For first 4 weeks the series would consist of 30 seconds of exercise and 30 seconds rest. exercises will consist of burpees, skipping, lunges, 1-legged squat, leg lever, push ups. for next four weeks the duration of exercise will be 45 seconds followed by 30 seconds recovery.
89032898|NCT02923869|Active Comparator|Group L|Children will receive 0.15 ml/kg of 0.2% Levobupivacaine
89503769|NCT05010967|Active Comparator|Yoga Training|Yoga will be administered 3 days a week for 8 weeks. the session would be of 30-50 minutes with 5 minutes breathing followed by 15-35 minutes yoga and 10 minutes supine meditation. cat-cow stretch, child's pose, downward dog, plank, cobra pose will be used.
89503770|NCT02164175||HeRO Graft|End stage renal disease patients who receive HeRO Graft implant for dialysis access
89503771|NCT04438603||IgAN patients at low risk of disease progression|n = 30, incipient disease
89503772|NCT04438603||IgAN patients at high risk of disease progression|n = 60, incipient disease
89503773|NCT04438603||Long-term stable patients|n = 30, follow-up for at least 15 years
89503774|NCT04438603||Progressive IgAN patients|n = 30
89503775|NCT04438603||Healthy control|n = 30
89503776|NCT02167841|Experimental|Knee-Chest position|In this arm, the women will perform daily the Knee-Chest position between weeks 32-37. In week 37 the investigators will check via ultra sound if there was a successful version (if not, the woman would go to External Cephalic Version)
89503777|NCT02167841|No Intervention|External Cephalic Version|In this group the women will perform External Cephalic Version without doing maternal Knee-Chest position before.
89503778|NCT02171741|Experimental|Docetaxel + BIBW 2992|
89503779|NCT04438291|Experimental|Intervention schools|A 2-hour education session with multicomponent interventions including education sessions with small group dialogues with a registered nurse and trained healthcare and lay volunteers and educational computer games
89503780|NCT04438291|Other|Control schools|Control and usual care
89503781|NCT02167919|Experimental|Prostatic artery embolization|Microspheres measuring 100-300 microns will be injected under fluoroscopic guidance into the left and right prostatic arteries for embolization.
89023686|NCT04935203|Experimental|Health benefits priming group|"Participants will be cueing with health benefits by asking to do a word-search exercise beginning with: In the following, please choose words/statements that can indicate that having a healthy and sustainable diet can have health benefits, such as..."
89023687|NCT04935203|Experimental|Environmental benefits priming group|"Participants will be cueing with environmental benefits by asking to do a word-search exercise beginning with: In the following, please choose words/statements that can indicate that having a healthy and sustainable diet can have environmental benefits, such as..."
89023688|NCT04935203|Experimental|Environmental and health co-benefits priming group|"Participants will be cueing with environmental and health co-benefits by asking to do a word-search exercise beginning with: In the following, please choose words/statements that can indicate that having a healthy and sustainable diet can have both benefits for health and the environment, such as..."
89023689|NCT04928807|Experimental|Short course radiotherapy sequential camrelizumab and chemotherapy|"Radiotherapy will employ conformal or intensity-modulated radiation therapy, with a pelvic irradiation dose of 25 Gy/5 Fractions/1 week. Then rest for 1 week after radiotherapy and begin to receive neoadjuvant chemotherapy CAPOX and camrelizumab, for 2 cycles.~The patients were operated within 10 weeks after the last radiotherapy, and the surgical method is total mesorectal excision.~Postoperative adjuvant therapy will be started 4-6 weeks after surgery, and the adjuvant regimen was the same as that before operation (CAPOX + camrelizumab) for 6 cycles"
89503782|NCT00835705|Experimental|Amoxicillin Clavulanic Acid|Amoxicillin Clavulanic Acid 400-57 mg Chewable Tablet (test) dosed in first period followed by Augmentin® 400-57 mg Chewable Tablet (reference) dosed in second period
89023690|NCT04928807|Active Comparator|Long term concurrent chemoradiotherapy and sequential chemotherapy|"The patients received neoadjuvant therapy of CAPOX 2 weeks after long-term concurrent chemoradiotherapy (28*1.8Gy, during the same period, capecitabine was 825 mg / m2, twice a day, 5 days a week).~The patients were operated within 10 weeks after the last radiotherapy. Adjuvant therapy should begin within 4-6 weeks after surgery, and the adjuvant regimen was the same as that before operation (CAPOX) for 6 cycles"
89023691|NCT04922164|No Intervention|Control group|Receive education-based messages about the health benefit of breastfeeding
89023692|NCT04922164|Other|Social normative cues|Receive social normative cues related to breastfeeding
89023693|NCT04922164|Other|Goal-related cues|Receive goal-related cues related to breastfeeding
89023694|NCT04921969|Experimental|Ruxolitinib (1.5% Cream)|Study drug will be administered twice daiily.
89503783|NCT00835705|Active Comparator|Augmentin®|Augmentin® 400-57 mg Chewable Tablet (reference) dosed in first period followed by Amoxicillin Clavulanic Acid 400-57 mg Chewable Tablet (test) dosed in second period
89503784|NCT02171897|Experimental|Patients treated with osteosynthesis|
89023695|NCT04921969|Experimental|Ruxolitinib (0.75% cream)|Study drug will be administered twice daily.
89023696|NCT04921969|Placebo Comparator|Vehicle Cream|Vehicle cream will be administered twice daily.
89023697|NCT04919642|Experimental|Cohort A1|FGFR2 fusions who have failed at least one previous treatment with an FGFR inhibitor
89503785|NCT02171897|Experimental|Patients treated with total hip replacement|
89503786|NCT02759471|Experimental|comfilcon A asphere (test)|Habitual wearers of comfilcon A sphere lens (control) are refitted with comfilcon A asphere lens (test).
89503787|NCT02759471|Active Comparator|comfilcon A sphere (control)|Habitual wearers of comfilcon A sphere lens (control) are refitted with comfilcon A asphere lens (test).
89503788|NCT00713401|Experimental|Cohort A|Period 1: 75 mcg, i.v. bolus. Period 2: 75 mcg, i.v. bolus + esmolol low dose infusion
89503789|NCT00713401|Experimental|Cohort B|Period 1: 150 mcg, i.v. bolus. Period 2: 150 mcg, i.v. bolus + esmolol low dose infusion
89503790|NCT00713401|Experimental|Cohort C|Period 1: 300 mcg, i.v. bolus. Period 2: 300 mcg, i.v. bolus + esmolol low dose infusion
89503791|NCT00713401|Experimental|Cohort D|Period 1: 75 mcg, i.v. bolus. Period 2: 75 mcg, i.v. bolus + esmolol high dose infusion
89503792|NCT00713401|Experimental|Cohort E|Period 1: 150 or 300 mcg, i.v. bolus. Period 2: 150 or 300 mcg, i.v. bolus + esmolol high dose infusion
89503793|NCT02171975|Active Comparator|Group C|Patients in this group underwent Conventional landmark guided midline spinal anaesthetic.
89503794|NCT02171975|Experimental|Group P|This group had their spinal anaesthetic done based on pre-procedure ultrasound guided paramedian spinal
88815221|NCT00975650|Experimental|Test 14.0, Test 11.0, Test 8.0, Ref 5.0|Treatment C: 14.0 mg Nasobol® (2 syringes), b.i.d. for 7 days; Treatment B: 11.0 mg Nasobol® (2 syringes), b.i.d. for 7 days; Treatment A: 8.0 mg Nasobol® (2 syringes), b.i.d. for 7 days; Treatment D: 5.0 mg Androderm® (Positive Control)-Patch, q.d. for 7 days;
89023698|NCT04919642|Experimental|Cohort A2|FGFR2 fusions who have previously responded on at least one previous treatment with an FGFR inhibitor and discontinued due to disease progression
89032899|NCT02923869|Active Comparator|Group B|Children will receive 0.15 ml/kg of 0.2% Bupivacaine
89503795|NCT00835549|Experimental|1|
89503796|NCT00835549|Active Comparator|2|
89503797|NCT02164253|Experimental|Deferiprone|Deferiprone, 25 to 30 mg/kg per day, oral use
89503798|NCT02172053|Active Comparator|Compensatory Workplace Exercise (CWE)|Comparative Group will receive a light training protocol including warming up, stretching and resisted exercise using elastic bands.
89503799|NCT02172053|Experimental|Individual Resistance Exercise (IRE)|Intervention group will receive training protocol including warming up, stretching a specific resistance training with increase progressive load.
88956825|NCT03762915|Experimental|SRP with minocycline HCl microspheres|The intervention of minocycline HCl microspheres, 1 mg will be administered in the experimental group at baseline and the three month periodontal maintenance visit.
88956826|NCT03762915|No Intervention|SRP without minocycline HCl microspheres|The control group will not have minocycline HCl microspheres, 1 mg administered.
88956827|NCT03735121|Experimental|Atezolizumab (Part 2)|Atezolizumab
88956828|NCT03735121|Experimental|Cohort 1: Atezolizumab+rHuPH20 (Part 1)|Atezolizumab+recombinant human hyaluronidase (rHuPH20), followed by Atezolizumab
89032900|NCT00528905|Placebo Comparator|1|Placebo
89503800|NCT00755287|Active Comparator|insulin glargine|insulin glargine starting dose 10 IU daily in addition to continued prestudy metformin treatment
89503801|NCT00755287|Experimental|taspoglutide 10 mg|taspoglutide 10 mg once weekly in addition to continued prestudy metformin treatment
89503802|NCT00755287|Experimental|taspoglutide 10 mg/20 mg|taspoglutide 20 mg once weekly (after 4 weeks of taspoglutide 10 mg once weekly) in addition to continued prestudy metformin treatment
89503803|NCT02164331|Experimental|JNC guideline training|Providers will receive current JNC guideline training for treating patients with uncontrolled hypertension.
89503804|NCT02164331|No Intervention|Control|Provider patient panels will be assessed for number of uncontrolled hypertensives before receiving the JNC guidelines training. These baseline characteristics will serve as their control conditions.
89503805|NCT02168075|Experimental|Group 1|0.25g/kgof 20% mannitol administered at drilling of skull.
89503806|NCT02168075|Experimental|Group 2|0.5g/kg of 20% mannitol administered at drilling of skull.
89503807|NCT02168075|Experimental|Group 3|1.0 g/kg of 20% mannitol administered at drilling of skull.
89503808|NCT02168075|Experimental|Group 4|1.5g/kg of 20% mannitol administered at drilling of skull.
89503809|NCT02164409||Patient|Subjects for this study will be either H. pylori positive with an active infection, cleared of an H. pylori infection or be both H. pylori antibody positive and have a malignancy of the gastrointestinal tract, specifically gastric adenocarcinoma.
89503810|NCT02164409||Control|A small subset of patients without H. pylori infection will be enrolled as well (n=30) to serve as a control group.
89503811|NCT00712699|Experimental|Sequence 1: XR-MAS then placebo|Depending on whether 1) child has had previous medication trial or 2) is on psychotropic medication at time of screening, children will either enter the washout period of 3 days before extended release mixed amphetamine salts (XR-MAS) or placebo (PBO) is initiated or proceed directly to the active treatment sequence they were randomized to. Participants randomized to Sequence 1 first receive treatment with XR-MAR for 3 weeks and then placebo for 3 weeks. Flexible, forced dosing will start at 5 mg/day for the first week, increase to 10 mg/day for the second week and continue to 15 mg/day on the third week. No washout period otherwise occurs (XR-MAS is not clinically suspected to have lingering effects beyond initial dosing/day of administration), including the crossover week to PBO.
89503812|NCT00712699|Experimental|Sequence 2 Placebo then XR-MAS|Depending on whether 1) child has had previous medication trial or 2) is on psychotropic medication at time of screening, children will either enter the washout period of 3 days before extended release mixed amphetamine salts (XR-MAS) or placebo (PBO) is initiated or proceed directly to the active treatment sequence they were randomized to. Participants randomized to Sequence 2 will first receive treatment with PBO for 3 weeks and then XR-MAS for 3 weeks. Flexible, forced dosing will start at 5 mg/day for the first week, increase to 10 mg/day for the second week and continue to 15 mg/day on the third week. No washout period (stimulants are not clinically suspected to have lingering effects beyond initial dosing/day of administration)otherwise occurs, including the crossover week to XR-MAS.
89503813|NCT03945825|Experimental|Group 1|0.5 mL of 2018/2019 Fluzone QIV intramuscular injection on Day 1 and 0.5 ml of 2019/2020 Fluzone QIV intramuscular injection on Day 90, n=40
89503814|NCT03945825|Experimental|Group 2|0.5 mL of 2018/2019 Fluzone QIV + 0.25 mL of AF03 (admixed with vaccine) intramuscular injection on Day 1 and 0.5 ml of 2019/2020 Fluzone QIV intramuscular injection on Day 90, n=40
89503815|NCT03945825|Experimental|Group 3|0.5 mL of 2018/2019 Fluzone QIV + 0.5 mL of Delta Inulin-CpG55.2 (admixed with vaccine) intramuscular injection on Day 1 and 0.5 2019/2020 of Fluzone QIV intramuscular injection on Day 90, n=40
89503816|NCT03945825|Experimental|Group 4|0.5 mL of 2018/2019 Flublok QIV intramuscular injection on Day 1 and 0.5 ml of 2019/2020 Flublok QIV intramuscular injection on Day 90, n=40
89503817|NCT03945825|Experimental|Group 5|0.5 mL of 2018/2019 Flublok QIV + 0.25 mL AF03 (admixed with vaccine) intramuscular injection on Day 1 and 0.5 ml of 2019/2020 Flublok QIV intramuscular injection on Day 90, n=40
89503818|NCT03945825|Experimental|Group 6|0.5 mL of 2018/2019 Flublok QIV + 0.5 mL of Delta Inulin-CpG55.2 (admixed with vaccine) intramuscular injection on Day 1 and 0.5 ml of 2019/2020 Flublok QIV intramuscular injection on Day 90, n=40
89503819|NCT00706537|Experimental|CP-945598 20 mg|
89503820|NCT00706537|Placebo Comparator|Placebo|
88956829|NCT03735121|Experimental|Cohort 2: Atezolizumab+rHuPH20 (Part 1)|Atezolizumab+rHuPH20, followed by Atezolizumab
88956830|NCT03735121|Experimental|Cohort 3: Atezolizumab+rHuPH20(Part 1)|Atezolizumab+rHuPH20, followed by Atezolizumab
88956831|NCT03735121|Experimental|Atezolizumab + rHuPH20 (Part 2)|Atezolizumab + rHuPH20
88956834|NCT03714711||Total hip arthroplasty|Patient who are scheduled to undergo total hip replacement.
88956835|NCT03714711||Total knee arthroplasty|Patient who are scheduled to undergo total knee replacement.
89503821|NCT05008159|Experimental|The EMBOLDEN program|3 month community-based mobility and healthy aging intervention
88815222|NCT00975650|Experimental|Ref 5.0, Test 14.0, Test 11.0, Test 8.0|Treatment D: 5.0 mg Androderm® (Positive Control)-Patch, q.d. for 7 days; Treatment C: 14.0 mg Nasobol® (2 syringes), b.i.d. for 7 days; Treatment B: 11.0 mg Nasobol® (2 syringes), b.i.d. for 7 days; Treatment A: 8.0 mg Nasobol® (2 syringes), b.i.d. for 7 days
88815223|NCT02249429|Experimental|bimiralisib (PQR309)|
89503822|NCT05008159|No Intervention|Usual care|
89503823|NCT04987333|Experimental|Group 1: Chinese participants - efavaleukin alfa dose level 1|Chinese participants will receive a single dose of efavaleukin alfa at dose level 1.
89503824|NCT04987333|Experimental|Group 2: Chinese participants - efavaleukin alfa dose level 2|Chinese participants will receive a single dose of efavaleukin alfa at dose level 2.
89503825|NCT04987333|Experimental|Group 3: Japanese participants - efavaleukin alfa dose level 2|Japanese participants will receive a single dose of efavaleukin alfa at dose level 2.
89503826|NCT04987333|Experimental|Group 4: Caucasian participants - efavaleukin alfa dose level 2|Caucasian participants will receive a single dose of efavaleukin alfa at dose level 2.
89503827|NCT02759315|Experimental|GT1: Uprifosbuvir 450 mg + Ruzasvir 60 mg|Participants will receive an oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast and at least one hour before a meal, once a day, for 12 weeks. The GT1 Arm is sub-divided into GT1a and GT1b Arms. GT1a Arm will enroll approximately 35 participants including up to 10 participants who are compensated cirrhotics and GT1b Arm will enroll approximately 15 participants including up to 5 participants who are compensated cirrhotics.
89503828|NCT02759315|Experimental|GT2: Uprifosbuvir 450 mg + Ruzasvir 60 mg|Participants will receive an oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast and at least one hour before a meal, once a day, for 12 weeks. The GT2 Arm of the study will enroll approximately 50 participants including up to 15 participants who are compensated cirrhotics.
89503829|NCT02759315|Experimental|GT3: Uprifosbuvir 450 mg + Ruzasvir 60 mg|Participants will receive an oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast and at least one hour before a meal, once a day, for 12 weeks. The GT3 Arm of the study will enroll approximately 50 participants including up to 15 participants who are compensated cirrhotics.
89503830|NCT02759315|Experimental|GT4: Uprifosbuvir 450 mg + Ruzasvir 60 mg|Participants will receive an oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast and at least one hour before a meal, once a day, for 12 weeks. The GT4 Arm of the study will enroll approximately 50 participants including up to 15 participants who are compensated cirrhotics.
89503831|NCT02759315|Experimental|GT5: Uprifosbuvir 450 mg + Ruzasvir 60 mg|Participants will receive an oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast and at least one hour before a meal, once a day, for 12 weeks. The GT5 Arm of the study will enroll approximately 25 participants including both non- cirrhotics and compensated cirrhotics.
89503832|NCT02759315|Experimental|GT6: Uprifosbuvir 450 mg + Ruzasvir 60 mg|Participants will receive an oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast and at least one hour before a meal, once a day, for 12 weeks. The GT6 Arm of the study will enroll approximately 25 participants including both non- cirrhotics and compensated cirrhotics.
89503833|NCT05461898|Experimental|Inpatient Rehabilitation + Inspiratory Muscle Training|"The inpatient rehabilitation program included individualized, functional goal-oriented treatment, with approximately 5 hours of intervention a day, 5 days/week for a total of 6 weeks, with integrated rehabilitation care.~The inspiratory muscle training included a 6 weeks intervention with electronic-controlled valve device"
89503834|NCT05461898|Active Comparator|Inpatient Rehabilitation|- The inpatient rehabilitation program included individualized, functional goal-oriented treatment, with approximately 5 hours of intervention a day, 5 days/week for a total of 6 weeks, with integrated rehabilitation care.
89503835|NCT00699517|Experimental|1|
89503836|NCT00699517|Placebo Comparator|2|
89503837|NCT05633433|Experimental|cohort A （Phase II）|Azvudine 5 mg, QD PO, D1-D7
89503838|NCT05633433|Experimental|cohort B （Phase II）|Azvudine 3 mg + placebo 2 mg, QD PO, D1-D7
89503839|NCT05633433|Placebo Comparator|cohort C （Phase II）|placebo 5 mg, QD PO, D1-D7
89503840|NCT05633433|Experimental|Arm 1 (Phase III)|Azvudine, dose to be determined according to phase II, QD PO, D1-D7
88815224|NCT02245958||BOTOX®|Retrospective chart review of doses of BOTOX® (onabotulinumtoxinA) used as standard of care in clinical practice. No treatment (intervention) was administered.
88815225|NCT02245958||Xeomin®|Retrospective chart review of doses of Xeomin® (incobotulinumtoxinA) used as standard of care in clinical practice. No treatment (intervention) was administered.
88815226|NCT02249507|No Intervention|Control|sited rest for 45 minutes
88815227|NCT02249507|Experimental|higher intensity aerobic exercise|45 minutes of aerobic exercise at 75%HRmax
88815228|NCT02249507|Experimental|lower intensity aerobic exercise|45 minutes of aerobic exercise at 50%HRmax
88815229|NCT00976352|Experimental|rAAV1-CMV-GAA administration-cohort 1|rAAV1-CMV-GAA (study agent) Administration: 1.0 x 10e12 vector genomes. The following study assessments/interventions will be completed: Respiratory Muscle Strength Training (RMST), Safety labs, pulmonary function testing.
88815230|NCT00976352|Experimental|rAAV1-CMV-GAA administration-cohort 2|rAAV1-CMV-GAA (study agent) Administration: 5.0 x 10e12 vector genomes Cohort 2 = 6 subjects. The following study assessments/interventions will be completed: Respiratory Muscle Strength Training (RMST), Safety labs, pulmonary function testing.
88815231|NCT03018782|Other|Brief Pain Inventory Short Form|Completes the Brief Pain Inventory Short Form
88815232|NCT00976664|Active Comparator|Orthotic group|Subjects are asked to wear custom-made shoe orthotics for a 12 week study period.
88815233|NCT00976664|Other|Shoe Orthotic Wait group|The group serves as a cross-over control group. Subjects are asked to avoid any new therapies for the first 6 weeks of the 12 week study and during the last 6 weeks they are fitted for the custom-made shoe orthotics.
88815234|NCT05362448|Active Comparator|80 Hz|Stimulation with a frequency of 80 Hz
88815235|NCT05362448|Active Comparator|130 Hz|Stimulation with a frequency of 130 Hz
88815236|NCT05362448|Active Comparator|180 Hz|Stimulation with a frequency of 180 Hz
89503841|NCT05633433|Placebo Comparator|Arm 2 (Phase III)|Placebo, dose to be the same as Arm1, QD PO, D1-D7
89503842|NCT00697099|Experimental|Semuloparin|"Semuloparin sodium 20 mg (10 mg if Severe Renal Impairment [SRI]) once daily for 7-10 days with an initial dose given 8 hours after surgery~Placebo for Enoxaparin sodium prior to surgery according to local standard for Enoxaparin and 12 hours after surgery to maintain the blind"
89503843|NCT00697099|Active Comparator|Enoxaparin|"Enoxaparin sodium 40 mg (20 mg if Severe Renal Impairment [SRI]) once daily for 7-10 days with an initial dose given prior to or 12 hours after surgery according to local standard for Enoxaparin sodium~Placebo for Semuloparin sodium 8 hours after surgery to maintain the blind"
89206592|NCT00956865|Active Comparator|Voucher and call|Voucher for transportation and telephone calls
89503844|NCT02261363||Ecig group 1|
89503845|NCT02261363||Ecig group 2|
89503846|NCT02172131|Experimental|BI 1744 CL|Single rising dose of BI 1744 CL as intravenous (i.v.) infusion
89503847|NCT02172131|Placebo Comparator|Placebo|
89503848|NCT05631951|Active Comparator|bone transport through induced membrane|"First stage~antibiotic impregnated cement spacer was applied to the bone defect~external fixator was applied for 6-8 weeks ϖ Second stage~1.removal of cement spacer done 2.metaphyseal osteotomy done"
89503849|NCT05631951|Active Comparator|bone transport|"removal of all hardware~resection of infected bone segments~external fixator was applied~metaphyseal osteotomy done"
89503850|NCT02168231||Complex abdominal wall repair Strattice|Complex abdominal wall repair Strattice
89503851|NCT05435768||Group A :RANKL inhibitor subsequently HFRT+GM-CSF+PD-1 inhibitor|Group A(6 patients):patients were subcutaneously injected with 120mg desomumab, and on the second day after injection, the metastatic lesions were treated with hypofractioniated radiotherapy (8Gy×3F or 5Gy×3F), and subcutaneously injected with GM-CSF(200 μg/d) for 7 days, followed by IL-2 (2 million IU/d) for 7 days,and a 200mg PD-1 inhibitor administered within one week after completion of radiotherapy. The course was repeated every 28 days for 2-4 cycles.After combination therapy, maintenance therapy with PD-1inhibitor and desomumab was administered until disease progression or unacceptable toxicity.
89503852|NCT05435768||Group B:HFRT+GM-CSF+PD-1 inhibitor subsequently RANKL inhibitor|Group B(6 patients):patients were treated with hypofractioniated radiotherapy (8Gy×3F or 5Gy×3F), and subcutaneously injected with GM-CSF(200 μg/d) for 7 days, followed by IL-2 (2 million IU/d) for 7 days.On the second day after radiotherapy, 200mg pd-1 inhibitor was administered. After treatment, 120mg desomumab was subcutaneously injected. The course was repeated every 28 days for 2-4 cycles.After combination therapy, maintenance therapy with PD-1inhibitor and desomumab was administered until disease progression or unacceptable toxicity.
89503853|NCT00835081|Experimental|1|
89503854|NCT00835081|Active Comparator|2|
89503855|NCT02543918|Experimental|Ixekizumab + Boostrix® + Pneumovax®23|"Ixekizumab administered once by subcutaneous injection (SQ) at week 0 and once at week 2.~Boostrix® and Pneumovax®23 administered once by intramuscular (IM) injection into opposing arms at week 2."
89503856|NCT02543918|Other|Boostrix® + Pneumovax®23|Boostrix® and Pneumovax®23 administered once by IM injection into opposing arms at week 2.
89503857|NCT03539003|Experimental|sevoflurane (Group S)|general anesthesia with sevoflurane
89503858|NCT03539003|Active Comparator|desflurane (Group D)|general anesthesia with desflurane
89503859|NCT03539003|Active Comparator|total intravenous anesthesia (Group T)|general anesthesia with total intravenous anesthesia
89503860|NCT02164487||B1 blood levels|
89503861|NCT02164565|Experimental|Tranexamic Acid (TXA) treatment|Tranexamic Acid (TXA) treatment
89503862|NCT02164565|Experimental|control grup: without Tranexamic Acid (TXA) treatment.|control grup: without Tranexamic Acid (TXA) treatment.
89503863|NCT04265534|Experimental|Telaglenastat with Pembrolizumab and Chemotherapy|The glutaminase inhibitor telaglenastat will be administered orally, twice daily with food, every day in combination with standard-of-care pembrolizumab plus chemotherapy by intravenous (IV) infusion every 3 weeks.
89503864|NCT04265534|Placebo Comparator|Placebo with Pembrolizumab and Chemotherapy|Placebo will be administered orally twice daily with food every day in combination with standard-of-care pembrolizumab plus chemotherapy by IV infusion every 3 weeks.
89503865|NCT00750685|Other|Reconstruction|"The study population will consist of women aged 18 or over who are undergoing primary breast reconstruction.~The Reconstruction cohort will include subjects with loss of breast tissue due to mastectomy, contralateral breast for post-reconstruction symmetry or subjects with deformities secondary to disease, malignancy, trauma, and congenital deformity. Subjects in this cohort cannot have been implanted with breast implants, but may have tissue expanders. A Becker implant is considered a tissue expander until the port and fill tube have been removed. Women who undergo surgery primarily for a mastopexy will not be part of the reconstruction cohort."
89503866|NCT02168465|Other|teaching self-management of intermittent catheter|Single group pre-post test of feasibility, teaching self-management
89503867|NCT00750295|Experimental|1|
89503868|NCT00750295|Experimental|2|
89503869|NCT00750295|Experimental|3|
89503870|NCT00750295|Experimental|4|
89206593|NCT00956865|Active Comparator|Voucher and call and contact|Voucher for transportation, telephone calls, and a contact at the senior center
89206594|NCT00837564|Experimental|CBASP|CBASP psychotherapy
89206595|NCT00837564|Experimental|Escitalopram|Escitalopram pharmacotherapy and clinical management
89206596|NCT00957099||Imaging|Women diagnosed with breast cancer having pre-treatment MRI for spread of disease
89206597|NCT00954135|Active Comparator|letrozolo+cyclophosphamide|
89503871|NCT00750295|Experimental|5|
89503872|NCT00750295|Experimental|6|
89206598|NCT00954135|Experimental|letrozolo+sorafenib+cyclophosphamide|
89503873|NCT00750295|Experimental|7|
89503874|NCT02172209|Experimental|BI 10773 tablet administered with food|50 mg BI 10773 after a standardised high fat breakfast
89503875|NCT02172209|Active Comparator|BI 10773 tablet administered to fasted subjects|50 mg BI 10773 p.o. after an overnight fast of at least 10 hours
89503876|NCT02168543|Experimental|Alendronate|1% Alendronate gel once in periodontal pocket (Gums)
89503877|NCT02168543|Placebo Comparator|Placebo|Placebo gel once in periodontal pocket (Gums)
89503878|NCT01372995|Experimental|Enteral vitamin D3 50,000 IU|An arm where subjects receive 50,000 IU of Vitamin D for 5 days.
89023699|NCT04919642|Experimental|Cohort B|Other FGFR alterations, including FGFR2 mutations and FGFR1/3 alterations, including fusions
89503879|NCT01372995|Experimental|Enteral Vitamin D3 100,000 IU|Arm where subjects receive 100,000 IU of Vitamin D for 5 days
88815237|NCT05362448|Sham Comparator|DBS off|Absence of stimulation
89503880|NCT01372995|Placebo Comparator|Inactive Substance|Arm where patients receive inactive substance for 5 days.
89503881|NCT03725657||Pediatric|Pediatric Type1 Diabetes Mellitus patients
89503882|NCT00748501|Active Comparator|Cohort 1|SB-509 drug administration via IM injection of neck, arms, and legs
89503883|NCT00748501|Active Comparator|Cohort 2|SB-509 drug administration via IM injection of legs
89503884|NCT02168621|Active Comparator|Full-mouth ultrasonic debridement|Motivation and instruction in proper oral hygiene. Before initiation of the subgingival debridement the patient must show sufficient self-performed infection control (full-mouth plaque score <30%). One session of full-mouth ultrasonic pocket/root debridement using a piezoceramic ultrasonic instrument. A follow-up visit after 2-4 weeks is scheduled for oral hygiene control and re-motivation/re-instruction if indicated. At 3 and 6 months re-evaluation is performed and re-instrumentation of all sites showing a remaining probing pocket depth of ≥5 mm carried out. Final evaluation at 18 months.
89503885|NCT02168621|Active Comparator|Section-wise scaling and root planing|Conventional treatment approach comprising motivation, oral hygiene instructions and section-wise scaling and root planing at required number of consecutive appointments with 1-2 week interval. Follow-up 2-4 weeks after the last session of SRP for oral hygiene control and re-instruction if indicated. At 3 and 6 months re-evaluation is performed and re-instrumentation of all sites showing a remaining pocket depth of ≥5 mm carried out. Final evaluation at 18 months.
89503886|NCT04239859|Experimental|Secukinumab|"Participants will be offered secukinumab as first-line systemic treatment for moderate to severe PsO. The indication for secukinumab will be equivalent to current registered indications. Standard dose of subcutaneous secukinumab for moderate to severe PsO will be given at 300 mg at weeks 0, 1, 2, 3, and 4, then monthly thereafter, for a total duration of 6 months.~secukinumab will be withdrawn after 6 months. For some participants, there may be relapse of PsO. Relapses will be managed as per standard care."
89503887|NCT04239859|Active Comparator|Standard Care|"The management of PsO in the control arm will be the same as that in the standard care.~The standard care for moderate to severe PsO in Singapore is to start either phototherapy, methotrexate, acitretin or cyclosporin A."
89503888|NCT03875157|Experimental|IBI318 DL1|
89503889|NCT03875157|Experimental|IBI318 DL2|
89503890|NCT03875157|Experimental|IBI318 DL3|
89503891|NCT03875157|Experimental|IBI318 DL4|
89503892|NCT03875157|Experimental|IBI318 DL5|
89503893|NCT03875157|Experimental|IBI318 DL6|
89503894|NCT03875157|Experimental|IBI318 DL7|
89503895|NCT03875157|Experimental|IBI318 DL8|
89503896|NCT03875157|Experimental|IBI318 DL7b|
89503897|NCT03875157|Experimental|IBI318 DL8b|
89503898|NCT03875157|Experimental|IBI318 RP2D|
89503899|NCT02255903||Group 1(Control Group):|ultrasound and Doppler examination: of 100 pregnant females with gestational age 37-40 weeks.
89503900|NCT02255903||Group 2 (post date Group)|ultrasound and Doppler examination:will be done for 100 pregnant females with gestational age 41 weeks or more
89503901|NCT04923919|Experimental|Single arm|CLL-1 targeting CAR-T treatment
89503902|NCT03114189|Active Comparator|Footbath, care of sleep|"Warm water (37°C) filled up to the level of the ankle. Water has to be heated up to 42°C and increased to the calf 's half height within 15 minutes.~Information about wrong and correct behaviour."
89503903|NCT03114189|Active Comparator|Care of sleep|Information about wrong and correct behaviour.
89503904|NCT02164799||Shock|Patients found to have persistent hypotension after resuscitation or vasopressor requirement
89503905|NCT02164799||Pre-shock|Patients with markedly abnormal vital signs (Heart Rate (HR)>130, Respiratory Rate (RR)>24, Shock Index >1, Lactate > 4.0mmol/L, or Systolic Blood Pressure (SBP) <90mm/hg) without shock, as defined previously.
89503906|NCT05653141||Stroke patients|Adults with first-ever anterior circulation stroke
89503907|NCT02168699|Other|Ultrasound examination|Ultrasound examination of the axillary region in children
89503908|NCT02757521|Placebo Comparator|Placebo|50% nitrogen {inert}/ 50% oxygen, 3 one hour inhalation treatments per Stage, every other day (M,W,F)
89503909|NCT02757521|Experimental|Nitrous Oxide|50% nitrous oxide/ 50% oxygen, 3 one hour inhalation treatments per Stage, every other day (M,W,F)
89503910|NCT00744367|Placebo Comparator|Placebo|Placebo in addition to continued stable metformin plus pioglitazone treatment. After the first 24 weeks patients on placebo will be switched to taspoglutide 10mg once weekly or taspoglutide 20mg once weekly (after 4 weeks of taspoglutide 10mg once weekly.
89503911|NCT00744367|Experimental|Taspoglutide 10mg|Taspoglutide 10mg once weekly in addition to continued stable metformin plus pioglitazone treatment
88815238|NCT03018470||Control cohort|Patient with COPD and home NIV admitted for planned respiratory review and without any sign of exacerbation
88815239|NCT03018470||Exacerbation cohort|Patient with COPD and home NIV admitted for acute exacerbation of COPD
88815240|NCT03018470||Outpatient exacerbation|Patient with COPD and home NIV admitted for planned respiratory review and with signs of acute exacerbation of COPD but not requiring inpatient management
88815241|NCT03018548|Experimental|subject blood drawns|subjects will have blood drawn which will then be exposed to blast via CO2 cartridge
88815242|NCT03018158|No Intervention|dentulous|MR Imaging was collected with condition at the tongue at rest position.
88815243|NCT03018158|No Intervention|edentulous without denture wear.|MR Imaging was collected without denture wear.
88815244|NCT03018158|Experimental|edentulous with denture wear.|MR Imaging was collected with denture wear.
88815245|NCT03830294|Experimental|Self-adhesive Group|The participants used the adhesive breast prosthesis that adheres to the skin.
88815246|NCT03830294|Active Comparator|Conventional Group|The participants used the conventional breast prosthesis that was placed inside a bra and did not directly adhere to the skin.
88815247|NCT00979940|No Intervention|No atorvastatin|Patients do not receive Atorvastatin prior to PCI in cath lab
88815248|NCT00979940|Experimental|atorvastatin|Atorvastatin 80mg po given prior to PCI in cath lab
88956836|NCT03701308|Active Comparator|Arm I (daunorubicin, cytarabine)|"INDUCTION: Patients receive daunorubicin IV on days 1-3 and cytarabine via CIVI over 168 hours on days 1-7. Patients with residual disease indicated by bone marrow examination receive a second induction including daunorubicin IV on days 1-3 and cytarabine CIVI over 12 hours on days 1-5.~CONSOLIDATION: Patients receive cytarabine IV over 3 hours on days 1-5. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity."
89206599|NCT00832806|Active Comparator|1|Extended IVR (integrated voice response technology) vs. no extended IVR
89206600|NCT00832806|Active Comparator|2|Extended IVR (integrated voice response technology) vs. no extended IVR
89503912|NCT00744367|Experimental|Taspoglutide 10mg/20mg|Taspoglutide 20 mg once weekly (after 4 weeks of taspoglutide 10 mg once weekly) in addition to continued stable metformin plus pioglitazone treatment.
89503913|NCT02172287|Experimental|Tiotropium (Ba679 BR)|Tiotropium capsule once daily by oral inhalation
89503914|NCT02172287|Active Comparator|Salmeterol|Salmeterol inhalation aerosol twice daily
89503915|NCT02172287|Placebo Comparator|Placebo|"Tiotropium (Ba679 BR)- placebo one capsule once daily by inhalation~Salmeterol- placebo, inhalation aerosol twice daily"
89503916|NCT02255669|Active Comparator|partially covered SEMS|Deployment of Partially covered biliary self expandable metal stent
89503917|NCT02255669|Active Comparator|fully covered SEMS|Deployment of Fully covered biliary self expandable metal stent
89503918|NCT00695305|Placebo Comparator|placebo|placebo to match
89503919|NCT00695305|Active Comparator|rilapladib|250 mg/day
89503920|NCT02261129|Experimental|Telmisartan, film-coated tablet|one tablet of telmisartan
89503921|NCT02261129|Active Comparator|Telmisartan, conventional tablet|Two tablets of telmisartan
89503922|NCT03540173||Training Cohort|In the training cohort, we evaluated the impact of patient-related factors on the pain during the colonoscopy. In univariatelogistic regression analysis, All factors associated with the pain during colonoscopy (p<0.1) were included in multivariate analysis.
89503923|NCT03540173||Validation group|The validation cohort was used to verify the intubation discomfort score.
89503924|NCT00694135|Active Comparator|EGP-437 1.6 mA-min at 0.4 mA|Ocular iontophoresis with EGP 437 1.6 mA-min at 0.4 mA
89503925|NCT00694135|Active Comparator|EGP-437 4.8 mA-min at 1.2 mA|Ocular iontophoresis with EGP-437 4.8 mA-min at 1.2 mA
89503926|NCT00694135|Active Comparator|EGP-437 10.0 mA-min at 2.5 mA|Ocular iontophoresis with EGP-437 10.0 mA-min at 2.5 mA
89503927|NCT00694135|Active Comparator|EGP-437 14.0 mA-min at 3.5 mA|Ocular iontophoresis with EGP-437 14.0 mA-min at 3.5 mA
89503928|NCT03540095|Experimental|Erector Spinae Plane Block|The patients randomized to the Erector Spinae Plane Block arm will receive this nerve block at the level corresponding to the rib fractures. Ropivicaine 0.5% 25 mL will be used during the procedure for initiation of pain control. Bupivicaine 0.0625% will be used for continuous infusion of local anesthetic. It will be titrated to effect, at maximum 12 mL/hr. Bupivicaine 0.0625% 3mL will be given every hour as a bolus additionally.
89503929|NCT03540095|Experimental|Paravertebral Nerve Block|The patients randomized to the Paravertebral Nerve Block arm will receive this nerve block at the level corresponding to the rib fractures. Ropivicaine 0.5% 25 mL will be used during the procedure for initiation of pain control. Bupivicaine 0.0625% will be used for continuous infusion of local anesthetic. It will be titrated to effect, at maximum 12 mL/hr. Bupivicaine 0.0625% 3mL will be given every hour as a bolus additionally.
89503930|NCT03071185|Experimental|Group PCA+B|Both intravenous PCA and lower limb blocks were used. For patients with fibular flaps harvested, femoral nerve block and common peroneal nerve block with ropivacaine were administered. For patients with ALT flaps harvested, femoral nerve block with ropivacaine was administered.The interventions are femoral nerve block, common peroneal nerve block.
89503931|NCT03071185|No Intervention|Group PCA|Only intravenous patient controlled analgesia (PCA) was used postoperatively.
89503932|NCT03071185|Experimental|Group PCA+B+D|Both intravenous PCA and lower limb blocks with dexmedetomidine as additivewere used.
89503933|NCT02169011|Active Comparator|Latissimus Dorsi Flap Reconstruction|Patients are allocated to delayed breast reconstruction with the Latissimus Dorsi flap and if needed an implant.
89503934|NCT02169011|Active Comparator|TAP Flap Reconstruction|Patients are allocated to delayed breast reconstruction with the TAP-flap and if needed an implant in combination with an acellular dermal matrix.
89503935|NCT00741715|Placebo Comparator|1|
89503936|NCT00741715|Experimental|2|AVE5530 25mg
89503937|NCT00741715|Experimental|3|AVE5530 50mg
89503938|NCT00741715|Active Comparator|4|atorvastatin 10mg
89503939|NCT00741715|Experimental|5|atorvastatin 10mg + AVE5530 25mg
89503940|NCT00741715|Experimental|6|atorvastatin 10mg + AVE5530 50mg
89503941|NCT00741715|Active Comparator|7|atorvastatin 20mg
89503942|NCT00741715|Experimental|8|atorvastatin 20mg + AVE5530 25mg
89503943|NCT00741715|Experimental|9|atorvastatin 20mg + AVE5530 50mg
89503944|NCT00741715|Active Comparator|10|atorvastatin 40mg
89503945|NCT00741715|Experimental|11|atorvastatin 40mg + AVE5530 25mg
89503946|NCT00741715|Experimental|12|atorvastatin 40mg + AVE5530 50mg
89503947|NCT00741715|Active Comparator|13|atorvastatin 80mg
89503948|NCT00741715|Experimental|14|atorvastatin 80mg + AVE5530 25mg
89503949|NCT00741715|Experimental|15|atorvastatin 80mg + AVE5530 50mg
89503950|NCT02169167|Experimental|Resin salve treatment|The resin salve may be spread directly onto the diabetic ulcer, after which the area is covered with a bandage suitable for local wound care. The bandage prohibits salve from moving away from the ulcer area. If the skin condition is more widespread or contains cavities or fistulae, the salve may be spread as a film with a thickness of at least 1 mm onto a gauze or gauze ribbon that is then used to fill the cavity or fistulae channel. Bandages are changed every 1-3 days, depending on the degree of infection and amount of ulcer secretion.
89503951|NCT02169167|Active Comparator|Octenidine treatment|Octenidine treatment is implemented with the similar manner as resin salve treatment by using sterile gauze that is impregnated with the octenidine dihydrochloride.
89503952|NCT02172443|Experimental|tiotropium inhalation capsules|
89503953|NCT02172443|Active Comparator|Atrovent MDI|
89503954|NCT00740623|Experimental|001|Carisbamate 800 mg/day for 14 weeks
89503955|NCT00740623|Experimental|002|Carisbamate 1,200 mg/day for 14 weeks
89503956|NCT00740623|Placebo Comparator|003|placebo for 14 weeks
89503957|NCT03540641|Active Comparator|1500 pulses|This group will receive 1500 pulses of transcranial magnetic stimulation at 5Hz over the left dorsolateral prefrontal cortex, until completing 15 sessions
89503958|NCT03540641|Sham Comparator|1500 pulses sham|this group will receive the sham modality of the protocol of 1500 pulses at 5Hz of transcranial magnetic stimulation during 15 sessions.
89503959|NCT03540641|Active Comparator|5000 pulses|This group will receive 5000 pulses of transcranial magnetic stimulation at 5Hz over the left dorsolateral prefrontal cortex, until completing 15 sessions.
89503960|NCT03540641|Sham Comparator|5000 pulses sham|this group will receive the sham modality of the protocol of 5000 pulses at 5Hz of transcranial magnetic stimulation during 15 sessions.
89503961|NCT00834613|Experimental|1|
89503962|NCT00834613|Active Comparator|2|
89503963|NCT02172521||COPD and proven hyperinflation|Patients with COPD and proven hyperinflation receiving tiotropium bromide 18 microgram
89503964|NCT03037411||ELUVIA stent implantation|Peripheral stenting
89503965|NCT02169245|Experimental|Average Protein and Fiber at Breakfast|Dietary control of protein and fiber intake at breakfast. Participants will eat a 400 kcal breakfast with an average amount of protein and fiber for this age group for 2 weeks.
89503966|NCT02169245|Experimental|Average Protein and High Fiber at Breakfast|Dietary control of protein and fiber intake at breakfast. Participants will eat a 400 kcal breakfast with an average amount of protein and higher than average amount of fiber for this age group for 2 weeks.
89503967|NCT02169245|Experimental|High Protein and Average Fiber at Breakfast|Dietary control of protein and fiber intake at breakfast. Participants will eat a 400 kcal breakfast with an average amount of fiber and higher than average amount of protein for this age group for 2 weeks.
89503968|NCT02169245|Experimental|Higher Protein and Fiber at Breakfast|Dietary control of protein and fiber intake at breakfast. Participants will eat a 400 kcal breakfast with a higher than average amount of protein and fiber for this age group for 2 weeks.
89503969|NCT00834535|Experimental|1|
89503970|NCT00834535|Active Comparator|2|
89503971|NCT02169323|Experimental|Step-down|Step-down of the inhaled corticosteroid (ICS) dose
88956837|NCT03701308|Experimental|Arm II (uproleselan, daunorubicin, cytarabine)|"INDUCTION: Patients receive uproleselan IV QD on day 1 and then every 12 hours on days 2-10. Patients also receive daunorubicin IV on days 2-4 and cytrarabine CIVI over 168 hours on days 2-8 over 168 hours. Patients with residual disease indicated by bone marrow examination receive a second induction including uprleselan IV QD on day 1 and then every 12 hours on days 2-8, daunorubicin IV on days 2-3, and cytarabine CIVI over 120 hours on days 2-6.~CONSOLIDATION: Patients who achieve a CR or CRi receive uproleselan IV QD on day 1 and every 12 hours on days 2-8 and cytarabine IV over 3 hours on days 2-6. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity."
88956838|NCT03698994|Experimental|Treatment (ulixertinib)|Patients receive ulixertinib PO BID. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
88956839|NCT03691883||TB patients|TB patients diagnosed and followed-up in Barcelona, at the following Hospitals/Clinics: Servicios Clínicos, Hospital Universitari Germans Trias i Pujol, Hospital Universitari Vall d'Hebron-Drassanes, Hospital del Mar.
89503972|NCT02169401||Treated subjects|All subjects recruited and treated with the Axium Neurostimulator
89503973|NCT00691717|Experimental|24 mg Anecortave Acetate|Anecortave Acetate Sterile Suspension, 30 mg/mL, single depot administration of 0.8 mL in the study eye
89503974|NCT00691717|Experimental|48 mg Anecortave Acetate|Anecortave Acetate Sterile Suspension, 60 mg/mL, single depot administration of 0.8 mL in the study eye
89503975|NCT00691717|Experimental|60 mg Anecortave Acetate|Anecortave Acetate Sterile Suspension, 75 mg/mL, single depot administration of 0.8 mL in the study eye
89503976|NCT00691717|Placebo Comparator|Anecortave Acetate Vehicle|Single depot administration of 0.8 mL in the study eye
89503977|NCT03036319|Experimental|Active TES|"Participants will receive real tES (tDCS, tACS, tRNS) in which they receive up to 4 milliamps (mA) of stimulation per electrode for up to 40 minutes for up to 260 sessions. As this may be a cross-over design, some participants may receive active and sham conditions."
89503978|NCT03036319|Placebo Comparator|Sham TES|Participants undergoing this condition will have the exact same procedures as the active group, with the exception that they will receive only sham stimulation for up to 260 sessions.
89503979|NCT03036319|Experimental|Cognitively based intervention|Participants may receive a cognitively based intervention that targets the particular cognitive and/or functional abilities of interest. This includes methods of cognitive training, cognitive remediation, and cognitive rehabilitation.
89503980|NCT03036319|Experimental|Active TES + Cognitively based intervention|This condition combines active TES and cognitively based interventions for some or all of the study sessions
89503981|NCT03036319|Experimental|Sham TES + Cognitively based intervention|This condition combines sham TES and cognitively based interventions for some or all of the study sessions
89503982|NCT03036319|Experimental|Active TES, Sham TES, Cognitively based interventions|This condition combines active and sham TES with cognitively based interventions using a cross-over design
89503983|NCT03036319|Experimental|Active and Sham TES|Participants will receive active and sham TES
89503984|NCT03539939|Experimental|Smoker Group|This group included smoker gingival recession patients.
89503985|NCT03539939|Active Comparator|Non-smoker Group|This group included non-smoker gingival recession patients.
89503986|NCT00688441|Experimental|Active|CO2 Gas
89503987|NCT00688441|Placebo Comparator|Placebo|Inactive Placebo Gas
89503988|NCT02172599|Experimental|multi-component intervention|"Sit-stand workstation provision~The multi-component intervention will align with the World Health Authority's promotion of a healthy workplace model, which emphasises that best-practice workplace health interventions should involve an integrated approach involving organisation and individual level approaches to behaviour change (WHO, 2010). Thus, participants will receive a sit-stand workstation with additional support to use the sit-stand workstation."
89503989|NCT02172599|Experimental|Sit-stand workstation only|"Sit-stand workstation provision~Participants in this arm will receive a sit-stand workstation. They will not receive any support to use the sit-stand workstation, except some health and safety advice upon installation."
89503990|NCT02172599|No Intervention|Usual practice (seated workstation)|This arm is the control group. They will continue to use their usual seated workstation for the duration of the study.
89503991|NCT00834067|Experimental|1|
89503992|NCT00834067|Active Comparator|2|
89503993|NCT00682981|Experimental|Phase I A|Obatoclax for 3 hours for 3 days with carboplatin/etoposide.
89503994|NCT00682981|Experimental|Phase I B|Obatoclax for 24 hours for 3 days with carboplatin/etoposide.
89503995|NCT00682981|Experimental|Phase II A|Obatoclax for 3 hours for 3 days with carboplatin/etoposide.
89503996|NCT00682981|Active Comparator|Phase II B|Carboplatin/etoposide without continued study treatment
89503997|NCT02758613|Experimental|2 milligram (mg) Baricitinib|2mg Baricitinib administered orally, once on Day 1 and once a day (QD) on Days 4 through 10 (7 days).
89503998|NCT02758613|Experimental|4mg Baricitinib|4mg Baricitinib administered orally, once on Day 1 and QD on Days 4 through 10 (7 days).
89503999|NCT02758613|Experimental|10mg Baricitinib|10mg Baricitinib administered orally, once on Day 1 and QD on Days 4 through 10 (7 days).
89504000|NCT02758613|Placebo Comparator|Placebo|Placebo matching Baricitinib administered orally, once on Day 1 and QD on Days 4 through 10 (7 days).
89504001|NCT02758301||Diagnostic|The Reveal LINQ™ Insertable Cardiac Monitor (ICM) device will be inserted in all subjects for continuous monitoring. After the Reveal LINQ™ device is inserted, the LINQ™ HF investigational RAMware will be downloaded to the LINQ™ ICM.
89504002|NCT00833521|Experimental|Zolpidem|Zolpidem Tartrate 10 mg Tablet (test) dosed in first period followed by Ambien® 10 mg Tablet (reference) dosed in second period
89504003|NCT00833521|Active Comparator|Ambien®|Ambien® 10 mg Tablet (reference) dosed in first period followed by Zolpidem Tartrate 10 mg Tablet (test) dosed in second period
89504004|NCT02669667|Experimental|Cohort 1|single dose of MEDI9314 or placebo
89504005|NCT02669667|Experimental|Cohort 2|single dose of MEDI9314 or placebo
89504006|NCT02669667|Experimental|Cohort 3|single dose of MEDI9314 or placebo
89504007|NCT02669667|Experimental|Cohort 4|single dose of MEDI9314 or placebo
89504008|NCT02669667|Experimental|Japanese Cohort|single dose of MEDI9314 or placebo
89023700|NCT04919642|Experimental|Cohort C|Negative for FGFR alterations (FGFR wild-type)
89504009|NCT02669667|Experimental|Cohort 5|single dose of MEDI9314 or placebo
89504010|NCT00832507|Experimental|Cicletanine 150 mg QD|Cicletanine 150 mg administered once daily (QD)
89504011|NCT00832507|Experimental|Cicletanine 150 mg BID|Cicletanine 150 mg administered twice daily (BID)
89504012|NCT00832507|Experimental|Cicletanine 300 mg QD|Cicletanine 300 mg administered once daily (QD)
89504013|NCT00832507|Placebo Comparator|Placebo|Placebo to match cicletanine administered once daily
89504014|NCT02172677|Experimental|Healthy participants|Structural and functional MRI and memory assessment
89504015|NCT02169557|Experimental|Fexinidazole|
89504016|NCT03538769|No Intervention|Baseline group|This will be the pre and post alert phase where e-alerts will not be sent to providers
89504017|NCT03538769|Other|Alert group|This will be the phase when e-alerts will be sent to the provider
88956841|NCT03675282|Experimental|Parkinson Disease - Stage 1|MRI Brain at Baseline and 24 Months PE2i PET Scan or DaT Scan at Baseline and 24 Months Office Visit at Baseline and 24 Months
88956842|NCT03675282|Experimental|Parkinson Disease - Stage 2|MRI Brain at Baseline and 24 Months PE2i PET Scan or DaT Scan at Baseline and 24 Months Office Visit at Baseline and 24 Months
88956843|NCT03675282|Experimental|Parkinson Disease - Stage 3|MRI Brain at Baseline and 24 Months PE2i PET Scan or DaT Scan at Baseline and 24 Months Office Visit at Baseline and 24 Months
88956844|NCT03675282|Experimental|Parkinson Disease - Stage 4|MRI Brain at Baseline and 24 Months PE2i PET Scan or DaT Scan at Baseline and 24 Months Office Visit at Baseline and 24 Months
88956845|NCT03675282|Experimental|REM Sleep Behavior Disorder|MRI Brain at Baseline and 24 Months PE2i PET Scan or DaT Scan at Baseline and 24 Months Office Visit at Baseline and 24 Months
88956846|NCT03675282|Experimental|Healthy Controls|MRI Brain at Baseline and 24 Months PE2i PET Scan or DaT Scan at Baseline and 24 Months Office Visit at Baseline and 24 Months
88956847|NCT03663530|Experimental|Circadian misalignment|Meals in this condition will be delayed by 4 hours relative to the circadian alignment condition. Food intake during this period will be from 1 PM to 11 PM.
88956848|NCT03663530|Active Comparator|Circadian alignment|Meals in this condition will be aligned to the sleep episode. Food intake during this period will be from 9 AM to 7 PM.
89032901|NCT00528905|Experimental|2|AZD3480 oral
89032902|NCT00528905|Experimental|3|AZD3480 oral dose
89504018|NCT04187209|Other|Non-traumatic hemiplegia in post stroke acute subacute phase|
89504019|NCT02802943|Experimental|Peptide Vaccine MRD +|MRD-positive (MRD+) patients (flow cytometry based, CLL cells in peripheral blood or bone marrow ≥ 10-4 6-10 weeks after the end of first line treatment)
89504020|NCT02802943|Experimental|Peptide Vaccine MRD-|MRD-negative (MRD-) patients (flow cytometry based, CLL cells in peripheral blood and bone marrow <10-4 6-10 weeks after the end of first line treatment)
89504021|NCT02164877|Experimental|pectin|Patients allocated to experiment group will receive standard enteral nutrition formula(Fresubin) supplemented with 15g pectin each day for 4 weeks.
89504022|NCT02164877|Placebo Comparator|control|Patients allocated to control group will receive standard enteral nutrition formula(Fresubin) for 4 weeks
89504023|NCT02169635|Experimental|Macula buckle|Macular buckle: perform episcleral macular buckle surgery using a three-armed silicone capsule to support the posterior staphyloma in high myopia.
89504024|NCT00735085|Experimental|SLV334|
89206601|NCT00954213|Experimental|DIR/Floortime parent intervention|
89504025|NCT00735085|Placebo Comparator|Placebo|
89504026|NCT02165033|Experimental|Budesonide/Procaterol 180/10 X 4 puffs|Multiple dose of SYN006 HFA MDI (Budesonide 180ug + Procaterol 10ug/puff), 4 puffs each day for consecutive 7 days
88956849|NCT03663218|Other|Single Arm|This is a modified dose escalation and de-escalation study with an expansion of 3 or 6 pts to allow the recommended phase II dose (RP2D) be examined in a total of 9 pts. The dose limiting toxicity (DLT) is defined as Grade 3 or higher toxicity related to preoperative radiotherapy according to the Clavien-Dindo Classification. 3 radiation dose levels, 5 Gy, 6 Gy and 6.5Gy are considered. At the start of each dose level, 3 pts will be enrolled and treated for five days. If none of the 3 pts develop the DLT, the testing dose will escalate to the next level. If 1 of the 3 pts develops the DLT, the current dose will be tested in an additional 3 pts. If no additional pts develop the DLT, the dose will escalate.
89504027|NCT00734461|Placebo Comparator|Placebo|Placebo, single dose
88956850|NCT03642002|Experimental|Toning|Vocal Tonal Holding
88956851|NCT03642002|Other|Ocean drum & SOK melody|Ocean drum followed by melody of song of kin
88956852|NCT03642002|Experimental|SOK|Song of kin with lyric content
88956853|NCT03642002|Experimental|Process|Processing of experience
89206602|NCT00832884|Active Comparator|Group 1A|Lacosamide, IV, 50 mg, once, 30 minutes
89504028|NCT00734461|Active Comparator|Oxycodone 20 mg|Oxycodone 20 mg single dose tablet
89504029|NCT00734461|Active Comparator|Oxycodone 40 mg|Oxycodone 40 mg single dose tablet
89504030|NCT00734461|Experimental|PTI-801 20/.001 mg|Oxycodone 20 mg / Naltrexone 0.001 mg
89504031|NCT00734461|Experimental|PTI-801 40/.001 mg|Oxycodone 40 mg / Naltrexone 0.001 mg
89504032|NCT00734461|Experimental|PTI-801 20/.0001 mg|Oxycodone 40 mg / Naltrexone 0.0001 mg
89504033|NCT00734461|Experimental|PTI-801 40/.0001 mg|Oxycodone 40 mg / Naltrexone 0.0001 mg
89504034|NCT02169713|Experimental|Treatment Sequence 1|Tamsulosin HCl alone (with matching placebo for solifenacin and mirabegron) then followed by tamsulosin HCl with solifenacin and mirabegron
89504035|NCT02169713|Experimental|Treatment Sequence 2|Tamsulosin HCl with solifenacin and mirabegron then followed by tamsulosin HCl alone (with matching placebo for solifenacin and mirabegron)
89504036|NCT03980041|Experimental|IPI-549 + Nivolumab|Participants receive IPI-549 orally (PO) daily in combination with nivolumab IV infusion every 4 weeks
89504037|NCT03980041|Active Comparator|Placebo + Nivolumab|Participants receive placebo orally (PO) daily in combination with nivolumab IV infusion every 4 weeks
89504038|NCT04800835|Active Comparator|Group 1- Spatz3 adjustable balloon 12-month implantation;|A 12 month adjustable intragastric balloon for weight loss that can have the balloon volume increased or decrease as needed
89504039|NCT04800835|Active Comparator|Group 2- 6-month non adjustable balloon implantation with additional 6 months follow-up|A 6-month non adjustable intragastric balloon for weight loss
89504040|NCT02669433|Experimental|RVT-101 35 mg|RVT-101 35 mg once daily
89504041|NCT02669433|Experimental|RVT-101 70 mg|RVT-101 70 mg once daily
88956854|NCT03642002|Experimental|Holding Harmonic Container|
88982923|NCT02695342|Experimental|Home balance exercise program|The home-based exercise program will be tailored to address the underlying balance deficits in COPD and individualized according to each participant's ability. Physiotherapists will teach the program in four home visits over the first 6 weeks of the study; in the event of an exacerbation, a fifth visit will be provided to modify the program. Participants will be given an exercise DVD (with portable player), and will be instructed to perform the program 3 times/week for 6 months. Therapists will provide bi-monthly telephone support.
88982924|NCT02682485|Experimental|Cipro, metronidazole, neomycin combo|As part of each serial endoscopic surveillance, a second lavage of the anastomosis will be performed prior to removing the endoscope. In this arm, the lavage will be with a direct topical antibiotics solution composed of metronidazole, ciprofloxacin and neomycin.
89032903|NCT02923791|Experimental|Filgrastim Hospira|
89032904|NCT02923791|Active Comparator|US-Approved Neupogen|
89504042|NCT02669433|Placebo Comparator|Placebo|Placebo
89504043|NCT02756819||Azilsartan Medoxomil|Overweight or obese participants with hypertension who received azilsartan medoxomil tablets, orally, as prescribed by physician according to local summary of product characteristics (SmPC) were observed for approximately 6 months.
89032905|NCT02926092||Arm 1|Observation of progression of disease over time.
89032906|NCT04689243|Experimental|ALA-PDT|
89032907|NCT04689243|Other|red light|
89032908|NCT00528944||Cohort A|Patients with obstructive defects and radiological evidence of emphysema
89032909|NCT00528944||Cohort B|Patients with obstructive ventilatory defects and no radiological evidence of emphysema
89032910|NCT00528944||Cohort C|Non-smokers without obstructive ventilatory defects or history of cardiopulmonary disease
89504044|NCT00829309|Experimental|Pravastatin|Pravastatin 80 mg Tablet (test) dosed in first period followed by Pravachol® 80 mg Tablet (reference) dosed in second period
89504045|NCT00829309|Active Comparator|Pravachol®|Pravachol® 80 mg Tablet (reference) dosed in first period followed by Pravastatin 80 mg Tablet (test) dosed in second period
89504046|NCT02169947|Active Comparator|Weight loss core|Participants will receive a culturally adapted version of the Diabetes Prevention Program core (16 session) program.
89504047|NCT02169947|Experimental|Weight loss core plus maintenance|Participants will receive a culturally adapted version of the Diabetes Prevention Program core (16 session) program PLUS 12 maintenance sessions.
89504048|NCT04796935|Experimental|Experimental Group 1: Tactile Imaging (VerTouch)|VerTouch used to identify and mark, or begin placement of a needle, at an insertion site.
89504049|NCT04796935|Active Comparator|Group 2: Control (palpation)|Palpation used to identify and mark an insertion site.
89504050|NCT02173067||2% lidocaine|35 patients received 5.4 mL of 2% lidocaine.
89504051|NCT02173067||2% lidocaine with epinephrine|35 patients recieved 5.4 mL of 2% lidocaine with 1:100,000 epinephrine.
89504052|NCT02165189|Experimental|Simeprevir plus Sofosbuvir plus Ribavirin (Arm 1)|Participants will be administered simeprevir capsule 150 milligram (mg), sofosbuvir 400 mg tablet, and ribavirin 2 x 200 mg tablets (for participants weighing less than 75 kilogram [kg]) or 3 x 200 mg tablets (for participants weighing more than 75 kg weight), orally once daily up to 12 weeks.
89504053|NCT02165189|Experimental|Simeprevir plus Sofosbuvir (Arm 2)|Participants will be administered simeprevir capsule 150 mg and sofosbuvir 400 mg tablet orally once daily up to 12 weeks.
89504054|NCT02165189|Experimental|Simeprevir plus Sofosbuvir (Arm 3)|Participants will be administered simeprevir 150 mg capsule and sofosbuvir 400 mg tablet orally once daily 24 weeks.
89504055|NCT00725881|Experimental|1|.25 mg/kg TSC
89504056|NCT00725881|Experimental|2|.5 mg/kg TSC
89504057|NCT00725881|Experimental|3|.75 mg/kg TSC
89504058|NCT00725881|Experimental|4|1.0 mg/kg TSC
89504059|NCT00725881|Experimental|5|1.25 mg/kg TSC
89504060|NCT00725881|Experimental|6|1.5 mg/kg TSC
89504061|NCT00725881|Experimental|7|1.75 mg/kg TSC
89504062|NCT00725881|Experimental|8|2.0 mg/kg TSC
89504063|NCT00725881|Placebo Comparator|9|5.0 mL 0.9% normal saline
89504064|NCT02669121|Placebo Comparator|Placebo|NoV placebo-matching 0.5 mL solution for injection, intramuscularly (IM), once, on Day 1.
89504065|NCT02669121|Experimental|NoV GI.1/GII.4 Bivalent VLP Vaccine|NoV GI.1/GII.4 bivalent virus-like particle (VLP) vaccine, 0.5 mL injection, intramuscularly (IM), once, on Day 1.
89504066|NCT02165267|Experimental|Arm 1: VRC01 (6 IV infusions)|Participants will receive an IV infusion of 40 mg/kg of VRC01 administered in 100 mL of normal saline over 1 hour at Day 0, followed by IV infusions of 20 mg/kg of VRC01 administered in 100 mL of normal saline over at least 30 minutes to 1 hour at Days 28, 56, 84, 112, and 140.
89504067|NCT02165267|Experimental|Arm 2: VRC01 (3 IV infusions)|Participants will receive an IV infusion of 40 mg/kg of VRC01 administered in 100 mL of normal saline over 1 hour at Day 0 and over at least 30 minutes to 1 hour at Days 56 and 112.
89504068|NCT02165267|Experimental|Arm 3a: VRC01 (1 IV infusion plus multiple SC injections)|Participants will receive an IV infusion of 40 mg/kg of VRC01 administered in 100 mL of normal saline over 1 hour at Week 0, followed by SC injection of 5 mg/kg of VRC01 administered every 2 weeks for 20 weeks.
89504069|NCT02165267|Placebo Comparator|Arm 3b: Placebo for VRC01 (infusion plus injections)|Participants will receive an IV infusion of sodium chloride placebo administered in 100 mL of normal saline over 1 hour at Week 0, followed by SC injection of placebo for VRC01 administered every 2 weeks for 20 weeks.
89504070|NCT02165267|Experimental|Arm 4: 10 mg/kg of VRC01 (3 IV infusions)|Participants will receive an IV infusion of 10 mg/kg of VRC01 administered in 100 mL of normal saline over 1 hour at Month 0 and over at least 30 minutes to 1 hour at Months 2 and 4.
89504071|NCT02165267|Experimental|Arm 5: 30 mg/kg of VRC01 (3 IV infusions)|Participants will receive an IV infusion of 30 mg/kg of VRC01 administered in 100 mL of normal saline over 1 hour at Month 0 and over at least 30 minutes to 1 hour at Months 2 and 4.
89504072|NCT00725803|Experimental|Cohort 1|Subjects randomized 3:1 (active:placebo) to receive GS-9450 10 mg/day or placebo.
89504073|NCT00725803|Experimental|Cohort 2|Subjects randomized 3:1 (active:placebo) to receive GS-9450 40 mg/day or placebo.
89504074|NCT00725803|Experimental|Cohort 3|Subjects randomized 3:1 (active:placebo) to receive GS-9450 80 mg/day or placebo.
89504075|NCT00725803|Experimental|Cohort 4|Subjects randomized 3:1 (active:placebo) to receive GS-9450 5 mg/day or placebo. Cohort may or may not be conducted pending blinded review of previous cohorts.
89504076|NCT03750513|Experimental|Treatment (LET optimized IMPT)|Patients receive LET optimized IMPT for up to 6 weeks.
89504077|NCT02165423|Experimental|Control|Ten parents will be randomized to the control group defined as 'usual care' and ten to the intervention group, stratified by type of transplant.
89504078|NCT02165423|Experimental|Intervention|Ten parents will be randomized to the control group defined as 'usual care' and ten to the intervention group, stratified by type of transplant.
89504079|NCT04473001||Surgical patients|Adult patients admitted for major abdominal-, orthopedic or arterial vascular surgery.
89504080|NCT00825955|Experimental|Brivanib|
89504081|NCT00825955|Placebo Comparator|Placebo|
89504082|NCT02292225|Experimental|IPI-145 in Combination with Obinutuzumab|
89504083|NCT02743117|Experimental|Monovalent Influenza Vaccine|A single dose of 10^(7.0 +/- 0.5) fluorescent focus units (FFU) strain of monovalent influenza vaccine will be administered as intranasal spray on Day 1.
88982925|NCT02682485|Placebo Comparator|Saline|As part of each serial endoscopic surveillance, a second lavage of the anastomosis will be performed prior to removing the endoscope. In this arm, the lavage will be with direct topical saline.
89504084|NCT02743117|Placebo Comparator|Placebo|A single dose of placebo matched to monovalent influenza vaccine will be administered as intranasal spray on Day 1.
89504085|NCT00677053|Experimental|TAK-442 10 mg BID|Added with standard care for recurrent ischemic events.
89504086|NCT00677053|Experimental|TAK-442 20 mg BID|Added with standard care for recurrent ischemic events
89504087|NCT00677053|Experimental|TAK-442 40 mg QD|Added with standard care for recurrent ischemic events
89504088|NCT00677053|Experimental|TAK-442 40 mg BID|Added with standard care for recurrent ischemic events
89504089|NCT00677053|Experimental|TAK-442 80 mg QD|Added with standard care for recurrent ischemic events
89504090|NCT00677053|Experimental|TAK-442 80 mg BID|Added with standard care for recurrent ischemic events
89504091|NCT00677053|Experimental|TAK-442 160 mg QD|Added with standard care for recurrent ischemic events
89504092|NCT00677053|Experimental|TAK-442 120 mg BID|Added with standard care for recurrent ischemic events
89504093|NCT00677053|Placebo Comparator|Placebo|Added with standard care for recurrent ischemic events
89504094|NCT00644839|Experimental|CP-945,598|
89504095|NCT00643669|Experimental|AL-3789|AL-3789 Sterile Suspension, single depot administration of 0.8 mL in the study eye
89504096|NCT00643669|No Intervention|No treatment|Fellow eye, as randomized
89504097|NCT00674635|Placebo Comparator|Placebo|matching placebo
89504098|NCT00674635|Active Comparator|GSK315234A|Part A single IV dose; Part B 3 repeat IV dose at Day 1, Day 28 and Day 56; Part C single SC dose
89504099|NCT03875053|Experimental|Monitoring device, Quality of Life Assessment, Questionnaire|Patients wear the home sleep apnea machine overnight. Patients undergoing standard of care CRT wear the home sleep apnea machine a second time 3 months after completion of CRT.
89504100|NCT01950403|Experimental|Arm I (linaclotide acetate)|Participants receive linaclotide acetate PO QD on days 1-7.
89504101|NCT01950403|Placebo Comparator|Arm II (placebo)|Participants receive placebo PO QD on days 1-7.
89538744|NCT04488029|Experimental|Experimental Group|At the start of the study, subjects will be provided with a tablet with videoconferencing software and the PCT app pre-installed. Research staff will remotely setup a PCT account for the subjects, and provide instructions for logging into the PCT application. During the treatment period, patients will be instructed to use PCT for at least 30 minutes a day and at least 5 days a week. Performance data (accuracy and latency) will be reported by the PCT software to the treating clinician and will be used to modify task assignment over time. PCT tracks usage of the program so that research staff can access automated reporting of subject use to monitor participant adherence to the treatment program.
89538745|NCT04488029|Active Comparator|Control Group 1 [Conventional Workbook Therapy]|At the start of the study, subjects will be provided with a tablet with videoconferencing software and the PCT app pre-installed. Subjects in the control group will be told they will have access to 3-months of PCT after their participation in the study has concluded. Subjects in this group will be provided with a standard regime of paper workbooks and instructions to complete approximately 30 minutes a day at least 5 days a week.
89538746|NCT03060681|Experimental|T group|Ultrasound guided Bilateral TLIP Block will be performed 15 minute before the start of surgery Using 15 ml of bupivacaine 0.25 for each side.
89538747|NCT03060681|No Intervention|C group|
89538748|NCT02456753||trans-perineal ultrasonography|"Patients included are women about to give birth, they undergo a clinical examination done by midwives. Followed by a trans-perineal ultrasonography examination done by a technical operator in order to measure the perineal-cephalic distance.~These examination are done the day of enrollment, they last for a few minutes and no further tests will be done afterwards."
89538749|NCT04974411||Infection|Patients diagnosed with infection but did not reach the sepsis marker.
89538750|NCT04974411||sepsis|The patient was diagnosed with sepsis but did not develop septic shock
89538751|NCT04974411||sepsis shock|The patient was diagnosed with sepsis shock
89538752|NCT03261479||Respiratory distress|Inclusion criteria are 1) subjects 28-days to 17-years of age, 2) who have respiratory distress, and 3) who receive a chest x-ray. We will exclude subjects with known chronic lung disease.
89538753|NCT04831203|Experimental|Protein-hydrolysate|Dietary supplement: an egg-protein hydrolysate (NWT-03) Study volunteers will receive a daily powder of 5 g of protein hydrolysate to mix with 200 mL of water for 36 weeks.
89538754|NCT04831203|Placebo Comparator|Control|Control: 5 g of maltodextrin powder mixed with 250 mL of water for 36 weeks.
89538755|NCT03260777||children with Alopecia Areata|
89538756|NCT03260777||children with tinea capitis|
89538757|NCT03260777||children with trichotillomania|
88956855|NCT03606967|Experimental|Arm I (neoantigen vaccine, durvalumab, nab-paclitaxel)|"PART A: Patients receive gemcitabine hydrochloride IV over 30 minutes and carboplatin IV on days 1 and 8 of each cycle. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Beginning cycle 4, patients with progression of disease within the first 18 weeks may switch and receive nab-paclitaxel IV on days 1, 8, and 15 of each cycle for 2 cycles at the discretion of the treating physician.~PART B: Patients receive personalized synthetic long peptide vaccine and poly-ICLC SC on days 1, 4, 8, 15, 22, 50, and 78 in the absence of disease progression or unacceptable toxicity. Patients also receive tremelimumab IV on day 1 of cycles 1-4, durvalumab IV on day 1 of each cycle and nab-paclitaxel IV on days 1, 8, and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Patients undergo tumor biopsy, blood sample collection, CT scan and MRI on study."
88982926|NCT02638298|Experimental|NPWT dressing|
88982927|NCT02638298|Placebo Comparator|Standard dry gauze dressing|
89538758|NCT03260777||children with tractional alopecia|
89538759|NCT03060837|Active Comparator|Patients given single lung ventilation|The first group will have single lung ventilation applied to ensure reduction. Preoperative Parameters : Hmg, serum creatinine levels Peroperative Parameters : Scope duration, perforation, hemorrhage, etc. complications) Postoperative parameters (stone-free rates, complications like postoperative hemorrhage and fever, hospital stay, etc) Movement of kidney : Changes in renal stone position during simultaneous normal ventilation and single lung ventilation.
89538760|NCT03060837|Active Comparator|Patients given standard ventilation|This group will have standard ventilation. Preoperative Parameters : Hmg, serum creatinine levels Peroperative Parameters : Scope duration, perforation, hemorrhage, etc. complications) Postoperative parameters (stone-free rates, complications like postoperative hemorrhage and fever, hospital stay, etc) Movement of kidney : Changes in renal stone position during simultaneous normal ventilation and single lung ventilation.
89538761|NCT04967547|Experimental|Intervention group|be evaluated by using the self-care PD feasibility assessment in addition to education on renal replacement therapy and dialysis
89538762|NCT04967547|Active Comparator|Control group|education on renal replacement therapy and dialysis
88956856|NCT03606967|Active Comparator|Arm II (durvalumab, nab-paclitaxel)|"PART A: Patients receive gemcitabine hydrochloride IV over 30 minutes and carboplatin IV on days 1 and 8 of each cycle. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with progression of disease within the first 18 weeks may switch and receive nab-paclitaxel IV on days 1, 8, and 15 of each remaining cycle.~PART B: Patients receive tremelimumab IV over on day 1 of cycles 1-4, durvalumab IV on day 1 of each cycle and nab-paclitaxel IV on days 1, 8, and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo tumor biopsy, blood sample collection, CT scan and MRI on study."
89504102|NCT03607539|Experimental|Sintilimab in combination with pemetrexed and platinum|Injection; dosage form: 10ml: 100mg; frequency: 200mgQ3W (qualer 3 weeks); duration: randomization to the date of the first documented tumor progression per RECIST v1.1 criteria Sintilimab 200mg + pemetrexed/ platinum 4 cycles then Sintilimab 200mg + pemetrexed maintains
89504103|NCT03607539|Placebo Comparator|Sitilimab Placebo Comparator|placebo 2 vials + pemetrexed/ platinum 4 cycles then Sintilimab 200mg + pemetrexed maintains
89504104|NCT04472923|Active Comparator|Control group|Patients belonging to the control group received conventional physical therapy program in the form of diet and Kegel exercises.
88956859|NCT03604835||Patients with MPS VII receiving vestronidase-alfa|via prescription, or early access/ compassionate use program
88956860|NCT03604835||Patients with MPS VII not receiving vestronidase-alfa|no treatment or treatment other than vestronidase alfa
88956861|NCT03602586|Experimental|Treatment (epacadostat, pembrolizumab)|Patients receive epacadostat PO BID and pembrolizumab IV over 30 minutes Q3W. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
88956862|NCT03598244|Experimental|Treatment (volitinib)|Patients receive volitinib PO QD. Treatment repeats every 28 days for up to 39 courses in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection, X-ray imaging, and MRI scans throughout study.
88956863|NCT03583606|Experimental|ChAd3-EBO-Z + ChAd3-EBO-Z|ChAd3-EBO-Z (2 x 10^11 virus particles (vp)) intramuscularly into the deltoid on Day 1 and ChAd3-EBO-Z (2 x 10^11 vp) intramuscularly into the opposite arm on Day 8, n = 20
88956864|NCT03583606|Experimental|ChAd3-EBO-Z + Placebo|ChAd3-EBO-Z (2 x 10^11 virus particles (vp)) intramuscularly into the deltoid on Day 1 and placebo intramuscularly into the opposite arm on Day 8, n = 20
88956865|NCT03583606|Experimental|ChAd3-EBO-Z + MVA- BN-Filo|ChAd3-EBO-Z (2 x 10^11 virus particles (vp)) intramuscularly into the deltoid on Day 1 and MVA-BN-Filo (1 x 10^8 Infectious Units (IU)) intramuscularly into the opposite arm on Day 8, n = 20
88956866|NCT03580356|Experimental|Ligelizumab 120 mg|Ligelizumab 120 mg arm: 1 injection of 1.0 mL ligelizumab + 1 injection of 1.0 mL ligelizumab placebo q4w
88956867|NCT03580356|Experimental|Ligelizumab 72 mg|Ligelizumab 72 mg arm: 1 injection of 0.6 mL ligelizumab + 1 injection of 1.0 mL ligelizumab placebo q4w
88956868|NCT03580356|Active Comparator|Omalizumab 300 mg|Omalizumab 300 mg arm: 2 injections of 1.2 mL omalizumab q4w
88956869|NCT03580356|Placebo Comparator|Placebo|Placebo-ligelizumab arm: 2 injections of 1.0mL of ligelizumab placebo from Week 0 through Week 20; 1 injection of 1.0mL of ligelizumab 120 mg + 1 injection of 1.0 mL ligelizumab placebo from Week 24 through Week 48
88956870|NCT03572374|Experimental|TEAMWork App|"The 2-pronged approach of the intervention is operationalized through 2 menus, 1 focused on interactions with the employer and the other with the clinic team. Each menu has a list of features from which participants can choose to learn about a particular topic. A My notes button allows participants to take notes directly on the app. These notes will not be available to the research team, such that participants may use the tool without concerns about privacy. The workplace accommodations menu includes sample videos using trained actors to demonstrate how to approach an employer to request accommodations. Additional features include suggestions for accommodations that may be helpful, templates for letters participants can use when requesting accommodations, links to relevant websites, information about legal protections, and contact information for lawyers and firms that provide pro bono assistance."
88982928|NCT02636725|Experimental|Axitinib Plus Pembrolizumab Group|Participants in this group will receive combination treatment of Axitinib plus Pembrolizumab for up to 2 years followed by monotherapy of Axitinib until withdrawal of consent, disease progression and/or unacceptable toxicity as assessed by treating physician, whichever occurs first.
88982929|NCT02636725|Experimental|Axitinib Plus Pembrolizumab Expansion Cohort|Expansion cohort for up to 10 additional patients with alveolar soft part sarcoma. Participants in this group will receive combination treatment of Axitinib plus Pembrolizumab for up to 2 years followed by monotherapy of Axitinib until withdrawal of consent, disease progression and/or unacceptable toxicity as assessed by treating physician, whichever occurs first.
89206603|NCT00832884|Active Comparator|Group 2A|Lacosamide, IV, 100 mg, once, 30 min
89504105|NCT04472923|Experimental|Study group|Patients belonging to the study group were subjected to the same conventional physical therapy program in addition to biofeedback training
89504106|NCT02151669|Experimental|Mediterranean Diet Group|Nutritional intervention to enhance the traditional Mediterranean diet pattern using new technology as an educational tool in primary care: DIET blog. Participants will be referred to a single annual visit and one group session per year for two years.
89504107|NCT02151669|No Intervention|Control group|Participants of control group will be referred to your doctor or nurse with reference to a report on specific according to your personal situation dietary recommendations.
89504108|NCT00629941|Experimental|1|
89504109|NCT02404779|Experimental|CISATRACURIUM|To compare the evolution of intracranial pressure (ICP) of severely brain injured patients with intracranial hypertension after administration of cisatracurium versus placebo.
89504110|NCT02404779|Placebo Comparator|PLACEBO|To compare the evolution of intracranial pressure (ICP) of severely brain injured patients with intracranial hypertension after administration of cisatracurium versus placebo.
89504111|NCT00629551|Experimental|Saredutant 100mg and Paroxetine 20 mg|combined saredutant 100mg and paroxetine 20mg once daily for a maximum of 8 weeks
89504112|NCT00629551|Experimental|Saredutant 30mg and Paroxetine 20mg|combined saredutant 30mg and paroxetine 20mg once daily for a maximum of 8 weeks
89504113|NCT00629551|Active Comparator|Paroxetine 20 mg and saredutant placebo|paroxetine 20mg and saredutant placebo once daily for a maximum of 8 weeks
88956871|NCT03572374|Active Comparator|Information Booklet (control)|Participants will receive a booklet that includes the information in the app that can practicably be converted to paper. These participants will not have access to the multimedia aspects of the intervention, such as the videos, but they will have all of the relevant information in the app described above, including suggestions for accommodations, written templates for letters, links to websites, information about legal protections, and contact information for pro bono legal assistance. The booklet will also contain information about chemotherapy, radiation therapy and surgery, recommendations for management of common symptoms, and advice for communicating with the clinic team. The information booklet will be provided entirely on paper, although participants may independently access websites recommended in the booklet. The booklet content will mirror the app with regard to cultural responsiveness and appropriateness for different job types and characteristics.
88956872|NCT03571737|Active Comparator|Ibuprofen|Ibuprofen 800mg every 8 hours for 3 days
88956873|NCT03571737|Experimental|Ibuprofen & Lidocaine Patch 4%|Ibuprofen 800mg every 8 hours for 3 days and Lidocaine patch 4% 1 patch applied for 12 hours then removed for 12 hours, for 3 days
89504114|NCT00629551|Placebo Comparator|Placebo|Saredutant placebo and paroxetine placebo once daily for one week during screening period and maximum of 8 weeks for the active phase
89504115|NCT05231577|Experimental|Experimental: Patients in Group 0 undergo 7.5fr ultra-fine ureteroscopy|
89504116|NCT05231577|Experimental|Experimental: Patients in Group 2 undergo 9.2fr ureteroscopy|
89504117|NCT00625651|Experimental|AMG 655 Low Dose|AMG 655 (low dose) + mFOLFOX6 + Bevacizumab
89504118|NCT00625651|Placebo Comparator|Placebo|Placebo + mFOLFOX6 + Bevacizumab
89504119|NCT00625651|Experimental|AMG 655 High Dose|AMG 655 (high dose) + mFOLFOX6 + Bevacizumab
89504120|NCT05671263||cases women LSc|women with LSc- vulvar lesional skin (including mons pubis, labia minora and labia majora) in women with genital LSc
89504121|NCT05671263||cases men LSc|men with LSc -penile lesional skin (including glans penis and coronal sulcus) in men with genital LSc
89504122|NCT05671263||control women|women without genital disease
89504123|NCT05671263||control men|men without genital disease
89504124|NCT00672997|Experimental|Travoprost/Timolol BAC-free|Travoprost 0.004%/Timolol 0.5% BAC-free ophthalmic solution, 1 drop in each eye, once daily (QD) at 9 AM (±30 minutes), for 6 weeks
89504125|NCT00672997|Active Comparator|Travoprost/Timolol|Travoprost 0.004%/Timolol 0.5% ophthalmic solution, 1 drop in each eye, once daily (QD) at 9 AM (±30 minutes), for 6 weeks
89504126|NCT02669043|Experimental|Ketamine|All participants receive open-label ketamine
89504127|NCT02283385|Experimental|PROTECT Intervention|Participants will receive a brief psychotherapy that builds on Problem Solving Therapy (PST)
89504128|NCT02283463|Active Comparator|Standard Cervical Tenaculum|Single tooth tenaculum, pierces the tissue of the cervix to allow provider to stabilize and place traction on the cervical cal/uterus
89504129|NCT02283463|Experimental|Bioceptive Cervical Retraction Device|Suction based method for stabilizing the cervix and uterus. Achieves suction 360 degrees around cervical os creating a portal through which instruments can be passed into the cervical canal and uterus. Provider can still place traction on uterus with this device just as with tenaculum.
89504130|NCT02283541|Experimental|ASTM|Participants in Automatic self-transcending meditation (ASTM) arm will complete a 12 week meditation training program in addition to their existing treatment plan. This involves participating in 120-minute sessions on each of four consecutive days of the first week. Participants will individually be given a mantra on day one, and then be instructed in use of the mantra according to specific criteria over the four session program. This will be followed by weekly 60-minute follow up sessions for the 11 subsequent weeks. In addition, participants will be asked to practice ASTM at home for 20 minutes twice daily over the study period. Assessments of depression severity will be completed at specific times over the 12 week training period: at Weeks 0, 4, 8 and 12.
89504131|NCT02283541|No Intervention|TAU|Participants in TAU arm will continue with their existing treatment schedule as usual. Assessments of depression severity will be completed at specific times over the 12 week training period: at Weeks 0, 4, 8 and 12. However, no assessments will be done or information collected on the TAU arm from week 12 onwards. After week 12, TAU arm participants will be offered the opportunity to learn ASTM and attend follow up meditation.
89504132|NCT02283619||Patients with LBBB being evaluated for ACS|Patients who present to the emergency department with left bundle branch block on the electrocardiogram, who are being evaluated for acute coronary syndrome, and who qualify based on the inclusion/exclusion criteria listed in the detailed description.
89504133|NCT02280967|Experimental|Education about HPV by school nurse|The educational intervention consists of education about HPV and a special designed leaflet and self-reported questionnaires. The educational intervention is included in the regular health interview with the school nurse (scheduled for about one hour) and includes information about HPV; facts about the virus, transmission, what it can cause and prevention (i.e. safe sex with condom use and HPV vaccination), facts about HPV vaccine and the importance of attending future cervical cancer screening controls. Students complete questionnaires before the health interview at baseline and after three months. A follow-up with parts of the boys will be performed with qualitative interviews. Participants (n=40)
89504134|NCT02280967|No Intervention|Control group 1|Students allocated to control group 1 receives standard treatment, the regular health interview with the school nurse. Students complete questionnaires before the health interview at baseline and after three months (n=400).
89504135|NCT02404857|Experimental|Chronic post-stroke|Patients >6 months post-stroke with little to no hand movement. use of EEG based BCI in the neurorehabilitation process
89504136|NCT02281045|Experimental|EVODIAL dialyzer and Selectbag citrate|Intervention for anticoagulation during dialysis: Combination of Heparin-coated AN69ST membrane (EVODIAL, Gambro-Hospal, Meyzieu, France) and citrate-containing dialysate (Selectbag citrate, Gambro, Lund, Sweden).
89504137|NCT02281045|Active Comparator|Regional citrate anticoagulation|Regional citrate anticoagulation, using a hypertonic sterile solution of trisodium citrate dihydrate (1.035 Mol/L, Baxter, Lessines, Belgium), infused into the afferent blood line. Citrate will be infused at a rate of 62.1 mM/h (60 mL/h). The anticoagulant effect of citrate will be neutralized using calcium containing dialysate (Ca 1.50 mmol/L). Dialysate sodium content will be set at 135 mEQ/L, and bicarbonate will be reduced to 25 mEq/L.
89504138|NCT03514329|Experimental|Vapor Ablation|Patients treated with Bronchoscopic Thermal Vapor Ablation for lung cancer
89504139|NCT04472689|Active Comparator|Lidocaine group|patients will receive a loading dose of IV lidocaine 1.5mg/kg slowly diluted with 20 ml normal saline just before induction of anesthesia, then the lidocaine infusion started at a rate of 2mg/kg/h diluted in normal saline by rate of 2 ml/ kg/h.
89504140|NCT04472689|Placebo Comparator|Control group|patients will receive an equal volume of normal saline (both the loading, and the infusion). The infusion in both groups will be started just after induction of anesthesia induction, and continued until the end of the operation.
89504141|NCT02405013|Experimental|Sofosbuvir+Ribavirin|Sofosbuvir 400mg QD (Sovaldi®) + Ribavirin weight-adjusted dosing (1000mg BID in patients < 75kg and 1200mg BID in patients ≥ 75kg) in treatment-naïve patients infected with HCV genotype 2 (12-week course)
89504142|NCT02405013|Experimental|Sofosbuvir+Ledipasvir|Sofosbuvir/Ledipasvir 400mg/90mg (Harvoni®) in treatment-naïve patients infected with HCV genotype 1 or genotype 4 (12-week course)
89504143|NCT02283697|Experimental|Dietary Counseling|Apart from standard care, an additional one on one (family members allowed) one hour long counseling by certified dietician who will assess the patient's dietary habits, endorse and describe the Dietary Approach to Stop Hypertension (DASH) diet, and will establish four weekly half an hour follow ups by telephone to address compliance and any question raised by patient and family members.
89504144|NCT02283697|Other|Control: Standard Care|A standard endorsement of low salt diet and other non-pharmacological interventions such as moderation of alcohol intake, optimal body weight, daily exercise by hypertension nurse and physician
89504145|NCT02173145|Active Comparator|Azithromycin first, Placebo second|Medication with Azithromycin 500mg/d 3x/week p.o. o.d. for 12 weeks or placebo.
89504146|NCT02173145|Active Comparator|Placebo first, Azithromycin second|Medication with Azithromycin 500mg/d 3x/week p.o. o.d. for 12 weeks or placebo. Placebo will be capsulated similar to verum and given 3 times a week.
89504147|NCT04472455||Screen Negative Group|All women who screen negative at Visit 1.
88956874|NCT03564691|Experimental|Dose Escalation, Part A: MK-4830 Monotherapy|MK-4830 monotherapy (with MK-4830 doses determined by an accelerated titration design [ATD]) will be administered intravenously (IV), every 3 weeks (Q3W), starting with Cycle 1, Day 1, for a maximum of 35 cycles (up to approximately 2 years). Each cycle is 21 days. Participants enroll with histologically or cytologically confirmed pancreatic adenocarcinoma.
88956875|NCT03564691|Experimental|Dose Escalation, Part B: MK-4830 Monotherapy|MK-4830 monotherapy (with MK 4830 doses determined by a modified toxicity probability interval [mTPI] method) will be administered IV, Q3W, starting with Cycle 1, Day 1, for a maximum of 35 cycles (up to approximately 2 years). Each cycle is 21 days. Participants enroll with histologically or cytologically confirmed pleural or peritoneal malignant mesothelioma, epithelial, sarcomatoid, or biphasic subtypes.
88956876|NCT03564691|Experimental|Dose Escalation, Part C: MK-4830 and Pembrolizumab|Combination therapy with MK-4830 and pembrolizumab (with MK-4830 doses determined by an mTPI design). MK-4830 will be administered IV following pembrolizumab infusion, Q3W, starting with Cycle 1, Day 1, for a maximum of 35 cycles. Each cycle is 21 days. Pembrolizumab will be administered by IV, Q3W, starting with Cycle 1, Day 1. Each cycle is 21 days. The combination may be administered for a maximum of 35 cycles (up to approximately 2 years).
88956877|NCT03564691|Experimental|Dose Expansion, Arm A: Pancreatic Adenocarcinoma|Combination therapy with the preliminary recommended phase 2 dose (RP2D) A of MK-4830, and pembrolizumab, in participants with histologically or cytologically confirmed pancreatic adenocarcinoma. MK-4830 will be administered IV following pembrolizumab infusion, Q3W, starting with Cycle 1, Day 1, for a maximum of 35 cycles. Each cycle is 21 days. Pembrolizumab will be administered by IV, Q3W, starting with Cycle 1, Day 1. Each cycle is 21 days. The combination may be administered for a maximum of 35 cycles (up to approximately 2 years).
88956878|NCT03564691|Experimental|Dose Expansion, Arm B: Glioblastoma (GBM)|Combination therapy with the preliminary RP2D A of MK-4830, and pembrolizumab, in participants with histologically or cytologically confirmed GBM. MK-4830 will be administered IV following pembrolizumab infusion, Q3W, starting with Cycle 1, Day 1, for a maximum of 35 cycles. Each cycle is 21 days. Pembrolizumab will be administered by IV, Q3W, starting with Cycle 1, Day 1. Each cycle is 21 days. The combination may be administered for a maximum of 35 cycles (up to approximately 2 years).
88982930|NCT02592499|Experimental|HM III|Patients randomized to mechanical circulatory support will be treated with the HeartMate III (HM III) left ventricular assist device system.
88982931|NCT02592499|Active Comparator|OMM, Optimal Medical Management|"Patients randomized to OMM will be treated according to international guidelines.~ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Eur Heart J. 2012 Jul;33(14):1787-84"
89023701|NCT04912830||20 years follow-up after TVT surgery|Women who had tension free vaginal tape surgery during January 2001-December 2002 in Norway, identified in the National Incontinence Registry
89504148|NCT04472455||Screen Positive Group|All women who screened positive at Visit 1 and were invited to Visit 2
89504149|NCT04472455||10% Of Screen Negative Group|10% of women who screened negative at Visit 1 and were invited to Visit 2
89504150|NCT02404701|Experimental|Aloe vera with cactus|1 capsule (500 mg), 2 times/day
89504151|NCT02404701|Experimental|Cranberry|3 capsules (810 mg), 2 times/day
89504152|NCT02404701|Experimental|Green tea extract|2 capsules (630 mg), 2 times/day
89504153|NCT02404701|Experimental|Bilberry|1 softgel (1000 mg), 2 times/day
89504154|NCT02404701|Experimental|Cinnamon|1 capsule (500 mg), 2 times/day
89504155|NCT02404701|Experimental|Milk thistle|1 capsule (250 mg), 3 times/day
89206604|NCT00832884|Active Comparator|Group 3A|Lacosamide, IV, 150 mg, once, 30 min
89504156|NCT02404701|Experimental|Turmeric|1 capsule (450 mg turmeric + 50 mg turmeric extract), 1 time/day
89504157|NCT02404701|Experimental|Aloe vera|1 capsule (470 mg), 2 times/day
89504158|NCT03538379|Active Comparator|Combat Application Tourniquet (CAT)|The combat application tourniquet (CAT) is the type of commercial tourniquet taught in the B-Con course as administered by the investigators. It will serve as the control group to which all other types of tourniquets, which are not explicitly taught in the course, are compared to.
89504159|NCT03538379|Active Comparator|Sof Tourniquet (Sof-T)|The Sof-Tourniquet (Sof-T) is a commercial windlass type tourniquet similar to the CAT tourniquet in that it is based on a windlass mechanism. Its application not explicitly taught in the B-Con course.
89504160|NCT03538379|Active Comparator|Stretch-Wrap-And-Tuck (SWAT) Tourniquet|The Stretch-Wrap-And-Tuck (SWAT) Tourniquet is a commercial elastic tourniquet. Its application not explicitly taught in the B-Con course.
89504161|NCT03538379|Active Comparator|Rapid Application Tourniquet (RAT)|The Rapid Application Tourniquet (RAT) is a commercial elastic tourniquet similar to a bungee cord. Its application not explicitly taught in the B-Con course.
89504162|NCT03538379|Active Comparator|Improvised Tourniquet|The improvised tourniquet arm will involve participants being given supplies to enable them to fashion a tourniquet. The supplies will include a leather belt, gauze, shoestring, and a rod to act as a windlass.
89504163|NCT00670033|Experimental|Travoprost new formulation|Travoprost ophthalmic solution (new formulation), 1 of 3 dose levels, 1 drop in the study eye(s) once daily, at 8 PM, for 4 weeks
89504164|NCT00670033|Active Comparator|TRAVATAN|Travoprost ophthalmic solution 0.004%, 1 drop in the study eye(s) once daily, at 8 PM, for 4 weeks
89504165|NCT00670033|Placebo Comparator|Vehicle|Inactive ingredients, 1 drop in the study eye(s) once daily, at 8 PM, for 4 weeks
89504166|NCT02170259|Experimental|suboccipital technique|The suboccipital technique (ST) aims to release the spasm of the muscles affected in tension-type headaches and in general of suboccipital soft tissues, as they are responsible for the mobility dysfunction of the occiput-atlas-axis joint; this releases the facial restriction of this region.
89504167|NCT02170259|Experimental|The articulatory technique|- The articulatory technique (AT) was administered to correct and restore the mobility of joints between occiput, atlas and axis - correcting a global joint dysfunction. This technique was performed in supine position, in the same manner as the preceding technique, bilaterally and in two phases.
89504168|NCT02170259|Experimental|Combined treatment|Combined treatment (ST and AT). Combination treatment consisted of the application of the two preceding treatments in the same sequence: first, treatment with ST and then AT.
88956879|NCT03564691|Experimental|Dose Expansion, Arm C: R/M HNSCC|Combination therapy with the preliminary RP2D A of MK-4830, and pembrolizumab, in participants who have histologically or cytologically-confirmed recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) whose disease progressed on an anti-programmed cell death 1/programmed cell death ligand 1 (PD1/L1) therapy. MK-4830 will be administered IV following pembrolizumab infusion, Q3W, starting with Cycle 1, Day 1, for a maximum of 35 cycles. Each cycle is 21 days. Pembrolizumab will be administered by IV, Q3W, starting with Cycle 1, Day 1. Each cycle is 21 days. The combination may be administered for a maximum of 35 cycles (up to approximately 2 years).
89206605|NCT00832884|Active Comparator|Group 4A|Lacosamide, IV, 200 mg, once, 30 min
89206606|NCT00832884|Active Comparator|Group 1B|Lacosamide, IV, 50 mg, once, 15 min
89206607|NCT00832884|Active Comparator|Group 2B|Lacosamide, IV, 100 mg, once, 15 min
89206608|NCT00832884|Active Comparator|Group 3B|Lacosamide, IV, 150 mg, once, 15 min
89206609|NCT00832884|Active Comparator|Group 4B|Lacosamide, IV, 200 mg, once, 15 min
89206610|NCT00954291||Granisetron|14 mg Granisetron
89206611|NCT00832962||1|Adult Rh negative pregnant patients from 7 selected centers (SAINT ANTOINE hospital, CHU Marseille, CHU Nantes, CHU Lille, LOUIS MOURIER Hospital, SAINT VINCENT-PAUL Hospital, CH POISSY)
89206612|NCT00832962||2|Adult Rh negative pregnant patients from 6 selected centers (Tenon hospital, Jean VERDIER Hospital, La Pitie-Salpetriere Hospital, Cochin Hospital, Robert Debre Hospital, BICHAT Hospital)
89504169|NCT02170259|No Intervention|Control group|Control group. The control group was not applied a treatment technique
89504170|NCT03170973|Experimental|Comparison of fatty acids before and after exercise|
89504171|NCT03170973|No Intervention|Comparison of fatty acids at baseline and 24 hours after|
89504172|NCT02283775|Experimental|PomdeSAR|"Part A: Isatuximab (escalating dose) on Day 1, 8, 15, and 22, then Day 1 and 15 + pomalidomide 4 mg on Day 1 to 21 + dexamethasone 40 mg (20 mg in patients of 75 years or older) on Day 1, 8, 15, 22 in 28-day cycles up to disease progression~Part B: Isatuximab 10 mg/kg on Day 1, 8, 15, and 22, then Day 1 and 15 + pomalidomide 4 mg on Day 1 to 21 + dexamethasone 40 mg (20 mg in patients of 75 years or older) on Day 1, 8, 15, 22 in 28-day cycles up to disease progression"
89504173|NCT00505219|Experimental|Ixmyelocel-T|Core decompression & treatment with Tissue Repair Cells (TRCs), demineralized bone matrix bound in autologous plasma
89504174|NCT00505219|Active Comparator|Standard of Care Only|Core decompression, demineralized bone matrix bound in autologous plasma, without any TRCs.
89504175|NCT02165579||Age > 21, diabetes, osteomyelitis|1 Cohort, standard care, observational patients are: Diagnosis of diabetes mellitus Age ≥ 21 years Infectious Disease Society of America stage 3 infection
89504176|NCT04479891|Experimental|pyrotinib alone, pyrotinib + itraconazole|Sequential treatments of pyrotinib alone followed by pyrotinib + itraconazole, with a washout period in between.
89504177|NCT02281123||Patient suspected of being infected by chikungunya|Patient (>= 45 ans) suspect d'infection par le virus du chikungunya et présentant des symptomes depuis moins de 10 jours
89504178|NCT02173223|Experimental|0.7% Rho-Kinase Inhibitor|AR-12286 is a novel Rho-kinase inhibitor developed by Aerie Pharmaceuticals, Inc., Bridgewater, NJ. It is a potent Rho-kinase inhibitor with single-digit nanomolar inhibitory activity against Rho-kinase in enzymatic inhibition assays (deLong MA, et al. IOVS 2009; 50: ARVO E-abstract 4058). Mechanism-of action studies in monkeys demonstrate that AR-12286 lowers IOP primarily by increasing aqueous humor outflow through the trabecular meshwork (Wang RF, et al. IOVS 2009; 50:ARVO E-abstract 1465). Rho-kinase AR-12286 is well tolerated and produces clinically and statistically significant ocular hypotensive efficacy in patients with ocular hypertension and glaucoma. It is well tolerated by most of patients and the only side effect was ocular hyperemia in a minority of subjects (Williams, Novack, Van Haarlem, & Kopczynski, 2011). It is currently in phase II testing.
89504179|NCT02173223|Experimental|0.5% Rho-Kinase Inhibitor|AR-12286 is a novel Rho-kinase inhibitor developed by Aerie Pharmaceuticals, Inc., Bridgewater, NJ. It is a potent Rho-kinase inhibitor with single-digit nanomolar inhibitory activity against Rho-kinase in enzymatic inhibition assays (deLong MA, et al. IOVS 2009; 50: ARVO E-abstract 4058). Mechanism-of action studies in monkeys demonstrate that AR-12286 lowers IOP primarily by increasing aqueous humor outflow through the trabecular meshwork (Wang RF, et al. IOVS 2009; 50:ARVO E-abstract 1465). Rho-kinase AR-12286 is well tolerated and produces clinically and statistically significant ocular hypotensive efficacy in patients with ocular hypertension and glaucoma. It is well tolerated by most of patients and the only side effect was ocular hyperemia in a minority of subjects (Williams, Novack, Van Haarlem, & Kopczynski, 2011). It is currently in phase II testing.
89504180|NCT02281201|Experimental|BE1116|Single intravenous (I.V.) infusion, dosage depending on baseline INR and body weight
89504181|NCT02170337|Experimental|AMG 282|AMG 282 administered as subcutaneous and intravenous doses.
89504182|NCT02170337|Placebo Comparator|Placebo|No active drug
89504183|NCT01726257|Experimental|Nellix System|Nellix Endovascular Aneurysm Sealing System is the only arm for this study. This is a single arm study.
89504184|NCT02281279|Experimental|Treatment (rituximab, romidepsin, lenalidomide)|Patients receive rituximab IV over 90 minutes on day 1; romidepsin IV over 4 hours on either day 1, days 1 and 8, or days 1, 8, and 15; and lenalidomide PO on days 1-21. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
88956880|NCT03564691|Experimental|Dose Expansion, Arm D: PD-L1 positive HNSCC, Dose A|Combination therapy with the preliminary RP2D A of MK-4830, and pembrolizumab, in participants who have histologically or cytologically-confirmed advanced programmed death-ligand 1 (PD-L1) positive head and neck squamous cell carcinoma (HNSCC). MK-4830 will be administered IV following pembrolizumab infusion, Q3W, starting with Cycle 1, Day 1, for a maximum of 35 cycles. Each cycle is 21 days. Pembrolizumab will be administered by IV, Q3W, starting with Cycle 1, Day 1. Each cycle is 21 days. The combination may be administered for a maximum of 35 cycles (up to approximately 2 years).
88956881|NCT03564691|Experimental|Dose Expansion, Arm E: First-Line Advanced NSCLC, Dose A|Combination therapy with the preliminary RP2D A of MK-4830, and pembrolizumab, in participants who have histologically-confirmed, first-line treatment advanced non-small-cell-lung-cancer (NSCLC) (Stage IIIB or IV). MK-4830 will be administered IV following pembrolizumab infusion, Q3W, starting with Cycle 1, Day 1, for a maximum of 35 cycles. Each cycle is 21 days. Pembrolizumab will be administered by IV, Q3W, starting with Cycle 1, Day 1. Each cycle is 21 days. The combination may be administered for a maximum of 35 cycles (up to approximately 2 years).
88956882|NCT03564691|Experimental|Dose Expansion, Arm F: First-Line Advanced NSCLC, Dose B|Combination therapy with the preliminary RP2D B of MK-4830, and pembrolizumab, in participants who have histologically-confirmed, first-line treatment advanced non-small-cell-lung-cancer (NSCLC) (Stage IIIB or IV). MK-4830 will be administered IV following pembrolizumab infusion, Q3W, starting with Cycle 1, Day 1, for a maximum of 35 cycles. Each cycle is 21 days. Pembrolizumab will be administered by IV, Q3W, starting with Cycle 1, Day 1. Each cycle is 21 days. The combination may be administered for a maximum of 35 cycles (up to approximately 2 years).
88956883|NCT03564691|Experimental|Dose Expansion, Arm G: NSCLC, +Carboplatin/Pemetrexed|Combination therapy with the preliminary RP2D A of MK-4830, pembrolizumab, and carboplatin/pemetrexed in participants with advanced non-squamous non-small-cell-lung-cancer (NSCLC) (Stage IIIB or IV). MK-4830 will be administered IV following pembrolizumab infusion, Q3W, starting with Cycle 1, Day 1, for a maximum of 35 cycles. Each cycle is 21 days. Pembrolizumab will be administered by IV, Q3W, starting with Cycle 1, Day 1. Each cycle is 21 days. The combination may be administered for a maximum of 35 cycles. Carboplatin and pemetrexed will be administered IV Q3W, starting with Cycle 1, Day 1, for 4 cycles, followed by pemetrexed Q3W continuous with MK-4830 and pembrolizumab, up to 35 cycles. Each cycle is 21 days (up to approximately 2 years).
88956884|NCT03564691|Experimental|Dose Expansion, Arm H: RCC, +Lenvatinib|Combination therapy with the preliminary RP2D A of MK-4830, pembrolizumab, and lenvatinib in participants with advanced renal cell carcinoma (RCC). MK-4830 will be administered IV, Q3W, starting with Cycle 1 following pembrolizumab infusion, Day 1, for a maximum of 35 cycles. Each cycle is 21 days. Pembrolizumab will be administered by IV, Q3W, starting with Cycle 1, Day 1. Each cycle is 21 days. The combination may be administered for a maximum of 35 cycles (up to approximately 2 years). Lenvatinib will be administered orally once daily for up to 35 cycles of 21 days (up to approximately 2 years).
88956885|NCT03564691|Experimental|Dose Expansion, Arm I: R/M Gastric/GE Junction Adenocarcinoma|Combination therapy with the preliminary RP2D A of MK-4830, and pembrolizumab, in participants who have histologically or cytologically-confirmed recurrent or metastatic (R/M) gastric or gastroesophageal (GE) junction adenocarcinoma and who have been previously treated with at least 2 prior lines of therapy. MK-4830 will be administered IV following pembrolizumab infusion, Q3W, starting with Cycle 1, Day 1, for a maximum of 35 cycles. Each cycle is 21 days. Pembrolizumab will be administered by IV, Q3W, starting with Cycle 1, Day 1. Each cycle is 21 days. The combination may be administered for a maximum of 35 cycles (up to approximately 2 years).
88956886|NCT03564691|Experimental|Dose Expansion, Arm J: Ovarian Cancer|Triple combination therapy with pembrolizumab plus preliminary RP2D A of MK-4830 plus paclitaxel in participants who have histologically confirmed, ovarian cancer. MK-4830 will be administered IV following pembrolizumab infusion, Q3W, starting with Cycle 1, Day 1, for a maximum of 35 cycles. Each cycle is 21 days. Pembrolizumab will be administered by IV, Q3W, starting with Cycle 1, Day 1 for a maximum of 35 cycles (up to approximately 2 years). Each cycle is 21 days. Paclitaxel will be administered by IV, once every week (QW) on Days 1, 8, and 15 of each 21-day cycle until disease progression or prohibitive toxicity.
89023702|NCT04912830||10 years follow-up after TVT surgery, age 42 or younger|Women who had tension free vaginal tape surgery and aged < 42 years at the time of surgery during 2011-2012 in Norway, identified in the National Incontinence Registry
89023703|NCT04912375|Experimental|Low EF with priming|Participants will be first stratified by their Executive function (EF). In this arm, participants have low EF. They will play a puzzle task that will ask participants to take 5 min to search Chinese words for meaningful statements. Each statement represents an implicit goal of healthy eating.
89023704|NCT04912375|No Intervention|Low EF without priming|Participants will be first stratified by their Executive function (EF). In this arm, participants have low EF. They will play a similar puzzle task but the statements they searched are neutral.
89023705|NCT04912375|Experimental|High EF with priming|Participants will be first stratified by their Executive function (EF). In this arm, participants have high EF. They will play a puzzle task that will ask participants to take 5 min to search Chinese words for meaningful statements. Each statement represents an implicit goal of healthy eating.
89023706|NCT04912375|No Intervention|High EF without priming|Participants will be first stratified by their Executive function (EF). In this arm, participants have high EF. They will play a similar puzzle task but the statements they searched are neutral.
89023707|NCT04910607||Patient|Participating patients will be recruited from the Specialised Obesity Centres =CSO (CHU and Follow-up and rehabilitation care (SSR), as well as patient associations) to fill in a questionnaire and take part in an interview (varied panel representative of the target population in terms of place of residence, socio-professional category, sex and age).
89023708|NCT04910607||Professional|Medical and paramedical staff involved in the partner CSOs will also be asked to participate in a semi-structured interview.
89023709|NCT04899362|Experimental|RIC group|RIC was induced by 4 cycles of extremities ischemia (5-minute blood-pressure cuff inflation to 200 mm Hg, followed by 5-minute cuff deflation).All subjects will take 14 RIC intervention, blood collection and 10 dCA measurements.
89023710|NCT04894344|Experimental|Educational program|"Participants will be randomly assigned. Intervention Group: 57 participants Each participant will receive the same educational information throughout the study, each week a newsletter will be provided with recommendations and information that teaches them to choose low-sodium foods for 4 weeks.~Urine samples of 24 h before and after the Intervention will be analyzed."
89206613|NCT00947973|Experimental|Challenging Horizons Program after-school model|Participants will receive the CHP after-school model.
89504185|NCT02173457|Experimental|Arm 1|Patients administrate Chiglitazar 32mg once daily for 24 weeks
89504186|NCT02173457|Experimental|Arm 2|Patients administrate Chiglitazar 48mg once daily for 24 weeks
89504187|NCT02173457|Active Comparator|Arm 3|Patients administrate Sitagliptin 100mg once daily for 24 weeks
89504188|NCT05652855|Experimental|MHB088C administered|MHB088C will be administered intravenously at a frequency of once every 2 weeks (Q2W).
89504189|NCT05604885|Experimental|AP1189, 60 mg|Part A: (AP1189, 60 mg); Part B: (TBD)
89504190|NCT05604885|Experimental|AP1189, 80 mg|Part A: (AP1189, 80 mg); Part B: (TBD)
89504191|NCT05604885|Experimental|AP1189, 100 mg|Part A: (AP1189, 100 mg); Part B: (TBD)
89504192|NCT05604885|Placebo Comparator|Placebo|Part A: (placebo); Part B: (placebo).
89504193|NCT02165657|Experimental|Excimer laser|Excimer laser treatment
89504194|NCT00805129|Experimental|Everolimus|Everolimus will be administered at a dose of 10 mg orally once daily continuously.
89504195|NCT03375723|Experimental|Information on anatomy and physiology, and breathing technique|"Information on anatomy and physiology, and breathing technique~Information about anatomy~Information about physiology~Breathing technique"
89504196|NCT03375723|Active Comparator|Usual care treatment|Usual care treatment given to patients with respiratory associated pain in acute PE, which is treatment with analgesics. The information on anatomy and physiology in acute PE is the usual information given by the physician at the ward that the patient is treated.
89504197|NCT00501709|Experimental|Treatment|Allogenic pancreatic islet transplant using belatacept and raptiva
88815249|NCT04353518|Experimental|Suspension of Mw|"Intradermal suspension of Mw will be administered in two divided doses:~Dose 1 at Day 0: 0.2 ml (0.1 ml x 2 injection) of intradermal Mw in two divided dose.~Dose 2 at Day 15 after the first dose: 0.1 ml injection of intradermal Mw administered."
89504198|NCT02165891|Other|Urokinase|insertion of a chest drain with urokinase instillation
89504199|NCT02165891|Other|VATS|primary video-assisted thorascopic surgery Other interventions except drainage procedure are the same in both arms
89504200|NCT05572827|Experimental|Experimental|Breathing exercises will be taught to COVID-19 patients after intensive care.
89504201|NCT05572827|No Intervention|Control|Breathing exercises will not be taught to COVID-19 patients after intensive care.
89504202|NCT02273635|Experimental|andrographolides|Coated tablets containing 140 mg andrographolides twice a day orally administered for a period of 24 months.
89504203|NCT02273635|Placebo Comparator|sugar tablets|Coated tablets containing 140 mgs excipients twice a day orally administered for a period of 24 months.
89504204|NCT03539471||psychiatric resident in NTUH|
89206614|NCT00947973|Experimental|Challenging Horizons Program consultation model|Participants will receive the CHP consultation model.
89206615|NCT00947973|No Intervention|Community care|Participants will have access to standard community care.
89504205|NCT02404467||Patients receiving transfermoral TAVI|TF TAVI
89504206|NCT00622765|Experimental|001|R256918 5 mg capsule twice daily
89504207|NCT00622765|Experimental|002|R256918 10 mg capsule twice daily
89504208|NCT00622765|Experimental|003|R256918 15 mg capsule twice daily
89504209|NCT00622765|Placebo Comparator|004|placebo Placebo capsule twice daily
89504210|NCT02170415|Active Comparator|Intervention limb|"Medical review and analgesic optimisation.~Pain education (in the form of leaflet and website recommendations)~Psychological input for patients with evidence of psychological morbidity.~Protective analgesia - one pre-procedure dose of 150mg oral pregabalin.~Five days post-procedure oral pregablin twice daily at a dose of 75mg twice a day.~Patients offered a paravertebral block, local anaesthetic infiltrated around the wound by the surgeon.~Daily, focused visits from the hospital pain team.~Any patient displaying concerning pain symptoms, behaviour or who underwent prolonged (>3 hours surgery) may be booked for early 'preemptive' review in pain clinic."
89023711|NCT04894344|No Intervention|Control group|Participants will be randomly assigned. Control group:57 participants Follow-up for 4 weeks. Urine samples of 24 h before and after the educational program will be analyzed.
89023712|NCT04890613|Experimental|Main Study Cohort patients receiving CX-5461 at 250mg/m2|Eligible patients with histologically confirmed pancreatic, ovarian, prostate, or breast cancers with pathogenic/likely pathogenic germline BRCA2 and/or PALB2 mutation will be enrolled to receive CX-5461 at a dosing concentration of 250mg/m2, delivered as a 60-minute IV infusion on Day 1 and Day 8 of a 28-day cycle.
89023713|NCT04890613|Experimental|Exploratory cohort patients receiving CX-5461 at 250mg/m2|Eligible patients with ovarian cancer and pathogenic/likely pathogenic BRCA1 and/or other HRD-associated mutation will be enrolled to receive CX-5461 at a dosing concentration of 250 mg/m2, delivered as a 60-minute IV infusion on Day 1 and Day 8 of a 28-day cycle.
89023714|NCT04890613|Experimental|Main Study Cohort patients receiving CX-5461 at 325mg/m2|After confirming the dose of 250mg/m2 to be safe and tolerable, eligible patients with histologically confirmed pancreatic, ovarian, prostate, or breast cancers with pathogenic/likely pathogenic germline BRCA2 and/or PALB2 mutation will be enrolled to receive CX-5461 at a dosing concentration of 325mg/m2, delivered as a 60-minute IV infusion on Day 1 and Day 8 of a 28-day cycle.
89023715|NCT04890613|Experimental|Exploratory cohort patients receiving CX-5461 at 325mg/m2|After confirming the dose of 250mg/m2 to be safe and tolerable, eligible patients with ovarian cancer and pathogenic/likely pathogenic BRCA1 and/or other HRD-associated mutation will be enrolled to receive CX-5461 at a dosing concentration of 325 mg/m2, delivered as a 60-minute IV infusion on Day 1 and Day 8 of a 28-day cycle.
89023716|NCT04870606|Active Comparator|GT0918+ standard of care|Proxalutamide 200mg, oral, QD, for continuous 14 days, plus standard of care(n=334)
89023717|NCT04870606|Placebo Comparator|placebo+ standard of care|Placebo 200mg, oral, QD, for continuous 14 days, plus standard of care(n=334)
89023718|NCT04862923||Patients with type 2 diabetes|Adult patients with type 2 diabetes and naïve to injectable glucose-lowering treatment.
89023719|NCT04861337|Experimental|Remimazolam Group|Remimazolam infusion is initiated after induction of general anesthesia at a rate of 0.25 mg/kg/h and stopped 15 minutes before the end of surgery.
89023720|NCT04861337|Placebo Comparator|Placebo Group|Placebo (0.9% saline) infusion is initiated after induction of general anesthesia at the same rate as in the remimazolam group and stopped 15 minutes before the end of surgery.
89023721|NCT04857463|Experimental|Nutritional supplement drink|Nutritional supplement, this group receives a nutritional supplement for a period of 12 weeks.
89023722|NCT04857463|Placebo Comparator|Nutritional education|Qualified clinical dietitians provide regular nutrition education and ensure the effectiveness of nutrition education
89504211|NCT02170415|No Intervention|Usual care|These partcipants will receive usual care before, during and after their breast surgery
89504212|NCT02668185|Experimental|Active drug first|Baseline period - 2 weeks NK3R antagonist - AZD4901 - 40mg bd - 4 weeks Washout period - 2 weeks Matched placebo orally bd - 2 weeks Monitoring period - 2 weeks
89504213|NCT02668185|Placebo Comparator|Placebo|Baseline period - 2 weeks Matched placebo orally bd - 2 weeks Washout period - 2 weeks NK3R antagonist - AZD4901 - 40mg bd - 4 weeks Monitoring period - 2 weeks
89504214|NCT02165969|Experimental|endoscopic endonasal surgery with UPSIT|endoscopic endonasal surgery with UPSIT prior to surgery and at months 1, 3, 6, and 12 after surgery.
89504215|NCT03134365|Experimental|Mixed meal|
89504216|NCT03134365|Active Comparator|Combined meal|
89504217|NCT02166125||Endoscopic suturing|Any patient who has undergone clinically indicated and/or standard of care endoscopic suturing within the Gastrointestinal tract.
89504218|NCT02173691|Experimental|Tiotropium|
89504219|NCT02173691|Active Comparator|Salmeterol|
89504220|NCT02173691|Placebo Comparator|Placebo|
89504221|NCT02274259|Active Comparator|Aflibercept|Aflibercept injection is given at every visit. Time to next treatment according to presence of macular edema
89504222|NCT02274259|Active Comparator|Ranibizumab|Ranibizumab injection is given at every visit. Time to next treatment according to presence of macular edema
89504223|NCT05571111|Experimental|Dose 1 of FE 999302|Subcutaneous injection of Dose 1 of FE 999302 as a single dose.
89504224|NCT05571111|Experimental|Dose 2 of FE 999302|Subcutaneous injection of Dose 2 of FE 999302 as a single dose.
89504225|NCT05571111|Experimental|Dose 3 of FE 999302|Subcutaneous injection of Dose 3 of FE 999302 as a single dose.
89504226|NCT05571111|Active Comparator|250 μg OVITRELLE|Subcutaneous injection of 250 μg of OVITRELLE. 0.5 mL as a single dose.
89504227|NCT05571111|Active Comparator|10,000 IU NOVAREL|"Subcutaneous injection of 10,000 IU NOVAREL.~1 mL as a single dose."
89504228|NCT02404623|Experimental|Intervention Group|800 IU of Vitamin D once daily
89504229|NCT02404623|Other|Control Group|400 IU of Vitamin D once daily, the standard of care
89504230|NCT00618319|Experimental|1|BIIB021
89504231|NCT02170571|Experimental|Dabigatran etexilate|
89504232|NCT05570799|No Intervention|Control group|No augmented reality or Kahoot game-based learning group (traditional lectures group)
89504233|NCT05570799|Experimental|Experimental group|Augmented reality learning and Kahoot game group
89504234|NCT00618007|Experimental|30 mg QD|
89504235|NCT00618007|Experimental|20 mg QD|
89504236|NCT00618007|Placebo Comparator|Placebo|
89504237|NCT02256059||Plate osteosynthesis|Patients with fracture of the lateral clavicle and indication for surgical treatment
89504238|NCT02388399||OCT and Pressure wire pullback tracing|This study is pilot study evaluating the feasibility of invasive measurement and estimation of hemodynamic stress acting on plaque as well as co-registration of hemodynamic data with plaque geometric data, which is obtained by optical coherence tomography
89023723|NCT04857463|No Intervention|Healthy control|No intervention was done to this group, only blood collection, physical performance and anthropometric assessment were done.
89504239|NCT02173847|Experimental|Penetrating keratoplasty|Femtosecond laser sculptured anvil graft. Diode laser welding of the flap in its final position. 12 months follow up study
89504240|NCT04481841|Experimental|experimental group|"On the basis of classical Gu-Nucleus-E triple drug therapy, the experimental group was treated with head yuanshi dian therapy twice a day for 1 months as a course of treatment."
89504241|NCT04481841|Active Comparator|control group|oryzanol + vitamin B2 (riboflavin) + vitamin E, oryzanol tablets, oral, 10 mg/time, 3 times/day; vitamin B2 tablets, oral, 10 mg/time, 3 times/day; vitamin E pills, oral, 100 mg/time, 1 time/day, 1 months as a course of treatment.
89504242|NCT00493441|Experimental|Treatment|
89504243|NCT02388477|Active Comparator|Doxycycline|oral doxycycline, 2 weeks, twice a day,
89504244|NCT02388477|Placebo Comparator|sugar pill|sugar pill, same size, shape, and color as comparator, twice a day for 2 weeks.
89504245|NCT02166359|Active Comparator|Glucose group|Glucose use of 2.5% or 4.25% dextrose solution at least 4 hours
89504246|NCT02166359|Experimental|Extraneal (Icodextrin) group|Extraneal (Icodextrin) use at least 8 hours
89504247|NCT00488839|Other|IPX056 20 mg - OLE|A single dose of IPX056 20 mg, Placebo IPX056 40 mg and Placebo Baclofen Tablet (Part 1), 9 week Open label extension of IPX056 (flexible dose design, IPX056 10 mg, IPX056 20 mg, IPX056 30 mg, IPX056 35 mg, or IPX056 40 mg)
89504248|NCT00488839|Other|IPX056 40 mg - OLE|A single dose of IPX056 40 mg, Placebo IPX056 20 mg and Placebo Baclofen Tablet (Part 1), 9 week Open label extension of IPX056 (flexible dose design, IPX056 10 mg, IPX056 20 mg, IPX056 30 mg, IPX056 35 mg, or IPX056 40 mg)
89504249|NCT00488839|Other|Baclofen 20 mg - OLE|A single dose of Encapsulated Baclofen 20 mg, Placebo IPX056 20 mg and Placebo IPX056 40 mg (Part 1), 9 week Open label extension of IPX056 (flexible dose design, IPX056 10 mg, IPX056 20 mg, IPX056 30 mg, IPX056 35 mg, or IPX056 40 mg)
89504250|NCT00488839|Other|Placebo - OLE|A single dose of Placebo Baclofen Tablet, Placebo IPX056 20 mg and Placebo IPX056 40 mg (Part 1), 9 week Open label extension of IPX056 (flexible dose design,IPX056 10 mg, IPX056 20 mg, IPX056 30 mg, IPX056 35 mg, or IPX056 40 mg)
89504251|NCT03539315|Experimental|Intervention: ARCHES|All women attending facilities assigned to the intervention arm receive the Addressing Reproductive Coercion within Healthcare Settings (ARCHES) intervention.
89504252|NCT03539315|No Intervention|Control|All women attending facilities assigned to the control arm receive the standard of care (no intervention).
89504253|NCT04479501||Asthma group|Patients with asthma
89504254|NCT02166437||Alendronate|Patients treated with alendronate
89504255|NCT02166437||Minodronate|Patients treated with minodronate
89504256|NCT02166437||Denosmab|Patients treated with denosmab
89023724|NCT04856891|Experimental|3.0 mg/kg of Lirentelimab (AK002)|Subjects in this arm will receive 6 monthly doses of lirentelimab (AK002) at 3 mg/kg.
89023725|NCT04856891|Placebo Comparator|Placebo|Subjects in this arm will receive 6 monthly doses of placebo at 3 mg/kg.
89023726|NCT04853810||Major diabetic subjects having used a system with adhesives|Major diabetic subjects, whatever the etiology of diabetes, using or having used in the last 10 years a system with skin adhesives, i.e. insulin patch pump (e.g. OMNIPOD®, cell Novo®), pump with externalized catheter (e.g. MINIMED 640G®, YpsoPump®) or continuous glucose measurement system (Free Style®, DexCom® sensors, Enlite® sensors).
89023727|NCT04851145|Experimental|Experimental|
89023728|NCT04850781|Active Comparator|Daily Meals|A lunch-time meal delivered to participants' homes multiple times per week with wellness check and socialization.
89504257|NCT03115671|Experimental|Intervention|Each child participant in the Intervention group will be taking 4 capsules of Vayarin per day for 3 months. Each capsule contains 167mg Lipirinen, providing 75mg Phosphatidylserine (PS), 21.5mg EPA and 8.5mg DHA. This gives a daily dosage of 300mg PS and 120mg EPA/DHA. They may continue their treatment as usual provided there is no change in medication and intervention during the trial.
89504258|NCT03115671|No Intervention|Control|Participants in the Control group will not be given Vayarin. They may continue their treatment as usual provided there is no change in medication and intervention during the trial.
89206616|NCT02549118|Experimental|Tenoxicam|Intravenous administration of tenoxicam, a lyophilisate with 20 mg to be dissolved and diluted in 10 mL of sterile water (single dose), as an analgesic during the first stage of labor, given by a member of the study team.
89504259|NCT02166515||experiment group|patients with cervical cancer, endometrial cancers or ovary cancer
89504260|NCT02166515||control group|postmenopausal women with benign tumor
89504261|NCT02275273||Patients with adnexal masses|Every patient that are at least 18 years old with a planned pelvic magnetic resonance imagery and an adnexectomy within the institution.
89504262|NCT02255747|Active Comparator|anal dilatation|
89504263|NCT02255747|Active Comparator|Oral Lactulose|
89504264|NCT01654731|Experimental|Bezafibrate|400 mg/Day
89504265|NCT01654731|Placebo Comparator|Placebo|1 tablet/ day
89504266|NCT02174705|Experimental|Sucrose|Sucrose prior to vaccine injections
89504267|NCT02174705|Active Comparator|Rotavirus|Rotavirus prior to vaccine injections
89504268|NCT02255825|Active Comparator|Control Group|Amniocentesis will be performed, Whole Genome Sequencing will not be performed, and psychosocial assessment will be performed.
89504269|NCT02255825|Experimental|Intervention Group|Amniocentesis will be performed, Whole Genome Sequencing will be performed if the karyotype is normal, and psychosocial assessment will be performed.
89504270|NCT03134287|Active Comparator|two-finger method|Those who received nasogastric tube placement by two-finger method
89504271|NCT03134287|Active Comparator|reverse sellick's method|Those who received nasogastric tube placement by reverse sellick's method
89504272|NCT02388243|Experimental|Brief Intervention in Public Clinic|Written information after screening; 15 minutes or so brief intervention at recruitment with follow-up visit of about the same length after one month; in public clinic.
89504273|NCT02388243|Active Comparator|Screening results in Public Clinic|Written information after screening; No brief intervention; in public clinic.
89504274|NCT02388243|Experimental|Brief Intervention in Private Clinic|Written information after screening; 15 minutes or so brief intervention at recruitment with follow-up visit of about the same length after one month; in private clinic.
89504275|NCT02388243|Active Comparator|Screening results in Private Clinic|Written information after screening; No brief intervention; in private clinic.
89504276|NCT02173925||Functional dyspepsia group|Patients who had epigastric pain or discomfort with normal upper endoscopy and no organic evidence for explaining these symptoms
89504277|NCT02173925||Control group|Subjects with normal endoscopic finding who do not have any gastrointestinal symptoms
89504278|NCT02170805|Experimental|Substudy 1|"Three treatments of single administrations of BIBR 1048 MS 50 mg with or without pantoprazole; randomised sequence~BIBR 1048 MS capsule formulation A without pantoprazole;~BIBR 1048 MS capsule formulation A with coadministration of 40 mg pantoprazole (bid);~BIBR 1048 MS powder plus solution without pantoprazole"
89504279|NCT02170805|Experimental|Substudy 2|"Three treatments of single administrations of BIBR 1048 MS 50 mg with or without pantoprazole; randomised sequence~BIBR 1048 MS capsule formulation B without pantoprazole;~BIBR 1048 MS capsule formulation B with coadministration of 40 mg pantoprazole (bid);~BIBR 1048 MS powder plus solution without pantoprazole"
89504280|NCT00606697|Active Comparator|Overall study|Male and female subjects, 18-64 years of age (inclusive), with a primary diagnosis of primary insomnia
89504281|NCT05560893|Experimental|Intervention Group|In this randomized controlled waitlist design, following a baseline assessment, we will randomly assign CSPs into the experimental group (n = 40) or a waitlist group (n = 40). The experimental group will receive the intervention immediately, whereas the waitlist control will wait 4 weeks and have a second baseline assessment before receiving the intervention. All participants will complete an identical assessment battery at pre-intervention baseline, immediately post-intervention, and 3-months following the intervention.
89504282|NCT05560893|Other|Waitlist Control Group|In this randomized controlled waitlist design, following a baseline assessment, we will randomly assign CSPs into the experimental group (n = 40) or a waitlist group (n = 40). The experimental group will receive the intervention immediately, whereas the waitlist control will wait 4 weeks and have a second baseline assessment before receiving the intervention. All participants will complete an identical assessment battery at pre-intervention baseline, immediately post-intervention, and 3-months following the intervention.
89504283|NCT02174003||Open Treatment Group|The Open Treatment Group (all participants in this study) will receive the active / WBH treatment in an open fashion.
89504284|NCT00604123|Experimental|JNJ-17166864|
89504285|NCT00604123|Placebo Comparator|Placebo|
89206617|NCT02549118|Active Comparator|Pethidine|Slow intravenous administration of pethidine, 50 mg to be diluted in 10 mL of sterile water (single dose), as an analgesic during the first stage of labor, given by a member of the study team.
89504286|NCT02404077||Clonidine|Patients who received clonidine following prolonged dexmedetomidine infusions
89504287|NCT02174783|Active Comparator|Control group|Standard of care group
89504288|NCT02174783|Experimental|Mediterranean diet|Mediterranean diet for 6 months
89504289|NCT02174783|Experimental|Protein-Sparing Modified Fast (PSMF)|PSMF for 6 months
89504290|NCT02174939|Active Comparator|Cilostazol|One tablet (100 mg) twice per day for 12 weeks
89504291|NCT02174939|Placebo Comparator|Dummy Placebo|One tablet twice per day for 12 weeks
89504292|NCT02404233|Experimental|Darunavir/ cobicistat and Rilpivirine|"Single arm study:~Darunavir/ cobicistat 800/ 150 mg tablet once daily taken with food Rilpivirine tablet 25 mg once daily taken with food"
89504293|NCT00603577|Placebo Comparator|Placebo|
89504294|NCT00603577|Experimental|Xaliproden|
89504295|NCT02178215|Placebo Comparator|Placebo shower gel|•Wash forearm by prepared placebo shower gel twice a day
89504296|NCT02178215|Active Comparator|Holly Mangrove Shower Gel|•Wash forearm by Holly Mangrove Showver gel twice a day
89504297|NCT02388087|Active Comparator|ROX COUPLER|Iliac arterio-venous anastamosis created by insertion of ROX coupler device.
89504298|NCT02388087|Sham Comparator|ROUTINE CARE|Right heart catheterisation and Routine care of Neurally mediated syncope.
89504299|NCT02178293|Active Comparator|Benzidamine hydrochloride|
89504300|NCT02178293|Experimental|Ketoprofen lysine salt|
89206618|NCT00957177|Placebo Comparator|Placebo|Placebo
89206619|NCT00957177|Active Comparator|Pregabalin group|Receiving 300mg pregabalin preoperative
89206620|NCT00837642||ART (Assited reproductive technologies)|In participants born after IVF will be performed a transthoracic echocardiography
89206621|NCT00837642||Control|In participants naturally conceived will be performed a transthoracic echocardiography
89504301|NCT03170895|Experimental|sorafenib and Omacetaxine Mepesuccinate|"The starting dose of sorafenib will be 400 mg twice daily. Sorafenib should be taken continuously throughout the treatment period unless there is no evidence of response at first assessment on day 28 or progressive disease at any time during the treatment.~OM will be given at 1.5 mg/m2/day (maximum dose 3 mg) for 7 days (concurrently with sorafenib) in 28-day cycle.~Sorafenib and OM will be continued until leukemia progression or allogeneic HSCT. Thereafter, patients will be followed up and information about disease status and survival will be collected."
89504302|NCT02277847|Experimental|IDA 8mg/M2|IDA 8mg/M2 per day, D1-3. iv injection in 10 minutes;Ara-C：100-200mg/M2 per day, D1-7. administration advice: at first, 25 mg/M2 of Ara-C is given by fast intravenous injection, then 100 mg/M2 of Ara-C is given by continuous iv drip for 24 hours for successive 7 days.
89504303|NCT02277847|Active Comparator|IDA 10mg/M2|IDA 10mg/M2 per day, D1-3. iv. injection in 10mimutes;Ara-C：100-200mg/M2 per day, D1-7. administration advice: at first, 25 mg/M2 of Ara-C is given by fast intravenous injection, then 100 mg/M2 of Ara-C is given by continuous iv drip for 24 hours for successive 7 days.
89504304|NCT02174237|Experimental|LNP1892|Dosage Form: Tablet Two Parts. Part A: Single Ascending Dose (SAD) starting with 25 mg (Maximum 5 cohorts). Part B: Multiple Ascending Dose (MAD), 10 days dosing, Maximum 3 cohorts. Six subjects in each cohort will receive LNP1892
89504305|NCT02174237|Placebo Comparator|Placebo|Two subjects in each cohort will receive matching placebo.
89504306|NCT03171207|Experimental|Start with Lite Run Gait Trainer|Patients start therapy with the Lite Run Gait Trainer device, followed by a Current Harness System in an ABAB design.
89504307|NCT03171207|Experimental|Start with Current Harness System|Patients start therapy with a Current Harness System, followed by the Lite Run Gait Trainer in an ABAB design.
89504308|NCT04471753||Patients with disorders of consciousness|Patients with medical diagnosis of prolonged disorders of consciousness (≥28 days) were included in neurosurgery, neurology, and neurorehabilitation units.
89504309|NCT02178371|Experimental|UTWC (control group)|the control group performs the same tasks than the experimental group, but without healthy hand constraint/containment.
89504310|NCT02178371|Experimental|mCIMT|"The study is conducted over a period of 5 weeks of treatment, using a movement restriction time healthy upper extremity of 2 hours daily.~The restriction applied in the study is performed with the closed hand position and thumb inside the fist through a transparent film that reaches the wrist joint.~In periods mCIMT, monitored the activities designed to enhance their functionality, based on motivation, avoiding frustrations are made."
89504311|NCT01457781|Active Comparator|0.025 mg inhaled nitric oxide|Inhaled nitric oxide (iNO) 0.025 mg/kg IBW/hr for up to 24 hours/day x 16 weeks (3.0 mg/L [2440 ppm] NO mini-cylinder; change q 24 hours) delivered via INOpulse® DS delivery device.
89504312|NCT01457781|Active Comparator|0.075 mg inhaled nitric oxide|Inhaled nitric oxide (iNO) 0.075 mg/kg IBW/hr for up to 24 hours/day x 16 weeks (6.0 mg/L [4880 ppm] NO mini-cylinder; change q 24 hours) delivered via INOpulse® DS delivery device.
89504313|NCT01457781|Placebo Comparator|placebo|Placebo 0.075 mg/kg IBW/hr for up to 24 hours/day x 16 weeks* (99.999% Nitrogen [N2] mini-cylinder; change q 24 hours) delivered via INOpulse® DS delivery device.
89504314|NCT00664573|Experimental|Group 2|Drug: BG9924 - dose administered as per Biogen-Idec protocol
89504315|NCT00664573|Experimental|Group 1|Drug: BG9924 - dose administered as per Biogen-Idec protocol
88956887|NCT03564691|Experimental|Dose Expansion, Arm K: Triple negative Breast Cancer (TNBC)|Triple combination therapy with pembrolizumab plus preliminary RP2D A of MK-4830 plus paclitaxel in participants who have histologically confirmed TNBC. MK-4830 will be administered IV following pembrolizumab infusion, Q3W, starting with Cycle 1, Day 1, for a maximum of 35 cycles. Each cycle is 21 days. Pembrolizumab will be administered by IV, Q3W, starting with Cycle 1, Day 1 for a maximum of 35 cycles (up to approximately 2 years). Each cycle is 21 days. Paclitaxel will be administered by IV on Days 1, 8, and 15 every 4 weeks (Q4W) until disease progression or prohibitive toxicity.
88956888|NCT03564691|Experimental|Dose Expansion, Arm L: Mesothelioma|Triple combination therapy with pembrolizumab plus preliminary RP2D A of MK-4830 plus pemetrexed plus cisplatin in participants who have histologically confirmed advanced mesothelioma. MK-4830 will be administered IV following pembrolizumab infusion, Q3W, starting with Cycle 1, Day 1, for a maximum of 35 cycles. Each cycle is 21 days. Pembrolizumab will be administered by IV, Q3W, starting with Cycle 1, Day 1 for a maximum of 35 cycles (up to approximately 2 years). Each cycle is 21 days. Pemetrexed will be administered by IV, on Day 1 of each Q3W cycle for a maximum of 6 cycles. Each cycle is 21 days. Cisplatin will be administered by IV, on Day 1 of each Q3W cycle for a maximum of 6 cycles. Each cycle is 21 days.
88956889|NCT03564691|Experimental|Dose Expansion, Arm M: Advanced Solid Tumor in Chinese Participants In China|Combination therapy with the preliminary RP2D A of MK-4830, and pembrolizumab, in Chinese participants, who reside in China, have histologically or cytologically-confirmed advanced/metastatic solid tumor, and who have been previously treated with at least 2 prior lines of therapy. MK-4830 will be administered IV following pembrolizumab infusion, Q3W, starting with Cycle 1, Day 1, for a maximum of 35 cycles. Each cycle is 21 days. Pembrolizumab will be administered by IV, Q3W, starting with Cycle 1, Day 1. Each cycle is 21 days. The combination may be administered for a maximum of 35 cycles (up to approximately 2 years).
88956890|NCT03564691|Experimental|Coformulation Phase, Arm N: MK-4830A (Coformulation of MK-4830 + pembrolizumab)|Monotherapy with MK-4830A, a coformulation of MK-4830 800 mg + pembrolizumab 200 mg, in participants with histologically or cytologically-confirmed advanced/metastatic solid tumor, and who and have received, been intolerant to, been ineligible for, or refused all treatment known to confer clinical benefit. MK-4830A will be administered IV, Q3W, starting with Cycle 1, Day 1, for a maximum of 35 cycles (up to approximately 2 years). Each cycle is 21 days.
88956891|NCT03547882||Other|Target interviewees will be primary care providers at six facilities and their staff (e.g., nurse care managers).
88956892|NCT03547882||Patients|Ten interviews were conducted with VA patients receiving ORT.
88956893|NCT03527043|Experimental|Escitalopram|10mg by mouth daily for 6 weeks
89206622|NCT00948051|Experimental|Fructo-oligosaccharides|
89206623|NCT00948051|Placebo Comparator|Placebo|
89504316|NCT00664573|Experimental|Group 3|Drug: BG9924 - dose administered as per Biogen-Idec protocol
89504317|NCT00664573|Experimental|Group 4|Drug: BG9924 - dose administered as per Biogen-Idec protocol
89504318|NCT03537677|Experimental|Sedentary Behavior Intervention|A behavioral intervention that targets prolonged sitting and encourages frequent activity breaks.
89504319|NCT02281435|Experimental|PrePex with Incision|Adult male circumcision by the PrePex™ device using foreskin incision
89504320|NCT02174393|Experimental|Microneedling Plus Universal Peel|"(1) Microneedling treatment by the MicroPen with a Post-Microneedling Skin Care Regimen and the (2) Universal Peel by Topix with a Post-Universal Peel Skin Care Regimen will both be performed on a monthly basis for a total of three treatment sessions each.~Microneedling will be done on Study Weeks 1, 5, and 9. Universal Peel will be done on Study Weeks 3, 7, and 11."
89504321|NCT00468403|Experimental|Allogeneic Pancreatic Islet Cells|Participants will receive up to three islet transplantations and continuous immunosuppressive therapy including belatacept
89504322|NCT02278549||Asymptomatic|Individuals between 30 and 50 years old that have had no episode of low back pain in the last two years requiring medical attention
89504323|NCT02278549||Patients with Low Back Pain|Individuals between 30 and 50 years old that present with non-specific low back pain for more than 3 months
89504324|NCT02175017|Experimental|ONO-4538|ONO-4538 water-soluble injection, 100 mg/vial, 3 times once every 2 weeks in each 6-week cycle
89504325|NCT02388009|Active Comparator|Flexyn2a|2 doses of 10 μg of Flexyn2a will be injected intramuscularly 4 weeks apart
89504326|NCT02388009|Active Comparator|Flexyn2a plus adjuvant|2 doses of 10 μg of Flexyn2a plus adjuvant will be injected intramuscularly 4 weeks apart
89504327|NCT02388009|Placebo Comparator|Placebo|2 doses of saline buffer plus adjuvant will be injected intramuscularly 4 weeks apart
89504328|NCT02178449|Experimental|Verum|Dexamethasone and Ropivacaine
89504329|NCT02178449|Active Comparator|Placebo|Ropivacaine and Saline
89504330|NCT02387775|Experimental|Esophageal temperature control|The Esophageal Cooling Device (ECD) will be inserted and utilized for temperature control for up to 36 hours in this arm. The ECD will be used for all three phases of therapeutic hypothermia; induction, maintenance, and rewarming. Conventional cooling or warming techniques (e.g. cold saline, ice packs, cooling or warming blankets) will still be made available to the treating ICU team to be used at their discretion.
89504331|NCT02278705||Weight-status improved|"Cases, termed, weight-status improved, are defined as children whose BMI percent relative to their age/sex-specific BMI at the 95th percentile decreases from one visit to the next; and from one well-child visit to the next well-child (or primary-care visit approximately 9-18 months later)."
89504332|NCT02278705||Weight-status unchanged/worse|Controls are defined as children whose BMI percent relative to their age/sex-specific BMI at the 95th percentile remains unchanged or increases from one visit to the next; and from one well-child visit to the next well-child (or primary-care visit approximately 9-18 months later).
89504333|NCT05142137|Experimental|Novel alpha glucan_dose1|Total of 180 g of the novel alpha glucan per day, consumed in 4 individual doses (i.e. 4x45 g, with each dose dissolved in 300 ml of water)
89504334|NCT05142137|Experimental|Novel alpha glucan_dose2|Total of 80 g of the novel alpha glucan + 100 g glucose syrup per day, consumed in 4 individual doses (i.e. 4x45 g, with each dose dissolved in 300 ml of water)
89504335|NCT05142137|Active Comparator|glucose syrup|Total of 180 g glucose syrup per day, consumed in 4 individual doses (i.e. 4x45 g, with each dose dissolved in 300 ml of water).
89504336|NCT02387931|Experimental|Vitamin D|Vitamin D3 2000 IU daily taken for 6 months
89504337|NCT02387931|Experimental|Fish Oil|Fish Oil 1000 mg daily for 6 months
89504338|NCT02387931|Placebo Comparator|Placebo|Placebo taken daily for 6 months.
89504339|NCT02281669||Research group|The study group includes all CL cases for whom the treating physician decides to treat by IL Pentostam. The patients will return to follow up and additional treatment every 3 weeks until full recovery [as our current policy].
89504340|NCT00466765|Experimental|Single Arm|Use Brava system for pre-expansion of breast prior to fat grafting
89504341|NCT02178527|Experimental|Mulitfaceted podiatry Intervention|Foot and ankle exercises, foot orthoses, footwear provision
89504342|NCT02178527|Placebo Comparator|Usual podiatry care|Continued provision of usual NHS (National Health Service) podiatry care
89504343|NCT00662389|Experimental|A|
89504344|NCT02178605||Cervical arthrodesis candidates|Patients scheduled to undergo cervical arthrodesis to treat their spinal pathology will undergo cervical arthrodesis with rhBMP-2
89504345|NCT02178683|No Intervention|Tacrolimus and Mycophenolate Mofetil|Non-myeloablative allogeneic SCT from an HLA-Identical or non-identical family onor or unrelated donors, with fludarabine and low-dose TBI, with immunosuppression utilizing tacrolimus and MMF.
89504346|NCT03170739|Experimental|Dexmedetomidine|Dexmedetomidine 0.5ug/kg iv follow by 0.2ug/kg/h ivpump at the beginning of surgery.
89504347|NCT03170739|Experimental|Dopamine|Dopamine 3ug/kg/min ivpump at the beginning of surgery.
89504348|NCT03170739|Experimental|Dexmedetomidine+dopamine|Dexmedetomidine 0.5ug/kg iv follow by 0.2ug/kg/h ivpump, combined with dopamine 3ug/kg/min ivpump at the beginning of surgery.
88956894|NCT03527043|Placebo Comparator|Placebo|Matched placebo control by mouth for 6 weeks.
88956895|NCT03516994|Experimental|Structured Advance Care Planning|In the structured advance care planning approach, patients will participate in a 60 to 90 minute facilitated advance care planning conversation with a trained person using Respecting Choices (First Steps) guide and will receive a state advance directive form. The advance care planning facilitator will follow-up as needed after the session to answer additional questions.
88956896|NCT03516994|Active Comparator|Patient Driven Advance Care Planning|In the patient-driven advance care planning approach, patients receive a Five Wishes Form (easy to understand advance directive written in plain language), a state advance directive form, and at least two follow-up phone calls with an advance care planning contact who will answer questions.
89504349|NCT03170739|No Intervention|Control group|No intervention
88956897|NCT03429036||1|Subjects must be diagnosed with a disorder of the head and neck region
88956898|NCT03424850|Experimental|HDR brachytherapy - 21 Gy|-All patients will be treated with a single implant and single HDR fraction. Treatment will be delivered within a single 24-hour period measured from the beginning of the implant procedure. All patients will receive a dose of 21 Gy.
89504350|NCT04514159|Experimental|ZN-c5 + abemaciclib combination therapy|Participants will take abemaciclib (150mg) orally twice a day and ZN-c5 (dose escalation) orally once or twice a day to determine the safety, tolerability, and maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D).
89504351|NCT00459745|Active Comparator|Pravastatin|Pravastatin 40 mg
89504352|NCT00459745|Active Comparator|Fenofibrate|Fenofibrate 160 mg
88956899|NCT03424850|Experimental|HDR brachytherapy - 23 Gy|-All patients will be treated with a single implant and single HDR fraction. Treatment will be delivered within a single 24-hour period measured from the beginning of the implant procedure. All patients will receive a dose of 23 Gy.
88956900|NCT03424850|Experimental|HDR brachytherapy - 25 Gy|-All patients will be treated with a single implant and single HDR fraction. Treatment will be delivered within a single 24-hour period measured from the beginning of the implant procedure. All patients will receive a dose of 25 Gy.
88956901|NCT03419585|Experimental|Intervention light|30 minutes of intervention systematic light exposure daily for the course of radiation therapy (approximately 8 weeks).
88956902|NCT03419585|Active Comparator|Comparison light|30 minutes of comparison systematic light exposure daily for the course of radiation therapy (approximately 8 weeks).
88956903|NCT03414970|Active Comparator|Group I (radiation therapy)|Patients undergo radiation therapy daily on Monday-Friday for 5-6 weeks.
89504353|NCT00459745|Experimental|Pravafen (Parvastatin and Fenofibrate)|Combined Therapy of Pravastatin 40 mg and Fenofibrate 160 mg.
89504354|NCT02175095|Experimental|Regorafenib and FLT-PET|After checking the eligibility for the study entry, patients will be scheduled to perform [18F]FLT-PET scans before and on 21st day from the administration of regorafenib. Regorafenib will be administered 160 mg/day given orally on day 1 to days 21 following 7 days break, which consists of 4 weeks as 1 cycle. Treatment will be repeated every 4 weeks and continued until disease progression, unacceptable toxicity or the patient's refusal. Standard anatomical response evaluation will be performed every 8 weeks (without regard to the cycles or schedules of chemotherapy). Additional [18F]FDG-PET will be performed before treatment and at 8 weeks (just once at the point of first response evaluation).
88956904|NCT03414970|Experimental|Group II (hypofractionated radiation therapy)|Patients undergo hypofractionated radiation therapy daily on Monday-Friday for 3-4 weeks.
89504355|NCT03170505||Acellular Dermal Matrix|
89504356|NCT03170505||Conchal Cartilage|
88956907|NCT03401320|Experimental|Cohort 1: Letrozole ISM 50 mg|14 oral doses of 2.5 mg Femara (once daily) + single IM injection of 50 mg Letrozole ISM
88956908|NCT03401320|Experimental|Cohort 2: Letrozole ISM 100 mg|14 oral doses of 2.5 mg Femara (once daily) + single IM injection of 100 mg Letrozole ISM
88956909|NCT03401320|Experimental|Cohort 3: Letrozole ISM 200 mg|14 oral doses of 2.5 mg Femara (once daily) + single IM injection of 200 mg Letrozole ISM
88956910|NCT03401320|Experimental|Cohort 4: Letrozole ISM 400 mg|14 oral doses of 2.5 mg Femara (once daily) + single IM injection of 400 mg Letrozole ISM
88956911|NCT03361800|Experimental|Entinostat|Nine days prior to their scheduled surgery, entinostat 5mg PO given once weekly on day 1 and day 8
88956912|NCT03346668|Experimental|Topical gabapentin|gabapentin 6% solution, 1mL applied twice daily for 12 weeks
88956913|NCT03304639|Active Comparator|Group I (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
88956914|NCT03304639|Experimental|Group II (pembrolizumab, SBRT)|Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo SBRT for 3 doses during cycle 1.
89206624|NCT00954369|Experimental|[F-18]W372|Approximately twenty (20) adult subjects including ten (10) healthy volunteers and ten (10) high probability AD subjects, as defined by protocol criteria
89206625|NCT00828438|Experimental|Lorcaserin 10mg|
89206626|NCT00957255|Active Comparator|RCR without augmentation|Rotator cuff repair without OrthoADAPT augmentation
89206627|NCT00957255|Experimental|RCR with augmentation|Rotator cuff repair with OrthoADAPT augmentation
89504357|NCT02284087||V_PAS|Visuomotor paired associative stimulation protocol
89504358|NCT02284087||Sham V_PAS|Placebo group of Visuomotor paired associative stimulation protocol
89504359|NCT02284087||CER_PAS|cerebellar-motor associative stimulation protocol
89504360|NCT02284087||Sham CER_PAS|Placebo group of cerebellar-motor associative stimulation protocol
89504361|NCT02178761|Active Comparator|Angioplasty alone|plain old balloon angioplasty alone
89504362|NCT02178761|Active Comparator|Stenting|Balloon angioplasty plus stenting
89504363|NCT02178761|Active Comparator|drug-eluting balloon|Balloon angioplasty with drug-eluting balloon
89504364|NCT02178761|Active Comparator|biodegradable vascular scaffold stent|Stenting with biodegradable vascular scaffold stent
89504365|NCT02742181|Experimental|Alvimopan group|In addition to standard postoperative care, patients randomized to the study group will be given 12mg of alvimopan orally twice a day, from the time of diagnosis of postoperative ileus to the time of return of bowel function or for 5 days.
89504366|NCT02742181|Other|Control Group|Patients randomized to the control group receive standard postoperative care which includes but is not limited to NPO status, IV fluid rehydration, and nasogastric decompression.
89504367|NCT02175329|Experimental|CAD/CAM veneering|CAD/CAM manufactured e.max CAD veneers on zirconia framework
89504368|NCT02175329|Active Comparator|manually layered|Manually layered veneering on CAD/CAM fabricated zirconia bridge framework
89504369|NCT02175407|Experimental|ASP1707 alone|
89504370|NCT02175407|Experimental|ASP1707 + itraconazole|
89504371|NCT02182193|Experimental|BIBF 1120 capsules charge 1|
89504372|NCT02182193|Experimental|BIBF 1120 capsules charge 2|
89504373|NCT02182193|Active Comparator|BIBF 1120 drinking solution|
89504374|NCT02178839|Experimental|β- glucan|8.5 g/d of Oat Supplement Containing 3g β- glucan
89504375|NCT02178839|Placebo Comparator|Maltodextrin|8.5 g/d Maltodextrin
89504376|NCT02182271|Experimental|BI 201335 ZW - single rising dose|
89504377|NCT02182271|Placebo Comparator|Placebo|
89504378|NCT02742103|Experimental|CSL_112|CSL112 will be administered intravenously, once weekly for 4 consecutive weeks (4 infusions in total).
89504379|NCT02742103|Placebo Comparator|Placebo|Placebo will be administered at the same frequency, volume and duration as the CSL112 infusion.
89504380|NCT02175485|Experimental|Fexofenadine HCl|2 tablets of Dellegra Combination Tablets (Fexofenadine Hydrochloride 30 mg+Pseudoephedrine Hydrochloride 60 mg/tablet), oral, administrated 2 hours after start of exposure with 8,000 grains/cubic meter of Japanese cedar pollen
89504381|NCT04575779||Group A|Cyclosporin of a daily dose of 3 mg/kg/day intravenously over 2 h (short infusion) every 12 h
89504382|NCT04575779||Group B|Administer cyclosporin daily dose of 3 mg/kg/day in a continuous infusion over 23 h every 24 h.
89504383|NCT02178917|Experimental|patients with central neuropathic pain|Randomised to 20 neurofeedback therapy sessions
89504384|NCT02178917|Other|Control: patients with central neuropathic pain|Randomised to no neurofeedback treatment
89504385|NCT02178917|No Intervention|patients with no central neuropathic pain|Observed for development of central neuropathic pain
89504386|NCT02387697|Experimental|Group A|Transfemoral implantation of an Edwards Sapien XT Valve into the vena cava inferior (VCI). For better stability and for downsizing of the VCI diameter the valve will be implanted after preparation of a landing zone. This includes implantation of one or two self expandable stents into the VCI prior to the final deployment of the valve.
89504387|NCT02387697|No Intervention|Group B|Control group (no surgery) with optimal medical treatment.
89504388|NCT02182349|Experimental|BI 201335 NA|multiple doses of BI 201335 NA soft gelatin capsule on days 1-8 and 11-15 and one single dose of [14C]-BI 201335 NA radiolabelled drug on day 9
89504389|NCT02741713|Sham Comparator|Interscalene Block plus Sham Block|"Twenty subjects will receive an ultrasound guided interscalene nerve block using the Solution for Injection in Interscalene Block dosed at the upper trunk location near the 6th cervical vertebral level, per standard clinical practice. A Sham Block of in area of PECS Pectoralis block will be done to allow for assessment of the intervention. Using the Solution for Injection in Sham Block."
89504390|NCT02741713|Active Comparator|Interscalene plus PECS Blocks|"Twenty patients will receive an ultrasound guided interscalene nerve block Solution for Injection in Interscalene Block dosed at the upper trunk location near the 6th cervical vertebral level, per standard clinical practice. For the Intervention, these subjects will also a PECS Pectoralis 1 and 2 Blocks using the Solution for Injection PECS Blocks, dosed at the PECS1 location and PECS2 location as described by Blanco, et al."
89504391|NCT03170427|Sham Comparator|8 mg (2 mL) levobupivacaine|8mg (2ml) levobupivacaine plus 20 µg fentanyl will be given intrathecally by spinal anesthesia. The impendance cardiography, the sensory and motor block will be monitored
88956915|NCT03283878|Experimental|Study Group 1|"Patients in Group #1 will receive a single weight-based dose of prophylactic cefazolin antibiotic that is administered intravenously within less than 60 minutes prior to skin incision in elective total knee arthroplasty. No further antibiotic administration will be given.~< 120 kg - patients will receive 2 grams of cefazolin~≥ 120 kg - patient will receive 3 grams of cefazolin~Patients with documented allergy/anaphylactic reaction to penicillin or cephalosporin may receive intravenous vancomycin monotherapy or dual therapy with vancomycin and gentamicin as an alternative. In addition, the use of clindamycin as an alternative is also permitted at a minimum recommended dose."
88956916|NCT03283878|Experimental|Study Group 2|"Patients in Group #2 will receive a single weight-based dose of prophylactic cefazolin antibiotic that is administered intravenously within less than 60 minutes prior to skin incision in elective total knee arthroplasty. In addition, two weight-based doses of cefazolin will be administered within 24 hours postoperatively.~< 120 kg - patients will receive 2 grams of cefazolin~≥ 120 kg - patient will receive 3 grams of cefazolin~Patients with documented allergy/anaphylactic reaction to penicillin or cephalosporin may receive intravenous vancomycin monotherapy or dual therapy with vancomycin and gentamicin as an alternative. If allergic, patients will also receive two weight-based doses vancomycin postoperatively but not gentamicin postoperatively. In addition, the use of clindamycin as an alternative is also permitted. Vancomycin schedule: one dose preoperatively, one dose 8-12 h postoperatively, one dose 24 h postoperatively (opt.)."
88956917|NCT03277729|Experimental|Treatment (CD20-specific CAR T cell, chemotherapy)|Patients undergo leukapheresis and may receive treatment after if needed for disease control. Patients then receive cyclophosphamide IV. Patients may also receive fludarabine IV. After 36-96 hours, patients receive CD20-specific CAR T cell infusion IV over 20-30 minutes.
89023729|NCT04850781|Experimental|Frozen, Drop-shipped Meals|10 frozen meals that are mailed to participants every two weeks.
89206628|NCT00828594|Experimental|Phase 1: RAD001 plus sorafenib|
89206629|NCT00833118||Intubation|
89206630|NCT00550407|Placebo Comparator|Placebo|
89206631|NCT00550407|Active Comparator|BW430C(lamotrigine)|
89504392|NCT03170427|Active Comparator|6 mg (1.6 mL) levobupivacaine|6mg (1.6ml) levobupivacaine plus 20 µg fentanyl will be given intrathecally by spinal anesthesia. The impendance cardiography, the sensory and motor block will be monitored
89504393|NCT03537521||DOA|N= 130 patients treated with direct oral anticoagulants (DOAC) with acute bleeding N= 65 patients treated with direct oral anticoagulants (DOAC) with urgent surgical intervention
89504394|NCT03537521||VKA|N= 130 patients treated with vitamin K antagonists (VKA) with acute bleeding N= 65 patients treated with vitamin K antagonists (VKA) with urgent surgical intervention
89504395|NCT00459277|Experimental|Nasalfent, Fentanyl Citrate Nasal Spray|
89504396|NCT00459277|Placebo Comparator|Placebo Spray|
89504397|NCT02175563|No Intervention|Without feedback|Participants compress the chest of the manikin without smartphone based feedback app.
89504398|NCT02175563|Experimental|With feedback|Participants compress the chest of the manikin with a smartphone based feedback app.
89504399|NCT00602329|Experimental|Arm I|Patients receive leucovorin calcium IV over 2 hours and oxaliplatin IV over 2 hours on day 1 and fluorouracil IV continuously over 46 hours (FOLFOX) beginning on day 1. Patients also receive bevacizumab at 5 mg/kg IV over 90 minutes on day 1. Treatment repeats every 14 days for 6 months in the absence of disease progression or unacceptable toxicity.
89504400|NCT00602329|Experimental|Arm II|Patients receive FOLFOX as in arm I and bevacizumab at 10 mg/kg IV over 90 minutes on day 1. Treatment repeats every 14 days for 6 months in the absence of disease progression or unacceptable toxicity.
89504401|NCT00602329|Active Comparator|FOLFOX alone (control)|Patients receive FOLFOX as in arm I.
89504402|NCT02175719||E2014|
88956921|NCT03257215|Active Comparator|Stoss vitamin D|Stoss vitamin D at Day 1 and daily placebo for 90 days (Day 1 to 90)
88956922|NCT03257215|Active Comparator|Daily vitamin D|Stoss placebo at Day 1 and daily vitamin D for 90 days (Day 1 to 90)
88956923|NCT03257215|Placebo Comparator|Placebo|Stoss placebo at Day 1 and daily placebo for 90 days (Day 1 to 90)
88956924|NCT03238794|Active Comparator|Roux-En-Y Gastric Bypass (RYGB)|Participants will have elected to have RYGB surgery per standard of care.
88956925|NCT03238794|Active Comparator|Low-calorie Diet|Participants will have a low-calorie diet prescribed by a registered dietitian.
88956926|NCT03220035|Experimental|Treatment (vemurafenib)|Patients receive vemurafenib PO BID on day 1-28. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
88956927|NCT03217747|Experimental|Arm A (utomilumab, avelumab)|Patients receive utomilumab IV over 60 minutes on day 1 of each cycle and avelumab IV over 60 minutes on days 1 and 15 beginning day 15 of cycle 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88956928|NCT03217747|Experimental|Arm B (PF-04518600, avelumab)|Patients receive anti-OX40 agonist monoclonal antibody PF-04518600 IV over 60 minutes on days 1 and 15 of each cycle and avelumab IV over 60 minutes on days 1 and 15 beginning day 15 of cycle 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88956929|NCT03217747|Experimental|Arm C (PF-04518600, utomilumab, avelumab)|Patients receive anti-OX40 agonist monoclonal antibody PF-04518600 IV over 60 minutes on days 1 and 15 of each cycle, utomilumab over 60 minutes on day 1, and avelumab IV over 60 minutes on days 1 and 15 beginning day 15 of cycle 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89504403|NCT02179073||neurogenic bladder dysfunction|
89504404|NCT02281825||Control|Adolescents without any psychiatric disorder
89504405|NCT02281825||Study|Adolescents with psychiatric disorder of the following: Attention-Deficit and Hyperactivity Disorder, Conduct, Oppositional defiant Disorder, Anxiety, Depression, Disruptive Mood Dysregulation Disorder
89504406|NCT02182505|Experimental|Berodual® Respimat®, low dose|
89504407|NCT02182505|Experimental|Berodual® Respimat®, high dose|
89504408|NCT02182505|Active Comparator|Berodual® MDI Aerochamber®|
89504409|NCT02281903|Experimental|Chest compression of manikins chest|Compression of pediatric manikins chest according European Resuscitation Council 2010 guidelines for cardiopulmonary resuscitation.
89504410|NCT02276521||Zero dose group|Participants that did not received any HPV vaccine previously.
89504411|NCT02276521||One dose group|Participants that received one dose of Gardasil® vaccine 5-6 years ago from a vaccination campaign.
89504412|NCT02276521||Two dose group|Participants that received two dose of Gardasil® vaccine 5-6 years ago from a vaccination campaign.
89504413|NCT02276521||Three dose group|Participants that received three dose of Gardasil® vaccine 5-6 years ago from a vaccination campaign.
89504414|NCT02387619|Experimental|Group 1 of part 1|Rosuvastatin and Telmisartan/Amlodipine: Rosuvastatin 20mg 1T during the period 1 and Rosuvastatin 20mg 1T and Telmisartan/Amlodipine 40/5mg 2T during the period 2
89504415|NCT02387619|Experimental|Group 2 of part 1|Rosuvastatin and Telmisartan/Amlodipine: Rosuvastatin 20mg 1T, Telmisartan/Amlodipine 40/5mg 2T during the period 1 and Rosuvastatin 20mg 1T during the period 2
89504416|NCT02387619|Experimental|Group 1 of part 2|Rosuvastatin and Telmisartan/Amlodipine: Telmisartan/Amlodipine 40/5mg 2T during the period 1 and Rosuvastatin 20mg 1T, Telmisartan/Amlodipine 40/5mg 2T during the period 2
89504417|NCT02387619|Experimental|Group 2 of part 2|Rosuvastatin and Telmisartan/Amlodipine: Rosuvastatin 20mg 1T, Telmisartan/Amlodipine 40/5mg 2T during the period 1 and Telmisartan/Amlodipine 40/5mg 2T during the period 2
89504418|NCT02175797|Other|Pacemaker + leads|all patients must have a MRI exam after pacemaker implantation
89504419|NCT00599989|Experimental|APBI|
89504420|NCT03537443|Placebo Comparator|Group A (Placebo)|Children whose mothers were randomized to receive a weekly dose of placebo from 17-24 weeks of gestation to 26 weeks postpartum.
89504421|NCT03537443|Experimental|Group B (4200:0 IU/week)|Children whose mothers were randomized to receive a prenatal:postpartum regimen of 4200 IU/week vitamin D3 from 17-24 weeks of gestation to delivery, followed by placebo from delivery to 26 weeks postpartum.
89504422|NCT03537443|Experimental|Group C (16800:0 IU/week)|Children whose mothers were randomized to receive a prenatal:postpartum regimen of 16800 IU/week vitamin D3 from 17-24 weeks of gestation to delivery, followed by placebo from delivery to 26 weeks postpartum.
89504423|NCT03537443|Experimental|Group D (28000:0 IU/week)|Children whose mothers were randomized to receive a prenatal:postpartum regimen of 28000 IU/week vitamin D3 from 17-24 weeks of gestation to delivery, followed by placebo from delivery to 26 weeks postpartum.
89504424|NCT03537443|Experimental|Group E (28000:28000 IU/week)|Children whose mothers were randomized to receive a prenatal:postpartum regimen of 28000 IU/week vitamin D3 from 17-24 weeks of gestation to delivery, followed by the same dose (28000 IU/week vitamin D3) from delivery to 26 weeks postpartum.
89504425|NCT00595699|Placebo Comparator|2|Double-blind
89504426|NCT00595699|Experimental|1|escitalopram group
89504427|NCT05268705|Active Comparator|High-carbohydrate-low-fat-low-protein diet|
89504428|NCT05268705|Active Comparator|Low-carbohydrate-high-fat-low-protein diet|
88956930|NCT03217747|Experimental|Arm D (avelumab, utomilumab, radiation therapy)|Patients undergo radiation therapy on days -5 to -1. Patients receive avelumab IV over 60 minutes on days 1 and 15 of beginning day 15 of cycle 1 and utomilumab IV over 60 minutes on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88956931|NCT03217747|Experimental|Arm E (avelumab, PF-04518600, radiation therapy)|DISCONTINUED AS OF AMENDMENT 9 (02/11/2020) Patients undergo radiation therapy on days -14 to -1. Patients receive avelumab IV over 60 minutes on days 1 and 15 beginning day 15 of cycle 1 and anti-OX40 agonist monoclonal antibody PF-04518600 IV over 60 minutes on days 1 and 15, and. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88956932|NCT03217747|Experimental|Arm F (avelumab, PF-04518600, radiation therapy)|DISCONTINUED AS OF AMENDMENT 9 (02/11/2020) Patients undergo radiation therapy on days -14 to -1. Patients receive avelumab IV over 60 minutes on days 1 and 15 beginning day 15 of cycle 1, utomilumab IV over 60 minutes on day 1, and anti-OX40 agonist monoclonal antibody PF-04518600 IV on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89206632|NCT00837798||No history of AF|Patient should not have had a documented history of AF for a period of 3 months prior to enrollment.
89504429|NCT05268705|Active Comparator|Low-carbohydrate-low-fat-high-protein diet|
89504430|NCT05141591||ENT surgical patients|ASA physical status I-IV adult subjects, ≥ 18 years of age, scheduled for elective ENT surgeries in the Department of ENT at the Medical University of Vienna. On the day before elective ENT- surgery patients will be asked to complete self-administered questionnaires (STOA, APAIS, PCS) concerning their emotional and anxiety state. These questionnaires will be re-tested on the day of surgery and opioid consumption during the stay in the recovery room documented.
89504431|NCT02256215|Experimental|Vitamin D|• All patients will have their serum vitamin D levels measured at the baseline visit. Those assigned to the treatment arm (group A) will receive either 50,000 international units of vitamin D3 by mouth once or more per week for six to eight weeks, then 800 to 1000 (or more) international units of vitamin D3 daily thereafter, this is according to the recommendations of the Endocrine Society clinical practice guideline 2011. Group B patients will receive placebo supplements identical in appearance to the vitamin D supplements.
89504432|NCT02256215|Placebo Comparator|Placebo|
89504433|NCT00591799|Experimental|Jarvik 2000 Ventricular Assist System|Jarvik 2000 Ventricular Assist System
89504434|NCT02175875||comatose patients|180 mg ticagrelor followed by 90 mg BID for comatose patients after cardiac arrest
89504435|NCT00587275|Experimental|1|AST-120, 2 gram sachets
89504436|NCT00587275|Placebo Comparator|2|Celphere CP-305, stained to match appearance of AST-120 in 2g sachets.
89504437|NCT02182583|Experimental|Ba253BINEB|
89504438|NCT02182583|Active Comparator|Ba253MDI|
89504439|NCT03133975|Experimental|Treatment|Single high dose IM VIT D
89504440|NCT03133975|Active Comparator|Control|Usual diet mix of carbohydrates - lipid - protein - minerals & vitamins
89504441|NCT02282137|Experimental|68Ga-PSMA|Evaluation of concordance and discordance between the results of 68Ga-PSMA PET/CT and other available conventional imaging modalities (such as CT, MRI, FDG, NaF scan), histology or follow up.
89504442|NCT02182661|Experimental|Ba253BINEB|
89504443|NCT00586651|Experimental|lestaurtinib|
89504444|NCT02663271|Experimental|Optune+Pulsed Bevacizumab|The subjects will undergo 12 months of planned continuous treatment with Optune. The treatment will begin at week 0 and will be continuous throughout the study. Pulsed bevacizumab dosing is defined by at least one cycle on and at least one cycle off. A cycle is defined as 8 weeks in length. If after one cycle on, there is no evidence of a repeat response; bevacizumab will be continued for one more cycle. If after two cycles on, there is no repeat response; bevacizumab will be continued with or without other standard chemotherapy until death. If after at least one cycle on, there is evidence of repeat response, bevacizumab will be discontinued for at least one cycle. In addition, the following will be performed: Bevacizumab will be given, physical examination and quality of life questionnaires will be performed and brain MRI.
89504445|NCT02256293|Experimental|Group Therapy|Diabetes self-management group based on Acceptance and Commitment Therapy (ACT).
89504446|NCT02182739||Meloxicam|
89504447|NCT02175953|Experimental|Interventiongroup|Psychotherapy
89504448|NCT02175953|No Intervention|Waitling list group|waiting list
89504449|NCT00583609|Experimental|1|PEG3350
89504450|NCT03170115|Experimental|Aspirin|Induction chemotherapy followed by chemoradiotherapy with aspirin Aspirin 100mg daily during the chemoradiotherapy
89504451|NCT03170115|Placebo Comparator|Placebo Oral Tablet|Induction chemotherapy followed by chemoradiotherapy without aspirin Placebo daily during the chemoradiotherapy
89504452|NCT02179229|Placebo Comparator|CONTROL|Patient in the CONTROL arm will receive a powder containing only tapioca-resistant starch comparable in colour, texture and taste to the synbiotic.
89504453|NCT02179229|Experimental|SYNBIOTIC|Patients in this group will receive Probinul neutro® a synbiotic preparation containing (perpacket): lyophilised bacteria (5×109 Lactobacillus plantarum, 2×109 Lactobacillus casei subsp. rhamnosus and 2×109 Lactobacillus gasseri, 1×109 Bifidobacterium infantis and 1×109 Bifidobacterium longum, 1×109 Lactobacillus acidophilus, 1×109 Lactobacillus salivarius and 1×109 Lactobacillus sporogenes and 5×109 Streptococcus thermophilus), prebiotic inulin (2.2 g; VB Beneo Synergy 1) and 1.3 g of tapioca-resistant starch.
89504454|NCT00583531|Experimental|I|Active treatment with AST-120
89504455|NCT03169959|Experimental|Cohort 1: Sequence 1 (ABC)|"Subjects were randomized to treatment sequence 1 ABC:~On Day 1, each subjects will receive orally single-dose of the treatment assigned to that treatment period.~A= Reference product - 2.5mg ONGLYZA (2.5mg saxagliptin) and 5/1000mg XIGDUO XR (5 mg dapagliflozin / 1000mg Metformin XR) after food.~B = Test product - Triple FCDP consisting of 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR after food.~C = Test product - Triple FCDP tablet consisting of 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR without food."
89023730|NCT04844775|Experimental|Drep-HIV-PT1 0.2mg and CN54gp140/MPLA-L|"0.1mL of DREP-HIV-PT1 will be diluted with saline (Sodium Chloride for Injection, 0.9%) and administered intramuscularly (total volume of 0.5mL) in the LEFT deltoid muscle using a needle-free device (Pharmajet Stratis®)~0.4mL of MPLA-L from a vial containing 0.55mL of MPLA-L (25µg/mL) and add this to a vial containing 0.35mL of CN54gp140 (500µg/mL). The vial contents will be mixed by gentle agitation and 0.45mL of will be withdrawn from the vial to make a concentration of 100µg CN54gp140 and 5µg MPLA-L . The combined products will be injected into the RIGHT deltoid muscle using a needle and syringe."
89023731|NCT04844775|Experimental|Drep-HIV-PT1 1.0mg and CN54gp140/MPLA-L|"0.5mL of DREP-HIV-PT1 will be administered intramuscularly in the LEFT deltoid muscle using the a needle-free device (Pharmajet Stratis®)~0.4mL of MPLA-L from a vial containing 0.55mL of MPLA-L (25µg/mL) and add this to a vial containing 0.35mL of CN54gp140 (500µg/mL). The vial contents will be mixed by gentle agitation and 0.45mL of will be withdrawn from the vial to make a concentration of 100µg CN54gp140 and 5µg MPLA-L . The combined products will be injected into the RIGHT deltoid muscle using a needle and syringe."
89023732|NCT04844775|Experimental|DNA HIV PT123 4mg and CN54gp140/MPLA-L|"1ml of DNA-HIV-PT123 will be injected into the LEFT deltoid muscle using a needle and syringe.~0.4mL of MPLA-L from a vial containing 0.55mL of MPLA-L (25µg/mL) and add this to a vial containing 0.35mL of CN54gp140 (500µg/mL). The vial contents will be mixed by gentle agitation and 0.45mL of will be withdrawn from the vial to make a concentration of 100µg CN54gp140 and 5µg MPLA-L . The combined products will be injected into the RIGHT deltoid muscle using a needle and syringe."
89504456|NCT03169959|Experimental|Cohort 1: Sequence 2 (ACB)|"Subjects were randomized to treatment sequence 1 ACB:~On Day 1, each subjects will receive orally single-dose of the treatment assigned to that treatment period.~A= Reference product - 2.5mg ONGLYZA (2.5mg saxagliptin) and 5/1000mg XIGDUO XR (5 mg dapagliflozin / 1000mg Metformin XR) after food.~B = Test product - Triple FCDP consisting of 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR after food.~C = Test product - Triple FCDP tablet consisting of 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR without food."
89504457|NCT03169959|Experimental|Cohort 1: Sequence 3 (BAC)|"Subjects were randomized to treatment sequence 1 ABC:~On Day 1, each subjects will receive orally single-dose of the treatment assigned to that treatment period.~A= Reference product - 2.5mg ONGLYZA (2.5mg saxagliptin) and 5/1000mg XIGDUO XR (5 mg dapagliflozin / 1000mg Metformin XR) after food.~B = Test product - Triple FCDP consisting of 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR after food.~C = Test product - Triple FCDP tablet consisting of 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR without food."
89504458|NCT03169959|Experimental|Cohort 1: Sequence 4 (BCA)|"Subjects were randomized to treatment sequence 1 ABC:~On Day 1, each subjects will receive orally single-dose of the treatment assigned to that treatment period.~A= Reference product - 2.5mg ONGLYZA (2.5mg saxagliptin) and 5/1000mg XIGDUO XR (5 mg dapagliflozin / 1000mg Metformin XR) after food.~B = Test product - Triple FCDP consisting of 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR after food.~C = Test product - Triple FCDP tablet consisting of 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR without food."
89504459|NCT03169959|Experimental|Cohort 1: Sequence 5 (CAB)|"Subjects were randomized to treatment sequence 1 ABC:~On Day 1, each subjects will receive orally single-dose of the treatment assigned to that treatment period.~A= Reference product - 2.5mg ONGLYZA (2.5mg saxagliptin) and 5/1000mg XIGDUO XR (5 mg dapagliflozin / 1000mg Metformin XR) after food.~B = Test product - Triple FCDP consisting of 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR after food.~C = Test product - Triple FCDP tablet consisting of 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR without food."
89504460|NCT03169959|Experimental|Cohort 1: Sequence 6 (CBA)|"Subjects were randomized to treatment sequence 1 ABC:~On Day 1, each subjects will receive orally single-dose of the treatment assigned to that treatment period.~A= Reference product - 2.5mg ONGLYZA (2.5mg saxagliptin) and 5/1000mg XIGDUO XR (5 mg dapagliflozin / 1000mg Metformin XR) after food.~B = Test product - Triple FCDP consisting of 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR after food.~C = Test product - Triple FCDP tablet consisting of 2.5mg saxagliptin / 5mg dapagliflozin / 1000 mg metformin XR without food."
89504461|NCT03169959|Experimental|Cohort 2: Sequence 1 (DEF)|"Subjects were randomized to treatment sequence 1 ABC:~On Day 1, each subjects will receive orally single-dose of the treatment assigned to that treatment period.~D= Reference product - 5mg ONGLYZA (5mg saxagliptin) and 10/1000mg XIGDUO XR (10 mg dapagliflozin / 1000mg Metformin XR) after food.~E = Test product - Triple FCDP consisting of 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR after food.~F = Test product - Triple FCDP tablet consisting of 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR without food."
89504462|NCT03169959|Experimental|Cohort 2: Sequence 2 (DFE)|"Subjects were randomized to treatment sequence 1 ABC:~On Day 1, each subjects will receive orally single-dose of the treatment assigned to that treatment period.~D= Reference product - 5mg ONGLYZA (5mg saxagliptin) and 10/1000mg XIGDUO XR (10 mg dapagliflozin / 1000mg Metformin XR) after food.~E = Test product - Triple FCDP consisting of 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR after food.~F = Test product - Triple FCDP tablet consisting of 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR without food."
89504463|NCT03169959|Experimental|Cohort 2: Sequence 3 (EDF)|"Subjects were randomized to treatment sequence 1 ABC:~On Day 1, each subjects will receive orally single-dose of the treatment assigned to that treatment period.~D= 5mg ONGLYZA (5mg saxagliptin) and 10/1000mg XIGDUO XR (10 mg dapagliflozin / 1000mg Metformin XR) after food.~E = Triple FCDP consisting of 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR after food.~F = Triple FCDP tablet consisting of 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR without food."
89504464|NCT03169959|Experimental|Cohort 2: Sequence 4 (EFD)|"Subjects were randomized to treatment sequence 1 ABC:~On Day 1, each subjects will receive orally single-dose of the treatment assigned to that treatment period.~D= Reference product - 5mg ONGLYZA (5mg saxagliptin) and 10/1000mg XIGDUO XR (10 mg dapagliflozin / 1000mg Metformin XR) after food.~E = Test product - Triple FCDP consisting of 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR after food.~F = Test product - Triple FCDP tablet consisting of 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR without food."
89023733|NCT04844203||Patients with unsteadiness|Patients with unsteadiness referred for an ENMG
89023734|NCT04842591||kidney transplant candidates|Patients listed for first kidney transplantation
89206633|NCT02548884|Active Comparator|Pancreatic sphincterotomy|Pancreatic sphincterotomy technique used in difficult biliary cannulation
89206634|NCT02548884|Active Comparator|Double guide wire|Double guide wire technique used in difficult biliary cannulation
89504465|NCT03169959|Experimental|Cohort 2: Sequence 5 (FDE)|"Subjects were randomized to treatment sequence 1 ABC:~On Day 1, each subjects will receive orally single-dose of the treatment assigned to that treatment period.~D= Reference product - 5mg ONGLYZA (5mg saxagliptin) and 10/1000mg XIGDUO XR (10 mg dapagliflozin / 1000mg Metformin XR) after food.~E = Test product - Triple FCDP consisting of 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR after food.~F = Test product - Triple FCDP tablet consisting of 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR without food."
89504466|NCT03169959|Experimental|COhort 2: Sequence 6 (FED)|"Subjects were randomized to treatment sequence 1 ABC:~On Day 1, each subjects will receive orally single-dose of the treatment assigned to that treatment period.~D= Reference product - 5mg ONGLYZA (5mg saxagliptin) and 10/1000mg XIGDUO XR (10 mg dapagliflozin / 1000mg Metformin XR) after food.~E = Test product - Triple FCDP consisting of 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR after food.~F = Test product - Triple FCDP tablet consisting of 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR without food."
89504467|NCT02176187|Experimental|natural technique, without instructions|randomised sequence of Berodual® Respimat® and Berodual® MDI
89504468|NCT02176187|Experimental|optimal technique, with instructions|randomised sequence of Berodual® Respimat® and Berodual® MDI
89504469|NCT03169803|Experimental|Single arm, NeuroTronik CANS Therapy System|
89504470|NCT02279251|Active Comparator|Brief CBT (VÅG)|This is a brief five session CBT group intervention developed at Uni Research. The intervention include self-help material (Psychological First Aid) for the adolescents to use at home between sessions.
88956933|NCT03213691|Experimental|Treatment (selumetinib)|Patients receive selumetinib sulfate PO BID on days 1-28. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
88956934|NCT03213665|Experimental|Treatment (tazemetostat)|Patients receive tazemetostat PO BID on days 1-28. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
88956935|NCT03194672|Experimental|Intervention Condition|"This experimental condition has three major components:~Individual sessions: Roughly 12 90-minute sessions over 3 months Prenatal sessions covering contraceptive options, including long-acting reversible contraception. Prenatal and postnatal sessions will also cover (a) financial benefits of smoking cessation; (b)financial literacy/budgeting skills based upon selected components of the Money Matters curriculum; (c) establishing concrete steps to reach educational/career goals; (d) healthy eating habits; and (e) importance of HPV vaccinations and getting a medical home.~Transportation assistance for medical home appointments.~Electronic Prompts/Reminders to Encourage Completion of Goals."
88956936|NCT03194672|No Intervention|Treatment as Usual Control Condition|"The comparison group will be a Usual Care control group. The control group will have access to standard medical and behavior health services as part of routine care. Prior to randomization, each enrolled participant will receive a listing of contact information for organizations offering this routine care.~The only interaction the HAT providers will have with control group participants is to have periodic and brief phone conversations in which updated changes in contact information will be collected. The HAT providers will also obtain updated changes in contact information for HAT intervention group participants."
88956937|NCT03163368|Experimental|Neoadjuvant stereotactic radiosurgery|Stereotactic radiosurgery will be performed prior to neurosurgical resection of the indexed brain metastasis. The dose of radiation to be administered to the indexed lesion will be established as a function of tumor size.
88956938|NCT03117387||moderate neuromuscular block, normal body mass index|Patients with normal BMI (< 30) who will receive a moderate neuromuscular block (train of four 1-3 twitches)
88956939|NCT03117387||deep neuromuscular block, normal body mass index|Patients with normal BMI (< 30) who will receive a deep neuromuscular block (post tetanic count of 1-2 twitches)
88956940|NCT03117387||moderate neuromuscular block, high body mass index|Patients with high BMI (> 30) who will receive a moderate neuromuscular block (train of four 1-3 twitches)
88956941|NCT03117387||deep neuromuscular block, high body mass index|Patients with high BMI (> 30) who will receive a deep neuromuscular block (post tetanic count of 1-2 twitches)
88956942|NCT03049254||Proband|Proband - the person who is the first to present with a diagnosis of AVC
88956943|NCT03049254||Family members (consultands)|First-degree relatives of probands with AVC (who may be living or deceased) In some circumstances where multiple family members are or may be affected, they may be eligible.
88956944|NCT03026062|Experimental|Arm I (sequential tremelimumab, durvalumab)|Patients receive tremelimumab IV over 60 minutes on day 1. Treatment repeats every 4 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity. Upon progression, patients then receive durvalumab IV over 60 minutes on day 1. Treatment repeats every 4 weeks for up to 9 cycles in the absence of disease progression or unacceptable toxicity. This arm is closed to enrollment.
88956945|NCT03026062|Experimental|Arm II (combination tremelimumab, durvalumab)|Patients receive tremelimumab IV and durvalumab IV over 60 minutes on day 1. Treatment repeats every 4 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive durvalumab IV over 60 minutes on day 1. Treatment repeats every 4 weeks for up to 9 cycles in the absence of disease progression or unacceptable toxicity.
88956946|NCT03017885||Group A|Patients who started treatment with nintedanib & docetaxel after 23rd January, 2017 and have discontinued the drug at the time of participation in the active surveillance.
89504471|NCT02279251|Active Comparator|Established CBT program (Cool Kids)|An established, 10 session CBT group program (school version) developed by researchers at Macquarie University, Australia. The intervention has previously not been evaluated with Norwegian adolescents.
89504472|NCT02279251|No Intervention|Waitlist|Waiting period is ten weeks, then participants are randomized to one of the two active interventions
89504473|NCT02176265|Experimental|Qvanteq bioactive coronary stent system|Open-label, single arm, non-randomized study
89504474|NCT02391675||Appendicitis patients|Patients presenting with acute appendicitis
89504475|NCT02176499|Experimental|Telmisartan, low dose|3 weeks placebo run-in (normal diet), 1 week placebo run-in (controlled sodium diet), 2 weeks double-blind treatment ,1 week placebo wash-out (controlled sodium diet)
89504476|NCT02176499|Experimental|Telmisartan, high dose|3 weeks placebo run-in (normal diet), 1 week placebo run-in (controlled sodium diet), 2 weeks double-blind treatment, 1 week placebo wash-out (controlled sodium diet)
89504477|NCT02176499|Placebo Comparator|Placebo|3 weeks placebo run-in (normal diet), 1 week placebo run-in (controlled sodium diet), 2 weeks double-blind treatment, 1 week placebo wash-out (controlled sodium diet)
89504478|NCT02391441||Pulmonary arterial hypertension|Patients who are on the waiting list for double-LTX for pulmonary arterial hypertension.
89504479|NCT02391441||Control group|Control patients without increased pulmonary artery pressure (i.e. RV peak pressure <35 mmHg measured with echocardiography) who are on the waiting list for double-LTX.
89504480|NCT02176577|Experimental|Product 0405|Topically Active Investigational Product 0405
89504481|NCT02403765||Family cases|Family-based Parkinson patients carrying genetic variants associated with the disease
89504482|NCT02403765||Family controls|Family-based Control subjects
89504483|NCT05219253|Experimental|HZ/su Group|Participants randomized to the HZ/su Group receive two doses of the HZ/su vaccine.
89504484|NCT05219253|Placebo Comparator|Placebo Group|Participants randomized to the Placebo Group receive two doses of Placebo.
89504485|NCT02176733|Experimental|cyclosporine|
88956947|NCT03017885||Group B|Patients who started treatment with nintedanib & docetaxel after 23rd January, 2017 and are continuing the drug at the time of participation in the active surveillance .
88956948|NCT03017885||Group C|Patients who have been newly prescribed nintedanib & docetaxel at the time of participation in the active surveillance.
89504486|NCT03536741|Experimental|ALR|
89504487|NCT03536741|Active Comparator|EV|
89023735|NCT04827433||Women having a persistent low-lying placenta with an IOD between 6 and 20 mm|Women having a persistent low-lying placenta with an IOD between 6 and 20 mm who will be offered a vaginal birth, considering 3 subgroups: 1) 6-10 mm; 2) 11-20mm; 3) > 20 mm (resolution of previa or low-lying placenta)
89023736|NCT04827433||Women with normal located placenta|Women with a normally located placenta at the II trimester scan will represent the control group.
89504488|NCT02403609|Experimental|BPT, Computerized Assessment|Participants will first take the Brain Performance Test (BPT) on two consecutive days
89504489|NCT02182817||GA-Exposed Group|Exposure to general anaesthesia below 15 months of age
89504490|NCT02182817||Unexposed Group|Children not exposed to general anaesthesia or surgery from GUSTO cohort. (GUSTO: Growing Up Towards Healthy Outcomes in Singapore: a prospective longitudinal study providing normative data from the local population)
89504491|NCT02742649|Experimental|Fixed Combination (FC) Ocular Insert|Washout plus Placebo Ocular Insert in each eye for 24 to 48 days, followed by one segment of bimatoprost and one segment of timolol maleate combined onto a single ocular insert in each eye for 70 days. Following a second washout period, 0.5% timolol drops twice daily in each eye from Day 99 to 112.
89504492|NCT02742649|Experimental|Bimatoprost Ocular Insert|Washout plus Placebo Ocular Insert in each eye for 24 to 48 days, followed by one segment of bimatoprost and one placebo segment (no drug product) combined onto a single ocular insert in each eye for 70 days. Following a second washout period, 0.5% timolol drops twice daily in each eye from Day 99 to 112.
89504493|NCT02742649|Experimental|Timolol Ocular Insert|Washout plus Placebo Ocular Insert in each eye for 24 to 48 days, followed by one segment of timolol and one placebo segment (no drug product) combined onto a single ocular insert in each eye for 70 days. Following a second washout period, 0.5% timolol drops twice daily in each eye from Day 99 to 112.
89504494|NCT02183051|Experimental|Meloxicam 15 mg|
89504495|NCT02183051|Experimental|Meloxicam 7.5 mg|
89504496|NCT02183051|Experimental|Meloxicam 3.75 mg|
89504497|NCT02183051|Experimental|Meloxicam 1.875 mg|
89504498|NCT02183051|Active Comparator|Ibuprofen 400 mg|
89504499|NCT02183051|Active Comparator|Ibuprofen 200 mg|
89504500|NCT02183051|Placebo Comparator|Placebo|
89504501|NCT02391285|Experimental|pelvic floor dynamometry|
89504502|NCT05200767||COVID-19|Adults aged 18 at the least of any sex and race hospitalized for SARS-CoV-2 infection
89504503|NCT02179307|Experimental|Arm label 1-Set, 3-Set|12-week progressive strength training protocol of different volumes
89504504|NCT00453271|Experimental|NB-002 0.25% BID|
89504505|NCT00453271|Experimental|NB-002 0.5% QD|
89504506|NCT00453271|Experimental|NB-002 0.5% BID|
89504507|NCT00453271|Sham Comparator|Vehicle control|
89504508|NCT02176811||Non-alcoholic Fatty Liver Disese|no treatment
89504509|NCT02176811||healthy controls|no treatment
89504510|NCT03169725|Experimental|Test group 1|Low dose (Stage2: Lot A) of investigational inactivated poliomyelitis vaccine based on Sabin strains (LBVC)
89504511|NCT03169725|Experimental|Test group 2|Middle dose (Stage2: Lot B) of investigational inactivated poliomyelitis vaccine based on Sabin strains (LBVC)
89504512|NCT03169725|Experimental|Test group 3|High dose (Stage2: Lot C) of investigational inactivated poliomyelitis vaccine based on Sabin strains (LBVC)
89504513|NCT03169725|Active Comparator|Comparator|Cormmercialized inactivated poliomyelitis vaccine based on Sabin strains (Imovax Polio)
89504514|NCT02176889|Experimental|Lactospore|One tablet once daily, 30 minutes before a meal, preferably in the morning for 30 days
89504515|NCT02176889|Placebo Comparator|Placebo|One tablet once daily, 30 minutes before a meal, preferably in the morning, for 30 days.
89504516|NCT02403531|Active Comparator|Concurrent chemoradiotherapy|Patients assigned to this Arm received concurrent chemoradiotherapy. The prescribed dose of radiotherapy is generally 50-60 Gy/25-28fr. The concomitant chemotherapy is docetaxel 20 mg/m2 on day 1, cisplatin 25 mg/m2 on day 1, repeated weekly during radiation.
89504517|NCT02403531|Experimental|Induction chemotherapy plus chemoradiotherapy|Patients assigned to this Arm first received two cycles of 3-weekly schedule of IC before definitive chemoradiotherapy, consisting of docetaxel 75 mg/m2 on day 1 and cisplatin 75 mg/m2 on day 1. The prescribed dose of radiotherapy is generally 50-60 Gy/25-28fr. The concomitant chemotherapy is docetaxel 20 mg/m2 on day 1, cisplatin 25 mg/m2 on day 1, repeated weekly during radiation.
89504518|NCT02279953|Experimental|Vortioxetine 10-20 mg|daily, encapsulated, orally
89504519|NCT02279953|Experimental|Vortioxetine 10-20 mg + SSRI|daily, encapsulated, orally
89504520|NCT02279953|Experimental|SSRI|licensed doses, encapsulated, orally
89504521|NCT02183207|Experimental|PEG insertion arm via EG Scan|Percutaneous endoscopic insertion of gastrostomy via visualization through E.G. ScanTM
89504522|NCT02391207||patients having at least one CLM|Hepatic vein-sparing hepatectomy guided by intraoperative ultrasonography
89504523|NCT02179385|Experimental|Health coaching|Patients receive health coaching via the phone, face to face or group support, according to patients' choice
89504524|NCT02179385|Placebo Comparator|Standard of Care|
89504525|NCT00578773|Experimental|Moxidex|Moxidex otic solution
89504526|NCT00578773|Active Comparator|Moxifloxacin|Moxifloxacin otic solution
89504527|NCT00578773|Other|TT only|Tympanostomy tubes only
89504528|NCT02387307|Experimental|Cohort: Dose-Escalation and Expansion|"Dose-Escalation: Dose escalation in solid tumors utilizing a 3+3 design with intra-subject dose escalation. 4 dose levels of rSIFN-co are planned for determining the RD. Dose of rSIFN-co: 15, 21, 24, 27 and 30 ug.~Dose-Expansion: The Expansion Cohort will be initiated at the RD. Depending on the RD, the lead in period will occur accordingly. After the lead in period, a period from Cycle 1 to the final administration will be performed as the Treatment Phase during which subjects will undergo a standardized evaluation for the safety and efficacy of rSIFN-co at the RD. Follow-up evaluations will be performed 28 days (±5 days) after the last rSIFN-co administration."
89504529|NCT02177045|Experimental|Microbubbles contrast media for US|Sonovue, Bracco, microbubbles contrast media
89504530|NCT02403375|Experimental|Continuous Subcutaneous Insulin Infusion (CSII)|Continuous Subcutaneous Insulin Infusion (CSII) in Children and Adolescents 2-17 Years of Age
89504531|NCT00578695|Experimental|Active|Lixivaptan
89504532|NCT00578695|Placebo Comparator|Placebo|Placebo
89504533|NCT02179463||Neoadjuvant Chemotherapy|undergo neoadjuvant chemotherapy before surgery
89504534|NCT02183285|Experimental|PHL 00747 capsules|
89504535|NCT02183285|Experimental|PHL 00747 tablets|
89504536|NCT02183285|Placebo Comparator|Placebo|
89504537|NCT02183363|Experimental|BI 1356 - Tablet TFII|
89504538|NCT02183363|Experimental|BI 1356 - Tablet iFF|
89504539|NCT02183363|Active Comparator|BI 1356 - Tablet TFIIb|
89504540|NCT02387151|Experimental|mesenchymal stromal cells|allogeneic mesenchymal stromal cell infusion
89023738|NCT04822272|Experimental|Thermometry MRI|MRI sequence of 5 to 10 minutes to measure the variation of temprerature in the prostate
89023739|NCT04821154||1) Revision Splined CCK|Patients who were implanted with a splined tibial stem, 0 degree Persona Revision tibial component, constrained condylar knee (CCK) articular surface, Persona Revision femoral component, and splined femoral stem.
89504541|NCT02179541||Group 1|All Group 1 patients were diagnosed with OME, diagnoses made by endoscopic-otoscopic examination findings and type-B tympanograms. They were all scheduled for ventilation tube insertion. Diagnosis of OME was confirmed during this surgery. All patients were examined by 4 mm 0-degree Storz endoscope and light source. The Adobe Photoshop Elements 7.0 program was used for RGB measurements. Viscosity was measured by the Brookfield DV-II+ProCP Viscometer.
89504542|NCT02179541||Group 2|Children in Group 2 had totally normal tympanic membranes and type A tympanograms. They had no hearing loss, Eustachian tube dysfunction, or any other ear-related problem, and were included in the study as healthy controls. Excluded from the study were patients presenting with acute otitis media, tympanosclerotic plaques, mental retardation, and children who were difficult to cooperate with. All subjects were examined by 4 mm 0-degree Storz endoscope and light source. The Adobe Photoshop Elements 7.0 program was used for RGB measurements.
89504543|NCT02179541||Group 1a|To determine whether higher or lower viscosity of an effusion impacted RGB values, the patient group was subdivided into two subgroups according to viscosity level. Patients with an effusion below the mean viscosity value of 450 cP (centipoise) were assigned to Group 1a.
89504544|NCT02179541||Group 1b|To determine whether higher or lower viscosity of an effusion impacted RGB values, the patient group was subdivided into two subgroups according to viscosity level. Patients with an effusion above the mean viscosity value of 450 cP (centipoise) were assigned to Group 1b.
89504545|NCT02387073||Electrical version|Electrical version patient reported outcome questionnaire was used for patients who had filled-up same questionnaire in a paper version
89504546|NCT02179619|Experimental|Dermalax(Deep)|subject injected in one nasolabial fold (NLF) of one side of their face (blinded, split-face study design) in the Initial Treatment period
89504547|NCT02179619|Active Comparator|Restylane|Subject injected in one nasolabial fold (NLF) of one side of their face (blinded, split-face study design) in the Initial Treatment period
89504548|NCT02183441|Experimental|BI 1356 plus ritonavir|Treatment A: 3 days of ritonavir, 1 day BI 1356
89504549|NCT02183441|Active Comparator|BI 1356|Treatment B: BI 1356 alone
89504550|NCT02403219|Experimental|Botulinum toxin type A injection|An injection of 4 international units of botulinum toxin type A will be applied in the medial in the medial part of the lower eyelid near the punctum directed along the medial canthal tendon in a single application by subcutaneous injection.
89504551|NCT02403219|Sham Comparator|Sham injection|An injection of 4 international units of sham will be applied in the medial in the medial part of the lower eyelid near the punctum directed along the medial canthal tendon in a single application by subcutaneous injection.
89504552|NCT03537287|Active Comparator|17 alpha hydroxyprogestrone caproate Group|Patients will receive 250 mg of 17 alpha hydroxyprogestrone caproate intramuscularly once weekly starting from 16 weeks till delivery or 36 weeks.
89504553|NCT03537287|Active Comparator|Vaginal progesterone Group|Patients will receive vaginal progesterone 200 mg once per day starting from 16 weeks till delivery or 36 weeks.
89023740|NCT04821154||2) Revision Cemented CCK|Patients who were implanted with a cemented tibial stem, 0 degree Persona Revision tibial component, CCK articular surface, Persona Revision femoral component, and cemented femoral stem.
89023741|NCT04821154||3) Revision Splined PS/CPS|Patients who were implanted with a splined tibial stem, 0 degree Persona Revision tibial component, posterior stabilized/constrained posterior stabilized (PS/CPS) articular surface, Persona Revision femoral component, and splined femoral stem.
89023742|NCT04821154||4) Revision Cemented PS/CPS|Patients who were implanted with a cemented tibial stem, 0 degree Persona Revision tibial component, PS/CPS articular surface, Persona Revision femoral component, and cemented femoral stem.
89023743|NCT04821154||5) Revision Splined PS/CPS|Patients who were implanted with a splined tibial stem, 0 degree Persona Revision tibial component, PS/CPS articular surface, Persona primary PS femoral component, with no femoral stem.
89023744|NCT04821154||6) Revision Cemented PS/CPS|Patients who were implanted with a cemented tibial stem, 0 degree Persona Revision tibial component, PS/CPS articular surface, Persona primary PS femoral component, with no femoral stem.
89023745|NCT04821154||7) Revision Cemented CCK with 5 Degree Primary Tibia|Patients who were implanted with a cemented tibial stem, 5 degree Persona primary tibial component, CCK articular surface, Persona Revision femoral component, and cemented femoral stem.
89023746|NCT04821154||8) Primary Splined CCK/CPS/PS with 0 Degree Tibia|Patients with a primary implant (non-revision case) who were implanted with a splined tibial stem, 0 degree Persona Revision tibial component, CCK/PS/CPS articular surface, Persona Revision femoral component, and splined femoral stem.
89023747|NCT04821154||9) Primary Cemented CCK/PS/CPS with 0 Degree Tibia|Patients with a primary implant (non-revision case) who were implanted with a cemented tibial stem, 0 degree Persona Revision tibial component, CCK/PS/CPS articular surface, Persona Revision femoral component, and cemented femoral stem.
89504554|NCT03537287|Active Comparator|Oral dydrogesterone Group|Patients will receive 2 tablets of oral dydrogesterone daily starting from 16 weeks till delivery or 36 weeks
89504555|NCT02280031|Active Comparator|Experimental|Acetylsalicylic Acid 80mg administered daily at bedtime
89504556|NCT02280031|Placebo Comparator|Control|Identical placebo administered daily at bedtime
89504557|NCT02386761|Experimental|Single Ascending Dose (SAD)|"Dose 1 (SAD1): 6 inhalations of CHF 6001 400 µg giving a total dose of 2400 µg~Dose 2 (SAD2): 10 inhalations of CHF 6001 400 µg giving a total dose of 4000 µg~Dose 3 (SAD3): 12 inhalations of CHF 6001 400 µg giving a total dose of 4800 µg Placebo (P): the number of placebo inhalations will match that of the active CHF 6001 pertaining to the same dose period.~In case the actual doses are modified, the number of inhalations will be adapted accordingly."
89504558|NCT02386761|Experimental|Multiple Ascending Dose (MAD)|"Dose 1 (MAD1): Multiple doses of CHF 6001 - Total daily dose 2400 µg or placebo~Dose 2 (MAD2): Multiple doses of CHF 6001 - Total daily dose 4000 µg or placebo~Dose 3 (MAD3): Multiple doses of CHF 6001 - Total daily dose 4800 µg or placebo~Duration 14 days b.i.d."
89504559|NCT00449605|Experimental|Rimonabant|Rimonabant 20 mg once daily on top of metformin
89504560|NCT00449605|Active Comparator|Glimepiride|Glimepiride from 1 mg up to 6 mg once daily on top of metformin
89504561|NCT02403297||Healthy|"Saliva will be collected from 58 subjects determined to be healthy according to the protocol."
89504562|NCT02403297||Gingivitis|Saliva will be collected from 58 subjects determined to have gingivitis according to the protocol.
89504563|NCT02403297||Periodontal disease|Saliva will be collected from 58 subjects determined to have periodontal disease according to the protocol.
89504564|NCT02774239|Experimental|SC Treatment Period|"Participants will receive 2gm/kg of Human normal immunoglobulin G (IgG) infused over 4 weeks in a dose escalating manner as follows:~1st week: 2-3 SCIG infusions of 10ml per site at four sites (total dose 16 to 24g)*~2nd week: 2-3 SCIG infusions of 15ml per site at four sites (total dose 24 to 36g)*~3rd week: 2-4 SCIG infusions of 20ml per site at four sites (total dose 32 to 64g)*~4th week: 2-4 SCIG infusions of 25ml per site at four sites (total dose 40 to 80g)*~Doses indicated are study recommended. Doses may be adjusted depending on tolerance and total dose required by the patient."
89504565|NCT02179697|Active Comparator|Surgery + Bracing vs. Bracing Alone|"Randomize between 2 treatments:~Treatment 1: Surgery + Bracing Treatment 2: Bracing alone"
89504566|NCT02179697|Other|Patient's choice|Patient will decide which group is best for him/her. The patient will be followed at the same points as Group 1.
89504567|NCT02386683|Active Comparator|Group L|lung-protective ventilation applied in anesthesia
89504568|NCT02386683|No Intervention|Group T|traditional ventilation applied in anesthesia
89504569|NCT02280109|Active Comparator|Tenofovir Gel|Women will receive a single dose of tenofovir gel (1%;equivalent to 40 mg in 4ml's of gel) to determine the pharmacokinetics of tenofovir in the blood, cervical tissue, and cervicovaginal fluid.
89504570|NCT02280109|Active Comparator|Tenofovir Film|Women will receive a single dose of tenofovir film (1.3%;40 mg) to determine the pharmacokinetics of tenofovir in the blood, cervical tissue, and cervicovaginal fluid.
89504571|NCT02183597||Advanced breast cancer|Women with advanced breast cancer
89023748|NCT04821154||10) Primary Cemented CCK/PS/CPS with 5 Degree Primary Tibia|Patients with a primary implant (non-revision case) who were implanted with a cemented tibial stem, 5 degree Persona primary tibial component, CCK/PS/CPS articular surface, Persona Revision femoral component, and cemented femoral stem.
89504572|NCT02403141||Normal glucose tolerance|Patients with normal fasting glucose. Blood glucose less than 5.6mmol/L
89504573|NCT02403141||Impaired fasting glycaemia|Patients with blood glucose between 5.6mmol/L - 7mmol/L
89504574|NCT02403141||Type 2 diabetes|Patients with blood glucose higher than 7mmol/L and negative IA2 and GAD antibodies.
89023749|NCT04821154||11) Infection Cases|Any configuration of PRK components used for end stage (non-temporary) treatment
89206635|NCT02547558|Experimental|Indacaterol|"Drug:~-Indacaterol, inhaled, single dose, 300 mcg~Diagnostic Interventions:~Arterial blood gases~Cardiac output~Vital signs~Exhaled breath~Spirometry"
89504575|NCT02403141||Type 1 diabetes|Patients on insulin and with positive IA2 and/or GAD antibodies.
89504576|NCT02183753|Active Comparator|Wood smoke|The dose of WSP to be used (500 µg/m3 for 2 hours) is based on prior studies which indicate the exposure is well tolerated, and is similar to that found in some indoor exposures in homes heated by wood burning (24-26). The route of administration (breathing air containing WSP at rest, nasally) is intended to mimic natural exposures.
89504577|NCT02183753|Placebo Comparator|clean air|Chapel Hill air which has been filtered to remove ambient air pollutants.
89504578|NCT00576667|Experimental|Rimonabant|Rimonabant 20 mg once daily.
89504579|NCT00576667|Placebo Comparator|Placebo|Placebo (for Rimonabant) once daily.
89504580|NCT02403063|Active Comparator|sugammadex|Selective relaxant binding agent
89504581|NCT02403063|Active Comparator|neostigmine|Acetylcholinesterase inhibitor
89504582|NCT02403063|Experimental|neostigmine-sugammadex|Acetylcholinesterase inhibitor followed by a selective relaxant binding agent
89504583|NCT02177279|Other|Visit A- 120g wheat bran cereals|A morning vist where volunteers consumed 120g of wheat bran cereals with 125ml semi-skimmed milk
89504584|NCT02177279|Other|Visit B-40g wheat bran cereals|A morning vist where volunteers consumed 40g of wheat bran cereals with 375 ml semi-skimmed milk
89504585|NCT02177279|Other|Follow up-40g (8days), 120g (1day) wheat bran cereals|Volunteers follow their normal diet but they were asked to consume 40g wheat bran cereals with 125 ml semi-skimmed milk for eight days and on day nine 120g wheat bran cereals with 375ml semi-skimmed milk
89504586|NCT04472221|Experimental|Vascular Access Venous Hypertension|Swollen upper limb with synthetic Arteriovenous graft
89504587|NCT02177357|Experimental|Pramipexole - escalation dose|
89504588|NCT02177357|Placebo Comparator|Placebo|
89504589|NCT02391051|Experimental|Focal Brachytherapy|HDR-Brachytherapy, 2 fractions within at least 24 but max. 30 hours, each 13,5 Gy
89504590|NCT04471831|Experimental|Stroke survivors with COVID19|The active intervention group
89504591|NCT04471831|Placebo Comparator|Non-stroke individuals with COVID19|Matching for age, sex and co-morbid status with the stroke survivors
89504592|NCT02030093||High-frequency telephone-based continuing care|High-frequency telephone-based continuing care
89504593|NCT02030093||Low-frequency telephone-based continuing care|Low-frequency telephone-based continuing care
89504594|NCT02030093||SMS group|SMS group
89504595|NCT02030093||Control group|Control group
88956952|NCT02997020||CRS Patients|Endoscopically-directed sinus potential difference (EDSPD) will be conducted in either the operating room or in the rhinology clinic setting to quantify CFTR activity in the sinus cavities. The potential difference will be monitored in actively inflamed areas as judged by endoscopy in comparison to an agar-filled reference butterfly electrode placed in the volar aspect of the forearm. A stable potential with the mean value of a 10-s scoring interval after perfusion of each solution will be recorded by a blinded investigator.
88956953|NCT02997020||Control Patients|Endoscopically-directed sinus potential difference (EDSPD) will be conducted in either the operating room or in the rhinology clinic setting to quantify CFTR activity in the sinus cavities. The potential difference will be monitored in actively inflamed areas as judged by endoscopy in comparison to an agar-filled reference butterfly electrode placed in the volar aspect of the forearm. A stable potential with the mean value of a 10-s scoring interval after perfusion of each solution will be recorded by a blinded investigator.
88956954|NCT02960776|No Intervention|Habitual Sleep (HS)|Participants will be asked to follow a fixed bedtime routine based on the participant's regular bed- and wake-times during the habitual sleep (HS) phase.
88956955|NCT02960776|Experimental|Sleep Restriction (SR)|Participants will be asked to keep their habitual wake time constant but delay their bedtime to achieve a reduction of 1.5 hours in total sleep time during the sleep restriction (SR) phase.
88956956|NCT02953990|Experimental|MOMS Program|The MOMS Program involves: (1) mindfulness of symptoms and goal-setting through a nurse-participant partnership, and (2) 12 weeks of weekly community-based group prenatal yoga classes (75 minutes each) and self-directed home activity. Participants will engage in 12 weeks of weekly community-based group prenatal yoga classes (75 minutes each) and self-directed home practice.
88956957|NCT02947308||Adolescents with NSSI|12-16 year old females who have a history of non-suicidal self-injury are included in this cohort. No interventions will be administered.
88956958|NCT02947308||Healthy Controls|12-16 year old females with no history of non-suicidal self-injury are included in this cohort.
88956959|NCT02936752|Experimental|Treatment (entinostat, pembrolizumab)|Patients receive lower dose entinostat PO on days 1 and 8 or higher dose entinostat PO on days 1, 8, and 15, and pembrolizumab IV over 30 minutes on day 1 of cycle 2 and cycles thereafter. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients who achieve an objective response or maintain a SD status after the first 4 cycles may continue to receive entinostat and pembrolizumab for up to 1 year.
88956960|NCT02921997|Experimental|Arm 1|10 Subjects: one dose of 15 µg of A/H3N2v, at Day 1
88956961|NCT02921997|Experimental|Arm 2|10 Subjects: two doses of 3.75 µg of AH7N9 AS03,at Day 1 and at Day 29
88956962|NCT02921997|Experimental|Arm 3|10 Subjects: two doses of 3.75 µg of A/H7N9, at Day 1 and Day 29
89504596|NCT02386449|Experimental|Picoprep|sodium picosulfate, magnesium oxide and citric acid
89504597|NCT02386449|Active Comparator|Mannitol and Bisacodyl|
89504598|NCT00656539|Experimental|1|AzaSite®
89504599|NCT00656539|No Intervention|2|
89504600|NCT02391129||Hyperion Prosthesis|Patients treated with the second generation long-stem revision prosthesis
89504601|NCT02391129||Helios Prosthesis|Patients treated with the first generation long-stem revision prosthesis
89504602|NCT02391129||Locking compression plate|Patients treated with LCP
89504603|NCT02179775|Active Comparator|propranolol|
89504604|NCT02179775|Active Comparator|Quince's oxymel|
89504605|NCT02179775|Placebo Comparator|placebo|
89504606|NCT00566449|Experimental|001|JNJ-31001074 10 mg daily for 4 weeks
89504607|NCT00566449|Placebo Comparator|003|Placebo one dose daily for 4 weeks
89504608|NCT00566449|Experimental|002|JNJ-31001074 30 mg daily for 4 weeks
89504609|NCT02390973|Active Comparator|Sleeve gastrectomy|
89504610|NCT02390973|Active Comparator|Roux-en-Y Gastric Bypass|
89504611|NCT02390973|Active Comparator|Biliopancreatic Diversion|
89504612|NCT02390973|Active Comparator|Control|the best medical management of their diabetes, non-surgical group
89504613|NCT02177435|Experimental|Telmisartan plus Hydrochlorothiazide|
89504614|NCT02177435|Experimental|Telmisartan|
89504615|NCT02402829||Hemophilia Patients|Subjects diagnosed with moderate or severe Hemophilia A or B who use a central venous line (CVL) for regular prophylaxis factor infusions and are at the clinic for a standard of care visit. As part of the study all subjects will have blood drawn through their CVL and will also undergo a peripheral vein blood draw.
89504616|NCT02183831||Capsular tension ring non insertion group|The patients who had same cataract surgery procedure without CTR insertion
89504617|NCT02183831||Capsular tension ring insertion group|The patients who underwent capsular tension ring insertion just before IOL implantation during cataract surgery
89504618|NCT02284477|Experimental|non- PVC containing packing materials|Participants will be provided food for lunch and dinner with 360mL apple juice which was stored in glass bottle for 24 hours in 4 ℃. After 1 week, participant will cross over to other intervention.
89504619|NCT02284477|Experimental|PVC containing packing materials|Participants will be provided food for lunch and dinner with 360mL apple juice which was stored in PVC blood bag for 24 hours in 4 ℃. After 1 week, participant will cross over to other intervention.
89504620|NCT02284477|No Intervention|Only lunch and dinner|Participant received food for lunch and dinner After 1 week, participant get over to each experimental arms.
89504621|NCT02402985|Other|High animal protein diet group AP|6-weeks diet intervention with high animal protein
89504622|NCT02402985|Other|High plant protein diet group PP|6-weeks diet intervention with high plant protein
89504623|NCT02280265|Experimental|ADVATE|The baseline ABR will be assessed from bleeding log and clinic records from preceding year. Subjects will initially be treated standard prophylaxis(20 - 40 IU/Kg body weight every 48 ± 6 hours) with Recombinant Human Coagulation Factor VIII for injection(ADVATE) for 1 year. Subjects must be prescribed ADVATE by the treating physician. Data will be collected over a period of 2 years from the time of study enrollment. Study visits are to coincide with routinely rescheduled and emergency visits. Available data from these visits shall be transcribed onto the case report forms (CRFs).
89504624|NCT02179931|Experimental|Flupentixol/melitracen film-coated tablet|test treatment - 0.5 mg/10 mg; oral as a single dose
89504625|NCT02179931|Other|Flupentixol/melitracen coated tablet (Deanxit®)|reference treatment - 0.5 mg/10 mg, oral as a single dose
89504626|NCT00655369|Experimental|15 mg|
89504627|NCT00655369|Experimental|25 mg|
89504628|NCT00655369|Experimental|35 mg|
89504629|NCT00655369|Experimental|5 mg|
89504630|NCT00655369|Experimental|50 mg|
89504631|NCT00655369|Placebo Comparator|Placebo|
89504632|NCT02184065||Meloxicam|
89504633|NCT03538067||Paired sample group|Patients with symptomatic coronary artery disease (stable, NSTEACS) undergoing planned percutaneous coronary intervention with intravascular ultrasound (IVUS) guidance
89504634|NCT03537989|Experimental|Restricted group|"Oral fluid to 2 h before surgery. Intra-operatively: Glucose 5% (500 ml - volume drunk during fast); HAES 6% for blood loss volume to volume; IV-medicine in saline 0.9% for anesthesia and antibiotics. Blood products after current rules.~Postoperatively: 1000 ml glucose containing fluid in the recovery room. Free oral intake of fluid and food as well as enteral feeding by tube 500 ml.~In the wards: Enteral feeding by tube 1000 ml postoperative day 1-3. Free fluid and food by mouth. If less than 1500 ml fluid pr. mouth supplement with VI-fluid.~Pathological fluid loss (high output stoma, aspirate, vomit etc.) - replace with IV-fluid. Goal: zero fluid balance with up to 1-kilogram body weight increase.~Urine < 0.5 ml/kg/h: supplement with fluid. MAP < 60 and hypovolemia: treat with fluid."
89504635|NCT03537989|Active Comparator|Standard group|"Oral fluid to 2 h before surgery. Intra-operatively: Saline 500 ml for fasting; 500 ml HAES 6% for the epidural, Saline for the third space: 7 ml/kg/h first hour, 5 ml/kg/h 2.-3. Hour, 3 ml/kg/h subsequent hours. 1000-1500 ml Saline replaced lost blood up to 500 ml, additional HAES 6% for additional blood loss; IV-medicine in saline.~Postoperatively: 1000-2000 ml isotonic fluid in the recovery room. Free oral fluid and food as well as enteral feeding by tube 500 ml.~In the wards: Enteral feeding by tube 1000 ml postoperative day 1-3. Free fluid and food by mouth. Supplemental iv-fluid according to department rules. Pathological fluid loss (high output stoma, aspirate, vomit etc.) - replace with IV-fluid.~Urine < 0.5 ml/kg/h: supplement with fluid. MAP < 60 and hypovolemia: treat with fluid."
89504636|NCT00564421|Experimental|Epinastine low concentration:low dose volume|
89504637|NCT00564421|Experimental|Epinastine low concentration:high dose volume|
89504638|NCT00564421|Experimental|Epinastine high concentration:low dose volume|
89504639|NCT00564421|Experimental|Epinastine high concentration:high dose volume|
89504640|NCT00564421|Placebo Comparator|Placebo nasal spray|
89504641|NCT00653185|Experimental|SYR-472 25 mg QD|(with lifestyle modification and/or metformin therapy)
89504642|NCT00653185|Experimental|SYR-472 50 mg QD|(with lifestyle modification and/or metformin therapy)
89504643|NCT00653185|Experimental|SYR-472 100 mg QD|(with lifestyle modification and/or metformin therapy)
88956963|NCT02891603|Experimental|Phase 1, Level 1: Pacritinib with Sirolimus and Tacrolimus|"After standard of care allogenic hematopoietic cell transplantation, Pacritinib will be added to standard treatment with Sirolimus and Tacrolimus (PAC/SIR/TAC).~100 mg Pacritinib will begin taken by mouth the day of the participant's transplant (Day 0) and will continue until 70 days after the transplant..~Sirolimus will be given the day before transplant and continued daily for at least one year.~Tacrolimus will begin 3 days before transplant and will be given for at least 50 days."
88956964|NCT02891603|Experimental|Phase 1, Level 2: Pacritinib with Sirolimus and Tacrolimus|"After standard of care allogenic hematopoietic cell transplantation, Pacritinib will be added to standard treatment with Sirolimus and Tacrolimus (PAC/SIR/TAC).~100 mg Pacritinib will begin taken by mouth twice daily starting the day of the participant's transplant (Day 0) and continuing until 70 days after the transplant..~Sirolimus will be given the day before transplant and continued daily for at least one year.~Tacrolimus will begin 3 days before transplant and will be given for at least 50 days."
89210466|NCT00906360|Experimental|Treatment (enzyme inhibitor and monoclonal antibody therapy)|Patients receive sunitinib malate orally or by percutaneous gastrostomy tube once daily, cetuximab IV over 60-120 minutes once weekly, and undergo concurrent radiotherapy once or twice daily, 5 days a week, for 7-9 weeks in the absence of disease progression or unacceptable toxicity. Patients with persistent disease undergo surgical resection.
89504644|NCT00653185|Experimental|SYR-472 200 mg QD|(with lifestyle modification and/or metformin therapy)
89504645|NCT00653185|Placebo Comparator|Placebo QD|(with lifestyle modification and/or metformin therapy)
89504646|NCT02665689|Active Comparator|Regular Glycemic Control|Diabetic macular edema will be treated with 3 monthly ranibizumab (0,5mg) injections followed by PRN regimen. Patients randomized into this group will be controlled by their general practitioner or private diabetologist (usual care). The glycemic control (blood measurements of HbA1c) will be performed at trial site (Department of diabetology, endocrinology and nutritional medicine) every 3 months. The site will not influence or change the diabetes medication given by general physician and serves as an observer only to monitor the diabetic control.
89504647|NCT02665689|Experimental|Intensified Glycemic Control|"Diabetic macular edema will be treated with 3 monthly ranibizumab (0,5mg) injections followed by PRN regimen.~Patients randomized into this group will be controlled at the trial site (Department of diabetology, endocrinology and nutritional medicine) during first year monthly, in the second study year every 3 months. The individual HbA1c will be targeted according to the general status reflecting other risk factors for the vasculopathy (e.g. BMI, smoking, blood pressure, lipid status). All effort will be done to reach the target blood pressure ≤ 140/90 mmHg and blood triglyceride level < 140 mg/dl: Further the patients will be educated to improve their eating habits in regard to reduce the carbohydrate intake."
89210467|NCT00643682|Experimental|A|Patients in this arm will be given an educational card in addition to the standard pre-endoscopy instructions.
89504648|NCT02386293|Placebo Comparator|Placebo|Sugar pill identical to Avapro provided for 7 day prescription
89504649|NCT02386293|Active Comparator|Irbesartan|150 mg of Avapro once daily for 7 days.
89504650|NCT02180009||normal control|healthy people
89504651|NCT02180009||sepsis|mild response to infection
89504652|NCT02180009||severe sepsis|infection with at least one organ dysfunction
89504653|NCT02180009||septic shock|patients with septic shock
89504654|NCT00563563|Experimental|NB32|Naltrexone SR 32 mg/Bupropion SR 360 mg daily subjects will receive ancillary therapy including counseling on smoking cessation, diet and exercise.
89504655|NCT02184221|Experimental|High frequency stimulation|alpha burst, 8~12Hz, run 2 seconds, rest 8 seconds, lasts 20 minutes each time
89504656|NCT02184221|Active Comparator|Low frequency stimulation|0.5Hz, run 0.5 seconds, rest 1.5 seconds, lasts 20 minutes each time
89504657|NCT05149365|Experimental|Sitagliptin Group|95 adult patients with hematologic malignancies receiving Alternative Donor HSCT, who will receive Sitagliptin combined with Standard prophylaxis regimen for GVHD of Alternative Donor HSCT.
89504658|NCT05149365|Active Comparator|Standard Group|95 adult patients with hematologic malignancies receiving Alternative Donor HSCT, who will only receive Standard prophylaxis regimen for GVHD of Alternative Donor HSCT
89504659|NCT02180087|Placebo Comparator|placebo group|Group 1 : Placebo group (P). 0 mg/kg ketoprofen IV every 6 hours for 48 hours (or 0 mg/kg every 24 hours) for 48 hours
89504660|NCT02180087|Other|ketopofen quarter dose|"Group 2 : Ketoprofen quarter dose (K ¼). 0,125 mg/kg ketoprofen IV every 6 hours (0,5 mg/kg every 24 hours) for 48 hours."
89504661|NCT02180087|Other|ketoprofen half-dose|"Group 3 : Ketoprofen half-dose (K ½). 0,25 mg/kg ketoprofen IV every 6 hours (1 mg/kg every 24 hours) for 48 hours."
89504662|NCT02180087|Other|Ketoprofen full dose|"Group 4 : Ketoprofen full dose (KPD). 0,5 mg/kg ketoprofen IV every 6 hours (or 2 mg/kg every 24 hours) for 48 hours"
89504663|NCT02390583|Active Comparator|control|CBT treatment of internet dependence each two weeks during 3 months
89504664|NCT02390583|Experimental|intervention|CBT treatment of internet dependence plus CBT treatment of sleep disorders during 3 months
89504665|NCT02402751|Experimental|Acquisition of normative database|Development, implementation and initiation of normative database (image and data) quantitative ultra high field MRI paramaters
89210468|NCT00643682|No Intervention|B|Patients in this arm will be given the standard pre-endoscopy instructions.
89504666|NCT02184299|Experimental|Nevirapine + Prednisone|"week 1-2: Nevirapine + Prednisone~week 3-24: Nevirapine alone"
89504667|NCT02184299|Active Comparator|Nevirapine|week 1-24: Nevirapine
89504668|NCT02402673|Other|Intervention|
89504669|NCT03537053|Experimental|A plan to Move a Little and Often|"The intervention will consist of 3 components: a short video will raise awareness about the impact of sedentary behaviours, a booklet, and an online forum on Facebook to encourage participants to support each other.~At the end of the baseline data collection, participants will be asked to watch the video. They will then be given the booklet and invited to join the Facebook group. A minimum of 5 participants must be recruited prior to running the Facebook group."
89504670|NCT00549679|Experimental|25 mcg|25 microgram inhaled once daily
89504671|NCT00549679|Experimental|87.5 mcg|87.5 microgram inhaled once daily
89504672|NCT00549679|Placebo Comparator|Placebo|Placebo inhaled once daily
89504673|NCT02386137|Experimental|Patient|Woman aged more than 18 years having one or two symptomatic fibroid with size < 15cm.
89504674|NCT04481763|Other|camrelizumab + radiotherapy|This is a open-labeled, single-arm, Investigator-initiated clinical trial ,Compared with historical data
89504675|NCT02282371|Experimental|Cetuximab + BYL719 + IMRT|Cetuximab loading dose, 400 mg/m2 intravenously (IV). IMRT, 1 fraction/day, up to total of approximately 70 Gy, over approximately 33 treatment days Cetuximab 250 mg/m2 weekly IV X 7 weeks Daily BYL719, according to dose escalation scheme followup clinic visits every 3 months for 2 years,every 6 months for the next 3 years, and annually thereafter.
89504676|NCT02184377||RLN+SLN paralysis|unilateral recurrent laryngeal and superior laryngeal nerve paralysis
89504677|NCT02184377||RLN paralysis|unilateral recurrent laryngeal nerve paralysis
89504678|NCT02402595|Experimental|Sequence 1 - Period 1|AVP-923 and placebo matching AVP-786- BID Day 1 until am of Day 15 Itraconazole - 200 mg BID on Day 9 followed by QD dosing on Days 10-15
89504679|NCT02402595|Experimental|Sequence 1 - Period 2 (after 3-week washout)|AVP-786 and placebo matching AVP-923 - BID on Day 1 until am of Day 15 Itraconazole - 200 mg BID on Day 9 followed by QD dosing on Days 10-15
89504680|NCT02402595|Experimental|Sequence 2 - Period 1|AVP-786 and placebo matching AVP-923 - BID on Day 1 until am of Day 15 Itraconazole - 200 mg BID on Day 9 followed by QD dosing on Days 10-15
89504681|NCT02402595|Experimental|Sequence 2 - Period 2 (after 3-week washout)|AVP-923 and placebo matching AVP-786- BID on Day 1 until am of Day 15 Itraconazole - 200 mg BID on Day 9 followed by QD dosing on Days 10-15
89504682|NCT02177513|Active Comparator|1|
89504683|NCT02177513|Active Comparator|2|
89504684|NCT02177513|Active Comparator|3|
89504685|NCT02177513|Placebo Comparator|4|
89504686|NCT02177513|Active Comparator|5|
89504687|NCT00548587|Active Comparator|1|Participants will receive one 50 mg E5555 tablet and two 100 mg placebo tablets, once daily for 12 weeks.
89504688|NCT00548587|Active Comparator|2|Participants will receive one 50 mg placebo tablet, one 100 mg E5555 tablet, and one 100 mg placebo tablet, once daily for 12 weeks.
89504689|NCT00548587|Active Comparator|3|Participants will receive one 50 mg placebo tablet and two 100 mg E5555 tablets, once daily for 12 weeks.
89504690|NCT00548587|Placebo Comparator|4|Participants will receive one 50 mg placebo tablet and two 100 mg placebo tablets, once daily for 12 weeks.
89504691|NCT02177591||CAD and MI|Patients with a history of coronary artery disease who have had a myocardial infarction in the past.
89504692|NCT02177591||CAD, no MI|Patients who have a history of coronary artery disease and have not had a myocardial infarction in the past.
89504693|NCT02177591||no CAD|Patients with no documented history of coronary artery disease.
89504694|NCT00548119|Experimental|NeoCart|
89504695|NCT00548119|Active Comparator|microfracture|
89504696|NCT02180321|Active Comparator|Control|
89504697|NCT02180321|Experimental|Tranexamic acid|
89504698|NCT00547651|Experimental|Amrubicin|Amrubicin
89210469|NCT00904800|Experimental|1|Low dose
89210470|NCT00904800|Experimental|2|Middle dose
89210471|NCT00904800|Experimental|3|High dose
89210472|NCT00904800|Placebo Comparator|4|placebo
89210473|NCT00906438|Placebo Comparator|Control|
89210474|NCT00906438|Experimental|Treated|
89210475|NCT00819494|Sham Comparator|Healthy controls|
89504699|NCT00547651|Active Comparator|Topotecan|Topotecan
89504700|NCT02665455|Experimental|Intervention|FreeStyle Libre Flash Glucose Monitoring System
89504701|NCT03537911|Experimental|Cognitive Support Program|Three individual sessions of supportive psychoeducation, mindfulness practice, and strategy training (e.g., strategies to improve memory or concentration), with practice applying program content between sessions.
89504702|NCT02177669||Normals without ocular disease|
89504703|NCT05479461|Experimental|Mobile Health Technology|
89504704|NCT05479461|Active Comparator|Usual Care|
89504705|NCT02386215|Experimental|HIV Self-test|Following a baseline interview, participants in the intervention group will be shown how to correctly use the self-tests and given two HIV self-tests. Subsequently, we will contact participants periodically over a 3 month period to see if they have used the test(s) with their sexual partners and conduct a follow-up interview.
89504706|NCT02386215|No Intervention|Control|Following the baseline interview, participants in the control group will be given referral vouchers for themselves and their partners to obtain HIV testing at Voluntary Counseling & Testing (VCT) centers. We will contact the participants at the end of 3 months to see if they and/or their partner(s) have sought HIV testing.
89504707|NCT00546793|Experimental|veltuzumab|veltuzumab is a humanized CD20 antibody administered subcutaneously in this study.
89504708|NCT02385981|Experimental|Stivax|an intermittent stimulation of afferent vagus nerve at earlap
89504709|NCT02390661|No Intervention|No drain|Control group
89504710|NCT02390661|Experimental|Penrose drain placement|Placement of a penrose drain after irradiation catheter is removed
89504711|NCT04470583||Mild/moderate COVID-19 affected pregnant and postnatal women|Pregnant and postnatal women who contracted COVID-19 and recovered without the need for ventilation will be classified as mild to moderate. Participants will be aged between 18-50 years old.
89504712|NCT04470583||Severe/Critical COVID-19 affected pregnant and postnatal women|"Pregnant and postnatal women who are admitted to hospital after contracting COVID-19 and received ventilatory support before recovering will be classified as severe to critical. Participants will be aged between 18-50 years old.~These participants will be identified from Intensive Treatment Unit (ITU), and standard COVID-19 wards."
89210476|NCT00819494|Active Comparator|Patients with immediate reactions|
89210477|NCT02550626||Delirium|occurrence of post-operative delirium
89210478|NCT02550626||No delirium|no presence of post-operative delirium
89210479|NCT00603798|Active Comparator|3.75% imiquimod cream|
89504713|NCT04470583||Mild/moderate COVID-19 affected non-pregnant participants|Both male and non-pregnant female participants who contracted COVID-19 and recovered without the need for ventilation will be classified as mild to moderate. Participants will be aged between 18-60 years old.
89504714|NCT04470583||Severe/Critical COVID-19 affected non-pregnant participants|Both male and non-pregnant female participants who are admitted to hospital after contracting COVID-19 and received ventilatory support before recovering will be classified as severe to critical. Participants will be aged between 18-60 years old. These participants will be identified from Intensive Treatment Unit (ITU), and standard COVID-19 wards.
89504715|NCT05128799||3WP|Patients who had 3WP as part of their end-of-life care
89504716|NCT05128799||Usual Care|Patients who did not have 3WP as part of their end-of-life care
89504717|NCT02402283|Experimental|Test Product|Metronidazole benzoate oral granules
89504718|NCT02402283|Active Comparator|Reference Product|Flagyl 400 mg Tablets
89504719|NCT02184533|Experimental|Treatment (sodium selenite and radiation therapy)|Patients receive sodium selenite PO 2 hours before daily radiation therapy treatments. Treatment continues for the duration of the course of radiation therapy in the absence of disease progression or unacceptable toxicity.
89504720|NCT05141279||1|Stable
89504721|NCT05141279||2|Partial response
89504722|NCT05141279||3|Moderate response
89504723|NCT05141279||4|Excellent response
89504724|NCT05141279||5|Complete response
89504725|NCT04470739|Active Comparator|Infants born to COVID-19 positive mothers|Infants, born to COVID-19 positive mothers, will be evaluated for cardiothymic index in their first chest X-ray.
89504726|NCT04470739|No Intervention|Infants born to COVID-19 negative mothers|Infants, born to COVID-19 negative mothers, will be evaluated for cardiothymic index in their first chest X-ray.
89504727|NCT02402205|Experimental|Web Implementation of TF-CBT|"Web implementation (W)provides only web-based (distance learning) training and consultation to mental health therapists providing TF-CBT treatment to adjudicated youth in RTF. Therapists access the initial 10 hour training course(www.musc.edu/tfcbt) and follow-up consultation (www.musc.edu/tfcbtconsult) at their own convenience and as needed during the course of the study, with RTF administrators guaranteeing that therapists have time to do so. This implementation strategy is free and more convenient to therapists and administrators as it can be accessed whenever desired."
89504728|NCT02402205|Experimental|Web + Live Implementation of TF-CBT|"Web + Live (W+L) implementation provides web-based training and consultation as described in W, and also provides 1) face-to-face training and 2) twice monthly phone consultation with an expert TF-CBT trainer. W+L requires greater resource commitment from therapists and administrators and is less convenient, but provides more specific consultation on the therapists' personal TF-CBT treatment cases."
89504729|NCT02386059|Placebo Comparator|PLACEBO Group|Received normal saline
89504730|NCT02386059|Active Comparator|DEXAMETHASONE Group|Received 4 mg Dexamethasone.
89504731|NCT02386059|Active Comparator|ONDANSETRON|Received 4 mg Ondansetron
89504732|NCT02386059|Active Comparator|DEXAMETHASONE + ONDANSETRON|Received 4mg Dexamethasone + 4mg Ondansetron
89504733|NCT02184689|Experimental|Fexinidazole|
89504734|NCT00443287|Placebo Comparator|1|
89504735|NCT00443287|Experimental|2|dose level 1
89504736|NCT00443287|Experimental|3|dose level 2
89504737|NCT00443287|Experimental|4|dose level 3
89504738|NCT00443287|Active Comparator|5|
89504739|NCT02385747|Experimental|women with anbormal bleeding|women with perimenopausal and postmenopausal bleeding who will be evaluated with transvaginal ultrasound, saline sonohysterography,hystroscopy and endometrial currettage
89504740|NCT02962895|Experimental|VAY736 dose 1|VAY736 low
89504741|NCT02962895|Experimental|VAY736 dose 2|VAY736 medium
89504742|NCT02962895|Experimental|VAY736 dose 3|VAY736 high
89504743|NCT02962895|Placebo Comparator|Placebo|Placebo control
89504744|NCT00442039|Experimental|Lithium dosing 1|The starting dose of lithium was 300 mg for patients weighing < 20 kg [no patients were enrolled that weighed less than 20 kg] and 600 mg for patients weighing ≥ 20 kg.
89504745|NCT00442039|Experimental|Lithium dosing 2|"The starting dose of lithium was 900 mg and the dose of lithium was increased weekly by 300 mg to maximum tolerated dose depending upon the patients response and tolerability."
89504746|NCT00442039|Experimental|Lithium dosing 3|"The starting dose of lithium was 900 mg and the lithium dose was increased by 300 mg every 3 days, (no more than twice weekly) to maximum tolerated dose based upon the patients response and tolerability."
89504747|NCT00442039|Placebo Comparator|Placebo|
89504748|NCT04481217|Experimental|Schizophrenia|Patients included will be diagnosed with schizophrenia or schizoaffective disorder, and experience AVH at the time of the inclusion (n= 350). All will be inpatients.
89504749|NCT00546247|Experimental|1|
88956965|NCT02891603|Experimental|Phase 2: Pacritinib with Sirolimus and Tacrolimus|"After standard of care allogenic hematopoietic cell transplantation, Pacritinib will be added to standard treatment with Sirolimus and Tacrolimus (PAC/SIR/TAC).~Patients will take Pacritinib at the MTD: 100 mg Pacritinib will begin taken by mouth twice daily starting the day of the participant's transplant (Day 0) and continuing until 70 days after the transplant..~Sirolimus will be given the day before transplant and continued daily for at least one year.~Tacrolimus will begin 3 days before transplant and will be given for at least 50 days."
88956966|NCT02828358|Experimental|Treatment (azacitidine, combination chemotherapy)|See Detailed Description
89504750|NCT02956265|Experimental|Patients - Suffering from carcinomatous or polymorphous skin|
89504751|NCT02390739|Experimental|Single Arm|All patients will receive a non-myeloablative lymphocyte depleting preparative regimen of cyclophosphamide and fludarabine followed by antithyroglobulin mTCR PBL and aldesleukin.
89504752|NCT02177747|Experimental|Diabet patients|Smartphone ophthalmoscopy followed by traditional slit-lamp dilated ophthalmoscopy
89504753|NCT00544297|Experimental|PEP005 gel administration|0.05% PEP005 Topical Gel administered for two consecutive days to a 25cm2 contiguous AK treatment area on the top of the hand
89504754|NCT02385825|Experimental|Group 1: 10 μg RVEc|10 μg RVEc is to be administered in the lower two-thirds of the deltoid region by intramuscular (IM) injection with a needle and syringe (0.5 mL/dose). There are 4 doses planned for this group: 1 primary dose on Days 0, 28, and 106, and a booster dose on Day 365 (1 year).
89504755|NCT02385825|Experimental|Group 2: 50 μg RVEc|50 μg RVEc is to be administered in the lower two-thirds of the deltoid region by intramuscular (IM) injection with a needle and syringe (0.5 mL/dose). There are 4 doses planned for this group: 1 primary dose on Days 0, 28, and 106, and a booster dose on Day 365 (1 year).
89504756|NCT02385825|Experimental|Group 3: 75 μg RVEc|75 μg RVEc is to be administered in the lower two-thirds of the deltoid region by intramuscular (IM) injection with a needle and syringe (0.5 mL/dose). There are 4 doses planned for this group: 1 primary dose on Days 0, 28, and 106, and a booster dose on Day 365 (1 year).
89504757|NCT02755805|Experimental|CO-OP|Cognitive Orientation to daily Occupational Performance (CO-OP) is a strategy training approach that trains individuals to identify problems in the performance of their daily activities, develop strategies to address these problems, and monitor their own performance in the course of their daily routines. Participants use a workbook to support their application of the strategy training.
89504758|NCT02755805|Placebo Comparator|Attention Control|The attention control intervention controls for the non-specific effects of strategy training. The therapists administer the standardized and dose-matched protocol, using scripted open-ended questions to facilitate participants' reflections on their rehabilitation activities and experiences. Participants complete a daily journal, merely reviewing their rehabilitation activities.
89504759|NCT02286349|Experimental|Real rTMS group|Submitted to 20 minutes of neuropsychological assessment (on average) + 5 blocks of real stimulation intensity of 10 Hz, each block containing 15 series of repetitive transcranial magnetic stimulation with 1 second duration and presenting interval of 10 seconds between sets + 20 minutes of neuropsychological reassessment (on average).
89504760|NCT02286349|Sham Comparator|Sham rTMS group|Submitted to 20 minutes of neuropsychological assessment (on average) + 5 stimulation sham blocks, each block containing 15 series of repetitive transcranial magnetic stimulation with 1 second duration and presenting interval of 10 seconds between sets + 20 minutes of neuropsychological reassessment (on average)
88956967|NCT02779751|Experimental|NSCLC KRAS mt, PD-L1+|Abemaciclib given orally every 12 hours (Q12H) on days 1 to 21 of each 21 day cycle in combination with pembrolizumab given intravenously (IV) on day 1 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
88956968|NCT02779751|Experimental|NSCLC Squamous|Abemaciclib given orally Q12H on days 1 to 21 of each 21 day cycle in combination with pembrolizumab given IV on day 1 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
88956969|NCT02779751|Experimental|HR+, HER2- Metastatic Breast Cancer|Abemaciclib given orally Q12H on days 1 to 21 of each 21 day cycle in combination with pembrolizumab given IV on day 1 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
89210480|NCT00603798|Active Comparator|2.5% imiquimod cream|
89504761|NCT02286349|Experimental|Real tDCS group|Submitted to 20 minutes of neuropsychological assessment (on average) + 10 minutes of real anodal transcranial direct current stimulation with intensity of 1 mA + 20 minutes of neuropsychological reassessment (on average).
89504762|NCT02286349|Sham Comparator|Sham tDCS group|Submitted to 20 minutes of neuropsychological assessment (on average) + 10 minutes of sham transcranial direct current stimulation + 20 minutes of neuropsychological reassessment (on average)
89504763|NCT03169647|Experimental|Intervention|listening-based protocol (type A)
89504764|NCT03169647|Placebo Comparator|Control|listening-based protocol (type B)
89504765|NCT00542035|Experimental|ARRY-371797|
89504766|NCT00542035|Experimental|Placebo, ARRY-371797|
89504767|NCT00542035|Placebo Comparator|Placebo|
89504768|NCT02177825|Experimental|Imatinib Mesylate|Imatinib Mesylate at 110 mg/m2 up to 440mg/m2 PO per day for twelve months taken in one morning dose (if dose is less than 200 mg/day) or two doses (morning and evening)
89504769|NCT02402049|Active Comparator|1: Natrum muriaticum 30C|Natrum muriaticum 30C
89504770|NCT02402049|Active Comparator|2: Lachesis 30C|Lachesis 30C
89504771|NCT02402049|Active Comparator|3: Sepia 30C|Sepia 30C
89504772|NCT02402049|Active Comparator|4: Nux vomica 30C|Nux vomica 30C
89504773|NCT02402049|Active Comparator|5: Pulsatilla 30C|Pulsatilla 30C
89504774|NCT02402049|Active Comparator|6 Folliculinum 30C|Folliculinum 30C
89504775|NCT02402049|Placebo Comparator|1: Placebo Natrum muriaticum|Placebo Natrum muriaticum
89504776|NCT02402049|Placebo Comparator|2: Placebo Lachesis|Placebo Lachesis
89504777|NCT02402049|Placebo Comparator|3: Placebo Sepia|Placebo Sepia
89504778|NCT02402049|Placebo Comparator|4: Placebo Nux vomica|Placebo Nux vomica
89504779|NCT02402049|Placebo Comparator|5: Placebo pulsatilla|Placebo pulsatilla
89504780|NCT02402049|Placebo Comparator|6: Placebo Folliculinum|Placebo Folliculinum
89504781|NCT00539929|Experimental|E6201 0.005% BID|Participants applied E6201 0.005% cream to a pre-identified marker lesion twice a day (BID) for 8 weeks. Participants applied matching placebo cream to another pre-identified marker lesion at the same treatment regimen.
89210481|NCT00603798|Placebo Comparator|Placebo cream|
89210482|NCT00819572|Experimental|1|DLX105 low dose
89210483|NCT00819572|Experimental|2|DLX105 high dose
89210484|NCT00819572|Placebo Comparator|3|
89504782|NCT00539929|Experimental|E6201 0.01% BID|Participants applied E6201 0.01% cream to a pre-identified marker lesion BID for 8 weeks. Participants applied matching placebo cream to another pre-identified marker lesion at the same treatment regimen.
89504783|NCT00539929|Experimental|E6201 0.03% BID|Participants applied E6201 0.03% cream to a pre-identified marker lesion BID for 8 weeks. Participants applied matching placebo cream to another pre-identified marker lesion at the same treatment regimen.
89504784|NCT00539929|Experimental|E6201 0.03% QD|Participants applied E6201 0.03% cream to a pre-identified marker lesion once a day (QD) for 8 weeks. Participants applied matching placebo cream to another pre-identified marker lesion at the same treatment regimen.
89504785|NCT05141825|Experimental|proton and carbon ion radiotherapy|proton and carbon ion radiotherapy
89504786|NCT02180477|Experimental|UHAC 62 XX TF1 tablet|
89504787|NCT02180477|Experimental|UHAC 62 XX TF2 tablet|
89504788|NCT02180477|Active Comparator|UHAC 62 XX capsule|
89504789|NCT02390817|Active Comparator|Sugammadex|At the wakeup status Sugammadex 2 mg/kg single dose will perform.
89504790|NCT02390817|Placebo Comparator|Neostigmine|At the wakeup status Neostigmine 0,04 mg/kg single dose will perform.
89504791|NCT02177903|Other|Bair PawsPatient Adjustable Warming System|Bair PawsPatient Adjustable Warming System for active pre-warming
89504792|NCT02177903|Other|Passive pre-warming|Passive pre-warming
89504793|NCT02180555||ICU patients|
89504794|NCT00387907|Experimental|Larotaxel + Trastuzumab|
89504795|NCT02184845|Experimental|NobelActive 3.0|
89504796|NCT02282449|Experimental|Power Injectable Port|The subjects randomized to this group will receive the newer, power injectable port.
89504797|NCT02282449|Active Comparator|Non-Power Injectable Port|The subjects randomized to this group will receive the older, non-power injectable port.
89504798|NCT02180633||Fellow Eyes|Patients that suffer from unilateral idiopathic macular hole, and whose fellow eyes don't show any sign of retinal pathology.
89504799|NCT02180633||Controls|Healthy subjects age-matched to the other group, with no visible retinal pathologies.
89504800|NCT02286427|Active Comparator|Standard Dressing|J0 to J42 : once a week, primary dressing with Mepitel®
89504801|NCT02286427|Experimental|Amniotic Membrane|J0 to J42: once a week, Mepitel® and amniotic membrane (one or several depending on the graft size, so that the ulcer was completely covered with MAH). The last amniotic membrane is left in place.
89504802|NCT05125133|Experimental|ITENs + ITWS|Deltamethrin at 3g AI/kg, which corresponds to 144 mg/m², and PBO synergist at 10g/kg which corresponds to 480 mg/m² are coated in ITENs and ITWS nets that will be installed to cover opened eaves and windows. This was manufactured by Moon Netting FZCO, United Arab Emirates.
89504803|NCT05125133|No Intervention|Negative arm|The houses allocated NOT to receive ITENs and ITWS.
89504804|NCT00533377|Experimental|CP-533,536 Dose Level 2|
89504805|NCT00533377|Placebo Comparator|Placebo|
89504806|NCT00533377|Other|Standard of Care|
89504807|NCT00533377|Experimental|CP-533,536 Dose Level 1|
89504808|NCT00533377|Experimental|CP-533,536 Dose Level 3|
89504809|NCT00533377|Experimental|CP-533.536 Dose Level 4|
89504810|NCT02180789|Experimental|Harnalidge® OCAS®|
89504811|NCT02286505|Experimental|Brain Morphometry|Quantitative, automated reading of hippocampal volume from MRI scans, complemented by a general measure of brain atrophy, in addition to standard neuroradiological report.
89504812|NCT02286505|Other|Standard radiological assessment.|Standard neuroradiological report of the structural MRI only.
89504813|NCT00434473|Placebo Comparator|Placebo|
89504814|NCT00434473|Experimental|A-001|
89504815|NCT02286583|No Intervention|Microwave Thermography RTM-01-RES|Microwave thermography with sensitive probe that can detect skin and up to 8 cm microwave radiation deep tissues
89504816|NCT00427219|Experimental|Ozarelix|All participants completing the placebo run in period were randomized to enter the treatment phase of the study and received ozarelix on Day 0 and Day 14.
89504817|NCT00427219|Placebo Comparator|Placebo|All participants completing the placebo run in period were randomized to enter the treatment phase of the study and received placebo Day 0 and Day 14.
89210485|NCT00908622|Experimental|Skeletal myoblasts|Percutaneous autologous myoblast implantation
89210486|NCT00908622|Placebo Comparator|No cells|Percutaneous culture medium without cells implantation
89210487|NCT02538588|Experimental|Nebulizer 1|Nebulization with akita nebulizer
89504818|NCT02282683|Experimental|Prednisone|Prednisone (10 to 20 mg/day, orally) combined with maximum tolerated guideline-directed medical therapy for at least 12 months.
89504819|NCT02282683|No Intervention|Control|Maximum tolerated guideline-directed medical therapy
89504820|NCT02755649|Experimental|Placebo QW + TCS|Participants received one subcutaneous (SC) injection of dupilumab matching placebo once per week (QW) (following two SC injections on day 1) from Week 1 to Week 15. All participants were required to undergo treatment with topical corticosteroids (TCS) using a standardized regimen that continued through the end of the treatment period (Week 16). Starting at week 16, participants could roll over into an open-label extension (OLE) study (R668-AD-1225), if they were considered eligible. Participants who did not enter the OLE study were followed for up to an additional 12 weeks for safety ([Week 28, end of study (EOS) period]).
89504821|NCT02755649|Experimental|Dupilumab 300 mg Q2W + TCS|Participants received one subcutaneous (SC) injection of dupilumab 300 mg every 2 weeks (Q2W) from Week 1 to Week 15 (following a SC loading dose of 600 mg on day 1). During weeks in which dupilumab was not administered, participants received matching placebo. All participants were required to undergo treatment with topical corticosteroids (TCS) using a standardized regimen that continued through the end of the treatment period (Week 16). Starting at week 16, participants could roll over into an open-label extension (OLE) study (R668-AD-1225), if they were considered eligible. Participants who did not enter the OLE study were followed for up to an additional 12 weeks for safety ([Week 28, end of study (EOS) period]).
89504822|NCT02755649|Experimental|Dupilumab 300 mg QW + TCS|Participants received one subcutaneous (SC) injection of dupilumab 300 mg once per week (QW) (following an SC loading dose of 600 mg on day 1) from Week 1 to Week 15. All participants were required to undergo treatment with topical corticosteroids (TCS) using a standardized regimen that continued through the end of the treatment period (Week 16). Starting at week 16, participants could roll over into an open-label extension (OLE) study (R668-AD-1225), if they were considered eligible. Participants who did not enter the OLE study were followed for up to an additional 12 weeks for safety ([Week 28, end of study (EOS) period]).
89504823|NCT02183909|Experimental|Study intervention|
89504824|NCT02286661|Active Comparator|Short Arm Cast|Short arm cast below the elbow
89504825|NCT02286661|Active Comparator|Long Arm Cast|Long arm cast above the elbow
89504826|NCT02282839|Active Comparator|Study group|Oral glutamine 10 g TID (total 30 g/day) one week before radiotherapy till the end of radiotherapy
89504827|NCT02282839|Placebo Comparator|Control group|Placebo (Same ingredients without glutamine) one week before radiotherapy till the end of radiotherapy
89504828|NCT02286739|Sham Comparator|Group A TKA without VERASENSE|will consist of 250 consecutive patients who will undergo primary PCL-retaining or - sacrificing TKA without the use of VERASENSE to guide rotational alignment and balance.
89504829|NCT02286739|Active Comparator|Group B TKA with VERASENSE|will consist of 250 consecutive patients who will undergo primary PCL-retaining or - sacrificing TKA with the use of VERASENSE to guide rotational alignment and balance.
89504830|NCT00421525|Other|Multiple Doses|Multiple Dose levels
89504831|NCT00375193|Experimental|1|Amrubicin 40mg/m<2> IV days 1, 2, 3 of each 21-day cycle until cycle 6 or no longer beneficial.
89504832|NCT02177981|Active Comparator|Remote ischemic preconditioning|A blood pressure cuff will be placed on the left arm and three cycles of 5 min ischemia followed by 5 min reperfusion will be applied.
89504833|NCT02177981|Sham Comparator|Control|The cuff will be placed around the arm but not inflated.
89504834|NCT02284711|Active Comparator|Bipolar|Coagulation during salpingectomy using conventional bipolar electric energy
89504835|NCT02284711|Active Comparator|Ultrasound|Coagulation during salpingectomy using UltraCision HARMONIC ACE® ultrasound energy
89504836|NCT02184923|Experimental|verticality measurements|
89504837|NCT05208385|Other|Standard umbilical trocar incision closure (UC)|standard umbilical trocar incision closure
89504838|NCT05208385|Active Comparator|Video-assisted umbilical trocar incision closure (UCVA))|video-assisted umbilical trocar incision closure
89504839|NCT02185001|Active Comparator|Surgical Treatment Group|Direct Medial Patellofemoral Ligament (MPFL) Repair
89538763|NCT03522701|Experimental|Group CBTI|Behavioral: Cognitive Behavioural Therapy for Insomnia (CBT-I) The intervention will consist of 8 weekly group sessions (90-min, 5-8 adolescents in each group) of CBT-I delivered within a 10-week window. The treatment components in the CBT-I aim to address the behavioural, cognitive and physiological perpetuating factor of insomnia and include: psycho-education about sleep and sleep hygiene, stimulus control, sleep restriction, relaxation training, structured worry time, cognitive restructuring (targeting sleep-related dysfunctional cognitions), and relapse prevention.
89538764|NCT03522701|Active Comparator|Email-delivered CBTI|The email delivered self-guided CBT-I consists of 8 weekly learning sessions. Participants will receive an email embedded with session materials each week.
89538765|NCT03522701|No Intervention|Waiting-list control|Participants will not receive any active treatment.
89538766|NCT04964037||Treatment success group|No intervention
89538767|NCT04964037||Treatment failure group|No intervention
89538768|NCT03255239|Experimental|Preperitoneal mesh repair|Ventral hernia repair using polyester preperitoneal mesh repair
89538769|NCT03255239|Experimental|Retromuscular mesh repair|Ventral hernia repair using polyester retromuscular mesh repair
89538770|NCT03255239|Experimental|Suture repair|Ventral hernia repair using suture repair
89538771|NCT03255161|Experimental|Immediate communication education and support group|
89538772|NCT03255161|No Intervention|Waitlist|
89538773|NCT03261011|Experimental|AK-104|Single-arm
89538774|NCT04954755||RFS|
89538775|NCT04954755||non-RFS|
89538776|NCT03254849|Experimental|empagliflozin 25 mg|Each patient will take 2 tablets each day to ensure double-blind Treatment. Arm 1: 25 mg/d empagliflozin + hydrochlorothiazide placebo
89538777|NCT03254849|Experimental|hydrochlorothiazide 25 mg|Each patient will take 2 tablets each day to ensure double-blind Treatment. Arm 2: 25 mg/d hydrochlorothiazide + empagliflozin placebo
89538778|NCT04954209||Hospital program of resumption|Program of resumption with physical activities in the hospital
89538779|NCT04954209||Non hospital program of resumption|Program of resumption outside hospital with discovery sessions
89538780|NCT02455895|Active Comparator|iLid Cleanser (Avenova)|iLid Cleanser - applied 2 times per day for 10 days
89538781|NCT02455895|Placebo Comparator|iLid Cleanser Vehicle|iLid Cleanser Vehicle - applied 2 times per day for 10 days
89538782|NCT00701051|Active Comparator|Arm 1|Older adults, normal glucose tolerance
89538783|NCT00701051|Experimental|Arm 2|Older adults, impaired glucose tolerance
89206636|NCT00948207|Experimental|My Living Story|"My Living Story elicits a dignity-enhancing life story via a telephone interview, and delivers the edited transcript on the patient's personal miLivingStory social network. miLivingStory also provides a direct link to miStory, a life review education website with links to high quality websites that provide cancer information, databases to do your own research, social support, interactive planning tools, and a page to add their own weblinks.~miLivingStory and miStory are both password protected."
88956970|NCT02779751|Experimental|HR+, HER2- Locally Advanced or Metastatic Breast Cancer|Abemaciclib given orally Q12H on days 1 to 21 of each 21 day cycle in combination with pembrolizumab given IV on day 1 of each 21 day cycle and anastrozole given orally Q24H on days 1 to 21 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
89504840|NCT02185001|Active Comparator|Conservative Treatment Group|Immobilization, stabilization bracing, and physical therapy
89504841|NCT02256371|Experimental|Hypnotic analgesia|"Hypnosis sessions:~Hypnosis will consist of 45 minutes hypnosis session with a trained hypnotherapist"
89504842|NCT02256371|Experimental|Relaxation|"Relaxation group:~Relaxation will be conducted in 45 minutes sessions with a trained psychotherapist."
89504843|NCT02256371|No Intervention|Routine care|The patients will receive their usual pain treatments throughout the study
89504844|NCT00151411|Experimental|Metformin|Metformin
89504845|NCT00151411|Placebo Comparator|Placebo|Placebo
89504846|NCT02185079|Active Comparator|Group C|Conventional training for epidural catheter placement as per department protocols will be given to the trainees in this arm. Access to epidural simulator for 2 days will be given.
89504847|NCT02185079|Experimental|Group M|Conventional training for epidural catheter placement as per department protocols will be given to the trainees in this arm as well.Trainees in this arm in addition will be subjected to training to proficiency based on the metrics developed for labor epidural catheter placement in a epidural simulator.
89504848|NCT02256449||BVS patients|Use of bioresorbable coronary device, according to the indications of use, in daily clinical practice, in patients undergoing PCI in de novo coronary artery lesions.
89504849|NCT04471441|Experimental|CertiroBell Tablet|De novo liver transplant recipients will be randomized after liver transplant operation.
89504850|NCT04471441|Active Comparator|Mycophenolate mofetil Tablet/Capsule|De novo liver transplant recipients will be randomized after liver transplant operation.
89504851|NCT05141045|Experimental|omega-3 PUFA supplement|omega-3 PUFA supplement, 3.0 grams per day
89504852|NCT05141045|Placebo Comparator|placebo|safflower oil, 3.0 grams per day
89504853|NCT02662569|Active Comparator|Atorvastatin (Q2W)|Participants received placebo subcutaneous injection once every 2 weeks (Q2W) and 20 mg atorvastatin orally once a day for up to 12 weeks.
89206637|NCT00948207|Active Comparator|My Own Resources|"My Own Resources offers usual care access to high quality websites that provide cancer information, databases to do your own research, social support, and interactive planning tools. Participants will receive access to the website miOwnResources."
89504854|NCT02662569|Active Comparator|Atorvastatin (QM)|Participants received placebo subcutaneous injection once a month (QM) and 20 mg atorvastatin orally once a day for up to 12 weeks.
89504855|NCT02662569|Experimental|Evolocumab Q2W + Atorvastatin|Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and 20 mg atorvastatin orally once a day for up to 12 weeks.
89504856|NCT02662569|Experimental|Evolocumab QM + Atorvastatin|Participants received 420 mg evolocumab by subcutaneous injection once a month and 20 mg atorvastatin orally once a day for up to 12 weeks.
89504857|NCT00374413|Experimental|Kineflex-C|
88956971|NCT02769975||Case Only|Children ages 3 months to 100 with known or suspected endocrine or metabolism disorders. Family members ages 3 months to 100. They may participate in the DNA part of the study
88956974|NCT02735746||High fidelity functional lung imaging|High fidelity functional lung imaging (HFFLI) is an improved method of measuring pulmonary function by analyzing 3-Dimensional (3D) motion. Using this technique, we are able to detect and localize pathological changes in the lung with sub-segmental resolution. The approach uses a unique cross-correlation analysis and non-linear optimization to reconstruct lung tissue motion from a small number of standard projections. All participants will undergo standard 4D Computed Tomography (CT), standard Cone Beam CT, research Low-dose Cinefluorography, and additional research Pulmonary Function Tests.
88956975|NCT02734394|Experimental|Cardiovascular and strength training exercise|24 sessions (~12 weeks) exercise
88956976|NCT02722382|No Intervention|Usual Nephrology Care|Nephrology care at Geisinger Health System.
88956977|NCT02722382|Active Comparator|Patient-Centered Kidney Transitions Care|Health system intervention which will implement informatics tools (including a disease registry, predictive modeling, and advance directives) and a disease specific care manager who will provide services and navigate patients through kidney disease transitions.
89206638|NCT00957411|Active Comparator|Arm I|Patients receive cisplatin IV over 1 hour once weekly during weeks 1-6. Patients also undergo pelvic radiotherapy 5 days a week during weeks 2-5 or 2-6.
89210488|NCT02538588|Active Comparator|Nebulizer 2|Nebulization with eFlow nebulizer
89504858|NCT00374413|Active Comparator|ACDF|
89504859|NCT02185157|Experimental|Experimental: Dual Task exercises|Dual-task training, includes 18 sessions model of cognitive and 12 motor dual-task exercises model, were administered in groups of four participants in a comfortable environment, without distraction effects. The 50-minute sessions included 30 minutes of motor dual-task exercises, and then, the participants were divided into pairs. The first pair performed free walks during 10 minutes at their maximal speeds, while the other received individual cognitive dual-task training for the same time, and these activities will be exchanged, so that all pairs could walk and receive cognitive training.
89504860|NCT02185157|Other|Control intervention: Aerobic training|The same doses of aerobic training, i.e., 50 minutes, was delivered in groups of five participants. Each session will include 10 minutes of warm-up, 30 minutes of aerobic training on an ergometric bicycle at 60 to 80% of the participants' maximum heart rates,and 10 minutes of cool-down exercises.
89504861|NCT02178137|Active Comparator|Glucosamine/Chondroitin|"Glucosamine/Chondroitin twice a day for a daily total dose of 1500 mg of Glucosamine and 1200 mg of Chondroitin.~Tablets will have 750 mg Glucosamine Sulphate and 600 mg of Chondroitin Sulphate. These will be taken twice a day after breakfast and dinner."
89504862|NCT02178137|Active Comparator|Diacerien|Diacerien 50 mg twice a day in capsule form. To be taken twice a day after breakfast and dinner
89504863|NCT02178137|Placebo Comparator|Placebo pill|Placebo tablets with Zinc sulfate twice a day. These will contain pharamacologically non active ingredients (Usually expedients).
89504864|NCT02284789|Other|CAJAS evaluation|
89504865|NCT02180945||Intracranial Dural Arteriovenous Fistula|Adult patients requiring endovascular treatment of Intracranial Dural Arteriovenous Fistulae.
89504866|NCT02185313|Experimental|gaze holding|
89504867|NCT02741635|Experimental|New Nasal Pillows Mask|Participants to use nasal pillows mask one night in lab overnight polysomnography.
89504868|NCT02185391|Experimental|fact-finding group|Intervention: Audience Response System and motivational telephone interview
89504869|NCT02185391|No Intervention|control group|
89504870|NCT02286817|Experimental|Single arm of 30 subjects|Subjects will be administered single dose of NFC-1 to assess safety, tolerability, and pharmacokinetics, then proceed to continuous, daily administration of NFC-1 for 4 weeks to assess safety, tolerability, and impact on ADHD severity.
89504871|NCT02181023|Experimental|Aclidinium - Glycopyrronium|Patients will assume Aclidinium Bromide 322 dry powder by Genuair inhaler and Glycopyrronium 44 dry powder inhaler by Breezehaler inhaler (placebo) after 72 hours from inhalatory therapy washout (only short acting bronchodilators permitted). Then, after 72 hours of inhalatory drugs washout (only short acting bronchodilators permitted), they will receive Glycopyrronium Bromide 322 mcg via Breezehaler inhaler and Aclidinium Bromide 322 dry powder by Genuair inhaler (placebo).
89504872|NCT02181023|Experimental|Glycopyrronium - Aclidinium|Patients will assume Glycopyrronium Bromide 44 mcg dry powder by Breezehaler inhaler and Aclidinium Bromide 322 dry powder by Genuair inhaler (placebo) after 72 hours of inhalatory therapy washout (only short acting bronchodilators permitted). Then, after 72 hours of inhalatory drugs washout (only short acting bronchodilators permitted) they will receive Aclidinium Bromide 322 mcg via Genuair inhaler and Glycopyrronium Bromide 44 mcg dry powder by Breezehaler inhaler (placebo).
89504873|NCT02282995||•FDR-Relatives of FD patients|"Relatives of FD patients. Patients may bring at most two FDRs to participate in this study.~Up to 20 ml of fasting blood sample will be collected~Serology test of Hp status will be performed for healthy volunteers and all FDRs"
89504874|NCT02282995||•FDC-Healthy control|"Healthy control. Controls who are self-referred to this study will be recruited.~Up to 20 ml of fasting blood sample will be collected~Fasting glucose test will be performed for FD patients~Serology test of Hp status will be performed for healthy volunteers and all FDRs"
89504875|NCT02282995||•FD-Patients with FD|"Patients with FD. Patients referred for OGD in Endoscopy Center, Prince of Wales Hospital, with symptoms suggestive of FGID will be invited to participate in this study.~Up to 20 ml of fasting blood sample will be collected~Fasting glucose test will be performed for FD patients"
89504876|NCT02282995||•FDCR-Relatives of healthy controls|"Relatives of healthy controls. Each participating control is required to bring at least one and up to two FDRs to participate in this study.~Up to 20 ml of fasting blood sample will be collected~Serology test of Hp status will be performed for healthy volunteers and all FDRs"
88956978|NCT02670291|Active Comparator|active cTBS|Determination of resting motor threshold (RMT); Coil position: temporoparietal cortices halfway between T3/P3 and T4/P4 (EEG 10/20 system); active cTBS (80% of RMT);
88956979|NCT02670291|Sham Comparator|Sham cTBS|Determination of resting motor threshold (RMT); Coil position: temporoparietal cortices halfway between T3/P3 and T4/P4 (EEG 10/20 system); sham cTBS;
89504877|NCT02185469|Active Comparator|pneumatic retinopexy group|First, a 5/8-in 25-gauge needle will be used to perform an anterior chamber paracentesis, aiming to withdraw a minimum of 0.3 ml of aqueous fluid form the anterior chamber. Then, sulfur hexafluoride (SF6) will be injected in the vitreous cavity. The total volume of gas injected will exceed by 0.3 ml the amount of fluid withdrawn by the anterior chamber paracentesis (ex: 0.6 ml of SF6 would be injected after having withdrawn 0.3 ml). The laser retinopexy will be performed 48 hours later with laser.
89504878|NCT02185469|Active Comparator|vitrectomy group|Under certain circumstances, pneumatic retinopexy can't be considered as a primary treatment for rhegmatogenous retinal detachment. In these cases, the patient will be booked for urgent 25 G vitrectomy with intraoperative laser retinopexy and gas injection to treat retinal detachment
89504879|NCT02286973|Active Comparator|Only Intravenous Group|Only Intravenous Injection During Operation, 10mg/kr
89504880|NCT02286973|Active Comparator|Intravenous + Topical 1g Group|"Intravenous Injection During Operation, 10mg/kr~After Capsule Closure, Tranexamic acid Topical Injection 1g"
89504881|NCT02286973|Active Comparator|Intravenous + Topical 2g Group|"Intravenous Injection During Operation, 10mg/kr~After Capsule Closure, Tranexamic acid Topical Injection 2g"
89504882|NCT02286973|Active Comparator|No Intravenous, Only Topical 2g Group|Only Topical Injection 2g
89504883|NCT02283073||Idiopathic Parkinson's disease|Patient with clinical diagnosis of Idiopathic Parkinson's Disease according to Queen Square Brain Bank Criteria up to one year prior to enrollment in study.
89504884|NCT02283073||Differential Diagnosis Group|MSA, PSP, CBD, Lewy body dementia, Essential Tremor, and Healthy Controls
89504885|NCT02181101|Experimental|AA-BA|FEC-DocGemzar adjuvant chemotherapy; zoledronic acid i.v. 5 years
89504886|NCT02181101|Experimental|AB-BA|FEC-Doc adjuvant chemotherapy; zoledronic acid i.v. 5 years
89504887|NCT02181101|Experimental|AA-BB|FEC-DocGemzar adjuvant chemotherapy; zoledronic acid i.v. 2 years
89504888|NCT02181101|Active Comparator|AB-BB|FEC-Doc adjuvant chemotherapy; zoledronic acid i.v. 2 years
89504889|NCT02390349|Experimental|CuraMed (BCM-95)|67 patients, treatment with CuraMed (BCM-95), one capsule (500 mg) orally, three times daily for 12 weeks
89504890|NCT02390349|Experimental|Curamin|67 patients, treatment with Curamin, one capsule (500 mg) orally, three times daily for 12 weeks
89504891|NCT02390349|Placebo Comparator|Placebo|67 patients, treatment with placebo, one capsule (500 mg) orally, three times daily for 12 weeks
89504892|NCT00413725|Experimental|1|Three doses of MRKAd5 HIV-1 gag/pol/nef vaccine
89504893|NCT00413725|Placebo Comparator|2|Placebo
89504894|NCT03536351|Experimental|Interdisciplinary process drama|Process drama program (3 days/week, 12 weeks, 1-1.5 hours per session) of movement-based activities combining music and drama. Activities have been planned by a collaborative team of drama teachers, occupational therapists, and speech language pathologists, and target understanding emotion, intentions and appropriate social interactions.
89023750|NCT04814992|Active Comparator|Computer-Assisted Preoperative CBT Intervention|"Patients will receive the computer-assisted preoperative CBT intervention (n=75). A particularly promising internet-based CBT pain program for the population of interest, PAINTrainer, demonstrated improved pain, function, coping and global health in patients with chronic knee arthritic pain in comparison to an internet education control, with benefits persisting for up to 52 weeks. In addition to the PAINTrainer, there will be an integration of a motivational interviewing (MI) intervention delivered by a trained coach across the sessions about (1) the benefits of opioid tapering for post-operative pain control, (2) approaches for safely tapering, (3) identifying and managing withdrawal symptoms patients may experience."
89504895|NCT02287051||colonoscopy population|
89504896|NCT02383095|Experimental|Art-therapy|16 Art-therapy sessions
89504897|NCT02383095|Active Comparator|Metacognitive therapy|16 Metacognitive therapy sessions
89504898|NCT02185703|Experimental|Chordate System S020 in treatment mode|
89504899|NCT02185703|Sham Comparator|Chordate System S020 in placebo mode|
89504900|NCT02385903|Other|Standard dressing procedure|One arm receive standard dressing procedure according to the wound
89504901|NCT02385903|Active Comparator|Flammacerium|"Necrosis covering with Flammacerium 3 mm thick each day during one week then one day on two.~On each dressing, remove excess and add flammacerium. Not to remove crust forming until eliminating furrow appears.~Cover Flammacerium by compress."
89504902|NCT02181179|Active Comparator|Yoga|This will involve participating in at least two 60-minute Vinyasa yoga sessions each week for eight weeks (weeks 1-8). This will begin the week following a baseline laboratory appointment. These sessions will be conducted at a local Austin studio that has numerous locations in the area.
89504903|NCT02181179|No Intervention|Waitlist|If randomized to this group, participants will complete weekly assessments only and not yoga during their time in the study. Following full completion of the study (i.e., after week 10), participants will be compensated with a voucher for 2 free months of yoga.
89504904|NCT02284945|Experimental|Posterior percutaneous instrumentations|
89504905|NCT02284945|Other|Traditional open surgery with pedicle screw fixation|
89504906|NCT02390271|Experimental|emotion focused therapy training CCT|The general training includes in an individual adjusted way the following techniques: biofeedback-assisted breathing classes that erase negative emotion involving the cardiac and limbic neural pathways, control one's own and other's emotions, mastering positive cognition and enhance self-concept, anchoring positive memories, learning how to recognize psychological reversal in others
89504907|NCT02256683|Experimental|Dabigatran|Dabigatran etexilate (Pradaxa®) 150 mg capsule by mouth twice daly for 3 up to 6 weeks depending on treatment response
89504908|NCT02256683|Active Comparator|Phenprocoumon|Phenprocoumon (Marcumar®) 3 mg capsule by mouth according to INR (2-3) for 3 up to 6 weeks depending on treatment response
89504909|NCT00411385|Experimental|1|900 mcg alb-IFN every 2 weeks (12 doses) + Ribavirin 800 micrograms per day
89504910|NCT00411385|Experimental|2|1200 mcg alb-IFN every 2 weeks (12 doses) + Ribavirin 800 micrograms per day
89504911|NCT00411385|Active Comparator|3|180 mcg PEG-IFNx2a every 1 week (24 doses)+ Ribavirin 800 micrograms per day
89504912|NCT02390193|Experimental|Hemodialysis|Chronic kidney disease patients undergoing hemodialysis will be recruited consecutively and screened for eligibility using a standardised protocol.
89504913|NCT03536273|Experimental|Functional Movement Screen|
89504914|NCT03536273|Experimental|Posture Analysis|
89504915|NCT03536273|Experimental|Depression Level|
89504916|NCT03536273|Experimental|Quality of Life|
89504917|NCT02385513|Active Comparator|6 + 10 weeks of age PCV10 priming|10 valent pneumococcal conjugate vaccine administered (PCV10) at 6 and 10 weeks of age with a booster at9 months of age and routine vaccines administered as per the Nepal EPI schedule
89504918|NCT02385513|Active Comparator|6 + 14 weeks of age PCV10 priming|10 valent pneumococcal conjugate vaccine administered (PCV10) at 6 and 14 weeks of age with a booster at 9 months of age and routine vaccines administered as per the Nepal EPI schedule
89504919|NCT02185547|Experimental|ICBT in combination with sertraline treatment|Internet cognitive behavioral therapy in combination with sertraline treatment
89504920|NCT02185547|Active Comparator|ICBT|Only Internet cognitive behavioral treatment, no additional depression treatment
89504921|NCT02382861|Experimental|NAVA group|Management of the difficult weaning from mechanical ventilation by the NAVA.
89504922|NCT02382861|Active Comparator|Control group|Conventional management of the difficult weaning from mechanical ventilation, with the pressure ventilation.
89504923|NCT02385591|Experimental|Telephone Support|Participants will receive bi-weekly 20 minute telephone calls from a trained professional facilitator offering physical activity advice with the goal of increasing moderate-to-vigorous intensity physical activity.
89504924|NCT02385591|Experimental|SMS Support|Participants will receive weekly text messages (3-5 text messages per week) offering physical activity advice with the aim of increasing moderate-to-vigorous intensity physical activity.
89504925|NCT02385591|Active Comparator|Attention-control|Participants will receive telephone-based general nutrition advice.
89504926|NCT02030483|Experimental|All Subjects|Palbociclib (PD 0332991) will be given at a prespecified dose by cohort orally on days 1-14 of a 28-day cycle. For cycle 1 only, PD 0332991 will start on Day 0. Lenalidomide (Revlimid®) will be given at a prespecified dose by cohort orally on days 8-21 of a 28-day cycle (or days 1-21 as defined by dose cohort level). Dexamethasone (Decadron®) will be given orally at a dose of 20 mg on days 1, 8, 15, and 22 of a 28-day cycle. For cycle 1 only, the dexamethasone will be omitted on Day 1.
89504927|NCT00528697|Experimental|1|Lowest ABT-089 dose
89504928|NCT00528697|Experimental|2|Low-medium ABT-089 dose
89504929|NCT00528697|Experimental|3|Medium-high ABT-089 dose
89504930|NCT00528697|Experimental|4|Highest ABT-089 dose
89504931|NCT00528697|Active Comparator|5|atomoxetine
89504932|NCT00528697|Placebo Comparator|6|placebo
89504933|NCT02385435|Active Comparator|Bupivacaine|single shot caudal plain bupivacaine at a dose of 2mg/kg is used as a reference control drug.
89504934|NCT02385435|Active Comparator|dexmedetomidine 1μg.kg-1|Single shot Caudal dexmedetomidine 1μg.kg-1 used as the second arm intervention
89504935|NCT02385435|Active Comparator|dexmedetomidine 2μg.kg-1|Single shot Caudal dexmedetomidine 2 μg.kg-1 used as the second arm intervention
89504936|NCT00526045|Experimental|Escalation|
89504937|NCT00526045|Experimental|HER2 Positive|
89504938|NCT00526045|Experimental|ER+ breast cancer|
89504939|NCT02287207|Active Comparator|Anodal tDCS|20 minutes, 1.0 mA unilateral-anodal motor cortex (M1) tDCS stimulation
89504940|NCT02287207|Sham Comparator|Sham tDCS|20 minutes, sham tDCS stimulation
89504941|NCT02382783|Other|FLARE Intervention Group|"In the FLARE Intervention Group, we ask that you participate in all of the following, over the course of two years:~Baseline Study Visit~Monthly: Complete FLARE Questionnaires, at home, and report results. The last question on this questionnaire will ask you if you feel you are having a flare of your disease.~FLARE Study Visit (if applicable): We will schedule you to be seen when/if you feel you are having a flare of your disease.~Follow-up Visits (minimum of every 6 months): These are done as the standard of care for your RA.~At one time-point, during your first return visit after the baseline visit you will have an examination by ultrasound~Patient Satisfaction Surveys at three time-points: Baseline, 1 year, 2 year~Also, your rheumatology health care provider (RHCP) will be asked to participate in the study by completing three satisfaction surveys over the course of two years."
89504942|NCT02382783|No Intervention|Standard of Care (SOC) Group|"If you are randomized to the SOC Group, your care will not be any different than your usual care of rheumatoid arthritis (RA). You will be seen by a rheumatologist at a minimum of every six months, which is the standard of care for RA.~Additionally (for research), we ask the following of you...~At one time-point, during your first return visit after the baseline visit you will have an examination by ultrasound~Patient Satisfaction Surveys at three time-points: Baseline, 1 year, 2 year~Also, your rheumatology health care provider (RHCP) will be asked to participate in the study by completing three satisfaction surveys over the course of two years."
89504943|NCT02753075|Experimental|Experimental Oral Rinse 1|Brushing with fluoride toothpaste for 1 minute followed by rinsing with 10 ml of Experimental Oral Rinse 1 for 1 minute. This regimen will be performed twice daily for 8 weeks.
89504944|NCT02753075|Experimental|Experimental Oral Rinse 2|Brushing with fluoride toothpaste for 1 minute followed by rinsing with 10 ml of Experimental Oral Rinse 2 for 1 minute. This regimen will be performed twice daily for 8 weeks.
89504945|NCT02753075|Placebo Comparator|Placebo Oral Rinse|Brushing with fluoride toothpaste for 1 minute followed by rinsing with 10 ml of Placebo Oral Rinse 2 for 1 minute. This regimen will be performed twice daily for 8 weeks.
89504946|NCT03133897|Active Comparator|Prednisone|Prednisone group: Children will receive four doses (days) of prednisone 1 mg/kg/dose once daily (maximum dose 50 mg) following the initial dose of corticosteroid received in the ED under the Nursing Medical Directive or Pre-Printed Order form.
89504947|NCT03133897|Experimental|Dexamethasone|"Dexamethasone group: Children will receive the approximate pharmacologic equivalent of two doses (days) of dexamethasone 0.6 mg/kg/dose (maximum dose 16 mg per dose) once daily as follows. The standard dose of prednisone/prednisolone provided in the emergency department is 2 mg/kg/dose (maximum dose 50 mg), which is approximately equivalent to 0.3 mg/kg/dose of dexamethasone. Therefore, patients who received prednisone/prednisolone in emergency department as per the current Nursing Medical Directive and Pre-Printed Order form will receive a top-up These patients will then receive a dose of dexamethasone 0.6 mg/kg (maximum dose 16 mg) 24 hours after the initial corticosteroid dose received in the Emergency Department of dexamethasone 0.3 mg/kg (maximum dose 8 mg) upon enrollment."
88956980|NCT02665923||Newborn (gastric emptying)|A total of 100 healthy newborns who will be given formula feeding of known volume, and then serial ultrasound imaging of gastric antral volume will be performed until gastric emptying. Follow up of these newborns at two later time intervals will be performed (between ages 4-6 months, and 9-12 months).
89504948|NCT02390115|Active Comparator|Elastic Tape|"Tape placing will consider as the initial anchor the acromioclavicular joint, and as the final one the point immediately below the insertion of the deltoid muscle. Two centimeters anchor will be considered for all the participants, and the active zone will be equivalent to the distance between two anchors. The first tape will be placed to the anterior portion of the deltoid with the shoulder at 30° passive extension. The second tape will be placed to the middle portion of the deltoid with the shoulder at 30° of passive horizontal adduction. For placing the third tape to the posterior deltoid, the limb will be positioned at 90° of passive flexion of the shoulder. The elastic tape tension will be placed as previously described as paper tension and it is equivalent to 10-15% of the total elastic tape tension."
88956981|NCT02665923||Infants (4-6mons)|50 Patients will undergowill be given formula feeding of known volume, and then serial ultrasound imaging of gastric antral volume will be performed until gastric emptying.
88956982|NCT02665923||Infants (9-12 months)|50 Patients will undergowill be given formula feeding of known volume, and then serial ultrasound imaging of gastric antral volume will be performed until gastric emptying.
88956983|NCT02649790|Experimental|Part A1: RRMM- KPT-8602 single agent; QoDx5/week|Participants received KPT-8602 once daily for 5 days per week (QDx5/week) at escalated doses (completed).
88956984|NCT02649790|Experimental|Part A2: RRMM- KPT-8602 single agent; QoDx3/week|Participants received KPT-8602 once daily for 3 days per week (QoDx3/week). The starting dose for Part A2 will be informed by Part A1 (completed).
89504949|NCT02390115|Sham Comparator|Sham|The sham elastic tape will be placed using the same tape to the paretic shoulder. However, the rigid tape will be placed without tension with the upper limb supporting at 90 degree elbow flexion, 0 degrees abduction and adduction of the shoulder.
88956985|NCT02649790|Experimental|Part B: RRMM- KPT-8602 with low-dose dexamethasone; QDx5/week|Participants received KPT-8602 for 5 consecutive days (QDx5/week) in combination with low dose dexamethasone (20 milligram [mg] on Days 1, 3, 8, 10, 15, 17, 22, and 24 of each 28-day cycle) (completed).
88956986|NCT02649790|Experimental|Part C: CRC- KPT-8602 single agent|Participants were treated with KPT-8602 at a dose and schedule that has been cleared in Part A (completed).
88956987|NCT02649790|Experimental|Part D: mCRPC- KPT-8602 single agent|Participants were treated with KPT-8602 at a dose and schedule that has been cleared in Part A (completed).
88956988|NCT02649790|Experimental|Part E: mCRPC- KPT-8602 with abiraterone and corticosteroids|Participants were treated with KPT-8602 at a dose and schedule that had been cleared in Part A in combination with abiraterone and corticosteroids. Participants continued to receive the dose and schedule of abiraterone and corticosteroids that they were receiving at the time of enrollment (completed).
88956989|NCT02649790|Experimental|Part F: High-risk Myelodysplastic Syndrome (MDS)- KPT-8602 single agent|Participants were treated with KPT-8602 at a dose and schedule that had been cleared in Part A. In select cases (for example, participants achieving stable disease [SD], hematological improvement [HI], partial response [PR] and tolerating treatment, etc.), the dose may be escalated 1 level based on safety and efficacy considerations (completed).
89206639|NCT00957411|Experimental|Arm II|Patients receive cisplatin and undergo radiotherapy as in arm I. Patients also receive cetuximab IV over 1 hour once weekly during weeks 1-6.
89206640|NCT00837954|Active Comparator|1|distal Anastomosis Lyostypt®, proximal Anastomosis Surgicel®
89206641|NCT00837954|Active Comparator|2|distal Anastomosis Surgicel®, proximal Anastomosis Lyostypt®
89206642|NCT00837954|Active Comparator|3|distal and proximal Anastomosis Lyostypt®
89206643|NCT00837954|Active Comparator|4|distal and proximal Anastomosis Surgicel®
89206644|NCT00948285|Experimental|MRI|Preoperative staging with mammogram, ultrasound, and MRI, followed by surgery (n=200)
89206645|NCT00948285|No Intervention|Non-MRI|Preoperative staging with mammogram and ultrasound alone, followed by surgery (n=200)
89206646|NCT00954525|Experimental|Intravenous Vitamin C|
89206647|NCT00833274|Experimental|1|Using a computerized test, each patient is asked to press a button (mouse of the computer) each time the screen of the computer becomes completely white.
89206648|NCT00833352|Experimental|1|Right ventricular lead located in Mid Septum
89206649|NCT00833352|Active Comparator|2|Right ventricular lead located in Apex
89206650|NCT00838032|Experimental|Quetiapine fumarate|Quetiapine fumarate should be initiated on Day 1 and titrated to at least 600 mg/day before Day 7 according to clinical experience and prescribe information. After Day 7, the dose of quetiapine fumarate should be adjusted between 600 mg/day to 750 mg/day at the discretion of the investigator.
89206651|NCT00838032|Active Comparator|Haloperidol|Haloperidol should be initiated with the dose range from 5 mg/day to 15 mg/day from Day 1 to Day 5 (using injection) according to the clinical experience and prescribe information. After Day 7, the dose of haloperidol should be adjusted between 8 mg/day to 20 mg/day (change from injection to oral formulation between Day 6 to Day 7) at the discretion of the investigator.
89206652|NCT00954603|Experimental|quetiapine|atypical antipsychotic drug
89206653|NCT00954603|Active Comparator|haloperidol|typical antipsychotic drug
89206654|NCT00531934|Experimental|1|
89206655|NCT00531934|Active Comparator|2|
89206656|NCT02548806|Experimental|Clonidine MBT 50µg|Each subject will receive the following treatments in random order over 3 Treatment Periods (1 treatment/period): Clonidine MBT 50µg single dose, Clonidine MBT 100μg single dose ,a single-dose of reference catapres 100μg tablets.
89206657|NCT02548806|Experimental|Clonidine MBT 100µg|Each subject will receive the following treatments in random order over 3 Treatment Periods (1 treatment/period): Clonidine MBT 50μg single dose, Clonidine MBT 100µg single dose ,a single-dose of reference catapres 100μg tablets..
89206658|NCT02548806|Active Comparator|Catapres 100μg|Each subject will receive the following treatments in random order over 3 Treatment Periods (1 treatment/period): Clonidine MBT 50μg single dose, Clonidine MBT 100μg single dose ,a single-dose of reference catapres 100μg tablets.
89206659|NCT00828828||Sarcoidosis|Sarcoidosis patients who are assigned to receive influenza vaccine
89206660|NCT00828828||Healthy Controls|Healthy controls who are assigned to receive influenza vaccine
89206661|NCT00833508|Experimental|Test arm|Patients undergoing preoperative chemoradiotherapy will have their exercise capacity measured before and after chemoradiotherapy.
89206662|NCT00549939|Placebo Comparator|Placebo|Matching placebo 0.1 mg/kg/day or 0.2 mg/kg/day
89206663|NCT00549939|Experimental|Alfuzosin 0.1 mg/kg/day|
89206664|NCT00549939|Experimental|Alfuzosin 0.2 mg/kg/day|
89206665|NCT00838188||1|computer-generated random numbers in sealed opaque envelopes to assign the breast/bottle sequence
89206666|NCT00838188||2|computer-generated random numbers in sealed opaque envelopes to assign the breast/bottle sequence
89206667|NCT00838188||Breast - feeding first|computer-generated random numbers in sealed opaque envelopes to assign the breast/bottle sequence
89504950|NCT05443425|Experimental|Treatment of aGVHD (steroid therapy, leflunomide)|Patients receive steroid therapy at the discretion of the treating physician. Beginning within 3 days of starting steroids, patients receive leflunomide PO QD on days 1-28 in the absence of disease progression or unacceptable toxicity. Patients who respond to leflunomide treatment will be tapered off from day 29 until day 56.
88956990|NCT02649790|Experimental|Part F Phase 2: RR High-risk MDS- KPT-8602 single agent|Participants will be enrolled at recommended Phase 2 doses (RP2D) of 10 mg daily on Days 1 to 5 of each week, in a dose expansion, based upon the results from the Phase 1 portion of Part F.
88956991|NCT02649790|Experimental|Part G: Newly Diagnosed Intermediate/High-Risk MDS -KPT-8602 with ASTX727|Participants will receive KPT-8602 once daily at escalated doses. The starting dose for KPT-8602 is 5 mg orally once daily from Day 8 to Day 28 (Weeks 2 to 4) on a 28-day cycle in combination with ASTX727.
89206668|NCT00838188||Bottle first|computer-generated random numbers in sealed opaque envelopes to assign the breast/bottle sequence
89206669|NCT00838188||Way of feeding|Each infant is evaluated twice, once after breastfeeding and once after bottle feeding of breast milk using a Premature Nipple & Ring (Ross Products Division, Columbus OH, USA). In this way, each infant serves as its own control. REE is recorded for 20 minutes after each meal
89206670|NCT00833742|Experimental|1|ISTDP therapy was provided
89206671|NCT00833742|No Intervention|2|People referred but never seen
89206672|NCT00833820|Active Comparator|A|Patients receiving real rTMS
89504951|NCT00370981|Experimental|0.15 mg|
89504952|NCT00370981|Experimental|0.30 mg|
89206673|NCT00833820|Sham Comparator|B|patients receiving sham stimulation
89504953|NCT00370981|Experimental|0.60 mg|
89504954|NCT00370981|Placebo Comparator|PBO|
89504955|NCT03536975|Other|Platform|"Group with access to the web platform CAREGIVERSPRO-MMD"
89504956|NCT03536975|No Intervention|Control|Group without any access to the web platform
89504957|NCT02385357|Placebo Comparator|Control|330 ml of commercial protein-enriched drink (2.5 g/100 ml of protein)
89504958|NCT02385357|Experimental|Experimental|330 ml of protein-enriched drink (6 g/100 ml of protein)
89504959|NCT03134053|Experimental|extracorporeal shock-wave|
89504960|NCT03134053|Sham Comparator|massage|
89504961|NCT02185625|Experimental|Safe Delivery smartphone application|
89504962|NCT02185625|No Intervention|Control|
89504963|NCT02190149||ADVATE (Factor VIII)|Participants will remain on their current (pre-study) treatment regimen of ADVATE throughout the study period
88956992|NCT02649790|Experimental|Part H: AML Maintenance Therapy- KPT-8602 single agent|Participants with high-risk acute myeloid leukemia (AML) prior to transplant will be enrolled to receive maintenance therapy with KPT-8602 post-allogeneic stem cell transplantation. The dose for KPT-8602 will be 10 mg (RP2D from Part F) oral, to be administered once daily from Day 1 to Day 21 (Weeks 1 to 3) on a 28-day cycle.
88956993|NCT02637687|Experimental|Phase 1 dose escalation|"Patients will receive the different levels of dose on Day 1 (BID in accordance with the cohort assignment). Each cycle will consist of 28 days of continuous dosing.~Individual patients will continue daily larotrectinib dosing until PD, unacceptable toxicity, or other reason for treatment discontinuation. (arm closed)"
88956994|NCT02637687|Experimental|Phase 1 dose expansion|"Patients who are enrolled in the expansion cohort, following the formal dose escalation phase of the study.~Distinct from the Phase 1 dose escalation cohort, the Phase 1 expansion cohort will enroll pediatric patients with advanced solid or primary CNS tumors with a documented NTRK gene fusion, or in the case of IFS, CMN or SBC with documented ETV6 rearrangement by FISH or RT-PCR or a documented NTRK fusion by NGS.~This expansion cohort will follow the same schedule of assessments as the dose escalation cohorts. (arm closed)"
89504964|NCT02190149||RIXUBIS (Factor IX)|Participants will remain on their current (pre-study) treatment regimen of RIXUBIS throughout the study period
89504965|NCT00366145|Active Comparator|Prochymal®|Participants who receive standard of care plus treatment with ex vivo cultured adult human mesenchymal stem cells.
89504966|NCT00366145|Placebo Comparator|Placebo|Participants who receive standard of care and do not receive treatment with ex vivo cultured adult human mesenchymal stem cells.
89504967|NCT02190227|Other|Tumor RDA biopsy|Tumor RDA score measured from an FNA biopsy after cycle 1-2-3 of neoadjuvant chemotherapy and after first cycle of second chemotherapy agent if palpable tumour present.
89504968|NCT02382471|Placebo Comparator|CVD, Placebo|patients with cardiovascular disease who receive 4 cap of placebo/day
89504969|NCT02382471|Active Comparator|CVD, Omega-3|patients with Cardiovascular disease who receive 4g/d omega-3
89504970|NCT02185859|Experimental|Perioperative lidocaine infusion|
89504971|NCT02185859|Experimental|Perioperative magnesium infusion|
89504972|NCT02185859|Active Comparator|Noraml saline infusion|
89504973|NCT02332720|Experimental|A1: GT3 NC TN Grazoprevir+Uprifosbuvir+Elbasvir (8 weeks)|In Part A, HCV GT3-infected NC TN participants will take grazoprevir (100 mg) + uprifosbuvir (300 mg) + elbasvir (50 mg) q.d. by mouth for 8 weeks. Part A participants who relapsed following completion of therapy were offered the option of retreatment with 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. and RBV (weight-based dosing) b.i.d. by mouth for 16 weeks during Part C.
89504974|NCT02332720|Experimental|A2: GT3 NC TN Grazoprevir+Uprifosbuvir+Ruzasvir (8 weeks)|In Part A, HCV GT3-infected NC TN participants will take grazoprevir (100 mg) + uprifosbuvir (300 mg) + ruzasvir (60 mg) q.d. by mouth for 8 weeks. Part A participants who relapsed following completion of therapy were offered the option of retreatment with 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. and RBV (weight-based dosing) b.i.d. by mouth for 16 weeks during Part C.
89504975|NCT02332720|Experimental|A3: GT3 NC TN Grazoprevir+Uprifosbuvir+Elbasvir (8 weeks)|In Part A, HCV GT3-infected NC TN participants will take grazoprevir (100 mg) + uprifosbuvir (450 mg) + elbasvir (50 mg) q.d. by mouth for 8 weeks. Part A participants who relapsed following completion of therapy were offered the option of retreatment with 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. and RBV (weight-based dosing) b.i.d. by mouth for 16 weeks during Part C.
89504976|NCT02332720|Experimental|A4/B4: GT3 NC TN Grazoprevir+Uprifosbuvir+Ruzasvir (8 weeks)|Participants will be randomized to either Part A or Part B. In Part A, HCV GT3-infected NC TN participants will take grazoprevir (100 mg) + uprifosbuvir (450 mg) + ruzasvir (60 mg) q.d. by mouth for 8 weeks. In Part B, HCV GT3-infected NC TN participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. by mouth for 8 weeks. Part A participants who relapsed following completion of therapy were offered the option of retreatment with 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. and RBV (weight-based dosing) b.i.d. by mouth for 16 weeks during Part C.
89504977|NCT02332720|Experimental|B5: GT3 NC TN MK-3682B + RBV (8 weeks)|In Part B, HCV GT3-infected NC TN participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d., and RBV (weight-based dosing) b.i.d., by mouth for 8 weeks.
89504978|NCT02332720|Experimental|B6: GT3 NC TN MK-3682B (12 weeks)|In Part B, HCV GT3-infected NC TN participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. by mouth for 12 weeks.
89504979|NCT02332720|Experimental|B7: GT3 NC TN MK-3682B + RBV (12 weeks)|In Part B, HCV GT3-infected NC TN participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d., and RBV (weight-based dosing) b.i.d., by mouth for 12 weeks.
89504980|NCT02332720|Experimental|B8: GT3 NC TE MK-3682B (8 weeks)|In Part B, HCV GT3-infected NC TE participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. by mouth for 8 weeks.
89504981|NCT02332720|Experimental|B9: GT3 NC TE MK-3682B + RBV (8 weeks)|In Part B, HCV GT3-infected NC TE participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d., and RBV (weight-based dosing) b.i.d., by mouth for 8 weeks.
89504982|NCT02332720|Experimental|B10: GT3 NC TE MK-3682B (12 weeks)|In Part B, HCV GT3-infected NC TE participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. by mouth for 12 weeks.
89504983|NCT02332720|Experimental|B11: GT3 NC TE MK-3682B + RBV (12 weeks)|In Part B, HCV GT3-infected NC TE participants will take 2 MK-3682 FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d., and RBV (weight-based dosing) b.i.d., by mouth for 12 weeks.
89504984|NCT02332720|Experimental|B12: GT3 NC TE MK-3682B (16 weeks)|In Part B, HCV GT3-infected NC TE participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. by mouth for 16 weeks.
89504985|NCT02332720|Experimental|B13: GT3 C TN MK-3682B (12 weeks)|In Part B, HCV GT3-infected C TN participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. by mouth for 12 weeks.
89206674|NCT00272779|Active Comparator|Atazanavir (ATV) + Ritonovir (RTV)|Participants were administered an oral dose of ATV 300 mg and RTV 100 mg once daily along with food on a background of fixed dose combination TDF 300 mg plus FTC 200 mg (TDF/FTC) once daily. Doses of ATV and RTV were taken 24 hours apart at the same time as the background TDF/FTC, up to 96 Weeks.
89206675|NCT00272779|Active Comparator|Lopinavir (LPV) + RTV|Participants were administered an oral dose of LPV 400 mg and RTV 100 mg once daily along with food on a background of fixed dose combination TDF 300 mg plus FTC 200 mg (TDF/FTC) once daily. Doses of LPV and RTV were taken 24 hours apart at the same time as the background TDF/FTC, up to 96 Weeks.
89504986|NCT02332720|Experimental|B14: GT3 C TN MK-3682B + RBV (12 weeks)|In Part B, HCV GT3-infected C TN participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d., and RBV (weight-based dosing) b.i.d., by mouth for 12 weeks.
89504987|NCT02332720|Experimental|B15: GT3 C TN MK-3682B (16 weeks)|In Part B, HCV GT3-infected C TN participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. by mouth for 16 weeks.
89504988|NCT02332720|Experimental|B16: GT3 C TE MK-3682B (12 weeks)|In Part B, HCV GT3-infected C TE participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. by mouth for 12 weeks.
89504989|NCT02332720|Experimental|B17: GT3 C TE MK-3682B + RBV (12 weeks)|In Part B, HCV GT3-infected C TE participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d., and RBV (weight-based dosing) b.i.d., by mouth for 12 weeks.
89504990|NCT02332720|Experimental|B18: GT3 C TE MK-3682B (16 weeks)|In Part B, HCV GT3-infected C TE participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. by mouth for 16 weeks.
89504991|NCT02332720|Experimental|B19: GT3 C TE MK-3682B + RBV (16 weeks)|In Part B, HCV GT3-infected C TE participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d., and RBV (weight-based dosing) b.i.d., by mouth for 16 weeks.
89504992|NCT02332720|Experimental|B20: GT4 NC TN MK-3682B (8 weeks)|In Part B, HCV GT4-infected NC TN participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. by mouth for 8 weeks.
89504993|NCT02332720|Experimental|B21: GT5 NC TN MK-3682B (12 weeks)|In Part B, HCV GT5-infected NC TN participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. by mouth for 12 weeks.
89504994|NCT02332720|Experimental|B22: GT6 NC TN MK-3682B (12 weeks)|In Part B, HCV GT6-infected NC TN participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. by mouth for 12 weeks.
89504995|NCT02283151|Other|energy-restricted diet|The control group was given an energy-restricted diet (ER diet). Energy-restricted diet was designed in the traditional Chinese style with an initial target for a total energy intake of 1200 kcal/d (5021 kJ/d). Supplementation of multivitamins and minerals was provided per day.
89538784|NCT04963335|Experimental|Intervention|Participants perform 16 exergame training (video game-based physical exercise) sessions over a period of 4 to 8 weeks (depending on in-patient or out-patient). Each training lasts between 15 to 25 minutes. Exergames automatically adjust the game difficulty to the abilities of the respective participant.
89538785|NCT04963335|No Intervention|Control|Participants of the control group are instructed to continue their normal daily routine for eight weeks and to record their physical activities.
89206676|NCT04011423|Experimental|Unstable shoes|Wearing unstable shoes during the whole-body vibration training
89206677|NCT04011423|Active Comparator|Stable shoes|Wearing stable shoes during the whole-body vibration training
89206678|NCT00828906|Experimental|1|DuoTrav
89206679|NCT00948363|Active Comparator|Kiwi fruits|
89538786|NCT03260543|Experimental|fermented ginseng powder|tablets (2 tablets/day, 125 mg & 500 mg/day) for 12 weeks.
89206680|NCT00948363|Placebo Comparator|Apple|
89206681|NCT00829062|No Intervention|Glucose sensor|Children who have assented to wear a 72 hour physician ordered continuous glucose monitor.
89504996|NCT02283151|Experimental|diet nutrition bar|The experimental group was given individual instructions on how to follow the VLCD (very low carbohydrate diet). Energy intake was restricted to less than 800kcal/day (3349kJ/d) (carbohydrate intake < 20g/d). Carbohydrate-rich foods, such as white rice, steamed bread and tubers, were substituted with fish, poultry and plant oil. All daily meals were replaced as follows: a cup of soybean milk (200 mL) and a boiled egg at breakfast; a diet nutrition bar (106 Kcal: 2.8 g carbohydrate, 11.2 g protein and 5.6 g fat; Nutriease Health Technology Co., Ltd., Hangzhou, China), nonstarchy vegetables (<200 kcal), and 50 g protein from meat (i.e., beef, lean pork, skinned chicken, fish) at lunch and dinner. Supplementation of multivitamins and minerals was provided per day.
89504997|NCT02382315|Experimental|Intervention Group|Fear of Cancer Recurrence Intervention.
89504998|NCT02382315|No Intervention|Wait-list Control Group|Patients assigned to this arm will be asked to wait 6 weeks before being offered the fear of cancer recurrence intervention.
88956995|NCT02637687|Experimental|Phase 2: Patients with tumors bearing NTRK fusions (IFS)_Cohort 1|"Patients will receive larotrectinib dose on Day 1 (BID in accordance with the cohort assignment) at the recommended Phase 2 dose as determined in the Phase 1 portion of this study. Each cycle will consist of 28 days of continuous dosing.~Individual patients will continue daily larotrectinib dosing until PD, unacceptable toxicity, or other reason for treatment discontinuation. (arm closed)"
88956996|NCT02637687|Experimental|Phase 2: Other extra-cranial solid tumors_Cohort 2|"Patients will receive larotrectinib dose on Day 1 (BID in accordance with the cohort assignment) at the recommended Phase 2 dose as determined in the Phase 1 portion of this study. Each cycle will consist of 28 days of continuous dosing.~Individual patients will continue daily larotrectinib dosing until PD, unacceptable toxicity, or other reason for treatment discontinuation. (arm closed)"
88956997|NCT02637687|Experimental|Phase 2: Primary CNS tumors_Cohort 3|"Patients will receive larotrectinib dose on Day 1 (BID in accordance with the cohort assignment) at the recommended Phase 2 dose as determined in the Phase 1 portion of this study. Each cycle will consist of 28 days of continuous dosing.~Individual patients will continue daily larotrectinib dosing until PD, unacceptable toxicity, or other reason for treatment discontinuation."
88956998|NCT02637687|Experimental|Phase 2: Bone health assessment_sub-cohort|"Patients will receive larotrectinib dose on Day 1 (BID in accordance with the cohort assignment) at the recommended Phase 2 dose as determined in the Phase 1 portion of this study. Each cycle will consist of 28 days of continuous dosing.~Individual patients will continue daily larotrectinib dosing until PD, unacceptable toxicity, or other reason for treatment discontinuation.~Patients in this group will undergo bone health assessments in addition to all other efficacy and safety assessments."
88956999|NCT02619448|Experimental|Chemotherapy with hypofractionated RT|Carboplatin AUC 2 + Paclitaxel 50 mg/m2 given weekly x 4 concurrently with radiation therapy (70 Gy in 20 fractions) over 4 weeks
89504999|NCT05089175||Women at high risk for preeclampsia|Using FIGO recommended preeclampsia screening model for the first-trimester which combined maternal risk factors, mean arterial pressure, placental growth factor, uterine artery pulsatility index to evaluate pregnant's risk for preeclampsia. Risk value≥1/100 is defined as screened high risk.
89505000|NCT05089175||Women at low risk for preeclampsia|Using FIGO recommended preeclampsia screening model for the first-trimester which combined maternal risk factors, mean arterial pressure, placental growth factor, uterine artery pulsatility index to evaluate pregnant's risk for preeclampsia. Risk value<1/100 is defined as screened low risk.
89505001|NCT02181335|Experimental|Respimat ® Budesonide low dose + Turbohaler® Placebo|
89505002|NCT02181335|Experimental|Respimat ® Budesonide high dose + Turbohaler® Placebo|
89505003|NCT02181335|Active Comparator|Turbohaler® Budesonide + Respimat Placebo®|
89505004|NCT04945317|Other|ROSE arm|Presence of trained cytotechnologist providing on-site cytopathology feedback to bronchoscopist
89505005|NCT04945317|Other|NO-ROSE arm|Absence of trained cytotechnologist providing on-site cytopathology feedback to bronchoscopist
89505006|NCT02185937|No Intervention|water|imatinib intake with water
89505007|NCT02185937|Active Comparator|cola|imatinib intake with cola
89505008|NCT00517153|Experimental|1|OGT-918 - Zavesca (miglustat)
88957000|NCT02595957||Cascade Testing|Family members of individuals who have received secondary genomic findings after exome/genome sequencing
88957001|NCT02595957||Secondary findings recipients|Individuals who have received secondary genomic findings after exome/genome sequencing
88957002|NCT02589522|Experimental|Group I (VX-970, whole-brain radiation therapy)|Patients undergo whole-brain radiation therapy QD 5 days a week for 15 fractions. Patients also receive berzosertib IV over 60-90 minutes twice a week, 18-30 hours after first radiation therapy. Treatment continues for 3 weeks in the absence of disease progression or unacceptable toxicity.
89505009|NCT00517153|No Intervention|2|Standard treatment
89505010|NCT02384811|Experimental|Radiation group|Radiation therapy
89538787|NCT03260543|Placebo Comparator|Placebo|Placebo for 12 weeks.
89538788|NCT04432155|Experimental|NBTX-001|Combination Product: NBTX-001 Xenon Inhaler The NBTX-001 medical gas consists of 30% xenon, 30% oxygen, and 40% nitrogen. The dose of medical gas is 10 L by volume.
89206682|NCT01838512||Cohort 1|Participants with relapsed/refractory multiple myeloma (RRMM) followed up for up to 5 years
89206683|NCT01838512||Cohort 2|Participants with newly-diagnosed multiple myeloma (NDMM) followed up for up to 8 years
89206684|NCT00957879|Active Comparator|ergocalciferol|Weekly ergocalciferol for 12 weeks
89206685|NCT00957879|Active Comparator|calcitriol|Daily calcitriol for 12 weeks
89206686|NCT00838266|Experimental|1|Antiplaque mouthrinse containing active component (Grape Seed Extract + nicométhanol fluorhydrate)
89206687|NCT00838266|Placebo Comparator|2|Antiplaque mouthrinse containing non-active component
89206688|NCT00957957||1|Participants having elective Roux-en-Y gastric bypass surgery (RYGBP)
89206689|NCT00957957||2|Participants having elective gastric banding surgery (GB)
89206690|NCT00834054||Double-lung transplanted patients|
89206691|NCT00838344|No Intervention|Usual care|Usual prescription refill system and pharmacy care.
89206692|NCT00838344|Experimental|Intervention|Telephone follow-up call to individuals with diabetes (Type 2) who have missed a prescription refill by 6 or more days. Call includes assessment of refill need, discussion of diabetes care progress and any medication adherence barriers with intervention to resolve barriers.
89206693|NCT04011033|Experimental|TACE+iNKT for unresectable HCC|TACE combined with autologous iNKT cells infusion will be applied for patients in experimental group. TACE will be performed at 0th and 4th week. 5×10^8-10^9/m2 iNKT cells will be infused to patients at 1st, 3rd, 5th, 7th, 8th and 12th week.
89206694|NCT04011033|Other|TACE for unresectable HCC|TACE will be conducted at 0th week and 4th week.
89505011|NCT02285101|Experimental|Cohort 1|PEG-BCT-100 at 0.5 mg/kg administered as a single dose on day 1 (week 1); if not DLTs are observed, PEG-BCT- 100 will be administered at 0.5 mg/kg on days 22 (week 4) and 29 (week 5). Patients responding to treatment or with stable disease may receive 8 additional weekly administrations of PEG-BCT-100 at 0.5 mg/kg. Beyond week 13, patients responding to treatment or with stable disease may continue to receive weekly PEG-BCT-100 at 0.5 mg/kg until disease progression at the discretion of the investigator.
89505012|NCT02285101|Experimental|Cohort 2|PEG-BCT-100 at 1.0 mg/kg administered as a single dose on day 1 (week 1); if not DLTs are observed, PEG-BCT- 100 will be administered at 1.0 mg/kg on days 22 (week4) and 29 (week 5). Patients responding to treatment or with stable disease may receive 8 additional weekly administrations of PEG-BCT-100 at 1.0 mg/kg. Beyond week 13, patients responding to treatment or with stable disease may continue to receive weekly PEG-BCT-100 at 1.0 mg/kg until disease progression at the discretion of the investigator.
88957003|NCT02589522|Experimental|Group II (VX-970, surgery, whole-brain radiation therapy)|Patients receive berzosertib IV over 60-90 minutes 2-4 hours prior to surgery. After surgery, patients undergo whole-brain radiation therapy and receive berzosertib as in Group I.
88957004|NCT02576431|Experimental|Arm 1_NSCLC|Patients with solid non-small cell lung cancer (NSCLC) harboring NTRK fusions (arm closed)
88957005|NCT02576431|Experimental|Arm 2_Thyroid|Patients with solid thyroid tumors harboring NTRK fusions (arm closed)
88957006|NCT02576431|Experimental|Arm 3_Sarcoma|Patients with soft-tissue sarcoma harboring NTRK fusions (arm closed)
88957007|NCT02576431|Experimental|Arm 4_Colorectal|Patients with solid colorectal tumors harboring NTRK fusions (arm closed)
88957008|NCT02576431|Experimental|Arm 5_Salivary|Patients with solid salivary tumors harboring NTRK fusions (arm closed)
88957009|NCT02576431|Experimental|Arm 6_Biliary|Patients with solid biliary tumors harboring NTRK fusions (arm closed)
88957010|NCT02576431|Experimental|Arm 7_Primary CNS|Patients with solid tumors in the primary central nervous system (CNS) harboring NTRK fusions (arm closed)
88957011|NCT02576431|Experimental|Arm 8_Other tumors|Patients with e.g. kidney cancer, squamous cell cancer of head or neck or ovarian solid tumors harboring NTRK fusions (arm closed)
88957012|NCT02576431|Experimental|Arm 9_Solid tumors without confirmed NTRK fusion|Patients eligible for arms 1 to 8, but with documented NTRK fusion from a laboratory where CLIA or equivalent certification cannot be confirmed by the sponsor at the time of consent (arm closed)
88957013|NCT02576431|Experimental|Arm 10_Prospective cohort|Patients with melanoma, non secretory breast and colorectal cancer or other tumor types harboring NTRK fusions, except soft tissue sarcoma, salivary gland and thyroid cancer (arm closed)
89206695|NCT00829140|Placebo Comparator|Placebo BID|
89206696|NCT00829140|Experimental|Lorcaserin 10mg BID|
89206697|NCT00998608|Experimental|HR|risperidone 2mg/d + haloperidol 2mg/d
89206698|NCT00958113||Autoimmune Thyroid Disease|Patients with Hashimoto's disease or Graves' disease
89206699|NCT00958113||Unaffected Population|Population not known to be affected by Hashimoto's Disease or Graves' Disease
89206700|NCT02547324|Experimental|Slump sitting|Slump sitting flexion of lumbar spine
89206701|NCT02547324|Active Comparator|Forward bending|Forward erect bending of lumbar spine
89206702|NCT04011813||"Control arm, H-"|semen treated without hypotaurine supplementation in density gradient centrifugation, washing and cryopreservation media
89206703|NCT04011813||"Experimental arm, H+"|semen treated with a 50mM hypotaurine supplementation in density gradient centrifugation, washing and cryopreservation media
89206704|NCT00998686|Experimental|dutogliptin/PHX1149T|
89206705|NCT00998686|Active Comparator|sitagliptin|
89206706|NCT00829218|Active Comparator|1 - Glutamate challenge|Glutamate challenge: After the one month glutamate free diet, subjects will receive 5 grams of glutamate for three days on one week and placebo for three days on the next week. Arm 1 is the 5 grams of glutamate which will be given in a mixed juice.
89206707|NCT00829218|Placebo Comparator|2- Placebo|Glutamate challenge: After the one month glutamate free diet, subjects will receive 5 grams of glutamate for three days on one week and placebo for three days on the next week. Arm 2 is the placebo arm, which will be juice with nothing added.
89206708|NCT00948519|Experimental|Laser + ICG|ICG arm- will be defined as local application on a pledget soaked with ICG with a concentration of 200µg, upon removal of the pledget a NIR diode laser set at 6W with light emittance introduced intranasally with a 30mm diffuser fiber capable of radiating light circumferentially allowing the light energy to reach all treatable areas. Laser will be activated for 180 seconds. Assuming an approximate radius of the nasal cavity is 3mm, energy density will be around 200J/cm². Treatment will be repeated twice, 5-7 day apart. Cultures will be collected at the end of all treatments
89505013|NCT02285101|Experimental|Cohort 3|PEG-BCT-100 at 1.7 mg/kg administered as a single dose on day 1 (week 1); if not DLTs are observed, PEG-BCT- 100 will be administered at 1.7 mg/kg on days 22 (week 4) and 29 (week 5). Patients responding to treatment or with stable disease may receive 8 additional weekly administrations of PEG-BCT-100 at 1.7 mg/kg. Beyond week 13, patients responding to treatment or with stable disease may continue to receive weekly PEG-BCT-100 at 1.7 mg/kg until disease progression at the discretion of the investigator.
89505014|NCT02285101|Experimental|Cohort 4|PEG-BCT-100 at 1.7 mg/kg administered as a single dose on day 1 (week 1); if not DLTs are observed, PEG-BCT- 100 will be administered at 2.7 mg/kg on days 22 (week 4) and 29 (week 5). Patients responding to treatment or with stable disease may receive 8 additional weekly administrations of PEG-BCT-100 at 2.7 mg/kg. Beyond week 13, patients responding to treatment or with stable disease may continue to receive weekly PEG-BCT-100 at 2.7 mg/kg until disease progression at the discretion of the investigator.
89505015|NCT02285101|Experimental|Cohort 5|PEG-BCT-100 at 1.7 mg/kg administered as a single dose on day 1 (week 1); if not DLTs are observed, PEG-BCT- 100 will be administered at 4.0 mg/kg on days 22 (week 4) and 29 (week 5). Patients responding to treatment or with stable disease may receive 8 additional weekly administrations of PEG-BCT-100 at 4.0 mg/kg. Beyond week 13, patients responding to treatment or with stable disease may continue to receive weekly PEG-BCT-100 at 4.0 mg/kg until disease progression at the discretion of the investigator.
89505016|NCT02285101|Experimental|Cohort 6|PEG-BCT-100 at a dose to be determined administered as a single dose on day 1 (week 1); if not DLTs are observed, PEG-BCT-100 will be administered at at a dose to be determined on days 22 (week 4) and 29 (week 5). Patients responding to treatment or with stable disease may receive 8 additional weekly administrations of PEG-BCT-100 at at a dose to be determined. Beyond week 13, patients responding to treatment or with stable disease may continue to receive weekly PEG-BCT-100 at at a dose to be determined until disease progression at the discretion of the investigator.
89505017|NCT02382237|Other|PET/TDM|Evaluation by PET/TDM at 2 times
89505018|NCT00359437|Experimental|Satavaptan|
89505019|NCT00359437|Placebo Comparator|Placebo|
89505020|NCT02382393|Experimental|BPT, Computerized Assessment|Participants will first take the Brain Performance Test (BPT) and then a third party validated assessment battery.
89505021|NCT02382393|Experimental|Computerized Assessment, BPT|Participants will take a third party validated assessment battery and then the Brain Performance Test (BPT).
89505022|NCT02190383|Experimental|Habit Reversal Training|At first patients get informed about Tics in general. Then the individual Tics are specified and the tic-reaction is looked at further. The Tic-Symptoms are observed and the premonitory urge is specified. For all individual tics a specific reversal movement is developed. Relaxation methods are introduced.
89206709|NCT00948519|Active Comparator|Laser only|same as above, without ICG
89505023|NCT02331394|Experimental|Chinese herbs formula: Shu Yu Wan|All participants will be offered the choice of taking the CH formula in capsules or sachets in addition to standard care. This study will use the Shu Yu Wan formula which comprises 23 different herbs and is based on the best evidence in the literature of use of CH in lung cancer.
89505024|NCT02283307|Experimental|Reduced contrast DECT scan|Reduced Contrast Dual Energy CT
89505025|NCT02384733|Experimental|Hypofractionated loco-regional RT|40 Gy / 15 fractions, 2.67 Gy per fraction, 5 fractions weekly
89505026|NCT02384733|Active Comparator|Normofractionated loco-regional RT|50 Gy / 25 fractions, 2.00 Gy per fraction, 5 fractions weekly
89505027|NCT02181491|Experimental|P943 PET Scan|
89505028|NCT02287285|Experimental|Exendin9|Longitudinal study of insulin secretion and sensitivity in patients with type 2 diabetes before and after gastric bypass surgery.
89505029|NCT02190461|Experimental|Early Respiratory Rehabilitation|Starting the Early Respiratory Rehabilitation programme during the admission and continues it at home immediately after discharge for a period of 3 months.
89505030|NCT02190461|Active Comparator|Conventional Respiratory Rehabilitation|Started a conventional Respiratory Rehabilitation programme at home one month after discharge from hospital and continues for 3 months.
89505031|NCT04471129|Other|High-Flow Oxygen Therapy, followed by Non-Invasive Ventilation|oxygenation first by High-Flow Oxygen Therapy, then by O2C, then by Non-Invasive Ventilation
89505032|NCT04471129|Other|Non-Invasive Ventilation, followed by High-Flow Oxygen Therapy|oxygenation first by Non-Invasive Ventilation, then by O2C, then by High-Flow Oxygen Therapy
89505033|NCT02186093||Korea|patients in South of Korea
89505034|NCT02186093||United Kingdom|patients in England
89505035|NCT02186093||Spain|patients in Spain
89505036|NCT02186093||United State of America|patients in USA
89505037|NCT02382003|Experimental|Positive Training+Anxious Imagery Prime|Positive Cognitive Bias Modification - Interpretation training paired with a preceding Anxious Imagery Prime
89505038|NCT02382003|Experimental|Positive Training+Neutral Imagery Prime|Positive Cognitive Bias Modification - Interpretation training paired with a preceding Neutral Imagery Prime
89505039|NCT02382003|Active Comparator|50/50 Training+Anxious Imagery Prime|50/50 Cognitive Bias Modification - Interpretation (half positive & half negative scenarios) paired with a preceding Anxious Imagery Prime
89505040|NCT02382003|Active Comparator|50/50 Training+Neutral Imagery Prime|50/50 Cognitive Bias Modification - Interpretation (half positive & half negative scenarios) paired with a preceding Neutral Imagery Prime
89505041|NCT02382003|Other|No Scenario+Anxious Imagery Prime|No scenarios paired with a preceding Anxious Imagery Prime
89505042|NCT02382003|Other|No Scenario+Neutral Imagery Prime|No scenarios paired with a preceding Neutral Imagery Prime
89505043|NCT00401011|Experimental|Phase II: Perifosine + Bortezomib|All patients will start with perifosine at bedtime daily and Bortezomib IV on days 1, 4, 8, and 11 q 21 days. Patients will be evaluated at q 3 weeks. If the patient has a CR, PR, MR or stable disease, they will continue treatment.
89206710|NCT00838422||FD-OCT, ORA, USP|
89206711|NCT00958269|Experimental|dutogliptin (double-blind, placebo-controlled period)|weeks 1-26
89505044|NCT00401011|Experimental|Phase II: Perifosine + Bortezomib + Dexa|If the patient shows progressive disease, dexamethasone 20 mg will be added on days 1, 2, 4, 5, 8, 9, 11, 12, 15, 16, 18, and 19 to perifosine at bedtime and bortezomib IV on days 1, 4, 8, and 11 q 21 days.
89505045|NCT00401011|Experimental|Phase I: Dose 1: Perifosine + Bortezomib|Perifosine 50 mg at bedtime and bortezomib 1 mg/m2 on days 1, 4, 8, and 11 every 3 weeks.
88957014|NCT02576431|Experimental|Arm 11_Bone health cohort|Patients with all tumor types harboring NTRK fusions, not eligible for the main prospective cohort, including patients with non-measurable disease
89505046|NCT00401011|Experimental|Phase I: Dose 2: Perifosine + Bortezomib|Perifosine 100 mg at bedtime and bortezomib 1 mg/m2 on days 1, 4, 8, and 11 every 3 weeks
89505047|NCT00401011|Experimental|Phase I: Dose 3: Perifosine + Bortezomib|Perifosine 50 mg at bedtime and bortezomib 1.3 mg/m2 on days 1, 4, 8, and 11 every 3 weeks
89505048|NCT00401011|Experimental|Phase I: Dose 4: Perifosine + Bortezomib|Perifosine 100 mg at bedtime and bortezomib 1.3 mg/m2 on days 1, 4, 8, and 11 every 3 weeks
89505049|NCT02381769|Experimental|Parenteral Nutrition|Soybean based lipid emulsion
89505050|NCT02287363||TPP group|TPP patients(between episodes of paralysis), the inclusion criteria consisted of a certain history of acute limb muscle weakness, hypokalemia and decreased TSH with elevated free FT4, FT3. Subjects who suffered from hyperthyroid myopathy with long term muscle weakness, family periodic paralysis, renal tubular acidosis, hyperaldosteronism, hemiplegia, paraplegia, or any history of other metabolic or traumatic muscular disease were excluded.
89505051|NCT02287363||hyperthyroidism group|Control group, we included subjects with evidence of aberrant thyroid function (decreased TSH, elevated FT4, FT3) without paralysis. Graves' disease(GD) was preferred which required information concerning either increased thyrotrophin receptor antibody(TRAb) level, ophthalmopathy or diffusively enlarged goiter. Individuals with pure thyroid associated ophthalmopathy, history of thyroidectomy due to malignancy or adenoma as well as subacute thyroiditis and pituitary hyperthyroidism were excluded.
89505052|NCT02382081|Experimental|Patient-initiated shared care|"Patient-initiated shared care hospital reviews in which there were one planed hospital review every year and if needed additional reviews initiated by the patient.~Access to nurse-run telephone helpline with direct access to a contact nurse."
89505053|NCT02382081|No Intervention|Control|Traditional, routine hospital reviews every three-fourth month.
89505054|NCT02190539|Experimental|Homeopathic treatment|A feasibility study examining whether patients with advanced breast cancer would follow a homeopathic protocol for three to six months.
89505055|NCT02389491|Active Comparator|normal density formula (Neocate)|In control group,infants intake normal density formula (Neocate,67kcal/100ml) when starting enteral nutrition after operation and continue for 7days
89505056|NCT02389491|Experimental|high density formula (Infatrini)|In the intervention group,infants intake high density formula (Infatrini, 100kcal/100ml) when starting enteral nutrition after operation and continue for 7days
89505057|NCT00397345|Experimental|Trovax|
89505058|NCT00397345|Placebo Comparator|Placebo|
89505059|NCT02181647|Experimental|Intervention|Safe Touches Personal Safety Training for Children
89505060|NCT02181647|Other|Comparison|Received Safe Touches after week-1 assessment completed (delayed intervention).
89505061|NCT01645930|Experimental|Ixazomib+Lenalidomide+Dexamethasone|Ixazomib 4 mg, capsules, orally, once on Days 1, 8, and 15; lenalidomide 25 mg, capsules, orally, once on Days 1 through 21; and dexamethasone 40 mg, tablets, orally, once on Days 1, 8, 15, and 22 of a 28-day treatment cycle until progressive disease (PD) or unacceptable toxicity (up to 20 cycles)
89505062|NCT02389413|Experimental|PQ912 oral|PQ912 will be administered orally twice daily for 12 weeks.
89505063|NCT02389413|Placebo Comparator|Placebo|Placebo will be administered orally twice daily for 12 weeks.
89505064|NCT02190617|Active Comparator|Enhanced Clinic+ Unified Management Plan|"Patients in study arm will receive:~Enhanced Clinic Intervention~Enhanced Health Plan~Unified Management Plan"
89505065|NCT02190617|Active Comparator|CHW Home Visit Only|"Patients in study arm will receive:~CHW Home Visit~Usual clinic care with enhanced health plan"
89505066|NCT02190617|Active Comparator|Enhanced Clinic+ Unified Plan+ CHW|"Patients in study arm will receive:~CHW Home Visit~Enhanced Clinic intervention~Enhanced health plan~Unified asthma management plan"
89505067|NCT02190617|No Intervention|Usual Care|-Usual clinic care with enhanced healthplan
89206712|NCT00958269|Experimental|dutogliptin (single-blind, active-controlled period)|weeks 27-52
89505068|NCT02389569|Experimental|Adhesive system treatment|Four groups ( Two will be treat with Etch-and-Rinse Adhesive System and two will be treated with two step Self-Etch Adhesive System).
89505069|NCT02389569|Experimental|Restoration protocol|Four groups ( Two will be treat with experimental Biosilicate and two will be the control groups).
89505070|NCT02181725|Experimental|Multimodal Rehabilitation Program|Multimodal Rehabilitation Program, consisting of a Graded Exposure Module (GE), a Combination Module (HMGE) and a Parent Module (PM)
89505071|NCT02181725|Active Comparator|Care as Usual|Care as usual is the care currently provided to adolescents with musculoskeletal chronic pain and is based on the principles of Graded Activity.
89505072|NCT02190695|Active Comparator|Decitabine|Decitabine 20mg/m2 IV over 1hour daily times 5 days every 28 days
89505073|NCT02190695|Experimental|Decitabine and Carboplatin|Decitabine 20mg/m2 IV over 1hour daily times 5 days, plus Carboplatin AUC 5 IV over 1hour on day 8. repeat every 28 days.
89505074|NCT02190695|Experimental|Decitabine and Arsenic|Decitabine 20mg/m2 IV over 1 hour daily for 5 days plus Arsenic Trioxide 0.15mg/kg IV daily for 5 days. repeat every 28 days
89505075|NCT00514267|Experimental|1. HRPC|
89505076|NCT00514267|Experimental|2. Solid Tumors|
88957015|NCT02511002||1|Post influenza infection
88957016|NCT02500381|Experimental|SRP-4045|Participants amenable to exon 45 skipping will receive SRP-4045 IV infusions, weekly, at 30 mg/kg for up to 96 weeks in the double-blinded period. This will be followed by an open-label extension period in which all participants will receive open-label active treatment of SRP-4045 at 30 mg/kg/week IV infusions for 48 weeks (up to Week 144 in the study).
89206713|NCT00958269|Placebo Comparator|placebo (double-blind, placebo-controlled period)|weeks 1-26
89206714|NCT00958269|Placebo Comparator|placebo (single-blind, active-controlled period)|weeks 27-52
89206715|NCT00958269|Active Comparator|sitagliptin (single-blind, active-controlled period)|weeks 27-52
88957017|NCT02500381|Experimental|SRP-4053|Participants amenable to exon 53 skipping will receive SRP-4053 IV infusions, weekly, at 30 mg/kg for up to 96 weeks in the double-blinded period. This will be followed by an open-label extension period in which all participants will receive open-label active treatment of SRP-4053 at 30 mg/kg/week IV infusions for 48 weeks (up to Week 144 in the study).
89206716|NCT02547402|Experimental|CXA-10|CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitrated oleic acid
89505077|NCT02384967|Experimental|Darunavir 400mg/d|Tri-therapy containing Darunavir at dose of 400 mg/d.
89505078|NCT02287441|Placebo Comparator|Raw Group|Vegetables Prepared Raw (raw)
89505079|NCT02287441|Experimental|Tomato Group|Tomato Products (tomato)
89505080|NCT02190773||Chronic periodontitis|Surgical periodontal treatment and GCF collection 3 months after treatment
89505081|NCT02190773||Agressive periodontitis|Surgical periodontal treatment and GCF collection 3 months after treatment.
89505082|NCT02190773||Control group|Periodontally healthy individuals
89505083|NCT02389335||Group 1a|Patients with type 1 diabetes who have undetectable c-peptide ( ≤0.1 ng/mL) levels after mixed meal tolarance test: group 1a
89505084|NCT02389335||Group 1b|Patients with type 1 diabetes who have c-peptide levels between 0.1-0.8 ng/mL after mixed meal tolerance test: group 1b
89505085|NCT02389335||Group 1c|Patients with type 1 diabetes who have c-peptide levels ≥0.8ng/mL after mixed meal tolerance test: group 1c
89505086|NCT02389335||Control|Healthy subjects
89505087|NCT02287519|Experimental|Support Group|"One group educational session will include information on resources, self-help strategies, and relaxation techniques.~One telephone coaching session after the group session Or~Pilot webinar format of the educational session"
89505088|NCT00511459|Experimental|A|Paclitaxel 90 mg/m² IV QW (3 on/1 off) + bevacizumab 10 mg/kg IV Q2W + AMG 386 10 mg/kg IV QW
89505089|NCT00511459|Experimental|D|Paclitaxel 90 mg/m² IV QW (3 on/1 off) + Open Label AMG 386 10 mg/kg IV QW
89505090|NCT00511459|Experimental|B|Paclitaxel 90 mg/m² IV QW (3 on/1 off) + bevacizumab 10 mg/kg IV Q2W + AMG 386 3 mg/kg IV QW
89505091|NCT00511459|Active Comparator|C|Paclitaxel 90 mg/m² IV QW (3 on/1 off) + bevacizumab 10 mg/kg IV Q2W + AMG 386 placebo IV QW
89505092|NCT02381847|No Intervention|without HIPEC|Patients will be treated with a D2 radical gastrectomy for advanced gastric cancer and postoperative chemotherapy (SOX or XELOX).
89505093|NCT02381847|Experimental|with HIPEC|"Patients will be treated with a D2 radical gastrectomy for advanced gastric cancer and intraperitoneal chemoperfusion with cisplatin and postoperative chemotherapy as described for the control group.~Cisplatin: 75mg/m2 (max 150mg/m2 max 5L )"
89505094|NCT02384889|Experimental|Difluoromethylornithine|Subjects may be given daily dose of DFMO
89505095|NCT02384889|Placebo Comparator|Placebo|Subjects may be given daily dose of placebo
89505096|NCT02186327|No Intervention|Standard care|The control arm will continue to receive standard care as they did prior to enrollment.
89505097|NCT02186327|Experimental|Integrative health coaching|Subjects in this arm will receive 6 sessions of integrative health coaching over a 3 month period, in addition to standard care.
89505098|NCT02381691|Experimental|maternal breast milk odor|"In the first group breast milk, venipuncture was performed to the neonate while his mother's milk odor was being diffused."
89505099|NCT02381691|Placebo Comparator|no odor|In a second control group, venipuncture was performed to the neonate with an odorless diffusor.
89505100|NCT02256527||Promus Premier|observational data
89505101|NCT00510133|Experimental|GRNVAC1|Autologous dendritic cell vaccine
89505102|NCT02389647||Endovascular group|Subjects undergoing elective endovascular catheterization for coiling of unruptured cerebral aneurysms. Four blood draws of 5mL each: (1) prior to initiation of procedure; (2) at the time of catheterization of major cerebral vessels, (3) immediately after the procedure, and (4) 24-hours after the procedure.
89505103|NCT02389647||Ischemic stroke group|Subjects who present to the emergency department with ischemic infarcts of <6 hours. Four blood draws of 5mL each: (1) at time of enrollment but prior to tPA, (2) 6 hours post-tPA, (3) 12 hours post-tPA, and (4) 24 hours post-tPA.
89505104|NCT02389647||Intracranial hemorrhage|Subjects who present to the emergency department with intracranial hemorrhage. One 5mL blood draw within 24 hours of onset.
89505105|NCT02186405|Experimental|LEVOTHYROXINE|administration of levothyroxine
89505106|NCT02299336|Other|PRN (pro re nata)|2 mg intravitreal aflibercept (Eylea) PRN, focal laser administered based on pre-specified criteria, 104 weeks
89505107|NCT02384655|Experimental|Fenugreek|Mothers will take fenugreek for 14 days
89505108|NCT00395317|Placebo Comparator|Arm 1|placebo (4 tablets)
89505109|NCT00395317|Experimental|Arm 2|SB-683699 150 mg bid (1 x 150mg + 3 placebo tablets)
89505110|NCT00395317|Experimental|Arm 3|SB-683699 600 mg bid (2 x 300mg + 2 placebo tablets)
89505111|NCT00395317|Experimental|Arm 4|SB-683699 900 mg bid (3 x 300 mg + 1 placebo tablet)
89505112|NCT00395317|Experimental|Arm 5|SB-683699 1200 mg bid, male subjects only (4 x 300 mg tablets)
89505113|NCT02186483|Experimental|Metformin|Metformin and Rosuvastatin: Volunteers will be taken Metformin-Rosuvastatin-Co-administration
89505114|NCT02186483|Experimental|Rosuvastatin|Metformin and Rosuvastatin: Volunteers will be taken Rosuvastatin-Co-administration-Metformin
89505115|NCT02186483|Experimental|Co-administration|Metformin and Rosuvastatin: Volunteers will be taken Co-administration-Metformin-Rosuvastatin
89505116|NCT02381613|Active Comparator|Baked beef|A meal based on baked beef
89505117|NCT02381613|Experimental|Baked herring|A meal based on baked herring
89505118|NCT02381613|Experimental|Pickled herring|A meal based on pickled herring
89505119|NCT02190851|Experimental|electrical nerve stimulation (TENS)|"Two electrodes are attached around the internal malleolus and connected to the TENS unit, by UROSTIM 2.~The sessions last 20 minutes daily (frequency 10Hz, duration 200µs), at maximum intensity of painless stimulation, every day at the same time, on the right side for 3 months."
89505120|NCT02190851|Placebo Comparator|Control group|The device will have been previously set to deliver a stimulation below the effective threshold. In all cases, the device displays 20mA. Stimulation sessions are 20 minutes daily, every day at the same time, on the right side for 3 months.
89538789|NCT04432155|Placebo Comparator|Placebo|Combination Product: Placebo The placebo medical gas consists of 30% oxygen and 70% nitrogen. The dose of placebo medical gas is 10 L by volume.
89505121|NCT03133819|Other|Q-Sense_QST (TSA II)|"QST measurement will perform on the thenar eminence of the dominant hand and the lateral distal aspect of the foot dorsum of the same side.~Using the method of limits, a threshold will determine as the average of four successive stimuli for cold and warmth sensation and two for heat pain."
89505122|NCT02256995||Pregnant Women (>22 weeks gestation)|Biomarkers tracked over 3 antenatal care visits via standard of care (dipstick, manually/visually assessed) and via uChek (automated assessment via computer application)
89505123|NCT02381301||Venous blood sampling prior to CCTA.|In patients undergoing routine Cardiac Computed Tomography Angiography (CCTA) and given written informed consent blood sampling will be performed. The samples will be stored for a period of 15 years at the Biobank for future analyses.
89505124|NCT02256605||Insufficient Group|D-3 Chewable Wafer - 14,000 IU/wafer weekly Vitamin D-3 Caps - 2,000 IU/Cap daily Vitamin D-3 Liquid - 5,000 IU/ml (0.4) ml daily
89505125|NCT02256605||Deficient Group|D-3 Chewable Wafer - 50,000 IU/wafer weekly Vitamin D-3 Liquid - 5,000 IU/ml daily
89505126|NCT00393991|Experimental|1|FlutiForm 100/10 μg
89505127|NCT00393991|Active Comparator|2|Fluticasone 100 μg
89505128|NCT00393991|Active Comparator|3|Formoterol 10 μg
89505129|NCT00393991|Placebo Comparator|4|Placebo
89505130|NCT02181959|Experimental|Pharmaton® with DMAE|
89505131|NCT02181959|Active Comparator|Pharmaton® without DMAE|
89505132|NCT02181959|Placebo Comparator|Placebo|
89505133|NCT02190929||Vasculitis Contact Registry Patients|Patients will be recruited from within the Vasculitis Clinical Research Consortium (VCRC) Patient Contact Registry to participate in an online questionnaire. More than 3000 patients, representing all the different types of idiopathic vasculitis, are currently enrolled into the on-line registry. The different types of vasculitis available for study include: Behçets disease, Churg-Strauss Syndrome, CNS Vasculitis, Giant Cell Arteritis, granulomatosis with polyangiitis (Wegener's granulomatosis), Henoch-Schöenlein Purpura, Microscopic Polyangiitis, Polyarteritis Nodosa, or Takayasu's Arteritis.
89505134|NCT02664441|Active Comparator|Exenatide once weekly extended-release|Injections of glucagon-like peptide (GLP)-1 agonist exenatide once weekly extended-release (Bydureon®) for 36 weeks in randomized intervention followed by 18 weeks open label exenatide once weekly extended-release.
89505135|NCT02664441|Placebo Comparator|Matching placebo|Weekly injections of placebo for 36 weeks followed by 18 weeks open label exenatide once weekly extended-release.
89505136|NCT02191007|Experimental|Calcipotriol/Betamethasone and Calcipotriol|Calcipotriol/Betamethasone ointment 1/d for 4 weeks; Calcipotriol ointment bid for 6 weeks on-demand treatment period;
89505137|NCT02191007|Sham Comparator|Calcipotriol/Betamethasone and urea cream|alcipotriol/Betamethasone ointment 1/d for 4 weeks , urea cream 1/d for 6 weeks on-demand treatment period
89505138|NCT02191007|Active Comparator|Calcipotriol/Betamethasone|Calcipotriol/Betamethasone ointment 1/d for 4 weeks, Calcipotriol/Betamethasone ointment 1/d for 6 weeks on-demand treatment period
88957018|NCT02500381|Placebo Comparator|Placebo followed by SRP-4045 or SRP-4053|Participants amenable to exon 45 or 53 skipping will receive SRP-4045 or SRP-4053 placebo-matching IV infusions, weekly, at 30 mg/kg for up to 96 weeks in the double-blinded period. This will be followed by an open-label extension period in which all participants will receive open-label active treatment of SRP-4045 or SRP-4053 at 30 mg/kg/week IV infusions for 48 weeks (up to Week 144 in the study).
88957019|NCT02446262|Other|Substudy 1: Instructed subjects|Participants are instructed about outcomes
88957020|NCT02446262|Other|Substudy 1: Uninstructed subjects|Participants learn through experience
88957021|NCT02446262|Other|Substudy 2: heat group|Participants learn about heat outcomes through conditioning
89505139|NCT04470271||Patients under routine hepatitis C care|Patients who are routinely followed at the treating institution. Investigators will evaluate baseline demographic, liver fibrosis stage, liver-related complications, and antiviral therapy.
89505140|NCT04470271||Patients with hepatitis C lost of follow-up|Patients who were lost of follow-up. Participants will be contacted to evaluate if the continued HCV care at another institution, were not routinely followed by a liver-specialist or if they died. Investigators will also evaluate baseline demographic, liver fibrosis stage, liver-related complications, and antiviral therapy.
89505141|NCT02186639||COPD|40 COPD patients (20 non-frequent and 20 frequent-exacerbators). No intervention.
89505142|NCT02186639||Controls|"Subjects with no apparent lung disease and normal lung function testing. Matched for age, gender and smoking history (pack years).~No intervention."
89505143|NCT02182037|Experimental|BIBT 1011 BS|
88957022|NCT02446262|Other|Substudy 2: salt group|Participants learn about salt outcomes through conditioning
88957023|NCT02446262|Other|Substudy 2: sugar group|Participants learn about sugar outcomes through conditioning
88957024|NCT02446262|No Intervention|Substudy 3: healthy volunteers|All participants experience all outcomes, within subjects designs
88957025|NCT02446262|Other|Substudy 4: healthy volunteers|Participants are instructed to attend toward or away from the stimulus
89505144|NCT02182037|Placebo Comparator|BIBT 1011 BS placebo|
89505145|NCT04470193|Experimental|MyChildCMC Intervention Group|Parents/patients randomized into the MyChildCMC Intervention Group will use the MyChildCMC app to monitor their child's daily symptoms for the duration of the study period (3 months). The MyChildCMC app includes a daily form consisting of 12 questions assessing child's vitals, pain, seizures, mood, and feeding as well as caregiver worry for the day. Daily reminders are sent to the parent to fill out the vitals form in the app. Parents/participants will also fill out a quality of life survey at baseline, 1 month, and 3 months as well as a caregiver satisfaction survey at 3 months.
89505146|NCT04470193|No Intervention|Standard of Care Group|Parents/patients randomized into the Standard of Care Group do not use the MyChildCMC app to monitor their child's daily symptoms and are instructed to continue with regular care for their child and to continue monitoring their child's symptoms on their own without the use of the app for the duration of the study period (3 months). Parents/participants will also fill out a quality of life survey at baseline, 1 month, and 3 months as well as a caregiver satisfaction survey at 3 months.
89538790|NCT04487951||Moderate|Moderate: moderate COVID -19 pneumonia
89538791|NCT04487951||Severe|_severe COVID-19 pneumonia
89538792|NCT03260621|Other|echocardiographic increase in left atrial pressure|
89206717|NCT01068925|Experimental|ARM 1|"Arm 1:~GSK1349572 QD for 5 days (Treatment A)."
89505147|NCT02298946|Experimental|DL1 - CTX, SBRTx1 day, & AMP-224|Dose Level 1 (DL1) Cyclophosphamide (CTX) 200mg/m(2) intravenous (IV) on day 0. Stereotactic body radiation therapy (SBRT) 8 (gray)Gy x 1 day on day 0, AMP-224 10mg/kg on day 1 then every (q)14 days for a total of 6 doses
88815250|NCT04353518|Placebo Comparator|Placebo|"Placebo will be administered in two divided doses:~Dose 1 at Day 0: 0.2 ml (0.1 ml x 2 injection) of intradermal placebo in two divided dose.~Dose 2 at Day 15 after the first dose: 0.1 ml injection of intradermal placebo."
89505148|NCT02298946|Experimental|DL2 - CTX, SBRTx3 days, and AMP-224|Dose Level 2 (DL2) CTX 200mg/m(2) IV on day 0, SBRT 8Gy x 3 day on days -2, -1, and 0. AMP-224 10mg/kg on day 1 then q14 days.
89505149|NCT02389257|Experimental|MINIMAG / MEG|Cerebral magnetic fields
89505150|NCT02389257|Experimental|MINIMAG / ECG|Cardiac magnetic fields
89505151|NCT02186717|Experimental|Chewing gum|Chewing gum
89505152|NCT02186717|No Intervention|No Chewing Gum|No Chewing Gum
89505153|NCT04470115|Active Comparator|General anesthesia|Patients will receive general endotracheal anesthesia with propofol, fentanyl, sevoflurane and rocuronium.
89505154|NCT04470115|Experimental|Regional anesthesia|Patients will receive femoral and lateral femoral cutaneous nerves block under ultrasonographical guidance before operation.During surgical procedure they will receive deep sedation with propofol.
89505155|NCT02384343|Active Comparator|Dexmedetomidine|Dexmedetomidine 4 mcg/ml, 30 mcg (7,5 ml), single intravenous bolus
89505156|NCT02384343|Placebo Comparator|Normal saline|NaCl 0,9% 7,5 ml, single intravenous bolus
89505157|NCT05033639|Experimental|Treatment Group|Other than the Standard Management of preterm infant, treatment group A infants will receive 6 mg tablet dissolved in 5 ml breastmilk via oral gastric tube administered once a day at 10 pm.
89505158|NCT05033639|Placebo Comparator|Control Group|Human breast milk 5ml would be used as the placebo in this study. It would be indistinguishable from the treatment group as this will also be the diluent used.
89505159|NCT02193581||Suspicious skin lesions.|Patients with a suspicious skin lesion referred for a biopsy are tested using MDS
89505160|NCT02328040|Placebo Comparator|Part A|Placebo and Insulin monotherapy via CL
89505161|NCT02328040|Active Comparator|Part B|Sitagliptin and insulin/novolog via CL
89505162|NCT02285335|Experimental|Low group|GINST15 3g/day
89505163|NCT02285335|Experimental|High group|GINST15 6g/day
89505164|NCT02381457||Pregnancies undergoing prenatal microdeletion screening|"Pregnant women undergoing non-invasive prenatal screening for microdeletion and aneuploidy syndromes.~No drug will be administrated, this cohort will undergo a non invasive prenatal blood test and then follow up data and specimens will be collected for research analysis."
89505165|NCT02191085|No Intervention|Standard Management|"Patients in the Standard Management arm will be assessed without any interventions.Patients will be assessed by a sleep respirologist and follow a management plan that is determined by the sleep physician and patient. This plan may involve polysomnography or the initiation of PAP therapy. If further testing is ordered, follow-up may occur with the physician or with an ACP, at the physician's discretion. For patients initiating PAP therapy, the decision to delegate follow-up to an ACP will be left up to the physician, as the intent of this study is to observe real-world practice and not to change the management of individual patients."
89505166|NCT02191085|Active Comparator|Fast Track|"In the Fast Track arm, an ACP will perform the initial assessment and will determine the management plan with the patient."
89505167|NCT00355849|Experimental|1|Intensified Glargine
89505168|NCT00355849|Experimental|2|HIIP
89505169|NCT00355849|Experimental|3|Intensified Glargine plus HIIP
89505170|NCT02191163|Experimental|Antistax®|1 x 360 mg for 42 days
89505171|NCT02191163|Placebo Comparator|Placebo|
89505172|NCT02384499|Experimental|ALLO-ASC group|Allogenic-adipose-derived mesenchymal stem cell (ALLO-ASC) with fibrin glue injection to the anal sphincter
89505173|NCT02384499|Placebo Comparator|Normal saline group|0.9% normal saline with fibrin glue injection to the anal sphincter
89505174|NCT01647958|Experimental|Treatment Arm|Transoral incisionless esophago-gastric fundoplication using the EsophyX system with SerosaFuse fasteners (EndoGastric Solutions, Inc., Redmond, WA, USA) and following TIF2.0 protocol.
89505175|NCT01647958|Active Comparator|Control|Patients who are dependent upon daily PPIs will continue on single dose twice daily or increase to single dose twice daily for the first six months of the clinical trial. Patients will be offered TIF crossover procedure upon completion of month-6 follow-up visit.
89505176|NCT02186951|Experimental|Amoxicillin clavulanic acid|Amoxicillin-clavulanic acid 1g, three times a day during 2 days, started within one hour after randomization and before the beginning of hypothermia.
89505177|NCT02186951|Placebo Comparator|Placebo|Placebo 1g, three times a day during 2 days, started within one hour after randomization and before the beginning of hypothermia.
89538793|NCT03260621|Other|echocardiographic no increase in left atrial pressure|
89505178|NCT02384109|Experimental|Intervention|Pharmacist-coordinated shared decision making about treatment for pre-diabetes (lifestyle change and/or metformin), using a decision tool
89505179|NCT02384109|Placebo Comparator|Usual Care|Usual care for patients with a diagnosis of pre-diabetes
89206718|NCT01068925|Experimental|ARM 2|ARM 2: TPV/RTV 500/200mg BID (Treatment B).
89505180|NCT02285413|Experimental|DC vaccination|mature DC injected intradermally and intravenously loaded with mRNA encoding tumor-associated antigens gp100 and tyrosinase
89505181|NCT02285413|Experimental|DC vaccination with cisplatinum|mature DC injected intradermally and intravenously loaded with mRNA encoding tumor-associated antigens gp100 and tyrosinase. each DC vaccine will be preceded by cisplatin infusion: 50 mg/m2, 1-2h before DC injection.
89505182|NCT02193659|Experimental|Cereals|For 30 days, participants in group 1 took cereals with omega-3 in the breakfast with diet, group 2 took cereals and diet, and group 3 only received the diet. The energy intake of the designed diet was similar into the three groups (ranging 1900-2000 Kcal per day).
89505183|NCT02287597||Cohort|
89505184|NCT02381379|Active Comparator|Peginterferon-α-2a (Pegasys®)|Subcutaneous peginterferon-α-2a (PEGASYS®) starting at 180µg weekly for one year
89505185|NCT02381379|No Intervention|Observation|Stop tyrosine kinase inhibitor that was on and no active medication that might affect CML, for example any immune-modulatory agents, traditional herbs or medications, chemotherapeutic agents, growth factors, or colony stimulating factors is allowed during the trial period.
89505186|NCT02187107|Experimental|TMC114 + rtv|Every participant recieves 2 tablets of TMC114, 300 mg, combined with one tablet of rtv (ritonavir), 100mg, orally twice daily, every 12 hours
89505187|NCT02285491|Experimental|bupivacaine group|This is the group of patients that will receive 10ml of bupivacaine 0.5% injection in both angles of the rectus sheath incision
89505188|NCT02285491|Placebo Comparator|saline group|This group will receive saline injections as placebo into both angles of the rectus sheath incision
89505189|NCT02285491|Experimental|bupivacaine and saline group|This group will receive saline injection in one angle and 10ml of bupivacaine 0.5% injection in the opposite angle.
89505190|NCT02298868|Experimental|Treatment|All patients will be administered a standing dose of Baclofen initially at 5 mg three times a day for the first week and then increased to 10 mg three times a day for the next 3 weeks with a tapering dose the final week, a total of 5 weeks of therapy.
89505191|NCT02381067|Other|NuCel with Allograft Bone|NuCel will be used with allograft bone for the surgical treatment of one, two or three level degenerative disease of the cervical spine.
89505192|NCT02187185|Active Comparator|Sonicare Elite-Flexcare|Arm 1 participants will abstain from brushing and flossing teeth in selected sites which will typically be one maxillary and mandibular posterior sextant during a three week, no-hygiene phase via placement of acrylic stents. After the stent-induced biofilm overgrowth (SIBO) induction, the resolution phase of the study will involve a randomization that places half of the subjects on the Sonicare/Elite/Flexcare toothbrush. Thus, the resolution phase is a RCT designed to treat SIBO in subjects with varying levels of disease. Participants will reinstate normal full mouth oral hygiene and daily plaque control, exclusive of flossing, with dispensed dentifrice and toothbrush. Participants will be followed for four weeks during SIBO resolution.
89505193|NCT02187185|Active Comparator|Manual Toothbrush|Arm 2 participants will abstain from brushing and flossing teeth in selected sites which will typically be one maxillary and mandibular posterior sextant during a three week, no-hygiene phase via placement of acrylic stents. After the stent-induced biofilm overgrowth (SIBO) induction, the resolution phase of the study will involve a randomization that places half of the subjects on the manual toothbrush. Thus, the resolution phase is a RCT designed to treat SIBO in subjects with varying levels of disease. Participants will reinstate normal full mouth oral hygiene and daily plaque control, exclusive of flossing, with dispensed dentifrice and toothbrush. Participants will be followed for four weeks during SIBO resolution.
89206719|NCT01068925|Experimental|ARM 3|ARM 3: GSK1349572 50mg QD and TPV/RTV 500/200mg BID (Treatment C).
89206720|NCT00511810|Experimental|Low Dose Fish Oil|Capsule omega-3 fatty acids 2.4g/day (4 capsules/day)
89505194|NCT02389179|Active Comparator|25 000 IU monthly|The dose stated above are doses of Vitamin D3/Cholecalciferol which is formulated as spray dried powder stabilized with DL-alpha tocopherol (dry vitamin D3 100 SD/S)(DSM Nutritional Products Switzerland Ltd). The spray dried powder will be diluted in 10 mls of water and ingested orally by subjects under direct supervision in a clinic setting.
89206721|NCT00511810|Experimental|High Dose Fish Oil|Liquid omega-3 fatty acid 15 g/day (2 tablespoons/day)
89505195|NCT02389179|Active Comparator|50 000 IU monthly|The dose stated above are doses of Vitamin D3/Cholecalciferol which is formulated as spray dried powder stabilized with DL-alpha tocopherol (dry vitamin D3 100 SD/S)(DSM Nutritional Products Switzerland Ltd).The spray dried powder will be diluted in 10 mls of water and ingested orally by subjects under direct supervision in a clinic setting.
89505196|NCT02389179|Active Comparator|50 000 IU bi-weekly|The dose stated above are doses of Vitamin D3/Cholecalciferol which is formulated as spray dried powder stabilized with DL-alpha tocopherol (dry vitamin D3 100 SD/S)(DSM Nutritional Products Switzerland Ltd).The spray dried powder will be diluted in 10 mls of water and ingested orally by subjects under direct supervision in a clinic setting.
89505197|NCT02285647|Experimental|Rolapitant - Oral|Investigational Product: Rolapitant Dose: 200 mg (4 x 50mg) Route of Administration: Oral Dosage Form: Capsule Dosing Condition: Fasted (10 hours overnight)
89505198|NCT02285647|Experimental|Rolapitant - IV|Investigational Product: Rolapitant Dose: 185 mg Route of Administration: IV (30 minutes) Dosage Form: 2 mg/mL solution Dosing Condition: Fasted (10 hours overnight)
89505199|NCT02187263||hereditary DCM|
89505200|NCT02187263||inflammatory DCM|
89505201|NCT02187263||LVNC|
89505202|NCT02187263||HCM|
89505203|NCT02187263||ARVC|
89505204|NCT02187263||acute myocarditis|
89505205|NCT02388867|Experimental|Group I|Intervention: Polytetrafluoroethylene (PTFE) bypass grafting.
89505206|NCT02388867|Experimental|Group II|Intervention: Autogenous vein bypass grafting.
89505207|NCT00113893|Experimental|Scio-469 30 Milligram (mg)|SCIO-469 tablet will be administered orally at a dose of 30 mg thrice daily (90 mg per day) for 16 weeks. Participants with hematologic improvement at Week 16 and as per Investigator's discretion on clinical benefit from treatment will continue the treatment for additional 36 weeks.
89505208|NCT00113893|Experimental|Scio-469 60 mg|SCIO-469 tablet will be administered orally at a dose of 60 mg thrice daily (180 mg per day) for 16 weeks. Participants with hematologic improvement at Week 16 and as per Investigator's discretion on clinical benefit from treatment will continue the treatment for additional 36 weeks.
88957026|NCT02446262|Other|Substudy 5: healthy volunteers|Participants experience both placebo and cue-based expectations within subjects
88957027|NCT02352116|Experimental|Additional education|Subjects undergoing ambulatory surgery who receive standard of care management with additional face-to-face education in postoperative pain management.
88957028|NCT02352116|Active Comparator|No additional education|Subjects undergoing ambulatory surgery who receive standard of care management with no additional education in postoperative pain management.
89505209|NCT00113893|Experimental|Scio-469 90 mg|SCIO-469 tablet will be administered orally at a dose of 90 mg thrice daily (270 mg per day) for 16 weeks. Participants with hematologic improvement at Week 16 and as per Investigator's discretion on clinical benefit from treatment will continue the treatment for additional 36 weeks.
89505210|NCT00113893|Experimental|Scio-469 120 mg|SCIO-469 tablet will be administered orally at a dose of 120 mg thrice daily (360 mg per day) for 16 weeks. Participants with hematologic improvement at Week 16 and as per Investigator's discretion on clinical benefit from treatment will continue the treatment for additional 36 weeks.
89505211|NCT02187341|Experimental|5-HTP|200 mg 5-HTP capsule will be ingested 2h prior to reporting to the laboratory.
89505212|NCT02187341|Placebo Comparator|Placebo|For these visit subjects will ingest placebo (Sugar pill) capsule 2 hours before reporting to the laboratory.
89505213|NCT02327260|Experimental|Video + MI for CR|This group receives the educational video and an MI session for CR participation.
89505214|NCT02327260|Experimental|MI for medication adherence|This group receives an MI session for taking prescribed cardioprotective medications.
89505215|NCT02327260|No Intervention|Control group (standard care)|The control group receives standard care while hospitalized.
89505216|NCT02388945|Experimental|A APDGroup|PDGO APD machines used in the PD patients for 8 weeks
89505217|NCT02388945|Active Comparator|B CAPDGroup|CAPD used in the PD Patients for 8 weeks
89505218|NCT02187419|Active Comparator|5 Therapist-Delivered Hypnosis Session|Participants will complete five therapist-delivered hypnosis relaxation sessions with a hypnosis research therapist, and receive five audio (CD or MP3) recordings of hypnotic inductions and instructed in daily home practice.
89505219|NCT02187419|Active Comparator|3 Therapist-Delivered Hypnosis Session|Participants will complete three therapist-delivered hypnosis relaxation sessions with a hypnosis research therapist, and receive five audio (CD or MP3) recordings of hypnotic inductions and instructed in daily home practice.
88957031|NCT02319837|Experimental|Enzalutamide plus leuprolide|Enzalutamide (160 mg) administered as four 40-mg capsules by mouth once daily in combination with leuprolide administered as a single intramuscular or subcutaneous injection once every 12 weeks
88957032|NCT02319837|Experimental|Enzalutamide monotherapy|Enzalutamide (160 mg) administered as four 40-mg capsules by mouth once daily
88957033|NCT02319837|Active Comparator|Leuprolide plus placebo|"Enzalutamide placebo (placebo) capsules (identical in appearance to enzalutamide) administered as 4 capsules by mouth once daily in combination with leuprolide administered as a single intramuscular or subcutaneous injection once every 12 weeks.~The randomized blinded portion of the study has concluded following primary endpoint analyses. In the Open Label Period the placebo is no longer applicable in this study arm, and patients continue to receive leuprolide alone."
89505220|NCT02187419|Active Comparator|5 Phone Calls; Hypnosis Recordings Only|Participants will complete five phone calls with a hypnosis research therapist, and receive five audio (CD or MP3) recordings of hypnotic inductions and instructed in daily home practice.
89505221|NCT02187419|Active Comparator|3 Phone Calls; Hypnosis Recordings Only|Participants will complete three phone calls with a hypnosis research therapist, and receive five audio (CD or MP3) recordings of hypnotic inductions and instructed in daily home practice.
89505222|NCT02389023|Other|standard gauze dressing|a standard post-operative dressing consisting of dry gauze and tape will be placed over the surgical site
89505223|NCT02389023|Other|Prevena Incision Management System|the Prevena™ Incision Management System (PIMS) or ActiVAC® with the PrevenaTM Dressings (Peel and Place™ or Customizable™) will be placed over the surgical site. The Prevena dressing is not considered experimental and has FDA approval for coverage of at risk closed-surgical incisions. The dressing is already in clinical use for vascular surgery bypass operations at the University of Vermont Medical Center.
89505224|NCT02187497|Experimental|Low dose of BIBR 277|
89505225|NCT02187497|Experimental|Medium dose of BIBR 277|
89505226|NCT02187497|Experimental|High dose of BIBR 277|
89505227|NCT02256761|Experimental|BIRT 2584 XX - single dose|"Part 1 - bioavailability/food effect~two single doses, 30 minutes prior to the second drug administration after a one week wash-out period, a standardised high fat, high caloric meal was served"
89505228|NCT02256761|Placebo Comparator|Placebo|Part 2
89505229|NCT02256761|Experimental|BIRT 2584 XX - multiple escalating dose|Part 2 - multiple escalating dose, 14 days and 28 days
89505230|NCT00099853|Experimental|Vildagliptin 50 mg qd + pioglitazone 45 mg qd|Vildagliptin 50 mg qd + pioglitazone 45 mg qd for 24 weeks
89505231|NCT00099853|Experimental|Vildagliptin 50 mg bid + pioglitazone 45 mg qd|Vildagliptin 50 mg bid + pioglitazone 45 mg qd for 24 weeks
89505232|NCT00099853|Placebo Comparator|Vildagliptin placebo + pioglitazone 45 mg qd|Vildagliptin placebo + pioglitazone 45 mg qd for 24 weeks
89505233|NCT02381145|Placebo Comparator|Placebo|micro-cellulose-filled Placebo
89505234|NCT02381145|Active Comparator|EGCG+RSV-supplementation|EGCG+RSV: 300mg/d + 80mg/d
89505235|NCT02187575|Experimental|UHAC 62 XX tablet|
89505236|NCT02187575|Active Comparator|UHAC 62 XX capsule|
89505237|NCT00097357|Experimental|A1|"Apixaban: 2.5 mg, BID~PLUS~Enoxaparin Placebo"
89505238|NCT00097357|Experimental|A2|"Apixaban: 5 mg, BID~PLUS~Enoxaparin Placebo"
89505239|NCT00097357|Experimental|A3|"Apixaban: 10 mg, BID~PLUS~Enoxaparin Placebo"
89505240|NCT00097357|Experimental|A4|"Apixaban: 5 mg, QD~PLUS~Enoxaparin Placebo"
89505241|NCT00097357|Experimental|A5|"Apixaban: 10 mg, QD~PLUS~Enoxaparin Placebo"
89505242|NCT00097357|Experimental|A6|"Apixaban: 20 mg, QD~PLUS~Enoxaparin Placebo"
89505243|NCT00097357|Active Comparator|E1|"Enoxaparin: 30 mg~PLUS~Apixaban Placebo"
89505244|NCT00097357|Active Comparator|W1|Warfarin: 5 mg tablets dose titrated to a targeted INR of 1.8 to 3.0
89505245|NCT02187653||Lumbar|Patients undergoing lumbar surgery
89505246|NCT02187653||Cervical|Patients undergoing cervical surgery
89505247|NCT02191241|Experimental|Red Vine Leaf Extract|
89505248|NCT03535493|Active Comparator|Acceptance and Commitment Therapy (ACT)|
89505249|NCT03535493|Active Comparator|Float REST|
89505250|NCT03535493|Experimental|ACT + Float REST|
89505251|NCT02296840|Experimental|Ibuprofen|After undergoing adenotonsillectomy, patients who are randomized into the test intervention arm will receive ibuprofen (10mg/kg/day every 6-8 hours) after surgery.
89505252|NCT02296840|Active Comparator|Hydrocodone-acetaminophen (Control)|After undergoing adenotonsillectomy, patients who are randomized into the control intervention will receive hydrocodone-acetaminophen (0.15mg/kg/day every 4-6 hours).
89505253|NCT02191319||Viramune®|Patients switching from protease inhibitor (PI) or nonnucleoside reverse transcriptase inhibitor (NNRTI) containing antiretroviral regimen to Viramune®
89505254|NCT00336973|Experimental|1|
88957034|NCT02315599||1|Patients screening for, participating in, or have participated in a POB gene therapy clinical trial and have received/or be scheduled to receive a genetically engineered cellular therapy.
88957035|NCT02231710|Experimental|BPX-501 and Rimiducid|Single administration of BPX-501 T cells post partially-mismatched, related T cell depleted HCT followed by Rimiducid infusion on day 7
89505255|NCT02191475|Active Comparator|glycopeptide plus carbapenem|The control group antibiotic selection according to the classical scheme use of glycopeptide plus carbapenem antibiotic (or oxazolidinone antibiotics), with or without antifungal therapy, dose of imipenem/cilastatin 500mg, IVdrip, 3~4 times/d, or meropenem 1g, IVdrip, 3 times/d; vancomycin for 15mg/kg,2 times/d, or linezolid 300mg, IVdrip, 2 times/d; these drugs are required to state organ function in patients with drug doses adjustment, treatment for 3-5 days.
89505256|NCT02191475|Experimental|Haizheng Li Xing ® plus tazocin ®|Tigecycline (Haizheng Li Xing ®) combined with piperacillin / tazobactam (tazocin ®), with or without antifungal therapy, dose of tigecycline first dose 100 mg, 50 mg, every 12 hours, piperacillin / tazobactam 4.5g, ivdrip, 3-4 times a day, each time the infusion of 3 hours, treatment for 3-5 days.
89505257|NCT02191553|Active Comparator|Control Group: Relaxation Techniques|Relaxation techniques which do not involve either formal or informal mindfulness training. Subjects in this group practice Jacobson's progressive muscular relaxation, emotional imagining and Schultz's autogenic training.
89505258|NCT02191553|Experimental|Loving Kindness Meditation (Metta)|Loving-kindness meditation following Kristin Neff protocol
89505259|NCT02191553|Experimental|Body Scan|Body scan as described in standard MBSR protocol
89505260|NCT02191553|Experimental|Sitting Practice|Sitting practice as mindfulness meditation described in standard MBSR protocols.
89505261|NCT02287753|Experimental|Vascular occlusion test (VOT)|Pediatric patients aged under 8 years old are enrolled in this study. VOT is performed in 3 times : after induction of anesthesia, during cardiopulmonary bypass (CPB) for main surgical procedure and after weaning from CPB. The relationship between postoperative outcome variables and the dynamic parameters from VOT, such as desaturation and reoxygenation rate, and reactive hyperemic area, will be evaluated.
89505262|NCT02384031|Active Comparator|Traumatic group|Traumatic needle
89505263|NCT02384031|Active Comparator|Atraumatic group|Atraumatic needle
89505264|NCT02191631|Experimental|Internet-delivered CBT|Participants will receive 12 weeks of internet-delivered cognitive behavior therapy with psychologist support.
89505265|NCT02191631|No Intervention|Wait list|Participants will receive no treatment for 12 weeks. After that period participants will receive Internet-delivered Cognitive Behavior Therapy.
89505266|NCT02285803|Active Comparator|TRT and real tDCS|
89505267|NCT02285803|Sham Comparator|TRT and sham tDCS|
89505268|NCT02191709|Experimental|Dextromethorphan syrup|Bisoltussin® Syrup
89505269|NCT02191709|Active Comparator|Dextromethorphan soft pastilles|Silomat® DMP soft pastilles
89505270|NCT02285881|Experimental|shared decision making|In the intervention practices the SDM process is used. In the SDM proces the patient and GP use a decision aid to discuss the pros and cons of two evidence based treatment possibilities, according to the Dutch College of General Practitioners (NHG) versus the ADDITION guideline, and the patients' preferences for either of these treatments. Together they choose one of these treatments, and set the five treatment targets (blood pressure, cholesterol, HbA1c, smoking status and weight) in order of priority. Subsequent treatment will take place according to the priorities of these OPTIMAL treatment targets. The priorities will be evaluated every 12 months.
89505271|NCT02285881|No Intervention|control group|Patients in the control practices will receive treatment-as-before, which means that the patients will not be offered the structured SDM process. So the GP will treat the former ADDITION patients as they were used during the period that followed after the ADDITION study (2009), either according to the national guidelines or to the ADDITION intensive treatment algorithm.
89505272|NCT02383797|Experimental|Cartilage-hair hypoplasia (CHH)|Selected CHH patients will be vaccinated against varicella with Varilrix, one dose of 0,5 ml subcutaneously. If no response is documented to the first dose, the second dose of 0,5 ml can be administered.
89505273|NCT02191787|Experimental|Seresis® + Placebo|"2 capsules Seresis® o.d. for 5 days~2 capsules Placebo o.d. the day before treatment with Seresis®"
89206722|NCT00834600|Experimental|HCTZ , ARB|Patients randomized to the Experimental Arm have initial drug choice determined by Plasma Renin Activity level. Low renin subjects are assigned to the diuretic hydrochlorothothiazide. Those with PRA >.65 ng/hr are assigned to the angiotensin receptor blocker, olmesartan.
89206723|NCT00834600|Active Comparator|Conventional antihypertensive therapy|All patients randomized to Active Comparator Arm received hydrochlorothiazide 25 mg, which is increased to 50 mg at 3-4 weeks. At 6 weeks, olmesartan may be added if BP > 140 mmHg
89206724|NCT00958425|Experimental|Hyaluronic acid gel|
89505274|NCT00326287|Experimental|Ceftobiprole medocaril|Ceftobiprole medocaril 500mg q8h as 2h infusions, 7-14d
89505275|NCT00326287|Active Comparator|Ceftriaxone with or without Linezolid|Ceftriaxone 2g qd as 0.5h infusions with or without Linezolid 600mg q12h as 1h infusions, 7-14d
89505276|NCT02191943|Active Comparator|Control (fluoride varnish)|
89505277|NCT02191943|Experimental|resin infiltration (Icon)|
89505278|NCT02663895|Experimental|Oral treprostinil|Treprostinil 0.125 mg TID orally, which will be increased by 0.125 mg TID every 3 to 4 days as tolerated for 12 months
89505279|NCT02192177||Group 1|Pregnant subjects diagnosed with obstetric cholestasis who didn't have any foreknown systemic disease.
89505280|NCT02192177||Group 2|entirely healthy pregnant subjects, the control group.
89505281|NCT04441333|Experimental|AspivixTM cervical vacuum tenaculum|Traction of the cervix for IUD insertion using the AspivixTM cervical vacuum tenaculum.
89505282|NCT02257151|Experimental|Group 1: BMS-986142 or placebo|BMS-986142 or placebo Single dose oral Solution or spray dried dispersion as specified
89206725|NCT00958425|Active Comparator|Saline|
89505283|NCT02257151|Experimental|Group 2: BMS-986142 or placebo|BMS-986142 or placebo Multiple dose oral Solution as specified
89505284|NCT00074425|Experimental|1|BufferGel
89505285|NCT00074425|Experimental|2|Pro 2000/5 Gel (P)
89505286|NCT00074425|Placebo Comparator|3|Placeo Gel
89505287|NCT00074425|No Intervention|4|
89505288|NCT02192255|Experimental|Intervention phone call|The intervention arm consisted of one protocol-structured telephone call from an interventionist who was a nurse health manager (1 site), diabetes educator or diabetes educator trainee (1 site), or pharmacist (2 sites). Interventionists followed the same structured telephone interview protocol to ascertain whether the subject had started taking the new prescription. Those taking the new medication as prescribed received positive reinforcement. Those who either had not filled the prescription or were not taking the medication as directed, were asked about reasons for nonadherence and assisted in identifying and resolving barriers. The median call lasted < than 5 minutes, and up to 3 call attempts were made. Most intervention calls occurred within 2 to 6 weeks after the prescription date.
89505289|NCT02192255|No Intervention|Control arm - usual care|Those in the control arm received usual care.
89505290|NCT02663817|Experimental|IMRT|Study participants being treated according to the standard of care with intensity modulated radiotherapy (IMRT). Several CT scans will be performed for each enrolled subject: one before the radiotherapy course for patient treatment planning purposes (as part of the standard of care), one during the radiotherapy treatment course (between fraction 10 and 20), and one at follow up visit or at least 6 weeks post-radiotherapy treatment (whichever comes first).
89505291|NCT00325507|Experimental|TroVax|TroVax given as first or second line treatment in conjuntion with low dose IL-2.
89206726|NCT02547480|Experimental|TACE with irinotecan loaded LifePearl|10 patients receiving unilobar treatment: day 1=chemoembolization of first lobe of liver, day 14=chemoembolization of second lobe of liver, day 30=chemoembolization of first lobe of liver, day 44= chemoembolization of second lobe of liver; AND 10 patient receiving bilobar treatment: day 1=chemoembolization of both lobes of the liver, day 30=chemoembolization of both lobes of the liver
88957041|NCT02057133|Experimental|LY2835219 + Letrozole|LY2835219 administered orally. Letrozole administered orally. This arm is closed to enrollment.
88957042|NCT02057133|Experimental|LY2835219 + Anastrozole|LY2835219 administered orally. Anastrozole administered orally. This arm is closed to enrollment.
89206727|NCT00291499|Active Comparator|Chondroitin 4&6 sulfate (Condrosulf)|
89206728|NCT00291499|Placebo Comparator|placebo|
89505292|NCT02193737|Experimental|Early oral fluid recovery.|
89505293|NCT02193737|Active Comparator|Delayed oral fluid recovery.|
89505294|NCT03106155|Experimental|vistusertib (AZD2014)|vistusertib (AZD2014), 50 mg,BID, per os, every 12 hours
89505295|NCT00320203|Experimental|Anecortave Acetate 3 mg Depot|Single injection, anterior juxtascleral depot (AJD)
89505296|NCT00320203|Experimental|Anecortave Acetate 15 mg Depot|Single injection, anterior juxtascleral depot (AJD)
89505297|NCT00320203|Experimental|Anecortave Acetate 30 mg Depot|Single injection, anterior juxtascleral depot (AJD)
89505298|NCT00320203|Other|Anecortave Acetate Vehicle|Single injection, anterior juxtascleral depot (AJD)
89505299|NCT02188043|Other|Relay Model|"AUDIT score 8+: Brief Motivational Intervention with alcohol therapist. AUDITscore16+:Brief Motivational Intervention and appointment at Alcohol Treatment Clinic~-"
88957043|NCT02057133|Experimental|LY2835219 + Tamoxifen|LY2835219 administered orally. Tamoxifen administered orally. This arm is closed to enrollment.
88957044|NCT02057133|Experimental|LY2835219 + Exemestane|LY2835219 administered orally. Exemestane administered orally. This arm is closed to enrollment.
88957045|NCT02057133|Experimental|LY2835219 + Exemestane + Everolimus Dose Escalation|LY2835219 administered orally. Exemestane administered orally. Everolimus administered orally. This arm is closed to enrollment.
89206729|NCT00838500|Active Comparator|Immediate SPA treatment|Immediate spa treatment during 18 days soon after randomization (1 year)
89206730|NCT00838500|Sham Comparator|Late SPA treatment|Late spa treatment during 18 days soon after 12 months visit (2nd year)
89206731|NCT00838656|Experimental|Arm I|Patients receive carboplatin IV over 1 hour and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients may undergo treatment with paclitaxel and may also receive 6 more courses of neoadjuvant chemotherapy. Patients may then undergo surgery. After surgery, patients receive paclitaxel IV over 3 hours on day 1. Treatment repeats every 2 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
89023751|NCT04814992|No Intervention|Treatment-as-usual (control)|Patients scheduled to undergo total joint arthroplasty at the study site are automatically enrolled in a mandatory 4-hour education class delivered by a nurse educator or physical therapist. Utilizing an in-person Powerpoint presentation format, patients are informed about pre-habilitation exercises to do prior to surgery; what to expect the day of surgery; the multimodal analgesia protocol used in the perioperative period; options for anesthesia and analgesia; and the expectation of physical therapy after surgery.
89505300|NCT02188043|No Intervention|Usual Referral Procedure|Hospital staff refer patient to Alcohol Treatment Clinic according to usual procedure
89505301|NCT03105687|No Intervention|Control|"Participants in the Control group will receive standard Pharmaceutical Care according to the principles of Good Pharmaceutical Practice and national Slovak legislation requirements only.~Participants in the control group will also receive a welcome SMS one day after enrollment and an end-of-trial SMS three months after the enrollment. Additionally, prior to their scheduled follow-up visit (Visit 2), three months following the enrollment, trial pharmacists will call the participants to remind them of their follow-up visit."
89505302|NCT03105687|Experimental|Intervention|Participants in the intervention group will also receive standard Pharmaceutical Care provided by the trial pharmacist, the welcome SMS and the end-of-trial SMS. Additionally, they will receive daily SMS reminders of their blood pressure-lowering medication intake from a trial pharmacist for a period of 3 months after the enrollment. The structure of the SMS reminder will follow the information provided as a part of the usual drug dispensation and counselling process as described in the Slovak national Decree No. 129/2012 Coll. Thus, most of the data are available on the prescription and all of the collected data are already a well-established and required part of the standard Pharmaceutical Care in Slovakia. The simple structure of the SMS reminder will allow for future reproducibility.
89505303|NCT00071461|Experimental|1|"Initial dose: 62.5 mg b.i.d. for 4 weeks.~Target dose: - body weight > 40 kg (90 lb): 125 mg b.i.d., (if the initial dose is well tolerated).~body weight < 40 kg (90 lb): 62.5 mg b.i.d."
89505304|NCT00071461|Placebo Comparator|2|"Initial dose: 62.5 mg b.i.d. for 4 weeks.~Target dose: - body weight > 40 kg (90 lb): 125 mg b.i.d., (if the initial dose is well tolerated).~body weight < 40 kg (90 lb): 62.5 mg b.i.d."
88957046|NCT02057133|Experimental|LY2835219 + Exemestane + Everolimus Dose Expansion|LY2835219 administered orally. Exemestane administered orally. Everolimus administered orally. This arm is closed to enrollment.
88957047|NCT02057133|Experimental|LY2835219+ Trastuzumab Dose Escalation|LY2835219 administered orally. Trastuzumab administered intravenously (IV) infusion. This arm is closed to enrollment.
89505305|NCT02192333|No Intervention|Arm I (usual care)|Participants receive usual care. After 12 months, participants may receive a survivorship clinic visit and boosters as in Arm II.
89505306|NCT02192333|Experimental|Arm II (survivorship care)|Participants attend a survivorship clinic visit that includes care plans, screening recommendations, physician coordination, health promotion education, symptom management and palliative care, late effects education, psychosocial and medical assessments, and referrals for services and care as appropriate. Participants also receive phone-based survivorship boosters over approximately 15-30 minutes at 4-8 weeks and 12-16 weeks after the initial clinic visit.
89505307|NCT02192411|Active Comparator|Standard Lidocaine|50mL 1% lidocaine in 450mL normal saline
89505308|NCT02192411|Experimental|1/4 dose lidocaine|12.5mL 1% lidocaine in 487.5mL normal saline
89505309|NCT01372605|Experimental|Collaborative depression care|Measurement-Based Care: Decision support from paraprofessional to HIV medical provider around initiating and monitoring antidepressant treatment.
89505310|NCT01372605|Other|Enhanced usual care|Usual care. Enhanced through pre-study training of providers, provision of psychiatric diagnostic information at enrollment to HIV provider, and availability of best-practices guidelines for reference in clinic.
89505311|NCT02192489|Experimental|CC-220 0.3mg|CC-220 0.3 mg capsules by mouth (PO) daily for 12 weeks
89505312|NCT02192489|Experimental|CC-220 0.6mg|CC-220 0.6mg capsules by PO daily for 12 weeks
89505313|NCT02192489|Placebo Comparator|Placebo|Identically matching placebo PO daily for 12 weeks
89505314|NCT02193893|Active Comparator|Stem/progenitor cells transplantation.|Intervention: Biological: Cell-based therapeutics Autologous bone marrow-derived stem/progenitor cells will be transplanted intrathecally (via a standard lumbar puncture) into early vs. progressive ALS subjects.
89505315|NCT02193893|Sham Comparator|Standard treatment of ALS|Symptomatic treatment of ALS without biologic cell-based treatment
89505316|NCT02380989|Experimental|Ayurveda|
89505317|NCT02380989|Placebo Comparator|Placebo|
89505318|NCT04863209|Experimental|Upper cervical manipulation group|The patient will be in the supine position. The cephalic hand will make contact with one side of the patient's skull, leaving the sternocleidomastoid muscle between the third and fourth fingers. The caudal hand will make global contact with the patient's skull on the opposite side. The therapist should place his torso on the patient's head, leaving the two forearms aligned with the axis of the patient's spine, as this technique is applied to the axis of the odontoid process of the ax. With neutral flexion-extension the therapist will place the rotation parameter to the opposite side (70-80 degrees) and a small contralateral inclination. Then it will search for the driving barrier with a small axial traction movement. When the driving barrier is found, the thrust should be applied in a helical direction, increasing rotation and traction. It will be applied bilaterally.
88957048|NCT02057133|Experimental|LY2835219+ Trastuzumab Dose Expansion|LY2835219 administered orally. Trastuzumab administered IV infusion. This arm is closed to enrollment.
88957049|NCT02057133|Experimental|LY3023414 + LY2835219 + Fulvestrant Dose Escalation|LY3023414 administered orally. LY2835219 administered orally. Fulvestrant administered intramuscularly (IM).
88957050|NCT02057133|Experimental|LY3023414 + LY2835219 + Fulvestrant Dose Expansion|LY3023414 administered orally. LY2835219 administered orally. Fulvestrant administered IM.
88957051|NCT02057133|Experimental|LY2835219 +Trastuzumab +Pertuzumab +Loperamide Dose Escalation|LY2835219 administered orally. Loperamide administered orally. Trastuzumab administered IV infusion. Pertuzumab administered IV infusion.
89505319|NCT04863209|Experimental|Sphenopalatine ganglion group|The patient will be supine on the bench and the therapist with gloves will sit next to the patient contralateral to the manipulated sphenopalatine ganglion (SPG). One of the therapist's hands will be placed flat in contact with the apex of the patient's head to stabilize it. The patient will be instructed to open his mouth and deviate the mandible laterally to the same side of the ganglion to be treated. The therapist will then apply pressure to the SPG with the fifth finger of your other hand in the patient's mouth, moving up along the alveolar process of the maxilla teeth to reach the pterygoid process. The therapist will keep the patient's head elevated until the lateral pterygoid muscle relaxes. Then, the pressure will be applied into the pterygopalatine fossa. The therapist will then apply gentle pressure on the SPG with the pulp of the fifth finger until tissue relaxation. He will then release the contralateral SPG in the same way.
89505320|NCT04863209|No Intervention|Control Group|The patient will lie down on the bench for 10 minutes.
89505321|NCT02383875|Experimental|Opticourses education intervention|People living in the northern districts of Marseille with in very deprived social situation: very low incomes, heavy financial dependence on social benefits, over-representation of people covered by arrangements for controlling poverty and people covered by free social security
88957052|NCT02057133|Experimental|LY2835219 +Trastuzumab + Pertuzumab +Loperamide Dose Expansion|"Hormone Receptor Negative (HR-): LY2835219 administered orally. Loperamide administered orally. Trastuzumab administered IV infusion. Pertuzumab administered IV infusion.~Hormone Receptor Positive (HR+): LY2835219 administered orally. Loperamide administered orally. Trastuzumab administered IV infusion. Pertuzumab administered IV infusion. Endocrine therapy administered orally."
89505322|NCT02380911|Experimental|Intervention Group|The intervention group will receive a multifaceted educational intervention targeting physicians and pharmacist assistants to improve detection, treatment and control of hypercholesterolemia among uninsured patients with moderate-high cardiovascular risk in Argentina.
89505323|NCT02380911|No Intervention|No Intervention Group|This group will continue with the usual care. Irrespective of the assignment of the clinic to the intervention or control group, all physicians from participating PCCs have received previous training on global cardiovascular risk management, given by the Ministry of Health
89505324|NCT02192567|Experimental|DS-5573a does escalation (step 1) and expansion (step 2)|"Step 1 of this study will follow a 3+3 study design with a starting intravenous (IV) dose of 0.1 mg/kg.~Eight dose levels are planned, level 1: 0.1 mg/kg, level 1.5: 0.1 mg/kg, 0.3 mg/kg, level 2: 0.3 mg/kg, level 3: 1 mg/kg, level 4: 3 mg/kg, level 5: 10 mg/kg, level 6: 20 mg/kg, level 7: 30 mg/kg Step 2: 30 subjects will be enrolled and treated at the dose determined in Step 1."
89505325|NCT02192645|Experimental|Sanfujiu|"Formula for Sanfujiu: Huangjiezi; Xixin; Yanhusuo; and so on Acupoint for Sanfujiu: Different ten acupoints determined according to Chinese medicine theory for each time.~Timepoint: Five times of 3 years at Sanfu Point application: The patients will be treated with herbal cake-separated moxibustion on acupoints and lasted 60 minutes each time."
89505326|NCT02192645|Placebo Comparator|placebo|"Formula for placebo: Fuxiaomai; and so on. the appearance is similar as drugs of Sanfujiu Acupoint for placebo: Ten acupoints determined according to Chinese medicine theory are the same as Sanfujiu group of each timepoint .~Timepoint: Five times per year for 3 years. Point application: The patients will be treated with placebo on acupoints and lasted 60 minutes each time."
89505327|NCT02192645|No Intervention|waiting list|No intervention in the first year. Accept Sanfujiu in the second and the third years.
89505328|NCT02388711|Experimental|Usual Care with C-TraC Intervention|Patients/caregivers randomized to this group will receive all routine hospital discharge education/materials (same as usual care group), but will also be enrolled in the C-TraC Program. C-TraC is a low-resource, telephone-based, protocol-driven program designed to reduce 30-day rehospitalizations and to improve care transitions during the early post-hospital period.
89505329|NCT02388711|No Intervention|Usual Care|Usual care group patients will receive all routine University of Wisconsin Hospital and Clinics (UWHC) discharge education/materials. This includes pharmacy-led medication teaching, physician discussions and routine nursing education. No post hospital education/contact is performed by these providers. Caregivers are sometimes, but not always, involved. Patients may receive home health services, depending on their physician's discharge plan.
89505330|NCT02257073|Experimental|CBT|Cognitive-behavioral treatment
89505331|NCT02257073|Sham Comparator|WLT|Waiting in list
89505332|NCT02384187|Placebo Comparator|Group C|Patients in this group will receive 0.3 ml/kg of a placebo solution identical in taste, shape and color to the study medication two hours before the induction of anesthesia.
89505333|NCT02384187|Experimental|Group GAB|Patients in this group will receive 0.3 ml/kg (16 mg/kg) oral gabapentin solution (Neurontin 50 mg/ml, Pfizer Pharmaceutical) as premedication two hours before the induction of anesthesia
89505334|NCT02286115|Experimental|Life-Stress Interview|The Life-Stress Interview is an experiential assessment technique
89505335|NCT02286115|No Intervention|Wait-list Control|Wait-list Control
89505336|NCT02192723|Experimental|Typical antipsychotic|Haloperidol (6~20mg/day) and perphenazine (16~64mg/day) for 8 weeks.
89505337|NCT02192723|Active Comparator|Risperidone|Risperidone, 2~6mg/day, twice day, 8 weeks
89505338|NCT02192723|Active Comparator|Olanzapine|5~20mg/day
89505339|NCT02192723|Active Comparator|Quetiapine|400~750mg/day
89505340|NCT02192723|Active Comparator|Aripiprazole|Aripiprazole, 10~30mg/day, twice per day, 8 weeks
89505341|NCT02192723|Active Comparator|Ziprasidone|Ziprasidone, 80~160mg/day, twice per day, 8 weeks
89505342|NCT02388789|Experimental|active movement|use a light treadmill run to raise feet temperature
89505343|NCT00319969|Experimental|1|Amrubicin 40mg/m<2> IV days 1, 2, 3 of each 21-day cycle until disease progression.
89505344|NCT00319969|Active Comparator|2|Topotecan 1.5mg/m<2> IV, days 1, 2, 3, 4, 5 of each 21-day cycle until disease progression.
88957053|NCT02057133|Experimental|LY2835219 + Endocrine Therapy|LY2835219 administered orally. Ongoing endocrine therapy administered orally.
88957054|NCT02055872|Experimental|Intravenous albumin|Administration of 25% albumin by intravenous infusion, twice daily for a total of 72 hours (6 treatments)
88957055|NCT02055872|Placebo Comparator|Normal saline|Administration of 100 mL normal saline by intravenous infusion, twice daily, for 72 hours (6 treatments)
89505345|NCT02388555||Pre-operative group|Respectively recruited patients with DLS. Patients in this group were not surgically treatment. Only pre-operative radiographic parameters were measured.
89505346|NCT02388555||Surgically treated group|All DLS patients received posterior osteotomy correction of spinal deformity. The immediate post-operative radiographic measurements were performed.
89505347|NCT02380599|Experimental|Experimental Group|Crossover assignment of mid-thoracic spinal manipulation, spinal mobilization, or sham ultrasound
89505348|NCT02188199||Knee Replacement|Patients undergoing knee replacement surgery
89505349|NCT02188199||Hip Replacement|Patients undergoing hip replacement
89505350|NCT00317395|Experimental|Otamixaban Dose 1|dosage regimen 1
89505351|NCT00317395|Experimental|Otamixaban Dose 2|dosage regimen 2
89505352|NCT00317395|Experimental|Otamixaban Dose 3|dosage regimen 3
89505353|NCT00317395|Experimental|Otamixaban Dose 4|dosage regimen 4
89505354|NCT00317395|Experimental|Otamixaban Dose 5|dosage regimen 5
89505355|NCT00317395|Active Comparator|UFH/Eptifibatide|
89505356|NCT02383563|Active Comparator|Metformin Treatment Arm|500 mg metformin Extended Release tablets - one tablet daily increased at 4 weeks to 2 tablets (1000 mg) daily.
89505357|NCT02383563|No Intervention|Observational Arm|Observation only
89505358|NCT03535961|Other|apatinib+oral etoposide|apatinib 425/500mg qd, 21days/cycle oral etoposide 50mgmg/m2 d1-10 21days/cycle
89505359|NCT02380755|Placebo Comparator|Placebo|One pill every other day during 12 weeks
89505360|NCT02380755|Active Comparator|Clomiphene Citrate|Clomiphene citrate 50 mg orally daily (Serophene) during 12 weeks
89505361|NCT02188277|Experimental|Xeomin®|4-8 Units per kg body weight. Single injection cycle.
89505362|NCT02188277|Active Comparator|Botox®|4-6(8) Units per kg body weight. Single injection cycle.
89505363|NCT00316771|Experimental|P38 Inhibitor (4) 150mg|
89505364|NCT00316771|Experimental|P38 Inhibitor (4) 25mg|
89505365|NCT00316771|Experimental|P38 Inhibitor (4) 300mg|
89505366|NCT00316771|Experimental|P38 Inhibitor (4) 50mg|
89505367|NCT00316771|Experimental|P38 Inhibitor (4) 75mg|
89505368|NCT00316771|Placebo Comparator|Placebo|
89505369|NCT02380833|Active Comparator|MyPlate|To consume a weight maintenance diet based on the United States Department of Agriculture MyPlate nutrition recommendations for eight weeks.
88957057|NCT01922440||Natpar(a)|Participants receiving parathyroid hormone (rhPTH(1-84) (Natpar[a]) for treatment of chronic hypoparathyroidism as per standard clinical practice will be enrolled and evaluated during the study period.
88957058|NCT01922440||Conventional Therapy|Participants receiving conventional therapy/standard of care (including calcium supplements, active vitamin D, vitamin D) for treatment of chronic hypoparathyroidism as per standard clinical practice will be enrolled and evaluated during the study period.
89505370|NCT02380833|Active Comparator|MyPlate + Exercise|To consume a weight maintenance diet based on the United States Department of Agriculture MyPlate nutrition recommendations and aerobic and resistance training four days per week for eight weeks.
88957059|NCT01862731||1/Control Volunteers|Healthy controls
88957060|NCT01862731||2/Volunteers with Pain|Subjects with Chronic Idiopathic Patellofemoral Pain
89505371|NCT02380833|Active Comparator|Paleolithic|To consume a weight maintenance diet based on alternative (Paleolithic based) nutrition recommendations for eight weeks.
89505372|NCT02380833|Active Comparator|Paleolithic + Exercise|To consume a weight maintenance diet based on alternative (Paleolithic based) nutrition recommendations and aerobic and resistance training four days per week for eight weeks.
89505373|NCT02380521|Experimental|60 patients with T2DM|These patients will be treated with exenatide once weekly for a period of 8 months
89505374|NCT00315757|Active Comparator|A|Bortezomib
89505375|NCT00315757|Experimental|B-10|Bortezomib and Mapatumumab 10 mg/kg
89505376|NCT00315757|Experimental|B-20|Bortezomib and Mapatumumab 20 mg/kg
89505377|NCT02377401|Experimental|Zanamivir 300 mg|Subjects will receive a single dose of IV zanamivir 300 mg on Day 1 morning. The repeat dose session will begin on Day 3 evening. Subjects will receive IV zanamivir 300 mg every 12 hours for 5 days. Each dose will be administrated intravenously at a constant rate over 30 minutes (500 milliliter per hour [mL/hr]).
89505378|NCT02377401|Experimental|Zanamivir 600 mg|Subjects will receive a single dose of IV zanamivir 600 mg on Day 1 morning. The repeat dose session will begin on Day 3 evening. Subjects will be receive IV zanamivir 600 mg every 12 hours for 5 days. Each dose will be administrated intravenously at a constant rate over 30 minutes (500 mL/hr).
89505379|NCT02383485|Experimental|After-school exercise program|40 min/day vigorous aerobic games after school
89505380|NCT02383485|Active Comparator|Sedentary after-school program|Attention-control condition similar to experimental condition with the exception of exercise
89505381|NCT00312091|Experimental|A, Stage 1|Tablet containing d4T, 3TC, and NVP taken orally twice daily for the first 4 weeks, then liquid formulations of d4T, 3TC, and NVP taken orally twice daily for the final 4 weeks
89505382|NCT00312091|Experimental|A, Stage 2|Tablet containing d4T, 3TC, and NVP taken orally twice daily for 4 weeks, then liquid formulations of d4T, 3TC, and NVP taken orally twice daily for 4 weeks
89505383|NCT00312091|Experimental|B, Stage 1|Liquid formulations of d4T, 3TC, and NVP taken orally twice daily for 2 weeks, then tablet containing d4T, 3TC, and NVP taken orally twice daily for 2 weeks
89505384|NCT00312091|Experimental|B, Stage 2|Liquid formulations of d4T, 3TC, and NVP taken orally twice daily for 4 weeks, then tablet containing d4T, 3TC, and NVP taken orally twice daily for 4 weeks
89505385|NCT02383329|Experimental|Oral Nutritional Supplement (ONS)|Diet consultation for the child/family + ONS
89505386|NCT02383329|No Intervention|No Oran Nutritional Supplement (ONS)|Diet consultation for the child/family
89505387|NCT00389779|Experimental|Darusentan|Placebo to match darusentan for 2-week placebo run-in period, followed by darusentan capsules titrated to an optimal dose of 50 mg, 100 mg, or 300 mg administered orally once daily for 14 weeks
89505388|NCT00389779|Active Comparator|Guanfacine|Placebo to match darusentan for 2-week placebo run-in period, followed by guanfacine 1 mg capsules administered orally once daily for 14 weeks
89505389|NCT00389779|Placebo Comparator|Darusentan Placebo|Placebo to match darusentan for 2-week placebo run-in period, followed by placebo to match darusentan administered orally once daily for 14 weeks
89505390|NCT02377323|Other|Treatment with Rebif|Patients treated with Rebif only, for at least two years, and for up to 18 years
89505391|NCT02377323|Other|Never treated|Patients never treated with a disease-modifying drug (DMD)
89505392|NCT02380365||Outpatients on the Waiting List and after Lung Transplantation|Electrocardiography
88957065|NCT01737502|Experimental|Treatment (auranofin and sirolimus)|Patients receive auranofin PO on days 1-28 and sirolimus PO on days 1-28 (days 8-28 of course 1). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88957066|NCT01679548|Experimental|Single-port LAVH group|single-port laparoscopic assisted vaginal hysterectomy
88957067|NCT01679548|Active Comparator|Three-port LAVH group|three-port laparoscopic assisted vaginal hysterectomy
88957068|NCT01572480|Experimental|Group A - (closed) - Carfilzomib with Revlimid and Dexamethasone|Carfilzomib (intravenous (IV), Days 1, 2, 8, 9, 15, and 16 of the 28-day cycle); Revlimid (by mouth (PO), Days 1-21 of the 28-day cycle; exception: not given on cycle 1 day 1); and Dexamethasone (PO or IV, Days 1, 2, 8, 9, 15, 16, 22, and 23 of the 28-day cycle; exception: not given on cycle 1 day 1)
88957069|NCT01572480|Experimental|Group B - Carfilzomib with Revlimid and Dexamethasone|Carfilzomib (intravenous (IV), Days 1, 2, 8, 9, 15, and 16 of the 28-day cycle); Revlimid (by mouth (PO), Days 1-21 of the 28-day cycle); and Dexamethasone (PO or IV, Days 1, 2, 8, 9, 15, 16, 22, and 23 of the 28-day cycle)
89505393|NCT02372019|Experimental|CBM With Active Fear Reactivation|
89505394|NCT02372019|Active Comparator|CBM With Inert Fear Reactivation|
89505395|NCT02372019|Placebo Comparator|Inert CBM With Inert Fear Reactivation|
89505396|NCT00389155|Experimental|vinflunine and gemcitabine|solution for injection, IV, vinflunine: 280/320 mg/m2 + gemcitabine: 1000 mg/m2, every 3 wks, variable duration
89505397|NCT00389155|Placebo Comparator|placebo and gemcitabine|solution for injection, IV, placebo + gemcitabine, 1000 mg/m2, every 3 wks, variable duration
89505398|NCT02380209|Experimental|Optimization|CEST MRI of the breast for estimation of tumor pH.
89505399|NCT02188433|Experimental|Cut down to quit (CDTQ)|"For those subjects who claim that they cannot quit smoking ≤7 days, they will receive a leaflet (i.e. include a roadmap of smoking reduction strategy) plus a brief intervention using the AWARD model: (a) Ask about smoking history, (b) Warn about the high risk, (c) Advise to quit as quitting can greatly reduce risks, and participants will be advised to cut down cigarette consumption at their own pace, but the process should not exceed 3 months. (d) Refer smokers to a smoking cessation clinic, and (e) Do it again: repeat the intervention and encourage smokers who fail to quit or relapse to reduce again during each telephone follow-up.~For the subjects have intention to quit smoking ≤7 days, the investigator will follow-up them after a week. For those who report quitted, they will be followed up as other participants. However, if they report failed to quit, they will receive the same interventions and will be followed-up as other participants in the experimental group."
89505400|NCT02188433|Active Comparator|Quit Immediately (QI)|QI group subjects will receive a smoking cessation booklet (provided by COSH) plus brief intervention using AWARD model similar to CDTQ group. For the subsequent telephone follow-up repeat the health warning that 'one in two smokers will be killed by smoking' and encourage smokers who fail to quit or relapse to try again.
89505401|NCT02380443|Experimental|Dosing Schedule A|"The priming step with ID injections of AlloStim on Days 0, 7, and 14~The vaccination step with cryoablation and IT (intratumoral) injection of AlloStim on Day 21~The activation step with IV infusion of AlloStim on Day 28~The booster step with two IV booster infusions of AlloStim on Days 56 and 84~Protocol follow-up procedures continue until day 112. Efficacy evaluation will continue monthly for each subject until death or loss to follow-up"
89505402|NCT02380443|Experimental|Dosing Schedule B|"The priming step with ID injections of AlloStim on Days 0, 3 and days 7 and 10~The vaccination step with cryoablation and IT (intratumoral) injection of AlloStim on Day 14~The activation step with IV infusion of AlloStim on Day 21~The booster step with two IV booster infusions of AlloStim on Days 49 and 77~Protocol follow-up procedures continue until day 105. Efficacy evaluation will continue monthly for each subject until death or loss to follow-up"
89505403|NCT02380443|Experimental|Dosing Schedule C|"The priming step with ID injections of AlloStim on Days 0, 3, 7, 10 and day 14~IV AlloStim on Day 21~The booster step with two IV booster infusions of AlloStim on Days 49 and 77~Protocol follow-up procedures continue until day 105. Efficacy evaluation will continue monthly for each subject until death or loss to follow-up"
89505404|NCT02380443|Experimental|Dosing Schedule D (reducing dose)|"The priming step with ID injections of AlloStim on Days 0, 3, 7, 10 and day 14~IV AlloStim on Day 21~The booster step with two IV booster infusions of AlloStim on Days 49 and 77~Protocol follow-up procedures continue until day 105. Efficacy evaluation will continue monthly for each subject until death or loss to follow-up Protocol follow-up procedures continue until day 105. Efficacy evaluation will continue monthly for each subject until death or loss to follow-up"
89505405|NCT02188511|Experimental|Group A|Electronic cigarette (nicotine/placebo) - Day 8 Intervention: Electronic cigarette exposure will be limited to one day.
89505406|NCT02188511|Experimental|Group B|Electronic cigarette (nicotine/placebo) - Days 7 through 8 Electronic cigarette exposure will be limited to two days
89505407|NCT02188511|Experimental|Group C|Electronic cigarette (nicotine/placebo) - Days 6 through 8 Electronic cigarette exposure will be limited to 3 days
89505408|NCT02188511|Experimental|Group D|Electronic cigarette (nicotine/placebo) - Days 5 through 8 Electronic cigarette exposure will be limited to 4 days
89505409|NCT02188511|Experimental|Group E|Electronic cigarette (nicotine/placebo) - Days 4 through 8 Electronic cigarette exposure will be limited to 5 days.
89505410|NCT02380131|Experimental|Herceptin|"drug: Oxaliplatin;Capecitabine;Herceptin A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk、Oxaliplatin 130 mg/m2 D1 q3wk add and subtract. Herceptin 8mg/kg D1 q3wk for the first time,after Herceptin 6mg/kg D1 q3wk.Evaluation for every two cycles.Each of preoperative and postoperative chemotherapy was 3 cycles.~To explore the effect of herceptin with chemotherapy for potentially resectable HER-2 positive gastric cancer with liver metastasis"
89505411|NCT03535103|Experimental|ARM A|Gonal-F®
89505412|NCT03535103|Experimental|ARM B|LM001
89505413|NCT00389077|Experimental|Perifosine Daily Dose|Daily dose perifosine 50 mg.
89505414|NCT00389077|Experimental|Perifosine Twice Daily Dose|Twice daily dose perifosine 50 mg.
89505415|NCT02188667|Active Comparator|Providers of Novel Care|Providers in the treatment group will be asked (1) to complete a series of six online education modules in pain care, (2) will be given access to new patient reported outcomes questionnaire data collected from patients within the electronic health record, (3) asked to review this data and related care recommendations during the patient visit, and (4) asked to complete baseline and monthly online surveys related to experiences and satisfaction with providing care to patients with chronic noncancer pain.
89505416|NCT02188667|Sham Comparator|Providers of Usual Care|Providers in the control group will provide care as usual to patients and will be asked to complete baseline and monthly online surveys related to experiences and satisfaction with providing care to patients with chronic noncancer pain.
89505417|NCT00388609|Experimental|T|5 mg (ST) to 50 mg (LT)
89505418|NCT00388609|Experimental|U|10 mg (ST) to 50 mg (LT)
89505419|NCT00388609|Experimental|V|25 mg (ST) to 50 mg (LT)
89505420|NCT00388609|Experimental|W|50 mg (ST and LT)
88957070|NCT01496625||Cohort 1|Participants with age-related macular degeneration (AMD), diabetic retinopathy, and other retinal diseases.
88957071|NCT01496625||Cohort 2|Participants without any retinal diseases.
88957072|NCT01468883|Active Comparator|M|Modified radical mastectomy
88957073|NCT01468883|Experimental|X|Excisional biopsy plus radiation
89505421|NCT00388609|Experimental|X|25 mg/d (X1 wk), 5 mg/d (X11 wks) (ST) to 50 mg (LT)
89505422|NCT00388609|Experimental|Z|"Open label: 50 mg/d (X 4 wks) 100 mg/wk (X8 wks) (ST) to 50 mg (LT)~Once daily (x 4 weeks), once daily (x 8 weeks)"
89505423|NCT00388609|Placebo Comparator|Y|0 mg (ST and LT)
89505424|NCT04551365|Experimental|Obese patients I|Undergoing lifestyle changes (rehabilitation) along daily intake of chitosan supplement, 4 capsules twice daily at main meals.
89505425|NCT04551365|Placebo Comparator|Obese patients II|Undergoing lifestyle changes (rehabilitation) along daily intake of placebo, 4 capsules twice daily at main meals.
89505426|NCT04551365|Experimental|Control I|Daily intake of chitosan supplement, 4 capsules twice daily at main meals.
89505427|NCT04551365|Placebo Comparator|Control II|Daily intake of placebo 4 capsules twice daily at main meals.
89505428|NCT00304525|Experimental|RAF265 - Arm 1|Patients received 10mg RAF265 as a once weekly dose until progressive disease was confirmed.
89505429|NCT00304525|Experimental|RAF265 - Arm 2|"RAF265 is given as a single PK run-in dose, a single loading dose on day 1 of cycle 1, followed by once daily maintenance doses."
89505430|NCT00304525|Experimental|RAF265 - Arm 3|Patients were treated with once weekly dosing of RAF265
89505431|NCT00304525|Experimental|RAF265 - Arm 4|Patients with locally advanced or metastatic melanoma will utilize a dose close to or at the MTD/RPTD of the liquid formulation that was determined in Arm 2.
89505432|NCT00304525|Experimental|RAF265 - Arm 5|RAF265 was administered as a continuous dose for 2 weeks followed by a dose holiday of 1 week.
89505433|NCT02377167|Experimental|Early Tracheostomy|"Patients randomized to early tracheostomy receive (preferably dilatative) tracheostomy within 5 days from intubation.~Intervention: Procedure: Early Tracheostomy"
89505434|NCT02377167|Active Comparator|Prolonged Intubation|"Patients randomized to this arm will be tried to wean off the ventilator and get (an) extubation trial(s) if regarded feasible. In case of failure or non-feasibility, they receive tracheostomy after intubation day 10.~Intervention: Procedure: Late Tracheostomy"
89505435|NCT02188823|Experimental|Low Carbohydrate Diet|"Participants will be instructed to follow a low carbohydrate, ketogenic diet: carbohydrate intake 20-35 grams a day not including fiber. Foods permitted include: meats, poultry, fish, eggs, cheese, cream, some nuts and seeds, green leafy vegetables, and most other non-starchy vegetables. Because most individuals self-limit caloric intake, no calorie restriction will be recommended.~Participants will also be taught information about exercise, sleep, mindfulness, and positive affect practices. The mindfulness-based curriculum will focus on the following elements: training on topics such as mindful meditation, mindful eating, awareness of fullness and hunger signals, and taste satiety. The positive emotion curriculum will include: training on topics such as noticing and savoring positive events, gratitude, positive reappraisal, personal strengths, attainable goals, and acts of kindness."
89505436|NCT05725681|Experimental|High protein ramen|
89505437|NCT05725681|Active Comparator|Standard ramen|
89505438|NCT02377011|Experimental|PS CBT|"Problem solving cognitive behaviour therapy (PS CBT) will be delivered remotely by means of telephone or video calling by a cognitive behaviour therapist in addition to their usual care.~The duration of the intervention will be 10 sessions. Research measures will be completed at baseline, 3,6,9 and 12 months"
89505439|NCT02377011|No Intervention|Treatment as Usual|Participants will not receive any CBT therapy in addition to their usual care. Research measures will be completed at baseline,3,6,9 and 12 months.
89505440|NCT02188901|Other|single arm|
89505441|NCT02751983|Experimental|Treatment as usual plus ACT|Participants in this condition will be enrolled in the ACT for Life intervention and still able to engage in treatment as usual.
89505442|NCT02751983|Active Comparator|Treatment as usual|Participants in this condition will not be enrolled in ACT for Life, but will continue to participate in treatment as usual (e.g., inpatient and outpatient mental health care).
89505443|NCT00298987|Experimental|A1|
89505444|NCT02380053|Experimental|Bisoprolol|2.5mg once daily for 2 weeks then 5mg once daily for 2 weeks.
89505445|NCT02380053|Experimental|Celiprolol|200mg once daily for 2 weeks then 400mg once daily for 2 weeks.
89505446|NCT02192957|Other|Ottawa AF Cardioversion|elective electrical cardioversion for atrial fibrillation (AF) using the Ottawa AF protocol
89505447|NCT02371707|Experimental|Idalopirdine 60 mg formulation A (test)|
89505448|NCT02371707|Experimental|Idalopirdine 60 mg formulation B (reference)|
89505449|NCT02193971|Active Comparator|BS-DES with prasugrel 10mg daily|BS-DES with prasugrel 10mg daily
89505450|NCT02193971|Active Comparator|BS-DES with prasugrel 5mg daily|BS-DES with prasugrel 5mg daily
89505451|NCT02193971|Experimental|BD-DES with prasugrel 10mg daily|BD-DES with prasugrel 10mg daily
89505452|NCT02193971|Experimental|BD-DES with prasugrel 5mg daily|BD-DES with prasugrel 5mg daily
89505453|NCT02379975|Experimental|rheumatoid arthristis|individuals with rheumatoid arthritis
89505454|NCT02379975|Active Comparator|health|healthy individuals
89505455|NCT03530605|Experimental|Optune TTF Device|Optune TTF treatment
89505456|NCT03530605|No Intervention|Historical matched control|age-matched historical controls
89505457|NCT02193035|Experimental|Single group|Patients with severe aortic stenosis treated with transcatheter aortic valve replacement (TAVR). Microparticle levels will be measured before and after TAVR.
89505458|NCT02379897|Experimental|LowGI+ModCarb|Low glycemic index + moderate carbohydrate/moderate fat diet
89505459|NCT02379897|Experimental|LowGI+HighCarb|Low glycemic index + high carbohydrate/low fat diet
89505460|NCT02379897|Experimental|HighGI+ModCarb|High glycemic index + moderate carbohydrate/moderate fat diet
89505461|NCT02379897|Experimental|HighGI+HighCarb|High glycemic index + high carbohydrate/low fat diet
89505462|NCT02287987|Active Comparator|Clamp|Laparoscopic robot-assisted partial nephrectomy with clamping the renal pedicle during the resection of the tumor
89505463|NCT02287987|Experimental|Off clamp|Laparoscopic robot-assisted partial nephrectomy without clamping the renal pedicle during the resection of the tumor
89505464|NCT03535415|Experimental|rhGH Injection|rhGH 0.05mg/kg/d by subcutaneous injection
89505465|NCT03535415|No Intervention|Non-treatment control group|Only follow-up without treatment
89505466|NCT02379741|Experimental|ADC-1013 intratumoral|ADC-1013 (agonistic human monoclonal IgG1 anti-CD40 antibody) administered by intratumoral injection every second week for 8 weeks. Patients that do not progress will be offered continued treatment until complete response, confirmed progressive disease, or clinical deterioration.
89505467|NCT02379741|Experimental|ADC-1013 intravenous|ADC-1013 (agonistic human monoclonal IgG1 anti-CD40 antibody) administered by intravenous infusion every second week until complete response, confirmed progressive disease, or clinical deterioration.
89505468|NCT02030717|Experimental|Spinal anesthesia|The drugs used in the spinal injection are: 12 mg bupivacain, 160 ug morfin och klonidin( < 60 years 75 ug, 60 - 85 years old 60 ug and older than 85 years 45 ug)
89505469|NCT02030717|Active Comparator|Epidural anesthesia|Epidural anesthesia patients group gets an epidural catheter at level Th 8- 10 with per- and postoperative infusion with a routine mixture of: bupivacain 1 mg/ml, fentanyl 1 ug/ml, and adrenalin 1 ug/ml) until termination.
89505470|NCT02371473|Experimental|#1 (Acetazolamide-placebo)|The arm #1 consists of 6 eligible patients who receive Acetazolamide 250mg once daily an hour before sleep for first six nights and after two weeks washout they receive placebo for six nights in the same order. After each six-day period they undergo polysomnography.
89505471|NCT02371473|Experimental|#2 (Placebo-acetazolamide)|The arm #2 consists of 6 eligible patients who receive placebo once daily an hour before sleep for first six nights and after two weeks washout they receive acetazolamide 250mg for six nights in the same order. After each six-day period they undergo polysomnography.
89505472|NCT04301661||ABC/3TC Cohort|"Persons on abacavir/lamivudine-containing therapy as part of their standard HIV care will continue to take their prescribed HIV medications.~Participants will be on study for 4 weeks, and will participate in directly observed therapy for the 4 weeks leading up to a single blood draw."
89505473|NCT04301661||TAF/FTC Cohort|"Persons on tenofovir alafenamide/emtricitabine-containing therapy as part of their standard HIV care will continue to take their prescribed HIV medications.~Participants will be on study for 4 weeks, and will participate in directly observed therapy for the 4 weeks leading up to a single blood draw."
89505474|NCT04301661||Switch Cohort|"Persons switching from abacavir/lamivudine-containing therapy as part of their standard HIV care will change to their newly prescribed regimen.~Participants will be on study for 3 weeks, and will have blood drawn at Days 0, 1, 3, 7, 10, 14, 18, and 21 following their switch."
89505475|NCT03530527|Active Comparator|ERCP with biliary stenting|Patient will be undergone ERCP with biliary stenting for biliary decompression to relieve biliary obstruction.
89505476|NCT03530527|Active Comparator|EUS guided biliary drainage|Patient will be undergone EGBD for biliary decompression to relieve biliary obstruction.
89505477|NCT02189057|Experimental|GeneSight guided treatment|GeneSight guided group will have their research psychiatrist make treatment recommendations based on AssureRx GeneSight genotyping results.
89505478|NCT02189057|Active Comparator|Treatment as usual group|Treatment as usual group will have treatment recommendations based on clinical judgment
89505479|NCT02371551||1|All patients
89505480|NCT02194049|Experimental|BKM 120, cisplatin, etoposide|Patients receive PI3K Inhibitor BKM120 PO QD on days 1-21, cisplatin IV over 2 hours on day 1 and etoposide IV over 1 hour on days 1-3. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
89505481|NCT02371317|Experimental|Mindfulness-Based Stress Reduction|The Mindfulness-Based Stress Reduction intervention includes eight 2.5-hour weekly group sessions and an all-day retreat.
89505482|NCT02371317|Active Comparator|Stress Management Education|The Stress Management Education intervention includes eight 2.5-hour weekly group sessions and an all-day retreat.
89505483|NCT02371317|Other|AHA Recommended Self-Care|All participants will receive the American Heart Association - Understanding and Controlling Your High Blood Pressure Brochure and information on the Dietary Approach to Stop Hypertension from the National Institutes of Health. These brochures describe ways that individuals can improve their lifestyle through better diet and exercise. Participants will get a chance to try and make healthy lifestyle changes on their own, using this information.
89505484|NCT02189135|No Intervention|Usual care|Usual care from physician/ doctor
89505485|NCT02189135|Experimental|Telemedicine|Mobile wireless glucometer with feedback from physicians
89023753|NCT04800315|Experimental|Dose 1: CC-93538 SC QW|Administration of CC-93538 Subcutaneous (SC) Once weekly (QW) for 16 weeks.
89210489|NCT03323502|Experimental|ACP Specialist Program|The ACP Specialist will work with nursing home leaders to: i. Consolidate nursing home ACP procedures; ii. Train and educate staff; and iii. Facilitate ACP with patients who have Alzheimer's Disease/related dementias and their family caregivers.
89210490|NCT03323502|No Intervention|Control|There is no study interaction with control facilities. Facility will follow usual ACP procedures.
89210491|NCT00630812|Experimental|A|active treatment
89505486|NCT02379663|Active Comparator|Oral direct Factor Xa inhibitor|Rivaroxaban
89505487|NCT02379663|Active Comparator|Low molecular weight heparin|Enoxaparin
89505488|NCT02379663|Placebo Comparator|Normal Saline|Normal Saline
89505489|NCT02288065||responders|amelioration of dyspnea radiological amelioration after sterile talc pleurodesis
89505490|NCT02288065||failed intervention|unchanged symptoms and radiology after sterile talc pleurodesis
89505491|NCT02189291|Experimental|Immediate catheter removal|The indwelling Foley catheter will be removed prior to exiting the operating room.
89505492|NCT02189291|Active Comparator|Post op day 1 catheter removal|Patients assigned to this group will follow the standard of care at present, with removal of indwelling catheter on the morning of postoperative day 1.
89505493|NCT02379507|Experimental|DEC033 Study Product|Apply twice a day
89505494|NCT02288143|Experimental|COOL-COS|All women will receive the intervention: Letrozole, Clomiphene, and low-dose hMG for the controlled ovarian stimulation.
89505495|NCT02379351|Experimental|In-Home Non-Stress Test Device|Patients with physician-ordered twice-weekly NSTs scheduled in the OB Diagnostic Center at University of Utah Hospital will be eligible for enrollment. After being taught how to use the Airstrip® Sense4Baby™ system machine, participants will use the device on a weekly basis (at home) until the time of delivery. Participants will also receive an in clinic NST once a week.
89505496|NCT03535805|Experimental|Mind My Mind (MMM)|Mind My Mind (MMM)
89505497|NCT03535805|Active Comparator|Treatment as Usual (TAU)|Treatment as Usual (TAU)
89505498|NCT04469647||High-risk|Employees at high-risk of Coronavirus exposure areas (physicians, nurses, respiratory therapists, radiology technologists, lab technologists, housekeepers)
89505499|NCT04469647||Low-risk|Employees working at lower risk areas such as (administration, HR, Public relations)
89505500|NCT02030639|Experimental|[14C]-rigosertib|A single dose of 450 mg of rigosertib containing 250 microcuries of carbon 14-labeled rigosertib ([14C]-rigosertib) administered as a continuous intravenous (CIV) infusion over 24 hours to healthy volunteers.
89505501|NCT02189369|Experimental|Day 3 embryo-Own-above cutoff|Day 3 embryo transfer for IVF with own oocytes, and prostaglandine levels with higher receptivty rates
89505502|NCT02189369|Experimental|Day 5 embryo-Own-above cutoff|Day 5 embryo transfer for IVF with own oocytes, and prostaglandine levels with higher receptivty rates
89505503|NCT02189369|Experimental|Day 3 embryo-Donor-above cutoff|Day 3 embryo transfer for IVF with donor oocytes, and prostaglandine levels with higher receptivty rates
89505504|NCT02189369|Experimental|Day 5 embryo-Donor- above cutoff|Day 5 embryo transfer for IVF with donor oocytes, and prostaglandine levels with higher receptivty rates
89505505|NCT02189369|Experimental|Day 3 embryo-Donor-lower cutoff|Day 3 embryo transfer for IVF with donor oocytes, and prostaglandine levels with lower receptivty rates
89505506|NCT02189369|Experimental|Day 5 embryo-Donor-lower cutoff|Day 5 embryo transfer for IVF with donor oocytes, and prostaglandine levels with lower receptivty rates
89505507|NCT02189369|Experimental|Day 3 embryo-own-lower cutoff|Day 3 embryo transfer for IVF with own oocytes, and prostaglandine levels with lower receptivty rates
89505508|NCT02189369|Experimental|Day 5 embryo-own-lower cutoff|Day 5 embryo transfer for IVF with own oocytes, and prostaglandine levels with lower receptivty rates
89505509|NCT02189447|Experimental|Refractive surgery|Patients with keratoconus treated with simultaneous photorefractive keratectomy and Corneal collagen cross-linking.
89505510|NCT02189525||Sports induced concussion|Exposure to sports induced concussion
89505511|NCT02189525||Routine Athletic Exertion|Exposure to routine athletic exertion without sports-induced concussion (non-concussion control)
89505512|NCT02288299|Experimental|non invasive mechanical ventilation|Patients suffering from neuromuscular disease with NIV indication and cough inefficiency
89023754|NCT04800315|Experimental|Dose 2: CC-93538 SC Q2W and Placebo alternating every other week SC Q2W|Starting at the baseline visit, active IP will be administered. On the alternate weeks, placebo will be administered to maintain the blind.
89023755|NCT04800315|Experimental|Dose 3: CC-93538 SC Q2W and Placebo SC weekly|"Starting at the baseline visit, active IP and matching placebo will be administered.~On the alternate weeks, placebo will be administered weekly to maintain the blind."
89023756|NCT04800315|Placebo Comparator|Placebo SC QW|Administration of placebo each week.
89023757|NCT04789252||Patients with NSCLC or with colon cancer|"The subjects are men or women with aged more than 18 years suffering from colon or lung cancer; The lesions are more than 1 cm. They are also able to give informed consent.~The pathologist will sample the material and select the tissue that can be used for the experiment after having taken all that is needed for diagnostic purposes. The research sample will be placed in test tubes and kept on ice.~It will then be sent to University of Milano-Bicocca laboratory whrere It will analyze approximately 60 patients for immunofluorescence studies and 4 patients for single cell transcriptomic analyzes"
89023758|NCT04780516||Participants Treated With Risankizumab|Participants will receive risankizumab (Skyrizi) as prescribed by the physician according to the local label.
89023759|NCT04776486|Experimental|Critically ill patients with augmented renal clearance|ICU patients with estimated renal clearance over 130ml/min/1.73m2
89538794|NCT04963257|Experimental|sertraline combined with fluvoxamine|Sertraline combined with fluvoxamine treatment group: Gradually add the drug to the treatment dose, and monitor the symptom change, scale score, blood drug concentration and other indicators
89538795|NCT04963257|Active Comparator|sertraline combined with aripiprazole|sertraline combined with aripiprazole treatment group:Gradually add the drug to the treatment dose, and monitor the symptom change, scale score, blood drug concentration and other indicators
89538796|NCT04953819||Revascularization group|This group includes patients with dialysis who have received revascularization by percutaneous coronary intervention or coronary artery bypass grafting for coronary artery disease.
89023760|NCT04776005||Patients with malignant disease undergoing chemotherapy|Patients with malignant disease undergoing chemotherapy within the University Hospital Centre AP-HP.Nord, who have voluntarily agreed to be vaccinated with an approved vaccine against the Sars-CoV-2 virus.
89206732|NCT00838656|Experimental|Arm II|Patients receive carboplatin IV over 1 hour on day 1. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients may undergo treatment with paclitaxel and may also receive 6 more courses of neoadjuvant chemotherapy. Patients may then undergo surgery. After surgery, patients receive paclitaxel IV over 3 hours and gemcitabine hydrochloride IV over 30 minutes on day 1. Treatment repeats every 2 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
89538797|NCT04953819||Medical treatment group|This group includes patients who have received medical therapy for coronary artery disease, not percutaneous coronary intervention or coronary artery bypass grafting.
89538798|NCT03260309|Experimental|semi-closed system group|"Semi-closed loop infusion system tactic. Programmed iv fluid and blood infusion system ,,Belmont Rapid Infuser and programmable syringe pump for adrenaline infusion."
89538799|NCT03260309|Experimental|control group|Routine infusion therapy tactic
89538800|NCT03260153|Experimental|Deproteinised Calf Blood Serum Injection|Participants will be randomly assigned to receive Deproteinised Calf Blood Serum Injection or placebo within 1 hour after randomization, once a day for 14 days.
89538801|NCT03260153|Placebo Comparator|Sodium Chloride Physiological Solution|Participants will be randomly assigned to receive Deproteinised Calf Blood Serum Injection or placebo within 1 hour after randomization, once a day for 14 days.
89023761|NCT04776005||Patients with malignant disease undergoing chemotherapy + immunotherapy|Patients with malignant disease undergoing chemotherapy + immunotherapy within the University Hospital Centre AP-HP.Nord, who have voluntarily agreed to be vaccinated with an approved vaccine against the Sars-CoV-2 virus.
89538802|NCT04966845||Smokers|Exclusive smokers of convnetional cigarettes
89538803|NCT04966845||HNBC|Exclusive smokers of Heat-Not-Burn Cigarettes (HNBC)
89538804|NCT04966845||Nonsmokers|Subjects that abstain from smoking for at least one year
89538805|NCT04953741|Active Comparator|Stop Fluticasone propionate Inhaled Aerosol Firstly|Reduced dose Fluticasone propionate Inhaled Aerosol 125 ug once a day and continuation of montelukast once a day，and then stopped Fluticasone propionate Inhaled Aerosol and continuation of montelukast once a day
89538806|NCT04953741|Active Comparator|Stop Montelukast Secondly|Reduced dose Fluticasone propionate Inhaled Aerosol 125 ug once a day and continuation of montelukast once a day，and then stopped montelukast and continuation of Fluticasone propionate Inhaled Aerosol 125 ug once a day
89538807|NCT04953741|Active Comparator|Stop Montelukast Firstly|stopped montelukast and continuation of Fluticasone propionate Inhaled Aerosol 125 ug twice daily, and then Reduced dose Fluticasone propionate Inhaled Aerosol 125 ug once a day
89538808|NCT03254771|No Intervention|Control group|In the control group, the usual explanation about the disease and the possibilities of treatment will be followed
89538809|NCT03254771|Experimental|Intervention group|In the Intervention group, the Decision Aid (DA) will be presented and explained to the patient by research personnel at a schedule previously agreed with the patient. The patient will be given a paper copy of the (DA) to take home, as well as a web link to the computer application, and oral and written instructions to review the material again and perform value clarification exercises.
89538810|NCT02455739|Experimental|chewing gum positive|chewing gum group will chew gum
89538811|NCT02455739|No Intervention|chewing gum negative|chewing gum group will not chew gum
89538812|NCT04966143|Experimental|Treatment group|
89538813|NCT03260231|Active Comparator|Intervention group|Dietary Supplement: Milled Seed Mix Intervention arm includes milled mix of flax, sesame and pumpkin seeds (18/6/6 g) in sour milk taken as dietary replacement meal during the day, and between lunch and dinner. Seeds are provided with the same producer at the Belgrade market.
89538814|NCT03260231|No Intervention|Control group|No supplement Control arm includes nutritional counseling with a similar dietary regime as for the intervention arm, but without milled seed mix. patients were instructed to avoid plant seeds during the study.
89206733|NCT03964636||no contraceptive intake|
89538815|NCT04953663|Experimental|Low dose group|0.5 × 10 ^ 6 / kg (body weight) of it-hMSC per person
89538816|NCT04953663|Experimental|Middle dose group|1 × 10 ^ 6 / kg (body weight) of it-hMSC per person
89538817|NCT04953663|Experimental|High dose group|2 × 10 ^ 6 / kg (body weight) of it-hMSC per person
89538818|NCT04953663|Experimental|Highest dose cell group|Highest dose of it-hMSC
89538819|NCT04953663|Experimental|Sub high dose cell group|Sub high dose of it-hMSC
89538820|NCT04953663|Placebo Comparator|placebo group|placebo
89538821|NCT03255005|Active Comparator|Treatment group|Endoscopic sleeve gastroplasty (Endomina) at J0 with multidisciplinary follow-up for 1 year
89538822|NCT03255005|Active Comparator|Controled group|Diet for 6 months then Endoscopic sleeve gastroplasty (Endomina) with multidisciplinary follow-up for 1 year
89538823|NCT04953585||Normal D-dimer group|preoperative plasma D-dimer levels less than or equal to 1mg/L
89538824|NCT04953585||Elevated D-dimer group|preoperative plasma D-dimer levels greater than 1mg/L
89538825|NCT03440801|Experimental|Synergy|Biodegradable-polymer everolimus-eluting stent Synergy
89538826|NCT03440801|Active Comparator|Xience|Durable-polymer everolimus-eluting stent Xience
89538827|NCT04953429||nurses|nurses in a third-grade hospital in Beijing
89538828|NCT03254537|Experimental|Mediterranean Organic|
89206734|NCT03964636||combined 1st/2nd generation oral contraceptives intake|
89206735|NCT03964636||3rd/4th generation combined oral contraceptives intake|
89206736|NCT00838734||1|Pre-LASIK
89206737|NCT00838734||2|Post-LASIK
89206738|NCT03998098||Oxygen Saturation (Oximetry)|Arm to determine the performance of the Oxygen Saturation measurement in LifeLight First
89206739|NCT03998098||Heart Rate (Pulse)|Arm to determine the performance of the Heart Rate measurement in LifeLight First
89210492|NCT00630812|Placebo Comparator|B|
89538829|NCT03254537|Experimental|Mediterranean conventional|
89538830|NCT04953351|Experimental|cognitive registration targeted biopsy|
89538831|NCT04953351|Active Comparator|MRI-ultrasound fusion targeted biopsy|
89538832|NCT04963491|Experimental|3D printed personalized TKA prosthesis|Design：Personalized TKA prosthesis Manufacture：3D
89538833|NCT04963491|Active Comparator|Zimmer NexGen TKA prostheses|Prosthesis has been widely used in clinic
89538834|NCT03259919|Experimental|Metformin|Metformin 850 mg x 2 daily
89538835|NCT03259919|Placebo Comparator|placebo|Placebo 1 tablet x 2 daily
89538836|NCT04965987|Active Comparator|Oxaloacetate|"Oxaloacetate (OAA) is a four-carbon molecule involved in many metabolic pathways, including gluconeogenesis, citric acid cycle, glyoxylate cycle, urea cycle, and amino acid metabolism. In the glyoxylate and citric acid cycles, oxaloacetate is formed as the result of the catalysis by malate dehydrogenase.~Subjects will take either 500mg BID, 1000mg BID, or 2000mg BID each day for 4 weeks, depending on which cohort they are assigned to."
89538837|NCT04965987|Placebo Comparator|Placebo|Subjects will take either 500mg BID, 1000mg BID, or 2000mg BID each day for 4 weeks, depending on which cohort they are assigned to.
89538838|NCT02455973|Experimental|Transtheoretical model of change|In this type of intervention, the focus will be the development of skills through educational activities on health based on interdisciplinary motivational strategies.
89538839|NCT02455973|Placebo Comparator|Health information|In this type of intervention, the focus will be the development of skills through educational activities on health using the pedagogy of transmission.
89538840|NCT04962945|Active Comparator|Oblique-axis approach group|The first two attempts via the oblique-axis approach will be performed . If the first two attempts failed, the subsequent attempts of venipuncture were performed using the long-axis approach.
89538841|NCT04962945|Active Comparator|Long-axis approach group|The first two attempts via the long-axis approach will be performed . If the first two attempts failed, the subsequent attempts of venipuncture were performed using the oblique-axis approach.
89538842|NCT03254615|Experimental|Group 1|"Group I will receive I Prefer Plain Water only during the first grade"
89538843|NCT03254615|Experimental|Group 2|"Group II will receive I Prefer Plain Water during first and second grades"
89538844|NCT03254615|Experimental|Group 3|"Group III will receive I Prefer Plain Water during first, second, and third grades"
89538845|NCT04965831|Experimental|Furmonertinib|Furmonertinib as perioperation therapy
89538846|NCT03254693|Active Comparator|1-step self-etch approach (SE)|According to the manufacturer's instructions.
89505513|NCT02189603|Experimental|Senior group(over 65 years old)-HE|Anti-HEV IgG seronegative participants over 65 years old were enrolled. Hepatitis E vaccine, containing 30mcg of HEV239 recombinant antigen adsorbed to alum adjuvant suspended in 0.5ml phosphate buffer, was given at 0, 1, 6m for three doses.
89505514|NCT02189603|Active Comparator|Younger groups(16-65 years old)|Participants aged 16-65 years old were enrolled. Hepatitis E vaccine, containing 30mcg of HEV239 recombinant antigen adsorbed to alum adjuvant suspended in 0.5ml phosphate buffer, was given at 0, 1, 6m for three doses.
89206740|NCT03998098||Respiratory Rate|Arm to determine the performance of the Respiratory Rate measurement in LifeLight First
89505515|NCT02189603|No Intervention|Senior group(over 65 years old)-Cont|Anti-HEV IgG seropositive participants over 65 years old were enrolled. This is the safety control group, without any intervention.
89505516|NCT03530449||Subjects with Normal Eyes|Color Fundus Photography, Optical Coherence Tomography, and OCT Angiography scans as per protocol in subjects without ophthalmic pathology
89505517|NCT03530449||Subjects with Retinal Vascular Pathology|Color Fundus Photography, Optical Coherence Tomography, and OCT Angiography scans as per protocol in subjects with retinal vascular ophthalmic pathology
89505518|NCT02376855|No Intervention|Control|Providers in the Control group followed standard care protocols. If they deemed a patient was in need of cardiology consultation, a referral was created using the standard process. The referral was processed by a referral coordinator and transmitted to an appropriate cardiologist. An appointment was then scheduled for the patient to have an in-person consultation with a cardiologist.
89505519|NCT02376855|Experimental|eConsult|"The intervention consisted of an eConsult pathway and standardized protocol for PCPs to obtain cardiology consults using a secure messaging peer to peer (P2P) module embedded within the EHR. Intervention providers were asked to send all cardiology referrals for their adult patients through the eConsult system. Providers could bypass the eConsult pathway for patients with established relationships with a cardiologist or for whom providers felt a consult was urgent (required a face-to-face visit within a week or less). eConsults contain reason for consult, relevant test results, records or reports but are sent electronically to a Cardiology Consultant for review. eConsults were responded to within two business days. Responses were case-specific and generally contained recommendations for management, additional testing, or a face-to-face cardiology visit. The PCP was responsible for considering/acting upon recommendations and determining when an eConsult was complete."
89505520|NCT02030795|Active Comparator|Disconnection group|The single lumen tube was disconnected from the ventilator for 60 s allowing the surgical lung to collapse.
89505521|NCT02030795|Active Comparator|Bronchial Suction group|The suction port of the bronchial blocker, and connected to -30 cm H2O of suction.
89505522|NCT02376777||Patient receiving NOAC|Follow up of patients receiving new oral anticoagulants (NOAC) medication
89505523|NCT02376777||Patient receiving VKA|Follow up of patients receiving vitamin K antagonist (VKA) medication
89505524|NCT02030873|Experimental|Virtual simulation training first|Participants in this arm receive virtual simulation training before dissection training.
89505525|NCT02030873|No Intervention|Dissection training first|Participants in this arm receive dissection training first and then virtual simulation training.
89505526|NCT02193113|Experimental|KVD001 Injection Dose 1|Single 100 microliters (uL) intravitreal injection of KVD001 Injection Dose 1
89505527|NCT02193113|Experimental|KVD001 Injection Dose 2|Single 100uL intravitreal injection KVD001 injection Dose 2
89505528|NCT02193113|Experimental|KVD001 Injection Dose 3|Single 100uL intravitreal injection of KVD001 injection Dose 3
89505529|NCT02193269|Placebo Comparator|sugar pill|0.0mg
89505530|NCT02193269|Active Comparator|Minocycline|200mg
89206741|NCT03998098||Blood Pressure|Arm to determine the performance of the Blood Pressure measurement in LifeLight First
89505531|NCT02371239|Experimental|Sitting regime|The subjects will follow the sitting regime during four days. Each day: 14 hours sitting, 1 hour walking and 1 hour standing for daily care and 8 hours sleeping or lying.
89505532|NCT02371239|Experimental|Sit Less regime|Subjects will follow the sit less regime during four days. Each day will consist of 3 hours walking, 4 hours standing, 9 hours sitting and 8 hours sleeping or lying. The additional 2 hours of walking and 3 hours of standing, compared to the sitting regime, will be done in a minimum of four bouts with a time interval of > 1 hour. The subjects will be instructed to walk on a slow pace. i.e. 2-3 km/h, which is comparable to walking during shopping, walking to the office etc.
89505533|NCT02371239|Experimental|Exercise regime|Subjects will follow the exercise regime during four days. Each day will consist of 13 hours and 15 minutes sitting, ± 45 minutes supervised cycling on an ergometer, 1 hour walking and 1 hour standing for daily care and 8 hours sleeping or lying.
89505534|NCT02194127|Experimental|Anthocyan capsules|capsules containing 160 mg standardised bilberry extract (25% anthocyanidines)
89505535|NCT02194127|Placebo Comparator|Placebo|
89505536|NCT02371083|No Intervention|Routine|Subjects will continue with regular pessary care every 12 weeks.
89505537|NCT02371083|Experimental|Extended|Subjects will have extended time between pessary care visits which will occur every 24 weeks.
89505538|NCT02189681|Active Comparator|Group C|Patients in this group underwent Conventional landmark guided midline spinal anaesthesia.
89505539|NCT02189681|Experimental|Group P|This group had pre-procedure ultrasound guided L5S1 paramedian spinal anaesthesia performed
89505540|NCT04188639|Experimental|Treatment with emicizumab|
89505541|NCT05715385|Active Comparator|Laser photocoagulation|"Grid laser was performed under topical anesthesia with frequency doubled Nd YAG laser of wavelength 532 nm.~Laser Parameters for grid photocoagulation Lens used: Mainster grid lens Spot size: 75-100μ The burn intensity for grid laser: barely visible (light grey) Power: 80-100mw depending on the condition of the laser, the opacities in the media and background pigmentation.~Duration: 100msec No. of spots: 80-100 Laser burns were placed at least one burn width apart. Wider if the thickening was less severe. If necessary, the grid laser extended up to 2 disc diameters superiorly, inferiorly and temporally from the centre of the macula. Treating the area within 500 microns of the disc margin or the centre of the macula was avoided."
89505542|NCT05715385|Active Comparator|Bromfenac 0.09%|Twice daily eye drop bromfenac 0.09% for 6 weeks
89505543|NCT05715385|Placebo Comparator|Observation|Eye drop carboxymethyl cellulose 0.5% to be instilled thrice a day for 6 weeks
89505544|NCT02189993||Total Parenteral Nutrition Use|The cohort investigated consisted of patients with intestinal failure requiring total parenteral nutrition use.
89505545|NCT03133507|Experimental|Reapprasial Condition|Children in this condition will be instructed to think about how the procedure will help them become adjusted to cold weather.
89505546|NCT03133507|Experimental|Reassurance Condition|Children will receive empathic support from the experimenter.
89505547|NCT03133507|Experimental|Distraction Condition|Children in this condition will be instructed to focus their attention on a picture on a computer screen rather than on the pain.
89505548|NCT02194205|Experimental|COMBIVENT HFA|
89505549|NCT02194205|Placebo Comparator|Placebo HFA|
89505550|NCT02194205|Active Comparator|COMBIVENT (CFC)|
89505551|NCT02194205|Placebo Comparator|Placebo CFC|
89505552|NCT03133663|Active Comparator|Control group|Pulse oximeter and auscultation to determine heart rate during neonatal resuscitation. Pulse oximeter will be used to determine oxygen saturation.
89505553|NCT03133663|Experimental|Electrocardiogram group|Electrocardiogram to determine heart rate during neonatal resuscitation. Pulse oximeter will still be used per Neonatal Resuscitation Program guidelines for oxygen saturation.
89505554|NCT02194361|Experimental|Anthocyan capsules|
89505555|NCT02194361|Placebo Comparator|Placebo|
89505556|NCT03133741|Placebo Comparator|Placebo|Saline
89505557|NCT03133741|Other|GIP-A|Infusion of GIP-A alone as study tool.
89505558|NCT03133741|Other|GLP-1 receptor antagonist Exendin[9-39]|Infusion of GLP-1 receptor antagonist Exendin[9-39] alone as study tool.
89505559|NCT03133741|Other|GIP-A + Exendin[9-39]|Infusion of GIP-A + GLP-1 receptor antagonist Exendin[9-39] together as study tools.
89505560|NCT02371005|Other|Measurement of the periodontal ligament space|Evaluation of the width of the ligament in patients with SSc and comparison to the width found in control.
89505561|NCT02371005|Other|Radiographic analysis of oro-facial manifestations|Establishment of a complete clinical phenotypic description of oral manifestations associated with SSc and comparison with the control group.
89505562|NCT02288455|Experimental|RELIEF II - GTU AUS|Prospective, non-randomized multi-center study testing the safety and efficacy of the GTU Artificial Urinary Sphincter device in males with stress urinary incontinence.
89505563|NCT02194517|No Intervention|control (B)|Patients performing CHO and FP exchanges calculation with standard method.
89505564|NCT02194517|Experimental|ELKa (A)|Patients counting CHO and FP exchanges with ELKa toolset.
89505565|NCT02371161|Experimental|R-DHAP/R-ICE|High-dose myeloablative therapy (R-DHAP or R-ICE) and conditioning therapy (BEAM or FEAM) in elderly patients with relapsed NHL or resistant to firs line therapy
88815251|NCT00980642|Other|General anesthesia|Temperature is measured by Draeger double-sensor and esophageal stethoscope temperature sensor every 5-min during the surgery.
89505566|NCT03532633||23-27w|preterm infants 23+0-27+6SSW
89505567|NCT03532633||28-31w|preterm infants 28+0-31+6SSW
89505568|NCT03532633||32-34w|preterm infants 32+0 - 34+6SSW
89505569|NCT03532633||35-36w|preterm infants 35+0-36+6 SSW
89505570|NCT03532633||37-42w|term infants 37+0-42+6
89505571|NCT02195843|Active Comparator|Emperical|Anatomical optimization of device and leads
89505572|NCT02195843|Active Comparator|Electrical|Electrical optimization by RVLV Conduction Time with VectSelect
89505573|NCT00266461|Experimental|TU-100 7.5g/day|Subjects will be randomized to TU-100 7.5g, 15g, or no active treatment group. Subjects will take a daily dose divided into 3 times a day.
89505574|NCT00266461|Experimental|TU-100 15g/day|Subjects will be randomized to TU-100 7.5g, 15g, or no active treatment group. Subjects will take a daily dose divided into 3 times a day.
89505575|NCT00266461|No Intervention|Water|Subjects will be randomized to TU-100 7.5g, 15g, or no active treatment group. Subjects will take a daily dose divided into 3 times a day.
89505576|NCT02194283|Experimental|Ambroxol - in single rising doses|
89505577|NCT02194283|Placebo Comparator|Placebo|
89505578|NCT02376543|Active Comparator|19 Gauge EUS FNA BNX|Subjects receiving EUS and fluoroscopic guidance for placement of fiducial markers into the pancreas will have the 19 gauge technique (ARM 1) of EUS guided fiducial marker technique.
89505579|NCT02376543|Active Comparator|22 Gauge EUS FNA BNX|Subjects receiving EUS and fluoroscopic guidance for placement of fiducial markers into the pancreas will have the 22 gauge technique (ARM 2) of EUS guided fiducial marker technique.
89505580|NCT02195999||Individuals with DMD|"Magnetic Resonance Imaging is a non-invasive method to determine ventricular size, volumes, mass, and ejection fraction.~Pulmonary Function testing (PFT) are a series of non-invasive breathing tests that characterize respiratory muscle function, as well as lung compliance and physiology.~Metabolic exercise testing using stationary bicycle (exercise capacity and MVO2) evaluates global cardiopulmonary functional status.~Echocardiogram with multiple-echo Dixon method helps to assess cross-sectional and longitudinal variations in myocardial structure."
89505581|NCT02370771|Experimental|Patient with hand osteoarthritis|Biological sampling and Radiographic evaluation of patient with erosive and non erosive hand osteoarthritis
89505582|NCT05725447||Patients group|Individuals with premenstrual syndrome
89505583|NCT02376621|Active Comparator|PronovaPure 150:500 triglycerides|3 × PronovaPure 150:500 triglycerides (TG) European Union (EU)
89505584|NCT02376621|Active Comparator|Pronovum PRF-048|3 × Pronovum PRF-048
89505585|NCT02376621|Active Comparator|Pronovum PRF-037|3 × Pronovum PRF-037
88957081|NCT01132976|Active Comparator|Goal-based motivational interview|Participants randomised to this group will receive the goal based motivational interview - Personal Concerns Inventory (PCI) in addition to treatment as usual.
89538847|NCT03254693|Active Comparator|selective enamel etching (SEE)|According to the manufacturer's instructions.
89538848|NCT03254693|Experimental|1-step self-etch for double time (SE2X)|According to the manufacturer's instructions, but for the double time (20 s) in the each application.
89538849|NCT03254693|Experimental|1-step self-etch additional layer (SE1+)|According to the manufacturer's instructions, but apply tree times.
89538850|NCT03259997|Active Comparator|Probiotic supplement|
89538851|NCT03259997|Placebo Comparator|Placebo|
89538852|NCT04953117|Experimental|small vessel cohort: DCB of Lepu Medical|receiving the treatment with DCB of Lepu Medical(dimeter≥2.00 mm) in small vessel cohort
89538853|NCT04953117|Active Comparator|small vessel cohort:Restore DEB|receiving the treatment with Restore DEB in small vessel cohort
89538854|NCT04953117|Other|very small vessel cohort: DCB of Lepu Medical|receiving the treatment with DCB of Lepu Medical(dimeter<2.00 mm) in very small vessel cohort
89538855|NCT02455661|Experimental|Radial PCI with TR Band (TM)|Patients with a PCI using the radial approach and the above radial compression device.
89538856|NCT02455661|Active Comparator|Femoral PCI with AngioSeal device|Patients with a PCI using the femoral approach and the above femoral vascular closure device.
89538857|NCT02455661|Active Comparator|Femoral PCI with StarClose device|
89538858|NCT03259841||Fasted patients for cholecyctectomy|The fasted patients for cholecyctectomy except exclusion criteria are included
89538859|NCT04965441||Computer-assisted surgery (CAS) group|
89538860|NCT04965441||Non-CAS group|
89538861|NCT03260075||ward cat|Patients and staff at wards that have a cat present
89538862|NCT03260075||no ward cat|Patients and staff at wards that have no cat present
89538863|NCT03060525|Experimental|Immediate Group Intervention|This arm will receive the DWW 2.0 Group intervention in Year 1 of the clinical trial. The group intervention will consist of groups of approximately 6-8 subjects who meet together for 16 weeks, for two hours each week. A trained, deaf, American Sign Language (ASL)-fluent DWW 2.0 counselor will lead the sessions. Subjects will be asked to complete a daily food and physical activity diary during the course of the 16-week intervention. Each intervention session will include a weigh-in, group sharing and problem solving, discussion of a weight management topic, which may include watching a powerpoint presentation and/or video; and a discussion on goal setting and action planning for the next week.
89538864|NCT03060525|Experimental|Immediate Videophone Intervention|This arm will receive the DWW 2.0 Individual Videophone intervention in Year 1 of the clinical trial. The participant and their intervention counselor will have one-on-one sessions that take place via videophone (like a Skype call), for one hour each week. Each session will be led by a trained deaf, ASL-fluent DWW 2.0 counselor and will be held at a scheduled appointment time that is agreed upon by the subject and the counselor. Subjects will be asked to complete a daily food and physical activity diary during the course of the 16-week intervention. Each intervention session will include a weigh-in, personal sharing and problem solving, discussion of a weight management topic, which may include watching a powerpoint presentation and/or video; and a discussion on goal setting and action planning for the next week.
88957082|NCT01132976|Other|Treatment as usual|Participants randomly allocated to this group will receive treatment as usual only, ie no specific motivational intervention.
88957083|NCT01132898||cross-sectional TBI|Participants with a mild, moderate, or severe Traumatic Brain Injury enrolled within 5 years from injury. Seen at only one visit.
88957084|NCT01132898||HV|Healthy Volunteer with no history of TBI
88957085|NCT01132898||Prospective TBI|Participants with a mild, moderate, or severe Traumatic Brain Injury enrolled within 1 year from injury.
89538865|NCT03060525|Other|Delayed Group Intervention|This arm will receive the DWW 2.0 Group intervention in Year 2 of the clinical trial. The group intervention will consist of groups of approximately 6-8 subjects who meet together for 16 weeks, for two hours each week. A trained, deaf, American Sign Language (ASL)-fluent DWW 2.0 counselor will lead the sessions. Subjects will be asked to complete a daily food and physical activity diary during the course of the 16-week intervention. Each intervention session will include a weigh-in, group sharing and problem solving, discussion of a weight management topic, which may include watching a powerpoint presentation and/or video; and a discussion on goal setting and action planning for the next week.
89538866|NCT03060525|Other|Delayed Videophone Intervention|This arm will receive the DWW 2.0 Individual Videophone intervention in Year 2 of the clinical trial. The participant and their intervention counselor will have one-on-one sessions that take place via videophone (like a Skype call), for one hour each week. Each session will be led by a trained deaf, ASL-fluent DWW 2.0 counselor and will be held at a scheduled appointment time that is agreed upon by the subject and the counselor. Subjects will be asked to complete a daily food and physical activity diary during the the course of the 16-week intervention. Each intervention session will include a weigh-in, personal sharing and problem solving, discussion of a weight management topic, which may include watching a powerpoint presentation and/or video; and a discussion on goal setting and action planning for the next week.
89538867|NCT02456051||High AM|Newly diagnosed diabetic patients with high Adrenomedullin serum levels
89538868|NCT02456051||Low AM|Newly diagnosed diabetic patients with low Adrenomedullin serum levels
89206742|NCT00829608|Experimental|Human Papillomavirus Vaccine|There are 9 participants currently being followed in the faculty sponsor's clinic that carry the clinical and histologic diagnosis of RRP. The 9 participants meet one or more of the following criteria: Surgery requirement of more than 4 procedures per year, distal multisite spread of disease, and rapid regrowth of papilloma disease with airway compromise.
89505586|NCT02376621|Active Comparator|PronovaPure 500:200 TG|3 × PronovaPure 500:200 TG EU
89505587|NCT02376621|Active Comparator|Pronovum PRF-047|3 × Pronovum PRF-047
89505588|NCT02288533|Experimental|real-tDCS|Participants will receive tDCS over the primary motor cortex bilaterally (M1). The excitability-enhancing anode electrode (saline-soaked sponge electrode - 16cm2) will be placed over the primary motor cortex, C3 and C4 (10/20 international EEG system). The excitability-diminishing cathode electrode will be placed over the supraorbital area. We will use the following stimulation parameters: intensity of 2 milliampere and for 40 minutes (10 consecutive sessions).
89505589|NCT04347941|Experimental|Prone Positioning|Intervention patients will remain up to 16 hours per day in Prone Positioning with 45 minutes breaks for meals
89505590|NCT04347941|Active Comparator|Standard Care|Control patients will receive full standard care. Prone Positioning as a rescue intervention is permitted and is recorded.
89505591|NCT02378727|Active Comparator|A Standard Care Group (SCG)|Standard Care Conventional Group (SCG): 158 subjects to receive lumbar epidural procedure with the loss of resistance syringe used to identify the epidural space
89505592|NCT02378727|Experimental|Experimental Procedure Group (EPG).|158 of subjects to receive lumbar epidural procedure with the CompuFlo® Epidural System used to identify the epidural space
89505593|NCT03534869|Experimental|Ear Acupuncture and Oral Analgesics|"The acupuncture treatment consisted of three acupuncture needles on the dominant ear according to French auriculotherapy guidelines - internal genital area, external genital area and Shen Men point that is used to increase the anaesthetic effect according to both French and Chinese traditions.~Additional oral analgesics (NSAID) could be supplied at any time upon patients request during hospitalization. Oral ibuprofen was given as first line therapy, while oral paracetamol was given as second line therapy."
89505594|NCT03534869|Active Comparator|Oral Analgesics Only|Postoperative standard oral analgesic therapy (NSAID) supplied at any time upon patients request during hospitalization. Oral ibuprofen would be given as first line therapy, while oral paracetamol would be given as second line therapy.
89505595|NCT03532321||Caregivers|Caregivers in the participating hospital departments : medical (doctors, midwives) and paramedical (nurses' aides, registered nurses, specialized nurses and head nurses) staff, working in hospital departments drawn at random among five volunteer hospital centers in Paris, and who will be present at the time of investigator's passage, at a date drawn at random during the inclusion phase.
89505596|NCT02370849|Experimental|NCS|nimotuzumab plus cisplatin and S-1
89505597|NCT02370849|Active Comparator|CS|cisplatin and S-1
89505598|NCT02194673|Experimental|Trans free palm margarine|One high fat muffin will be serves together with a glass of low fat milk shake.
89505599|NCT02194673|Experimental|Interesterified palm based margarine|One high fat muffin will be serves together with a glass of low fat milk shake.
89505600|NCT02194673|Experimental|IE soybean oil-based margarine|One high fat muffin will be serves together with a glass of low fat milk shake.
89505601|NCT03532165|Other|Positive lower extremity ultrasound|This group found to to have a deep venous thrombosis on lower extremity ultrasound will not have a CT of the chest ordered from the emergency department, and will be treated for the DVT and presumed PE.
89505602|NCT03532165|Other|Negative lower extremity ultrasound|This group that does not have a deep venous thrombosis on lower extremity ultrasound will proceed to get the CT of the chest .
88957086|NCT01132898||Remote Select Exposure Samples|Participants who are unable to travel to the NIH Clinical Center to participate can remote consent, answer questionnaires remotely, and have biospecimens sent to our lab for analysis.
89505603|NCT02197091||Observational (communication in oncology treatment)|Patients complete questionnaires, including the FACIT-TS-G, the FACIT-Sp12, the MOS-SSS, and the DT. Doctors also complete a questionnaire. Patients' medical records may be reviewed, if necessary.
89505604|NCT02378649|Experimental|Sildenafil|"PDEI or placebo will be administered in the surgical ICU 4-6 hours after arriving from the Operative Room. The initial Dose will be 20mg X 3 NG and can be increase to 40mg X 3, it will be administered PO if the patient extubated.~PDEI or placebo will continue up to 8 days or discharge."
88957087|NCT01132898||Select Exposure Group|US government associated personnel experiencing TBI-like symptoms arising after possible exposure to a non-natural energy source
88957088|NCT01132898||Select Exposure Matched Unaffected|a longitudinal control group comprised of unaffected volunteers matched to the Select Exposure group
89206743|NCT00838812|Other|clindamicin and tretinoin gel|
89206744|NCT00553605|Active Comparator|I|Ketoprofen plus placebo parecoxib
89206745|NCT00553605|Active Comparator|II|Parecoxib plus placebo ketoprofen
89206746|NCT02547246|Experimental|rTMS session|Patients will have a 20 minute session of rTMS at a frequency of 10 Hz.
89206747|NCT02547246|Placebo Comparator|rTMS placebo (SHAM) session|Patients will have a 20 minute session of placebo rTMS
89505605|NCT02378649|Placebo Comparator|Placebo|"PDEI or placebo will be administered in the surgical ICU 4-6 hours after arriving from the Operative Room. The initial Dose will be 20mg X 3 NG and can be increase to 40mg X 3, it will be administered PO if the patient extubated.~PDEI or placebo will continue up to 8 days or discharge."
89505606|NCT03534791|Experimental|Reminders|Reminders customized for each PLS, containing a name of the PLS indicated in the message. If the participants do not translate PLS within 2 months from PLS assignment, we will stop sending them reminders and we will consider them as dropouts.
89538869|NCT03058965|Experimental|[18F]MNI-958|To evaluate [18F]MNI-958, a tau targeted PET radioligand.
88957089|NCT01111617|Experimental|Real-Time fMRI|Real-Time fMRI
89505607|NCT03534791|No Intervention|Control group|Control group will receive no intervention, i.e. standard procedure. Participants in the control group will receive PLSs for translation, in the frequency they indicated, and they will not receive any reminders. They will be assigned new PLSs once they translate the ones that were previously assigned.
89505608|NCT02378571|No Intervention|Usual care|Participants assigned to usual care will also be provided with a GlowCap prior to discharge and will be instructed to take their loop diuretic from this bottle and to notify the study team about prescribed dose changes. This information, however, will solely be used to measure medication adherence and will not be provided to a member of the study team nor to any of the participants' health care providers until the completion of the study period, at least 1 month later. Participants will not be provided with any advice on heart failure adherence.
89505609|NCT02378571|Experimental|Medication adherence telemonitoring|At discharge, participants in the intervention group will be instructed to take their loop diuretic exclusively from the GlowCap in the manner prescribed by their physician. A study team member will review the adherence data on a daily basis (except holidays and weekends) during the first 7 days after discharge, and then on, at minimum, a weekly basis. The study team member will respond to adherence data using clinical judgment as they would if the information was obtained during clinical care. Specifically, when contacting nonadherent participants, the member of the study team will provide participants with feedback on their electronic adherence; will inquire about potential consequences of missed doses; and will assess and respond to reasons for missed doses.
89505610|NCT03530137|Other|families living at Families Moving Forward (FMF)|
89505611|NCT02197169|Experimental|DNX-2401 alone|Single intratumoral injection of DNX-2401
89505612|NCT02197169|Experimental|DNX-2401 + Interferon gamma (IFN-γ)|Interferon gamma (IFN-γ) beginning at Day 14
89505613|NCT02376309|Experimental|Leu during inactivity|Leucine supplements
89505614|NCT02376309|Experimental|ND during inactivity|Nandrolone injection
89505615|NCT05165849|Experimental|GFS101A+Toripalimab|Patient will be administrated with GFS101A IV in combination with Toripalimab IV. The duration of the treatment cycle is defined as 21 days.
89505616|NCT02376231|No Intervention|Standard Surgery without trial (PJ) device|Standard debulking surgery for EOC without interventional device
89505617|NCT02376231|Active Comparator|Surgery with trial (PJ) device|Debulking surgery for EOC with interventional trial device (PJ)
89505618|NCT00232141|Experimental|1|
89505619|NCT00232141|Placebo Comparator|2|
89505620|NCT02378415|Placebo Comparator|Normal Saline Infusion|A single IV bolus dose of normal saline solution.
89505621|NCT02378415|Experimental|Subanesthetic IV Bolus Ketamine|a single sub-anesthetic rapid IV bolus dose of ketamine administered to acutely depressed patients with or without suicidality
89505622|NCT02197325|Active Comparator|PICSO|Participants enrolled in the PICSO treatment Group will be treated with PICSO concomitant to pPCI in patients with anterior non ST-segment Elevation Myocardial Infarction or following pPCI in ST-segment Elevation Myocardial Infarction
89505623|NCT02197325|No Intervention|Parallel control|Participants enrolled in will receive treatment based on the standard guidelines for treatment of a myocardial infarction.
89505624|NCT02370459|No Intervention|control|This arm includes 30 high-volume primary care clinics in each of three states (Washington, Illinois, Michigan) for a total of 90 clinics. Clinics randomly assigned to this arm will receive no AFIX consultation.
89505625|NCT02370459|Experimental|AFIX in-person consultation|This arm includes 30 high-volume primary care clinics in each of three states (Washington, Illinois, Michigan) for a total of 90 clinics. Clinics randomly assigned to this arm will receive an in-person AFIX consultation. Consultations will be delivered by state health department staff.
89505626|NCT02370459|Experimental|AFIX webinar consultation|This arm includes 30 high-volume primary care clinics in each of three states (Washington, Illinois, Michigan) for a total of 90. Clinics randomly assigned to this arm will receive an AFIX consultation via interactive webinar. Consultations will be delivered by state health department staff.
89505627|NCT02196311||Supracondylar humerus fractures|We are looking to compare open reduction internal fixation versus circular external fixation for supracondylar humerus fractures.
89505628|NCT02378337||Retrospective development cohort|A total of 85 18F-FDG-PET adult studies were gathered over a 3-month period and retrospectively evaluated.
89505629|NCT02378337||Prospective validation cohort|To verify the application of methodology in clinical routine, we conducted a second phase of the study prospectively in 250 subjects (phase 2) using inclusion and exclusion criteria of the retrospective study (phase 1).
89505630|NCT02194751|Experimental|Oncoquest-L vaccine|Patients will receive a total of 5 single injections of Oncoquest-L; the first 2 doses administered will be separated by a 2-week interval and the remaining 3 doses will be administered each at 1-month intervals. With each dose of Oncoquest-L vaccine, the vaccine will be administered subcutaneously at 2 different sites in the upper arms or upper legs, with alternation of the injection sites with each administration.
89519330|NCT05697341|Active Comparator|Stented SWL Group (B)|In the stented ESWL group, a 5 Fr open-ended ureteral catheter was introduced in the renal pelvis, and a retrograde pyelogram was performed in the Lithotomy position after the induction of general anathesia. JJ is applied either 5-26 or 5-28 accorging to the patient. Extracorporeal shock wave lithotripsy ESWL was administered with an electromagnetic shockwave lithotripter (Siemens electromagnetic lithotripters devices). Patients were positioned supine with the shock head from the back. Fluoroscopy was used for the localization and monitoring of stone fragmentation. All patients received shocks at a frequency of 60/min. An average of approximately 2500-3000 shocks was targeted in all patients.
88957090|NCT01046825|Other|Group A|"Completely resected stage I or completely resected abdominal stage II lesions.~Group A will include: COPAD x 2 cycles."
88957091|NCT01046825|Other|Group B|"All cases not eligible for Group A or Group C. (Murphy Stage III and non-CNS Stage IV)~Group B will include the intervention COP, COPD M3, CYM as follows:~Pre-Phase: COP~Induction: COPAD M3 x 2 cycles~Consolidation: CYM x 2 cycles."
89505631|NCT02378493||Exposure: Concordance between tests|"The study population is composed of diabetic patients with foot wounds (at least stage >=2) that are infected by at least 1 strain of S. aureus. Patients whose antibiogrammes and Antibiofilmogrammes are concordant will fall into this group (the exposed group).~Upon inclusion, 1) all patients' wounds will be sampled, and 2) the associated bacterial strains identified via Vitek and 3) antibiograms performed; the latter are all part of routine procedure. 4) S. aureus isolates will be further analysed via an antiobiofilmogramme, which is an experimental element added by this research. At the end of the 1st regimen of antibiotics prescribed, if the treatment failed steps 1 to 4 can be repeated. 30 days after the end of the 1st regimen of antibiotics prescribed, steps 1 to 4 are systematically performed."
89505632|NCT02378493||Non exposure: Not concordance between tests.|"The study population is composed of diabetic patients with foot wounds (at least stage >=2) that are infected by at least 1 strain of S. aureus. Patients who do not fall into the concordance (exposure) group, will fall into the non exposure group. The latter includes semi-concordance or discordance between antibiogrammes and Antiobiofilmogrammes.~Upon inclusion, 1) all patients' wounds will be sampled, and 2) the associated bacterial strains identified via Vitek and 3) antibiograms performed; the latter are all part of routine procedure. 4) S. aureus isolates will be further analysed via an antiobiofilmogramme, which is an experimental element added by this research. At the end of the 1st regimen of antibiotics prescribed, if the treatment failed steps 1 to 4 can be repeated. 30 days after the end of the 1st regimen of antibiotics prescribed, steps 1 to 4 are systematically performed."
89505633|NCT02197403|Experimental|alcohol drinker & dexmedetomidine|dexmedetomidine, 200mcg in 50mL of normal saline 0.75mcg/Kg bolus injection in 10 minutes 0.1~1.0mcg/Kg infusion during surgery
89505634|NCT02197403|Active Comparator|alcohol drinker & propofol|Propofol (2% fresofol) 25~75mcg/kg/min continuous infusion
89505635|NCT02197403|Active Comparator|Non-alcohol drinker & dexmedetomidine|dexmedetomidine, 200mcg in 50mL of normal saline 0.75mcg/Kg bolus injection in 10 minutes 0.1~1.0mcg/Kg infusion during surgery
89505636|NCT02197403|Active Comparator|Non-alcohol drinker & propofol|Propofol (2% fresofol) 25~75mcg/kg/min continuous infusion
89505637|NCT02370381||Epistaxis|Patients with active anterior epistaxis
89505638|NCT02196389|Active Comparator|Nozovent|Nasal Dilator
89505639|NCT02196389|Active Comparator|Nasanita|Nasal Dilator
89505640|NCT02196389|Active Comparator|Breath Right|Nasal Dilator
89505641|NCT02196389|Active Comparator|Airmax|Nasal Dilator
89505642|NCT02197559||BMS group, DES group|All the participants in this group will be performed with bare-metal stents or drug -eluting stents
89505643|NCT02196467|Experimental|Myoblast transplantation & strength|30 million myoblasts will be transplanted per centimeter cube in the Extensor carpi radialis of one of the patient's forearms, resuspended in saline. The strength will be evaluated after 3 and 6 months and the presence of dystrophin after 3 or 6 months.
89505644|NCT02196467|Sham Comparator|Saline injection & strength|The same saline solution used in the previous arm, but without cells, will be injected similarly per centimeter cube in the Extensor carpi radialis of the contralateral patient's forearm. The strength will be evaluated after 3 and 6 months and the presence of dystrophin after 3 or 6 months.
89505645|NCT02370147|Experimental|Smoking reduction intervention arm|Smoking reduction intervention arm (SRI) consisting of a minimal face-to-face individual smoking reduction intervention lasted for about one minute, and five follow-up interventions lasted for about one minute each.
89505646|NCT02370147|Active Comparator|Control arm|Control arm (UC) consisting of a brief face-to-face individual exercise and dietetic advices lasted for the same intervention time as SRI, and five follow-up interventions lasted for about one minute each with different intervention contents.
89505647|NCT04247009|Active Comparator|Meat|Patients with RA served a meal of meat
89505648|NCT04247009|Active Comparator|Fish|Patients with RA served a meal of fish
89505649|NCT04247009|Active Comparator|Vegan|Patients with RA served a vegan meal
89505650|NCT04247009|Active Comparator|Meat controls|Matched controls served a meal of meat
89505651|NCT02370069|Active Comparator|Previous immunization with PPV23|Participants who have received a previous vaccination with 1 or more dose of PPV23 at least 12 months previously will receive one dose of 0.5 mL Prevnar 13 study vaccine.
89505652|NCT02370069|Active Comparator|Naive to PPV23|Participants who have never received a previous vaccination with PPV23 will receive one dose of 0.5 mL Prevnar 13 study vaccine.
89505653|NCT02378103||Case|Diagnosis of aortic dissection was based on history and physical examination, and confirmed by imaging, visualization at surgery, and/or postmortem examination. Simple aortic aneurysm and pseudoaneurysm were excluded. Simple aortic aneurysm and pseudoaneurysm were excluded. Surgical and endovascular treatments were the main interventions and performed in the case group.
89505654|NCT02378103||Control|As the control group, patients without AD were obtained from the hospitalized patients in the same period.
89505655|NCT02196545|Experimental|Exercise|Exercise, patients train on a specifically programmed movement trainer three times a week for 30 minutes (total duration 12 weeks)
89505656|NCT02196545|No Intervention|Treatment as usual|Treatment according to guidelines of German Society for Psychiatry, Psychotherapy and Nervous Diseases (DGPPN) and German Society of Neurology (DGN) without movement trainer exercise
89505657|NCT02370225|Experimental|aerobic exercise|Subjects were submitted to a supervised walking, 3 times a week for 16 weeks.
89519331|NCT04857307|Experimental|Staccato alprazolam|The study participants will receive a single dose of Staccato alprazolam.
88957092|NCT01046825|Other|Group C|"Any CNS involvement and/or bone marrow involvement ≥ 25% blasts. For CNS involvement one or more of the following applies:~Any L3 blasts in CSF~Cranial nerve palsy (if not explained by extracranial tumor)~Clinical spinal cord compression~Isolated intracerebral mass~Parameningeal extension: cranial and/or spinal~Group C will include the intervention COP, COPADM8, CYVE as follows:~Pre-Phase: COP~Induction: COPADM8 cycle 1~Induction: COPADM8 Cycle 2~Consolidation: CYVE x 2 cycles~and Maintenance"
88957093|NCT00923442||1|patients (from >/= 1 to 75 years old) diagnosed with any hematologic malignancy or pre-malignant condition
88957094|NCT00923104||1/healthy volunteers|healthy volunteers
88957095|NCT00923104||2/patients|subjects with breast cancer, ductal carcinoma in situ, and adenocarcinoma of prostate
88957096|NCT00674882||Participants|Data Collection
88957097|NCT00501826|Experimental|Treatment (nelarabine and combination chemotherapy)|See Detailed Description
88957098|NCT00499330|Other|Arm A|Patients undergo a standard operation for lung cancer called a lobectomy.
89505658|NCT02370225|No Intervention|no exercise|Subjects randomized to control group did not participate of the walking exercise initially, but after completing 16 weeks they were invited to participate of the training group.
89505659|NCT02196623|Experimental|Hypoxic Exercise|Supervised, progressive aerobic exercise for 8 weeks under hypoxic conditions
89505660|NCT02196623|Sham Comparator|Normoxic exercise|Supervised, progressive aerobic exercise for 8 weeks under normoxic conditions
89505661|NCT02375919|No Intervention|Control|Emergency physician will assess low risk patients for PE with conventional strategy, using D-Dimer testing with subsequent CTPA if positive
89505662|NCT02375919|Other|Intervention|PERC based Strategy : Emergency physician will assess low risk patients for PE first with calculation of PERC score. If all PERC criteria are negative, then no further testing for PE is recommended. If at least one criterion is positive, then the patient undergoes D-Dimer testing with subsequent CTPA if positive
89505663|NCT02194907|Active Comparator|Anterior insula cortex activation|Participants will receive training sessions using a special feedback technique to learn to actively increase blood flow in the front of the brain, while thinking of and viewing emotional faces, scenes, and text.
89505664|NCT02194907|Active Comparator|Primary auditory cortex activation|Participants will have training sessions using a special feedback technique to learn to actively increase blood flow in the back of the brain while thinking of and viewing emotional faces, scenes, and text.
89505665|NCT00226759|Experimental|OMS103HP irrigation solution|Drug
89505666|NCT00226759|Placebo Comparator|vehicle irrigation solution|Vehicle
89505667|NCT02195063||Pain management|patients undergoing transdermal treatment for pain
89505668|NCT02195063||Scar care|patients undergoing transdermal treatment for scars
89505669|NCT02195063||Wound care|patients undergoing transdermal treatment for wounds
89505670|NCT02195063||UDT|patients receiving urinary drug tests
89505671|NCT04469335|Experimental|mobile neurofeedback|
89505672|NCT04469335|Sham Comparator|sham control|
89505673|NCT04469335|Experimental|medication +mobile neurofeedback|
89505674|NCT04469335|Sham Comparator|medication + sham control|
89505675|NCT02195141|Active Comparator|conventional fraction|Radiotherapy (25x 2 Gy) + capecitabine 825mg/m2 p.o. twice daily
89505676|NCT02195141|Experimental|SIB|Concomitant chemoradiotherapy Radiotherapy with boost Radiotherapy (25 x 2 Gy), with a simultaneous integrated boost up to 56 Gy on the primary tumor capecitabine 825mg/m2 p.o. twice daily
89505677|NCT02376075|Placebo Comparator|Placebo|Placebo, tablets, administered once daily as add on to pre-existing antihypertensive treatment
89505678|NCT02376075|Active Comparator|Linagliptin|Linagliptin, tablets containing 5 mg, administered once daily as add on to pre-existing antihypertensive treatment
89505679|NCT04469257|Experimental|Sunbathing|During the activities for the intervention group, the individuals were exposed directly to sun in the nursing home garden on open and sunny days without sunscreen for five days a week for a month with an average of 21.0 ± 5.0 min (min 15 min - max 30 min). About 30-35% of their bodies (hand, face, neck, forearm open up to elbows and legs open up to the knee caps) were open. Sunbathing sessions were held between 10:30 and 11:30 to prevent elderly individuals from being affected by extreme temperatures, and UV index values were monitored during the time and duration of the event at WHO website (http://www.who.int/uv/resources/link/indexlinks/en/, Access date: July 1, 2018). During the hours of the day when UV index was > 6-7, elderly individuals were not taken out. After each sunbathing session, elderly individuals in the intervention group were evaluated for sensitivity and erythema that may occur in the exposed body areas
89505680|NCT04469257|No Intervention|Control|Elderly individuals in the control group were not invited to the activities held in the nursing home garden. There were no restrictions on them for not going out in the sun or spending time inside the nursing home
89505681|NCT02197637|Experimental|ORAL VINORELBINE|Orally vinorelbine 60 mg/m2 D1, 8 and 15 Cycle of 28 days For a maximum of 12 cycles The dose of vinorelbine should be increased to 80 mg/m2 from the 2nd cycle
89505682|NCT04469413||standard IV intermittent bolus infusion group|
89505683|NCT04469413||continuousIV intermittent bolus infusion group|
89505684|NCT02369913||Heart failure subjects|Heart failure subjects undergoing cardiac resynchronization will have a blood drawn for this study.
89505685|NCT02369913||Heart arrhythmia patients|Heart arrhythmia patients undergoing ablation will have a blood drawn for this study.
89505686|NCT04374149|Experimental|1 - TPE Alone|TPE, five single plasma volume exchanges over 7 days (every day x 2 then every other day x 3) with albumin or fresh frozen plasma (FFP) replacement if underlying coagulopathy
89505687|NCT04374149|Experimental|2 - TPE Plus Ruxolitinib|TPE, five single plasma volume exchanges over 7 days (every day x 2 then every other day x 3) with albumin or fresh frozen plasma (FFP) replacement if underlying coagulopathy combined with ruxolitinib 5mg po twice daily (BID) beginning day prior to first TPE and continuing BID for total of 14 days.
89505688|NCT02377713|Experimental|KHK6640|KHK6640
89505689|NCT02377713|Placebo Comparator|Placebo|Placebo
88815252|NCT00980642|Other|Regional anesthesia|Temperature is measured by Draeger double-sensor and Foley catheter temperature sensor every 5-min during the surgery.
89505690|NCT02288611|Placebo Comparator|Maltodextrin/Dextrose mix|"Twenty-two healthy human individuals were randomly assigned to consume a control (maltodextrin-dextrose, 40.2g) at one of the arms period. Each arm was 21 days in duration, separated by a 14 days washout period.~P.S. placebo is called control in this study, where the bioactive comparator is a fruit."
89023762|NCT04776005||Patients with malignant disease undergoing immunotherapy|Patients with malignant disease undergoing immunotherapy within the University Hospital Centre AP-HP.Nord, who have voluntarily agreed to be vaccinated with an approved vaccine against the Sars-CoV-2 virus.
89206748|NCT00838968|Active Comparator|interferon-alpha (IFN-alpha)|the interferon-alpha is intramuscular injected 3,000,000U three times a week for 18 months
89206749|NCT00838968|No Intervention|control|no interventions were assigned
89206750|NCT00829842|Placebo Comparator|1|Placebo
89505691|NCT02288611|Active Comparator|Date fruit - Ajwa variety|Twenty-two healthy human individuals were randomly assigned to consume date fruits (approx. 50g) at one of the arms period. Each arm was 21 days in duration, separated by a 14 days washout period.
89505692|NCT02369757|Experimental|Intervention of navigators|Navigators accompany the target population towards OCCS.
89505693|NCT02369757|No Intervention|No Intervention|Population is not accompanied by navigators
89505694|NCT02195219|Experimental|open reduction internal fixation|open reduction internal fixation
89505695|NCT02195219|Active Comparator|non operative treatment|'sling rest and early functional recovery
89505696|NCT00166543|Experimental|TAS-108 40 mg|
89505697|NCT00166543|Experimental|TAS-108 80 mg|
89505698|NCT00166543|Experimental|TAS-108 120 mg|
89505699|NCT03533933|Active Comparator|Autologous connective tissue graft|Soft tissue harvesting from patient palate
88815253|NCT04353908|Active Comparator|kabat|Rehabilitation will be started in both groups of patients and it will be carried out according to Kabat et al., i.e. a proprioceptive neuromuscular facilitation procedure, twice a week for 8 weeks, by an experienced physioptherapist
88815254|NCT04353908|Experimental|collagen injection|Injections of an equally-balanced solution of MD Neural, MD Matrix and MD Muscle (Guna S.p.a., Milan-Italy), containing collagen of porcine origin, will be administered subcutaneously after applying lidocaine/prilocaine cream on the affected side, by a skilled otonaryngologist in the field of injection treatments, twice a week for 8 weeks
88815255|NCT03018314||Group 1|The first group will comprise of 30 women with polycystic ovaries in ultrasound examination or anovulatory cycles.
89206751|NCT00829842|Experimental|2|
89206752|NCT00954759|Experimental|Chiropractic treatment|Manipulation and/or mobilisation
89505700|NCT03533933|Experimental|collagen matrix|Mucograft collagen matrix manufactured by Geistlich AG, Switzerland Device: Collagen matrix
89505701|NCT02375997|Experimental|Standard oncology care plus palliative care|
89505702|NCT02375997|No Intervention|Standard oncology care|
89505703|NCT02195297|Active Comparator|ANTICELLULITE GMG GIULIANI|Each included subject applied ANTICELLULITE GMG GIULIANI mono-laterally (on the left or on right side according to a previously defined randomization list) once a day, at evening, for an uninterrupted period of 4 weeks.
89505704|NCT02195297|Active Comparator|SOMATOLINE|Each included subject applied SOMATOLINE CREAM mono-laterally (on the left or on right side according to a previously defined randomization list) once a day, at evening, for an uninterrupted period of 4 weeks.
89505705|NCT03532087|No Intervention|No denosumab|All patients undergo surgery followed by adjuvant chemotherapy. Patients in this study arm are not additionally treated with denosumab.
89505706|NCT03532087|Experimental|Denosumab 120 mg|All patients undergo surgery followed by adjuvant chemotherapy. Patients in this study arm are additionally treated with denosumab 120 mg every 3 weeks. First denosumab gift is before surgery, last denosumab gift is together with the last cycle of chemotherapy.
89519332|NCT03463291||Study group|All patients with bony lesions
89519333|NCT03463213|Experimental|SHE Tribe|SHE Tribe is a social network-based peer-facilitated intervention to promote adoption of health behaviors
89505707|NCT03532087|Experimental|Denosumab 60 mg|All patients undergo surgery followed by adjuvant chemotherapy. Patients in this study arm are additionally treated with denosumab 60 mg every 6 months. First denosumab gift is before surgery, last denosumab gift is together with the last cycle of chemotherapy.
89505708|NCT02376153|Experimental|ABS deployed and active|Air Barrier System (ABS) will be deployed onto the surgical field and activated.
89505709|NCT02376153|Sham Comparator|ABS deployed and NOT active|Air Barrier System (ABS) will be deployed onto the surgical field and NOT activated. This is a sham comparator to reduce the influence of the presence of the device and provide user blinding.
89505710|NCT04348019|Experimental|Time restricted feeding|Participants in the intervention arm of the study will consume food and beverages of their choice within one hour of waking and the feeding window will extend 6 hours. Beyond these hours, participants will observe a prolonged fast (i.e., an 18-h overnight fast).
89505711|NCT04348019|Placebo Comparator|Control|Participants in the control arm of the study will fast each night for 8 hours.
89505712|NCT02288767|Active Comparator|Control group|For the traditional method group, crystalloid and colloid (maximum 50 ml/kg) are provided through the traditional method of assessing the blood pressure, heart rate and urine volume.
89505713|NCT02288767|Experimental|SVV group|The method of fluid administration to be employed (traditional or SVV via a FloTrac/ EV1000™ monitor) is determined based on the group. Fluid administration is performed in accordance with the group; in general, about 10 ml/kg/h is administered although it may vary for each patient depending on the preoperative fasting, fluid loss during surgery (evaporation, emanation, urination, surgical area, etc.), and blood loss. Crystalloid is administered in the SVV-monitored group with a target below SVV 12%, and a 200-300 ml of colloid (maximum 50 ml/kg) is loaded when SVV is above 12%. If the patient shows hypertension even when SVV is below 12%, a vasoconstrictor should be administered intermittently or consistently.
89505714|NCT02369679|Experimental|Precast Adjustable Compression Wrap|Precast Adjustable Compression Wrap will be adjusted by the physiotherapist each visit
89505715|NCT02369679|Active Comparator|Multilayer Compression Bandages|Multilayer Compression Bandages will be adjusted by the physiotherapist each visit
89505716|NCT02197715|Experimental|computer-adaptive SAFE|Computer-adaptive SAFE will consist of 4 60-minute sessions. Sessions 1 and 2 will explore participants' reasons to become and rewards for becoming pregnant/having children or avoiding it, introduce reproductive biology in the context of different contraceptive methods and explore the participant's ambivalence toward using different contraceptive methods. Session 3 will provide in-depth coverage of contraceptive methods and the need for use of a barrier method. Session 4 will focus on effective strategies to communicate with a sexual partner. Computer-adaptive SAFE will use an audio computer-assisted self-interviewing (ACASI) format.
89505717|NCT02197715|Experimental|Face-to-face SAFE|Face-to-face SAFE will consist of 4 60-minute sessions using motivational interviewing techniques. Each session will be led by an experienced counselor. Sessions 1 and 2 will explore participants' reasons to become and rewards for becoming pregnant/having children or avoiding it, introduce reproductive biology in the context of different contraceptive methods and explore the participant's ambivalence toward using different contraceptive methods. Session 3 will provide in-depth coverage of contraceptive methods and the need for use of a barrier method, and relevant skills regarding how to use and negotiate use of contraceptive methods. Session 4 will focus on effective strategies to communicate with a sexual partner.
89505718|NCT02197715|Active Comparator|Usual Care|Usual care comprises four 60-minute provider-led individual care sessions about HIV, STIs, and their risks, as well as prevention methods. Contraceptive methods are discussed within this context. There will be no demand on participants to attend these sessions. Participants will receive written take-home materials to review on their own and/or with their sex partners.
89505719|NCT02031185|No Intervention|Wait-list control|No intervention
89505720|NCT02031185|Experimental|FitBit only|Participants will use the FitBit device
89505721|NCT02031185|Experimental|FitBit and Text Messages|Participants will use the FitBit device and receive daily affective text messages
89505722|NCT04181879|Experimental|Intervention|GPs will receive the intervention package and conduct medication reviews with recruited patients
88957099|NCT00499330|Experimental|Arm B|Patents undergo a limited resection (segentectomy or wedge resection), which a smaller portion of the lung is removed.
88957100|NCT00352924||Cohort of Agricultural Workers|Cohort of Agricultural Workers
88957101|NCT00339287||Healthy volunteers|Healthy adult volunteers at least 18 years of age.
88957102|NCT00071045||1|patients undergoing allogeneic stem cell transplantation
88957103|NCT00071045||2|HLA compatible donors
89206753|NCT00954759|Placebo Comparator|Visit without active treatment|The child is brought in for chiropractic treatment, but no active treatment is delivered. The parents are unaware whether treatment is delivered or not.
89505723|NCT04181879|No Intervention|Usual care|GPs will continue to treat recruited patients as usual
89505724|NCT02288923|Active Comparator|Femoral nerve block|Femoral nerve block with 20ml 0.375% Levobupivacaine
88957104|NCT00051857||1/Healthy Controls|Subjects 5 years old and up with musculoskeletal impairment, pathology, or variant.
88957105|NCT00051857||2/Healthy Volunteers|Subjects 5 years old and up without musculoskeletal impairment, pathology, or variant.
89505725|NCT02288923|Active Comparator|Local Infiltration Analgesia|Local infiltration of knee joint using 40ml of bupivacaine 0.25% with adrenaline 1:200 000, diluted to 150ml with saline 0.9%. This is then divided into thirds; 50ml into the posterior capsule before cementing, 50ml into the medial and lateral capsules and 50ml into subcutaneous tissues and in and around the vastus medialis and sartorius muscles (where it may block the saphenous nerve).
89519334|NCT01328431|No Intervention|Standard Care|Subjects receive a brochure for the state's Smokers' Quitline only.
88957107|NCT00001352||Genetic Relatives|Controls
88957108|NCT00001352||Healthy Volunteers|Controls
88957109|NCT00001352||Patient Population|Adult patients with cryptococcosis no predisposing conditions except ICL
89023763|NCT04776005||Patients with malignant disease treated with targeted therapies|Patients with malignant disease treated with targeted therapies within the University Hospital Centre AP-HP.Nord, who have voluntarily agreed to be vaccinated with an approved vaccine against the Sars-CoV-2 virus.
89023764|NCT04776005||Patients with malignant disease undergoing radiotherapy|Patients with malignant disease undergoing radiotherapy within the University Hospital Centre AP-HP.Nord, who have voluntarily agreed to be vaccinated with an approved vaccine against the Sars-CoV-2 virus.
89206754|NCT02548182|No Intervention|control|A standardized education material on diet, exercise, and behavior modification were provided to all participants, and each participant received a one-to-one education on diet and exercise from a trained nurse for 5 minutes each session.
89505726|NCT02369445|Experimental|Moisture Pager (MP) Intervention Group|"This group receives the innovative toilet training intervention comprised of a wireless moisture pager (i.e., an app based on an iPod that communicates via electronic signal with a disposable moisture sensor located in the child's underwear)."
89505727|NCT02369445|Active Comparator|Standard Behavioral Intervention Group|This group receives standard-of-care intervention as presented in the Autism Treatment Network's Toilet Training Tool Kit (https://www.autismspeaks.org/site-wide/atn-tool-kits).
89505728|NCT02195375|Experimental|Flutiform 500/20 µg BID|Flutiform 250/10 (2 puffs BID)
89505729|NCT02195375|Experimental|Flutiform 250/10 µg BID|Flutiform 125/5 (2 puffs BID)
89505730|NCT02195375|Active Comparator|Seretide Accuhaler 50/500 µg BID|Seretide Accuhaler 50/500 (BID)
89505731|NCT02031263|Experimental|thermoplasty group|Check on the quality of life, emergency room uses, and sudden progress of the disease of the patients before and after the treatment by using bronchial thermoplasty system by using paired t test.
89505732|NCT03531775|Other|Upright MRI|All participants will be scanned using an upright MRI in seated/standing position and supine position. They will also be scanned supine using a conventional MRI.
89505733|NCT02197793|Experimental|Community Mobilization Program|Intervention activities will map onto six mobilization domains identified as key components for communities to mobilize for change around testing, linkage and retention in care (Treatment as Prevention (TasP)).
89505734|NCT02197793|No Intervention|Control Arm|The control arm does not receive the Community Mobilization Intervention.
89505735|NCT03534557||COPD|FEV1/FVC and FEV1/FEV6 will be compared within the same cohort of COPD patients
89505736|NCT02195453|Experimental|Yangzhengxiaoji Capsule|"Gemcitabine or Pemetrexed~Cisplatin~Yangzhengxiaoji Capsule four granules t.i.d po"
89505737|NCT02195453|Placebo Comparator|Placebo Capsule|"Gemcitabine or Pemetrexed~Cisplatin~Placebo Capsule four granules t.i.d po"
89505738|NCT03531697|Experimental|Generic Loteprednol Etabonate - RLD|Period 1: Generic Loteprednol Etabonate - Period 2 (Cross-Over): Reference Listed Drug (RLD)
89505739|NCT03531697|Active Comparator|RLD - Generic Loteprednol Etabonate|Period 1: Reference Listed Drug (RLD) - Period 2 (Cross-Over): Generic Loteprednol Etabonate
89505740|NCT02197871|No Intervention|blank control|usual diet
89505741|NCT02197871|Experimental|nutrition supplementation|In addition to usual diet,the patients will be given enteral nutrition emulsion, which is a oral nutrition liquid composed of proteins,omega-3 fatty acids,carbohydrate,vitamins.Every package contains 200ml and provides 260 kcal energy.
89505742|NCT05724979|No Intervention|control|Oocytes of the control group were injected with conventionally selected spermatozoa based on sperm morphology and motility after being processed density gradient centrifugation
89505743|NCT05724979|Experimental|treatment|ZP-bound sperm were selected from the surface of the immature oocytes through the use of a microneedle (Sunlight Medical, Jacksonville, FL, USA) and transferred in a 10 % polyvinylpyrrolidone (PVP) solution (SAGE, USA), immobilized, and then used to inject sibling MII oocytes
89505744|NCT02375763|Experimental|Sortware suggestions|Children will fill a questionnaire regarding their dietary habits. Afterwards a dietary analysis will be performed using a computer software, and dietary instructions will be given to the children.
89505745|NCT02375763|Placebo Comparator|Traditional suggestions|
89505746|NCT05161871|Active Comparator|Cathodal transcranial direct current stimulation|
89505747|NCT05161871|Sham Comparator|Sham transcranial direct current stimulation|
89505748|NCT02375607|Other|Algometer|Algometer used patients
89505749|NCT03529747|Experimental|Online self-help|A website providing information and psycho-education aimed at parents and carers of children with food allergies.
89023765|NCT04769362|Experimental|β-blocker discontinuation arm|Discontinuation of β-blocker therapy after at least 1 year of β-blocker therapy after acute myocardial infarction
89023766|NCT04769362|No Intervention|β-blocker maintenance arm|Continuation of β-blocker therapy after acute myocardial infarction
89505750|NCT03529747|No Intervention|Wait list control|A waiting list control group, who will receive access to the online self-help once the RCT is complete.
89505751|NCT02369133|Active Comparator|Group Paracetamol (Group P),|Drugs were given intravenously by a nurse unaware of the study 15 min before surgery. Patients in group P (n = 30) received 1 g iv paracetamol
89505752|NCT02369133|Placebo Comparator|Group Saline (Group S)|Drugs were given intravenously by a nurse unaware of the study 15 min before surgery. Patients in group S (n = 30) received 100 ml iv %0,9 saline
89505753|NCT02195609|Other|Omega-3|600 mg (EPA, DHA and Omega-3) twice a day
89505754|NCT02195609|Other|Soy Isoflavones|54.4mg oral twice a day
89505755|NCT02377635|Experimental|Treatment|Drug: Anhydrous selenite (Se-77), single dose 0.8mg, orally administered as a 100 ml purified water solution
89505756|NCT02377635|Placebo Comparator|Control|Drug: Placebo sodium chloride (table salt), orally administered as a 100 ml purified water solution
89505757|NCT03534479|Experimental|CVID-IVIgG, polyclonal IgG i.v. infusion|The patients of the CVID-IVIgG, polyclonal IgG infusion, group are studied five weeks from their last therapeutic polyclonal IgG i.v. infusion (IVIgG). On the mornings of day 0, vascular reactivity of the brachial artery, assessed as Flow mediated dilation (FMD), is measured and blood collected for biochemistry (baseline). Immediately after the FMD measurements and the blood collection, the 24 patients receive half dose of IVIgG necessary to treat their disease (400 mg/kg body weight in 10% solution). Twenty-four hours later, before infusing the second half of the dose of the IVIgG, vascular reactivity is again measured and blood collected. Vascular reactivity is again measured 1, 2, and 3 weeks after the first IVIgG infusion.
89505758|NCT02197949||Breast cancer patients with infiltrated axillary l|
89505759|NCT02195765|Experimental|enamel matrix derivative|Open flap debridement associated with Enamel matrix derivative gel (Emdogain, Straumann)
89505760|NCT02195765|Active Comparator|Open flap debridment|Open flap debridement
89505761|NCT02368977|Experimental|All subjects|All subjects will undergo examination with a Third Eye Panoramic device in conjunction with a standard colonoscope to evaluate the feasibility of using the study device to provide video imaging of areas of the colon that are difficult to evaluate with the colonoscope alone.
89023767|NCT04769219|Experimental|secondary prevention training|Secondary prevention training will be given to 43 randomly selected patients between the fourth and sixth hours after AMI (in accordance with the patient's request). Secondary protection training will be carried out in two parts. First of all, the anatomical structure and functions of the heart, the definition of AMI, its causes, symptoms and risk factors will be explained, and then the issues to be considered after AMI will be explained. The content of the training will also be given to the participants in a written booklet.
89505762|NCT03531541|Active Comparator|active TENS and CJM|"The active unit will be applied with the patient in a supine position at a high frequency of 100 Hz, and pulse duration of 100 µs. Strong but comfortable intensity as dictated by each subject will be applied for 20 minutes.~After application of TENS The examiner 3, who is responsible for cervical joint manipulation, will enter the room and stand at the head of the patient. Using the middle phalanx of the second finger of one hand, the examiner will apply pressure laterally on the joint processes of C6 and C7 vertebrae; the examiner will cradle the patient's opposite side with the other hand and then perform an ipsilateral inclination towards the C6, C7 segments, followed by a contralateral rotation to the tissue barrier to perform a high-velocity low-amplitude manipulation (thrust)."
89505763|NCT03531541|Placebo Comparator|placebos TENS and CJM|"The application of placebo TENS will be at a frequency of 100 Hz and pulse duration of 100 µs for 30 seconds. After the initial 30 seconds, the current amplitude will gradually decrease over 15 seconds until it reaches zero value.~Placebo CJM will be performed using an identical position to the active manipulation, however, for only 15 seconds, as proposed by some authors that have used placebo group in their studies[42-44]. The examiner shall not exert tension in the joint capsule of the segment to ensure the placebo effect"
89505764|NCT03531541|Active Comparator|placebo TENS and active CJM|"The application of placebo TENS will be at a frequency of 100 Hz and pulse duration of 100 µs for 30 seconds. After the initial 30 seconds, the current amplitude will gradually decrease over 15 seconds until it reaches zero value.~After application of placebo TENS The examiner 3, who is responsible for cervical joint manipulation, will enter the room and stand at the head of the patient. Using the middle phalanx of the second finger of one hand, the examiner will apply pressure laterally on the joint processes of C6 and C7 vertebrae; the examiner will cradle the patient's opposite side with the other hand and then perform an ipsilateral inclination towards the C6, C7 segments, followed by a contralateral rotation."
89505765|NCT03531541|Active Comparator|active TENS and placebo CJM|"The active unit will be applied with the patient in a supine position at a high frequency of 100 Hz, and pulse duration of 100 µs. Strong but comfortable intensity as dictated by each subject will be applied for 20 minutes.~After application of placebo TENS The examiner 3, who is responsible for cervical joint manipulation, will enter the room and stand at the head of the patient. Using the middle phalanx of the second finger of one hand, the examiner will apply pressure laterally on the joint processes of C6 and C7 vertebrae; the examiner will cradle the patient's opposite side with the other hand and then perform an ipsilateral inclination towards the C6, C7 segments, followed by a contralateral rotation."
89505766|NCT02198027|Experimental|Bupivacaine infiltration|10 ml of 0.25 % Bupivacaine
89505767|NCT02198027|Placebo Comparator|Normal saline infiltration|10 ml of normal saline
89505768|NCT02257463|Active Comparator|Study group (group A)|"pharmacologic treatment: theophylline uniphyllin, long acting bronchodilators foradil/spiriva or combined LABD and inhaled steroids miflonide according to GOLD recommendations peripheral muscles exercise training: (upper limb and lower limb strength and endurance training) inspiratory muscle training: (at intensity that progressively increased from 30% to 60% of patients' maximal inspiratory pressure)"
89505769|NCT02257463|Active Comparator|control positive group (group B)|"pharmacologic treatment: theophylline uniphyllin, long acting bronchodilators foradil/spiriva or combined LABD and inhaled steroids miflonide according to GOLD recommendations peripheral muscles exercise training: (upper limb and lower limb strength and endurance training)"
89505770|NCT02257463|Active Comparator|control negative group (group C)|"pharmacologic treatment: theophylline uniphyllin, long acting bronchodilators foradil/spiriva or combined LABD and inhaled steroids miflonide according to GOLD recommendations"
89505771|NCT02369055||Stroke survivors in North Norway|Patients with ischemic or heamorrhagic stroke admitted to stroke units in UNN Tromso, Narvik or Harstad (Norway), and living in the defined geographic area of these 3 hospitals.
89505772|NCT02369055||Stroke survivors in Denmark|Patients with ischemic og heamorrhagic stroke admitted to a stroke unit in Aarhus University Hospital and living in the municipalities of Randars or Favrskov in Central Denmark Region
89505773|NCT02198105||Femoropopliteal stenosis|"Consecutive patients with symptomatic peripheral artery disease due to femoro-popliteal stenosis/occlusion.~Intervention with Cutting-Balloon-PTA (VascuTrak) and Drug Coated Ballon-PTA."
89505774|NCT02375685|Experimental|gevokizumab|
89505775|NCT02196779||Patients undergoing abdominoplasty|Skin circulation to abdominal flap is evaluated during surgery using laser fluorescent imaging.
89505776|NCT04371081||Amplatzer Piccolo Occluder|Amplatzer Piccolo Occluder device implant
89505777|NCT03534089|Placebo Comparator|Standard infant fomula|Infants with iron deficiency anemia randomly divided into this arm were given the same dose of ferralia with other arms,but were fed with standard infant formula (without lactoferrin supplementation)
89505778|NCT03534089|Experimental|Low level LF infant formula group|Infants with iron deficiency anemia randomly divided into this arm were given the same dose of ferralia with other arms,but were fed with infant formula supplemented with low level of lactoferrin (38mg/100g). Lactoferrin:38mg/100g
89505779|NCT03534089|Experimental|High level LF infant formula group|Infants with iron deficiency anemia randomly divided into this arm were given the same dose of ferralia with other arms,but were fed with infant formula supplemented with high level of lactoferrin (76mg/100g)
89505780|NCT02369289||vegans|a vegan diet in the last 3 years
89505781|NCT02369289||omnivores|aminal-based diet, comsumption of aminal products at least 3 times a week
89505782|NCT00160147|Experimental|1|
89505783|NCT00160147|Placebo Comparator|2|
89538870|NCT03254303|Other|60s (group E)|The Time of catheterization at 60s (group E) was applied in this study group,after sevoflurane inhalation induction, 30 children have a catheterization after a time of 60 seconds following the eye closure and the loss of lid reflex.Difficulty with intravenous catheterization, limb movement and laryngospasm were recorded.Difficulty of catheterization in group 60 s
89538871|NCT03254303|Other|90s (groupe L)|In this study group,after sevoflurane inhalation induction, 30 children have a catheterization after a time of 90 seconds following the eye closure and the loss of lid reflex.Difficulty with intravenous catheterization, limb movement and laryngospasm were recorded.Difficulty of catheterization in group 90 s
89538872|NCT03254303|Other|120s (groupe L)|In this study group,after sevoflurane inhalation induction, 30 children have a catheterization after a time of 120 seconds following the eye closure and the loss of lid reflex.Difficulty with intravenous catheterization, limb movement and laryngospasm were recorded.Difficulty of catheterization in group 120 s
89538873|NCT03058887|Experimental|Arm cranking|exercising for 3 months twice per week.
89538874|NCT03058887|Experimental|Cycling|exercising for 3 months twice per week.
89538875|NCT03058887|No Intervention|Control group|No exercise intervention.
88957111|NCT01980537|Experimental|Stereotaxis|Magnetic wire navigation
88957112|NCT01980537|Active Comparator|Conventional|Conventional wire navigation
88957113|NCT01980550|Experimental|sublingual nicotine，placebo|sublingual nicotine：one or two tablets per hour, up to a maximum of 20 tablets per day Subjects were advised to use the full treatment dose for 4 weeks
88957114|NCT01980563|Active Comparator|ultrasound|
88957115|NCT01980563|Active Comparator|combined monitoring|
88957116|NCT01980576||Pre-operative pain measurement|Patients with low back pain
88957117|NCT01980602|Experimental|Supervised Exercise Program|
88957118|NCT01980615|Experimental|BGF MDI (PT010) Dose 1|BGF MDI Dose 1 taken as 2 inhalations
88957119|NCT01980615|Experimental|BGF MDI (PT010) Dose 2|BGF MDI Dose 2 taken as 2 inhalations
88957120|NCT01980615|Experimental|BGF MDI (PT010) Dose 3|BGF MDI Dose 3 taken as 2 inhalations
89206755|NCT02548182|Active Comparator|smartcare|Participants allocated to a smartcare arms received the Fit.life™ wireless physical activity tracker (Fit.life™, Suwon, Korea) that measures daily and weekly physical activity. It is convenient for data upload via Bluetooth on participant mobile phone or wirelessly via a personal computer, and has been validated for measurement of free-living physical activity in adults [REF]. Participants allocated to a smartcare arms were also provided a standardized education material on diet, exercise, and behavior modification.
89538876|NCT03259529|Experimental|Gemcitabine 500|"Days 1,2 Bendamustine Hydrochloride 70 mg/m2/day iv; Days 1,8,15 Gemcitabine 500 mg/m2/day iv; Days 1,15 Nivolumab 1mg/kg/day iv; Day 0 Rituximab 375mg/kg/day iv.~Duration of cycle 28 days"
89538877|NCT03259529|Experimental|Gemcitabine 700|"Days 1,2 Bendamustine Hydrochloride 70 mg/m2/day iv; Days 1,8,15 Gemcitabine 700 mg/m2/day iv; Days 1,15 Nivolumab 1mg/kg/day iv; Day 0 Rituximab 375mg/kg/day iv.~Duration of cycle 28 days"
89538878|NCT03259529|Experimental|Gemcitabine 1000|"Days 1,2 Bendamustine Hydrochloride 70 mg/m2/day iv; Days 1,8,15 Gemcitabine 1000 mg/m2/day iv; Days 1,15 Nivolumab 1mg/kg/day iv; Day 0 Rituximab 375mg/kg/day iv.~Duration of cycle 28 days"
89538879|NCT04962555||Meniscus Suture|The patient underwent meniscus suture surgery
89538880|NCT04962555||Partial meniscus resection|The patient underwent partial meniscus resection
89538881|NCT04962555||Subtotal meniscus resection|The patient underwent Subtotal meniscus resection
89538882|NCT04962555||Complete meniscectomy|The patient underwent complete meniscectomy
89538883|NCT03252821|Experimental|High-intensity aerobic training group|High intensity interval training
89538884|NCT03252821|Active Comparator|Resistance training group|Muscle strengthening
88957121|NCT01980615|Active Comparator|GFF MDI (PT003)|GFF MDI (PT003) taken as 2 inhalations
88957122|NCT01980615|Active Comparator|Symbicort MDI Dose 1|Symbicort MDI taken as 2 inhalations
88957123|NCT01980615|Active Comparator|Symbicort MDI Dose 2|Symbicort MDI Dose 2 taken as 2 inhalations
88957124|NCT01980641|No Intervention|Control group|Assessment of each participant's home and his or her performance of ADL.
88957125|NCT01980641|Experimental|Experimental group|Educational intervention: Assessment of each participant's home and his or her performance of ADL and the therapist will provide to the participants of the experimental group a list of advice related to the HTAS items that are evaluated negatively.
88957126|NCT01980641|Experimental|Application smartphone-based group|Smartphone-based application group (SG) sample will have a reminder. The app will provide the advice previously given by the therapist in the participants' homes.
88957127|NCT01980641|No Intervention|Non Application smartphone-based group|Non Smartphone-based application group (NSG) sample won't have a reminder
88957128|NCT01980667|Experimental|lurbinectedin (PM01183) / cisplatin|Patients will receive cisplatin as a 90-min i.v. infusion. In addition, patients will receive PM01183 as an i.v. infusion over 1-hour.
88957129|NCT01980680|Experimental|Agonist trigger|Agonist trigger Buserelin 0,5 mg and Pregnyl (hCG)
88957130|NCT01980680|Active Comparator|hCG|hCG trigger Pregnyl (hCG) and Progesterone and Estradiol
88957131|NCT01980693|Other|bone age assessment by ultrasound|The aim of this phase is to collect the ultrasound reading values of Speed of Sound (SOS) and Distance (DIS) of all participants by performing a one time measurement of the left hand by the SonicBone's BA device. Each measurement will be performed on three sites of the hand: the wrist the phalanx and the metacarpal bones.
88957132|NCT01980719||Healthy, Age-Matched|
88957133|NCT01980719||Fatigued|
88957134|NCT01980719||Not Fatigued|
88957135|NCT01980745|Active Comparator|Chloroquine diphosphate|chloroquine diphosphate 250mg/day
88957136|NCT01980745|Placebo Comparator|sugar pill|sugar pill
88957137|NCT01980758|Experimental|Surgery|Laparoscopic Gastric Plication
89023768|NCT04769219|No Intervention|nursing care|43 randomly selected patients will form the control group and this group will be provided with routine care and follow-up in the clinic. No intervention will be made.
89023769|NCT04768114|Experimental|Genetically-Informed RiskProfile|
89505784|NCT03533777|Active Comparator|Antegrade Intravenous Catheter|A 20 gauge 30 millimeter peripheral intravenous catheter will be placed in an upper extremity vein in standard antegrade fashion (with the tip pointed towards the direction of blood flow). Blood draws from this IV catheter will be attempted twice throughout the study. An infusion of 0.9% normal saline will be connected to the catheter and infused at a rate of 20 milliliters per hour to keep open (TKO) for future use by preventing blood clot development within the catheter.
89505785|NCT03533777|Experimental|Retrograde Intravenous Catheter|A 20 gauge 30 millimeter peripheral intravenous catheter will be placed in an upper extremity vein in a retrograde fashion (with the tip pointed away from the direction of blood flow). Blood draws from this IV catheter will be attempted twice throughout the study. An infusion of 0.9% normal saline will be connected to the catheter and infused at a rate of 20 milliliters per hour to keep open (TKO) for future use by preventing blood clot development within the catheter.
89023770|NCT04768114|Active Comparator|Brief Cessation Advice|
89023771|NCT04767672|Experimental|Test product|Food ingredient containing non digestible carbohydrates, in shape of powder
89505786|NCT02198261||Predicted as non-responders|Patients that the minoxidil response in-vitro diagnostic kit predicted as non-responders. 5% minoxidil topical foam will be administered to subjects in this group.
89505787|NCT02198261||Predicted as responders|Patients that the minoxidil response in-vitro diagnostic kit predicted as responders. 5% minoxidil topical foam will be administered to subjects in this group.
89505788|NCT02368899|Experimental|Computerized Alcohol Misuse Intervention|Arm 1 is a cross-over randomized controlled trial (XRCT) comparing the short-term effects of the computerized alcohol misuse intervention (CAMI) vs. a generic health education attention-control (AC) condition in reducing past 30 day: (a) days of alcohol use, (b) days of heavy episodic drinking, (c) typical number of drinks consumed on a day of drinking, and (d) alcohol use in dangerous situations; (2) investigate changes in (a) patient motivation and (b) perceived norms as mediators of intervention effectiveness.
89505789|NCT02368899|Placebo Comparator|Attention Control (AC)|Arm 2 is not an active intervention but an attention control condition - it is not expected to exert any real intervention effect. Hence, any observed effects for the AC condition can be attributed to natural change via regression-to-the-mean, assessment reactivity, or a placebo effect. The effect size estimate of the intervention, both from an efficacy standpoint (i.e., above and beyond what change would have normally occurred) and an effectiveness standpoint (i.e., the magnitude of behavior change that can be expected in real-world implementation), can be readily calculated.
89505790|NCT00147277|Active Comparator|8 pulses|8 pulses Anti-Tachycardia Pacing (ATP) delivered in the right ventricle to treat Fast Ventricular Tachycardia (FVT)
89505791|NCT00147277|Experimental|15 pulses|15 pulses Anti-Tachycardia Pacing (ATP) delivered in the right ventricle to treat Fast Ventricular Tachycardia (FVT)
89505792|NCT02031341||Patients with type 2 diabetes mellitus|
89505793|NCT02031341||Normoglycemic individuals|Control group
89505794|NCT02191917||Measurement of Respiratory Muscle Strength|
89505795|NCT03657745||Participants who adhere to the protocol|All participants are encouraged to exercise with AlzLife daily for 30 minutes a day. The actual duration is to be measured through participant's interactions with ALZLIFE. Participants adhere to the protocol if they exercise with AlzLife the minimum of 1hour/week.
89505796|NCT03657745||Participants who do not adhere to the protocol|All participants are encouraged to exercise with AlzLife daily for 30 minutes a day. The actual duration is to be measured through participant's interactions with ALZLIFE. Participants do not adhere to the protocol if they exercise with AlzLife less than 1hour/week.
89505797|NCT03533699|Active Comparator|Propranolol|101 women with uncomplicated term pregnancy who will be admitted to the Ain Shams University Maternity hospital and will receive syntocinon intravenous infusion for induction or augmentation of labour.
89505798|NCT03533699|Placebo Comparator|placebo|101 women with uncomplicated term pregnancy who will be admitted to the Ain Shams University Maternity hospital and will receive syntocinon intravenous infusion for induction or augmentation of labour.
89505799|NCT00135421|Experimental|A1|
89505800|NCT00135421|Active Comparator|A2|
89505801|NCT00135421|Placebo Comparator|A3|
89505802|NCT02200991|Experimental|Lixisenatide|"Lyxumia solostar: Initially started with 10 μg once-daily and increased up to 20 μg once daily (dose increased by 5 μg every week), subcutaneous injection in the abdomen, administered 30 minutes before breakfast. The period of administration is 4 weeks.~Lantus solostar as base treatment: Subcutaneous injection in the abdomen."
89505803|NCT02200991|Active Comparator|Sitagliptin - Januvia|"50 mg tablet, administered orally once-daily, 30 minutes before breakfast. The period of administration is 4 weeks.~Lantus solostar as base treatment: Subcutaneous injection in the abdomen."
89505804|NCT02368821||normal pregnancy|placental from normal pregnancy
89505805|NCT02368821||complacted pregnancy|placental from complicated pregnancy ( intrauterine growth restriction, preeclampsia , placenta accrete
89505806|NCT02201069|Experimental|health coaching|12 weeks of health coaching using weekly contact in the first month and biweekly contacts in months 2-3.
89505807|NCT03531385||Behcet|Patients diagnosed with Behcet disease
89505808|NCT03531385||Healthy controls|Individuals without any chronic disease
89505809|NCT02368743||mesalazine|Treatment according to standard clinical practice.
89505810|NCT02201147|Experimental|cold biopsy polypectomy|
89023772|NCT04767672|Placebo Comparator|Placebo|Food ingredient containing containing 95% of maltodextrin
89023773|NCT04763200|Experimental|Impella Arm|Impella CP® or Impella 2.5 placement prior to high-risk PCI
89023774|NCT04763200|Active Comparator|Control Arm|Subjects randomized to the Control group will be treated per standard of care PCI with or without an intra-aortic balloon pump (IABP).
89023775|NCT04753138|Experimental|SBO with calcium silicate sealer|The teeth will be obturated with the single cone technique and BC sealer
89023776|NCT04753138|Active Comparator|WVC with resin based sealer|The teeth will be obturated with warm vertical compaction and AH+ sealer
89023777|NCT04742959|Experimental|Monotherapy Cohorts|TT-00420 tablets will be administered once daily in 28-day cycles.
89538885|NCT03252821|No Intervention|Control group|Usual care
89538886|NCT03254069|Experimental|Stainless Steel Crown Arm|Children with SSCs placed and followed longitudinal. Consent was obtained from all parents and verbal assent was obtained. The following data was collected: Demographic Data of the Children, clinical examination, radiographs, treatment planning, details of stainless steel crowns placement, OBF measurements were made before the SSC placement and periodically post placement
89538887|NCT03254069|No Intervention|Control Arm|A second group consisted of twenty-two children (11 females and 11 males; a mean age of 5.20 ± 0.36 years) were selected to act as a control sample and received no dental treatment. MOBF was recorded in these subjects at T0 and T5 (6 months after).
89538888|NCT03060369||Established Shock (Cohort A)|"Meeting criteria i or ii, AND iii:~i. SBP ≤ 90mm Hg for greater than 30 minutes ii. Requirement for vasopressor or ionotrope to maintain SBP > 90mm Hg iii. New dysfunction of at least one organ, including altered mental status, acute renal failure (increase from baseline in serum creatinine >0.3 mg/dL or by 50%), oliguria (<0.5 mL/kg/h for >6h) , or hepatic injury (ALT, AST, or total bilirubin >2xULN)suspected by the treating physician to be caused by organ hypoperfusion"
89538889|NCT03060369||Emerging Shock (Cohort B)|"Meeting criteria i or ii, AND iii:~i. New SBP ≤ 90mm Hg for greater than 30 minutes or recurrent shorter episodes, requiring use of or clinical anticipation of the need for fluid resuscitation or vasopressor/inotropic support to maintain SBP > 90 mm Hg ii. New dysfunction of at least one organ (as defined above), including altered mental status, acute renal failure, oliguria, or hepatic injury not explained by a specific non-hemodynamic cause iii. Does not meet criteria for Established Shock"
89538890|NCT03252743|Experimental|Internet-delivered CBT|Exposure-based internet-delivered CBT with ten weekly modules distributed over the internet during ten weeks, and weekly therapist support over the internet.
89538891|NCT03252665|Experimental|alprostadil|alprostadil,2ug, dilivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients
89538892|NCT03252665|Experimental|nicorandil|nicorandil,2mg, dilivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients
89538893|NCT03252665|Placebo Comparator|nitroglycerin|nitroglycerin,200ug, dilivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients
89538894|NCT03059745||Cholecystitis|Patients consented for robotic assisted cholecystectomy evaluated in study.
89538895|NCT02455583|No Intervention|Standard of Care|All Form 1 learners at 25 of the 50 schools will receive HIV prevention sessions from the Botswana life skills education program for junior secondary school students called LIVING.
89538896|NCT02455583|Experimental|Intervention|Form 1 learners at the 25 intervention schools will receive the Project AIM intervention and LIVING (standard of care).
89538897|NCT03059667|Active Comparator|Arm A : chemotherapy|"Patients randomly assigned to the control arm will receive either:~topotecan (oral 2.3 mg/m² or IV 1.5 mg/m² day 1-4 recommended)~or re-induction by carboplatin - etoposide chemotherapy."
89538898|NCT03059667|Experimental|Arm B : immune therapy|Patients randomly assigned to the experimental arm will receive Anti PDL1 ATEZOLIZUMAB (MPDL3280A) at a fixed dose of 1200 mg IV every three weeks until progression or unacceptable toxicity.
88957138|NCT01980810|Experimental|albumin-bounded paclitaxel plus S-1|arm 1:albumin-bounded paclitaxel 200mg iv d1 and S-1 80mg/m2/d po d1-10, repeated every 2 weeks,up to 9 cycles,then S-1 as single agent to treat to disease progression
88957139|NCT01980836|Active Comparator|Seasonal influenza vaccine in tocilizumab treated RA patients|RA patients treated with tocilizumab
88957140|NCT01980836|Active Comparator|Seasonal influenza vaccine to Healthy controls|Healthy controls will be vaccinated against seasonal influenza
88957141|NCT01980849|Experimental|Long term prophylaxis|Nadroparin, 0.4mL, subcutaneously, qid, given by long-term
88957142|NCT01980849|Active Comparator|Short-term prophylaxis|Nadroparin, 0.4mL, subcutaneously, qid, given during hospitalization
88957143|NCT01980862||Heart Failure patients|No interventions for this study. Blood draw provided by patients.
88957144|NCT01980901||Ovation™/Ovation Prime™ Abdominal Stent Graft System|Adult male and female patients.
88957145|NCT01980927|Experimental|NUCCA atlas correction|NUCCA atlas correction for migraine patients
88957146|NCT01980953|Experimental|Part 1: Food Effect|GDC-0032 will be administered orally over 3-Treatment Period (TP) in 6-sequence as one 3 milligrams (mg) capsule in TP-A after 10 hour fasting from food, one 3 mg Phase III tablet in TP-B after 10 hour fasting from food and one 3 mg Phase III tablet in TP-C following the start of standard Food and Drug Administration (FDA) high-fat breakfast. Washout period o 14 to 20 days will be given between each TP.
88957147|NCT01980953|Experimental|Part 2: Tablet Formulation Comparison|Different formulations of tablets (Tablet A and Tablet B) of GDC-0032 will be administered orally over 2-TP having 10 hour fasting from food. Participants will receive one 3 mg Tablet A in TP-A and one 3 mg Tablet B in TP-B after 14 to 20 days washout period.
88957148|NCT01980953|Experimental|Part 3: Capsule API Lot Comparison|Two different lots of GDC-0032 active pharmaceutical ingredient (API) capsule formulation will be administered orally in crossover fashion over 2-TP to 20 participants having 10 hour fasting from food. Participants will receive one 3 mg capsule in TP-A and one 3 mg capsule in TP-B after 14 to 20 days washout period.
89538899|NCT03058419|Experimental|Drug Cocktail + JNJ-54175446|All subjects will receive a single dose of drug cocktail (consisting of midazolam [2 milligram (mg)], warfarin [10 mg], caffeine [50 mg], dextromethorphan [30 mg], bupropion [150 mg] and omeprazole [20 mg]) on Day 1, 7 and 11; JNJ-54175446 150 mg on Day 7, 9, 10 and 11 and JNJ-54175446 600 mg on Day 8.
89538900|NCT04952649||pacemaker dependent patients after cardiac surgery|Pacemakers are widely used in cardiotomy patients, while it's common that the patients happen to be pacemaker dependent. When the doctor decides to set the heart rate of the pacemaker, we record the hemodynamic parameters and peripheral perfusion index from 70-80-90-100-110 bpm.
89538901|NCT03252509|Experimental|Percutaneous radiologic gastrostomy.|Outpatient percutaneous radiologic gastrostomy in patients with head and neck tumors before, during or after the oncologic treatment.
88957149|NCT01980953|Experimental|Part 4: Tablet Relative Bioavailibity|GDC-0032 will be administered orally in crossover fashion over 2-TP to 20 participants having 10 hour fasting from food. Participants will receive one 3 mg capsule in TP-A and one 2 mg Phase III tablet in TP-B after 14 to 20 days washout period.
89505811|NCT02201147|Experimental|Cold snare polypectomy|
89505812|NCT02365311|Experimental|one lung group|
89505813|NCT00135343|Experimental|A|
89505814|NCT00135343|Experimental|B|
89505815|NCT02201225|Active Comparator|Nutritional supplement with micronutrient|Nutritional supplement powder with micronutrients packed as 27 g individual sachet, administered orally as a single serve twice daily
89505816|NCT02201225|Sham Comparator|Nutritional supplement without micronutrient|Nutritional supplement powder without micronutrients packed as 27 g individual sachet, administered orally as a single serve twice daily
89505817|NCT02365155|Experimental|Intervention group.|Multicomponent training intervention; Nutrition intervention; Cognitive intervention; D-vitamin intervention; Occupational intervention; Heart failure follow up.
89505818|NCT02365155|Active Comparator|Control group.|Nutrition intervention; Cognitive intervention; D-vitamin intervention; Occupational intervention; Heart failure follow up.
89505819|NCT02201303|Experimental|Part 1|Blood sample will be collected from the RSV-infected children <2 years and healthy adults participants. Escalating concentrations of CXCL1 will be added to whole blood in vitro and CD11b up regulation on peripheral blood neutrophils will be analyzed
89505820|NCT02201303|Experimental|Part 2|Blood sample will be collected from the RSV-infected children <2 years and healthy adults participants. Escalating concentrations of danirixin will be added to whole blood in vitro with a fixed concentration of CXCL1 to determine inhibition of CD11b expression on peripheral blood neutrophils
89505821|NCT05724745|Other|Healthy volunteers, Asthmatic patients and COPD patients|This arm of the study is essential to establish nominal flow-volume maps of nominal flow-volume curves and to determine the dependence of normal breathing on gravity and response to a bronchodilator in order to evaluate the sensitivity and specificity of the technique for the known lung diseases asthma and COPD by comparing data from healthy the data from healthy subjects with those from sick subjects.
89505822|NCT02375451||Radioiodine|Patients with a history of childhood treatment with radioiodine will be assessed for symptoms of salivary function and measurement of saliva production. These data will be compared to a normal control group.
89505823|NCT02375451||Control|Patients who are similar in age to those in the Radioiodine group, but who did not recieve I-131 therapy.
89505824|NCT02198339|Experimental|BIBN 4096 BS - ranging dose|"sequential adaptive design, allocation of verum treated patients to dose groups not fixed in advance~IV infusion over 10 minutes"
88957150|NCT01980966|Experimental|MHAA4549A|
89505825|NCT02198339|Placebo Comparator|Placebo|IV infusion over 10 minutes
89505826|NCT02198807|Experimental|Fosmidomycin-Piperaquine|Fosmidomycin sodium capsules 450 mg, dosage: 30mg/kg twice daily for 3 days Piperaquine phosphate tablets 320 mg, dosage: 16 mg/kg once a day for 3 days
89505827|NCT02198417|Experimental|Metformin|Metformin ER 1500 mg per day treatment for 12 weeks
89505828|NCT03527953|Active Comparator|Tetric EvoCeram BulkFill resin|Randomly applied
89505829|NCT03527953|Active Comparator|Surefil SDR Flowable bulk-fill resin|Randomly applied
89505830|NCT03527953|Active Comparator|everX fiber-reinforced resin|Randomly applied
89505831|NCT02201459|Active Comparator|Nilotinib|Control arm, this compound been licensed in this indication.
89505832|NCT02201459|Experimental|Peg-IFN alfa 2a (Pegasys®) and Nilotinib|Arm testing the efficacy of a combination of nilotinib and Peg-IFN alfa 2a as frontline therapy for first line chronic phase CML patients.
89505833|NCT02365389|Active Comparator|Group A received in situ MTZ vaginal gel|Received in situ MTZ vaginal gel once daily for 5 days. Treatment in this group was offered in the form of a bottle of an aqueous liquid (100 mL of a preparation composed of 0.8% MTZ, 20% pluronic F-127, 10% pluronic F-68, and 0.01% benzalkonium chloride). Women were asked to put 5 cc of the liquid into the vagina once daily for 5 days using a graded syringe and 10-cm long soft applicator.
89505834|NCT02365389|Active Comparator|Group B received conventional MTZ vaginal gel|Group B (control group) received conventional MTZ vaginal gel (Tricho gel 0.8%, Sedico, Egypt) twice daily for 5 days, using the supplied nozzle, which applies about 5 gm of gel again in the same laying back position.
89505835|NCT02201537|Other|Imag-NCT|"The ultrasound functional imaging will be performed at J15 (before the patient is discharged from service Transplantation) and at 3 and 12 months after the transplant.~The functional imaging examinations will be held as follows:~1st stage - the conventional Doppler ultrasound:~2nd stage - the elastography:.~Step 3 - CEUS: It is performed on an ultrasound machine with a specific module with the same probes as conventional ultrasound. It requires the injection of 1.5 ml of SonoVue ®, a contrast ultrasound.~Renal biopsy will be performed after the functional ultrasound at 3 and 12 months."
89505836|NCT04441411|Other|NEMOST-AIS|This study is designed as a cohort study.
89505837|NCT02201615|Experimental|Perineal Massage & Control|"Perineal Massage every 30 min, a 10 min 4 times in the first stage of labour, 1 times in the second stage of labour.~Control routine care procedure at the clinic."
89505838|NCT04441177|Experimental|Study group|Participants in the study group receive conventional rehabilitation therapy over 50 minutes on weekdays and 7 sessions (flexible schedule in different day) of PlayStation®VR of 20 minutes each in the main 16-day study period.
89505839|NCT04441177|No Intervention|Control group|Participants in the control group receive conventional rehabilitation therapy over 50 minutes on weekdays.
89505840|NCT02201693|Experimental|Cyclic exclusive MODULEN IBD|Cyclic exclusive MODULEN IBD for 2 weeks every 8 weeks
89505841|NCT02201693|Experimental|MODULEN IBD supplementation (25% of caloric requirements)|MODULEN IBD supplementation (25% of caloric requirements) alone A Physician not involved in the study design and blinded to the treatment arm will perform the evaluation of the patients during each study visit.
89505842|NCT02375529|Experimental|Single Incision Cholesystectomy (SILC)|Single Incision Laparoscopic Cholecystectomy (SILC): The umbilicus is grasped and a 2 cm vertical skin and fascial incision is performed. A multiport (TriPort®) is inserted under direct vision. Principles of cholecystectomy are the same as traditional laparoscopic cholecystectomy.
88957151|NCT01980966|Placebo Comparator|Placebo|
88957152|NCT01980966|Active Comparator|Tamiflu|
88957153|NCT01980979|Experimental|Remodulin|Subcutaneous (SQ) remodulin will be initiated at 1.25 ng/kg/min, and increased by 2-6 ng/kg/min weekly to a target dose of 40 ng/kg/min. If the initial infusion rate cannot be tolerated it will be reduced to 0.625 ng/kg/min. If subjects cannot tolerate the SQ therapy, we will attempt to switch to IV therapy.
88957154|NCT01981005|Experimental|RO5424802|
88957155|NCT01981018|Experimental|Imagery-focused Cognitive Therapy|"10 sessions of imagery-focused Cognitive Therapy delivered approximately weekly by two co-therapists, divided in 4 assessment, 4 treatment and 4 consolidation sessions; additional 2 blip management sessions during therapy and 3 blip management and booster session during follow up can be delivered if necessary."
88957156|NCT01981031|Experimental|A|Drug: BioChaperone® Combo
88957157|NCT01981031|Active Comparator|B|Drug: Humalog® Mix25
88957158|NCT01981070|Other|Mindfulness Intervention for Parents|"The mindfulness intervention program incorporates the same structure as the Support and Information for Parents intervention (orientation session, six 2-hour sessions over 6 weeks, co-facilitated by two leaders) but different content. Instead of presentations by experts and open-ended discussions and peer support, sessions will offer experiential training in meditation practice (sitting meditation, gentle yoga, and walking meditation), as outlined in the MBCT Program (Segal et al., 2012). Each week, parents will be required to practice a mindfulness skill, and also participate in a mindful parenting exercise as homework, such as joining their child in an activity of the child's choice."
88957159|NCT01981070|Active Comparator|Support and Information for Parents|This 6-week program includes orientation session, six 2-hour sessions, held weekly. Parents will be provided with information on existing services in the region, and strategies to be strong advocates and plan and access services for their child. Each session will include a presentation by an expert, with a question answer period, a break, and facilitated discussion with other parents. The sessions will be co-facilitated by clinicians from the Disability Services Ontario (DSO) and Centre for Addiction and Mental Health (CAMH).
88957160|NCT01981083|Experimental|Egg albumin-based protein supplement|Powder form, dosage 30 g daily, duration 6 months
88957161|NCT01981083|Active Comparator|Renal-specific oral supplement|Liquid form, dosage 237 ml (one can) daily, duration 6 months
88957162|NCT01981135|Sham Comparator|Clean Air|Exposure to clean air will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus.
88957163|NCT01981135|Experimental|Ozone|Exposure to ozone will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus.
88957164|NCT01981161||Fingolimod|patients treated by Fingolimod will have biological samples and clinical data
88957165|NCT01981161||Natalizumab|patients treated by Natalizumab will have biological samples and clinical data
88957166|NCT01981200|Experimental|Resistance training in AECOPD|The patients conduct daily training during admission with weight cuff 3 set of 10 rep.
89505843|NCT02375529|Active Comparator|Four Ports Cholecystectomy (4PCL)|Four Ports Conventional laparoscopic cholecystectomy (4PCL): A 10mm supraumbilical incision is made and the pneumoperitoneum insufflated through a Veress needle. 4 ports are introduced: 2 of 10mm in supraumbilical and left flank and 2 of 5mm in epigastric and right flank.
89505844|NCT02198495|Active Comparator|Ferric carboxymaltose|Supplementation of ferric carboxymaltose 500 mg at week 0, 10, 20, 30
89505845|NCT02198495|Active Comparator|Iron sucrose|Supplementation of iron sucrose 100 mg at week 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38
89505846|NCT02368509|Experimental|Bronchial cancer|Patients with bronchial cancer will perform sensory tests before and after a 6-week period of chemotherapy.
89505847|NCT02368509|Placebo Comparator|Control group|Healthy individuals will perform sensory tests before and after a 6-week period without chemotherapy.
89505848|NCT02201849|Experimental|Study Drug|Oral capsules
89505849|NCT02201849|Active Comparator|Active Control|Oral capsules
89505850|NCT02201849|Placebo Comparator|Placebo|Oral capsules
88957167|NCT01981226|Experimental|Extracoporeal shock wave|Extracoporeal shock wave, 3000 shots/time, once a week for 3 weeks, treatment duration:30 minutes/time, shock wave freqency：2-4Hz, energy level:0.8-1.0 mJ/mm2
89505851|NCT02375217|Active Comparator|Group 1 : (NS)|"Group 1 Drug combination:~patients receive half of the recommended dose of sugammadex plus dose of neostigmine~Sugammadex IV= -1 mg/kg( moderate NMB) or~2 mg/kg (deep NMB)~neostigmine IV = 50mcg/kg~glycopyrrolate 10 mcg/kg"
88957168|NCT01981239|Experimental|LPC analysis group|Voice sampling is executed before and immediately after drinking of 20ml N/S and linear voice analyses using LPC method are performed to calculate LPC index, residual variance, coefficiency mean, coeffiency variance, and coeffiency skewness.
88957169|NCT01981239|Active Comparator|spectral analysis group|Voice sampling is executed before and immediately after drinking of 20ml N/S and spectral voice analyses using Dr. Speech program are performed to calculate HNR (dB), RAP (%: Jitter), Mean and SD Fundamental Frequency (Hz: Fo), Shimmer (%) and SNR (dB).
89505852|NCT02375217|Active Comparator|Group 2 : (S)|"patients receive Full recommended dose of sugammadex~Sugammadex IV= 2mg/kg (Moderate NMB) 4mg/kg ( Deep NMB)"
88957170|NCT01981252|Experimental|Ulthera® System Treatment|Ulthera® System treatment of the peri-orbital and peri-oral regions.
89505853|NCT05724433|Experimental|Virtual HF care|Patients will receive virtual HF care to optimize medical therapies
89538902|NCT04965051|Experimental|IDegAsp group|IDegAsp twice daily
88957171|NCT01981265||Hand osteoarthritis|
89505854|NCT05724433|Other|Routine HF care|Participants will receive routine HF care
89505855|NCT02198885||Control|This group receives the standard prehospital care en route to hospital, and they do not receive the FAST ultrasound en route.
89505856|NCT02198885||FAST|This group receives the FAST ultrasound en route to hospital.
89505857|NCT02368587|Placebo Comparator|Intracoronary infusion WJMSCs|Intracoronary infusion WJMSCs or placebo in patients with ischemic heart failure
89505858|NCT02368587|Placebo Comparator|Intravenous infusion WJMSCs|Intravenous infusion WJMSCs or placebo in patients with ischemic heart failure.
89505859|NCT03527875|Experimental|PTBD group|Percutaneous Transhepatic Biliary Drainage
89505860|NCT03527875|Experimental|ENBD group|Endoscopic Nasobiliary Biliary Drainage
89505861|NCT03527875|Experimental|EBS group|Endoscopic Biliary Stenting
89505862|NCT03527875|No Intervention|Without PBD group|receive surgery without PBD
89505863|NCT02206295|Experimental|Treatment Sequence AB|"Subjects will receive Treatment A in Period 1 followed by Treatment B in Period 2. There will be a washout period lasting at least 6 days between treatments.~Treatment A: up-titration from Day 1-18 will performed in 200 μg steps every fourth day with multiples of 200 μg film-coated tablets starting with 400 μg selexipag b.i.d. The up-titration will be followed by treatment with 8 film-coated tablets, 200 μg each, b.i.d. from Day 19 to the morning dose of Day 23.~Treatment B: up-titration from Day 1-18 will be performed in 200 μg steps every fourth day with multiples of 200 μg film-coated tablets starting with 400 μg selexipag b.i.d. The up-titration will be followed by treatment with one single film-coated tablet, 1600 μg, b.i.d. from Day 19 to the morning dose of Day 23."
89505864|NCT02206295|Experimental|Treatment Sequence BA|"Subjects will receive Treatment B in Period 1 followed by Treatment A in Period 2. There will be a washout period lasting at least 6 days between treatments.~Treatment A: up-titration from Day 1-18 will performed in 200 μg steps every fourth day with multiples of 200 μg film-coated tablets starting with 400 μg selexipag b.i.d. The up-titration will be followed by treatment with 8 film-coated tablets, 200 μg each, b.i.d. from Day 19 to the morning dose of Day 23.~Treatment B: up-titration from Day 1-18 will be performed in 200 μg steps every fourth day with multiples of 200 μg film-coated tablets starting with 400 μg selexipag b.i.d. The up-titration will be followed by treatment with one single film-coated tablet, 1600 μg, b.i.d. from Day 19 to the morning dose of Day 23."
88957172|NCT01981278|Experimental|Treatment A|Tapentadol ER 250-mg tamper-resistant formulation (TRF) tablet will be administered as a single oral dose under fasted condition.
89505865|NCT02375139|Experimental|DA-1229_01 → E+M|DA-1229_01 : Evogliptin/Metformin XR 2.5/500mg x 2 Tablets E : Evogliptin 5 mg M : Metformin XR 1000 mg
89505866|NCT02375139|Experimental|E+M → DA-1229_01|DA-1229_01 : Evogliptin/Metformin XR 2.5/500mg x 2 Tablets E : Evogliptin 5 mg M : Metformin XR 1000 mg
89505867|NCT04468945|Experimental|mirror box therapy|The objects use for task-specific mirror therapy are duster, glass, the wooden block of different sizes and shapes, beads, coin, paper cards and spongy ball. In all these activities shoulder horizontal flexion-extension, adduction-abduction, elbow flexion-extension, forearm supination-pronation, wrist flexion-extension, finger flexion-extension, abduction, adduction, opposition, are performed automatically.
89505868|NCT04468945|Experimental|Repetitive Facilitation Exercise|Treatment involved rapid passive stretching of the muscles of the targeted joints in conjunction with tapping and rubbing the skin to assist in the generation of a contraction.Shoulder horizontal flexion-extension , adduction-abduction ,elbow flexion-extension, forearm supination-pronation, wrist flexion-extension, finger flexion-extension, abduction, adduction, opposition, are performed
89505869|NCT02199119|Experimental|Control|Sitting quietly for 30 min No TV No exercise
89505870|NCT02199119|Experimental|TV viewing only|watching TV for 30 min
89505871|NCT02199119|Experimental|Exercise only|exercising for 30 min
89505872|NCT02199119|Experimental|TV viewing and Exercise|30 min of moderate exercise on a treadmill while watching TV
89505873|NCT02375061|Experimental|e-BPS intervention|"Participants are asked to write and imagine about a future in which they have reached all their goals in four different domains: personal, professional, social and health domain. They carry out the exercise in a Positive Technology System called the Book of Life, which has shown efficacy in the enhancement of positive mood (Baños, Etchemendy, Farfallini, García-Palacios, Quero & Botella, 2014). This application looks like a personal diary, where participants can write all that they want and these essays are supported by multimedia content (pictures, songs and videos). Additionally, they can continue doing the exercise in a web platform (TEO-Emotional Therapy Online) in which they can visualize all the content they had developed previously."
89505874|NCT02375061|Placebo Comparator|Daily Activities|Participants are asked to think and write about all that they have done the last 24 hours. They carry out the exercise in a powerpoint document, where they can record all the activities, situations and thoughts.
89505875|NCT04468867|Experimental|Patient group|
89505876|NCT02201927|Experimental|patient with right parietal lobe lesion|Patient with right parietal lobe lesion
88957173|NCT01981278|Experimental|Treatment B|Tapentadol ER 250-mg prolonged-release formulation 2 (PR2) tablet will be administered as a single oral dose under fasted condition.
88957174|NCT01981291|Active Comparator|Perineural|Patients in this group will receive a perineural injection of mepivacaine for subgluteal sciatic nerve block, in addition to a femoral nerve block and patient-controlled postoperative analgesia.
88957175|NCT01981291|Experimental|Intraneural|Patients in this group will receive an intraneural injection of mepivacaine for subgluteal sciatic nerve block, in addition to a femoral nerve block and patient-controlled postoperative analgesia.
88957176|NCT01981304||DES with a biodegradable polymer coating|Patients receiving the first carbonized bio-absorbable coated rapamycin-eluting coronary stent at time of percutaneous coronary intervention
89023778|NCT04742959|Experimental|Dose Escalation Cohorts (Combination Therapy)|TT-00420 tablets will be administered once daily in 28-day cycles. Nab-paclitaxel 100 mg/m^2 will be administered intravenously on Day 1, 8, and 15 of each 28-day cycle. Dose escalation will be guided by a 3+3 design in Phase Ib to determine the recommended phase 2 dose (RP2D).
89505877|NCT02201927|Experimental|patient stroke|patient with cerebral vascular accident
89505878|NCT02201927|Experimental|healthy volunteers|healthy volunteers
89505879|NCT02365077||Control|The patients of necrosis group was defined by a history of taking 1800 mg prednisolone or an equivalent over 4 week without the symptom of femur head necrosis after 1 year.
89505880|NCT02365077||Necrosis|The patients of necrosis group was defined by a history of taking 1800 mg prednisolone or an equivalent over 4 week with the diagnosis of femur head necrosis.
89505881|NCT02202005|Experimental|Nevirapine|
89505882|NCT02202005|Active Comparator|Viramune®|
89505883|NCT02364921|Experimental|Two-layer compression bandage|Two multilayer compression bandage: Usual clinical practice in venous ulcer in wound care in assessing, cleaning, desinfection, debridement and topical treatment.Measure the ankle circumference and choose the correct kit accordingly (ankle size 18-25cm or 25-32cm). Apply one to seven days
89505884|NCT02364921|Active Comparator|crepe bandage|Crepe bandage: Usual clinical practice in venous ulcer in wound care. crepe bandage apply one to seven days
89505885|NCT02741245|Active Comparator|Ezetimibe 10 mg|1 Ezetimibe 10 mg tablet and 2 Rosuvastatin placebo capsules once daily for 12 weeks
89505886|NCT02741245|Active Comparator|Rosuvastatin 2.5 mg|1 Rosuvastatin 2.5 mg capsule, 1 Rosuvastatin placebo capsule and 1 Ezetimibe placebo tablet once daily for 12 weeks.
89505887|NCT02741245|Active Comparator|Rosuvastatin 5.0 mg|2 Rosuvastatin 2.5 mg capsules and Ezetimibe placebo tablet once daily for 12 weeks.
89505888|NCT02741245|Experimental|Ezetimibe 10 mg+ Rosuvastatin 2.5 mg|1 Ezetimbie 10 mg tablet, 1 Rosuvastatin 2.5 mg capsule and 1 Rosuvastatin placebo capsule once daily for 12 weeks.
89505889|NCT02741245|Experimental|Ezetimibe 10 mg+ Rosuvastatin 5.0 mg|1 Ezetimbie 10 mg tablet and 2 Rosuvastatin 2.5 mg capsules once daily for 12 weeks.
88957177|NCT01981317|Experimental|Stepped Care CBT|"All participants in this arm receive Step One which includes 3-in-office sessions lasting 1 hour each over 6 weeks and 6 weekly phone calls lasting 15 minutes or less. The in-office sessions are devoted to psychoeducation, cognitive therapy, and hierarchy development. These sessions will include all procedures of the standard therapist-delivered CBT but will be parent-led, therapist guided; thus, the parent is delivering evidence-based strategies with clinician guidance.~Children are then stepped up to Step Two of SC-CBT if it is determined that more therapy is needed following the post assessment. Step Two is a continuation of therapy and will include 9 additional in-office weekly session lasting 1 hour each over 9 weeks. These sessions will be therapist-led and are devoted to exposure and response prevention."
88957178|NCT01981317|Active Comparator|Standard CBT|All patients in this arm will receive 12 sessions of therapy over 12 weeks using the evidence-based cognitive behavioral therapy protocol in POTS (2004). Sessions 1-3 do not include exposures and are devoted to psychoeducation, cognitive therapy, and hierarchy development. Sessions 4-12 involve exposure and response prevention exercises specific to each youth.
88957179|NCT01981330|Experimental|aMSC with and without hyaluronan gel|autologous mesenchymal stem cells (aMSC) injected into the vocal folds in 8 patients and aMSC mixed with hyaluronan gel in 8 patients
88957180|NCT01981343|Experimental|A-F Betafood|Two A-F Betafood tablets taken with a meal, 3 times daily for 12 weeks
88957181|NCT01981343|Placebo Comparator|Placebo|2 Placebo tablets taken with a meal, 3 times daily for 12 weeks
88957182|NCT01981369|Active Comparator|Propofol sedation.|This group will have infraclavicular block and sedation during surgery with intravenous Propofol. Patients will receive intravenous Propofol sedation 50-100 mcg/kg/min infusion. The infusion will be stopped 15 minutes before the end of surgery.
88957183|NCT01981369|Experimental|Dexmedetomidine sedation.|This group will have infraclavicular block and sedation with intravenous Dexmedetomidine. Patients will receive intravenous Dexmedetomidine sedation bolus 0.5mcg/kg in 10 minutes and then 0.2-0.5 mg/kg/hr infusion. The infusion will be stopped 15 minutes before the end of surgery.
88957184|NCT01981382||Incident cases|Persistent nonspecific low back pain
88957185|NCT01981382||Controls|Acute low back pain that resolves in <6 months
88957186|NCT01981395|Experimental|Treatment regimn 1|150 mg Fenobam Orally - once
88957187|NCT01981395|Placebo Comparator|Treatment Regimen 2|Placebo orally - once
88957188|NCT01981408|Experimental|[^14C]-LY2801653|Single oral dose of LY2801653 containing 100 micro curies of radioactivity
88957189|NCT01981421||Liver fibrosis|patients who had chronic liver disease
89505890|NCT02202083|Experimental|oxytocin|"There are two groups. Acoording to the bishop score, one group uses the oxytocin , and the other uses the cook balloon.~This group is term gestaion,with bishop score less than 6."
89505891|NCT02368353|Experimental|Cognitive behavioral therapy group|weekly group stress-management CBT (SM-CBT) - 1/week 3 months
89505892|NCT02368353|Active Comparator|Reference group|weekly supportive therapy - 1/week 3 months
89505893|NCT02368275||prospective cohort of patients undergoing mastectomy|Prospective cohort
89505894|NCT02368275||cross sectional cohort of patients|Cross sectional cohort
89505895|NCT03529279|Experimental|Experimental Group|The patients in the Experimental Group are allocated to receive CNG staging and CNG chemotherapy strategy and CNG radiation strategy
89505896|NCT03529279|Active Comparator|Controlled Group|The patients in the Controlled Group are allocated to receive the eighth edition of UICC/AJCC staging and NCCN chemotherapy strategy and NCCN radiation strategy
89538903|NCT04965051|Active Comparator|basal insulin plus pre-prandial insulin group|basal insulin once or twice daily plus pre-prandial insulin
89538904|NCT02455427|Active Comparator|Active tDCS+ Physical Therapy|Active tDCS (transcranial direct current stimulation) will be applied for 20 minutes. After active session of tDCS, the patient will receive physical therapy for 60 minutes. Number of treatment sessions: 6 (3 times a week, for 2 weeks)
89538905|NCT02455427|Sham Comparator|Sham tDCS+Physical Therapy|"Sham tDCS (transcranial direct current stimulation) will be applied for 20 minutes. After sham session of tDCS, the patient will receive physical therapy for 60 minutes.~Number of treatment sessions: 6 (3 times a week, for 2 weeks)"
89538906|NCT03253601|Experimental|Strategy Training: iADAPT Application|Participants will use the iADAPT mobile health application to supplement to in-person and remote intervention sessions.
89538907|NCT03253601|Active Comparator|Strategy Training: Workbook|Participants will use a printed workbook to supplement to in-person and remote (by telephone) intervention sessions.
89538908|NCT04953195|Experimental|levothyroxine sodium|levothyroxine sodium
89538909|NCT03253523|No Intervention|Continued maximal medical management|
89538910|NCT03253523|Experimental|Surgical occipital nerve neurolysis|
89538911|NCT04952883||COPD patients|The COPD questionnaire was conducted to collect the data of lung function, echocardiography and blood gas analysis, and the pulmonary vessels of HRCT were determined. Blood samples were collected for H2S-related indicators detection.
89538912|NCT03253211||State|North Carolina
89538913|NCT03253211||SCD Patients|
89538914|NCT03253211||Providers|Primary care and emergency department clinicians
89538915|NCT03253211||Year|Baseline, year 2, year 3
89538916|NCT03252119|No Intervention|standard therapy group|standard treatment of viral bronchiolitis with low flow oxygen.
89538917|NCT03252119|Experimental|high flow humidified oxygen group|treatment of viral bronchiolitis with high flow humidified oxygen therapy.
89538918|NCT03253445|Experimental|Acceptance and commitment therapy|All participants are given a brief educational talk on encouraging quitting smoking, a self-help leaflet on smoking cessation and an additional 10-session face-to-face ACT on a weekly basis.
89538919|NCT03253445|Placebo Comparator|Control|All participants are given a brief educational talk on encouraging quitting smoking , a self-help leaflet on smoking cessation and 10-sessions of face-to-face social support on a weekly basis.
89538920|NCT04952259|Experimental|Intervention group|Shexiang Tongxin dripping pills + routine treatment
88957190|NCT01981434|Active Comparator|Video game based obesity education|This is the intervention group. They will be given the opportunity to play an interactive educational video game for teaching health and nutrition.
88957191|NCT01981434|No Intervention|No intervention|This is the control group that will receive only printed information about health and nutrition and will not be given the opportunity to play the educational video game.
89538921|NCT04952259|Active Comparator|Control group|routine treatment
89538922|NCT03252197|Experimental|New device group|participants who are tested performance for ultrasound guided cannulation using device
89538923|NCT03252197|Active Comparator|Conventional group|participants who are tested performance for ultrasound guided cannulation using conventional method
89538924|NCT04962399||DKD group|Patients with type 2 diabetes mellitus complicated with diabetic nephropathy diagnosed by the second hospital of Shanxi Medical University
89538925|NCT04962399||TDM group|Type 2 diabetes mellitus without diabetic nephropathy
89538926|NCT04962399||control group|Health examination population in the same period
89538927|NCT03252275|Experimental|Intervention|Standard HBB and ECEB training with peer learning
88957192|NCT01981447|Active Comparator|Group A|IV Lacosamide administered (intravenously) over 30 minutes: 0.7mg/kg, 1.4 mg/kg, 2.1 mg/ kg and 2.9 mg/kg over 30 minutes.
88957193|NCT01981447|Active Comparator|Group B|IV Lacosamide to be administered (intravenously) over 15 minutes: 0.7mg/kg, 1.4 mg/kg, 2.1mg/kg, 2,4 mg/kg
88957194|NCT01981460|No Intervention|Chloroprep and biopatch|Both arms are cleaned with chloroprep and a biopatch is placed on each arm.
88957195|NCT01981460|Experimental|Methylene blue and light treatment|Methylene blue and light treatment for 17 minutes are done twice over 1 week intervals.
89538928|NCT03252275|No Intervention|Control|Standard HBB and ECEB training only
89538929|NCT04962243||Patients undergoing repair of Achilles tendon rupture|Patients undergoing repair of Achilles tendon rupture
89538930|NCT04962243||Subjects who underwent physical examination during the same period|Subjects who underwent physical examination in the Physical Examination Center of Peking University Third Hospital during the same period
89538931|NCT04487483|Experimental|Sleep App|"Participants in this condition will receive full free access to the Pro version of the sleep app and asked to use the app every day for three months."
89538932|NCT04487483|No Intervention|Control|Participants in this condition will be asked to continue their life as normal and abstain from downloading or using any sleep aid and/or sleep tracker app for three months.
89538933|NCT03253367||Current/former clozapine users|This group has only one visit.
89538934|NCT03253367||New clozapine users|This group will be followed for 6 months prospectively.
89538935|NCT03060135|No Intervention|No Intervention: Control|A questionnaire that asks individuals what components of an online intervention they might find useful.
89538936|NCT03060135|Active Comparator|Check Your Drinking (CYD)|The CYD is a brief online intervention designed to provide personalized normative feedback aimed at motivating reductions in drinking
89538937|NCT03060135|Experimental|Hello Sunday Morning|Internet based program designed to assess drinking patterns, and support self-determined goals for abstinence, by providing users with an online platform and community to discuss progress and goals.
89538938|NCT03252977|Experimental|Tailored group|Tailored regimen of IV PCA according to pain sensitivity The regimen of IV PCA will be determined according to preoperative pain sensitivity of patients. Pressure pain threshold will be measured preoperatively in these patients using pressure algometer. Patients with low pain threshold will use high dose IV PCA containing fentanyl 1500mcg, while patients with high pain threshold will use low dose IV PCA containing fentanyl 1000mcg.
89538939|NCT03252977|Sham Comparator|control group|Regimen of IV PCA without considering pain sensitivity The regimen of IV PCA will be determined according to experimental group patient assignments. Pressure pain threshold will not be measured in these patients. Patients will use IV PCA with fentanyl 1000mcg or fentanyl 1500mcg. The determination will be paired to assignment of experimental group.
89023779|NCT04742959|Experimental|PK Run-in Cohorts|TT-00420 tablets will be administered once or twice daily in 28-day cycles according to assigned cohort.
89505897|NCT02368119|Experimental|Group 1|VRC-EBOADC069-00 VP (cAd3-EBO bivalent (Zaire plus Sudan) vaccine (2 x 10(10) vp (n=10) or VRC-EBOADC069-00 VP (cAd3-EBO bivalent (Zaire plus Sudan) vaccine (2 x 10(11) vp (n=10). Randomization to booster of MVA-EbolaZ or PBS placebo will be completed 4 to 16 weeks after priming dose.
89505898|NCT02368119|Experimental|Group 2|VRC-EBOADC069-00 VP (cAd3-EBO bivalent (Zaire plus Sudan) vaccine (2 x 10(10) vp (n=20) or VRC-EBOADC069-00 VP (cAd3-EBO bivalent (Zaire plus Sudan) vaccine (2 x 10(11) vp (n=20). Randomization to booster of MVA-EbolaZ or PBS placebo will be completed 4 to 16 weeks after priming dose.
89505899|NCT02202239|Experimental|Group E|Etomidate was used in both induction and maintenance of anesthesia.
89505900|NCT02202239|Active Comparator|Group P|Propofol was used in both induction and maintenance of anesthesia.
89505901|NCT05370001|No Intervention|Routine procedure - use of ETT size 9|When using HFJV in liver tumour ablation procedures for optimizing surgical conditions, an ETT size 9 is routinely being used in our department.
89505902|NCT05370001|Experimental|Experimental group - use of ETT size 8|In this arm an endotracheal tube of size 8 will be used. This is one size smaller than is routine when HFJV is being used for liver tumour ablation procedures in our department. Worth to note is that an endotracheal tube of size 8 is routine in all other surgical procedures, in men, during general anaesthesia.
89505903|NCT02368197|Active Comparator|Standard balloon angioplasty|Dilatation of stenosis with standard non drug eluting balloon catheter
89505904|NCT02368197|Experimental|Drug eluting balloon angioplasty|Dilatation of stenosis with paclitaxel eluting balloon catheter
89505905|NCT03533153|Experimental|WJ-MSC cells implantation group|"MSC cells (allogeneic transplantation from WJ-MSC primary cells); the frequency: for one time within12h after emergency coronary artery revascularization; dose levels: 1X10^8; method of administration: intravenous injection. Other kinds of treatment are in accordance with the treatment guidelines for MI patients, listed in the column Conventional drug therapy."
89505906|NCT03533153|Placebo Comparator|CTSTMD PBS without WJ-MSC group|"Saline only was injected in the control group. The frequency: for one time 2-12h after emergency coronary artery revascularization. Dose levels: the same dosage given to MSC group. Method of administration: intravenous injection. Other kinds of treatment are in accordance with the treatment guidelines for MI patients, listed in the column Conventional drug therapy."
89505907|NCT03527797|No Intervention|Control|Standard of care
89505908|NCT03527797|Experimental|Intervention|Titration of support level
89505909|NCT02364765|Other|Orthognatic surgery|Elective bimaxillary orthognathic surgery consisting of a unsegmented LeFort I osteotomy combined with a bilateral sagittal split osteotomy, under the influence of mean remifentanil administration of 0.3 mg/kg/hour.
89505910|NCT02206529|Active Comparator|Social Network Engagement+Std Treatment|"Social Network Engagement = content and activities to help the parent engage his/her social network in supporting healthy lifestyle behaviors.~Standard Treatment = family-based behavioral pediatric obesity treatment, as per protocol outlined in FOCUS trial (Family Overweight: Comparing Use of Strategies; NCT00746629)"
89505911|NCT02206529|Other|Standard Treatment|"This comparator arm consists of historical controls, participants in the FOCUS trial who received standard treatment.~Standard Treatment = family-based behavioral pediatric obesity treatment, as per protocol outlined in FOCUS trial (Family Overweight: Comparing Use of Strategies; NCT00746629)"
89505912|NCT04547049|Active Comparator|Non-first-degree donor|Each patient receive graft from a non-first degree donor aged ≤40
89505913|NCT04547049|Active Comparator|First-degree donor|Each patients receive graft from a first-degree donor aged >50
89505914|NCT02202395|Active Comparator|0.25mg|LTS 0.25mg,qd MTX qw
89505915|NCT02202395|Active Comparator|0.5mg|LTS 0.5mg, qd MTX qw
89505916|NCT02202395|Active Comparator|1.0mg|LTS 1.0mg,qd MTX qw
89505917|NCT02202395|Placebo Comparator|Placebo|Placebo qd MTX qw
89505918|NCT03533075|Experimental|Teachable Moment Brief Intervention|The TMBI is informed by evidence based strategies to collaboratively identify 1) drivers of suicidal ideation, 2) functional aspects of the recent suicide attempt, 3) the patient's relationship with the concept of suicide, 4) what has been lost and gained as a result of the suicide attempt, 5) short term management suicide prevention management strategies, and 6) documentation of factors to address in a suicide-specific treatment plan.
89505919|NCT03533075|No Intervention|Care as Usual|Usual care at Veterans Affairs Medical Centers (VAMC) for Veterans who have attempted suicide involves psychiatric evaluation/treatment and ongoing medical stabilization.
89505920|NCT05647291|Experimental|extracorporeal Shock wave therapy (ESWT)|ESWT was performed by the same physician. The applicator was placed at the point of maximum sensitivity. Two thousand pulses with a frequency of 6 Hz and a pressure of 3 bar were applied to patients with an Auto Wave 695 (Mettler electronics, USA) brand device. Patients underwent two sessions of ESWT per week for two weeks, adding up to a total of 4 sessions. Local or regional anesthesia was not administered to any patient during ESWT.
89505921|NCT05647291|Active Comparator|Kinesiotaping|Kinesio tape (KinesioTex, KinesioTaping, US) was applied to the relevant extremity of the patient by the physical therapy and rehabilitation physician once a week, three times in total. During KT, the patient was positioned with the knee and ankle joints in the neutral position. The first strip was adhered along the plantar fascia from the calcaneus to the toes using maximum stretch. The other four strips of tape were attached medially and laterally to support the medial longitudinal arch with a 45° inclination. While maximum stretching was applied to the middle 1/3 of all bands, no stretching was applied to the ends.
89505922|NCT05647291|Active Comparator|Corticosteroid injection|In the CI group, 40mg/1ml methylprednisolone was applied from the inferior-medial side of the heel to the most sensitive area of the calcaneus medial tubercle of the plantar fascia. The same physician performed a total of two sessions once a week.
89505923|NCT03105765|Active Comparator|Ketamine|"The patients in this Group underwent General anaesthesia with total intravenous anaesthesia containing remifentanil (0,02-0,04 mg/kg ideal Body weight), propofol (4-6 mg/kg ideal Body weight) and atracurium.~Ketamine 0,2 mg/kg ideal Body weight per hour for 24 hours."
89505924|NCT03105765|Placebo Comparator|Placebo|"The patients in this Group underwent General anaesthesia with total intravenous anaesthesia containing remifentanil (0,02-0,04 mg/kg ideal Body weight), propofol (4-6 mg/kg ideal Body weight) and atracurium.~Placebo (normal Saline) for 24 hours."
89538940|NCT03251807|Experimental|Twin-block|The patients in this control group will be treated using the Twin-block appliance.
89538941|NCT03251807|Experimental|Twin-block combined with LIPUS|The patients in this experimental group will be treated using the Twin-block combined with LIPUS (Low-intensity pulsed ultrasound).
89538942|NCT03251885||women with preterm labor|pregnant women < 37 weeks of gestations with regular uterine contractions and > 3 cm dilation, > 80% effacement
89538943|NCT03251885||women with term pregnancy|pregnant women > 37 weeks of gestation
89538944|NCT04951869|Experimental|Protescal group|Caesarean-section was done in the usual manner. The transverse suprapubic skin incision was made and abdominal layers opened as usual. After delivering the baby, uterine muscle is closed in two layers with braided absorbable suture, polyglactin 910 (Vicryl no 1). After hemostasis secure, 1 mL Protescal gel was applied at the uterine suture site in Protescal group. Peritoneal layer closed using braided absorbable suture, polyglactin 910 (Vicryl no 1). Rectus sheath was sutured using braided absorbable suture, polyglactin 910 (Vicryl no 1). Subcutaneous tissue closed interruptedly using braided absorbable suture, polyglactin 910 (Vicryl no 1). Protescal gel (0.5 mL) was applied over the subcutaneous tissue prior to skin closure in Protescal group. The skin was then closed with the subcuticular method using braided absorbable suture, polyglactin 910 (Vicryl 3-0).
89538945|NCT04951869|No Intervention|Control group|Caesarean-section was done in the usual manner. The transverse suprapubic skin incision was made and abdominal layers opened as usual. After delivering the baby, uterine muscle is closed in two layers with braided absorbable suture, polyglactin 910 (Vicryl no 1). After hemostasis secure, No Protescal gel was applied at the uterine suture site in this Control group. Peritoneal layer closed using braided absorbable suture, polyglactin 910 (Vicryl no 1). Rectus sheath was sutured using braided absorbable suture, polyglactin 910 (Vicryl no 1). Subcutaneous tissue closed interruptedly using braided absorbable suture, polyglactin 910 (Vicryl no 1). No application of Protescal gel (0.5 mL) over the subcutaneous tissue prior to skin closure in this Control group. The skin was then closed with the subcuticular method using braided absorbable suture, polyglactin 910 (Vicryl 3-0).
89538946|NCT03251261||Specimen collection|
89538947|NCT02455271||Participants with insomnia|Participants with insomnia who will receive eszopiclone per approved label.
89538948|NCT04964661||SpA women MRI|Women affected by spondyloarthritis and performed a sacroiliac MRI
89538949|NCT03251339|Experimental|MSB11455|Participants received a single subcutaneous injection of MSB11455 6 milligram (mg) per (/) 0.6 milliliter (mL) on Day 1 in morning of treatment period 1 (28 Days) and 2 (28 Days). Period 1 and Period 2 are separated by a washout period of 35 Days.
89538950|NCT03251339|Experimental|US-Neulasta|Participants received a single subcutaneous injection of US-Neulasta 6 mg/0.6 mL on Day 1 in morning of treatment period 1 and 2. Period 1 and Period 2 are separated by a washout period of 35 Days.
89538951|NCT04961853|Experimental|Cases|
89538952|NCT04964583|Experimental|Hydroxychloroquine with Azithromycin|Fixed combination of Hydroxychloroquine with Azithromycin 200 mg / 250 mg one tablet every 12 hours for five days and continue with Hydroxychloroquine 200 mg one tablet every 12 hours for 5 more days.
89538953|NCT04964583|Active Comparator|Hydroxychloroquine|Hydroxychloroquine 200 mg, one tablet every 12 hours for ten days.
89538954|NCT04964583|Placebo Comparator|Placebo|Placebo one tablet every 12 hours for ten days.
89538955|NCT03251417|Experimental|Combination treatment|Combination treatment of irinotecan and apatinib.
89538956|NCT04426773|Experimental|tDCS treatment|Cathode transcranial direct current stimulation over the right OFC will be applied once a day, 5 days a week, for 2 weeks.
88957196|NCT01981486|Placebo Comparator|Placebo|Placebo tablets
88957197|NCT01981486|Experimental|PF-05180999|Modified-release tablets of PF-05180999
88957198|NCT01981499|Experimental|Arm A1|Part A of study to assess safety, tolerability, and pharmacokinetics of PF-05180999
88957199|NCT01981499|Placebo Comparator|Arm A2|Part A of study to assess safety, tolerability, and pharmacokinetics of PF-05180999 relative to placebo
88957200|NCT01981499|Experimental|Arm B1|Part B of study to assess effects of PF-05180999 on histamine-induced wheal
88957201|NCT01981499|Experimental|Arm B2|Part B of study to assess effects of PF-05180999 on histamine-induced wheal
88957202|NCT01981499|Experimental|Arm B3|Positive control to ensure histamine-induced wheal assay integrity
88815256|NCT03018314||Group 2|The second group will comprise of 30 women with diagnosis of unexplained infertility, normal menstrual periods and without known male factor infertility.
88815257|NCT03018314||Group 3|The third group will comprise of 30 women those partners with sperm count between 5x106 -15x106 /mL, type A + type B motility <%32 and Kruger morphology <4%.
88815258|NCT00981812|Experimental|PEM Breast Biopsy|All patients underwent PEM biopsy.
88815259|NCT05160038|Experimental|Bodily illusions|Participants in the experimental group see a bodily illusion applied to their embodied virtual avatar.
88815260|NCT05160038|No Intervention|No bodily illusions|Participants in the control group embody a virtual avatar, but without bodily illusions
88815261|NCT05127512|No Intervention|Control Group|Control participants will only complete the knowledge questionnaire in addition to a non-validated survey created by the investigators to collect demographic information as well as attitudes towards treatments of pelvic floor disorders.
88815262|NCT05127512|Experimental|Video Group|These participants will be administered the study intervention, which entails viewing an education video on pelvic floor disorders.
88815263|NCT03016364|Experimental|APP in dosage adjustment|Through the guidance of APP software, clinical doctors try to adjust the dose of Oxycodone Hydrochloride Prolonged-release Tablets for advanced patient's with cancer pain.
88815264|NCT03018002|No Intervention|Control group|HIV-infected participants identified from the churches randomized to CG will be referred to PEPFAR-supported HIV clinics that provide comprehensive care including counseling, laboratory testing, ART and ongoing support during treatment as the standard of care. The study team will not be involved in their care beyond data collection.
88957203|NCT01981499|Experimental|Arm B4|Placebo control
89505925|NCT03660371|Experimental|PPV/MP|Study Group: Subjects undergo internal limiting membrane (ILM) peeling during vitrectomy for the indication of diabetic vitreous hemorrhaging
88815265|NCT03018002|Experimental|iSTAR|HIV-infected participants identified from the churches clustered within the randomized health facilities will receive interventions from the study team.
89505926|NCT03660371|Active Comparator|PPV without MP|Control Group: Subjects do not undergo ILM peeling during vitrectomy for the indication of diabetic vitreous hemorrhaging
89505927|NCT03105609||Naive wet age-related macular degeneration|Patients recruited to the study will be patients who meet the Australian MBS criteria for treatment of exudative CNV with Lucentis. For the duration of the study, the patients will have standard induction and monthly dosing of Lucentis (Ranibizumab; intravitreal; 0.5 mg) to allow comparison with published studies. The only extra intervention for the study is the acquisition of hyperspectral mages with the hyperspectral camera and the acquisition of additional fundus autofluorescence images to the clinical norm.
89505928|NCT03531307||Lactate and Ki 67 levels|Neurosurgical patients between June 2017 and February 2018 for tumoral and non-tumoral craniectomy with lactate levels at the beginning of surgery and Ki-67 index in biopsies.
89505929|NCT02202473|Active Comparator|Lamivudine|Lamivudine (Manufacturer: GlaxoSmithKline) 100mg po, qd
89505930|NCT02202473|Experimental|Lamivudine+Oxymatrine Capsules|Lamivudine (Manufacturer: GlaxoSmithKline) 100mg po, qd; oxymatrine Capsules (Chia Tai Tianqing Pharmaceutical Group Co., Ltd) 200 mg, po, tid.
89505931|NCT02364531||Abiraterone Acetate (ZYTIGA): Prostate Cancer Registry|Participants will not receive any intervention in this study. The chemotherapy-naive metastatic castrate-resistant prostate cancer (mCRPC) participants who, on failing conventional androgen deprivation therapy (ADT), are prescribed to initiate Abiraterone Acetate (ZYTIGA) therapy as part of their physician's treatment approach for their asymptomatic or mildly symptomatic disease, will be observed in this study. Participants will receive standard of care therapy.
89505932|NCT05346133|Other|SPI-A Adolescents|Adolescents with moderate risk will receive the SPI-A intervention from the provider. Adolescents with high risk will be immediately taken to the mental health specialist at the primary care clinic. Following creation of the safety plan, patients are followed-up with at least twice to assess risk and review their plan. Following completion of the pilot, the investigators will interview all included providers as well as 18 adolescents who participated in SPI-A and their caregivers.
89505933|NCT02206763|Experimental|Momelotinib (MMB)+erlotinib|Participants will receive momelotinib (MMB) plus erlotinib.
89505934|NCT03531229|Placebo Comparator|Placebo|Placebo to Lu AF76432
89505935|NCT03531229|Experimental|Lu AF76432|Lu AF76432
89505936|NCT02202629|Placebo Comparator|Cherry flavoured beverage 1|10floz cherry flavoured test article
89505937|NCT02202629|Experimental|Cherry flavoured beverage 2|10floz of cherry flavoured test article with fruit, vegetable and herbal extracts
89505938|NCT02202629|Experimental|Cherry flavoured beverage 3|10floz of cherry flavoured test article with fruit, vegetable and herbal extracts
89505939|NCT02202629|Experimental|Cherry flavoured beverage 4|10floz of cherry flavoured test article with fruit, vegetable and herbal extracts
89505940|NCT02367963|Experimental|Intervention|A Training period and a Peer-group intervention are asigned to this arm. Peer-group intervention is designed to make the subjects participate actively in their healthcare. Through the different activities subjects will begin to successfully make various changes that increase their confidence in the ability to manage risk factors and problems arising from unhealthy habits. Along the twelve sessions (60-90 minutes) subjects propose assumable health goals; learn to manage their emotions, to resolve problems, to control their diet, to increase their physical activity, to control their state of mind and how the acquisition or not of healthy habits influences their relationships.
89505941|NCT02367963|Other|Control|"A Training period intervention is asigned to this arm. Once the workshops have been carried out, the control group will be provided with written and visual documentation of risk factors and overall health habits. The members of this group will have access to the study website, where they will be able to find information on risk factors and health habits and links to the same websites related to health as the intervention group.~They won't participate in the sessions of peer education group dynamics for a period of 12 months."
89505942|NCT05724355|Experimental|Dalpiciclib plus Camrelizumab|
89505943|NCT02202707|Other|Gabapentin|Open label single arm study. All participants will receive Gabapentin.
89519335|NCT01328431|Experimental|SBIRT+NRT|Subjects receive a 6 week course of NRT, a motivational Brief Negotiated Interview, and a facilitated referral to the state's Smokers' Quitline.
89519336|NCT03457363|Experimental|Double Trunk Mask|DTM will be add above nasal cannula
89505944|NCT05724277|Experimental|Experimental group (meditation)|Meditation will be applied to the patients in the meditation group for 10 minutes in the evening and morning of the operation in the preoperative period, and at the 2nd and 12th hours in the postoperative period. In the preoperative period, the patients were evaluated by using the Descriptive Characteristics Form, the Surgery-Specific Anxiety Scale, the Surgical Fear Scale, the Richard Campbell Sleep Scale, and the Recovery Quality-15 Scale and in the postoperative period, the patients were evaluated by using the Richard Campbell Sleep Scale, Nausea Numerical Scale, Numerical Rating Scale, Recovery Quality-15 Scale and Watson Caritas Patient Score. In addition, data will be collected using the Patient Follow-up Form (Experimental Group) both before and after the interventions.
89505945|NCT05724277|Experimental|Experimental group (virtual reality)|Virtual reality will be applied to the patients in the virtual reality group for 10 minutes in the evening and morning of the operation in the preoperative period, and at the 2nd and 12th hours in the postoperative period. In the preoperative period, the patients were evaluated by using the Descriptive Characteristics Form, the Surgery-Specific Anxiety Scale, the Surgical Fear Scale, the Richard Campbell Sleep Scale, and the Recovery Quality-15 Scale and in the postoperative period, the patients were evaluated by using the Richard Campbell Sleep Scale, Nausea Numerical Scale, Numerical Rating Scale, and Recovery Quality-15 Scale. In addition, data will be collected using the Patient Follow-up Form (Experimental Group) both before and after the interventions.
89505946|NCT05724277|No Intervention|Control group|The patients in the control group will not undergo any intervention in the pre- and postoperative period and will receive the routine nursing care of the clinic. In the preoperative period, the patients were evaluated by using the Descriptive Characteristics Form, the Surgery-Specific Anxiety Scale, the Surgical Fear Scale, the Richard Campbell Sleep Scale, and the Recovery Quality-15 Scale and in the postoperative period, the patients were evaluated by using the Richard Campbell Sleep Scale, Nausea Numerical Scale, Numerical Rating Scale, and Recovery Quality-15 Scale. In addition, data will be collected by using the Patient Follow-up Form (Control Group) in the determined periods after the surgery in parallel with the experimental groups.
89505947|NCT05261789|Experimental|Turkish Get Up exercise group|Turkish Get Up exercise was given this group
89505948|NCT05261789|Experimental|Core stability exercise group|Core stability exercise was given this group
89505949|NCT05261789|Active Comparator|Control group|No intervention
89505950|NCT02364609|Experimental|Arm I (afatinib dimaleate, pembrolizumab)|DOSE DE-ESCALATION COHORT: Patients receive afatinib dimaleate PO QD on days 1-21 and pembrolizumab IV over 30 minutes on day 1. Courses repeat every 21 days (for up to 2 years for pembrolizumab) in the absence of disease progression or unacceptable toxicity.
89505951|NCT02364609|Experimental|Arm II (pembrolizumab, afatinib dimaleate)|EXPANSION COHORT: Patients receive pembrolizumab IV over 30 minutes on day 1 for 2 courses. Beginning course 3, patients receive afatinib dimaleate PO and pembrolizumab IV as in Arm I. Courses repeat every 21 days (up to 2 years for pembrolizumab) in the absence of disease progression or unacceptable toxicity.
89505952|NCT02202863|Experimental|Red Wine Grape Pomace Flour (WGPF)|Subjects were asked to maintain their regular eating habits and lifestyles for 16 weeks, except for the daily intake of 20 g of WGPF. WGPF was consumed in bread, biscuits or as flour mixed with water during lunch. Bread and biscuits with 20% WGPF were prepared especially in a bakery. WGPF intake was supervised every day at lunch. Participants were asked to consume the flour supplement with their regular meals on weekends.
89505953|NCT02202863|No Intervention|Control|Subjects were asked to maintain their regular eating habits and lifestyles for 16 weeks.
89505954|NCT05328115|Active Comparator|ALZ-101 125 μg|Intramuscular injection of 125 μg of ALZ-101 adjuvanted vaccine dosed once a month at four doses
89505955|NCT05328115|Active Comparator|ALZ-101 250 μg|Intramuscular injection of 250 μg of ALZ-101 adjuvanted vaccine dosed once a month at four doses
89505956|NCT05328115|Placebo Comparator|Placebo|Intamuscular Saline solution mixed adjuvant and dosed once a month at four doses
89505957|NCT05328115|Active Comparator|ALZ-101 400 μg|Intramuscular injection of 400 μg of ALZ-101 adjuvanted vaccine dosed once a month at four doses
89505958|NCT02367651|Experimental|Pazopanib|Subjects will receive pazopanib 800 mg once daily during each 28-day treatment period until disease progression, unacceptable adverse event (AE)/serious adverse event (SAE), death or withdrawal of consent
89505959|NCT02367651|Placebo Comparator|Placebo|Subjects will receive placebo once daily during each 28-day treatment period until disease progression, unacceptable AE/SAE, death or withdrawal of consent
89505960|NCT03533621|Experimental|Probiotic|1 Probiotic pill, twice a day, for 12 weeks + 20 min weekly support to increase fruit and vegetable consumption
89505961|NCT03533621|Placebo Comparator|Placebo|1 placebo pill (soy protein powder), twice a day, for 12 weeks + 20 min weekly support to increase fruit and vegetable consumption
89505962|NCT02364453|Experimental|Placebo to PACAP38|Pre-treatment with placebo. PACAP38 8pmol/kg/min
89505963|NCT02364453|Experimental|Clemastin 1 mg/ml to PACAP38 8pmol/kg/min|Pre-treatment with Clemastin 1 mg/ml PACAP38 8 pmol/kg/min
89505964|NCT02258009|Experimental|Group 1|Monthly intravitreal injections of 0.5 mg ranibizumab
89505965|NCT02258009|Experimental|Group 2|Three monthly intravitreal injections of 2 mg aflibercept followed by three monthly intravitreal injections of 0.5 mg ranibizumab
89505966|NCT02364219|No Intervention|Standard|"Study arm in which patients are treated according to standard operating procedures. Acting as control arm."
89505967|NCT02364219|Experimental|Standard + Microdialysis|Study arm in which patients are treated according to standard operating procedures but also receive Microdialysis through a small catheter which is inserted into subcutaneous upper arm fatty tissue.
89210493|NCT00906516|Experimental|Neuradiab in combination with Avastin|"Patients will be treated following surgical removal of recurrent glioblastoma with a single intracavitary dose of Neuradiab® delivering 44 Gy±10% to the ridge of the surgically created resection cavity followed by therapy with Bevacizumab (Avastin) at a minimum of 30 days after Neuradiab administration.~Treatment with Bevacizumab will consist of 10mg/kg iv on days 1 and 15 every 28 days. Other chemotherapies (in addition to Avastin) will be permitted based on most current clinical practice and clinical evaluation of the patient."
89505968|NCT02364219|Experimental|Prewarm|Study arm in which patients are treated according to standard operating procedures plus prewarming period of at least 30 minutes during induction of combined general and epidural anesthesia.
89505969|NCT02364219|Experimental|Prewarm + Microdialysis|Study arm in which patients are treated according to standard operating procedures plus prewarming period of at least 30 minutes during induction of combined general and epidural anesthesia and Microdialysis through a small catheter which is inserted into subcutaneous upper arm fatty tissue
89505970|NCT03532997|Experimental|Intervention|"The investigators aim to introduce patients with advanced cancer to supportive care resources, including specialty palliative care, through a novel app called ELOS (stands for extra layer of support) in a prospective cohort study. The investigators will compare participant acceptance of this new electronic tool to industry standards and follow ultimate referrals to outpatient palliative care compared to historical, matched controls."
89505971|NCT02374827|Active Comparator|Standard postpartum tubal ligation|In this arm, patients will receive the standard postpartum tubal ligation by accepted methods (procedure names are the following: Modified pomeroy technique or Parkland method). These methods are procedures for completing a partial salpingectomy.
89505972|NCT02374827|Experimental|Complete Salpingectomy|In this arm, patients will receive a complete salpingectomy by documented accepted methods.
89505973|NCT02202941|Experimental|Procalcitonin guided treatment|Patients who will be randomized to this arm will receive antibiotics therapy based on procalcitonin-guided algorithm.
89505974|NCT02202941|Active Comparator|Conventional treatment|Patients who will be randomized to this arm will receive antibiotic therapy based on conventional practice.
89505975|NCT02374983||Research group|The group will consist of 100 patients (200 observations) receiving Gamma Knife treatment. Radiosurgery treatments will be re-planned using the convolution algorithm and compared to the TMR plans used to treat the patients.
89505976|NCT02203097|Experimental|Propofol|Propofol is administered to all patients via target-controlled infusion (TCI) to reach 4 mcg/ml constant plasma concentration according to the Schneider model during the course of the narcosis.
89505977|NCT02367573|Active Comparator|2D TAPP|Trans-abdominal pre-peritoneal laparoscopic inguinal hernia repair operated with two dimensional view
89505978|NCT02367573|Experimental|3D TAPP|Trans-abdominal pre-peritoneal laparoscopic inguinal hernia repair operated with three dimensional view
89505979|NCT02364141|Experimental|Trunk restraint therapy|Reaching training with trunk restraint by a harness that limited the trunk movements.
89505980|NCT02364141|Active Comparator|Trunk unrestraint therapy|Unrestraint reaching training, only with verbal feedback to maintain the trunk right position.
89505981|NCT05618977|Active Comparator|Control|In-class case studies will be conducted.
89505982|NCT05618977|Experimental|Experimental|Case studies will be done in the form of dramatization simulation.
89505983|NCT02367183|Experimental|GED-0301 160mg QD 12 WK|GED-0301 160 mg once daily (QD) for 12 weeks
89505984|NCT02367183|Experimental|GED-0301 160 mg QD 8 WK|GED-0301 160 mg QD for 8 weeks followed by 4 weeks of placebo
89505985|NCT02367183|Experimental|GED-0301 160 mg QD 4 WK|GED-0301 160 mg QD for 4 weeks followed by 8 weeks of placebo
89505986|NCT03527641|Experimental|Salud sin Barreras, Health without Barriers|"Salud sin Barreras is a manualized community-delivered program tailored for Latino families and their adolescent children at-risk for type 2 diabetes. Salud sin Barreras is based upon a lifestyle intervention called the Healthy Living Program (HeLP), which includes 6 weekly 2-hour nutrition/cooking sessions and 6 weekly 2-hour Multidisciplinary Sessions that include parent education on nutrition, fitness, goal-setting, parenting, and a brief mindfulness curriculum, a teen group physical fitness class, and a teen mindfulness curriculum called Learning 2 BREATHe. In between sessions, participants are encouraged to practice brief mindfulness skills in their daily lives and to complete the homework assignments, such as an audio-guided body scan. Participants have access to home-practice audio-recordings and will be queried about their completion of home-practice assignments."
89505987|NCT03527641|Active Comparator|La Vida Saludable, Healthy Living|The Health Living Program (HeLP) is a manualized community-delivered program tailored specifically for Latino families and children at-risk for adult obesity. HeLP includes 6 weekly 2-hour nutrition/cooking sessions and 6 weekly 2-hour Multidisciplinary Sessions, that include parent education on nutrition, fitness, goal-setting, and parenting, a teen group physical fitness class, and a teen health knowledge curriculum derived from a health education curriculum called Hey DURHAM.
89505988|NCT02364297|Active Comparator|Early TIPS|"Standard treatment to achieve initial hemostasis: vasoactive drugs (somatostatin or terlipressin) + endoscopic injection of tissue adhesives according to the center protocol.~Performance of TIPS in the first 5 days following acute gastric variceal bleeding."
89505989|NCT02364297|Placebo Comparator|Control|"Standard treatment to achieve initial hemostasis: vasoactive drugs (somatostatin or terlipressin) + endoscopic injection of tissue adhesives according to the center protocol.~Standard combined endoscopic and pharmacological therapy as a secondary prophylaxis (beta-blockers or carvedilol + repeated injection of tissue adhesives until the erradication of the fundal varices)."
88957204|NCT01981525|Experimental|Arm 1|Patients will receive metformin at level 1 dose for 2 weeks. If dose is tolerated, patient will receive level 2 dose for 2 weeks and if tolerated will escalate to level 3 dose, and if tolerated will escalate to level 4 dose.
88957205|NCT01981577||Patients with Parkinson's Disease|
88957206|NCT01981577||Healthy volunteers|
89538957|NCT03251573||Normal cognitive function|The cognitive impairment classification algorithm We classified subjects as having no, mild, or major cognitive impairment using criteria from the fifth version of the Diagnostic and Statistical Manual of Mental Disorders (DSM-V) as a guideline.20 The age and/or education-adjusted raw score of each individual cognitive test was calculated and compared with the age and/or education-adjusted published norms for Chinese populations.14 Specifically, age- and education-adjusted scores less than 1.5 standard deviations (SDs) below the adjusted mean of the published population norms on all tests in all domains indicated no cognitive impairment; scores of 1.50 to 1.99 SDs and 2.0 or more SDs below the adjusted mean of the published norms on at least one test in at least one domain indicated mild cognitive impairment and major cognitive impairment, respectively
89538958|NCT03251573||cognitive impairment|The cognitive impairment classification algorithm We classified subjects as having no, mild, or major cognitive impairment using criteria from the fifth version of the Diagnostic and Statistical Manual of Mental Disorders (DSM-V) as a guideline.20 The age and/or education-adjusted raw score of each individual cognitive test was calculated and compared with the age and/or education-adjusted published norms for Chinese populations.14 Specifically, age- and education-adjusted scores less than 1.5 standard deviations (SDs) below the adjusted mean of the published population norms on all tests in all domains indicated no cognitive impairment; scores of 1.50 to 1.99 SDs and 2.0 or more SDs below the adjusted mean of the published norms on at least one test in at least one domain indicated mild cognitive impairment and major cognitive impairment, respectively
89538959|NCT04961931|Other|diabetes group|After qualifying for the study subjects with diabetes and chornic kidney disease received oral empagliflozin 10 mg once daily for 7 days.
89538960|NCT04961931|Other|non-diabetes group|After qualifying for the study subjects with chronic kidney disease without diabetes received oral empagliflozin 10 mg once daily for 7 days.
89538961|NCT04961931|Other|control|After qualifying for the study healthy subjects received oral empagliflozin 10 mg once daily for 7 days.
89538962|NCT03251105|Active Comparator|ProSeal group|This group received the ProSeal LMA for supraglottic airway intubation and ventilation during anaesthesia.
89538963|NCT03251105|Active Comparator|Supreme group|This group received the Supreme LMA for supraglottic airway intubation and ventilation during anaesthesia.
89538964|NCT04952181|Experimental|optical biometry|
89538965|NCT04952181|Experimental|ultrasonic biometry|
89538966|NCT02454881|Active Comparator|Placebo|Oxycodone 1 mg / ml alone
89538967|NCT02454881|Active Comparator|Dexmedetomidine 2.5|Oxycodone 1 mg / mL + Dexmedetomidine 2,5 μg / mL
89538968|NCT02454881|Active Comparator|Dexmedetomidine 5|Oxycodone 1 mg / mL + Dexmedetomidine 5 μg / mL
89538969|NCT02454881|Active Comparator|Dexmedetomidine 10|Oxycodone 1 mg / mL + Dexmedetomidine 10 μg / mL
89538970|NCT04431687|Experimental|Sequence 1|"Period 1: CKD-501 - A single oral dose of 1 tablet under fasting conditions for 5 days.~Period 2: CKD-501, D759, D150 - A single oral dose of 4 tablets under fasting conditions for 5 days (CKD-501: 1 tablet, D759: 1 tablet, D150: 2 tablets)."
89538971|NCT04431687|Experimental|Sequence 2|"Period 1: CKD-501, D759, D150 - A single oral dose of 4 tablets under fasting conditions for 5 days (CKD-501: 1 tablet, D759: 1 tablet, D150: 2 tablets).~Period 2: CKD-501 - A single oral dose of 1 tablet under fasting conditions for 5 days"
89538972|NCT04431687|Experimental|Sequence 3|"Period 1: D759, D150 - A single oral dose of 3 tablets under fasting conditions for 5 days (D759: 1 tablet, D150: 2 tablets).~Period 2: CKD-501, D759, D150 - A single oral dose of 4 tablets under fasting conditions for 5 days (CKD-501: 1 tablet, D759: 1 tablet, D150: 2 tablets)."
89538973|NCT04431687|Experimental|Sequence 4|"Period 1: CKD-501, D759, D150 - A single oral dose of 4 tablets under fasting conditions for 5 days (CKD-501: 1 tablet, D759: 1 tablet, D150: 2 tablets).~Period 2: D759, D150 - A single oral dose of 3 tablets under fasting conditions for 5 days (D759: 1 tablet, D150: 2 tablets)."
89538974|NCT02455037|No Intervention|Body Strengthening (Only)|All participants will complete a general resistance exercise training program.
89538975|NCT02455037|Experimental|Body Strengthening + Neck Strengthening|Participants assigned to the neck strengthening group will complete additional supervised exercises specifically designed to strengthen the neck.
89538976|NCT03058341|Sham Comparator|Group S|Patients will be anaesthetized by inhalational anaesthesia using sevoflurane.
89538977|NCT03058341|Experimental|Group P|Patients will be anaesthetized using total intravenous propofol.
89538978|NCT03250949|No Intervention|Conventional-Drilling Tight Fit (Control) group|osteotomy will be achieved with no. 6 round , then widened , using a drill 1 mm larger than the final drill provided by the manufacturer. the final size of the control osteotomies were same diameter of the implant.
89538979|NCT03250949|Experimental|Over-drilling Loose Fit (Test) group|Osteotomy preparations for the loose fit group will be identical to those of the tight fit group until final drill, which will be 0.2mm wider than the diameter of the implant.
89538980|NCT03058575|Experimental|Dietary MACs|Dietary fiber supplement (blend of resistant starch and dietary fiber food ingredients providing 15g of microbiota accessible carbohydrate/1 scoop serving) will be provided in a powder that will be mixed with 6-10 oz of water (depending on desired thickness) and consumed as a chocolate shake.
89538981|NCT03058575|Other|Control|No Intervention
89538982|NCT03250871|Placebo Comparator|Placebo|"Placebo will be the suggestion of self-relaxation methods (for example, try to relax ,try to think of pleasant moment ) and the diffusion of white noise during surgery."
89206756|NCT02548182|Active Comparator|smartcare plus financial incentives|Participants in the 'smartcare plus financial incentive' arms were told that they are entitled to receive financial incentives depending on their achievement of the physical activity and weight target, and the amount they ca expect .The investigators provide financial incentives classified as process-based incentive and outcome-based incentive in addition to smartcare group intervention. A smartphone application was customized for the use of the investigators' intervention, different for the 'smart care' group and 'smartcare plus financial incentive' group.
88815266|NCT03018236|Experimental|Alcohol N-acetylcysteine|600 mg N-acetylcysteine capsule by mouth, every 12 hours for 8 weeks
88815267|NCT03018236|Placebo Comparator|Alcohol Placebo|A placebo capsule matching color and smell of the active medication
89206757|NCT05352477|Experimental|Balneotherapy with thermal water|Daily balneotherapy with Acquabios thermal water at 33°C for 20 minutes each, for a total of 12 applications carried out over a period of 2 weeks
89206758|NCT05352477|Placebo Comparator|Balneotherapy with tap water|Daily balneotherapy with tap water at 33°C for 20 minutes each, for a total of 12 applications carried out over a period of 2 weeks
89206759|NCT00835302|Experimental|Manipulation + Exercise Group|Cervicothoracic manipulation and ROM exercises
89206760|NCT04010955||Edoxaban Monotherapy|"edoxaban monotherapy without additional antiplatelet therapy in long term stroke prevention.~However, transient additional antiplatelet therapy will be allowed at the discretion of duty physicians."
89206761|NCT04010955||Edoxaban and antiplatelet combination|edoxaban plus additional antiplatelet therapy in long term stroke prevention. However, transient cessation of antiplatelet therapy will be allowed at the discretion of duty physicians.
89210494|NCT03299478||NSCLC patients|
89210495|NCT00908700|Experimental|Occlusion arm|Surgical intervention: Occlusion of the left atrial appendage (LAA) using 'cut-and-sew' technique appendage occlusion.
89210496|NCT00908700|Active Comparator|Medical arm|Medical arm: The comparator is best medical practice for atrial fibrillation related stroke prevention as per guidelines.
89538983|NCT03250871|Experimental|Hypnosis|"Hypnosis will be associated with the usual anesthesia. Hypnosis is a temporary modification of consciousness technique based on suggestion.~It is divided into three phases:~induction: attention of the patient fixed on an object or a part of the body,~the dissociation where the patient cuts off auditory, visual and tactile perceptions,~and finally the opening towards a hypnotic experience thanks to the imaginary."
89538984|NCT03058497|Active Comparator|Temperature-Controlled Laminar Airflow Device Active|Temperature-Controlled Laminar Airflow Device
89538985|NCT03058497|Placebo Comparator|Temperature-Controlled Laminar Airflow Device Placebo|Temperature-Controlled Laminar Airflow Device
89538986|NCT03250793|Experimental|Neonate with congenital diaphragmatic hernia|Neonates with congenital diaphragmatic hernia in post-surgical period under mechanical ventilation during weaning of mechanical ventilation
89538987|NCT04961463|Experimental|İnterventions group|İnterventions group:The 7-session psychoeducation program prepared on the basis of the Roy Adaptation Model was applied to the intervention group once a week for 90-120 minutes
89538988|NCT04961463|No Intervention|Control group|Except for the routine hospital controls, no intervention was made to the control group
89538989|NCT03250559|Active Comparator|ultrasound guided group|"The group of renal stones that would have percutaneous nephrolithotomy under ultrasound guidance.~Intervention: percutaneous nephrolithotomy."
89519337|NCT03457363|Active Comparator|Nasal Cannula Alone|Patients receive oxygen only thought nasal Cannula
89519338|NCT05170711|Experimental|hypotensive anesthesia|hypotensive anesthesia group
89538990|NCT03250559|Active Comparator|fluoroscopy guided group|"The group of renal stones that would have percutaneous nephrolithotomy under fluoroscopy guidance.~Intervention: percutaneous nephrolithotomy."
89519339|NCT05170711|Active Comparator|normotensive anesthesia|normotensive anesthesia group
89519340|NCT03130231||POD group|POD group refers to the patients who were diagnosed to be delirious by the Confusion Assessment Method.
89519341|NCT03130231||Non-POD group|Non-POD refered to the patients who did not become delirious by the Confusion Assessment Method.
89519342|NCT03454945|Experimental|Doxycyline|Oral Vibramycin antibiotic100 mg capsule every 12 hours for 3 months
89519343|NCT03454945|Active Comparator|Phototherapy|UVA+ psoralen 3 sessions per week for 3 months
89519344|NCT03467737|Experimental|Normal sorghum porridge, algal starch|Sorghum porridge with 13C-algal starch
89519345|NCT03467737|Experimental|Normal sorghum porridge, algal dextrins|Sorghum porridge with 13C-algal starch limit dextrins
89519346|NCT03467737|Experimental|Normal sorghum porridge, labeled flour|Sorghum porridge with 13C-labeled sorghum flour
89519347|NCT03467737|Experimental|Modified sorghum porridge, labeled flour|Modified sorghum porridge with 13C-labeled sorghum flour
89519348|NCT03467737|Experimental|Thinned sorghum porridge, labeled flour|Modified thinned sorghum porridge with 13C-labeled sorghum flour
89206762|NCT04016688|Active Comparator|ES Erector Spinae Plane Block|"bilateral ESP block at the level of T9 by a linear ultrasound (US) transducer (Phillips Saronno Italy) placed vertically 3cm lateral to the midline to visualize the back muscles superior to the transverse process.~A 22-G short bevel needle (spinocan, B.Braun, melsungen AG, Germany) will be inserted in cranial-caudal direction until it make contact with the transverse process. Confirmation of the correct position of the tip of the needle is by injection of 1 ml saline causing hydrodisscetion between the erector spinae muscle and the transverse process. After careful aspiration to exclude vascular puncture, 20 ml 0.25 % bupivacaine is injected.The same procedure is done on the other side of the back."
89505990|NCT02364375|Experimental|Full Face|Participants will trial the same mask type/variant (full face, nasal, pillows) as the variant they are using as part of their current treatment. Participants in this arm will trial the Menai mask (full face) and Comparison Menai Standard mask (full face) for 7 nights each.
89505991|NCT02364375|Experimental|Nasal|Participants will trial the same mask type/variant (full face, nasal, pillows) as the variant they are using as part of their current treatment. Participants in this arm will trial the Menai mask (nasal) and Comparison Menai Standard mask (nasal) for 7 nights each.
89505992|NCT02364375|Experimental|Pillows|Participants will trial the same mask type/variant (full face, nasal, pillows) as the variant they are using as part of their current treatment. Participants in this arm will trial the Menai mask (pillows) and Comparison Menai Standard mask (pillows) for 7 nights each.
89505993|NCT03527563|Other|Internet Medical Model|Using Internet blood pressure management model: home blood pressure self-monitoring + Internet diagnosis + Maintained or adjusted anti-hypertension drug(s) treatment.
89505994|NCT03527563|No Intervention|Conventional Medical Model|Using Conventional blood pressure management model: home blood pressure monitoring + face-to-face diagnosis in clinic + Maintained or adjusted anti-hypertension drug(s) treatment.
89505995|NCT02364063|Experimental|Children with CP - Therapy|Children receive incontinence treatment during one year, after which a follow-up period of 6 months will be applied. Intervention includes standard urotherapy with or without pharmacotherapy/specific urotherapy
89505996|NCT02364063|No Intervention|Children with CP - Control|Children are followed for 6 months, not receiving any treatment. After this follow-up period, children also receive incontinence treatment for 6 months.
89505997|NCT02364063|Active Comparator|Children without CP|Children receive incontinence treatment during 1 year. Intervention includes standard urotherapy with or without pharmacotherapy/specific urotherapy
89505998|NCT05300893|No Intervention|Treatment with night splint after percutaneous needle fasciotomy|
89505999|NCT05300893|Experimental|No treatment with night splint after percutaneous needle fasciotomy|
89506000|NCT04439487||Obese patients requiring general anesthesia|Group consists of consecutive, adult, obese patients undergoing elective surgical procedures requiring general anaesthesia, direct laryngoscopy and intubation. All patients undergo general anesthesia according to a standardised protocol. They are preoxygenated with 100% oxygen breathed through a face mask for 3-5 minutes. Induction of general anaesthesia is achieved with propofol 1,5-2 mg·kg-1 (of Ideal Body Weight) and 0,1mg fentanyl or sufentanil 10µg. Muscle relaxation is accomplished with rocuronium 0.6 mg ·kg-1 (of Ideal Body Weight). Depth of muscular blockade is monitored using Train of Four (TOF) method. The first laryngoscopy attempt is performed at TOF 0. The patient is placed in an optimal, sniffing or ramped position as appropriate and a #3 or #4 Macintosh blade is used. Successful intubation is confirmed with bilateral auscultation and capnography.
89506001|NCT03528967|Experimental|Arm 1|"Patients going on ASPIRIN 100 mg/day combined with ENOXAPARIN 4000 IU per dat prevention treatment according to randomization:~Administer Aspirin 100 mg Oral Tablet, Enteric Coated once daily~Administer the Enoxaparin preventive dose of 4000 IU as a subcutaneous Enoxaparin 40 mg / 0.4 mL Prefilled Syringe once daily~Start treatment from inclusion visit~Maintain treatment until the day of delivery, or the appearance of a complication (Retroplacental hematoma (RPH), preeclampsia (PE) , In utero fetal death (IUFD), or Intrauterine growth restriction (IUGR) and its complications)"
89506002|NCT03528967|Other|Arm 2|"Patients going on ASPIRIN 100 mg/day prevention treatment alone according to randomization:~Administer only Aspirin 100 mg Oral Tablet, Enteric Coated once daily~Administer orally~Start treatment from inclusion visit~Maintain treatment until 35 Weeks of Amenorrhea (WA)"
89506003|NCT05723965||rectal cancer lesion images for training|"Rectal cancer lesion images. Images with threatened (<2mm) circumferential margin of rectal cancer were labeled as diseased. Otherwise, images were labeled as normal. Using these materials as training materials for AI deep learning model buildup."
89506004|NCT05723965||rectal cancer lesion images for testing.|Using the buildup AI deep learning models from training cohort. Evaluating prediction rate of the model and analysis survival outcomes.
89506005|NCT02374905|Experimental|Drinksmeter|Web-based application delivering Identification and Brief Advice of Alcohol Use
89506006|NCT02374905|Active Comparator|Brief Advice of Alcohol Use|Lifestyle counseling regarding alcohol intake and completion of Audit-10 questionnaire done chair-side with clinician
89506007|NCT05723809|Experimental|Percussive Therapy Device|Participants will be going to physical therapy - 1 session per week for 6 weeks and will use a percussive therapy device daily for 3-7 minutes
89506008|NCT05723809|Active Comparator|Control group|Participants will be going to physical therapy - 1 session per week for 6 weeks
89506009|NCT05271565|Experimental|Oligomeric enteral feeding group|Oligomeric enteral nutrition will be administered according to the study protocol
89506010|NCT05271565|Active Comparator|Polymeric enteral feeding group|Polymeric enteral nutrition will be administered according to the study protocol
88815268|NCT03018236|Experimental|Cocaine N-acetylcysteine|600 mg N-acetylcysteine capsule by mouth, every 12 hours for 8 weeks
88815269|NCT03018236|Placebo Comparator|Cocaine Placebo|A placebo capsule matching color and smell of the active medication
89506011|NCT02374749|Active Comparator|comorbidities|Evaluation of the prevalence and the presence of the risks factors of the four most frequently observed comorbidities in spondyloarthritis (cardiovascular diseases, cancers, infections osteoporosis and gastro-intestinal) as it is recommended by the French Society of Rheumatology.
89519349|NCT03467737|Experimental|Modified sorghum porridge, octanoic acid|Modified sorghum porridge with 13C-labeled octanoic acid
89538991|NCT04961385||ChAd0x1 nCoV-19 vaccinees|Participants who received first dose of ChAdox-1 n COV-19 were recruited. Participants were eligible if they were more than 18 years old
88957207|NCT01981603|Experimental|navigator|Kidney transplant recipients will serve as navigators to educate and assist other patients with the transplant process.
88957208|NCT01981603|No Intervention|usual care|usual care
89506012|NCT02374749|Active Comparator|self-assessment|"During the initial visit, the clinical research nurse exempt a learning program of assessment of disease activity/severity :~for assessing the activity in SpA;~for the calculation of BASDAI and the ASDAS-CRP~for the transfer technique and for the calculation of the disease activity on a monthly basis during the next 12 months.~for the risk of tobacco exposure~for the benefit of an NSAID intake in case of painful episode of the disease~for the benefit of home exercises~for the spine and indication of a treatment under the supervision of a physiotherapist in case of severe disease~for learning the patient to calculate his BASDAI and ASDAS-CRP Then, the patient will return home with his calculator and his notebook. Each month, the patient will be asked to perform the BASDAI and ASDAS-CRP calculations and to report the data on the notebook. 12 months later, the patient comes for a visit in the current practice to assess both such program and comorbidities."
89506013|NCT02363985|Other|Multiple vitamin A exposer|"55 children who are using~Mega-dose vitamin A supplementation~Food diversification (promotion and education on vitamin A rich food consumption)~Promotion of orange flash sweet potato production and consumption in collaboration with international potato center (CIP) in one of the study area"
89506014|NCT02363985|Other|Only vitamin A supplementation|"55 children who are using~Mega-dose vitamin A supplementation~Food diversification (promotion and education on vitamin A rich food consumption)"
89506015|NCT05723731|Experimental|Treatment group|patients will receive taVNS at left tragus for four weeks.
89506016|NCT05723731|Sham Comparator|Sham-treatment group|patients will receive sham-taVNS at left earlobe for four weeks.
89506017|NCT05653791||Filgotinib treated patients|
89506018|NCT02367495|Experimental|PCB|Paclitacel-coated balloon (Agent, Boston Scientific)
89506019|NCT02363829|Experimental|Treatment|Nelfinavir and Cisplatin
89506020|NCT03528889|Active Comparator|Goniometer|Extension FDO: classic procedure with goniometer controlled extension and derotation
89506021|NCT03528889|Experimental|EMT|Extension FDO: procedure with electromagnetic tracking (EMT) controlling extension and derotation
89506022|NCT03113019|Experimental|Immunotherapy based on dendritic cells|Intravenous administration dendritic cell and activated mononuclear cells at least 3 times 20-30 million cells / injection
89506023|NCT03528811|Other|Five points test of Tongji university|"We established the evaluatation and follow-up system of diabetes vascular disease based on the method called Five points test of Tongji university ."
89506024|NCT02363673|Experimental|Individualised Homoeopathic Remedy|Each participant is to receive an individualised homoeopathic remedy in aqua distilla according to their symptoms and characteristic manifestations of their disorder. Although different individualised remedies may be dispensed, each remedy will be homoeopathic. Remedies will be dispensed in aqua distilla. Each individualised homoeopathic remedy will have an individualised dosage, frequency and duration based on the laws of individualised homoeopathic prescribing.
89506025|NCT03527329||Prewarming|Active Prewarming will be performed using a forced-air blanket (WarmTouch lower body blanket, Covidien Ltd, Mansfield, USA) over the whole body and connected to a forced-air warmer (WarmTouch Model 5900, Covidien Ltd, Mansfield, USA). Patients will be warmed using a surgical blanket during the intraoperative period. Tympanic thermometer (Genius 2 Tympanic Thermometer and Base, Covidien Ltd, Mansfield, USA) will be used to measure the temperature throughout the perioperative period.
89506026|NCT03527329||Control|Non-active prewarming. Patients will be warmed using a surgical blanket during the intraoperative period. Tympanic thermometer (Genius 2 Tympanic Thermometer and Base, Covidien Ltd, Mansfield, USA) will be used to measure the temperature throughout the perioperative period.
88957209|NCT01981629||Shock|Defined by systolic blood pressure less than 95 mmHg or shock index (heart rate/systolic blood pressure) greater than 0.9
88957210|NCT01981655|Experimental|0.5M Sodium lactate|A bolus of 0.5M Sodium lactate of 3 ml per kg body weight (BW) is administered in 15 minutes, followed by a continuous infusion with 1 ml per kg per hour for 24 hours, i.e. in total 27 ml per kg over 24 hours
88957211|NCT01981655|Active Comparator|Hartmann's solution|Hartmann's solution of 3 ml per kg BW is administered in 15 minutes. There is NO continuous infusion infused thereafter; i.e. in total 3 ml per kg over 24 hours
88957212|NCT01981668|Experimental|Cabazitaxel, Eligard and Radiotherapy|This study utilizes a conventional phase I study design with a '3+3 cohort expansion' design(15), to determine the MTD of 1) Cabazitaxel, in Part A, and 2) Radiotherapy, in Part B. The determination of the MTD is given in Section 5.2, Definition of Dose - Limiting Toxicity. All patients who enter the study, and begin concurrent chemo-radiation are analyzable for the primary endpoint of the study.
88957213|NCT01981681|Experimental|Cohort 1 Experimental Arm|
88957214|NCT01981681|Experimental|Cohort 2 Experimental Arm|
88957215|NCT01981681|Experimental|Cohort 3 Experimental Arm|
88957216|NCT01981681|Placebo Comparator|Cohort 3 Placebo Arm|
89506027|NCT02367261|Experimental|SPI dental implant|Subjects implanted with SPI implant
89506028|NCT03528733|Experimental|Multi-Energy Detector|Multi-Energy Digital Radiography Detector System
89506029|NCT02363751|Experimental|1|Patients will be treated for a maximum of 6 (21 days) chemotherapy cycles (Gemcitabine+platinum salt+bevacizumab)
89506030|NCT03530839|Experimental|Arthrodesis|Arthrodesis of the proximal interphalangeal joint by using a threaded K-wire
89506031|NCT03530839|Active Comparator|Resection arthroplasty|Resection arthroplasty of the proximal interphalangeal joint using a normal K-wire
89506032|NCT03530761||Acute kidney injury|Increase in serum creatinine more than 0.3 mg/dl within 48 hours or a percentage increase serum creatinine more than 50% from baseline.
89538992|NCT04944459|Experimental|Muse-S|multi-sensor neurofeedback-assisted mindfulness training device (Muse-S)
89538993|NCT04952025||ALS patients|
89538994|NCT04952025||normal controls|
89538995|NCT04951791|Experimental|treatment|patients will receive intravenous infusion of SMOFlipid 20%
89538996|NCT04951791|Placebo Comparator|control|patients will receive intravenous infusion of normal saline 0.9%
89538997|NCT04951713|Experimental|XZP-3287 combined with clarithromycin|XZP-3287 combined with clarithromycin
88957217|NCT01981681|Experimental|Cohort 4 Experimental Arm|
88957218|NCT01981681|Placebo Comparator|Cohort 4 Placebo Arm|
88957219|NCT01981694|Experimental|Single ascending doses|
88957220|NCT01981694|Experimental|Measurement of eye blink rate|
88957221|NCT01981707|Experimental|F-Choline PET|The F-Choline-PET will be performed before and at 6 weeks of the beginning of treatment by abiraterone acetate or enzalutamide.
88957222|NCT01981733|Experimental|Device|
88957223|NCT01981746|Experimental|30 ml|30 ml ropivacaine 0.1%, single bolus
88957224|NCT01981746|Experimental|10 ml|10 ml 0.1% ropivacaine, single bolus
88957225|NCT01981785||Immune deficiencies/Immune disorders|Patients with abnormal immune responses or potential primary immune deficiencies or immune disorders (allergies, autoimmune diseases) will be enrolled as the study group.
88957226|NCT01981785||No prior immune abnormalities|Patients with no prior immune abnormalities will be enrolled as the control group.
88957227|NCT01981798|Active Comparator|Training group|Physiotherapy and occupational therapy: Training group received 9 units of physiotherapy and 2 units of occupational therapy, each with a duration of one hour.
88957228|NCT01981798|No Intervention|Control Group|Members of the control group were referred to their general practitioner or specialist for further care.
88957229|NCT01981811|Active Comparator|Aripiprazole and Ingestible Event Marker (IEM)|All subjects will continue to receive their previously prescribed dose of aripiprazole (10 mg, 15 mg, 20 mg, or 30 mg) through the trial. Subjects will discontinue dosing of the conventional oral aripiprazole tablet and will begin taking MIND1 (aripiprazole embedded with an Ingestible Event Marker) tablet once-daily for 12 weeks.
88957230|NCT01981889|Other|Prednisone|Participants who are started on Prednisone 40 mg per day for 2 weeks and then tapered.
89538998|NCT04951713|Experimental|XZP-3287 combined with rifampicin|XZP-3287 combined with rifampicin
89538999|NCT04944303|Active Comparator|Sugammadex|In the early group, the injection of muscle relaxant was stopped 2min the operation finish, and 4mg kg-1 of sugammadex was injected .
89539000|NCT04944303|Placebo Comparator|Normal Saline|the injection of muscle relaxant was stopped 2min the operation finish, and equal normal saline was injected .
88957231|NCT01981915|Experimental|Lung Insufflation Volume|Measurement of the lung volume after hyperinsufflation with positive pressure by IPPB or LIAM
88957232|NCT01981915|Experimental|Peak Cough Flow|Measurement of the peak cough flow after hyperinsufflation with positive pressure by IPPB or LIAM
88957233|NCT01981928|Experimental|ASP7962|Each dose level group will include 8 subjects, of which 6 will be randomized to receive active ASP7962
89539001|NCT04944069|Experimental|Almonertinib With Bevacizumab|Almonertinib 110 mg oral once daily with Bevacizumab 15 mg/kg intravenous on Day 1 of 21 day cycles (every 3 weeks)
89539002|NCT04951167|Active Comparator|PB: prophylactic bolus|an IV bolus of 4 mcg Norepinephrine will be administered immediately after spinal anesthesia, and then SF infusion will be started at 1 ml/min.
89539003|NCT04951167|Active Comparator|PI:prophylactic infusion|1ml of saline is administered immediately after spinal anesthesia, and then infusion will be started with the study drug at 1 ml/min.(4mcg/min)
89539004|NCT04951167|Active Comparator|TB:therapeutic bolus|immediately after spinal anesthesia, 1 ml of saline, followed by 1 ml/min infusion of SF, and when the blood pressure decreases by 20%, 1 ml of working solution and then 1 ml/min of saline infusion will be started.
89539005|NCT04951167|Active Comparator|TBI:therapeutic bolus-infusion|1 ml of study drug and 1 ml/min of study drug infusion will be started immediately after spinal anesthesia, after 1 ml of saline followed by 1 ml/min of SF infusion when blood pressure decreases by 20% of the entry
89539006|NCT04950933|Experimental|Test group|
88957234|NCT01981928|Placebo Comparator|Placebo|Each dose level group will include 8 subjects, of which 2 will be randomized to receive placebo
88957235|NCT01981941|Experimental|Treatment group|Oral
88957236|NCT01981980|Experimental|Carboxytherapy|It was administered using the beveled end of a 30G ½ needle introduced in the skin in an angle of approximately 30ºC and delivered at a velocity of 40 mL/min. The total quantity of CO2 infused was approximately 20 mL (0,3 to 0,6 mL/kg of patient's body weight) encompassing the whole delimited area.
88957237|NCT01981980|Experimental|Radiofrequency|The epidermal temperature was controlled using an infrared thermometer monitored to reach 40ºC and treatment time was of five minutes starting after having reached this temperature.
88957238|NCT01982006|Active Comparator|Phaco|Cataract surgery by phacoemulsification
89539007|NCT04950933|Placebo Comparator|Control group|
89539008|NCT04961307||Women with breast cancer using trastuzumab|
89539009|NCT04961229|Experimental|Third dose of BNT162b2 vaccine with Immunosuppression reduction|Third dose of BNT162b2 vaccine with reduction of mycophenolic acid dose
89539010|NCT04961229|Experimental|Third dose of BNT162b2 vaccine without immunosuppression reduction|Third dose of BNT162b2 vaccine without reduction of mycophenolic acid dose
89539011|NCT04961229|Experimental|Third dose of BNT162b2 vaccine|Third dose of BNT162b2 vaccine with no change in immunosuppression for patients that are excluded from the randomised trial
88957239|NCT01982006|Experimental|Femto|Corneal incision, anterior capsulorhexis and lens fragmentation by femtosecond laser
88957240|NCT01982019|Other|Obese patients with type 2 diabetes|Meal test taking and hormones measure including 26RFa
88957241|NCT01982019|Other|Obese patients witout diabetes|Meal test taking and hormones measure including 26RFa
88957242|NCT01982019|Other|healthy volonteers|Meal test taking and hormones measure including 26RFa
88957243|NCT01982032|Active Comparator|Edwards SAPIEN bioprosthesis|Transcatheter aortic valve replacement with an Edwards SAPIEN bioprosthesis
88957244|NCT01982032|Active Comparator|Medtronic CoreValve® system|Transcatheter aortic valve replacement with the Medtronic CoreValve system
88957245|NCT01982045|Experimental|AttraX condition|8-10cc of AttraX® Putty per spinal level at the randomized allocation side of the spine (left or right).
89506033|NCT03530761||Hepatorenal syndrome|"Diagnosis of cirrhosis and ascites,~Diagnosis of AKI according to ICA-AKI criteria~No response after 2 consecutive days of diuretic withdrawal and plasma volume expansion with albumin 1 g per kg of body weight~Absence of shock~No current or recent use of nephrotoxic drugs (non-steroidal anti-inflammatory drugs, aminoglycosides, iodinated contrast media, etc.)~No macroscopic signs of structural kidney injury, defined as: absence of proteinuria (> 500 mg/day), absence of microhaematuria (> 50 RBCs per high power field), normal findings on renal ultrasonography."
89506034|NCT02374437|Active Comparator|PART A (single dose)-200 mg|200 mg ARAMCHOL
89506035|NCT02374437|Active Comparator|PART A (single dose)-400 mg|400 mg ARAMCHOL
89506036|NCT02374437|Active Comparator|Part B ( food effect)- -Fasting|600 mg Aramchol tablets under fasting conditions (fasting for at least 10 hours before and 4 hours after dosing)
89506037|NCT02374437|Active Comparator|Part B ( food effect)- -Fed|600 mg Aramchol tablets under fed conditions (fasting for at least 10 hours before dosing, consumption of a high calorie high fat meal within 30 minutes prior to drug administration and no food for additional 4 hours after dosing)
89506038|NCT02374437|Active Comparator|Part C ( multiple doses)- 200 mg|200 mg Aramchol tablets for ten consecutive days.
89506039|NCT02374437|Active Comparator|Part C ( multiple doses)- 400 mg|400 mg Aramchol tablets for ten consecutive days.
89506040|NCT02374437|Active Comparator|Part C ( multiple doses)- 600 mg|600 mg Aramchol tablets for ten consecutive days.
89506041|NCT02374437|Placebo Comparator|Part C ( multiple doses)- Placebo|Placebo tablets for ten consecutive days.
88957246|NCT01982045|Active Comparator|Autograft condition|8-10cc autologous bone graft per spinal level at the control side of the spine. This can be a combination of local bone and iliac crest bone, but at least 50% of the volume has to be iliac crest bone graft.
88957247|NCT01982071|Experimental|Treatment group|Intravenous (IV)
88957248|NCT01982097||Group 1|
88957249|NCT01982110|Experimental|Mindfulness Based Therapy|Craving to Quit mobile application is provided for participants
88957250|NCT01982110|Active Comparator|Behavioral Smoking Cessation|NCI Quit Pal via a mobile phone application is provided for participants
88957251|NCT01982136||Urethral stricture|patients requiring surgery for urethral stricture
88957252|NCT01982149||Group 1|Non-smokers (n=20)
88957253|NCT01982149||Group 2|Non-smokers (n=20), Smokers (n=20) and Individuals with lung cancer (n=20)
88957254|NCT01982149||Group 3|Subjects with abnormalities (nodules) detected on CT (n=20)
88957255|NCT01982162||Cohort A|severe school aged asthma cohort
88957256|NCT01982162||Cohort B|mild to moderate school aged asthma cohort
89506042|NCT05576623|Experimental|1 dose of AdCLD-CoV19-1 OMI (Part A)|Group in Part A will receive 1 dose of AdCLD-CoV19-1 OMI
89506043|NCT05576623|Experimental|1 dose of AdCLD-CoV19-1 OMI (Part B)|Group 1 in Part B will receive 1 dose of AdCLD-CoV19-1 OMI
89506044|NCT05576623|Placebo Comparator|Placebo (Part B)|Group 2 in Part B will receive 1 dose of placebo
89506045|NCT02374515|Active Comparator|Endocuff assisted Colonoscopy|Endocuff assisted Colonoscopy
89506046|NCT02374515|Active Comparator|Standard Colonoscopy|Standard colonoscopy
89506047|NCT03528655|Experimental|Decision aid group|Shared decision making using decision aid
89506048|NCT03528655|No Intervention|Controlled group|Standard oral explanation with booklet.
89506049|NCT02374281|Experimental|Glucose sucking|"The newborn will receive one minute before the painful care either a compress with sucrose.~The puncture made in the veins of the back of the hand, will be performed only once per patient per test.~Glucose 30% by oral route (1 ml)."
89506050|NCT02374281|Active Comparator|Water sucking|"The newborn will receive one minute before the painful care either a compress with water.~The puncture made in the veins of the back of the hand, will be performed only once per patient per test.~Sterile water by oral route (1 ml)."
89506051|NCT02374281|Placebo Comparator|No sucking|The puncture made in the veins of the back of the hand, will be performed only once per patient per test.
89506052|NCT04605211|Experimental|Being Present (Supportive Care)|Patients and caregivers receive Being Present intervention consisting of online audio-based mindfulness meditation exercise over 15 minutes at least 5 times per week, daily meditation reminders, and online webinars over 30-60 minutes every week.
89506053|NCT03527251|Experimental|Sequential group|intravenous ipilimumab following by intravenous SHR-1210
89506054|NCT02363517|No Intervention|Group A|"Primary (n=40) and secondary (n=100) participants will receive supportive care only (includes a clinical review, questionnaire and blood sample collected at baseline and weeks 12, 24, 36, 48, 60, 72 and 84).~Participants with HCV not allocated to treatment arms will receive deferred treatment at the end of the follow-up period."
89506055|NCT02363517|Active Comparator|Group B|"Primary participants (n=40) will be treated with 'Sofosbuvir/ledispasvir fixed dose combination (SOF + LDP) for 12 weeks. Secondary participants (n=100) will receive supportive care only.~Participants with HCV not allocated to treatment arms will receive deferred treatment at the end of the follow-up period."
89539012|NCT04943991|Other|Patients with HCM/LVH at University Hospital Wuerzburg|
89539013|NCT04942977|Experimental|Cardiac tele-rehabilitation|Patients in the Intervention Group will come to the hospital 4 times during two consecutive weeks, undergoing physical exercise sessions and the same educational talks as in the control group. Subsequently, they will follow the scheduled physical activities and adherence to the risk factor management according to individualised guidelines in their App, until the end of the study period. All data generated are recorded on the professional website. The degree of compliance with the objectives set is monitored by means of 7 coloured icons, which vary according to the target achievement.
89539014|NCT04942977|Active Comparator|Centre-based cardiac rehabilitation|Patients in the control group will come to the hospital 16 times during eight weeks for cycling and muscle strengthening exercises. Educational talks will be given. At the end of the hospital phase, a conventional outpatient follow-up by primary care and the corresponding specialist will be carried out.
89539015|NCT04960839|No Intervention|Standard group|Standard loco-regional treatment without prophylactic contralateral breast irradiation
89539016|NCT04960839|Experimental|Prophylactic irradiation group|Standard loco-regional treatment with prophylactic contralateral breast irradiation
89539017|NCT04950699||Control|Patients without typical symptoms of coronary heart disease, and coronary angiography or coronary CT showed no significant stenosis (coronary stenosis less than 30%), they were non coronary heart disease group, namely control group.
89539018|NCT04950699||myocardial infarction|This group includes acute myocardial infarction (ST segment elevation and non ST segment elevation) and old myocardial infarction. The diagnostic basis of acute myocardial infarction: cardiac biomarkers (cardiac troponin and / or myocardial enzymes) increased or decreased, at least once the value exceeded the upper limit of normal, and there was the following evidence of myocardial ischemia: (1) clinical symptoms of myocardial ischemia（ 2) New changes of myocardial ischemia appeared in ECG, i.e. new ST segment changes or left bundle branch block（ 3) Pathological Q wave appeared in ECG（ 4) Imaging evidence showed new loss of myocardial viability or regional wall motion abnormalities. Diagnosis of old myocardial infarction: the patient provided a history of previous myocardial infarction and confirmed as old myocardial infarction by the third or First Hospital of Peking University.
89539019|NCT04950387|Experimental|Experimental group|Participants took part in breathing exercises
89539020|NCT04950387|No Intervention|Control group|Participant did not take part in intervention
89539021|NCT04943055|Experimental|Low temperature plasma ablation with lacrimal duct catheterization|The experimental group received low temperature plasma lacrimal duct obstruction ablation combined with lacrimal duct catheterization
89539022|NCT04943055|Placebo Comparator|YAG lacrimal duct laser combined with lacrimal duct catheter|Control group received YAG lacrimal duct laser combined with lacrimal duct catheterization
89539023|NCT04943133|Active Comparator|3rd-term group: Pregnant women included in the last 3 months of pregnancy|Comparison of the profile of the curve according to whether there is presence or absence of blood pressure disorders.
89539024|NCT04943133|Active Comparator|Before 20 weeks group. Pregnant women (normal blood pressure) included before 20 weeks of pregnancy.|Comparison of the profile of the curve according to the presence or absence of risk factors for pre-eclampsia
89539025|NCT03058263|Experimental|partial dose of neostigmine|Those who received partial dose of neostigmine as rocuronium reversal
89539026|NCT03058263|Experimental|TOF ratio-based dose of neostigmine|Those who received TOF ratio-based dose of neostigmine as rocuronium reversal
88957257|NCT01982162||Cohort C|Severe pre school wheeze cohort
88957258|NCT01982162||Cohort D|Mild to moderate pre school wheeze cohort
89539027|NCT04942821|Experimental|Platelet rich fibrin and coronally advanced flap|Coronally advanced flap and platelet rich fibrin were used in treatment arms.
89539028|NCT04942821|Active Comparator|Connective tissue graft and coronally advanced flap|Coronally advanced flap and connective tissue graft were used in treatment arms.
89539029|NCT04415853|Experimental|Lerotinib Arm|350 mg,qd, orally about half an hour after a meal, continuous administration, every 21 days for a treatment cycle.
89539030|NCT04415853|Active Comparator|Active Comparator Arm|"Irinotecan: Intravenously administered at a dose of 180 mg/m2 every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends.~Tegafur: 40-60mg po bid(d1-d14),every 21 days as a cycle, continuous drug administration from 1 to 14 days of each cycle, and then stopped 7 days."
89539031|NCT04415151|Experimental|Tofacitinib|Tofacitinib will be administered in a dose of 10 mg PO BID until return to their clinical baseline (as defined by supplementary oxygen requirement), and then will continue to be administered at 5 mg PO BID for a total treatment duration of 14 days.
89539032|NCT04415151|Placebo Comparator|Placebo|Matching placebo will be administered.
89539033|NCT04942743||control group|patients with normal TMJ
89539034|NCT04942743||Study group|patients with TMJ internal derangement
89539035|NCT04949997||control|patients without heart failure
89539036|NCT04949997||HF|patients with heart failure
88957259|NCT01982188||Single incision sling|
88957260|NCT01982201|Experimental|Lesinurad and Tums|Day 1: 240 mL water or 240 mL water and Tums Day 2: Lesinurad 400 mg or Lesinurad 400 mg and Tums; Day 6: 240 mL water and Tums or 240 mL water; Day 7: Lesinurad 400 mg and Tums or Lesinurad 400 mg
88957261|NCT01982201|Experimental|Lesinurad and MINTOX|Day 1: 240 mL water or 240 mL water and MINTOX ; Day 2: Lesinurad 400 mg or Lesinurad 400 mg and MINTOX; Day 6: 240 mL water and MINTOX or 240 mL water; Day 7: Lesinurad 400 mg and MINTOX or Lesinurad 400 mg
88957262|NCT01982214|Sham Comparator|sedentary|No intervention
88957263|NCT01982214|Experimental|Vibration|Subjects in this group will be submitted to the WBV for 5 to 20 minutes, 2 or 3 times a week while 12 months. The training included light squats at 35-50 Hz and ended up by stretching and relaxation exercises.
89539037|NCT04960761|Experimental|Intervention Group|Pre-operative training will be given by the clinic nurse with audio and picture book. Training content with audio and picture book; Before the operation, the procedures performed during the admission of the patient to the service (introducing the clinic and staff to the patient), what are the preoperative preparations (checking vital signs, intravenous (IV) catheter application, wearing a surgical gown), wearing a patient tag on the wrist, taking him to the operating room on a stretcher), which will be used during the operation anesthesia techniques and how to provide sedation (the anesthetic agent can be given by mask or IV catheter, the reasons are the clothes worn by doctors and nurses in the operating room), what are the procedures that can be applied after the surgery (vital signs control, monitoring, oxygen administration, serum insertion, etc.).
89539038|NCT04960761|No Intervention|Control Group|Routine training will be given by a nurse working in the clinic during the preoperative period. The content of the routine training: What are the procedures performed during the admission of the patient to the service before the operation (introducing the clinic and the staff to the patient), what the preoperative preparation is (checking vital signs, intravenous (IV) catheter application, wearing a surgical gown, wearing a patient tag on the wrist, with a stretcher. being taken to the operating room), what are the procedures that can be applied after the surgery (vital signs control, monitoring, oxygen administration, serum insertion, etc.), there may be some medical materials that were applied to the patient during the surgery (nasogastric tube, IV catheter, types of drains placed in the wound site) includes information such as
89539039|NCT03059277|Experimental|Intravitreal Aflibercept|Intravitreal Aflibercept Injection (IAI)
89539040|NCT04942509|Experimental|Coloring|This group did mindful coloring for at least 5 days or at least 100 minutes in total during a 10-day period
89539041|NCT04942509|No Intervention|Wait-list control|This group did not do mindful coloring at all during a 10-day period.
89539042|NCT04942587|Experimental|mother's voices|Standard nursing care including, eye, mouth, nose, diaper change, skin care with baby oil and nurturing was applied respectively to the study groups for approximately 20 minutes. The baby was made listen to the lullaby recorded in the voice of mother's starting with, during and after the care for 10 minutes. Heart rate, saturation, respiration rate and comfort behiavour scores of the newborn was measured 1 minutes before, during and 15 minutes after the care.
89539043|NCT04942587|Experimental|father's voices group|Standard nursing care including, eye, mouth, nose, diaper change, skin care with baby oil and nurturing was applied respectively to the study groups for approximately 20 minutes. The baby was made listen to the lullaby recorded in the voice of father's starting with, during and after the care for 10 minutes. Heart rate, saturation, respiration rate and comfort behiavour scores of the newborn was measured 1 minutes before, during and 15 minutes after the care.
89539044|NCT04942587|No Intervention|control group|Standard nursing care including, eye, mouth, nose, diaper change, skin care with baby oil and nurturing was applied respectively to the study groups for approximately 20 minutes.Heart rate, saturation, respiration rate and comfort behiavour scores of the newborn was measured 1 minutes before, during and 15 minutes after the care.
89539045|NCT04942431|Experimental|Interventiongroup|60 min per day school based Physical activity program (for one year)
89539046|NCT04942431|No Intervention|Waitinggroup|Intervention starts after one year.
89539047|NCT04942119|No Intervention|Routine standard care group|This group will continue to receive the usual recommended care provided in the clinic and usual follow-up appointment as well as clinical assessment. Any required nutrition education by the dietitian or medication counseling will be provided at any visit or when requested.
89539048|NCT04942119|Experimental|Multifactorial intervention group|"Correction of magnesium and/or potassium levels, and correction of the underlying disease, if possible by a endocrinologist.~Education at each follow-up visit by a specialized dietitian, reinforcing optimal diet and exercise, with pre-& post-nutrition and physical activity assessment using the validated revised summary of diabetes self-care activities (SDSCA) scale.~Medication reconciliation and counseling, online post adherence questionnaire and confirm adherence by fixed medication possession ratio (FMPR) approach."
89539049|NCT04949451|Placebo Comparator|TRF-C|Follows time restricted feeding protocol.
89539050|NCT04949451|Experimental|TRF-P|Follows time restricted feeding protocol, consumes protein supplement
89539051|NCT04949451|Experimental|TRF-S|Follows time restricted feeding protocol, consumes ketogenic supplement
89539052|NCT04942197|Experimental|Arm 1|Participants who received three dimensional ultrasound with pregnancy application
88957264|NCT01982227||patients|Patients (Aged 18 to 70 inclusive) with progressive colorectal cancer in intra-abdominal surgery requiring resection +/- Chemotherapy Hyperthermic Intraperitoneal
89539053|NCT04942197|Placebo Comparator|Arm 2|Participants who received three dimensional ultrasound without pregnancy management application
89539054|NCT04949217|Experimental|Inlay Bristow Group|Inlay Bristow procedure
89539055|NCT04949217|Active Comparator|Onlay Bristow Group|Onlay Bristow procedure
89539056|NCT04960449||patients with partial-thickness rotator cuff tendon tears|Partial rotator cuff tears can be divided into three categories, bursa side tears, tendon tears and joint side tears. Studies have found that rotator cuff tendon tears account for 55% of partial tears, compared to the other two types of partial tears, there has been very little research on partial-thickness rotator cuff tendon tears, which has no consensus on diagnosis and treatment.
89539057|NCT04410393||sacrocolpopexy patients|Patients who underwent sacrocolpopexy for the treatment of vaginal cuff prolapse in patients who had previously undergone hysterectomy for benign causes
89539058|NCT04410393||lateral suspension surgery patients|Patients who underwent lateral suspension surgery for vaginal cuff prolapse in patients who had previously undergone hysterectomy for benign causes
89539059|NCT04960527|Experimental|Tart cherry juice|30 mL tart cherry concentrate (CherryActive, UK, 100% Montmorency) diluted with 220 mL water (totalling 250 mL). According to available manufacturers data, this is equivalent to consuming 90-100 fresh cherries.
88957265|NCT01982266|Experimental|GRADION™ Hip Total Cartilage Replacement (TCR)™|
88957266|NCT01982305|Experimental|Simulator|One training session with the simulator.
88957267|NCT01982305|Active Comparator|Cadaver|One training session with a cadaver.
88957268|NCT01982318|Active Comparator|VitroGro®ECM|A topical application of synthetic extracellular matrix (ECM) protein formulation to the wound bed) plus Standard Care (moisture retentive dressing and multi-layer compression therapy).
89539060|NCT04960527|Other|Water|250 mL water (neutral control)
89539061|NCT00700817|Experimental|Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg|Once-daily subcutaneous dose of liraglutide 1.2 mg with at least 1500 mg metformin/day (tablets) for 26 weeks. First week for up-titration of liraglutide from 0.6 mg to 1.2 mg. Subjects continued to receive liraglutide 1.2 mg once daily in extension period 1 (weeks 26-52) and extension period 2 (weeks 52-78).
89539062|NCT00700817|Experimental|Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg|Once-daily subcutaneous dose of liraglutide 1.8 mg with at least 1500 mg metformin/day (tablets) for 26 weeks. First 2 weeks for up-titration of liraglutide from 0.6 mg to 1.8 mg. Subjects continued to receive liraglutide 1.8 mg once daily in extension period 1 (weeks 26-52) and extension period 2 (weeks 52-78).
89539063|NCT00700817|Active Comparator|Sita -> Sita|Once-daily dose of sitagliptin 100 mg (tablets) with at least 1500 mg metformin/day (tablets) for 26 weeks. Subjects continued to receive 100 mg sitagliptin once daily in extension period 1 (weeks 26-52).
89539064|NCT00700817|Experimental|Sita -> Sita -> Lira 1.2 mg|Once-daily dose of sitagliptin 100 mg (tablets) with at least 1500 mg metformin/day (tablets) for 26 weeks. Subjects continued to receive 100 mg sitagliptin once daily in extension period 1 (weeks 26-52). In extension period 2 (weeks 52-78), subjects were randomised to liraglutide 1.2 mg + metformin.
89539065|NCT00700817|Experimental|Sita -> Sita -> Lira 1.8 mg|Once-daily dose of sitagliptin 100 mg (tablets) with at least 1500 mg metformin/day (tablets) for 26 weeks. Subjects continued to receive 100 mg sitagliptin once daily in extension period 1 (weeks 26-52). In extension period 2 (weeks 52-78), subjects were randomised to liraglutide 1.8 mg + metformin.
89539066|NCT04960293|Experimental|Spherical gelfoam|Patients who receive uterine artery embolization for symptomatic fibroids
89539067|NCT04960293|Active Comparator|Microsphere|Patients who receive uterine artery embolization for symptomatic fibroids
89539068|NCT04941495|Active Comparator|Control Group|It Includes the TENS, Infrared, Isometric and stretching exercises along with the home plan and postural education
89539069|NCT04941495|Experimental|Experimental Group|It Includes the TENS, Infrared, Isometric and stretching exercises along with the home plan and postural education. It also include the cervical proprioceptive training
89539070|NCT04941417|Experimental|neoadjuvant PD-(L)1 inhibitor with chemotherapy followed by PD-(L)1 inhibitor for up to 1 year|
89539071|NCT03058029|Experimental|Gelesis200|Gelesis200: Three (3) Gelesis200 capsules (2.10 gram (g)) two (2) times per day (id est (i.e.), lunch and dinner)
89539072|NCT03058029|Placebo Comparator|Placebo|Placebo: Three (3) placebo capsules two (2) times per day (i.e., lunch and dinner)
89539073|NCT04948125|Experimental|treatment group|camrelizumab combined with apatinib
89539074|NCT04960137|Experimental|Button Plates fixation system|Patients receiving surgery fixed with Button Plates fixation system
89539075|NCT04960137|Active Comparator|Non-absorbable Suture Anchor|Patients receiving surgery fixed with Non-absorbable suture anchor
89539076|NCT04410315||Tumorcraniotomy patients|
89539077|NCT04960371||anxiety group|the score of Self-rating Anxiety Scale greater than 50
89539078|NCT04960371||non-anxiety group|the score of Self-rating Anxiety Scale less than 50
89539079|NCT02455115|Experimental|60 mmHg|Alternating mean arterial pressure by lowering of the infusion rate of norepinephrine
89539080|NCT02455115|Experimental|75 mmHg|Alternating mean arterial pressure by adjust of the infusion rate of norepinephrine
89539081|NCT02455115|Experimental|90 mmHg|Alternating mean arterial pressure by augmentation of the infusion rate of norepinephrine
89539082|NCT04948281||Infection Group|A group of joint infection patients after arthroscopic ACL reconstruction surgery , diagnose was made according to American CDC criteria of joint infection
89539083|NCT04948281||Control Group|A group of patients which were matched to infections group retrospectively one-to-three who did not sustain any kind of infection after ACL reconstruction.
89539084|NCT04940793||Group 1|Patients indicated for cataract surgery who are candidates for a trifocal IOL implantation and have corneal astigmatism over 1.00 D will be selected for inclusion by the investigators
89539085|NCT03094247|Active Comparator|Conventional RUTF (S-RUTF)|This is the control group for the study, which will receive the international standard of care therapeutic food. S-RUTF is made with conventional peanuts, which are inherently high in omega-6 linoleic acid.
89539086|NCT03094247|Experimental|High oleic RUTF (HO-RUTF)|The treatment provided to children randomized to this arm of the study includes nutritional content comparable to S-RUTF with the exception of a low lineoleic acid/high oleic acid ratio formulated with high oleic content peanuts.
89539087|NCT03094247|Experimental|DHA-supplemented HO-RUTF (D-HO-RUTF)|The treatment provided to children randomized to this arm of the study mirrors that provided by HO-RUTF with that addition of supplemental DHA at a level higher than attainable with optimal precursors.
89539088|NCT04947891||Study group|Patients will be treated with intensive recovery method after surgery.
89539089|NCT04947891||Control group|Patients will be treated with regular recovery method after surgery.
89539090|NCT02904629|Experimental|RCL Intervention|"Respecting the Circle of Life (RCL) includes peer-group & youth-parent components. The peer-group component has 8 educational lessons, each lasting 90-120 minutes, delivered to self-selected same-sex peer groups of 8-10 AI teens. RCL lessons are delivered once/day during an 8-day summer basketball camp. The youth-parent component is one educational lesson lasting 90-120 minutes delivered within 3 months after camp to a teen and parent together at home. Total RCL duration is 810-1,080 minutes over 3 months. All 8 days of the camp are study days, in which RCL youth will receive one lesson each day. The investigators will evaluate RCL's impact on key sexual and reproductive health risk factors at 3-, 9-, 12-, 24-, and 36-month post-intervention follow-up time points."
89506056|NCT02363517|Active Comparator|Group C|Primary (n=40) and secondary participants with chronic HCV infection (approx. n=50%*100) will be treated with 'Sofosbuvir/ledispasvir fixed dose combination (SOF + LDP) for 12 weeks. Participants in Group C who have evidence of HCV re-infection will be offered re-treatment with SOF + LDP for 12 weeks.
89506057|NCT04467463|Experimental|GPN|administrated bilateral greater palatine nerve block using levobupivacaine 0.25%
89506058|NCT04467463|Experimental|SMN|administrated bilateral suprazygomatic nerve block using levobupivacaine 0.25%.
89506059|NCT02363361|Experimental|Imatinib|Day 1. 800 mg, Day 2-14: 2 * 400 mg per day
89506060|NCT04594915||Study Group|Patients diagnosed with AF who are currently using Edoxaban for stroke prevention in Turkey.
89506061|NCT05560087||Coronary artery disease|
89506062|NCT05560087||control|
89506063|NCT05546749|Active Comparator|RelieVRx|RelieVRx was designed for at-home use and comes with a sequence of daily immersive experiences. Participants in the intervention group will complete 20-30 minute VR sessions twice per week over the course of 6 weeks.
89506064|NCT05546749|Sham Comparator|Sham Virtual Reality|The sham virtual reality (VR) device is also by RelieVRx. However, it lacks the immersive nature of the interventional VR. Control participants will complete 20-30 minute VR sessions twice per week over the course of 6 weeks.
89506065|NCT03525535||Pulmonary embolism|data from routine care will be collected for patient eligible and willing to participate
89506066|NCT02367027|Experimental|Arm 1 - BAY59-7939|10 mg oral suspension (dry powder) in fasted conditions
89506067|NCT02367027|Experimental|Arn 2 - BAY59-7939|20 mg oral suspension (dry powder) in fed conditions.
89506068|NCT02367027|Experimental|Arm 3 - BAY59-7939|10 mg oral suspension in fasted conditions
89506069|NCT02367027|Experimental|Arm 4 - BAY59-7939|10 mg tablet in fasted conditions.
89506070|NCT03527095|Experimental|Regimen A|FDL169 200 mg reference tablet
89506071|NCT03527095|Experimental|Regimen B|FDL169 200 mg testing tablet 1
89506072|NCT03527095|Experimental|Regimen C|FDL169 200 mg testing tablet 2
89506073|NCT03527095|Experimental|Regimen D|FDL169 200 mg testing tablet 1 or 2 with high fat diet
89506074|NCT03527095|Experimental|Regimen E|FDL169 200 mg testing tablet 1 or 2, fasted
89506075|NCT03527095|Experimental|Regimen F|FDL169 200 mg testing tablet 1 or 2, with standard diet
89506076|NCT02374359||atrial tachycardia group|Patients diagnosed of cryptogenic stroke with atrial tachycardia in holter
89506077|NCT02374359||Non atrial tachycardia group (control group)|Patients diagnosed of cryptogenic stroke with a normal holter
88815270|NCT05096546||Group I|"20 years old or older (regardless of sex)~Outpatients~Newly-diagnosed with dry eye disease (DED) within 6 months prior to signing the informed consent under hospital-based practice in Taiwan"
89506078|NCT04512781|Experimental|Conventional Legacy Cannula Design (Control) - Prosoft Cannula - Unicorn Cannula|"During this session, patients will be placed on HVNI therapy with an appropriately fitted Vapotherm conventional legacy cannula. Physiologic and ventilation parameters will be recorded.~Patients will be randomly assigned to Prosoft or Unicorn cannula testing groups. Physiologic and ventilation parameters will be recorded."
89506079|NCT04512781|Experimental|Conventional Legacy Cannula Design (Control) - Unicorn Cannula - Prosoft Cannula|"During this session, patients will be placed on HVNI therapy with an appropriately fitted Vapotherm conventional legacy cannula. Physiologic and ventilation parameters will be recorded.~Patients will be randomly assigned to Prosoft or Unicorn cannula testing groups. Physiologic and ventilation parameters will be recorded."
89506080|NCT05187793|Experimental|Olokizumab|"Subject randomized to receive intravenous infusion of 0,8 ml solution of Olokizumab, one (128 mg), or two (256 mg) doses, in addition to standard therapy in line with the current temporary guidelines Prevention, diagnosis and treatment of new coronavirus infection (COVID-19) of the Ministry of Health of Russian Federation.~Standard therapy includes:~Baricitinib, p.o., 4 mg once daily for 7 days~Favipiravir, p.o.,~for patients weighing <75 kg: 1600 mg twice daily on Day 1, then 600 mg twice daily from the 2nd to the 10th day;~for patients weighing ≥ 75 kg: 1800 mg twice daily on Day 1, then 800 mg twice daily from the 2nd to the 10th day; (Patients who have started etiotropic therapy with favipiravir or remdesivir prior to randomization will continue the initiated treatment.)~dexamethasone at doses of 4 - 20 mg / day or methylprednisolone at a dose of 1 mg / kg / intravenous injection every 12 hours."
89506081|NCT05187793|Active Comparator|Standard therapy|"Standard therapy in line with the current temporary guidelines Prevention, diagnosis and treatment of new coronavirus infection (COVID-19) of the Ministry of Health of Russian Federation including:~Baricitinib, p.o., 4 mg once daily for 7 days~Favipiravir, p.o.,~for patients weighing <75 kg: 1600 mg twice daily on Day 1, then 600 mg twice daily from the 2nd to the 10th day;~for patients weighing ≥ 75 kg: 1800 mg twice daily on Day 1, then 800 mg twice daily from the 2nd to the 10th day; (Patients who have started etiotropic therapy with favipiravir or remdesivir prior to randomization will continue the initiated treatment.)~dexamethasone at doses of 4 - 20 mg / day or methylprednisolone at a dose of 1 mg / kg / intravenous injection every 12 hours."
89506082|NCT03525457|Experimental|Experimental|Non surgical periodontal therapy
89506083|NCT03525301|Active Comparator|standard treatment|patients in this group are treated with 3000 cGy in 10 daily fractions
89506084|NCT03525301|Experimental|short course treatment|patients in this group are treated with 1800 cGy in 4 fractions administered twice a day (at least 6-8 hours interval)
89506085|NCT03528499|Experimental|Scapular Movement Training|Orientation and scapular exercises, performed twice a week, for 8 weeks.
89506086|NCT03528499|Active Comparator|General Exercises|Scapulothoracic muscle stretching and strengthening exercises, performed twice a week, for 8 weeks.
89506087|NCT02751827||Prospective cohort|"Prospective cohort involving patients treated in four distinct centers. Patients were treated with a tyrosine kinase inhibitor (TKI) prescribed as part of a marketing authorization (MA).~All patients without major violations of the eligibility criteria are included in the eligible population. In case of violation of the eligibility criteria, the steering committee will assess for each patient, whether the violation is minor or major.~All eligible patients who have received at least one TKI administration were included in analysis."
89539091|NCT02904629|Other|Control|"The control program includes peer-group & youth-parent components. The peer-group component has 8 educational lessons, each lasting 90-120 minutes, delivered to self-selected same-sex peer groups of 8-10 AI teens. Control lessons are delivered once/day during an 8-day summer basketball camp. The youth-parent component is one educational lesson lasting 90-120 minutes delivered within 3 months after camp to a teen and parent together at home. Total control duration is 810-1,080 minutes over 3 months. All 8 days of the camp are study days, in which control youth will receive one lesson each day. The investigators will evaluate the control program's impact on key sexual and reproductive health risk factors at 3-, 9-, 12-, 24-, and 36-month post-intervention follow-up time points."
89539092|NCT04947969|Experimental|Rear laser acupuncture group|Patients in the Real laser acupuncture group will receive real laser pen irradiation.
89539093|NCT04947969|Sham Comparator|Shame laser acupuncture group|Patients in the Shame laser acupuncture group will receive shame laser pen irradiation.
89539094|NCT03250403|Experimental|PRP injection|
89539095|NCT03250403|Active Comparator|medical treatment|
89539096|NCT04947423|Experimental|DPI-386 Nasal Gel|Each 0.12 gram of the gel contains 0.2 mg of scopolamine HBr
89539097|NCT04947423|Placebo Comparator|Placebo|Placebo Nasal Gel (0.12 g)
89539098|NCT03250481|Active Comparator|'Sedation guidance with RASS-group|Sedation is guided with RASS. Targeted sedation level is RASS -3 - 0. Propofol: an initial rate of 2.4 mg/kg/h for one hour. Thereafter, the infusion rate of propofol is 0.8-4 mg/kg/h to reach or maintain the target RASS score. Propofol bolus of 20-40 mg is allowed. Oxycodone as 3-6 mg boluses for pain management. Other opiates are not allowed. Midazolam may given if the maximum dose of propofol is reached and pain management by oxycodone restricted achievement of the target sedation level. Midazolam will supply intravenously in boluses of 1-2 mg (based on the weight of the patient), starting at 3 boluses/h for the first hour. Dexmedetomidine and other sedatives are not allowed.
89539099|NCT03250481|Experimental|'Sedation guidance with RI|Sedation is guided with RI. Targeted sedation level is RI 40-80. Propofol: an initial rate of 2.4 mg/kg/h for one hour. Thereafter, the infusion rate of propofol is 0.8-4 mg/kg/h to reach or maintain the target RI score. Propofol bolus of 20-40 mg is allowed. Oxycodone as 3-6 mg boluses for pain management. Other opiates are not allowed. Midazolam may given if the maximum dose of propofol is reached and pain management by oxycodone restricted achievement of the target sedation level. Midazolam will supply intravenously in boluses of 1-2 mg (based on the weight of the patient), starting at 3 boluses/h for the first hour. Dexmedetomidine and other sedatives are not allowed.
89539100|NCT03250715|Experimental|Low Level Laser Therapy group|Six points of application will be defined in the quadriceps and two points of application in the gastrocnemius. The parameters adopted for the irradiation will be: 30 Joules per application point, wavelength of 660 and 850 nm and output power of 200 mW. Each point will be radiated for 30 seconds.
89539101|NCT03250715|No Intervention|Control group|This group will receive no intervention. This group will be evaluated before the intervention, after four and eight weeks of follow up.
89539102|NCT04947267|Experimental|3% mepivacaine|3% mepivacaine was administered via inferior alveolar nerve block.
89539103|NCT04947267|Active Comparator|2% mepivacaine with 1:100,000 epinephrine|2% mepivacaine with 1:100,000 epinephrine was administered via inferior alveolar nerve block.
89539104|NCT03250637||Colorectal cancer cases|1038 participants diagnosed with colorectal cancer from the Diet, Cancer and Health cohort.
89539105|NCT03250637||Sub-cohort members|1857 persons randomly selected within the full cohort at time of entry into the Diet, Cancer and Health cohort. These participants serve as controls for the colorectal cancer cases.
88957269|NCT01982318|Placebo Comparator|Dulbecco's Phosphate Buffered Saline|Dulbecco's Phosphate Buffered Saline plus Standard Care (moisture retentive dressing and multi-layer compression therapy).
89539106|NCT04941885|Experimental|Inetetamab Plus Cyclophosphamide Metronomic Chemotherapy Plus AI|Each participant receives Inetetamab(8mg/kg iv day 1 followed by 6mg/kg iv day 1, cycled every 21 days) plus cyclophosphamide metronomic chemotherapy(50mg once a day orally) plus aromatase(once a day orally).
89539107|NCT03250091||Gastric cancer|Gastric adenocarcinoma and other gastric malignancies
89539108|NCT03250091||Gastric mucosal dysplasia|Includes: a. High-grade dysplasia; b. Low-grade dysplasia; c. Indefinite for dysplasia
89539109|NCT03250091||High-risk IM gastritis stages|High-risk stages according to OLGIM classification: OLGIM Stage IV and OLGIM Stage III.
89539110|NCT03250091||High-risk atrophic gastritis stages|High-risk stages according to OLGA classification: OLGA Stage IV and OLGA Stage III.
88957270|NCT01982344|Experimental|mini-exchange-room (G2)|the other group will utilize disposable mini-exchange-room group
89539111|NCT03250091||Extensive gastric intestinal metaplasia|Intestinal metaplasia of any grade both in gastric corpus and antrum/incisura (other than OLGIM III-IV).
88957271|NCT01982344|No Intervention|usual care (G1)|The one group perform traditional PD procedure (G1)
88957272|NCT01982396|Active Comparator|Twice daily|
89539112|NCT03250091||Extensive atrophy|Moderate to severe (++ or +++) atrophy both in corpus and antrum/incisura, other than OLGA III-IV.
89539113|NCT03250091||Isolated corpus atrophy|Isolated moderate-to-severe atrophy or IM in the corpus.
89539114|NCT04959747|Experimental|acupuncture group|"Subject will be scheduled for a total of 8 sessions of acupuncture treatment, to be done by the 30 minutes for each session, twice per week over a 4-week period.~Body acupuncture will choose eight acupoints as Yingxiang (LI20),Shangxing (GV23), BiTong, Yintang, Hegu. Disposable acupuncture needle (0.25 mm in diameter and 25-30mm in length) are inserted at a depth of 10-25 mm obliquely into scalp acupuncture points (ShangXing, YinTang) and straightly into face/body acupuncture points (Yingxiang, BiTong, Hegu).~We will also deliver electro-acupuncture will be applied to the face points at fast and dispersed waves through electric needle stimulator which is provided by Chinese Medicine Clinic (ES-160 6-Channel Programmable electro-acupuncture) for 30 minutes."
88957273|NCT01982396|Experimental|Once daily|
89539115|NCT04959747|Placebo Comparator|sham-acupuncture group|"For subjects assigned to control group, Streitberger's non-invasive acupuncture needles (Gauge 8 x 1.2 / 0.30 x 30 mm) will be applied to serve as sham control at the same acupoints with the same stimulation modality, except that the needles are only adhered to the skin instead of insertion. Its validity and credibility have been well demonstrated."
89539116|NCT03249857|Experimental|patients|Patients suffering bipolar affective disorders and who will perform cognitive tasks + IQ + MINI + experimental task
89539117|NCT03249857|Active Comparator|control group|Healthy volunteers (Control group) who will perform cognitive tasks + experimental task
89539118|NCT04959669|No Intervention|Control group|Usual care
89539119|NCT04959669|Experimental|Intervention group|DeSSBack (Decision Support System for Low Back Pain)
89539120|NCT03249701|Experimental|TEAS group|Transcutaneous Electrical Acupoint Stimulation on Neiguan, Quchi, Zusanli, Sanyinjiao. Intensity: maximal tolerance by subject; Time span: 30minutes before anesthesia induction and 30 minutes after wound closure.
89539121|NCT03249701|Placebo Comparator|Electroacupuncture group|Hand-needle on Neiguan, Quchi, Zusanli, Sanyinjiao.Intensity: maximal tolerance by subject; Time span: 30minutes before anesthesia induction and 30 minutes after wound closure.
89539122|NCT03249701|Sham Comparator|sham TEAS group|Sham transcutaneous electrical acupoint stimulation on Neiguan, Quchi, Zusanli, Sanyinjiao; Intensity: maximal tolerance by subject; Time span: 30minutes before anesthesia induction and 30 minutes after wound closure.
89539123|NCT04940715|Experimental|Passive joint mobilization|Patients lay down on a prone position, with their hands around the body and neck placed comfortable. The therapist performed a postero-anterior joint mobilization using Maitland's technique, applying pressure to spinous process of targeted vertebra (the one who reproduces patient's symptoms).
89539124|NCT04940715|Experimental|Mobilization with movement|Patients perform their painful movement (flexion, extension…). If pain wasn't reproduced, a combination of movements will be performed (flexion + rotation…). The most painful vertebral level was assessed too with passive accessory vertebral movements. Afterwards, with the patient on a seated position on a stretcher with feet supported and a belt around the waist, the therapist performed a sustained glide on the targeted vertebra (spinous process) with the force and direction that relieved pain to the lowest level.
89539125|NCT04940715|No Intervention|Control group|"Patients were measured at baseline and then were placed on wait list until the end of the study. At this time, they were measured again."
88957274|NCT01982409|Experimental|Live Attenuated Varicella Vaccine|use the arm flank deltoid muscle adheres to stick cohere place the skin after 75% ethyl alcohol disinfection the hypodermic injection
88957275|NCT01982422|Experimental|Dietary Intervention|A whole food, nutrient-dense dietary intervention which restricts processed foods high in food additives and optimizes micronutrient intake.
88957276|NCT01982422|Placebo Comparator|Standard-of Care Group|This group will receive normal standard-of-care for pregnancy.
89539126|NCT04947111|Other|Serological survey|A blood sample will be taken to estimate the specific serotype prevalence for dengue virus in groups of 5 to 35 years in areas of low and high dengue endemicity.
89539127|NCT03249623|Experimental|Beacon Caresystem|On randomisation to the Beacon group, a Beacon Caresystem will be connected to the patient. This involves connecting a pulse oximeter to the patient's finger (toe or ear) to measure pulse oximetry oxygen saturation and pulse, and placing a standard clinical respiratory gas analysis and flow sensor in the respiratory tubing connecting the ventilator to the patient. This sensor allows measurement of respiratory pressure, flow and volume; plus respiratory gas CO2 and O2.
89539128|NCT03249623|No Intervention|Standard Care|For this group mechanical ventilation is managed according to standard care. A Beacon CareSystem will be connected to the patient, as for the Beacon Randomisation group, but the system will be used solely for data collection, and advice will be disabled. Physiological variables captured in this arm of the study will mirror the intervention arm. Decision relating to weaning, extubation, reintubation and sedation including level of seniority of personnel involved in the decision tree process will be documented accordingly.
89539129|NCT04947345|Experimental|Experimental group: Remimazolam Besylate|Patients should be given study drugs as soon as possible after entering the ICU. Syringe pump is used to administer medication. Loading dose of Remimazolam is 0.2 mg/kg, which is administered for less than 1 min initially. Maintaining dose is 0.2-1 mg/kg/h. Sedative target is RASS between 0 and -2 points. Excepts for fentanyl and Remimazolam, no analgesic or sedative could be used during the experimental time period.
89608631|NCT04142151|Active Comparator|SanchiTongshu group|"Drug: SanchiTongshu The study drugs were manufactured according to Good Manufacturing Practice (GMP) by the Pharmaceutical Factory of Chengdu Huasun Group Inc. Ltd. and presented in the form capsules. Every Sanchitongshu capsule weighed 200 mg, contained 100 mg of panaxatriol saponin (PTS) and 100 mg inactive excipient (starch). PTS comprised of dried extracts from roots of Radix Notoginseng, and had been standardised with respect to Ginsenoside Rg1 (50%), Ginsenoside Re (6%), Notoginsenoside R1 (11%). The amounts of the active ingredients were determined by analytical RP-HPLC using an acetonitrile-water gradient system as mobile hase. The peaks were detected by UV-DAD.~Drug: Aspirin or Clopidogrel"
88957277|NCT01982461|Experimental|Rosuvastatin|One Rosuvastatin tablet 10mg taken once daily.
88957278|NCT01982461|Active Comparator|Crestor®|One Crestor® tablet 10mg taken once daily.
88957279|NCT01982474|Experimental|Grass pollen extract injection|Grass pollen extract injected intralymphatically q 4 weeks x 3
88957280|NCT01982474|Placebo Comparator|Placebo injection|Normal saline injected intralymphatically q 4 weeks x 3
88957281|NCT01982474|No Intervention|Observational group|Subjects already receiving traditional subcutaneous allergy immunotherapy for grass pollen, being observed for safety of their subcutaneous injections. Not receiving active intervention during this study.
88957282|NCT01982487|No Intervention|Arm A (no treatment)|Patients receive no treatment.
88957283|NCT01982487|Experimental|Arm B (IDO1 inhibitor INCB024360)|Patients receive IDO1 inhibitor INCB024360 PO BID on days 1-28.
88957284|NCT01982487|Experimental|Arm C (vaccine, IDO1 inhibitor INCB024360)|Patients receive ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine SC on day 1 and IDO1 inhibitor INCB024360 PO BID on days 1-28.
89539130|NCT04947345|Active Comparator|Positive control group: Propofol|"Patients should be given study drugs as soon as possible after entering the ICU. Syringe pump is used to administer medication. Loading dose of propofol is 0.2 mg/kg, which is administered for less than 1 min initially. Maintaining dose is 0.3-4.0 mg/kg/h. Sedative target is RASS between 0 and -2 points. Excepts for fentanyl and propofol, no analgesic or sedative could be used during the experimental time period.~Rescue therapy for experimental group During the treatment of the experimental group, if the RASS cannot be maintained at 0 to -2 points at the maximum Remimazolam maintenance dose of 1 mg/kg/h, a loading dose of propofol (0.2 mg/kg) can be given intravenously. If RASS fails to satisfied after three loading doses of propofol, Remimazolam is discarded and 0.3-4.0 mg/kg/h of propofol are used as rescue therapy for experimental group."
89539131|NCT03249311|Experimental|Levomilnacipran|Participants will be randomly assigned to receive levomilnacipran, duloxetine, or placebo
89539132|NCT03249311|Active Comparator|Duloxetine (Cymbalta)|Participants will be randomly assigned to receive levomilnacipran, duloxetine, or placebo
89539133|NCT03249311|Placebo Comparator|Levomilnacipran Placebo-matched capsules|Participants will be randomly assigned to receive levomilnacipran, duloxetine, or placebo
89539134|NCT04940559|Experimental|Group 1: Sequence 1|"Participants received danicopan once each period as a single dose under fasted or fed (medium-fat meal) conditions as follows:~Period 1: Danicopan as an LFC under fasted conditions. Period 2: Danicopan as a tablet under fed (medium-fat meal) conditions. Period 3: Danicopan as a tablet under fasted conditions. There was a washout period of at least 4 days (96 hours) between each danicopan dosing."
89539135|NCT04940559|Experimental|Group 1: Sequence 2|"Participants received danicopan once each period as a single dose under fasted or fed (medium-fat meal) conditions as follows:~Period 1: Danicopan as a tablet under fed (medium-fat meal) conditions. Period 2: Danicopan as a tablet under fasted conditions. Period 3: Danicopan as an LFC under fasted conditions. There was a washout period of at least 4 days (96 hours) between each danicopan dosing."
89539136|NCT04940559|Experimental|Group 1: Sequence 3|"Participants received danicopan once each period as a single dose under fasted or fed (medium-fat meal) conditions as follows:~Period 1: Danicopan as a tablet under fasted conditions. Period 2: Danicopan as an LFC under fasted conditions. Period 3: Danicopan as a tablet under fed (medium-fat meal) conditions. There was a washout period of at least 4 days (96 hours) between each danicopan dosing."
89539137|NCT04940559|Experimental|Group 2: Sequence 1|"Participants received danicopan once each period as a single dose under fasted conditions as follows:~Period 1: Danicopan as an LFC under fasted conditions. Period 2: Danicopan as a softgel capsule under fasted conditions. There was a washout period of at least 4 days (96 hours) between each danicopan dosing."
89539138|NCT04940559|Experimental|Group 2: Sequence 2|"Participants received danicopan once each period as a single dose under fasted conditions as follows:~Period 1: Danicopan as a softgel capsule under fasted conditions. Period 2: Danicopan as an LFC under fasted conditions. There was a washout period of at least 4 days (96 hours) between each danicopan dosing."
89539139|NCT03249389|Experimental|Blood sample|patients will have a blood sample of 20 ml (4 x 5ml) for inclusion, the J1 of each course and at the end of treatment
89539140|NCT03248921||High-Fit obese|Cardiac surgery patients will be segregated into the high-fit group based on 6 minute walk test distance and other measures of functional capacity
89539141|NCT03248921||Low-Fit obese|Cardiac surgery patients will be segregated into the low-fit group based on 6 minute walk test distance and other measures of functional capacity
89539142|NCT04940325|Experimental|DS-1062a|All participants included in the study will receive a starting dose of 6 mg/kg of DS-1062a every 3 weeks until progression or until unacceptable toxicity
89539143|NCT02454725|Experimental|Social Network|Leaders of social networks will communicate messages endorsing regular HIV testing to network members.
89539144|NCT02454725|Active Comparator|Comparison|HIV counseling and testing
89539145|NCT03059199|Experimental|Single-Arm Feasibility Study|12-week, 1x/week, 90-minute face-to-face sessions.
89539146|NCT02454491|Active Comparator|standard of care|intraradial heparin (5000 UI) immediately after a 6 F sheath insertion
89539147|NCT02454491|Experimental|experimental therapy|intraradial verapamil (5 mg) immediately after a 6 F sheath insertion
89539148|NCT04940091||Epidural labor analgesia|All participants will receive epidural analgesia during labor.
88957285|NCT01982487|Experimental|Arm D (vaccine)|Patients receive ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine SC on day 1.
88957286|NCT01982500||Avastin regimens|Patients who are going to receive chemotherapy plus Avastin (bevacizumab)
89506088|NCT02751827||Retrospective cohort A|"Retrospective cohort of patients treated at the Institut Bergonié (Bordeaux, France). Patients were treated with a tyrosine kinase inhibitor (TKI) prescribed as part of a marketing authorization (MA).~All patients without major violations of the eligibility criteria are included in the eligible population. In case of violation of the eligibility criteria, the steering committee will assess for each patient, whether the violation is minor or major.~All eligible patients who have received at least one TKI administration were included in analysis."
89519350|NCT03454087|Experimental|Enteral Dextrose Infusion|Critically-ill participants with sepsis enrolled in the interventional arm will receive a 24-hour infusion of dextrose solution by the enteral route to be initiated via an existing nasogastric or orogastric tube within the first 48 hours of meeting sepsis criteria.
89539149|NCT03249155|Experimental|AO - plus sonification|patients re-learn 8 motor gestures watching video-clips showing an actor performing the same gestures, and then tried to repeat the gesture.
89539150|NCT03249155|Active Comparator|CUE - visual and auditory|patients re-learn 8 motor gestures practicing a traditional protocol combining visual and auditory cues.
89539151|NCT03058809|Experimental|Metastatic Breast, Colon and Prostate Cancer|Metastatic breast, colon or prostate cancer patients will have their CTC levels determined on 3 days before treatment with the Viatar Oncopheresis System to establish a baseline value, a pretreatment value, a post treatment value and on 4 additional instances over a period of 7 days post treatment to establish a CTC rebound profile using a validated CTC enumeration system.
89539152|NCT03248765||Chronic pain group|post-surgical opioid use measured at 1 day and 1 week.
89539153|NCT03248765||No chronic pain|post-surgical opioid use measured at 1 day and 1 week.
89539154|NCT04939857|Experimental|experimental group|Trimetazidine was given 2 weeks before radiotherapy, 20 mg each time, three times a day for 3 months.
89539155|NCT04939857|No Intervention|control group|No intervention
88957287|NCT01982513||Term pregnant patients|"ASA I-II term (36-40 weeks) non-laboring women with singleton pregnancies who are admitted at MSH for induction of labor, elective cesarean section or for observation for any medical reason.~These patients will be examined in 4 positions with the ultrasound."
89506089|NCT02751827||Retrospective cohort B|"Retrospective cohort of patients treated at the Centre Antoine Lacassagne(Nice, France). Patients were treated with a tyrosine kinase inhibitor (TKI) prescribed as part of a marketing authorization (MA).~All patients without major violations of the eligibility criteria are included in the eligible population. In case of violation of the eligibility criteria, the steering committee will assess for each patient, whether the violation is minor or major.~All eligible patients who have received at least one TKI administration were included in analysis."
89506090|NCT02374203|Experimental|high protein enteral nutrition|supply protein over 1.5 gm/kg body weight
89506091|NCT02363049|Experimental|colectomy|surgery followed by chemotherapy +/- targeted therapy regime according to each centre
89506092|NCT02363049|Active Comparator|no colectomy|Chemotherapy +/- targeted therapy alone, regime according to each centre.
89506093|NCT05521009|Experimental|endotracheal tube fixation|Tube fixation will be performed using a bandage in one of the groups. The patients identified with the bandage will form the control group of the study. The group of the patients to be included in the groups will be determined by drawing lots. Except for the different fixation material, no different application will be made to the patients in oral care. As soon as the patients are intubated, a swab will be taken twice, from the outer surface of the endotracheal tube from the fixation distance, and from the same area 3 days after intubation
89506094|NCT05521009|Experimental|Enfection|Tube fixation will be performed with adhesive tube fixation material to one of the groups. In which group the patients to be included in the groups will be will be determined by drawing lots. Except for the different fixation material, no different application will be made to the patients in oral care. As soon as the patients are intubated, a swab will be taken twice, from the outer surface of the endotracheal tube from the fixation distance, and from the same area 3 days after intubation.
89506095|NCT02206997||Passive Insulation standard treatment|no active warming before start of anesthesia and no active warming at PACU
89506096|NCT02206997||Active prewarming treatment|active warming before start of anesthesia and active warming at PACU following recommendations of S3-guideline
88957288|NCT01982526||Endmetrioma surgery|
88957289|NCT01982565|Experimental|Treatment Arm|NOx dressing applied and changed at least every 2 days for 12 weeks or until ulcer is healed.
88957290|NCT01982565|Active Comparator|Control Arm|Standard of Care
88957291|NCT01982578|Experimental|Product: Genistein|60 mg of genistein BID for 360 days. Intervention: Product: Genistein
89506097|NCT04199533||Classroom Observation|The investigators will use day-long observational and interview procedures with eight staff from four schools. The classroom observation will focus on documenting episodes of classroom disruptive behavior, including antecedents and consequences to the behaviors. The interview will involve discussing with staff decision-making processes and current needs around classroom behavioral management.
89506098|NCT04199533||RUBI Redesign|Two separate demonstration studies comprising 6 staff members each will focus on informing adaptation or pruning needs related to RUBI content and structure to ensure the redesigned curriculum (RUBIES) is contextually appropriate for schools.
89506099|NCT04199533||RUBIES Collaborative Design|Eight staff from 4 schools will attend one of four 2-hour in-person feedback sessions to support collaborative feedback around RUBI redesign, including feasibility and appropriateness and methods supporting implementation.
89506100|NCT04199533||RUBIES Redesign|Two separate demonstration studies comprising 6 staff members each will focus on informing final RUBIES adaptation or pruning needs.
89506101|NCT02366949|Experimental|Arm 1|Experimental Treatment (combination of BAY1217389 with paclitaxel in an intermittent dosing schedule) Expansion Cohort - Maximum tolerated dose of BAY1217389 and Paclitaxel
89506102|NCT02366949|Placebo Comparator|Arm 2|Standard Treatment (Single-agent Paclitaxel )
89506103|NCT05503225|Active Comparator|Colchicine|0.5 mg of Colchicine for 12 months to be orally taken
89506104|NCT05503225|No Intervention|Standard of care|Standard medical therapy
88957292|NCT01982578|Placebo Comparator|Product: Placebo|1 placebo capsule BID for 360 days. Intervention: Product: Placebo
88957293|NCT01982591||Ancillary-Correlative (heavy metal and neurotoxicity)|Patients undergo serum and urine sample collection for heavy metal analysis by ICP-MS at baseline and at the completion of treatment. Patients also complete neurotoxicity assessment questionnaire at baseline and at the completion of treatment.
89506105|NCT02362893|Experimental|Direct Observed Therapy|Direct Observed Therapy immediately followed by mounting of ambulatory blood pressure device and measurement of ambulatory blood pressure according to ESH 2013 guidelines.
89506106|NCT02362893|No Intervention|Control|Standard care
88957294|NCT01982604|Experimental|Sequence (Group) 1|"Subjects randomized to Sequence 1 will receive TI in the following sequence:~TI-Inhalation Powder A TI-Inhalation Powder B~*30 units (10 units + 20 units)"
88957295|NCT01982604|Experimental|Sequence (Group) 2|"Subjects randomized to Sequence 2 will receive TI in the following sequence:~TI-Inhalation Powder B TI-Inhalation Powder A~*30 units (10 units + 20 units)"
88957296|NCT01982617|Experimental|Motivational Interviewing|The Cognitive Behavioral Therapy/Motivational Interviewing group consisted of four group sessions focused on using motivational interviewing to enhance motivation to quit smoking and on presenting cognitive-behavioral techniques for preparing to cut down or quit smoking. The following four topics were covered in this program: 1) Positive and Negative Aspects of Smoking, 2) Concerns and Hopes about Cutting Down or Quitting, 3) Small Changes that Can Help You Get Motivated, and 4) Planning for the Future.
89506107|NCT05261555|Experimental|Using the NoObesity app|"A mobile digital app (NoObesity) that enables families to set goals, track progress, play games, and access additional information and healthcare professionals to access training and monitor patients' progress."
89506108|NCT02203175|Placebo Comparator|Group C (plasebo): no pretreatment|saline injection
89506109|NCT02203175|Active Comparator|propofol and fentanyl|propofol 50 mg with fentanyl 50 mcgr iv during anesthesia induction ones time
89519351|NCT03454087|Placebo Comparator|Placebo|Critically-ill participants with sepsis in the placebo arm will receive a 24-hour enteral free water infusion via an existing orogastric or nasogastric tube within 48 hours of meeting sepsis criteria.
89023780|NCT04742673|Placebo Comparator|Placebo|"Participants will flow through the trial in the following manner:~Consent in ICU: perform required inclusion/exclusion assessments; discuss study goals, activities, and requirements; obtain informed consent~Pre-randomization phase: twice daily assessments of mental status~Randomize delirious patients: IV guanfacine or placebo~Interventional Trial phase: study drug administration, mental status assessments, safety monitoring~Blood draws: collect blood samples on Interventional Trial Phase days 1 and 2~Follow-up assessments: telephone and online questionnaires at 30, 90, and 180 days after hospital discharge."
89023781|NCT04742673|Experimental|IV Guanfacine|"Participants will flow through the trial in the following manner:~Consent in ICU: perform required inclusion/exclusion assessments; discuss study goals, activities, and requirements; obtain informed consent~Pre-randomization phase: twice daily assessments of mental status~Randomize delirious patients: IV guanfacine or placebo~Interventional Trial phase: study drug administration, mental status assessments, safety monitoring~Blood draws: collect blood samples on Interventional Trial Phase days 1 and 2~Follow-up assessments: telephone and online questionnaires at 30, 90, and 180 days after hospital discharge."
89023782|NCT04739852|Active Comparator|Healthy Participants|Healthy participants
89023783|NCT04739852|Active Comparator|Metabolic Syndrome|Participants with diagnosed metabolic syndrome
89023784|NCT04739852|Active Comparator|Rheumatoid Arthritis|Participants with diagnosed rheumatoid arthritis
89023785|NCT04732052|Active Comparator|Active tDCS|Transcranial Direct Current Stimulation: Soterix tDCS kit will be used to deliver the stimulation using two sponge electrodes soaked in a saline solution. The stimulation montage will comprise of left anodal Dorsal Lateral Prefrontal cortex (DLPFC) stimulation. The anodal electrode will be placed over the area corresponding to the left DLPFC (F5 of the EEG10-20 international system) and the reference (cathodal) electrode over the right supraorbital ridge. The active stimulation condition will use a constant current of 2mA, delivered via gradual increase and decrease over 10 seconds at the onset and offset of stimulation (current ramps), respectively. The duration a single tDCS session will be 20 minutes.
89506110|NCT05792072|Active Comparator|active rTMS|The patient will receive one daily rTMS session for 5 days of HF-rTMS, delivered through an H-coil applied to the primary motor area of the leg. Each session will last 20 minutes during which 30 consecutive trains of 50 stimuli will be delivered at 20 Hz at 100% of resting motor threshold (RMT), with an intertrain interval of 30s
89506111|NCT05792072|Sham Comparator|Sham rTMS|Sham stimulation will be delivered using a sham coil.
89506112|NCT05791994|Experimental|Intervention group|
89506113|NCT05791994|Active Comparator|Comparator group|
89506114|NCT05791955|No Intervention|Holdout Condition: No reminder|Eligible, randomized participants will receive no text message reminder.
89506115|NCT05791955|Experimental|Control Reminder|Eligible, randomized participants will receive a generic text message reminding them to close their outstanding health gap by clicking on the link to make an appointment.
89506116|NCT05791955|Experimental|Personal Responsibility Reminder|Eligible, randomized participants will receive a text message reminding them to close their outstanding health gap. This message will ask them to click on the link to schedule an appointment, or to text back to acknowledge they are taking responsibility for closing the health gap on their own.
89506117|NCT05791955|Experimental|Planning prompt reminder|Eligible, randomized participants will receive a text message reminding them to close their outstanding health gap. This message will prompt participants to either click on the link to schedule an appointment right away, or text back when they will do so
89506118|NCT05791890||Patients who receive or have received Gilteritinib|the retrospective part, clinical data will be collected on all patients with LMA FLT3+ (ITD or TKD mutation) treated with Gilteritinib from when the drug was approved and marketed in Italy (April 2, 2020) until April 30, 2022. Enrollment in the prospective cohort will have an estimated duration of 24 months from the time of study approval.
89506119|NCT05791890||Case control|for each case of a patient receiving salvage monotherapy with Gilteritinib, a control patient with R/R AML FLT3+ on salvage chemotherapy should also be included.
89506120|NCT05791851||HIV infected|
89506121|NCT05791851||HIV uninfected|
89506122|NCT05791825|Experimental|Receives CHIME|Half of the educators participating in the trial will be assigned to this condition. CHIME is an 8-week, mindfulness and self-compassion based intervention that teaches educators strategies to enhance socioemotional learning in the classroom. The primary endpoints are: educator mindfulness and self-compassion, educator emotional regulation, educator heart rate variability, educator wellbeing and socio-emotional learning, and educator responsiveness, support, and sensitivity in the classroom. The secondary endpoints are: child self-regulation and social skills and family-school relationships.
89506123|NCT05791825|No Intervention|Wait-listed comparison|Half of the HS/EHS educators will be assigned to a waitlisted control group. Specifically, these educators will be scheduled to receive the intervention after a 6-month waiting period. During the interim period, they will complete the same assessments as Arm 1, but will continue to receive 'business as usual' support and professional development through typical Head Start/EHS programming.
89506124|NCT05791799|Experimental|Etonogestrel implants group|Women will be subjected to etonogestrel implant (68mg) insertion.
89506125|NCT05791799|No Intervention|control group|This group of women will not be intervened.
89506126|NCT05791760|Experimental|Compassion-focused therapy (CFT)|
89506127|NCT05791734||assessing preoperative skin cleanliness|2 skin swabs for ATPmetry measurement and direct skin visual observation by a nurse
89506128|NCT05791721|Active Comparator|Etoricoxib group|One hour preoperatively, preemptive, single-dose etoricoxib tablet in dosage of 90 mg will be administered orally
89506129|NCT05791721|Active Comparator|Dexamethasone group|One hour preoperatively, preemptive, single-dose dexamethasone in dosage of 4 mg will be administered intramuscularly
89506130|NCT05791721|No Intervention|Control group|In this group, one hour preoperatively no medication will be administered
89506131|NCT05791682|Active Comparator|MICROFILLED RESIN SEALANT|-Microfilled rein sealant (fissurit FX) after etching, washing, drying, sealant was gradually applied along the fissure of first permanent molar, Immediately light cured for 20 sec
88957297|NCT01982617|Experimental|Psychoeducation|The education group also consisted of four group sessions that were co-led by a doctoral-level clinical psychologist and at bachelors-level research assistant. However, the focus of the education group was to present factual information about health risks of smoking, benefits of quitting, pharmacological smoking cessation aides, and smoking cessation programs in the area. The four group topics included: 1) Health Risks of Smoking, 2) Benefits of Quitting, 3) Nicotine Replacement Therapy and Bupropion (Zyban), and 4) Options for Treatment Programs.
88957298|NCT01982656|Experimental|Massage technique|In addition to standard medical care and pharmacologic interventions, massage technique for 20 minutes for 5 to 14 days while in the ICU will be provided to help alleviate pain and anxiety in the patient.
88957299|NCT01982656|Placebo Comparator|No intervention|Patients with an aneurysmal subarachnoid hemorrhage will receive standard medical care to include pharmacologic interventions prescribed by the primary physician and nonpharmacologic interventions provided by the bedside RN such as ice or heat to address their pain and anxiety needs.
88957300|NCT01982669||Different degree of spicy food intake|
88957301|NCT01982721|Experimental|Transfemoral amputees|Locking mechanism for prosthetic knee (no trade mark provided)
89506132|NCT05791682|Active Comparator|NANOFILLED RESIN SEALANT|Nanofilled resin sealant (Grandioseal) after etching, washing, drying, sealant was gradually applied along the fissure. Immediately light cured for 20 sec.
89506133|NCT05791682|Active Comparator|FLOWABLE COMPOSITE|Flowable composite (Te-Econom Flow) after etching, washing, drying, adhesive was applied and dried under gentle air flow for 2-3 sec and was light cured. A uniform layer of flowable composite was applied and light cure for 20 sec.
89506134|NCT05791682|Active Comparator|UNFILLED RESIN SEALANT|Unfilled resin sealant (clinpro) after etching, washing, drying, sealant will be gradually applied along the fissure. Immediately light cure for 20 sec.
89506135|NCT05791669|Experimental|38% silver diamine fluoride|
89506136|NCT05791669|Active Comparator|5% sodium fluoride varnish|
89506137|NCT05791630|No Intervention|WHO partograph|all study sites use the WHO partograph as standard care in the first step of the trial
89506138|NCT05791630|Experimental|WHO labour care guide|All study sites will cross over to the intervention according to randomization and use the LCG for assessing labour progression and wellbeing in labour
89506139|NCT05791552|Other|Group A|Patient WITH cognitive impairment and no nasal pathologies. CSF analysis is planned or results are already available
89506140|NCT05791552|Other|Group B|Patient WITHOUT cognitive impairment and without nasal pathologies
89506141|NCT05791539|Experimental|Group 1 Erector spinae plane block|Group 1 (ESPB (control group): (n = 15) patients will receive preoperative US-guided ESPB on the operated side by 20 ml bupivacaine 0.25%.
89506142|NCT05791539|Experimental|Group 2: Erector spinae plane block|US-guided ESPB with 10 ml bupivacaine 0.25% (n = 15) on the operated side.
89506143|NCT05791539|Experimental|Retro laminar block|the US-guided retrolaminar block 10 ml bupivacaine 0.25% group: (n = 15) on the operated side.
89506144|NCT05791500|Experimental|lifestyle intervention group|People in intervention group are required to have a daily work and rest time of 7-8 hours, adjusted according to their original work and rest, but no later than 9:00 to get up and 23:00 to fall asleep; change their intimate clothes every day and clean themselves at least twice a day（mainly including brushing their teeth and washing their faces at least twice in the morning and evening, and showering once）The bed is guaranteed to sun/wash the quilt once a month, the sheets are changed twice a week in spring and autumn, and once a month in winter. The desk in the dorm is arranged neatly and orderly, the study and daily necessities are sorted and placed, at least there is place for office and study, the bed is clean and tidy, no garbage, no dirt. It is required to upload the hygiene situation of the bedroom (including the desk and the bed) once a week, and take a photo every time the bedding is changed.
89506145|NCT05791500|No Intervention|lifestyle control group|This group doesn't conclude any intervention measures.But the data of participants is obtained at the same time as the intervention group.
89506146|NCT05791500|Experimental|dietary habits intervention group|Before the interventions,data such as dietary health scores which includes Dietary Quality Index(DQI) ,score based on dietary health questionaire and so on are collected.Then people in the intervention group are gathered to participate in dietary health education lectures,after which the data such as DQI will be obtained again.
89506147|NCT05791500|No Intervention|dietary habits control group|This group doesn't conclude any intervention measures.But the data of participants is obtained at the same time as the intervention group.
89506148|NCT05791500|Experimental|physical activity intervention Group A-jogging|People in the Group A-jogging need to training at least 4 times a week, each time at least 50 minutes for boys and at least 40 minutes for girls, for 4 months. Before the experiment, students in the Group A-jogging learned the basic movements and complete sets of movements of this exercise prescriptions.
88957302|NCT01982721|No Intervention|Healthy volunteers|
88957303|NCT01982734|Active Comparator|Native curcumin|80 mg curcumin as native powder
88957304|NCT01982734|Experimental|Native curcumin plus phytochemicals|80 mg curcumin as native powder plus 80 mg sesamin, 40 mg naringenin, 40 mg ferulic acid and 40 mg xanthohumol
88957305|NCT01982734|Experimental|Curcumin micelles|80 mg curcumin incorporated into liquid micelles
88957306|NCT01982734|Experimental|Curcumin micelles plus phytochemicals|80 mg curcumin incorporated into liquid micelles plus 80 mg sesamin, 40 mg naringenin, 40 mg ferulic acid, 40 mg xanthohumol incorporated into micelles
89506149|NCT05791500|Experimental|physical activity intervention Group B-rope skipping|People in the Group B-rope skipping need to training at least 4 times a week, each time at least 50 minutes for boys and at least 40 minutes for girls, for 4 months. Before the experiment, people in the Group B-rope skipping learned the basic movements and complete sets of movements of this exercise prescriptions.
89506150|NCT05791500|No Intervention|physical activity Control Group|This group doesn't conclude any intervention measures.But the data of participants is obtained at the same time as the intervention group.
89539156|NCT03248609|Experimental|Milano grapes|Unique grape varietal to test glycemic response.
89539157|NCT03248609|Active Comparator|Table grapes|Common grape varietal to test glycemic response and compare to the glycemic response elicited by the Milano grape varietal.
89539158|NCT03248609|Active Comparator|Grape juice|Used to test the glycemic response without a complex food matrix and compare to the glycemic response elicited by the Milano grape varietal.
89539159|NCT03248609|Placebo Comparator|Glucose beverage|Used to test the glycemic response with a standardized glucose beverage and compare to the glycemic response elicited by the Milano grape varietal.
89539160|NCT04959513|Experimental|GBR with L-PRF bone block|Guided bone regeneration using Leukocyte and platelet-rich fibrin
89539161|NCT03248687|Experimental|Home follow up|Patients with a distal radius buckle fracture treated in a removable splint will be provided with discharge instructions and anticipatory guidance without any scheduled physician follow up.
89539162|NCT03248687|Active Comparator|Primary Care Physician Follow up|Patients with a distal radius buckle fracture treated in a removable splint will be provided with discharge instructions and anticipatory guidance with scheduled primary care physician follow up at 1-2 weeks post visit to the emergency department.
89539163|NCT04959357||coronary microvascular dysfunction group|
89539164|NCT04959357||obstructive coronary artery disease|
89539165|NCT04959357||control group|
89539166|NCT04487015|No Intervention|Part I: Non-Digital (Control)|Participants who currently receive performance nutrition support, via a qualified practitioner as indicated by a member of the sports science team at their sporting organisation, will be assigned to the non-digital approach (control). These participants will not receive any intervention from the research team for the duration of this study (6 weeks).
89539167|NCT04487015|Experimental|Part I: MP+ Call + MesC [6 weeks]|For part one of study, participants who currently do not receive performance nutrition support, will be given access to an app-based menu planner (MP) for 6 weeks with coach support that gives ad-hoc messaging and calls.
89539168|NCT04487015|Experimental|Part II: Stage 1- MP [1week]|For the pilot SMART trial (part two of study), participants (not the same participants as part one) who currently do not receive performance nutrition support, will be given access to a menu planner app (MP) for 4 weeks. In the first 1 week, participants will only receive MP.
89506151|NCT05791487|Experimental|Ulcerative colitis Exclusion Diet + Partial enteral nutrition|Participants in Group 1 will receive the UCED combined with partial enteral nutrition (PEN) using a novel nutritional formula for 6 weeks (diet phase 1) that will add to oral budesonide 9 mg topical therapy for 6 weeks and will follow diet + PEN (phase 2: wk6-wk12) and diet phase 3 for 24 weeks.
89539169|NCT04487015|Experimental|Part II: Stage 2 - R1-MP [1 week]|"For participants in Part II: Stage 1- MP [1week], after the first 1week, this group of participants are considered responders (R1) so they continue with MP only for another 1 week.~Participants' response status is dependent on whether they are randomised to using the stringent or relaxed engagement criteria as described in study details."
89608632|NCT04142151|Placebo Comparator|SanchiTongshu Placebo group|"Drug: placebo of Sanchitongshu The Sanchitongshu placebo capsule contained dark brown muscovado sugar and the same inactive excipient (starch).~Drug: Aspirin or Clopidogrel"
89608633|NCT02985099|Active Comparator|Rosuvastatin group|Oral prophylaxis followed by 1.2% Rosuvastatin drug in gel form placed in intrabony defects
89608634|NCT02985099|Placebo Comparator|Placebo group|Oral prophylaxis followed by placebo gel placement in intrabony defects
89506152|NCT05791487|Active Comparator|Free diet|Participants in Group 2 will receive oral budesonide 9 mg topical therapy alone for 6 weeks with no dietary intervention
88957307|NCT01982747|Other|MGN - Placebo|Subjects of the MGN-Placebo arm will receive 60mg MGN1703 as 2 s.c. injections of 2 ml each during period 1 and physiological saline solution as Placebo as 2 s.c. injections of 2 ml each during period 2
88957308|NCT01982747|Other|Placebo-MGN|Subjects of the Placebo-MGN arm will receive physiological saline solution as Placebo as 2 s.c. injections of 2 ml each during period 1 and 60mg MGN1703 as 2 s.c. injections of 2 ml each during period 2
88957309|NCT01982760|Experimental|DDAVP|Arm receiving DDAVP prior to the operation. Drug is administered intravenously at .3mcg per kg, over 30 minutes prior to the operation.
88957310|NCT01982760|No Intervention|No DDAVP|Patients Will not receive DDAVP prior to Rhinoplasty
89506153|NCT05791461||Intervention cohort|Patients with work-related stress (F43.2/8/9 or Z56.3 (ICD-0)) who received the stress management intervention between 2011-2018 (N>400). The intervention is based on cognitive behavioral therapy, delivered by a trained psychologist in groups of 8-10 patients. The intervention consists of 8 sessions in 3 months, with a booster session 3 months after the intervention has ended.
89608635|NCT04142229|Experimental|Automated Insulin Delivery|Participants will use the Automated Insulin Delivery (AID) iAPS system for 2 weeks in the outpatient setting, and come to the clinical center twice for supervised stress assessments.
89608636|NCT04142229|Active Comparator|SAP/PLGS|Participants will use their home pump with a CGM sensor (sensor augmented pump) or in Predictive Low Glucose Suspend (PLGS) mode if their home pump supports this mode, for 2 weeks in the outpatient setting, and come to the clinical center twice for supervised stress assessments.
89608637|NCT04149873|Placebo Comparator|Control group|Control group' has the treatment with [Physical chest care ]
89206763|NCT04016688|Active Comparator|TAP Transversus Abdominis Plane Block|"bilateral TAP block: while the patient in the supine position, a linear ultrasound (US) transducer (Phillips Saronno Italy) is placed transversally on the anterolateral abdominal wall in the midaxillary line between the iliac crest and the costal margin identifying external oblique, internal oblique and transversus abdominis muscles. The TAP is between internal oblique and transversus abdominis.~A 22-G needle (spinocan, B.Braun, melsungen AG, Germany) is introduced anteriorly to the transducer and advanced to reach the TAP between internal oblique muscle and transversus abdominis muscle. After careful aspiration to exclude vascular puncture, 20 ml 0.25 % bupivacaine is injected causing an elliptical separation of the two muscles. The same procedure is done on the other side."
89206764|NCT05300061|Experimental|Personal Values Intervention|Brief personal values intervention
89608638|NCT04149873|Placebo Comparator|Experimental group-A|'Experimental group-A' has the treatment with [Mechanical-Insufflation- Exsufflation]
88957311|NCT01982799|Experimental|Endododontic Tx + Long acting local anesthetic|long acting local anesthetic
88957312|NCT01982799|Experimental|Endodontic Tx plus local anesthetic|local anesthetic
89539170|NCT04487015|Experimental|Part II: Stage 2 - NR1-MP [1 week]|"For participants in Part II: Stage 1- MP [1week], after the first 1 week, this group of participants are considered non-responders (NR1) and are re-randomised to continue with MP only for another 1 week.~Participants' response status is dependent on whether they are randomised to using the stringent or relaxed engagement criteria as described in study details."
89539171|NCT04487015|Experimental|Part II: Stage 2 - NR1-MP + Call + MesC [1 week]|"For participants in Part II: Stage 1- MP [1 week], after the first 1 week, this group of participants are considered non-responders (NR1) and are re-randomised to have MP and additional coach support for another 1 week. The coach support consists of up to 3 coach-initiated messaging and ad-hoc calls to participant.~Participants' response status is dependent on whether they are randomised to using the stringent or relaxed engagement criteria as described in study details."
89539172|NCT04487015|Experimental|Part II: Stage 3 - R2-MP [2 weeks]|"After going through Part II: Stage 2, this group of participants are considered responders (R2) so they continue with MP only for 2 weeks.~Participants' response status is dependent on whether they are randomised to using the stringent or relaxed engagement criteria as described in study details."
89539173|NCT04487015|Experimental|Part II: Stage 3 - NR2-MP [2 weeks]|"After going through Part II: Stage 2, this group of participants are considered non-responders (NR2) and are re-randomised to use MP only for another 2 week.~Participants' response status is dependent on whether they are randomised to using the stringent or relaxed engagement criteria as described in study details."
89539174|NCT04487015|Experimental|Part II: Stage 3 - NR2-MP + Call + MesC [2 weeks]|"After going through Part II: Stage 2, this group of participants are considered non-responders (NR2) and are re-randomised to have MP and additional coach support for another 2 weeks. The coach support consists of up to 3 coach-initiated messaging and ad-hoc calls to participant.~Participants' response status is dependent on whether they are randomised to using the stringent or relaxed engagement criteria as described in study details."
89539175|NCT04939779|Experimental|Group A|Period 1: LCB01-0371 tablet 400mg (Reference drug, Batch# 1650006) Period 2: LCB01-0371 tablet 400mg (Test drug, Batch# 3183817R)
89539176|NCT04939779|Experimental|Group B|Period 1: LCB01-0371 tablet 400mg (Test drug, Batch# 3183817R) Period 2: LCB01-0371 tablet 400mg (Reference drug, Batch# 1650006)
89539177|NCT04940169|Experimental|quadriceps tendon autograft|Ramdomized half of the patient underwent quadriceps graft harvesting. Arthroscopic technique fixation methods rehabilitation style follow periods kept same as hamstring group except graft type.
89539178|NCT04940169|Experimental|hamstring tendon autograft|Ramdomized half of the patient underwent hamstring graft harvesting. Arthroscopic technique fixation methods rehabilitation style follow periods kept same as hamstring group except graft type.
89539179|NCT03249233|Experimental|Keratoconics wearing ZenLens with high central clearance|Scleral contact lenses designed to provide approximately 450 microns of central clearance.
89539180|NCT03249233|Experimental|Keratoconics wearing ZenLens with low central clearance|Scleral contact lenses designed to provide approximately 350 microns of central clearance.
89539181|NCT03249233|Active Comparator|Healthy controls wearing ZenLens with high central clearance|Scleral contact lenses designed to provide approximately 450 microns of central clearance.
89539182|NCT03249233|Active Comparator|Healthy controls wearing ZenLens with low central clearance|Scleral contact lenses designed to provide approximately 350 microns of central clearance.
89539183|NCT04946565||Sinopharm vaccine group|Participants scheduled to receive the Sinopharm vaccine will be evaluated on its effect on semen parameters for up to 6 months post vaccination.
89539184|NCT04939155||Patients infected with SARS-CoV-2|The first part of this study looks at the methylation patterns in individuals who have a baseline test taken of their DNA methylation patterns in their epigenome and then a follow-up test after they contracted SARS-CoV-2
89539185|NCT04939155||Patients who have received an mRNA vaccination|The second part of the study looks at the methylation patterns in individuals who have a baseline test taken of their DNA methylation patterns in their epigenome and then a follow-up test after SARS CoV-2 mRNA vaccine injection.
89539186|NCT03248999|Experimental|Experimental|realization of a rectal swab or stool sample for all the résidents included in the study.
89608639|NCT04149873|Experimental|Experimental group-B|'Experimental group-B' has the treatment with [Mechanical-Insufflation- Exsufflation] and [Physical chest care]
88957313|NCT01982825|Experimental|Online intervention arm|Bi-weekly (MTh) for 6 weeks, participants will receive an email asking them to report number of cigarettes smoked, alcoholic drinks, engagement in physical activity, and overall mood the two-three days before. Upon answering, they will be launched to the site which will contain health messaging focused on smoking and other health topics.
88957314|NCT01982825|Active Comparator|Online control arm|Control participants will receive bi-weekly emails (MTh) over 6 weeks but in the context of a standard smoking cessation website. Because we are primarily testing the check-ins, tailored feedback, and market research-based mini-drama and other web content, we feel that this control group will isolate the hypothesized active elements of our program.
89608640|NCT03904329||Obese Patients with non valvular AF|Obese Patients with non valvular AF using oral anti coagulants
88957315|NCT01982838|Active Comparator|Group E|Epidural de novo technique
88957316|NCT01982838|Active Comparator|Group BF|Combined spinal epidural (CSE) technique with intrathecal 0.5% Bupivicaine 2.5mg + Fentanyl 15mcg
88957317|NCT01982838|Active Comparator|Group F|Combined spinal epidural (CSE) technique with intrathecal fentanyl 25mcg
88957318|NCT01982851|Active Comparator|Group E|Epidural de novo technique
88957319|NCT01982851|Active Comparator|Group BF|Combined spinal epidural (CSE) technique with intrathecal 0.5% Bupivicaine 2.5mg + Fentanyl 15mcg
88957320|NCT01982851|Active Comparator|Group F|Combined spinal epidural (CSE) technique with intrathecal fentanyl 25mcg
88957321|NCT01982864|Experimental|hemodialysis patients|The administration of gentamicin at the beginning of the hemodialysis.
88957322|NCT01982877|Experimental|Family Support Intervention|Multifaceted family support intervention as well as ICU educational component.
88957323|NCT01982877|Experimental|Educational Control|ICU educational component
88957324|NCT01982903||Kidney transplant recipients|Adult recipients of a primary or secondary cadaveric or living donor single renal allograft at the University Hospitals Leuven between July 2014 and June 2016
88957325|NCT01982916|Experimental|AGR & Placebo|AGR tablet by qd and Placebo by bid for 4 weeks
88957326|NCT01982916|Placebo Comparator|Placebo|Placebo by bid for 4 weeks
89506154|NCT05791461||Comparison cohort|Patients with work-related stress (diagnoses F43.2/8/9 or Z56.3 (ICD-10)) who was seen at a consultation at Department of Occupational and Environmental Health in Odense (DOEM) in 2011-2012, but did not receive the intervention because it was not yet offered. The patients were offered advice and support by a psychologist (usual care). The intervention was introduced at DOEM in 2011 for a limited number of patients due to introducing the intervention and establishing the capacity of psychologists involved. In 2013 the intervention was implemented at full scale to include every eligible patient.
89506155|NCT05791409|Experimental|Arm A|6 cycles epcoritamab + 26 cycles venetoclax
89506156|NCT05791409|Experimental|Arm B|12 cycles epcoritamab + 26 cycles venetoclax
89506157|NCT05791396|Experimental|Donor FMT|Patients enrolled in this arm will receive donor FMT
89506158|NCT05791396|Placebo Comparator|Placebo FMT|Patients enrolled in this arm will receive placebo FMT (that will be made of water)
89506159|NCT05791383|Experimental|transcutaneous auricular neurostimulation (low dose)|All taVNS procedures will be conducted using the Spark Biomedical device. Electrodes will be placed on the left auricle and we will use stimulation parameters similar to ongoing taVNS work (25Hz, 500us pulse width) and a duty cycle of 1 minute on, 30 s off, repeated for 30 minutes. The low dose taVNS group will receive up to 3 treatments per day over the course of 3 days (for a total of up to 9 treatments).
89506160|NCT05791383|Experimental|transcutaneous auricular neurostimulation (high dose)|All taVNS procedures will be conducted using the Spark Biomedical device. Electrodes will be placed on the left auricle and we will use stimulation parameters similar to ongoing taVNS work (25Hz, 500us pulse width) and a duty cycle of 1 minute on, 30 s off, repeated for 30 minutes. The high dose taVNS group will receive up to 9 treatments in a single day.
89506161|NCT05791370|Experimental|Red palm olein|Meals enriched with Red palm olein
89506162|NCT05791370|Experimental|Extra virgin coconut oil|Meals enriched with Extra virgin coconut oil
89506163|NCT05791370|Experimental|Extra virgin olive oil|Meals enriched with Extra virgin olive oil
89506164|NCT05791357|Experimental|Endocarditis patients|Patients with endocarditis who respect including criteria
89506165|NCT05791331|Active Comparator|A/Control|Surfactant administration following clinical assessment
89506166|NCT05791331|Experimental|B/Intervention|Surfactant administration following both lung mechanics assessment and clinical assessment
89506167|NCT05791292|Other|Patients group|To evaluate hand grip strength, neck discomfort, arm, shoulder and hand problems, and overall quality of life.
89506168|NCT05791292|Other|Healthy group|To evaluate hand grip strength, neck discomfort, arm, shoulder and hand problems, and overall quality of life.
89506169|NCT05791266|Experimental|Sticker pads containing lavender and ylang ylang oil|Sticker pads , size 160 mm2, were produced by a certified ISO 9001 manufacturer and contained 0.3% lavender oil and 0.7% ylang ylang oil. The sticker pad was attached to the shirts of healthy volunteers for 2 hours. The outcomes were evaluated before, during and 30 minutes after removal of the pad.
89506170|NCT05791149|Experimental|OSCC patients|
89506171|NCT05791149|Active Comparator|controls|
89506172|NCT05791136|Experimental|Radiotherapy Sequential Toripalimab|Radiotherapy:Intensity-modulated radiotherapy (IMRT) Immunotherapy: Toripalimab
89506173|NCT05791123|Experimental|a bone graft mixed with PRF & covered by PRF membrane in fresh extraction socket|
89506174|NCT05791084|No Intervention|A=Control group who receives customary information prior to RT with DIBH.|Usual care and information before start of radiotherapy with DIBH.
89506175|NCT05791084|Experimental|B=Intervention group usual care and the DIBH-App to practice at-home before RT with DIBH.|Usual care and information and a mobile application with breathing instructions and a sensor to attach around the chest. To be able to train at home before radiotherapy with DIBH starts.
89506176|NCT05791058|Active Comparator|Group A (ultrasound guided pericapsular nerve group shoulder block)|
89506177|NCT05791058|Active Comparator|Group B( ultrasound guided suprascapular and axillary nerve block)|
89506178|NCT05791058|Active Comparator|control group|
89506179|NCT05791045|Active Comparator|double lumen tube|In the DLT group, the lung on the side to be treated was distinguished from the ventilator and extinguished and single lung ventilation was performed with the other lung.
89506180|NCT05791045|Active Comparator|single lumen tube|In the SLT group, after thoracoscopic input, the anesthetist was in contact with the surgeon and his lung pressures were reduced manually until the lowest pressure, where the surgeon's vision was optimal.
89506181|NCT05791006||Patients with Parkinson's Disease/Parkinsonisms|
89506182|NCT05791006||Patients with brain tumors|
89506183|NCT05791006||Patients with ischemic or haemorrhagic stroke|
89506184|NCT05791006||Healthy Controls|
89506185|NCT05790941|Experimental|Topical Latanoprost/Minoxidil formulation|8 participants: Topical Latanoprost/Minoxidil formulation applied to both eyebrows once a day for 90 days
89506186|NCT05790941|Placebo Comparator|Control Group|4 participants: Vehicle applied to both eyebrows once a day for 90 days
89506187|NCT05790902|Experimental|Silodosin Group|The patients used Silodosin for ureteric calculi
88957327|NCT01982916|Active Comparator|Active comparator|Active Comparator and Placebo by bid for 4 weeks
89206765|NCT05300061|Experimental|Prosocial Values Intervention|Brief prosocial values intervention
89206766|NCT05300061|No Intervention|Control|No intervention control
89506188|NCT05790902|Experimental|Tamsulosin Group|The patients used Tamsulosin for ureteric calculi
89506189|NCT05790876|Experimental|SSO2 therapy|After successful PCI of a proximal or middle LAD lesion, the patient will be informed and emergency consent will be obtained. SSO2 therapy will then be performed. Overoxygenated blood will be delivered to the origin of the LAD for 60 minutes. Improvement in CMD will be assessed by comparing angio-IMR before and after 60 minutes of SSO2 therapy measured on conventional angiographic images
89206767|NCT05352087|Active Comparator|early cholecystectomy|In early cholecystectomy group after antibiotherapy was started with ceftriaxone and metronidazole, laparoscopic cholecystectomy was performed in the first 7 days following the hospitalization.
89206768|NCT05352087|Active Comparator|delayed cholecystectomy|Patients who accepted delayed surgery were also given the same antibiotherapy and operated after 6 weeks following their discharge
89506190|NCT05790863|Experimental|High-intensity interval training group|Each ergometer cycling training session consists of a warm-up phase lasting two minutes, five interval bouts of one minute each at 76% to 90% of one's HRmax, separated by one minute of passive or low-intensity recovery, and a three-minute cool-down phase. After 4 weeks of the intervention, the minimal intensity that had to be met will be progressively raised (weeks 1-4: 76-85%, weeks 5-7: 85-90%HRmax, respectively). For individuals who are unable to reach 76% HRmax, scores of 15 to 17 (hard to very hard) on the Borg scale will be followed.
89506191|NCT05790863|Active Comparator|Moderate-intensity continuous training group|During the first four weeks, participants will be advised to modify the pedal cadence and/or resistance of the ergometer to obtain an HR equivalent to 65-70% HRmax, rising to 70-75% HRmax during the final 3 weeks. Each session lasts less than 30 minutes of moderate-intensity continuous ergometer cycling, which starts with a two-minute warm-up and ends up with a three-minute cool-down.
89506192|NCT05790798|Experimental|intervention group|The universe of this research, which has a randomized controlled design, is all people with disabilities aged 18 and older who are attended at the Etimesgut Family and Life Center in Ankara. The inclusion criteria of this study were to be 18 years of age or older, to have a score of 17 and below according to the Lawton-Brody Instrumental Activity of Daily Living Scale, to have a score of 24 and above in the Modified Mini-Mental test. In addition, there are some exclusion criteria for research. Exclusion criteria from the study were: Having a communication problem that prevented the participant from completing the assessment and the kits; not participating regularly in the intervention program. For this study, people who attended the Family and Life Center and people with disabilities who regularly come to this center for various reasons were contacted. People (n=35) who met the criteria of the study were informed about the study and invited to participate in this study.
89506193|NCT05790798|Active Comparator|Control Group|The universe of this research, which has a randomized controlled design, is all people with disabilities aged 18 and older who are attended at the Etimesgut Family and Life Center in Ankara. The inclusion criteria of this study were to be 18 years of age or older, to have a score of 17 and below according to the Lawton-Brody Instrumental Activity of Daily Living Scale, to have a score of 24 and above in the Modified Mini-Mental test. In addition, there are some exclusion criteria for research. Exclusion criteria from the study were: Having a communication problem that prevented the participant from completing the assessment and the kits; not participating regularly in the intervention program. For this study, people who attended the Family and Life Center and people with disabilities who regularly come to this center for various reasons were contacted. People (n=35) who met the criteria of the study were informed about the study and invited to participate in this study.
89506194|NCT05790759|Experimental|PD patients|See inclusion criteria in the right section. See procedures in the the right section.
89506195|NCT05790694|Experimental|HBM9378 (SKB378) Injection|Dose: 20 mg/60 mg/200 mg/600 mg/900 mg Frequency: Once Injection subcutaneously
89506196|NCT05790694|Placebo Comparator|Placebo|Dose: 20 mg/60 mg/200 mg/600 mg/900 mg Frequency: Once Injection subcutaneously
89506197|NCT05790655|Experimental|oPRP injections|Patients own prepared PRP will be injected into each ovary
89506198|NCT05790655|Placebo Comparator|Placebo|Patient's serum will be injected into the ovary (not rich with platelets)
89506199|NCT05790629|Active Comparator|Group (I) control|young permanent pulpy exposed carious tooth of the selected participants will be treated with specific technique called apexogenesis using bio-compatible material (endo-sequence putty ). This material is administrated to the tooth by placing about 2-4 mm bulk of material in the pulp champers at the cervical line then sealing the capping material with glass ionomer and stainless steel crown.
89506200|NCT05790629|Experimental|Group (II)|young permanent pulpy exposed carious tooth of the selected participants will be treated with specific technique called apexogenesis using bio-compatible material (neo-MTA putty). This material is administrated to the tooth by placing about 2-4 mm bulk of material in the pulp champers at the cervical line then sealing the capping material with glass ionomer and stainless steel crown.
89506201|NCT05790616|Experimental|NI(Fast-Sitting)|"Subgroup Non-Invasive (Fast-Sitting): sitting volunteers undergo an ambient oxygen decrease from 21% to 10% (SpO2 <73% for 1 minute) followed by a fast increase of ambient oxygen concentration.~Fast: if the study is completed for a volunteer reaching SpO2 ≤73%, the subject leaves the room and breaths 21% oxygen. The hypoxia inducing device is stopped after all subjects left the hypoxia room and the door of the hypoxia room is opened, allowing air with 21% O2 to enter the room. Airco fan stays running."
89506202|NCT05790616|Experimental|NI(Slow-Sitting)|"Volunteers of subgroup Non-Invasive (Slow-Sitting) follow the NI (Rapid-Sitting) protocol, but after hypoxia at FiO2=0,10 oxygen normalization is programmed to increase at the same speed as the hypoxia creation.~Slow: after target hypoxia has been reached, air with 21% of oxygen is allowed to enter the room in such a way that the speed of increase of O2 to 21% is approximately equal to the decrease of the room's oxygen to 10%"
89506203|NCT05790616|Experimental|NI(Fast-Lying)|Volunteers included in the Non-Invasive (Fast-Lying) group follow the NI (Rapid-sitting) protocol although in lying position.
89506204|NCT05790616|Experimental|IN(Fast-Sitting)|After full completion of the Non-Invasive (NI) studies, and a defined algorithm to compute SpO2 by TDw1 is achieved, the study is repeated as described for the NI (Rapid-Sitting) protocol, but arterial blood oxygen saturation (SaO2) will be determined during 5 stable ambient oxygen plateaus (the Invasive (Fast-Sitting) study). These results are used as benchmark to define the final accuracy of TDw1 for SpO2 reproduction. In this part of the study, according to the minimal requirements of the regulatory agencies, 12 volunteers that successfully completed the study will be included.
89506205|NCT05790603|Experimental|Low pressure group|This group will use the radial artery hemostatic device with quantitative pressure which will be the new patent product made by Shandong Weigao Group Medical Polymer Products Co. LTD,China. The compression pressure on radial artery after PCI was 120% of upper arm systolic BP measured preoperatively. Pressure will be released by 4% hourly until the bleeding is stopped.
89206769|NCT00948987|Experimental|Aspirin|single dose of aspirin 325 mg p.o.
89539187|NCT04939077|Experimental|CABG with hUC-MSC treatment group|In the CABG with hUC-MSC treatment group, 1×10^7 human umbilical cord Mesenchymal Stem Cells were injected to the edge of the myocardial infarction area at 20 points at the same time in CABG.
89539188|NCT04939077|No Intervention|CABG group|CABG was performed under general anesthesia.
89539189|NCT03248453|Experimental|CoPS feedback|Each participant will as feedback be given the actual CoPS after reaching the cecum on the standardized Kagaku Training Model. A leaderboard with experts performances will be present for comparison.
88957328|NCT01982929|Sham Comparator|Sham block & Oral Meds|Definition intervention. Sham procedure. Blocks mimicked the TAP blocks, but neither needle nor injectate was used. Patients had bilateral ultrasound scans over the lateral aspect of the abdomen. To mimic the injection of medicine, a blunt needleless syringe was firmly pressed on either side of the abdomen. An adhesive bandage was applied over the injection or sham injection sites.
88957329|NCT01982929|Experimental|TAP block & Oral Meds|Definition intervention. TAP block (Bupivacaine 0.25% with epinephrine 1:400,000 50 cc). TAP blocks were placed using ultrasound-guided identification of the transversus abdominis fascial plane, and in-plane needle guidance. Injection sites were near the Triangle of Petit, located at the lateral edge of the mid-abdomen, near the iliac crests. After negative aspiration for blood, the local anesthetic was injected in 5 cc aliquots. The total dosage injected never exceeded 0.25 mg/kg of 0.25% bupivacaine with epinephrine 1:400,000.
88957330|NCT01982981|No Intervention|control|The control group only be assessed
88957331|NCT01982981|Experimental|water provision|The experimental group get water every 15 days
88957332|NCT01982994|Experimental|Education/Daily Planning|Physical Activity Education and Daily Planning Tool
88957333|NCT01982994|No Intervention|No Education/Daily Planning|No Physical Activity Education/ Daily Planning Tool
88957334|NCT01983007|Experimental|high-intensity exercise group|Patients undergoing high-intensity exercise group. Intervention: high-intensity exercise.
88957335|NCT01983007|Experimental|low-intensity exercise group|Patients undergoing low-intensity exercise group Intervention: low-intensity exercise
88957336|NCT01983033|Experimental|active treatment condition (ATC)|training protocol 'drop it'
88957337|NCT01983033|Other|waiting list control|no treatment other than treatment as usual
88957338|NCT01983046|Placebo Comparator|placebo|placebo
89539190|NCT03248453|No Intervention|No CoPS feedback|No feedback is given and the participants are not aware of the CoPS
89539191|NCT04946487||group 1|patients in this group destructed the posterior ligamentous complex of the adjacent segment
89539192|NCT04946487||group 2|patients in this group did not destruct the of the posterior ligamentous complex of the adjacent segment
89539193|NCT04946331|Experimental|Control|participants receive no surgical treatment
89539194|NCT04946331|Experimental|Rib Fixation Surgery|participants receive surgical treatment
89539195|NCT03247907|Active Comparator|Condition A: CPAP with No Humidification|CPAP with No Humidification with no mouth leak
89539196|NCT03247907|Active Comparator|Condition B: CPAP with No Humidification|CPAP with No Humidification with mouth leak
89539197|NCT03247907|Active Comparator|Condition C: CPAP with Cold Passover humidifier|CPAP with Cold Passover humidifier with mouth leak
89539198|NCT03247907|Active Comparator|Condition D: CPAP with Modified Humidifier|CPAP with Modified Humidifier with mouth leak
89539199|NCT03247907|Active Comparator|Condition E: CPAP with Ambient Tracking|CPAP with Ambient Tracking with mouth leak
89539200|NCT03247907|Active Comparator|Condition F: CPAP with Heated Humidification|CPAP with Heated Humidification at default setting with mouth leak
89539201|NCT03247907|Active Comparator|Condition G: CPAP with Heated Humidification|CPAP with Heated Humidification at max setting with mouth leak
89539202|NCT03247907|Active Comparator|Condition H: CPAP with New level humidification|CPAP with New level humidification with mouth leak
89539203|NCT04938531|Experimental|Exercise|Exercise, passive
89539204|NCT03247595|Active Comparator|Polyethylene Glycol|Polyethylene Glycol 3350: 4 Liters
89539205|NCT03247595|Experimental|Magnesium Citrate Capsules|36 Magnesium citrate capsules
89539206|NCT04938843|Experimental|F. prausnitzii and D. piger|1 capsule administered once daily 45 minutes before breakfast for 12 weeks
89539207|NCT04938843|Placebo Comparator|Placebo|1 capsule administered once daily 45 minutes before breakfast for 12 weeks
89539208|NCT03247751|Experimental|one group|one group receiving NIDEK intraocular lens
89539209|NCT03247829||Patients with CardioMEMS and LVAD|Patients with CardioMEMS and LVAD, previously implanted, will receive hemodynamic management using CardioMEMS
89539210|NCT04946097|Experimental|study group|received the conventional selected exercise program in addition to gross Myofascial Release
89539211|NCT04946097|Experimental|control group|the control group which received the conventional selected exercise program
89539212|NCT03247439|Experimental|Cartiva|Synthetic Cartilage Implant
88957339|NCT01983046|Active Comparator|high acetate ratio|high acetate ratio
88957340|NCT01983046|Active Comparator|high butyrate ratio|high butyrate ratio
88957341|NCT01983046|Active Comparator|high propionate ratio|high propionate ratio
89539213|NCT03247361|Experimental|High-intensity IMT|"High-intensity IMT + Aerobic/resistance exercise~IMT: Training loads will be adjusted weekly to the maximal inspiratory pressure (MIP). In the first 2 weeks as adaptation, the protocol will be of 2 minutes warm-up with intensity 20% of MIP. The training will have 7 peaks of intensity with 70% of MIP for 30 sec, with 30-sec of passive rest between the peaks, finishing the training with 20% of MIP for 2 min, totaling 10 min and 30 sec. From the third week the protocol will be of 2 min warm-up with intensity 30% of MIP. The training will have 7 peaks of intensity with 70% of MIP for 60 sec, with 60-second of passive rest between the peaks, finishing the training with 20% of MIP for 2 min, totaling 17 min.~Exercise: see group Combined aerobic/resistance exercise"
88957342|NCT01983059||Patients with Liver Venous Thrombosis|
88957343|NCT01983072|Active Comparator|Infant starter formula|standard infant formula
88957344|NCT01983072|Experimental|Infant starter formula + prebiotics + probiotics|infant formula
88957345|NCT01983072|Other|Breastfeeding group|reference group
89539214|NCT03247361|Active Comparator|Low-intensity IMT|"Low-intensity IMT + Aerobic/resistance exercise~IMT:Training loads will be also adjusted weekly to the maximal inspiratory pressure (MIP). In the first two weeks as adaptation, the protocol will be of 2 minutes warm-up with intensity 20% of MIP. The training will be held with 3 sets of 15 repetitions, with 40% of MIP, finishing the training with 20% of MIP for 2 minutes. From the third week the protocol will be of 2 minutes warm-up with intensity 30% of MIP. The training will be held with 3 sets of 15 repetitions, with 60% of MIP, finishing the training with 30% of MIP for 2 minutes.~Exercise: see group Combined aerobic/resistance exercise"
89539215|NCT03247361|Sham Comparator|Aerobic/resistance exercise|"Sham IMT + Aerobic/resistance exercise~Aerobic session will consist of a 4-min of warm-up, 20 minutes of exercise, and 4 min of cool-down. Intensity will set by the formula: Training HR = (maximum HR - resting HR) × intensity % + resting HR. Patients will exercise using 30 seconds, high-intensity work phases 0.7% followed by 1-minute recovery bouts 0.5%. Resistance exercise will consist of dynamic lower and upper limb exercise. Upper limb exercises will include 3 sets of exercises for each muscle group performed with 10 repetitions each. Lower limb exercises will include 3 sets of exercises for each muscle group performed with 12 repetitions each. Resistance exercises will be performed at 12-MR."
89539216|NCT04959045|Experimental|intervention group (Flipped Teaching Method Group)|Intervention group students will be given skill training with the Flipped Teaching method.
89539217|NCT04959045|No Intervention|Control group (Traditional Method Group)|Control group students will receive skill training with the traditional method. No intervention will be made.
89539218|NCT03247283|Experimental|Single Oral Dose of BMS-986205|
89539219|NCT03247127|Other|HA-WBRT|Patients with brain metastases outside a 5-mm margin around either hippocampus and are eligible to this study will receive hippocampal avoidance whole brain radiotherapy 30 gray (Gy) in 10 fractions. The primary endpoint is Wechsler Memory Scale (Chinese) and cognitive abilities screening instrument (CASI) at 4 months.
89539220|NCT04938297|Experimental|Primary CNS Lymphoma，age>65|8 cycles of induction ZR2 , followed by Zanubrutinib or Lenalidomide maintenance for CR/PR fit patients through randomization by 1:1 ration
89539221|NCT04938297|Experimental|Recurrent/refractory primary CNS lymphoma|8 cycles of induction ZR2, followed by Lenalidomide maintenance for CR/PR fit patients.
89539222|NCT04938297|Experimental|Recurrent/refractory diffuse large B-cell lymphoma with CNS invasion|8 cycles of induction ZR2, followed by Lenalidomide maintenance for CR/PR fit patients.
89539223|NCT02454413|Sham Comparator|brush + water|denture brushing with water and soap + overnight storage in water
89539224|NCT02454413|Active Comparator|brush + cleansing tablet|denture brushing with water and soap + overnight storage in water with a cleansing tablet
89539225|NCT02454413|Sham Comparator|ultrasonic cleaning + water|ultrasonic denture cleaning + overnight storage in water
89539226|NCT02454413|Active Comparator|ultrasonic cleaning + cleansing tablet|ultrasonic denture cleaning + overnight storage in water with a cleansing tablet
89539227|NCT03057873|Experimental|High protein, high fiber|Participants receive a high protein, high fiber dietary supplement twice daily (30 minutes before breakfast and lunch) for 12 weeks
89539228|NCT03057873|Placebo Comparator|Low protein, low fiber|Participants receive a low protein, low fiber supplement twice daily (30 minutes before breakfast and lunch) for 12 weeks
89539229|NCT03246815||universal opt-out screening for STDs|Patients who present to primary care practices who employee a universal opt-out strategy to medical assistants or nurses
89539230|NCT03246815||without universal opt-out screening for STDs|Patients who present to primary care practices who do not employee a universal opt-out strategy to medical assistants or nurses
89539231|NCT04945551|Experimental|Diabetes|Aerobic exercise training
89539232|NCT04945551|Experimental|Healthy|Aerobic exercise training
89539233|NCT03246893|Placebo Comparator|Noninvasive positive pressure ventilation|After extubation, patient will receive non invasive positive pressure ventilation (NIV) for prevent respiratory and reintubation
89539234|NCT03246893|Experimental|High flow oxygen nasal cannula|After extubation, patient will receive high flow oxygen cannula for prevent respiratory and reintubation
89539235|NCT04421937|Experimental|Neuromuscular Electrical Stimulation (NMES) with TDT|
89539236|NCT04421937|Active Comparator|Traditional Dysphagia Therapy (TDT)|
88957346|NCT01983085|Other|SPT Burn Wound|Each wound will be divided into 2 with half the wound being treated with the NOx dressing and the other half with standard of care
88957347|NCT01983085|Other|SPT graft donor site|Each wound will be divided into 2 with half the wound being treated with the NOx dressing and the other half with standard of care
88957348|NCT01983124|Experimental|Fotemustine + Vemurafenib|Fotemustine 100 mg/m2 q21 + Vemurafenib gelatin capsules supplied as 240-mg strengths. Vemurafenib will be administered continuous oral dosing at 960 mg twice daily or dose administered at time of disease progression with Vemurafenib previous treatment.
88957349|NCT01983150|Experimental|Crush the Crave Application|Crush the Crave (CTC) intervention group will receive a quit smoking smartphone intervention via the internet that is based on scientific findings related to tobacco use among young adults. It is a multi-component intervention informed by evidence on quitting smoking. The app was developed with the input of key experts in the field of smoking cessation, was assessed against Fiore's practice guidelines for treating tobacco use and dependence, and was tested with eight focus groups of male and female young adult smokers (n=57) on functionality, look and feel and usability, as well as being piloted by over 300 smokers.
88957350|NCT01983150|Active Comparator|On the Road to Quitting - Self Help|"The control group will receive an evidence-based self-help guide known as On the Road to Quitting(45) that has been developed by Health Canada for young adult smokers. Participants will be able to both view the self-help guide via the internet and will receive a printed version of the guide."
88957351|NCT01983163|Active Comparator|ketogenic diet|ketogenic diet (2.5 to 4:1)
88957352|NCT01983163|Active Comparator|Modifid Atkin's diet|Modified Atkin's Diet
88957353|NCT01983189|Experimental|Low frequency rTMS|low frequency, repetitive transcranial magnetic stimulation (rTMS) for 20 minutes daily, 5 times a week for 3 weeks
89023786|NCT04732052|Sham Comparator|Sham tDCS|Sham Transcranial Direct Current Stimulation: Soterix tDCS kit will be used to deliver the sham stimulation using two sponge electrodes soaked in a saline solution. The sham stimulation montage will comprise of left anodal Dorsal Lateral Prefrontal cortex (DLPFC) stimulation for 10s only. The anodal electrode will be placed over the area corresponding to the left DLPFC (F5 of the EEG10-20 international system) and the reference (cathodal) electrode over the right supraorbital ridge. The sham tDCS is identical to the active tDCS except that the current will be delivered only in the first 10 seconds, after which the stimulation will cease but with the electrodes still in place throughout the session. The duration of each sham tDCS session will be 20 minutes.
89539237|NCT03246737||pregnant women|
89539238|NCT03246971|Experimental|Wafermine™|
89539239|NCT03246971|Placebo Comparator|Placebo|
89539240|NCT02625909|Experimental|Drug: SOF/VEL for 6 weeks|Open-label SOF/VEL 400mg/100mg co-formulated tablet once daily will be given to participants who are randomised into the short treatment duration arm (A) for 6 weeks.
89539241|NCT02625909|Experimental|Drug: SOF/VEL for 12 weeks|Open-label SOF/VEL 400mg/100mg co-formulated tablet once daily will be given to participants who are randomised into the standard treatment duration arm (B) for 12 weeks.
89539242|NCT03246659|Experimental|arm 1|111In-CP04
89539243|NCT03246659|Experimental|arm 2|111In-CP04 with co-administration of gelofusine/gelaspan
89539244|NCT04945005||Lead implantation with transesophageal echocardiography|All patients undergoing pacemaker/CRT implantation with concomitant transesophageal echocardiography in addition to fluoroscopic guidance
89539245|NCT04945005||Lead implantation without transesophageal echocardiography (retrospective)|All patients undergoing standard pacemaker/CRT implantation guided by fluoroscopy only (retrospective historical control group)
89539246|NCT03246581|Experimental|Test Product|tiotropium pMDI 2 inhalations
89539247|NCT03246581|Active Comparator|Commercial Product|tiotropium pMDI 2 inhalations
89539248|NCT03246269||MoCA cohort|The German MoCA is administered once to all study participants.
89539249|NCT04937985||UULEX Test Group|Patients with chronic neck pain
89539250|NCT04938063||Cerebral palsy children|Sample size estimation was carried out to determine the recruited number of the diplegic CP children from the outpatient clinic at the Faculty of Physical Therapy, Cairo University, Physical Therapy Department at the National Institute of Neuromotor Disorder, Abu El-Reesh Hospital, and private physiotherapy clinics. The age of patients will range from 18 months to 5 years old. Both sexes will participate in this study
89539251|NCT03246113|Experimental|Cannabis + Chemoradiation|Patients will receive a cannabis strain with high cannabidiol (4.8%) and low Delta-9-THC (3.23%). Patients will smoke the cannabis over a 2 hour session (from 0.5 - 2.0 cannabis cigarettes) before receiving chemoradiation therapy with radiation and concurrent temozolomide.
89539252|NCT04937673|Experimental|Camrelizumab+ Paclitaxel+ Cisplatin|The subjects were randomly divided into the group of camrelizumab combined with paclitaxel and cisplatin or the group of camrelizumab combined with albumin bound paclitaxel and cisplatin according to the ratio of 1:1. Esophageal cancer resection was performed after 3 cycles of medication (the researchers decided the follow-up treatment according to the postoperative pathological situation). At the end of the treatment, the patients were followed up for safety and effectiveness.
89539253|NCT04937673|Experimental|Camrelizumab+ Albumin bound paclitaxel+ Cisplatin|The subjects were randomly divided into the group of camrelizumab combined with paclitaxel and cisplatin or the group of camrelizumab combined with albumin bound paclitaxel and cisplatin according to the ratio of 1:1. Esophageal cancer resection was performed after 3 cycles of medication (the researchers decided the follow-up treatment according to the postoperative pathological situation). At the end of the treatment, the patients were followed up for safety and effectiveness.
89539254|NCT03245957||Ischemic stroke|Patients with ischemic stroke diagnosed by MRI or CT scan
89539255|NCT03245957||Haemorrhagic stroke|Patients without haemorrhagic stroke diagnosed by MRI or CT scan
89539256|NCT03245957||Mimick stroke|Patients without haemorrhagic or ischemic stroke diagnosed by MRI or CT scan
89539257|NCT03245879|Active Comparator|Program 1|Implementation of a basic antibiotic stewardship program focusing on education, access to Infectious Diseases physicians, and availability of antibiotic use data.
89539258|NCT03245879|Active Comparator|Program 2|This arm increases antibiotic stewardship education and interventions. Program 2 hospitals performed audit and feedback of pre-specified antibiotics and implemented locally controlled restrictions.
89539259|NCT03245879|Active Comparator|Program 3|This arm was the most intensive antibiotic stewardship intervention. It included signficant audit and feedback, ID controlled restrictions, and ID review of designated culture/lab results.
89539260|NCT04958343||reconstruction group|Patients will receive pelvic reconstruction following radical cystectomy during the operation.
89539261|NCT04958343||non-reconstruction group|Patients will not receive pelvic reconstruction following radical cystectomy during the operation.
89539262|NCT02454335|Active Comparator|Anterior Approach|For the anterior approach, an incision will be made in the 1 to 2 o'clock position of the esophageal wall.
89539263|NCT02454335|Active Comparator|Posterior Approach|For the posterior approach, a mucosal incision will be made at the 5 to 6 o'clock position
89539264|NCT04937439|Experimental|Segmental trunk training A|Children in this group will receive specially designed physical therapy program while wearing a segmental trunk support from the level of pelvis to a level just below the rib cage.
89539265|NCT04937439|Active Comparator|Segmental trunk training B|Children in this group will receive the same program given to (group A) while wearing a segmental trunk support from the level of pelvis to a level just below the inferior angle of scapula.
89539266|NCT04937439|Active Comparator|Segmental trunk training C|will receive the same program given to (group A and B) while wearing a segmental trunk support from the level of last rib to the level of the inferior angle of scapula.
89539267|NCT03245567|Experimental|Pre, post, delayed test|Participants will not do the PLM, but will perform a pretest, a posttest and a delayed test at 6 months
89539268|NCT03245567|Experimental|PLM group (pre, post, delayed test, PLM)|Participants will do a pretest, the PLM, a posttest and a delayed test at 6 months
89539269|NCT04944381|Experimental|SARS-Cov-2 mRNA vaccine immunization group|The 98 participants will be inoculated with one dose SARS-Cov-2 mRNA vaccine from Stemirna Therapeutics Co., Ltd.
89539270|NCT04944381|Experimental|Inactivated SARS-Cov-2 vaccine immunization group|The 14 participants will be inoculated with one dose inactivated SARS-Cov-2 vaccine from institute of medical biology, Chinese academy of medical sciences(IMBCAMS).
89539271|NCT03245177|Experimental|Pembrolizumab plus radiotherapy|Pembrolizumab is given by intravenous infusion over 30 minutes at a maximum dose of 200mg. The first dose of pembrolizumab is administered 14 days prior to the initiation of radiotherapy and every 3 weeks thereafter. Radiotherapy is given as a standard dose (60-66 Gy in 2 Gy/fraction) over 40-45 days (daily on Mon-Fri) Following completion of radiotherapy, participants will continue to receive pembrolizumab every 3 weeks for up to 12 months of maintenance treatment.
89539272|NCT03245333|Experimental|Stage 1-experimental group|JINTOPIN AQ 0.2IU/kg/d（0.46mg/kg /wk）, for 52 weeks.
89539273|NCT03245333|Other|Stage 1-negative control|observed only for 52 weeks.
89539274|NCT03245333|Experimental|Stage 2-experimental group|After completing the stage 1, experimental groups is administrated the appropriate dose of JINTOPIN AQ, the highest dose should be no more than 0.2IU/kg/d, from the 53rd week to the final height.
89539275|NCT03245333|Other|Stage 2-negative control|After completing the stage 1, negative control groups is administrated the appropriate dose of JINTOPIN AQ, the highest dose should be no more than 0.2IU/kg/d, from the 53rd week to the final height.
89539276|NCT04944537||ICU management for patients with severe trauma|Group to investigate the current status of ICU management for patients with severe trauma
89539277|NCT03245255|Experimental|Sonazoid for pressure measurements|48 µl of Sonazoid microbubbles (GE Healthcare, Oslo, Norway) will be co-infused at a rate of 0.024 µl/kg body weight/minute together with a 0.9% sodium chloride solution infused at a rate of at least 2 ml/min.
89539278|NCT03244787|Experimental|patient navigation|PN will contact patients during their visits to health cancer or over the phone. During this initial contact, the PN will educate patients about CRC, screening and explore their barriers to screening. The PN will coordinate scheduling of CRC screening and remind patients about the tests. PN will explain preparation for colonoscopy and whenever feasible, accompany patient to obtain the test. Further interventions may include: reminding the patient about the test, helping with translation, insurance issues, transportation, and overcoming any other system barriers as needed.
89539279|NCT03244787|No Intervention|usual care|patients randomly assigned to the control will receive usual care and be eligible for navigation after the study period.
89539280|NCT04937049|Experimental|EMAeHealth digital tool|This team has designed a digital tool called EMAeHealth involving healthcare professionals. It is organized into 4 areas: 1) an Information area, 2) a Communication area, 3) a Health Self-management area, 4) a Clinical data area, The tool is conceived as a complement that can reinforce maternal health education with resources that facilitate its accessibility, and rapid remote response, which will also improve its results. It will be incorporated into the Osakidetza-Basque Health Service corporate Website.
89539281|NCT04937049|No Intervention|No EMAeHealth digital tool|Usual care. This group, like experimental group, receives the usual care, which includes traditional maternal education, but does not receive the EMAeHealth intervention
89539282|NCT03244631|Active Comparator|Lumbar Plexus Block|"A lumbar plexus 'nerve block' is a procedure in which local anesthetic (numbing medicine) is injected around a specific group of nerves to provide pain relief directly to the nerves supplying the area of the body undergoing surgery."
89539283|NCT03244631|Active Comparator|Pericapsular Injection|"The pericapsular injection is a procedure in which local anesthetic (numbing medicine) is injected around the hip joint to provide direct pain relief to the area undergoing surgery."
89539284|NCT04932993|No Intervention|Standard care|Will not write down goals their goals for their medical care (usual care).
89539285|NCT04932993|Experimental|Writing down goals|Will write down goals their goals for their medical care.
89539286|NCT03244709|Experimental|Patients with GCA (ACR 1990 criteria)|"At diagnosis, all GCA patients with or without involvement of aorta and its thoracic branches will receive PDN 50 mg/day and TCZ 8 mg/Kg/iv monthly. In all patients PDN dose will be reduced of 10 mg every 2 weeks until interruption at week 12.~Week 12. Subcutaneous TCZ 162 mg/weekly will be administered for additional 12 weeks.~Week 24. TCZ tapering every 8 weeks as follows:~1 injection every 2 weeks~1 injection every 3 weeks~1 injection every 4 weeks Week 48. TCZ withdrawal. Week 72. Remission evaluation."
89539287|NCT04409145|Experimental|VT30|VT30 is a PI3K-inhibitor prodrug, formulated as a topical gel and dispensed from a metered dose pump; administration is once or twice daily, applied to target-treatment area(s) on the skin. One pump action dispenses 250 µL of gel, intended to treat an area of 140 cm2.
89023787|NCT04730271|Active Comparator|Manual Arm|Subjects enrolled into this arm of the study will receive an ATTUNE primary total knee replacement that has been implanted using manual instrumentation which is the current standard of care at the participating sites.
89539288|NCT03244943|Other|Non surgical periodontal treatment|The NSPT, which consisted of subgingival debridement - scaling and root planning (SRP) under local anesthesia.
89539289|NCT04958187|Experimental|ANG-3777|Administered IV as a single dose over 30 minutes on Day 1, greater than 24 hours before receiving scheduled hemodialysis (HD).
89539290|NCT03244319|Experimental|Edoxaban|
89539291|NCT03244319|Active Comparator|Warfarin|
89539292|NCT03244553|Experimental|Active intervention|Prucalopride for 5 days. Dosage: day 1 2mg, days 3-5 4mg
89539293|NCT03057327|Active Comparator|comparator|As women exit the changing are they will be asked if they regularly check their skin for concerning moles
89539294|NCT03057327|Experimental|Improve awareness of checking moles|Posters, brochures, and skin self-examination kits consisting of a ruler, and a lighted magnifying lens will be placed into each of the 8 changing rooms in the mammogram facility.
89539295|NCT03244397|Experimental|PT group|"The participants assigned to this group will receive 16 sessions of physical therapy. Each session will last 45/50 minutes, 2 sessions a week for 8 weeks.~A directly pelvic floor muscle(PFM) training protocol will be applied. Throw vaginal palpation and in lithotomy position, participants will perform PFM exercises per the treatment proposed by the PERFECT scheme. Biofeedback exercises will be also performed in lithotomy position. Hypopressive exercises which are also home daily from the eighth session. Plus educational strategy."
88957354|NCT01983202||Women with PCOS|208 women diagnosed with PCOS and giving birth after singleton pregnancies at Odense University Hospital during 2003-2011.
88957355|NCT01983202||Controls|1040 women giving birth after singleton pregnancies at Odense University Hospital during 2003-2011, matched 1:5 to women with PCOS according to date-of-childbirth.
89539296|NCT03244397|Active Comparator|Control group|Only educational strategy 1 session per week for 6 weeks (every session will last 40/45 minutes). The educational strategy will consist of instruction of printed materials and dimensional anatomical models about the anatomy of the pelvic floor and the physiology of the pelvic organs. It will be recommended to avoid risk factors, such as gaining weight, weight lifting, high impact sports, constipation, smoking, or drinking too much caffeine. They will be also instructed in toilet habits, and will be taught to use the knack maneuver before and during increases of intra-abdominal pressure.
89539297|NCT03244241|Active Comparator|Intervention|Basal-bolus insulin regime with Insulin Degludec and insulin aspart
89539298|NCT03244241|No Intervention|Standard|Standard treatment according to hospital guidelines with sliding scale insulin
89206770|NCT00954837|Other|Fine needle aspiration|Patient with solid nodules more than 10 mm in diameter will be biopsied by ultrasound-guided fine-needle aspiration(FNA)after consultation with an endocrinologist or ENT specialist.
89539299|NCT04932837||migrant worker residents|The target population will be the 124 residents in the 2 migrant worker residences who were included in the previous seroprevalence study and those who arrived at the 2 residences since September 1st, 2020
89539300|NCT04937205||Cohort 2|This group of study participants started the 52-week parent randomized controlled trial (NCT03411356) on February 13, 2019.
89539301|NCT04937205||Cohort 3|This group of study participants started the 52-week parent randomized controlled trial (NCT03411356) on November 5, 2019.
89539302|NCT04937205||Cohort 4|This group of study participants started the 52-week parent randomized controlled trial (NCT03411356) on October 22, 2020.
89539303|NCT03244085|Experimental|100 mg BID|Drug: QL-007 tablet; Tablet QL-007 will be administered orally daily (100 mg two times a day) over the 28 days under fasted state. Patients fast for 2h before administration and 1h after administration.
89539304|NCT03244085|Experimental|200 mg BID|Drug: QL-007 tablet; Tablet QL-007 will be administered orally daily (200 mg two times a day) over the 28 days under fasted state. Patients fast for 2h before administration and 1h after administration.
89539305|NCT03244085|Experimental|600 mg QD|Drug: QL-007 tablet; Tablet QL-007 will be administered orally daily (600 mg once a day) over the 28 days under fasted state. Patients fast for 2h before administration and 1h after administration.
89539306|NCT03243929|Experimental|Intervention|All participants in the Translation of District Sun Safe Policies to Schools arm received 1) initial coaching meeting that guided principals through an evaluation of current sun safety practices, the selection of goals for the implementation of sun safety practices, and guidance on the use of intervention materials to support implementation of sun safety practices in the school, 2) follow-up communications from coaches including email, telephone, and virtual meetings, 3) access to media and online resources to support implementation of sun safety practices, 4) mini-grants to support changes in school sun safety practices.
89539307|NCT03243929|Other|Attention Control|All participants in the attention control arm received three emails during the 20 month intervention period including (1) NASBE's Fit Healthy and Ready to Learn; A School Health Guide Part II: Policies to Promote Sun Safety and Prevent Skin Cancer, (2) CDC's Guidelines for Sun Safety to Prevent Skin Cancer, and (3) a link to the Surgeon General's 2014 Call to Action to Prevent Skin Cancer. This attention-control treatment will equalize schools on awareness of recommendations to implement school sun safety.
89539308|NCT03243851|Experimental|Temozolomide+metformin|"Temozolomide :~1 cycle of 4 weeks with daily dose 50mg/m2(BSA: Body Surface Area) up to 6 cycles for 24 weeks~Metformin :~1st cycle (4 weeks)~1 week(1st~7th day) = 1,000mg/day~1 week(8th~14th day) = 1,500mg/day~2 weeks(15th ~28th day) = 2,000mg/day~2nd to 6th cycle (20 weeks) = 2,000mg/day"
89539309|NCT03243851|Placebo Comparator|Temozolomide+placebo|"Temozolomide :~1 cycle of 4 weeks with daily dose 50mg/m2(BSA: Body Surface Area) up to 6 cycles for 24 weeks~Placebo:~1st cycle (4 weeks)~1 week(1st~7th day) = 1,000mg/day~1 week(8th~14th day) = 1,500mg/day~2 weeks(15th~28th day) = 2,000mg/day~2nd to 6th cycle (20 weeks) = 2,000mg/day"
88957356|NCT01983215|Experimental|negative pressure dressing vs. standard of care|single arm study- randomized Prevena vac or standard of care
88957357|NCT01983267|Active Comparator|cannabis|Patient using cannabis during chemotherapy treatment
88957358|NCT01983267|No Intervention|control|Patients under chemotherapy treatment
88957359|NCT01983280|Experimental|Healing Touch|
88957360|NCT01983319|Experimental|CIMT + active anodal tDCS|Subjects in this group will be trained with constraint-induced movement therapy for the hand (10 consecutive sessions Monday- Friday) while concurrently receiving active anodal transcranial Direct Current Stimulation 1,5 mA for 30 min.
88957361|NCT01983319|Sham Comparator|CIMT + sham tDCS|Subjects in this group will be trained with constraint-induced movement therapy for the hand (10 consecutive sessions Monday- Friday) while concurrently receiving sham transcranial Direct Current Stimulation
88957362|NCT01983319|No Intervention|Healthy control subjects|20 healthy age-matched control subjects will undergo MRI spectroscopy of the brain.
89206771|NCT05351931|Active Comparator|SPC-flakes with or without Salovum|SPC-flakes flat dose of 75 g/d divided in 2 - 4 doses started 5 days prior to start of RCT and continued during the RCT. Salovum egg powder 4 g/sachet. Four sachets, ie 16 g q 8 h for 5 days prior to start of RCT. The appropriate amount of Salovum is mixed with 100 - 200 ml of suitable liquid, eg fruit juice, and ingested orally.
88957363|NCT01983332||occupational therapists|Occupational Therapists
88957364|NCT01983345|No Intervention|Control|No prenatal surgical repair of myelomeningocele
88957365|NCT01983345|Experimental|Case - open surgical repair|Prenatal surgical repair of fetal myelomeningocele
88957366|NCT01983358|Experimental|JPI-289|Each cohort, volunteers will be infused JPI-289 through I.V for 30 min.(6 volunteers per each cohort, total 7 cohort)
88957367|NCT01983358|Placebo Comparator|Placebo|Each cohort, volunteer will be infused placebo through I.V for 30 min.(2 volunteers per each cohort, total 7 cohort)
88957368|NCT01983371|Experimental|Ferumoxytol-enhanced MRI|This is a single-arm study. All enrolled patients will have a ferumoxytol-enhanced MRI scan.
89539310|NCT02623959|Experimental|Indwelling Pleural Catheter (IPC) + Saline|"Symptom and quality of life questionnaires completed at baseline and at 10 - 14 days after receiving Saline. Participant given a Fentanyl patch which should be worn at follow up visit 5 days after IPC placement. Fentanyl patch then be removed and Fentanyl by vein given prior to catheter draining. Study staff drains the IPC and places Saline in the catheter.~After the IPC is removed, participant is called one time each month by study staff to check on their status."
89539311|NCT02623959|Active Comparator|Indwelling Pleural Catheter (IPC) + Doxycycline|"Symptom and quality of life questionnaires completed at baseline and at 10 - 14 days after receiving Doxycycline. Participant given a Fentanyl patch which should be worn at follow up visit 5 days after IPC placement. Fentanyl patch then be removed and Fentanyl by vein given prior to catheter draining. Study staff drains the IPC and places Doxycycline in the catheter.~After the IPC is removed, participant is called one time each month by study staff to check on their status"
89539312|NCT02454023|Active Comparator|Standard of care|Patients receive usual standard of care for investigating obstructive sleep apnea after stroke/transient ischemic attack, which is in-laboratory polysomnography.
89539313|NCT02454023|Experimental|Portable sleep monitor (ApneaLink Air)|Patients will undergo screening for obstructive sleep apnea using the ApneaLink Air portable sleep monitor.
89539314|NCT04936503|Experimental|High-level athletes|"High level athletes are rugby players, intervention unit agents of the National Police, sports students.~Definition of a COVID-19 positive subject : Any subject whose serology is positive (IgM and/or IgG) and/or the Reverse Transcription Polymerase Chain Reaction (RT-PCR) result is positive and/or the questionnaire is positive and/or a new electrocardiogram (ECG) abnormality.~The COVID-19 negative subjects do not meet the definition of COVID-19 positive subjects."
89539315|NCT03244007||Eyes with residual fragment|The eyes with residual fragments detected with intraoperative optical coherence tomography
89539316|NCT03244007||Eyes without residual fragment|The eyes without residual fragments detected with intraoperative optical coherence tomography
89539317|NCT03243617|Active Comparator|AO+Mist|Cosmetic Product AO+Mist
89539318|NCT03243617|Placebo Comparator|Placebo|Placebo
89539319|NCT04936659|Experimental|Treatment group|
89539320|NCT03243695|Experimental|Angled abutment|According to the allocation, the experimental group will receive an angled abutment on the immediately placed implant. A vaccum stent will be used to fabricate a temporary crown using tooth colored auto-polymerizing resin(structur 2 SC/ QM , VOCO GmbH, Germany)
89539321|NCT03243695|Active Comparator|Straight abutment|According to the allocation, the control group will receive on the immediately placed implant a Straight zero degree abutment . A vaccum stent will be used to fabricate a temporary crown using tooth colored auto-polymerizing resin(structur 2 SC/ QM , VOCO GmbH, Germany)
89539322|NCT04957797|Other|ROT-Group|reamed with round tunnel
89539323|NCT04957797|Experimental|FLT-Group|reamed with flat tunnel
89539324|NCT04936347|Experimental|Cold knife|The interference of the experimental group is to perform intrauterine adhesiolysis with scissors
89539325|NCT04936347|Other|Hot knife|The interference of the control group is to perform intrauterine adhesiolysis with bipolar electric needle electrode, part of the scar tissue removed by electronic loop when it is necessary.
88957369|NCT01983384|Placebo Comparator|Anesthetic Depth: standard care|A cohort of older patients undergoing major non-cardiac surgery will be randomized to receive routine anesthetic management not guided by the processed electroencephalogram
88957370|NCT01983384|Experimental|Anesthetic Depth: interventional|A cohort of older patients undergoing major non-cardiac surgery will be randomized to receive anesthetic management guided by the processed electroencephalogram (processed EEG-guided anesthetic depth)
88957371|NCT01983397|Experimental|Resistance training|Resistance training
88957372|NCT01983397|Experimental|Multicomponent training|Multicomponent training
88957373|NCT01983397|No Intervention|Control Group|The Control Group did not realize any intervention.
88957374|NCT01983423|Experimental|Endometrial Biopsy|Endometrial biopsy performed within 5-10 days prior to starting controlled ovarian stimulation, as part of in vitro fertilization treatment.
88957375|NCT01983423|No Intervention|Without Biopsy|Those proceeding with in vitro fertilization routinely, without an endometrial biopsy.
89539326|NCT03243227|Experimental|Neurodynamic techniques|4 sessions of Neurodynamics treatment will be provided by an experienced physiotherapist. It will include manual therapy, median nerve gliding exercise, median nerve tension exercise. patients will continue the exercises as home exercise program during and after the treatment period.
89539327|NCT03243227|Active Comparator|Exercise|Exercise therapy 4 sessions of exercise treatment will be provided by an experienced physiotherapist. It will include active range of motion, stretching, and strengthening exercise. patients will be given a brochure to continue the exercises as home exercise program during and after the treatment period.
89539328|NCT03243383|No Intervention|Low-risk Group|Low-risk as determined by the predicted risk of readmission by the DERRI. The low-risk group will be followed in a prospective, observational arm of the study.
89539329|NCT03243383|Experimental|High-risk Group - Intervention|High-risk as determined by the predicted risk of readmission by the DERRI. Subjects in the high-risk group will be randomly assigned to receive either the intervention (DiaTOHC Program) or usual care (control).
89539330|NCT03243383|No Intervention|High-risk Group - Usual Care|Patients in the high-risk usual care group will receive the standard hospital discharge process and post-discharge followup.
89539331|NCT04957563|Experimental|experimental rehabilitation|recived olfactory rehabilitation
89539332|NCT04957563|No Intervention|control|withouth olfactory rehabilitation
89539333|NCT03242993|Experimental|treatment group|"all patients successfully enrolled will be assigned to the treatment group:~1 mg folic acid (corresponding to 0.2 mL Folarell®) will be injected 5 min prior to [18F]-AzaFol"
89539334|NCT04957407||non-atrophic gastritis|OLGA-0 group；OLGA (Operative Link on Gastritis Assessment)
89539335|NCT04957407||mild-moderate atrophic gastritis|OLGA I-II group；OLGA (Operative Link on Gastritis Assessment)
89539336|NCT04957407||severe atrophic gastritis|OLGA III-IV group；OLGA (Operative Link on Gastritis Assessment)
89539337|NCT04957407||gastric cancer|gastric cancer
89539338|NCT04487093|Experimental|neoantigen vaccine + EGFR-TKI|
89539339|NCT04487093|Experimental|neoantigen vaccine + anti-angioge|
88957376|NCT01983436|Experimental|Manual Lymphatic Drainage|"9 daily sessions of manual lymphatic drainage (except on Saturday/Sunday) starting at Day 1 after surgery.~4 more sessions (one every two days)."
88957377|NCT01983436|No Intervention|Control|No session of manual lymphatic drainage
88957378|NCT01983449|Experimental|Adventitial Dexamethasone|In patients receiving either angioplasty or atherectomy-based revascularization (pre-stratified to each by 50% of the total study), dexamethasone will be delivered to the adventitia following revascularization.
88957379|NCT01983475|Placebo Comparator|Placebo|A group of participants will be randomized to the placebo group and will receive the identical volume of normal saline at parallel time points.
88957380|NCT01983475|Experimental|Denosumab|A group of participants will be randomized to the experimental group and will have Denosumab (Prolia, 60 mg SC) administered at baseline, 6 and 12 months.
88957381|NCT01983488||Uveitis|Patient with a clinical diagnosis of Uveitis.
89206772|NCT05351931|Placebo Comparator|SPC-flakes placebo with or without Salovum placebo|SPC-placebo flat dose of 75 g/d divided in 2 - 4 doses started 5 days prior to start of RCT and continued during the RCT. Salovum placebo egg powder 4 g/sachet. Four sachets, ie 16 g q 8 h for 5 days prior to start of RCT. The appropriate amount of Salovum placebo is mixed with 100 - 200 ml of suitable liquid, eg fruit juice, and ingested orally.
89206773|NCT05351697|Experimental|BR105|BR105 infusions will be administered weekly 21 days after the initial dose
89506206|NCT05790603|Experimental|Medium pressure group|This group will use the radial artery hemostatic device with quantitative pressure which will be the new patent product made by Shandong Weigao Group Medical Polymer Products Co. LTD,China. The compression pressure on radial artery after PCI was 125% of upper arm systolic BP measured preoperatively. Pressure will be released by 5% hourly until the bleeding is stopped.
89506207|NCT05790603|Experimental|High pressure group|This group will use the radial artery hemostatic device with quantitative pressure which will be the new patent product made by Shandong Weigao Group Medical Polymer Products Co. LTD,China. The compression pressure on radial artery after PCI was 130% of upper arm systolic BP measured preoperatively. Pressure will be released by 6% hourly until the bleeding is stopped.
89506208|NCT05790603|Active Comparator|Control group|The control group will use the radial artery hemostatic device named by Radial Pressure Hemostat made by Rayon Medical Corporation,Japan (hemostatic device traditionally used in Peking University First Hospital). Pressure will be released hourly based on medical staff's experiences until the bleeding is stopped.
89506209|NCT05790564|Active Comparator|Almonds|Daily consumption of 2 ounces of unsalted, dry roasted almonds for 12 weeks
89506210|NCT05790564|Placebo Comparator|Crackers|Daily consumption of non-whole grain crackers for 12 weeks (caloric equivalent to 2 ounces of dry roasted almonds)
89506211|NCT05790538||Observational (survey, assessment, instrumented socks, activity monitor)|Patients complete surveys and clinic assessments at baseline, every 4-6 weeks during chemotherapy, and every 3 months for 1 year after completion of chemotherapy. Clinic assessments include tests of neuropathy, upper and lower body strength, balance, and mobility. Patients complete weekly symptom surveys and wear instrumented socks and an activity monitor at regular intervals at home during chemotherapy treatment and for 1 year after completion of chemotherapy. Patients' medical records are also reviewed.
89506212|NCT05790447|Experimental|Intervention group|"A treatment cycle includes:~Loading dose with thymalfasin was administrated based on the absolute number of T lymphocytes.~Radiotherapy (5 or 8Gy three fractions)was administrated to a metastatic lesion GM-CSF 200ug was subcutaneous injected for seven days from the first day of radiotherapy PD-1/L1 inhibitor was intravenous injected within one week after radiotherapy"
89506213|NCT05790434||Cases|Patients with septic arthritis
89506214|NCT05790434||Controls|Patients with osteoarthritis, rheumatoid arthritis
89506215|NCT05790395|Experimental|Intervention group|The participants will also be given a Practical Resource Hub for Healthy Life leaflet containing information on various applications. The participants will receive a brief telephone intervention using the Ask, Warn, Advise, Refer and Do-it-again (AWARD) model. For the advice step, the research assistant will ask about the priority the participants place on engagement in desirable health-related lifestyle practices identified in the completed behavioural risk factor survey. The participants will also be asked to choose the goal that they consider easiest to achieve, such as quitting or reducing smoking, consuming more vegetables or less fatty foods or sugary drinks, performing more exercise or reducing alcohol consumption. The participants will be encouraged to quit health-risk behaviours (or adopt a healthy lifestyle) sequentially, but they will also be able to choose to quit them simultaneously if they are confident in doing so.
89506216|NCT05790395|Placebo Comparator|Control group|The control group participants will also be given a Practical Resource Hub for Healthy Life leaflet containing information on various applications. However, the health ambassadors will simply advise the participants to modify their health-risk behaviours and/or adopt a healthy lifestyle practice. The participants will also receive follow-up for outcome assessments with the same schedule as those in the intervention group.
89506217|NCT05790382|Experimental|NM-101|Ascending doses of NM-101. IV infusion over 2 hours
89506218|NCT05790382|Placebo Comparator|Placebo|IV infusion over 2 hours
89506219|NCT05790356|Experimental|Fecal Microbial Transplant|Participants will be administered 35-40 FMT capsules orally with water, for a total dose of 80-100g. This will only occur once and takes approximately 30 minutes.
89506220|NCT05790356|Placebo Comparator|Placebo|Participants will be administered 35-40 placebo capsules orally with water. This will only occur once and takes approximately 30 minutes.
89506221|NCT05790330||Severe eczema|Patients aged 5-18 who have been diagnosed with atopic eczema and require starting systemic therapy.
89506222|NCT05790330||Less severe eczema|Patients aged 5-18 who have been diagnosed with atopic eczema and require topical steroid therapy only.
89506223|NCT05790330||Healthy controls|Patients ages 5-18 who do not have atopic eczema.
89539340|NCT04936269||Group 1|Children under five years old
89539341|NCT03242837|Experimental|Army Resilience Training|Resilience training: four training sessions of 90 minutes each (in week 3, 5, 6 and 7 of military training), in classroom, psychoeducational inputs on stress management and resilience related topics, cognitive behavioral interventions and moderated exercises
88957382|NCT01983501|Experimental|Tucatinib (ONT-380) in combination with T-DM1|
89539342|NCT03242837|Active Comparator|Diversity Management Training|Diversity Management: four training sessions of 90 minutes each (in week 3, 5, 6 and 7 of military training), classroom, psychoeducational inputs on social awareness and exercises
89539343|NCT03242681|Experimental|Endoscopy Assisted Probing|Endoscopy Assisted Probing
89539344|NCT03242681|Active Comparator|Simple Probing|Simple Probing
89539345|NCT03242525||Emergency room|Twelve bleeding patients who are assigned to the emergency department receive a simultaneous blood analysis with POCT and central laboratory.
89539346|NCT03242525||Delivery room|Twelve bleeding patients who are assigned to the delivery room receive a simultaneous blood analysis with POCT and central laboratory.
89539347|NCT03242603|Experimental|Anti-GD2 in combination with NK cells|This is a single arm study. Patients with high risk neuroblastoma who have residual measurable disease will receive a combination of 5 days of anti-GD2 with expanded activated NK cells.
89539348|NCT04931433|Experimental|Lignocaine|This arm will receive intravenous Lignocaine bolus and infusion
89539349|NCT04931433|Placebo Comparator|Placebo|This arm will receive Normal saline 0.9% bolus and infusion
89539350|NCT03242369|Experimental|PEG group|100 patients undergoing colonoscopy.
89539351|NCT03242369|Experimental|SBS group|100 patients undergoing colonoscopy
89539352|NCT03242369|Experimental|PEG 2L + ascorbic acid group|100 patients undergoing colonoscopy.
89539353|NCT03242369|Experimental|PICO group|100 patients undergoing colonoscopy.
89539354|NCT03242291|Active Comparator|conventional resin-based flowable composite|
89539355|NCT03242291|Other|Hydroxyapatite Nanofiber reinforced flowable composite|
89539356|NCT04486937|Experimental|SC10914|400mg TID，oral admination on an fasting state
89539357|NCT03242213|No Intervention|Usual Care|Standard of Care
89539358|NCT03242213|Active Comparator|Mobile App|Standard of Care and Mobile App
89539359|NCT04931121||Osteoarthritic patients|Subjects are patients referred for knee osteoarthritis and treated with an hyaluronic acid injection (viscosupplementation)
89539360|NCT03241979||laryngeal microsurgery|
89539361|NCT04931277|Other|stepped cataract surgery|
89539362|NCT03241823||Patients with hepatitis c virus related liver cirrhosis|"Patients with chronic hepatitis C virus whose ultrasound shows liver cirrhosis, fibroscan F3 and F4, Child score A and B, of any MELD score, who achieved Sustained Virological Response after direct acting antiviral drugs (Sofosbuvir, Daclatasvir ± Ribavirin)."
89539363|NCT03241901|Active Comparator|3 Days Artemether-Lumefantrine + Placebo|"Oral tablets of artemether-lumefantrine (20-120mg):~tablet for 5-14kg;~tablets for 15-24 kg;~tables for 25 - 34kg and~tablets for above 35 Kg. The full course of treatment is 6-doses for 3 days given twice daily, at 0, 8, 24, 36, 48, 60 with the dose being given as directly observed therapy.~Oral placebo after completion of the standard 3 days-six dose regimen. A fatty snack (biscuits) will be administered together with all artemether-lumefantrine doses to optimize absorption."
89539364|NCT03241901|Experimental|6Days Artemether/Lumefantrine+Primaquine|"Artemether-lumefantrine (20-120mg) twice daily for 6 days according to body weight as in the active comparator arm.~And in addition to that, , a single 0.25 mg/kg primaquine dose (Primaquine phosphate) will be administered concomitantly with the last (i.e. twelfth) artemether-lumefantrine dose. Primaquine will be prepared and administered in an aqueous solution."
89539365|NCT04930575|Experimental|Muscle Energy Technique group|"Patients in the group (B) will receive muscle energy technique on tonic muscles in the neck (sternocleidomastoid, scalenes, levator scapulae, and upper trapezius) in addition to strengthening exercise for deep cervical flexors and advice to correct positions three times per week for 4 weeks.~The aim of the Muscle Energy Technique in the context of NP is to decrease pain, improve movement, motor control, and function and thereby reduce disability.~A biomechanical correction approach can lead to the normalization of spinal curvatures and a decrease in the compressional and tensional stress on joints and soft tissues of the body thus alleviating the patient's signs and symptoms."
89539366|NCT04930575|Experimental|Mulligan Technique group|Patient in group A will receive specialized SNAGs technique adapted from Mulligan (2005), in addition to strengthening exercise for DNF muscles and advice to correct position three times per week for 4 weeks.
89539367|NCT03242057|Experimental|NI-NAVA|"Wait to meet extubation criteria within 14 days postnatal age~Pre-extubation mode of invasive ventilation will be per physician discretion (NAVA, CMV, high frequency oscillator ventilation (HFOV) or high frequency jet ventilation (HFJV)) Pi to determine eligibility or exclusion~Randomize to either NIPPV or NI-NAVA, 1:1 randomization~PI will not be blinded to the intervention (not feasible)~If extubating to NAVA then place the catheter to optimize position and Edi 1 hr. prior to planned extubation.~ABG or CBG to be obtained at 4 hrs. post extubation~NI-NAVA settings will be weaned or increased as the clinical situation demands and outlined in the protocol"
89539368|NCT03242057|Active Comparator|NIPPV|"Wait to meet extubation criteria within 14 days postnatal age~Pre-extubation mode of invasive ventilation will be per physician discretion (NAVA, CMV, high frequency oscillator ventilation (HFOV) or high frequency jet ventilation (HFJV)) PI to determine eligibility or exclusion~Randomize to either NIPPV or NI-NAVA, 1:1 randomization~PI will not be blinded to the intervention (not feasible)~ABG or CBG to be obtained at 4 hrs. post extubation~NIPPV settings will be weaned or increased as the clinical situation demands and outlined in the protocol"
89539369|NCT04957017|Active Comparator|Intervention group|"The women with chronic disease were met, and the Descriptive Information Form, Social Hand-Washing Knowledge Form and the Nutritional Knowledge Level Scale for Adults were filled with the volunteer ones face-to-face at their homes, complying with the social distance rules before the training. After the data was collected, the women in the intervention group were trained on Hand-Washing and Nutrition during the COVID-19 period. The training on hand-washing and nutrition was given using the Hand-Washing and Nutrition Training Guide prepared by the researchers, and the Hand-Washing and Nutrition Training Manual covering the content of the training, was distributed to the women at the end of the training. The data collection forms were re-filled three months after the training."
89539370|NCT04957017|No Intervention|Control group|The women with chronic disease were met, and the Descriptive Information Form, Social Hand-Washing Knowledge Form and the Nutritional Knowledge Level Scale for Adults were filled face-to-face at their homes with the ones volunteering to participate in the study, complying with the social distance rules. The same survey was re-filled after three months. No training was given to the women with chronic disease during the three-month period. After the research was completed, a 45 minute-training which is the same with the one provided to the intervention group was given individually to the control group, complying the social distance rules.
89539371|NCT03241433|Active Comparator|High intensity interval training|Exercise training will be conducted 3 times per week using cycle ergometers at commercial fitness facilities for 12 weeks 2 minute warmup/3 minute cooldown- at 50W Intensity- 3 X 20-second sprint interval cycling -as fast as possible at 90-95% peak power low intensity- 2 X 2 minute cycling at slow pace 50W
89539372|NCT03241433|Active Comparator|Moderate intensity continuous training|Exercise training will be conducted 3 times per week using cycle ergometers at commercial fitness facilities for 12 weeks 2 minute warmup/3 minute cooldown- at 50W Intensity- 45 minutes of continuous cycling at 45-60% peak power
89539373|NCT03241433|Active Comparator|No exercise|No excercise training will be done
89539374|NCT03058731||Matristem|Hernia repair with MatriStem Surgical Matrix
89539375|NCT03058731||Control|Other biological mesh
89539376|NCT03241511|Experimental|Test|Briefly, treatment sessions will include oral hygiene behavioral modification and scaling and root planning (removing the bacterial biofilm and calculus below the gum line) in order to eliminate etiologic factors and control periodontal inflammation. Once the treatment sessions are completed, the patients will enter the maintenance phase and will be followed for 6 months. In this phase, the patients will receive systematic and repeated supportive periodontal treatment (tooth cleanings above the gum line with re-enforcement of oral hygiene). Outcomes will be assessed at 2-, 4-, and 6-months. Throughout the course of the study, additional dental needs will be addressed with immediate referral to the subject's general dentist or clinics at the University of Connecticut.
89539377|NCT03241511|No Intervention|Control|The Control arm will receive only a single treatment session without maintenance sessions (see visit Table in Human Subject Protection section). Outcomes will be assessed at 2-, 4-, and 6-months.
89539378|NCT04936737|Experimental|Beta-alanine supplementation and high intensity exercise|Individuals will participate in a high-intensity exercise and will be supplemented with beta-alanine. This protocol will be conducted for six non-consecutive days.
89539379|NCT04936737|Experimental|Beta-alanine supplementation only|In this protocol, the individuals will be supplemented with beta-alanine without the exercise protocol for six non-consecutive days.
89539380|NCT04956861|No Intervention|Phase 1|Phase 1 is a cross-sectional study to compare endothelial vasodilator and fibrinolytic function in ART-treated HIV-1-seropositive adults who habitually sleep more than 7 hours/night (normal sleep) and those who habitually sleep less than 7 hours/night (short sleep).
89539381|NCT04956861|Experimental|Phase 2|Phase 2 is an intervention study to determine the effects of individualized targeted sleep interventions that increase sleep duration and improve sleep quality on endothelial vasodilator and fibrinolytic function in ART-treated HIV-1-seropositive adults who habitually sleep less than 7 hours/night.
89539382|NCT00700739|Other|Anterior Cervical Discectomy and Fusion (ACDF)|Anterior Cervical Discectomy and Fusion with Cervical CFRP I/F CAGE® and SLIM LOC(R) Anterior Cervical Plate System with allograft
89539383|NCT00700739|Active Comparator|Cervical Total Disc Replacement|DISCOVER™ Artificial Cervical Disc
89539384|NCT03057405||intra-operative CBCT|
89539385|NCT03057405||3D virtual planning + intra-operative navigation|
89539386|NCT03057405||3D virtual planning + intraoperative navigation + IO CBCT|
89539387|NCT04486703|Experimental|Exercise with music group|physical therapy program combined with music therapy
89539388|NCT04486703|Experimental|Exercise group|physical therapy program without music
89023788|NCT04730271|Experimental|Robotic-Assisted Arm|Subjects enrolled into this arm will receive an ATTUNE primary total knee replacement that has been implanted with the use of the VELYS Robotic-Assisted Solution device.
89539389|NCT04930497|Experimental|vestibular socket technique with bone grafting|
89539390|NCT04930497|Active Comparator|vestibular socket technique without bone grafting|
89539391|NCT03241277|Experimental|Social phobia|Patients with social phobia with no psychiatric treatment Intervention- non surgical periodontal treatment
89539392|NCT03241277|Experimental|Social phobia under Psych T|Patients with social phobia under psychiatric treatment (Psych T) Intervention- non surgical periodontal treatment
89539393|NCT03241277|Active Comparator|Controls|Patients without social phobia Intervention- non surgical periodontal treatment
89539394|NCT02623335|Experimental|QPL (question prompt list) brochure|Patients were mailed the QPL (question prompt list) prior to their appointment with an enrolled surgeon.
89539395|NCT02623335|No Intervention|Usual care|The investigators observed that usual care included informed consent and a surgeon-directed deliberative phase in which surgeons presented their own evaluation of the trade-offs and goals of the proposed intervention.
89539396|NCT03241199|Experimental|Imatinib Mesylate|imatinib 400mg daily
89539397|NCT03241355|Active Comparator|prebiotic inulin-type fructan|
89539398|NCT03241355|Placebo Comparator|placebo maltodextrin|
89539399|NCT04930419|Other|Videolaryngoscopy group|
89539400|NCT04930419|Other|Direct laryngoscopy group|
89539401|NCT02349893|Experimental|RFA treatment|RFA treatment performed with CelonProSleep plus device
89539402|NCT04935333||Leiomyoma samples|Leiomyoma samples and peripheral blood samples obtained from women between 18 and 80 years with suspected myometrial tumour
89023789|NCT04718844|Experimental|1.0mg/kg - Thalassaemia|
89023790|NCT04718844|Experimental|3.0mg/kg - Thalassaemia|
88957383|NCT01983514|Active Comparator|1 international unit (IU) intravenous oxytocin|Using a double-dummy design participants will be administered 1 IU oxytocin (mixed in 200 ml 0.9% sodium chloride) slow infusion with varying infusion rate over 20 minutes and placebo delivered with the OptiNose Breath Powered Bi-Directional liquid device. Subject to pilot data this may be increased to 2 IU oxytocin (mixed in 200 ml 0.9% sodium chloride) and the infusion time/rate may change to best match the pharmacokinetic profile of intranasally administered oxytocin.
89023791|NCT04718844|Experimental|6.0mg/kg - Thalassaemia|
89506224|NCT05790317|Experimental|Surgical Procedure with ERAS Protocol|ERAS Maintenance Protocol The basic philosophy of the ERAS Protocol is to reduce metabolic stress due to surgical trauma, and to return to normal activity as soon as possible by supporting the normalization of functions in a short time. ERAS protocols are a protocol consisting of a total of 24 items covering the perioperative period of a patient, which starts in the outpatient clinic in the preoperative period and ends at home with discharge. includes applications. Elements of this preparation and treatment method, which is different from the traditional, were applied to our patients in this group before (11), during the operation (6) and after the operation (7). In the study, the data were collected with the personal introduction form introducing the characteristics of the patients, the Rhodes Nausea-Vomiting and Regurgitation Index (WPI), the Mcgill Pain Scale and the Postoperative Evaluation Form created within the scope of the ERAS Care Protocol.
89506225|NCT05790317|No Intervention|Surgery Procedure with the traditional method|"ItThe group that underwent surgery with the traditional method is the control group. The surgical procedure preparation procedure in the institution where the study was conducted was not exceeded.~The data in the control group were collected with the patient information form, the Postoperative Evaluation Form to evaluate the symptoms after the surgical intervention, the McGill Pain Scale Short Form, the Rhodes Nausea-Vomiting Regurgitation Index."
89506226|NCT05790291|Experimental|checklist|checklist
89506227|NCT05790291|No Intervention|no intervention|no intervention
89506228|NCT05790265|Experimental|Comparison of ANNE One system blood pressure measurements to arterial line|
89506229|NCT05790239|Experimental|MDMA-Assisted Therapy|Participants will receive a flexible divided-dose of MDMA plus therapy at Experimental Sessions.
89506230|NCT05790239|Active Comparator|Low Dose D-Amphetamine Assisted Therapy|Participants will receive a flexible divided dose plus therapy at Experimental Sessions.
89506231|NCT05790226|Experimental|Raman Spectroscopy|Acquiring Raman spectroscopy data points ex vivo on recently excised lung tissue
89506232|NCT05790200|Experimental|Cadonilimab (AK104) combined with chemotherapy|Cadonilimab (200 mg, administered on the first day of each cycle, Q3W, until there is no clinical benefit)+platinum-based chemotherapy, Q3W, 4-6 cycles), every 3 weeks (21 days) is a treatment cycle
89506233|NCT05790187|Experimental|visual test|Presentation of differents face pictures
89506234|NCT05790148|Other|Evaluation precision of different scan-bodies|Three different brand scanbodies (Straumann, Medentika, 3Shape) that applied in same participant group with randomization are used in this clinical study. These three different scan bodies are digitized using an intraoral scanner. Three different temporary restorations are designed in the CAD program and three different bridges are produced with the milling technique using the temporary restoration block. Clinical and analytic evaluations were perform and primarly, seconderly outcomes were achieved.
89506235|NCT05790135|Experimental|Multiparametric ultrasound evaluation|Multiparametric ultrasound evaluation will be applied to all patients who will develop diarrhea above 500 ml per day.
89506236|NCT05790122||Group PN|The patients undergoing partial nephrectomy.
89506237|NCT05790122||Group TE|The patients undergoing renal tumor enucleation.
89506238|NCT05789823|Experimental|Ischemic post-conditioning group|Mechanical thrombectomy combined with ischemic post-conditioning
89506239|NCT05789823|Sham Comparator|Control group|Mechanical thrombectomy alone
89506240|NCT05787353|Experimental|Home based cardiopulmonary rehabilitation group|This was a retrospective study. 43 patients who had home based cardiopulmonary rehabilitation programme between January and July 2023, in our rehabilitation clinic.
89506241|NCT05787353|Experimental|Hospital based cardiopulmonary rehabilitation group|This was a retrospective study. 45 patients who had hospital based cardiopulmonary rehabilitation programme between January and July 2023, in our rehabilitation clinic.
89539403|NCT04935333||Leiomyosarcoma samples|Leiomyosarcoma samples and peripheral blood samples obtained from women between 18 and 80 years with suspected myometrial tumour
89539404|NCT04935333||Control samples|Peripheral blood samples obtained from women between 18 and 80 years without suspected myometrial tumour
89539405|NCT03241043|Experimental|Envarsus - Advagraf|
89539406|NCT03241043|Active Comparator|Advagraf - Envarsus|
89506242|NCT05786235||pregnant patients with primary APS|Diagnosis of primary APS, according to international classification criteria
89506243|NCT05786235||pregnant patients who do not have APS|Patients with at least one previous full-term pregnancy No diagnosis of APS, according to international classification criteria
89506244|NCT05781165|Experimental|Intervention|Participants in the intervention arm will be able to access the augmented reality page in the web app to perform the HIV self-test
89506245|NCT05781165|No Intervention|Control|Participants in the control arm will be asked to follow the instruction sheet to perform the HIV self-test
89506246|NCT05775744|Experimental|Prospective interventional arm|The prospective cohort will identify patients in the postpartum period of their delivery hospitalization who are at risk of readmission for hypertensive disorders in the initial six weeks postpartum. Those at risk include patients with diagnosed with chronic hypertension or PIH. Chronic hypertension is defined as either taking antihypertensive medications or a blood pressure of greater than or equal to 140/90 mm Hg prior to 20 weeks of gestation. Pregnancy induced hypertension includes gestational hypertension, preeclampsia without severe features, preeclampsia with severe features and Hemolysis, Elevated Liver enzymes and Low Platelets (HELLP). The minimum requirement to be diagnosed with this spectrum of disorders is having two blood pressures of greater than or equal to 140/90 mm Hg during the antepartum, intrapartum or postpartum periods.
89539407|NCT03240497|Experimental|Cold Exposure|A group of subjects (n=12) that will receive an extensive course in cold exposure similar in length to our previous study (total of 10 days) before the endotoxemia experiment.
89539408|NCT03240497|Experimental|Strength Ventilation|A group of subjects (n=12) that will be trained in the strength ventilation breathing technique before the endotoxemia experiment.
89539409|NCT03240497|Experimental|Cold Exposure and Strength Ventilation|A group of subjects (n=12) that will receive both the cold exposure course (same as the STV group) as well as the training in the strength ventilation breathing technique (same as the CEX group) before the endotoxemia experiment.
89539410|NCT03240497|No Intervention|Control group|A group of subjects (n=12) that will receive no training and will not be exposed to cold before the endotoxemia experiment.
89539411|NCT03057171||Gastric ulcer|patients who will undergo EGD for gastric ulcer
89539412|NCT03057171||Duodenal ulcer|patients who will undergo EGD for duodenal ulcer
89539413|NCT03057171||Stomach cancer|patients who will undergo EGD for stomach cance
89539414|NCT03057171||health individuals|patients who will undergo screening EGD
89539415|NCT02453945|Experimental|Medical Support Bra|ClearPoint Medical Support Bra worn by patients during their post-cardiac surgery hospital stay (approximately 5-7days).
89539416|NCT02453945|No Intervention|Control|Usual Care
89539417|NCT04956315||Examiner effect group|Two examiners performed the test on one healthy subject with both devices for ten consecutive days. We measured the AD of both knees and calculated the ADD of every test. We evaluated the contralateral-side effect by comparing the AD standard deviations of each knee with both devices, and compared the average ADD tested by different examiners with the same device, to estimate examiner effect.
89539418|NCT04956315||Method effect group|The experienced examiner performed tests on 20 healthy subjects using both devices. The means and standard deviations of both knees were calculated. We examined the difference in measurements using each device to determine the method effect.
89539419|NCT04956315||Equipment effectiveness group|The experienced examiner performed tests on 200 ACL ruptureand 200 healthy subjects using each device. Effectiveness was analyzed using 1.5 mm and 3 mm threshold values in ACL tears.
89539420|NCT02453867|Active Comparator|Standard immunosuppression|starting immunosuppression: tacrolimus (Advagraf) (target trough levels >5 ng/ml), mycophenolate mofetil >1g/d in MMF or >720 mg/d in mycophenolic acid, steroids from month 1-3 dosing according to local practice; 200 pts are planned to carry on with standard immunosuppression (tacrolimus (Advagraf), Mycophenolate, steroids) as stated above according to international guidelines for kidney transplant recipients from month 3 posttransplant to month 12 posttransplant
89539421|NCT02453867|Experimental|Reduced immunosuppression|"The Intervention is stopping medication:~200 pts are planned to receive a reduced immunosuppression after month 3: carry on with tacrolimus (Advagraf; trough levels >5 ng/ml) steroids stop at month 3 mycophenolate stop at month 6"
89539422|NCT04956471||hospitalized patients with swallowing disorder after stroke,.|
89539423|NCT04935645|Experimental|Experimental Group|The experimental group was informed about progressive muscle relaxation (PMR) before colonoscopy. PMR audio recordings were given to the patients. Abdominal pain and distention scores were determined after colonoscopy. PMR was applied to the patients for 30 minutes. These scores were determined again after exercise and at the 2nd, 4th, 8th, 12th, 16th, and 24th hours.
89539424|NCT04935645|No Intervention|Control Group|VAS pain and VAS distension scores of the control group were determined after colonoscopy and 30 minutes later. VAS form was given to all patients to determine VAS abdominal pain and VAS distension scores at the 2nd, 4th, 8th, 12th, 16th and 24th hours after the procedure. The day after the colonoscopy, post test data were collected.
89539425|NCT02453789|Active Comparator|Alginate oligosaccharide|Inhalation of a dry powder OligoG in the first treatment period, and placebo in the second period
89539426|NCT02453789|Placebo Comparator|Placebo|Inhalation of placebo dry powder in the first treatment period, and OligoG in the second period
89539427|NCT03240185||Hemroidectomy patients|Patients undergoing hemorrhoid surgery who receive education regarding deep breathing exercises for pain control as part of their preoperative appointment
89539428|NCT03240107|Active Comparator|levator resection|20 patients who will undergo levator aponeurosis resection technique
89539429|NCT03240107|Active Comparator|levator tucking|20 patients who will undergo two point fixation levator tucking technique
89539430|NCT03057561|Experimental|3.0 Tesla Cardiac MRI using Dotarem contrast agent|60 randomly selected participants with suspected or known cardiovascular disease will have a 3.0 Tesla Cardiac MRI with contrast agent, Dotarem
89539431|NCT03057561|Experimental|3.0 Tesla Cardiac MRI using a Gadovist contrast agent|60 randomly selected participants with suspected or known cardiovascular disease will have a 3.0 Tesla Cardiac MRI with contrast agent, Gadovist
89539432|NCT03240029|Experimental|Children in cancer remission|Children in cancer remission sent to ordinary schools: primary (3rd, 4th, 5th grade) and middle (6th, 7th grade) schools.
89539433|NCT03240029|Other|Control children|Children (not in cancer remission) sent to ordinary schools (age and sex matched): primary (3rd, 4th, 5th grade) and middle (6th, 7th grade) schools.
89539434|NCT04935567|Experimental|Predicted responders|Patients indicated VNS therapy as their standard for clinical care and are concerned about the prediction of VNS efficacy based on pre-implantation EEG, (≥50% seizure reduction).
89539435|NCT04935567|Active Comparator|Predicted non-responders|Patients indicated VNS therapy as their standard for clinical care and are concerned about the prediction of VNS efficacy based on pre-implantation EEG, (<50% seizure reduction).
89539436|NCT03239795|Experimental|Intervention group|Family physicians' patients exposed to advertisement in waiting rooms consisting in a poster and pamphlets promoting seasonal influenza vaccination (+ usual mandatory information)
89023792|NCT04718844|Placebo Comparator|Placebo - Thalassaemia|
89539437|NCT03239795|No Intervention|Control group|Family physicians' patients exposed to usual laying out of waiting rooms
89539438|NCT03057093||TIII>TI|Subjects with TIII>TI in initial ECG
89539439|NCT03057093||Non TIII>TI|Subjects without TIII>TI in initial ECG
89539440|NCT03239951|Experimental|Device|Temporary implant (iTind)
89539441|NCT04935099|Experimental|Blueberry/Placebo|In this arm, participants will receive the blueberry intervention first, followed by the placebo one week later.
89539442|NCT04935099|Experimental|Placebo/Blueberry|In this arm, participants will receive the placebo first, followed by the blueberry intervention one week later.
89539443|NCT03239717|Placebo Comparator|Whey protein powder|Participants in the Placebo Arm will replace two-thirds of participants dietary protein intake with meal replacement beverages utilizing a complete protein powder.
89539444|NCT03239717|Experimental|Experimental|Participants in the Experimental Arm will replace two-thirds of participants dietary protein intake with BCAD2 (Mead Johnson), a BCAA-free medical food.
89539445|NCT03056781|Experimental|social interaction|Participants will engage in a social interaction with another person
89539446|NCT03056781|Experimental|food consumption|Participants will be offered food stuffs to eat/drink
89539447|NCT03239327|Experimental|study group|For the study group the enrolled women will receive 50 microgram misoprostol vaginally 60 minutes before CS
89539448|NCT03239327|No Intervention|control group|For the control group mothers enrolled will receive nothing.
89539449|NCT04930185|Experimental|Pamphlet|Participants will received pamphlet about COVID-19 vaccination
89539450|NCT04930185|Experimental|Webinar|Participants will received webinar about COVID-19 vaccination
89539451|NCT04930185|Experimental|SMS|Participants will received SMS about COVID-19 vaccination
89539452|NCT03239639|Experimental|Advance care planning education session|Delivery of an advance care planning education session at the family doctor's office
88957384|NCT01983514|Placebo Comparator|Placebo|Using a double-dummy design participants will be administered Placebo delivered with the OptiNose Breath Powered Bi-Directional liquid device and placebo delivered intravenously (0.9% sodium chloride 200 ml slow infusion for 20 minutes)
88957385|NCT01983514|Experimental|8IU intranasal oxytocin|Using a double-dummy design participants will be administered 8IU oxytocin liquid delivered with the OptiNose Breath Powered Bi directional liquid device and IV placebo (0.9% sodium chloride, 200 ml slow infusion for 20 minutes)
88957386|NCT01983514|Experimental|24IU intranasal oxytocin|Using a double-dummy design participants will be administered 24IU oxytocin liquid delivered with the OptiNose Breath Powered Bi directional liquid device and IV placebo (0.9% sodium chloride, 200 ml slow infusion for 20 minutes)
88957387|NCT01983527|Experimental|Arthrographic distention + intra-articular corticosteroid|Arthrographic distention of the glenohumeral joint with injection of 5 ml contrast, 1 ml (40 mg) Depo Medrol(Methylprednisolone Acetate Injectable Suspension), 15 ml local anaesthetic (Prilocaine) and up to 15 ml saline.
88957388|NCT01983527|Active Comparator|Arthrographic distention|Arthrographic distention of the glenohumeral joint with injection of 5 ml contrast, 15 ml local anaesthetic (Prilocaine) and up to 15 ml saline.
89539453|NCT03239639|Sham Comparator|Wait list control|The intervention is not provided.
89539454|NCT03239171|Active Comparator|Cancer ablation|In this group, the patients will receive ablation therapy (e.g. cryosurgery or irreversible electroporation) first for big tumors (> 2 cm). The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
89539455|NCT03239171|Active Comparator|Life information rehabilitation therapy|"In this group, the patients will drink Qilisheng Immunoregulatory Oral Solution for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
89539456|NCT03239171|Experimental|Combination therapy|"In this group, the patients will receive the combination therapy including ablation and life information rehabilitation therapy. The ablation therapy (e.g. cryosurgery or irreversible electroporation) will be performed first for big tumors (> 2 cm), then Qilisheng Immunoregulatory Oral Solution will be provided for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
89539457|NCT03239171|No Intervention|Control|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
89539458|NCT04956237||Tenonian surgery|Hospital recruitment with outpatient surgery without the presence of an anesthesiologist, without loco-regional anesthesia and without intravenous route
89539459|NCT04956237||Peribulbar surgery|Gold standard: City recruitment with outpatient surgery with the presence of an anesthesiologist and with loco-regional anesthesia
89539460|NCT02314559|Experimental|Propofol (manual titration)|
89539461|NCT02314559|Active Comparator|Propofol (target controlled infusion)|
89539462|NCT04934709|Experimental|PBMT-sMF|Volunteers underwent intervention (active PBMT-sMF) in the non-dominant lower limb. A single application was performed at each phase of the trial, between the first and second set of the exercise protocol.
89539463|NCT04934709|Placebo Comparator|Placebo|Volunteers underwent intervention (placebo PBMT-sMF) in the non-dominant lower limb. A single application was performed at each phase of the trial, between the first and second set of the exercise protocol.
88957389|NCT01983527|Active Comparator|Intra-articular corticosteroid|Arthrographic pseudodistention of the glenohumeral joint with injection of 5 ml contrast and 1 ml (40 mg) Depo Medrol(Methylprednisolone Acetate Injectable Suspension).
88957390|NCT01983540|Experimental|Study Group 1|Participants who received 3 doses of DTaP-IPV-Hep B-PRP~T vaccine at 2, 4, 6 months of age concomitantly with Prevenar (PCV7) and Rotarix (2 doses at 2 and 4 months of age), and a booster of the same investigational vaccine concomitantly with Prevenar (PCV7) at 12 to 24 months of age in a previous study.
89023793|NCT04718844|Experimental|Xmg/kg - Thalassaemia|
89023794|NCT04718844|Experimental|1.0mg/kg - Myelodysplastic Syndrome|
89023795|NCT04718844|Experimental|3.0mg/kg - Myelodysplastic Syndrome|
89539464|NCT04934631||CBT-ED trainees and therapists.|Qualified clinicians delivering CBT-ED throughout a variety of treatment settings, working with adult eating disorder patients. Clinicians will audio-record CBT-ED therapy sessions with their eating disorder patients.
89539465|NCT04934631||Eating Disorder patients.|Adult (18+ years) eating disorder patients currently accessing CBT-ED from one of the CBT-ED therapists/trainees stated above. Patients will have one of their therapy sessions audio-recorded.
89539466|NCT04934631||Raters/Judges.|Either experts or non-experts in the field of CBT-ED. Raters will use the CBTS-ED to assess clinician competence when listening to the therapy session audio-recordings.
89539467|NCT03238937|Other|Phrenic Nerve Stimulator|Phrenic Nerve Stimlator
89539468|NCT03238937|No Intervention|no intervention|Patients without phrenic nerve stimulation
89539469|NCT03056859||Enrolled Patients|Procedure: Central venous catheter placement with extravascular blood pressure transducer
89539470|NCT03238859|Experimental|Real cTBS|10 days of real cTBS treatment will be given (3600 pulses to the left frontal pole as defined by EEG coordinate: FP1; 60 second pause after 1800 pulses; 110% RMT including a 30 second initial ramp period 80%-110% RMT; Magventure MagPro X100 Cool Coil).
89539471|NCT03238859|Sham Comparator|Sham cTBS|10 days of sham cTBS treatment will be given (3600 pulses to the left frontal pole as defined by EEG coordinate: FP1; 60 second pause after 1800 pulses; 110% RMT including a 30 second initial ramp period 80%-110% RMT; Magventure MagPro X100 Cool Coil).
89539472|NCT04929873|Placebo Comparator|routine treatment|routine nursing
89539473|NCT04929873|Experimental|Experimental group|Immediately after the establishment of the side branch cycle, the closed transdone is connected for real-time monitoring of pressure, and clinical nursing practice is guided by transdictor pressure.
89539474|NCT04486547|No Intervention|Follow up Posttest and HbA1c|56.0% of the adolescents with type 1 diabetes were aged 12-14 years and 52.0% were male in the control group (n=25)
89539475|NCT04486547|Experimental|Information Motivation Behavioral Skills Based Intervention|52.0% of the adolescents with type 1 diabetes were aged 15-18 years and 52.0% were female(n=25)
89539476|NCT03239405||SCS|Treated via suction callibrated system
89539477|NCT03239405||Bougie|Treated with multiple tubes & bougie
89539478|NCT03238703|Experimental|Treatment (AI, SERM)|Patients receive exemestane PO QD, anastrozole PO QD, letrozole PO QD, tamoxifen citrate PO QD, or toremifene citrate PO QD at the discretion of the treating physician. Treatment continues in the absence of disease progression or unacceptable toxicity.
88957391|NCT01983540|Experimental|Study Group 2|Participants who received 3 doses of DTaP-IPV-Hep B-PRP~T vaccine at 2, 4, 6 months of age concomitantly with Prevenar (PCV7) and Rotarix (2 doses at 2 and 4 months of age), and a booster of Infanrix hexa vaccine concomitantly with Prevenar (PCV7) at 12 to 24 months of age in a previous study.
88957392|NCT01983540|Active Comparator|Study Group 3|Participants who received 3 doses of Infanrix hexa vaccine at 2, 4, 6 months of age concomitantly with Prevenar (PCV7) and Rotarix (2 doses at 2 and 4 months of age), and a booster of DTaP-IPV-Hep B-PRP~T vaccine concomitantly with Prevenar (PCV7) at 12 to 24 months of age in a previous study.
88957393|NCT01983579|Experimental|Anti-VEGF substance|At the first study visit patients receive anti-VEGF injection with the standard substance (comparator) and at the second visit with an alternative anti-VEGF substance.
88957394|NCT01983579|Experimental|Sclerotomy occlusion|In the first session patients receive anti-VEGF injection without occlusion of the injection hole, while in the second session no occlusion is done.
88957395|NCT01983579|Experimental|Injection volume|In the first session patients receive anti-VEGF injection with the standard injection volume, while in the second session they receive anti-VEGF injection with a modified injection volume.
88957396|NCT01983592|Active Comparator|Homeopathic medicine|The study medication will be administered in one of two forms: (1) 3.5 mm diameter lactose/sucrose globule to be administered sublingually; or (2) 3.5 mm diameter lactose/sucrose globule dissolved in 250 ml spring water and administered orally. The medication will be administered as either 1 globule sublingual or 5 mL oral remedy/water up to 3 times per day. The dosage regimen is varialble at the discretion of the study clinician.
88957397|NCT01983592|Placebo Comparator|Unmedicated lactose/sucrose globule|The placebo will be administered in one of two forms: (1) 3.5 mm diameter lactose/sucrose globule to be administered sublingually; or (2) 3.5 mm diameter lactose/sucrose globule dissolved in 250 ml spring water and administered orally. The medication will be administered as either 1 globule sublingual or 5 mL oral remedy/water up to 3 times per day. The dosage regimen is varialble at the discretion of the study clinician.
88957398|NCT01983605|Experimental|Treatment|LAA exclusion with the LARIAT Suture Delivery Device
88957399|NCT01983618|Placebo Comparator|Interscalene catheter|No block will be performed prior to surgery. An interscalene catheter will be inserted under ultrasound guidance by the anesthesiologist before the induction of anesthesia. Local anesthetics will only be administered once all TCD assessments are completed but prior to the end of surgery.
89539479|NCT03238547||diabetes|Diabetes patients with normal renal function and normal urinalysis
89539480|NCT03238625|Active Comparator|Group 1|"Consisting of 24 individuals between 18 and 75 years, able to understand German, not pregnant, with no intolerance of local anesthetics, with intact skin and no skin diseases, not prone to bleeding or taking anticoagulation or aspirine.~Intervention: Every individual receives four injections IMP1: Lidocaine and sodium bicarbonate ratio 3:1, IMP 2: Lidocaine and sodium bicarbonate ratio 9:1, IMP 3: Lidocaine, and IMP 4: Sodium cloride 0.9% (=placebo), namely two in every volar forearm, and has to rate the pain associated during the injection of the fluid, not the needle stitch. Afterwards the anesthetic effect on the four areals which got injected will be checked with a palomar laser after 5, 30, 60, 90, 120 and 180 minutes."
89539481|NCT03238625|Placebo Comparator|Group 2|"Consisting of 24 different individuals than those belonging to Group 1. Between 18 and 75 years, able to understand German, not pregnant, with no intolerance of local anesthetics, with intact skin and no skin diseases, not prone to bleeding or taking anticoagulation or aspirine.~Intervention: Every individual receives two injections:~IMP 3 Lidocaine, and IMP 4 Sodium cloride 0.9% (=placebo), namely one in every volar forearm, and has to rate the pain associated during the injection of the fluid, not the needle stitch. Afterwards the anesthetic effect on the two areals which got injected will be checked with a palomar laser after 5, 30, 60, 90, 120 and 180 minutes."
88957400|NCT01983618|Experimental|Interscalene nerve block and catheter|The anesthesiologist will perform the interscalene nerve block and insert an interscalene catheter under ultrasound guidance before induction of anesthesia. A standardized mixture of bupivacaine, lidocaine and epinephrine will be administered prior to surgery.
88957401|NCT01983631|Experimental|WBV group|Stage 1: Short-term Whole body vibration(3 minutes in half-squatting position)
88957402|NCT01983631|No Intervention|Non-WBV group|Stage 1 : Controlled group
88957403|NCT01983631|Experimental|training group|Stage 2: Long-term WBV training (3 sessions per week for 4 weeks)
88957404|NCT01983631|No Intervention|non-training group|Stage 2: Controlled group
88957405|NCT01983644|Experimental|RECO thrombectomy|IA thrombectomy is executed by RECO flow restoration device which is a novel, self-expanding stent retriever designed to yield rapid flow restoration in acute cerebral ischaemia.
88957406|NCT01983644|Active Comparator|Solitaire FR thrombectomy|IA thrombectomy is executed by Solitaire FR flow restoration device
88957407|NCT01983657|Experimental|D1|"Patients diagnosed with PAP will be received rhGM-CSF 1.25 ug/kg/d subcutaneously for 1 month, before evaluation on the 30th day (±3 day).~If the treatment is effective, participants may be entered into low-dose group(D1)(rhGM-CSF administration 1.25 ug/kg/d, qd, sc, for 2 months，then rhGM-CSF administration 1.25 ug/kg/d, qod, sc, for 3 months), when the chest CT absorption≥25% , and /or the PaO2 elevated by 5 mm Hg."
89023796|NCT04718844|Experimental|10.0mg/kg - Myelodysplastic Syndrome|
89023797|NCT04718844|Experimental|Xmg/kg - Myelodysplastic Syndrome|
89506247|NCT05775744|No Intervention|Retrospective observational arm|The retrospective cohort will include all patients diagnosed with chronic hypertension or pregnancy-induced hypertensive (PIH) disorders at Robert Wood Johnson University Hospital and Cooperman Barnabas Medical Center in the past two years, including those presenting to the Emergency Department or readmitted for hypertensive disorders, during the immediate six weeks postpartum.
89506248|NCT05774548|Experimental|(PHASE I) Attributes identification|To identify attributes of importance for our research question and assign possible levels to these attributes, a combination of literature review and qualitative approaches will be conducted
89506249|NCT05763706|Experimental|Experimental: PBM1 group|The patients allocated to the first PBM-group will receive twelve PBM sessions of 6 J/cm² over six weeks (2x/week).
89506250|NCT05763706|Experimental|Experimental: PBM2 group|The patients allocated to the second PBM-group will receive twelve PBM sessions of 8 J/cm² over six weeks (2x/week).
89506251|NCT05760027|Experimental|Plyometric exercise|The group of athletes will perform plyometric stability exercises and their usual exercise for 30 days.
89506252|NCT05760027|Other|Regular exercise|The group of athletes will their usual exercise for 30 days.
89506253|NCT05747534|Experimental|Larazotide Acetate (AT1001)|Subjects will receive 250 or 500 µg of Larazotide Acetate orally four times a day (QID) for 21 days. Subjects <25.0 kg will receive 250 µg dose of Larazotide Acetate (AT1001), and subjects ≥25.0 kg will receive 500 µg dose of Larazotide Acetate (AT1001).
89506254|NCT05747534|Placebo Comparator|Placebo|Subjects will receive 250 or 500 µg of placebo orally four times a day (QID) for 21 days. Subjects <25.0 kg will receive 250 µg dose of placebo and subjects ≥25.0 kg will receive 500 µg dose of placebo.
89506255|NCT05746234|Experimental|Music-Based ER module|"The program will involve the following modules: a) VALUES & SETTING GOALS FOR ENHANCING MOTIVATION, b) MODULE 2. UNDERSTANDING EMOTIONS, c) MODULE 3. MINDFUL EMOTION AWARENESS AND RELAXATION, d) MODULE 4. THINKING FLEXIBLY, e) MODULE 5. COUNTERING INAPPROPRIATE BEHAVIORS.~The rationale of the training was built based on the framework of Unified Protocol (Barlow, et al. 2018) and training activities were selected and adapted from a compilation of foundational works on contemporary evidence-based approaches, (i.e. Cognitive Behavioral approach, Acceptance and Commitment approach, and Dialectical Behavior approach). Activities were adapted using core components of music-based interventions (Dingle & Fay, 2016; McFerran, 2016; Saarikallio, 2019) with emphasis on emotion recognition in music, regulation of stress and negative emotions through active music listening, and self-reflective awareness of emotional responses to music."
89506256|NCT05746234|Active Comparator|Standard ER module|Participants will receive the same training modules in the same chronological order as the music-based group. The only difference is that modules will be mainly text/language based (instead of using music methodologies).
89506257|NCT05727605|Other|Primary brain and skull-base tumors|Primary brain and skull-base tumors who are amenable for radiotherapy (photon or proton therapy) will all be examined with neurocognitive tests, questionnaires and advanced MR imaging
89506258|NCT05719532||Healthy adults|Healthy adults between 18 and 35 years
89506259|NCT05713110|Experimental|tazemetostat combined with HMP689 open-label treatment arm|"Dose Escalation Phase (Phase IIa):~patients with relapsed or refractory lymphoma who have failed standard treatment and have no standard treatment options~Dose Expansion Phase (Phase IIb):~Cohort 1 (DLBCL, FL 3b): Histologically confirmed DLBCL, FL 3b (including primary mediastinal B-cell lymphoma) with relapsed/refractory disease ；~Cohort 2 (FL) patients with histologically confirmed R/R FL (Grade 1, 2, 3a)；~Cohort 3 (MCL): Patients with R/R MCL who had prior therapies ；~Cohort 4 (PTCL): Patients with histologically confirmed R/R PTCL who have failed or cannot tolerate standard therapy"
89506260|NCT05709106||Rimegepant treatment group|this group would use Rimegepant 75mg ODT, use it when needed for 1year
88957408|NCT01983657|Experimental|D2|"Patients diagnosed with PAP will be received rhGM-CSF 1.25 ug/kg/d subcutaneously for 1 month, before evaluation on the 30th day (±3 day).~When the treatment is ineffective, and anti-GM-CSF antibody titers level ≥1:1000，the dose will be increased to 2.5 ug/kg/d. After 2 months, if the clinical response was optimal, that dose is continued for 3 months, and defined as group 2(D2)."
89023798|NCT04718844|Experimental|3.0mg/kg - Thalassaemia multi dose|
89023799|NCT04718844|Experimental|10.0mg/kg - Thalassaemia multi dose|
89023800|NCT04718844|Experimental|Xmg/kg - Thalassaemia multi dose|
89023801|NCT04718844|Experimental|3.0mg/kg - Myelodysplastic Syndrome multi dose|
89506261|NCT05702047|Active Comparator|Nose-only breathing|Participants will be instructed to breathe only through their nose (mouth closed) during rest and submaximal exercise.
89506262|NCT05702047|Active Comparator|Mouth-only breathing|Participants will be instructed to breathe only through their mouth (nose clips prevent nose breathing) during rest and submaximal exercise.
89506263|NCT05687370|Active Comparator|Modified dynamic needle tip positioning technique|In Modified dynamic needle tip positioning technique, short-axis in-plane is used, needle tip was dynamic guided by ultrasound that added two developing lines on the ultrasonic probe.
89506264|NCT05687370|Active Comparator|Long-axis in-plane technique|
89506265|NCT05683444|Other|Healthy participant 1|
89506266|NCT05683444|Other|Healthy participant 2|
89023802|NCT04718844|Experimental|10.0mg/kg - Myelodysplastic Syndrome multi dose|
89023803|NCT04718844|Experimental|Xmg/kg - Myelodysplastic Syndrome multi dose|
89023804|NCT04718844|Placebo Comparator|Placebo - Thalassaemia multi dose|
89506267|NCT05671692|Active Comparator|Pregnenolone|
89506268|NCT05671692|Placebo Comparator|Placebo|
89506269|NCT05669274|Experimental|Old World milk|Old World milk containing only a2 beta-casein vs. New World milk that includes both a1 and a2 beta-casein
89506270|NCT05669274|Experimental|New World milk|Old World milk containing only a2 beta-casein vs. New World milk that includes both a1 and a2 beta-casein
89506271|NCT05667090|Experimental|Vitamin D group|Oral supplementaiton of 2,304,000 IU vitamin D3 in 4 weeks
89506272|NCT05667090|Placebo Comparator|Placebo Group|Oral supplementaiton of placebo in 4 weeks
89506273|NCT05663606|Active Comparator|Happy Bob Arm|Subjects, who are using Happy Bob App in addition to CGM
89506274|NCT05663606|Placebo Comparator|Controls|Subjects, who are using CGM only
89506275|NCT05628740|Experimental|Part 1-Period 1-Treatment A|3 mg NOC-100 (via nebulizer)
89506276|NCT05628740|Placebo Comparator|Part 1-Periods 2 through 4 -Treatment B|1 mg NOC-110 DPI (1 capsule)
89506277|NCT05628740|Placebo Comparator|Part 1-Periods 2 through 4 - Treatment C|3mg NOC-110 DPI (1 capsule)
89506278|NCT05628740|Placebo Comparator|Part 1-Periods 2 through 4- Placebo|Placebo (1 capsule)
89506279|NCT05628740|Placebo Comparator|Part 1-Period 5- Treatment D|6mg NOC-110 DPI (2 capsules)
89506280|NCT05628740|Placebo Comparator|Part 1-Period 5- Placebo|Placebo (2 capsules)
89506281|NCT05628740|Placebo Comparator|Part 2- Active|6mg NOC-110 DPI (2 capsules)
89506282|NCT05628740|Placebo Comparator|Part 2- Placebo|Placebo DPI (2 capsules)
89506283|NCT05622981|Experimental|Behavioral intervention|Behavioral intervention for healthy lifestyle goals, four analysis groups divided by age (2-4, 5-8, 9-11, 12-17)
89506284|NCT05619614||Patients|Participating patients who undergo colonoscopy
89506285|NCT05619614||Endoscopists|Physicians performing colonoscopy
89506286|NCT05604937|Other|Manual therapy group|Patients receive Shi's traumatology osteopathic manipulative treatment twice a week and continues for 2 weeks. Receive a total of 4 manipulative treatments.
89506287|NCT05604937|Other|Merislon group|Merislon (Betahistine Mesilate Tablets), specification 6mg, Sinopharm H20040130, Eisai (China) Pharmaceutical Co., LTD., is given to the control group, for 2 weeks, 6mg a day, three times a day.
89506288|NCT05592808|Experimental|Low-Dye Taping|In addition to the ESWT applied to the participants in the control group, Low-Dye Taping will be applied to the participants in this group once a week for 3 sessions.
89506289|NCT05592808|Experimental|Kinesio Taping|In addition to the ESWT applied to the participants in the control group, Kinesio Taping will be applied to the participants in this group once a week for 3 sessions.
89506290|NCT05592808|Active Comparator|Extracorporeal Shockwave Therapy (ESWT)|Participants in the control group will receive 3 sessions of ESWT once a week.
89506291|NCT05583032||ScanNav Anatomy PNB aided|Participants completing scans for regional anaesthesia with the aid of ScanNav Anatomy PNB.
89506292|NCT05583032||ScanNav Anatomy PNB unaided|Participants completing scans for regional anaesthesia without the aid of ScanNav Anatomy PNB.
89506293|NCT05553392|Experimental|StrataXRT|Studied products will be applied as per the patient information leaflet following manufacturer guidelines to the treatment area. The studied products will be used starting on the first day of radiation therapy. The studied products will be applied twice a day to both the right and left inguinal regions. The studied products will be used daily during the entire course of radiotherapy including on weekends and holidays until at least 4 weeks upon completion of radiation therapy or otherwise until resolution of RD on both sides.
89023805|NCT04718844|Placebo Comparator|Placebo - Myelodysplastic Syndrome|
89023806|NCT04718844|Placebo Comparator|Placebo - Myelodysplastic Syndrome multi dose|
89506294|NCT05553392|Active Comparator|Aquaphor|Studied products will be applied as per the patient information leaflet following manufacturer guidelines to the treatment area. The studied products will be used starting on the first day of radiation therapy. The studied products will be applied twice a day to the entire treatment field. The studied products will be used during the entire course of radiotherapy and for a further 4 weeks upon completion of radiation therapy.
89506295|NCT05518734|Experimental|Part A: VX-708 (Cohort A1-A3)|Participants will receive multiple doses of one of different dose levels of VX-708 under fasting condition.
89506296|NCT05518734|Placebo Comparator|Part A: Placebo|Participants will receive placebo matched to VX-708.
89506297|NCT05518734|Experimental|Part A: Midazolam With or Without VX-708 (Cohort A4)|Participants will receive a single dose of Midazolam with or without VX-708 under fasting condition.
89506298|NCT05518734|Experimental|Part B: VX-708 With Itraconazole|Participants will receive a single dose of VX-708 in treatment period 1, followed by itraconazole, which will be dosed daily with a single dose of VX-708 administered in treatment period 2 under fasting conditions. A washout period of 6 days will be maintained between the 2 treatment periods.
89506299|NCT05513365|Active Comparator|Combined androgen blockade (CAB)|Patients from cohort A (ADT-naïve) may be randomized in this arm to receive CAB.
89023807|NCT04706715|Experimental|Dose finding cohort|In part A of this imaging trial, a dose finding study will be performed to establish safety, to assess the appropriate protein dose for PET-scanning and to assess the appropriate PET scanning interval. After completion of imaging, patients will start treatment with cemiplimab with or without platinum-based chemotherapy.
89506300|NCT05513365|Experimental|Combined androgen blockade (CAB) + dutasteride|Patients from cohort A (ADT-naïve) may be randomized in this arm to receive CAB+dutasteride, and patients from cohort B (ADT-resistant) will receive CAB+dutasteride without having been randomized.
89506301|NCT05497518||People with chronic kidney disease|No interventions will be administered as part of this registry.
89506302|NCT05492604|Experimental|Connected soles|FEETME® connected tool
89206774|NCT00744497|Placebo Comparator|Placebo|Participants received placebo, given orally once daily, plus docetaxel, 75 mg/m^2, given intravenously every 3 weeks as a 1-hour infusion, plus prednisone, 5 mg, given orally twice daily
89506303|NCT05492604|Other|Treadmill|Reference system the GAITRite® walkway
88957409|NCT01983657|Experimental|D3|"Patients diagnosed with PAP will be received rhGM-CSF 1.25 ug/kg/d subcutaneously for 1 month, before evaluation on the 30th day (±3 day).~When the treatment is ineffective, and anti-GM-CSF antibody titers level ≥1:1000，the dose will be increased to 2.5 ug/kg/d. After 2 months, if the clinical response was not optimal, the patients will receive whole lung lavage(WLL), who are defined as group 3(D3)."
89506304|NCT05487313|Active Comparator|10 ml ESP group|ESP group using 10 ml mixture of local anesthetics and contrast medium
89506305|NCT05487313|Active Comparator|20 ml ESP group|ESP group using 20 ml mixture of local anesthetics and contrast medium
89506306|NCT05473455|Experimental|Follicular aspiration with addition of follicular flushing.|All follicles will be aspirated with the addition of follicular flushing if necessary (up to 5 times per follicle)
89506307|NCT05473455|No Intervention|Follicular aspiration only.|All follicles will be aspirated and no flushing will be applied.
89506308|NCT05454735||Group 1|patients with known insulin-requiring type 2 diabetes mellitus undergoing planned on-pump coronary artery bypass graft surgery
89506309|NCT05454735||Group 2|patients with known non-insulin-requiring type 2 diabetes mellitus undergoing planned on-pump coronary artery bypass surgery
89506310|NCT05454735||Group 3|non-diabetic patients undergoing planned aortic valve replacement surgery
89506311|NCT05454735||Group 4|non-diabetic patients undergoing planned on-pump coronary artery bypass graft surgery
88957410|NCT01983657|Active Comparator|D4|"Patients diagnosed with PAP will be received rhGM-CSF 1.25 ug/kg/d subcutaneously for 1 month, before evaluation on the 30th day (±3 day).~When the treatment is ineffective, and anti-GM-CSF antibody titers level <1:1000，the patients will receive whole lung lavage(WLL), then give rhGM-CSF administration (1.25 ug/kg/d) for 3 months, which belong to group4(D4)."
88957411|NCT01983670|Experimental|health group 1|Health subjects received 30 mins delay antagonist activation temporal ES.
88957412|NCT01983670|Experimental|SCA group 1|SCA subjects received four weeks temporal ES assisted home training program.
88957413|NCT01983670|No Intervention|health group 2|health subjects controlled group
88957414|NCT01983670|No Intervention|SCA group 2|SCA subjects controlled group
88957415|NCT01983696|Experimental|5% oxygen|the oocytes and embryos are cultured in 5% oxygen concentration after oocytes retrieval until Day 6 (counting from fertilization)
88957416|NCT01983696|No Intervention|20% oxygen|the oocytes and embryos are cultured in 20% oxygen concentration (in atmosphere) after oocytes retrieval until Day 6(counting from fertilization)
88957417|NCT01983709|Experimental|Allogeneic Human Mesenchymal Stem Cells|"This will be a dose escalation study. The first 3 subjects will receive a single dose of 1 x 10^6 cells/kg or a maximum dose of 1 x 10^8 total cells IV.~The remaining subjects will receive a single dose of 2 x 10^6 cells/kg or a maximum dose of 2 x 10^8 total cells IV."
88957418|NCT01983735|Experimental|TELMINUVO Tab. (80/2.5mg, 80/5mg)|
89206775|NCT00744497|Active Comparator|Dasatinib|Participants received dasatinib, 100 mg, orally once daily plus docetaxel, 75 mg/m^2, given intravenously every 3 weeks as a 1-hour infusion, plus prednisone, 5 mg, given orally twice daily
89506312|NCT05442879|Experimental|Knowledge Translation Intervention|The group participating in the KT intervention program will participate in focus groups, individual meetings, and receive videos, informational handouts and on-field training from the researchers. The researchers and participants will work together to determine barriers and facilitators towards implementation of an ACL-IPP, and create an ACL-IPP that follows established clinical practice guidelines and is individualized to the local contextual needs.
89506313|NCT05442879|Active Comparator|Educational Handout|The coaches will receive an educational handout describing an ACL-IPP.
88957419|NCT01983735|Active Comparator|S-Amlodipine 2.5, 5mg|
88957420|NCT01983761|Experimental|Fludarabine, Clofarabine, Busulfan, ATG, TBI (Myeloablative)|"Fludarabine, Clofarabine, Busulfan, Anti-thymocyte Globulin (ATG), Total Body Irradiation (TBI) (Myeloablative) Day Treatment~Day0 Admit, IV hydration, rituximab 375 mg/m2 (B cell malignancy)~Day 1 Fludarabine 10 mg/m2, clofarabine 30 mg/m2, busulfan AUC 5,000~Day2 Fludarabine 10 mg/m2, clofarabine 30 mg/m2, busulfan AUC 5,000~Day3 Fludarabine 10 mg/m2, clofarabine 30 mg/m2, busulfan AUC 5,000~Day4 Fludarabine 10 mg/m2, clofarabine 30 mg/m2, busulfan AUC 5,000, rabbit ATG 1.25 mg/kg~Day5 Low-dose TBI 2 Gy in AM, rabbit ATG 1.75 mg/kg~Day6 Rest~Day7 Rest~Day8 Cord blood infusions"
88957421|NCT01983761|Experimental|Fludarabine, Melphalan, ATG (Reduced Intensity)|"Day Treatment~Day0 Admit, hydration~Day1 Fludarabine 40 mg/m2 IV~Day2 Fludarabine 40 mg/m2 IV, rabbit ATG 1.25 mg/kg~Day3 Fludarabine 40 mg/m2 IV, rabbit ATG 1.75 mg/kg~Day4 Fludarabine 40 mg/m2 IV and Melphalan 140 mg/m2 IV~Day5 Rest Day6 Cord blood infusions"
89506314|NCT05442749|Experimental|Niraparib|
89506315|NCT05441488|Experimental|Masitinib (4.5)|Participants receive masitinib (3.0 mg/kg/day), given orally twice daily, with a dose escalation to 4.5 mg/kg/day after 4 weeks of treatment. Each ascending dose titration is subjected to a safety control.
89506316|NCT05441488|Placebo Comparator|Placebo|Participants receive a matched dose placebo, given orally twice daily.
89506317|NCT05437120|Experimental|Cohort 1: Moderate Hepatic Impairment|Participants with moderate hepatic impairment will receive single dose of VX-121/TEZ/D-IVA .
89506318|NCT05437120|Experimental|Cohort 2: Matched Healthy Participants|Healthy participants will receive single dose of VX-121/TEZ/D-IVA.
89506319|NCT05404633|Experimental|Intradialytic exercise (patients)|Participants in this group will use the tested device to perform a 30-minute session of aerobic training (cycling during hemodialysis) at 3-4/10 on the Borg scale of perceived exertion.
89506320|NCT05404633|Experimental|Acute care exercise (patients)|Participants in this group will use the tested device to perform 2 x 10-minute of aerobic training (cycling in the hospital) interspersed with a 5-minute break. Exercise intensity will be of 2/10 on the Borg scale of perceived exertion (around 3 +/- 2 watts at 20 rpm).
88957422|NCT01983800|Active Comparator|intravenous propofol/midazolam|Sedation using intravenous propofol/midazolam, sedation will be titrated to a Riker Agitation Sedation Score
89506321|NCT05361655||Palbociclib + an aromatase inhibitor|Adult metastatic breast cancer patients who initiated Palbociclib + an aromatase inhibitor as first line therapy between Feb 3, 2015 to March 31, 2020 in the Flatiron Health Analytic Database.
89506322|NCT05361655||Aromatase inhibitor|Adult metastatic breast cancer patients who initiated an aromatase inhibitor as first line therapy between Feb 3, 2015 to March 31, 2020 in the Flatiron Health Analytic Database.
89506323|NCT05316831|Experimental|Group A|Group A CLL patients: Previously immunized with PCV13, in this study receiving PCV13 followed by PPSV23
89506324|NCT05316831|Experimental|Group B|Group B CLL patients: Previously immunized with PPSV23, in this study receiving PCV13 followed by PCV13
88957423|NCT01983800|Active Comparator|isoflurane|Sedation using inhaled isoflurane, sedation will be titrated to a Riker Agitation Sedation Score
88957424|NCT01983813|Experimental|PHCVRS intervention|Each participant will receive communication with a clinical pharmacist for 12 months to decrease risk of developing cardiovascular disease.
88957425|NCT01983813|Other|Usual care/Personal Health Record|Will receive usual medical care plus access to an online Personal Health Record, where the participant can document medications and diagnosed conditions.
88957426|NCT01983852||1|Children during End of Life Care
88957427|NCT01983865|Other|Exposure to birch pollen|
88957428|NCT01983891|Experimental|Intervention|6-week nutrition education and cooking course
88957429|NCT01983904|Experimental|Long Pulse Width|deep brain stimulation with short & long pulse width
88957430|NCT01983904|Experimental|Short Pulse Width|deep brain stimulation with short & long pulse width
88957431|NCT01983917|Other|Use of the Diabetes Application|
88957432|NCT01983943|Experimental|Hydroxytyrosol|Hydroxytyrosol, the major polyphenol in olive oil, 40mg will be taken once per day for 6 months.
88957433|NCT01983943|Placebo Comparator|Placebo|Placebo 40mg will be taken once per day for 6 months.
88957434|NCT01983956|Experimental|Experimental arm|The structured approach intervention with the SENS model is based on the bio-psycho-social-spiritual model of care and the WHO definitions of palliative care as well as the NCCN Practice Guidelines for Palliative Care. It supports the assessment of areas and complexity of concerns from the patient perspective, determines the priority and structures the support needed. The intervention is performed by palliative care physicians and nurses collaboratively. It is utilized as baseline assessment and afterwards integrated in each routine oncology care out-patient and in-patient visit. Depending on the goals it may be applied between routine visits. In addition, patients will receive usual oncology care throughout the study period.
88957435|NCT01983956|No Intervention|Control arm|Patients in the usual care group will receive routine oncology care throughout the study. This incorporates a routine assessment according to the standard SAKK - protocol which assesses overall symptoms. Patients are not seen by nurses during a routine visit to the outpatient clinic unless they need a blood withdrawal or any intravenous or subcutaneous treatment. Only nursing staff of the palliative care unit is familiar with using the SENS-assessment instrument. Participants assigned to usual care may meet with the palliative care service on request according to established practice.
88957436|NCT01983982||Adjuvant chemotherapy|Subjects will undergo pain testing, then receive standard of care chemotherapy, and then undergo pain testing.
88957437|NCT01983995||Actigraphy|Postmenopausal women starting aromatase inhibitor therapy will undergo assessment with questionnaires and actigraphy before starting AI therapy and after 3 months of treatment.
88957438|NCT01984008|Experimental|picosulfate,MgO, citric acid, bowel preparation, powder|colonoscopy picosulfate,MgO, citric acid, bowel preparation, powder
88957439|NCT01984008|Active Comparator|polyethylene glycol, bisacodyl,|colonoscopy polyethylene glycol,powder bisacodyl,tablet
88957440|NCT01984021|Experimental|traditional acupuncture (tACP)|In the upper trapezius muscle with the greatest area pain and lowest PPT score will be chosen for acupuncture. Sterile acupuncture needles measuring 0.25 x 13 mm (Suzhou Huanqiu Acupuncture Medical Appliance Co. Ltd.®) will be inserted in TE-5 (located on the dorsal face of the forearm between the radius and ulna 3 cm above the joint line of the wrist) and LI-11 (located at the outermost point of the skinfold of elbow flexion in the direction of the lateral epicondyle of the elbow).
88957441|NCT01984021|Placebo Comparator|sham acupuncture (sACP)|The needles will be inserted 1 cm to the side of TE-5 (located on the dorsal face of the forearm between the radius and ulna 3 cm above the joint line of the wrist) and 1 cm to the side of LI-11 (in the direction of the styloid process of the radius).The acupuncture needles are positioned at different acupoints.
88957442|NCT01984034|Experimental|Educational Outreach Visits|The intervention is three educational outreach visits, one per prescription guideline. During each 15 to 20 minutes visit an academic detailer will promote one of the guidelines to a family doctor (up to three physicians may be present in each visit if they wish to, but one to one visits will be preferred and encouraged). The detailer will also distribute a point of care summary highlighting the main messages. The detailers will be mainly Family Physicians and family medicine residents.
88957443|NCT01984034|Active Comparator|Passive Dissemination|Usual guideline implementation consists of passive dissemination by their publication on the National Health Directorate's website. Doctors in units randomized to the control group will be offered an unrelated training session (coding with the International Classification of Primary Care, second edition) as a token of good will for participating in the trial.
88957444|NCT01984047|Experimental|GSK3050002 0.1 mg|Six subjects in this cohort will receive a single dose of GSK3050002 0.1 mg and two subjects will receive a single dose of placebo intravenously. Sentinel subjects (i.e. 1 subject will be dosed with GSK3050002 and 1 with placebo before the remainder of the cohort is dosed) will be used in the cohort.
89206776|NCT00949065|Active Comparator|Intravenous immunoglobulins (IvIg)|3 x 0.36-0.44g/Kg IvIg every 4 weeks, then 3 months washing out, then 3x NaCl 0.9% every 4 weeks
89506325|NCT05316831|Active Comparator|Group C|Group C controls: Previously immunized with PCV13, in this study receiving PCV13
89506326|NCT05316831|Active Comparator|Group D|Group C controls: Previously immunized with PPPSV23, in this study receiving PCV13
89506327|NCT05315635||Epidemiology|"Inpatients who initiate treatment for a substance use disorder (SUD) will have to complete self-questionnaires, a clinical psychiatric assessment (MINI) and a cognitive assessment (MoCA).~These participants will be assessed at admission in addiction unit and at discharge, 3 weeks after withdrawal.~Outpatients who begin treatment for an eating disorder (ED) will have to complete self-questionnaires and a clinical psychiatric assessment (MINI) at the beginning of the outpatient treatment program"
89506328|NCT05308056||ECT-patients|Patients receiving routine ECT.
89506329|NCT05306717||Epidemiology|The study will compare the rates of isolation and restraint of the two sectoral admission units welcoming people in care without consent for a period of one year.
89506330|NCT05293730|Experimental|Community Health Worker (CHW)-Led Hybrid In-Person/Telehealth Program Pathway (eFRIEND)|Participants in the eFRIEND arm will receive regularly scheduled in-person and telehealth contacts with a CHW.
89506331|NCT05293730|Active Comparator|Usual Care|Usual care group will be monitored passively for outcomes under a waiver of informed consent
89506332|NCT05285267|Active Comparator|Parent-Child Activities|"Families assigned to the active control group will participate in weekly parent-child open house where the parents will be permitted to meet with other parents in the meeting room and the children will be invited to attend an open gym. There will be no formal curriculum for the parent meetings, but the facilitator will be available to inform the parents of community resources (e.g., mentorship programs) and a resources table will be made available of community activities and referrals in the same manner as the other two groups."
89506333|NCT05285267|Experimental|Nurturing Fathers|The Nurturing Fathers program (Perlman, 2021) is an adaptation of the Nurturing Parent program. It is a 13-week program that covers the role of fathers, the importance of nurturance rather than fear in fathering, how to effectively play and discipline a child, how to build relationships with the child and co-parent, and it ends with a graduate ceremony. For the present study, consistent with a prevention approach, the investigators will modify the Nurturing Fathers program to focus on the content directly related to parenting skills. The investigators will implement an eight-week program, which is consistent with the duration of prior, successfully attended father-focused interventions (e.g., Fabiano et al., 2009).
89506334|NCT05285267|Experimental|Nurturing Fathers + COACHES|The Nurturing Fathers program described above will be implemented as described. For the last 45 minutes of the sessions, fathers will join the child activity group and participate in shared parent-child activities consistent with the COACHES model. For the present study, several adaptations to the clinic-based COACHES program will be made, similar to those successfully deployed in our preliminary study in Head Start preschool settings (Caserta, Fabiano, et al., 2018). The investigators will use the Nurturing Fathers curriculum as the substantive content for each meeting, and then use the parent-child interactions within recreational sports as the forum for practicing skills.
89506335|NCT05277805||EMPOWER-UP participants|People with cancer, diabetes, or mental disorders answering the EMPOWER-UP questionnaire
89506336|NCT05276284|Experimental|TEMPLE|Study drugs: Atezolizumab, 6-mercaptopurine and 6-thioguanine
89506337|NCT05259605||Gliomas, glioneuronal tumors, and neuronal tumors|
89506338|NCT05259605||Choroid plexus tumors|
89506339|NCT05259605||Embryonal tumors|
89506340|NCT05259605||Cranial and paraspinal nerve tumors|
89506341|NCT05259605||Mesenchymal, non-meningothelial tumors|
89506342|NCT05259605||Melanocytic tumors|
89506343|NCT05259605||Germ cell tumors|
89506344|NCT05259605||Tumors of the sellar region|
89506345|NCT05259605||Diffuse midline glioma, H3 K27M-mutant|
89506346|NCT05259605||Diffuse hemispheric glioma, H3 G34-mutant|
89506347|NCT05259605||Gliomas and glioneuronal tumors driven by MAPK pathway alterations|
89506348|NCT05259605||Gliomas with MYB/MBL1 alterations|
89506349|NCT05259605||Ependymoma|
89506350|NCT05259605||Pineal tumors|
89506351|NCT05259605||Meningioma with specific driver mutations|
89506352|NCT05259605||Hemangiopericytoma (Solitary fibrous tumor)|
89506353|NCT05259605||Hemangioblastoma|
89506354|NCT05259605||Genetic tumor syndromes|
89506355|NCT05258019||Geistlich Bio-Oss ® Particles + Bio-Gide ® collagen membrane|The first group of patients selected for site preservation will be performed with Bio-Oss ® Particles + Bio-Gide ® collagen membrane after tooth extraction
89506356|NCT05258019||Geistlich Bio-Oss ® Collagen + Bio-Gide ® collagen membrane|The second group of patients selected for site preservation will be performed with Bio-Oss ® Collagen + Bio-Gide ® collagen membrane after tooth extraction
89506357|NCT05258019||Conventional healing after tooth extraction, without site preservation|The third group of patients selected will be performed without site preservation after tooth extraction, and only conventional healing
89506358|NCT05251194|Experimental|video laryngoscope at thyroid surgical position|"After induction of anesthesia and muscle relaxation, the patient will be positioned with a standard pillow to exposure neck for thyroid surgery (thyroid surgical position). Then, tracheal intubation will be performed with a McGrath video laryngoscope. During laryngoscopy with the McGrath video laryngoscope, the intubation practitioner will record the modified Cormack-Lehane grade and the percentage of glottic opening (POGO) score when it is assumed that a direct laryngoscope is used and when using the video laryngoscope, respectively.~Next, the intubation practitioner will perform tracheal intubation with it."
89506359|NCT05245799|Active Comparator|Speech Language Therapy|Children who are deaf/hard of hearing will receive standard of care speech and language therapy with a speech language pathologist. Reading time is prescribed 20 min, 3x/week.
89506360|NCT05245799|Experimental|Speech Language Therapy + Digital Phase|Children who are deaf/hard of hearing will receive standard of care speech and language therapy with a speech language pathologist with the addition of the digital app named, Hear Me Read, that will be used to achieve reading, speech and language goals through interactive digital storybook reading. Reading time is prescribed 20 min, 3x/week.
89506361|NCT05243082|Other|Historical controls|Historical controls
89023808|NCT04706715|Experimental|Feasibility cohort|The purpose of part B of the study is to analyze the PK of 89Zr-DFO-REGN3767 in patients before and during treatment with cemiplimab with or without platinum-based chemotherapy.
89023809|NCT04706598|Experimental|Intravesical therapy group|"Camrelizumab(SHR-1210) is administered on the first day of each treatment cycle (D1) at a dose up to 200 mg. The recommended phase II dose(RP2D) to be decided after safety run-in.~The cycle is divided into an induction course and a maintenance course. The induction course is initiated 2 weeks after TURBT and repeat once a week for 6 weeks . After that, the maintenance course starts every 3 weeks. The maximum duration of dosing is 2 years."
89023810|NCT04700722||Parkinson's disease|Looking for 105 patients with a clinically established diagnosis of Parkinson's disease between 40-99 years of age.
89023811|NCT04700722||Multiple System Atrophy|Looking for 40 patients with a clinically established diagnosis of Multiple System Atrophy between 40-99 years of age.
89023812|NCT04700722||Dementia with Lewy bodies|Looking for 95 patients with a clinically established diagnosis of Dementia with Lewy bodies between 40-99 years of age.
89023813|NCT04700722||Pure Autonomic Failure|Looking for 60 patients with a clinically established diagnosis of Pure Autonomic Failure between 40-99 years of age.
89206777|NCT00949065|Placebo Comparator|NaCl 0.9%|NaCl 0.9%, 3x, every 4 weeks, then 3 months washing out, then 0.36-0.44g/Kg IvIg, 3x, every 4 weeks
89506362|NCT05237960|Experimental|Arm I (extended release metformin)|Patients receive extended release metformin hydrochloride PO QD for 24 weeks in the absence of disease progression or unacceptable toxicity. Patients will also undergo biopsies and blood collections on study.
89506363|NCT05237960|Placebo Comparator|Arm II (placebo)|Patients receive a placebo PO QD for 24 weeks in the absence of disease progression or unacceptable toxicity. Patients will also undergo biopsies and blood collections on study.
89506364|NCT05236803|Other|Epidemiology|Recording of participant's performance during eye, fine motor and gross motor tests Passing self and hetero questionnaires.
89506365|NCT05220345|Other|colonoscopy with a combined BFT and CADe assisted approach|This multicenter single-arm colonoscopy trial will compare colonoscopy assisted by both balloon-BFT visualizing and CADe to CADe-only assisted colonoscopy in diagnostic, screening (non-iFOBT based)), or surveillance colonoscopy. The latter group will be selected from the interventional arm from the Discovery II trial, using corresponding participating centers. All subjects in this trial will undergo the same treatment, i.e., combined balloon and CADe-assisted colonoscopy.
89506366|NCT05206630|Experimental|Embedded ED Physical Therapy|An ED physical therapist will be embedded with the primary treatment team to evaluate patients presenting with low back pain at the beginning of the overall treatment course. The physical therapist will utilize a clinical protocol that matches the patient's history and exam findings to an appropriate treatment classification consisting of directional preference exercises, manual traction, stabilization exercises, non-thrust manipulation/mobilization, and/or psychologically informed rehabilitation. The embedded PT intervention will supplement any usual care performed by the treating physician.
89506367|NCT05206630|No Intervention|Usual Care|Usual care consists of any ED testing or treatment not involving an ED physical therapist in accordance with the treating physician's usual and customary practice. This could include diagnostic imaging, patient education and reassurance, and administration and/or prescribing of analgesic medications.
89506368|NCT05204004|Experimental|Sunrise|Participants under investigation for OSA will use both devices (Sunrise solution and overnight polygraphy) simultaneously for a single overnight sleep study. Participants randomised to the 'Sunrise' arm will receive their treatment decision based on the Sunrise solution.
89506369|NCT05204004|Active Comparator|Polygraphy|Participants under investigation for OSA will use both devices (Sunrise solution and overnight polygraphy) simultaneously for a single overnight sleep study. Participants randomised to the 'polygraphy' arm will receive their treatment decision based on the polygraphy.
89506370|NCT05201924|Experimental|Bedtime routine|A bedtime routine intervention handbook and check list, including bedtime brushing, limited sugar consumption around bedtime, reading books instead of using screen devices before bed, setting a regular bedtime, turning off the light, and reaching a 9 to 11-hour sleep duration
89506371|NCT05201924|Active Comparator|control group|healthy lifestyle checklist
89506372|NCT05192057|Experimental|Hypertonic Saline inhalation|Participants randomized to the Hypertonic Saline inhalation arm will be prescribed a nebulizer for Hypertonic Saline Inhalation (5ml, 5.8%) two times a day for 12 weeks. Participants will also receive best supportive care for 12 weeks (see below).
89506373|NCT05192057|No Intervention|Best supportive care|Participants randomized to the best supportive care arm will receive standard of care including management of predisposing (lung) disease, guidance in smoking cessation, respiratory physiotherapy (e.g. airway clearance), nutritional guidance, but no antimycobacterial treatment.
89506374|NCT05183542|Experimental|Patients|Patients with bone scan
89506375|NCT05167500||Experimental : Lorlatinib inn ALK Or ROS1 Metastatic NSCLC patient|Patients with metastatic non-small cell lung cancer treated with lorlatinib who were included in the compassionate use program in Spain between November 2016 and February 2019 for those with an ALK alteration, and between November 2016 to March 2021 for those with ROS1 alteration.
89506376|NCT05148871|Active Comparator|3 week arm|Subjects will receive two doses of vaccine 3 weeks apart
89506377|NCT05148871|Active Comparator|4 week arm|Subjects will receive two doses of vaccine 4 weeks apart
89506378|NCT05148871|Active Comparator|5 week arm|Subjects will receive two doses of vaccine 5 weeks apart
89506379|NCT05148871|Active Comparator|6 week arm|Subjects will receive two doses of vaccine 6 weeks apart
89023814|NCT04700722||Healthy Controls|No history of clinical or symptoms suggestive of Parkinson's disease, Multiple System Atrophy, Dementia with Lewy bodies or Pure Autonomic Failure between 40-99 years of age.
89023815|NCT04686747||Esophageal Cancer|
89023816|NCT04686747||Gastric Cancer|
89206778|NCT05351619|Experimental|An intervention group|An intervention group: will include 41 patients who will receive the oral care bundle.
89023817|NCT04686747||Pancreatic Cancer|
89023818|NCT04686747||Colorectal Cancer|
89023819|NCT04670874||Observational (quality of life questionnaire)|Patients complete quality of life questionnaires over 10-20 minutes about symptoms, emotions, and functioning related to diagnosis of cutaneous lymphoma.
89539482|NCT03238391|Experimental|Study group|Patients will receive ischemia and reperfusion of the arm by inflating a blood pressure cuff around the arm at 50 mmHg above the systolic blood pressure for 5 minutes, followed by 5 minutes of reperfusion and this cycle will be repeated three times
89539483|NCT03238391|Sham Comparator|Sham group|Patients will receive ischemia and reperfusion of the arm by inflating a blood pressure cuff around the arm at 10 mmHg below the diastolic blood pressure for 5 minutes, followed by 5 minutes of reperfusion and this cycle will be repeated three times
89539484|NCT03238469|Experimental|Microwave ablation|One-sided single microwave ablation (MWA) treatment in one axillary region with a miraDry device.
89539485|NCT03238469|No Intervention|No microwave ablation|Lesion intervention in the non-MWA treated contralateral axilla consists of once daily topical clindamycin 1% lotion.
89539486|NCT04486469|Experimental|Subjects with Irritable bowel syndrome|Experimental group is formed with 24 patients diagnosed with IBS treated in the digestive system service of the Virgen de la Arrixaca and Reina Sofía General University Hospitals.
89539487|NCT04486079|Experimental|Carbohyrate loading|Group A will receive 400ml of the carbohydrate rich drink, Nutricia preOp 2 hours before operation. This is the intervention group.
89539488|NCT04486079|No Intervention|Fasting|Group B will be prepared before the operation with a 24-hour fasting. This is the current clinical standard.
89539489|NCT03238313|Experimental|Plan A|Plan A is the treatment condition. It is a 23-minute video that is designed to promote effective contraceptive use, use of dual methods of protection (condom use and prescription birth control use), and HIV/STI testing in African/American and Latina young women.
89539490|NCT03238313|Active Comparator|Toxic Life Cycle of a Cigarette|The Toxic Life Cycle of a Cigarette is the counterfactual condition. It is a 17-minute video, but contains no information about reproductive health. Instead, the video teaches about the harms of cigarettes.
89539491|NCT03238079|Experimental|Open-Label 10% IGIV|"IMP will be administered every 21 or 28 days in accordance with the subject's weekly regimen at screening for a period of 12 months. Subjects on a 21-day regimen will receive approximately 17 infusions, and subjects on a 28-day regimen will receive approximately 13 infusions.~The starting dose will be the previous IGIV dose or a dose calculated from the previous SCIG dose up to a maximum of 900 mg/kg/mo."
89539492|NCT05387681|Experimental|Envafolimab, Endostatin and SOX regimen|Preoperative short course radiotherapy with Envafolimab, Endostatin and SOX regimen
89539493|NCT03238157|No Intervention|Observation|"The study will only include those patients that are ascertained be at more than 50% risk for vision loss (20/200 or worse at 3 years) because of total radiation dose of >40 Gy to the center of the macula. These at risk patients included in the study will receive intravitreal triamcinolone (4 mg in 0.1 ml) injected at the time of plaque removal. If lack of IOP rise (30 mm Hg or more) at 3 months, then randomized to either observation (2:1) (standard of care)."
89023820|NCT04669288|Active Comparator|Treatment - Active|Eligible patients will be randomly assigned to one of two treatment groups (1:1) and one arm will be administered the active drug per the randomization schedule. Study medication will be provided to parents/guardians, along with instructions, for home-based administration. The first dose of the study medication will be administered before discharge from the ED.
89023821|NCT04669288|Placebo Comparator|Treatment - Placebo|Eligible patients will be randomly assigned to one of two treatment groups (1:1) and one arm will be administered placebo per the randomization schedule. Study medication will be provided to parents/guardians, along with instructions, for home-based administration. The first dose of the study medication will be administered before discharge from the ED.
89023822|NCT04666987||Xultophy®|Participants are patients with Type 2 Diabetes (T2D) treated with Xultophy® (IDegLira) in a real-world setting in Italy
89023823|NCT04666454|Active Comparator|Randomisation 1: Adenosine and Dipyridamole|Adenosine infusion 70 µg/kg/min for 3 hours, followed (first dose 60 minutes apart from the end of the adenosine infusion) by daily oral treatment with the adenosine reuptake inhibitor dipyridamole (200 mg b.i.d.) until normalization of Left Ventricular (LV) function (EF≥50%) is documented on the study-specific echocardiographic assessment at 48-96 hours or at any subsequent echocardiographic examination, or for 30+7 Days.
89023824|NCT04666454|Other|Randomisation 1: Control|Care as recommended by the Taskforce on Takotsubo Syndrome of the Heart Failure Association of the European Society of Cardiology.
89023825|NCT04666454|Active Comparator|Randomisation 2: Apixaban|Apixaban 5mg b.i.d. per oral until normalization of LV function (EF≥50%) is documented on the study-specific echocardiographic assessment at 48-96 hours or any subsequent echocardiographic examination, or for 30+7 Days.
89023826|NCT04666454|No Intervention|Randomisation 2: No anticoagulant therapy|
89023827|NCT04648254|Experimental|Dose escalation (Q702)|Participants will receive escalating doses of Q702
89539494|NCT03238157|Active Comparator|Intervention|"The study will only include those patients that are ascertained be at more than 50% risk for vision loss (20/200 or worse at 3 years) because of total radiation dose of >40 Gy to the center of the macula.1 These at risk patients included in the study will receive intravitreal triamcinolone (4 mg in 0.1 ml) injected at the time of plaque removal. If lack of IOP rise (30 mm Hg or more) at 3 months, then randomized to intravitreal Fluocinolone Acetonide (FA) implant."
89539495|NCT04485845|Active Comparator|metformin treated group|A group of patients treated with a daily dose of metformin
89539496|NCT04485845|Experimental|vildagliptin treated group|A group of patients treated with a daily dose of vildagliptin
89539497|NCT03237767|Experimental|Moderate vs. High-intensity exercise (randomised)|Compare the effects of a single session of moderate continuous exercise versus high-intensity interval exercise (MIE completed first)
89539498|NCT03237767|Experimental|High-intensity vs. Moderate intensity exercise (randomised)|Compare the effects of a single session of moderate continuous exercise versus high-intensity interval exercise (HIIE completed first)
89539499|NCT00700427|Experimental|Atomoxetine|Atomoxetine 40-100 milligrams per day (mg/day) orally, once daily or twice daily for 24 weeks, followed by atomoxetine 80-100 mg/day orally, once daily or twice daily for 25 weeks.
89539500|NCT00700427|Placebo Comparator|Placebo|Atomoxetine 40-100 mg/day orally, once daily or twice daily for 24 weeks, followed by placebo orally, once daily for 25 weeks.
89539501|NCT03237533|Active Comparator|Study Group|in this group patients will be treated with Dexamethasone local application
89539502|NCT03237533|Active Comparator|Control Group|in this group patients will be treated with dexamethasone, doxycycline and nystattin
89539503|NCT03107663|Experimental|⁸⁹Zr-Df-IAB22M2C Infusion|3.0 (±20%) mCi of ⁸⁹Zr-Df-IAB22M2C (with 0.2 mg, 0.5 mg, 1.0mg, 1.5 mg, 5.0 mg, or 10.0 mg of protein) will be administered intravenously over 5-10 minutes
89539504|NCT02453633|Experimental|Emotional SMS text|Patients in this arm will receive an emotion-based SMS reminder of their scheduled outpatient clinic appointment.
89539505|NCT02453633|Active Comparator|Standard SMS text|Patients in this arm will receive the standard SMS reminder of their scheduled outpatient clinic appointment.
89539506|NCT03236831|Other|Subjects Undergoing Prospective VAD|Patients undergoing VAD placement. The investigators will provide clinical recommendations to the subject's primary care provider.
89539507|NCT03236753|Experimental|Thread-Embedding Acupuncture (TEA)|The TEA group will be treated once a week for 8 weeks, using 29G x 40mm or 29G x 60mm TEA on predefined 23 acupoints selected by expert group according to STRICTA. All other treatment affecting the outcomes will be prohibited during the trial period. All therapeutic procedure will be performed by acupuncture specialists who have received training for the consensus of multicenter.
89539508|NCT03236753|Sham Comparator|Sham Thread-Embedding Acupuncture (STEA)|The STEA group will be treated once a week for 8 weeks, using 29G x 40mm or 29G x 60mm sham TEA on predefined 23 acupoints selected by expert group according to STRICTA.
89539509|NCT02453477|Experimental|Adults|"≥18 years (3 subjects) The ATIMP consists of autologous CD34+ cell enriched fraction containing hematopoietic stem cells (HSC) transduced with the GLOBE lentiviral vector encoding for the beta-globin gene re-suspended in their final formulation medium.~Dosage indications The target dose in the transduced product is 5x10(6) cells/Kg CD34+cells, with a minimum dose of 2x10(6)/Kg and a maximum dose of 20x10(6)/Kg, depending on the yield of cells.~The product will be injected intraosseously."
89539510|NCT02453477|Experimental|Elderly children|"8-17 years (3 subjects) The ATIMP consists of autologous CD34+ cell enriched fraction containing hematopoietic stem cells (HSC) transduced with the GLOBE lentiviral vector encoding for the beta-globin gene re-suspended in their final formulation medium.~Dosage indications The target dose in the transduced product is 5x10(6) cells/Kg CD34+cells, with a minimum dose of 2x10(6)/Kg and a maximum dose of 20x10(6)/Kg, depending on the yield of cells.~The product will be injected intraosseously."
89539511|NCT02453477|Experimental|Younger children|"3-7 years (4 subjects) The ATIMP consists of autologous CD34+ cell enriched fraction containing hematopoietic stem cells (HSC) transduced with the GLOBE lentiviral vector encoding for the beta-globin gene re-suspended in their final formulation medium.~Dosage indications The target dose in the transduced product is 5x10(6) cells/Kg CD34+cells, with a minimum dose of 2x10(6)/Kg and a maximum dose of 20x10(6)/Kg, depending on the yield of cells.~The product will be injected intraosseously."
89539512|NCT03236675||EML4-ALK|ALK positive patients
89539513|NCT03236675||T790M EGFR|T790M positive patients
88957445|NCT01984047|Experimental|GSK3050002 0.5 mg|Six subjects in this cohort will receive a single dose of GSK3050002 0.5 mg and two subjects will receive a single dose of placebo intravenously. Sentinel subjects will be used in the cohort.
88957446|NCT01984047|Experimental|GSK3050002 1 mg|Six subjects in this cohort will receive a single dose of GSK3050002 1 mg and two subjects will receive a single dose of placebo intravenously. Sentinel subjects will be used in the cohort
88957447|NCT01984047|Experimental|GSK3050002 5 mg|Six subjects in this cohort will receive a single dose of GSK3050002 5 mg and two subjects will receive a single dose of placebo intravenously. Sentinel subjects will be used in the cohort.
89206779|NCT05351619|No Intervention|A control group|A control group: will include 41 patients who will receive the traditional oral care.
89206780|NCT05351463|Other|one arm study|in each case one site was assigned as control site and one site was assigned as test site.
89206781|NCT04226391||RAS Partial Nephrectomy|
89206782|NCT04226391||RAS Radical Prostatectomy|
89539514|NCT03236597|No Intervention|Usual Desk|participants will work at their usual desk for four weeks.
89539515|NCT03236597|Experimental|Treadmill desk|Participants will be asked to use a treadmill desk for a minimum of 30 minutes per day for four weeks (Participants will sign up for a total of 30 minutes each day). Additional time may be spent on the treadmill, time permitting (two treadmills will be available to up to 10 people over the four week period).
89539516|NCT02453165|Experimental|TRANSVAGINAL SUTURE|INTERVENTION: Transvaginal suturE of the vaginal vault at the end of a total laparoscopic hysterectomy using vaginal valves and needleholders.
89539517|NCT02453165|Active Comparator|LAPAROSCOPIC SUTURE|INTERVENTION: Laparoscopic suturE of the vaginal vault at the end of a total laparoscopic hysterectomy using with laparoscopic needleholders.
89539518|NCT02453243|No Intervention|Baseline|Retrospective Chart Reviews will be conducted for the period between the original ED-SAFE and the new study to test the long-term sustainability of nurse administered universal screening implemented in the original study.
89539519|NCT02453243|Other|Intervention|"Safety Plan Intervention: Clinician training in safety planning, and~A Lean Implementation Strategy: The Implementation of the safety planning guided by Lean~Combine, this is expected to increase safety planning by clinicians."
89539520|NCT02453243|No Intervention|Maintenance|Test sustainability of safety planning during the Maintenance phase.
89539521|NCT03236363|Experimental|MOVI-da 10! active breaks|It is a physical activity intervention that consists on two daily physical activity active breaks of 10 minutes of duration (intensity: 4-6 METs, Heart rate ≥150 bpm). It is aimed to enhance physical activity, motor skills and cognition among 5 years old children
89539522|NCT03236363|No Intervention|Control|No intervention
89539523|NCT03236363|Experimental|MOVI-da10! integrated physical activity|It is an integrated physical activity intervention that consists on two daily cognitive demanding physical activity breaks of 10 minutes of duration (intensity: 2-3 METs, Heart rate <150 bpm). It is aimed to enhance physical activity, motor skills and cognition among 5 years old children
89539524|NCT03236285|Experimental|HIIT only|Volunteers will be submitted to high-intensity interval training (HIIT) performed in fed state
89539525|NCT03236285|Experimental|CT+FAST|Volunteers will be submitted to continous training (CT) performed in the fasting state
89539526|NCT03236285|Experimental|CT only|Volunteers will be submitted to continous training (CT) performed in fed state.
89539527|NCT03236285|Experimental|HIIT+FAST|Volunteers will be submitted to high-intensity interval training (HIIT) performed in the fasting state.
89539528|NCT03235895|Experimental|Internet based|"Six days of Instructional online CME educational material using Test-Enhanced E-Learning strategy.~Followed by one day face to face CME activity"
89539529|NCT03235895|Active Comparator|Face to Face|Three days face to face Conventional CME educational materials
88957448|NCT01984047|Experimental|GSK3050002 10 mg|Six subjects in this cohort will receive a single dose of GSK3050002 10 mg and two subjects will receive a single dose of placebo intravenously. Sentinel subjects will be used in the cohort.
88957449|NCT01984047|Experimental|GSK3050002 20 mg|Six subjects in this cohort will receive a single dose of GSK3050002 20 mg and two subjects will receive a single dose of placebo intravenously. Sentinel subjects will be used in the cohort.
88957450|NCT01984060|Other|HOME-EX|"Motivational Counseling: Six patient-centered motivational counseling sessions based on the self-determination theory (SDT) of behavior change will be conducted with the patients in the HOME-EX group over 12 weeks.~Exercise Intervention: an individually tailored home-based exercise program performed 5-7 days a week that consists of walking prescription, and individualized strength training exercise designed to provide moderately intense progressive resistance exercise. Subjects will be given a set of 3 color-coded therapeutic resistance bands representing varying levels of resistance and they will start with a number of sets which is customized for each individual and they will be encouraged to progressively increase from their individual baseline sets."
88957451|NCT01984060|No Intervention|Control|Subjects are instructed to maintain their usual activities during the study period. This group did not receive any PA counseling or recommendations.
88957452|NCT01984073|Active Comparator|ER Niacin Oral Fat Challenge|ER Niacin (Niaspan) 2000mg one hour prior to Oral Fat Challenge using fresh cream at a dose of 50 g fat per square meter of body surface area. This is followed by frequent plasma and urine collections for next 12 hours to assess markers of fat metabolism and inflammation.
88957453|NCT01984073|Active Comparator|IR Niacin Oral Fat Challenge|Immediate-Release Niacin (Nialor) 500 mg one hour prior to Oral Fat Challenge and again 1, 3 and 5 hours after the oral fat load for a total dose of 2 grams.Subjects will undergo plasma and urine collections for 12 hours to assess markers of fat metabolism and inflammation.
88957454|NCT01984073|Placebo Comparator|Placebo Oral Fat Challenge|Placebo one hour before and 1,3, and 5 hours after oral fat load using heavy cream at 50 grams of fat per square meter of body surface area. Plasma and urine collections for 12 hours
88957455|NCT01984086|Experimental|Part A|Subjects will receive following six treatments each in six period, with a 3-days minimum wash-out period, between each treatment period: 1) Single dose (SD) salbutamol (200mcg per blister from 1.6% blend) delivered via the UD-DPI by inhalation of 3 Blisters (BTR) giving a total dose of 600mcg; 2) SD salbutamol sulphate (200mcg per BTR from a 1.0% blend) delivered via the UD-DPI by inhalation of 3 BTR giving a total dose of 600mcg; 3) SD salbutamol (150mcg per BTR from a 1.6% blend) delivered via the UD-DPI by inhalation of 3 BTR giving a total dose of 450mcg; 4) SD salbutamol (250mcg per BTR from a 1.6% blend) delivered via the UD-DPI by inhalation of 3 BTR giving a total dose of 750mcg; 5) SD of salbutamol (200mcg per BTR) delivered via the Diskus by inhalation of 3 BTR giving a total dose of 600mcg; 6) SD salbutamol (100mcg per actuation) delivered via the MDI giving a total dose of 600mcg
89206783|NCT00949143|Experimental|forward position|
89206784|NCT00949143|Experimental|rear position|
89206785|NCT00955071|No Intervention|Control|
89206786|NCT00955071|Active Comparator|Exercise: LVLI|low volume, low intensity
89539530|NCT03235895|No Intervention|Wait listed|No CME activity will be given
89539531|NCT03236051|Experimental|multimodal analgesia|Patients received multimodal analgesia after laparoscopic gastrectomy .
89539532|NCT03236051|Active Comparator|PCIA analgesia|Patients received PCIA analgesia after laparoscopic gastrectomy.
89539533|NCT03236207|Experimental|Test infant formula|Test non-commercial extensively hydrolyzed infant formula with HMOs
89539534|NCT03236207|Active Comparator|Control infant formula|Control non-commercial extensively hydrolyzed infant formula without HMOs
89539535|NCT03235973|Experimental|Fludarabine-Cladribine-Busulfan conditioning regimen|
89539536|NCT03235661|Experimental|BiPAP|BiPAP as a primary mode of ventilation in one of the preterm infants with respiratory distress syndrome
89539537|NCT03235661|Active Comparator|nCPAP|nCPAP is used as a primary mode of ventilation in another of the preterm infants with respiratory distress syndrome
89539538|NCT03235427||Received Radiation Therapy(RT)|Patients who had received radiotherapy will be sub-stratified into those who received treatment to the left or right breast.
89539539|NCT03235427||Did not receive Radiation Therapy (RT)|Patients who did not receive radiation treatment, but received chemotherapy, hormonal therapy, and/or surgery will be used as study controls to compare the prevalence and burden of cardiac disease as compared to radiation patients.
89539540|NCT02453087|Experimental|DCDS0780A Monotherapy|Participants will receive escalating doses of DCDS0780A as intravenous infusion as monotherapy on Day 1 of each 21-day cycle up to approximately 1 year or until disease progression or unacceptable toxicity (whichever comes first).
89539541|NCT02453087|Experimental|DCDS0780A + Rituximab|Participants will receive escalating doses of DCDS0780A on Day 2 of Cycles 1 and 2, and from Cycle 3 onwards on Day 1 of each 21-day cycle in combination with rituximab at a dose of 375 milligrams per square meter (mg/m^2) of body surface area as intravenous infusion on Day 1 of each 21-day cycle up to approximately 1 year or until disease progression or unacceptable toxicity (whichever comes first).
89539542|NCT02453087|Experimental|DCDS0780A + Obinutuzumab|Participants will receive escalating doses of DCDS0780A on Day 2 of Cycles 1 and 2, and from Cycle 3 onwards on Day 1 of each 21-day cycle in combination with obinutuzumab at a dose of 1000 milligrams (mg) as intravenous infusion on Days 1, 8, and 15 of Cycle 1, and from Cycle 2 onwards on Day 1 of each 21-day cycle up to approximately 1 year or until disease progression or unacceptable toxicity (whichever comes first).
89539543|NCT03235583|Other|MotionPod Validation|Medical device validation
89539544|NCT03235193|Experimental|With InSight|Healthcare provider receives an alert from InSight for patients trending towards severe sepsis. Healthcare provider also receives information from the severe sepsis detector in the CHH electronic health record.
89539545|NCT03235193|Active Comparator|Without Insight|Healthcare provider does not receive any alerts from InSight. Healthcare provider receives information from the severe sepsis detector in the CHH electronic health record.
89539546|NCT02128763|Experimental|Omega-3 supplements|Total 2000 mg EPA and 1000 mg DHA per day taken in 5 gelcaps
89539547|NCT02128763|Placebo Comparator|Placebo|Olive oil-5 gelcaps per day
89539548|NCT02124772|Experimental|Part A - TMT 0.0125 mg/kg/day|Participants treated with trametinib 0.0125 mg/kg/day
89539549|NCT02124772|Experimental|Part A - TMT 0.025 mg/kg/day|Participants treated with trametinib 0.025 mg/kg/day
89539550|NCT02124772|Experimental|Part A - TMT 0.032 mg/kg/day|Participants under 6 years of age treated with trametinib 0.032 mg/kg/day
89539551|NCT02124772|Experimental|Part A - TMT 0.04 mg/kg/day|Participants treated with trametinib 0.04 mg/kg/day
89539552|NCT02124772|Experimental|Part B - Neuroblastoma|Participants with refractory or relapsed neuroblastoma treated with trametinib 0.025 mg/kg/day
89539553|NCT02124772|Experimental|Part B - LGG fusion|Participants with refractory or relapsed neuroblastoma treated with trametinib 0.025 mg/kg/day
89539554|NCT02124772|Experimental|Part B - NF-1 with PN|Participants with neurofibromatosis Type -1 associated plexiform neurofibromas (NF-1 with PN) treated with trametinib 0.025 mg/kg/day
89539555|NCT02124772|Experimental|Part B - BRAF V600 mutant solid tumor|Participants with BRAF V600 mutant solid tumors treated with trametinib 0.025 mg/kg/day
89539556|NCT02124772|Experimental|Part C - TMT 0.025 mg/kg/day + 50% DRB RP2D|Participants treated with a combination therapy of trametinib (0.025 mg/kg/day) plus 50% of the recommended phase II dose (RP2D) of dabrafenib monotherapy (2.63 mg/kg/day for <12 years old subjects and 2.25 mg/kg/day for ≥12 years old subjects)
89539557|NCT02124772|Experimental|Part C - TMT 0.025 mg/kg/day + 100% DRB RP2D|Participants treated with a combination therapy of trametinib (0.025 mg/kg/day) plus 100% of the recommended phase II dose (RP2D) of dabrafenib monotherapy (5.25 mg/kg/day for <12 years old subjects and 4.5 mg/kg/day for ≥12 years old subjects)
89539558|NCT02124772|Experimental|Part C - TMT 0.032 mg/kg/day + 100% DRB RP2D|Participants under 6 years of age treated with a combination therapy of trametinib (0.032 mg/kg/day) with 100% of the recommended phase II dose (RP2D) of dabrafenib monotherapy (5.25 mg/kg/day)
89539559|NCT02124772|Experimental|Part D - LGG|Participants with low grade glioma (LGG) treated with a combination therapy of trametinib (0.032 mg/kg/day for < 6 years old subjects and 0.025 mg/kg/day for ≥ 6 years old subjects) plus 100% of the recommended phase II dose (RP2D) of dabrafenib monotherapy (5.25 mg/kg/day for <12 years old subjects and 4.5 mg/kg/day for ≥12 years old subjects)
89023828|NCT04633005|Experimental|Polypill Arm|Patients will be randomized to receiving a fixed-dose polypill in addition to other guideline-directed medical therapies prescribed by their physician. Polypill formulations will include metoprolol succinate (a beta-blocker), empagliflozin (an SGLT2-inhibitor), and spironolactone (a mineralocorticoid antagonist). Three dose formulations of the pill, varied in metoprolol succinate dose, will be available for up-titration of the beta-blocker dose per ACC/AHA/HFSA guidelines.
89539560|NCT02124772|Experimental|Part D - LCH|Participants with Langerhans cell histiocytosis (LCH) treated with a combination therapy of trametinib (0.032 mg/kg/day for < 6 years old subjects and 0.025 mg/kg/day for ≥ 6 years old subjects) plus 100% of the recommended phase II dose (RP2D) of dabrafenib monotherapy (5.25 mg/kg/day for <12 years old subjects and 4.5 mg/kg/day for ≥12 years old subjects)
89539561|NCT02159482|Experimental|interferon-alfa-2a|Starting within 6 months after completion of the dendritic cell vaccine, a dose of interferon alfa-2a will be administered subcutaneously in the skin of the arm, thigh or abdomen every other day for a total of 6 injections.
89539562|NCT05269030|Experimental|Case group|The patients will receive ivermectin nasal drops
89539563|NCT05269030|Active Comparator|Control group|The patients will receive local steroid spray
89539564|NCT02622321|Experimental|Arm A: 1.5 mg/kg Emicizumab QW|Participants who were receiving episodic treatment with bypassing agents prior to study entry and were randomized to study Arm A started to receive emicizumab prophylaxis. Emicizumab was administered at a loading dose of 3 milligrams per kilogram (mg/kg) once a week (QW) subcutaneously (SC) for the first 4 weeks followed by a maintenance dose of 1.5 mg/kg emicizumab QW SC up to the end of study. Participants continued to receive bypassing agent therapy to treat any breakthrough bleeds.
89539565|NCT02622321|Active Comparator|Arm B (Control): No Prophylaxis, Then Emicizumab|Participants who were receiving episodic treatment with bypassing agents prior to study entry and were randomized to study Arm B continued with their prior episodic treatment regimen for the first 24 weeks of the study; they did not receive emicizumab prophylaxis during that time. After completing at least 24 weeks on study, participants in Arm B were allowed to switch to emicizumab prophylaxis (as described for Arm A) up to the end of study. Participants continued to receive bypassing agent therapy to treat any breakthrough bleeds.
89539566|NCT02622321|Experimental|Arm C: 1.5 mg/kg Emicizumab QW|Participants who were receiving prophylactic bypassing agents prior to study entry were enrolled in Arm C to receive prophylactic emicizumab. Emicizumab was administered at a loading dose of 3 mg/kg QW SC for the first 4 weeks followed by a maintenance dose of 1.5 mg/kg emicizumab QW SC up to the end of study. Participants continued to receive bypassing agent therapy to treat any breakthrough bleeds.
89539567|NCT02622321|Experimental|Arm D: 1.5 mg/kg Emicizumab QW|Participants who were either: 1) Receiving episodic bypassing agents prior to study entry but were unable to enroll in Arms A or B; or 2) Receiving bypassing agent prophylaxis prior to study entry but were unable to enroll in Arm C, were enrolled in Arm D to receive emicizumab prophylaxis. Emicizumab was administered at a loading dose of 3 mg/kg QW SC for the first 4 weeks followed by a maintenance dose of 1.5 mg/kg emicizumab QW SC up to the end of study. Participants continued to receive bypassing agent therapy to treat any breakthrough bleeds.
89539568|NCT02187172|Active Comparator|Ustekinumab (Stelara)|Ustekinumab (Stelara) subcutaneous injection 45mg (if person's weight is 100kg or less) or 90mg (if person's weight is greater than 100kg) at day 0 and week 4 followed by every 12-week dosing thereafter. Patient will receive total of 52 weeks of ustekinumab (12 weeks during RCT phase, 40 weeks post RCT phase). The end of study is at Week 52 for this arm.
89539569|NCT02187172|Placebo Comparator|Placebo|Placebo subcutaneous injection will be given according to the same dose and schedule as the active comparator until week 12 (end of RCT phase). At week 12, ustekinumab will be administered according according to the same injection schedule as the active comparator arm for 52 weeks. Patient will receive total of 52 weeks of ustekinumab (0 weeks during RCT phase, 52 weeks post RCT phase). The end of study is at Week 64 for this arm.
89539570|NCT03056937||Obese with metabolic syndrome|bariatric surgery
89539571|NCT03056937||Obese without metabolic syndrome|bariatric surgery
89539572|NCT03056937||Healthy|Control
89539573|NCT03057015|Experimental|Clonidine|50 mcg clonidine + 0.5% ropivacaine + 2 mg dexamethasone + 5 mcg/ml epinephrine in 20 ml solution
89539574|NCT03057015|Placebo Comparator|Placebo|0.5 ml normal saline + 0.5% ropivacaine + 2 mg dexamethasone + 5 mcg/ml epinephrine in 20 ml solution
89539575|NCT04934085||Study group|subjects who had tested positive and recovered from COVID-19
89539576|NCT04934085||Control group|healthy subjects who did not have COVID-19, the controls will be matched to the study group for gender and age
89539577|NCT04929717|Experimental|Intervention|The personal information form and BSES-SF were administered to women in the hospital before the intervention. Breastfeeding education and counseling were provided via social media (WhatsApp) to support women for breastfeeding and to ensure the continuity of breastfeeding in the postpartum period. Breastfeeding education was given to women in the first four weeks after discharge from the hospital. After the breastfeeding education was completed via social media, the counseling process started. Counseling was conducted via social media with a question-answer method between the first and 6th months of postpartum.
89539578|NCT04929717|Other|Control|The women in the control group were pre-tested at the hospital before discharge. The BSES-SF was re-administered by phone at the 3rd and 6th postpartum months. The control group received the routine breastfeeding postpartum educational training given to all women by healthcare personnel as part of the hospital procedures. Except for routine breastfeeding training, no intervention was applied to the control group.
89539579|NCT04955613|Active Comparator|Standard care|"12 sessions in total: sessions 1: Meeting with a doctor and physical therapist. sessions 2-11:Mirror therapy (standard care) for a total of 10 sessions over a period of 5 weeks (15-20 minutes per session).~sessions 12: Meeting with a doctor and physical therapist."
89539580|NCT04955613|Active Comparator|MyMove/VR system|"sessions 1: Meeting with a doctor and physical therapist. sessions 2-11:MyMove devices and VR gear for a total of 10 sessions over a period of 5 weeks 15-20 minutes per session.~sessions 12: Meeting with a doctor and physical therapist."
89539581|NCT04431531|Active Comparator|yogatherapy-EMDR|one of the two groups will have yogatherapy treatment and Eye movement desensibilization reprocessing (EMDR)
89539582|NCT04431531|Active Comparator|waiting list and EMDR|The other group will have Eye movement desensibilization reprocessing
88815271|NCT05096546||Group II|"20 years old or older (regardless of sex)~Outpatients~Patients who had undergone cataract surgery and~was suspected to have dry eye disease (dry eye evaluations conducted based on the routine practice) within 6 months prior to signing the informed consent or~was diagnosed with dry eye disease within 6 months prior to signing the informed consent"
89206787|NCT00955071|Active Comparator|Exercise: HVLI|high volume, low intensity
89023829|NCT04633005|Active Comparator|Control Arm|Patients will receive GDMT as usually prescribed by their provider. All of the individual components will be available at low- or no-cost to participants as individual pill formulations.
89539583|NCT04929561|Experimental|Video-conferencing group|The mothers in the video-conferencing group were counseled via video-conferencing a total of six times (three times a week, at equal intervals) during the first 2 weeks after birth. Each interview was approximately 15-20 minutes. In video-conferencing sessions, the breastfeeding position, the mother's grasping the breast, the baby's latch-on, and sucking duration were observed. Mothers' questions were answered and solutions were offered for breastfeeding problems (sore nipple, engorgement, etc.).
89539584|NCT04929561|No Intervention|Control group|The mothers in the control group were given usual care before discharge and no intervention was made after discharge.
89539585|NCT04934241|Experimental|Self-Acupressure|Self-Acupressure Each application to the acupressure points (HT 7, CV17,PC 6, LI4,SP 6) will be done in 2 minutes and right and left)
89539586|NCT04934241|No Intervention|Control group|Routine maintenance will be applied
89539587|NCT04929093|Experimental|Novel dose adjustment schedule|The patients in this group had late injections of more than 16 weeks in maintenance period, and restarted SCIT with novel dose adjustment schedule.
89539588|NCT04929093|Active Comparator|Conventional dose adjustment|The patients in this group had late injections of more than 16 weeks in maintenance period, and restarted SCIT with conventional dose adjustment schedule.
89539589|NCT04929093|Active Comparator|Continuous cluster SCIT schedule|The subjects had a routine cluster SCIT schedule without interrupted period.
89539590|NCT04408209|Experimental|Convalescent Plasma|Convalescent Plasma - early treatment of patients with severe COVID-19
89023830|NCT04627103|Experimental|Device Placement|The subjects in this arm will receive the Self-Forming Magnet (SFM) System that will be used to create a duodenal-ileal diversion. Following the diversion creation, a sleeve gastrectomy will also be performed.
89539591|NCT03057483||Elderly|People over 60 years of age. seasonal influenza vaccine
89023831|NCT04622527|Active Comparator|A = Virtual Reality paradigm A|Begin with Paradigm A virtual reality headgear
89023832|NCT04622527|Active Comparator|B = Virtual Reality paradigm B|Begin with Paradigm B virtual reality headgear
89023833|NCT04622527|Sham Comparator|C = Non-Virtual Reality paradigm A|Begin with Paradigm A without virtual reality headgear
89023834|NCT04622527|Sham Comparator|D = Non-Virtual Reality paradigm B|Begin with Paradigm B without virtual reality headgear
89206788|NCT00955071|Active Comparator|Exercise: LVHI|low volume, high intensity
89206789|NCT00955149|Experimental|Arm A|Erlotinib (Tarceva) 25 mg by mouth once daily.
89206790|NCT00955149|Experimental|Arm B|Erlotinib (Tarceva) 50 mg by mouth once daily for 6 months
89206791|NCT00747227|Experimental|ZV9003|modified light transmission intraocular lens
89206792|NCT00747227|Active Comparator|ZA9003|monofocal acrylic intraocular lens
89539592|NCT03057483||Health care workers|People working in health care services seasonal influenza vaccine
89539593|NCT03057483||Pregnant women|Pregnant women seasonal influenza vaccine
89539594|NCT03057483||Post partum women|Women who have given birth < 45 days seasonal influenza vaccine
89539595|NCT03057483||Children|Children from 6 months to 5 years of age seasonal influenza vaccine
89539596|NCT04929327|Active Comparator|Self-etch resin based sealant|Self-etch resin based sealant (prevent seal) without prior sandblasting.
89539597|NCT04929327|Active Comparator|Prior Sandblasting|Self-etch resin based sealant prevent seal) with prior sandblasting.
89539598|NCT04929327|Active Comparator|Total-etch resin based sealant|Total-etch resin based sealant (ultraseal XT) (Ultradent Pro. Inc., USA)
89539599|NCT04955145|Active Comparator|Ruta C 60 group|Ascorbic Acid/Rutoside 60 tablet , each tablet contains: Rutin 60mg and Ascorbic acid 160mg Dosage:2 tablets three times daily for 4 months
88957456|NCT01984086|Experimental|Part B|Prior to the start of Part B, a decision will be made regarding the UD-DPI products to be used in Part B. Subjects will receive following 6 treatments each in 6 period, with a 3-days minimum wash-out period, between each treatment period: 1) SD salbutamol (selected from Part A) delivered via the UD-DPI without activated charcoal (AC) by inhalation of 3 BTR (total dose dependant on UD-DPI formulation chosen); 2) SD salbutamol (selected from Part A) delivered via the UD-DPI with AC by inhalation of 3 BTR (total dose dependant on UD-DPI formulation chosen); 3) SD salbutamol by inhalation of 3 BTR (200mcg per BTR) delivered via the Diskus without AC (total dose 600mcg); 4) SD salbutamol by inhalation of 3 BTR (200mcg per BTR) delivered via the Diskus with AC (total dose 600mcg); 5) SD salbutamol 6 inhalations (100mcg) delivered via the MDI without AC (total dose 600mcg); 6) SD salbutamol 6 inhalations (100mcg) delivered via the MDI with AC (total dose 600mcg)
89206793|NCT05351307||POAG patients|OCT angiography will be performed
89206794|NCT05351307||Normal participants|OCT angiography will be performed
89206795|NCT04090541|No Intervention|Control|Tests were applied with any taping.
89206796|NCT04090541|Sham Comparator|Sham Taping|In ST stage; medical purpose, hypoallergenic OctaCare® Rigid Transparent Plaster was applied as a rigid tape. This tape is also used under rigid tapes for protecting the skin. In this study investigators didn't prefer extra rigid tape on the plaster because that was very light and less sensitive material to our knowledge so it suited our aim of placebo control.
89506380|NCT05144698|Experimental|Administration of RAPA-201 cells|RAPA-201 cells will be administered at a target flat dose of 400 x 10^6 cells per infusion.
89506381|NCT05142761||Posterior component separation|Patients undergoing posterior component separation
89506382|NCT05142150||Patient|Patient satisfaction with end of life care. Questionnaire to be completed at baseline and every 8 week.
89506383|NCT05142150||Carer|Carer satisfaction with care leading up to the time of death and the quality of the patient's death. Questionnaire to be completed at baseline and every 8 weeks,and 5-7 weeks after patient deceased.
89506384|NCT05123391|Experimental|Low-Intermediate favorable risk 5 Fraction SBRT arm|36.25 Gy in 5 fractions to the prostate weekly or every other day
89506385|NCT05123391|Experimental|Low-Intermediate favorable risk 2 Fraction SBRT arm|26 Gy in 2 fractions to the prostate
89506386|NCT05123391|Experimental|Intermediate unfavorable-high risk prostate only SBRT arm|36.25 Gy in 5 fractions to the prostate and seminal vesicles base, weekly or every other day
89506387|NCT05123391|Experimental|Intermediate unfavorable-high risk prostate and pelvis SBRT arm|25 Gy in 5 fractions to the elective pelvic nodes and simultaneous integrated boost to 36.25 Gy in 5 fractions to the prostate and seminal vesicles base, weekly
89506388|NCT05123391|Experimental|Pelvic node positive moderate hypofractionated radiotherapy|44 Gy in 20 daily fractions to the elective pelvic nodes and simultaneous integrated boost to 60 Gy to the prostate and seminal vesicles base and 54 Gy to positive lymph nodes
89506389|NCT05123391|Experimental|Pelvic node positive moderate ultra-hypofractionated radiotherapy|25 Gy in 5 fractions to the elective pelvic nodes and simultaneous integrated boost to 36.25 Gy in 5 fractions to the prostate and seminal vesicles base and to 30 Gy to positive lymph nodes.
89506390|NCT05048472|Experimental|Intervention|Use of point of care viral load monitoring (Abbott PoC devices)
89506391|NCT05048472|No Intervention|Control|Use of the standard of care viral load monitoring (centralized viral load monitoring)
89506392|NCT05032326|Other|OXYTOCIN (OT) Treated cohort|babies treated with Oxytocin during the OTBB3 study
89506393|NCT05032326|Other|Untreated cohort|babies not included in the OTBB3 study and therefore never treated with Oxytocin
88957457|NCT01984099|Active Comparator|Chemoprohylaxis Group|Chemoprohylaxis Group: the treatment group, will be given a single course of methotrexate within fourteen days from molar evacuation. Methotrexate will be given at 0.4 mg/kg intramuscularly per day for 5 days. No chemotherapy will be administered if the hemoglobin is lower than 10 g/L, WBC is less than 3.0 x 10 g/L or more than 10.0 x 10 g/L, absolute neutrophil count is less than 1.5, platelet count is lower than 100,000/cu.cc., patient has elevated liver and renal function test and has concurrent infection.
88957458|NCT01984099|Placebo Comparator|Control Group|Control Group: will be given a placebo in a form of Vitamin B Complex (Bee ALL), intramuscularly or intravenously.
88957459|NCT01984112|Experimental|Intramedullary Locked Nail|
88957460|NCT01984112|Active Comparator|Locked Plate|
89206797|NCT04090541|Experimental|Kinesiology Taping|In KT stage; the original Kinesio Tex® Tape Classic was applied as a kinesiology tape. In this study, investigators applied the tape with muscle activation technique and paper of tension (it was declared %10) according to Kenzo Kase's Kinesio Taping concept. It was implemented on both bileral Rectus Femoris and Calf muscles with same technique.
89206798|NCT04090541|Experimental|Biomechanical Taping|In BT stage; Dynamic Tape® was applied as a biomechanical tape. In this study, investigators applied the tape with offload technique and paper of tension according to Ryan Kendrick's Biomechanical Taping concept. It was implemented on both bileral Rectus Femoris and Calf muscles with same technique.
89506394|NCT04993300|Experimental|transcranial magnetic stimulation (TMS)|This arm constitute of methamphetamine users who undergone abstinent period
89506395|NCT04986345|Experimental|Rest, HIIT-4, HIIT-10|"Both arms start with the rest condition and the order of the two other conditions (HIIT-4 and HIIT-10) is determined at random.~This arm's sequence of intervention is : 1-Rest; 2- HIIT-4 and 3- HIIT-10."
89506396|NCT04986345|Experimental|Rest, HIIT-10, HIIT-4|"Both arms start with the rest condition and the order of the two other conditions (HIIT-4 and HIIT-10) is determined at random.~This arm's sequence of intervention is : 1- Rest; 2- HIIT-10 and 3- HIIT-4."
89506397|NCT04969133|Active Comparator|TAP Block|"Transverse abdominal block is realisated at the beginning of the surgery with ultrasound guided technique with levobupivacaine 2.5mg/mL, 0.3mL/kg each side.~The patient receives usual analgesia protocol."
89506398|NCT04969133|Active Comparator|local infiltration of the trocar wounds|"local infiltration of the trocar wounds is realisated at the end of the surgery by the surgeon with levobupivacaine 2.5mg/mL 0.6mL/kg distributed in each trocar opening.~The patient receives usual analgesia protocol."
89506399|NCT04921800|Experimental|Wearable Sensor Applied|For these participants, the wearable ADAM sensor will be placed in the sternal notch to record anatomical data during the post-surgical period for up to 14 days
89506400|NCT04910061|Experimental|NMN-C|Healthy individuals receiving NMN-C
88957461|NCT01984125|Experimental|Point-of-Care Prompt|A prompt, either electronically or by a nurse, will notify a provider if an adolescent is due for a vaccination. This prompt will appear at any type of visit where the patient is seen by a health provider.
88957462|NCT01984125|No Intervention|Control|
89506401|NCT04896593|Experimental|Intervention|Smartphone app teaching suicide prevention skills.
89506402|NCT04887610|Sham Comparator|Ischemic preconditioning control|
89506403|NCT04887610|Active Comparator|Ischemic preconditioning|
89506404|NCT04887610|Active Comparator|High fat meal|
89506405|NCT04887610|Placebo Comparator|Low fat meal|
89506406|NCT04887467|Experimental|Patients with Parkinson disease|Apomorphine 5mg/mL, solution for infusion, intraveinous use
89506407|NCT04878393||Patients with type 2 diabetes|Adult patients with type 2 diabetes and naïve to injectable glucose-lowering treatment
89506408|NCT04867642|Experimental|Part A Sequence 1|Study participants randomized to Part A will receive single ascending doses of UCB0022 or placebo (PBO) at pre-specified time points during the Treatment Period of alternating cohorts in a crossover design.
89506409|NCT04867642|Experimental|Part A Sequence 2|Study participants randomized to Part A will receive single ascending doses of UCB0022 or placebo (PBO) at pre-specified time points during the Treatment Period of alternating cohorts in a crossover design.
89506410|NCT04867642|Experimental|Part B UCB0022|Study participants randomized to Part B will receive multiple ascending doses of UCB0022 at pre-specified time points during the Treatment Period of cohorts in a parallel design.
89506411|NCT04867642|Placebo Comparator|Part B Placebo|Study participants randomized to Part B will receive placebo (PBO) comparator at pre-specified time points during the Treatment Period of cohorts in a parallel design.
89506412|NCT04867642|Experimental|Part C UCB0022|Study participants randomized to this cohort in Part C will receive fixed multiple doses of UCB0022 at pre-specified time points during the Treatment Period.
89506413|NCT04867642|Placebo Comparator|Part C Placebo|Study participants randomized to this cohort in Part C will receive placebo (PBO) comparator at pre-specified time points during the Treatment Period.
89506414|NCT04846335|Experimental|Active Bassado|patients with D178N/M129 mutation on prion protein will be treated with Bassad
89506415|NCT04846335|Placebo Comparator|Placebo|subject without the mutation will be treated with plac
89506416|NCT04827875|Experimental|AIV001 Treatment Dose 1|Intradermal, Dose 1
89506417|NCT04827875|Experimental|AIV001 Treatment Dose 2|Intradermal, Dose 2
89506418|NCT04826094|Experimental|Group 1: Vaccine or Placebo|3 doses of prime vaccination or placebo at weeks 0, 4, 12 followed by 3 doses of boost vaccination or placebo at weeks 20, 32, 56
89506419|NCT04826094|Experimental|Group 2: Vaccine or Placebo|3 doses of prime vaccination or placebo at weeks 0, 4, 12 followed by 3 doses of boost vaccination or placebo at weeks 20, 32, 56
89506420|NCT04826094|Experimental|Group 3: Vaccine or Placebo|3 doses of prime vaccination or placebo at weeks 0, 4, 12 followed by 3 doses of boost vaccination or placebo at weeks 20, 32, 56
89506421|NCT04826094|Experimental|Group 4: Vaccine or Placebo|3 doses of prime vaccination or placebo at weeks 0, 4, 12 followed by 3 doses of boost vaccination or placebo at weeks 20, 32, 56
89506422|NCT04826094|Experimental|Group 5: Vaccine or Placebo|3 doses of prime vaccination or placebo at weeks 0, 4, 12 followed by 3 doses of boost vaccination or placebo at weeks 20, 32, 56
89506423|NCT04826094|Experimental|Group 6: Vaccine or Placebo|3 doses of prime vaccination or placebo at weeks 0, 4, 12 followed by 3 doses of boost vaccination or placebo at weeks 20, 32, 56
89506424|NCT04826094|Experimental|Group 7: Vaccine or Placebo|3 doses of prime vaccination or placebo at weeks 0, 4, 12 followed by 3 doses of boost vaccination or placebo at weeks 20, 32, 56
89506425|NCT04797052|Experimental|Post operative patients|Post operative patient in orthopedic and digestive surgery
89506426|NCT04796220|Experimental|Arm A: GEM|
89506427|NCT04796220|Experimental|Arm B: FUS|
89506428|NCT04796220|Experimental|Arm C: GEM/FUS|
89506429|NCT04777045|Experimental|Diltiazem|When signs of vascular dysfunction with the coronary function test.
88957463|NCT01984177||cocaine-dependent (CD)|cocaine-dependent individuals
88957464|NCT01984177||healthy control (HC)|healthy age and sex-matched individuals who do not use cocaine
88957465|NCT01984190||Lower Extremity Joint Arthroplasty|Postoperative venous thromboembolism incidence in lower extremity joint arthroplasty using only the mobile compression device with or without aspirin for venous thromboembolism prevention. Sub-analysis of Total Hip Arthroplasty and Total Knee Arthroplasty will be included.
88957466|NCT01984203|Experimental|Progressive Heavy Strength Exercises|"The Progressive Heavy Load Exercise group gradually increases the external load from 60%RM to 90%RM and correspondently decreases the number of performed repetitions pr. set for the two rotator cuff exercises. Furthermore 4 sets is performed.~A progressive exercise program consisting of 6 active exercises. Two exercises for the rotator cuff: Full Can and Sidelying external rotation Two exercises for the scapulae stabilizing muscles: Low Row and Push-Up Plus Two glenohumeral/postural corrective exercises: Posterior GH stretch and Scapular Retraction."
88957467|NCT01984203|Active Comparator|Low Load Exercises|"Active exercises comparator continuously training with 60%RM through 12 weeks.~An exercise program consisting of 6 active exercises. Two exercises for the rotator cuff: Full Can and Sidelying external rotation Two exercises for the scapulae stabilizing muscles: Low Row and Push-Up Plus Two glenohumeral/postural corrective exercises: Posterior GH stretch and Scapular Retraction."
88957468|NCT01984216|Experimental|Roux-en-Y|Roux-en-Y for the gastrojejunostomy reconstruction
88957469|NCT01984216|Active Comparator|Billroth II|Billroth II for the gastrojejunostomy reconstruction
89506430|NCT04777045|Placebo Comparator|Placebo|When signs of vascular dysfunction with the coronary function test.
89506431|NCT04771455|Experimental|Condition 1|Behavioral weight loss intervention
89506432|NCT04771455|Experimental|Condition 2|Behavioral weight loss intervention and decrease negative affect
89506433|NCT04771455|Experimental|Condition 3|Behavioral weight loss intervention and decrease unhealthy weight control practices
89506434|NCT04771455|Experimental|Condition 4|Behavioral weight loss intervention, decrease unhealthy weight control practices, and decrease negative affect
89539600|NCT04955145|Active Comparator|C- Retard group|Ascorbic acid 500mg capsule dosage: 1 capsule two times daily for 4 months
89539601|NCT04955145|No Intervention|Control group|No intervention
89539602|NCT04933461|Other|Simulation of skin pricking by using Medlance Plus|Estimation of the true failure rate of the device. Estimation of the sharps' injury prevention feature of the tested safety lancets are effective in preventing needle stick injuries.
89539603|NCT04933461|Other|Simulation of skin pricking by using myLance|Estimation of the true failure rate of the device. Estimation of the sharps' injury prevention feature of the tested safety lancets are effective in preventing needle stick injuries.
89539604|NCT04955067||Normal control group-Grade 0|Arthroscopic examination of the ankle joint was normal, and the ligament was intact without injury or tear.
89539605|NCT04955067||Ligament injury -Grade 1|Arthroscopic examination of the ankle joint showed ligament degeneration or injury, but no local or complete tear.
89539606|NCT04955067||Ligament tear-Grade 2|Arthroscopy of the ankle joint revealed partial or complete loss of ligaments.
89539607|NCT04929171||Patients with myofascial pain having centralized pain features|Adult patients with myofascial pain having centralized pain features who will be undergoing physical therapy
89023835|NCT04616534|Experimental|Treatment (gemcitabine, elimusertib)|Patients receive gemcitabine IV over 30 minutes on days 1 and 8 and elimusertib PO QD or BID on days 2-3 and 9-10. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. All patients also undergo medical imaging scans after cycle 2 and then every 9 weeks throughout the trial and collection of blood samples during screening and on days 1, 2, and 9-10 of cycle 1. Patients in the dose-expansion portion of the trial also undergo biopsies during screening and on day 9 of cycle 1.
89023836|NCT04612244|Experimental|FARAPULSE Pulsed Field Ablation System|
89023837|NCT04612244|Active Comparator|Force Sensing Radiofrequency Ablation and Cryoballoon Ablation|
89023838|NCT04606056||Patients who underwent contrast enhanced CT scans|
89023839|NCT04601753||Patients with type 2 diabetes|Adult patients with type 2 diabetes and naïve to injectable glucose-lowering treatment.
89023840|NCT04589754|Experimental|Sintilimab plus chemotherapy|Adriamycin and ifosfamide combined with sintilimab in the treatment of advanced or unresectable soft tissue sarcoma
89023841|NCT04589754|Placebo Comparator|Adriamycin-based chemotherapy|Adriamycin-based chemotherapy in the treatment of advanced or unresectable soft tissue sarcoma
89539608|NCT04928937||bariatric surgery|consisting of gastric bypass surgery: Roux-en-Y gastric bypass (RYGB), sleeve gastrectomy (SG)
89539609|NCT04928937||conservative therapy|consisting of medical visits, nutritional counseling, physiotherapy, anti-obesogenic medication and psychological coaching
89539610|NCT04928469||P.1|Patients infected with the P.1 SARS-CoV-2 variant
89539611|NCT04928469||Other variants|Patients infected with SARS-CoV-2 variants other than P.1
89539612|NCT04922151|Experimental|group I|601 1.25mg
89539613|NCT04922151|Active Comparator|group II|Ranibizuman 0.5 mg
89539614|NCT04928859||the albumin group|The albumin group, the patients who used albumin for resuscitation during their hospitalization in the burn ward constituted the albumin group.
89539615|NCT04928859||the control group|The control group, the patients who did not use albumin during their hospitalization in the burn ward constituted the control group.
89539616|NCT04928001|Other|Youth Thrive iCBT program|Youth Thrive iCBT online program
89539617|NCT04928547||U.S.|
89539618|NCT04928547||MRI|
89539619|NCT04928625|Experimental|SHR-A1904|
89539620|NCT04920747||S group|platin-5FU + trastuzumab
89539621|NCT04920747||T group|taxanes + platin-5FU + trastuzumab
89539622|NCT04927767|Experimental|Denture adhesives|Participants will be shown to apply the adhesive following the manufacturer's instructions. The denture is pressed firmly into place, then held firmly as the participant bites down to secure it. Participants will be instructed to apply the adhesive twice daily with an 8-hour interval.
89023842|NCT04585763|Experimental|Shockwave Medical M5+ Peripheral Intravascular Lithotripsy (IVL)|
89023843|NCT04581512|Experimental|EP0042|
89023844|NCT04572165||semaglutide|New users of Ozempic® or Rybelsus®
89023845|NCT04572165||Active comparator|First-time ever users of an active comparator drug
89023846|NCT04563871|Experimental|80mg Osimertinib|One tablet of 80mg Osimertinib for oral administration per day
89023847|NCT04563325|Active Comparator|Experimental|"< 5 years: High-dose oral co-amoxiclav (1:8) 33 mg amoxicillin/kg/dose (max. 1 g) three-times daily (TDS) until clinical and paraclinical improvement (min. 3 days) followed by oral co-amoxiclav (1:4) 17 mg amoxicillin/kg/dose (max. 500 mg) TDS for 7 days (arthritis) or 21 days (osteomyelitis).~=/> 5 years: High-dose oral dicloxacillin 50 mg/kg/dose (max. 2 g) four-times daily (QID) until clinical and paraclinical improvement (min. 3 days) followed by oral dicloxacillin 25 mg/kg/dose (max. 1 g) QID for 7 days (arthritis) or 21 days (osteomyelitis).~Treatment will be adjusted according to microbiological findings."
89023848|NCT04563325|Active Comparator|Standard|"IV ceftriaxon 100 mg/kg/dose (max. 4 g) once daily (QD) (all ages) until clinical and paraclinical improvement (min. 3 days) followed by:~< 5 years: Oral co-amoxiclav (1:4) 17 mg amoxicillin/kg/dose (max. 500 mg) TDS for 7 days (arthritis) or 21 days (osteomyelitis).~>/= 5 years: Oral dicloxacillin 25 mg/kg/dose (max. 1 g) QID for 7 days (arthritis) or 21 days (osteomyelitis).~Treatment will be adjusted according to microbiological findings."
89539623|NCT04927611||Gastroenteropancreatic neuroendocrine neoplasms|Collect biopsy/surgical fresh tissue of gastroenteropancreatic neuroendocrine neoplasms.
89539624|NCT04927611||Pancreatic ductal adenocarcinoma|Collect biopsy/surgical fresh tissue of pancreatic ductal adenocarcinoma.
89539625|NCT04927299|Experimental|Group A: Losartan + chlorthalidone|Administered orally, one tablet a day, for 2 months.
89539626|NCT04927299|Active Comparator|Group B: Losartan + hydrochlorothiazide|Administered orally, one tablet a day, for 2 months.
89539627|NCT03056625|Experimental|Fortified rice|Participant will be given vitamin A fortified rice 1 meal/day
89539628|NCT03056625|Placebo Comparator|Control|Participant will be given normal rice 1 meal/day
89539629|NCT03056547|Experimental|Induced dyspnea|
89539630|NCT04913181||Sepsis prediction model|This group of people was used for the clinician's decision, and the sepsis prediction model was used simultaneously for the prediction, but the model was not involved in the decision, and was only used for verification
89539631|NCT04913181||Daily clinical judgment of doctors|This group of people was used for the clinician's decision without sepsis prediction model.
89539632|NCT04913103|Experimental|single arm, open-label|combination of polatuzumab-vedotin, bendamustine and rituximab
89539633|NCT04913259|Other|Remote monitoring for elderly patients with cancer|
89539634|NCT04912635|No Intervention|Control|
89539635|NCT04912635|Experimental|Intervention|
89539636|NCT04920669|Experimental|erector spinae block|erector spinae block with 20 ml bupivacaine
89539637|NCT04920669|Experimental|erector spinae block + dexmedetomidine|erector spinae block with 19 ml bupivacaine + dexmedetomidine
89539638|NCT04920669|No Intervention|control group|standard general anesthesia without any block
89539639|NCT04912947|Active Comparator|Dietary supplement|One cp/day of the IMMUSYSTEM food supplement for 3 months
89539640|NCT04912947|Placebo Comparator|Placebo|One cp/day of Placebo for 3 months
89539641|NCT04926753|Experimental|Experimental|5-Fluorouracil(750 mg/m2/d, CIV d1-5) Cisplatin(75mg/m2,d1)/Carboplatin(AUC5, d1) Toripalimab 240mg d1
89539642|NCT04920357||Post-COVID-19|Persons with a verified previous COVID-19 infection
89539643|NCT04920357||COVID-19 naive|Persons that have no history of COVID-19
89539644|NCT04402437|Active Comparator|Receives LP Block|Subjects randomized to the lumbar plexus block group will receive a subcutaneous lidocaine skin wheal 3-4 cm lateral to midline on the operative side along the intercristal line. A nerve stimulator will be sent to 1-1.5mA and a stimulating needle inserted perpendicular to the skin. The needle will be advanced slowly until the quadriceps muscle is stimulated and maintained at less than 0.6mAs. Ropivacaine (20ml, 0.5%) will be injected slowly with frequent aspiration to rule out inadvertent intravascular needle placement.
89539645|NCT04402437|Active Comparator|Receives QL Block|Subjects randomized to the quadratus plexus block group will receive a subcutaneous lidocaine skin wheal that will be placed after ultrasound identification of external oblique, internal oblique, transverse abdominus and quadratus lumborum muscles. A needle will then be advanced under ultrasound guidance below the internal oblique aponeurosis and lateral to the quadratus lumborum muscle. Ropivacaine (20ml, 0.5%) will be injected slowly with frequent aspiration to rule out inadvertent intravascular needle placement. Local anesthetic injection will also be observed with real time ultrasound guidance.
89539646|NCT04920591|Experimental|doll therapy (DT)|doll therapy (emathy dolls)
89539647|NCT04920591|No Intervention|Standard treatment (ST)|standard clinical practice
89539648|NCT02621931|Placebo Comparator|Placebo|Matching Placebo
89539649|NCT02621931|Experimental|Fremanezumab 675 mg/placebo/placebo|Participants randomized to the fremanezumab 675 mg/placebo/placebo treatment arm received 675 mg of fremanezumab as 3 active injections (225 mg/1.5 mL) on Day 0, and placebo as a single 1.5-mL injection on Days 28 and 56.
89539650|NCT02621931|Experimental|Fremanezumab 675/225/225 mg|Participants randomized to the fremanezumab 675/225/225 mg treatment arm received 675 mg of fremanezumab as 3 active injections (225 mg/1.5 mL) on Day 0 and 225 mg of fremanezumab as 1 active injection (225 mg/1.5 mL) on Days 28 and 56.
89539651|NCT04926441||Students from 8 European Universities, regardless of field of study and academic year|At the beginning of the summer semester of the 2020/2021 academic year, stress levels as well as symptoms of anxiety and depression were assessed in students at four universities.
89539652|NCT02621073|Active Comparator|VeraFlo with Prontosan|V.A.C. VeraFlo™ Therapy, the only NPWT system with an instillation feature which allows solution to dwell in the wound for thorough contact with the wound bed. The solution being instilled is Prontosan: Unlike other antiseptics, the antimicrobial efficacy of Prontosan® is not impaired in human wound fluid, human tissue or by high loads of blood or albumin. Furthermore, Prontosan® blocks the microbial attachment to surfaces and has been shown to effectively remove biofilms in vitro and in vivo (Hubner et al 2010).
89539653|NCT02621073|Active Comparator|V.A.C Ulta System|The V.A.C.Ulta™ Therapy System is an integrated wound therapy system that provides NPWT (negative pressure wound therapy), without instillation.
89539654|NCT04431297|Other|Health Care Workers|Voluntary participation in the virtual presentations
89539655|NCT04926519||Aggressive periodontitis|Patients that got the diagnosis aggressive periodontitis at baseline. Since 2018 we have the classification system with stage and grade why patients get this classification at the clinical examination.
89539656|NCT04926519||Chronic periodontitis|Patients that got the diagnosis chronic periodontitis at baseline. Since 2018 we have the classification system with stage and grade why patients get this classification at the clinical examination.
88957470|NCT01984255|Active Comparator|A- Bavituximab plus Ipilimumab|Arm A-Interventions Drug: Bavituximab Dose:3mg/kg IV over 90 minutes weekly x 2 followed by Bavituximab 3mg/kg IV over 90 minutes weekly Duration-x 12 weeks plus Drug :Ipilimumab 3mg/kg IV over 90 minutes every 3 weeks Duration-x 4.weeks
89023849|NCT04559815||Patients with type 2 diabetes|Adult patients with type 2 diabetes and naïve to injectable glucose-lowering treatment.
89539657|NCT03056235|Experimental|ELAPR002f|ELAPR002f is a tropoelastin gel cross-linked with derivatised hyaluronic acid
89539658|NCT03056235|Placebo Comparator|Saline control|Saline
89539659|NCT04912167|Experimental|ARNI-Sacubitril-Valsartan|patients randomized to angiotensin receptor neprilysin inhibitor (ARNI) group will receive 2 doses of angiotensin receptor blocker (ARB) to ensure a minimum 36-hour washout period prior to initiation of ARNI therapy, and then be started with the first dose or sacubitril-valsartan.
89539660|NCT04912167|Active Comparator|ACEI-Enalapril|patients randomized to angiotensin-converting enzyme inhibitor (ACEI) group will directly start with the first dose of enalapril
89539661|NCT04925661|Experimental|HEC53856|Drug: HEC53856 TIW dosing, capsule There will be a total of 3 dose cohorts: 100mg, 150mg, 200 mg
89539662|NCT04925661|Active Comparator|Roxadustat|Drug: roxadustat TIW dosing There will be only one cohort: 70mg
89539663|NCT04925661|Placebo Comparator|Placebo|Drug: placebo TIW dosing, capsule There will be a total of 3 dose cohorts: 100mg, 150mg, 200 mg
89539664|NCT04925115|Experimental|Interventional group|"Interventional group:~Warm up and cool down (10 minutes before physical activity)~Brisk walking ( 30 minutes each session for 5 days in a week)~Week 1 to week 6 same protocol"
89539665|NCT04925115|No Intervention|Control group|Routine activity of daily life
89539666|NCT03056703|Experimental|Acetylsalicylic acid [1000mg]|
88957471|NCT01984255|Experimental|Arm B Ipilimumab|Arm B-Interventions Drug- I3mg/kg IV over 90 minutes day 1 followed three weeks later by Drug: Ipilimumab every 3 weeks x 3weeks. Total number of treated patients will be 8.
88957472|NCT01984281|Experimental|Pedometer-based prescription|After baseline assessments, the control group will receive a educational session, regarding important aspects of asthma (symptoms, treatment, exacerbations, triggers, etc) plus a unsupervised exercise prescription (walking, 5 times per week, for at least 30 minutes) and a pedometer-based physical activity prescription, consisting of targets to be achieved (in terms of steps per day).
88957473|NCT01984281|No Intervention|Control|After baseline assessments, the control group will receive a educational session, regarding important aspects of asthma (symptoms, treatment, exacerbations, triggers, etc) plus a unsupervised exercise prescription (walking, 5 times per week, for at least 30 minutes).
88957474|NCT01984320|Active Comparator|Coasting|In their ICSI cycle patients will continue their agonist treatment while stopping the human menopausal gonadotropin (hMG) injections for 1 to 3 days until drop of estradiol to a safe level to prevent OHSS. Early OHSS is assessed at day of embryo transfer and 7 days after this date. Late OHSS is assessed 14 days after embryo transfer.
89506435|NCT04771455|Experimental|Condition 5|Behavioral weight loss intervention and decrease overvaluation of weight and shape
89506436|NCT04771455|Experimental|Condition 6|Behavioral weight loss intervention, decrease overvaluation of weight and shape, and decrease negative affect
89506437|NCT04771455|Experimental|Condition 7|Behavioral weight loss intervention, decrease overvaluation of weight and shape, and decrease unhealthy weight control practices
89506438|NCT04771455|Experimental|Condition 8|Behavioral weight loss intervention, decrease overvaluation of weight and shape, decrease unhealthy weight control practices, and decrease negative affect
89506439|NCT04770116|Experimental|Intervention group|Participants in this group will receive all-night auditory stimulation during sleep over one week using a portable, in-home device (MHSL-SleepBand).
89506440|NCT04770116|Sham Comparator|Control group|Participants in this group will receive sham-stimulation, i.e. the device will be applied (biosignals will be recorded), but no tones will be played.
89506441|NCT04751786|Experimental|PRECIOUS-01|Eligible subjects will receive three i.v. infusions of PRECIOUS-01 at a 3-weekly interval in three dose-finding cohorts (low: 0.4 mg/kg, intermediate: 0.8 mg/kg, and high: 1.6 mg/kg fixed doses). Subjects will be monitored for safety and the occurrence of Dose-Limiting Toxicities (DLTs). A 3+3 design is used for the dose escalation steps. Three subjects will be enrolled sequentially per cohort. If the maximum tolerated dose (MTD) is not reached in the planned dose escalation cohorts, the RP2D will be based on the observed safety and immune modulatory activity as pharmacodynamic parameter supporting the RP2D. The sample size is based on the determination of the MTD/RP2D. In order to collect sufficient information regarding changes in immune related parameters as readout for pharmacodynamics of the particles, it is planned to extend the two highest dosing cohorts to a total of six subjects or to extend the highest dosing cohort to a total of nine subjects, depending on observed toxicity
89506442|NCT04746612|Experimental|HH30134|HH30134 administered orally on a continuous once daily(QD), start from 100mg QD.
89506443|NCT04733677||OSR M-1 N95|All subjects will be fitted with an OSR M1 N95 mask
89506444|NCT04705324|Experimental|Operative Hysteroscopy|Hysteroscopic separation
89506445|NCT04705324|Active Comparator|Dilation and Curettage|Curettage separation
89506446|NCT04705324|Experimental|Feasibility and safety|The first 15 patients recruited will not undergo randomization and will compose the preliminary safety and feasibility phase
89506447|NCT04681404|Active Comparator|Total Knee Arthroplasty (TKA)|Patients intended to undergo surgery for total knee arthroplasty
89506448|NCT04681404|Active Comparator|Unicompartmental Knee Arthroplasty (UKA)|Patients intended to undergo surgery for unicompartmental knee arthroplasty
89506449|NCT04681404|No Intervention|Healthy Control|
89506450|NCT04668066|Experimental|Single ascending doses of PF-07242813 or placebo in healthy participants|Participants will receive a single intravenous dose of either PF-07242813 or placebo
89506451|NCT04668066|Experimental|Multiple ascending doses of PF-07242813 or placebo in healthy participants|Participants will receive multiple subcutaneous doses PF-07242813 or placebo
89506452|NCT04668066|Experimental|Single dose of PF-07242813 or placebo in participants with moderate to severe atopic dermatitis|Participants will receive a single intravenous dose of either PF-07242813 or placebo
89506453|NCT04628715|Experimental|Supervised RSA biofeedback|5 weeks with weekly supervised sessions of 30 minutes and daily home practice sessions of 20 minutes. The latter sessions can be divided into four bouts of 5 minutes which can be spread across the day. The main goal during this intervention is to breath at resonance frequency which is slower than the usual breathing frequency. Participants will be guided towards this lower breathing frequency by using appropriate breathing techniques and the provision of a breathing pacer during the supervised sessions. During home practice, the participants will be provided with an application which will visualise a breathing pacer at their resonance frequency. At the third session, participants will no longer receive a breathing pacer but are instructed to breath in phase with their heart rate which is visualised on the computer screen instead of the breathing pacer.
89506454|NCT04628715|Sham Comparator|Supervised sham RSA biofeedback|5 weeks with weekly supervised sessions of 30 minutes and daily home practice sessions of 20 minutes. The latter sessions can be divided into four bouts of 5 minutes which can be spread across the day. The sham-control treatment will follow the same steps as outlined in the supervised intervention arm. However, the participants in this control group will not receive any information regarding their own heart rate and they will not practice at their resonance frequency. Instead, a default mode will be shown during the sessions and in their application for home practice.
89023850|NCT04547192|No Intervention|Pre TIF introduction|Emergency Health Service prior to introduction of TIF.
89023851|NCT04547192|Experimental|Post introduction of TIF|Emergency Health Service after introduction of TIF.
89539667|NCT03056703|Active Comparator|Acetylsalicylic acid [500mg]|
89539668|NCT02158936|Experimental|Eltrombopag|Eligible subject will receive a starting dose of eltrombopag of 200 milligrams (mg) (100 mg for subjects of East Asian heritage). Dose modifications of eltrombopag will be permitted by 100 mg increments (50 mg increments for East Asians) to a lowest dose of 100 mg (50 mg for East Asian heritage) or a maximum dose of 300 mg (150 mg for East Asian heritage) in order to maintain platelet counts at a safe and effective level (i.e. a level sufficient to avoid platelet transfusions and bleeding events). Subjects will receive azacitidine 75 mg/meter^2 subcutaneously once daily for 7 days (+/- 3 day treatment window permitted) every 28 days, for at least 6 cycles if tolerated and until they are no longer receiving benefit (defined as at least stable disease per the investigator's assessment) or until disease progression, death, or unacceptable toxicity/adverse event. The subject may receive eltrombopag daily for the full 28 days each cycle for as long as the subject is receiving azacitidine
89539669|NCT02158936|Placebo Comparator|Placebo|Eligible subject will receive eltrombopag matching placebo. Subjects will receive azacitidine 75 mg/meter^2 subcutaneously once daily for 7 days (+/- 3 day treatment window permitted) every 28 days, for at least 6 cycles if tolerated and until they are no longer receiving benefit (defined as at least stable disease per the investigator's assessment) or until disease progression, death, or unacceptable toxicity/adverse event. The subject may receive eltrombopag daily for the full 28 days each cycle for as long as the subject is receiving azacitidine
89539670|NCT03054441||Experimental group|Children, Adolescents and Young with hemiplegia
89539671|NCT03054441||Control group|Children, Adolescents and Young with typical development
89539672|NCT04924647|Experimental|RD|lenalidomide and dexamethasone
89539673|NCT04919577||RSS- Group|Patients without RSS after distal gastrectomy.
89539674|NCT04919577||RSS+ Group|Patients with RSS after distal gastrectomy.
89539675|NCT04919421|Active Comparator|Virtual reality|Participants will wear a virtual reality headset during the dental injection in which a video is playing.
89539676|NCT04919421|Active Comparator|Topical gel|Participants will receive application of topical anesthetic gel on the site of dental injection.
89539677|NCT04924959||Modeling Group|
89539678|NCT04924959||Validation Group|
89539679|NCT04924725|Experimental|CEH-EUS-guided FNB group|In CEH-EUS-guided FNB group, needle puncture directly to the enhancing area 15-20 times without passing to the non-enhancing area under CEH mode was performed.
89539680|NCT04924725|Active Comparator|Conventional-EUS-guided FNB with fanning technique group|In conventional-EUS-guided FNB with fanning technique group, the needle was positioned at four different areas within the mass and then moved back and forth four times in each area to procure tissue (4 × 4).
89539681|NCT04911933|Experimental|Intervention|The form of treatment involve systemic family therapy sessions every two weeks about an hour each.
89539682|NCT04911933|No Intervention|Waitlist Control|Participants assigned to the control condition will be placed on a waitlist for future enrollment. After primary data collection has ceased, those assigned to the control arm will receive the identical intervention delivered in the experimental condition.
89206799|NCT04011657|Experimental|Voluntary CDSS|Voluntary use of computerized decision support with prospective review and feedback
89539683|NCT04912011|Experimental|Canrenoate potassium|Administration of 200 mg of potassium Canrenoate potassium dissolved in 100 ml of 0.9% sodium chloride intravenously twice a day for 7 days.
89539684|NCT04912011|Placebo Comparator|Placebo|Administration of 100 ml of 0.9% sodium chloride intravenously twice a day for 7 days.
88957475|NCT01984320|Active Comparator|Cabergoline|In their ICSI cycle patients will take 0.25 mg of cabergoline daily for 8 days from HCG triggering day to prevent OHSS. Early OHSS is assessed at day of embryo transfer and 7 days after this date. Late OHSS is assessed 14 days after embryo transfer.
88957476|NCT01984320|Active Comparator|Coasting and Cabergoline|In their ICSI cycle patients will continue their agonist treatment while stopping the human menopausal gonadotropin (hMG) injections for 1 day plus receiving 0.25 mg of cabergoline daily for 8 days from HCG triggering day to prevent OHSS. Early OHSS is assessed at day of embryo transfer and 7 days after this date. Late OHSS is assessed 14 days after embryo transfer.
88957477|NCT01984333|Experimental|Online cognitive training|Online cognitive training will provides eight sessions of a computerized training game. Each session will last about 30-40 minutes, and participants will undergo 2 sessions each week over a 4-week period.
88957478|NCT01984333|No Intervention|Waitlist control|This is a 1-month waitlist control to be compared with the active online cognitive training intervention. This is a no intervention control group.
89206800|NCT04011657|No Intervention|Compulsory CDSS|Compulsory use of computerized decision support with prospective review and feedback
89206801|NCT04019951|Experimental|Propionate (1 g)|Participants will receive 1 g of Ca-propionate in a colon-release form. Volunteers will receive the product on visits 2, 3 and 4. Each of the visits will be separated by > 5 days. Visit 5, the end of study visit, will occur within 5 days of visit 4.
89539685|NCT04918719|Experimental|NAC arm|"Both arms are subjects who present with neurological deficits consistent with stroke without hemorrhage less than 24 hours since symptom onset. Both arms will receive standard of care with the study intervention being considered an add-on therapy. Thirty minutes after enrollment, eligible subjects will be randomized into one of two arms: placebo or N-Acetylcysteine (NAC). Any patient receiving t-PA who enrolls in the study will have their study drug infusion delayed by 24 hours after the completion of the t-PA infusion.~The dosing of NAC will be similar to the standard intravenous acetaminophen toxicity dosing: 150mg/kg in 200 milliliters of 5% Dextrose (D5W) infused over 1 hour, immediately followed by 50mg/kg in 500mL D5W infused over 4 hours, then 100mg/kg in 1000 milliliters D5W infused over 16 hours."
89539686|NCT04918719|Placebo Comparator|Placebo arm|"Both arms are subjects who present with neurological deficits consistent with stroke without hemorrhage less than 24 hours since symptom onset. Both arms will receive standard of care with the study intervention being considered an add-on therapy. Thirty minutes after enrollment, eligible subjects will be randomized into one of two arms: placebo or N-Acetylcysteine(NAC). Any patient receiving t-PA who enrolls in the study will have their study drug infusion delayed by 24 hours after the completion of the t-PA infusion.~The placebo will consist of a 5% Dextrose in Water (D5W) instead of NAC (dosage and timings are the same as the NAC arm)."
88957479|NCT01984359|Other|Single arm|Biosamples will be obtained at multiple time-points for all participants
88957480|NCT01984372||Tresiba® users|
89506455|NCT04628715|Experimental|Non-supervised RSA biofeedback|1 short guided session (30 minutes) and daily practice (20 minutes; 4 bouts of 5 minutes) for 5 weeks. The biofeedback protocol will be provided by an application, similar to the supervised protocol but without guidance throughout the sessions, except for the first session. During this first session, the information will be provided about the application and the heart rate sensor (Polar band) which will detect changes in heart rate during the training. In addition, the resonance frequency of the participant will be determined so they can practice breathing at this frequency for the next 5 weeks.
89506456|NCT04628715|No Intervention|No intervention|No intervention is given.
89506457|NCT04614896|Experimental|Ultrasound for measuring DOI in tongue tumors|All patients included with tongue carcinoma
89506458|NCT04601272||Breast Cancer Screening|Women between the ages of 35-55 when they received a decision aid for breast cancer screening with no prior diagnosis of breast cancer. These people will see items only pertaining to breast cancer screening.
89506459|NCT04601272||Colon Cancer Screening|Men and women between the ages of 45-75 when they received a decision aid for colon cancer screening with no prior diagnosis of colon cancer. These people will see items only pertaining to colon cancer screening.
89506460|NCT04601272||Prostate Cancer Screening|Men between the ages of 45-74 when they received a decision aid for prostate cancer screening with no prior diagnosis of prostate cancer. These people will see items only pertaining to prostate cancer screening.
89506461|NCT04591860|Active Comparator|Sutures only|"Patients with a large hiatal hernia undergo the cruroplasty with sutures only.~A large hiatal hernia is defined as > 5cm in manometry or gastroscopy or at least 1/3 of the stomach lying intrathoracically."
89506462|NCT04591860|Active Comparator|Absorbable Mesh|"Patients with a large hiatal hernia undergo the cruroplasty with mesh implantation.~A large hiatal hernia is defined as > 5cm in manometry or gastroscopy or at least 1/3 of the stomach lying intrathoracically."
89506463|NCT04591860|Active Comparator|Pledgeted sutures|"Patients with a large hiatal hernia undergo the cruroplasty with pledgeted sutures.~A large hiatal hernia is defined as > 5cm in manometry or gastroscopy or at least 1/3 of the stomach lying intrathoracically."
89506464|NCT04551092|Experimental|Single|Single group to receive intervention
89506465|NCT04539158|Active Comparator|single-DCCV group|"Patients randomized to single-DCCV will be given a single 200J shock using the primary (or right anterior-left posterior) pair of pads."
89506466|NCT04539158|Experimental|dual-DCCV group|"Patients assigned to dual-DCCV will receive two simultaneous 200J shocks (from both the primary and secondary set of defibrillator pads), totaling 400J delivered."
89506467|NCT04527614|Other|COVID+|Participants with a previous SARS-CoV-2 infection
89506468|NCT04527614|Other|COVID-|Participants without a previous SARS-CoV-2 infection
89506469|NCT04517799|Experimental|cannabidiol|cannabidiol arm
89506470|NCT04517799|Placebo Comparator|placebo|placebo arm
89506471|NCT04513444|Other|Standard arm (A): music listening therapy|
89506472|NCT04513444|Experimental|Experimental arm (B): music listening and hypnosis therapy|
89506473|NCT04509648|Experimental|Hypofractionated radiotherapy|Patients with an indication for regional nodal irradiation will receive 5.2 Gy in 5 fractions to chest wall or whole breast and regional lymph regions (including supraclavicular/infraclavicular region, internal mammary nodes, and any part of the axillary bed at risk) and a sequential tumor bed boost of 5.2 Gy in 2 fractions to the conserved breast.
89506474|NCT04496518||Patients with ICD/CRT device with iATP programmed on|Patients implanted with an iATP-capable device with iATP on in at least one device detection zone will be enrolled in the iATP PAS. Patients must also be enrolled in the CareLink network for remote monitoring. All patients must have provided signed informed consent.
89506475|NCT04495296|Experimental|dose escalation Q2W|Dosed every 2 weeks IV with TST001, multiple dose levels will be tested.
89506476|NCT04495296|Experimental|dose escalation Q3W|Dosed every 3 weeks IV with TST001, multiple dose levels will be tested.
89506477|NCT04495296|Experimental|Cohort A|Participants with gastric or gastroesophageal junction cancers and CLDN18.2 expression
89506478|NCT04495296|Experimental|Cohort B|Participants with ductal adenocarcinoma of pancreas and CLDN18.2 expression and CLDN18.2 expression
89506479|NCT04495296|Experimental|Cohort E|Participants with advanced or metastatic solid tumors other than G/GEJ adenocarcinoma and CLDN18.2 expression
89506480|NCT04495296|Experimental|Cohort C|Participants with HER2 negative or unknown locally advanced or metastatic G/GEJ adenocarcinoma
89506481|NCT04495296|Experimental|Cohort D|Participants with locally advanced or metastatic G/GEJ adenocarcinoma
89506482|NCT04495296|Experimental|Cohort F|Participants with locally advanced or metastatic biliary tract cancer
89506483|NCT04495296|Experimental|Cohort G|Participants with HER2 negative or unknown locally advanced or metastatic G/GEJ adenocarcinoma
89506484|NCT04495296|Experimental|Cohort H (TST001 plus nivolumab)|Participants with locally advanced or metastatic G/GEJ adenocarcinoma
89206802|NCT04019951|Experimental|Propionate (3 g)|Participants will receive 3 g of Ca-propionate in a colon-release form. Volunteers will receive the product on visits 2, 3 and 4. Each of the visits will be separated by > 5 days. Visit 5, the end of study visit, will occur within 5 days of visit 4.
89506485|NCT04416217||Topical Steroid Treatment|Pediatric patients with eosinophilic esophagitis scheduled to begin topical steroid treatment for the treatment of their condition. The type of topical steroid is not limited and is at the discretion of the treating physician as are dosing and concomitant treatments.
89506486|NCT04404062||Trial Participants|Male and female participants aged 5-70 years
89506487|NCT04389489||COVID-19|Pregnant women with COVID-19 who have given birth
89506488|NCT04389489||Control|Healthy pregnant women who have given birth
89506489|NCT04350515|Experimental|Cyberball: Other Exclusion|Cyberball Paradigm - the avatar will be excluded by the player
89506490|NCT04350515|Experimental|Cyberball: Player Exclusion|Cyberball Paradigm - the player will be excluded by the other players
89506491|NCT04348630|Experimental|HOT condition|Participants are exposed to 36°C and 45% relative humidity for 8 hours. These conditions were chosen to represent an extreme heat condition (i.e., heatwave) and are similar to peak domicile conditions measured in low-income high-rise apartment complexes during heatwaves.
89506492|NCT04348630|Experimental|WARM Condition|Participants are exposed to 31°C and 45% relative humidity for 8 hours. These conditions are similar to mean domicile conditions measured in a variety of domicile types during heat waves complexes during heatwaves and are consistent with the World Heath Organization recommendation for maximal indoor temperatures.
89506493|NCT04348630|Experimental|TEMPERATE Condition|Participants are exposed to 26°C and 45% relative humidity for 8 hours. These conditions are consistent with Toronto Public Health recommendation for maximal indoor temperatures, which are based on the increase in mortality associated with increases in outdoor temperature above these limits.
89506494|NCT04348630|Experimental|COOL Condition|Participants are exposed to 22°C and 45% relative humidity for 8 hours. These conditions are consistent with actively cooled (air-conditioned) domicile.
89506495|NCT04342884||Clients of Wake Forest Baptist Health (WFBH)|
89023852|NCT04543903|Experimental|DaRT Seeds|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds
89023853|NCT04540692|Active Comparator|Start with Cyclophosphamide + Doxorrubicin|Patients will receive the following treatment schedule: Doxorubicin 60mg/m²; Cyclophosphamide 600mg/m² intravenously every 21 days for 3 cycles, followed by docetaxel 75-100mg/m2 intravenously every 21 days for 4 cycles or weekly paclitaxel 80mg/m2 for 12 weeks.
89506496|NCT04342884||Health care workers of Wake Forest Baptist Health (WFBH)|
89506497|NCT04339374||Ex vivo imaging|"Patients with known adenomatous polyps or malignancies in the colon or rectum undergoing resection will be considered for enrollment~Participation will include imaging of both normal and known pathologic portions of the specimen ex vivo immediately following resection. The specimen will then undergo fixation and standard pathologic evaluation, with subsequent correlation between imaging and pathologic findings.~This data will also be used to develop a convolutional neural network (CNN) to assist in interpreting photoacoustic imaging data."
89506498|NCT04339374||In vivo imaging|"Patients with distal rectal lesions (benign or malignant tumors within 15cm of the anal verge) will be enrolled for the in vivo imaging portion of the study~Participation will include an intraoperative, in vivo evaluation of the tumor with a novel endorectal photoacoustic ultrasound probe as well as ex vivo imaging post-resection as described above. Following the induction of anesthesia, patients will undergo a 20 minute endorectal imaging evaluation performed by their colorectal surgeon. After imaging, the patient will then undergo standard-of-care surgical resection of the rectum. The resection specimen will then be imaged ex vivo as performed in the ex vivo cohort of this study.~For this portion of the pilot, enrollment will be limited to 40 participants"
89023854|NCT04540692|Experimental|Start with Docetaxel or Paclitaxel|Patients will receive the following treatment schedule: Docetaxel 75-100mg/m² intravenously every 21 days for 4 cycles or weekly paclitaxel 80mg/m² for 12 weeks, followed by Doxorubicin 60mg/m²; Cyclophosphamide 600mg/m² intravenously every 21 days, for 3 cycles.
89023855|NCT04537039|Other|All the participants.|This study only includes 1 arm.
89506499|NCT04338503||HF patients|Decompensated heart failure patients undergoing right heart catheterization.
89506500|NCT04330742||0 mL crystalloid|These are the measurements (aortic velocity time integral, inferior vena cava diameter, vital signs) that will be taken at time 0, at which time 0 mL of fluids will have been administered.
89506501|NCT04330742||250 mL crystalloid.|These are the measurements (aortic velocity time integral, inferior vena cava diameter, vital signs) that will be taken at time 1, after the spinal has been placed and approximately 250 mL fluids has been administered.
89506502|NCT04330742||500 mL crystalloid|These are the measurements (aortic velocity time integral, inferior vena cava diameter, vital signs) that will be taken at time 2, at which time 500 mL of fluids will have been administered.
89506503|NCT04330742||1000 mL crystalloid|These are the measurements (aortic velocity time integral, inferior vena cava diameter, vital signs) that will be taken at time 3, at which time 1000 mL of fluids will have been administered.
89506504|NCT04305093||Precision Analytical patients|Individuals who had laboratory work completed at Precision Analytical and completed the associated questionnaire on symptoms and comorbidities.
89506505|NCT04295044|Experimental|High protein diet|received high protein diet, prescribed by dietitian
89506506|NCT04295044|Active Comparator|Normal protein diet|received normal protein diet, prescribed by dietitian
89023856|NCT04532372|Experimental|Phase I (leflunomide, SOC)|Patients receive leflunomide PO QD on days 1-14. Patients may receive SOC drugs in addition to leflunomide.
89023857|NCT04532372|Experimental|Phase II Arm I (leflunomide, SOC)|Patients receive leflunomide PO QD on days 1-14. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive SOC.
89023858|NCT04532372|Placebo Comparator|Phase II Arm II (placebo, SOC)|Patients receive placebo PO QD on days 1-14. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive SOC.
89023859|NCT04532307|Experimental|Standard of Care SOC|Youth friendly services at Isisekelo Sempilo clinics
89023860|NCT04532307|Experimental|SRH enhanced Isisekelo Sempilo|Self-collected vaginal and urine samples for gonorrhea, chlamydia and trichomonas
89023861|NCT04532307|Experimental|Peer-support (Thetha-Nami)|Peer support and needs assessment from an area-based peer navigator
89023862|NCT04532307|Experimental|SOC + SRH + peer-support|Combination of all arms
89023863|NCT04514510|Experimental|Participants with Sickle Cell Disease Receiving Isoquercetin|Isoquercetin 1000 mg, once daily by mouth for 28 days in participants with Sickle Cell Disease.
89206803|NCT04019951|Placebo Comparator|Placebo|Participants will receive 2.6 g of cellulose in a colon-release form. Volunteers will receive the product on visits 2, 3 and 4. Each of the visits will be separated by > 5 days. Visit 5, the end of study visit, will occur within 5 days of visit 4.
89206804|NCT05351073|Experimental|Normobaric Oxygen Inhalation Group|Participants in the intervention group will receive oxygen inhalation through a mask at a rate of 10 L/min at 1 absolute atmosphere pressure (1 ATA = 101.325 kPa) after randomization until adimisson to the hospital. Participants will subsequently receive standard diagnosis and treatment service according to the guidelines during hospitalization.
89206805|NCT05351073|No Intervention|Control Group|Participants in the control group will not receive oxygen inhalation therapy during ambulance transportation. Participants will subsequently receive standard diagnosis and treatment service according to the guidelines during hospitalization.
89023864|NCT04514510|Placebo Comparator|Participants with Sickle Cell Disease Receiving Placebo|Placebo once daily, by mouth for 28 days in participants with Sickle Cell Disease.
89023865|NCT04509752||Dysphagia clinicians|Clinicians from swallowing centers (from all over the world)
89023866|NCT04507854|Experimental|Operated athletes|
89506507|NCT04238598|Active Comparator|Active|intra-articular 4 milliliters 0.5% bupivacaine + 10mg dexamethasone + sham Pulsed Radiofrequency
89506508|NCT04238598|Placebo Comparator|Control|intra-articular 5 milliliters 0.9% saline + sham Pulsed Radiofrequency
89506509|NCT04238598|Experimental|Experimental|intra-articular 5 milliliters 0.5% bupivacaine + Pulsed Radiofrequency
89506510|NCT04224324||T & A patients|pediatric patients undergoing tonsillectomy and adenoidectomy
89506511|NCT04218643|Active Comparator|Standard technique|Intravenous catheter inserted via standard technique
89506512|NCT04218643|Experimental|Ultrasound-guided technique|Intravenous catheter inserted via ultrasound guidance
89506513|NCT04202900|Other|Phototherapy protocol|"Pretest：Common symptoms in the elderly include insomnia, depression, pressure sore wounds, blood sugar, blood pressure, body temperature,fatigue,cold limbs.~Intervention：LED light therapy for 6 weeks, 2-3 times a week, every 30 minutes. Post test：Common symptoms in the elderly include insomnia, depression, pressure sore wounds, blood sugar, blood pressure, body temperature,fatigue,cold limbs."
89506514|NCT04197856|Active Comparator|Control / Family-mediated disclosure (standard care)|Genetic counseling according to current clinical practice
89506515|NCT04197856|Experimental|Intervention / Health-care assisted disclosure|Genetic counseling according to current clinical practice with the addition of an offer from health care provider to mail letters directly to eligible at-risk relatives.
89506516|NCT04169139|Active Comparator|MIST - minimally invasive surgical therapy|"Beginning with the papilla preservation technique (Takei et al), further improved by Cortellini et al (1995) and combined with minimally invasive approaches (Harrel et al 1995), MIST, using minimally invasive surgical approaches and micro-surgery instruments, has evolved into a decision tree guideline for treating periodontitis based on periodontal pocket morphology and papilla width/ interdental space (Cortellini P, Tonetti MS (2007) J Clin Periodontol;34(1):87-93)."
89506517|NCT04169139|Experimental|REPaiR - laser periodontal therapy|The REPaiR regimen is a step-by-step protocol for using the Waterlase Express Er,Cr:YSGG laser for periodontitis. The protocol steps and associated laser delivery is controlled by a computer interface that dictates laser tip, energy and associated air and water mixes. Like MIST, REPaiR uses a set, decision tree approach for periodontal therapy, with prescribed steps and laser settings to quantify and standardize treatment. Potential clinical benefit, as with MIST, are not only effective periodontal therapy with reduced recession compared with traditional surgical approaches, but also reduced patient morbidity (Arnabat-Domínguez et al (2010). Lasers Med Sci;25(3):459-64).
89506518|NCT04159831|Experimental|400,000 U LTI-01|400,000 U LTI-01 once a day (qd) x 3 days administered intrapleurally
89506519|NCT04159831|Experimental|800,000 U LTI-01|800,000 U LTI-01 qd x 3 days administered intrapleurally
89506520|NCT04159831|Experimental|1,200,000 U LTI-01|1,200,000 U LTI-01 qd x 3 days administered intrapleurally
89506521|NCT04159831|Placebo Comparator|Placebo|placebo (normal saline) 6ml qd x 3 days administered intrapleurally
89506522|NCT04158752|Experimental|Open Label Galcanezumab|Participants will receive their 1st injectable dose during the Day 30 visit. Participants will then inject themselves at home on Day 60 and again on Day 90.
89023867|NCT04505956|Experimental|Moses Laser Lithotripsy|Patients will have flexible URS performed in standard fashion, without deviation from the standard of care. Laser settings will be at the surgeons' discretion but will be within the range identified as standard for dusting technique using Moses laser technology.
89023868|NCT04505956|Active Comparator|Standard Laser Lithotripsy|Patients will have flexible URS performed in standard fashion, without deviation from the standard of care. Laser settings will be at the surgeons' discretion but will be within the range identified as standard for dusting technique (between 0.2-0.5 J and 40-80 Hz). The short pulse setting will be utilized for non-Moses settings.
88957481|NCT01984385||Patients with a hip fracture|
88957482|NCT01984411|Experimental|Radial Technical|Radial technical is the procedure for catheterization
88957483|NCT01984411|Active Comparator|Femoral Technical|Vascular Access for cardiac catheterization
88957484|NCT01984450|Active Comparator|ACIC|The patients in this group will be treated by the ACIC technique, which uses autologous collagen to regenerate articular cartilage. ACIC is a single stage arthroscopic procedure. It is done as a day case procedure. The cartilage defect is debrided and implanted with a collagen + fibrin gel mixture under CO2 insufflation.
88957485|NCT01984450|Active Comparator|MCIC|The patients in this group will be treated by the MCIC technique, which uses concentrated BMAC to regenerate articular cartilage. MCIC is a single stage arthroscopic procedure. It is done as a day case procedure. BMAC is harvested intraoperatively and concentrated. It is then mixed with a fibrin gel and implanted under CO2 insufflation.
88957486|NCT01984463|Active Comparator|Fentanyl|Patients will be randomized to receive by the epidural catheter a bolus dose of 100 mcg of fentanyl followed by an infusion of epidural bupivacaine 0.1% and fentanyl 2 mcg/mL.
88957487|NCT01984463|Experimental|Morphine|Patients will be randomized to receive by the epidural catheter a bolus dose of 3 mg of morphine followed by an infusion of epidural bupivacaine 0.1% and morphine 50 mcg/mL.
88957488|NCT01984476||Older Able-Bodied Controls|Subjects must be between the age of 55 and 65 years old, be English-literate and able to provide informed consent. They must score at least 20/60 minimum acuity in their worst eye on the Snell Eye Exam, and score at least 24 on the Montreal Cognitive Assessment. Subjects MUST NOT HAVE: an acute illness or infection, history of stroke, recent illicit drug abuse (<6 months), controlled or uncontrolled hypertension or diabetes mellitus, history of epilepsy or other seizure disorder, history of Traumatic Brain Injury (as determined by TBI screening tool), any significant history of neurological disease/disorder, and diagnosis of a psychiatric disorder such as post-traumatic stress disorder, schizophrenia or bipolar disorder.
88957489|NCT01984476||Spinal Cord Injured|Subjects must be between the age of 25 and 49 years old, be English-literate and able to provide informed consent. They must be injured between 5 to 10 years, level of injury between C1-T12, non-ambulatory (wheelchair dependent), and AIS grade of A or B. They must score at least 20/60 minimum acuity in their worst eye on the Snell Eye Exam, and score at least 24 on the Montreal Cognitive Assessment. Subjects MUST NOT HAVE: an acute illness or infection, history of stroke, recent illicit drug abuse (<6 months), controlled or uncontrolled hypertension or diabetes mellitus, history of epilepsy or other seizure disorder, history of Traumatic Brain Injury (as determined by TBI screening tool), any significant history of neurological disease/disorder, and diagnosis of a psychiatric disorder such as post-traumatic stress disorder, schizophrenia or bipolar disorder.
89506523|NCT04153240|Experimental|Positional Therapy|The Night Shift™ Sleep Positioner (Advanced Brain Monitoring, USA) - set in 'THERAPY' mode (ie. vibration feedback will be given in response to supine position)
89506524|NCT04153240|Sham Comparator|Sham Positional Therapy|The Night Shift™ Sleep Positioner (Advanced Brain Monitoring, USA) - set in 'MONITOR' mode (ie. no vibration feedback will be given)
89506525|NCT04151693|Experimental|Research group ME/CFS|"Health Psychological Group Rehabilitation for Patients With Chronic Fatigue Syndrome (ME/CFS)~8 sessions in 4 months. n=35-40 patients~ME/CFS -Current knowledge Smart goals Stress management in every day life Pacing Psychological effects of illness and adaptation Coping strategies Emotional support Focus on autonomic nervous system (hyperarousal, cognitive disabilities) Focus on health"
89506526|NCT04151693|Experimental|Control group ME/CFS|"Control group~6 sessions in 3 months n=35-40 patients~Health, lifestyle and wellbeing counselling (sleep, nutrition, activities in daily life)"
89506527|NCT04147546|Experimental|Intervention arm|"A full course of dihydroartemisinin-piperaquine (DP) over 3 days. The first dose of DP will be administered under direct observation at the antenatal care clinic (ANC) and the subsequent doses of the intervention in days 2 and 3 will be taken unsupervised at home.~At each ANC visit, study nurses will perform an HS-RDT for participants in this arm. Reminders will be sent in this group in order to improve IPTp-SP uptake"
89506528|NCT04147546|No Intervention|Control arm|"A full course of artemether-lumefantrine (AL) over 3 days. The first dose of AL will be administered under direct observation at the antenatal care clinic (ANC) and the subsequent doses of the intervention in days 2 and 3 will be taken unsupervised at home.~At each ANC visit, study nurses will perform a conventional RDT for participants in this arm if the participant have symptoms suggestive of malaria. No reminder will be sent"
89506529|NCT04141579|Experimental|Treatment arm|Evolocumab (140mg) will be administered subcutaneously every two weeks (Q2W) on day 1 through week 12 with personal injectors, containing 1 mL deliverable volume of 140 mg/mL Evolocumab.
89506530|NCT04141579|Placebo Comparator|Comparator arm|Placebo will be administered subcutaneously every two weeks (Q2W) on day 1 through week 12 with personal injectors, containing 1 mL deliverable volume of placebo.
89506531|NCT04130191||Participants with hereditary angioedema (HAE)|Participants who initiate treatment with lanadelumab according to current product labelling will be enrolled and followed for up to 24 or 36 months (depending on their enrollment date).
89506532|NCT04103671|Experimental|Group A|Prompt panretinal photocoagulation
89506533|NCT04103671|Experimental|Group B|Micro-invasive Pars-plana vitrectomy
89506534|NCT04097977|Experimental|Intervention: RENEW in a psychiatric ward|Intervention The RENEW-S intervention consists of two key elements: collaborative networking and a youth group that will form the basis of real user involvement.
89506535|NCT04097977|No Intervention|Conventional clinical practice in a psychiatric standard ward|The comparison group patients were admitted to a standard psychiatric ward that offered conventional care.
89506536|NCT04089046|Experimental|TEAM-UP for Teens Intervention|TEAM-UP for Teens pairs school-based and video-supported directly observed therapy (DOT) of daily preventive asthma medications with specialist care and ongoing self-management support using live, real-time telemedicine through school.
89539687|NCT04911699||breast adenocarcinoma|"The surgical pathological tissue report confirms the diagnosis of breast adenocarcinoma women with stage I~III~Those who are admitted to the hospital and receive adjuvant chemotherapy for the first time.~Age (inclusive) over 20 years old."
89539688|NCT04911699||Control|"The surgical pathological tissue report establishes women diagnosed as stage 0 to stage III breast cancer~Those who are admitted to the hospital to receive anti-hormonal drug treatment.~Age (inclusive) over 20 years old."
89539689|NCT04924335|Active Comparator|ESP group|ESP group patients will be performed ultrasound-guided erector spinae plane block with 20 ml 0.025% Bupivacaine, preoperatively and will receive ERAS cardiac anesthesia protocol
89539690|NCT04924335|No Intervention|Conventional group|The conventional group will receive ERAS cardiac anesthesia protocol
89539691|NCT03056391|Experimental|Paracetamol|">50kg: Paracetamol 1gm PO/NG 6 hourly for 72 hours (maximum dose 4g/24h) plus IV artesunate or oral artemether/lumefantrine.~<50kg: Paracetamol 12.5-15mg/kg/dose 6 hourly for 72 hours (maximum total dose 5doses/24hours;75mg/kg) plus IV artesunate or oral artemether/lumefantrine."
89539692|NCT03056391|No Intervention|No Paracetamol|"No Paracetamol plus IV artesunate or oral artemether/lumefantrine.~If temperature >39.5°C, tepid sponging and mechanical antipyresis will be performed by research staff and/or relatives."
89539693|NCT04924413|Experimental|L-TIL and Tislelizumab|L-TIL（3-10）x10*9/m2, Q3W, 4 cycles Tislelizumab 200mg, iv, Q3W, 1 year
89539694|NCT04923789||ASCT Without CART|Patients who undergone ASCT successfully and did not receive CART cell infusion.
89539695|NCT04923789||ASCT Bridging CART|Patients who undergone ASCT and received CART cell infusion sequently within 1 month. Patients with disease recurrence or progression prior to the infusion of CART cells will be excluded.
89539696|NCT02158546|Experimental|ALKS 5461|
89539697|NCT02158546|Placebo Comparator|Placebo|
89539698|NCT04923711|Experimental|Moderate Intensity Group|Group received a moderate exercise prescription of moderate intensity
88957490|NCT01984476||Age-Matched Able-Bodied Controls|Subjects must be between the age of 25 and 49 years old, be English-literate and able to provide informed consent. They must score at least 20/60 minimum acuity in their worst eye on the Snell Eye Exam, and score at least 24 on the Montreal Cognitive Assessment. Subjects MUST NOT HAVE: an acute illness or infection, history of stroke, recent illicit drug abuse (<6 months), controlled or uncontrolled hypertension or diabetes mellitus, history of epilepsy or other seizure disorder, history of Traumatic Brain Injury (as determined by TBI screening tool), any significant history of neurological disease/disorder, and diagnosis of a psychiatric disorder such as post-traumatic stress disorder, schizophrenia or bipolar disorder.
88957491|NCT01984489|Placebo Comparator|Placebo/Metformin|patients are administered oral tablets of placebo once daily and 500mg TID for 4 weeks at the run-in period. After randomized ,patients administer the drugs too.
88957492|NCT01984489|Experimental|SHR117887 (50mg q.d)/Metformin|patients are administered oral placebo once daily and metformin 500mg TID for 4 weeks at the run-in period.After randomised,patients adminitered SHR117887 50mg QD and metformin 500mg TID for 12 weeks.
88957493|NCT01984489|Experimental|SHR117887 (100mg q.d)/Metformin|patients are administered oral placebo once daily and metformin 500mg TID for 4 weeks at the run-in period.After randomised,patients adminitered SHR117887 100mg QD and metformin 500mg TID for 12 weeks.
88957494|NCT01984528|Experimental|Prick Test|Alternaria alternata allergen extract Positve control Negative control
88957495|NCT01984541|Experimental|1|Artemisia vulgaris allergen extract(four concentrations 10, 1, 0,1 y 0,01 mg/ml) Positive Control Negative Control
88957496|NCT01984554||Ferric Carboxymaltose (FCM)|Dosing levels, treatment choice, number and scheduling of infusions are all at the discretion of the subject and the subject's prescribing physician.
88957497|NCT01984554||Iron Sucrose|Dosing levels, treatment choice, number and scheduling of infusions are all at the discretion of the subject and the subject's prescribing physician
88957498|NCT01984554||Iron Dextran|Dosing levels, treatment choice, number and scheduling of infusions are all at the discretion of the subject and the subject's prescribing physician
89539699|NCT04923711|Experimental|High Intensity Group|Group received a moderate exercise prescription of high intensity
89539700|NCT04923945|Experimental|Savolitinib|NSCLC
89539701|NCT03056469|Active Comparator|Care providers do have access to PROs|Participants complete patient-reported outcome (PRO) questionnaires. Care providers do have access to the PROs and use them in clinical decision making.
89539702|NCT03056469|Active Comparator|Care providers do not have access to PROs|The participants complete patient-reported outcome (PRO) questionnaires. Care providers do not have access to the PROs.
89539703|NCT03056469|No Intervention|Control group|Standard follow-up. The participants do not complete PRO questionnaires.
89539704|NCT04918563|Active Comparator|nitroglycerin|"NO donor (Nitropohl) vs pgysiological saline~1mg/ml nitorhlycerin"
89539705|NCT04918563|Active Comparator|acethylcholine|10 mg/ml acetylcholine vs physiological saline
89539706|NCT04918641||No treatment|This is a longitudinal, prospective, observational, natural history study of patients with MPS IIIA to identify potential surrogate endpoints for future trials via standardized clinical, biochemical, neurocognitive, developmental, behavioral, and imaging measures.
89539707|NCT02123446|Experimental|Cephalexin (Reference)|Cephalexin manufactured in Mexico by Eli Lilly administered once orally in one of two study periods.
89539708|NCT02123446|Active Comparator|Cephalexin (Test)|Cephalexin manufactured in Italy by Facta administered once orally in one of two study periods.
89539709|NCT04918953|Experimental|group 1|oral methylprednisolone, 40 mg for 3 days, 20 mg for 3 days, and 8 mg for 6 days
89539710|NCT04918953|Experimental|group 2|oral methylprednisolone, 20 mg for 3 days, 10 mg for 3 days, and 4 mg for 6 days
89539711|NCT04918953|Experimental|group 3|budesonide atomization suspension (AstraZeneca Trading Co., Ltd, AU.) inhaled through the nose atomized with an air compression atomizer for 4 weeks, 2 mg for the first 2 weeks and reduced to 1 mg for the last 2 weeks.
89539712|NCT04923399||TN (Trigeminal Neuralgia) group|Trigeminal neuralgia patients undergoing trigeminal nerve microvascular decompression
89539713|NCT04923399||Non-TN group|patients without chronic pain or history of chronic pain
89539714|NCT04918485|Experimental|the experimental group received psychological intervention|
89539715|NCT04918485|No Intervention|the control group receive normal process before surgery|
89506537|NCT04089046|Active Comparator|Enhanced Care Comparison|Teens in the EC group will receive a symptom assessment and asthma education materials at baseline, and their PCPs will be contacted by facsimile or email to recommend DOT of preventive asthma medication through school as well as referral to an asthma specialist. Systematic reminders will be sent to the family and PCPs to schedule recommended healthcare visits and consider specialist referral at the same intervals as the TEAM-UP group's virtual visits.
89506538|NCT04070924|Active Comparator|Conventional post-operative bulky soft tissue dressing|"Intraoperative: MAC-Local Anesthesia; Local anesthetic mixture will be distributed in both the subcutaneous tissue and within the carpal canal~Postoperative: Non-opioid medications only; Conventional post-operative bulky soft tissue dressing (Xeroform, 4x4s, Webril, Ace Wrap; Worn until first postoperative visit)"
89506539|NCT04070924|Experimental|Bandaid post-operative dressing|"Intraoperative: MAC-Local Anesthesia; Local anesthetic mixture will be distributed in both the subcutaneous tissue and within the carpal canal~Postoperative: Non-opioid medications only; Bandaid over incision (Patient given an edema glove to wear starting post-operative day 1; Dressing change be changed post-operative day 2 and as needed after that)"
89506540|NCT03987451|Experimental|Semaglutide|Dose escalation to 2.4 mg of semaglutide once-weekly
89506541|NCT03987451|Placebo Comparator|Placebo|Semaglutide placebo once-weekly
89506542|NCT03971162|Experimental|Group A|patients were given intravitreal injection of Conbercept 0.5mg every month repeated for 3 months. Thereafter, intravitreal Conbercept 0.5mg injections should be administered in case CNV persisted or recurred (based on the assessment of defined criteria for retreatment) at a maximum frequency of once every 4 weeks through 12 months
89506543|NCT03971162|Experimental|Group B|patients were given intravitreal injection of Conbercept 0.5mg every month repeated for 6 months.Thereafter, intravitreal Conbercept 0.5mg injections should be administered in case CNV persisted or recurred (based on the assessment of defined criteria for retreatment) at a maximum frequency of once every 4 weeks through 12 months
89506544|NCT03965091|Placebo Comparator|Placebo|Participants will receive placebo matching to fremanezumab SC on Days 1, 29, 57, and 85.
88815272|NCT05061602||Diabetic Group|The patients were included if they were of 18 years or older, with a diagnosis of diabetes mellitus for more than three years.
88815273|NCT05061602||NonDiabetic Group|The healthy age-matched control group was included.
88815274|NCT02248103|Experimental|periosteal pedicle graft|autogenous marginal periosteal pedicle graft harvested by partial thickness periodontal flap.
88815275|NCT02248103|Active Comparator|Bioresorbable collagen membrane|Equine Achilles tendon collagen barrier membrane
88815276|NCT02242019|Experimental|Erchonia LUNULA|The Erchonia LUNULA emits both red light (635 nm) and blue light (405 nm) to the affected toenail for 12 minutes per treatment for 4 treatments, each treatment one week apart.
88815277|NCT04431323|Experimental|biopsychosocial intervention|"Young adults with MS will receive an intervention (group setting) composed of physical activities (duration: 10-12 weeks; either dancing or walking) and psychosocial interventions (6-8 encounters).~[The intervention will start as soon as 8-10 patients will have been enrolled. A waiting list will be then created and patients contacted when the subsequent group starts. This waiting list does not serve as control group.~One or more groups, respectively for the psychological intervention and the physical activities, may start at the same time but on different days, considering also the results of the co-creation phase.]"
88815278|NCT05532683|Experimental|Health Behavior Group|9- week health behavior promotion group intervention
88815279|NCT02563145|Experimental|Real-time fMRI feedback|"After a pre-training assessment at baseline, subjects will be randomized to either treatment arm or treatment as usual. Subjects in the experimental condition will receive 10 sessions of real-time fMRI feedback of insula- or amygdala activation (dependent on activation patterns during pre-testing), 1 session/week. Each session will last about 1 1/2 hours.~After training completion (10 weeks after the beginning of the treatment phase), subjects will undergo post-treatment assessment and follow up (6 months after the end of the training phase)."
88815280|NCT02563145|Active Comparator|Treatment as usual|"After a pre-training assessment at baseline, subjects will be randomized to either treatment arm or treatment as usual. Subjects in the comparator TAU arm will receive several sessions of psychoeducation and counseling with their parents/caregivers or group training over 10 weeks.~Within the sessions, investigators will focus on psychoeducational issues and provide general counseling for the families. After 10 weeks, subjects will undergo post-treatment assessment and follow up (6 months after the end of the treatment phase)."
88815281|NCT02563145|No Intervention|Typically developing (TD) control group|Healthy typically developing subjects will only participate in pre-training assessment to allow for comparison.
88815282|NCT00982592|Experimental|Arm I (FOLFOX regimen and placebo)|Patients receive FOLFOX chemotherapy comprising oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and fluorouracil bolus and then IV over 46-48 hours on day 1. Patients also receive placebo PO QD on days 1-14. Courses repeat every 2 weeks in the absence of unacceptable toxicity or disease progression.
88815283|NCT00982592|Experimental|Arm II (FOLFOX regimen and vismodegib)|Patients receive FOLFOX chemotherapy as in arm I. Patients also receive vismodegib PO on days 1-14. Courses repeat every 2 weeks in the absence of unacceptable toxicity or disease progression.
88957499|NCT01984554||Ferumoxytol|Dosing levels, treatment choice, number and scheduling of infusions are all at the discretion of the subject and the subject's prescribing physician
88957500|NCT01984567|Experimental|Vitamin E|
88815284|NCT00983216|Active Comparator|Colchicine alone|-baseline colchicine pharmacokinetics
88815285|NCT00983216|Experimental|Colchicine with Steady-State Ketoconazole|-colchicine pharmacokinetics in presence of steady-state ketoconazole
88815286|NCT00984308|Experimental|Intervention|The intervention group received unattended polysomnography and auto-titrating CPAP if sleep apnea was diagnosed
88815287|NCT00984308|Other|Control|The control group received usual clinical care which may include receipt of sleep diagnostic and therapeutic services
88815288|NCT02249585|Experimental|CS|Patients who receive laparoscopic colon surgery under Trendelenberg position with conventional neuromuscular blockade and standard abdominal pressure.
88815289|NCT02249585|Experimental|DS|Patients who receive laparoscopic colon surgery under Trendelenberg position with deep neuromuscular blockade and standard abdominal pressure.
88957501|NCT01984567|Experimental|Lipoic acid|
88957502|NCT01984567|Placebo Comparator|Control|
88957503|NCT01984580|Experimental|Zinc|
88957504|NCT01984580|Placebo Comparator|sodium|
88957505|NCT01984593|No Intervention|Control|No changes will be made for the participants in the control group, but they will undergo the same measurements and evaluations as the intervention group.
88957506|NCT01984593|Active Comparator|yoga|Two yoga exercises to perform at home 15 minutes twice daily.
88957507|NCT01984606|Experimental|Empagliflozin|Empagliflozin once daily
88957508|NCT01984606|Active Comparator|Sitagliptin|Sitagliptin once daily
88957509|NCT01984619||Blunt Tip Cannula|
88957510|NCT01984632|Experimental|Single-port laparoscopic myomectomy|We will use barbed suture (V-Loc) under intervention of single-port laparoscopic myomectomy
88957511|NCT01984632|Active Comparator|Multi-port laparoscopic myomectomy|We will use barbed suture(V-Loc) under intervention of multi-port laparoscopic myomectomy.
89506545|NCT03965091|Experimental|Fremanezumab Dose A|Participants will receive fremanezumab SC on Days 1, 29, and 57 and placebo matched to fremanezumab SC on Day 85.
88957512|NCT01984645|Experimental|Notification|Providers in this arm will receive a secure online notification whenever their patients are visited in the emergency department or admitted as an inpatient.
89506546|NCT03965091|Experimental|Fremanezumab Dose B|Participants will receive fremanezumab SC on Days 1, 29, and 57 and placebo matched to fremanezumab SC on Day 85.
89506547|NCT03956030|Experimental|Intervention|Intervention group will receive educational handout on contraception.
88957513|NCT01984645|No Intervention|No intervention|Providers in this arm will not get a secure online notification about their patient's visit to the emergency department or inpatient admission.
88957514|NCT01984658|Experimental|Alecsat|The ALECSAT CBMP will be administered as single dose at week 4, 7 and week 10 which is considered an appropriate time for ALECSAT CBMP to strengthen the immune system and thus have the ability to kill tumour cells. It is the aim that the patients will receive three doses during the study period however, if the patient wish and it is recommended by the investigator, patients may receive more than three doses, continuing until progression or as judged by the Investigator. Continued treatment after the 24 week study period is only possible under the condition that no safety issues have been discovered. The interval between injections for continued treatment will be decided based on e.g. tumour response and clinical examinations.
88957515|NCT01984723|Experimental|EVP-6124, single dose|Single dose, Tablet, single administration, Day 1
89506548|NCT03956030|Experimental|Control|Control group will receive educational handout on nutrition.
88957516|NCT01984736|Experimental|EVP-6124, single dose|Single dose, Tablet, single administration, Day 1
88957517|NCT01984749|Experimental|Febuxostat treatment group|Once daily after breakfast (generally within 30 minutes after eating)
88957518|NCT01984749|No Intervention|Non-febuxostat treatment group|No febuxostat treatment
88957519|NCT01984775|Experimental|GSK2894512 0.5%|Each subject will receive a topical application of GSK2894512 0.5% under semi-occlusive patch conditions once daily (OD) for 21 days.
88957520|NCT01984775|Experimental|GSK2894512 1%|Each subject will receive a topical application of GSK2894512 1% under semi- occlusive patch conditions OD for 21 days.
88957521|NCT01984775|Experimental|GSK2894512 2%|Each subject will receive a topical application of GSK2894512 2% under semi-occlusive patch conditions OD for 21 days.
88957522|NCT01984775|Placebo Comparator|Vehicle|Each subject will receive a topical application of Vehicle cream under semi-occlusive patch conditions OD for 21 days.
88957523|NCT01984775|Active Comparator|Sodium lauryl sulfate 0.1%|Each subject will receive a topical application of 0.2 milliliter (mL) of Sodium lauryl sulfate under semi-occlusive patch conditions OD for 21 days. This will serve as a positive control.
88957524|NCT01984775|Active Comparator|Petrolatum|Each subject will receive a topical application of 0.2 mL of Petrolatum under semi-occlusive patch conditions OD for 21 days. This will serve as a negative control.
88957525|NCT01984801|Experimental|Part 1|Each of the following 6 treatments will be randomized to one of 6 designated locations on either upper arm or other locations, such as the lower or upper back, within each healthy subject: (A) 200 mg of 0.3% GSK1940029 gel, (B) 200 mg of 1% GSK1940029 gel, (C) 200 mg of 0.3%/1% vehicle gel only, (D) 200 µL of sterile distilled water, (E) Patch only, and (F) 200 µL of 0.5% SLS in sterile distilled water, Each treatment will be applied using individual patches, daily for 2 days
89506549|NCT03949556|Experimental|Intervention program - stress management program|This intervention program on stress management is developed to prevent suicidal ideation in medical students and residents.
89506550|NCT03949556|Active Comparator|Intervention program - health promotion program|This intervention program on health promotion is developed to prevent suicidal ideation in medical students and residents.
89506551|NCT03949556|Placebo Comparator|Control condition - general information|Participants will receive weekly emails and SMSs, over the same periods of time, with general information about health except mental health, e.g. prevention of melanoma, dental care….
89506552|NCT03927508|Experimental|BEC Treatment|The Bashir™ Endovascular Catheter is a device intended for the localized infusion of therapeutic agents into the pulmonary artery.
89506553|NCT03907345|Experimental|Exposure|Participants of this arm receive one 120-minute session of exposure treatment for spider fear.
89506554|NCT03907345|No Intervention|No Exposure|Participants of this arm receive no exposure or other adequate treatment.
89506555|NCT03852433|Active Comparator|Pegylated Interferon alfa-2a (PEG-IFN alfa) (Arm A)|Participants will receive PEG-IFN alfa 180 microgram (mcg) once a week for 48 weeks
89506556|NCT03852433|Experimental|Bulevirtide 2 mg/day + PEG-IFN alfa (Arm B)|Participants will receive bulevirtide 2 mg/day in combination with PEG-IFN alfa 180 mcg once a week for 48 weeks followed by bulevirtide 2 mg/day for 48 weeks
89506557|NCT03852433|Experimental|Bulevirtide 10 mg/day + PEG-IFN alfa (Arm C)|Participants will receive bulevirtide 10 mg/day in combination with PEG-IFN alfa 180 mcg once a week for 48 weeks followed by bulevirtide 10 mg/day for 48 weeks
88957526|NCT01984801|Experimental|Part 2|Each of the following 6 treatments will be randomized to one of 6 designated locations on either upper arm or other locations, such as the lower or upper back, within each healthy subject: (A) 200 mg of 0.3% GSK1940029 gel, (B) 200 mg of 1% GSK1940029 gel, (C) 200 mg of 0.3%/1% vehicle gel only, (D) 200 µL of sterile distilled water, (E) Patch only, and (F) 200 µL of 0.1% SLS in sterile distilled water. Each treatment will be applied using individual patches, daily for 21 days
88957527|NCT01984801|Experimental|Part 3|Each acne patient will apply a thin coat of one or two concentration of GSK1940029 gel or vehicle to acne affected facial/neck skin by hand, once daily for 28 days
88957528|NCT01984814|Experimental|Stem cell|Autologous bone marrow mononuclear cells intrathecal and intramuscular transplantation
88957529|NCT01984814|No Intervention|Control|No cell transplantation was done
88957530|NCT01984827|Experimental|hyper-glycaemic clamp:|hyper-glycaemic clamp: intra-venous Glucose as an initial bolus of 250mg/kg followed by a variable maintenance infusion for 4 hours
88957531|NCT01984827|Experimental|Moxifloxacin|Single oral dose of 400 mg Moxifloxacin
88957532|NCT01984827|Placebo Comparator|Placebo|Placebo
88957533|NCT01984840|Active Comparator|Telemedicine|A tablet (a Samsung GALAXY TAB 2 (10.1)) that holds information on handling COPD in general and software that automatically instructs the patient in handling COPD during exacerbations. The device can also collect and transmit relevant disease-specific data, which are indicative of their current state of health, via an attached Fingertip Pulse Oximeter (Nonin, Onyx II % SpO2), a Digital Blood Pressure Monitor (Model UA-767, plus BT-C) and a scale. The device can measure four vital signs, which are transferred wirelessly: blood pressure, pulse, blood oxygen saturation and weight. The tablet can be activated and give a sound, when it is time for taking measurements again.
88957534|NCT01984840|No Intervention|Usual care|In Denmark, usual practice for treating, monitoring and caring for patients with COPD are the responsibility of the patient's general practitioner (treatment and monitoring) and the municipalities (practical help and nursing care). COPD patients can make appointments with their general practitioner or practice nurse free of charge in order to get help in managing COPD. Community based care and practical help varies. As a rule community care comes at regular intervals based on a clinically based estimate of the patients' needs, but the personnel are not necessarily certified nurses and often not fully educated in COPD and definitely not on call
88957535|NCT01984853||OBSERVATIONAL REGISTRY|Individuals presenting with signs and/or symptoms of Acute Coronary Syndrome at the Henry Ford Hospital Emergency Department (ED).
89506558|NCT03852433|Experimental|Bulevirtide 10 mg/day (Arm D)|Participants will receive bulevirtide 10 mg/day for 96 weeks
89506559|NCT03849469|Experimental|Arm 1|Arm 1: XmAb®22841 Monotherapy
89506560|NCT03849469|Experimental|Arm 2|Arm 2: Combination of XmAb®22841 and Pembrolizumab (Keytruda®)
89506561|NCT03845400||Type I or Type II HAE Participants|Participants with Type I or Type II HAE will be followed for 24 or 36 months depending upon enrollment date. Data collection will cease at the end of follow-up period, at the time of withdrawal, lost to follow-up, or death whichever comes first.
89506562|NCT03843554|Placebo Comparator|Standard of Care Oral Hygiene|Standard of Care Oral Hygiene group (SOC-OH): Subjects assigned to SOC-OH will attend weekly oral care visits where they will have their teeth brushed with a soft bristled toothbrush by the interventionist. No treatment to the oral mucosa will be provided to this group as part of the intervention. Subjects will receive oral care instructions and will be asked to follow SOC oral hygiene instructions at home.
89506563|NCT03843554|Experimental|Oral Mucosal Deterging and Dental Prophylaxis (OMDP)|Oral Mucosal Deterging & Dental Prophylaxis (OMDP) protocol: Subjects assigned to OMDP will attend weekly intervention visits during which they will have their teeth cleaned and will receive the OMDP intervention as follows: subjects will receive a professional dental prophylaxis including periodontal surface debridement and deterging of the oral mucosal surfaces. Subjects will be asked to follow OMDP oral hygiene instructions at home.
89506564|NCT03837522|Active Comparator|Procurement Biopsy: Frozen section|In the routine care condition, biopsies will be processed immediately as a frozen section.
89506565|NCT03837522|Active Comparator|Procurement Biopsy: Permanent section|In the intervention group, the biopsy processing will be delayed to permanent section, and therefore not available until allocation is complete.
89506566|NCT03805607|Placebo Comparator|Placebo|1 ml of normal saline
89506567|NCT03805607|Experimental|Ketorolac|30 mg of ketorolac in 1 ml
89506568|NCT03744013|Active Comparator|Perforated|Fortiva® 1mm perforated ADM
89506569|NCT03744013|Active Comparator|Non-perforated|Fortiva® 1mm non-perforated ADM
89506570|NCT03719703||Case 1|Children conceived by frozen embryo transfer
89506571|NCT03719703||Case 2|Children conceived by fresh embryo transfer
89506572|NCT03719703||Control|Naturally conceived children
89506573|NCT03678194|Experimental|Smartphone application|This group of subjects receives mobile support system and conventional treatment (clinical evaluation and follow-up). The smartphone application will be downloaded on patients' smartphone to daily evaluate symptomatology, medication adherence…
89506574|NCT03678194|No Intervention|Standard services|This group of patients receives conventional treatment only. Clinical evaluations are provided at the same endpoint. Patients still receive standard services for depression.
89506575|NCT03646383|Experimental|Treatment with radiofrequency|Treatment of symptomatic benign nodules with radiofrequency ablation as an alternative to surgical treatment
89506576|NCT03643848|Experimental|Sleep with Sound Cues|Sounds played at time of memory encoding will be replayed during sleep to cue memory processing.
89506577|NCT03643848|Sham Comparator|Sleep with Sham Cues|Sounds that were not played at time of memory encoding will be played during sleep as a sham comparison
89506578|NCT03496766|Experimental|Experimental Arm|Tipifarnib 600 mg, po, bid daily on days 1-7 and 15-21 of 28-day treatment cycles for up to 24 months
89506579|NCT03418909||Oropharyngeal carcinoma (excluding M+ stage)|"Eligible patients with histologically verified early stage squamous cell carcinoma of the oropharynx.~Patients will be treated in accordance with current hospital protocols with transoral robotic surgery (T1-2, N1, M0) or radio(chemo)therapy (any T-stage, any N-stage, M0)."
89506580|NCT03406715|Experimental|Combination Immunotherapy Plus Vaccine|Combination immunotherapy with Ipilimumab and Nivolumab plus a Dendritic Cell based p53 Vaccine (Ad.p53-DC). Induction Immunotherapy, followed by Maintenance Immunotherapy and potentially Retreatment. During retreatment, participants would receive the combination of Ipilimumab and Nivolumab or Nivolumab alone every three weeks for a maximum of one additional year.
89506581|NCT03385720|Experimental|Experimental group|
89506582|NCT03385720|Active Comparator|Control group|
88957536|NCT01984866||Breast tumors sensitive to neoadjuvant|"Treated patients as usual clinical practice with unicentered tumors in stages II or III and good response determined by MR after 6 cycles of treatment (less than 2 cm apparent residual injury) will be consecutively subjected to radiofrequency biopsy and the surgery previously established for each case (Tumorectomy or mastectomy). Before surgery, the sentinel node will be biopsied in order to define the surgical treatment on the axilla (none in case of negative sentinel node, axillary lymphadenectomy if positive).~The tumor samples obtained by percutaneous radiofrequency and mastectomy-Tumorectomy biopsy will be studied thoroughly to define the correlation between the two."
88957537|NCT01984918|Active Comparator|SMS reminder|A text message reminder via Short Message Service (SMS) will be sent to remind subjects 7-10 days before his colonoscopy appointment
88957538|NCT01984918|No Intervention|Non-SMS reminder|No text message reminder via Short Message Service (SMS) will be sent
88957539|NCT01984931|Experimental|Trimebutine Maleate 300 mg Tab|A single dose of NEWBUTIN SR 300 mg Tab will be given orally one hour prior to the said operation time and another 300 mg orally as soon as the patient wakes post operatively.
88957540|NCT01984931|Active Comparator|Metoclopramide hydrochloride monohydrate 8.46 mg/2ml/A|Anti-emetic medication protocol of Chungmu Hospital includes MACPERAN (Metoclopramide hydrochloride monohydrate 8.46 mg/2ml/A)thru IV twice in a day
88957541|NCT01984944|Other|Autistic Patient|"50 adults~25 childs"
88957542|NCT01984944|Other|Controls|"50 adults~25 childs"
89506583|NCT03363763|Active Comparator|Arm 1|Sirolimus 0.2% ointment applied topically hs x 12 weeks
89506584|NCT03363763|Active Comparator|Arm 2|Sirolimus 0.4% ointment applied topically hs x 12 weeks
89506585|NCT03363763|Placebo Comparator|Arm 3|Placebo ointment applied topically hs x 12 weeks
89506586|NCT03359096|Experimental|Therapeutic HGNS|Therapeutic Hypoglossal Nerve Stimulation (HGNS). Prior to enrollment in this study, the HGNS will have been implanted as part of clinical care, and a therapeutic voltage setting will have been determined via overnight sleep study.
89506587|NCT03359096|Sham Comparator|Subtherapeutic 'Sham' HGNS|"Sham threshold determination will be performed as follows. The patient will be in a reclined position with the mouth open while nasal breathing. Stimulation will be increased from 0.1V up by 0.1V until bulk tongue motion is detected without obvious protrusion. This process is repeated twice and the average value is used to determine sham-HGNS. The electrode configuration will remain consistent between the patient's therapeutic and sham thresholds."
89506588|NCT03330158|Experimental|ASTS device|Implantation of device ASTS (for ACTIVE TREATMENT SCOLIOSIS SYSTEM ) in children between 4 and 10
89506589|NCT03314155|Experimental|Cerebral neuroinflammation evaluation|The density of TSPO (which is an inflammation maker) is evaluated by the tracer's brain distribution volume ([18F] DPA-714).
89506590|NCT03313128||Historic intervention|Infants born into the historic intervention arm of sanitation trial (NCT02362932)
89506591|NCT03313128||Historic control|Infants born into the historic control arm of sanitation trial (NCT02362932)
89506592|NCT03310190||Participants receiving venetoclax|Participants with Chronic Lymphocytic Leukemia (CLL) receiving venetoclax.
89506593|NCT03309683|Experimental|Clip group|Olympus Quick Clip Pro - Single Use Repositionable Clips will be used for Prophylactic clipping after EMR
89506594|NCT03309683|No Intervention|Control group|Standard treatment after EMR (as described in the detailed study description above)
89506595|NCT03306485||Patients with GERD symptoms refractory to PPI therapy|"Patients with proven GERD (gastro-esophageal reflux disease) off PPI (proton pump inhibitor) (Los Angeles grade B, C or D esophagitis and/or esophageal acid exposure > 5% on pH monitoring performed off PPI).~These patients have persistent heartburn and/or regurgitation despite double dose proton pump inhibitor. Patients are referred for esophageal high resolution impedance manometry and ambulatory 24-h pH-impedance monitoring on proton pump inhibitor."
89506596|NCT03182751|Active Comparator|Tranexamic Acid Arm (TXA)|Subjects will be treated with early administration of TXA in the Emergency Department
89506597|NCT03182751|Placebo Comparator|Control Arm|Subjects will be treated with a placebo in the Emergency Department
89506598|NCT03139149|Active Comparator|Early surgery|After exclusion of indications for an emergency operation, conservative treatment is performed up to 12 hours from the moment of admission. Each patient receive blood test, blood lactate investigation, blood biochemistry, X-ray of the abdomen, ultrasound and CT on the admission. Each patient receive water-soluble contrast in 3 h after admission. In case of of clinical and radiologic signs of obstruction in 12 h after admission, surgery is performed. On the first stage of surgical treatment laparoscopic adhesiolysis is performed. If it is impossible to eliminate the cause of obstruction by laparoscopic technique laparotomy is performed.
89539716|NCT04922931||Post-COVID-19 group|The Post-COVID-19 group or case group includes post-COVID patients (confirmed by PCR) >18 years undergoing scheduled surgery without pulmonary disease prior to SARS-CoV-2 infection that at the time of surgery present negative PCR and absence of clinic due to SARS-CoV-2.
89539717|NCT04922931||Control group|The control group includes patients over the age of 18 who did not have COVID-19 and without moderate-severe pulmonary pathology prior to surgery and in conditions of hemodynamic and respiratory stability at time of surgery.
89539718|NCT02123134|Placebo Comparator|Placebo|Participants received placebo administered in 0.2 mL subcutaneous (SC) injections, up to 10 milliliters (mL) per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
89539719|NCT02123134|Experimental|ATX-101 deoxycholic acid injection|Participants received deoxycholic acid 2 mg/cm^2 administered in 0.2 mL SC injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
88957543|NCT01984957|Other|disease (ALS, SMA or SBMA)|muscle biopsy
88957544|NCT01984970||videolaryngoscope|The patients received videolaryngoscope for double-lumen tube intubation
88957545|NCT01984983|Experimental|VEEV DNA Vaccine 0.5 mg/ml Intramuscular|Venezuelan Equine Encephalitis Virus DNA Vaccine Candidate
89539720|NCT03054207|Experimental|HIV clopidogrel|clopidogrel 300 mg single dose oral route
89539721|NCT03054207|Experimental|HIV prasugrel|prasugrel 60 mg single dose oral route
89539722|NCT03054207|Active Comparator|Control clopidogrel|clopidogrel 300 mg single dose oral route
89539723|NCT03054207|Active Comparator|Control prasugrel|prasugrel 60 mg single dose oral route
89539724|NCT03055689|Experimental|Educational telephone intervention|This group will receive a nurse-led educational telephone intervention for bowel preparation 24-48 before the colonoscopy
89539725|NCT03055689|Active Comparator|Standard education for colonoscopy|The control group will receive standard education for bowel preparation at the time of colonoscopy scheduling
89539726|NCT02185534|Experimental|European clopidogrel tablets, 75 mg|Treatment A: a single oral dose of clopidogrel 75 mg film-coated tablet (Zyllt, KRKA - test)
89539727|NCT02185534|Active Comparator|Japanese clopidogrel tablets, 75 mg|Treatment B: a single oral dose of clopidogrel 75 mg film-coated tablet (Plavix®, Brystol-Myer Squibb,Sanofi-Aventis, reference)
89539728|NCT02185534|Active Comparator|US clopidogrel tablets, 75 mg|Treatment C: a single oral dose of clopidogrel 75 mg film-coated tablet (Plavix®, Sanofi-Aventis, reference)
89539729|NCT03056079|Other|AMD/RVO/DME|Patients presenting to St. Michael's Hospital retina clinic with neovascular AMD, macular edema secondary to retinal vein occlusion and diabetic macular edema treated with intravitreal aflibercept in a variable dosing regimen.
89023869|NCT04502576|Active Comparator|High-flow nasal cannula|"High-flow nasal cannula will be delivered with the Optiflow system. Initial set flow will be ≥ 50 /min and flows will be decreased in case of intolerance and/or according to patients' requirements: flows≥30 L/min will be mandatory in all enrolled patients. Humidification chamber (MR860, Fisher and Paykel healthcare, New Zealand) will be set at 37 °C or 34 °C according to patient's comfort. FiO2 will be titrated to obtain an SpO2≥92% and ≤98%.~The treatment according to the assigned protocol will be continued until the patient requires endotracheal intubation or (in case of no intubation) up to ICU discharge. Weaning from high-flow will be considered as standardized criteria are met."
89023870|NCT04502576|Experimental|Helmet noninvasive ventilation|"Patients will receive continuous helmet pressure support ventilation for at least 16 hours/day the first 2 calendar days. Continuous noninvasive ventilation without interruptions will be strongly encouraged in the first 24 hours of treatment. The ventilator will be set in pressure support mode. Use of continuous positive airway pressure by flow generators and Venturi systems instead of pressure support ventilation will be allowed in case of shortage of ventilators. Maintenance of positive end-expiratory pressure ≥ 8-10 during the treatment is mandatory.~After weaning and during any interruption from noninvasive ventilation, patients will undergo low-flow or high-flow oxygen, according to the decision of the attending physician.~The treatment according to the assigned protocol will be continued until the patient requires endotracheal intubation or (in case of no intubation) up to ICU discharge."
89539730|NCT04923009|Experimental|Simple-ICE group|Patients undergoing ablation using only ICE visualization and ablation catheter
89539731|NCT04923009|Active Comparator|Standard mapping catheter without ICE|Patients undergoing ablation using standard approach including diagnostic and mapping electrodes as well as ablation electrode
89539732|NCT02121808|Experimental|Supine|NIPPV and Tidal volume
89539733|NCT02121808|Experimental|Beach-chair (Back : 25 deg)|NIPPV and Tidal volume
89539734|NCT02121808|Experimental|Proclive (Global 25 deg)|NIPPV and Tidal volume
89539735|NCT04923087||Patient hospitalized in geriatrics or EHPAD|Subjects 65 years of age or older, hospitalized in geriatrics or EHPAD residents
89539736|NCT03055845|Experimental|STA363 dose 1|
89539737|NCT03055845|Experimental|STA363 dose 2|
89539738|NCT03055845|Experimental|STA363 dose 3|
89539739|NCT03055845|Placebo Comparator|Placebo|
89539740|NCT04922775|Other|conventional taping-Chinese medicine technique taping|Participants will accept conventional taping before muscle fatigue exercise for the first course then accept Chinese medicine technique taping before muscle fatigue exercise for the second course.
89539741|NCT04922775|Other|Chinese medicine technique taping-conventional taping|Participants will accept Chinese medicine technique taping before muscle fatigue exercise for the first course then accept conventional technique taping before muscle fatigue exercise for the second course.
89539742|NCT02157376|Experimental|Esomeprazole active treatment|iv esomeprazole 30 min intermittent infusions given for maximum 14 days
89539743|NCT02157376|Active Comparator|Cimetidine active treatment|iv cimetidine 30 min bolus infusion followed by iv cimetidine continuous infusion given for maximum 14 days
89539744|NCT04918251||Controls|Individuals from the Irish population with no psychiatric, psychological, neurological or muscular disease diagnosis
89539745|NCT04918251||Amyotrophic lateral sclerosis patients|
89539746|NCT04918251||Multiple sclerosis patients|
89539747|NCT04918251||Frontotemporal dementia patients|
89539748|NCT03055455||Sepsis|Children with severe sepsis or septic shock
89539749|NCT02157298|Experimental|dapagliflozin 5mg|dapagliflozin tablet 5mg
89539750|NCT02157298|Placebo Comparator|Placebo|dapagliflozin tablet 5mg placebo
89539751|NCT04904055||Value-based Formulary Beneficiaries|enrolled in the value-based formulary
89539752|NCT04904055||Standard Formulary Beneficiaries|enrolled in a standard (i.e., non-value-based formulary)
89539753|NCT04430907||Vaccine Accepting|This group will receive the HPV vaccine in the inpatient postpartum period prior to discharge from the hospital.
89539754|NCT04430907||Vaccine Rejecting|This group will not receive the HPV vaccine in the inpatient postpartum period prior to discharge from the hospital.
89539755|NCT03054285|No Intervention|No seizure prophylaxis|Participants randomized to this arm will not receive anti-seizure prophylaxis
89539756|NCT03054285|Experimental|Seizure Prophylaxis|Participants randomized to this arm will receive the anti-seizure prophylaxis drug Levetiracetam for seven days post traumatic brain injury.
89539757|NCT04917627|Active Comparator|vancomycin group (intervention arm)|We will use one vial of vancomycin that contains 1000 mg of the drug in powder form on the surgical site before closing the wound
89539758|NCT04917627|No Intervention|control group|no vancomycin powder will be used
88957546|NCT01984983|Experimental|VEEV DNA Vaccine 0.5 mg/ml Intradermal|Venezuelan Equine Encephalitis Virus DNA Vaccine Candidate
89539759|NCT04904133|Active Comparator|Saccharine Group|140 mg saccharin (Hermesetas) dissolved in 330 mL water for 4 weeks.
89539760|NCT04904133|Active Comparator|Sucralose Group|66 mg sucralose (Splenda) dissolved in 330 mL water for 4 weeks.
89539761|NCT04904133|Active Comparator|Aspartame+Acesulfame-K Group|88 mg aspartame+88 mg acesulfame-K (Takita) dissolved in 330 mL water for 4 weeks.
89539762|NCT04904133|Placebo Comparator|Control Group|330 mL water for 4 weeks.
88815290|NCT02249585|Experimental|DL|Patients who receive laparoscopic colon surgery under Trendelenberg position with deep neuromuscular blockade and low abdominal pressure.
88957547|NCT01984983|Experimental|VEEV DNA Vaccine 2.0 mg/ml Intramuscular|Venezuelan Equine Encephalitis Virus DNA Vaccine Candidate
88957548|NCT01984983|Experimental|VEEV DNA Vaccine 2.0 mg/ml Intradermal|Venezuelan Equine Encephalitis Virus DNA Vaccine Candidate
88957549|NCT01984983|Placebo Comparator|Placebo: 0.9% saline|0.9% saline
88957550|NCT01984996|Experimental|Freedom ProFlor Inguinal Hernia Implant|
88957551|NCT01985009|Other|Fibroscan®|Single arm study. See intervention item for détails..
88957552|NCT01985022|Active Comparator|Group-ESI|Infants 12 months of age at risk of developing ASD who are randomized to receive the Group-ESI intervention for 9 months.
88957553|NCT01985022|Experimental|Individual-ESI plus Group-ESI|Infants 12 months of age at risk of developing ASD who are randomized to receive Individual-ESI intervention in addition to the Group-ESI intervention for 9 months.
89539763|NCT04904211|Experimental|Feasiblity and Safety|All eligible patients will be assigned to this arm
89539764|NCT04903743|Placebo Comparator|group B|28ml of 0.25% bupivacaine and 2ml normal saline
89539765|NCT04903743|Active Comparator|group BM|received 28 ml of 0.25% bupivacaine and 2 ml magnesium sulfate 10%.
89539766|NCT02184988|Experimental|Botulinum neurotoxin, Type A|DWP-450 (Botulinum purified neurotoxin, Type A) Injection
89539767|NCT04917939||epilepsy with HS|
89539768|NCT04917939||epilepsy without HS|
89539769|NCT03055143|Experimental|SPARC-08-038|2 mg/ml
89539770|NCT03055143|Active Comparator|Ref-08-038|
89539771|NCT04753840|Experimental|Experimental A: Drug group+lifestyle intervention|Experimental group A used only one antihypertensive drug (ACEI / ARB, beta blocker, calcium channel blocker, diuretic, etc.) plus lifestyle intervention to control blood pressure.
89539772|NCT04753840|Experimental|Experimental B: RIPC group+lifestyle intervention|The experimental group B received ripc treatment of upper limbs every day plus lifestyle intervention until the end of the follow-up. The treatment time was 40 minutes per day, 10 minutes as a cycle (cuff inflated to 200 mmHg and maintained for 5 minutes, then deflated for 5 minutes to start the next cycle), a total of 4 cycles.
89539773|NCT04753840|Other|Experimental c: lifestyle intervention|The control group take lifestyle intervention to control blood pressure, such as changing dietary habits, smoking cessation and alcohol restriction, exercise and so on.
89539774|NCT04903275|Experimental|Fluoride and Laser|In the split-mouth design, the left maxillary anterior teeth receive topical fluoride application and carbon dioxide (CO2) laser irradiation.
89539775|NCT04903275|Active Comparator|Fluoride|In the split-mouth design, this arm - the contralateral teeth (right maxillary incisors), will receive topical fluoride application.
88815291|NCT00984698|Experimental|Structured Therapy|Cognitive Behavioral Social Rhythm Group Therapy is designed to improve mood and sleep by stabilizing social rhythms, increasing exposure to ambient light, changing dysfunctional bed/bedtime associations, activating the imagery system by changing nightmare content, and challenging dysfunctional automatic thoughts that might contribute to behavioral inactivation and nonadherence to the therapy protocol. There is no discussion of past traumatic events.
88815292|NCT00984698|Active Comparator|Unstructured Therapy|Present Centered Group Therapy includes education about the typical symptoms and features associated with PTSD and MDD, with a focus on how these symptoms affect interpersonal relationships. It uses the group format to decrease isolation, normalize symptoms, and provide the experience of giving and receiving support. Some relaxation training is provided early in therapy. There is no discussion of past traumatic events.
88815293|NCT03016520|Experimental|Test drug|DWJ1392
88815294|NCT03016520|Experimental|Reference drug|DWC20164
88815295|NCT02240069|Experimental|Education (Tx1)|Education on best burn practices
88815296|NCT02240069|Active Comparator|Air Filtration Unit Treatment (Tx2)|"A 20 x 18 Filtrete air filtration unit (3M, St. Paul, MN) will be placed in the same room as the wood stove."
88815297|NCT02240069|Sham Comparator|Placebo Intervention (Tx3)|"A 20 x 18 Filtrete air filtration unit will be installed within the wood stove home. Instead of a high efficiency filter, the units will utilize a placebo filter."
88815298|NCT01023074|No Intervention|Non-MS Control|Non-MS control group
88815299|NCT01023074|Active Comparator|MS: Auditory Training|MS group receiving auditory training
88815300|NCT01023074|Placebo Comparator|MS: Control Activity|MS group not receiving auditory training, doing control activity
88815301|NCT04171583||mucoid S. aureus|CF patients with mucoid S. aureus
88815302|NCT04171583||non-mucoid S. aureus|CF patients with non-mucoid S. aureus
88815303|NCT04368962||MMF group|Post-transplant patients accept immunosuppression protocol based on MMF for at least 12 months.
88815304|NCT04340492|Experimental|Adapted Physical Activity group|
88815305|NCT04340492|Sham Comparator|control group|
89539776|NCT03055299|Experimental|COMEX|Patients receive comprehensive exercise intervention
89023871|NCT04496219|Experimental|Arm I (acupuncture, BCG)|Patients undergo acupuncture therapy and receive BCG via intravesical injection on days 1, 8, 15, 22, 29, and 36 in the absence of unacceptable toxicity. Patients also receive standard of care symptom management.
89539777|NCT04917003|Experimental|RIC group|"Patients who are allocated into RIC group will undergo the first EDAS surgery combined 3-month remote ischemic conditioning (RIC) treatment. The opposite operation will be performed at 3 months after the first operation.~RIC is a non-invasive therapy that performed by an electric auto-control device with cuff placed on arm. RIC procedures consist of five cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on one arm.~EDAS involves placement of an external carotid artery branch beneath the dura in the ischemic territories. The superficial temporal artery (STA) was commonly used."
89539778|NCT04917003|Other|control group|"Patients who are allocated into the control group will accept EDAS surgery twice. The second operation will be performed at 3 months after the first operation.~EDAS involves placement of an external carotid artery branch beneath the dura in the ischemic territories. The superficial temporal artery (STA) was commonly used. Under certain circumstances, depending on the territory at risk, the occipital artery was also used. The donor vessel with the strip of galea (the arterial bridge) was detached from the pericranium or the fascia below, and two burr holes are made beneath the proximal and distal ends of the arterial bridge. The burr holes, with an average size of 3.0 × 8.0 cm, were connected by mill to make an oval bone flap and the dura was exposed. The target artery was then sewn to the dura using 10-0 Prolene suture. The bone flap was closed after cutting out the entry and exit sites for the target artery."
89539779|NCT04902963|Experimental|Meeting indication for short term ventilation tube placement|Adult patients meeting standard criteria for short-term ventilation tube placement were offered placement of a bioabsorbable ear tube in place of a durable ear tube that would later be removed.
89539780|NCT04902807||Patients|"based on the potential for inclusion of patient's cohort followed in Necker hospital with PIDs and poly-autoimmunity related to known genetic defects. Recruitments will be made at Pediatric Rheumatology Immuno Hematology department, and paediatric Gastroenterology department (n=250).~Collection of blood, urine and stools at inclusion and blood at 12 months consultation/ follow-up."
89539781|NCT04902807||Patients' relatives (control)|Brothers or sisters of the patients (n=125). Collection of blood, urine and stools at inclusion.
89539782|NCT04902807||Patients with unrelated diseases (control)|"Recruitments will be made at the Paediatric Gastroenterology Department, in the Department of Paediatric Visceral and Urologic Surgery and the Department of Maxillofacial Surgery and Paediatric Plastic Surgery at Necker's Hospital. Participants will be included if not diagnosed PIDs and poly-autoimmunity (n=125).~Collection of blood, urine and stools."
89539783|NCT02121262|Other|Laser Photocoagulation|Laser photocoagulation was administered in the study eye on Day 1, and on Months 3, 6, and 9, if retreatment indicated.
89539784|NCT02121262|Experimental|Dexamethasone|Dexamethasone 700 μg was administered as intravitreal injection in the study eye on Day 1, Months 5, and 10.
89539785|NCT03053739|Active Comparator|Combination arm A-Sildenafil and Bosentan|"Combination Arm A -Intervention- Drug~Tab Sildenafil 20 mg - three times a day for 6 months,and~Tab Bosentan 62.5mg - twice a day for 6 months"
89539786|NCT03053739|Placebo Comparator|Monotherapy arm-Sildenafil and Placebo|Monotherapy arm B Intervention-Drugs Tab Sildenafil 20mg- three times a day for 6 months, and Placebo tab (matched for bosentan) for 6 months
89539787|NCT04916925|Experimental|pcos resistant to cc plus vit d|100 patients who are PCOS and resist CC will receive Vitamin D 10000 IU orally plus 150mg clomid orally for 3 months number and size of growing follicles will be monitored
89539788|NCT04917081|Experimental|Mindful Self-Compassion|
89539789|NCT04917081|Active Comparator|Progressive Muscle Relaxation|
89539790|NCT04909749|Experimental|PGx-guided antidepressant therapy|These individuals will be prescribed medication guided by the Oneome RightMed Test.
89539791|NCT04909749|No Intervention|Treat as usual based on Clinical Physician Recommendation|These individuals will receiving medication as usual based on the clinics internal guidelines and physician recommendations.
89539792|NCT04430751|Active Comparator|Immediate start|
89539793|NCT04430751|Active Comparator|wait time control|
89539794|NCT04902183|Experimental|10^9 dose of exosomes overexpressing CD24|The patients will receive the dose of 10^9 exosomes overexpressing CD24
89539795|NCT04902183|Experimental|10^10 dose of exosomes overexpressing CD24|The patients will receive the dose of 10^10 exosomes overexpressing CD24
89539796|NCT03052413|Active Comparator|Active|
89539797|NCT03052413|Placebo Comparator|Placebo|
89539798|NCT03052335|Experimental|Pillcam® COLON 2 Capsule and colonoscopy|Persons with positive immunochemical fecal occult blood tests will be examined by second generation colon capsule endoscopy (CCE2) and optical colonoscopy afterwards.
89539799|NCT03052179|Active Comparator|VSL#3|VSL#3 poly-biotic 450 billion in sachet orally, two sachets in the morning and two sahcets in the evening for 30 days
89539800|NCT03052179|Placebo Comparator|Placebo|Maltose in sachet orally, two sachets in the morning and two sahcets in the evening for 30 days
89539801|NCT04902105|Other|Cohort A|"Ecopipam HCL - 2 doses of 200mg~Mefenamic acid 250mg Q6H for 7 days"
89539802|NCT04902105|Other|Cohort B|"Ecopipam HCL - 2 doses of 200mg~Divalproex acid 1250mg QD for 10 days"
89539803|NCT04901949||BMI Group 1|If BMI is less than 24,9 kg/m2
89539804|NCT04901949||BMI Group 2|If BMI is between 25 - 30 kg/m2
89539805|NCT04901949||BMI group 3|If BMI is more than 30,1 kg/m2
89539806|NCT04916379|Experimental|Momordica charantia|Two 500 mg capsules of Momordica charantia twice daily before breakfast and dinner for 12 weeks
89506599|NCT03139149|Active Comparator|Late surgery|After exclusion of indications for an emergency operation, conservative treatment is performed up to 48 hours from the moment of admission. Each patient receive blood test, blood lactate investigation, blood biochemistry, X-ray of the abdomen, ultrasound and CT on the admission. Each patient receive water-soluble contrast 3 h after admission. In case of present of obstruction and absence of contrast in colon in 36 h after intake (48 h after admission) a surgery is perform. On the first stage of surgical treatment laparoscopic adhesiolysis is performed. If it is impossible to eliminate the cause of obstruction by laparoscopic technique laparotomy is performed.
89506600|NCT03121989|Active Comparator|Hyperpolarized Pyruvate (13C) Injection|"The Participants in the active comparator arm will be injected with study drug Hyperpolarized Pyruvate (13C) Injection at a dose of 0.43/ml/kg.~After the injection research, MRI will be done and images evaluated."
89506601|NCT03121989|Placebo Comparator|Coil Testing|Participants will receive an MRI with a 1 cm diameter plastic ball that contains 13C-urea that acts as test object. It provides a signal that is used to ensure that the MRI system is functioning properly.
89506602|NCT03105245|Active Comparator|Short time interval + Normal ventilation|
89506603|NCT03105245|Active Comparator|Short time interval + Hyperventilation|
89506604|NCT03105245|Active Comparator|Long time interval + Normal ventilation|
89506605|NCT03105245|Active Comparator|Long time interval + Hyperventilation|
89506606|NCT03075397|Other|HIV-1 infected patients|Blood sample and sperm sample are collected
89506607|NCT03019588|Experimental|Pembrolizumab 200 mg|Participants receive pembrolizumab 200 mg intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 cycles (up to approximately 2 years).
89506608|NCT03019588|Active Comparator|Paclitaxel 80 mg/m^2|Participants receive paclitaxel 80 mg/m^2 IV infusion on Days 1, 8 and 15 of each 4-week cycle for up to approximately 2 years.
89506609|NCT02959944|Experimental|Ibrutinib + Prednisone|"Ibrutinib (420 mg) given orally once daily continuously starting on Week 1 Day 1 until cGVHD progression, progression of underlying malignancy, participant begins another systemic treatment for cGVHD or unacceptable toxicity. The 420 mg dose was adjusted for cytochrome P450 [CYP] inhibitors or hepatic dysfunction as applicable.~Prednisone 1 mg/kg/d given orally once daily continuously starting on Week 1 Day 1 until unacceptable toxicity or until participant is successfully tapered from the prednisone. Starting prednisone dose may be as low as 0.5 mg/kg/d if a participant cannot tolerate higher doses."
89506610|NCT02959944|Placebo Comparator|Placebo + Prednisone|"Placebo given orally once daily continuously starting on Week 1 Day 1 until cGVHD progression, progression of underlying malignancy, participant begins another systemic treatment for cGVHD or unacceptable toxicity.~Prednisone 1 mg/kg/d given orally once daily continuously starting on Week 1 Day 1 until unacceptable toxicity or until participant is successfully tapered from the prednisone. Starting prednisone dose may be as low as 0.5 mg/kg/d if a participant cannot tolerate higher doses."
89506611|NCT02806687|Experimental|Gene Therapy product CYL-02|Two EUS-guided intratumor injections of CYL-02 at one month interval plus Gemcitabine (3 weeks/month) during two months followed by four months Gemcitabine alone (3 weeks/month) or until progression.
89506612|NCT02806687|Active Comparator|Standard of care|Gemcitabine alone 3 weeks/month during 6 months (or until progression).
89506613|NCT02774668|Active Comparator|"Grab-and-Go meal plan"|"The intervention of this arm is to use a Grab-and-Go meal plan. This meal plan provides Atkins shakes and bars for breakfast, lunch, and snacks for 2 weeks. For dinner the subject is given a freshly-prepared meal. Upon finishing the 2-week provided food phase, the subject will consume a self-prepared meal of similar nutrient composition at home for another 2 weeks. For the next four weeks while he/she is still enrolled in the study, he/she will have his/her options for food choices which are not controlled for the study."
89506614|NCT02774668|Active Comparator|"Jump-Start meal plan"|"The intervention of this arm is to use a Jump Start meal plan. This meal plan provides Atkins frozen meals at breakfast, lunch and dinner for 2 weeks and these meals are supplemented with fresh salads and vegetables. Upon finishing the 2-week provided food phase, the subject will consume a self-prepared meal of similar nutrient composition at home for another 2 weeks. For the next four weeks while he/she is still enrolled in the study, he/she will have his/her options for food choices which are not controlled for the study."
89506615|NCT02761668|Experimental|ParS+Ortho 4W|Orthodontic alignment starts 4 weeks post surgical
89506616|NCT02761668|Active Comparator|ParS+Ortho 6M|Orthodontic alignment starts 6 months post surgical
89506617|NCT02698449|Experimental|cognitive rehabilitation + transcranial stimulation|specific cognitive rehabilitation combined to transcranial direct current stimulation
89506618|NCT02698449|Experimental|cognitive rehabilitation + stimulation sham|specific cognitive rehabilitation combined to transcranial direct current stimulation sham
89506619|NCT02698449|Experimental|placebo rehab + transcranial stimulation|nonspecific cognitive rehabilitation (placebo rehab) combined to transcranial direct current stimulation
89506620|NCT02698449|Experimental|placebo rehab + stimulation sham|nonspecific cognitive rehabilitation (placebo rehab) combined to transcranial direct current stimulation sham
89506621|NCT02633891|Experimental|Balance exercise program|Participants will attend weekly group training sessions and will keep an exercise log of home activity during a three month exercise program designed to improve balance. Balance exercises will be performed three times per week in a home-based training program.
89506622|NCT02633891|Active Comparator|standard care|Participants will meet in person on a weekly basis for a general education class regarding health and fall prevention but will not participate in an exercise class.
89506623|NCT02596568|Experimental|Active tDCS stimulation|Anodal tDCS will be applied bi-frontally using Chattanooga Ionto™ Iontophoresis System - Phoresor. A square wave will be delivered at 0.75 Hz for five blocks of five minutes each with one minute inter-train interval. Stimulation will be applied following 8 epochs of consecutive stage 2 or deeper sleep.
89506624|NCT02596568|Sham Comparator|Sham tDCS stimulation|tDCS electrodes will be applied bi-frontally using Chattanooga Ionto™ Iontophoresis System - Phoresor, however stimulation will never be turned on.
89506625|NCT02589821|Experimental|Surufatinib|Surufatinib 300 mg, orally, once daily (QD)
89506626|NCT02589821|Placebo Comparator|Placebo|Placebo 300 mg, orally, once daily (QD)
89506627|NCT02588170|Experimental|Surufatinib|Surufatinib 300 mg, orally, once daily (QD)
89506628|NCT02588170|Placebo Comparator|Placebo|Placebo 300 mg, orally, once daily (QD)
89506629|NCT02559180|Experimental|Single Arm|aflibercept 2mg given intravitreally every month until resolution of fluid in retina and then continued every 2 months for a total of 24 months of treatment
89506630|NCT02539966|Experimental|Cohort A|Fantom Sirolimus-Eluting Coronary Bioresorbable Scaffold - Treatment Group A (6-month angiographic follow-up)
89506631|NCT02539966|Experimental|Cohort B|Fantom Sirolimus-Eluting Coronary Bioresorbable Scaffold - Treatment Group B (9-month angiographic follow-up)
89506632|NCT02539966|Experimental|Cohort C|Fantom Sirolimus-Eluting Coronary Bioresorbable Scaffold - Treatment Group C (6-month angiographic follow-up), Long Lesion/Multi-Vessel
89506633|NCT02526225|Active Comparator|ginkgo diterpene lactone meglumine injection|ginkgo diterpene lactone meglumine injection
89506634|NCT02526225|Placebo Comparator|Ginkgo diterpene lactone meglumine injection simulation|Ginkgo diterpene lactone meglumine injection simulation
89506635|NCT02443961|Experimental|Mesenchymal Stem Cell (MSC) therapy|There will only be one treatment arm to evaluate the security of the treatment with MSC.
89506636|NCT02401139|Active Comparator|Treatment arm|Ketamine
89506637|NCT02401139|Placebo Comparator|Placebo arm|Placebo
89506638|NCT02367846|Experimental|Combined Oral Contraceptive (COC)|We are testing the effects of a COC (Apri (Reclipsen); 30 µg EE, 150 µg desogestrel). On the first day of the intervention, the participants randomized to COC will begin taking the pill. One pill will be ingested orally at the same time each day for days 1-49 of the intervention. Pills ingested during days 1-21 and during days 29-49 will be active tablets. Pills ingested on days 22-28 will be tablets without active ingredients. Each participant in the COC group will ingest a pill from the first pack each day for the first 28 days then begin the second pack. If a participant is unable to collect a 24-h urine sample on day 49, she will take active tablets from the third pill pack until she has collected the 24-h urine sample.
89506639|NCT02367846|Experimental|Contraceptive Vaginal Ring (CVR)|We are testing the effects of the vaginal ring (Nuva Ring; 15 µg/d EE, 120 µg/d etonogestrel). When randomized to CVR, participants will insert the contraceptive ring into their vagina . The ring will be worn during weeks 1-3, and again during weeks 5-7. During week 4, no ring will be worn to allow for withdrawal bleeding. If a participant is unable to collect a 24-h urine sample on day 49, they will insert a third ring which will remain in the vagina until she has collected a 24-h urine sample.
89506640|NCT02270450|Experimental|Arm I (randomized to surgery)|Patients undergo therapeutic conventional surgery (abdominal) as defined by the treating physician.
89506641|NCT02270450|Experimental|Arm II (randomized to non-surgical management)|Patients are offered gastrointestinal complications management/prevention (non-surgical management) as determined by the treating physician.
89506642|NCT02270450|Experimental|Arm III (no randomization, surgery)|Patients undergo therapeutic conventional surgery (abdominal) as defined by the treating physician as in Arm I.
89506643|NCT02270450|Experimental|Arm IV (no randomization, non-surgical management)|Patients are offered gastrointestinal complications management/prevention (non-surgical management) as determined by the treating physician as in Arm II.
89506644|NCT02241109|Other|All patients|Compare patients with high calcification propensity do have faster valve-stenosis progression
89506645|NCT02195895|Experimental|Alendronate, Calcium, Vitamin D|"Drug: Weekly oral alendronate 70 mg for 12 months~Supplements: 1000 mg Calcium and 1000 IU Vitamin D daily for 12 months"
89506646|NCT02194842|Active Comparator|Enzalutamide|Enzalutamide will be given at a dose of 160 mg daily
89506647|NCT02194842|Experimental|Enzalutamide and Ra223|Ra223 will be administered 55kBq/kg standard dose monthly for 6 months and given in combination with enzalutamide at a dose of 160 mg daily.
89506648|NCT02185781|Experimental|Autologous NK Cells infusions|
89506649|NCT01992432||Single-group study: chemotherapy|Single-group study: chemotherapy
89506650|NCT01970722|Experimental|Treatment (surgery, HIPEC cisplatin)|"Patients undergo surgery and receive hyperthermic cisplatin IP over 60 minutes.~Beginning at least 3 weeks after surgery, patients may receive carboplatin, paclitaxel, pegylated liposomal doxorubicin hydrochloride, or gemcitabine hydrochloride IP or IV at the discretion of the medical and gynecologic oncologists."
89506651|NCT01913951|Experimental|Treatment (vosaroxin, azacitidine)|Patients receive vosaroxin IV over 10 minutes on days 1 and 4 and azacitidine SC or IV over 15 minutes on days 1-7. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
89506652|NCT01885702|Experimental|MSI-positive CRC patients|I) Adjuvant DC vaccinations for MSI-positive CRC patients (n=5)
89506653|NCT01885702|Experimental|Carriers of germline MMR-gene mutation|II) Preventive DC vaccinations for carriers of germline MMR-gene mutation (n=20) withhout manifestation of CRC
89506654|NCT01867320|Experimental|Raltegravir|Raltegravir at 400mg by mouth twice daily in an initial 6 months treatment phase, followed by an additional 9 months post treatment phase.
89506655|NCT01709136|Experimental|Sirolimus|
89506656|NCT01630850|Experimental|Allogenic islet cells (human, U. Chicago)|
89506657|NCT01565499|Experimental|Nab-Paclitaxel|The patients will be included to receive 3 weekly nab-paclitaxel doses of 150 mg/m2 with one week of rest for 4 cycles.
89506658|NCT01435668|Other|Control|A simple written advice.
89506659|NCT01435668|Experimental|Brief Motivational Intervention (BMI)|Brief Motivational Intervention (BMI)
89506660|NCT01346306|Experimental|DCS 1|
89506661|NCT01346306|Experimental|DCS 2|
89506662|NCT01036087|Experimental|PNC + FEC|"PNC = Panitumumab + Nab-paclitaxel + Carboplatin, and~FEC = 5-fluorouracil, epirubicin, and cyclophosphamide"
89506663|NCT00869817||1|Mutation Positive
89506664|NCT00869817||2|Mutation Negative
89506665|NCT00794001|Experimental|Data Feedback|The intervention is systematic feedback on performance (using predefined quality indicators) to cardiology, ED, and EMS-stakeholders and staff.
89506666|NCT00783367|Experimental|Lenalidomide plus rituximab with dexamethasone|Lenalidomide-low dose dexamethasone plus rituximab
89506667|NCT00572156|Active Comparator|1. rhGH Alone|
89506668|NCT00572156|Experimental|2. Combination Dose|
89023872|NCT04496219|Active Comparator|Arm II (BCG, standard of care)|Patients receive BCG via intravesical injection on days 1, 8, 15, 22, 29, and 36 in the absence of unacceptable toxicity. Patients also receive standard of care symptom management. Patients may undergo acupuncture therapy after completion of intravesical BCG therapy.
89023873|NCT04494412|Experimental|Hospitalized neonates and infants with influenza infection|Preterm neonates and infants who have reached Post-Menstrual Age (PMA) of at least 28 weeks and have a confirmed complicated influenza infection will be included. Participants will receive daily IV infusion of zanamivir for up to 5 days. This initial 5-day treatment course may be extended for up to 5 additional days if clinical symptoms, participant characteristics or virological tests warrant further treatment. The initial dose of IV zanamivir will be determined by PMA/corrected age and body weight. The maintenance dose and interval between the initial dose and subsequent twice-daily maintenance dose will be further determined by Principal Investigator based on renal function.
89506669|NCT00572156|Experimental|3. Combination Dose|
89506670|NCT00572156|Experimental|4. Combination Dose|
89506671|NCT00447772|Experimental|1|
89506672|NCT02199353|Experimental|Stimulation of Activities Daily Living|"The experimental group received the Stimulation of Activities of Daily Living (SADL) programme which is a new treatment approach created by the authors of this study for the training of activities of daily living (ADL) through cognitive intervention. The programme is based on the reestablishment of the cognitive functions implied in the performance of basic activities of daily living.~The sequence of the sessions was always the same, varying the activities, subject, cognitive functions and BADL to work on. Each session started with an activity of temporal and space orientation, continued with the performance of the specific activity of the session and finished with a reminiscence activity.~The treatment was applied twice a week (Tuesday and Thursday) for 45 minutes during 5 weeks."
89506673|NCT02199353|Active Comparator|Conventional ADLoccupational therapy|"The control group treatment was based on a conventional occupational therapy intervention for the management of ADL deficits. The compensation approach was used and environment modifications and simplification of activities were applied as the intervention method.~The treatment was carried out twice a week (Tuesday and Thursday) for 45 minutes during 5 weeks."
89506674|NCT02207153||Chronic Hemodialysis|Initiation of chronic hemodialysis or currently undergoing chronic hemodialysis at one of the study centres
89506675|NCT02207153||Peritoneal Dialysis|Initiation of chronic peritoneal dialysis or currently undergoing chronic peritoneal dialysis at one of the study centres
89506676|NCT04504773|Experimental|Virtual Reality Exposure Therapy|Participants will receive a single session of exposure therapy to address specific phobia that includes the use of virtual reality exposures.
89506677|NCT02207309|Active Comparator|Pazopanib|800mg, oral, 24 months
89506678|NCT02207309|Placebo Comparator|Placebo|800mg, oral, 24 months
89506679|NCT02374125|Experimental|Fibrolysis Group|Actual Diacutaneous Fibrolysis and protocolized physiotherapy
89506680|NCT02374125|Experimental|Pressure Group|Trigger Point Pressure Release and protocolized physiotherapy
89506681|NCT02374125|Active Comparator|Control Group|Protocolized physiotherapy
89506682|NCT02257697|Experimental|Mizoribine (MZR)|Oral administration, daily dose of 150mg (50mg/tablet, t.i.d) All study subjects will receive standard steroid therapies during the study.
89506683|NCT02257697|Active Comparator|Cyclophosphamide (CTX)|"Intravenous injection with between 0.5 to 1.0 g/m2 body surface area each time (the maximum dose is 1.0 g/day each time).~All study subjects will receive standard steroid therapies during the study."
89506684|NCT04468555|Experimental|Global postural reeducation|Patients completed 3 sessions of global postural reeducation for 3 weeks.
89506685|NCT04468555|No Intervention|Control group|Patients allocated to the control group did not receive any treatment.
89506686|NCT02366793|Experimental|Accessory joint mobilization|Humeral head slides, anterior, posterior and caudal slides.
89506687|NCT02366793|Experimental|Nerve mobilization|neural tissue longitudinal slide using the median neurodynamic test 1 (Butler).
89506688|NCT04468711|Active Comparator|treatment group|vitamin D plus topical 1% hydrocortisone cream twice daily
89506689|NCT04468711|Placebo Comparator|placebo group|placebo plus plus topical 1% hydrocortisone cream twice daily
89506690|NCT02207387|Experimental|MCW|Music Contingent Walking (MCW) group: study-specific musical device that measures gait and plays music in a portable manner as the participant is walking is set at a threshold individually calculated per participant, and the music will stop playing when walking strides fall below this threshold.
89023874|NCT04482556|Other|Q-NRG+ Indirect Calorimetry Device|Q-NRG+ device will be compared to current V(max) device in each enrolled patient in subsequent, alternating fashion.
89023875|NCT04482556|Other|V(max) Encore Indirect Calorimetry Device|V(max) Encore device, currently institution's standard device, will be compared to Q-NRG+ device in each enrolled patient in subsequent, alternating fashion.
89506691|NCT02207387|Experimental|NCMW|Non-contingent Music Walking (NCMW) group: music on all the time regardless of the stride size.
89506692|NCT02207387|Experimental|NMW|Non-music walking (NMW/silent) group: no music on at all regardless of step size.
89506693|NCT02207387|Experimental|MCW+rasagiline|"Music contingent walking with rasagiline group: same paradigm as the previous MCW, but with rasagiline prescribed as adjunct therapy.~Dosage: 0.5 mg/day for the first 2 weeks to be subsequently increased to 1 mg/day"
89506694|NCT02207387|Experimental|MMW+rasagiline|"Non-music (silent) walking with rasagiline group: same paradigm as the previous NMW, but with rasagiline prescribed as adjunct therapy.~Dosage: 0.5 mg/day for the first 2 weeks to be subsequently increased to 1 mg/day"
89506695|NCT03528421|Experimental|IM19 CAR-T cells|3*10^5/kg，1*10^6/kg，3*10^6/kg IM19 CAR-T cell.Two days before cell infusion, all patients will be treated with fludarabine and Cyclophosphamide for 3 days
89506696|NCT04059939|Experimental|Reading Plus Attention Control|
89506697|NCT04059939|Experimental|Reading Plus Anxiety|
89506698|NCT04059939|Active Comparator|BAU|
89506699|NCT02207543|Experimental|Medical telephonecontact|Evaluations will be conducted by telephone 15 days after hospital discharge, 30 days and then every month until 6 months.
89032911|NCT02926053|Experimental|Patient group|"All patients receive the same treatment.~Surgical removal of tumor tissue for T cell production, which takes 4-6 weeks, is performed initially.~All patients are hospitalized during treatment (one week in advance of the T cell product being ready and for approximately 3 weeks in total) and receive treatment only once.~The patients are admitted to hospital day -8 and receive lymphodepleting chemotherapy (cyclophosphamide and fludarabine on day -7 to day -1.~The TILs are infused on day 0 and Interleukin-2 therapy is administered on day 0 to day 5. Interleukin-2 is administered as high-dose i.v. bolus every eight hour starting approximately 6 hours after TIL infusion and for up to 5 days (maximum of 15 doses)."
89506700|NCT02374047|Experimental|Cohort A1, Dose Level 1: CAT-2054 or placebo fasting|Single dose
89506701|NCT02374047|Experimental|Cohort A2, Dose Level 2: CAT-2054 or placebo fasting and fed|Single dose
89506702|NCT02374047|Experimental|Cohort A3, Dose Level 3: CAT-2054 or placebo fasting and fed|Single dose
89506703|NCT02374047|Experimental|Cohort A4, Dose Level 4: CAT-2054 or placebo fasting and fed|Single dose
89506704|NCT02374047|Experimental|Cohort A5, Dose Level 5: CAT-2054-C or placebo fasting and fed|Single dose
89506705|NCT02374047|Experimental|Cohort B1, Dose Level 1: CAT-2054 or placebo|Multiple dose for 14 days
89506706|NCT02374047|Experimental|Cohort B2, Dose Level 2: CAT-2054 or placebo|Multiple dose for 14 days
89506707|NCT02374047|Experimental|Cohort B3, Dose Level 3: CAT-2054 or placebo|Multiple dose for 14 days
89506708|NCT02374047|Experimental|Cohort B4, Dose Level 4: CAT-2054 or placebo|Multiple dose for 14 days
89506709|NCT02374047|Experimental|Cohort B5, Dose Level 5: CAT-2054 or placebo|Multiple dose for 14 days
89506710|NCT02374047|Experimental|Cohort B6, Dose Level 6: CAT-2054 with atorvastatin|Multiple dose for 14 days
89506711|NCT02374047|Experimental|Cohort B7, Dose Level 7: CAT-2054 or placebo|Multiple dose for 14 days
89506712|NCT03526939||HIV negative from RDS round 1|HIV negative PWID subjects from RDS round 1
89506713|NCT03526939||HIV negative from RDS round 2|HIV negative PWID subjects from RDS round 2
89506714|NCT03526939||HIV negative from RDS round 3|HIV negative PWID subjects from RDS round 3
89506715|NCT02203253|Active Comparator|Thalidomide Group|Thalidomide 100 mg by mouth twice a day on days 1-5; Palonosetron 0.25 mg intravenously on day 1; Dexamethasone 12 mg by mouth or intravenously before chemotherapy on day 1 and 8 mg on days 2-4; cycle 1.
89506716|NCT02203253|Placebo Comparator|Placebo Group|Placebo (for Thalidomide) tablet 100 mg by mouth twice a day on days 1-5; Palonosetron 0.25 mg intravenously on day 1; Dexamethasone 12 mg by mouth or intravenously before chemotherapy on day 1 and 8 mg on days 2-4; cycle 1.
89506717|NCT03528343|Experimental|Tylenol/Motrin|Group of patients who will receive instructions to use tylenol and motrin for pain control, and parents will be sent home with a paper prescription with a rescue does of standard of care narcotics. They will be instructed to only use the rescue dose if pain is uncontrolled using over the counter medications.
89506718|NCT03528343|No Intervention|Narcotic|Group of patients who will receive the standard of care narcotic prescription filled upon discharge.
89506719|NCT02207699|Experimental|Benzonatate 200 mg|
89506720|NCT02207699|Experimental|Benzonatate 800 mg|
89506721|NCT02207699|Active Comparator|Moxifloxacin 400 mg|
89506722|NCT02207699|Placebo Comparator|Placebo|
89506723|NCT02296138|Experimental|tiotropium + olodaterol high dose|Once daily 2 puffs solution for inhalation Respimat
89506724|NCT02296138|Active Comparator|tiotropium|Once daily 2 puffs solution for inhalation Respimat
89506725|NCT01306942|Experimental|Dasatinib + trastuzumab + paclitaxel|Eligible patients will be enrolled and treated with 4-week cycles of trastuzumab 2 mg/kg IV weekly (following a loading dose of 4 mg/kg in cycle 1) and paclitaxel 80 mg/m2 weekly x 3 weeks followed by a rest period of 7 days. Dasatinib will be administered orally in two dose levels 100 and 140 mg once daily (QD) (a -1 dose level is included just in case dose de-escalation is needed). Treatment will be repeated on Day 1 of a 28-day cycle until radiographic or symptomatic progression or unacceptable toxicity occurs. Only in the phase I, the first cycle will last 38 days.
89506726|NCT02203487|Experimental|BIIF 1149 BS - single rising dose|
89506727|NCT02203487|Placebo Comparator|Placebo|
89506728|NCT03528265||Patients with melioidosis-like symptoms admitted to Kapit Hosp|
89506729|NCT02366715|Experimental|HeatedHumidifiedHighFlowNasalCannula|Treatment for moderate-severe cases of Bronchiolitis while monitoring medical parameters
89506730|NCT02207855||Chloroprocaine|Neonates and infants who have received chloroprocaine for epidural anesthesia.
89506731|NCT03532841|Experimental|Group I (tramadol group)|Group I will receive an oral tramadol 50 mg(Tramal, Memphis, Giza, Egypt) tablet one hour before the procedure.
89506732|NCT03532841|Placebo Comparator|Group II (placebo oral tablet group)|group II will receive a placebo one hour before the procedure.the Treatment and placebo will be identical in form and packaging, without any identifying label.
89506733|NCT02199431|Experimental|Lu AF1167 capsule 0.5 mg|Single oral dose (day 1)
89506734|NCT02199431|Experimental|Lu AF11167 0.5 mg capsule + itraconazole 200 mg capsule|Itraconazole administered once daily for 7 days (day 3-9); Lu AF11167 administered as a single dose on day 8
89506735|NCT02207933|Experimental|AP shifting group|
89506736|NCT02207933|Active Comparator|gait training group|
89506737|NCT02199587|Active Comparator|Endocrine test with medical clown|children who are referred to endocrine test will have the procedure with a medical clown, or without. The pain and anxiety perception of the child and caregivers will be compare between the two scenarios
89506738|NCT02199587|No Intervention|Endocrine test without medical clown|
89506739|NCT02208167|Other|Chronic HIV infection|HXTC infusion
89506740|NCT02208167|Other|Acute HIV infection|HXTC infusion
89506741|NCT03532763|Experimental|Tocotrienol-rich fraction|
89506742|NCT03532763|Placebo Comparator|Placebo|
89506743|NCT02208245|Active Comparator|Ultrasound: Axillary block|For the axillary group, the ultrasound probe will be placed upright in the armpit to obtain a cross section of this region. After visualization of the nerves form the brachial plexus by ultrasound, 5 mL of ropivacaine 0.5% will be injected around each nerve to be blocked (median, ulnar, radial and musculocutaneous). If resistance to the injection of the solution is present or the patient complains of severe pain, the needle will be immediately repositioned.
88957554|NCT01985035|Experimental|Obese Apneic carbohydrate diet|Obese apneic individuals will be subject to a energy restriction diet rich in carbohydrates
89539807|NCT04916379|Placebo Comparator|Placebo|Two 500 mg capsules of calcined magnesia twice daily before breakfast and dinner for 12 weeks
89539808|NCT04901871|Active Comparator|1 (0.02 mg/kg, age<65)|Remimazolam of 0.02 mg/kg will be infused in patients aged<65.
89539809|NCT04901871|Active Comparator|2 (0.07 mg/kg, age<65)|Remimazolam of 0.07 mg/kg will be infused in patients aged<65.
89539810|NCT04901871|Active Comparator|3 (0.12 mg/kg, age<65)|Remimazolam of 0.12 mg/kg will be infused in patients aged<65.
89539811|NCT04901871|Active Comparator|4 (0.17 mg/kg, age<65)|Remimazolam of 0.17 mg/kg will be infused in patients aged<65.
89539812|NCT04901871|Active Comparator|5(0.22 mg/kg, age<65)|Remimazolam of 0.22 mg/kg will be infused in patients aged<65.
89539813|NCT04901871|Active Comparator|6(0.27 mg/kg, age<65)|Remimazolam of 0.27 mg/kg will be infused in patients aged<65.
89539814|NCT04901871|Active Comparator|7 (0.02 mg/kg, age≥65)|Remimazolam of 0.02 mg/kg will be infused in patients aged≥65.
89539815|NCT04901871|Active Comparator|8 (0.07 mg/kg, age≥65)|Remimazolam of 0.07 mg/kg will be infused in patients aged≥65.
89539816|NCT04901871|Active Comparator|9 (0.12 mg/kg, age≥65)|Remimazolam of 0.12 mg/kg will be infused in patients aged≥65.
89539817|NCT04901871|Active Comparator|10 (0.17 mg/kg, age≥65)|Remimazolam of 0.17 mg/kg will be infused in patients aged≥65.
89539818|NCT04901871|Active Comparator|11 (0.22 mg/kg, age≥65)|Remimazolam of 0.22 mg/kg will be infused in patients aged≥65.
89539819|NCT04901871|Active Comparator|12 (0.27 mg/kg, age≥65)|Remimazolam of 0.27 mg/kg will be infused in patients aged≥65.
89539820|NCT04901793|Experimental|Virtual Reality Intervention Group|Patient is fitted with a Virtual Reality headset and handheld remote control. Subject is able to play an interactive game during the duration of the in-office procedure.
89539821|NCT04901793|No Intervention|Control Group|standard of care
89539822|NCT02120950|Experimental|Aflibercept + Sham PDT|Participants received 2 milligram (mg) Intravitreal aflibercept injection (IAI) (Eylea, VEGF Trap-Eye, BAY86-5321) every month for the first 3 months (run-in period). At Week 12, subjects were randomized to receive Aflibercept injection plus sham photodynamic therapy (only in subjects qualifying for rescue therapy)
88957555|NCT01985035|Experimental|Obese Apneic protein diet|Obese apneic individuals will be subject to a energy restricted diet rich in protein
88957556|NCT01985035|Experimental|Obese Non Apneic carbohydrate diet|Obese individuals without Obstructive sleep apnea will be subjected to a energy restricted diet rich in carbohydrates
88957557|NCT01985035|Experimental|Obese Non Apneic protein diet|Obese individuals without Obstructive Sleep Apnea will be subjected to a energy restricted diet rich in protein
89539823|NCT02120950|Experimental|Aflibercept + Active PDT|Participants received 2 mg Intravitreal aflibercept injection (IAI) (Eylea, VEGF Trap-Eye, BAY86-5321) every month for the first 3 months (run-in period). At Week 12, subjects were randomized to receive Aflibercept injection plus active photodynamic therapy (only in subjects qualifying for rescue therapy)
88957558|NCT01985061|Active Comparator|BX2|Fludarabine (Fludara®): 30 mg/m2 on D-6, D-5, D-4, D-3 and D-2 Busulfan IV (Busilvex®) : 3.2 mg/kg/d on D-4 and D-3 Thymoglobuline®: 2.5 mg/kg/d on D-3 and D-2
88957559|NCT01985061|Experimental|BX3|Fludarabine (Fludara®): 30 mg/m² on D-6, D-5, D-4, D-3 and D-2 Busulfan IV (Busilvex®) : 3.2 mg/kg/d on D-5, D-4 and D-3 Thymoglobuline® : 2.5 mg/kg/d on D-3 and D-2
88957560|NCT01985061|Active Comparator|BX4-Suspended|Fludarabine (Fludara®): 30 mg/m²on D-6, D-5, D-4, D-3 and D-2 Busulfan IV (Busilvex®) : 3.2 mg/kg/d on D-6, D-5, D-4 and D-3 Thymoglobuline® : 2.5 mg/kg/d on D-3 and D-2
88957561|NCT01985074|Experimental|Case-management intervention|Receiving nurse-managed intervention
88957562|NCT01985074|No Intervention|Control arm|Control group not receiving any intervention
88957563|NCT01985087|Experimental|Hypofractionated radiotherapy and temozolomide|All subjects will receive treatment as is a single arm study. Two weeks of combined hypofractionated radiotherapy with concurrent temozolomide followed by up to 6 cycles of adjuvant temozolomide treatment.
89539824|NCT04916145|No Intervention|No any treatment|Participants randomly assigned to this group will maintain a routine life without any treatments (no use of SAT-008).
89539825|NCT04916145|Experimental|Use of SAT-008|Participants randomly assigned to this group will be treated by SAT-008 during the study.
89539826|NCT03053817|Experimental|Exercise group|The 45 minute exercise program will be performed 3 times a week and will consist of aerobic exercise and resistance training for 12 weeks.
89539827|NCT03053817|No Intervention|Control|No treatment
89539828|NCT03053895|Experimental|CSDH Bedside twist drill technique|For patients randomized to bedside drainage of Chronic Subdural Hematoma, the twist-drill procedure will be conducted at the patient's bedside using local anesthetic.
89539829|NCT03053895|Active Comparator|CSDH Operating Room Burr-hole technique|For patients randomized to burr-hole drainage, the procedure will be performed in the operating room under local or general anesthesia based on the surgeon's and anesthesiologist's judgement of the clinical stability of the patient.
89539830|NCT03053661||primary surgery + adj. C)RT|treatment naive patients to be treated by conventional primary surgery followed by adjuvant (chemo-)radiotherapy with curative intent
89539831|NCT03053661||primary chemoradiation|treatment naive patients to be treated by conventional primary chemoradiotherapy with curative intent
89539832|NCT04901481|Experimental|Active treatment|Participants will self-administer treatment with the Empower device at the active treatment anatomic location twice daily for six weeks. Treatment adherence will be assessed and participants will complete surveys to evaluate the feasibility and acceptability Empower active treatment.
89539833|NCT04901481|Sham Comparator|Sham treatment|Participants will self-administer treatment with the Empower device at the sham treatment anatomic location twice daily for six weeks. Treatment adherence will be assessed and participants will complete surveys to evaluate the feasibility and acceptability Empower sham treatment.
89539834|NCT04901559||BQT|Patients treated with the Bone Quadriceps Tendon (BQT) autograft
89539835|NCT04901559||STG|Patients treated with the Semitendinosus-Gracilis (STG) autograft
89539836|NCT04901559||BPTB|Patients treated with the Bone-Patellar Tendon-Bone (BPTB) autograft
88957564|NCT01985100|Experimental|single group|single group of 6 patients will be treated with hyperbaric oxygen at 2 atmospheres absolute (ATA) for 90 minutes 5 days per week for 4 weeks (20 treatments) to see if the previously reported increase in cell metabolism following such treatment can be better documented by the more sensitive and precise method for assessing this, i.e. PET/MRI, than the previously reported SPECT/CT method
89506744|NCT02208245|Active Comparator|Ultrasound: Infraclavicular block|For the infraclavicular group, the ultrasound probe will be placed in the infraclavicular region (the junction between the clavicle and the coracoid process) to obtain a cross-sectional imaging of the axillary artery. After visualization of the axillary artery by ultrasound, the block will be performed using the technique in plan for visualization of the needle. The needle is placed in position 6-8 hours of the artery, and 20 mL of ropivacaine 0.5% will be injected, observing a dispersal of local anesthetic around the artery.
89506745|NCT03532685|Active Comparator|Severe Asthma Obese Patients Surgery|Bariatric surgery
89506746|NCT03532685|No Intervention|Severe Asthma Obese Patients|usual care
89506747|NCT03532685|No Intervention|Severe Obese Patients|usual care
89506748|NCT02199821|Active Comparator|Soybean oil formula commonly used in the hospita|
89506749|NCT02199821|Experimental|Formula with soybean oil, medium-chain triglyce|
89506750|NCT03514901|Experimental|Experimental combination beyond Focal Progression|Local treatment (i.e. surgery, radiotherapy) + Vemurafenib 240mg tablets (4 tabs/twice daily for 28 consecutive days) + Cobimetinib 20mg tablets (3 tabs/day for 21 consecutive days) beyond focal progression.
89506751|NCT03514901|Active Comparator|Pembrolizumab or Nivolumab|Pembrolizumab daily dose 2 mg/kg milligram(s)/kilogram or Nivolumab daily dose 3 mg/kg milligram(s)/kilogram.
89506752|NCT02203877|Placebo Comparator|Maltodextrin|1 capsule/day for 16 weeks
89506753|NCT02203877|Experimental|Lactobacillus fermentum CECT5716|L.fermentum 3,00E+09cfu/day. 1 capsule/day for 16 weeks
89506754|NCT03526783|Other|Failed sleeve gastrectomy - RNYGB|Intervention: Roux en Y gasric bypass (RNYGB)
89506755|NCT03526783|Other|Failed sleeve gastrectomy - MGB/OAGB|Inervention: Mini/One anastomosis gasic bypass (MGB/OAGB)
89506756|NCT02203955|Active Comparator|Short-Chain Fructooligosaccharide|4 chews (8.0 g scFOS) orally per day for 12 months
89506757|NCT02203955|Placebo Comparator|Maltodextrin|4 chews (maltodextrin) daily for 12 months
89506758|NCT02208323|Experimental|Bubble CPAP|Bubble CPAP for 28 days
89506759|NCT05263661|Experimental|LIFT|ligation of interesphincteric fistula tract
89506760|NCT05263661|Active Comparator|FLAP|Rectal advancement flap
89506761|NCT04468477|Active Comparator|Patients attending cardiac outpatient clinic|
89506762|NCT05058313|Experimental|Postmenopausal patients|
89506763|NCT02199899|Experimental|BIIF 1149 BS - single rising doses|BIIF 1149 BS oral drinking solution and a BIIF 1149 BS tablet
89506764|NCT02199899|Placebo Comparator|Placebo|
89506765|NCT04441021||Penicillin Allergy Risk Stratification and Evaluation|This standard of care intervention will provide an antibiotic allergy risk stratification assessment and subsequent amoxicillin oral challenge in patients who stratify as low risk for true allergy
89506766|NCT02208401|Active Comparator|conventional cold snare polypectomy|conventional cold snare polypectomy
89506767|NCT02208401|Experimental|Cold snare polypectomy with suction|Cold snare polypectomy with suction
89506768|NCT02208479||cardiac surgery|
89506769|NCT04440787||Three point cuff palpation and Blck mark line technique|"In Three point cuff palpation technique the cuff will be palpated just below the cricothyroid membrane,at the level of suprasternal notch and below the suprasternal notchand the tube is re-positioned in case of any discrepancy between the black mark line technique and three point cuff at three different over the trachea."
89506770|NCT02199977|Other|test only (free)|The participant is entitled to a free malaria rapid diagnostic test, but no ACT voucher.
89506771|NCT02199977|Other|test (free) & conditional ACT voucher|The participant is entitled to a free malaria rapid diagnostic test, and an ACT voucher conditional on a positive test result.
89506772|NCT02199977|Other|test only (not free)|The participant is entitled to a malaria rapid diagnostic test for a charge (i.e., not for free), but no ACT voucher.
88957565|NCT01985113||early staged non-small cell lung cancers|patients who diagnosed as early staged non-small cell lung cancer after surgery
88957566|NCT01985113||lung benign mass patients|patients who diagnosed as lung benign mass after surgery
88957567|NCT01985139|Experimental|Obese patients|Computer-based tasks evaluating size and time discrimination capacities Blood sampling for the determination of plasma endocannabinoids levels
89506773|NCT02199977|Other|test (not free) & conditional ACT voucher|The participant is entitled to a malaria rapid diagnostic test for a charge (i.e., not for free), and an ACT voucher conditional on a positive test result.
89506774|NCT04440709|Experimental|Brain/neural hand exoskeleton (B/NHE)|
89506775|NCT03533387|Experimental|Extended-release formulation 1 (ER1)|50mg MN-166 tablet. This formulation is intended for once-a-day dosing, hence, the label of extended-release.
89506776|NCT03533387|Experimental|Extended-release formulation 2 (ER2)|50mg MN-166 tablet. This formulation is intended for once-a-day dosing, hence, the label of extended-release.
89506777|NCT03533387|Active Comparator|Intermediate-release formulation (IR)|10mg MN-166 capsule. This formulation is typically given two or three times daily, hence, the label of intermediate-release.
89506778|NCT04235023|Other|OSA patients|30 patients investigated for suspected OSA with an apnea hypopnea index ≥ 15 per hour
89506779|NCT04235023|Other|non OSA patients|30 patients investigated for suspected OSA with an apnea hypopnea index < 15 per hour
89506780|NCT02324842|Active Comparator|Canagliflozin|canagliflozin (film-coated tablet), 100 mg/day, increased to 300 mg/day after week two if tolerated without side effects
89506781|NCT02324842|Active Comparator|liraglutide|liraglutide, 1.2 mg/day, increased to 1.8 mg/day after week two if tolerated without side effects
89506782|NCT02324842|Active Comparator|canagliflozin plus liraglutide|canagliflozin, 100 mg/day, plus liraglutide, 1.2 mg/day, increased to 300 mg/day and 1.8 mg/day, respectively at week two, if tolerated without side effects
89506783|NCT02208557|Active Comparator|Control|Laparotomy closure will be done by continuous PDS suture following a SL:WL ratio of 4:1 only is used for midline laparotomy closure.
88957568|NCT01985139|Experimental|Normal-weight healthy volunteers|Computer-based tasks evaluating size and time discrimination capacities Blood sampling for the determination of plasma endocannabinoids levels
89506784|NCT02208557|Experimental|Reinforcement with Absorbable Mesh|"Closure of the midline laparotomy incision is reinforced with insertion of a rectangular segment (1 cm wide and the length corresponding to the incision) of a prosthetic commercially available GORE® BIO-A® Tissue Reinforcement prosthesis (W. L. Gore & Associates, Flagstaff, Arizona, USA) mesh. The BIO-A® prosthesis is inserted using a sandwich method between the edges of the incision and maintained in situ with a continuous polydioxanone (PDS) suture following a suture length to wound length (SL:WL) ratio of 4:1."
89506785|NCT04467385|Experimental|Experimental Group|Virtual Reality training(VR) + Sensory Integration therapy + conventional therapy
89506786|NCT04467385|Experimental|Control Group|VR training + conventional therapy
89506787|NCT02295280|Active Comparator|Metoclopramide IV & Diphenhydramine IV|Intravenous (IV) access will be obtained and administration of 10mg Metoclopramide IV and 25mg Diphenhydramine IV Group A
89506788|NCT02295280|Active Comparator|Codeine|Group B (control group) will receive standard treatment consisting of a codeine 30mg tablet.
89506789|NCT05263505|Experimental|Baricitinib|4mg daily
89506790|NCT05263505|Active Comparator|Antiproliferative|methotrexate, azathioprine, or mycophenolate
89506791|NCT04467307|Active Comparator|Foreign body aspiration.|Patients undergoing bronchoscopy with suspicion of foreign body aspiration. There is a foreign body in the bronchoscopy performed on these patients and it is the treated group.
89506792|NCT04467307|Active Comparator|Group with no foreign body aspiration|Patients undergoing bronchoscopy with suspicion of foreign body aspiration, but there is no foreign body in bronchoscopy.
89506793|NCT02208635|Experimental|Biofortified Maize|Participants in this arm were fed zinc biofortified maize (~30 µg Zn/g).
88957569|NCT01985152|Experimental|1.Azilsartan Trimethylethanolamine|Single dose of Azilsartan Trimethylethanolamine with 8.75mg,orally
88957570|NCT01985152|Experimental|2.Azilsartan Trimethylethanolamine|Single dose of Azilsartan Trimethylethanolamine with 17.5mg,orally
88957571|NCT01985152|Experimental|3.Azilsartan Trimethylethanolamine|Single dose of Azilsartan Trimethylethanolamine with 35mg,orally
88957572|NCT01985152|Experimental|4.Azilsartan Trimethylethanolamine|Single dose of Azilsartan Trimethylethanolamine with 70mg,orally
88957573|NCT01985152|Experimental|5.Azilsartan Trimethylethanolamine|Single dose of Azilsartan Trimethylethanolamine with 140mg,orally
88957574|NCT01985152|Experimental|6.Azilsartan Trimethylethanolamine|Single dose of Azilsartan Trimethylethanolamine with 210mg,orally
88957575|NCT01985152|Experimental|7.Azilsartan Trimethylethanolamine|Single dose of Azilsartan Trimethylethanolamine with 280mg,orally
88957576|NCT01985152|Placebo Comparator|Placebo|Placebo-matching tablets, orally
89506794|NCT02208635|Experimental|Fortified Maize|Participants in this arm were fed zinc-oxide fortified maize (total level of ~60 µg Zn/g).
89506795|NCT02208635|Active Comparator|Control Maize|Participants in this arm were fed maize that was not fortified or biofortified (~15 µg Zn/g maize).
89506796|NCT04881214|No Intervention|Control|Patients in this arm will receive standard of care
88957577|NCT01985165|Experimental|Imrecoxib|0.1g,BID,po
88957578|NCT01985178|Experimental|Omega-3 Fatty Acid Supplement|
88957579|NCT01985191|Experimental|Arm 1|SAR405838 and pimasertib in escalating doses
88957580|NCT01985204|Placebo Comparator|Placebo|Placebo tablet
88957581|NCT01985204|Experimental|Intervention|Iodine tablet
88957582|NCT01985243|Experimental|Nutrition and agriculture|Intervention arm with integrated nutrition and agriculture education, skill building, and animal husbandry promotion
88957583|NCT01985243|Experimental|Iron-rich food & business literacy|Integrated business literacy and food supplementation program to promote school retention among female adolescents
88957584|NCT01985243|No Intervention|IYC Comparison|Comparison group of infants and young children for the nutrition-agriculture intervention
88957585|NCT01985243|No Intervention|Adolescent comparison|Comparison group for the adolescent business-food supplement intervention
88957586|NCT01985256|Experimental|Single Arm|Toca 511 vector/Toca FC
88957587|NCT01985269|Active Comparator|Home visits|Minimal physical examination at home Drug adherence/pill counts
88957588|NCT01985269|No Intervention|Control|Normal standard of care
89506797|NCT04881214|Experimental|Pulmonary Rehabilitation|Patients will undergo a 12-weeks Pulmonary rehabilitation program. It will include 3 sessions of supervised exercise per week, as initially proposed on COPD patients. Patients will exercise on electromagnetically braked cycle ergometers for 45 min by alternating 30-s exercise intervals at 100% of peak-work rate estimated during the initial incremental test, with 30-s rest periods. Total workload will be increased (by 5%) on a weekly basis. Strength training of lower and upper limbs, will also be included.
88957589|NCT01985282||Nutrition Status and Physical Function|Nutrition questionnaire will be administered Physical functional status will be tested
88957590|NCT01985295|Other|cohort|"Dose level Dose of pazopanib orally, once daily, # patients -1 200 mg --~(starting) 400 mg 3~600 mg 3~(maximum) 800 mg 3"
88957591|NCT01985308|Experimental|MRT-Active|Magnetic Field, modulated as per EEG analysis, is active for 6 seconds every minute for 30 minutes per day, 5 days per week x 5 weeks.
88957592|NCT01985308|Sham Comparator|MRT-SHAM|Magnetic field is not active, but a sham coil is used, for 6 seconds every minute for 30 minutes per day, 5 days per week x 5 weeks.
88957593|NCT01985347|Active Comparator|Obstructive Sleep Apnoea|Patients with newly diagnosed obstructive sleep apnoea and who have anxiety and depression would be given continuous positive airway pressure (CPAP) treatment.
88957594|NCT01985347|No Intervention|Chronic obstructive pulmonary disease and western population|(For this group no intervention needed).Patients with COPD, who have anxiety and depression & normal population in Western Adelaide who also have anxiety and depression their prevalence would be compare with patients of Obstructive sleep apnoea.
89506798|NCT04467151|Experimental|anti-SARS-CoV-2 plasma|Patients receive one dose (250-300ml) of anti-SARS-CoV-2 convalescent plasma
89506799|NCT04467151|Placebo Comparator|Placebo|Patients receive one dose (250-300ml) of placebo (albumin 5%)
89506800|NCT02204033|Experimental|99mTc - labelled hMAb BIWA 4 - low dose|
89506801|NCT02204033|Experimental|99mTc - labelled hMAb BIWA 4 - medium dose|
89506802|NCT02204033|Experimental|99mTc - labelled hMAb BIWA 4 - high dose|
89506803|NCT02204033|Experimental|186 Re - labelled hMAb BIWA 4 - escalating dose|
89506804|NCT03526705|Experimental|nb-uvb|psoriasis patients will receive 26 sessions of nb-uvb phototherapy
89506805|NCT03533309|Experimental|computer guided|"Group (A): comprised 6 patient undergoing surgical alveolar ridge splitting using computer guided surgical cutting stent.~."
89506806|NCT03533309|Active Comparator|conventional|Group (B) comprised 6 patient undergoing surgical alveolar ridge splitting using conventional technique
89506807|NCT02200133|Experimental|Individualized Survivorship Care Plan (SCP)|"Participant information sheet and instructions on how to use the SCP~Patient version of individualized SCP that includes but is not limited to: (1) a treatment summary that consists of disease characteristics and treatment details (including HCT), and (2) recommendations for preventive care and screening for late complications based on patient treatment exposures (age, type of transplant, use of TBI, corticosteroid exposure as part of HCT, and history of GVHD)~Newest Vital Sign nutrition label to measure health literacy and its instructions~Participants may receive other materials their transplant center routinely provides to patients for follow-up care (e.g., discharge summary or clinic note)"
89506808|NCT02200133|No Intervention|Usual care (no SCP)|"Materials that their transplant center routinely provides to patients for follow-up care~Newest Vital Sign nutrition label to measure health literacy and its instructions~Participants randomized to the usual care arm who complete the 6 month study assessments will receive their individualized SCP upon completion of the patient's participation. Participants who withdraw from the study or who do not complete the 6 month assessment will not receive the individualized SCP."
89506809|NCT02208713|Experimental|Stem cell recipient|The patients with FSHD who underwent muscle derived stem cell and Adipose derived mesenchymal stem cell with intramuscular injection.
89506810|NCT04189159|Experimental|PROMPT Treated|PROMPT treatment, twice a day, for 5 days a week, for 3 consecutive weeks
89506811|NCT04189159|No Intervention|Control|Usual treatment
89506812|NCT02204111||Control Cluster|Care as usual
89506813|NCT02204111||Treatment Cluster|Care as usual and patient directed, multidimensional treatment proposals
89506814|NCT02204189|Experimental|TongFuSan|TongFuSan 1g per time, change every day, the duration is seven days
89506815|NCT02204267|Experimental|prolonged ECG monitoring|Regular stroke unit treatment and diagnostic procedures according to guidelines and additional prolonged ECG monitoring
89506816|NCT02204267|No Intervention|no additional ECG recording|Regular stroke unit treatment and diagnostic procedures according to guidelines
89506817|NCT05263271|Experimental|Experimental cohort|Gentulizumab administered IV once a week and a dosing cycle is 4 weeks
89506818|NCT02204423|Experimental|Trans-Radial PCI|
89506819|NCT02917187|Experimental|Randomized Group 1|After two week run-in, BIIB074 three times a day (TID) followed by placebo (TID) after two week washout period
89506820|NCT02917187|Experimental|Randomized Group 2|After two week run-in, Placebo three times a day (TID) followed by BIIB074 (TID) after two week washout period
89506821|NCT02204501|Experimental|Vapendavir 528 mg QD|Twelve subjects (6 male and 6 female) will receive 528 mg vapendavir (achieved with four 132 mg vapendavir capsules) QD in the morning for seven days
89506822|NCT02204501|Experimental|Vapendavir 264 mg BID|Twelve subjects (6 male and 6 female) will receive 264 mg vapendavir (achieved with two 132 mg vapendavir capsules) BID daily as divided dose given in the morning and evening 12 hours apart for seven days.
89506823|NCT05471089|Experimental|Experimental|Application of radiofrequency diathermy in addition to the exercises protocol same Exercise protocol than control group. Ten sessions of treatment were applied: daily the first week (Monday to Friday), three the second week (Monday, Wednesday, Friday) and two the last week (Monday and Thursday)
89506824|NCT05471089|Active Comparator|Control|Exercise protocol consisting of: eccentric and concentric strengthening of quadriceps (three squat series of 20 repetitions), hamstrings (three series of 20 seconds performing the bridge exercise), gluteus medius (three series of 20 seconds performing the clam exercise), gastrocnemius and soleus (three series of stretching exercises for 1 minute each). These exercises will be performed along 20 minutes approximately with a minute of rest between each exercise series, never exceeding 3mm in VAS. Participants have to assist to a local facility center to be supervised at doing the exercises daily (from Monday two Friday) along three weeks.
89506825|NCT02204735|Experimental|MORNING|Participants will be instructed to consume 50% of their energy intake in their first eating bout, 30% in their second eating bout, and 20% in their third eating bout. For example, a participant prescribed a 1200 kcal/d diet needs to consume 600 kcal in their first eating bout, 360 kcal in their second bout, and 240 kcal in their third bout. Participants will be provided with sample meal plans meeting this prescription.
89506826|NCT02204735|Experimental|EVENING|Participants will be instructed to consume 20% of their energy intake in their first eating bout, 30% in their second eating bout, and 50% in their third eating bout. For example, a participant prescribed a 1200 kcal/d diet needs to consume 240 kcal in their first eating bout, 360 kcal in their second bout, and 600 kcal in their third bout. Participants will be provided with sample meal plans meeting this prescription.
89506827|NCT02204813|Experimental|Post RYGB Surgery|Healthy, weight stable individuals, with previous Roux-en-Y gastric bypass surgery. No clinical evidence of type 2 diabetes before and after surgery. Each participant will receive placebo or the indicated doses of xenin-25.
89506828|NCT02294734|Experimental|GSK2269557 repeat dose|Participants will receive 2 inhalation of GSK2269557 dry powder once daily via DISKUS™ 'device' (DISKUS is a trademark of the GSK group of companies)
89506829|NCT02294734|Placebo Comparator|Matching placebo repeat dose|Participants will receive 2 inhalation matching placebo dry powder once daily via DISKUS 'device'
89506830|NCT03581383|No Intervention|Current Care Model (Control)|The Current Care Model will not have any intervention beyond the standard of care for Hepatitis C provided by an interdisciplinary team at the University of Kentucky.
89539837|NCT02120794|Experimental|530G insulin pump|Subjects will use 530G insulin pump with Threshold Suspend (TS) feature for one year.
89539838|NCT04915911||adult patients with Crohn's disease|multi-center cross-sectional study
89506831|NCT03581383|Experimental|PREP-C Model|The PREP-C care model will provide Hepatitis C care with the standard interdisciplinary team expanded by a social worker and a patient navigator team. The social worker/ patient navigator team will use the standardized Psychosocial Readiness Evaluation and Preparation for hepatitis C treatment (PREP-C) tool and will guide PREP-C related interventions to overcome barriers to HCV treatment uptake and completion.
89506832|NCT03581383|Experimental|Modified ECHO Model|The modified Extension for Community Healthcare Outcomes (ECHO) Model will provide patient care through collaboration of the expanded interdisciplinary team (including social worker patient navigator team) with community providers.
89506833|NCT03581383|Experimental|Telemedicine Arm|The telemedicine Model will track outcomes and record patient experiences with HCV management and treatment with telemedicine.
89506834|NCT02204891|Experimental|Probiotics in SIBO|Administration of probiotics in patients with IBS and SIBO
89506835|NCT02204891|Active Comparator|Probiotics|Administration of probiotics in patients with IBS without SIBO
89506836|NCT03533231|Active Comparator|Triple Antibiotic Paste (TAP)|It consisted of Ciprofloxacin (Ciprocin 250 mg tablets; EPICO, Cairo, Egypt), Metronidazole (Flagyl 500 mg tablets; Sanofi Aventis Pharma, Cairo, Egypt), Doxycycline (Vibramycin 100 mg capsules; Pfizer, Cairo, Egypt). One Doxycycline capsule content was evacuated in a sterile mortar, one tablet of metronidazole and one tablet of ciprofloxacin were crushed and ground in the same mortar using a pestle into homogenous powder. Saline drops (Otrivin baby saline; Novartis, Cairo, Egypt) were added and mixed using the pestle until a creamy paste was achieved (Sabrah et al. 2013, Nagy et al. 2014). TAP was then used for canal disinfection.
89506837|NCT03533231|Experimental|Ciprofloxacin + Propolis Paste|Ethanol extract of raw propolis (EEP; ElEzaby Co. Labs, Cairo, Egypt.) was prepared by adding 10 gm of propolis (Imtinan, Cairo, Egypt) to 40 gm of 70% ethanol (ElGomhorya Co., Cairo, Egypt) (for 20% tincture) in a dark container to prevent reduction of propolis. The container was sealed and placed at room temperature for a period of three weeks. The sealed container was manually shaken every 2 days to ensure proper mixing. After 3 weeks, the container was opened and ethanol extract of propolis was obtained. Ethanol-free EEP was made by evaporating the ethanol in a water bath. EEP was then mixed with Ciprofloxacin powder in the ratio 1:1. Saline drops were added and mixed using the pestle until a creamy paste was achieved. This paste was then used for canal disinfection.
89506838|NCT03533231|Active Comparator|Ciprofloxacin + Metronidazole Paste|Ciprofloxacin powder was mixed with Metronidazole powder in the ratio 1:1. Saline drops were added and mixed using the pestle until a creamy paste was achieved. This paste was then used for canal disinfection.
89506839|NCT03533231|Experimental|Propolis + Metronidazole paste|Ethanol Extract of Propolis (EEP) was mixed with Metronidazole powder in the ratio 1:1. Saline drops were added and mixed using the pestle until a creamy paste was achieved. This paste was then used for canal disinfection.
89506840|NCT02200289||Mother-infant pairs|Mother-infant pairs from the GRAPHS birth cohort study
89506841|NCT02200601|Experimental|Seipher Wellness|
89506842|NCT02200679||Autism Spectrum Disorders|Cases were children living in target communities who are identified as positive based on questionnaire screen and the following diagnosis with DSM-Ⅳ, ADOS and ADI-R
88957595|NCT01985373|Experimental|Intravenous immunoglobulin infusion|One intravenous infusion with Nanogam 50 mg/ml and 4 with Nanogam 100 mg/ml (0.2-0.8 g/kg)
89506843|NCT04172623|Experimental|Real-Time Smoking Intervention|Adult smokers will use wearable technology in order to receive real-time feedback as a smoking intervention in addition to standard treatment.
89506844|NCT04172623|Active Comparator|Standard Treatment|Adult smokers will receive standard outpatient tobacco treatment.
89506845|NCT02200757|Experimental|Aldoxorubicin|
89506846|NCT02200757|Active Comparator|Topotecan|
89506847|NCT03525067||Patients with Bile Samples|Patients underwent pancreaticoduodenectomy who had intraoperative bile sampling for bacterial examination.
89506848|NCT02200913|Experimental|core stabilization exercise|core stabilization exercise 2 times/week 10 weeks
89506849|NCT02200913|Experimental|general trunk strengthening exercise|general trunk strengthening exercise, 2 times/week, 10 weeks
89506850|NCT02208791|Active Comparator|Tacrolimus/MPS/Prednisone|This arm will be maintained with current conventional triple immunosuppression. Sirolimus will not be added to this arm
89506851|NCT02208791|Experimental|Sirolimus/Low Tacrolimus/MPS/Prednisone|Sirolimus, 2mg once daily, will be added to the maintenance immunosuppression composed of tacrolimus, prednisone and mycophenolate. The prescription of tacrolimus will be tapered down to achieve a peripheral blood trough level between 3 e 5 ng/mL and micophenolate will be reduced to 540mg bid..
89506852|NCT03526627||patient with advanced heart failure|we included the patients with advanced heart failure who had the poor cardiac function(LVEF<=30%) and was admitted to the general ward or emergency room within one year.
89506853|NCT05223101|Experimental|Sequence A|TRTR
89506854|NCT05223101|Experimental|Sequence B|RTRT
89506855|NCT05448391|Experimental|RIST4721 400 mg|RIST4721 400 mg: 4 active (100 mg) tablets once daily for 12 weeks
89506856|NCT02204969|Sham Comparator|Transcranial magnetic stimulation|All participants will receive standard medical therapy for AD. In addition, patients recruited for the study will receive 16 sessions of TMS with the H2 coil over 8 weeks. The first group will receive excitatory stimulation of 10 Hz over the prefrontal and parietal cortex, the second group will receive inhibitory stimulation of 1 Hz over similar brain areas and control patients will receive the same amount of Sham sessions. Patient will receive 3 treatments per week in the first 3 weeks and then 1 treatment per week for additional 4 weeks.
89506857|NCT02204969|Placebo Comparator|lithia water|"Experimental: Lithia spring water Lithia water (active) for 4 weeks then placebo water for 4 weeks Intervention: Dietary Supplement: Lithia water~Placebo Comparator: Natural spring water Placebo water for 4 weeks then lithia water (active) for 4 weeks Intervention: Dietary Supplement: Natural spring water with negligible lithium levels"
89506858|NCT02258087|Active Comparator|LDRPBT|Patients with low and selected intermediate risk prostate cancer are treated with Prostate LDR brachytherapy as monotherapy. 145 Gy is prescribed to the prostate. I-125 radioactive sources are used. Transperineal approach, rectal ultrasound guidance, inverse treatment planning, real time dose optimization is applied.
89506859|NCT02258087|Experimental|HDRPBT|Patients with low and selected intermediate risk prostate cancer are treated with prostate HDR brachytherapy as monotherapy. The prescribed dose is 1x19 Gy to the whole prostate. Ir-192 radioactive source is used. Transperineal approach, rectal ultrasound guidance, inverse treatment planning, real time dose optimization is applied.
89506860|NCT02852057|Experimental|Subjects Receiving Lenses|All subjects who meet inclusion criteria will receive lenses loaded with timolol maleate and dorzolamide hydrochloride.
89506861|NCT04132999|Active Comparator|Family-informed intervention (INT)|Multiple face-to-face visits, telephone calls and-person visits with the PAP psychologist and team.
89506862|NCT04132999|Active Comparator|Standard Clinical Care|Support which is given as part of the standard clinical care for patients who are currently prescribed PAP.
89506863|NCT02208869||Patients diagnosed with FH|"Subjects of both sexes above the age of 18 with TC ≥7.5 mmol/L or LDL-C ≥4.9 mmol/L will be included in the Program. Clinical diagnosis of FH will be established using both the Dutch and the British criteria.~Those with secondary causes of hypercholesterolemia, such as untreated diabetes mellitus (HbA1c >8%) or hypothyroidism (thyroid-stimulating hormone >1.5 upper normal limit), renal failure (creatinine clearance <30 ml/min), holestatic liver diseases, including biliary cirrhosis, tumors with an active process in the last 5 years will be excluded from the study."
89506864|NCT05203523|Experimental|Group 1 (G1)|Participants will receive active tACS simultaneously with cognitive exercises.
89506865|NCT05203523|Sham Comparator|Group 2 (G2)|Participants will receive sham tACS simultaneously with cognitive exercises.
89506866|NCT03524833|Other|Intraluminal Metronidazole eradication|Twenty patients receive intraluminal Metronidazole eradication of H. pylori.
89506867|NCT03524833|Other|oral antibiotic triple therapy|Patients fail to achieve intraluminal eradication of H. pylori will be assigned to the oral antibiotic triple therapy which contains Lansoprazole, Amoxicillin and Metronidazole for 14 days.
89506868|NCT02220647|Experimental|Treatment A (FDC)|
89506869|NCT02220647|Active Comparator|Treatment B (single agents)|
89506870|NCT02205203|Active Comparator|Face-to-Face w/ Anxiety Coach (FTF-AC)|In this condition therapists will provide 6 to 12 50-minute, face-to-face therapy sessions using Mayo Clinic Anxiety Coach. The sessions are expected to initially occur weekly and be within the office although the therapist can leave the office to conduct exposure. The therapist is expected to utilize Anxiety Coach within the session, encourage the patient to use the application to complete homework, and review progress in-session via the web-based portal.
89506871|NCT02205203|Experimental|Treatment as Usual (TAU)|In the TAU condition therapists provide treatment consistent with their orientation and clinical judgment. Previous research suggests that TAU will include supportive therapy, relaxation, and cognitive restructuring. The format of treatment will be 6 to 12, 50-minute, face-to-face therapy sessions in the therapist's office, with flexibility to leave the office (e.g., for exposure). Therapists can communicate with patients between sessions (e.g., phone calls), as long as this medium is not the primary mode of treatment.
89506872|NCT02257931||HSCT recipient|Allogeneic or autologous HSCT recipients, of all ages, for any indications. From this group we take those with a gram-negative bacteremia within 6 months after HSCT.
89506873|NCT04155385|Active Comparator|Measurement-only|Patients will complete weekly measures of treatment progress and goals; however, the information from these measures will not be shared with clinicians or patients.
89506874|NCT04155385|Experimental|Measurement and feedback|Patients will complete weekly measures of treatment progress and goals; the information from these measures will be shared with clinicians.
89506875|NCT02208947|Active Comparator|PREPARE|"Partnership HealthPlan of California (PHC) pays primary care physicians (PCPs) to discuss and document ACP with Medi-Cal beneficiaries aged 65 and older and those younger than 65 with a life-limiting illness (usual care). The control condition, or enhanced usual care, adds a packet of educational information about ACP and access to the PREPARE website and verbal encouragement by their PCP delivered during a routine clinic visit to usual care."
89539839|NCT04915521|Active Comparator|erector spinae plane block group|ESPB group received ultrasound-guided bupivacaine and lidocaine injection at T9 vertebral level before anesthesia induction.
88957596|NCT01985386|Experimental|GDS (gastric delivery system), meal|GDS capsule with meal
89506876|NCT02208947|Experimental|PREPARE + consumer financial incentive|The experimental condition adds a consumer-directed financial incentive to enhanced usual care (provider-directed financial incentive and educational packet with information about the PREPARE website). Specifically, subjects will receive an immediate financial reward upon completing self-directed ACP (e.g., PREPARE steps 1-4) and a small probability of a large reward for discussing the plans with their physician (e.g., PREPARE step 5, documented by the PHC ACP attestation form).
89506877|NCT03544567|Experimental|Oraxol|Oraxol will be administered once daily for 3 consecutive days every week from Weeks 1 through 25. Subjects who do not have documented disease progression by the end of the Treatment Period will be eligible to receive therapy in the Treatment Extension Period; additional doses of Oraxol may be administered from Week 26 onwards. Subjects may receive Oraxol until they meet 1 of the criteria for withdrawal from the study.
89506878|NCT02209025|Placebo Comparator|Placebo drink|A drink with the same components as the theobromine drink except for the theobromine
88957597|NCT01985386|Active Comparator|Ferrous sulfate, meal|Ferrous sulfate with meal
88957598|NCT01985399||EFV containing ARV regimen|Pts on Efavirenz containing ARV regimen will have neuropsychological testing performed
88957599|NCT01985399||Non -EFV ontaning ARV regimen|Pts on a Non-Efavirenz containing ARVregimen will have neuropsychological testing measures performed
88957600|NCT01985412||Adult Heart Transplant Recipients|Patients >18 yrs old that received a heart-only transplant and are followed at Stanford Hospital
89506879|NCT02209025|Experimental|Theobromine|500mg theobromine in a drink
89506880|NCT03526471|Experimental|Left Atrial Appendage (LAA) Occluder|Left Atrial Appendage (LAA) Occluder
89506881|NCT03524755|Experimental|Training Group|Warm up period for 5 minutes on a bicycle ergometer or an upper body cycle with individual selectable wattage. A leg press, a latissimus pull-down and a chest press formed the three equipment supported core exercises. All exercises were performed with 8-12 repetitions and 3 sets. 3 training sessions (30min for each session) per week for during the course of radiotherapy (~6 weeks).
89506882|NCT03524755|No Intervention|Control Group|The control group received usual care.
89506883|NCT02209103|Experimental|Citrus flavonoid|Citrus flavonoid
89506884|NCT02209103|Experimental|Citrus flavonoid formulation|Citrus flavonoid formulation
89506885|NCT02209103|Placebo Comparator|Placebo|Placebo
88957601|NCT01985412||Pediatric Heart Transplant Recipients|Patients <18 yrs old that received a heart-only transplant and are followed at Lucile Packard Hospital
88957602|NCT01985412||Adult Lung Transplant Recipients|Patients >18 yrs old that received a lung-only transplant and are followed at Stanford Hospital
88957603|NCT01985412||Pediatric Lung Transplant Recipients|Patients <18 yrs old that received a lung-only transplant and are followed at Lucile Packard Hospital
88957604|NCT01985412||Kaiser Adult Heart Transplant Recipients|Patients >18 yrs old that received a heart-only transplant at Stanford Hospital but are followed at Kaiser Permanente in Santa Clara
88957605|NCT01985438|Active Comparator|percutaneous endoscopic gastrostomy tube|Percutaneous endoscopic gastrostomy tube placement - A 20 Fr PEG tube (Cook Medical, or Boston Scientific) will be placed endoscopically using Ponsky's pull technique, under conscious sedation, as a day-case procedure. A single dose of a prophylactic intravenous antibiotic (1.2g co-amoxiclav, 30 minutes prior to the procedure, unless evidence of penicillin allergy) will be given to all patients undergoing PEG tube insertion. Patients will be monitored for one hour prior to discharge following PEG tube insertion
88957606|NCT01985438|Active Comparator|nasogastric tube|Nasogastric tube placement - All nasogastric tubes will be inserted in a standard manner by a Gastroenterology Fellow or an Internal Medicine resident. Ordinarily, a 14 Fr, fine-bore NG feeding tube will be inserted at the bedside or, if unsuccessful, inserted under radiological guidance. A post-procedure abdominal x-ray will be performed to confirm correct placement of all NG tubes.
88957607|NCT01985451|Experimental|Pemetrexed and Temozolomide|Patients with relapsed PCNSL patients were treated with high-dose pemetrexed (900mg/m2) and temozolomide (200mg/m² day 1-5, 28 day cycle).
89506886|NCT02205281|No Intervention|Standard Care|
89506887|NCT02205281|Experimental|Lifestyle Intervention|
89506888|NCT03524677||Non metastatic pancreatic cancer|patients with biopsy or fnac proven ductal adenocarcinoma without any systemic metastatic spread at preoperative imaging
89506889|NCT02323204|Experimental|Psychological First Aid|Link for Injured Kids, a form of psychological first aid
89506890|NCT02323204|Active Comparator|Trauma Education|"Educational materials, So you've been in an accident provided to parents."
89506891|NCT02220803|Active Comparator|Acetazolamide and CPAP|"Acetazolamide: Diamox®. Hard white capsule, 250 mg. The total treatment is 4 weeks (2+2 weeks). Dosing of acetazolamide will be up-titrated during 3 days according to manufacturer instruction and titration scheme of the study. Maximum dosage (750mg) following titration will be administered as morning (250 mg) and evening(500mg) dosages.Evening medication should be taken 2 hours before bedtime.~CPAP: Continuous positive nasal airway pressure (nCPAP) delivers slightly pressurized air throughout the breathing cycle and will be given through a mask that is placed and secured over the person's nose. nCPAP titration will follow clinical routines. The standard setting is a pressure delivery in the pressure range 5-15 mbar. The adequate performance of the device is controlled by user time readers and built-in memory cards and control readings are routinely performed at the end of each treatment regimen. Total duration of CPAP treatment is 4(2+2) weeks."
89506892|NCT02220803|Active Comparator|CPAP|Continuous positive nasal airway pressure (nCPAP) delivers slightly pressurized air throughout the breathing cycle and will be given through a mask that is placed and secured over the person's nose. nCPAP titration will follow clinical routines whereby the patient is equipped with an autotitrating device (Sullivan S9). The standard setting is a pressure delivery in the pressure range 5-15 mbar and the full treatment is maintained in the patient´s home. The adequate performance of the device is controlled by user time readers and built-in memory cards and control readings are routinely performed at the end of each treatment regimen. Patients will be encouraged via telephone calls for maximum use. Total duration of CPAP treatment is 4(2+2) weeks.
89539840|NCT04915521|No Intervention|non block control group|Control group received 5 ml 0.5% bupivacaine injection to each trocar site (total of 25 ml) at the beginning of the operation.
89539841|NCT04901013|Active Comparator|Affinity plus SOC|Affinity is an aseptically processed, hypothermically stored fresh allograft with viable cells, growth factors/cytokines, and extracellular matrix (ECM). Affinity is human allograft tissue that is regulated as a Human Cells, Tissues, and Cellular and Tissue-Based Product (HCT/P) as defined by FDA 21 CFR Part 1271. Affinity may be applied as a wound covering to partial- and full-thickness acute and chronic wounds
89539842|NCT04901013|No Intervention|Standard of Care (SOC)|Standard of Care (SOC) includes, but is not limited to, surgical debridement, aggressive infection management, offloading, and maintenance of appropriate cleansing at the time of each dressing change.
89539843|NCT04900857|Active Comparator|Dry needling treatment group|Dry needling treatment group will be treated with acupuncture needles (0.25x25 mm Hua Long Brand).In this group, one active trigger point area in the trapezius muscle was precisely determined and marked with a permanent pen, and dry needling treatment was applied to that area with disposable acupuncture needles in a single session. the trigger point was palpated. From the center, the needle tip was inserted perpendicular to the skin quickly into the subcutaneous tissue and inserted into the muscle with the needle tip until it found the trigger point in the muscle band. Local twitch responses (LTRs) were similar to Hong's rapid entry and exit technique. It was obtained by inserting a large number of rapid needles in and out of. The needle was not removed from that area for the maximum stimulation time of 1 minute to 3 minutes after a local twitch response was obtained.
89539844|NCT04900857|Experimental|Localized vibration treatment group|The tight band in the muscle was determined by palpation, and the location of the most painful points (the middle of the most vertical fibers of the upper part of the trapezius muscle) in the muscle tension band was digitally determined. It was determined with a permanent marker. The skin was cleaned with a suitable antiseptic agent. Localized vibration therapy was applied for 20 minutes with a vibration frequency of 110 Hz and an amplitude of 5.57 mm using a vibrator device. Vibration therapy was applied to our patients by attaching an apparatus with a small area of 1 cm2 to the skin on the trigger point in the trapezius muscle and fixed with medium pressure. We applied a total of 3 sessions every other day in hospital conditions by a single practitioner to all patients.
89539845|NCT04900389||Case Group: Nurses with COVID-19|"The questionnaire form is included in the section on COVID-19. 2nd question; They will mark the answer Yes to the question Have you been diagnosed with COVID-19? 5th question; Individuals who answer No to the question Have you been subjected to discriminatory behaviors by your environment because you were a healthcare worker during the COVID-19 pandemic process? Will move on to the 11th question in the same section."
89539846|NCT04900389||Kontrol Group: Nurses who have not had COVID-19|"The questionnaire form is included in the section on COVID-19. 2nd question; They will mark No to the question Have you been diagnosed with COVID-19? And move on to the 4th question in the same section.~The 5th question in Annex 2 of the questionnaire form; Individuals who answer No to the question Have you been subjected to discriminatory behaviors by your environment because you were a healthcare worker during the COVID-19 pandemic process? Will move on to the 11th question in the same section."
89539847|NCT03053583|Active Comparator|Miller Laryngoscope blade|A photo of the best glottic view will be taken during laryngoscopy using Miller blade. The view of the larynx will be assessed using the POGO score by a blinded assessor.
89539848|NCT03053583|Active Comparator|Wis-Hipple Laryngoscope blade|A photo of the best glottic view will be taken during laryngoscopy using Wis- Hipple blade. The view of the larynx will be assessed using the POGO score by a blinded assessor.
89539849|NCT03053583|Active Comparator|C-Mac Laryngoscope blade|An image of the best glottic view will be saved on C-MAC monitor's SD card during laryngoscopy using C-MAC straight blade. The view of the larynx will be assessed using the POGO score by a blinded assessor.
89539850|NCT04915443|Experimental|Periotome Group|An Atraumatic simple extraction procedure is done to teeth or roots with sound form indicated for simple extraction using H.ZEPF 26.182.13 & 26.182.11 periotome instrument.
89539851|NCT04915443|Experimental|Piezotome Group|An Atraumatic simple extraction procedure is done to teeth or roots with sound form indicated for simple extraction using SOLO LED PIEZOTOME Kit with ESSENTIAL tips from SATELEC ACTEON.
89539852|NCT04900467|Active Comparator|Pfizer-Pfizer|Pfizer-Pfizer Length of use : 1 day
89539853|NCT04900467|Experimental|Pfizer-Moderna|Pfizer-Moderna Length of use : 1 day
89539854|NCT04900467|Active Comparator|Moderna- Moderna|Moderna- Moderna Length of use : 1 day
89539855|NCT04900467|Experimental|Moderna - Pfizer|Moderna - Pfizer Length of use : 1 day
88957608|NCT01985464|Experimental|Umbilical cord mesenchymal stem cells|
88957609|NCT01985477|Experimental|Lenalidomide + Dexamethasone + All-Trans Retinoic Acid (ATRA)|"Phase I All Patients - Induction: Lenalidomide starting dose 25 mg by mouth 1 time every day on Day 1-21. Dexamethasone starting dose 40 mg by mouth on Days 1,8,15,22. ATRA starting dose 25 mg/m2 by mouth 2 times each day on Days 1-21.~Phase II Group A: Lenalidomide starting dose: Dose tolerated prior to enrollment. Dexamethasone starting dose: Dose previously on when progressing prior to study entry. ATRA starting dose: MTD from Phase I.~Maintenance Therapy Group A: Lenalidomide at dose level tolerated at completion of cycle 3 for 21/28 days, with ATRA at dose determined in Phase I for 14/28 days, and Dexamethasone at last tolerated dose on Days 1, 8, 15 and 22. After 3 months on therapy at MTD in Phase I study, patients must be switched to this dose schedule. Patients unable to tolerate either Dexamethasone during maintenance phase may dose reduce Dexamethasone as needed."
89539856|NCT02184442|Experimental|TAVR - SAPIEN XT|TAVR (transaortic valve replacement) with SAPIEN XT
89539857|NCT02184442|Active Comparator|TAVR - SAPIEN|TAVR (transaortic valve replacement) with SAPIEN is the control arm
89032912|NCT00527657|Experimental|Lomustine + Temozolomide + Thalidomide|Lomustine starting dose 30 mg/m^2 by mouth daily on Day 1 and 29. Temozolomide 75 mg/m^2 by mouth daily on Days 1 to 42. Thalidomide 200 mg/m^2 by mouth daily.
89206806|NCT04091399|Experimental|Patient cohort|Patients suffered from alveolar osteitis and treated using a Stomatological tamponade Contipro, composed of the Hyaluronic acid and Octenidine dihydrochloride. Firstly, the extraction wound had been irrigated with 2 ml of 3% solution of H2O2 to disinfect the site and then flushed by 2 ml of Aqua pro injectione to clear any remaining debris. After, the tested drug was applied into the extraction wound. This procedure was repeated on a daily basis for a maximum of 7 days or until the pain subsided below 20 mm and remained there for at least 2 days.
89206807|NCT00955227|No Intervention|Statins only|In this arm- 15 Patients with heart disease and hypercholesterolemia will receive standard statin treatment as determined by the Cardiologist. Patients in this arm will be excluded if they are on ezetimibe.
89506893|NCT02220803|Experimental|Acetazolamide|Acetazolamide (Diamox®) 250 mg. Hard white capsule. The total length of acetazolamide treatment will be 4 weeks (2x2) including 3 days of titration phase of the drug. Dosing of acetazolamide will be up-titrated during 3 days according to manufacturer instruction and titration scheme of the study. Maximum dosage (750mg) following titration will be administered as morning (250 mg) and evening(500mg)dosages.Evening medication should be taken 2 hours before bedtime. The tablets will be swallowed with 300 ml of water (room temperature) in an upright body position and preferably in connection to a meal.
89506894|NCT02258321|Experimental|PPI-668 tablet followed by capsule|On day 1, one 200 mg PPI-668 tablet will be administered. On day 6, two 100 mg PI-668 capsules will be administered.
89506895|NCT02258321|Experimental|PPI-668 capsule followed by tablet|On day 1, two 100 mg PI-668 capsules will be administered. On day 6, one 200 mg PPI-668 tablet will be administered.
89506896|NCT02258399|Active Comparator|Breakfast Rest|
89506897|NCT02258399|Active Comparator|Breakfast Exercise|
89506898|NCT02258399|Experimental|Fasted Exercise|
89506899|NCT02209337|Experimental|SRS-I|Implantation of SRS-I
89506900|NCT02220881|Experimental|Mold making silicone toe separator|The subject in experimental group will use mold making silicone toe separator everyday
89506901|NCT02220881|Other|Observation|This group will follow the physician instruction of care for the hallux valgus
89506902|NCT02322892|Placebo Comparator|Control Arm|50 mL normal saline solution
89506903|NCT02322892|Experimental|Thiamine|200 mg thiamine in 50 mL normal saline solution
89506904|NCT03274375|Experimental|IA session|"4 Rituximab injections~10 IA sessions"
89506905|NCT02220959|Experimental|walk test|morbid obese patients (BMI>40) undergoing laparoscopic sleeve gastrectomy walking 60 meters under 1 minute before and after the measurement of Forced vital capacity (FVC)
89506906|NCT03526393|Experimental|Support Equipment|Were selected high performance athletes with various kinds of disabilities found in sitting volleyball functional classification. Three equipment was built to aid high-performance athletes. All the volunteers tested the survey training equipment, attack and serve training equipment and pass training equipment The motor sign captured footage of each athlete, lasted 30 minutes and the data collected provided the data for the construction of the equipment, later there was the interaction of the athletes with the equipment ready to test effectiveness.
89506907|NCT04466839||parkinsonian patients|Cohort of parkinsonian patients followed by doctors from the Parkinson Expert Centers in teaching hospitals.
89506908|NCT04467073|Experimental|Stepped-Care Online Reciprocal Imitation Training (Online RIT)|"Participants completed four telehealth modules over a period of 5 weeks (~1 per week, 1 week to practice). Two variables were selected as tailoring variables for this stepped-care model. Fidelity (RIT-PFF) and self-efficacy (EIPSES) at 5 weeks were used to determine which participants were in need of a step up in care, in the form of remote parent coaching.~Parents who demonstrated ≥80% on the RIT-PFF, and who reported gains on the EIPSES continued to have access to Online RIT and practiced on their own for the next 5 weeks, but did not receive any remote coaching. Parents who demonstrated <80% fidelity on the RIT-PFF and/or who didn't report increases in the EIPSES were directed into coaching. Coaching involved videoconferences once per week (wks. 6-10) with a parent coach (PI), and followed the occupational performance coaching model. Sessions included review of successes and challenges, parent practice with feedback, problem solving, and planning."
89506909|NCT04467073|No Intervention|Wait List Control|Participants provided with information about available community resources after randomization. These participants were given the opportunity to engage in the stepped-care format of Online RIT after the post-intervention data collection time point; however their data was included exclusively in control group analyses.
89506910|NCT04466605|Experimental|Tele-Yoga Therapy|All patients randomized to the intervention group had one to one yoga sessions with yoga therapist twice a week for 45 minutes on secure virtual platform. Patients were encouraged with home practice to follow everyday at least for 30-mins.
89506911|NCT04466605|Active Comparator|Usual Care|Patients randomized to usual care continued to receive care for their chronic musculoskeletal pain from their primary care physician. There was no attempt by to influence clinical management unless an emergency arose
89506912|NCT03916081|Active Comparator|Roflumilast Cream 0.05%|Participants apply roflumilast cream 0.05% QD for 28 days.
89506913|NCT03916081|Active Comparator|Roflumilast Cream 0.15%|Participants apply roflumilast cream 0.15% QD for 28 days.
89506914|NCT03916081|Placebo Comparator|Vehicle Cream|Participants apply vehicle cream QD for 28 days.
89506915|NCT04961827|Experimental|Intervention: Self-efficacy based images|Intervention group with self-efficacy based images sent through instant messaging biweekly for 6 times.
89506916|NCT04961827|Active Comparator|Active control: knowledge based images|Active control group with knowledge based images sent through instant messaging biweekly for 6 times.
88815953|NCT02524119|Experimental|LEE001 with Chemoembolization|A total of 40 patients will be enrolled and undergo chemoembolization. Patients will receive LEE011 (600 mg PO once daily, 3 weeks on/1 week off) on Day 1 with chemoembolization. Patients can receive a total of 4 chemoembolization treatments within 6 month following first treatment as needed to treat initial HCC lesion.
89206808|NCT00955227|Active Comparator|Statins and ezetimibe|In this arm- 15 Patients with heart disease and hypercholesterolemia will receive standard statin treatment as determined by the Cardiologist. In addition, these patients will be on ezetimibe.
89506917|NCT03524599|Experimental|Intervention municipality|In the intervention municipalities, primary health care providers will receive ongoing training and support in undertaking screening and brief advice for heavy drinking. They will also receive community-based five adoption mechanisms and five support systems.
89206809|NCT00955227|Experimental|Statins and flax oil only|In this arm- 15 Patients receiving standard statin treatment as determined by their cardiologist will also receive two flaxseed oil capsules/day each containing 500 mg of ALA.
89506918|NCT03524599|No Intervention|Comparator municipality|In the comparator municipalities, the primary health care providers will be given a summary card of screening and brief advice for heavy drinking, with no instruction
89506919|NCT04467229|Experimental|Focus group with chronically painful adolescents|Adolescents with chronic pain
89506920|NCT03524521|Active Comparator|Standard Walking|This arm is prescribed standard of care exercise prescription; 30 minutes of moderate intensity walking, 5 days/week.
89506921|NCT03524521|Experimental|Interval Training|This arm is prescribed body-weight based interval training 3 days per week with progressive increase in exercise intervals and sets.
89506922|NCT03116113|Experimental|Part 1: BIIB112 Dose 1|Participants will receive a single Dose 1 of BIIB112 by sub-retinal injection on Day 0.
89506923|NCT03116113|Experimental|Part 1: BIIB112 Dose 2|Participants will receive a single Dose 2 of BIIB112 by sub-retinal injection on Day 0.
89506924|NCT03116113|Experimental|Part 1: BIIB112 Dose 3|Participants will receive a single Dose 3 of BIIB112 by sub-retinal injection on Day 0.
89506925|NCT03116113|Experimental|Part 1: BIIB112 Dose 4|Participants will receive a single Dose 4 of BIIB112 by sub-retinal injection on Day 0.
89506926|NCT03116113|Experimental|Part 1: BIIB112 Dose 5|Participants will receive a single Dose 5 of BIIB112 by sub-retinal injection on Day 0.
89506927|NCT03116113|Experimental|Part 1: BIIB112 Dose 6|Participants will receive a single Dose 6 of BIIB112 by sub-retinal injection on Day 0.
89506928|NCT03116113|Experimental|Part 2: BIIB112 High Dose|Participants will receive a single high dose of BIIB112 by sub-retinal injection.
89506929|NCT03116113|Experimental|Part 2: BIIB112 Low Dose|Participants will receive a single low dose of BIIB112 by sub-retinal injection.
89506930|NCT03116113|No Intervention|Part 2: Untreated Group|Participants will receive no intervention to allow for a controlled comparison.
89506931|NCT04468009|No Intervention|Standard of care|Standard of care for Covid-19
89506932|NCT04468009|Experimental|PCC-19|Treatment with convalescent plasma
89506933|NCT03766555|Experimental|Microwave Ablation|Microwave ablation (MWA) will be performed in patients randomized to this arm.
89506934|NCT03766555|Active Comparator|Liver Resection|Liver resection will be performed in patients randomized to this arm.
89506935|NCT02739997|Experimental|MK-7625A + metronidazole|MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g) plus metronidazole 500 mg administered as an intravenous (IV) infusion every 8 hours for 4 to 14 days. The dose may be reduced to 750 mg (ceftolozane 500 mg/tazobactam 250 mg) for participants with a creatinine clearance (CrCl) of 30-50 mL/min.
89506936|NCT04467931||1.1 Outpatient SARS-CoV-2 Positive, ACEI/ARB vs non-ACEI/ARB|Among Veterans with treated hypertension and without compelling indications who test positive for SARS-CoV-2, compare all-cause hospitalization and all-cause mortality rates between current users of a range of doses of ACEI/ARB- vs. non-ACEI/ARB-based regimens.
89506937|NCT04467931||1.2 Outpatient SARS-CoV-2 Positive, ACEI vs. ARB|Among Veterans with treated hypertension who test positive for SARS-CoV-2, compare all-cause hospitalization and all-cause mortality rates between current users of a range of doses of ACEI- vs. ARB-based regimens.
89506938|NCT04467931||2.1 COVID-19 Hospitalized, ACEI/ARB vs non-ACEI/ARB|Among Veterans with treated hypertension and without compelling indications who are hospitalized for COVID-19, compare all-cause mortality rates between current users of a range of doses of ACEI/ARB- vs. non-ACEI/ARB-based regimens.
89506939|NCT04467931||2.2 COVID-19 Hospitalized, ACEI vs. ARB|Among Veterans with treated hypertension who are hospitalized for COVID-19, compare all-cause mortality rates between current users of a range of doses of ACEI- vs. ARB-based regimens.
89506940|NCT03524443||Patient suffering from anorexia/bulimia|Each patient will receive standard care: multidisciplinary and corresponding to the HAS recommendations for anorexia nervosa and bulimia nervosa associated with semimonthly or weeklies sessions of art therapy treatment, using all types of art, realized by trained professional, in Toulouse. Each patient will be her own control before art therapy Female patients with anorexia nervosa or bulimia according to DSM-5 criteria, patient will be above 16 years-old
89506941|NCT04744129|Active Comparator|NN414|To investigate the role of NN414 compared with placebo in migraine patients.
89506942|NCT04744129|Placebo Comparator|Saline|To investigate the role of NN414 compared with placebo in migraine patients.
89506943|NCT03133117|Experimental|Cerebral Bases of Central and Peripheral Visual Integration|
89506944|NCT03524287|Experimental|No.10 lymph node dissections|Patients with locally advanced upper third gastric carcinoma will performed robotic assisted spleen-preserving No.10 lymph node dissections. After the surgery the patients will be treated with oxaliplatin or platinum-based chemotherapy.
89506945|NCT03522883|Placebo Comparator|group control|the subjects will not take any type of nutrient intake
89506946|NCT03522883|Experimental|experimental group 1|carbohydrate intake prior to exercise
89506947|NCT03522883|Active Comparator|experimental group 2|carbohydrate intake prior to exercise
89506948|NCT03522805|Experimental|Non-invasive ventilation|Subjects will undergo a baseline night with standard polysomnography, followed by a treatment night using non-invasive ventilation under polysomnography
89506949|NCT03522727|No Intervention|Control|Participants will be asked to complete a questionnaire.
89506950|NCT03522727|Experimental|Intervention 1|"Single self-incentivising implementation intention~After completing a questionnaire, participants will be asked to form a self-incentivising implementation intention:~Research shows that rewarding yourself for success can help you to lose weight, but that people often forget to reward themselves. We want you to plan to reward yourself if you achieve your personal weight-loss goal, at the end of 4 weeks. To help you do this, we would like you to complete the following sentence by telling us how you will reward yourself.~Please complete the following sentence with a reward of your own choosing.~If I lose at least ___lbs/kg by the end of 4 weeks, then I will reward myself by…~**Drop down menu**~Learning a new skill..."
89023876|NCT04464993|Experimental|CORE|"Participants will receive a core intervention which will include a basic version of the StandUPTV app and a Fitbit watch to use throughout the 16-week intervention.The Fitbit will provide device-based behavioral feedback through the StandUPTV self-monitoring component. SST feedback will be Self-monitoring will provide passive and objective feedback regarding SST behaviors and MVPA drawn from Fitbit and SCREENTIME sources. StandUPTV will also contain basic education including information on the risks of SST and tips for reducing SST. As part of this education, all participants will be provided a behavioral target of reducing their SST by 50% from their baseline. This target will be customized for the participant within StandUPTV based on a baseline week of observation."
89023877|NCT04464993|Experimental|CORE + text|CORE components + The TEXT component uses app-based prompts (i.e., prompts generated through StandUPTV app) that will provide simple adaptive content based upon length of most recent SST bout and time of day. These prompts will specifically target outcome expectations around SST and MVPA.
89023878|NCT04464993|Experimental|CORE + Lockout|CORE components + Lockout component will enforce a 50% per week reduction in SST, based upon a baseline week of observation. If SST reaches the prescribed threshold, the investigators will use the limits from the StandUPTV app to restrict screen time through the end of the week (Monday-Sunday); at which point, 50% baseline allotment will be reinstated for an additional week. Participants will be provided with a planning tool for planning SST on a daily basis in order to reach their over 50% reduction goal.
89023879|NCT04464993|Active Comparator|CORE + Earn|CORE components + the investigators will enforce a 50% per week reduction in SST, based upon a baseline week of observation. If SST reaches the prescribed threshold, the investigators will use the limits from the StandUPTV app to restrict screen time through the end of the week (Monday-Sunday); at which point, 50% baseline allotment will be reinstated for an additional week. Participants will be provided a planning tool for planning SST on a daily basis in order to reach their over 50% reduction goal.
89023880|NCT04464993|Active Comparator|CORE + Text + Earn|"Intervention components will be delivered as described in simpler factorial conditions.~App shows progress toward SST goal or if goal is exceeded. Can earn additional SST through exercise based on 3:1 ratio , simple adaptive content (by SST bout, time of day). Lockout component will enforce a 50% per week reduction in SST, based upon a baseline week of observation."
89023881|NCT04464993|Active Comparator|CORE + Text + Lockout|"Intervention components will be delivered as described in simpler factorial conditions, and...~If exceeded, the limits feature will restrict screen time through the end of the week (Monday-Sunday) so cannot exceed limit. Simple adaptive content (by SST bout, time of day)."
89506951|NCT03522727|Experimental|Intervention 2|"Multiple self-incentivising implementation intentions~After completing a questionnaire, participants will be asked to form self-incentivising implementation intentions:~Research shows that rewarding yourself for success can help you to lose weight, but that people often forget to reward themselves. We want you to plan to reward yourself if you achieve your personal weight-loss goal, at the end of 4 weeks. To help you do this, we would like you to complete the following sentence by telling us how you will reward yourself. You can choose as many rewards as you like! Please complete the following sentence with a reward of your own choosing.~If I lose at least ___lbs/kg by the end of 4 weeks, then I will reward myself by… and/or…~**Drop down menu**~Learning a new skill..."
89506952|NCT03522727|Experimental|Intervention 3|"Self-generated self-incentivising implementation intentions~After completing a questionnaire, participants will be asked to form a self-incentivising implementation intention:~Research shows that rewarding yourself for success can help you to lose weight, but that people often forget to reward themselves. We want you to plan to reward yourself if you achieve your personal weight-loss goal, at the end of 4 weeks. To help you do this, we would like you to complete the following sentence by telling us how you will reward yourself.~Please complete the following sentence with a reward of your own choosing.~If I lose at least ___lbs/kg by the end of 4 weeks, then I will reward myself by…"
89506953|NCT03522649|Experimental|Napabucasin plus FOLFIRI|Napabucasin 240 mg will be administered orally, twice daily, with doses separated by approximately 8~12 hours. For patients who have failed bevacizumab with irinotecan-based chemotherapies, bevacizumab may be administered with FOLFIRI. FOLFIRI infusion will start at least 2 hours following the first daily dose of napabucasin and will be administered every 2 weeks, starting on C1D1. If bevacizumab is added to FOLFIRI, bevacizumab infusion should start at least 2 hours following the first daily dose of napabucasin and will be administered every 2 weeks. Irinotecan/leucovorin infusion will follow bevacizumab infusion. 5-FU 400 mg/ m^2 bolus will be administered intravenously immediately following irinotecan/leucovorin infusion, followed by 5-FU 1200 mg/ m^2/day continuous infusion. For patients who could not tolerate FOLFIRI at the full dose previously, FOLFIRI should be started at the same dose level the patient tolerated FOLFIRI previously.
89506954|NCT03522649|Other|Napabucasin|Napabucasin 240 mg will be administered orally, twice daily, with doses separated by approximately 8~12 hours.
89506955|NCT02366481|Placebo Comparator|Placebo-Control|The placebo-control group will take two placebo softgel capsules every day for 8 weeks.
89506956|NCT02366481|Active Comparator|Low-Dose Vitamin K2 (90-mcg/d)|The low-dose vitamin K group will take one 90-mcg vitamin K2 (menaquinone-7) softgel capsule and one placebo softgel capsule every day for 8 weeks.
89506957|NCT02366481|Active Comparator|High-Dose Vitamin K2 (180-mcg/d)|The high-dose vitamin K group will take two 90-mcg vitamin K2 (menaquinone-7) softgel capsules every day for 8 weeks.
89506958|NCT02373891|Experimental|T1|
89506959|NCT02373891|Experimental|T0|
89506960|NCT05353231|Experimental|Intervention 1 - Attention Feedback Awareness and Control Training|
89506961|NCT05353231|Experimental|Intervention 2 - Mindful Disengagement from Thoughts Training|
89506962|NCT05353231|Placebo Comparator|Placebo|
89506963|NCT02366247|Experimental|PEG-Tα1|PEG-Tα1 (3.2 mg/ml, once a week, taken subcutaneously) and adefovir (10 mg, once daily, taken orally) for 48 weeks
89506964|NCT02366247|Placebo Comparator|Placebo to match PEG-Tα1|PEG-Tα1 placebo (1ml, once a week, taken subcutaneously) and adefovir (10 mg, once daily, taken orally) for 48 weeks
89506965|NCT05321173||Extubation ≤ 8 hour|Patients who mechanically ventilated less than 8 hours postoperatively
89023882|NCT04464993|Active Comparator|CORE + Earn + Lockout|"Intervention components will be delivered as described in simpler factorial conditions, and...~If exceeded, the limits feature will restrict screen time through the end of the week (Monday-Sunday) so cannot exceed limit. Can earn additional SST through exercise based on 3:1 ratio."
89023883|NCT04464993|Active Comparator|CORE + Earn + Lockout + Text|"Intervention components will be delivered as described in simpler factorial conditions, and...~If exceeded, the limits feature will restrict screen time through the end of the week (Monday-Sunday) so cannot exceed limit. Can earn additional SST through exercise based on 3:1 ratio). Simple adaptive content (by SST bout, time of day)."
89023884|NCT04443907|Experimental|OTQ923|Single intravenous infusion of OTQ923 Part A - Adults treated with OTQ923; Part B - Children age 2-17 treated with OTQ923 based on review of data from Part A by Health agency after a formal interim analysis.
89023885|NCT04439123|Experimental|Treatment (capivasertib)|Patients receive capivasertib PO BID on days 1-4, 8-11, 15-18, and 22-25. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89023886|NCT04434729|Experimental|Fetal embolization of vein of Galen malformation|This is a single-arm study. Fetal subjects will undergo a one-time intervention of fetal embolization of vein of Galen malformation.
89023887|NCT04429542|Experimental|BCA101 Monotherapy|Route: IV Infusion Frequency: QW Current Dose: 1500mg
89023888|NCT04429542|Experimental|BCA101 + pembrolizumab|Route: IV Infusion Frequency: Q3W Dose: 200mg
89023889|NCT04418154|Experimental|EC-ABX/PD-1|Patients who are treated with epirubicin hydrochloride andcyclophosphamide followed by nanoparticlealbumin-bound paclitaxel and Toripalimab
89023890|NCT04404985|Active Comparator|Surgical AVFs|Participants who initiated dialysis with a catheter or have advanced chronic kidney disease ,these patients who an Surgical AVF intervention group that will undergo a routine surgical AVF creation.
89023891|NCT04404985|Experimental|Endo-vascular AVF|Participants who initiated dialysis with a catheter or have advanced chronic kidney disease ,these patients who an endo-vascular AVF intervention group that will undergo a per-cutaneous AVF creation.
89023892|NCT04402086||Biorepository|Participants with rheumatic diseases who contributed biospecimen samples (blood, saliva, urine, stool, tissue).
89023894|NCT04384341|Experimental|Haemophilic patients|Blood sampling Bone Densitometry (BMD)
89023895|NCT04384341|Other|Healthy volunteers|Bone Densitometry (BMD)
89506966|NCT05321173||Extubation > 8 hour|Patients who mechanically ventilated more than 8 hours postoperatively
89506967|NCT02373735|Active Comparator|Group A (SVV <10% group)|"infuse crystalloid (Hartmann's solution) 6-10 ml/kg/hr continuously during surgery~infuse colloid (Volulyte) 200 ml if SVV is ≥ 10% during the surgery~Interventions: crystalloid (Hartmann's solution), colloid (Volulyte)"
89506968|NCT02373735|Experimental|Group B (SVV 10-20% group)|"infuse crystalloid (Hartmann's solution) 2-4 ml/kg/hr until cystectomy, 6-10 ml/kg/hr after cystectomy~infuse colloid (Volulyte) 200 ml if SVV is > 20%~infuse mannitol 0.5 g/kg or lasix 5 mg if SVV < 10%~Interventions: crystalloid (Hartmann's solution), colloid (Volulyte), mannitol, lasix"
89506969|NCT03526315|Active Comparator|CPP-ACP paste|Casein phosphopeptide amorphous calcium phosphate is a product that contains calcium, phosphate, protein and casein.
89506970|NCT03526315|Active Comparator|Fluoride toothpaste|Fluoride toothpaste
89506971|NCT03526315|Active Comparator|Both (Fluoride and CPP-ACP)|Fluoride toothpaste and CPP-ACP paste
89506972|NCT03524131|Experimental|risk-framed leaflet|Patients sent 2-sided risk-framed leaflet with NHS Health Check invitation
89506973|NCT03524131|Experimental|benefits-framed leaflet|Patients sent 2-sided benefits-framed leaflet with NHS Health Check invitation
89506974|NCT03524131|Active Comparator|control|Patients sent 4-sided current national leaflet with NHS Health Check invitation
89506975|NCT03112551|Active Comparator|group 1|group one will be treated with 24 hours maintenance dose of magnesium sulphate
89506976|NCT03112551|Experimental|group 2|group 2 will be treated with 12 hours maintenance dose of magnesium sulphate
89506977|NCT03133351||PCM|All enrolled subjects will have a blood sample tested using PCM.
89506978|NCT03112629||symptomatic AS|Patients diagnosed with severe aortic stenosis in echocardiography who display one or more of the following symptoms: exertional shortness of breath, chest pain, exertional dizziness or syncope.
89506979|NCT03112629||asymptomatic AS|Patients diagnosed with severe aortic stenosis in echocardiography who do not display symptoms
89506980|NCT02366325|Experimental|EPO-018B 0.025 mg/kg|EPO-018B starting dose of 0.025 milligram per kilogram (mg/kg) administered subcutaneously (SC) once every 4 weeks (Q4W) for a total of 6 doses
89506981|NCT02366325|Experimental|EPO-018B 0.05 mg/kg|EPO-018B starting dose of 0.05 milligram per kilogram (mg/kg) administered subcutaneously (SC) once every 4 weeks (Q4W) for a total of 6 doses
89032913|NCT02925897|Experimental|Intervention|participants will receive their usual treatment from nurses who have had some training in behaviour change and motivational interviewing.
89506982|NCT02366325|Experimental|EPO-018B 0.08 mg/kg|EPO-018B starting dose of 0.08 milligram per kilogram (mg/kg) administered subcutaneously (SC) once every 4 weeks (Q4W) for a total of 6 doses
89506983|NCT03522571|Experimental|Patients with altered passive eruption - APE|3 teeth of the patients with altered passive eruption that will undergo to experimental gingivitis
89506984|NCT03522571|Active Comparator|Patients with normal gingival anatomy - Non APE|3 teeth of the patients with normal gingival anatomy that will undergo to experimental gingivitis
89506985|NCT05373433|Experimental|Experimental group|SSD8432 750mg and Ritonavir 100mg
89506986|NCT05373433|Placebo Comparator|Control group|SSD8432 placebo and Ritonavir placebo
89506987|NCT02362971||Included|Patients included into the randomized controlled trial
89506988|NCT02362971||Non-consenters|Patients eligible for participation in the randomized controlled trial but did not give their informed consent and thus excluded in the randomized controlled trial.
89506989|NCT02362971||Excluded|Patients, by different reasons excluded from participation in the randomized controlled trial.
89506990|NCT02363127|Experimental|Prolutex|Subcutaneous progesterone
89506991|NCT02363127|Active Comparator|Progeffik|Vaginal progesterone
89506992|NCT03522493|Active Comparator|Young group|This arm include 20 young subjects that will perform the same experiment as the old group for a comparison reasons.
89023896|NCT04381117||No Treatment|Subjects who participated in and completed study EN3835-201 and had composite improvement of at least 2-levels on both the Clinician Reported-Photonumeric Cellulite Severity Scale (CR-PCSS) and Patient Reported-Photonumeric Cellulite Severity Scale (PR-PCSS) in EN3835-201 study will be eligible for this study. The study will consist of a single day evaluation approximately 4 years after the first dose of the study drug was received in the EN3835-201 study.
89023897|NCT04367116|Experimental|spinal cord stimulation|the spinal cord stimulation was performed and operated
89023898|NCT04361825|Experimental|Durvalumab(MEDI4736) and AZD6738 combination|
89023899|NCT04354064||Healthy Donor Samples|"Donation of blood and/or urine samples as often as bi-monthly and as many as 24 times in total~These samples will be used to generate reference data to compare patient data to and/or to correct stereotypic noise."
89023900|NCT04354064||Samples from Repository and Banking Studies|"Healthy prostate and/or blood and/or urine samples from Genitourinary Repository~Tissue, blood, and/or drain fluid samples from Head and Neck Banking studies~Tissue and/or blood samples from Esophageal Repository~Tissue and/or blood samples from Genitourinary Repository~Tissue and/or plasma from Sarcoma Tissue Bank~Tissue and/or plasma from Breast Cancer Bank~Tissue, plasma, and/or urine from GI Tissue and Blood Bank~Tissue, blood, and/or urine from Solid Tumor Bank~Tissue, blood, and/or urine from Lung Cancer Bank~Tissue and/or blood from Skin Cancer Bank~Tissue and/or blood from Pediatric Neurosurgery Tissue Bank"
89539858|NCT04915209|Other|Narrative interviews|Narratives are stories that are based on the unfolding of events or actions from the perspective of a patient's life experience. Patients and care partners tell their stories of illness and how they live with illness over time . The researcher could focus on the care priorities, the support needed, the information needed and the challenges faced. The narrative interview will be used to get an overview of the patient's trajectory.
89539859|NCT04915053|Experimental|ABG Black Garlic Extract|Daily intake of a 550 mg tablet, containing 250 mg of Black Garlic Extract and 300 mg of excipients.
89539860|NCT04915053|Placebo Comparator|Placebo|Daily intake of a 550 mg tablet, containing 250 mg of microcrystalline cellulose and 300 mg of excipients
89539861|NCT04900311|Experimental|pyrotinib + trastuzumab + nab-paclitaxel|
89539862|NCT04900311|Active Comparator|pertuzumab + trastuzumab + nab-paclitaxel|
89539863|NCT02155738|Placebo Comparator|Placebo|100 cc of normal saline administered intravenously 10-30 minutes prior to anesthesia induction on the day of surgery.
89539864|NCT02155738|Experimental|IV Acetaminophen|100 cc of Acetaminophen (1000mg/100mL) administered intravenously 10-30 minutes prior to anesthesia induction on the day of surgery.
89539865|NCT03053505|Experimental|Recurrent CDI FMT|"Non-randomized group (R) for treatment of recurrent CDI with FMT"
89539866|NCT03053505|Active Comparator|Primary CDI antibiotic|"Randomized group (F AB) for the treatment of primary CDI with antibiotics (vancomycin or fidaxomicin)"
89539867|NCT03053505|Experimental|Primary CDI FMT|"Randomized group (F FMT) for the treatment of primary CDI with FMT"
89539868|NCT04914039||CTA examination|CTA examination group for suspected brain death
89539869|NCT04914039||Confirmed|Confirmed group for brain death
89539870|NCT02181790|Experimental|First Group|excimer laser treatment to one palm and/or one sole
89539871|NCT02181790|Experimental|Second Group|excimer laser treatment to both palms and/or soles
89539872|NCT04909281||Long-term non-attenders in the cervical screening program|All women who had not attended tthe cervical screening program in Sweden for at least 10 years were eligeble.
89539873|NCT03052023|Experimental|group A (dual approach lap hernioplasty)|dual approach laparoscopic inguinal hernioplasty by combination of TAPP (group B) and pneumo-dissection preperitoneal instead of sharp dissection
89539874|NCT03052023|Active Comparator|group B (TAPP)|trans-abdominal preperitoneal hernioplasty (TAPP) after induction of pneumoperitoneum through peritoneal approach peritoneal incision and preperitoneal dissection then mesh fixation done
89539875|NCT03052023|Active Comparator|group C (Lichtenstein hernioplasty)|open inguinal hernioplasty (lichtenstein) repair through inguinal incision and dissection of the sac anteriorly , excision of the sac and then mesh fixation in the posterior wall of inguinal canal
89539876|NCT03051945|Experimental|Ketamine|Ketamine will be infused via intravenous catheter over 40 minutes (0.75 mg/kg/hr over 40 minutes, 0.5 mg/kg total).
89539877|NCT03051945|Placebo Comparator|Placebo|Normal saline will be infused via intravenous catheter over 40 minutes (0.75 mg/kg/hr over 40 minutes, 0.5 mg/kg total).
89539878|NCT04900233||Control group|
89539879|NCT04900233||Pandemic group|
89539880|NCT04899453|Experimental|Zanubrutinib/rituximab & intravitreal MTX|Experimental arm will be treated with rituximab plus zanubrutinib (ZR) regimen for 6 cycles and followed by zanubrutinib maintenance for 2 years, meanwhile, intravitreal methotrexate will be given as protocol during the 1st year of treatment.
89539881|NCT04899531||Longitudinal observation|No specific intervention, pre-post measurements only
89539882|NCT04914273|Experimental|Sequence A: 1. Ingestion 2. Inhalation|Group A is treated in the following sequence: 1. oral drug 2. inhalative drug
89539883|NCT04914273|Experimental|Sequence B: 1. Inhalation 2. Ingestion|Group B is treated in the following sequence: 1. inhalative drug 2. oral drug
89539884|NCT04909359||Crohn's disease (CD)|People with CD recently receiving vedolizumab as standard of care will be followed up to 5 years.
89539885|NCT04909359||Ulcerative colitis (UC)|People with UC recently receiving vedolizumab as standard of care will be followed up to 5 years.
89539886|NCT04908891|Experimental|persons with Multiple Sclerosis|
89539887|NCT04908891|Active Comparator|Healthy controls|
89539888|NCT04908891|Active Comparator|Stroke Patients|
89539889|NCT03054987|Active Comparator|EUS-BD|EUS-BD is a minimally invasive technique where the common bile duct (choledochoduodenostomy) is punctured under EUS-guidance and after transmural dilation, a stent is deployed for biliary drainage.
89539890|NCT03054987|Active Comparator|ERCP|At ERCP, the common bile duct will be selectively cannulated using a sphincterotome and guide wire technique. Once biliary access is obtained a stent will be deployed to facilitate biliary drainage.
89539891|NCT03054753|Other|Abduction brace wearing time analysis|The abduction brace wearing time analysis is performed in patients, who undergo a rotator cuff repair with postoperative abduction brace treatment
89506993|NCT03522493|Experimental|Old group|This group us the group of interest. This group will wear the mask and is expected to show differences from the younger group.
89539892|NCT03051867||Third-trimester pregnant women|Women differing in their reproductive state (pregnant versus nonpregnant) will consume equivalent dietary intakes of vitamin D and related nutrients as part of a feeding study.
88957610|NCT01985477|Experimental|Lenalidomide + All-Trans Retinoic Acid (ATRA)|"Phase II Group B: Lenalidomide will be given as a single oral dose at the level patient was on at the time of progression on single agent Lenalidomide prior to study enrollment. All-Trans Retinoic Acid (ATRA) starting dose: MTD from Phase I.~Maintenance Therapy: Maintenance therapy consists of lenalidomide at the dose level tolerated at the completion of cycle 3 for 21/28 days, with ATRA at the dose determined in the phase I portion of the trial for 14/28 days. Dexamethasone will not be administered. After 3 months on therapy at the MTD in the phase 1 study, patients must be switched to this dose schedule."
88957611|NCT01985490|Experimental|epiretinal membrane|
88957612|NCT01985503||Phase 1 group|Subjects were studied in 2009 and their follow-up is in 2014.
88957613|NCT01985503||Phase 2 group|Subjects were studied in 2011 and their follow-up is in 2016.
88957614|NCT01985516|Experimental|Instillation into the urethra|5mL of 2% lidocaine gel will be instilled directly into the urethra 5 minutes before catheterization
88957615|NCT01985516|Active Comparator|Pouring the gel on the tip of the catheter|5mL of 2% lidocaine gel will be poured on the distal part of the catheter (from the distal tip to 10 cm proximally)
88957616|NCT01985529|Experimental|Exercise|Enrollment in pulmonary rehabilitation
88957617|NCT01985529|No Intervention|Control|
88957618|NCT01985555|Experimental|Volitinib(HMPL-504)|There are 5 dose cohorts,including600 QD,800QD and 400BID mg,500BID in the dose escalation stage and HMPL-504 will be administered orally to patients once daily for each dose cohort., in the dose expansion stage 500BID will be administered orally to patients.
88957619|NCT01985594|Active Comparator|Utrogestan|oral tablet Utrogestan 400mg daily for 2 days
88957620|NCT01985594|Placebo Comparator|Nifedipine|tablet Nifedipine 20 mg stat then 20 mg after 30 minutes then another 20 mg after 30 minutes followed by 10 mg three times daily for 2 days
88957621|NCT01985607|Experimental|Thickened|
88957622|NCT01985607|Active Comparator|Control|
88957623|NCT01985620|Active Comparator|study group|Educational intervention with the parents
88957624|NCT01985620|No Intervention|control group|
88957625|NCT01985633|Experimental|Mesenchymal stem cell, PRP|Twelve patients will be placed in supine position with knee in full extension and under full aseptic precautions 10 ml of Mesenchymal stem cell suspension and 8-10 ml of platelet rich plasma would be injected by lateral approach with an 18-20 G needle
89506994|NCT02362737|Experimental|Active and Healthy Brotherhood (AHB)|16-week behavioral intervention
89506995|NCT02362737|No Intervention|Control|Usual care.
89506996|NCT02362659||Antiplatelet agent plus anticoagulant|an antithrombotic regimen comprising one single antiplatelet agent plus an anticoagulant
89506997|NCT02362659||DAPT alone|an antithrombotic regimen consisting of dual antiplatelet therapy (DAPT) alone
89506998|NCT02362659||DAPT plus anticoagulant|an antithrombotic regimen consisting of DAPT plus anticoagulant therapy
89506999|NCT03524053|Experimental|Exercise induced bronchoconstriction|An exercise challenge will then be performed according to international guidelines. The exercise will consist of 8 minutes of cycling on a cycle ergometer while breathing medical grade dry air from a reservoir (Douglas bag) via a two-way non-rebreathing valve. The workload will be increased progressively over the first 2 minutes, and will then be maintained for 6 minutes at a target workload (in Watts) of [53.76 * measured forced expiratory volume in 1 sec (FEV1)-11.07].
89507000|NCT03524053|Active Comparator|Inhibited EIB|An exercise challenge will then be performed according to international guidelines. The exercise will consist of 8 minutes of cycling on a cycle ergometer while warm-humid air from a reservoir (Douglas bag) via a two-way non-rebreathing valve. The workload will be increased progressively over the first 2 minutes, and will then be maintained for 6 minutes at a target workload (in Watts) of [53.76 * measured forced expiratory volume in 1 sec (FEV1)-11.07].
89507001|NCT03524053|No Intervention|Control|Participants will attend the laboratory but no exercise trial will be performed.
89507002|NCT02362815|Active Comparator|Apple juice|Patient are allowed to drink up to 400 ml of apple juice
89507003|NCT02362815|No Intervention|Control|Patient are not allowed to drink
89507004|NCT04467541|Experimental|Inactivated enterovirus type 71 vaccine|Inactivated enterovirus type 71 vaccine safety in healthy adults followed by safety and immunogenicity administered in two consecutive doses, one-month apart among children aged 6 to 71 months
89507005|NCT02373423|Experimental|Advocacy program|A series of commonly used advocacy actions which will incorporate a theory of change model. Each advocacy action is targeted to change organizational capability, opportunity, or motivation of food companies to reduce salt in processed packaged foods. The intervention will span 24 months from 2013-2015.
89507006|NCT02373423|No Intervention|Control|No intervention program
89507007|NCT03526237|Experimental|The 24-week treatment|The 24-week treatment, Sisters Health And Primary CarE Uniting and Preventing Diabetes (SHAPE UP) 12 weekly peer group (adapted Group Lifestyle Balance Program) sessions followed by 3 monthly group maintenance sessions held in Public Housing locations; b) Individual coaching and patient activation during 24 week period; 2) Community Outreach Care Coordination: Referral, navigation assistance, patient activation, and cross-linkage to FQHC services.
88957626|NCT01985633|Active Comparator|platelet rich plasma|About 100 ml of venous blood would be drawn with aseptic technique from the antecubital vein with an 18g needle , in order to avoid irritation and trauma to the platelets which are in a resting state. The blood would be collected in a 100 ml paediatric bag with CPDA(citrate phosphate dextrose adenine) as anti coagulant. A leucocyte filter will be also used to filter off the leucocytes. The blood will be then centrifuged for 15 min at 1300 rpm. This separates blood in to RBC( packed red blood cells) and platelet rich plasma. Next the PRP will be passed through a leucocyte filter to obtain leucocyte poor platelet rich plasma. 10 ml of PRP will be dispensed in a sterile syringe. The PRP would be used for injection.
89507008|NCT03526237|Other|Wait-list Control|Control arm participants will receive: 1) Usual care in FQHC/primary care clinic 2) Individual counseling about pre-diabetes risk at baseline; mailed written NIDDK patient education materials (weight loss, physical activity, nutrition) at weeks 6, 12, 18; 2) At the end of the 24 week intervention, the wait list control arm will be invited to participate and receive the group based DPP sessions.
89507009|NCT02373501|Experimental|intra-abdominal repair|intra-abdominal repair of uterine incision, after delivery of the fetus and the placenta.
89507010|NCT02373501|Experimental|extra-abdominal repair|extra-abdominal repair of uterine incision, after delivery of the fetus and the placenta.
89507011|NCT02778295||Observation|Patients with Fabry disease or high-grade suspicion for Fabry disease
89507012|NCT02373657|Experimental|WASH Intervention|"In these seven communities we built a well in a central location for all state team residents. We plan on providing tippy-taps (water and soap dispensers), instruction in soap-making, and hygiene education to these communities. We will also put fly traps in the communities to see if wells reduce flies. We plan on performing monitoring visits at 12 months and 24 months, in order to assess clinically active trachoma, ocular chlamydia infection, nasopharyngeal macrolide resistance, soil transmitted helminths, and childhood growth (height and weight). We will also perform assessments of the adequacy of the intervention, by conducting household surveys to assess hygiene behavior, access to water and latrines, and fly density."
89507013|NCT02373657|No Intervention|Control|In these seven communities, we plan to perform monitoring visits at 12 months and 24 months, in order to assess clinically active trachoma, ocular chlamydia infection, nasopharyngeal macrolide resistance, soil transmitted helminths, and childhood growth (height and weight). We will also perform assessments of the adequacy of the intervention, by conducting household surveys to assess hygiene behavior, access to water and latrines, and fly density.
89507014|NCT02723799|Experimental|Hope Promotion Program (HPP)|Plus to the standard treatment protocol, all the participants in this group attend the HPP, consisting of a three individual session's carried out by the nurse in patients' homes. It includes viewing the film Hopeful Living, enrolling in a hope activity from the Hope activity book, a relaxation activity and a negotiated plan to exercise hope in a regular basis.
89507015|NCT02723799|Other|Standard Treatment Protocol|Participants in this group has not access to a hope intervention. Data collection for outcome variables is the same as the participants in the other arms.
89507016|NCT03526159|Experimental|Gentamicin Sulfate|"IV Arm:~7.5 mg/kg gentamicin once daily for 14 days.~Topical Arm:~0.5% gentamicin ointment applied twice daily for 14 days to selected skin sites."
89507017|NCT02362347|Active Comparator|Usual care + exercise|Usual care + exercise
89507018|NCT02362347|No Intervention|No care, no exercise|No care, no exercise
89507019|NCT02362347|Experimental|Usual care + exercise + compression vest|Usual care + exercise + London Health Sciences Centre - Compression Vest
89507020|NCT03522337|Placebo Comparator|Control group|The main intervention is conventional leaflets. Tooth-brushing training (toothbrushes and toothpastes provided) and oral health instruction are reinforced by leaflets.
89507021|NCT03522337|Experimental|Test group|The main intervention is visual pedagogy (social stories). Tooth-brushing training (toothbrushes and toothpastes provided) and oral health instruction are reinforced by social stories.
89507022|NCT02362581|Experimental|On demand treatment, prophylaxis treatment|"On demand treatment arm:Patients received factorVIII concentrate(Hemofil M) when they had bleeding episodes.~Prophylaxis arm: patients received factorVIII concentrate (Hemofil M) 30-35 unit/kg once a week"
89507023|NCT03526081|Experimental|Chamomile Tea|Chamomile Tea in 300mL hot water
89507024|NCT03526081|Experimental|Parsley based drink|3.2 g dried parsley in 300mL hot water
89507025|NCT03526081|Experimental|Parsley Yogurt|3.2 g dried parsley in 100g plain yogurt
89507026|NCT03526081|Experimental|Apigenin|Apigenin capsule mixed with 300mL hot water
89507027|NCT03526081|Experimental|Parsley-based drink (II)|3.2 g of dried parsley in 300 ml of hot water
89507028|NCT02366013|Experimental|Group 1|1 dose of rcAd26.MOS1.HIV-Env 1x10^8 vp or placebo
89507029|NCT02366013|Experimental|Group 2|1 dose of rcAd26.MOS1.HIV-Env 1x10^9 vp or placebo
89507030|NCT02366013|Experimental|Group 3|1 dose of rcAd26.MOS1.HIV-Env 1x10^10 vp or placebo
89507031|NCT02366013|Experimental|Group 4|1 dose of rcAd26.MOS1.HIV-Env 1x10^11 vp or placebo
89507032|NCT03526003||Surgical patients|Adult patient scheduled for laparoscopic surgery under general anesthesia
89507033|NCT02362113||Isfahani adults|GI/GL
89539893|NCT03051867||Nonpregnant control women|Women differing in their reproductive state (pregnant versus nonpregnant) will consume equivalent dietary intakes of vitamin D and related nutrients as part of a feeding study.
89507034|NCT02373579|Active Comparator|Intervention arm with Omega 3 FA|"included standard risk ALL pediatric patients who were supplemented with oral omega-3 capsule (one capsule / day) .~Omega-3 was supplied as soft gelatin capsules in a dose of 1000 mg of omega-3 fatty acids/day ."
89507035|NCT02373579|Active Comparator|control group|control group, included pediatric patients with standard risk acute lymphoblastic leukemia in maintenance phase day 0 and receiving oral Methotrexate (20 mg / m2) weekly without any supplementation .
88957627|NCT01985646|Experimental|surgery treatment|one stage pull through left-colectomy
88957628|NCT01985646|Experimental|conservative treatment|anal dilation, colonic lavage, oral probiotic
88957629|NCT01985659||open thoracotomy|In the first cohort(20007-2009) almost all patients where operated through a thoracotomy.
88957630|NCT01985659||Early VATS|In a second cohort, (2010-2011) the experience with vats was early.
89206810|NCT00955227|Experimental|Statins and ezetimibe and flax oil|In this arm- 15 Patients with heart disease and hypercholesterolemia that are on standard statin treatment as determined by their cardiologist, will also receive (as an intervention) ezetimibe and flaxseed oil capsules containing 500mg of ALA.
89507036|NCT02221037|Experimental|GSK2862277|GSK2862277 will be administered as single orally inhaled aerosol over approximately 3 to 5 minutes; approximately 1-3 hours prior to the subjects scheduled surgery, before the initiation of pre-operative procedures. After surgery subject will undergo either ventilated or collapsed lung BAL procedure. Regular assessments will be conducted until the time of patient discharge. Subjects will be followed up as outpatients at Day 28
88957631|NCT01985659||Standardized VATS|In the third period (2012-2013), a standardized vats technique with extensive intrapulmonary and mediastinal lymphadenectomy was used.
88957632|NCT01985672||Vitamin D deficient patients|Serum 25-OH Vitamin D levels <20ng/L undergoing Frozen embryo transfer (vitamin D levels are measured on the day of embryo transfer)
88957633|NCT01985672||Vitamin D sufficient patients|Serum 25-OH Vitamin D levels >20ng/L undergoing Frozen embryo transfer (vitamin D levels are measured on the day of embryo transfer)
88957634|NCT01985698|Experimental|Robotic-assisted resection|patients with low rectal cancer receiving robotic-assisted abdominoperineal resection.
88957635|NCT01985698|Active Comparator|Laparoscopic resection|patients with low rectal cancer receiving laparoscopic abdominoperineal resection.
88957636|NCT01985711|Experimental|web-based,CBT,MI,TTM, outpatient|Participants in web-based collaborative care group will receive 24 weekly 40-minute web-based Cognitive Behavioral Therapy (CBT) sessions, undergo structured Transtheoretical Model of Behavior Change or Motivational interviewing to set up proper life-style and healthy behavior to improve their live quality，conducted on the web. Besides, they will receive usual diabetes outpatient care and web-based diabetes care.
88957637|NCT01985711|Other|waitlist, usual diabetes outpatient|Participants assigned to the wait-list group will be given usual diabetes outpatient service (diabetic medication guidance and appointment to see doctor as routine, without specific anti-depression therapy). After 6 months, they will receive web-based collaborative care for 6 months too.
88957638|NCT01985724|Active Comparator|A|FEC -> TXT
88957639|NCT01985724|Experimental|B|Docetaxel/Cyclophosphamide (TC)
88957640|NCT01985737||Infants with infected PICC line|After informed consent the subjects that develop a PICC line infection in the NICU will serve as the cases.
88957641|NCT01985737||Infants without infected PICC line|After informed consent the subjects that do not develop a PICC line infection in the NICU will serve as the controls.
88957642|NCT01985750|Placebo Comparator|Drug: d-cycloserine or placebo|"Other Names:~comparison of d-cycloserine or placebo on enhancing the beneficial effects of pulmonary rehabilitation on breathlessness perception~250mg d-cycloserine or identical placebo given immediately to the first 4 sessions of a 6-week course pulmonary rehabilitation"
88957643|NCT01985750|Active Comparator|D-cycloserine|"Placebo Comparator: Drug: d-cycloserine or placebo~Other Names:~comparison of d-cycloserine or placebo on enhancing the beneficial effects of pulmonary rehabilitation on breathlessness perception~250mg d-cycloserine or identical placebo given immediately to the first 4 sessions of a 6-week course pulmonary rehabilitation"
88957644|NCT01985776|Active Comparator|Exercise intervention|Patients will functional stabilisation exercise for the trunk.
88957645|NCT01985776|Active Comparator|Exercise and e-stim|Patients will receive exercise intervention and electrical stimulation simultaneously.
88957646|NCT01985776|No Intervention|Patients control|Patients will not receive any treatment but could use compression belt as per usual.
88957647|NCT01985776|No Intervention|Healthy control|Healthy asymptomatic participants who will not receive any treatment.
88957648|NCT01985789|Active Comparator|diphenhydramine|50mg dose given as two 25mg capsules
88957649|NCT01985789|Active Comparator|cetirizine|10mg dose given as 1 10mg capsule and 1 placebo capsule
88957650|NCT01985789|Active Comparator|desloratadine|5mg dose given as 1 5mg capsule and 1 placebo capsule
88957651|NCT01985789|Placebo Comparator|placebo|given as 2 placebo capsules
88957652|NCT01985802|Other|Pacing - Cross-over|Pacing will be conducted in 3 different ways (atrial, dual chamber and His-bundle pacing) at 2 different rates (basal and 100 bpm).
88957653|NCT01985815|Experimental|VC/VS stimulation ON followed by OFF|triple blind, randomised, two periods of three months
89206811|NCT00747149|Experimental|Rosuvastatin 1|titrated
89206812|NCT00747149|Experimental|Rosuvastatin 2|Non-titrated
89507037|NCT02221037|Placebo Comparator|Placebo|Placebo will be administered as single orally inhaled aerosol over approximately 3 to 5 minutes; approximately 1-3 hours prior to the subjects scheduled surgery, before the initiation of pre-operative procedures. After surgery subject will be undergo either ventilated or collapsed lung BAL procedure. Regular assessments will conducted until the time of patient discharge. Subjects will be followed up as outpatients at Day 28
89507038|NCT02365857|Active Comparator|DEX-5|Dexmedetomidine & Bupivacaine. Patients will receive intrathecal 12.5 mg isobaric bupivacaine and 5 μg Dexmedetomidine using a total volume of injectate of 2.5 ml, and intrathecal injections will be given over approximately 10 to 15 seconds.
89507039|NCT02365857|Active Comparator|DEX-10|Dexmedetomidine & Bupivacaine. Patients will receive intrathecal 12.5 mg isobaric bupivacaine and 10 μg Dexmedetomidine using a total volume of injectate of 2.5 ml, and intrathecal injections will be given over approximately 10 to 15 seconds.
89507040|NCT02365857|Active Comparator|DEX-15|Dexmedetomidine & Bupivacaine. Patients will receive intrathecal 12.5 mg isobaric bupivacaine and 15 μg Dexmedetomidine using a total volume of injectate of 2.5 ml, and intrathecal injections will be given over approximately 10 to 15 seconds.
89507041|NCT02365857|Active Comparator|Control|Bupivacaine Only. Patients will receive intrathecal 12.5 mg isobaric bupivacaine only using a total volume of injectate of 2.5 ml, and intrathecal injections will be given over approximately 10 to 15 seconds.
89507042|NCT03523507|Experimental|Active: rTMS|Participants will receive 20 bilateral treatment sessions provided over approximately a 5-week period. Daily sessions entail approximately 60 minutes of time.
89507043|NCT03523507|Sham Comparator|Sham: rTMS|Sham: Repetitive Transcranial Magnetic Stimulation; Participants will receive sham treatment designed to have similar sound and tactile sensation, without producing active stimulation.
89507044|NCT00592293|Experimental|Proton Beam Radiation|Proton Beam Radiation
89507045|NCT04640155|Other|Regular Diet|
89507046|NCT04640155|Experimental|Low FODMAP|
89507047|NCT02365935|Experimental|Group A to administer 4 cycles|In Group A, all patients received 4 cycles of adjuvant chemotherapy every three weeks according to the scheme Cisplatin 100 mg/mq and Paclitaxel 175 mg/mq.
89507048|NCT02365935|Experimental|Group B to administre 6 cycles|In Group B, all patients received instead 6 cycles of adjuvant chemotherapy every three weeks according to the same chemotherapic regimen.
89507049|NCT02205437||Controls|Healthy subjects without psychotic disorder.
89507050|NCT02205437||Drug-naive patients|Drug-naive (never medicated) schizophrenia patients.
89507051|NCT02205437||Patients responder to treatment|Patients with a good clinical response to treatment (define by a marked improvement of positive symptoms) at 3 months and at 1 year.
89507052|NCT02205437||Patients non-responder to treatment|Patients with a poor clinical response to treatment at 3 months and at 1 year.
89507053|NCT02205437||Patients with metabolic side effects|Patients with metabolic side effects associated to treatment.
89507054|NCT02205437||Patients with non-metabolic side effects|Patients with no metabolic side effects associated to treatment.
89507055|NCT02205593|Placebo Comparator|Control|patient group receiving regular follow-up visits (baseline, 3 months, 6 months, 9 months)
89507056|NCT02205593|Active Comparator|Haut Tief patient education|patient group receives the educational program with regular follow-up visits (baseline, 3 months, 6 months, 9 months).
89507057|NCT02365701|Experimental|Motilitone 30mg|Motilitone will be administered in tablet form, 3 times daily to subjects randomized to this arm of the study. Subjects will be expected to take this medication for 4 weeks.
89507058|NCT02365701|Placebo Comparator|Placebo|Placebo (same formulation as Motilitone but without the active ingredients) will be administered in tablet form, 3 times daily to subjects randomized to this arm of the study. Subjects will be expected to take this tablet for 4 weeks.
89507059|NCT02209415|Active Comparator|Standard outpatient follow-up|Outpatient clinic visits 3,6,9,12,18 and 24 mths after surgery
89507060|NCT02209415|Experimental|Intervention PET/CT and EUS|PET/CT and EUS at 3,6,9,12,18 and 24 months after surgery
89507061|NCT02365623|Experimental|TMC207 (bedaquiline) + Background Regimen (BR)|Participants will receive TMC207 (bedaquiline) 400 milligram (mg) as 4*100 mg tablets once daily 2 weeks (14 days). From Week 3, participants will receive 200 mg (2 tablets) TMC207 (bedaquiline) 3 times a week up to Week 24 along with background regimen (BR). Based on the discussion with the Pharmaceuticals and Medical Devices Agency (PMDA), the extension of 24-week TMC207 treatment with BR drugs may occur up to Week 48, under certain circumstances, such that many BR drugs which are susceptible at the beginning of the Treatment Phase show resistance during the Treatment Phase. After TMC207 is stopped, the BR will be continued up to 78 weeks after conversion or 102 weeks after day 1 (what happens first).
89507062|NCT02361957|Active Comparator|Probiotics|Multispecies probiotic product Ecologic 825, 2x10-9 colony forming units per gram, 6 grams per day.
89507063|NCT02361957|Placebo Comparator|Placebo|Similar in appearance as the probiotics, but not containing any bacteria.
89507064|NCT02221115|Other|Google Glass|Investigators using Google Glass during clinic visit
89507065|NCT02221115|No Intervention|No Google Glass|Investigator will not be using Google Glass during clinic visit
89507066|NCT02221193|Experimental|site specific vs panoral disinfection|
89507067|NCT03927261|Experimental|Dose Escalation and Dose Expansion of PRGN-3006|Participants will be treated in dose expansion phase to evaluate the safety and efficacy of the identified dose of PRGN-3006.
89507068|NCT02209493|Experimental|Food supplementation: nopales|Consumption of 2 cups/day of cooked nopales (prickly pear cactus leaves) with each of two main meals for 2 weeks
89507069|NCT02209493|Sham Comparator|Food supplementation: cucumber|Consumption of 2 cups/day peeled and chopped cucumber with each of two main meals for 2 weeks
89507070|NCT02365779|Experimental|bilateral laparoscopic salpingectomy|
89507071|NCT02221271|Experimental|NPB-01|
89507072|NCT02205671|Experimental|Intervention|Building Better Caregivers Small-group Workshop
88815954|NCT01119794|Experimental|ofatumumab and bortezomib|Ofatumumab 1000 mg IV Cycle 1 on day 1, 8, 15 and 22 Bortezomib 1.6 mg/m2 IV Ofatumumab 1000 mg IV on day 1 maintenance phase Patients will remain until progression
89507073|NCT03112707|Experimental|Study arm|1023 real world high-bleeding risk (HBR) patients with coronary artery disease (stable as well as acute coronary syndromes) who qualify for percutaneous coronary interventions will be included in the study.
89507074|NCT02209571|Experimental|Cystic Fibrosis|Breath test and venous blood markers in cystic fibrosis patients
89507075|NCT02209571|Active Comparator|Control|Breath test and venous blood markers in healthy subjects
89507076|NCT05262413|Experimental|QL1706 Plus Lenvatinib|QL1706 5mg/kg administered intravenously (IV), every 3 weeks, plus Lenvatinib 20 mg or 14mg administered orally, once daily.
89507077|NCT02704429|Experimental|PRN1008|Part A: Open-label PRN1008, 12 weeks; 12 weeks follow-up; Part B: Open-label PRN1008, 24 weeks; 4 weeks follow-up
89507078|NCT02209649|Experimental|Telmisartan and Lacidipine FDC, formulation A|
89507079|NCT02209649|Experimental|Telmisartan and Lacidipine FDC, formulation B|
89507080|NCT02209649|Active Comparator|Lacidipine and Telmisartan, mono|
89507081|NCT02361567|Active Comparator|Tramacet|Tramacet 1-2 tabs PO q4h prn
89507082|NCT02361567|Active Comparator|Percocet|Percocet (5/325) 1-2 tab PO q4h PRN
89507083|NCT02205749|Other|Study-specific consent model|• Review plain language brochure describing consent to a biobank based on the study-specific model of consent
89507084|NCT02205749|Other|Broad consent model|• Review plain language brochure describing consent to a biobank based on the broad model of consent
89507085|NCT02205749|Other|Notice consent model|• Review plain language brochure describing consent to a biobank based on the notice model of consent
89206813|NCT00271609|Other|Anaplastic Glioma (AG)|Anaplastic astrocytoma Anaplastic oligodendroglioma Anaplastic mixed oligoastrocytoma Malignant astrocytoma (not otherwise specified) 10 mg/kg intravenously over 90 minutes every 2 weeks on a 28 day cycle. First dose is given over 90 minutes and subsequent doses are given over 30 minutes.
88815955|NCT02464449|Experimental|AI CBT|AI CBT engine will make recommendations to step-down or step-up intensity of CBT FU based on what patient reports and what other similar patients report. Stepped care model.
89206814|NCT00271609|Other|Glioblastoma Multiforme (GBM)|Glioblastoma multiforme Gliosarcoma 10 mg/kg intravenously over 90 minutes every 2 weeks on a 28 day cycle. First dose is given over 90 minutes and subsequent doses are given over 30 minutes.
89206815|NCT00548847|Experimental|GM-CSF, Interferon-α-2b|
89206816|NCT00949377|Experimental|Methylnaltrexone Bromide|
89206817|NCT00949377|Placebo Comparator|Normal Saline|
89206818|NCT04090151||Austrian HIV Cohort Study (AHIVCOS)|
89206819|NCT04090151||The Australian HIV Observational Database (AHOD)|
89206820|NCT04090151||CHU Saint-Pierre|
89206821|NCT04090151||University Hospital Cologne|
89206822|NCT04090151||The EuroSIDA cohort|
89206823|NCT04090151||Frankfurt HIV Cohort Study|
89206824|NCT04090151||Georgian National AIDS Health Information System (AIDS HIS)|
89206825|NCT04090151||Modena HIV Cohort|
89206826|NCT04090151||San Raffaele Scientific Institute|
89206827|NCT04090151||Swiss HIV Cohort Study (SHCS)|
89206828|NCT04090151||Royal Free HIV Cohort Study|
89206829|NCT04090151||The ATHENA national observational HIV cohort|ATHENA: AIDS Therapy Evaluation in the Netherlands
89206830|NCT04090151||Nice HIV Cohort|
89206831|NCT04090151||Italian Cohort Naive Antiretrovirals (ICONA)|
89206832|NCT04090151||PISCIS Cohort Study|
89206833|NCT04090151||Swedish InfCare HIV Cohort|
89206834|NCT04090151||Bonn University Hospital|
89206835|NCT05350683|No Intervention|Control group|EVAR patients no ischemic preconditioning
89206836|NCT05350683|Active Comparator|Preconditioning Group|EVAR patients with remote ischemic preconditioning
89206837|NCT01070017|Experimental|Intervention: DOT-HAART|Intervention group will receive community-based monthly adherence visits, standard care, and DOT-HAART.
89206838|NCT01070017|No Intervention|No DOT-HAART|Control group receives community-based monthly adherence visits and standard care, but no DOT-HAART.
89206839|NCT00955383|Active Comparator|GSK2190915|GSK2190915 is a high affinity 5-lipoxygenase-activating protein (FLAP) inhibitor
89206840|NCT00955383|Placebo Comparator|Placebo|Matching placebo
89206841|NCT02597387|Experimental|Mitoxantrone HCL Liposome Injection|Each treatment cycle lasts for 28 days with 20mg/m2
89206842|NCT01069081|Active Comparator|arm A|docetaxel and cisplatin chemotherapy
89206843|NCT01069081|Experimental|arm B|docetaxel and cisplatin chemotherapy combined with PPI 160mg per day.
89206844|NCT01069081|Experimental|arm C|docetaxel and cisplatin chemotherapy combined with PPI 200mg per day.
89206845|NCT05350605|Experimental|Experimental: Laid back breastfeding position education group|Breastfeeding education will be given to pregnant women in the laid-back breastfeeding position group, which includes the laid back breastfeeding position with a lactation simulation model.
89206846|NCT05350605|Experimental|Experimental: Upright breastfeeding position education group|Breastfeeding education will be given to pregnant women in the upright breastfeeding position group, which includes the upright breastfeeding position with a lactation simulation model.
89507086|NCT02205827|No Intervention|Single-arm|healthy volunteers
89507087|NCT02361879|Experimental|Ulipristal acetate|Womens will be treated with 5 mg/day of oral ulipristal acetate for 3 months
89507088|NCT02361879|Active Comparator|Leuprolile acetate|women will be treated with 1 IM injection of leuprolide acetate 11,25 mg in in the luteal phase
88815956|NCT02464449|Active Comparator|Standard telephone CBT|Controls receive 10 hour-long standard telephone CBT sessions, a pedometer/log after baseline, and a Patient Handbook.
88815957|NCT02914496|Experimental|Diabetes in Balance|"The intervention consists of the manual-based CBT-group intervention Diabetes in Balance. It is given in a group format with six to ten participants and consists of 7 sessions. The sessions are given bi-weekly for two hours. Each session has a specific theme such as Stress and acceptance The life-compass; what is important in my life. The participants also conduct assignments related to the themes between the sessions. A licensed psychologist specialised in CBT and a diabetes specialist nurse, both trained in ACT-stress management will be leading the intervention group."
88815958|NCT02914496|No Intervention|Control|The control group receives regular care including regular visits at the out-patient clinic, 3-4 times per year.
88815959|NCT02464917|Experimental|Supplemental oxygen|Subjects in this arm will receive 10L/min via simple facemask
88815960|NCT02464917|No Intervention|Room air|This control arm will receive no supplemental oxygen
88815961|NCT01120808|Experimental|All Participants|Participants were registered competitors in RacingThePlanet 6 stage 7 day 155mile (250km) ultramarathon.
88815962|NCT02465073|Active Comparator|NXTSC|This group will receive the NXTSC gel only. The NXTSC wound gel and its active agents are applied on the wound bed. A synthetic microfiber dressing will be applied to the surface of the wound. Determine the effect on wound treatment outcomes using a novel antimicrobial wound gel for the treatment of infected wounds as the sole topical treatment of microbial infection at the wound site. ( NXTSC).
88815963|NCT02465073|Active Comparator|NXTSC plus SOC|This group will receive the NXTSC wound gel plus Standard of Care. The NXTSC wound gel is applied to the wound bed. Local wound management will consist of diagnosing the wound biofilm and providing specific measures to suppress the wound biofilm to allow host healing. Determine the effect on wound treatment outcomes using a novel antimicrobial wound gel for the treatment of infected wounds when this gel is used in conjunction with the current standard of care infection controls to treat microbial infection at the wound site.( Next Science Wound Gel, plus standard of care).
88815964|NCT02465073|Active Comparator|SOC|This group will receive Standard of Care only. The Standard of Care is based on wound management intervention to remove wound slough by frequent debridement. Moist interactive wound care with multiple strategies to suppress biofilm is instituted. Determine the effect on wound treatment outcomes using standard of care treatment
89507089|NCT03133429|Experimental|Patients with MER stent|Patients eligible for Carotid Artery Stenting
89507090|NCT02361645|No Intervention|Control Group|No NSAIDs were administered prior to surgery
89507091|NCT02361645|Experimental|Ketorolac eyedrops|Ketorolac 0.5% eyedrops were administered prior to surgery
89507092|NCT02361645|Experimental|Indomethacin eyedrops|Indomethacin 0.5% eyedrops were administered prior to surgery
89507093|NCT02361645|Experimental|Nepafenac eyedrops|Nepafenac 0.1% eyedrops were administered prior to surgery
89507094|NCT02361645|Experimental|Bromfenac eyedrops|Bromfenac 0.09% eyedrops were administered prior to surgery
89507095|NCT03525769||Type 2 Diabetes Mellitus|
89507096|NCT02205905|Experimental|14C PER977|Open-label, single-dose, non-randomized study of 14C PER977 in six healthy male subjects
89507097|NCT03522181|Placebo Comparator|control group|saline
89507098|NCT03522181|Experimental|GIK group|glucose-Insulin-Potassium(GIK) infusion
89507099|NCT02359461|Experimental|Stendo group|Subjects will be randomized into two groups determining the sequence: stendo then control, or control then stendo
89507100|NCT02359461|Other|control group|Subjects will be randomized into two groups determining the sequence: stendo then control, or control then stendo
89507101|NCT03695783|Experimental|Online decision aid called IBD&me|IBD&me is an online, freely available tool that allows patients to explore decision-making around biologic therapies for IBD at their own pace. It includes an educational component and an interactive exercise with a series of ratings tasks that generates a personalized preferences report for patients to share and discuss with their physician.
89507102|NCT03695783|Active Comparator|Standardized educational material|PDF file corresponding to the CCFA's online resource on biologic therapies, which is a well-researched and clearly presented overview of IBD biologic therapies, but without an active shared-decision making component.
89507103|NCT02290015|Experimental|true acupuncture|12 sessions of ACP treatment were performed twice a week. Before ACP was performed, patients were examined based on the diagnostic pattern of TCM. Then, the appropriate acupoints for treatment were selected according to the tinnitus-related syndrome. The experimental group was treated with true ACP (stimulating selected meridian points), and the control group was treated with sham-ACP (stimulating false meridian points). The patients were blinded to the identity of their treatment group. Disposable stainless steel ACP needles (0.25 x 30 mm, Dong Bang Acupuncture, Korea) were used in both groups. Needles were inserted manually at each meridian point, and the retention time was twenty minutes.
89507104|NCT02290015|Sham Comparator|sham acupuncture|The control group was treated with sham-ACP (stimulating false meridian points). Disposable stainless steel ACP needles (0.25 x 30 mm, Dong Bang Acupuncture, Korea) were used. Needles were inserted manually at each false meridian point, and the retention time was twenty minutes.
89507105|NCT02373033|Active Comparator|Intervention: Natural food folate|Food group consumed folate-rich foods (providing additional 250 μg/d folate).
88957654|NCT01985815|Experimental|VC/VS stimulation OFF followed by ON|triple blind, randomised, two periods of three months
88957655|NCT01985828|Experimental|Intermediate Risk|"Short term (4-6 months) androgen deprivation therapy (ADT) per current standard of care + CyberKnife 21 Gy (7 Gy x 3) and Prostate/SV Intensity Modulated radiation therapy (IMRT) 45-50.4 Gy~OR~Short term (4-6 months)androgen deprivation therapy + CyberKnife 36.35 Gray (7.27 Gray x 5)"
88957656|NCT01985828|Experimental|High Risk|Short or Long term (6 months - 3 years) androgen deprivation therapy (ADT) + 45-50.4 Gy and Pelvis Intensity Modulated radiation therapy (IMRT) per current standard of care + 21 Gy (7 Gy x 3) CyberKnife boost
88957657|NCT01985841|Experimental|Bevacizumab/FEC/Docetaxel|Bevacizumab plus 5-Fluorouracil/Epirubicin/Cyclophosphamide (FEC) -> Bevacizumab plus Docetaxel
88957658|NCT01985854|Active Comparator|Propofol|Propofol target-controlled infusion will be kept 2-4μg /ml plasma concentration throughout procedure.
88957659|NCT01985854|Experimental|Desflurane|After taking off the electrophysiological monitoring from the patients, discontinue propofol and start desflurane from 6% (dialed concentration) at flow rate of 4L/min for 2 minutes in desflurane group. When achieve end tidal concentration of 4-5%, decrease the flow rate to 2L/min.
88957660|NCT01985880||Hunner's ulcer interstitial cystitis|Hunner's ulcer interstitial cystitis
88957661|NCT01985880||non-ulcer interstitial cystitis|non-ulcer interstitial cystitis
88957662|NCT01985880||Control|Control
88957663|NCT01985893|Other|Lapatinib plus trastuzumab|Drug intervention: Lapatinib IMP, Trastuzumab on prescription. Lapatinib 1000 mg p.o. once daily for 21 days. Trastuzumab i.v. infusion 8 mg/kg loading dose; 6 mg/kg on Day 1 of each subsequent 3 weekly cycle.
88957664|NCT01985893|Other|Lapatinib plus Capecitabine|Drug intervention: Lapatinib and Capecitabine on prescription. Lapatinib 1250 mg p.o. once daily. Capecitabine 2000 mg/m2 p.o. in two divided doses on days 1 to 14 of a 21 day cycle.
88957665|NCT01985906|Experimental|Pararenal aortic aneurysm|"The aneurysm is adjacent to (proximal/distal landing zone < 15mm) or involving vital branches, including the celiac artery, superior mesenteric artery, or renal artery.~The intervention is endovascular management of the aneurysms with multiple overlapping uncovered stents"
88957666|NCT01985945|Other|Yoga|
88957667|NCT01985945|No Intervention|Without Yoga|
89032914|NCT02925897|No Intervention|Control|The participants will receive their usual treatment from nurses who have had no additional training in behaviour change and motivational interviewing.
89507106|NCT02373033|Active Comparator|Intervention: Folic acid|Folic acid group received a folic acid supplement (providing additional 500 μg/d folic acid).
89507107|NCT02373033|Placebo Comparator|Intervention: Control|Control group received apple juice containing no folate or folic acid every day.
89507108|NCT05186129|Experimental|Clopid® 75 mg(Clopidogrel)Tablet of Ferozsons Laboratories Ltd. Pakistan|Single dose of Clopid® 75 mg Tablet administered under fasting condition
89507109|NCT05186129|Active Comparator|Plavix® 75mg Tablet of Sanofi Winthrop Industrie France for Sanofi Pakistan.|Single dose of Plavix® 75 mg Tablet administered under fasting condition
89507110|NCT02361723|Experimental|ovarian cancer, fallopian cancer, or primary peritoneal cancer|60mg BID oral.
89507111|NCT02361723|Experimental|Breast Cancer|60mg BID Ora
89507112|NCT02361723|Experimental|Prostate Cancer|60mg BID Oral
89507113|NCT02361723|Experimental|Small Cell Lung Cancer|60mg BID Oral
89507114|NCT02361723|Experimental|Gastric Cancer|60mg BID Oral
89507115|NCT03596281|Experimental|Cohort A|
89507116|NCT03596281|Experimental|Cohort B|
89507117|NCT02221505|Experimental|LOP628 - Solid Tumor|with LOP628
89507118|NCT02221505|Experimental|LOP628 - AML|With LOP628
88957668|NCT01986023|Experimental|SMS Short Message Service Arm plus Prescription|"Intervention is as follows: Drug reminder SMS will be sent to the participants in the intervention arm customised to their stroke prescription. These SMS will be interactive in a way that the participants will have to answer back if they have taken their medicine or not in a Yes/No format. Moreover behaviour change SMS will also be sent to the intervention arm twice weekly. In addition , Participants will be encouraged to take medication using a taxonomy of behavioral change intervention techniques."
88957669|NCT01986023|No Intervention|Standard Prescriptions and Counselling|The usual care arm will undergo standard treatment and counselling regarding their treatment and the education regarding their medication as per standard of care. They will receive a standard written prescription and no SMS
88957670|NCT01986036|Sham Comparator|CONTROL|Control breakfast low in protein and calcium. Porridge-based breakfast.
88957671|NCT01986036|Active Comparator|PROTEIN|High-protein breakfast.
88957672|NCT01986036|Active Comparator|CALCIUM|High-calcium breakfast.
88957673|NCT01986036|Experimental|PRO-CAL|High-protein and calcium breakfast.
88957674|NCT01986049|Experimental|Bupivicaine 0.5%|Drug Bupivacaine 0.5%
88957675|NCT01986049|Experimental|Bupivicaine 0.25%|Drug Bupivacaine 0.25%
89507119|NCT02221505|Experimental|LOP628 - Solid Tumor Expansion|With LOP628
89507120|NCT02038803||Adults- Cystic Fibrosis|Adults with cystic fibrosis who have respiratory colonization with Pseudomonas Aeruginosa. The actual study will involve instructing adult patients with CF on the use of a new form of Tobramycin for inhalation (powder) and then assessing this new form of TOBI podhaler vs the old TOBI solution related to patient preference on use, time involved in taking the new medication vs the old, and impact on their pulmonary function and subsequent exacerbation rate plus quality of life.
89507121|NCT05172167||Early vaccinated against COVID-19|80 subjects with less than 4 months after being fully vaccinated against COVID-19
89507122|NCT05172167||Late vaccinated against COVID-19|80 subjects with more than 4 months after being fully vaccinated against COVID-19
89507123|NCT05172167||COVID-19 infection|40 patients diagnostic of COVID-19
89507124|NCT03583879|Experimental|Exoskeleton exercise|8-week exercise program using the exoskeleton
89507125|NCT03583879|Active Comparator|Standard exercise|8-week exercise program not using the exoskeleton
89507126|NCT03583879|Placebo Comparator|No exercise|8-weeks of no treatment (wait-list control)
88957676|NCT01986049|Placebo Comparator|Normal Saline|Saline Normal
89507127|NCT02361489|Active Comparator|Titration Algorithm A|All patients that are initiated on a V-Go 20 will have a starting bolus dose of 6 clicks (12 units) during the day and all patients who are initiated on a V-Go 30 will have a starting bolus dose of 9 clicks (18 units) during the day. All patients randomized to Algorithm A will use a fixed starting dose of either 2 clicks per meal (if on the V-Go 20) or 3 clicks per meal (if on the V-Go 30).
88957677|NCT01986088|Placebo Comparator|Placebo|
88957678|NCT01986088|Experimental|Eletriptan 40 mg|
88957679|NCT01986088|Experimental|Eletriptan 80 mg|
89507128|NCT02361489|Active Comparator|Titration Algorithm B|All patients that are initiated on a V-Go 20 will have a starting bolus dose of 6 clicks (12 units) during the day and all patients who are initiated on a V-Go 30 will have a starting bolus dose of 9 clicks (18 units) during the day. All patients randomized to Algorithm B will have 50% of their initial bolus dose given at the largest meal with less bolus insulin at the other meals as noted below:
89507129|NCT02209727|Experimental|131I-Sibrotuzumab|single therapy dose administered over 60 minutes at week 4
89507130|NCT03547453||Regular Menstrual Cycles|Women will be assigned to this category if they report a history of regular menstrual cycles (every 21 to 35 days). Recruitment will be targeted to obtain 20 lean (BMI<25 kg/m2) and 20 overweight or obese (BMI>24.9kg/m2) women in each of the following age groups: 18-24y (early), 25-34y (mid), ≥35y (later adulthood).
89507131|NCT03547453||Polycystic Ovarian Syndrome|Women will be assigned to this category if they have clinical or biochemical androgen excess and report a history of irregular menstrual cycles (<21 days or >35 days), including women with a pre-existing diagnosis of PCOS. Recruitment will be targeted to obtain 20 lean (BMI<25kg/m2) and 20 overweight or obese (BMI>24.9kg/m2) women in each of the following age groups: 18-24y (early), 25-34y (mid), ≥35y (later adulthood).
88957680|NCT01986088|Experimental|Sumatriptan 50 mg|
88957681|NCT01986088|Experimental|Sumatriptan 100 mg|
88957682|NCT01986127|Experimental|Adalimumab|single administration of Adalimumab 80mg diluted in 5ml saline
88957683|NCT01986127|Placebo Comparator|saline|5 ml of saline
88957684|NCT01986153||Home parenteral nutrition patients|Patients who receive home parenteral nutrition.
88957685|NCT01986153||Healthy controls|Those who don't receive home parenteral nutrition and consume a normal diet.
88957686|NCT01986166|Experimental|MEHD7945A + Cobimetinib - Stage 1|Patients will receive MEHD7945A 1100 milligrams (mg) intravenous (IV) infusion every 2 weeks (q2w) in combination with cobimetinib. Cobimetinib will be administered at a starting dose of 80 mg oral tablet q2w. Cobimetinib doses will be escalated to establish maximum tolerated dose (MTD) of MEHD7945A+cobimetinib combination for Stage 2.
88957687|NCT01986166|Experimental|MEHD7945A + Cobimetinib - Stage 2 (CRC)|CRC patients will receive MEHD7945A in combination with cobimetinib until disease progression or unacceptable toxicity. The doses and schedule of the combination treatment will be according to the MTD established in Stage 1.
88957688|NCT01986166|Experimental|MEHD7945A + Cobimetinib - Stage 2 (NSCLC)|NSCLC patients will receive MEHD7945A in combination with cobimetinib until disease progression or unacceptable toxicity. The doses and schedule of the combination treatment will be according to the MTD established in Stage 1.
88957689|NCT01986179|Active Comparator|Telephone Interpretation|These families will be assigned to use telephone interpretation throughout the ED visit.
88957690|NCT01986179|Experimental|Video Interpretation|These families will be assigned to use video interpretation throughout the ED visit.
88957691|NCT01986192|Experimental|rivaroxaban|Rivaroxaban 15mg bid for 3 weeks and 20mg qd for 6 months
88957692|NCT01986192|Active Comparator|warfarin|Enoxaparin 1mg/kg bid overlapping with warfarin (target PT INR 2.0-3.0) for 6 months
88957693|NCT01986218|Experimental|Arm A: Dose Escalation (BMS-986115)|Continuous daily dosing until disease progression or unacceptable toxicity
88957694|NCT01986218|Experimental|Arm A: Dose Expansion (BMS-986115)|Continuous daily dosing until disease progression or unacceptable toxicity
88957695|NCT01986218|Experimental|Arm B: Dose Escalation (BMS-986115)|Twice weekly dosing until disease progression or unacceptable toxicity
88957696|NCT01986218|Experimental|Arm B: Dose Expansion (BMS-986115)|Twice weekly dosing until disease progression or unacceptable toxicity
88957697|NCT01986244||STAR Total Ankle Replacement|Procedure: Total Ankle Replacement Surgery using the STAR
88957698|NCT01986244||Salto Talaris Total Ankle Replacement|Procedure: Total Ankle Replacement Surgery using the Salto Talaris
88957699|NCT01986244||In-Bone Total Ankle Replacement|Procedure: Total Ankle Replacement Surgery using the In-Bone
88957700|NCT01986257|Experimental|Emotion Regulation Group Therapy (ERGT).|
88957701|NCT01986270|Placebo Comparator|Placebo|
89507132|NCT02359149|Experimental|nurse|intravitreal injections with anti-VEGF agents given by a nurse
89507133|NCT02359149|Active Comparator|physician|intravitreal injections with anti-VEGF agents given by a physician
88957702|NCT01986270|Experimental|Eletriptan 40 mg|
89507134|NCT05168891|Experimental|Test group (TG)|Patients will receive professional supragingival teeth/implant prophylaxis, oral hygiene instructions, and implant-supported prosthesis corrections if needed. After 1 week, peri-implant non-surgical therapy combined with antibiotic regimen consisting on metronidazole 500 mg every 8 hours for 7 days will be performed. Finally, the patients will be enrolled in a peri-implant maintenance therapy (PIMT) program every 3 months.
89507135|NCT05168891|Experimental|Control group (CG)|Patients will receive professional supragingival teeth/implant prophylaxis, oral hygiene instructions, and implant-supported prosthesis corrections if needed. After 1 week, peri-implant non-surgical therapy combined with antibiotic regimen consisting on metronidazole 500 mg every 8 hours for 7 days will be performed. After one month, the regenerative surgical therapy will be performed as it follows: the intrabony component of the defect will be filled with a xenograft and covered with a collagen membrane allowing a non-submerged healing. Finally, the patients will be enrolled in a PIMT program every 3 months.
89507136|NCT03113097|Active Comparator|Good-quality embryo transfer|Women who had only good-quality embryo transfer
89507137|NCT03113097|Active Comparator|good- and poor-quality embryo transfer|Women who had both good- and poor-quality embryo transfer
89507138|NCT02209805|Experimental|BIRB 796 BS, low dose|
89507139|NCT02209805|Experimental|BIRB 796 BS, high dose|
89507140|NCT02209805|Placebo Comparator|Placebo|
89507141|NCT02209805|Experimental|BIRB 796 BS, medium dose|
89507142|NCT02290093|Active Comparator|Standard full-volume PEG|
89507143|NCT02290093|Experimental|Split-dose full-volume PEG|
89507144|NCT02290093|Experimental|Split-dose low-volume PEG|
89507145|NCT02358837||Conventional Sonography|Conventional Sonography to detect breast lesion
89507146|NCT02358837||Ductosonography Technique|Ductosonography Technique to detect breast lesion
89507147|NCT02221583|Experimental|Group 1|Astagraf XL + Mycophenolate mofetil then cross over to Prograf + Mycophenolate
89507148|NCT02221583|Experimental|Group 2|Prograf + Mycophenolate mofetil then cross over to Astagraf XL + Mycophenolate
89507149|NCT03112941|Experimental|control group|Patients with traumatic incomplete spinal cord injury (SCI) in the control group are treated with pedicle screw fixation and decompressive laminectomy.
89507150|NCT03112941|Experimental|hyperbaric oxygen group|Patients with traumatic incomplete spinal cord injury (SCI) in the hyperbaric oxygen group are treated with pedicle screw fixation and decompressive laminectomy, and are given 0.2 MPa hyperbaric oxygen (HBO), once a day, 10 times as a course, with 5-7 days of resting between two courses, totally four courses.
89507151|NCT02361333|Experimental|Teaching Intervention|Patients will be taught how to install and use a remote monitor.
89507152|NCT02361333|No Intervention|No Intervention|Patients will not be taught how to install and use a remote monitor
89507153|NCT02290171|Active Comparator|Intervention group|The intervention groups start the intervention 6 months ahead of the control group.
89507154|NCT02290171|No Intervention|Delayed intervention group|The control groups will start intervention with 6 months delay
89507155|NCT02751359|Active Comparator|Active CBD|Each subject will receive each active dose of cannabidiol, one active dose per 3 of the 4 study days. The active cannabidiol doses include 200, 400 and 800 mg of cannabidiol.
89507156|NCT02751359|Placebo Comparator|Placebo|On 1 of the 4 study days, participants will receive placebo cannabidiol (0 mg)
89507157|NCT04465825|Active Comparator|Interspersing HITT in exercise|We will test whether introducing HITT into an acute exercise bout will increase overall energy expenditure or time to fatigue.
89507158|NCT04465825|No Intervention|Acute exercise bout with no HITT|Exercise will occur at 50% peak without introducing HITT.
89507159|NCT02358993|Experimental|Methenamine|Methenamine hippurate is a medication that exhibits antibacterial activity by converting to formaldehyde in the presence of acidic urine. It is currently FDA approved for the prophylaxis of recurrent urinary tract infections. It has been previously used in studies for prevention of UTI after gynecologic surgery. Dosage will be methenamine hippurate 1g, 1 tablet by mouth every 12 hours for 24 hours (total of two doses), with the first dose taken at least one hour prior to catheter removal.
89507160|NCT02358993|Active Comparator|Ciprofloxacin|Ciprofloxacin is a commonly used antibiotic commonly used for prevention of UTI after catheterization. It belongs to a class of antibiotics known as the fluoroquinolones. Dosage will be ciprofloxacin 500 mg, 1 tablet by mouth every 12 hours for 24 hours (total of two doses), with the first dose taken at least one hour prior to catheter removal.
89507161|NCT05262179|Experimental|CTO0101|
89507162|NCT05262179|Placebo Comparator|Placebo (Vehicle)|
89507163|NCT03523195|Active Comparator|Arm 0 (written information)|Participants wear Fitbit and receive written information on healthy exercise and diet recommendations.
89507164|NCT03523195|Experimental|Arm I (exercise program)|Participants complete exercise program including aerobic and resistance exercises over 60 minutes 3 times per week for 12 weeks. Exercise is supervised all 3 times during weeks 1-2. During weeks 3-12, exercise is supervised 2 times a week, with home-based coaching for an additional 60 minutes a week.
89507165|NCT04059445|Experimental|Regenerative therapy w/BCP and collagen membrane|In this arm, treatment of furcation grade II defects includes open flap debridement and regenerative therapy with biphasic calcium phosphate (BCP) and collagen membrane.
89507166|NCT04059445|Active Comparator|Regenerative therapy w/BCP and enamel matrix proteins|In this arm, treatment of furcation grade II defects includes open flap debridement and regenerative therapy with biphasic calcium phosphate (BCP) and enamel matrix proteins.
89507167|NCT02361099|Experimental|Monitoring by SENTINEL application|Patients randomized to this arm will connect once a week to SENTINEL application to do a self-evaluation of several symptoms. A CT- scan will be scheduled only when there is an alert of the application.
89507168|NCT02361099|No Intervention|Conventional Monitoring|Patients randomized to this arm will have a CT-scan every 3 months.
89507169|NCT02298673||Observation|Patients with Mucolipidosis Disorder type I,II,III or IV or high-grade suspicion for Mucolipidosis Disorder type I,II,III or IV
89507170|NCT02209883||Group normal|The patients which have not clinical diagnosis of chronic obstructive lung disease.
89507171|NCT02209883||Group COPD|The patients which have chronic obstructive lung disease in clinical evaluation
89507172|NCT02361255||Drug-induced parkinsonism|subjects with drug-induced parkinsonism
89507173|NCT02361255||antipsychotic treated non-parkinsonian control|subjects treated with antipsychotic but without parkinsonism
89507174|NCT02290249|Active Comparator|normal airway|İntubation with glidescope or airtraq in normal airway
89507175|NCT02290249|Active Comparator|tongue edema|intubation with glidescope or airtraq in tongue edema simulation
89507176|NCT02290249|Active Comparator|face-to-face|intubation with glidescope or airtraq in face-to-face intubation
89507177|NCT02224859|Other|Safety|"Following an initial examination of the scalp and head for baseline evidence of skin integrity (intact, without breaks, lacerations, etc.) and appearance (healthy/normal, no erythema/irritation, etc.) the HCP will place the CSD on the patient and secure the attached Velcro strap to hold the device in place~At specific time points (approximately 15 minutes, 1 hour, 3 hours and 6 hours) the HCP (through human intervention)will remove the CSD for examination and completion of the Skin Assessment Scale based on the appearance of the patient's scalp and adjacent areas of the head. Additionally, the patient's head will be observed for excessive scalp sweating/moisture accumulation."
89507178|NCT03160677|Experimental|Intensive blood pressure management|
89507179|NCT03160677|Active Comparator|Standard blood pressure management|
89507180|NCT02221895|Experimental|Early Follow-up|Postpartum follow up appointment 2-3 weeks after delivery
89507181|NCT02221895|Active Comparator|Traditional Follow-up|Postpartum follow up 6-8wk after delivery (current clinical standard)
89507182|NCT02358915|Experimental|Peri-auricular muscles voluntary contraction training paradigm|The whole training paradigm consists of two steps. At the first step of training, the electrical stimulation (FastStart neuromuscular electrical stimulator) will be applied to facilitate the voluntary contractions of the ear muscles, and the motion of the outer ear in two directions (up/down, forward/backward) will be videotaped and played back to the participants so that they can get real-time visual feedback about their ear movement. At the second step of training, surface EMG electrodes will be placed on the skin around participants' ears. During the training, they are required to move a cursor to a specific target that will randomly appear on the computer screen. The cursor will be controlled by the electrical signal from the contraction of their bilateral peri-auricular muscles. In the computer game, contraction of the left ear muscles will move the cursor to the left side and contraction of your right ear muscles will move the cursor to the right side.
89507183|NCT02221973|Experimental|milk with 1.2g/d sterols and 8g/d hawthorn powder|
89507184|NCT02221973|Experimental|milk with 1.8g/d sterols and 8g/d hawthorn powder|
89507185|NCT02221973|Active Comparator|milk without sterols and hawthorn powder|
89507186|NCT02359071||Handovers with lower durations|equal or lower than 20 minutes
89507187|NCT02359071||handovers with higher durations|Higher than 20 minutes
89507188|NCT02358759|Active Comparator|Giant Oocytes after ICSI|abnormally produced oocyte after ART or Controlled ovarian stimulation. Correction of abnormally fertilized oocytes using nucleus removal.
89507189|NCT02358759|Active Comparator|3PNs zygotes developed after ICSI|Abnormally developed embryos these produced 3PNs. Correction of abnormally fertilized oocytes using nucleus removal.
88957703|NCT01986270|Experimental|Eletriptan 80 mg|
88957704|NCT01986270|Experimental|Sumatriptan 25 mg|
88957705|NCT01986270|Experimental|Sumatriptan 50 mg|
89507190|NCT02209961||glaucoma and ocular hypertension|glaucoma and ocular hypertension
89507191|NCT05092841|Experimental|PXT3003|Liquid oral solution, 10 mL twice a day, morning and evening with food
89507192|NCT05092841|Placebo Comparator|PXT3003 Placebo|Liquid oral solution, 10 mL twice a day, morning and evening with food
89507193|NCT02358447||SPECT/CT before/after navigated TKR|SPECT/CT in patients before and after navigated TKR (assessment of bone tracer uptake, 3D CT component position)
89507194|NCT02358447||SPECT/CT before/after conventional TKR|SPECT/CT in patients before and after conventional TKR (assessment of bone tracer uptake, 3D CT component position)
89507195|NCT02224937|Experimental|Melatonin:Melatonincreme 12,5%|Application of melatonincream 12,5% on 80% of the body-surface at start of investigation.
89507196|NCT02224937|Placebo Comparator|Placebo|Application of placebo cream on 80% of the body-surface at start of investigation.
89507197|NCT02210429|Active Comparator|IV Opioids|
89507198|NCT02210429|Active Comparator|Supraclavicular Single-Shot Block|
89507199|NCT02210429|Active Comparator|Supraclavicular Catheter|
89507200|NCT02210429|Active Comparator|Supraclavicular Angiocath|
89507201|NCT02373111|Active Comparator|Isoflavone and Astaxanthin|Each subject takes one active tablet per day for 24 weeks. Each tablet contains isoflavone 27mg and astaxanthin 4mg.
89507202|NCT02373111|Placebo Comparator|Placebo|Each subject takes one placebo tablet per day for 24 weeks.
89507203|NCT02225015|Active Comparator|FTGC at 1 month|Individuals randomized to the intervention group will receive a tailored cancer risk assessment via a follow-up telephone genetic counselling (FTGC) session within one month of study enrollment.
89507204|NCT02225015|No Intervention|Standard Care + FTGC in 12 months|Individuals randomized to the intervention group will receive a tailored cancer risk assessment at 12 months following study enrollment
89507205|NCT02358291|Active Comparator|open discectomy|patients diagnosed as lumbar disc herniation undergoing open simple discectomy(OD)
89507206|NCT02358291|Active Comparator|microendoscopic discectomy|patients diagnosed as lumbar disc herniation undergoing microendoscopic discectomy(MED)
89507207|NCT02358291|Active Comparator|transforaminal endoscopic discectomy|patients diagnosed as lumbar disc herniation undergoing transforaminal endoscopic lumbar discectomy(TELD)
89507208|NCT02290327|Placebo Comparator|Placebo|50 ml of 0.9% Normal Saline Intravenously once daily
89507209|NCT02290327|Active Comparator|Pantoprazole|Pantoprazole 40 mg in 50 ml 0.9% Normal Saline Intravenously once daily
89507210|NCT02750813|Other|DT1, then AO1D|Delefilcon A contact lenses worn first, followed by senofilcon A contact lenses. Each product worn bilaterally (in both eyes) for 14 days in a daily wear, daily disposable modality.
89507211|NCT02750813|Other|AO1D, then DT1|Senofilcon A contact lenses worn first, followed by delefilcon A contact lenses. Each product worn bilaterally for 14 days in a daily wear, daily disposable modality.
89507212|NCT02358213|Other|Procedure|5 ultrasounds were done on 20 patients by 5 different sonographers
89507213|NCT02222051|Experimental|Tai Chi|Simplified 24 Yang Style 12 weeks, 1x/week, 60-90 minutes
89507214|NCT02222051|Active Comparator|Neck exercise|conventional neck exercises 12 weeks, 1x/week, 60 min stretching and strengthening, neck education
89507215|NCT02222051|No Intervention|Usual care|Usual care, no specific study intervention this group is offered Tai Chi or neck exercises at the end of the study
89507216|NCT02372955|Experimental|dapagliflozin 10 mg daily|dapagliflozin, 10 mg daily for 16 weeks
89507217|NCT02372955|Active Comparator|glimpiride|glimpiride 4 mg daily for 16 weeks
89507218|NCT02211053|Active Comparator|Levothyroxine|Levothyroxine infusion 20 mg IV bolus then 10 mg/h infusion
89507219|NCT02211053|Placebo Comparator|Placebo|Infusion matched to intervention arm
89507220|NCT02358057|Experimental|Dexmedetomidine and Alfentanil|"Patients included in the study will receive an injection of dexmedetomidine via a TIVA Injectomat Agilia, specially programmed for the injection of dexmedetomidine.~At time zero, the patient will receive a bolus 1 mcg/ kg of dexmedetomidine during 10 minutes.~Patients over 65 years will receive a bolus of 0.5 mcg/kg of dexmedetomidine during 10 minutes.~Afterwards, the patient will receive a continuous injection of 0.6 mcg/kg/h of dexmedetomidine~Patients will also receive a dose of alfentanil 1 mcg /kg, 1 minute before the technical act.~A new alfentanil dose of 0.5 mcg / kg may be injected if pain reported by the patient corresponds to an EN > 50.~The maximum dose of alfentanil the patient can receive is 5 mcg / kg."
89507221|NCT02225093|Experimental|1:Caffeine, Dextromethorphan and Enzalutamide|1-sequence crossover here
89507222|NCT02372721||Sepsis with Severe AKI|"History of a pediatric admission with sepsis related AKI which lead to classification of injury or failure. This group will have urinary and serum studies to measure glomerular filtration rate, renal plasma flow followed by cardiovascular assessments using blood pressure monitoring, peripheral arterial and applanation tonometry."
89507223|NCT02372721||Sepsis without AKI|History of a pediatric admission with sepsis which lead to no classification of AKI. This group will have urinary and serum studies to measure glomerular filtration rate, renal plasma flow followed by cardiovascular assessments using blood pressure monitoring, peripheral arterial and applanation tonometry.
89507224|NCT02372721||Control|No history of an admission for AKI. This group will have urinary and serum studies to measure glomerular filtration rate, renal plasma flow followed by cardiovascular assessments using blood pressure monitoring, peripheral arterial and applanation tonometry.
89507225|NCT02357667||Exposed cases|African American women with concern for severe preterm (37 weeks gestation) preeclampsia who are admitted to the inpatient obstetrical unit at HUP.
89507226|NCT02357667||Unexposed controls|African American women without preeclampsia or medical comorbidity who are matched by gestational age, maternal age, and BMI in the outpatient setting.
89507227|NCT02212535|Experimental|Plerixafor|Adult patients affected by major sickle cell syndrome (SS or Sβ thalassemia)
89507228|NCT02372487|Active Comparator|fluid therapy and sildenafil citrate|Patients in first group will receive 2 liters of isotonic saline through intravenous infusion over a period of 4 hours using a rate of 250 ml per hour in addition to sildenafil citrate therapy (Viagra®) as 25 mg 3 times daily during hospitalization. After discharge patients in first group will be asked to continue sildenafil citrate therapy (Viagra®) as 25 mg 3 times daily plus a daily oral fluid intake of 2 liters
89507229|NCT02372487|Active Comparator|fluid therapy|Patients in second group will receive 2 liters of isotonic saline through intravenous infusion over a period of 4 hours using a rate of 250 ml per hour. After discharge patients wil be asked to have 2 liters daily oral fluid
89507230|NCT02588885|Experimental|Trauma-sensitive Care|Participants will attend 7, one-hour psychotherapy sessions, which will be concurrent with trauma-sensitive care at physical therapy appointments.
89507231|NCT02213861|Experimental|1.0% SHAPE Gelled Solution once daily|
88957706|NCT01986283|Placebo Comparator|Treatment A|Placebo solution +placebo capsule + placebo capsule chewed.
89507232|NCT02213861|Experimental|0.5% SHAPE Gelled Solution twice daily|
89206847|NCT05350605|No Intervention|No Intervention: Control Group|Mothers in the control group will receive routine hospital care
88957707|NCT01986283|Experimental|Treatment B|PF-00345439 taken whole + placebo solution + placebo chewed
89206848|NCT04019795|Sham Comparator|Non-Active REVIAN (Sham) Cap 100|Sham (Control) Group
89507233|NCT02213861|Experimental|1.0% SHAPE Gelled Solution twice daily|
89507234|NCT04478799|Experimental|Group A (Transcutanous Posterior Tibial Nerve Stimulation)|Patients belonging to the group A received Transcautanoues posterior tibial nerve stimulation plus diet and Kegel exercises
89507235|NCT04478799|Sham Comparator|Group B (Sham Control)|Patients belonging to the group B received Sham Transcautanoues posterior tibial nerve stimulation plus diet and Kegel exercises
89507236|NCT05057195|Experimental|Interstitial radiation therapy|Duration: 11 days
89507237|NCT05057195|Active Comparator|Postoperative external beam therapy, on the bed of the removed tumor|Duration: 4 weeks
89507238|NCT02361177|Experimental|oxytocin|Intranasal 24 IU oxytocin self-administration.
89507239|NCT02361177|Placebo Comparator|placebo|Intranasal placebo. 125 mg of 0.5% cholorobutanol to 50 ml saline, with approximately 5 pH. The solution will then be sterilized using a 0.22 micron filter.
89507240|NCT05055713|Experimental|Secondary prevention-1|Endoscopic therapy+ beta blockers
89507241|NCT05055713|Experimental|Secondary prevention-2|Endoscopic therapy+ PSE+beta blockers
89507242|NCT05055713|Experimental|Primary prevention-1|Endoscopic therapy
89507243|NCT05055713|Experimental|Primary prevention-2|Endoscopic therapy+ PSE
89507244|NCT05055713|Experimental|Acute bleeding-1|Endoscopic therapy+somatostatin
89507245|NCT05055713|Experimental|Acute bleeding-2|Endoscopic therapy+PSE+somatostatin
89507246|NCT02360865|Experimental|COPD|Acute exercise bouts
89507247|NCT02360865|Active Comparator|Healthy|Acute exercise bouts
89507248|NCT02225327|Active Comparator|Fluad alone|56 Fluad recipients: one vaccine injection administered on Day 0
89507249|NCT02225327|Active Comparator|Fluad and PPV23 on the different arms|56 concomitant Fluad-PPV23 recipients on the different arms: one dose of each vaccine administered on Day 0
89507250|NCT02225327|Active Comparator|Fluad and PPV23 on the same arm|56 concomitant Fluad-PPV23 recipients on the same arm with 1 inch distance: one dose of each vaccine administered on Day 0
89507251|NCT02225327|Active Comparator|PPV23 alone|56 PPV23 recipients: one vaccine injection administered on Day 0
89507252|NCT02357745||Pre-menopausal with periodontitis|non surgical periodontal therapy ( scaling and root planing)
89507253|NCT02357745||Post-menopausal with periodontitis|non surgical periodontal therapy ( scaling and root planing)
89507254|NCT02214641|Experimental|Lifestyle intervention|Resilient, Empowered, Active Living (REAL) Diabetes
89507255|NCT02214641|Active Comparator|Information Control|Participants will receive a packet of informational materials about diabetes, and receive periodic follow-up phone calls to match for attention dose.
89507256|NCT02360787|Experimental|Energy restriction|Energy restriction (-500 kcal/day) (N=40), where participants will receive dietary counseling to reduce energy intake to achieve 500 kcal/day deficits to support weight loss. Participants will also be asked to avoid all nuts during the intervention period.
89507257|NCT02360787|Experimental|Energy restriction with almonds|Energy restriction (-500 kcal/day) with dry-roasted, lightly salted almonds supplying 15% of estimated energy requirement. Participants will receive dietary counseling to reduce energy intake to achieve 500 kcal/day deficits. Energy from almonds will be accounted for during dietary modeling so that a 500 kcal/day deficit is achieved.
89507258|NCT02225483||Hemophilia A|Boys with Factor VIII coagulant activity less than or equal to 1%.
89507259|NCT02225561|Experimental|Intervention arm|Pharmaco- mechanical optimization
88957708|NCT01986283|Experimental|Treatment C|PF-00345439 chewed + placebo solution + placebo taken whole
88957709|NCT01986283|Active Comparator|Treatment D|Oxycodone HCl immediate-release 40 mg tablets (eg, 2 x 5 mg + 1 x 30 mg) + placebo taken whole + placebo chewed
88957710|NCT01986296|Experimental|ExAblate Treatment|
89206849|NCT04019795|Experimental|Active REVIAN Cap 101|(625 nm and 660 nm)
89206850|NCT04019795|Experimental|Active REVIAN Cap 102|(425 nm)
89206851|NCT04019795|Experimental|Active REVIAN Cap 103|(425 nm, 625 nm and 660 nm)
89206852|NCT01581463|Active Comparator|Liothyronine, Sodium|Healthy adults.
89206853|NCT00955461|Experimental|Laser treatment|Split-Face Comparison of an Electro-optic Q-Switched Nd: YAG Laser to a Fractionated Laser
89206854|NCT00917033|Experimental|GlideScope|Orotracheal intubation using the GlideScope videolaryngoscope
89206855|NCT00917033|Active Comparator|Macintosh|Orotracheal intubation using the Macintosh direct laryngoscope
89206856|NCT00949455|Experimental|Arm I|Patients receive oral lapatinib ditosylate once daily in the absence of disease progression or unacceptable toxicity.
89206857|NCT00949455|Placebo Comparator|Arm II|Patients receive oral placebo once daily in the absence of disease progression or unacceptable toxicity.
89507260|NCT02225561|Active Comparator|Mechanical optimization only|Mechanical optimization only
89507261|NCT02357823||Group 1|Immunological and microbiological status of HIV- positive adults with pneumococcal vaccinal status of 2 PCV13 doses received from more than 3 years that have prescription for a single booster dose of PCV13.
89507262|NCT02357823||Group 2|Immunological and microbiological status of HIV- positive adults with pneumococcal vaccinal status of 1 PPV23 dose received from more than 3 years that have prescription to receive 2 doses (priming + boost) of PCV13.
89507263|NCT02357823||Group 3|HIV- positive adults that have never received a pneumococcal vaccine (naive) and have a CD4+ cell count < 200 cells/ul that have prescription to be primed with a single dose of PCV13 then boosted with a single dose of PPV23.
89507264|NCT02357823||Group 4|Immunological and microbiological status of HIV- positive adults that have never received a pneumococcal vaccine (naive) and have a CD4+ cell count > 200 cells/ul that have prescription to be primed with a single dose of PCV13 then boosted with a single dose of PPV23.
89507265|NCT02357823||Group 5|Immunological and microbiological status of HIV- positive adults with pneumococcal vaccinal status of 1 PPV23 dose received from more than 3 years and that that have prescription to receive a single dose of PCV13.
89507266|NCT02222285|Placebo Comparator|Sequence 3: placebo/placebo|Placebo/placebo consists of placebo for 7 weeks followed by 7 weeks of placebo treatment
89507267|NCT02222285|Active Comparator|Sequence 2: placebo/ Treatment|Sequence 2: placebo/ Treatment , consists of placebo for 7 weeks followed by 7 weeks of treatment with Vayarin_005
89507268|NCT02222285|Active Comparator|Sequence one: Treatment/Treatment|Treatment/Treatment- consists of PS_005 for 7 weeks followed by 7 weeks of additional treatment with Vayarin_005
89507269|NCT04439097|Experimental|Experimental Group|"Patients allocated to the intervention group will perform a MPEP during 6 months, with a frequency of 3 sessions per week, and approximately 45-50 minutes of duration each session. In addition, they will have a Mediterranean Diet.~The patients in the MPEP will be carried out in small groups of 5-8 people. Structure of sessions: 3 different parts: an initial warm-up, a main part and a final cool-down and relaxation."
88957711|NCT01986309|Active Comparator|Group L|Group L Lidocaine load dose 1.5 mg / kg over 5 minutes, followed by continuous infusion of 2 mg / kg / h, which is maintained until the end of surgical procedure
88957712|NCT01986309|Placebo Comparator|Group P|Normal saline solution administered under the same regimen
88957713|NCT01986322|Experimental|DTP/HB/Hib vaccine|"Group A will receive DTP/HB/Hib combination vaccine at 6-11, 10-15 and 14-19 weeks of age.~DTP/HB/Hib component:~Purified diphteria toxoid Purified tetanus toxoid Inactivated Bordetella pertussis HbsAg PRP-TT Aluminum phosphate Natrium Chloride Thimerosal"
89507270|NCT04439097|Active Comparator|Control Group|Participants allocated to the control group will receive usual care and continue with their life normally, without participating in a standardized exercise program. They will be instructed to maintain their current physical activity level.
89507271|NCT02214797|Other|Presbyopic group - Low Add|"40 years and over Add of less than +1.50D~Control lens : Lotrafilcon B and Senofilcon A~Test lens: Etafilcon A~Up to 4 test lens designs will be assessed against commercial control/s in each parallel arm in a randomised cross over fashion. Each lenses will be worn for a week with a minimum 2 day washout period between the lens types. Each lens will require 2 scheduled clinic attendances - a fitting visit and an evaluation visit."
89507272|NCT02214797|Other|Presbyopic group - Med Add|"40 years and over Add of +1.50D to +1.75D~Control lens : Lotrafilcon B and Senofilcon A~Test lens: Etafilcon A~Up to 4 test lens designs will be assessed against commercial control/s in each parallel arm in a randomised cross over fashion, with a minimum 2 day washout period between the lens types. Each lens assessment will require 2 scheduled clinic attendances - a fitting visit and an evaluation visit."
89507273|NCT02214797|Other|Presbyopic group - High Add|"40 years and over Add of +2.00D to +2.50D~Control lens : Lotrafilcon B and Senofilcon A~Test lens: Etafilcon A~Up to 4 test lens designs will be assessed against commercial control/s in each parallel arm in a randomised cross over fashion, with a minimum 2 day washout period between the lens types. Each lens assessment will require 2 scheduled clinic attendances - a fitting visit and an evaluation visit."
89507274|NCT02214797|Other|Non-presbyopic group|"18 to 39 years old No Add~Control lens : Lotrafilcon B and Etafilcon A~Test lens: Etafilcon A~Up to 4 test lens designs will be assessed against commercial control/s in each parallel arm in a randomised cross over fashion, with a minimum 2 day washout period between the lens types. Each lens assessment will require 2 scheduled clinic attendances - a fitting visit and an evaluation visit."
89507275|NCT02357589|Active Comparator|2D laparoscopic cholecystectomy|The normal laparoscopic cholecystectomy with two dimensional view
89507276|NCT02357589|Experimental|3D laparoscopic cholecystectomy|The normal laparoscopic cholecystectomy with three dimensional view
89507277|NCT02357511|Experimental|Study goup|Vital values are being measured for the time of two hours at postoperative setting at postanesthesia care unit. A novel method is compared to golden standard: invasive measurement. Also Saturation measurements are being compared between standard and study monitor.
89507278|NCT02225639|Active Comparator|PRC-063|
89507279|NCT02225639|Placebo Comparator|Placebo|
89507280|NCT05231109|Other|vestibular rehabilitation group|Vestibular rehabilitation was performed. The following exercises were done with the patients: vestibular adaptation exercises, oculo-motor exercises, standing by changing the support area, the support surface and the arm positions, heel-toe walking, walking with head rotation, backward walking, counting on a soft surface with eyes open and closed, and dynamic balance exercises were taught to the patients. The exercise program was arranged 3 times a day for 6 months, and each exercise was 10 repetitions. The patients were called for physiotherapist control once every 2 weeks.
89507281|NCT03159975|Experimental|Dose level 1 (GX-70 0.26mg)|Administrating GX-70 0.26mg
89507282|NCT03159975|Experimental|Dose level 2 (GX-70 1mg)|Administrating GX-70 1mg
89507283|NCT03159975|Experimental|Dose level 3 (GX-70 4mg)|Administrating GX-70 4mg
89507284|NCT02222363|Experimental|VLX600|Dose of VLX600 in patients with refractory advanced solid tumors
89507285|NCT02360709||CRE8 group|CRE8 sirolimus-eluting stent
89507286|NCT02215421|Experimental|Play Mommio for 2 months|"The objective is to build parent's skills in encouraging their child to eat vegetables. The player is asked to read a novella, Totally Frobisher (providing backstory to the game), and play a game called Mommio (a casual video game for parents of 3 to 5 year old children). The player calls Kiddio, the child character, to dinner, and offers a vegetable (V) (selected from among several). Kiddio refuses. The player is offered a selection of V parenting statements (from the scientific literature on food parenting) or manipulation of the environment (e.g. turning off the kitchen TV) to control the situation and encourage the child to eat the V. As problems arise (e.g. a permissive father saying he doesn't like vegetables), the player must select ways to cope. Players set a goal to do with their child at home what they learned in the game. Game episodes include food store shopping, eating in the car, at grandma's, and at a fast food store."
88957714|NCT01986322|Active Comparator|DTP/HB and Hib vaccine|"Group B will receive DTP/HB and Hib Vaccines separately at 6-11,10-15, 14-19 weeks of age~DTP/HB component:~Purified diphteria toxoid Purified tetanus toxoid Inactivated Bordetella pertussis rHbsAg Aluminum phosphate Natrium Chloride Thimerosal~Hib component:~Purified Haemophilus influenzae type b polysaccharide 10 mcg"
89023901|NCT04345601|Experimental|Safety Run In|The study will first enroll and treat six patients with MSCs for safety run in. If no more than 2 treatment-related severe adverse events (tSAEs) are observed, the study will enroll and randomize additional patients in a ratio of 1:1 to receive either MSCs or routine/supportive care.
89023902|NCT04345601|Experimental|Mesenchymal stromal cells|Patients randomized to the MSC arm will be administered an intravenous infusion of MSCs at a dose of 1 x 10^8. A second infusion will be allowed if the patient does not have improvement in respiratory parameters per discretion of the investigator, or ARDS clinically worsens, within 3-5 days following the initial infusion.
89023903|NCT04345601|Other|Control Group|Patients randomized to the control arm will receive supportive care or treatment designated by their treating physicians.
89023904|NCT04341246||Cases|Cases are defined as those patients who have undergone liver biopsy and have confirmed NASH and fibrosis
89507287|NCT02215421|No Intervention|No game play|No intervention control.
89507288|NCT02372643|Other|Sexually healthy women|20 sexually healthy volunteer women will be enrolled from subjects consulting our outpatient clinic (subjects free from sexual dysfunction). Hormonal and ultrasound parameters and self-administered questionnaires will be evaluated.
89507289|NCT02215577|Experimental|In-situ split with portal vein ligature|In-situ liver split at time when portal vein ligature is performed
89507290|NCT02215577|Active Comparator|Portal embolization or ligation|Intervention: Preoperative portal embolization (+/-ablation) followed by liver resection, or local resections and/or ablations followed by lobectomy, two-stage hepatectomy
89507291|NCT02357277|Experimental|Budesonide 360 mcg|Budesonide dry powder inhaler 2 puffs of 90 mcg twice daily for 4 weeks
89507292|NCT02357277|Experimental|Budesonide 720 mcg|Budesonide dry powder inhaler 2 puffs of 180 mcg twice daily for 4 weeks
89507293|NCT02357277|Placebo Comparator|Placebo|Placebo inhaler 2 puffs twice daily for 4 weeks
89507294|NCT02217293|Active Comparator|Pulsed Radiofrequency|Pulsed radiofrequency (PRF) treatment, a relative novel pain intervention at recent decade, was found to be able to alleviate pain by delivering an electrical field and heat bursts at a temperature less than 42°C to neural tissue in the absence of neural injury
89507295|NCT02217293|No Intervention|Night splint|The wrist night splint was firmly fixed in a neutral position to immobilize the affected wrist. Patients were ordered to wear the splint while resting at night and at least 8 hours per day during the period of study
89507296|NCT02372175|Experimental|Low dose DENV-1-LVHC|Dengue-1 Virus-Live Virus Human Challenge (DENV-1-LVHC) single low dose (0.5 mL of 6.5 x 10^3 plaque forming units/milliliter (PFU/mL) inoculated subcutaneously
89507297|NCT02372175|Experimental|Medium dose DENV-1-LVHC|Dengue-1 Virus-Live Virus Human Challenge (DENV-1-LVHC) single medium dose (0.5 mL of 6.5 x 10^4 PFU/mL) inoculated subcutaneously
89507298|NCT02372175|Experimental|High dose DENV-1-LVHC|Dengue-1 Virus-Live Virus Human Challenge (DENV-1-LVHC) single high dose (0.5 mL of 6.5 x 10^5 PFU/mL) inoculated subcutaneously
89507299|NCT02222441|Experimental|Fixed sequence modafinil DDI arm (Cohort 1)|Fixed sequence study with treatment A of palbociclib alone, followed by treatment B of palbociclib with modafinil in Cohort 1.
89507300|NCT02222441|Experimental|Fixed sequence pioglitazone DDI arm (Cohort 2)|For Cohort 2, fixed sequence study with treatment A of palbociclib alone, followed by treatment C of palbociclib with pioglitazone.
89507301|NCT02290639|Experimental|Immediate Treatment|Four 30-minute sessions of Brief Cognitive Behavioral treatment starting immediately upon randomization.
89507302|NCT02290639|Active Comparator|Minimal Contact followed by treatment|6-week Minimal Contact period consisting of weekly phone calls starting immediately upon randomization. Experimental treatment will be provided to all subjects upon completion of Minimal Contact period.
89507303|NCT02372565|Experimental|Facebook and Text Message|Participants randomized to the technology-based physical activity intervention will receive a culturally-relevant physical activity promotion intervention delivered via text messages and the social media website Facebook. The purpose of the intervention materials is to encourage participants to achieve a minimum of 150 minutes/week of moderate-intensity aerobic physical activity each week.
89507304|NCT02372565|Active Comparator|Standard Print-based Intervention|Participants randomized to the standard print-based physical activity intervention group will be mailed 4 self-help booklets promoting physical activity produced by the American Heart Association. Booklets will be mailed one at a time in 2 week intervals over the 1st 6-weeks of the intervention. These high quality booklets provide general information on the benefits of physical activity, tips and strategies to increase daily physical activity, and encourage recipients to perform a minimum of 10,000 steps per day.
89507305|NCT02225717|Experimental|Non pregnant women|Healthy pregnancy : women 15-16 weeks of gestation, at 35-36 weeks of gestation, and >37 weeks of gestation and planed cesarean prior labor
89507306|NCT02225717|Experimental|Preterm Labor|Pregnant women admitted for preterm labor
89507307|NCT02225717|Experimental|Healthy pregnancy|Healthy pregnancy : women 15-16 weeks of gestation, at 35-36 weeks of gestation, and >37 weeks of gestation and planed cesarean prior labor
89507308|NCT02372331|No Intervention|Conventional perioperative management|"Preop usual biliary drainage~Preop smoking and alcohol~Preop parenteral nutrition~Oral bowel preparation (mechanical bowel preparation )~Preoperative fasting > 12 hours~Pre-anesthetic medication~Anti-thrombotic prophylaxis~Antimicrobial prophylaxis and skin preparation~Intravenous analgesia : PCA~Prevention of postoperative nausea and vomiting (PONV) (X)~Incision : surgeon direction~Avoiding hypothermia~Nasogastric intubation (O)~Postop glycemic control~Positive fluid balance~Perianastomotic drain removal over POD #5~Somatostatin analogues~Transurethral catheter removal~Delayed gastric emptying(DGE) (+) , parenteral nutrition (+)~Postop routine artificial nutrition (O), soft diet at POD #5~Early and scheduled mobilization"
89507309|NCT02372331|Experimental|ERAS perioperative management|"behavioral intervention (counselling, audit)~dietary supplement~procedure (preoperative and postoperative)~drug"
89507310|NCT02290717|Experimental|Laser+fluticason+UVB|The treatment site will be superficially abraded using an ablative fractional laser (10,600nm CO2 laser). 5 days after laser therapy topical steroids (fluticasone cream) 4 times a week will be applied on the treatment site until the end of the study.
89507311|NCT02290717|Experimental|Laser+UVB|In one session the treatment site will be superficially abraded using an ablative fractional laser (10,600nm CO2 laser).
89507312|NCT02290717|Active Comparator|UVB|As control site, 1 similar depigmented lesion will be used. This site will receive the same NB-UVB treatment as sites 1 and 2.
89023905|NCT04341246||Controls|Controls are patients have undergone a liver biopsy with neither significant NASH nor significant fibrosis
89023906|NCT04337554||Older healthy|Individuals over 40 years of age
89023907|NCT04337554||Peripheral artery disease|Individuals over 40 years of age with peripheral artery disease.
89023908|NCT04330313|Experimental|Traction and stretching|This grup received stretching exercises after traction therapy for 18 sessions, 3 times per week.
89023909|NCT04330313|Experimental|Laser therapy and stretching|This grup received stretching exercises after laser therapy for 18 sessions, 3 times per week.
89023910|NCT04330313|Experimental|Hot pack and stretching|This grup received stretching exercises after hotpack therapy for 18 sessions, 3 times per week.
89023911|NCT04330313|Experimental|Stretching only|This grup received only stretching exercises for 18 sessions, 3 times per week.
89023912|NCT04322708|Placebo Comparator|Placebo|Subjects in this arm will receive 6 monthly doses of placebo.
89023913|NCT04322708|Experimental|1 mg/kg of lirentelimab (AK002)|Subjects in this arm will receive 6 monthly doses of lirentelimab (AK002) (1mg/kg).
89023914|NCT04322708|Experimental|3 mg/kg of lirentelimab (AK002)|Subjects in this arm will receive 6 monthly doses of lirentelimab (AK002): A first dose of 1 mg/kg, followed by 5 monthly doses of 3 mg/kg.
89023915|NCT04322604|Placebo Comparator|Placebo|Placebo
89507313|NCT02225795|Experimental|Single Arm: All subjects|Hematopoietic stem cell transplantation
89507314|NCT02360553|Experimental|Intervention|ObeseGO!-web-based intervention
89507315|NCT02360553|Other|Control|Given pamphlets education mainly on diet and physical activity
89507316|NCT02290795||healthy subjects|Healthy subjects (not diagnosed with any eye disease affecting the vitreous or optic nerve head).
89507317|NCT02290795||Glaucoma patients|Glaucoma patients visiting the glaucoma consultation.
89507318|NCT02290795||Patients scheduled for trabeculectomy|Glaucoma patients scheduled for filtering surgery (=trabeculectomy)
89507319|NCT02290795||Vitreomacular traction patients|Patients with symptomative vitreomacular adhesion scheduled for treatment with Ocriplasmin
89507320|NCT02360241|Experimental|Robot|A robot will be used and it's position will be evaluated
89507321|NCT02225873|Experimental|strength-endurance exercises|Group 1 (experimental) will carry out motor control exercises through cranio-cervical flexion training and strength-endurance exercises.
89507322|NCT02225873|Placebo Comparator|strength-endurance and proprioception|Group 2 (control) will carry out exercises to improve muscle strength-endurance and proprioception.
89507323|NCT02294149|Placebo Comparator|Placebo|A ineffective placebo drug with the same taste, route of administration and physical appearance as the study drug (omega 3/Vit D 3) that has received approval by health Canada.
89507324|NCT02294149|Experimental|Omega 3 FA/Vitamin D3 sublingual|patients will be allocated randomly to receive Sub-lingual Omega 3 FA and Vitamin D3 supplements for 6 months, twice daily ,1/2 tea spoon with instructions to keep it under the tongue for 45 sec.
89507325|NCT02360163|Active Comparator|Landmark Technique Attempt|Patients will undergo an additonal TLT attempt
89507326|NCT02360163|Experimental|USGPIVA Technique Attempt|Patients will be offered a USGPIVA attempt after two failed attempts using the traditional landmark technique (TLT)
89507327|NCT02217449||HD|Prediction of histology
89507328|NCT02217449||Virtual Chromoendoscopy|Prediction of histology
89507329|NCT02291107|Experimental|Experimental group|Participants received 25 sessions of robotically driven gait orthosis training on the Lokomat. Training occurred approximately 5 days/ week for 5 weeks, and each training session on the Lokomat lasted 30 minutes. All sessions were supervised by a trained research therapist. All participants started with 40% body weight-support and an initial treadmill speed of 1.5 km/h. Body weight-support was used primarily to facilitate an increase in walking speed; therefore, progression of training across subsequent sessions was standardized by preferentially increasing speed and then unloading body weight-support. Speed was increased to a range of 2.2 to 2.5 km/h before body weight-support was decreased. There was an active attempt to enhance the level of training at each session. After every Lokomat session, participants performed also 60 minutes of physiotherapy including general exercise program and a conventional gait training
89519352|NCT03454009|Experimental|Multimodal hygiene intervention|"Employees will receive hygiene supplies including hand sanitizer, hand sanitizer surface disinfectant wipes and tissues, along with the following educational materials: a 2-minute electronic educational video; weekly 30-second electronic videos; and an educational flyer. Training materials discuss the importance of performing hygiene behaviors to prevent the spread of pathogens, such as, cleaning hands, using tissues to cover one's mouth and nose when coughing or sneezing, and keeping office surfaces clean.~In addition, hygiene materials will be placed in common areas frequented by employees in the intervention group that include, educational hygiene posters, free standing hand sanitizer delivery stands, and bottles of hand sanitizer ."
89023916|NCT04322604|Experimental|3 mg/kg of lirentelimab (AK002)|Subjects in this arm will receive 6 monthly doses of lirentelimab (AK002): a first dose of 1 mg/kg followed by 5 monthly doses of 3 mg/kg.
89023917|NCT04317807|Active Comparator|Study Drug group|Participants in this group will receive 500 mg of levetiracetam twice daily for 12 weeks. After 12 weeks, levetiracetam will be gradually decreased and stopped over the next 9 days. Questionnaires will be administered at each visit to examine how participants are responding to the treatment. In addition, a brain scan and cognitive testing will be performed when feasible at the beginning and the end of the study.
89032915|NCT00528983|Experimental|Subcutaneous (SC) Azacitidine and Oral Azacitidine|Cycle 1 subjects receive SC Azacitidine for first 7 days of 28 day cycle. For Cycle 2 and beyond subjects receive Oral Azacitidine (experimental) for first 7 days of 28 day cycle.
89507330|NCT02291107|Active Comparator|Control group|Participants received 25 sessions of conventional physiotherapy. Training occurred approximately 5 days/week for 5 weeks, and each training session lasted 1 hour and half. Patients allocated to the Control Group performed the same conventional physiotherapy training of the other group: a general exercise program and a conventional gait training. The general exercise program consisted in cardiovascular warm-up exercises, muscle stretching exercises, active-assisted or active isometric and isotonic exercises for the main muscles of the trunk and limbs, relaxation exercises, coordination and static/dynamic balance exercises. The conventional gait therapy was based on the proprioceptive neuromuscular facilitation concept, training in walking on different surfaces with or without appropriate walking aids, exercises for the restoration of a correct gait pattern, implementation of residual compensatory strategies and progressive increase of walking resistance
88957715|NCT01986335|Experimental|DTP/HB/Hib Vaccine (Batch: A)|Purified diphteria toxoid Purified tetanus toxoid Inactivated Bordetella pertussis HbsAg PRP-TT Aluminum phosphate Natrium Chloride Thimerosal
88957716|NCT01986335|Experimental|DTP/HB/Hib vaccine (Batch: B)|Purified diphteria toxoid Purified tetanus toxoid Inactivated Bordetella pertussis HbsAg PRP-TT Aluminum phosphate Natrium Chloride Thimerosal
88957717|NCT01986335|Experimental|DTP/HB/Hib vaccine (Batch: C)|Purified diphteria toxoid Purified tetanus toxoid Inactivated Bordetella pertussis HbsAg PRP-TT Aluminum phosphate Natrium Chloride Thimerosal
89507331|NCT02357355|Active Comparator|CMT 1A Group|Patients with CMT 1A will undergo a driving simulation study. The intervention will be the SIREN driving simulator.
89507332|NCT02357355|Active Comparator|Control Group|Patients without CMT 1A who are our normal controls will undergo a driving simulation study. The intervention will be the SIREN driving simulator.
89507333|NCT02218229|Experimental|Shock waves|Shock waves are defined a sequence of acoustic pulse characterized by a high peak pressure (100 MPa), fast pressure rise (< 10 ns) and short duration (10 μs). Different studies and clinical experiments have demonstrated the efficacy of shock waves in the treatment of musculoskeletal system such as chronic tendinopathies or hypertrophic pseudoarthrosis.
89507334|NCT02218229|No Intervention|Night splint|The wrist night splint was firmly fixed in a neutral position to immobilize the affected wrist. Patients were ordered to wear the splint while resting at night and at least 8 hours per day during the period of study
89507335|NCT02360007|Experimental|Interim Buprenorphine Treatment|IBT participants will visit the clinic every 2 weeks while receiving the IBT package. Our integrative IBT treatment package includes five key components, each strategically chosen to maximize patient access to pharmacotherapy for opioid dependence while minimizing nonadherence, abuse and diversion: (1) Buprenorphine (BUP), (2) Computerized adherence monitoring (CAM), (3) Mobile health clinical support, (4) Urinalysis and adherence monitoring, and (5) HIV+Hepatitis Education.
89507336|NCT02360007|No Intervention|Waitlist Control|WLC participants will remain on the waitlist for their treatment of choice but complete the same scheduled follow-up assessments as IBT participants.
89507337|NCT02294305|Experimental|Vortioxetine|Vortioxetine 10 to 20 mg PO QD for 12 weeks.
89507338|NCT02294305|Placebo Comparator|Placebo|Placebo PO QD for 12 weeks.
89507339|NCT02225951|Active Comparator|Test group|Nutritional product as breakfast.
89507340|NCT02225951|Other|Control Group|Standard breakfast according to ADA recommendations for pregnant women diagnosed with Gestational Diabetes Mellitus.
89507341|NCT02357199|Experimental|Intensive oral care & didactic training|Professional (dental hygienist) intensive oral care intervention and individual patient training/didactic instruction to promote patient compliance and patient capability of oral preventive measures in a long-term perspective.
89507342|NCT02357199|No Intervention|Standard oral care|Standard oral care protocol consisting of referral by staff in the Department of Nephrology to general dental practitioner followed by patient self-administration of tooth brushing, fluoride toothpaste and oral lubricants.
89507343|NCT03133039|Active Comparator|bioabsorbable screw|
89507344|NCT03133039|Active Comparator|titanium screw|
89507345|NCT05013983|Experimental|Low-dose vaccine (6-11 years)|three doses of low-dose Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21，42.
88957718|NCT01986374|Experimental|HCG is introduced with small catheter.|phase 1 non randomized pilot
89032916|NCT00528983|Experimental|Oral Azacitidine|Subjects receive Oral Azacitidine (experimental) QD or BID for the first 14 or 21 days of 28 day cycle.
89507346|NCT05013983|Experimental|Medium-dose vaccine (6-11 years)|three doses of medium-dose Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21，42.
89507347|NCT05013983|Experimental|Medium-dose vaccine (12-17 years)|three doses of medium-dose Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21，42.
89507348|NCT05013983|Experimental|High-dose vaccine (12-17 years)|three doses of high-dose Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21，42.
89507349|NCT05013983|Placebo Comparator|Low-dose placebo (6-11 years)|three doses of low-dose placebo at the schedule of day 0, 21，42.
88957719|NCT01986387|Experimental|Virtual Peer-to-Peer Support Mentoring|In addition to standard medical care, adolescents in the experimental group will receive the VP2P support program, a manualized peer-mentorship program that will provide modeling and reinforcement by peers (young adults with chronic pain aged 16-25 years who have learned to function successfully with their chronic pain to the mentored participants).
89507350|NCT05013983|Placebo Comparator|Medium-dose placebo (6-11 years)|three doses of medium-dose placebo at the schedule of day 0, 21，42.
89032917|NCT00529022|Experimental|Azacitidine + Valproic Acid + Carboplatin|Azacitidine 75 mg/m^2 subcutaneous injection or by vein daily for 5 Days. Valproic Acid 40 mg/kg by mouth daily for 7 days. Carboplatin area under the curve (AUC) 2 by vein on Days 3 and 10 over 60 Minutes.
89507351|NCT05013983|Placebo Comparator|Medium-dose placebo (12-17 years)|three doses of medium-dose placebo at the schedule of day 0, 21，42.
89507352|NCT05013983|Placebo Comparator|High-dose placebo (12-17 years)|three doses of high-dose placebo at the schedule of day 0, 21，42.
89507353|NCT02359773||Group 1 - Non ischemic chest pain|No coronary artery disease (CAD) as confirmed by myoview, MRI or stress echo. Subjects will receive one MCG scan (intervention) using the QI Model 1.0 Magentocardiogram. This will be in addition to their current care and it will not be used to support clinical decision making.
89507354|NCT02359773||Group 2 - Myocardial infarction|Myocardial infarction confirmed by a troponin test (>50ng/l) 12 hours after the onset of chest pain. Subjects will receive one MCG scan (intervention) using the QI Model 1.0 Magentocardiogram. This will be in addition to their current care and it will not be used to support clinical decision making.
89507355|NCT02357433|Experimental|High doses CPFA|High doses CPFA (coupled plasma-filtration adsorption) with AMPLYA™ (BELLCO ITALY): >0.20 L/kg/day of plasma treated in the first 3 days after randomization
89507356|NCT02357433|No Intervention|Control Group|Standard practice
89507357|NCT02222519||Statin use group|patients taking statins for at least 3 months
89507358|NCT02222519||non statin use|no history of taking statin
89507359|NCT02357121|Experimental|Laser ablation|All patient will undergo focal ablation of prostate tissue utilizing laser energy.
89507360|NCT01458613||Observation|Patients with Maroteaux-Lamy disease
89507361|NCT02220023|Experimental|Nitric Oxide|40 ppm, one time administration, inhaled.
89507362|NCT02352909|Active Comparator|Control|Education will be given on how to modify running training to encourage improvement of symptoms.
89507363|NCT02352909|Experimental|Muscle recruitment|Subjects will receive an additional exercise program targeting non task-specific strengthening and motor control exercises of the lower limb.
89507364|NCT02352909|Experimental|Reduction of knee loading|Subjects will receive additional personalized advice on how to modify running gait in order to reduce mechanical loads at the knee (gait retraining).
89507365|NCT03132961||Block 1|Participants in the cohort will undergo testing in the order of: ECoG, oVEMP, cVEMP
89507366|NCT03132961||Block 2|Participants in the cohort will undergo testing in the order of: ECoG, cVEMP, oVEMP
89507367|NCT03132961||Block 3|Participants in the cohort will undergo testing in the order of: oVEMP, cVEMP, ECoG
89507368|NCT03132961||Block 4|Participants in the cohort will undergo testing in the order of: oVEMP, ECoG, cVEMP
89507369|NCT03132961||Block 5|Participants in the cohort will undergo testing in the order of: cVEMP, ECoG, oVEMP
89507370|NCT03132961||Block 6|Participants in the cohort will undergo testing in the order of: cVEMP, oVEMP, ECoG
89507371|NCT02222597||positive infrascanner finding|
89507372|NCT02356965|Experimental|Ketamine 70 mg Sublingual Wafer|Single dose of 70 mg ketamine sublingual wafer
89507373|NCT02356965|Experimental|Ketamine 100 mg Sublingual Wafer|Single dose of 100 mg ketamine sublingual wafer
89507374|NCT02356965|Placebo Comparator|Placebo|Single dose of placebo sublingual wafer
89507375|NCT02222675|Experimental|Sonographically assisted breast surgery|Sonographically assisted breast surgery
89507376|NCT02222675|Active Comparator|Conventional breast surgery|Conventional breast surgery
89507377|NCT04478955||normal|no make up
89507378|NCT04478955||eyeliner only|three days a week at least for 6 months
89507379|NCT04478955||mascara only|three days a week at least for 6 months
89507380|NCT04478955||eyeliner and mascara|three days a week at least for 6 months
89507381|NCT02294383||Pre/post surgery pelvic floor assessment|
89507382|NCT02294383||Conservative treatmen monitoring|
89507383|NCT02294383||Pelvic floor muscle contrictions|
89507384|NCT02294383||Imaging reproducibility|
89507385|NCT02359695|Experimental|GH cycle|Subsequent IVF cycle, supplemented with a low dose of growth hormone.
89507386|NCT02294539|Experimental|Losartan 50mg/amlodipine 5mg|Once daily, 1T, PO medication
89507387|NCT02294539|Experimental|Losartan 100mg/amlodipine 5mg|Once daily, 1T, PO medication
89507388|NCT02294539|Active Comparator|Losartan50 mg/Hydrochlorothiazide12.5 mg|Once daily, 1T, PO medication
89507389|NCT02294539|Active Comparator|Losartan100 mg/Hydrochlorothiazide25 mg|Once daily, 1T, PO medication
89507390|NCT02356809|Experimental|pl-vegf165|Patients of this group will receive 2,4 mg of pl-vegf165 administered by intramuscular injection which is given in the hand
89507391|NCT02356809|No Intervention|standard care|Patients of this group will receive standard therapy accepted in a clinical centre
89507392|NCT01457443||Observation|Patients with Pompe disease
89519353|NCT03454009|No Intervention|Control|Employees will complete all surveys but will not have access to additional hygiene products. Will follow usual hygiene behaviors.
89519354|NCT03467659|Experimental|Cracked whole wheat porridge|Large particle whole wheat porridge
89032918|NCT02923596||Patients with Ear Keloids|Records of Patients with Ear Keloids will be reviewed. Data and photographs will be analysed.
89032919|NCT02923596||Patients with Neck Keloids|Records of Patients with Neck area Keloids will be reviewed. Data and photographs will be analysed.
88957720|NCT01986387|No Intervention|Waitlist Control|The control group will receive usual care but without the mentorship intervention. They will be offered the VP2P support program after completion of outcome measures (T1 - to be completed online prior to randomization; T2 - at program completion).
88957721|NCT01986400|Experimental|Virtual Peer-to-Peer Support Mentoring|In addition to standard medical care, adolescents in the experimental group will receive the VP2P support program, a manualized peer-mentorship program that will provide modeling and reinforcement by peers (young adults with JIA aged 16-25 years who have learned to function successfully with their JIA to the mentored participants).
89519355|NCT03467659|Experimental|Semolina wheat porridge|Large particle refined wheat porridge
89519356|NCT03467659|Experimental|Whole wheat flour porridge|Small particle whole wheat porridge
89519357|NCT03467659|Experimental|Refined wheat flour porridge|Small particle refined wheat porridge
89519358|NCT03467659|Experimental|Refined wheat flour porridge,fine bran|Small particle refined wheat porridge with small particle bran
89519359|NCT03467659|Experimental|Refined wheat flour porridge,coarse bran|Small particle refined wheat porridge with large particle bran
89519360|NCT04754893|Experimental|Group A|Healthdot directly after surgery and leave the hospital on the same day (evening) (group A)
89519361|NCT04754893|No Intervention|Group b|Standard of care by staying one night in the hospital before returning home (group B)
89519362|NCT03462901|Experimental|Elastic rod fixation|Percutaneous intramedullary fixation of displaced midshaft clavicular fractures
89519363|NCT03462823|Active Comparator|Control treatment|ACL-reconstruction using hamstring autograft with hybrid fixation in accordance with in-house standard of care.
89519364|NCT03462823|Experimental|Experimental treatment|ACL-reconstruction using hamstring autograft with hybrid fixation combined with the osteoconductive device under study.
89519365|NCT03453541|Experimental|Ketorolac Tromethamine|This group receives Ketorolac Tromethamine 0.5 mg/kg IV up to a maximum dose of 30mg, in the form of Ketorolac Tromethamine solution for IV/IM use 30mg/ml single dose vial at the completion of the tonsillectomy in the operating room.
89519366|NCT03453541|Placebo Comparator|0.9% Normal Saline|This group will receive 0.9% Normal Saline solution 1ml/60kg up to 1ml IV bolus (an equivalent volume as per kg Ketorolac Tromethamine dose) at the completion of the tonsillectomy in the operating room.
89519367|NCT03453463|Experimental|exercise and protein supplementation|Predominately resistance exercise training 2-3x week for 18 months; 1.5-1.7 g/kg/d total protein supplementation, Calcium and Vitamin-D-supplementation (i.e. 800 mg/800 IE/d)
89519368|NCT03453463|No Intervention|control|Calcium and Vitamin-D-supplementation (i.e. 800 mg/800 IE/d)
89519369|NCT03462667|Experimental|Stoma Boot Camp|Participants will attend the Stoma Boot Camp session prior to surgery.
89519370|NCT03462667|Active Comparator|Regular Care|Participants will receive normal standard of care prior to surgery.
89519371|NCT03462589|Experimental|SY-008 dose 1|A single dose of SY-008 (2~30mg) taken orally.
89519372|NCT03462589|Experimental|SY-008 dose 2|A single dose of SY-008 (2~30mg) taken orally.
89519373|NCT03462589|Experimental|SY-008 dose 3|A single dose of SY-008 (2~30mg) taken orally.
89519374|NCT03462589|Experimental|SY-008 dose 4|A single dose of SY-008 (2~30mg) taken orally.
89519375|NCT03462589|Experimental|SY-008 dose 5|A single dose of SY-008 (2~30mg) taken orally.
89519376|NCT03462589|Placebo Comparator|SY-008 matching placebo|from 6mg to 30mg
89519377|NCT04944277|No Intervention|Without ThoughtFullChat Application|Participants will not use the app during the 3 months
89519378|NCT04944277|Experimental|With ThoughtFullChat Application|Participants will be using the app during the 3 months
89519379|NCT00893789|Experimental|1|Armodafinil 50 mg/day
89519380|NCT00893789|Experimental|2|Armodafinil 150 mg/day
89519381|NCT00893789|Experimental|3|Armodafinil 250 mg/day
89519382|NCT00893789|Placebo Comparator|4|Placebo
89519383|NCT04864483|Experimental|Early sahoor with predawn snack|"To take the Sahoor meal 1:30-2 hours before dawn with insulin dose then a pre-dawn snack with no insulin~(Sahoor is the latest meal before starting the fast at dawn during the month of Ramadan. The intervention is meal timing in relation to start of fast and does not involve any medications)."
89519384|NCT04864483|Experimental|Late Sahoor meal (within 30 minjted of dawn) with insulin dose|"To take sahoor meal as late as possi le with usual insulin dose~(Sahoor is the latest meal before starting the fast at dawn during the month of Ramadan. The intervention is meal timing in relation to start of fast and does not involve any medications)."
88957722|NCT01986400|No Intervention|Wait-list Control|The control group will receive usual care but without the mentorship intervention. They will be offered the VP2P support program after completion of outcome measures (T1 - to be completed online prior to randomization; T2 - at program completion).
88957723|NCT01986413|Active Comparator|BIPAP ST|one night, NIV with pressure controlled ventilation (BIPAP ST) with individually titrated pressure parameters.
89507393|NCT02359617|Experimental|glucose sensing and insulin delivery|"Subcutaneous insulin delivery with an insulin pump plus glucose sensing with a continuous glucose sensor placed at the site of subcutaneous insulin delivery.~In parallel, capillary glucose determinations using a conventional glucose meter as well as glucose sensing in subcutaneous, insulin-unexposed tissue using a continuous glucose sensor."
88957724|NCT01986413|Experimental|IVAPS|one night, NIV with volume assured pressure support (IVAPS).The pressure parameters will be adjusted according to the BIPAP pressure levels.
89507394|NCT02359539|Experimental|PRF|Platelets rich fibrin,
89507395|NCT02359539|Experimental|MPP|Marginal periosteal pedicle
89507396|NCT02291263|Active Comparator|Arm A|Group A will receive 3 doses of bivalent oral polio vaccine (bOPV) at 6, 10 and 14 weeks of age. Group A participants will also receive inactivated polio vaccine (IPV) at 6 weeks of age. An additional dose of IPV will be administered at 18 weeks of age.
89507397|NCT02291263|Active Comparator|Arm B|Group B will receive 3 doses of bivalent oral polio vaccine (bOPV) at 6, 10 and 14 weeks of age. Group B participants will also receive inactivated polio vaccine (IPV) at 14 weeks of age. An additional dose of IPV will be administered at 18 weeks of age.
88957725|NCT01986426|Experimental|Arm A: LTX-315 monotherapy singe lesion|"Cohort 1-3: First induction treatment (6 weeks): In week 1 the first index lesion will be injected Twice daily on 3 consecutive days. During week 2-6 the injection will be once a week.~Second induction treatment (6 weeks) and Maintenance treatment (20 weeks)- At week 7 the second index lesion will be injected with same dosing schedule as the first index lesion.~Cohort 4 and above: Once daily on 3 consecutive days week 1. Week 2-6 one injection per week. From week 8, one dosing days every 2 weeks."
88957726|NCT01986426|Experimental|Arm B: LTX-315 monotherapy in multiple concurrent lesions|"Patients with at least one injectable lesion and one bystander lesion will receive LTX-315 to one or more lesions:~Once daily on 2 consecutive days week 1-3."
88957727|NCT01986426|Experimental|Arm C|Patients with melanoma and at least one injectable lesion will receive LTX-315 to one or more lesions on two consecutive days week 1-3 in combination with ipilimumab given for 4 cycles every 3 weeks.
89507398|NCT02291263|Active Comparator|Arm C|Group C will receive 3 doses of bivalent oral polio vaccine (bOPV) at 6, 10 and 14 weeks of age. Group C participants will also receive inactivated polio vaccine (IPV) at 6 and 14 weeks of age. An additional dose of IPV will be administered at 18 weeks of age.
88957728|NCT01986426|Experimental|Arm D|Patients with TNBC and at least one injectable lesion will receive LTX-315 to one or more lesions on two consecutive days week 1-3 in combination with pembrolizumab given every 3 weeks.
89507399|NCT02226029|Experimental|Lipid emulsion 1|Rapeseed oil 20%, sucrose FAE P-1670 0.7%, water 79.3%
89507400|NCT02226029|Experimental|Lipid emulsion 2|Rapeseed oil 20%, sodium stearoyl lactylate P45 veg 1.5%, water 78.5%
89507401|NCT03154125|Experimental|Abdomen|Sayana® Press (MPA injectable suspension, 104 mg/0.65 mL, pre-filled in the UnijectTM delivery injection system) injected subcutaneously every 4 months (17-18 weeks) for 3 treatment cycles (12 months).
89507402|NCT03154125|Experimental|Upper thigh|Sayana® Press (MPA injectable suspension, 104 mg/0.65 mL, pre-filled in the UnijectTM delivery injection system) injected subcutaneously every 4 months (17-18 weeks) for 3 treatment cycles (12 months).
89507403|NCT03154125|Experimental|Back of the upper arm|Sayana® Press (MPA injectable suspension, 104 mg/0.65 mL, pre-filled in the UnijectTM delivery injection system) injected subcutaneously every 4 months (17-18 weeks) for 3 treatment cycles (12 months).
89206858|NCT04010799|Experimental|CHF6333|"CHF6333 Active (part I - SAD). Once daily inhaled single dose of CHF6333 at each period (three dose level).~CHF6333 Active (part II -MD). Once daily inhaled multiple dose of CHF6333 for 7 consecutive days."
89206859|NCT04010799|Placebo Comparator|CHF6333 Placebo|"Part I (SAD): Single dose of placebo matching CHF6333 at each period~Part II (MD): Once daily multiple doses of placebo matching CHF6333 for 7 consecutive days"
89206860|NCT00749411|Experimental|Arm 1|
88957729|NCT01986452|Active Comparator|Unattended CPAP therapy|Therapy data will be examined by reading out the CPAP device after 6 months. Patients can obtain help on own request, corresponding to the standard CPAP prescription routine.
89032920|NCT02923596||Patients with Scalp Keloids|Records of Patients with Scalp Keloids will be reviewed. Data and photographs will be analysed.
89507404|NCT02226107|Experimental|Peer-PN|Peer Patient Navigation
89032921|NCT00527696|Active Comparator|TVT SECURE|sling
89507405|NCT02226107|Active Comparator|Pro-PN|Professional Patient Navigation
89507406|NCT02294617|Active Comparator|Nicotrol Inhaler|Subjects will use the Nicotine Inhaler for 3 days.
89507407|NCT02294617|Active Comparator|Electronic Cigarette|Subject will use the electronic cigarette for 3 days.
89507408|NCT03112161|Experimental|Eucaloric|Participants will consume a eucaloric diet with a macronutrient composition of 20% protein, 30% fat and 50% carbohydrate for 4 days (Eucaloric Feeding Period). The caloric value of the diet will be calculated based on lean body mass plus an activity factor to ensure energy and macronutrient balance.
89507409|NCT03112161|Experimental|Overfed|Following 3 days of eucaloric feeding, participants will complete a 1-day overfeeding period (Overfeeding Feeding Period), during which their diet will have a daily energy value of 40% greater than the eucaloric diet (Eucaloric Arm), although the macronutrient composition will remain the same (20% protein, 30% fat, 50% carbohydrate).
89507410|NCT03112161|Experimental|Underfed|Following 3 days of eucaloric feeding, participants will complete a 1-day underfeeding period (Underfeeding Feeding Period), during which their diet will have a daily energy value of 40% less than the eucaloric diet (Eucaloric Arm), although the macronutrient composition will remain the same (20% protein, 30% fat, 50% carbohydrate).
89507411|NCT02226185|Experimental|Berberine hydrochloride|supplement of Berberine hydrochloride 0.3g two times per day for 2-3 years
89507412|NCT02226185|Placebo Comparator|placebo|identical-appearing placebo supplements for 2-3 years
89507413|NCT02291341|Experimental|Duloxetine Delayed-Release Capsules, 60 mg|Duloxetine Delayed-Release Capsules, 60 mg of Dr. Reddys Laboratories Limited
89507414|NCT02291341|Active Comparator|Cymbalta|Cymbalta® 60 mg capsule of Eli Lilly and Company
89507415|NCT02258633|Experimental|Intervener Brief Intervention (IBI)|Subjects and parents will complete a Brief Motivational Interview (BMI) incorporating personalized feedback, discussion of choices and changes, and therapist led intervention message relating behavioral change and future goals.
89507416|NCT02258633|No Intervention|Enhanced Usual Care|Subjects and parents will receive standard trauma care, plus complete brief questionnaires and receive general safety information.
89507417|NCT03112317||Hypothermia|Patients with mild hypothermia at start of the surgery
89507418|NCT03112317||Normothermia|Patients with normal core temperature at start of surgery.
89507419|NCT02258711|Experimental|SIMPLe 2.0 plus Treatment as Usual (TAU)|Psychoeducative and self-monitoring smart-phone application plus treatment as usual which includes pharmacological and psychological treatment.
89507420|NCT02258711|No Intervention|Treatment as usual (TAU)|Treatment as usual which includes pharmacological and psychological treatment.
89507421|NCT02294695||Appropriate empiric antibiotic therapy|"Based on the microbiological results patients were grouped post hoc into appropriate and inappropriate groups by two independent experts (intensivist, infectologist) who were blinded for PCT."
89507422|NCT02294695||Inappropriate empiric antibiotic therapy|"Based on the microbiological results patients were grouped post hoc into appropriate and inappropriate groups by two independent experts (intensivist, infectologist) who were blinded for PCT."
89507423|NCT02220179|No Intervention|control|service as usual
89507424|NCT02220179|Experimental|Intervention group 1|Participants are offered access to the web based resilience program
89507425|NCT02220179|Experimental|Intervention group 2|Participants are offered access to the web based resilience program and are also invited to join a short introduction course about the program
89507426|NCT02352987|Experimental|Patients treated with 3 drugs|Neem plus propylene glycol plus salicylic acid: Neem extract, propylene glycol (40%) and salicylic acid (10%) once daily on palm for 12 weeks
89507427|NCT02352987|Active Comparator|Patients treated with 1 drug|Salicylic acid once daily on palm for 12 weeks
89507428|NCT02226263|Experimental|probiotics Lactobacillus acidophilus boucardii strain.|Lactobacillus acidophilus boucardii strain was added at a dose of 125 mg/ kg/dose twice daily for 4 weeks .The probiotic presentation used was powder in an envelope with 160mg (Carnot ® Laboratories), scientific products, Mexico, (Registration Number 274M91SSA). This was stored in a dry place at room temperature, avoiding sunlight.
89032922|NCT00527696|Active Comparator|TVT O|sling
89206861|NCT00749411|Placebo Comparator|Arm 2|
89507429|NCT04439019|Experimental|All patients referred to the Alberta Hip and Knee Clinic|All patients who are diagnosed with severe osteoarthritis undergoing total hip/knee replacement surgery and show interest to be part of the study.
89507430|NCT03521947||One group of children below 18 years old|
89519385|NCT03449329|Placebo Comparator|placebo SIP block|This group will receive a placebo SIP block injection with 60mL NaCl 0.9%
89539894|NCT03054675||Pneumonia|"Patients suffering from postoperative pneumonia including all three of the following:~Clinical signs of a pulmonary infection (i.e. fever ≥ 38°C combined with productive cough and/or dyspnea)~A new rise of inflammatory markers (i.e. WBC count ≥ 10.5 x 109 and elevated CRP)~New radiographic infiltrates on chest x-ray without another explanation. Patients with pneumonia undergo spirometry before and on every second day after lung surgery"
89539895|NCT03054675||No Pneumonia|Patients without pneumonia undergo spirometry before and on every second day after lung surgery
89539896|NCT03054675||Open (no pneumonia)|"Patients undergoing open anatomical lung resection who did not show postoperative pneumonia.~All patients undergo spirometry before and on every second day after lung surgery."
89539897|NCT03054675||Minimally invasive (no pneumonia)|"Patients undergoing minimally invasive anatomical lung resection who did not show postoperative pneumonia.~All patients undergo spirometry before and on every second day after lung surgery."
89539898|NCT04899375|Experimental|One group taking part in 2 separate conditions|Subjects will be randomly assigned to either group A or B. Session 1 will serve to familiarize all participants with the battery of tests including the 100 mm VAS, Short-form Mcgill Pain Questionnaire (SF-MPQ), Likert perception scale adapted from Kiefer et al. (2017), algometry, manual muscle testing, assessed via hand-held dynamometer (HHD), and grip strength assessed via hydraulic hand dynamometer; subjects will also be instructed in the AROM protocol. Familiarization will be conducted a minimum of 24 hours prior to the first condition. There will be a minimum washout period of 1 week to reduce both order and carry-over effects. Only the principal investigator will be abreast to the order of intervention, sufficiently blinding the raters. Prior to each trial, participants will be instructed to refrain from resistance training for a minimum of 48 hours and to abstain from the use of stimulants or analgesic medication for a minimum of 6 hours prior to reporting to the lab.
89539899|NCT03051555|Experimental|18F-FDG PET/CT-based prognostic model of NK/T-cell lymphoma|The new prognostic model is based on 18F-FDG PET/ CT scans, and combined with clinical and pathological prognostic factors.
89539900|NCT04898751||Cutaneous toxicity|Patients who reported a cutaneous immune related adverse event following ICI initiation with appropriate chronology that indicates drug toxicity.
89539901|NCT04898907|Experimental|ANG-3777 (Therapeutic Dose)|Administered IV as a single dose on two occasions for 30 minutes on the morning of Day 1 of each treatment period (total of 4), following an 8 hour overnight fast. There will be a minimum washout of 3 days between each study drug administration.
89206862|NCT05342805|Experimental|Subtotal stomach|The vessels at the anastomosis of right and left gastric arteries were separated, then the proximal haft of lesser curvature and cardia was resected using linear staplers.
89206863|NCT05342805|Active Comparator|Narrow gastric tube|At the lesser curvature, the resection began at the point that was 5-cm from the pyloric, toward to the greater curvature, then the stomach was divided along 3 cm from the greater curvature using linear stapler.
89206864|NCT00955539|Active Comparator|CRT group 1|
89206865|NCT00955539|Active Comparator|CRT group 2|
89206866|NCT05296161|No Intervention|Standard interval dosing|The standard group will receive ocrelizumab every 24 weeks following the current label.
89539902|NCT04898907|Placebo Comparator|Normal Saline|The placebo will be administered as a single dose on separate occasions intravenously as 30-minute infusions on the morning of Day 1 of each treatment period (total of 4), following an 8 hour overnight fast. There will be a minimum washout of 3 days between each study drug administration.
89023918|NCT04317807|Placebo Comparator|Placebo Group|Participants in this group will receive a placebo that looks like the levetiracetam pill twice daily for 12 weeks. After 12 weeks, the levetiracetam dose will be tapered for the next 9 days. Questionnaires will be administered at each visit to examine how participants are responding to the treatment. In addition, a brain scan and cognitive testing will be performed when feasible at the beginning and the end of the study.
89023919|NCT04284839|Active Comparator|Direct Oral Anticoagulation (DOAC)|Patients in the intervention group will receive a DOAC at doses recommended for the indication, adjusted for their renal function is required. The choice of DOAC will be at the discretion of the treating physician.
89023920|NCT04284839|Placebo Comparator|Vitamin K Antagonist|Patients in the control group will receive VKA once daily; the individual dose will be titrated to achieve a guideline-recommended INR range.
89023921|NCT04278560|Experimental|Behavioral intervention plus tDCS|This intervention will consist of a two-month, personalized, goal-based counseling approach to promote physical activity. Over the first two weeks of the behavioral intervention, participants will also received 10, once-daily, 20-minute sessions of transcranial direct current stimulation (tDCS) designed to increase the excitability of the left dorsolateral prefrontal cortex.
89023922|NCT04278560|Active Comparator|Behavioral intervention plus sham stimulation|This intervention will consist of a two-month, personalized, goal-based counseling approach to promote physical activity. Over the first two weeks of the behavioral intervention, participants will also received 10, once-daily, 20-minute sessions of sham stimulation.
89023923|NCT04272294|Experimental|Use of Optical Spectroscopy|Optical spectroscopy used to characterize treatment response
89023924|NCT04272073|Active Comparator|Standard Care|"Participants will perform standard cardiac rehabilitation involving weekly (1-3 days) aerobic-focused exercise sessions in community gyms.~Participants will have received guidance on weight management and healthy eating from cardiac rehabilitation staff but will not receive any further dietary support."
89032923|NCT02923557|No Intervention|Blank control|do not use prophylactic intravesical chemotherapy.
89507431|NCT02226341|Active Comparator|CellCept daily & ACTHar gel biw|Patients will be treated with CellCept 3 grams daily and ACTHar gel 80 U biw for 3 months. After 3 months, patients with complete response will stop ACTHar gel but continue CellCept 3 grams daily for another 3 months whereas patients with partial response will continue CellCept 3 grams daily and be offered the option to continue ACTHar 80 U biw for another 3 months. After 6 months, all patients will continue CellCept at a dose of 2 grams daily for another 18 months.
89507432|NCT02226341|Active Comparator|CellCept daily & ACTHar gel qod|Patients will be treated with CellCept 3 grams daily for 3 months, and ACTHar gel 80 U qod for the first month and ACTHar gel 80 U biw for the following 2 months. After 3 months, patients with complete response will stop ACTHar gel but continue CellCept 3 grams daily for another 3 months whereas patients with partial response will continue CellCept 3 grams daily and be offered the option to continue ACTHar 80 U biw for another 3 months. After 6 months, all patients will continue CellCept at a dose of 2 grams daily for another 18 months.
89507433|NCT02291575|Experimental|Training|Of the 304 participants in the study, half will be randomized into the treatment arm in which they will receive training from the Liver Foundation.The objective of the Liver Foundation's training program will be capacity building through information in health sciences, training in referral techniques during emergencies, and maternal and child health care priorities in rural areas. The training will be in the form of two three-hour classes per week and will continue for nine months, with three mid-term exams administered every three. During this time, the evaluation team will only collect the rosters of the attendees of the training classes and conduct sporadic random visits to the sessions to gain a better sense of the training methods and attendance rates.
89507434|NCT02291575|Active Comparator|Control|Half of the sample will be randomized into the control group, for whom there will be no training. They will be phased into training the following year. For the current year, the control group will experience no difference in their routine, aside from some (infrequent) opportunities to participate in other public health activities as provided by the Liver Foundation to any provider involved in their various programs.
89032924|NCT02923557|Experimental|Single intravesical instillation|intravesical instillation within 24 hours postoperatively
89032925|NCT02923635|Active Comparator|Standard Wide Local Excision group|Group A (35 patients) have standard curative conservative breast surgery without integration of plastic techniques .
89032926|NCT02923635|Active Comparator|Oncoplastic group|Group B(35 patients) have curative oncoplastic surgery in which plastic techniques integrated with oncological procedures
89032927|NCT00529139|Active Comparator|A|
89032928|NCT00529139|Active Comparator|B|
88957730|NCT01986452|Experimental|Telemonitoring and support|CPAP device therapy data will be downloaded by the study site via GSM modules once a week. In case of poor therapy adherence (defined by a minimum average usage of 3h/night over the week) a contact call will be initiated to motivate patients or solve problems identified by telemonitoring. If active home intervention is required, the study site will inform the healthcare provider to visit the patient in a timely manner.
89507435|NCT04465903||Dysphagia patients|The first group consists of 85 dysphagia patients who have at least six months of dysphagia complaints. The participants will given the Turkish version of Sydney Swallow questionnaire (SSQ-T), consisted of 17 questions, eating assessment tool-10 and two scales evaluated with FEES. After the two weeks, 30 participants will given the SSQ-T for sampling.
89507436|NCT04465903||Healthy adults|The second group consists of 85 healty participants will given the SSQ-T consists of 17 questions, eating assessment tool-10.
89507437|NCT02222987|Active Comparator|Terbogrel|
89507438|NCT02222987|Experimental|Terbogrel with Clopidogrel|
89507439|NCT02222987|Active Comparator|Clopidogrel|
89507440|NCT03147573|Experimental|Blood pressure monitoring|
89507441|NCT03521245||Trastuzumab monotherapy|Her2-positive breast cancer patients treated with Trastuzumab (monotherapy)
89507442|NCT03521245||Chemotherapy plus Trastuzumab|Her2-positive breast cancer patients treated with Trastuzumab in combination with other regimens of chemotherapy
89507443|NCT02220257||Newly diagnosed type 1 diabetes|
89507444|NCT04479033|No Intervention|Control|Participants assigned to the control group had screened positive for cognitive impairment but refused the intervention. They were provided with a GP referral letter and information on helplines and caregiver support. Follow-up interviews were scheduled at week 24.
89507445|NCT04479033|Experimental|Intervention|Weekly meeting/communication sessions with members of intervention team for a total of 24 weeks.
89507446|NCT03521869|Active Comparator|Compression bandage group|
89507447|NCT03521869|Active Comparator|Standard gauze group|
89507448|NCT02481245|Experimental|Bipolar I and Bipolar II Disorder|30 currently depressed patients with DSM-IV bipolar I or bipolar II disorder who are currently taking an adequate dose of an FDA-approved anti-manic medication will receive Bezafibrate treatment.
89507449|NCT02352597|Active Comparator|clomiphene citrate|only50 mg orally every 8 hours started from cycle day 3 for 5 days
89507450|NCT02352597|Active Comparator|estradiol valerate and CC|2mg estradiol valerate orally daily from cycle day 7 - 11 in addition to CC
89507451|NCT02352597|Active Comparator|Phytoestrogen and CC|20mg of cimifuga racemosaorally from day 1- 12) in addition to CC
89507452|NCT02294851|Experimental|Single Ascending dose cohorts|Single ascending dose escalation, safety, tolerability, PK, PD and immunogenicity study of BMS-986168 administered by an intravenous infusion in healthy subjects.
89507453|NCT02294851|Placebo Comparator|Placebo|BMS-986168 Placebo
89507454|NCT02352675||Congenital Heart Disease|Infants with congenital heart disease (CHD) who are scheduled to undergo an elective cardiac catheterization lab procedure at Boston Children's Hospital
89507455|NCT02352675||Non Congenital Heart Disease|Infants who do not have congenital heart disease (No-CHD) and are scheduled to undergo a non-cardiac surgery (such as craniofacial surgery, neurosurgery, or orthopedic surgery) in the operating room at Boston Children's Hospital.
89507456|NCT02226419|Experimental|Break in L-carnitine treatment|Patients do not take their L-carnitine (Levocarnitine) treatment for 2-4 days until plasma carnitine and acylcarnitine have fallen. While patients abstain from taking the treatment, they are admitted for cardiac telemetry monitoring.
89507457|NCT02294929|Other|Atrial fibrillation ablation|Cryoballoon ablation for pulmonary vein isolation
89507458|NCT02226497|Active Comparator|Arm I (standard outpatient supportive care)|Patients receive standard outpatient supportive care after completion of chemotherapy.
89507459|NCT02226497|Experimental|Arm II (home telemonitoring device)|Patients receive standard outpatient supportive care as in Arm I and use the home telemonitoring device for the duration of chemotherapy-induced cytopenia (up to 3-4 weeks).
89507460|NCT03521167|No Intervention|T|traditional opioid based regimen
89507461|NCT03521167|Active Comparator|MD|multimodal group with dexmedetomidine
89507462|NCT03521167|Placebo Comparator|M|multimodal with saline placebo
89507463|NCT02352519|Experimental|UGBRSB|Under sterile conditions,the posterior rectus sheath will be identified by ultrasound, and an insulated 22 gauge 50 mm needle inserted till the tip is seen to be directly between the rectus abdominis muscle and the posterior rectus sheath. Bupivacaine 0.25% (0.2 ml/kg with maximum 5 ml in each side) will be injected observing the spread on the ultrasound image.
89507464|NCT02352519|Active Comparator|Local infiltration|In those patients randomized to the LAI group, the surgeon will perform infiltration of 0.5 ml/kg of 0.25% bupivacaine (maximum, 10 ml) around the incision.
89507465|NCT02226575|Experimental|Distress management|The distress management program (cognitive behavioral therapy) alongside standard care
89507466|NCT02226575|No Intervention|Control|Controls only dilivery standard care
89507467|NCT02291653|Experimental|Intubation without chest compressions|Endotracheal intubation of pediatric mannikin during resuscitation without chest compressions.
89507468|NCT02291653|Experimental|Intubation with uninterrupted chest compressions|Endotracheal intubation of pediatric mannikin during resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
88957731|NCT01986465|Experimental|Depomedrol|The trial pharmacist prepares a series of similar vials containing either 4 mg of Depomedrol or Normal Saline and coded them either 1, 2, 3 or 4, the group assignments are not decoded until the end of the trial when the final analysis is due to take place. Patients take their envelopes to the trial pharmacist who give them a coded vial which they take to the orthopaedic surgeon who make the injection. After the injection the trial clerk take the patients to a technician who give patients in groups 1 and 3 long arm splints.
89507469|NCT02356419|Experimental|experimental 0.5 ug/kg|there are four groups in this study and healthy subjects of all groups receiving different doses of recombinant erythropoiesis stimulating protein
89507470|NCT02356419|Experimental|experimental 1.0ug/kg|there are four groups in this study and healthy subjects of all groups receiving different doses of recombinant erythropoiesis stimulating protein
89023925|NCT04272073|Experimental|High-Protein mediterranean Diet and Resistance Exercise|"Participants will be asked to perform resistance exercise. This involves weights or weight machines aimed at building muscle strength. Participants will be required to attend 3 sessions per week and each session is expected to last approximately 45 minutes.~Personalised dietary advice: we will ask participants to make changes to their diet to adapt it to a high-protein, Mediterranean-style diet~eating more fruit and vegetables,~reducing commercial pastries, and replacing refined carbohydrate foods (white bread, white rice, white pasta) by wholegrains (wholegrain bread, rice and pasta),~replacing butter and margarine by olive oil as the main culinary fat,~reducing fatty meat and replacing by lean meat, fish, and legumes (peas, beans, lentils), and by high-protein, low fat foods, such as low-fat dairy (participants will be provided with 2 dairy-based protein shakes to consume each day)."
89023926|NCT04263922|Experimental|Huaiqihuang group|Combine the use of Huaiqihuang granules and Valsartan capsule simulant.
89023927|NCT04263922|Active Comparator|Valsartan Group|Combine the use of Valsartan capsule and Huaiqihuang granules simulant.
89023928|NCT04261556|Experimental|Real tDCS + CCT|"40 min/day of computerised cognitive training (CCT) + 20 min/day of real anodal transcranial direct current stimulation (tDCS).~In the first 20 min of the 40 min-intervention, tDCS and CCT will be provided simultaneously."
89507471|NCT02356419|Experimental|experimental 2.0ug/kg|there are four groups in this study and healthy subjects of all groups receiving different doses of recombinant erythropoiesis stimulating protein
89507472|NCT02356419|Experimental|experimental 3.0ug/kg|there are four groups in this study and healthy subjects of all groups receiving different doses of recombinant erythropoiesis stimulating protein
89507473|NCT02220335|Experimental|Pulmonary Arterial Denervation (PADN)|Contrast pulmonary artery （PA) angiography was performed to localize the pulmonary artery bifurcation level and calculate the PA diameter.Once the anatomy was deemed acceptable, the radiofrequency ablation catheter was introduced into ostium of the left PA, ostium of the right PA , and the distal bifurcation area of the main PA.This was then maneuvered within the PA to allow energy delivery in a circumferential manner to ensure that the electrodes were tightly in contact with the endovascular surface. About four to eight ablations at 10 W for 60 seconds each were performed in ostium of the left PA, ostium of the right PA , and the distal bifurcation area of the main PA.
89507474|NCT02220335|Active Comparator|Standard treatment|Patients in the standard treatment group will take their baseline anti-heart failure medications at the original doses, without any changes except when medically required.The anti-heart failure drugs treatment is consistent in both arms.
89507475|NCT02291731|Experimental|Continuous use of autologous serum|with continuous use of topical autologous serum for an additional 2 weeks after total re-epithelialization.
89507476|NCT03147339|Experimental|AGEs restricted diet|Low calorie diet + AGEs restricted diet
89507477|NCT03147339|No Intervention|control|Low calorie diet
89507478|NCT02223221|Experimental|With PGS|"IVF/ICSI cycles with PGS. Select embryos by SNP-array based PGS for the number of all chromosomes on day 5, only euploid embryos will be transferred.~A maximum of 2 embryos will be transferred for each treatment cycle. Up to 3 treatment cycles will be offered."
89507479|NCT02223221|Active Comparator|Without PGS|"IVF/ICSI cycles without PGS. Selection of embryos are based on blastocyst morphology criteria on day 5.~A maximum of 2 embryos will be transferred for each treatment cycle. Up to 3 treatment cycles will be offered."
89507480|NCT02223299|Experimental|Deplin w Supplements|deplin 15mg plus L-Tyrosine 6g/d and L-Tryptophan 2g/d for 30 days
89507481|NCT02223299|Placebo Comparator|Deplin w placebo|deplin 15mg daily plus Placebo A and Placebo B for 30 days
89507482|NCT02356341||NovaTears®|
89507483|NCT02295007|Other|text message|all families will receive text messages to which they can respond to report symptoms
89507484|NCT02356029||EMS Healthcare Providers|Healthcare Providers working in Emergency Medical Services and directly involved in treatment of cardiac arrest patients (out-of-hospital or in the Emergency Department)
89507485|NCT05256121|No Intervention|control|At 6 months and 12months the study team will communicate with the participants by phone to inquire about risk factors data, propose alternative activities, and provide positive reinforcement and feedback
89507486|NCT05256121|Experimental|intervention|"At baseline, participants in the intervention group will be asked to fill a daily risk-factor diaries (Risk factors log using the REDCap (Research Electronic Data Capture) software's survey).~In the Risk factors log, participants will need to answer shortly questions about their specific unbalanced risk factor.~In addition, during the 18-months intervention period, the study team will communicate with the participants' every 3-4 weeks by phone. Before each phone call, participants' Risk factors log data since previous phone call will be analyzed. The team will propose alternative activities, and provide positive reinforcement and feedback."
89507487|NCT02355873|Experimental|AN69ST|AN69ST:Surface-treated Polyacrylonitrile Membrane Hemofilter
89507488|NCT02355873|Active Comparator|AN69|AN69:original Polyacrylonitrile Membrane Hemofilter
89507489|NCT02226731|Experimental|Early Belfort-Dildy balloon device|
89507490|NCT02226731|Other|Late Belfort-Dildy balloon device|
89507491|NCT02291809|Experimental|REMUNE|Remune vaccine consists of a suspension of killed HIV-1 virus particles that have been emulsified with Incomplete Freund's Adjuvant (IFA, a mixture of mannide mono-oleate and a highly purified mineral oil). Each dose is given by IM injection and contains 10 μg of p24 antigen in approximately 100 μg of total protein.
89507492|NCT02291809|Placebo Comparator|REMUNE Low Dose|Remune low dose vaccine consists of a suspension of killed HIV-1 virus particles that have been emulsified with Incomplete Freund's Adjuvant (IFA, a mixture of mannide mono-oleate and a highly purified mineral oil). Each dose is given by IM injection and contains 2.5 μg of p24 antigen in approximately 25 μg of total protein.
89507493|NCT02226809||General anesthesia|Evaluation of RNMB. Application of accelerometry to patients after general anesthesia receiving at least one intermediate action nondepolarizing neuromuscular blocking agent dose
89023929|NCT04261556|Sham Comparator|Sham tDCS + CCT|40 min/day of CCT + 20 min/day of apparent (sham) tDCS. In the first 20 min of the 40 min-intervention, tDCS and CCT will be provided simultaneously.
88957732|NCT01986465|Placebo Comparator|Placebo|The trial pharmacist prepares a series of similar vials containing either 4 mg of Depomedrol or Normal Saline and coded them either 1, 2, 3 or 4, the group assignments are not decoded until the end of the trial when the final analysis is due to take place. Patients take their envelopes to the trial pharmacist who give them a coded vial which they take to the orthopaedic surgeon who make the injection. After the injection the trial clerk take the patients to a technician who give patients in groups 1 and 3 long arm splints.
88957733|NCT01986491|Experimental|Part 1; Period 1|Three participants will receive JNJ 39393406 of 2 different solid formulations (X and Y) with 2 different doses (30 mg and 120 mg) in following sequence (on Day 1 of each sequence) with a washout period of 1-2 weeks. 30 mg of solid X, 120 mg of solid Y, 30 mg of solid Y, and 120 mg of solid X.
88957734|NCT01986491|Experimental|Part 1; Period 2|Three participants will receive JNJ 39393406 of 2 different solid formulations (X and Y) with 2 different doses (30 mg and 120 mg) in following sequence (on Day 1 of each sequence) with a washout period of 1-2 weeks. 30 mg of solid Y, 30 mg of solid X, 120 mg of solid X and 120 mg of solid Y.
88957735|NCT01986491|Experimental|Part 1; Period 3|Three participants will receive JNJ 39393406 of 2 different solid formulations (X and Y) with 2 different doses (30 mg and 120 mg) in following sequence (on Day 1 of each sequence) with a washout period of 1-2 weeks: 120 mg of solid X, 30 mg of solid Y, 120 mg of solid Y, and 30 mg of solid X.
88957736|NCT01986491|Experimental|Part 1; Period 4|Three participants will receive JNJ 39393406 of 2 different solid formulations (X and Y) with 2 different doses (30 mg and 120 mg) in following sequence (on Day 1 of each sequence) with a washout period of 1-2 weeks: 120 mg of solid Y, 120 mg of solid X, 30 mg of solid X, and 30 mg of solid Y.
89507494|NCT02352441|Experimental|Implementation Intentions|This group will receive training in Implementation Intentions during 3 sessions, 1 day/week, over 3 weeks. They will receive usual care through the standard program, 1 day/week during these 3 weeks.
89507495|NCT02352441|No Intervention|Usual Care|This group will participate in the usual group intervention provided to Service members experiencing executive dysfunction associated with mild traumatic brain injury, 2 days / week during 3 weeks.
89507496|NCT02291887||Neovascular ARMD Patients|Patients with Neovascular Age-Related Macular Degeneration Responsive to Ranibizumab but Resistant to Aflibercept Treatment
89507497|NCT02352285|Experimental|Tolvaptan|Tovaptan tablet 15mg, 30mg, 60mg, once a day, oral
89507498|NCT02352285|Placebo Comparator|placebo|placebo tablet 15mg, 30mg, 60mg, once a day, oral
89507499|NCT02220491|Active Comparator|Whole-brain radiotherapy|"All subjects will have a non-contrast CT scan using a slice thickness of 2.5mm or less.~The Brain contour will be generated using the segmentation wizard and edits as required.~PTV_Brain is an expansion of the Brain by 5mm. 99% of PTV_Brain is to be covered by 95% of 20 Gy in 5 fractions using 6-10 MV photons in a parallel-opposed pair lateral beam arrangement."
89507500|NCT02220491|Experimental|Single-fraction radiotherapy|Immobilized in the mask, the subject will be imaged for radiotherapy planning with a CT slice thickness of 1.25 mm or less and an axial resolution of < 0.7 mm (CT field of view < 35 cm). Subjects that require contrast with GFR 45-59 will have pre-hydration, contrast dose modification and/or Mucomyst administration to preserve renal function, according to standard practice for radiological imaging at the institution.
89507501|NCT03521713|Experimental|EPORON|"<Part 1 Treatment Period> Week 1 to Week 24 Initial Phase (Week 1 to Week 4) : 50 IU/kg of Erythropoietin Alpha, three times a week (3 x 50 IU/kg/week) No dose adjustments will be permitted during the first 4 weeks of the study. Maintenance Phase (Week 5 to Week 24) The dose will be adjusted to maintain Hb levels between 10 and 12 g/dL.~<Part 2 Treatment Period> : Week 25 to Week 52 The dose of Erythropoietin Alpha will be adjusted to maintain hemoglobin levels between 10 and 12 g/dL as subcutaneous administration in accordance with the given dosing algorithm. The further details are the same as those for maintenance phase of Part 1 Treatment Period."
89507502|NCT03521713|Active Comparator|EPREX|"<Part 1 Treatment Period> Week 1 to Week 24 Initial Phase (Week 1 to Week 4) : 50 IU/kg of Erythropoietin Alpha, three times a week (3 x 50 IU/kg/week) No dose adjustments will be permitted during the first 4 weeks of the study. Maintenance Phase (Week 5 to Week 24) The dose will be adjusted to maintain Hb levels between 10 and 12 g/dL.~<Part 2 Treatment Period> : Week 25 to Week 52 The dose of Erythropoietin Alpha will be adjusted to maintain hemoglobin levels between 10 and 12 g/dL as subcutaneous administration in accordance with the given dosing algorithm. The further details are the same as those for maintenance phase of Part 1 Treatment Period."
89507503|NCT02355717||Prospective Cohort|400 otherwise healthy children and adolescents aged 9-15 years will be recruited to participate in a 2-year longitudinal study.
89507504|NCT02226887|Experimental|MESH|
89507505|NCT02226887|Active Comparator|NO MESH|
89507506|NCT04465513|Active Comparator|Best Standard of Care + CARDIO|Combination of CARDIO and Best Standard of Care
89507507|NCT04465513|Placebo Comparator|Best Standard of Care|Placebo and Best Standard of Care
89507508|NCT02355795|Experimental|low-fat diet|Participants will be provided low-fat diet for 6 months
89507509|NCT02355795|Experimental|moderate-fat diet|Participants will be provided moderate-fat diet for 6 months
89507510|NCT02355795|Experimental|high-fat diet|Participants will be provided high-fat diet for 6 months
89507511|NCT03517501|Active Comparator|ART-123|
89507512|NCT03517501|Placebo Comparator|Placebo|
89507513|NCT02295163|Sham Comparator|Sham procedure|injection of NACL 0,9% in the stellate ganglion
89507514|NCT02295163|Experimental|Stellate ganglion block|injection of Bupivacaine 0,5% in the stellate ganglion
89507515|NCT02223533|Experimental|Wound catheter|analgesia with wound catheter after colon surgery
89507516|NCT02223533|Active Comparator|morphine|analgesia with morphine after colon surgery
89507517|NCT02231021|Experimental|alogliptin + pioglitazone|alogliptin 25 mg 1 tablet daily for 24 weeks pioglitazone 30 mg 1 tablet daily for 24 weeks metformin for 24 weeks as the same dose and frequency as before enroll
89507518|NCT02231021|Active Comparator|alogliptin|alogliptin 25 mg 1 tablet daily for 24 weeks pioglitazone matching placebo 1 tablet daily for 24 weeks metformin for 24 weeks as the same dose and frequency as before enroll
89507519|NCT02231021|Active Comparator|Pioglitazone|alogliptin matching placebo 1 tablet daily for 24 weeks pioglitazone 30 mg 1 tablet daily for 24 weeks metformin for 24 weeks as the same dose and frequency as before enroll
89023930|NCT04251377|Experimental|Single-stage surgery + DAC® + topical antibiotics|Experimental group is composed of single-stage procedure associated to the use of biofilm inhibitor (Defensive Antibacterial Coating® DAC®) and topical antibiotics=new strategy
89023931|NCT04251377|No Intervention|control group : two-stage surgery|Control group is composed of two-stage procedure without biofilm inhibitor (standard protocol)
89023932|NCT04248920|Experimental|Intervention Group|Intervention Group. Participants randomized to the intervention group will complete the C2C program. They will receive an in-person one-on-one 60-minute education session and will be introduced to, and encouraged to participate in, the programs and support services that are provided by Epilepsy Southwestern Ontario (ESWO). As part of the C2C program, participants will be contacted 6 months later for a supplementary consultation over the telephone and to answer any questions. Epilepsy is unique among chronic, episodic disorders in that PWE lose their ability to make choices during a seizure and depend to a greater degree on the decisions of others including family, friends and colleagues. For this reason, we encourage the PWE to invite their support network to attend the patient education sessions.
89023933|NCT04248920|Other|Waitlist Control Group|Waitlist Control Group. The control group continues TAU and will be followed up 12 months after randomization. The control group will receive C2C after the 12-month follow-up.
89023934|NCT04232280|Experimental|mRNA-1647 Dose Level A|Participants will receive mRNA-1647 vaccine at Dose Level A by intramuscular (IM) injection on Day 1, Day 56, and Day 168.
89023935|NCT04232280|Experimental|mRNA-1647 Dose Level B|Participants will receive mRNA-1647 vaccine at Dose Level B by IM injection on Day 1, Day 56, and Day 168.
89023936|NCT04232280|Experimental|mRNA-1647 Dose Level C|Participants will receive mRNA-1647 vaccine at Dose Level C by IM injection on Day 1, Day 56, and Day 168.
89023937|NCT04232280|Placebo Comparator|Placebo|Participants will receive placebo matching to the mRNA-1647 vaccine dose by IM injection on Day 1, Day 56, and Day 168.
89023938|NCT04226313|Active Comparator|Self-sampling device sent at home|Women randomly selected from a commercial vendor database (both attenders and non-attenders) receive a mail inviting them to perform a cervicovaginal self-sampling at their home (with the device provided). Returned self-sampled swabs will be tested by CE-IVD-marked (Conformité Européenne, In Vitro Diagnostics) HPV diagnostic test validated for use in primary cervical cancer screening. The arm will include approx. 5000 participants.
89023939|NCT04226313|Experimental|Self-sampling device sent by gynecologist(s)|Women selected from databases of cooperating gynecologists (non-attenders for at least 3 years) receive a mail inviting them to perform a cervicovaginal self-sampling at their home (with the device provided). Returned self-sampled swabs will be tested by CE-IVD-marked HPV diagnostic test validated for use in primary cervical cancer screening. The arm will include approx. 5000 participants.
89023940|NCT04226313|Experimental|Self-sampling device obtained from general practitioner(s)|Women selected from databases of cooperating general practitioners (non-attenders for at least 3 years) receive a self-sampling device. Returned self-sampled swabs will be tested by CE-IVD-marked HPV diagnostic test validated for use in primary cervical cancer screening. The arm will include approx. 5000 participants.
89023941|NCT04213079|Experimental|Vestibulo-ocular reflex (VOR)|Treatment by re-adaptation of the vestibulo-ocular reflex (VOR) for participants with motion triggered MdDS
89023942|NCT04213079|Experimental|Habituation of velocity storage|Participants with motion triggered MdDS
89023943|NCT04209595|Experimental|Phase I Arm 1 Level -1A, PLX038 (PEGylated SN38) 1.3 g/m^2 and Rucaparib 200 mg|"Phase I - Participants with solid tumors enrolled to PLX038 (PEGylated SN38) and rucaparib escalation dose levels.~PLX038, every 3 weeks, 1.3 g/m^2, intravenous (IV); Rucaparib, days 5-19 twice a day (BID), total dose, 200 mg by mouth (PO)"
89023944|NCT04209595|Experimental|Phase I Arm 1 Level 1, PLX038 (PEGylated SN38) 1.3 g/m^2 and Rucaparib 400 mg|"Phase I - Participants with solid tumors enrolled to PLX038 (PEGylated SN38) and rucaparib escalation dose levels.~PLX038, every 3 weeks, 1.3 g/m^2, intravenous (IV); Rucaparib, days 3-19 twice a day (BID), total dose, 400 mg by mouth (PO)"
89023945|NCT04209595|Experimental|Phase I - Arm 1 Level 1A, PLX038 (PEGylated SN38) 1.3 g/m^2 and Rucaparib 300 mg|"Phase I Participants with solid tumors enrolled to PLX038 (PEGylated SN38) and rucaparib escalation dose levels.~PLX038, every 3 weeks, 1.3 g/m^2, intravenous (IV); Rucaparib, days 5-19 twice a day (BID), total dose, 300 mg by mouth (PO)"
89023946|NCT04209595|Experimental|Phase IIA Arm 2|"Phase IIA Participants with small cell lung cancer (SCLC) enrolled at the maximum tolerated dose (MTD) of PLX038 (PEGylated SN38) and rucaparib after the MTD of PLX038 and rucaparib is established.~Level 2, PLX038, every 3 weeks, 1.3 g/m^2, intravenous (IV); Rucaparib, days 3-19 twice a day (BID), total dose, 600 mg by mouth (PO); Level 3, PLX038, every 3 weeks, 1.7 g/m^2, intravenous (IV); Rucaparib, days 3-19 twice a day (BID), total dose, 600 mg by mouth (PO); Level 4, PLX038, every 3 weeks, 2.3 g/m^2, intravenous (IV); Rucaparib, days 3-19 twice a day (BID), total dose, 600 mg by mouth (PO); Level 2A PLX038, every 3 weeks, 1.3 g/m^2, intravenous (IV); Rucaparib, days 5-19 twice a day (BID), total dose, 400 mg by mouth (PO); and/or Level 3A. PLX038, every 3 weeks, 1.3 g/m^2, intravenous (IV); Rucaparib, days 5-19 twice a day (BID), total dose, 600 mg by mouth (PO)."
89032929|NCT02925975|Other|Healthy controls|Healthy volunteers are enrolled as controls to get a normal range of pressure gradient in different sites of hepatic portal system (HPS), such as portal vein, superior mesenteric vein, inferior mesenteric vein and splenic vein. All enrolled healthy subjects should undergo anatomic computed tomographic angiography (CTA) and Doppler ultrasound for only one time, to rebuild a 3D-vHPS by computer.
89032930|NCT02925975|Experimental|Treatment group guided by vPVPG|Enrolled cirrhotic patients with virtual portal vein pressure gradient (vPVPG) above 12mmHg are only treated by oral carvedilol. Once there are visible varies under the endoscopy, participants will be treated with routine endoscopic procedures.
89206867|NCT05296161|Experimental|Personalized B cell tailored ocrelizumab treatment|The personalized group will start with B cell measurements 24 weeks after the last infusion (baseline). The infusion interval will never be shorter than 24 weeks. The personalized group will start the study with a possible extension of the interval. The infusion will be postponed as long as CD19 B cell count stays below 10 cells/µL (determined every 4 weeks). When CD19 B cell count exceeds or is equal to 10 cells/µL, ocrelizumab infusion will be scheduled within two weeks
89206868|NCT00949611|Experimental|FRAX + Decision Aid|
89206869|NCT00949611|No Intervention|Usual care|
89206870|NCT00949611|Experimental|FRAX estimated fracture risk|
88957737|NCT01986491|Experimental|Part 2; Period 1|Four participants will receive 30 mg of JNJ 39393406 of 2 different formulations (solid formulation selected from Part 1 and solution) in following sequence (on Day 1 of each sequence) with a washout period of 1-2 weeks: 30 mg of solid formulation, and 30 mg of solution.
89507520|NCT04465123|Experimental|Furosemide with spironolactone or hydrochlorothiazide|"IV furosemide dosage will be adjusted according to the protocol as follows. Level 1: previous oral furosemide dose ≤80 mg/day; furosemide 80 mg IV bolus every 6 hours Level 2: previous oral furosemide dose 81-160 mg/day; furosemide 160 mg IV bolus every 6 hours Level 3: previous oral furosemide dose >160 mg/day; furosemide 250 mg IV bolus every 6 hours Furosemide dosage will be adjusted to keep urine output between 3,000 and 5,000 ml/day and >600 ml during 6 hours after furosemide administration.~If the urine output <3,000 ml/day or <600 ml per 6 hours, furosemide dosage will be increase 1-level up per protocol above.~If the urine output >5,000 ml/day, furosemide dosage will be reduced 1-level down per protocol above.~Patients will be received spironolactone or hydrochlorothiazide in combination with intravenous furosemide according to patients' serum potassium levels."
89507521|NCT04465123|Active Comparator|Furosemide with placebo|"IV furosemide dosage will be adjusted according to the pre-defined protocol as shown in the experimental group.~Patients will be received spironolactone placebo or hydrochlorothiazide placebo in combination with intravenous furosemide according to patients' serum potassium levels."
89507522|NCT04658303||Pimonidazole|Single dose of 0.5 gm/m^2 of pimonidazole (approximately 13 mg/kg)
89507523|NCT04465279|Experimental|Trifocal Diffractive Intraocular Lens (FineVision)|36 eyes having implantation of trifocal diffractive IOL (FineVision)
89507524|NCT02231099|Experimental|prolift + m|surgery with mesh (prolift+M)
89507525|NCT02231099|Active Comparator|conventional vaginal prolapse surgery|conventional vaginal prolapse surgery; anterior colporrhaphy or posterior colporrhaphy or spinal ligament fixation
89507526|NCT02292043||idiopathic dilated cardiomyopathy group|idiopathic dilated cardiomyopathy group treated with HTEA
89507527|NCT02292043||post-myocardial infarction group|post-myocardial infarction group treated with TEA
89507528|NCT02401347|Experimental|Cohort A - Triple-negative Breast Cancer|"Participants with advanced triple-negative breast cancer (TNBC) with homologous recombination deficiency (HRD) based on the Myriad HRD Assay.~Participants receive talazoparib 1 mg by mouth daily."
89507529|NCT02401347|Experimental|Cohort B - HER2-negative solid tumor|"Participants with advanced HER2-negative solid tumor with a deleterious hereditary or cancer somatic mutation in one of the following genes:~PTEN, PALB2, CHEK2, ATM, NBN, BARD1, BRIP1, RAD50, RAD51C, RAD51D, MRE11, ATR, Fanconi anemia complementation group of genes.~Participants receive talazoparib 1 mg by mouth daily."
89507530|NCT02295319|Experimental|Individual discharge|Discharge based on the patients individual needs and conditions. The discharge focus on information, communication, follow-up plans and collaboration, as well as the patients understanding and accept of the discharge plan. In addition, it includes a telephone interview 2 days after discharge to home.
89507531|NCT02295319|No Intervention|Control|Usual discharge procedures
89507532|NCT02231255||Idiopathic Parkinson's disease patients|
89507533|NCT02352051|Active Comparator|Atomoxetine group|The drug was initiated at a dose of 0.5 mg/kg/day which was then gradually increased at 2-week intervals and it was attempted to titrate the dose to 1.2 mg/kg/day.
89507534|NCT02352051|Active Comparator|Methylphenidate group|The drug was initiated at the lowest commercially available dose this was then increased at one-month intervals and it was attempted to titrate the dose to 1 mg/kg/day using daily doses of 36-54 mg.
89507535|NCT04465981||Patients with lab-confirmed COVID-19|Subject has lab-confirmed diagnosis of COVID-19 by RT-PCR
89507536|NCT04465981||Patients who are suspected to have or are confirmed to not have COVID-19|Subject has suspected COVID-19 according to medical evaluation, but does not yet have lab-confirmed diagnosis of COVID-19 (results outstanding, or has tested negative by RT-PCR)
89507537|NCT02227277|Experimental|Conditional 12-week ART interruption|18 participants will receive peg-IFN-α2b (1 μg/kg/week) for 20 weeks.
89507538|NCT02227277|Experimental|Continuous ART|18 participants will receive peg-IFN-α2b (1 μg/kg/week) for 20 weeks.
89507539|NCT02227277|No Intervention|Control with continuous ART|18 participants will continue their current ART regimens and be observed for 20 weeks.
89507540|NCT03147183||candidates for renal transplant|
89507541|NCT02292121|Experimental|obese group|40 obese subjects undergoing gastric bypass explored at baseline and 30 explored post-surgery at 6 months
89507542|NCT02292121|Active Comparator|non-obese control group (T1)|30 non-obese control subjects investigated for bio-clinical measures, IPT, zonulin, and LPS
89507543|NCT02292121|No Intervention|non obese control group undergoing a surgery (T2)|40 non-obese candidates to a surgery that gives access to surgical jejunal samples to measure the expression of tight junctions proteins
88957738|NCT01986491|Experimental|Part 2; Period 2|Four participants will receive 30 mg of JNJ 39393406 of 2 different formulations (solid formulation selected from Part 1 and solution) in following sequence (on Day 1 of each sequence) with a washout period of 1-2 weeks: 30 mg of solution, and 30 mg of solid formulation.
88957739|NCT01986491|Experimental|Part 3|Eight participants (same participants from Part 2) will receive JNJ 39393406 (dose will likely be 30 mg, or another multiple of the 30 mg solid dose form selected in Part 1, but not higher than 210 mg) from Days 1 to 7.
88957740|NCT01986517|Experimental|Feedback|Therapists assigned to this group will receive standardized feedback on their psychotherapeutic competency after every fourth treatment session with a patient for a period of 20 therapy sessions. The feedback will be given by two experienced raters who are licensed as psychological psychotherapists.
88957741|NCT01986517|Experimental|No feedback|Therapists assigned to this group will receive no feedback
88957742|NCT01986530||Healthy individuals|Participants will be healthy volunteers of both sexes recruited from the Greek Military Medical School personnel, Thessaloniki, Greece.
88957743|NCT01986530||Boost Subgroup|After an overnight fast, 40 participants will be provided a standardized mixed meal in two different quantities (125 ml, n=20 and 250 ml, n=20) and blood samples will be obtained before as well as 30 min after mixed meal ingestion
88957744|NCT01986530||Aerobic exercise|After an overnight fast, 20 participants will be subjected to aerobic exercise for 30 min and blood samples will be obtained at baseline and at 30 min
88957745|NCT01986530||Circadian variation Subgroup|20 of the participants will be hospitalized and closely monitored for 24 hours. A catheter will be inserted in a vein and blood samples will be obtained every 3 hours through the 24-hour period.
88957746|NCT01986530||Seasonal variation Subgroup|20 of the participants will be monitored for one year and blood samples will be obtained every 3 months (at the middle of month January - April - July - October). Subjects will be instructed to maintain their normal exercise routine and dietary habits.
88957747|NCT01986543|Experimental|Arm 1|8 weeks R20mg/Kg + HZE and efavirenz 600mg
89206871|NCT03958149|Other|Spinal collar|Participants will undergo MRI scans in and out a spinal collar to assess whether the measurements of angulation of the C-spine change whilst wearing a spinal collar.
89507544|NCT03147105|Experimental|arm ergometry|Home-based treatment after education in center, training following interval training plan on chip cards for 12 weeks at least 4-5 times/week
89507545|NCT03147105|Active Comparator|waiting group|training after 12 weeks.
89507546|NCT02223611|Experimental|S1 capsule plus Cisplatin|"S1: 40mg, bid, when body surface area (BSA)<1.25 m2, 50mg; bid when 1.25 m2≤BSA<1.5 m2; 60mg, bid when 1.5 m2≤BSA 60mg from day 1 to 14. Cisplatin: 75 mg/m2 on day 1.~3 weeks/4cycles"
89507547|NCT02223611|Active Comparator|Vinorelbine plus Cisplatin|"Vinorelbine: 25 mg/m2 intravenously on day 1, and day 8. Cisplatin: 75 mg/m2 intravenously on day 1.~3 weeks/4cycles"
89507548|NCT03520777|Other|Artist Intervention|One of the three artists (visual artist, music therapist, creative writer) will work with subjects for up to 90 minutes.
89507549|NCT03147027||VT ablation group|
89507550|NCT03147027||medication group|
89507551|NCT03517345|Experimental|Prebiotic group|Given a prebiotic product (inulin + oligofructose; 5 g) mixed with conventional yogurt (100 g) which given as snack, twice a day.
89507552|NCT03517345|Experimental|Control group|Given conventional yogurt (100 g) which given as snack, twice a day.
89507553|NCT02227355||PD Patients < 70 years of age|Patients with Parkinson's Disease (PD) <70 years of age.
89507554|NCT02227355||PD Patients ≥ 70 years of age|Patients with Parkinson's Disease (PD) ≥ 70 years of age.
89507555|NCT02355561|Experimental|Sequence 1 (ABC)|Participants will receive Treatment A (single dose of JNJ-54861911 25 milligram [mg] formulation 1 [reference] under fasted conditions) in Period 1; followed by Treatment B (single oral dose of JNJ-54861911 25 mg formulation 2 [test] under fasted conditions) in Period 2; followed by Treatment C (single oral dose of JNJ-54861911 25 mg formulation 2 under fed conditions) in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
89507556|NCT02355561|Experimental|Sequence 2 (ACB)|Participants will receive Treatment A in Period 1; followed by Treatment C in Period 2; followed by Treatment B in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
89507557|NCT02355561|Experimental|Sequence 3 (BAC)|Participants will receive Treatment B in Period 1; followed by Treatment A in Period 2; followed by Treatment C in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
89507558|NCT02355561|Experimental|Sequence 4 (BCA)|Participants will receive Treatment B in Period 1; followed by Treatment C in Period 2; followed by Treatment A in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
89507559|NCT02355561|Experimental|Sequence 5 (CAB)|Participants will receive Treatment C in Period 1; followed by Treatment A in Period 2; followed by Treatment B in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
89507560|NCT02355561|Experimental|Sequence 6 (CBA)|Participants will receive Treatment C in Period 1; followed by Treatment B in Period 2; followed by Treatment A in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
89206872|NCT00949689|Experimental|Cognitive Behavioral Therapy for insomnia and depression|cognitive behavioral therapy for insomnia followed by cognitive behavioral therapy for depression
89206873|NCT00949689|Active Comparator|contol|participants will receive sleep hygiene, time management techniques and cognitive therapy for depression
89206874|NCT00955773|Experimental|Group I|20 to 30 solid tumor subjects will be dosed with GSK1120212 in combination with everolimus to identify Maximum Tolerated Dose. Subjects will continue on study drug until disease progression or withdraw consent.
89206875|NCT00955773|Experimental|Group II|20 subjects with pancreatic cancer will receive the recommended dose identified in group I. Subjects will remain on study drug until disease progression or withdrawal from consent.
89507561|NCT02231333|Experimental|S-adenosylmethionine (SAMe)|
89507562|NCT02231333|Active Comparator|pentoxiphylline (PTX)|
89507563|NCT02348229|Experimental|ERAS group|ERAS protocols
89507564|NCT02348229|Other|conventional pathway group|using conventional pathway
89507565|NCT02227433|Experimental|brentuximab vedotin (BV)|
89507566|NCT03517189|Experimental|Aorta no-touch|Aorta no-touch off-pump coronary artery bypass surgery.
89507567|NCT02351973|Active Comparator|Hydrochlorthiazide|Hydrochlorothiazide (HCTZ) ATC class: C03AA03 Form: Tablet Dose range: Phase 1: 25mg (2 x 12.5mg tablet) Phase 2: 50mg (4 x 12.5mg tablet) Maximum allowed dose: 50mg Administration: oral
89507568|NCT02351973|Active Comparator|Amiloride|Amiloride ATC class: C03DB01 Form: Tablet Dose range: Phase 1: 10mg (2 x 5mg tablet) Phase 2: 20mg (4 x 5mg tablet) Maximum allowed dose: 20mg Administration: oral
88957748|NCT01986543|Experimental|Arm 2|8 weeks R20mg/Kg + HZE and efavirenz 800mg
88957749|NCT01986543|Active Comparator|Standard arm|8 weeks R10mg/Kg + HZE and efavirenz 600mg
88957750|NCT01986556|Experimental|Lesinurad 400 mg Fasted (Site 1 and Site 2, Lot A)|Day 1: Lesinurad 400 mg (Site 1 or Site 2, Lot A) Day 5: Lesinurad 400 mg (Site 1 or Site 2, Lot A)
88957751|NCT01986556|Experimental|Lesinurad 400 mg Fed (Site 1 and Site 2, Lot A)|Day 1: Lesinurad 400 mg (Site 1 or Site 2, Lot A) Day 5: Lesinurad 400 mg (Site 1 or Site 2, Lot A)
88957752|NCT01986556|Experimental|Lesinurad 400 mg Fasted (Site 1 and Site 2, Lot B)|Day 1: Lesinurad 400 mg (Site 1 or Site 2, Lot B) Day 5: Lesinurad 400 mg (Site 1 or Site 2, Lot B)
88957753|NCT01986556|Experimental|Lesinurad 400 mg Fed (Site 1 and Site 2, Lot B)|Day 1: Lesinurad 400 mg (Site 1 or Site 2, Lot B) Day 5: Lesinurad 400 mg (Site 1 or Site 2, Lot B)
88957754|NCT01986569|Experimental|[18F]fluoroestradiol (FES)|The injectable radioactive dose of 111-222 megabecquerel. One single IV injection over 1-2 min. [18F]FES PET/CT for imaging.
88957755|NCT01986582|Active Comparator|Group A|One puff of oxymetazoline immediately followed by one puff of hydroxyl-propyl-methyl cellulose powder, morning & evening, for 8 days.
88957756|NCT01986582|Placebo Comparator|Group B|One puff of oxymetazoline immediately followed by one puff of placebo, morning & evening, for 8 days.
88957757|NCT01986608|Experimental|Lacosamide 30-minute iv|A 30-minute intravenous constant infusion of Lacosamide (LCM) 200 mg (200 mg/20 mL single-use vial).
88957758|NCT01986608|Experimental|Lacosamide 60-minute iv|60-minute intravenous constant infusion of Lacosamide (LCM) 200 mg (200 mg/20 mL single-use vial).
88957759|NCT01986608|Experimental|Lacosamide oral tablet|Oral administration of Lacosamide (LCM) 200 mg (2 x 100 mg film-coated tablet) with 200 mL of water.
88957760|NCT01986621||Patients undergoing elective PCI|
88957761|NCT01986660|Experimental|Ibuprofen Cream (SST-0225)|
88957762|NCT01986673|Experimental|5% Sildenafil Cream (SST-6006)|5% Sildenafil Cream
88957763|NCT01986673|Active Comparator|Oral Sildenafil 50 mg|Oral Sildenafil 50 mg
88957764|NCT01986699||Standard Therapy|Patients are treated as per current standard of care
88957765|NCT01986699||Laparoscopic Assisted Polypectomy|Patients treated with Laparoscopic Assisted Colonoscopic Polypectomy
88957766|NCT01986712||Intron A, HDI|High-dose interferon alfa (Intron A, HDI)
88957767|NCT01986712||Sylatron|Pegylated alfa-interferon 2b (Sylatron, PEG IFN)
88957768|NCT01986725|Active Comparator|Standardized care|During treatment and routine follow-up consultations, patients randomized to standardized care will be provided with usual care and a predefined set of additional written information leaflets about supportive care options in the early treatment phase designed for the study.
89206876|NCT00955773|Experimental|Group III|Approximately 40 lung cancer subjects will receive the recommended dose identified in group I. Subjects will remain on study until disease progression or withdrawal of consent.
89206877|NCT00549549|Active Comparator|1|
89507569|NCT02351973|Active Comparator|Hydrochlorthiazide and Amiloride|Hydrochlorothiazide (HCTZ) + Amiloride Form: Tablets (separate tablet of each drug) Dose range: Phase 1: HCTZ 12.5mg (1 tablet) + Amiloride 5mg (1 tablet) Phase 2: HCTZ 25mg (2 x 12.5mg tablet) + Amiloride 10mg (2 x 5mg tablet) Maximum allowed dose: HCTZ 25mg/ Amiloride 10mg Administration: oral
89507570|NCT03520621||High Prevalence Population|Prevalence of kwashiorkor (as diagnosed by bipedal pitting edema) is >2% among children 36 to 59 months old in the population, in Murambi/Malehe Health Area of eastern Democratic Republic of the Congo
89507571|NCT03520621||Low Prevalence Population|Prevalence of kwashiorkor (as diagnosed by bipedal pitting edema) is <2% among children 36 to 59 months old in the population, in Murambi/Malehe Health Area of eastern Democratic Republic of the Congo
89507572|NCT04831619|Experimental|PET scanner in addition to MRI|
89507573|NCT02295397|Experimental|food provocation|open and placebo-controlled food challenges
89507574|NCT02231411|Active Comparator|Ventilation during DCC (V-DCC)|Measuring the volume of placental transfusion with ventilation (CPAP 5 cm H2O between inflations) in infants born by C/S or VG using, as an initial surrogate marker, Hematocrits at 12 hours of life (HOL)
89507575|NCT02231411|Active Comparator|DCC plus dry and stimulate|Measuring the volume of placental transfusions with delayed cord clamping alone (DCC) in infants born by C/S or VD using, as an initial surrogate marker, Hematocrits at 12 hours of life (HOL)
89507576|NCT03520543|Experimental|Part A : Imput function|Compartmental model of the volume of distribution of [11C]Yohimbine in Brain by PET
89507577|NCT03520543|Experimental|Part B : validity of the measure|Part B1 : Test Retest Variability in the distribution of [11C]Yohimbine Part B2 : Percentage of alpha2-adrenergic receptor occupancy
89507578|NCT02227511|Active Comparator|fruit|Participants are given +7kCal/kg body weight of fruit to be eaten as snack in between regular meals
89507579|NCT02227511|Active Comparator|nuts|Participants are given +7kCal/kg body weight of nuts to be eaten as snack in between regular meals
89507580|NCT02231489|Experimental|Treatment Sequence AB|Participants will receive treatment A (JNJ-42756493 tablet 10 milligram [mg] as single oral dose) along with JNJ-61818549, 100 microgram (mcg) intravenous infusion over 5 minutes, 2 hours after administration of JNJ-42756493 tablet on Day 1 in Treatment Period 1. Participants will receive treatment B (JNJ-42756493 capsule 10 mg as single oral dose) on Day 1 of Treatment Period 2.
89206878|NCT00549549|Experimental|2|
89507581|NCT02231489|Experimental|Treatment Sequence BA|Participants will receive treatment B (JNJ-42756493 capsule 10 mg as single oral dose) along with 100 microgram (mcg) intravenous infusion over 5 minutes, 2 hours after administration of JNJ-42756493 capsule on Day 1 in Treatment Period 1. Participants will receive treatment A (JNJ-42756493 tablet as single oral dose) on Day 1 of Treatment Period 2.
89507582|NCT02355639|Experimental|Clobetasol propionate 0.05 % ointment|Active drug
89507583|NCT02355639|Experimental|Betamethasone dipropionate 0.064 % ointment|Active drug
89507584|NCT02355639|Placebo Comparator|Petrolatum ointment|Placebo drug
89507585|NCT02355249|Experimental|A group (MIE)|Via minimally invasive thoracol-laparoscopic esophagectomy.
89507586|NCT02355249|Active Comparator|B group (OE)|Via traditional three incisions esophagectomy.
89519386|NCT03449329|Active Comparator|Locoregional SIP block|"This group will receive a SIP block using:~3mg/kg Ropivacain 1%~1mcg/kg dexmedetomidine (Dexdor®) 100mcg/ml Addition of NaCl 0.9% up to 60ml"
89023947|NCT04209595|Experimental|Phase IIB Arm 2|"Phase IIB Participants with extra-pulmonary small cell carcinomas enrolled at the maximum tolerated dose (MTD) of PLX038 (PEGylated SN38) and rucaparib after the MTD of PLX038 and rucaparib is established.~Level 2, PLX038, every 3 weeks, 1.3 g/m^2, intravenous (IV); Rucaparib, days 3-19 twice a day (BID), total dose, 600 mg by mouth (PO); Level 3, PLX038, every 3 weeks, 1.7 g/m^2, intravenous (IV); Rucaparib, days 3-19 twice a day (BID), total dose, 600 mg by mouth (PO); Level 4, PLX038, every 3 weeks, 2.3 g/m^2, intravenous (IV); Rucaparib, days 3-19 twice a day (BID), total dose, 600 mg by mouth (PO); Level 2A PLX038, every 3 weeks, 1.3 g/m^2, intravenous (IV); Rucaparib, days 5-19 twice a day (BID), total dose, 400 mg by mouth (PO); and/or Level 3A. PLX038, every 3 weeks, 1.3 g/m^2, intravenous (IV); Rucaparib, days 5-19 twice a day (BID), total dose, 600 mg by mouth (PO)."
89023948|NCT04208477|Experimental|BSG patients|
89023949|NCT04202640|Experimental|Arm A - Mechanical Stimulation|Patients in this arm will receive, in addition to standard rehabilitation physiotherapy, mechanical stimulation
89206879|NCT00549549|Experimental|3|
89507587|NCT03520465|Experimental|Supraaponeurotic mesh|"Patients with laparotomy closure by conventional approach of aponeurosis (continuous suture with monofilament of slow absorption), and posterior placement of supraaponeurotic mesh of polyvinylidene fluoride (PVDF) medium / low density and wide pore. The mesh has a longitudinal measurement that exceeds about 3 cm the upper and lower ends of the wound and width should not be less than 10 cm, therefore the mesh selected is DynaMesh®-CICAT longitudinal measure 10x35 cm.~The mesh is fixed to the aponeurosis with a crown of loose stitches and points to the midline. A prolene 2/0 non-reabsorbable monofilament suture of cylindrical needle is used.~A 10 Fr suction drainage is placed in the supraaponeurotic plane, with an exit to the exterior beyond the edges of the prosthesis. Drainage will be preserved for a minimum of 48 hours after surgery, and will be withdrawn when a debit of less than 50 ml is presented in 24 h."
89507588|NCT03520465|No Intervention|Monofilament|Patients with conventional closure of the middle laparotomy with approach of aponeurosis in a plane by continuous suture with monofilament of slow absorption. In this study, the suture used in all patients will be poly-4-hydroxybutyrate or Mono-max loop®.
89507589|NCT02227589|Experimental|MET/CBT-12 plus CBT-D|CBT-D is an integrated cognitive behavior therapy targeting depression, delivered by the same study therapist who delivers MET/CBT-12 to the adolescent. All adolescents receiving CBT-D remain in MET/CBT-12 with their study provider.
89507590|NCT02227589|Active Comparator|MET/CBT-12 plus D-TAU|D-TAU (Depression Treatment as Usual) consists of referral to a depression treatment provider in the community. In this study D-TAU will be enhanced by assistance from the study team in locating providers and, with consent, an assessment report about the adolescent from the study team to the provider. All adolescents receiving TAU for depression remain in MET/CBT-12 with their study provider.
89507591|NCT02227589|Active Comparator|MET/CBT-12 alone|MET/CBT-12 consists of two sessions of motivation enhancement therapy and 10 sessions of cognitive behavior therapy, targeting alcohol or cannabis abuse. All adolescents in the study receive MET/CBT-12 over 12 to 14 weeks.
89507592|NCT02259101|Experimental|CBT-I Treatment Condition|The CBT-I treatment condition will be delivered in a one-hour per week group format (10 participants) occurring over the course of six-weeks. Four total CBT-I groups occurring over the course of two years will be implemented, with at total of 40 participants enrolled for the CBT-I condition.
89507593|NCT02259101|Active Comparator|SH Comparison Condition|The SH comparison condition will also be delivered in a one-hour per week group format (10 participants) occurring over the course of six-weeks. Four total SH groups over the course of two years will be conducted, with a total of 40 participants enrolled for the SH condition.
89507594|NCT02351895||Copper linens|One ward during each period (23 weeks each) used copper impregnated linen on the bed and as patient gowns. The second ward used regular linen on the bed and as patient gowns
89507595|NCT00503035|Experimental|Celecoxib|Celecoxib 400 mg orally twice daily for 6 months. Up to 23 additional colon tissue biopsies (the size of a pencil tip), additional 20 minutes on colonoscopy procedure.
89507596|NCT02227745||Dorzolamide hydrochloride (2%)|dorzolamide: diabetic patients with clinical significally macular edema with treatment photocoagulation dorzolamide (2%) application 1 drop every 8 hours for 4 weeks
89507597|NCT02227745||Placebo Sodium hyaluronate4mg|placebo: diabetic patients with clinically significant macular edema(focal), with photocoagulation sodium hyaluronate (0.5%) application 1 drop every 8 hours for 4 weeks
89507598|NCT02348073|Active Comparator|PS-OMEGA 3, capsules twice daily|Vayarin®, supplementation of n-3 PUFA: each capsule contains 8.5 mg of docosahexaenoic acid (DHA), 21.5 mg of eicosapentaenoic acid (EPA) and 75 mg of phosphatidylserine.
89507599|NCT02348073|Placebo Comparator|PLACEBO, capsules twice daily|The placebo will be made of cellulose and a small amount of fish powder to maintain the double-blind in odor and taste. The supplementation in n-3 PUFA in the placebo group may be considered as negligible. Placebo will be administered as indistinguishable capsules, identical to the active product.
89507600|NCT03517033|Experimental|Test|Torrent's Nebivolol Tablets 20 mg
89507601|NCT03517033|Active Comparator|Reference|Forest Pharmaceuticals Inc's Bystolic Tablets 20 mg
89507602|NCT02355327|Experimental|Laselle Kegel Exerciser|
89507603|NCT02355327|Active Comparator|Pelvic floor muscle exercises|
89507604|NCT02223845|Experimental|Music|Played music during embryo transfer
89507605|NCT02223845|No Intervention|Control|No music played during embryo transfer
89507606|NCT02348151|Experimental|Treadmill|The Shuttle is going to play on treadmill
89507607|NCT02348151|Active Comparator|Corridor|The Shuttle is going to play on corridor
89507608|NCT02259179|Active Comparator|Fed Group|Reference and test product naltrexone SR/bupropion SR combination trilayer tablets tested in the fed state.
89507609|NCT02259179|Active Comparator|Fasted group|Reference and test product naltrexone SR/bupropion SR combination trilayer tablets tested in the fasted state.
89206880|NCT00549549|Experimental|4|
89206881|NCT00270205|Experimental|A: 0.1 mg DNA/participant vaccination at weeks 1,7,13|Participants receiving three separate low-dose vaccinations of LC002 (0.1 mg DNA/participant, 0.8 ml total, administered over two skin sites [on the left and right upper back] of 80 cm^2 each, 0.4 ml/site) at weeks 1, 7, and 13.
89507610|NCT03520153||FD/MAS with diabetes mellitus|"Fibrous Dysplasia/McCune-Albright Syndrome with diabetes mellitus.~Participants will receive the following interventions: Hyperinsulinemic Euglycemic Clamp and 2H20; Hyperglycemic Clamp; and Oral Glucose Tolerance Test."
89539903|NCT04898907|Active Comparator|Moxifloxacin Hydrochloride|The comparator will be administered as a single dose oral Moxifloxacin Hydrochloride tablet (open-label), with a total of 240 mL of water. There will be a minimum washout of 3 days between each study drug administration.
89539904|NCT04898907|Experimental|ANG-3777 (Supra-therapeutic Dose)|Administered IV as a single dose on two occasions for 30 minutes on the morning of Day 1 of each treatment period (total of 4), following an 8 hour overnight fast. There will be a minimum washout of 3 days between each study drug administration.
89539905|NCT03052647|Active Comparator|Subcuticular arm|closure technique that the Adhesive Latch arem (dermaclip) arm is being compared to
89539906|NCT03052647|Active Comparator|Adhesive Latch Arm (Demaclip arm)|This is the arm which the adhesive latch system is used and it is being compared to the arm of subcuticular
89539907|NCT04908813|Experimental|HLX22(25mg/kg)+Trastuzumab + Chemotherapy (XELOX)|Participants receive 25mg/kg HLX22 IV every 3 weeks (Q3W) plus trastuzumab (8 mg/kg loading dose, 6 mg/kg maintenance thereafter) IV Q3W in combination with XELOX chemotherapy
89539908|NCT04908813|Experimental|HLX22(15mg/kg)+Trastuzumab + Chemotherapy (XELOX)|Participants receive 15mg/kg HLX22 IV Q3W plus trastuzumab (8 mg/kg loading dose, 6 mg/kg maintenance thereafter) IV Q3W in combination with XELOX chemotherapy
89539909|NCT04908813|Active Comparator|Placebo +Trastuzumab + Chemotherapy (XELOX)|Participants receive placebo IV Q3W plus trastuzumab (8 mg/kg loading dose, 6 mg/kg maintenance thereafter) IV Q3W in combination with XELOX chemotherapy
89539910|NCT04913571|Experimental|TMB High group|
89539911|NCT04913571|Experimental|PD-L1 positive group|
89539912|NCT04913571|Experimental|Immunomodulatory (IM) group|
89539913|NCT04913571|Experimental|NanoString superiority group|
89539914|NCT04913571|Experimental|other types|
89539915|NCT03051789|Experimental|Menstrual Cup|One menstrual cup (Mooncup®), an insertable menstrual hygiene product, together with handwash soap termly; puberty and hygiene education and cup training given at intervention.
89539916|NCT03051789|Experimental|Cash Transfer|Cash transfer (CT; girls' pocket money; of Ksh 1500 per term) via local community/mobile banking with financial literacy, puberty and hygiene education and cash pocket money financial literacy training given at intervention.
89539917|NCT03051789|Experimental|Cups and Cash|A combination of cup and cash transfer interventions; puberty and hygiene education, cup training, and cash pocket money financial literacy training given at intervention.
88957769|NCT01986725|Active Comparator|Standardized care + WOMAN-PRO II program|During treatment and routine follow-up consultations, patients randomized to standardized care + WOMAN-PRO II program will be provided with usual care and nurse-led follow-up consultations with the WOMAN-PRO II program complementary to physician appointments.
88957770|NCT01986738||Radiation Treatment|Patients undergoing standard of care radiation treatment with Active Breathing Control (ABC)
88957771|NCT01986764|Active Comparator|lisdexamfetamine|lisdexamfetamine 20 mg/d to 60 mg/d for 12 weeks
88957772|NCT01986764|Active Comparator|Estradiol|Estradiol 1 mg/d to 3 mg/d for 12 weeks
88957773|NCT01986764|Placebo Comparator|Placebo|
89206882|NCT00270205|Experimental|B|Participants receiving three separate vaccinations of LC002 placebo (0.8 ml total, administered over two skin sites [on the left and right upper back] of 80 cm^2 each, 0.4 ml/site) at weeks 1, 7, and 13.
89539918|NCT03051789|No Intervention|Control|'Usual practice' (control) with handwash soap termly; puberty and hygiene education given at intervention.
89539919|NCT04894461|Experimental|Moxibustion|Moxibustion treatment sessions eight weeks from the baseline.
89539920|NCT04894461|No Intervention|Waiting|A waiting period of eight weeks by moxibustion treatment sessions in the same way with moxibustion group.
89539921|NCT04898361|Active Comparator|PFO closure|Patients with embolic stroke of undetermined source (ESUS) with patent foramen ovale (PFO) eligible for interventional PFO occlusion receiving a structured electrophysiological study due to palpitations before the PFO closure. Extensive cardiac monitoring.
89539922|NCT04898361|No Intervention|NO PFO|Patients with embolic stroke of undetermined source (ESUS) with NO patent foramen ovale (PFO) receiving a structured electrophysiological study due to palpitations. Extensive cardiac monitoring.
89539923|NCT04894149|Experimental|Physiotherapy|
89539924|NCT04894227|Experimental|Inactivated SARS-CoV-2 vaccine Lot 1|Participants (n=360) aged 26-45 years will receive Inactivated SARS-CoV-2 vaccine Lot 1 according to 0,28-day immunization schedule.
89539925|NCT04894227|Experimental|Inactivated SARS-CoV-2 vaccine Lot 2|Participants (n=360) aged 26-45 years will receive Inactivated SARS-CoV-2 vaccine Lot 2 according to 0,28-day immunization schedule.
89539926|NCT04894227|Experimental|Inactivated SARS-CoV-2 vaccine Lot 3|Participants (n=360) aged 26-45 years will receive Inactivated SARS-CoV-2 vaccine Lot 3 according to 0,28-day immunization schedule.
89539927|NCT03051711|Experimental|GBT440 Dose 1|Dose 1
89539928|NCT03051711|Experimental|GBT440 Dose 2|Dose 2
89539929|NCT04908345|Experimental|Methadone|Methadone 0,075mg/kg for induction and half of induction dose of boluses as needed during surgery
89539930|NCT04908345|Active Comparator|Fentanyl|Fentanyl 3 mcg/kg for induction and half of induction dose of boluses as needed during surgery
89539931|NCT04893993|Other|Thiamine-Placebo|"12 weeks: 4 weeks with Thiamine, 4 weeks wash-out, 4 weeks placebo~Both placebo and Thiamine are oral tablets of 300mg pr. tablet. The dosage depends on gender and weight of the participants, with a maximum of 1800mg intake pr. day."
89539932|NCT04893993|Other|Placebo-Thiamine|"12 weeks: 4 weeks placebo, 4 weeks wash-out, 4 weeks with Thiamine~Both placebo and Thiamine are oral tablets of 300mg pr. tablet. The dosage depends on gender and weight of the participants, with a maximum of 1800mg intake pr. day."
89539933|NCT04907955|Active Comparator|panoptix PANFOCAL intraocular lens|panoptix PANFOCAL intraocular lensis a single-piece aspheric non-apodized diffractive panfocal IOL that distributes light energy to three focal points in both small and large pupil conditions
89539934|NCT04907955|Active Comparator|Trifocal Diffractive the AT LISA intraocular lens|Trifocal Diffractive the AT LISA is a preloaded single-piece aspheric diffractive trifocal IOL and made of hydrophilic acrylic with a hydrophobic surface with an ultraviolet absorber. This aspheric IOL is aberration -correcting in order to reduce and compensate for corneal spherical aberrations.
89507611|NCT03520153||FD/MAS without diabetes mellitus|"Fibrous Dysplasia/McCune-Albright Syndrome without diabetes mellitus.~Participants will receive the following interventions: Hyperinsulinemic Euglycemic Clamp and 2H20; Hyperglycemic Clamp; and Oral Glucose Tolerance Test."
89507612|NCT03520153||FD/MAS without diabetes and without IPMN|"Fibrous Dysplasia/McCune-Albright Syndrome without diabetes mellitus and without intraductal papillary mucinous neoplasms.~Participants will receive the following interventions: Hyperinsulinemic Euglycemic Clamp and 2H20; Hyperglycemic Clamp; and Oral Glucose Tolerance Test."
89507613|NCT03520153||FD/MAS without diabetes and with IPMN|"Fibrous Dysplasia/McCune-Albright Syndrome without diabetes mellitus and with intraductal papillary mucinous neoplasms.~Participants will receive the following interventions: Hyperinsulinemic Euglycemic Clamp and 2H20; Hyperglycemic Clamp; and Oral Glucose Tolerance Test."
89507614|NCT03520153||Healthy Controls|Participants will receive the following interventions: Hyperinsulinemic Euglycemic Clamp and 2H20; Hyperglycemic Clamp; and Oral Glucose Tolerance Test.
89507615|NCT02355093|Experimental|adductor canal block (ACB)|We performed an ultrasound survey at the medial part of the thigh，the needle is introduced in-plane and 2 to 3 mL of saline is used to ensure correct placement of the needle in the vicinity of the saphenous nerve in the adductor canal,the catheter is introduced and advanced 1 to 2 cm beyond the tip of the needle.The study medication is administered as an infusion of 0.2% ropivacaine at a rate of 5mL/h during the next 48 hours.
89507616|NCT02355093|Active Comparator|Femoral nerve block (FNB)|the catheter is inserted in-plane with the probe parallel to the inguinal crease, to obtain a short-axis view of the nerve. The correct needle placement is confirmed by injecting 2 to 3 mL of saline to cause tissue expansion below the iliac fascia, lateral to the femoral artery, and in the vicinity of the femoral nerve. The catheter is introduced 1 to 2 cm beyond the tip of the needle，an infusion of 0.2% ropivacaine at a rate of 5mL/h is administered during the next 48 hours.
89507617|NCT03516799|Experimental|Acupuncture (ACU) Group|The group of participants who opt in to acupuncture
89507618|NCT03516799|No Intervention|Treatment-as-Usual (TAU) Group|The group of participants who enroll in the study but opt out of acupuncture (treatment-as-usual)
89507619|NCT03146949|Active Comparator|Sorin Inspire Oxygenator|Sorin Inspire Oxygenator is used on the cardiopulmonary bypass machine
89507620|NCT03146949|Active Comparator|Medtronic Affinity Fusion Oxygenator|Medtronic Affinity Fusion Oxygenator is used on the cardiopulmonary bypass machine
89507621|NCT02227901|Experimental|Treatment (tipifarnib, EBRT, temozolomide)|"TIPIFARNIB: Patients receive tipifarnib PO BID on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~CONCURRENT CHEMOTHERAPY DURING RADIATION THERAPY: Within 5-9 days after starting tipifarnib, patients undergo EBRT daily and receive temozolomide PO daily for 6 weeks.~POST-RADIATION CHEMOTHERAPY: Beginning at week 10 post-radiation therapy, patients receive temozolomide PO on days 1-5. Treatment repeats every 28 days for 1 year or 12 complete courses in the absence of disease progression or unacceptable toxicity."
89507622|NCT03146715|Active Comparator|High-carotenoid food feeding trial|Twenty-three children were randomly assigned to a treatment with a high carotenoid baked food (4.3mg carotenoids/120g, 360 kcal)
89507623|NCT03146715|Placebo Comparator|No-carotenoid food feeding trial|Twenty-five children were randomly assigned to consume a baked food with no carotenoids (300 kcals/73g)
89507624|NCT03160053|Experimental|Treatment Group|Keloids that were randomized to the treatment group, were exposed to Narrowband-UVB (NB-UVB). Targeted UVB will be delivered to the keloid for up to 16 weeks using the Lumera UVB light phototherapy device (Daavlin, Bryan Ohio, USA).The affected skin will be irradiated using a hand-held fiber optic cable with an adjustable aperture.
89507625|NCT03160053|No Intervention|Control Group|Keloids that were randomized to a non treatment group, were not exposed to the NB-UVB light.
89507626|NCT02227979|Experimental|Group I|The PURPLE Cry Intervention group will get an 11-page booklet and 12-minute DVD to review.
89507627|NCT02227979|Active Comparator|Group II|The control intervention group will get 1 brochure and a DVD on infant safety to review.
89507628|NCT03133195|Experimental|Teriparatide|Teriparatide 20 μg subcutaneous once daily for 12 weeks
89507629|NCT03133195|Placebo Comparator|Placebo|Placebo subcutaneous once daily for 12 weeks
89507630|NCT02258789|Experimental|intervention - control|15 hours ( 3 times a week in 5 weeks) intense visio spatial scanning training Virtual Reality-method
89507631|NCT02292199|Experimental|TENS High Frequency 100 Hz|TENS was applied for thirty minutes, with the frequency defined according to randomization. The intensity of the current was delivered at sensory-level intensity, adjusted every 5 minutes by the sensory threshold, during the 30 minutes as tolerated by each subject, but without motor contraction or pain reported by the subject.
89507632|NCT02292199|Active Comparator|TENS Low Frequency 4 Hz|TENS was applied for thirty minutes, with the frequency defined according to randomization. The intensity of the current was delivered at sensory-level intensity, adjusted every 5 minutes by the sensory threshold, during the 30 minutes as tolerated by each subject, but without motor contraction or pain reported by the subject.
89507633|NCT02292199|Placebo Comparator|TENS Placebo|The placebo group received an active current for 30 seconds, and then gradually decreased for 15 seconds to not pass any current. This approach aims at masking the investigator and subject (RAKEL et al., 2010).
89507634|NCT02231567|Experimental|Neurocognitive Rehabilitation|Rehabilitative approach based on exercises proposed as sensory-motor problems, whose solution involves the use of higher cognitive functions (attention, memory, language).
89507635|NCT02231567|Active Comparator|Traditional Rehabilitation|It is a rehabilitative approach based on exercises for the recovery of hip's range of motion, muscle strengthening exercises, stretching exercises of the hamstring muscles, adductor and iliopsoas and proprioceptive exercises.
89507636|NCT02224001|Experimental|Asian rhinoplasty, septal cartilage|"A New Concept in the Tip Plasty of Asian Rhinoplasty : The Flag Technique by Use of Only A Septal Cartilage without Septal Extension Grafts~The investigators propose the new technique, so called 'Flag Technique' by a tip-strut complex in a flag-like shape : using only the septal cartilage as an elongated columellar septal strut graft, a shield graft , bilateral mini-spreader grafts of the upper part in the elongated columellar septal strut graft without the septal extension graft to achieve the desired the result."
89507637|NCT02039037|Active Comparator|Acupuncture group|This group perform acupuncture needles brand Dong Bang 20x15 in specific spots for the treatment of low back pain.
88957774|NCT01986777|Active Comparator|lisdexamfetamine|Participants will have a 50% chance of receiving the active study medication. They will begin at 20 mg/d and will increase up to 60 mg/d after 4 weeks, if well tolerated. Total time on the study drug is up to 10 weeks.
88957775|NCT01986777|Placebo Comparator|Placebo|Participants will have a 50% chance of receiving the placebo for this study. They will begin with 1 sugar pill and will increase up to 3 pills after 4 weeks. Maximum time for taking the placebo is 8-10 weeks.
88957776|NCT01986803|Experimental|PCI with ABSORBTM bioresorbable vascular scaffold system (BVS)|All patients assigned to the experimental arm will be treated with a primary Percutaneous Coronary Intervention using the Abbott Vascular ABSORB TM everolimus eluting bioresorbable vascular scaffold system (BVS)
88957777|NCT01986803|Active Comparator|PCI with XIENCE Xpedition stent|All patients assigned to the experimental arm will be treated with a primary Percutaneous Coronary Intervention using the XIENCE Everolimus Eluting Coronary Stent System (XIENCE Xpedition) (commercial product)
88957778|NCT01986842|Experimental|Low protein|Subject will receive a low protein diet (0.7 g/kg BW/day) for 14 days prior to the experimental trial
88957779|NCT01986842|Experimental|High protein|Subjects will receive a high protein diet (1.5 g/kg BW/day) for 14 days prior to the experimental trial
88957780|NCT01986868|Other|Coronary MR Angiography (CMRA)|Coronary MR Angiography(CMRA). A gadolinium-based contrast (Optimark or MultiHance) will be administered as well as a beta blocker which will be assigned based upon heart rate.
88957781|NCT01986894|Placebo Comparator|Treatment 1 (placebo)|Five placebo capsules matching the appearance of the 4 mg pomalidomide capsule will be administered orally on the morning of Day 1
88957782|NCT01986894|Experimental|Treatment 2 (4 mg pomalidomide)|Five capsules (one 4 mg pomalidomide capsule and four placebo capsules matching the appearance of the 4 mg pomalidomide capsule) will be administered orally on the morning of Day 1
88957783|NCT01986894|Experimental|Treatment 3 (20 mg pomalidomide)|Five 4 mg pomalidomide capsules will be administered orally on the morning of Day 1
88957784|NCT01986894|Active Comparator|Treatment 4 (moxifloxacin)|One 400 mg moxifloxacin tablet (AVELOX®, moxifloxacin hydrochloride, Bayer Pharmaceuticals Corporation) will be administered orally on the morning of Day 1
89507638|NCT02039037|Active Comparator|Electroacupuncture group|Electro Group, will be added through the use of electrical stimulation of electroacupuncture using the apparatus Accurate pulse 585 at the same points.
88957785|NCT01986959|Experimental|Surgery with Periodontal dressing|After the Surgical crown lengthening, the patients were randomly allocated to the periodontal dressing group (PDG) and control group (CG - non-placement of periodontal dressing).
88957786|NCT01986959|Other|Surgery without Periodontal dressing|After surgery, the patients were randomly allocated to the periodontal dressing group (PDG) and control group (CG - non-placement of periodontal dressing).
89507639|NCT02295631|Experimental|ETI during immobilized spine (oral intubation)|intubation with immobilized cervical spine endotracheal intubation with immobilized cervical spine
88957787|NCT01986972|Active Comparator|Toothbrushing With Dentifrice|After 72 hours of absence oral hygiene, patients performed toothbrushing with common dentifrice.
89507640|NCT02295631|Experimental|ETI during immobilized spine (nasal intubation)|intubation with immobilized cervical spine endotracheal intubation with immobilized cervical spine
89507641|NCT02224079|Experimental|BIIB 722 CL|
89507642|NCT02224079|Placebo Comparator|Placebo|
89507643|NCT03159741|Experimental|Inhibitor + GLP-2|
89507644|NCT03159741|Experimental|Placebo + GLP-2|
89507645|NCT03159741|Active Comparator|Placebo + GIP|
89507646|NCT03159741|Placebo Comparator|Placebo + Saline|
89507647|NCT03516721|Other|Obese adolescents|
89507648|NCT03516721|Other|Lean adolescents|
89507649|NCT02231645|Experimental|STN DBS group|Experimental protocol is executed in PD patients with STN DBS implant in STN DBS ON and OFF conditions
89507650|NCT02231645|No Intervention|Control group|Experimental protocol is executed in PD patients without STN DBS implant twice without experimental variable manipulation.
89507651|NCT03159585|Experimental|TAEST16001|Patients who meet the inclusion criteria receive TAEST16001treatment after lymphodepleting by fludarabine and cyclophosphamide.
89507652|NCT02228057||operated group|all patients who had upper extremity artery surgery at least 6 months ago
89507653|NCT02292277||NSTEMI patients|Subjects eligible for the study will be ticagrelor naïve patients with NSTEMI presenting at the emergency room. Upon arrival to the emergency room written informed consent will be obtained before the patients receive their 180 mg loading dose of ticagrelor, as prescribed by the responsible physician.
89507654|NCT02292277||SCAD controls|Patients with stable coronary artery disease (SCAD) planned for elective angiography. If PCI is to be performed and if the responsible physician decides to administrate a loading dose of 180 mg ticagrelor, written informed consent will be obtained before loading dose and blood sampling.
89507655|NCT02292355|Experimental|Pilates|Intervention group will undergo Pilates sessions in addition to conventional treatment with occlusal splint
89507656|NCT02292355|No Intervention|Occlusal splint|Control group who receive conventional treatment with occlusal splint
89507657|NCT03152799|Experimental|Remote Ischaemic Pre-Conditioning (RIPC) Intervention|Remote Ischaemic Pre-Conditioning intervention to be applied via peripheral blood pressure cuff inflation/deflations to upper lower limb contra-lateral to affected side of hemiparesis
89507658|NCT03152799|Sham Comparator|Sham Control|Sham Control to be applied via peripheral blood pressure cuff inflation/deflations to upper lower limb contra-lateral to affected side of hemiparesis
89507659|NCT02231801||Mother-Infant Dyad|Skin-to-skin holding of preterm infants by their mothers
89206883|NCT00270205|Experimental|C: 0.4 mg DNA/participant vaccination at weeks 1, 7, 13|Participants receiving three separate high-dose vaccinations of LC002 (0.4 mg DNA/participant, 3.2 ml total, administered over four skin sites [on the left and right upper back and left and right upper ventral thigh] of 80 cm^2 each, 0.8 ml/site) at weeks 1, 7, and 13.
89206884|NCT00270205|Experimental|D|Participants receiving three separate vaccinations of LC002 placebo (3.2 ml total, administered over four skin sites [on the left and right upper back and left and right upper ventral thigh] of 80 cm^2 each, 0.8 ml/site) at weeks 1, 7, and 13.
89507660|NCT03516643|Experimental|Shockwave|Extracorporeal Shockwave treatment on Ischemic Myocardium
89507661|NCT02228135||Non post-tonsillectomy hemorrhage|Children who do not have post-tonsillectomy hemorrhage.
89507662|NCT02228135||Post-tonsillectomy hemorrhage|Children return to the hospital after surgery with post-tonsillectomy hemorrhage.
89507663|NCT03152877|Experimental|Liposomal bupivacaine treatment group|20cc of liposomal bupivacaine will be injected into the vaginal/perineal laceration site, in subjects in the experimental arm, following completion of the surgical repair.
89507664|NCT03152877|Active Comparator|0.25% plain bupivacaine treatment group|20cc of 0.25% plain bupivacaine will be injected into the vaginal/perineal laceration site, in subjects in the active comparator arm, following completion of the surgical repair.
89507665|NCT02295709|Experimental|USNR steroid injection|the patient who are treated with steroid (dexamethasone) injection through selected cervical spinal nerve block approach guided by ultrasound and C arm.
89507666|NCT02295709|Experimental|UCTF steroid injection|the patients who are treated with steroid (dexamethasone) injection through cervical transforaminal approach guided by ultrasound and C arm.
89507667|NCT02295709|Experimental|XCTF steroid injection|the patients who are treated with steroid (dexamethasone) injection through cervical transforaminal approach guided only by C arm.
89507668|NCT02228213|Experimental|Treatment|500 mcg MIS416 500 at 0.2 mg/mL administered i.v. once weekly for 52 weeks
89507669|NCT02228213|Placebo Comparator|Saline|Saline administered i.v. once weekly for 52 weeks
89507670|NCT02354937|Experimental|Subjects with renal impairment|Subjects with severe renal impairment will receive single oral dose of 744 30 mg
89507671|NCT02354937|Active Comparator|Subjects with normal renal function|Subjects with normal renal function will receive single oral dose of 744 30 mg
89507672|NCT02289001|Experimental|Education on SBAR worksheet|Training in the use of the SBAR worksheet created to structure information exchange between healthcare professionals
89507673|NCT02289001|No Intervention|No education on SBAR worksheet|The control group will participate in the simulation without any prior training in teamwork skills beyond those included in the undergraduate nursing degree curriculum, which the intervention group also received.
89507674|NCT03152331|Experimental|Receptive Awareness Training|
89507675|NCT02295787|Experimental|Ketamine|Intranasal Ketamine 50mg administered six times over three weeks.
89507676|NCT02295787|Placebo Comparator|Placebo|Intranasal saline solution administered six times over three weeks.
89507677|NCT02228291|Placebo Comparator|Placebo|Cellulose
88957788|NCT01986972|Experimental|Toothbrushing Without Dentifrice|After 72 hours of absence oral hygiene, patients performed toothbrushing without dentifrice.
88957789|NCT01986998|Active Comparator|oMP 1250 mg: Group A|Methylprednisolone 1250 mg/24h x3 days
88957790|NCT01986998|Active Comparator|oMP 625 mg: Group B|Methylprednisolone oral 625 mg/24h x3 days
88957791|NCT01987011|Experimental|MG1109|MG1109 0.5 mL Intramuscularly injection, twice at an interval of 21 days
88957792|NCT01987011|Placebo Comparator|Placebo|Placebo(for MG1109) 0.5 mL Intramuscularly injection, twice at an interval of 21 days
88957793|NCT01987024|Active Comparator|group A-usual procedure|
88957794|NCT01987024|Experimental|groupB- actim partus|
88957795|NCT01987037||tests evaluation|children with autism spectrum disorder subjected to the NP-MOT tests
88957796|NCT01987063||pregnant woman with twins|pregnant woman with twins
88957797|NCT01987076|Active Comparator|Corticosteroids per os: Prednisone + Emollient|
88957798|NCT01987076|Experimental|Topical corticosteroid: Clobetasol + Emollient|
88957799|NCT01987115|Experimental|Fascial Manipulation|Group will receive fascial manipulation at 3 centers of coordination (C.C) at: 1. C.C above the pronator teres muscle. (M.F unit of INTRA-CUBITUS), 2. C.C above proximal part of pronator quadratus muscle, between the palmaris longus and the flexor carpi radialis tendons (M.F unit of INTRA-CARPUS), 3. C.C in the mid-palmar region between metacarpus 3-4 (M.F unit of INTRA-DIGIT).4. C.C. over the muscle belly of Ext. Digit and Ext. Pollicis Longus (M.F unit of EXTRA-CARPUS).
88957800|NCT01987115|Active Comparator|Traditional physiotherapy|Group will receive U.S. treatment delivered to the A1 pulley area (3 Megahertz, over 1cm², for 5 minutes), Metacarpophalangeal and Proximal interphalangeal joint mobilization (for 5 minutes), eccentric stretching, and self exercises at home (self-stretch and self-massage).
89539935|NCT04907955|Active Comparator|Symphony EDOF (extended depth of focus) intraocular lens|SYMPHONY EDOF intraocular lens is a single-piece aspheric biconvex hydrophobic acrylic IOL with a 6.0 mm optic and an 13.0 mm overall diameter. This IOL consists of a wavefront-designed anterior aspheric surface (negative spherical aberration of -0.27 mm to counterbalance the net positive spherical aberration from cornea) and a posterior achromatic diffractive surface with echelette design.
89539936|NCT04893369|Experimental|The Low Back Pain and Disability Drivers Management model|Participating clinicians in the intervention arm will use the PDDM model to guide assessment and treatment of their patients and data will be collected over a 12-weeks period.
89539937|NCT04893369|Active Comparator|Low back pain clinical practice guidelines|Participating clinicians in the active comparator arm will perform assessment and treatment of their patients based on the recommendations from the most recent and high-quality clinical practice guidelines (CPGs) and data will be collected over a 12-weeks period.
89539938|NCT04898205|Experimental|Treadmill Exercise with Supplemental Oxygen|Participants will receive 24 sessions (2 x week for 12 weeks) of treadmill exercise combined with 6 liters per minute of supplemental oxygen via nasal cannula during exercise and 5-minutes of recovery. The first treadmill session will last 25% longer than the exercise tolerance test, but at a lower intensity, such that 80-100% of peak exercise intensity calculated from the exercise tolerance test MET is achieved within three sessions, after which time and intensity will be increased by no more than 0.5 METS, as tolerated based on symptoms and vitals. Heart rate, rhythm, and oxygen saturation will be continuously monitored, and blood pressure readings will be obtained every three to five minutes.
89539939|NCT04898205|Sham Comparator|Treadmill Exercise with Air|Participants will receive 8 sessions (2 x week for 4 weeks) of treadmill exercise combined with air delivered via nasal cannula during exercise and 5-minutes of recovery. They will then cross-over to 16 sessions of treadmill exercise combined with 6 liters per minute of supplemental oxygen via nasal cannula during exercise and 5-minutes of recovery. The first treadmill session will last 25% longer than the exercise tolerance test, but at a lower intensity, such that 80-100% of peak exercise intensity calculated from the exercise tolerance test MET is achieved within three sessions, after which time and intensity will be increased by no more than 0.5 METS, as tolerated based on symptoms and vitals. Heart rate, rhythm, and oxygen saturation will be continuously monitored, and blood pressure readings will be obtained every three to five minutes.
89539940|NCT04898205|Sham Comparator|Supplemental Oxygen Only|Participants will receive 8 treatment sessions (2 x week for 4 weeks) of 6 liters per minute of continuous oxygen via nasal cannula for 30 minutes at rest. Heart rate, rhythm, and oxygen saturation will be continuously monitored, and blood pressure readings will be obtained every three minutes. They will then cross-over to 16 sessions of treadmill exercise combined with 6 liters per minute of supplemental oxygen via nasal cannula during exercise and 5-minutes of recovery. The first treadmill session will last 25% longer than the exercise tolerance test, but at a lower intensity, such that 80-100% of peak exercise intensity calculated from the exercise tolerance test MET is achieved within three sessions, after which time and intensity will be increased by no more than 0.5 METS, as tolerated based on symptoms and vitals. Heart rate, rhythm, and oxygen saturation will be continuously monitored, and blood pressure readings will be obtained every three to five minutes.
88957801|NCT01987128|Experimental|Intraneural injection|All patients in the arm will receive a single intraneural injection of 12 ml Ropivacaine 1% BBraun, Germany, in the sciatic nerve under echographic guidance.
88957802|NCT01987128|Active Comparator|extraneural injection|All patients in the arm will receive a single extraneural injection of 12 ml Ropivacaine 1% BBraun, Germany, around the sciatic nerve under echographic guidance.
88957803|NCT01987141|Experimental|EMR intervention|Patients will have an electronic medical record popup/highlight in their chart, displaying the recommended guidelines for weight gain in pregnancy.
88957804|NCT01987141|No Intervention|Control|The patient's medical record will be displayed as usual, with no flag or highlight for weight gain recommendations
88957805|NCT01987154|Active Comparator|Marketed cow milk-based premature infant formula|
88957806|NCT01987154|Experimental|Marketed extensively hydrolyzed casein infant formula|
88957807|NCT01987167|Experimental|-ACHTHAR|Subcutaneous ACTHAR 5 days of 80 IU and 10 Days of 40 IU
88957808|NCT01987180||Usual standard care|Parents will be provided with the usual standard of care in the NICU. Discharge information will be provided to parents as is typically done in the NICU for VLBW infants getting ready to go home. Typical handouts are given to parents that describe their child's care and needs specifically as well as general guidelines. The project coordinator for the research study will verify that parents received information prior to discharge from the NICU staff. Parents will determine how you use this information.
89023950|NCT04202640|Sham Comparator|Arm B - Massages|Patients in this arm will receive, in addition to standard rehabilitation physiotherapy, massages.
89023951|NCT04200443|Experimental|Treatment (cabozantinib, temozolomide)|Patients receive cabozantinib PO QD on days 1-28 and temozolomide PO QD on days 1-5. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89023952|NCT04199221|No Intervention|Lecture|an initial brief lecture with no further training
89507678|NCT02228291|Experimental|Citric flavonoid|Citric flavonoid
89507679|NCT02292511|Experimental|Square-Stepping Exercise Intervention|Participants in this group will attend a square-stepping exercise intervention 60 minutes on two days a week at a community location.
88957809|NCT01987180||NICU-2-Home mobile app user|Parents will receive smartphone and unique NICU-2-Home app for their use. A pair of parents will be given two smartphones and will be asked to use the devices in their preferred way. Within the given app there is a baby tracking tool (baby-connect.com) that enables parents to keep track of the baby's feeding, diapers, sleep, health, medicines, vaccines, photos, etc. The objective in doing this is not to monitor the growth and development of the child; rather, it is to observe what tools within the app parents use and how frequently they use them.
89507680|NCT02292511|No Intervention|Usual-care wait-list control|This group will receive standard care and be invited to partake in the intervention after all assessments have been completed.
89507681|NCT03152487|Active Comparator|Celiac Plexus Neurolysis|CPN will be undertaken at the celiac space which is located between the aorta and the celiac artery origin. A 22 or 19-gauge Fine Needle Aspiration (FNA) needle is used, and its tip is placed slightly anterior and cephalic to the origin of the celiac artery. Aspiration is first performed using a syringe to ensure that vascular puncture has not occurred. 10 mL Bupivacaine is injected first, followed by 20 mL of 98% alcohol.
89507682|NCT03152487|Active Comparator|Radiofrequency Ablation|Once the celiac ganglia are identified on EUS, a 19-gauge FNA needle is inserted into the center of the ganglion or area of celiac plexus under EUS guidance. The radiofrequency (RF) probe (EMcision, Montreal, Canada) is advanced through the FNA needle. Radiofrequency ablation is performed via the probe for 90 seconds, followed by a 90 second rest and repeated as required.
89507683|NCT04464967|Experimental|Phase 1, Cohort 1|SNK01 (low dose) administered once every three weeks in combination with trastuzumab (loading dose of 8 mg/kg on Cycle 1, Day 1, followed by a 6 mg/kg on Cycle 2, Day 1 once every three weeks)
89507684|NCT04464967|Experimental|Phase 1, Cohort 2|SNK01 (high dose) administered once every three weeks in combination with trastuzumab (loading dose of 8 mg/kg on Cycle 1, Day 1, followed by a 6 mg/kg on Cycle 2, Day 1 once every three weeks)
89507685|NCT04464967|Experimental|Phase 1, Cohort 3|SNK01 (low dose) administered once every week in combination with cetuximab (loading dose of 400 mg/m2 on Cycle 1, Day 1, followed by a 250 mg/m2 on Cycle 2, Day 1 once every week)
89507686|NCT04464967|Experimental|Phase 1, Cohort 4|SNK01 (high dose) administered once every week in combination with cetuximab (loading dose of 400 mg/m2 on Cycle 1, Day 1, followed by a 250 mg/m2 on Cycle 2, Day 1 once every week)
89507687|NCT04464967|Experimental|Phase 2, Expansion Cohort 1|SNK01 (TBD RP2D) administered once every three weeks in combination with trastuzumab (loading dose of 8 mg/kg on Cycle 1, Day 1, followed by a 6 mg/kg on Cycle 2, Day 1 once every three weeks)
89507688|NCT04464967|Experimental|Phase 2, Expansion Cohort 2|SNK01 (TBD RP2D) administered once every week in combination with cetuximab (loading dose of 400 mg/m2 on Cycle 1, Day 1, followed by a 250 mg/m2 on Cycle 2, Day 1 once every week)
89507689|NCT02228369|Experimental|Daily dose of AZD3759|Daily oral dose of AZD3759
89507690|NCT02228369|Experimental|Daily Dose of AZD9291|Daily oral dose of AZD9291
89507691|NCT03146871|Experimental|Treatment (sEphB4-HSA, azacitidine, decitabine)|Patients receive recombinant EphB4-HSA fusion protein intravenously (IV) over 60 minutes on days 1 and 15. Patients also receive azacitidine IV or subcutaneously (SC) on days 1-7 or days 1-5 and 8-9, or decitabine IV on days 1-5. Administration of recombinant EphB4-HSA fusion protein occurs before or after the HMA (not concurrently). Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
89507692|NCT02289235|Experimental|Ginger|Ginger powder capsule 500 mg
89507693|NCT02289235|Placebo Comparator|Placebo|Placebo powder capsule
89507694|NCT03519841|Experimental|RSP-13-01|Experimental: IMD data collection Subjects will intensively collect spectral Raman data on P0.1 in a home-based setting for 5 days. Data will be paired with reference measurements.
89507695|NCT03519841|Experimental|RSP-13-02|Experimental: IMD data collection Subjects will collect spectral Raman data on P0.1 during four measuring sessions a day for 30 days distributed over a time period of 60 days. Each timepoint is conducted in duplicate. Spectral data will be compared to standard BG measurements.
89507696|NCT02354625|Experimental|ahSC transplantation|Autologous human Schwann cells
88957810|NCT01987206|Active Comparator|PID algorithm with HMS|"The control algorithm, at its core, is a Proportional-Integral-Derivative (PID)controller that incorporates an Internal Model Control (IMC) based tuning rule using an explicit model of human T1DM glucose-insulin dynamics. Parameters of the model are personalized based on a priori easily available subject parameters. This controller divides the control action into three components - the proportional distance between the current measurement and the target setpoint, the accumulated integral error as expressed by the area between the current state curve and the target set point over time, and the derivative rate of change of the current measurement.~The Health Monitoring System algorithm uses the same glucose monitoring (CGM) data as the PID control algorithm but utilizes a separate algorithm for trending and predictions of future glucose values. Using a redundant and independent algorithm is an important safety feature of the overall AP device."
88957811|NCT01987206|Experimental|MPC algorithm with HMS|"The first control strategy is a flavor of Model Predictive Control (MPC) algorithm. MPC employs an explicit model of the process to be controlled when optimizing the input. Specifically, MPC controllers for glycemia control use a model of a human's T1DM insulin-glucose dynamics to predict the evolution of the blood glucose values over a so-called prediction horizon of controller steps, and optimize a predicted insulin input trajectory in order to optimize a specified cost objective that penalizes unsafe glycemic values, and also insulin usage.~The Health Monitoring System algorithm uses the same CGM data as the MPC control algorithm but utilizes a separate algorithm for trending and predictions of future glucose values. Using a redundant and independent algorithm is an important safety feature of the overall AP device."
88957812|NCT01987258|No Intervention|Control|No exercise (control experiment)
89539941|NCT04898205|Placebo Comparator|No Intervention|Participants will receive 8 treatment sessions (2 x week for 4 weeks) of air via nasal cannula for 30 minutes at rest. Heart rate, rhythm, and oxygen saturation will be continuously monitored, and blood pressure readings will be obtained every three minutes. They will then cross-over to 16 sessions of treadmill exercise combined with 6 liters per minute of supplemental oxygen via nasal cannula during exercise and 5-minutes of recovery. The first treadmill session will last 25% longer than the exercise tolerance test, but at a lower intensity, such that 80-100% of peak exercise intensity calculated from the exercise tolerance test MET is achieved within three sessions, after which time and intensity will be increased by no more than 0.5 METS, as tolerated based on symptoms and vitals. Heart rate, rhythm, and oxygen saturation will be continuously monitored, and blood pressure readings will be obtained every three to five minutes.
89539942|NCT04893603|Experimental|Severe Aortic Valve Stenosis|Patients will be treated with Transcatheter Aortic Valve Systerm
89539943|NCT04892979|Experimental|Centre-based|Centre-based exercise cardiopulmonary rehabilitation program for 6 weeks
89539944|NCT04892979|Experimental|Online-based|Online-based exercise cardiopulmonary rehabilitation program for 6 weeks
89539945|NCT04892979|Experimental|Combined|Combined centre- and online-based exercise cardiopulmonary rehabilitation program for 6 weeks
89539946|NCT03051243|Active Comparator|Linagliptin and Basal Insulin|linagliptin (trajenta) 5mg once daily combined with basal insulin (glargine Lantus; sanofi) 0.15-0.3 units/kg TDD before bed time.
89539947|NCT03051243|Active Comparator|Basal Insulin and Bolus Insulin|Basal Insulin (Glargine Lantus; Sanofi) based therapy once daily before bedtime and glulisine (Apidra; sanofi) before meals. insulin dose will be 0.5 units/kg divided half as insulin glargine once daily and half as insulin glulisine before meals.
89539948|NCT04897737|Experimental|Intervention|HIV self-testing kits and counseling on use for participant and partner use + enhanced adherence counseling including urine tenofovir test to provide biofeedback in women using PrEP
89539949|NCT04897737|No Intervention|Control|Standard of care intervention including facility based HIV testing, referral for partner to attend facility for testing, and PrEP adherence counseling without biofeedback
89539950|NCT04897815||20 patients with type 2 diabetes mellitus|Fasting blood glucose and TCD will be measured in 20 patients with type 2 diabetes mellitus, and the data of Vm, PI and cerebrovascular reactivity of cerebral artery will be obtained. One hour after drinking 300ml lukewarm water which has dissolved 75g glucose powder, the blood glucose will be detected again and TCD examination will be performed again.
89539951|NCT04897815||20 healthy volunteers whose sex and age and BMI matched with the experimental group|Fasting blood glucose and TCD will be measured in healthy control group, and the data of Vm, PI and cerebrovascular reactivity of cerebral artery will be obtained. One hour after drinking 300ml lukewarm water which has dissolved 75g glucose powder, the blood glucose will be detected again and TCD examination will be performed again.
89539952|NCT03054597|Experimental|Adults|"The arm consisted of adult participants who underwent:~Circular Light Motion exercises: 4 times over 2 weeks Diagonal Light Motion exercises: 4 times over 2 weeks Peripheral Light Motion exercises: 4 times over 2 weeks"
89539953|NCT03054597|Experimental|Children|"The arm consisted of child participants who underwent:~Circular Light Motion exercises: 4 times over 2 weeks Diagonal Light Motion exercises: 4 times over 2 weeks"
89539954|NCT04892589||Active Comparator: Control group|Thumb orthosis at night and day for 3 to 4 hours during Activities of Daily Living that included thumb metacarpophalangeal joint (MCP) for three months. In addition to a classic home exercise program.
89539955|NCT04892589||Experimental: Experimental group|The experimental group will receive thumb orthosis at night and daytime use for 3 to 4 hours during Activities of Daily Living that included the thumb MCP for three months. In addition to a classic home exercise program and a proprioceptive home exercises program divided in three phases.
89539956|NCT04897191||Healthy|Healthy people age 20-70 years
89539957|NCT04897113|Experimental|plasmapheresis with albumin compensation|a course of hardware plasmapheresis procedures with replacement by colloidal (5% albumin solution) and crystalloid solutions (saline) in a ratio of 1: 3
88957813|NCT01987258|Experimental|Interval Walking|A one hour interval walking exercise bout
88957814|NCT01987258|Experimental|Continuous walking|A one hour continuous walking exercise bout
88957815|NCT01987271|Experimental|With noninvasive ventilation|When patients do the six minute walk test with the noninvasive ventilation.
88957816|NCT01987271|No Intervention|Without noninvasive ventilation|When patients do the six minute walk test without noninvasive ventilation.
88957817|NCT01987284|Experimental|SER100|SER100 10 mg s.c. twice daily
88957818|NCT01987284|Placebo Comparator|Placebo|Placebo administered s.c. twice daily
88957819|NCT01987297|Experimental|ATRA+Arsenic|All low- and intermediate-risk patients receive retinoic acid and arsenic trioxide based consolidation. High-risk patients receive ATRA+Arsenic+Anthracycline consolidation.
88957820|NCT01987297|Active Comparator|ATRA+chemo|All low-risk and intermediate-risk patients receive retinoic acid and chemotherapy with idarubicin or daunorubicin as consolidation. High-risk patients receive ATRA+anthracycline and cytarabine as consolidation.
88957821|NCT01987310|Active Comparator|Statin|statin therapy (atorvastatin 20 mg/d) for 6 months
88957822|NCT01987310|No Intervention|usual care|follow up group with no intervention
88957823|NCT01987310|Active Comparator|lifestyle counseling|lifestyle modification by dietician counseling and follow-up
89023953|NCT04199221|Experimental|Stress management|an initial brief lecture with stress management lecture
89539958|NCT04897113|Experimental|plasmapheresis without albumin compensation|a course of hardware plasmapheresis procedures without replacement by albumin solution, only crystalloid solutions (saline).
89539959|NCT04148781|Experimental|Fampridine-SR|Fampridine-SR 10 mg Orally Twice Daily for 8 weeks.
89539960|NCT04891887|Experimental|Intervention|Health education program
89539961|NCT04907331|Active Comparator|Corminaty twice|The participants receive Comirnaty twice 3-7 weeks apart
89539962|NCT04907331|Active Comparator|Vaxzevria twice|The participants receive Vaxzevria twice 12 weeks apart.
89539963|NCT04907331|Experimental|Heterologous|The recipients receive Vaxzevria followed by Comirnaty 12 weeks apart
89539964|NCT04906863||Mild Cognitive Impairment|Individuals with mild cognitive impairment that began before age 70
89539965|NCT04906863||Dementia/Alzheimer's Disease|Individuals with Alzheimer's Disease or other dementia that began before age 70
89539966|NCT04906863||Cognitively Healthy|Cognitively healthy individuals over the age of 30 years
88957824|NCT01987323|Experimental|Lipolat|Subconjunctival injection of Lipolat into the superior bulbar conjunctiva of all enrolled participants
88957825|NCT01987362|Experimental|RO6870810 (Part 1)|Participants will receive escalated doses of RO67870810 SC. RO6870810 will be escalated at a starting dose of 0.03 milligrams per kilogram (mg/kg) to a maximum of 0.85 mg/kg. Treatment will be administered in treatment cycles of either 21 days or 28 days and continued until PD, adverse events which justify treatment withdrawal, non-adherence, non-compliance, investigator decision, lost to follow-up, enrollment in other clinical study, or unacceptable toxicity.
88957826|NCT01987362|Experimental|RO6870810 (Part 2)|Participants will receive RO6870810 at doses up to the MTD or up to the highest dose tested if the MTD is not defined. Treatment will be administered in treatment cycles of either 21 days or 28 days and continued until PD, adverse events which justify treatment withdrawal, non-adherence, non-compliance, investigator decision, lost to follow-up, enrollment in other clinical study, or unacceptable toxicity.
88957827|NCT01987375|Experimental|Cetuximab-IRDye800 Participants|Participants who received the study drug cetuximab-IRDye800, following a loading dose of unlabeled cetuximab
88957828|NCT01987388|Experimental|High Intensity Exercise, High Carbohydrate Beverage|Study participant consumes a high carbohydrate beverage as part of the day's meals, and performs high intensity exercise (85% of VO2 max), while in the calorimeter.
88957829|NCT01987388|Experimental|High Intensity Exercise, High Fat Beverage|Study participant consumes a high fat beverage as part of the day's meals, and performs high intensity exercise (85% of VO2 max), while in the calorimeter.
89539967|NCT04896723||Chronic liver disease|
89539968|NCT04896723||Healthy volunteers|
89539969|NCT04896879||Patients|Patients with major LARS
89539970|NCT04896879||Informal caregivers|Informal caregivers of patients with major LARS
88957830|NCT01987388|Experimental|Low Intensity Exercise, High Carbohydrate Beverage|Study participant consumes a high carbohydrate beverage as part of the day's meals, and performs low intensity exercise (65% of VO2 max), while in the calorimeter.
88957831|NCT01987388|Experimental|Low Intensity Exercise, High Fat Beverage|Study participant consumes a high fat beverage as part of the day's meals, and performs low intensity exercise (65% of VO2 max), while in the calorimeter.
88957832|NCT01987440|Experimental|Lubricating Gel|The speculum was warmed, and patients were informed about what was going to happen. The labia were spread from below to introduce the speculum, which was inserted at a 45-degree angle pointing downward then rotated horizontally as the insertion continued. A VAS score (insertion) was obtained at this point. Next, the bill of the speculum was opened up until the vaginal cuff could be seen, and the speculum was secured by turning the thumbnut. A second VAS score (dilation) was recorded. During speculum examination, cervical smear with cervical brush was obtained for pathologic assessment if necessary. The speculum was withdrawn slightly, which allowed the bill to close together, and at this stage (extraction) the final VAS score was obtained. In the gel group , a doctor placed 6,5 mL mL sterile lubricating gel on the top and bottom blades of the speculum. Length of the vagina was measured by the index finger.
89539971|NCT04896879||Healthcare professionals|Healthcare professionals taking care for patients with LARS
89539972|NCT04891653|Experimental|5-65mg QD|
89539973|NCT04891731||leuprorelin 3M plus AIs|leuprorelin 3M: 11.25 mg subcutaneous administration every 3 months for 1 year AIs: anastrozole 1mg /letrozole 2.5mg/exemestane 25mg daily for 1 year
89539974|NCT04891731||leuprorelin 3M plus TAM|leuprorelin 3M: 11.25 mg subcutaneous administration every 3 months for 1 year TAM: daily for 1 year
89539975|NCT04896177|Experimental|Sirolimus drug-eluting coronary balloon catheter|Manufacturer: Shenzhen Salubris Pharmaceuticals Co., Ltd. This product is a sirolimus drug eluting balloon catheter for coronary artery therapy. It is a rapidly exchangeable PTCA balloon catheter (RX), effective length is 140cm, and compatible with 0.014 in. (0.36mm) guide wire. The balloon at the distal end of the catheter was coated with sirolimus, an anti-proliferative and anti-inflammatory drug.
89539976|NCT04896177|Active Comparator|Drug-eluting balloon catheter|Manufacturer: Liaoning Yinyi Biotechnology Co., Ltd Coated with paclitaxel.
89539977|NCT03050853|Experimental|E-Cigarette|The E-cigarette arm will be asked to use e-cigarettes in place of regular tobacco products. The group will be assessed at baseline, 2 weeks, 4 weeks, 6 weeks, 8 weeks, 13 weeks, and 26 weeks.
89539978|NCT03050853|No Intervention|Assessments only|The Assessment only group will be asked to refrain from use of e-cigarettes during participation. The group will be assessed at baseline, 2 weeks, 4 weeks, 6 weeks, 8 weeks, 13 weeks, and 26 weeks.
89539979|NCT04896255||interferon cohort|Patients who are going to take peginterferon alpha based regimen
89023954|NCT04199221|Active Comparator|Hands-on training|an initial brief lecture with addition hands-on training for the task
89539980|NCT04896255||nucleos(t)ide cohort|Patients who are going to take nucleos(t)ide alone
89539981|NCT04895865|Experimental|Self-selected|"Participants in the self-selected arm will choose the initial resistance in view of their preferences, and complete as many repetitions as they wish in order to reach the target rating of perceived exertion RPE of 7/10"
89539982|NCT04895865|Active Comparator|Predetermined|"Participants in the predetermined arm will be instructed to complete ten repetitions per set and exercise, while aiming to reach a rating of perceived exertion (RPE) of 7/10 by the 10th repetition. This means that participants will need to select and adjust the resistance of each exercise (e.g., band's resistance) to achieve this goal."
89539983|NCT04906785|Experimental|Sequence1|"Period 1: Reference drug(D744)~Period 2: Test drug(CKD-385)"
89539984|NCT04906785|Experimental|Sequence2|"Period 1: Test drug(CKD-385)~Period 2: Reference drug(D744)"
89539985|NCT04906473|Experimental|KY100001|KY100001; Tablet; Oral route; Dose escalation and dose extension
89539986|NCT04895397|Active Comparator|Group A: (30 patients)|modified pectoral nerve block will be done.
89539987|NCT04895397|Active Comparator|Group B: (30 patients)|serratus plane block will be done.
89539988|NCT04430595|Experimental|Multiple 4SCAR T cells to treat breast cancer|Multiple 4SCAR T cells to treat breast cancer
89539989|NCT04890951||Uterine Preservation|
89539990|NCT04890951||Hysterectomy|
89539991|NCT03051399|Placebo Comparator|Placebo|Maltodextrin, 500 mg/day, single serving
89539992|NCT03051399|Active Comparator|EpiCor|EpiCor, 500 mg/day, single serving
89539993|NCT04906317|Active Comparator|Sedation and Analgesia|0.05 mg/kg midazolam and 5mg dezocine iv infusion
89539994|NCT04906317|Active Comparator|Anesthesia|continuous 1.5mg/kg propofol iv infusion
89023955|NCT04199221|Experimental|Stress management and hands-on training|an initial brief lecture with both stress management lecture and additional hands-on training
89023956|NCT04190446|Experimental|Arm I (proton beam radiation therapy)|Patients undergo proton beam radiation therapy 5 days a week over 3 weeks. Patients undergo PET scan, CT scan, MRI, and blood sample collection throughout the study.
89539995|NCT03051321|Experimental|Wellness toileting system|Subjects given SchwabCare Wellness Toileting system
89539996|NCT04890795|Experimental|AL8326|Subject will received AL8326 once daily for 28-days cycle until intolerable toxicity or disease progression or death or voluntary withdrawal the end of this study.During treatment, subjects will be evaluated for anti-tumor efficacy and corresponding safety examinations every 2 cycles, and tumor disease status will be according to RECIST 1.1.
89539997|NCT03051087|Experimental|Ganilever (ganirelix acetate)|Prefilled syringe / 0.25mg/0.5mL
89539998|NCT03051087|Active Comparator|Orgalutran (ganirelix acetate)|Prefilled syringe / 0.25mg/0.5mL
89539999|NCT04430361|Experimental|Megestrol|Palonosetron 2.5mg, Dexamethasone 12mg on the first day, 8mg on the 2nd-4th day, Megestrol acetates 160mg orally every morning on the day of the beginning of chemotherapy for 10 days.
89540000|NCT04430361|Other|Control|Palonosetron 2.5mg, Dexamethasone12mg on the first day, 8mg on the 2nd-4th day
89540001|NCT04412343|Experimental|Virtual group exercise|Individuals in the (virtual) group-based exercise program, will have the opportunity to take part in (virtual) group exercise classes, delivered via videoconferencing, by experienced older adult exercise instructors. Personnel who analyze the data collected from the study are not aware of the treatment applied to any given group. Classes will be offered multiple days a week at 9am PST (12 noon EST), and will last approximately 50 minutes. Classes include a warm-up component, moderate intensity exercises as the core component of the class, and a cool-down. At the end of classes participants will have the opportunity to connect in small groups (videoconferencing breakout groups) to socially connect over a beverage (coffee, water) from their own homes. Participants in the group condition will also be sent, by mail, a program t-shirt to foster a sense of distinctiveness.
89540002|NCT04412343|Experimental|Personal exercise|Each of the older adult instructors described above will also contribute to delivering pre-recorded exercise classes (involving the same exercises, intensity, music, and so forth as those described above for the group condition). However, in this instance, instructors will deliver those classes to each participant by referring to themselves as each participant's personal trainer/coach, with language directed to the individual and not the group. That is, no sense of 'groupness' or 'shared social identities/connectivity' will be primed. Also, participants in this condition will not have the opportunity to interact with other older adults after classes have ended and will not receive the same program t-shirts designed to foster a sense of group distinctiveness.
89540003|NCT04412343|No Intervention|Wait-list control|Those randomized to the wait-list control condition will go about their daily lives for the duration of the 12-week trial. They will be asked to complete the same questionnaires (and will be remunerated in the same way as those in the other two conditions via $10 per questionnaire completion). At the end of the 12-week trial, participants in this condition will have access to the personal exercise programming.
89540004|NCT04895163||Foreign workers|Foreign workers aged 18-50 who were admitted to our institution between January 1st, 2013 and October 31st, 2018, with the diagnosis of acute appendicitis.
89540005|NCT04895163||Local patients|Local patients aged 18-50 who were admitted to our institution between January 1st, 2013 and October 31st, 2018, with the diagnosis of acute appendicitis.
89540006|NCT03052881|Experimental|Robot assisted surgery|To investigate use of an intraocular robotic system to assist the surgeon in performing one of two operation: i) epiretinal, or inner limiting, membrane peel and ii) displacement of sub macular haemorrhage.
89540007|NCT03052881|No Intervention|Control|A control group of patients underwent either i) epiretinal, or inner limiting, membrane peel and ii) displacement of sub macular haemorrhage without the use of a robot i.e. the surgery was done in the standard manner.
89023957|NCT04190446|Experimental|Arm II (IMRT)|Patients undergo IMRT 5 days a week over 5 weeks. Patients undergo PET scan, CT scan, MRI, and blood sample collection throughout the study.
89540008|NCT04906083|Experimental|Intervention group|Avatrombopag+Standard medical treatment
89023958|NCT04182672|Experimental|FX006|
89540009|NCT04906083|Other|Control group|Standard medical treatment
89023959|NCT04175431|Active Comparator|Group I (fluciclovine PET/CT)|Patients for whom initial fluciclovine or PSMA PET/CT does not reveal any abnormalities outside the prostatic fossa undergo PSA rechecks every 3 months, and undergo fluciclovine or PSMA PET/CT once PSA is > 2 ng/ml. If still no abnormalities are found outside of the prostatic fossa, patients continue to undergo PSA rechecks every 3 months, and undergo fluciclovine or PSMA PET/CT once PSA is > 5 ng/ml. Patients are off study for treatment plan once PSA reaches 10 ng/ml.
89507697|NCT02228447|No Intervention|No intervention group|The control group will not receive any intervention during the one year of this study. Only the baseline, 6-12 months assessments (anthropometrics, PA, dietary intake, social cognitive mediators and sedentary behaviors). To prevent compensatory rivalry and resentful demoralization, the control school will be provided with a condensed version of the following 12-month assessments. The condensed version of the program will include the professional learning workshops for intervention schools and the intervention materials (i.e., nutrition and PA handbooks and PA leadership handbook).
88957833|NCT01987440|Placebo Comparator|water|A VAS score (insertion) was obtained at this point. Next, the bill of the speculum was opened up until the vaginal cuff could be seen, and the speculum was secured by turning the thumbnut. A second VAS score (dilation) was recorded. During speculum examination, cervical smear with cervical brush was obtained for pathologic assessment if necessary. The speculum was withdrawn slightly, which allowed the bill to close together, and at this stage (extraction) the final VAS score was obtained. In the water group the speculum's top and bottom blades were moistened with 6,5 mL tap water previously loaded into a syringe kept at room temperature.After the speculum examination, pelvic examination was performed and length of the vagina (defined as distance from vaginal cuff to vaginal apex) was measured by the index finger.
89507698|NCT02228447|Experimental|Healthy habits, healthy girls group|The intervention group will receive a 6-month multicomponent intervention (i.e., enhanced physical education classes; interactive seminars; nutrition workshops; text messages; and parents newsletters) and materials (i.e., nutrition and PA handbooks; cooking books; Choreographies CDs and PA leadership handbook).
89507699|NCT03516565||Pregnancy group|Pregnant group included women, who were in their second trimester (weeks 16-24) and third trimester (weeks 25-34)
89507700|NCT03516565||Postpartum group|Postpartum group included women, who were evaluated 6 months after giving birth
89507701|NCT03516565||Non-pregnant group|Women who were systemically healthy and non-pregnant.
89507702|NCT02351661||medica/surgical|Medical or surgical patients from 18 hospitals
89507703|NCT02258555|Experimental|GS-9901|Participants will receive one of 6 escalating doses of GS-9901 once daily until unacceptable toxicity, substantial noncompliance, disease progression, pregnancy, initiation of another anti-cancer or experimental therapy, or other protocol-specified reasons for GS-9901 discontinuation.
89507704|NCT02295943|Other|Positioning measuring device|The supine time during the first postoperative day is measured
89507705|NCT02354391|Experimental|Ingenol mebutate and MAL PDT|Participants will recieve Ingenol mebutate 0.015% topical gel treatment applied day 2,3 and 4 to quadrant 1. Patients will recieve ingenol mebutate 0.015% applied on day 1 followed by methyl aminolevulate and photodyamnic therapy on day 5 to quadrant 2. Particpants will recieve methyl aminolevulate and photodynamic therapy on day 5 to quadrant 3, and quadrant 4 will act as the control, with no treatment.
89507706|NCT02231957|Experimental|educational text message reminders|receipt of education-embedded text message vaccine reminders
89507707|NCT02231957|Active Comparator|conventional text message reminders|receipt of conventional text message vaccine reminders
89507708|NCT03519763||Control group|Fifteen patients without isthmocele
89507709|NCT03519763||Study subgroup1|15 patients with 1 previous C-Section
89507710|NCT03519763||Study subgroup2|15 patients with 2 or more previous C-Section.
89507711|NCT04478253|Experimental|HypnoVR|Insertion of the drain according to the usual management protocol supplemented by the use of a hypnosis software application (HYPNO-VR).
89507712|NCT04478253|No Intervention|Usual care|Insertion of the drain according to the usual management protocol
89507713|NCT02228603|Experimental|high-intensity exercise|community-based group program: weekly supervised high-intensity exercise training during 8 weeks, followed by group counselling every third month for 12 months
89507714|NCT02228603|Active Comparator|web-based follow-up|web-based follow-up program: home-based group will be followed up by mail and telephone calls the first 8 weeks, then every third month for 12 months
89507715|NCT02228603|Other|control|control group will receive usual care: information about recommended physical activity and healthy lifestyle
89507716|NCT02354547|Experimental|SGT-53 with Topotecan/Cyclophosphamide|There will be 4-6 cycles (21 days/cycle) of therapy in this trial. In cycle 1, SGT-53 will be given as a single agent twice weekly starting at 1.4 mg/m² of DNA per infusion to evaluate single-agent toxicity. Pharmacokinetic studies will be performed. In the absence of dose limiting toxicity, patients will proceed to cycle 2 even if they have progressive disease. Starting in cycle 2, SGT-53 will be administered twice-weekly in combination with topotecan and cyclophosphamide administered daily for 5 days, days 1-5 of each cycle. Day 1 of each combination cycle is the first day on which topotecan and cyclophosphamide are administered with SGT-53. If a subject has at least stable disease after four cycles of therapy and is tolerating protocol therapy, two additional cycles may be considered.
89507717|NCT02232035|Placebo Comparator|normal saline, active phase of labor|A single dose intravenous injection of normal saline (2ml) at the beginning of active phase of labor in the group.
89507718|NCT02232035|Experimental|diazepam, active phase of labor|A single dose intravenous injection of diazepam (10mg, 2ml) at the beginning of active phase of labor in the group.
89507719|NCT02296021|Experimental|berberine quadruple therapy|Berberine 500 mg, esomeprazole 20 mg,amoxicillin 1000 mg, and clarithromycin 500 mg by mouth, twice daily for 14 days.
89507720|NCT02296021|Active Comparator|bismuth quadruple therapy|Bismuth 220 mg, esomeprazole 20 mg, amoxicillin 1000 mg, and clarithromycin 500 mg by mouth,twice daily for 14 days.
89507721|NCT03516409|Active Comparator|Bio-Kult Infantis|1 sachet once a day mixed with milk, water or food.
89507722|NCT03516409|Placebo Comparator|Placebo|1 sachet once a day mixed with milk, water or food.
89507723|NCT02232113|Experimental|CERA|We included HD patients with stable hematocrit (between 30~36%) under intravenous administration of CERA 100 μg once monthly for two months. Then they were shifted to receive CERA 50μg twice monthly for anther two months and finally they were shifted back to receive CERA 100 μg once monthly again for additional two months. Then we compared the hematocrit, nutrition status and inflammation markers every two months for 6 months totally. Those who had bleeding or received surgery or blood transfusion were excluded.
89507724|NCT02289391|Placebo Comparator|non-asthma group|"Non-asthma history~Infusion of normal saline(1μg/kg) at 10 minutes before anesthesia induction.~Infusion of normal saline at 0.4μg•kg-1•h-1during anesthesia maintenance.~Stop infusion of normal saline at 10 minutes before the end of surgery."
88957834|NCT01987466||Post cardiac arrest patient|
88957835|NCT01987492|Experimental|Lebrikizumab High Dose|Participants will receive lebrikizumab at high dose level as subcutaneous (SC) injection every 4 weeks during the 44-week DBPC period, followed by a 32-week ATE period, and during the LTE period.
88957836|NCT01987492|Experimental|Lebrikizumab Low Dose|Participants will receive lebrikizumab at low dose level as SC injection every 4 weeks during the 44-week DBPC period, followed by a 32-week ATE period, and during the LTE period.
88957837|NCT01987492|Placebo Comparator|Placebo|Participants will receive placebo matching to lebrikizumab SC injection every 4 weeks during the 44-week DBPC period. Participants will then be randomized to receive either high- or low-dose lebrikizumab every 4 weeks during the 32-week ATE period and will continue same treatment in the LTE period.
88957838|NCT01987518||digestive polyposis|Family adenomatous polyposis (APC or MYH genes) Peutz Jeghers Disease Cowden Disease Festooned Polyposis Juvenile Polyposis Hyperplastic Polyposis
88957839|NCT01987531|Experimental|left ventricular epicardial pacing lead|Enrolled patients will have a temporary left ventricular epicardial pacing lead placed in addition to the standard right ventricular and right atrial temporary epicardial pacing leads after open cardiac chamber cardiac surgery.
89507725|NCT02289391|Experimental|Dexmedetomidine A|"With a history of asthma~Infusion of dexmedetomidine(1μg/kg) at 10 minutes before anesthesia induction.~Infusion of dexmedetomidine at 0.4μg•kg-1•h-1during anesthesia maintenance.~Stop infusion of dexmedetomidine at 10 minutes before the end of surgery."
88957840|NCT01987544|Active Comparator|Self-Control|3 months of ergometer training under self control at home without any interventional motivation.
88957841|NCT01987544|Experimental|Motivation|3 months of ergometer training at home with telemonitoring and motivation phone calls once a week when training sessions drop below 20 minutes per day.
88957842|NCT01987570|Experimental|Allopurinol|One tablet of allopurinol is administrated orally at a dose of 300 mg/24 hours, during the time that the patient remains immobilized for 15 days.
88957843|NCT01987570|Placebo Comparator|Placebo|One tablet/24 hours of placebo orally, during the time that the patient remains immobilized for 15 days.
88957844|NCT01987622|Experimental|Acupuncture|A series of acupuncture sessions within six weeks from the baseline
88957845|NCT01987622|Active Comparator|Usual care|An intervention consisting of patient education for a healthier lifestyle, including diet, exercise, self-management of symptoms, and the use of other treatments as needed.
88957846|NCT01987661|Active Comparator|bilevel ventilation BIPAP ST|one night, BIPAP ST ventilation with individually optimised pressure parameters and supplemental oxygen if necessary.
88957847|NCT01987661|Experimental|BIPAP ST plus Airtrap|"one night, BIPAP ST ventilation with Airtrap control, same pressure parameters and oxygen."
88957848|NCT01987674|Experimental|Pre-meal protein drink|A dose of 100 ml is taken just before breakfast, lunch and dinner.
88957849|NCT01987674|Placebo Comparator|Water drink|A dose of 100 ml is taken just before breakfast, lunch and dinner.
88957850|NCT01987687|Active Comparator|Rest|Breakfast followed by a rest period prior to OGTT.
88957851|NCT01987687|Experimental|Exercise-immediate|Breakfast followed by exercise and an immediate OGTT
88957852|NCT01987687|Experimental|Exercise-delay|Breakfast followed by exercise and a delayed (1 h) OGTT.
88957853|NCT01987700|Active Comparator|FLEX-HD (underlay)|FLEX-HD human acellular dermal matrix applied using an underlay technique
88957854|NCT01987700|Active Comparator|FLEX-HD (overlay)|FLEX-HD human acellular dermal matrix applied using an overlay technique
88957855|NCT01987700|Active Comparator|Strattice (underlay)|Strattice porcine acellular dermal matrix applied using an underlay technique
88957856|NCT01987700|Active Comparator|Strattice (overlay)|Strattice porcine acellular dermal matrix applied using an overlay technique
88957857|NCT01987713|Experimental|lifestyle intervention|the intervention strength (amount, frequency, duration) including a reduction in energy intake and an increase in physical activity level will be reported. The guidance/description of the treatment protocol, preparation and training of intervener, techniques to retain the research subjects will be covered to prevent the lack of intervention integrity. Besides, the schooler admitted in a university hospital will be invited to explore their health lifestyles and receive the intervention.
88957858|NCT01987726||Observational (NGS, FMI testing)|"PART I: Within 10 weeks of beginning a treatment regimen, tumor tissue samples, Blood Collection and CTCs(Circulating tumor cell)from patients are collected for NGS and FMI testing, respectively. Patients remain on current line of therapy until a change in treatment is warranted. The physician's treatment recommendation is documented prior to the release of the FMI results.~PART II: Physicians are furnished with FMI test results when patients become eligible for a change in therapy and new treatment recommendations are documented. Treatment is dependent on preferences of the physician, patient, and/or results of the FMI test."
88957859|NCT01987739|Experimental|Arm 1|Subjects were randomized to receive single, oral doses of study medication in the sequence ABFCED, where, Treatment A was: 200 mg almorexant; Treatment B was 400 mg almorexant; Treatment C was 1000 mg almorexant; Treatment D was 20 mg zolpidem; Treatment E was 40 mg zolpidem; and Treatment F was placebo. The duration of each Treatment Visit was 1 day/2 nights. Study drug was administered on Day 1 of each Treatment Visit. Each treatment was separated by a washout period of at least 10 days.
89032931|NCT02925975|Experimental|Follow-up group guided by vPVPG|Cirrhotic patients with vPVPG lower than 12mmHg are followed-up with anatomic CTA and Doppler ultrasound every six months. Once vPVPG is higher 12mmHg or visible varies under the endoscopy, participants will be rescheduled to treatment group guided by vPVPG.
89540010|NCT02616783|Experimental|E/C/F/TAF|Participants will switch from tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) or 3TC plus a third agent to E/C/F/TAF and will receive treatment for 48 weeks.
89507726|NCT02289391|Experimental|Dexmedetomidine B|"With a history of asthma~Infusion of dexmedetomidine(1μg/kg) at 10 minutes before anesthesia induction.~Infusion of dexmedetomidine at 0.7μg•kg-1•h-1during anesthesia maintenance.~Stop infusion of dexmedetomidine at 10 minutes before the end of surgery."
88957860|NCT01987739|Experimental|Arm 2|Subjects were randomized to receive single, oral doses of study medication in the sequence BCADFE, where, Treatment A was: 200 mg almorexant; Treatment B was 400 mg almorexant; Treatment C was 1000 mg almorexant; Treatment D was 20 mg zolpidem; Treatment E was 40 mg zolpidem; and Treatment F was placebo. The duration of each Treatment Visit was 1 day/2 nights. Study drug was administered on Day 1 of each Treatment Visit. Each treatment was separated by a washout period of at least 10 days.
88957861|NCT01987739|Experimental|Arm 3|Subjects were randomized to receive single, oral doses of study medication in the sequence CDBEAF, where, Treatment A was: 200 mg almorexant; Treatment B was 400 mg almorexant; Treatment C was 1000 mg almorexant; Treatment D was 20 mg zolpidem; Treatment E was 40 mg zolpidem; and Treatment F was placebo. The duration of each Treatment Visit was 1 day/2 nights. Study drug was administered on Day 1 of each Treatment Visit. Each treatment was separated by a washout period of at least 10 days.
88957862|NCT01987739|Experimental|Arm 4|Subjects were randomized to receive single, oral doses of study medication in the sequence DECFBA, where, Treatment A was: 200 mg almorexant; Treatment B was 400 mg almorexant; Treatment C was 1000 mg almorexant; Treatment D was 20 mg zolpidem; Treatment E was 40 mg zolpidem; and Treatment F was placebo. The duration of each Treatment Visit was 1 day/2 nights. Study drug was administered on Day 1 of each Treatment Visit. Each treatment was separated by a washout period of at least 10 days.
88957863|NCT01987739|Experimental|Arm 5|Subjects were randomized to receive single, oral doses of study medication in the sequence EFDACB, where, Treatment A was: 200 mg almorexant; Treatment B was 400 mg almorexant; Treatment C was 1000 mg almorexant; Treatment D was 20 mg zolpidem; Treatment E was 40 mg zolpidem; and Treatment F was placebo. The duration of each Treatment Visit was 1 day/2 nights. Study drug was administered on Day 1 of each Treatment Visit. Each treatment was separated by a washout period of at least 10 days.
88957864|NCT01987739|Experimental|Arm 6|Subjects were randomized to receive single, oral doses of study medication in the sequence FAEBDC, where, Treatment A was: 200 mg almorexant; Treatment B was 400 mg almorexant; Treatment C was 1000 mg almorexant; Treatment D was 20 mg zolpidem; Treatment E was 40 mg zolpidem; and Treatment F was placebo. The duration of each Treatment Visit was 1 day/2 nights. Study drug was administered on Day 1 of each Treatment Visit. Each treatment was separated by a washout period of at least 10 days.
88957865|NCT01987778|Experimental|Resistance training|The resistance training will be supervised and individualized by an experienced physiotherapist. First the relative load will be lighter during three weeks, thereafter the intensity and load will be increased over another 12 weeks.
89507727|NCT02289391|Placebo Comparator|Control group|"With a history of asthma~Infusion of normal saline(1μg/kg) at 10 minutes before anesthesia induction.~Infusion of normal saline at 0.4μg•kg-1•h-1during anesthesia maintenance.~Stop infusion of normal saline at 10 minutes before the end of surgery."
89507728|NCT02354313|Experimental|Lenalidomide|lenalidomide 10-15 mg once daily on days 1-21, every 28 day, for two years
89507729|NCT02354313|No Intervention|Observation|no therapy is planned but only observation
89507730|NCT02224547|Experimental|Radiotherapy|For centrally located T1 and T2 lesions 4 x 12 Gy over 2 weeks will be delivered. Lesions located peripherally will be treated with 3 x 17 Gy, also delivered within 2 weeks. For both schedules, there should be a minimum of 40 hours and a maximum of 8 days between 2 separate fractions. There should be a maximum of 2 fractions per week.
89507731|NCT02292667|Experimental|TAP BLOCK|"Patients included in the ETAP group will receive the combination of a bilateral ultrasound-guided Transversus Abdominis Plane (TAP) block and a multimodal intravenous analgesia protocol for the postoperative pain management after the surgical open repair of an aortic abdominal aneurysm.~The TAP block consists in 2 ultrasound-guided injections of Ropivacaine 0.375% on each side of the abdominal wall between the internal oblique and transversus abdominis muscles: 1 subcostal injection and 1 supra-iliac injection (i.e 10 ml of Ropivacaine 0.375% by injection).~The multimodal intravenous analgesia protocol consists in the association of intravenous infusion of 1 g of Acetaminophen every 6 h and intravenous patient-controlled analgesia (PCA) with Chlorhydrate of Morphine 1 mg/ml."
89507732|NCT02292667|Active Comparator|CONTROL|"Patients included in the CONTROL group will receive a multimodal intravenous analgesia protocol alone for the postoperative pain management after the surgical open repair of an aortic abdominal aneurysm.~The multimodal intravenous analgesia protocol consists in the association of intravenous infusion of 1 g of Acetaminophen every 6 h and intravenous patient-controlled analgesia (PCA) with Chlorhydrate of Morphine 1 mg/ml."
89507733|NCT02228759|Experimental|Adductor canal block|The study is an open label pilot study to determine the feasibility of same day discharge following total knee arthroplasty with the use of a fast track regimen employing motor sparing knee blocks. The study will be performed on 25 American Society of Anesthesiologists class (ASA) 1-2 patients satisfying the inclusion criteria and undergoing unilateral primary total knee arthroplasty. First and second patients of the day undergoing surgery between Monday to Thursday in a week will be accessed for the study.
89507734|NCT02296177|No Intervention|Control|The control group will receive the standard practice of care related to mammography phone call reminders. If a clinic currently conducts reminders, they will receive that standard call. If no reminders are done, then they will not receive a call during the control period.
89507735|NCT02296177|Active Comparator|Intervention|The intervention group will receive a reminder call about their upcoming appointment that assesses their intent to attend the appointment and counsels them through barriers to attendance. The call is conducted by a trained patient navigator using an adapted NCI RTIP to increase mammography appointment adherence.
89507736|NCT02232269|Placebo Comparator|Water plus Felodipine|Felodipine extended-release tablet ,10 mg, single dose, 8 hours
89507737|NCT02232269|Active Comparator|Black Coffee|Black Coffee, 300 ml, 0 and 1 hour
89507738|NCT02232269|Experimental|Black Coffee plus Felodipine|"Black Coffee, 300 ml, 0 and 1 hour~Felodipine extended-release tablet ,10 mg, single dose, 8 hours"
89507739|NCT02232269|Active Comparator|Grapefruit Juice plus Felodipine|"Grapefruit Juice, 300 ml, 0 and 1 hour~Felodipine extended-release tablet ,10 mg, single dose, 8 hours"
89540011|NCT02616783|Active Comparator|Remain current regimen|Participants will remain on current TDF and FTC (or FTC/TDF) or 3TC plus continuing third agent.
88957866|NCT01987778|No Intervention|Control group|No intervention for 15 weeks but the same registrations, diaries and forms as the intervention group. The control group will however be omitted from muscle strength testing.
89507740|NCT04478331|No Intervention|CONTROL|The Control group will receive the usual care. In the physical activity (PA) field, this includes two individual motivational interviews with a PA professional, and a group workshop during the first year after BS. PA recommendations will be explained to each participant, and their achievement will be encouraged and supported during these sessions. No face-to-face PA sessions will be offered as part of the usual care.
88957867|NCT01987804|Experimental|Oxytocin 100 i.u.|N=24 patients are administrated Oxytocin 100 i.u. vaginally
88957868|NCT01987804|Experimental|Oxytocin 400 i.u.|N=24 patients are administrated Oxytocin 400 i.u. vaginally
88957869|NCT01987804|Placebo Comparator|Placebo|N=16 patients are administrated placebo vaginally
88957870|NCT01987843|Experimental|MT-1303-Low|MT-1303-Low Dose
88957871|NCT01987843|Experimental|MT-1303-Middle|MT-1303-Middle Dose
88957872|NCT01987843|Experimental|MT-1303-High|MT-1303-High Dose
88957873|NCT01987843|Placebo Comparator|Placebo|Placebo
88957874|NCT01987856|Active Comparator|aCGH screen|aCGH screen; euploid blastocyst chosen on 23 plus XY chromosome screening plus blastocyst morphology
88957875|NCT01987856|Placebo Comparator|Blastocyst morphology|blastocysts chosen on morphological criteria only; scaled assessment of blastocyst expansion, inner cell mass and trophectoderm morphology
88957876|NCT01987882||"A. Natural History or Watchful Waiting"|
88957877|NCT01987882||B. Serial Botulinum Toxin Injections +/- Abduction Bracing|
88957878|NCT01987882||C. Adductor (+/- psoas) Muscle Releases Alone|
88957879|NCT01987882||D. Hip Reconstructive Surgery|
88957880|NCT01987882||E. Salvage Hip Surgery|
88957881|NCT01987921||Pediatric Intensive Care Unit Patients|All patients will be included in a single cohort initially (admission to the PICU) and then cohorted into groups based on development of severe AKI (Stage 2-3 KDIGO by either Cr or UOP criteria) within the first seven days, renal angina risk strata, medical admission diagnoses, and outcomes.
88957882|NCT01987934||Normal or Control group|Those subjects with normal oral epithelium will be included in this group.
88957883|NCT01987934||Study Group|Those subjects with oral squamous cell carcinoma will be included in this group.
88957884|NCT01987947|Placebo Comparator|Placebo|
88957885|NCT01987947|Active Comparator|Quilizumab|
88957886|NCT01987999|Experimental|Acetogenins|Acetogenins twice (BID) per day for 12 months
88957887|NCT01988038||No treatment|
88957888|NCT01988064|Experimental|Face-to-face training|One-to-one face-to-face training on calculating the pulse rate and detecting pulse abnormalities performed by the nurse.
88957889|NCT01988064|Experimental|Group training|Group training using a tutorial film on calculating the pulse rate and detecting pulse abnormalities.
88957890|NCT01988077|Other|Adoptive cell transfer combined with Ipilimumab|Adoptive cell transfer combined with Ipilimumab
88957891|NCT01988116|Experimental|Oral Calcitriol|Oral Calcitriol 0.5 mcg once daily for 6 weeks
88957892|NCT01988116|Placebo Comparator|Placebo Arm|Placebo capsule 1 Capsule once daily for 6 weeks
88957893|NCT01988142|Experimental|SCI|
88957894|NCT01988155|Active Comparator|Eccentric Exericse|
88957895|NCT01988155|Experimental|Astym|
89507741|NCT04478331|Experimental|ACTI-VISIO|The two PA sessions per week will be delivered via videoconferencing (developed by Mooven™). The PA program consists in tailored adapted PA sessions led by a professional specialized in adapted PA. These sessions were specifically designed to be appropriate for the population and were developed in collaboration with the authors to ensure standardization of the recommended volume of PA. The PA sessions will be given live, individually at the beginning and then in groups of four women. During sessions, the professional and the participants will interact simultaneously, and the execution of the exercises will be monitored and adapted live by the professional. To ensure the safety of the PA, a rating of perceived exertion will be requested after each session on a 10-point scale. If the RPE exceed 7, the professional specialized in adapted PA will adjust the training load. In addition to the exercises, the sessions will also include advice and tips for reaching the recommended PA level.
89507742|NCT04478331|Experimental|ACTI-MOBIL|The PA sessions will be delivered by an eHealth platform (developed by BePatient™) associated with an activity bracelet. The researchers enrich PA content on the platform and ensure standardization of the recommended volume of PA. The platform consists of tips for reaching the PA level, PA questionnaires, PA feedback measured by the activity bracelet, and a video demonstration of PA sessions performed by a peer. The PA sessions are automatically broadcasted twice a week for 12 weeks. To ensure the safety of the PA, the sessions were designed to be appropriate for this population and the RPE will be measured after each session on a 10-point scale. If the RPE exceeds 7 for 3 consecutive sessions, the training load will be adjusted. The platform will also include a variety of content, including dietary tips, obesity-related facts, information about surgery, and frequently asked questions.
89507743|NCT02292745|Experimental|Stereotactic radiotherapy|Standard of care FOLFIRINOX treatment followed by stereotactic radiotherapy
89507744|NCT02031575|Experimental|Basic Treatment|Sends messages to participants about reproductive health.
89507745|NCT02031575|Experimental|Interactive Treatment|Sends multiple choice questions and receives texts message responses from participants with incentive for responding correctly
89507746|NCT02031575|Placebo Comparator|Control|Sends messages to students about malaria prevention and control.
89507747|NCT03516331|Experimental|Part 1:FDL176 & FDL169 coadministration|To receive a single dose of FDL176 on Day 1, followed up FDL169 TID starting Day 8; and another single dose of FDL176 on Day 22.
89507748|NCT03516331|Experimental|Part 2:FDL176 & FDL169 coadministration|To receive FDL176 QD starting Day 1, and FDL169 TID starting Day 8
89507749|NCT04486313|Active Comparator|Nitazoxanide|Two nitazoxanide 300 mg tablets orally twice daily for 5 days
89507750|NCT04486313|Placebo Comparator|Placebo|Two placebo tablets orally twice daily for 5 days
89507751|NCT02354001|Experimental|Raloxifene Hydrochloride|120 mg per capsule (1 tablet daily)
89507752|NCT02354001|Placebo Comparator|placebo tablet|1 tablet daily for 12 weeks
88957896|NCT01988168|Experimental|Suture closure|Closure of skin with a running subcuticular, absorbable monofilament suture.
88957897|NCT01988168|Active Comparator|Staples closure|Closure of skin with stainless-steel surgical staples.
88957898|NCT01988181|Active Comparator|Best clinical practice HD|All study patients will be dialyzed with the Fresenius 5008 HD machine (Fresenius Medical Care, Bad Homburg, Germany) using high flux dialyzers. For an 8-week period, patients in the best clinical practice (control) phase will use their same prescription as the run-in phase, dialysate sodium of 138mmol/L, dialysate calcium of 1.25mmol/L, dialysate temperature of 36oC, and constant UF rate. BVM will be disabled in this group.
88957899|NCT01988181|Experimental|Best clinical practice plus BVM-guided UF biofeedback|Patients in the BVM-guided UF biofeedback (intervention) phase will have the same prescription as the control group but will also have the ultrafiltration rate automatically adjusted by the Fresenius 5008 HD machine based on the changes in the relative blood volume.
88957900|NCT01988194|No Intervention|Usual care|Participants will receive usual care in the hospital.
88957901|NCT01988194|Experimental|Usual care with acupuncture|Participants will receive usual care with acupuncture treatments up to four days per week for the duration of their hospital stay.
88957902|NCT01988207|Experimental|12 Exercise Sessions|Patients will receive 12 treatment sessions with flow phonation exercises, as well as education on vocal hygiene.
88957903|NCT01988207|Active Comparator|6 Hygiene and 6 Exercise|Patients will receive 6 sessions of vocal hygiene training for initial comparison to patients in Arm 1. They will then receive 6 sessions of vocal exercise training and vocal hygiene training combined.
88957904|NCT01988220|Experimental|sensory retraining|sensory identification and discrimination training. using different attention and sensation modalities for sensory retraining
88957905|NCT01988220|Active Comparator|repeated exposure to sensory input|
88957906|NCT01988259|Active Comparator|Bilateral approach for laminoplasty|Open approach for laminoplasty
88957907|NCT01988259|Active Comparator|Unilateral approach for laminoplasty|Minimally invasive approach for laminoplasty
88957908|NCT01988259|Active Comparator|Subperiosteal approach for foraminotomy|Open approach for foraminotomy
88957909|NCT01988259|Active Comparator|Transmuscular approach for foraminotomy|Minimally invasive approach for foraminotomy
88957910|NCT01988298|Experimental|Ibuprofen|Experimental: Ibuprofen 400 mg each 8 hours for 2-3 days.
88957911|NCT01988298|Active Comparator|Acetaminophen|Acetaminophen 1 g oral each 6 hours, 2-3 days.
88957912|NCT01988311|Experimental|Drug Only|psilocybin dose manipulation as described in the protocol
89507753|NCT03516253|Experimental|Intervention group|Dietary Supplement: Fish oil + EPO. Fish oil (2 gel capsules, each 1g fish oil with 500 mg EPA+DHA) and EPO (Evening primrose oil 3 gel capsules with 117 mg GLA), 3 months with lunch.
89507754|NCT03516253|No Intervention|Control group|Dietary Supplement: Mineral oil (5 gel capsules, each 1g mineral oil), 3 months with lunch.
89507755|NCT02228837|Placebo Comparator|Placebo|12 weeks of consuming 50 g pear-flavored placebo powder mixed with 480 ml per day (1/2 in the morning and 1/2 in the evening at least 6-8 hours apart).
89507756|NCT02228837|Experimental|Pear|12 weeks of consuming 2 medium-sized pears per day (1 in the morning and 1 in the evening at least 6-8 hours apart).
89507757|NCT02347839|Experimental|Intervention group|Gefitinib-surgery-gefitinib. Induction gefitinib therapy was given for 8 weeks. Patients' resectability was assessed after 8-week gefitinib. Adjuvant gefitinib was given within 3-6 weeks after surgery until progression or unacceptable toxic effects.
89507758|NCT02289547|No Intervention|Group A|observational arm
89507759|NCT02289547|Experimental|Group B|arm of capecitabine maintenance treatment
89507760|NCT02353923|Experimental|OcuStem Supplementation|Twice daily supplementation with OcuStem. Subjects will take 2 capsules in the morning and 2 capsules at night for a total of 2800 mg/day of active ingredients.
89507761|NCT03516175|Active Comparator|Tight fitting mask|Pre oxygenation with tight facemask with 100% oxygen
89507762|NCT03516175|Experimental|High flow nasal oxygen|High flow nasal oxygen that is Transnasal Humidified Rapid Insufflation Ventilatory Exchange is used for pre oxygenation
89507763|NCT04461275|Experimental|ERAS 2.0 group|Patients included in the ERAS 2.0 group will follow the ERAS 2.0 accelerated care protocol.
89507764|NCT02292901|Active Comparator|Macintosh laryngoscope|Tracheal intubation will be performed using a Macintosh laryngoscope
89507765|NCT02292901|Experimental|McGrath Mac videolaryngoscope|Tracheal intubation will be performed using a McGrath Mac videolaryngoscope
89507766|NCT02347449|Experimental|Early stage breast cancer|"Women with node positive (1-3 nodes), ER positive breast cancer who are receiving (or will receive) endocrine therapy, and who are candidates for chemotherapy.~Study subjects will have ONCOTYPE Dx assay performed on their breast tumors, and will complete study questionnaires."
89507767|NCT02289625|Active Comparator|Attentional performance in OSA|To investigate the attentional performance and muscle sympathetic nerve activity (MSNA) response during Color Word Stroop Test (CWST) in patients with obstructive sleep apnea (OSA) before and after intervention with exercise training.Individuals with no other comorbidities (age=52±1 years, body mass index=29±0.4) were divided in control (n=15) and untreated OSA (n=20) defined by polysomnography.
89507768|NCT02289625|Active Comparator|metaboreflex in OSA|"To investigate the metaboreflex control of MSNA before and after intervention with exercise training in patients with obstructive sleep apnea.~Methods: Thirty-five patients underwent conventional polysomnography. The MSNA was assessed by microneurography technique. Beat to beat blood pressure was measured during 4 minutes at rest, 3 minutes of isometric exercise at 30% maximal voluntary contraction, followed by 2 minutes of occlusion of the circulation in previously exercised muscle. The metaboreflex sensitivity was calculated during the first and second minutes of circulatory occlusion when metaboreceptors are evaluated independently of central command and muscle mechanoreceptors."
89507769|NCT02228993||Awake Craniotomy|
89507770|NCT02228993||General Anesthesia Craniotomy|
88957913|NCT01988311|No Intervention|Cognitive/Behavioral Tasks Only|
88957914|NCT01988311|No Intervention|Imaging Only|
88957915|NCT01988324|Experimental|FES/FDHT-PET|
88957916|NCT01988350||Non-smokers|
88957917|NCT01988350||Smokers|
89540012|NCT04906005|Experimental|gadopiclenol|"Dose per administration: dose/volume of gadopiclenol to be administered will be calculated based on patient's weight at the dose of 0.025; 0.05 or 0.1 mmol/kg BW (depending on each group).~6 volunteers will receive gadopiclenol per group"
89540013|NCT04906005|Placebo Comparator|Placebo|"Dose per administration: similar dose (Volume/weight) as the one used for Gadopiclenol in the considered group.~3 volunteers will receive gadopiclenol per group"
89540014|NCT04895007||Group, vaccinated with Inactive Vaccine (Sinovac Life Sciences, Beijing, China).|- Any person, male or female, over 18 years of age, were vaccinated with Inactive Vaccine.
89540015|NCT04895007||Group, vaccinated with recombinant human adenovirus serotype number 26 (rAd26 of Sputnik V).|- Any person, male or female, over 18 years of age, were vaccinated with recombinant human adenovirus serotype number 26.
89540016|NCT04895007||Group, vaccinated with mRNA Vaccine (Pfizer/BionTEC).|- Any person, male or female, over 18 years of age, were vaccinated with mRNA Vaccine.
89540017|NCT04890561|Experimental|Lemborexant 10 mg|Participants will receive a single dose of lemborexant 10 mg tablet, orally on Day 1.
89540018|NCT04890405|Active Comparator|FMT group|Standardized FMT once.Extract all the flora from the feces provided by the donor to make fecal bacteria transplant capsules. The patient took orally on an empty stomach, each time using 3.2g of fecal bacteria.
89540019|NCT04890405|Experimental|JZ group|1.6g Po perday,for 28 days. probiotics that are effective against diarrhea were selected to make precise flora capsules, which are taken when the patient is on an empty stomach, once a day, using 1.6 g of bacteria per day, orally for 28 consecutive days.
89540020|NCT04894851|Experimental|Contingency Management|Receives contingency payments each month based on decluttering scores
89540021|NCT04894539|Experimental|TENS1|TENS with 4/100 Hz in frequency, 200 µs in pulse duration, and intensity individually adjusted.
89540022|NCT04894539|Experimental|TENS2|TENS with 80/100 Hz in frequency, 200 µs in pulse duration, and intensity individually adjusted.
89540023|NCT04894539|Sham Comparator|Sham-TENS|Sham with 100 Hz in frequency, 200 µs in pulse duration, and intensity below 5 mA.
89540024|NCT04894617|Active Comparator|Amantadine|The intervention group will receive a dose at day 1 of amantadine 100 mg followed by 100 mg amantadine after 6 hours. The following 4 consecutive days, study participants will receive a daily dose of 200mg amantadine, 100 mg (1 capsule) morning and 100 mg (1 capsule) evening, yielding 5 days of treatment in total (10 capsules in total).
89540025|NCT04894617|Placebo Comparator|Placebo|The control group will receive placebo treatment with lactose monohydrate; 1 capsule, followed by 1 capsule after 6 hours on day 1. The following 4 consecutive days, study participants will receive 1 capsule morning and 1 capsule evening, yielding 5 days of treatment in total (10 capsules in total).
89023960|NCT04175431|Experimental|Group II (surgery, radiotherapy, abiraterone, prednisone)|Patients undergo fluciclovine or PSMA PET/CT and who have =< 3 regions of metastatic disease outside of the prostatic fossa that are amenable to metastasis-directed therapy undergo lymphadenectomy or radiation therapy. Six to ten weeks after surgery, patients receive abiraterone acetate 1000 mg PO QD and prednisone PO QD. Treatment repeats every 4 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients may start radiation therapy after 2 cycles of abiraterone acetate and prednisone.
89023961|NCT04175431|Experimental|Group III (abiraterone, prednisone)|Patients undergo fluciclovine or PSMA PET/CT and who have > 3 regions of metastatic disease receive abiraterone acetate and prednisone as in Group II.
89023962|NCT04171037|Experimental|Arm I (oxygen via Optiflow THRIVE)|Patients receive 100% oxygen at a high flow rate via Optiflow THRIVE over 3 minutes prior to anesthetic induction and at a higher flow rate until the end of procedure.
89023963|NCT04171037|Active Comparator|Arm II (oxygen via non-rebreather mask)|Patients receive 100% oxygen at a lower flow rate via non-rebreather mask over 3 minutes prior to anesthetic induction and maintain the same flow rate until the end of procedure.
89023964|NCT04124315||PAD Patients Completing SET|This single-group study includes patients with peripheral artery disease (PAD) who are completing a physician-prescribed supervised exercise training (SET) program.
89023965|NCT04117295|Experimental|Treatment|Subjects implanted with the Carmat TAH
89540026|NCT04894695||healthy control (HC)|healthy control
89540027|NCT04894695||Systemic Lupus Erythematosus (SLE)|Systemic Lupus Erythematosus
89540028|NCT04894695||lupus nephritis (LN)|lupus nephritis
89540029|NCT04397991|Experimental|Furosemide|Patients will receive nebulised furosemide
89540030|NCT04397991|Placebo Comparator|Placebo|Patients will receive nebulised 0.9% saline
89540031|NCT04906161||Successful dental implant|Patients showed a successful implant placement with no complications before loading
89540032|NCT04906161||Early dental implant failure|Early complications and failure of dental implant before loading
89540033|NCT04885023|Experimental|Study group|Twenty six patients who received hippotherapy combined with Schroth exercises for ten weeks
89023966|NCT04115163|Experimental|Treatment (gemcitabine, nab-paclitaxel)|Patients receive gemcitabine IV over 30 minutes on days 1 and 15 and nab-paclitaxel IV over 30 minutes on days 3 and 17. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89023967|NCT04113759|Placebo Comparator|Control Group|The control group will receive sham BFR, in which a non-occlusive pressure is applied with the cuff. The exercises performed will be identical to the BFR group.
89023968|NCT04113759|Experimental|BFR Postoperative Rehabilitation|The experimental group will receive BFR postoperative rehabilitation, which will involve performing a series of blood flow restriction exercises identical to the control group.
89023969|NCT04102189|Experimental|Semaglutide|2.4 mg or maximum tolerated dose (MTD) injected subcutaneously (under the skin, s.c.) once weekly
89023970|NCT04102189|Placebo Comparator|Placebo|Placebo injected s.c. once weekly .
89540034|NCT04885023|Other|Control group|Twenty six patients who received only Schroth exercises for ten weeks
89540035|NCT04890015|Experimental|Intraoperative transanal decompression tube placement|Intraoperatively under direct vision in the lower rectum, the balloon of the catheter will be inflated with 5-10cc of distilled water and it will be secured with a dressing / tape to the buttock connected to a collection bag.
89540036|NCT04890015|No Intervention|Non intraoperative transanal decompression tube placement|The usual postoperative care approved by the unit will be followed.
89507771|NCT02351427|Active Comparator|Bortezomib|"Bortezomib (subcutaneous) 1.3mg/m2 on day 1, 4 and 7~with~Steroid - Methylprednisolone (intravenous) Day 1 - 7: 500 mg/500 mg/500 mg/250 mg/250 mg/125 mg/125 mg After day 7: prednisolone (oral) 30 - 60 mg, then taper the dosage"
89507772|NCT02351427|Active Comparator|Steroid|Steroid - Methylprednisolone (intravenous) Day 1 - 7: 500 mg/500 mg/500 mg/250 mg/250 mg/125 mg/125 mg After day 7: prednisolone (oral) 30 - 60 mg, then taper the dosage
88957918|NCT01988363|Other|GON injection at C2 location|A 25 gauge, 2 inch spinal needle will be inserted into the symptomatic side after locating the GON via US at the level of C2. Subjects will receive an injection of 4 ml of injectate consisting of 1 ml of 2% Lidocaine, 3 mg betamethasone and 2.5 ml of 0.25% Bupivicaine to the greater occipital nerve at the novel, proximal C2 location.
88957919|NCT01988389|Experimental|whole apples|Subjects are asked to consume 2 apples a day for 8 weeks in addition to their habitual diet
88957920|NCT01988389|Other|apple juice squash|Subjects are asked to consume 100 ml of apple juice squash (recommended dilution with water up to 500 ml) for 8 weeks in addition to their habitual diet. The apple juice is used as a sugar matched control.
88957921|NCT01988428|No Intervention|standard care|"standard care~training of ambulance personnel in recognizing sepsis and initiating pre-hospital treatment"
88957922|NCT01988428|Experimental|Antibiotics|"ceftriaxone 2000 mg (after taking bloodcultures)~training of ambulance personnel in recognizing sepsis and initiating pre-hospital treatment"
88957923|NCT01988467|Experimental|nasal breathing|"At the time that the exposure took place with nasal breathing, the study was as follows:~Before the exposure: rhinomanometry, IOS , FeNO , spirometry, plethysmography, P.100.~Exposure to second hand smoking:Each volunteer was exposed to secondhand smoking twice, for 20 minutes, once with nasal breathing and once with oral breathing, with 3 days interval and in random sequence.~After the exposure: rhinomanometry, IOS , FeNO , spirometry,plethysmography , P.100."
89507773|NCT04437563|No Intervention|Control|('Standard' care). No intervention offered.
89507774|NCT04437563|Experimental|Intervention|('Standard' care +) The 'Herlev Hospital Empowerment of Relatives through More and Earlier information Supply' (HERMES) intervention.
89507775|NCT02293057|Active Comparator|VOICES Group|VOICES: A program of self-discovery and empowerment includes four modules: Self (A), Connecting with others (B), Healthy living (C), and the Journey Ahead (D). All sessions are 60 minutes long and include required and optional activities.
89507776|NCT02293057|Placebo Comparator|Girl Health Group (Attention Control)|The Girl Health group comparison condition includes adolescent groups matched for time and attention to VOICES groups. Intervention take a psychoeducational/didactic approach and content focuses on a range of health behaviors, including substance use, exercise, nutrition and sleep.
89507777|NCT03149835|Experimental|COPD|"After study enrollment, 15 days before the performance of the experimental protocol, patients performed neurocognitive tests (Digit Span Test, Digit Symbol-Coding, Corsi Block-tapping, Trail Making Test A and B and Stroop Test) and NIV adaptation. Pulmonary function (spirometry) was measured in all subjects after a thorough medical history and physical examination. Before initiating the protocol, patients were asked about discomfort related to NIV or any aspect of the experiment.~CBF was measured by transcranial Doppler by mean of LMCAFV immediately before NIV, during NIV at 5, 30 and 60 minutes and after NIV removal at 5 and 30 minutes. ABG were collected immediately before the experiment, after one hour of NIV breathing and 30 minutes after NIV discontinuation."
89519387|NCT03451357||patients with Dependence degree|Dependence degree already certificated by Dependence Law: It is calculated by accepting an expected proportion of 40% patients with dependence, with a precision 6.5% and confidence level of 95%, obtaining a N= 200 patients. Assuming a 15% of loses, we estimate we will need N=230 to be followed. This sample size would enable us to construct logistic regression models including simultaneously up to 5 predictive factors to assess the relationship between each of the independent variables and the occurrence of dependency.
88957924|NCT01988467|Experimental|oral breathing|"At the time that the exposure took place with oral breathing, the study was as follows:~Before the exposure: IOS, exhaled nitric oxide (FeNO), spirometry, plethysmography and P.100.~Exposure to second hand smoking: each volunteer was exposed to secondhand smoking twice, for 20 minutes, once with nasal breathing and once with oral breathing, with 3 days interval and in random sequence.~After the exposure: IOS, FeNO, spirometry,plethysmography and P.100."
88957925|NCT01988480|Experimental|Image-guided surgery|Image-guided implant placement
88957926|NCT01988480|Sham Comparator|sinus graft|Sinus lift surgery : Patients receive sinus graft before implant placement
88957927|NCT01988506|Experimental|Interleukin 2|Interleukin 2, 1MUI.= Proleukin®, RhIL-2
88957928|NCT01988519|Active Comparator|Closed suction drain|Two closed suctions drains will be placed near the pancreatic anastomosis or suture line. The drains will be removed on the 4th or 5th day if the amylase activity is not increased.
88957929|NCT01988519|Active Comparator|Closed gravity drain|Two closed gravity drains will be placed near the pancreatic anastomosis or suture line. The drains will be removed on the 4th or 5th day if the amylase activity is not increased.
88957930|NCT01988532||Adult PWH|
88957931|NCT01988545|Active Comparator|GLP-1|1,5 nmol/kg,GLP-1 sc injection
88957932|NCT01988545|Active Comparator|GLP-1 9-36amide|1,5 nmol/kg GLP-1 9-36amide, sc injection
88957933|NCT01988545|Active Comparator|Exendin-4|Exendin-4 ;10 ug,sc injection
88957934|NCT01988545|Placebo Comparator|isotonic saline|2 ml of isotonic saline, sc injection
88957935|NCT01988558|Experimental|Treated Group|Children diagnosed as suffering from recurrent Tonsillitis (at least 4 episodes per year) to receive DL-Lactic acid syrup twice a day for a month.
88957936|NCT01988558|Placebo Comparator|Placebo Group|
88957937|NCT01988597||Dry Eyes|
88957938|NCT01988610|Experimental|Intervention Group|Open-label trial to assess the effects of Mifepristone on mood and cognition in people with a history of depression.
88957939|NCT01988623|Experimental|Pivotal Response Treatment (PRT)|
88957940|NCT01988636|Experimental|Group 1|Pilot Safety Group- 135000 PfSPZ + 270000 PfSPZ; staggered at Day 0 and 2 weeks
88957941|NCT01988636|Active Comparator|Group 4|Group to start at week 4 after Group 1 is deemed safe - 5 immunizations of 270000 PfSPZ at weeks 4, 8, 12, 16 and 24
88957942|NCT01988636|Placebo Comparator|Group 5|Group to receive placebo at same points as Group 4 - 5 immunizations of normal saline at weeks 4, 8, 12, 16 and 24
88957943|NCT01988649|Active Comparator|Intranasal Oxytocin|Administration of 32 units of Oxytocin administered intranasally
88957944|NCT01988649|Placebo Comparator|Placebo (saline)|Administration of 4 sprays intranasally of normal saline.
88957945|NCT01988675||Partial Brain Irradiation|Patients will receive partial brain irradiation for malignant or benign brain tumors as standard of care. Patients will also have MRI (Magnetic Resonance Imaging) scans and neuropsychological/QOL (Quality of Life Questionnaire) tests prior during and after RT (Radiation Therapy).
88957946|NCT01988675||Whole Brain Irradiation|Patients will receive whole brain irradiation for brain metastases as standard of care. Patients will also have MRI (Magnetic Resonance Imaging) scans and neuropsychological/QOL (Quality of Life Questionnaire) tests prior during and after RT (Radiation Therapy).
88957947|NCT01988688|Experimental|Bilateral DBS placement in area LC|Bilateral DBS placement in area LC. Devices include Medtronic Activa DBS model 3387 and 3389; Medtronic DBS extension; Medtronic Activa PC or Activa RC neurostimulator; Medtronic Patient Programmer; Medtronic Test Stimulator; Medtronic N/Vision Clinician Programmer
88957948|NCT01988701||Allogeneic SCT Groups|Patients who have received stem cell transplantation at The Ohio State University are eligible and who are at or beyond day +75 following allogeneic SCT regardless of previous diagnosis of acute or chronic GVHD.
88957949|NCT01988701||Autologous SCT group|Patients who have received an autologous stem cell transplant at The Ohio State University and who have achieved platelet and neutrophil engraftment.
88957950|NCT01988714|Experimental|(TCT) plus evidence-based SE|(TCT) plus evidence-based SE
88957951|NCT01988714|Placebo Comparator|(CG) plus evidence-based SE|(CG) plus evidence-based SE
88957952|NCT01988753||Subjects with Liver Fibrosis|"Shearwave elastography is a non-invasive procedure for assessing liver status. Measurements of liver tissue elasticity will be obtained in the right lobe of the liver by using a curvilinear transducer (C5-1, Philips Healthcare) through intercostal spaces.~Biomarker Analysis~A. Blood: Blood will be drawn at the same time the IV is placed for the liver biopsy for the purposes of the serum biomarker study. If subjects return for an additional liver biopsy in the future or a standard of care visit they may be asked to provide an additional sample for biomarker analysis. Blood will be processed, aliquoted and stored by pathology.~B. Tissue: Unstained slides from pathology will be prepared from leftover tissue taken during the liver biopsy to be stained for additional biomarker analysis."
88957953|NCT01988766||Thrombosis|incidence of thrombosis in subjects who had PICC line placement
89206885|NCT00270205|Experimental|E: 0.4 mg DNA/participant vaccination at weeks 0,1,6,7,12,13|Participants receiving six separate high-dose vaccinations of LC002 (0.4 mg DNA/participant, 3.2 ml total, administered over four skin sites [on the left and right upper back and left and right upper ventral thigh] of 80 cm^2 each, 0.8 ml/site) at study entry and weeks 1, 6, 7, 12, and 13.
89206886|NCT00270205|Experimental|F|Participants receiving six separate vaccinations of LC002 placebo (3.2 ml total, administered over four skin sites [on the left and right upper back and left and right upper ventral thigh] of 80 cm^2 each, 0.8 ml/site) at study entry and weeks 1, 6, 7, 12, and 13.
89206887|NCT00955851||Pneumonia patients|The study group will consist of individuals diagnosed with pneumonia and admitted to the Medicine ward under the Pneumonia Core Measure Protocol.
89206888|NCT00949767|Experimental|BMS-866949 (Panel 1)|
89206889|NCT00949767|Experimental|BMS-866949 (Panel 2)|
89507778|NCT03149835|Experimental|Healthy Control|"After study enrollment, 15 days before the performance of the experimental protocol, patients performed neurocognitive tests (Digit Span Test, Digit Symbol-Coding, Corsi Block-tapping, Trail Making Test A and B and Stroop Test) and NIV adaptation. Pulmonary function (spirometry) was measured in all subjects after a thorough medical history and physical examination.~CBF was measured by transcranial Doppler by mean of LMCAFV immediately before NIV, during NIV at 5, 30 and 60 minutes and after NIV removal at 5 and 30 minutes. ABG were collected immediately before the experiment, after one hour of NIV breathing and 30 minutes after NIV discontinuation."
89507779|NCT02296255|No Intervention|no HPV vaccine|No delivery of HPV vaccine
89507780|NCT02296255|Experimental|HPV vaccine (Cervarix®, GlaxoSmithKline)|Delivery of HPV vaccine (Cervarix®, GlaxoSmithKline) at 0, 1, 6 months
89507781|NCT02353845||aMCI|aMCI means a group of patients who do not qualify for a diagnosis of dementia but do display memory impairment beyond what is expected for their age and with regards to the educational history and with positive β-amyloid PET
89507782|NCT02353845||normal control|
89507783|NCT02353845||aMCIp|progressive aMCI：aMCI subjects who will convert to AD during the follow-up period
89507784|NCT02353845||aMCIs|stable aMCI：aMCI subjects who will not convert to AD during the follow-up period
89507785|NCT02229071|Experimental|Donafenib(200mg)|Donafenib 200 mg orally twice daily,each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
89507786|NCT02229071|Active Comparator|Donafenib(300mg)|Donafenib 300 mg orally twice daily,each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
89507787|NCT03150147|Experimental|Non-ischemic preservation.|Non-ischemic hypothermic perfusion (NIHP): The device, a portable heart-lung machine, is continous/intermittent perfused the heart with a new preservation solution at a temperature of 8°C.
89507788|NCT03150147|Other|Standard ischemic storage.|Ischemic cold static storage: a crystalloid solution (cardioplegia) is used to stop and preserve the heart. The heart is storage i a transport box containing ice to keep the temperature around 8°C.
89507789|NCT03516097|Experimental|Experimental Group A|Structured school based intervention + mobile app usage
89507790|NCT03516097|Experimental|Experimental Group B|mobile app usage
89507791|NCT03516097|Active Comparator|Control Group|Structured school based intervention
89519388|NCT03451201|Experimental|High Intensity Interval Training|High Intensity Interval Exercise Training in cycle ergometer 3 times a week for 8 weeks
88957954|NCT01988766||No Thrombosis|no incidence of thrombosis in subjects who had PICC line placement
88957955|NCT01988792|Active Comparator|Fortification at 20 ml/kg/day feeding volume|Human milk fortifiers will be added to the human milk when neonates reach to feeding volume of 20 ml/kg/day.
88957956|NCT01988792|Active Comparator|Fortification at 100 ml/kg/day feeding volume|human milk fortifiers will be added to the human milk when neonates reach to feeding volume of 100 ml/kg/day.
88957957|NCT01988805||Blood Draw|Normal healthy individuals will be consented and their blood drawn at the time of their visit.
88957958|NCT01988818|Active Comparator|Standard wound dressing|As comparator will be used a standard Cosmopor E®adhesive, island wound dressing (Paul Hartmann LTD)after hip or knee arthroplasty or spinal surgery
89540037|NCT03051009|Experimental|Desmopressin ODT 25 μg (female previous on 25 μg)|Subjects received 25 μg in trial 000129.
89540038|NCT03051009|Experimental|Desmopressin ODT 25 μg (female previously on placebo)|Subjects received placebo in trial 000129
89540039|NCT03051009|Experimental|Desmopressin ODT 25 μg (female)|New female subjects
89540040|NCT03051009|Experimental|Desmopressin ODT 25 μg (male previous on 25 μg)|Subjects received 25 μg in trial 000130
89540041|NCT03051009|Experimental|Desmopressin ODT 50 μg (male previous on 50 μg)|Subjects received 50 μg in trial 000130
89540042|NCT03051009|Experimental|Desmopressin ODT 50 μg (male previous on placebo)|Subjects received placebo in trial 000130
89540043|NCT03051009|Experimental|Desmopressin ODT 25 μg (male)|Subjects received placebo in trial 000130
89540044|NCT03051009|Experimental|Desmopressin ODT 50 μg (male)|New male subjects
89540045|NCT04884711||Interviews: Older people living at the Leach Court (Brighton, UK).|Older adults who will be enrolled at the Leach Court (Brighton, UK) as a part of the INNOVATEDIGNITY project will be involved in 1:1 open ended interviews.
89540046|NCT04884711||Focus Group Discussions: Older People Living at the Leach Court (Brighton, UK)|10 older people who have previously participated in the interview stage will be involved in two focus group discussions in a group of 5 participants each to co-design digital health technologies that are 'dignity' sensitive and aims to resolve the barriers older people face in technology adoption.
89540047|NCT04889781|Experimental|Rotatory Instruments without Dexamethasone injection|Surgical extraction of Impacted Mandibular Third Molar using conventional rotatory instruments to perform osteotomy without Intramuscular Dexamethasone injection
89540048|NCT04889781|Experimental|Rotatory Instruments with Dexamethasone injection|Surgical extraction of Impacted Mandibular Third Molar using conventional rotatory instruments to perform osteotomy with 8 mg Intramuscular Dexamethasone injection 30 min before surgery
89540049|NCT04889781|Experimental|Piezosurgery technique without Dexamethasone injection|Surgical extraction of Impacted Mandibular Third Molar using the piezosurgery technique without Intramuscular Dexamethasone injection
89540050|NCT04889781|Experimental|Piezosurgery technique with Dexamethasone injection|Surgical extraction of Impacted Mandibular Third Molar using the piezosurgery technique with 8 mg Intramuscular Dexamethasone injection 30 min before surgery
89540051|NCT04884555||post-stroke patient|patients with subacute stroke who have a stroke for the first time and admitted to the hospital for the first rehabilitation treatments
89540052|NCT04884555||Control|healthy volunteers who have not got any known disease and any sign in physical examination
88957959|NCT01988818|Experimental|Mepilex® Border Post-Op|wound dressing with Mepilex® Border Post-Op with Safetac®Technology, self-adherent soft silicone surgical dressing
88957960|NCT01988831|Placebo Comparator|Placebo|"113 patients will be enrolled in the placebo group with respect to randomization.~Placebo group will be prescribed placebo pills in the same packaging as propranolol treated group.~The frequency and duration of the treatment is the same as propranolol arm. The placebo group will have the same cardiology consultation as propranolol treated group to ensure the respect of blindness."
88957961|NCT01988831|Experimental|Betablocker|"drug: 'Propranolol hydrochloride' 338 patients will be enrolled in the Propranolol Group and treated with propranolol.~The dosage will be determined by the cardiologist as the maximum tolerated dose to a maximum of 160mg/day.~One long acting pill a day until an evidence of disease progression or the end of the study."
89540053|NCT03052491|Experimental|Stem Cell 100+ Intervention|Subjects take one 650 mg capsule by mouth twice daily for an average of 15 weeks
89540054|NCT04889391|Experimental|[14C]-Danicopan|Participants were administered a single oral dose of danicopan between 151 and 154 mg (nominal dose of 150 mg), providing approximately 100 μCi of [14C] radiolabel in the form of [14C]-danicopan.
89540055|NCT04884009|Experimental|SHR-1701+ Famitinib|
89540056|NCT04884009|Experimental|SHR-1701|
89540057|NCT04883853|Experimental|Mild -Moderate Ptosis with good levator function (more than 8 mm)|The upper eyelid crease was marked for the incision site, up to 5-7 mm from the lid margin, guided by the fellow eyelid crease position. The skin incision was done and the orbicularis occuli muscle was dissected to the tarsus. The anterior surface of the tarsal plate was then identified with the aponeurosis at its insertion, the orbital septum was then opened with a resultant fat prolapse, and the levator aponeurosis exposed until Whitnall's ligament. Three double-armed 5/0 polyester white braided, non-absorbable sutures, with spatulated needle 1/4 circle (Astralen, Assut Medical Sàrl, Pully-Lausanne, Switzerland) were passed between the levator aponeurosis near Whitnall's ligament and the anterior surface of the tarsus in a mattress form
89540058|NCT04889235||Sarcopenia|Sarcopenia will be defined as either low estimated muscle mass measured by CT-muscle volumetry or reduced muscle function measured by handgrip strength, or reduced physical condition as defined by the European Working Group on Sarcopenia in Older People (EWGSOP)
89540059|NCT04889235||No Sarcopenia|Sarcopenia will be defined as either low estimated muscle mass measured by CT-muscle volumetry or reduced muscle function measured by handgrip strength, or reduced physical condition as defined by the European Working Group on Sarcopenia in Older People (EWGSOP)
89206890|NCT00949767|Experimental|BMS-866949 (Panel 3)|
89507792|NCT03519607|Active Comparator|Treatment Group|Participants who are in the intervention group will receive the FertiStrong app downloading instructions as soon as they have been randomized. They will have access to this app for a period of 30 days during the intervention phase of the study.
89507793|NCT03519607|No Intervention|Control Group|Participants in the control group will not have access to the FertiStrong app for the first 30 days. After a period of 30 days, participants will be provided downloading instructions to this app.
89507794|NCT02232971|Placebo Comparator|Placebo|Isotonic Saline
89507795|NCT02232971|Experimental|Glucagon 0.1 mg|GlucaGen(r) 0.1 mg administration
89507796|NCT02232971|Experimental|Glucagon 0.2 mg|GlucaGen(r) 0.2 mg administration
89507797|NCT02232971|Experimental|Glucagon 0.3 mg|GlucaGen(r) 0.3 mg administration
89507798|NCT02347293|Experimental|+ ind. CHO|Test meals: intake of high levels of indigestible carbohydrates the evening prior to measurements of variables
89507799|NCT02347293|Experimental|- ind. CHO|Reference meal: scarce intake of indigestible carbohydrates the evening prior to measurements of variables
89507800|NCT03146637|Experimental|Activated CIK armed with bispecific antibody treatment group|CIK cells were activated by bispecific antibody of anti-CD3-MUC1/CEA/EpCAM/GPC3
89507801|NCT03146637|Active Comparator|Traditional CIK treatment group|CIK cells were not activated
89507802|NCT02296333|Active Comparator|ondansetron|ondansetron iv, 8 mg, skin closure time
89507803|NCT02296333|Placebo Comparator|isotonic|isotonic 2ml, once, skin closure time
89507804|NCT04409561||Interventions|This patient pool shall be representative of the US population in term of the relative proportion of race/ethnicities. In addition, the population shall be enriched with patients above 60 year old as the target population of the PSP test is mostly the elderly.
89507805|NCT03149913|Experimental|Drug coated balloon|SeQuentPlease OTW paclitaxel coated balloon catheter
89507806|NCT03149913|Active Comparator|uncoated PTA balloon catheter|Standard of care uncoated BTK balloon catheter
89507807|NCT02289703|Experimental|Group A|Participants with end-stage renal disease (ESRD), will receive a single 15-milligram (mg) oral dose of rivaroxaban in Treatment Period 1 on Day 1, administered 2 hours before the start of a 4-hour hemodialysis session followed 7 to 14 days later by Treatment Period 2 wherein a single 15-mg oral dose of rivaroxaban will be given 3 hours after the completion of a 4-hour hemodialysis session on Day 1.
89507808|NCT02289703|Experimental|Group B|Healthy control participants matching to 'Group A' participants, will receive a single 15-mg oral dose of rivaroxaban on Day 1.
89507809|NCT02232347|Experimental|ketamine|ketamine 5 mg/kg/h, continuous infusion for 48 hours
89507810|NCT02232347|Active Comparator|sufentanil|sufentanil 0,5 mcg/kg/h, continuous infusion for 48 hours
89507811|NCT03521557|Experimental|Gaze and Postural Stability|"The duration and content of the Gaze and Postural Stability (GPS) intervention is specifically designed to focus on gradually increasing difficulty of gaze and postural stability exercises.~The target duration of each in clinic visit will be 90 min (15 min of gaze stability exercises, 15 min of postural stability exercises and approximately 60 min for the standard care control intervention with rest interspersed throughout the exercise session.~Gaze stability exercise will consist of progressive Vestibular-occular training.~Postural stability exercises will consist of progressive static and dynamic postural training."
89507812|NCT03521557|Active Comparator|Standard Care Control|The Standard Care Control intervention is specifically designed to be focused on improving overall endurance and lower extremity muscular strength. The target duration of each in clinic visit will be 90 min (30 min of aerobic exercise, 30 min of lower extremity resistance exercises, and 30 min of rest interspersed throughout the exercise session.
89507813|NCT03545321|Experimental|MOON+|MOON+ includes pharmacist online training on opioid safety and naloxone provision, academic detailing of the pharmacy, materials for use at the pharmacy, standardized overdose response safety protocols, and reminder tools for training reinforcement
89206891|NCT00949767|Experimental|BMS-866949 (Panel 4)|
89507814|NCT03158961|Experimental|TOETVA|a new approach in surgery which can treat the thyroid disease
89507815|NCT03542669|Experimental|6B11-OCIK injection|
89507816|NCT03146481|Experimental|Aceclofenac|Aceclofenac 100 mg tablet
89507817|NCT03146481|Placebo Comparator|placebo|Placebo
89206892|NCT00949767|Experimental|BMS-866949 (Panel 5)|
89507818|NCT03521401|Experimental|ACE - Exercise Group|Participants with ACE scores of 4 or higher who will undergo exercise training for the duration of the study (experimental).
89507819|NCT03521401|No Intervention|ACE - Non-Exercise Group|Participants with ACE scores of 4 or higher who will not undergo exercise training for the duration of the study (+ control).
89507820|NCT03521401|No Intervention|Non-ACE - Non-Exercise Group|Participants with ACE scores of 0 who will not undergo exercise training for the duration of the study (- control).
89507821|NCT02353767||Cases|Presence of metabolic syndrome according to the International Diabetes Foundation (IDF)
89507822|NCT02353767||Controls|"age ± 7 years from cases~duration of HIV-1 infection ± 3 years from cases~HIV-1 viral load matched to cases according to 3 thresholds: 50 - 500, 501 - 1000 or > 1000 copies/mL"
89507823|NCT03541655|Active Comparator|Standard of care analgesia|0.25% Bupivacaine HCl administered following total knee replacement
89507824|NCT03541655|Experimental|F14 (celecoxib)|3.5 mL dose of F14 (celecoxib) concurrent with 0.25% Bupivacaine HCl administered following total knee replacement
89507825|NCT02296411|Experimental|CHF 5259 12.5 µg|CHF 5259 12.5 µg: 2 inhalations bid (50µg daily dose)
89507826|NCT02296411|Placebo Comparator|CHF 5259 placebo|CHF 5259 placebo: 2 inhalations bid
89507827|NCT02353689|Experimental|low FODMAP group|consumed EN formula containing low FODMAPs (0.320g/can) during 14-day intervention
89507828|NCT02353689|Experimental|moderate FODMAP group|consumed EN formula containing moderate FODMAPs (0.753g/can) during 14-day intervention
89507829|NCT02353689|Experimental|high FODMAP group|consumed EN formula containing high FODMAPs (1.222g/can) during 14-day intervention
89507830|NCT02229305|Active Comparator|Usual Care Treatment|Usual Care therapists could use any treatment procedures they used regularly in their clinical practice.
89507831|NCT02229305|Experimental|Modular Approach to Therapy for Children|Therapists used a modular manual (Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, or Conduct Problems; Chorpita & Weisz, 2010) to help children with primary problems of anxiety, depression, trauma, and conduct.
89507832|NCT02347137|Active Comparator|Isolated Whey Protein|20 g isolated whey protein + 15 g non-essential amino acids
89507833|NCT02347137|Experimental|Micellar Whey Protein|20 g micellar whey protein + 15 g non-essential amino acids
89507834|NCT02347137|Experimental|Micellar Whey Protein + Citrulline|20 g micellar whey protein + 5 g citrulline
89507835|NCT03516019|Experimental|Weekday am personalized notices|Participants in this arm receive personalized weekday am notices on Wednesday at 7am.
89507836|NCT03516019|Experimental|Weekday pm personalized notices|Participants in this arm receive a personalized weekday pm notices on Wednesday at 7pm.
89507837|NCT03516019|Experimental|Weekend am personalized notices|Participants in this arm receive a personalized weekend am notices on Saturday at 7am.
89507838|NCT03516019|Experimental|Weekend pm personalized notices|Participants in this arm receive personalized pm notices on Saturday at 7pm.
89507839|NCT03516019|Experimental|Weekday am standard notices|Participants in this arm receive standard weekday notices on Wednesday at 7am.
89507840|NCT03516019|Experimental|Weekday pm standard notices|Participants in this arm receive standard weekday notices on Wednesday at 7pm
89507841|NCT03516019|Experimental|Weekend am standard notices|Participants in this arm receive standard weekend notices on Saturday at 7am
89507842|NCT03516019|Experimental|Weekend pm standard notices|Participants in this arm receive standard weekend notices on Saturday at 7pm
89507843|NCT02293135|Experimental|Group 1|Verum Stendo session on V1 and Phantom Stendo session on V2
89507844|NCT02293135|Experimental|Group 2|Phantom Stendo session on V1 and Verum Stendo session on V2
89507845|NCT02293213|Active Comparator|Counseling only|All participants who receive EMR referral to CTIS because they are taking class D or X medications AND are randomized to counseling only will receive: CTIS Counseling, Baseline Questionnaire, 3 Month Follow up Questionnaire, and 6 Month Follow up Questionnaire.
89507846|NCT02293213|Experimental|Counseling + Contraception Appointment|All participants who receive EMR referral to CTIS because they are taking class D or X medications AND are randomized to counseling + Contraception Appointment will receive: CTIS Counseling, Baseline Questionnaire, Contraception Provision Appointment, 3 Month Follow up Questionnaire, and 6 Month Follow up Questionnaire.
89507847|NCT02229617|Active Comparator|Injectable testosterone|We will take a group of transgender males, already on a stable dosage of intramuscular testosterone, and then using their same type and dosage, switch them to the subcutaneous injection route. Weekly trough (just before their weekly injection) levels of total serum testosterone will be taken to compare the steady states of those two injection routes.
89507848|NCT02347059|Experimental|L-dopa|L-dopa will be administered as monotherapy. The dosage and the frequency of intakes are not pre-specified and will be individualized.
89507849|NCT02347059|Active Comparator|Dopamine agonist|Dopamine agonists (either pramipexole or ropirinole) will be administered as monotherapy. The dosage and the frequency of intakes are not pre-specified and will be individualized.
89507850|NCT02296489||Healthy volunteers|
88957962|NCT01988844||Children with cerebral palsy|Children diagnosed with cerebral palsy are included in this group. An assessment and an intervention will be carried out.
89507851|NCT02296489||Asthma patients|
88957963|NCT01988870|Experimental|Intra-operative Radiation Therapy (IORT)|Following breast conserving surgery, a CT-based plan will be prepared to deliver highly conformal IORT and the treatment will be administered.
89023971|NCT04090268|Experimental|Children with malignant hemopathies|Children with malignant hemopathies attending a precision exercise training
89507852|NCT02353611|Experimental|6% bleaching agent|One upper hemiarch will be bleached with 6% hydrogen peroxide with titanium oxide nanoparticles, activated by a led/laser hybrid light. Whitening compound will be mixed according to manufacturer's instructions and distributed uniformly over the buccal surface of the teeth of one upper hemiarch. In each bleaching session the gel will be applied twice for 12 minutes each and activated with continuous irradiance using the LED/laser light (Whitening Lase Plus-DMC Equipamentos, São Carlos, SP, Brazil). Three bleaching sessions will be completed with an interval of 7 days between them.
89507853|NCT02353611|Active Comparator|35% bleaching agent|Together with the experimental agent application, the other upper hemiarch will be bleached with 35% hydrogen peroxide whitening compound. The compound will be mixed according to manufacturer's instructions and distributed uniformly over the buccal surface of the teeth of the corresponding hemiarch. The gel will be applied twice for 12 minutes each and irradiated using the LED/laser light (Whitening Lase Plus-DMC Equipamentos, São Carlos, SP, Brazil). Three bleaching sessions will be completed with an interval of 7 days between them.
89507854|NCT02258867|Placebo Comparator|Placebo|
89507855|NCT02258867|Experimental|Gevokizumab|
89507856|NCT02296567|Active Comparator|Group 1 Lucentis 4 weeks|Blood samples will be collected from patients receiving ranibizumab following the first dose of standard care therapy.
89507857|NCT02296567|Active Comparator|Group 2 Avastin 4 weeks|Blood samples will be collected from patients receiving bevacizumab following the first dose of standard care therapy.
89507858|NCT02296567|Active Comparator|Group 3 Eylea 4 weeks|Blood samples will be collected from patients receiving aflibercept following the first dose of standard care therapy.
88957964|NCT01988896|Experimental|Dose-Escalation: Cobimetinib, Atezolizumab|Participants will receive single dose of 800 milligrams (mg) of atezolizumab IV infusion on Day 1, 15 and 29 of Cycle 1 (cycle length=42 days [14-day run-in period + 28-day concomitant dosing period]), thereafter with atezolizumab IV dosing every 2 weeks (q2w) in all subsequent treatment cycles (28 days each). Combination with cobimetinib will begin on Cycle 1 Day 15 and will be given at increasing dose levels during Stage 1. During Stage 1, cobimetinib will be administered once daily (QD) orally for 21 consecutive days out of 28 days (21/7 dosing schedule) at a starting dose of 20 mg with escalation of 20 mg until the maximum tolerated dose (MTD; not more than 60 mg) for the two-drug combination.
88957965|NCT01988896|Experimental|Dose-Expansion: Cobimetinib, Atezolizumab|Participants will receive single dose of 800 mg of atezolizumab IV infusion q2w in all subsequent treatment cycles (28 days each). Participants will receive cobimetinib at the selected recommended RP2D on Days 1-14 of each 28-day cycle during Stage 2.
89507859|NCT02296567|Active Comparator|Group 4 Lucentis 6 weeks|Blood samples will be collected from patients receiving ranibizumab following the first dose of standard care therapy.
89507860|NCT02296567|Active Comparator|Group 5 Avastin 6 weeks|Blood samples will be collected from patients receiving bevacizumab following the first dose of standard care therapy.
89507861|NCT02296567|Active Comparator|Group 6 Eylea 6 weeks|Blood samples will be collected from patients receiving aflibercept following the first dose of standard care therapy.
89507862|NCT02296567|Active Comparator|Group 7 Lucentis 8 weeks|Blood samples will be collected from patients receiving ranibizumab following the first dose of standard care therapy.
89507863|NCT02296567|Active Comparator|Group 8 Avastin 8 weeks|Blood samples will be collected from patients receiving bevacizumab following the first dose of standard care therapy.
89507864|NCT02296567|Active Comparator|Group 9 Eylea 8 weeks|Blood samples will be collected from patients receiving aflibercept following the first dose of standard care therapy.
89507865|NCT02296567|Active Comparator|Group 10 Control Group no treatment|Blood samples will be collected from patients who are not receiving anti-VEGF treatment.
89507866|NCT02351193||Group I|poor responder females with age less than 35
89507867|NCT02351193||Group II|poor responder females with age more than 35
89507868|NCT02353533|Other|EMR|Standard EMR technique
89507869|NCT02353533|Experimental|FTRD|
89507870|NCT02296723|Experimental|Valganciclovir Hydrochloride Tablets 450 mg|Valganciclovir Hydrochloride Tablets 450 mg of Dr. Reddys Laboratories Limited
89507871|NCT02296723|Active Comparator|Valcyte|Valcyte® 450 mg tablets of Genentech USA Inc., Sanfrancisco
89507872|NCT03158649|Experimental|Positive Psychology Internet-based Intervention condition|Internet-based positive psychology training
89507873|NCT03158649|No Intervention|Waiting List condition|Waiting List control condition
89507874|NCT02289859|Active Comparator|Wound Closure with Undermining|The side assigned to undermining will have undermining performed prior to wound closure in the subcutaneous plane. The amount of undermining will range from 1 cm for wounds with low tension to 2 cm for those with moderate tension. Since wound diameter will be 3 cm or less and exclude the scalp, high tension wounds are not anticipated.
89507875|NCT02289859|Active Comparator|Wound Closure without Undermining|One side of the wound will remain un-undermined.
89507876|NCT03519139|Experimental|individual dietary counselling|three individual dietary counsellings. The first at the hospital by discharge, then in week 1 and week 3 at the subject's home/the respite care after discharge and, if necessary, telephone follow-up in weeks 2 and 4 after discharge
89507877|NCT03519139|No Intervention|Control|standard counselling provided by the hospital at discharge. The standard counselling may include nutritional prescription and nutritional plan, but no follow-up to the nutrition plan after the discharge.
89507878|NCT02346981|Experimental|Intervention gruop|The intervention group was submitted to a resistance training program that consisted of eight exercises performed in two sets of 10 to 15 repetitions, three times per week.
89507879|NCT02346981|No Intervention|Control group|The control group performed a stretching training program for the major muscle groups, in sessions of 30 minutes, twice a week
89507880|NCT02289937|Experimental|Ropivacaine|8 ml of ropivacaine 7,5 mg/ml will be injected around nervus cutaneous femoral lateralis. Ultrasound-guided.
89507881|NCT02289937|Placebo Comparator|Placebo|8 ml of isotonic saline will be injected around nervus cutaneous femoral lateralis. Ultrasound-guided
89507882|NCT03146559|Experimental|EMG and TENS|"Wireless Bluetooth EMG (Myo) bracelet will be placed on the healthy forearm. A voluntary dorsi flexion of the healthy wrist produces data that will be transmitted to a PC and will be used to activate (via Arduino controller) a Transcutaneous Electric Nerve Stimulator (TENS), placed on the paretic forearm, that will stimulate wrist dorsi flexors.~5 days per week, for 3 weeks, 15 minutes per day."
89507883|NCT03146559|Active Comparator|TENS only|"Custom-built software & hardware: PC + Arduino controller and Transcutaneous Electric Nerve Stimulator (TENS) device, will be used to stimulate wrist dorsi flexors of the paretic forearm.~5 days per week, for 3 weeks, 15 minutes per day."
89507884|NCT03446807|Experimental|Droxidopa|The Droxidopa starting dose for all eligible patients in the Titration Periods are 100mg three times daily (TID). Doses will be titrated by 100mg TID; increments will be made weekly until the optimal dose is achieved or the subject doesn't notice an improvement in their subjective fatigue on a higher dose compared to the most recent dose. Half of the subjects will be on Droxidopa for 3 months during the double-blind phase. All subjects will be on Droxidopa for 3 months during the open-label phase.
89507885|NCT03446807|Placebo Comparator|Placebo Oral Tablet|The placebo starting dose for all eligible patients in the Titration Period is 100mg TID. Doses will be titrated by 100mg TID; increments will be made weekly until the optimal dose is achieved. Half of the subjects will be on placebo for 3 months during the double-blind phase.
89507886|NCT02258945||Continuous Subcutaneous Insulin Infusion|This group will consist of patients with Type 1 diabetes using continuous subcutaneous insulin infusion therapy.
89507887|NCT02258945||Multiple Daily Injections|This group will consist of patients with Type 1 diabetes using multiple daily injection therapy.
89507888|NCT03521323|Experimental|Umbilical Cord Mesenchymal Stem Cells|Intrathecal Transplantation of Umbilical Cord Mesenchymal Stem Cells, 1*10^6 cells/kg, once a month for 4 months
89507889|NCT03521323|Placebo Comparator|Control|Sham operation and 10ml saline as placebos, once a month for 4 months
89507890|NCT03158259|Experimental|Intervention group MSU|Patient will be diagnosed (NIHSS, CT and conventional blood-measures) and given thrombolytic treatment (when indicated) prehospitally by anesthesiologist in Mobile Stroke Unit (MSU)
89507891|NCT03158259|Active Comparator|Conventional ambulance|Patient will be brought to hospital by normal ambulance according to existing procedures. Diagnosis (NIHSS, CT and conventional blood-measures) and thrombolytic treatment (when indicated) will be given in hospital.
89507892|NCT03519061|Experimental|Treatment|This is the group of enrollees who receive budesonide
89507893|NCT02229773|Experimental|BIBB 1464 MS low dose|
89507894|NCT02229773|Placebo Comparator|Placebo|
89507895|NCT02229773|Active Comparator|Pravastatin|
89507896|NCT02229773|Experimental|BIBB 1464 MS medium dose|
89507897|NCT02229773|Experimental|BIBB 1464 MS high dose|
89507898|NCT02296879|Experimental|SAIT301|"For Stage 1, subjects will be sequentially assigned to 1 of approximately 8 cohorts comprised of 3 to 6 subjects each. SAIT301 will be administered according to a modified Fibonacci sequence and following a 3 + 3 design.~For Stage 2, the MTD or (RP2D) determined in the Stage 1 will be administered to additional subjects with selected diagnoses, 15 subjects per selected diagnosis. After completion of Stage 1 the SRC may elect to increase the interval between doses (i.e., increase cycle length to 28 days) based on the emerging PK data from the lower SAIT301 dose levels."
88957966|NCT01988909|Experimental|WR 279,396|All patients with the same Study drug: WR 279,396 (Topical Paromomycin and Gentamicin Cream)
89507899|NCT03515863||Grave's disease with TAO|Patients with Grave's disease and TAO
89507900|NCT03515863||Grave's disease without TAO|Patients with Grave's disease but without TAO
89507901|NCT02346669|Active Comparator|FMT from a lean donor+ high fat diet|"Patients will undergo FMT (Fecal Microboita Transplantation) from a lean donor twice during study through a gastroscopy:~at time 0~after 6 weeks Patient will start high fat low fiber diet 2 weeks before first FMT and continue on consuming the same diet 9 weeks after the first FMT. Patient will be followed up by a nutritionist through the the study."
89519389|NCT03451201|Active Comparator|Moderate Continuous Exercise Training|Moderate Continuous Interval Training
88957967|NCT01988935|Experimental|Prolonged Exposure + Smoking Cessation|Prolonged Exposure therapy plus smoking cessation intervention
88957968|NCT01988935|Active Comparator|Smoking Cessation|Smoking cessation intervention
88957969|NCT01988948|Other|student cohort|"Various biological sampling~blood sampling,~oral, vulvar, vaginal and anal sampling for women,~oral and genital sampling for men"
88957970|NCT01988961|Experimental|Golimumab|Participants will receive the approved induction subcutaneous (SC) dose regimen of 200 mg at Week 0 followed by 100 mg at Week 2. At Week 6 and thereafter through Week 50, participants will receive the SC maintenance dosage of golimumab that has been approved for UC in the country in which the study is being conducted. In countries where golimumab is not approved for UC, a maintenance dosage of 100 mg every 4 weeks will be used.
88957971|NCT01988974|Experimental|Alert for AF Program|1) participation in the Alert for Atrial Fibrillation program ) .
88957972|NCT01988974|Active Comparator|Attention control condition|2) participation in the healthy sleep program
88957973|NCT01988987||Inpatient Postpartum GTT|Women with gestational diabetes will undergo a 75 gram, 2 hour, oral glucose tolerance test 2-4 days postpartum prior to hospital discharge, in addition to undergoing the standard of care, outpatient glucose tolerance test performed 6-12 weeks postpartum
89023972|NCT04090268|No Intervention|Healthy children|Healthy children
89206893|NCT00949767|Experimental|BMS-866949 (Panel 6)|
89206894|NCT00949767|Experimental|BMS-866949 (Panel 7)|
89519390|NCT03451201|Other|Non-exercise|Sedentary Type 1 Diabetes Controls.
88957974|NCT01989000|Active Comparator|Neoadjuvant radiochemotherapy|Patients elected for neoadjuvant radiochemotherapy undergo DWI-MRI, DCE-MRI (Gadobutrol),T2*-MRI and [F-18]HX4 PET/CT imaging within two weeks before start of the chemoradiation and again after radiochemotherapy (Gemcitabine/Radiotherapy), within two weeks before surgery (Pancreaticoduodenectomy).
89507902|NCT02346669|Sham Comparator|FMT from a lean donor+ sham diet|"Patients will undergo FMT (Fecal Microboita Transplantation) from a lean donor twice during study through a gastroscopy:~at time 0~after 6 weeks Patient will start sham diet (no change in fat/fiber consumption) 2 weeks before first FMT and continue on consuming the same diet 9 weeks after the first FMT. Patient will be followed up by a nutritionist through the the study."
89507903|NCT02346669|Active Comparator|FMT from lean donor+ low fat diet|"Patients will undergo FMT (Fecal Microboita Transplantation) from a lean donor twice during study through a gastroscopy:~at time 0~after 6 weeks Patient will start low fat high fiber diet 2 weeks before first FMT and continue on consuming the same diet 9 weeks after the first FMT. Patient will be followed up by a nutritionist through the the study."
89507904|NCT03357029|Active Comparator|Gammacore Device|The GammaCore Device is a non-Invasive vagus nerve stimulator. One stimulation dose bilaterally to the cervical vagal neck area, three times per day (morning 8 am., afternoon 2 pm, and evening 8 pm) for two weeks
88957975|NCT01989000|Active Comparator|Primary Surgery|Patients elected for primary surgery undergo DWI-MRI, DCE-MRI (Gadobutrol),T2*-MRI and [F-18]HX4 PET/CT imaging within two weeks before surgery (Pancreaticoduodenectomy).
88957976|NCT01989026|Active Comparator|BCG at admission to NICU|These children will receive the BCG (and OPV) vaccines at admission to the Neonatal Intensive Care Unit (NICU).
88957977|NCT01989026|No Intervention|BCG at discharge (as usual)|These children will only receive the BCG (and OPV) vaccines at discharge, as per current standard of care.
88957978|NCT01989052|Experimental|Phase 1: CTO and lomustine|The combination of CTO with the standard dosing of 100 mg/m2 of lomustine among patients with recurrent malignant glioma (World Health Organization (WHO) grade III or IV) that have not previously received bevacizumab as treatment for their disease
88957979|NCT01989052|Experimental|Phase 2: CTO alone|CTO alone at the MTD established in the Phase 1 portion of this study
88957980|NCT01989052|Experimental|Phase 2: CTO and lomustine|CTO at the same daily dose of as in the CTO alone arm in combination with 110 mg/m2 oral lomustine every 6 weeks
88957981|NCT01989052|Experimental|Phase 2: Lomustine alone|Oral lomustine alone at 110 mg/m2 every 6 weeks
88957982|NCT01989065|Active Comparator|Lifestyle counseling|The Duke Healthy Lifestyles program is a comprehensive childhood obesity treatment program. Standard of care is active engagement and Lifestyle Counseling of families by nutritionist, physician, mental health provider, and physical therapist. Monthly visits for 1 year are recommended.
88957983|NCT01989065|Experimental|Lifestyle counseling PLUS text messaging|Patients in this arm will receive full standard of care as described for the Active Comparison group. In addition, parents will be texted daily with a motivational message that provides information and support for healthy behaviors.
88957984|NCT01989078|Experimental|Losartan|Participants taking losartan, in addition to taking hydroxyurea therapy, as prescribed per standard of care
88957985|NCT01989091|Experimental|B-Lock (IMD)|Investigational Medical Device (IMD)
88957986|NCT01989091|Active Comparator|Heparin 5,000 U/mL (ACH)|Active Comparator Heparin (ACH)
88957987|NCT01989117||Osteopathy|
88957988|NCT01989117||No osteopathy|
88957989|NCT01989182|Experimental|Treatment with Spiration Valve System|Subjects assigned to the treatment group will undergo a bronchoscopic procedure to have valves placed in the most diseased lobe of the lung to occlude all segments of the lobe. Subjects assigned to this group will also receive medical management.
88957990|NCT01989182|Active Comparator|Medical Management|The control group for this study will receive medical management. This medical management group will be evaluated and followed in the same manner as the treatment group, but without having a bronchoscopic procedure.
88957991|NCT01989247|Experimental|Self-management program|Seven weekly sessions of a group-based self-management programme for people with anxiety and depressive symptoms
88957992|NCT01989247|No Intervention|Control group|
88957993|NCT01989260|Other|Anti-adhesive gel|An anti-adhesive gel will be administered to one ovary (randomised at the time of laparoscopic surgery to severe endometriosis). The coated ovary will be compared to the non-coated ovary 3 months after surgery to assess for the presence of post-operative ovarian adhesions. Neither the patient nor the person performing the ultrasound scan assessing for the presence of ovarian adhesions will know which was the ovary coated in the anti-adhesive gel.
88957994|NCT01989273||IVC Collapsibility >50% or IVC < 12mm|Major Trauma Victims admitted at Level I Trauma Center with an inferior vena cava collapsibility >50% or IVC diameter less than or equal to 12mm
88957995|NCT01989273||IVC Collapsibility <50% or IVC >12mm|Major Trauma Victims admitted at Level I Trauma Center with an inferior vena cava collapsibility <50% or IVC diameter >12mm
88957996|NCT01989286||Plagiocephaly group-Assessment|Children (3-5 years) who were diagnosed and treated because of positional plagiocephaly are included in this group. An asssessment of posture will be performed.
88957997|NCT01989312|Active Comparator|supraclavicular block|A supraclavicular block with 32 mL of lidocaine 1.5% + epinephrine 5µg/mL was performed for the anaesthetic management of the forearm and hand.
88957998|NCT01989312|Active Comparator|Supraclavicular and median, ulnar, radial blocks|Patients in this group received 20 mL of lidocaine 1.5% + epinephrine 5µg/mL for supraclavicular block and after the supraclavicular block they recieved a distal median, radial, and ulnar nerve blocks using 50:50 mixture of lidocaine 2% + levobupivacaine 0.5% (4 mL/nerve).
88957999|NCT01989338||Hallux valgus patients|Females patients with hallux valgus asses for pain, function, and quality of life
88958000|NCT01989351||VAS<4|
88958001|NCT01989351||VAS>4|
88958002|NCT01989403||Lumbar disc herniation patients|LBP with sciatica, with a numeral rating scale (NRS) leg pain intensity of 5 or higher and onset within 1 year; (2) LDH confirmed by MRI
88958003|NCT01989416|Placebo Comparator|Soap bathing|ICU patients will be bathing with soap at least once daily
88958004|NCT01989416|Experimental|2% chlorhexidine wipes|Use 2% chlorhexidine wipes to clean the patient at least once daily
89023973|NCT04087317|Experimental|Fixed time interval group.|Patients received oral 1-gram paracetamol and 400 milligram ibuprofen every 6 hours, in the first 24 hours postpartum. After 24 hours postpartum and until discharge, they will receive analgesics at maternal request. At any time, if a woman experienced pain despite the prescribed treatment, the next line of treatment was MIR (morphine immediate release, 10 mg tablet).
89023974|NCT04087317|Experimental|'On-demand' group.|Patients received oral 1-gram paracetamol and 400 milligram ibuprofen at maternal request. At any time, if a woman experienced pain despite the prescribed treatment, the next line of treatment was MIR (morphine immediate release, 10 mg tablet).
89023975|NCT04079361|Other|Pregnancy complication|Intervention: blood samples
89507905|NCT03357029|Sham Comparator|Sham Device|"The Sham GammaCore device looks and operates like the Active GammaCore device, but does not deliver a therapeutic stimulation treatment.~One stimulation dose bilaterally to the cervical vagal neck area, three times per day (morning 8 am., afternoon 2 pm, and evening 8 pm) for two weeks."
89507906|NCT02293291|Active Comparator|Lithium Water|"To empirically test the effects of Lithium water in violence prevention program on rates of violent attitudes and behavioral inclinations in populations whose drinking water supplies contain little or no lithium.~To utilize an experimental design to establish statistical support for the impact of community habits related variables (protective factors) on violent attitudes and behavioral inclinations among at-risk communities To demonstrate the effect of drinking water variables (protective factors) to existing evidence-based factors (risk factors) that have proven effective in reducing violence based on previous research."
89507907|NCT02293291|Placebo Comparator|MIneral water|"To empirically test the effects of Lithium water in violence prevention program on rates of violent attitudes and behavioral inclinations in populations whose drinking water supplies contain little or no lithium.~To utilize an experimental design to establish statistical support for the impact of community habits related variables (protective factors) on violent attitudes and behavioral inclinations among at-risk communities To demonstrate the effect of drinking water variables (protective factors) to existing evidence-based factors (risk factors) that have proven effective in reducing violence based on previous research."
89507908|NCT03157557|Experimental|Lifestyle treatment|Lifestyle treatment
89507909|NCT03157557|No Intervention|Treatment as Usual|Treatment as Usual
89507910|NCT04305275|Experimental|SAGE-324 60 mg|Participants will receive SAGE-324 60 mg dose (tablets) orally in the morning for 28 days.
89507911|NCT04305275|Placebo Comparator|SAGE-324 Matched Placebo|Participants will receive SAGE-324 matched placebo, oral tablets for 28 days.
89507912|NCT03515785||Ph+ ALL Patients|Patients with Ph+ ALL being treated with Iclusig®.
89507913|NCT05231031|Active Comparator|Aerobic exercise|This group received continuous aerobic exercise only in the form of walking on a treadmill 3 sessions/week for 6 weeks
89507914|NCT05231031|Experimental|Aerobic, Breathing exercises , and relaxation training|This group received continuous aerobic exercise only in the form of walking on a treadmill 3 sessions/week for 6 weeks in addition to breathing exercises and relaxation training for the same period
89507915|NCT02347215|Other|All patients|All patients undergo quality of life assessment at 2-3 time points and stress imaging at two time points
89507916|NCT03337451|Experimental|OPN-305|
89507917|NCT03515707|Experimental|Treatment (busulfan, etoposide, ASCT)|Patients receive busulfan IV or oral every 6 hours on days -7 to -4 and etoposide IV on day -3. Patients then undergo autologous stem cell transplant on day 0.
89507918|NCT02346513||A: Ceramic on Metal THA|"Subgroup A1: Consist of ceramic on metal THAs with short term follow-up (less than 2years)~Subgroup A2: Consist of ceramic on metal THAs with midterm follow-up (more than 2years)~Subgroup A3: Consist of bilateral ceramic on metal THAs"
89507919|NCT02346513||B: Non-Ceramic on Metal THA|Patients have THA with non COM bearing
89507920|NCT02346513||C: Healthy subjects|Patients without any implant or systemic disease, to served as controls
89507921|NCT02296957|Experimental|Intervention|Intervention towards hospital physicians to promote hypnosedative discontinuation in patients initiated during the hospital stay, intervention towards patients and their general practitioners to heighten awareness about the hypnosedative-related risks.
89507922|NCT02296957|No Intervention|Control|Usual Care
89507923|NCT02346591|Experimental|Jauntly|Mobile app designed to take advantage of the known connections between positive emotions, stress reduction and stress resilience; goal was to lead users through research-proven positive emotion enhancing exercises and relevant educational materials. Intervention activities covered five well-being generating content areas: 1) promoting the experience and recognition of gratitude; 2) encouraging positive social relationships and feelings of social support; 3) improving stress resilience via mindfulness and other relaxation-focused activities; 4) focusing and capitalizing on individual strengths (as opposed to limitations and weaknesses); and 5) general positive mood inducing activities.
89507924|NCT02346591|Active Comparator|Online stress management information|The control participants were emailed links to vetted online information about stress and encouraged to visit the websites.
89507925|NCT02298205|Other|Provider-based adjustment|Primary care provider will adjust the dose of asthma controller medication based on asthma control at each encounter
89507926|NCT02298205|Active Comparator|Symptom-based adjustment|The dose of asthma controller medication is adjusted based on the symptoms
89023976|NCT04061226||Central obesity group|Normal weight central obesity patients (by BMI and WHR).
89023977|NCT04061226||Without central obesity group|Normal weight patients without central obesity (by BMI and WHR).
89023978|NCT04054167|Experimental|Treatment (ultra low dose radiation therapy)|Patients undergo ultra low dose radiation for 1-2 days before chemotherapy free-targeted therapy. Patients may receive a second, longer course of radiation if the lesion treated does not respond.
89507927|NCT03307577|Experimental|UHE-101 cream, 1%|Cream is applied twice a day
89023980|NCT04040634|Experimental|Intensive Control of Systolic Blood Pressure (SBP)|Participants randomized into the Intensive Blood Pressure arm will have a goal of SBP <120 mm Hg.
89023981|NCT04040634|Active Comparator|Standard Control of Systolic Blood Pressure (SBP)|Participants randomized into the Standard arm will have a goal of SBP <140 mm Hg.
89507928|NCT03307577|Placebo Comparator|Vehicle cream|Cream is applied twice a day
89507929|NCT03514771|Other|All Subjects|All subjects will have one side of their face treated with the laser and one side not treated to serve as the control.
89507930|NCT02346279||Persons in physical therapy treatment|Questionnaires (MSQPT, HAQUAMS, Transition Questionnaire for Patient and treating physiotherapist), physical tests (9HPT, 6MTWT, BBS, 6MWT), EDSS
89507931|NCT01639937||1|Subjects with palliated congenital heart disease including, but not limited to, d TGA, ccTGA, single ventricles, hypoplastic left heart syndrome and tricuspid atresia will be recruited
89507932|NCT02298283|Experimental|study treatment|"induction = BEACOPP-escalated (bleomycin, etoposide, adriamycin, cyclophosphamide, oncovin, procarbazine, and prednisone) : 2 cycles every 3 weeks~radiotherapy = involved field radiotherapy (IFRT) will be given 3 to 4 weeks after the last day of second BEACOPP at 30 Grays (+boost 6 Grays to area with residual lesion) in 3 weeks~Consolidation = brentuximab vedotin treatment will start 4 weeks after the last day of IFRT and up to 6 weeks. The dose of study treatment is 1.8 mg/kg"
89507933|NCT02346357|Active Comparator|Obturator nerve block|Ultrasound-guided single-injection obturator nerve block with 20 mL ropivacaine 0.5%
89507934|NCT02346357|Placebo Comparator|Sham block|Placebo arm. Ultrasound-guided injection of 3-5 mL normal saline in the subcutaneous tissue in the same location as would for an obturator nerve block.
89507935|NCT03146247|Other|One arm|all patients receive same dose and dosing regimen with Apremilast
89507936|NCT03263273|Placebo Comparator|Topical Vehicle Gel|Topical administration of vehicle gel. Regimen: Apply once daily, at bedtime to the face
89507937|NCT03263273|Active Comparator|1% Topical Minocycline Gel|Topical administration of 1% Topical Minocycline Gel. Regimen: Apply once daily, at bedtime to the face
89507938|NCT03263273|Active Comparator|3% Topical Minocycline Gel|Topical administration of 3% Topical Minocycline Gel. Regimen: Apply once daily, at bedtime to the face
89507939|NCT02293369|Active Comparator|Cuff closure via vaginal route|For vaginal cuff closure both in laparoscopic approach and vaginal route, we will use the same horizontal method, which can be described as closing the vagina anterior to posterior by leaving a horizontal scar. The repair will start at one end of the vaginal cuff, taking care to incorporate the uterosacral ligament into the initial bite and will continue toward the surgeon until the other uterosacral ligament will be incorporated into the repair, using a continuous 0-Vicryl suture in the vaginal route.
89507940|NCT02293369|Active Comparator|Cuff closure via laparoscopic route|For vaginal cuff closure both in laparoscopic approach and vaginal route, we will use the same horizontal method, which can be described as closing the vagina anterior to posterior by leaving a horizontal scar. In the laparoscopic approach, needles will be introduced through the umbilical trocar and removed through the peripheral trocars and intracorporeal knots will be utilized.
89507941|NCT03146325|Experimental|PYLERA AND OMEPRAZOLE|14-DAY COURSE OF 3-1 PYLERA (3 CAPSULES QID) PLUS OMEPRAZOLE (BID)
89507942|NCT03146325|Placebo Comparator|PLACEBO|MATCHING PLACEBOS
89507943|NCT03518905|Sham Comparator|sham-treatment|Patients with symptomatic large heterotopic gastric mucosa receive an esophagoscopy without radiofrequency ablation under sedation
89507944|NCT03518905|Active Comparator|treatment arm|Patients with symptomatic large hetertotopic gastric mucosa receive an esophagoscopy with radiofrequency ablation (12J/cm2) using the Barrx channel RFA endoscopic catheter (Medtronic)
89507945|NCT03518749|Active Comparator|1mA anodal tDCS + cognitive control training|1 mA anodal tDCS will be administered to the left dlPFC (F3) for 23 mins during the performance of a cognitive control training.
89507946|NCT03518749|Active Comparator|2mA tDCS + cognitive control training|2 mA anodal tDCS will be administered to the left dlPFC (F3) for 23 mins during the performance of a cognitive control training.
89507947|NCT03518749|Placebo Comparator|sham tDCS + cognitive control training|Sham tDCS (30 secs of tDCS) will be administered to the left dlPFC (F3) with 2mA at the beginning of a cognitive control training.
89507948|NCT02346123||Single group|Group which contains all the patients of the study.
89507949|NCT03514693|Active Comparator|PVI alone|PVI, and ablation for AF triggers from non-PV foci, the cavotricuspid isthmus, clinical coexisting tachyarrhythmia such as atrial flutter (AFL), atrial tachycardia (AT), and supraventricular tachycardia, if necessary
89507950|NCT03514693|Placebo Comparator|PVI plus additional ablation|PVI, additional CFAE or linear ablation after PVI, and ablation for AF triggers from non-PV foci, the cavotricuspid isthmus, clinical coexisting tachyarrhythmia such as atrial flutter (AFL), atrial tachycardia (AT), and supraventricular tachycardia, if necessary
89507951|NCT02233049|Experimental|R1: erlotinib versus dasatinib|EGFR+ only Tarceva® (erlotinib): 25 mg and 100 mg tablets. The prescribed dose is 125 mg/m²/day orally, once daily. Sprycel® (dasatinib): 20 mg and 50 mg tablets. The prescribed dose is 85 mg/m²/dose, orally, twice daily, i.e. 170 mg/m2/day.
89507952|NCT02233049|Experimental|R2: everolimus versus dasatinib|PTEN-loss only Votubia® (everolimus): 2.5 mg tablets. The prescribed dose is 5 mg/m²/day, orally, once daily. Sprycel® (dasatinib): 20 mg and 50 mg tablets. The prescribed dose is 85 mg/m²/dose, orally, twice daily, i.e. 170 mg/m2/day.
89507953|NCT02233049|Experimental|R3: erlotinib versus everolimus versus dasatinib|EGFR+ and PTEN-loss or inconclusive biopsy Tarceva® (erlotinib): 25 mg and 100 mg tablets. The prescribed dose is 125 mg/m²/day orally, once daily. Votubia® (everolimus): 2.5 mg tablets. The prescribed dose is 5 mg/m²/day, orally, once daily. Sprycel® (dasatinib): 20 mg and 50 mg tablets. The prescribed dose is 85 mg/m²/dose, orally, twice daily, i.e. 170 mg/m2/day.
89507954|NCT02233049|Experimental|Cohort Dasatinib|Neither EGFR overexpression nor loss of PTEN expression Sprycel® (dasatinib): 20 mg and 50 mg tablets. The prescribed dose is 85 mg/m²/dose, orally, twice daily, i.e. 170 mg/m2/day
88958005|NCT01989442|Experimental|Nasal Mask|patients who receive NIV by nasal mask interface after randomization
89507955|NCT02350725|Experimental|Group 1|Furosemide injection solution for subcutaneous administration (80 mg) over 5 hours followed by Oral Furosemide tablets (80 mg) in second period.
89023982|NCT04038515|Experimental|E-liquid Order 'A'|Order 'A' for E-liquid Self-Administration: All participants will be given all e-liquids (i.e., all 20 nicotine*flavor combinations (4 nicotine* 5 flavor combinations)) in this within-subject, cross-over design study. Participants will be randomized the order in which they self-administer the 20 nicotine*flavor combinations of e-liquid (across and within the 4 visits). The specific order cannot be described here without disrupting the double-blind nature of the study design.
89023983|NCT04038515|Experimental|E-liquid Order 'B'|Order 'B' for E-liquid Self-Administration: All participants will be given all e-liquids (i.e., all 20 nicotine*flavor combinations (4 nicotine* 5 flavor combinations)) in this within-subject, cross-over design study. Participants will be randomized the order in which they self-administer the 20 nicotine*flavor combinations of e-liquid (across and within the 4 visits). The specific order cannot be described here without disrupting the double-blind nature of the study design.
89023984|NCT04038515|Experimental|E-liquid Order 'C'|One nicotine level condition is a medium nicotine e-liquid (12 mg/mL nicotine). All participants will be given all e-liquids (i.e., all 20 nicotine*flavor combinations (4 nicotine* 5 flavor combinations)) in this within-subject, cross-over design study. Participants will be randomized the order in which they self-administer the 20 nicotine*flavor combinations of e-liquid (across and within the 4 visits). The specific order cannot be described here without disrupting the double-blind nature of the study design.
89540060|NCT02616393|Experimental|Cohort A: Brain Metastases (BM)|Tesevatinib 300 mg orally (PO) once daily (QD) administered to subjects with NSCLC who had progressed with brain metastases (BM)
89540061|NCT02616393|Experimental|Cohort B: Leptomeningeal Metastases (LM)|Tesevatinib 300 mg PO QD administered to subjects with NSCLC who had progressed with leptomeningeal metastases (LM)
89540062|NCT02616393|Experimental|Cohort C: Brain Metastases at Initial Presentation (BM-IP)|Tesevatinib 300 mg PO QD administered NSCLC who presented initially with BM at initial presentation
89540063|NCT04905147|Active Comparator|The mosapride group|The mosapride group received 15 mg of mosapride by mouth or feeding via NG with 50 ml of water three times a day, starting on the morning of postoperative day 1, until hospital discharge or for a maximum of 10 postoperative days if the patient remained hospitalized.
89540064|NCT04905147|Placebo Comparator|The control group|The control group received 15 mg of placebo drug with 50 ml of water three times a day, starting on the morning of postoperative day 1, until hospital discharge or for a maximum of 10 postoperative days if the patient remained hospitalized.
89540065|NCT04904991|Experimental|Qigong group|Participants in the Qigong group were given a structured program about Chan-Chung qigong for 3 months which was a modified form of the manual of Chan-Chuang qigong (Yeh et al., 2006), to tailor to patients with cognitive impairment. The Chan-Chuang qigong program included warmup prior to qigong practice, preparation for qigong practice . The movements should be repeated and maintained for 10 minutes per time, 3 time a day .
89540066|NCT04904991|No Intervention|Control group|those in the control group received usual care for cognitive impairment during the same study period.
89540067|NCT04883151|Experimental|SOFUS pilot program|
89540068|NCT04883307|Experimental|Coaching Intervention|Paired with a coach outside of their specific area of interest; encouraged to meet 3 times over 9 months for a 1:1 coaching meeting
89540069|NCT04883307|Active Comparator|Wellness Resources|Emailed wellness resources
89540070|NCT04889001|Other|Before/After|Before and after comparison- one arm study
89540071|NCT03050229|Experimental|Empagliflozin|Empagliflozin 10mg/day is administrated orally before or after breakfast for 12 weeks while continuing the existing treatment for hypertension (include AngiotensinII Receptor Blocker [ARB]) and diabetes.
89540072|NCT03050229|Placebo Comparator|Placebo|Placebo is administrated orally before or after breakfast for 12 weeks while continuing the existing treatment for hypertension (include AngiotensinII Receptor Blocker [ARB]) and diabetes.
89540073|NCT03050151|Experimental|1 - Dupilumab (Part A)|Dose (dose 1) as per protocol delivered by auto-injector device
89540074|NCT03050151|Experimental|2 - Dupilumab (Part A)|Dose (dose 1) as per protocol delivered by prefilled syringe
89540075|NCT03050151|Experimental|3 - Dupilumab (Part B)|Dose (dose 2) as per protocol delivered by auto-injector device
89540076|NCT03050151|Experimental|4 - Dupilumab (Part B)|Dose (dose 2) as per protocol delivered by prefilled syringe
89540077|NCT04882761|Active Comparator|Socket shield in direct contact with dental implant|eight partially extracted sockets where implant (Neobiotech) was placed in direct contact to socket shield
89540078|NCT04882761|Active Comparator|Socket shield with gap and xenograft with dental implant|eight partially extracted sockets where a gap was left between implant (Neobiotech) and socket shield
89540079|NCT04888533||All Patients evaluated by PESP during the trial period.|EHSSA tool applied to every patient in cohort.
89540080|NCT03049527|Experimental|Education, Incentives and Feedback|Education, Incentives and Feedback are all directed to all study participants.
89540081|NCT03049605|Experimental|Magnetic Therapy|Twenty five patient were exposed to low intensity pulsed magnetic therapy with a frequency of 200 Hertz and intensity of 50 Gauss for 30 minutes / session for 2 times per week for 3 months .
89540082|NCT03049605|Experimental|Laser Therapy|Twenty five patients were treated with 24 sessions of laser therapy at a rate of two sessions / week for three months. Each patient will be exposed to Helium neon infrared laser (850 nano-meter continuous wave mode from a comfortable prone lying position.
89540083|NCT03049605|Experimental|Medical therapy|Fifteen patients were received only medical treatment .
89540084|NCT04904367|Active Comparator|Deep tissue massage|For 4 weeks 20 session, this groups were applied hot pack with 20 minutes of conventional Transcutaneous Electrical Nerve Stimulation(TENS) to back and neck region, followed by 4 minutes of ultrasound at a frequency of 3 Megahertz(MHz) and at a dosage of 1 w / cm2. Also, administered DTM to the back and neck region for 20 min in 12 sessions in addition to the conventional physical therapy.
89540085|NCT04904367|Experimental|Conventional physiotherapy|For 4 weeks 20 session, this groups were applied hot pack with 20 minutes of conventional TENS to back and neck region, followed by 4 minutes of ultrasound at a frequency of 3 MHz and at a dosage of 1 w / cm2.
89206895|NCT05299827||Children diagnosed with lower urinary system dysfunction (LUTD Group)|Children who are between the ages of 5-18 and diagnosed with lower urinary system dysfunction by pediatric urologist.
89206896|NCT05299827||Healty Group|Healthy participants in the same age group in the control group; The siblings or cousins of the cases who applied to Tuğtepe Pediatric Urology Center but did not meet the inclusion and exclusion criteria and/or the cases who applied to the outpatient clinic were determined to be healthy after being examined by the relevant physician, and consisted of girls and boys who volunteered to participate in the study. .
89206897|NCT00622284|Experimental|BI 1356 5mg, once daily|patient to receive a tablet containing 5mg BI 1356 plus one (two in US) inactive placebo capsule matching Glimepiride
89206898|NCT00622284|Active Comparator|Glimepiride|patient to receive 1mg or 2mg or 3mg (not in US) or 4mg Glimepiride capsule plus one inactive placebo tablet matching BI 1356 (plus one inactive placebo capsule in US)
89206899|NCT00269113|Experimental|1|
88958006|NCT01989442|Active Comparator|nasal prong|patients who receive NIV by nasal prongs as interface after randomization
89206900|NCT00269113|Active Comparator|2|
89206901|NCT04010487||Endometrial carcinoma arising in adenomyosis|Patients pathologically conformed endometrial carcinoma arising in adenomyosis (EC-AIA)
89507956|NCT02350725|Experimental|Group 2|Oral Furosemide tablets (80 mg) followed by Furosemide injection solution for subcutaneous administration (80 mg) over 5 hours in second period.
89507957|NCT02297035|Experimental|PPA patients|Experimental (Patients responding to current diagnostic criteria for Primary Progressive Aphasia (PPA) patients) : Behavioural testing, Brain imaging (MRI, PET), Genetic screening (APOE, Progranulin)
89507958|NCT02297035|Experimental|healthy controls|Healthy controls : Behavioural testing, Brain imaging (MRI, PET).
89507959|NCT02350959|Experimental|High dose statin|In high dose statin group, atorvastatin 40mg will be used
89507960|NCT02350959|Active Comparator|Moderate dose statin|in moderate dose statin group, atorvastatin 10mg will be used
89507961|NCT04088357|Active Comparator|5 Percent TolaSure Topical Gel|5%(w/w) TolaSure Gel
89507962|NCT04088357|Placebo Comparator|Topical Vehicle Gel|Vehicle Gel
89507963|NCT02297113|Active Comparator|conventional endotracheal intubation|Patients assigned to this group will be intubated using conventional Macintosh blade in adequate size.
89507964|NCT02297113|Active Comparator|C-MAC|Patients assigned to this group will be intubated using C-MAC videolaryngoscope in adequate size.
89507965|NCT02350803|Placebo Comparator|distraction osteogenesis|treatment of maxillary deficiency was done just by distraction osteogenesis and no mini plate was used after removal of distractor
89507966|NCT02350803|Active Comparator|distraction osteogenesis+ mini plate|treatment of maxillary deficiency was done just by distraction osteogenesis and after removal of distractor 4 mini plate L shaped was used after removal of distractor as an intervention
89507967|NCT03202901|Experimental|B-turmactive|1 pill of B-turmactive: 500 mg hydrosoluble fraction (free curcuminoid fraction) + 19.5 mg of lipid soluble fracion (curcuminoids enriched) + 22.5 mg vitamin C.
89507968|NCT03202901|Placebo Comparator|Placebo|"Yeast brew extract (200 mg)~Excipients:~120 mg cellulose (food additive E-460) 40 mg Compritol® E ATO (food additive E-471) 4 mg Magnesium stearate (food additive E-572)"
88958007|NCT01989494||Attendings|Anesthesiology Attendings who will wear a pedometer for five days while at work
88958008|NCT01989494||CA1 Residents|Anesthesiology residents in their first year of anesthesiology residency who will wear a pedometer for five days while at work
88958009|NCT01989494||CA2 and CA3 Residents|Anesthesiology residents in their second year of anesthesiology residency who will wear a pedometer for five days while at work
88958010|NCT01989507|Experimental|Very low nicotine content cigarettes|Cigarettes with Nicotine Yield 0.07 ± 0.02
89206902|NCT04010487||Adenomyosis without malignancy|Patients pathologically diagnosed with adenomyosis
89206903|NCT00949923|Active Comparator|tea capsules|3 tea capsules daily for 3 weeks
89206904|NCT00949923|No Intervention|Control|No tea capsules
89507969|NCT03518593|Experimental|Intervention|Additional cash transfer and nutritional counselling
89507970|NCT03518593|No Intervention|Control|Existing cash transfer only
89507971|NCT02350335|Active Comparator|NRT|"Active smokers with acute aneurysmal hemorrhage randomly assigned to transdermal nicotine replacement after securing of the aneurysm.~Patient management for all patients is according to the institutional treatment guidelines and independent of group assignment.~The dose is dependent on smoke consumption prior to the ictus. Nicorette 7 mg/day for smokers smoking 1-10 cigarettes /day Nicorette 14mg/day for smokers smoking 11-19 cigarettes/day Nicorette 21 mg/day for smokers smoking 20 or more cigarettes daily"
89507972|NCT02350335|No Intervention|no NRT|Active smokers with acute aneurysmal hemorrhage that were assigned to not receive transdermal nicotine replacement.
89507973|NCT02350335|No Intervention|non-smokers|Non-smokers with acute aneurysmal hemorrhage. Non-smokers do not receive transdermal nicotine replacement. This group is to be compared to the group of active smokers receiving transdermal nicotine replacement and to the group of active smokers not receiving transdermal nicotine replacement.
89507974|NCT02297191|Experimental|Thoracolumbar Interfascial Plane Block|"All participants will have two injections at the same vertebral level on each side of the back. Each injection will consist of four 5cc incremental injections with aspiration prior to each 5cc of injectate of 0.5% Ropivicaine. . Each side of the back will be injected with 20cc of .05% Ropivicaine. Ultrasound will be used in real time to guide the needle, evaluate for spread of local anesthesia and to minimize the risk of Ropivicaine being injected intravascularly.~a. Ultrasound images will be saved using the nomenclature TLIP Anat"
89507975|NCT02350413||Endometriosis|Women referred to five Obstetrics and Gynecological Department for the treatment of endometriosis
89206905|NCT01581385||Carotid endarterectomy|Adult patient volunteers, male and female, undergoing clinically indicated carotid endarterectomy surgery.
88958011|NCT01989507|Active Comparator|Conventional nicotine content cigarettes|Cigarettes with Nicotine Yield 0.8 ± 0.15
89507976|NCT03189173|Experimental|All patients|"Patients will receive all four interventions in randomized order.~Note: Data will not be analyzed separately for the 16 cross-over combinations of intervention order:~Interventions: Oral appliance | Oral appliance plus oxygen | Oxygen | No treatment"
89507977|NCT03514615|Placebo Comparator|Placebo Gel|Each participant will be allocated to only one dosing group. The treatments will be paired anatomically so that for each pair of sites, one closed incision site will receive the active gel and the other placebo.
89507978|NCT03514615|Experimental|Active Gel|Each participant will be allocated to only one dosing group. The treatments will be paired anatomically so that for each pair of sites, one closed incision site will receive the active gel and the other placebo.
89507979|NCT03149523||Colorectal cancer|Patient with stage III colon carcinoma
89507980|NCT03149523||Kidney cancer|Patient with clear cell kidney carcinoma more than 4 cm surgically removed
89507981|NCT03149523||Liver cancer|Patient with advanced hepatocellular carcinoma : biopsy or resected BCLC (Barcelona Clinic Liver Cancer) stage B or C for diagnostic and/or therapeutic purposes
89507982|NCT02293447|No Intervention|Control|The control group will undergo uterine artery embolization according to regular protocol, without the administration of lidocaine.
89507983|NCT02293447|Experimental|Lidocaine per-embolization|This group will receive 10mL of 1% lidocaine in both uterine artery during the embolization; the lidocaine will be mixed with the embolization particles.
89507984|NCT02293447|Experimental|Lidocaine post-embolization|10mL of 1% lidocaine will be injected in both uterine arteries after embolization endpoint is achieved.
89507985|NCT02353455||healthy|"donors/patients without liver disease, with and without ongoing drug therapy including buffy coat samples of healthy blood / thrombocyte donors.~After pseudonymisation a detailed history and clinical data are obtained and blood sampling will be performed . Buffy coats are obtained anonymously."
89507986|NCT02353455||prior to therapy|History will be obtained and blood sampling will be performed in patients in whom a drug therapy with a drug with DILI potential is planned.
89507987|NCT02353455||iDILI|Patients with clinical suspicion of idiosyncratic drug-induced liver injury. After pseudonymisation a detailed history and clinical data are obtained and blood sampling will be performed.
89507988|NCT02353455||non DILI|Patients with other forms of liver injury. After pseudonymisation a detailed history and clinical data are obtained and blood sampling will be performed.
89507989|NCT03149601||Healthy Weight|Participants with BMI < 95th percentile
89507990|NCT03149601||Obese|Participants with BMI > or = 95th percentile
89507991|NCT02345967|Experimental|Study Group|Device: Model 100 Sensor
89507992|NCT04464811||Heart failure with diuretic resistance|This group includes acute heart failure patients who has diuretic resistance from furosemide stress test. Furosemide stress test will be performed by administration of intravenous furosemide 1 mg/kg in patients who do not receive oral furosemide before and 1.5 mg/kg patients who have received oral furosemide before. Diuretic resistance was defined as urine output <250 hr at 2 hours after furosemide administration.
89507993|NCT04464811||Heart failure without diuretic resistance|This group includes acute heart failure patients who do not have diuretic resistance from furosemide stress test. Furosemide stress test will be performed by administration of intravenous furosemide 1 mg/kg in patients who do not receive oral furosemide before and 1.5 mg/kg patients who have never received oral furosemide before. Patients will be defined not to have diuretic resistance if their urine output ≥250 hr at 2 hours after furosemide administration.
89507994|NCT03155451||Epithelial ovarian cancer|patients receive the ctDNA methylation markers screening
89507995|NCT02293525|Active Comparator|Ropivacaine|Continuous 0.2% Ropivacaine infusion until catheter removal (typically 36 hours)
89507996|NCT02293525|Placebo Comparator|Saline|Continuous saline infusion until catheter removal (typically 36 hours)
89507997|NCT02346045|Experimental|Renal sympathetic denervation|Renal sympathetic denervation procedure plus antihypertensive medication (doses and types of medication are maintained as previously prescribed)
89507998|NCT02346045|Sham Comparator|Medical therapy|renal angiogram plus antihypertensive medications (doses and types of medication are maintained as previously prescribed)
89507999|NCT02298517|No Intervention|Control|Individuals will be treated with conventional physiotherapy according to the routine service of physiotherapy of the hospital.
89508000|NCT02298517|Experimental|Incentive spirometry to flow|Was determined for this study that the flow of inspired air will be sufficient to raise up to three spheres. In addition to direct them to do explosive, fast and deep, lifting the ball explosively breaths. Every fifteen inspirations volunteers will be invited to rest for intervals of 30-60 seconds and repeat six times. The use of incentive spirometry was adapted from the recommendations of the American Association for Respiratory Care (1991).
89508001|NCT02298517|Experimental|incentive spirometry to volume|Use of this incentive spirometry will be done as follows: the participants will be instructed to inhale deeply through the mouthpiece, to total lung capacity, starting from functional residual capacity. Will be performed 6 sets of 15 breaths each (deep, slow and sustained) intervals with 30-60 seconds between each series.
89508002|NCT02298517|Experimental|inspiratory load equipment-Threshold|This group will use the device Threshold™. Where adjustment is considered 40% of PNSN achieved by the patient evaluation. The volunteer will be instructed to remain in a supine position with 45 ° fowler comfortably with arms and shoulders relaxed and perform an inspiration with enough force to overcome the linear load of the device, then make a normal expiration. This study was determined to carry six sets of 15 repetitions. The rest will be about one to two minutes in each intervention.
89508003|NCT02298517|Experimental|inspiratory load equipment-Power breathe|To exercise inspiratory muscle in this group will be used device Power breathe ® K2 have the same resistance setting, allowing us to tailor your level of inspiratory muscles. Such adjustment will be made considering 40% of PNSN achieved by the patient in the assessment sniff. For its implementation, the patient will be lying with a tilt of the head of the litter at 45 °, the patient will be asked to inspire to overcome the resistance of the linear unit and after performing a normal expiration. This group will also be achieved 6 series with 15 repetitions each, with an interval of one to two minutes between sets.
89508004|NCT02345421||At risk population|
89508005|NCT02293603|Experimental|Allogeneic Cardiosphere-Derived Cells|"The Phase I study consists of a Phase Ia portion and a Phase Ib portion. The Phase Ia portion (N=14 subjects) consists of an open-label, single-arm, study design. The potentially conducted Phase Ib portion of the study (N=28 subjects) consists of a double-blind, randomized, placebo-controlled study design.~The Phase Ia portion is an open-label, dose escalation of Allogeneic Cardiosphere-Derived Cells (CDCs)."
89508006|NCT02293603|Placebo Comparator|Placebo|The placebo study arm only applies to the Phase Ib portion of the study design. The Phase Ia portion (N=14 subjects) consists of an open-label, single-arm, study design. The potentially conducted Phase Ib portion of the study (N=28 subjects) consists of a double-blind, randomized, placebo-controlled study design.
88958012|NCT01989520|Experimental|Treatment A|Phase IIb formulation
88958013|NCT01989520|Experimental|Treatment B|Putative phase III formulation
88958014|NCT01989520|Experimental|Treatment C|Slow dissolution variant 1
88958015|NCT01989520|Experimental|Treatment D|Slow dissolution variant 2
88958016|NCT01989520|Experimental|Treatment E|Optional treatment that may use one of 3 45 mg (intermediate dissolution variant) of AZD5069
88958017|NCT01989533|Placebo Comparator|A|Placebo controlled (blinded)
88958018|NCT01989533|Active Comparator|B|Intranasal Randomized
88958019|NCT01989533|Experimental|C|Oral Open label
88958020|NCT01989533|Experimental|D|Intranasal Open Label
88958021|NCT01989559|Experimental|Treatment (vaccine therapy)|Patients receive gp100:209-217(210M) peptide vaccine and HPV 16 E7:12-20 peptide vaccine with Montanide ISA 51 VG or Montanide ISA 51 SC on day 1 and between days 25-30. After 6 months, patients free of disease receive booster injections every 6 months for 3 years in the absence of unacceptable toxicity or disease progression.
88958022|NCT01989611|Other|emtricitabine / tenofovir 200/300 mg|Fixed dose combination of emtricitabine / tenofovir 200/300 mg once daily orally during one year.
88958023|NCT01989637|Experimental|Strawberry Meal|40 g freeze-dried strawberries included in test meal
88958024|NCT01989637|Placebo Comparator|Control Meal|Control consisting of matched test meal with strawberry flavoring instead of freeze-dried strawberry powder
88958025|NCT01989650|Active Comparator|Break|A break of 15 minute will be provided after 3rd colonoscopy in a session of 6 colonoscopies in total
88958026|NCT01989650|No Intervention|No break|No break will be provided
89508007|NCT02345499|Experimental|Laparoscopic radical cystectomy|Surgery: Laparoscopic radical cystectomy with open urinary diversion
89508008|NCT02345499|Active Comparator|Open radical cystectomy|Surgery: Open radical cystectomy with open urinary diversion
89508009|NCT03137381|Experimental|Cohort 1: CTP-543 4 mg BID|Participants will receive CTP-543 4 mg tablets, twice daily for up to 24 weeks.
89508010|NCT03137381|Experimental|Cohort 2: CTP-543 8 mg BID|Participants will receive CTP-543 8 mg tablets, twice daily for up to 24 weeks.
89508011|NCT03137381|Experimental|Cohort 3: CTP-543 12 mg BID|Participants will receive CTP-543 12 mg tablets, twice daily for up to 24 weeks.
89508012|NCT03137381|Placebo Comparator|Combined Placebo|Participants will receive CTP-543 matched placebo tablets, twice daily for up to 24 weeks in Cohorts 1, 2, and 3.
89508013|NCT02298595|Experimental|1: Low risk|3 cycles (3 weeks) of induction chemotherapy (cisplatin+paclitaxel+BYL719) followed by transoral resection (TORS or TLM) and then observation.
89508014|NCT02298595|Experimental|2: Intermediate risk|3 cycles (3 weeks) of induction chemotherapy (cisplatin+paclitaxel+BYL719) followed by transoral resection (TORS or TLM) and then Intensity Modulated Radiation Therapy (IMRT).
89508015|NCT02298595|Experimental|3: High risk|3 cycles (3 weeks) of induction chemotherapy (cisplatin+paclitaxel+BYL719) followed by transoral resection (TORS or TLM) and then Intensity Modulated Radiation Therapy (IMRT) + cisplatin.
89508016|NCT03155139||Patients without primary aldosteronism (PA)|PA case detection or confirmatory tests was negative.
89508017|NCT03155139||Patients with primary aldosteronism (PA)|PA case detection and confirmatory tests were positive.
89508018|NCT02297269||group laparoscopic surgery|Participants undergo laparoscopic gastrointestinal malignancy surgery will be included in this group. The pressure of pneumoperitoneum maintain in 10-12mmHg.
89508019|NCT02297269||group open surgery|Participants undergo open gastrointestinal malignancy surgery will be included in this group.
89508020|NCT02353143|Experimental|MEN1112|Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation
89508021|NCT02233127||Birth Cohort|The cohort will comprise approximately 3000 pregnant women and their unborn babies, enrolled to participate in the control arm of a cluster-randomized controlled intervention trial (NCT02130856).
89508022|NCT03518515|Experimental|White potato (French fries)|Participants will be asked to consume 1 serving of French fries each day for 30 days.
89508023|NCT03518515|Experimental|White potato (French fries), +seasoning|Participants will be asked to consume 1 serving of French fries with added seasoning each day for 30 days.
89508024|NCT03518515|Active Comparator|Almond|Participants will be asked to consume 1 serving of almonds (calorie-matched to other arms) day for 30 days.
89508025|NCT02345343||Drug: Apixaban|Patients with VTE who are being given apixaban for the treatment and/or prevention of recurrence of DVT and PE at the sentinel site
89508026|NCT01541345|Active Comparator|Control Group (A)|Bone augmentation will be performed using autogenous bone from the retromolar or chin area followed by a fixation with titanium screws at the recipients site; filled with deproteinized bovine bone mineral (DBBM) particles (Bio-Oss®, Geistlich Pharma AG, Wolhusen, Switzerland) and covered with a collagen membrane (Bio-Gide®, Geistlich Pharma AG, Switzerland). These course of action is well documented in the literature and standard procedures.
89508027|NCT01541345|Experimental|Test group (B)|The bone augmentation will be performed using a deproteinized bovine bone mineral (DBBM) block (Bio-Oss Spongiosa Block®, Geistlich Parma AG, Wolhusen, Switzerland) and a collagen membrane (Bio-Gide®, Geistlich Pharma AG, Switzerland) similarly to the control group. In addition, DBBM will be loaded with rhBMPH-2 (InductOs®, Pfizer AG, Zurich, Switzerland).
89519391|NCT05697263|Experimental|Follicle phase based training|Follicular phase-based training five times a week during the follicular phase (the first two weeks of the menstrual cycle) and thereafter once a week for the rest of the cycle.
88958027|NCT01989663|Experimental|1% vaginally applied tenofovir gel|1% vaginally applied tenofovir gel administered for 7 daily doses
89540086|NCT04904523||Cases|"Cases:~1. Children and young people up to age 18 years, admitted to PCCU with probable or confirmed COVID-19, irrespective of severity of illness. This includes patients transferred from other hospitals as well as those admitted from Accident and Emergency department."
89540087|NCT04904523||Controls|"Controls:~Children proven to have a non COVID infectious illness on laboratory testing.~Children with sepsis or septic shock due to non-COVID infectious illness.~Children or young people admitted to PCCU following accidental trauma."
89540088|NCT03049839|Experimental|Intervention_ structured|One year Structured intervention program for members of high-risk group (People with glucose intolerance in the OGTT and FINDRISC score ≥12 points) 10 educational group sessions where they will receive information to change lifestyle (1 per 1.5 month)
89540089|NCT03049839|Experimental|Intervention_ Informative|"Program information intervention for the group with moderate risk. One year Informative intervention program (People with normotolerant or impaired fasting glucose in the OGTT and FINDRISC score ≥12 points).~There is a single group session where they receive information to prevent cardiomatabolic risk factors"
89540090|NCT03049839|Experimental|Intervention_ Communitarian|"One year, Intervention program at Community level. People with a FINDRISC less than 12 points.~Campaigns are carried out at the community level with different strategies (leaflets, booklets) to prevent cardiomatabolic risk factors"
89540091|NCT03049683||Normal subjects|Thirty healthy volunteers without a previous history of vertigo or neuro-otologic diseases will be enrolled in this study. The subjects will be also screened with a full history on vestibular disorders, with pure tone audiogram, and head-impulse tests to exclude the possibility of previous vestibular disorders or migraine which may cause abnormal VEMPs.
89540092|NCT03049683||Acute unilateral vestibular neuritis|The criteria for inclusion as a patient with vestibular neuritis involving the superior division (superior VN) included the following: (1) acute onset of vertigo, (2) the appearance of mixed horizontal and torsional nystagmus, (3) impaired horizontal semicircular canal (SCC) function on head-impulse test and a unilaterally absent or reduced caloric response (i.e., a caloric paresis score > 25%), (4) intact inferior division of vestibular nerve as evidenced by normal cVEMP and normal head-impulse test for vertical SCCs, and (5) the absence of auditory and neurologic signs. Thirty patients (aged 32-82 years; mean age, 51.7 years; 16 males) fulfilled the criteria of superior VN.
89540093|NCT03049761|Active Comparator|Water Flosser|Power interdental Cleaning Device
89540094|NCT03049761|Active Comparator|String floss|Manual interdental cleaning device
89540095|NCT03049761|Active Comparator|Manual Toothbrush|ADA standard manual toothbrush
88958028|NCT01989663|Placebo Comparator|HEC placebo vaginal gel|HEC placebo vaginal gel administered for 7 daily doses
88958029|NCT01989663|Experimental|Tenofovir film- 10mg|Tenofovir Film 10mg inserted vaginally, administered for 7 daily doses
88958030|NCT01989663|Experimental|Tenofovir Film-40 mg|Tenofovir Gel 40 mg inserted vaginally, administered for 7 daily doses
88958031|NCT01989663|Placebo Comparator|Placebo Film|Placebo Film inserted vaginally, administered for 7 daily doses
88958032|NCT01989676|Experimental|PF-05280014|
88958033|NCT01989676|Active Comparator|Herceptin®|
88958034|NCT01989702|Active Comparator|Fermented blueberry product|
88958035|NCT01989702|Placebo Comparator|Placebo|
88958036|NCT01989702|Active Comparator|Probiotic bacteria|
88958037|NCT01989715|Experimental|adult patients waiting for orthognathic surgery|
88958038|NCT01989728|Active Comparator|care as usual|
88958039|NCT01989728|Experimental|psychiatric examination and feedback|
88958040|NCT01989741|Other|sleep restriction|Longitudinal study of response to sleep restriction. Comparison between baseline values and sleep restriction values
88958041|NCT01989767|Active Comparator|control|Rehabilitation as usual
88958042|NCT01989767|Experimental|education|education of rehabilitation officers in psychiatric topics plus rehabilitation as usual
88958043|NCT01989806|Active Comparator|Robotic-assisted body weight supported treadmill training|Robotic assisted body weight supported treadmill training with conventional PT training
88958044|NCT01989806|Placebo Comparator|Passive lower limbs mobilization training|Passive lower limbs mobilization training with conventional PT training
88958045|NCT01989819||patients with Sjögren's syndrome|A skin biopsy will be performed in patients
88958046|NCT01989819||control group|A skin biopsy will be performed in control group
88958047|NCT01989819||non auto-immune small fiber neuropathies|
88958048|NCT01989832||Biological and clinical Data collected|
88958049|NCT01989845|Experimental|oral rivaroxaban in cancer-associated VTE|
88958050|NCT01989858|Experimental|peri-operative CHT (Arm A)|In peri-operative CHT arm CHT will be administered within 1 week (+3 days) after randomization, surgery will be performed after re-staging and 3+1 weeks after completion of the third cycle of CHT (approximately 13+1 weeks after randomization). Then CHT will be re-administered 5+1 weeks after surgery.
88958051|NCT01989858|Active Comparator|post-operative CHT (Arm B)|In post-operative CHT arm, surgery will take place 3+1 weeks after randomization and CHT will be administered 5+1 weeks after surgery (approximately 8+1 weeks after randomization).
88958052|NCT01989858|Experimental|peri-operative CHT + post-operative CHT-RTX (Arm C)|CHT 1 week (+3 days) after randomization surgery after re-staging and 3+1 weeks after completion of the third cycle of CHT CHT 5+1 weeks after surgery.
88958053|NCT01989858|Active Comparator|post-operative CHT + post-operative CHT-RTX (Arm D)|surgery will take place 3+1 weeks after randomization and CHT will be administered 5+1 weeks after surgery (approximately 8+1 weeks after randomization).
88958054|NCT01989871|No Intervention|protocol feeding|Feeding of preterm infants according to current unit protocol: every 3 hours a prescribed amount
88958055|NCT01989871|Experimental|Adjusted individual feeding|Feeding every 2-4 hours, starting with que of hunger and finished upon infant signs.
88958056|NCT01989884|Experimental|Ortataxel|75 on day 1 every 21 days mg/m2 milligram(s)/square meter (intravenous use)
89540096|NCT04392999|Experimental|Platelet Rich Plasma|One time injection of 1.5-6cc of platelet rich plasma prepared from a blood sample into cervical facet joints. There is no trade/generic name
88958057|NCT01989897|Experimental|diluents|Negative control = diluent, saline with HSA--phenol Positive control = saline with 1mg/ml Histamine base
88958058|NCT01989923|Active Comparator|Nicotine replacement therapy|"Women in this arm of the study will receive 24-hour Nicotine Patches - either 21 mg patches (for 1 pack per day smokers), or 14 mg patches (for 1/2 pack per day smokers) smokers). Patients will use one patch per day for 6 weeks for a total of 42 patches. Women will receive 3 weeks of original strength nicotine patches, and will receive patches half as strong during the last 3 weeks of the study. This will allow for a lower strength of nicotine as each woman continues with smoking cessation.~Women will also receive nicotine gum or lozenges (subject choice)- these will be 2 mg pieces of nicotine gum or lozenge (approximately 210 pieces). This will account for using 8-10 per day at the beginning of the study and tapering to 2-3 pieces per day by the end of the study."
88958059|NCT01989923|Active Comparator|Electronic Cigarettes|"Women in this arm of the study will receive one Blu Cig Electronic Nicotine Delivery Device (E-cigarette) along with 2 electronic cigarette batteries, 1 wall charger and 1 USB charger, cartridges/refills in menthol or regular (patient choice). The number of cartridges is determined by asking each patient the number of packs currently smoked per day, and multiplying 1.5 times the number of packs smoked per day. We plan to decrease the strength of the cartridges by one half after three weeks of intervention. We will give each women supplies and instructions accordingly. This will allow for a lower strength of nicotine as each woman continues with smoking cessation."
88958060|NCT01989936|Placebo Comparator|Placebo|
88958061|NCT01989936|Experimental|Eletriptan 40 mg|
88958062|NCT01989936|Experimental|Eletriptan 80 mg|
88958063|NCT01989962|Experimental|E4E Intervention Group|E4E Intervention Group is a group of family physicians who will participate in the first wave of E4E intervention.
89508028|NCT02345577|Active Comparator|Physiotherapeutical intervention|3 WBV-sessions per week for 3 consecutive months. Each session consists of 5 series with a duration of 60 sec with 60 sec rest-time with vibration of increasing frequency starting at 1Hz / Noise 4 going up to 6Hz / Noise 5 depending on patients' tolerability and with a fixed 3mm amplitude.
89508029|NCT02345577|Sham Comparator|Sham physiotherapeutical intervention|3 WBV-sessions per week for 3 consecutive months. Each session consists of 5 series with a duration of 60 sec with 60 sec rest-time at 1 Hz / Noise 1 and 3mm amplitude.
89508030|NCT02297425|Experimental|Single agent - study drug|The study will evaluate single-agent PF-06459988
89508031|NCT02345109|Experimental|Transtek DUT|Which measured by DUT: GBF-835-N2, GBF-835-N2 Plus, LS202-B1, Ls202-B1 Plus, LS206-E1, LS206-E1 Plus, GBF-1251-B1, and GBF-1251-B1 Plus.
89508032|NCT02345109|Experimental|Reference|Measured by Reference: TRANSTEK® Glass Body Fat Analyzer GBF-1251-B, Tanita® Body Composition Monitor BC-533.
89508033|NCT03146169|Experimental|Training group|Four two-hour training sessions were conducted at baseline, and one week, one month and three months after the first session.
89508034|NCT03515473||CI532|Patients with CI532 cochlear implant
89508035|NCT03515473||CI522|Patients with CI522 cochlear implant
89508036|NCT03515473||CI512|Patients with CI512 cochlear implant
89508037|NCT03122405|Experimental|Test group|The subjects will be enrolled in the test group and will simultaneously receive both RAM sensors.
89508038|NCT02350491||RA group|Pregnant women suffering from Rheumatoid Arthritis.
89508039|NCT02350491||SLE group|Pregnant women suffering from Systemic Lupus Erythematosus.
89508040|NCT02350491||healthy group|Healthy pregnant woman.
89508041|NCT02298751|Experimental|CET via smartphone|Cue Exposure Treatment
89508042|NCT02298751|Experimental|CET via group sessions|Cue Exposure Treatment
89508043|NCT02298751|No Intervention|Aftercare as usual|
89508044|NCT02350257|Experimental|ICBT|Internet-based cognitive behavior therapy
89508045|NCT02350257|No Intervention|Supportive control|Control participants has weekly contact with a therapist and receives internet-based training in child directed play. Participants are informed that this training will not likely reduce anxiety.
89508046|NCT05196295|Experimental|Hydrogen capsules|Participants will be allocated by doctors and receive either 1 (n=5), 3 (n=5) or 6 (n=5) capsules every day for one month.
89508047|NCT02353065|Active Comparator|Control|Assessment of adequacy of reduction by bedside x-ray during period of intravenous regional anaesthesia (Biers block)
89508048|NCT02353065|Experimental|Ultrasound|Assessment of adequacy of reduction by bedside ultrasound performed by the treating clinician during period of intravenous regional anaesthesia (Biers block)
89508049|NCT02298829||No Treatment|Subjects who received AA4500 in a 12-month double blind placebo-controlled study (AUX CC 803 or AUX-CC-804) or in a 9-month open label study (AUX-CC-802 or AUX-CC-806) sponsored by Auxilium Pharmaceuticals, Inc.
89508050|NCT02350179|Experimental|cases|Women assigned to the study group will receive 1 gr of Tranexamic acid injection (Kapron, AMOUN Pharmaceutical co.) given slowly I.V over 10 minutes before the operation.
89508051|NCT02350179|Placebo Comparator|control|The control group will receive 30ml of 5% glucose. Both provider and patient will be double-blinded until the conclusion of the study.
89508052|NCT03146013||HTLV Repeat Reactive (RR) / Non Reactive (NR)|Blood donor specimens that tested repeat reactive on the first FDA licensed HTLV screening assay and non-reactive on the second FDA licensed HTLV screening assay
89508053|NCT04464889|Experimental|MDG1021|Dose-escalation part of the study to investigate 3 MDG1021 doses. Dose-expansion part of the study to investigate the selected optimal MDG1021 dose.
89508054|NCT02233205|Experimental|microbubbles & platinum and gemcitabine|In 30min after chemotherapy, inject ultrasonic microbubbles 1 ml once and inject 5 times in 20min and locate the ultrasonic probe on the lesion The chemotherapy of pancreatic is gemcitabine.The chemotherapy of liver metastases is oxaliplatin with taxol.
89508055|NCT03145311|Active Comparator|Real rTMS|Each patient received real repititive transcranial magnetic stimulation (rTMS) 20 HZ at 100% RMT (a total of 2000 pulses to each hand area consisting of 10 trains of 200 pulses with intertrain interval 30 s), over the hand motor area area for 10 consecutive days
89508056|NCT03145311|Sham Comparator|Sham rTMS|Each patient received repetitive transcranial magnetic stimulation (rTMS) with the same pulse delivery as the 1st group but with the coil placed perpendicular to the scalp.
89519392|NCT05697263|Experimental|Luteal phase based training|Luteal phase-based training five times a week during the luteal phase (from ovulation to next menstruation) and once a week in the follicular phase.
89508057|NCT02297581||GFC: Geriatric Fracture Center|"Patient treatment in a geriatric fracture center~A GFC is defined as follows:~General geriatrician or ortho-geriatrician available in trauma/orthopaedic department~Geriatrician sees the patient prior to surgery (except if the patient is admitted over night or during weekends)~Local medical guidelines, consented by orthopedic surgeons and geriatrician~Pre-defined order set for assessing laboratory values~Pre-defined patient pathway to guarantee a fast track in the emergency room~Daily communication among involved specialists~Postoperative phase up to discharge from orthopaedic / trauma department (i.e. Discharge 1):~Daily patient visit by geriatrician~Daily patient visit by orthopedic surgeon in combination with nurse~Daily therapy by physiotherapists, except for weekends~Access to social workers, if required"
89508058|NCT02297581||UCC: Usual Care Center|"Patient treatment in an usual care center~A UCC is defined as follows:~No geriatrician available in trauma/orthopaedic department~No pre-operative visit by a geriatrician as a standard~No pre-defined medical guidelines for geriatric fracture patients~Postoperative phase up to discharge from orthopaedic / trauma department (i.e. Discharge 1):~No daily patient visits by a geriatrician as a standard"
88958064|NCT01989962|Sham Comparator|E4E Late Intervention Control Group|E4E Late Intervention Control Group is a group of family physicians who will participate in the second wave of E4E intervention 12 month later after the completion of the first wave of E4E intervention.
89508059|NCT02843633|Experimental|BioFreedom™ Drug Coated Stent|
89508060|NCT02293681||Cohort 1: Infliximab and/or NSAIDs and DMRADs|Participants receiving intravenous infusion of infliximab with or without non-steroidal anti-inflammatory drugs (NSAIDs: aspirin, ibuprofen and naproxen) and Disease-modifying anti-rheumatic drugs (DMRADs: methotrexate (MTX), sulfasalazine, and thalidomide) will be observed.
89508061|NCT02293681||Cohort 2: NSAIDs and DMARDs|Participants receiving NSAIDs (aspirin, ibuprofen and naproxen) and DMARDs (MTX, sulfasalazine, and thalidomide) will be observed.
89508062|NCT02297659|Active Comparator|Crystalloid resuscitation|Patients to receive normal saline resuscitation at a rate of 30cc/hr.
89508063|NCT02297659|Active Comparator|Hypertonic saline resuscitation|Patients to receive 3% hypertonic saline resuscitation at a rate of 30cc/hr.
89508064|NCT02259491|Experimental|Manuka Honey Dressing|Patient receive manuka honey dressings on skin graft and free flap donor sites
89508065|NCT02259491|No Intervention|Tegaderm and xeroform gauze|Patient receive standard wound care on skin graft and free flap donor sites which includes a tegaderm over the STSG site and xeroform gauze covered with dry gauze, kerlex and a cast for the STSG recipient site
89508066|NCT05255523|Experimental|Arm 1|Pyrotinib：400mg qd po continuous medication Capecitabine: 1000 mg/m2 bid po for 14 consecutive days with 7 days off, every 21 days as a cycle.
89508067|NCT02297737|Experimental|Tai Chi|A manual consisting of 8 movements learned over a period of 12 weeks will be used to teach participants in the Tai Chi condition. Classes will include around 5-6 subjects, each class lasting one hour, including a 10-minute warm-up and cool-down, and meet twice per week. Patients will be told to practice Tai Chi three times/week at home. After 12 weeks of training patients will be told to practice at home five times/week for 8 more weeks, until the 8-week follow-up visit. Subjects will be asked to rate their perceived exertion/work intensity during each session using the Borg's perceived exertion scale and asked to increase the size of their movements to reach 12-13 (moderate difficulty), which consistently matches with 65-70% of HR max.
88958065|NCT01989988|Active Comparator|LRYGB|20 subjects Randomized will undergo LRYGB surgery
88958066|NCT01989988|Active Comparator|SADJB|20 subjects will undergo SADJB surgery
88958067|NCT01989988|Active Comparator|LMGB|20 subjects will undergo LMGB surgery
88958068|NCT01990001|Experimental|Office enrollment in the online contraceptive reminder system|Members of this arm were enrolled in the reminder system during their visit.
88958069|NCT01990001|No Intervention|Control|Members in the control group were not enrolled in the reminder system
88958070|NCT01990014||craniectomy|Adult subjects who experienced a cerebral infarction extended the sylvian area, and having received treatment by decompressive craniectomy.
88958071|NCT01990027||SKSC Patients group|"A group a 1000 subjects affected by kidney stone as described in the eligibility criteria will be recruited in the period 2014-2024 and the same exams will be repeated for each participants for a period of 3 years.~No intervention will be undertaken."
88958072|NCT01990027||SKSC Control group|"A group of 250 stone-free participants will be recruited and analysed with the same protocol as the patients but in a single visit. This group will be used for comparison with the patients group in future studies.~No intervention will be undertaken."
88958073|NCT01990066|Experimental|Intervention|Subjects randomized to intervention will receive Physical Therapist instructed exercise teaching. They will receive a home exercise DVD and flip ring of exercises. Subjects will be asked to perform home exercise 3 days weekly consisting of 13 strengthening/stretching exercises and 20 mins of aerobic exercise, walking or seated aerobics using ergometer. Subjects will record their exercise on a log and return on day 1 of every cycle.
88958074|NCT01990066|No Intervention|Observation|Subjects randomized to observation will only have physical therapy assessment using the Berg Balance Test and 6min Walk Test at baseline and end point. These subjects will not receive any exercise teaching.
89508068|NCT02297737|Active Comparator|Health Education|Participants in the Health Education condition will also meet for one hour, twice per week for 12 weeks for a total of 24 hours. Sessions will be highly structured and will emphasize key concepts in the presentations. Medical and allied health experts will provide twelve didactic videotaped presentations on a series of health-related themes and a group leader will be present to answer questions. Themes will include: Epidemiology of Cardiovascular Disease, Patient/Physician Communication, Medication Adherence, Nutrition and Exercise, The Nature and Structure of Sleep, and Navigating the Health Care System.
89508069|NCT02259335|Experimental|patients under invasive ventilation|those patients failing a T-piece trial beacuse of a PaCO2 rise>20% of baseline and/or a rapid shallow-breathing index >100 will be reconnected to the ventilator Two hours later they will repeat a T-piece trial after connection to the CO2 removal device
89508070|NCT03149679|Experimental|Cyclophosphamide arm|Dose dense cyclophosphamide (1800 Mg/m2) administered intravenously every second week.
89508071|NCT02298985|Active Comparator|curcumin|curcumin 3 g/day for 6 months
89508072|NCT02298985|Placebo Comparator|placebo|curcumin 3 g/day for 6 months
89508073|NCT03926117|Placebo Comparator|Placebo|Matching placebo
89508074|NCT03926117|Experimental|Ziltivekimab 7.5 mg|
88958075|NCT01990079|Experimental|QUIT4Ever|QUIT4EVER is an intervention that combines 4 guideline-based smoking cessation counseling sessions, bupropion and nicotine replacement therapy, mobile contingency management, and the smart-phone application Stay Quit Coach.
88958076|NCT01990079|Active Comparator|Control Contact Condition|This intervention combines 4 guideline-based smoking cessation counseling sessions, bupropion and nicotine replacement therapy, and mobile contingency management.
89508075|NCT03926117|Experimental|Ziltivekimab 15 mg|
89508076|NCT03926117|Experimental|Ziltivekimab 30 mg|
88958077|NCT01990092|Experimental|Metanx|Subjects will take 2 Metanx tablets once daily for 48 weeks.
88958078|NCT01990092|Placebo Comparator|Placebo|Subjects will take 2 placebo tablets once daily for 48 weeks.
88958079|NCT01990105||Patients with AF in the ER|All patients with ECG-diagnosed AF who attend emergency clinics for examination or treatment of arrhythmia or other cardiac diseases during the study period will be included.
88958080|NCT01990118|Active Comparator|Neoral|Patients who continued to be treated with the drug Neoral.
88958081|NCT01990118|Experimental|Gengraf arm|Patients were randomly selected to be converted to 'Gengraf® capsule containing 25mg or 100mg cyclosporine'
89508077|NCT03514537|Experimental|Lipoaspiration|Closed microcannula harvesting of small volume of subdermal adipose tissue, including the stromal cellular and stromal tissue using sterile, disposable, microcannula system
89508078|NCT03514537|Experimental|Isolation & Concentration of cSVF|Isolation and Concentration of cellular stromal vascular fraction (cSVF) using a Healeon Medical CentriCyte 1000 centrifuge, incubator and shaker plate with sterile Liberase enzyme (Roche Medical) per manufacturer protocols
89508079|NCT03514537|Experimental|Delivery cSVF via Intravenous|cSVF from Arm 2 is suspended in a 500cc of sterile Normal Saline and deployed through 150 micron in-line filtration and intravenous route over 30-60 minute time frame.
89508080|NCT02293759|Active Comparator|HoLEP|Holmium laser enucleation of the prostate
89508081|NCT02293759|Active Comparator|Greenlight laser PVP|Phtoselective vaporization of the prostate
89508082|NCT02345187|Active Comparator|Treatment Arm|Entire content of a sachet of the beverage powder fortified with multiple micronutrients and bacopa monnieri extract will be emptied in a graduated drinking tumbler and reconstituted with 180 mL potable lukewarm water. Water will be added to the tumbler gradually with stirring to avoid lump formation. The reconstituted beverage will be administered to the participants orally twice daily for 17 weeks
89508083|NCT02345187|Placebo Comparator|Control arm|Entire content of a sachet of the non-fortified isocaloric beverage powder will be emptied in a graduated drinking tumbler and reconstituted with 180 mL potable lukewarm water. Water will be added to the tumbler gradually with stirring to avoid lump formation. The reconstituted beverage will be administered to the participants orally twice daily for 17 weeks
89508084|NCT02299063|Placebo Comparator|Placebo (0.9% Saline)|0.9% Saline: bolus dose of 0.125mL/kg infused over 10 minutes, followed by a continuous infusion (CI) dose at 0.15mL/kg/hr for the duration of surgery.
89508085|NCT02299063|Experimental|Dexmedetomidine|Dexmedetomidine: bolus dose of 0.5 mcg/kg infused over 10 minutes, followed by a continuous infusion (CI) dose at 0.6 mcg/kg/hr for the duration of surgery.
89508086|NCT03149289||HCV RNA positive|hemoglobinopathies with hepatites C treated with antiviral drugs
89508087|NCT04478097|Experimental|Reference-Reference-Test|
89508088|NCT04478097|Experimental|Reference-Test-Reference|
89508089|NCT04478097|Experimental|Test-Reference-Reference|
89508090|NCT01161641|Experimental|ODSH at 0.125 mg/kg/h|First cohort of 3 subjects to be administered the lowest dose of ODSH.
89508091|NCT01161641|Experimental|ODSH at 0.250 mg/kg/h|Second cohort of 3 subjects to receive the medium dose of ODSH
89508092|NCT01161641|Experimental|ODSH at 0.375 mg/kg/h|Third and last cohort of subject to receive the high dose of ODSH.
89508093|NCT03518281|Placebo Comparator|Placebo|
89508094|NCT03518281|Experimental|Treatment|Whole Cell Euglena delivering βeta Glucan
89508095|NCT03897257|Experimental|UHE-103A1 cream|Topical cream applied twice daily for 2 weeks.
89508096|NCT03897257|Experimental|UHE-103A2 cream|Topical cream applied twice daily for 2 weeks.
89508097|NCT03897257|Experimental|UHE-103B cream|Topical cream applied twice daily for 2 weeks.
89508098|NCT03897257|Experimental|UHE-103A1B cream|Topical cream applied twice daily for 2 weeks.
89508099|NCT03897257|Experimental|UHE-103A2B cream|Topical cream applied twice daily for 2 weeks.
89508100|NCT02297893|Experimental|Dexterity training program (HOMEDEXT)|This program is a a high intensity training program adapted from a previously published arm ability training program
89508101|NCT02297893|Active Comparator|Theraband training program|7 different Theraband exercises. Total duration is 30 minutes, trained 5 times a week over a period of 4 weeks
89508102|NCT03149367|Experimental|Fixed suture|
89508103|NCT03149367|Experimental|Adjustable suture|
89508104|NCT02233283|Active Comparator|Hypercaloric diet and basal|Volunteers fed a hypercaloric diet for one month will be submitted to a fasting period of ten hours duration
89508105|NCT02233283|Experimental|Hypercaloric diet and clamp|Volunteers fed a hypercaloric diet for one month will be submitted to a hyperinsulinemic and euglycemic clamp of ten hours duration
89508106|NCT02233283|Active Comparator|Isocaloric diet and basal|Volunteers fed a isocaloric diet for one month will be submitted to a fasting period of ten hours duration
89508107|NCT02233283|Experimental|Isocaloric diet and clamp|Volunteers fed a isocaloric diet for one month will be submitted to a hyperinsulinemic and euglycemic clamp of ten hours duration
89508108|NCT02343471|Experimental|20 g whey protein|20 g whey protein dissolved in 200 milliliter (mL) water is consumed as a pre-meal 15 min prior to the main meal. Additionally, 200 mL water is consumed as a part of the main meal.
89508109|NCT02343471|Placebo Comparator|Water|200 milliliter (mL) water consumed as pre-meal 15 min prior to the main meal. 20 g whey protein dissolved in 200 mL water is consumed as a part of the main meal.
89508110|NCT03514381|Other|Patients starting a treatment with Doxorubicin and Ifosfamide|
89508111|NCT02233361|Experimental|Counseling|The intervention group will be informed in advance of a follow-up appointment six month after they have received their hearing aid. They will know that support will be given and time-use of the hearing aid will be checked out. Counseling on hearing aid use will be given.
88958082|NCT01990131|Experimental|Intervention|The anxiety risk reduction condition will be a combination of psychoeducation plus Cognitive Bias Modification (CBM-I) for anxiety sensitivity (AS). The psychoeducational component will focus on the nature of stress and its effect on the body. Interoceptive exposure (IE) exercises, designed to correct the conditioned fear to these bodily sensations, will be explained and practiced.
88958083|NCT01990131|Placebo Comparator|Control|The control condition will be a combination of information about general health and wellness (e.g. diet, exercise etc.) plus an inert Cognitive Bias Modification (CBM-I) task.
88958084|NCT01990144|Experimental|Bendamustine|Bendamustine is a novel chemotherapeutic agent, a hybrid of a purine analogue and an alkylator. It shows only partial in vitro cross-resistance with other alkylating agents and it is clinically well tolerated. In fact it has shown to be active in vitro against cell lines which are resistant to other alkylating agents. Preclinical data demonstrate that bendamustine acts in two distinct ways to kill cancer cells: it damages the DNA in cancer cells, which leads to cell death by a process known as apoptosis (programmed cell death) as well as by an alternate cell death pathway known as mitotic catastrophe (a disruption of normal cell division). This dual-effect may be attributable to its unique chemical structure.Bendamustine has demonstrated clinical activity in patients with chronic lymphocytic leukaemia, patients with relapsed indolent NHL, mantle cell lymphoma, multiple myeloma and several solid tumors.
88958085|NCT01990157|Experimental|TAB08|Multiple TAB08 administrations as intravenous infusions.
88958086|NCT01990170||ultrasound-guided foam sclerotherapy|This project is ongoing from an original study conducted by our research group looking at short- and mid-term clinical outcomes after UGFS. The original patient cohort from the aforementioned study was made up of 132 patients who underwent UGFS between 1 March 2005 and 31 December 2009 for treatment of a chronic venous ulcer (CEAP classification C5 or C6 disease) with significant (>0.5s) SVR confirmed with duplex ultrasound.
89508112|NCT02233361|No Intervention|Counselling|The control group will not receive any information of a follow-up appointment. However, they will receive a notice on this after six month.
89508113|NCT02343393|Experimental|H-ISDN|Eligible patients randomised to treatment arm will be initiated on a starting dose of hydralazine 60mg and ISDN 30mg daily (20/10mg three times daily). After 7 days following the first dose, if the starting medication is well-tolerated, the patient is instructed to double the dose of study medication to the target maintenance dose of hydralazine 120mg and ISDN 60mg daily for 24 weeks
89508114|NCT02343393|No Intervention|Standard Medical Therapy|Current standard HF therapy include the use of beta-blockers, ACE inhibitors/ARBs and diuretics.
89508115|NCT03514303||Ragweed|Subjects will test positive or negative to the allergen Ragweed.
89508116|NCT03514303||Timothy Grass|Subjects will test positive or negative to the allergen Timothy Grass.
89508117|NCT03514303||Johnson Grass|Subjects will test positive or negative to the allergen Johnson Grass.
89508118|NCT03514303||Bermuda Grass|Subjects will test positive or negative to the allergen Bermuda Grass.
89508119|NCT03514303||Cladosporium|Subjects will test positive or negative to the allergen Cladosporium.
89508120|NCT03514303||Cat Dander|Subjects will test positive or negative to the allergen Cat Dander.
89508121|NCT03514303||Cockroach|Subjects will test positive or negative to the allergen Cockroach.
89508122|NCT03514303||Dust Mite|Subjects will test positive or negative to the allergen Dust Mite.
89508123|NCT03514303||Oak|Subjects will test positive or negative to the allergen Oak.
89508124|NCT03514303||Dog Dander|Subjects will test positive or negative to the allergen Dog Dander.
89508125|NCT02344875|Experimental|Male elder subjects|Male 65- Years
89508126|NCT02344875|Experimental|Male non-elder subjects|Male 20-35 Years
89508127|NCT02344875|Experimental|Female elder subjects|Female 65- Years
89508128|NCT02344875|Experimental|Female non-elder subjects|Female 20-35 Years
89508129|NCT02293915|Experimental|sodium oligo-mannurarate 900mg|
89508130|NCT02293915|Placebo Comparator|Placebo|
89508131|NCT02343315|Experimental|TENS|Participants will receive Active-TENS along with SMCE and UHEP. Six treatment sessions will be given over two weeks. Total duration of the treatment session may last from 40 - 60 minutes.
89508132|NCT02343315|Experimental|SMCE|Participants will receive SMCE and UHEP. Six sessions of supervised Motor control exercises will be provided over the period of two weeks.
89508133|NCT02343315|Active Comparator|UHEP|Unsupervised home exercise program will be prescribed with home exercise leaflet and education leaflet in the form of back book on first treatment session.
89508134|NCT02298049|Other|Scanning|"Repeated measures:~Satiation scan + Pre-meal scan~All participants undertook both scans"
89508135|NCT02343237|Experimental|Osteopathy +|75 patients will make 6 osteopathic sessions
89508136|NCT02343237|Active Comparator|Osteopathy -|75 patients will make 6 factitious osteopathic sessions
89508137|NCT03885011|Experimental|CSF-1|This treatment arm consists of 2 different concentrations of CSF-1. Subjects randomized to the CSF-1 treatment arm will receive their first dose of CSF-1 in-office at Visit 2. All subjects will dose twice a day in both eyes with a single drop for approximately 1 week. At Visit 3, subjects randomized to the CSF-1 arm will now receive a different concentration of CSF-1. Subjects will continue dosing twice a day in both eyes for approximately 1 week.
89508138|NCT03885011|Active Comparator|CSF-1 Component #1|"This treatment arm consists of 2 different concentrations of CSF-1 Component #1.~Subjects randomized to the CSF-1 Component #1 treatment arm will receive their first dose of CSF-1 Component #1 in-office at Visit 2. All subjects will dose twice a day in both eyes with a single drop for approximately 1 week. At Visit 3, subjects randomized to the CSF-1 Component #1 arm will now receive a different concentration of CSF-1 Component #1. Subjects will continue dosing twice a day in both eyes for approximately 1 week."
89508139|NCT03885011|Active Comparator|CSF-1 Component #2|This treatment arm consists of a single concentration of CSF-1 Component #2. Subjects randomized to the CSF-1 Component #2 treatment arm will receive their first dose of CSF-1 Component #2 in-office at Visit 2. All subjects will dose twice a day in both eyes with a single drop for approximately 1 week. At Visit 3, subjects randomized to the CSF-1 Component #2 arm will continue dosing with the same concentration of CSF-1 Component #2. Subjects will continue dosing twice a day in both eyes for approximately 1 week.
89508140|NCT02294071|Experimental|acetaminophen|acetaminophen 15mg/kg (max 975mg)
89508141|NCT02294071|Experimental|ibuprofen|ibuprofen 10mg/kg (max 600mg)
88958087|NCT01990183|Experimental|CareToy|CareToy intervention
89508142|NCT02294071|Experimental|combination|acetaminophen 15mg/kg (max 975mg) and ibuprofen 10mg/kg (max 600mg)
89508143|NCT03145389||With epidural catheter placement|In this group of patients, after explaining about the procedure an 18 Gauge epidural catheter was placed in thoracic 11-12 inter vertebral space under strict asepsis.
89508144|NCT03145389||Without epidural catheter placement|In this group of patients epidural catheter was not inserted and post operative pain was managed by using intravenous drugs.
89508145|NCT03515161|Experimental|Closed-loop|Study patients will receive a baseline crystalloid infusion of 3 cc/kg/hr and all additional fluid management will be performed manually using the assisted fluid management sofware from the EV1000 monitor. A closed-loop system will automatically administer vasopressor based on the predefined target MAP chosen by the anesthesiologist in charge of the patient
89508146|NCT02344797|Active Comparator|Intervention|Remote ischemic preconditioning, 4 cycles of 5 minutes ischemia and 5 minutes reperfusion of the forearm before surgery.
89508147|NCT02344797|No Intervention|Control|
89508148|NCT02233439|Placebo Comparator|Placebo|a placebo identical in appearance to the galactagogue product
89508149|NCT02233439|No Intervention|No treatment|Usual care and breastfeeding support
89508150|NCT02233439|Experimental|Herbal galactagogue|A commercially available product containing a combination of Silybum marianum 400 mg and Galega officinalis 150 mg, once a day for 6 weeks
89508151|NCT03514225|Other|Metacognitive Therapy for Social Anxiety|Exact sessional content of the MCT intervention is likely to involve attention training and situational attentional refocussing techniques, verbal reattribution strategies aimed to facilitate a reduction of self-processing strategies and to challenge metacognitive beliefs, and between-session tasks for participants to practice at home.
89508152|NCT02350023|Active Comparator|Topical latanoprost|Topical latanoprost 0.005%
89508153|NCT02350023|Active Comparator|Topical betamethasone|Topical betamethasone 0.05%
89508154|NCT03514147|Experimental|Experimental|Pelvic Floor Muscle Training in group. Exercise Protocol: The exercise group was supervised and met for 1 hour, one time per week, for 12 weeks. Participants were instructed to perform their respective daily exercises.
89508155|NCT03514147|Active Comparator|Control|Pelvic Floor Muscle Training in home Exercise Protocol:The same exercise were performed at home for 12 weeks, without supervision. Participants were instructed to perform their respective daily exercises.
89508156|NCT02342925|Experimental|RG1662 plus metformin|
89508157|NCT02342925|Experimental|metformin alone|
89508158|NCT03518047|Placebo Comparator|Placebo|Placebo for risankizumab by subcutaneous (SC) injection.
89508159|NCT03518047|Experimental|Risankizumab|Risankizumab by subcutaneous (SC) injection.
89508160|NCT03879863|Experimental|Reproxalap Ophthalmic Solution (0.25%) QID|
89508161|NCT03879863|Placebo Comparator|Vehicle Ophthalmic Solution QID|
89508162|NCT03879863|Experimental|Reproxalap Ophthalmic Solution (0.25%) QID to BID|
89508163|NCT03879863|Placebo Comparator|Vehicle Ophthalmic Solution QID to BID|
89508164|NCT02344641|Experimental|Exenatide|exenatide group receive exenatide (5μg, subcutaneous injection, Bid）
89508165|NCT02344641|No Intervention|control group|control group do not receive exenatide
89508166|NCT03513991|Experimental|IF-VLP (very low protein)|Participants were exclusively fed with an infant formula containing 1g of protein/dL, 26% alpha lactoalbumin, and 100% A2 casein for 4 months.
89508167|NCT03513991|Other|IF-LP (low protein)|Participants were exclusively fed with an infant formula containing 1.3 g of protein/dL, 26% alpha lactoalbumin, 100% A2 casein for 4 months.
89508168|NCT03513991|Other|IF-CSP (control standard protein)|Participants were exclusively fed with an infant formula containing 1.5 g of protein/dL, 50% A1 casein and 50% A2 casein for 4 months.
89508169|NCT03513991|No Intervention|HM (human milk)|Participants were exclusively breastfed
89508170|NCT03853343|Placebo Comparator|Placebo|3 capsules per day (1 before each meal) of cellulose
88958088|NCT01990183|Other|Standard Care|Standard Care
88958089|NCT01990235|Experimental|PREPARE intervention|The PREPARE arm will review the PREPARE website plus the easy-to-read advance directive (AD). Participants will review PREPARE on their own for ≥ 20 minutes with staff present to answer questions. During PREPARE, participants answer preference questions and make an action plan (i.e., commitment to engage in advance care planning). To ensure home access to PREPARE content, participants will be given a website login and PREPARE content in digital video disc (DVD), booklet, and pamphlet format as well as the action plan and AD. One to three days before a primary care visit, the PREPARE arm will receive a reminder to come to their appointment and to bring their action plan.
88958090|NCT01990235|No Intervention|Control|The Control arm will review an easy-to-read AD. Controls will review the AD for ≥ 15 minutes with study staff present to answer questions and will take the AD home to complete if desired. One to three days before a primary care visit, controls will receive a reminder to come to their appointment.
88958091|NCT01990248||Cohort|
88958092|NCT01990274|Experimental|Novel|Patients in this arm will receive 3 sputum samples for GeneXpert MTB/RIF assay and MGIT liquid TB culture.
89508171|NCT03853343|Active Comparator|Seaweed extract|3 capsules per day (1 before each meal) of seaweed extract
89508172|NCT02344719|Active Comparator|6 capsules Taurin per day|After baseline HVPG (Hepatic Venous Pressure Measurement)patients take 6x1g capsules of GMP produced Taurin per day, on day 28, after intake of the 6x1g Taurin capsules, HVPG measurement will be repeated.
89508173|NCT02344719|Placebo Comparator|6 capsuless placebo per day|After baseline HVPG measurement patients take 6x1g capsules of placebo per day, on day 28, after intake of the 6x1g placebo capsules, HVPG measurement will be repeated.
89508174|NCT03515005|Experimental|Lay Health Advisors|Intervention patients will meet monthly in small groups with a trained Lay Health Advisor.
89508175|NCT03515005|No Intervention|Usual Care|Control patients will receive usual care from their doctors.
89508176|NCT03798743|Experimental|Sintilimab Combined With Docetaxel|Sintilimab Combined With Docetaxel for Double Platinum-based Chemotherapy Failure Advanced Non-small Cell Lung Cancer
89519393|NCT05697263|Experimental|Regular training|Regular training three times a week throughout the menstrual cycle (control group).
89519394|NCT03450811|Active Comparator|Study group|The patients underwent elective open or laparoscopic inguinal hernia repair at a general surgery clinic.
88958093|NCT01990274|Active Comparator|Standard|Patients in this arm will receive 2 sputum samples for fluorescence smear microscopy and MGIT liquid TB culture.
88958094|NCT01990287|Experimental|SCS and PNfS|Eon or Eon Mini IPG with epidural leads in the spinal column and subcutaneous leads in the peripheral field
88958095|NCT01990287|Active Comparator|SCS Alone|Eon or Eon Mini IPG with epidural leads in the spinal column
88958096|NCT01990326|Experimental|XAF5 Gel|The patient will apply XAF5 Gel to the skin of the submental area once a night.
88958097|NCT01990326|Placebo Comparator|Placebo Gel|The patient will apply a Placebo Gel to the skin of the submental area once a night.
88958098|NCT01990391|Placebo Comparator|Cassava flavored flour|The placebo group (cassava flour flavored) received 9g/day of cassava flour flavored during three months (12 weeks)
88958099|NCT01990391|Experimental|Brazil nut flour|The Brazil nut group received 13g/day of Brazil nut flour during three months (12 weeks)
88958100|NCT01990404|Active Comparator|Premixed 50% nitrous oxide and oxygen|The patient will be taken care by the physician SMUR or home emergency. Upon acceptance of participation in the study, the clock will be started at the time of the establishment of the face mask. Premixed 50% nitrous oxide and oxygen is administered for 30 minutes and an opioid titration is started 10 minutes after the introduction of gas, unless the patient expresses pain score EN <3/10.
88958101|NCT01990404|Placebo Comparator|Medical air|The patient will be taken care by the physician SMUR or home emergency. Upon acceptance of participation in the study, the clock will be started at the time of the establishment of the face mask. The medical air is administered for 30 minutes and an opioid titration is started 10 minutes after the introduction of gas, unless the patient expresses pain score EN <3/10.
88958102|NCT01990417|Experimental|Passive stretching|After evaluation, the participants were randomly divided into four groups: A, B, C and D. Group A. stretched before and after workout ; group B stretched only before workout; group C stretched only after workout; and group D did not stretch at all.
88958103|NCT01990430|Experimental|Exercise Intervention|"The exercise program was designed and conducted by a qualified exercise physiologist with oncologic training. The exercise program consisted in a twice weekly supervised training program developed in a social framework. The sessions included instructions in training exercises, as well as included time to speak about their fears and doubts with other patients, who were in the same situation.~The nutrition program consisted of three theoretical and practice classes, where specific terms of nutrition and diet were explained. Teachers did not promote avoiding any group of aliments and a Mediterranean diet was encouraged to be followed."
88958104|NCT01990430|No Intervention|Control|Patients will be asked to maintain their usual life style, without special changes
88958105|NCT01990443|Experimental|Reslizumab IV|Reslizumab 220-mg administered Intravenously (IV)
88958106|NCT01990443|Experimental|Reslizumab SC|Reslizumab 220-mg administered Subcutaneously (SC)
88958107|NCT01990456|Experimental|PHASE 1: impact of tidal ventilation on VILI|In the first phase we will test whether administering a distending inspiratory pressure to produce tidal ventilation is superior to a strategy where only continuous positive airway pressure (CPAP) is applied for ventilation induced lung injury (VILI) mitigation, as assessed by its impact on biotrauma (serum cytokines) and physiologic measurements.
88958108|NCT01990456|Experimental|PHASE 2: impact of PEEP on VILI|In the second phase we will gain more insight as to whether a strategy that utilizes a PEEP level that correspond to best compliance is beneficial over Zero End-Expiratory Pressure (ZEEP). We will test the impact of both strategies on biotrauma (serum cytokines), physiologic parameters, and right ventricular function (transesophageal echocardiographic assessment).
88958109|NCT01990469|Experimental|Gemigliptin|Gemigliptin 50mg qd
88958110|NCT01990469|Placebo Comparator|Placebo|Gemigliptin placebo
88958111|NCT01990482|Experimental|coffee|coffee
88958112|NCT01990482|Placebo Comparator|water group|water
88958113|NCT01990508|Experimental|Targeted beverage education and financial incentives|Study subjects receive monthly letters with beverage education and financial incentives for not purchasing sugar-sweetened beverages
88958114|NCT01990508|Sham Comparator|Control|Monthly letters with generic nutrition information only
88958115|NCT01990547||Healthy Veterans|Healthy veterans, who have been deployed in support of OIF/OEF who do not have blast exposure or PTSD
88958116|NCT01990547||Veterans with history of blast exposure|OIF/OEF veterans with a history of blast exposure who do not meet criteria for PTSD
88958117|NCT01990547||Veterans with PTSD receiving usual care|OIF/OEF veterans with PTSD (with or without blast exposure) only who receive usual care (i.e., pharmacotherapy and/or supportive or psychodynamic individual or group therapy, not involving exposure therapy)
89032932|NCT02925975|Active Comparator|Follow-up group guided by endoscopy|Cirrhotic patients are followed-up by routine endoscopy. Once there are visible varies, participants will be treated according to Baveno V consensus in portal hypertension, such as oral carvedilol and routine endoscopic procedures.
89032933|NCT00527774||A|HCV(+) maintenance hemodialysis patients
89508177|NCT02302417|Other|All Subjects|Approximately 1000 subjects with clinical diagnoses of asthma and/or COPD or clinical presentations suggestive of either or both will be included. Subjects will undergo spirometry assessments and also will be asked a series of questions by a qualified health care practitioner using a questionnaire containing 41 questions concerning their respiratory condition.
89508178|NCT03796637|Experimental|nmDMD Participants|Participants who have been receiving ataluren, will be dosed daily 10 milligrams per kilogram (mg/kg) in the morning, 10 mg/kg at midday, and 20 mg/kg in the evening, for >=9 months from ongoing PTC-sponsored nmDMD clinical trials.
89508179|NCT02342769||Dolutegravir/Abacavir/Lamivudin|Prospective, non-interventional observational study on the use of TRIUMEQ and the respective monitoring measures in the practice of HIV care in Germany. No drug will be provided. No study visits or procedures are mandated per protocol.
89508180|NCT03514927|Experimental|Treatment (HIFU, radical prostatectomy)|"HIFU PHASE: Participants undergo mpMRI and CEUS pre-HIFU treatment and then CEUS post-HIFU treatment. Participants then undergo HIFU treatment over 2-2.5 hours.~PROSTATECTOMY PHASE: Within 2-4 weeks post-HIFU treatment, participants undergo mpMRI 1-2 days prior to radical prostatectomy. On the day of surgery, participants undergo CEUS prior to radical prostatectomy."
89508181|NCT02298127|Experimental|Shenmen, mouth, lung & stomach|Participants in this group will receive 4 weekly treatment sessions of auricular acupressure via the shenmen, mouth, lung and stomach.
89508182|NCT02298127|Experimental|Subcortex,endocrine&sympathetic systems|Participants in this group will receive 4 weekly treatment sessions of auricular acupressure via the subcortex, endocrine and sympathetic systems.
89508183|NCT02298127|Sham Comparator|Elbow, shoulder & knee|Participants in this group will receive 4 weekly treatment sessions of sham-controlled acupressure on the elbow, shoulder and knee acupoints on the auricle that is non-specific to smoking cessation.
88958118|NCT01990547||Veterans with PTSD receiving Virtual Reality Exposure Therapy|"OIF/OEF veterans with PTSD (with or without blast exposure) that will receive Virtual Reality Exposure Therapy through the WRNMMC IRB approved protocol entitled Enhancing Exposure Therapy for PTSD: Virtual Reality and Imaginal Exposure with Cognitive Enhancer ClinicalTrials.gov Identifier: NCT01352637, which is also open to new enrollment"
89508184|NCT02342847||Pateints with metastatic pancreatic cancer|"Patients diagnosed with metastatic pancreatic cancer confirmed histologically or cytologically, who will be treated with chemotherapy as first-line treatment of metastatic pancreatic cancer.~This study is designed to observe patients treated in routine clinical practice, without the exclusion limitations of a clinical trial. The decision to treat patients will be performed prior to the decision to include the patient in the study.~The follow-up of patients will be performed according to standard clinical practice of each site"
89508185|NCT03514849|Experimental|PCI group|
89508186|NCT03514849|Placebo Comparator|Control group|
89508187|NCT03766295|Experimental|Masitinib & gemcitabine|Participants receive masitinib (6 mg/kg/day), given orally twice daily, plus gemcitabine at 1000mg/m2 by intravenous infusion during 30 minutes, once every 7 days, for up to 7 weeks, followed by a week of rest. Subsequent cycles should consist of an IV infusion, once every 7 days, for 3 consecutive weeks out of every 4 weeks, until disease progression, death, limiting toxicity or patient consent withdrawal.
89519395|NCT03450811|No Intervention|Control group|patients who were admitted to the outpatient clinics with various diseases or healthy persons
89519396|NCT02522819|Experimental|obstructive sleep apnea in the acute phase of stroke|Use of CPAP over 5 nights for the treatment of obstructive sleep apnea in the acute phase of stroke
88958119|NCT01990599|Other|Nasopharyngeal Tube|Every patient undergoing trigeminal thermal coagulation of the Gasserian ganglion will be ventilated by a nasopharyngeal placed ID 5mm tube during the whole neurosurgical intervention.
88958120|NCT01990625|Experimental|Ultrasound scan|The group is pregnant women who reside in an intervention cluster who receive at least one antenatal ultrasound scan during antenatal care during the study time period.
88958121|NCT01990625|No Intervention|Routine antenatal care|The group is pregnant women that reside in the control clusters during the study time period. The group received routine antenatal care.
88958122|NCT01990638||DM group|
88958123|NCT01990638||non-DM group|
88958124|NCT01990690|Active Comparator|anti oxidant omega 3|The patients were randomized to receive either a daily dose of omega-3 plus as antioxidant once daily for two weeks or a daily placebo then stored in envelopes numbered from 1 to 140
88958125|NCT01990690|Placebo Comparator|placebo|"Group 1 was given omega -3 plus (Sedico medical company) as antioxidant once daily for two weeks.~Group 2 was given a placebo once daily for two weeks."
88958126|NCT01990716|Other|IBD patients|Patients (diagnosed with IBD) having a screening colonic biopsy
88958127|NCT01990716|Other|Control Group|individuals undergoing screening colonic biopsy for colon cancer or polyp detection, who have not been diagnosed with any intestinal pathology.
88958128|NCT01990729||ARTRA|Patients with low back pain treated with ARTRA.
88958129|NCT01990755|Active Comparator|CBT (Cognitive Behavioral Therapy)|"Investigates the effects of cognitive-behavioral therapy (CBT), on the secretion of brain dopamine (DA), noradrenalin (NE) and serotonin (5-HT) in a group of 50 female inpatients, 14 with AN restricter type (AN-R), 14 with the bingeing-purging type (AN-BP), and 22 with BN.~Associated intervention (non of interest): psychiatric management (with tranquillizer: delorazepam), nutritional rehabilitation"
88958130|NCT01990755|Active Comparator|IBPP (IP brief psychotherapy )|"Investigates the effects in 15 AN and 17 BN patients of an individual psychology brief psychotherapy (IBPP) on psychological alterations and DA secretion measured as peripheral blood values of HVA before and after treatment.~Associated intervention (non of interest): psychiatric management (with tranquillizer: delorazepam), nutritional rehabilitation."
88958131|NCT01990755|Active Comparator|CBT + OLANZAPINE (5 MG)|"The study evaluated in 18 AN-R and 12 AN-BP patients the effects of CBT and of CBT associated with orally administered 5 mg olanzapine on the psychopathological aspects of the disease and on the secretion of HVA.~Associated intervention (non of interest): psychiatric management (with tranquillizer: delorazepam), nutritional rehabilitation"
88958132|NCT01990781|Experimental|Group LD: Lidocaine and Dexamethasone|lidocaine 1.5 mg/kg and dexamethasone (dexona) 8 mg iv prior to induction of anesthesia
88958133|NCT01990781|Active Comparator|Group L: Lidocaine|Group L: lidocaine 1.5 mg/kg iv prior to induction of anesthesia
88958134|NCT01990781|Active Comparator|D: Dexamethasone|Dexamethasone 8 mg iv prior to induction of anesthesia
88816011|NCT03013322|Active Comparator|Treatment Group|The treatment group receives an infusion of 0.04 mg/kg physostigmine salicylate with a maximum dose of 4 mg. The infusion is administered at 0.4 mg/min (= 1 mL/min = 60 mL/h). The initial dose is followed by a continuous infusion of 0.017 mg/min, i.e. 1 mg/h (= 0.042 mL/min = 2.5 mL/h) for 2-5 days, i.e. 48-120 hours (treatment phase).
88816012|NCT03013322|Placebo Comparator|Placebo Group|The placebo group is treated with 0.9% sodium chloride.
88958135|NCT01990781|Placebo Comparator|N: normal saline|N: normal saline (placebo): 2 ml
88958136|NCT01990807|Active Comparator|Idarubicin(IDA)|philadelphia negative high -risk ALL : Induction therapy: IDA(6mg/m2/time) one time for each week,altogether 3 times
88958137|NCT01990846|Experimental|Flufirvitide-3 dose level 1|Single dose administration for dose level 1
88958138|NCT01990846|Experimental|Flufirvitide 3-Dose level 2|Single dose administration for Dose Level 2
88958139|NCT01990846|Placebo Comparator|Placebo|Single Dose administration Placebo for Flufirvitide-3
89032934|NCT00527774||B|HCV(-) maintenance hemodialysis patients
89032935|NCT00527813|Experimental|A|prone position for at least 16 hours per day
88958140|NCT01990846|Experimental|Flufirvitide-3 Dose level 1- Repeat dose|Repeat dose administration for five days
88958141|NCT01990846|Experimental|Flufirvitide-3-Dose level 2 Repeat dose|Repeat dose administration for 5 days
88958142|NCT01990846|Placebo Comparator|Placebo for Flufirvitide-3 Repeat dose|Repeat dose administration for 5 days
89032936|NCT00527813|No Intervention|B|semi-recumbent position
89508188|NCT03766295|Active Comparator|Placebo & gemcitabine|Participants receive matching placebo, given orally twice daily, plus gemcitabine at 1000mg/m2 by intravenous infusion during 30 minutes, once every 7 days, for up to 7 weeks, followed by a week of rest. Subsequent cycles should consist of an IV infusion, once every 7 days, for 3 consecutive weeks out of every 4 weeks, until disease progression, death, limiting toxicity or patient consent withdrawal.
88958143|NCT01990872|Placebo Comparator|Placebo in high calcium group|Placebo + habitual dietary calcium intake (>1000 mg/d)
88958144|NCT01990872|Active Comparator|Vitamin D3 in low/moderate calcium group|Vitamin D3 (20 microgram/day) + habitual calcium intake <700 mg/d
88958145|NCT01990872|Placebo Comparator|Placebo in low/moderate calcium group|Placebo + habitual calcium intake <700 mg/d
89508189|NCT02344563|Experimental|Meropem|0.5g/vial,one vial
89508190|NCT02344563|Active Comparator|Mepem|0.25g/vial ,two vials
89508191|NCT03513913|Experimental|IVF|Oocytes fertilized by conventional in vitro fertilization (IVF) method
89508192|NCT03513913|Experimental|ICSI|Oocytes fertilized by intracytoplasmic sperm injection (ICSI) method
89508193|NCT02349945|Experimental|Arm 1|FSHR A680G SNP homozygous for allele N treated with follitropin alpha
89508194|NCT02349945|Experimental|Arm 2|FSHR A680G SNP homozygous for allele S treated with follitropin alpha
89508195|NCT03513835||Mitochondrial myopathy|
89508196|NCT03513835||Healthy controls|
89508197|NCT02299219|Experimental|Taking Charge Experimental Group|
89508198|NCT02299219|Active Comparator|Control Group|
89508199|NCT03759197|Experimental|Drug: 188-0551 Spray|188-0551 Spray applied topically twice daily to psoriatic lesions within the assigned treatment area for up to four (4) weeks
89508200|NCT03759197|Placebo Comparator|Vehicle Spray|Vehicle Spray applied topically twice daily to psoriatic lesions within the assigned treatment area for up to four (4) weeks
89508201|NCT02302495|Other|Carfilzomib weekly+Melphalan+Prednisone|one arm, two steps and two parts.In the first step of the study: 5 cohorts of 6 patients with Carfilzomib weekly administrated at different dose regimen will be opened one after the other to determine Maximum tolerated dose of Carfilzomib based on definition of Dose-limiting toxicities.In the second step of the study:expanded Cohort, 50 patients received Carfilzomib at the MTD. In Part 1. Induction.Nine 5 weeks cycles of weekly CMP are plannedCarfilzomib. 36, 45, 56 or 70 mg/m² on days 1, 8, 15, 22 IV route . Patients will start the first cycle day 1 with 20mg/m². In combination with oral Melphalan 0.25mg/kg/j and oral prednisone 60mg/m², both on days 1 to 4.Part 2. Maintenance.Carfilzomib. 36 mg/m² weekly, every two weeks IV route for 1 year.
88958146|NCT01990872|Active Comparator|Vitamin D3 in high calcium group|Vitamin D3 (20 microgram/day) + habitual calcium intake (>1000 mg/d)
88958147|NCT01990885|Experimental|Cohort A|Each subject will receive a single administration of either BL-7010 (at different amounts) or matching Placebo on 3 treatment occasions in a randomized double-blind fashion
88958148|NCT01990885|Experimental|Cohort B|Each subject will receive a single administration of either BL-7010 (at different amounts) or matching Placebo on 3 treatment occasions in a randomized double-blind fashion
89508202|NCT02342457|Experimental|Child suspected of Hirschsprung disease|Children admitted for biopsy, so that Hirschsprungs desease may be ruled out or diagnosed, whom are planned for rectal biopsy, by clinical decision.
89508203|NCT02342301|Experimental|Standing Desk|Will use standing desk for 3 months
89508204|NCT02342301|Active Comparator|Traditional Desk|Will use traditional desk for 3 months
88958149|NCT01990885|Experimental|Cohort C|Each Subject will receive either BL-7010 or Placebo 3 times a day for 14 days(amount to be based on results from Cohorts A and B) in a randomized double-blind fashion
88958150|NCT01990885|Experimental|Cohort D|Each Subject will receive either BL-7010 or Placebo 3 times a day for 14 days(amount to be based on results from previous cohorts) in a randomized double-blind fashion
88958151|NCT01990885|Experimental|Cohort E|Each Subject will receive either BL-7010 or Placebo 3 times a day for 14 days(amount to be based on results from previous cohorts) in a randomized double-blind fashion
88958152|NCT01990924|Experimental|7.5 FPS|Low rate fluoroscopy at 7.5 frames per second (FPS)
88958153|NCT01990924|Active Comparator|15 FPS|Conventional rate fluoroscopy at 15 FPS
88958154|NCT01990937|Active Comparator|Oral midazolam|Oral midazolam (5 mg) in 15 mL of apple juice was drunk 30 minutes before EGD
88958155|NCT01990937|Placebo Comparator|Apple juice|15 mL of apple juice was drunk 30 minutes before EGD
88958156|NCT01990976||FSHD training|Only the patients who have participated to the FSHD1 study (NCT01116570) and the FSHD2 study (NCT01689480) can be included in this study.
88958157|NCT01990989||Clopidogrel treated patients|A consecutive cohort with 500 cases treated with 75mg/day maintenance dose of clopidogrel.
89023985|NCT04038515|Experimental|E-liquid Order 'D'|One nicotine level condition is a high nicotine e-liquid (24 mg/mL nicotine). All participants will be given all e-liquids (i.e., all 20 nicotine*flavor combinations (4 nicotine* 5 flavor combinations)) in this within-subject, cross-over design study. Participants will be randomized the order in which they self-administer the 20 nicotine*flavor combinations of e-liquid (across and within the 4 visits). The specific order cannot be described here without disrupting the double-blind nature of the study design.
89023986|NCT04035278|Experimental|Dengusiil|
89023987|NCT04035278|Placebo Comparator|Placebo|
89023988|NCT04034927|Active Comparator|Arm I (olaparib)|Patients receive olaparib PO BID in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI as well as blood sample collection throughout the trial.
89023989|NCT04034927|Experimental|Arm II (olaparib, tremelimumab)|Patients receive olaparib as in Arm I. Patients also receive tremelimumab IV over 60 minutes on day 1. Cycles of tremelimumab repeat every 4 weeks for 4 doses and then every 12 weeks for up to 2 years total in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI as well as blood sample collection throughout the trial.
89023990|NCT04033926|Other|Arm A|"Treatment Period 1: KZR-616 30 mg SC weekly for 2 weeks, then 45 mg SC weekly for 14 weeks~Treatment Period 2: Placebo SC weekly for 16 weeks"
89508205|NCT02306395|Experimental|Endometrial local injury|Endometrial local injury is carried in the first 3-5 days after menstrual period at the same time of hysteroscopy.
89508206|NCT02306395|No Intervention|The blank group|Any processing does not carry on the endometrium in the first 3-5 days after menstrual period except hysteroscopy.
89508207|NCT02813447|Active Comparator|Pulmonary Rehab + Study Drug|Subjects randomized into this arm will be given active study drug (sertraline). Subjects will take 25mg tablets by mouth daily starting at visit 1 along with participating in the intensive pulmonary rehab program. Subjects will be assessed at one week intervals +/- 7 days for tolerability and side effects, and if tolerating study drug, the dose will be increased weekly by 25mg over the course of the first four weeks with maximum effective dose of 100mg daily by the end of week four. Subjects will continue this dose over the course of the remaining 8 weeks of the study, while participating in the graduate program of pulmonary rehab.
89508208|NCT02813447|Placebo Comparator|Pulmonary Rehab + Placebo|Subjects randomized to the placebo arm will have the same procedures as described above in the study drug arm with the exception that they will be receiving matched placebo drug.
89508209|NCT02342145|Active Comparator|group A|The patients were used cycloaporine A:2mg/kg combined with methotrexate 15mg/m2 +1d，10mg/m2 +3,+6,+11d,mycophenolate mofetil: 0.25g/d, -1d to 90d and basiliximab: 10mg each time, 0d and +4 d for prevention of graft-versus-host-disease.
89508210|NCT02342145|Experimental|group B|The patients were used cyclosporine A 2mg/kg,methotrexate,15mg/m2 +1d，10mg/m2 +3,+6,+11d,mycophenolate mofetil: 0.25g/d, -1d to 90d for prevention of graft-versus-host-disease.
89508211|NCT02302573|Experimental|placenta accreta|contast-enhanced ultrasound with sonovue
89508212|NCT03746015|Experimental|Takeda's Tetravalent Dengue Vaccine Candidate (TDV) 0.5 mL|TDV 0.5 mL, subcutaneous (SC) injection on Day 1 (Month 0) and Day 90 (Month 3) in flavivirus-naïve participants (Group 1) and dengue-immune participants (Group 2). TDV comprised of 1 molecularly characterized, attenuated dengue virus strain and 3 chimeric dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4 containing not less than 3.3, 2.7, 4.0, and 4.5 log10 plaque forming units (PFU) respectively.
89508213|NCT02349321|Experimental|School Strengthening|Skhokho Supporting Success for Schools: (a) Full year Grade 8 Life Orientation Learner Workbook (following the national curriculum), Educator Guide, and LO Educator support workshops; (b) Educator workshops including values, positive discipline skills, adolescent development, and stress and coping; (c) Learner club workshops (Grade 8s-11s) including creating change for a safe and vibrant school community, human rights at school, communication and conflict resolution skills, and stress and coping.
89508214|NCT02349321|Experimental|School + Family Strengthening|"Skhokho Supporting Success for Schools: See description above.~Skhokho Supporting Success for Families: Participatory four-day workshop for parents/caregivers and their young adolescent children including parallel and joint dialogue sessions. This workshop aims to promote supportive, open relationships between parents/caregivers and their teens and includes communication, negotiation and conflict resolution skills; positive discipline skills; challenging traditional gender constructions; understanding the impact of child abuse; stress and coping."
89508215|NCT02349321|No Intervention|Arm 3: Control (Delayed Intervention)|"This group will continue with treatment as usual (i.e: school services, activities, and textbooks without specialised intervention). At the end of primary data collection, these schools will be eligible to receive the Schools Strengthening Intervention."
89508216|NCT03507985||The exposed group|The exposed group where patients receive morphine analgesia The patient will realise two tests evaluating memory and attention, for the first at the inclusion visit after giving his consent, and in a second time during the follow up visit 15 days or 1 month later.
89508217|NCT03507985||The unexposed group|"The unexposed group where patients receive 1 +/- 2-stage analgesia is non-opioid analgesics.~The patient will realise two tests evaluating memory and attention, for the first at the inclusion visit after giving his consent, and in a second time during the follow up visit 15 days or 1 month later."
89508218|NCT00882791||Historical Arm|266 cases of BCC treated with Mohs surgery approximately 2-5 years ago will be assessed for recurrence.
89508219|NCT00882791||Prospective Arm|300 cases of BCC will be followed annually for 3 years after Mohs surgery to assess for recurrence.
89508220|NCT02349399||Drug Utilisation / Cohort 1|New users of CPA/EE in 2011/2012 and in 2014
88816013|NCT02532933|Active Comparator|Medialized Dome Patella|Subjects with total knee arthroplasty using the DePuy Synthes Attune Posterior Stabilized Rotating Platform including patella resurfacing with a medialized dome component geometry
89023991|NCT04033926|Other|Arm B|"Treatment Period 1: Placebo SC weekly for 16 weeks~Treatment Period 2: KZR-616 30 mg SC weekly for 2 weeks, then 45 mg SC weekly for 14 weeks"
89023992|NCT04025606|Active Comparator|Thoracic epidural analgesia|Standard thoracic epidurals preoperatively at the dag of surgery.
89023993|NCT04025606|Experimental|Paravertebral block|Paravertebral block inserted at the end of the operation by the surgeons
89023994|NCT04025580|Experimental|Flucelvax, Fluvirin, or Fluzone High Dose|Healthy Volunteer between ages 18-65 receiving Flucelvax
88958158|NCT01991002|Other|14/21 diet|"Diet program is divided into 3 periods: 1. Low carb diet for 14 days; 2. Low carb and regular diet in alternating days for 21 days; 3. Individual carbohydrate-rich diet for 21 days.~The diet consists of a free choice of food ingredients from a detailed list of foods in each category (proteins, carbohydrates, vegetables, fat etc.). The participants are free to choose the types of food as long as they are within the specified allowance (quantity) for each food group."
88958159|NCT01991028|Experimental|Radiolabelled OligoG CF-5/20 DPI|Single dose OligoG CF-5/20 Dry Powder for Inhalation by 3 capsules of 32mg OligoG via Miat Monodose Inhaler, radiolabelled ca10MBq 99mTc.
88958160|NCT01991028|Active Comparator|Radiolabelled OligoG CF-5/20 6% Solution|Single dose of 1.5mL (90mg) aerosolised OligoG CF-5/20 6% solution via Sidestream Plus nebuliser, radiolabelled ca10MBq 99mTc.
88958161|NCT01991041||Rufinamide|
88958162|NCT01991041||Anti-Epileptic Drugs|Includes those used off label as part of local clinical practice
89508221|NCT02306473|Experimental|Asthma|Subjects with asthma will be exposed to inhaled mannitol according to FDA approved protocols.
89508222|NCT02306473|Experimental|Controls|Healthy control subjects will be exposed to inhaled mannitol according to FDA approved protocols.
89508223|NCT02349555|Experimental|Nutritional Supplement Blend|The nutritional supplement contains a proprietary blend consisting of 15 unique nutritional ingredients.
89508224|NCT03507907|Experimental|Study Group|Mulligan mobilization techniques were applied to the older adults.
89508225|NCT03507907|Other|Control Group|Conventional physiotherapy programs were applied to the older adults who included in control group.
89508226|NCT02344329|Active Comparator|Control|TCC-EZ and Standard Wound Care (Topical wound dressing) Two dressing and cast changes in week one followed by weekly applications until 12 weeks or closure which ever occurs first. Usual wound care would involve assessment, debridement, moist wound environment, and off-loading.
89508227|NCT02344329|Experimental|Intervention|TCC-EZ and Human Amnion Allograft One dressing and two cast changes in week one followed by dressing change every two to three weeks and weekly cast changes until 12 weeks or closure which ever occurs first. Usual wound care would involve assessment, debridement, moist wound environment, and off-loading.
89508228|NCT03513679|Experimental|Surgical Group|Gait and balance testing as well as self-reported outcome assessments to be administered before and after surgery
89508229|NCT03513679|No Intervention|Control Group|Gait and balance testing to be administered once in healthy subjects
89508230|NCT03709121|Experimental|Reproxalap Ophthalmic Solution (0.25%)|
89206906|NCT01069159|Active Comparator|Propranolol|The protocol of the study requires that two doses of propranolol (regular propranolol 40 mg followed two hours later by long-acting propranolol 60 mg) be given at the first visit, to be taken within one hour of the reactivation of the traumatic memory. Half of the subjects (33) will be randomized to receive propranolol.
89508231|NCT03709121|Experimental|Reproxalap Ophthalmic Solution (0.5%)|
89508232|NCT03709121|Placebo Comparator|Vehicle Ophthalmic Solution|
89508233|NCT02344095|Experimental|weekly paclitaxel with oncothermia|Paclitaxel group are treated with weekly paclitaxel and oncothermia for 4-cycles.
89508234|NCT02344095|Experimental|weekly cisplatin with oncothermia|Cisplatin group are treated with weekly cisplatin and oncothermia for 4-cycles.
89508235|NCT00157339|Experimental|1|
88958163|NCT01991054|Experimental|vitamin D3 supplementation|The study group participants will receive vitamin D3 supplementation (120,000 I.U per month)for 6 months
88958164|NCT01991054|Placebo Comparator|placebo group|placebo group, 15 ml per month for 6 months
88958165|NCT01991080|Active Comparator|Wheatgerm juice|patients will drink Wheatgerm juice
89206907|NCT01069159|Placebo Comparator|Placebo|The protocol of the study requires that two doses of placebo be given at the first visit, to be taken within one hour of the reactivation of the traumatic memory. Half of the subjects (33) will be randomized to receive placebo.
89508236|NCT00157339|Active Comparator|2|
88958166|NCT01991080|Active Comparator|Biofeedback|The patients will undergo biofeedback relaxation therapy
88958167|NCT01991106|Experimental|High intensity interval training|10-minute warm up at 60-70% of maximal heart rate (HRmax). Then walking, running or cycling at 85-95% of maximal heart rate at intervals of 4 x 4 minutes, with 3 minute active breaks (50-70% of HRmax) between intervals. A 5-minute cool down period.
88958168|NCT01991106|Experimental|Moderate intensity continuous training|walking, running or cycling continuously at 60-70% HRmax for 44 minutes.
89508237|NCT02342067|Experimental|Group 1 (Cenicriviroc, PGZ, CVC+PGZ)|Treatment A: CVC 150 mg QD for 10 days followed by 10-day washout Treatment B: PGZ 45 mg QD for 10 days Treatment C: co-administration of PGZ 45 mg QD + CVC 150 mg QD for 10 days
89508238|NCT02342067|Experimental|Group 2 (Pioglitazone, CVC, CVC+PGZ)|Treatment B: PGZ 45 mg QD for 10 days followed by 10-day washout Treatment A: CVC 150 mg QD for 10 days Treatment C: co-administration of CVC 150 mg QD + PGZ 45 mg QD for 10 days
89508239|NCT02750501|Other|Single Arm: Open label RELiZORB Cartridge & Impact Peptide 1.5|RELiZORB (immobilized lipase) cartridge and Impact Peptide 1.5 with enteral feedings ranging from 500 mL to 1,000 mL per feeding for a period of 90 days.
89508240|NCT02344017|Experimental|ODM-204 Phase I dose escalation|Dose escalation
89508241|NCT02344017|Experimental|ODM-204 Phase II dose expansion|
89508242|NCT02343861|Active Comparator|Tailored leaflet group|Participants (parents of children with atopic dermatitis) receive a tailored leaflet about the detailed amount of emollients as well as general information about use of emollients.
89508243|NCT02343861|Placebo Comparator|Control group|Participants (parents of children with atopic dermatitis) receive general information about use of emollients only.
89508244|NCT03676751|Active Comparator|Azithromycin|A single dose of azithromycin will be administered to children between the ages of 8 days and 59 months old.
89508245|NCT03676751|Placebo Comparator|Placebo|A single dose of placebo will be administered to children between the ages of 8 days and 59 months old.
89508246|NCT02302651|Other|Osteoid Osteoma|MR guided High Intensity focused ultrasound
89508247|NCT02343783|Experimental|Healthy + Atopic Dermatitis + Allergic Asthmatic Participants|Healthy participants will be enrolled in order to allow for training on the overall skin blister induction and fluid aspiration process. Participants with atopic dermatitis (AD) or allergic asthma (AA) will be observed for the use of induced skin blisters after allergic skin reaction (ASR).
88958169|NCT01991106|Active Comparator|nutritional advice|10 individual nutrition consultations with an accredited dietitian over the 12 month period. Content of consultations will include healthy food choices, portion sizes and regular mealtimes.
89032937|NCT02925936|Active Comparator|Cathode|Thyroid facing the cathode end of xray machine
89032938|NCT02925936|Active Comparator|Anode|Thyroid facing the anode end of xray machine
89508248|NCT02302729|Experimental|Micronutrients No responsive feeding|Micronutrient powder and no responsive feeding
89508249|NCT02302729|Placebo Comparator|Placebo and Responsive Feeding|Placebo (vitamin B2) and Responsive Feeding
89508250|NCT02302729|Experimental|Micronutrients and Responsive caregiving|Micronutrients and Responsive feeding intervention
89508251|NCT02302729|Placebo Comparator|Placebo and No responsive caregiving|Placebo and No responsive caregiving
89508252|NCT02343705|Experimental|Latella Knee Implant System|
89508253|NCT03513601|Experimental|(R)-CHOP regimen|(R)-CHOP regimen((rituximab)，cyclophosphamide，epirubicin，vincristine and prednisone)，(rituximab 375mg/m2 d0 ivgtt),cyclophosphamide 750mg/m2 d1、8 ivgtt,epirubicin 50mg/m2 d1、8 ivgtt,vincristine 2mg d1、8 ivgtt,prednisone 60mg d1-5 po.Every 21 days for one cycle and six cycles are required. Efficacy was evaluated every two cycles.
89508254|NCT03513601|Experimental|(R)-CVP regimen|(R)-CVP regimen((rituximab)，cyclophosphamide，vincristine and prednisone) The dose of the chemical was reduced by 20%，(rituximab 375mg/m2 d0 ivgtt),cyclophosphamide 750mg/m2 d1、8 ivgtt,vincristine 2mg d1、8 ivgtt,prednisone 60mg d1-5 po.Every 21 days for one cycle and one or two cycles are required. Efficacy was evaluated every two cycles. Subsequent (rituximab 375mg/m2 d0 ivgtt)， oral cyclophosphamide .
89508255|NCT03648827|Experimental|Ataluren|Participants will receive ataluren oral suspension 10 milligrams per kilogram (mg/kg) in the morning, 10 mg/kg at midday, and 20 mg/kg in the evening each day for 40 weeks.
89508256|NCT03149133|Experimental|Classical Hypertrophy|The classical hypertrophy group performs strength training with 75-80% of 1-Repetition Maximum.
89508257|NCT03149133|Experimental|Occlusive Training|The occlusive hypertrophy group performs strength training with %35-50 of 1-Repetition Maximum.
89508258|NCT03513523|Experimental|Group 1: 1X dose of NRPT|250 mg of NR and 50 mg of PT
89508259|NCT03513523|Experimental|Group 2: 2X dose of NRPT|500 mg of NR and 100 mg of PT
89508260|NCT03513523|Placebo Comparator|Group 3: Placebo|Placebo capsules contain microcrystalline cellulose, silicon dioxide and magnesium stearate
89508261|NCT03148977||Patients admitted to the burn center|Patients admitted to the Burn Service with acute burn injuries requiring at least one surgical excision and grafting operation.
89508262|NCT03507829|Active Comparator|Basal insulin|NPH Insulin Titration Regimen : Pre-dinner Capillary blood glucose NPH dose initiation (IU/day) NPH dose adjustment(IU/day) > 240 mg/dl 14 Increase by 4 > 180 mg/dl 12 Increase by 4 > 140 mg/dl 10 Increase by 4 > 120 mg/dl 0 Increase by 2 100 to 119 mg/dl 0 Maintain the dose 80 - <100 mg/dl 0 Decrease by 4 60 - <80 mg/dl 0 Decrease by 8 < 60 mg/dl 0 Give ½ of previous dose
89508263|NCT03507829|Active Comparator|Standard of care|Patients assigned in this arm will receive standard of care following their kidney transplantation
89508264|NCT03507829|Active Comparator|Sensor-augmented Insulin Pump|Continuous subcutaneous sensor-augmented insulin-pump therapy (SAPT) with an insulin pump from Medtronic (Paradigm® Velo) for a period of approximately 3 months post-transplantation.
89508265|NCT02232581|Experimental|Alovudine - low|
89508266|NCT02232581|Experimental|Alovudine - medium|
89508267|NCT02232581|Experimental|Alovudine - high|
89508268|NCT02232581|Placebo Comparator|Placebo|
89508269|NCT02341833|Active Comparator|Sevoflurane|1 MAC of sevoflurane for 15 minutes before organs procurement.
89508270|NCT02341833|No Intervention|No intervention|No volatile anesthetics during organs procurement
89508271|NCT04464499||atrial fibrillation (AF)|Patients diagnosed with AF during reference ECG
88958170|NCT01991106|No Intervention|non-obese children|100 healthy non-obese children aged 7-16 (controls)
88958171|NCT01991119|Active Comparator|Propafenone|Propafenone group
88958172|NCT01991119|Active Comparator|Dronedarone|Dronedarone group
88958173|NCT01991132|Other|MediView 2.0 software|
88958174|NCT01991145|Experimental|UCB and EPO|UCB + EPO + Rehabilitation
88958175|NCT01991145|Active Comparator|UCB and placebo EPO|UCB + placebo EPO + Rehabilitation
88958176|NCT01991145|Active Comparator|placebo UCB and EPO|placebo UCB + EPO + Rehabilitation
88958177|NCT01991145|Placebo Comparator|placebo UCB and placebo EPO|placebo UCB + placebo EPO + Rehabilitation
88958178|NCT01991158|Experimental|GAD-M regimen|GAD-M regimen means High dose of methotrexate combined with gemcitabine, pegaspargase and dexamethasone
88958179|NCT01991171|Experimental|Kinesio Taping|Participant will receive application of Kinesiotaping in their thigh on quadriceps muscle
88958180|NCT01991171|Placebo Comparator|Kinesio Taping Placebo|Participant will receive application of placebo Kinesiotaping in their thigh on quadriceps muscle
88958181|NCT01991171|No Intervention|Control Group|This participants will not receive intervention
88958182|NCT01991223|Placebo Comparator|Placebo group|NS infusion will be done during surgery.
88958183|NCT01991223|Experimental|Dex group|DEX infusion will be done during surgery.
88958184|NCT01991236|Experimental|Video|An educational video discussing the benefits and risk associated with long term usage of systemic corticosteroids.
88958185|NCT01991236|Other|Standard script|Standard scripted discussion of risks and benefits of systemic corticosteroids read to participants.
88958186|NCT01991262||Group 1 phone call and SMS reminder.|cloosed no one enrolled
88958187|NCT01991262||Group 2 phone call only.|cloosed no one enrolled
88958188|NCT01991262||Group 3 SMS reminder only .|cloosed no one enrolled
88958189|NCT01991262||Group 4 (Control) no support|cloosed no one enrolled
88958190|NCT01991275|Experimental|The ITM group|The postoperative pain management includes both the intrathecal morphine injection and the intravenous patient-controlled analgesia.
88958191|NCT01991275|Placebo Comparator|The IV-PCA group|The postoperative pain management includes only the intravenous patient-controlled analgesia.
89032939|NCT04692428|Experimental|FIBSI group|ultrasound supra inguinal Fascia iliaca block
89032940|NCT04692428|Experimental|FNB group|ultrasound femoral nerve block
88958192|NCT01991288|Experimental|SNB Saphenous Nerve block|Patients received SNB preoperatively at mid thigh level with ultrasound guidance. 10 mls 0.5% bupivacaine was administered for nerve block by the anesthetist. All patients also received peri operative Local Infiltration Analgesia by the surgeon. All patients will receive preoperative oxycontin, peri operative paracetamol and diclofenac. Post operatively all patients received regular paracetamol 1g 6 hourly, Diclofenac sodium 12 hourly and oxycontin 10-20 mg 12 hourly. All patients received standardized spinal block by the same anesthetist, post nerve block for surgery.
88958193|NCT01991288|Active Comparator|NSNB Non Saphenous Nerve Block|Patients only received Local Infiltration Analgesia. As per protocol all patients received the same pre, peri and post operative analgesia as described in the experimental group. All patients had a standardized spinal block for surgery.
89206908|NCT03975205|Active Comparator|Doxil|This group of patients will receive Intravenous Doxil of 50mgm/m2 over 15 minutes and plasma concentration will be measured at time Frame: 0, 1, 2, 3, 4, 8, 12, 24, 48 and 72 hours. Cycle is defined as 28 days
89206909|NCT03975205|Experimental|doxorubicin|This group of patients will receive Intravenous Doxorubicin of 50mgm/m2 over 15 minutes and plasma concentration will be measured at time Frame: 0, 1, 2, 3, 4, 8, 12, 24, 48 and 72 hours. Cycle is defined as 28 days
89206910|NCT01325779|Active Comparator|subcutaneous heparin|
89508272|NCT04464499||sinus rhythm (SR)|Patients diagnosed with SR during reference ECG
89508273|NCT02232659|Experimental|Primary Arm|Use of the SynCardia 70cc TAH-t for Destination Therapy to support an HDE Application.
89508274|NCT02232659|Experimental|Secondary Arm|Use of the SynCardia 70cc TAH-t for Destination Therapy in a less-restrictive patient population to further characterize the use of the 70cc TAH-t for DT.
89508275|NCT02337231|Other|GG genotype|Healthy participants with genotype GG at rs174537 will take gel capsules that contain soybean oil (4-weeks) and borage oil (4-weeks) in a crossover study.
89508276|NCT02337231|Other|GT genotype|Healthy participants with genotype GT at rs174537 will take gel capsules that contain soybean oil (4-weeks) and borage oil (4-weeks) in a crossover study.
89508277|NCT02337231|Other|TT genotype|Healthy participants with genotype TT at rs174537 will take gel capsules that contain soybean oil (4-weeks) and borage oil (4-weeks) in a crossover study.
89508278|NCT02341677|Experimental|Biopsy|Single Arm Study. Biopsy Intervention.
89508279|NCT02306629|Experimental|Epratuzumab dose 1 sc|This group of Caucasian and Japanese subjects will receive one single dose 1 of epratuzumab subcutaneous
89508280|NCT02306629|Experimental|Epratuzumab dose 2 sc|This group of Caucasian and Japanese subjects will receive one single dose 2 of epratuzumab subcutaneous
89508281|NCT02306629|Experimental|Epratuzumab dose 3 sc|This group of Caucasian subjects will receive one single dose 3 of epratuzumab subcutaneous
89508282|NCT02306629|Active Comparator|Epratuzumab dose 2 iv|This group of Caucasian and Japanese subjects will receive one single dose 2 of epratuzumab as an intra venous infusion
89508283|NCT03513367||Boys with Muscular Duchenne Dystrophy|"105 boys with Muscular Duchenne Dystrophy (DMD) distributed as follows: 35 patients with Duchenne muscular dystrophy by age category, 8-12 years old and 13-18 years old.~Children will complete the questionnaire of Duchenne Muscular Dystrophy of the PedsQL ™ 3.0 scale regardless of his parents"
89508284|NCT03513367||Parents of boys with Muscular Duchenne Dystrophy|105 parents of boys with Muscular Duchenne Dystrophy For the 5-7 age group, only parents answer the questionnaire but medical data are collected : 35 by age category (5-7; 8-12; 13-18) Parents will complete the questionnaire of Duchenne Muscular Dystrophy of the PedsQL ™ 3.0 scale regardless of their children
89508285|NCT01337297|Placebo Comparator|sham-tDCS|the electrodes are positioned in the same manner as the active-tDCS, activated for 20 s (time to climb ramp of the current until reach the current intensity used in the experiment), enough to produce the sensation of itch, and turned off until the end of the session.
89508286|NCT01337297|Experimental|active-tDCS|low-intensity transcranial Direct Current Stimulation (tDCS)applied over the dorsolateral prefrontal cortex
89508287|NCT03510793||Balanced anesthesia|Patients receiving balanced anesthesia (desflurane + remifentanil) according to the attending physician's decision
89508288|NCT03510793||Total intravenous anesthesia|Patients receiving total intravenous anesthesia (TIVA) using propofol + remifentanil with target-controlled infusion according to the attending physician's decision.
89508289|NCT02336997|Experimental|FAT-GRAFT|Fat graft transplantation
89508290|NCT02336997|Experimental|SVF-TRANSPLANTATION|Transplantation of resuspended SVF
89508291|NCT02336997|Placebo Comparator|CONTROL|Same volume saline injection
89508292|NCT02299453|Experimental|Experimental|Participants receive 9 sessions of telephone-administered PT and have access to standard community-based services. As part of the 9 sessions, participants discuss the extent to which interpersonal issues such as bereavements, role transitions, interpersonal disputes, and relationship difficulties may be related to their depression.
89508293|NCT02299453|No Intervention|Standard of Care|Participants receive no active intervention but do have access to standard community-based services, such as individual therapy, support groups, 12-step programs, and other social serves.
89508294|NCT02341443|Experimental|Rigid|Surgery using mandibulo-maxillary fixation, implants providing rigid fixation on most anterior fracture and non-rigid fixation on the most posterior fracture.
89508295|NCT02341443|Active Comparator|Non-rigid|Surgery using mandibulo-maxillary fixation and implants providing non-rigid fixation on both fracture sides.
89508296|NCT02299531|Experimental|Low Energy Density, Small Portions|Low meal energy density and small portion sizes
89508297|NCT02299531|Experimental|Low Energy Density, Medium Portions|Low meal energy density and medium portion sizes
89508298|NCT02299531|Experimental|Low Energy Density, Large Portions|Low meal energy density and large portion sizes
89508299|NCT02299531|Experimental|High Energy Density, Small Portions|High meal energy density and small portion sizes
89508300|NCT02299531|Experimental|High Energy Density, Medium Portions|High meal energy density and medium portion sizes
89508301|NCT02299531|Experimental|High Energy Density, Large Portions|High meal energy density and large portion sizes
89508302|NCT02234375|Experimental|Gadolinium enhancement|Gadolinium enhancement will be performed using intravenous Dotarem[recommended dose of 0.2 mL/kg (0.1 mmol Gd/kg )]
89519397|NCT03450655|Experimental|Intervention Group|Weeks 1-10: exercise program in group. Weeks 11-20: no intervention. Weeks 21-31: no intervention.
89508303|NCT03507595||Patients with initial diagnosis of PCa|"T2 stage: PSA>20ng/ml, Gleason Score >= 8;~T3 or T4 stage;~The imaging examination was negative or localized metastasis of the pelvic lymph node, but there was no distant metastasis of lymph nodes or bone and internal organs other than the pelvic cavity."
88958194|NCT01991301|Experimental|carfilzumib|Carfilzomib at a dose of 20mg/m2 I.V. will be administrated at day 1, 2 post infusion of the stem cell (SC) graft to the first 10 patients. If no > grade II toxicity* the next 10 patients will receive Carfilzomib (27 mg/m2) at day 1,2 and 8, 9, 15 and 16. If no > grade II toxicity* the next 10 patients will receive 2-3 cycles of Carfilzomib (27 mg/m2) administered at day 1,2 8,9,15 and 16 post SC graft infusion.
88958195|NCT01991327|Experimental|Androxal|Androxal 25 mg capsules once a day for 7 days
88958196|NCT01991327|Active Comparator|Placebo Androxal|
88958197|NCT01991340||Cohort|
89508304|NCT03507595||Patients with biochemical recurrent PCa|"After the RRP surgery,the serum PSA was over 0.2 ng/ml in two consecutive sera;~After the radiotherapy: the lowest PSA is up to 2 ng/ml."
89508305|NCT03507595||Patients with CRPC|"The serum testosterone is in the castration level (< 50 ng/dL or < 1.7 nmol/L);~The PSA is elevated 3 times in a row, the base value is increased by more than 50%, and the PSA > 2ng/mL(the interval is one week);~The continuation of the anti-androgen drugs, flunamine was stopped for at least 4 weeks, and biglumide was suspended for at least 6 weeks;~Despite the continued standard androgen deprivation therapy, the PSA is still progressing."
89508306|NCT02341521|Experimental|OC000459 50 mg|OC000459 50 mg daily for 8 days
89508307|NCT02234453|Experimental|Cancer patients|Adult patients with solid tumours receiving systemic anti-cancer therapy who are able to use the Minicare H-2000.
89508308|NCT05230797|Experimental|zinc-oxide propolis|Propolis is a natural resinous mixture produced by honeybees from substances collected from parts of plants, buds, and exudates. The essential principle compounds responsible for biological activities are polyphenols, aromatic acids, and diterpenic acids. Numerous biological properties of propolis have been reported including cytotoxic, antiherpes, free radical scavenging, antimicrobial, and anti-HIV activities The antibacterial effect of propolis is bactericidal by inhibiting their mobility. Propolis kills the fungi and also inhibits the growth of the viruses.
89508309|NCT05230797|Active Comparator|zinc-oxide eugenol|Zinc oxide-eugenol cement (ZOE) has been used as a root canal filling material for primary teeth and has long been the material of choice of pediatric dentists worldwide, although it fails to meet the ideal requirements of root canal filling material for primary teeth due to limited antimicrobial action, and a slower rate of resorption than the roots of the primary teeth. Studies report that the success rate of ZOE ranges from 65% to 86% so it's materials of choice if primary teeth are not nearing exfoliation.
89508310|NCT02234609|Other|adults with incisor dental caries lesion|modified ART class IV with glass ionomer cement
89508311|NCT02299609|Active Comparator|Beam Receiver|Philips HD11 XE® 30 min qid x 4 days
89508312|NCT02299609|Sham Comparator|Beam Non-Receiver|Philips HD11 XE® (ultrasound turned-off) 30 min qid x 4 days
89508313|NCT04899999|Experimental|Financial reward graphic message|
89508314|NCT04899999|Experimental|Health reward graphic message|
89508315|NCT04899999|Experimental|Self-efficacy graphic message|
89508316|NCT04899999|Experimental|Social norms graphic message|
89508317|NCT02299687|Experimental|CYP2C19 EM|CYP2C19 EM
88958198|NCT01991353|Experimental|With PRP|Standardized meniscal repair with PRP (platelet rich plasma) in the meniscal healing bed.
88958199|NCT01991353|Active Comparator|Without PRP|Standardized meniscal repair without PRP (platelet rich plasma).
88958200|NCT01991366||Eptifibatide Pre PCI|Receive eptifibatide pre PCI
88958201|NCT01991366||Eptifibatide during PCI|Receive eptifibatide during PCI
88958202|NCT01991366||No Eptifibatide|Receive no eptifibatide
88958203|NCT01991392|Active Comparator|Maintaining tube|Maintain nasogastric tube after extubation following pancreaticoduodenectomy
88958204|NCT01991392|Experimental|Non-tube|Remove nasogastric tube after extubation following pancreaticoduodenectomy
88958205|NCT01991405|Sham Comparator|Computerized Working Memory Training.|The Working Memory Training, includes both auditive and visual tasks, administrated on a computer, under guidance. 5 x 45 minutes per week, for 5 weeks. The placebo group will train at an fixed level (non-adaptive), but with otherwise identical computer programs.
88958206|NCT01991418||early staged non-small cell lung cancer|patients diagnosed as early staged non-small cell lung cancer and received surgery in HunanPTH
89206911|NCT01325779|Active Comparator|subcutaneous enoxaparin|
89206912|NCT00829920||Bladder cancer|Patients with muscle invasive or metastatic bladder cancer who will be planning for treatment with surgery or chemotherapy.
89508318|NCT02299687|Experimental|CYP2C19 IM|CYP2C19 IM
88958207|NCT01991431||TAVI|All Patients undergoing transaortic transcatheter valve implantation with commercially available Edwards SAPIEN XT Transcatheter Heart Valve with the Ascendra+ Delivery-System in participating sites
89508319|NCT02299687|Experimental|CYP2C19 PM|CYP2C19 PM
89508320|NCT02349243|Experimental|entacapone|An approach of 200mg entacapone at a time and 4 times a day(0.5 hour after every breakfast, lunch and supper and at 0.5 hours before bedtime) is adopted. Every participant is required to record his/her diet, exercise, and drug intake condition in a standard record card which is provided by the researchers.
89508321|NCT02349243|Placebo Comparator|placebo|Except for taking the placebo rather than the entacapone, any intervention in the placebo group is the same with that in the entacapone group.
89508322|NCT03513289||Patient, Carer, and Clinician Interviews|This group/cohort consists of patients who experienced critical illness and were hospitalized in an ICU setting.
89508323|NCT02341131|Experimental|Cognitive Remediation Therapy|Cognitive Remediation Therapy -Frontal/Executive Program (Delahunty)- (Wykes & Reeder, 2005)
88958208|NCT01991444||TAVI patients of > 79 years|"All patients undergoing transcatheter valve implantation with commercially available Edwards SAPIEN XT Transcatheter Heart Valve in participating sites.~Routine data about the intervention (transcatheter valve Implantation) will be collected. In addition, data describing the geriatric status of the patient, including a patient questionnaire evaluating his/her Quality of life will be collected."
88958209|NCT01991509|Experimental|LBR-101 IV Dose 1|LBR-101 Dose 1 Administered Intravenously
88958210|NCT01991509|Experimental|LBR-101 SC Dose 1|LBR-101 Dose 1 Administered Subcutaneously
88958211|NCT01991509|Placebo Comparator|Placebo IV|Placebo Administered Intravenously
88958212|NCT01991509|Placebo Comparator|Placebo SC|Placebo Administered Subcutaneously
89508324|NCT02341131|Active Comparator|Psychoeducation|Symptom Management Module from the University of California. Liberman & Kopelowicz (1995)
88958213|NCT01991509|Experimental|LBR-101 Dose 2 IV|LBR-101 Dose 2 Administered Intravenously
89508325|NCT02341131|No Intervention|Healthy Controls|No intervention
89508326|NCT02341209|Experimental|Doxycycline monohydrate|Doxycycline in either capsules or tablets will be administered at 400mg total per day. Patients will be treated for five months, or up to one year for those with a partial response at 5 months.
89508327|NCT02349165|Active Comparator|epithelium off CXL|epithelium removal + 30 minute isotonic riboflavin eye drops (3 minute interval) + 30 minutes ultraviolet-A irradiation (riboflavin every 5 minutes)
89508328|NCT02349165|Experimental|Ricrolin TE CXL|Ricrolin-TE eye drops for 15 minutes (2 minute interval) and 15 minute Ricrolin TE pooled on the cornea using a silicone ring + 30 minutes ultraviolet-A irradiation (Ricrolin TE every 5 minutes).
89508329|NCT02302963|Experimental|AP System (DiAs or inControl) with USS Virginia|Subject will complete an 8-hour inpatient assessment of hypoglycemia counterregulation. Subject will then proceed through 7 weeks of training and use of the AP System with USS Virginia and study pump. The inpatient testing will be repeated after wearing the AP System at home.
89508330|NCT02302963|Placebo Comparator|Sensor-Augmented Pump Therapy|Subject will complete an 8-hour inpatient assessment of hypoglycemia counterregulation. Subject will then wear a continuous glucose monitor and their own insulin pump at home for 5 weeks. The inpatient testing will be repeated at the completion of the 5 weeks at home.
89508331|NCT02341053|Other|Load-measuring platform|"Load-sensing platform A load-sensing platform will be placed under each foot of the subject to record the time course of load borne by each of the lower extremities during weight-bearing training in an assisted standing device.~Intervention: Assisted Standing Treatment Program. Assisted standing treatment program will gradually increase their duration of standing by up to 75% after the baseline phase."
89508332|NCT02303197|Experimental|ChiNing decoction|60ml ChiNing decoction by mouth，three times a day for 46 days.
89508333|NCT02303197|No Intervention|rhEGF spray|The rhEGF spray spray on the oral mucosal surface irradiated area, 3 times a day for 46 days.
89508334|NCT03111849||hospitalized chronic obstructive patients|
89508335|NCT03507361|Experimental|MUSIC|Music will be administered through a normal computer equipped with a technology (Sound-of-Soul) that translates the patient's heart rate variability (HRV) into sounds according to a digital computer music-library. Music will start 10 minutes before and will end at the completion of the interventional procedure
89508336|NCT03507361|No Intervention|DUMB EARPHONES|Dumb earphones will be placed over patient's ears starting 10 minutes before and ending at the completion of the interventional procedure.
89508337|NCT03111771||Group K +|Group K +: cancer of the upper aerodigestive tract with or without cachexia
89508338|NCT03111771||Group K-|Group K-: absence of cancer and absence of cachexia
89508339|NCT03111771||Control group|The MYOMEC study includes the inclusion of healthy patients (to form a control group
88958214|NCT01991509|Experimental|LBR-101 Dose 2 SC|LBR-101 Dose 2 Administered Subcutaneously
88958215|NCT01991561|Experimental|Low dose of H5 VLP vaccine + Alhydrogel|Biological: low dose of H5 VLP vaccine 2 doses given 21 days apart of low dose of H5 VLP vaccine mixed with Alhydrogel
88958216|NCT01991561|Experimental|Med dose H5 VLP vaccine + Alhydrogel|Biological:Med dose of H5 VLP vaccine + Alhydrogel, 2 doses given 21 days apart of Med dose H5 VLP vaccine mixed with Alhydrogel
88958217|NCT01991561|Experimental|High dose of H5 VLP vaccine + Alhydrogel|Biological: High dose of H5 VLP vaccine 2 doses given 21 days apart of High dose of H5 VLP vaccine mixed with Alhydrogel
88958218|NCT01991561|Experimental|Low dose of H5 VLP vaccine + GLA-SE|Biological: low dose of H5 VLP vaccine 2 doses given 21 days apart of low dose of H5 VLP vaccine mixed with GLA-SE
88958219|NCT01991561|Experimental|High dose of H5 VLP vaccine + GLA-SE|Biological: High dose of H5 VLP vaccine 2 doses given 21 days apart of High dose of H5 VLP vaccine mixed with GLA-SE
88958220|NCT01991561|Placebo Comparator|Placebo comparator: Placebo|Biological: Placebo 2 doses given 21 days apart of the placebo
88958221|NCT01991574|Placebo Comparator|Methylcellulose|On one of the study days: ingest one methylcellulose capsule with a test meal rich in phosphate.
88958222|NCT01991574|Active Comparator|Calcium Acetate|On one of the study days: ingest 667 mg calcium acetate, equivalent to 169 mg elemental calcium, with a test meal rich in phosphate.
88958223|NCT01991574|Experimental|Iron Hydroxide Adipate|On one of the study days: ingest 800 mg ferric hydroxide adipate, equivalent to 175 mg elemental iron, with a test meal rich in phosphate.
88958224|NCT01991587|Experimental|Low dose of quadrivalent VLP vaccine|Biological: A single low dose of quadrivalent VLP vaccine
88958225|NCT01991587|Experimental|Medium dose of quadrivalent VLP vaccine|A single medium dose of quadrivalent VLP vaccine
88958226|NCT01991587|Experimental|High dose of quadrivalent VLP vaccine|A single high dose of quadrivalent VLP vaccine
89540097|NCT04392999|Active Comparator|Dexamethasone Sodium Phosphate|Corticosteroid: 0.5 cc saline and 0.5cc of 10 mg/mL dexamethasone per facet joint (up to 6 mL total volume for 4 facet injections)
89540098|NCT03048981|Experimental|Fish oil intake|Healthy volunteers given maximum dose of fish oil for 10 days.
89540099|NCT03050385|Active Comparator|active stimulation during cognitive rehabilitation|"active transcranial direct current stimulation 20 minutes per session twice a day interval between sessions: more than 20 minutes 7 cm x 5 cm electrodes anodal electrode on F3 cathodal electrode on right forehead 2 mA(milliampere)~cognitive rehabilitation 10-minute calculation task followed by 10-minute task of local (Japanese) language test"
89540100|NCT03050385|Sham Comparator|sham stimulation during cognitive rehabilitation|"sham transcranial direct current stimulation 20 minutes per session twice a day interval between sessions: more than 20 minutes 7 cm x 5 cm electrodes anodal electrode on F3 cathodal electrode on right forehead 2 mA~cognitive rehabilitation 10-minute calculation task followed by 10-minute task of local (Japanese) language test"
89540101|NCT04882605||Donor/recipient couple with Matched Sibling Donor|"Donor/recipient couple = Patient undergoing a hematopoietic stem cell transplantation~+ its 10/10 HLA-matched donor recruited among his siblings"
89540102|NCT04882605||Donor/recipient couple with Haploidentical Donor|"Donor/recipient couple = Patient undergoing a hematopoietic stem cell transplantation~+ its 5/10 HLA-matched donor recruited among his relatives"
89540103|NCT04882371||MRI RECIST|Radiological responses were evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST) and changes in contrast enhancement patterns on MRI
88958227|NCT01991587|Placebo Comparator|Placebo|A single dose of Placebo
88958228|NCT01991600|Active Comparator|Ferrous Sulphate|The active comparator was the standard-of-care therapy for iron deficiency anaemia (namely ferrous sulphate). Generic uncoated ferrous sulphate tablets BP 300 mg containing 60mg elemental iron were purchased from a local pharmacy. The route of administration was oral. Each participant ingested one ferrous sulphate tablet (60 mg Fe) on one of the study visits.
88958229|NCT01991600|Experimental|ferric iron oxide-organic acid (Fe-OA)|Fifteen different ferric iron oxide-organic acid preparations were investigated. Most organic acids used were generally recognised as safe (GRAS) and all were used at dietary equivalent levels. The dosage was 58 ± 6 mg elemental iron equivalent (average of all compounds). The route of administration was oral using methyl-cellulose capsules. On one of the study visits, each participant ingested a single dose, equivalent to ca. 60 mg iron, of the Fe-OA preparation allocated to her.
88958230|NCT01991613|Experimental|liquid protein supplement|Study subjects will receive standard of care nutrition with the addition of a liquid protein supplement when the baby is able to tolerate an enteral feeding volume of 40mL/kg/day.
88958231|NCT01991613|No Intervention|Control group|Study subjects will receive standard of care nutrition
88958232|NCT01991626|Other|LNS|Maize meal mixed with Lipid Nutrient Supplement (LNS) containing micronutrient powder
88958233|NCT01991626|Other|FePP-Emulsion mixed|Fat emulsion mixed to the meal containing FePP
88958234|NCT01991626|Other|FeSO4-Mixed|meals containing FeSO4 mixed with a fat emulsion
88958235|NCT01991626|Other|FePP-Emulsion before|Fat emulsion taken before a meal containing FePP
88958236|NCT01991626|Other|FeSO4- Emulsion before|Fat emulsion taken before a maize meal containing FeSO4
88958237|NCT01991626|Other|LNS-Phytase|Maize meal mixed with LNS containing micronutrient powder and phytase
88958238|NCT01991626|Other|phytase|Maize meal containing micronutrient powder and phytase
88958239|NCT01991626|Other|MNP-control|maize meal containing micronutrient powder (MNP)
88958240|NCT01991626|Other|FePP control|Maize meal containing FePP
88958241|NCT01991626|Other|FeSO4 control|Maize meal containing FeSO4
88958242|NCT01991639|No Intervention|cognitive training|Participants are visited twice a week by buddies, but they do not specifically monitor the nutritional status or perform physical training in the first 10-12 weeks. Instead of that buddies are provided with a portfolio of possible activities, especially cognitive training, which they could perform together with the frail, malnourished subjects.
88958243|NCT01991639|Experimental|nutritional & physical activity|Buddies visit malnourished, frail, elderly subjects twice a week for approximately one hour and they perform nutritional and physical activity interventions.
88958244|NCT01991652||Wilms tumour|"Children diagnosed with a Wilms tumour receive SIOP PODC Wilms tumour treatment; preoperative chemotherapy, surgery and postoperative chemotherapy (= standard care).~One group of patients."
89206913|NCT05352165|Experimental|standard long-term therapy|The standard whole-course neoadjuvant therapy group was treated with neoadjuvant simultaneous radiotherapy and chemotherapy (Total Neoadjuvant Therapy, TNT) based on guidelines and clinical experience.
89540104|NCT04882371||PET-CT PERCIST|Radiological responses were evaluated according to the classification of PET Response Criteria in Solid Tumors (PERCIST) on PET-CT.
89540105|NCT04887753|Experimental|persons with cerebellar lesions|
89540106|NCT04887753|Active Comparator|Healthy controls|
89540107|NCT04882683|Experimental|control group|Prednisone+Azathioprine/Adalimumab
89540108|NCT04882683|Experimental|UCB-MNCs group|Prednisone+Azathioprine/Adalimumab+UCB-MNCs
89540109|NCT02155660|Experimental|Benralizumab Arm A|Benralizumab administered subcutaneously
89540110|NCT02155660|Experimental|Benralizumab Arm B|Benralizumab administered subcutaneously
89540111|NCT02155660|Experimental|Benralizumab Arm C|Benralizumab administered subcutaneously
89540112|NCT02155660|Placebo Comparator|Placebo|Placebo administered subcutaneously
89540113|NCT04882215|Experimental|Adaptive Training (AT)|For AT participants, difficulty of the training tasks is progressively increased in response to task performance.
89540114|NCT04882215|Active Comparator|Non Adaptive Training (NA)|For NA participants, task difficulty is fixed at a relatively low level across all sessions.
89540115|NCT04881981|Experimental|SCART Arm|Single Arm patients will be treated with SCART to different dose levels.
89540116|NCT04881513|Other|Structure /function of the taste buds and QoL|"The structure of the taste buds is measured by Narrow Band Imaging (NBI) technique prior to the operation, one month and six months after the surgery.~The tongue sensation is measured by two point discrimination before the operation, one month and six months after the operation.~The taste is tested by the taste strips prior to, on month and six month after the surgery.~The quality of life is measured by the SF36 questionnaire. The threshold change is measured by the stimulating electrode at the beginning and at the end of the surgery."
89540117|NCT04881591|Experimental|APP+Usual Treatment|Participants at this condition will receive the usual medical treatment for their scoliosis but also they will be monitored daily using the Scoliosis Pain Monitor APP. Alarms will be generated in the face of certain preestablished undesired events. Physicians will be asked to call patients and change/stop treatment if an alarm is received.
89540118|NCT04881669|Experimental|low group|low thickness group
89540119|NCT04881669|Experimental|moderate group|moderate thickness group
89540120|NCT04881669|Experimental|high group|high thickness group
89540121|NCT04881435|Experimental|Hydrogen gas inhalation therapy accompanied with standard steroid treatment|
89540122|NCT04881435|Active Comparator|Standard steroid treatment|
89540123|NCT02119936|Experimental|Heart Rate Variability Biofeedback Tool|Intervention: Participants will be taught how to use the Heart Rate Variability Biofeedback tool (emWave 2) as a mechanism to reduce stress and anxiety, then use the tool, coupled with deep breathing exercises, to visualize their stress reduction.
89540124|NCT03048357|Active Comparator|Freedom Bed|Freedom Bed Continuous Lateral Rotation Therapy System
89540125|NCT03048357|Other|Standard Hospital Bed & Protocol|Standard Hospital Bed with manual caregiver re-positioning every 2 hours
89540126|NCT05154123|Experimental|AT-527 + rosuvastatin (simultaneous) n=14|
89540127|NCT05154123|Experimental|AT-527 + rosuvastatin (staggered) n=14|
88958245|NCT01991665|Other|Group A|Digital examination before instrumental delivery to determine fetal head station and position
88958246|NCT01991665|Other|Group B|Digital examination before instrumental delivery to determine fetal head station and position + sonography evaluation of fetal head position
89540128|NCT04887675|Active Comparator|Patients switched from PI/EFV based ART to INSTI based ART|60 patients on PI/EFV based ART, stable on treatment (undetectable viral load for at least 6 months). At the beginning of the study they are switched to INSTI based regimen. The reasons for the switch will be side effects or long-term toxicities like hyperlipidemia, diarrhea, (PI), insomnia, headache (EFV), high Framingham score (PI/EFV)
89540129|NCT04887675|Active Comparator|Patients initially treated with INSTI based regimens|60 patients initially started on INSTI based ART (raltegravir and dolutegravir), stable on treatment (undetectable viral load for at least 6 months).
89540130|NCT04887363|Experimental|Core exercise group|The healthy community-dwelling older adults (60-74 years old), who had not received any core stability or Tai Chi Chuan training within the previous 6 months, were recruited in this study. All the subjects were independent in basic daily living activities and able to move freely without any assistance.
89540131|NCT04887363|Experimental|Tai Chi exercise group|The healthy community-dwelling older adults (60-74 years old), who had not received any core stability or Tai Chi Chuan training within the previous 6 months, were recruited in this study. All the subjects were independent in basic daily living activities and able to move freely without any assistance.
88958247|NCT01991678|Experimental|normal hepatic function|12 Patients will receive a 90-minute IV infusion
88958248|NCT01991678|Experimental|mild hepatic dysfunction|6 Patients will receive a 90-minute IV infusion
88958249|NCT01991678|Experimental|severe hepatic dysfunction|6 Patients will receive a 90-minute IV infusion
88958250|NCT01991691|Experimental|Tablet-based reported outcome|With the start of chemotherapy until the end of the last cycle of chemotherapy the study participants have to document all signs of discomfort or changes to their overall coenesthesia in the tablet-based questionnaire.
89540132|NCT04887363|No Intervention|Young adults group|The healthy young adults who have not any neurological, musculoskeletal or rheumatic disease were recruited as a reference group. They would not receive any training program in the study.
89540133|NCT03048435||Cervical Cancer Patients|Adult, English-speaking cervical cancer patients, who have been treated with curative intent chemo-radiotherapy.
89540134|NCT03048435||Oncologist|Oncologists who treat cervix cancer, with at least one consenting patient enrolled in the study.
89540135|NCT04880811|Experimental|Afatinib plus toripalimab|
89540136|NCT04880343|No Intervention|Group (C)|Control
89540137|NCT04880343|Experimental|Group (A)|Treatment
89540138|NCT04880343|Experimental|Group (B)|Treatment
89540139|NCT04412109|Active Comparator|injection of low volume of saline|low volume (5 cc) saline injection during thoracic epidural catheterization
89540140|NCT04412109|Active Comparator|injection of intermediate volume of saline|intermediate volume (10 cc) saline injection during thoracic epidural catheterization
89540141|NCT04412109|Active Comparator|injection of high volume of saline|high volume (20 cc) saline injection during thoracic epidural catheterization
89540142|NCT04886661||PATIENTS WITH CHRONIC NECK PAIN|Patients between the ages of 18-65 who are eligible for the inclusion criteria will be included in the study who have cervical X-RAY and cervical MRIs taken in the last 3 months.
89540143|NCT02181634|Experimental|Nab-Paclitaxel and Gemcitabine|Nab-Paclitaxel 125 mg/m² IV and Gemcitabine 1000 mg/m² on days 1, 8 and 15 every 28 days until progression or unacceptable toxicity.
89540144|NCT04879953||PIPAC CHEM|PIPAC associated with systemic chemotherapy
89540145|NCT04879953||ONLY CHEM|systemic chemotherapy alone
89540146|NCT04569045|Experimental|HA + Lidocaine|Sodium Hyaluronate with Lidocaine Hydrochloride
89540147|NCT04569045|Active Comparator|HA|Sodium Hyaluronate
89540148|NCT04887051|Experimental|telerehabilitation|pre-post telerehabilltation
89540149|NCT04425291|Experimental|4-valent HPV Vaccine|Participants in this arm would receive 4-valent Human Papillomavirus (Types 6, 11, 16 and18) Recombinant Vaccine (Hansenula Polymorpha)
89540150|NCT04425291|Experimental|9-valent HPV Vaccine|Participants in this arm would receive 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha)
89540151|NCT04425291|Active Comparator|GARDASIL®|Participants in this arm would receive GARDASIL®
89540152|NCT04879719|Experimental|Ego-depletion group|Participants in this condition are asked to suppress their emotion while watching an emotional video of a surgery. Suppressing the natural emotional reaction to such a video demands cognitive resources and thus can induce a state of ego-depletion.
89540153|NCT04879719|Active Comparator|Control group|Participants in the control group are asked to watch the same emotional video. However, they are required to simply watch the video without suppressing any emotions.
88958251|NCT01991717|Experimental|Victus Group|The anterior capsulotomy and lens fragmentation will be performed by means of femtosecond laser surgery
88958252|NCT01991717|Other|Conventional Group|The Conventional Group acts as a control group where the capsulotomy as well as the lens fragmentation is performed manually
88958253|NCT01991756||AAA|Subjects with a documented untreated, unruptured, infrarenal abdominal aorto-iliac aneurysm will be treated with the Altura Endograft System.
88958254|NCT01991769|Experimental|exercise diabetes type 2|4x4 min interval training, 47 min moderate intensity training, or no exercise preceding an 'unhealthy' meal.
88958255|NCT01991769|Active Comparator|exercise healthy volunteers|4x4 min interval training, 47 min moderate intensity training, or no exercise preceding an 'unhealthy' meal.
88958256|NCT01991782|No Intervention|Control|Control patients with all follow-up visits in person at the Vanderbilt Orthopaedic Trauma clinic (2 weeks, 6 weeks, 3 months, and 6 months post-operative).
88958257|NCT01991782|Experimental|Telemedicine|Experimental cohort with two follow-up visits (6 weeks and 6 months) occurring via telemedicine video calls and two follow-up visits (2 weeks and 3 months) occurring in person.
88958258|NCT01991834|Placebo Comparator|Placebo|Patients in this arm will receive intravenous sterile saline 30 minutes before the gynecologic laparoscopy.
88958259|NCT01991834|Active Comparator|Cefazolin|Patients in this arm will receive intravenous cephazolin 1g, 30 minutes before the gynecologic laparoscopy.
88958260|NCT01991847|Experimental|Physical activity|Physical activity
88958261|NCT01991886|Experimental|nasal High Flow applied|Application of nasal High Flow 6-7l/min via nasal prongs after birth using a mobile Vapotherm Precision Flow device
88958262|NCT01991899|Experimental|MMR Bio-Manguinhos|Arm 1:1170 children will receive MMR Bio-Manguinhos, 3 diferents lots
88958263|NCT01991899|Active Comparator|MMR GlaxoSmithKline|Arm 2:390 children will receive MMR GlaxoSmithKline
88958264|NCT01991912|Experimental|irrigation endoscopic decompression|endoscopic decompression is performed for cases of lumbar spinal stenosis.Portals 0.5cm in size are used for the introduction of the instruments and the endoscope. Saline under pump pressure is used to open a potential working space. This is followed by performing an ipsilateral hemilaminotomy and contralateral decompression under the midline structure
88958265|NCT01991938|Experimental|VS-5584|Oral VS-5584 administered once daily on Day 1, 3, 5, 8, 10, 12, 15, 17 and 19 of each cycle
88958266|NCT01991951|Experimental|Short term warfarin group|taking warfarin for only 2 weeks after catheter ablation of atrial fibrillation
89540154|NCT04879485|No Intervention|Standard transfusion|Includes standard transfusion with a mixture of red blood cells and plasma
89540155|NCT04879485|Active Comparator|Plasma|Transfusion with plasma
89540156|NCT04879485|Active Comparator|Red Blood cells|Transfusion with red blood cells
89540157|NCT04886193|Experimental|FLOT combined with PD-1|"The enrolled patients will receive 4 cycles of FLOT regimen + teriprizumab treatment before surgery Q2W.~If the transformation is successful, the patient undergoes R0 surgical resection of D2 lymph node dissection, and will continue to receive 4 cycles of FLOT regimen + Teripril after surgery. Anti-treatment, the treatment plan is the same as before.~After completing the 4 cycles of treatment, oral Tiggio Capsule (S-1) and Teriprizumab were maintained for 1 year."
89540158|NCT04878939|Experimental|Anterior segment retraction using sliding mechanics (friction)|Power chain
89540159|NCT04878939|Experimental|Anterior segment retraction using segmental mechanics (frictionless)|T-loop
88958267|NCT01991951|Active Comparator|Conventional therapy arm|conventional warfarin therapy of 3 weeks before and 8 weeks after catheter ablation of AF
89540160|NCT04879173||Hyperthyroidism caused by Graves' disease|
89540161|NCT04879173||Hyperthyroidism caused by painless/subacute thyroiditis|
89540162|NCT04878861|Experimental|Training in blind field|All participants undergo this intervention. Internal control is comparing sighted and non-sighted parts of the field.
89540163|NCT04337073|Placebo Comparator|normal saline (N) group|Before anesthesia induction, N group received corresponding intravenous normal saline of the same volume.
89540164|NCT04337073|Active Comparator|propofol (P) group|Before anesthesia induction, P group received intravenous injection of 0.3mg/kg propofol
89540165|NCT04275141|Other|Mauriac syndrome|An oral dose of glucose (labelled with 1% U-13C6-glucose) will be given at time 0 min followed by a 30-min cycling exercise at time 300 min.
89540166|NCT04275141|Other|Type 1 diabetes mellitus|An oral dose of glucose (labelled with 1% U-13C6-glucose) will be given at time 0 min followed by a 30-min cycling exercise at time 300 min.
89540167|NCT04886037||women with endometriosis|It consists of women between the ages of 18-45 who have been diagnosed with endometriosis by surgery or ultrasonography.
89540168|NCT04886037||control|It consists of healty women between the ages of 18-45
89540169|NCT03049995||CHEF:Cardiac Resynchronization therapy Forecast|Patients evaluated prior to cardiac resynchronization therapy (CRT), with class I, IIa or IIb for CRT according to ESC 2016 guidelines, and with ejection fraction ≤ 35% and QRS duration ≥ 130 ms. Contractile reserve will be assessed through variations in Wall Motion Score Index and with more advanced parameters such as left ventricular elastance reserve, as the peak stress/baseline ratio of end - systolic pressure/ end-systolic volume (Left ventricular contractile reserve SE). All patients will be followed-up with resting echocardiographic examination to assess left ventricular remodelling and recovery of function. A sample size of 277 patients is required and about the same number is required to predict the response to medical therapy in patients eventually not undergoing CRT (4).
89540170|NCT03049995||BHEF: B-lines in HEart Failure|B- lines are a semiquantitative sign of extravascular lung water present in 1 out of 3 HF patients at rest and in 1 out of 2 during stress, and potentially useful for refining prognostic stratification and titrating diuretic therapy in these patients. We will enroll patients referred to SE with known or suspected HF, with either reduced or preserved ejection fraction. B-lines will be detected using the B-lines SE intervention. A sample size of about 2500 patients is required if the effect on mortality is evaluated.
89540171|NCT03049995||SEHCA: SE in Hypertrophic Cardiomyopathy|Current guidelines recommend SE in hypertrophic cardiomyopathy (HC) solely for evaluation of left ventricular outflow tract obstruction. Large-scale registry data show that SE positivity for ischemic criteria rather than provocable gradients predict adverse outcome in HC. Low-to-intermediate risk symptomatic or asymptomatic HC patients will undergo exercise SE with assessment at each stage and during recovery of wall motion, mitral insufficiency, left ventricular outflow tract gradient (in orthostatic position)(following specific SE protocol), E/e', B-lines and, if feasible, coronary flow velocity reserve. A sample size of about 250 patients is required.
89540172|NCT03049995||SEDIA: SE in Diastolic Heart failure|Patients with suspected diastolic heart failure according to guidelines (3) will be selected (1).The diastolic assessment should be included into all exercise SE tests by measuring standard Doppler-derived mitral inflow velocity, pulsed Tissue Doppler of mitral annulus, and retrograde tricuspid gradient of tricuspid regurgitation as well as diastolic left ventricular volume index and B-lines (to provide a direct imaging of extra-vascular lung water accumulation as a direct cause of dyspnea). The test is considered positive for diastolic dysfunction when all of the following three conditions are met during exercise: average E/e' > 14 or septal E/e' ratio > 15, peak tricuspid regurgitant jet velocity >2.8 m/sec and septal e' velocity < 7 cm/s. A sample size of about 250 patients is required.
89540173|NCT03049995||SETA: SE in Transcatheter Aortic Valve implantation|Transcatheter Aortic Valve Implantation is an extraordinarily effective novel technology, and its short and long term morbidity and mortality remains significant. Patients with previous (from 6 months to 10 years) surgical or Transcatheter Aortic Valve Implantation capable of exercising will be enrolled and studied with semisupine SE. The full quantitative evaluation of mitral regurgitation and aortic stenosis will be performed. A sample size of about 100 patients is required to detect a significant stress-induced increase in mitral regurgitation severity. For the prognostic analysis 250 patients with 3 years follow-up are required.
89540174|NCT03049995||SEO: SE in Outdoor in Extreme conditions|SE can also be performed outdoors, with pocket size or portable instruments, in a setting of ecological stress entirely different from standard indoor testing. The diagnostic target is the early subclinical identification of pulmonary edema. Subjects involved in extreme sporting events (competitive triathlon, marathon, apnea diving etc) or ordinary exercise in extreme environments (trekking at high altitude) will undergo lung ultrasound scan for B-lines before, soon after (within 10 minutes) and (when positive) soon after, later after (6 to 24 h) the acute extreme exercise. A sample size of 80 patients is required to detect a significant stress-induced increase in B-lines in each of the three major study subgroups: high altitude trekkers (n=100); marathon runners (n=80) and apnea divers (n=70).
88958268|NCT01991964|Experimental|laryngeal ultrasound stridor|During the study period, infants referred for FLB and bronchoscopy due to congenital stridor at the Department of Pediatric Pulmonology, Critical Care and Sleep Medicine at the Tel Aviv Sourasky Medical Centre will undergo an awake US of the larynx prior to performing the Flexible bronchoscopy.
88958269|NCT01991964|Other|laryngeal ultrasound -control|Infants matched for age referred for flexible bronchoscopy for reasons other than stridor will undergo an awake US of the larynx.
88958270|NCT01992003||Patients undergoing spine surgery|
88958271|NCT01992029||ALS Patients|
88958272|NCT01992029||Control patients suffering from neuropathy|
88958273|NCT01992029||Control patients suffering from myopathy|
88958274|NCT01992029||Control subjects|control patients without any neurological disease having an orthopedic surgery for shoulder disease
88958275|NCT01992042|Experimental|Fluvastatin/Pimonidazole|Patients will take 40mg BID of fluvastatin. The day before surgery patients will take a single dose of pimonidazole that will be calculate based on body surface area.
89023995|NCT04021277|Experimental|Part 1a: ACT with chemotherapy in metastatic solid tumours|20 uL/kg or 40 uL/kg PS101 administered together with standard of care chemotherapy (FOLFOX or FOLFIRI) and ultrasound insonation over the targeted liver metastasis in patients with solid tumours
89206914|NCT05352165|Active Comparator|FOLFOX and standard long-term radiotherapy|FOLFOX and standard long-term radiotherapy based on organoids drug sensitivity
89206915|NCT05352165|Active Comparator|FOLFIRI and standard long-term radiotherapy|FOLFIRI and standard long-term radiotherapy based on organoids drug sensitivity
89508340|NCT02306785|Experimental|Formulation D|TP05 Coating D
89508341|NCT02306785|Experimental|Formulation E|TP05 Coating E
89508342|NCT02306785|Experimental|Formulation H|TP05 Coating H
89508343|NCT03148587|Experimental|Multi-level pregnancy test (MLPT)|Patients randomized to multi-level pregnancy test (MLPT) arm will receive MLPTs to perform at home one and two weeks after taking mifepristone. They will be asked to interpret the results of the MLPT as it relates to their pregnancy termination status.
89508344|NCT03148587|Experimental|Low sensitivity pregnancy test (LSPT)|Patients randomized to low sensitivity pregnancy test (LSPT) arm will receive LSPTs to perform at home at one and two weeks after taking mifepristone. They will be asked to interpret the results of the LSPT as it relates to their pregnancy termination status.
89508345|NCT02306863|Experimental|whole-body vibration|40 Hz Whole-body vibration applied via physioaccoustic method for 12 weeks, 3 times a week
89508346|NCT02306863|Sham Comparator|sham treatment|simulated whole-body vibration applied 3 times a week for 12 weeks
89508347|NCT03112239|Active Comparator|photobiomodulation by active LEDT|The subjects will be initially pre-evaluated by performing pulmonary function tests, peripheral muscle strength tests, functional capacity tests, physical activity questionnaires and clinical control of asthma, and cardiopulmonary exercise test. After the evaluation, patients will be randomized into two resistance training groups, one of them being associated to the intervention with active photobiomodulation by LEDT to increase peripheral muscle function post resistance training.
89508348|NCT03112239|Placebo Comparator|photobiomodulation by Placebo LEDT|The subjects will be initially pre-evaluated by performing pulmonary function tests, peripheral muscle strength tests, functional capacity tests, physical activity questionnaires and clinical control of asthma, and cardiopulmonary exercise test. After the evaluation, patients will be randomized into two resistance training groups, one of them being associated to the intervention with placebo LEDT photobiomodulation to increase peripheral muscle function post resistance training.
89508349|NCT02340741|Other|conventional prophylaxis of aeroembolism|"Procedure: cardiac surgery with opening of heart chambers.~Will be including 167 patients to undergo cardiac surgery. After the main operation phase all heart cavities are sealed, left vent drainage is stopped, ascending aorta is punctured and cardiac massage is performed, ventilation is started and the heart is filled with volume. Operating table is positioned in the Trendelenburg position, and aorta is opened. The amount of air in the cavities is evaluated by transesophageal echocardiography."
89508350|NCT02340741|Other|conventional prophylaxis plus CO2 insufflation|"Procedure: cardiac surgery with opening of heart chambers.~Will be including 167 patients to undergo cardiac surgery. After the main phase of the operation standard measures of aeroembolism prevention are carried out. The amount of air in the cavities is evaluated by transesophageal echocardiography."
89508351|NCT02299765|Experimental|Arm A|"Four cycles gemcitabine(d1,8 ) + carboplatin (d1) + gefitinib (15-25), gefitinib 250mg/d from d15 of last cycle until disease progression.~Gemcitabine=1000mg/m2;Carboplatin 5×AUC ; One cycle is 28 days"
89508352|NCT02299765|Active Comparator|Arm B|Gefitinib 250mg/d until disease progression
89508353|NCT03112395|Experimental|Combined SOC/Pio treatment|Prospective trial (1 month SOC, 2 month SOC + Pio Medical Device, 1 month SOC follow-up) month, with collection of endpoints every second week
89508354|NCT02299843|Active Comparator|ALPPS|Using ALPPS for the the treatment of hepatocellular carcinoma.
89508355|NCT02299843|Experimental|RALPPS|Using radiofrequency ablation instead of in-situ split of liver in ALPPS stage I（RALPPS）.Habib 4X was used in RFA.
89508356|NCT02340897||Nontuberculous lung disease|Patients with Nontuberculous Mycobacteria satisfying American Thoracic Society and British Thoracic Society guidelines
89508357|NCT02340897||pulmonary tuberculosis|Patients with culture confirmed tuberculosis
89508358|NCT02340897||bronchiectasis|Patients with bronchiectasis based on chest CT findings as well as symptoms
89519398|NCT03450655|Experimental|Control group|Weeks 1-10: no intervention. Weeks 11-20: no intervention. Weeks 21-31: exercise program at home.
89206916|NCT05352165|Active Comparator|5-FU and standard long-term radiotherapy|5-FU and standard long-term radiotherapy based on organoids drug sensitivity
89540175|NCT03049995||SETOF: SE in operated Tetralogy of Fallot|Patients with repaired Tetralogy of Fallot or Fallot-like pathology (double-outlet right ventricle Fallot type, tetralogy of Fallot with pulmonary atresia), evaluated at least 1 year after the last surgical or percutaneous procedure, will be recruited by regional reference centers for congenital heart disease. Additional inclusion criteria are age > 10 years, height > 140 cm, New York Heart Association class I or II. Right ventricular function will be assessed at baseline and peak stress with variations (rest and peak stress) of tricuspid annular plane systolic excursion. A sample size of about 250 patients is required to detect a significant stress-induced increase in tricuspid annular plane systolic excursion.
89540176|NCT03049995||DOSPAH: Doppler SE in Pulmonary Arterial Hypertension|Patients at risk, borderline, or early established pulmonary hypertension capable of exercising will be recruited by regional reference centers, a physical stress will be performed and the hemodynamic assessment will include the assessment of pulmonary hemodynamics. The primary positivity criteria are the increase in systolic pulmonary artery pressure (> 40 mmHg) and the flow-adjusted variation in pulmonary vascular resistances. A sample size of about 250 patients is required to detect a significant stress-induced hemodynamic changes with a 3 -year follow-up.
89540177|NCT03049995||DITSE: Diagnosis of CAD by imaging SE|"A clear step-up in diagnostic sensitivity (with a modest loss in specificity) and risk stratification capability is obtained with assessment of coronary flow velocity reserve in the left anterior descending coronary artery,left ventricular contractile reserve through changes in left ventricular elastance, and B-lines. Allcomers referred to the SE lab with suspected CAD will be evaluated with standard regional wall motion analysis and also - whenever feasible - with left ventricular coronary flow reserve and left ventricular elastance reserve and - when possible- B-lines (quadruple imaging).A sample size of about 5,000 patients will be required."
89540178|NCT03049995||GENES: Genetic Stress echocardiography|The identification of phenotype-negative and genotype positive carriers of pathologic mutations is an important, still elusive, target. We will initially select 75 patients (25 for each disease) with documented disease and mutant gene. We will enroll 250 first-degree relatives of the initially considered probands, with normal findings at rest and age range preferentially between 10 and 21 years. SE testing will be tailored on the specific question: hypertrophic cardiomyopathy as in protocol 3 (left ventricular outflow tract gradient); pulmonary hypertension as in protocol 8 (pulmonary vascular resistances);dilated cardiomyopathy as in protocol 1 (left ventricular elastance). A sample size of about 80 patients for each disease will be required.
89540179|NCT04138017|Experimental|ViviGen Cellular Bone Matrix|Patients will receive the vivigen cellular bone matrix
89540180|NCT04878705|Experimental|TWP-201|
89540181|NCT04878705|Placebo Comparator|placebo|
89540182|NCT04885803|Experimental|Nano Liquid D3|Arm receiving Nano Liquid Vitamin D3
89540183|NCT04885803|Active Comparator|Softgel D3|Group receiving Softgel Vitamin D3
89540184|NCT04885803|Placebo Comparator|Placebo Control|Liquid mixture, identical in process, taste, smell, and appearance to Nano Liquid D3, but containing no active ingredient (no Vitamin D3)
89540185|NCT04878237|Placebo Comparator|Non Allergic Patients|
89540186|NCT04878237|Active Comparator|Allergic Asthma Patients|Allergy to Grass Pollen
89540187|NCT04878237|Active Comparator|Allergic Rhinitis Patients|Allergy to Grass Pollen
89540188|NCT04878159||Emergency high-risk abdominal surgery|Patients undergoing emergency high-risk abdominal surgery, defined as immediate emergency laparoscopy or laparotomy, including intestinal obstruction, perforated viscus, intestinal ischemia and intraabdominal bleeding. Includes both primary surgery and re-operation after elective surgery.
89540189|NCT04395339|Experimental|Experimental arm(GM1)|This arm will be treated with GM1.
88816014|NCT02532933|Active Comparator|Anatomic Patella|Subjects with total knee arthroplasty using the DePuy Synthes Attune Posterior Stabilized Rotating Platform including patella resurfacing with an anatomic component geometry
89023996|NCT04021277|Experimental|Part 1b ACT with chemotherapy in metastatic CRC|20 uL/kg or 40 uL/kg PS101 administered together with standard of care chemotherapy (FOLFIRI) and ultrasound insonation over the targeted liver metastasis in patients with metastatic colorectal cancer
89206917|NCT05352165|Active Comparator|5-FU and pembrolizumab and standard long-term radiotherapy|5-FU and pembrolizumab and standard long-term radiotherapy based on organoids drug sensitivity
89206918|NCT05352165|Active Comparator|Other individualized treatments|Other individualized treatments based on organoids drug sensitivity
89206919|NCT02548260|Experimental|Syndactyly without compression|Relative immobilization with a syndactyly (CE conformity), no compression is worn.
89540190|NCT04395339|Placebo Comparator|Control arm|This arm will be treat with blank placebo.
88816015|NCT01123928|Experimental|Counseling|Subjects will be asked to watch a 5-10 min video and participate in a 10-15 min pre-operative counseling session with a trained nurse. Subjects will also participate in a 5 min post-operative counseling session.
88816016|NCT01123928|No Intervention|Non-counseling|
88816017|NCT02469597|Experimental|Single Dose of Furosemide|Furosemide 1 dose
88816018|NCT02469597|Placebo Comparator|Placebo|Normal saline 1 dose
88816019|NCT02183792|Experimental|Tolvaptan|Tolvaptan 30-60mg once daily (with rescue loop diuretic or metolazone)
88816020|NCT02183792|Active Comparator|Furosemide|Furosemide continuous infusion 5mg/h with option to titrate (with rescue metolazone)
88816021|NCT02533089|Experimental|KT intervention|Multifaceted KT strategy employing peer-trainer led educational outreach, a point of care reminder tool, and a peer mentoring network.
88816022|NCT02533089|No Intervention|Control|Control sites will receive no intervention, with LHW training left to the discretion of the health centers TB focus LHW. Control sites will not have access to the point of care tool.
88816023|NCT02533167|Experimental|skin to skin|skin to skin initiated on all consented CS while in the operating room
88816024|NCT02538783|No Intervention|Control|Participants will receive weekly tips and weekly feedback for months 1-6 and will be observed without intervention in Phase II (months 7-12). The weekly feedback will pertain to whether or not the participant met his/her goal of weighing at least 6/7 days. The weekly tips will give information and suggestions on how to make it easier to weigh-in most days of the week. No financial incentive other than for the midpoint and end of study surveys will be given.
89540191|NCT04391517|Experimental|Study Population|Included patients will be evaluated by an anaesthesiologist according to national and international guidelines as it is routine at the pre-operative clinic. In addition, all included patients will have their Hb measured non-invasively by a trained health care provider. SpHb values will be recorded in the documentation software already in use at the clinic.
89540192|NCT04877769|Experimental|AT-527 Group A|n=8
89540193|NCT04877769|Experimental|AT-527 Group B|n=8
89540194|NCT04877769|Experimental|AT-527 Group C|n=8
89540195|NCT03049059|Experimental|Fractional Picosecond 1,064 nm laser and 4% hydroquinone cream|
89540196|NCT03049059|Active Comparator|4% hydroquinone cream alone|
89540197|NCT03049137|Experimental|Computer Guided Stent Augmentation|Patients with defective maxillary anterior alveolar ridges requiring implant insertion will have simultaneous implant placement with ridge augmentation using autogenous bone ring graft covering them with Platelet-rich fibrin (PRF) using computer guided stent.
89540198|NCT03049137|Active Comparator|Free Hand Augmentation|Patients with defective maxillary anterior alveolar ridges requiring implant insertion will have simultaneous implant placement with ridge augmentation using Free hand simultaneous implant placement with ridge augmentation and covering them with Platelet-rich fibrin (PRF).
89540199|NCT03048591|Experimental|Electroacupuncture group|
89540200|NCT03048591|No Intervention|control group|
88958276|NCT01992055|Experimental|Goal Management Training|The modified GMT intervention will consist of seven group sessions and, similar to van Hooren et al (2007), an individual session with a neuropsychologist on Session 5. Sessions will be held twice weekly. The manualized group sessions will include: (1) structured psychoeducation introducing participants to the brain and executive functioning, the relationship between stress and cognitive functioning, and relaxation training; (2) stepwise learning of GMT, including education regarding attentional lapses and goal neglect, as well as in-session practice targeting individual everyday functional deficits with the goal of maximizing generalization. Homework assignments targeting individual functional deficits will be assigned following each session.
88958277|NCT01992055|Active Comparator|Education & relaxation training|Education and relaxation training control group
88958278|NCT01992068||Lung cancer patients ≥ 18 years of age|"Lung cancer patients age ≥ 18 years or older who have:~Histologically confirmed lung cancer scheduled to undergo conventionally fractionated radiation treatment~Absence of any severe disorders of esophageal motility (patients with reflux and/or a hiatal hernia are eligible)"
88958279|NCT01992081|Experimental|Telecoaching|Participants will receive daily coaching by an automated telehealth system and coaching by the investigator during study visits, in addition to the usual care.
88958280|NCT01992081|Other|Control|Participants will receive the usual care but will NOT receive daily coaching by telehealth system.
88958281|NCT01992120|Experimental|Debriefing of high-fidelity sepsis simulation scenarios|"First visit:~Subjects will fill out a self-assessment focusing on perceptions of their knowledge and ability in the recognition and management of sepsis in hospitalized patient~Subjects will be specifically exposed to high-fidelity simulated sepsis scenarios and be debriefed on their performance in these scenarios (intervention)~Subjects will take a written test focusing on early recognition and management of sepsis~Subjects will receive a didactic teaching session focusing on recognition and management of early sepsis in the hospitalized patient~In the second visit:~Subjects will be exposed to a number of high-fidelity simulated sepsis scenarios and be scored on their performance in management of these scenarios~Subjects will take a written test of knowledge focusing on early recognition and management of sepsis~Subjects will then be debriefed specifically on their performance in the simulation scenarios"
88958282|NCT01992120|Placebo Comparator|Debriefing of high-fidelity non-sepsis simulation scenarios|"First visit:~Subjects will fill out a self-assessment survey of their perceptions of their knowledge and ability in the recognition and management of sepsis in the hospitalized patient~Subjects will be exposed to high-fidelity simulation scenarios (non-sepsis) and be debriefed in terms of their performance in these scenarios~Subjects will take a written test of knowledge focusing on early recognition and management of sepsis~Subjects will receive a didactic teaching session focusing on recognition and management of early sepsis in the hospitalized patient~In the second visit:~Subjects will be exposed to a number of high-fidelity simulated sepsis scenarios and be scored on their performance in management of the scenarios~Subjects will take a written test of knowledge focusing on early recognition and management of sepsis~Subjects will then be debriefed specifically on their performance in the simulation scenarios"
88958283|NCT01992133|Experimental|Vitamin D3|Vitamin D3 at 4000 iu per day for 6 months
89540201|NCT04885413|Experimental|study arm|Sintilimab： 200mg i.v., d1, 21days one cycle Niraparib： 200mg p.o qd，d1-d21, 21days one cycle
89540202|NCT03049293|No Intervention|Control group using Propofol|Sedation will be established by administering 100mcs of Fentanyl, and 1-1.5mg/kg of body weight of Propofol.
89540203|NCT03049293|Experimental|Study group Midazolam group|Sedation will be established by administering Midazolam 1mg, 100mcs of Fentanyl, and 0.5-1mg/kg of body weight of Propofol. Further boluses of Propofol will be given according to the need of the patient and time consumed for oocyte retrieval.
88958284|NCT01992133|Placebo Comparator|Placebo|matching placebo- capsules containing soya oil at 4 capsules a day for 6 months
89540204|NCT04872075|Experimental|Experimental|People at the concert
89540205|NCT04872075|Active Comparator|Control|People staying at home
89540206|NCT01595529|Experimental|Active treatment|5 days of active therapy to match the physician-initiated therapy, Trimethoprim sulfamethoxazole, Cefixime or Cefdinir or Cephalexin (subjects originally receiving Cefdinir will receive Cefixime)
89540207|NCT01595529|Placebo Comparator|Placebo treatment|5 days of placebo treatment to match physician-initiated therapy
89540208|NCT04411017|Active Comparator|1L PEG|
89540209|NCT04411017|Active Comparator|2L PEG|
89540210|NCT04411017|Active Comparator|2L sodium picosulfate|
89540211|NCT04410705|Experimental|Tendinopathy patients|Patients with tendinopathy will be administered ESWT
89540212|NCT04368507|Experimental|YYB101+Irinotecan|"b (Dose level 0 cohort): YYB101 20mg/kg, Irinotecan 150 mg/m2 of each dose level, IV infusion on Day 1, Day15, and followed by every 2 weeks~a Stage 1: YYB101 RP2D, Irinotecan 150 mg/m2 of each dose level, IV infusion on Day 1, Day15, and followed by every 2 weeks"
89540213|NCT04871841||Sputnik V Vaccinees|Participants (healthy adults aged >=18) will receive rAd26-S prime at day 0 and rAd5-S boost at day 21.
89540214|NCT04871685||Covid Center UOC Vanvitelli, Naples|Patients hospitalized due to Sars-Cov-2 disease either in emergency or ordinary medicine/intensive care units
89540215|NCT04871685||Covid Center Cotugno Hospital, Naples|Patients hospitalized due to Sars-Cov-2 disease either in emergency or ordinary medicine/intensive care units
89540216|NCT04871685||"Covid Center Del Mare Hospital, Naples"|Patients hospitalized due to Sars-Cov-2 disease either in emergency or ordinary medicine/intensive care units
89540217|NCT04871685||Covid Center Santa Maria delle Grazie Hospital, Pozzuoli|Patients hospitalized due to Sars-Cov-2 disease either in emergency or ordinary medicine/intensive care units
89540218|NCT04871685||Covid Center Monaldi Hospital, Naples|Patients hospitalized due to Sars-Cov-2 disease either in emergency or ordinary medicine/intensive care units
89540219|NCT04871685||Covid Center Vannini Hospital, Rome|Patients hospitalized due to Sars-Cov-2 disease either in emergency or ordinary medicine/intensive care units
89540220|NCT04871685||Covid Center Bassini Hospital, ASST Milano Nord|Patients hospitalized due to Sars-Cov-2 disease either in emergency or ordinary medicine/intensive care units
89540221|NCT04871685||Covid Center Melfi Hospital|Patients hospitalized due to Sars-Cov-2 disease either in emergency or ordinary medicine/intensive care units
89540222|NCT04871685||Covid Center Messina University Hospital|Patients hospitalized due to Sars-Cov-2 disease either in emergency or ordinary medicine/intensive care units
89540223|NCT04870983||SAE group|SAE was defined as cerebral dysfunction in the presence of sepsis or septic shock and the absence of any of the exclusion criteria. For patients undergoing sedation during the ICU stay, the GCS scores were evaluated before sedation; for patients who have been sedated prior to ICU admission, the assumed GCS scores, i.e., the scores measured before any administration of sedative/relaxant drug were used for analysing; for postoperative patients, the GCS scores measured before surgery was used. The CAM-ICU was assessed daily by the nurse or the physician in charge of the patient during the ICU stay. For patients who were sedated, spontaneous awakening trials were performed daily; the longest evaluate time after withdrawal of sedation was 24 h during the trials. In this evaluation period, patients should be awake to evaluate their consciousness, and they were diagnosed of SAE if the patients were not awake.
89540224|NCT04870983||non-SAE group|The patient was diagnosed with sepsis or septic shock but could not be diagnosed with SAE
89540225|NCT05257395|Experimental|XZP-3287+ Letrozole/Anastrozole|
89540226|NCT05257395|Placebo Comparator|Placebo + Letrozole/Anastrozole|
89540227|NCT05257317|Experimental|Intervention|It will consist of osteopathic manual therapy techniques applied to the occipital and temporal bones.
89540228|NCT05257317|Placebo Comparator|Placebo|It consists of a light contact applied to the cranial vault (frontal and parietal bones) where circular movements will be induced.
89540229|NCT05257161|Active Comparator|Emboshield NAV6™ Embolic Protection System + CGuard™ (The CGuardTM Embolic Prevention System (EPS))|183 Carotid stenting (Emboshield NAV6™ Embolic Protection System + CGuard™ (The CGuardTM Embolic Prevention System (EPS))
89540230|NCT05257161|Experimental|MO.MA Proximal Cerebral Protection Device+ CGuard™ (The CGuardTM Embolic Prevention System (EPS)|183 Carotid stenting (MO.MA Proximal Cerebral Protection Device+ CGuard™ (The CGuardTM Embolic Prevention System (EPS))
89540231|NCT05256693|Experimental|Vancomycine|Oral vancomycine 125 mg twice a day, from inclusion (at the time of hospitalization for allogeneic stem cell transplant) until hospital discharge or 5 weeks in hospital at most.
89540232|NCT05256693|Placebo Comparator|Placebo|Vancomycine placebo, twice a day, from inclusion (at the time of hospitalization for allogeneic stem cell transplant) until hospital discharge or 5 weeks in hospital at most.
89540233|NCT03046953|Experimental|Avleumab|Avelumab 10mg/kg by IV infusion once every 2 weeks. A maximum of 8 cycles, each cycle is 28 days.
89540234|NCT00964977|No Intervention|no irradiation|Patients within this arm only receive curative intended radical surgery
89540235|NCT00964977|Active Comparator|Radiation|Patients receive radiation within 6 weeks after curative intended radical surgery.
89540236|NCT04877925|Active Comparator|Standard Group|Patients with 2 standard chest tubes
89206920|NCT02548260|Experimental|Syndactyly with compression|Relative immobilization with a syndactyly (CE conformity), compression (CE conformity) is worn over the finger
89540237|NCT04877925|Experimental|Coaxial Group|Patients with 1 coaxial tube
89540238|NCT03048903|Experimental|Rheum Palmatum Root|Rheum Palmatum Root is commercially certified rhubarb(Rheum palmatum ,Sichuan origin, provided by the pharmacy of my hospital)
89540239|NCT03048903|Placebo Comparator|Starch Corn|Medical Starch is harmless to people
89540240|NCT03047109|Active Comparator|Group P|Patients will receive Phenylephrine 30 µg/minute by syringe pump infusion for 30 minutes.
89540241|NCT03047109|Active Comparator|Group E|Patients will receive Ephedrine 3 mg/ minute by syringe pump infusion for 30 minutes.
89540242|NCT03047265|Experimental|Paclitaxel|Paclitaxel plus Cisplatin combine with IMRT
89540243|NCT03047265|Active Comparator|Cisplatin|Cisplatin combine with IMRT
89540244|NCT03047343||Uni-ventricular reparation|All patients treated with pulmonary artery strapping between 2005 and 2016 at the Queen Fabiola Children Hospital. Patients benefiting from an uni-ventricular reparation.
89540245|NCT03047343||Bi-ventricular reparation|All patients treated with pulmonary artery strapping between 2005 and 2016 at the Queen Fabiola Children Hospital. Patients benefiting from an bi-ventricular reparation.
89540246|NCT04871373|Experimental|Experimental group|A trained periodontist delivered oral hygiene instructions and motivational interviewing sessions. All the participants received a G.U.M. kit with special orthodontic hygiene tools.
89540247|NCT04871373|Active Comparator|Control group|A trained periodontist delivered only oral hygiene instructions. All the participants received a G.U.M. kit with special orthodontic hygiene tools.
89540248|NCT05256147|Experimental|Intervention group|There is one group in this study and they will receive ibuprofen 400 mg before their narrow band UVB phototherapy session which occurs two to three times weekly. The treatment dose of NBUVB will start off at 150 mJ/cm2 and will be increased 10% as tolerated til the patient reaches 700 mJ/cm2. They will receive ibuprofen before each phototherapy session.
89540249|NCT04877067|Active Comparator|WJ-MSC combine witf rEMS|WJ-MSC was applied first to the patients after necessary preparations. rEMS application was started 10 days after WJ-MSC application.
89540250|NCT04877067|Active Comparator|Only rEMS|rEMS applications were repeated 10 times with a 1-week interval.
88958285|NCT01992198|Experimental|cefoperazone + metronidazole|cefoperaozone 2g q8h + MDZ 0.5g q8h Oral care Somatostatin 3-6mg per 24h enteral nutrition
89508359|NCT03510559|Active Comparator|Brachial Plexus Block|It will be at the discretion of the anesthesiologist performing the block to choose a supraclavicular, infraclavicular or axillary block to achieve adequate surgical anesthesia of the operative arm. After sterile skin preparation with chlorhexidine, a linear array transducer probe is placed on the skin and the appropriate nerve structures are identified. Local anesthetics (30 mL of 50:50 mix of 0.5% bupivacaine and 2% lidocaine) will then be injected in 5 mL aliquots after negative aspiration for blood to achieve circumferential spread around the brachial plexus. Patients who have a failed brachial plexus block may undergo a rescue forearm block, and will be recorded as requiring supplemental local anesthetic.
89508360|NCT03510559|Experimental|Forearm Nerve Block|Patients allocated to the forearm block will have it performed in the semi-setting position. After sterile skin preparation with chlorhexidine and infiltration with 1 mL of 1% lidocaine, a linear array transducer probe is placed at the distal forearm to visualize each peripheral nerve (radial, ulnar, median, and lateral antebrachial cutaneous). A 5 cm 22 G insulated needle is then used to target each nerve individually and infiltrate 7.5mL of the 50:50 mixture (similar to the brachial plexus block group) at each nerve to a total of 30mL.
89508361|NCT04771923|Experimental|Tranexamic acid|
89508362|NCT04771923|Experimental|Adrenaline|
89508363|NCT02306941|Experimental|Internet-delivered CBT|10 sessions of ICBT during 10 weeks for the adolescents. 5 session of parent training during 10 weeks for parents. Therapist support is provided at least once weekly through the platform developed for the purpose. Therapists are trained CBT-psychologists.
89508364|NCT04631549|Experimental|Healthy participants|Intervention: Drug: SHR3680 single dose
89508365|NCT04631549|Experimental|Mild liver impairment|Intervention: Drug: SHR3680 single dose
89508366|NCT04631549|Experimental|Moderate liver impairment|Intervention: Drug: SHR3680 single dose
89508367|NCT02303275|Other|Lifestyle Change|Lifestyle Change
89508368|NCT02307019|Experimental|Program on specific prevention of health|The caregivers will be randomly assigned to an experimental group, to receive the program on specific prevention of health. The workshop will be performed twice a month, two hours a day, during a 4-week period.
89508369|NCT02307019|Active Comparator|Program on general prevention of health|Control group will receive an intervention by mean of a general health program to manage the common situations when a caregiver is caring for a patient with dependency. The workshop will be performed two a month, two hours a day, during a 4-week period.
89508370|NCT04616573|Active Comparator|Ab-interno transluminal viscoelastic delivery with trabeculotomy using OMNI surgical System|Ab-interno transluminal viscoelastic delivery with trabeculotomy using OMNI surgical System
89508371|NCT04616573|Active Comparator|Ab-interno transluminal viscoelastic delivery using OMNI surgical System|Ab-interno transluminal viscoelastic delivery using OMNI surgical System
89508372|NCT04616573|Active Comparator|iStent Inject implantation|iStent Inject implantation using the iStent device
89508373|NCT02300155|Experimental|PregVit®|Women will be randomized to the '35 mg' group, who will start supplementation with PregVit® (low iron content, small size)
89508374|NCT02300155|Active Comparator|Orifer F®|Women will be randomized to the '60 mg' group, who will start supplementation with Orifer F® (high iron content, small size).
89508375|NCT03510403|Experimental|Device : nasal airway stent|Patients with OSA or snoring use the nasal airway stent nastent™ each night for sleeping. The device is a tube-shaped medical device that is inserted from the nose and the tip of the tube reaches the soft palate. The inserted tube aids breathing by preventing the obstruction of the airway which causes poor sleep, frequent awakening during sleep and snoring.
89508376|NCT02234765|Active Comparator|Sleep Unit|Patients diagnosed and followed up in the Sleep Unit.
89508377|NCT02234765|Experimental|Primary Care|Patients diagnosed and followed up in the Primary Care.
89508378|NCT03513133|Experimental|working memory training|Patients with severe TBI will receive a hierarchical training of working memory according to a previously described methodology. They will receive 3 sessions per week during three months (each session=1 h approximately)
89508379|NCT05254899|Experimental|Inductive and concurrent anti-PD-1 antibody combined with chemo-radiotherapy|All the enrolled patients receive 3 cycles of anti-PD-1 antibody (Tislelizumab 200mg d1) + P-GEMOX (Pegaspargase 3000u d2, Gemcitabine 1g/m2 d2, Oxaliplatin 85mg/m2 d2) systemic treatment every 14 days, followed by involved-site radiotherapy with concurrent anti-PD-1 antibody (Tislelizumab 200mg) every two weeks.
89508380|NCT02307097|Experimental|CBB|
88958286|NCT01992198|Active Comparator|meropenem|Meropenem 0.5g q6h or adapted with renal function. Oral care Somatostatin 3-6mg per 24h enteral nutrition
88958287|NCT01992211|Experimental|Treatment Sequence 1(ABC)|"Participant will be co-administered a single oral dose of Rosuvastatin 10mg and Metformin SR 1000mg under Fed condition on 1Day.~Participant will be administered a single oral dose of BCWP_C003 under Fasting condition on 8Day.~Participant will be administered a single oral dose of BCWP_C003 under Fed condition on 15Day."
88958288|NCT01992211|Experimental|Treatment Sequence 2(ACB)|"Participant will be co-administered a single oral dose of Rosuvastatin 10mg and Metformin SR 1000mg under Fed condition on 1Day.~Participant will be administered a single oral dose of BCWP_C003 under Fed condition on 8Day.~Participant will be administered a single oral dose of BCWP_C003 under Fasting condition on 15Day."
89508381|NCT02307097|Experimental|CBT|
89508382|NCT02307097|Active Comparator|WAIT|
89508383|NCT03148509|Experimental|bupropion|receive bupropion
89508384|NCT03148509|Experimental|risperidone|receive risperidone
89508385|NCT03148509|Experimental|aripiprazole|receive aripiprazole
89508386|NCT03148431|Experimental|LY3002815|Escalating doses of LY3002815 administered intravenously (IV) once in healthy participants
89508387|NCT03148431|Placebo Comparator|Placebo|Placebo administered IV once in healthy participants
89508388|NCT04464343||Posterior cruciate ligament injury group|According to the previous clinical diagnosis, volunteers who has never suffered the Posterior cruciate ligament injury.
89508389|NCT04464343||normal control group|According to the previous clinical diagnosis, volunteers who has never suffered the lower extremity sports injuries.
89508390|NCT02039271|No Intervention|Standard of Care|Subjects will receive standard post-operative care after total knee replacment surgery
89508391|NCT02039271|Experimental|Music Therapy|Subjects will receive music therapy in addition to standard post-operative therapy.
89508392|NCT02307175||Cyclotec|The first 10 consecutively enrolled patients will have thyroid and whole body scan with CycloTec
89508393|NCT02307175||generator produced Tc99m-pertechnetate|20 subsequent case-matched controls will have thyroid and whole body scan with conventional Tc99m-pertechnetate
89508394|NCT05254665|Experimental|Docetaxel Polymeric Micelles for Injection|Docetaxel Polymeric Micelles for Injection
89508395|NCT03513055|Experimental|inject premixed insulin|patients inject premixed insulin themselves then nurse inject premixed insulin
89508396|NCT03148353|Experimental|Modified subacromial injection|"Intervention procedure: corticosteroid injection into the subacromial bursa and biceps tendon~Device for guidance: high-resolution ultrasound~Drug: 40 mg triamcinolone acetonide (a kind of corticosteroid)~Intervention procedure: lidocaine injection into the subacromial bursa and biceps tendon~Device for guidance: high-resolution ultrasound~Drug: 3 mL of lidocaine (the medication will be mixed with 40 mg triamcinolone acetonide)"
89508397|NCT03148353|Placebo Comparator|Standardized subacromial injection|"Intervention procedure: corticoseroid injection into the subacromial bursa only~Device for guidance: high-resolution ultrasound~Drug: 40 mg triamcinolone acetonide (a kind of corticosteroid)~Intervention procedure: lidocaine injection into the subacromial bursa only~Device for guidance: high-resolution ultrasound~Drug: 3 mL of lidocaine (the medication will be mixed with 40 mg triamcinolone acetonide)"
89508398|NCT03512977|Experimental|Sphenopalatine Ganglion Block Group|patients will be performed transnasal sphenopalatine block and conservative treatment ( iv hydration, analgesic agents, caffeine or theophylline)
89508399|NCT03512977|Active Comparator|Standard Treatment Group|patients will receive standard supportive treatment ( Conservative treatments are iv hydration, analgesic agents, caffeine or theophylline)
89508400|NCT03148119|Experimental|Topical QRH Heptapeptide Administration|
89508401|NCT03132727||Pharyngo laryngeal MRI|Patient with a laryngeal or hypopharyngeal cancer at any stage, with a doubt about cartilage invasion and eligible for surgical treatment for which there is an indication for performing an MRI in addition to CT at the discretion of the investigator
89508402|NCT02336919|Experimental|Txt2Prevent|The treatment group will receive all the usual discharge treatment, instructions and information for acute coronary syndrome patients as well as the Txt2Prevent text-messaging program. The program will include a variety of topics such as standard follow-up care reminders as well as general self-management and healthy living texts. There will be two streams, one for current/recent smokers and one for non-smokers. Texts will be sent out every 1-3 days for 60 days. All participants in the same stream will receive the same texts in the same order.
89508403|NCT02336919|No Intervention|Usual Care|The usual care group will receive all standard discharge treatment, instructions and information for patients with acute coronary syndrome, but no text-messaging program. Nurses typically go over important information with patients before they leave as well as give them printed materials.
89508404|NCT02349009|Placebo Comparator|placebo|C-82 Topical Gel, Placebo
89508405|NCT02349009|Active Comparator|Active|C-82 Topical Gel, 1%
89508406|NCT03507205||HOST-BIOLIMUS-Korea-3000|Active prospective registration of patients receiving biodegradable polymer-coated biolimus-eluting stents (BP-BES; Biomatrix, Biomatrix Flex, Nobori)
89508407|NCT03507205||EXCELLENT-PRIME|Active prospective registration of patients receiving durable polymer-coated everolimus-eluting stents (DP-EES; Xience Prime)
89508408|NCT03507205||EXCELLENT Prospective cohort|Active prospective registration of patients receiving durable polymer-coated everolimus-eluting stents and sirolimus-eluting stents (Xience V/Promus; Cypher)
89508409|NCT03507205||HOST-RESOLINTE|Active prospective registration of patients receiving durable polymer-coated zotarolimus-eluting stents (DP-ZES-RI; Resolute Integrity)
89508410|NCT03507205||RESOLUTE-Korea|Active prospective registration of patients receiving durable polymer-coated zotarolimus-eluting stents (DP-ZES; Endeavor; Resolute)
89508411|NCT03507439|Experimental|HFrEF|Participants with established diagnosis of heart failure with reduced ejection fraction (HFrEF; EF ≤ 35%) wore the AVIVO MPM System or VitalPatch biosensor for 5 monitoring periods with patches applied on Day 0, 9, 16, 77 and 84; and the DynaPort Move Monitor belt for 2 monitoring periods with belts applied on Day 9 and Day 77.
89508412|NCT03507439|Experimental|HFpEF|Participants with established diagnosis of heart failure with preserved ejection fraction (HFpEF; EF ≥ 45%) wore the AVIVO MPM System or VitalPatch biosensor for 5 monitoring periods with patches applied on Day 0, 9, 16, 77 and 84; and the DynaPort Move Monitor belt for 2 monitoring periods with belts applied on Day 9 and Day 77.
89508413|NCT03148197||Admitted for allogeneic HSCT|Patients admitted for performance of an allogeneic HSCT after high dosis chemotherapy.
89508414|NCT03148197||First diagnosis AML|Patients admitted with a first diagnosis of an acute myeloid leukemia for chemotherapy. Depending on factors like age or molecular risk profile some of these patients will proceed to allogeneic HSCT.
89508415|NCT03510325|Experimental|Olanzapine|dosage form:po dosage:5-20mg frequency:qn duration:If the drug is effective, it can be taken for a long time. If the drug is ineffective or the side effect is too difficult to tolerate, the drug should be changed according to the treatment stage.
89508416|NCT03510325|Experimental|Risperidone|dosage form:po dosage:4-6mg frequency:2 doses duration:If the drug is effective, it can be taken for a long time. If the drug is ineffective or the side effect is too difficult to tolerate, the drug should be changed according to the treatment stage.
89508417|NCT03510325|Experimental|Amisulpride|dosage form:po dosage:0.4-1.2g frequency:2 doses duration:If the drug is effective, it can be taken for a long time. If the drug is ineffective or the side effect is too difficult to tolerate, the drug should be changed according to the treatment stage.
89023999|NCT03999827|Experimental|Immediate Diet Group|Adhere to Low Glycaemic Index diet for 52 weeks, beginning immediately after randomisation.
89024000|NCT03999827|Active Comparator|Delayed Diet Group|Adhere to Low Glycaemic Index diet for 52 weeks, beginning 12 weeks after randomisation.
89024001|NCT03998020|Other|chronic sleep disorders|Subjects with chronic sleep disorders responsible of hypersomnolence measured by a scale of severity of sleep disorder, and blood parameters (blood sample)
89206921|NCT02548260|Experimental|Rigid splint without compression|Rigid immobilization with a custom made thermoplastic splint (CE conformity), no compression is worn
89508418|NCT03510325|Experimental|Aripiprazole|dosage form:po dosage:15-30mg frequency:qd duration:If the drug is effective, it can be taken for a long time. If the drug is ineffective or the side effect is too difficult to tolerate, the drug should be changed according to the treatment stage.
89508419|NCT03510325|Experimental|Paliperidone long-acting injection|dosage form:im dosage:75-150mg frequency:once a month duration:If the drug is effective, it can be taken for a long time. If the drug is ineffective or the side effect is too difficult to tolerate, the drug should be changed according to the treatment stage.
89508420|NCT02337075|Experimental|Now Group - PATH Program|The Now Group will receive the PATH program. They will participate in a brief education session, use a wearable physical activity tracker, and physical activity mentoring by an Activity Mentors. In Month 1 and 2, participants will meet with their Activity Mentor once every 2 weeks to review their physical activity status, activity goals, and the health programs available at the Centre. In Month 3 and 4, they will continue to use physical activity tracker but will no longer have regular meetings with the Activity Mentor.
89508421|NCT02337075|Active Comparator|Later Group|The Later Group will receive the PATH program in Month 1-2. Intervention will be provided two months later (i.e., Month 3 and 4).
89508422|NCT03507127|Active Comparator|Varenicline|
89508423|NCT03507127|Placebo Comparator|Placebo|
89508424|NCT02340351|Active Comparator|Auricular acupuncture|Within this arm, patients were treated with auricular acupuncture according to the NADA protocol. Each setting involved not more than eight patients at a time and was performed in a sitting position. Each session lasted 30 minutes and took place twice a week over a period of 4 weeks.
89508425|NCT02340351|Active Comparator|Progressive muscle relaxation|Within this arm, patients were treated with who chose treatment with progressive muscle relaxation. Each setting involved not more than eight patients at a time and was performed in a sitting position. Each session lasted 30 minutes, took place twice a week over a period of 4 weeks.
89508426|NCT02307409||Decompensated Chronic Liver Disease|Decompensated Chronic Liver Disease patients will be enrol
89508427|NCT02307409||Healthy Controls|Healthy Controls will be enrol
89508428|NCT02336841|Experimental|Intervention|Participants in this condition will receive the guided self-help intervention.
89508429|NCT02336841|Active Comparator|Control|Participants in this condition will not receive the guided self-help intervention. They will receive treatment as usual and weekly feedback on their eating disorder symptoms for a period of 6 weeks.
89508430|NCT03512821|Experimental|Ursodiol 500mg tablets|Ursodiol 500mg tablets followed by Urso Forte 500mg tablets
89508431|NCT03512821|Active Comparator|Urso Forte 500mg tablets|Urso forte 500mg tablets followed by Ursodiol 500mg tablets
89508432|NCT02336529|Experimental|ICBN, active|Ultrasound guided injection of bupivacain, 10mL, 0.5% in proximity of the ICBN
89508433|NCT02336529|Placebo Comparator|ICBN, placebo|Ultrasound guided injection of NaCl, 10mL in proximity of the ICBN
89508434|NCT02336529|Experimental|Tenderpoint, active|Ultrasound guided injection of bupivacain, 20mL, 0.25% in the tenderpoint
89508435|NCT02336529|Placebo Comparator|Tenderpoint, placebo|Ultrasound guided injection of NaCl, 20mL in the tenderpoint
89508436|NCT02303353||Cancer patients|Patients suffering from a carcinoma (either breast, ovarian, lung, colon, stomach, pancreas, rectum or plasmacytoma)
89508437|NCT04658433|Experimental|n-3FA group|Dietary Supplement: 1,000 mg of wild salmon and fish oil complex once daily, which contains 300 mg of omega3-FA for 8 weeks.
89508438|NCT04658433|No Intervention|Control group|
89508439|NCT02307487|Experimental|Cohort A2|120 mg MMC in 90ml gel
89508440|NCT02307487|Experimental|Cohort B2|140 mg MMC in 90ml gel
89508441|NCT02307487|Experimental|Cohort C2|160 mg MMC in 90ml gel
89508442|NCT02307487|Experimental|Cohort A|120 mg MMC in 60ml gel
89508443|NCT02307487|Experimental|Cohort B|140 mg MMC in 60ml gel
89508444|NCT02307487|Experimental|Cohort C|160 mg MMC in 60ml gel
89508445|NCT03148041|Active Comparator|intensive health education program|Participants in the intervention group will have an intensive health education program of the introductory lecture and brochures about stroke as well as they fill up the questionnaire at baseline. At week 6 and 12 of the study the participants will only fill up the questionnaire.
89508446|NCT03148041|Placebo Comparator|routine care|Participants in the control group will have a routine care of different lecture and brochures than the intervention group as well as they fill up the questionnaire at baseline. At week 6 and 12 of the study the participants will only fill up the questionnaire.
89508447|NCT02307565|Experimental|Midodrine|Arm 1 last 30 days. Subject will either be given midodrine or placebo to take during Arm 1.
89508448|NCT02307565|Placebo Comparator|Placebo|Arm 2 is followed by a 14 day washout period. Arm 2 last 30 days. Subject will be given a drug (placebo or midodrine) to take during Arm 2.
89508449|NCT02340429|Experimental|video otoscopy|children under 18y admitted to the pediatric emergency room for any reason, will undergo video otoscopy
89508450|NCT02340429|No Intervention|standard otoscopy|children under 18y admitted to the pediatric emergency room for any reason, undergoing routine otoscopy
89508451|NCT02307643|Experimental|Part 1|MT-1303 Low dose+Corticosteroid
89508452|NCT02307643|Experimental|Part 2-A|MT-1303 High dose+Corticosteroid
89508453|NCT02307643|Experimental|Part 2-B|MT-1303 Low dose+Corticosteroid+Immunosuppressant
89508454|NCT02348931|Active Comparator|Surgery plus device (Nasella)|Person in need of surgery has cast for one week, then use of customized nasal brace for nose (Nasella) deformities during 8 weeks.
89508455|NCT02348931|Experimental|Surgery, no device thereafter|Person in need of surgery has cast for 1 week; thereafter no use of customized nasal brace (Nasella) .
89508456|NCT02348931|Active Comparator|Only device (Nasella)|No need for surgery; use of customized nasal brace (Nasella) for nose deformities is made to improve look (cosmetic reason).
89508457|NCT05253885||Smartphone addiction group|
89508458|NCT02300389|Experimental|Hypofractionated IMRT boost radiotherapy|All patients included into this arm are irradiated to 46 Gy a 2 Gy fraction to the whole pelvis and seminal vesicles and prostate gland (I phase) and than the boost dose is limited to the prostate gland with some part of seminal vesicles with hypofractionated dose of 7.5 Gy in two fractions (II phase) to the total dose of 61 Gy. Additionally all patients received neoadjuvant Androgen Deprivation Therapy (3-4 months prior starting radiotherapy) and during radiotherapy and during the follow-up up to 24 months.
88958289|NCT01992211|Experimental|Treatment Sequence 3(BAC)|"Participant will be administered a single oral dose of BCWP_C003 under Fasting condition on 1Day.~Participant will be co-administered a single oral dose of Rosuvastatin 10mg and Metformin SR 1000mg under Fed condition on 8Day.~Participant will be administered a single oral dose of BCWP_C003 under Fed condition on 15Day."
89508459|NCT02300389|Active Comparator|Conventional Fractionated IMRT boost radiotherapy|All patients included into this arm are irradiated to 46 Gy a 2 Gy fraction to the whole pelvis and seminal vesicles and prostate gland (I phase) and than the boost dose is limited to the prostate gland with some part of seminal vesicles with conventional fractionated dose of 2 Gy in 15 fractions (II phase) to the total dose of 76 Gy. Additionally all patients received neoadjuvant Androgen Deprivation Therapy (3-4 months prior starting radiotherapy) and during radiotherapy and during the follow-up up to 24 months.
89508460|NCT02348853|Experimental|Healthy Weight For Living (HWL)|HWL is a behavioral intervention designed to effectively facilitate hunger suppression with several concurrent approaches. Hunger suppression is a core behavioral goal of the intervention, and strategies will be used to support that goal, for example increasing meal frequency and encouraging the use of highly satiating low-energy foods to reduce hunger acutely. A unique combination of healthy dietary goals will be recommended that support hunger suppression and/or maintenance of satiety: high total dietary fiber, moderately high protein, moderately low glycemic load (GL) and low energy density.
89508461|NCT02348853|Experimental|Current Best Practice (CBP)|This intervention is an adapted version of Group Lifestyle Balance which is a validated weight loss program for community groups and military populations that is an official adaptation of the gold standard Diabetes Prevention Program Lifestyle Balance intensive research intervention. It has both training programs for interventionists and program material available on the web and is also slightly modified from the Diabetes Prevention Program study to take into account changing national nutrition recommendations.
89508462|NCT02300467|Experimental|NOV120401 (CKD-516 Tablet)|5 to 45 mg/day PO for 5 consecutive days and 2 days off
89508463|NCT04477551|Experimental|Diode laser (device) with scaling and root planing|Diode laser (device) with conventional scaling and root planing
89508464|NCT04477551|Active Comparator|Conventional scaling and root planing|Conventional scaling and root planing
89508465|NCT03510013|Experimental|1-1-8 wash-in|Wash-in using O2:N2O or O2:air 1:1 L/min with sevoflurane 8%
89508466|NCT05253729|Experimental|Focused Extracorporeal Shock Wave Therapy (F-ESWT)|Participants in the intervention group received low-intensity F-ESWT once a week for three sessions plus conservative treatment.
89508467|NCT05253729|Active Comparator|Control|Participants in the control group received only conservative treatment including disease education, advice about proper posture and activity, night wrist splint and nerve gliding exercise.
89508468|NCT03512665|Experimental|Full dose supplement group|Patients assigned to this group will receive a daily dose of 7 mL of the study supplement (a mixture of pine, macadamia and pomegranate oils). The appearance and organoleptic properties will be similar to those of the interventions in the other two groups
89508469|NCT03512665|Experimental|Low dose Supplement group|Patients assigned to this group will receive a daily dose of 7 mL of a mixture containing 50% study supplement and 50% sunflower oil. The appearance and organoleptic properties will be similar to those of the interventions in the other two group
89508470|NCT03512665|Other|Control Oil Group|Patients assigned to this group will receive a daily 7 mL dose of an oil (sunflower oil) with appearance and organoleptic properties similar to those of the supplement provided in the intervention groups
89206922|NCT02548260|Experimental|Rigid splint with compression|Rigid immobilization with a custom made thermoplastic splint (CE conformity), compression (CE conformity) is worn over the finger
89206923|NCT00291187|Placebo Comparator|Placebo|Take orally 30 minutes prior to bedtime.
89508471|NCT02340507|Experimental|High glycemic index|The subject will consume a high glycemic index glutinous rice for breakfast (75g available carbohydrates), and a high glycemic index white bread for snack (25g available carbohydrates). The lunch is a standardized, weighed portion buffet.
89508472|NCT02340507|Experimental|Low glycemic index|The subject will consume a low glycemic index parboiled basmati rice for breakfast (75g available carbohydrates), and a low glycemic index multigrain bread for snack (25g available carbohydrates). The lunch is a standardized, weighed portion buffet.
89508473|NCT02307721|Experimental|intranasal naloxone|8 mg/ml naloxone 0,1 mL IN as one puff in one nostril in supine position
89508474|NCT02307721|Active Comparator|Intramuscular naloxone|0,4 mg/ml Naloxone B Braun 2 ML in deltoid muscle
89508475|NCT02348541|Other|CollaGUARD|
89508476|NCT03506815|Experimental|Rivaroxaban Thromboprophylaxis|Rivaroxaban 10 mg po daily for 90 days(+/- 3 days). After the Day - 90 follow up, the study treatment will be discontinued and subsequent treatment will be at the discretion of the attending physician.
89508477|NCT03506815|No Intervention|Standard of care|No rivaroxaban prophylaxis. Management will be at the discretion of the attending physician.
89508478|NCT03509935|Experimental|Intervention Ultrasound Group|"Patients will be submitted to Ultrasound protocol, namely:~In the first 6 to 12 hours of admission to ICU~Second US after 12-24 hours of inclusion.~Third US after 24-48 hours of inclusion.~Protocol:~US 4 pulmonary quadrants in each hemithorax: anterior and lateral, upper and lower regions.~US inferior vena cava, collapsability or distensibility index according to the patient's conditions, in spontaneous or controlled ventilation, respectively.~Cardiac US: subjective evaluation of contractility between normal, reduced or severely reduced.~The US findings will be communicated to the attending physicians who will conduct the patient, according to the protocol, recommending the administration of volume or not, and the use of vasopressors and/or inotropic drugs."
89540251|NCT04877067|Active Comparator|Only WJ-MSC|WJ-MSC was applied only one time for both eyes.
89540252|NCT04877145|Experimental|single drill|one drill to place the implants 3.25mm diameter stainless steel drill was used.
89540253|NCT04877145|Active Comparator|sequential drills|For the control group, four drills (2.2mm, 2.75mm, 3.25mm and 4mm diameter),
89540254|NCT04870749||lower urinart tract syptoms|Lower urinary tract symptoms (LUTS) are common in older men and one of the main reasons for this is the enlargement in prostate gland volume caused by hormonal changes.
89540255|NCT04877301|Experimental|Ultrasound guidance|Ultrasound guidance used to facilitate insertion of PIV catheter.
89540256|NCT04877301|Active Comparator|Non-ultrasound guidance|Ultrasound guidance will not be used for insertion of PIV catheter.
89032941|NCT02945033|Experimental|Patient with aspirin intake|Surgical resection of colonic adenocarcinoma stage III or II high risk will be done in accordance with local guidelines. Molecular analysis of exon 9 and 20 of PI3K will be done using operative piece. If the mutation is detected, patient with colonic adenocarcinoma stage III or II high risk will take aspirin 100 mg/day during 3 years. Blood intake will be done every 6 months to evaluate patient compliance to treatment
89206924|NCT00291187|Experimental|20 mg VEC-162|20 mg taken orally 30 minutes prior to bedtime.
89508479|NCT03509935|No Intervention|Control Group|Patients randomized to this group will receive care according to the indication of the attending physicians, composed mainly of intensive care physicians, without bedside US. Patients may be submitted to echocardiographic, abdominal and vascular examinations, among others, requested to ultrasound service, according to the indication.
89508480|NCT02336061||male|It will be stratified based on biological sex, age and smoking to guarantee homogeneity between the cohorts.
89508481|NCT02336061||female|It will be stratified based on biological sex, age and smoking to guarantee homogeneity between the cohorts.
89508482|NCT03506737|Experimental|Conventional exercise protocol|Conventional global exercise
89508483|NCT03506737|Experimental|Cycle ergometer exercise protocol|Stationary cycle ergometer exercise
89508484|NCT02442973||Control group (CG):|Standard practice group
89508485|NCT02442973||Ultrasound group (UG):|"SpineView3D™ anatomical scouting approach"
89508486|NCT02348463||treatment of bacterial vaginosis|women with bacterial vaginosis will be offered treatment with clindamycin-2-phosphate
89508487|NCT03512509|Experimental|A|Low glycaemic potato
89508488|NCT03512509|Experimental|B|High glycaemic potato
89508489|NCT02340273|Experimental|Therapeutic ultrasound device|Patients receive treatment from the long duration therapeutic ultrasound device for 4 hours every day for 6 weeks. The active device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity.
89508490|NCT02340273|Placebo Comparator|Placebo therapeutic ultrasound device|"Patients receive the sham long duration therapeutic ultrasound device for 4 hours every day for 6 weeks. The placebo device appears and operates identically to the active device except that it does not emit ultrasound."
89508491|NCT02300623|Active Comparator|Control|Antiretroviral therapy alone
89508492|NCT02300623|Experimental|Treatment|Antiretroviral therapy plus Interleukin-2'
89508493|NCT04463953|Experimental|ZID regimen|Zanubrutinib, 160mg orally, twice a day; Ixazomib, 4 mg orally, day 1, 8, 15; Dexamethasone, 20mg orally, days 1, 8, 15.
89508494|NCT02340039|Experimental|Blackcurrant &Apple|600 mg blackcurrant anthocyanins + 600 mg apple polyphenols delivered in a low sugar fruit drink
89508495|NCT02340039|Experimental|Apple|1200 mg apple polyphenols delivered in a low sugar fruit drink
89508496|NCT02340039|Placebo Comparator|Control drink|No polyphenols delivered in a low sugar fruit drink
89508497|NCT03509779||NSCLC|NSCLC localized disease treated by surgery
89508498|NCT02336295|Other|Food Frequency Questionnaires|Filling out a Food Frequency Questionnaires (FFQ)
89508499|NCT02307955|Experimental|firefly|participants treated with firefly device
89508500|NCT02307955|Other|Control|Standard of care
89508501|NCT03147963|Experimental|Docetaxel 2-Weeks regimen group|Docetaxel injection 50mg/m2,iv,d1,every 2 weeks
89508502|NCT03147963|Active Comparator|Docetaxel 3-Weeks regimen group|Docetaxel injection 75mg/m2,iv,d1,every 3 weeks
89508503|NCT03512431||Study group|Only one arm in the present study
89508504|NCT02348307|Active Comparator|FYU-981|
89508505|NCT02348307|Placebo Comparator|Placebo|
89508506|NCT02303509|Experimental|UCB5857 Part 1|Part 1: Subjects assigned to UCB5857 or placebo single dose.
89508507|NCT02303509|Experimental|UCB5857 Part 2|Part 2: Subjects assigned to UCB5857 or placebo multiple doses.
89508508|NCT02340117|Experimental|SGT-53 with gemcitabine/nab-paclitaxel|A course of therapy will include 7 weeks of treatment. SGT-53, at 3.6 mg DNA/infusion, will be administered bi-weekly on days 1 and 5 in weeks 1-3, weekly on day 3 in week 4, and weekly on day 1 in weeks 5-7. Patients who are responding to treatment may receive two additional courses (7 weeks) of SGT-53/gemcitabine/nab-paclitaxel therapy at investigator discretion. If still responding to treatment, they may continue on SGT-53/gemcitabine/nab-paclitaxel at investigator discretion with the approval of the sponsor.
89508509|NCT02300701|Experimental|Xolair/Omalizumab|
89508510|NCT02300701|Placebo Comparator|Placebo|
89508511|NCT02336139|Experimental|Sofosbuvir (SOF)/GS-5816|12 weeks of Sofosbuvir (SOF)/GS-5816 (400mg/100mg) in an oral once-daily fixed dose combination
89508512|NCT02300779|Experimental|Low-residue diet|Subjects will follow a low-residue diet for 4 days. Their usual treatment for diabetes will be adjusted to the degree of glycemic control.
89508513|NCT02300779|Active Comparator|Usual care|Subjects will follow a low-residue diet for 3 days (from 4 to 2 days before the procedure) and a liquid diet on the following day (the one before the procedure). No changes in their treatment for diabetes will be made
89508514|NCT02340195|Experimental|Idalopirdine (Lu AE58054) 60 mg (Group A)|8 patients with severe renal impairment and not on dialysis
89508515|NCT02340195|Experimental|Idalopirdine (Lu AE58054) 60 mg (Group B)|8 healthy subjects
89508516|NCT02340195|Experimental|Idalopirdine (Lu AE58054) 60 mg (Group C)|"Group C will not be tested, if severe renal impairment does not alter the pharmacokinetics to a clinically relevant extent, based on results from group A and B~8 patients with moderate renal impairment"
89508517|NCT02340195|Experimental|Idalopirdine (Lu AE58054) 60 mg (Group D)|"Group D will not be tested, if severe renal impairment does not alter the pharmacokinetics to a clinically relevant extent, based on results from group A and B~8 patients with mild renal impairment"
89508518|NCT02300857|Active Comparator|Low carbohydrate diet|
89508519|NCT02300857|Active Comparator|Moderate carbohydrate diet|
89508520|NCT02300857|Active Comparator|High carbohydrate diet|
89508521|NCT04464733|Experimental|Treatment group A|
89508522|NCT04464733|Experimental|Treatment group B|
89508523|NCT04464733|Experimental|Treatment group C|
89508524|NCT04464733|Experimental|Treatment group D|
89508525|NCT04464733|Experimental|Treatment group E|
89508526|NCT04464733|Experimental|Treatment group F|
89508527|NCT04464733|Experimental|Treatment group C-|
89508528|NCT04464733|Experimental|Treatment group G|
89508529|NCT04464733|Experimental|Treatment group H|
89508530|NCT04464733|Experimental|Treatment group I|
89508531|NCT04464733|Experimental|Treatment group J|
89508532|NCT02335827|Experimental|Group A|irreversible electroporation with voltage in level A for renal tumors
89508533|NCT02335827|Experimental|Group B|irreversible electroporation with voltage in level B for renal tumors
89508534|NCT02335827|Experimental|Group C|irreversible electroporation with voltage in level C for renal tumors
89508535|NCT04465045||Unique cohort|All women, 18 to 43 years, operated from laparoscopy-hysteroscopy for unexplained infertility in montpellier university hospital
89508536|NCT04421703|Experimental|Distance Collaborative|For sites randomized to the distance arm, training will be delivered via web conference, and technical assistance and assessment and feedback will be delivered by phone.
89508537|NCT04421703|Experimental|Blended in-person/distance collaborative|For the QI collaborative arm, training will be delivered in two in-person collaborative meetings; and the remainder of the strategies will be delivered via web-conferencing.
89508538|NCT03147651||Cystic Fibrosis (CF) bronchiectasis|Diagnosis of Cystic Fibrosis (CF), follow up in a CF center, evidence of bronchiectasis on computed tomography (CT).
89508539|NCT03147651||non-Cystic Fibrosis (CF) bronchiectasis|Negative evaluation for of Cystic Fibrosis (CF), evidence of bronchiectasis on computed tomography (CT).
89508540|NCT02300935|Experimental|trametinib and nab-paclitaxel|Trametinib will be dosed at 1mg, 1.5mg, and 2mg orally (PO) daily based on Phase I data of this drug as a single agent. All patients entering this study will receive intravenous (IV) nab-paclitaxel on Day 1, 8, and 15. Dose levels will be assigned to each patient, and dose escalation decisions will be based on the evaluation of safety data from the prior cohort.
89508541|NCT02339805|Experimental|next generation sequencing|Determination of clonotypic evolution of the minimal residual disease by next generation sequencing.
89508542|NCT02301013|Experimental|Urinary incontience surgery|Patients who is between 25 to 70 years old and positive stress test and have TVT or TOT operations with diagnoses of stress urinary incontinence and mixed urinary incontinence .
89508543|NCT03511885||high cardiovascular risk patients|"Coronary patients~Elective coronary artery bypass surgery (CABG).~Elective percutaneous coronary intervention (PCI) .~Acute coronary syndromes (acute myocardial infarction with ST elevation (STEMI) and Non ST elevation MI (Non- STEMI) including those treated with primary PCI and/or CABG, and unstable angina).~People at high risk of cardiovascular disease (CVD) who have been prescribed one or more of the following medications: (i) blood pressure and/or (ii) lipid and/or (iii) glucose lowering (diet and/or oral hypoglycaemic agents and/or insulin) treatments prescribed by a physician."
89508544|NCT03147729|Other|Radiofrequency in anal incontinence: a pilot study|It will be a single arm study with a group of anal incontinence with 10 women with anal incontinence
89508545|NCT02301091|Experimental|TACE-RFA|2 times TACE first, RFA for residual viable tumors and PVTT within 1 month.
89508546|NCT02301091|Active Comparator|TACE alone|repeated TACE and 1 to 2 months interval between two sessions of TACE.
89508547|NCT02335593|Experimental|Zinc group|Zinc Sulphate Hard Gel Capsules 110 mg once daily for three months plus Epoetin alfa 2000-4000 IU solution for injection andIron Hydroxide Saccharate Complex Solution for injection.
89508548|NCT02335593|Active Comparator|Placebo group|Corn starch filled Hard Gel capsules once daily plus 'Epoetin alfa 2000-4000 IU solution for injection and Iron Hydroxide Saccharate Complex Solution for injection.
89508549|NCT02339727|Active Comparator|Omega-6/omega-3=2/1 milk formula|Preterm infants will receive a formulas supplemented with Docosahexaenoic acid and Arachidonic acid with a relationship omega 6/omega 3 = 2/1.
89508550|NCT02339727|Active Comparator|Omega-6/omega-3=1/1 milk formula|preterm infants will receive other formulas with Docosahexaenoic acid and Arachidonic acid, but with a ratio of 1/1.
89508551|NCT02335515|Experimental|Soctec / Capsule|HS intakes one(1) Soctec Capsule after standardized breakfast
89508552|NCT03511651|Other|FRC at clinical PEEP level|Measuring FRC at clinical PEEP level
89508553|NCT03511651|Experimental|FRC at clinical PEEP + 5cmH2O|Increasing PEEP to clinical PEEP + 5cmH2O
88958290|NCT01992211|Experimental|Treatment Sequence 4(BCA)|"Participant will be administered a single oral dose of BCWP_C003 under Fasting condition on 1Day.~Participant will be administered a single oral dose of BCWP_C003 under Fed condition on 8Day.~Participant will be co-administered a single oral dose of Rosuvastatin 10mg and Metformin SR 1000mg under Fed condition on 15Day."
88958291|NCT01992211|Experimental|Treatment Sequence 5(CAB)|"Participant will be administered a single oral dose of BCWP_C003 under Fed condition on 1Day.~Participant will be co-administered a single oral dose of Rosuvastatin 10mg and Metformin SR 1000mg under Fed condition on 8Day.~Participant will be administered a single oral dose of BCWP_C003 under Fasting condition on 15Day."
88958292|NCT01992211|Experimental|Treatment Sequence 6(CBA)|"Participant will be administered a single oral dose of BCWP_C003 under Fed condition on 1Day.~Participant will be administered a single oral dose of BCWP_C003 under Fasting condition on 8Day.~Participant will be co-administered a single oral dose of Rosuvastatin 10mg and Metformin SR 1000mg under Fed condition on 15Day."
89508554|NCT02339649|Other|Sepsis/septic Shock|"Men and women seen at the intensive care units of the Anesthesiology Department of the University Hospital Bonn aged 25-80; fulfill the criteria of sepsis and/or septic shock patients according to theThird International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3, Singer et al, 2016).~Interventions: Neurocognitive Assessment, Clinical Scales, Questionnaires, Blood Sample, voluntary Lumbar Puncture, Resting State EEG, MRI"
89508555|NCT02339649|Other|Postoperative ICU Patients|"Men and women seen at the intensive care units of the Anesthesiology Department of the University Hospital Bonn aged 25-80:~Admitted to the intensive care units of the Anesthesiological-Operative Intensive Care Unit of the University Hospital Bonn, which includes a surgical ICU, an anesthesiological ICU, and a cardio-surgical ICU~Duration of ICU stay must be a minimum of 24 hours.~Mini-Mental State Examination (MMSE) Score of 25 or above~Interventions: Neurocognitive Assessment, Clinical Scales, Questionnaires, Blood Sample, voluntary Lumbar Puncture, Resting State EEG, MRI"
89508556|NCT02339649|Other|Healthy Controls|"Healthy Controls will only be included in the study if they meet all of the following criteria: Written informed consent of the subject, Aged 25-80 years, Male or female.~Interventions: Neurocognitive Assessment, Clinical Scales, Questionnaires, Blood Sample, voluntary Lumbar Puncture, Resting State EEG, MRI"
89508557|NCT03511495||Keratoconic Patients|
89206925|NCT00291187|Experimental|50 mg VEC-162|50 mg taken orally 30 minutes prior to bedtime.
89508558|NCT02339337|Experimental|RGT group|For subjects who were randomized into the RGT group, the duration of Peg-IFN and RBV therapy was abbreviated to 24 weeks in subjects with HCV genotype 1, a pre-treatment low viral load (LVL, < 400000 IU/mL) and RVR (defined asHCV RNA <50 IU/mL at 4th week of therapy); the duration was 16 weeks in subjects with HCV genotype 2/3 and RVR.
89508559|NCT02339337|Active Comparator|GGT group|Subjects who were randomized into the GGT group received Peg-IFN and standard dose RBV (1200 mg/day) for 48 weeks in subjects infected with HCV genotype 1 or Peg-IFN and low dose RBV (800 mg/day) for 24 weeks in subjects infected with HCV genotype 2/3; the patients were then followed for 6 months.
89508560|NCT02301247|Experimental|Experimental Group|The experimental group will receive memory retraining exercises administered on a laptop computer twice a week for 5 weeks (10 training sessions).
89508561|NCT02301247|Placebo Comparator|Placebo|The placebo group will receive placebo control memory exercises administered on a laptop computer twice a week for 5 weeks (10 training sessions).
89508562|NCT02339259||Febrile patients|Febrile patients admitted to CMCH who have had malaria film and scrub typhus and murine typhus rapid test will be screened for enrolment.
89508563|NCT02339259||Healthy|Healthy subjects with no recent history of fever will be recruited to provide control samples for the blood and plasma assays.
89508564|NCT02308267||Cystic fibrosis|Cystic fibrosis patients More than 18 years old DF508/DF508 mutation colonized or not with Pseudomonas aeruginosa
89508565|NCT02308267||Controls|Controls patients More than 18 years old Without CF Smokers or nonsmokers
89508566|NCT03105219|Experimental|Ivabradine|Ivabradine 5mg twice a day (on day 0), heart rate evaluated at day 14 and 28 repeatedly, and the targeted value of heart rate 50-60bpm, the largest dosage 7.5mg twice a day.
89508567|NCT03105219|Sham Comparator|Sham Comparator|Urinary albumin excretion (UAE) assessment will be performed before randomization (Day 0), 28-day after randomization (Day 28), and 90-day after randomization (Day 28).
89508568|NCT02308345|Experimental|Video summary|Participants in this arm will be given online access to a 5-minute video summary of their pre-chemotherapy visit, recorded by their physician.
89508569|NCT03105141|Experimental|RIC substudy 1|A total of 120 patients in this substudy will receive standard medical therapy and bilateral upper limb remote ischemic conditioning intervention (Doctormate®) (200 mmHg or 40 mmHg above systolic pressure) twice daily for 12 months.
89508570|NCT03105141|Experimental|RIC substudy 2|A total of 180 patients in this substudy will receive standard medical therapy and bilateral upper limb remote ischemic conditioning intervention (Doctormate®) (200 mmHg) twice daily for 12 months.
89508571|NCT03105141|Experimental|RIC substudy 3|A total of 180 patients in this substudy will receive standard medical therapy and bilateral upper limb remote ischemic conditioning intervention (Doctormate®) (200 mmHg) twice daily for 12 months.
89508572|NCT03105141|Experimental|RIC substudy 4|A total of 120 patients in this substudy will receive standard medical therapy and bilateral upper limb remote ischemic conditioning intervention (Doctormate®) (200 mmHg) once or twice daily for 12 months.
89508573|NCT03506659|Active Comparator|Test|2000 patients healthy in anesthesiology consultation
89508574|NCT03506659|Experimental|Patients|2000 patients in pain clinic consultation
89508575|NCT03105453||Study arm|Women in the study arm will undergo microbiome samplings described in the interventions section (3 sampling points)
89508576|NCT02308579||Multiple Sclerosis|Patients diagnosed with Multiple Sclerosis (MS), identified in the CTEVD trial
89508577|NCT02308579||Clinically Isolated Syndrome|Patients diagnosed with Clinically Isolated Syndrome (CIS), identified in the CTEVD trial.
89508578|NCT02308579||Other Neurological Disorders|Patients diagnosed with Other Neurological Disorders (OND), identified in the CTEVD trial. ONDs fall into one of four categories: Neurodegenerative, Vascular, Autoimmune, and Neuromuscular; and the following disorders: Acute Disseminated Encephalomyelitis (ADEM); Antiphospholipid Antibody (syndrome; APLA); Atypical, short-lasting neurodegenerative disease; Autoimmune disease not otherwise specified (NOS); Cerebellum Syndrome; Charcot-Marie Tooth Disease; Chiari Malformation; Chronic Fatigue Syndrome; Central Nervous System Vasculitis; Demyelinating Disease; Epilepsy; Headaches; Idiopathic Chronic Neuropathy; Migraines; Mitochondrial Disease; Myelopathy; Neurofibromatosis; Neuropathy; Optic Neuritis; Parasthesia related to Transient Ischemic Attacks (TIA); Parkinson's Disease; Restless legs syndrome; Seizures; Spinal Cerebellum Disease; Spinal Disc Degeneration; Syringomyelia; and Vertigo
89508579|NCT02308579||Healthy Controls|Individuals who are healthy (i.e., free from neurological conditions; HC) , identified in the CTEVD trial.
89508580|NCT02339493|Experimental|Alert Group|If the patient is randomized to the alert group, their ordering provider will receive a computer electronic alert notifying the responsible provider that his or her patient is high-risk for stroke due to AF or atrial flutter and that the patient is not ordered to receive anticoagulant therapy.
89508581|NCT02339493|No Intervention|Control Group|If the patient is randomized to the control group, the computer program will not issue an on-screen electronic alert.
89508582|NCT02339103|No Intervention|Shivering only|Pt placed in sleeping bag and warmed by shivering only
89508583|NCT02339103|Experimental|Warmed IV fluids|2 Liter of 42 degree celsius normal saline
89508584|NCT02339103|Experimental|Warmed perfusion pads|Warmed perfusion pads placed to palms and soles to rewarm through arteriovenous anastomoses
89508585|NCT03512587|Experimental|Personal quantum sonotherapy group|Patients who will listen through MP3 devices the personalized quantum sonotherapy previously created through a especialized software, before the application of regional anesthesia.
89508586|NCT03512587|Placebo Comparator|Control group|Patients will wear headphones but without playing the personalized quantum sonotherapy
89508587|NCT02335437||Acute EBV infection|
89508588|NCT02335437||Healthy controls|
89206926|NCT00291187|Experimental|100 mg VEC-162|100 mg taken orally 30 minutes prior to bedtime.
89206927|NCT00956163|Experimental|Diagnostic (fluorine F 18 sodium fluoride PET)|Patients undergo technetium Tc 99m methylene diphosphonate bone scan, fluorine F 18 sodium fluoride PET/CT scan, and whole-body MRI for the detection of bone metastases. Patients with discordant imaging results (negative bone scan and positive PET/CT scan and/or MRI) undergo additional imaging at 6, 12, 18, and 24 months.
89206928|NCT04016766|Experimental|Prepartying mobile app intervention|Mobile app intervention
88958293|NCT01992224|Experimental|early mechanical ventilation|"Fulfillment of three or more criteria below:~respiratory rate > 28 per minute serum lactate > 3 mmol/L PaO2/FiO2 Index <300 mmHg SvO2 < 65% lung infiltration or atelectasis, pleural exudation~Abbreivation: PaO2, arterial partial pressure of oxygen; FiO2, fraction of inspired oxygen; SvO2, venous oxygen saturation"
89508589|NCT03506503|Experimental|processed Nanofat grafting|processed autologous Nanofat will be injected into the area of the scalp with androgenic alopecia.
89508590|NCT02308813|Experimental|Braking and functionality with hip osteoarthritis|Cohort testing of driving performance in a drive simulator and correlation with clinical functionality in patients with hip osteoarthritis
89508591|NCT02308813|Experimental|Braking and functionality with hip arthroplasty|Cohort testing of driving performance in a drive simulator and correlation with clinical functionality in patients with total hip arthroplasty
89508592|NCT02332317|No Intervention|Control arm|150 patients will receive standard oncology treatment.
89508593|NCT02332317|Active Comparator|Intervention arm|150 patients will receive standard oncology treatment alongside a 12-week specialized palliative rehabilitation program
89508594|NCT02308891|Experimental|vigorous hydration arm|"Patients will be randomly allocated to vigorous hydration arm. Patients in the vigorous hydration arm will receive fluids via infusion by the following protocol.~Initial bolus of lactated Ringer's solution at 10mL/kg over 1 hour prior to ERCP~Intravenous lactated Ringer's solution at a rate of 3mL/kg/h during the procedure and continued for 8 hours.~At the end of ERCP, post-procedure bolus of lactated Ringer's solution at 10mL/Kg over 1hour"
89508595|NCT02308891|Active Comparator|standard hydration arm|"Patients will be randomly allocated to standard hydration arm. Patients in the standard hydration arm will receive fluids via infusion by the following protocol.~- Patients will receive lactated Ringer's solution at the start of the ERCP and the fluids will be administered at a rate of 1.5ml/kg/h during the procedure and for 8hours after ERCP."
89508596|NCT02332083|Experimental|Intervention group|T0 - intervention over 4 weeks with stochastic resonance whole-body vibration (SR-WBV) (start with 3 up to 6 Hz, noise 4) T1 - intervention 4 weeks (SR-WBV (start with 3 up to 6Hz, noise 4 & Exergame) - T2
89508597|NCT02332083|Sham Comparator|Sham Comparator|T0 - intervention 4 weeks (SR-WBV 1 Hz, noise 1) - T1 - intervention 4 weeks (SR-WBV 1 Hz, noise 1 & Aktiv Tramp) - T2
89508598|NCT02308969|Other|Placebo, LSD|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but two treatment conditions in the same subject.
89508599|NCT02338947|Active Comparator|Off-pump coronary-artery bypass grafting - OPCAB|"Pre-frail and frail patients will be randomly assigned to OPCAB after the evaluation of the target vessels by an internet-based, password protected database program. The surgery will be performed as described in the intervention section and the patients will be followed up for two years."
89508600|NCT02338947|Active Comparator|On-pump coronary-artery bypass grafting - CABG|"Pre-frail and frail patients will be randomly assigned to CABG after the evaluation of the target vessels by an internet-based, password protected database program. The surgery will be performed as described in the intervention section and the patients will be followed up for two years."
89508601|NCT02309047||WHO anovulation|WHO I, II. III anovulation. See inclusion criteria
89508602|NCT02309203|Experimental|Flow Re-Direction Endoluminal Device|Flow Re-Direction Endoluminal Device (FRED Device)
89508603|NCT02339025||Tricare Participants|From WRNMC
89508604|NCT02309281|Other|aflibercept 2mg|Aflibercept 2mg (Eylea) is intravitreally applied. The first treatment interval with aflibercept will be 4 weeks and corresponding to the treat and extend regime intervals will be increased in 2-weeks-steps.
89508605|NCT02335281|Experimental|Standardized FMT|The group include 20 patients. They will receive standardized FMT. The FMT was given to mid-gut by nose-jejunum nutrition tube. It was given only once.
89508606|NCT02335281|Active Comparator|Mesalazine|This group include 20 patients . The patients will receive traditional medicine of mesalazine treatment.
89508607|NCT02309437|Experimental|Mild group|Use oxycodone when pain is mild level. Start from 10 mg every 12 hours and titrate for appropriate dose.
89508608|NCT02309437|Active Comparator|Moderate group|Use oxycodone when pain is moderate or severe level. Start from 10 mg every 12 hours and titrate for appropriate dose.
89508609|NCT02335359|Experimental|Tranexamic Acid|A 500 mg loading dose of tranexamic acid diluted in 100 ml of saline solution will be slowly administered intravenously to patients 20 minutes before surgery, followed by a continuos infusion of 250 mg/h of tranexamic acid from surgical incision until skin closure.
89508610|NCT02335359|Placebo Comparator|Placebo|Saline
89508611|NCT02338869|Experimental|Dialogue-based psychosocial intervention|Participants receive six individual meetings with trained health care professional in additional to usual rehabilitation and care. Dialogues focus on individual psychosocial challenges and needs and provide emotional and informational support to encourage and facilitate coping.
89508612|NCT02338869|No Intervention|Usual care Control group|Participants receive usual rehabilitation and care.
89508613|NCT02338791|Experimental|Manual Mobilization|Grade I, II and III manual mobilizations in the inferior, posterior and distractive directions.
89508614|NCT03511261|Active Comparator|10%Curcumin mucoadhesive gel|"Drug: Curcumin arm Curcumin10% mucoadhesive gel~Group 1 patients:~Drug : 10% curcumin mucoadhesive gel usage : Topical application Frequency : Twice daily Duration : 6 months"
89206929|NCT04016766|No Intervention|Control|Control participants receive a personalized attention control task (i.e., listing and ranking favorite movies, music, and books), which controls for the time needed by the intervention group to view the intervention material.
89540257|NCT03046875|Experimental|Transcutaneous Spinal Cord Stimulation|Subjects will participate in a single session of Transcutaneous Spinal Cord Stimulation, involving 30 minutes of stimulation with isokinetic strength testing of knee extension.
89540258|NCT03046875|Sham Comparator|Sham|Subjects will participate in a single session of isokinetic strength testing of knee extension with sham stimulation.
89540259|NCT05214417|Experimental|KAP (Ketamine-assisted Psychotherapy) Recipients|Two separate IM ketamine injection sessions, with possible multiple doses administered at each session not to exceed 100 mg IM ketamine total for the session.
89540260|NCT05214417|Other|Naturalistic Comparator|Pre-existing conventional treatment will continue for this group during the study period.
89540261|NCT02615145||Genotype 1a (G1a) Participants|"Treatment-naïve or -experienced participants with confirmed chronic hepatitis C (CHC) genotype 1a (G1a, includes all GT1-participants except participants with GT1b or GT1b/4), receiving combination therapy with the interferon-free paritaprevir/ritonavir - ombitasvir with dasabuvir (ABBVIE REGIMEN) + ribavirin (RBV) according to standard of care and in line with the current local label.~The prescription of a treatment regimen is at the discretion of the physician in accordance with local clinical practice and label, is made independently from this observational study and precedes the decision to offer the patient the opportunity to participate in this study."
89540262|NCT02615145||Genotype 1b (G1b) Participants|"Treatment-naïve or -experienced participants with confirmed CHC genotype 1b (G1b; includes G1b/Genotype 4 [G4]), receiving combination therapy with the interferon-free paritaprevir/ritonavir - ombitasvir with dasabuvir (ABBVIE REGIMEN) according to standard of care and in line with the current local label.~The prescription of a treatment regimen is at the discretion of the physician in accordance with local clinical practice and label, is made independently from this observational study and precedes the decision to offer the patient the opportunity to participate in this study."
89540263|NCT02615145||Genotype 4 (G4) Participants|"Treatment-naïve or -experienced participants with confirmed CHC genotype 4 (G4; non-G1), receiving combination therapy with the interferon-free paritaprevir/ritonavir - ombitasvir (ABBVIE REGIMEN) + RBV according to standard of care and in line with the current local label.~The prescription of a treatment regimen is at the discretion of the physician in accordance with local clinical practice and label, is made independently from this observational study and precedes the decision to offer the patient the opportunity to participate in this study."
89540264|NCT04388241|Experimental|Behavioral Intervention|Children and adolescents with SCD between the ages of 8 and 17 years old (n=20) will be recruited to complete a four-week behavioral intervention designed to reduce pain-related impairment in SCD.
89540265|NCT04876911|No Intervention|Control/Usual Care|No intervention delivered and care is provided as usual.
89540266|NCT04876911|Experimental|Simulated Presence Therapy (SPT)|Participants begin to receive the SPT.
89540267|NCT04876833||HC，healthy control|18-65 years old，no smoking history，normal pulmonary function，normal compatible computed tomography.
89540268|NCT04876833||HG，high-risk COPD group|18-60 years old，≥10 pack-years smoking history，normal pulmonary function，normal compatible computed tomography.
89540269|NCT04876833||EG，early COPD group|"18-60 years old，≥10 pack-years smoking history，and with any of the following abnormalities：~Forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) less than 80%;~Compatible computed tomography abnormalities：airway abnormality and/or emphysema，air trapping, or bronchial thickening；~FEV1 decline (≥60 mL per year)."
89540270|NCT04876833||MG，mild and moderate COPD group|18-65 years old，FEV1/FVC<70%，FEV1%predicted ≥50%.
89540271|NCT03046485|Experimental|Self management program|Self management program 'Living with Vision Loss' 6 week course that met for 2 hours each week led by a trained leader.
89540272|NCT03046485|No Intervention|Wait list control|Wait list control
89540273|NCT04387461|Experimental|Single Arm|"CG0070 will be administered intravesically (IVE) following a sequence of bladder washes with 5% DDM and normal saline. CG0070 will be administered weekly x 6 on Day 1 to Week 6. If the patient shows persistent high-grade disease at Week 12, the patient will receive another cycle of 6 weekly treatments. If there is no disease present at Week 12 (e.g., complete response) then the patient will receive 3 weekly treatments.~Beginning at Week 24, patients will receive weekly x 3 treatments every 3 months through Week 48 then every 24 weeks thereafter.~Pembrolizumab will be given intravenous (IV) concurrently starting on Day 1 and continue every 3 weeks for up to 2 years."
89540274|NCT03046563|Experimental|Acupressure and Abdominal Massage|Pressing the Hegu (LI 4), Zusanli (ST 36) , Tianshu(ST 25) and abdominal massage for eight minutes total, press once in the morning and afternoon, seven days total and two days for follow the trail.
89540275|NCT03046563|Sham Comparator|Pressing the sham points|Pressing the sham points for eight minutes total, press once in the morning and afternoon, seven days total and two days for follow the trail.
89540276|NCT04865757|Experimental|Space Flap|A space flap is formed out of Palacos®, adjusted to the skull surface with temporal augmentation
89540277|NCT03046719|Active Comparator|Bupivacaine 0,5%|Subjects received subconjunctival bupivacaine 0,5% 2,5ml in between stitches.
89032942|NCT02945033|Placebo Comparator|Patient with placebo intake|Surgical resection of colonic adenocarcinoma stage III or II high risk will be done in accordance with local guidelines. Molecular analysis of exon 9 and 20 of PI3K will be done using operative piece. If the mutation is detected, patient with colonic adenocarcinoma stage III or II high risk will take placebo of aspirin 100 mg/day during 3 years. Blood intake will be done every 6 months to evaluate patient compliance to treatment
89508615|NCT03511261|Active Comparator|Curcumin capsules 500mg|"Group 2 patients:~Drug : curcumin 500 mg capsules usage : oral intake Frequency : Twice daily Duration : 6 months"
89508616|NCT03511261|Active Comparator|5% Curcumin gel+Curcumin capsules 250mg|"Group 3 patients:~Drug: 5% Curcumin mucoadhesive gel & Curcumin capsules 250mg usage : Topical application and oral intake Frequency : Twice daily Duration : 6 months"
89508617|NCT03511261|Placebo Comparator|Placebo capsules|Group 4 patients Drug: Placebo capsules usage : oral intake Frequency : Twice daily Duration : 6 months
89508618|NCT04125069||Patients aged from 18 to 85 years|Cardiac surgery patients aged from 18 to 85 years,programmed for Coronary artery bypass graft requiring ECC.
89508619|NCT03509701||Subject (RCVS)|Patients who meet the definition of RCVS. (1) acute and severe headache with or without focal deficits or seizures, (2) uniphasic course without new symptoms more than 1 month after clinical onset, (3) segmental vasoconstriction of cerebral arteries shown by computed tomography angiography (CTA), magnetic resonance angiography (MRA) or transfemoral cerebral angiography (TFCA),(4) normal or near normal cerebrospinal fluid analysis and (5) complete or substantial normalisation of arteries shown by follow-up angiography within 12 weeks.
89508620|NCT03509701||Control|Patients with thunderclap headache and intracranial stenosis, but not diagnosed as RCVS.
89508621|NCT03511183|Experimental|alternative regiment|"The first stage:XELOX + bevacizumab chemotherapy and XELIRI + bevacizumab chemotherapy (alternation of every two cycles) until one of the schemes appears imaging progress or intolerance.And then enter the second stage.~The second stage: continue to apply another plan until there is progress or intolerance."
89508622|NCT03511183|Placebo Comparator|classical regiment|Use the XELOX + bevacizumab chemotherapy until appears imaging progress or intolerance.And then change to the XELIRI + bevacizumab chemotherapy until there is progress or intolerance.
89508623|NCT02303587|Experimental|low dose group|methylprednisolone 2mg-4mg/Kg
89508624|NCT02303587|Experimental|high dose group|methylprednisolone 10mg/Kg
89508625|NCT02301325|Other|0.03 mg Nicotine Cigarette|Participants will be assigned to smoke 0.03 mg nicotine Spectrum cigarettes
89508626|NCT02301325|Other|0.03 mg Nicotine Cigarette and NRT|Participants will be assigned to smoke 0.03 mg nicotine Spectrum cigarettes and use nicotine replacement patches.
89508627|NCT02301325|Other|0.80 mg Nicotine Cigarette|Participants will be assigned to smoke 0.80 mg nicotine Spectrum cigarettes.
89508628|NCT02301325|Other|0.80 mg Nicotine Cigarette and NRT|Participants will be assigned to smoke 0.80 mg nicotine Spectrum cigarettes and use nicotine replacement patches.
89508629|NCT02303665|No Intervention|The control group|No Intervention
89508630|NCT02303665|Experimental|The dual therapy group|TCM prescriptionⅡof cultivated emotion and assisted reproduction +auricular acupoint therapy.
89508631|NCT02303665|Experimental|The triple therapy group|TCM prescriptionⅡof cultivated emotion and assisted reproduction + auricular acupoint therapy+ retention enema of TCM.
89508632|NCT02301481|Experimental|Neoadjuvant Chemoradiotherapy (NCRT)|NCRT arm receives intensity-modulated radiotherapy with a simultaneous integrated boost (SIB-IMRT) (45.1Gy and 40.04Gy in 22 fractions) concurrently with oral S-1(40mg/m2, orally twice daily every weekday) followed by surgery and four to six cycles of SOX at the same dosage with NCT arm.
89508633|NCT02301481|Active Comparator|Neoadjuvant Chemotherapy (NCT)|NCT arm consists of neoadjuvant three cycles of SOX(S-1: 40~60mg, orally twice daily on days 1 to 14, oxaliplatin 130mg/m2 intravenously on day 1, 21 days per cycle followed by radical surgery and another postoperative three cycles of SOX.
89508634|NCT02301559|Experimental|Pilates Group|Pilates Group, Pilates exercises, 20 sessions, lasting 40 minutes each, 3 times per week. Soil and ball exercises, with emphasis on the pelvic region. The program began with the work of breathing and postural correction, with warm-up exercises or preparatory, followed by the framework of classical movements of the method.
89508635|NCT03107871|Experimental|Arm A|Valganciclovir 16 mg/kg PO twice daily (BID) x 6 months
89508636|NCT03107871|Placebo Comparator|Arm B|Flavored Simple Syrup, volume equivalent to active arm dose, PO BID x 6 months
89508637|NCT03506035||Rheumatoid arthritis|Patients who meet the criteria of the 1987 ACR
89508638|NCT03506035||Arthritis not Rheumatoid arthritis|Patients with psoriatic arthritis, peripheric spondyloarthropathies and connective tissue diseases.
89508639|NCT03506035||Healthy controls|From health blood donors
89508640|NCT02309749||Naive cohort|
89508641|NCT03509623|Experimental|Blood coagulation and aflibercept|Blood sampling through direct peripheral venous puncture will be collected from treatment naive patients commencing treatment with intravitreal injections of aflibercept for neovascular AMD before the first intravitreal injection of aflibercept and at 7 and 30 days post-injection. Blood coagulation parameters will be evaluated at each timepoint.
89508642|NCT03064113|Experimental|Sequence 1|Period 1 = Placebo; Period 2 = TD-4208 700 μg; Period 3 = TD-4208 350 μg; Period 4 = Ipratropium 500 μg
89540278|NCT03046719|Placebo Comparator|NaCl 0,9%|Subjects received subconjunctival NaCl 0,9% in between stitches.
89540279|NCT03046797|Experimental|B group|Mask ventilation will be continued and fiberoptic intubation will be performed from Boussignac valve opening by an experienced anesthetist.
89540280|NCT03046797|Active Comparator|C group|mask ventilation will be terminated then fiberoptic intubation will be done by an experienced anesthetist.
89540281|NCT03046641|Experimental|continuous training group|With the continuous training program
89540282|NCT03046641|Experimental|interval training group|With the interval training program
89540283|NCT04876755|Experimental|Cohort 1|Cohort 1 patients will administered 600 mg/day of MBM-02 for 20 weeks.
89540284|NCT04876755|Experimental|Cohort 2|Cohort 2 patients will administered 1000 mg/day of MBM-02 for 20 weeks.
89540285|NCT04876755|Experimental|Cohort 3|Cohort 3 patients will administered 1200 mg/day of MBM-02 for 20 weeks.
89540286|NCT04876755|Experimental|Cohort 4|Cohort 4 patients will administered 600 mg/day of MBM-02 for 20 weeks.
89540287|NCT04876755|Experimental|Cohort5|Cohort 5 patients will administered 600 mg/day of MBM-02 for 20 weeks.
89540288|NCT04876755|Experimental|Cohort 6|Cohort 6 patients will administered 600 mg/day of MBM-02 for 20 weeks.
89540289|NCT04876287||patients treated by 1.1 GBq|
89540290|NCT04876287||patients treated by 3.7 GBq|
89540291|NCT04876521|Experimental|Amisulpride Group|The patients will receive low dose Amisulpride at 100-300 mg/day.
89540292|NCT04876521|Active Comparator|Olanzapine-Fluoxetine Group|the patients will receive Olanzapine-Fluoxetine Combinations at 5/10-5/20 mg/day.
89540293|NCT03044847||COPD group|The post-bronchodilator FEV1/FVC ratio < 0.70 was used as definition of COPD, which was proposed by the Global Initiative for Chronic Obstructive Lung Disease
89540294|NCT03044847||GOLD 0 group|GOLD 0 is defined as having chronic respiratory symptoms and/or high risk factors, but without airflow (post-BD FEV1/FVC ≥ 0.7). Chronic respiratory symptoms is defined as chronic cough, phlegm production, chest tightness, short of breath, dyspnea, wheeze, ect. High risk factors is defined as cigarette smoking, passive smoking, occupational exposures, bio-fuels exposures ect.
89540295|NCT02119156|Experimental|Treatment Holiday Group|Subjects in the Treatment Holiday Group will undergo a 6 month belimumab treatment holiday while remaining on standard of care SLE therapy, then re-start belimumab therapy for 6 months while receiving standard of care SLE therapy.
89540296|NCT02119156|Active Comparator|Control Group|Subjects in the Control Group will continue to receive monthly belimumab therapy, in addition to standard of care SLE therapy for 52 weeks.
89540297|NCT02119156|No Intervention|Long-Term Discontinuation Group|Subjects in the Long-Term Discontinuation Group have elected to discontinue further belimumab therapy and will remain on standard of care SLE therapy as directed by the investigator, and agree to return for monthly visits for 52 weeks.
88958294|NCT01992224|Experimental|conventional mechanical ventilation|other group who don't start early mechanical ventilation and fulfillment four criteria below: respiratory rate > 28 bpm dyspnea PaO2/FiO2 Index <200 mmHg Chest X-ray: lung infiltration exclude chronic heart failure and pulmonary disease
89540298|NCT02181556|Experimental|FOLFIRI + Aflibercept|FOLFIRI and aflibercept (4 mg/m²) each 14 days until progression of disease
89540299|NCT02614131|Experimental|LY2599666 (Part A)|LY2599666 given subcutaneously (SC) once.
89540300|NCT02614131|Placebo Comparator|Placebo (Part A)|Placebo matching LY2599666 given SC once.
89540301|NCT02614131|Experimental|LY2599666 (Part B)|LY2599666 given SC once weekly for 12 weeks (13 doses).
89540302|NCT02614131|Placebo Comparator|Placebo (Part B)|Placebo given SC once weekly for 12 weeks (13 doses).
88958295|NCT01992237||ALI patients|Patients with ARDS by Berlin definition and with or without clinical indication for ECMO treatment.
88958296|NCT01992250|Other|Low Risk - Age 70+|Age 70+. Patients treated with the Visica 2 Treatment System, followed by adjuvant therapies
88958297|NCT01992250|Other|Moderate Risk - Age 50-69|Age between 50-69. Patients treated with the Visica 2 Treatment System, followed by adjuvant therapies
88958298|NCT01992263|Experimental|Vitamin D (600 IU)|
88958299|NCT01992263|Experimental|Vitamin D (2000 IU)|
88958300|NCT01992263|Experimental|Vitamin D (4000 IU)|
88958301|NCT01992263|Placebo Comparator|Placebo|
88958302|NCT01992276|Experimental|CR8020|Investigational monoclonal antibody against influenza A viruses
88958303|NCT01992276|Experimental|CR6261|Investigational monoclonal antibody against influenza A viruses
88958304|NCT01992276|Placebo Comparator|Placebo|Dextrose: 5% in water
88958305|NCT01992289||No treatment|This is a long-term follow-up study of subjects that received EDI200 as part of protocol ECP-002.
88958306|NCT01992302||Rapid Cycling Group|Patients who develop a rapid cycling course during the follow-up period.
88958307|NCT01992302||Non Rapid Cycling Group|Patients who do not develop a rapid cycling course during the follow-up period.
88958308|NCT01992315|Experimental|Adipose-Derived ECM|
88958309|NCT01992328|Experimental|Immune Globulin|Immunoglobulin G Deficiency Associated with persistent asthma subtypes
88958310|NCT01992341|Experimental|AMG 386 15mg/kg and paclitaxel 80mg/m2|
88958311|NCT01992367|Placebo Comparator|Placebo|placebo arm
89540303|NCT02614131|Experimental|Solanezumab (Part C)|Solanezumab given intravenously (IV) once weekly or once every 4 weeks for 12 weeks.
89540304|NCT02614131|Placebo Comparator|Placebo (Part C)|Placebo given IV once weekly or once every 4 weeks for 12 weeks.
89540305|NCT04429815||Active smokers.|Active smokers since October 2019.
89540306|NCT04429815||Smokers undergoing smoking cessation|Smokers undergoing smoking cessation and taking nicotine substitutes on a regular basis since October 2019.
89540307|NCT04429815||Non-smoking.|Person who's never smoked before.
89540308|NCT03044769||Patient with CLA with surgery|
89540309|NCT03044769||Patient with CLA without surgery|
89540310|NCT04876443||Alcohol-related liver disease|
88958312|NCT01992367|Other|ASLAN003|Active drug
88958313|NCT01992406||Transrectal hybrid-NOTES anterior resection|
88958314|NCT01992445||Suicidal|
88958315|NCT01992445||Other mental health|
88958316|NCT01992445||Control (non suicidal, non mental health)|
88958317|NCT01992471||history of breast cancer who have undergone BRCA1/2 testing|This is a single-arm observational study. Subjects with a history of breast cancer who have undergone BRCA1/2 testing and have received uninformative findings will enroll in this study, and then receive pre-test counseling for multiplex testing.
88958318|NCT01992497|Placebo Comparator|Formula + placebo|
88958319|NCT01992497|Experimental|Formula + probiotic|Formula + probiotic
88958320|NCT01992497|Experimental|Breastfed + probiotic|Breastfed + probiotic
88958321|NCT01992497|Placebo Comparator|Breastfed + placebo|
88958322|NCT01992510||silicone oil fiiled eye|those with a condition
88958323|NCT01992510||fellow eye|the contralateral eye in the same patient
88958324|NCT01992562|Experimental|Treatment|5 mcg ziconotide in 1ml of normal saline bolus intrathecal injection
88958325|NCT01992562|Placebo Comparator|Placebo|1ml of normal saline bolus intrathecal injection
88958326|NCT01992588|Experimental|FIAsp followed by NovoRapid®|Each subject will be randomly allocated to a treatment sequence consisting of 2 dosing visits separated by a wash-out period of 3-12 days
88958327|NCT01992588|Experimental|NovoRapid® followed by FIAsp|Each subject will be randomly allocated to a treatment sequence consisting of 2 dosing visits separated by a wash-out period of 3-12 days
88958328|NCT01992601|Experimental|1|This arm is consist of 12 subject. Crestor 20mg alone for 6 day during period 1. Crestor 20mg and Micardis 80mg for 6 day during period 2.
88958329|NCT01992601|Experimental|2|This arm is consist of 12 subject. Crestor 20mg and Micardis 80mg for 6 day during period 1. Crestor 20mg alone for 6 day during period 2.
88958330|NCT01992601|Experimental|3|This arm is consist of 12 subject. Micardis 80mg alone for 6 day during period 1. Crestor 20mg and Micardis 80mg for 6 day during period 2.
88958331|NCT01992601|Experimental|4|This arm is consist of 12 subject. Crestor 20mg and Micardis 80mg for 6 day during period 1. Micardis 80mg alone for 6 day during period 2.
88958332|NCT01992614|Experimental|Cohort 1|Single ascending doses of PF-06678552 or placebo to investigate the safety, tolerability, PK, and PD.
88958333|NCT01992614|Experimental|Cohort 2|Single ascending doses of PF-06678552 or placebo to investigate the safety, tolerability, PK, and PD.
88958334|NCT01992614|Experimental|Cohort 3|Single ascending doses of PF-06678552 or placebo to investigate the safety, tolerability, PK, and PD.
88958335|NCT01992627|Experimental|High Intensity Laser Therapy|High Intensity Laser Therapy (HILTERAPIA HIRO 3.O)will be used among diagnosed patients with elbow epicondylosis. A five minutes duration of HILTERAPIA HIRO 3.0 along the epicondyle area in a targeted manner will be use on the initial treatment, one week after the initial treatment, two weeks after the initial treatment and four weeks after the initial treatment thereafter.
88958336|NCT01992666|Experimental|Blood sampling|
88958337|NCT01992679|No Intervention|Control|Participants in the control group will undergo the same assessments but receive no exercise stimulus and be asked to maintain current physical levels
88958338|NCT01992679|Experimental|Exercise group|The exercise program will consist of biweekly training sessions for 20 weeks. Per neurorecovery network guidelines, each training session will include a minimum of 20 minutes of locomotor training and 20 minutes of balance training.
88958339|NCT01992692||PD group|Parkinsonian patients undergoing deep brain stimulator insertion and pulse generator placement
88958340|NCT01992692||non-PD group|Non-Parkinsonian patients undergoing intracranial surgery
88958341|NCT01992705|Other|Chemotherapy+SBRT prior to surgery if applicable|"FOLFIRINOX Drugs:~Calcium Folinate (Folinic Acid) 400 mg IV on Day 1 of each cycle (21d/cycle for a total of 4 cycles.~Stereotactic Body Radiotherapy (SBRT):~30 Gy in 5 fractions given to radiographically defined pancreatic mass alone"
88958342|NCT01992718|Active Comparator|Evaluation of MRI, US for pelvic conditions|MRI and ultrasound imaging will be used clinically to evaluate pelvic pain and abnormal uterine bleeding. The goal is to determine which exams are most helpful to the clinician in providing an accurate diagnosis as well as evaluating patient preference.
88958343|NCT01992718|Active Comparator|Patient preference MRI vs. US|We are asking subjects to evaluate patient preference between MRI (magnetic resonance imaging) and ultrasound to determine which they would rather undergo.
88958344|NCT01992731|Active Comparator|IUI group|"Group 1: Patients undergo a standard treatment with 3 consecutive gonadotrophin stimulated IUI cycles Intervention: treatment choice and drug:(Follitropine Bèta, Puregon, MSD).~vs."
88958345|NCT01992731|Active Comparator|IVF/ICSI arm|"Group 2: 1 Patients start immediately with IVF/ICSI instead of IUI. A standard antagonist protocol with treatment with a recombinant FSH (Follitropine Bèta, Puregon, MSD) is used.~Intervention: treatment choice and drug: recombinant FSH (Follitropine Bèta, Puregon,"
88958346|NCT01992744||Healthy Pregnant Women|Participants 8 to 12 weeks gestational age as determined by their physician.
88958347|NCT01992770|Experimental|Tailored behavioural medicine|After having received a minimal intervention (step 1) comprising 'stay-active advice', participants scoring >90 on the Örebro Musculoskeletal Pain Questionnaire (ÖMPQ) are randomly allocated to an eight-week treatment in step 2, depending on risk profile. The experimental condition includes supervised physical exercises integrated with either (a) graded activity, or (b) hierarchical graded exposure depending on risk profile, i.e. absence or presence of pain catastrophizing and fear-avoidance beliefs.
88958348|NCT01992770|Active Comparator|Control group|"Participants will be scheduled for supervised, regular Physical exercises twice a week during eight weeks 8. Participants with a moderate to high disability risk profile will receive: Tailored graded activities training."
88958349|NCT01992783|Experimental|Hi-maize resistant starch|13.5 g/day
88958350|NCT01992783|Placebo Comparator|Maltodextrin|13.5 g/day
89032943|NCT02945111|Experimental|Real-time view|Women undergoing Visual Inspection with Acetic Acid (VIA) and Lugol's Iodine (VILI) will watch the cervical images taken throughout the examination in real-time on a digital screen. The patients' anxiety level both before and after the examination will be measured using the Spielberg's State Anxiety Inventory.
89508643|NCT03064113|Experimental|Sequence 2|Period 1 = TD-4208 700 μg; Period 2 = Ipratropium 500 μg; Period 3 = Placebo; Period 4 = TD-4208 350 μg
88958351|NCT01992796|Experimental|irbesartan|"Irbesartan (total dose of 75 mg) or placebo administered every 24 hrs for 15 days. Moreover, the sepsis management will follow standard international guidelines (Crit Care Med.2008 Jan;36(1):296-327. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock).~Duration of treatment: Irbesartan 75 mg daily for 15 days; only one cycle. Follow up will last 90 days both for treatment and control arm.~Route of administration : oral by nasogastric tube.~Medication permitted and not permitted during the trial:~all the therapeutic interventions for sepsis management as indicated by international guidelines are admitted. During the trial are not permitted: ACE inhibitors, ARBs different from Irbersartan, angiotensin I synthesis inhibitors"
88958352|NCT01992796|Placebo Comparator|Placebo|Packaging and labelling for blinding purposes: tablets of placebo looking like the study drug
88958353|NCT01992809|Active Comparator|Omega 3|Omega-3 group (n=30) received capsules containing 945 mg of Omega-3 PUFA [α linolenic acid/ 64%, eicosapentaenoic acid (EPA)/16% and docosahexaenoic acid (DHA)/21%], in 3 capsules/ day
88958354|NCT01992809|Placebo Comparator|placebo mineral oil|placebo mineral oil 3 ml/day
88958355|NCT01992822|Experimental|experimental pain induction|application of a pre-fixed pressure (160 kPa) on the forearm
88958356|NCT01992835|Placebo Comparator|measurement of mediators in biological fluids|
88958357|NCT01992835|Experimental|Grass pollen allergen extract|
88958358|NCT01992848|Experimental|All participants|"Venous blood sampling 4-day food diary~1 week UV Dosimeter Peripheral Quantitative Computed Tomography of the radius"
88958359|NCT01992887||In-depth Interview|Up to 20 in-depth interviews will be conducted among adult ART naïve patients, balanced by gender, site and reason for ART naiveté (determined ineligible or eligibility not yet determined) as much as possible. Up to 4 in-depth interviews will be conducted with health care providers.
88958360|NCT01992887||Focus Group Participants|Up to 40 patients ineligible or not yet eligible for ART will be invited to join a focus group discussion. Patients will be eligible for selection for either in-depth interviews or focus group discussions if they have made at least one prior visit to the clinic. Selected patients will be balanced as much as possible by gender and by pre-ART status (e.g. roughly half pre-ART eligibility determined, and roughly half pre-ART eligibility indeterminate).
88958361|NCT01992887||Prospective Cohort|Based on historical patient data from the four study CTCs, we expect that approximately 1,000 patients will enroll in HIV care at these clinics during the study period and be determined not eligible for ART or of unknown eligibility. Assuming a 10% refusal rate, approximately 900 patients would then enroll in this study and complete baseline interviews. These 900 patients will be prospectively monitored using routinely collected patient care data for up to 24 months. Outreach workers will attempt to trace all of the enrolled patients who are observed to be LTF during the study period, and complete a defaulter tracing survey.
88958362|NCT01992900|Experimental|Eurartesim dispersible oral tablets|Each patient will receive a specific amount of drug according to his/her body weight, once a day for three consecutive days (from 5 to <7 kg: 1 tablet containing 80 mg PQP and 10 mg DHA; from 7 to < 13 kg: 1 tablet containing 160 mg PQP and 20 mg DHA).
88958363|NCT01992900|Active Comparator|Eurartesim film coated tablet|Each patient will receive a specific amount of drug according to his/her body weight, once a day for three consecutive days (from 5 to <7 kg: half tablet equal to 80 mg PQP and 10 mg DHA; from 7 to < 13 kg: 1 tablet containing 160 mg PQP and 20 mg DHA).
88958364|NCT01992913|Experimental|iCBT|integrated CBT with computerized cognitive remediation
88958365|NCT01992913|Other|UC|usual care
88958366|NCT01992926|Active Comparator|interactive educational intervention|Physicians will use an interactive educational worksheet during the standard-of-care clinic visit.
88958367|NCT01992926|No Intervention|control group|Physicians will conduct the standard-of-care clinic visit as usual.
88958368|NCT01992939|Active Comparator|Non-Healthy Subjects arm|Subjects in this arm will have peripheral vascular disease (PVD), vasoconstriction, or hypothermic extremities and they will receive two pulse oximetry probes. One probe will be a standard of care pulse oximetry probe and the second probe is the specialized pulse oximetry probe with external heat pack
88958369|NCT01992939|Active Comparator|Healthy Subjects Arm|Subjects who do not have peripheral vascular disease (PVD), vasoconstriction, or hypothermic extremities will be considered healthy subjects and they will receive two pulse oximetry probes. One probe will be a standard of care pulse oximetry probe and the second probe is the specialized pulse oximetry probe with external heat pack.
88958370|NCT01992965|Experimental|Continuous Glucose Monitoring Group|"Continuous Glucose Monitoring Group:~Different methods of blood glucose monitoring between groups, and this group will use real-time continuous glucose monitoring system with alarm limits（high and low limit is 10 mmol/L and 8 mmil/L , respectively ) up to five days for glucose control, the target mean glucose level is between 8 and 10 mmol/L."
88958371|NCT01992965|Active Comparator|Conventional Group|"Conventional Group：~Different methods of blood glucose monitoring between groups, and this group will use finger prick blood glucose measurements for glucose control with the same target mean glucose level of 8 -10 mmol/L. Patients also wear real-time continuous glucose monitoring system to collect glucose measurements. The values of real-time continuous glucose monitoring system are blinded to investigator and patients."
88958372|NCT01992978|Experimental|radiofrequency-assisted resection group（RF-R)|Radiofrequency-assisted resection: separating the tumor from liver by using the probe of radiofrequency to block the arterial and vessels before parenchymal transection.
88958373|NCT01992978|Active Comparator|conventional liver resection group（CLR-R）|Conventional liver resection group: hepatectomy only without RF assisted during parenchymal transection.Separating and dissecting the tumor with the routine clamp-crushing technical.
88958374|NCT01992991|Experimental|Transcranial direct current stimulation|Anodal stimulation
89540311|NCT04870437|Experimental|Extracorporeal phototherapy|
89540312|NCT04865991|Experimental|TCI propofol group|Subjects in the TCI propofol group received TCI propofol for anesthesia maintenance, Ce value was titrated until a targeted BIS score of 40-60 achieved.
88958375|NCT01992991|Sham Comparator|Sham stimulation|30 sek of Transcranial direct current stimulation
88958376|NCT01993004||Healthy subjects|Self-explanatory
88958377|NCT01993004||Untreated patients|Patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) or clinically isolated syndrome (CIS) who are not on any disease-modifying treatment approved for MS
88958378|NCT01993004||Treated patients|Patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) or clinically isolated syndrome (CIS) who were prescribed Glatiramer acetate prior to enrollment
88958379|NCT01993056|Experimental|warm-up with 11+|"The FIFA 11+ is a complete warm up program aiming on reduce common soccer injuries"
88958380|NCT01993056|Placebo Comparator|control|the control group follows its regular training routine
88958381|NCT01993069|Experimental|Iyengar-based Yoga Training|6 weekly Iyengar-based yoga classes
88958382|NCT01993095|Experimental|Experimental: FlexToBa physical activity DVD|Participants in this arm will receive a physical activity program delivered by DVD that focuses on exercises targeting flexibility, toning and balance. These exercises will be progressive in nature throughout the six months and will also focus on modifications for all ability levels. Participants will be provided with three DVDs including: an Introduction to physical activity, Sessions 1-3, and Sessions 4-6, which they will be asked to watch and participate in over the course of six months.
88958383|NCT01993095|Active Comparator|Usual care-Wait list|Participants in this arm will receive a DVD that focuses on healthy aging topics but does not include physical activity. They will receive the FlexToBa DVD after the completion of the 6-month follow-up testing.
88958384|NCT01993121|Experimental|Three-month exercise training program|All subjects will perform three months of supervised exercise training.
88958385|NCT01993134|Experimental|Cefazolin|2g of Cefazolin, 20minutes before sugery. After surgery, 1g of cefazolin 06/06h.
88958386|NCT01993134|Active Comparator|Cefazolin Single Dose|2g of Cefazolin, 20minutes before sugery. After surgery, no drugs.
88958387|NCT01993147|Other|Dual Task Paradigm|This arm does not involve any drug intervention, it is an experimental type consisting of 80 subjects to study the dual task paradigm implemented during the fMRI scanning session. 80 subjects will perform the fMRI scan but will not undergo any drug intervention.
88958388|NCT01993160|Experimental|18F-FCH PET MR|Integrated whole body PET-MR or PET-CT and separate whole body MRI with use of 18F-FCH as the molecular probe
88958389|NCT01993173|Experimental|ADACEL Vaccine Group|Children, adolescents and adults randomized to receive a single booster dose of ADACEL (Tdap vaccine)
88958390|NCT01993173|Active Comparator|Local DT/Td Vaccine Group|Participants randomized to receive either a single booster dose of local DT vaccine (children aged 4 through 11 years) or local Td vaccine (adolescents and adults aged 12 through 64 years)
88958391|NCT01993199|Active Comparator|deep biopsy|
88958392|NCT01993212|Placebo Comparator|Placebo|Androxal Placebo and Gel Placebo
88958393|NCT01993212|Active Comparator|AndroGel Treatment|AndroGel 1.62% and Placebo Capsules
88958394|NCT01993212|Experimental|Androxal Treatment|Androxal 12.5 mg or 25mg and Placebo Gel
88958395|NCT01993225|Placebo Comparator|Placebo|Placebo Gel and Placebo capsules
88958396|NCT01993225|Experimental|Androxal Treatment|Androxal 12.5mg/25 mg and Placebo gel
88958397|NCT01993225|Active Comparator|AndroGel Treatment|AndroGel 1.62% and Placebo Capsules
88958398|NCT01993251|Active Comparator|melatonin 0.5mg|
88958399|NCT01993251|Active Comparator|melatonin 2mg|
88958400|NCT01993251|Active Comparator|melatonin 6mg|
88958401|NCT01993251|Placebo Comparator|placebo|
88958402|NCT01993277|Active Comparator|Fischer Wallace Stimulator|30 20-minute sessions of the Fischer Wallace Stimulator administered twice-per-day within a 3-week time-frame;
88958403|NCT01993277|Active Comparator|Nexalin Brain Stimulator|15 40-minute sessions of Nexalin Brain Stimulator adminsitered once-per-day within a 3-week time-frame
88958404|NCT01993277|Active Comparator|DAVID Delight Stimulator|15 40-minute sessions of the DAVID Delight administered once-per-day within a 3-week time-frame
88958405|NCT01993277|Active Comparator|Relaxation Therapy|15 40-minute relaxation therapy sessions once-per-day within a 3-week time-frame
88958406|NCT01993290|Active Comparator|USG Supraclavicular block|20 ml of ropivacaine 0,75% is administered to brachial plexus at supraclavicular level.
88958407|NCT01993290|Active Comparator|Lateral infraclavicular block|20 ml of ropivacaine 0,75 % is administered to brachialis plexus at lateral infraclavicular level
88958408|NCT01993290|Active Comparator|USG Axillaris block|20 ml of ropivacaine 0,75% is administered to plexus brachialis at axillaris level
88958409|NCT01993303||Single Cohort|Population: 19 subjects, mean age 65 years, mean BMI 30 kg/m2, 79% male. Radionuclide Dosage: Rb-82 doses were rest 53+/-5 mCi and stress 53+/-6 mCi All were stress with Dipyridamole.
88958410|NCT01993316|Experimental|neurofeedback training|Subjects will undergo neurofeedback training to either the right primary motor cortex or the right superior parietal gyrus. The EEG measurements will be analyzed using LORETA.
89508644|NCT03064113|Experimental|Sequence 3|Period 1 = TD-4208 350 μg; Period 2 = Placebo; Period 3 = Ipratropium 500 μg; Period 4 = TD-4208 700 μg
89508645|NCT03064113|Experimental|Sequence 4|Period 1 = Ipratropium 500 μg; Period 2 = TD-4208 350 μg; Period 3 = TD-4208 700 μg; Period 4 = Placebo
89508646|NCT04464109|Active Comparator|Retro-scleral placement of the implant|"Surgical steps;~Two anterior scleral relaxing incisions~A 360° scleral incision around the optic nerve to disinsert it~Two posterior scleral relaxing incisions~The implant is inserted posterior to posterior scleral edges~The posterior sclera is closed then the anterior sclera is overlapped and closed.~The implant is completely seated in the intraconal space"
88958411|NCT01993342||Inflammatory knee osteoarthritis|We recruited patients with osteoarthritis and synovial effusion to diagnostic the effusion and to confirm that this this synovial fluid had mechanical characteristics. Now we are going to determine the adipocytokines and traditional parameters of inflammation in this synovial fluid to correlate it, and we will associate it with the ultrasound explanation of the knee that we have in our database.
88958412|NCT01993355|Active Comparator|TAU|Control group. Treatment as usual (TAU): Physiotherapy program for CLBP.
88958413|NCT01993355|Experimental|Intervention 1 Relaxation techniques-sophrology|Intervention group 1: TAU + relaxation techniques-sophrology program.
88958414|NCT01993355|Experimental|Intervention 2 Cognitive-behavioral therapy|Intervention group 2: TAU + cognitive-behavioral therapy.
88958415|NCT01993368|Other|chronic periodontitis|biopsy of periodontal granulation tissue (surgical waste)
89508647|NCT04464109|Active Comparator|Intrascleral placement of the implant|"Anterior and posterior sclerotomies with the implant partly in the scleral shell and partly in the intraconal space.~Anterior relaxing sclerotomies not reaching the optic nerve~A 360° scleral incision around the optic nerve.~The anterior sclera flaps are overlapped and closed~Part of the implant remains in the scleral shell, while the remaining part is sitting in the intraconal space."
88958416|NCT01993368|Other|aggressive periodontitis (AP)|biopsy of periodontal granulation tissue (surgical waste)
88958417|NCT01993368|Other|controls|necessitating an extraction of wisdom teeth
88958418|NCT01993381||CINV of FOLFOX, FOLFIRI|moderate emetogenic chemotherapy
88958419|NCT01993394|Experimental|ventilation|hypergravity gas mixture
88958420|NCT01993407|Experimental|Task Switching Training|Participants will complete four, one-hour training sessions in which they will practice switching between tasks within an alternating runs task switching paradigm.
89508648|NCT02309827|Experimental|Cohort 1: PF-06651600 or Placebo|Single ascending doses of PF-06651600 or placebo to evaluate safety, tolerability and PK.
89508649|NCT02309827|Experimental|Cohort 2: PF-06651600 or Placebo|Single ascending doses of PF-06651600 or placebo to evaluate safety, tolerability and PK.
88958421|NCT01993407|Placebo Comparator|Pure Task Training|Participants will complete four, one-hour training sessions in which they will perform a single task each session, alternating tasks between but not within sessions.
88958422|NCT01993420|Experimental|DRM02|DRM02 Topical Gel, 0.25%
88958423|NCT01993420|Placebo Comparator|Vehicle|DRM02 Topical Gel, Vehicle
88958424|NCT01993433|Experimental|DRM02|DRM02 Topical Gel, 0.25%
88958425|NCT01993433|Placebo Comparator|Vehicle|DRM02 Topical Gel, Vehicle
88958426|NCT01993446|Experimental|DRM02|DRM02 Topical Gel, 0.25%
89508650|NCT02309827|Experimental|Cohort 3: PF-06651600 or Placebo|Single ascending doses and multiple ascending doses of PF-06651600 or placebo to evaluate safety, tolerability and PK.
88958427|NCT01993446|Placebo Comparator|Vehicle|DRM02 Topical Gel, Vehicle
89024002|NCT03996837|Experimental|Fresh embryo transfer with intra uterine infusion of PRP|In IVF-ICSI cycles, ovulation will be stimulated through the standard protocol using a gonadotropin-releasing hormone agonist for all patients. 48 hours after the oocyte retrieval and ensuring that at least 3 good quality embryos are formed, patients will be randomized into two groups of with and without PRP intrauterine injection. For all patients, 2 embryos in the blastocyst stage with excellent or good quality will be transferred. One milliliter PRP will be injected into the patients' uterine cavity using an embryo transfer catheter (Labotect Gmbh, Labor-Technik-Gottingen Kampweg 12, 37124 Rosdorf, Germany) 48 hours before embryo transfer. In order to eliminate the effects of catheter insertion, the same catheter will be applied to the patients in the control group 48 hours before the embryo transfer without any injections.
89508651|NCT02309827|Experimental|Cohort 4: PF-06651600 or Placebo|Single ascending doses and multiple ascending doses of PF-06651600 or placebo to evaluate safety, tolerability and PK.
89508652|NCT02309827|Experimental|Cohort 5: PF-06651600 or Placebo|Single ascending doses and multiple ascending doses of PF-06651600 or placebo to evaluate safety, tolerability and PK.
89508653|NCT02309827|Experimental|Cohort 6: PF-06651600 or Placebo|Single ascending doses and multiple ascending doses of PF-06651600 or placebo to evaluate safety, tolerability and PK.
89508654|NCT02309827|Experimental|Cohort 7: PF-06651600 or Placebo|Single ascending doses and multiple ascending doses of PF-06651600 or placebo to evaluate safety, tolerability and PK.
89508655|NCT02309827|Experimental|Cohort 8: PF-06651600 or Placebo|Single ascending doses and multiple ascending doses of PF-06651600 or placebo to evaluate safety, tolerability and PK.
89508656|NCT02309827|Experimental|Cohort 9: PF-06651600 or Placebo|Multiple ascending doses of PF-06651600 or placebo to evaluate safety, tolerability and PK.
89508657|NCT02301715|Active Comparator|Oxytocin|24 IU Oxytocin, 3 puffs per nostril, each with 4 IU OXT, intranasal application 45 min prior to the experiment
88958428|NCT01993459|Experimental|Midazolam intravenous|3mg/ml midazolam given intravenously
88958429|NCT01993459|Placebo Comparator|NaCl (sodium chloride) 0,9%|NaCl (sodium chloride) 0,9% given intravenously 3ml.
88958430|NCT01993472|Experimental|Andrographolides with Capecitabine|Capecitabine1250mg/m2 , bid，d1-14，q3w, Andrographolides 500mg，qd，d1-14，q3w;
88958431|NCT01993472|Active Comparator|Capecitabin alone|Capecitabine1250mg/m2 , bid，d1-14，q3w,
88958432|NCT01993511||RYGB patients with type 2 diabetes|Preoperative oral glucose tolerance test with 2 h P-glucose >11.1 mmol/L
88958433|NCT01993511||RYGB patients with IGT|Preoperative oral glucose tolerance test with 2 h p-glucose >7.8 and <11.1 mmol/L
88958434|NCT01993511||RYGB patients with NGT|Preoperative oral glucose tolerance test with 2 h p-Glucose <7.8 mmol/L
88958435|NCT01993524|Experimental|probiotic|At I visit standard treatment(500mg oral metronidazole twice daily for 7 days) and probiotic twice daily for 10 days. At II visit, participants were checked for signs of vaginal infection; if they were still present they were given a targeted antibiotic according to the microbiological analysis. Antibiotic was taken together with probiotic twice daily for 10 days. Participants showing positive response to metronidazole treatment on the II visit were given only the probiotic once daily for 10 days in the peri-menstrual period for the next 3 months. Participants with targeted antibiotic were to come to the visit IIbis, and if treatment was successful they were to proceed for the next 3 months in the same manner as those successfully treated with metronidazole, as described above.
88958436|NCT01993524|Placebo Comparator|placebo|At I visit standard treatment (500mg oral metronidazole twice daily for 7 days) and placebo twice daily for 10 days. At the II visit, participants were checked for signs of vaginal infection; if they were present they were given a targeted antibiotic according to the microbiological analysis. Antibiotic was taken together with placebo twice daily for 10 days. Participants showing positive responses to metronidazole on the II visit were given only placebo once daily for 10 days in the peri-menstrual period for the next 3 months. Participants with targeted antibiotic were to come to the visit IIbis, and if treatment was successful they were to proceed for the next 3 months in the same manner as those successfully treated with metronidazole, as described above.
88958437|NCT01993537|No Intervention|Sufficeint|In this arm the participants have a Vitamin D level of greater than 75 ng/ml. They will continue to be monitored throughout the study but will not receive any intervention.
88958438|NCT01993537|No Intervention|Mild Insufficiency|In this arm the participants have a Vitamin D level between 37.5 - 75 ng/ml. The participants will be monitored throughout the study but will receive no intervention.
88958439|NCT01993537|No Intervention|Severe Deficiency no treatment|In this arm the participants have a low Vitamin D level of less than 37.5 ng/ml. The participants will be monitored but will receive no intervention.
89508658|NCT02301715|Placebo Comparator|Placebo|intranasal application, sodium chloride solution, 3 puffs per nostril, 45 min prior to the experiment
89508659|NCT02301871|Active Comparator|Conventional group|The treatment was given for 5 days per week for 2 weeks such as MHP (Moist Heat Pack) for 20 minutes, Static Stretching exercises for upper trapezius, levator scapulae and scalene muscle which is held for 10-30 seconds- repeated 3-5 times, Cervical spine non-thrust mobilization (Grade 3) was given to each segment from C2-C7 was oscillated for 10 repetitions, followed by a 10 seconds rest between segments, Cervical spine active ROM (Range of Motion) exercises with 10 repetitions- 2-3 times a day and Postural exercises were given as home programme.
88958440|NCT01993537|Experimental|Severe Deficiency - Treatment|In this arm the participants will be treated with Vitamin D. The participants will be prescribed a dose of 1000 IU a day (1 pill a day). At 6 weeks the dosage will increase to 2000 IU a day (2 pills a day).
88958441|NCT01993550|Experimental|Telephone counseling|Telephone counseling to enhance symptom management and reduce distress
88958442|NCT01993550|Active Comparator|Education|Overview of resources for psychosocial support and health information
88958443|NCT01993563|Experimental|Graded Motor Imagery|
88958444|NCT01993563|Active Comparator|Standard treatment|
88958445|NCT01993576|Experimental|indocyanine green|Indocyanine green is injected intravenously.
88958446|NCT01993589|No Intervention|Control group|Control group
88958447|NCT01993589|Active Comparator|Pain reliever|1000 mg paracetamol (Parol 1 g Atabay ilaç Turkey)
89508660|NCT02301871|Experimental|DNF Group|"DNF training along with conventional treatment. In this programme, emphasis was placed on first attaining the correct craniocervical flexion action, with minimal activity of the superficial cervical flexor muscles. The craniocervical flexion action involves a specific craniocervical movement (nodding - yes movement) of head such that it remains in contact with the supporting surface. Once the correct action had been achieved, participants were instructed in the use of the sphygmomanometer to guide the training of the CCF muscle contraction at the various incremental levels of pressure (22 to 30 mmHg, progressively inner range positions)."
89508661|NCT02301871|Experimental|MET Group|MET in additional to conventional treatment. MET was applied to Upper trapezius, Levator scapulae and Scalene Following the 7-10 seconds isometric contraction and complete relaxation of all elements, the stretch is maintained for 30 seconds. The effort and the counter-pressure should be modest (20% of available strength) and painless. The process is repeated 3-5 times.
88958448|NCT01993589|Active Comparator|Dexketoprofen trometamol|25 mg oral Dexofen Atabay ilaç Turkey
88958449|NCT01993589|Active Comparator|Lidocaine spray|2 puff on cervical mucosa (Xylocain Pump 100 Mg 50 Ml Sprey Astra Zeneca)
88958450|NCT01993589|Active Comparator|pethidine|Aldolan 100 mg Liba Laboratuarı İstanbul Turkey
88958451|NCT01993589|Active Comparator|diclofenac sodium|Dicloron amp 75 mg Deva İlaç Levent İstanbul/Turkey
88958452|NCT01993602|No Intervention|Control group|no intervention was performed in this group during postoperative period,
89508662|NCT03053037|Active Comparator|Group S|mesial canals in Group S will be instrumented to size 25
88958453|NCT01993602|Active Comparator|volumetric incentive spirometry|patients performed breathing exercises using volumetric incentive spirometer during five postoperative days
88958454|NCT01993602|Active Comparator|Flow oriented incentive spirometry|patients performed breathing exercises using flow oriented incentive spirometer during five postoperative days
88958455|NCT01993602|Active Comparator|Deep breathing group|patients performed deep breathing exercises without any device during five postoperative days
88958456|NCT01993602|Active Comparator|Continuous positive airway pressure group|patients performed breathing exercises using continuous positive airway pressure group during five postoperative days
88958457|NCT01993628|Experimental|Alzheimer's disease (AD)|Rey figure test and MRI
89508663|NCT03053037|Active Comparator|Group L|mesial canals in Group L will be instrumented to size 35
89508664|NCT03509545|Experimental|CHF Patients: ER Torsemide 40 mg|CHF patients will be given 40 mg ER Torsemide
88958458|NCT01993628|Experimental|Lewy body's dementia (LBD)|Rey figure test and MRI
88958459|NCT01993654||Nevus|
88958460|NCT01993654||Racial Melanosis|
88958461|NCT01993654||Primary Acquired Melanosis|
88958462|NCT01993654||Malignant Melanoma|
88958463|NCT01993654||Normal|
88958464|NCT01993680|Experimental|Pyridostigmine bromide|14 days of active treatment followed by 21 days wash out
88958465|NCT01993680|Active Comparator|fludrocortisone|14 days of fludrocortisone treatment; 21 days wash out
88958466|NCT01993693|Experimental|Ultrasonic Diathermy Device|Therapeutic ultrasound used daily.
88958467|NCT01993693|Placebo Comparator|Sham Ultrasonic Diathermy Device|Sham device that does not deliver ultrasound
89508665|NCT03509545|Active Comparator|CHF Patients: Furosemide 40 mg|CHF patients are on 40 mg of Furosemide
89508666|NCT02301949|Active Comparator|Thalidomide Retreatment Group|
89508667|NCT02301949|Placebo Comparator|Placebo Group|
88958468|NCT01993732|Experimental|Retrieval and Cryopreservation|Females undergoing therapeutic procedures that will potentially lead to the irreversible loss of ovarian function will have their ovarian tissue retrieved and cryopreserved. Ideally, after treatment, the cryopreserved ovarian tissue can be thawed and auto-transplanted and ovarian function resumed.
88958469|NCT01993745||Study group|ECMO Patients survived
88958470|NCT01993745||Control|ECMO Patient died
88958471|NCT01993758|Active Comparator|Conventional tourniquet pressure|The patients in this group will undertake total knee arthroplasty under conventional tourniquet pressure, which will be set as the pressure added by 150mmHg on the last systolic blood pressure just before tourniquet inflation.
88958472|NCT01993758|Experimental|Low tourniquet pressure|The patients in this group will undertake total knee arthroplasty under low tourniquet pressure, which will be set as the pressure added by 120mmHg on the last systolic blood pressure just before tourniquet inflation.
88958473|NCT01993771||Males and females with alopecia|Males and females with alopecia scheduled for general anaesthesia.
88958474|NCT01993784|Experimental|Nimotuzumab|the nimotuzumab treatment: 2 levels (400 mg/w, 600 mg/w, weekly, until disease progression)
88958475|NCT01993797||Bronchiolitis|children presented with signs suggestive of bronchiolitis
89508668|NCT02338557|Experimental|GROUP A|Subjects in Group A received MRP exercises for training of Wrist Extensors, Extension of wrist and holding objects, training of supination of forearm, opposition of thumb, cupping of hand and training of manipulation of the objects.
89508669|NCT02338557|Active Comparator|GROUP B|Group B received Mirror therapy in which patient was seated close to the table in front of mirror (35x35 cm). The involved hand was placed behind the mirror. : the practice consisted of intransitive exercises as Hand opening, Wrist extension and flexion, Forearm pronation and supination, Hand sliding on a flat surface. During the session patient were asked to try to do the same movement with the paretic hand while they were moving the non-paretic hand.In both the groups total treatment was given for 1 hour/day for 6 days/week
89508670|NCT03510949|Other|Group N|Patients' nasal mucosa will be anaesthetized and vasoconstricted. K-Y gel will be applied to the tip of nasopharyngeal airway (NPA) of appropriate size. The NPA will then be advanced into the dominant nostril along the septum horizontally.
89508671|NCT03510949|Other|Group L|K-Y gel will be applied to the tip of the laryngeal mask (LMA) of appropriate size. The LMA will be introduced along the hard palate towards the hypopharynx until resistance is felt.
89508672|NCT02335203|Experimental|Depot medroxyprogesterone acetate|Women randomized to receive one intramuscular injection of 400mg depot medroxyprogesterone acetate prior to hysterectomy.
89508673|NCT02335203|Placebo Comparator|Placebo injection|Women randomized to receive one intramuscular injection of 1mL normal saline prior to hysterectomy.
89508674|NCT02335047|Other|lower back pain|
89508675|NCT02303899|Experimental|Gemcitabine & Imatinib mesylate|Gemcitabine 1000 mg/m2, i.v., days 3 and 10 of a 21-days schedule; Imatinib mesylate 400 mg/die orally on days 1-5 and 8-12 of a 21-days schedule.
89508676|NCT02338635|Experimental|URSA group|Drug: Ursodeoxycholic acid Other Name: URSAⓇ (Daewoong Pharmaceutical Co., Ltd) Ursodeoxycholic acid (100 mg/tablet) 300 mg/day ( 100mg tid) for 6 months 3 times after meal
89508677|NCT02338635|Placebo Comparator|Placebo group|Placebo drug 1 tablet tid for 6 months
89508678|NCT03510871|Experimental|nivolumab plus ipilimumab|nivolumab plus ipilimumab
89508679|NCT02331771|Active Comparator|donepezil|Subjects will receive donepezil 5 mg before before they start ECT and continue the agent through the ECT procedures up to 4 weeks.
89508680|NCT02331771|Placebo Comparator|Placebo|Subjects will receive the placebo before they start ECT and continue the agent through the ECT procedures up to 4 weeks.
88958476|NCT01993862|No Intervention|Next Day Discharge|The patient will have a 23 hour standard of care observational stay in the hospital after an implantable cardioverter defibrillator implant procedure.
88958477|NCT01993862|Active Comparator|Same Day Discharge|The patient will be discharged from the hospital the same evening after an implantable cardioverter defibrillator implant procedure. Follow up after surgery will be done via remote device follow up (1) on the day of discharge and (2) 24 hours after surgery.
88958478|NCT01993901|Experimental|CSRT led telephone follow up|Patients in the experimental arm will be telephoned by the CSRT 4-6 weeks after completion of their treatment to assess any symptoms.
88958479|NCT01993901|No Intervention|Standard Follow up|"Patients in the control group will have the standard follow up (CT of the chest, abdomen and pelvis prior to follow-up with the radiation oncologist 4 months after the completion of their treatment). In order to control for an attention effect that may be seen in the intervention group, patients in the control group will get a placebo or sham telephone call initiated by a research assistant 4-6 weeks after completion of their treatment. This telephone call will simply confirm their follow up appointment."
88958480|NCT01993953|Active Comparator|BodyPump|Resistance training in group, with one instructor. This pre-choreographed class contains 10 to 12 exercises with a barbell, weights and a step. Number of repetitions throughout the class varies between muscle groups, but is generally high (20-100).
88958481|NCT01993953|Active Comparator|Personal training|The PT will instruct proper technique to their clients, correct the training and technique, control the intensity and serve as a motivator at each training session.
89508681|NCT02309905||Control group before telemedicine|Inmates of prisons not having telemedicine before implementation of telemedicine in prisons having telemedicine
89508682|NCT02309905||Control group after telemedicine|Inmates of prisons not having telemedicine after implementation of telemedicine in prisons having telemedicine
89508683|NCT02309905||Exposed group, before telemedicine|Inmates of prisons having telemedicine before implementation of telemedicine
89508684|NCT02309905||Exposed group, after telemedicine|Inmates of prisons having telemedicine after implementation of telemedicine
89508685|NCT02338401|Experimental|Omega-3 Complete|Oral ingestion of 3000 mg (5 capsules) of Omega-3 Complete (Jamieson Laboratories Ltd., Windsor, Ontario, Canada) per day for 12 weeks.
89508686|NCT02338401|Placebo Comparator|Placebo Pill|Oral ingestion of 3 capsules of a placebo olive oil pill (Swanson Health Products, PO Box 2803 - Fargo, ND 58108 USA) per day for 12 weeks.
89508687|NCT02883387|Experimental|Preoperative CT Angiography|Patients will receive preoperative CT angiography to map the blood vessels potentially used for reconstruction
89508688|NCT02883387|Active Comparator|No Imaging Preoperatively|No preoperative vessel mapping will be done
89024003|NCT03996837|No Intervention|Fresh embryo transfer without intra uterine infusion of PRP|In IVF-ICSI cycles, ovulation will be stimulated through the standard protocol using a gonadotropin-releasing hormone agonist for all patients. 48 hours after the oocyte retrieval and ensuring that at least 3 good quality embryos are formed, patients will be randomized into two groups of with and without PRP intrauterine injection. For all patients, 2 embryos in the blastocyst stage with excellent or good quality will be transferred. One milliliter PRP will be injected into the patients' uterine cavity using an embryo transfer catheter (Labotect Gmbh, Labor-Technik-Gottingen Kampweg 12, 37124 Rosdorf, Germany) 48 hours before embryo transfer. In order to eliminate the effects of catheter insertion, the same catheter will be applied to the patients in the control group 48 hours before the embryo transfer without any injections.
89024004|NCT03996837|Experimental|Freeze embryo transfer with intra uterine infusion of PRP|In frozen embryos transfer cycles, the endometrium of all patients will be prepared through the standard protocol using a gonadotropin-releasing hormone agonist. Following this process, 2 embryos in the blastocyst stage with good or excellent quality will be transferred. It is worth mentioning that in 48 hours prior to the embryo transfer; 1 mL of PRP will be injected into the uterine cavity using an embryo transfer catheter. In order to eliminate the effects of catheter insertion, the same catheter will be applied to the patients in the control group 48 hours before the embryo transfer without any injections.
89508689|NCT02309983|Active Comparator|Electrical Stimulation Alone Group|Group 1 will receive 1hr of electrical stimulation while lying down followed by 15 min of overground training. Electrical stimulation will be applied through leads and self-adhesive electrodes over muscles of both legs. Two electrodes will be used for each muscle. Electrical stimulation will be induced by using the EMPI, Inc., St. Paul, MN [Respond Select Neuromuscular Stimulation]. There will be 60 sessions/3x week for 20 weeks.
89508690|NCT02309983|Placebo Comparator|Stand Retraining Alone with BWS|Group 2 will receive standing retraining with BWS alone on a treadmill without functional electrical stimulation. Locomotor training consists of (step training and stand retraining) on the treadmill, over ground training, and community ambulation. BWS will be given when a subject can not maintain his/her body weight while executing limb locomotion. BWS will be given when a subject can not maintain his/her body weight while executing limb locomotion. The duration of stand retraining sessions will be up to 1 hour or determined by subject's fatigue. There will be 60 sessions/3x week for 20 weeks.
89508691|NCT02309983|Experimental|Stand Retraining and ES Group|Group 3 will receive standing retraining with BWS with electrical stimulation, followed by 15 min of overground training. Locomotor training consists of (step training and stand retraining) on the treadmill, over ground training, and community ambulation. BWS will be given when a subject can not maintain his/her body weight while executing limb locomotion. Electrical stimulation will start while participant is seated and before he/she is brought up to full standing. There will be 60 sessions/3x week for 20 weeks.
89508692|NCT02334969|Experimental|Experimental group|On the basis of the secondary prevention of ischemic stroke，Volunteers will be taken Naoxintong capsule, 2 times a day, three granule per time
89508693|NCT02334969|Active Comparator|Control group|On the basis of the secondary prevention of ischemic stroke，Volunteers will be taken Placebo capsule，which is identical with Naoxintong capsule in the appearance, shape, color and content, 2 times a day, three granule per time
89508694|NCT03505645|Active Comparator|Treatment group 1: Periarticular infiltration|Patients undergoing total knee replacement who are randomised to Treatment Group 1.
89508695|NCT03505645|Active Comparator|Treatment Group 2: Intra-articular infiltration|Patients undergoing total knee replacement who are randomised to Treatment Group 2.
89508696|NCT03505567|Other|Random Sequenced Interventions|Participants from three condition groups (normal, glaucoma, retinal disease) assigned two interventions (Kowa OCT Bi-μ and the Optovue iVue 100) under random sequence assignments.
89508697|NCT02334501|Experimental|Treatment A (Period 1) and Treatment B (Period 2)|Treatment A (240mg Neratinib x1) Treatment B (30mg Lansoprazole X 7 days + 240mg Neratinib x1)
89508698|NCT02302027|Experimental|platinium IRC9LXO2AWQ|Normobaric oxygen therapy with high flow concentrator to treat headaches attacks, 30 minutes of oxygene inhalation with mask, 9l/minute, no frequency limitation
89024005|NCT03996837|No Intervention|Freeze embryo transfer without intra uterine infusion of PRP|In frozen embryos transfer cycles, the endometrium of all patients will be prepared through the standard protocol using a gonadotropin-releasing hormone agonist. Following this process, 2 embryos in the blastocyst stage with good or excellent quality will be transferred. It is worth mentioning that in 48 hours prior to the embryo transfer; 1 mL of PRP will be injected into the uterine cavity using an embryo transfer catheter. In order to eliminate the effects of catheter insertion, the same catheter will be applied to the patients in the control group 48 hours before the embryo transfer without any injections.
89024006|NCT03993327|Experimental|Diagnostic (iodine I 124 monoclonal antibody M5A, PET scan)|Patients receive iodine I 124 monoclonal antibody M5A IV on day 0 and undergo PET scan on days 2 and 6.
89024007|NCT03982368|Experimental|rhNGF 20 μg/ml TID|One drop of rhNGF 20 μg/ml will be instilled in both eyes three times daily (every 6-8 hours)
89024008|NCT03982368|Experimental|rhNGF 20 μg/ml BID + vehicle OD|One drop of rhNGF 20 μg/ml will be instilled in both eyes two times daily (BID) plus one drop (40 μL) of vehicle will be instilled in both eyes once daily (OD) (every 6-8 hours)
89024009|NCT03982368|Placebo Comparator|Vehicle TID|Vehicle eye one drop will be instilled in both eyes three times daily (every 6-8 hours)
89508699|NCT02331927|No Intervention|Randomized Part: Arm A|Conventional switch of chemotherapy together with the antiangiogenic treatment: Bevacizumab and mFOLFOX6 (continuation of same regimen until progressive disease (PD) according to RECIST v1.1, followed by switch to aflibercept and FOLFIRI after PD).
89508700|NCT02331927|Experimental|Ramdomized Part: Arm B|Early marker-driven switch of anti-angiogenic agent and maintenance of chemotherapy: Bevacizumab and mFOLFOX6 will be administered until change of the CAF-profile and at least stable disease according to RECIST v1.1. Change to Aflibercept and mFOLFOX6 (change of bevacizumab to aflibercept and continuation of mFOLFOX6) until PD according to RECIST v1.1, followed by change to FOLFIRI after PD).
89508701|NCT02302183|Experimental|Experimental: device FreeO.|Automatic adjustment of oxygen
89508702|NCT02302183|Active Comparator|Manual oxygenation|Manual adjustment of oxygen
89508703|NCT02839629||Cohort 1: National patient cohorts in Scandinavia|Scandinavian countries: Denmark, Norway and Sweden Cohort 1 will include all patients with a diagnosis of NSCLC between 2005 and 2013
89024010|NCT03969446|Experimental|Cohort I Arm I (pembrolizumab, decitabine)|Patients receive pembrolizumab IV over 30 minutes on days 1 and 22 and decitabine IV over 1 hour on days 1-10. Patients who achieve a CR receive decitabine on days 1-5. Treatment repeats every 42 days for up to 8 cycles or 1 year from start of therapy, whichever comes first, in the absence of disease progression or unacceptable toxicity.
89024011|NCT03969446|Experimental|Cohort I Arm II (pembrolizumab, decitabine, venetoclax)|Patients with pembrolizumab IV over 30 minutes on days 1 and 22 and decitabine IV over 1 hour on days 1-10 or 1-5. Patients who achieve a CR receive decitabine on days 1-5. Patients also receive venetoclax PO QD on days 1-14. Treatment repeats every 42 days for up to 8 cycles or 1 year from start of therapy, whichever comes first, in the absence of disease progression or unacceptable toxicity.
89024012|NCT03969446|Experimental|Cohort II (pembrolizumab, decitabine)|Patients with MDS receive pembrolizumab IV over 30 minutes on days 1 and 22 and decitabine over 1 hour on days 1-5. Treatment repeats every 42 days for up to 8 cycles or 1 year from start of therapy, whichever comes first, in the absence of disease progression or unacceptable toxicity.
89024013|NCT03968068|Experimental|Exercise|
89508704|NCT02839629||Cohort 2: Electronic Medical Records based cohort (Sweden)|Patient as data is available (~2010) to 2013
89508705|NCT02302261||Status Asthmaticus|Any patient presenting to the ED with status asthmaticus.
89508706|NCT05157321|Active Comparator|Study Group|The patients in this group will receive active repetitive transcranial magnetic stimulation sessions for 4 weeks.
89508707|NCT05157321|Sham Comparator|control group|The patients in this group will receive sham repetitive transcranial magnetic stimulation sessions for 4 weeks.
89508708|NCT02322190|No Intervention|Investigator chosen second line therapy|Investigator chosen second line therapy
89508709|NCT02322190|Experimental|Second line therapy + Extracorporeal Photopheresis|Second line therapy in addition to Extracorporeal Photopheresis (ECP)
89508710|NCT02304055|Active Comparator|Carbetocin|100 women with atonic PPH will receive Carbetocin 100 µgm slowly iv.
89508711|NCT02304055|Active Comparator|Oxytocin|100 women with atonic PPH will receive oxytocin 5IU slowly iv.
89508712|NCT02331849|Other|Eosinophilic esophagitis|Patients with eosinophilic esophagitis after exclusion of GERD
89508713|NCT02334579|Experimental|CyberKnife Stereotactic Radiosurgery|This treatment concentrates large doses of radiation onto the tumor so that injury from radiation to the nearby normal tissue will be minimal. CyberKnife Stereotactic Radiosurgery is not investigational and is considered standard of care.
89508714|NCT03505489|Experimental|Mannitol challenge|Mannitol challenge performed per standard mannitol challenge procedure with deep inhalation technique
89508715|NCT03505489|Experimental|Mannitol challenge w/ TBI|Mannitol challenge performed per standard mannitol challenge procedure except with tidal breathing technique
89508716|NCT03505489|Experimental|Methacholine challenge w/ DI|Methacholine challenge performed per standard 2-minute tidal breathing challenge procedure except with deep inhalation technique
89508717|NCT03505489|Experimental|Methacholine challenge|Methacholine challenge performed per standard 2-minute tidal breathing challenge procedure (tidal breathing technique)
89508718|NCT02334657||non-aneurysmal subarachnoid hemorrhage|patients with non-aneurysmal subarachnoid hemorrhage, short-term outcome measured by modified Rankin Scale and long-term outcome by SF-36
89508719|NCT02334657||perimesencephalic SAH|subgroup of non-aneurysmal subarachnoid hemorrhage
89540313|NCT04865991|Active Comparator|sevoflurane group|Subjects in the sevoflurane group received sevoflurane 2 volume%, which were titrated up/down every 5 minutes to get a targeted BIS score of 40-60.
89540314|NCT04875897|Experimental|treatment with keepMED PAP device|Therapy night is performed with the keepMED PAP during a polysomnography in the sleep lab
89024014|NCT03968068|Experimental|Remote Ischaemic Conditioning|
89024015|NCT03960840|Experimental|CLL/SLL|Dose escalation and expansion of rapcabtagene autoleucel in combination with ibrutinib
89024016|NCT03960840|Experimental|3L+ DLBCL|Dose escalation and expansion of rapcabtagene autoleucel single agent in 3L+ DLBCL
89508720|NCT02334657||non-perimesencephalic (NPM) SAH|subgroup of non-aneurysmal subarachnoid hemorrhage
89508721|NCT02334657||subgroup of NPM-SAH with Fisher 3|patients with non-aneurysmal (non-perimesencephalic) SAH and a Fisher 3 bleeding pattern
89508722|NCT02334657||subgroup of NPM-SAH w/o Fisher 3|patients with non-aneurysmal (non-perimesencephalic) SAH and not a Fisher 3 bleeding pattern
89508723|NCT02310373|Experimental|Nicotine free hookah (herbal/steam stones) smoking|Healthy habitual Hookah smokers will undergo microneurography, myocardial contrast echocardiogram or venous occlusion plethysmography before and after nicotine free hookah smoking.
89508724|NCT02338323|Experimental|Febuxostat|take orally, 40mg per day, for 1 year
89508725|NCT02338323|Experimental|Benzbromarone|take orally, 50mg per day, for 1 year
89508726|NCT02311465|Experimental|Palliative Care + Standard of Care|Consenting patients will be approached by a research nurse to complete quality of life questionnaires (baseline measures) either in the oncology clinics or infusion clinics. Patients assigned to early palliative care will meet with a member of the palliative care team after enrollment and completion of the initial questionnaires to receive and review patient-oriented materials detailing palliative care services. Patients will then receive a comprehensive initial consult with a palliative care provider (a trained physician, nurse or nurse practitioner). Additional consults with the palliative care service will be scheduled approximately every 6 weeks for the duration of the study period (one year) at the discretion of the patient and palliative care provider.
89508727|NCT02311465|No Intervention|Standard of Care|Patients will receive standard care from their oncologist. An assessment of health related quality of life will be conducted at regular oncology clinic visits at baseline and 3,6,9,and 12 months.
89508728|NCT03112083|Active Comparator|Krill oil|Krill powder capsules, 4 g
89508729|NCT03112083|Placebo Comparator|Placebo|Placebo capsules, maize strach, 4 g
89508730|NCT03509311||Asthma Group|"That group consists from patients who had diagnosed as asthma by doctors from Chest Diseases Department of Gazi University Hospital.~Physical activity level assesment, maximal and submaximal exercise capacity assesment, respiratory function assesment, respiratory muscle strength assesment, respiratory muscle endurance assesment, peripheral muscle strength assesment, quality of life assesment about disease specific, respiratory, sleep and cough associated, fatigue severity assesment, depression and anxiety level assesment and asthma management knowledge assesment apply to this group."
89540315|NCT04865211|Experimental|Liposomal Bupivicaine|Administration of a combination of lioposomal bupivicane 20ml/266mg mixed with 20mL of 0.375% bupivicaine
89540316|NCT04865211|Active Comparator|Bupivicane|Administration of 40 ml of 0.375% Bupivicaine with epinephrine 1:400,000
89540317|NCT04865211|Placebo Comparator|Placebo|Saline injection with 40mL preservative-free saline
89540318|NCT04865445|Experimental|AT-527 550 mg + midazolam (simultaneous)|n=12
89540319|NCT04865445|Experimental|AT-527 mg + midazolam (staggered)|n=12
89540320|NCT04875819|Experimental|Menveo + Bexsero|
89540321|NCT04875819|Experimental|Prevenar13 + Pneumovax23|
89540322|NCT04875663|Experimental|Lifestyle medicine intervention with self-tracking tools|Lifestyle intervention including diet, sleep, exercise, relaxation, and mindfulness. Self-tracking tools including a smartphone application and an Actigraphy will be given.
89540323|NCT04875663|Experimental|Pure lifestyle medicine intervention|Lifestyle intervention including diet, sleep, exercise, relaxation, and mindfulness.
89540324|NCT04875663|No Intervention|Care-As-Usual|continue receiving the routine care as usual and be given a smartphone-based LM intervention after the completion of follow-up assessments
89540325|NCT04869423|No Intervention|Control group|Participants in this group will simply continue with their daily living and therapies. Assessments will be conducted before and after the 7wk program but patients in this group will not take part in it
89540326|NCT04869423|Experimental|Experimental group|Participants in this group will take part in 7 dog-assisted therapy sessions (1 per week). This therapy will be added to their usual daily living and therapies. Assessments will be conducted before and after the 7-week program.
89540327|NCT04875741|Active Comparator|Neural mobilization|Patient in this study group will get 30 minutes session, twice weekly for 6 weeks. Neural mobilization technique will be applied to the subjects in addition to conventional treatment.
88958482|NCT01993953|Active Comparator|Resistance training with instructor|Participants in this group are aimed to perform resistance training individually, based on two sessions with an instructor and a standarized training program given prior to the intervention. After six weeks, all participants in this group received a second instruction, as well as evaluation of the training protocol.
88958483|NCT01993953|No Intervention|Controlgroup|Control group - This group will be instructed to continue their activity and diet patterns. After the intervention period, they will be offered free exercise with BP at a fitness centre (12 weeks) and resistance training with a instructor at the Norwegian School of Sport Science.
88958484|NCT01993966||drug-resistant|specimens com from drug-resistant bladder urothelial carcinoma patients
88958485|NCT01993966||normal|specimens come from normal bladder urothelial carcinoma patients
88958486|NCT01993966||non-tumoral|specimens come from non-tumoral patients
88958487|NCT01993979|Other|Surveillance|Patients allocated to surveillance will be seen at 4, 7, 10 and 13 weeks post randomisation - equivalent to the end of cycle in patients receiving chemotherapy - in order to collect details of early treatment failure in this group and comparative data relating to toxicity and quality of life. Patients on surveillance will then be followed up for signs of recurrence at the same intervals as those who received chemotherapy
88958488|NCT01993979|Experimental|Chemotherapy|Patients allocated adjuvant chemotherapy will receive 4 x 21 day cycles of gemcitabine-cisplatin. Patients who have a sub-optimal renal function (GFR 30-49ml/min) will receive carboplatin instead of cisplatin.
88958489|NCT01994005|Placebo Comparator|Standard + Pamphlet|Subjects receiving standard counseling + ACOG pamphlets
88958490|NCT01994005|Active Comparator|Group 2: standard + facebook|Subjects receiving standard counseling + facebook education Intervention is 30 mins of use of facebook page
88958491|NCT01994018||Control Group (Vitamin D level)|Twenty (20) healthy individuals not on vitamin D supplementation will be used as controls to get a baseline vitamin D level.
88958492|NCT01994018||MS Group|RR-MS patients treated with a FDA approved immuno-modulatory drug with and without vitamin D supplementation for at least 2 years.
88958493|NCT01994018||Retrospective Chart Review|RR-MS patients treated with a FDA approved immuno-modulatory drug for MS.
88958494|NCT01994031|Experimental|Dose level A|Paclitaxel liposome injection 135mg/m2 on day 1, First cycle 28 days and subsequent cycles each 21 days
88958495|NCT01994031|Experimental|Dose level B|Paclitaxel liposome injection 175mg/m2 on day 1, First cycle 28 days and subsequent cycles each 21 days
88958496|NCT01994031|Experimental|Dose level C|Paclitaxel liposome injection 210mg/m2 on day 1, First cycle 28 days and subsequent cycles each 21 days
89540328|NCT04875741|Experimental|Muscle energy technique|Patient in this study group will get 30 minutes session, twice weekly for 6 weeks. Muscle energy technique will be applied to the subjects in addition to conventional treatment.
89540329|NCT04864977|Experimental|LY2963016|Participants with type 2 diabetes will be started on insulin glargine and dose will be titrated. Insulin glargine will be delivered via insulin pen each evening subcutaneously (SC). They will also check fasting blood glucose values on a study meter and prior to treating hypoglycemia. Participants will be asked to report the time and dose of their last administration.
89540330|NCT04869735||With information about booster vaccination|Adults aged 25 years in 2020 without delivery of DTPolio vaccine in 2019 or 2020, to whom information concerning this vaccination is given
89540331|NCT04869735||Without information about booster vaccination|Adults aged 25 years in 2020 without delivery of DTPolio vaccine in 2019 or 2020, to whom information concerning this vaccination is not given.
89540332|NCT03046407|Experimental|retinal pigment epithelium transplantation|transplant retinal pigment epithelium derived from human embryonic stem cells into subretinal space of patients with dry age-related macular degeneration(dry AMD).
89540333|NCT04864821|Other|T cell injection targeting CD276 chimeric antigen receptor|
89540334|NCT04865055|Active Comparator|cyclic merocyanine|cyclic merocyanine long-UVA absorber
89540335|NCT04865055|Placebo Comparator|placebo|
89540336|NCT03048123|Experimental|Hepatic arterial infusion chemotherapy|Procedure/Surgery: Hepatic arterial infusion chemotherapy Drug: Folfox Protocol. Hepatic intraarterial infusion via the tumor feeding arteries of Oxaliplatin , fluorouracil, and leucovorin
89540337|NCT03048123|Active Comparator|Transarterial chemoembolization|Procedure/Surgery: Transarterial chemoembolization Drug: TACE Drug Protocol. Hepatic intra-arterial infusion with lipiodol mixed with chemotherapy drugs (EADM, lobaplatin, and MMC), and embolization with polyvinyl alcohol particles (PVA)
89540338|NCT03046173|Experimental|the experimental group|These patients were randomly assigned to receive concentrated growth factors, hydroxyapatite and autogenous bone at bone defect sites in the experimental group.
88958497|NCT01994031|Experimental|Dose level D|Paclitaxel liposome injection 250mg/m2 on day 1, First cycle 28 days and subsequent cycles each 21 days
88958498|NCT01994031|Experimental|Dose level E|Paclitaxel liposome injection 300mg/m2 on day 1, First cycle 28 days and subsequent cycles each 21 days
89206930|NCT00839046|Active Comparator|1 Community Health Worker Intervention|This is the active control group, which all 150 participants will receive. It consists of visits from trained community health workers, who will provide asthma education, as well as provision of equipment and supplies to reduce indoor environmental exposures for asthma. These will include: vacuum cleaners, mattress and pillow covers, cleaning supplies.
89540339|NCT03046173|Experimental|the control group|These patients were randomly assigned to receive hydroxyapatite and autogenous bone at bone defect sites in the control group.
89540340|NCT04869579|Experimental|Selenious Acid + Standard Of Care (SOC)|Participants who are moderately-ill, severely-ill, or critically ill will receive a Selenious Acid infusion of 2000µg on day 1 as a loading dose infusion, followed by a continuous infusion of Selenious Acid at a maintenance dose of 1000µg daily on days 2-14 together with continued Standard Of Care therapy.
89540341|NCT04869579|Active Comparator|Standard Of Care (SOC) + Placebo|Participants will receive a Saline-based placebo infusion of 2000µg on day 1 as a loading dose, followed by continuous infusion of a Saline-based placebo at a maintenance dose of 1000µg daily on days 2-14. Standard Of Care is to be determined according to patients' clinical picture and may include Dexamethasone, Azithromycin, Ceftriaxone, Remdesivir, Convalescent Plasma.
89540342|NCT06212466||CMD Positive|Patients who have confirmed presence of CMD via invasive angiography/CFR
89540343|NCT06212466||CMD Negative|Patients who have confirmed absence of CMD via invasive angiography/CFR
89540344|NCT06212440|Experimental|A|Sentinel LN biopsy by mapping with Radioactive isotope(RI) and Indocyanine Green Fluorescence (ICG-F)
89540345|NCT06212440|Experimental|B|Sentinel LN biopsy by mapping with Radioactive isotope(RI) and vital dye
89540346|NCT06212440|Experimental|C|Sentinel LN biopsy by mapping with vital dye and Fluorescence (ICG-F)
89540347|NCT06212414|Experimental|Mind programme|"This group will receive the Mind programme. This intervention comprises 8 weekly group sessions, with the duration of 120 minutes each, to be delivered via Zoom. Integration of Acceptance and Commitment Therapy, mindfulness and Compassion Focused Therapy components, adapted to women with breast cancer.~All participants will continue on receiving the recommended medical treatment for their clinical diagnosis."
89206931|NCT00839046|Experimental|2 Air Filter|The 50 families in the Air Filter Arm will receive an air filter in addition to the standard community health worker intervention. The Air Filter will be installed right after baseline measurements in the home.
89206932|NCT00839046|Experimental|3 Air Filter and Air Conditioner|"Fifty families will be assigned to the Air Filter and Air Conditioner Arm. In addition to the standard community health worker intervention, they will receive an air filter and an air conditioner (for the warmer months)."
88958499|NCT01994031|Active Comparator|Comparator|Paclitaxel injection 175mg/m2 on day 1, each 21 days
89540348|NCT06212414|Active Comparator|Support group|"This group will receive a 8-week support group intervention (weekly sessions, with the duration of 120 minutes each), via Zoom.~All participants will continue on receiving the recommended medical treatment for their clinical diagnosis."
89540349|NCT06212414|No Intervention|Waiting list (Treatment As Usual / No psychological intervention)|This group will receive the (psychological) treatment as usual in Portugal (no treatment), besides the recommended medical treatment for their clinical diagnosis. At the end of this research project, the intervention that proves to be most efficacious will be offered to participants from the waiting list condition.
89540350|NCT06212401|Experimental|Dexmedetomidine|Dexmedetomidine in a 2 ml ampule of 100 ug/ml diluted in 18 ml of normal saline, making a total volume of 20 ml.
88958500|NCT01994044|Active Comparator|Multimodal rehabilitation|
88958501|NCT01994044|Active Comparator|Cervical fusion|
88958502|NCT01994070|Active Comparator|Electrical-first|"Patients in atrial fibrillation for less than 48 hours will be administered procedural sedation and analgesia and an electrical current applied across their chest (cardioversion) to attempt conversion to normal sinus rhythm. If this does not succeed, they will be given intravenous procainamide (chemical cardioversion). If procainamide is required, physicians will be informed as follows: 50% of patients convert to normal sinus rhythm within one hour and 90% of patients convert within two hours. Physicians can then proceed at their discretion."
89206933|NCT00956241|Other|j-pouch coloanal anastomosis|although a j-pouch coloanal anastomosis is a common type of anastomosis, a comparison with the side-to-end has not been made.
89024017|NCT03960840|Experimental|Adult ALL|Dose escalation and expansion of rapcabtagene autoleucel single agent in adult ALL
89024018|NCT03960840|Experimental|1L HR LBCL|Rapcabtagene autoleucel single agent in 1L HR LBCL
89024019|NCT03954574||Retrospective patient cohort|
89206934|NCT00956241|Other|side-to-end coloanal anastomosis|in the Netherlands, the side-to-end anastomosis is the standard procedure to perform an anastomosis in case of rectal resection. therefore, the side-to-end group was our control group
89206935|NCT00956319|Experimental|Zolpidem group|
89024020|NCT03954574||Prospective patient cohort|
89206936|NCT00956319|Active Comparator|Estazolam group|
89540351|NCT06212401|Active Comparator|Ketofol|2 ml ketamine (50mg/ml) and 10 ml of propofol 1% (10mg/ml) diluted in 8 ml of normal saline. This mixture was 20 ml each, making 5mg/ml of ketamine and propofol.
89540352|NCT06212375|Experimental|All subjects|Within subject study design: All children receive the four possible combinations of interventions.
89540353|NCT06212362|Experimental|Step-by-Step treatment|
89540354|NCT06212362|Active Comparator|Cool Kids treatment|
89540355|NCT06212336|Experimental|Favipiravir 1600|Oral favipiravir: 2400 mg BID D1; 1600 mg BID D2-D10
89540356|NCT06212336|Active Comparator|Ribavirin|Intravenous ribavirin (Irrua regimen - 100 mg/kg Day 1 (dose is divided: 2/3 stat, 1/3 8 hours later, maximum dose is 7g/day) then 25 mg/kg single dose days 2-7, 12.5 mg/kg single dose days 8-10).
89540357|NCT06212336|Experimental|Favipiravir 1200 + ribavirin|Oral favipiravir: 2400 mg BID D1; 1200 mg BID D2-D10 Intravenous ribavirin (Irrua regimen - 100 mg/kg Day 1 (dose is divided: 2/3 stat, 1/3 8 hours later, maximum dose is 7g/day) then 25 mg/kg single dose days 2-7, 12.5 mg/kg single dose days 8-10).
89540358|NCT06212336|Experimental|Ribavirin + dexamethasone|IV ribavirin, Irrua regimen IV or oral dexamethasone 6mg/day (For the first 48 hours, dexamethasone will be given intravenously (i. Afterwards, a switch to oral dexamethasone (same dosage) is permitted at the discretion of the study physician.)
89206937|NCT02547948|Experimental|CAR T cells|In interventional studies, participants are assigned to accept CD19-targeting CAR T Cells infusion so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes. Arm refers to each group or subgroup of participants in a clinical trial that receives specfic interventions (or no intervention) according to the study protocol. This is decided before the trial begins.
89206938|NCT02547948|No Intervention|No Intervention|
89540359|NCT06212310|No Intervention|In-person genetic counseling|Patients referred for standard of cancer genetic counseling are seen in-person with a genetic counselor for service.
89540360|NCT06212310|Active Comparator|Telephone genetic counseling|Patients referred for standard of cancer genetic counseling are on the telephone with a genetic counselor for service.
89540361|NCT06212297|Experimental|LX101 Subretinal Administration|
89540362|NCT06212245|Experimental|Inebilizumab|Participants will receive IV inebilizumab 300 mg
89540363|NCT06212219|Active Comparator|Standard Neurofeedback Procedure|"The standard NF (sensory feedback) will consist of motor imagery tasks, that is to say that the patient will have to imagine themselves carrying out movements, without real motor execution.~Two types of movements will be alternately requested: a complete sustained extension of the fingers of the paralyzed hand, a global movement of the arm (e.g. opening of the elbow) of the paralyzed arm."
89540364|NCT06212219|Experimental|Personalized Neurofeedback Procedure|Personalized NF will consist of adding to these motor imagery tasks, personalized aspects depending on the patient's profile, for example in terms of level of support and emotional support (addition of a relaxation exercise using an audio recording at the start of training - and in the middle of training if necessary, adding the presence of a virtual companion to provide social presence and emotional support, depending on the user's performance and progress) , of the virtual environment.
89540365|NCT06212206|Experimental|PillBot|Patient will swallow the PillBot and be assessed with EGD after two hours of the examination
89540366|NCT06212193|Experimental|Innoventric Trillium™ Stent Graft|Transcatheter cross-caval tricuspid valve replacement with the Innoventric Trillium™ Stent Graft
89540367|NCT06212167|Experimental|Nursing Interventions for Stroke Patient Care|"Within the scope of nursing interventions for caregivers;~Oral or enteral nutrition application steps and the use of necessary materials will be explained,~Oral or enteral drug administration, in-bed exercises, suctioning, simple ROM exercises, in-bed bathing, pressure sore care, position change, oral care, and whole body care will be taught,~Videos regarding the use of all medical devices and materials to be taken home with the patient will be shown and demonstration methods will be used,~Information about the storage conditions of drugs, side effects and nutrition will be explained, supported by powerpoint presentations,~Motivational interviews will be held regarding communication with the stroke patient and the emotional state of the caregivers."
89540368|NCT06212141|Active Comparator|VisCalor Bulk|Thermoviscous Bulkfill composite resin Warming of the material makes it flowable for the application and then sculptable immediately afterwards (thermoviscous technology) Optimal flowing to margins and undercut regions One universal and three aesthetic shades Cannula form
89540369|NCT06212141|Active Comparator|Admira Fusion x-tra|"Ormocer based bulkfill composite Purely ceramic-based, bulk fill restorative material Reliable curing of 4 mm layersby far the lowest polymerisation shrinkage (1.25 % by volume) and particularly low level of shrinkage stress, providing optimal marginal integrity.~inert, so excellent biocompatible and extremely resistant to discolouration Easy handling, simple high-lustre polishing procedure coupled with high surface hardness guarantee first-class long-term results Universal shade with chameleon effect"
89540370|NCT06212141|Active Comparator|Filtek One Bulk|"Conventional bulkfill compositeFocused options powered by 3M technology help you complete posterior restorations in a single bulk placement.~5 shades avaible : A1, A2, A3, B1, and C2. Excellent adaptation and sculptability for fast, easy placement. One-step placement : Tackle deep cavities with up to 5 mm depth of cure"
89206939|NCT00961779|Placebo Comparator|Placebo (Normal saline infusion)|
89024021|NCT03944304|Experimental|Paclitaxel|Paclitaxel will be administered at 80mg/m2/day every four weeks at Day 1, Day 8 and Day 15 per cycle. One cycle consists of 4 weeks (28 days).
89508731|NCT03509311||Healthy Group|That group consists from participants who do not have any diagnosed disease. Physical activity level assesment, maximal and submaximal exercise capacity assesment, respiratory function assesment, respiratory muscle strength assesment, respiratory muscle endurance assesment, peripheral muscle strength assesment, quality of life assesment about disease specific, respiratory, sleep and cough associated, fatigue severity assesment and depression and anxiety level assesment apply to this group.
89508732|NCT03790683|Experimental|EnsoETM|Participants receive esophageal warming. Original study design anticipated esophageal warming in addition to standard of care surface warming from the time they enter the OR until released to the PACU. After 7 patients, protocol was adjusted to specify only esophageal warming unless addition of surface warming was warranted.
89508733|NCT03790683|Active Comparator|Standard of Care|Participants receive standard of care surface warming from the time they enter the OR until released to the PACU.
89508734|NCT02310529|Experimental|Interpersonal Psychotherapy|Interpersonal Psychotherapy will be delivered to Intervention group. The intervention group will be further divided into 3 groups (8 depressed mothers in each group). IPT is 12-16 week treatment, contains a supportive element, an educational element, parenting element and an interpersonal relationship element. Its goals include helping mothers feel supportive, empowered and confident about their parenting abilities, which will directly influence in reducing their depressive symptoms as well as resolution of interpersonal conflicts. Groups will assist people who have become withdrawn, isolated and disconnected. Intervention will be delivered by trained clinical psychologists.
89508735|NCT02310529|No Intervention|Treatment as usual|Patients including in this group will be taking only treatment as usual (in Pakistan it means that participants attending in outpatients' clinic at regular intervals and may or may not be taking prescribed medication).
89508736|NCT02338167||Advanced/metastatic breast cancer|3,500 patients with locally advanced, inoperable/metastatic breast cancer in any line of treatment (e.g. 1st, 2nd, 3rd, or ≥ 4th line).
89508737|NCT02338167||Early breast cancer|10,000 patients with breast cancer in the neoadjuvant and adjuvant (early breast cancer) setting independent of treatment regimen.
89508738|NCT02304133|Active Comparator|Intervention|participating in a four-hour course in abdominal POC US
89508739|NCT02304133|Placebo Comparator|Control|no training
89540371|NCT06212128||RAPIDO TNT|neoadjuvant therapy per RAPIDO protocol
88958503|NCT01994070|Active Comparator|Chemical-first|"Patients in atrial fibrillation for less than 48 hours will be administered intravenous procainamide (chemical cardioversion) to attempt conversion to normal sinus rhythm. If procainamide is required, physicians will be informed as follows: 50% of patients convert to normal sinus rhythm within one hour and 90% of patients convert within two hours. Physicians can then proceed at their discretion. If this does not succeed, patients will be administered procedural sedation and analgesia and an electrical current applied across their chest (electrical cardioversion) to attempt conversion to normal sinus rhythm."
88958504|NCT01994083|Placebo Comparator|Placebo|Placebo
88958505|NCT01994083|Experimental|IX-01|Up to 4 different dose groups within 50 to 1,200 mg of IX-01 oral aqueous dispersion, administered once daily for 10 days
88958506|NCT01994096|Experimental|Caspofungin|1 arm, dose adjustment of caspofungin when exposure is inadequate
88958507|NCT01994122||People who have dropped out of school|
88958508|NCT01994122||College students (control group)|
88958509|NCT01994135|Active Comparator|Reference food|The reference food is white bread
88958510|NCT01994135|Experimental|Test food dose 1|Test food dose 1 response will be compared to reference test food
88958511|NCT01994135|Experimental|Test food dose 2|Test food dose 2 response will be compared to reference test food as well as to test food dose 1
88958512|NCT01994148|Experimental|Laparoscopy|Laparoscopy has been increasingly applied in patients with abdominal trauma , as an diagnostic and therapeutic modality. In this arm, we will include 100 Hemodynamically stable patients with gastrointestinal trauma, all of them will receive laparoscopic exploration,laparoscopic repair of the gastrointestinal injury will be attempted.
89508740|NCT02321800|Experimental|Cefiderocol|Participants received 2 g cefiderocol by intravenous injection once every 8 hours for 7 to 14 days.
89508741|NCT02321800|Active Comparator|Imipenem/cilastatin|Participants received 1 g each of imipenem/cilastatin by intravenous injection once every 8 hours for 7 to 14 days.
89508742|NCT02310295|Active Comparator|IVB-Laser|Intravitreal Bevacizumab combined with focal laser therapy
89508743|NCT02310295|Active Comparator|IVTA-Laser|Intravitreal Triamcinolone combined with focal laser therapy
89508744|NCT02310295|Active Comparator|Laser|focal laser therapy
89508745|NCT02310685|Active Comparator|Intervention|Active Comparator: Intervention The primary focus is CVD risk factors. Subjects will be shown how to update Cardiovascular Age or Cardiometabolic Age on website. Pharmacists will give overview of comprehensive ehealth wellness program. Subjects will complete additional health assessments which include questionnaires considered gold standard. Pharmacists will explain that participants have access to ehealth coaching based educational modules with information relevant to a better understanding of cardiovascular risk factors. The ehealth coaching modules are guides to help understand risk factors and importance of making lifestyle changes. As information alone is often insufficient to promote change, participants will have access to online physical activity challenges.
89519399|NCT05322499|Experimental|Combined chemotherapy group|"Camrelizumab: Subjects were infused at a dose of 200 mg/time, D1, once every 3 weeks (q3w);~Chemotherapy (considered by investigator on a patient-by-patient basis):~Irinotecan: 100-125mg/m2, d1, d8; q21d; Paclitaxel: 135-175mg/m2, d1, Q3W; Docetaxel: 60-75mg/m2, d1, Q3W Albumin paclitaxel: 100-135mg/m2, d1, d8, Q3W. Treat until disease progression or intolerable toxicity"
89519400|NCT05322499|Experimental|Combined anlotinib group|Camrelizumab: Subjects were infused at a dose of 200 mg/time, D1, once every 3 weeks (q3w); Anlotinib: 12mg, qd, d1-d14, q3w; Treat until disease progression or intolerable toxicity.
89540372|NCT06212128||LCRT|long course chemoradiotherapy
89540373|NCT06212128||upfront surgery|directly went for surgery after diagnosis of rectal cancer
89540374|NCT06212063|Experimental|Aim High Program|Integrated physical and mental optimization training program used as tool for young individuals readying themselves to join the military
89024022|NCT03934684|Experimental|Carfilzomib + Dexamethasone|"Drug: Carfilzomib + Dexamethasone~Carfilzomib 20 mg/m2 on days 1 and 2, and if tolerated, escalated to a target dose of 56 mg/m2 starting on day 8 of cycle 1 and thereafter.~Dexamethasone 20 mg taken by mouth or intravenously on days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle. An individual subject will receive study treatment for a maximum of 3 years if the subject has not yet experienced disease progression"
89024023|NCT03934684|Experimental|Carfilzomib+Lenalidomide+Dexamethasone|"Drug: Carfilzomib + Lenalidomide + Dexamethasone~Carfilzomib is 20 mg/m2 on days 1 and 2, and if tolerated, escalated to a target dose of 27 mg/m2 starting on day 8 of cycle 1 and thereafter. From cycle 13, the day 8 and day 9 doses of Carfilzomib will be omitted.~Lenalidomide 25 mg is taken orally on days 1 to 21.~Dexamethasone 40 mg on days 1, 8, 15, and 22 of the 28-day cycles. An individual subject will receive study treatment for a maximum of 18 months consistent with the approved use in this combination."
89024024|NCT03927768||200 women undergoing clinical breast MRI|At time of previously scheduled clinical breast MRI, 60 second postcontrast imaging sequence will be added to the clinical breast MRI. MRI will be interpreted according to usual departmental protocols.
89024025|NCT03927768||50 women undergoing clinical breast MRI|At time of previously scheduled clinical breast MRI, 60 second postcontrast imaging sequence will be added to the clinical breast MRI. MRI will be interpreted according to usual departmental protocols.
89024026|NCT03912207|Experimental|Group 1, 2 Day Bronchoscopy|Group 1: 10 volunteers will receive 1 x 10^7 cfu aerosol inhaled BCG and 3 volunteers will receive aerosol inhaled normal saline placebo. All Group 1 volunteers will have a bronchoscopy 2 days post challenge
89024027|NCT03912207|Experimental|Group 2, 7 Day Bronchoscopy|Group 2: 10 volunteers will receive 1 x 10^7 cfu aerosol inhaled BCG and 3 volunteers will receive aerosol inhaled normal saline placebo. All Group 2 volunteers will have a bronchoscopy 7 days post challenge
89024028|NCT03912207|Experimental|Group 3, 14 Day Bronchoscopy|Group 3: 10 volunteers will receive 1 x 10^7 cfu aerosol inhaled BCG (Arm A) and 3 volunteers will receive aerosol inhaled normal saline placebo (Arm B). All Group 3 volunteers will have a bronchoscopy 14 days post challenge Volunteers in group 7 and group 3 (arm A) will be offered an optional follow up at 12 months, in order of enrolment until 10 such visits have been conducted. For group 3 volunteers this will be offered after unblinding.
89024029|NCT03912207|Experimental|Group 4, 28 Day Bronchoscopy|Group 4: 10 volunteers will receive 1 x 10^7 cfu aerosol inhaled BCG and 3 volunteers will receive aerosol inhaled normal saline placebo. All Group 4 volunteers will have a bronchoscopy 28 days post challenge
89024030|NCT03912207|Experimental|Group 5, 56 Day Bronchoscopy|Group 5: 10 volunteers will receive 1 x 10^7 cfu aerosol inhaled BCG and 3 volunteers will receive aerosol inhaled normal saline placebo. All Group 5 volunteers will have a bronchoscopy 56 days post challenge
89024031|NCT03912207|Experimental|Group 6, Intradermal injection, 14 Day Bronchoscopy|Group 6: 6 volunteers will receive 1 x 10^6 cfu intradermal injection BCG + aerosol saline and will have a bronchoscopy 14 days post challenge All volunteers in group 6 will be offered an optional follow up at 12 months
89024032|NCT03912207|Experimental|Group 7, 14 Day Bronchoscopy|"Group 7: 10 volunteers will receive 1 x 10^7cfu aerosol inhaled BCG. All Group 7 volunteers will have a bronchoscopy 14 days post challenge.~Volunteers in group 7 and group 3 (arm A) will be offered an optional follow up at 12 months, in order of enrolment until 10 such visits have been conducted"
89540375|NCT06212050||Patients with severe symptomatic BAV stenosis|Patients with severe symptomatic BAV stenosis who underwent TAVI using the ACURATE neo2 THV.
89540376|NCT06212024|Experimental|MBT-early|See intervention description. Within subject comparison.
89540377|NCT06211998|Active Comparator|Group receiving inhaled treatment with compressor nebulizer|Salbutamol inhaler, Omron® CompAIR Pro NE-C900 Compressor Nebulizer (Omron Healthcare Co., Ltd., Kyoto, Japan) was used in Group 1
89540378|NCT06211998|Active Comparator|Group receiving inhaled treatment with mesh nebulizer|Salbutamol inhaler, Mesh nebulizer (Aerogen Solo®, Aerogen Ltd, Galway, Ireland) was used in Group 2
89540379|NCT06211985|Active Comparator|Bronchopnomonia Group|patients admitted to the ward with a diagnosis of bronchopneumonia (Group 1)
89540380|NCT06211985|Active Comparator|Lobar Pneumonia Group|patients admitted to the ward with a diagnosis of lobar pneumonia (Group 2)
89540381|NCT06211985|Active Comparator|Receiving Ventilator Support Group|patients requiring invasive or non-invasive ventilator support with a diagnosis of pneumonia (Group 3)
89540382|NCT06211985|Active Comparator|Control Group|the control group without pneumonia (Group 4)
89540383|NCT06211920|Experimental|Non-invasive ventilation (NIV) + standard medical treatment|"The intervention will consist of application of NIV through a facemask. This will happen as soon as possible after the patient has been randomized by opening the opaque envelope. All patients will receive the same standardized ventilator settings at initiation. The IPAP will be set at 12 cm H2O and the PEEP at 5 cm H2O. These settings are preset on the ventilator used in the physician manned mobile emergency care unit (MECU) in the Central Denmark Region. Oxygen delivery will be adjusted to an arterial oxygen saturation of 88-92%. Further adjustment of ventilator settings and evaluation of treatment effect will be at the discretion of the prehospital physician.~NIV will be administered together with standard medical treatment described below."
89508746|NCT02310685|No Intervention|No Intervention|Individuals randomized to the non active intervention group will have access to modified version of ehealth website. The pharmacist will show participants how to update Cardiovascular Age or Cardiometabolic Age on website. They will have access to health assessments but not ehealth coaching educational modules or challenges. They will have online support tools including public domain education material on exercise, healthy eating, understanding and managing blood pressure, diabetes and smoking cessation. Participants will return to the pharmacist for follow-up visits at 3, 6 months and one year. The pharmacist will update their cardiovascular risk profile with current information At the first follow up visit and at 1 year participants will be asked to have blood lipids reassessed.
89508747|NCT02338089|No Intervention|Control (no oxytocin) pretreatment|Physiological saline solution (PSS). Every 15-minutes, the PSS will be flushed and fresh PSS will be added.
89508748|NCT02338089|Active Comparator|Continuous oxytocin (desensitizing) pretreatment|Continuous oxytocin 10-5M. This desensitizing treatment is based on previous experiments in our laboratory demonstrating this phenomenon (reference 25 of Internal Review). The desensitizing pretreatment mimics the clinical setting of labor augmentation. Every 15-minutes, the 10-5M oxytocin will be flushed and fresh 10-5M oxytocin will be added.
89508749|NCT02338089|Active Comparator|Pulsatile oxytocin pretreatment|15-minutes of 10-5M oxytocin, followed by PSS for 15-minutes, followed by 10-5M oxytocin, followed by 15-minutes PSS, and so-on, for a total duration of two-hours,
89508750|NCT02310841|Experimental|unilateral transfemoral amputees|
89508751|NCT02338245|Experimental|Treatment Arm A|ASLAN001 + Capecitabine
89508752|NCT02338245|Active Comparator|Treatment Arm B|Lapatinib + Capecitabine
89508753|NCT02311543|No Intervention|Arm A: no TachoSil®|After axillary lymph node dissection no surgical sealing patch (TachoSil®) is applied.
89508754|NCT02311543|Active Comparator|Arm B: TachoSil®|After axillary lymph node dissection, 3 large TachoSil® patches in the dissected axilla are positioned to cover as much of the axillary walls as possible.
89508755|NCT02332005|Active Comparator|Group 1 150 mg|150 mg diepalrestat choline administered as twice daily dosing morning and evening with an oral tablet of either 150 mg diepalrestat choline or placebo
89508756|NCT02332005|Active Comparator|Group 2 300 mg|300 mg diepalrestat choline administered as twice daily dosing morning and evening with an oral tablet of 150 mg diepalrestat choline
89508757|NCT02332005|Placebo Comparator|Group 3|Tablet administered twice daily morning and evening containing placebo
89508758|NCT02311699|Experimental|Women Only|Groups of women will receive the behavioral intervention to reduce IPV and HIV. Sessions will be led by female facilitators.
89508759|NCT02311699|Experimental|Men Only|Groups of men will receive the behavioral intervention to reduce IPV and HIV. Sessions will be led by male facilitators.
89508760|NCT02311699|Experimental|Couples|Couples will receive the behavioural intervention to reduce IPV and HIV. Sessions will be led by a male and a female facilitator.
89508761|NCT02311699|No Intervention|Control Group|Community members in the control villages will receive a short informational session on violence reduction.
89508762|NCT02331693|Experimental|anti-EGFR CAR T|
89508763|NCT02304211|Experimental|Intra-Arterial Microdose Insulin|Healthy volunteers will receive microdose insulin intra-arterially into the radial artery.
89508764|NCT02304211|Active Comparator|Systemic Insulin|Healthy volunteers will receive full-dose insulin intra-venously.
89508765|NCT02311777|Active Comparator|Pregabalin-ketamine|Pregabalin and ketamine will be given preoperative period
89508766|NCT02311777|Placebo Comparator|Placebo|Placebo will be given preoperative period
89508767|NCT04097223||Subjects with Pulmonary Disease, Chronic Obstructive|
89508768|NCT03504865|Experimental|Liposomal bupivacaine|"If a patient is randomized to the LB arm, at the appropriate time, under a surgeon's direction, 266 mg of (liposomal bupivacaine) LB in 20 cc of solution was expanded with various amounts of normal saline to cover the appropriate surgical field. Our routine expansion for a bilateral mastectomy is to add 80 mL of saline to 20 mL (266 mg) of LB. In our practice,we use an 18-gauge needle to inject the medication in a field-effect encompassing all 4 quadrants of the chest muscles (pectoralis and serratus) followed by injecting around the edges of the skin incision and drain site. This occurs prior to dissection of the pectoralis muscle and implant or tissue expander placement."
89508769|NCT03504865|Active Comparator|Standard bupivacaine|Patients randomized to the SB arm will receive weight-based dosing of bupivacaine, administered in the same manner as the LB arm.
89508770|NCT03504865|Placebo Comparator|Placebo|Patients who are in the placebo arm will have a similar volume of saline injected into the operative site.
89508771|NCT02304289|Experimental|Oral Artesunate|The first patient will receive 200 mg Artesunate once-daily for 14 days. If no dose-limiting toxicity (DLT) is observed after 14 days, the next patient will start at a daily dose of 300 mg Artesunate. If no DLT is observed after 14 days, a cohort of 3 patients will receive 400 mg once-daily for 14 days. For each subsequent cohort of 3 patients 200 mg will be added to the dose, until the maximum tolerated dose (MTD) is determined.
89508772|NCT02292784|Placebo Comparator|Placebo (200719 study)|All infants and children born to women who received the placebo (0.9 percent sodium chloride infusion matched for retosiban volume, intravenous [IV] loading dose over 5 minutes and continuous infusion rate including dose increase in participants with an inadequate response any time after first hour of treatment) in 200719 study. Current study will not require any medical interventions or study visits to an investigational site.
89508773|NCT02292784|Experimental|Retosiban (200719 and 200721 study)|All infants and children born to women who received retosiban (6 milligram [mg] IV loading dose of retosiban over 5 minutes followed by a 6 mg per hour continuous infusion of retosiban over 48 hours. Participants with an inadequate response any time after first hour of treatment were administered another 6 mg retosiban loading dose followed by 12 mg per hour continuous infusion for remainder of 48-hour treatment period) in 200719 study or 200721 study. Current study will not require any medical interventions or study visits to an investigational site.
89508774|NCT02292784|Active Comparator|Atosiban (200721 study)|All infants and children born to women who received atosiban (in 3 successive stages; an initial bolus dose of 6.75 mg using atosiban 6.75 mg per 0.9 milliliter [mL] solution for injection, followed by continuous high dose infusion at 18 mg per hour for 3 hours, then a lower 6 mg per hour infusion for the remainder of the 48-hour using the atosiban 37.5 mg per 5 mL concentrate for solution) in 200721 study. Current study will not require any medical interventions or study visits to an investigational site.
89508775|NCT02338011|Experimental|Gefitinib alone|Patients harboring an EGFR mutation with multiple BM from NSCLC will receive Gefitinib 250mg per day until progression of disease.
89508776|NCT02338011|Experimental|Gefitinib concurrent WBRT|Patients harboring an EGFR mutation with multiple BM from NSCLC will receive Gefitinib concurrent WBRT until progression of disease.Gefitinib was given 250mg per day. WBRT was delivered in 3.0 Gy fractions once per day 5 days per week to a total dose of 30Gy (10 fractions).
89508777|NCT02311855|Other|Influenza vaccination|all patients are vaccinated per protocol
89508778|NCT02334189|Experimental|Letter|Patients receive a letter containing information on alternative healthcare options for non-emergency health concerns.
89508779|NCT02334189|No Intervention|No letter|Patients receive no letter (this is the usual care).
89508780|NCT04463407|No Intervention|Control group|Participants keep their normal routine without intervention.
89508781|NCT04463407|Experimental|Experimental group|Participants receive a single nutritional intervention previous to a critical period.
89508782|NCT04463485|Experimental|Delayed Clamping|The intervention group was waited 60 seconds for umbilical cord clamping in the second stage of labor.
89508783|NCT04463485|No Intervention|Early Clamping|No interventions have been assigned.
89508784|NCT02337855|Experimental|Group A|N=10 subjects will receive single dose intramuscular (IM) 10mcg Sm-TSP-2/Alhydrogel® on Day1, 57 and 113
89508785|NCT02337855|Experimental|Group B|N=10 subjects will receive single dose intramuscular (IM) 10mcg Sm-TSP-2/Alhydrogel®/GLA-AF on Day 1, 57 and 113
89508786|NCT02337855|Placebo Comparator|Group C|N= 4 subjects will receive single dose intramuscular (IM) Placebo (normal saline (0.9% NaCl) on Day 1, 57 and 113
89508787|NCT02337855|Experimental|Group D|N=10 subjects will receive single dose intramuscular (IM) 30mcg Sm-TSP-2/Alhydrogel® on Day 1, 57 and 113
89508788|NCT02337855|Experimental|Group E|N=10 subjects will receive single dose intramuscular (IM) 30mcg Sm-TSP-2/Alhydrogel®/GLA-AF on Day 1, 57 and 113
89508789|NCT02337855|Placebo Comparator|Group F|N= 4 subjects will receive single dose intramuscular (IM) Placebo (normal saline (0.9% NaCl) on Day 1, 57 and 113
89508790|NCT02337855|Experimental|Group G|N=10 subjects will receive single dose intramuscular (IM) 100mcg Sm-TSP-2/Alhydrogel® on Day 1, 57 and 113
89508791|NCT02337855|Experimental|Group H|N=10 subjects will receive single dose intramuscular (IM) 100mcg Sm-TSP-2/Alhydrogel®/GLA-AF on Day 1, 57 and 113
89508792|NCT02337855|Placebo Comparator|Group I|N= 4 subjects will receive single dose intramuscular (IM) Placebo (normal saline (0.9% NaCl) on Day 1, 57 and 113
89508793|NCT04463329|Active Comparator|Group C|conventional two-operator axillary brachial plexus blockage
89508794|NCT04463329|Active Comparator|Group J|axillary brachial plexus block with single operator using Jedi grip
89508795|NCT02309125|Experimental|implant A|will include implants with immediate progressive loading using gingival formers of different sizes
89508796|NCT02309125|Other|implant B|The implants will remain submerged from surgery time till loading time 2 month.(submerged healing)
89508797|NCT02320396|Experimental|Desloratadine|After a 1-week single-blinded placebo run-in during which SAR symptoms are confirmed (Confirmation of Symptom Period), participants receive double-blinded desloratadine (one 5 mg tablet) orally (PO) once daily (QD) in the morning for 2 weeks during the Treatment Period.
89508798|NCT02320396|Placebo Comparator|Placebo|After a 1-week single-blinded placebo run-in during which SAR symptoms are confirmed (Confirmation of Symptom Period), participants receive double-blinded placebo (one tablet) PO QD in the morning for 2 weeks during the Treatment Period.
89508799|NCT02333955|Experimental|3 mg IV push|GCS-100
89508800|NCT03509233|Active Comparator|Q-SRP|Quadrant scaling and root planing
89508801|NCT03509233|Experimental|FMS|Full mouth scaling and root planing
89508802|NCT03509233|Experimental|FMD|Full mouth disinfection
89508803|NCT03509233|Experimental|FMDP|Full mouth disinfection with periopolishing
89508804|NCT02334111|No Intervention|(Control)|Patients will receive standard of care
89508805|NCT02334111|Experimental|(Intervention)|Patients will receive RESPECT-Plus intervention
89508806|NCT02331459|Experimental|Intervention group|"Multicomponent training intervention :~3 sessions a week of 45 minutes of resistance activity (24 weeks) 2 sessions a week of 45 minutes of strength training (24 weeks) 5 sessions a week of 15 minutes of proprioceptive training (24 weeks)"
89508807|NCT02331459|Placebo Comparator|Control group|Normal routine during 24 weeks.
89508808|NCT02310997|Experimental|Fludarabine + Cyclophosphamide + TBI|"Patients aged 2-45 years (excluding AML, JMML and MDS patients aged <16 years) will receive an umbilical cord blood transplant using a myeloablative conditioning regimen comprising:~Fludarabine 25mg/m^2/day day -8 to -6 (total 75mg/m^2) Cyclophosphamide 60mg/kg day -7 and -6 (total 120mg/kg) Total body irradiation 13 - 14.4Gy in 6-8 fractions"
89508809|NCT02310997|Experimental|Busulfan + Cyclophosphamide + Melphalan|"Patients aged < 2 years and AML, JMML and MDS patients <16 years will receive an umbilical cord blood transplant using a myeloablative conditioning regimen comprising:~Busulfan 3.2mg/kg/day in 2 or 4 doses per day, days -9 to -6 (total 12.8mg/kg). Cyclophosphamide 60mg/kg days -4 and -3 (total 120mg/kg) Melphalan 140mg/m^2 day -2"
89508810|NCT02337699||Treated Subjects|All subjects recruited into the main study treated with the Axium neurostimulator
89508811|NCT02337699||QST Group|A sub-set of the main study group who also consent to take part in the Quantitative Sensory Testing based feasibility study
89508812|NCT02337543|Experimental|Active: NEO6860|NEO6860 suspension is the drug under evaluation
89508813|NCT02337543|Placebo Comparator|placebo|Placebo matching NEO6860 suspension formulation
89508814|NCT03505411|Experimental|melatonin, submaximal effort|1 arm 5 mg melatonin 1 hr before bedtime for 30 days
89508815|NCT02292238|Experimental|Benfotiamine|The patients in this arm will be treated with benfotiamine
89024033|NCT03912207|Experimental|Group 8, Bronchoscopy Day 14|Group 8: 10 historically BCG vaccinated volunteers will receive aerosol inhaled BCG at a dose to be confirmed from emerging study data TB044 (Clinicaltrials.gov NCT04777721). All Group 8 volunteers will have a bronchoscopy 14 days post challenge.
89206940|NCT00961779|Experimental|NNZ-2566|NNZ-2566 reconstituted in bicarbonate buffer and normal saline. 6/8 subjects in each cohort (5 cohort in total) to receive NNZ-2566 experimental treatment.
89508816|NCT02292238|Placebo Comparator|Placebo|The patients in this arm will be treated with placebo
89508817|NCT03509155|No Intervention|Control group|The first arm as a control group obtaining only routine IYCF consultation by the posyandu (integrated health service post) cadres and without the provision of biscuits.
89508818|NCT03509155|Active Comparator|National portion & IYCF counseling|The second arm as the national portion & IYCF counseling group to get biscuit with standardized portion as recommended by Ministry of Health and also given the IYCF counseling by the cadres and nutritionist.In the second and third arm, treatment was administered for 3 months according to the recommended duration of biscuit delivery by the Ministry of Health, but all respondents from three arms will continue to be followed in third, sixth, and ninth months from the beginning of treatment.
89508819|NCT03509155|Experimental|Adjusted portion & local food counseling|the third arm as the adjusted portion & local food counseling group receiving biscuit with adjustment in portion and IYCF Counseling that emphasize the optimization of local food. In the second and third arm, treatment was administered for 3 months according to the recommended duration of biscuit delivery by the Ministry of Health, but all respondents from three arms will continue to be followed in third, sixth, and ninth months from the beginning of treatment.
89508820|NCT02772159|Experimental|Study Population|One dose each of treatments A: [14C] TD-4208 20 μg IV administered in a fasted state over 30 minutes. B: [14C] TD-4208 200 μg oral solution administered in a fasted state.
89508821|NCT03505333|Experimental|conventional suture ligature|use of conventional sutures for hysterectomy
89508822|NCT03505333|Active Comparator|Liga Sure|use of conventional sutures plus use of Liga-sure for hysterectomy
89508823|NCT02311075|Experimental|Patient comparative approach|Assessing the availability of biological markers (NO, EETs, ET-1 and ROS) during endothelial stimulation using blood samples.
89508824|NCT02311075|Experimental|Control subjects comparative approach|Assessing the availability of biological markers (NO, EETs, ET-1 and ROS) during endothelial stimulation using blood samples.
89508825|NCT02311075|Experimental|Healthy volunteers metabolic approach|Assessing the availability of biological markers (NO, EETs, ET-1 and ROS) during endothelial stimulation using blood samples during hyperglycemia or hyperinsulinemia.
89508826|NCT02312167|Experimental|confocal laser endomicroscopy|confocal laser endomicroscopy : 10 to 15 minutes endomicroscopy procedure to obtain real time microscopical images of healthy and malignant tissue of the targeted organs
89508827|NCT02333877|Experimental|Skinlink|applying Skinlink on simple laceration (length < 5cm)
89508828|NCT02333877|Other|Nylon|applying conventional suture using nylon on simple laceration (length < 5cm)
89508829|NCT02337309|Other|SF1126|Patients will receive SF1126 IV over 90 minutes on Days 1 and 4 of each week during each cycle.
89508830|NCT03504631||Breast cancer patients on tamoxifen|Patients currently on treatment with tamoxifen for at least 4 months.
89508831|NCT03867123|Experimental|Arm 1 (chemoradiation phase)|"Radiotherapy (RT) + temozolomide (TMZ) + LAM561 (during Concurrent phase - duration 6 weeks)*:~LAM561 will be initiated at the start of the concurrent phase and will be administered on a continuous daily basis together with TMZ and RT for 6 weeks at the selected dose, either 12 g/day (4 g tid), 8 g/day (4 g bid) or 4 g/day (4 g od).~RT will be administered only during the concurrent phase, consisting of fractionated focal irradiation administered using 1.8- 2 Gy/fraction, daily for 5 days/week for 6 weeks, for a total dose of up to 60 Gy.~TMZ will be administered during the concurrent phase at a starting dose of 75 mg/m2/day given daily for 6 weeks.~* One extra week may be allowed."
89508832|NCT03867123|Experimental|Arm 2 (maintenance phase)|"TMZ + LAM561 (during Maintenance phase with TMZ 200 mg/m2/day at Cycle 2 - duration 8 weeks):~LAM561 will be initiated on day 2 of Cycle 2 of the maintenance phase, when TMZ 200 mg/m2/day is given and administered on a continuous basis for two 28-day cycles. LAM561 will be administered at the selected dose, either 12 g/day (4 g tid), 8 g/day (4 g bid) or 4 g/day (4 g od).~TMZ will be administered at 200 mg/m2/day given daily the first 5 days for two 28-day cycles (if no toxicity is seen). In case of toxicity, TMZ dose may be reduced to 150 mg/m2/day at Cycle 3 to allow for recovery.~Both arms will be followed by a 4-week safety follow-up"
89508833|NCT03504475|Experimental|Paroxetine Hydrochloride Tablet|During the study session, healthy subjects will be administered a single dose of Paroxetine Hydrochloride Tablet 20mg under Fasting and Fed conditions.
89508834|NCT03504475|Active Comparator|Paxil®|During the study session, healthy subjects will be administered a single dose of Paxil® 20mg under Fasting and Fed conditions.
89508835|NCT02327247|Experimental|Test|Felodipine Extended Release Tablets USP 10 mg
89508836|NCT02327247|Active Comparator|Reference|Plendil® Extended release tablets 10 mg
89508837|NCT03505255|Active Comparator|Group A|Group A: 40 patients will receive intraperitoneal neostigmine 0.25 mg in 30 ml normal saline and 1 ml normal saline intramuscular.
88958513|NCT01994161||Intracranial stenting group|all the participants in this group will be performed with intracranial stenting
88958514|NCT01994187||CAS or CEA|CAS:the patient who accepted carotid angioplasty due to catotid artery stenosis CEA:the patient who accepted carotid endarterectomy due to catotid artery stenosis
88958515|NCT01994200|Experimental|Interdisciplinary Team-Based Approach|The delivered intervention will be to provide patients with an interdisciplinary team-based approach defined as care provided by a variety of professionals, each having their own domain of expertise, defined roles and responsibilities, who work together and meet to discuss patient needs and develop comprehensive treatment plans. Team composition will include physicians, a dedicated nurse, and allied professionals (e.g., dieticians, social workers, psychologists). The dedicated nurse will have a central integrative role in this interdisciplinary team and will provide patients with information about their illness and treatment, symptom management, emotional support, and reference to other resources when needed
89540384|NCT06211920|No Intervention|Standard medical treatment alone|"The standard treatment may include inhaled bronchodilators, intravenous corticosteroids, and titrated oxygen supplementation. Although this treatment is based on regional standard operating procedures (SOP), it may differ from patient to patient because it is based on the clinical judgement by the emergency physician in the MECU.~Inhaled bronchodilators can be given in the form of Fenoterol and Ipratropium as a combination drug and/or Salbutamol. Both as a nebulizer solution. One dose (4 ml) of the combination drug contains 1,25 mg Fenoterol and 0,5 mg Ipratropium. Salbutamol will be administered in a concentration of 1 mg/ml. Five mg will be given initially, which can be repeated if necessary.~Corticosteroids can be given in the form of Methylprednisolone 40-80 mg administered intravenously after establishing an intravenous access.~Oxygen therapy will be delivered through a nasal cannula if possible or a non-rebreather mask to maintain an arterial saturation of 88-92%."
89540385|NCT06211907|Active Comparator|Gas tamponade|Intravitreal gas tamponade
89540386|NCT06211907|Experimental|Air tamponade|Intravitreal Air tamponade
89540387|NCT06211894||the urethra at the bladder neck to the nearest proximal edge of the tape: < 5 mm|Patients who achieved continence after surgery were split into two subgroups based on the distance from the posterior of the urethra at the bladder neck to the nearest proximal edge of the tape: < 5 mm and >5 mm. The position of the sling along the urethra was measured as a percentage of urethral length and referred to as the sling percentile. This measurement was calculated as follows: the proximal urethral length (distance from the sling's proximal point to the bladder neck) divided by the total urethral length (distance from the bladder neck to the external urethral meatus) on the sagittal plane, where the bladder neck and the external urethral meatus represent 0% and 100% of urethral length, respectively. Additionally, perineal ultrasound was used to evaluate various parameters including bladder descent, pubo-urethral distance, urethral thickness, detrusor thickness, cystocele descent, rectal descent, and uterine descent.
89540388|NCT06211894||the urethra at the bladder neck to the nearest proximal edge of the tape: > 5 mm|Patients who achieved continence after surgery were split into two subgroups based on the distance from the posterior of the urethra at the bladder neck to the nearest proximal edge of the tape: < 5 mm and >5 mm. The position of the sling along the urethra was measured as a percentage of urethral length and referred to as the sling percentile. This measurement was calculated as follows: the proximal urethral length (distance from the sling's proximal point to the bladder neck) divided by the total urethral length (distance from the bladder neck to the external urethral meatus) on the sagittal plane, where the bladder neck and the external urethral meatus represent 0% and 100% of urethral length, respectively. Additionally, perineal ultrasound was used to evaluate various parameters including bladder descent, pubo-urethral distance, urethral thickness, detrusor thickness, cystocele descent, rectal descent, and uterine descent.
89540389|NCT06211881|Experimental|Chi-GVM|"Chi-GVM regimen (every 21 days is a treatment cycle):~Chidamide 20 mg orally;gemcitabine 1g/m2, twice a week, intravenous infusion on day 1, vinorelbine 20 mg/m2, infusion on day 1; Mitoxantrone Hydrochloride Liposome12 mg/m2, intravenous infusion on day 1; Chidamide maintenance therapy: 20 mg orally twice a week/28 days/cycle."
89540390|NCT06211868||Observational cohort|
89540391|NCT06211868||Randomised cohort|
89540392|NCT06211855||Idiopathic Polyhydramios Cases|The group with polyhydramnios was divided into two groups according to whether the CPR value was below 1.08 or 1.08 and above
89024034|NCT03899402|Active Comparator|Control|Standard of care insulin will be used as an active comparator arm for 1/3 of patients (38 patients) for the entire duration of the study.
89206941|NCT00835848|Active Comparator|Exenatide|25 μg Byetta (Lilly, Exenatide) is added to 250 ml isotonic NaCl. Infusion is started immediately at 72ml/hour for 15 min, followed by 26ml/hour to be contoinued for 6 hours.
89024035|NCT03899402|Experimental|Dual Therapy|Once a week injection of Semaglutide (a GLP-1 receptor agonist) in addition to standard of care insulin for the first six months in 2/3 of patients (76 patients). Semaglutide is a clear, colorless solution that contains 2 mg of semaglutide in a 1.5 mL (1.34 mg/mL) pre-filled, disposable, single-patient-use pen injector. Semaglutide will be started at the 0.25 mg dose for the first two weeks, then increased to 0.5 mg at week 2, and then yet again increased to 1.0 mg at week 4.
89206942|NCT00835848|Placebo Comparator|Saline|Isotonic saline infusion is started immediately at 72ml/hour for 15 min, followed by 26ml/hour to be contoinued for 6 hours.
89206943|NCT00961857|Active Comparator|Treatment A|Individual Tablets of 50 mg sitagliptin and 500 mg metformin
89206944|NCT00961857|Experimental|Treatment B|Sitagliptin/metformin 50 mg/500 mg tablet
89206945|NCT00961857|Active Comparator|Treatment C|Individual Tablets of 50 mg sitagliptin and 1000 mg metformin
89206946|NCT00961857|Experimental|Treatment D|sitagliptin/metformin 50 mg/1000 mg tablet
89206947|NCT02547792|Experimental|VXA-BYW.10 (Low Dose) Oral Vaccine|Single administration of Influenza B (Low Dose) oral vaccine tablets
89206948|NCT02547792|Experimental|VXA-BYW.10 (High Dose) Oral Vaccine|Single administration of Influenza B (High Dose) oral vaccine tablets
89206949|NCT02547792|Placebo Comparator|Placebo Tablets|Matching placebo dose (size and number of tablets) to low dose vaccine (part 1) and high dose (part 2)
89206950|NCT00836082|Experimental|Cohort 1 (N=10)|Placebo-controlled, escalating multiple doses of 0.5mg per day for 14 days.
89206951|NCT00836082|Experimental|Cohort 2 (N=10)|Placebo-controlled, escalating multiple doses of 1mg per day for 14 days.
89024036|NCT03899402|Experimental|Triple therapy|Once a day oral pill (green, plain, diamond shaped film coated 5 mg tablet) of Dapagliflozin (an SGLT-2 inhibitor) added to once a week injection of semaglutide and standard of care insulin in the second 6 months of 1/2 of the dual therapy arm (1/3 of total patients (38 patients)). Dapagliflozin will be started at 5 mg for one week, and then increased to 10 mg for the remainder of the study
89024037|NCT03899402|Placebo Comparator|Triple therapy control|Once a day oral pill (green, plain, diamond shaped film coated 5 mg tablet) of the Placebo form of Dapagliflozin added to once a week injection of semaglutide and standard of care insulin in the second 6 months of 1/2 of the dual therapy arm (1/3 of total patients (38 patients)).
89024038|NCT03880019|Experimental|Treatment (olaparib, temozolomide)|Patients receive olaparib PO BID and temozolomide PO QD on days 1-7 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT or MRI throughout the trial and undergo tumor biopsy at screening and on study.
89508838|NCT03505255|Active Comparator|Group B|Group B: 40 patients will receive intraperitoneal neostigmine 0.5 mg in 30 ml normal saline and 1 ml normal saline intramuscular.
89024039|NCT03864419|Experimental|Cohort I (pediatric BL)|Patients receive cyclophosphamide IV and vincristine IV on day 1, and prednisone IV or PO on days 1-7 in the absence of disease progression or unacceptable toxicity. Patients then receive rituximab IV or rituximab hyaluronidase SC, cyclophosphamide IV, vincristine IV, and methotrexate IV on day 1. Cycles repeat every 14 days for 6 cycles in the absence of disease progression or unacceptable toxicity.
89024040|NCT03864419|Experimental|Cohort II (DLBCL)|Patients receive rituximab IV or rituximab and hyaluronidase human SC, cyclophosphamide IV, doxorubicin IV, and vincristine IV on day 1, and prednisone PO on days 1-5 of cycle 1. Cycles repeat every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity.
89508839|NCT03505255|Active Comparator|Group C|Group C: 40 patients will receive intramuscular neostigmine 0.5 mg in 1 ml volume plus 30 ml normal saline intraperitoneal.
89508840|NCT03505255|Placebo Comparator|Group D|Group D (control group): 40 patients will receive intraperitoneal 30 ml normal saline and 1 ml normal saline intramuscular.
89024041|NCT03864419|Experimental|Cohort III (Adult BL)|Patients receive rituximab IV or rituximab and hyaluronidase human SC in day 1, etoposide IV, doxorubicin IV, and vincristine IV on days 1-4. Patients also receive cyclophosphamide IV on day 5 and prednisone PO on days 1-5. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity.
89024042|NCT03864419|Experimental|Cohort IV (MCD)|Patients receive rituximab IV or rituximab and hyaluronidase human SC on days 1, 8, 15, and 22 in the absence of disease progression or unacceptable toxicity.
89024043|NCT03850795|Experimental|HC-1119|Oral dose of 80 mg/day
89024044|NCT03850795|Active Comparator|enzalutamide|Oral dose of 160 mg/day
89024045|NCT03847844|Experimental|Group A|Cyto-MSC (5 million UCMSCs per kg bodyweight) and standard treatment
89024046|NCT03847844|Placebo Comparator|Group B|Placebo (normal saline) and standard treatment
89024047|NCT03829111|Active Comparator|Arm I (nivolumab, ipilimumab)|Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Beginning in cycle 5, patients receive nivolumab IV over 30 minutes on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89024048|NCT03829111|Experimental|Arm II (CBM588, nivolumab, ipilimumab)|Patients receive clostridium butyricum CBM 588 probiotic strain PO BID, nivolumab IV over 30 minutes on day 1, and ipilimumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Beginning in cycle 5, treatment with clostridium butyricum CBM 588 probiotic strain and nivolumab repeats every 28 days in the absence of disease progression or unacceptable toxicity.
89024049|NCT03828227|Active Comparator|"Candidate group OPTIMOX plus bevacizumab (Arm A)"|"Patients with :~Serum albumin level ≥ 30g/L,~ECOG PS 0-1 (whatever mini GDS score) or ECOG PS 2 with mini GDS 0 (ie, no depression).~Adapted FOLFOX7 (aFOLFOX7)-bevacizumab for 6 cycles and then Adapted LV5FU2 (aLV5FU2)-bevacizumab (until progression or or unacceptable limiting toxicity)"
89024050|NCT03828227|Active Comparator|"Candidate group - Capecitabine-bevacizumab (Arm B)"|"Patients with :~Serum albumin level ≥ 30g/L,~ECOG PS 0-1 (whatever mini GDS score) or ECOG PS 2 with mini GDS 0 (ie, no depression).~This treatment regimen will be given until disease progression (PD) or unacceptable limiting toxicity, as follows:"
89508841|NCT02333799|Experimental|Bedaquiline + PA-824 + Linezolid|bedaquiline 400 mg once daily for 2 weeks then 200mg 3 times per week plus PA-824 200mg once daily plus linezolid 1200mg once daily .
89508842|NCT02311231|Experimental|bivalirudin|bivalirudin as intravenous bolus of 0,75 mg per kilogram followed by an infusion of 1,75 mg per kilogram per hour
89508843|NCT02311231|Active Comparator|heparin|unfractionated Heparin 5 000 IU/ml as intravenous bolus according to local practice
89508844|NCT03508999|Experimental|Metronidazole Gel|Group A subjects will be given standard oral hygiene instructions on the visit with a standard 0.8 % metronidazole gel instructed to apply topically on the marginal gingiva for the next 4 weeks, twice a day for 30 minutes, after morning and evening tooth brushing.
89508845|NCT03508999|Other|SMS Text Reminder|Subjects will be provided biweekly reminder via SMS in the form of text message reinforcing oral hygiene. Additionally, patients will be given standard oral hygiene instructions on the visit with a placebo gel topically instructed to apply on the marginal gingiva for the next 4 weeks, twice a day for 30 minutes, after morning and evening tooth brushing.
89206952|NCT00836082|Experimental|Cohort 3 (N=10)|Placebo-controlled, escalating multiple doses of 4mg per day for 14 days.
88958516|NCT01994200|Other|Usual Care Control Group|Patients in the control group will be provided with usual care, comprised of meetings with surgeons and endocrinologists. All patients in this study will be provided with an information website containing information on their cancer, treatments, and treatment side-effects.
89206953|NCT00836082|Experimental|Cohort 4 (N=10)|Placebo-controlled, escalating multiple doses of 8mg per day for 14 days.
89206954|NCT04009941|Experimental|PEG-rhG-CSF|Patients with breast cancer who were treated with intensive chemotherapy received PEG-rhG-CSF.
89206955|NCT00830466|Experimental|Laser and rapamycin versus laser alone|Laser and rapamycin versus laser alone
89206956|NCT04412265||Covid 19 patients|The study will be conducted on all patients hospitalized affected by pneumonia COVID related.
89508846|NCT03508999|Placebo Comparator|Placebo|Group C will be subjects will be given standard oral hygiene instructions on the visit with a placebo gel topically instructed to apply on the marginal gingiva for the next 4 weeks, twice a day for 30 minutes, after morning and evening tooth brushing.
89508847|NCT02333721|Experimental|D2 Lymphadenectomy including No. 10|Laparoscopic total gastrectomy with D2 lymphadenectomy including spleen-preserving No. 10 lymph node dissection will be performed for the treatment of patients assigned to this group
89508848|NCT02333721|Active Comparator|D2 lymphadenectomy excluding No. 10|Laparoscopic total gastrectomy with D2 lymphadenectomy excluding spleen-preserving No. 10 lymph node dissection will be performed for the treatment of patients assigned to this group
89508849|NCT03505177|Experimental|Chitin-glucan|Supplementation during 3 weeks with 4.5g per day of chitin-glucan fiber
89508850|NCT03105375|Experimental|Single ascending dose of X842|Single ascending oral dose of X842 administered to subjects in cohorts. Cohorts are administered in sequence.
89508851|NCT03105375|Experimental|Multiple ascending dose of X842|Multiple ascending oral dose of X842 administered to subjects in cohorts. Cohorts are administered in sequence.
89508852|NCT03105375|Active Comparator|Losec|Standard oral dose of omeprazole administered to subjects in one cohort.
89508853|NCT02304445|Active Comparator|Transarterial Chemoembolization (TACE)|Subjects will randomized receive one TACE treatment then receive observation or up to 3 additional TACE treatments as clinically indicated.
89508854|NCT02304445|Experimental|TACE+Stereotactic Body Radiotherapy|Subjects will receive one TACE treatment then receive 1-5 Stereotactic Body Radiotherapy treatments.
89508855|NCT02316301|Experimental|Long interval misoprostol|A small envelope including two labeled plastic bags (A & B) (each bag containing either 2 misoprostol tablets(400µg) or 2 identically appearing placebo tablets) will be packaged in sequentially numbered sealed envelopes. In long interval misoprostol group, bag (A) contains misoprostol tablets and bag (B) contains placebo tablets. After signing the informed consent, the sequentially numbered sealed envelopes will be opened (according to the sequence of attendance of the patient) by the study nurse. Tablets in bag (A) will be inserted 12 hours before office hysteroscopy and tablets in bag (B) will be inserted 3 hours before office hysteroscopy.
89508856|NCT02316301|Active Comparator|Short interval misoprostol|A small envelope including two labeled plastic bags (A& B) (each bag containing either 2 misoprostol tablets(400µg) or 2 identically appearing placebo tablets) will be packaged in sequentially numbered sealed envelopes. In short interval misoprostol group, bag (A) contains placebo tablets and bag (B) contains misoprostol tablets. After signing the informed consent, the sequentially numbered sealed envelopes will be opened (according to the sequence of attendance of the patient) by the study nurse. Tablets in bag (A) will be inserted 12 hours before office hysteroscopy and tablets in bag (B) will be inserted 3 hours before office hysteroscopy.
89508857|NCT02333409|Active Comparator|Electroacupuncture|A Hong Kong registered Chinese Medicine practitioner will give Electroacupuncture treatments. Patients will be treated in a comfortable prone position. Jiaji (Ex-B2) points form T8 to T12 bilaterally are chosen based on traditional Chinese medicine (TCM) theory and neurophysiologic basis of Jiaji points. After De Qi sensation is achieved, the handles of needles on homolateral T8-T12 Jiaji are respectively connected to the Han's acupoint nerve stimulator at a frequency of 2/100 Hz and a current of 1 mA with a disperse-dense waveform. The needles remained for 30 min. The treatment was given twice weekly on week 1 and week 3.
89508858|NCT02333409|Sham Comparator|Sham|For placebo acupuncture, sham placebo acupuncture needles (DongBang AcuPrime Acupuncture Inc., South Korea) will be used. Its validity and credibility have been well demonstrated. The needles with blunt tips are quickly put onto the same points used in the electroacupuncture group without inserting into the skin. The needles on homolateral T8 and T12 Jiaji are then connected to the electric stimulator, but with zero frequency and electric current.
89508859|NCT03504319||Lean Group|Pre-pregnancy BMI between 18.5 and 24.9 kg/m2
89508860|NCT03504319||Obese Group|Pre-pregnancy BMI ≥30 kg/m2
89508861|NCT03144609|Active Comparator|PEEP 4|Active Comparator low PEEP: obese patient during oral-surgical procedures under general anesthesia ventilated with Positive endexpiratory pressure (PEEP) 4 cm H2O(water)
89508862|NCT03144609|Experimental|PEEP 7 & ARM|Experimental ARM & Experimental high PEEP: obese patient during oral-surgical procedures under general anesthesia ventilated with PEEP( positive endexpiratory pressure) 7 cm H2O with ARM(alveolar recruitment maneuver) provided every 30 min
89508863|NCT03144609|Experimental|PEEP 10 & ARM|Experimental ARM & Experimental high PEEP:obese patient during oral-surgical procedures under general anesthesia ventilated with PEEP( positive endexpiratory pressure) 10 cm H2O with ARM(alveolar recruitment maneuver) provided every 30 min
89508864|NCT02312323|Experimental|Definitive 65 HPT|The Test product were the Definitive 65 (Filcon V4) lenses with Hydra PEG surface coating. This material is produced by Contamac Ltd. and the contact lenses were manufactured by Appenzeller Kontaktlinsen AG.
89508865|NCT02312323|Active Comparator|Definitive 65|The Control product was the commercially available Definitive 65 (Efrofilcon A) lens. This material is produced by Contamac Ltd. and the contact lenses were manufactured by Appenzeller Kontaktlinsen AG.
89508866|NCT02327091|Placebo Comparator|white rice flour capsule|One group of 47 subjects received alfacalcidol 0.5 mcg/day and the other group received placebo for 12 weeks
89508867|NCT02327091|Active Comparator|alfacalcidol|One group of 47 subjects received alfacalcidol 0.5 mcg/day and the other group received placebo
89024051|NCT03828227|Active Comparator|"Non candidate group - Capecitabine-bevacizumab"|"Patients with:~Serum albumin level < 30g/L.~And/ or ECOG PS 2 and mini GDS ≥ 1 (ie, depression).~This treatment regimen will be given until disease progression (PD) or unacceptable limiting toxicity, as follows:"
89024052|NCT03809793|Active Comparator|Acipimox ingestion|Individuals in this group will undergo pre-assessments for body composition (DXA), Insulin sensitivity (Hyperinsulinaemic Euglycaemic clamp and continuous glucose monitor), muscle biopsies pre- and post- clamp for analysis of lipid metabolites, liver fat (MRI) and exercise capacity (VO2 max). Participants will then ingest 250 mg of Acipimox 1 hour before each exercise session of the 12 week intervention.
89206957|NCT00830544|Experimental|1|Experimental chemotherapy using neoadjuvant approach
89508868|NCT02304523|Experimental|Test 1|"CDFR0612 Solution 150mL will be mixed with water of 350ml to prepare a bowel cleansing preparation solution 500mL. Take it within 30min. After then, take additional water 500ml within 30min.~These processes will be in evening at one day before colonoscopy and in early morning at the same day of colonoscopy."
89508869|NCT02304523|Experimental|Test 2|"CDFR0613 Solution 150mL will be mixed with water of 350ml to prepare a bowel cleansing preparation solution 500mL. Take it within 30min. After then, take additional water 500ml within 30min.~These processes will be in evening at one day before colonoscopy and in early morning at the same day of colonoscopy."
89508870|NCT02304523|Active Comparator|Comparator|"Coolprep Powder A and B will be mixed with water to prepare a mixture of a bowel cleansing preparation solution 500mL. Repeat it twice. Take these of IL (2 * 500mL) within 1 hour. After then, take additional 500ml water.~These processes will be in evening at one day before colonoscopy and in early morning at the same day of colonoscopy."
89508871|NCT02316535|Active Comparator|standard-dose|capecitabine, oral administration, 1,250 mg/m2 twice daily on days 1-14, and repeated on day 22; 8 circles in total.
89508872|NCT02316535|Experimental|reduced-dose|capecitabine, oral administration, 1,000 mg/m2 twice daily on days 1-14, and repeated on day 22; 8 circles in total.
89508873|NCT02304601||Comorbid symptoms|
89508874|NCT02304601||No comorbid symptoms|
89508875|NCT03105063|Experimental|US GROUP|All patients will first undergo ultrasound scan of the hip in attempt to recognize the AIIS, on the same day , the true morphology of the AIIS will be evaluated using 3d imaging
89508876|NCT03501823||Peripheral vascular disease|"All adult patients (aged 18 years and above) proven or highly suspected to have peripheral arterial or venous disease.~Ultrasound to be performed first in order to correct Photoacoustic tomography positioning.~Photoacoustic tomography to be performed after ultrasound"
89508877|NCT03501823||Oncology|"All adult patients (ages 18 years and above) proven or highly suspected to have solid organ malignancy Ultrasound to be performed first in order to correct Photoacoustic tomography positioning.~Photoacoustic tomography to be performed after ultrasound"
89508878|NCT02326857||Women with breast cancer|Observational study of women with Stage II/III locally advanced breast cancer in Latin America
89508879|NCT03501745|Other|Management Group|
89508880|NCT03501745|Other|control group|
89508881|NCT02333253|Active Comparator|Delayed start protocol|First group received 300 U r FSH +150 U urinary GN from day 2 till day of HCG ,dose adjusted according to the response then 0.25 cetrotide S.c was added on when leading follicle reach >12 mm, HCG was given only if we have at least 3 mature follicles >14 mm and the leading one >17mm then OPU done after 36 hrs of HCG, oocytes were denuded and fertilized by ICSI to avoid low fertilization rate by conventional IVF,embryo transfer were done on day 3 when we have at least one embryo GI other wise cancelled ET, then cyclogest 800mg were given intravaginal for 14 days then quantitative BHCG done and considered positive if > 5miu/ML
89508882|NCT02333253|Active Comparator|conventional antagonist protocol|Second group were received cetrotide 0.25 mg s.c alone from day 2 to day 8then we initiate GN therapy by same initial GN dose (300FSH+150U urinary GN).same adjustment of dose were done and antagonist restarted when DF >12mm, till day of HCG, OPU done after 36 hrs of HCG, oocytes were denuded and fertilized by ICSI to avoid low fertilization rate by conventional IVF,embryo transfer were done on day 3 when we have at least one embryo GI other wise cancelled ET, then cyclogest 800mg were given intravaginal for 14 days then quantitative BHCG done and considered positive if > 5miu/ML
89508883|NCT02316691||Thyroid Eye Disease|Blood samples will be drawn from subjects diagnosed with Thyroid Eye Disease. This study is observational. No interventions will be given as part of this study.
89508884|NCT03501667|Active Comparator|Use of decision support tool|Trainee using decision support tool while assessing a clinical case. This intervention will affect the study participant fund of knowledge on the case.
89508885|NCT03501667|Active Comparator|Use of UpToDate|Control group, participants using current literature prior to assessing a clinical case. Allowing 10 minutes to read on a topic during clinical care is an active intervention in the study participant fund of knowledge.
89508886|NCT02039661|Active Comparator|Lidocaine Spray|
89508887|NCT02039661|Placebo Comparator|Placebo|These patients received placebo spray.
89508888|NCT02312479|Experimental|Nyxoah SAT therapy|
89508889|NCT02331537|Experimental|Internet-based cognitive-behavior therapy|The experimental group will go through active internet-based treatment. The treatment is 10 weeks long and is based on the principles of exposure i.e. the participant is instructed to stay with the frightening thought until it is no longer associated with anxiety.
89508890|NCT02331537|No Intervention|Waitlist|Waitlist control that will get the internet-based treatment when the first group has finished (i.e. Week 10). There are no active treatment for these participants at all.
89519401|NCT03449173|Experimental|Sunitinib|Sunitinib orally administered at 50 mg once daily for 4 consecutive weeks, followed by a 2-week rest period (schedule 4/2) to comprise a complete cycle of 6 weeks
88958517|NCT01994213|Experimental|Famitinib|Famitinib 25 mg qd p.o., 4 weeks per cycle.The treatment continued until disease progression or intolerable toxicity happened or patients withdrawal of consent.
88958518|NCT01994265|Active Comparator|Warfarin|Treatment with Warfarin once daily, taken at fast, to maintain INR between 2 and 3.
88958519|NCT01994265|Active Comparator|Dabigatran|Dabigatran 150 mg twice daily
88958520|NCT01994278|Experimental|Tooth brush|Periclean is a soft rubber gentle toothbrush
88958521|NCT01994304|No Intervention|No safe childbirth checklist|The selected control districts include Bharatpur, Pali, Jhunjhunu, and Nagaur
88958522|NCT01994304|Active Comparator|Safe Childbirth Checklist|The selected districts for SCC intervention include Alwar, Jalore, Sirohi, Sikar, Dausa, and Churu
88958523|NCT01994317|Active Comparator|Standard sedation dose|IV sedation dose calculated using current standard of care
88958524|NCT01994317|Experimental|Algorithm|IV sedation dose calculated by study algorithm
88958525|NCT01994330|Experimental|Desmopressin|"0,3 mcg per kilogram of desmopressin in 100 ml of saline, labeled as study drug and administered in 30 minutes a half hour before surgical incision"
88958526|NCT01994330|Placebo Comparator|placebo|"100 of saline labeled as study drug administered in 30 minutes a half hour before surgical incision"
88958527|NCT01994343|Experimental|Experimental group|Adult women aged over 18 years old with pain during more than six months are included in the study. These patients will receive a global posture reeducation.
88958528|NCT01994343|No Intervention|Control group|Adult women aged over 18 years old without chronic pain. will receive no intervention.
88958529|NCT01994356|Active Comparator|Usual contraceptive counseling|subjects received usual contraceptive counseling
88958530|NCT01994356|Experimental|Physician self-disclosure of IUC use|subjects received usual contraceptive counseling plus intervention which was Physician self-disclosure of personal IUC use during the counseling
88958531|NCT01994369|Experimental|EC17 Injection group|This group with receive a single dose of EC17, infused over 10 minutes, prior to surgery. Then, during surgery, they will be imaged with a camera and an imaging probe the investigators have developed.
88958532|NCT01994408|Experimental|default intensification arm (all)|all subjects will receive blister packs with weekly increasing blood pressure medications. There is no control arm for this study
88958533|NCT01994421|Sham Comparator|Kinesiotape|
89508891|NCT02304679|Experimental|LIESWT arm|"Patients randomized to this arm will have two sequences of Low-Intensity Extracorporeal Shock Wave Therapy (LIESWT).~Interventions: Pre-inclusion questionnaires; 1 month of PDE5i treatment; PDE5i follow-up questionnaires; Inclusion questionnaires; 4 weekly LIESWT (Wave 1) with the RENOVA device; Follow-up questionnaires 1 month after Wave 1; Follow-up questionnaires 3 months after Wave 1; 8 bi-weekly LIESWT (Wave 2) with the RENOVA device; Follow-up questionnaires 1 month after Wave 2; Questionnaires via postal mail; Final follow-up questionnaires 12 months after Wave 2."
89508892|NCT02304679|Placebo Comparator|Sham arm|"Patients randomized to this arm will have one sequence of sham Low-Intensity Extracorporeal Shock Wave Therapy and then three months later one sequence of Low-Intensity Extracorporeal Shock Wave Therapy.~Interventions: Pre-inclusion questionnaires; 1 month of PDE5i treatment; PDE5i follow-up questionnaires; Inclusion questionnaires; 4 weekly sham LIESWT (Wave 1) with the RENOVA device; Follow-up questionnaires 1 month after Wave 1; Follow-up questionnaires 3 months after Wave 1; 8 bi-weekly LIESWT (Wave 2) with the RENOVA device; Follow-up questionnaires 1 month after Wave 2; Questionnaires via postal mail; Final follow-up questionnaires 12 months after Wave 2."
89508893|NCT02326935|Experimental|Adipose derived mesenchymal cells|"Intervention: Autologous adipose derived mesenechymal stem cells, 150 million cells deployed via two (2) treatments via intravenous injection~Other Names:~ADSC, mesenchymal cells, stromal cells"
89508894|NCT02331615|Experimental|Right|Electrode positioning will be determined according to the EEG 10-20 international system for EEG electrode placement: Right hemisphere anodal stimulation of the dorso lateral frontal area (F3), left hemisphere catodal stimulation of the dorso lateral frontal area (F4). Intensity of 1.5 mA (milliampere) for duration of 15 minutes. A total of 9 sessions: 4 sessions a week for 2 weeks.
89508895|NCT02331615|Experimental|left|Electrode positioning will be determined according to the EEG 10-20 international system for EEG electrode placement: left hemisphere anodal stimulation of the dorso lateral frontal area (F3), right hemisphere catodal stimulation of the dorso lateral frontal area (F4). Intensity of mA1.5 (milliampere) for duration of 15 minutes. A total of 9 sessions: 4 sessions a week for 2 weeks.
89508896|NCT02331615|Sham Comparator|sham|The stimulator will be turned on for only a very short duration of time (msec) no meaningful stimulation is believed to be administered in such a way.
89508897|NCT03503851|Active Comparator|One CLIP|Implantation of single MitraClip
89508898|NCT03503851|Active Comparator|Two CLIPs|Implantation of second MitraClip (after successful Implantation of single MitraClip)
89508899|NCT02326779|Experimental|Experimental Arm|Experimental Arm: acetylsalicylic acid (Aspirin) 100 mg OD for 3 years
88958534|NCT01994434|Other|Decompression of the ulnar nerve|Surgical decompression of the Guyon's canal and ganglion excision
88958535|NCT01994447|No Intervention|Traditional Nurse Enrollment|Research nurses will obtain verbal consent from patient/caregiver.
88958536|NCT01994447|Experimental|Student Enrollment|Trained research students will use digital video discs (DVD's) of primary investigators explaining study information to obtain informed consent
88958537|NCT01994460|Active Comparator|Arm 1 (control arm)|Standard treatment for drug-sensitive pulmonary TB using isoniazid (6 months), rifampicin (6 months), pyrazinamide (2 months), and ethambutol (2 months)
88958538|NCT01994460|Experimental|Arm 2 (experimental arm 1)|Isoniazid (6 months), rifampicin (6 months), pyrazinamide (2 months), and linezolid (600 mg/day, 2 weeks)
88958539|NCT01994460|Experimental|Arm 3 (experimental arm 2)|Isoniazid (6 months), rifampicin (6 months), pyrazinamide (2 months), and linezolid (600 mg/day, 4 weeks)
88958540|NCT01994473|Experimental|SEP-363856|Dosing will be initiated at 10 mg SEP-363856 as a single oral dose. Subsequent cohorts will be dosed at 25, 50, and 100 of SEP-363856.
88958541|NCT01994473|Placebo Comparator|Placebo|An oral of matched placebo
88958542|NCT01994473|Experimental|SEP-363856 Open Label|75 mg SEP-363856 given once-daily
88958543|NCT01994512|Experimental|Decompression without fusion|Surgery of the stenotic spinal segments with decompression of the neural elements without concommitant fusion.
88958544|NCT01994512|Experimental|Decompression with fusion|Surgery of the stenotic spinal segments with decompression of the neural elements with concommitant fusion.
88958545|NCT01994525|Experimental|Cohort 1: PfRAS-infected|"5 doses (immunizations) of approximately 200 infectious bites (200-400 bites total) from PfRAS-infected mosquitoes (true-immunization). The target dose is 960 infectious bites.~Challenge occurs 3 weeks after final immunization."
88958546|NCT01994525|Placebo Comparator|Cohort 1: Noninfected|"Placebo immunization. 5 doses of approximately 200 noninfected bites (200-400 bites total) from irradiated uninfected mosquitoes (mock-immunization). The target dose is 960 noninfected bites.~Challenge occurs 3 weeks after final immunization."
88958547|NCT01994525|Other|Cohort 1: Nonimmunized|"No protective intervention given.~Challenge occurs directly after screening."
88958548|NCT01994525|Experimental|Cohort 2: PfRAS-infected|"3 to 7 doses (immunizations) of approximately 200 infectious bites (200-400 bites total) from PfRAS-infected mosquitoes (true-immunization). The target dose is dependent on protection results in cohort 1.~Challenge occurs 3 weeks after final immunization."
88958549|NCT01994525|Placebo Comparator|Cohort 2: Noninfected|"Placebo. 3 to 7 doses of approximately 200 noninfected bites (200-400 bites total) from irradiated, uninfected mosquitoes (true-immunization). The target dose is dependent on protection results in cohort 1.~Challenge occurs 3 weeks after final immunization."
88958550|NCT01994525|Other|Cohort 2: Nonimmunized|"No protective intervention given.~Challenge occurs directly after screening."
88958551|NCT01994525|Experimental|Hyperimmunity PfRAS-infected|"Cohort 1 sub-cohort~3 doses (immunizations) of approximately 200 infectious bites (200-400 bites total) from PfRAS-infected mosquitoes. This arm will receive the first 3 immunizations of Cohort 2.~Challenge occurs at the same time as Cohort 2 (3-20 weeks after the final immunization)"
88958552|NCT01994577||Adults (18+) presenting to the ED with symptoms of ACS|
88958553|NCT01994603|Experimental|Opt-in testing|"Participants will be scheduled for a two-hour appointment to complete the written consent procedure, enroll in the study, and participate in the study activities, testing and a focus group. Opt-in: Common barriers to HIV screening testing will be removed as much as possible (i.e., providing rapid testing, results shortly available, testing on-site, confidentiality). There is voluntary HIV testing available to all study participants if you wish to do it. "
88958554|NCT01994603|Experimental|Opt-out testing|Participants will be scheduled for a two-hour appointment to complete the written consent procedure, enroll in the study, and participate in the study activities, testing and a focus group. Opt-out multicomponent testing. Participants will be informed that a bundled routine health test is available on a voluntary basis to study participants, and the participant may elect to decline all or part of the testing.
88958555|NCT01994616||keloid or hypertrophic scars|All patient including all skin types with keloid or hypertrophic disease receiving Intralesional Cryotherapy
88958556|NCT01994642|Active Comparator|Reference|CIPRODEX® (ciprofloxacin 0.3%/dexamethasone 0.1%)
88958557|NCT01994642|Placebo Comparator|Placebo|Placebo Sterile Otic Suspension
88958558|NCT01994642|Experimental|Test|Ciprofloxacin 0.3%/dexamethasone 0.1% sterile otic suspension
88958559|NCT01994655|Experimental|Doing exercise|We want to use Kupperman Index to assess the severity of climacteric symptoms,and assess the effect of doing exercise fof the climacteric symptoms
88958560|NCT01994668|Experimental|Lorazepam|
88958561|NCT01994668|Placebo Comparator|Placebo|
88958562|NCT01994681||Pancreatic Cancer|
89508900|NCT02326779|No Intervention|Comparator Arm|Non-aspirin use arm as comparator
88958563|NCT01994681||Healthy|
88958564|NCT01994694||adults with ADHD|adults with ADHD, without neurological and psychiatric comorbidities
88958565|NCT01994694||controls|people without ADHD, with no neurological and psychiatric disorders
88958566|NCT01994707|Active Comparator|Remote ischemic preconditioning|Left arm blood pressure cuff inflation for 5 min then deflation of cuff for 5 min- cycle repeated 3 times before coronary artery bypass grafting.
88958567|NCT01994707|Placebo Comparator|Placebo|Deflated cuff on arm for 30 minutes.
88958568|NCT01994733|Experimental|Intensive phosphate control|Individuals randomized to this arm will be exposed to a treatment strategy that targets a P of < 1.50 mmol/L, reflecting the recommendations of current guidelines. Titration of the calcium carbonate dose will be the core of this approach and this will be complemented by usual recommendations regarding dietary P restriction. Dietitians will be available to provide counseling with regards to any aspect of the end-stage renal disease diet, as per usual dialysis unit practice.
89508901|NCT03503539|Experimental|Mini percutaneous nephrolithotomy|All operations were performed or supervised by the same surgeon. Right after the patients in mini-PNL group were placed a 5F ureteral catheter with general anesthesia, they were had a prone position and the access was performed by choosing the optimal calyx to reach the stone following the contrast agent was given. The guide wire was then placed and the stones were broken with a laser lithotripter using a 12F nephroscope (Modular minimally invasive PCNL system, Karl Storz, Tuttlingen, Germany) following the dilatation using an one step dilator with a 16.5F access sheath. When necessary, stones were removed using the stone removal forceps. Right after a 14-Fr nephrostomy tube was inserted and an antegrade pyelography was taken, the operation was terminated.
89508902|NCT03503539|Active Comparator|Retrograde intrarenal surgery|Following the general anesthesia performed, a safety guide wire was placed and semirigid ureteroscopy (9.5 / 11.5F) was performed. Stones were fragmented using a 270 micron meter laser fiber with the help of 7.5-F fiber optic flexible ureterorenoscope after the placement of ureteral access sheat (9.5 / 11.5 F). Stone fragmentation was accomplished using a laser energy of 0.5-1.5 J and a rate of 5-15 Hz and adjusting this range according to stone hardness. 4.7F JJ stent was routinely placed at the end of the operation because of worries about possible edema etc. due to access sheath. In this group, access sheath could not be placed in 2 patients due to the small diameter of the ureter, and JJ stent was placed, and 2 weeks later, the procedure was performed as it was in the others.
89508903|NCT02331303||Group1|"This is a single-arm descriptive observational drug utilization study based on secondary data collection of patients treated with Xofigo in Sweden.~This study will include patients receiving treatment of Xofigo at certified nuclear medicine centers across Sweden during a two year period."
89508904|NCT02316925|Placebo Comparator|Crystalline Cellulose|looks like and is given in the same way as the experimental treatment but contains no active ingredient
89508905|NCT02316925|Experimental|Glutathione supplement|500 mg/day Setria glutathione supplement
88958569|NCT01994733|Active Comparator|Liberalized phosphate control|"Individuals in this arm will be exposed to a treatment strategy that allows P to rise above 2.00 mmol/L. This will be accomplished through structured reduction of P binders already in use (as per the algorithm detailed below). Rescue P binding will be instituted if P rises above 2.50 mmol/L. Dietitians will be available to provide counseling regarding any aspect of the end-stage renal disease diet, as per usual dialysis unit practice, but will not provide counseling on dietary P restriction unless the P rises above 2.50 mmol/L."
88958570|NCT01994759|Active Comparator|Training|strengthening and stretching exercises.
88958571|NCT01994759|Active Comparator|Glucocorticosteroid injection|Injection of 40 mg methylprednisolone.
88958572|NCT01994759|Active Comparator|Training and Glucocorticosteroid injections|A combination treatment of the two above.
88958573|NCT01994772|Active Comparator|Targeted controlled temperature between 32.5 and 33.5°C|Patients will be placed in targeted temperature control between 32.5 and 33.5 ° C for 24 hours and then slowly rewarmed for targeted temperature control between 36.5 and 37.5 ° C for 24 hours.
89508906|NCT03144375|Active Comparator|Medical Optimization|Medical treatment and education x 4 months, re- eval at 4 months and possible cross-over to surgery
89508907|NCT03144375|Active Comparator|Surgical treatment|Surgical treatment up front
89508908|NCT03508531|Active Comparator|ESP Block|Ultrasound-guided bilateral Erector spinae plane block performed at end of the surgery with 40 ml of a bupivacaine/lidocaine mixture. Perioperative and postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed.
89508909|NCT03508531|Active Comparator|OSTAP Block|Ultrasound-guided bilateral OSTAP block performed at end of the surgery with 40 ml of a bupivacaine/lidocaine mixture. Perioperative and postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed.
89508910|NCT03508531|Sham Comparator|Control|Perioperative and postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed. No block will be performed in this group.
89508911|NCT02039895|Experimental|HITS for CTCL|Cutaneous T-cell lymphoma treats by helical irradiation of the total skin (HITS) using helical tomotherapy
89508912|NCT02317081|Experimental|Axetis Inert Coronary Stents|Axetis Inert Coronary Stents for de novo coronary lesion
89508913|NCT02331381|Experimental|MRI|Participants will have a custom immobilization device created for them for the purpose of the study. They will be scanned from one to four occasions during radiation treatment. If enrolled in the study prior to the first radiation treatment, the first imaging scan may be scheduled prior to the first radiation treatment, with subsequent scans during treatment separated by at least one day. Patients will be in the scanner for approximately 30 minutes to one hour, either prior to or following their standard of care radiotherapy treatment.
89508914|NCT03503461||Control group|Control group is a population of subjects admitted to day hospitalization for renal function tests or in conventional hospitalization, but without kidney transplant. Exosome analysis will be perform in urine sample.
89508915|NCT03503461||Kidney transplants group|Kidney transplants group is a kidney transplant subjects population 3 months ago. Exosome analysis will be perform in urine sample collected at 3 months.
89508916|NCT02312635|Experimental|Cogmed + D-cycloserine|Partifcipants will receive 6 weeks of cogmed working memory training M-F for 45 min each day. Participants in this arm will also take drug Monday, Wednesday, Friday throughout 6 weeks.
89508917|NCT02312635|Placebo Comparator|Cogmed + Placebo|Participants will receive 6 weeks of cogmed training M-F and also take a placebo pill Monday, Wednesday, Friday throughout 6 week period.
89508918|NCT03991533||affected|patients with a histologically confirmed head and neck tumour
88958574|NCT01994772|Placebo Comparator|Targeted controlled temperature between 36.5 and 37.5°C|Patients will be placed in targeted temperature control between 36.5 and 37.5 ° C for 48 hours.
88958575|NCT01994915|Experimental|Occupational therapy group|35 patients diagnosed with chronic obstructive pulmonary disease attending to the Hospital because of an exacerbation are going to be included in this group.
88958576|NCT01994915|No Intervention|Control group|35 patients diagnosed with chronic obstructive pulmonary disease are going to be included in this group. They are not going to receive other than standard care (medical and physical therapy intervention).
89508919|NCT03991533||control|histologically confirmed Whartin tumour or pleomorphic adenoma of the parotid gland, without malignant transformation
89508920|NCT03503383||Controlled group|pregnant women without any medical disorders during pregnancy
89508921|NCT03503383||Diseased group|Patients complaining of hypertension with pregnancy
89508922|NCT03144453|Experimental|Sugammadex|The patients received sugammadex as neuromuscular blockade reversal
89508923|NCT03144453|Active Comparator|Standard|The patients received neostigmine + atropine as neuromuscular blockade reversal
89508924|NCT02317159|Experimental|imatinib，Capsule|400mg imatinib qd
89508925|NCT02333175|Active Comparator|Specialist review|Specialist review with individually tailored treatment strategies suggested by specialist
89508926|NCT02333175|No Intervention|Care as usual|Care as usual
89508927|NCT04463173|Experimental|High fat food oral administration|Anaprazole 40mg, single dose, oral administration 30 minutes after breakfast with high fat food.
89508928|NCT04463173|Experimental|Fasting oral administration|Anaprazole 40mg, single dose, oral administration before breakfast.
89508929|NCT02332941|Experimental|Single Arm|This is a pilot study. It will be an interventional, prospective, observational, clinical study that seeks to evaluate the effect of intravitreal rituximab over a period of one month.
89508930|NCT02312791||Palliative Patients|Inpatients evaluated for palliative radiation therapy.
89508931|NCT02333019|Experimental|Let's Talk About Sex|Participants assigned to the treatment condition viewed a multimedia web site designed to help parents of pre-adolescent children, aged 10 to 14 years old, build skills to communicate effectively about parental values and issues relating to sexuality, sex and relationships, and preventing pregnancy and sexually transmitted infections.
89508932|NCT02333019|Active Comparator|Websites; preventing teen pregnancy|Participants assigned to the control condition were emailed urls for websites with information similar to the Let's Talk about Sex program. Parents were directed to the parents section of the National Campaign to Prevent Teen and Unplanned Pregnancy and children were directed to Nemours' KidsHealth website.
89508933|NCT03503227|Active Comparator|Aspirin|Patients will receive daily oral low dose Acetylsalicylic acid (75 mg) starting day 20 of the previous cycle withGonadotrophin releasing hormone agonist (GnRH agonist)
89508934|NCT03503227|Active Comparator|Aspirin and prednisolone|Patients will receive daily oral low dose Acetylsalicylic acid (75 mg) and Low dose prednisolone (10 mg/day) starting day 20 of the previous cycle withGonadotrophin releasing hormone agonist (GnRH agonist).
89508935|NCT02305069|Placebo Comparator|Placebo|"Placebo tablet taken once daily for 12 weeks.~For study visits performed pre- and post 12-week placebo treatment for the assessment of muscle protein synthesis and leg protein breakdown, the following substances are administered as part of the analytical technique: insulin, octreotide, glucose, mixed amino acids, [2H5]phenylalanine and [1-13C]leucine. The doses administered change as the analytical technique is conducted and for clarity are described in detail in the protocol."
89508936|NCT02305069|Experimental|Pioglitazone|"30mg pioglitazone encapsulated and taken once daily for 12 weeks.~For study visits performed pre- and post 12-week pioglitazone treatment for the assessment of muscle protein synthesis and leg protein breakdown, the following substances are administered as part of the analytical technique: insulin, octreotide, glucose, mixed amino acids, [2H5]phenylalanine and [1-13C]leucine. The doses administered change as the analytical technique is conducted and for clarity are described in detail in the protocol."
89508937|NCT02331225||Systemic sclerosis, no pulmonary hypertension|This group will be systemic sclerosis patients without pulmonary hypertension
89508938|NCT02331225||Systemic sclerosis/pulmonary hypertension|This group will be systemic sclerosis patients with pulmonary hypertension
89508939|NCT02331225||Healthy controls|These will be healthy age- and sex-matched controls
89508940|NCT02330913|Experimental|Intracorporeal esophagojejunostomy|Patient group with intracorporeal esophagojejunostomy with linear stapler
89508941|NCT02331069|Active Comparator|Dextrose 5% (D5W) Injection|Glucose injection in 5% concentration, administered weekly X 4 times in a volume of 12 ml or less.
89508942|NCT02331069|Active Comparator|Physical Therapy|Physical therapy for a month in the posterior deltoid region 3 times a week.
89508943|NCT03144531|Experimental|SKIP Intervention|
89508944|NCT02312947|Active Comparator|coblation|coblation adenoidectomy
89508945|NCT02312947|Active Comparator|cold dissection|cold dissection adenoidectomy
89508946|NCT02313025|Experimental|Speech sound intervention|This group receives a speech sound and phonemic awareness intervention for four months.
89508947|NCT02313025|Active Comparator|World-project|This group receives the WORLD intervention for four months.
89508948|NCT02332785||Composite Data Collection of Endoscopy of Serrated Polyps|Goal is to collect data from endoscopy reports & electronic medical record system to complete a descriptive analysis of the demographics, colonoscopy resection procedure, and outcome of resection - immediate and delayed complications, tumor recurrence, and cancer during follow-up 010/01/2014 - 12/31/2025.
89508949|NCT03501511|Active Comparator|IDF modules|Diabetes educations using IDF Arabic translated modules
89508950|NCT03501511|Experimental|Conversational Maps|Diabetes Educations using Ramadan fasting conversational maps (Arabic maps)
89508951|NCT02317237|No Intervention|General Anesthesia|The patients, who will receive general anesthesia during intervention
89508952|NCT02317237|Experimental|Local Anesthesia|The patients, who will receive local anesthesia/conscious sedation during intervention
89508953|NCT02332473|Active Comparator|Arm A|Ypeginterferon alfa-2b,sc. Qw. 48 weeks.
89508954|NCT02332473|Experimental|Arm B|Ypeginterferon alfa-2b,sc. Qw. 48 weeks. Granulocyte-macrophage colony stimulating factor,sc.qd, the first three day of every 28 days, starting from interferon treatment week 13.
89508955|NCT03501433|Experimental|Nicotinamide Riboside Chloride (Niagen)|7 days of nicotinamide riboside supplementation (250 mg/d x 2/day).
89508956|NCT03501433|Placebo Comparator|Placebo|7 days of placebo supplementation (2/day)
89508957|NCT02317315||Preterm labor group|Patients who are admitted for evaluation of preterm labor.
89508958|NCT02317393|Other|K5-RGD PET + FDG|Both PET examinations will be performed within 4-6 weeks after the end of chemotherapy, with a maximal delay from end of chemotherapy of 2 months. Delay between FDG and 18F-K5-RGD PET scans will not exceed 2 weeks.
89508959|NCT02313103|Other|Lofexidine HCl|End Stage Renal Disease (ESRD) subjects will be dosed with 400 micrograms of lofexidine HCl with 240 mL water after their hemodialysis session.
89508960|NCT02313103|Other|Matched Control|normal renal function subjects (enrolled to match each End Stage Renal Disease subject) will be dosed with 400 micrograms of lofexidine HCl with 240 mL water at the same clock time as ESRD subjects.
89508961|NCT01959633|Experimental|Vemurafenib+Cobimetinib + Peg-interferon|Vemurafenib 960 mg b.i.d. + Cobimetinib 60 mg o.d.(21 days on followed by 7 days off) + Peg-interferon 1/2/3 micrograms/Kg once weekly
89508962|NCT02305147||Patients with an idiopathic Parkinson Disease,|Patients with recent onset of Parkinson Disease: N=200
89508963|NCT02305147||Subjects at risk of PD|"Subjects at risk to develop Parkinson Disease:~subjects with idiopathic Rem-sleep behavior disorder (iRBD): N=50~subjects related to a patient with genetically confirmed Parkinson Disease: N=30"
89508964|NCT02305147||Controls|Healthy controls: N=50
89508965|NCT02305147||Patients with Parkinson Disease with genetic mutation|Patients with Parkinson Disease with a genetic mutation in parkin, LRRK2, SNCA or GBA (N=30)
89508966|NCT02326545|Experimental|MindLight|MindLight is the video game being tested for effectiveness to reduce child anxiety
89508967|NCT02326545|Active Comparator|Online CBT|Online CBT program for children
89508968|NCT02313181|Experimental|Early Limited Formula|10 milliliters (mL) Nutramigen fed to baby by syringe after each breastfeeding and discontinued at the start of mature milk production
89508969|NCT02313181|Other|Standard Care|Continue exclusive breastfeeding unless otherwise instructed by a health care provider
89024053|NCT03809793|Placebo Comparator|No drug|Individuals in this group will undergo pre-assessments for body composition (DXA), Insulin sensitivity (Hyperinsulinaemic Euglycaemic clamp and continuous glucose monitor) with muscle biopsies pre- and post- clamp for analysis of lipid metabolites, liver fat (MRI) and exercise capacity (VO2 max). Participants will then ingest nothing prior to their exercise sessions during the 12-week exercise programme.
89024054|NCT03804892|Experimental|Acipimox ingestion|Participants will undergo pre assessment testing of a body composition (DEXA), a maximal aerobic fitness test, and an oral glucose tolerance test. Following this, participants will ingest 250 mg of Acipimox, before undertaking 45 minutes walking on a treadmill. A muscle biopsy will be taken pre, immediately post and 3 hours post the walking trial. Blood samples will be taken at regular intervals throughout.
89024055|NCT03804892|Other|No drug|Participants will undergo pre assessment testing of a body composition (DEXA), a maximal aerobic fitness test, and an oral glucose tolerance test.Participants will then undergo a 45 minute walk on a treadmill with no Acipimox ingestion. A muscle biopsy will be taken pre, immediately post and 3 hours post the walking trial. Blood samples will be taken at regular intervals throughout.
89024056|NCT03798093|Active Comparator|Umbilical Cord Milking|The delivering practitioner will place the newborn below the level of the incision (at the edge of the table) at C/S and a second team member will milk the cord four times. For vaginal delivery, the delivering obstetrician, midwife or perinatal provider will hold the infant against their body or place the infant on the mother's abdomen and the cord will be milked either four times by the obstetrical provider or by a second team member. For the cord milking procedure, the obstetrical provider will milk the entire length of umbilical cord over two seconds, repeating three additional times as described previously. This time is not significantly different from the time for ECC as we have demonstrated in our previous trials.
89024057|NCT03798093|Active Comparator|Early Cord Clamping|This will occur by clamping the umbilical cord as soon as possible. Since both ECC and UCM will occur after a brief assessment, it is important to note that the cord clamping time will be longer than in previously conducted preterm trials (average 20 seconds) which performed the intervention on all subjects regardless of whether or not they were vigorous. In all cases, the cord clamping time will be documented to ensure consistency.
89024058|NCT03794921|No Intervention|Usual Care|Patients referred to conventional PR or eligible for PR but declined or cannot access. Using a standardized script at the randomization phone call, study staff will deliver verbal instructions to slowly and steadily increase one's walking and exercise each week. Participants will be asked to perform exercise of moderate intensity for at least 30 minutes on most days of the week, defined as a dyspnea level of 4-5 on the Borg scale and taking 1-2 minutes to recover. Use of the Borg rating scale for dyspnea will be reviewed with each participant. Exercise is defined as planned PA, outside of activities performed as part of one's daily routine. Exercise can be walking in the community or using exercise equipment at a local gym. Adapted written materials reinforce the verbal instructions. Participants will receive this 45-page spiral-bound book with information about aerobic and strength training exercises.
89024059|NCT03794921|Experimental|Every Step Counts Intervention|Patients referred to conventional PR or eligible for PR but declined or cannot access. After randomization to ESC, participants will be mailed detailed instructions about the website. They will be asked to wear the lightweight, unobtrusive pedometer every day, except while asleep or showering/bathing, during the 12-week intervention period. Subjects will be instructed to upload their date and time-stamped step-count data to the study website at least weekly. Each week, the study computer will run the goal calculation algorithm and provide each participant with his/her daily step-count goal for the week. The week's step-count goal will be displayed on each subject's personal study web page. Participants will be instructed to exercise and reach their individualized step-count goals with walking of moderate intensity for at least 30 minutes on most days of the week, defined as a dyspnea level of 4-5 on the Borg scale and taking 1-2 minutes to recover.
89024061|NCT03750227|Active Comparator|Arm A (Post-operative SRS)|Patients undergo surgery on day 1. Within 2 weeks, patients undergo stereotactic radiosurgery.
89024062|NCT03750227|Experimental|Arm B (Pre-operative SRS)|Patients undergo stereotactic radiosurgery on day 1. Within 4 weeks, patients undergo surgery.
89024063|NCT03749057|Other|rivaroxaban|15-20 mg rivaroxaban daily
89024064|NCT03744104|Experimental|Quadrivalent influenza vaccine|Quadrivalent influenza vaccine(containing 2 subtypes of B lineage)
89024065|NCT03744104|Active Comparator|Trivalent influenza vaccine A|Trivalent influenza vaccine (containing B/Victoria lineage)
89024066|NCT03744104|Active Comparator|Trivalent influenza vaccine B|Trivalent influenza vaccine (containing B/Yamagata lineage)
89024067|NCT03736304|Placebo Comparator|Usual care|Patients will receive standard clinical care by the doctor in charge.
89024068|NCT03736304|Experimental|AKI alert|An AKI alert will send to the the doctor in charge. The team of nephrologists would give suggestions if the doctor in charge need a renal consultation.
89024069|NCT03729999|Experimental|Ultrasonography|Patients requiring single lung ventilation for a surgical procedure will have a bedside ultrasound to evaluate lung isolation.
89024070|NCT03685175|Experimental|Formal Study|Hyperpolarized 13C-pyruvate, is injected into patients before receiving cardiotoxic therapy and immediately after, for a cardiac MRI scan
89024071|NCT03685175|Experimental|Feasibility Study|Hyperpolarized 13C-pyruvate injection, is given to patients after completing cardiotoxic therapy, and again at 1 to 6 six months after the first cardiac MRI scan
89032944|NCT02945111|Active Comparator|No visual support|Women in this arm will undergo Visual Inspection with Acetic Acid (VIA) and Lugol's Iodine (VILI) without any visual support. Their anxiety level both before and after the examination will be measured using the Spielberg's State Anxiety Inventory.
89206958|NCT04407897|Experimental|Radiotherapy|Patients with oligometastatic lesions, fulfilling the inclusion/exclusion criteria's will be assigned to SABR.
89508970|NCT02326389|Experimental|Exercise and Cognitive Remediation|The exercise intervention is a 10-week program involving 40 minutes of aerobic exercise targeting 60-75% of maximum heart rate on 3 days each week, with an additional 5-minute stretching warm up and cool down. The experimental group will participate in the exercise intervention as well as cognitive remediation.
89508971|NCT02326389|Active Comparator|Cognitive Remediation Only|Participants will be engaged in 30 hours of computer-based cognitive exercises with a standardized, widely used software package (Cogpack, Version 7.0, Marker Software), shown to improve cognitive functioning in multiple studies. One-hour sessions will be conducted 3 times per week for 10 weeks.
89508972|NCT02313259||AMD controls|15 patients with early to intermediate AMD (grade 2-8) were enrolled using the Age-Related Eye Disease Study (AREDS) severity scale for AMD.
89508973|NCT02313259||Age-matched controls|15 drivers without ocular disease.
89508974|NCT02313259||Young controls|15 drivers without ocular disease. Between 18 and 25 years old.
89508975|NCT02313259||Glaucoma patients|15 patients having a Humphrey visual field mean deviation between -10 and -12 (better eye).
89508976|NCT02326623|Experimental|iPad distraction|The intervention will be the use of an iPad that will include a selection of child-appropriate games. We will select popular, age-appropriate items to include on the iPad, chosen based on the most current online consumer ratings. Children and parents will be able to select their choice of distraction and can change their selection as desired during the course of the procedure. These choices will be recorded for study purposes.
89508977|NCT02326623|Other|standard care|The control group will receive standard care, which generally includes the use of topical anesthetic cream.
89508978|NCT02317471|Experimental|gp96 group|autologous gp96 vaccination + basal treatment for gastric cancer
89508979|NCT02317471|Other|control group|Oxaliplatin+S-1
89508980|NCT02332551|Experimental|NanoKnife IRE System|90 pulses of 70 microseconds each in duration will be administered per electrode pair
89508981|NCT02332551|No Intervention|Control|
89508982|NCT03501355|Active Comparator|Strength training group|Intervention:Inspiratory muscle strength training group received inspiratory muscle training (IMT) using POWERbreathe Classic threshold loading device
89508983|NCT03501355|Active Comparator|Endurance training group|Intervention: Inspiratory muscle endurance training group received inspiratory muscle endurance training (IMT) using POWERbreathe Classic threshold loading device
89508984|NCT02326077||Intervention group|"Clinical evaluation in active labor: Leopold manoeuvres, vaginal digital examination.~Transabdominal and transperineal ultrasound evaluations of the mechanism of labor: fetal head position, progression and rotation.~Investigation by questionnaire regarding the psychological impact of labor monitoring assisted by sonoraphy."
89508985|NCT02305225|Experimental|SDSR|first total then partial Sleep deprivation
89508986|NCT02305225|Experimental|SRSD|first partial then total Sleep deprivation
89508987|NCT02332395||Emergency caesarean section|patients whose underwent emergency caesarean section operation
89508988|NCT02332395||Elective caesarean section|patients whose underwent elective caesarean section operation
89508989|NCT03501199|Experimental|PRF Group|PRF is will be used in immediate dental implant placement.
89508990|NCT03501199|Experimental|Graft Group|The xenogenic graft is will be used in immediate dental implant placement.
89508991|NCT03501199|Experimental|Control Group|No extra material is will be used in immediate dental implant placement.
89508992|NCT02332629|Active Comparator|Methylprednisolone|Preoperative single high dose of Solu-Medrol 125 mg iv.
89508993|NCT02332629|Placebo Comparator|Isotonic Sodium Chloride|Preoperative single dose of isotonic Sodium Chloride
89508994|NCT02313337|Experimental|Oral administration|-Oral administration of a mixture at preoperative 30 minutes : ketamine 3 mg/kg, midazolam 0.5 mg/kg and atropine 0.02 mg/kg, plus 50% glucose solution to 0.5ml /kg.
89508995|NCT02313337|Experimental|Intramuscular injection|-At preoperative 30 minutes intramuscular injection of atropine 0.02 mg/kg, 5 minutes before entering the operation room, intramuscular injection of ketamine 5 mg/kg.
89508996|NCT02313337|Experimental|Rectal perfusion|-At preoperative 30 minutes rectal infusion of midazolam 0.5mg/kg
89508997|NCT02313337|Experimental|Dripping nose|-At preoperative 30 minutes dripping nose of Imidazole valium 0.2 mg/kg
89508998|NCT02305303|Experimental|Diary|Use of diary
89508999|NCT02305303|No Intervention|Without Diary|
89509000|NCT02330835|Experimental|In the Driver's Seat|Treatment materials. In the Driver's Seat: A Roadmap to Managing Student Behavior on the Bus is a comprehensive multimedia program that guides transportation departments in creating and maintaining a safe, responsible, and positive environment on the school bus through effective student behavior management. The program includes three components: 1) In the Driver's Seat: Transportation Supervisor Program for transportation department administrative staff, 2)In the Driver's Seat: Group Lessons DVD for Drivers. The DVD-based curriculum is designed to be facilitated by a transportation supervisor or driver trainer in groups and 3)In the Driver's Seat: Bus Driver Program. This CD-ROM-based program for bus drivers.
89509001|NCT02330835|Active Comparator|School bus driver training videos|Control materials. Bus drivers in the control condition viewed two linear videos on study computers. In Session 1 of the intervention, Control drivers viewed School Bus Driving, Part 1, 2nd Edition, © 1991, AIMS Media, 23-minute linear video showing defensive driving techniques. In Session 2, Control drivers viewed Decide Smart, Arrive Safe, © 2005, Operation Lifesaver, Inc., a video about school bus safety at railroad crossings produced in conjunction with the National Association of State Directors of Pupil Transportation services. Supervisors in the control condition received no materials until completing the study (waitlisted).
89509002|NCT04463563|Active Comparator|NIRS group. Brain oxygen saturations group.|A monitor by means of non-invasive stickers will display cerebral oximetry (brain oxygen saturations) throughout the heart surgery.This gives a direct reading of brain frontal lobe oxygen levels. The baseline is recorded before the patient goes to sleep (anaesthetised) and throughout the surgery and time on cardiopulmonary bypass if the brain oxygen levels fall below baseline then various physiological changes are made to restore oxygen to baseline.
89509003|NCT04463563|No Intervention|Standard Patient Monitoring|No cerebral monitoring. Standard patient monitoring according to normal practice at Castle Hill Hospital apply.
89509004|NCT02325999|Experimental|ESD and LRLD|The experimental group accept Endoscopic Submucosal Dissection Combine With Laparoscopic Regional Lymph Node Dissection.
89509005|NCT02325999|No Intervention|Endoscopic Submucosal Dissection (ESD)|The group accept Endoscopic Submucosal Dissection only.
89509006|NCT04463017|Active Comparator|Active Treatment: HU6|Planned doses of HU6; N = 74
89509007|NCT04463017|Placebo Comparator|Placebo Comparator|Non-active study drug N = 14
89509008|NCT05078073|Experimental|aGVHD-HBOT|Patients after allo-HSCT will receive hyperbaric oxygen therapy (HBOT) on the next day of the aGVHD diagnosis was determined.
88958577|NCT01994928|Active Comparator|Nose-mouth mask|Performance of intubation after preoxygenation using a nose-mouth mask.
88958578|NCT01994928|Experimental|High flow nasal cannula oxygen|Performance of intubation after preoxygenation using high flow nasal cannula oxygen.
89509009|NCT05078073|No Intervention|aGVHD-HBOT free|Patients after allo-HSCT will NOT receive hyperbaric oxygen therapy (HBOT) on the next day of the aGVHD diagnosis was determined.
89509010|NCT02305459||Patients treated with Radioembolisation|"All Patients treated with Radioembolisation with yttrium-90 loaded SIR-Spheres microspheres are asked to be enrolled. In no way will participation in the registry influence the way in which the patient is treated or will it influence the quality of the treatment.~In order to measure the palliative aspect of RE with SIR-Spheres microspheres, CIRT will incorporate a quality-of-life questionnaire. CIRT will be using EORTC's QLQ-C30 with the Hepatocellular carcinoma (HCC) Module to measure changes in the quality of life of the patient."
89509011|NCT03500965|Experimental|Text-only PWL, absol risk|Exposure to FDA-mandated warning labels, without a graphic image, accompanied by risk information about smoker's risk of a smoking-related disease
89509012|NCT03500965|Experimental|text-only PWL, relative risk|Exposure to FDA-mandated warning labels, without a graphic image, accompanied by risk information about smoker's risk and non-smoker's risk of a smoking-related disease
89509013|NCT03500965|Experimental|graphic PWL, absol risk|Exposure to FDA-mandated warning labels, paired with a graphic image, accompanied by risk information about smoker's risk of a smoking-related disease
89509014|NCT03500965|Experimental|graphic PWL, relative risk|Exposure to FDA-mandated warning labels, paired with a graphic image, accompanied by risk information about smoker's risk and non-smoker's risk of a smoking-related disease
89509015|NCT03502837||Healthy controls|age-matched right-handed healthy volunteers
89509016|NCT03502837||the mininally conscious state|Patients present reproducible signs of awareness such as purposeful eye movements or response to verbal order
89509017|NCT03502837||the vegetative state|Patients preserved autonomous functioning (e.g., preserved sleep-wake cycles),but without awareness of oneself or of the environment
89509018|NCT03500887|Other|1. Bag inflated so that intrabagpressure increases with 2 mmHg|
89509019|NCT03500887|Other|2. Bag inflated to ¾ volume of 1|
89509020|NCT03500809|Experimental|Aqueous release (Burping) of the wound|"Following uneventful cataract surgery, wound burping will be performed in all eligible patients who gave their informed consent. The procedure will be offered whenever the intraocular pressure (IOP) is either higher than 30 mmHg or deemed inappropriate in view of the ocular condition (e.g. glaucoma).~After 'burping' the wound, patients will have their IOP measured using Goldmann application tonometry (GAT) immediately and at 2 hours. The 'burping' procedure will be repeated until satisfactory pressure is achieved and care will be taken to avoid shallowing of the anterior chamber while fluid is released. We will assess for the presence of leaks from the wound with a Seidel test with fluorescein 5% once the IOP is satisfactory. To prevent any infection after each procedure, we will prescribe post-op drops including chloramphenicol 0.5% four times a day for 2 weeks or minimum of 3 days and these will continue as per routine. All other complications will be recorded at follow-up."
89509021|NCT02305615||Participants with CRC|This is an observational study; thus, no intervention or treatment is required by the protocol. During the study, the treatment will be determined according to the treating physician decision. Eligible participants will be observed for safety and efficacy of continued bevacizumab plus fluoropyrimidine-based doublet chemotherapy treatment in routine clinical practice for 1 year.
89509022|NCT02313415|Experimental|UC-MSCs therapy|transplant collagen scaffold loaded with UC-MSCs to treat infertility caused by recurrent intrauterine adhesions
89509023|NCT02313493|Experimental|Baby Triple P parent training group|The 8- session program delivered in four group sessions before birth and four telephone sessions after birth is developed for parents at the transition to parenthood or with a baby (up to 12 months of age).
89509024|NCT02313493|No Intervention|Care as usual control group|
89509025|NCT02305693|Active Comparator|Letrozole|70 women will receive Letrozole (Femara®, Novartis, Switzerland) 2.5mg twice daily for 5 days starting from the 3rd day of menstruation or progesterone withdrawal bleeding
88958579|NCT01994941|Experimental|Genotype guided group|"Patients are given standard doses of clopidogrel (either 300mg or 600mg according to clinical protocol). Blood will be drawn for rapid genetic testing (Verigene) and results will be expected in 2-4 hours. If patients are intermediate or poor clopidogrel metabolisers, loading dose of ticagrelor 180mg are given to enhance the antiplatelet response.~Apart from the approach in guiding the use of P2Y12 receptor blocker, all patients will be treated according to usual clinical care including medications and coronary intervention. Blood will also be sent to standard laboratory for CYP2C19 genotyping using conventional polymerase chain reaction (PCR) method so as to confirm the accuracy of rapid genetic test. 24 hours after initial clopidogrel loading, blood will be taken to measure platelet reactivity by verifyNow P2Y12 assay (Accumetrics). In case glycoprotein IIbIIIa inhibitor (Integrilin) is used, verifyNow P2Y12 assay will be performed 48 hours after cessation of Integrilin."
88958580|NCT01994941|Active Comparator|Clinical guided group|"Patients are given standard doses of clopidogrel (either 300mg or 600mg according to clinical protocol).~Apart from the approach in guiding the use of P2Y12 receptor blocker, all patients will be treated according to usual clinical care including medications and coronary intervention. Blood will also be sent to standard laboratory for CYP2C19 genotyping using conventional polymerase chain reaction (PCR) method so as to confirm the accuracy of rapid genetic test. 24 hours after initial clopidogrel loading, blood will be taken to measure platelet reactivity by verifyNow P2Y12 assay (Accumetrics) which is an FDA approved, point-of-care device using light-transmission based optical detection which measures platelet aggregation. In case glycoprotein IIbIIIa inhibitor (Integrilin) is used, verifyNow P2Y12 assay will be performed 48 hours after cessation of Integrilin."
88958581|NCT01994967|Experimental|Levobupivacaine|"Presentation: injectable solution - ampoule of Levobupivacaine Hydrochloride~Indication: production of subarachnoid block (spinal/ spinal anesthesia)."
88958582|NCT01994967|Active Comparator|Bupivacaine|"Presentation: injectable solution - ampoule of Bupivacaine Hydrochloride~Indication: production of subarachnoid block (spinal/ spinal anesthesia)."
89509026|NCT02305693|Active Comparator|Ovarian drilling|70 women will have LOD in which the ovaries will be stabilised by grasping the ovarian ligament and monopolar diathermy will be used to do 4-10 punctures in each ovary. The number of punctures will be individualised according to the size of the ovary.
89509027|NCT02317861|Experimental|Cohort 1|The half of patients randomized to this cohort will be dosed in the order of Febuxostat 10mg, RDEA3170 2.5 mg + Febuxostat 10mg, RDEA3170 2.5 mg + Febuxostat 20mg, and Febuxostat 20mg. The other half will be dosed in the reverse order.
89509028|NCT02317861|Experimental|Cohort 2|The half of patients randomized to this cohort will be dosed in the order of Febuxostat 10mg, RDEA3170 5 mg + Febuxostat 10mg, RDEA3170 5 mg + Febuxostat 20mg, and Febuxostat 20mg. The other half will be dosed in the reverse order.
89509029|NCT02317861|Experimental|Cohort 3|The half of patients randomized to this cohort will be dosed in the order of Febuxostat 20mg, RDEA3170 5 mg + Febuxostat 20mg, RDEA3170 5 mg + Febuxostat 40mg, and Febuxostat 40mg. The other half will be dosed in the reverse order.
89509030|NCT02317861|Experimental|Cohort 4|The half of patients randomized to this cohort will be dosed in the order of Febuxostat 20mg, RDEA3170 10 mg + Febuxostat 20mg, RDEA3170 10 mg + Febuxostat 40mg, and Febuxostat 40mg. The other half will be dosed in the reverse order.
89509031|NCT02317861|Experimental|Cohort 5|RDEA3170 2.5mg, RDEA3170 5mg, RDEA3170 10mg, RDEA3170 15mg
89509032|NCT02317861|Experimental|Cohort 6|The half of patients randomized to this cohort will be dosed in the order of Benzbromarone 50 mg, Febuxostat 10mg+RDEA3170 2.5 mg, then Febuxostat 20mg+RDEA3170 5 mg. The other half will be dosed in the order of Febuxostat 10mg+RDEA3170 2.5 mg, Febuxostat 20mg+RDEA3170 5 mg, then Benzbromarone 50mg.
89509033|NCT02317939|Experimental|online instruction at followup visits|patients in this group will be subjected to view video instructions online prior to performing the follow-up joint scoring at home
89509034|NCT02317939|Active Comparator|standard baseline instruction|after the initial training patients in this group will not be subjected to any subsequent instructions prior to performing the follow-up joint scoring at home
89509035|NCT02318017|Active Comparator|Methylphenidate|Methylphenidate 0.5mg/kg - once
89509036|NCT02318017|Placebo Comparator|Placebo|Placebo - once
89509037|NCT02313727|Active Comparator|pamidronate|pamidronate
89509038|NCT02313727|Placebo Comparator|placebo|placebo
89509039|NCT02313805|Experimental|With checklist|Students will simulate insulin initiation with the aid of a checklist
89509040|NCT02313805|No Intervention|Without checklist|Students will simulate insulin initiation without the aid of a checklist
89509041|NCT03508453|Active Comparator|IC14 (monoclonal anti-CD14 antibody)|IC14 4 mg/kg intravenously twice weekly for 12 weeks
89509042|NCT03508453|Placebo Comparator|Placebo|Placebo intravenously twice weekly for 12 weeks
89509043|NCT02313883|Placebo Comparator|SRP only|Scaling and root planing only
89509044|NCT02313883|Placebo Comparator|SRP and Placebo|Scaling and root planing followed by placebo drug administration
89509045|NCT02313883|Experimental|SRP and 0.3% PerioSept(r)|Scaling and root planing followed by 0.3% PerioSept(r) drug administration
89509046|NCT02313883|Experimental|SRP and 1 % PerioSept(r)|Scaling and root planing followed by 1% PerioSept(r) drug administration
89509047|NCT02313883|Experimental|SRP and 3% PerioSept(r)|Scaling and root planing followed by 3% PerioSept(r) drug administration
88958583|NCT01995006|Experimental|Metamizole|Metamizole 1000mg TID Day 1 till Day 7
89509048|NCT02313961|Experimental|RIC patients|Subjects submitted to remote ischaemic conditioning (RIC)
88958584|NCT01995006|Active Comparator|Naproxen|Naproxen 500 mg BID Day 1 till Day 7
88958585|NCT01995019|Placebo Comparator|Physiologic saline|Sodium chloride 9 mg/ml liquid for parental use
88958586|NCT01995019|Experimental|Methylprednisolone|Depo-Medrol 40 mg/ml, single dose, injection, intra-articular
88958587|NCT01995032|Experimental|750 mg metformin and 7.5 g L-citrulline daily p.o.|7.5 g L-citrulline p.o. and 750 mg metformin daily p.o. (3x 2.5 g, respectively 3x 250 mg) for 26 weeks
89509049|NCT02313961|No Intervention|No RIC patients|Subjects not submitted to remote ischaemic conditioning (RIC)
89509050|NCT03500653|Active Comparator|Active|4 gr Curcumin daily for 1 year in addition to vedolizumab 300 mg per infusion (standard of care)
89509051|NCT03500653|Placebo Comparator|Sham|4 gr placebo daily for 1 year in addition to vedolizumab300 mg per infusion (standard of care)
89509052|NCT02318251|Experimental|Involuntary muscle contractions|Standard physiotherapy program (focus on involuntary reflexive pelvic floor muscle contractions)
89509053|NCT02318251|Active Comparator|Voluntary muscle contractions|Physiotherapy program (focus on voluntary pelvic floor muscle contractions)
89509054|NCT02305927|Experimental|Vitamin D3 (cholecalciferol)|
89509055|NCT02305927|Placebo Comparator|Placebo|
89509056|NCT02318407|Experimental|AMG 403|AMG 403 administered as subcutaneous doses
89509057|NCT02318407|Placebo Comparator|Placebo|No active drug
89509058|NCT03500575|Experimental|photopheresis|
89509059|NCT03500575|No Intervention|control|
89509060|NCT02440009|Active Comparator|Glucocorticoid group|Oral prednisolone 0.5 mg/kg/day for 4 weeks; 0.25 mg/kg/day for 4 weeks; 0.125 mg/kg/day for 4 weeks. Then taper by 5 mg every 4 weeks and discontinue by the end of 4 months. Patients will also receive inhaled formoterol/fluticasone (6/125 mcg) 1 puff BD and as needed as per the SMART approach for control of asthma
89509061|NCT02440009|Experimental|Itraconazole plus glucocorticoid group|Oral itraconazole 200 mg BD for 6 months AND oral prednisolone 0.5 mg/kg/day for 4 weeks; 0.25 mg/kg/day for 4 weeks; 0.125 mg/kg/day for 4 weeks. Then taper by 5 mg every 4 weeks and discontinue by the end of 4 months. Patients will also receive inhaled formoterol/fluticasone (6/125 mcg) 1 puff BD and as needed as per the SMART approach for control of asthma.
89509062|NCT02318485|Experimental|Transplant|A limbal epithelial stem cell graft will be transplanted onto the limbal stem cell deficient eye after it has been debrided of fibrovascular pannus
89509063|NCT02318563|Experimental|Cannabidiol Oral Solution|Participants will receive cannabidiol oral solution at an appropriate dose (no higher than 40 mg/kg/day) determined by data from a previous trial. The total daily dose will be administered in twice daily doses, approximately 12 hours apart.
89509064|NCT02318563|Placebo Comparator|Placebo Solution|Participants will receive matching placebo solution administered twice daily, approximately 12 hours apart.
89509065|NCT02314195|Active Comparator|Standard treatment + music therapy|Selective serotonin re-uptake inhibitor plus cognitive behavioral therapy. Music therapy encompassing 12 half-hour sessions of therapist-supervised receptive music therapy scheduled over four weeks
89509066|NCT02314195|Active Comparator|Standard treatment only|Selective serotonin re-uptake inhibitor plus cognitive behavioral therapy.
89509067|NCT02314273|Experimental|rhIL-11 group|patients receive rhIL-11(50 mcg/kg，subcutaneously)after standard chemotherapy，once a day for 10 days or until platelet count ≥80,000/mL
89509068|NCT02314273|No Intervention|control group|control group
89509069|NCT03502525|Experimental|Break the Cycle Intervention|All study participants are assigned to this experimental arm.
89509070|NCT02314351|Active Comparator|Intravenous metoclopramide|Intravenous metoclopramide, 10 mg (2 mL) in 98 mL 0.9% normal saline solution (total 100 mL)
89509071|NCT02314351|Placebo Comparator|Placebo|0.9% normal saline solution (total 100 mL)
89509072|NCT02306005||Type 1 diabetic patients|Newly diagnosed diabetes type 1 admitted to the Department of Internal Medicine and Diabetology. Measurement of lipid profile and lipoproteins before and after administration of insulin. Further continuous observation with follow-up every year and evaluation of final end-points after 5 and 10 years.
89509073|NCT02314429|Experimental|Vaginal Ring|A vaginal ring that slowly releases lactic acid (racemic mixture) into the vaginal environment, will be inserted in healthy volunteering women and left in place for 7 days.
89024072|NCT03674112|Experimental|A: P+H IV Followed by PH FDC SC|In the Treatment Cross-Over Period of the study, participants randomized to Arm A first received pertuzumab IV and trastuzumab IV (P+H IV) administration for 3 treatment cycles followed by the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized.
89024073|NCT03674112|Experimental|B: PH FDC SC Followed by P+H IV|In the Treatment Cross-Over Period of the study, participants randomized to Arm B first received the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles followed by pertuzumab intravenous (IV) and trastuzumab IV (P+H IV) administration for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized.
89509074|NCT02314507|Experimental|Gua sha|Paritcipants in this group will receive a single treatment of Gua sha conducted by a well-trained nurse or Chinese practitioner
89509075|NCT02314507|Active Comparator|Hot Pack Therapy|Participants in this group will receive a single treatment of Hot Pack conducted by a well-trained nurse or Physiotherapist
89509076|NCT04464031|Experimental|Alert group|
89509077|NCT04464031|No Intervention|Control group|
89509078|NCT03500185|Experimental|PFMT in group|Participants randomized to this group will perform the PFMT protocol in a group, with physiotherapeutic supervision, lasting 1 hour, in the Outpatient Clinic of Gynecology of Hospital of Clinics of Porto Alegre (HCPA), for a period of 3 months. You will also be instructed to perform exercises at home. After this period, they will be reassessed and will follow the same protocol for another 3 months now at home. After this period, they will be evaluated again.
89509079|NCT03500185|Active Comparator|PFMT at home|Randomized participants for this group will receive guidance on the home PFMT protocol on the day of the initial evaluation. They will be instructed to perform the exercises daily for a period of 3 months. After 3 months they will be re-evaluated and will follow the same protocol for another 3 months at home. After this period they will be evaluated again.
89509080|NCT02314585|Other|Education|In the second phase, participants will partake in an instructional class relating to gait, balance, and falls.
89509081|NCT02314585|Other|Exercise|In the second phase,participants will partake in an exercise course relating to gait, balance, and falls.
88958588|NCT01995032|Placebo Comparator|Placebo|metformin placebo and L-citrulline placebo 3 times daily p.o. for 26 weeks
89509082|NCT02314663|Experimental|Intervention group|"COMBINED STRATEGY (a + b + c). Participants in the intervention group will be supplied with: a) printed matter; b) mobile-telephone text messages; and, c) self-report cards.~This group receive routine recommendations from their GPs, in accordance with current European clinical practice guidelines on the management of hypercholesterolaemia and cardiovascular risk"
89509083|NCT02314663|No Intervention|Control group|This group receive routine recommendations from their GPs, in accordance with current European clinical practice guidelines on the management of hypercholesterolaemia and cardiovascular risk
89509084|NCT03500029|Experimental|TMS treatment group|In the Transcranial magnetic stimulation (TMS) treatment group patients with severe depression receive rTMS treatment without drug treatment.
89509085|NCT03500029|Active Comparator|medication group|In the medication group patients with severe depression are treated with anti-depressants.
89509086|NCT03500029|No Intervention|healthy control group|The control group don't accept intervention and treatment.
89509087|NCT03508375|Experimental|SSc without ILD|
89509088|NCT03508375|Experimental|SSc with ILD|
89509089|NCT03508375|Active Comparator|patients with idiopathic pulmonary fibrosis|
89509090|NCT03502447|Experimental|TearCare|TearCare subjects will receive TearCare thermal treatment followed by manual clearing of the meibomian glands.
89509091|NCT03502447|Active Comparator|Warm Compress & Lid Massage|Subjects will perform warm compress and lid massage at home daily.
89509092|NCT02306083|Placebo Comparator|Administration of the Placebo|Placebo three times a day.
89509093|NCT02306083|Placebo Comparator|Administration of the glucosamine sulfate|glucosamine sulfate 1500 mg three times a day
89509094|NCT03502369|Experimental|QL group|Anterior Quadratus lumborum block will be done for all patients of these group. Local anaesthetic (30ml of bupivacaine) will be injected in fascial plane between the quadratus lumborum muscle and Psoas major muscle by using the ultrasound.
89509095|NCT03502369|No Intervention|C group|Patients of these group will be the control group. The will receive acetaminophen 1g every 8h, ketorolac 30mg ever 12h and as required morphine 2mg for post operative analgesia after hip arthroplasty.
89509096|NCT02318875|Experimental|Kritech group|Subjects take 1 Kritech capsule per day (dose of 300mg)
89509097|NCT02318875|Placebo Comparator|Placebo group|Subjects take 1 placebo capsule per day
88958589|NCT01995058|Experimental|Cabozantinib arm 1|Subjects randomized to this arm will receive cabozantinb 40 mg daily with abiratarone and prednisone
88958590|NCT01995058|Experimental|Cabozantinib arm 2|Subjects randomized to this arm will receive cabozantinib 20 mg daily with abiraterone and prednisone
88958591|NCT01995058|Experimental|Cabozantinib arm 3|Subjects randomized to this arm will receive cabozantinb 20 mg every other day with abiraterone and prednisone
88958592|NCT01995058|Active Comparator|Abiraterone only arm (4)|Subjects randomized to this arm will receive abiraterone with prednisone only
88958593|NCT01995084|Experimental|Optimization|Patients undergo a [F-18]HX4 PET/CT scan 2,3 and 4h after [F-18]HX4 injection.
88958594|NCT01995084|Experimental|Reproducibility|Patients undergo two [F-18]HX4 PET/CT scans 3.5h after [F-18]HX4 injection within a 10-day time frame.
88958595|NCT01995097|Experimental|SGR + Support Messages|scheduled gradual reduction text messages for first 3-5 weeks of participation; support text messages through 35th week of pregnancy
88958596|NCT01995097|Active Comparator|Support Messages Only|support text messages through 35th week of pregnancy
88958597|NCT01995110|Experimental|normal weight subjects|
88958598|NCT01995110|Experimental|obese subjects|
88958599|NCT01995149|Experimental|Weight loss and dietary intervention|The weight loss intervention had a total duration of 6 months. Each participant's caloric prescription represented a deficit of 600 kcal per day as calculated from the person's resting energy expenditure and activity level using the Harris-Benedict equation. In general, prescribed energy intake was between 1200 kcal and 1600 kcal/day. Dietary composition consisted on 50-55% of carbohydrates, 15-20% of protein and 30% of fat and included a wide variety of foods typical of a Mediterranean diet. Patients were also provided with recipes and shopping counselling to improve intervention compliance and to achieve the weight loss goal. Individual consultations with a nutritionist were performed twice a month to motivate the weight loss and reinforce the intervention.
88958600|NCT01995162|Experimental|Free-living conditions|
88958601|NCT01995188|Experimental|Dose Escalation Cohort: DNIB0600A+Carboplatin|DNIB0600A at an initial dose of 1.2 milligrams per kilogram (mg/kg) will be administered via intravenous (IV) infusion further following a dose-escalation until DLT under consultation of the investigator in combination with Carboplatin fixed dose of area under the curve (AUC)=6 mg/milliliter(mL)*minute (min) administered by IV infusion on Day 1 of a 21-day cycle.
88958602|NCT01995188|Experimental|NSCLC Dose Expansion Cohort: DNIB0600A+Carboplatin|Recommended phase 2 dose (RP2D) of DNIB0600A administered via IV infusion in combination with Carboplatin, AUC=6 mg/mL*min administered via IV infusion on Day 1 of each 21-day cycle in participants with NSCLC until disease progression or death, whichever occurs first.
89509098|NCT02318953|Experimental|Mobile app follow-up care|"The mobile app follow-up group will have no planned in-person follow-up at one- and four weeks postoperative. However, these visits will be replaced with surgical site examination via submitted photos, visual analog scale (VAS) to assess pain, and the quality of recovery-9 (QoR9) questionnaire monitoring. All of this information is submitted via the mobile application (QoC Health Inc. Toronto). Patient will use daily monitoring for two weeks and then weekly monitoring for four weeks. The surgeon will use a wireless interface to access that data and monitor the patient's condition (not in real time). Physicians will summarize the clinical findings recorded by the mobile app at one week and four weeks postoperative using the prototypical SOAP note."
89509099|NCT02318953|Active Comparator|Conventional, in-person follow-up care|Patients in the conventional, in-person follow-up group will have a planned clinic follow-up at one- and 4-weeks postoperative. This is the follow-up schedule currently used by both surgeons. At these scheduled follow-ups, patients will be asked to complete the VAS to assess pain and the QoR9 questionnaire.
88958603|NCT01995188|Experimental|PSOC Dose Expansion Cohort: DNIB0600A+Carboplatin|RP2D of DNIB0600A administered via IV infusion in combination with AUC=6 mg/mL*min administered via IV infusion on Day 1 of each 21-day cycle in participants with PSOC until disease progression or death, whichever occurs first.
89509100|NCT04462939|Experimental|Healthy lactating women - Supplement|At randomization (Visit 2), from four to six weeks after delivery, eligible actating women will be equally randomized to one of the study arms (supplementation arm or placebo arm) and will assume the supplement or placebo once daily for a duration of 12 weeks.
89509101|NCT04462939|Placebo Comparator|Healthy lactating women - Placebo|At randomization (Visit 2), from four to six weeks after delivery, eligible actating women will be equally randomized to one of the study arms (supplementation arm or placebo arm) and will assume the supplement or placebo once daily for a duration of 12 weeks.
89509102|NCT03502291|Active Comparator|Study One: LAIV + Inoculation|LAIV Nasal Spray: Inoculation (FLUMIST or FLUENZ) plus intramuscular placebo then inoculation with pneumococci bacteria
89509103|NCT03502291|Placebo Comparator|Study One: Placebo + inoculation|Quadrivalent Inactivated Influenza Vaccine Intramuscular (Fluarix Tetra) plus nasal placebo then inoculation with pneumococci bacterial
89509104|NCT03502291|Active Comparator|Study Two: Inoculation + LAIV|Inoculation with pneumococci bacteria then Live attenuated Influenza Vaccine Nasal Spray (FLUMIST or FLUENZ) plus intramuscular placebo
89509105|NCT03502291|Placebo Comparator|Study Two: Inoculation + placebo|Inoculation with pneumococci bacteria then Quadrivalent Inactivated Influenza Vaccine Intramuscular (Fluarix Tetra) plus nasal placebo
88958604|NCT01995188|Experimental|PSOC Dose Expansion Cohort: DNIB0600A+Carboplatin+Bevacizumab|RP2D of DNIB0600A administered via IV infusion in combination with Carboplatin, AUC=6 mg/mL*min and Bevacizumab 15 milligrams per kilogram (mg/kg) administered via IV infusion on Day 1 of each 21-day cycle in participants with PSOC until disease progression or death, whichever occurs first.
88958605|NCT01995214|Experimental|P|Anesthesia maintenance with propofol+remifentanil
88958606|NCT01995214|Experimental|S|Anesthesia maintenance with sevoflurane+remifentanil
88958607|NCT01995227|Experimental|AlloVax Treatment|Intradermal injection (ID) of AlloStim(TM) (1ml) on day 4 and 7. AlloVax Treatment: ID injection of AlloSim(TM) (1 ml) followed immediately by the ID injection of CRCL (1ml) on day 11 and 14 in same location on the left arm and on day 18 and 21 in the same location on the right arm. Intravenous infusion of AlloStim(TM)(5ml) and a CRCL alone Intradermal injection on Day 27.
88958608|NCT01995240|Experimental|Optimization|For optimization of the protocol patients will undergo one DCE-MRI (Gadobutrol), T2* MRI and DWI MRI scan.
88958609|NCT01995240|Experimental|Reproducibility|For determination of the reproducibility patients will undergo two DCE-MRI (Gadobutrol), T2* MRI and DWI MRI scans within one week.
88958610|NCT01995253|Experimental|Controlled conditions|
88958611|NCT01995253|Experimental|Free-living conditions|
88958612|NCT01995279|Experimental|French ear acupuncture|Application of single session of French ear acupuncture at specific points used to reduce low back pain.
88958613|NCT01995279|Placebo Comparator|Sham Ultrasound|Sham ultrasound will be applied at lumbar spine.
89509106|NCT02306239|Active Comparator|norepinephrine|patients received norepinephrine
89509107|NCT02306239|Experimental|terlipressin|patients received terlipressin
89509108|NCT02314741|Experimental|POEM Treatment Arm|Patients treated with the POEM (per-oral endoscopic myotomy) procedure.
89509109|NCT02319187|Active Comparator|Arm A|S1
88958614|NCT01995292|Experimental|bronchoscope|Patients will receive local anaesthetics via the working channel of the bronchoscope.
88958615|NCT01995292|Experimental|Enk Fiberoptic Atomizer|Patients will receive local anaesthetics for the awake fiberoptic intubation via the Enk Fiberoptic Atomizer.
88958616|NCT01995318|Placebo Comparator|Elastic bandage|Elastic bandage application as one of routine treatment choice of acute ankle sprains.
88958617|NCT01995318|Other|Kinesiotaping|Application of anti-edema kinesiotaping
88958618|NCT01995331|Other|moderate-dose cyclophosphomide|
88958619|NCT01995370|Active Comparator|Monotherapy group|"Aspirin (81mg or 100mg) or clopidogrel (50mg or 75mg) will be orally administered once daily.~The treatment period will begin with the first visit of the first subject and end one year after the first visit of the last subject."
88958620|NCT01995370|Experimental|DAPT group|"Cilostazol (100mg twice daily) will be orally administered in combination with aspirin (81 or 100mg once daily) or clopidogrel (50 or 75mg once daily).~The treatment period will begin with the first visit of the first subject and end one year after the first visit of the last subject."
88958621|NCT01995383|Placebo Comparator|Part 1: Placebo (PL)|
88958622|NCT01995383|Experimental|Part 1: Single Ascending Doses (SAD) of RO6836191|
88958623|NCT01995383|Placebo Comparator|Part 2: PL: Low-salt (LS) followed by normal-salt (NS) diet|
88958624|NCT01995383|Placebo Comparator|Part 2: PL: NS followed by LS diet|
88958625|NCT01995383|Experimental|Part 2: RO6836191: LS followed by NS diet|
88958626|NCT01995383|Experimental|Part 2: RO6836191: NS followed by LS diet|
88958627|NCT01995422|Experimental|Physical activity program|A 5-month follow-up including a 3-month period of supervised physical activity
88958628|NCT01995435|Experimental|Telemedicine refraction before traditional refraction|We will first refract an individual using telemedicine refraction, and then refract them using a traditional refraction method.
88958629|NCT01995435|Experimental|Traditional refraction before telemedicine refraction|We will first refract an individual using a traditional refraction, and then refract them using a telemedicine refraction method.
88958630|NCT01995448||SEPSIS Blood test|Patient with two criteria of systemic inflammatory response syndrome and a progressive infection which is clinically or microbiologically documented.
89509110|NCT02319187|Experimental|Arm B|S1 and irinotecan
89509111|NCT02306317|Active Comparator|Control by nursing.|FiO2 adjusted manually by nursing staff. Intervention: Other. Standard procedure
89509112|NCT02306317|Experimental|Control by parents.|FiO2 adjusted manually by parents. Intervention. Other. Experimental procedure
89509113|NCT02319265|Experimental|Melatonin|Melatonin at a dose of either 50mg (50ml) or 100mg (100ml) to be decided after an initial PK study to be given at intervals to be decided after PK data is available, for 72h. Oral liquid via nasogastric tube.
89509114|NCT02319265|Placebo Comparator|Placebo|Placebo at a dose of either 50ml or 100ml (to be decided after an initial PK study) to be given at intervals to be decided after PK data, is available for 72h. Oral liquid via nasogastric tube.
88958631|NCT01995474|Experimental|Twisted Syringe|briefly disconnecting the syringe from the biopsy channel after a specimen is obtained and then reconnecting it
88958632|NCT01995474|Active Comparator|Conventional Technique|syringe is exchanged for the needle stylet and negative pressure is applied allowing acquisition of a cytology specimen.
88958633|NCT01995500|Experimental|BioNIR|"The BioNIR Ridaforolimus Eluting Coronary Stent System is a single use device/drug combination product comprising:~Stent - a mounted Cobalt Chromium (CoCr) alloy based stent~Delivery System - Rapid Exchange (RX) Coronary System~Polymer matrix coating - Poly n-butyl methacrylate (PBMA) and CarboSil®~Ridaforolimus drug - CAS Registry Number: 572924-54-0 The drug Ridaforolimus is utilized on the stent system at a dose of 1.1 μg/mm2 (with a drug load of 100 μg per 2.75/3.00 x 17 mm stent)."
88958634|NCT01995500|Active Comparator|Resolute|"The Endeavor Resolute Zotarolimus-Eluting Coronary Stent System consists of four subsystems:~Endeavor Resolute Stent - a premounted cobalt alloy based stent~Delivery system - Rapid Exchange (RX) Coronary System~Polymer system~Zotarolimus - drug The Resolute has a nominal drug dose of 1.6 µg zotarolimus per mm2 of the stent surface area."
88958635|NCT01995604|Experimental|dHACM|UltraPulse laser therapy with application of dHACM
88958636|NCT01995604|Placebo Comparator|Sterile 0.9% Saline Solution|UltraPulse laser therapy with application of Sterile 0.9% Saline Solution
88958637|NCT01995617|Experimental|Low Dose (Cohort 1)|
88958638|NCT01995617|Experimental|Mid Dose (Cohort 2)|
88958639|NCT01995617|Experimental|High Dose (Cohort 3)|
88958640|NCT01995630|Experimental|Hypermetropic, spherical IOL|AMO Sensar AR40e
88958641|NCT01995630|Experimental|Hypermetropic, aspheric IOL|AMO Tecnis ZA9003
89509115|NCT02319343|Active Comparator|Methylprednisolone|Preoperative single high dose of Solu-Medrol 125 mg iv.
89509116|NCT02319343|Placebo Comparator|Isotonic Sodium Chloride|Preoperative single dose of isotonic Sodium Chloride.
89509117|NCT02314819|Active Comparator|treatment arm|treatment arm- subjects will receive Fruquintinib 5mg orally, QD, plus BSC for 3 wks on/ 1 wk off. Patients will receive a cycles of 4 weeks of study treatment (1 cycle of study treatment includes 3 weeks of treatment and 1 week of drug discontinuation) or until the occurrence of progressive disease (PD), death, unacceptable toxicity, withdrawal of consent or other conditions that meet the end of treatment criteria.
89509118|NCT02314819|Placebo Comparator|control arm|control arm- subjects will receive Fruquintinib placebo 5mg orally, QD, plus BSC for 3 wks on/ 1 wk off. Patients will receive a cycles of 4 weeks of study treatment (1 cycle of study treatment includes 3 weeks of treatment and 1 week of drug discontinuation) or until the occurrence of progressive disease (PD), death, unacceptable toxicity, withdrawal of consent or other conditions that meet the end of treatment criteria.
88958642|NCT01995630|Active Comparator|Emmetropic, spherical IOL|AMO Sensar AR40e
89509119|NCT02314897|Experimental|LV pacing|Left ventricular pacing lead implanted via coronary sinus
89509120|NCT02314897|Active Comparator|RV pacing|Conventional right ventricular pacing lead.
89509121|NCT03508141|Experimental|Fibrinogen Concentrate|Fibrinogen Replacement using Fibrinogen Concentrate as per ROTEM (FIBTEM) FIBTEM A5 0mm = 60mg/kg FC FIBTEM A5 1-4mm = 50mg/kg FC FIBTEM A5 5-6mm = 40mg/kg FC FIBTEM A5 7-8mm = 30mg/kg FC FIBTEM A5 9-10mm = 20mg/kg FC
89509122|NCT03508141|Active Comparator|Cryoprecipitate|Fibrinogen Replacement using Cryoprecipitate as per ROTEM (FIBTEM) FIBTEM A5 0mm = 6ml/kg Cryoprecipitate FIBTEM A5 1-4mm = 5ml/kg Cryoprecipitate FIBTEM A5 5-6mm = 4ml/kg Cryoprecipitate FIBTEM A5 7-8mm = 3ml/kg Cryoprecipitate FIBTEM A5 9-10mm = 2ml/kg Cryoprecipitate
89509123|NCT02314975|Experimental|AcceleDent vibrational device|Fixed appliances with supplementary vibrational force
89509124|NCT02314975|Sham Comparator|Sham AcceleDent device|Fixed appliances with supplementary sham device
89509125|NCT02314975|Active Comparator|Fixed appliance only|Fixed appliances only
89509126|NCT02315053|Other|Low dose FDG PET/CT 5x|Stage II/III NSCLC will undergo a Low dose FDG PET/CT 5x during treatment (CCRT).
89509127|NCT02319421|Experimental|Primary Subjects|"Physicians and nurse practitioners caring for patients in the Pediatric Intensive Care Unit (PICU). An alarm reduction script will be used to help facilitate discussion of alarm data during weekday morning team huddles."
89509128|NCT02319499|Experimental|Zinc Alone|Zinc Sulphate (10 mg Zn/day)
89509129|NCT02319499|Experimental|Iron and Zinc|Ferrous Sulphate and Zinc Sulphate (10 mg/day of each zinc and iron)
88958643|NCT01995630|Active Comparator|Emmetropic, aspheric IOL|AMO Tecnis ZA9003
89509130|NCT02319499|Experimental|Iron, Zinc and Vitamin A|Ferrous Sulphate, Zinc Sulphate and Vitamin A (10 mg/day of each zinc and iron, plus 1,000 IU vitamin A/day)
88958644|NCT01995643|Active Comparator|Active Capsule|Grape Seed Extract Capsule: 300 mg
88958645|NCT01995643|Placebo Comparator|Placebo Capsule|Placebo Capsule: Maltodextrin
88958646|NCT01995656|Placebo Comparator|Placebo - Healthy|Part A. Healthy participants will receive a single oral dose of placebo matching LY3108732 in at least 1 of 3 study periods.
89024074|NCT03673501|Experimental|Ripretinib|Ripretinib (150 mg) once a day continuous dosing for 6-week (42 days) cycles
89509131|NCT02319499|Placebo Comparator|Placebo|No minerals/vitamin
89509132|NCT03508063||Healthy population|Healthy subjects receiving stimuli (thermal stimuli and stressogenic physical stimuli) at rest, and being monitored MCPM.
89509133|NCT03499639|Other|patients with HCV and ESKD|Ombitasvir / Paritaprevir / Ritonavir/Ribavirin Oral Tablet
89509134|NCT03499561||pregnant women in first Trimester|A urine sample will be taken from pregnant women before 14 weeks of pregnancy
89509135|NCT03499561||pregnant women in second Trimester|A urine sample will be taken from pregnant women from 14 weeks +1 day till 28 weeks
89509136|NCT03499561||pregnant women in third Trimester|A urine sample will be taken from pregnant women from 28 weeks +1 day till 40 weeks
89509137|NCT03502135|Experimental|Intranasal Anesthesia|Two intranasal sprays of tetracaine HCl and oxymetazoline HCl nasal spray anesthetic administered 4 minutes apart into the nostril corresponding to the side of the treated tooth. If inadequate anesthetic response obtained within 10 minutes, a third spray will be administered and assessed for effective anesthesia after 4 minutes.
89509138|NCT02320747|Experimental|Tai Chi Group|Experienced instructor at teaching tai chi delivered in a group setting in the community lasted approximately 40 minutes. Participants in the program served as an active control group that matched to the program and delivered.The class comprised mainly seated exercises including stretching, low-level strength, and low-level cardiovascular exercise. Participants walked (warm-up and cool-down) for 7 min in class, remaining seated or standing with arm support the rest of the time.
89509139|NCT02320747|No Intervention|Control Group|
89509140|NCT02315287|Active Comparator|Metformin, Sitagliptin, Pioglitazone|Thiazolidinedione
89509141|NCT02315287|Active Comparator|Metformin, Sitagliptin, Lobeglitazone|Thiazolidinedione
89509142|NCT02319577|Experimental|Gefitinib plus oral vinorelbine|"Arm A (21-days cycles until progressive disease or unacceptable toxicity):~Oral vinorelbine 60 mg/mq on days 1,8 Gefitinib 250 mg daily from day 9 to day 21"
89509143|NCT02319577|Active Comparator|Gefitinib alone|"Arm B (21-days cycles until progressive disease or unacceptable toxicity):~Gefitinib 250 mg daily from day 1 to day 21"
89509144|NCT03499405|Experimental|Intervention group|Intervention group will receive a family navigator intervention from a culturally matched family navigator.
89509145|NCT03499405|No Intervention|Control group|Control group will not receive a family navigator intervention from a culturally matched family navigator.
89509146|NCT04462783|Experimental|Patient's symptom data without pulse oximeter|Some patients may not be given a pulse oximeter to enter heart rate and O2 saturation into the CovidX application.
89509147|NCT04462783|Experimental|Patient's symptom data with a pulse oximeter|Some patients will be given (or may have) a pulse oximeter in order to enter heart rate and O2 saturation data into the CovidX application.
89509148|NCT02319655|Active Comparator|Air tamponade|Air is injected after vitrectomy/membrane peeling
89024075|NCT03673501|Active Comparator|Sunitinib|Sunitinib (50 mg) once a day in 6-week (42 days) cycles with 4 weeks continuous dosing followed by 2 week break.
89509149|NCT02319655|Active Comparator|Balanced salt solution filling|Balances salt solution is injected after vitrectomy/membrane peeling
89509150|NCT02319733|Experimental|Bioresorbable vascular scaffold|Implantation of Bioresorbable vascular scaffold in vulnerable plaques
89509151|NCT03132259|Experimental|High dose dexmedethomidine|High dose is 0.5 microgram/kg/hr
89509152|NCT03132259|Experimental|Low dose dexmedethomidine|Low dose is 0.2 microgram/kg/hr
89509153|NCT02315677|Active Comparator|Nasal intubation-Standard RAE ETT|This arm will receive nasal intubation with the standard RAE endotracheal tube with bevel facing left.
89509154|NCT02315677|Active Comparator|Nasal intubation-Parker Flex-Tip ETT|This arm will receive nasal intubation with the Parker Flex-tip ETT with bevel facing posteriorly.
89509155|NCT02315833|Experimental|Acetium|Patient will administer Acetium capsules (100mg l-cysteine) twice a day for three months
89509156|NCT02315833|Placebo Comparator|Placebo|Patient will administer placebo capsules twice a day for three months
89509157|NCT02315911|No Intervention|expectancy for mild-moderate OSA|6 months expectancy
89509158|NCT02315911|Experimental|ATE for mild-moderate OSA|adeno-tonsillectomy
89509159|NCT02315911|Experimental|ATE for severe OSA|adeno-tonsillectomy
89509160|NCT02315911|Experimental|APP for severe OSA|adeno-pharyngoplasty
89509161|NCT02316067|Experimental|Rehabilitation|Eight weeks of rehabilitation (CHORDATA® Method)
89509162|NCT02316067|No Intervention|Control|Participants maintained their daily-life activities routine during the same eight weeks period and were tested before and after this control period.
89509163|NCT02316145|Other|'Habilitation (Internet-based support)|Before the individual started with the internet-based support and coaching (IBSC), a meeting with the coach was compulsory to discuss what specific issues they were going to work with during the period of IBSC. The IBSC was offered at fixed times twice a week during an eight-week period. Two meetings between the individual and the coach were included. Between chat sessions the individuals and the coaches could get in touch using the programme's e-mail. The content of the support and coaching was individualised based on each individual's requirement. Once a fortnight a meeting was held with the head of the project and coaches. Issues regarding ongoing support and coaching were addressed.
89509164|NCT02319811||Cryopreserved meniscus transplant|Intervention: Lateral or medial cryopreserved meniscus transplant implanted into appropriately indicated patients.
89509165|NCT03499171|Experimental|Citalopram|20mg, once a day
89509166|NCT03499171|Placebo Comparator|Placebo|Once a day
89509167|NCT02447419|Experimental|Gefitinib|Gefitinib 250 mg will be administered orally daily
89509168|NCT02319889|Experimental|Treatment (SBRT, carboplatin, Abraxane)|Patients undergo Stereotactic Body Radiotherapy every other day for up to 14 days for a total of 5 fractions. After a break period of about 30 days, patients will then start chemotherapy. Patients will receive carboplatin IV over 30-40 minutes on day 1 and paclitaxel albumin-stabilized nanoparticle formulation IV over 30-40 minutes on days 1, 8, and 15. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
89206959|NCT04382235||Covid-19 related Pneumonia patients|The cohort is defined by subjects with a diagnosis of COVID 19-related pneumonia requiring non-invasive ventilatory support.
89509169|NCT03499093||Prosthetic patient with esthetic expectations|Prosthetic patients with esthetic expectations (PP-E, n=35), Patients seeking for restoration or replacement of anterior teeth, or expressing any esthetic expectation
89509170|NCT03499093||Prosthetic patients without esthetic expectations|Prosthetic patients without esthetic expectations (PP-NE, n=35) Patients pending restoration or replacement of posterior teeth (premolars and molars), expressing only functional expectation
89509171|NCT03499093||Dental patient with esthetic concern|Dental patient with esthetic concern(C-E, n=35) Patient consulting for follow up, having crowns or removable denture replacing anterior teeth
89509172|NCT03499093||Dental patient without any esthetic concern|Dental patient without any esthetic concern (C-NE, n=35) Patient consulting for follow up, having no crown or removable denture replacing anterior teeth.
89509173|NCT03499015|No Intervention|Ear without BET|ear without BET treatment works as control
89509174|NCT03499015|Experimental|BET ear|ear with BET treatment works as intervention arm
89509175|NCT03498547|Active Comparator|Caudal Block|For the caudal block, sacral horns are palpated and sacral hiatus and epidural area will be determined at S4-S5 level through ultrasonography. The 20 G adult caudal needle will then be placed to the caudal epidural space and 25 mL bupivacaine at a concentration of 0.5% will be applied in the prone Jack-Knife position with resistance loss.
89509176|NCT03498547|Active Comparator|Saddle Block|In the saddle block group hyperbaric bupivacaine at a dose of 7 mg will be given to the intrathecal space after a 25 G quincke spinal needle is inserted with ultrasonography guidance between L4-L5 vertebral disc and clear cerebrospinal fluid is seen. The patient will be placed in sitting position for 5 minutes.
89509177|NCT03498937|Experimental|Group 1|Subjects suffering from Borderline Personality Disorder randomly assigned to start the trial by 10 active tDCS sessions, followed by 10 sham tDCS sessions
89509178|NCT03498937|Experimental|Group 2|Subjects suffering from Borderline Personality Disorder randomly assigned to start the trial by 10 sham tDCS sessions, followed by 10 active tDCS sessions
89509179|NCT04461613|Experimental|Group 1|"In the first week, this group will receive a physical activity diary and be required to fill it out for 7 days. After completion of the activity diary, group 1 will receive an original International Physical Activity Questionnaire short form (IPAQ-sf). Group 1 will be asked to fill it out with information about physical activities in the last 7 days.~In the second week, the group will need to fill another physical activity diary for 7 days. After the completion of this, group 1 will be asked to fill a revised version of IPAQ-sf to describe physical activities in the last 7 days."
89509180|NCT04461613|Experimental|Group 2|"In the first week, this group will receive a physical activity diary and be required to fill it out for 7 days. After completion of the activity diary, group 2 will receive a revised version of International Physical Activity Questionnaire short form (IPAQ-sf). Group 2 will be asked to fill it out with information about physical activities in the last 7 days.~In the second week, the group will need to fill another physical activity diary for 7 days. After the completion of this, group 2 will be asked to fill an original IPAQ-sf to describe physical activities in the last 7 days."
89509181|NCT04461769|Experimental|Slow Oscillation Synchronization with TES|Transcranial Electrical Stimulation, 0.5 Hz sine wave, 0.5 mA, between frontal (frontopolar and inferior lateral frontal) and posterior (mastoid and occipital) electrodes.
89509182|NCT04461769|Sham Comparator|Sham Control|No current delivered.
89509183|NCT02324413|Active Comparator|clonidine|Clonidine intravenous 1 or 2 micrograms / kg
89509184|NCT02324413|Placebo Comparator|Placebo|
89509185|NCT03498703|Experimental|Azathioprine|
89509186|NCT03498703|Placebo Comparator|Control|
89509187|NCT03498469|Active Comparator|No Parenting program|Participants assigned to this comparison arm will receive a standardized reintegration package that includes individualized case management support and a reunification cash grant. Individualized case management will consist of a caseworker-developed individualized care plan with routine caseworker visits at the household level. At a minimum, each family will be visited on a monthly basis during the first 6 months post-placement and then every other month for the next 9 months. For the cash grant, the family of each enrolled child will receive a reunification cash grant in the Ugandan Shilling equivalent of $125, administered in two equal disbursements. It is designed to offset the cost of child care.
89509188|NCT03498469|Experimental|Parenting program|Those in the intervention arm will receive an enhanced reintegration package of services that consist of the standard package (case management and cash grant) plus a parenting program called 'Esanyu Mu Maka' or Happiness in the Home. The parenting curriculum used will be an adaptation of the evidence-based Sinovuyo Kids curriculum, tailored for caregivers of children age 1 to 13 years. It will have specifically designed components to address parenting challenges under reunification/reintegration conditions and to support the child and caregiver in building their relationship. It will be delivered at the household level by project trained parenting facilitators. The program will consist of approximately 13 bi-weekly sessions, which will be delivered over the course of 7 months.
89509189|NCT02324491|Experimental|ZGN-440 Injectable Suspension (1.2mg)|ZGN-440 for Injectable Suspension
89509190|NCT02324491|Experimental|ZGN-440 Injectable Suspension (1.8mg)|ZGN-440 for Injectable Suspension
89509191|NCT02324491|Placebo Comparator|Placebo|ZGN-440 Placebo for Injectable Suspension
89509192|NCT02320981||EGD with Biopsy|Pediatric patients scheduled for standard of care EGD with biopsy also received measurement of mucosal impedance
89509193|NCT03494413|Experimental|20 patients (1-20) validation arm|Accuracy of cerebral flow measurement between TPS and CDS in 20 patients undergoing cardiovascular surgery with cardiopulmonary bypass
89206960|NCT00843570|No Intervention|1|Natural FER (frozen embryo replacement)
89206961|NCT00843570|Active Comparator|2|HRT-FER (Down regulated frozen embryo replacement)
89206962|NCT04010877|Experimental|Multiple CAR T cells to treat AML|Multiple CAR T cells to treat AML
89206963|NCT00843648||preterms|mother and preterm babies
89206964|NCT00843648||term-bfing|term breastfed babies and mothers
89206965|NCT00843648||term-PIF|term non breastfed babies and mothers
89509194|NCT03494413|Experimental|20 patients (21-40) HCA arm|Assessment and comparison of TPS and CDS in hypothermic circulatory arrest (HCA) during cardiovascular surgery
88958647|NCT01995656|Experimental|LY3108743 - Healthy|Part A. Healthy participants will receive a single oral dose of LY3108743 in dose escalation cohorts in up to 2 of 3 study periods.
89206966|NCT00843648||c-section|c-section babies and their mothers
88958648|NCT01995656|Placebo Comparator|Placebo - Diabetes|Part B. Participants with diabetes mellitus will receive a single oral dose of placebo matching LY3108732 in at least 1 of 3 study periods.
88958649|NCT01995656|Experimental|LY3108743 - Diabetes|Part B. Participants with diabetes mellitus will receive a single oral dose of LY3108743 in dose escalation cohorts in up to 2 of 3 study periods.
88958650|NCT01995656|Placebo Comparator|Placebo - Solution|Part C. Contingent on results from Parts A and B. Healthy participants will receive a single oral dose of placebo matching LY3108743 in 1 of 2 study periods.
88958651|NCT01995656|Experimental|LY3108743 - Solution|Part C. Contingent on results from Parts A and B. Healthy participants will receive a single oral dose of LY3108743 in 1 of 2 study periods.
88958652|NCT01995695|Experimental|Group 1: One Vaccine Dose and One Booster Vaccine Dose|Participants will receive one dose of live attenuated H7N9 A/Anhui/13 ca influenza virus vaccine at study entry. They will then receive one dose of inactivated subvirion H7N9 influenza vaccine on Day 98.
88958653|NCT01995695|Experimental|Group 2: Two Vaccine Doses and One Booster Vaccine Dose|Participants will receive two doses of live attenuated H7N9 A/Anhui/13 ca influenza virus vaccine: one dose at study entry and one dose on Day 28. They will then receive one dose of inactivated subvirion H7N9 influenza vaccine on Day 98.
88958654|NCT01995721|Experimental|4-valent HPV vaccine|4-valent HPV vaccine administered in months 0., 2., 6.
88958655|NCT01995773||Healthy Controls|Healthy control women
88958656|NCT01995786|No Intervention|Conventional Intravenous Fluid therapy|Basal infusion of crystalloid (normal saline,Ringer's lactate,Ringer's solution)variable from 4 to 12 ml/kg/hour
89206967|NCT05169723|Experimental|Respiratory Activity 1|
89509195|NCT03494257|Active Comparator|Brinzolamide-Brimonidine fixed combination|1 drop of the brinzolamide-brimonidine fixed combination instilled in the patients cul de sac immediately after surgery
89509196|NCT03494257|No Intervention|No topical IOP reducing medication|No IOP reducing drops instilled after surgery
89509197|NCT03132181|Experimental|Empagliofizin|Patients will receive empagliflozin 10 mg qd for a period of 3 months.
89509198|NCT03132181|Placebo Comparator|Placebo|Patients of the placebo arm will receive placebo tablets qd for a period of 3 months.
89509199|NCT02320045|Experimental|Group 1: Normal|Normal Subjects estimated creatinine clearance (eGFR) ≥90 mL/min/1.73 m2
89509200|NCT02320045|Experimental|Group 2: Mild Renal Dysfunction|Subjects with Mild Renal Dysfunction estimated creatinine clearance (eGFR) 60-89 mL/min/1.73 m2
89509201|NCT02320045|Experimental|Goup 3: Moderate Renal Dysfunction|Subjects with Moderate Renal Dysfunction estimated creatinine clearance (eGFR) 45-59 mL/min/1.73 m2
89509202|NCT02320045|Experimental|Group 4: Moderate Renal Dysfunction|Subjects with Moderate Renal Dysfunction estimated creatinine clearance (eGFR) >30-44 mL/min/1.73 m2
89509203|NCT02320357|Experimental|Clopidogrel|
89509204|NCT02320513||Control Group|Subjects will wear the activity monitoring device to track their activity between dialysis treatments, however, the feedback from the device will not be shared with them.
89509205|NCT02320513||Feedback Group|The feedback from the activity monitoring device will be shared with subjects at each visit.
89509206|NCT03498235|Experimental|Team Sevoflurane|
89509207|NCT03498235|Experimental|Team Propofol|
89509208|NCT02320591|Experimental|Treatment group|Practices assigned to the treatment group received per member per month care management fees for each Medicare beneficiary attributed to their practice. They also received quarterly feedback reports on their patients' average Medicare expenditures and use of hospital and emergency room services. Practices also had access to regional learning faculties for technical assistance with transformation activities and to share lessons across practices.
89509209|NCT02320591|No Intervention|Comparison group|Within each of the 7 regions, this group is comprised of practices that were matched to the treatment practices on a wide range of baseline characteristics of the practices (including their service utilization patterns) and their patients. Comparison practices were selected from a pool of practices including those that applied to participate but were not selected, and practices serving nearby external comparison areas.
89509210|NCT02324803|Experimental|pazopanib once daily|Patients received continuous treatment of 800 mg pazopanib once daily until disease progression, unacceptable toxicity, or withdrawal of consent occurred. Dose reductions by 400 mg to a lowest dose of 200 mg daily were allowed on the basis of tolerability and according to protocol-defined guidelines.
89509211|NCT02324881|Experimental|Health Services Research (PMSA)|"Patients/caregivers are instructed to download the PMSA and are demonstrated how to properly use the application. Beginning on the first day of radiation therapy (day 1), patients are instructed to use the PMSA for the duration of their radiation therapy (up to day 50). The patient will fill out a satisfaction questionnaire at the completion of their treatment (Questionnaire administration). The timing of use may change depending on the availability of the app. The use of the app is classified as the telephone-based intervention per NCI."
89509212|NCT03498157|Experimental|Partly Supervised Prehabilitation|Will be offered an initial one week (5 days for 3 hours each) supervised exercise prehabilitation program including a two hour group-based prehabilitation class at Penn State Rehabilitation Hospital, Hummelstown. The following weeks till surgery the learned exercise program should be done home-based for 5 times a week. A weekly phone call during this period will help to support and adapt the exercise program.
89206968|NCT05169723|Experimental|Respiratory Activity 2|
89206969|NCT05169723|Experimental|Respiratory Activity 3|
89206970|NCT05169723|Experimental|Respiratory Activity 4|
89206971|NCT05169723|Experimental|Respiratory Activity 5|
89206972|NCT00839124|Active Comparator|Allergic asthma|subjects with allergic asthma will undergo challenge with 20,000 EU CCRE
89206973|NCT00839124|Active Comparator|healthy control|Healthy volunteers will undergo challenge with 20,000 EU CCRE
89509213|NCT03498157|Active Comparator|Home-based Prehabilitation|Will be offered an individual one-on-one appointment for an exercise introduction session with an exercise and cancer specialist and weekly phone calls to support and adapt the exercise program. The exercises should be done home-based for 5 times a week until the time of surgery. Furthermore, a two hour group-based prehabilitation class at the Penn State Hershey Cancer Institute will be offered.
89509214|NCT03498157|Active Comparator|Control Group|Will be offered a two hour group-based prehabilitation class at the Penn State Hershey Cancer Institute.
89509215|NCT03498157|No Intervention|Comparison group- women too active|Added comparison group: Women who are ineligible on the basis of 'engaging in systematic intense exercise training (at least 1h twice a week) will be recruited to complete measures only, with no randomization
89509216|NCT02324959|Active Comparator|Acupuncture|Needling of affected meridian groups in line with Traditional Chinese Medicine procedures (Baihui and Shenting).
89509217|NCT02324959|Active Comparator|Computer-based|Computer-based attention training (RehaCom).
89509218|NCT02324959|Experimental|ACoTrain|A combination of computer-based attention training with acupuncture.
89509219|NCT02325037|Experimental|GLPG1837 single dose|Single oral dose of GLPG1837 suspension - ascending doses
89509220|NCT02325037|Placebo Comparator|Placebo single dose|Single oral dose of placebo suspension
89509221|NCT02325037|Experimental|GLPG1837 muliple doses|Multiple oral doses of GLPG1837 suspension - ascending doses
89509222|NCT02325037|Placebo Comparator|Placebo multiple doses|Multiple oral doses of placebo suspension
89509223|NCT02325115||students (STUD)|The STUD population was a convenient sample of 75 first year students (51 females and 24 males); with 45 from a School of Business Management and 30 from a medical university.
89509224|NCT02325115||working adults (WORK)|The WORK population was also a convenient sample of 113 (63 females and 256 males) working adults including 217 soldiers from Paris Fire Brigade, 93 nurses and 9 individuals from a research laboratory.
89509225|NCT02325115||remitted schizophrenia (PRS)|The PRS population was comprised of 121 remitted schizophrenia patients (39 females and 82 males) who were all clients of the rehabilitation centre for psychotic disorders (Le Vinatier hospital),
89509226|NCT02320669|Experimental|Triostat|Active Medication - Synthetic Thyroid Hormone
89509227|NCT02320669|Placebo Comparator|Placebo|Placebo Control
89509228|NCT02325271||Control group|Subjects with normal glucose tolerance
89509229|NCT02325271||Diabetes group|Patients with type 2 diabetes
89509230|NCT05129917|Placebo Comparator|Placebo|consume 1 sachet per day for 14 day
89509231|NCT05129917|Experimental|Gojinsen® drinks|consume 1 sachet per day for 14 day
89509232|NCT02321059||No incisional hernia group|Healthy volunteers with an intact abdominal wall.
89509233|NCT02321059||Incisional hernia group|Patients with a ventral incisional hernia.
89509234|NCT04789213||Patients with Living Donor Liver Transplantation|
89509235|NCT04789213||Patients with Deceased Donor Liver Transplantation|
89509236|NCT04774003|Experimental|300 mg inclisiran sodium (equivalent to 284 mg inclisiran)|300 mg inclisiran sodium (equivalent to 284 mg inclisiran) x 1 dose (n=15) at Day 1
89509237|NCT04774003|Experimental|100 mg inclisiran sodium (equivalent to 94.5 mg inclisiran)|100 mg inclisiran sodium (equivalent to 94.5 mg inclisiran) x 1 dose (n=15) at Day 1
89509238|NCT04774003|Placebo Comparator|Placebo|Placebo x 1 dose (n=10) at Day 1
89509239|NCT03132103|Experimental|Solar simulated radiation (SSR)|Solar simulated radiation (SSR)
89509240|NCT03132103|Placebo Comparator|Placebo SSR|Placebo SSR
89509241|NCT03132103|Experimental|Oral Vitamin D3|Oral Vitamin D3
89509242|NCT03132103|Placebo Comparator|Placebo Oral Vitamin D3|Placebo Oral Vitamin D3
89509243|NCT02321215|No Intervention|Control|Usual care: This group will receive usual care from their physician without any special focus on education. At the end of the study period, patients that were assigned to the control group will receive the booklet at home and be offered two education sessions by phone or in-person if the patient is willing to return to the hospital.
89509244|NCT02321215|Active Comparator|Education Intervention|Introductory disease education: This group will attend two one-on-one education sessions. The educational content will be standardized and a checklist will be used to ensure that all topics are addressed. The sessions will focus on enhancing self-efficacy in areas that are thought to be important to individuals who recently had an AECOPD.
89509245|NCT04635943|Active Comparator|Ivermectin|Participants on this arm will receive orally one (1) daily dose of ivermectin 300 mcg/kg for three (3) consecutive days, starting at the enrolment visit.
89509246|NCT04635943|Placebo Comparator|Placebo|Participants on this arm will receive orally one (1) daily dose of placebo for three (3) consecutive days, starting at the enrolment visit.
89509247|NCT04398355|No Intervention|control|basic treatment+Swallowing rehabilitation training
89509248|NCT04398355|Experimental|Combination treatment|basic treatment+Swallowing rehabilitation training+Chinese traditional rehabilitation
89509249|NCT04398355|Experimental|Liu-Zi-Jue treatment|basic treatment+Swallowing rehabilitation training+Liu-Zi-Jue
89509250|NCT04398355|Experimental|acupuncture treatment|basic treatment+Swallowing rehabilitation training+acupuncture
89509251|NCT04344535|Active Comparator|Convalescent Donor Plasma|
89509252|NCT04344535|Placebo Comparator|Standard Donor Plasma|
89509253|NCT04461847|Experimental|patients underwent ESM|
89509254|NCT04461847|Active Comparator|patients underwent SM|
89509255|NCT04461925|Experimental|Experimental group|"On the basis conventional symptomatic treatment and supportive therapy, P-MMSCs were given at 1 million cells/kg body weight/ time, once every 3 days for a total of 3 times: Day 1, Day 4, Day 7."
89509256|NCT04461925|Active Comparator|Control Group|Conventional symptomatic treatments such as antibacterial (ceftriaxone, azithromycin), anticoagulants, hormones, oxygen therapy, mechanical ventilation and other supportive therapies
89509257|NCT02325583|Experimental|Intraoral 30% Glucose in Newborns|0.5-1 mL 30% glucose solution was administered orally and the motionless and sleepiness of newborn was evaluated. If the target conditions was not achieved, 0.5-1 mL increments of glucose was added. After 2 consecutive oral glucose administration the newborns who did not keep motionless or sleep and had motion artefacts sedated with midazolam. The routine blood glucose level measurement was also performed in ICU.
89509258|NCT02325661|Other|cognitive interviewing|individual cognitive interviewing, 30 minutes per patient
89509259|NCT03494101||Non-typhoid Salmonella infection|Patients with a non-typhoid Salmonella infection. Blood samples, stool samples and clinical information will be collected.
89509260|NCT03494101||Acute, infectious diarrhea|Patients with acute, infectious diarrhea without non-typhoid Salmonella infection. Blood samples, stool samples and clinical information will be collected.
88958657|NCT01995786|Experimental|GDT|Basal infusion of crystalloids (normal saline,Ringer's lactate,Ringer's solution) at 2,5 ml/kg/h and boluses of crystalloids for values of stroke volume (SV) < SV TRIGGER. Every additional infusion of colloids, blood derivates, drugs must be recorded
88958658|NCT01995799|Experimental|USPIO timepoint 2-4 days|USPIO given 2-4 days post MI Ferumoxytol enhanced MRI
88958659|NCT01995799|Experimental|USPIO timepoint 5-7 days|USPIO given 5-7 days post MI Ferumoxytol enhanced MRI
88958660|NCT01995799|Experimental|USPIO tiempoint 11-21 days|USPIO given 11-21 days post MI Ferumoxytol enhanced MRI
88958661|NCT01995812|Experimental|Hula and heart health education|12 weeks of hula classes, 2 times a week for one hour. An additional 3 hours of heart health education was given to participants
88958662|NCT01995812|No Intervention|Control group|
88958663|NCT01995851||Intervention (LAIV)|Healthy children and adolescents between Junior Kindergarten (JK) and Grade 8 in the intervention schools will be immunized with LAIV (FluMist influenza vaccine) recommended for the 2013-14 the influenza season.
88958664|NCT01995851||Control (TIV)|Healthy children and adolescents between JK and Grade 8 in schools assigned to TIV will be immunized with inactivated influenza vaccine (Vaxigrip vaccine) recommended for the 2013-14 influenza season.
88958665|NCT01995864|Experimental|CTI-TS|CTI-TS is a time-limited, 9-month long intervention, provided at the critical time when a person is first offered services at a mental health clinic, or, at the similarly critical time when a person first seeks to reconnect with a mental health clinic after a long lapse.
89509261|NCT03494101||Healthy individuals|Healthy individuals with no symptoms of acute or chronic diarrhea. Blood samples, stool samples and clinical information will be collected.
89509262|NCT02321293|Experimental|1|"CurcuVIVA™ (NPN 80027414) at a single dose of 80 mg PO daily without any dose escalation to be taken in conjunction with an EGFR-TKI therapy.~CurcuVIVA™ is given in capsule forms. Unit strength of CurcuVIVA™ is equal to Turmeric Extract 25:1 348 mg (containing 80mg Longvida® Optimized Curcumin)~Tyrosine Kinase Inhibitors:~Gefitinib is a targeted therapy, given in a capsule form once daily. The daily dose is 250 mg .~Erlotinib is a targeted therapy, given in a capsule form once daily. The daily dose is 150 mg .~Study intervention is 8 weeks, following which the patients will continue taking their EGFR-TKI without curcumin until progression. The side effects of curcumin will be followed for another 8 weeks from the date of stopping curcumin."
89509263|NCT03493867|Other|Vitaliti|The subject's blood pressure will be simultaneously determined and recorded using the invasive arterial line blood pressure reading and the test Vitaliti device readings.
89509264|NCT04462549|Experimental|Resource Facilitation|This group is receiving Resource Facilitation
89509265|NCT04462549|No Intervention|Control|Not receiving Resource Facilitation
89509266|NCT02325817|Experimental|Drug-eluting balloon|Treat the side branch of bifurcation lesion with drug-eluting balloon
89509267|NCT02325817|Active Comparator|Uncoated balloon|Treat the side branch of bifurcation lesion with uncoated balloon
89509268|NCT02325895|No Intervention|Control (0 g Dried plum/day)|Participants only received 400IU of vitamin D and 500mg of calcium daily for 6 months.
89509269|NCT02325895|Experimental|50 g Dried plum/day|Participants received 400IU of vitamin D and 500mg of calcium and 50g of dried plum daily for 6 months.
89509270|NCT02325895|Experimental|100 g Dried plum/day|Participants received 400IU of vitamin D and 500mg of calcium and 100g of dried plum daily for 6 months.
89509271|NCT03491605||peripheral EBV-DNA load|subjects with high load (>1×103 copies/ml）of EBV-DNA copies in peripheral blood.
89509272|NCT02321371|Experimental|Lactulose + Rifaximin|Continuation of Lactulose + addition of Rifaximin 400 mg 8th hourly through enteral route.
89509273|NCT02321371|Active Comparator|Lactulose therapy|
89509274|NCT03931681|Experimental|Experimental: Phase 1 - Dose Escalation|Dose escalation trial evaluating OKI-179 given orally on a daily basis. Patients will take OKI-179 orally (PO) on Days 1 - 4, 8 - 11 and 15 - 18 in 21-day cycles (± 3 days), under fasted conditions. The design is a modified 3+3 design to determine the maximum tolerated dose and allows for additional cohorts enrolling subjects with an alternative dosing schedule such as OKI-179 orally (PO) daily on Days 1 - 5, 8 - 12 and 15 - 19 per 21-day cycles or Days 1 - 21 per 21-day cycles to determine the maximum tolerated dose for continuous daily dosing.
89509275|NCT05144425|Active Comparator|group A|underwent TKA with using pneumatic tourniquet
89509276|NCT05144425|Placebo Comparator|group B|underwent TKA without using pneumatic tourniquet
89509277|NCT05143879|Placebo Comparator|Placebo|8 subjects took 3 g/kg/day of placebo during 9 weeks
89509278|NCT05143879|Active Comparator|Nitrate|8 subjects took 3 g/kg/day of nitrate during 9 weeks
89509279|NCT05143879|Active Comparator|Citrulline|8 subjects took 3 g/kg/day of citrulline during 9 weeks
89509280|NCT05143879|Active Comparator|Nitrate plus Citrulline|8 subjects took 3 g/kg/day of nitrate plus citrulline during 9 weeks
89509281|NCT05143411|Experimental|Use of mobile application|Single arm: At the first time, the researcher will collect all glycemic levels before using the mobile application. Then, all the participants will receive the mobile application to select their main meals, breakfast, lunch, and dinner. Then, the application must calculate the insulin bolus according to their initial profile and the food before being eaten.
89509282|NCT04462237|Experimental|collagen matrix + platelet-derived growth factor|Root coverage procedure using collagen matrix + platelet-derived growth factor for the treatment of multiple adjacent gingival recessions
89509283|NCT04462237|Active Comparator|collagen matrix alone|Root coverage procedure using collagen matrix alone (without the use of the platelet-derived growth factor) for the treatment of multiple adjacent gingival recessions
89509284|NCT05129839|Experimental|Lightened and Musical Baby Mobile Group|The children in the study group were applied a lightened and musical baby mobile before sleeping at night.
89509285|NCT05129839|No Intervention|Control Group|The children in the control group were not given lightened and musical baby mobile, and their routine sleep patterns were continued.
89024076|NCT03668340|Experimental|Part A: AZD1775|-AZD1775 will be taken by mouth daily on days 1 through 5 and days 8 through 12 of each 21-day cycle
89024077|NCT03668340|Experimental|Part B: AZD1775 in Carcinosarcoma|-AZD1775 will be taken by mouth daily on days 1 through 5 and days 8 through 12 of each 21-day cycle
89024078|NCT03668340|Experimental|Part C: AZD1775 in Uterine Serous with biopsiable disease|-AZD1775 will be taken by mouth daily on days 1 through 5 and days 8 through 12 of each 21-day cycle
89024079|NCT03654547|Experimental|Dose Escalation|Eligible adult patients with advanced solid tumors will be enrolled into Dose Escalation cohorts and treated with TT-00420 at different dose cohorts. Starting dose will be 1 mg p.o., q.d. An ABLRM guided by the EWOC principle will evaluate the risk of under-dose or over-dose for the dose tested in each cohort and provide the recommendation dose for next cohort. Dose Escalation Teleconference will be held after the last evaluable patient complete Cycle 1 treatment in each dose cohort to evaluate DLT, determine MTD and/or DRDE.
89024080|NCT03654547|Experimental|Dose Expansion|A Dose Expansion cohort will be opened to enroll patients with selected advanced solid tumors and evaluate the safety, PK and preliminary efficacy of TT-00420 to determine the recommended phase 2 dose in patients with advanced solid tumors.
89509286|NCT03497611||Patients with aortic stenosis|Patients receiving Edwards SAPIEN 3 Transcatheter aortic valve implantation
89509287|NCT03493555|Experimental|Intervention Development|Peer Health Navigator for PrEP
89509288|NCT03493477||Skeletal Class II Group|From the lateral cephalometric radiograph , Steiner analysis (ANB angle should be higher than mean value, mean value 3 ±2), Witt's appraisal should be higher than mean value (mean value zero), and McNamara analysis (A-B diff NV should be higher than mean value, mean value 4±2).At least two of the three mentioned analyses should verify skeletal class II relation
89509289|NCT03493477||Skeletal Class III Group|From the lateral cephalometric radiograph , Steiner analysis (ANB angle should be lower than mean value, mean value 3 ±2), Witt's appraisal should be lower than mean value (mean value zero), and McNamara analysis (A-B diff NV should be lower than mean value, mean value 4±2).At least two of the three mentioned analyses should verify skeletal class III relation
89509290|NCT03493399|Experimental|Problem Gamblers|Interference
89509291|NCT03491449|Experimental|Group A: pressure ≥140 and ≤160mmHg|Intensive management of blood pressure, maintaining a systolic blood pressure ≥ 140 and ≤ 160 mm Hg for 72 hours.
89509292|NCT03491449|Active Comparator|Group B: Keep systolic pressure <185mmHg|Intensive management of blood pressure, maintaining systolic blood pressure <185 mm Hg for 72 hours.
89509293|NCT03491371|Experimental|osteosarcoma|all patients had been given apatinib alone
89509294|NCT03491371|Experimental|Ewing sarcoma|Some of patients had been given apatinib alone while some of them had been given apatinib+everolimus
89509295|NCT03491371|Experimental|soft tissue sarcoma|Some of the patients had been given apatinib alone while some of the patients had been given apatinib together with GT chemotherapy, which was gemcitabine 1000 mg/m2 d1,8 and docetaxel 75 mg/m2 d8 once every 21 day.
89509296|NCT03491371|Experimental|Chondrosarcoma|Patients were given apatinib alone
89509297|NCT03546829|Experimental|Arm 1 - Experimental|
89509298|NCT03546829|Active Comparator|Arm 2 - Control Arm|
89509299|NCT03493321|Experimental|PRF with MTA|PRF with MTA with PRF with Theracal as intervention
89509300|NCT03491293|Active Comparator|Behavioral Weight Loss + Text chat|Internet delivery of a behavioral weight control program via text in a group format facilitated by an experienced registered dietitian. Participants will have access to study materials including behavioral weight loss lessons on the study's website. Participants will weigh themselves daily and report their weight privately (data will only be accessible by research personnel) on the study website.
89509301|NCT03491293|Experimental|Behavioral Weight Loss + Video chat|Internet delivery of a behavioral weight control program via video in a group format facilitated by an experienced registered dietitian. Participants will have access to study materials including behavioral weight loss lessons on the study's website. Participants will be given smart scales to weigh daily, and weight will be transmitted to a secure website accessible only by research personnel.
89509302|NCT03497533|Experimental|TriCAR-T-CD19|Tri-functional anti-CD19 chimeric antigen receptor transduced autologous T cells will be administered intravenously
89509303|NCT03284047|Experimental|2.5 U dose|"Participants with more than 4 mm of upper anterior gingival exposure measured from the central incisor tooth will be randomly assigned (1:1:1) to receive different doses of botulinum toxin type A (abobotulinumtoxin A) on the levator labii superioris alaeque nasi as follows:~2.5 U~5 U~7.5 U"
89509304|NCT03284047|Experimental|5 U dose|"Participants with more than 4 mm of upper anterior gingival exposure measured from the central incisor tooth will be randomly assigned (1:1:1) to receive different doses of botulinum toxin type A (abobotulinumtoxin A) on the levator labii superioris alaeque nasi as follows:~2.5 U~5 U~7.5 U"
89509305|NCT03284047|Experimental|7.5 U dose|"Participants with more than 4 mm of upper anterior gingival exposure measured from the central incisor tooth will be randomly assigned (1:1:1) to receive different doses of botulinum toxin type A (abobotulinumtoxin A) on the levator labii superioris alaeque nasi as follows:~2.5 U~5 U~7.5 U"
89509306|NCT02321605|Experimental|BPS exercise|Intervention group which requires people to envision themselves in a future in which all has gone in the best possible way.
89509307|NCT02321605|Placebo Comparator|Daily Activities|Control group which consists of thinking and writing about all the activities and situations that had taken place during the last 24 h.
89509308|NCT03493243||Adolescents exposed|Only clinical questionnaires
89509309|NCT05046847|Experimental|TQB3811|The initial dose is 2.5mg, once a day (QD), and the medication stage is divided into single administration and continuous administration. The single administration is given once a day, and the continuous administration is entered 4 days after drug withdrawal. The drug is administered continuously until the disease progresses.
89509310|NCT02321683|Experimental|Bonemaster|Cement-less femoral stems with electrochemical deposition of hydroxyapatite
89509311|NCT02321683|Active Comparator|Hydroxyapatite|Cement-less femoral stems with plasmasprayed hydroxyapatite
89509312|NCT03493087|Active Comparator|Menakinon-7|Menakinon-7 360 µg tablet by mouth, every day for 6 weeks
89509313|NCT03493087|Active Comparator|Diet with vitamin K|Diet rich in vitamin K for 6 weeks
89509314|NCT03493009|Experimental|10mg Magnesium citrate|subjects will be required to follow a specific bowel preparation instruction consisting of dietary restrictions (no dried fruit, seeds or nuts) starting 5 days prior to the colonoscopy, an low residue diet at the day before the procedure, followed by a split dose of 10 mg of Magnesium citrate, followed by colonoscopy procedure with Pure-Vu System
89509315|NCT03493009|Experimental|15mg Magnesium citrate|subjects will be required to follow a specific bowel preparation instruction consisting of dietary restrictions (no dried fruit, seeds or nuts) starting 5 days prior to the colonoscopy, an low residue diet at the day before the procedure, followed by a split dose of 15 mg of Magnesium citrate, followed by colonoscopy procedure with Pure-Vu System
89509316|NCT03490747|Experimental|Co-developed referral scheme|A physical activity referral scheme co-developed by multidisciplinary stakeholders to incorporate behaviour change support and ensure pragmatic relevance and feasibility.
89509317|NCT03490747|Active Comparator|Usual care referral scheme|Comparative, usual care exercise referral scheme.
89509318|NCT03490747|No Intervention|No treatment control|Lifestyle advice leaflet only (provided to participants in all arms during baseline assessments).
89509319|NCT03497377|Experimental|18F-DCFPyL Injection & 18F-NaF|A bolus of ~9 mCi (333 MBq) of 18F-DCFPyL injected by slow IV push. A dose of 5 mCi 18F-NaF is injected through the IV and followed by at least 10 ml of saline to flush the IV line of the remaining dose
89509320|NCT03173521|Experimental|open label|"Adeno-associated viral vector serotype 8 with liver-specific thyroxine-binding globulin (TBG) promoter driving the expression of the human ARSB gene diluted in its final formulation medium [Drug product (DP) diluted in 0.9% saline solution and 0.25% of human serum albumin].~Four dose levels are available:~'Starting dose' is 6x1011 gc of vector per kg of body weight.~'High dose' is 2x1012 gc of vector per kg of body weight.~'Very high dose' is 6x1012 gc of vector per kg of body weight.~'Low dose' is 2x1011 gc of vector per kg of body weight. Intermediate doses are also possible. The administration of the IMP will be performed into a peripheral vein (e.g. median cubital vein) over 2-4 hours using an infusion pump. The IMP final volume to be injected is calculated based on the patient's weight (determined on the day of hospital admission), as 3 mL/kg."
89509321|NCT03136627|Experimental|Tivozanib (AV-951) plus Nivolumab|Tivozanib plus Nivolumab:Tivozanib will be administered once daily for 3 weeks followed by 1 week off. Nivolumab will be administered every 2 weeks starting on Day 1.
89206974|NCT05156463|No Intervention|Control|Participants will receive standard follow-up survivorship care, an accelerometer to measure physical activity and NCCN (National Comprehensive Cancer Network) patient materials.
89509322|NCT02922985|Placebo Comparator|Placebo Control Group|Patients will receive a placebo dose of all three study medications: Patients will receive the pre-operative dose of IV normal saline placebo within 30 minutes of going to the OR for CD. The patient will receive the subcutaneous infiltration of 20 mL of subcutaneous normal saline placebo after positioning and preparation but prior to skin incision. At the time of fascial closure, the patient will receive an IM dose of normal saline placebo.
89509323|NCT02922985|Active Comparator|Multimodal Pain Regimen Group|Patients will receive the actual study medication for all three study medications: Patients will receive the pre-operative dose of IV acetaminophen 1 g within 30 minutes of going to the OR for CD. The patient will receive the subcutaneous infiltration of either 20 mL of bupivacaine 0.25% after positioning and preparation but prior to skin incision. At the time of fascial closure, the patient will receive 60 mg of IM ketorolac.
89509324|NCT02765191|Experimental|Study group|Subjects investigated according to protocol after administration of bolus of Ringer's Acetate
89509325|NCT04881955|Experimental|[14C]-Ecopipam|Single oral capsule dose of 200 mg ecopipam HCl containing approximately 88.5 µCi of [14C]-ecopipam HCl
89509326|NCT03490591|Experimental|Robotic-assisted intervention|In the Robotic-assisted intervention :12 training sessions of Robot-assisted hand rehabilitation(60 minutes a time, 2 times a week)
89509327|NCT02234843|Experimental|BAY59-7939|Rivaroxaban (tablets and oral suspension) Dose: Age and body weight-adjusted dosing of rivaroxaban to achieve a similar exposure as that observed in adults treated for venous thromboembolism (VTE) with 20 mg rivaroxaban.
89509328|NCT02234843|Experimental|Standard of Care|Subcutaneous low molecular weight heparin (LMWH), subcutaneous fondaparinux and/or oral vitamin K antagonist (VKA) Dose : as per standard of care
89509329|NCT02740231|Active Comparator|Reference product|Hylan G-F 20
89509330|NCT02740231|Experimental|JTA-004 50 (2 ml)|Sodium hyaluronate, plasma proteins and clonidine
89509331|NCT02740231|Experimental|JTA-004 50 (4 ml)|Sodium hyaluronate, plasma proteins and clonidine
89509332|NCT02740231|Experimental|JTA-004 100 (2 ml)|Sodium hyaluronate, plasma proteins and clonidine
89509333|NCT02672215|Experimental|tailored group|Received a web-based computer-tailored intervention including personalized feedback and tips on how to reduce and/or interrupt workplace sitting.
89509334|NCT02672215|Active Comparator|generic group|Received a web-based intervention containing generic information and tips to reduce and/or interrupt workplace sitting.
89509335|NCT02672215|No Intervention|control group|A waitlist control condition and received the generic intervention after completing all measurements
89509336|NCT03492931|Experimental|Treatment arm|Single dose of ticagrelor based on age
89509337|NCT02234921|Experimental|DRibble Vaccine|Patients will receive cyclophosphamide 3 days prior to the first of 9 planned DRibble vaccine injections. Imiquimod will be applied following 6 injections. Patients will receive 2 HPV vaccinations (Human papillomavirus).
89509338|NCT02321761|Experimental|study group|"Dosage (mg) Day days 0-14 no drug will be given days 15-21 dosage is 100 mg days 22-28 dosage is 200mg days 29-42 dosage is 400mg days 43-56 dosage is 200mg~days 57-70 no drug will be given"
89509339|NCT03492853||patients with AMD|150 patients with age related macular degeneration more than 50 years old who will have retina photodocumented and genotyped for AMD SNP's
89509340|NCT03492853||control group|150 patients in control group without the clinical signs of the disease more than 50 years old who will have retina photodocumented and genotyped for AMD SNP's
89509341|NCT02234999|Experimental|3mg [14C]-CC-122 (Single Dose)|Single oral capsule of 3mg [14C]-CC-122. given as a suspension under fasting conditions on Day 1
89509342|NCT02235155||Pregnant women of 13-22 weeks gestation|Pregnant women of 13-22 weeks gestation will receive 200 mg mifepristone followed 24-48 hours later by 400 mcg sublingual misoprostol every three hours until complete expulsion.
89509343|NCT04674241|Active Comparator|DEX group|The DEX group will receives dexmedetomidine intraoperative.
89509344|NCT04674241|Placebo Comparator|Placebo group|The placebo group will receives 0.9% saline intraoperative.
89509345|NCT02259569|Experimental|PCV group|After insertion of I-gel, mechanical ventilation of the lungs was commenced. Mechanical ventilator was set to obtain a tidal volume of 8ml/kg in pressure-controlled mode.
89509346|NCT02259569|Active Comparator|VCV group|After insertion of I-gel, mechanical ventilation of the lungs was commenced. Mechanical ventilator was set to obtain a tidal volume of 8ml/kg in volume-controlled mode.
89509347|NCT04650295|Experimental|Household Remedy|
88958666|NCT01995864|No Intervention|Usual Care|The Usual Care group will receive mental health services as provided by the local mental health services clinic.
88958667|NCT01995877||Subjects scheduled for IVC filter placement|A filter may be needed to be placed in the IVC (inferior vena cava) to prevent blood clots from traveling from legs to lungs. Patients who have had a pelvic fracture, or have blood clots in the leg(s) may need an IVC. Filter placement may be ordered when a patient is scheduled for major surgery and extensive bed rest.
88958668|NCT01995890|Experimental|nepafenac|Nepafenac 0.1% eye drops, 3 times a day
88958669|NCT01995890|No Intervention|control|No intervention in the control arm
88958670|NCT01995903|Experimental|Amyotrophic lateral sclerosis|Clinical examination for ALS(amyotrophic lateral sclerosis) and subjects with lower motor neuron signs will be completed. These subjects will undergo MRI (magnetic resonance imaging) scans of the brain to assess neurological conditions.
88958671|NCT01995903|Active Comparator|Healthy controls (MRI)|These subjects will undergo MRI (magnetic resonance imaging) scans of the brain to compare against diseased subjects.
88958672|NCT01995916|Experimental|Mindfulness Intervention|Mindfulness Based Stress Reduction Intervention
88958673|NCT01995916|Active Comparator|Social Support Group|Social Support Group Intervention
88958674|NCT01995942||Group 1|Patients with mrEMVI positive rectal cancer
88958675|NCT01995942||Group 2|Patients with mrEMVI negative rectal cancer
88958676|NCT01995955|Experimental|a new non-invasive imaging technique|a new non-invasive imaging technique for evaluation of cardiac microciculation in coronary artery disease
89509348|NCT04650295|Placebo Comparator|Tap Water|
88958677|NCT01995968||SGA stillbirths (Cases)|Stillbirths, SGA births (below the 10th percentile of French customised birthweight curves), born in 2012-13, at or after 24 completed weeks of gestational age, without lethal congenital anomalies, to mothers residents in Isère, Savoie or Haute-Savoie
88958678|NCT01995968||SGA livebirths (Controls)|Livebirths, SGA births (below the 10th percentile of French customised birthweight curves), born in 2013, at or after 24 completed weeks of gestational age, without lethal congenital anomalies, to mothers residents in Isère, Savoie or Haute-Savoie
89509349|NCT02259647|Experimental|Sorafenib +intravenous infusion ofVit K1|Sorafenib 400mg twice daily + intravenous infusion ofVit K1 50 mg/day with daily increase of dose by 50 mg for 6 days, followed by oral Vitamin K1 20mg twice daily for 3month
89509350|NCT02259647|Active Comparator|Sorafenib+Placebo|Sorafenib 400 mg twice daily + Intravenousinfusion of placebo daily for 6 days, followed by oral placebo twice daily till 3month
89509351|NCT03490435||Study participants|Both healthy and ailing individuals, both sex, including adults and children.
89509352|NCT02321839|Experimental|Intraviteal Ranibizumab 0.5mg|Intraviteal Ranibizumab 0.5mg
89509353|NCT03490279|Experimental|A|Lactoferrin CRX 100 mg, capsule formulation, 2 tablets taken together once daily, on an empty stomach (before breakfast)
89509354|NCT03490279|Placebo Comparator|B|Placebo 100 mg, capsule formulation, 2 tablets taken together once daily, on an empty stomach (before breakfast)
89509355|NCT02750345|Experimental|Sequence TP 1 - TP 2 - Reference|Subjects will receive a single 10 mg tablet of Nitisinone (Test Product 1 (TP 1)) in treatment period 1, 10 mg tablet of Nitisinone Baked Tablet (Test Product 2 (TP 2)) in treatment period 2, and 10 mg hard capsule of Orfadin (Reference) in treatment period 3 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
89509356|NCT02750345|Experimental|Sequence TP 1 - Reference - TP 2|Subjects will receive a single 10 mg tablet of Nitisinone (Test Product 1) in treatment period 1, 10 mg hard capsule of Orfadin (Reference) in treatment period 2, and 10 mg tablet of Nitisinone Baked Tablet (Test Product 2) in treatment period 3 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
89509357|NCT02750345|Experimental|Sequence TP 2 - TP 1 - Reference|Subjects will receive a single 10 mg tablet of Nitisinone Baked Tablet (Test Product 2) in treatment period 1, 10 mg tablet of Nitisinone (Test Product 1) in treatment period 2, and 10 mg hard capsule of Orfadin (Reference) in treatment period 3 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
88958679|NCT01995981||Advanced soft tissue sarcoma patients|Advanced soft tissue sarcoma patients, who have an indication for pazopanib treatment.
88958680|NCT01995994||RT-CGM|
88958681|NCT01996007||Children|Pneumococcal nasopharyngeal carriage and immunogenicity in children aged 6-48 months who have previously received PCV13
88958682|NCT01996007||Parents|Pneumococcal nasopharyngeal carriage and immunogenicity in parents of children also participating in the study
88958683|NCT01996059|Experimental|Functional Jejunal Interposition|First, an end-to-side esophagojejunostomy was performed at 40 cm anal to Treitz's ligament. Then, an end-to-side duodenojejunostomy was created at the efferent limb 35 cm distal to the esophagojejunostomy, followed by a side-to-side jejunostomy at 5 cm distal to duodenojejunostomy and 20 cm distal to Treitz's ligament. Finally, 2 jejunal proper ligations were made at 5 cm oral to esophagojejunostomy and 2 cm distal to duodenojejunostomy.
88958684|NCT01996059|Active Comparator|Roux-en-Y|The distal end of the duodenum was closed. The jejunum was separated 15-20cm distal to the Treitz's ligament, and an end-to-side esophagojejunostomy was done at the distal side of the jejunum. Then, the continuity of the jejunum was reconstructed with side-to-end jejunojejunostomy at 40-45cm distal to esophagojejunostomy.
88958685|NCT01996072|Experimental|EC17 Injection Group|The group will receive a single dose of EC17, infused over 10 minutes, prior to surgery. Then, during surgery, the EC-17 will be imaged with a camera that the investigators have developed.
88958686|NCT01996085|Experimental|Hemodynamic group|"The treatment choice based on hemodynamic parameters established with ICG method.~Monotherapy or combined therapy in case of 1/ complex hemodynamic disturbances and/or 2/ office SBP ≥ 160 mm Hg and/or DBP ≥ 100 mmHg and/or 24-h mean SBP ≥ 140 mm Hg and/or 24-h mean DBP ≥ 90 mm Hg"
88958687|NCT01996085|Active Comparator|Empiric Group|"The treatment choice based on current guidelines (blinded to ICG).~Monotherapy or combined therapy in case of office SBP ≥ 160 mm Hg and/or DBP ≥ 100 mmHg and/or 24-h mean SBP ≥ 140 mm Hg and/or 24-h mean DBP ≥ 90 mm Hg"
88958688|NCT01996098|Experimental|6-month icotinib|Icotinib 125 mg three times daily (375 mg per day) by mouth for 6 months
88958689|NCT01996098|Experimental|12-month icotinib|Icotinib 125 mg three times daily (375 mg per day) by mouth for 12 months
88958690|NCT01996098|No Intervention|Chemotherapy alone|No intervention
88958691|NCT01996111|Experimental|• Group 2:|Injection of 1.0 cc of 10 mg/ml micrograft dHACM suspension
88958692|NCT01996111|Experimental|• Group 3:|Injection of 1.0 cc of 20 mg/ml micrograft dHACM suspension
88958693|NCT01996111|Experimental|• Group 4:|Injection of 1.0 cc of 40 mg/ml micrograft dHACM suspension
88958694|NCT01996111|Placebo Comparator|• Group 1|• Injection of 1.0 cc of 0.9% Saline
88958695|NCT01996124|Experimental|Indacaterol|Indacaterol Fumarate 150 mcg Breezehaler,Onbrez Novartis International AG, Basel Switzerland. Once daily.
88958696|NCT01996124|Placebo Comparator|Placebo|Placebo Breezehaler
88958697|NCT01996137|Experimental|VASST II|Stroke patients selected to undergo VASST II treadmill training for 60 minutes x15 sessions over 5 weeks Outcomes at week 0.3 6.12.24
88958698|NCT01996150|Experimental|Dilute bleach bath|Subjects will take a diluted bleach bath (0.005% Sodium hypochlorite) for 5-10 minutes twice a week for 12 weeks.
88958699|NCT01996163||Male|
88958700|NCT01996163||Female|
88958701|NCT01996176|Experimental|Intervention group|Intervention group
88958702|NCT01996176|Placebo Comparator|Intervention control|Control group
88958703|NCT01996189|Experimental|Insulin|Arterial puncture with an insulin syringe followed by arterial puncture with standard needle.
88958704|NCT01996189|Active Comparator|Standard|Arterial puncture with standard needle followed by arterial puncture with insulin syringe.
88958705|NCT01996202|Other|Resected Melanoma|Subjects with resected melanoma.
88958706|NCT01996202|Other|Unresected Melanoma|Subjects with unresected melanoma.
88958707|NCT01996215||AMD controls|
88958708|NCT01996215||AMD cases|
88958709|NCT01996228|Experimental|Cord Blood-derived multipotent stem cells|Human cord blood-derived multipotent stem cells (CB-SC) display unique phenotypes, such as the expression of embryonic stem (ES) cell markers, multipotential of differentiations, very low immunogenecity, and immune modulations in patients.
88958710|NCT01996280|Placebo Comparator|Motivational Interviewing|The MI is a single brief motivational intervention lasting 1.5 hours that includes MI structured strategies tailored to the patient's readiness to change such as: the Typical Day exercise, the use of personal feedback reports (e.g., normative feedback about their drinking), discussions about the pros and cons of use, and completion of a change plan. The MI is designed to follow MI principles of invoking autonomy and emphasizing collaboration with the interventionist.
88958711|NCT01996280|Experimental|Culturally Tailored MI|The CTMI is a single brief motivational interview lasting 1.5 hours. It follows the same sequence of structured strategies as the MI, but the focus of the components is different. CTMI has augmented some of the components with culturally relevant material, including discussion about acculturation stress. The CTMI components are culturally tailored to address relevant concerns and issues. There are also culturally tailored feedback elements in the CTMI, such as ethnic normative feedback about drinking. To control for time across conditions, interventionists are instructed to select CTMI components based on participant interests, not the entire array of components.
88958712|NCT01996306|Active Comparator|FOLFIRI +/- Bevacizumab|Bevacizumab 5 mg/kg IV 90-30 min Day 1 CPT-11 180 mg/m2 (150 mg/m2) IV 90 min Day 1 l-LV (dl-LV) 200 mg/m2 (400 mg/m2) IV 120 min Day 1 5-FU - bolus 400 mg/m2 IV bolus Day 1 5-FU - infusional 2400 mg/m2 IV continuous (46 hours) Day 1 - 3
88958713|NCT01996306|Experimental|XELIRI +/- Bevacizumab|Bevacizumab 7.5 mg/kg IV 90-30 min Day 1 CPT-11 200 mg/m2 (150 mg/m2) IV 90 min Day 1 Capecitabine 800 mg/m2 p.o. twice daily 14 Days consecutively
88958714|NCT01996345|Experimental|Cervical Pessary Placement|For the patients assigned to receive a cervical pessary, they will be evaluated and fitted for a pessary by the physician within 3-4 days unless exclusion criteria develop. After it is placed she will be evaluated for comfort. She will be asked to leave it in at all times but informed that removal and withdrawal from the study is always her option.
89540393|NCT06211855||low-risk pregnant women|The control group included low-risk pregnant women who did not have polyhydramnios. Women who had chromosomal or anatomical abnormalities, multiple pregnancies, oligohydramnios (AFI 5 cm), severe polyhydramnios, fetal growth restriction, elective cesarean section (CS), pre-existing conditions (hypertension, diabetes, thrombophilia), or obstetric complications (gestational hypertension, preeclampsia, gestational diabetes) were excluded.
89540394|NCT06211816|Other|Nurse prior to intervention|
89540395|NCT06211803||J-PET group|The patient is referred for a PET/CT scan, in accordance with recognized indications for examining the brain or the entire body.
89540396|NCT06211790|Experimental|FuDan-GP1 subtype|FuDan-GP1 subtype is targeted sensitive type. Treatment regimen：anlotinib 12 mg PO, QD, 14 days on - 7 days off.
89540397|NCT06211790|Experimental|FuDan-GP2 subtype|FuDan-GP2 subtype is Cold tumor type. Treatment regimen：anlotinib 12 mg PO, QD, 14 days on - 7 days off combined with everolimus 5 mg PO, QD.
89540398|NCT06211790|Experimental|FuDan-GP3 subtype|FuDan-GP3 subtype is progenitor infiltrating type. Treatment regimen：anlotinib 12 mg PO, QD, 14 days on - 7 days off combined with tislelizumab 200 mg, IV, Q3W.
89540399|NCT06211751|Experimental|TQB3909 tablets+ TQB3702 tablets|TQB3909 tablets combined with TQB3702 tablets, administered orally, 28 days as a treatment cycle.
89540400|NCT06211725||neurovascular patients|
89540401|NCT06211712|Experimental|Human Urinary Kallidinogenase|
89540402|NCT06211712|Placebo Comparator|Placebo|
89540403|NCT06211699|Active Comparator|Omentopexy with Laparoscopic Sleeve Gastrectomy|Patients who underwent continuous through-and-through omentopexy of the omentum to the remnant stomach staple line after resection during Laparoscopic Sleeve Gastrectomy (omentopexy group).
89540404|NCT06211699|Active Comparator|Clips with Laparoscopic Sleeve Gastrectomy|Patients who underwent consecutive clippping along the staple line of the remnant stomach during Laparoscopic Sleeve Gastrectomy (clips group)
88958715|NCT01996345|No Intervention|Expectant Managment|Each participant will have standard care for placenta previa. This is the same care that a patient with a placenta previa would ordinarily receive even if she were not participating in the trial. The trial's participating investigators agree that the management outlined in this section is standard management for placenta previa.
88958716|NCT01996358|Active Comparator|Succinylcholine|Succinylcholine 0,5mg/kg as muscle relaxant during induction of anaesthesia for rigid bronchoscopy
88958717|NCT01996358|Active Comparator|Rocuronium 0,3|Rocuronium 0,3 mg/kg during induction of anaesthesia for rigid bronchoscopy. At the end of procedure 2mg/kg sugammadex for reversal of neuromuscular block are applied.
88958718|NCT01996358|Active Comparator|Rocuronium 0,6|Rocuronium 0,6 mg/kg during induction of anaesthesia for rigid bronchoscopy. At the end of procedure 2mg/kg sugammadex for reversal of neuromuscular block are applied.
88958719|NCT01996384|Experimental|Classical Acupuncture + Lidocaine|Study participants will attend 18 classical acupuncture sessions, twice a week for Weeks 1-6, and once a week for Weeks 7-12. A standardized acupuncture treatment will be assigned with classical acupuncture points and may or may not be stimulated with electroacupuncture. Very thin needles (0.18mm) will be inserted into locations either on the front or the back of the body and may be placed near or far from the affected area based on up to three Traditional Chinese Medicine Diagnosis categories. Study participants will also be asked to gently apply 5% lidocaine cream four times daily (breakfast, lunch, dinner, and before bed).
88958720|NCT01996384|Active Comparator|Non-classical acupuncture + lidocaine|Study participants will attend 18 non-classical acupuncture sessions, twice a week for Weeks 1-6, and once a week for Weeks 7-12. A standardized acupuncture treatment will be assigned with non-classical acupuncture points and may or may not be stimulated with electroacupuncture. Very thin needles (0.18mm) will be inserted into locations either on the front or the back of the body and may be placed near or far from the affected area. Study participants will also be asked to gently apply 5% lidocaine cream four times daily (breakfast, lunch, dinner, and before bed).
88958721|NCT01996397|Other|CRT implantation|Standard CRT indication. Assessment of acute response to CRT.
89540405|NCT06211686|Experimental|Protein supplement and Resistance exercise|
89540406|NCT06211647|Experimental|[177Lu]Lu-XT117 dose escalation|
89540407|NCT06211634|Experimental|Single or Multiple ascending dose of HMB-001|Open-label, single or multiple ascending dose of HMB-001
89540408|NCT06211608||Arm 1|Polycystic ovary syndrome (PCOS)
89540409|NCT06211608||Arm 2|Hypothalamic-pituitary-ovarian axis dysfunction (HPOD)
89540410|NCT06211595|Experimental|The treament of DragonFire Transcatheter myocardial ablation system|If drug therapy does not work or drug side effects are not tolerated, transaortic interventional surgery can be evaluated
89540411|NCT06211582|Experimental|Cention N (Ivoclar Vivadent, Schaan, Liechtenstein)|Powder: Calcium-fluoro-silicate glass, barium glass, calcium-barium-aluminium fluoro-silicate glass, iso-fillers, ytterbium trifluoride, initiators and pigments. Liquid: Dimethacrylates, initiators, stabilizers, additives and mint flavour. The mixing ratio was 2 parts powder and 2 drops of liquid or 3 parts powder and 3 drops.After distributing the powder and liquid side by side on a mixing pad, the liquid was spread to expand the surface.The first part of the powder was mixed with the entire liquid dispensed on the mixing pad.After the components have been thoroughly mixed, add the remaining powder and stirred again until a homogeneous consistency is obtained (45 - 60 seconds). After careful adaptation to the cavity and densification, occlusal excesses were removed.
89540412|NCT06211582|Experimental|Equia Forte HT ( GC, Tokyo, Japan)|"Powder: 95% strontium fluoroalumino-silicate glass. Liquid: 5% polyacrilic acid.~Equia Forte HT was mixed in a capsule (10 seconds) and injected into the cavity. After a 2.5 min curing time, occlusal excesses were removed. Equia Coat (GC, Tokyo, Japan) was then applied and light-cured (D-Light Pro, GC, Tokyo, Japan 1,400 mW/cm2) for 20 seconds."
88958722|NCT01996423|Experimental|Vitamin D3 supplementation|Subjects in the experimental arm will receive weekly vitamin D3 doses in oral suspension during 6 weeks. Weekly dose varies according to age group: VD3 8000 IU between ages 2-5.9 years, VD3 12000 IU between ages 6-11.9 years, VD3 16000 IU between ages 12-17.9 years.
88958723|NCT01996423|Placebo Comparator|Placebo|Subjects in the placebo arm will receive weekly placebo oral suspension during 6 weeks.
88958724|NCT01996462|Experimental|Torrent's of Escitalopram Oxalate Tablet 20 mg|
88958725|NCT01996475|Experimental|Torrent's of Escitalopram Oxalate Tablet 20 mg|
88958726|NCT01996488|Experimental|Torrent's Olanzapine Orally Disintegrating Tablets 5mg|
88958727|NCT01996501|Experimental|Torrent's Olanzapine Orally Disintegrating Tablets 5mg|
88958728|NCT01996514|Experimental|Sweetener, non-food advertisements|non-caloric sweetener with water followed by TV program with non-food advertisements while feeding at 30 min
89509358|NCT02750345|Experimental|Sequence TP 2 - Reference - TP 1|Subjects will receive a single 10 mg tablet of Nitisinone Baked Tablet (Test Product 2) in treatment period 1, 10 mg hard capsule of Orfadin (Reference) in treatment period 2, and 10 mg tablet of Nitisinone (Test Product 1) in treatment period 3, and under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
88958729|NCT01996514|Experimental|Glucose, non-food advertisements|Glucose with water followed by TV program with non-food advertisements while feeding at 30 min
89509359|NCT02750345|Experimental|Sequence Reference - TP 1 - TP 2|Subjects will receive a single 10 mg hard capsule of Orfadin (Reference) in treatment period 1, 10 mg tablet of Nitisinone (Test Product 1) in treatment period 2, and 10 mg tablet of Nitisinone Baked Tablet (Test Product 2) in treatment period 3 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
89509360|NCT02750345|Experimental|Sequence Reference - TP 2 - TP 1|Subjects will receive a single 10 mg hard capsule of Orfadin (Reference) in treatment period 1, 10 mg tablet of Nitisinone Baked Tablet (Test Product 2) in treatment period 2, and 10 mg tablet of Nitisinone (Test Product 1) in treatment period 3, and under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
89509361|NCT02640625|Experimental|Probiotic compound|Lactobacillus rhamnosus GG, Lactobacillus acidophilus, Lactobacillus bulgaricus, Bifidobacterium animalis subsp. lactis, and Streptococcus thermophilus.
89509362|NCT01329263|Experimental|Nonmenthol|Participants switch from menthol to non-menthol cigarettes.
89509363|NCT01329263|No Intervention|Menthol|Participants smoke own brand of menthol cigarettes.
89509364|NCT02474329||Cohort 1|"Dutch Parkinson's patients resident in the region of Noord-Holland whose fulfill the eligibility criteria.~Interventions/Exposures to be administered:~PPMI (Parkinson's Progression Markers Initiative) protocol Trained physiotherapists will perform once a standardized clinical assessment to every included patient. This assessment will last for 60 minutes, and it will be done once.~Fox Insight self-monitoring android app and falls detector Patients will wear a smartwatch and a pendant movement sensor during day and night, for a period of 13 weeks. Additionally, a self-monitoring App on a Smartphone is used, where the patient reports when (s)he takes any PD medication. An additional, optional button allows the patient to report general feeling."
89509365|NCT02474329||Cohort 2|"Dutch Parkinson's patients resident in the region of Zuid-Holland whose fulfill the eligibility criteria.~Interventions/Exposures to be administered:~PPMI (Parkinson's Progression Markers Initiative) protocol Trained physiotherapists will perform once a standardized clinical assessment to every included patient. This assessment will last for 60 minutes, and it will be done once.~Fox Insight self-monitoring android app and falls detector Patients will wear a smartwatch and a pendant movement sensor during day and night, for a period of 13 weeks. Additionally, a self-monitoring App on a Smartphone is used, where the patient reports when (s)he takes any PD medication. An additional, optional button allows the patient to report general feeling."
89519402|NCT03823001|Experimental|Virtual prostate biopsy (VB) monitoring|"Prostate-specific antigen (PSA) and digital rectal exam (DRE) are standard of care for monitoring patients on active surveillance or at risk of having low-risk prostate cancer. A novel virtual biopsy (VB) monitoring protocol will be implemented:~PSA bi-annually or more often according to the discretion of the urologist.~Annual DRE.~Visit with the urologist bi-annually.~Multi-parametric MRI (mpMRI) every year for 3 years.~Transrectal ultrasound (TRUS) biopsy at the end of the 3rd year."
88958730|NCT01996514|Experimental|Sweetener, food advertisements|non-caloric sweetener with water followed by TV program with food advertisements while feeding at 30 min
88958731|NCT01996514|Experimental|Glucose, food advertisements|Glucose with water followed by TV program with food advertisements while feeding at 30 min
88958732|NCT01996527|Experimental|3-Tesla magnetic resonance imaging|Patients undergo 3-Tesla magnetic resonance imaging to measure tumor protein content (using CEST-MRI), cellularity (using DW-MRI), and blood flow (using DCE-MRI and DSC-MRI with IV administration of gadolinium-containing contrast agent) no more than 2 weeks before, and 2 and 4 weeks after, the initiation of treatment.
88958733|NCT01996540|Experimental|Interventional arm|Interventional arm
88958734|NCT01996540|No Intervention|Standard arm|Standard arm
88958735|NCT01996553||Transradial cardiac catheterization|Patients undergoing cardiac catheterization through the radial artery.
88958736|NCT01996579|Experimental|Lactoferrin|Patients randomized to the Lactoferrin arm will receive Lactoferrin delivered to the oral cavity as a mouth swab and Lactoferrin down a nasogastric tube; a total of 2 grams administered in 4 divided doses per day.
88958737|NCT01996579|Placebo Comparator|Placebo (sterile water)|Placebo (sterile water) will also be delivered down the nasogastric tube; administered in 4 divided doses per day.
88958738|NCT01996618|Experimental|Ranolazine|Subjects will be consented by the study investigator and then randomly assigned in an allocation-concealed fashion to double blinded treatment with either titrated doses of ranolazine or matched placebo. After the initial 6 days of treatment with ranolazine, 500 mg twice daily or matched placebo, subjects will undergo repeat 24 hour electrocardiographic monitoring. If tolerated, the subjects will then have their study medication increased (Ranolazine 1,000 mg twice daily or matching placebo) with the plan to then undergo a repeat 24 hour ambulatory electrocardiographic monitoring in 6 days. When the subject returns the monitor, subjects will enter the washout period (cessation of the study medication) for 6 days and have electrocardiographic monitoring prior to return to the subject's referring provider for care.
89509366|NCT02474329||Cohort 3|"Dutch Parkinson's patients resident in the region of Gelderland and Utrecht whose fulfill the eligibility criteria.~Interventions/Exposures to be administered:~PPMI (Parkinson's Progression Markers Initiative) protocol Trained physiotherapists will perform once a standardized clinical assessment to every included patient. This assessment will last for 60 minutes, and it will be done once.~Fox Insight self-monitoring android app and falls detector Patients will wear a smartwatch and a pendant movement sensor during day and night, for a period of 13 weeks. Additionally, a self-monitoring App on a Smartphone is used, where the patient reports when (s)he takes any PD medication. An additional, optional button allows the patient to report general feeling."
89509367|NCT02474329||Cohort 4|"Dutch Parkinson's patients resident in the region of Groningen, Friesland, Drenthe and Overijssel whose fulfill the eligibility criteria.~Interventions/Exposures to be administered:~PPMI (Parkinson's Progression Markers Initiative) protocol Trained physiotherapists will perform once a standardized clinical assessment to every included patient. This assessment will last for 60 minutes, and it will be done once.~Fox Insight self-monitoring android app and falls detector Patients will wear a smartwatch and a pendant movement sensor during day and night, for a period of 13 weeks. Additionally, a self-monitoring App on a Smartphone is used, where the patient reports when (s)he takes any PD medication. An additional, optional button allows the patient to report general feeling."
89509368|NCT02474329||Cohort 5|"Dutch Parkinson's patients resident in the region of Zeeland, Noord-Brabant and Limburg whose fulfill the eligibility criteria.~Interventions/Exposures to be administered:~PPMI (Parkinson's Progression Markers Initiative) protocol Trained physiotherapists will perform once a standardized clinical assessment to every included patient. This assessment will last for 60 minutes, and it will be done once.~Fox Insight self-monitoring android app and falls detector Patients will wear a smartwatch and a pendant movement sensor during day and night, for a period of 13 weeks. Additionally, a self-monitoring App on a Smartphone is used, where the patient reports when (s)he takes any PD medication. An additional, optional button allows the patient to report general feeling."
89509369|NCT04392869|Experimental|CRAFT group|This arm will instruct the students on an adapted and extended version of the CRAFT program. This is a mindfulness based program which is a systematic combination of practices derived from ancient philosophies, such as yoga and Buddhism, in conjunction with more recent disciplines such as mindfulness, emotional intelligence and positive psychology. The contents are structured along in five consecutive modules aimed at cultivating and enhancing consciousness, relaxation and regulation, attention, bliss and transcendence.
89509370|NCT04392869|Experimental|MBSR group|This arm will instruct the students on an adapted and extended version of the Mindfulness-Based Stress Reduction (MBSR) program. The MBSR is a secular, evidence-based practice originally developed for chronic pain, but which has reported positive results among an array of clinical and nonclinical populations. This program aims to cultivate non-judgmental attention to and awareness of present moment experience while promoting stress reduction.
89509371|NCT04392869|No Intervention|No intervention group|This group does not receive any instruction. The aim of this arm is to determine if there are any differences in outcomes between the two groups that receive intervention and this one.
89509372|NCT03490123|Experimental|Intervention|"Repeated total community treatment, TCT with study drug: Azithromycin tablets, 30mg/Kg (maximum 2g), a single dose every 6 months, for 12 months (3 doses).~Study interventions are:~R1-Total community treatment with azithromycin, R2-Total community treatment with azithromycin, R3-Total community treatment with azithromycin."
89509373|NCT03490123|Active Comparator|Control|"Single total community treatment, TCT, with study drug: Azithromycin tablets, 30mg/Kg (maximum 2g), a single, at month 0 (1 dose); followed by two total targeted treatment, TTT, with study drug: Azithromycin tablets, 30mg/Kg (maximum 2g), a single, at months 6 and 12.~Study interventions are:~R1-Total community treatment with azithromycin, R2-Total targeted treatment with azithromycin, R3-Total targeted treatment with azithromycin."
89509374|NCT02235233|Experimental|Patients with NASH|Each subject will be injected with ~2.5 mCi of Technetium Tc 99M Mebrofenin
89509375|NCT02235233|Active Comparator|Healthy Normal Volunteers|Each subject will be injected with ~2.5 mCi of Technetium Tc 99M Mebrofenin
89509376|NCT02235389||Administration of thrombolytic treatment with PHARAOH|Pre-Hospital Alteplase Remote Advice of Hospital (PHARAOH)
89509377|NCT02235389||Standard therapy with thrombolytic treatment in Hospital|
89509378|NCT02235467|Active Comparator|ABA parent training|Applied Behavior Analysis parent training using videomodeling in 21 sessions
89509379|NCT02235467|No Intervention|ABA parent training control|
89509380|NCT03489967|Active Comparator|16g of carbohydrates - Glucose levels < 3.0 mmol/L|Hypoglycemia treatment with 16g of carbohydrates will be given when glucose levels are below 3.0 mmol/L.
89509381|NCT03489967|Active Comparator|16g of carbohydrates - Glucose levels 3.0-3.5 mmol/L|Hypoglycemia treatment with 16g of carbohydrates will be given when glucose levels are between 3.0 and 3.5 mmol/L.
89509382|NCT03489967|Active Comparator|32g of carbohydrates - Glucose levels < 3.0 mmol/L|Hypoglycemia treatment with 32g of carbohydrates will be given when glucose levels are below 3.0 mmol/L
89509383|NCT03489967|Active Comparator|32g of carbohydrates - Glucose levels 3.0-3.5 mmol/L|Hypoglycemia treatment with 32g of carbohydrates will be given when glucose levels are between 3.0 and 3.5 mmol/L.
89509384|NCT02235545||St. Jude Medical Optisure Lead|Patients implanted with St. Jude Medical Optisure Lead
89509385|NCT03489889|Experimental|capsule|pharmaceutical form: capsule ursodeoxycholic acid 300 mg 13-15mg/kg day 3 months
89509386|NCT03489889|Experimental|tablet|pharmaceutical form: tablet ursodeoxycholic acid 300 mg 13-15mg/kg day 3 months
89509387|NCT02235779|Other|Cryobiopsy|
89519403|NCT04760041|Active Comparator|nebulized midazolam group|36 children will receive nebulized midazolam 0.2 mg/kg in 3 ml normal saline plus 5 ml clear juice 30 min before undergoing general anesthesia
89024081|NCT03650764|Experimental|Phase I: Ramucirumab + Pembrolizumab|-Ramucirumab will be administered IV over 1 hour on Day 1 of each 21-day cycle. Pembrolizumab will be administered as per standard of care (IV at a dose of 200 mg over 30 minutes on Day 1 of each 21-day cycle). On Day 1, pembrolizumab will be given after ramucirumab.
89024082|NCT03650764|Experimental|Phase II: Ramucirumab + Pembrolizumab|-Patients will be treated with ramucirumab at the RP2D on Day 1 and SOC pembrolizumab (200 mg IV over 30 minutes) on Day 1 of each 21-day cycle.
89509388|NCT04062383|Experimental|Positive Psychology + Motivational Interviewing|Participants will complete weekly positive psychology exercises and will systematically set goals related to physical activity. Study trainers will review the positive psychology exercises on the phone each week and will use motivational interviewing techniques to facilitate goal setting.
89509389|NCT01388491|Experimental|Treatment I: (DR-102)|21 days of combination active pills (containing 150 mcg desogestrel [DSG]/20 mcg ethinyl estradiol [EE]), followed by 7 days of 10 mcg EE, taken orally for 6 consecutive 28-day cycles
89509390|NCT01388491|Active Comparator|Treatment II|21 days combination active pills (containing 150 mcg DSG/20 mcg EE), taken orally and followed by 7 days of no treatment for a total of 6 consecutive 28-day cycles
89509391|NCT02235935||diabetic patients, hyperbaric chamber, diabetic retinopathy|
89509392|NCT02236091||Inpatients|
89509393|NCT02236169|Experimental|Ipratropium bromide|
89509394|NCT02236169|Active Comparator|ATROVENT|
89509395|NCT01352533|Active Comparator|Running polypropylene closure|Half of every linear wound will be closed with running polypropylene sutures. This technique is Standard of Care.
89509396|NCT01352533|Experimental|Tissue Adhesive (Derma-Bond)|The experimental half of the wound will be randomized to receive closure with tissue adhesive alone.
89509397|NCT01352533|Experimental|Subcuticular polyglactin-910 combined with tissue adhesive|The experimental half of the wound will be randomized to receive closure with running subcuticular polyglactin-910 combined with tissue adhesive.
89509398|NCT05101057||Treated|Patients who underwent ACDF surgery and who received post surgical therapy with the SpinalogicTM Non-Invasive Bone Graft Stimulation Device.
89509399|NCT05101057||Control|Patients who underwent ACDF surgery and did not receive post surgical Bone Graft Stimulation.
89509400|NCT03492697|Experimental|PF-06882961|
89509401|NCT02236247|Experimental|ivabradine|I(f) inhibitor, heart rate controller
89509402|NCT02236247|Placebo Comparator|placebo|placebo pill will be administered orally twice daily
89509403|NCT03492619|Active Comparator|Non-Intensive Intervention|Three short group sessions that promote healthy lifestyles
89509404|NCT03492619|Experimental|Intensive Intervention|a) Individual level: a six-month intervention comprised of 12 two-hour sessions, three follow-up monthly sessions, two workshops with the participants' household members and community members and one final session that will be graduation day; b) Household level: 2 workshops about co-responsibility in the household, and self-care and nutrition, including a theater performance. Six assignments with household members' participation; c) Community level: Distribution of 2 different educational materials (one about co-responsibility and another about self-care, including healthy nutrition) and carry out the 2 workshops mentioned above, both with household and community members.
89509405|NCT03796481||Cases|People with chronic spinal pain (i.e. chronic low back pain or chronic neck pain) with comorbid insomnia
89509406|NCT03796481||Controls|People with chronic spinal pain (i.e. chronic low back pain or chronic neck pain) without comorbid insomnia
89509407|NCT03755219||StdPPM|"Standard pure polypropylene mesh.~Standard is defined in SHR by weight ≥ 50 g/square meter."
89509408|NCT03755219||LWM|"Lightweight mesh: Either a pure polypropylene mesh, or a polypropylene-based composite mesh.~The study uses SHR's classification of light-weight = <50 g/square meter."
89509409|NCT03755219||Tacks, metal|Metal staples or tacks. Material specification of staples/tacks was introduced in SHR 2012.
89509410|NCT03755219||Tacks, absorbable|Absorbable synthetic staples or tacks. Material specification of staples/tacks was introduced in SHR 2012.
89509411|NCT03755219||Tacks, uncategorized|"Staples or tacks were in SHR 2005-2011 not further categorized.~This category also includes staples/tacks registered from 2012 and forth, not being specified as either metal or absorbable."
89509412|NCT03755219||Fibrin glue|Biologic glue/sealant produced from human donor blood
89509413|NCT03755219||Non-fixation|Mesh is deployed without fixation
89509414|NCT03755219||3D Mesh|Mesh categorized by anatomical shaped, rather than material or weight. Therefore, this category will be excluded in the original study. Depending on the volume of casess found, the 3D mesh category may eventually be analyzed separately in another study..
89509415|NCT03492541|Experimental|SYSTANE Complete|Propylene glycol-based eye drops, 1 drop in each eye twice a day (BID) (morning and evening) for 28 days. Patients can administer additional doses in between the scheduled daily doses as needed
89509416|NCT03492385|Experimental|1: 100 mg PB2452 or Placebo (no Ticagrelor)|PB2452 Infusion or Placebo - Sodium Chloride
89509417|NCT03492385|Experimental|2: 300 mg PB2452 or Placebo (no Ticagrelor)|PB2452 Infusion or Placebo - Sodium Chloride
89509418|NCT03492385|Experimental|3: 1000 mg PB2452 or Placebo (no Ticagrelor)|PB2452 Infusion or Placebo - Sodium Chloride
89509419|NCT03492385|Experimental|4: 1000 mg PB2452 or Placebo (Ticagrelor Pre-Trx)|PB2452 Infusion or Placebo - Sodium Chloride With Ticagrelor Oral Tablet: 180 mg+90 mg BID for a total of 5 doses
89509420|NCT03492385|Experimental|5: 3000 mg PB2452 or Placebo (Ticagrelor Pre-Trx)|PB2452 Infusion or Placebo - Sodium Chloride with Ticagrelor Oral Tablet: 180 mg+90 mg BID for a total of 5 doses
89509421|NCT03492385|Experimental|6: 9000 mg PB2452 or Placebo (Ticagrelor Pre-Trx)|PB2452 Infusion or Placebo - Sodium Chloride with Ticagrelor Oral Tablet: 180 mg+90 mg BID for a total of 5 doses
89509422|NCT03492385|Experimental|7: 18000 mg PB2452 or Placebo (Ticagrelor Pre-Trx)|PB2452 Infusion or Placebo - Sodium Chloride with Ticagrelor Oral Tablet: 180 mg+90 mg BID for a total of 5 doses
89509423|NCT03492385|Experimental|8: Dose TBD mg PB2452 or Placebo (Ticagrelor Pre-Trx)|PB2452 Infusion or Placebo - Sodium Chloride with Ticagrelor Oral Tablet: 180 mg+90 mg BID for 5 doses
89509424|NCT03492385|Experimental|9: Dose TBD mg PB2452 or Placebo (Ticagrelor Pre and Post-Trx)|PB2452 Infusion or Placebo - Sodium Chloride with Ticagrelor Oral Tablet: 180 mg+90 mg BID for 5 doses and 180 mg 24 hours post-dose
89509425|NCT03492385|Experimental|10: Dose TBD mg PB2452 or Placebo (Ticagrelor Pre-Txt)|PB2452 Infusion or Placebo - Sodium Chloride with Ticagrelor Oral Tablet: 180 mg+90 mg BID for 5 doses
89509426|NCT03736265|Experimental|Carvedilol+ Nucleos(t)ide Analogues|Based on nucleoside analogue (NUCs), carvedilol will added to the patients. Carvedilol is started at a dose of 6.25 mg once daily. After 1 week, this will increased to a dose of 12.5 mg once daily. Target dose of 12.5 mg once daily will be maintained if systolic blood pressure does not fall below 90 mm Hg and HR 50 beats per minute.
88958739|NCT01996618|Placebo Comparator|Placebo|Subjects will be consented by the study investigator and then randomly assigned in an allocation-concealed fashion to double-blinded treatment with either titrated doses of ranolazine or matched placebo. After the initial 6 days of treatment with ranolazine, 500 mg twice daily or matched placebo, subjects will undergo repeat 24 hour electrocardiographic monitoring. If tolerated, the subjects will then have their study medication increased (Ranolazine 1,000 mg twice daily or matching placebo) with the plan to then undergo a repeat 24-hour ambulatory electrocardiographic monitoring in 6 days. When the subject returns the monitor, subjects will enter the washout period (cessation of the study medication) for 6 days and have electrocardiographic monitoring prior to return to the subject's referring provider for care.
88958740|NCT01996670||<2h group|
88958741|NCT01996670||2-4h group|
89509427|NCT03736265|No Intervention|Nucleos(t)ide Analogues|Continuing take nucleoside analogue (NUCs) including lamivudine (LAM), adefovir dipivoxil (ADV), entecavir (ETV), telbivudine (TBV), tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF).
88958742|NCT01996670||>4h group|
88958743|NCT01996683|Active Comparator|iron chelation|Included 25 thalassemia patients with low serum ferritin (< 500) or downward ferritin trend inspite of reduction of chelation dose over the last 6 months. They will continue their chelation therapy.
88958744|NCT01996683|Placebo Comparator|blood transfusion only|Included 25 thalassemia patients with low serum ferritin (< 500) or downward ferritin trend inspite of reduction of chelation dose over the last 6 months. They will be subjected to discontinuation of their chelation therapy.
88958745|NCT01996735|Active Comparator|Ticagrelor 180 mg single dose|Ticagrelor 180 mg single dose
88958746|NCT01996735|Placebo Comparator|Placebo|Placebo single dose
88958747|NCT01996761|Experimental|Study Group 1|Study Group 1: 30ml Cerebrolysin
88958748|NCT01996761|Placebo Comparator|Study Group 2|Study Group 2: Placebo (0.9% NaCl)
88958749|NCT01996774||Child, peanut/ nut allergy, no treatment|
88958750|NCT01996774||Child, peanut/nut allergy, tolerance|
88958751|NCT01996774||Non allergic child, without atopia|
88958752|NCT01996787|Active Comparator|Air Optix Aqua|Compare safety and efficacy of the lens using OptiFree Replenish solution
88958753|NCT01996787|Active Comparator|Clariti with Handling Tint|Compare safety and efficacy of the lens using OptiFree Replenish solution
88958754|NCT01996800|Experimental|Spinal Manipulative Therapy (SMT)|Patients will receive 12 weeks of chiropractic SMT
88958755|NCT01996800|Active Comparator|SMT and Neuromuscular Reeducation|"Spinal manipulation is a therapeutic intervention performed on spinal articulations which are synovial joints. These articulations in the spine that are amenable to spinal manipulative therapy include the z-joints, the atlanto-occipital, atlanto-axial, lumbosacral, sacroiliac, costotransverse and costovertebral joints.~A neuromuscular re-education program will consist of repetitive movements, posturing, and stimulation designed to reinforce nerve signals for functional movements. It is theorized that when the nerve signals are retrained and appropriate muscle movements are repeated, movement patterns become automatic again. Neuromuscular re-education is usually done along with other types of treatment to promote functional muscle movement."
89509428|NCT04939363|Experimental|combination of Ibrutinib, Venetoclax and Obinutuzumab|"Obinutuzumab intravenous infusion:~Cycles 1: Day 1: Obinutuzumab 100 mg Day 1 (or 2): Obinutuzumab 900 mg Day 8: Obinutuzumab 1000 mg Day 15: Obinutuzumab 1000 mg Cycles 2-6: Day 1: Obinutuzumab 1000 mg The first infusion of Obinutuzumab may be administered at the full dose (1000 mg) on day 1 of cycle 1, if the infusion of a test-dosage of 100 mg is well tolerated by the patient. Alternatively, if the first 100 mg infusion on day 1 is not well tolerated, the remaining 900 mg of the first dose should be administered on day 2.~Ibrutinib PO 560mg daily starting on cycle 1 day 1 for 12 cycles.~Venetoclax with an accelerated ramp-up and close inpatient TLS monitoring starts on cycle 1 day 15 to the target dose of 400mg daily for a total of 12 cycles:~Cycle 1: Day 15: Venetoclax 20 mg Days 16-17: Venetoclax 50 mg Days 18-21: Venetoclax 100 mg Days: 22-28: Venetoclax 200 mg Cycles 2-12: Days 1-28: Venetoclax 400 mg"
89509429|NCT03625427|Placebo Comparator|Placebo|The placebo is olive oil, stripped of polyphenols, 70% oleic acid, and will be administered at two 1 gram capsules per day for twelve weeks. The doses will be administered in single serve packets containing two capsules for each daily dose to be taken at breakfast.
89509430|NCT03625427|Experimental|Palmitoleic acid, 500 mg (Dose 1)|POA Dose 1 is a 1 gram capsule containing 500 mg POA and one placebo capsule containing 500 mg olive oil per day for twelve weeks. The doses will be administered in single serve packets containing two capsules for each daily dose to be taken at breakfast.
89509431|NCT03625427|Experimental|Palmitoleic acid, 1,000 mg (Dose 2)|POA Dose 2 is two, 1 gram capsules containing 500 mg POA, totaling 1,000 mg POA per day for twelve weeks.The doses will be administered in single serve packets containing two capsules for each daily dose to be taken at breakfast.
89509432|NCT02321917|Active Comparator|Rheoparin coating|MECC system with rheoparin coating
89509433|NCT02321917|No Intervention|No rheoparin coating|MECC system without rheoparin coating
89509434|NCT02236325|Experimental|DBT Brief Suicide Intervention|
89509435|NCT02236325|Active Comparator|Relaxation Training|
89509436|NCT02236403|Experimental|Ivermectin 0.1% Metronidazole 1%|30 patients will receive the treatment and at 15 days a second visit will be done and changes in mite counts will be determinated and correlated with symtoms and signs.
89509437|NCT02236403|Placebo Comparator|Control|30 volunters with no signs of blepharitis and with eyelashes with no demodex .None intervention. Symptoms and signs will be compared with experimental group
89509438|NCT02236481|Experimental|Anakinra|100 mg of anakinra once daily by subcutaneous injection for 24 months
89509439|NCT02236481|Active Comparator|TNF alpha inhibitors|treatment with TNF-alpha inhibitors according to the relative summary of product charateristics
89509440|NCT03491527|Active Comparator|Conventional Resin Cement|Resin cement without MTA
89509441|NCT03491527|Active Comparator|MTA Resin Cement|Resin cement with MTA
89509442|NCT03253393|Experimental|Silicone hydrogel (with EDTA) in Smart Touch vs. in conventional packaging|Silicone hydrogel (with EDTA) in Smart Touch vs. in conventional packaging
89509443|NCT03253393|Experimental|Hydrogel (no EDTA) in Smart Touch vs. in conventional packaging|Hydrogel (no EDTA) in Smart Touch vs. in conventional packaging
89509444|NCT03253393|Experimental|Silicone hydrogel (no EDTA) vs. hydrogel (with EDTA) in Smart Touch|Silicone hydrogel (no EDTA) vs. hydrogel (with EDTA) in Smart Touch
88958756|NCT01996878||Case (Parkinson's disease patients)|Clinical diagnosis of Parkinson's disease (cases are diagnosed by the presence of at least three of the five following primary signs: rest tremor, bradykinesia, rigidity, impaired postural refluxes, and the presence of a sustained L-dopa response.)
88958757|NCT01996878||Control (Healthy volunteers)|Healthy volunteers without Parkinson's disease
88958758|NCT01996891|Other|Anti-Inflammatory Diet First|For the first 6 weeks, subjects will receive the anti-inflammatory diet. For the second 6 weeks, subjects will consume their habitual diet.
88958759|NCT01996891|Other|Anti-Inflammatory Diet Second|For the first 6 weeks, subjects will consume their habitual diet. For the second 6 weeks, subjects will receive the anti-inflammatory diet.
89509445|NCT02261441||Group 1|Subjects irrespective of the presence of risk factors or cardiovascular disease throughout Spain will be included. This is an observational and non-interventional study
89509446|NCT03128671|Experimental|FAVoR Intervention Group|In the intervention group, scripted audio messages recorded by the patient's family (FAVoR intervention) will be played for the patient at hourly intervals during daytime hours. These messages will be personalized, delivered automatically, and provide information about the ICU environment. The FAVoR intervention, a standardized protocol developed and tested in preliminary work, will be delivered by audio recording for 5 consecutive days (120 hours), or until ICU discharge if discharge occurs within the first 5 days. The number of episodes of delirium during ICU stay is the primary outcome measure. Data will also be collected at 1 month and 6 months following hospital discharge for secondary aim 3.
88958760|NCT01996930|Active Comparator|Haelan tape (steroid impregnated tape)|"Haelan tape, medicated tape for cutaneous use, containing 4mcg Fludroxycortide per centimetre squared.~Maximum daily dosage of 0.1mg = 25cm squared per day. Application = once daily and left in situ for 24 hours Maximum duration of treatment = 28 days"
88958761|NCT01996930|Active Comparator|Silver nitrate|Avoca caustic applicator 95% w/w cutaneous stick Cautery with silver nitrate cutaneous stick undertaken twice weekly Maximum duration of treatment = 28 days
88958762|NCT01996956|Other|Volume loading|
88958763|NCT01996969|Other|Regorafenib|This study is a single arm study with biomarker analysis
88958764|NCT01996995|Experimental|Nd:YAG laser pulse therapy|Nd:YAG laser pulse therapy Patients are treated with laser session in week 0, 2, 4, and 12. The settings are; 1064 nm, spot size 3 mm, 20 J /cm2, 5 Hz, power 10 W, pulse duration 132 millisecond. A maximum of two sequential sessions (one session on the horizontal and one the vertical passing) will be applied to eliminate potential safety issues in those patients with a lack protective sensibility.
88958765|NCT01996995|Sham Comparator|Sham|Sham treatment Patients are treated with a sham session in week 0, 2, 4, and 12. The study settings are similar to the laser except the laser beam. Because the patient is also blinded, they can't see the procedure. The sound and the beeps are audible similar to the laser treatment.
89509447|NCT03128671|No Intervention|Control Group|The control group will not receive the FAVoR intervention. The number of episodes of delirium during ICU stay is the primary outcome measure. Data will also be collected at 1 month and 6 months following hospital discharge for secondary aim 3.
89509448|NCT02261519|Experimental|NaBen®|NaBen® is a oral tablet (500 mg), which will be taken twice daily at a total dose of 1000 mg/day during this study.
89509449|NCT02261519|Placebo Comparator|Placebo|The control treatment is placebo.
89509450|NCT02654327|No Intervention|Standard Care|Standard care with conventional lung protective mechanical ventilation
89509451|NCT02654327|Experimental|ECCO2R to enable lower tidal volume mechanical ventilation|VV-ECCO2R to enable lower tidal volume mechanical ventilation (target tidal volume of ≤ 3ml/kg predicted body weight and a Pplat ≤ 25cmH20)
89509452|NCT02638805|Experimental|Group 1|ITCA 650 20/60 mcg/day
89509453|NCT02638805|Experimental|Group 2|ITCA 650 60 mcg/day
89509454|NCT02261675|No Intervention|control group|children undergoing selective lower abdominal surgery received saline before induction
89509455|NCT02261675|Experimental|D1 group|children undergoing selective lower abdominal surgery received a bolus dose of 0.5 µg/kg dexmedetomidine followed by a continuous infusion of 0.5 µg/kg /h before induction
89509456|NCT02261675|Experimental|D2 group|children undergoing selective lower abdominal surgery received a bolus dose of 1.0µg/kg dexmedetomidine followed by a continuous infusion of 1.0 µg/kg /h before induction
89509457|NCT02261753|Active Comparator|A: Classical ketogenic diet|The KD is a high fat, low carbohydrate, low protein diet designed to mimic the effects of fasting on the body. It will be administered by calculation as per local standardised classical KD protocol with utilisation of long chain fat in a ratio of 2:1 to 4:1 carbohydrate and protein.
89509458|NCT02261753|No Intervention|B: No pretreatment|Following the decision to proceed to surgery, if randomised to this arm a date will be given for surgery as per routine clinical practice. No KD pre-treatment will be undertaken.
89509459|NCT02261831|Experimental|obese patients|Total blood sample, and 4 biopsies : collection of 2 colonic and 2 ileal biopsies
89509460|NCT02261831|Experimental|Diabetic patients|Total blood sample, and 4 biopsies : collection of 2 colonic and 2 ileal biopsies
89509461|NCT02261831|Experimental|Patients free of obesity and diabetes|Total blood sample, and 4 biopsies : collection of 2 colonic and 2 ileal biopsies
89509462|NCT02261831|Experimental|patients free type 2 diabetes.|Total blood sample, and 4 biopsies : collection of 2 colonic and 2 ileal biopsies
89509463|NCT02261987|Active Comparator|Autogenic drainage (AD)|Patients will perform the autogenic drainage technique following the Chevallier and Agostini recommendations.
89509464|NCT02261987|Active Comparator|Resistive inspiratory manoeuvre (RIM)|Patients will perform the repetitive inspiratory manoeuvers by breathing through a fixed resistance (Power Breathe device, model KH1) . Each session will comprise to cycles of 5 inspiratory breaths (60% of maximal inspiratory pressure). Patients will be stay in both lateral decubitus position (15 min per side).
89509465|NCT02261987|Active Comparator|Resistive inspiratory manoeuvre+autogenic drainage|First, patients will perform the resistive inspiratory manoeuvre during 10 minutes (5 min per side). Right after, patients will perform the autogenic drainage during 20 minutes.The instructions will be similar to described previously.
89024083|NCT03644485|Experimental|Standard Prograf group|Participants received from day 1 tacrolimus immediate-release formulation (Prograf) 0.1 - 0.15 milligrams/kilograms/day (mg/kg/day) orally at 12-hour interval (twice daily 1 hour before meal or 2 hours after meal) for approximately 1 month. At 1 month after Kidney transplant, Prograf was converted to Advagraf on a 1:1 (mg: mg) total daily dose basis. The Advagraf was administered orally once daily in the morning, 1 hour before the breakfast; the whole blood target trough level for Advagraf was maintained as 6 - 12 nanograms/milliliter(ng/mL) within months 2 to 3, and 6 - 8 ng/mL within months 4 to 6.
89024084|NCT03644485|Experimental|Delayed Prograf group|Participants received from day 3 to 5 Prograf 0.1 - 0.15 mg/kg/day orally at 12-hour interval (twice daily 1 hour before meal or 2 hours after meal) for approximately 1 month. At 1 month after Kidney transplant, Prograf was converted to Advagraf on a 1:1 (mg: mg) total daily dose basis. The Advagraf was administered orally once daily in the morning, 1 hour before the breakfast; the whole blood target trough level for Advagraf was maintained as 6 - 12 ng/mL within months 2 to 3, and 6 - 8 ng/mL within months 4 to 6.
89509466|NCT02262065||Patients|Patients with suspected arthroplasty intolerance
89509467|NCT02262065||Controls|Patients with well tolerated arthroplasties
89509468|NCT02262143|Experimental|Experimental|Rosuvastatin 10 mg, Fenofibrate 160 mg
89509469|NCT02262143|Active Comparator|Comparator|Rosuvastatin 10 mg
89509470|NCT02620553|Experimental|Human Insulin|Oral Insulin at 2.5 mg, 7.5 mg, 22.5 mg, or 67.5 mg per day
89509471|NCT02620553|Placebo Comparator|Placebo|Oral Placebo
89509472|NCT02262299|Placebo Comparator|Placebo|Receive placebo tablets
89509473|NCT02262299|Active Comparator|Pirfenidone|Upon enrollment, subjects will be randomized to either the treatment group (Pirfenidone) or to the placebo group (1:1 ratio). The trial medication will be administered as 267-mg oral capsules and titrated to a maintenance dose of 2403 mg/d (3 capsules TID, for a total of 9 capsules/day).
89509474|NCT02608697|Experimental|Group 1: CAT-2054 or Placebo Dose 1|A run-in phase with 40 mg atorvastatin tablet administered daily for at least 28 days, followed by a 28-day blinded treatment phase with 250 mg CAT-2054 or placebo QD and open label 40 mg atorvastatin tablet administered daily.
89509475|NCT02608697|Experimental|Group 2: CAT-2054 or Placebo Dose 2|A run-in phase with 40 mg atorvastatin tablet administered daily for at least 28 days, followed by a 28-day blinded treatment phase with 400 mg CAT-2054 or placebo QD and open label 40 mg atorvastatin tablet administered daily.
89509476|NCT02608697|Experimental|Group 3: CAT-2054 or Placebo Dose 3|A run-in phase with 40 mg atorvastatin tablet administered daily for at least 28 days, followed by a 28-day blinded treatment phase with 250 mg CAT-2054 or placebo BID and open label 40 mg atorvastatin tablet administered daily.
89509477|NCT02608697|Experimental|Group 4: CAT-2054 or Placebo Dose 4|A run-in phase with 40 mg atorvastatin tablet administered daily for at least 28 days, followed by a 28-day blinded treatment phase with 400 mg CAT-2054 or placebo BID and open label 40 mg atorvastatin tablet administered daily.
89509478|NCT02262455|Experimental|STM 434|
89509479|NCT02262455|Experimental|STM 434 and Liposomal Doxorubicin|
89509480|NCT02262533|Experimental|Treatment A: Apixaban|Apixaban tablet by mouth on specified day
89509481|NCT02262533|Experimental|Treatment B: Atenolol|Atenolol tablet by mouth on specified day
89509482|NCT02262533|Experimental|Treatment C: Apixaban and Atenolol|Apixaban and Atenolol tablets by mouth on specified day
89024085|NCT03641092|Experimental|Experimental Clinical Site|5 experimental clinical sites will receive the implementation of CenteringParenting assistance early. This arm will include the CenteringParenting intervention.
89024086|NCT03641092|Active Comparator|Comparison Clinical Site|5 comparison clinical sites will receive Routine Well Child Care and CenteringParenting implementation assistance later and serve as control sites. This arm will include the Routine Well Child Care intervention.
89032945|NCT02944760|Experimental|Low-Level Light Therapy Group|The patient was placed supine on a stretcher and the application will take place with the Chattanooga device, with the laser diode cluster probe from the same manufacturer consisting of five diodes 850 nm and power output of 200 mW. Six points in quadriceps and four points in gastrocnemius, were irradiated, bilaterally, by 30 seconds.
89032946|NCT02944760|Placebo Comparator|Placebo Group|The patient was placed supine on a stretcher and the application of laser therapy occured with apparatus off.
89032947|NCT02923518||Inclusion group|Inclusion group: Those with a positive score in a questionnaire including symptoms and family history and/or high risk-score in the NORRISK-score system.
89509483|NCT02262611||Hypertension patients - Pneumology|
89509484|NCT02262611||Hypertension patients - Cardiology|
89509485|NCT02262611||Hypertension patients - Nephrology|
89509486|NCT02262611||Hypertension patients - Diabetology|
89509487|NCT02607683|Experimental|XAF5 (concentration A: 0.1%)|Participants will apply XAF5 Ointment (concentration A: 0.1%) to the lower eyelids once daily.
89509488|NCT02607683|Experimental|XAF5 (concentration B: 0.035%)|Participants will apply XAF5 Ointment (concentration B: 0.035%) to the lower eyelids once daily.
89509489|NCT02607683|Placebo Comparator|Placebo|Participants will apply Placebo Ointment to the lower eyelids once daily.
89509490|NCT02262689|Experimental|GSK2256294 15 mg|Randomised subjects will be instructed to take three capsules of GSK2256294 15 mg, each morning for 7 days. Subjects will undergo echocardiography under normoxic and hypoxic conditions on Day 1 pre-dose and on Day 7 post-dose.
89509491|NCT02262689|Placebo Comparator|Placebo|Randomised subjects will be instructed to take three capsules of matching placebo, each morning for 7 days. Subjects will undergo echocardiography under normoxic and hypoxic conditions on Day 1 pre-dose and on Day 7 post-dose.
89509492|NCT04476875|Active Comparator|Open outpatient clinic programme (OOCP)|OOCP patients had no scheduled appointments but were allowed acute appointments with their rheumatologist, and had access to nurse-led consultations and telephone helpline.
89509493|NCT04476875|No Intervention|Traditional scheduled routine follow up (TSRF)|Appointments for the TSRF group were scheduled according to routine procedures.
89509494|NCT04476719|Experimental|Atafenovir 200 mg Kapsül|Capsules containing 207.009 mg umifenovir hydrochloride monohydrate equivalent to 200 mg umifenovir hydrochloride (Atabay-Turkey).
89509495|NCT04476719|Active Comparator|Arbidol 100 mg Kapsül|Capsules containing 103.504 umifenovir hydrochloride monohydrate equivalent to 100 mg umifenovir hydrochloride (OTC-Pharma Russia).
89509496|NCT04476563||ChILI|Patients who are already on CPI therapy and have developed liver injury
89509497|NCT04476563||Control|Patients with cancer who are starting on checkpoint inhibitors
89509498|NCT04476485||experimental group|If the expression of sj-subway in the surgical wax block is eligible, it is recommended but not mandatory that patients follow the guidelines to choose the appropriate extended endocrine therapy.
89509499|NCT02262767|Experimental|Single Ascending Doses Cohort 1|Single doses, given by oral solution, starting at 0.75 mg up to a possible maximum of 3.0 mg. The subject will have been fasted for 10 hours prior to the single dose. For each dosing period, 3 subjects will be given a placebo as a comparator while 6 are given active dose. The subjects will be given concomitant trimethobenzamide hydrochloride for the 3 weeks that the subject is in the CRU. For each of the three periods, subjects will be crossed-over from placebo or PF-06649751. Each PF-06649751 dose is separated by one week.
89509500|NCT02262767|Experimental|Single Ascending Doses Cohort 2|Single doses, given by oral solution, starting at 4.5 mg up to a possible maximum of 9.0 mg. The subject will have been fasted for 10 hours prior to the single dose. For each dosing period, 3 subjects will be given a placebo as a comparator while 6 are given active dose. The subjects will be given concomitant trimethobenzamide hydrochloride for the 3 weeks that the subject is in the CRU. For each of the three periods, subjects will be crossed-over from placebo or PF-06649751. Each PF-06649751 dose is separated by one week.
89509501|NCT02589275|Experimental|TNX-102 SL Tablet 2.8 mg|1x TNX-102 SL 2.8 mg sublingual tablet taken daily at bedtime for 3 months
89509502|NCT02262845||Group A: PEP Risk|In subjects deemed at high risk for acute pancreatitis post-endoscopic retrograde cholangiopancreatography (ERCP)
89509503|NCT02262845||Group B: Impaired Pancreatic Duct Drainage|In subjects with a pancreatic duct stricture and/or pancreatic duct stones and/or pancreatic duct sludge or debris, possibly, but not exclusively before or after ESWL or before pancreatic surgery
89509504|NCT02262845||Group C: Pancreatic Duct Leak|In subjects with a pancreatic duct leak
89509505|NCT02262845||Group D: Post Pancreatic Surgery|In subjects at risk of pancreatic duct leak or strictures after resection of a pancreatic lesion close to the main pancreatic duct or at the level of the pancreatico-jejunostomy after pancreatico-duodenectomy
89509506|NCT02262845||Group E: Other|In subjects with other indications
89509507|NCT04476641|Experimental|DC-CIK|
89509508|NCT02263001|Experimental|Auricular Acupuncture Plus Usual Care|Auricular acupuncture therapy for treatment of musculoskeletal pain, plus usual care therapy consisting of over-the-counter and prescribed pharmacotherapy.
89509509|NCT02263001|Active Comparator|Usual Care Only|Usual care therapy for treatment of musculoskeletal pain. Usual care therapy consists of over-the-counter and prescribed pharmacotherapy.
89509510|NCT02263157||BSI group with thrombocytopenia|BSI patients with thrombocytopenia
89509511|NCT02263157||Non-BSI group with thrombocytopenia|Non-BSI patients with thrombocytopenia
88958766|NCT01997008|Experimental|Intervention|"Participants receive a five week intervention providing the following activities:~EMA:~Ecological Momentary Assessment (EMA) of Emotion throughout the day.~Intervention:~Positive Events: Participants identify a positive event and then describe how they capitalized on this event.~Gratitude: Participants identify one more more things that make them feel grateful.~Mindfulness: Participants participate in a 30 minute guided mindfulness/meditation practice.~Positive Reappraisal: Participants identify how they reappraised a negative event making it into a positive event.~Personal Strengths: Participants identify one more more personal strengths. Attainable goals: Participants identify a short-term attainable goal. Participants will outline what they did that day to work toward attaining their week's goal.~Acts of Kindness: Participants will identify one more more acts of kindness that they engaged in and how it made them feel."
88958767|NCT01997008|No Intervention|Emotion reporting and EMA notification|"Participants report emotions and receive EMA (ecological momentary assessment) text messages on the same regular basis as intervention participants, but receive no interventions.~EMA detail:~Ecological Momentary Assessment (EMA) of Emotion throughout the day. We will assess current emotions via email or text message 4 times per day, 2 days per week (one randomly selected week/work day and one randomly selected weekend/non-work day) during the 8 week study period, for a total of 16 days of EMA reporting. Participants will be asked to rate how much they are currently feeling several positive and negative emotions that have been associated with mortality and health: happy, excited, content, appreciative, sad, worried, and fearful."
89032948|NCT02923518||Control group|Those without a positive score on the two scores listed above.
89509512|NCT02263157||BSI group without thrombocytopenia|BSI patients without thrombocytopenia
89509513|NCT02263157||Non-BSI group without thrombocytopenia|Non-BSI patients without thrombocytopenia
89509514|NCT02515175|Experimental|GEN-003 60ug / Matrix-M2 50ug|GEN-003/M2 (60 ug of each antigen) with Matrix-M2 adjuvant (50ug), administered as a 0.5mL intramuscular (IM) injection
89509515|NCT02515175|Experimental|GEN-003 60ug / Matrix-M2 75ug|GEN-003/M2 (60 ug of each antigen) with Matrix-M2 adjuvant (75ug), administered as a 0.5mL intramuscular (IM) injection
89509516|NCT02515175|Placebo Comparator|Placebo|0.9% Normal Saline administered as a 0.5 mL intramuscular (IM) injection
89509517|NCT02513303|Experimental|Treatment Group|AV fistula surgery Single administration of sirolimus-eluting Collagen implant
89509518|NCT02513303|Other|Control Group|AV fistula surgery
89509519|NCT02476019|Experimental|ISIS-FGFR4RX|ISIS-FGFR4RX administered subcutaneously
89509520|NCT02476019|Placebo Comparator|Placebo|Placebo administered subcutaneously
89509521|NCT01620515|No Intervention|Active Surveillance|Subjects with low risk localized (T1c) prostate cancer who are being followed with active surveillance and not undergoing active treatment for prostate cancer.
89509522|NCT01620515|Experimental|NX-1207 2.5 mg|
89509523|NCT01620515|Experimental|NX-1207 15 mg|
89509524|NCT01616303|Active Comparator|carboplatin & paclitaxel|first-line chemotherapy for ovarian cancer
89509525|NCT01616303|Experimental|carboplatin & paclitaxel & oregovomab|first-line chemotherapy for ovarian cancer plus oregovomab
89509526|NCT02263313||EGO-COMBO group|Previously enrolled into EGO-COMBO Pilot study and with combo stent
89509527|NCT01597349|Experimental|FP01 High dose|
88958768|NCT01997021|Experimental|US/IW/CW|This is a 3 arm crossover design. Arm US/IW/CW corresponds to the group of participants randomized to uninterrupted sitting (US) first, then Intermittent Walking (IW) and then continuous walk (CW).
88958769|NCT01997021|Experimental|IW/US/CW|This is a 3 arm crossover design. Arm IW/US/CW corresponds to the group of participants randomized to Intermittent Walking (IW) first, then uninterrupted sitting (US), and then continuous walk (CW).
88958770|NCT01997021|Experimental|IW/CW/US|This is a 3 arm crossover design. Arm IW/CW/US corresponds to the group of participants randomized to Intermittent Walking (IW) first, then Continuous Walk (CW) and then Uninterrupted Sitting (US).
88958771|NCT01997021|Experimental|CW/IW/US|This is a 3 arm crossover design. Arm CW/IW/US corresponds to the group of participants randomized to Continuous Walk (CW) first, then Intermittent Walking (IW) and then Uninterrupted Sitting (US).
88958772|NCT01997021|Experimental|CW/US/IW|This is a 3 arm crossover design. Arm CW/IW/US corresponds to the group of participants randomized to Continuous Walk (CW) first, then Uninterrupted Sitting (US), and then Intermittent Walking (IW).
88958773|NCT01997021|Experimental|US/CW/IW|This is a 3 arm crossover design. Arm US/CW/IW corresponds to the group of participants randomized to Uninterrupted Sitting (US) first, then Continuous Walk (CW), and then Intermittent Walking (IW).
88958774|NCT01997034||Intensive Lifestyle Intervention|Former participants of Ubberup Folk High Schools intensive lifestyle intervention programme.
88958775|NCT01997047||Tachypneic children|All tachypneic children under 5 yrs age presenting to study centres. No exclusions.
88958776|NCT01997060|Experimental|Intensive Lifestyle Intervention|Intensive Lifestyle Intervention at Ubberup Folk High School for 10-14 weeks. Daily exercise for 1-3hrs. Calorie restriction (~-700KCal/day). Education within nutrition, exercise and healthy living in general.
88958777|NCT01997086|Active Comparator|Transforaminal discectomy|patients diagnosed as lumbar disc herniation undergoing percutaneous transforaminal endoscopic discectomy (PTED).
88958778|NCT01997086|Active Comparator|Microendoscopic discectomy|Patients diagnosed as lumbar disc herniation undergoing microendoscopic discectomy (MED).
88958779|NCT01997099||Library Creation|Individuals responsible for creating the drug library
88958780|NCT01997099||Pump Programming|Individuals responsible for programming ambulatory infusion pumps
88958781|NCT01997099||Home Implementation|Individuals responsible for implementing ambulatory infusion pumps in patients' homes
88958782|NCT01997099||Workflow|Individual at the facility responsible for describing the workflow of processing and implementing an ambulatory infusion pump prior to and after introducing the CADD®-Solis VIP System.
88958783|NCT01997099||Ambulatory Infusion Pump Patients|Patients that receive a prescription requiring use of the CADD®-Solis VIP pump
88958784|NCT01997112|Active Comparator|Paracetamol|paracetamol 1g (500mg x2) four times daily for 14 day period
88958785|NCT01997112|Placebo Comparator|Placebo|Matched placebo control: hard gelatin placebo capsules containing Lactose Ph Eur. Taken for 14 days
88958786|NCT01997138|Experimental|Anakinra|Anakinra 100 mg in 2 ml saline IA
88958787|NCT01997138|Placebo Comparator|Placebo|Saline 2 ml IA
88958788|NCT01997151|Experimental|Healthy Pregnancy: Step by Step|Pregnant women interacted with a multiple behavior change iPad- delivered program at federally funded health centers. The 20-30 minute program offered onscreen assessments of Transtheoretical Model strategies of change, and then provided individually tailored feedback messages matched to their readiness to change for relevant target behaviors. The program addressed smoking cessation and relapse prevention, stress management, and fruit and vegetable consumption. The feedback screens were interactive and engaging. The messages were written at a 4th-5th grade level and were reviewed for multicultural relevancy. Participants in the treatment group interacted with the program up to 3 times during pregnancy. A printed multiple behavior change guide also was distributed. All program components are available in English and Spanish.
88958789|NCT01997151|No Intervention|Usual Care|Pregnant women received regular prenatal care as delivered by the health care center from where they were receiving care. Standard informational March of Dimes brochures related to the target behaviors were distributed to usual care participants.
88958790|NCT01997164|Experimental|Cohorts 1 through 4|Participants in cohorts 1 through 4 will receive IVT REGN910-3 and IAI
88958791|NCT01997164|Experimental|Cohort 5|Participants in cohort 5 will receive IVT REGN910 and IAI
88958792|NCT01997177||novices|novice endoscopists, fellows of gastroenterology
88958793|NCT01997177||experienced endoscopist|consultant doctors of gastroenterology
88958794|NCT01997203|Experimental|HCV patients under treatment|"Fifty patients study group administered vitamin D were compared with 50 patients control group without vitamin D.~Dose of vitamin D 15,000 IU/week"
88958795|NCT01997203|No Intervention|HCV without Vit D|
88958796|NCT01997242||stenting undergoing surgery|Patients with prior coronary stenting undergoing urgent or elective surgical/endoscopic procedures
88958797|NCT01997255|Experimental|Everolimus|Afinitor tablets will be administered at a starting dosage of 5 mg/ m2/ day, dosed once per day in the morning. To achieve appropriate doses for all subjects 2mg, 3mg, 5mg of everolimus Disperz tablets will be used. Subjects will take one or more of these tablets in combination to achieve the required dose. Dosages will be rounded to the nearest 2 mg when calculating doses for individual subjects.
88958798|NCT01997268|Placebo Comparator|Placebo|Placebo 6 capsules (1.24 g each) daily for 12 weeks
88958799|NCT01997268|Experimental|SC401B 2 capsules|SC401B 2 capsules (1.24 g each) + 4 placebo capsules daily for 12 weeks
88958800|NCT01997268|Experimental|SC401B 4 capsules|SC401B 4 capsules (1.24 g each) + 2 placebo capsules daily for 12 weeks
88958801|NCT01997268|Experimental|SC401B 6 capsules|SC401B 6 capsules (1.24 g each) daily for 12 weeks
88958802|NCT01997294|Active Comparator|sequential therapy group|80mg atorvastatin before primary PCI (PPCI) followed by 40mg/d for 7 days after PPCI followed by 20mg/d for 1 year
88958803|NCT01997294|Placebo Comparator|Usual Therapy of atorvastatin|20mg/d before and after PPCI for 1 year
88958804|NCT01997307||Stratification by gender and age, including 4 age categories|>=55-64 years
88958805|NCT01997307||Age >=65 to 74|
88958806|NCT01997307||Age >=75 to 84|
88958807|NCT01997307||Age >=85|
89032949|NCT02945189||Peri menopausal|Participants aged 41-55 years
89032950|NCT02945189||post menopausal|participants aged 56-65 years
89024087|NCT03631940|Active Comparator|Umbilical Cord Milking|The delivering practitioner will place the newborn below the level of the incision (at the edge of the table) at C/S and a second team member will milk the cord four times. For vaginal delivery, the delivering obstetrician, midwife or perinatal provider will hold the infant against their body or place the infant on the mother's abdomen and the cord will be milked either four times by the obstetrical provider or by a second team member. For the cord milking procedure, the obstetrical provider will milk the entire length of umbilical cord over two seconds, repeating three additional times as described previously. This time is not significantly different from the time for ECC as we have demonstrated in our previous trials.
89024088|NCT03631940|Active Comparator|Early Cord Clamping|This will occur by clamping the umbilical cord as soon as possible. Since both ECC and UCM will occur after a brief assessment, it is important to note that the cord clamping time will be longer than in previously conducted preterm trials (average 20 seconds) which performed the intervention on all subjects regardless of whether or not they were vigorous. In all cases, the cord clamping time will be documented to ensure consistency.
89024089|NCT03621943|Active Comparator|Umbilical Cord Milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 15-20 seconds.
89024090|NCT03621943|Active Comparator|Early Cord Clamping|The umbilical cord is clamped within 30 seconds of delivery.
89032951|NCT02923479|Experimental|Experimental: ARBOT Group|"The patients in the ARBOT Group underwent to following interventions:~General Rehabilitation~Specific ankle rehabilitation by ARBOT device"
89032952|NCT02923479|Other|Control Group|"The patients in the Control Group underwent to following interventions:~General Rehabilitation~Specific ankle rehabilitation performed by physiotherapist~Specific ankle rehabilitation by Biodex System 3 dynamometer~Specific ankle rehabilitation by ProKin PK254 platform."
89206975|NCT05156463|Experimental|Treatment|Participants will receive same materials as standard of care group. In addition participants will use PAI Activity tool, Garmin activity tracker and exercise logs, and also receive periodic exercise coaching.
89509528|NCT01597349|Experimental|FP01 Low dose|
89509529|NCT01597349|Placebo Comparator|Placebo|
89509530|NCT02263391|Experimental|Opt-in testing|"Common barriers to HIV screening testing will be removed as much as possible (i.e., providing rapid testing, results shortly available, testing on-site, confidentiality). The research assistant will say: There is voluntary HIV testing available to all study participants if you wish to do it. It is free, private, it is only a finger stick, and you will learn your HIV results in just minutes. Participants will be scheduled for a two-hour appointment to complete the written consent procedure, enroll in the study, and participate in the study activities, testing and a focus group."
89509531|NCT02263391|Experimental|Opt-out testing|"Participants will be informed that a routine health test bundle is available on a voluntary basis to study participants, and the participant may elect to decline all or any individual part of the testing. The assistant will say: We are offering a voluntary panel of routine health screening test today for study participants. It includes blood sugar, cholesterol, and HIV. We recommend all of them for everyone, but you can choose to decline any or all of them. This is free, private, it is only a finger stick, and you will learn your results for all the tests in just minutes. Participants will be scheduled for a two-hour appointment to complete the written consent procedure, enroll in the study, and participate in the study activities, testing and a focus group."
89509532|NCT02263469|Experimental|Replenine®-VF|
89509533|NCT02263703|Experimental|HPV vaccine|Quadrivalent HPV vaccine
89509534|NCT01590719|Experimental|Onartuzumab (MetMAb) with mFOLFOX6|Onartuzumab (MetMAb) in combination with mFOLFOX6 (modified 5-fluorouracil, folinic acid [leucovorin], and oxaliplatin)
89509535|NCT01590719|Placebo Comparator|Placebo with mFOLFOX6|Placebo in combination with mFOLFOX6 (modified 5-fluorouracil, folinic acid [leucovorin], and oxaliplatin)
89509536|NCT01571297|Active Comparator|RM-131|
89509537|NCT01571297|Placebo Comparator|Placebo|
89509538|NCT02263781|Experimental|Control Blood|Patients on routine postinfectious control, blood draw
89509539|NCT02263781|Experimental|Primary PREPL deficiency Blood|Patients with primary PREPL deficiency, blood draw
89509540|NCT02263781|Experimental|Prader Willi syndrome Blood|Patients with Prader-Willi syndrome, blood draw
89509541|NCT02263781|Experimental|Primary PREPL deficiency like Blood|Patients with symptoms overlapping with primary PREPL deficiency (like hypotonia, growth hormone deficiency, obesity), blood draw
89509542|NCT02263781|Experimental|Control muscle|Patients without hypotonia, growth hormone deficiency, obesity, undergoing elective surgery, muscle biopsy from the surgical site and blood draw
89509543|NCT02263781|Experimental|Prader-Willli syndrome muscle|Patients with Prader-Willi syndrome undergoing elective anesthesia or surgery, muscle biopsy (from surgical site if applicable) and blood draw
89509544|NCT01543919|Experimental|PH-787904 (arm1)|
89509545|NCT01543919|Experimental|PH-787904 (arm2)|
89509546|NCT01543919|Experimental|PH-787904 (arm3)|
89509547|NCT01543919|Experimental|PH-787904 (arm4)|
89509548|NCT01543919|Experimental|PH-787904 (arm5)|
89509549|NCT01543919|Experimental|Placebo|
89509550|NCT01543451|Experimental|Elsiglutide|
89509551|NCT01543451|Placebo Comparator|Placebo|
89509552|NCT01536041|Experimental|Experimental 200 mg dose|
89509553|NCT01536041|Experimental|Experimental 20 mg dose|
89509554|NCT01536041|Active Comparator|Active Comparator Montelukast|
89509555|NCT01536041|Placebo Comparator|Placebo Comparator|
89509556|NCT01534403|Experimental|Epratuzumab 4x600 mg every 12 weeks Group|
89509557|NCT01523171|Experimental|SAR302503 400 mg|once daily in consecutive 28-day cycles, flexible dosing regimen (the starting dose is 400mg/day), orally, empty stomach, approximately same time each day
89509558|NCT02263937|Active Comparator|Bilateral Nucleus Basalis Meynert DBS|6 week period of active NBM DBS
89509559|NCT02263937|Sham Comparator|Sham Nucleus Basalis Meynert DBS|6 week period of Sham DBS
89509560|NCT02264015|Experimental|Cilobradine low|
89509561|NCT02264015|Placebo Comparator|Placebo|
89509562|NCT02264015|Active Comparator|Moxifloxacin|
89509563|NCT02264015|Experimental|Cilobradine high|
89509564|NCT02264093|Experimental|Talsaclidine with Propranol|
88958808|NCT01997320|Experimental|Heavy resistance exercise and nutrition|Heavy resistance exercise of the lower extremities three times weekly for 12 weeks combined with nutrient supplementation twice daily each containing 20g of milk protein.
89509565|NCT02264093|Active Comparator|Propranolol|
88958809|NCT01997320|Active Comparator|Nutrition supplement|Nutrient supplementation twice daily for 12 weeks. Each supplement contains 20g of milk protein.
88958810|NCT01997346||Key Informant Interviews|We will conduct interviews with 4 clinic personnel (16 across the 4 sites) to learn about practices and provider perspectives in the HIV clinic or ancillary clinics such as VCT. The 4 clinic personnel in each site will include: the physician-in-charge, a nurse, one peer educator, and a nurse or community counselor from the VCT clinic. A semi-structured interview guide will be used to query respondents about: procedures for enrolling new clients, conducting active testing, identifying and initiating patients on ART, CD4 monitoring, tracking clients who have missed appointments, support programs, and peer education. We will also aim to understand how each respondent views her/his role, how s/he counsels patients on pre-ART care, and the challenges faced from each one's perspective.
88958811|NCT01997359||Key Informant Interviews|Eligible patients will undergo a one hour structured interview about barriers and facilitators to early ART initiation.
88958812|NCT01997359||Prospective Cohort|The prospective cohort will include all patients initiating ART at one of the six study sites, estimated at 1,200 patients. Cases will be adults initiating ART with either: CD4 count <150 cells/µL. Controls will be adults who initiate ART with CD4≥200 . Individuals initiating ART with CD4 counts of 150-199 cells per µL and at WHO Stage I-III will be excluded from the case-control analysis in order to ensure meaningful distinction between the two groups. We will enroll 720 patients for the case control study nested in the prospective cohort, which will include 360 cases and 360 controls, who will be frequency matched by sex, month of ART initiation, and clinic.
88958813|NCT01997372|Experimental|high dose ATG,low dose ATG|
88958814|NCT01997385|Active Comparator|KAPD-C|KAPD-C is a treatment prescribed 2000 mL fill volume per each 4 cycles of dialysis session with an exchange cycle of 90 minutes.
88958815|NCT01997385|Experimental|KAPD-A|KAPD-A is a treatment initially prescribed 1500 mL fill volume per each 2 cycles of dialysis session with an exchange cycle of 45 minutes and followed by 2 cycles of 2500 mL fill volume with an exchange cycle of 135 minutes.
88958816|NCT01997476|Experimental|Combined EUS, e-PFT and sEUS Testing|"Establish the advantage of combined EUS, ePFT & sEUS testing to provide a more definitive diagnostic assessment, rather than each test alone.~Establish the advantage of reduced time and cost of combining EUS and ePFT, rather than when done separately."
88958817|NCT01997489|Experimental|Fabry patients during treatment|39 patients with Fabry disease having had baseline examinations of the eyes were assessed also at follow-up 10 years after enzyme replacement therapy
89206976|NCT00836160||1|
89509566|NCT02264093|Active Comparator|Talsaclidine|
89509567|NCT01516541|Experimental|Dalcetrapib|Dalcetrapib 600 mg orally daily on a background of contemporary, guidelines-based medical care.
89509568|NCT01516541|Placebo Comparator|Placebo|Placebo orally daily, on a background of contemporary, guidelines-based medical care.
89509569|NCT01516307|Experimental|OPT-822/OPT-821 (30 μg/100 μg) and Cyclophosphamide|Patients will be randomized 2:1 to receive OPT-822/OPT-821(30 μg/100 μg) plus Cyclophosphamide IV (300mg/m2).
89509570|NCT01516307|Placebo Comparator|Phosphate Buffer Saline (PBS) and Cyclophosphamide|Patients will receive Phosphate Buffer Saline (PBS) plus Cyclophosphamide IV (300mg/m2).
89509571|NCT01516073|Experimental|Fluticasone Propionate (FP) - arm 1|FP BID (twice daily)
89509572|NCT01516073|Experimental|Fluticasone propionate (FP) - arm 2|FP BID
89509573|NCT01516073|Experimental|Fluticasone Propionate (FP) - arm 3|FP BID
89509574|NCT01516073|Experimental|FLuticasone Propionate (FP) - Arm 4|FP BID
89509575|NCT01516073|Experimental|Fluticasone Propionate (FP) - Arm 5|FP BID
89509576|NCT01516073|Placebo Comparator|Placebo - Arm 6|Placebo inhalation solution 2mL
89509577|NCT01495247|Experimental|BEZ235 100 mg bid + paclitaxel 80 mg (phase lb)|Increasing doses of oral BEZ235 100 mg administered on a continuous twice daily (BID) schedule + weekly paclitaxel infusion at a fixed dose of 80 mg/m2. Treatment was organized into cycles of 28 days.
89509578|NCT01495247|Experimental|BEZ235 200 mg bid + paclitaxel 80 mg (phase lb)|Increasing doses of oral BEZ235 200 mg administered on a continuous twice daily (BID) schedule + weekly paclitaxel infusion at a fixed dose of 80 mg/m2. Treatment was organized into cycles of 28 days
89509579|NCT01495013|Active Comparator|Glimepiride Atorvastatin fixed dose combination|All subjects will start on 1mg glimepiride/10 mg atorvastatin fixed dose combination (FDC) and either treatment can be titrated up based on fasting glucose or LDL levels. The following glimepiride/atorvastations FDCs will be available for use 1mg/10mg, 2mg/10mg, 3mg/10mg, 4mg/10mg, 1mg/20mg, 2mg/20mg, 3mg/20mg, 4mg/20mg.
89206977|NCT00836160||2|
89509580|NCT01495013|Active Comparator|Glimepiride +Atrovastatin loose combination|All subjects will start on 1mg glimepiride/10 mg atorvastatin loose combination (given as separate tablets) and either treatment can be titrated up based on fasting glucose or LDL levels. Glimepiride single dose tablets are available for 1mg, 2mg, 3mg and 4mg. Atorvastatin single dose tablets are available for 10mg and 20mg.
89509581|NCT01491971|Experimental|Degarelix - Cohort 1|(gonadotrophin-releasing hormone (GnRH) receptor blocker)
89509582|NCT01491971|Experimental|Degarelix - Cohort 2|(gonadotrophin-releasing hormone (GnRH) receptor blocker)
89509583|NCT01491971|Experimental|Degarelix - Cohort 3|(gonadotrophin-releasing hormone (GnRH) receptor blocker)
89509584|NCT02264171|Experimental|Ketoconazole + Tamsulosin HCl|Ketoconazole given once daily in the morning on days -3 to 2 Tamsulosin HCl given at day 1
89509585|NCT02264171|Active Comparator|Tamsulosin HCl|Tamsulosin HCl given at day 1
89509586|NCT02264327|Experimental|MI Training + SIM|"Service Providers in all group will receive a free two-day Motivational Interviewing training. Service Providers in this group will also receive access and a brief introduction to the Motivational Interviewing Simulator (SIM). Sim is designed to help Service Providers practice, learn, maintain, and implement MI skills.~Clients of Service Providers from this group will receive no study related intervention. All Clients will receive identical surveys to collect client centered observational data of the interventions effect."
89540413|NCT06211582|Experimental|Gradia Direct Posterior ( GC, Tokyo, Japan)|"Matrix: Urethanedimethacrylate (UDMA), dymethacrylate camphorquinone. Filler: fluoro-alumino-silicate glass silica powder.~After completing the cavity, the enamel surface was selectively roughened using 37% orthophosphoric acid for 30 seconds. Subsequently, GC Solare Universal Bond adhesive agent (GC Corp., Tokyo, Japan) was utilized. It was applied in 2mm layers in accordance with the composite manufacturer's instructions. Each layer was polymerized for 20 seconds."
88958818|NCT01997528|Experimental|Extracorporeal CO2 elimination by ILA Activve(R)|
88958819|NCT01997541||plain tube|
88958820|NCT01997541||reinforced tube|
88958821|NCT01997554|Experimental|less than 60 years old with clinical symptom of hypothyroidism|Group of patients less than 60 years old, with at least one clinical symptom of hypothyroidism
88958822|NCT01997554|Experimental|less than 60 years old without clinical symptoms|Group of patients less than 60 years old, without clinical symptoms of hypothyroidism
88958823|NCT01997554|Experimental|more than 60 years old|Group of patients more than 60 years old at recruitment.
88958824|NCT01997580|Experimental|Escitalopram|depressed patients receiving escitalopram treatment
88958825|NCT01997580|No Intervention|Control|healthy controls matched for age, gender, and BMI
88958826|NCT01997593|Experimental|ropivacaine|Preincisional wound intraperitoneal infiltration of 1% ropivacaine 0.3ml/kg was performed in group I patients before surgery.
88958827|NCT01997606|Experimental|Purotex|use of Purotex treated bedding covers
88958828|NCT01997606|Placebo Comparator|Placebo|no use of Purotex treated bedding covers
88958829|NCT01997632|Active Comparator|control vaccine: Imovax Polio®|
88958830|NCT01997632|Experimental|investigational vaccine|
88958831|NCT01997645|Active Comparator|Rectal advanced mucosal flap|"Procedure will be performed in general anesthesia without mechanical bowel preparation. Antibiotic prophylaxis (Metronidazole 1g) will be applied intravenously 60 minutes prior the surgery.~In RAF procedure, internal opening will identified and after infiltration with saline-adrenalin solution (1/100000) the mucosal flap will be mobilized proximally. The external tract and internal opening will be excised and the defect will be sutured. After that, the flap will be advanced from both sides with absorbable suture and overlapped over the internal opening. External openings will be left open."
88958832|NCT01997645|Active Comparator|Ligation of intersphincteric fistula tract|"Procedure will be performed in general anesthesia without mechanical bowel preparation. Antibiotic prophylaxis (Metronidazole 1g) will be applied intravenously 60 minutes prior the surgery.~Before LIFT procedure the fistula tract will be identified with small probe. The intersphincteric space will be reached by dissection from small (2-4cm) incision. The fistula tract will be divided and ligated on both sides with Polydioxanone (PDS) suture. The external and internal openings will be left open to drain."
88958833|NCT01997658|Experimental|Methylprednisolone|Injection, 500 mg, single use, over 15 to 20 minutes.
88958834|NCT01997658|Placebo Comparator|Control|In Control arm, patients will receive the standardized surgical treatment without receiving methylprednisolone preoperatively (placebo).
88958835|NCT01997671|Experimental|Information Support System|Practitioners in the intervention group may have access, whenever they want and through the computerized medical record program, to personalized information on their assigned patients who have started treatment of cardiovascular primary prevention with lipid-lowering.
88958836|NCT01997671|No Intervention|Control group|Routine clinical practice
89206978|NCT02547870|Experimental|Rilpivirine Long-Acting Parenteral Formulation (RPV-LA)|Participants will receive oral tablet of rilpivirine 25 milligram (mg) once on Day 1 of session 1 and intramuscular (IM) injection of rilpivirine long-acting parenteral formulation 600 mg once on day 1 of session 2.
89519404|NCT04760041|Active Comparator|oral midazolam group|36 children will receive oral midazolam 0.5 mg/kg in 5 ml clear juice plus nebulizer of 3 ml normal saline 30 min before undergoing anesthesia
89519405|NCT05164445|Active Comparator|Transbronchial forceps biopsy|Patients, whose transbronchial forceps biopsy was performed
89519406|NCT05164445|Active Comparator|Transbronchial forceps biopsy+Transbronchial cryobiopsy|Patients, whose transbronchial forceps biopsy and transbronchial cryobiopsy were performed as well
89519407|NCT03449017|Experimental|E-cig use condition|Participants self-administer their own electronic cigarette device
89519408|NCT05391347|Experimental|Intervention|3 ml of orange oil were dripping onto the sponge, and the patient was told to breathe slowly at a distance of 3 cm and to smell during the process
89519409|NCT05391347|No Intervention|Control|
89519410|NCT05322421|Experimental|Olive Oil|Will include10 patients receiving topical olive oil application, twice daily
89519411|NCT05322421|Active Comparator|Sodium Bicarbonate|Will include 10 patients receiving Sodium bicarbonate 5% solution, twice daily
89519412|NCT05163977|Active Comparator|Cattell Warren Anastomosis|
89519413|NCT05163977|Experimental|Blumgart Anastomosis|
89519414|NCT04452643|Active Comparator|Bacmune (MV130)|Subject included in the active group will receive Bacmune. The dose consists on 2 spray puff every 12 hours for 45 days.
89519415|NCT04452643|Placebo Comparator|Placebo|Subject included in the placebo group will receive placebo. The dose consists on 2 spray puff every 12 hours for 45 days.
89519416|NCT04455659|Experimental|TENS + Conventional physical therapy exercise|
89519417|NCT04455659|Active Comparator|conventional physical therapy exercise|
89519418|NCT05322265||complicated patients|patients underwent to laparoscopic renal and adrenal surgery with intraoperative complications
89519419|NCT05322265||uncomplicated patients|patients underwent to laparoscopic renal and adrenal surgery with no complication during surgical procedure
89519420|NCT04455581|Experimental|Treatment group|SHR-1209 administered by subcutaneous injection Atorvastatin or Rosuvastatin combined with Ezetimibe oral
89519421|NCT02164864|Experimental|Dabigatran Etexilate 110mg|Patient to receive Dabigatran Etexilate 110mg twice a day (BID)
89519422|NCT02164864|Experimental|Dabigatran Etexilate 150mg|Patient to receive Dabigatran Etexilate 150mg twice a day (BID)
89519423|NCT02164864|Active Comparator|Warfarin|Warfarin doses to maintain INR
89540414|NCT06211556|Experimental|Very-low calorie diet|Two weeks of ~800kcal/day
89540415|NCT06211556|No Intervention|Free-living control|No intervention control group
89540416|NCT06211543||LMV cohort|Patients will receive oral or intravenous (if available ) LMV at a dose of 480mg/day. For patients receiving concomitant cyclosporine treatment, the LMV dose will be 240mg/day. LMV will be administered daily through week 14 after transplantation for up to 8 weeks (~Day 100) beginning
89540417|NCT06211543||Historical cohort|An historical control cohort for comparison purposes will be used. Historical data will be obtained from a national CMV data base (GETH-GRUCINI), that includes stem cell transplant recipients from September 2014 to December 2022
89540418|NCT06211530|Experimental|SpO2 Measurements - All Subjects|Participants participating in this study will be connected to eight (8) Portrait Mobile P-SA01PL/P-SP01PL prototype sensors provided by GEHC and two reference monitors, Nellcor N-600X V 1.6.0.0 and a forehead sensor, used as standard operating procedures at the site. Data will be collected using the Portrait Hub patient monitor. The participants are exposed to a desaturation protocol that sequentially decreases the SpO2 in a stepwise fashion. The goal is to achieve six stable oxygenation plateaus between 100 and 70% SpO2, while recording simultaneous SpO2 readings from the prototype and reference devices. The protocol is consistent with the ISO 80601-2-61 pulse oximetry standard.
89540419|NCT06211504|Active Comparator|MDCO without STI|"For patients with preoperative gastrocnemius-soleus complex tightness, defined as a preoperative dorsal extension of the ankle less than 5 degrees, with the knee completely extended, a Strayer´s procedure will be performed before the other procedures.~MDCO will be performed where the distal aspect of the calcaneus is separated from the proximal aspects, slided medially and fixed with two screws.~After the MDCO, FDL will be transferred to the navicular bone.~The spring ligament will be assessed. If ruptured, it will be reconstructed. If not ruptured, it will be tightened.~A plantarflexing open wedge osteotomy of the medial cuneiform (Cotton osteotomy) will be performed if pre-/perioperative findings indicate it."
88958837|NCT01997684|Experimental|Colonic Stenting with Elective Surgery|"In the experimental group, the patients will undergo colonic stenting within 24 h of inclusion. For this study, the WallFlex ™ Colonic Stent (Boston Scientific, Natick, MA) will be employed.~Candidates for elective surgery, after clinical success of colonic stenting, will be preferably operated on 5-14 days after inclusion, and no later than 4 weeks. Type and extent of the elective surgery will be selected by the surgeon.~In this group, unplanned emergency surgery will be indicated in case of technical failure of colonic stenting, iatrogenic morbidity, or clinical failure.~In case of a primary colostomy, restoration of bowel continuity was attempted within 3-6 months."
88958838|NCT01997684|Active Comparator|Emergency Surgery|"In the comparator group, patients will be undergo emergency surgery. Surgical options including but not limited to: loop colostomy, Hartmann's procedure, and (sub) total colectomy with ileostomy or ileorectal anastomosis.~In case of a primary colostomy, restoration of bowel continuity was attempted within 3-6 months."
88958839|NCT01997736|Experimental|Ablation|
89206979|NCT02547870|Experimental|Aged RPV-LA|Participants will receive oral tablet of rilpivirine 25 milligram (mg) once on Day 1 of session 1 and IM injection of aged rilpivirine long-acting parenteral formulation 600 mg once on day 1 of session 2.
89206980|NCT04251897|Active Comparator|Standard care mattress|Patient will have 2 days to familiarize with the novel support surface. Patient will be on standard care mattress. They will be turned over every 2 hours for 3 days.
89206981|NCT04251897|Experimental|Novel support surface|"After the standard care mattress, the same patient will be placed on novel support surface. They will be turned over every 2 hours for 3 days.~Patient will then continue with the novel support surface and turned every 3 hours for 3 days.~They will then continue with the novel support surface and turned every 4 hours for 3 days."
89206982|NCT00836238||Questionnaire + Fall Risk Assessment|Physical Function Interview + Physical Function Tests + Symptom Assessment Interview
89206983|NCT02547168|Experimental|iRhythm ZIO XT patch group|This is the only arm in the study and patients within it will have a small, pebble shaped device adhered to their chests. This is an ECG (electrocardiogram) monitor and will measure the incidence of atrial fibrillation. It will have to be worn for 14 days before and after the lung resection procedure
89206984|NCT04016610|Experimental|ASR Treatment|Single and/or multi-treatment ASR device applied to the keloid scar for a period of 2 minutes for each 3 cm.
89206985|NCT00962169|Experimental|Quality improvement program|
88958840|NCT01997749|Experimental|Ketogenic diet|Acute stroke patients will receive a ketogenic diet (Ketocal 4:1 and ketogenic meals) for the first week after inclusion
88958841|NCT01997749|Active Comparator|Control diet|Acute stroke patients will receive a control diet (the regular diet, enteral or oral, offered at the hospitals) for the first week after inclusion.
88958842|NCT01997762|Placebo Comparator|Placebo|Corn starch capsules, 1 capsule twice a day for 3 months
88958843|NCT01997762|Experimental|Resveratrol|Resveratrol capsules, 250 mg twice a day for 3 months
88958844|NCT01997775|Experimental|METFORMIN|For patients with stage IV lung adenocarcinoma and IL-6 level higher than 2.0 pg/ml after 2 cycles of standard treatment, metformin 500mg tid orally will be given.
89206986|NCT00962169|Experimental|Electronic patient device (EPD)|
89206987|NCT00836394|Experimental|Intervention Group|Will undergo whole body vibration (WBV) therapy (6 minutes of training on 5 days a week for 3 months)
89206988|NCT00836394|No Intervention|Control|Will follow daily habitual activities
89206989|NCT00843960|Active Comparator|1|intervention group
89206990|NCT00843960|No Intervention|2|control group
89206991|NCT00962325|Experimental|Activity behaviors counseling|
89509587|NCT02264327|Active Comparator|MI Training + MI eBook|"Service Providers in all group will receive a free two-day Motivational Interviewing training. Service Providers in this group will also receive a Motivational Interviewing eBook designed to help Service Providers learn, maintain, and implement MI skills.~Clients of Service Providers from this group will receive no study related intervention. All Clients will receive identical surveys to collect client centered observational data of the interventions effect."
89509588|NCT02264327|Active Comparator|MI Training Only|"Service Providers in this group will only receive a free two-day Motivational Interviewing training.~Clients of Service Providers from this group will receive no study related intervention. All Clients will receive identical surveys to collect client centered observational data of the interventions effect."
89206992|NCT00962325|No Intervention|Standard care control|6 weeks of standard preoperative care
89509589|NCT01488929|Experimental|5 mg TC-5619|One tablet of 5 mg TC-5619 will be administered orally once a day.
89509590|NCT01488929|Experimental|50 mg TC-5619|One tablet of 50 mg TC-5619 will be administered orally once a day.
89509591|NCT01488929|Placebo Comparator|Placebo|One tablet of placebo will be administered orally once a day.
89509592|NCT01486277|Experimental|Quisinostat|Participants will receive quisinostat 12 mg capsule orally (by mouth) on Days 1, 3, and 5 of each week in a 21-day treatment cycle, until a reason for discontinuation is met (ie, disease progression, toxicity, availability of other effective medications that the participant may receive, or treating physician advice).
89509593|NCT01480583|Experimental|GRN1005|GRN1005 alone in HER2- MBC patients with brain mets. 18F-FLT may also be administered to this arm (if patient enrolled at NCI)
89509594|NCT01480583|Experimental|GRN1005 with trastuzumab|GRN1005 in combination with trastuzumab in MBC patients with brain mets 18F-FLT may also be administered to this arm (if patient enrolled at NCI)
89509595|NCT02264483||COPD exacerbation|"No intervention.~The subjects will be divided in 2 subgroups according to the image study:~COPD exacerbation with pneumonia~COPD exacerbation without pneumonia"
89509596|NCT02264483||COPD stable patients|
89509597|NCT04476407|Experimental|G1|subjects with nomal renal function
89509598|NCT04476407|Experimental|G2|subjects with mild renal impairment
89509599|NCT04476407|Experimental|G3|subjects with moderate renal impairment
89509600|NCT03135587|Experimental|Weight 0|The participants will not carry any loading to walk on treadmill.
89509601|NCT03135587|Experimental|Weight 10|The participants will wear 10kg loading suit to walk on treadmill.
89509602|NCT03135587|Experimental|Weight 20|The participants will wear 20kg loading suit to walk on treadmill.
89509603|NCT03135587|Experimental|Weight 30|The participants will wear 30kg loading suit to walk on treadmill.
89509604|NCT03135587|Experimental|Weight 40|The participants will wear 40kg loading suit to walk on treadmill.
89509605|NCT03135587|Experimental|Weight 50|The participants will wear 50kg loading suit to walk on treadmill.
89509606|NCT01474421|Experimental|AQW051 High Dose|AQW051 high dose daily given orally for 28 days.
89509607|NCT01474421|Experimental|AQW051 Low Dose|AQW051 low dose daily given orally for 28 days.
89509608|NCT01474421|Placebo Comparator|Placebo|Placebo daily given orally for 28 days.
89509609|NCT01470131|Experimental|Masitinib|Masitinib (6 mg/kg/day) in combination with Bortezomib and Dexamethasone
89509610|NCT01470131|Placebo Comparator|Placebo|Placebo in combination with Bortezomib and Dexamethasone
89509611|NCT02264561|Placebo Comparator|Placebo|Mannitol administered at visit 1 and at visit 2
89509612|NCT02264561|Active Comparator|caffeine|caffeine administered at visit 1 and at visit 2
89509613|NCT01464437|Active Comparator|AMG 151 - Arm 1|AMG 151 - Arm 1
89509614|NCT01464437|Active Comparator|AMG 151 - Arm 2|AMG 151 - Arm 2
89509615|NCT01464437|Active Comparator|AMG 151 - Arm 3|AMG 151 - Arm 3
89509616|NCT01464437|Active Comparator|AMG 151 - Arm 4|AMG 151 - Arm 4
89509617|NCT01464437|Active Comparator|AMG 151 - Arm 5|AMG 151 - Arm 5
89509618|NCT01464437|Active Comparator|AMG 151 - Arm 6|AMG 151 - Arm 6
89509619|NCT01464437|Placebo Comparator|Placebo Arm|AMG 151 Placebo Arm
89509620|NCT02925338||Patients treated with Inflectra|
89509621|NCT02264717|Active Comparator|Cardiac MRi|A minimum of 150 patients will be randomized to Cardiac MRI followed by conventional angiography CCA-FFR, after detection of obstructive anatomic coronary artery stenoses on coronary Computed Tomography Angiography (cCTA)
89509622|NCT02264717|Active Comparator|SPECT|A minimum 150 patients will be randomized to SPECT followed by conventional angiography CCA-FFR, after detection of obstructive anatomic coronary artery stenoses on coronary Computed Tomography Angiography (cCTA).
89509623|NCT01461317|Experimental|Etrolizumab|Etrolizumab 100 milligrams (mg) subcutaneous (SC) administration every 4 weeks during the treatment period of up to 240 weeks.
89509624|NCT01449071|Placebo Comparator|Placebo Group|
89509625|NCT01449071|Experimental|Epratuzumab 600 mg Group|
89509626|NCT01449071|Experimental|Epratuzumab 100 mg Group|
89509627|NCT01449071|Experimental|Epratuzumab 400 mg Group|
89509628|NCT01449071|Experimental|Epratuzumab 1200 mg Group|
89509629|NCT01445795|Experimental|200 mg INX-08189 Fasted|Cohort 1: 200 mg INX-08189 QD fasted for seven days
89509630|NCT01445795|Placebo Comparator|Placebo QD Fasted|Cohort 1: Placebo QD fasted for seven days
89509631|NCT01445795|Experimental|100 mg INX-08189 with Ribavirin|Cohort 2: 100 mg INX-08189 100 mg dosed with ribavirin x7 days (ribavirin will be dosed in a weight-based fashion as labeled BID, the AM dose will be taken 4 hours after INX-08189 so it may be taken with food)
89509632|NCT01445795|Active Comparator|Placebo QD dosed with ribavirin|Cohort 2: Placebo QD dosed with ribavirin x7 days (ribavirin will be dosed in a weight-based fashion as labeled BID)
89509633|NCT01445795|Experimental|100 mg INX-08189 with a low-fat meal|Cohort 3: 100 mg INX-08189 with a low-fat meal QD x7 days
89509634|NCT01445795|Placebo Comparator|Placebo with low-fat meal|Cohort 3: Placebo administered with a low-fat meal QD for 7 days
89509635|NCT01445795|Experimental|100 mg INX-08189 Fasted|Cohort 4: 100 mg INX-08189 BID fasted x7 days
89509636|NCT01445795|Placebo Comparator|Placebo BID Fasted|Cohort 4: Placebo BID fasted x7 days
89206993|NCT00839202|Experimental|FVIII immuno-assay|The study is not designed as a therapeutic evaluation, but an assessment of clotting factor VIII timed responses after the infusion of specified doses of licensed clotting factor VIII concentrates. The purpose of the study is to measure the levels of infused licensed clotting factor VIII by standard assay techniques and comparing these standard assays with an experimental assay. Measurements of possible co-factors that might impact the results were also carried out.
89509637|NCT04423328|Experimental|acupressure|Every day before going to sleep, massage acupoints for eight consecutive weeks, followed by Shenmen→Neiguan→Hegu acupoints.
89206994|NCT00962403|Experimental|Yoga treatment|
89206995|NCT00962403|No Intervention|Waitlist|Waitlist control, no active treatment, treatment as usual, active treatment offered after waitlist control period. This study began as a single arm treatment trial and then transitioned to a randomized controlled trial.
89206996|NCT00844038||1|Sick
89206997|NCT05010837|Experimental|Kinesio taping with abdominal exercises|Kinesio taping will be applied along with abdominal exercises.
89206998|NCT05010837|Active Comparator|Abdominal Exercises|Only abdominal exercises will be administered to the participants.
89206999|NCT04043754|Experimental|PRF treated patients|Periodontal surgery with Platelet Rich Fibrin is performed, after local anaesthesia, mucoperiosteal SPPFs will be raised. Autogenous corticocancellous BG material will be collected using bone scrapers , the PRF membrane cut into small pieces and mixed with the ABG will be placed within the IBDs until they will be completely filled. Then the other two PRF membranes in each patient will be adapted over the grafted defect Finally horizontal mattress and interrupted sutures will be carried out.
89207000|NCT04043754|Active Comparator|GTR treated patients|"Periodontal surgery with MEMBRANE is performed, after local anaesthesia, mucoperiosteal SPPFs will be raised. Autogenous corticocancellous BG material will be collected using bone scrapers ; then, ABG will be applied alternatively with MEMBRANE into the IBD according to the sandwich technique until the IBD will be completely filled. Finally the flap will be repositioned and sutures completed by interrupted sutures."
89207001|NCT00836550|Active Comparator|Control|The participants spoke with a live counselor prior to answering the knowledge measure
88958845|NCT01997788|Experimental|The ITM group|The postoperative pain management includes both the intrathecal morphine injection and the intravenous patient-controlled analgesia. Demerol on demand will be injected intravenously.
89207002|NCT00836550|Experimental|Video|
89207003|NCT02546778|Experimental|Dermosux RF|The group received the radio frequency for 20 minutes with the frequency of 1 MHz with 40 W.
89207004|NCT00546819|Experimental|ZOSTAVAX™|Participants administered ZOSTAVAX™ on Day 1.
89207005|NCT00546819|Placebo Comparator|Placebo|Participants administered Placebo on Day 1.
89207006|NCT04010643|Active Comparator|online cognitive behavioural therapy (oCBT)|"20 hours of online engagement with the oCBT programme over 5 weeks, distributed as follows.~Each week, the participants complete 1 hour of of the MoodGym program, followed by 2 hours of practical online CBT homework. To equate time and type of engagement spent in doing oCBT and oCBT+NCRT, 1 final hour per week is dedicated to completing online puzzles."
89207007|NCT04010643|Experimental|online neurocognitively-enhanced CBT (oCBT+oNCRT)|"20 hours of online engagement with the oCBT+oNCRT programme over 5 weeks, distributed as follows.~Each week, the participants complete 1 hour of the MoodGym program, followed by 1 hour of practical online CBT homework & 3 hours of the online NCRT programme Cognifit targeting attention, memory, and planning ability."
89207008|NCT00962481|Active Comparator|Bimosiamose|
89207009|NCT00962481|Placebo Comparator|Placebo|
89207010|NCT05299437|Experimental|Optimized therapy|"Patients with ascertained metastatic differentiated thyroid cancer will be studied with FDG PET, CT, and for genetic characterization. 100 MBq of 124-I are administered for blood and PET lesion dosimetry.~According Jentzen et al, good efficacy (Tumour Control Probability > 80%) is obtained with absorbed dose higher than 80 Gy to soft tissue metastases, and > 650 Gy to bone metastases. These values ae pursued with the limit of 2 Gy to blood.~Only soft tissue lesions will be considered as target for the calculation of the complete response rate.~However, for ethical reasons, therapeutic activity will be chosen in order to be effective both on soft tissue and bone lesions. Patients with too low predicted lesion absorbed dose even administering the Maximum Tolerable Activity (2 Gy to blood) will exit the protocol to receive the standard of care."
89207011|NCT00621504|Experimental|Ceftaroline fosamil for Injection|"Ceftaroline fosamil was administered in two consecutive 300-mg IV infusions over 30 minutes, every 12 hours (q12h).~In both treatment groups, two doses of oral clarithromycin (500 mg q12h), defined as adjunctive therapy, were initiated on Study Day 1 with study drug therapy in order to provide an immunomodulatory benefit and initial therapy for possible infection due to an atypical organism."
89207012|NCT00621504|Active Comparator|IV Ceftriaxone|"Ceftriaxone was administered as a 1-g IV infusion over 30 minutes followed by IV saline placebo infused over 30 minutes, every 24 hours (q24h).~In both treatment groups, two doses of oral clarithromycin (500 mg q12h), defined as adjunctive therapy, were initiated on Study Day 1 with study drug therapy in order to provide an immunomodulatory benefit and initial therapy for possible infection due to an atypical organism."
89207013|NCT00548145|Experimental|1|
89207014|NCT00548145|Active Comparator|2|
89509638|NCT04423328|Sham Comparator|sham acupressure|Every day before going to sleep, massage acupoints for eight consecutive weeks, followed by Waiguan→Liangqiu→Tiaokou→ Chengshan acupoints
89509639|NCT02264795|Placebo Comparator|Placebo|Intraperitoneal instillation of normal saline.
89509640|NCT02264795|Active Comparator|Lidocaine|Intraperitoneal instillation lidocaine 2% (400mg) with epinephrine 5mcg/ml.
89509641|NCT02264873|Other|Decitabine|This is a 3+3 design of dose escalation
88958846|NCT01997788|Placebo Comparator|The IV-PCA group|The postoperative pain management includes only the intravenous patient-controlled analgesia. Demerol on demand will be injected intravenously.
88958847|NCT01997801|Placebo Comparator|C group|In C group, NS infusion will be done intraoperatively.
89024091|NCT03598270|Placebo Comparator|Arm A (Control Arm)|"Placebo of atezolizumab in combination with one of the platinum based regimens below (investigator's choice) followed by maintenance niraparib with placebo:~Carboplatin (AUC = 5, d1) plus paclitaxel and placebo every 3 weeks. Non-progressing patients will be switched to maintenance niraparib in combination with placebo every 3 weeks~Carboplatin (AUC = 4, d1) plus gemcitabine and placebo every 3 weeks. Non-progressing patients will be switched to maintenance niraparib in combination with placebo every 3 weeks.~Carboplatin (AUC = 5, d1) plus pegylated liposomal doxorubicin (PLD) and placebo every 4 weeks. Non-progressing patients will be switched to maintenance niraparib in combination with placebo every 3 weeks."
89024092|NCT03598270|Experimental|Arm B (experimental arm)|"Atezolizumab in combination with one of the platinum based regimens below (investigator's choice) followed by maintenance niraparib with atezolizumab:~Carboplatin (AUC = 5, d1) plus paclitaxel and atezolizumab every 3 weeks. Non-progressing patients will be switched to maintenance niraparib in combination with atezolizumab every 3 weeks.~Carboplatin (AUC = 4, d1) plus gemcitabine and atezolizumab every 3 weeks. Non-progressing patients will be switched to maintenance niraparib in combination with atezolizumab every 3 weeks.~Carboplatin (AUC = 5, d1) plus pegylated liposomal doxorubicin (PLD) and atezolizumab every 4 weeks. Non-progressing patients will be switched to maintenance niraparib in combination with atezolizumab every 3 weeks."
89024093|NCT03596671|Experimental|Treatment arm|RENOVA iStim™ System implanted patients
89024094|NCT03593317|Experimental|Spironolactone group|
89024095|NCT03593317|Placebo Comparator|Placebo group|
89024096|NCT03581214|Active Comparator|Room air|Room air (no mask)
89024097|NCT03581214|Placebo Comparator|Oxygen|10L/min Oxygen by facemask
89024098|NCT03571763||acute ischemic stroke patient|acute ischemic stroke patient acute ischemic stroke patient Patient age ≥18 years .Acute ischemic stroke patient confirmed by imaging(SWI sequence) .Time of onset: within 3 months
89024099|NCT03568058|Experimental|vaccine and anti-PD-1|personalized vaccine and anti-PD-1 administered concurrently at the start of study therapy
89024100|NCT03568058|Experimental|anti-PD1 before vaccine|anti-PD-1 antibody for 6 weeks followed by personalized vaccine therapy
89024101|NCT03568058|Experimental|anti-PD1 and vaccine|anti-PD-1 antibody followed by personalized vaccine therapy
89024102|NCT03568058|Experimental|vaccine|personalized vaccine therapy
89024103|NCT03534700|Active Comparator|Open excision|open excision and healing by secondary intention, marsupialization, excision and primary closure (midline or off-midline), excision and repair by flap.
89024104|NCT03534700|Experimental|parasacral flap reconstruction|The parasacral perforator flap has been described. It appears to be a good alternative, offering all the benefits of the reconstruction of the natal cleft in terms of lower rate of recurrence and lower time for complete wound healing. It also gives a better aesthetic result.
89024105|NCT03517969|Active Comparator|Arm A (docetaxel, carboplatin)|Patients receive docetaxel IV over 60 minutes and carboplatin IV over 30 minutes, or carboplatin alone on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients who have PSA progression or radiographic progression may crossover to Arm B.
89024106|NCT03517969|Experimental|Arm B (carboplatin, berzosertib)|Patients receive carboplatin IV over 30 minutes on day 1 and berzosertib IV over 60-90 minutes on days 2 and 9. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89024107|NCT03517722|Experimental|Ustekinumab|Participants will receive ustekinumab approximately 6 milligram per kilogram (mg/kg) intravenously (IV) based on body weight-range at Week 0 followed by 90 mg ustekinumab subcutaneously (SC) at Week 8 and every 8 weeks (q8w) thereafter through Week 48 during double-blind period. Eligible participants who will enter the extension period will continue to receive 90 mg ustekinumab SC q8w through Week 160.
89024108|NCT03517722|Experimental|Placebo|Participants will receive matching placebo to ustekinumab IV at Week 0, followed by matching placebo to ustekinumab SC at Week 8 and q8w thereafter through Week 48 during double-blind period. Eligible participants who will enter the extension period will cross-over to receive 90 mg ustekinumab SC q8w through Week 160.
89024109|NCT03507491|Experimental|Gemcitabine + Nab-paclitaxel|Participants receiving gemcitabine and nab-paclitaxel for refractory and/or relapsed solid tumors of childhood.
89024110|NCT03503370|Experimental|Chlorhexidine|Participants randomized to the intervention will wash their feet using 2% CHLORHEXIDINE GLUCONATE CLOTHS to wipe down their feet each day and then apply supplied chlorhexidine-compatible over-the-counter moisturizer.
89024111|NCT03503370|Placebo Comparator|Placebo|Participants randomized to the placebo will wash their feet using COMFORT BATH CLOTHS to wipe down their feet each day and then apply supplied chlorhexidine-compatible over-the-counter moisturizer.
89024112|NCT03484884||Thyroid cancer/nodal metastasis|Participants will have thyroid cancer and nodal metastasis in the neck, supraclavicular, axillary and/or inguinal area.
89207015|NCT00547911|Experimental|LDOPS + Placebo; LDOPS + CAR; LDOPS + ENT|Each subject received 400 mg of droxidopa (LDOPS) with three separate interventions, i.e., LDOPS with 200 mg placebo, LDOPS with 200 mg carbidopa (CAR), and LDOPS with 200 mg entacapone (ENT). The order of the three interventions was randomly assigned prior to drug administration and each intervention was followed by a wash out period of at least two days. This arm received the three interventions in the order of: LDOPS + Placebo, followed by LDOPS + CAR, followed by LDOPS + ENT.
89509642|NCT02264951|Active Comparator|A meal containing carrot and tributyrin|A meal containing 200 g grated carrot and 0.0216 mol tributyrin; blood test taken from 0 - 2 hours postprandial
89509643|NCT02264951|Active Comparator|A meal containing carrot and C8-diet oil|A meal containing 200 g grated carrot and 0.0216 mol of C8-diet oil; blood test taken from 0 - 2 hours postprandial
89024115|NCT03465696|No Intervention|Group #1 (Control)|"Group #1 (Control)~Oral survey 1 will be administered and patients will be asked:~Stelara® inhibits interleukin 23, one of the immune signaling molecules involved in psoriasis.~How willing would you be to take Stelara® to treat your psoriasis, on a scale of (1 = definitely willing, 2 = probably willing, 3 = probably not willing, 4 = definitely not willing)"
89024116|NCT03465696|Experimental|Group #2 (Intervention)|"Group #2 (Intervention)~Survey 2 will be administered, and patients will be asked the following primer:~Stelara® inhibits interleukin 23, one of the immune signaling molecules involved in psoriasis. People who are born with a genetic deficiency in the immune signal interleukin-23 are generally healthy, but also have a LOWER risk of getting immune diseases like psoriasis.~How willing would you be to take Stelara® to treat your psoriasis, on a scale of (1 = definitely willing, 2 = probably willing, 3 = probably not willing, 4 = definitely not willing)"
89024117|NCT03465696|Experimental|Group #3 (Intervention)|"Group #3 (Intervention)~Survey 3 will be administered, and patients will be asked the following primer:~Stelara® inhibits interleukin 23, one of the immune signaling molecules involved in psoriasis. People who are born with a genetic deficiency in the immune signal interleukin-23 are generally healthy, but also have a LOWER risk of getting immune diseases like psoriasis.~What do you think would be the best way to describe this to a patient?~Stelara® acts in an almost all-natural way to help control psoriasis.~Stelara® blocks one of the genetic causes of psoriasis.~Stelara® makes psoriasis better by blocking the overactive signal that gets the immune system out of balance~Stelara® blocks interleukin-23, an important immune system signaling molecule involved in psoriasis~How willing would you be to take Stelara® to treat your psoriasis, on a scale of (1 = definitely willing, 2 = probably willing, 3 = probably not willing, 4 = definitely not willing)"
89024118|NCT03441282||ASA Patients I|"Age 18-80 years old, English-speaking, not on current Fentanyl/opioid therapy, no use of opioid medications in the 3 months prior to surgery, scheduled for elective surgery at UAB main.~A normal healthy patient Healthy, non-smoking, no or minimal alcohol use"
89509644|NCT02264951|Active Comparator|A meal containing carrot and olive oil|A meal containing 200 g grated carrot and 0.0216 mol of olive oil; blood test taken from 0 - 2 hours postprandial
89509645|NCT02264951|Placebo Comparator|A meal containing carrot|A meal containing 200 g grated carrot; blood test taken from 0 - 2 hours postprandial
89509646|NCT01438775|Experimental|Open Label Injection of NX-1207|Intraprostatic injection of 2.5 mg NX-1207
89509647|NCT02543528|Experimental|etafilcon A (1-Day) and etafilcon A (Reusable)|Prior to randomization, all subjects will participate in a 2-week contact lens adaptation period wearing etafilcon A (1-Day). Subjects will then be randomized to one of four experimental contact lenses to be worn continuously in 6 nights/7 days wear cycles for 6 months of total wear.
89509648|NCT02543528|Experimental|etafilcon A (1-Day) and Investigational Lens 1|Prior to randomization, all subjects will participate in a 2-week contact lens adaptation period wearing etafilcon A (1-Day). Subjects will then be randomized to one of four experimental contact lenses to be worn continuously in 6 nights/7 days wear cycles for 6 months of total wear.
89509649|NCT02543528|Experimental|etafilcon A (1-Day) and Investigational Lens 2|Prior to randomization, all subjects will participate in a 2-week contact lens adaptation period wearing etafilcon A (1-Day). Subjects will then be randomized to one of four experimental contact lenses to be worn continuously in 6 nights/7 days wear cycles for 6 months of total wear.
89509650|NCT02543528|Experimental|etafilcon A (1-Day) and Investigational Lens 3|Prior to randomization, all subjects will participate in a 2-week contact lens adaptation period wearing etafilcon A (1-Day). Subjects will then be randomized to one of four experimental contact lenses to be worn continuously in 6 nights/7 days wear cycles for 6 months of total wear.
89509651|NCT02265029|Active Comparator|Immediate spa treatment|Spa treatment during 18 days soon after randomization : the most adapted to the concerned pathology and common to all of spa resorts (whirpool bath with automatic air and water massage cycles, massaging shower,...)
89509652|NCT02265029|Sham Comparator|Late SPA treatment|Spa treatment during 18 days soon after 6 months visit : the most adapted to the concerned pathology and common to all of spa resorts (whirpool bath with automatic air and water massage cycles, massaging shower,...)
89509653|NCT04458974|Experimental|Experimental group (Exp)|Active tDCS + conventional rehabilitation therapy (physiotherapy and neuropsychological rehabilitation)
89509654|NCT04458974|Sham Comparator|Sham-tDCS (Sham)|Sham tDCS + conventional rehabilitation therapy (physiotherapy and neuropsychological rehabilitation
89509655|NCT04458974|Other|Control group (Control)|Conventional rehabilitation therapy (physiotherapy and neuropsychological rehabilitation) without tDCS.
89509656|NCT03135509|Experimental|Treatment A (Reference)- CC-220 gelatin capsules|A single dose of 0.6 mg CC-220, administered as two 0.3-mg formulated CC-220 gelatin capsules.
89509657|NCT03135509|Experimental|Treatment B (Test)- CC-220 HPMC capsule|A single dose of 0.6 mg CC-220, administered as one 0.6-mg formulated CC-220 hydroxypropyl methylcellulose (HPMC) capsule.
89509658|NCT05461118|Experimental|Treatment group|Consented subjects will undergo osteotomies for their resective and reconstructive procedures using mixed reality adjuncts (Magic Leap ®, Microsoft Hololens ®) to commercially available navigation platforms (BrainLAB ®).
89509659|NCT02265107|Experimental|cardiac rehabilitation|We invited all consecutive patients submitted to CABG alone at Cardiologic Hospital Doctor Pedro Bertoni of the Associação de Caridade Santa Casa do Rio Grande in the period of October, 2011 until October, 2012, who resided in the city of the Rio Grande (RS/Brazil), to participate of the exercise training (ET). All patients were evaluated by cardiologist, and were ranked in Functional Classification of New York Heart Association (NYHA) such class I and II. Initially, twenty-four patients accepted and start to participate of ET, but only nine patients completed the program until the end.
89519424|NCT05163743|Experimental|Ketogenic Diet-obese|LCKD (1200-1400kcal/day) low in carbohydrates (<50g per day) with a moderate protein intake (1-1.5g/kg of ideal body mass) but otherwise no other dietary restrictions. The participants will be counselled by a trained nutritionist at baseline and every two weeks, and compliance will be assessed through a 3-day dietary recall at each follow up visit and capillary beta hydroxybutyrate levels as well as urinary acetoacetate levels. The follow up visits take place at the time of the first vaccine dose, two weeks after the first vaccine dose, one week after the second vaccine dose. Then, gradual reintroduction of carbohydrates will take place following the second vaccine dose.
89509660|NCT05434910|Experimental|Intervention|"Changes in mean arterial pressure (MAP).~In all subjects MAP is temporally adjusted using noradrenaline to the following three levels:~MAP 65 mmHg.~MAP 80 mmHg.~MAP 95 mmHg. When MAP has been stable at the given level for 20 min, measurements are conducted over 5 min. When the measurements are done, the study is finished. The study will last approximately 2 hours.~Measurements include internal carotid and vertebral artery blood flow, mean arterial pressure, heart rate, peripheral O2 saturation, cardiac output, left ventricle ejection fraction, frontal lobe and muscle oxygenation, blood velocity in the middle cerebral artery, pupillometry, and arterial, central venous, and internal jugular venous gas variables and blood samples for analysis of metabolomics."
89509661|NCT02265185||ED Patients|Children aged 2-10 visiting the Emergency Department.
89509662|NCT02265263||Surgical patients - 3 Tesla MRI|"A study group of at maximum n= 1200 is collected for measuring 3 Tesla MRI at two timepoints (Baseline and 90 days) in Berlin/Utrecht. They include surgical procedures within body cavity e.g. abdomen or thorax from departments of general surgery, urology, gynecology or thoracic surgery; orthopaedic operations (hip-, knee-, endoprosthesis or spine (including neurosurgical spine operations)); cardiac surgery and operation of extracranial/intracranial head and neck~Data collection from study center Utrecht ist within one year after initial hospital stay. Data collection from study center Berlin is within two years after initial hospital stay."
89509663|NCT02265263||Patients ASA II/III - 3 Tesla MRI|"A control group of at maximum n= 300 ASA II/III- patients is collected for measuring the learning experience during the cognitive testings. They are matched on age, education, and gender to the study patients. The 104 ASA II/III- patients should receive additionally MRI-scan (3 Tesla) at baseline, after 3 months and after 1 year in Utrecht, after 3 months, after 1, 2 years in Berlin.~Data collection from study center Utrecht ist within one year after initial hospital stay. Data collection from study center Berlin is within five years after initial hospital stay."
89509664|NCT02265263||Volunteers ASA I/II - 3 Tesla MRI|To analyze scanner variability we additionally measure at maximum 20 subjects (Age ≥ 65 years) from Utrecht in the MRI scanner (3-Tesla) in Berlin and vice versa.
89509665|NCT02265263||Surgical patients - 7 Tesla MRI|A study Group of at maximum n= 80 should be collected for measuring 7 Tesla MRI at two timepoints (Baseline and 90 days) in Berlin.
89509666|NCT02265419|Experimental|Cytosorb group|Extracorporeal treatment with the Cytosorb adsorber for 24 hours after heart surgical operation.
89509667|NCT01494233|Experimental|Low dose|500 mg LX1033 two times daily
89509668|NCT01494233|Experimental|Mid dose|500 mg LX1033 three times daily
89509669|NCT01494233|Experimental|High dose|1000 mg LX1033 two times daily
89509670|NCT01494233|Placebo Comparator|Placebo|Matching placebo dosing
89509671|NCT05379296|Active Comparator|Diabetes Prevention Program (DPP)|CDC-approved 12-month DPP virtual lifestyle program
89509672|NCT05379296|Experimental|Diabetes Prevention Program Plus (DPP+)|CDC-approved 12-month DPP virtual lifestyle program expanded to include a CDC-approved module on hypertension prevention and treatment
89509673|NCT02265497||Hodgkin's or non-Hodgkin lymphoma|All patients with diagnoses of Hodgkin's or non-Hodgkin lymphoma with available with available clinical, histopathology and treatment data.
89509674|NCT05378828|Other|Use of an electric wheelchair with or without sensors|During 3 weeks, the electric weehlchair will not have sensors, then sensors will be put on the wheelchair for the next 3 weeks then removed for 3 other weeks.
89509675|NCT01418261|Experimental|Renal Denervation|Subjects are treated with the renal denervation procedure after randomization and maintained baseline anti-hypertensive medications
89509676|NCT01418261|Sham Comparator|Control group|Subjects go through renal angiogram and Subjects maintained baseline anti-hypertensive medications
89509677|NCT01417091|Experimental|Treatment group|
89509678|NCT01417091|No Intervention|Untreated reference group|
89509679|NCT01412177|Experimental|OTO-104|
89509680|NCT01412177|Placebo Comparator|Placebo|
89509681|NCT01411163|Experimental|Creatine|
89509682|NCT00156533|Placebo Comparator|Placebo|QHS dosing with placebo (i.e. nightly dose)
89509683|NCT00156533|Active Comparator|QHS Zolpidem|QHS dosing with 10mg of zolpidem (i.e. nightly dose)
89509684|NCT00156533|Experimental|Intermittant Zolpidem|Intermittent dosing with 10mg of zolpidem (3-5 pills per week as needed
89509685|NCT00156533|No Intervention|Control|Monitor only condition (no placebo, no drug).
89509686|NCT01410695|Experimental|masitinib 3 mg|masitinib 3 mg/kg/day, tablets, orally, twice a day
89509687|NCT01410695|Experimental|masitinib 6.0 mg|masitinib 6.0 mg/kg/day, tablets, orally, twice a day
89509688|NCT01410695|Active Comparator|methotrexate|methotrexate at the dose of 15 or 20 mg per week
89509689|NCT01660022|Experimental|OZ439 100mg|100mg OZ439 single oral dose
89509690|NCT01660022|Experimental|OZ439 100 mg + PQP 160mg|100mg OZ439 single oral dose + 160mg Piperaquine single oral dose
89509691|NCT01660022|Experimental|OZ439 100 mg + PQP 480mg|100mg OZ439 single oral dose + 480mg Piperaquine single oral dose
89509692|NCT01660022|Experimental|OZ439 100 mg + PQP 1440mg|100mg OZ439 single oral dose + 1440mg Piperaquine single oral dose
89509693|NCT01660022|Experimental|OZ439 300mg|300mg OZ439 single oral dose
89509694|NCT01660022|Experimental|OZ439 300 mg + PQP 1440mg|300mg OZ439 single oral dose + 1440mg Piperaquine single oral dose
89509695|NCT01660022|Experimental|OZ439 800mg|800mg OZ439 single oral dose
89509696|NCT01660022|Experimental|OZ439 800 mg + PQP 1440mg|800mg OZ439 single oral dose + 1440mg Piperaquine single oral dose
89509697|NCT01660022|Placebo Comparator|Placebo|Placebo
89509698|NCT01406561|Experimental|OMS103HP-S|OMS103HP-S injected into vehicle irrigation solution for administration during meniscectomy surgery
89509699|NCT01406561|Placebo Comparator|Vehicle Irrigation Solution|Vehicle Irrigation Solution
89509700|NCT02265575|Experimental|hyaluronic acid|Rehydration using hyaluronidase-assisted subcutaneous infusion
89509701|NCT02265653|Experimental|BIIL 284 BS tablet C|
89509702|NCT02265653|Experimental|BIIL 284 BS tablet D|
89509703|NCT02265653|Active Comparator|BIIL 284 BS WIF tablet|
89509704|NCT01396811|Experimental|Active|Product 33525
89509705|NCT01396811|Placebo Comparator|Placebo|Product 33525 Placebo
89509706|NCT03135353|Experimental|3D saline infusion sonohysterography|participants presenting with abnormal uterine bleeding will undergo 3D saline infusion sonohysterography
89509707|NCT03135353|Experimental|Office hysteroscopy|after undergoing 3D SIS, cases would undergo office hysteroscopy and the investigator would be blinded to the results of SIS
89509708|NCT02265731|Experimental|Arm A (Phase 1)|Step-up doses of venetoclax to the designated cohort dose administered in participants with relapsed or refractory (R/R) Non-Hodgkin lymphoma (NHL) or multiple myeloma (MM)
89509709|NCT02265731|Experimental|Arm B (Phase 1)|Step-up doses of venetoclax to the designated dose administered in participants with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
89509710|NCT02265731|Experimental|Arm C (Phase 1)|Step-up doses of venetoclax to the designated dose with the addition of azacitidine administered in participants with acute myeloid leukemia (AML)
89509711|NCT02265731|Experimental|Arm D (Phase 2)|Step-up doses of venetoclax to the designated dose with the addition of rituximab in participants with R/R CLL
89509712|NCT02265809|Experimental|Aldesleukin|Aldesleukin will be administered subcutaneously at varying doses and frequencies for a period of up to 98 days from first administration depending on the treatment assignment. The maximum dose allowed is 0.6 X 10^6 IU/m2.
89509713|NCT01388933|Experimental|TU-100|15g TU-100 (oral, daily) for 8 consecutive weeks (administered as 5g three times daily)
89509714|NCT01388933|Placebo Comparator|Matching placebo|Matching placebo given 5g three times daily orally for 8 consecutive weeks
89509715|NCT01372475|Active Comparator|Hymovis Viscoelastic Hydrogel|Intra-articular Injection
89509716|NCT01372475|Placebo Comparator|Placebo|Phosphate Buffered Saline Intra-articular Injection
89509717|NCT04453631|Experimental|active tDCS + CBT-UP|Active tDCS combined with the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders.
89509718|NCT04453631|Active Comparator|sham tDCS + CBT-UP|Sham tDCS (control for active tDCS) combined with the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders.
89509719|NCT04453631|Active Comparator|active tDCS + Psychoeducation|Active tDCS combined with psychoeducation (control condition for CBT-UP).
89509720|NCT04453631|Placebo Comparator|sham tDCS + Psychoeducation|Sham tDCS combined with psychoeducation (control conditions for active tDCS and CBT-UP).
89509721|NCT01369589|Experimental|P-552 on Day 1 and Placebo on Day 2|Randomly assigned subjects will receive a single dose of P-552 on Day 1 followed by a single dose of Placebo on Day 2
89509722|NCT01369589|Experimental|Placebo on Day 1 and P-552 on Day 2|Randomly assigned subjects will receive a single dose of Placebo on Day 1 followed by a single dose of P-52 on Day 2
89509723|NCT00156065|Active Comparator|Haloperidol/Haloperidol|Haloperidol in original study (NCT00156104) and in current long-term extension.
89509724|NCT00156065|Experimental|Asenapine/Asenapine|Asenapine in original study and asenapine in current long-term extension.
89509725|NCT00156065|Experimental|Placebo/Asenapine|Double-Blind subjects randomized to only placebo medication for 6 weeks in the short-term 041023 asenapine trial, were randomized (double-blind) into the long-term 041513 asenapine extension trial and received asenapine 5 mg BID for Week 1. After Week 1, subjects received asenapine (either 5 mg BID or 10 mg BID) for the remainder of the 52-week trial.
89509726|NCT05570981||Chronic Refractory Cough (CRC)|Individuals with a diagnosis of chronic refractory cough
89509727|NCT05570981||Healthy controls|Healthy control subjects matched to the CRC group by age and gender
89509728|NCT02266199||conservative patients|in-patients on pneumology, cardiology, neurology, gastroenterology, endocrinology
89509729|NCT02266199||operative patients|inpatient on Traumatology, Plastic Surgery, Cardiothoracic Surgery, Gynecology, Abdominal Surgery
89509730|NCT01361555|Experimental|Arm 1: Placebo + BMS-820836 (0.5 mg/day)|
88958848|NCT01997801|Experimental|KET group|In KET group, ketamine infusion will be done intraoperatively(0.25 mg/kg bolus injection following 100 mcg/kg/hr till the end of surgery).
88958849|NCT01997814|Active Comparator|Test Group|Patients in Test Group were given Herbal Immunomodulators (SeptilinTM) 2 tablets twice daily for 3 weeks then medications were stopped and changes in all parameters were again checked after 6 weeks.
88958850|NCT01997814|Placebo Comparator|Control Group|Patients in Control Group were given placebo drug 2 tablets twice daily for 3 weeks then medications were stopped and changes in all parameters were again checked after 6 weeks.
88958851|NCT01997827|Active Comparator|metal-ceramic RBFDP|Treatment with a metal-ceramic RBFDP
88958852|NCT01997827|Experimental|all-ceramic RBFDP|Treatment with an all-ceramic RBFDP
88958853|NCT01997853|Active Comparator|Test Group|Patients with Chronic Periodontitis in Test Group were prescribed Omega 3 fatty acid tablets 300mg once daily for 12 weeks
89509731|NCT01361555|Experimental|Arm 2: Placebo + BMS-820836 (1 mg/day)|
89509732|NCT01361555|Experimental|Arm 3: Placebo + BMS-820836 (2 mg/day)|
89509733|NCT01554956|Experimental|Human Plasminogen|Human Plasminogen Eye Drop treatment
89509734|NCT01360853|Experimental|Arm A: Combination|Arm A: Gemcitabine, 1000 mg/m2 weekly for 3 weeks of a 4 week cycle, + ON 01910.Na, 1800 mg/m2 via 2 hr CIV infusions administered twice weekly for 3 weeks of a 4 week cycle.
88958854|NCT01997853|Placebo Comparator|Control Group|Patients with Chronic Periodontitis in Control Group were prescribed Placebo tablets once daily for 12 weeks
88958855|NCT01997866|Other|Patients with Congestive Heart Failure|"STOP-BANG Scoring Model~Polysomnogram Sleep Study"
88958856|NCT01997944|Experimental|Human Serum Albumin/interferon alpha2a|Human Serum Albumin/interferon alpha2a 600,750 or 900 mcg multiple dose S.C.
89509735|NCT01360853|Active Comparator|Arm B: Gemcitabine only|Arm B: Gemcitabine only, 1000 mg/m2 weekly for 3 weeks of a 4 week cycle.
89519425|NCT03129685|Experimental|Devascularization|Patients undergoing ipsilateral hepatic artery ligation with extrahepatic collaterals division (HALED)
89509736|NCT01355393|Experimental|Stage I, Arm 1 (HER-2/neu peptide vaccine and rintatolimod)|"Arm 1: HER2 peptide vaccine + 4 mcg Ampligen®~Five groups of randomized patients with each group receiving the synthetic HER-2/neu peptide vaccine admixed with rintatolimod (different doses)."
89509737|NCT01355393|Active Comparator|Stage II, Arm I (HER-2/neu peptide vaccine and sargramostim)|Patients receive synthetic HER-2/neu peptide vaccine admixed with GM-CSF ID.
89509738|NCT01355393|Experimental|Stage II, Arm II (HER-2 vaccine, sargramostim, rintatolimod)|Patients receive synthetic HER-2/neu peptide vaccine admixed with GM-CSF and rintatolimod ID
89509739|NCT01355393|Experimental|Stage I, Arm 2 (HER-2/neu peptide vaccine and rintatolimod)|"Arm 2: HER2 peptide vaccine + 20 mcg Ampligen®~Five groups of randomized patients with each group receiving the synthetic HER-2/neu peptide vaccine admixed with rintatolimod (different doses)."
89509740|NCT01355393|Experimental|Stage I, Arm 3 (HER-2/neu peptide vaccine and rintatolimod)|"Arm 3: HER2 peptide vaccine + 79 mcg Ampligen®~Five groups of randomized patients with each group receiving the synthetic HER-2/neu peptide vaccine admixed with rintatolimod (different doses)."
89509741|NCT01355393|Experimental|Stage I, Arm 4 (HER-2/neu peptide vaccine and rintatolimod)|"Arm 4: HER2 peptide vaccine + 495 mcg Ampligen®~Five groups of randomized patients with each group receiving the synthetic HER-2/neu peptide vaccine admixed with rintatolimod (different doses)."
89509742|NCT01355393|Experimental|Stage I; Arm 5 (HER-2/neu peptide vaccine and rintatolimod)|"Arm 5: HER2 peptide vaccine + 2000 mcg Ampligen®~Five groups of randomized patients with each group receiving the synthetic HER-2/neu peptide vaccine admixed with rintatolimod (different doses)."
89509743|NCT05425472|Experimental|HR070803|HR070803 monotherapy will be administered by intravenous infusion
89509744|NCT02266355|Experimental|OmalizumabTreatment Group|Omalizumab (Xolair) 300 mg SQ every 2 weeks
89509745|NCT05542901|Other|Diabetic Group (DG)|Examine the effect of joint position sense on compliance with the prosthesis, balance and functional performance in individuals with lower extremity amputation due to diabetic polyneuropathy.
89509746|NCT05542901|Other|Traumatic Group (TG)|Examine the effect of joint position sense on compliance with the prosthesis, balance and functional performance in individuals with lower extremity amputation due to traumatic causes.
89509747|NCT02266511|Experimental|Sequence 1|Flomax®, Nishine facility followed by Flomax®, Norman II facility
89509748|NCT02266511|Experimental|Sequence 2|Flomax®, Norman II facility followed by Flomax®, Nishine facility
89509749|NCT02266589|Experimental|Hydrocortisone|little doses of hydrocortisone
89509750|NCT02266589|No Intervention|Placebo|Placebo
89509751|NCT02266667|Experimental|Progressive scoliosis|Children with progressive scoliosis
89509752|NCT02266667|Experimental|Neuromuscular scoliosis|Children with neuromuscular scoliosis
89509753|NCT02266823|Active Comparator|Intervention: Lifestyle A.|"Lifestyle A will receive an iPad loaded with a self-monitoring program used to support vigilance, reduce the information processing requirements, make readily available the information required to make good self-management decisions, provide real-time feedback, and permit targeted counseling in the context within which lifestyle behaviors occur.~Using Social Cognitive Theory, the study dietitian will counsel participants via videoconferencing software on the iPad. Using the detailed nutritional and physical activity feedback from the self monitoring programs, the dietitian will use SCT to engage the participants in order to initiate healthy behavior change whilst reducing the demands of commuting for in person nutritional counseling."
89509754|NCT02266823|Other|Intervention: Lifestyle B.|"Participants randomized to this group will receive 6 months of routine care followed by a delayed intervention. Lifestyle B will employ the same diet and physical activity prescription as Lifestyle A as described above.~Using Social Cognitive Theory, the study dietitian will counsel participants via videoconferencing software on the iPad. Using the detailed nutritional and physical activity feedback from the self monitoring programs, the dietitian will use SCT to engage the participants in order to initiate healthy behavior change whilst reducing the demands of commuting for in person nutritional counseling."
89509755|NCT01321463|Experimental|PH-797804|
89509756|NCT01321463|Placebo Comparator|Placebo|
89509757|NCT02266901||Cases (endoscopic drainage)|Septic patients presenting post-bariatric collections related to leaks not adequately drained by percutaneous drain, for whom endoscopic drainage of the collections was performed by transluminal or percutaneous route.
89509758|NCT01300013|Experimental|Omecamtiv mecarbil|
89509759|NCT01300013|Placebo Comparator|Placebo|
88958857|NCT01997944|Active Comparator|Pegasys|Peginteferon 180 mcg multiple dose S.C.
88958858|NCT01997957|Experimental|TACE+HAIC-OXA+S-1|
88958859|NCT01997957|No Intervention|TACE+HAIC-OXA|
88958860|NCT01997970|Experimental|Treadmill workstation|Will receive a health talk with recommendations about diet and physical activity habits and will also receive a treadmill workstation at regular office site for 12 months.
88958861|NCT01997970|Experimental|Control group|Will receive a health talk with recommendations about diet and physical activity habits. Will continue to work with conventional office work at their regular desk.
88958862|NCT01997983|Experimental|TC-3 Gel with Botox|open label observational study
88958863|NCT01997996||PROLIFT+M|Patients that undergo surgery due to prolapse POP ≥ stage II with PROLIFT+M device having had ≥ 2x/4 weeks sexual intercourse before surgery.
88958864|NCT01998009|Other|Fecal occult blood tests|Each patient will perform one guaiac and two immunochemical fecal occult blood tests at home.
88958865|NCT01998048|Active Comparator|Latarjet|60 patients treated with open Latarjet operation
88958866|NCT01998048|Active Comparator|Bankart|60 patients treated with arthroscopic Bankart operation
88958867|NCT01998061|Experimental|Arm A|TKI alone until rapid progression
88958868|NCT01998061|Experimental|Arm B|TKI combined with investigator's choice of chemotherapy regimen and subsequent line of treatment until rapid progression.
88958869|NCT01998074|Experimental|Study formula|
89509760|NCT01298687|Experimental|Trav 0.00013%|Travoprost Ophthalmic Solution, 0.00013%, 1 drop administered in each eye 12 times per day at 2-hour intervals for 5 days
89509761|NCT01298687|Experimental|Trav 0.00033%|Travoprost Ophthalmic Solution, 0.00033%, 1 drop administered in each eye 12 times per day at 2-hour intervals for 5 days
89509762|NCT01298687|Experimental|Trav 0.001%|Travoprost Ophthalmic Solution, 0.001%, 1 drop administered in each eye 12 times per day at 2-hour intervals for 5 days
88958870|NCT01998087|Experimental|Breastfeeding support|A breastfeeding brochure will be distributed to expectant mothers from 20 weeks gestation during their regular antenatal visit. This will be followed 2 weeks later by a phone call offering clarification/explanation of the brochure. Three standardized phone calls, offering breastfeeding support, will be conducted at 2,6 and 10 weeks following birth of the baby.
88958871|NCT01998087|Active Comparator|General Support|The active control group of mothers will receive a brochure in pregnancy covering general pregnancy and parenting issues and follow-up phone calls but breastfeeding issues will not be specifically addressed. If a mother raises any breastfeeding issue she will be referred to appropriate support.
89509763|NCT01298687|Experimental|Trav 0.00267%|Travoprost Ophthalmic Solution, 0.00267%, 1 drop administered in each eye 12 times per day at 2-hour intervals for 5 days
89509764|NCT01298687|Active Comparator|TRAVATAN|Travoprost Ophthalmic Solution, 0.004%, 1 drop administered in each eye at 8 pm for 5 days, with 1 drop of vehicle administered at all other timepoints (2-hour intervals)
89509765|NCT01298687|Placebo Comparator|Vehicle|Travoprost vehicle, 1 drop administered in each eye 12 times per day at 2-hour intervals for 5 days
89509766|NCT02267057|Active Comparator|Paracetamol or buprenorphine treatment|Paracetamol tablets 1 g three times daily or Buprenorphine transdermal system 5 micrograms/hour every 7 days, may be titrated up to 10 micrograms/hour every 7 days if clinically appropriate.
89509767|NCT02267057|Placebo Comparator|Paracetamol placebo or buprenorphine placebo|Paracetamol placebo tablet three times daily or buprenorphine transdermal system placebo every 7 days.
89509768|NCT04476095|Experimental|Active PBMT|Active PBMT will be performed twice a week (at the same time of the day), with intervals of three or four days between sessions, during three-week period (a total of 6 sessions).
89509769|NCT04476095|Placebo Comparator|Placebo PBMT|Placebo PBMT will be performed twice a week (at the same time of the day), with intervals of three or four days between sessions, during three-week period (a total of 6 sessions).
89509770|NCT04475861|Experimental|L-arginine supplements|The enrolled subjects will then be randomized into two groups. Study Group: will take a supplementation pill containing 5 g L-arginine (0.5g/ pill, GNC, USA) All the food intake of the subjects during the 4 weeks of the study will be recorded and supervised by responsible dietitians.
89509771|NCT04475861|No Intervention|nutritional supports|"The enrolled subjects will then be randomized into two groups. Control group: will take a supplementation pill containing 5 g whey protein (5g/ pack, Santosa,Taiwan).~All the food intake of the subjects during the 4 weeks of the study will be recorded and supervised by responsible dietitians."
89509772|NCT05328557|Experimental|CUG252|Participants will be randomized in a 3:1 ratio to CUG252 or placebo. CUG252 or placebo will be administered at a single ascending dose in healthy volunteers.
89509773|NCT05328557|Placebo Comparator|Placebo|Participants will be randomized in a 3:1 ratio to CUG252 or placebo. CUG252 or placebo will be administered at a single ascending dose in healthy volunteers.
89509774|NCT02267213|Experimental|Lipotecan|Administer 40mg of Lipotecan at D1, D8, D15 of each cycles.
89509775|NCT02267291|Experimental|All patients|Ventilatory support to alter intrathoracic pressure
89519426|NCT02419807|Experimental|Diagnostic (indocyanine green, 99mTc-labeled radiotracer)|Participants receive technetium Tc-99m sulfur colloid injection and undergo lymphoscintigraphy according to clinical practice. Prior to surgery, participants also receive indocyanine green solution subdermally close to the tumor or into subareolar region of the breast skin. Participants then undergo Axillary Lymph Node Biopsy and surgery.
89519427|NCT05163509|Experimental|MR-Linac Guided Adaptive Radiotherapy|Patients will receive Adaptive Radiotherapy on the MR-Linac treatment machine.
88958872|NCT01998087|No Intervention|Standard Care|This group will receive standard antenatal care provided by their chosen gynaecologist and obstetrician, consisting of regular antenatal visits. No written materials or telephone calls are routinely provided to pregnant women in Croatia.
88958873|NCT01998100|Experimental|Prolonged Exposure + Exercise|
88958874|NCT01998100|Active Comparator|Prolonged Exposure Alone|
88958875|NCT01998113||Glyburide (Glyburide vs Insulin)|Glyburide vs Insulin trials
88958876|NCT01998113||Insulin (Glyburide vs Insulin)|Glyburide vs Insulin trials
88958877|NCT01998113||Metformin (Metformin vs Insulin)|Metformin vs Insulin trials
88958878|NCT01998113||Insulin (Metformin vs Insulin)|Metformin vs Insulin trials
88958879|NCT01998113||Metformin (Metformin vs Glyburide)|Metformin vs Glyburide trials
88958880|NCT01998113||Glyburide (Metformin vs Glyburide)|Metformin vs Glyburide trials
88958881|NCT01998126|Experimental|EGFR patients with ipilimumab|ipilimumab and erlotinib in EGFR mutated patients
88958882|NCT01998126|Experimental|ALK patients plus ipilimumab|ipilimumab and crizotinib in ALK mutated patients
88958883|NCT01998126|Experimental|EGFR patients with nivolumab|nivolumab and erlotinib in EGFR mutated patients
88958884|NCT01998126|Experimental|ALK patients plus nivolumab|nivolumab and crizotinib in ALK mutated patients
88958885|NCT01998139||Test Cohort|EMP levels will be measured at ICU admission in subjects with physician-suspected sepsis. For each subject, the final diagnosis of sepsis or non-sepsis critical illness will be adjudicated using standard criteria. The subjects without sepsis will form the Test Cohort.
88958886|NCT01998139||Validation Cohort|EMP levels will be measured at ICU admission in subjects with physician-suspected sepsis. For each subject, the final diagnosis of sepsis or non-sepsis critical illness will be adjudicated using standard criteria.The subjects determined to have sepsis will serve as the Validation Cohort .
88958887|NCT01998152|Experimental|Nutritional counseling|Individualized nutritional counselling by a registered dietitian
88958888|NCT01998152|No Intervention|No intervention|Usual nutritional care by the oncologist. A dietitian is only involved when serious nutritional problems occur.
88958889|NCT01998165|Experimental|Remifentanil (0.25 µg/kg/min)|
88958890|NCT01998204||PD group|Patients with Parkinson's disease undergoing deep brain stimulator implantation and pulse generator placement
88958891|NCT01998204||non-PD group|Patients without Parkinson's disease undergoing intracranial surgery
89509776|NCT02267369|Active Comparator|Basic fitness program|The control condition provides study participants with online tools for enrolling in offline fitness workshops offered by the university's recreation department and recording their progress in the program. All fitness workshops are pre-programmed in an online calendar. Upon clicking a workshop, participants can read a detailed description and register for it directly on the calendar. The registration then triggers a confirmation email sent to the participant immediately and a reminder email 12 hours before the workshop starts. In addition, an online tracking tool is built that participants can use to keep a daily journal of their health activities and fitness status.
89509777|NCT02267369|Experimental|Media-assisted fitness program|"The media condition evaluates the effects of informational and motivational messages on physical activity by supplementing the basic program tools with promotional media, including: high arousal videos encouraging physical activity, real-time email notifications about upcoming fitness workshops, and informational graphics with exercise tips and motivational messages. In the media condition, participants receive two videos on the website and one informational graphic that encourage physical activity on a weekly basis."
89509778|NCT02267369|Experimental|Social network-assisted fitness program|"The social condition, by contrast, omits the media content. Instead, the basic program is supplemented with a network of four to six anonymous health peers, composed of other participants of the program. Within the program website, each participant is able to see their peers' basic profile information, as well as information about their peers' progress in the program, and real-time notifications about their peers' completion of program activities. These networks do not provide any added incentives or additional content to promote physical activity, nor can participants directly communicate with, or message their peers through the website."
89509779|NCT01293461|Experimental|CBX129801|
89509780|NCT01293461|Placebo Comparator|Placebo|
88958892|NCT01998217|Active Comparator|Rem group|Patients in this group receive single infusion of remifentanil with target concentration infusion.
88958893|NCT01998217|Experimental|Flur group|Patients in this group receive both infusion of flurbiprofen and remifentanil
88958894|NCT01998230|Experimental|Early oral feeding group|In this goup patients with esophagectomy are encouraged to begin the oral intake carefully and adjust according to tolerance on post operative day 1.
88958895|NCT01998230|No Intervention|Delayed oral feeding group|In delayed oral feeding group the patients receive isotonic saline by the nasoenteral feeding tube at 20 mL/h until the morning of post operative day1. Nutrition was then commenced at 20 mL/h. The rate was increased by 20 mL/h each day if tolerated, up to 80 mL/h.Esophagography was performed on postoperative day 7. Sip of water were allowed after confirming the absence of anastomosis leakage, and a full liquid diet was implemented on the following day and enteral infusion halted.
88958896|NCT01998256|Sham Comparator|Group I|All patients were programmed in the same nominal AV delay settings (sensed AV delay 120ms, paced AV delay 150 ms) before randomization. Patients in group I received a sham AV optimization; patients in group II received a real AV optimization. Baseline echocardiography measurements were repeated after (sham)optimization. At 4 weeks cross-over was done by AV optimization in group I and resetting pacemaker settings to nominal values in group II. At 8 weeks patients were evaluated with the same investigations as at week 4; every pacemaker was programmed in the most optimal AV setting. All optimizations were performed by 2 unblinded echocardiographists with experience in the field.
88958897|NCT01998256|Active Comparator|Group II|All patients were programmed in the same nominal AV delay settings before randomization. Patients in group I received a sham AV optimization; patients in group II received a real AV optimization. Baseline echocardiography measurements were repeated after (sham)optimization. At 4 weeks cross-over was done by AV optimization in group I and resetting pacemaker settings to nominal values in group II. At 8 weeks patients were evaluated with the same investigations as at week 4; every pacemaker was programmed in the most optimal AV setting. All optimizations were performed by 2 unblinded echocardiographists with experience in the field.
88958898|NCT01998282||Household water filter and improved cook stove|Vestergaard-Frandsen LifeStraw Family 2.0 filter and Ecozoom stove
88958899|NCT01998282||Control|Traditional water management practices and cooking stoves
88958900|NCT01998295|Active Comparator|Artemether/lumefantrine|"Artemether/lumefantrine tablets, 6 doses, for 3 days~Dosage:~tablet for body weight between 5-14.9 Kilograms.~tablets for body weight between 15-24.9 Kilograms.~tablets for body weight between 25-34.9 Kilograms."
88958901|NCT01998308||Group 1|50 Knees will have single injection of Crespine gel
88958902|NCT01998308||Group 2|50 Knees will have single injection of 2 ampules of intragel
89509781|NCT05260541|Experimental|Double-blind PRAX-114|Double-blind period - 40 or 60 mg PRAX-114 once daily in the evening
89509782|NCT05260541|Placebo Comparator|Double-blind Placebo|Double-blind period - placebo once daily in the evening
89509783|NCT05260541|Experimental|Open-label Extension PRAX-114|Open-label extension period - 40 mg PRAX-114 once daily in the evening
89509784|NCT01291901|Experimental|Active NP2|Single intradermal dose of active NP2. An open label study extension will offer up to two additional doses of active NP2 between weeks 4-10 following the previous dose.
89509785|NCT01291901|Placebo Comparator|Placebo|Single intradermal dose of placebo (vehicle). An open label study extension will offer up to two additional doses of active NP2 between weeks 4-10 following the previous dose.
89509786|NCT04475627||Participants randomised to 1.5T then 3T|Participants randomized to be scanned at 1.5T first followed by 3T
89509787|NCT04475627||Participants randomised to 3T then 1.5T|Participants randomized to be scanned at 3T first followed by 1.5T
89509788|NCT05252663|Experimental|Study group|Quake breathing, patients were advised to take a deep breath and hold it for 3-5 seconds.
89509789|NCT05252663|Active Comparator|Control group|Percussion, vibration and shaking were used accompanied with postural drainage.
89509790|NCT01262261|Experimental|Probuphine|patients are first inducted on sublingual buprenorphine then switched to 4 Probuphine Implants
89509791|NCT05231525|Experimental|WiTOF|
89509792|NCT05231525|Active Comparator|TOFscan|
89519428|NCT05386589|Experimental|Moderate Hepatic Impairment|Participants with moderate hepatic impairment will receive a single oral 800mg dose of molnupiravir.
88958903|NCT01998308||Group 3|50 knees will have single injection of crespine plus gel
88958904|NCT01998308||Group 4|50 knees will have single injection of Monovisc
88958905|NCT01998321|Experimental|TKA using PSI|Total Knee Arthroplasty using Patient Specific Instrument
88958906|NCT01998321|Experimental|2 TKA using conditional technique.|Total Knee Arthroplasty using conditional technique.
89509793|NCT02267681|Experimental|Group A|The patients in Group A will be given 100 mcg/kg/min propofol infusion and 10 mcg/kg loading dose of alfentanil and 5 mcg/kg additional bolus of alfentanil whenever FPS (Faces Pain Scale) is greater than 3 or the patients can not tolerate the procedure.
89509794|NCT02267681|Experimental|Group F|The patients in Group F will be given 100 mcg/kg/min propofol infusion and 1 mcg/kg loading dose of fentanyl and 5 mcg/kg additional bolus of fentanyl whenever FPS (Faces Pain Scale) is greater than 3 or the patients can not tolerate the procedure.
89509795|NCT02267681|Active Comparator|Group P|Group P is designated as the control group and the patients will be given 100mcg/kg/min infusion and sedation will be achieved via 1 mg/kg propofol loading dose and 0.5 mg/kg propofol additional bolus will be given whenever the patients can not tolerate the procedure or FPS is greater than 3.
89509796|NCT02267759|Experimental|McGrath|Nasotracheal intubation was performed with McGrath videolaryngoscopy
89509797|NCT02267759|Active Comparator|Macintosh|Nasotracheal intubation was performed with Macintosh direct laryngoscopy
89509798|NCT02138786|Experimental|selinexor|"oral tablets~10 mg & 25 mg (bottled); or~20 mg (blister pack)"
89509799|NCT05177939|Experimental|NPB-01|Intravenous immunoglobulin
89509800|NCT05177939|Active Comparator|NPB-01-ME|methylprednisolone sodium succinate
89509801|NCT05172869|Active Comparator|Group S: Suprainguinal Performed FICB|Suprainguinal Performed FICB
89509802|NCT05172869|Active Comparator|Group I: Infrainguinal Performed FICB|Infrainguinal Performed FICB
89509803|NCT02267915|Experimental|subcutaneous rituximab|MabThera 1400 mg solution for subcutaneous injection
89509804|NCT02233595||Adjuvant chemotherapy|
89509805|NCT02267993|Experimental|Arm A|At the first chemotherapy cycle (treatment cycle), patients receive recombinant human thrombopoietin treatment. At the second chemotherapy cycle (control cycle), recombinant human thrombopoietin therapy is not given.
89509806|NCT02267993|Experimental|Arm B|At the first chemotherapy cycle (control cycle), recombinant human thrombopoietin therapy is not given; at the second chemotherapy cycle (treatment cycle), patients receive recombinant human thrombopoietin treatment.
89509807|NCT04258592|Experimental|Patients|A single dose of 18F-MFBG will be intravenously injected in 10 patients with neural crest tumors or neuroendocrine tumors. Adult patients will first undergo a dynamic PET scan, followed by whole-body PET/CT scans at various time points for a pharmacokinetics study and efficacy assessment. Pediatric patients will undergo, depending on what is feasible for the child, at least 1 and up to 2 static whole-body PET/CTs. In patients 12 years or older, also a dynamic PET scan can be performed.
89509808|NCT02268071|Experimental|Hypertensive patients|Antihypertensive treatment will be stopped for 1 year unless hypertension recurrence
88958907|NCT01998334|Experimental|CVVH 6h|CVVH 6h for first three days
88958908|NCT01998334|Experimental|CVVH 10h|CVVH 10h for first three days
89509809|NCT02233673|Experimental|Behavioral, incentives|Participants receive behavioral intervention and financial incentives for meeting gestational weight gain goals
89509810|NCT02233673|No Intervention|Standard care|Participants receive standard obstetrical care from their provider
89509811|NCT01261403|Experimental|Group 1|1 Unit of PDA001 or 4 units Vehicle Control intravenous on Day 0 and Day 7
89509812|NCT01261403|Experimental|Group 2|4 Units PDA001 or 4 units Vehicle Control intravenous (Placebo) on Day 0 and Day 7
89509813|NCT01261403|Placebo Comparator|Vehicle control|Placebo - Vehicle Control Arm
89509814|NCT02268149|Experimental|BIIL 284 BS + Prednisone|BIIL 284 BS 9 days; prednisone 2 single doses
88958909|NCT01998334|Experimental|CVVHDF|CVVHDF 6h for first three days
88958910|NCT01998347|Experimental|Paclitaxel liposome and Cisplatin|"Drug: paclitaxel liposome 175mg/m2, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles:up to 6 cycles.~Drug: cisplatin 37.5 mg/m2, IV (in the vein) on day 1~2 of each 21 day cycle. Number of Cycles: up to 6 cycles."
88958911|NCT01998347|Active Comparator|Cisplatin plus 5-fluorouracil|"Cisplatin:~37.5 mg/m2, IV (in the vein) on day 1-2 of each 21 day cycle. Number of Cycles: up to 6 cycles.~5-fluorouracil: 200mg/m2, CIV (continuous intravenous infusion) on day 1~5 of each 21 day cycle. Number of Cycles: up to 6 cycles."
88958912|NCT01998373|Experimental|patient training and patient without training|Experimental group 1: patient education intervention group (PIGE) Experimental group 2: patient without intervention group (PWIG)
88958913|NCT01998373|No Intervention|control without education|this group did not receive an education
89509815|NCT02268149|Placebo Comparator|Placebo|
89509816|NCT01258907|Experimental|A|
89509817|NCT01258907|Experimental|B|
89509818|NCT01258907|Placebo Comparator|C|
89509819|NCT01255709|Experimental|Arm T1 Primatene Mist HFA|epinephrine inhalation aerosol, 90 mcg/inhalation, 12 inhalations over 6 minutes
89509820|NCT01255709|Active Comparator|Arm C Primatene Mist|epinephrine inhalation aerosol, 220 mcg/inhalation, 12 inhalations over 6 minutes
89509821|NCT01255709|Experimental|Arm T2 Primatene Mist HFA|epinephrine inhalation aerosol, 100 mcg/inhalation, 12 inhalations over 6 minutes
89509822|NCT02529488|Experimental|TFNT00|AcrySof® IQ PanOptix™ Presbyopia-Correcting IOL, bilateral implantation
89509823|NCT02233907||Chronic obstructive pulmonary disease patients|
89509824|NCT05407454||Study Group|Patients with diabetes (all types)
89509825|NCT01254773|Experimental|Bapineuzumab SC Dose 1; 2 mg|
89509826|NCT01254773|Experimental|Bapineuzumab SC Dose 2; 7 mg|
89509827|NCT01254773|Experimental|Bapineuzumab SC Dose 3; 20 mg|
89509828|NCT01254773|Placebo Comparator|Placebo|
89509829|NCT01253603|Experimental|1|QAW039 capsules once daily for 28 days
89509830|NCT01253603|Experimental|2|Placebo to QAW039 capsules once daily for 28 days
89509831|NCT01253603|Experimental|3|Fluticasone propionate inhaler twice daily for 28 days
89509832|NCT02268305|Experimental|MSM 1000mg twice a day (6000 mgs)|Group 1 will take by mouth three 1000 mg capsules twice a day (6000 mgs) of MSM plus standard of care naproxen
89509833|NCT02268305|Placebo Comparator|Placebo capsules twice a day|Group 2 will take by mouth three placebo capsules twice a day plus standard of care naproxen
88958914|NCT01998386|Placebo Comparator|Placebo gel without hydrogen peroxide|The volunteers of this group will receive a placebo gel without hydrogen peroxide for whitening treatment.
89509834|NCT02268383|Experimental|ACE-536|ACE-536 1.0 mg/kg once every 3 weeks by subcutaneous injection.
89509835|NCT01329419||adefovir dipivoxil|Patients administrated adefovir at the site
89509836|NCT01235585|Experimental|Bitopertin oral dose level 1|
89509837|NCT01235585|Experimental|Bitopertin oral dose level 2|
89509838|NCT01235585|Placebo Comparator|Placebo|
89509839|NCT01329341|Experimental|Arm 1|Service Dogs
89509840|NCT01235039|Experimental|Formulation A|VIAject®25 for subcutaneous application
89509841|NCT01235039|Experimental|Formulation B|VIAject®7 for subcutaneous application
89509842|NCT01235039|Experimental|Formulation C|Insulin Lispro for subcutaneous application
89509843|NCT02268539|Active Comparator|Ablation at 20 watt / 30 seconds|Participants randomised to 20 watt ablation for 30 seconds
89509844|NCT02268539|Active Comparator|Ablation at 20 watt /45 seconds|20 watt ablation for 45 seconds
89509845|NCT02268539|Active Comparator|Ablation at 25 watt / 30 seconds|25 watt ablation for 30 seconds
89509846|NCT02268539|Active Comparator|iAblation at 25 watt / 45 seconds|25 watt ablation for 45 seconds
88958915|NCT01998386|Experimental|6.0% hydrogen peroxide - White Class|Volunteers of this group will receive a gel with 6.0% hydrogen peroxide - White Class with calcium for whitening treatment.
88958916|NCT01998386|Experimental|7.5% hydrogen peroxide - White Class|The volunteers of this group will receive a gel with 7.5% hydrogen peroxide -White Class with calcium for whitening treatment.
88958917|NCT01998386|Experimental|7.5% hydrogen peroxide - Oral-B 3D White|The participants in this group will receive disposable whitening strips - Oral-B 3D White for whitening treatment.
88958918|NCT01998425||Non-small cell lung cancer|The cohort data of patients with NSCLC will follow up from diagnosis, treatment response and final survival. Fibrocytes will be checked on the date of diagnsis (before treatment), re-staing (3months after treatment) and disease progression.
88958919|NCT01998451|Experimental|Double sphincter group|patients from double sphincter group all received Tauroursodeoxycholic acid after surgery for 6 months.
89509847|NCT02268617|Experimental|Treadmill Walking|All subjects will walk on treadmill for a total of 20 minutes.
89509848|NCT05129501|Experimental|Treatment: Tiwahe Wicaghwicayapi|Part 1: Conduct informed consent process, perform baseline assessments (time 1 survey) Part 2: Complete the program over 7 weeks, fidelity checking during program Part 3: Takes survey immediately after program (time 2 survey) Part 4: Time 3 survey six months after Time 2 survey
89509849|NCT05129501|No Intervention|Wait List Control: Tiwahe Wicaghwicayapi|"Part 1: Conduct informed consent process, perform baseline assessments (time 1 survey) Part 2: Waitlist with access to resources while treatment group completes program Part 3: Takes survey immediately after experimental group completes program (time 2 survey) Part 4: Time 3 survey six months after Time 2 survey~*Complete program"
89509850|NCT01232543|Experimental|Product 0405|Topical Active Investigational Product 0405
89509851|NCT01221077|Experimental|Arm A: Erlotinib plus OSI-906|As of 01 March 2013, OSI-906 is no longer being administered
89509852|NCT01221077|Placebo Comparator|Arm B: Erlotinib plus Placebo|As of 01 March 2013, the matching placebo is no longer being administered
89509853|NCT02234297|Experimental|BLZ-100|
89509854|NCT04475159|Experimental|PIPAC arm|Together with neoadjuvant systemic therpay PIPAC will be performed twice and regional chemotherpay will be administered before planned CRS/HIPEC
89509855|NCT01208129|Experimental|Active drug|
89509856|NCT01208129|Placebo Comparator|Vehicle alone|
89509857|NCT01207115|Experimental|ABT-652 high dose|ABT-652 capsules- twice daily for 8 weeks. The dose of ABT-652 will depend on the Arm.
89509858|NCT01207115|Experimental|ABT-652 low dose|ABT-652 capsules - twice daily for 8 weeks. The dose ABT-652 will depend on the Arm
89509859|NCT01207115|Active Comparator|Naproxen|Naproxen capsules- twice daily for 8 weeks
88958920|NCT01998451|Other|general gallbladder sphincter group|patients from general gallbladder sphincter group all received Tauroursodeoxycholic acid after surgery for 6 months.
88958921|NCT01998490|Experimental|Animal-assisted activity|30 minutes group session with animal-assisted activity twice a week for 12 weeks in groups of 4-6 participants.
88958922|NCT01998490|Experimental|Robot-assisted activity|30 minutes group session with robot-assisted activity with the robot seal Paro twice a week for 12 weeks in groups of 4-6 participants
89509860|NCT01207115|Placebo Comparator|Placebo|Placebo capsules- twice daily for 8 weeks
89509861|NCT01186991|Experimental|Onartuzumab + Bevacizumab + Paclitaxel|Participants will receive treatment with onartuzumab, bevacizumab, and paclitaxel, which may continue until disease progression, unacceptable drug-related toxicity, investigator decision, death, or completion of study, whichever occurs first (up to approximately 5 years).
89509862|NCT01186991|Experimental|Onartuzumab + Placebo + Paclitaxel|Participants will receive treatment with onartuzumab, placebo matching to bevacizumab, and paclitaxel, which may continue until disease progression, unacceptable toxicity, investigator decision, death, or completion of study, whichever occurs first (up to approximately 5 years).
89509863|NCT01186991|Active Comparator|Placebo + Bevacizumab + Paclitaxel|Participants will receive treatment with placebo matching to onartuzumab, bevacizumab, and paclitaxel, which may continue until disease progression, unacceptable toxicity, investigator decision, death, or completion of study, whichever occurs first (up to approximately 5 years).
89509864|NCT02268773|Experimental|Acetylsalicylic acid low dose with Asasantin®|
89509865|NCT02268773|Active Comparator|Acetylsalicylic acid high dose|
89509866|NCT01183949|Experimental|Treatment|Patients will be enrolled into 3 groups which will run sequentially. Groups A and B will receive AT7519M only, whereas Group C will receive AT7519M in combination with Bortezomib.
88958923|NCT01998490|No Intervention|Control|Control group with treatment as usual
89509867|NCT01183637|Experimental|Treatment|Patients assigned to the treatment arm will receive treatment with the Kensey Nash Corp. Cartilage Repair Device.
89509868|NCT01183637|Active Comparator|Control|Patients assigned to the Control Arm will receive treatment with the standard surgical technique known as microfracture.
89509869|NCT02268929|Other|Control Group|Patients treated by usual customary medical practice (Usual Care)
89509870|NCT02268929|Other|Intervention Group|"Patients treated with Integrated Personalized Diabetes Management"
89509871|NCT01096979|Experimental|LIPO-102, High|LIPO-102, High
89509872|NCT01096979|Experimental|LIPO-102, Low|LIPO-102, Low
89509873|NCT01096979|Experimental|Placebo|Pbo
89509874|NCT02269007|Experimental|0.5ml influenza vaccine|0.5ml inactivated quadrivalent influenza vaccine (split virion) for each subject, one dose
89509875|NCT02269085|Experimental|Ibrutinib + Carfilzomib|"Phase I: Ibrutinib administered by mouth daily at 420 or 560 mg on Days 1 - 28 of a 28-day cycle. Carfilzomib administered by vein 20/27 mg/m^2, 20/36 mg/m^2, 20/45 mg/m^2 or 20/56 mg/m^2 on days 1, 2, 8, 9, 15 and 16 of a 28-day cycle for Cycles 1- 12 and on Days 1, 2, 15 and 16 for Cycle 13 and higher.~Phase II: Once the MTD has been established 5 additional patients treated at the MTD to a maximum of 35 patients with MCL.~Study staff calls participant after end-of-dosing visit every 6 months for 5 years."
89509876|NCT02532764|Experimental|QR-010|QR-010 administered via inhalation either as a single dose or three times weekly for four weeks.
89509877|NCT02532764|Placebo Comparator|Placebo|Placebo (normal saline) administered via inhalation either as a single dose or three times weekly for four weeks.
89509878|NCT01173731|Experimental|AFQ056|
89509879|NCT01092065|Experimental|AFQ056 100 mg (Bid)|
89509880|NCT01092065|Placebo Comparator|Placebo|
89509881|NCT01173497|Experimental|INIPARIB, irinotecan|
89509882|NCT02528942|Experimental|Radiation therapy|The functional avoidance radiation therapy plan will be delivered using a standard course of radiation treatment on a linear accelerator. Patients will receive daily radiation treatment for 15-35 days.
89509883|NCT01171313|Experimental|Treatment sequence 1|Subjects will receive XP21279 and carbidopa, Sinemet, placebo for XP21279 and carbidopa, placebo for Sinemet in a randomized sequence.
89509884|NCT01171313|Experimental|Treatment sequence 2|Subjects will receive XP21279 and carbidopa, Sinemet, placebo for XP21279 and carbidopa, placebo for Sinemet in a randomized sequence.
89509885|NCT01171313|Experimental|Treatment sequence 3|Subjects will receive XP21279 and carbidopa, Sinemet, placebo for XP21279 and carbidopa, placebo for Sinemet in a randomized sequence.
89509886|NCT01171313|Experimental|Treatment sequence 4|Subjects will receive XP21279 and carbidopa, Sinemet, placebo for XP21279 and carbidopa, placebo for Sinemet in a randomized sequence.
89509887|NCT01071239|Experimental|Bone marrow processing|Bone Marrow processing using the CliniMACs device
89509888|NCT02269397||Individuals with suspected epilepsy|The study will enroll individuals who are attending their first visit at the University of Pennsylvania for suspected epilepsy.
89509889|NCT02269553|Active Comparator|TMJ NextGeneration(TM)|The TMJ NextGeneration(TM) device consists of a pair of small, hollow ear inserts. These ear inserts are custom-fit to each subject's ear canals. They are constructed from methacrylate polymers - the same material as has been used in hearing aids. The devices rest in the outer third of the ear canal and have a small retraction post that allows for removal of the device from the ear. The devices conform to the shape of the individuals' ear canals when the jaw is in the open position and permit full passage of sound into each ear. The device is FDA cleared under a 510(k) with an indication of reducing TMD pain.
89509890|NCT02269553|Active Comparator|Standard Hard TMJD Splint|The occlusal splint to be used in this study will be a hard, full-arch splint with at least one occlusal contact on each tooth of the opposing arch. Each patient assigned to the occlusal splint treatment group may wear either maxillary or mandibular splints or both, as prescribed by the subject's dentist, during the study. All occlusal splints used in the study will be custom fit to each patient using standard dental processes. All occlusal splints used in the study will be manufactured by Paul O'Neill Dental Lab, Yucaipa , CA, USA using clear ADA approved orthodontic acrylic
89509891|NCT05624489|Experimental|Intervention|"Each participant-time point will be randomized between a prompt containing an engagement strategy vs. no prompt. A Bayesian algorithm will iteratively adjust the probability of receiving a prompt or no prompt at any time point, using brushing behavior data. Patterns suggesting positive effects of the prompts on brushing adherence will result in higher subsequent probabilities of receiving the prompts, whereas patterns suggesting null or negative effects will result in lower probabilities of receiving the prompts. A participant is assigned to an engagement prompt will be randomized equally between the three types of engagement strategies: (1) Standard reciprocity prompt: delivering non-contingent reward points as a gift to support goals; (2) Reciprocity by proxy prompt: delivering a message indicating a donation to the person's selected charity; (3) Curiosity prompt: delivering oral health information in a manner that motivates the participant to seek new knowledge and information."
89509892|NCT01156415|Experimental|Agomelatine (AGO178) 0.5 mg|
89509893|NCT01156415|Experimental|Agomelatine (AGO178) 1 mg|
89509894|NCT01057667|Experimental|Arm A: With RO5024048|Patients in arm A will receive RO5024048 (1000mg orally twice daily) for 24 weeks in addition to Pegasys (180 micrograms sc weekly) and Copegus (1000mg or 1200mg orally daily).
89509895|NCT01057667|Active Comparator|Arm B: Standard treatment|Patients in arm B will receive standard treatment with Pegasys (180 micrograms sc weekly) and Copegus (1000mg or 1200mg orally daily) for 48 weeks.
88958924|NCT01998503|Active Comparator|BD induction followed by ASCT|The BD regimen included bortezomib 1.3 mg/m2 i.v. and dexamethasone 40 mg p.o. on days 1, 4, 8 and 11 of the 21 day cycle. This process was repeated for 2 cycles. After two cycles of BD therapy, the collection of peripheral blood stem cells (PBSC) should be completed within 4 weeks. Patients receive filgrastim (G-CSF) on days 1 to 5 and undergo autologous hematopoietic stem cell (HSC) collection. Patients will receive ASCT therapy in 8 weeks after collection of PBSC (Recorded as day 0), while melphalan (day -2) with a dose of 140 or 200 mg/m2 (choosing a dose according to the degree of risk for patients). Melphalan will be administered by central venous catheter.
89509896|NCT01039805|Experimental|Cohort 1|Subjects randomized to either GSK962040 (50 mg) or placebo
89509897|NCT01039805|Experimental|Cohort 2|Subjects randomized to either GSK962040 (75 mg) or placebo
88958925|NCT01998503|Experimental|ASCT alone|the patients who assigned to this arm will receive ASCT alone as an initial treatment. At first, patients receive the collection of peripheral blood stem cells (PBSC), Patients receive filgrastim (G-CSF) on days 1 to 5 and undergo autologous hematopoietic stem cell (HSC) collection. After then patients will receive ASCT therapy in 8 weeks after collection of PBSC (Recorded as day 0), while melphalan (day -2) with a dose of 140 or 200 mg/m2 (choosing a dose according to the degree of risk for patients). Melphalan will be administered by central venous catheter.
88958926|NCT01998516||Schizophrenia Patients|
88958927|NCT01998516||Bipolar I Patients|
88958928|NCT01998516||Siblings of Schizophrenia Patients|
88958929|NCT01998516||Siblings of Bipolar I Patients|
88958930|NCT01998516||Healthy Controls|
88958931|NCT01998542|Experimental|AlloStim+CRCL|AlloStim priming followed by AlloStim+CRCL priming and AlloStim IV. 3 cycles
88958932|NCT01998555|Other|CAD-CBT group therapy|CAD receive web-based CBT group therapy
89509898|NCT02527148|Active Comparator|OtisMed® ShapeMatch® with Triathlon|Participants randomised to the Intervention Group will undergo Total Knee Replacement (TKR) with the Stryker Triathlon® Total Knee System and OtisMed® ShapeMatch® Technology with the goal of kinematic alignment (re-aligning the limb to its pre-disease kinematic alignment).
89509899|NCT02527148|Active Comparator|Stryker Precision Knee Navigation|Participants randomised to the Control Group will undergo Total Knee Replacement (TKR) with the Stryker Triathlon® Total Knee System guided by Stryker Precision Knee Navigation with the goal of neutral alignment to the mechanical axis. This is the standard method for TKR with Triathlon® Knee System and this group will serve as a control reference for the intervention group.
89509900|NCT01037231|Experimental|Oxabact (tm)|
89509901|NCT01037231|Placebo Comparator|Placebo|
89509902|NCT03135197||Migalastat|Migalastat administered according to SmPC
89509903|NCT05624255|Experimental|ophthalmology consultation|Patients eligible to calcium score will be offered an ophthalmologic consultation including Angio-Optical Coherence Tomography [OCT]
89509904|NCT02291614|Experimental|AMG 211 200 μg/day for 7/14 Days|In cycle 1 participants receive 200 µg/day AMG 211 administered as a continuous intravenous infusion (cIV) infusion at a constant flow rate for 7 days followed by a 3-week treatment-free interval. In cycle 2 and thereafter, participants receive 200 µg/day AMG 211 administered as a cIV infusion for 14 days followed by a 2-week treatment-free interval.
89509905|NCT02291614|Experimental|AMG 211 200 μg/day for 14 Days|Participants receive 200 µg/day AMG 211 administered as a cIV infusion for 14 days followed by a 2-week treatment-free interval.
89509906|NCT02291614|Experimental|AMG 211 400 μg/day for 14 Days|Participants receive 400 µg/day AMG 211 administered as a cIV infusion for 14 days followed by a 2-week treatment-free interval.
89509907|NCT02291614|Experimental|AMG 211 800 μg/day for 14 Days|Participants receive 800 µg/day AMG 211 administered as a cIV infusion for 14 days followed by a 2-week treatment-free interval.
89509908|NCT02291614|Experimental|AMG 211 1600 μg/day for 14 Days|Participants receive 1600 µg/day AMG 211 administered as a cIV infusion for 14 days followed by a 2-week treatment-free interval.
89509909|NCT02291614|Experimental|AMG 211 1600 µg/day for 28 Days|Participants receive 1600 µg/day AMG 211 administered as a cIV infusion for 28 days followed by a 2-week treatment-free interval.
89509910|NCT02291614|Experimental|AMG 211 3200 µg/day for 14 Days|Participants receive 3200 µg/day AMG 211 administered as a cIV infusion for 14 days followed by a 2-week treatment-free interval.
89509911|NCT02291614|Experimental|AMG 211 3200 µg/day for 28 Days|Participants receive 3200 µg/day AMG 211 administered as a cIV infusion for 28 days followed by a 2-week treatment-free interval.
89509912|NCT02291614|Experimental|AMG 211 6400 µg/day for 14 Days|Participants receive 6400 µg/day AMG 211 administered as a cIV infusion for 14 days followed by a 2-week treatment-free interval.
89509913|NCT02291614|Experimental|AMG 211 6400 µg/day for 28 Days|Participants receive 6400 µg/day AMG 211 administered as a cIV infusion for 28 days followed by a 2-week treatment-free interval.
88958933|NCT01998555|Other|CAD-CBT group therapy waiting list|CAD waiting list will receive web-based CBT group therapy later
88958934|NCT01998568||Corneal edema|Intraocular pressure measurement
88958935|NCT01998594|Active Comparator|Arthroplasty without HADM|Three - five (3 - 5) subjects with Eaton stage III-IV thumb CMC osteoarthritis undergo the basilar joint arthroplasty procedure without using a spacer constructed from human acellular matrix (HADM). Their postoperative DASH scores, grip strength, pinch strength, pain scale scores and quality of life questionnaires are compared to their preoperative scores. These subjects will be compared with a group of twenty-five (25) similar subjects who received the arthroplasty procedure with the use of the HADM spacer.
89509914|NCT02291614|Experimental|AMG 211 12,800 µg/day for 28 Days|Participants receive 12,800 µg/day AMG 211 administered as a cIV infusion for 28 days followed by a 2-week treatment-free interval.
89509915|NCT02270177|No Intervention|Regular consultation|Regular headache consultations
89509916|NCT02270177|Other|Videoconsultation|Headache consultations through telemedicine technology
89509917|NCT05372900|Experimental|Test - Control product|Subject will start with consuming the test product daily for total 14 days (during intervention 1 period). After the 4 - 6 weeks wash out, subject will then consume the control product daily for total 14 days (during intervention period 2).
89509918|NCT05372900|Experimental|Control - Test product|Subject will start with consuming the control product daily for total 14 days (during intervention 1 period). After the 4 - 6 weeks wash out, subject will then consume the test product daily for total 14 days (during intervention period 2).
89509919|NCT01027013|Experimental|rebamipide 2% ophthalmic suspension|
89509920|NCT01027013|Placebo Comparator|Placebo eye drops|
89509921|NCT01024907|Experimental|Arm I|Patients undergo proton beam radiation therapy for 6 weeks in the absence of disease progression or unacceptable toxicity.
88958936|NCT01998594|Experimental|Arthroplasty with HADM|Twent-five (25) subjects with Eaton stage III-IV thumb CMC osteoarthritis undergo the basilar joint arthroplasty procedure with an interposition arthroplasty technique using a spacer constructed from human acellular matrix (HADM). Their postoperative DASH scores, grip strength, pinch strength, pain scale scores and quality of life questionnaires are compared to their preoperative scores. These subjects will be compared with a group of three - five (3 - 5) similar subjects who received the arthroplasty procedure without the use of the HADM spacer.
88958937|NCT01998607||Round 1|Survey of 210 oncologists 12 - 18 months after commercial availability of XGEVA® in the respective country
89509922|NCT02270333|Active Comparator|Treatment group|Intervention: Treatment group received inspiratory muscle training (IMT) using POWERbreathe Classic threshold loading device .
89509923|NCT02270333|Sham Comparator|Control group|Sham: Control group received sham inspiratory muscle training using POWERbreathe Classic threshold loading device .
88958938|NCT01998607||Round 2|Survey of 210 oncologists 24 - 30 months after commercial availability of XGEVA® in the respective country
88958939|NCT01998620|Experimental|Ademetionine 1|Ademetionine 2000mg
88958940|NCT01998620|Experimental|Ademetionine 2|Ademetionine 1000mg
88958941|NCT01998620|Active Comparator|Ademetionine 3|no treatment in first 2 weeks, then Ademetionine 1000mg bid po with general antiviral treatment for 8 weeks
88958942|NCT01998646|Experimental|ASP4058 Tablet Dose Escalation Cohort|
88958943|NCT01998646|Experimental|ASP4058 Tablet - Fasting conditions|
89509924|NCT04197076||Neoadjuvant immunotherapy|pd-1 or pd-l1 inhabitors
88958944|NCT01998646|Experimental|ASP4058 Tablet - Fed conditions|
88958945|NCT01998646|Placebo Comparator|Placebo|
88958946|NCT01998659|Active Comparator|Px-102|Px-102 drinking solution, single dose
89509925|NCT04197076||Neoadjuvant targeted therapy|TKIs
88958947|NCT01998659|Placebo Comparator|Placebo|Placebo drinking solution, single dose
88958948|NCT01998672|Active Comparator|Px-102|Px-102 drinking solution, 0.5 mg/kg, 1.0 mg/kg and 1.5 mg/kg
88958949|NCT01998672|Placebo Comparator|Placebo|Oral drinking solution
88958950|NCT01998685|Experimental|Balanced (BAL) anaesthesia|In the BAL group anaesthesia is induced with midazolam 0.1mg kg-1 and fentanyl 1.5 μg kg- 1 Anaesthesia is maintained with sevoflurane 2.0% , oxygen 40% and air 70% with positive pressure ventilation in a circle system, in order to achieve normocapnia.
88958951|NCT01998685|Active Comparator|Totally Intravenous Anesthesia (TIVA-TCI)|In the TIVA-TCI group anaesthesia is induced with propofol 6 microg ml-1 and remifentanyl 0.4-1 microg kg-1 min, simultaneously administered using two separate modules of a continuous computer-assisted TCI system. Anaesthesia is maintained with propofol 4 microg ml-1 and remifentanil 0.25 microg Kg-1 min. This infusion is modified by 0.05 microg kg-1 min steps according to analgesic needs.
89509926|NCT04197076||Neoadjuvant chemotherapy|chemotherapy
89509927|NCT02270489|Experimental|AFFITOPE® PD01A + Adjuvant|"4 injections of 75µg AFFITOPE® PD01A/ adjuvanted, once every 4 weeks~1 boost immunization 36 weeks after first injection"
88958952|NCT01998698|Active Comparator|Monovision Group|Phacoemulsification surgery with intraocular lens implantation (monovision correction)
88958953|NCT01998698|Active Comparator|Multifocal Group|Phacoemulsification surgery with intraocular lens implantation (multifocal lens insertion)
88958954|NCT01998711|Experimental|Memory group|Memory training
88958955|NCT01998711|No Intervention|Control|Standard care
88958956|NCT01998724|No Intervention|Standard Care|No intervention
88958957|NCT01998724|Experimental|Tai Chi Exercise|24 week Tai Chi intervention designed for individuals with COPD
89509928|NCT02270489|Experimental|AFFITOPE® PD03A + Adjuvant|"4 injections of 75µg AFFITOPE® PD03A/ adjuvanted, once every 4 weeks~1 boost immunization 36 weeks after first injection"
88958958|NCT01998724|Experimental|Group Walking Exercise|24 week group walking intervention
88958959|NCT01998763|Placebo Comparator|Placebo|5 placebo pills per day, 20 weeks
88958960|NCT01998763|Experimental|2000 IU/d Vitamin D3|5 vitamin D3 pills per day, 20 weeks
88958961|NCT01998776|Active Comparator|Misoprostol|ASA 100 mg daily + misoprostol 200 four times daily (misoprostol group)
88958962|NCT01998776|Placebo Comparator|Placebo misoprostol|ASA 100 mg daily + placebo misoprostol four times daily (placebo group)
88958963|NCT01998789|Experimental|Everolimus Conversion Arm|"Everolimus will be initiated within 24 hours of baseline at a dose of 1 mg po BID (2 mg/day). Therapeutic Drug Monitoring will be performed throughout the study. Tacrolimus should be eliminated when the everolimus target range has been reached. Complete tacrolimus elimination will not occur earlier than 90 days post transplant and no later than 120 days post transplant. Enteric coated mycopenolic acid will be maintained for the duration of the study. Oral corticosteroids may not be eliminated sooner than 180 days post transplantation.~Everolimus doses will be adjusted based on local lab results of everolimus trough levels."
89509929|NCT02270489|Placebo Comparator|Adjuvant without active component|"4 injections of Placebo once every 4 weeks~1 administration 36 weeks after first injection"
89509930|NCT02270723|Active Comparator|"Human Albumin  Behring"|Infusion of 5% Human Albumine, maximal 25 ml/kg, is administered intravenously during anaesthesia, duration up to 6 hours
89509931|NCT02270723|Placebo Comparator|Lactated Ringer|Infusion of Lactated Ringer solution 25 ml/kg, is administered intravenously during anaesthesia, duration up to 6 hours
89509932|NCT04475237||Healthy mandibles|Belgian adults (between 20 and 60 years old), 50/50 male/female, with no major mandibular problems/deformities
89509933|NCT01138163|Experimental|Docetaxel plus bavituximab 1 mg/kg|
89509934|NCT01138163|Experimental|Docetaxel plus bavituximab 3 mg/kg|
89509935|NCT01138163|Placebo Comparator|Docetaxel plus placebo|
89509936|NCT02526524|Experimental|600 mg Met DR qAM|600 mg metformin delayed-release once daily in the morning
89509937|NCT02526524|Experimental|900 mg Met DR qAM|900 mg metformin delayed-release once daily in the morning
89509938|NCT02526524|Experimental|1200 mg Met DR qAM|1200 mg metformin delayed-release once daily in the morning
89509939|NCT02526524|Experimental|1500 mg Met DR qAM|1500 mg metformin delayed-release once daily in the morning
89509940|NCT02526524|Placebo Comparator|Placebo-1|placebo match for 600 and 1200 mg Met DR qAM treatment groups
89509941|NCT02526524|Placebo Comparator|Placebo-2|placebo match for 900 and 1500 mg Met DR qAM treatment groups
88958964|NCT01998789|Active Comparator|Standard Tacrolimus Immunosuppresion Arm|"Subjects will be maintained on standard maintenance immunosuppression per local protocol, consisting of a tacrolimus plus enteric coated mycophenolic acid. Oral corticosteroids may not be eliminated sooner than 180 days post transplantation.~Tacrolimus doses will be adjusted based on local lab results of tacrolimus trough levels."
88958965|NCT01998802|Active Comparator|Active Comparator: EBI-005|Drug: EBI-005 The investigational drug EBI-005, is an intervention to one of two study arms: 5 mg/mL topical administered 3 times per day.
88958966|NCT01998802|Placebo Comparator|Placebo Comparator|One of two study arms: placebo topical administered 3 times per day.
88958967|NCT01998854||VizAblate treatment|VizAblate System with subject serving as her own control
89509942|NCT02526524|Active Comparator|2000 mg Met IR|1000 mg metformin immediate-release twice daily
89509943|NCT01022801|Experimental|Entecavir (0.01 mg)|
89509944|NCT01022801|Experimental|Entecavir (0.1 mg)|
89509945|NCT01022801|Experimental|Entecavir (0.5 mg)|
89509946|NCT05628389|Other|Ask-Advice-Assist (AAA)|All patients will be screened for tobacco use, and offer brief cessation advice and counseling.
89509947|NCT05628389|Experimental|Ask-Advise-Connect (AAC)|Patients in will be connected to phone counseling and will receive six sessions of telephone counseling.
89509948|NCT05628389|Experimental|Ask-Advise-Connect (AAC) + Nicotine Replacement Therapy (NRT)|In addition to AAC, patients will be offered NRT.
89509949|NCT05422274|Experimental|Transcranial Pulse Stimulation (TPS group)|Subjects in the TPS group will be given 6 verum TPS sessions (Pulse: 800 / session) across two weeks time, with 3 sessions per week.
89509950|NCT05422274|Sham Comparator|Sham TPS Group|Subjects in the Sham TPS group will be given 6 sham TPS sessions across two weeks time, with 3 sessions per week.
89509951|NCT05422118|Active Comparator|case|people who have spontaneous bacterial peritonitis
89509952|NCT05422118|Active Comparator|control|people who donot have spontaneous bacterial peritonitis
89509953|NCT01128335|Active Comparator|Arm 1|MMF(1000mg bid) + tacrolimus + standard of care medications
89509954|NCT01128335|Experimental|Arm 2|sotrastaurin (200mg bid) + tacrolimus + standard of care medications
89509955|NCT01128335|Experimental|Arm 3|sotrastaurin (200mg bid) + tacrolimus + standard of care medications
89509956|NCT01128335|Experimental|Arm 4|sotrastaurin (300 mg bid) + tacrolimus + standard of care medications
89509957|NCT04422938||Manuel compression|Manuel chest compressions will be handled by clinicians
89509958|NCT04422938||Mechanical compression|Mechanical chest compressions will be handled via mechanical chest compression device
89509959|NCT01012895|Experimental|Arm 1: Sentinel A|BMS-790052 (60mg) once daily + BMS-650032 (600 mg) twice daily
89509960|NCT01012895|Experimental|Arm 2: Sentinel B|BMS-790052 (60mg) once daily + BMS-650032 (600mg) twice daily + Pegylated-interferon alfa-2a + Ribavirin
89509961|NCT01012895|Experimental|Arm 3: Expansion A1|BMS-790052 (60mg) once daily + BMS-650032 (200mg) twice daily
89509962|NCT01012895|Experimental|Arm 4: Expansion A2|BMS-790052 (60mg) once daily + BMS-650032 (200mg) once daily
88958968|NCT01998932||Chronic Venous Ulcer|Patients with a chronic venous ulcer defined as a wound of greater than four weeks in duration between the foot and the ankle with an Ankle Brachial Pressure Index greater than 0.85 and a colour venous duplex evidence of chronic venous insufficiency showing either reflux or obstruction.
88958969|NCT01998945|Experimental|Exposure-based Cognitive Behavioral Therapy (ET)|Participants will receive exposure-based cognitive behavioral therapy
89509963|NCT01012895|Experimental|Arm 5: Expansion B1|BMS-790052 (60mg) once daily + BMS-650032 (200 mg) twice daily + Pegylated-interferon alfa-2a + Ribavirin
89509964|NCT01012895|Experimental|Arm 6: Expansion B2|BMS-790052 (60mg) once daily + BMS-650032 (200 mg) once daily + Pegylated-interferon alfa-2a + Ribavirin
89509965|NCT01012895|Experimental|Arm 7: Expansion B3|BMS-790052 (60 mg) once daily + BMS-650032 (200 mg) twice daily + Ribavirin
89509966|NCT02526290|Experimental|Active - Device|The Oculeve Intranasal Lacrimal Neurostimulator will be administered two to ten times per day for up to three minutes per administration.
89509967|NCT01009775|Experimental|YM155 plus docetaxel|
89509968|NCT02319148|Experimental|Treatment B|Treatment B subjects receive single dose administration of 20 mg PF-00489791 and multiple dose administration of itraconazole (200 mg once daily).
89509969|NCT02319148|Experimental|Treatment C|Treatment C subjects receive single dose administration of 20 mg PF-00489791 and multiple dose administration of diltiazem (240 mg once daily).
89509970|NCT02319148|Experimental|Treatment D|Treatment D subjects receive single dose administration of 20 mg PF-00489791 and multiple dose administration of verapamil (240 mg once daily).
89509971|NCT03904277||No PFO|Research subjects who present no evidence of PFO - IE no appearance of saline contrast microbubbles within 3 cardiac cycles
89509972|NCT03904277||Small PFO|Research subjects who present evidence of having a small PFO or ASD - IE appearance of 1-11 saline contrast microbubbles within 3 cardiac cycles
89509973|NCT03904277||Large PFO|Research subjects who present evidence of having a large PFO - IE appearance of 12+ saline contrast microbubbles within 3 cardiac cycles.
89509974|NCT02526212|Experimental|G-BMT, Buprenorphine|This arm will receive the G-BMT intervention, which will include group visits where 5-10 patients simultaneously receive care from a multidisciplinary team of a generalist physician and a behavioral specialist. The G-BMT intervention will last 90 minutes and include: BMT education, instruction on self-management skills, peer support, and individual medical management.
89509975|NCT02526212|Active Comparator|Treatment as usual, Buprenorphine|Primary care physicians who prescribe buprenorphine will be trained to follow a protocol of BMT intensification, which includes increased visit frequency, referral for mental health counseling, and referral to addiction treatment specialist.
89509976|NCT05627921|Experimental|botulinum toxin group|
89509977|NCT05627921|Experimental|botilinum toxin and ESWT group|
89509978|NCT04423172|Experimental|Using the New Tissue Containment System group|using the new tissue containment system during Laparoscopic Hysterectomy. The divice is a soft specimen bag in which the uterus tissue is sealed and quickly morcellation and removed through vagina. The divice is named the new tissue containment system.
89509979|NCT04423172|No Intervention|Open group|Without using any procteciton system during Laprascopic Hysterectomy.
88958970|NCT01998945|Active Comparator|Relaxation Training (RT)|Participants will receive relaxation training
88958971|NCT01998997|Active Comparator|Family educational intervention|A family educational, non-pharmacologic intervention will be administered to educate family members on how to prevent delirium. Family members will be encouraged to actively participate in this non-pharmacologic intervention.
88958972|NCT01998997|Placebo Comparator|general health education|The placebo group will be given a brochure on good health habits
88958973|NCT01999010|No Intervention|"Treatment as usual (A Stage)"|The treatment as usual (TAU) group will continue to receive their usual treatment from their current treatment team - i.e. MHT will not be introduced during this phase.
88958974|NCT01999010|Experimental|"MHT (B Stage)"|Patients will be given software for Mental Health Telemetry (MHT), which allows them to record symptom intensity, hospital / ER visits, life events, etc., and to visualize their MHT data. Patients will be encouraged to make MHT entries once daily at a pre-determined time while in this arm, and will be prompted via text message by the MHT software to do so.
88958975|NCT01999010|Experimental|"Choice (A'  Stage)"|Patients exiting the MHT arm will be given the choice to continue with MHT for a further two months or whether to resume TAU (i.e., no further use of MHT) for the remaining two months.
88958976|NCT01999023|No Intervention|Observational group|No intervention
88958977|NCT01999023|Experimental|Dietary supplement|Low protein formula formula (28.5 g) twice a day
88958978|NCT01999036||Resuscitation of OHCA|Resuscitation of out-of-hospital cardiac arrest
88958979|NCT01999075|Placebo Comparator|Conventional Treatment|Conventional Treatment
88958980|NCT01999075|Active Comparator|Lung Volume Recruitment|Conventional treatment plus the use of Lung Volume Recruitment (LVR) twice per day
88958981|NCT01999088|Experimental|Functional meat|During the I period, volunteers weekly consumed three 150g/serving Functional Meat (FM) products (cooked Ham and Turkey breast). It was firmly recommended that all other meats and meat derivatives had to be excluded from the diet.
88958982|NCT01999088|Placebo Comparator|Control Meat|During the C period, volunteers consumed identical amounts of meat products that did not include functional ingredients (Control Meat (CM)).
88958983|NCT01999101|Experimental|Px-104|Px-104 capsules, 5 mg
88958984|NCT01999140||Primary prevention|
88958985|NCT01999153|Experimental|DRUG : ROPIVACAINE|20 mL topically used during alginate dressing
88958986|NCT01999153|Placebo Comparator|PLACEBO : NaCl 0.9 %|20 mL topically used during alginate dressing
88958987|NCT01999166||Osteoarthritis|
88958988|NCT01999205|Experimental|Physical activity promotion|A nominated team in each participating company develops a plan to promote physical activity and to reduce sedentary behavior of the employees
89509980|NCT05627843|Experimental|Trial group|Children on regular hemodialysis whose weight 30 kg or above
89509981|NCT05627843|Placebo Comparator|Placebo group|Children on regular hemodialysis whose weight 30 kg or above
89509982|NCT05627765|Experimental|Standard treatment (ST) arm|Participants will receive a brief smoking cessation intervention based on the asking about tobacco use, Advising smokers to quit, Assessing their willingness to quit,Assisting in quitting, and Arranging for follow-up and relevance, risks, rewards, roadblocks and repetition models at baseline. Booster interventions will be provided to ST arm at 1-week, 1-month, 3-month, and 6-month follow-up.
89509983|NCT05627765|Experimental|Integrated Intervention (II) arm|Participants in the II arm will receive brief advice on alcohol use based on the FRAMES model in addition to the brief smoking cessation intervention at baseline. Booster interventions will be provided to ST arm at 1-week, 1-month, 3-month, and 6-month follow-up.
89509984|NCT05627765|No Intervention|Control arm|Participants will be provided with two leaflets designed by Department of health: one for smoking cessation and another for alcohol abstinence.
89509985|NCT01004081|Experimental|BIIB021 BID + exemestane|BIIB021 100 mg BID + exemestane 25 mg QD
89509986|NCT01004081|Experimental|BIIB021 TIW + exemestane|BIIB021 450 mg TIW + exemestane 25 mg QD
88958989|NCT01999244|Experimental|SC|Self-guided self-monitoring condition. Participants will receive standard self-monitoring tools and information on weight regulation.
88958990|NCT01999244|Experimental|TECH|Technology condition. Participants will receive self-monitoring technology and information regarding weight regulation.
88958991|NCT01999244|Experimental|TECH+INT|Technology plus interventionist contact arm. Participants will receive self-monitoring technology, information regarding weight regulation, and interventionist contact via telephone.
88958992|NCT01999257|No Intervention|In-person counselling|Similar to standard of care, wherein Ashkenazi Jewish individuals seeking carrier genetic screening meet a genetic counsellor for an in-person education and counselling session.
88958993|NCT01999257|Active Comparator|Online pre-test genetic education tool|Use of a web-based pre-test education program, wherein the information from a typical genetic counselling session for carrier screening in Ashkenazi Jewish individuals is presented.
89509987|NCT01003379|Experimental|TC-5619|TC-5619 capsules will be administered once a day in a forced titration scheme at 1 mg for 4 weeks, 5 mg for 4 weeks and 25 mg for 4 weeks (12 weeks total).
89509988|NCT01003379|Placebo Comparator|Placebo|
89509989|NCT01119833|Experimental|GMI-1070|
89509990|NCT01119833|Placebo Comparator|Placebo|
88958994|NCT01999270|Experimental|Irinotecan, Bevacizumab and FDOPA-PET/MRI imaging|Irinotecan can be removed from the treatment plan at the discretion of the healthcare provider.
89509991|NCT01113593|Experimental|1|
89509992|NCT01113593|Experimental|2|
89509993|NCT01113593|Experimental|3|
89509994|NCT01113593|Experimental|4|
89509995|NCT01113593|Experimental|5|
89509996|NCT01001351|Placebo Comparator|Placebo|
89509997|NCT01001351|Experimental|PRT-201|
89509998|NCT04137068|Other|Sedentary to Active|Participants will visit the research laboratory for baseline measurements at visit 1 after wearing a pedometer for one week and maintaining their typical level of physical activity. After the baseline visit, participants will reduce their step count by more than half for two weeks. Participants will visit the laboratory once every week during the 2 week interventional period for a total of 3 visits.
89509999|NCT05401760|Active Comparator|Group A: includes eyes for whom combined phacoaspiration & angle surgery will be done.|"Group A: for whom combined phacoaspiration & angle surgery trabeculotomy will be done.~continuous curvilinear anterior capsulorhexis of approximately 5.0 mm diameter will be done.~The nucleus and cortex will be aspirated.~Posterior capsulrehxis and limited anterior vitrectomy will be done.~Corneal incisions will be sutured with 10-0 Nylon suture.~Using metal trabeculotomes to open thetrabecular meshwork after accessing the canal of schlemm.~Suturing of scleral flap with 10-0 Nylon suture."
88958995|NCT01999283|Active Comparator|Yoga Group Exercise|Yoga group exercise will be taught by a licensed Physical Therapist. Groups consist of 4-8 individuals with 12 sessions once weekly over 12 weeks.
88958996|NCT01999283|Active Comparator|Pilates Group Mat Exercise|Pilates mat exercise will be taught by a licensed Physical Therapist with additional Rehabilitation Pilates certification.
88958997|NCT01999283|No Intervention|Control|Wait Listed control group. Participants complete the same testing and were offered the option of attending the exercise classes on completion. The controls were not included in the exercise groups after completion.
88958998|NCT01999296||Patients undergoing laparoscopic surgery|
88958999|NCT01999309|Experimental|Simvastatin|The lipid-lowering drug simvastatin is added to normal antipsychotic treatment. One 40 mg simvastatin tablet daily for the treatment period of one year.
88959000|NCT01999309|Placebo Comparator|Placebo|Placebo is added to normal antipsychotic treatment. One identical looking placebo tablet daily for the treatment period of one year.
88959001|NCT01999387||Completed OIT|Patients who completed OIT >6 months prior to enrollment
88959002|NCT01999413|Experimental|OMEGAVEN - Daunorubicin - Cytarabine|"If WBC ≥ 30 G/L, chemotherapy the induction cycle :~Daunorubicin 60 mg/m²/day IV on D1, D2, and D3~Cytarabine 200 mg/m²/day D1 to D7~OMEGAVEN® 2 ml/kg D1 to D9,~If WBC ≤ 30 G/L, OMEGAVEN during 48 hours~Induction cycle :~OMEGAVEN® 2 ml/kg D-2 to D7 Daunorubicin 60 mg/m²/day IV on D1, D2, and D3~- Cytarabine 200 mg/m²/day IV D1 to D7~bone marrow aspirate at D15: If BM blasts are > 5% or if second induction course :~Daunorubicin 35 mg/m²/day IV D17 and D18~OMEGAVEN® 2 ml/kg~Cytarabine 1000 mg/m²/12h IV on D17, D18, and D19~For all patients: G-CSF 5 µg/kg/day subcutaneously from D21 to hematopoietic recovery (PMN > 1 G/L or > 0.5 G/L during 3 days).~Consolidation will be administered at investigator's discretion"
88959003|NCT01999426|Experimental|Airway clearance intervention|Non-respiratory on-call physiotherapy treatment using airway clearance techniques
88959004|NCT01999426|Active Comparator|Airway clearance intervention 2|Specialist respiratory physiotherapy intervention using airway clearance techniques
88959005|NCT01999439|Experimental|Eosinophilic Esophagitis with Dysphagia|To assess quantitative magnetic resonance imaging(MRI)as a potential diagnostic tool for evaluating esophageal wall thickness and stiffness and response to treatment in children and adolescents with a diagnosis of eosinophilic esophagitis (EoE) presenting with difficulty swallowing(dysphagia)and food impaction.
88959006|NCT01999452|Experimental|Paleolithic diet first|Starting with Paleolithic diet and then switching to Diabetes diet
88959007|NCT01999452|Experimental|Diabetes diet first|Starting with Diabetes diet and then switching to Paleolithic diet
88959008|NCT01999478||Patients undergoing colonoscopy|Patients undergoing colonoscopy per standard of care.
88959009|NCT01999504|Experimental|PAL-2|Based on WHO dietary guidelines for protein, fat and carbohydrate but made with ingredients that would have been available in palaeolithic times (e.g. no cereals, no dairy).
88959010|NCT01999504|Experimental|TFH-1|Based on WHO dietary guidelines for protein, fat and carbohydrate but made with ingredients that would have been available in palaeolithic times, (e.g. no cereals, no dairy).
88959011|NCT01999504|Placebo Comparator|Reference|Meal based on WHO dietary guidelines for protein, fat and carbohydrate.
88959012|NCT01999543|Other|Reference food format|reference food format with and without plant-based ingredient added
88959013|NCT01999543|Experimental|Food format one|Food format one with and without plant-based ingredient added
89510000|NCT05401760|Active Comparator|Group B : includes eyes with only phacoaspiration will be done|"Group B: for whom phacoaspiration only will be done.~2 side ports will be fashioned.~Trypan blue will be injected to aid visualization of the anterior capsule & continuous curvilinear anterior capsulorhexis of approximately 5.0 mm diameter will be done.~The nucleus and cortex will be aspirated.~Posterior capsulrehxis and limited anterior vitrectomy will be done.~Corneal incisions will be sutured with 10-0 Nylon suture."
89510001|NCT05367752|Experimental|Group 1: Myofascial release with TENS conductive glove|Participants allocated to this group received six sessions of a myofascial release protocol with a TENS conductive glove applying a TENS current of 120Hz frequency through an electrotherapy device.
89510002|NCT05367752|Experimental|Group 2: Myofascial release without TENS conductive glove|Participants allocated to this group received the same myofascial release protocol with group 1 without the TENS conductive glove.
89510003|NCT05367752|Experimental|Group 3: Conventional TENS|Participants allocated to this group received the application of a conventional TENS current.
89510004|NCT05367752|Active Comparator|Control: Sham TENS|Participants allocated to this group received the same TENS treatment with group 3, but with the current intensity set to zero to ensure that they received no current.
89510005|NCT02532374|Experimental|Nicorette® inhalator then P3L|Each subject will use the Nicorette® inhalator (15 mg) on Visit 3, and then use the P3L aerosol at nicotine dose levels of approximately 50 µg/puff, 80 µg/puff and 150 µg/puff on Visits 4, 5 and 6, respectively.
88959014|NCT01999543|Experimental|Food format two|Food format two with and without plant-based ingredient added
88959015|NCT01999543|Experimental|Food format three|Food format three with and without plant-based ingredient added
88959016|NCT01999582|Experimental|Intravenous Dose Group 1, 2, and 3|Intravenous Dose Group 1 starting at 0.1 mg/kg and escalated in Dose Groups 2 (0.2 mg/kg) and Dose Group 3 (0.1, 0.2, 0.3, 0.4 mg/kg, titrated based on titration rules, administered every 14 days)
88959017|NCT01999582|Experimental|Subcutaneous Dose Group 1, 2, and 3|Subcutaneous Dose Group 1 starting at 0.13 mg/kg and escalated in Dose Groups 2 (0.26 mg/kg) and Dose Group 3 (0.4 to 0.5 mg/kg, titrated based on titration rules, administered every14 days)
88959018|NCT01999608||Vitamin D deficient patients|Serum 25-OH Vitamin D levels <20ng/L
88959019|NCT01999608||Vitamin D sufficient patients|Serum 25-OH Vitamin D levels ≥20ng/L
88959020|NCT01999621||lung cancer|Each lung cancer patient with organ failure, admitted in emergency, thoracic oncology or directly in ICU
89510006|NCT05399186|No Intervention|Control group|Usual care group - receiving traditional preoperative preparation and assessment (1 week) prior to total joint arthroplastic surgery
89510007|NCT05399186|Experimental|Early preoperative assessment and optimization|Interventional group - receiving early preoperative assessment and optimization (6-12 months) in wait of total joint arthroplastic surgery
88959021|NCT01999634|Experimental|cma microdialysis catheter placement|At the end of the surgery the cma microdialysis catheter is placed near the anastomosis
89510008|NCT05367128|Experimental|Posture-focus group|Participants will be instructed to pay most attention to practice the posture task during training
89510009|NCT05367128|Experimental|Supraposture-focus group|Participants will be instructed to pay most attention to practice the cognitive task during training
89024119|NCT03441282||ASA Patients III|"Age 18-80 years old, English-speaking, not on current Fentanyl/opioid therapy, no use of opioid medications in the 3 months prior to surgery, scheduled for elective surgery at UAB main.~A patient with severe systemic disease Substantive functional limitations; One or more moderate to severe diseases. Examples include (but not limited to): poorly controlled DM or HTN, COPD, morbid obesity (BMI ≥40), active hepatitis, alcohol dependence or abuse, implanted pacemaker, moderate reduction of ejection fraction, ESRD undergoing regularly scheduled dialysis, premature infant PCA < 60 weeks, history (>3 months) of MI, CVA, TIA, or CAD/stents."
89024120|NCT03439462|Experimental|nab-sirolimus (also known as ABI-009, nab-rapamycin, albumin-bound rapamycin)|Single arm, open-label, multi-institutional study to identify the RP2D and determine the efficacy and safety profile of nab-sirolimus administered as first-line therapy in combination with mFOLFOX6 and bevacizumab in patients with metastatic CRC.
89024121|NCT03432936|Experimental|MRI guided procedure software evaluation|Evaluate the workflow and effectiveness of the Philips Interventional iSuite software during biopsies and/or ablations versus standard MR imaging in aiding needle placement.
89024122|NCT03427099|Active Comparator|Control group|usual care
89510010|NCT05367128|Active Comparator|Control group|Participants will not be receive any instruction to prioritize either task
89510011|NCT05366738|Experimental|Treatment Sequence 1|Participants assigned to Treatment Sequence 1 will receive vonoprazan 20 mg as a sprinkle capsule on 1 tablespoon of pudding on Day 1 of Treatment Period 1, vonoprazan 20 mg as a sprinkle capsule on 1 tablespoon of applesauce on Day 1 of Treatment Period 2, and vonoprazan 20 mg as a tablet on Day 1 of Treatment Period 3.
89510012|NCT05366738|Experimental|Treatment Sequence 2|Participants assigned to Treatment Sequence 2 will receive vonoprazan 20 mg as a tablet on Day 1 of Treatment Period 1, vonoprazan 20 mg as a sprinkle capsule on 1 tablespoon of pudding on Day 1 of Treatment Period 2, and vonoprazan 20 mg as a sprinkle capsule on 1 tablespoon of applesauce on Day 1 of Treatment Period 3.
89510013|NCT05366738|Experimental|Treatment Sequence 3|Participants assigned to Treatment Sequence 3 will receive vonoprazan 20 mg as a sprinkle capsule on 1 tablespoon of applesauce on Day 1 of Treatment Period 1, vonoprazan 20 mg as a tablet on Day 1 of Treatment Period 2, and vonoprazan 20 mg as a sprinkle capsule on 1 tablespoon of pudding on Day 1 of Treatment Period 3.
89510014|NCT05399030|Experimental|ICP-332|Single ascending doses of ICP-332 tablet; Multiple ascending doses of ICP-332 tablet
89510015|NCT05399030|Placebo Comparator|Placebo|Single ascending doses of placebo; Multiple ascending doses of placebo
89510016|NCT05398874|Active Comparator|Ginkgo + standard|the patients received Ginkgo biloba extract in addition to standard treatment
89510017|NCT05398874|Placebo Comparator|placebo + standard|the patients received a placebo in addition to the standard treatment
89510018|NCT02525744|Experimental|LY900014 7.5 Units (U)|Single dose of 7.5 U LY900014 administered subcutaneously (SC) in one to two of five periods.
89510019|NCT02525744|Active Comparator|Insulin Lispro|Reference formulation. Single dose of Insulin Lispro administered SC in one to two of five periods.
89510020|NCT02525744|Experimental|LY900014 15 U|Single dose of 15 U LY900014 administered subcutaneously (SC) in one to two of five periods.
89510021|NCT02525744|Experimental|LY900014 30 U|Single dose of 30 U LY900014 administered subcutaneously (SC) in one to two of five periods.
89510022|NCT05360810|Active Comparator|Wei Nasal Jet Tube Group (Group W)|After induction of anesthesia, the Wei Nasal Jet Tube was placed in the patients.
89510023|NCT05360810|Active Comparator|Gastro-Laryngeal Tube Group (Group G)|After the induction of anesthesia, the Gastro Laryngeal Tube was placed in the patients.
89510024|NCT00152477|Experimental|Carboplatin/Paclitaxel|Carboplatin and paclitaxel alone.
89024123|NCT03427099|Experimental|Intervention group|Rehabilitation with a biopsychosocial focus
89024124|NCT03414502|Active Comparator|Methotrexate Therapy|Subjects will receive methotrexate therapy for RA treatment.
89510025|NCT00152477|Experimental|Carboplatin/Paclitaxel/CDP791 10mg|Carboplatin and paclitaxel plus CDP791 10mg/kg
89510026|NCT00152477|Experimental|Carboplatin/Paclitaxel/CDP791 20mg|Carboplatin and paclitaxel plus CDP791 20mg/kg
89510027|NCT01112423|Experimental|BMS-823778 (2 mg)|
89510028|NCT01112423|Experimental|BMS-823778 (10 mg)|
89510029|NCT01112423|Experimental|BMS-823778 (20 mg)|
89510030|NCT01112423|Placebo Comparator|Placebo|
89510031|NCT05558891|Experimental|Experimental: THRIVE + Usual Care|Individuals presenting to a community-based crisis stabilization center who are age 18-plus and screen positive for suicide risk
89510032|NCT05558891|Active Comparator|Usual Care|Individuals presenting to a community-based crisis stabilization center who are age 18-plus and screen positive for suicide risk
89510033|NCT01111955|Active Comparator|BMS-823778 (2 mg)|+ metformin
89510034|NCT01111955|Active Comparator|BMS-823778 (10 mg)|+ metformin
89510035|NCT01111955|Active Comparator|BMS-823778 (20 mg)|+ metformin
89510036|NCT01111955|Placebo Comparator|Placebo|+ metformin
89510037|NCT01106807|Experimental|CD07223 1.5% gel|500 microliters of CD07223 1.5% gel on one half-face twice daily for six weeks and Epiduo vehicle gel on the other half-face
89510038|NCT01106807|Experimental|CD07223 0.5% gel|500 microliters of CD07223 0.5% gel on one half-face twice daily for six weeks and Epiduo vehicle gel on the other half-face
89510039|NCT01106807|Active Comparator|Epiduo (adapalene and benzoyl peroxide) 0.1%/2.5% gel|500 microliters of Epiduo (adapalene and benzoyl peroxide) 0.1%/2.5% gel on one half-face and 500 microliters of the Epiduo vehicle gel on the other half-face in the morning and in the afternoon, 500 microliters of Epiduo vehicle gel on both half-faces
89510040|NCT04256174|Experimental|Part 1:15mg cohort|Single dose of 15mg AK120 or placebo is administered subcutaneously to healthy subjects.
89510041|NCT04256174|Experimental|Part 1: 50mg cohort|Single dose of 50mg AK120 or placebo is administered subcutaneously to healthy subjects.
89510042|NCT04256174|Experimental|Part 1: 150mg cohort|Single dose of 150mg AK120 or placebo is administered subcutaneously to healthy subjects.
89510043|NCT04256174|Experimental|Part 1: 300 mg cohort|Single dose of 300mg AK120 or placebo is administered subcutaneously to healthy subjects.
89510044|NCT04256174|Experimental|Part 1: 600 mg cohort|Single dose of 600mg AK120 or placebo is administered subcutaneously to healthy subjects.
89510045|NCT04256174|Experimental|Part 2: low dose cohort|Multiple low doses of AK120 or placebo are administered subcutaneously to subjects with moderate- to- severe atopic dermatitis.
89510046|NCT04256174|Experimental|Part 2: medium dose cohort|Multiple medium doses of AK120 or placebo are administered subcutaneously to subjects with moderate- to- severe atopic dermatitis.
89510047|NCT04256174|Experimental|Part 2: high dose cohort|Multiple high doses of AK120 or placebo are administered subcutaneously to subjects with moderate- to- severe atopic dermatitis.
89510048|NCT04256174|Experimental|Part 2: Loading dose cohort|A loading dose followed by multiple high doses of AK120 or placebo are administered subcutaneously to subjects with moderate- to- severe atopic dermatitis.
89510049|NCT05533229||Pregnant patients scheduled for C section|Spinal anesthesia
89510050|NCT00153179|Active Comparator|1|Acipimox treatment for 7 days
89510051|NCT00153179|Placebo Comparator|2|placebo treatment for 7 days
89510052|NCT05532839|Experimental|High intensity interval training|High-intensity interval training is a training that cycles between high bursts of activity and predetermined times of less intensive exercise or rest period.
89510053|NCT05532839|Experimental|Moderate intensity continuous interval training|Moderate-intensity continuous training consists of periods followed by 50 minutes of exercise - bicycling, running, jogging, marching, paddling, etc. - at a recorded frequency of 70-75 percent maximal heart rate.
89510054|NCT02743949|Active Comparator|Esomeprazole 40 mg|Esomeprazole 40 mg over-encapsulated tablets, orally, once daily for 4 weeks then esomeprazole placebo-matching capsules, orally, once daily for 2 weeks during the run-in period, followed by esomeprazole 40 mg, over encapsulated tablets, orally, once daily for 4 weeks during the active treatment period.
89510055|NCT02743949|Experimental|Vonoprazan 20 mg|Esomeprazole 40 mg over-encapsulated tablets, orally, once daily for 4 weeks then esomeprazole placebo-matching capsules, orally, once daily for 2 weeks during the run-in period, followed by vonoprazan 20 mg, over-encapsulated capsules, orally, once daily for 4 weeks during the treatment period.
89510056|NCT02743949|Experimental|Vonoprazan 40 mg|Esomeprazole 40 mg over-encapsulated tablets, orally, once daily for 4 weeks then esomeprazole placebo-matching capsules, orally, once daily for 2 weeks during the run-in period, followed by vonoprazan 40 mg, over-encapsulated capsules, orally, once daily for 4 weeks during the active treatment period.
89510057|NCT05627297||SR|
89510058|NCT05627297||RFA|
89510059|NCT05627141|Experimental|Photobiomodulation|10 participants will receive active photobiomodulation immediately after the muscle damage and fatigue induction protocol in a randomized and crossover manner, with an interval of 15 days between each evaluation session
89510060|NCT05627141|Sham Comparator|Sham Photobiomodulation|10 participants will receive sham photobiomodulation immediately after the muscle damage and fatigue induction protocol in a randomized and crossover manner, with an interval of 15 days between each evaluation session
89510061|NCT05627141|Experimental|Active Cryotherapy|10 participants will receive effective cryotherapy (10-12°C for 20 min) combined with high compression on the lower limbs, or sham (25°C for 20 min) damage and fatigue induction protocol. muscle.
89510062|NCT05627141|Sham Comparator|Sham Cryotherapy|10 participants will receive sham cryotherapy (25°C for 20 min) combined with light compression on the lower limbs immediately after the damage and fatigue induction protocol. muscle.
88959022|NCT01999647|Active Comparator|Perineural|Patients in this group will receive a perineural injection for subgluteal sciatic nerve block under real-time, short-axis, in-plane ultrasound guidance, in addition to a femoral nerve block and patient-controlled postoperative analgesia. Ropivacaine will be used for the sciatic nerve block, whereas the choice of agent for the femoral nerve block is left to the attending anesthesiologist.
89510063|NCT05627141|Experimental|Massage|10 participants will receive the effective massage immediately after the muscle damage and fatigue induction protocol in a randomized and crossover manner, with an interval of 15 days between each evaluation session.
89510064|NCT05627141|Sham Comparator|Sham Massage|10 participants will receive the sham massage immediately after the muscle damage and fatigue induction protocol in a randomized and crossover manner, with an interval of 15 days between each evaluation session.
89510065|NCT02531438|Experimental|Omadacycline|Omadacycline IV; Omadacycline tablets
89510066|NCT02531438|Active Comparator|Moxifloxacin|Moxifloxacin IV; Moxifloxacin tablets
89510067|NCT02289898|Experimental|Abraxane® and gemcitabine plus placebo|Abraxane® and gemcitabine plus placebo (3 cycles), Abraxane® and gemcitabine (3 cycles), Abraxane® and gemcitabine plus placebo (3 cycles) and then Abraxane® and gemcitabine until disease progression
89510068|NCT02289898|Experimental|Abraxane® and gemcitabine plus demcizumab plus placebo|Abraxane® and gemcitabine plus demcizumab (3 cycles), Abraxane® and gemcitabine (3 cycles), Abraxane® and gemcitabine plus placebo (3 cycles) and then Abraxane® and gemcitabine until disease progression
89510069|NCT02289898|Experimental|Abraxane® and gemcitabine plus demcizumab|Abraxane® and gemcitabine plus demcizumab (3 cycles), Abraxane® and gemcitabine (3 cycles), Abraxane® and gemcitabine plus demcizumab (3 cycles) and then Abraxane® and gemcitabine until disease progression
89510070|NCT01660412|Active Comparator|pH altered first|The first injection administered will be the pH altered solution. The second injection will be the standard of care solution (opposite order). The remaining injections will be randomly assigned as either standard of care or pH altered.
89510071|NCT01660412|Active Comparator|Standard of Care first|The first injection administered will be the standard of care solution (SOC). The second injection will be the pH altered solution. The remaining injections will be randomly assigned as either standard of care or pH altered.
89510072|NCT04255628||with cancer pain|head and neck and esophageal cancer patients. with cancer pain
89510073|NCT04255628||without cancer pain|head and neck and esophageal cancer patients. without cancer pain=30
89510074|NCT01659554|Experimental|Out-Patient Intraperitoneal Chemotherapy|Intraoperative (hyperthermic) cisplatin followed by 4 courses of intraperitoneal cisplatin and doxorubicin given on days 1 & 8 during a 3 week cycle.
89510075|NCT05355350|Experimental|piperacillin tazobactam|
89510076|NCT05355350|Active Comparator|meropenem|
89510077|NCT05415020|Active Comparator|Virtual Therapy Group|
89510078|NCT05415020|Sham Comparator|Attention Placebo Group|
89510079|NCT05355116|Experimental|Group A: Physiolab S1|The cryocompression device will be attached to the lower limb of participants using a cuff spanning from the mid-thigh to mid-calf. The device will exert an intermittent pressure of 25-50 mmHg throughout each test session. The device will pump temperature-controlled cold water through the cuff in order to reduce the skin temperature around the knee (and intra-articular temperature). The temperature of the water being pumped through the device will be 8℃. Each test session will last for 30 minutes. Participants will take part in all conditions, with at least 24 hours rest in between test sessions. Skin temperature around the knee will be measured prior to the cryocompression device being applied; every 5 minutes during the 30 minute test; and every 5 minutes after the test until skin temperature >15℃.
89510080|NCT05355116|Experimental|Group B: Breg Vpulse|The cryocompression device will be attached to the lower limb of participants using a cuff spanning from the mid-thigh to mid-calf. The device will exert a dynamic peak pressure of 50 mmHg throughout each test session. The device will pump temperature-controlled cold water through the cuff in order to reduce the skin temperature around the knee (and intra-articular temperature). The temperature of the water being pumped through the device will not be lower than 5.5℃. The selected pressure and temperature represents the maximum capability of this device. Each test session will last for 30 minutes. Participants will take part in all conditions, with at least 24 hours rest in between test sessions. Skin temperature around the knee will be measured prior to the cryocompression device being applied; every 5 minutes during the 30 minute test; and every 5 minutes after the test until skin temperature >15℃.
89510081|NCT05355116|Experimental|Group C: Cryo/Cuff|The cryocompression device will be attached to the lower limb of participants using a cuff spanning from the mid-thigh to mid-calf. The pressure and temperature that the device applies to the treatment area is non-modifiable and undefined. The device will be used according to the manufacturer's recommendations, which will represent the maximum capability of this device. Each test session will last for 30 minutes. Participants will take part in all conditions, with at least 24 hours rest in between test sessions. Skin temperature around the knee will be measured prior to the cryocompression device being applied; every 5 minutes during the 30 minute test; and every 5 minutes after the test until skin temperature >15℃.
89510082|NCT05355116|Experimental|Group D: GameReady|The cryocompression device will be attached to the lower limb of participants using a cuff spanning from the mid-thigh to mid-calf. The device will exert an intermittent pressure of 5-50 mmHg throughout each test session. The device will pump temperature-controlled cold water through the cuff in order to reduce the skin temperature around the knee (and intra-articular temperature). The temperature of the water being pumped through the device will be 1℃. Each test session will last for 30 minutes. Participants will take part in all conditions, with at least 24 hours rest in between test sessions. Skin temperature around the knee will be measured prior to the cryocompression device being applied; every 5 minutes during the 30 minute test; and every 5 minutes after the test until skin temperature >15℃.
89510083|NCT05355116|Experimental|Group E: Physiolab Gel Therapy Wrap|The cryocompression device will be attached to the lower limb of participants using a cuff spanning from the mid-thigh to mid-calf. The pressure and temperature that the device applies to the treatment area is non-modifiable and undefined. The device will be used according to the manufacturer's recommendations, which will represent the maximum capability of this device. Each test session will last for 30 minutes. Participants will take part in all conditions, with at least 24 hours rest in between test sessions. Skin temperature around the knee will be measured prior to the cryocompression device being applied; every 5 minutes during the 30 minute test; and every 5 minutes after the test until skin temperature >15℃.
89510084|NCT01659320|Experimental|Minocycline|Open label treatment using minocycline.
89510085|NCT05414084|Experimental|(Poly)phenol tablets|Single ingestion of 3 tablets containing different amounts of the most representative dietary (poly)phenols (i.e. flavonoid subclasses, phenolic acids, lignans, ellagitannins, stilbenes, flavonols, procyanidins and phenylethanoids)
89510086|NCT05392712|Other|healthy volunteers|
89510087|NCT05392712|Experimental|Chest pain patients who will undergo CAG or CTA|
89510088|NCT05392712|Experimental|AMI patients|
89510089|NCT05413148|Active Comparator|Wharton jelly-derived mesenchymal stem cell|Single subtenon injection of Wharton jelly-derived mesenchymal stem cells will be performed on a single eye after randomization
89510090|NCT05413148|Active Comparator|Mesenchymal stem cell exosome (Wharton jelly-derived)|Single subtenon injection of mesenchymal stem cell exosomes (Wharton jelly-derived)will be performed on a single eye after randomization.
89510091|NCT05413148|Placebo Comparator|Placebo|A single subtenon injection of saline will be performed on a single eye after randomization.
89510092|NCT05412992|Active Comparator|DMTS Patch|DMTS applied to upper outer arm
89510093|NCT05412992|Placebo Comparator|Placebo Patch|Placebo system (with no drug) to match DMTS applied to the upper arm
89510094|NCT05392322|Active Comparator|Self-help skills|Effect of self-help skills on fine motor skills in children with down's syndrome
89510095|NCT05392322|Experimental|Virtual video reality gaming|Effects of virtual video reality gaming on fine motor skills in children with down's syndrome
88959023|NCT01999647|Experimental|Intraneural|Patients in this group will receive an intraneural injection for subgluteal sciatic nerve block under real-time, short-axis, in-plane ultrasound guidance, in addition to a femoral nerve block and patient-controlled postoperative analgesia. Ropivacaine will be used for the sciatic nerve block, whereas the choice of agent for the femoral nerve block is left to the attending anesthesiologist.
88959024|NCT01999660||SpaceOAR™|prostate cancer patient prophetically treated by SpaceOAR™
88959025|NCT01999673|Experimental|bavituximab plus docetaxel|Six 21-day cycles of docetaxel plus weekly bavituximab. Patients who have not experienced disease progression will continue to receive bavituximab weekly until progression.
88959026|NCT01999673|Placebo Comparator|placebo plus docetaxel|Six 21-day cycles of docetaxel plus weekly placebo. Patients who have not experienced disease progression will continue to receive placebo weekly until progression.
88959027|NCT01999686|Experimental|Treatment I : DLBS3233|DLBS3233 100 mg capsule once daily, and Placebo metformin caplet twice daily; orally, for 6 months
88959028|NCT01999686|Active Comparator|Treatment II : Metformin|Metformin XR 750 mg caplet twice daily, and Placebo DLBS3233 once daily; orally, for 6 months
89024125|NCT03414502|Active Comparator|Abatacept Therapy|Subjects will receive abatacept therapy for RA treatment.
88959029|NCT01999686|Experimental|Treatment III : Combination DLBS3233 and Metformin|DLBS3233 100 mg capsule once daily, and Metformin XR 750 mg caplet twice daily; orally, for 6 months.
88959030|NCT01999699|Experimental|HEPLISAV|
88959031|NCT01999712||LVAD recipients|Patients who are scheduled for LVAD implantation will undergo preoperative echocardiography
88959032|NCT01999725|Experimental|EDP-788|Single doses with dose escalation to continue in successive cohorts
88959033|NCT01999725|Placebo Comparator|Placebo|Single dose with matching placebo
88959034|NCT01999738|Experimental|Part A - MTD (Treatment 1)|"Treatment 1 is BIW on Days 1, 4, 8, and 11 of a 3-week schedule (BIW).~Intervention: EC1456 and EC20"
88959035|NCT01999738|Experimental|Part A - MTD (Treatment 2)|"Treatment 2 is EC1456 QW on Days 1 and 8 of a 3-week schedule (QW).~Intervention: EC1456 and EC20"
88959036|NCT01999738|Experimental|Part A - MTD (Treatment 3)|"Treatment 3 is EC1456 QW on Days 1, 8, and 15 of a 3-week schedule (CWD).~Intervention: EC1456 and EC20"
88959037|NCT01999738|Experimental|Part A - MTD (Treatment 4)|"Treatment 4 is EC1456 QIW on Days 1, 2, 3, 4, 8, 9, 10, and 11 of a 3-week schedule (QIW).~Intervention: EC1456 and EC20"
89207016|NCT00547911|Experimental|LDOPS + Placebo; LDOPS + ENT; LDOPS + CAR|There are three interventions that every subject orally received over the duration of the study; 400 mg of droxidopa (LDOPS) + 200 mg placebo, 400 mg of droxidopa (LDOPS) + 200 mg carbidopa (CAR), and 400 mg of droxidopa (LDOPS) + 200 mg entacapone (ENT). The order of the three interventions was randomly assigned prior to drug administration and each intervention was followed by a wash out period of at least two days to clear previous intervention from subject's systems. This arm received the three interventions in the order of: LDOPS + Placebo, followed by LDOPS + ENT, and lastly LDOPS + CAR.
89510096|NCT00821132||ALS families|Patients with either inherited or sporadic ALS or PLS and selected family members
89510097|NCT01660334||Voriconazole|Subjects who are treated with voriconazole
89510098|NCT05352932||patient group|Patients with chronic pancreatitis or idiopathic recurrent acute pancreatitis are considered as study subjects.
89510099|NCT05006378|Placebo Comparator|Placebo Capsule|
89510100|NCT05006378|Experimental|Chamomile Tea|Subjects will consume three servings of chamomile tea throughout the day for the one-week treatment period. Each tea serving will be prepared using 3 grams of chamomile tea steeped in hot water according to the study protocol.
89510101|NCT05006378|Experimental|Chamomile Extract Capsule|Subjects will consume three chamomile capsules throughout the day for the one-week treatment period. Each capsule consists of 500 milligrams of a chamomile extract that has been standardized to 1.2% apigenin content.
89510102|NCT04973072|No Intervention|Control|Participants in this arm will not receive any intervention.
89510103|NCT04973072|Experimental|One large reward|Participants in this arm will receive S$300 if they reach the PBF goal at the end of 12 weeks.
89510104|NCT04973072|Experimental|Small wins|Participants in this arm will receive cash rewards capped by S$300, depending on which intermediate goals they reach and the PBF at the end of the 12 weeks.
89510105|NCT01660256|Experimental|OPC-12759 ophthalmic solution|OPC-12759 ophthalmic solution
89510106|NCT01660256|Placebo Comparator|Placebo|OPC-12759 ophthalmic solution 0%
89510107|NCT01660256|Active Comparator|OPC-12759 ophthalmic suspension|OPC-12759 ophthalmic suspension
89510108|NCT02034123|Experimental|Dose Escalation Cohort|The safety and PK/PD data will be reviewed prior to the dose decision, and the dose escalation will be guided by the Neuenschwander -continuous reassessment method (N-CRM).The dose escalation will complete when RP2D is determined. The RP2D will be the MTD or a lower dose that provides adequate PK exposure and biologic activity with superior tolerability.
89510109|NCT02034123|Experimental|Dose Expansion Cohort|Once the RP2D has been determined, an expansion cohort of up to 30 subjects will be enrolled in order to better characterize the clinical activity and safety profile of the RP2D
89510110|NCT05076825|Experimental|Neurodynamic Sliding|participents receive routine physical therapy along with TENS, Hot pack and Neurodynamic Stretching. (For 30 seconds, 3 times per session for 3 alternative days a week & duration of 4 weeks).
89510111|NCT05076825|Active Comparator|Static Streching|Participent receive the routine physical therapy treatment that will include TENS, Hot pack and static stretching for 30 seconds and 3 times per session for 3 alternative days a week (duration of 4 weeks).
89510112|NCT03144141|Other|Patients with the diagnosis of threat of uterine delivery|
89510113|NCT02330367|Experimental|AC0010|Oral AC0010 monotherapy
89510114|NCT05352464|Experimental|cervical traction with EMG biofeedback|"Continuous traction for 15-20 minutes in sitting position on average at an angle of 15-25 degrees of cervical flexion or in the most pain-free position.~Ask the patient to assume sitting position on a comfortable chair. Place surface electrodes of EMG biofeedback at the level of C5-6 Para spinal muscles to pick up the activity of the muscles and convert it to vis-ual and auditory impulses produced from the device. Tell the patient to try to relax the tension of the neck muscles as much as he can by lowering the visual and auditory impulses from the device"
89510115|NCT05352464|Active Comparator|cervical traction and conventional physical therapy|Continuous traction for 15-20 minutes in sitting position on average at an angle of 15-25 degrees of cervical flexion or in the most pain-free position.
89510116|NCT02318602|Experimental|Infants|"Participants 1 to<2 years of age. Participants who completed INS011-14-029 initiated this study on the dose with which they were being treated previously, and dose modifications were made at the Investigator's discretion if tolerability or efficacy issues were observed for a particular participant. The maximum daily dose was 40 mg/kg/day.~Participants who enrolled from INS011-15-054 continued treatment with the dose at which they were being treated previously, and dose modifications were made at the Investigator's discretion if tolerability or efficacy issues were observed for a particular participant.~The total daily dose, milligrams per kilograms per day (mg/kg/day), will be evenly split between morning and evening doses (12 hours apart). If tolerability issues arise, the participant's dose may be changed at the investigator's discretion."
89519429|NCT05386589|Experimental|Healthy-Matched Control Group|Healthy matched participants will receive a single oral 800mg dose of molnupiravir.
89024126|NCT03414502|Active Comparator|Adalimumab Therapy|Subjects will receive adalimumab therapy for RA treatment.
89510117|NCT02318602|Experimental|Children|"Participants 2 to <12 years of age. Participants who completed INS011-14-029 initiated this study on the dose with which they were being treated previously, and dose modifications were made at the Investigator's discretion if tolerability or efficacy issues were observed for a particular participant.The maximum daily dose was 40 mg/kg/day.~Participants who enrolled from INS011-15-054 continued treatment with the dose at which they were being treated previously, and dose modifications were made at the Investigator's discretion if tolerability or efficacy issues were observed for a particular participant.~The total daily dose (mg/kg/day) will be evenly split between morning and evening doses (12 hours apart). If tolerability issues arise, the participant's dose may be changed at the investigator's discretion."
89510118|NCT02318602|Experimental|Adolescents|"Participants 12 to <17 years of age. Participants who completed INS011-14-029 initiated this study on the dose with which they were being treated previously, and dose modifications were made at the Investigator's discretion if tolerability or efficacy issues were observed for a particular participant. The maximum daily dose was 40 mg/kg/day.~Participants who enrolled from INS011-15-054 continued treatment with the dose at which they were being treated previously, and dose modifications were made at the Investigator's discretion if tolerability or efficacy issues were observed for a particular participant.~The total daily dose (mg/kg/day) will be evenly split between morning and evening doses (12 hours apart). If tolerability issues arise, the participant's dose may be changed at the investigator's discretion."
89024127|NCT03414502|Active Comparator|Azathioprine Therapy|Subjects will receive azathioprine therapy for RA treatment.
89510119|NCT05352152||Patients with ascites infection|Patients who is confirmed with ascites infection or clinically diagnosed as ascites infection will be enrolled in this cohort.
89510120|NCT02330679|Other|Desvenlafaxine|2-week single-blind placebo run-in phase followed by a 12-week open-label trial with desvenlafaxine
89510121|NCT03144063||Toronto Lupus Cohort|"Objective 1 and 3 Cohort:~≥4 American College of Rheumatology (ACR) criteria or 3 ACR criteria plus a typical histological lesion of SLE on renal or skin biopsy~Clinician's diagnosis based on his/her assessment~Patients from the Toronto Lupus Clinic with regular follow-up, defined as having follow up visits at 3 and 6 months from the baseline visit (1st study visit)."
89510122|NCT03144063||BLISS-52 Cohort|"Objective 2 Cohort:~Validation of the SLEDAI-2KG will be completed on BLISS-52 trial data. The extracted trial data consists of data on all patients that participated in the trial."
89510123|NCT03144063||BLISS-76 Cohort|"Objective 2 Cohort:~Validation of the SLEDAI-2KG will be completed on BLISS-76 trial data. The extracted trial data consists of data on all patients that participated in the trial."
89510124|NCT05559008|Experimental|T1 subtypes based on next generation sequencing results|T1 subtypes based on next generation sequencing results
89510125|NCT05559008|Experimental|T2 subtypes based on next generation sequencing results|T2 subtypes based on next generation sequencing results
89510126|NCT05559008|Experimental|T3.1 subtypes based on next generation sequencing results|T3.1 subtypes based on next generation sequencing results
89510127|NCT05559008|Experimental|T3.2 subtypes based on next generation sequencing results|T3.2 subtypes based on next generation sequencing results
89510128|NCT05076669|Active Comparator|Control|The control group will receive the routine care prescribed by the sites and will be provided with ostomy equipment by FSK.
89510129|NCT05076669|Experimental|interventional group|The interventional group will benefit from delivery and enhanced follow-up by the FSK HHN provided, in particular, by stomal therapy nurse consultants and patient-relation experts during in-person or remote appointments in addition to the routine care delivered and prescribed by the sites.
89510130|NCT05389904|Active Comparator|Patients colonized with toxigenic C. difficile who do not receive the prevention bundle|Patients colonized with toxigenic C. difficile, identified by testing routinely collected swabs for vancomycin-resistant enterococcus screening, who receive standard of care
89510131|NCT05389904|Active Comparator|Patients colonized with toxigenic C. difficile who receive the prevention bundle|Patients colonized with toxigenic C. difficile, identified by testing routinely collected swabs for vancomycin-resistant enterococcus screening, who receive a preemptive prevention bundle for C. difficile including enhanced room cleaning, C. difficile precautions, pharmacist review and optimization of antibiotics and antacids, and consideration of vancomycin prophylaxis.
89510132|NCT02318368|Experimental|Ficlatuzumab plus erlotinib|150 mg Erlotinib orally once daily starting on Day 1 of Cycle 1 with 20 mg/kg Ficlatuzumab administered intravenously once every 2 weeks on Day 1 and Day 15 of each 28 day cycle.
89024128|NCT03414502|Active Comparator|Barcitinib Therapy|Subjects will receive barcitinib therapy for RA treatment.
89024129|NCT03414502|Active Comparator|Certolizumab Therapy|Subjects will receive certolizumab therapy for RA treatment.
89024130|NCT03414502|Active Comparator|Etanercept Therapy|Subjects will receive etanercept therapy for RA treatment.
89024131|NCT03414502|Active Comparator|Golimumab Therapy|Subjects will receive golimumab therapy for RA treatment.
89024132|NCT03414502|Active Comparator|Hydroxycholoroquine Therapy|Subjects will receive hydroxychloroquine therapy for RA treatment.
89024133|NCT03414502|Active Comparator|Infliximab Therapy|Subjects will receive infliximab therapy for RA treatment.
89024134|NCT03414502|Active Comparator|Leflunomide Therapy|Subjects will receive leflunomide therapy for RA treatment.
89024135|NCT03414502|Active Comparator|Minocycline Therapy|Subjects will receive minocycline therapy for RA treatment.
89024136|NCT03414502|Active Comparator|Rituximab Therapy|Subjects will receive rituximab therapy for RA treatment.
89510133|NCT02318368|Active Comparator|Placebo plus erlotinib|150 mg Erlotinib orally once daily starting on Day 1 of Cycle 1 with Placebo administered intravenously once every 2 weeks on Day 1 and Day 15 of each 28 day cycle.
89510134|NCT05351840|Experimental|Period I|Subject will receive Drug(LivaloV), then take it by oral, once-daily form Day 1 to Day 7
89510135|NCT05351840|Experimental|Period II|Subject will receive Drug(A), then take it by oral, once-daily form Day 14 to Day 23
89510136|NCT05351840|Experimental|Period III|Subject will receive Drug(LivaloVA), then take it by oral, once-daily form Day 24 to Day 30
89510137|NCT05076201|Experimental|Patients with completed rehab|The aim of this research is to follow-up a cohort of patients at the end of their detoxification cure (cocaïne).
89510138|NCT05557526|No Intervention|Standard Medical Care Control Group|Patients with atrial fibrillation receiving catheter ablation of atrial fibrillation without additional intervention.
89510139|NCT05557526|Experimental|Optimize Expectation Group|Patients with atrial fibrillation receiving catheter ablation of atrial fibrillation and an additional verbal intervention to optimize the expectation of the patient towards the procedure.
89510140|NCT05063175|Active Comparator|Control Group|Children in the control group received the conventional physical therapy protocol which was prescribed to correct the kyphotic posture of the dorsal spine, and improve postural balance stability during standing and walking.
89510141|NCT05063175|Experimental|Experimental Group|The children in the experimental group received the conventional protocol applied to the control group. Further, they wore TheraTog orthotic undergarment with its strapping system for 8 hours daily for 12 successive weeks.
89510142|NCT05053425|Experimental|Venetoclax group|"Induction therapy: venetoclax d1 100mg, d2 200mg, d3-28 400mg, po; azacytidine 75mg/m2, d1-7, sc.~Consolidation therapy: Regimen A or B was chosen according to the wishes of the patients. In addition, venetoclax was used for 14 days for positive minimal residual disease(MRD) and 7 days for MRD negative.~regimen A: the first two cycles: venetoclax 400mg, d1-7/14, po; cladribine 5mg/m2, d1-3, ivgtt; cytarabine 10mg/m2, q12h, d1-10, sc; the last two cycles: venetoclax 400mg, d1-7/14, po; cytarabine 0.5-1.0g/m2, d1-3, ivgtt; regimen B: the first two cycles: venetoclax 400mg, d1-7/14, po; cytarabine 100mg/m2, d1-5/7, ivgtt; idarubicin 8mg/m2, d1-2/3, ivgtt; the last two cycles: venetoclax 400mg, d1-7/14, po; cytarabine 0.5-1.0g/m2, d1-3, ivgtt; If the patient's ECOG performance status ≥2,the reduction of regimen IA(cytarabine+idarubicin)was 5+2.~Maintenance therapy: azacytidine 75mg/m2, d1-7, sc."
89510143|NCT02318134|Experimental|FMT group|In the FMT group, participants received 200 mL fresh donor feces for twice (once every two days) via a nasoduodenal tube.
89510144|NCT02318134|Placebo Comparator|Control group|In the control group, participants received 200 mL normal saline for twice (once every two days) via a nasoduodenal tube.
89510145|NCT03142503|Placebo Comparator|Placebo|Soybean supplementation
89510146|NCT03142503|Active Comparator|Diet + placebo|Soybean supplementation and diet intervention
89510147|NCT03142503|Experimental|Diet + Supplementation|Omega 3 and diet intervention
89510148|NCT05350436|Experimental|Young adult non singers|
89510149|NCT05350436|Experimental|Young adult singers|
89510150|NCT05350436|Experimental|Older adult non singers|
89510151|NCT05350436|Experimental|Older adult singers|
89510152|NCT03142269|Active Comparator|polished group|360°anterior capsule polishing was performed with double-ended capsule polisher randomly in one eye
89510153|NCT03142269|Placebo Comparator|unpolished group|the opposite unpolished was used as the control
89510154|NCT02317510|Active Comparator|group 1|Laparoscopic cholecystectomy in General Anesthesia
89510155|NCT02317510|Active Comparator|group 2|Laparoscopic cholecystectomy in combined anesthesia (Spino epidural).
89510156|NCT05350124|Experimental|Group 1|Vitamin C (200 mg) capsule, and vitamin E (400 IU) capsule every day for 12 weeks.
89510157|NCT05350124|Experimental|Group 2|Vitamin C (200 mg) capsule, and placebo every day for 12 weeks.
89510158|NCT05350124|Experimental|Group 3|Vitamin E (400 IU) capsule, and placebo every day for 12 weeks.
89024137|NCT03414502|Active Comparator|Sarilumab Therapy|Subjects will receive sarilumab therapy for RA treatment.
89024138|NCT03414502|Active Comparator|Sulfasalazine Therapy|Subjects will receive sulfasalazine therapy for RA treatment.
89024139|NCT03414502|Active Comparator|Tofacitinib Therapy|Subjects will receive tofacitinib therapy for RA treatment.
89024140|NCT03410615|Active Comparator|Radiation/Cisplatin|"All patients will receive standard fractionation radiation therapy (RT) scheme: 70 Gy in 35 fractions over 7 weeks (i.e. 2 Gy per fraction)~Cisplatin IV 100 mg/m2 days 1, 22, 43 concurrently with RT"
89510159|NCT05350124|Experimental|Group 4|Placebo capsule (2 pills) every day for 12 weeks.
89510160|NCT02329899||Possible MBD|"Defined by:~a bleeding score >= 4 in adults;~a bleeding score >= 2 in children (for girls, up to menses);~a past medical history that include menorrhagia, haemorrhage from the umbilical stump, bleeding at circumcision, cephalhematoma at birth, hematuria, whatever the bleeding score is;~a past medical history suggestive of a MBD with no haemostatic challenge and a low bleeding score.~In this group, the second step of investigations will be performed."
89510161|NCT02329899||MBD unlikely|"Patients without criteria for possible MBD as listed above.~In this group, no further investigation will be performed if the first step is normal. The second step of investigations will be performed only in case of significant abnormalities in the first step of investigation."
89510162|NCT02329977||Recurrent group|Patients with history of recurrent common bile duct stone after successfully ERCP stone remove.
89510163|NCT02329977||Control group|Patients without history of recurrent common bile duct stone after successfully ERCP stone remove.
89510164|NCT05389436|Experimental|Experimental|The patient is discharged from the ER following X-ray, casting, charts. The patient is contacted when surgery is scheduled, and this is performed in a ambulatory setting
89510165|NCT05389436|Active Comparator|Standard|The patient is admitted from the ER, surgery is performed when possible in regards to surgical capacity and swelling. Discharged when mobilised with cast.
89510166|NCT02317432|Experimental|CBT + InVEST exercise|10 sessions of individual CBT plus 36 sessions of InVEST group exercise, provided over a 12-week intervention period.
89510167|NCT02317432|Active Comparator|Enhanced Usual Care|Usual care, as accessed through the community-based organization, plus written material from the NIH on depression, anxiety, and physical health for elders.
89510168|NCT05075655|Experimental|EBUS-MFB and EBUS-TBNA|patient will have both TBNA and MFB in the same operating time
89510169|NCT05018871|Experimental|Treatment Group|Single intravenous infusion of 100 million cells
89510170|NCT05388578||Primary cohort|All participants will receive the Stroke Box containing a wearable bloodpressure monitor, activity tracker and weighting scale, and associated apps.
89510171|NCT05388578||Patients with indication for AF|All participants will receive the Stroke Box containing a wearable bloodpressure monitor, activity tracker and weighting scale, and associated apps. Patients with an indication for atrial fibrillation (AF) will additionally receive a wrist-worn single-lead ECG device.
89510172|NCT05018793|Experimental|Treatment Group|Single intrathecal injection of 100 million cells
89510173|NCT05344586|Experimental|Intervention group|Hamstring stretching program with neural load
89510174|NCT05344586|Experimental|Control group|Hamstring stretching program without neural load
89510175|NCT03143907|Other|Group-A - Immediate Intervention|Immediate Mindfulness Ambassador Council for Early Psychosis (MAC-EP)
89510176|NCT03143907|Other|Group-B - Delayed Intervention|6 month treatment as usual waitlist followed by Mindfulness Ambassador Council for Early Psychosis (MAC-EP)
89510177|NCT05348174|Active Comparator|Virtual Reality Assisted Guided Imagery (VRAGI )|20 participants will be randomized to this arm. Participants in this arm will experience the immersive VR guided imagery on VR Head Mounted Displays (Meta Quest 2). They will experience video content and the accompanying guided imagery and nature soundscapes.
89510178|NCT05348174|Sham Comparator|Virtual Reality No Guided Imagery or other audio ( VR No GI or other audio)|20 participants will be randomized to this arm. Participants in this arm will experience the immersive VR visual content on VR Head Mounted Displays (Meta Quest 2) but will not experience the accompanying guided imagery narration or nature soundscapes.
89510179|NCT05348174|Active Comparator|Laptop Assisted Guided Imagery (Laptop AGI)|20 participants will be randomized to this arm. Participants in this arm will experience the VR content on laptops. They will not receive the VRHMDs. They will experience video content and the accompanying guided imagery and nature soundscapes on a laptop.
89510180|NCT05348174|Sham Comparator|Laptop no Guided Imagery or other audio (Laptop no GI or other audio)|20 participants will be randomized to this arm. Participants in this arm will experience the VR content on laptops. They will not receive the VRHMDs. They will experience only the video content on a laptop and will no experience the accompanying guided imagery or nature soundscapes.
89510181|NCT03143751|Experimental|Continuous hyperosmolar therapy|Standard cares plus continuous hyperosmolar therapy (NaCl20%)
89510182|NCT03143751|No Intervention|Control|Standard cares alone.
89510183|NCT02330133|Experimental|Women's Reproductive Health|Targeted text and video information on website for women aged 25-55 to avoid unplanned pregnancy and sexually transmitted infections
89510184|NCT02330133|Active Comparator|Online sexual health content|Online general text-based information about reproductive health issues and STD prevention strategies
89510185|NCT03143517||Inflammatory Bowel Disease (IBD)|A stool sample will be collected from adult subjects with Inflammatory Bowel Disease (IBD), confirmed by endoscopy and histologic examination.
89510186|NCT03143517||Irritable Bowel Syndrome (IBS)|A stool sample will be collected from adult subjects with adult subjects with Irritable Bowel Syndrome meeting the Rome III criteria.
89510187|NCT03143517||Other GastroIntestinal (GI) Disorders|A stool sample will be collected from adult subjects with adult subjects with gastrointestinal disorders other than IBD or IBS.
89510188|NCT03143595||Control group|Patients in this group have normal cognition as assessed by the validated Mini-Cog test before the elective operation.
89510189|NCT03143595||Impaired group|Patients in this group have impaired cognition as assessed by the validated Mini-Cog test before the elective operation.
89510190|NCT02329821||HCC group|patients with hepatocellular carcinoma
89510191|NCT02329821||donor group|patient for liver transplantation donation
89510192|NCT03143439||Program group|The program group will be comprised of all individuals who enrolled in the FACT program from July 2016 through September 2019 and have active child support cases with the Contra Costa County Department of Child Support Services.
89510193|NCT03143439||Comparison group|The comparison group will be comprised of individuals with active child support cases with the Contra Costa County Department of Child Support Services who are demographically comparable to the treatment group (i.e., FACT fathers with active child support cases), yet did not participate in or receive FACT services.
89510194|NCT02329665|Experimental|NeedleWays™ System|A total of 50 consecutive subjects scheduled for clinically indicated CT guided needle intervention procedure will be invited to enroll in the study.
89510195|NCT02329509|Active Comparator|one stage cleft palate surgery|Subjects submitted to one stage palate surgical repair after 9 months old and before 24 months old ,
89510196|NCT02329509|Active Comparator|two stage palate repair|Subjects submitted to two stage palate surgical repair (first soft palate repair between 6 and 12 months old and hard palate closure at 3 to 4 years old)
89510197|NCT05346770||Individual Patient|Each case will represent one individual patient and patient case. The cases may not be related and may cover different clinical practice areas.
89510198|NCT04815993|Experimental|SYN-020, 5 mg|6 subjects to receive a single 5 mg dose of SYN-020
89510199|NCT04815993|Experimental|SYN-020, 15 mg|6 subjects to receive a single 15 mg dose of SYN-020
89510200|NCT04815993|Experimental|SYN-020, 45 mg|6 subjects to receive a single 45 mg dose of SYN-020
89510201|NCT04815993|Experimental|SYN-020, 150 mg|6 subjects to receive a single 150 mg dose of SYN-020
89510202|NCT04834869||Pfizer-BioNTech COVID-19 Vaccine|Recently vaccinated individuals by Pfizer-BioNTech COVID-19 Vaccine (Comirnaty)
89510203|NCT04834869||Moderna COVID-19 Vaccine|Recently vaccinated individuals by Moderna COVID-19 Vaccine
89510204|NCT04834869||AstraZeneca-Oxford University COVID-19 Vaccine|Recently vaccinated individuals by AstraZeneca-Oxford University COVID-19 Vaccine (Vaxzevria)
89510205|NCT04834869||CoronaVac|Recently vaccinated individuals by CoronaVac (Sinovac COVID-19 Vaccine)
89510206|NCT04834869||Sinopharm|Recently vaccinated individuals by Vero Cells (Sinopharm COVID-19 Vaccine)
89510207|NCT04834869||Sputnik V|Recently vaccinated individuals by Sputnik V COVID-19 Vaccine
89510208|NCT04834869||Janssen|Recently vaccinated individuals by Janssen COVID-19 Vaccine
89510209|NCT04834869||CureVac|Recently vaccinated individuals by CureVac COVID-19 Vaccine
88959038|NCT01999738|Experimental|Part B - Efficacy (Treatment 5)|"Treatment 5 is EC1456 BIW. Once a dose is determined in Part A, Part B will begin with 3-6 subjects who will receive consecutive day dosing on Days 1, 2, 8, and 9 of a 3-week schedule. If this is not tolerated, the BIW cohort will continue with dosing on Days 1, 4, 8, and 11 of a 3-week schedule.~Intervention: EC1456 and EC20"
89510210|NCT04834869||Novavax|Recently vaccinated individuals by Novavax COVID-19 Vaccine
89510211|NCT04834869||Covaxin|Recently vaccinated individuals by Covaxin COVID-19 Vaccine
89510212|NCT04834869||CanSino|Recently vaccinated individuals by CanSino COVID-19 Vaccine
89510213|NCT05341544|Experimental|Active|Patients will receive 1 hour of active low level tragus stimulation daily for 10 days.
89510214|NCT05341544|Sham Comparator|Sham|Patients will receive 1 hour of sham low level tragus stimulation daily for 10 days.
88959039|NCT01999738|Experimental|Part B - Efficacy (Treatment 6)|"Treatment 6 is EC1456 QW on Days 1 and 8 of a 3-week schedule or CWD on Days 1, 8 and 15 of a 3-week schedule.~Intervention: EC1456 and EC20"
88959040|NCT01999738|Experimental|Part B - Efficacy (Treatment 7)|"Treatment 7 is EC1456 QIW on Days 1, 2, 3, 4, 8, 9, 10, and 11 of a 3-week schedule for at least two cycles. If the patient is eligible to continue treatment (based upon treatment response and tolerability), he/she may opt to continue on the QIW schedule or change to the Treatment 6 regimen schedule (once its MTD and schedule have been determined).~Intervention: EC1456 and EC20"
88959041|NCT01999751||MRI Scan|Patients with implantable cardioverter-defibrillator or pacemaker who undergo an MRI scan
88959042|NCT01999790|Experimental|Blepharothomy|Patients treated with blepharotomy to correct upper lid retraction secondary to Grave's orbitopathy
89510215|NCT04803591|Experimental|A: Tranexamic Acid group|Patients in the Tranexamic Acid (TXA) group (arm-A) will be administered with 2 doses of intravenous tranexamic acid (cumulative dose 10ml=1g) as follows: the first dose 10 minutes before the surgical incision (1 vial of 5 ml = 0,5g by slow intravenous injection(=1ml/minute)), and the second 3 hours after the start of surgery (1 vial of 5 ml = 0,5g, by slow intravenous injection).
89510216|NCT04803591|No Intervention|B : No treatment group|In the control group, will not be administered TXA or any other drugs.
89510217|NCT04555863|Experimental|haMSter app|Patients receiving the app for personal use for 6 months
89510218|NCT04750785||All Participants|Participants who have been diagnosed with CHM will be enrolled.
89510219|NCT04251806||Prenatal Repair|This group received prenatal myelomeningocele repair.
88959043|NCT01999790|Experimental|posterior approach|Patients treated with a posterior approach to correct upper lid retraction secondary to Grave's orbitopathy
88959044|NCT01999803|Experimental|sNN0029 (VEGF)|4 µg/d of sNN0029 administered by continuous intracerebral infusion during12 weeks
88959045|NCT01999803|Placebo Comparator|Placebo|Placebo administered by continuous intracerebral infusion during12 weeks
88959046|NCT01999816|Experimental|Lifestyle Redesign|Occupational therapist led lifestyle redesign program to prevent pressure ulcers
88959047|NCT01999816|No Intervention|Control|Usual care
88959048|NCT01999829|Experimental|citrate of caffeine|
88959049|NCT01999829|Placebo Comparator|placebo|
88959050|NCT01999842|Experimental|Formulation 1 Group|Subjects in this group will receive two doses of GSK3206641A H7N9 vaccine formulation 1 at a 21 day interval
89510220|NCT04251806||Postnatal Repair|This group received postnatal myelomeningocele repair.
89510221|NCT04468893|Experimental|Positive Psychology Intervention with chat|Participants in this group will receive from 15 sessions of a Positive Psychology focused on the increase of wellbeing and sleep quality and decrease of anxiety and depression with the support of a chat service provided by therapists.
89510222|NCT04468893|Active Comparator|Positive Psychology Intervention without chat|Participants in this group will receive from 15 sessions of a Positive Psychology focused on the increase of wellbeing and sleep quality and decrease of anxiety and depression without the support of the chat service.
89510223|NCT04735263|Other|Intermediate Age-Related macular degeneration patients|"Subjects can have either:~Bilateral high-risk iAMD~High-risk iAMD in one eye with GA and/or CNV in the fellow eye No control arm"
89510224|NCT04730115||Group 1. The treatment group (T)|The treatment group comprised of 30 cases treated with functional appliance for one year in puberty.
89510225|NCT04730115||Group 2. The control group (C)|The control group consists of 12 patients who had insufficient oral hygiene; didn't take any orthodontic treatment for one year.
88959051|NCT01999842|Experimental|Formulation 2 Group|Subjects in this group will receive two doses of GSK3206641A H7N9 vaccine formulation 2 at a 21 day interval
89510226|NCT02329119|Experimental|G1-SCZ|patients with schizophrenia as defined in DSM IV-TR
89510227|NCT02329119|Active Comparator|G2-TAB|patients with bipolar affective disorder (BD) type I as defined by the DSM IV-TR
89510228|NCT02329041|Experimental|McGrath Series 5|DLT intubation with McGrath Series 5 videolaryngoscope
89510229|NCT02329041|Active Comparator|Airtraq|DLT intubation with Airtraq videolaryngoscope
89510230|NCT04343469|Active Comparator|Bariatric surgery|The effect of bariatric surgery (RYGB or LSG) on central inflammation
89510231|NCT04343469|No Intervention|No intervention|Healthy lean volunteers
89510232|NCT02329353|Experimental|Smoker group|30 chronic periodontitis patients, having habit of smoking, with probing pocket depth of equal or greater than 5 mm with bleeding on probing and radio-graphic evidence of bone loss in at at least 2 sites at each quadrant will be given three probiotic lozenge per day for 8 weeks
89510233|NCT02329353|Experimental|Non-smoker|30 chronic periodontitis patients, not having habit of smoking, with probing pocket depth of equal or greater than 5 mm with bleeding on probing and radio-graphic evidence of bone loss in at at least 2 sites at each quadrant will be given three probiotic lozenge per day for 8 weeks
89510234|NCT03143205|Experimental|AWARENESS for sexual minorities|Group receives new CBT-based intervention
89510235|NCT03143205|Active Comparator|Writing tasks|Group receives writing-based sessions
89510236|NCT02329197|Experimental|Group A|women undergoing IVF treatment will be subjected for intrauterine injection of 10 IU of human chorionic gonadotropin (HCG) (diluted in 0.025ml of tissue culture), 10 minutes before embryo transfer procedure.
89540420|NCT06211504|Experimental|MDCO with STI|"In patients with preoperative gastrocnemius-soleus complex tightness, defined as a preoperative dorsal extension of the ankle less than 5 degrees, with the knee completely extended, a Strayer´s procedure will be performed before the other procedures.~Thereafter, an STI (ProStop® Arthroereisis Subtalar Implant, Arthrex GmbH, Munich, Germany) will be inserted into the sinus tarsi.~MDCO will be performed where the distal aspect of the calcaneus is separated from the proximal aspects, slided medially and fixed with two screws.~After the MDCO, FDL will be transferred to the navicular bone.~The spring ligament will be assessed. If ruptured, it will be reconstructed. If not ruptured, it will be tightened.~A plantarflexing open wedge osteotomy of the medial cuneiform (Cotton osteotomy) will be performed if pre-/perioperative findings indicate it."
89540421|NCT06211478|Experimental|cases who are taking vitamin E|gaucher disease patients with oxidative stress and vitamin E defeciency taking vitamin E treatment (weigh below 20 kg dose will be 200mg daily and whose weight above 20 kg dose will be 400mg daily for duration 6 months )
89540422|NCT06211478|No Intervention|controls who are not taking vitamin E treatment|gaucher disease patients with oxidative stress and vitamin E defeciency not taking vitamin E treatment but take the standard of care which is enzyme replacement therapy
89540423|NCT06211465||Cases|Patients with end-stage osteoarthritis (OA), who were eligible for total joint arthroplasty in Tartu University Hospital. Exclusion criteria: posttraumatic OA, infectious or endocrine arthropathy, acute or chronic inflammatory disease, malignancies, end-stage renal impairment (eGFR < 60ml/min/1.73m2), dysrhythmias, clinically relevant heart failure, heart valve-disease, diabetes.
89540424|NCT06211465||Controls|Gender and age matched control group, who is recruited from the general practitioner (GP) list and who are from the same geographical regions as the cases. Excluding criteria: acute or chronic inflammatory disease, GP visitation due to hip or knee problems, persistent knee or hip pain, diabetes, symptomatic coronary disease, dysrhythmias, cerebrovascular or peripheral artery disease, malignancy or renal impairment.
89510237|NCT02329197|No Intervention|Group B|women undergoing IVF treatment will embryo transfer procedure performed in the standard way without intrauterine injection of HCG.
88959052|NCT01999842|Experimental|Formulation 3 Group|Subjects in this group will receive two doses of GSK3206641A H7N9 vaccine formulation 3 at a 21 day interval
88959053|NCT01999842|Experimental|Formulation 4 Group|Subjects in this group will receive two doses of GSK3206641A H7N9 vaccine formulation 4 at a 21 day interval
88959054|NCT01999842|Experimental|Formulation 5 Group|Subjects in this group will receive two doses of GSK3206640A H7N9 vaccine formulation 5 at a 21 day interval
88959055|NCT01999842|Placebo Comparator|Placebo Group|Subjects in this group will receive two doses of placebo at a 21 day interval
88959056|NCT01999855|Active Comparator|control group|"the Phonatory Maximum Time~Vocal Handicap Index~Scale GRBAS of Hirano~Videolaryngoscopy"
88959057|NCT01999855|Experimental|Asthmatic patients|"The Phonatory Maximum Time~Vocal Handicap Index~Scale GRBAS of Hirano~Videolaryngoscopy"
88959058|NCT01999881|Experimental|Arm A (aerobic and exercise training)|Patients and their support persons undergo a supervised combined aerobic exercise comprising walking, cycling, or video-based aerobics and strength training using resistance bands for 40 minutes 2 days a week at the UWHC and 3 days a week at home over 8 weeks.
88959059|NCT01999881|Active Comparator|Arm II (usual care)|Patients and their support persons undergo the usual care over 8 weeks.
88959060|NCT01999907|Placebo Comparator|Placebo|bolus placebo given in a 2ml dose by mouth at baseline. This group receives daily vitamin D supplement by mouth for the 6 month study (400IU cholecalciferol per day).
88959061|NCT01999907|Active Comparator|Vitamin D|Vitamin D (100,000IU) bolus in a 2ml dose by mouth given at baseline. This group receives a daily vitamin D supplement by mouth for 6 months (400IU cholecalciferol per day).
88959062|NCT01999933|Active Comparator|CCRT with cisplatin(DDP) weekly|concurrent chemotherapy: cisplatin（DDP） weekly, 40mg/m2, begin with radiation
88959063|NCT01999933|Experimental|CCRT with TP|concurrent TP tri-weekly, docetaxel plus cisplatin tri-weekly (75mg/m2), begin with radiation
88959064|NCT01999933|Experimental|concurrent and adjuvant TP|2 cycles of concurrent TP, docetaxel plus cisplatin tri-weekly (75mg/m2),begin with radiation; and 4 cycles of adjuvant TP, the same regimen, after radiation
88959065|NCT01999959|Experimental|Pertubation performed|Study group had pertubation and insemination
88959066|NCT01999959|No Intervention|Pertubation not performed|Study group had insemination only
88959067|NCT01999998|Experimental|Pilot|
88959068|NCT02000024|Experimental|Lifestyle coaching|The existing Weight Watchers lifestyle modification program including the online support tools.
88959069|NCT02000024|Active Comparator|Lifestyle counseling|Brief advice regarding risk factors and strategies to reduce them by lifestyle modification guided by National Diabetes Education Program (NDEP) materials.
88959070|NCT02000076|Experimental|Sleep deprivation|Partial sleep deprivation allowing 3 h sleep at night
88959071|NCT02000076|Experimental|Full sleep|Sleep with no restriction
88959072|NCT02000102||Diabetic Macular Edema Patients Switched to Aflibercept|
88959073|NCT02000128|Experimental|bioimpedance monitoring group|patients whose fluid status will be monitored and guided by bioimpedance analysis
88959074|NCT02000128|Other|clinical monitoring group|patients whose fluid status will be monitored and guided by clinical experience
88959075|NCT02000167||Phelan-McDermid Syndrome only|Diagnosed with Phelan-McDermid Syndrome; 50 subjects to be recruited. 1-21 years of age
89510238|NCT03142347|Active Comparator|Remote endarterectomy|Open endarterectomy of the common, deep, initial of superficial femoral artery was performed. Delamination factory complex into the lumen of the loop. After that, the translational and rotational motions loops under fluoroscopic guidance, continuing detachment of plaque in the antegrade direction to the distal end of plaque. Plastic arteriotomy wounds performed patches of xenopericardium. Control patency of the arterial lumen is performed intraoperatively by X-ray angiography.
88959076|NCT02000167||Co-morbid Phelan-McDermid Syndrome & Mitochodrial Disorder|1-21 years of age; Diagnosed with Phelan-McDermid Syndrome AND diagnosed with Mitochondrial Disorder; 50 subjects to be recruited.
88959077|NCT02000193|Experimental|1|"drug: Fulvestrant treatment : Eligible patients will receive fulvestrant 500 mg intramuscular injection on day 1, 15, 29, then every 28 days.~The treatment will continue until disease progression or intolerable adverse event"
88959078|NCT02000206|Active Comparator|propofol + alfentanil|"Patients from the Propofol / Alfentanil group will receive in addition:~A loading dose of 10-15 mcg/kg Alfentanil + 0.4 mg/kg Propofol, 2 minutes prior to the beginning of the procedure.~Additional boluses of Propofol (aliquots of 10-50 mg) throughout the procedure if required"
88959079|NCT02000206|Active Comparator|propofol + ketamine|"Patients from the Propofol / Ketamine group will receive in addition:~A loading dose of 0.2-0.3 mg/kg Ketamine + 0.4 mg/kg Propofol, 2 minutes prior to the beginning of the procedure.~Additional boluses of Propofol (aliquots of 10-50 mg) and/or Ketamine (aliquots of 5-25 mg) throughout the procedure if required."
88959080|NCT02000245|Active Comparator|verbal expression for compassion|verbal expression for compassion
88959081|NCT02000245|Active Comparator|verbal expression and touch|verbal expression and touch
88959082|NCT02000245|No Intervention|control|control
88959083|NCT02000258|Other|Double-bundle ACL reconstruction|Double-bundle ACL reconstruction
88959084|NCT02000258|Other|Magnetic resonance imaging (MRI)|MRI of the ACL double-bundle reconstructed knee was done at 2 years after surgery.
88959085|NCT02000271|Other|Vaginal packing|Vaginal packing will be placed as is typical following vaginal reconstructive surgery.
88959086|NCT02000271|Experimental|No vaginal packing|No vaginal packing will be used following vaginal reconstructive surgery.
88959087|NCT02000297|Active Comparator|Allogenic bone graft group|Patients in this arm is treated with allogenic bone graft to fill the bone defect created with medial open wedge high tibial osteotomy
88959088|NCT02000297|Experimental|Synthetic bone substitute (geneX®) group|Patients in this arm is treated with synthetic bone substitute(geneX®) to fill the bone defect created with medial open wedge high tibial osteotomy
88959089|NCT02000323|Active Comparator|early enteral nutrition|"Naso-gastro-jejunal tube will be set up by X-ray within 24 hours of admission.~The distal end of the feeding tube would be placed at the remote end of Treitz ligament, and verified by X-ray.~After catharsis, Standard enteral nutrition liquid regimen （Peptisorb Liquid）will be used step by step.~Patients are targeted to receive calories for 25 kcal/kg/day."
88959090|NCT02000323|Active Comparator|modified early enteral nutrition|"Naso-gastro-jejunal tube will be set up by X-ray within 24 hours of admission.~The distal end of the feeding tube would be placed at the remote end of Treitz ligament, and verified by X-ray.~After catharsis, Only Normal Saline were given through Naso-gastro-Jejunal tube until 2 or more followed requirements were met mean arterial pressure≥65mmHg; oxygenation index≥ 300;APCHEII≤8; intra-abdominal pressure <20mmHg).Then Standard enteral nutrition liquid regimen (Peptisorb Liquid) will be used step by step.~Patients are targeted to receive calories for 25 kcal/kg/day."
88959091|NCT02000336|Experimental|Prednisolone 10|Prednihexal (Prednisolon), daily oral tablet, 10 mg during week one to four, 7,5 mg during week five to eight. Finally 5 mg for four weeks.
88959092|NCT02000336|Experimental|Prednisolone 60|Prednihexal (Prednisolon), daily oral tablet, 60 mg during the first week, weekly tapering: 40 mg, 20mg, 15mg, 10mg, 7,5mg. 7,5mg continued for one more week. Finally 5 mg for four weeks
88959093|NCT02000336|Placebo Comparator|Placebo|daily oral tablet
89510239|NCT03142347|Experimental|Remote endarterectomy + DCB balloon|Open endarterectomy of the common, deep, initial of superficial femoral artery was performed. Delamination factory complex into the lumen of the loop. After that, the translational and rotational motions loops under fluoroscopic guidance, continuing detachment of plaque in the antegrade direction to the distal end of plaque. Plastic arteriotomy wounds performed patches of xenopericardium. And balloon angioplasty of superficial femoral artery with DCB balloon is perform. Control patency of the arterial lumen is performed intraoperatively by X-ray angiography.
89510240|NCT04662723|Experimental|Corticosteroids combined with RASBs|Patients assigned to the corticosteroid group will receive (pulse) methylprednisolone succinate 500-1000 mg/day for 3 consecutive days followed by oral prednisolone (0.5 mg/kg/bw) on alternate days until the end of month. This treatment will be repeated for three consecutive months. In addition, patients will receive RASBs that will be titrated to their maximum anti-proteinuric effect. The dose of methylprednisolone succinate will be individualized (15 mg/kg) based on the ideal body weight. In overweight and obese IgAN patients the ideal body weight will be considered. The drug will be administered in a single daily dose intravenously for 30-60 min. To avoid obesity and diabetes corticosteroids will be administered only in the morning.
89510241|NCT04662723|Active Comparator|RASBs|Patients will receive RASBs for 3 months, titrated to their maximum anti-proteinuric effectf followed by oral corticosteroids.
88959094|NCT02000349|Experimental|Frozen Embryo Transfer with PGD|All embryos will be hatched on day 3. Patients will have hatching blastocysts (*) biopsied on day 5 or day 6, embryos will then be vitrified, analyzed by NGS, and will have one or two euploid embryo(s) thawed and transferred on a FET cycle, before noon. If more than two euploid blastocysts are available the one(s) to be transferred will be selected based on morphology (*).
88959095|NCT02000349|Experimental|Fresh Embryo Transfer with PGD|All embryos will be hatched on day 3. Patients will have hatching blastocysts (*) biopsied on day 5, analyzed by NGS, and will have one or two euploid embryo transferred on day 6, in the am. If more than two euploid blastocysts are available the one(s) to be transferred will be selected based on morphology (*). Any morulas developing to hatching blastocyst on day-6 will be also analyzed but vitrified for use in a future cycle.
88959096|NCT02000362|Experimental|Treatment|"cohort 1. 5.0 x 10^7 stem cells after registration~cohort 2. 1.0 x 10^8 stem cells after registration"
88959097|NCT02000375|Experimental|DHEA|Daily oral administration of DHEA at the dosage of 100 mg/die in combination with a daily oral administration of anastrozole at dosage of 1 mg/die or letrozole at the dosage of 2.5 mg/die or exemestane at the dosage of 25 mg/die without interruption.
89510242|NCT04662723|Experimental|SGLT2i combined with Ramipril|IgAN patients with chronic renal lesions (T1,2) or moderate renal lesions (M0,1; S0,1; T0; E0; C0) at high or very high CKD risk (proteinuria> 0.5 g/day and GFR >30ml/min/1.73 m2) will receive SGLT2i combined with RASBs.
89510243|NCT04662723|Active Comparator|Ramipril combined with corticosteroids|IgAN patients with chronic renal lesions (T1,2) or moderate renal lesions (M0,1; S0,1; T0; E0; C0) at high or very high CKD risk (proteinuria> 0.5 g/day and GFR >30ml/min/1.73 m2) will receive RASBs for 3 months followed by oral corticosteroids.
89510244|NCT00326690|Experimental|treatment|
89510245|NCT00326690|No Intervention|Control|
89510246|NCT05307926||PD-1 based therapy cohort|Patients who received PD-1 inhibitors or PD-1 inhibitors plus Lenvatinib therapy 2-4 weeks after the operation were included in the PD-1-based therapy cohort.
89510247|NCT05307926||TACE cohort|Patients who received 1 TACE about a month after the operation were included in the control cohort.
89510248|NCT02329275||Azoospermic men|
89510249|NCT02329275||Men with proven fertility|
89510250|NCT04026945|Other|Active Treatment (ST-CP) Group|"This study uses a dose-escalating approach in the active treatment arm. There is no comparator product. All qualifying patients receive the active treatment ST-CP as an injection in the region around the spermatic cord. The following dosing cohorts will be used:~I: 1 x 2 mL of 140 mg/mL ST-CP (= 280 mg lidocaine) II: 1 x 3 mL of 140 mg/mL ST-CP (= 420 mg lidocaine) III: 1 x 4 mL of 140 mg/mL ST-CP (= 560 mg lidocaine)"
89510251|NCT03895047|Active Comparator|dACC,I,AC|"Within each training session, participants will receive 7 minutes training for each of the three brain areas Insula (I), dorsal anterior cingulate cortex (dACC) & the auditory cortex (AC) resulting in 21Minutes of training for each session. The arm Title describes the order in which participants within this Arm will receive the three trainings. (E.g. dACC,I,AC: each participant in this group receives the training of the dACC first and the AC last.) This sequence order is kept stable during all training sessions.~12 sessions of Neurofeedback Training, 1-2 times per week."
89510252|NCT03895047|Active Comparator|dACC,AC,I|"Within each training session, participants will receive 7 minutes training for each of the three brain areas Insula (I), dorsal anterior cingulate cortex (dACC) & the auditory cortex (AC) resulting in 21Minutes of training for each session. The arm Title describes the order in which participants within this Arm will receive the three trainings. (E.g. dACC,I,AC: each participant in this group receives the training of the dACC first and the AC last.) This sequence order is kept stable during all training sessions.~12 sessions of Neurofeedback Training, 1-2 times per week.12 sessions of Neurofeedback Training, 1-2 times per week."
89510253|NCT03895047|Active Comparator|I,dACC,AC|"Within each training session, participants will receive 7 minutes training for each of the three brain areas Insula (I), dorsal anterior cingulate cortex (dACC) & the auditory cortex (AC) resulting in 21Minutes of training for each session. The arm Title describes the order in which participants within this Arm will receive the three trainings. (E.g. dACC,I,AC: each participant in this group receives the training of the dACC first and the AC last.) This sequence order is kept stable during all training sessions.~12 sessions of Neurofeedback Training, 1-2 times per week."
89510254|NCT03895047|Active Comparator|I,AC,dACC|"Within each training session, participants will receive 7 minutes training for each of the three brain areas Insula (I), dorsal anterior cingulate cortex (dACC) & the auditory cortex (AC) resulting in 21Minutes of training for each session. The arm Title describes the order in which participants within this Arm will receive the three trainings. (E.g. dACC,I,AC: each participant in this group receives the training of the dACC first and the AC last.) This sequence order is kept stable during all training sessions.~12 sessions of Neurofeedback Training, 1-2 times per week."
89510255|NCT03895047|Active Comparator|AC,dACC,I|"Within each training session, participants will receive 7 minutes training for each of the three brain areas Insula (I), dorsal anterior cingulate cortex (dACC) & the auditory cortex (AC) resulting in 21Minutes of training for each session. The arm Title describes the order in which participants within this Arm will receive the three trainings. (E.g. dACC,I,AC: each participant in this group receives the training of the dACC first and the AC last.) This sequence order is kept stable during all training sessions.~12 sessions of Neurofeedback Training, 1-2 times per week."
89510256|NCT03895047|Active Comparator|AC,I,dACC|"Within each training session, participants will receive 7 minutes training for each of the three brain areas Insula (I), dorsal anterior cingulate cortex (dACC) & the auditory cortex (AC) resulting in 21Minutes of training for each session. The arm Title describes the order in which participants within this Arm will receive the three trainings. (E.g. dACC,I,AC: each participant in this group receives the training of the dACC first and the AC last.) This sequence order is kept stable during all training sessions.~12 sessions of Neurofeedback Training, 1-2 times per week."
88959098|NCT02000388|Other|Ketorolac tromethamine (SPRIX)|A SPRIX dose will be one 15.75 mg spray in each nostril for a total dose of 31.5 mg which can be repeated every 6-8 hrs as needed for post vasectomy pain with a maximum daily dose of 126 mg to be continued for up to 5 days.
88959099|NCT02000388|Other|Standard of care|The intervention used will be standard of care
89510257|NCT02328729||Mandibular block with Epinephrine|Lidocaine 2% with 1:100,000 Epinephrine
89510258|NCT02328729||C-CLAD-IL with Epinephrine|Lidocaine 2% and 1:100,000 Epinephrine
89510259|NCT02328729||Infiltration with Epinephrine|Lidocaine 2% and 1:100,000 Epinephrine
89510260|NCT02328729||Mandibular block without Epinephrine|Mepivacain HCl 3% without Epinephrine
89510261|NCT02328729||Infiltration without Epinephrine|Mepivacain 3% without Epinephrine
89510262|NCT02328729||CCLAD-IL without Epinephrine|Mepivacain HCl 3% without Epinephrine
89510263|NCT04608513|Experimental|ACT-1014-6470 single dose (dose level 1)|Soft capsule for oral administration
89510264|NCT04608513|Placebo Comparator|Placebo single dose (dose level 1)|Soft capsule for oral administration
89510265|NCT04608513|Experimental|ACT-1014-6470 single dose (dose level 2)|Soft capsule for oral administration
89510266|NCT04608513|Placebo Comparator|Placebo single dose (dose level 2)|Soft capsule for oral administration
89510267|NCT04608513|Experimental|ACT-1014-6470 multiple dose (dose level 1)|Soft capsule for oral administration
89510268|NCT04608513|Placebo Comparator|Placebo multiple dose (dose level 1)|Soft capsule for oral administration
89510269|NCT04608513|Experimental|ACT-1014-6470 multiple dose (dose level 2)|Soft capsule for oral administration
89510270|NCT04608513|Placebo Comparator|Placebo multiple dose (dose level 2)|Soft capsule for oral administration
88959100|NCT02000401|Other|Ketorolac Tromethamine|Ketorolac Tromethamine one 15.75 mg spray in each nostril for a total dose of 31.5 mg which can be repeated every 6-8 hrs. as needed for pain with a maximum daily dose of 126 mg. The treatment may be continued for up to 5 days.
88959101|NCT02000414|Experimental|intraperitoneal daptomycin|3 first patients : 200mg/day 3 following patients : 300mg/day
88959102|NCT02000453|Experimental|GSK2586184|A total of 15 subjects to be administered 400 mg GSK2586184 Tablet (200 mg X 2) twice daily for up to 56 days
88959103|NCT02000466||Exposed cohort|
88959104|NCT02000479|Experimental|training|12 weeks (2 x 6 weeks) of combined exercise training programme (supervised)
88959105|NCT02000479|No Intervention|Control|Continued usual care, habitual lifestyle
88959106|NCT02000492|Experimental|Training|Football, circuit training or running 5x12 minutes or 3x 40 minutes
88959107|NCT02000492|No Intervention|Control|
88959108|NCT02000505|No Intervention|Control|5 minutes chest-compression-only CPR, without any support
88959109|NCT02000505|Experimental|PocketCPR|5 minutes chest-compression-only CPR, with support
88959110|NCT02000505|Experimental|Metronome|5 minutes chest-compression-only CPR, with support
88959111|NCT02000505|Experimental|110bpm Song|5 minutes chest-compression-only CPR, with support
88959112|NCT02000518||external beam radiotherapy|emergency radiotherapy within 12 hours after neurological deficit due to MSCC
88959113|NCT02000544|Other|Modular Cardiopulmonary Bypass Circuit|Patients undergoing open heart surgery with a modular hybrid extracorporeal circulation circuit.
88959114|NCT02000557||Class II Malocclusion|
89510271|NCT04608513|Experimental|ACT-1014-6470 multiple dose (dose level 3)|Soft capsule for oral administration
89510272|NCT04608513|Placebo Comparator|Placebo multiple dose (dose level 3)|Soft capsule for oral administration
89510273|NCT04608513|Experimental|ACT-1014-6470 multiple dose (dose level 4)|Soft capsule for oral administration
89510274|NCT04608513|Placebo Comparator|Placebo multiple dose (dose level 4)|Soft capsule for oral administration
89510275|NCT04577313|Active Comparator|Continuous Counseling|Receives up to 16 weekly behavioral counseling sessions over the phone to achieve optimal medication adherence. Counseling adjusts to patient needs and determines the dose to achieve optimal adherence / HIV suppression, in contrast to the fixed dose condition that does not adjust to patient response.
89510276|NCT04577313|Active Comparator|Fixed Counseling|Receives up to five weekly behavioral counseling sessions over the phone focused on improving HIV medication adherence / viral suppression.
89510277|NCT02328963|Experimental|Everolimus|Everolimus + reduced dose of cyclosporine A
89510278|NCT02328963|Active Comparator|mycophenolic acid|mycophenolic acid + standard dose of cyclosporin A
89510279|NCT04536207|Experimental|the study group|Group (A) the study group received cryotherapy
89510280|NCT04536207|No Intervention|the control group|Group (B) the control group not received cryotherapy
89510281|NCT03353259|No Intervention|SS-TG|Standard surgery using burr-hole procedure, irrigation and drainage.
89510282|NCT03353259|Active Comparator|SS-TXA-TG|Standard surgery using burr-hole procedure, irrigation and drainage combined withTranexamic acid (Cyklokapron) administration. Cyklokapron tablets will be administered postoperatively in dosage 500 mg twice a day until complete hematoma disappearance.
89510283|NCT03353259|Active Comparator|SS-TXA-RoA|Standard surgery using burr-hole procedure, irrigation and drainage combined with Tranexamic acid (Cyklokapron) and Tocilizumab (RoActemra) administration. Cyklokapron tablets will be administered postoperatively in dosage 500 mg twice a day combined with RoActemra subcutaneous injection of 162 mg once a week until complete hematoma disappearance.
89510284|NCT04527627|Experimental|Experimental Group (EG)|The nursing empowerment intervention will be administered in the experimental group
89510285|NCT04527627|No Intervention|Control Group (CG)|The nursing empowerment intervention will not be administered in the control group
89510286|NCT04477239|Placebo Comparator|Placebo|Oral administration of one capsule of Placebo
89510287|NCT04477239|Active Comparator|Purified gluten (10 mg)|Oral administration of capsules containing 10 mg of purified gluten.
89510288|NCT04477239|Active Comparator|Purified gluten (50 mg)|Oral administration of capsules containing 50 mg of purified gluten.
89510289|NCT04477239|Active Comparator|Purified gluten (100 mg)|Oral administration of capsules containing 100 mg of purified gluten.
89510290|NCT04477239|Active Comparator|Purified gluten (500 mg)|Oral administration of capsules containing 500 mg of purified gluten.
89510291|NCT04477239|Active Comparator|Purified gluten (1000 mg)|Oral administration of capsules containing 1000 mg of purified gluten.
88959115|NCT02000570|Experimental|sitting position|
88959116|NCT02000609|Active Comparator|CHF 1535 NEXThaler 800/48 ug|single dose administration of CHF 1535 100/6 NEXThaler DPI, total dose: 800ug BDP, 48 ug Formoterol Fumarate
88959117|NCT02000609|Placebo Comparator|CHF 1535 NEXThaler PLACEBO|single dose administration of placebo via NEXThaler DPI
88959118|NCT02000609|Active Comparator|CHF 1535 pMDI 200/12|single dose administration of CHF 1535 100/6 pMDI , total dose: 200 ug BDP, 12 ug Formoterol Fumarate
88959119|NCT02000609|Active Comparator|CHF 1535 100/6 pMDI 800/48|single dose administration of CHF 1535 100/6 pMDI total dose: 800ug BDP, 48 ug Formoterol Fumarate
88959120|NCT02000609|Active Comparator|CHF 1535 NEXThaler 200/12|single dose administration of CHF 1535 100/6 pMDI, total dose: 200 ug BDP, 12 ug Formoterol Fumarate
89510292|NCT04513743|Experimental|Healthy adults|UNEEG™ medical 24/7 EEG™ SubQ
89510293|NCT04248218|No Intervention|Normal/Control|Control Group/Standard Care
89510294|NCT04248218|Active Comparator|Active Rehabilitation Group/Case|Active Rehabilitation Cohort/Intervention
89510295|NCT02289820|Experimental|MEDI7510 (120 mcg sF + 1 mcg GLA), Cohort 1|Participants will receive a single dose of MEDI7510 (120 microgram [mcg] respiratory syncytial virus [RSV] soluble fusion protein [sF] plus 1.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by intramuscular (IM) injection on Day 1.
88959121|NCT02000648||Patients diagnosed with chronic rhinitis or chronic urticaria|Patients diagnosed with chronic rhinitis/urticaria and followed-up at Allergy Clinics, Chulalongkorn University
89510296|NCT02289820|Experimental|MEDI7510 (120 mcg sF + 2.5 mcg GLA), Cohort 2|Participants will receive a single dose of MEDI7510 (120 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV or MEDI7510 plus placebo administered by IM injection in contralateral arms on Day 1.
89510297|NCT02289820|Experimental|MEDI7510 (120 mcg sF + 5 mcg GLA), Cohort 3|Participants will receive a single dose of MEDI7510 (120 mcg RSV sF plus 5.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV or MEDI7510 plus placebo administered by IM injection in contralateral arms on Day 1.
89510298|NCT02289820|Experimental|MEDI7510 (80 mcg sF + 2.5 mcg GLA), Cohort 4|Participants will receive a single dose of MEDI7510 (80 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by IM injection on Day 1.
89510299|NCT02289820|Active Comparator|Inactivated Influenza Vaccine (IIV)|Participants will receive a single dose of IIV by intramuscular injection in contralateral arms on Day 1.
89510300|NCT04437537||Pilot Group|Ten subjects with a DFU non-responsive to standard of care for a minimum of treatment period of 28 days.
89510301|NCT04425915|Experimental|Convalescent Plasma with Standard of Care|Two doses of 250 ml Convalescent plasma from recovered COVID-19 patients + Standard of Care will be given to severely sick COVID-19 patients in the treatment arm
89510302|NCT04425915|Active Comparator|Standard of Care|The Ministry of Health and Family Welfare has issued detailed guidelines for the management of sCOVID-19 based on varying grades of severity which may be periodically updated. For the management of ARDS or sepsis the respective guidelines issued by ARDSNet and Surviving Sepsis campaign will be followed. Other institutional protocols for supportive management will be implemented. (Ref: Guidelines on Clinical Management of COVID-19. MoHFW, GoI.2020.)
89510303|NCT04350723|Experimental|Intervention - Awake Proning|"The oxygen mask or NIPPV or HFNC will be initiated at the treating team's discretion. The patient will be observed for 15 minutes to ensure that: SPO2 > 90% and the patient is tolerating oxygen mask or NIPPV or HFNC treatment.~Once the patient achieves the above parameters within 15 minutes of initiating oxygen therapy through any modality, the healthcare team will start awake proning."
89510304|NCT04350723|No Intervention|Control - Standard of Care|"The patient will receive usual care without proning at the discretion of the treating team.~The oxygen mask or NIPPV or HFNC will be initiated, the choice of starting oxygen mask versus NIPPV versus HFNC will be up to the treating team, the patient will be observed for 15 minutes to ensure that: SPO2 > 90% and the patient is tolerating NIPPV or HFNC treatment."
89510305|NCT05307536|Experimental|Autologous BMMNCs infusion combined with educational intervention|"Bone marrows are harvested from the patient's iliac depending on the patient's body weight as follows: 8 ml/kg for patients under 10 kg; [80 ml + (body weight in kg - 10) × 7 ml] for patients above 10 kg. Mononuclear cells from collected bone marrow are infused intrathecally through a space between number vertebrae 4th and 5th. Two transplantations will be conducted at an interval of 6 months. The educational intervention will be developed based on the Early Start Denver Model for 6 months after the first infusion.~Evaluation: The efficacy outcomes will be measured using the CARS, Vineland Adaptive Behavior Scales - second Edition (VABS), Autism Behavior Checklists (ABC), and Clinical Global Impression (CGI). In addition, Health-related quality of life (HRQoL) in patients will be evaluated at baseline, two months, six months, and 12 months with those in the control group (educational intervention only) using the Pediatric Quality of Life Inventory (PedsQL)"
89510306|NCT05307536|Active Comparator|Educational intervention (controlled group)|"The educational intervention will be developed based on the Early Start Denver Model for six months after enrollment.~Evaluation: The efficacy outcomes will be measured using the CARS, Vineland Adaptive Behavior Scales - second Edition (VABS), Autism Behavior Checklists (ABC), and Clinical Global Impression (CGI). In addition, Health-related quality of life (HRQoL) in patients will be evaluated at baseline, two months, six months, and 12 months with those in the control group (educational intervention only) using the Pediatric Quality of Life Inventory (PedsQL)"
89510307|NCT02289742|Other|Arm1: Presbyopes|Nelfilcon A contact lenses (multifocal and sphere) worn as randomized in a crossover design during Periods 1 and 2, with nelfilcon A sphere contact lenses in Period 3. Each product worn bilaterally (in both eyes) for 12 hours.
89510308|NCT02289742|Other|Arm2: Astigmats|Nelfilcon A contact lenses (toric and sphere) worn as randomized in a crossover design during Periods 1 and 2, with nelfilcon A sphere contact lenses in Period 3. Each product worn bilaterally (in both eyes) for 12 hours.
89510309|NCT04310787||HBV-ACLF|To investigate the clinical events and prognosis of patients with hepatitis b associated acute on-chronic liver failure
89510310|NCT02328651|Experimental|Ribavirin treatment plus testing drug|
89510311|NCT02328651|Active Comparator|Ribavirin treatment|
89510312|NCT03111693||obese patients|obese patients of our clinical nutrition service, hospitalized for nutrional assessement, are included.
89510313|NCT02289352|Experimental|brimonidine 0.33% gel|Brimonidine Topical Gel, 0.33%, 30 gram fill (Watson Laboratories, Inc., USA)
89510314|NCT02289352|Active Comparator|Mirvaso gel|Mirvaso® (brimonidine) topical gel, 0.33% (Galderma Laboratories, L.P., USA)
89510315|NCT02289352|Placebo Comparator|Placebo|Topical gel base only (Watson Laboratories Inc., USA)
89510316|NCT02039973|Experimental|Task-sharing approach to group therapy|The intervention will consist of problem-solving therapy as well as cognitive behavioral components. Core problem-solving therapy components will involve lay CBHW facilitated discussions to explore symptoms of depression and how problems are related to depression. Core cognitive behavioral components will include lay CBHW facilitated discussions to explain the purpose of the sessions, as well as effect a number of behavioral changes in participants.
88959122|NCT02000661|Experimental|Routine use of FFR|Fractional Flow Reserve (FFR) used in most cases to guide PCI
88959123|NCT02000661|Active Comparator|Selective use of FFR|Fractional Flow Reserve (FFR) used at investigator discretion (Current practice)
88959124|NCT02000674|Active Comparator|Administration of Succinylcholine|Intubation after IV administration of Succinylcholine 1mg/kg
88959125|NCT02000674|Experimental|Administration of Rocuronium|Intubation after IV administration of Rocuronium 1.2 mg/kg
88959126|NCT02000700|Experimental|Canagliflozin (Dose Group 1)|Participants will receive 100 mg (as 1 x 100-mg tablet) of canagliflozin daily for 14 days.
88959127|NCT02000700|Experimental|Canagliflozin (Dose Group 2)|Participants will be enrolled into Dose Group 2 to receive either 50 mg (as 1 x 50-mg tablet) or 300 mg (as 1 x 300-mg tablet) of canagliflozin daily for 14 days.
88959128|NCT02000713|Experimental|Amyotrophic Lateral Sclerosis|All subjects will be interviewed and administered a brief questionnaire to determine current disease severity. A brief neurological examination will be given to determine reflexes. Subjects will also have magnetic resonance imaging(MRI)scans of the cervical spine (neck). Women of child-bearing potential will need to have a urine pregnancy test immediately prior to the MRI scan. Mri scan will take approximately 60 minutes to complete. The clinical examinations will take approximately 30 minutes to complete. Subject participation in this study will be complete following the MRI and clinical examinations.
89510317|NCT02039973|Active Comparator|Enhanced standard of care|The control condition will promote an enhanced standard of care. Clinicians and nurses at MCH clinics included in the study will receive a structured one day re-orientation training consistent with the World Health Organization (WHO) mh-GAP guidelines for assessment as well as basic psychosocial and drug treatment of moderate to severe depression in primary care settings. The training will be consistent with the standard of care for mental health among HIV-positive populations as outlined in Tanzanian health policy. In addition, clinical staff will be trained to encourage women to invite their male partners to accompany them at clinic visits, where psycho-education on perinatal depression for couples will be offered for those opting to participate.
89510318|NCT03143361||Aortic valve replacement patients|All the patients operated on aortic valve replacement in the study period at all the centers participating in the study
89510319|NCT05338034|Experimental|HPG1860 3 mg|20 subjects will be treated with HPG1860 3 mg once daily at a similar time with or without food.
88959129|NCT02000713|Active Comparator|Healthy controls (MRI)|Subjects will also have magnetic resonance imaging (MRI) scans of the cervical spine(neck). Women of child-bearing potential will need to have a urine pregnancy test immediately prior to the MRI scan. Mri scan will take approximately 60 minutes to complete. Subject participation in this study will be complete following the MRI.
88959130|NCT02000726|Experimental|Placebo and Citalopram|4 weeks of 1 placebo pill/day and 12 weeks of citalopram 20-40 mg/day
88959131|NCT02000739|Other|Genetically Informed Therapy|"The treatment participants get will depend on the results of the DNA sequencing and the availability of targeted therapies that match the genetic profile of the tumor identified by the DNA sequencing.~If there is a genetic mutation that can be identified with current DNA sequencing and a drug has been developed for this mutation, participants may be able to receive that drug. If there is more than one drug available, the participant and his/her oncologist will decide which is the best one for the participant."
88959132|NCT02000765|Experimental|GSK2140944 for Injection and Capsule|Each subject will receive a single 1000 milligram (mg) IV dose of GSK2140944 containing [14C]-GSK2140944 of approximately 22.5 microcurie [μCi] (approximately 0.8 megabecquerel [MBq]) of radioactivity given as a 2 hour infusion on Day 1 of treatment period 1 and 2000 mg oral dose of GSK2140944 containing [14C]-GSK2140944 of approximately 45 μCi (approximately 1.7 MBq) of radioactivity on Day 1 of treatment period 2. Each treatment period will be followed with washout of atleast 8 Days.
88959133|NCT02000778|Experimental|EC17 Injection Group|The group will receive a single dose of EC17, infused over 10 minutes, prior to surgery. Then, during surgery, the EC-17 will be imaged with a camera that the investigators have developed.
88959134|NCT02000791|Experimental|cLMA insertion via laryngoscopic technique|Comparison of cLMA insertion via laryngoscope view by fiberscope
88959135|NCT02000791|Active Comparator|cLMA insertion via standart technique|Comparison of cLMA insertion via standart technique view by fiberscope
88959136|NCT02000804|Experimental|darapladib 160mg|drug
89510320|NCT05338034|Experimental|HPG1860 5 mg|20 subjects will be treated with HPG1860 5 mg once daily at a similar time with or without food.
89510321|NCT05338034|Experimental|HPG1860 8 mg|20 subjects will be treated with HPG1860 5 mg once daily at a similar time with or without food.
89510322|NCT05338034|Placebo Comparator|Placebo|20 subjects will be treated with Placebo once daily at a similar time with or without food.
89510323|NCT02315560|Experimental|Tibial Nerve Stimulation|The subject/parents will be instructed to record a night-time voiding log specifying the number of incontinent episodes per night. This log is included in the Institutional Review Board application. Subjects/parents will fill out the log for a two week period prior to foot stimulation to determine a baseline average of nocturnal enuresis episodes, during the two week foot stimulation period to measure any acute effect on nocturnal enuresis episodes and finally during the two weeks after stimulation to evaluate any post-stimulation residual benefit
89510324|NCT02328417||Control|Consecutive radical cystectomies up to 94 patients in 13 participating hospitals in Madrid, Spain. These patients will be taken care of as it is done regularly in each of participating hospitals. All study variables will be prospectively collected in this group
89510325|NCT02328417||Active Treatment|"After recruiting cotrol group, another consecutive radical cystectomies up to 94 patients in 13 participating hospitals will be recruited and the following measures will be followed with them:~I.-PREOPERATIVE MEASURES: (eight measures according to Protocol) II.- INTRAOPERATIVE MEASURES: (six measures according to Protocol) III.- POSTOPERATIVE MEASURES: (eight measures according to Protocol)"
89510326|NCT02328495|Active Comparator|Misoprostol|Misoprostol (400µg) is administered vaginally 12 hours before office hysteroscopy
88959137|NCT02000830||Placebo|Participants received placebo during the earlier study
88959138|NCT02000830||Stannsoporfin 3.0 mg/kg|Participants received Stannsoporfin 3.0 mg/kg during the earlier study
88959139|NCT02000830||Stannsoporfin 4.5 mg/kg|Participants received Stannsoporfin 4.5 mg/kg during the earlier study
88959140|NCT02000843|Other|perichondrium graft perforation|tympanoplasty -- conchal cavum approach is used.
88959141|NCT02000856|Active Comparator|Nitrate rich beetroot juice|Eligible subjects will be randomised, in a double-blind crossover design, to receive treatment with either nitrate rich beetroot juice (70 ml containing approximately 8 mmol nitrate - active comparator) or nitrate depleted beetroot juice (70 ml - placebo) twice daily for 7 days (treatment period 1) followed by a 7 day washout period followed by treatment twice daily with the active comparator or placebo depending on initial treatment for another 7 days (treatment period 2) .
89510327|NCT02328495|Active Comparator|bladder Filling|Uterine straightening by bladder filling before office hysteroscopy
89510328|NCT04197453||Consented Arm|Subjects with a recent (within 18 months) hospitalization for myocardial infarction, unstable angina, ischemic stroke, or critical limb ischemia, and subjects undergoing coronary, peripheral, or carotid revascularization, including surgical and percutaneous revascularization, with an LDL-C greater than or equal to 70 mg/dL who may be eligible for PCSK9 inhibitor therapy.
89510329|NCT04197453||Electronic Health Record (EHR) arm|Subjects with an inpatient or outpatient diagnosis of clinical ASCVD within the prior 12 months including coronary heart disease, ischemic cerebrovascular disease, atherosclerotic peripheral arterial disease, or prior coronary or peripheral or carotid revascularization.
89510330|NCT02522624|Experimental|Decision Aid (DA)|The decision aid (DA) will be provided to participants randomized to the experimental/intervention group.
89510331|NCT02522624|No Intervention|Control|Participants randomized to the control group will receive usual care. They will be directed to the healthcare.gov website and asked to follow the prompts to view and select (if applicable) a health insurance plan.
89510332|NCT02287402|Experimental|AO-128 0.6 mg|One AO-128 0.2 mg tablet was taken orally 3 times a day before meals.
89510333|NCT02993601||20 outpatients with peripheral oedema|20 outpatients with clinically detectable peripheral oedema for 1 set of measurements.
88959142|NCT02000856|Placebo Comparator|Nitrate depleted beetroot juice|Eligible subjects will be randomised, in a double-blind crossover design, to receive treatment with either nitrate rich beetroot juice (70 ml containing approximately 8 mmol nitrate - active comparator) or nitrate depleted beetroot juice (70 ml - placebo)twice daily for 7 days (treatment period 1) followed by a 7 day washout period followed by treatment twice daily with the active comparator or placebo depending on initial treatment for another 7 days (treatment period 2) .
88959143|NCT02000947|Experimental|Dose Escalation|MEDI4736 and tremelimumab received by intravenous infusion.
88959144|NCT02000947|Experimental|Arm A|Medi4736 and tremelimumab received by intravenous infusion
88959145|NCT02000947|Experimental|Arm B|MEDI4736 and tremelimumab received by intravenous infusion
88959146|NCT02000947|Experimental|Arm C|MEDI4736 and tremelimumab received by intravenous infursion
88959147|NCT02000960|Experimental|Triheptanoin|All subjects will receive the study treatment which includes adding triheptanoin to the ketogenic diet with a goal intake of 35% total calories provided by triheptanoin (max 100 ml oil/day.
88959148|NCT02000986|Experimental|Specimen Collection/Risk Factor Assessment -> Diet/Exercise ->|Specimen Collection/Risk Factor Assessment -> Diet/Exercise -> Chemotherapy
88959149|NCT02000999||Patients with bile duct strictures|
88959150|NCT02001012|Active Comparator|Artemether-lumefantrine|"Artemether-lumefantrine.~1 tablet = 20mg arthemether and 120mg lumefantrine. Dosing at 0, 8, 24, 36, 48 and 60 hours. Dose according to bodyweight; >35kg = 2 tablets, 26-35kg = 3 tablets, 16-25kg = 2 tablets, >10-15kg = 1 tablet."
88959151|NCT02001012|Active Comparator|Chloroquine|"Chloroquine.~1 tablet contains 155mg chloroquine base. Adult dose (>35kg); 620mg (4 tablets) at 0 hours, and 310mg (2 tablets) at 6-8, 24 and 48 hours.~Child dose (>10-35kg); 10mg/kg at 0 hours, and 5mg/kg at 6-8, 24 and 48 hours."
88959152|NCT02001025||Absorb scaffold|Bioresorbable vascular scaffold implanted in coronary arteries, which are completely resorbed over a period of approximately two years
88959153|NCT02001025||Xience stent|Second generation drug-eluting stent to treat coronary artery lesions
89510334|NCT02993601||20 cardiology controls|20 outpatients with heart failure without clinically detectable peripheral oedema (control group) for 1 set of measurements.
89510335|NCT02993601||10 in-patients peripheral oedema|10 in patients hospitalised as a result of heart failure and fluid congestion with peripheral oedema, those patients will have several sets of measurements taken over time to measure the reduction of peripheral oedema which is likely to show common features with the formation of peripheral oedema.
89510336|NCT02993601||30 control without cardiac conditions|less than 30 normal controls (healthy volunteers and patients without heart failure) in the age group 55 and above who agree to have images taken using the Heartfelt-1 device (not the whole set of measurements).
89510337|NCT02913495|Experimental|Vaginal Progesterone|200mg micronized progesterone vaginally, to be taken daily starting at 16 0/7 - 23 6/7 weeks, and continued daily until 36 6/7 weeks' gestation or delivery
89510338|NCT02913495|Active Comparator|Intramuscular Progesterone|250mg intramuscular progesterone to be administered weekly starting at 16 0/7 - 23 6/7 weeks, and continued weekly until 36 6/7 weeks' or delivery.
88959154|NCT02001038||Orthopaedic surgeons|Orthopaedic surgeons who perform surgical procedures for foot deformities in CMT patients at participants centres.
88959155|NCT02001077|Active Comparator|CBT-I|Participants will complete 8 weekly therapy sessions focused on improving sleep. A multicomponent CBT-I (Cognitive Behavioral Therapy for Insomnia) protocol will involve: sleep hygiene, stimulus control, sleep restriction, relaxation, and cognitive restructuring.
88959156|NCT02001077|Active Comparator|CBT-P|Participants will complete 8 weekly therapy sessions focused on improving pain. A multicomponent CBT-P (Cognitive Behavioral Therapy for Pain) protocol will involve: pain education, relaxation, activity pacing, and cognitive restructuring.
88959157|NCT02001077|No Intervention|Waitlist Control (WLC)|Participants in the WLC group will not receive any treatment between the baseline and post-treatment assessments. After the final follow-up assessment, they will be offered the opportunity to receive therapy which combines aspects of both CBT-I and CBT-P.
88959158|NCT02001090||CABG patients|Patients undergoing cardiac surgery for coronary artery disease with the use of heart-lung machine in St Olavs Hospital Trondheim University Hospital.
88959159|NCT02001116|Experimental|Pilot Hospitals|
88959160|NCT02001116|No Intervention|Control Hospitals|
88959161|NCT02001129|Experimental|Automated Telephone System|In addition to a standardized reminder letter, participants also received a telephone call from an automated system to remind them of a recommended follow-up appointment.
88959162|NCT02001129|Experimental|Personalized Telephone Call|In addition to the usual care letter, a staff member called participants one month prior of recommended follow-up appointment. During this call, participants were given the option to schedule an appointment.
88959163|NCT02001129|Active Comparator|Usual Care|"Participants randomized to this arm receive a usual care letter which is a standard reminder letter from the primary eye care office. This is usual practice in many primary eye care facilities."
88959164|NCT02001155||Trabeculectomy|Individuals in this group will have undergone a trabeculectomy for the treatment of glaucoma.
88959165|NCT02001155||Tube Shunt|Individuals in this group will have undergone a tube shunt for the treatment of glaucoma.
88959166|NCT02001168|Experimental|Pemetrexed &Cis-platinum|Pemetrexed d1＋Cis-platinum , d1, 21 d as a cycle.
88959167|NCT02001168|Experimental|Pemetrexed & Cis-platinum & rh-Endostatin|Pemetrexed d1＋Cis-platinum , d1； rh-Endostatin d1-14; 21 d as a cycle.
88959168|NCT02001168|Experimental|Docetaxel & Cis-platinum|Docetaxel 60mg/m2 d1＋Cis-platinum 60mg/m2, d1, 21 d as a cycle.
88959169|NCT02001168|Experimental|Docetaxel & Cis-platinum & rh-Endostatin|Docetaxel ＋ Cis-platinum ＋ rh-Endostatin，21 d as a cycle.
88959170|NCT02001207||MICU patients|
88959171|NCT02001220|Active Comparator|Once daily screening|Patients will undergo assessments to determine readiness to undergo an SBT once daily.
88959172|NCT02001220|Experimental|At least twice daily screening|Patients will undergo assessments to determine readiness to undergo an SBT at least twice daily.
88959173|NCT02001246|Active Comparator|Real Deal program for Anger Management|"The Real Deal Anger Management Program is a structured, video-based intervention, which is an easy-to-implement, plug and play program that engages students in: (a) cognitive exercises for learning to recognize and correct thinking errors that lead to anger, (b) active practice of social-behavioral skills through role-playing, and (c) participation in progressive muscle relaxation exercises. The program features three training videos that focus on specific skills for controlling conflict."
88959174|NCT02001246|Experimental|Mind-body Bridging program|The Mind-Body Bridging program for anger management, includes experiential awareness activities, in which individuals learn to become aware of their thoughts, feelings, emotions, and bodily sensations, to help them identify and deal with ruminative and negative thoughts that might be associated with their anger. MBB helps participants use their senses to listen to sounds, and experience visual or tactile input, to calm their minds and relax their bodies. Written 'mapping' exercises enable them to recognize and defuse requirements, which are expectations of how they or the world should be. For the MBB anger management program, participants will be provided with a variety of mapping exercises to identify the source of their anger, and how they can effectively control it.
88959175|NCT02001259|Active Comparator|Epidural lidocaine|epidural lidocaine: 3 mL of 1% lidocaine with adrenaline and 3 mL of 1% lidocaine without adrenaline into epidural catheter at 48 hr after surgery
88959176|NCT02001259|Experimental|epidural triamsinolone|epidural triamsinolone: 40 mg of triamsinolone (1 mL), 2.5 mL of 1% lidocaine with adrenaline and 2.5 mL of 1% lidocaine without adrenaline into epidural catheter at 48 hr after surgery
89510339|NCT05335226|Experimental|Haplo-HSCT group|58 patients will be involved in this group
89510340|NCT05335226|Experimental|Combined haploidentical and umbilical cord blood allogeneic stem cell transplantation group|58 patients will be involved in this group
89510341|NCT02314780|Experimental|Heme arginate (high dose)|24 hours prior to the planned surgical aortic valve replacement, heme arginate at a dose of 3 mg/kg diluted to 110ml with 0.9% sodium chloride was administered at a single intravenous infusion using an infusion pump.
89510342|NCT02314780|Experimental|Heme arginate (low dose)|24 hours prior to the planned surgical aortic valve replacement, heme arginate at a dose of 1 mg/kg diluted to 110ml with 0.9% sodium chloride was administered at a single intravenous infusion using an infusion pump.
89510343|NCT02314780|Placebo Comparator|Placebo|24 hours prior to the planned surgical aortic valve replacement, subjects received a single intravenous infusion of an equivalent volume of 0.9% sodium chloride solution.
89510344|NCT02288182|Experimental|Straumann VivOss|Straumann® VivOss™Straumann® VivOss™, is a synthetic bone graft substitute in granulated form. It consists of > 90% TCP (Tri-Calcium-Phosphate -Ca3(PO4)2) and < 10% Hydroxyapatite (Ca10(PO4)6 (OH)2). The granules have a size of 250-1000 μm.
89510345|NCT02288182|Active Comparator|Geistlich Bio-Oss|The control device is Geistlich Bio-Oss® spongiosa granules (Geistlich Pharma AG, Wolhusen, Switzerland), 0.25-1 mm in diameter. It's a natural bone mineral of bovine origin. It shall be used according to the instructions of the manufacturer.
89510346|NCT03143049|Experimental|Pomalidomide, Cyclophosphamide, Dex (PCD)|
89510347|NCT03143049|Active Comparator|Pomalidomide, Dex (PD)|
89510348|NCT03110835||15 mCi radioiodine|6 patients with low risk differentiated thyroid cancer, as determined by histology
89510349|NCT03110835||30 mCi radioiodine|6 patients with low risk differentiated thyroid cancer, as determined by histology
89510350|NCT02286466|Active Comparator|Health Education Program|The presence and usage of Health Education Program.
89510351|NCT02286466|Experimental|CBT Mobile Application|The presence and usage of a CBT Mobile Application.
89510352|NCT03111069|Experimental|Resectable Intra-Abdominal/Pelvic Tumors|Participants receive complete surgical tumor resection with no gross residual disease, followed by hyperthermic intra-peritoneal chemotherapy (HIPEC) using Doxorubicin.
89510353|NCT03111069|Experimental|Unresectable Intra-Abdominal/Pelvic Tumors|"Participants receive debulking surgery followed by intra-operative radiation (IORT) in the form of brachytherapy to the gross residual pelvic tumor sites.~Participants have the option of returning for HIPEC 4 weeks (or more) after IORT, if active disease remains."
89510354|NCT03110757|Experimental|Group A|10mcg Sm-TSP-2/Alhydrogel® (n=8)
89510355|NCT03110757|Experimental|Group B|10mcg Sm-TSP-2/Alhydrogel®/+ AP 10-701 (n=8)
89510356|NCT03110757|Experimental|Group D|30mcg Sm-TSP-2/Alhydrogel® (n=8)
89510357|NCT03110757|Experimental|Group E|30mcg Sm-TSP-2/Alhydrogel®/+ AP 10-701 (n=8)
89510358|NCT03110757|Experimental|Group G|100mcg Sm-TSP-2/Alhydrogel® (n=8)
89510359|NCT03110757|Experimental|Group H|100mcg Sm-TSP-2/Alhydrogel®/+ AP 10-701 (n=8)
89510360|NCT03110757|Active Comparator|Pooled Active Comparator Group|Euvax B Hepatitis B vaccine (n=12)
89510361|NCT02313766|No Intervention|spontaneous breathing (SB)|"preoxygenation through a face mask firmly applied and connected to the anaesthesia machine delivering a fresh gas flow of 12 l min-1. The inspired O2 concentration was set at 100%.~End of preoxygenation FEO2=90%"
89510362|NCT02313766|Experimental|positive pressure ventilation (PPV)|"PPV : positive pressure ventilation : preoxygenation with noninvasive positive inspiratory pressure ventilation (12 cmH2O) without PEEP.~Preoxygenation through a face mask firmly applied and connected to the anaesthesia machine - non invasive inspiratory ventilation mode - inspiratory trigger sensitivity was set at -2 l min-1, the adjustable pressure limiting valve was opened, and maximal airway pressure was limited at 18 cmH2O - PEEP=0 cmH2O End of preoxygenation FEO2=90%"
89510363|NCT02313766|Experimental|PPV + PEEP|"PEEP : PPV + PEEP : preoxygenation with noninvasive positive inspiratory pressure ventilation (12 cmH2O) with PEEP at 6 cmH2O.~Preoxygenation through a face mask firmly applied and connected to the anaesthesia machine - non invasive inspiratory ventilation mode - inspiratory trigger sensitivity was set at -2 l min-1, the adjustable pressure limiting valve was opened, and maximal airway pressure was limited at 18 cmH2O - PEEP=6 cmH2O End of preoxygenation FEO2=90%"
89510364|NCT05303870|Experimental|IAPT|
89510365|NCT03110991|Experimental|Cognitive-behavioral intervention via App|The participants of the two experimental groups will receive a cognitive-behavioral intervention for depression prevention via a smartphone App, adapted from an indicated depression prevention program for caregivers in face-to-face group format developed by our research team, based on the model by Lewinsohn, Hoberman, Teri, & Hautzinger (1985), which has proven to be efficacious in the prevention of the onset of new major depressive episodes and the decrease of depressive symptoms both short- and long-term (Vázquez et a., 2014, 2016). In both groups the intervention administered via App will consist of 5 modules.
89510366|NCT03110991|Experimental|Cognitive-behavioral intervention via App + multiconference|Additionally, this experimental group will receive phone group conference calls during four 30 minute-sessions.
89510367|NCT03110991|No Intervention|Usual care|Individuals assigned to this group will receive no intervention or material, but they will have unrestricted access to any routine medical or psychological care that they might want to seek to treat depressive symptoms.The use of such treatments will be recorded.
88959177|NCT02001272|Experimental|A:Paclitaxel + Carboplatin every 3 weeks|Patients randomized to the arm A receive 6 courses the following regimen: Paclitaxel 175 mg/m²/3 hours, I.V. and carboplatin AUC 5, I.V. every 3 weeks (1 cycle = 21 days).
88959178|NCT02001272|Experimental|B:Carboplatin monotherapy every 3 weeks|Patients randomized to the arm B receive 6 courses the following regimen: Carboplatin monotherapy AUC 5 or 6 every 3 weeks (1 cycle = 21 days).
89510368|NCT03110913|Experimental|Methionine bioavailability in lentils|"Participants will be seen initially for pre-study assessment (3 hour). They will then be studied for up to 10 times. levels of phenylalanine intake (7 Study periods).~You could be expected to participate in up to 10 different sets of experiments which will take 11 weeks to 6 months. Each set of experiment consists of a 3 day period. During the first 2 days (Adaptation Days) you will be expected to consume 4 meals per day consisting of a protein liquid drink and protein free-cookies and/or a lentil stew with or without rice, which will be provided by the investigators"
89510369|NCT05610566|Experimental|A single set of test|The HighLife Trans-Septal TMVR System comprises a 28mm Transcatheter Mitral Valve, a loop placement catheter, a sub-annular implant and its delivery systems.
89510370|NCT05080569|Experimental|MOH/IUI treatment with LPS|(Mild) Ovarian stimulating treatment and insemination are according to regular treatment protocol. Females assigned to the treatment group start LPS, applying 3dd200mg Utrogestan in vaginal capsules, on the day of IUI. Treatment is continued until the onset of menstruation, a negative pregnancy test, miscarriage or confirmed vital intra-uterine pregnancy at 7 weeks gestation
89510371|NCT05080569|Placebo Comparator|MOH/IUI treatment with placebo|"Females will receive regular MOH/IUI treatment. The female cycle is mildly stimulated and monitored until the desired amount of ripe follicles is achieved. In the absence of other reasons to cancel the treatment, ovulation is triggered and subsequently pre-washed semen is inseminated into the uterus.~Females assigned to the placebo group start placebo, applying 3dd1 vaginal capsules, on the day of IUI. Treatment is continued until the onset of menstruation, a negative pregnancy test, miscarriage or confirmed vital intra-uterine pregnancy at 7 weeks gestation"
89510372|NCT05383508|Active Comparator|Product Sequence 1|"After at least 12 hours of abstinence from the use of any nicotine/tobacco containing products (referred to as nicotine wash-out), subjects will smoke a cigarette or use one of the e-liquid variants with P4M3 Gen 2.0 according to randomized product use sequence ad libitum for 6 minutes (± 30 seconds).~CA35 on Day 1; Cig on Day 2; CM35 on Day 3"
88959179|NCT02001272|Experimental|C:Weekly Paclitaxel and Carboplatin|Patients randomized to the arm C receive 6 courses the following regimen: weekly paclitaxel 60 mg/m²/1 hour and weekly carboplatin AUC 2 (d1, d8, d15 ; d1=d29) (1 cycle = 28 days).
88959180|NCT02001285|Experimental|Double lumen tube|This arm contains patients who are needed endobronchial intubation with double lumen tube for general anesthesia. After propofol infusion of effect site concentration 4 μg/ml, remifentanil infusion will be started with effect site concentration of 3.5 ng/ml. According to change arterial blood pressure and heart rate from baseline value, next remifentanil concentration will be regulated using up-and-down method. Step size of dose is 0.5 ng/ml.
89510373|NCT05383508|Active Comparator|Product Sequence 2|"After at least 12 hours of abstinence from the use of any nicotine/tobacco containing products (referred to as nicotine wash-out), subjects will smoke a cigarette or use one of the e-liquid variants with P4M3 Gen 2.0 according to randomized product use sequence ad libitum for 6 minutes (± 30 seconds).~CA35 on Day 1; CM35 on Day 2; Cig on Day 3"
89510374|NCT05383508|Active Comparator|Product Sequence 3|"After at least 12 hours of abstinence from the use of any nicotine/tobacco containing products (referred to as nicotine wash-out), subjects will smoke a cigarette or use one of the e-liquid variants with P4M3 Gen 2.0 according to randomized product use sequence ad libitum for 6 minutes (± 30 seconds).~Cig on Day 1; CA35 on Day 2; CM35 on Day 3"
89510375|NCT05383508|Active Comparator|Product Sequence 4|"After at least 12 hours of abstinence from the use of any nicotine/tobacco containing products (referred to as nicotine wash-out), subjects will smoke a cigarette or use one of the e-liquid variants with P4M3 Gen 2.0 according to randomized product use sequence ad libitum for 6 minutes (± 30 seconds).~Cig on Day 1; CM35 on Day 2; CA35 on Day 3"
89510376|NCT05383508|Active Comparator|Product Sequence 5|"After at least 12 hours of abstinence from the use of any nicotine/tobacco containing products (referred to as nicotine wash-out), subjects will smoke a cigarette or use one of the e-liquid variants with P4M3 Gen 2.0 according to randomized product use sequence ad libitum for 6 minutes (± 30 seconds).~CM35 on Day 1; Cig on Day 2; CA35 on Day 3"
89510377|NCT05383508|Active Comparator|Product Sequence 6|"After at least 12 hours of abstinence from the use of any nicotine/tobacco containing products (referred to as nicotine wash-out), subjects will smoke a cigarette or use one of the e-liquid variants with P4M3 Gen 2.0 according to randomized product use sequence ad libitum for 6 minutes (± 30 seconds).~CM35 on Day 1; CA35 on Day 2; Cig on Day 3"
89510378|NCT03145467|Experimental|Paracetamol|1000 mg of paracetamol (Parol Tablet - Atabay İlaç Fabrikası A.Ş.) Oral (PO) was given 100 patients
89510379|NCT03145467|Experimental|Zolmitriptan|Second Group: Zolmitirptan 2,5 mg (Zomig Tablet - Astra Zeneca) oral (PO) was given 100 patients.
89510380|NCT05302856|Experimental|Presumably fertile male patients going through ART treatment|
89510381|NCT05302856|Experimental|Subfertile/infertile male patients with abnormal semen analysis|
89510382|NCT05302856|Experimental|Male patients suffering from unexplained infertility|
89510383|NCT02030925|Experimental|IW-3718|Twice a day
89510384|NCT02030925|Placebo Comparator|Matching Placebo|Twice a day
88959181|NCT02001285|Active Comparator|single lumen tube|This arm contains patients who are needed endotracheal intubation with single lumen tube for general anesthesia. After propofol infusion of effect site concentration 4 μg/ml, remifentanil infusion will be started with effect site concentration of 3.5 ng/ml. According to change arterial blood pressure and heart rate from baseline value, next remifentanil concentration will be regulated using up-and-down method. Step size of dose is 0.5 ng/ml.
88959182|NCT02001298|Experimental|nitroprusside|After induction of anesthesia, controlled hypotension was induced with continuous infusion of nitroprusside. Cardiac index, stroke volume index, and total peripheral resistance index were continuously measured using noninvasive cardiac output monitor (Cheetah NICOM, Cheetah Medical Inc, UK).
89510385|NCT05080413|Experimental|Parkinson disease group|A total of 10 patients in this group will walk under the same conditions (off- state of antiparkinson drugs). Participants will be instructed to walk three laps on a 10-meter track under each of the following three conditions : 1) without stimulation, 2) with visual cues using a laser shoe, 3) with auditory cues using a metronome.
89510386|NCT05506826|Experimental|fine motor activities group|Patients in this group will receive conventional therapy for 1 month sixty minutes/day, 5 days/week in addition to performing fine motor exercises like therapy ball exercises, therapy putty exercises, table top exercises, moving beans, stacking pennies and rubber band resistances exercises etc. for 30 minutes
89510387|NCT05506826|Active Comparator|control group|Patients in this group will receive conventional therapy for four weeks sixty minutes per day, five days per week. In addition, receive thirty minutes of mirror therapy, which included periodic wrist flexion-extension, flexion and extension exercises of fingers on non paralyzed limb
89510388|NCT04039893|Other|Node-positive breast cancer patients|All patients with positive lymph nodes for who an axillary node clearance is proposed as part of the surgical treatment
89510389|NCT05301764|Experimental|LVGN6051 combined with Anlotinib|LVGN6051 Dose Escalation in the combination treatment with Anlotinib
89510390|NCT03143283|No Intervention|Usual care|Hospital EDs are observed under usual care conditions (families receive usual care at the ED).
89510391|NCT03143283|Experimental|Safety Study Lethal Means Counseling|During the intervention phase, mental health clinicians at EDs of participating hospitals are trained in lethal means counseling and implement the new protocol uniformly with eligible families.
89510392|NCT05332574|Experimental|GB263T|Experimental: GB263T
89510393|NCT02328183|Experimental|Polymyxin B|Polymyxin B 1.5-2.5 mg/kg/day intravenous q 12 hrs duration 7-14 days
89510394|NCT05610488|Experimental|Vabysmo (Faricimab) 6 mg|Vabysmo (Faricimab) 6 mg solution for intravitreal injection All consenting, enrolled patients will receive an intravitreal injection of faricimab 6 mg at baseline (week 0), at week 4, 8, 12 (=4x loading) and each of the following treat and extend visits up to month 12.
89510395|NCT01646398|Experimental|>= 65-year age group-13vPnC|
89510396|NCT01646398|Active Comparator|>= 65-year age group-23vPS|
89510397|NCT02328261|Experimental|Icotinib|Icotinib (125 mg tablet) is orally administered three times daily
89510398|NCT02328339|Experimental|Black tea|Approximately 400 mg total polyphenols in 240 ml hot water (loading dose; 2 hours before the start of measurements; t=0) and 130 mg total polyphenols in 120 ml hot water (maintenance dose just before start of the measurements; t=120 min)
89510399|NCT02328339|Placebo Comparator|Placebo|Caramel colour, maltodextrin and tea flavour in 240 ml hot water (2 hours before the start of measurements; t=0) and 120 ml hot water (maintenance dose just before start of the measurements; t=120 min)
89510400|NCT05301452|Placebo Comparator|Control Group|This group will receive an application of placebo ILIB and an orofacial myofunctional therapy (MFT) exercise protocol.
89510401|NCT05301452|Active Comparator|ILIB Group|This group will receive an application of ILIB and an orofacial myofunctional therapy (MFT) exercise protocol.
89510402|NCT03141723|Active Comparator|KMC & WHO protocol (0-1 hour)|The combination of Kangaroo Mother Care (KMC) as continuously as possible together with routine World Health Organization (WHO) thermoregulation care (warm delivery rooms, immediate drying after birth, early and exclusive breastfeeding, postponement of bathing and weighing, and appropriate bundling.
89510403|NCT03141723|Active Comparator|KMC & WHO protocol (1-24 hours)|The combination of Kangaroo Mother Care (KMC) as continuously as possible together with routine World Health Organization (WHO) thermoregulation care (warm delivery rooms, immediate drying after birth, early and exclusive breastfeeding, postponement of bathing and weighing, and appropriate bundling.
89510404|NCT03141723|Experimental|KMC, WHO protocol & bag (0-1 hour)|The combination of Kangaroo Mother Care (KMC) as continuously as possible together with the use of a plastic bag in combination with routine World Health Organization (WHO) thermoregulation care (warm delivery rooms, immediate drying after birth, early and exclusive breastfeeding, postponement of bathing and weighing, and appropriate bundling.
89510405|NCT03141723|Experimental|KMC, WHO protocol & bag (1-24 hours|The combination of Kangaroo Mother Care (KMC) as continuously as possible together with the use of a plastic bag in combination with routine World Health Organization (WHO) thermoregulation care (warm delivery rooms, immediate drying after birth, early and exclusive breastfeeding, postponement of bathing and weighing, and appropriate bundling.
89510406|NCT05301374|Experimental|Cartoon Group|Children in the cartoon group before the procedure, they chose one of the cartoons predetermined by the researchers. The children in the cartoon group started watching a cartoon of their choice 2 minutes before the procedure and they kept watching until the procedure was ended. Parent was with their children during the procedure in both groups.
89510407|NCT05301374|No Intervention|Control Group|No intervention was performed to reduce anxiety and pain for children in the control group. Parent was with their children during the procedure in both groups.
88959183|NCT02001298|Experimental|remifentanil|After induction of anesthesia, controlled hypotension was induced with continuous infusion of remifentanil. Cardiac index, stroke volume index, and total peripheral resistance index were continuously measured using noninvasive cardiac output monitor (Cheetah NICOM, Cheetah Medical Inc, UK).
88959184|NCT02001311|Experimental|chlorhexidine gel|anti microbial agent that prevents the formation of plaque and reduces caries risk
88959185|NCT02001324|Active Comparator|Paper-based data collection|Paper-based data collection
88959186|NCT02001324|Active Comparator|Web-based data collection|Web-based data collection
88959187|NCT02001350||Resistant hypertension|
89510408|NCT05079867||Perimodiolar (PM)|Patients to be implanted with: Mid Scala or CI532 / 632 (Slim modiolar) electrode
89510409|NCT05079867||Lateral wall (PL)|Patients to be implanted with: Slim J or CI522 / 622 (Slim Lateral) electrode
89510410|NCT03892239|Experimental|Intervention|Monitoring and suggestion of training progress. Behaviour change strategy based on increasing knowledge.
89510411|NCT03892239|Active Comparator|Control|Monitoring and suggestion of training progress.
89510412|NCT03141879|Experimental|Physical Activity Intervention|HUR resistance training intervention
89510413|NCT03141879|No Intervention|Regular care|(Wait-list control)
89510414|NCT05079711||Symptomatic for vaginal yeast|Women presenting to the clinic with symptoms of vulvovaginal candidiasis.
89024141|NCT03410615|Experimental|Radiation/Durvalumab + Adjuvant Durvalumab|"All patients will receive standard fractionation radiation therapy (RT) scheme: 70 Gy in 35 fractions over 7 weeks (i.e. 2 Gy per fraction)~Concurrent Phase: Durvalumab IV 1500 mg, days -7 and 22 (the second dose is given concurrently with RT).~Adjuvant Phase (to start 4 weeks after completion of concurrent phase): Durvalumab IV 1500 mg q4 weekly for 6 doses."
89024142|NCT03410615|Experimental|Radiation/Durvalumab + Adjuvant Durvalumab/Tremelimumab|ARM CLOSED TO ACCRUAL WITH AMENDMENT #1
89510415|NCT05079711||Asymptomatic for vaginal yeast|Women presenting to the clinic with no symptoms of vulvovaginal candidiasis.
89024143|NCT03389230|Experimental|Arm I (intratumoral/intracavitary delivery)|Patients receive autologous HER2(EQ)BBzeta/CD19t+ Tcm cells via intratumoral/intracavitary catheter over 5 minutes weekly for 3 weeks. Beginning as early as 1 week later, patients may receive additional T cell infusions as long as patients remain eligible and there is product available. Patients who progress on intracavitary or intratumoral administration may move to alternative delivery routes for the optional infusions.
89510416|NCT01646320|Experimental|Arm1: Dapagliflozin (10 mg) + Saxagliptin + Metformin IR|
89510417|NCT01646320|Experimental|Arm 2: Placebo + Saxagliptin + Metformin IR|
89510418|NCT05331950||Office workers|The office workers will do their routine job tasks and will be observed through injury predictor (functional movement screen) at baseline and after actual injuries happened 6 months
89510419|NCT05079555|No Intervention|Control group|The control group consisted of patients who followed conventional therapy.
89510420|NCT05079555|Experimental|Intervention group|The intervention group consisted of patients rehabilitated using the robotic platform.
89510421|NCT03141645|Experimental|Fluid loading group|Patients will receive ringer lactate solution 10ml/kg in 15 minutes before starting operation
89510422|NCT03141645|Active Comparator|Ondansetron group|Patients will receive an 8 mg of intravenous ondansetron in 15 minutes before finishing operation.
89510423|NCT03141645|No Intervention|Control group|Patients will receive neither preoperative intravenous fluid loading nor intravenous ondansetron.
89510424|NCT05610410||Patients with angina and no obstructive coronary arteries|
89510425|NCT05610410||Patients with HFpEF|
89510426|NCT05330546|Experimental|Osseodensification technique group|10 patients will be randomly assigned to the osseodensification group so the implant osteotomy will be prepared using densah burs
89510427|NCT05330546|Active Comparator|Ridge expansion screw group|10 patients will be randomly assigned to the ridge expansion screw group so the implant osteotomy will be prepared using ridge expansion screws
89510428|NCT05300204|Experimental|Intervention Group 1 - Self-help Strategies for depression|Exposure to information about self-help strategies for depression
89510429|NCT05300204|Experimental|Intervention Group 2 - General information about depression|Exposure to general information about depression
89510430|NCT05610332|Experimental|Immune activated experimental group|Albumin paclitaxel 260mg/m2, ivgtt, d1, d8 Carrelizumab: 200mg, ivgtt, d1, q3w
89510431|NCT05610332|Active Comparator|Immune activated control group|Docetaxel 50mg/m2, ivgtt, d1, q14d; Oxaliplatin 85mg/m2, ivgtt, d1, q14d; Calcium folinate 200mg/m2, ivgtt, d1, q14d; 5-fluorouracil 2600mg/m2, 24h civ, d1, q14d
89510432|NCT05610332|Experimental|Immune silence experimental group|Carrelizumab: 200mg, ivgtt, d1, q3w Docetaxel 50mg/m2, ivgtt, d1, q14d; Oxaliplatin 85mg/m2, ivgtt, d1, q14d; Calcium folinate 200mg/m2, ivgtt, d1, q14d; 5-fluorouracil 2600mg/m2, 24h civ, d1, q14d
89510433|NCT05610332|Active Comparator|Immunosilent control group|Docetaxel 50mg/m2, ivgtt, d1, q14d; Oxaliplatin 85mg/m2, ivgtt, d1, q14d; Calcium folinate 200mg/m2, ivgtt, d1, q14d; 5-fluorouracil 2600mg/m2, 24h civ, d1, q14d
89510434|NCT05329142||Stage 1: Usual Care clinical data:|The patient will firstly be identified as having attended the ED due to acute illicit drug toxicity and must fit the inclusion and exclusion criteria. The research team will complete the electronic Case Report Form (eCRF), which will include defined data.
89510435|NCT05329142||Stage 2: Surplus sampling Mass Spectrometry|"The research team will select patients with acute moderate / severe toxicity, which will be defined as those requiring at least one of:~Patient admitted to hospital due to acute illicit drug toxicity~Pre-hospital cardio/pulmonary resuscitation~Any part of patient's ED care was in the Resuscitation area of the ED~Patient died in the ED or within 72 hours~A surplus sample of the standard of care SST sample from this group will be analysed by way of Mass Spectrometry."
89024144|NCT03389230|Experimental|Arm II (dual delivery Tcm enriched)|Patients receive autologous HER2(EQ)BBzeta/CD19t+ Tcm cells via intratumoral/intracavitary catheter and intraventricular catheter over 5 minutes weekly for 3 weeks. Beginning as early as 1 week later, patients may receive additional T cell infusions as long as patients continue to remain eligible and there is product available. Based on clinical response after the first 3 infusions, the study principal investigator may decide to continue with the optional infusions at either one or both sites (instead of requiring injections at both sites).
89024145|NCT03389230|Experimental|ARM III (dual delivery Tn/mem enriched)|Patients receive autologous HER2(EQ)BBzeta/CD19t+ Tn/mem cells via intratumoral/intracavitary catheter and intraventricular catheter over 5 minutes weekly for 3 weeks. Beginning as early as 1 week later, patients may receive additional T cell infusions as long as patients continue to remain eligible and there is product available. Based on clinical response after the first 3 infusions, the study principal investigator may decide to continue with the optional infusions at either one or both sites (instead of requiring injections at both sites).
89510436|NCT05609396|No Intervention|Usual care|Standard reminder letter only
89510437|NCT05609396|Experimental|Enhanced reminder letter only|Behaviorally enhanced reminder letter
89510438|NCT05609396|Experimental|Usual care plus test kit|Standard reminder letter plus test kit
89510439|NCT05609396|Experimental|Enhanced reminder plus test kit|Behaviorally enhanced reminder letter plus test kit
89510440|NCT05297630||Jet Echo group|Biological markers from heart failure patients who underwent therapeutic adjustment according to a daily ultrasound scan
89510441|NCT05297630||Conventional management group|Biological markers from heart failure patients who had conventional management.
89510442|NCT05526092|Experimental|Oat-rich and low-gluten diet|Participants will consume oats and oat products and follow low-gluten diet for 6 weeks.
89510443|NCT05526092|Placebo Comparator|Rice-rich and low-gluten diet|Participants will consume rice and rice products and follow low-gluten diet for 6 weeks.
89510444|NCT05269082||Cohort 1|Pediatric and adult participants who are on Gammagard S/D prescribed for any approved indication will be enrolled in this cohort and evaluated during the observation period (approximately 6 months).
89510445|NCT05269082||Cohort 2|Pediatric and adult participants who were previously treated with Gammagard S/D prescribed for any approved indication and are on another human immunoglobulin treatment will be enrolled in this cohort and evaluated during the observation period (approximately 6 months).
88959188|NCT02001363|Experimental|liraglutide|drug: liraglutide (Novo Nordisk, Bagsværd, Denmark) duration:7 days(from admission (primary percutaneous coronary intervention) to discharge) the intervention:once-daily subcutaneous liraglutide 0.6 mg for 2 days, then gradually increase the dosage, once-daily subcutaneous liraglutide 1.2 mg for 2 days ,once-daily subcutaneous liraglutide 1.8 mg for 3 days
88959189|NCT02001363|Placebo Comparator|liraglutide placebo|drug:liraglutide placebo (Novo Nordisk) duration:7 days(from admission (primary percutaneous coronary intervention) to discharge) the intervention:once-daily subcutaneous liraglutide placebo 0.6 mg for 2 days, then gradually increase the dosage, once-daily subcutaneous liraglutide placebo 1.2 mg for 2 days ,once-daily subcutaneous liraglutide placebo 1.8 mg for 3 days
89510446|NCT05269082||Cohort 3|Pediatric and adult primary immunodeficiency (PID) participants with immunoglobin A (IgA) deficiency who have a serum IgA level of less than (<) 7 milligrams per deciliter (mg/dL) (0.07 grams/liter [g/L]) or below the detectable limit and have received other therapies (prophylactic antibiotics or immunoglobulin treatment other than Gammagard S/D) will be enrolled in this cohort and evaluated during the observation period (approximately 6 months).
89510447|NCT05324696|Placebo Comparator|Treatment with placebo device|Device similar to the one developed, but which does not generate pressure
89510448|NCT05324696|Experimental|Treatment with a working device|Treatment with a functioning device, which generates the necessary pressure to open the Eustachian tube
89510449|NCT05324696|Active Comparator|Surgical treatment|Surgical treatment (myringotomy with placement of ventilation tubes) which is the treatment currently applied in children with otitis media with effusion that do not resolve with medical treatment and/or autoinflation
89510450|NCT05497856|Experimental|Integrated neuromuscular inhibition technique|ischemic compression, strain counter strain, muscle energy techniques
89510451|NCT05497856|Active Comparator|Myofascial Release|Deep sustained pressure on the trigger points
89510452|NCT01658150|Experimental|isradipine|open label
89510453|NCT02285998|Experimental|Flublok Quadrivalent Influenza Vaccine|Intramuscular injection of vaccine containing 4 x 45µg (180µg total) of each recombinant hemagglutinin (rHA) derived from influenza A/H1N1 and A/H3N2 and two lineages of influenza B viruses identified for the season in which the trial is conducted in a total volume of 0.5 mL
89510454|NCT02285998|Active Comparator|Inactivated Influenza Vaccine|Intramuscular injection of vaccine contains 4 x 15µg (60µg total) of HA derived from the same influenza A/H1N1 and A/H3N2 and influenza B strains in a total volume of 0.5mL.
89510455|NCT05295524|Experimental|Patients with Cystic Fibrosis, with KAFTRIO® treatment prescription|Patients with Cystic Fibrosis, for whom treatment with KAFTRIO® is prescribed, regardless of previously prescribed CFTR modulator treatments.
89510456|NCT05295368|Experimental|multicomponent intervention|1) 1. Training Nurses/service coordinators as Health Coaches and Hybrid Follow-up Approach of in-person, Telephone and Secure Video Sessions; 2)Training physicians in algorithm-based standardized management of CKD and hybrid care delivery;3) subsidy on sodium-glucose transport protein-2 inhibitors (SGLT-2i) for CKD; and 4) regular CKD case review meetings.
89510457|NCT05295368|No Intervention|Usual care|treated by physicians and nurses who are not trained in SKOPE treatment algorithms.
89510458|NCT05294510|No Intervention|Control|Children who present to a village health worker during a control period are evaluated and managed using the current standard of care per Uganda National Guidelines for Integrated Community Case Management (ICCM). Each village will experience both Control and Intervention conditions as the study employs a stepped wedge design.
89510459|NCT05294510|Experimental|Intervention|Children who present to a village health worker during an intervention period are evaluated and managed using a modified ICCM algorithm that includes point-of-care C-reactive protein testing. Each village will experience both Control and Intervention conditions as the study employs a stepped wedge design.
89510460|NCT01658072|Experimental|Peri-Articular Injection|
89510461|NCT01658072|Active Comparator|Epidural Patient Controlled Analgesia (Epidural PCA)|
88959190|NCT02001376|Experimental|Intensive exercise & home exercise|Intensive exercise group Home exercise group
89510462|NCT05293184||Individuals with Angelman Syndrome|Individuals from birth to adulthood with Angelman Syndrome
89510463|NCT05322668|Experimental|Condition 1|"All the subjects will receive all the treatment in the same order.~The following prototypes will be applied on hands areas:~Application of the prototype (812A-v1) at Day 0, Application of the prototype (812C-v1) at Day 0, Application of the prototype (812D-v1) at Day 0, Application of the prototype (812F-v1) at Day 0,"
89510464|NCT02285920|Active Comparator|Spironolactone 12.5 mg|Participants will initiate treatment at 12.5 mg daily and continue at this dose for 36 weeks.
89510465|NCT02285920|Active Comparator|Spironolactone 25 mg|Participants will initiate treatment at 12.5 mg daily for 2 weeks at which time the dose will be increased to 25 mg daily for a total treatment time of 36 weeks.
88959191|NCT02001376|Experimental|Intensive exercise & control|Intensive exercise group Control group
88959192|NCT02001376|Experimental|Home exercise & control group|Home exercise Control group
88959193|NCT02001389|Experimental|EVP-6308; Arm 1|low dose, Capsule, Twice Daily, Day 1 through Day 3
88959194|NCT02001389|Experimental|EVP-6308; Arm 2|low intermediate dose, Capsule, Twice Daily, Day 1 through Day 3
88959195|NCT02001389|Experimental|EVP-6308; Arm 3|high intermediate dose, Capsule, Once Daily, Day 1 through Day 3
89510466|NCT02285920|Active Comparator|Spironolactone 50 mg|Participants will initiate treatment at 12.5 mg daily for 2 weeks at which time the dose will be increased to 25 mg daily for 2 weeks, and increased to 50 mg daily for a total treatment time of 36 weeks.
89510467|NCT02285920|Placebo Comparator|Placebo|Participants will be treated with placebo for 36 weeks.
88959196|NCT02001389|Experimental|EVP-6308; Arm 4|high dose, Capsule, Once Daily, Day 1 through Day 3
89510468|NCT05292872||OCA Treatment Group|PBC patients with a history of inadequate response or intolerance to UDCA who initiated OCA in the study window (01 Jun 2015 to 31 Dec 2021)
88959197|NCT02001415|Active Comparator|Spectacles|Spectacles are the most common lens treatment to correct myopia. This arm is set to be as a control group for the other two arms. Myopia patients who enter in this group will wear a normal pair of glasses after the baseline examinations (axial length, refraction...).
88959198|NCT02001415|Active Comparator|Myovison|Myovision is a kind of specially designed, commercially available spectacle lenses that could control the peripheral refraction of myopia patients. Latest studies have changed the understanding of myopia--correcting both central and peripheral vision during lens treatment is indicating to be an effective way of slowing down eye growth. Patients who entered this group will wear a pair of Myovision after baseline examinations.
88959199|NCT02001415|Active Comparator|Ortho-K|Orthokeratology has recently been reported as an effective way to control eye growth for myopia adolescents. Patents who enter this group will wear ortho-K lenses during sleep after baseline examinations.
89510469|NCT05292872||Control Group|PBC patients with a history of inadequate response or intolerance to UDCA who were eligible but were not treated with OCA (or off-label fibrates) in the study window (01 Jun 2015 to 31 Dec 2021)
89510470|NCT04422548|Active Comparator|AI-assisted Group|
88959200|NCT02001428|Experimental|Intermittent Screening and Treatment|Infants enrolled at Village health posts will be randomly allocated to receive intermittent screening and treatment (IST) on every scheduled immunization visit at 2, 3, 4 and 9 months of age. Infants in this group will be screened for malaria by Rapid Diagnostic Test (RDT), and if positive, treated with dihydroartemisinin-piperaquine (DHP). Infants will also receive follow up home visits at 6 and 12 months.
88959201|NCT02001428|No Intervention|Passive Case Detection|Infants in the control arm will only be checked for malaria if they have fever, or history of fever in the 24 hours prior to the scheduled immunization visit at 2,3,4 and 9 months of age, or at a follow up home visit at 6 and 12 months. Infants with malaria will be treated with DHP once daily for 3 days according to local treatment guidelines.
88959202|NCT02001441||No treatment|
88959203|NCT02001454||Patients in pain|There is no intervention, only questionnaires for the patient
88959204|NCT02001454||Attending Physicians and Nurses|The staff physicians and nurses will also fill out a questionnaire
89510471|NCT04422548|Active Comparator|Standard|
89510472|NCT05321888|Active Comparator|Mechanical Ventilation|Mechanical Ventilation
89510473|NCT05321888|Experimental|Mechanical Ventilation with Postural drainage|Mechanical Ventilation with Postural drainage
89510474|NCT02035137|Active Comparator|Single-Agent 131I-MIBG|Single-agent 131I-MIBG (Arm A) 18 mCi/kg 131I-MIBG on Day 1 and autologous stem cell infusion on Day 15.
89510475|NCT02035137|Active Comparator|131I-MIBG with Vincristine/Irinotecan|Vincristine / irinotecan / 131I-MIBG (Arm B): vincristine 2 mg/m2 (maximum dose 2 mg) intravenously on Day 0; irinotecan 50 mg/m2 (maximum dose 100 mg) intravenously on Days 0 to 4. Patients will also receive diarrhea prophylaxis with cefixime 8 mg/kg/day orally on Days -1 to +6. 131I-MIBG, 18 mCi/kg on Day 1 and autologous stem cell infusion on Day 15.
89510476|NCT02035137|Active Comparator|131I-MIBG with Vorinostat|Vorinostat / 131I-MIBG (Arm C); vorinostat 180 mg/m2 (maximum dose 400 mg) orally once daily on Days -1 to +12 (14 total doses). 131I-MIBG, 18 mCi/kg on Day 1 and autologous stem cell infusion on Day 15.
89510477|NCT03142737|Experimental|Red kidney bean intake|Subjects will consume 1/2 cup of cooked red kidney bean following diet normalization for 3 days.
89510478|NCT03142737|Experimental|Eggs intake|Subjects will consume 2 cooked large eggs following diet normalization for 3 days.
89510479|NCT03142737|Experimental|Peanut butter intake|Subjects will consume 2 tablespoons of peanut butter following diet normalization for 3 days.
89510480|NCT03142737|Experimental|Ground beef intake|Subjects will consume 2 ounces of 90% lean ground beef following diet normalization for 3 days.
89510481|NCT03142737|Experimental|Intact beef intake|Subjects will consume 2 ounces of intact beef following diet normalization for 3 days.
89510482|NCT03141801|Experimental|Eccentric Exercise with Delfi Blood Flow Restriction Training|Patients randomized to the eccentric exercise + blood flow restriction training group will receive eccentric exercise two times per week for 8 weeks, beginning 8-12 weeks after anterior cruciate ligament reconstruction. Patients will completed the exercise with knee range of motion limited to 20-60 degrees of knee flexion and will train at an intensity equal to 70% of their eccentric 1-repetition maximum for 4 sets of 10 repetitions. During exercise, patients will have the DELFI personalized tourniquet system applied over the quadriceps to restrict blood flow. The tourniquet will be set to a limb occlusion pressure of 80%.
89510483|NCT03141801|Experimental|Concentric Exercise with Delfi Blood Flow Restriction Training|Patients randomized to the concentric exercise group will receive concentric exercise two times per week for 8 weeks, beginning 8-12 weeks after anterior cruciate ligament reconstruction. Patients will completed the exercise with knee range of motion limited to 20-60 degrees of knee flexion and will train at an intensity equal to 70% of their concentric 1-repetition maximum for 4 sets of 10 repetitions.
89510484|NCT03141801|Active Comparator|Eccentric Exercise|Patients randomized to the eccentric exercise group will receive eccentric exercise two times per week for 8 weeks, beginning 8-12 weeks after anterior cruciate ligament reconstruction. Patients will completed the exercise with knee range of motion limited to 20-60 degrees of knee flexion and will train at an intensity equal to 70% of their eccentric 1-repetition maximum for 4 sets of 10 repetitions.
89510485|NCT03141801|Active Comparator|Concentric Exercise|Patients randomized to the concentric exercise group will receive concentric exercise two times per week for 8 weeks, beginning 8-12 weeks after anterior cruciate ligament reconstruction. Patients will completed the exercise with knee range of motion limited to 20-60 degrees of knee flexion and will train at an intensity equal to 70% of their concentric 1-repetition maximum for 4 sets of 10 repetitions. During exercise, patients will have the DELFI personalized tourniquet system applied over the quadriceps to restrict blood flow. The tourniquet will be set to a limb occlusion pressure of 80%.
89510486|NCT03141957||Young patients|Patients with non-small cell lung carcinoma younger than 75y
89510487|NCT03141957||Elderly patients|Patients with non-small cell lung carcinoma aged 75 or more
89024146|NCT03384914|Active Comparator|Dendritic Cell (DC1) Vaccine|"The vaccine will be administered in two phases: a vaccination phase and a booster phase.~Approximately 6 months from the initiation of the first vaccine, patients will receive the first of 3 booster vaccines."
89024147|NCT03384914|Active Comparator|pUMVC3-IGFBP2-HER2-IGF1R (WOKVAC)|"The vaccine will be administered in two phases: a vaccination phase and a booster phase.~Approximately 6 months from the initiation of the first vaccine, patients will receive the first of 3 booster vaccines."
89024148|NCT03375762|Experimental|Usual care plus RIPerC|Usual care for stroke code patients, with or without revascularization therapies, with Remote ischemic perconditioning (RIPerC) using an electronic tourniquet.
89024149|NCT03375762|Sham Comparator|Usual care plus Sham RIPerC|Usual care for stroke code patients, with or without revascularization therapies, with Sham remote ischemic conditioning (RIPerC)
89024150|NCT03374982|Experimental|DentalVibe turned On then turned Off|DentalVibe will be turned on during local anesthetic injection at the first appointment. DentalVibe will be turned off during local anesthetic injection at the second appointment.
89024151|NCT03374982|Experimental|DentalVibe turned Off and then turned On|DentalVibe will be turned off during local anesthetic injection at the first appointment. DentalVibe will be turned on during local anesthetic injection at the second appointment.
89024152|NCT03371498|Experimental|Methylprednisolone Group|Ventilated patients presenting moderate to severe ARDS with a procollagen III alveolar level above 9 µg/L will receive methylprednisolone
89024153|NCT03371498|Placebo Comparator|Control Group|Ventilated patients presenting moderate to severe ARDS with a procollagen III alveolar level above 9 µg/L will receive placebo
89024154|NCT03368729|Experimental|Phase 1: Niraparib 200 mg + Trastuzumab 6 mg/kg|In phase 1 patients in this first arm will receive 200 mg Niraparib in combination with 6 mg/kg Trastuzumab given IV every 3 weeks.
89024155|NCT03368729|Experimental|Phase 1: Niraparib 100 mg + Trastuzumab 6 mg/kg|In phase 1 patients in this second arm will receive Niraparib 100 mg in combination with 6 mg/kg Trastuzumab given IV every 3 weeks.
89024156|NCT03368729|Experimental|Phase 2: Niraparib 200 mg or 100 mg + Trastuzumab 6 mg/kg|The dosage of Niraparib in phase 2 will be determined by the response of patients in Phase 1. A dosage of Niraparib 200 mg will be given along with Trastuzumab 6 mg/kg IV unless a dose limiting toxicity occurs in Phase 1. If so, Niraparib 100 mg will be given with Trastuzumab 6 mg/kg (instead of Niraparib 200 mg).
89510488|NCT05291624||Patients with preoperative suspicion of endometriosis|Consecutive patients undergoing ultrasonographic preoperative assessment and subsequent surgical approach for deep endometriosis
89510489|NCT05264870|Active Comparator|Group A|combined spinal epidural anesthesia (CSE) with 7,5mg hyperbaric Marcaine and 2,5mcg Sufentanil
89510490|NCT05264870|Active Comparator|Group B|combined spinal epidural anesthesia (CSE) anesthesia with 10mg hyperbaric Marcaine and 2,5mcg Sufentanil
89510491|NCT02327871|Experimental|Esophageal cooling|Specific treatment: The placement of the ECD will follow standard recommendations as per Instructions for Use. The ECD will be connected to the Gaymar console (Meditherm III, Gamida, France). In our institution, TH is performed in all patients resuscitated from an OHCA except those presenting exclusion criteria. TH can be initiated as soon as possible by administration of cold saline at 4°C if necessary followed by application of the available cooling device (blankets, endovascular methods, etc) aiming a target temperature of 32-34°C for 24 hours as recommended. 8-11,13 For all enrolled patient, the ECD will hereby replace the other cooling device usually used in our ICU.
89510492|NCT02327559|Experimental|Mind in Labor (MIL)|Mind in Labor: Working with Pain in Childbirth (MIL) is a 16-hour mindfulness-based childbirth education course. It is an abbreviated weekend workshop form of the 9-week Mindfulness-Based Childbirth and Parenting (MBCP) education program, which is a tailored form of Mindfulness-Based Stress Reduction.
89510493|NCT02327559|Active Comparator|Treatment As Usual (TAU)|Treatment As Usual (TAU) refers to standard hospital- and community-based childbirth preparation courses (high quality childbirth education that excludes a mindfulness or mind/body stress reduction focus).
89510494|NCT05079087|Experimental|PENG BLOCK arm|The first arm will consist of patients that undergo PENG block administering a mixture of Ropivacaine 0.5% + Dexamethasone 4 mg in a volume of 20 ml before performing the spinal anaesthesia.
89510495|NCT05079087|Active Comparator|Ketamine- Midazolam arm|The second arm consist in Patients that will undergo sedation and analgesic treatment with Ketamine and Midazolam titrated to the best Verbal Rating Score without respiratory and cardiovascular depressant effect.
89510496|NCT03144999|Experimental|Low Dose|AAVCAGsCD59
89510497|NCT03144999|Experimental|Mid Dose|AAVCAGsCD59
89510498|NCT03144999|Experimental|High Dose|AAVCAGsCD59
89510499|NCT02327949|Experimental|WP group|WP group:treated with W-Shaped Angular Plate
89510500|NCT02327949|Active Comparator|RP group|RP group:treated with Reconstruction Plate
89510501|NCT03145233|Experimental|Isometric exercise|12 week Isometric exercise programme - two exercises (one side-lying and the other standing); six repetitions of each with muscle contraction sustained for 30 seconds. Exercises performed once daily with each session lasting no longer than 10 minutes.
89510502|NCT03145233|Experimental|Isotonic exercise|12 week Isotonic exercise programme - two exercises (one side-lying and the other standing); each exercise - 3 sets of 10 repetitions, each repetition 6 seconds duration. Exercises performed once daily with each session lasting no longer than 10 minutes.
89510503|NCT05262842|Experimental|JS001+IMP4297|
89510504|NCT02522780|Experimental|Mesalamine|Mesalamine 2 g extended release granules (sachet), administered orally once daily (QD) for 6 months.
89510505|NCT02522780|Placebo Comparator|Placebo|Placebo matched to mesalamine extended release granules (sachet), administered orally QD for 6 months.
89510506|NCT03618225|Active Comparator|duloxetine group|duloxetine 60 mg orally 2 hours before the surgical procedure and at 24 hours after the surgical procedure.
89510507|NCT03618225|Placebo Comparator|placebo pill group|placebo pill orally 2 hours before the surgical procedure and at 24 hours after the surgical procedure.
89510508|NCT03566199|Experimental|Treatment (MTX110)|Participants receive panobinostat nanoparticle formulation MTX110 IT by CED infusion on day 1 or days 1 and 2 as determined by dose level. Courses repeat every 4-8 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity.
89510509|NCT05290688|Other|Untreated RRMS patients|Untreated RRMS patients with a 50 ml blood sample during their routine care
89510510|NCT03561831|Active Comparator|propofol group|patients who anesthesized by propofol
89510511|NCT03561831|Active Comparator|sevoflurane group|patients who anesthesized by sevoflurane
89510512|NCT03145155|Experimental|Intervention|Pregnant women in intervention arm will receive CoC card and health education on CoC in maternal, newborn and child health (MNCH), NCD and nutrition. The CoC card will include CoC services from first antenatal care(ANC) to last postnatal care(PNC) including four ANC, skilled birth attendance (SBA) and four PNC and essential services. Pregnant women will get stickers if they receive above services. Health education will be given three times during pregnancy and one time during postpartum period.
89510513|NCT03145155|Placebo Comparator|Control|Pregnant women in control arm will receive ordinary health education on pregnancy care
89510514|NCT05230485|Experimental|Higher CPAP|CPAP level will be 2 cmH2O higher than pre-extubation measured mean airway pressure
88959205|NCT02001467|Active Comparator|Simulation-based training|Simulation-based training to an expert criterion followed by clinical training until proficiency and certification.
89510515|NCT05230485|Active Comparator|Equivalent CPAP|CPAP level will be equal to the pre-extubation measured mean airway pressure
89510516|NCT03142971|Experimental|Intervention:f-ESWT (focused shock wave therapy)|In the study-group, a device powered by a piezoelectric generator (PIEZOSON 100PLUS, Richard Wolf) was used . At the beginning of each treatment session, the enthesis of the gluteal tendons at the greater trochanter (at the anterior half of its lateral facet) was targeted through a non-inline sonographic focusing, using a linear probe (7.5-12 MHz) connected to an ultrasound scanner (ESAOTE MYLAB FIVE, Genova and Florence, Italy). All patients received 1800 pulses (frequency=4Hz) of an energy flux density of 0.15 mJ/mm2 once a week for three consecutive weeks. At the first treatment session, the energy flux density was gradually increased from 0.05 to 0.15 mJ/mm2 during the first 500 pulses.
88959206|NCT02001467|No Intervention|Control|No training is provided the control group participants.
88959207|NCT02001480|Other|Echocardiography|"12 lead holter for 7 days~CGM = continuous Glucose Monitoring"
88959208|NCT02001506|Active Comparator|FEC3-D3|"3 cycles of FEC followed by 3 cycles of Docetaxel~Fluorouracil 500 mg/m2, every 3 weeks Epirubicin 100 mg/m2, every 3 weeks Cyclophosphamide 500, every 3 weeks~Docetaxel 75 mg/m2, every 3 weeks"
88959209|NCT02001506|No Intervention|AC4-D4|"4 cycles of Adriamycin plus Cyclophosphamide (AC) followed by 4 cycles of Docetaxel~Adriamycin 60 mg/m2, every 3 weeks Cyclophosphamide 600 mg/m2, every 3 weeks~Docetaxel 75 mg/m2, every 3 weeks"
88959210|NCT02001519|Experimental|adriamycin,cytoxan, cisplatin|4 cycles of Adriamycin 60 mg/m2 and Cyclophosphamide 600 mg/m2 every 3 weeks followed by 4 cycles of cisplatin 75 mg/m2 every 3 weeks
88959211|NCT02001532||Diabetes type 2|Patients diagnosed with type 2 diabetes within 5 years from baseline (i.e. 10 years at follow-up)
88959212|NCT02001532||Healthy controls|Sex and age-matched healthy controls
88959213|NCT02001545||Patients with STEMI and NSTEMI|Patients aged 18 years or older, hospitalized and diagnosed with STEMI (ST-segment elevation myocardial infarction) or NSTEMI (non-ST-segment elevation myocardial infarction) within 24 hours of symptom onset.
88959214|NCT02001571|Experimental|Cohort 1|Mild Hepatic participants administered to four 250 mg tablets (1000 mg) orally on Day 1.
88959215|NCT02001571|Experimental|Cohort 2|Moderate Hepatic participants administered to four 250 mg tablets (1000 mg) orally on Day 1.
88959216|NCT02001571|Experimental|Cohort 3|Normal Hepatic participants administered to four 250 mg tablets (1000 mg) orally on Day 1.
88959217|NCT02001584|Experimental|Healthy Volunteers|
88959218|NCT02001584|Experimental|Obese, Otherwise Healthy Volunteers|
88959219|NCT02001597||Surgery patients|
88959220|NCT02001610|Active Comparator|Hard shell gelatin capsules|"Comparison delivery vehicle in the form of gelatin capsule~One capsule (containing at least 1 x 10^9 colony forming units) every morning for 12 days"
88959221|NCT02001610|Experimental|Acidophilus pearls|"Encapsulated using patented process~One capsule (containing at least 1 x 10^9 colony forming units) every morning for 12 days"
88959222|NCT02001636|Experimental|Protein group|"Patient group which takes daily protein supplements after bariatric surgery over 6 months.~Protein product: Resource Instant Protein 88, Nestlé Health Nutrition"
88959223|NCT02001636|Placebo Comparator|Control group|"Patient group which takes daily isocaloric placebo after bariatric surgery over 6 months and thus can be compared to the protein group.~Placebo product: Resource Maltodextrin, Nestlé Health Nutrition"
88959224|NCT02001649|Other|Inpatient group SNP Genotyping|"Patients will be recruited from pediatric departments in which 13 -17 y old adolescents are hospitalized for a suicide attempt. Data will be collected through self-administered questionnaires and face to face interview. DNA will be extracted from saliva sample.~Individuals will be genotyped at a total of 96 SNPs"
88959225|NCT02001649|Other|Control group SNP Genotyping|Control subjects are young adults without suicide attempt and without mental disorders
88959226|NCT02001662|Experimental|Intervention group, block no. 1 - Ropivacain|"Adductor-Canal-Block no.1: 30mL ropivacaine (7.5 mg/ml) when postoperative VAS-score is > 40mm (on a 0-100 mm VAS-scale) during a 45 degree active flexion of the knee.~Adductor-Canal-Block no.2: after 45 min (t45) - 30mL isotonic saline."
88959227|NCT02001662|Sham Comparator|Control group, block no. 1 - saline|"Adductor-Canal-Block no.1: 30mL isotonic saline when postoperative VAS-score is above 40mm (on a 0-100 mm VAS-scale) during a 45 degree active flexion of the knee.~Adductor-Canal-Block no.2: after 45 min (t45) - 30mL ropivacaine (7.5 mg/ml)"
88959228|NCT02001675|Experimental|Volunteer healthy|
88959229|NCT02001701|Experimental|Intravitreal Gas|Intravitreal injection of sulfahexafluoride gas
88959230|NCT02001727|Active Comparator|Hp-screened group|Screened for Helicobacter Pylori and eradication therapy (1998-99)
88959231|NCT02001727|Other|Control group|primarily unscreened group
88959232|NCT02001740|Placebo Comparator|lidocaine|frequency = once
88959233|NCT02001740|Experimental|Triamcinalone (steroid) and lidocaine|frequency = once
88959234|NCT02001753|Experimental|CMR group|Endothelial function, oxidative stress and inflammation were measured before and after CMR.
89510517|NCT03142971|Active Comparator|Intervention:UST (ultrasound therapy)|In the control-group, we used a mono-frequency device (ROLAND, RT-20 series, frequency=1MHz). We treated an area of 5cm2, softly moving the US-probe around the most painful point of the greater trochanter at the clinical palpation. UST was supplied in a continuous modality, with an intensity of 1.5 W/cm2, for ten consecutive daily sessions of ten minutes each.
89510518|NCT05078697||early pregnancy women|According to the 2020 high-risk population score model, participants with high risks for GDM and normal health participants will be enrolled into the study.
89510519|NCT05261750|Experimental|Auto-Dendritic Adjuvant Therapy|Patients will be given standard medical therapy (radiotherapy or chemoradiation) and auto-dendritic adjuvant therapy via intramuscular 3 times injection every 1 week.
89510520|NCT05261750|Experimental|Allo-Dendritic-secretome and Auto-Dendritic Adjuvant Therapy|Patients will be given standrad medical therapy (radiotherapy or chemoradiation) and allo-dendritic-secretome adjuvant therapy 2 cc 1 times injection, and then followed by auto-dendritic therapy via intramuscular 3 times injection every 1 week.
89510521|NCT03144843|Experimental|Experimental group|Apatinib: 500mg, po, qd, every 4 weeks Paclitaxol: 80mg/m2, d1, d8, d15, every 4 weeks
89510522|NCT03144843|Placebo Comparator|Placebo group|Placebo: 500mg, po, qd, every 4 weeks Paclitaxol: 80mg/m2, d1, d8, d15, every 4 weeks
89510523|NCT03401307||Responders to Fampridine Treatment|Participants, who are classified as responders to Fampridine treatment, have already been identified in the MS-centers in the Region of Southern Denmark, where they undergo outpatient treatment and clinical controls. A 2-week Fampridine treatment phase, as described in the trial outline section, has been used to identify responders to Fampridine. Participants who improve with ≥20% on the T25FW are categorized as responders.
89510524|NCT03401307||Non-Responders to Fampridine Treatment|Participants, who are classified as non-responders to Fampridine treatment, have already been identified in the MS-centers in the Region of Southern Denmark, where they undergo outpatient treatment and clinical controls. A 2-week Fampridine treatment phase, as described in the trial outline section, has been used to identify non-responders to Fampridine. Participants who do not improve with ≥20% on the T25FW are categorized as non-responders.
89510525|NCT03111615|Experimental|Aromatase Inhibitor group|Female patients of 50 and above y.o. shall initiate hormone therapy (Letrozol 2.5 mg or Anastrazol 1 mg) immediately after the diagnosis until surgery.
89510526|NCT03111615|No Intervention|Control group|Female patients of 50 and above y.o. that follow standard protocol (no pre-surgery (Letrozol 2.5 mg or Anastrazol 1 mg))
89510527|NCT03111615|Other|Aromatase Inhibitor Active surveillance|Female patients of 50 and above y.o. that refuse surgery and therefor follow standard protocol (only Letrozol 2.5mg or Anastrazol 1 mg) until disease progression, death or will of surgery In this subgroup we are going to include, under HT, female patients with CDis,that refuse the standard treatment with surgery plus eventual rt and/or ht
89510528|NCT03111615|Other|Aromatase Inhibitor Active surveillance + aas|emale patients of 50 and above y.o. that refuse surgery and therefor follow standard protocol (only Letrozol 2.5mg or Anastrazol 1 mg plus acetilsalicilic acid) until disease progression, death or will of surgery In this subgroup we are going to include, under HT, female patients with CDis,that refuse the standard treatment with surgery plus eventual rt and/or ht
89510529|NCT05078151|Other|Metastatic prostate cancer|Patients will receive whole-body MRI with diffusion-weighted imaging at baseline and after 4 and 8 weeks of treatment.
89510530|NCT05257382|Active Comparator|Endoscopy suite|In this arm, ENB procedure will be performed in a classical endoscopy suite equipped by a fluoroscopy.
89510531|NCT05257382|Experimental|CBCT suite|In this arm, ENB procedure will be performed in a n hybrid room equipped by a cone beam CT (CBCT). This will allow to perform a real time visualisation of the lesion, enhanced fluoroscopy and to use the CrossCountry technique if required.
89510532|NCT05287490|Experimental|treatment|
89510533|NCT03111303||HAP patients|Mechanical ventilation, patients fulfilled HAP criteria
89510534|NCT03111303||non HAP patients|Mechanical ventilation, patients without HAP
89510535|NCT05287334|Experimental|Voluntary blood donors|Voluntary blood donors undergoing standard blood donation while measuring electrical impedance of the chest .
89510536|NCT03199755|Active Comparator|ACT|"Standard Artemisinin Combination Therapy (ACT) being used as currently approved antimalarial therapy at WHO and manufacturer recommended dosage. The specific ACT used is artemether-lumefantrine (Coartem). Form is scored tablets that each contain 20 mg artemether and 120 mg lumefantrine.~Tablets per dose, are given BID for 3 days as shown below:~Coartem tablets/dose by bodyweight; tablets/day morning and evening for total of 6 doses over 3 days~Body weight (kg) and Tablets: 5 to <15 kg, 1 tab; 15 to <25 kg, 2 tabs; 25 to <35 kg, 3 tabs; 35 kg and over, 4 tabs."
89510537|NCT03199755|Experimental|DLA1|"Dried leaf Artemisia annua (DLA) from 0.25-1 g total/day, BID. DLA is given as 500 mg tablets according to body weight (see below) for 5 days.~DLA tablets/dose by bodyweight; tablets/day, morning and evening, for total of 10 doses over 5 days.~Body weight (kg) and tablets/dose:~For DLA1x: 5 to < 15 kg, 1/4 tab; 15-30 kg, 1/2 tab; 1/2>30 kg, 1 tab."
89510538|NCT03199755|Experimental|DLA2|"Dried leaf Artemisia annua (DLA) from 0.5-2 g total/day, BID. DLA is given as 500 mg tablets according to body weight (see below) for 5 days.~DLA tablets/dose by bodyweight; tablets/day, morning and evening, for total of 10 doses over 5 days.~Body weight (kg) and tablets/dose:~For DLA2x: 5 to < 15 kg, 1/2 tab; 15-30 kg, 1 tab; >30 kg, 2 tabs."
89510539|NCT05318066|Active Comparator|Arm Fluids (FL)|500 mL of ringer lactate over 10 minute prior to the administration of procedural medications.
89510540|NCT05318066|Active Comparator|Arm Vasopressor (VP)|Patients in this group would receive norepinephrine infusion at a dose of 0.08 μg/kg/min over 10 minutes prior and 5 minutes after tracheal intubation.
89510541|NCT05317910|Experimental|Music intervention|Music intervention (duration 20 minutes) every day for 30 days
89510542|NCT05387109|Experimental|penpulimab combined with anlotinib|penpulimab: fixed dose of 200 mg, administered on the first day of each cycle, repeated every 3 weeks; Anlotinib: 12 mg, administered on days 1-14, orally once a day, about half an hour before breakfast (the daily dose should be as much as possible), taken with warm water, and repeated every 3 weeks
89510543|NCT04422704|Experimental|Retired people|People who are either ordinarily or early retired and who have previously held a paid employment.
89510544|NCT02327793|No Intervention|Mean Arterial Pressure <100 mmHg|Patients with mean arterial pressure <100 mmHg at the time of the perfusion weighted magnetic resonance imaging will not be treated. After 15 minutes of the baseline perfusion imaging a repeat perfusion weighted magnetic resonance imaging would be performed.
89510545|NCT02327793|Experimental|Mean Arterial Pressure 100-120 mmHg|Patients with mean arterial pressure between 100-120 mmHg at the time of the perfusion weighted magnetic resonance imaging will be treated with sublingual 0.3 mg nitroglycerin. A repeat blood pressure would be assessed at 5min, 10min, 15min and 20 min of nitroglycerin administration. After a sustained drop of blood pressure (>10% of the baseline reading) as defined by two reading 5minutes apart, a perfusion weighted magnetic resonance imaging will be performed.
89510546|NCT02327793|Experimental|Mean Arterial Pressure >120 mmHg|Patients with mean arterial pressure >120 mmHg at the time of the perfusion weighted magnetic resonance imaging will be treated with intravenous 10-20mg labetalol injection. A repeat blood pressure would be assessed at 5min, 10min, 15min and 20 min of labetalol injection. After a sustained drop in blood pressure (>10% of the baseline reading) as defined by two reading 5minutes apart, a perfusion weighted magnetic resonance imaging will be performed.
89510547|NCT02327715|Experimental|Chinese naive pregnant HBsAg positive patients|single group patients were enrolled to receive emtricitabine(200mg one time per day) till 24 weeks after dilivery,patients and followed up for 24 weeks.
89510548|NCT02966379|Experimental|Cochlear implantation|Cochlear implantation with EVO electrode lead. This electrode lead has been specially designed for atraumatic surgery, in order to preserve the residual hearing of the patients included in the study. All patients are implanted with the same electrode lead.
89510549|NCT05314946|Active Comparator|Percutaneous enteral access|Feeding tube, either gastrostomy (G-) tube or gastrojejunostomy (GJ-) tube (placed by Interventional Radiology) or J-tube (surgically placed)
89510550|NCT05314946|Experimental|No percutaneous enteral access|No feeding tube placed.
89510551|NCT02957799|Experimental|Accountable Condition- 8 clinics|In the Accountable Condition, the intervention includes mothers who will receive home visits from government-funded CHW who will be trained once under Philani and receive ongoing monitoring and supervision.
89510552|NCT02957799|Experimental|Control Condition- 8 clinics|The Control Condition will include mothers who receive home visits from government-funded CHW who will be trained once under Philani and receive supervision and monitoring consistent with local government practices.
89510553|NCT02951013|Experimental|restrictive group|Patients in this group will have a transfusion when the hemoglobin concentration falls below 6g/dL, with a target hemoglobin range of 7.5-8.0g/dL.
89510554|NCT02951013|Active Comparator|liberal group|Patients in this group will have a transfusion when the hemoglobin concentration falls below 8g/dL, with a target hemoglobin range of 9.5-10.0g/dL.
89510555|NCT03141489|Experimental|NICE guidelines for refeeding syndrome|High protein enteral tubefeeding solution. NICE guidelines regarding refeeding syndrome, based on a very cautious refeeding regime reaching estimated calorie and protein needs within 7 days, compared to a protocol at Diakonhjemmet Hospital using a higher starting rate, reaching estimated needs within 3 days.
89510556|NCT03141489|Experimental|Diakonhjemmet Hospital Protocol(DS)|High protein enteral tubefeeding solution. The intervention group, Diakonhjemmets feeding protocol, will start at 20 calories a kg a day, and increasing until estimated needs are met within 3days
89510557|NCT05081505|Experimental|Community-based physical fitness exercise course|Included 12-week structural exercise course (0-12 weeks) and 12-week autonomous group class (12-24 weeks).
89510558|NCT05283122|Experimental|The Mostafa Maged technique to prevent and control post-partum bleeding in placenta previa cases|primigravida patients with placenta previa conditions and their ages between ( 18 - 30 ) years old
89510559|NCT02285062|Experimental|R2-CHOP|Lenalidomide plus R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone)
89510560|NCT02285062|Active Comparator|R-CHOP|Placebo plus R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone)
89510561|NCT02431767|Experimental|Group 1: Treatment|Participants will receive the PENNVAX®-GP vaccine 0.6 mg admixed with IL-12 DNA 0.2 mg to be administered as 0.1 mL by intradermal (ID) injection over either deltoid at Months 0, 1, 3, and 6 using the CELLECTRA® 3P EP system.
88959235|NCT02001753|Placebo Comparator|Placebo group|"The subjects keep supine position the MR machine as same time as experimental group when the MR machine is power off. The endothelial function, oxidative stress and inflammation were measured before and after this procedure. This group is called the non-CMR group or sham CMR group."
88959236|NCT02001753|No Intervention|health subject group|Healthy subjects (30) will be enrolled as controls at baseline.
88959237|NCT02001766|Experimental|High intensity exercise|3 times per week in a total of 12 weeks
88959238|NCT02001766|Experimental|Low intensity exercise|3 times per week in a total of 12 weeks
88959239|NCT02001766|Experimental|Control|Normal lifestyle for 12 weeks
88959240|NCT02001779|Experimental|Biliary SEMS loaded with 125I seeds|A self-expandable metallic biliary stent loaded with 125 iodine seeds is inserted in patients with inoperable malignant biliary obstruction.
89207017|NCT00547911|Experimental|LDOPS + CAR; LDOPS + Placebo; LDOPS + ENT|There are three interventions that every subject orally received over the duration of the study; 400 mg of droxidopa (LDOPS) + 200 mg placebo, 400 mg of droxidopa (LDOPS) + 200 mg carbidopa (CAR), and 400 mg of droxidopa (LDOPS) + 200 mg entacapone (ENT). The order of the three interventions was randomly assigned prior to drug administration and each intervention was followed by a wash out period of at least two days to clear previous intervention from subject's systems. This arm received the three interventions in the order of: LDOPS + CAR, followed by LDOPS + Placebo, and lastly LDOPS + ENT.
89510562|NCT02431767|Placebo Comparator|Group 1: Placebo|Participants will receive placebo to be administered as 0.1 mL ID over either deltoid at Months 0, 1, 3, and 6 using the CELLECTRA® 3P EP system.
88959241|NCT02001779|Active Comparator|Conventional biliary SEMS|A self-expandable metallic biliary stent is inserted in patients with inoperable malignant biliary obstruction.
88959242|NCT02001792|Sham Comparator|Controll group|Patients lying in a supine position during colonoscopy
89510563|NCT02431767|Experimental|Group 2: Treatment|Participants will receive the PENNVAX®-GP vaccine 0.8 mg to be administered as 0.1 mL ID over their left and right deltoids (unless medically contraindicated) at Months 0, 1, 3, and 6 using the CELLECTRA® 3P EP system.
89510564|NCT02431767|Placebo Comparator|Group 2: Placebo|Participants will receive placebo to be administered as 0.1 mL ID over their left and right deltoids (unless medically contraindicated) at Months 0, 1, 3, and 6 using the CELLECTRA® 3P EP system.
89510565|NCT02431767|Experimental|Group 3: Treatment|Participants will receive the PENNVAX®-GP vaccine 0.8 mg admixed with IL-12 DNA 0.2 mg to be administered as 0.1 mL ID over their left and right deltoids (unless medically contraindicated) at Months 0, 1, 3, and 6 using the CELLECTRA® 3P EP system.
89510566|NCT02431767|Placebo Comparator|Group 3: Placebo|Participants will receive placebo to be administered as 0.1 mL ID over their left and right deltoids (unless medically contraindicated) at Months 0, 1, 3, and 6 using the CELLECTRA® 3P EP system.
89510567|NCT02431767|Experimental|Group 4: Treatment|Participants will receive the PENNVAX®-GP vaccine 8 mg admixed with IL-12 DNA 1 mg to be administered as 1 mL intramuscular (IM) injection in either deltoid at Months 0, 1, 3, and 6 using the CELLECTRA® 5P EP system.
89510568|NCT02431767|Placebo Comparator|Group 4: Placebo|Participants will receive placebo to be administered as 1 mL IM in either deltoid at Months 0, 1, 3, and 6 using the CELLECTRA® 5P EP system.
89510569|NCT04422782|Other|Single Arm|Single Arm
89510570|NCT05082363||systemic lupus wth renal affection|pt diagnosed with lupus nephritis
89510571|NCT05082363||systemic lupus without renal affection|pt diagnosed as systemic lupus without renal affection
89510572|NCT04422860|Experimental|Gum Arabic varnish|Gum arabic (Acacia senegal) is an exudate obtained from Acacia senegal stems and roots, and other similar African Acacia species. It consists mainly of high molecular weight polysaccharides high concentrations of calcium, magnesium, and potassium salts which can potentially increase tooth remineralization.
89510573|NCT04422860|Active Comparator|Sodium Fluoride varnish|The gold standard remineralizing agent recommended by the guidelines.
89510574|NCT04422860|Active Comparator|10% w/v CPP-ACP, 5% sodium fluoride varnish|CPP-ACP is the most studied non fluoride remineralizing agent.
89510575|NCT03141333|Experimental|Teleintervention|Participants of this group will have access to the following sections in the web plate-form: information, forum, chat and live online consultation. The teleintervention consists of having access to the forum, chat and live online consultation sections of the web plate-form.
89510576|NCT03141333|No Intervention|No intervention|Participants of this group will have access to the following section of the web plate-form: information, which is consistent with the standard of care for many families of children with DCD, who only have access to online information but do not have access to any type of intervention.
89510577|NCT02327637|No Intervention|Bedrest|"Bedrest is a standard recommendation for patients with PPROM. Subjects randomized to this arm of the study will undergo the following:~Receive recommendation for bedrest (standard of care).~Have maternal mood and muscle strength evaluated on enrollment and after delivery (observational study procedure).~Wear a pedometer to measure activity when out of bed (observational study procedure)."
89540425|NCT06211452|Active Comparator|ARM A: Conventional Consolidation|Conventional consolidation (CONS) (active comparator) (6-thioguanine 60 mg/m2/d, on days 1 to 43 orally; prednisone 40 mg/m2/d, on days 1 to 28 orally; vincristine 1.5 mg/m2/d, on days 1, 8, 15, 22; idarubicin 7 mg/m2/d, on days 1, 8, 15, 22; cytarabine 75 mg/m2/d, on days 3-6, 10-13, 17-20, 24-27, 31-34, 38-41; intrathecal cytarabine on days 1, 15, 29, 43 [age-dependent dose]; cyclophosphamide 500 mg/m2/d, on days 29, 43)
88959243|NCT02001792|Active Comparator|Intervention|Patients lying in a left lateral position during colonoscopy
88959244|NCT02001805||Marathon runners|Very active runners that have been running > 10 marathons, 2 within the last year, or an amount of 50 km/week for the last 5 years
88959245|NCT02001805||Control subjects|Healthy normal weight control subjects, with a low activity level < 1 hour phsyical activity pr. week. They are matched with runners on age, BMI and gender
88959246|NCT02001831|Experimental|Supplement|"Liquid nutrient support (quantity 200 mL per day; energy 200 kcal per day):~Carbohydrate 28.5 g~Protein 8 g as Whey Protein Isolate~ω-3 PUFA 3000 mg, as DHA 1500mg, as EPA 1500mg~Vitamin D3 10 μg~Resveratrol 150 mg"
88959247|NCT02001831|Placebo Comparator|Control|"Placebo control~Liquid nutrient support~Quantity 200 mL per day - fruit juice only i,e. in absence of bioactives present in the supplement (whey protein, omega 3, vitamin D and resveratrol)."
89024157|NCT03366636|No Intervention|Control|"The control/comparison group will be receiving only their usual services which are offered at the agencies they frequent, including mental health services, case management, job training, educational services, and, in specific venue contexts, may receive HIV risk reduction or other sex education interventions such as Street Smart. These same services are also open to the intervention group. Usage of these services varies by site (residential vs drop-in; city (San Diego vs Los Angeles) and type of service (case management, mental health, health care, etc.)."
89024158|NCT03366636|Experimental|Project Legacy|The experimental/intervention arm will receive the Project Legacy intervention
89024159|NCT03341247||Low-risk of obesity|Children whose biological mother and biological father have a body mass index between 18.5 - 25 kg/m2.
89024160|NCT03341247||High-risk of obesity|Children whose biological mother has a body mass index greater than or equal to 30 kg/m2 and whose biological father have a body mass index greater than or equal to 25 kg/m2.
89510578|NCT02327637|Experimental|Moderate Activity|"Subjects randomized to this arm of the study will undergo the following:~Receive recommendation to ambulate 150 feet, twice per day (interventional study procedure). Prior to each session of ambulation, an ultrasound will be performed to ensure adequate amniotic fluid volume and appropriate fetal position, and a fetal heart rate tracing will be obtained to ensure that there is reassuring fetal status (observational study procedure). During each session of ambulation, the fetal heart rate tracing will be monitored continuously (observational study procedure).~Have maternal mood and muscle strength evaluated on enrollment and after delivery (observational study procedure).~Wear a pedometer to measure activity when out of bed (observational study procedure)."
89510579|NCT05230563|No Intervention|Control Group|Participating clinicians will perform lung nodule detection on 200 cases of lung low-dose computed tomography images
89510580|NCT05230563|Experimental|"Experimental Group - with the aid of Taihao lung CT decision support system"|"Participating clinicians will perform lung nodule detection on 200 cases of lung low-dose computed tomography images with the aid of Taihao lung CT decision support system"
89510581|NCT05063019|Experimental|Magnetic resonance imaging and enterography following computed tomography|Magnetic resonance imaging and enterography will be performed after computed tomography but before surgery.
89510582|NCT04571697||Participants Initiating Therapy with Methotrexate or Anti-TNF|Data will be collected for participants initiating therapy with either methotrexate or an anti-tumor necrosis factor (TNF) from united states (US) claims databases: optum de-identified clinformatics data mart database and IBM marketscan medicare supplemental database (MDCR). Data collection period: 01-Jan-2000 through 31-Jul2019.
89510583|NCT05253794|Experimental|Colchicine|Colchicine 0.6mg PO daily for 6 months
89510584|NCT05253794|Placebo Comparator|Placebo|Placebo tablet daily for 6 months
89510585|NCT05081973||Intubated preterm infants|Infants with a birth weight < 1250 grams who have required endotracheal tube and mechanical ventilation within the first 7 days of life, and have been on an invasive mechanical ventilator for at least 48 hours, and have not completed 60 days after birth, and have met the traditional extubation criteria of the institution, and have been considered for elective extubation for the first time.
89510586|NCT03140943|Experimental|Carfilzomib, Thalidomide and Dexamethasone|
89510587|NCT05312138|Experimental|Transcutaneous Posterior Tibial Nerve Stimulation Group|The treatment will be carried out by the physiotherapist using the TenStem Eco Basic device.
89510588|NCT05312138|Active Comparator|Repetitive Transcranial Magnetic Stimulation Group|The treatment will be applied with a Power Mag device.
89510589|NCT04257279|Experimental|Robotic|Patients receiving spine surgery with posterior stabilization placed by ExcelsiusGPS
89510590|NCT04128423|Experimental|AMV564|
89510591|NCT05282966||Prospective Cohort with QSant Testing|2,000 participants will be enrolled across sites within 90-days post-kidney transplant and followed for 24-months
89510592|NCT05282966||Retrospective Control Cohort without QSant Testing|2,000 site-matched controls from UNOS database who underwent a kidney transplant no more than 5 years prior to the study completion date
89510593|NCT03137745||all patients undergoing CRS with HIPEC|thromboelastography was done in 60 patients undergoing CRS with HIPEC in RGCI FROM MARCH2015- MARCH 2016
89510594|NCT02035917|Experimental|Locking plate|
89510595|NCT02035917|Active Comparator|Non-Locking plate|
89510596|NCT05253716|Experimental|immune nutrition support|In the immune nutrition support group, in addition to diet, and patients will also consume two bottles per day of a high-calorie, high-protein ONS and three capsules of fish oil after discharge lasted for 6 months.
89510597|NCT05253716|No Intervention|control|In the control group, patients will receive nutrition counseling in addition to diet.
89510598|NCT02038257|Active Comparator|MKTP with CO2 Laser/Collagen Dressing|Each Subject will have a depigmented patch of skin treated with MKTP using the carbon dioxide laser for de-epithelialization and a collagen dressing for the wound dressing.
89510599|NCT02038257|Active Comparator|MKTP with CO2 laser/vaseline gauze|Each subject will have a depigmented patch of skin treated with MKTP using the carbon dioxide laser for de-epithelialization and vaseline impregnated gauze as the wound dressing.
89510600|NCT02038257|Active Comparator|MKTP with dermabrasion/collagen dressing|Each subject will have a depigmented patch of skin treated with MKTP using dermabrasion for de-epithelialization and a collagen dressing for the wound dressing.
89510601|NCT02038257|Active Comparator|MKTP with dermabrasion/vaseline gauze|Each subject will have a depigmented patch of skin treated with MKTP using dermabrasion for de-epithelialization and vaseline impregnated gauze as a wound dressing.
89510602|NCT05311436|Experimental|Experimental|"Pregnant women will receive monthly intensive dietary counseling, daily iron-folate, calcium supplementation, and at least four antenatal visits to local ANC service providers from enrollment before 16 weeks of gestation to delivery of the baby will be ensured.~Adolescent girls will receive twice-monthly nutrition education sessions to improve dietary diversity scores from enrolment to 6 months of enrollment.~Under 2y children will receive monthly growth monitoring and promotion, IYCF counseling~Severely stunted children: Daily 1 egg for 3 consecutive months and 1 sachet of multiple micronutrient powder supplementation for 6 months."
89510603|NCT05311436|No Intervention|Control|Participants will receive the standard of care in the area
89510604|NCT05210205|Experimental|EAA-enhanced food products|Consume approximately 1500 calories of EAA-enhanced food products plus ad libitum consumption of 3 combat rations each day during training.
89510605|NCT05210205|Experimental|Energy dense food products|Consume approximately 1500 calories of energy dense food products plus ad libitum consumption of 3 combat rations each day during training.
89510606|NCT05210205|Active Comparator|Control food products|Consume approximately 1500 calories of low energy dense food products plus ad libitum consumption of 3 combat rations each day during training.
89510607|NCT05253404|No Intervention|Anesthesia remove endotracheal tube|When craniotomy surgery was done, inhalation anesthestic sevoflurane level will control at MAC 2-3%, at the same time we perform suction secretions in endotracheal tube and oral cavity and give neostigmine 0.05-0.07 mg/kg and glycopyrrolate 0.01mg/kg via intravascular catheter. Removing endotracheal tube when spontaneously generating tidal volume of >4ml/kg, EtCO2<45mmHg, Train of four ratio >70-90%.
88959248|NCT02001844|Placebo Comparator|Control|"The control FOs, or placebo FOs was supplied to patients who were randomly included in the control group. The control FOs was made of leather board (1mm), grey Poron (1mm), and black EVA (0.75mm) as covering. This thin inner sole did not have any sort of biomechanical support, nor had it any effect on the distribution of pressure, as it was completely flat. In addition, the placebo FOs did not present with any intrinsic or extrinsic correction underneath the sub-talar-joint (STJ).~The use of black EVA as the covering material and the leather-board as a base, allowed for gathering of a dynamic impression over the 6 months of the trial."
89510608|NCT05253404|Experimental|Switching endotracheal tube to laryngeal mask|When craniotomy surgery was done, inhalation anesthestic sevoflurane level will control at 2.63%-2.97%, we perform suction secretions in endotracheal tube and oral cavity, then switching endotracheal tube to laryngeal mask. Then we discontinue inhalation anesthestic sevoflurane and support oxygen at the rate of 6L/min. At the same time, give neostigmine 0.05-0.07 mg/kg and glycopyrrolate 0.01mg/kg via intravascular catheter. Removing endotracheal tube when sevofulrane at MAC 0.4, spontaneously generating tidal volume of >4ml/kg, EtCO2<45mmHg, Train of four ratio >70-90%.
89510609|NCT05204355||Scleroderma|Patients with Scleroderma will be imaged with UTE MRI to compare MRI with CT for identifying Interstitial Lung Disease
89510610|NCT05204355||Scleroderma ILD|Patients with Scleroderma ILD who are initiating treatment will be imaged using hyperpolarized 129Xe MRI to assess treatment efficacy.
89510611|NCT05310890|Experimental|Tai chi training plus group activity|"Tai chi training: a teacher will give two 60-min lessons per week. Participants will play Tai Chi in the lessons, following teacher's instruction.~Group activity: a organizer will lead the subjects to participate in group activities, once per quarter."
89510612|NCT05310890|Other|Only group activity|Group activity: a organizer will lead the subjects to participate in group activities, once per quarter.
89510613|NCT05253092|Other|Virtual mindfulness meditation|
89510614|NCT01352741|Experimental|Tapentadol Prolonged Release|Tapentadol Prolonged Release (100 - 500 mg per day) Oral administration twice daily
89510615|NCT01352741|Active Comparator|Tapentadol Prolonged Release with Pregabalin|Tapentadol Prolonged Release (100 - 300 mg per day) with Pregabalin (150 - 300 mg per day) Both administered orally twice a day.
89510616|NCT03111225|Experimental|CRPS patients|CRPS patients that will be examined for trigger points in the thoracic muscles. 10 out of the 23 will also be included in the intervention stage and will recieve a month of conventional physiotherapy, and a month of conventional physiotherapy with addition of massage to the thoracic area.
89510617|NCT03111225|No Intervention|healthy controls|healthy controls that will be examined for trigger points in the thoracic muscles (and will be compared to the CRPS patients)
88959249|NCT02001844|Experimental|Trial Group|"Trial Group:~children who were randomly introduced into this group received the pre-formed semi-rigid FOs. The FOs were used as an off the-shelf device and subsequently customised with chair side modifications. In order to reproduce the exact same aesthetical appearance as the control FOs, grey poron (1mm) and black EVA (0.75mm) was used as well to cover the trial FOs.~Furthermore, depending on the type of correction applied to the trial patient, the black EVA also allowed the correction applied on the surface of the device to be masked."
88959250|NCT02001857|Experimental|TachoSil|TachoSil
88959251|NCT02001857|No Intervention|No TachoSil|No TachoSil
88959252|NCT02001870|Experimental|In Vitro Fecundation (IVF)|Couples will be treated by In Vitro Fecundation (IVF)
88959253|NCT02001870|Active Comparator|Intra Uterine Insemination (IUI)|Couples will be treated by Intra Uterine Insemination (IUI)
88959254|NCT02001883|Active Comparator|Association low-dose statin and nutraceuticals|Patients will receive the association between low-dose statin (10 to 20 mg/day of simvastatin or 5 to 10 mg/day atorvastatin) and a commercially available nutraceutical combined pill (1 capsule/day containing red yeast rice 200 mg, policosanol 10 mg, and berberine 500 mg).
88959255|NCT02001883|Active Comparator|Low-dose statin|Patients will receive low-dose statin (10 to 20 mg/day of simvastatin or 5 to 10 mg/day atorvastatin)
89510618|NCT05279768|Experimental|WJ-MSCs|Patients will be given tablet (placebo) once for 30 days, IV 0.3 million kg/bb UC-MSCs once, and nasal drop 0.5 ml/day (growth medium) for 30 days.
89510619|NCT05279768|Experimental|Secretomes|Patients will be given tablet (placebo) once for 30 days, IV placebo (NaCl 0.9%) once, and nasal drop 0.5 ml/day (Secretomes) for 30 days.
89510620|NCT05279768|Experimental|WJ-MSCs and Secretomes|Patients will be given tablet (placebo) once for 30 days, IV 0.3 million kg/bb UC-MSCs once, and nasal drop 0.5 ml/day (Secretomes) for 30 days.
89510621|NCT05279768|Placebo Comparator|Control|Patients will be given Metformin once for 30 days, IV placebo (NaCl 0.9%) once, and nasal drop 0.5 ml/day (growth medium) for 30 days.
89510622|NCT05176431|Active Comparator|Focused extracorporeal shock wave therapy|
89510623|NCT05176431|Active Comparator|Radial extracorporeal shock wave therapy|
89510624|NCT05176431|Sham Comparator|Sham extracorporeal shock wave therapy|
89510625|NCT04458987|Experimental|Expert patient in addictology|before/ after comparison, each patients being its own control
89510626|NCT04399863|Experimental|ETOILE therapeutic education|ETOILE is a patient education program, in accordance with French recommendations, which offers to patients and caregivers the opportunity to follow a customized educational training on their disease. Better quality of life and enhanced autonomy are the aim of this program.
89510627|NCT05310266|Active Comparator|Group TAP|The investigators performed transversus abdominis plane block to that patient group for postoperative analgesia
89510628|NCT05310266|Active Comparator|Group QLB|The investigators performed quadratus lumborum block to that patient group for postoperative analgesia
89510629|NCT05251532|Experimental|Kinesio Taping Group (KTG)|Distortion taping with Kinesio Tex will be applied to the patients in addition to conventional rehabilitation through a pediatric physiotherapist.
89510630|NCT05251532|Active Comparator|Conventional Rehabilitation Group (CRG)|Conventional rehabilitation program will be applied to the patients through a pediatric physiotherapist.
89510631|NCT03863067|Experimental|Lumbar spinal stenosis patients|Epiduroscopy in patients with lumbar spinal stenosis
89510632|NCT00911963|Experimental|Part A|This will be a 4 dose escalation study comparing VCH-222 to placebo treatment.
89510633|NCT00911963|Experimental|Part B|VCH-222 + peginterferon alfa-2a + ribavirin (12 weeks) followed by peginterferon alfa-2a + ribavirin for 36 weeks
89510634|NCT03139461|Experimental|Intervention|Receives PT-REFER Capacity-building toolkit to facilitate partnership building with physical therapists
89510635|NCT03139461|No Intervention|Control|Does not receive PT-REFER Capacity-building toolkit to guide partnership building, instead conducting business as usual.
89510636|NCT03139539|Active Comparator|Ioban|In this arm patients will be operated using Ioban as incisional drape.
89510637|NCT03139539|No Intervention|Control|In this arm patients will be operated using no incisional drape.
89510638|NCT00991757|Experimental|001|carisbamate Open-Label Extension: 400 mg/day (up to a maximum of 1200mg/day) given in 2 equally divided doses for up to 1 year (or until carisbamate is available by prescription or the sponsor terminates the study).
89510639|NCT01657292|Experimental|Oleogel-S10 ointment|Intra-individual comparison. Oleogel-S10 ointment is administered to one randomly assigned wound half.
89510640|NCT01657292|Other|Octenilin® wound gel|Intraindividual comparison: The other wound half receives disinfectant Octenilin® wound gel.
89510641|NCT04326491||HCC|Participants are diagnosed with HCC on top of cirrhosis
89510642|NCT04326491||Cirrhosis with no HCC|Participants are diagnosed with cirrhosis but have no HCC
89510643|NCT00907907|Experimental|Mycophenolate Mofetil (test) First|Mycophenolate Mofetil Tablets, 500 mg dosed in first period followed by CellCept® Tablets, 500 mg dosed in second period; sequence repeated in third and fourth periods.
89510644|NCT00907907|Active Comparator|Cellcept® (reference) First|CellCept® Tablets, 500 mg dosed in first period followed by Mycophenolate Mofetil Tablets, 500 mg dosed in second period; sequence repeated in third and fourth periods.
89510645|NCT03140553|Experimental|TCH|docetaxel/carboplatin/trastuzumab
89510646|NCT03140553|Active Comparator|EC-TH|epirubicin/cyclophosphamide followed by docetaxe plus trastuzumab
89510647|NCT05278988|Active Comparator|Group A|Treatment according to WHO MDR-TB treatment guidelines (2019).
89510648|NCT05278988|Experimental|Group B(PRS Regimen V)|bedaquiline, delamanid, clofazimine, pyrazinamide
88959256|NCT02001896|Experimental|erlotinib combine with chemotherapy|Drug: gemcitabine 1000mg/m2 iv on days 1 of each 4 week cycle for 6 cycles Drug: Platinum chemotherapy (cisplatin or carboplatin) cisplatin --75mg/m2 oon day 1 of each 4 week cycle for 6 cycles or carboplatin--5xAUC on day 1 of each 4 week cycle for 6 cycles Drug: Erlotinib[Tarceva] po on days 15-28 of each 4 week cycle until disease progression
88959257|NCT02001896|Active Comparator|erlotinib along|Drug: erlotinib [Tarceva] 150mg/day po until disease progression
88959258|NCT02001909|Experimental|Regorafenib|
88959259|NCT02001909|Experimental|Neomycin|
88959260|NCT02001922|Experimental|COPD integrated care|The intervention will target COPD integrated care, and include a combination of patient-related, professional and organizational elements. It will be centered on patients' needs and focus on self-management education, proactive follow-up (scheduled visits and/or phone contacts), team work, healthcare professionals' training, promotion of pulmonary rehabilitation, physical activity and smoking cessation.
88959261|NCT02001922|No Intervention|Usual care|Usual COPD care
88959262|NCT02001935|Other|theophylline|
89510649|NCT00905567|Experimental|Test First|Topiramate 2 x 25 mg Tablet
89510650|NCT00905567|Active Comparator|Reference First|Topamax® Tablet 2 x 25 mg
89510651|NCT02282020|Experimental|1/OLAPARIB|olaparib 300mg oral tablets; twice daily
89510652|NCT02282020|Active Comparator|2/CHEMOTHERAPY|Physician's choice single agent chemotherapy
89510653|NCT03847701|Active Comparator|High in SDS|Balanced diet high in Slowly Digestible Starch
89510654|NCT03847701|Placebo Comparator|Low in SDS|Balanced diet low in Slowly Digestible Starch
89510655|NCT05249972|Experimental|AKP02|cutaneous spray (calcipotriol 50 μg/g + betamethasone 0.5 mg/g/ AKVANO)
89510656|NCT05249972|Active Comparator|Enstilar|cutaneous foam (calcipotriol 50 μg/g + betamethasone 0.5 mg/g)
89510657|NCT05249972|Placebo Comparator|Placebo|cutaneous spray
89510658|NCT00904943|Experimental|Test First|Topiramate Capsules, 25 mg
89510659|NCT00904943|Active Comparator|Reference First|Topamax® Capsules, 25 mg
89510660|NCT03137979|Experimental|Group A: GMSCs and collagen scaffolds|Patients in group A will receive GMSCs seeded into collagen scaffolds at the local periodontal defects immediately after open flap debridement.
89510661|NCT03137979|Experimental|Group B: collagen scaffolds|Patients in group B will receive collagen scaffolds implantation at the local periodontal defects immediately after open flap debridement.
89510662|NCT03137979|Other|Group C: comparator|Patients in comparator group will only undergo an open flap debridement.
89510663|NCT03137589|No Intervention|Control|Patients of this group are routinely treated without telemedical support.
89510664|NCT03137589|Active Comparator|Telemedical support|Patients of this group are routinely treated with telemedical support.
89510665|NCT00902291|Active Comparator|1. Gemcitabine monotherapy|
89510666|NCT00902291|Experimental|2. Gemcitabine plus AGS-1C4D4|
89510667|NCT05276726|Experimental|Phase 1 ,Dose Exploration ,monotherapy|Dose escalation of JAB21822 will be administered as monotherapy to determine the MTD and RP2D
89510668|NCT05276726|Experimental|Phase 2, Dose Expansion, Part1 monotherapy|Part 1 dose expansion is to evaluate the safety and clinical activity of JAB-21822 at RP2D in subjects with previously untreated advanced non-small cell lung cancer (NSCLC)
89207018|NCT00547911|Experimental|LDOPS + CAR; LDOPS + ENT; LDOPS + Placebo|There are three interventions that every subject orally received over the duration of the study; 400 mg of droxidopa (LDOPS) + 200 mg placebo, 400 mg of droxidopa (LDOPS) + 200 mg carbidopa (CAR), and 400 mg of droxidopa (LDOPS) + 200 mg entacapone (ENT). The order of the three interventions was randomly assigned prior to drug administration and each intervention was followed by a wash out period of at least two days to clear previous intervention from subject's systems. This arm received the three interventions in the order of: LDOPS + CAR, followed by LDOPS + ENT, and lastly LDOPS + Placebo.
89540426|NCT06211452|Experimental|ARM B: Blocks Therapy|Block Therapy: AI block (randomized; cytarabine 500 mg/m2 as continuous infusion ×4 days and idarubicin 7 mg/m2 on days 3 and 5; intrathecal cytarabine on days 0 and 6), haM block (high-dose cytarabine 1 g/m2 every 12 hours for 3 days and mitoxantrone 10 mg/m2 on days 4 and 5, intrathecal cytarabine days 6 and 15)
89540427|NCT06211439|Active Comparator|Transcranial electrical stimulation HD-tES|real HD-tACS:anodal transcranial alternating current stimulation were delivered over the left DLPF cortex for patients in different frequencies (40Hz gamma, 4Hz theta) , with a current intensity of 2mA for 20 minutes per day.
89540428|NCT06211439|Sham Comparator|sham Transcranial electrical stimulation HD-tES|sham HD-tACS: sham transcranial alternating current stimulation were delivered over the left DLPF cortex for patients in different frequencies (40Hz gamma, 4Hz theta) , with a current intensity of 2mA for 20 minutes per day.
89540429|NCT06211400|Experimental|Vibration Exercise|
89540430|NCT06211400|No Intervention|Control|
89540431|NCT06211387|Experimental|Resistance exercise + joint mobilization|
89540432|NCT06211387|Active Comparator|Resistance Exercise|
89540433|NCT06211361|Experimental|Intervention|Participants will be included in a cardiac rehabilitation program.
89540434|NCT06211335|Experimental|Treatment (losartan, SBRT, pembrolizumab)|Patients receive losartan PO QD. One week later patients receive SBRT 2-3 times per week for approximately 2 weeks. Within 1 week of completing SBRT, patients receive pembrolizumab IV and repeat every 3 weeks. Treatment continues for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients undergo PET, tumor biopsy, and blood sample collection throughout the study.
89540435|NCT06211270|Experimental|Intervention|FRESH-T2D Intervention consisting of bimonthly food, recipes, and diabetes self-management resources + 4 meetings with Registered Dietitian Nutritionists x 6 months duration
89540436|NCT06211270|Other|Wait-Listed Control|Standard of Care for El Rio Community Health Center persons with type 2 diabetes.
89540437|NCT06211218||Cornea diseases diagnosed by artificial intelligence algorithm|
89540438|NCT06211205|Experimental|Customized nostril retainer combined with lip taping|
89540439|NCT06211205|Active Comparator|Lip taping|
89540440|NCT06211192||Group 1|"the first group consisted of infants who continued to receive ASM treatment after 12 months of age (referred to as infants still on ASM after 12 months, n=69)"
89540441|NCT06211192||Group 2|"the second group consisted of infants who had stopped ASM treatment before 12 months of age (referred to as infants who had ceased ASM before 12 months, n=88)"
89540442|NCT06211166||Acute Leukemia|Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia
89540443|NCT06211166||MDS or MDS/MPN|Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and other subtypes of Myelodysplastic/Myeloproliferative Neoplasm
88811532|NCT00845000|Experimental|Placebo→ SCH 420814 100 mg→SCH 420814 10 mg|Participants were to receive their assigned experimental treatment based on randomly assigned treatment sequence at Hour 0 following an overnight withdrawal of their antiparkinsonian medications of each treatment period. The levodopa infusion was to be started at Hour 1 and was to run for 2 hours. The participants were to also receive 25 mg of carbidopa at the following times: Hours 0, 2, and 4. Treatment periods were to be separated by at least 7 days but not more than 28 days washout between each dose.
89207019|NCT00547911|Experimental|LDOPS + ENT; LDOPS + Placebo; LDOPS + CAR|There are three interventions that every subject orally received over the duration of the study; 400 mg of droxidopa (LDOPS) + 200 mg placebo, 400 mg of droxidopa (LDOPS) + 200 mg carbidopa (CAR), and 400 mg of droxidopa (LDOPS) + 200 mg entacapone (ENT). The order of the three interventions was randomly assigned prior to drug administration and each intervention was followed by a wash out period of at least two days to clear previous intervention from subject's systems. This arm received the three interventions in the order of: LDOPS + ENT, followed by LDOPS + Placebo, and lastly LDOPS + CAR.
89540444|NCT06211166||CML|Chronic Myeloid Leukemia
89540445|NCT06211153||Asciminib|
89540446|NCT06211127|Experimental|Cold laser plaque ablation group|The disposable cold laser plaque ablation catheter (hereinafter referred to as the ablation catheter) is used in conjunction with the cold laser plaque ablation System), which is suitable for the treatment of arteriosclerosis stenosis and occlusive lesions of the lower limbs.
89510669|NCT05276726|Experimental|Phase 2 Dose Expansion, Part 2 monotherapy|Part 2 dose expansion is to evaluate the safety and clinical activity of JAB-21822 at RP2D in subjects who had received at least one previous line of systemic therapy for NSCLC
89510670|NCT03137667|No Intervention|Control|No school-located influenza vaccination clinic
89510671|NCT03137667|Experimental|School-located Influenza Vaccination|Children in intervention schools were offered a chance to receive influenza vaccination at a school-located influenza vaccination clinic, if their parent or legal guardian provided permission
89510672|NCT05218460|Experimental|All subjects will have an MRI examination|
89510673|NCT05152251||Study Group|Down Syndrome
89510674|NCT05152251||Control Group|Typically Developing Children
89510675|NCT05378009|Experimental|group A|This FD women group will include 30 females who will be treated for 8 weeks with oral proton pump inhibitors (taken one time daily with 40 mg pantoprazole-tablet dose), Benson relaxation daily sessions (twenty minutes at morning time and another 20 minutes at the evening time), physical activity ( five session per the week conducted on treadmill, 30 minutes in the first treatment month and 40 minutes in the second treatment month)
89510676|NCT05378009|Active Comparator|Group B|This FD women group will include 30 females who will be treated for 8 weeks with oral proton pump inhibitors (taken one time daily with 40 mg pantoprazole-tablet dose) and Benson relaxation daily sessions (twenty minutes at morning time and another 20 minutes at the evening time)
89510677|NCT03637023|Experimental|Virtual Reality|Virtual Reality will be applied in addition to the Anti-parkinsonian medication given by the Neurologist.
89510678|NCT03637023|Active Comparator|Exercise Therapy|Exercise Therapy will be applied in addition to the Anti-parkinsonian medication given by the Neurologist.
89510679|NCT02281552|Experimental|tofacitinib modified release tablet|
89510680|NCT02281552|Active Comparator|tofacitinib immediate release tablet|
89207020|NCT00547911|Experimental|LDOPS + ENT; LDOPS + CAR; LDOPS + Placebo|There are three interventions that every subject orally received over the duration of the study; 400 mg of droxidopa (LDOPS) + 200 mg placebo, 400 mg of droxidopa (LDOPS) + 200 mg carbidopa (CAR), and 400 mg of droxidopa (LDOPS) + 200 mg entacapone (ENT). The order of the three interventions was randomly assigned prior to drug administration and each intervention was followed by a wash out period of at least two days to clear previous intervention from subject's systems. This arm received the three interventions in the order of: LDOPS + ENT, followed by LDOPS + CAR, and lastly LDOPS + Placebo.
89207021|NCT00839280|Experimental|Arm 1|
89207022|NCT00839280|Active Comparator|Arm 2|
89510681|NCT03832647|Experimental|Salicylic acid & Epiduo 0.1%-2.5% Topical Gel|"Salicylic acid: Once-a-day, on the morning, during 12 weeks.~Epiduo gel: Once-a-day, on the evening (before bedtime) during 12 weeks."
89510682|NCT03832647|Placebo Comparator|Hydréane légère & Epiduo 0.1%-2.5% Topical Gel|"Hydréane légère: Once-a-day, on the morning, during 12 weeks.~Epiduo gel: Once-a-day, on the evening (before bedtime) during 12 weeks."
89510683|NCT00901979|Experimental|LCQ908 Dose 1|
89510684|NCT00901979|Experimental|LCQ908 Dose 2|
89510685|NCT00901979|Experimental|LCQ908 Dose 3|
89510686|NCT00901979|Experimental|LCQ908 Dose 4|
89510687|NCT00901979|Experimental|LCQ908 Dose 5|
89510688|NCT00901979|Placebo Comparator|Placebo|
89510689|NCT00901979|Active Comparator|Sitagliptin|
89510690|NCT05249582|Experimental|Virtual Reality Condition|Participants will be using a virtual reality headset to engage with a mountain climbing game.
89510691|NCT05249582|Active Comparator|Control Condition|Participants will be mimicking hand movements displayed on a television screen.
89510692|NCT03806361|Experimental|With ADRC|Supplementation of fat grafts with ADRC
89510693|NCT03806361|Active Comparator|Structural|Structural fat grafting
89510694|NCT03778671|Experimental|Group B|Patients will receive Levobupivacaine 5%
89510695|NCT03778671|Active Comparator|Group D|Patients will receive Levobupivacaine 5% + 1 µg/kg dexmedetomedine .
89510696|NCT03778671|Active Comparator|Group F|Patients will receive Levobupivacaine 5% + 1µg/kg fentanyl
89510697|NCT00978497|Placebo Comparator|1|Peginterferon and ribavirin + placebo BID for 12 weeks, followed by Peg-IFN and RBV for an additional 12 or 36 weeks
89510698|NCT00978497|Experimental|2|ANA598 200 mg BID + Peginterferon and ribavirin for 12 weeks, followed by Peg-IFN and RBV for an additional 12 or 36 weeks
89510699|NCT00978497|Experimental|3|ANA598 400mg BID + Peginterferon and ribavirin for 12 weeks, followed by Peg-IFN and RBV for an additional 12 or 36 weeks
89510700|NCT05478434|Experimental|Robot and stimulation PPC-M1|Combined paired pulse stimulation (PAS) with robot-assisted therapy
89510701|NCT05478434|Sham Comparator|Robot and sham stimulation PPC-M1|Combined sham PAS with robot-assisted therapy
89510702|NCT03692715|Experimental|ciprofloxacin|Single dose oral or intravenous ciprofloxacin prior to shockwave lithotripsy
89510703|NCT03692715|Placebo Comparator|Placebo|identical oral placebo if oral cipro was used, or intravenous saline alone in a blinded fashion if IV cipro was used prior to shockwave lithotripsy.
89510704|NCT05216120|Experimental|Pemigatinib|Participants will be provided with a bottle of pemigatinib tablets on Day 1 of each cycle (one cycle = 21 days). A bottle contains 4.5 mg X 42 tablets total. Each pemigatinib bottle is sufficient for one cycle. Resupply will be provided as necessary on Day 1 of each cycle.
89510705|NCT00973817|Experimental|ELAD|Use of ELAD for up to 6 days to stabilize liver function plus standard of care treatment plus standard of care treatment. Standard of care for acute on chronic hepatitis patients including medications and treatments typically given to patients admitted with acute hepatitis (Pentoxifylline, corticosteroids, abdominal paracentesis, nutritional therapy, etc., if indicated)
89510706|NCT00973817|Other|Standard of care|Standard of care for acute on chronic hepatitis patients including medications and treatments typically given to patients admitted with acute hepatitis (Pentoxifylline, corticosteroids, abdominal paracentesis, nutritional therapy, etc., if indicated)
89510707|NCT05161091|Experimental|Radio-induced oral mucositis / Medical Device|Patient with radio-induced oral mucositis at least grade 2 treated with experimental medical device
89510708|NCT05161091|Placebo Comparator|Radio-induced oral mucositis / Placebo comparator|Patient with radio-induced oral mucositis at least grade 2 treated with placebo
88959263|NCT02001948|Active Comparator|intrathecal morphine 0.1 mg|After routine monitorisation, intravenous cannulation and premedication, patients in this group will receive a spinal anaesthesia with 0.1 mg morphine combined with 7.5 mg heavy bupivacaine
88959264|NCT02001948|Active Comparator|0.4 mg of intrathecal morphine|After routine monitorisation, intravenous cannulation and premedication, patients in this group will receive spinal anesthesia with 0.4 mg of morphine combined with 7.5 mg of heavy bupivacaine.
89510709|NCT05161091|Experimental|Chemo-induced oral mucositis / Medical Device|Patient with chemo-induced oral mucositis at least grade 2 treated with experimental medical device
89510710|NCT05161091|Placebo Comparator|Chemo-induced oral mucositis / placebo comparator|Patient with chemo-induced oral mucositis at least grade 2 treated with placebo
88959265|NCT02001974|Experimental|Group 1|Paclitaxel 80 mg/m2 i.v. (Days 1, 8, and 15 of 28-day cycle) + reparixin oral 400 mg three times daily (t.i.d.) three weeks on one week off (three to six patients)
88959266|NCT02001974|Experimental|Group 2|Paclitaxel 80 mg/m2 i.v. (Days 1, 8, and 15 of 28-day cycle) + reparixin oral 100% increase to 800 mg t.i.d. if no toxicity in previous group (400 mg) three weeks on one week off (three to six patients)
89207023|NCT00836628|Experimental|experimental|
89207024|NCT00962637|Experimental|1|Androxal™ 12.5 mg
89207025|NCT00962637|Experimental|2|Androxal™ 25 mg
89510711|NCT00890591|Experimental|Treatment|
89510712|NCT05248334|Experimental|Ranibizumab group|"The Ranibizumab group was treated with one intravitreal injection of 0.5 mg/0.05 ml ranibizumab (Lucentis, Basel, Novartis) at baseline. While additional panretinal photocoagulation was performed if there was sufficient space and view to fill in the previously untreated areas, if needed. Repeated injections will be given after 4 weeks when the clearing of VH was incomplete (for a maximum of two injections).~If vitreous hemorrhage was not absorbed/vitreous hemorrhage aggravation/proliferation membrane formation/retinal detachment after 4 weeks of observation, the treatment was considered failed and PPV was performed."
89510713|NCT05248334|Active Comparator|PPV group|Vitrectomy to remove vitreous hemorrhage and take additional panretinal photocoagulation. If vitreous hemorrhage was not absorbed/vitreous hemorrhage aggravation/proliferation membrane formation/tractive retinal detachment after 4 weeks of observation, the treatment was considered failed and PPV was performed.
89510714|NCT05214560||All participants|Participants who require a BD Spinal needle
89510715|NCT03140787|Experimental|Nasal Spray of Lidocaine HCL|This group will receive treatment with an application of nasal spray for anesthetization.
89510716|NCT03140787|Active Comparator|Infiltration injection of Lidocaine HCL|Each patient in this group will receive an infiltration injection for anesthetization
89510717|NCT00889967|Experimental|1|Ciprofloxacin for Inhalation 100 mg/day by inhalation
89510718|NCT00889967|Experimental|2|Ciprofloxacin for inhalation 150 mg/day by inhalation
89510719|NCT00889967|Placebo Comparator|Placebo|Placebo by inhalation
88959267|NCT02001974|Experimental|Group 3|Paclitaxel 80 mg/m2 i.v. (Days 1, 8, and 15 of 28-day cycle) + reparixin oral 50% increase to 1200 mg t.i.d. if no toxicity in previous group (800 mg) three weeks on one week off (three to six patients).
88959268|NCT02002000|Experimental|vitamin D|Patients receiving 3 doses of vitamin D (cholecalciferol)
88959269|NCT02002000|Experimental|Placebo|Patients receiving 3 doses of placebo according to the same schedule as experimental arm
88959270|NCT02002013||Adult ICU patient receiving Fluid resus|Adult patients present in the ICU at the start of the study day or admitted during the 24-hour study period will be included in the study sample.
88959271|NCT02002026|Active Comparator|Ligation group|Uterine artery ligation will be done for patients in this group
88959272|NCT02002026|Placebo Comparator|Control group|Conventional CS
89207026|NCT00962637|Active Comparator|3|AndroGel®
89207027|NCT00962637|Placebo Comparator|4|Placebo
89207028|NCT00839358|Active Comparator|Albumin plus midodrine|Albumin 40 g every 15 days during 1 year or until liver transplantation. Midodrine 5mg/8h. It can be increased according the value of mean arterial pressure. If there is no increase (defined as at least 10mmHGin MAP)midodrine can be increased at a dose of 10mg/8h. This treatment will be given during 1 year or until liver transplantation.
89207029|NCT00839358|Placebo Comparator|salin solution plus pills|Placebo of albumin in the same schedule thats in arm 1; placebo of midodrine in the same schedule thats in arm 1.
89207030|NCT00962715|Experimental|TIV|TIV (Influenza Vaccine Trivalent Inactivated) alone
89207031|NCT00962715|Experimental|TIV + PEGrIFN-α|TIV + Pegylated Interferon
89510720|NCT05214404||Ulcerative colitis group|Patients with ulcerative colitis as observation group
89510721|NCT05214404||Non-ulcerative colitis group|Non-ulcerative colitis as control group
89510722|NCT03317223|Experimental|CJ-12420/Clarithromycin/Amoxicillin|CJ-12420 50mg /Clarithromycin 500mg /Amoxicillin 1g
89510723|NCT03317223|Active Comparator|Lansoprazole/Clarithromycin/Amoxicillin|Lansoprazole 30mg /Clarithromycin 500mg /Amoxicillin 1g
89510724|NCT00889889|Experimental|1|
89510725|NCT00889889|Placebo Comparator|2|
89510726|NCT02284906|Experimental|Pioglitazone 0.8 mg|Pioglitazone 0.8 mg, tablets, orally, once, daily, for minimum of 2 years.
89510727|NCT02284906|Placebo Comparator|Placebo|Pioglitazone placebo-matching tablets, orally, once, daily, for minimum of 2 years.
89510728|NCT05273138||Systemic sclerosis patients|Patients fulfilling the ACR/EULAR criteria for systemic sclerosis
89510729|NCT05273138||Healthy subjects|
89510730|NCT02566863|Experimental|Dexmedetomidine|Dexmedetomidine, 1 mcg/kg over 10 minutes, followed by a maintenance infusion, given to achieve sedation for eye surgery procedure
89510731|NCT02434263|Experimental|Hydra TAVI|Percutaneous Replacement of the Diseased Aortic Valve
89510732|NCT04127318|Experimental|Pedaling Group|During their 30 minute immunotherapy infusions, participants will pedal using a stationary cycle ergometer. Participants will be allowed to determine their pedaling intensity and cadence, however, will be encouraged to reach the established goal intensity level. A research personnel will monitor the patient's heart rate, blood pressure, and RPE at baseline and every 10 minutes throughout the pedaling session. Participants will also have treatment response biomarkers gathered at baseline and before and within 10 minutes of completing their first and fourth immunotherapy infusions. Lastly, participants will complete both a physical activity questionnaire and a quality of life questionnaire at baseline and following their fourth treatment.
89510733|NCT02398617|Other|Decision Making Intervention|At their regularly scheduled admission follow-up visit with seven days of discharge, participants will be asked to bring their medical decision maker and participate in a semi-structured supplemental palliative care/education session facilitated by a heart failure nurse practitioner trained in palliative care discussions. Domains included in the intervention will include disease literacy and understanding, goals of care, legal issues for patients with terminal illness, symptom management, health-related quality of life, caregiver burden, patient autonomy, healthcare utilization, and establishment of end-of-life plans.
89510734|NCT00968825|Active Comparator|Dose D|RT001
89510735|NCT00968825|Placebo Comparator|Dose E|Placebo
88810819|NCT05520099||Participants suspected of or diagnosed with Stage III or IV/metastatic cancer|"Subjects suspected or diagnosed with Stage III or IV:~Bladder: Urothelial Carcinoma (UC)~Kidney: Clear Cell Renal Cell Carcinoma (ccRCC)~Subjects suspected or diagnosed with Stage IV/metastatic:~Colon and Rectum: Microsatellite instability-high (MSI-H)/deficient mismatch repair (dMMR) Colorectal Cancer (CRC)~Head and Neck: Squamous Cell Carcinoma (HNSCC), excluding nasopharyngeal and salivary gland cancers~Lung: Non-small cell lung cancer (NSCLC)~Skin: Cutaneous Melanoma, excluding Uveal Melanoma~Uterus: endometrial cancer~Subjects suspected or diagnosed with:~Any metastatic solid tumor with high TMB, MSI-High or dMMR and are being considered for treatment with ICI therapy.~Any metastatic solid tumor that the clinician plans to treat with ICI therapy."
88810820|NCT05518461|Experimental|iThrive WI Intervention|Participants will receive COVID-19 and overdose-related educational and motivational content over the course of 12 weeks through the Thrive4Life Connect, a mobile health application. They will be invited to set goals for lowering overdose and COVID-19 risk.
88810821|NCT05514730|Experimental|Experimental Treatment|The experimental treatment is Phase-Based Treatment (PBT) for Problematic Sexual Behavior of Preteen Children, an innovative intervention demonstrating promise in preliminary testing.
89207032|NCT00962715|Experimental|TIV + IFNα|TIV + Interferon
89207033|NCT00836784|Experimental|1|
89207034|NCT00836784|Experimental|2|
89207035|NCT04886271|Experimental|HX009|
89207036|NCT00844116|Active Comparator|Conventional Spirometry|personal spirometry
89510736|NCT02346435||Active Surveillance|
89510737|NCT02346435||Immediate Intervention|May include patients undergoing open or minimally-invasive partial nephrectomy, radical nephrectomy or energy ablation.
89510738|NCT02346435||Crossover (Delayed Intervention)|Initially patients in active surveillance that meet progression criteria or elect to undergo delayed intervention.
89510739|NCT00967811|Experimental|1. Formulation E1|Formulation E1 of Latanoprost-PPDS
89510740|NCT00967811|Experimental|2. Formulation E2|Formulation E2 of Latanoprost-PPDS
89510741|NCT05214014|Experimental|Patients with systemic sclerosis receiving standard treatment and autologous regulatory Т-cells|Group 1: Patients with systemic sclerosis receiving standard treatment and autologous regulatory Т-cells
89510742|NCT05214014|Active Comparator|Patients with multiple sclerosis receiving standard treatment|Group 2: Patients with multiple sclerosis receiving standard treatment
89510743|NCT05074563|Active Comparator|Online REsOluTioN training|The active comparator arm will receive access to online REsOluTioN training to enhance resilience.
89510744|NCT05074563|Other|Control|The control arm will have no access to the online training.
89510745|NCT04474457||COVID-19/Favipiravir|"Turkish patient cohort diagnosed with COVID-19 and previously initiated treatment with Favipiravir."
89510746|NCT02879305|Experimental|Daprodustat|Participants will receive oral daprodustat once daily.
89510747|NCT02879305|Active Comparator|rhEPO|Participants on peritoneal dialysis (PD) will be administered darbepoetin alfa subcutaneously (SC) and participants on hemodialysis (HD) will be administered epoetin alfa intravenously (IV).
89510748|NCT05084469||Episodic Cluster Headache patients|Patients will perform two PET-MRI scans: (1) during cluster period and (2) during pain-free remission period. Scans during cluster periods will aim to acquire data before, during and after crisis. Sumatriptan 6mg will be injected subcutaneously under PET-MRI camera to relieve patient pain.
88810822|NCT05514730|Active Comparator|Control Treatment|The Control Treatment will utilize a Treatment-as-Usual (TAU) condition designed to mimic the types of treatment generally provided in the community for mental health concerns of children.
88810823|NCT05498025|Experimental|Activated charcoal pouch|The patients in this arm will receive an activated charcoal pouch (Deterra Medium Pouch, UPC #: 850006727001, Verde Environmental Technologies, Minnetonka, MN) for disposal of their opioids after their cesarean delivery pain has resolved.
88810824|NCT05497557|Experimental|Omeprazole + Sotorasib|
88810825|NCT05495984|Experimental|Primary Objective: Event-Related Potentials (ERPs)|Use ERPs elicited by unknown infant face and cry stimuli to determine whether neural markers translate to maternal mentalization in mothers with opioid use disorder (OUD) at 4-12 months postpartum
88810826|NCT05495984|Experimental|Secondary Objective: ERPs + Mothering from the Inside Out (MIO)|Use Event-Related Potentials (ERPs) elicited by unknown infant face and cry stimuli to determine whether neural response changes with participation in an evidence-based parenting intervention designed specifically for mothers with OUD: Mothering from the Inside Out (MIO).
88810827|NCT05483140||Low Energy Diet Group|A low energy diet comprising of three options and lifestyle modifications as part of a digitally enabled weight loss program.
88810828|NCT05474105|Experimental|Oral Nutritional Supplement|Daily active oral nutritional supplement (ONS) for 3 months + standard care
88810829|NCT05474105|No Intervention|Control|Standard care
88810830|NCT05468424|Experimental|FarmVille|tablet (iPad or android) based role-playing game (FarmVille)
88810831|NCT05468424|Active Comparator|puzzle games|selection of tablet (iPad or android) based word puzzles (Word Search Ultimate and Word Cookies) and image puzzles (Flow Free and Jigsaw HD)
88810832|NCT05464966|Experimental|Glucose-insulin-potassium|
88810833|NCT05464966|No Intervention|Control|
88810834|NCT05457816||family members|family members of those with rheumatoid arthritis
88810835|NCT05457816||rheumatoid arthritis|persons with rheumatoid arthritis
88810836|NCT05444699|Experimental|Prednisolone|"Prednisolone Sodium Phosphate (25 mg/5 mL) oral suspension administered 1 mg/kg* (up to 20 mg = 4 mL) once a day for 3 days.~*(0-5 kg: 5 mg; 5.01-7.5 kg: 7.5 mg; 7.51-10 kg: 10 mg; 10.01-12.5 kg: 12.5 mg; 12.51-15 kg: 15 mg; 15.01-17.5 kg: 17.5 mg; ≥ 17.51 kg: 20 mg)"
89510749|NCT00884507|Placebo Comparator|Placebo|
89510750|NCT00884507|Experimental|RO5313534 15mg|
89510751|NCT00884507|Experimental|RO5313534 1mg|
89510752|NCT00884507|Experimental|RO5313534 5mg|
89510753|NCT03139383|Placebo Comparator|normal saline solution|The patients received normal saline solution as a maintenance fluid during surgery in dose of 2 ml/kg/hour.
89510754|NCT03139383|Active Comparator|dextrose solution|The patients received dextrose solution as a maintenance fluid during surgery in dose of 2 ml/kg/hour.
89510755|NCT02281318|Experimental|Mepolizumab SC|Participants will receive Mepolizumab 100 mg subcutaneously (SC) into the upper arm or thigh every 4 weeks for a period of 24 weeks (total of 6 doses) along with their respective standard care of treatment
89510756|NCT02281318|Placebo Comparator|Placebo SC|Participants will receive placebo (0.9% sodium chloride) subcutaneously into the upper arm or thigh every 4 weeks for a period of 24 weeks (total of 6 doses) along with their respective standard care of treatment
89510757|NCT00880217|Experimental|001|JNJ-31001074 1 mg/d 1-mg capsule once daily for 42 days
89510758|NCT00880217|Experimental|002|JNJ-31001074 3 mg/d 3-mg capsule once daily for 42 days
89510759|NCT00880217|Experimental|003|JNJ-31001074 10 mg/d 10-mg capsule once daily for 42 days
89510760|NCT00880217|Active Comparator|004|Atomoxetine 80 mg/d 40-mg capsule for 3 days followed by 80-mg capsule once daily for 39 days
89510761|NCT00880217|Active Comparator|005|OROS methylphenidate HCl 54 mg/d 36-mg capsule for 3 days followed by 54-mg capsule once daily for 39 days
89510762|NCT00880217|Placebo Comparator|006|Placebo capsule once daily for 42 days
89510763|NCT05213390|Experimental|Dora follow-up phone call|DORA uses a variety of AI technologies to deliver the patient follow-up call, including: speech transcription, natural language understanding, a machine-learning conversation model to enable contextual conversations, and speech generation. Together, these technologies cover the input, processing and analysis, and output needed to maintain a natural conversation. DORA is configured to deliver calls through a telephone connection as a real-time, stand-alone system: the operator inputs individual patient details to initiate the call and completes a summary in the electronic health record (EHR) afterwards. The entire conversation will be supervised by a clinician. This clinician will be able to interrupt the call at any point if the system fails, the patient struggles to interact with it, or DORA does not collect sufficient information from the patient. The clinician will record a clinical assessment which will be compared to the DORA assessment.
89510764|NCT03139617|Active Comparator|Fascia Iliaca Compartment Block (FICB)|fascia iliaca compartment block is done using a blind technique with a blunt size 24 Gauge (G) needle. The technique is based upon the anatomical landmark and once located the space local anaesthetic ropivacaine 0.375% will be given based on the body weight.
89510765|NCT03139617|Experimental|3 in 1 femoral block (FNB)|Ultrasound guided femoral 3 in 1 block using insulated stimulating needle 22 Gauge (G). Ropivacaine 0.375% as per ideal body weight.
89510766|NCT01657760|Placebo Comparator|placebo|Intravenous saline control, in a double-blind, crossover study, with infusion days at least 2 weeks apart.
89510767|NCT01657760|Active Comparator|citalopram infusion|40 mg citalopram in 250 ml saline infused over 1 hour, in a double-blind, crossover study, with infusion days at least 2 weeks apart.
89510768|NCT00966953|Placebo Comparator|Fluoride Toothpaste|fluoride control
89510769|NCT00966953|Active Comparator|Total/Whitening|positive control
89510770|NCT00966953|Experimental|antibacterial plant extract 1|Honokiol
88810837|NCT05444699|Placebo Comparator|Placebo|Sugar syrup oral suspension containing saccharum 630-640 mg/g and aqua purificata 360-370 mg/g administered the same amount in milliliters as experimental product (up to 4 mL) once a day for 3 days.
89510771|NCT00966953|Experimental|antibacterial plant extract 2|magnolol
89510772|NCT03137511|Experimental|Intervention group|"General practitioners will be invited to screen for melanoma as part of their regular consultations.~The MG collects relevant clinical information~The MG takes 2 photographs of the lesion with his smartphone.~The MG sends to the dermatologist by e-mail the 2 photographs of the lesion accompanied by relevant clinical information~The MG calls the secretariat of the dermatologist to record the admissibility of the mail, to give the identity and the coordinates of the patient whose photos have just been sent and to obtain an appointment.~The dermatologist proposes an appointment to the patient."
89510773|NCT03137511|No Intervention|Control group|"General practitioners will be invited to screen for melanoma as part of their regular consultations.~General practitioners and dermatologists continue their practice in the usual way."
89510774|NCT00876863|Experimental|CERE-110|CERE-110: Adeno-Associated Virus Delivery of NGF
89510775|NCT00876863|Sham Comparator|Placebo|Placebo Surgery
89510776|NCT05084079|Experimental|Formula-based|Initial insulin regimen was decided according to the formula developed by the investigators previously.
89510777|NCT05084079|Placebo Comparator|Weight-based|Initial insulin regimen was decided according to current guidelines.
89510778|NCT02280304|Experimental|Inner Resources for Veterans (IRV) mindfulness and mantra|Complete a mindfulness and mantra therapy
89510779|NCT02280304|Active Comparator|Essential Skills therapy|Learn symptoms of mTBI and PTSD, coping skills
89510780|NCT03137277||Olympus 190|Olympus colonoscope 190 C (intervention group), screening colonoscopy examination with the latest generation colonoscope (190 series CF or PCF colonoscopies, Olympus Corp, Hamburg, Germany).
89510781|NCT03137277||Olympus 160/165|Olympus colonoscope 165 C (control group), screening colonoscopy examination with the 160/5 generation colonoscope (Olympus Corp, Hamburg, Germany),
88810838|NCT05431010|Experimental|electroacupuncture and rehabilitation training|Participants in this group will received electroacupuncture（EA） combined with Otago exercise program(OEP). Acupuncture will be executed with size 0.30×40mm needle. EA will be performed with electronic acupuncture instruments
89207037|NCT00844116|Experimental|Telematic Spirometry|"performed remotely on line"
89510782|NCT00963053|Experimental|VA111913 100mg twice daily|
89510783|NCT00963053|Placebo Comparator|Starch pill|
89510784|NCT05246852|Experimental|intervention group|
89510785|NCT05246852|No Intervention|control group|
89510786|NCT05084001|Experimental|38% SDF (Saforide, Toyo Seiyaku Kasei Co. Ltd., Japan)|application of silver diamine fluoride solution on occlusal surface of primary molars
88959273|NCT02001103|Active Comparator|Memantine 10 mg/day|Dosing titration with 5 mg incremental each week Clinical follow-up/assessment at week 1, 2, 4, 8, and 12 Treatment duration: 12 weeks
89510787|NCT05084001|Active Comparator|5% NaF varnish (Duraphat, Colgate Palmolive, USA)|application of sodium fluoride varnish on occlusal surface of primary molars
89510788|NCT05084001|Placebo Comparator|Tonic water|application of tonic water on occlusal surface of primary molars
89510789|NCT00961805|Experimental|Dance Group|Belly dance
89510790|NCT00961805|No Intervention|Control Group|Waiting list
89510791|NCT03137199|Experimental|Group receiving 20 million hMSCs|3 patients will receive a single administration of allogeneic hMSCs: 20 x106 (20 million) cells delivered via peripheral intravenous infusion
89510792|NCT03137199|Experimental|Group receiving 100 million hMSCs|3 patients will receive a single administration of allogeneic hMSCs: 1 x108 (100 million) cells delivered via peripheral intravenous infusion
89510793|NCT04878484|Experimental|Cohort 1: TCRT-ESO-A2: 0.3 × 1010 TCRT-ESO-A2 cells * ±30%|Subjects will be evaluated for DLTs up to 28 days post-TCRT-ESO-A2 infusion. Enrollment into a dose level will be suspended if two of no more than six subjects at a dose level experience dose-limiting toxicity. Prior to increasing the dose, a cohort management meeting will be held after the final enrolled subject has been followed for up to28 days. The decision to increase to the next dose level will be a joint decision of the clinical site Investigators and Sponsor. At each cohort, there will be at least 7 days between infusion of each subject in the cohort.
89510794|NCT04878484|Experimental|Cohort 2: TCRT-ESO-A2: 1.0 × 1010 TCRT-ESO-A2 cells ±30%|Subjects will be evaluated for DLTs up to 28 days post-TCRT-ESO-A2 infusion. Enrollment into a dose level will be suspended if two of no more than six subjects at a dose level experience dose-limiting toxicity. Prior to increasing the dose, a cohort management meeting will be held after the final enrolled subject has been followed for up to28 days. The decision to increase to the next dose level will be a joint decision of the clinical site Investigators and Sponsor. At each cohort, there will be at least 7 days between infusion of each subject in the cohort. The decision to increase to the next dose level will be a joint decision of the clinical site Investigators and Sponsor.
89510795|NCT04878484|Experimental|Cohort 3: TCRT-ESO-A2 : 3.0 × 1010 TCRT-ESO-A2 cells ±30%|Subjects will be evaluated for DLTs up to 28 days post-TCRT-ESO-A2 infusion. Enrollment into a dose level will be suspended if two of no more than six subjects at a dose level experience dose-limiting toxicity. Prior to increasing the dose, a cohort management meeting will be held after the final enrolled subject has been followed for up to28 days. The decision to increase to the next dose level will be a joint decision of the clinical site Investigators and Sponsor. At each cohort, there will be at least 7 days between infusion of each subject in the cohort.
89510796|NCT00875459|Experimental|VIAject™|Single injection
89510797|NCT05244746|Active Comparator|Rectus sheath block|
89510798|NCT05244746|Placebo Comparator|Control|
89510799|NCT03140709||Induced vaginal delivery|Saliva samples will be obtained both during induction and infusion, every 15 minutes after each change in dose. An estimated total of 5 saliva samples will be collected from each patient. Therefore, the last collection point (sample 5) will be during the oxytocin infusion after the 4th dose change. In addition, 2 blood samples will be collected from 5 patients - one baseline sample and another sample at same time as last saliva sample.
89510800|NCT03140709||Cesarian delivery|A total of 3 saliva samples will be collected from each patient - one at baseline preoperative, one intrapartum at least 15 min after starting the standard 250 ml/h oxytocin infusion, and one postpartum in post-anesthesia care unit (PACU) at least 15 min after starting the standard 125 ml/h oxytocin infusion. Therefore, the last collection point (sample 3) will be during the oxytocin infusion in PACU. In addition, 1 blood sample will be collected from each patient in this cohort - at same time as last saliva sample.
89510801|NCT05168150|No Intervention|Control Group No-expert mediated post hoc benchmark group|"30 participants. Individuals receive identical introductory information,same time, to perform, same scenarios as other groups.~Students receive their scores on 5 performance metrics compared to expert performance benchmarks. Scores are presented in the 5 minute breaks between tasks. Student goal is to be within the benchmark in all five metrics."
89510802|NCT05168150|Experimental|Experimental Group - Intelligent Continuous Expertise Monitoring System group|"30 Participants. Introductory information provided on simulator and scenario. They perform 5 simple practice subpial tumor resections with 5 minutes per trial. On 6th attempt 13 minutes to perform a complex realistic scenario.~During first practice task, participants receive no feedback. For the subsequent 4 practice tasks participants will receive real-time auditory feedback instruction by the intelligent system. After each of the 5 attempts, a student takes a 5-minute break. During each of the 5 breaks the participants will be shown the errors they made during the task by the intelligent system regarding five performance metrics monitored. After seeing each error outline, the participant will be shown a video demonstration to learn how to expertly perform on each performance metric. On their 6th attempt they will perform on the realistic scenario without any feedback given."
89510803|NCT05168150|Experimental|Experimental Group In-person expert-mediated instruction group|"30 Participants. Introductory information provided on simulator and scenario. They perform 5 simple practice subpial tumor resections with 5 minutes per trial. On 6th attempt 13 minutes to perform a complex realistic scenario.~During first practice task participants receive no feedback. For the subsequent 4 practice tasks participants receive real-time auditory feedback instruction by in-person expert during the task. After each of the 5 tasks, students takes a 5-minute break. During each of the 5 breaks the in-person expert provides feedback to the participant based on their OSATS score assessment during the previous trial. If the expert feels it is appropriate the expert will demonstrate how to do the specific procedure which has been found to be a concern on the simulator themselves so the participant can understand how to improve their performance. On their 6th attempt they will perform on the realistic scenario without any feedback given."
89510804|NCT05083767|Experimental|Whole Body Vibration|
89510805|NCT05083767|Placebo Comparator|Control Group|
88959274|NCT02001103|Active Comparator|Memantine 20 mg/day|Dosing titration with 5 mg incremental each week Clinical follow-up/assessment at week 1, 2, 4, 8, and 12 Treatment duration: 12 weeks
88959275|NCT02001103|Placebo Comparator|Placebo|Clinical follow-up/assessment at week 1, 2, 4, 8, and 12 Treatment duration: 12 weeks
89207038|NCT00836940|Placebo Comparator|1|
89540447|NCT06211127|Active Comparator|The excimer laser group|Excimer laser uses 308nm wavelength excimer laser to conduct atherosclerotic plaques through the intertwined optical fibers in the catheter, using three action mechanisms of photothermal energy, photochemical energy and acoustic mechanical energy.
89540448|NCT06211114|Experimental|PD-(L)1 inhibitor + Axitinib|Immune Checkpoint Inhibitors in Combination With Axitinib
89540449|NCT06211101|Experimental|Experimental: Intervention Group|Nurses were trained on the kangaroo care guide. Online training was given to neonatal nurses on the kangaroo care guide created by the researcher in line with the literature.
89540450|NCT06211101|No Intervention|No Intervention: Control Group|Nurses weren't trained on the kangaroo care guide.
89540451|NCT06211088|Active Comparator|famotidine plus10ml normal saline|Group A:(n. 25) will receive a 5 mg of famotidine that will be diluted to 10ml normal saline in 2 minutes preinduction.
89540452|NCT06211088|Placebo Comparator|10ml normal saline|Group B: Controlled group (n. 25) will receive a10ml normal saline preinduction.
89540453|NCT06211062|Active Comparator|Individuals with ME/CFS with IBS on active medication|Individuals with ME/CFS with IBS take Floradapt Intensive GI (another name i3.1), one high dose capsule (>3x10 to the ninth power) once daily for eight weeks.
89540454|NCT06211062|Placebo Comparator|Individuals with ME/CFS with IBS on placebo|Individuals with ME/CFS with IBS take a placebo, one capsule once daily for eight weeks.
89207039|NCT00836940|Experimental|2|GRC 8200-25mg OD
89540455|NCT06211062|Active Comparator|Individuals with ME/CFS without IBS on active medication|Individuals with ME/CFS without IBS take Floradapt Intensive GI (another name i3.1), one high dose capsule (>3x10 to the ninth power) once daily for eight weeks.
89540456|NCT06211062|Placebo Comparator|Individuals with ME/CFS without IBS on placebo|Individuals with ME/CFS without IBS take a placebo, one capsule once daily for eight weeks.
89540457|NCT06211036|Experimental|Tarlatamab in Combination With Durvalumab|Participants will receive tarlatamab once every 2 weeks (Q2W) and durvalumab once every 4 weeks (Q4W).
89540458|NCT06211036|Active Comparator|Durvalumab Alone|Participants will receive durvalumab Q4W alone.
89540459|NCT06211023|Experimental|Treatment group 1: SHR-1921|
89540460|NCT06211023|Experimental|Treatment group 2: SHR-1921 + carboplatin dose level 1|
89540461|NCT06211023|Experimental|Treatment group 3: SHR-1921 + carboplatin dose level 2|
89540462|NCT06211023|Other|Treatment group 4: platinum-based doublet chemotherapy|
89540463|NCT06210984|Experimental|Low caffeine dose|2 mg/kg dose of caffeine (in pill form)
89540464|NCT06210984|Experimental|Moderate caffeine dose|5 mg/kg dose of caffeine (in pill form)
89540465|NCT06210984|Placebo Comparator|Placebo|5 mg/kg dose of placebo (Maltodextrin in pill form)
89540466|NCT06210971|Experimental|Liposomal irinotecan-based TNT therapy|Concurrent Chemoradiotherapy (Radiation 50.4Gy/28 fractions + Capecitabine 625mg/m^2 bid + Liposomal irinotecan 50mg/m^2) followed by Chemotherapy (Capecitabine 1000mg/m^2 bid d1-7 + Liposomal irinotecan 70mg/m^2 or 50mg/m^2, d1, Q2W) before surgery.
88811533|NCT01330043|Active Comparator|Non-extended treatment|"26 weeks of CBT~10 weeks of combination bupropion plus nicotine patch~Additional 16 weeks of bupropion plus nicotine patch if increased craving or depression scores or varenicline if smoking at 10 weeks"
88811534|NCT01330043|Experimental|Extended treatment|"26 weeks of CBT~10 weeks of combination bupropion plus nicotine patch~Additional 16 weeks of bupropion plus nicotine patch if increased craving or depression scores or varenicline if smoking at 10 weeks~24 additional weeks of CBT"
89207040|NCT00836940|Experimental|3|GRC 8200-50mg OD
89207041|NCT00836940|Experimental|4|GRC 8200-50mg BD
88811535|NCT01330355|Experimental|Besivance|Besifloxacin 0.6% ophthalmic suspension
88811536|NCT01330355|Active Comparator|Gatifloxacin|Gatifloxacin 0.3% ophthalmic solution
88811537|NCT01359371||Peer telephone cessation counseling|The cohort is 131 veteran smokers who received the standard-of-care Tobacco Tactics intervention while in the hospital follow up volunteer peer telephone cessation counseling
88811538|NCT01276535|Experimental|Erchonia MLS + Erchonia THL|"The Erchonia® MLS contains 5 independent diodes: 4 each emitting 17 milliwatt (mW) 635 nanometers (nm) of red laser light and the fifth diode emitting 17 mW, 405 nm of blue laser light.~The Erchonia THL is a single diode pulsed laser that emits 4.9 milliwatts (mW) of red 635 nanometer (nm) light."
88811539|NCT01360229|Sham Comparator|Randomized Subjects receive a sham acupuncture.|Subjects will be randomized in a 1:1 ratio to receive either real or sham acupuncture.
88811540|NCT01360229|Active Comparator|Randomized Subjects receive real acupuncture.|Subjects will be randomized in a 1:1 ratio to receive either real or sham acupuncture.
88811541|NCT02193815|Experimental|One Arm|Study treatments 1-6 Study drug, vehicle, Tofacitinib, vehicle, Daivonex solution and ointment
88811542|NCT01277081|Active Comparator|Paracetamol hot drink|Hot drink containing paracetamol
88811543|NCT01277081|Active Comparator|Paracetamol tablets|Paracetamol tablets
88811544|NCT01361633|Experimental|Medication|250 mg d-cycloserine
88811545|NCT01361633|Placebo Comparator|Sugar Pill|
88811546|NCT01331213|Active Comparator|Pregabalin|Subjects randomized to this arm received a single dose of pregabalin 200mg orally.
88811547|NCT01331213|Placebo Comparator|Placebo|Subjects randomized to this arm received a single dose of placebo orally.
88811548|NCT01332071|Active Comparator|Avandamet test product|Test product: Avandamet (Rosiglitazone Maleate + Metformin) 4 miligrams (mg) + 1000 mg in Period 1, followed by a 7-day washout period during which no medication was administered, followed by reference product: Avandamet (Rosiglitazone Maleate + Metformin) 2 mg + 500 mg in Period 2
88811549|NCT01332071|Active Comparator|Avandamet reference product|Reference product: Avandamet (Rosiglitazone Maleate + Metformin) 2 miligrams (mg) + 500 mg in Period 1; followed by a 7-day washout period during which no medication was administered; followed by test product: Avandamet (Rosiglitazone Maleate + Metformin) 4 mg + 1000 mg in Period 2
88811550|NCT01277159|Experimental|Control Nerve Block. IV Dexamethasone (4 mg).|Control Nerve Block. IV Dexamethasone (4 mg).
88811551|NCT01277159|Experimental|Nerve Block with Dexamethasone (4 mg). IV saline.|B. Nerve Block with Dexamethasone (4 mg). IV saline.
88811552|NCT01277159|Experimental|Control Nerve Block. IV Dexamethasone (4 mg). IV Buprenorp|Control Nerve Block. IV Dexamethasone (4 mg). IV Buprenorphine (0.3 mg)
89540467|NCT06210958|Experimental|S-group|The patients will be received the single injection of ITPB at T5-6 level
89540468|NCT06210958|Experimental|T-group|The patients will be received the triple injection of ITPB at T4-5, 5-6, 6-7 levels
89540469|NCT06210945|Experimental|CM-101|CM-101 will be administered
89540470|NCT06210945|Placebo Comparator|Placebo|Placebo will be administered
89540471|NCT06210919|Experimental|TRTP-101|Micro-Block (MiB) manufactured from autologous Adipose-derived Mesenchymal Stem Cells
89540472|NCT06210789|Experimental|Surgical treatment|Surgical excision and periodontal reconstruction according to the remaining amount of keratinized gingiva
88959276|NCT02002039|Active Comparator|erythropoietin, perinatal asphyxia,|Treatment group
88959277|NCT02002039|Placebo Comparator|Normal saline, perinatal asphyxia|Normal saline on alternate days for 5 doses starting from first 6 hours of life
89540473|NCT06210763|Experimental|group A|twenty ICU-acquired weakness elderly patients will receive chest physiotherapy (cough training, vibration, percussion, rib springing, and postural drainage), 30 minutes of resisted training on upper- and lower-limb muscles (15 min on upper limb and 15 min on lower limb), and 30 minutes of neuromuscular electrical stimulation of lower- and upper-limb muscles (triceps and wrist extensors, dorsiflexors, and quadriceps). sessions will be executed 5 times weekly). this Group will receive 3-set IMT (two sessions daily via threshold IMT, the set contain 10 repetitions) 5 times weekly. The study duration will be 1 month.
89540474|NCT06210763|Active Comparator|group B|twenty ICU-acquired weakness elderly patients will receive chest physiotherapy (cough training, vibration, percussion, rib springing, and postural drainage), 30 minutes of resisted training on upper- and lower-limb muscles (15 min on upper limb and 15 min on lower limb), and 30 minutes of neuromuscular electrical stimulation of lower- and upper-limb muscles (triceps and wrist extensors, dorsiflexors, and quadriceps). sessions will be executed 5 times weekly). The study duration will be 1 month.
89540475|NCT06210750|Active Comparator|Arm 1 (AALL0434 regimen)|See detailed description for Arm 1
88959278|NCT02002052|Active Comparator|Standard Arm|Standard platinum-based chemoradiotherapy, total radiation dose 60 Gy in 30 fractions
88959279|NCT02002052|Experimental|Experimental Arm|Functional-lung avoidance radiotherapy, total dose 60 Gy in 30 fractions, with concurrent platinum-based chemotherapy
88959280|NCT02002065||Inactivated HAV vaccine|Inactivated vaccine: 0.5 ml per dose containing 250 u antigen, one dose
88959281|NCT02002065||Attenuated alive HAV vaccine|Attenuated alive vaccine: 1.0 ml per dose containing 6.50 lgCCID50 alive virus, one dose
88959282|NCT02002078|No Intervention|Methylprednisolone, caustic burns|
88959283|NCT02002104||EPCs|No proliferation and no differentiation on the ePTFEs
88959284|NCT02002104||Modified ePTFE|EPCs adherence, proliferation and differentiation on the ePTFEs.
88959285|NCT02002117||DNA mass spectrometry|DNA mass spectrometry
88959286|NCT02002143|Active Comparator|Individual Appointments (IAs)|"Participants randomly assigned to the IAs group will receive eight traditional 1-to-1 appointments, seeing their physician quarterly as per standard care in BC. They will be referred to ancillary services such as nutrition advice, counseling, and physical activity promotion according to 'usual care' practice. In addition, we will organize 4 1-hour social events for these participants annually. The 4 social events will be 1) a potluck lunch; 2) a movie night; 3) an event chosen by participants; and 4) a talent show. From our experience, these events enhance compliance to reporting and minimize dropouts. These events also serve to minimize 'socialization bias' that may otherwise potentially influence health measures including quality of life."
88959287|NCT02002143|Experimental|Group Appointments (GAs)|"Participants randomly assigned to the intervention group will participate in GAs of 8 patients for 1.5 hours, every 3 months for 2 years. The 3-member Care Team (MD, nurse, behaviorist) will attend each session. The nurse facilitates the session and curriculum. The MD responds to specific health questions. Patients may schedule time before or after to review their clinical results with the MD/nurse (e.g. HbAIC).~Key elements include 1) completed pre-appt questionnaires used to identify a patient's educational needs; 2) patients use goal setting and action plans to initiate and maintain healthy behaviors; 3) each class has a designated purpose and learning objectives; 4) sessional feedback, which is used to adapt the next class (3 months later) based on patient needs."
88959288|NCT02002156|Experimental|BCG at birth and routine vaccines|BCG, NeisVac-C®, Pediacel®, Infanrix™, Prevenar-13®, Menitorix®, Priorix®, Rotarix®
88959289|NCT02002156|Experimental|BCG at 3 months old and routine vaccines|BCG, NeisVac-C®, Pediacel®, Infanrix™, Prevenar-13®, Menitorix®, Priorix®, Rotarix®
88959290|NCT02002156|Experimental|Routine vaccines|NeisVac-C®, Pediacel®, Infanrix™, Prevenar-13®, Menitorix®, Priorix®, Rotarix®
88959291|NCT02002169|Experimental|Shower Technique Protocol (STP)|Participants will be given a minimum 30 minute personalized educational session by the study coordinator. They will be taught safe and clean techniques for showering with their CVC. If the participant passes the Shower Technique Test, they will be provided a pamphlet on the STP, not to be shared with other participants, to be kept as a reference and placed in their bathroom/household. They will also be given the necessary supplies for the STP.
88959292|NCT02002169|Active Comparator|Standard CVC care|Standard CVC Care consists of cleansing with chlorhexidine 2% or povidone (if allergic to chlorhexidine) at the CVC exit site by trained HD nurses followed by placement of a dry gauze dressing by the HD nurse 1x/week or when clinically indicated. In order to participate in the standard CVC care arm, participating sites must have in their policy that it is trained HD nurses who will apply the Polysporin Triple Ointment after standard cleansing with chlorhexidine 2% or povidone during HD, according to guideline recommendations or as per hospital patient care standards and nursing regulations.
88959293|NCT02002195||modified folfox|Oxaliplatin 85 mg/m2 in 2 hours intravenous infusion, + S-leucovorin 200 mg/m2, + 5-FU 2,400 mg/m2 as a 46 hours continuous infusion. The cycles are repeated every 2 weeks for a total of 8 cycle, if tumor response is stable disease, partial or complete response, then maintenance with Capecitabine 1,000 mg twice a day will be administered until disease progression, unacceptable toxicity or treatment refusal by the patient.
88959294|NCT02002234|Other|Medical Treatment Arm|Received standardized medical therapy in an intensive care unit (ICU), which included elevation of the head of bed at 30°, intermittent hyperventilation administered, and intravenous mannitol. Mean arterial pressure was maintained above 90 mm Hg. Hemoglobin concentration was maintained at all times above 90 g/L. Hyperglycemia, hyperthermia and hypotension were avoided or corrected when present.
89024161|NCT03325101|Experimental|Treatment (apheresis, pembrolizumab, cryosurgery, mDCs)|Patients undergo apheresis over 4 hours on day 1 or course 1. Patients also receive pembrolizumab IV over 30 minutes on day 1. Courses with pembrolizumab repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Within 36 hours after receiving pembrolizumab, patients undergo cryosurgery over 45 minutes on day 1 or 2 of courses 2 and 3. Patients also receive mature dendritic cells IT on day 1 or 2 of courses 2 and 3 after cryosurgery.
89024162|NCT03310918|Experimental|Collaborative palliative and oncology care|"1st palliative care visit within 96 hours of randomization in the outpatient or hospital~In outpatient setting: At least once weekly for the first 30 days and then at least twice per month thereafter palliative care clinic visits or contact via telephone~During hospital admissions to MGH: At least twice weekly palliative care visits"
89024163|NCT03310918|Active Comparator|Standard leukemia care|"Palliative care consults only upon request~Standard Leukemia care"
89024164|NCT03287544|Experimental|Combined rehabilitation|Linguistic training as well as communication training.
89024165|NCT03287544|Active Comparator|Linguistic rehabilitation|Rehabilitation only focused on linguistic processes.
89024166|NCT03260569|Active Comparator|Inhaled Nitric Oxide|Inhaled nitric oxide at 20 parts per million, administered once during first 36 hours following admission
89024167|NCT03260569|Placebo Comparator|Placebo|Nitrogen only, administered once during first 36 hours following admission
89540476|NCT06210750|Experimental|Arm 2 (AALL0434 regimen with venetoclax)|See detailed description for Arm 2
89540477|NCT06210750|Experimental|Arm 3 (AALL0434 regimen with navitoclax)|See detailed description for Arm 3
89024168|NCT03258593|Experimental|Run-In Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg|Durvalumab + Vicineum, escalating doses. Up to 2 dose levels will be evaluated in the first 6 - 12 participants.
89024169|NCT03258593|Experimental|Expansion Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg|Durvalumab + Vicineum, at the maximum tolerated dose (MTD). Up to 24 participants.
89024170|NCT03258593|Experimental|Level 1, Durvalumab 1500mg intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 20 mg|Level 1, Durvalumab 1500mg intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 20 mg
89024171|NCT03258593|Experimental|Arm 2, Durvalumab + Vicineum at the Maximum Tolerated Dose (MTD)|Arm 2, Durvalumab + Vicineum at the Maximum Tolerated Dose (MTD)
89024172|NCT03250663|Active Comparator|Arm 1 - Standard of Care|Subjects receive study medication, EUCRISA (crisaborole) ointment 2%, and follow standard of care
89024173|NCT03250663|Experimental|Arm 2 - Online Treatment Response|Subjects receive study medication, EUCRISA (crisaborole) ointment 2%, and electronic treatment response emails
89024174|NCT03241615||Neurogenic dysphagia|Patients with neurogenic dysphagia who will willing to participate in the study, being over the age of 18, normal cognitive function ([24 points according to the Mini Mental State Examination), suffering from dysphagia at least one month, and having clinically stable neurological disease will be included. Dysphagia evaluation will be performed.
89024175|NCT03223090|Experimental|Tool training group|Motor training with a tool during max 5 weeks (3 days per week, around 30 minutes per day)
89024176|NCT03223090|Active Comparator|Hand training group|Motor training with the right hand during max 5 weeks (3 days per week, around 30 minutes per day)
89207042|NCT00836940|Experimental|5|GRC 8200-100mg OD
89540478|NCT06210750|Experimental|Arm 4 (AALL0434 regimen with venetoclax and navitoclax)|See detailed description for Arm 4
89540479|NCT06210750|Active Comparator|Arm 5 (AALL0434 [no nelarabine])|See detailed description for Arm 5
89540480|NCT06210750|Experimental|Arm 6 (AALL0434 [no nelarabine] + navitoclax & venetoclax)|See detailed description for Arm 6
89540481|NCT06210750|Active Comparator|Arm 7 (AALL0434 regimen)|See detailed description for Arm 7
89540482|NCT06210750|Experimental|Arm 8 (Remission induction with venetoclax and navitoclax)|See detailed description for Arm 8
89540483|NCT06210737|Other|2 months group|
89540484|NCT06210737|Other|7-11 months group|
89540485|NCT06210737|Other|12-23 months group|
89540486|NCT06210737|Other|2-5 years old group|
89510806|NCT02283658|Experimental|Treatment (everolimus and letrozole)|Patients receive everolimus PO QD and letrozole PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89510807|NCT00872885|Experimental|A|Dose 1
89510808|NCT00872885|Experimental|B|Dose 2
89510809|NCT00872885|Experimental|C|Dose 3
89510810|NCT00872885|Active Comparator|D|Morphine
89510811|NCT00872885|Placebo Comparator|E|Placebo
89510812|NCT05088213|Experimental|Patients in Group 1 undergo suction mini percutaneous nephrolithotomy|
89510813|NCT05088213|Experimental|Patients in Group 2 undergo standard percutaneous nephrolithotomy|
89510814|NCT00871481|Experimental|Treatment (laboratory-treated T cells and ipilimumab)|Patients receive cyclophosphamide IV on day -2, therapeutic cytotoxic T lymphocytes IV over 30-60 minutes on day 0, low-dose aldesleukin SC BID on days 0-13, and ipilimumab IV over 90 minutes on days 1, 22, 43, and 64 in the absence of disease progression or unacceptable toxicity.
89510815|NCT05166122|Active Comparator|AI workflow|In AI work flow, patients will be screened by taking normal retinal images and all images will be assessed for the severity of diabetic retinopathy by a computerized artificial intelligence system immediately after the photograph is taken via the Internet and retinal images will be sent to the retinal ophthalmologist for overreading.
89510816|NCT05166122|No Intervention|Manual workflow|Volunteers who have been screened by manual workflow will be screened by imaging the retina and image that are not normal will be sent to assess the severity of diabetic retinopathy by specialist staff.
89510817|NCT05088135|Experimental|Bilateral Auricular Vagus Nerve Stimulation|
89510818|NCT05088135|Experimental|Unilateral - Right Auricular Vagus Nerve Stimulation|
89510819|NCT05088135|Experimental|Unilateral - Left Auricular Vagus Nerve Stimulation|
89510820|NCT05456165|Experimental|GRT-C901/GRT-R902 Vaccine arm|After surgical resection, patients who are circulating tumor DNA (ctDNA) positive will receive adjuvant chemotherapy for 12-24 weeks during which they will undergo neoantigen prediction, randomization, and vaccine manufacturing. After study treatment screening, patients who are still ctDNA positive with no evidence of residual or metastatic disease will receive a total of 6 doses of GRT-C901/ GRT-R902, 2 doses of ipilimumab, and 13 doses of atezolizumab. Study visits occur every 28 days.
89510821|NCT05456165|Active Comparator|Observation arm|After surgical resection, patients who are ctDNA positive will receive adjuvant chemotherapy for 12-24 weeks during which they will undergo neoantigen prediction and randomization. After study treatment screening, patients who are still ctDNA positive with no evidence of residual or metastatic disease will be observed via study visits occur every 12 weeks.
89207043|NCT00837018|Experimental|Physical exercise program|45 min, 3 times a week
89510822|NCT05083689|Active Comparator|Injections of 1.25 mg of intravitreal bevacizumab with topical drops of Timolol and Dorzolamide|31 cases in intervention group receive injections of 1.25 mg of intravitreal bevacizumab monthly for 3 months (months 0, 1 and 2) with topical drops of Timolol twice a day and Dorzolamide twice a day
89510823|NCT05083689|Placebo Comparator|Injections of 1.25 mg of intravitreal bevacizumab with artificial tears|31 cases in control group receive intravitreal injection of 1.25 mg bevacizumab monthly for 3 months (months 0, 1 and 2) plus artificial tears (twice a day as a placebo)
89510824|NCT00871325|Experimental|Daikenchuto (TU-100) 7.5g/day|Daikenchuto (TU-100) 2.5g TID (7.5g/day)
89510825|NCT00871325|Experimental|Daikenchuto (TU-100) 15g/day|Daikenchuto (TU-100) 5g TID (15g/day)
89510826|NCT00871325|Placebo Comparator|Placebo|Placebo TID
89510827|NCT05243264|Experimental|Internet-Based Program|Participants will be provided with access to a 10-session online program and will receive supportive remote assistance throughout regarding technical and programmatic issues.
89510828|NCT03492307|Active Comparator|Standard Flow Protocol|Patients randomized to this arm will receive HFNC according to our current protocol with a maximum of 8L/min.
89510829|NCT03492307|Experimental|Weight-Based Flow Protocol|Patients randomized to this arm will receive HFNC according to a weight-based algorithm at 2L/kg/min.
89510830|NCT05165966|Experimental|Experimental Group-High-dosage of COVID-19 vaccine (Vero cell), Inactivated|170 participants will receive one dose of booster vaccination with high-dosage of COVID-19 vaccine (Vero cell), Inactivated.
89510831|NCT05165966|Experimental|Experimental Group-Medium-dosage of COVID-19 vaccine (Vero cell), Inactivated|170 participants will receive one dose of booster vaccination with medium-dosage of COVID-19 vaccine (Vero cell), Inactivated.
89510832|NCT00870155|Experimental|Dirucotide|
89510833|NCT03122691|Placebo Comparator|Placebo Oral Cannabis|Single acute administration of placebo cannabis baked into a brownie
89510834|NCT03122691|Experimental|Low-Dose Oral Cannabis|Single acute administration of cannabis containing 10mg THC baked into a brownie
89510835|NCT03122691|Experimental|High-Dose Oral Cannabis|Single acute administration of cannabis containing 25mg THC baked into a brownie
89510836|NCT03122691|Placebo Comparator|Placebo Vaporized Cannabis|Single acute administration of placebo cannabis via commercial vaporizer
89510837|NCT03122691|Experimental|Low-Dose Vaporized Cannabis|Single acute administration of placebo cannabis containing 5mg THC via commercial vaporizer
89510838|NCT03122691|Experimental|High-Dose Vaporized Cannabis|Single acute administration of placebo cannabis containing 20mg THC via commercial vaporizer
89510839|NCT03497221|Other|Education intervention|The educational intervention is based on a hospital institutional protocol for patient using enteral tubes. A clinical simulation will be performed using a low fidelity manikin, where nursing technicians will identify and correct erros, such as: inconsistency between the patient's identification and the diet label, the administration of the diet with a low headboard, fixation of tube not detached and dirty, delay of the diet and others. The simulation will be described through a guide.
89510840|NCT03497221|Other|Visual identity campaign|"The visual identity will be given by a set of actions, called campaign. The campaign consists in the creation and implantation of different materials to be used at the bedside of the patients in use of diet by SNE, such as: (a) poster summarizing care, (b) colored adhesive label to identify devices (c) badge with safety care reminders."
89510841|NCT05165732|Experimental|Experimental Group 1|96 subjects who completed primary immunization with inactivated COVID-19 vaccine manufactured by Sinovac Research & Development Co.,Ltd. will receive one dose of booster immunization with inactivated COVID-19 vaccine manufactured by Sinovac Research & Development Co.,Ltd.
88959295|NCT02002234|Other|Surgery with Medical Treatment Arm|Aside from receiving standardized medical therapy, decompressive hemicraniectomy was performed by removing a large bone flap at least 12 cm in diameter and included parts of the frontal, temporal, parietal and occipital bones, with further craniectomy to the floor of the temporal fossa. The dura was opened widely and duraplasty was performed using periosteum and temporalis fascia. The bone flap was either stored in a subcutaneous pocket in the abdomen or placed in the bone bank. Cranioplasty was performed during a separate admission on an elective basis not earlier than 6 months from the initial surgery.
88959296|NCT02002247|Placebo Comparator|Placebo|Normal saline will be administered to subjects intravenously pre-operatively, upon admission to the ICU, then daily up to post-operative day 10 or ICU discharge, whichever occurs first.
88959297|NCT02002247|Active Comparator|sodium selenite|"High-dose sodium-selenite will be administered to subjects intravenously:~1) pre-operatively (2000 ug); 2) upon admission to the ICU (2000 ug), 3) then daily (1000 ug) up to post-operative day 10 or ICU discharge, whichever occurs first."
88959298|NCT02002260|Active Comparator|Levonorgestrel intrauterine system|levonorgestrel intrauterine system with 52 mg of levonorgestrel, levonorgestrel is released at a rate of approximately 20 μg/day. Inserted once, duration 5 years.
89510842|NCT05165732|Experimental|Experimental Group 2|96 subjects who completed primary immunization with inactivated COVID-19 vaccine manufactured by Beijing institute of Biological Products Co,Ltd. will receive one dose of booster immunization with inactivated COVID-19 vaccine manufactured by Sinovac Research & Development Co.,Ltd.
89510843|NCT05165732|Experimental|Experimental Group 3|96 subjects who completed primary immunization with inactivated COVID-19 vaccine manufactured by Beijing institute of Biological Products Co.,Ltd. will receive one dose of booster immunization with inactivated COVID-19 vaccine manufactured by Beijing institute of Biological Products Co.,Ltd.
89510844|NCT05165732|Experimental|Experimental Group 4|92 subjects who completed primary immunization with inactivated COVID-19 vaccine manufactured by Wuhan Institute of Biological Products Co.,Ltd will receive one dose of booster immunization with inactivated COVID-19 vaccine manufactured by Sinovac Research & Development Co.,Ltd.
89510845|NCT05165732|Experimental|Experimental Group 5|92 subjects who completed primary immunization with inactivated COVID-19 vaccine manufactured by Wuhan Institute of Biological Products Co.,Ltd will receive one dose of booster immunization with inactivated COVID-19 vaccine manufactured by Wuhan Institute of Biological Products Co.,Ltd.
89510846|NCT04474769|Experimental|Educational intervention|Intervention group's preceptors is given an eight-hour education entity about orientation and preceptorship. The objective is to enhance preceptors' knowledge and skills about the orientation and to give preceptors means to precept new graduate nurses better.
89510847|NCT04474769|No Intervention|No intervention|Nursing units at the control group continue to precept as before.
89510848|NCT04477083|Active Comparator|inhalable hydroxychloroquine (HCQ).|supportive and symptomatic treatment and inhalable hydroxychloroquine (HCQ).
89510849|NCT04477083|Placebo Comparator|Placebo|supportive and symptomatic treatment
89510850|NCT04674397||Test group|Living kidney donors
89510851|NCT04422158|Experimental|Nuun Single strength|3 Nuun electrolyte tablets will be dissolved in 1.4 liters of water. Subjects will drink one liter of the prepared solution over 30 min (250 mL every 7.5 min)
89510852|NCT04422158|Experimental|Nuun Double strength|6 Nuun electrolyte tablets will be dissolved in 1.4 liters of water. Subjects will drink one liter of the prepared solution over 30 min (250 mL every 7.5 min)
89510853|NCT04422158|Placebo Comparator|Control|Subjects will drink one liter of water over 30 min (250 mL every 7.5 min)
89510854|NCT02279524|Experimental|Aramchol 600mg|One tablet of Aramchol 400 mg and one tablet of Aramchol 200 mg.
89510855|NCT02279524|Experimental|Aramchol 400mg|One tablet of Aramchol 400 mg and one tablet of matching placebo for Aramchol.
89510856|NCT02279524|Placebo Comparator|Placebo|Two tablet of Aramchol matching placebo.
89510857|NCT03140319|Experimental|Fibroblast|Injection of Fibroblast
89510858|NCT03140319|Placebo Comparator|Placebo|the patient receive placebo injection
89510859|NCT03489655|Experimental|Maintenance Phase Intervention|Participants receive a phone-based Community Health Worker (CHW) intervention in addition to bi-monthly data collection calls with a research assistant.
89510860|NCT03489655|No Intervention|Maintenance Phase Control|Participants receive no further interventions, but have bi-monthly data collection calls with a research assistant.
89510861|NCT04474067||• Asymptomatic or Pre-symptomatic Infection|Individuals who test positive for SARS-CoV-2 by virologic testing using a molecular diagnostic (e.g., polymerase chain reaction) or antigen test, but have no symptoms.
89510862|NCT04474067||Mild COVID-19|"Individuals who have any of the various signs and symptoms of COVID-19 (e.g., fever, cough, sore throat, malaise, headache, muscle pain) without shortness of breath, dyspnea, or abnormal chest imaging.~According to NIH classification"
89510863|NCT04474067||Moderate COVID-19|COVID-19 patients who have evidence of lower respiratory disease by clinical assessment or imaging and a saturation of oxygen (SpO2) ≥94% on room air at sea level.
89510864|NCT04474067||Severe COVID-19|COVID-19 patients who have respiratory frequency >30 breaths per minute, SpO2 <94% on room air at sea level, ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (PaO2/FiO2) <300 mmHg, or lung infiltrates >50%
89510865|NCT04474067||Critical COVID-19|COVID-19 patients who have respiratory failure, septic shock, and/or multiple organ dysfunction.
89510866|NCT04474067||Sepsis|A control group of patients with sepsis-related cytokine storm
89510867|NCT04474067||CAR-T CRS|A control group of patients with cytokine release syndrome due to CAR-T therapy
89510868|NCT05478122|Experimental|Interventional|Subjects will be asked to inhale 4 ml lidocaine 4% via the Trachospray device
89510869|NCT04568395|Experimental|PLWH smoker|PLWH who smoke will undergo 3 interventions : acute TCIG use, acute ECIG use and acute sham control
88959299|NCT02002260|Active Comparator|Combined oral contraceptives|A combined ethinyl estradiol (ee) and progestin oral contraceptive pill chosen by the participants' primary gynecologic care provider. Monophasic with 30 or 35 mcg ee administered according to pill pack instructions (21 days active pills, 7 placebo pills)
88959300|NCT02002273|Experimental|Patients with regulated suction mode|On the morning of each postoperative day (starting with POD#1) patients of group 1 are switched for 4 hours to -8 cm H2O After this period of 4 hours both groups are switched back to their original pressure levels, with the effect on air leak and fluid leak measured. Pts are then left on their original pressure level until the next day, when the switch to -8 or - 20 cm H2O is again made.
89510870|NCT00861809|Experimental|Cohort 1 Period 1|All patients will receive placebo and 2 of the 3 possible doses of GSK962040 in a randomized, double blind, placebo controlled, incomplete block, three period crossover design.
89510871|NCT00861809|Experimental|Cohort 1 Period 2|All patients will receive placebo and 2 of the 3 possible doses of GSK962040 in a randomized, double blind, placebo controlled, incomplete block, three period crossover design.
89510872|NCT00861809|Experimental|Cohort 1 Period 3|All patients will receive placebo and 2 of the 3 possible doses of GSK962040 in a randomized, double blind, placebo controlled, incomplete block, three period crossover design.
89510873|NCT03138759|Experimental|Pexidartinib then Probenecid|Participants receive Sequence AB: Treatment A (pexidartinib) first, then Treatment B (probenecid), with a washout period between them
89510874|NCT03138759|Experimental|Probenecid then Pexidartinib|Participants receive Sequence BA: Treatment B (probenecid) first, then Treatment A (pexidartinib), with a washout period between them
89510875|NCT03079921|Active Comparator|Group 1-Propranolol Intra-hepatic islet|The dose of propranolol will be 0.48 μg/kilogram•minute, which will provide a total dose of 0.10 mg/kg. It will be administered 1 x only via intravenous infusion over 3.5 hours, starting 30 min before conduct of a hyperinsulinemic euglycemic (90 min) followed by hypoglycemia (90 min) clamp.
89510876|NCT03079921|Active Comparator|Group 1-Phentolamine Intra-hepatic islet|The dose of phentolamine will be 0.95 μg/kg•min, which will provide a total dose of 0.20 mg/kg. It will be administered 1 x only via intravenous infusion over 3.5 hours, starting 30 min before conduct of a hyperinsulinemic euglycemic (90 min) followed by hypoglycemia (90 min) clamp.
89510877|NCT03079921|Placebo Comparator|Group 1- Placebo Intra-hepatic islet|Placebo in 100mL NSS. Infuse Intravenously at 0.0095 ML/KG/MIN. 1 x only via intravenous infusion over 3.5 hours, starting 30 min before conduct of a hyperinsulinemic euglycemic (90 min) followed by hypoglycemia (90 min) clamp.
89510878|NCT03079921|No Intervention|Group 2 - Extra-hepatic islet|Hyperinsulinemic euglycemic (90 min) followed by hypoglycemia (90 min) clamp only.
89510879|NCT03079921|No Intervention|Group 3 - Intra-hepatic auto islet|Hyperinsulinemic euglycemic (90 min) followed by hypoglycemia (90 min) clamp only.
89510880|NCT04473989|Placebo Comparator|Placebo|Injection product without active teriparatide
89510881|NCT04473989|Experimental|PTH 40ug/w|Injection product with active teriparatide
89510882|NCT05209490|Other|Femoral nerve blockade under ultrasound control with a peripheral nerve stimulator|
89510883|NCT05209490|Other|Femoral nerve blockade under ultrasound control without a peripheral nerve stimulator|
89510884|NCT04414423|Experimental|Bone marrow concentrate|Bone marrow concentrate combined with Autogenous bone graft
89510885|NCT04414423|Active Comparator|autogenous bone graft|grafting with autogenous bone graft
89510886|NCT00861185|Experimental|Senicapoc|
89510887|NCT00861185|Placebo Comparator|Placebo|
89510888|NCT05083377||Patients who have been prescribed clozapine during 2018|Patients who have been prescribed (initially or regularly) clozapine during 2018, based on the casuistry provided by the Pharmacy service of the different hospitals.
89510889|NCT02322073||Lean healthy controls|Healthy controls with BMI 18.5-24.9 Laparoscopic surgery eg cholecystectomy, fundoplication or Heller myotomy and fundoplication or laparoscopic hernia repair.
89510890|NCT02322073||Obese|Obese BMI 35-55 Laparoscopic Roux-en-Y gastric bypass or Sleeve gastrectomy Phenotype according to cardiometabolic status
89510891|NCT03138915|Experimental|Single arm study|Patients will receive CTA, HVPG measurement, and rHVPG per protocol. Intervention: Procedure: HVPG measurement
89510892|NCT05162222|Experimental|Danicamtiv, followed by itraconazole + danicamtiv|
89510893|NCT05162222|Experimental|Danicamtiv, followed by diltiazem + danicamtiv|
89510894|NCT02283268|Experimental|Recombinant von Willebrand Factor (rVWF)|Surgery participants treated with Recombinant von Willebrand Factor (rVWF)
89510895|NCT05241158|Active Comparator|Group A|Group A: Counselling group Patients were given a briefing about the procedure; the use of local anesthetic along with potential benefits and side effects of the drug. The steps of the endoscopy procedure (gastroscopy or colonoscopy) were explained in detail including the position, intubation, biopsy or intervention wherever applicable, extubation and post-procedure observation period in the recovery room. Detailed instructions were provided regarding post-procedural care, introduction of diet & follow-up.
89510896|NCT05241158|Active Comparator|Group B|Group B: Video group Patients in the visual aid group (video group) were provided with the same information mentioned in intervention group A. In addition to that, patients watched a 5 minutes video of the respective procedure. Video showed the animation of a gastroscopy or colonoscopy procedure with a voice over explaining all the steps of the procedure in addition to the pre and post-procedure precautions to be observed.
89510897|NCT05088057|Experimental|Camrelizumab+Chemotherapy|"PD-1+AC-T: Participants receive Camrelizumab Q3W + doxorubicin Q3W + cyclophosphamide Q3W for 4 cycles, followed by Camrelizumab Q3W + docetaxel Q3W for 4 cycles as neoadjuvant therapy prior to surgery,followed by 9 cycles of Camrelizumab Q3W as adjuvant therapy post-surgery.~PD-1+TA: Participants receive Camrelizumab Q3W for 8 cycles , docetaxel Q3W + doxorubicin Q3W for 4 cycles as neoadjuvant therapy prior to surgery,followed by 9 cycles of Camrelizumab Q3W as adjuvant therapy post-surgery."
89510898|NCT03132025|Experimental|"A: apatinib and capecitabine"|"Arm A: apatinib and capecitabine apatinib 250mg qdpo; capecitabine 1000mg/m2 qdpo d1-14 q3w"
89510899|NCT03132025|Active Comparator|"B: capecitabine single drug"|"Arm B: capecitabine single drug capecitabine 1000mg/m2 qdpo d1-14 q3w"
89510900|NCT00857285|Experimental|1|olmesartan medoxomil
89510901|NCT00857285|Active Comparator|2|losartan potassium
89510902|NCT05087901||Silicone-filled eyes|
89510903|NCT04461457|Experimental|Intraperitoneal Radioimmunotherapy boost|Four groups of 3 patients with recurring ovarian cancer treated by salvage chemo-therapy and being in complete or good partial remission will receive one IP dose of 211astatine-MX35 F(ab'2). Starting at 50 MBq/L. Dose escalation 100 Mbq/L, 200 MBq/L and finally 300 MBq/L.
89510904|NCT05087511||only preterm birth|Peabody Motor Development Scale-2 was used to evaluate motor development performances and Dunn Sensory Profile was used to evaluate sensory processing
89510905|NCT05087511||riskly preterm birth|Peabody Motor Development Scale-2 was used to evaluate motor development performances and Dunn Sensory Profile was used to evaluate sensory processing
89510906|NCT02322307|Experimental|HealthPROMISE users|These are patients who will receive HealthPROMISE application. Patients will be asked to track their quality of life and quality of care using standardized metrics. A combination of different questionnaires (i.e. Short IBD Questionnaire), symptom updates, and IBD quality indicators will be the collected during this study through the HealthPROMISE application.
89510907|NCT02322307|Placebo Comparator|Control Group|After entering baseline questionnaire, control patients get a link to download education application along with PIN. Once patients install app on their devices and use the PIN, the patient is considered to be enrolled in the trial from intention to treat perspective. This control app allows access to patient education content only. There is not any direct feedback on Quality of Life, quality of care and resource utilization.
89510908|NCT00855179|Active Comparator|Antistax film-coated tablets 360 mg|Patient to receive 2 tablets daily as a morning dose, each containing 360 mg Antistax
89510909|NCT00855179|Placebo Comparator|Placebo|Patient to receive 2 tablets identical to those containing 360 mg Antistax daily as a morning dose
89510910|NCT05206604|Experimental|PF-07295324|Ointment
89510911|NCT05206604|Experimental|PF-07259955|Cream
89510912|NCT02278354|Experimental|Active Professional Fighters|Active professional fighters (with and without cognitive impairment) receiving a flortaucipir PET scan
89510913|NCT02278354|Experimental|Retired Professional Fighters|Retired professional fighters (with and without cognitive impairment) receiving a flortaucipir PET scan
89510914|NCT03137043||Severe Asthmatic Subjects|Subjects requiring high dose inhaled corticosteroids (ICS) plus a second controller (and/or systemic glucocorticosteroids) to prevent it from becoming 'uncontrolled' or which remains 'uncontrolled' despite the therapy.
89510915|NCT03137043||Non-Severe Asthmatic Subjects|Subjects with intermittent, persistent mild or moderate asthma.
89510916|NCT04461379|Experimental|BCG Vaccine|A single dose BCG vaccine intradermally 0.1 ml.
89510917|NCT04461379|Placebo Comparator|Placebo|A single dose intradermally 0.1 ml of NaCl 0.9% solution
89540487|NCT06210724||Study cohort|In addition to standard of care, three faecal samples will be obtained. On as soon as possible after diagnosis, one at three weeks post diagnosis and one at six.
89510918|NCT00854945|Experimental|ON 01910.Na|1800 mg/day of ON 01910.Na administered as a 24-hour continuous intravenous infusion on days 1, 2 and 3 of 14-day cycle.
89510919|NCT05238350|Experimental|Acupressure (intervention group)|The intervention group was performed with 45 patients. Acupressure was performed two days a week for four weeks with a total of eight sessions on the ST34, ST35, ST36, SP9, SP10, GB34 acupuncture points following an acupressure practice guide prepared by the researcher.
89510920|NCT05238350|No Intervention|Control group|Thecontrol group was performed with 45 patients. Any application was not performed for the control group.
89510921|NCT04461145|Other|ACL group|
89510922|NCT05650138|Experimental|jacobson's progressive muscular relaxation technique|Questionnaire will be used as subjective measurements of activity of daily living and Bp will be monitored for initial readings. They will receive Jacobsons muscle relaxation technique. Patients will be demonstrated with the technique to contract and relax various groups of muscles, to coordinate contractions and relaxations with deep breaths and to perform the entire procedure with eyes closed in supine lying down position. Every subject will perform this supervised relaxation for 6 repetitions during a single session on once a day basis twice a week for four weeks. At the end of 4 weeks of treatment session blood pressure will be recorded questionnaire will be filled
89510923|NCT05650138|Active Comparator|30 min walk|4 weeks, twice a week, 30 minutes walk
89510924|NCT05083221|Experimental|Hear-Talk-Activity audiological rehabilitation program|Audiological intervention program
89510925|NCT05083221|No Intervention|Control group|Waitlist control program
89510926|NCT00852839|Experimental|552-02|
89510927|NCT00852839|Placebo Comparator|Placebo|
89510928|NCT01517659|Experimental|Fat Reduction|The Zeltiq CoolSculpting System will be used to treat subcutaneous fat on each inner thigh.
89510929|NCT04876612|Placebo Comparator|Patients who received placebo after transforminal epidural steroid injection|Patients who took placebo for 12 weeks after TFESI
89510930|NCT04876612|Experimental|Patients who received limaprost (Opalmon®) after transforaminal epidural steroid injection|Patients who took limaprost (Opalmon®) for 12 weeks after TFESI
89510931|NCT05087433|Experimental|İntervention Group|"Practicing Progressive Relaxation Exercises The training of the Zoom application progressive relaxation exercise for the nurses was done in two sessions for a total of 60 minutes. During the first interview, the definition, purpose, benefits, and application techniques of PRE were explained to the nurses in the intervention group. In the second session, the steps of progressive relaxation exercises were demonstrated by the trainer.~The trainer performed the PRE exercise online with the nurses. Nurses were asked to perform the PRE application in accordance with the commands in the video recordings. In addition, a guide in which the steps of applying progressive relaxation exercises for each muscle group were written was given to the nurses. It was stated that they should do the application regularly for 25-30 minutes in the morning every day at home for a month."
89540488|NCT06210711|Placebo Comparator|Treatment as Usual|Participants in the Treatment as Usual group (TAU) will not receive the Brief PE therapy, but the standard clinical treatment received by all patients admitted to BUMC, BSWMC Temple or FH/MCW trauma centers. Treatment as usual participants will have follow-up assessments at 1, 3, and 6 months from Baseline.
89540489|NCT06210711|Experimental|Brief Prolonged Exposure|Participants in the experimental group will receive Brief Prolonged Exposure Therapy. In addition to the standard clinical treatment received by all patients at BUMC, BSWMC Temple and FH/MCW (treatment as usual), participants randomized to the intervention condition will also receive three 60-minute sessions of Brief PE. Participants in the BPE group will complete a screener and then questionnaires/interviews at 1, 2, and 6 months from Baseline.
89540490|NCT06210698||Recurrent Angioedema|Broad definition: Angioedema due to urticaria (histaminergic/mast-cell) or non-urticarial (non-histaminergic) etiology Narrow definition: non-urticarial angioedema - distinguishing between C1-Inhibitor deficiency/dysfunction, and Angioedema with normal levels of C1-Inhibitor.
89540491|NCT06210698||Healthy Subjects|Broad definition: No medical history of angioedema of any kind, including urticaria (histaminergic) or drug-induced angioedema (e.g. ACE-Inhibitor angioedema)
89540492|NCT06210659|Active Comparator|Intervention group|Theory of Planned Behavior Based Training Program will be implemented. The training program will consist of 4 sessions. Students will be monitored for 3 menstrual cycles. Starting from the end of the first menstrual period after completion of the training session, students will be asked to record their daily step count using a pedometer. In each menstrual period, the average of the students' monthly step count and average menstrual pain score will be evaluated. After the training sessions are completed, students will be given an end-of-menstrual motivational interview for 3 menstrual cycles.
89540493|NCT06210659|No Intervention|Control group|Students will be required to record their daily step count using a pedometer. Students will be monitored for 3 menstrual cycles. In each menstrual period, the average of the students' monthly step count and average menstrual pain score will be evaluated.
88959301|NCT02002273|Experimental|regulated seal mode (-8 cmH2O).|On the morning of each postoperative day (starting with POD#1) patients of group 1 are switched for 4 hours to -8 cm H2O and patients of group 2 are switched to -20 cm H2O. After this period of 4 hours both groups are switched back to their original pressure levels, with the effect on air leak and fluid leak measured. Pts are then left on their original pressure level until the next day, when the switch to -8 or - 20 cm H2O is again made.
89540494|NCT06210646|Active Comparator|citicoline arm|The citicoline arm consists of 400 patients who received 1000 mg citicoline once daily for 12 months and an open-label double antiplatelet in the form of 75 mg aspirin and 75 mg clopidogrel for three weeks, followed by a single antiplatelet in the form of 75 mg clopidogrel for the rest of our trial.
88959302|NCT02002286|Experimental|TwHF extract + cART|Use Tripterygium Wilfordii Hook F extract (TwHF extract) and continue current cART regimen
88959303|NCT02002286|Other|cART control|Continue current cART regimen
88959304|NCT02002312|Experimental|Lu-177-DOTA-girentuximab|Patients in receive 10 mg of girentuximab coupled to DOTA and labeled with 65 mCi/m2 of Lu-177 if targeting of In-111-DOTA-girentuximab is observed in at least 1 lesion. Patients may be retreated no sooner than 12 weeks after the prior treatment with a dose of no more than 75% of the previous dose, for a total of not more than three treatments.
88959305|NCT02002325|Experimental|Alteplase|Intravenous tissue-type plasminogen activator (alteplase)
88959306|NCT02002325|Other|Standard Care|Standard treatment for acute stroke
88959307|NCT02002338||Pterygium|Patients who were operated of pterygium
88959308|NCT02002351||Pulmonary disease|
88959309|NCT02002364|Active Comparator|Single use flexible optical scope|Single use flexible optical scope , Ambu aScope
88959310|NCT02002364|Active Comparator|Multiple use flexible optical scope|Multiple use flexible optical scope
88959311|NCT02002377|Experimental|Aflibercept|Aflibercept 2 mg (0.05 mL or 50 microliters) will be administered by intravitreal injection every 4 weeks for the first 8 weeks, followed by 2 mg (0.05 mL) via intravitreal injection once every 8 weeks for 36 weeks
88959312|NCT02002390|Experimental|Fingolimod (FTY720) group|Drug: Fingolimod capsules will be administered as 0.5mg/day over a course of 3 consecutive days after stroke onset.
88959313|NCT02002390|Placebo Comparator|Control group|Patients will receive usual care and drug use in hospital.
88959314|NCT02002403|Placebo Comparator|Placebo|
88959315|NCT02002403|Experimental|Optina Low Dose|Optina, 15 mg orally, twice daily
89540495|NCT06210646|Placebo Comparator|placebo arm|The placebo arm consists of 400 patients who received a placebo capsule daily for 12 months and an open-label double antiplatelet in the form of 75 mg aspirin and 75 mg clopidogrel for three weeks, followed by a single antiplatelet in the form of 75 mg clopidogrel for the rest of our trial.
89540496|NCT06210607|Experimental|HS-10511 Tablets|Subjects will be assigned to one of 5~6 planned dose cohorts in (single ascending dose)SAD and one of 4 planned dose cohorts in (multiple ascending dose)MAD.
88959316|NCT02002403|Experimental|Optina - High Dose|Optina, 45 mg orally, twice daily
88959317|NCT02002416||Metastatic gastric cancer patients|Selecte 100 cases of eligible metastatic gastric cancer patients with primary and metastatic lesion (1:1). Use the immunohistochemistry (IHC) and Fluorescence in situ hybridization (FISH) to detect the status of C-met.
88959318|NCT02002416||Early stage gastric cancer|Selected 100 cases of eligible gastric cancer patients with previously early stage gastric cancer
88959319|NCT02002429|Experimental|Intra-articular injection|Intra-articular injection into the affected facet joint(s) with 0.5 ml of a 50:50 solution containing 10 mg of depo-methylprednisolone and 0.5% bupivacaine
88959320|NCT02002429|Active Comparator|Medial branch block|Medial branch blocks at the nerves that supply the affected facet joint(s) with 0.5 ml of a 50:50 solution containing 10 mg of depo-methylprednisolone and 0.5% bupivacaine
88959321|NCT02002429|Sham Comparator|Saline injection|Injection into the affected facet joint(s) with 0.5 ml of normal saline
88959322|NCT02002442|Active Comparator|0.12% Chlorhexidine|Alcohol-free Chlorhexidine Gluconate Oral Rinse USP, 0.12% from GUM®
88959323|NCT02002442|Active Comparator|Essential oil|LISTERINE® ZERO™ Mouthwash
88959324|NCT02002442|Active Comparator|0.07% Cetylpyridinium Chloride|Crest Pro-Health Multi-Protection Rinse - Refreshing Clean Mint (Procter and Gamble)
89510932|NCT05087433|No Intervention|Control Group|No intervention was applied to the control group during the study. However, after the research was completed, the video of the application of the progressive relaxation exercises to the control group was shared on the WhatsApp group.
89510933|NCT00955799|Experimental|Neramexane mesylate|Double-blind treatment period of 29 weeks up to 75 mg Neramexane mesylate per day
89510934|NCT00955799|Placebo Comparator|Placebo|Placebo: identical placebo tablets
89510935|NCT04876534|Experimental|Tocilizumab|32 patients with active moderate-severe GO treated with i.v. tocilizumab; Tocilizumab weight adjusted, 8 mg/kg, 1 intravenous infusion every four weeks (+/- 72 hours) for 12 weeks
89510936|NCT04876534|Active Comparator|Methylprednisolone|32 patients with active moderate-severe GO treated with i.v. methylprednisolone; Methylprednisolone, 500 mg infusion weekly (+/- 48 hours) for 6 weeks, followed by 250 mg infusion weekly (+/- 48 hours) for another 6 weeks
89510937|NCT03492073|Experimental|Emotional Supportive Mindfulness-based Program|"The program is based on 15/20 minutes sessions of meditative practices in which can participate only the patients, only his/her caregiver, or both.~Number of sessions is an independent outcome, because it depends on the number of days of hospitalization."
89510938|NCT03492073|Active Comparator|Emotional Supportive Program|"The program is based on 15/20 minutes sessions based on narrative therapy, in which the patient or his/her caregiver or both can talk about their emotions.~Number of sessions is an independent outcome, because it depends on the number of days of hospitalization."
89510939|NCT05087043|Experimental|Oral Stimulation and Supplemental Nursing System group|Oral motor Stimulation (OMS) and an Supplemental Nursing System (SNS) were applied to preterm infants in the experimental group.
89510940|NCT05087043|No Intervention|control group|The clinic's routine feeding protocol was applied to the babies in the control group.
89510941|NCT02443831|Experimental|CD19/22 CAR T-cells|Patients meeting the eligibility criteria will have leukapheresis to isolate the blood immune cells used to manufacture the CD19/22CAR T-cells. Patients will receive lymphodepletion with fludarabine and cyclophosphamide prior to infusion of the CD19/22CAR T-cells.
89510942|NCT00851045|Active Comparator|Arm 1|Irinotecan/5-Fluorouracil (bolus)/5-Fluorouracil (infusional)/Leucovorin calcium/CT-322
89510943|NCT00851045|Active Comparator|Arm 2|Irinotecan/5-Fluorouracil(bolus)/5-Fluorouracil(infusional)/Leucovorin calcium /Bevacizumab/Bevacizumab Placebo(saline solution)
89510944|NCT05086887||Migrants from malaria endemic countries arriving to or living in Sweden|The study population consists of participants born in a malaria endemic country living in Sweden, irrespective of time of residency in Sweden (e.g newly arrived migrants as well as individuals with longer residency in Sweden or another non-endemic country). Participants of all ages can be included in the study.
89510945|NCT04876378||Diagnostic (questionnaires, MRI)|Patients complete a series of questionnaires over 15 minutes about knee function and pain, as well as physical activity. Patients also undergo an MRI over 60 minutes.
89510946|NCT00850577|Active Comparator|Paclitaxel/Carboplatin/CT-322|
89510947|NCT00850577|Active Comparator|Paclitaxel/Carboplatin/Bevacizumab/Placebo|
89510948|NCT04919733|Experimental|Non fluoroscopy CIED implant|Try to reduce as much as possible the fluoroscopy needed to implant a CIED pacemaker or defibrillator using a 3-D mapping system
89510949|NCT01657370|Placebo Comparator|Placebo|MK-1602 placebo-matching tablet orally for 3 doses: Dose 1 at the onset of a moderate or severe migraine (Day 1), Dose 2 in the evening of Day 3 and Dose 3 on Day 4. After 2 hours participants were able to take rescue medication if necessary.
89510950|NCT01657370|Experimental|MK-1602 1 mg|MK-1602 1 mg tablet orally for 3 doses: Dose 1 at the onset of a moderate or severe migraine (Day 1), Dose 2 in the evening of Day 3 and Dose 3 on Day 4. After 2 hours participants were able to take rescue medication if necessary.
89510951|NCT01657370|Experimental|MK-1602 10 mg|MK-1602 10 mg tablet orally for 3 doses: Dose 1 at the onset of a moderate or severe migraine (Day 1), Dose 2 in the evening of Day 3 and Dose 3 on Day 4. After 2 hours participants were able to take rescue medication if necessary.
89510952|NCT01657370|Experimental|MK-1602 25 mg|MK-1602 25 mg tablet orally for 3 doses: Dose 1 at the onset of a moderate or severe migraine (Day 1), Dose 2 in the evening of Day 3 and Dose 3 on Day 4. After 2 hours participants were able to take rescue medication if necessary.
89510953|NCT01657370|Experimental|MK-1602 50 mg|MK-1602 50 mg tablet orally for 3 doses: Dose 1 at the onset of a moderate or severe migraine (Day 1), Dose 2 in the evening of Day 3 and Dose 3 on Day 4. After 2 hours participants were able to take rescue medication if necessary.
89510954|NCT01657370|Experimental|MK-1602 100 mg|MK-1602 100 mg tablet orally for 3 doses: Dose 1 at the onset of a moderate or severe migraine (Day 1), Dose 2 in the evening of Day 3 and Dose 3 on Day 4. After 2 hours participants were able to take rescue medication if necessary.
89510955|NCT00838981|Active Comparator|Modafinil Plus Contingency Magagement|Modafinil from 200mg up to 400mg plus Contingency Management
89510956|NCT00838981|Placebo Comparator|Sugar Pill Plus Contingency Management|Placebo: sugar pill
89510957|NCT00838981|Active Comparator|Modafinil Plus Voucher Control|
89510958|NCT00838981|Placebo Comparator|Sugar Pill Plus Voucher Control|
88959325|NCT02002442|Placebo Comparator|Saline|
89510959|NCT00849797|Experimental|Oxcarbazepine|Oxcarbazepine 600 mg Tablet (test) dosed in first period followed by Trileptal® 600 mg Tablet (reference) dosed in second period
89510960|NCT00849797|Active Comparator|Trileptal®|Trileptal® 600 mg Tablet (reference) dosed in first period followed by Oxcarbazepine 600 mg Tablet (test) dosed in second period
89510961|NCT05082441|Experimental|experimental|Exparel group
89510962|NCT05082441|Active Comparator|control|plain bupivacaine
89510963|NCT00950885|Placebo Comparator|Placebo|placebo control group will receive 4 doses of identically-appearing capsules containing cellulose
89540497|NCT06210607|Placebo Comparator|HS-10511 Tablets Placebo|Subjects will be assigned to one of 5~6 planned dose cohorts in SAD and one of 4 planned dose cohorts in MAD.
89540498|NCT06210581|Experimental|Group I|The treatment sessions will be terminated by performing relaxation exercises combined with stretching and breathing exercises.
88959326|NCT02002455|Experimental|Multimodality imaging|PET/CT, PET/MRI, mpMRI
88959327|NCT02002468|Experimental|Test result sent by letter|The pap-smear test result is sent by letter directly to the women. Women in need of follow up are in the letter recommended to contact their general practitioner.
88959328|NCT02002468|Active Comparator|Test result conveyed by general practitioners|In Denmark it is a standard procedure that general practitioners convey the pap-smear test results to the women.
88959329|NCT02002481|No Intervention|Control|10 minutes ALS-CPR in a normal environment
88959330|NCT02002481|Experimental|Transport|10 minutes ALS-CPR during a transport
88959331|NCT02002520||case group|patients undergo third molar surgery
88959332|NCT02002520||control group|subjects do not require surgery
88959333|NCT02002546||ED chest pain presenting patients|
88959334|NCT02002559||NBI Magnify Endoscopy|Detection of esphageal neoplasia through recognition of brownish discolored area via NBI and characterize the lesion using IPCL upon magnifying endoscopy
88959335|NCT02002559||Lugol Chromoendoscopy|Detection of esophageal neoplasia through recognition of discolored area
88959336|NCT02002585|Experimental|RDN and optimal medical therapy|Renal denervation will be performed using the available denervation device with a european approval according to current guidelines. The same device will be used for all patients in this arm to avoid efficacy bias.
88959337|NCT02002585|No Intervention|optimal medical therapy alone|Group of patients who will be treated only with optimal medical therapy and will not be denervated. Subsequently, the patients will be followed in our cardiology and nephrology department according to the study flowchart for 3 years according to the standard of care in our institution for patients with chronic renal insufficiency.
89510964|NCT00950885|Experimental|Low dose melatonin|0.5 mg melatonin
89510965|NCT00950885|Experimental|High dose melatonin|3.0 mg melatonin
89510966|NCT02033421||Pharmacokinetics Beta-lactam antibiotics|Patients with infective endocarditis treated with Beta-lactam antibiotics
89510967|NCT00849485|Experimental|Levetiracetam|Levetiracetam 750 mg Tablet (test) dosed in first period followed by Keppra® 750 mg Tablet (reference) dosed in second period
89510968|NCT00849485|Active Comparator|Keppra®|Keppra® 750 mg Tablet (reference) dosed in first period followed by Levetiracetam 750 mg Tablet (test) dosed in second period
89510969|NCT03140397|Placebo Comparator|Placebo|Capsules filled with mannitol and silicon dioxide
89510970|NCT03140397|Experimental|6-prenylnaringenin|500 mg 6-PN plus mannitol and silicon dioxide
89510971|NCT03140397|Experimental|8-prenylnaringenin|500 mg 8-PN plus mannitol and silicon dioxide
89510972|NCT05235854|Active Comparator|Meniscal wall infiltration group|Administration of Diprostene: 1 ml syringe of Betamethasone 2 mg; injectable suspension in pre-filled syringe under ultrasound control.
89510973|NCT05235854|Active Comparator|Intra-articular infiltration group|"The procedure is identical in all respects to the experimental group, except that the ultrasound procedure is mimicked and the infiltration of dexamethasone 2 mg (Diprostene®) is performed intra-articularly.~Administration Diprostene: 1 ml syringe of Betamethasone 2 mg; injectable suspension in pre-filled syringe."
89510974|NCT05074251|Experimental|HIV self testing|HIV+ women will receive HIV self-tests (2) to bring home to her partner to offer for testing
89510975|NCT05074251|Active Comparator|Standard of care|In the standard of care arm, women will receive standard of care partner referrals for HIV testing, including counselling about disclosure and referral for her partner(s) to return to the facility for testing.
89510976|NCT05086445|Experimental|LY3502970 (Part A)|Single doses of LY3502970 administered orally.
89510977|NCT05086445|Experimental|LY3502970 (Part B)|Multiple doses of LY3502970 administered orally.
89510978|NCT05086445|Placebo Comparator|Placebo (Part A)|Placebo administered orally.
89510979|NCT05086445|Placebo Comparator|Placebo (Part B)|Placebo administered orally.
89510980|NCT05158478|Experimental|Subject glucometer measurement|
89510981|NCT05086185||Orange Juice (control)|Orange juice providing a 0.35 mEq/kg dose of potassium
89510982|NCT05086185||Orange Juice plus Fiber|Same amount of orange juice as Orange Juice treatment with 0.15 g/kg of psyllium-based fiber added
89510983|NCT05047445|Experimental|COVIDITY administered via needle-free intradermal injection (PharmaJet Tropis)|
89510984|NCT05047445|Experimental|COVIDITY administered via needle-free intramuscular injection (PharmaJet Stratis)|
89510985|NCT05203484|Experimental|Multielectrode mapping|Participants assigned to the Multielectrode Mapping arm will undergo VT ablation within 48 hours after baseline evaluation. The Mapping procedure will be performed with either a Pentaray or Octaray catheter (Biosense Webster; each 45 catheters, randomly allocated). Catheter ablation of potential diastolic pathways and Scar homogenisation will be performed with a irrigated 3.5mm tip catheter (QDot; Biosense Webster).
89510986|NCT05203484|Active Comparator|Point-by-Point Mapping|Participants assigned to the Point-by-Point Mapping arm will undergo VT ablation within 48 hours after baseline evaluation. The Mapping procedure will be performed with a QDot catheter (Biosense Webster). Catheter ablation of potential diastolic pathways and scar homogenisation will also be performed with the QDot catheter.
89510987|NCT04851405|Active Comparator|Otago Exercise Programme+ Intervention Group (OEP+)|"Physiotherapists receive OEP training, a 2 hour workshop on the coaching protocol using the OEP app, and online training on the Brief Action Plan Approach with 2 telephone practice sessions with an experienced Brief Action Plan counsellor.~Each PT will deliver exercise program to 8 older adults. PTs will help older adults to set-up OEP app and Fitbit. PT will return bi-weekly over the course of two months (four visits total) for follow-up. During months 3-5, PTs will call participants three times times to review the exercise plan. The last visit will be an at-home visit which will occur 6 months after the initial visit. Between Months 7-12, PTs will continue to a phone call follow-up once a month to review the exercise routine.~Older Adults will receive an OEP manual and cuff weights to be used with the strength training. They will also have access to the OEP app which allows the PT to prescribe exercises and record the participant's exercise goal."
89540499|NCT06210581|Other|Group II|Patients who are in the internet-based exercise program group will register cite ''https://www.telenororehab.com /'' which is web- based physiotherapy program for exercises.
89540500|NCT06210568||Infertile Male Patients|
89540501|NCT06210568||Fertile males|
89540502|NCT06210529|Experimental|Group A (treatmen once)|
89540503|NCT06210529|Experimental|Group B (treatmen twice)|
89540504|NCT06210503|Active Comparator|PENG group|The patient will undergo pericapsular nerve blockade with 0.5% ropivacaine based on 3 mg/kg ropivacaine using ultrasound scanning.
89540505|NCT06210503|Active Comparator|FICB group|The patient will undergo FICB with 0.5% ropivacaine based on 3 mg/kg ropivacaine using ultrasound scanning.
89540506|NCT06210490|Experimental|Adjuvant therapy group|
89540507|NCT06210490|Active Comparator|Non-adjuvant therapy group|
89540508|NCT06210477||Low compliance|Low urinary tract symptoms with low bladder compliance
89540509|NCT06210451|Experimental|Gel group|Speculum insertion using sterile water-based gel
89540510|NCT06210451|No Intervention|Sterile water group|Speculum insertion using sterile water
89540511|NCT06210438|Experimental|SHR-A1921 + Bevacizumab|
89540512|NCT06210412|Experimental|health education and yoga intervention group|"Health education program based on the Penderin Health Promotion Model; It consists of 10 sessions as a program focused on the management of menopause (increasing the quality of life by teaching physical, psychological and social coping methods in menopause, yoga practices and their importance). In the first week, introduction, first tests (Sociodemographic data form, MÖYKÖ), and general introduction of the program will be made. It is a program in which active education methods (question and answer, role play, demonstration, etc.) are used, with each session planned to last approximately 30 minutes. Final tests will be performed at the end of 12 weeks.~Yoga practice will be carried out as 45-minute sessions 2 days a week, which will last for 12 weeks, following the health education program.12. At the end of the week, MOQÖ and Yoga Transformation Impact Scale will be applied to those who have completed 10 weeks."
89540513|NCT06210412|No Intervention|Control group|Voluntary consent forms, which will be informed during the interview, and a sociodemographic data form, Menopause-Specific Quality of Life Scale, will be filled in by participants who wish to participate in the research. They will then be invited to undergo final testing after 12 weeks.
89540514|NCT06210399|Experimental|Extracorporeal Shockwave Therapy|The parameters for shock wave therapy will be: frequency 4-6 Hz, intensity 0.075-0.11 mJ/mm2 (millijoules per millimeter), number of pulses 350+10xcm2 (square centimetre) of wound surface (the number of pulsations is dependent of the surface), with sterile field (sterile gel on the wound and sterile transparent film to cover it). They will be applied by sweeping the surface of the wound and 1 centimetre around it. In each session, the session-specific data notebook and the appearance of side effects (pain, bleeding, others) will be recorded. Subsequently, the conventional healing procedure will be applied, according to the procedures for healing chronic wounds of the Guadarrama Hospital.
89540515|NCT06210373|Experimental|Myrialen Gel Group|Myrialen® gel: sterile ophthalmic gel containing 5% dexpanthenol
89540516|NCT06210373|Active Comparator|Recugel Group|Recugel®: sterile ophthalmic gel containing 5% dexpanthenol
89540517|NCT06210360|Experimental|Group A: NALIRIFOX + surgery + NALIRIFOX|Patients receive 8 cycles of NALIRIFOX. Then undergo surgery and receive 4 cycles of NALIRIFOX after surgery. NALIRIFOX consists of irinotecan liposome injection, oxaliplatin, 5 FU/LV
88959338|NCT02002598|Experimental|CFZ with bendamustine and dexamethasone|Subjects will receive Carfilzomib on Days 1, 2, 8, 9, 15, and 16 every 28 days with dose escalation from 27, 36, 45 to 56 mg/ m2 . No matter what target dose the subject will receive, days 1 and 2 doses in the first cycle will always be 20 mg/m2, followed by target dose for all subsequent dates and cycles. Bendamustine will be given IV on days 1 and 2 with dose escalation up to 90 mg/m2 and dexamethasone 20 mg orally or intravenously on 1, 2, 8, 9, 15, 16, 22 and 23 of each 28-day cycle. Study treatment will be given until 8 cycles of treatment are completed or until disease progression, whichever comes first.
88959339|NCT02002611|Experimental|Lobeglitazone|Subjects received Lobeglitazone 0.5 mg daily for 12 days in one period and in the other period, Subjects don't receive Lobeglitazone.
88959340|NCT02002611|Experimental|Warfarin|Subjects received Warfarin 25 mg once at period 1 and 2.
88959341|NCT02002624|Active Comparator|Conventional|Conventional instrumentation
88959342|NCT02002624|Experimental|PSI|Patient specific instrumentation
88959343|NCT02002637|Experimental|Latella Knee Implant System|
88959344|NCT02002663|Experimental|ropivacaine + methylprednisolone|Continuous infusion of Ropivacaine 0.2% and methylprednisolone 1mg/kg 10ml/h through intralesional catheter for 24 hours
88959345|NCT02002663|Placebo Comparator|saline|Continuous infusion of saline through intralesional catheter for 24 hs
88959346|NCT02002715|Active Comparator|Inhaled budesonide for 4 weeks|inhaled Budesonide 100µg , 2puff Q12h for 4 weeks
88959347|NCT02002715|Active Comparator|Inhaled budesonide for 8 weeks|inhaled Budesonide 100µg , 2puff Q12h for 8 weeks
88959348|NCT02002715|Active Comparator|Inhaled budesonide for 16 weeks|inhaled Budesonide 100µg , 2puff Q12h for 16 weeks
88959349|NCT02002741|Active Comparator|Ibuprofen + Paracetamol|"Ibuprofen 10mg/kg once --> 5mg/kg twice, q 24h for total of 3 doses~+ Intravenous Paracetamol : Loading dose 20mg/kg --> 10 mg/kg q6h for total of 12 doses"
88959350|NCT02002741|Placebo Comparator|Ibuprofen + Placebo|"Ibuprofen 10mg/kg once --> 5mg/kg twice, q 24h for total of 3 doses~+ Placebo (NaCl 0.9%) , Intravenous , at equal volume to the paracetamol in the paracetamol arm, total of 12 doses given q 6h."
88959351|NCT02002754|Active Comparator|Eosinophilic bronchitis|Bambuterol Hydrochloride tablets 10mg,QN,for 3 days
88959352|NCT02002754|Active Comparator|cough variant asthma|Bambuterol Hydrochloride tablets 10mg,QN,for 3 days
88959353|NCT02002780|Experimental|Subjects|"Children identified during the screening phase of the project as having elevated, but not clinically defined, levels of psychosocial stress will be invited to participate in the intervention phase of this research if they are between 8 and 11 years of age.~Screening will identify 6 girls and 6 boys eligible and willing to participate in the intervention phase of the project."
89540518|NCT06210360|Active Comparator|Group B: surgery + NALIRIFOX|Patients receive 12 cycles of NALIRIFOX after surgery. NALIRIFOX consists of irinotecan liposome injection, oxaliplatin, 5 FU/LV.
89540519|NCT06210321|Other|Intervention arm|Adjustment of antidepressant treatment according to pharmacogenetic results obtained by genetic testing for cytochrome CYP 2C19 (alleles *2, *3 and *17)
89540520|NCT06210321|No Intervention|Control arm|Delivery of escitalopram treatment as prescribed. Genetic analysis will be performed in batch at the end of the follow-up period.
89540521|NCT06210295||Anemia and Systemic lupus erythematosus|Systemic lupus patients with anemia and searching for causes of anemia and what is the most common and what are the causes of refractory anemia and relation of bone marrow affection
89540522|NCT06210282|Active Comparator|Usual Care|Participants assigned to the usual care group will receive the general practitoner's usual care of adults (≥ 18 years) presenting with symptoms of an acute lower respiratory tract infection (LRTI) where the GP suspects community-acquired pneumonia. Usual care will be used as a pragmatic comparator to reflect the current standard examinations and care of this patient population in general practices in Denmark. Usual care is recommended to follow applicable guidelines from the Danish Society of General Practitioners and The Doctor's Handbook. Focused lung ultrasound (FLUS) is currently not standard or even a common examination in Danish general practices. Even for GPs already using point-of-care ultrasound on a weekly basis, FLUS is not part of usual care for adults presenting with symptoms of an acute LRTI
89540523|NCT06210282|Experimental|Usual Care + Focused lung ultrasound (FLUS)|Participants assigned to the intervention group will receive a focused lung ultrasound examination (FLUS) during the index consultation (day 0) as an addition to usual care.
89540524|NCT06210269|Active Comparator|Antibiotic treatment|Oral moxifloxacin 400 mg once daily for seven days
89540525|NCT06210269|Active Comparator|Placebo|Identical oral administration and treatment duration of seven days
89540526|NCT06210256|Experimental|the unidirectional valve group|In the unidirectional valve group, as soon as disinfection and draping began, the lumen of the Y-connector to the non-ventilated lung was clamped and the unidirectional valve device was fastened to the bronchoscope port of the tracheal lumen to initial the one-lung ventilation.
89540527|NCT06210256|Active Comparator|the closed lumen group|In the closed lumen group, as soon as disinfection and draping began, the lumen of the Y-connector to the non-ventilated lung was clamped, and the bronchoscope port of the tracheal lumen was sealed off from the atmosphere until pleural opening. When the pleura opened, the bronchoscope port opened to the air for 30 seconds before closing once more until the one-lung ventilation was completed.
89540528|NCT06210243|Experimental|C752|
89540529|NCT06210217|Experimental|Dobutamine group|In the dobutamine group, 3~6μg/kg/min dobutamine will be injected intravenously after anesthesia induction until hemostasis is completed. To ensure preload, TEE will be used to monitor LVEDV and SV.
89540530|NCT06210217|Placebo Comparator|Control group|In the control group, 3mL/h normal saline will be injected intravenously after anesthesia induction until hemostasis is completed, and the liquid will be restricted according to the currently commonly used principle of LCVP, nitroglycerin can be used if necessary.
89540531|NCT06210204|No Intervention|In-Person|Patients will follow-up in-person after surgery
89024177|NCT03212742|Experimental|IMRT - Temozolomide - Olaparib|"The therapeutic regimen will be divided into 2 different periods:~Radiotherapy period The patient will start IMRT (60Gy/30fr/6 weeks), TMZ(Temozolomide) chemotherapy (75mg/m²/day), and olaparib on the same day, on a Monday (day 1), within 6 weeks after surgery. The daily dose of TMZ (75 mg/m²) will be continued until the end of radiotherapy (6 weeks) and olaparib will be continued with the same dose until 4 weeks after the end of IMRT, as a single agent.~Maintenance period TMZ will then be re-introduced 4 weeks after the end of IMRT at the dose of 150 mg/m2/day on days 1 to 5 every 28 days, for a total of 6 cycles. Concomitantly, olaparib will be daily given at the maintenance dose level up to confirmed disease progression or unacceptable toxicities.~We propose 7 dose levels to reach the target dose of 400 mg per day (200 mg twice daily) of olaparib continuously"
89540532|NCT06210204|Experimental|Telehealth|Patients will follow-up via phone after surgery
89540533|NCT06210178|Other|MRI|Noninvasive MRI is performed.
89024178|NCT03193814|Experimental|Chemotherapy + Apatinib|chemotherapy regimens include: Folfox (Oxaplatin 85 mg/m2 IV over 2 hours, day 1; Leucovorin 400 mg/m2 over 2 hours, day 1; 5-FU 400 mg/m2 IV bolus on day 1, then 1200mg/m2/day x 2 days; repeat every 2 weeks) or Folfiri (Irinotecan 150-180 mg/m2 IV over 30-90 minutes, day 1; Leucovorin 400 mg/m2 over 2 hours, day 1; 5-FU 400 mg/m2 IV bolus on day 1, then 1200mg/m2/day x 2 days; repeat every 2 weeks)； apatinib 500mg po qd
89024179|NCT03191916|Experimental|Experimental group|The experimental group will receive 2 milliamps of anodal transcranial direct current stimulation for 20 minutes daily for 5 days.
89024180|NCT03191916|Sham Comparator|Sham group|The sham group will be connected to the anodal transcranial direct current stimulation device daily for 5 days. During the 20 minute sessions, the participant will only receive stimulation for a 30-second ramp up period, at which point the stimulation will be discontinued for the remainder of the time.
89210497|NCT00629798|Experimental|1|This is a single arm phase II trial to assess the efficacy (decrease the transplant related mortality) and safety of peri-transplant Palifermin in combination with a preparative regimen with busulfan, melphalan, fludarabine, and anti-thymocyte globulin (ATG), and a T cell depleted stem cell transplant from a histocompatible related or unrelated donor in patients with advanced MDS and AML evolved from MDS. The addition of Palifermin is to decrease the toxicity and the infection rate associated with this regimen and transplant type and to foster earlier immune reconstitution.
89540534|NCT06210165|Experimental|Sugammadex|IV Sugammadex 4mg/kg once after Train of Four ratio 0.7 to 0.9
89540535|NCT06210165|Active Comparator|Neostigmine and atropine|IV Neostigmine 40mcg/kg and IV Atropine 10mcg/kg once after Train of Four ratio 0.7 to 0.9
89540536|NCT06210152||Radial Extracorporeal Shockwave Therapy|
89540537|NCT06210152||Sham Extracorporeal Shockwave Therapy|
89540538|NCT06210087|Experimental|Spontaneous pushing|The researcher provided training on the spontaneous pushing technique to the pregnant women selected for the experimental group in the first stage of labor and showed how to do it. During the second stage of labor, the women were encouraged and supported in this direction.
89540539|NCT06210087|No Intervention|Valsalva-type pushing|Routine procedures of the delivery room were performed on the pregnant women in the control group, and the researcher carried out no intervention.
89210498|NCT00160615|Experimental|Levetiracetam|Subjects received oral tablets of Levetiracetam. This study N01020 (NCT00160615) was designed as a single group assignment study and as follow-up study, open for patients from N165 (NCT00600509). The differentiation into placebo and Levetiracetam in the results reporting section is based on the treatment of the previously conducted study N165 (NCT00600509).
89540540|NCT06210061|Active Comparator|Group A (Propofol-Fentanyl)|Anesthesia will be induced with propofol (2mg/kg) and fentanyl (1 ug/kg). Anesthesia will be maintained with propofol and fentanyl infusion, commenced at 10 mg/kg/hr and 0.5 ug/kg/hr respectively and adjusted to keep BIS between 40 & 50 during surgery. Minimal dose of atracurium 0.1 mg/kg will be given at induction to facilitate intubation.
89540541|NCT06210061|Experimental|Group B (Propofol-Fentanyl-Dexmedetomidine)|"Anesthesia will be induced with propofol (2mg/kg) and fentanyl (1 ug/kg). Anesthesia will be maintained with propofol and fentanyl infusion, commenced at 10 mg/kg/hr and 0.5 ug/kg/hr respectively and adjusted to keep BIS between 40 & 50 during surgery.~In addition patients will receive Dexmedetomidine (0.5ug.kg) loading dose infused over 10 mins followed by a constant infusion rate of (0.2ug/kg/hr). Minimal dose of atracurium 0.1 mg/kg will be given at induction to facilitate intubation."
89540542|NCT06210061|Experimental|Group C (Propofol-Fentanyl-Sevoflurane)|"Anesthesia will be induced with propofol (2mg/kg) and fentanyl (1 ug/kg). Anesthesia will be maintained with propofol and fentanyl infusion, commenced at 10 mg/kg/hr and 0.5 ug/kg/hr respectively and adjusted to keep BIS between 40 & 50 during surgery.~In addition the anesthesia will be maintained with inhalational anesthesia of 50% oxygen , 50% air plus sevoflurane concentration adjusted to keep BIS between 40 & 50 . Minimal dose of atracurium 0.1 mg/kg will be given at induction to facilitate intubation"
89540543|NCT06210022||130|"Patients with diagnosis of DRE and DSE will be recruited among patients who are regularly followed at our Epilepsy Outpatients Service (OSR). The diagnosis of DRE and DSE focal cryptogenic epilepsy will be based on the most recent sets of criteria of different types of epilepsy. A small group of NDE patients will be also enrolled~A population of 30 focal cryptogenic epilepsy patients diagnosed with DRE (drug resistant epilepsy) A population of 90 focal cryptogenic epilepsy patients diagnosed with DRE (drug sensitive epilepsy) 10 patients newly diagnosed for focal cryptogenic epilepsy (NDE) will be recruited too."
89540544|NCT06209970|Experimental|35kDa hyaluronan fragment HA35 injection|A total of 2000 units of bovine testis hyaluronidase PH20 (hyaluronidase for injection H31022111, P.R.C) and 100 mg high molecular weight HA (sodium hyaluronate for injection, H20174089, P.R.C) were mixed at room temperature for 20 minutes, then was locally injected into patient's abdominal deep fat layer by a registered nurse or a physician in order to quickly alleviate pain associated with radiotherapy for treatment colorectal and rectal cancer.
89540545|NCT06209957|Active Comparator|Group I|Local corticosteroid injection in group I: 1 ml of triamcinolone acetonide (40 milligram/1.0 mL) was locally injected in the wrist using a 25-gauge needle, which was slowly inserted 1 cm proximal to the distal wrist-flexion crease just on the radial side of the palmaris longus tendon. The injection was held if the patient experienced pain or a sensation of pins and needles in the median nerve distribution.
89540546|NCT06209957|Active Comparator|Group II|Local PRP injection in group II: 2 ml of PRP was injected using the same technique of corticosteroid local injection after 2-step centrifugation of the patient's blood using a specific device. Non-steroidal anti-inflammatory drugs were avoided for two weeks before and after the procedure to prevent the possibility of inhibition of platelet function.
88959354|NCT02002780|No Intervention|Control|All families that were screened during the screening phase of this study will complete the final screening instrument assessment, whether or not the child participated in the day camp intervention. The control group will be comprised of those families that did not participate in the intervention.
88959355|NCT02002793|Other|Early stage abdominal drainage|SAP patients who matches one of the following criteria:1．Intravesical pressure≥20cmH2O or 2.CT images:acute peripancreatic liquid collection should have early stage abdominal drainage immediately;
88959356|NCT02002793|Other|Late stage abdominal drainage|Despite that it matches one of the cirteria as the study group:1．Intravesical pressure≥20cmH2O or 2．CT images:acute peripancreatic liquid collection, the patients continue acquire prearranged integrative treatment and will not accept early stage abdominal drainage until any of the followings emerge:1.Intra-abdominal apartment syndrome; 2. Pancreatic pseudocyst;3. Pancreatic or peripancreatic necrosis;
88959357|NCT02002806|Experimental|Alcohol Injection|Celiac plexus neurolysis by alcohol injection One time administration during surgery 20 ml of alcohol injection on each side of aorta at level of celiac axis
88959358|NCT02002806|Placebo Comparator|Placebo Injection|Celiac plexus injection - placebo injection
88959359|NCT02002845||Robotic arm|Patient who have undergone benign non-tumor TORS procedures using the da Vinci Surgical System
88959360|NCT02002858|Experimental|Depression and Anxiety Smoking Cessation Treatment|Cognitive-behavioral treatment program that blends smoking cessation, anxiety, and depression management/reduction treatment strategies
88959361|NCT02002858|Active Comparator|Educational-Support Psychotherapy|Educational-based psychotherapy and standard smoking cessation treatment program
88959362|NCT02002897|Experimental|Fractional carbon dioxide laser|Single session of fractional laser is done using DEKA machine , for 3 months .
88959363|NCT02002897|Active Comparator|Ultraviolet A1 phototherapy (UVA1)|24 sessions of UVA 1 phototherapy are give at a rate of 3 sessions per week , at a dose of 30 joules using a Waldman targeted machine.
88959364|NCT02002923|Active Comparator|PVI only|
88959365|NCT02002923|Active Comparator|PVI+BT injection|
88959366|NCT02002949|Experimental|Short daily hemodialsysis|Short Daily Hemodialysis (SDHD) - 5 or 6 treatments per week for approximately 3 hours (range 2 to 4 hours) per treatment, to be performed at the patient's home, using any hemodialysis machine as chosen by the responsible clinician in each participating center
88959367|NCT02002949|Active Comparator|Conventional hemodialysis|Conventional Hemodialysis (CHD) - 3 treatments per week for approximately 4 hours (range 3 hours and 30 minutes to 4 hours) per treatment, to be performed in a dialysis clinic using any hemodialysis machine as chosen by the responsible clinicians in each participating center
88959368|NCT02002962|Active Comparator|RFA+BT injection|Transseptal puncture is performed by used standard endovascular approach. Injection of the botulinum toxin is performed in main anatomical zones of ganglionated plexuses of left atrium using Myostar catheter (Biosense Webster).
88959369|NCT02002962|Active Comparator|RFA|Externally-irrigated tip (5-mm tip, Celsius Thermo-Cool, Biosense Webster, Diamond Bar, CA, USA). Temperature-controlled RF delivery was performed with a maximum power output of 50 W and temperature limit of 50 C. The catheter was irrigated using 0.9% saline infusion at a ﬂow rate of 20-40 mL/min during RF delivery and 2 mL/min between applications using a commercially available pump (Cool Flow, Biosense Webster).
88959370|NCT02002988|Experimental|BT injection|
88959371|NCT02003001|Experimental|BT injection|
88959372|NCT02003027|Experimental|BT injection|
88959373|NCT02003040||St. Michael's Hospital Patients|Patients admitted to the Cardiology ward at St Michael's Hospital with a main diagnosis of acute decompensated heart failure
88959374|NCT02003066|Experimental|Standard|
88959375|NCT02003066|Active Comparator|Conservative|
88959376|NCT02003079||Diagnosed with or without Chronic Rhinosinusitis|
88959377|NCT02003092|Experimental|RX-5902|RX-5902 will be taken daily for 4 weeks in each 4 week cycle. Subjects will be fasting for 8 hours before and food may be ingested approximately 3 hours after the dose has been administered.
88959378|NCT02001818|Experimental|Nilotinib or Imatinib with Peginterferon|"Nilotinib 300mg twice daily for 24 months. Pegylated interferon alpha-2b 30-50 micrograms subcutaneously once weekly for maxium 21 months (3 months after trial registration).~Patients intolerant of nilotinib may be switched to appropriate doses of imatinib"
88959379|NCT02003118|Experimental|AKR 202|
88959380|NCT02003118|Placebo Comparator|Placebo|
88959381|NCT02003131|Other|Intra-articular knee injection of MTF|Trophic factors from umbilical cord mesenchymal stem cells administered intra-articularly.
88959382|NCT02003131|Other|Subcutaneous injection of MTF|Trophic factors from umbilical cord mesenchymal stem cells administered subcutaneously once per week for 12 weeks.
88959383|NCT02003157|Active Comparator|hypnosis|embryo transfer procedure with hypnosis
88959384|NCT02003157|Active Comparator|usual|embryo transfer usual procedure
88959385|NCT02003235|Experimental|Single Arm|Daily watching videos using Reviview™, a dichoptic video display device
88959386|NCT02003248|Experimental|dyskinesia of PD|The proposed study is to evaluate the safety and initial effectiveness of the ExAblate Transcranial MRI-guided focused ultrasound (MRgFUS) treatment of patients with dyskinesia of Parkinson's Disease (PD)
88959387|NCT02003261|Experimental|Unified Protocol with Treatment As Usual|Unified Protocol is designed to help patients learn how to confront and experience uncomfortable emotions and learn how to respond to their emotions in more adaptive ways. Individual treatment sessions will be conducted by experienced clinicians who will be trained in the administration of this protocol. A workbook will be provided to each patient as part of this manualized treatment. During this treatment period, the participants continue the Treatment As Usual.
88959388|NCT02003261|Other|Waitlist Control with Treatment As Usual|Waitlist participants will not receive treatment during a 20-week waitlist period, but will receive the unified protocol immediately following the 20 week waiting period. During the waitlist period, the waitlist participants continue the treatment as usual.
88959389|NCT02003274|Other|Clamp-Mixed Meal Arm|Twenty adult patients with type 1 diabetes, regularly attending the Division of Endocrinology and Metabolic Diseases of University of Verona School of Medicine, using continuous subcutaneous fast insulin analogue infusion (CSII) through a permanent pump and on subcutaneous glucose sensing will be enrolled.
88959390|NCT02003274|Other|IVGTT-Mixed Meal Arm|Twenty healthy adult volunteers will be recruited.
89510988|NCT04851405|Placebo Comparator|Otago Exercise Programme Group (OEP)|"Physiotherapists receive OEP Training and a 2 hour workshop on just the counselling protocol.~Each PT will deliver exercise program to 8 older adults. PTs will help older adults to set-up the Fitbit. For the first two months, PTs will provide bi-weekly home visits. During months 3-5, PTs will call participants three times times to review the exercise plan. The last visit will be an at-home visit which will occur 6 months after the initial visit.~Older Adults will receive an OEP manual and cuff weights to be used with the strength training. They will also receive a Fitbit. Between Months 7-12, older adults will receive follow-up phone calls from the research staff."
89510989|NCT05235542|Experimental|Phase Ib#Dosage regimen 1#|Subjects receive AK104 plus AK117 every 3- week cycle (Q3W) until progression
89510990|NCT05235542|Experimental|Phase Ib#Dosage regimen 2#|Subjects receive AK104 plus AK117 every 6- week cycle (Q6W) until progression
89510991|NCT05235542|Experimental|Phase II#Cohort 1#|Gastric Cancer or Gastroesophageal Junction Cancer: AK104 + XELOX (Oxaliplatin + Capecitabine)+AK117 every 3- week cycle (Q3W) until progression
89510992|NCT05235542|Experimental|Phase II#Cohort 2#|Esophageal squamous cell cancer: AK104 + 5-FU/Paclitaxel+Cisplatin± AK117 every 3- week cycle (Q3W) until progression
89510993|NCT05235542|Experimental|Phase II#Cohort 3#|Gastric Cancer or Gastroesophageal Junction Cancer or Esophageal squamous cell cancer: AK117 +Paclitaxel/Docetaxel/Irinotecan every 3- or 4- week cycle (Q3W or Q4W) until progression
89510994|NCT00840281|Experimental|1|
89510995|NCT00840281|Active Comparator|2|
89510996|NCT05086029||Psoriatic arthritis patients|
89510997|NCT05086029||healthy volunteers|
89210499|NCT00819650|Experimental|Licartin|patients who receive Licartin therapy after liver resection
89510998|NCT03134807||Admission of elderly ICU patients (≥80)|All consecutibve admission in 3 month period or 20 pateints
89510999|NCT00840203|Experimental|Mesalamine|Mesalamine 4gm/60mL Rectal Enema (test) dosed in first period followed by Rowasa® 4gm/60mL Rectal Enema (reference) dosed in second period
89511000|NCT00840203|Active Comparator|Rowasa®|Rowasa® 4gm/60mL Rectal Enema (reference) dosed in first period followed by Mesalamine 4gm/60mL Rectal Enema (test) dosed in second period
89511001|NCT05155982|Experimental|Group A (18-54 yrs)|COVAC-1 25 ug
89511002|NCT05155982|Placebo Comparator|Group B (18-54 yrs)|Placebo Control
89511003|NCT05155982|Experimental|Group C (18-54 yrs)|COVAC-1 50 ug
89511004|NCT05155982|Placebo Comparator|Group D (18-54 yrs)|Placebo Control
89511005|NCT05155982|Experimental|Group E (55+ yrs)|COVAC-1 25 ug
89511006|NCT05155982|Placebo Comparator|Group F (55+ yrs)|Placebo Control
89511007|NCT05155982|Experimental|Group G (55+ yrs)|COVAC-1 50 ug
89511008|NCT05155982|Placebo Comparator|Group H (55+ yrs)|Placebo Control
89511009|NCT00838799|Experimental|1|
89511010|NCT00838799|Experimental|2|
89511011|NCT00838799|Experimental|3|
89511012|NCT00838799|Active Comparator|4|
89511013|NCT00838799|Placebo Comparator|5|
89511014|NCT05234216|Experimental|Comfort Group|Centers evaluating patients after surgery requiring postoperative opioid treatment with an ICU comfort scale.
89511015|NCT05234216|Other|Pain Group|Centers evaluating patients, after surgery requiring postoperative opioid treatment, with a pain numerical verbal scale in the postoperative care service.
89511016|NCT05025735|Experimental|Phase 2 study of Fulvestrant, alpelisib and dapagliflozin|"A cycle length is defined as 28 days.~Fulvestrant 500 mg intramuscular, Cycle 1, Day 1 and Day 15; Cycle 2 and beyond 500 mg Intramuscular Day 1.~Alpelisib 300 mg by mouth, daily, continuously beginning on Cycle 1, Day 1.~Dapagliflozin 10 mg by mouth, daily, continuously beginning Cycle 1, Day 3."
89511017|NCT05085639|Experimental|GLS-5310 1.2 mg (Group 1)|GLS-5310 1.2 mg (ID + Gene-Derm) at Day 0 and Week 8
89511018|NCT05085639|Experimental|GLS-5310 2.4 mg (Group 2)|GLS-5310 1.2 mg (ID + Gene-Derm) + 1.2 mg (IN) at Day 0 and Week 8
88810839|NCT05431010|Active Comparator|rehabilitation training only|The rehabilitation group will be only treated with the Otago exercise program(OEP). The Otago Exercise is a program developed by the research group of fall prevention in the elderly led by Campbell of Otago Medical University in the 1990s. It is a home exercise program aimed at strengthening lower extremity muscle, balance and preventing falls in the elderly. Otago Exercise combines resistance exercise, balance training and aerobic walking and is an exercise prescription for elderly patients with sarcopenia (details are as follows).
88810840|NCT05427461|Other|Patient with leiomyosarcoma|
88810841|NCT05410509|Experimental|RCC Participants|Receive Trans-arterial embolization (TAE)
89210500|NCT00819650|No Intervention|placebo|control group with patients who don't receive any adjuvant therapy after liver resection, to compare with the treatment group with patients who receive Licartin therapy after liver resection
89511019|NCT05085639|Experimental|GLS-5310 1.2 mg (Group 3)|GLS-5310 1.2 mg ID at Day 0 and Week 8
89511020|NCT05085639|Placebo Comparator|Placebo (Group 4)|Placebo (ID + Gene-Derm) at Day 0 and Week 8
89511021|NCT00836069|Experimental|PD 0332334-α2δ ligand (450mg)|PD 0332334, 450mg/day, for 8 weeks and then 2 weeks of dose tapering.
89511022|NCT00836069|Experimental|PD 0332334-α2δ ligand (600mg)|PD 0332334, 600mg/day, for 8 weeks and then 2 weeks of dose tapering.
89511023|NCT00836069|Active Comparator|Paroxetine|Paroxetine, 20mg/daym for 8 weeks and then 2 weeks of dose tapering.
89511024|NCT00836069|Placebo Comparator|Placebo|Inactive Substance (placebo) for 10 weeks.
89511025|NCT05155670|Experimental|Robotic therapy|All participants will receive a program of robot-assisted rehabilitation exercises., including passive, active-assisive and active MCP Range-of-Motion Exercises, and active bidigital pinching movements in the transparent mode.
89511026|NCT03134729|Experimental|Serratus Plane Loco-regional block|"Continuous infusion of Tramadol 200 mg or Ketorolac 60 mg~Rescue analgesia with Morphine (0.1 mg/kg) a single time every 24 hours, and/or Tramadol 100 mg up to three times every 24 hours and/ or Ketorolac 30 mg up to three times every 24 hours~plus~Ropivacaine (30 ml, 0.3%), for Serratus Plane Block"
89511027|NCT03134729|No Intervention|Standard of Care|"Continuous infusion of Tramadol 200 mg or Ketorolac 60 mg~Rescue analgesia with Morphine (0.1 mg/kg) a single time every 24 hours and/or Tramadol 100 mg up to three times every 24 hours and/ or Ketorolac 30 mg up to three times every 24 hours"
89511028|NCT03134651|Active Comparator|Monitoring brain function-low-anxiety|Anxiety has determined a cutoff score of 17. Patients were divided into two groups according to the recorded BAI score: a low-anxiety group and a high-anxiety group.The monitoring brain function values were recorded at baseline, 5 minutes, 15 minutes, and after anesthesia. Propofol was performed by ventilation with face mask. Monitoring brain function was keep value between 40 and 60.
89511029|NCT03134651|Active Comparator|monitoring brain function-high-anxiety|Anxiety has determined a cutoff score of 17. Patients were divided into two groups according to the recorded BAI score: a low-anxiety group and a high-anxiety group.The monitoring brain function values were recorded at baseline, 5 minutes, 15 minutes, and after anesthesia. Propofol was performed by ventilation with face mask. Monitoring brain function was keep value between 40 and 60.
89511030|NCT05202782|Experimental|Treatment (zanubrutinib and CAR T-cell therapy)|"LEAD- IN PHASE: Patients receive zanubrutinib PO BID for 7-14 days in the absence of disease progression or unacceptable toxicity.~CAR T-CELL THERAPY: Patients receive standard of care CAR T-cell therapy IV at 4 weeks.~MAINTENANCE PHASE: Patients receive zanubrutinib PO BID on days 1-28. Cycles repeat every 28 days for 12 months in the absence of disease progression or unacceptable toxicity."
89511031|NCT05430659||EBL equal or more than 500 ml|The intraoperative estimated blood loss equal or more than 500 ml
89511032|NCT05430659||EBL less than 500 ml|The intraoperative estimated blood loss less than 500 ml
89511033|NCT00935987|Experimental|CYT387|
89511034|NCT05155124|Experimental|Cetuximab and trifluridin tipiracil|Cetuximab will be administered at a fixed dose of 500 mg/m2 once every 2 weeks; trifluridin tipiracil will be administered in a dose de-escalation design: dose level 1: 35 mg/m2 twice daily on days 1-5 once every 2 weeks; Or dose level 0: 30 mg/m2, twice daily, Days 1-5, once every 2 weeks;
89511035|NCT04473677||Fecal Occult Blood Test|People in this group will detect hemoglobin in stool before colonoscopy by the new qFIT.
89511036|NCT05232578|Experimental|Arm A- early salvage radiotherapy (eSRT)|Early salvage radiotherapy (eSRT) will be administered immediately after the confirmation of the biochemical relapse (prostate-specific antigen PSA level increase to ≈ 0,2 ng/ml) after radical prostatectomy with defined risk factors and no clinical recurrence signs on prostate specific membrane antigen positron emission tomography and computed tomography (PSMA PET/CT).
89511037|NCT05232578|Experimental|Arm B- delayed salvage radiotherapy (dSRT)|The patient is by the biochemical relapse analysis (PSA level 0,2 ng/ml) referred for further follow-up of PSA values. dSRT is initiated, if PSA further increase to values of ≥ 0.4 ng/ml is confirmed and the presence of a potential clinical relapse is excluded with repeated PSMA-PET-CT in line with standard procedures
89511038|NCT04438343|Experimental|experimental group|
89511039|NCT04438343|Active Comparator|control group|
89210501|NCT00906594|Active Comparator|Latanoprost|Latanoprost mono therapy
89210502|NCT00906594|Experimental|Latanoprost + Fixed combination|Latnoprost + Fixed combination
89210503|NCT03970759||Stannous Fluoride Dentifrice|Twice daily brushing
89210504|NCT03970759||Positive Control Dentifrice|Twice daily brushing
89210505|NCT03970759||Negative Control Dentifrice|Twice daily brushing
89511040|NCT05200832||COVID+|Participants who have experienced COVID-19
89511041|NCT05200832||COVID-|Participants who have not experienced COVID-19
89511042|NCT00927641|Active Comparator|Ketoprofen Patch (HKT-500)|Two Ketoprofen HKT-500 patches applied to target ankle once daily for 14 days
89511043|NCT00927641|Placebo Comparator|Placebo Patch|Two placebo patches placed on target ankle once daily for 14 days
89511044|NCT05200364|Experimental|Experimental :STRO-002 treatment in combination with Bevacizumab|"Dose Escalation: STRO-002 at increasing dose levels plus bevacizumab at 15 mg/kg~Dose Expansion: STRO-002 at RP2D plus bevacizumab at 15 mg/kg"
89511045|NCT00835991|Experimental|Glyburide Metformin|Glyburide Metformin 5/500 Film-Coated Tablet (test) dosed in first period followed by Glucovance® 5/500 mg Tablet (reference) dosed in second period
89511046|NCT00835991|Active Comparator|Glucovance®|Glucovance® 5/500 mg Tablet (reference) dosed in first period followed by Glyburide Metformin 5/500 mg Film-Coated Tablet (test) dosed in second period
89511047|NCT05200052|Active Comparator|Colchicine 0.5 mg oral tablet|100 patients presented with anterior Myocardial infarction undergoing primary Percutaneous coronary intervention will receive colchicine tablet 1mg loading dose and colchicine 0.5 mg maintance dose for 6 months and will do longitudinal strain pattern echocardiography to asses left ventricles systolic function
89511048|NCT05200052|No Intervention|Standard anti ischemic treatment|100 patients presented with anterior myocardial infarction undergoing primary percutaneous coronary intervention will do longitudinal strain pattern echocardiography to asses left ventricles systolic function
89511049|NCT00925535|Active Comparator|Treatment A|Lersivirine
89511050|NCT00925535|Active Comparator|Treatment B|Rifabutin
89511051|NCT00925535|Experimental|Treatment C|Lersivirine and Rifabutin
89511052|NCT04964609|Experimental|Single Arm|Comparison of EmbracePlus SpO2 readings with arterial blood saturation laboratory analysis in the same subject
89511053|NCT02276872|Experimental|Cohort 1 (Transitioning from Parental)|Transitioned from IV or SC Remodulin to oral treprostinil
89511054|NCT02276872|Experimental|Cohort 2 (Transitioning from Inhaled)|Transitioned from inhaled prostacyclin to oral treprostinil
88810842|NCT05400369|Experimental|Sitafloxacin|Adult participants who will be randomized to receive 100 mg sitafloxacin (2 tablets) orally once a day.
88810843|NCT05400369|Active Comparator|Moxifloxacin|Adult participants who will be randomized to receive 400 mg moxifloxacin (1 tablet) orally every 24 hours.
88810844|NCT05397028|Experimental|Intervention Group|Replace meals with a plant-based meal replacement and self-prepared Meditteranean meals for a max 1200 calorie per day. Enroll in a 12 week intensive lifestyle intervention program.
88810845|NCT05397028|No Intervention|Standard of Care Group|
89511055|NCT02276872|Experimental|Cohort 3 (Add-on to Current PAH Therapy)|Treated with oral treprostinil as a de novo add-on to current PAH therapy
88810846|NCT05389332|Experimental|Mobile skin cancer intervention|Conduct a pilot of the refined intervention among Hispanics to evaluate the preliminary efficacy of the user-centered mobile skin cancer intervention program.
88810847|NCT05389332|Active Comparator|Control group: physical activity and nutrition information|Participants will complete a baseline survey first; and then they will be randomly assigned into either the intervention group or the control group. After the random allocation participants will receive instructions on how to use WhatsApp and then the intervention. The participants will receive WhatsApp messages about skin cancer for three months with optimal frequencies determined by prior aims and complete a post-intervention survey which contains the same questions in the pre-survey. The participants will be contacted at six months after the baseline survey to complete another survey similar to the post-intervention survey.
88810848|NCT05388851|Experimental|Prevention (Educational training)|Participants complete an educational training module and complete questionnaire at baseline (before educational training module) and 3 months after completing educational training.
88810849|NCT05386680|Experimental|OAV-101|Intrathecal administration of OAV101 at a dose of 1.2 x 10^14 vector genomes, one time dose
88810850|NCT05378035||DOAC Recipients|"We shall recruit the DOAC recipients that meet the following inclusion criteria:~Chinese NVAF patients on apixaban, dabigatran, edoxaban, or rivaroxaban for 6 months or more.~Patients aged 18-80 years old.~Patients who are able to provide an informed consent.~Patients who are indicated for elective medical procedures that require interruption of DOAC for 48 hours, such as colonoscopy, pleural biopsy, cardiac catheterization, digital subtraction angiograph, etc."
88810851|NCT05368870||Carlevale implantation|
88810852|NCT05364021|Experimental|LP352|Subjects will be titrated up to highest tolerated dose of LP352 during a 15-day period, followed by a 60-day maintenance period and a 15-day taper/down titration period.
89540547|NCT06209931||RIRS|Patients were performed under general anesthesia in the oblique supine lithotomy position. Initially, preliminary ureteroscopy was performed with a semirigid 8/9.8 Fr ureteroscope guided by zebra guide wire. Next, the patented tip flexible pressure-controlling ureteral access sheath (UAS,12/14 Fr) was inserted along the guidewire without the fluoroscopic guidance. The fully automatic mode was chosen to operate the platform.The pressure sensory and suctioning channels of UAS were connected to the irrigation and suctioning platform. After water injection, zero calibration was performed at platform. Perfusion flow rate was then set at 100-150 ml/min, the renal pelvic pressure (RPP) control value was set at -15~5 mmHg, the RPP warning value was set at 20 mmHg, and the RPP maximum value was set at 30 mmHg. Intraoperatively, a holmium laser was used to crush the stone at 1.5-2.0 J/pulse with a frequency of 20-30 pulses/s ( (CHUNHUI, CHINA, 276µm).
89024181|NCT03178149|Experimental|ASP7317 Dose Escalation/ Expansion (Group 1: Severe Vision Loss)|"Successive cohorts of participants (3 participants each) will be given escalating doses (cohort 1: low cells/dose; cohort 2: medium cells/dose; cohort 3: high cells/dose). Expansion cohorts (6 participants each) 3b will be opened after cohort 3 has been filled and 2b will be opened only if necessary. Dose levels for the expansion cohort will align with dose levels in escalation cohorts.~Sentinel dosing will be required for each dose level. After the first participant in Group 1 dose cohort is dosed and followed for 4 weeks, the Data Safety Monitoring Board (DSMB) will review the 4 week safety data and recommend if the second and third participants in Group 1 dose cohort may be treated.~The DSMB recommendation to progress to the next dosing cohort will be based on 4 week follow-up safety review of the second and third participants in the preceding dose cohort. Participants will receive tacrolimus and other medicines to stop infection."
89207044|NCT00839592|Experimental|Electroacupuncture|"Acupoints will be treated at bilateral Ear Shenmen, Sishencong (EX-HN1), Anmian, and unilateral Yintang (EX-HN3) and Baihui (GV20).~Acupuncture will be performed by a registered Chinese medicine practitioner. De qi(an irradiating feeling considered to be indicative of effective needling) is achieved if possible. An electric-stimulator (CEFAR Acus II, Lund, Sweden) will be connected to these needles to give an electric-stimulation in continuous wave, frequency of 4 Hz, 0.45 ms square wave pulses and constant current. The needles will be left for 30 min and then removed. Acupuncture treatment will consist of three sessions per week for 3 consecutive weeks."
89210506|NCT00905112|Experimental|MOMS|Receives manual therapy, stabilization exercise and patient education
89540548|NCT06209931||MPCNL|Patients were performed under general anesthesia. The patient was first placed in a lithotomy position. A 5 Fr ureteral catheter was then inserted retrogradely into the renal pelvis through cystoscopy or ureteroscopy , and saline was continuously infused to produce artificial hydronephrosis. The patient was then placed in the prone position. Ultrasound-guided percutaneous punctures were made with an 18-gauge coaxial needle into the targeted calix. The puncture point was in the 12th rib infracostal margin, between the posterior axillary line and scapula line. A Zebra guidewire was inserted and fixed. The puncture needle was then removed. After a 0.5-0.7 cm skin incision was made, the percutaneous tract was dilated serially over the guidewire with a fascial dilator to 18Fr. Holmium laser lithotripsy at 1.5-2.0 J/pulse with a frequency of 20-30 pulses/s (CHUNHUI, CHINA, 550µm) was performed with a 18 Fr peel-away sheath.
89540549|NCT06209918|Experimental|group that recieve bioptron light and advice and patient education|patients will recieve bioptron light therapy for 10 minutes per session, 3 sessions per week, for 4 weeks.
89540550|NCT06209918|Other|control group that recieve advice and patient education and wrist brace|will keep the wrist in a neutral position, not bent back or bent down too far
89540551|NCT06209905|Sham Comparator|Ti-PTFE|A mixture of autogenous bone (scrapped from the mandibular external oblique ridge) and bovine xenograft was administered on the atrophic recipient area after decortication by low-speed reducing drills, and covered with the Ti-PTFE membrane.
89540552|NCT06209905|Active Comparator|Khoury technique|A bone block was harvested from the mandibular external oblique ridge, then splitted into two plates; one fixated buccally and the other fixated occlusally by bone screws), and a mixture of autogenous bone (scrapped from the mandibular external oblique ridge) and bovine xenograft was administered on the atrophic recipient area after decortication by low-speed reducing drills.
89540553|NCT06209892|No Intervention|Conventional anticoagulation group|
89210507|NCT00905112|Active Comparator|STOB|Receive standard obstetrical care
89540554|NCT06209892|Experimental|Extended anticoagulation group|
89540555|NCT06209840|Active Comparator|Control Group|Classical physiotherapy program will be applied for gross motor functions and upper extremity functions.
89540556|NCT06209840|Experimental|Study (Music) Group|In addition to the classical physiotherapy program for gross motor functions, will be applied in the Neuro-Creative Music Therapy (NCMT) program for upper extremity.
89540557|NCT06209814|Active Comparator|Conventional denture|
89540558|NCT06209814|Experimental|maxillary open-faced denture|
89540559|NCT06208241|Experimental|Allocetra-OTS|Single IA dose of Allocetra-OTS cells in suspension
89540560|NCT06207409|Experimental|PARTS-SUD Arm|The Program for Alleviating and Reducing Trauma, Stress and Substance Use (PARTS-SUD) is a 12-week, Internal Family Systems-based, group intervention with 6 individual clinical sessions on a biweekly basis.
89540561|NCT06207214|Experimental|Self-help book for University Students|The Unbreakable Student: 6 Rules for Staying Sane at University by Dr Nic Hooper.
89540562|NCT06207058||Influenza Positive|Subjects testing positive will receive baloxavir marboxil as a single oral dose as soon as possible and within 48-hours of influenza symptom onset. Dosing will be delivered based on the package insert
89540563|NCT06207058||Influenza Negative|Subjects testing negative for influenza will have no drug administered
89511056|NCT05147480|Active Comparator|yoga group|infants whose gestational ages are between 32-37 weeks and completed the corrected age of the 6th week, and their mothers intervention: 6-week, once a week internet-based mother and baby yoga
89511057|NCT05147480|No Intervention|control group|infants whose gestational ages are between 32-37 weeks and completed the corrected age of the 6th week, and their mothers the standardized follow-up without intervention
89511058|NCT00835367|Experimental|Amlodipine Benazepril|Amlodipine Benazepril 10mg-20mg Capsule (test) dosed in first period followed by Lotrel® 10mg-20mg Capsule (reference) dosed in second period
89511059|NCT00835367|Active Comparator|Lotrel®|Lotrel® 10mg-20mg Capsule (reference) dosed in first period followed by Amlodipine Benazepril 10mg-20mg Capsule (test) dosed in second period
89511060|NCT04236518|Experimental|Hypertriglyceridimic/blood sugar/HDLcholesterol/blood pressure waist phenotype/animal protein source|20 men or postmenopausal women between 25 and 55 years old with a high waist circumference and at the choice, one of the following criteria high triglyceridemia, blood sugar above standards,a lower than standard HDL-cholesterol level,slightly elevated blood pressure receiving diets with predominantly animal protein sources
89511061|NCT04236518|Experimental|Hypertriglyceridimic/blood sugar/HDLcholesterol/blood pressure waist phenotype/plant protein source|20 men or postmenopausal women between 25 and 55 years old with a high waist circumference and at the choice, one of the following criteria high triglyceridemia, blood sugar above standards,a lower than standard HDL-cholesterol level,slightly elevated blood pressure receiving diets with predominantly plant protein sources
89511062|NCT04236440|Experimental|Part A: A1A2+Part B+Part C|"Part A: Participants will receive a single dose administration of BAY2586116 (A1) in treatment period 1, and a single dose administration of placebo (A2) in treatment period 2.~Part B: After successfully completing Part A, participants will proceed to Part B of the study.~Participants will receive a single dose administration of BAY2586116 (B1) in treatment period 3.~Based on the result of the interim analysis there are two possible scenarios regarding mode of application and doses of BAY2586116 to be administered in treatment period 4: 1) a single dose administration of BAY2586116 (B2) Or 2) a single dose administration of BAY2586116 (B3).~Part C: Participants completing Part B will be invited to participate in an additional treatment period with a single dose BAY2586116 (C)."
89511063|NCT04236440|Experimental|Part A: A2A1+Part B+Part C|"Part A: Participants will receive a single dose administration of placebo (A2) in treatment period 1, and a single dose administration of BAY2586116 (A1) in treatment period 2.~Part B: After successfully completing Part A, participants will proceed to Part B of the study.~Participants will receive a single dose administration of BAY2586116 (B1) in treatment period 3.~Based on the result of the interim analysis there are two possible scenarios regarding mode of application and doses of BAY2586116 to be administered in treatment period 4: 1) a single dose administration of BAY2586116 (B2) Or 2) a single dose administration of BAY2586116 (B3).~Part C: Participants completing Part B will be invited to participate in an additional treatment period with a single dose BAY2586116 (C)."
89511064|NCT00924989|Experimental|Arm A: OSI-906|150 mg twice daily
89511065|NCT00924989|Placebo Comparator|Arm B: Placebo|Matching placebo twice daily
89511066|NCT02276560|Experimental|Neoadjuvant Cisplatin,nab-paclitaxel|Neoadjuvant cisplatin (75 mg/m2) D1 and nab-paclitaxel (125 mg/m2) D1, 8, 15, repeat each 28D cycle x 3 and then surgery per standard of care
89511067|NCT02276560|Experimental|Adjuvant Cisplatin,nab-paclitaxel|Adjuvant cisplatin (75mg/m2) D1, nab-paclitaxel (125 mg/m2)for D1, 8, 15 repeat each 28D x 2
88810853|NCT05364021|Placebo Comparator|Placebo|Placebo for LP352
88810854|NCT05362760|Experimental|Abemaciclib + Aromatase-Inhibitor|The patients will receive Abemaciclib in combination with an Aromatase-Inhibitor (either Anastrozole, Letrozole or exemestane)
88810855|NCT05362760|Experimental|Abemaciclib + Fulvestrant|The patients will receive Abemaciclib in combination Fulvestrant
88810856|NCT05357105||Regional Nerve Block Patients|Patients who receive regional nerve blocks as part of the anesthetic management prior to surgery.
88810857|NCT05356104|Active Comparator|Exenatide extended release|Prescribe study drug: Exenatide extended release. The dosage and frequency is 2mg once weekly via subcutaneous injection for 78 weeks
88810858|NCT05356104|No Intervention|Standard of care|Standard medical therapy
88810859|NCT05355753|Experimental|Dose Escalation Phase 1/Part1: CFT8634|Up to approximately 40 subjects ≥18 years of age or between ≥16 and <18 years of age and weighing ≥50 kg with locally advanced or metastatic SMARCB1-perturbed cancers, including synovial sarcoma and SMARCB1-null tumors, having received ≥ 1 prior anticancer therapy
88810860|NCT05355753|Experimental|Dose Escalation Phase 1/Part 2: CFT8634|Up to approximately 6-12 subjects ≥12 and <16 years of age and weighing ≥40 kg or ≥16 and <18 years of age and weighing ≥40 kg and <50 kg with locally advanced or metastatic SMARCB1-perturbed cancers, including synovial sarcoma and SMARCB1-null tumors
88810861|NCT05355753|Experimental|Phase 2 - Arm A: CFT8634|Approximately 30 subjects with locally advanced or metastatic synovial sarcoma at the recommended phase 2 dose (RP2D) having received 1-2 prior anticancer therapies
88810862|NCT05355753|Experimental|Phase 2 - Arm B: CFT8634|Approximately 20 subjects with locally advanced or metastatic SMARCB1-null tumors at the RP2D having received ≥1 prior anticancer therapy
88810863|NCT05354778|Placebo Comparator|Placebo|Normal saline 100mL every 8 hours for 5 days or until patient dies or is discharged from the intensive care unit
88810864|NCT05354778|Active Comparator|Hydrocortisone|Hydrocortisone 100mg + normal saline 100mL every 8 hours for 5 days or until patient dies or is discharged from the intensive care unit
88810865|NCT05332262||High ABCD-GENE score (≥10)|"All patients in this cohort will have an ABCD-GENE score ≥10 and will be receiving clopidogrel following PCI as per standard of care.~The ABCD-GENE score encompasses a total of 5 variables: 4 clinical (age, body mass index, chronic kidney disease status, and diabetes mellitus) and 1 genetic (CYP2C19 LOF)."
88810866|NCT05332262||Low ABCD-GENE score (<10)|"All patients in this cohort will have an ABCD-GENE score <10 and will be receiving clopidogrel following PCI as per standard of care.~The ABCD-GENE score encompasses a total of 5 variables: 4 clinical (age, body mass index, chronic kidney disease status, and diabetes mellitus) and 1 genetic (CYP2C19 LOF)."
88810867|NCT05322122|Experimental|Treatment|Side-to-side anastomosis duodeno-ileostomy diversion
88810868|NCT05309616|Experimental|Talz|All participants receive Talz
89511068|NCT02276560|Other|Cisplatin+pemetrexed or gemcitabine|Adjuvant cisplatin (75mg/m2) D1, pemetrexed (500mgm2) D1 or; cisplatin (75 mg/m2),Gemcitabine (1000mg/m2) D1, 8 repeat each 21D cycle x 4
89511069|NCT05199896|Experimental|All protocols (behavioral and EEG and fMRI)|If participants accepts (non-sighted participants and Healthy volunteers), they will carry out the behavioral protocol and the EEG protocol and fMRI protocol.
89511070|NCT05199896|Experimental|Behavioral protocol and EEG protocol|"Participants who agree to participate in only one of the experiments (EEG or MRI) will be randomly (by a randomization list) assigned to either the EEG or fMRI type of study in each subgroup.~All participants (non-sighted participants and Healthy volunteers) will do the behavioral session and at least one EEG or MRI session depending on randomization."
89511071|NCT05199896|Experimental|Behavioral protocol and fMRI protocol|"Participants who agree to participate in only one of the experiments (EEG or MRI) will be randomly (by a randomization list) assigned to either the EEG or fMRI type of study in each subgroup.~All participants (non-sighted participants and Healthy volunteers) will do the behavioral session and at least one EEG or MRI session depending on randomization."
89511072|NCT05198414||Healthcare workers|Healthcare workers at the first line and healthcare directives.
89511073|NCT04954859|Experimental|Nucleos(t)ide analogue (NA) naïve participants|Participants who have not received NA therapy during the parent study. No study treatment will be administered in this study.
89511074|NCT04954859|Experimental|NA controlled participants|Participants who entered the parent study on stable NA therapy and remained on NA therapy for the duration of the treatment and follow-up periods. NA cessation at 3 months. No study treatment will be administered in this study.
89511075|NCT02276482|Experimental|Tedizolid Phosphate|Tedizolid Phosphate IV and/or oral 200 mg once per day for 6 days. Participants with gram-negative wound infection may receive aztreonam (IV) and/or metronidazole (IV or oral).
89511076|NCT02276482|Active Comparator|Antibiotic comparator drug|IV and/or oral antibiotic comparator drug for 10 days. Participants with gram-negative wound infection may receive aztreonam (IV) and/or metronidazole (IV or oral).
89511077|NCT05197166||Nursing students|Nursing students exposed to standing environments (prolonged walking and prolonged standing) during acute clinical settings (e.g., hospitals).
89511078|NCT00924833|Placebo Comparator|placebo|Placebo tablets. One tablet twice daily.
89511079|NCT00924833|Active Comparator|2: Carvedilol|Carvedilol 25 mg tablets. One tablet twice daily.
89511080|NCT00924833|Active Comparator|3: Nebivolol|Nebivolol 5 mg tablets. One nebivolo tablet daily. One placebo tablet daily.
89511081|NCT05228756|Other|Resistance Band exercise for Sickle Cell Disease|Participants will complete 16 exercise session at home wearing an accelerometer
89511082|NCT00922571|Experimental|FS Laser Surgery|For femtosecond laser-assisted cataract surgery (FS Laser Surgery), subjects will receive capsulotomy, lens segmentation and, at investigator discretion, lens softening using the OptiMedica Catalys™ Precision Laser System (Catalys System)
89511083|NCT00835211|Experimental|1|
89511084|NCT00835211|Active Comparator|2|
89511085|NCT05227820|Experimental|Experimental Arm: NE3107|All participants will take 200mg BID (12 hours apart) of NE3107 for 3 months.
89511086|NCT00834977|Experimental|Amlodipine Benazepril|Amlodipine Benazepril 10mg-20mg Capsule (test) dosed in first period followed by Lotrel® 10mg-20mg Capsule (reference) dosed in second period
88959391|NCT02003287|Experimental|FEES|Swallowing evaluation with the Fiberoptic Endoscopic Evaluation of Swallowing
88959392|NCT02003287|Active Comparator|VFSS|Swallowing evaluation with the Videofluoroscopic Swallowing Study
88959393|NCT02003313|Experimental|Group T|Participants of enrollment will receive 1 dose on Group A, C, Y and W135 Meningococcal Polysaccharide Vaccine.
88959394|NCT02003313|Active Comparator|Group C|Participants of enrollment will receive 1 dose on Group A, C, Y and W135 Meningococcal Polysaccharide Vaccine.
89210508|NCT00643448|Experimental|AZD1305 loading dose 250 mg + 125 mg|Tablets
89210509|NCT00643448|Experimental|AZD1305 loading dose 500 mg + placebo|Tablets
89511087|NCT00834977|Active Comparator|Lotrel®|Lotrel® 10mg-20mg Capsule (reference) dosed in first period followed by Amlodipine Benazepril 10mg-20mg Capsules (test) dosed in second period
89511088|NCT05227664|Experimental|cohort1(AK117 +AK112 +Nab-Paclitaxel/ Paclitaxel)|Subjects receive AK117 and AK112 Plus Nab-Paclitaxel/ Paclitaxel until disease progression or unacceptable toxicity.
89511089|NCT05227664|Experimental|cohort2(AK117 +Nab-Paclitaxel/ Paclitaxel)|Subjects receive AK117 Plus Nab-Paclitaxel/ Paclitaxel until disease progression or unacceptable toxicity.
89511090|NCT05227664|Experimental|cohort3(AK112 +Nab-Paclitaxel/ Paclitaxel)|Subjects receive AK112 Plus Nab-Paclitaxel/ Paclitaxel until disease progression or unacceptable toxicity.
89511091|NCT05226650|Experimental|Regular meal pattern|Participants will follow a regular meal pattern for a week
89511092|NCT05226650|Experimental|Irregular meal pattern|Participants will follow an irregular meal pattern for a week
89511093|NCT05304143|Experimental|Virtual Reality intervention group|The exploration in the intervention group will be carried out with virtual reality glasses compatible with the magnetic resonance imaging equipment.
89210510|NCT00643448|Placebo Comparator|Placebo corresponding to AZD1305 loading dose|Tablets
89511094|NCT05304143|Active Comparator|Conventional nurse support|The exploration in the control group will be carried out with the standard procedure for claustrophobic patients that includes close nursing support.
89511095|NCT05291819|Other|Conventional treat-to-target|Conventional treat-to-target follow-up strategy with structured clinical assessment of disease activity
89511096|NCT05291819|Experimental|Imaging informed treat-to-target|Imaging informed treat-to-target follow-up strategy with both structured clinical assessment of disease activity and structured imaging assessment of disease activity.
89511097|NCT05472662|Experimental|Test Treatment|"Placebo HFA-152a propellant via pMDI:~Administration: Single-dose administration."
89511098|NCT05472662|Placebo Comparator|Reference treatment|"Placebo HFA-134a propellant via pMDI:~Administration: Single-dose administration."
89511099|NCT05226338|Experimental|Sequence 1|3 period, 3 dose level
89511100|NCT05226338|Experimental|Sequence 2|3 period, 3 dose level
89511101|NCT05226338|Experimental|Sequence 3|3 period, 3 dose level
89511102|NCT05226338|Experimental|Sequence 4|3 period, 3 dose level
89511103|NCT05226338|Experimental|Sequence 5|3 period, 3 dose level
89540564|NCT06206109||with common extensor tendon tears|the participants who have common extensor tendon tears demonstrated with ultrasonography.
89540565|NCT06206109||without common extensor tendon tears|the participants who do not have common extensor tendon tears demonstrated with ultrasonography.
89540566|NCT06206044||Study Cohort|Healthy pregnant women of BMI between 20 and 40 kg/m2, height between 5 feet 2 inches and 5 feet 10 inches, who are having cesarean delivery under spinal or combined spinal epidural anesthesia.
89540567|NCT06205524|Experimental|cohort 1|Participants will receive 2 intramuscular (IM) injections of either TI-0010 or Placebo at Dose Level 1 on Day 0 and Day 28
89540568|NCT06205524|Experimental|cohort 2|Participants will receive 1 intramuscular (IM) injection of either TI-0010 or Placebo at Dose Level 1 on Day 0
89540569|NCT06205524|Experimental|cohort 3|Participants will receive 2 intramuscular (IM) injections of either TI-0010 or Placebo at Dose Level 2 on Day 0 and Day 28
89540570|NCT06205524|Experimental|cohort 4|Participants will receive 1 intramuscular (IM) injection of either TI-0010 or Placebo at Dose Level 2 on Day 0
89540571|NCT06205290|Experimental|Arm A: Liso-cel Monotherapy|
89540572|NCT06205290|Active Comparator|Arm B: Investigator's Choice|
89540573|NCT06204523||Popolation|
89540574|NCT06203808||COACH GROUP|The COACH group consists of newly diagnosed head and neck cancer patients seen in consultation for treatment information at Oncologic University Hospital during the first two months of the study. These patients receive coaching support from a specialized nurse, facilitating appointment scheduling, treatment coordination, and access to various rehabilitation services
89540575|NCT06203808||CONTROL GROUP|The control group includes patients who received the treatment information during the third and fourth months of the study, without receiving specific coaching support.
88810869|NCT05308979|Experimental|1 Injection Site|100u Botox® injected at one intradetrusor site
88810870|NCT05308979|Active Comparator|10 Injection Sites|100u Botox® injected at 10 intradetrusor sites
88810871|NCT05296408|Experimental|M+ML|MyoPro paired with motor learning based therapy
88810872|NCT05296408|Active Comparator|ML-alone|motor learning based therapy alone
88810873|NCT05267106|Experimental|Cohort A: IDH-wild-type GBM|Participants with histopathologically proven, WHO Grade 4, IDH-wild-type GBM OR molecular diagnosis of IDH-wild-type, diffuse astrocytic glioma with molecular features of Grade 4 GBM that are recurrent, harboring FGFR1-3 fusions/or other rearrangements, or with a defined FGFR1-3 mutation or in-frame deletion.
88810874|NCT05267106|Experimental|Cohort B: Other gliomas other than GBM|Participants with other histopathologically proven gliomas other than GBM, circumscribed astrocytic gliomas, and glioneuronal and neuronal tumors that are recurrent, harboring FGFR1-3 fusions/or other rearrangements or with a defined FGFR1-3 activating mutation or in-frame deletion
89511104|NCT05226338|Experimental|Sequence 6|3 period, 3 dose level
89511105|NCT00834743|Experimental|1|
89511106|NCT00834743|Active Comparator|2|
89511107|NCT04896502|Experimental|Telemedicine Arm|For the proposed study, participants will randomized to receive TM home assessments/interventions performed by a trained home visitor (HV) or standard of care asthma trigger education by the HV. Those who are randomized to TM home assessments/interventions will complete a baseline home assessment and two follow-up visits, 2 months apart. Visits will assess the presence of potential asthma triggers in the home and frequency of asthma symptoms/exacerbations. TM participants will be provided education and materials necessary to reduce asthma triggers in the home. Follow-up visits will assess the interval change in presence of asthma triggers, change in daily asthma symptoms/exacerbations, and participant/family retention of education.
89540576|NCT06202950|Experimental|Yoga|Applying yoga for one hour a week for eight weeks to with type 1 diabetes
89540577|NCT06202950|Active Comparator|Mindfulness|Applying mindfulness to youth with type 1 diabetes one hour a week for eight weeks
89540578|NCT06202950|No Intervention|control|the control group received the usual care
88810875|NCT05249556|Experimental|GNX|The suspension contains GNX (50 mg/mL), hydroxypropyl methylcellulose, polyvinyl alcohol, sodium lauryl sulfate, simethicone, methylparaben, propylparaben, citric acid, and sodium citrate at pH 3.5 to 4.2, and is sweetened with sucralose and flavored with artificial cherry.
88810876|NCT05249556|Placebo Comparator|Placebo|The PBO suspension consists of titanium dioxide, Avicel® (microcrystalline cellulose and carboxymethylcellulose sodium), sodium lauryl sulfate, simethicone, methylparaben, propylparaben, citric acid, sodium citrate and is sweetened with sucralose and flavored with artificial cherry
88810877|NCT05231200|Active Comparator|Control Arm- Current management|NICUs in the control arm can continue conducting QI activities relevant to current practice and current standard of care, but without receiving the interventions until they transition to the intervention arm.
88810878|NCT05231200|Experimental|Intervention Arm- Collaborative Quality implementation Strategies|The study intervention is a constellation of collaborative QI strategies: 1) QI Team Building; 2) QI Education; 3) Implementation of 2 standardized practice care bundles (Respiratory Care, and Nutritional Care); 4) QI mentoring; and 5) Collaborative networking.
88810879|NCT05231174|Experimental|A self-evlaution tool based on Large Language Model|The self-evlaution tool, powered by a large language model, processes user queries through a comprehensive generation, decision, action, and safety framework to deliver optimal responses. The system's key features include retrieval-augmented in-context learning, which enhances the responses generated by sourcing information from reliable websites. It also incorporates a Guardrail module to mitigate potential harmful content in the responses by validating the content before delivery. Additionally, the system features a Self-checking memory module that maintains essential clinical characteristics across multi-turn dialogues, ensuring consistent and continuous interactions with users.
89540579|NCT06201819|Experimental|Patients with morbid obesity in bariatric surgery preparation protocol|All patients with body mass index >48 kg/m2 in preoperative protocol for bariatric surgery using liraglutide for preoperative weight loss
89024182|NCT03178149|Experimental|ASP7317 Dose Escalation/ Expansion (Group 2: Moderate Vision Loss)|"Successive cohorts of participants (3 participants each) will be given escalating doses (cohort 4: low cells/dose; cohort 5: medium cells/dose; cohort 6: high cells/dose).~Expansion cohorts 5b and 6b (6 participants each) will be opened after cohorts 5 and 6 have been filled. Dose levels for the expansion cohorts will align with dose levels in escalation cohorts. Cohort 4 (low cells/dose) dosing may begin after the DSMB recommendation to begin dosing in Group 1 cohort 2 (medium cells/dose).~Cohort 5 (medium cells/dose) dosing may begin after DSMB review of the 4 week safety data of the first participant in Group 1 cohort 2 (medium cells/dose). Cohort 6 (high cells/dose) dosing may begin after DSMB review of 4 week safety data of the first participant in Group 1 cohort 3 (high cells/dose). Dosing in cohort 5 and 6 can only begin after the DSMB review and the completion of the preceding cohort. Participants will receive tacrolimus and other medicines to stop infection."
89540580|NCT06200909|Experimental|Mindfulness Meditation (MM)|8-week mindfulness meditation program is based on Kabat-Zinn's MBSR program and will be led by MBSR-trained facilitators. The program has been modified to make it more accessible to caregivers. Weekly sessions will be 120-minutes long (instead of original 150-180-minute sessions). Formal meditation practices described in the original MBSR program (i.e., body scan, sitting meditation, mindful movement, mindful eating and walking) will be taught, in addition to loving kindness meditation (LKM). Participants will be given guided meditation recordings and compliance with home practice will be monitored with a practice log. The prescribed home practice has been modified to accommodate the needs of the caregiver: each practice is offered in 5- to 10-minute intervals (5 min, 10 min, and 20 min practice) to accommodate the caregiver's schedule.
89540581|NCT06200909|Active Comparator|Psychoeducation|"Psychoeducation (PSY) condition will be similar to MM with respect to number and duration of weekly sessions and daily homework. PSY is a lecture-based program based on the 10 KeysTM to Healthy Aging Course, an evidence-based program for older adults. Each session focuses on a specific topic related to wellness (e.g., nutrition, physical activity, medical screening) and caregiver-specific topics (e.g., understanding dementia and neurodegenerative disease, legal and financial issues)."
89540582|NCT06200909|Active Comparator|Respite control|Participant allocated to RC will not be exposed to a program, but will be offered 120-minutes of weekly respite care. Caregivers will be asked to record how they spend respite hours each week.
89540583|NCT06198894|Experimental|Steroid-eluting Sinus Implant|In-office bilateral placement of the sinus stent; Systemic glucocorticoid placebo; saline irrigations (250ml) twice daily
89540584|NCT06198894|Sham Comparator|Control|In-office bilateral sham procedure; Systemic glucocorticoid; saline irrigations (250ml) twice daily
89540585|NCT06198010|Active Comparator|Arm I (enhanced usual care)|Patients receive enhanced usual care, which includes access to the educational and pain self-management materials developed for the ASCENT trial (the ASCENT guide).
89540586|NCT06198010|Experimental|Arm II (ASCENT intervention)|Patients receive the ASCENT guide and attend 3 video or phone calls over 30 minutes each with their CHW and/or PCM. During the first call, patients discuss barriers to receiving help for their pain with their CHW. During the second call, patients work with their PCM to develop an action plan for addressing their pain using the different techniques and interventions detailed in the ASCENT guide. During the third and final call, patients meet with both their CHW and PCM to discuss specialist recommendations for their pain management plan. After the final visit, patients will be contacted by the CHW or PCM every other week to monitor their progress and may also be contacted as-needed based on the their reported pain intensity, symptoms, or reported barriers.
89024183|NCT03164785|Experimental|Treatment Group|"Treatment：subjects receive Jinshuibao Capsule. ARB will be continued as a routine therapy.~Counseling: subjects will follow through regular check-up and receive lifestyle and other diabetes treatment counseling"
89024184|NCT03164785|No Intervention|Control Group|Patients receive a standard dose of ARB drug as a routine therapy. Counseling: subjects will follow through regular check-up and receive lifestyle and other diabetes treatment counseling
89024185|NCT03153553|Active Comparator|Ischaemic Preconditioning Group|The participant will rest in a sitting position for 10 minutes before measuring resting blood pressure. Blood pressure will be measured on the arm. IPC will be administered to the upper arm using cuff inflation pressures of 30mm Hg above the systolic BP using a manual BP. The IPC cycles comprised of three cycles of cuff inflation each lasting 5 min in duration followed by 5-min period of cuff deflation
89024186|NCT03153553|Sham Comparator|Control group|The participant will rest in a sitting position for 10 min before measuring resting blood pressure. Blood pressure will be measured on the upper arm. Sham intervention will be administered to the right upper limb using a manual BP cuff which will be inflated at a pressure 30mmg Hg below the diastolic blood pressure. The sham cycles comprised of three cycles of cuff inflation each lasting 5 minutes in duration followed by 5-min period of cuff deflation
89024187|NCT03136887||JOURNEY II XR TKA|This is a single arm study, all subjects will receive JOURNEY II XR TKA
89511108|NCT04896502|Active Comparator|Standard of Care Education|For subjects randomized to receive standard of care asthma education, written and verbal information will be provided regarding identification and removal of potential asthma triggers in the home but no formal assessment of the home will be performed, nor will participants in this arm receive trigger reduction materials.
89511109|NCT00834587|Experimental|Glipizide Metformin|Glipizide Metformin Hydrochloride 5/500 mg Tablet (test) dosed in first period followed by Metaglip™ 5/500 mg Tablet (reference) dosed in second period
89511110|NCT00834587|Active Comparator|Metaglip™|Metaglip™ 5/500 mg Tablet (reference) dosed in first period followed by Glipizide Metformin Hydrochloride 5/500 mg Tablet (test) dosed in second period
89511111|NCT04228094||TDApp1|This cohort will use TDApp1: an eHealth tool to formulate participatory, individualized and automated therapeutic recommendations for patients with Attention Deficit Hyperactivity Disorder
89511112|NCT05649592||Lumbar disc herniation patients|
89511113|NCT05649592||healthy volunteers|
89511114|NCT00918983|Experimental|NX-1207|
89511115|NCT00918983|Placebo Comparator|Placebo|
89511116|NCT05649514|Experimental|Single arm|Prodromal Alzheimer's patients
89511117|NCT00834431|Experimental|1|
89511118|NCT00834431|Active Comparator|2|
89511119|NCT05138900|Experimental|Stereotactic Body Radiation Therapy (SBRT)|A single fraction of targeted SBRT
89511120|NCT00917111|Experimental|CO2 Gas|
89511121|NCT00917111|Placebo Comparator|Inactive Placebo Gas|
89511122|NCT05191940|Other|Particle radiotherapy|According to the radiation plan using protons or carbon ions (between 25 and a maximum of 40 Gy). Planning Target Volume 1 : 25 Gy (Relative Biological Effectiveness) in 5 fractions of 5 Gy (Relative Biological Effectiveness) Planning Target Volume 2 : A simultaneous integrated boost (SIB) will be delivered to the Planning Target Volume 2: 40 Gy (Relative Biological Effectiveness) in 5 fractions of 8 Gy (Relative Biological Effectiveness).
89511123|NCT05653115||Bariatric surgery|Individuals with morbid obesity and clinically relevant portal hypertension undergoing bariatric surgery
89511124|NCT00834275|Experimental|1|
89511125|NCT00834275|Active Comparator|2|
89511126|NCT00834197|Experimental|1|
89511127|NCT00834197|Active Comparator|2|
89511128|NCT05224310|Active Comparator|Pectoral nerve block|Starting from the lateral third of the clavicle and moving distally and laterally to the midaxillary line. The pectoral major and minor muscles will be identified and 10 mL of bupivacaine 0.25% will be injected between the 2 muscles, and then move the ultrasound probe towards the axilla until the serratus anterior is identified above the second, third, and fourth ribs then injection of 20 mL of bupivacaine 0.25% after negative aspiration into the fascial plane between pectoralis minor and serratus anterior muscles.
89511129|NCT05224310|Active Comparator|Serratus anterior plane block|"Aiming to find the serratus anterior muscle the investigator will identify the fifth rib in the midaxillary line by the linear probe in the sagittal plane. The latissimus dorsi muscle (superficial and posterior), teres major muscle (superior) and serratus muscles (deep and inferior) will be detected using ultrasound.~The investigator will penetrate the serratus anterior muscle by a 23 GA, 35 mm needle in-plane to ultrasound probe from supero-anterior to postero-inferior to inject deep to it."
89511130|NCT00833495|Experimental|1|FOV1101-00 concentration 1 and Prednisolone Acetate 0.12% (Pred Mild®)
89511131|NCT00833495|Experimental|2|FOV1101-00 concentration 2 and Prednisolone Acetate 0.12% (Pred Mild®)
89024188|NCT03135652|Experimental|chemoradiotherapy|radiotherapy: adjuvant SBRT of liver lesions; chemotherapy: mFolfox6/ CAPEOX/ Folfiri±cetuximab or bevacizumab, 2 months for neoadjuvant treatment and 4 months for adjuvant treatment
89024189|NCT03135652|Active Comparator|chemotherapy|chemotherapy: mFolfox6/ CAPEOX/ Folfiri±cetuximab or bevacizumab, 2 months for neoadjuvant treatment and 4 months for adjuvant treatment
89024190|NCT03130244|Active Comparator|Device Placement|The patients in this arm will receive the Magnet Anastomosis System and an anastomosis will be created.
89024191|NCT03130244|No Intervention|Control|The patients in this arm will receive the best medical management.
89511132|NCT00833495|Experimental|3|Vehicle of FOV1101-00 and Prednisolone Acetate 1% (Pred Forte®)
89511133|NCT00833495|Placebo Comparator|4|Vehicle of FOV1101-00 and vehicle of FOV1101-00
89511134|NCT05223998|Experimental|Full-thickness skin microcolumns Implantation|implantation of FTSM on open wound
89511135|NCT00830219|Experimental|1|
89511136|NCT00830219|Active Comparator|2|
89511137|NCT05223062||Psoriatic arthritis|Patients with psoriatic arthritis according to the Classification Criteria for Psoriatic Arthritis (CASPAR).
89511138|NCT02274766|Experimental|ADS-5102 (amantadine HCl extended release)|ADS-5102 (amantadine HCl extended release)
89511139|NCT02274766|Placebo Comparator|Placebo|Placebo
89511140|NCT00829673|Experimental|1|
89511141|NCT00829673|Active Comparator|2|Focalin®
89511142|NCT05221658|Experimental|Arm A|As first-line therapy
89511143|NCT05221658|Experimental|Arm B1|EGFR H score ≥ 200, as third-line or above therapy
89511144|NCT05221658|Experimental|Arm B2|EGFR H score <200, as third-line or above therapy
89511145|NCT03134495||PPI exposed children|all children with at least one prescription of PPI
89511146|NCT03134495||non-exposed children|all children with no prescription of PPI
89024192|NCT03125928|Experimental|Investigational Arm|
89024193|NCT03113487|Experimental|Treatment (pembrolizumab, p53MVA)|Patients receive pembrolizumab IV over 30 minutes every 3 weeks and modified vaccinia virus ankara vaccine expressing p53 SC every 3 weeks for up to 3 vaccines. Cycles with pembrolizumab repeat every 3 weeks for up to 49 weeks in the absence of disease progression or unacceptable toxicity.
89024194|NCT03109197||Retrospective SUDC cases|All child biospecimens (including mucosal swab or blood samples for DNA analysis, pathology slides, tissue blocks, tissue samples or organs retained at autopsy) will be transferred to NYU Biorepository
89511147|NCT04875676|Active Comparator|Cohort 1 (4-week boost vaccination)|(4-week boost vaccination) 10 subjects will receive two doses of 1x10 log10 IU ± 0.5 log at Day 1 and Week 4
89511148|NCT04875676|Active Comparator|Cohort 2 (8-week boost vaccination)|(8-week boost vaccination) 10 subjects will receive two doses of 1x10 log10 IU± 0.5 log at Day 1 and Week 8
88810880|NCT05230459|Experimental|AB-1003 Cohort 1|
88810881|NCT05230459|Experimental|AB-1003 Cohort 2|
88810882|NCT05230459|Placebo Comparator|Placebo (Cohorts 1 and 2)|
89024195|NCT03109197||Prospective SUDC cases|Heart and brain tissue will undergo full cardiac pathology consultation or neuropathology consultation will be transferred to pathologists at NYU or Mayo (based on pathologist availability). The PHI will remain intact in these cases since they will need to know how to identify the deceased with the medical records they receive and to complete the entire investigation thoroughly. A full consultation report will be sent back to Dr. Orrin Devinsky and tissue will be returned to the NYU biorepository upon completion of the cardiac or neuropathology consultation.
89511149|NCT04875676|Active Comparator|Cohort 3 (12-week boost vaccination)|(12-week boost vaccination) 10 subjects will receive two doses of 1x10 log10 IU± 0.5 log at Day 1 and Week 12
89511150|NCT05375591||Benign Nodules|CT scans of patients with a new lung nodule(s) subsequently confirmed to be benign and in the context of a previous history of radically treated cancer, will be identified at participating NHS sites and recruited.
89511151|NCT05375591||Metastatic Nodules|CT scans of patients with a new lung nodule(s) subsequently confirmed to be metastatic in nature and in the context of a previous history of radically treated cancer, will be identified at participating NHS sites and recruited.
89511152|NCT05375591||Second Primary Lung Cancers|CT scans of patients with a new lung nodule(s) subsequently confirmed to be a new second primary lung cancer and in the context of a previous history of radically treated cancer, will be identified at participating NHS sites and recruited.
89511153|NCT05189288|Experimental|Reference-Test|D418 Tab. - CKD-388 Tab.
89511154|NCT05189288|Experimental|Test-Reference|CKD-388 Tab. - D418 Tab.
89511155|NCT05132114|No Intervention|Control Group|LLETZ (without intraoperative Lugol's iodine)
89511156|NCT05132114|Experimental|Iodine group|LLETZ after the intraoperative application of Lugol's iodine
89511157|NCT05187104|Experimental|Patients with age-related macular degeneration receiving standard treatment and retinal stem cells|Patients with age-related macular degeneration receiving standard treatment and autologous retinal stem and progenitor cells
89511158|NCT05187104|Active Comparator|Patients with age-related macular degeneration receiving standard treatment|Patients with age-related macular degeneration receiving standard treatment
89511159|NCT02370238|Experimental|paclitaxel+reparixin|"paclitaxel 80 mg/m2 i.v. (Days 1, 8, and 15) + reparixin oral tablets 1200 mg t.i.d.~continuing from D 1 to Day 21 of 28-day cycle"
89511160|NCT02370238|Active Comparator|paclitaxel+placebo|paclitaxel 80 mg/m2 i.v. (Days 1, 8, and 15) + placebo oral tablets 1200 mg t.i.d. continuing from D 1 to Day 21 of 28-day cycle
89511161|NCT05130164||Single group|Single group will be selected for age estimation using CBCT Scans
89511162|NCT05129384|Active Comparator|Treatment|B. infantis EVC001 infant probiotic
89511163|NCT05129384|Placebo Comparator|Placebo|Lactose
89511164|NCT05109104|Experimental|CAP UnScented|Single topical application: 80 +/- 2 milligrams (mg) (2.0 +/- 0.05 mg per square centimeter [mg/cm^2]) of CAP UnScented will be applied to the assigned test site using a fingercot. Test material will be evenly spread over the test site using light pressure for 35 +/- 15 seconds.
89511165|NCT05109104|Experimental|CAP Herbal Mint Flavour|Single topical application: 80 +/- 2 mg (2.0 +/- 0.05 mg/cm^2) of CAP Herbal Mint Flavour will be applied to the assigned test site using a fingercot. Test material will be evenly spread over the test site using light pressure for 35 +/- 15 seconds.
89511166|NCT05109104|Experimental|CAP Mountain Berry Flavour|Single topical application: 80 +/- 2 mg (2.0 +/- 0.05 mg/cm^2) of CAP Mountain Berry Flavour will be applied to the assigned test site using a fingercot. Test material will be evenly spread over the test site using light pressure for 35 +/- 15 seconds.
89511167|NCT05109104|Active Comparator|SPF Standard|Single topical application: 80 +/- 2 mg (2.0 +/- 0.05 mg/cm^2) of SPF Standard will be applied to the assigned test site using a fingercot. Test material will be evenly spread over the test site using light pressure for 35 +/- 15 seconds.
89511168|NCT05108636|Experimental|Therapeutic Touch|"TD process:~After the procedure was explained, the focus was on the child to be treated,~Intended to help the child's treatment and sleep,~The patient's energy field was scanned with the hands at a distance of 8-12 cm from the patient's skin (2 times)~To remove the blockages determined regarding the energy flow and to facilitate the energy flow, manual cleaning was performed (2 times),~Imbalances in the energy fields were tried to be treated by using mental visualization techniques such as dreaming, positive thinking and visualization, by directing the universal life energy to sick individuals with calm and rhythmic hand movements (2 times),~Reassessed to determine whether success has been achieved in treating imbalances in the energy field."
89540587|NCT06197282||COVID-19 Positive, Symptomatic|Patients undergoing major surgery with a documented positive COVID19 test with in 1 year of surgery and were symptomatic for COVID19 at the time of testing.
88810883|NCT05229029|Experimental|TCM decoction|Compound granules of Traditional Chinese Medicine
88810884|NCT05229029|Placebo Comparator|placebo|Placebo only
88811553|NCT01277159|Experimental|Nerve Block with Buprenorphine (0.3 mg). IV Dexamethasone (|Nerve Block with Buprenorphine (0.3 mg). IV Dexamethasone (4 mg).
88811554|NCT01277159|Experimental|Nerve Block with Dexamethasone (4 mg) / block Buprenorphine|Nerve Block with Dexamethasone (4 mg) / block Buprenorphine (0.3 mg). IV saline.
89511169|NCT05108636|Experimental|Music Rest|"Parents and children will be informed about the Music Rest before the procedure.~One day before the Music Rest practice, the child's sleep will be evaluated with Actigraphy. Starting the day after the first measurement, the Music Rest will be held for three days as a 20-minute practice period per day. In order to help the child sleep, the child will be listened to music (such as lullaby, classical music) preferred by the patient or his family.~Before the Music Rest application, the patient's room will be ventilated and a spacious and quiet environment will be provided during the application.~The sound level of the music played will be kept between 45-65 dB.~Nursing interventions will be written in more detail after the data of the research is collected."
89511170|NCT04421612|Experimental|Intensive|This group recieve access to a new module every 3rd day.
89511171|NCT04421612|Experimental|Ordinary|This group recieve access to a new module every 5th day.
89511172|NCT02370160|Experimental|DT2219ARL|A recombinant bispecific antibody-targeted toxin.
89511173|NCT05126342|Experimental|Cohort A|Recurrent ovarian-, fallopian tube, or primary peritoneal cancer with relapse after more than 6 months of PARPi maintenance therapy.
89511174|NCT05126342|Experimental|Cohort B|Recurrent ovarian-, fallopian tube, or primary peritoneal cancer with relapse within 6 months of PARPi maintenance therapy.
89511175|NCT05183516|Experimental|Tdap|Open label study, no placebo comparator
89511176|NCT02273908||Pregabalin|Patients will be treated for 8 weeks with pregabalin in primary care: no intervention
89511177|NCT02273908||Usual care|Patients will be treated for 8 weeks with other analgesics in usual care: no intervention
89511178|NCT05180708|Active Comparator|Active|
89511179|NCT05180708|Placebo Comparator|Vehicle|
89511180|NCT02273752|Experimental|Supportive care (real-time pharmacokinetic TDM of everolimus)|Patients receive everolimus PO daily on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients also undergo real-time pharmacokinetic TDM on days 4, 8, and 15 of course 1. Dosing adjustments of everolimus will be performed on day 8, if necessary. If the everolimus dose is adjusted, patients will continue to undergo real-time pharmacokinetic TDM weekly until goal concentrations are achieved on 2 consecutive measures. Patients whose everolimus dose is not adjusted undergo real-time pharmacokinetic TDM on day 1 of courses 2-6.
89511181|NCT05180630|Experimental|Custom earmolds, then Open domes, then Vented domes|Participants first fit with Audeo 90P hearing aids and custom earmolds with dynamic venting, then fit with the same hearing aids using open domes, then fit with the same hearing aids using vented domes.
89511182|NCT05180630|Experimental|Open domes, then Vented domes, then Custom earmolds|Participants first fit with Audeo 90P hearing aids and open domes, then fit with the same hearing aids using vented domes, then fit with the same hearing aids using custom earmolds with dynamic venting.
89511183|NCT05180630|Experimental|Vented domes, then Custom earmolds, then Open domes|Participants first fit with Audeo 90P hearing aids and vented domes, then fit with the same hearing aids using custom earmolds with dynamic venting, then fit with the same hearing aids using open domes.
89511184|NCT05179538|Experimental|Single Arm Treatment|Cued picture naming therapy will be delivered to all participants. There will be four cohorts of participants based on BDNF and ApoE genotypes.
89511185|NCT02273596|Experimental|ALXN1840|"Treatment Period: ALXN1840 at individualized doses ranging from 15 to 60 milligram (mg) per day. Dose increases or dose reductions were dependent on the individual NCC concentrations adjusted for Mo plasma concentration. ALXN1840 may have been administered every other day, once daily, or twice daily, depending on individualized dosing regimen, for 24 weeks.~Extension Period: Participants continued the same ALXN1840 daily dose maintained at Week 24 of the Treatment Period and the same dosing regimen. During the Extension Period, no up-titration was made unless NCC concentrations adjusted for Mo plasma concentration did not remain stable within (or below) the reference range. ALXN1840 could have been received for up to 36 months in the Extension Period."
89511186|NCT05124236|Experimental|Preoperative radiosurgery|The interventional arm is single fraction preoperative radiosurgery to a brain metastasis identified for neurosurgical resection.
88811555|NCT01361867|Other|Robot-induced perturbations|The subject walks on a treadmill with his/her legs strapped to a robotic system (Lokomat by Hocoma AG) that generates mechanical perturbations aimed to modify the subject's walking pattern.
88811556|NCT01277783|Experimental|Endocardial Left Ventricular pacing|All patients will undergo the intervention, and are followed at 1, 3, 6, and 12 months (minimum) and biannually thereafter until 1 year after enrollment of the last patient.
88811557|NCT01278485||Sulphonylurea (SU) Monotherapy or SU + Metformin|Participants with Type 2 diabetes that have been treated with SU monotherapy for at least 6 months by a cardiologist, nephrologist, or family practice doctor.
88811558|NCT01362959|Experimental|Nicotine patch|
88811559|NCT01362959|Placebo Comparator|Control patch|The control product is a look-alike patch compared to the test product, containing no nicotine or other active substances.
88811560|NCT01278953|Experimental|TactiCath|Catheter ablation to treat paroxysmal AF using the TactiCath catheter with contact force capability
88811561|NCT01278953|Active Comparator|Control|Catheter ablation to treat paroxysmal AF using a catheter with no contact force sensing capability
88811562|NCT01332461||COPD Patients|Patients over the age of 40 with a COPD-related hospital or ER visit
88811563|NCT01279109|Experimental|Social network building intervention|Healthy lifestyle intervention focused on building healthy lifestyle skills and reciprocal social ties between the intervention group members
88811564|NCT01279109|Active Comparator|Home visit|Home visits focused on preventable infant injuries
88959395|NCT02003326|Other|Inflammatory markers|All patients with inclusion criteria (ARDS moderate and severe: Berlin definition) and absence of non inclusion criteria will have a broncho alveolar wash at day 0 and blood sample every three day to measure inflammatory markers. All patients will receive protective ventilation with low tidal volume and pressures limited (Pplat <30cmH2O). End-Expiratory Lung Volume and strain will be measured every 6 hours from the inclusion to the extubation.
88959396|NCT02003339|Experimental|RMIs|
88959397|NCT02003378|Active Comparator|Minute Ventilation (MV)|Pacemaker sensor set to MV (Cross over study)
88959398|NCT02003378|Active Comparator|Accelerometer (XL)|Pacemaker sensor set to XL (Cross over study)
88959399|NCT02003417||Non-metastatic prostate cancer patients|Histologically-confirmed, non-metastatic prostate cancer patients who received external beam radiation treatment with androgen deprivation therapy (total ADT duration > 3 months) for definitive treatment.
88959400|NCT02003430||≥65 years old|20 patients greater than or equal to 65 years of age
88959401|NCT02003430||<65 years old|20 patients less than 65 years of age
88959402|NCT02003456|Experimental|Cardiac PET scan|To evaluate methods that could allow the use of two radiotracers(rubidium-82/18F-fluorodeoxyglucose(FDG)and rubidium-82, that are used in cardiac positron emission tomography(PET)imaging scans to be performed at one time instead of the current method which involves being imaged at separate times, several hours apart.
88959403|NCT02003469|Experimental|Ambulatory Blood Pressure Monitoring|All enrolled patients have an ambulatory blood pressure monitor placed, pre-transplant/donation, again at 3 months and finally at 12 months post-transplant/donation to measure blood pressure and blood pressure patterns
88959404|NCT02003482||Postop IMRT for Head/Neck cancer|CT for Radiation Treatment Planning
89511187|NCT05124236|Active Comparator|Postoperative hypofractionated stereotactic radiotherapy|The active comparator arm is the standard of care of postoperative hypofractionated stereotactic radiotherapy to the surgical cavity in 5 fractions following resection of the brain metastasis.
89511188|NCT01656200|Experimental|Vaccine|Single dose live attenuated Japanese encephalitis vaccine SA14-14-2
89511189|NCT05102552|Active Comparator|Cohort 1|BIS-001: Treatment A and SPN-817: Treatment B
89511190|NCT05102552|Active Comparator|Cohort 2|BIS-001: Treatment A and SPN-817: Treatment C
89511191|NCT02369848|Experimental|Lithoplasty Treatment|Shockwave Lithoplasty System
89511192|NCT05649202||All inmates entering the CPPLS|Patients with positive HCV serology
89511193|NCT05116982|Experimental|ORGONO Living Silica Acacia Gum-MMST Powder|ORGONO Living Silica Acacia gum-MMST Power. In capsules. One capsule a day for 7 days.
89511194|NCT05116982|Experimental|ORGONO Living Silica Malto-OSA Powder|ORGONO Living Silica Malto-OSA Powder. In capsules. One capsule a day for 7 days.
89511195|NCT05116982|Experimental|ORGONO Living Silica Collagen Booster|ORGONO Living Silica Collagen Booster. Liquid. One bottle a day for 7 days.
89511196|NCT05116982|Placebo Comparator|Placebo|Placebo. In capsules and liquid. One capsule and one bottle a day for 7 days.
89511197|NCT02368210|Experimental|122-0551 Foam|122-0511 Foam, topically applied twice daily
89511198|NCT02368210|Placebo Comparator|Vehicle Foam|Vehicle Foam, topically applied twice daily
89511199|NCT05178524|Experimental|Bifico Group|Continued administration during perioperative period
89511200|NCT05178524|No Intervention|Control Group|No intervention
89511201|NCT05177978|Experimental|Phosphatidylserine|100 mg elemental phosphatidylserine
89511202|NCT05177978|Placebo Comparator|Placebo|Placebo comparator
89511203|NCT02273050|Experimental|Saxagliptin 5 mg + Metformin (500 mg with titration)|Saxagliptin 5 mg once daily and metformin 500 mg once daily, then titrate. Acarbose will be used as rescue medication as needed.
89511204|NCT02273050|Active Comparator|Saxagliptin 5 mg + Placebo|Saxagliptin 5 mg once daily and Placebo 500 mg once daily, then titrate. Acarbose will be used as rescue medication as needed.
89511205|NCT02273050|Active Comparator|Metformin (500 mg with titration) + Placebo|Placebo 5 mg once daily and metformin 500 mg once daily, then titrate. Acarbose will be used as rescue medication as needed.
89511206|NCT02272816|Experimental|Carboplatin AUC-10|
89511207|NCT05173610|Experimental|SBRT arm|Patients will be treated with stereotactic body radiotherapy (SBRT) for oligometastasis from hepatocellular carcinoma
89511208|NCT05113238|Active Comparator|AGT-Initial|Oocytes will be injected with spermatozoa and will be incubated in 10 mM calcium ionophore (Sigma-Aldrich) for two rounds of 10 minutes at 37 C, 30 minutes after ICSI injection, and then will be rinsed and transferred into culture medium.
89511209|NCT05113238|Experimental|AGT-revised|"ejaculated spermatozoa will be exposed to calcium ionophore in a drop on the ICSI dish before injection. During the ICSI procedure, spermatozoa will be aspirated individually from the drop containing calcium ionophore and immobilized in a separate PVP drop. Next, approximately 0.4 pL of calcium ionophore will be aspirated into the micropipette and injected into the oocyte with the spermatozoa.~Post-ICSI oocytes will be then exposed to 50 mM calcium ionophore for 10 minutes at 37C, and then will be washed and placed in culture medium."
89511210|NCT02271880|Active Comparator|Medication as usual|Medication as typically prescribed by physician.
89511211|NCT02271880|Active Comparator|Medication as usual + STAR|Medication as typically prescribed with the addition of the psychosocial intervention to improve medication adherence
89511212|NCT05170256|Experimental|Treatment arm|
89511213|NCT05386979|Other|Opioid anesthesia group|Anesthesia induction with propofol 2.5mg/kg, rocuronium bromide 0.6mg/kg, sufentanil 0.3μg/kg, intubation was performed when BIS value reached 40-60. Intraoperative pump injection of propofol 4-12 mg/kg·h and remifentanil 0.2-0.5 μg/kg·min to maintain anesthesia. Ultrasound-guided transversus abdominis plane block (with 0.375% ropivacaine 40ml) will be implemented preoperatively. Ondansetron 8mg and sufentanil 10 μg will be given after surgery. For PCA, sufentanil 2μg/kg + dexmedetomidine 2μg/kg + ondansetron 24mg.
88959405|NCT02003482||Chemo/IMRT for bulky Head/Neck cancer|CT for Radiation Treatment Planning
88959406|NCT02003495|Experimental|MCV-ACYW135 Vaccine Group|"Participants at age 2 to 6 years of enrollment will receive 1 dose on Meningococcal ( A, C, Y and W 135) conjugate vaccine.~Participants at age 6 to 23 months of enrollment will receive 2 doses on Meningococcal ( A, C, Y and W 135) conjugate vaccine at 3 months apart.~Participants at age 3 to 5 months of enrollment will receive 3 doses on Meningococcal ( A, C, Y and W 135) conjugate vaccine at 1 month apart.~Participants at age 2 to 5 months of enrollment will receive 3 doses on Meningococcal ( A, C, Y and W 135) conjugate vaccine at 2 months apart."
88959407|NCT02003495|Active Comparator|MPV-ACYW135 Vaccine Group|Participants at age 2 to 6 years of enrollment will receive 1 dose on Group A, C, Y and W135 Meningococcal Polysaccharide Vaccine
88959408|NCT02003495|Active Comparator|MPV-A Vaccine Group|Participants at age 6 to 23 months of enrollment will receive 2 doses on Group A Meningococcal Polysaccharide vaccine at 3 months apart.
89511214|NCT05386979|Experimental|Opioid free anesthesia group|Anesthesia induction with propofol 2.5mg/kg, rocuronium bromide 0.6mg/kg, naborphine 0.2mg/kg，esketamine 0.3mg/kg, intubation was performed when BIS value reached 40-60. Intraoperative pump injection of propofol 4-12 mg/kg·h and esketamine 0.3～0.5mg/kg·h. Ultrasound-guided transversus abdominis plane block (with 0.375% ropivacaine 40ml) will be implemented preoperatively. Ondansetron 8mg and naborphine 0.2mg/kg will be given after surgery. For PCA, naborphine 2mg/kg + dexmedetomidine 2μg/kg + ondansetron 24mg.
88959409|NCT02003495|Active Comparator|MCV-AC Vaccine Group|Participants at age 3 to 5 months of enrollment will receive 3 doses on Group A and C Meningococcal conjugate vaccine at 1 month apart.
88959410|NCT02003495|Placebo Comparator|Hib Vaccine Group|Participants at age 2 to 5 months of enrollment will receive 3 doses on Haemophilus Influenzae Type b Conjugate Vaccine at 2 months apart.
88959411|NCT02003521||Intervension|Lung Flute
88959412|NCT02003547|Experimental|AMA0076 Formulation A|Topical Ocular Drop BID X 1 wk
88959413|NCT02003547|Experimental|AMA0076 Formulation B|Topical Ocular Drop BID X 1wk
88959414|NCT02003547|Experimental|AMA0076 Formulation C|Topical Ocular Drop BID X 1 wk
88959415|NCT02003547|Placebo Comparator|Placebo|Topical Ocular Drop BID X 1 wk
88959416|NCT02003560|Experimental|Accelerated partial breast irradiation|Accelerated partial breast irradiation delivered by 3 dimensional conformal radiotherapy or intensity modulated radiotherapy
88959417|NCT02003586|Other|Plant-based ingredient to a starchy meal|Plant-based ingredient
88959418|NCT02003586|Other|Starchy meal alone|No plant-based ingredient
88959419|NCT02003599|Placebo Comparator|Placebo|"In the control group, 26 patients will be submitted to a laser, but the laser will be disabled without affecting its apparent function , five days a week before radiotherapy .~Both arm will use institutional skin care protocol."
88959420|NCT02003599|Experimental|Laser therapy|"In the intervention group, 26 patients will be submitted a laser therapy .The low level laser therapy used in this trial will be Photon Lase III (DMC, approved by ANVISA for medicinal purposes). This InGaAIP laser emits a pulsed 660 nanometer beam with an average output of 80 milliwatts and the average energy density delivered to the breast will be 3 J/cm2. It will be administrated five days a week before radiotherapy.~Both arm will use institutional skin care protocol."
89511215|NCT05470556||Overweight adolescents|This group will consist of 20 overweight adolescents (Body mass index (BMI) percentile value is 85.-95)
89511216|NCT05470556||Obese adolescents|This group will consist of 20 obese adolescents (BMI percentile value is above the 95th)
89511217|NCT05470556||normal weight|This group will consist of 20 normal-weight adolescents (BMI percentile value is 5th-85th.)
89511218|NCT05111600|Experimental|Treatment|After confirmation of eligibility criteria and ICF signature, subject undergoes to skin biopsy for collection of autologous epidermal cells to be used to produce IMP under GMP process. Approximately 2 months later, IMP is transplanted on selected area.
89511219|NCT02367352|Experimental|Cohort 1 (Dose Escalation Phase)|Alisertib 15 mg, tablet, orally, twice daily, (3 days on/4 days off for 3 weeks) on Days 1 to 3, 8 to 10 and 15 to 17 in 28 day cycles in combination with Paclitaxel 60 mg/m^2, intravenous (IV), on Days 1, 8, and 15 in a 28-day cycle until disease progression or unacceptable toxicity (Up to 22 Cycles).
89511220|NCT02367352|Experimental|Cohort 2 (Dose Escalation Phase)|Alisertib 25 mg, tablet, orally, twice daily, (3 days on/4 days off for 3 weeks) on Days 1 to 3, 8 to 10 and 15 to 17 in 28 day cycles in combination with Paclitaxel 60 mg/m^2, intravenous (IV), on Days 1, 8, and 15 in 28-day cycle until disease progression or unacceptable toxicity. Dose of alisertib will be de-escalated to 20 mg if ≥ 2 participants experience a dose limiting toxicity (DLT).
89511221|NCT02367352|Experimental|Dose Expansion Cohort|Alisertib, MTD/RP2D determined in Dose Escalation Phase, orally, twice daily, (3 days on/4 days off for 3 weeks) on Days 1 to 3, 8 to 10 and 15 to 17 in 28 day cycles in combination with Paclitaxel 60 mg/m^2, IV on Days 1, 8, and 15 in 28-day cycle until disease progression or unacceptable toxicity.
89511222|NCT05468216|Experimental|MovIn-Lessons group|The schools which will implement the movement integration in the learning activities of primary education subjects (maths, natural science and English).
89511223|NCT05468216|No Intervention|Control group|Schools which will continues applying the same methodology in the realization of the learning activities.
89511224|NCT02365636|Experimental|TV-45070 4%|TV-45070 ointment in a 4% strength applied topically twice daily to the area of postherpetic neuralgia (PHN) pain during the treatment period from days 1 through 28.
89511225|NCT02365636|Experimental|TV-45070 8%|TV-45070 ointment in a 8% strength applied topically twice daily to the area of postherpetic neuralgia (PHN) pain during the treatment period from days 1 through 28.
89511226|NCT02365636|Placebo Comparator|Placebo|Placebo ointment applied topically twice daily to the area of postherpetic neuralgia (PHN) pain during the treatment period from days 1 through 28.
89511227|NCT01655498|Experimental|Vaginal Bowel Control|A vaginal bowel control system intended to manage fecal incontinence.
89511228|NCT05053256||HFpEF|Heart failure with preserved ejection fraction
89024196|NCT03103971|Experimental|Treatment (leukapheresis, chemotherapy, huJCAR014)|Patients undergo leukapheresis. Beginning 14-16 days after leukapheresis, patients undergo lymphodepleting chemotherapy comprising either cyclophosphamide IV daily for 1 day and fludarabine IV daily for 3 days or cyclophosphamide and fludarabine IV daily for 3 days. Within 36-96 hours after completion of lymphodepleting chemotherapy, patients receive huJCAR014 IV over 20-30 minutes on day 0.
89511229|NCT05053256||HFrEF|Heart failure with reduced ejection fraction
89024198|NCT03049033|Experimental|Neurologic Music Therapy (NMT)|Neurologic Music Therapy is a 5-week intervention using different musical instruments and auditory cues to specifically improve fine motor movements.
88816055|NCT02480439|Experimental|TAK-648 Sequence CAB|Regimen C TAK-648 0.3 mg, solution, orally, in fasted state, once on Day 1 of Period 1, followed by at least 7 day washout period, followed by Regimen A TAK-648 0.3 mg, tablet, orally, after a high fat meal, once on Day 1 of Period 2, followed by at least 7 day washout period, followed by Regimen B TAK-648 0.3 mg, tablet, orally, in fasted state, once on Day 1 of Period 3.
89024199|NCT03049033|Active Comparator|Occupational Therapy (OT)|Standard of care occupational therapy uses traditional motor training.
89024200|NCT03049033|No Intervention|Waitlist Control|Participants assigned to the waitlist-control condition will not immediately receive services. The no-treatment duration for these participants is yoked to the amount of time their respective NMT- and OT-condition participants receive services (5 weeks). After the wait period, these participants will then be randomized to receive either NMT, MST or OT sessions.
89024201|NCT03049033|Active Comparator|Music Supported Therapy (MST)|Music Supported Therapy uses musical instruments to train fine motor movements.
89024202|NCT03033225|Experimental|Treatment (verteporfin, EUS-guided PDT)|Patients receive verteporfin IV and undergo fluorescence imaging and after 60 minutes undergo EUS-guided PDT.
89511230|NCT04998266|Experimental|Individualized exercise group (IND)|Group with adapted and personalized exercises (IND).The IND group will perform strength, aerobic or flexibility exercises depending on their needs observed during the first assessment.
89511231|NCT04998266|Active Comparator|Traditional exercise group (CLA)|Group with traditional exercise (CLA). The CLA group will perform exercises following WHO (World Health Organization) prescription.
89511232|NCT02270944|Experimental|Liquid GBS trivalent vaccine|Healthy non-pregnant women aged 18-40 years that received a single dose of liquid GBS trivalent vaccine
89511233|NCT02270944|Active Comparator|Lyophilized GBS trivalent vaccine|Healthy non-pregnant women aged 18-40 years that received a single dose of lyophilized GBS trivalent vaccine
89511234|NCT05648734||Group A|Patients received Corticosteroids only
89511235|NCT05648734||Group B|Patients received Corticosteroids in combination with Colchicine
89511236|NCT05648734||Group C|Patients received Corticosteroids in combination with Pirfenidone
89511237|NCT05648734||Group D|Patients received Corticosteroids in combination with Colchicine and Pirfenidone
89511238|NCT05051462|Experimental|Intervention group|Study participants participating in family constellation therapy between assessment 1 and 2.
89511239|NCT05051462|No Intervention|Wait-list control group|Study participants participating in family constellation therapy only after all 3 assessment points.
89511240|NCT02365558|Experimental|Evacetrapib|Single oral dose of evacetrapib administered alone on Day 1 of Period 1.
89511241|NCT02365558|Experimental|Omeprazole + Evacetrapib|"In Period 2, participants will receive 40 mg oral dose of Omeprazole once daily (QD) on Days 8 through 20.~Evacetrapib will be co-administered once, orally on Day 14."
89511242|NCT05085548|Experimental|Dose Escalation|Participants will receive ProAgio in escalating doses.
89511243|NCT05085548|Experimental|Biopsy Arm|Participants will receive ProAgio at the RP2D and undergo tumor biopsy.
89511244|NCT05085548|Experimental|Standard Arm|Participants will receive ProAgio at the RP2D.
89511245|NCT02365480|Experimental|Arm I (berberine chloride)|Patients receive berberine chloride PO TID for 90 days in the absence of disease progression or unacceptable toxicity.
89511246|NCT02365480|Placebo Comparator|Arm II (placebo)|Participants receive placebo PO TID for 90 days in the absence of disease progression or unacceptable toxicity.
89511247|NCT05050526|Experimental|Exercise program|Participants in the experimental group will take part in a 12-week exercise program.
89511248|NCT05050526|No Intervention|Control|Participants in the control group will not receive any intervention.
89511249|NCT04875767|Experimental|HA-based scaffold with BMA (Hyalofast®; Anika Therapeutics, Bedford, MA, USA)|Those allocated to the scaffold treatment group will have 30 ml of BMA harvested from the ipsilateral iliac crest under fluoroscopic guidance. The hip arthroscopy will then be resumed, and the damaged cartilage lesion will be debrided using a mechanical shaver to remove loose and calcified tissue. Once the walls of the lesion are confirmed to be stable with a probe, the exact size of the defect will be measured for templating of the scaffold. The biodegradable HA-based scaffold (Hyalofast®; Anika Therapeutics, Bedford, MA, USA) will be prepared by cutting it to fit the focal defect. Once the cartilage lesion is dried manually, this scaffold will be implanted into the defect after it has been soaked in the BMA. The scaffold will then be secured to the defect in a press-fit fashion to the surrounding cartilage. In the case where additional fixation of the scaffold is needed, such as uncontained shoulder of cartilage, fibrin glue will be used to secure the scaffold.
89511250|NCT04875767|Active Comparator|Microfracture|As per current standard of care for focal articular cartilage lesions of the acetabulum, the unstable cartilage will be debrided and removed from the subchondral bone using a mechanical shaver until a stable margin is obtained. A ring curette will be used to remove the calcified cartilage layer and create a border of healthy cartilage tissue that can support the marrow clot. Through the mid-anterior portal, specialized 90˚ awls will then be placed with the tip perpendicular to the subchondral bone of the acetabulum, and a mallet will be used to penetrate the subchondral bone with perforations 3 mm deep to access the bone marrow elements. This is done until the defect is homogeneously covered with micro-perforations 2-3 mm apart.
89511251|NCT05648656|Active Comparator|TXA|Nebulization with TXA 500mg/ 5mL 8 hourly for 2 days.
89511252|NCT05648656|Placebo Comparator|Control|Nebulization with 0.9%normal saline 5mL 8 hourly for 2 days
89511253|NCT02270242|Active Comparator|Aspirin + Ticagrelor|enteric coated aspirin 81mg-100mg daily p.o. for 12 months and ticagrelor 90mg tablet bid for 12 months
89024203|NCT03030118|Active Comparator|Hydroxychloroquine|Hydroxychloroquine will be administered as a once daily dose of 200 or 400 mg, based on the patient's weight. Treatment will be for 96 weeks.
89024204|NCT03030118|Placebo Comparator|Placebo oral capsule|Placebo will be administered as one or two capsules as a single daily dose, based on the patient's weight. Treatment will be for 96 weeks.
89024205|NCT03011567|Experimental|Severe HDP- NSAID|This arm will be assigned a postpartum analgesic regimen with ibuprofen.
89024206|NCT03011567|Experimental|Mild HDP- NSAID|This arm will be assigned a postpartum analgesic regimen with ibuprofen.
89024207|NCT03011567|Experimental|Severe HDP- No NSAID|This arm will be assigned a postpartum analgesic regimen with acetaminophen.
89511254|NCT02270242|Placebo Comparator|Placebo + Ticagrelor|placebo pill daily p.o. for 12 months - match for enteric coated aspirin 81mg-100mg and ticagrelor 90mg tablet bid for 12 months
89511255|NCT04869124|Active Comparator|Dapagliflozin|Dapagliflozin tablet (10mg/tablet), orally, once daily for 12 weeks.
89511256|NCT04869124|Placebo Comparator|Placebo|Placebo tablet, matching Dapglilflozin, orally, once daily for 12 weeks.
89511257|NCT04421066||Peri-implantitis|Patients with at least one dental implant diagnosed with peri-implantitis undergoing treatment for peri-implantitis as their standard of care will be included in this study.
89511258|NCT04421066||Healthy|Patients with general good health and health gingiva undergoing extraction of wisdom tooth will be included in this study group.
89511259|NCT02364388|Active Comparator|Imagio IUS gray-scale ultrasound|Imagio gray-scale ultrasound
89511260|NCT02364388|Other|Imagio OA/US|Imagio OA/US (opto-acoustic+gray-scale ultrasound)
89511261|NCT05648578|Experimental|Experimental|Participants received reiki application for 4 weeks.
89511262|NCT05648578|No Intervention|Control|No intervention was applied to the participants in the control group
89511263|NCT05049356||Children referred to outpatient clinic|Diagnostic interview (Schedule for Affective Disorders and Schizophrenia (K-SADS) cf. Diagnostic and Statistical Manual of Mental Disorders (DSM-5)) with parents. Diagnostic groups/cohorts (e.g., DMDD, ADHD, Oppositional Defiant Disorder) will be based on the diagnoses given cf. K-SADS.
89511264|NCT05049356||Typical developing children and their parent(s)|Norm values on hair cortisol data will be obtained from typical developing children and their parent(s) by the same procedure as described under Outcome measure(s), 21. Stress Response by Cortisol levels.
89511265|NCT05648266|Active Comparator|Continuous SAPB|postoperative serratus-anterior-plane-block 20ml Ropivacain 0,75%, pain catheter with continous administered Ropivacain (5ml/h 0,2% for 48h)
89511266|NCT05648266|Placebo Comparator|Placebo|standard of care
89024208|NCT03011567|Experimental|Mild HDP- No NSAID|This arm will be assigned a postpartum analgesic regimen with acetaminophen.
89024209|NCT03006302|Experimental|Epacadostat/Pembrolizumab/CY/GVAX/CRS-207|
89024210|NCT03006302|Experimental|Epacadostat/Pembrolizumab/CRS-207|
89024211|NCT02997293||Enhanced Recovery|Those subjects who had major colorectal surgery at the University of Arkansas for Medical Sciences after Enhanced Recovery After Surgery implementation, between the dates of June 1, 2015 to November 30, 2016
89024212|NCT02997293||pre-Enhanced Recovery|Those subjects who had major colorectal surgery at the University of Arkansas for Medical Sciences prior to Enhanced Recovery After Surgery implementation between the dates of January 1, 2014 to December 31, 2014
89024213|NCT02988609|Experimental|Concussion Group|Players with a recent (<72 hours) history of concussion will be assessed 3 times. just after concussion, after disappearance of clinical symptoms and 3 months after the previous visit. During each visit, participant will undergo a neurological and a neuropsychological assessment and a structural and resting state fMRI.
89024214|NCT02988609|Active Comparator|Control Group|a control group with no history of concussion will be the comparator. Participants will be assessed 3 times. Visits will be the same for the control group and duration between visits in this group will be matched to the concussion group. During each visit, participant will undergo a neurological and a neuropsychological assessment and a structural and resting state fMRI.
89024215|NCT02962973|Experimental|Carmat TAH|The surgical intervention takes place through a midsternotomy utilizing cardiopulmonary bypass. The device is then connected via a percutaneous driveline to an external controller and batteries and takes over the circulation.
89024216|NCT02932553|Experimental|BVS and OMT|Optimal medical treatment + BVS implantation
89024217|NCT02924129|Experimental|Evoke SCS with Feedback|closed-loop/automatic stimulation
89511267|NCT02363686|Other|FEES & Bedside Swallow Evaluation (BSE)|Subjects will receive a Fiberoptic Endoscopic Evaluation of Swallowing (FEES), followed by a speech language pathologist (SLP) performing a bedside swallowing evaluation (BSE).
89511268|NCT05079776||Children aged 0-18 months of age|Children aged 0-18 months of age with no structural abnormalities of the lower limbs or orthopedic conditions
89511269|NCT02268916|Experimental|Intervention|OT-led counseling based on home activity pattern
89511270|NCT02268916|Placebo Comparator|Wait-listed|Usual activity during the study. At the end of the study, will receive OT-led counseling
89511271|NCT04992026|Experimental|ADT plus abiraterone + surgery|After 6 cycles of first-line treatment (Androgen deprivation therapy + abiraterone acetate along with prednisone) , patients will receive robot assisted laparoscopic prostatectomy + enlarged pelvic lymph node dissection (ePLND) within 9 months of being diagnosed. The ADT+abiraterone treatment will be maintained after surgery.
89024218|NCT02924129|Active Comparator|Evoke SCS with Conventional|open-loop/manual stimulation
89511272|NCT04992026|Active Comparator|ADT plus abiraterone|Patients will be only treated with Androgen deprivation therapy + abiraterone acetate along with prednisone. Prostatectomy won't be performed.
89511273|NCT04420832|Active Comparator|Surgical treatment|Patients with a distance of 5 mm or more between tendon ends will be treated surgically and with physiotherapy
89511274|NCT04420832|Other|Non-surgical treatment|Patients with a distance of less than 5 mm between tendon ends will be treated non-surgically and with physiotherapy
89511275|NCT02518490|Experimental|Sapphire lens|Each subject will be randomized to wear the test lens on one eye and control lens on one eye.
89511276|NCT02518490|Active Comparator|enfilcon A|Each subject will be randomized to wear the test lens on one eye and control lens on one eye.
89511277|NCT04989998|Experimental|Hip7 Software on Kick/ CORI platforms|Subjects will receive total hip arthroplasty surgery using Hip7 on Kick or CORI platform utilizing R3 Polarstem implants.
89540588|NCT06197282||COVID-19 Positive, Asymptomatic|Patients undergoing major surgery with a documented positive COVID19 test with in 1 year of surgery and were asymptomatic for COVID19 at the time of testing as well as at the time of surgery.
89540589|NCT06197282||Control: COVID-19 Negative|Patients undergoing major surgery with documented COVID19 negative testing prior to procedure.
89540590|NCT06193252|Experimental|Intervention|Large proportional increase in step count and minutes exerting moderate to vigorous physical activity (MVPA) relative to baseline level.
89540591|NCT06193252|Active Comparator|Active control|Small proportional increase in step count and minute exerting moderate to vigorous physical activity (MVPA) relative to baseline level.
89540592|NCT06192680|Experimental|liposomal irinotecan + capecitabine + bevacizumab|"liposomal irinotecan 70 mg/m², d1 + capecitabine 1000 mg/m² BID, d1~10 + bevacizumab 5mg/kg, d1.~q2w"
89540593|NCT06192589|Active Comparator|Cannabidiol (Part 1)|Subjects in this arm will receive oral solution cannabidiol at a dosage of 2.5 mg/kg twice a day, for a total of 5 mg/kg cannabidiol daily for 28 days.
89540594|NCT06192589|Placebo Comparator|Placebo (Part 1)|Subjects in this arm will receive oral solution placebo twice a day for 28 days.
89540595|NCT06192589|Active Comparator|Cannabidiol and Citalopram Drug Interaction (Part 2)|Subjects in this arm will receive citalopram (20 mg) on Day 1 and Day 13 and oral solution cannabidiol at a dosage of 2.5 mg/kg twice a day (5 mg/kg cannabidiol daily) for 12 days (Day 6-17).
89540596|NCT06192589|Active Comparator|Cannabidiol and Morphine Drug Interaction (Part 2)|Subjects in this arm will receive morphine (15 mg) on Day 1, Day 4, and Day 11 and oral solution cannabidiol at a dosage of 2.5 mg/kg twice a day (5 mg/kg CBD daily) for 9 days (Day 4-12).
89540597|NCT06191757|Experimental|experimental group|The sample consisted of n=57 premature infants, n=27 in the study group and n=30 in the control group. Data were collected in two stages. In the first stage, mothers sang lullabies to the infants in the study group three times a week and touched them tenderly. In the second stage, developmental support program (GEDEP) was applied to the same infants for three months starting from the 40th week of gestation. The infants in the control group were given routine care. In data collection, Mother and Newborn Descriptive Information Form, Premature Infant Comfort Scale (PICS), Developmental Support Program Evaluation Form, GEDEP user guide form and Sound Decibel Measurement Device were used.
89024219|NCT02891824|Placebo Comparator|Arm A: Placebo + Avastin + platinum-based chemotherapy|"The placebo arm:~Placebo 1200 mg x 6 cycles q3wk or 800mg x 6 cycles q4wk during treatment with chemotherapy and Avastin, followed by placebo 1200mg q3wk until progression"
89540598|NCT06191757|Experimental|control group|"The data of the control group were collected in two stages. No intervention was made to the control group by the researcher.~First stage application steps:~Before starting the application, the Mother and Newborn Information Form (Annex 1) was filled out by the researcher.~The babies in the control group were cared for and their daily care (hygienic care (oral care, eye care, body care, diaper cleaning, etc.), feeding, taking vital signs, other follow-ups) were carried out by the nurse.~Approximately 10-15 minutes and 20-25 minutes after the care was completed, the baby's responses were evaluated by the researcher with the premature comfort scale.~Second stage: When the babies in the control group reached their first corrected month, developmental evaluations were made by the researcher using the GEDEP evaluation form every four weeks for a total of three months."
89540599|NCT06191120|Experimental|One [18F]-ALF-FAPI-74 PET/CT scan|For patients presenting with metachronous disease, or synchronous disease without the need for two separate surgical sessions for removal of all lesions (i.e. separate liver and primary cancer surgery), and who do not receive any chemotherapy before surgery, only one pre-surgical [18F]-ALF-FAPI-74 PET/CT will be performed.
89540600|NCT06191120|Experimental|Two [18F]-ALF-FAPI-74 PET/CT scans|For patients presenting with synchronous disease who require two separate surgical sessions (i.e. separate liver and primary cancer surgery), and who do not receive pre-surgical chemotherapy, an [18F]-ALF-FAPI-74 PET/CT will be performed before each surgical session.
89024220|NCT02891824|Experimental|Arm B: Atezolizumab + Avastin+ platinum-based chemotherapy|"The atezolizumab arm:~Atezolizumab 1200 mg x 6 cycles q3wk or 800mg x 6 cycles q4wk during treatment with chemotherapy and Avastin, followed by atezolizumab 1200mg q3wk until progression~."
89024221|NCT02825654||Post-9/11 Gulf War Era Veterans|Military personnel who deployed to Central Asia, Southwest Asia, and Africa during the Post-9/11 Gulf War Era
89024222|NCT02824263|No Intervention|CPAP (Usual care)|Continuation of established CPAP therapy. CPAP will be worn during a metabolic sleep study in the research laboratory.
89024223|NCT02824263|Experimental|CPAP withdrawal;|Cessation of established CPAP therapy for 3 nights. CPAP will NOT be worn during this period, and a metabolic sleep study off CPAP is performed in the research laboratory on the third night.
89024224|NCT02814838|Experimental|Ladarixin|Ladarixin oral capsule
89024225|NCT02814838|Placebo Comparator|Placebo|Placebo oral capsule
89024226|NCT02783690|No Intervention|Conventional Fractionation|50.0 Gy (RBE) in 25 daily fractions
89024227|NCT02783690|Experimental|Hypofractionation|40 Gy (RBE) in 15 daily fractions
89024228|NCT02737046|Experimental|Belinostat + Zidovudine|Belinostat + Zidovudine (AZT) in combination as consolidation therapy, followed by standard zidovudine (AZT)-based maintenance therapy with optional Interferon-Alfa-2b (IFNalfa-2b) or Pegylated Interferon-Alfa-2b (PEG-IFN-alfa-2b)
89024229|NCT02713607|Experimental|doxycycline|Given doxycycline and assessment of gut, blood and skin
89024230|NCT02713607|No Intervention|Control|Control subjects to assess if there is baseline difference in these micro-evironments.
89540601|NCT06191120|Experimental|Pre-treated group, two [18F]-ALF-FAPI-74 PET/CT scans|For patients presenting with metachronous disease, or synchronous disease without the need for two separate surgical sessions for removal of all lesions (i.e. separate liver and primary cancer surgery), and who receive pre-surgical chemotherapy, two [18F]-ALF-FAPI-74 PET/CTs are performed: one before chemotherapy and one before surgery.
89540602|NCT06191120|Experimental|Pre-treated group, three [18F]-ALF-FAPI-74 PET/CT scans|For patients presenting with synchronous disease who require two separate surgical sessions (i.e. separate liver and primary cancer surgery), and who do receive pre-surgical chemotherapy, three [18F]-ALF-FAPI-74 PET/CTs will be performed: one before chemotherapy and one before each surgical session.
89540603|NCT06185543|Active Comparator|PrimeC|2 tablets of PrimeC administered twice daily (4 tablets a day), total daily dose of 1360 mg ciprofloxacin and 136 mg celecoxib orally.
89540604|NCT06185543|Placebo Comparator|Placebo|2 tablets of Placebo administered twice daily (4 tablets a day). Placebo tablets are matched in size, color and taste.
89540605|NCT06182059|Active Comparator|fast track|continuous adductor canal block and ipack block
89540606|NCT06182059|Experimental|traditional|continuous femoral nerve block and continuous sciatic block
89540607|NCT06180603|Active Comparator|Control group|Standard of care thoracentesis in the radiology department ( passively drainage using gravity)
89540608|NCT06180603|Experimental|Intervention group|Thoracentesis in the emergency department (manual fluid drainage using a syringe connected to a three-way stopcock)
89540609|NCT06178679|Experimental|ST-100-002|ST-100 (vezocolmitide) Ophthalmic Solution 60 μg/ml Bilaterally twice daily for 7 weeks (49 days)
89540610|NCT06178679|Placebo Comparator|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution Bilaterally twice daily for 7 weeks (49 days)
89540611|NCT06169696|Other|Patient Group / Arm|Use of non-invasive EEG headband device
89540612|NCT06169150||Healthy Controls|Biological relatives or unrelated persons without a known diagnosis of neuroinfectious disease or neuroinflammation.
89540613|NCT06169150||Primary or acquired immunodeficiency|Known or suspected infection or inflammation of the nervous system or post infection sequelae, or is at risk of developing such a neurologic complication.
89540614|NCT06166836|Experimental|Phase 1b-Dose Escalation Part|To evaluate the safety and Recommended Phase 2 dose (RP2D) of D-1553 in combination with IN10018 in previously-treated solid tumors.
89540615|NCT06166836|Experimental|Phase II Cohort A-previously-treated CRC with KRAS G12C mutation（Treatmnt Group）|To evaluate the safety and antitumor efficacy of D-1553 in combination with IN10018 in previously-treated CRCs with KRAS G12C mutation.
89540616|NCT06166836|Active Comparator|Phase II Cohort A-previously-treated CRC with KRAS G12C mutation (Control Group)|To evaluate the safety and antitumor efficacy of D-1553 in previously-treated CRCs with KRAS G12C mutation.
89024231|NCT02698254|Experimental|Arm I (conventional fractionation)|Patients undergo radiation therapy with conventional fractionation and dose constraints. Treatment continues for up to 6 weeks in the absence of disease progression or unacceptable toxicity.
89024232|NCT02698254|Active Comparator|Arm II (conventional fractionation, bevacizumab)|Patients undergo radiation therapy with conventional fractionation and dose constraints. Patients also receive bevacizumab concurrently at the discretion of the treating neuro-oncologist. Treatment continues for up to 6 weeks in the absence of disease progression or unacceptable toxicity.
89024233|NCT02688894||Small cell lung cancers|To provide molecular characteristics of Small cell lung cancers to proceed SUKSES trial, To assess success rate of molecular profiling of Small cell lung cancers
89024234|NCT02669173|Experimental|Treatment: Capecitabine + Bevacizumab|Capecitabine, PO dose to be determined by phase 1 dose escalation, cycle length 28 days. Treated with Bevacizumab, IV, 10 mg/kg days 1, 15 every 28 days, until progression.
89540617|NCT06166836|Experimental|Phase II Cohort B-treatment-naïve or previously-treated NSCLC with KRAS G12C mutation|To evaluate the safety and antitumor efficacy of D-1553 in combination with IN10018 in advanced NSCLCs with KRAS G12C mutation.
89540618|NCT06166836|Experimental|Phase II Cohort C-other previously-treated solid tumors with KRAS G12C mutation|To evaluate the safety and antitumor efficacy of D-1553 in combination with IN10018 in other solid tumors with KRAS G12C mutation
89540619|NCT06166550|Experimental|Training|Parents of children suffering from neurodevelopmental disorders will be the participants. They will get in-person training on emotional intelligence, stress reduction, and wellbeing along with access to a mobile app aimed at enhancing their psychological wellbeing.
89540620|NCT06166550|Sham Comparator|App user|Participants in this arm will not get any in-person training. Rather, they will be given access to the same mobile app which Group A will receive.
89540621|NCT06166550|No Intervention|Control|Experimental
89540622|NCT06148961|Experimental|intervention group|"botox injection prior to surgical intervention by 5 to 10 days A surgical marker was used to outline the boundaries of the surgical incision region.~the height of the superior incision was measured as 15 mm within the vestibule. Superior and inferior incisions were made with a scalpel blade number 15 and linked bilaterally by two vertical incisions.~A partial thickness dissection was used to remove the strip of the indicated mucosa, exposing the fascia of the connective tissue beneath. When necessary, all salivary glands and frenal attachments were removed. The surgical site was then properly closed using a periosteal simple interrupted suture was put in place prior to the continuous interlocking sutures. It was placed by commencing the needle 2 mm coronal to Per surgery site, 3 to 4 periosteal sutures were typically The new mucosal boundary to the gingiva was stabilized in its new place using this suture"
89540623|NCT06148961|Active Comparator|control group|"A surgical marker was used to outline the boundaries of the surgical incision region.~the height of the superior incision was measured as 15 mm within the vestibule. Superior and inferior incisions were made with a scalpel blade number 15 and linked bilaterally by two vertical incisions.~A partial thickness dissection was used to remove the strip of the indicated mucosa, exposing the fascia of the connective tissue beneath. When necessary, all salivary glands and frenal attachments were removed. The surgical site was then properly closed using a periosteal simple interrupted suture was put in place prior to the continuous interlocking sutures. It was placed by commencing the needle 2 mm coronal to Per surgery site, 3 to 4 periosteal sutures were typically The new mucosal boundary to the gingiva was stabilized in its new place using this suture"
89540624|NCT06147427|Experimental|ACL reconstruction with hamstrings combined with ALL plasty|Patient treated by ACL reconstruction with hamstrings combined anterolateral plasty using the ALL reconstruction technique (Gracilis throught the femur tunnel of the ACL graft and fixed to the tibia by an anchor on its point of isometry on the tibia).
89540625|NCT06147427|Experimental|ACL reconstruction with hamstrings combined with modified Lemaire's LET|Patient treated by ACL reconstruction with hamstrings combined with modified Lemaire's lateral extra-articular tenodesis technique (Fascia lata strip pedicled to the Gerdy and fixed to the femur throught the tunnel of the ACL graft).
89540626|NCT06143618|Experimental|escape room games|The escape room game will include a patient scenario of four female patients who are victims of violence and apply to different clinics. Necessary equipment and materials will be provided and stations will be established where four female patients who are victims of violence will be evaluated. In order for them to solve puzzles and puzzles related to the subject at the stations; Colorful puzzle set, lettered chest lock, ballot box, colorful stickers, digital countdown clock, and materials to be used by students will be provided by the researchers. In the game, each student will contact the patient at only one station and evaluate signs and symptoms of violence. The group, which completes the tasks and activities and collects the puzzle pieces that will lead to the code of the lock, will complete the puzzle and enter the number codes on it into the key of the locked box on the table (4 numerical codes received), open the box and get the message 'you can escape'.
89207045|NCT00839592|Placebo Comparator|Placebo Acupuncture|Placebo needles designed by Streitberger (1998) will be used. The placebo needles are blunt needle that will not penetrate the skin during needle insertion. The handles of these placebo needles will slide over the needle when it is compressed, giving it the appearance of penetrating the skin. The placebo needles are inserted to the same acupoints as stated in the electroacupuncture group. The needles are held by a surgical tape or hair pin in hairy region to imitate the retention of needles. The needles are connected to an electric-stimulator with zero frequency and amplitude. The number, duration and frequency of the treatment sessions, and the intervention procedure will be the same for electro-acupuncture and placebo acupuncture.
89207046|NCT04796649|Experimental|Standard and B-Cure Pro|Subjects from the Standard and B-Cure Pro group will receive standard care and in addition will self-treat at home daily with the B-Cure device.
89207047|NCT04796649|Active Comparator|Standard treatment + Sham laser|The sham device is externally identical to the B-Cure Pro and emit the same guiding light, but does not emit the therapeutic near infrared rays.
89207048|NCT00837174|Experimental|Combination Vorinostat + Bortezomib|Six cycle combination therapy with vorinostat and bortezomib.
88816056|NCT02322320|Active Comparator|Tandem Auto Transplant|Initial autologous transplant followed by a second autologous transplant and lenalidomide maintenance
88816057|NCT02322320|Active Comparator|RVD Consolidation|Initial autologous transplant followed by lenalidomide, bortezomib and dexamethasone (RVD) consolidation and lenalidomide maintenance
88816058|NCT02322320|Active Comparator|Lenalidomide Maintenance|Initial autologous transplant followed by lenalidomide maintenance
88816059|NCT02551653|Experimental|[11C]-GSK2256098|Subjects will receive single IV bolus injection of [11C]-GSK2256098 over about 30 seconds. Each unit dose will contain up to 500 millibecquerel (MBq) of [11C]-GSK2256098 with maximum [11C]-GSK2256098 mass <=10 microgram (mcg).
89207049|NCT00963183|Experimental|A|Drug: AZD5423
89207050|NCT00963183|Placebo Comparator|B|Drug: Placebo
89207051|NCT04042974|Experimental|dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia & Upjohn, Puurs, Belgium) inserted by the patient 12 hours before the scheduled office hysteroscopy.
89540627|NCT06143618|Experimental|role playing|In the role play application, there will be scenarios of four female patients who are victims of violence and apply to different clinics. Before the role play activities, students will be asked to form groups of 4-5 people, and each week, a group will be asked to choose one of the four scenarios given by lot and improvise the case-based role play activity within 40 minutes.
89540628|NCT06143618|No Intervention|control|No application will be given to the control group other than theoretical lectures. The theoretical course covers the definition of violence, types of violence, symptoms and findings seen in women exposed to violence, and evaluation of violence. The theoretical course will be delivered in the form of verbal explanation supported by power point presentation. Before the intervention, one week after the intervention and one month later, all students will be administered the Violence Against Women Knowledge Test, the Attitudes towards Violence Scale and the Scale for Nurses and Midwives to Recognize the Signs of Violence Against Women.
89540629|NCT06141720|Active Comparator|Standard of care for endometriosis surgery plus education|
89540630|NCT06141720|Experimental|Standard of care for endometriosis surgery plus mindfulness|
89540631|NCT06136884|Experimental|Part 1: Dose Escalation|Participants will be assigned to dose levels.
89540632|NCT06136884|Experimental|Part 2: Dose Expansion|After doses are decided in Part 1, participants entering part 2 will be assigned to a dose level.
89540633|NCT06135909||PH Patients receiving targeted drugs treatment|Patients with pulmonary hypertension receiving targeted drugs treatment
89540634|NCT06135779|Experimental|A Lust for Life programme group|A Lust for Life programme will be delivered to participants by their class teachers in ten weekly sessions
89540635|NCT06135779|Other|Waiting list control group|Participants will receive curriculum as usual from their class teacher, and placed on a 12-week waiting list for the programme.
89540636|NCT06135766|Experimental|A Lust for Life programme group|A Lust for Life programme will be delivered to participants by their class teachers in ten weekly sessions.
89540637|NCT06135766|Other|Waiting list control group|Participants will receive curriculum as usual from their class teacher, and placed on a 12-week waiting list for the programme.
88959421|NCT02003651|Experimental|Quick Defense|250 mg E. purpurea root and 83 mg E.angustifolia root standardized to 10 mg alkylamides, and 210 mg of a proprietary synergistic extract blend containing andrographis paniculata leaf, black elderberry berries, sambucus nigra, ginger root, and zingiber officinale
88959422|NCT02003651|Placebo Comparator|Placebo|Placebo will contain the excipients vegetable glycerin and olive oil. Placebo and echinacea capsules will be colored green and contain the same proportions of inert ingredients.
88959423|NCT02003664|Active Comparator|Baclofen ER versus Placebo|Baclofen ER versus Placebo (sugar pill)
88959424|NCT02003664|Placebo Comparator|Placebo versus Baclofen ER|Participants will receive either placebo (sugar pill) or Baclofen ER
88959425|NCT02003677|Experimental|FIAsp followed by NovoRapid®|Each subject will be randomly allocated to a treatment sequence consisting of 2 dosing visits separated by a wash-out period of 3-12 days
88959426|NCT02003677|Active Comparator|NovoRapid® followed by Insulin aspart|Each subject will be randomly allocated to a treatment sequence consisting of 2 dosing visits separated by a wash-out period of 3-12 days
88959427|NCT02003703|Experimental|Recombinant Hepatitis B Virus Vaccine (High Dose)|Patients allocated to this arm will receive three doses of 40mcg each of recombinant hepatitis B vaccine (Engerix-B (R)). Doses will be administered at 0, 1 and 2 months.
88959428|NCT02003703|Active Comparator|Recombinant Hepatitis B Virus Vaccine (Standard Dose)|Patients allocated to this arm will receive three doses of 20mcg each of recombinant hepatitis B vaccine (Engerix-B (R)). Doses will be administered at 0, 1 and 2 months.
88959429|NCT02003716||No treatment|
88959430|NCT02003729|Active Comparator|Portable Sleep Monitor|The clinical diagnosis of OSA will be done according to the American Academy of Sleep Medicine criteria, a combination of data from clinical examination, presenting symptoms, risk factors and results from portable monitor sleep studies.
88959431|NCT02003729|No Intervention|Polysomnography|The clinical diagnosis of OSA will be done according to the American Academy of Sleep Medicine criteria, a combination of data from clinical examination, presenting symptoms, risk factors and results from polysomnography from the sleep clinic.
88959432|NCT02003755|Experimental|Spastic CP|continuous passive motion training
88959433|NCT02003768|Experimental|TIVA|2% Propofol (Fresofol®), Remifentanil 20mcg/cc (Ultiva®)
88959434|NCT02003768|Active Comparator|Des|Desflurane (Suprane®), Remifentanil continuous infusion (20mcg/cc)
88959435|NCT02003781||cardiovascular disease|high risk cardiovascular disease patients and their relatives
88959436|NCT02003794|Experimental|IV Fluid|0.9% NaCl solution infusion: 100 ml/hr for three days.
88959437|NCT02003794|No Intervention|No IV Fluid|Not receive any intravenous fluid but can consume oral fluid normally for three days.
88959438|NCT02003807||Diverticulitis patients (case)|Cases were the patients who admitted to hospital because of acute diverticulitis attack.
88959439|NCT02003807||Non-diverticulitis patients (control)|Controls were the patients who admitted to hospital due to non-gastrointestinal disorder.
88959440|NCT02003820|Experimental|Group 1|Group 1 will receive plaque index exam and immediately start their three week intervention of watching a dental hygiene video immediately before brushing twice per day. Plaque index exams will be completed at start, t-10 days, and t-21 days. Parental surveys will be completed at each plaque index exam and 6 weeks after start.
88959441|NCT02003820|Experimental|Group 2|Group 2 will receive plaque index exam and immediately start their three week intervention of watching a control video immediately before brushing twice per day. Plaque index exams will be completed at start, t-10 days, and t-21 days. Parental surveys will be completed at each plaque index exam and 6 weeks after start.
88959442|NCT02003833|Experimental|Poly-L-lactic acid|Subjects in the treatment arm will receive three injections of 5 cc of poly-L-lactic acid (PLLA) into both sides of the face.
89207052|NCT04042974|Placebo Comparator|placebo|one tablet of placebo inserted by the patient 12 hours before the scheduled office hysteroscopy.
89207053|NCT00844272|Experimental|Psychoeducation|"PE group sessions lasted 60 minutes and were carried out under continuous supervision. The manualised program was especially tailored to (former) IDUs in HCV treatment, containing the following aspects:~Module 1: HCV infection and symptoms, course of illness, interaction with opioid dependence, further problems and risk factors~Module 2: HCV treatment, side effects, psychiatric and somatic comorbidities, reinfection and drug use, risk behaviour~Module 3: Coping strategies, resources and self-help, effective use of health-care support, the role of social environment, healthy living & nutrition"
89207054|NCT00844272|No Intervention|Treatment as usual|Control group did not received no intervention.
89207055|NCT04783545|Experimental|Single Ascending Dose Cohorts 1-6|Drug: VLX-1005
88816060|NCT05308160|Active Comparator|Dapagliflozin|This trial is a randomized, open label, two-arm, parallel-group, non-used comparator, single center trial to evaluate the efficacy of dapagliflozin in subjects with Nonalcoholic fatty liver disease.
89207056|NCT04783545|Placebo Comparator|Single Ascending Dose Cohorts 1-6, Placebo|Drug: Placebo
89207057|NCT04783545|Experimental|Multiple Ascending Dose Cohorts 7-9|Drug: VLX-1005
88816061|NCT05308160|Placebo Comparator|Non-used drug|This trial is a randomized, open label, two-arm, parallel-group, non-used comparator, single center trial to evaluate the efficacy of dapagliflozin in subjects with Nonalcoholic fatty liver disease.
88816062|NCT03013088|Experimental|CTO Crossing|With confirmation that the target vessel is completely occluded by the target CTO lesion, the operator shall initially attempt crossing the proximal end of the target CTO lesion by advancing ShockWireTM device ≥ 1cm. The SoundBite Crossing device can be activated as needed to perform the procedure and may be used for the entire length of the lesion(s).
88816063|NCT01163162|Experimental|Paricalcitol|After baseline measurements are complete, pt will receive 2 mcg Paricalcitol (Zemplar) for 7 consecutive days. After this, Kidney function will again be measured. The pt will then be washed off the paricalcitol for 7 days then kidney function will be measured for the last time.
88816064|NCT05307848||Female patients with bipolar disorder without medication|
88816065|NCT05307848||Female patients with bipolar disorder after stable prescription for ≥6 months|
88816066|NCT05307848||Age and BMI-matched healthy controls|
88816067|NCT01127438|Active Comparator|fospropofol disodium Subgroup 1 Lower Dose|
88816068|NCT01127438|Active Comparator|: fospropofol disodium Subgroup 1 Approved Dose|
88816069|NCT01127438|Active Comparator|fospropofol disodium Subgroup 2 Lower Dose|
88816070|NCT01127438|Active Comparator|fospropofol disodium Subgroup 2 Approved Dose|
88816071|NCT01127438|Active Comparator|fospropofol disodium Subgroup 3 Lower Dose|
88816072|NCT01127438|Active Comparator|fospropofol disodium Subgroup 3 Approved Dose|
88816073|NCT02481141|Active Comparator|5-ALA-SFC|"Study product administration will be as follows:~Beginning Week 0: 1 capsule of 50mg 5-ALA-SFC twice per day for 2 weeks Beginning Week 2: 1 capsule of 75mg 5-ALA-SFC twice per day for 2 weeks Beginning Week 4: 1 capsule of 100mg 5-ALA-SFC twice per day for 8 weeks"
88816074|NCT02481141|Placebo Comparator|Placebo|"Study matching placebo administration will be as follows:~Beginning Week 0: 1 capsule twice per day for 2 weeks Beginning Week 2: 1 capsule twice per day for 2 weeks Beginning Week 4: 1 capsule twice per day for 8 weeks"
88816075|NCT05307614|Experimental|Moksi® 400mg Tablet of Abbott|Healthy subjects were orally administered a single dose of Moksi® 400mg Tablet (Moxifloxacin) under fasting condition
88816076|NCT05307614|Active Comparator|Avelox® 400mg Tablet of Bayer|Healthy subjects were orally administered a single dose of Avelox® 400mg Tablet (Moxifloxacin) under fasting condition.
88816077|NCT02481219|Active Comparator|Bowel preparation regimen -Control|"Regimen includes administration of:~Drug: 4 Senna tablets 2 days before the procedure, Drug: 2-liters of polyethylene glycol (PEG) on the evening before the procedure Drug: 2-liters of PEG on the morning of the procedure, Drug:10mg Metoclopramide or 250 mg Erythromycin Drug: 2 SUPREP oral sulfate solution Drug: 10mg Bisacodyl suppository."
88816078|NCT02481219|Experimental|Bowel preparation regimen-Test|"Regimen includes administration of:~Drug: 4 Senna tablets 2 days before the procedure, Drug: 2-liters of PEG on the evening before the procedure Drug: 2-liters of PEG on the morning of the procedure, Drug:10mg Metoclopramide or 250 mg Erythromycin Drug: 2 SUPREP oral sulfate solution with Gastrografin Drug: 10mg Bisacodyl suppository."
88816079|NCT02481297|Experimental|Cohort 1: Refractory/Relapsed After Prior Therapy|Participants receive Rituximab 375 mg/m2 by vein weekly for the first 4 weeks (Days 1, 8, 15, 22), then with start of each course. Lirilumab 3 mg/kg by vein given on Day 1 of each cycle. Rituximab given for the first 12 cycles and Lirilumab continues for up to 24 cycles. Each cycle is 4 weeks.
88816080|NCT02481297|Experimental|Cohort 2: Untreated with High-rRisk mMolecular Features|Participants receive Rituximab 375 mg/m2 by vein weekly for the first 4 weeks (Days 1, 8, 15, 22), then with start of each course. Lirilumab 3 mg/kg by vein given on Day 1 of each cycle. Rituximab given for the first 12 cycles and Lirilumab continues for up to 24 cycles. Each cycle is 4 weeks.
88816081|NCT02481375|Experimental|Multiple micronutrients with iron|"Multiple micronutrient formulations were based on the UNICEF/WHO/UNU standard formulation for pregnant and lactating women (UNIMMAP) with increased iron (from 30 mg to 60 mg elemental iron) for comparability to the iron only group (60 mg). This formulation has 15 micronutrients including iron.~Women will receive the multiple micronutrient with iron for 12 weeks."
88816082|NCT02481375|Active Comparator|Multiple micronutrients without iron|"This formulation has the 14 micronutrients included in the UNIMMAP formulation, but does not include iron.~Women will receive the multiple micronutrient without iron for 12 weeks."
88816083|NCT02481375|Active Comparator|Iron only|"This formulation only has 60 mg elemental iron.~Women will receive iron for 12 weeks."
88816084|NCT02481375|Placebo Comparator|Placebo|"This formulation is a placebo.~Women will receive a placebo for 12 weeks."
88816085|NCT01164098|Active Comparator|Rituximab|Participants will receive Rituximab post within 24 of Kidney Transplant
88816086|NCT01164098|No Intervention|No rituximab|Participants will not receive Rituximab within 24 hours of Kidney Transplant
88816087|NCT02551809|Experimental|3 priming doses followed by 4 boosters|Subjects will receive 7 doses of UB-311.
88816088|NCT02551809|Experimental|3 priming doses followed by 2 boosters|Subjects will receive 5 doses of UB-311 and 2 doses of placebo.
88816089|NCT02551809|Placebo Comparator|Placebo|Subjects will receive 7 doses of placebo.
88816090|NCT01164644|Active Comparator|Arnica Montana|The subject will take twelve pills by mouth three times a day over four days.
88816091|NCT01164644|Placebo Comparator|Placebo|The subject will take twelve pills by mouth three times a day over four days.
88816092|NCT02551887|No Intervention|Usual Care|Usual Care Only
89540638|NCT06133777|Experimental|Respiratory Variability Monitoring|Respiratory variability will be measured using a belt equipped with an external sensor allowing automatic and continuous analysis of thoracic movement by frequency analysis
89540639|NCT06126653|Experimental|Phase 1: Low Dose|ARD-501 for 7 days at 0.2 mg/kg
89540640|NCT06126653|Placebo Comparator|Phase 2: Placebo|Placebo for 7 days
89540641|NCT06126653|Experimental|Phase 2: High Dose|ARD-501 for 7 days at 0.5 mg/kg
89540642|NCT06126653|Experimental|Phase 2: Crossover Placebo to High Dose|ARD-501 for 7 days at 0.5 mg/kg
89540643|NCT06126653|Placebo Comparator|Phase 2: Crossover High Dose to Placebo|Placebo for 7 days
89540644|NCT06116136|Experimental|S095029 and pembrolizumab|Participants diagnosed with gastric cancer (GC) or gastroesophageal junction cancer (GEJ), not previously treated with checkpoint inhibitors (CPIs) may first be enrolled into a Phase 1b safety lead-in part which will be used to identify the recommended Phase 2 dose (RP2D) of S095029 in combination with pembrolizumab. During the Phase 2 part, participants will receive the recommended Phase 2 dose (RP2D) of S095029, along with pembrolizumab.
89540645|NCT06112847|Experimental|Treatment (lenalidomide and epcoritamab)|Patients receive lenalidomide PO QD on days 1-21 of each cycle and epcoritamab SC on days 1, 8, 15, and 21 of cycles 1-3 and on day 1 of each subsequent cycle. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients may be re-treated with study treatment at any point during the follow-up period as long as they did not progress during treatment or stop due to unacceptable toxicity. Patients also undergo CT, PET/CT, or MRI as well as bone marrow biopsy throughout the trial. Patients undergo blood sample collection on trial and during follow-up.
89540646|NCT06111963||Septic patients|
89540647|NCT06111963||Non Septic patients|
89540648|NCT06106581|Experimental|VLA1553 full dose|
89540649|NCT06106581|Experimental|VLA1553 half dose|
89540650|NCT06106581|Active Comparator|Control|Single intramuscular vaccination on Day 1 with Nimenrix (Men ACWY vaccine), a conjugate vaccine indicated for the active immunization
89540651|NCT06103344|Experimental|Intervention|
88816093|NCT02551887|Active Comparator|Automated Reminder|Reminder
89207058|NCT04783545|Placebo Comparator|Multiple Ascending Dose Cohorts 7-9, Placebo|Drug: Placebo
89207059|NCT00844350|No Intervention|letrozole+hCG|
89540652|NCT06103344|No Intervention|Control|
89540653|NCT06096077||Retrospective Cohort|ED at MCMC for ACEi-AE with TXA
89540654|NCT06096077||Retrospective Chort|ED at MCMC for ACEi-AE without TXA
89540655|NCT06094179|Experimental|A1 300mg|Trial drug: Placebo 9:3 randomized double-blind admission. The last patient in each group was given the drug for 1 week, and the existing safety data was reviewed blind by SMC, and the next group was entered into the study after reaching the increasing standard
89540656|NCT06094179|Experimental|B1 600mg|Trial drug: Placebo 9:3 randomized double-blind admission. The last patient in each group was given the drug for 1 week, and the existing safety data was reviewed blind by SMC, and the next group was entered into the study after reaching the increasing standard
89540657|NCT06094179|Experimental|C1 600mg|Trial drug: Placebo 9:3 randomized double-blind admission. The last patient in each group was given the drug for 1 week, and the existing safety data was reviewed blind by SMC, and the next group was entered into the study after reaching the increasing standard
89540658|NCT06087406|Experimental|Imvotamab (Dose Escalation)|Imvotatmab administered intravenously
89540659|NCT06087406|Placebo Comparator|PBO IV QW x 4 doses|Placebo administered intravenously
89540660|NCT06086132||Breast cancer|"Newly diagnosed breast cancer undergoing treatment with anthracyclines analogues with or without radiotherapy, with or without trastuzumab, or other anticancer drugs.~(Non-interventional prospective patient registry)"
89540661|NCT06086132||Female and Male|"Diagnosis of cancer scheduled for treatment according to the treating physician's discretion.~(Non-interventional patient registry)"
89540662|NCT06083766||Transmasculine/transfeminine individuals and/or transgender men/women (whom are NOT receiving GAHT)|
89540663|NCT06083766||Transmasculine/transfeminine individuals and/or transgender men/women (whom ARE receiving GAHT)|
88816094|NCT02551887|Experimental|Automated Reminder Plus Script|Provider sees both reminder and script.
88816095|NCT03010280|Experimental|Immunonutrition|Patients receiving a preoperative balanced energy high-protein formula, enriched with Omega - 3 fatty acids (Immunonutrition formula)
88816096|NCT03010280|Active Comparator|Balanced high-protein formula|Patients receiving a preoperative balanced energy high-protein formula, without including Omega - 3 fatty acids
88816097|NCT02553135|Experimental|Injection of AAV2-REP1|Injection of AAV-REP1, 1.00x10e11 vg, subretinal injection of total volume of 100 μL.
88816098|NCT01165112|Experimental|Treatment (chemotherapy and monoclonal antibody therapy)|Patients receive bendamustine hydrochloride IV over 30-60 minutes on days 1 and 2, etoposide IV over 60 minutes on days 1-3, and carboplatin IV over 60 minutes on day 1. Patients with CD20+ T-cell lymphoma disease also receive rituximab IV on day 2 or 3. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.
88816099|NCT02555631|Experimental|lifestyle intervention|In this pilot study, each subject will receive the lifestyle intervention of the diabetes prevention program, a modified program for men from disadvantaged neighborhoods--a 16 weekly sessions of 1 hour each session
88816100|NCT01129778|Experimental|Received Zegerid (Ome-NaBic)|Administered Ome-NaBic 40 mg orally 1 h before breakfast and bedtime
88816101|NCT02484807||Bosentan + Sildenafil|Combination treatment with Bosentan + Sildenafil at baseline
88816102|NCT02484807||Bosentan + Tadalafil|Combination treatment with Bosentan + Tadalafil at baseline
88816103|NCT02484807||Ambrisentan + Sildenafil|Combination treatment with Ambrisentan + Sildenafil at baseline
88816104|NCT02484807||Ambrisentan + Tadalafil|Combination treatment with Ambrisentan + Tadalafil at baseline
89511278|NCT04989998|Active Comparator|Conventional procedures with standard, manual instrumentation and digital templating techniques|Subjects will receive total hip arthroplasty surgery using conventional procedures with standard instrumentation and digital templating techniques utilizing R3 Polarstem implants.
89511279|NCT05046938|Experimental|intervention group|It was planned to apply 5 sessions of MI to the intervention group, and to follow-up 2 months after the interviews were completed.
89511280|NCT05046938|No Intervention|control group|No application will be made to the students in the control group, and at the end of the study, a seminar on food addiction and quality of life will be given to the students.
88959443|NCT02003833|Placebo Comparator|Placebo|Subjects in the placebo arm will receive three injections of 5 cc of saline into both sides of the face. After the completion of the study, subjects in the placebo arm will receive free injections with Sculptra Aesthetic same as the treatment arm.
88959444|NCT02003846||Premature infant|Each premature infant will be on bubble nasal CPAP for 2 hours and on ventilator nasal CPAP for 2 hours
88959445|NCT02003872|Experimental|Spattz 3 intragastric balloon|obese patients, . BMI ≥ 35 kg/m² or BMI ≥ 30 kg/m² and hypertension or diabetes mellitus. All will have the intragastric balloon
89511281|NCT05077436|Experimental|Sequence 1|"Participants receive a single dose of study drug, every 4 days:~Day 1: Participants in fasted state receive Vamifeport Formulation 1~Day 5: Participants in fed state receive Vamifeport Formulation 1~Day 9: Participants in fed state receive Vamifeport Formulation 2~Day 13: Participants in fasted state receive Vamifeport Formulation 2"
89511282|NCT05077436|Experimental|Sequence 2|"Participants receive a single dose of study drug, every 4 days:~Day 1: Participants in fed state receive Vamifeport Formulation 1~Day 5: Participants in fasted state receive Vamifeport Formulation 2~Day 9: Participants in fasted state receive Vamifeport Formulation 1~Day 13: Participants in fed state receive Vamifeport Formulation 2"
89511283|NCT05077436|Experimental|Sequence 3|"Participants receive a single dose of study drug, every 4 days:~Day 1: Participants in fasted state receive Vamifeport Formulation 2~Day 5: Participants in fed state receive Vamifeport Formulation 2~Day 9: Participants in fed state receive Vamifeport Formulation 1~Day 13: Participants in fasted state receive Vamifeport Formulation 1"
88959446|NCT02003885|Experimental|Desflurane increment|increment of desflurane 0.5-1.5 MAC in remifentanil anesthesia for cardiac surgery
88959447|NCT02003937|Experimental|12 weeks of aerobic conditioning|12 weeks of aerobic conditioning, a total 42 sessions of 30min exercise on a stationary cycle ergometer
89511284|NCT05077436|Experimental|Sequence 4|"Participants receive a single dose of study drug, every 4 days:~Day 1: Participants in fed state receive Vamifeport Formulation 2~Day 5: Participants in fasted state receive Vamifeport Formulation 1~Day 9: Participants in fasted state receive Vamifeport Formulation 2~Day 13: Participants in fed state receive Vamifeport Formulation 1"
89511285|NCT05076890|Experimental|15 mg/g Full Spectrum Hemp Extract|A single capsule of 15 mg/g Full Spectrum Hemp Extract will be delivered.
88959448|NCT02003989||patients|HIV patients infected for more than ten years with undetectable viral load, undergoing ophthalmologic examination and MRI
88959449|NCT02003989||control|non HIV patients (same gender and age) undergoing ophthalmologic examination and MRI
89511286|NCT05076890|Experimental|50 mg/g Full Spectrum Hemp Extract|A single capsule of 50 mg/g Full Spectrum Hemp Extract will be delivered.
89511287|NCT05076266||Women Who Decline TMIST|Women who decline TMIST will be asked to fill out a survey with questions about demographics, income and employment, attitudes and experiences about COVID-19, and emotional well-being.
89511288|NCT05041010|Experimental|Neu2000KWL|
89511289|NCT05041010|Placebo Comparator|Placebo|
89511290|NCT04210076|Experimental|Mindfulness-Based Attention Training for Teams (MBAT-T)|Teams randomized to this group will receive 4, 2-2.5-hour sessions delivered over 4 weeks of mindfulness training and 15 minutes of daily, out-of-class mindfulness exercises, that will be delivered and tracked using a measuring mindfulness application.
89511291|NCT04210076|Active Comparator|Mindfulness-Based Attention Training for Individuals (MBAT-I)|Individuals randomized to this group will receive 4, 2-2.5-hour sessions delivered over 4 weeks of mindfulness training and 15 minutes of daily, out-of-class mindfulness exercises, that will be delivered and tracked using a measuring mindfulness application.
89511292|NCT04210076|No Intervention|No-training|Teams will not engage in any mindfulness training
89511293|NCT05075798||group patients|Patients followed at the University Hospital of Nîmes between 2017 and 2021 for a TTR neuropathy with proven mutation, having benefited from a brain MRI.
89511294|NCT05074472|Experimental|Active Treatment: ZB131|During the Dose Escalation Stage, patients will be treated with ZB131 at increasing dose levels, beginning with a starting dose level (DL0) of 3 mg/kg once weekly, up to a maximum dose level (DL3) of 15 mg/kg once weekly.
89540664|NCT06080464|Experimental|VERABAND information|"Consented patient participants will be given a VERABAND™ activity monitor during an initial clinic visit (baseline) and will then be tracked longitudinally after beginning a new pain treatment regime as part of their normal ongoing care. VERABAND™ activity data reports (including a summary broken down by week) will subsequently be provided to treating clinicians prior to each patient's follow-up clinic visit.~The arm is all of the clinicians of the participants."
89540665|NCT06080113|Experimental|Treatment group|Curative targeted focal brachytherapy treatment for localized unifocal prostate-cancer
89207060|NCT00844350|No Intervention|letrozole+oxytocin|
89207061|NCT00844350|No Intervention|letrozole+oxytocin+hCG|
88810885|NCT05216393|Experimental|intervention|The intervention group will be mailed a Fitbit device and provided access to the RecTech Match website. Intervention participants will receive weekly calls for the first 6 weeks, and a call every other week for the following 6 weeks (9 in total) from a health coach to discuss progress, facilitate setting physical activity goals, and help mitigate obstacles to participate in physical activity in the community. Participants will be free to access the features and resources of the website. The Fitbit data will be collected on an ongoing basis and the participants will receive daily texts asking them to rate the amount of physical activity for the day.
88959450|NCT02004002|Active Comparator|Weight maintenance with normal protein intake|Control group will consume 1.4 g protein/kg body wt/d; consistent with the average protein intake in the US population.
88959451|NCT02004002|Experimental|Weight maintenance with protein restriction|Protein restriction group will receive the Institute of Medicine RDA of 0.8 g protein/kg body wt/d.
88959452|NCT02004015|Experimental|Atracurium|injection of NMBA 0.5 mg/kg milligram(s)/kilogram in Intravenous bolus use
88959453|NCT02004015|Experimental|ROCURONIUM|injection of NMBA 0.6 mg/kg milligram(s)/kilogram in Intravenous bolus
88959454|NCT02004015|Placebo Comparator|placebo|injection of placebo Injection in Intravenous bolus use
88959455|NCT02004041|Experimental|VLY-686 x mg|Single dose, X mg VLY-686, administered as X 50 mg VLY-686 oral capsule(s)
88959456|NCT02004041|Placebo Comparator|Placebo|Single dose, placebo, administered as X 50 mg oral capsule(s)
88959457|NCT02004054||optic neurotis|measure of pupil diameter
88959458|NCT02004067|Active Comparator|Refresh Endura|Topical lubricant containing (glycerin; polysorbate 80; castor oil; carbomer, boric acid, sodium hydroxide, purified water), one drop 2 times a day, for 3 months.
88959459|NCT02004067|Experimental|Restasis|Topical immunomodulatory lubricant (Ophthalmic emulsion containing cyclosporine 0.5 mg/mL, i.e., 0.05%), one drop 2 times a day, for 3 months
88959460|NCT02004106|Experimental|Part 1: RO6895882 Single Ascending Dose|Participants will receive RO6895882 at ascending doses (</= 6 mg) as a single intravenous (IV) infusion.
88959461|NCT02004106|Experimental|Part 2: RO6895882 Dose Escalation Monotherapy|Participants in different cohorts will receive RO6895882 at ascending doses as IV infusion qw, q2w or q3w. After completion of Part 2 all participants have the option to receive the recommended RO6895882 dose once defined in Part 2 at the discretion of investigator.
88959462|NCT02004106|Experimental|Part 3: RO6895882 MTD Expansion|Participants will receive RO6895882 at MTD determined in Part 2 as IV infusion qw, q2w or q3w.
88959463|NCT02004119|Placebo Comparator|Placebo|
88959464|NCT02004119|Experimental|KHK4577|
88959465|NCT02004145|Experimental|Positive Psychology|"The Positive Psychology intervention consists of 6 exercises that will be completed by the participant with the guidance of a trainer.~Exercises:~Gratitude for positive events~Gratitude letter~Performing acts of kindness~Using personal strengths~Enjoyable and meaningful activities:~Repeating one of the previous exercises."
88959466|NCT02004145|Sham Comparator|Organizational Skills|"The Control Condition consists of 6 exercises that will be completed by the participant with the guidance of a trainer.~Exercises:~Daily Events~Health Events~Morning and Evening Events~Interactions with Others~Leisure Time Activities~Repeating one of the previous exercises."
88959467|NCT02004171|Experimental|electronic cigarette|electronic cigarette 24mg cartridges; 1-2 cartridges daily
88959468|NCT02004171|Active Comparator|nicotine inhaler|nicotine inhaler 10mg cartridge; max 16 cartridges daily
88959469|NCT02004184|Experimental|maintenance pemetrexed|maintenance pemetrexed immediately after induction chemotherapy
88959470|NCT02004184|Active Comparator|pemetrexed at progression|observation and pemetrexed therapy at disease progression
88959471|NCT02004197|Experimental|Pylorex plus|Pylorex plus consisting of medicinal plants.
89207062|NCT00844350|No Intervention|clomiphene citrate +oxytocin|
89207063|NCT00844350|No Intervention|clomiphene citrate +oxytocin+hCG|
89511295|NCT05036798|Experimental|Tislelizumab combined with Lenvatinib and GEMOX|"Chemotherapy regimen(GEMOX):~Gemcitabine 1g/m2,Oxaliplatin 100mg/m, D1, Q3W Tislelizumab 200mg D1 Q3w Lenvatinib 4mg Po QD~Receive at least 3 cycles of combined treatment, and perform imaging evaluation after 3 cycles of treatment. If surgical treatment is not possible, imaging evaluation will be performed every two cycles thereafter until surgical treatment is feasible. If more than 7 cycles are still not possible for surgical resection, enter Tislelizumab + Lenvatinib maintenance treatment until the disease progresses or the toxicity cannot be tolerated.~If patients undergoing R0 resection, start to receive Tislelizumab + Lenvatinib+Gemox regimen in 4-8 weeks after surgery for 7 cycles, and then entered Tislelizumab+Lenvatinib for 1 year or disease progression or toxicity cannot be tolerated"
89511296|NCT04983602|No Intervention|Usual care Control group|The usual care control group receives conventional care in the Emergency Department (ED) or Acute Medical Assessment Unit (AMAU)The comparison group will receive routine care as would be usual in the ED or AMAU. Currently there is no dedicated team to perform CGA in the ED and AMAU at UHL with ad hoc allied health assessment available only at the discretion of the referring ED doctor or medical team. This process will be continued during the study and will be documented. The participants in this group will under baseline data collection prior to randomisation and follow up.
88959472|NCT02004197|Active Comparator|Quadruple therapy|Omeprazole, Amoxicillin, Metronodazole and TRITEC (ranitidine bismuth citrate)
88959473|NCT02004210|Experimental|The TARE group|transarterial radioembolization group
88959474|NCT02004210|Experimental|The TACE group|Transarterial chemoembolization group
89207064|NCT00963261|Experimental|psycho-oncological intervention|stepped care psycho-oncological intervention
89207065|NCT00963261|No Intervention|control group|
89207066|NCT02547636||Subjects/specimens that meet the inclusion criteria|Subjects/specimens that meet the inclusion criteria
89207067|NCT00839670|Active Comparator|Modified Therapy|
89207068|NCT00839670|Active Comparator|Standard Therapy|
89207069|NCT00963339||Dry AMD|subjects diagnosed as intermediate AMD in at least one eye
89207070|NCT00839748||asthmatics|asthmatics registry for those interested in future asthma studies
89207071|NCT01563393|Other|STAMP using|Relevant to the third part of the study. 30 Children between 1 and 17 years of age from internal medicine department will undergo a complete evaluation by an investigating dietician and assessment by the STAMP tool in order to determine the extent of the nutritional risk on a numerical scale.
89207072|NCT01563393|Other|No STAMP using|Relevant to the third part of the study. Other 30 children that are not screened by dietitian and either not by STAMP
89207073|NCT04009707||patients with alcool use desorders|Patient cared for in the addictology department of the University Hospital of Nîmes
89540666|NCT06075498|Active Comparator|transversus abdominis plane block|The group that underwent bilateral transversus abdominis plane block with 0.375 mg 20 ml bupivacaine on each side after open retropubic prostatectomy operations
89540667|NCT06075498|Active Comparator|quadratus lumborum plane block|The group that underwent bilateral quadratus lumborum plane block with 0.375 mg 20 ml bupivacaine on each side after open retropubic prostatectomy operations
89540668|NCT06073899|No Intervention|Quiet Rest|Participants will sit quietly for two minutes, three times. Pressure pain threshold will be measured between each two-minute interval.
89540669|NCT06073899|Experimental|High Fatigue Exercise|"Participants will perform a leg extension exercise in a machine with weight equipment to 65% of their 1-repetition maximum. Participants will complete this exercise for three sets until they report the exercise is hard (8/10 on the OMNI perceived exertion scale)."
89540670|NCT06073899|Active Comparator|Low Fatigue Exercise|"Participants will perform a leg extension exercise in a machine with weight equipment to 65% of their 1-repetition maximum. Participants will complete this exercise for three sets until they report the exercise is somewhat easy (4/10 on the OMNI perceived exertion scale)."
89540671|NCT06072170|Experimental|Cohort 1, 1 g of Kratom|A total of 6 subjects will receive an oral single dose administration of the active product
89540672|NCT06072170|Experimental|Cohort 2, 2 g of Kratom|A total of 6 subjects will receive an oral single dose administration of the active product
89540673|NCT06072170|Experimental|Cohort 3, 4 g of Kratom|A total of 6 subjects will receive an oral single dose administration of the active product
89540674|NCT06072170|Experimental|Cohort 4, 6 g of Kratom|A total of 6 subjects will receive an oral single dose administration of the active product
89540675|NCT06072170|Experimental|Cohort 5, 8 g of Kratom|A total of 6 subjects will receive an oral single dose administration of the active product
89540676|NCT06072170|Placebo Comparator|Placebo|A total of 2 subjects per cohort will receive an oral single dose administration of placebo
89540677|NCT06071117|Experimental|Virtual Reality Glasses (VR)|
89540678|NCT06071117|Active Comparator|White noise|
89540679|NCT06071117|Sham Comparator|Basic behavior management techniques|
89540680|NCT06070779|Experimental|neuro linguistic programming group for primiparous|"NLP application to the experimental group will be done by the researcher Ayşegül Kılıçlı. The application session will 20 minutes. The application will be started in the active phase of labour when the cervical opening is 4 cm.~In the neuro linguistic programming (NLP); The system of representation of women in practice will be determined first. Then, with the anchoring technique, negative feelings and thoughts about labour will be tried to be erased from the mind or their severity will be reduced. Then, positive feelings and thoughts will be created instead of the mother's negative feelings and thoughts with belief change strategies. Then, with the swish technique, the mother's positive feelings and thoughts about labour will be made aware of and reinforced."
88959475|NCT02004223|Experimental|Dose escalation using stereotactic boost|Dose level allocation - Participants will be allocated to the current dose level, or if the current dose level has been filled and acceptable toxicity has been established, they will be enrolled into the next dose level
88959476|NCT02004301|Experimental|Radiolabelled T4 Tablet|Single dose of delayed release diclofenac potassium (25 mg) tablet with time delay of 4 h radiolabelled with 4 MBq 99mTc
88959477|NCT02004301|Experimental|Radiolabelled T6 Tablet|Single dose of delayed release diclofenac potassium (25 mg) tablet with time delay of 6 h radiolabelled with 4 MBq 99mTc
88959478|NCT02004314|Other|Chloroquine|This will be a single arm, pilot study with each subject as his/her own control. The study will last 44 weeks, with 8 weeks observation period on ART alone to assess stability of activated CD8CD38 T cells, followed by 24 weeks chloroquine treatment with ART and a 12-week follow-up period on ART alone. Twenty ART treated patients will be recruited. To maximize chances of demonstrating a treatment effect, the chloroquine will be administrated for 24 weeks.
88959479|NCT02004327|Experimental|A Group|"1st administration - DW1029M300mg PO Once~2nd administration - DW1029M600mg PO Once~3rd administration - DW1029M1200mg PO Once"
89207074|NCT00844584|Other|ablation|patients with atrial fibrillation underwent radiofrequency ablation with totally thoracoscope.
89207075|NCT00963417|Active Comparator|Triptorelin plus tamoxifen|Determination of bone mineral density in patients randomized in TEXT-1 or TEXT-2 trials to receive triptorelin (GnRH analogue) for 5 years plus tamoxifen for 5 years.
89207076|NCT00963417|Experimental|Triptorelin plus exemestane|Determination of bone mineral density in patients randomized in TEXT-1 or TEXT-2 trials to receive triptorelin (GnRH analogue) for 5 years plus exemestane for 5 years.
89207077|NCT00839826|Active Comparator|Arm 2|
89207078|NCT00839826|Experimental|Arm 1|
89207079|NCT00963495|Experimental|Clioquinol|Patients will take Clioquniol at various doses depending on which dose level they come into the study at. Once a MTD has been determined, the new patients that enter into the trial will then take it at that level.
89210511|NCT03972631|Placebo Comparator|Lifestyle education|The participants in this group will be provided usual recommendation, including the diet principles, activity guideline and behavioral strategies at baseline. In addition, the participants will have access to an APP, with which the participants could learn more information of body weight management, and keep records of diet, activity and body weight during the study.
89210512|NCT03972631|Experimental|Intensive Lifestyle Intervention|The participants in this group will be provided a comprehensive intervention, including goal setting, one to one support by the lifestyle counselors, and meal replacement products, in addition to the information and APP which are provided to the Lifestyle education group.
89511297|NCT04983602|Experimental|Comprehensive Geriatric assessment arm|The intervention will comprise initially of a detailed interdisciplinary assessment and intervention by one or more members of the dedicated geriatric team. The team (consisting of a geriatric specialist registrar, specialist geriatric nurse, senior pharmacist, senior physiotherapist, senior occupational therapist, and senior medical social worker) in both ED and AMAU will assess all participants in the intervention group and perform CGA. Potential participants will be approached regarding trial recruitment post ED triage thereby ensuring rapid assessment shortly after hospital arrival by the teams in both AMAU and in ED.
89511298|NCT04983602|Experimental|EDPLUS arm|The ED PLUS intervention will comprise initially of a detailed interdisciplinary assessment and intervention by one or more members of the dedicated geriatric team. The team in both ED and AMAU will assess all participants in the intervention group and perform CGA. Potential participants will be approached regarding trial recruitment post ED triage thereby ensuring rapid assessment shortly after hospital arrival by the teams in both AMAU and in ED. Additionally the participants in this arm will undergo a 6 week physiotherapy led intervention in the community involving 3 home visits and weekly telephone support. The intervention will involved assessment of the patients function in terms of strength, balance and mobility. Following assessment the intervention will be aimed at addressing deficits in the function of the participants, review of their medical management by a geriatrician trainee and focusing on self management of their own program.
89511299|NCT05071898|Experimental|Open label administration of semaglutide|Semaglutide: 0.25 mg, sc, q.week for 4 weeks followed by 0.5 mg, sc, q.week for 2 weeks
89210513|NCT00908778|Experimental|Vitreosolve I|Intravitreal injection
89210514|NCT00908778|Experimental|Vitreosolve|Intravitreal injection
89511300|NCT01364870|Active Comparator|Active TENS|High-frequency intense TENS provided with the EMPI Select TENS. The generator emits a balanced, asymmetrical, biphasic waveform and has buttons for variation of frequency and amplitude. A rate modulation frequency of 50pps and 150pps every 0.5 seconds will be used with a pulse width of 150 microseconds (μs).
89511301|NCT01364870|Placebo Comparator|Placebo TENS|"Subjects randomized to the placebo group will use an EMPI TENS Select device that emits a current for 45 seconds then shuts off. They will be asked when they first feel the current, then the device will be turned down a half-point to provide treatment at a sub-sensory level. This unit displays an active indicator light suggesting to the subject that the unit is actively emitting current. At discharge, subject will be sent home with an adequate supply of batteries and asked to change batteries when the device goes below 4 bars, further suggesting that the device is actively working."
89511302|NCT01364870|No Intervention|Standard Care|"Subjects randomized to Standard Care will be given no TENS unit."
89511303|NCT04209218|Placebo Comparator|Routine blood pressure management + placebo|Blood pressure is maintained according to routine practice. Placebo (normal saline 2 ml) is administered before anesthesia induction.
89511304|NCT04209218|Experimental|Routine blood pressure management + dexamethasone|Blood pressure is maintained according to routine practice. Dexamethasone (10 mg/2 ml) ia administered before anesthesia induction.
88810886|NCT05216393|No Intervention|Control|The control participants will not have access to the RecTech Match website; however, control participants will be directed to generic information available on the NCHPAD website, which includes the same information but is not delivered through RecTechMatch.com.
88810887|NCT05202808|Experimental|Light adjustable lens (LAL) and Light Delivery Device (LDD)|
88810888|NCT05202808|Active Comparator|Control IOL|
88810889|NCT05191472|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
88810890|NCT05189171||Metastatic colorectal cancer|Patients having a liver biopsy for suspected adenocarcinoma of the colon and/or rectum that is metastatic to the liver.
88810891|NCT05181618|Experimental|Cohort 1, Hemophilia A and Without Arthropathy: Emicizumab|Cohort 1 comprises participants with severe or moderate hemophilia A and with no synovitis and no osteochondral damage (Haemophilia Early Arthropathy Detection with Ultrasound [HEAD-US] score of 0) in all index joints.
88810892|NCT05181618|Experimental|Cohort 2, Hemophilia A and with Synovitis Only: Emicizumab|Cohort 2 comprises participants with severe or moderate hemophilia A and with synovitis (HEAD-US synovitis score of ≥1) in at least one index joint and no osteochondral damage (HEAD-US bone and cartilage score of 0).
88810893|NCT05181618|Experimental|Cohort 3, Hemophilia A and with Osteochondral Damage: Emicizumab|Cohort 3 comprises participants with severe or moderate hemophilia A and with osteochondral damage (HEAD-US bone and cartilage score of ≥1) in at least one index joint and with any synovitis score.
88810894|NCT05176223|Experimental|Treatment (68GA PSMA PET/CT)|Patients undergo 68GA PSMA PET/CT scans at baseline, and after 3, 6, 9, and 12 cycles of standard of care immunotherapy in the absence of disease progression or unacceptable toxicity.
88810895|NCT05171855|Experimental|Lonapegsomatropin|Lonapegsomatropin administered once-weekly by subcutaneous injection
88810896|NCT05171075|Experimental|Abelacimab|Abelacimab intravenous administration followed by monthly administration of the same dose subcutaneously
88810897|NCT05171075|Active Comparator|Dalteparin|Dalteparin administered subcutaneously daily
88810898|NCT05171049|Experimental|Abelacimab|Abelacimab intravenous administration followed by monthly administration of the same dose subcutaneously
88810899|NCT05171049|Active Comparator|Apixaban|Apixaban administered orally twice a day
88810900|NCT05164549|Experimental|XR-Bup|Extended-Release Buprenorphine, monthly, 300mg or 100mg
88810901|NCT05164549|Active Comparator|Bup/Met|Standard of Care; either Buprenorphine (including Subutex, Suboxone & Espranor) or Methadone (Participant Preference).
88810902|NCT05164549|Experimental|XR-Bup + PSI|Extended-Release Buprenorphine, monthly, 300mg or 100mg + Personalised Psychosocial Intervention (PSI)
88810903|NCT05164549|Active Comparator|Bup/Met + PSI|Standard of Care; either Buprenorphine (including Subutex, Suboxone & Espranor) or Methadone (Participant Preference) + Personalised Psychosocial Intervention (PSI)
88810904|NCT05140759|Experimental|Implanted device|Implantation and activation of an automated continual water removal system, including 4-months follow up
88816105|NCT02484807||Macitentan + Sildenafil|Combination treatment with Macitentan + Sildenafil at baseline
89540681|NCT06070779|No Intervention|control group for primiparous|The control group will not receive only the neuro-linguistic programming, but all other assessments will be parallel to the experimental group (neuro linguistic programming group for primiparous).
89540682|NCT06070779|Experimental|neuro linguistic programmig group for multiparous|"NLP application to the experimental group will be done by the researcher Ayşegül Kılıçlı. The application session will 20 minutes. The application will be started in the active phase of labour when the cervical opening is 4 cm.~In the neuro linguistic programming (NLP); The system of representation of women in practice will be determined first. Then, with the anchoring technique, negative feelings and thoughts about labour will be tried to be erased from the mind or their severity will be reduced. Then, positive feelings and thoughts will be created instead of the mother's negative feelings and thoughts with belief change strategies. Then, with the swish technique, the mother's positive feelings and thoughts about labour will be made aware of and reinforced."
89540683|NCT06070779|No Intervention|control group for multiparous|The control group will not receive only the neuro-linguistic programming, but all other assessments will be parallel to the experimental group (neuro linguistic programming group for muliparous).
89540684|NCT06062888|No Intervention|Standard of Care|Standard of Care Control Group
89540685|NCT06062888|Experimental|Standard of Care + FFP|Standard of Care + Experimental Treatment
89540686|NCT06059534|Placebo Comparator|Placebo|This group will be provided with placebo capsules for comparative purposes.
89540687|NCT06059534|Experimental|DracoBelleTM Nu|This group will be provided with DracoBelleTM Nu capsules, which will be compared to the placebo group.
89540688|NCT06058091|Placebo Comparator|Phase II-Placebo group|Receive the best basic treatment
88959480|NCT02004327|Experimental|B Group|"1st administration - DW1029M600mg PO Once~2nd administration - DW1029M1200mg PO Once~3rd administration - DW1029M300mg PO Once"
88959481|NCT02004327|Experimental|C Group|"1st administration - DW1029M1200mg PO Once~2nd administration - DW1029M300mg PO Once~3rd administration - DW1029M600mg PO Once"
88959482|NCT02004340|Active Comparator|Transcutaneous auricular vagal stimulation|Transcutaneous stimulation at auricular concha
88959483|NCT02004340|Sham Comparator|Transcutaneous auricular non-vagal stimulation|Transcutaneous stimulation at auricular edge
88959484|NCT02004340|No Intervention|control|No transcutaneous stimulation is given
88959485|NCT02004379||Patients with hepatitis C, genotype 1|Patients with hepatitis C, genotype 1, treated with telaprevir or boceprevir
88959486|NCT02004392|Experimental|EVP-6124, low dose|low dose, Tablet, Once Daily, Day 1 through Day 182
88959487|NCT02004392|Experimental|EVP-6124, high dose|high dose, Tablet, Once Daily, Day 1 through Day 182
88959488|NCT02004405|Experimental|strengthening exercise|"The experimental group (STRE) will receive strengthening training in Station for lifting weight exercises (Flex Mega 8, Flex Fitness Equipment Brand) using the recommendations of the American College of Sports Medicine (ACMS, 2010), twice a week, during 45 minutes for 16 weeks."
88959489|NCT02004405|Active Comparator|Flexibility exercise|The control group (FLEX) will receive stretching and flexibility exercise training according to the protocol of prescription and previously tested and described in appendix F (Valim et al., 2003), twice a week, during 45 minutes for 16 weeks.
88959490|NCT02004418|Experimental|C-Choline PET Scans|Radioactive doses of 11C-Choline: 400 MBq ± 10% per injection, pre-radiation treatment and following treatment at 3 and 6 months
88959491|NCT02004431||Pain (experimental)|The cases are patients with significant pain on day one after surgery
88959492|NCT02004431||No pain (control)|The controls are sex, age and operation matched individuals without pain.
89210515|NCT00905190|Experimental|Fed|A single oral dose of ondansetron (1 x 24 mg) will be administered with approximately 240 ml of water in the morning. The ondansetron dose will be administered after a 10-hour overnight fast and thirty minutes after consuming a high-fat, high-caloric breakfast
89210516|NCT00905190|Experimental|Fasting|A single oral dose of ondansetron (1 x 24 mg) will be administered with approximately 240 ml of water in the morning after a 10-hour overnight fast.
89210517|NCT00908856|Placebo Comparator|Placebo|Placebo
89540689|NCT06058091|Experimental|Phase II-low-does group|Receive the best basic treatment and a million cells per kilogram of body weight
89540690|NCT06058091|Experimental|Phase II-high does group|Receive the best basic treatment and two million cells per kilogram of body weight
89540691|NCT06058078|Experimental|RY_SW01 group 1 does 1 RY_SW01 cell injection|Receive the best basic treatment and one million cells per kilogram of body weight
89540692|NCT06058078|Experimental|RY_SW01 group 2 does 2 RY_SW01 cell injection|Receive the best basic treatment and two million cells per kilogram of body weight
89540693|NCT06058078|Other|control group|Receive the best basic treatment
88959493|NCT02004444||Natalizumab 18 months|10 patients on continuous natalizumab monotherapy for 18 months
88959494|NCT02004444||Natalizumab 24 months|10 patients on continuous natalizumab monotherapy for 24 months
88959495|NCT02004444||Natalizumab 36 months|10 patients on continuous natalizumab monotherapy for 36 months
88959496|NCT02004444||IFN-beta 36 months|10 patients on continuous interferon-beta monotherapy for 36 months
88959497|NCT02004444||Untreated|10 untreated patients
88959498|NCT02004457|Experimental|Acceptance-based behavior therapy (ABBT)|ABBT will consist of 2 sessions. The first session will be used to introduce the concept of acceptance and its possible benefits in the context of life values and patient-identified barriers to care engagement. Following a discussion of life values will be a discussion of which, if any, of these values are currently misaligned with the participant's HIV self-care. At the second session, acceptance-based coping skills will be practiced and a behavioral plan will be developed to targets barriers identified in the first session. These discussions will help the participant clarify how best to align their values with decisions on how to manage his/her HIV (e.g. when and how to disclose, what to expect at appointments).
89210518|NCT00908856|Active Comparator|autologous mononuclear cells|a single intravenous autologous bone marrow mononuclear cell transfusion
88959499|NCT02004457|Placebo Comparator|Treatment-as-usual (TAU)|TAU will consist of the standard sessions all individuals receive as they enter HIV care and attend their first follow-up visit to review lab results. TAU includes identification of environmental barriers to care, assessment of needs for additional care and corresponding referrals (i.e., for depression, substance abuse), and recommendations to attend HIV support groups.
88959500|NCT02004470|No Intervention|Passive exsufflation|Will not actively suction carbon dioxide from abdomen. Open laparoscopic trocars and allow C02 to passively empty from abdomen.
88959501|NCT02004470|Experimental|Active lavage and suction|This step is already employed in many ongoing surgeries where normal saline will be used to lavage the right upper quadrant and then will be suctioned out to remove as much Carbon dioxide from the patient's abdomen and to therefore decrease postoperative pain.
88959502|NCT02004483|Experimental|Percutaneous Coronary Intervention|Each patient will get elective percutaneous coronary angioplasty with balloon inflation(PCI). During and after PCI 2D-echography (strain) will be performed.
88959503|NCT02004496|No Intervention|Group A: no app|no use of an mobile application while treatment
88959504|NCT02004496|Active Comparator|Group B: only app|Patients, who use independently the mobile application named Consilium without involvement of the physician.
89511305|NCT04209218|Experimental|Targeted blood pressure management + placebo|Blood pressure is maintained within ±10% from baseline. Placebo (normal saline 2 ml) is administered before anesthesia induction.
89511306|NCT04209218|Experimental|Targeted blood pressure management + dexamethasone|Blood pressure is maintained within ±10% from baseline. Dexamethasone (10 mg/2 ml) is administered before anesthesia induction.
89207080|NCT04042896|Experimental|exergame group|"The exergame group performed exercise using the Exer Heart device (D&J Humancare, Seoul, South Korea), which consisted of a running/jumping board and a screen connected to the board. The exercise program Alchemist's Treasure, a running-based exergame, moves the avatar according to the user's motions and was used for the exercise session. Alchemist's Treasure is a game in which the user listens to stimulating music, runs with the avatar, avoiding obstacles, and wins items using the front, back, left, and right sensors on the exercise board. The subject can control the speed of the avatar movement by adjusting the walking or running speed on the board.~This study did not enforce exercise intensity in order to allow patients to enjoy the exergame. Thus, during the training period, the patients exercised at a self-selected pace for 40 minutes per day."
89511307|NCT04209062|Experimental|Study device|
89511308|NCT04209062|Active Comparator|Control device|
89511309|NCT02268526|Experimental|Cohort 1: CSJ148|Cohort 1: CSJ148 IV q 4weeks
89511310|NCT02268526|Experimental|Cohort 2: CSJ148|Cohort 2: CSJ148 IV q 4weeks
89511311|NCT02268526|Placebo Comparator|Cohort 2: Placebo|Cohort 2: Placebo IV q 4weeks
89511312|NCT04981262|Experimental|Stimulance|4 weeks intervention with Stimulance for all participants
89511313|NCT04981262|Experimental|Stimulance 6 months|6 months intervention
89511314|NCT04981262|No Intervention|No intervention|6 months control group
89511315|NCT05031338||SX-One MicroKnife with ultrasound guidance|Carpal Tunnel Release using the SX-One MicroKnife with ultrasound guidance
89511316|NCT05031338||Traditional mini-open technique without ultrasound guidance|Carpal Tunnel Release using the traditional mini-open technique without ultrasound guidance
89511317|NCT05070026|Experimental|uni-portal VATS group|
89511318|NCT05070026|Experimental|three port VATS group|
89511319|NCT04980326|Experimental|Stepped-care program (Step 1: DWM; Step 2: PM+)|"The treatment group will receive the stepped-care program consisting of Doing What Matters (DWM) (step 1) and Problem Management Plus (PM+) (step 2) in addition to Psychological First Aid (PFA) and care-as-usual (CAU). Step 2 will only be provided if the participant still has elevated levels of psychological distress at 2 weeks after DWM, i.e. during the second quantitative assessment at 2 weeks after DWM.~Participants allocated to the experimental arm will also receive training in PFA, which consists of a 30-min call that covers basic aspects about peer support in times of stress. Participants will also be allowed to continue with their mental health interventions (CAU), as long as they meet eligibility criteria."
89511320|NCT04980326|Active Comparator|Psychological First Aid (PFA)|Participants allocated to the control arm will also receive training in PFA, which consists of a 30-min call that covers basic aspects about peer support in times of stress. Participants will also be allowed to continue with their mental health interventions (CAU), as long as they meet eligibility criteria.
89511321|NCT04979702|Active Comparator|Active Control|Patients will have access to our online exercise resources throughout the 12-week intervention.
89511322|NCT04979702|Experimental|Experimental: mHealth technology assisted exercise counselling (mHealth)|Participants will complete a 12 week mHealth technology assisted exercise counselling intervention. Participants will co-develop a 3-month structured exercise and PA programme, with support from an exercise specialist. All participants will have 4 exercise consultations with their exercise specialist. The intervention will be supported by 3 mHealth elements; 1) a wrist worn fitness watch, 2) a smartphone app for patients, and 3) a coaching website for the exercise specialist. The 3 elements will be synced, allowing data to be transferred between platforms.
89511323|NCT05068466|Experimental|INCB054707 (Dose A)|Participants will be administered single-dose INCB054707 on Day 1 followed by once daily dose of INCB054707 on Days 5 to 12 (8 doses) administered orally after a fast of ≥ 8 hours
89511324|NCT05068466|Experimental|INCB054707 (Dose B)|Participants will be administered a single-dose INCB054707 on Day 1 followed by once daily dose of INCB54707 on Days 5 to 12 (8 doses) administered orally after a fast of ≥ 8 hours.
89511325|NCT05068466|Placebo Comparator|Placebo (Dose A)|Participants will be administered single-dose placebo on Day 1 followed by once daily dose of placebo on Days 5 to 12 (8 doses) administered orally after a fast of ≥ 8 hours
89511326|NCT05068466|Placebo Comparator|Placebo (Dose B)|Participants will be administered single-dose placebo on Day 1 followed by once daily dose of placebo on Days 5 to 12 (8 doses) administered orally after a fast of ≥ 8 hours
89511327|NCT04218032||blood pressure|blood pressure is measured from the participants, by using two methods. A new developed device and a reference device. The new device measures, using oscillometry, the blood pressure from the finger tip. The reference device is a standard sphygmomanometer.
88816106|NCT02484807||Macitentan + Tadalafil|Combination treatment with Macitentan + Tadalafil at baseline
88816107|NCT05307146|Experimental|micro/macro electrode|
88816108|NCT02556333|Experimental|FTC/TAF|Emtricitabine 200mg/tenofovir alafenamide 25mg (FTC/TAF) tablet to be given orally once daily to be added to a failing regimen for 10 days. If HIV RNA decline by >= 0.5 log copies/mL, patient will continue on FTC/TAF with a new antiretroviral regimen for 48 weeks. If < 0.5 log copies/mL decline, patient will be taken off FTC/TAF.
88816109|NCT01166126|Experimental|Treatment (temsirolimus and selumetinib)|"Treatment Phase: This period begins with the first intravenous (through the vein) infusion of TEMSIROLIMUS and the first AZD6244 administration by mouth (visit 2, Week 1) and will continue until Week 8 (Visit 4).~As many as 38 patients will receive the same dosage of TEMSIROLIMUS injected in the veins once a week for 8 weeks, and the AZD6244 will be given as capsules by mouth twice a day for 8 weeks. That is one cycle. The TEMSIROLIMUS and AZD6244 will be given to participants as an outpatient, unless admission to the hospital was needed for treatment of related side effects or underlying disease. The subsequent cycles of TEMSIROLIMUS and AZD6244 will be given every 8 weeks. The TEMSIROLIMUS will be injected in a vein over 30 minutes.~The continuation phase begins with visits at weeks 12 in patients who receive at least two cycles of treatments."
89511328|NCT04978142|Experimental|Active|Active tDCS stimulation at 2 mA for 20 minutes, with a 10 seconds of ramp-up and 10 seconds of ramp-down time as used in previous tinnitus studies. The stimulation will be delivered via two rubber electrodes attached using a layer of conductive paste (35 cm2). The anode will be placed over the right dlPFC and cathode over the left dlPFC).
89511329|NCT04978142|Sham Comparator|Sham|Placebo stimulation is performed using the same current intensity, but only applied for 45 seconds in addition to the 10 second ramp-up and 10 second ramp-down periods. The electrode configuration and placement will be identical to the active stimulation.
89511330|NCT05066750|Experimental|Mindful breathing video|Participants watch a 10 minute mindful breathing video
89511331|NCT05066750|Active Comparator|Control video|Participants watch a 10 minute control video
89210519|NCT00908856|Active Comparator|autologous marrow stromal cells|a single intravenous autologous marrow stromal cell transfusion
89511332|NCT02268214|Experimental|Arm A: Dapagliflozin|Dapagliflozin 5 mg tablet orally, once daily for 52 weeks
89511333|NCT02268214|Experimental|Arm B: Dapagliflozin|Dapagliflozin 10 mg tablet orally, once daily for 52 weeks
89511334|NCT02268214|Placebo Comparator|Arm C: Placebo for Dapagliflozin|Placebo tablet orally, once daily for 52 weeks
89511335|NCT02521376|Experimental|Cohort 1 (Moderate Hepatic Impairment)|Entospletinib administered twice daily on Days 1-4, and 1 morning dose only on Day 5.
89511336|NCT02521376|Experimental|Cohort 2 (Severe Hepatic Impairment)|Entospletinib administered twice daily on Days 1-4, and 1 morning dose only on Day 5.
89511337|NCT02521376|Experimental|Cohort 3 (Mild Hepatic Impairment)|Entospletinib administered twice daily on Days 1-4, and 1 morning dose only on Day 5.
89511338|NCT04421300|Experimental|smile exercise|smile exercise, 4 times a day，8 weeks
89511339|NCT04421300|Active Comparator|0.1% Sodium Hyaluronate Eye Drops|0.1% sodium hyaluronate, 4 times a day, 8 weeks.
89511340|NCT04868812|Experimental|Patient|All participants will be screened to ensure inclusion/exclusion criteria are met. A biopsy will be taken from each patient one month before the first laser treatment and one month after the last laser treatment. The MonaLisa treatment will be performed monthly for 3 months. A clinical evaluation will be recorded for each patient using validated questionnaires at baseline and one month after the last procedure.
89511341|NCT02268058|Active Comparator|tx 1: acetaminophen and education|"Patient took routinely acetaminophen every 4 hours when awake for a 72 hour period and documented their headaches for a week.~Patient and family received standard education on concussion management in the Emergency department."
89511342|NCT02268058|Active Comparator|Tx 2: ibuprofen and education|"Patient took routinely ibuprofen every 6 hours when awake for a 72 hour period and documented their headaches for a week.~Patient and family received standard education on concussion management in the Emergency department."
89511343|NCT02268058|Active Comparator|Tx 3: ibuprofen/acetaminophen/education|"Patient took routinely ibuprofen (Q6H) and acetaminophen (Q4H) for when awake for 72 hours post concussion and documented their headaches for a week.~Patient and family received standard education on concussion management in the Emergency Department."
88816110|NCT05306990|Active Comparator|Atorvastatin|Atorvastatin tablets Dosage and frequency: 40mg orally once daily
88816111|NCT05306990|Active Comparator|Rosuvastatin|Rosuvastatin tablets Dosage and frequency: 20mg orally once daily
88816112|NCT02557035|Experimental|I.V. palonosetron infusion plus dexamethasone|Intravenous palonosetron (Aloxi 0.25 mg solution for injection) as an infusion with oral dexamethasone, both given on Day 1, prior to the scheduled start of cisplatin; then dexamethasone from Days 2 through 4.
88816113|NCT02557035|Active Comparator|I.V. palonosetron bolus plus dexamethasone|Intravenous palonosetron (Aloxi 0.25 mg solution for injection) as a bolus with oral dexamethasone, both given on Day 1, prior to the scheduled start of cisplatin; then dexamethasone from Days 2 through 4.
88816114|NCT02385084|Experimental|Part A: LY2409021 Capsule|Single oral dose of LY2409021 capsule in one of three study periods.
88816115|NCT02385084|Experimental|Part A: LY2409021 Tablet Pre-commercial|Single oral dose of LY2409021 tablet (pre-commercial formulation) in one of three study periods.
88816116|NCT02385084|Experimental|Part A: LY2409021 Tablet Commercial|Single oral dose of LY2409021 tablet (commercial formulation) in one of three study periods.
88816117|NCT02385084|Experimental|Part B: LY2409021 Capsule|Single oral dose of LY2409021 capsule in one of two study periods.
88959505|NCT02004496|Active Comparator|Group C: app and physician|Patients use the mobile application named Consilium in collaboration with the physician.
88959506|NCT02004509|Active Comparator|anticoagulant|Prescription of oral anticoagulation for patients with silent AF (detected by the pacemaker).
88959507|NCT02004509|No Intervention|Control|Patients with silent FA detected only by the pacemaker will no receive oral anticoagulation.
88959508|NCT02004535|Experimental|Cochlear implantation|Cochlear implantation of the ear with severe to profound hearing loss
88959509|NCT02004548|Experimental|Metatinib Tromethamine|"Dose escalation is in accordance with the traditional 3 +3 design, and dose groups are subsequently set as: 25, 50, 100, 200, 300, 450, 600, 800 mg/d."
88959510|NCT02004574|Experimental|PRN treatment|Group 1: PRN treatment Apply Xamiol® gel (Calcipotriol/betamethasone dipropionate gel) once daily as needed (PRN)
88959511|NCT02004574|Experimental|Continuous treatment|Group 2: Continuous treatment Apply Xamiol® gel (Calcipotriol/betamethasone dipropionate gel)once daily
88959512|NCT02004574|Experimental|Weekends treatment|Group 3: Weekends treatment (twice weekly) Apply Xamiol® gel (Calcipotriol/betamethasone dipropionate gel) once daily at weekends (on Saturdays and Sundays)
88959513|NCT02004587|Experimental|Mild hepatic impairment group|Mild hepatic impairment group by Child-Pugh scores
88959514|NCT02004587|Experimental|Moderate hepatic impairment group|Moderate hepatic impairment group by Child-Pugh scores
89511344|NCT02268058|No Intervention|Tx 4: no routine meds and education|"Patient was advised to manage headaches as they typically would. There was no instruction given for the routine administration of either ibuprofen or acetaminophen.~The Patient and family received standard education in the ER department and diarized their headaches and medications they took for a one week period."
88959515|NCT02004587|Active Comparator|Healthy volunteers|Gemigliptin dosing in Healthy subjects
88959516|NCT02004600|Experimental|patient receiving one PDT session|patient receiving one photodynamic therapy (PDT) session
88959517|NCT02004626|Active Comparator|Collagenase|"Each gram of ointment contains :~Collagenase ...0.6 U~Vehicle qs ... 1 g~Presentation:~Topic use. 5 g tube of ointment containing smooth, lump-free , pale white to slightly brown with faint characteristic odor .~Dosage The ointment should have full contact with the entire injured area, and uniformly applied twice a day."
88959518|NCT02004626|Active Comparator|Kollagenase|"Each gram of ointment contains :~Collagenase ... 0.6 U~Vehicle qs ... 1 g~Presentation~Topic use. 5 g tube of ointment containing brownish clear, fat and weak characteristic odor.~Dosage The ointment should have full contact with all the injured area, being uniformly applied twice a day."
88959519|NCT02004639|Active Comparator|Mastictors sparing group|Using IMRT or HT to do masticators sparing techniques and physical therapy to prevent trismus.
88959520|NCT02004639|No Intervention|Masticators not sparing group|The patients do not receive masticators sparing technique as traditional techniques but still receive physical therapy after radiotherapy to prevent trismus.
88959521|NCT02004639|Active Comparator|EA group|Using masticators sparing techniques and electro-acupunture stimulation to prevent trismus
88959522|NCT02004639|Sham Comparator|Sham-EA group|Using masticators sparing techniques but with sham EA stimulation.
88959523|NCT02004652|Experimental|Prucalopride|Prucalopride, 2mg, tablet. First given 24 hours after surgery beginning on POD 1,until bowel movements or for a maximum of 7 days of postoperative treatment
88959524|NCT02004652|Placebo Comparator|Placebo|Vitamin C, 50mg, tablet
88959525|NCT02004665||acute coronary syndrome and delirium|patients with acute coronary syndrome and delirium
88959526|NCT02004678|Other|Cohort 1, 7.5 mg DS-1150b|"Dosing will occur over two periods. Subjects will receive either~a dose of placebo in Period 1 followed by a single dose of 7.5 mg DS-1150b in Period 2; or~a single dose of 7.5 mg DS-1150b in Period 1 followed by a dose of placebo in Period 2."
89210520|NCT00905502|Experimental|1: Restricted protocol (RG) group|Received 4 ml/kg•hr of Lactated Ringer's solution (RL) throughout the intra-operative period.
89511345|NCT05025878||[U-13C]glucose|All participants consented to the study will receive the [U-13C]glucose infusion and collection of ascites for research.
89511346|NCT02267824|Experimental|Extraoral OrthoPulse® PBM|Subjects assigned to this group receive full mouth fixed orthodontic appliance treatment in conjunction with receiving daily extraoral OrthoPulse® photobiomudulation (PBM) treatments.
89511347|NCT02267824|Other|Orthodontic Treatment (Control)|Subjects assigned to this group receive full mouth fixed orthodontic appliance treatment, only.
89511348|NCT05025722||Confirmed PXE participants|Participants who have index PXE/proband with established PXE and ABCC6 mutations identified.
89511349|NCT05025722||PXE carrier participants|Participants who are biological siblings of the PXE index case and confirmed as PXE carrier.
89511350|NCT05025722||Non-PXE normal participants|Participants who are biological siblings of PXE index case and confirmed as non-PXE normal.
89511351|NCT05648188||NSCLC patients|Patients with proven stage IA-IIB non-small cell lung cancer (NSCLC).
88959527|NCT02004678|Other|Cohort 2, 15 mg DS-1150b|"Dosing will occur over two periods. Subjects will receive either~a dose of placebo in Period 1 followed by a single dose of 15 mg DS-1150b in Period 2; or~a single dose of 15 mg DS-1150b in Period 1 followed by a dose of placebo in Period 2."
88959528|NCT02004717|Experimental|dose escalation then expansion|"Dose escalation of this study will follow a 3+3 study design with a starting intravenous (IV) dose of 0.1 mg/kg. Six dose levels are planned: level 1,0.1 mg/kg; level 2,0.3 mg/kg; level 3, 1.0 mg/kg; level 4,3.0 mg/kg; level 5,10 mg/kg; level 6,20 mg/kg.~Dose Expansion - Up to 20 subjects will be enrolled and treated at the dose determined in Dose Escalation arm."
88959529|NCT02004730|Experimental|long single vessel disease|ABSORB implantation for long single vessel disease
88959530|NCT02004730|Experimental|multivessel disease ABSORB only|multivessel disease treated with ABSORB implantation only
88959531|NCT02004730|Experimental|"multivessel disease hybrid"|multivessel disease treated with ABSORB implantation and other devices such as drug eluting stents
88959532|NCT02004743|Other|Control|Treatment as Usual
88959533|NCT02004743|Other|Intervention|Psychological management guidelines + patient education
88959534|NCT02004756|Experimental|Fontan Patients|Fontan patients who are monitored at the Hospital for Sick Children (SickKids) will undergo an exercise program
88959535|NCT02004756|No Intervention|Healthy Controls|Healthy age-matched adolescents
89024235|NCT02661464|Experimental|Exposed to Ad26.ZEBOV and/or MVA-BN Filo|Safety Data will be collected from participants who received Ad26.ZEBOV and/or MVA-BN-Filo in Phase 1, 2 or 3 clinical studies in 6-month intervals up to 60 months after prime vaccination, including the duration in the participant's original study (Cohort 1). Female participants who became pregnant with estimated conception within 28 days after vaccination with MVA-BN-Filo or within 3 months after vaccination with Ad26.ZEBOV will be followed to the end of their pregnancy for pregnancy outcomes (Cohort 2). After the end of pregnancy, female participants will continue to be followed in Cohort 1. Safety Data for live born children to female participants will be followed up to 60 months after birth (Cohort 3).
89024236|NCT02647203|Experimental|High Fluoride Toothpaste|5,000 ppm fluoridated toothpaste, high concentration. Self-administered fluoridated dentifrices. By the elderly subjects, twice per day Drug (including placebo)
89024237|NCT02647203|Active Comparator|Standard Fluoride Toothpaste|1,450 ppm fluoridated toothpaste, low concentration. Self-administered fluoridated dentifrices. By the elderly subjects, twice per day Drug (including placebo)
89024238|NCT02647021|Active Comparator|Therapeutic Exercise|"Therapeutic Exercise Program (standard care) will include:~Neck range of motion and strengthening, and posture retraining.~Shoulder specific progressive resistance exercise program that focuses on spinal accessory nerve dysfunction and rehabilitation of trapezius muscle function."
89207081|NCT04042896|Active Comparator|treadmill group|The treadmill group consisted of 40 minutes of walking or jogging at 60-80% of the heart rate (HR) reserve. The exercise intensity was determined using the Karvonen method target HR = [Exercise Intensity × (HRmax - resting HR)] + resting HR. The HR was recorded during each session using an HR monitor (Polar RS400sd; Madison Height, Michigan, USA). The control group was asked to maintain their regular physical activity level for 12 weeks.
89511352|NCT04974164||Clinic cases group|Those with a positive RT-PCR test will be the test-positive cases or clinic cases (approximate N=700)
89511353|NCT04974164||Clinic controls group|Those with a negative RT-PCR test will be the test-negative cases or clinic controls (N=700)
89511354|NCT05023772|Experimental|Experimental Treatment of Laser Interstitial Thermal Ablation Therapy and Stereotactic Radiosurgery|Patients will undergo laser interstitial thermal ablation and CT guided stereotactic radiosurgery via intensity-modulated radiation therapy on different dates within a one to fourteen day window. The order of treatment is at the treating physicians discretion.
89511355|NCT05062382|Experimental|Complementary feeding program|Promotion of eggs.
89511356|NCT05062382|No Intervention|Comparison|Comparison arm with no program
89511357|NCT05061758|Experimental|Four injections of 250µg LY3056480|"The treatment will be given transtympanically over the course of 2-7 weeks, according to dosing regimens below.~Group 1 - Regimen 1. Day 1, Day 4, Day 8, Day 11~Group 2 - Regimen 2. Weekly~Group 3 - Regimen 3. Every two weeks"
89511358|NCT05061758|Placebo Comparator|Four injections of placebo|"The treatment will be given transtympanically over the course of 2-7 weeks, according to dosing regimens below.~Group 1 - Regimen 1. Day 1, Day 4, Day 8, Day 11~Group 2 - Regimen 2. Weekly~Group 3 - Regimen 3. Every two weeks"
89511359|NCT02267746|Active Comparator|Fabior™(tazarotene)|Reference listed drug: Fabior™ 0.1% foam (Stiefel)
89511360|NCT02267746|Experimental|Tazarotene|Tazarotene 0/1% foam (Actavis)
89511361|NCT02267746|Placebo Comparator|Vehicle foam|Foam vehicle of the test product (Actavis)
89511362|NCT05021822|Active Comparator|Block Group|
89511363|NCT05021822|No Intervention|Control Group|
89511364|NCT05021666|Experimental|Group A1|PB-718 vs placebo
89511365|NCT05021666|Experimental|Group A2|PB-718 vs placebo
89511366|NCT05021666|Experimental|Group A3|PB-718 vs placebo
89511367|NCT05021666|Experimental|Group A4|PB-718 vs placebo
89511368|NCT05021666|Experimental|Group A5|PB-718 vs placebo
89511369|NCT05021666|Experimental|Group A6|PB-718 vs placebo
89511370|NCT05021666|Experimental|Group B1|PB-718 vs placebo
89511371|NCT05021666|Experimental|Group B2|PB-718 vs placebo
89511372|NCT05021666|Experimental|Group B3|PB-718 vs placebo
89511373|NCT05021666|Experimental|Group B4|PB-718 vs placebo
89511374|NCT04971824|Experimental|Physiotherapeutic arm|"There will be the physiotherapeutic intervention, total duration for each participant is three months.~The participants will be asked to fill three validated questionnaires in the beginning and in the end of study and keep records of their exercises, period and ovulation in their diaries."
89511375|NCT02362360|Experimental|Coloplast Test Product then Comparator|The subject first tests the Coloplast Test Product and then tests the Comparator
89511376|NCT02362360|Experimental|Comparator then Coloplast Test Product|The subject first tests the Comparator and then tests the Coloplast Test Product.
89511377|NCT02362282|Active Comparator|Gait plus cognitive training|Rehabilitation of walking/gait, combined with rehabilitation of cognitive function
89511378|NCT02362282|Active Comparator|Gait plus arm training|Rehabilitation of walking/gait, combined with rehabilitation of arm function
89511379|NCT04969952|Experimental|Group A|Group A had watching educational module plus ACP brochure
89511380|NCT04969952|Active Comparator|Group B|Group B ACP brochure only
89511381|NCT05061290|Experimental|Control Porridge|Wholegrain maize flour, Mango powder, Carrot powder, Ferrous sulfate, Corn starch
89511382|NCT05061290|Experimental|Reference Porride A|Wholegrain maize flour, Mango powder, Carrot powder, Ferrous sulfate, Ascorbic acid, Corn starch
89511383|NCT05061290|Experimental|Test Porridge B|Wholegrain maize flour, Moringa leaf powder, Mango powder, Carrot powder, Corn starch
89511384|NCT05061290|Experimental|Test Porridge C|Wholegrain maize flour, Baobab fruit powder, Mango powder, Carrot powder, Ferrous sulfate, Corn starch
89511385|NCT05061290|Experimental|Test Porridge D|Wholegrain maize flour, Baobab fruit powder, Moringa leaf powder, Mango powder, Carrot powder
89511386|NCT02361580|Experimental|Diary|Subjects that are randomized to the diary group will be told to keep a diary of their recovery. The study is focusing on the effect of keeping a diary on disability, rather than the content of the diary.
89511387|NCT02361580|No Intervention|No Diary|Control Group
89511388|NCT04421534|Experimental|Standard of care in addition to 400 mg lactoferrin|Standard of care treatment; as per MOHP protocol, in addition to 400 mg oral lactoferrin daily [two sachets 100 mg granules (Pravotin sachets, Hygint, Egypt) in 1/4 glass of water twice a day before meals]
89511389|NCT04421534|Experimental|Standard of care in addition to 600 mg lactoferrin|Standard of care treatment; as per MOHP protocol, in addition to 600 mg oral lactoferrin daily [three sachets 100 mg granules (Pravotin sachets, Hygint, Egypt) in 1/4 glass of water twice a day before meals]
88959536|NCT02004769|Experimental|Trastuzumab, Capecitabine, Docetaxel|Trastuzumab(8 mg/kg loading dose followed by 6 mg/kg every 3 weeks) Capecitabine(2000mg/m2d, d1-14,every 3 weeks) Docetaxel (60mg/m2 every 3 weeks for 6 cycles).All patients will continue to receive trastuzumab and Capecitabine until either disease progression, occurrence of unacceptable toxicity or withdrawal from the study for another reason.
88959537|NCT02004795|Experimental|BNCT+ IG-IMRT|single arm
88959538|NCT02004821|Experimental|Renutryl® Booster|Renutryl® Booster, an oral nutritional supplement in a 300 ml bottle (600 kcal, 30 g protein, 72 g carbohydrate, 21 g fat).
88959539|NCT02004860|Experimental|Protopic Arm|Protopic® 0.1% ointment - 2 applications per week for 6 months
89511390|NCT04421534|Active Comparator|Standard of care only|Standard of care treatment; as per MOHP protocol
89511391|NCT05059028|Active Comparator|Oxytocin massage|
88959540|NCT02004860|Active Comparator|Mycoster Arm|2 applications per week for 6 months
88959541|NCT02004899|Active Comparator|F20|Patients randomized to this arm of the study receive 20 mcg fentanyl and 8 mg bupivacaine as their epidural loading dose
89511392|NCT05059028|Active Comparator|music therapy|
89511393|NCT05059028|No Intervention|control group|
89511394|NCT05017064|Experimental|Cryotherapy group|An intraoral ice pack will be placed on the mucosal groove during root canal treatment.
89511395|NCT05017064|Placebo Comparator|Control group|No ice pack will be used.
89511396|NCT02520284|Experimental|Andecaliximab Every 2 Weeks|Participants will receive andecaliximab 150 mg administered via subcutaneous (SC) injection alternating with matching placebo weekly for a total of 4 doses of andecaliximab. Based on Week 8 assessment results, participants will either continue in Blinded Maintenance Treatment phase or will be offered Open-Label andecaliximab 150 mg administered via SC injection weekly for up to Week 51.
89511397|NCT02520284|Experimental|Andecaliximab Weekly|Participants will receive andecaliximab 150 mg administered via SC injection once weekly for a total of 8 doses. Based on Week 8 assessment results, participants will either continue in Blinded Maintenance Treatment phase or will be offered Open-Label andecaliximab 150 mg administered via SC injection weekly for up to Week 51.
89511398|NCT02520284|Placebo Comparator|Placebo|Participants will receive placebo matched to andecaliximab administered via SC injection once weekly for a total of 8 doses. Based on Week 8 assessment results, participants will either continue in Blinded Maintenance Treatment phase or will be offered Open-Label andecaliximab 150 mg administered via SC injection weekly for up to Week 51.
89511399|NCT02517866|Experimental|Azilsartan medoxomil|Azilsartan medoxomil 40 mg, tablets, orally, once, daily, for 12 weeks. Azilsartan medoxomil dose may be increased to 80 mg once daily if blood pressure has not reach BP goal of <140/85 mmHg at Week 6.
89511400|NCT05055440||Mechanically ventilated patients with COVID-19 in the ICU|Mechanically ventilated patients with COVID-19 admitted to the intensive care unit using sedation and neuromuscular blocker
89511401|NCT04965740||North American First Responders|Spread directly to union representatives for email and messaging to those interested in taking the survey
89511402|NCT04965740||Oceana and European first responders|First responder unions and groups that are located outside of North America - particularly Australia, New Zealand, United Kingdom, other commonwealth nations.
89511403|NCT05054738|Experimental|Combined Recovery Program (CRP)+Treatment-as-usual (TAU)|Combined Recovery Program (CRP) is a six-session motivational enhancement and daily living skills therapy workshop provided while on the inpatient unit. Attendance of CRP will be in addition to Treatment as Usual (TAU), that is, standard inpatient programming.
89511404|NCT05054738|Active Comparator|CRP+ Stable & Able (S&A)+TAU|Combined Recovery Program (CRP) a six-session motivational enhancement and daily living skills therapy workshop provided while on the inpatient unit, plus a home telehealth program (Stable & Able) which begins on day 1 of hospital discharge. Attendance of CRP and S&A will be in addition to TAU, that is, standard inpatient programming.
89511405|NCT05054738|No Intervention|Treatment-as-usual only (TAU):|TAU will only receive the usual care on the inpatient unit including medical and medication management.
89511406|NCT04205006||STROKE CARD Cohort|Consecutive patients treated at the Department of Neurology of the University Hospital Innsbruck with ischemic stroke or high-risk TIA between 2013 and 2018 and enrolled in the Stroke Card trial, (except for those who aborted the previous trial).
88959542|NCT02004899|Experimental|F50|Patients randomized to this arm of the study receive 50 mcg fentanyl with 8 mg bupivacaine as their epidural loading dose
88959543|NCT02004899|Experimental|F100|Patients randomized to this arm of the study receive 100 mcg fentanyl and 8 mg bupivacaine as their epidural loading dose
88959544|NCT02004912|Experimental|Mentoring intervention|The mentoring intervention involves periodic supportive visits and education to health center staff by nurse mentors.
88959545|NCT02004912|No Intervention|No mentoring intervention|The no mentoring intervention arm does not have supportive visits and education to health center staff by nurse mentors.
88959546|NCT02004925||Pneumoperitoneum|Patients with a diagnosis of pneumoperitoneum by CT or surgery
88959547|NCT02004925||no pneumoperitoneum|patients with acute abdominal pain with a diagnosis other than pneumoperitoneum in whom pneumoperitoneum was excluded by CT or surgery
88959548|NCT02004938||normal respiratory function|This will include the 40 subjects enrolled in the study
88959549|NCT02004951|Other|Misago RX (Misago RX, Terumo Corp., Tokyo|The Misago RX is a peripheral stent (Misago RX, Terumo Corp., Tokyo, Japan) indicated to treat iliac and femoropopliteal arteries. The Misago RX is a flexible self-expanding nitinol stent that is delivered via a RX monorail delivery catheter.
88959550|NCT02004951|Other|Zilver PTX (Cook Medical, Bloomington, IN, USA)|Zilver PTX (Cook Medical, Bloomington, IN, USA) is a nitinol stent with a polymer-free paclitaxel coating designed to treat the above- the-knee femoropopliteal arteries. The anti-proliferative drug is the paclitaxel, a cytotoxic drug. The Zilver PTX stent is delivered via a over-the-wire system.
89207082|NCT04042896|No Intervention|control group|The control group was asked to maintain their regular physical activity level for 12 weeks.
89207083|NCT00844662|Experimental|1|
89207084|NCT00844662|Active Comparator|2|
88959551|NCT02005003|Active Comparator|Probiotic|Probiotic pills given for 2 weeks, during one of the interventions that the participants is either randomized to as the first or second intervention period. At day 0 and following each intervention period (at week 2 and week 6), participants will be tested using Inhibitory task, Blood samples, Feces collection, Caloric preload, Food selection task, Memory task and Food consumption task.
88959552|NCT02005003|Placebo Comparator|Placebo|Placebo pills given for 2 weeks, during one of the interventions that the participants is either randomized to as the first or second intervention period. At day 0 and following each intervention period (at week 2 and week 6), participants will be tested using Inhibitory task, Blood samples, Feces collection, Caloric preload, Food selection task, Memory task and Food consumption task.
88959553|NCT02005042|No Intervention|Accelerometer only|Wear accelerometer only to measure activity levels (steps)
88959554|NCT02005042|No Intervention|Accelerometer plus EMA|Wear accelerometer and complete Ecological Momentary Assessment (EMA) surveys on smartphone 5 times daily
88959555|NCT02005042|Experimental|Feedback on smartphone|Wear accelerometer, complete EMA surveys on smartphone 5 times daily, receive intervention
88959556|NCT02005055||Patients with recalcitrant keloid scars|All patients with keloids insensitive to other treatments
88959557|NCT02005068|Experimental|Acute Osteomyelitis - Non MRSA|For treatment of Acute osteomyelitis (< 6 months duration) Non MRSA isolate- Ceftaroline 600 MG (milligram) IV (intra-venous) every 8 hours for 6 weeks.
88959558|NCT02005068|Experimental|Acute osteomyelitis MRSA isolate|For treatment of Acute osteomyelitis (< 6 months duration) MRSA isolate- Ceftaroline 600 MG IV every 8 hours for 8 weeks.
88959559|NCT02005068|Experimental|Prosthetic joint infection|For treatment of prosthetic joint infection Ceftaroline 600 mg IV every 8 hours for 6 weeks.
88959560|NCT02005081|Other|Actifuse SHAPE|Actifuse Synthetic Bone Graft substitutes mixed with bone marrow aspirate in cervical spine fusion. Actifuse is a synthetic, porous, silicate-substituted hydroxyapatite and has shown that this maximizes a favorable bony response.
88959561|NCT02005081|Other|Autograft with Demineralized Bone Matrix|autograft mixed with demineralized bone matrix in cervical spine fusion.
88959562|NCT02005094||Healthy group|patients without MAC/MAB lung disease and colonization
88959563|NCT02005094||MAC/MAB colonization group|patients with pulmonary MAC/MAB colonization
88959564|NCT02005094||MAC/MAB lung disease group|Patient with MAC/MAB lung disease
88959565|NCT02005107|Experimental|venlafaxine|Venlafaxine IR and XR, single dosages of each separated by a wash-out period
88959566|NCT02005107|Other|Venlafaxine XR and Venlafaxine IR|Each participant (3 groups of participants) will receive one dose of venlafaxine IR and one dose of venlafaxine XR seperated by a wash-out period.
88959567|NCT02005120|Experimental|Arm A|Bevacizumab
88959568|NCT02005120|Experimental|Arm B|recombinant human endostatin
88959569|NCT02005133||VEGF inhibitor naïve|
88959570|NCT02005133||VEGF inhibitor prior treated|
88959571|NCT02005146||Patients with chronic hepatitis B treated with nRTI|Patients with chronic hepatitis B with HBsAg loss treated with nucleoside/nucleotide analogues (Lamivudine, Adefovir, Tenofovir, Telbivudine, Entecavir, Emtricitabine)
88959572|NCT02005159||Positive blood-culture to bacteremia by enterobacteria|Patients with positive blood-culture to bacteremia by enterobacteria
88959573|NCT02005198||Survey|
88959574|NCT02005224|Other|LCHF diet and a bout of exercise|LCHF diet for 3 weeks, where E% 70 fat, E% 20-25 proteins and 20g or less carbohydrates. Oral glucose tolerance test on the morning of day 21 followed by a bout of exercise in the afternoon (indoor bicycle, 60min at 75% HFpeak). The following morning (day 22) a new oral glucose tolerance test. Oral glucose tolerance test results from pre-tests used to determine the effect of LCHF and a bout of exercise on insulin sensitivity.
88959575|NCT02005237|Experimental|Aerobic Exercise (12 Weeks)|Aerobic exercise on a bicycle ergometer, tailored to the individual's level of fitness. Duration: 12 weeks with 2-3 sessions per week.
88959576|NCT02005237|No Intervention|Waitlist Control Group|No intervention (patients randomized to this group will be offered access to the training program after completion of the trial)
88959577|NCT02005263|Experimental|Salpingography|Infusion of air bubbles through Fallopian tubes with hysteroscopic visualization; typically 1-2 mL is infused. This is less than that typically used in the established technique of sonosalpingography.
88959578|NCT02005302|Experimental|Vitamin D2 Treatment|
88959579|NCT02005302|Active Comparator|1,25(OH)2 Vitamin D3|
89511407|NCT04215848|Experimental|As-needed Budesonide/Formoterol|As-needed Budesonide/Formoterol (160/4.5 ug)
88959580|NCT02005302|Experimental|low protein diet|
88959581|NCT02005302|Active Comparator|normal protein diet|
88959582|NCT02005315|Experimental|Vanctictumab (OMP-18R5)|Vantictumab will be administered by intravenous (IV) infusion.
88959583|NCT02005315|Experimental|Nab-Paclitaxel|Nab-Paclitaxel will be administered by intravenous (IV) infusion.
88959584|NCT02005315|Experimental|Gemcitabine|Gemcitabine will be administered by intravenous (IV) infusion.
88959585|NCT02005328|Experimental|cross-over|Four periods separated by a wash out lasting up to 3 days at maximum. At each period, application of one product (twice). Duration of treatment period: From 4 to 13 days.
88959586|NCT02005341|Active Comparator|Autograft bone|
88959587|NCT02005341|Experimental|nanOss with bone marrow aspirate|
88959588|NCT02005367|No Intervention|DAP-CP|512 patients who elected to participate in the Drug Abuse Core Program alone (DAP-CP).
88959589|NCT02005367|Experimental|Natural Recovery-Horticulture|Participants in Natural Recovery-Horticulture received a one-hour small group therapy session during the week using one module per week with a staff facilitator and also pursued four hours of their hobby on each weekend day for up to 14 weeks.
88959590|NCT02005367|Experimental|Natural Recovery-Art/Music|Participants in Natural Recovery-Art/Music received a one-hour small group therapy session during the week using one module per week with a staff facilitator and also pursued four hours of their hobby on each weekend day for up to 14 weeks.
88959591|NCT02005380||Text-based Task|This group is required to do the text-based task
88959592|NCT02005380||Graphic-based Task|This group is required to do the graphic-based task
88959593|NCT02005406||wei group and control group|wei group(n=25) and control group(n=24)
88959594|NCT02005419|Placebo Comparator|gemcitabine + placebo|gemcitabine at 1000 mg/m^2 on days 1, 8, and 15; placebo at 2 g on days 1-28
88959595|NCT02005419|Experimental|gemcitabine + metformin|gemcitabine at 1000 mg/m^2 on days 1, 8, and 15; metformin at 2 g on days 1-28
89511408|NCT04215848|Active Comparator|Budesonide|Budesonide (200 ug) twice daily
88959596|NCT02005432|Active Comparator|SS-PRP arm|panfotocoagulation (PRP) single shoot (ETDRS) + 0,05ml intravitreal injection anti-VEGF (ranibizumabe)
88959597|NCT02005432|Experimental|MS-PRP arm|Multiple shoot panfotocoagulation (PASCAL) plus IVR
88959598|NCT02005432|Other|IVR arm|only IVR (intravitreal Ranibizumabe)
88959599|NCT02005458|Experimental|YPEG-rhG-CSF 20μg/kg|20μg/kg,single s.c. at 48hrs after chemotherapy for each experimental cycle
88959600|NCT02005458|Experimental|YPEG-rhG-CSF 30μg/kg|30μg/kg,single s.c. at 48hrs after chemotherapy for each experimental cycle
88959601|NCT02005458|Experimental|YPEG-rhG-CSF 45μg/kg|45μg/kg,single s.c. at 48hrs after chemotherapy for each experimental cycle
88959602|NCT02005458|Active Comparator|PEG-rhG-CSF 100μg/kg|100μg/kg,single s.c. at 48hrs after chemotherapy for each experimental cycle
89511409|NCT04215146|Active Comparator|Cohort 1|Patients receive paclitaxel alone.
89511410|NCT04215146|Experimental|Cohort 2|Patients receive pelareorep + paclitaxel.
89511411|NCT04215146|Experimental|Cohort 3|Patients receive pelareorep + paclitaxel + avelumab.
89511412|NCT02515994|Experimental|senofilcon C|JJVCI investigational contact lens daily wear replacement.
89511413|NCT02515994|Active Comparator|comfilcon A|Marketed contact lens daily wear replacement.
89511414|NCT04959266|Experimental|Arm A|Patients will receive a single oral dose of adavosertib alone, and a single oral dose of adavosertib concomitantly with itraconazole.
89511415|NCT04959266|Experimental|Arm B|Patients will receive a single oral dose of adavosertib alone, and a single oral dose of adavosertib concomitantly with rifampicin.
89511416|NCT04959266|Experimental|Arm C|Patients will receive a single oral dose of adavosertib alone, and a single oral dose of adavosertib concomitantly with omeprazole.
89511417|NCT04957862|Active Comparator|robotic assisted evacuation|In the intervention arm, patients will receive stereotactic robotic assisted HICH evacuation according to the protocol under general anesthesia.
89511418|NCT04957862|No Intervention|Concomitant care|All enrolled HICH patients in this study will receive standard medical treatment in the first 3-4 weeks according to the ASA/AHA guideline . Continued medical treatment is applied to patients in the control arm. Both arms will receive identical rehabilitation therapy three times per week for 180 days at one facility. Rehabilitation therapy includes identical physical therapy, occupational therapy, speech therapy, functional training, acupuncture and massage.
89511419|NCT04957628||Control group|2500 participants will be recruited before the intervention procedures are implemented at the respective hospitals. Baseline data on alcohol, psychoactive medicinal and illicit drug use (AUDIT-4 and DUDIT), stages-of-change questionnaire on alcohol, medicinal drugs and illicit drug use, and mental distress will be recorded. Left-over full blood from routine diagnostic testing will be collected and analyzed for alcohol biomarkers (ethanol and phosphatidylethanol (PEth)) and psychoactive medicinal and illicit drugs. The participants in the control group will receive acute medical treatment according to hospital procedures. After 12 months, the data from baseline will be coupled to data from patient journals and data from relevant registries.
89511420|NCT04957628||Case group|2500 participants will be recruited after the intervention procedures are implemented. Baseline data on alcohol, psychoactive medicinal and illicit drug use, stages-of-change questionnaires, and mental distress will be recorded. Left-over blood from diagnostic testing will be collected and analyzed for alcohol biomarkers (ethanol and phosphatidylethanol (PEth)) and psychoactive medicinal and illicit drugs. The participants in the case group will receive treatment according to new hospital procedures, including screening for harmful alcohol use and non-prescribed use of psychoactive medicinal drugs and intervention. If feasible, a new blood sample will be collected 2 months after inclusion, which will be analyzed for PEth. After 12 months, the data from baseline will be coupled to patient journals and relevant registries.
89511421|NCT04956458|Experimental|Lumbar motion style acupuncture treatment|"The MSAT group will recieve 3 sessions of MSAT; on second, third, fourth day after hospitalization.~A trained doctor of Korean medicine with at least 3 years of clinical experience will conduct the MSAT.~The MSAT group will be also treated with other Korean medical treatment everyday: acupuncture, chuna, pharmacoacupuncture and Korean herbal medicine."
89511422|NCT04956458|Active Comparator|Korean medical treatment|The control group will be received Korean medical treatment everyday after hospitalization: acupuncture, chuna, pharmacoacupuncture and Korean herbal medicine
89511423|NCT05009030||Study group|Patients with lung cancer of any histology and stage who receive an anti-COVID-19 vaccine approved by the health authorities. Patients would be eligible whether they have suffered from SARS-CoV2 infection or have not had COVID19.
89511424|NCT05007314|Experimental|Human Science|Arm 1 will include university graduates that hold at least a science undergraduate degree (or equivalent) in human science, including psychology, neuroscience, human biology, or medicine.
88959603|NCT02005497|Experimental|HealthLinks|Worksites in this arm will receive the standard HealthLinks intervention protocol, which includes on-site consulting, toolkits, and support via telephone and email to implement a worksite wellness program and adopt evidence-based practices.
88959604|NCT02005497|Active Comparator|HealthLinks+|Worksites in this arm will receive the standard HealthLinks intervention protocol, which includes on-site consulting, toolkits, and support via telephone and email plus support to form a worker wellness committee to implement a worksite wellness program and adopt evidence-based practices.
88959605|NCT02005497|No Intervention|Delayed Control|Worksites in this arm will not receive an intervention during the study. After they have provided their final follow-up data, they will receive the HealthLinks intervention.
88959606|NCT02005523|Experimental|RNS60|
88959607|NCT02005523|Placebo Comparator|Saline|
88959608|NCT02005575|Placebo Comparator|Group 1|an intercostal nerve block with a solution consisting of 0.46% bupivicaine (19.5 ml of 0.5% bupivicaine + .5ml normal saline)
88959609|NCT02005575|Active Comparator|Group 2|an intercostal nerve block with a solution consisting of 0.46% bupivicaine (19.5 ml of 0.5% bupivicaine + .5ml .4% dexamethasone)
89210521|NCT00905502|Active Comparator|2: Liberal protocol (LG) group|Received 10 ml/kg•hr of RL solution intraoperatively.
89207085|NCT04678089||Health group|The healthy control group mainly collected patients with other chronic diseases or blood tumors who did not meet the exclusion criteria and were not diagnosed with multiple myeloma. Also，we need some healthy volunteers. Healthy volunteers refer to people without serious physical disease, immune disease and family history of mental illness.There is no distinction between age, gender and nationality.
89207086|NCT04678089||Multiple Myeloma group|In the exposure group, all patients with multiple myeloma met the inclusion and did not meet exclusion criteria, including planning for autologous stem cell transplantation or not. There is no distinction between age, gender and nationality.
89207087|NCT00963573|Experimental|loratadine/betamethasone oral solution|loratadine/betamethasone oral solution (1 mg/0.05 mg/1 mL), at a dose of 10 mg/0.5 mg
89207088|NCT05299593|Experimental|tafluprost/timolol|Enrolled patients will be treated with one drop of the fixed combination Tafluprost-Thymol without preservative in the evening at 20.00 (+/- 1 hour). Patients will be administrered with one drop in the conjunctival sac of the affected eye (s) once a day.
89207089|NCT00839904|Experimental|exercise|two supervised, 60-minute weekly exercise sessions + instructions to perform additional physical activities throughout the day
89207090|NCT00839904|No Intervention|control|no intervention
89511425|NCT05007314|Active Comparator|Natural or non-science|Arm 2 will include university graduates from non-human or non-scientific fields such as engineering, history, language studies, or law.
89511426|NCT04945148|Experimental|Metformin|Patients who have been selected with an OXPHOS+ status, will start standard radiotherapy (RT, 60Gy/6 weeks), concomitant TMZ chemotherapy (75mg/m²/day), and metformin by 7 weeks after surgery and adjuvant TMZ + metformin will follow onwards until the 12th cycle of TMZ. Patients still in remission after this time-point will continue metformin alone until progression.
89511427|NCT02516306|Experimental|EV06 Ophthalmic Solution|EV06 Ophthalmic Solution: Day 1 - 7 one drop twice per day in one eye; Day 8 - 91 one drop twice per day in both eyes.
89511428|NCT02516306|Placebo Comparator|Placebo Ophthalmic Solution|Placebo Ophthalmic Solution (EV06 vehicle): Day 1 - 7 one drop twice per day in one eye; Day 8 - 91 one drop twice per day in both eyes.
89511429|NCT02516228|Experimental|GTEN 100|All patients will receive treatment according to the protocol with the GTEN 100 device, pulsed only.
89511430|NCT04420910||Parkinson's disease group|being diagnosed with PD by a neurologist, being in Hoehn & Yahr Stage 1-3
89511431|NCT04420910||Healthy group|20 healthy volunteers with matching ages and genders.
89511432|NCT05003570|Experimental|Remifentanil|Remifentanil analgesia combined with propofol sedation. Treatment was started in patients with an CPOT score of 2 or greater after completion of baseline assessments. All patients received an initial infusion of blinded opioid (placebo bolus dose(6ml) + 6ug/kg per hour infusion at 6 ml/hour). Optimal analgesia (CPOT score ≤2) was then targeted by titrating the infusion in 1.5 ml/hour increments (placebo bolus dose + 1.5ug/kg per hour rate increase).
89511433|NCT05003570|Active Comparator|Fentanyl|Fentanyl analgesia combined with propofol sedation. Treatment was started in patients with an CPOT score of 2 or greater after completion of baseline assessments. All patients received an initial infusion of blinded opioid (1ug/kg bolus(6ml) + 1ug/kg per hour infusion at 6ml/hour). Optimal analgesia (CPOT score ≤2) was then targeted by titrating the infusion in 1.5 ml/hour increments (1ug/kg bolus dose + 0.25ug/kg per hour rate increase).
89511434|NCT02519504||Duarte galactosemia|Pediatric subjects with Duarte galactosemia will undergo direct assessments of cognitive skills (memory, executive function, and auditory processing), communication processes (speech and language), physical development (including motor skills, coordination, and occurrence of tremors), and social-emotional development.
89511435|NCT02519504||Control|Pediatric subjects without Duarte galactosemia will undergo direct assessments of cognitive skills (memory, executive function, and auditory processing), communication processes (speech and language), physical development (including motor skills, coordination, and occurrence of tremors), and social-emotional development.
89511436|NCT04944680|No Intervention|Control group|Stroke patients accept the traditional rehabilitation alone.
89511437|NCT04944680|Active Comparator|Transcranial Direct Current Stimulation group|Stroke patients accept the Transcranial Direct Current Stimulation alone.
89511438|NCT04944680|Active Comparator|Motor imagery group|Stroke patients do the motor imagery alone.
89511439|NCT04944680|Experimental|Transcranial Direct Current Stimulation and motor imagery group|Stroke patients accept the Transcranial Direct Current Stimulation and do the motor imagery at the same time.
89511440|NCT05001698|Experimental|Anifrolumab|All eligible participants will receive anifrolumab via intravenous (IV) infusion pump.
89511441|NCT04421144|Experimental|study group|using CAD/CAM surgical cutting guides for maxilla and mandible and customized titanium plates to guide all osteotomies and fixation of both arches.
89511442|NCT02514824|Experimental|Dose Level 1: MLN01283 3 mg (Phase 1)|"Phase 1 dose level 1 participants receive MLN01283 3 mg orally once daily of a 28 day cycle.~Participants are treated indefinitely until disease progression, unacceptable toxicity or withdrawal for other reasons."
89511443|NCT02514824|Experimental|Dose Level 2: MLN01283 4 mg (Phase 1)|"Phase 1 dose level 2 participants receive MLN01283 4 mg orally once daily of a 28 day cycle.~Participants are treated indefinitely until disease progression, unacceptable toxicity or withdrawal for other reasons."
89511444|NCT02514824|Experimental|Dose Level 3: MLN01283 5 mg (Phase 1)|"Phase 1 dose level 3 participants receive MLN01283 5 mg orally once daily of a 28 day cycle.~Participants are treated indefinitely until disease progression, unacceptable toxicity or withdrawal for other reasons."
89511445|NCT02514824|Experimental|MLN01283 RP2D (Phase 2)|"Phase 2 participants receive MLN01283 at the recommended phase 2 dose (RP2D) orally once daily of a 28 day cycle.~Participants are treated indefinitely until disease progression, unacceptable toxicity or withdrawal for other reasons."
89511446|NCT02514746|Experimental|Live Attenuated JE SA-14-14-2 Vaccine (CD-JEV)|Participants previously vaccinated with CD-JEV will receive a booster dose of live, attenuated Japanese encephalitis SA-14-14-2 vaccine four years after initial vaccination.
89511447|NCT02483078|Active Comparator|PRO 140|PRO140 350mg weekly SC Inj. + existing ART for one week. After one week, all subjects will enter the 24-week single-arm, open-label treatment period. During this period, all subjects will receive PRO 140 SC injection and Optimized Background Therapy.
89207091|NCT04667403|Experimental|Telemedicine|"Pain is monitored, from the patient's home, using a computer application accessible from a smartphone or a computer with internet access.~This application will allow the patient to describe his or her pain by means of a self-questionnaire. Healthcare professionals (nurse coordinator, pain specialist and oncologist) will thus be able to remotely interpret the data collected, enabling them to provide patients with a rapid response to adapt their pain treatment without the patient having to travel to the establishment."
89207092|NCT00844740|Experimental|Cinacalcet|Stable patients with XLH already treated with Phosphate and calcitriol will add Cinacalcet to their treatment regimen. Sequential monitoring of blood and urine biochemical variables will follow, based on which adjustments to the doses of the 3 medications will be done.
89210522|NCT00908934|Experimental|1|50 or 400 mg AZD9056, Test formulation
89511448|NCT02483078|Placebo Comparator|Placebo|Placebo weekly SC Inj. + existing ART for one week. After one week, all subjects will enter the 24-week single-arm, open-label treatment period. During this period, all subjects will receive PRO 140 SC injection and Optimized Background Therapy.
89511449|NCT02452190|Experimental|Reslizumab|Reslizumab
89511450|NCT02452190|Placebo Comparator|Placebo|Matching Placebo
89511451|NCT02514122|Experimental|Ketamine|Participants will receive subcutaneous ketamine (1mg/kg) administered immediately after surgery, the evening after surgery, and every 12 hours thereafter for a total of 5 injections at a dose of 1mg/kg.
89511452|NCT02514122|Placebo Comparator|Saline|Participants will receive subcutaneous saline (0.02cc/kg) administered immediately after surgery, the evening after surgery, and every 12 hours thereafter for a total of 5 injections.
89511453|NCT00730639|Experimental|Melanoma - BMS-936558 (MDX-1106)|
89511454|NCT00730639|Experimental|RCC - BMS-936558 (MDX-1106)|
89511455|NCT00730639|Experimental|mCRPC - BMS-936558 (MDX-1106)|
89511456|NCT00730639|Experimental|NSCLC - BMS-936558 (MDX-1106)|
89511457|NCT00730639|Experimental|CRC - BMS-936558 (MDX-1106)|
89511458|NCT04017871|Experimental|Interventional|10 days of intensive and structured motor therapy, 5 hours a day = 50h
89511459|NCT04017871|Placebo Comparator|Control|10 days of care and classic activities
89511460|NCT02322463||Arab children (case subjects)|Arab patients who were admitted to the pediatric ED due to a limb fracture between 01 January 2011 and 31 October 2014, who were treated with Oxycodone
89511461|NCT02322463||Jewish children (controls)|Jewish patients who were admitted to the pediatric ED due to a limb fracture between 01 January 2011 and 31 October 2014, who were treated with Oxycodone
89511462|NCT03489421||HIV Infected|
89511463|NCT03489421||Un-infected controls|Controls without HIV from a historical pre-approved-IRB-protocol database
89511464|NCT03491995|Experimental|Quadruple therapy|Moxifloxacin, Nitazoxanide, Omeprazole sodium bicarbonate, Doxycyclin
89511465|NCT03491995|Active Comparator|Classic treatment|Omeprazole, clarithromycin, amoxicillin
89511466|NCT02322541|Experimental|Time Course|Measurement of garlic metabolites over 24 hours following garlic intervention.
89511467|NCT04462003|Active Comparator|Apixaban|50 patients with DVT with malignancy were randomized to apixaban 10 mg twice daily dose for 7 days followed by apixaban 5 mg twice daily
89511468|NCT04462003|Active Comparator|Enoxaparin|50 patients with DVT with malignancy were randomized to enoxaparin (1mg/Kg/SC every 12 h)
89511469|NCT04460989||standard implant|arthroplasty with a standard implant
89511470|NCT04460989||personalized implant|arthroplasty with a customized implant
89511471|NCT03489265|Other|Eluxadoline followed by Placebo|Following a 2-week run-in period, patients will receive Eluxadoline 100 mg twice daily for 4 weeks then placebo tablets taken twice daily for 4 weeks followed by a 2-week follow-up period during which placebo will be administered twice daily.
89511472|NCT03489265|Other|Placebo followed by Eluxadoline|Following a 2-week run-in period, patients will receive placebo twice daily for 4 weeks then Eluxadoline 100 mg twice daily for 4 weeks followed by a 2-week follow-up period during which placebo will be administered twice daily.
89511473|NCT03344341|Experimental|Dapagliflozin|Dapagliflozin is started from 5 mg once a day, taken orally in the morning, before or after breakfast. From the third week, the dose will be increased to 10 mg once a day and last to the end of the study.
89511474|NCT03344341|Active Comparator|Acarbose|Acarbose is started from 50 mg once a day at dinner during the first week, titrated up to 50 mg twice a day at lunch and dinner in the second week, 50 mg three times a day at three meals in the third week, and 100 mg three times a day till the end of the study.
89511475|NCT03238495|Active Comparator|Chemotherapy Only|Taxotere, Carboplatin, Herceptin + Pertuzumab (TCH+P)
89511476|NCT03238495|Experimental|Chemotherapy plus Metformin|TCH+P plus metformin
89511477|NCT03489031||Diabetes Mellitus, Type 1|patients with type 1 diabetes
89511478|NCT03489031||Diabetes Mellitus, Type 2|patients with type 2 diabetes
89511479|NCT02536339|Experimental|Pertuzumab + Trastuzumab|Participants with CNS metastases secondary to HER2-positive MBC will receive pertuzumab in combination with high-dose trastuzumab until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
89511480|NCT01869361|Placebo Comparator|Placebo|The patient will be given a loading dose of 50mg placebo by mouth followed by 25mg by mouth every six hours for a total of eight doses over 48 hours.
89511481|NCT01869361|Active Comparator|Indomethacin|The patient will be given a loading dose of 50mg indomethacin by mouth followed by 25mg by mouth every six hours for a total of eight doses over 48 hours.
89511482|NCT02322619|Experimental|Moxifloxacin Tablets 400 mg|Moxifloxacin Tablets 400 mg of Dr. Reddy's Laboratories Limited
89540694|NCT06056765|Experimental|ESWT group|"The therapy will be applied using a focused shock wave device (Minilith, Storz, Swiss) at the pulley of the first extensor channel under ultrasound guidance. Shock wave therapy will be performed with the patient's hand in intermediate between pronation and supination and will be administered once a week, for 3 sessions. For each treatment session, 2000 pulses will be applied with an energy flux density of 0.09 mJ/mm2 (between 0.05 and 0.12 mJ/mm2) and a frequency of 4 pulses per second (4 Hz). Gel will be used between the probe and the skin during applications to ensure conductivity. No local anesthetic will be used. Patients in both groups will be instructed to use a brace during the day for 4 weeks following recruitment."
89540695|NCT06056765|No Intervention|Exercise group|Patients will perform exercises for 4 weeks following recruitment. Patients in this group will be taught home exercises to improve the dynamic stability of the thumb metacarpal trapezius joint. The patient is instructed to perform a flexion of the trapeziometacarpal. If the individual is able to complete 10 repetitions with good technique, resistance will be added manually or with rubber bands. If this exercise is painful, they are asked to return to active movement only. Patients in both groups will be instructed to use a brace during the day for 4 weeks following recruitment.
89540696|NCT06055452|Experimental|Empagliflozin|
89540697|NCT06055452|Placebo Comparator|Placebo|
89540698|NCT06055439|Experimental|Autologous CDH17 CAR T-cell Therapy|"After receiving three daily doses of IV fludarabine and cyclophosphamide, participants will receive a single dose of IV CHM-2101.~The dose of CHM-2101 during Phase 1 will be based on 3+3 rules of dose escalation.~The recommended Phase 2 dose will be based on results from the Phase 1."
89540699|NCT06053307|Experimental|Acceptance commitment therapy via a mobile-application|The arm will pilot a behavioral intervention to treat psychosocial distress in patients with glaucoma using acceptance commitment therapy (ACT) delivered via a mobile-application. The intervention will be developed and refined using qualitative feedback from glaucoma patients and healthcare stakeholders.
89540700|NCT06046729|Experimental|Eltrekibart Dose 1|Eltrekibart will be given subcutaneously (SC).
89540701|NCT06046729|Experimental|Eltrekibart Dose 2|Eltrekibart will be given SC.
89540702|NCT06046729|Experimental|Eltrekibart Dose 3|Eltrekibart will be given SC.
89540703|NCT06046729|Placebo Comparator|Placebo|Placebo will be given.
89540704|NCT06044831||Expanded Population Health Access|Participants living in the neighborhood with access to expanded population health model.
88959610|NCT02005588|Active Comparator|amino acid chelated iron arm|this arm will contain 150 pregnant women with proved iron deficiency anemia and pregnant 14-18 weeks. these pregnant women will be given amino acid chelated iron capsules (15 mg iron/capsule) 1-2 capsules daily according to hemoglobin level (hemoglobin 7-9 g/dl will receive 2 capsules, and hemoglobin 9.1-11 g/dl will receive 1 capsule). complete blood picture and serum ferritin will be assessed at 22-23 weeks, 29-30 weeks and 36-37 weeks. possible side effects (colicky abdominal pains, constipation and metallic taste) will be asked about in each follow up visit.
88959611|NCT02005588|Active Comparator|iron salt arm|this arm will contain 150 pregnant women with proved iron deficiency anemia and 14-18 weeks gestation. these women will be given oral iron salt ferrous fumarate capsules (350 mg iron/ capsule containing about 70 mg elemental iron/ capsule) 1-2 capsules daily according to hemoglobin level (hemoglobin 7-9 g/dl will receive 2 capsules daily and hemoglobin 9.1-11 g/dl will receive 1 capsule daily. women will be followed up with complete blood picture and serum ferritin at 22-23 weeks, 29-30 weeks and 36-37 weeks. women will be asked about possible side effects (colicky abdominal pains, constipation, and metallic taste) in each visit.
88959612|NCT02005614|Experimental|Gamma Knife Radiosurgery|"Rational dose selection is a concept wherein doses used for stereotactic radiosurgery is selected based on tumor volume, prior irradiation with whole brain radiotherapy, and the relative radioresistance of the tumor (radioresistant = melanoma, renal cell carcinoma, sarcoma; radiosensitive = breast cancer, lung cancer, colorectal cancer, gastrointestinal cancers).~Dose may be altered for lesions in the brainstem, adjacent to the optic nerve, optic chiasm, or motor cortex, or other clinical scenarios as defined by the treating physician. Reason for dose alteration will be recorded at the time of treatment.~For patients with 10+ brain metastases with multimorbidity or difficulty in tolerating a supine position, doses may be modified by the treating physicians for patient comfort."
89540705|NCT06041568|Experimental|Imvotamab (Dose Escalation)|Imvotamab administered intravenously
89540706|NCT06033677|Other|Grup 1-Forearm radial artery cannulation (FRA)|The patients who were to undergo forearm radial artery catheterization were positioned with wrist dorsifection up to 30° and forearm supination. Intervention was planned after ultrasonographic measurements were taken.
88959613|NCT02005640||MSCT-based prothesis sizing|
88959614|NCT02005640||Echocardiographic-based prothesis sizing|
88959615|NCT02005653|Experimental|DEC + ALB sequential|Diethylcarbamazine 300 mg tablet and albendazole 400 mg tablet at 30 days post treatment sequentially
88959616|NCT02005653|Experimental|DEC + ALB co-admin|Diethylcarbamazine 300 mg tablet and albendazole 400 mg tablet per day given orally as single dose for 12 days
88959617|NCT02005653|Experimental|DEC + DOXY co-admin|Diethylcarbamazine 300 mg tablet and Doxycycline 100 mg per day given orally as single dose for 12 days
88959618|NCT02005653|Active Comparator|Diethylcarbamazine (DEC)|Diethylcarbamazine 300 mg tablet as single dose orally per day for 12 days
88959619|NCT02005679|Experimental|deaf persons with potential dementia|
88959620|NCT02005705|Active Comparator|Outpatient|
88959621|NCT02005705|Active Comparator|Inpatient|
88959622|NCT02005718|Experimental|Vitamin D|Cholecalciferol 300,000 twice
89207093|NCT00840138||1|Patients with common bile duct injury after open cholecystectomy
89540707|NCT06033677|Active Comparator|Grup 2-Distal radial artery cannulation (DRA)|The patients who will undergo distal radial artery catheterization were placed in the pronation position of the forearm with the anatomical snuffbox facing upwards. Intervention was planned after ultrasonographic measurements were taken.
89540708|NCT06014489|Experimental|single arm arm extension phase|prior to the extention phase, there is a run-in phase with (n= 20 patients of 142 total) with the same study scheme, except that cobicistat is added from cycle 2 onwards to the treatment instead of during cycle 1
89540709|NCT06007664|Experimental|occupational therapy intervention group|
89540710|NCT05989711|Experimental|Pemvidutide 1.2 mg (n=38)|
89540711|NCT05989711|Experimental|Pemvidutide 1.8 mg (n=76)|
89540712|NCT05989711|Placebo Comparator|Placebo (n=76)|
89540713|NCT05983367|Experimental|RGX-202-01 + FOLFIRI + Bevacizumab|Ompenaclid (RGX-202-01) 3000mg PO (tablets) BID; Irinotecan: 180 mg/m2 over 90 minutes concurrently with folinic acid 400 mg/m2 over 2 hours, followed by 5-FU 2400 mg/m2 over 46 hours, on Days 1 and 15 of each 28-day cycle. Bevacizumab: 5 mg/kg on Days 1 and 15 of each 28-day cycle.
89540714|NCT05983367|Placebo Comparator|Placebo + + FOLFIRI + Bevacizumab|Placebo (tablets) PO + Irinotecan: 180 mg/m2 over 90 minutes concurrently with folinic acid 400 mg/m2 over 2 hours, followed by 5-FU 2400 mg/m2 over 46 hours, on Days 1 and 15 of each 28-day cycle. Bevacizumab: 5 mg/kg on Days 1 and 15 of each 28-day cycle.
89540715|NCT05982340||Group 1|ICU patients with AKI
89540716|NCT05982340||Group 2|ICU patients with normal renal function
89540717|NCT05982340||Group 3|Healthy controls
89540718|NCT05972044|Experimental|Solriamfetol 150 mg|Up to 6 weeks
89540719|NCT05972044|Experimental|Solriamfetol 300 mg|Up to 6 weeks
89207094|NCT00840138||2|Patients with common bile duct injury after laparoscopic cholecystectomy
89540720|NCT05972044|Placebo Comparator|Placebo|Up to 6 weeks
89540721|NCT05970185|Experimental|PEG-rhG-CSF|Subcutaneous injection of polyethylene glycolized recombinant human granulocyte-stimulating factor injection 6mg bid in the experimental group the day after the end of chemotherapy
89540722|NCT05970185|Active Comparator|G-CSF|G-CSF 5ug/kg/d from day 5 after the end of chemotherapy until the end of collection
89540723|NCT05969041|Experimental|A (MT-302)|Participants will receive MT-302 through intravenous infusion.
89540724|NCT05958342|Experimental|Prehospital Intervention Arm|1 gram calcium gluconate provided intravenously over approximately 2-5 minutes, initiated prior to trauma bay arrival and infused to completion following arrival if needed
89540725|NCT05958342|Placebo Comparator|Prehospital Control Arm|Identical volume saline placebo to prehospital intervention arm provided intravenously over approximately 2-5 minutes, initiated prior to trauma bay arrival and infused to completion following arrival if needed
89207095|NCT01563159||Group A|All children ≤ 5 years old with a rotavirus detection test (inpatient and ambulatory tests) performed during the period of June the 1st 2010 and May the 31st 2011.
89207096|NCT00844818|No Intervention|Control|Moms and dads who were current smokers (1 cigarette, even a puff, in past 30 days) or recent quitters (smoked since one month prior to conception)
89207097|NCT00844818|Experimental|Intervention Group|Moms and dads who were current smokers (1 cigarette, even a puff, in past 30 days) or recent quitters (smoked since one month prior to conception)
89207098|NCT00963651||Suspicion of pulmonary nodules|Eligible participants will include those referred for x-ray computed tomography (CT) of the chest for suspicion of a pulmonary nodule or other unrelated reasons.
89207099|NCT02546700|Experimental|Lebrikizumab: Biomarker-high|Lebrikizumab will be administered subcutaneously once in every 4 weeks up to 24 weeks to the participants considered as biomarker-high.
89540726|NCT05958342|Experimental|Early In-Hospital Intervention Arm|4 unit vasopressin bolus followed by a vasopressin infusion at 0.04 U/min for eight hours, initiated within approximately two hours of hospital arrival
89540727|NCT05958342|Placebo Comparator|Early In-Hospital Control Arm|volume matched saline bolus followed by volume matched normal saline placebo infusion for eight hours initiated within approximately two hours of arrival
89540728|NCT05951101|Experimental|Zenith LAA Occlusion System|Zenith LAA Occlusion System Implantation
89540729|NCT05946876|Experimental|A (XH-S003)|"Participants will receive an oral dose of XH-S003 once daily on scheduled day(s).~Dosage: Part A : 50mg,100mg, 200mg, 25mg & 400mg Part B : 25mg, 50mg, 100mg. Part C : 200 mg"
89540730|NCT05946876|Placebo Comparator|B (Placebo)|Participants will receive oral matching placebo once daily on scheduled day(s)
89540731|NCT05944120|Experimental|Crisis Intervention Cart|To determine if a Crisis Intervention Cart filled with evidence-based stress-reducing interventions does reduce stress experienced during a shift.
89207100|NCT02546700|Experimental|Lebrikizumab: Biomarker-low|Lebrikizumab will be administered subcutaneously once in every 4 weeks up to 24 weeks to the participants considered as biomarker-low.
89210523|NCT00908934|Experimental|2|50 or 400 mg AZD9056, Reference formulation
89540732|NCT05942586|Active Comparator|Probiotic Arm|30 Participants in this arm will undergo a two-week run-in period consuming placebo sachet (maltodextrin) for the first week and then increasing the dosage in the second week. Following the run-in period, Participants will receive an eight-week intervention consisting of daily consumption of placebo sachets and probiotic capsule containing L. reuteri PB-W1™.
89540733|NCT05942586|Active Comparator|Prebiotic Arm|30 Participants in this arm will undergo a two-week run-in period consuming prebiotic sachets (Prebiotic Blend) for the first week and then increasing the dosage in the second week. During the eight-week intervention, Participants will consume prebiotic sachets three times daily and placebo capsule.
89540734|NCT05942586|Experimental|Synbiotic Arm|30 Participants in this arm will undergo a two-week run-in period consuming prebiotic sachets (Prebiotic Blend) for the first week and then increasing the dosage in the second week. Following the run-in period, Participants will receive an eight-week intervention consisting of daily consumption of prebiotic sachets, probiotic capsule containing L. reuteri PB-W1™.
89540735|NCT05942586|Placebo Comparator|Placebo Arm|30 Participants in this arm will undergo a two-week run-in period consuming placebo sachet (maltodextrin) for the first week and then increasing the dosage in the second week. During the eight-week intervention, Participants will consume placebo sachets three times daily and placebo capsule.
89511483|NCT02322619|Active Comparator|Avelox Tablets 400 mg|Avelox® Tablets 400 mg of Bayer Healthcare Pharmaceuticals Inc.
89511484|NCT01578967|Other|ABVD followed by Brentuximab vedotin|Single arm trial
89511485|NCT01186003|No Intervention|Standard insulin drip therapy|
89511486|NCT01186003|Active Comparator|Insulin drip and Detemir|Detemir 0.25 units per kg body weight given subcutaneously every 24 hours while patients are receiving intravenous (IV) standard insulin drip therapy
89511487|NCT03496909|Active Comparator|Standard OT|
89511488|NCT03496909|Experimental|PhysioTouch|
89511489|NCT02322697|Experimental|Carnitine group|Intravenous administration of L-carnitine 1000mg after each hemodialysis session (three times a week) for one year.
89511490|NCT02322697|No Intervention|control group|No intervention
89511491|NCT05149963|Experimental|Cognitive Behavioural Therapy (CBT) for Chronic Loneliness|Participants will receive an average of 12 50-minute sessions of CBT aiming to reduce their loneliness. The intervention is modular and has been developed for this study. In total there are 10 treatment modules, 1) Assessment, 2) Formulation and Psychoeducation, 3) Challenging Negative Interpersonal Appraisals and Counterproductive Behaviours, 4) Challenging Negative Thoughts and Cognitive Biases, 5) Challenging Self-focussed Attention, Hypervigilance and Camouflaging, 6) Values-based Social-skills Training, 7) Problem Solving, 8) Findings Friends, 9) Managing Emotions and 10) Relapse Prevention. All participants will complete module 1) Assessment and module 2) Formulation and Psychoeducation. They will then work with the clinician to collaboratively develop a treatment plan based on their formulation. The treatment will be comprised of one or more of the intervention modules. All participants will then complete module 10) Relapse Prevention at the end of their treatment.
89511492|NCT05149963|No Intervention|Baseline Phase 1 (12 days)|The design of the study is a randomised multiple-baseline single-case experimental design (SCED). Participants will be randomised to one of 4 baseline lengths (12 days, 19 days, 26 days or 33 days). The baseline phase will act as the control condition within and between participants.
89511493|NCT05149963|No Intervention|Baseline Phase 2 (19 days)|The design of the study is a randomised multiple-baseline single-case experimental design (SCED). Participants will be randomised to one of 4 baseline lengths (12 days, 19 days, 26 days or 33 days). The baseline phase will act as the control condition within and between participants.
89511494|NCT05149963|No Intervention|Baseline Phase 3 (26 days)|The design of the study is a randomised multiple-baseline single-case experimental design (SCED). Participants will be randomised to one of 4 baseline lengths (12 days, 19 days, 26 days or 33 days). The baseline phase will act as the control condition within and between participants.
89511495|NCT05149963|No Intervention|Baseline Phase 4 (33 days)|The design of the study is a randomised multiple-baseline single-case experimental design (SCED). Participants will be randomised to one of 4 baseline lengths (12 days, 19 days, 26 days or 33 days). The baseline phase will act as the control condition within and between participants.
89511496|NCT03488875|Experimental|mMBRT|Individuals in the mMBRT group will receive an 8-week mindfulness-based intervention in groups of approximately 15 individuals in 8 weekly 2-hour classes (one of these classes, toward the end of the course, is approximately 4 hours and integrates many of the practices and teachings covered throughout the training program).
89511497|NCT03488875|No Intervention|Waitlist control group|Individuals in the waitlist control group will complete the same assessments as those in the active treatment group, but will not be offered any intervention until the conclusion of the trial. At this time, control group participants will be offered the intervention.
89511498|NCT03485989|Experimental|Hazelnuts|Participants given 2 ounces (~57 grams) of dry roasted hazelnuts to consume each day.
89511499|NCT03485833|Experimental|EEO and EIO test|velocity time integral of the aorta measured by transesophageal echocardiography during end expiratory and end inspiratory occlusion test to predict volume responsiveness.Responders are defined by an increase in velocity time integral over 15% after infusion of 5ml/kg of crystalloid solution.
89511500|NCT03488797|Experimental|Experimental|Supervised web- and home-based exercise intervention
89511501|NCT03488797|No Intervention|No Intervention|"Control group - Standard of Care~Re-assessment 24 weeks (6 month) after enrolment.~Afterwards crossover into experimental group"
89511502|NCT02322853|Active Comparator|TAMOXIFEN|"Tamoxifen will be administered daily orally~Patients will receive study medication until disease progression or unacceptable toxicity"
89511503|NCT02322853|Experimental|TAMOXIFEN + LY2228820|"Tamoxifen will be administered daily orally LY2228820 dimesylate (Ralimetinib) will be administered orally~Patients will receive study medication until disease progression or unacceptable toxicity"
89511504|NCT02743871|Experimental|Cohort 1|10 mg of PF-06817024 or placebo
89511505|NCT02743871|Experimental|Cohort 2|30 mg of PF-06817024 or placebo
89511506|NCT02743871|Experimental|Cohort 3|100 mg of PF-06817024 or placebo
89511507|NCT02743871|Experimental|Cohort 4|300 mg of PF-06817024 or placebo
89511508|NCT02743871|Experimental|Cohort 5|1000 mg of PF-06817024 or placebo
89511509|NCT02743871|Experimental|Cohort 6|2000 mg of PF-06817024 or placebo
89511510|NCT02743871|Experimental|Cohort 7|30 mg subcutaneous dose of PF-06817024 or placebo
89511511|NCT02743871|Experimental|Cohort 8|300 mg of PF-06817024 or placebo
89511512|NCT02743871|Experimental|Cohort 9|IV dose to be determined of PF-06817024 or placebo
89511513|NCT02743871|Experimental|Cohort 10|PF-06817024 or placebo
89511514|NCT02743871|Experimental|Cohort 11|PF-06817024 or placebo
89511515|NCT02743871|Experimental|Cohort 12|PF-06817024 or placebo
89511516|NCT02743871|Experimental|Cohort 13|PF-06817024 or placebo
89511517|NCT02447653|Experimental|Hydroxyapatite Coating|G7 HA Acetabular component will be implanted
89511518|NCT02447653|Active Comparator|Plasma Porous Spray|G7 PPS Acetabular component will be implanted
89511519|NCT03485755||Children|Children 8-10 years of age
89511520|NCT03485755||Biological Mothers|Biological mothers of children now ages 8-10 years of age
89511521|NCT05150665|Experimental|En-Masse Retraction|Six anterior teeth (en-Masse) retracted using a crimpable hook distal to the upper lateral incisor and a power chain
89511522|NCT05150665|Experimental|two step retraction|Six anterior teeth are retracted by two step technique by canine retraction followed by four anterior teeth retraction using a crimpable hook distal to the upper lateral incisor and a power chain
89024239|NCT02647021|Experimental|Therapeutic + Lower Body Exercise|"The Therapeutic Exercise Program (standard care) will include:~Neck range of motion and strengthening, and posture retraining.~Shoulder specific progressive resistance exercise program that focuses on spinal accessory nerve dysfunction and rehabilitation of trapezius muscle function.~The Resistance Exercise component will target 6-8 muscle groups of the lower extremities and core including gluteal, quadriceps, hamstrings, abdominals, and gastrocnemius muscles. A progressive introduction of exercises will occur over the first 3 weeks.~a personalized program of lower extremity resistance exercises~core strengthening exercises"
89024240|NCT02618408|Experimental|Low dose SPN-810 (18 mg)|Oral
89024241|NCT02618408|Experimental|High dose SPN-810 (36 mg)|Oral
89024242|NCT02618408|Placebo Comparator|Placebo|Oral
89024243|NCT02611453|Experimental|Single arm|"All patients will undergo endoscopic retrograde cholangiopancreatography (ERCP) that is indicated for suspected or confirmed choledocholithiasis or biliary strictures. Air contrast cholangiography using carbon dioxide gas will be performed with standard fluoroscopy and digital subtraction fluoroscopic image capture followed by routine cholangiography using iodinated contrast and standard fluoroscopy. Carbon dioxide (CO2) is routinely used in ERCP procedures and would flow into the biliary tree of patients at the time of ERCP, irrespective of this study's interventions. Digital subtraction image capture is a commercially available setting on certain fluoroscopy units that optimizes resolution with air or CO2 used as a contrast medium."
89511523|NCT03496831||Rheumatoid Arthritis|Registered in DANBIO with a diagnosis of M05.9, M06.0 or M06.9.
89207101|NCT02546700|Placebo Comparator|Placebo: Biomarker-high|Matching placebo will be administered subcutaneously once in every 4 weeks up to 24 weeks to the participants considered as biomarker-high.
89207102|NCT02546700|Placebo Comparator|Placebo: Biomarker-low|Matching placebo will be administered subcutaneously once in every 4 weeks up to 24 weeks to the participants considered as biomarker-low.
89511524|NCT03496831||Spondyloarthritis|Registered in DANBIO with a diagnosis of M45.9, M46.1, M46.8+M02.9, M46.8+M07.4, M46.8+M07.5 or M46.9.
89511525|NCT03496831||Psoriatic Arthritis|Registered in DANBIO with a diagnosis of M07.3 or M46.8+M07.2.
89511526|NCT03488485|Other|DAA arm|"Direct Acting Antivirals therapy An algorithm was developed using DAA (Sofosbuvir-based regimens to treat all patients (RKD).~Non Cirrhotics: Sofosbuvir (SOF)+ Daclatasvir (DCV) for 12-weeks~Cirrhotics:~Genotype 3 were treated with SOF+DCV+ ribavirin (RBV) for 24 weeks, Non-Genotype 3 patients were treated with SOF+LDV+RBV for 12-weeks or with SOF+LDV for 24-weeks (in RBV intolerant patients)."
89511527|NCT00821249|Experimental|ARRY-520|
89511528|NCT00821249|Experimental|ARRY-520 + G-CSF support|
89511529|NCT00821249|Experimental|ARRY-520 + dexamethasone + G-CSF support|
89511530|NCT03496753|Experimental|Led Therapy|The following will be the phototherapeutic parameters: total spot area: 1.44 cm²; continuous emission mode; output power: 10 mW; infrared wavelength (880 to 904 nm); fluence: 4 J/cm²; and application time: 10 minutes/session. Sessions will be held three times a week on alternating days for six consecutive weeks, totaling 18 sessions.
89511531|NCT03496753|No Intervention|Control|The control group will receive orientation regarding breast care and adequate breastfeeding techniques. The experimental group will receive the same orientation plus phototherapy sessions using a device developed especially for the treatment of nipple trauma. Both groups will be followed up for six consecutive weeks.
89511532|NCT00825539|Placebo Comparator|Placebo|
89511533|NCT00825539|Experimental|AQW051|
89511534|NCT03485599||HIV infected people|Blood samples will be taken and rapid HIV test by ELIZA will be done ,for positive cases Westron blot done
89511535|NCT02322931|Experimental|Imaging interventions|Eligible patients who consent to participate in this study will undergo a combination of 4 different imaging interventions (based on the group they're in, as described in the protocol), intra-operatively, in addition to their standard LDR brachytherapy treatment.
89511536|NCT04472585|Active Comparator|Ivermectin alone|Sub-cutaneous injection ivermectin 200ug/kg body weight once every 48 hourly plus standard care
89511537|NCT04472585|Active Comparator|Ivermectin with Zinc|Sub-cutaneous injection ivermectin 200ug/kg body weight once every 48 hourly with 20mg Zinc Sulphate 8 hourly plus standard care
89511538|NCT04472585|Placebo Comparator|Placebo|Placebo drug plus standard care
89540736|NCT05941715|Active Comparator|group A: aflibercept first (part 1), switch to faricimab (part 2)|"Aflibercept 2.0mg/0.05ml intravitreal will be administered from baseline through to the first visit at or after 32 weeks in a treat-and-extend regime.~At the first visit at or after 32 weeks, faricimab 6.0mg/0.05ml intravitreal will be administered in a treat-and-extend regime through to the last visit before 56 weeks."
89207103|NCT00963729|Experimental|Arm I|Patients receive fluorouracil IV, epirubicin IV, and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
89540737|NCT05941715|Experimental|group B: faricimab monotherapy|Faricimab 6.0mg/0.05ml intravitreal will be administered from baseline through to the last visit before 56 weeks in a treat-and-extend regime.
89540738|NCT05931913|Experimental|ERP+iTBS|Participants will receive two weeks (10 sessions) of intermittent theta burst stimulation (iTBS; a form of TMS) targeting the dorsolateral prefrontal cortex (dlPFC), followed immediately by Exposure Plus Response Prevention (ERP).
89540739|NCT05931913|Experimental|ERP+cTBS|Participants will receive two weeks (10 sessions) of continuous theta burst stimulation (cTBS; a form of TMS) targeting the presupplementary motor area (pSMA), followed immediately by Exposure Plus Response Prevention (ERP).
89540740|NCT05931913|Active Comparator|ERP+Sham|"Participants will receive two weeks (10 sessions) of sham (fake) TMS, followed immediately by Exposure Plus Response Prevention (ERP)."
89540741|NCT05929612|Experimental|Ultra Low Dose 4 Gy Radiation|Participants will receive the ultra-low doses of radiation therapy over 1-2 days
89540742|NCT05923853|Experimental|Oxygen (FiO2) Titration per E-alerts|All eligible mechanically ventilated patients, FiO2 titration and SpO2 goal range will be based on the correlation between SpO2 and arterial oxygen saturation (SaO2). E-alerts will be sent in the intervention arm as reminders for FiO2 titration.
89540743|NCT05923853|No Intervention|Oxygen Titration per Standard of Care|In the control arm, patients will have oxygen titrated per current standard of care (SpO2=88-92%, titrate FiO2 at least every 4 hours). Physician place oxygen titration orders in EMR and respiratory therapists conduct FiO2 titration without electronic alerts.
89540744|NCT05923203|Experimental|Adult use of EAS|Clinical intervention; Adults with CI and the fitting of electric and acoustic stimulation (EAS) technology in the implanted ear(s).
89540745|NCT05923203|Experimental|Pediatric use of EAS|Clinical intervention; Children with CI and the fitting of electric and acoustic stimulation (EAS) technology in the implanted ear(s).
89540746|NCT05923203|No Intervention|Children with Normal Hearing|Children with normal hearing; acoustic only
89540747|NCT05923203|No Intervention|Adults with Normal Hearing|Adult with normal hearing; acoustic only
89540748|NCT05917353|Experimental|Hinex Jelly Nutritional Supplement Intervention Group|Week 0th, Week 4th (14 days before and after), Week 8th (14 days before and after), Week 12th (14 days before and after), diet and exercise health education was given, with daily intervention of Hinex Jelly nutritional supplements 1 serving per day during 0th to 8th Week;
89540749|NCT05917353|No Intervention|Routine care group|Week 0th, Week 4th (14 days before and after), Week 8th (14 days before and after), Week 12th (14 days before and after), the subjects were given regular dietary and exercise health education.
89540750|NCT05917145|Experimental|Group A (Dose Escalation)|WSD0628 treatment should be started the day before radiation therapy starts (Day 1). Radiation therapy is given for 10 consecutive business days (Day 2-15, not including weekends and holidays), and WSD0628 will only be given on those 10 consecutive business days ≥30 minutes but ≤2 hours before radiation.
89540751|NCT05917145|Experimental|Group B (Dose Expansion)|"WSD0628 treatment should be started the day before radiation therapy starts (Day 1). Radiation therapy is given for 10 consecutive business days (Day 2-15, not including weekends and holidays), and WSD0628 will only be given on those 10 consecutive business days ≥30 minutes but ≤2 hours before radiation.~The Group B (Dose Expansion) portion of the study will be opened after the Group A (Dose Escalation) is complete."
88959623|NCT02005731||Shockwaves|Low intensity linear focused shockwave device ('Renova')
88959624|NCT02005744|Experimental|Child Pugh A|CKD-501 will be administered to patients who are included Child Pugh A
88959625|NCT02005744|Experimental|Child Pugh B|CKD-501 will be administered to patients who are included Child Pugh B
88959626|NCT02005744|Experimental|Subject who are matched Child Pugh A|CKD-501 will be administered to the Subjects who are matched Child Pugh A
88959627|NCT02005744|Experimental|Subject who are matched Child Pugh B|CKD-501 will be administered to the subjects who are matched Child Pugh B
88959628|NCT02005757|Experimental|Bredinin tablet 150mg|dosage form: Tablet, dosage: 150mg qd, Duration: for 6months
88959629|NCT02005757|Active Comparator|Bredinin tablet 50mg|dosage form: Tablet, dosage: 50mg tid, Duration: for 6months
88959630|NCT02005770|Experimental|Sevoflurane|General anesthesia using Sevoflurane
88959631|NCT02005770|Active Comparator|Propofol|General anesthesia using propofol TCI
88959632|NCT02005783|Experimental|DBD arm|Epirubicin: 90mg/m2, d1, q3w*4 Cyclophosphamide: 600mg/m2, d1, q3w*4 DBD: one dose of medicine twice per day, orally OR; Docetaxel: 75mg/m2, d1, q3w*4 Cyclophosphamide: 600mg/m2, d1, q3w*4 DBD: one dose of medicine twice per day, orally
88959633|NCT02005783|Other|EC/TC|Epirubicin: 90mg/m2, d1, q3w*4 Cyclophosphamide: 600mg/m2, d1, q3w*4 OR; Docetaxel: 75mg/m2, d1, q3w*4 Cyclophosphamide: 600mg/m2, d1, q3w*4
88959634|NCT02005796|Experimental|Blue-fleshed potato tubers|Intervention: Steam cooked mashed potato tubers
88959635|NCT02005796|Experimental|Yellow-fleshed potato tubers|Intervention: Steam cooked mashed potato tubers
88959636|NCT02005796|Experimental|Bilberries and potato starch|Intervention: A gel boiled with bilberries and potato starch
88959637|NCT02005809|Active Comparator|Second look endoscopy|This group is performed second look endoscopy about 24 hours later from endoscopic submucosal dissection.
88959638|NCT02005809|No Intervention|without second look endoscopy|This group is not performed second look endoscopy after ESD
88959639|NCT02005822|Experimental|Valganciclovir|Valganciclovir 32 mg/kg per day in two doses (16 mg/kg per dose) during 6 weeks in an oral solution.
88959640|NCT02005822|No Intervention|Control|"Refusal control group:~Infants in the control group receive no antiviral therapy. Counseling and treatment assigned by an audiological center remain unchanged.~Historical control group:~Infants with birth date 1-11-2011 till 1-07-2012 with sensorineural hearing loss and congenital CMV."
88959641|NCT02005835|Other|Facility-based Peer Support|"Facility-based Peer Support to provide the following at the clinic~Routine standard clinical care based on the MoH guidelines~Mentor mothers provide education and psychosocial support at facility~Weekly support groups provided in clinic~Phone call, SMS, or home visit for each missed appointment"
89511539|NCT04472585|Active Comparator|Ivermectin (oral) alone|Oral ivermectin 0.2mg/kg/day
88959642|NCT02005835|Other|Community-based Peer Support|"Community-based Support from Peer Mothers (Expert mothers):~Routine standard clinical care based on the MoH guidelines~Mentor mothers provide education and psychosocial support in community prior to each visit~Monthly support groups in community~Home visits for each missed appointment"
88959643|NCT02005835|No Intervention|Standard of Care|The Standard of care as outlined in the Malawi HIV integrated Care Guidelines
88959644|NCT02005848|Experimental|Alpha1 Antitrypsin (Glassia)|60 mg/kg body weight
88959645|NCT02005848|Experimental|Alpha-1 Antitrypsin (Glassia)|120 mg/kg body weight
88959646|NCT02005848|Placebo Comparator|Placebo|Placebo
89511540|NCT04472585|Active Comparator|Ivermectin (oral) with Zinc|Oral ivermectin 0.2mg/kg/day with 20mg Zinc Sulphate 8 hourly plus standard care
88959647|NCT02005874||Dry eye|
89511541|NCT04472585|Active Comparator|Zinc Alone|20mg Zinc Sulphate 8 hourly plus standard care
89511542|NCT03496519|Experimental|Dose Escalation|"Dose escalation will occur following a 3+3 design in all advanced tumor types meeting the inclusion and exclusion criteria.~Cohort -1 (if necessary): Durvalumab 1125mg with Trabectedin 0.5mg/m2~Cohort 1: Durvalumab 1125mg with Trabectedin 0.75mg/m2~Cohort 2: Durvalumab 1125mg with Trabectedin 1.0mg/m2~Cohort 3: Durvalumab 1125mg with Trabectedin 1.2mg/m2~Cohort 4: Durvalumab 1125mg with Trabectedin 1.5mg/m2"
89511543|NCT03496519|Experimental|Dose Expansion|Patients at this level will receive the safest dose of Durvalumab and Trabectedin that was determined during the Dose Escalation Phase. There will be a fixed dosage of Durvalumab, 1125mg, given intravenously over 60 minutes on Day 2 every 21 days. There will be fixed dosage of Trabectedin for each cohort, given through intravenous infusion as an outpatient, over a 24 hour period on Day 1 every 21 days.
89511544|NCT03485521|Active Comparator|Practical Work|15 students who participate in a practical work lasting two hours about the procedures of the tracheobronchial aspiration
89511545|NCT03485521|Experimental|Stimulation Group|Group with competences and reasoning clinic 15 students Simulation with a procedural practice of tracheobronchial suction as part of a simulation sequence after reading the procedures of the tracheobronchial aspiration
89511546|NCT03726905|Experimental|respiratory muscles training|4 weeks guided respiratory muscles training followed by 12 weeks guided aerobic training - (treadmill walking)
89511547|NCT03726905|Sham Comparator|sham respiratory muscles training|"4 weeks sham respiratory muscles training (THRESHOLD® IMT breathing trainer with 0 pressure level) followed by 12 weeks guided aerobic training - (treadmill walking)"
89511548|NCT03485443|Active Comparator|Group I (%0.9 NaCl 10ml/kg)|"The group (Group 1) received 10 ml kg-1 throughout the entire surgical procedure.~Four point scale using scored vomiting. m CHEOPS Scale using scored between 0-10."
89511549|NCT03485443|Active Comparator|Group II (%0.9 NaCl 20ml/kg)|"The group (Group 2) received 30 ml kg-1 throughout the entire surgical procedure.~Four point scale using scored vomiting. m CHEOPS Scale using scored between 0-10."
89511550|NCT00814073|Experimental|Masitinib & BSC|Masitinib (6 mg/kg/day) administered as an add-on to optimal concomitant symptomatic treatment (i.e. best supportive care, BSC)
89511551|NCT00814073|Placebo Comparator|Placebo & BSC|Matching placebo administered as an add-on to optimal concomitant symptomatic treatment (i.e. best supportive care, BSC)
89511552|NCT02442115||ASD with GID|Children with Autism Spectrum Disorder with Functional Constipation will be treated with standard of care defined by NASPGHAN by a pediatric gastroenterologist, and evaluated at 4 visits over 1 year for their medical condition. These children will be enrolled in some ASD treatment program by their parents. The treatment program is not part of the current study. Measures of ASD symptoms will be done at each visit to determine social communication, emotional and cognitive improvement due to the FC treatment. Measures of F2-isoprostane, a marker of oxidative stress, will be done at each visit to determine if FC treatment and ASD symptom improvement relates to improvement in a child's physiology.
89511553|NCT02442115||ASD without GID|Children Autism Spectrum Disorder without Functional Constipation will be evaluated for their ASD symptoms at 4 times over 1 year. These children will be enrolled in some ASD treatment program by their parents. The treatment program is not part of the current study. Measures of F2-isoprostane, a marker of oxidative stress, will be done at each visit to determine if ASD symptom improvement relates to improvement in a child's physiology.
89511554|NCT05150353|Experimental|Patients with cardiac amyloidosis|
89511555|NCT05150353|Placebo Comparator|Healthy volunteers|
89511556|NCT00813605|Experimental|Arm A|AMG 655 10 mg/kg plus AMG 479 placebo in combination with FOLFIRI every 14 days
89511557|NCT00813605|Active Comparator|Arm C|AMG 479 Placebo plus AMG 655 Placebo in combination with FOLFIRI every 14 days
89511558|NCT00813605|Experimental|Arm B|AMG 479 12 mg/kg plus AMG 655 placebo in combination with FOLFIRI every 14 days
89511559|NCT05134285||control|pregnancy without preeclampsia
89511560|NCT05134285||preeclampsia|pregnancy complicated with preeclampsia at the first delivery or at the second delivery
89511561|NCT05134285||recurrent preeclampsia|pregnancy complicated with preeclampsia at two deliveries
89511562|NCT00724841|Experimental|1|40 mg/m2 GMX1777 with Temozolomide
88959648|NCT02005874||Non-dry eye|
88959649|NCT02005900|Experimental|DHA|Docosahexaenoic acid (DHA) administration to modulate Triglycerides in HIV patients under HAART
88959650|NCT02005900|Placebo Comparator|PLACEBO|
89511563|NCT00724841|Experimental|2|50 mg/m2 GMX1777 with Temozolomide
89511564|NCT00724841|Experimental|3|62 mg/m2 GMX1777 with Temozolomide
89511565|NCT00724841|Experimental|4|80 mg/m2 GMX1777 with Temozolomide
89207104|NCT00963729|Experimental|Arm II|Patients receive oral letrozole daily for 18-23 weeks until day of surgery.
89207105|NCT00851214||Acute CHF/COPD|Patients presenting with shortness of breath secondary to acute exacerbation of CHF/COPD
89207106|NCT00851214||Acute Trauma|Acute trauma patients with a trauma ISS>15
89207107|NCT00851214||Sepsis|Patients presenting with a suspicion of acute sepsis (fever, tachycardia, tachypnea)
89207108|NCT00851214||Stroke|Patients presenting with symptoms and signs of acute stroke (thrombotic or hemorrhagic)
89207109|NCT00851292|Active Comparator|Side-firing|prostate biopsies obtained with side-firing probe
89207110|NCT00851292|Active Comparator|End-firing|
89024255|NCT02502786|Experimental|humanized anti-GD2 antibody, hu3F8, when combined with GM-CSF|One cycle consists of treatment with hu3F8 at a dose of 2.4mg/kg/dose for 3 days (day 1, 3, and 5) in the presence of subcutaneous (sc) GM-CSF (day -4 through 5). These 3 doses of hu3F8 and 10 days of GM-CSF constitute a treatment cycle. Cycles are repeated at ~2-4 week intervals between first days of hu3F8, through 5 cycles. A maximum of 5 cycles will be administered on protocol. If elevations of amylase and/or lipase (>Grade 1) or clinical signs suggestive of pancreatitis (e.g. upper abdominal pain) occurs, naxitamab and GM-CSF doses should be held until improvement of toxicity to ≤Grade 1 if laboratory elevations and/or pancreatitis is possibly related to either naxitamab or GM-CSF.
89024256|NCT02499172|Experimental|Cohort 1|Cohort 1: Women who were pregnant and received at least one dose of ShancholTM during the mass OCV vaccination campaign.
89024257|NCT02499172|No Intervention|Cohort 2|Cohort 2: Women who received at least one dose and who became pregnant after the mass vaccination campaign; hence their fetuses were not exposed to the vaccine.
89024258|NCT02499172|No Intervention|Cohort 3|Cohort 3: Women who were pregnant in Chikwawa District at the time of the vaccination campaign in Nsanje District, but who did not receive the vaccine during the campaign.
89024259|NCT02499172|No Intervention|Cohort 4|Cohort 4: Women who become pregnant in Chikwawa District after the vaccination campaign in Nsanje District, and who did not receive the vaccine during the campaign.
89024260|NCT02478099|Experimental|1 Treatment with MPDL3280A|Treatment with MPDL3280A
89207111|NCT00963963|Active Comparator|health promotion materials|Parents receive health promotion booklets
89207112|NCT00963963|Active Comparator|attention-controlled parent print materials|Booklets on adolescent sexuality and health
89207113|NCT00963963|Experimental|audio-CD parent education|audio-CDs on parenting practices
89207114|NCT00844974|Other|1|
89511566|NCT00724841|Experimental|5|100 mg/m2 GMX1777 with Temozolomide
89511567|NCT00724841|Experimental|6|125 mg/m2 GMX1777 with Temozolomide
89511568|NCT03488329|Experimental|Intervention|"Intervention group~Individual nutritional therapy"
89511569|NCT03488329|No Intervention|Control|"Control group~Standard treatment"
89511570|NCT00811499|Experimental|ARRY-371797 (Schedule 1)|
89511571|NCT00811499|Experimental|ARRY-371797 (Schedule 2)|
89511572|NCT00811499|Placebo Comparator|Placebo|
89511573|NCT03677843||cerebral palsy|They are included in GMFCS level 3, 4, 5. and they have diplegia or quadriplegia
89511574|NCT03496441||Group 1|Colorectal cancer patients who will undergo a surgical resection with digestive anastomosis. Fecal sample collection for analysis before and after surgery (2 samples).
89207115|NCT00964041|Experimental|D-cycloserine|Participants will receive D-cycloserine weekly, one hour before any assessments, for eight weeks.
89207116|NCT00964041|Placebo Comparator|Placebo|Participants will receive placebo weekly, one hour before any assessments, for eight weeks.
89207117|NCT00840372||1|Chronic hemodialysis patients, native arterio-venous fistula
89207118|NCT00840372||2|Chronic hemodialysis patients, native arterio-venous fistula
89207119|NCT04009317|Experimental|TQ-B3139|TQ-B3139 tablet 600mg administered orally , twice daily in 28-day cycle.
89207120|NCT04009317|Active Comparator|Crizotinib|Crizotinib tablet 250mg administered orally, twice daily in 28-day cycle.
89207121|NCT00845052||First group of house staff|First group of house staff to be surveyed
89207122|NCT00845052||Second group of house staff|Second group of house staff to be surveyed
89207123|NCT00845052||Thirst group of house staff|Third group of house staff to be surveyed
89210524|NCT00604500|Experimental|MF/F MDI 100/10 mcg BID with dose counter|MF/F MDI 100/10 mcg BID with an integrated dose counter (administered as two inhalations of MFF MDI 50/5 mcg, twice a day) over a 4-week Treatment Period.
89210525|NCT00905658|No Intervention|Arm I|Patients are monitored via standard follow-up assessments every 3 weeks.
89511575|NCT03496441||Group 2|Patients having undergone surgical resection with digestive anastomosis for colorectal cancer or inflammatory bowel disease, complicated by anastomotic leakage. Fecal sample collection for analysis after surgery, once the leak is confirmed.
89511576|NCT03496441||Group 3|Patients with uncomplicated hernia pathology, without gastrointestinal comorbidity to undergo a surgery to heal this hernia without involving a gastrointestinal resection. Fecal sample collection for analysis before surgery (1 sample).
89511577|NCT03496441||Group 4|Inflammatory bowel disease patients waiting for elective surgery involving gastrointestinal resection. Fecal sample collection for analysis during surgery, directly from the bowel content (1 sample).
89511578|NCT05091697|Experimental|Multicomponent treatment VIRTUAL FIBROWALK + TAU|VIRTUAL FIBROWALK is a multicomponent non-pharmacological program based on Pain Neuroscience Education (PNE), therapeutic exercise, Cognitive Behavioural Therapy (CBT) and Mindfulness Training
89511579|NCT05091697|Active Comparator|Treatment as Usual (TAU)|Treatment-as-Usual (TAU) consisted of the prescribed drugs adapted to the symptomatic profile of each patient and basic face to face and written advice on PNE and aerobic exercise adapted to the physical capacities of the patients at the beginning of the study.patient
89511580|NCT03560609|Active Comparator|Subjects With Keratoconus|
89511581|NCT03560609|Active Comparator|Subjects with Glaucoma|
89511582|NCT04896619|Experimental|Daily dose of Kori-tofu mixed in 3 slices of bread|Kori tofu as part of bread
89511583|NCT04896619|Active Comparator|Daily dose of whey protein, soy oil and maltodextrin mixed in 3 slices of bread|Whey protein, soy oil and maltodextrin as part of bread
89210526|NCT00905658|Experimental|Arm II|Patients receive nutritional supplements and are monitored via standard follow-up assessments every 3 weeks.
89210527|NCT00905658|Experimental|Arm III|Patients receive nutritional supplements and are monitored via standard follow-up assessments every 3 weeks with additional biweekly assessments completed at home by a service provider.
89511584|NCT03131791|Experimental|shock wave|The interventions were focused in the hypertonic muscles of the upper limb of 3000 impulses, a pressure of 1.5 bar and frequency of 5Hz were used to treat the biceps brachii, flexor carpi ulnaris and flexor carpi radialis, mainly in the middle of the belly.
89511585|NCT03131791|Experimental|Botulinum toxin A|We performed BoNT-A 500 unit in 2cc 0.9% normal saline at biceps brachii, flexor carpi ulnaris and flexor carpi radialis, mainly in the middle of the belly.
89511586|NCT03131947||Union|Radiological union on RUST score (figure 2) (score of 3 on at least 3 cortices in AP, lateral, medial or posterior cortex - total of 9 or more) within 6 months of surgery
89511587|NCT03131947||Delayed union|Impaired bone healing at six months (RUST score < 9)
89511588|NCT03471065|Experimental|Transcatheter Aortic Valve Replacement (TAVR)|
89511589|NCT00805805|Experimental|1|Tetrathiomolybdate with ursodiol
89511590|NCT00805805|Placebo Comparator|2|Placebo with ursodiol
89511591|NCT03488173|Experimental|Lansoprazole Capsules|Lansoprazole Capsules 30 mg of Beijing Sihuan Pharm
89511592|NCT03488173|Active Comparator|Lansoprazole enteric-coated Capsules|Lansoprazole enteric-coated Capsules 30 mg of Takeda Pharmaceutical Company Limited
89511593|NCT03466541|Experimental|Riskbruk|The employees randomised to the Riskbruk group will be offered two consultations a ∼15 min with the OHS. The subjects will receive individual feedback on the screening results. During these sessions, Motivational Interviewing will be used.
88816118|NCT02385084|Experimental|Part B: LY2409021 Tablet Commercial|Single oral dose of LY2409021 tablet (commercial formulation) in one of two study periods.
88816119|NCT04341207|Experimental|Cohort 1|Advanced Cancer Patients with SARS-CoV-2 positive test & Covid19 symptoms
88816120|NCT04341207|No Intervention|Cohort 2|Advanced Cancer Patients with SARS-CoV-2 negative test & Covid19 symptoms. Patients with a chest CT-scan compatible with Covid19 disease shall be treated in part B.
88816121|NCT04341207|No Intervention|Cohort 3|Advanced Cancer Patients with SARS-CoV-2 positive or negative test & no Covid19 symptoms
88816122|NCT04341207|Experimental|Cohort 4|Advanced Cancer Patients with SARS-CoV-2 positive test AND chest CT-scan compatible with Covid19 disease & no Covid19 symptoms & Pretreated or with frail conditions following the HCSP definition
88816123|NCT02411292|Experimental|Enoxaparin metabolism|Eligible patients will have steady state peak and trough anti-Xa levels drawn after the third enoxaparin dose. For patients in-range (levels 0.3-0.5IUmL), no intervention will be undertaken. For patients out of range, enoxaparin dose will be adjusted according to an established dose adjustment algorithm. Repeat levels will be checked after the third administration of the new dose.
88816124|NCT01166984|Experimental|AB103 7.5 µg/kg|AB103 7.5 µg/kg administered as a single IV infusion
88816125|NCT01166984|Experimental|AB103 37.5 µg/kg|AB103 37.5 µg/kg administered as a single IV infusion
88816126|NCT01166984|Experimental|AB103 150 µg/kg|AB103 150 µg/kg administered as a single IV infusion
88816127|NCT01166984|Experimental|AB103 450 µg/kg|AB103 450 µg/kg administered as a single IV infusion
88816128|NCT01166984|Placebo Comparator|Placebo|Normal saline (0.9% sodium chloride) administered as a single IV infusion
88816129|NCT02486211|Placebo Comparator|Placebo|Placebo medication administered at 0600 and 1200 via mouth, gastric tube or duo-tube.
88816130|NCT02486211|Experimental|Amantadine|100mg Amantadine administered at 0600 and 1200 via mouth, gastric tube or duo-tube.
88816131|NCT04743531|Experimental|Intervention|Families living in rural Colorado will participate in the HEROs intervention in Fall 2019.
88816132|NCT04743531|Experimental|Staggered Intervention|Families in the staggered intervention arm will serve as controls for the first intervention arm during Fall 2019. Families the staggered intervention arm will then participate in the HEROs intervention in Spring 2020.
88816133|NCT01167452|Experimental|Sulfamethoxazole/trimethoprim|2 DS tablets of sulfamehtoxazole/trimethoprim (1600 mg/320 mg)
88816134|NCT04352192|Experimental|Kinesiotaping Group|The group in which kinesiotaping is going to be applied to biceps brachii muscle of participants and will assess EMG activities before KT, immediately after KT, after 30 minutes and 24 hours of KT. The EMG analysis will be performed during maximum isometric voluntary contraction of biceps brachii muscle.
88816135|NCT04352192|No Intervention|Control Group|The group in which kinesiotaping is not going to be applied. EMG activities will be assessed first assessment and after 10th minutes, 30th minutes and 24th hours of the first assessment. The EMG analysis will be performed during maximum isometric voluntary contraction of biceps brachii muscle.
88816136|NCT02487225|Experimental|Pentoxifylline|Pentoxifylline, 400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects to receive up to a maximum of 9 doses.
88816137|NCT02487225|Placebo Comparator|Placebo|Placebo 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects to receive up to a maximum of 9 doses.
88816138|NCT02384850|Experimental|Selinexor + mFOLFOX6|Different Dose Levels of Selinexor will be evaluated in combination with mFOLFOX6 (see interventions)
88816139|NCT01167608||People with Parkinson's disease|Individuals diagnosed with Parkinson's disease
88816140|NCT02558829|Experimental|GHST Sequence A|1st Macimorelin-GHST, 2nd Insulin Tolerance Test
88816141|NCT02558829|Experimental|GHST Sequence B|1st Insulin Tolerance Test, 2nd Macimorelin-GHST
88816142|NCT01132508||Treatment|
88816143|NCT02487303|Active Comparator|Acetaminophen Intravenous|(group 1) 1 gram IV acetaminophen every 8 hours for three doses
89511594|NCT03466541|Experimental|Balance|The group allocated to the Balance intervention will follow a comprehensive multi-session eHealth intervention with personalised feedback on the screening results.
88959651|NCT02005926|Experimental|negative FNA result of abnormal node|Axillary ultrasound examination was undergone for all breast cancer patients before sentinel lymph node biopsy (SLNB). If abnormal axillary lymph node was found, ultrasound-guided FNA cytology of these nodes were performed. The abnormal nodes were defined as completely hypoechoic node, asymmetric focal hypoechoic node, cortical lobulation and cortical thickness >3mm. Patients with negative results of FNA would undergo SLNB. Technetium-99m-labeled Rituximab was used for lymphatic mapping. Before the SLNB operation, a hookwire was placed at the suspicious axillary lymph node by ultrasound guidance. In the SLNB operation, radioactive nodes and wire-localized nodes were removed and labeled separately for pathological examination.
88959652|NCT02005939|Experimental|Pomegranate extract capsule|All participants receive 1.1 g pomegranate extract capsule daily for 4 weeks
89511595|NCT03466541|No Intervention|Control group/usual care|The control group will receive the usual follow-up provided by the OHS for persons with risky alcohol behaviour. In order to provide something that appears as a plausible follow-up to the control participants, they will be given a booklet that covers general information about alcohol and potential risks and harms of drinking. The booklet contains no advise on how to achieve a change in drinking behaviour.
89511596|NCT03488095|Other|Behavior changing intervention|Thirty minutes behavior counselling (PPT.) to experimental group. BCI for SLT and BQ Use in Adolescents: A CRT
89511597|NCT03488095|No Intervention|Control Cluster|No thirty minutes behavior counselling (PPT.) to control group
88959653|NCT02005939|Placebo Comparator|Placebo capsule|All participants receive a 1.1g placebo capsule daily for 4 weeks
88959654|NCT02005952||Spirometry, quality control, Pulmonary Function Laboratory|Performing spirometry, with control over the quality of the same, made from the pulmonary function laboratory of the Hospital de la Santa Creu i Sant Pau.
88959655|NCT02005952||Spirometry, quality control, software|Performing spirometry, with the support of software self-management quality of spirometry maneuvers incorporated therein
88959656|NCT02005952||Spirometry, quality control, control group|Performing spirometry in the way that is currently working in primary care (control group without any support).
88959657|NCT02005965||Staging and outcomes for patients with Low Rectal Cancer|Low Rectal Cancer defined on MRI as a cancer within 6cm of the anal verge
89511598|NCT02323009|Active Comparator|Esophageal balloon Arm|Patients in this arm were randomly assigned to have their PEEP adjusted to maintain a positive transpulmonary pressure (0 to 10 cm H20).
89511599|NCT02323009|Active Comparator|Cstat Arm|Patients in this arm had their PEEP adjusted to achieve the best static effective compliance (CStat).
89511600|NCT02323009|No Intervention|Historic Controls|These were historic controls with similar patient characteristics weaned by traditional methods in the 2-year period prior to the start of the study.
89511601|NCT03488017|Experimental|Placebo Ocular Coil (left eye)|Left eye
89511602|NCT03488017|Experimental|Placebo Ocular Coil (right eye)|Right eye
89511603|NCT04750759|Active Comparator|Niclosamide + Camostat|Patients will receive the combination of niclosamide chewing tablets (2000 mg, once daily) and camostat tablets (600 mg, 4-times daily) over a period of 7 days.
89511604|NCT04750759|Placebo Comparator|Placebo|Patients will receive placebo orally over a period of 7 days.
89511605|NCT03382925|Active Comparator|cervical interlaminar with lidocaine|Group #1: Interlaminar cervical ESI at the C7-T1 level with triamcinolone acetonide 80 mg (40 mg/mL) + 2 mL 1% lidocaine (total volume 4 mL).
89511606|NCT03382925|Active Comparator|cervical interlaminar with normal saline|Group #2: Interlaminar cervical ESI at the C7-T1 level with triamcinolone acetonide 80 mg (40 mg/mL) + 2 mL preservative saline (total volume 4 mL).
89511607|NCT03496363||CHD with Hypothyroidism|
89511608|NCT03485131|Experimental|Transcranial direct-current stimulation|Intervention of 2 mAmp Transcranial direct-current stimulation treatments given twice daily for 20 min each per day for 4 weeks on consecutive weekdays. Twice-daily sessions were separated by at least 3 hours (one in the AM and the other one in the PM)
89511609|NCT03485131|Sham Comparator|Sham tDCS|Intervention of placebo stimulation with ranscranial direct-current stimulation(sham tDCS), the stimulation parameters were displayed, but after 40 seconds of real stimulation of 2 mAmp to simulate the tDCS induced skin sensation, only a small current pulse was delivered every 550 msec (110 mAmp over 15 msec) through the remainder of the 20-minute period
89511610|NCT03487939|Experimental|FOLFOXIRI|Patients received 4 cycles of neoadjuvant FOLFOXIRI chemotherapy before surgical resection.
89511611|NCT00796523|Experimental|Happiest Baby videotape|videotape describing the Happiest Baby on the Block technique
89511612|NCT00796523|Placebo Comparator|control videotape|videotape with normal newborn instruction
88959658|NCT02005978||Acromegaly1|Acromegalic patients treated with radiation therapy
88959659|NCT02005978||Healthy controls|Health controls matched for age, gender and BMI to the patients
88959660|NCT02005978||Acromegaly 2|Acromegalic patients treated with pituitary surgery
88959661|NCT02005991|Experimental|PF-05212377 70 mg|
88959662|NCT02005991|Experimental|PF-05212377 20 mg|
88959663|NCT02005991|Experimental|PF-05212377 10 mg|
88959664|NCT02006017|Experimental|Group A|We will present to participants two general clinical scenarios. The first scenario will be accompanied by an evidence summary plus a recommendation and a second scenario will be accompanied by an evidence summary alone
88959665|NCT02006017|Experimental|Group B|We will present to participants two general clinical scenarios. The first scenario will be accompanied by an evidence summary alone and a second scenario will be accompanied by an evidence summary plus a recommendation
88959666|NCT02006043|Experimental|Erlotinib 150mg/day taken orally|Erlotinib 150mg/day taken orally until disease progression or intolerable toxicities
89210528|NCT00906672|Experimental|INTEGRA®|
89210529|NCT00906672|Active Comparator|Flap technique|
89511613|NCT03496129|Experimental|Personalized Feedback|Following the baseline assessment, participants will be sent a link via text message to a secure website containing substance-impaired driving specific personalized feedback. Feedback will include the following elements: a personalized substance use profile and substance-impaired driving profile, information on social norms related to substance use and substance-impaired driving, personalized information on BAC (or level of impairment due to drug use) prior to driving, costs associated with a DUI citation in Kentucky, and information on combined drug and alcohol impaired driving risk (if endorsed).
89511614|NCT03496129|Experimental|Personalized feedback and text messages|Following the baseline assessment, participants will be sent a link via text message to a secure website containing substance-impaired driving specific personalized feedback (described above). Participants will be asked to send a text message back to the study administrator after viewing the feedback document. After confirming receipt and processing of the document, the study administrator will then send the participant three text messages containing open-ended questions.
89511615|NCT03496129|Active Comparator|Information Only|Students randomized to the information condition will receive standard information about alcohol and other drugs and substance-impaired driving via a link to a website delivered through text message.
89511616|NCT05210543||Anaphylactic reaction (observational)|Patients who experienced an anaphylactic reaction will be observed
89511617|NCT00796289|Experimental|GnRH High Target Delivery|10 mg GnRH iontophoretic transdermal Lutrepatch with a high target delivery of pulsatile GnRH (every 90 minutes) for 21 days and oral placebo clomiphene citrate for 5 days
89511618|NCT00796289|Experimental|GnRH Medium Target Delivery|10 mg GnRH iontophoretic transdermal Lutrepatch with a medium target delivery of pulsatile GnRH (every 90 minutes) for 21 days and oral placebo clomiphene citrate for 5 days
89511619|NCT00796289|Experimental|GnRH Low Target Delivery|10 mg GnRH iontophoretic transdermal Lutrepatch with a low target delivery of pulsatile GnRH (every 90 minutes) for 21 days and oral placebo clomiphene citrate for 5 days
89511620|NCT00796289|Active Comparator|Clomiphene Citrate|Placebo GnRH iontophoretic transdermal Lutrepatch with a high target delivery of pulsatile current (every 90 minutes) for 21 days and oral 50 mg clomiphene citrate for 5 days
89511621|NCT00796289|Placebo Comparator|Placebo|Placebo GnRH iontophoretic transdermal Lutrepatch with a high target delivery of pulsatile current (every 90 minutes) for 21 days and oral placebo clomiphene citrate for 5 days
89511622|NCT04460443|Experimental|Sofosbuvir and ledipsavir|Sofosbuvir and ledipsavir plus standard of care treatment.
89511623|NCT04460443|Experimental|Sofosbuvir and Daklatasuvir|Sofosbuvir and Daklatasuvir plus standard of card treatment..
89511624|NCT04460443|No Intervention|Standard treatment|Standard treatment alone
89511625|NCT00711035|Experimental|Trivirus Specific CTLs for EBV, CMV and Adenovirus Infection|If a patient has a partial response they are eligible to receive up to 4 additional doses at biweekly intervals. These doses would come from the original infused line if sufficient vials were available but may come from another line if there are insufficient cells in the original line.
89511626|NCT04460521|Experimental|NAC Group|Participants in this group will given an N-acetylcysteine 500mg oral tablet daily in addition to wearing a standard carpal tunnel splint nightly (worn approximately 6-8 hours/day). Both interventions will take place concurrently for a total of 8 consecutive weeks.
89511627|NCT04460521|Placebo Comparator|Placebo Group|Participants in this group will be given a placebo table to be taken orally daily in addition to wearing a standard carpal tunnel splint nightly (worn approximately 6-8 hours/day). Both interventions will take place concurrently for a total of 8 consecutive weeks.
89511628|NCT00710567|Other|Historical Data|"DuraHeart Patients will be implanted with a DuraHeart Left Ventricular Assist System (LVAS) as a bridge to transplant until a suitable heart can be found as a replacement. Parameters collected will be compared to a performance goal based on historical data for congestive heart failure patients"
89511629|NCT02323087|Active Comparator|Culture and susceptibility testing|Urine culture and sensitivity testing will be performed using the FLEXICULT™ SSI-Urinary Kit
89511630|NCT02323087|Active Comparator|Culture|Point of care culture will be performed using ID FlexicultTM
89511631|NCT00698789|Experimental|Treatment A|5 mg of INCB019602 in AM with placebo administration in PM
89511632|NCT00698789|Experimental|Treatment B|20 mg of INCB019602 in AM with placebo administration in PM
89511633|NCT00698789|Experimental|Treatment C|5 mg of INCB019602 in PM with placebo administration in AM
89511634|NCT00698789|Experimental|Treatment D|20 mg of INCB019602 in PM with placebo administration in AM
89511635|NCT00698789|Experimental|Treatment E|7.5 mg of INCB019602 in PM QoD with placebo administration in AM as well as PM on non active dose days
89511636|NCT00698789|Placebo Comparator|Treatment F|Placebo BID
89511637|NCT03484975|Other|Observation group|Patients undergoing coronary angiography and intravascular imaging for either diagnostic purposes or for PCI following a presentation with either stable angina or an acute coronary syndrome.
89511638|NCT03367169|Active Comparator|minimally invasive method|The patients are treated with minimally invasive method
89511639|NCT03367169|Active Comparator|open reduction method|The patients are treated with open reduction method
88810905|NCT05133414|Experimental|Participants will receive stimulation of the left subclavian ansae.|Participants as self-controlled cases for the study. Human cardiac haemodynamics and electrophysiological in response to left subclavian ansae stimulation will be studied.
88810906|NCT05120869|Experimental|Treatment|A tailored HPV education and professional skills intervention.
88810907|NCT05120869|Active Comparator|Control|General/publicly available educational materials on HPV and communication skills.
88810908|NCT05120739|Experimental|Interventional|Skin preparations (the day before and the morning of the operation) with the 2% CHX cloths
88810909|NCT05120739|No Intervention|Control|Skin preparations (the day before and the morning of the operation) with the 4% CHX soap (standard of care)
88810910|NCT05118295|Experimental|SAVI Scout®|marker is accurately placed in the breast tumor
88810911|NCT05111041|Experimental|#EnufSnuff.TXT- First Responder|Participants in this group will receive a mobile gradual smokeless tobacco reduction intervention
88810912|NCT05111041|Active Comparator|Enough Snuff Intervention|Participants in this group will receive tobacco cessation materials
88810913|NCT05102123|Experimental|Cytisine and Video Messaging|Administration of cytisine (pharmaceutical support) to patients on a set dose schedule with behavioural support through video messaging.
88810914|NCT05102123|Placebo Comparator|Placebo and Video Messaging|Administration of placebo (inactive drug) to patients on a set dose schedule with behavioural support through video messaging.
88810915|NCT05102123|Active Comparator|Cytisine and No Video Messaging|Administration of cytisine (pharmaceutical support) to patients on a set dose schedule with behavioural support according to standard care such as a phone number for a self-help line.
88810916|NCT05102123|No Intervention|Placebo and No Video Messaging|Administration of placebo (inactive drug) to patients on a set dose schedule behavioural support according to standard care such as a phone number for a self-help line.
88810917|NCT05102110||Non-small cell lung cancer|A cohort of patients with known NSCLC who are assessed.
88810918|NCT05102110||Gastric cancer patient|A cohort of patients with known gastric adenocarcinoma who are assessed.
88810919|NCT05102110||Pancreatic cancer|A cohort of patients with known pancreatic adenocarcinoma who are assessed.
88810920|NCT05102110||Urothelial cancers|A cohort of patients with known uroepithelial cancers who are assessed.
88810921|NCT05102110||Biliary tract cancers|A cohort of patients with known biliary tract cancers who are assessed.
88810922|NCT05102110||Colorectal cacncers|A cohort of patients with known colorectal cancers have been added to the study following methodology change in analysis techniques.
88810923|NCT05079230|Experimental|Magrolimab + Venetoclax + Azacitidine|"Participants will receive~magrolimab: 1 mg/kg priming dose on Days 1 and 4; 15 mg/kg on Day 8; and 30 mg/kg on Days 11, 15, and then every week for 5 doses and every 2 weeks thereafter~venetoclax: 100 mg on Cycle 1 Day 1, 200 mg on Cycle 1 Day 2, 400 mg on Cycle 1 Day 3 and daily thereafter~azacitidine: 75 mg/m^2 on Days 1-7 or Days 1-5 and 8-9 of each cycle~Each cycle is 28 days."
88810924|NCT05079230|Placebo Comparator|Magrolimab Placebo + Venetoclax + Azacitidine|"Participants will receive~magrolimab placebo: Days 1, 4, 8, 11, and 15, then every week for 5 doses and every 2 weeks thereafter~venetoclax: 100 mg on Cycle 1 Day 1, 200 mg on Cycle 1 Day 2, 400 mg on Cycle 1 Day 3 and daily thereafter~azacitidine: 75 mg/m^2 on Days 1-7 or Days 1-5 and 8-9 of each cycle~Each cycle is 28 days."
88810925|NCT05077904|Experimental|Staccato alprazolam Arm|Participants randomized to this arm will receive a single dose of Staccato alprazolam by inhalation.
88810926|NCT05077904|Placebo Comparator|Placebo Arm|Participants randomized to this arm will receive a single dose of placebo by inhalation.
88810927|NCT05061134|Experimental|Main study: Ceralasertib + Durvalumab|Participants will receive ceralasertib on Days 1 to 7 plus durvalumab Day 8, once in 28 days (Q28D), until progressive disease, unacceptable toxicity, withdrawal of consent, or if a study treatment discontinuation criterion is met.
88810928|NCT05061134|Experimental|Main study: Ceralasertib|Participants will receive ceralasertib on Days 1 to 7, Q28D, until progressive disease, unacceptable toxicity, withdrawal of consent, or if a study treatment discontinuation criterion is met.
88810929|NCT05061134|Experimental|Biopsy Sub-study: Ceralasertib + Durvalumab|From Cycle 1, participants will receive combination of ceralasertib twice daily (BD) Days 1 to 7 plus durvalumab Day 8, Q28D, until progressive disease, unacceptable toxicity, withdrawal of consent, or a study treatment discontinuation criterion is met.
88810930|NCT05061134|Experimental|Biopsy study: Ceralasertib|During Cycle 0, participants will receive ceralasertib on Days 1 to 7, followed by an off-treatment period between Days 8 to 28.
88810931|NCT05052996|Experimental|ISL+LEN|"Participants will receive the following for at least 48 weeks:~Day 1: LEN oral 600 mg (2 x 300 mg) and ISL 2 mg (2 x 1 mg)~Day 2: LEN only oral 600 mg (2 x 300 mg)~Day 8 and weekly thereafter (ie, every 7 days): LEN oral 300 mg (1 x 300 mg) and ISL 2 mg (2 x 1 mg)"
88816144|NCT02487303|Active Comparator|Acetaminophen Oral|(group 2) 1 gram oral acetaminophen every 8 hours for three doses
89511640|NCT03484897|Experimental|P927 - LICHTENA DermAD CREMA CORPO|Application of the product under study mono-laterally at level of the forearm, including the antecubital fold, on the right or left side according to a randomization list defined by the investigator.
88816145|NCT02487303|No Intervention|No acetaminophen|(group 3) no acetaminophen
89511641|NCT00790127|Placebo Comparator|Placebo|Placebo
89511642|NCT00790127|Experimental|HQK-1001|HQK-1001
89511643|NCT03484741|Experimental|MSC and PRP|15 patients will be given autologous bone marrow-derived mesenchymal stem cells (BM-MSC) and mesenchymal stem cell from allogeneic umbilical cord tissue (UC-MSC) combined with platelet-rich plasma (PRP) by intravenous infusion.
89511644|NCT03360929|Experimental|experimental group|"Study drug: AZD3759 Strength: 50mg/tablet, 100mg/tablet Dose escalation:A treatment cycle consists of consecutive 21 days of dosing. two dose cohorts are planned for dose escalation, including: 150 and 250 mg twice daily.~RP2D in dose expansion."
89511645|NCT03487783|Experimental|Aripiprazole Oral Solution|1 mg/mL, 2-20 mg/day (2-20 mL/day), once daily for 8 weeks, administered at about the same time every day, either before or after meal
89511646|NCT03487783|Placebo Comparator|Placebo Oral Solution|2-20 mg/day (2-20 mL/day), once daily for 8 weeks, administered at about the same time every day, either before or after meal
89511647|NCT03335033|Active Comparator|Carotid Plaques with >70% Stenosis|Subjects being seen in the Mayo Clinic Gonda Vascular Center who have a plaque causing a > 70% stenosis will be approached for recruitment to receive an ultrasound examination including duplex imaging, shear wave elastography and contrast-enhanced ultrasound.
89511648|NCT03335033|Active Comparator|Carotid Plaques with 50-69% Stenosis|Cardiovascular high-risk patients with moderate (50-69% diameter) stenosis carotid plaques from the Mayo Clinic Gonda Vascular Center will be approached for recruitment to receive an ultrasound examination including duplex imaging, shear wave elastography and contrast-enhanced ultrasound.
89511649|NCT03495739|Experimental|RDG-17012® capsule|RDG-17012 ® capsule(dabigatran etexilate tosylate)
89511650|NCT03495739|Active Comparator|Pradaxa® capsule|Pradaxa® capsule(dabigatran etexilate mesylate)
89511651|NCT04188769|Sham Comparator|uninflated - rest|splint around the arm is not inflated both arms are in rest during the entire trial
89511652|NCT04188769|Sham Comparator|uninflated - triggered|splint around the arm is not inflated 5x flexion and extension with the contralateral arm (with weight of 5kg in the hands)
89511653|NCT04188769|Active Comparator|constantly inflated - rest|splint around the arm is constantly inflated both arms are in rest during the entire trial
89511654|NCT04188769|Active Comparator|constantly inflated - triggered|splint around the arm is constantly inflated 5x flexion and extension with the contralateral arm (with weight of 5kg in the hands)
89511655|NCT04188769|Experimental|intermittently inflated - rest|splint around the arm is intermittently inflated both arms are in rest during the entire trial
89511656|NCT04188769|Experimental|intermittently inflated - triggered|splint around the arm is intermittently inflated 5x flexion and extension with the contralateral arm (with weight of 5kg in the hands)
89511657|NCT04166539||Metallosis Patients|Patients who are being seen by surgeons for metal-related issues in the blood, pain, or revision surgery.
89511658|NCT04166539||Control Group|Patients who have had total hip or knee arthroplasty no less than 5-10 years ago, who have no symptoms.
89511659|NCT00686933|Experimental|1|
89511660|NCT04071613|Active Comparator|Intravenous tenecteplase (TNK)|Patients will receive intravenous tenecteplase (0.25mg/kg, maximum 25mg, administered as a bolus over ~10 seconds).
89511661|NCT04071613|Active Comparator|Intravenous tissue plasminogen activator (tPA)|Patients will receive intravenous t-PA at the standard licensed dose of 0.9 mg/kg up to a maximum of 90mg, 10% as bolus and the remainder over 1 hour.
89511662|NCT04063969||Endovascular team members|"All vascular surgeons, surgical trainees, nurses active in the hybrid angiography suite at one of the participating centers will be invited to participate in the study.~All participating team members complete an online questionnaire containing an assessment of their perceived radiation safety climate (28 items, 5 dimensions), radiation safety behaviors(2 items, 2 dimensions), radiation safety knowledge (single item) and radiation safety motivation (single item). All data will be stored pseudonymized."
89511663|NCT04063969||Vascular surgical patients|"In each center, five patients undergoing primary elective endovascular repair for an infrarenal abdominal aortic aneurysm (EVAR) will be enrolled in the study.~For each participating patient, a set of demographical (BMI, case difficulty, ASA-grade,etc.), procedure-related (procedure duration, contrast use, etc.) and radiation dose parameters (DAP, cumulative air kerma) will be collected and stored in a pseudonymized way.~Participation in this study has no effect on the interventional procedure, or the chosen approach."
89511664|NCT00683423|Experimental|A|
89511665|NCT00683423|Placebo Comparator|B|
89511666|NCT03484663|Experimental|Small catheter with chest tube after uniport vats|Insertion of small catheter drainage in the same opening with chest tube after uniport vats
89511667|NCT03484663|No Intervention|Chest tube only after uniport vats|After uniport vats we put chest tube only
89511668|NCT00680069|Experimental|High Dose Group|Volunteers will receive 90 mcg IM. Subjects who received previous clade 1 vaccine will get 1 dose, clade 1 vaccine-naive subjects receive 2 doses 28 days apart
89511669|NCT00680069|Experimental|Low Dose Group|Volunteers will receive 15 mcg intramuscularly (IM). Subjects who received previous clade 1 vaccine will get 1 dose, clade 1 vaccine-naive subjects receive 2 doses 28 days apart.
89511670|NCT05149807|Experimental|SHR-1701 + Tegafur Gimeracil Oteracil Potassium and Oxaliplatin|
89024261|NCT02446964|Experimental|Treatment (TMLI, chemotherapy, transplant, GVHD prophylaxis)|"CONDITIONING: Patients undergo TMLI BID on days -7 to -4 or -3 (depending on the dose level). Patients also receive fludarabine phosphate IV on days -7 to -3 and cyclophosphamide IV on days -7, -6, 3, and 4.~TRANSPLANT: Patients undergo bone marrow or peripheral blood stem cell transplant on day 0.~GHVD PROPHYLAXIS: Patients receive tacrolimus* IV QD or PO BID on days 5-180. Patients also receive mycophenolate mofetil PO TID or IV on days 5-35. Treatment with tacrolimus and mycophenolate mofetil may continue in the presence of active GVHD.~*NOTE: Patients intolerant of tacrolimus may receive cyclosporine."
89024262|NCT02426398||People with Alzheimer's disease|People with Alzheimer's disease
89024263|NCT02426398||Healthy volunteers|Healthy volunteers
89024264|NCT02351063|Experimental|Daily BNP|Subjects will be asked to test their BNP at home every day for a period of 180 days using the AlereTM HeartCheck System (the Test System). In addition to BNP, weights and signs and symptoms of HF will be collected each day of testing. The HeartCheck data is transmitted via a secure wireless protocol to the HealthCOM health monitoring portal where it is available to the medical staff. The subject's's physician and medical staff will be required to evaluate the data and determine if a change in HF treatment is advisable. All changes of heart failure medications are at the discretion of the treating physician and medical staff of the institution.
89024265|NCT02346396|Experimental|Patients with neuropathic chronic pain|
89210530|NCT00627458|Experimental|INFANRIX HEXA PF GROUP|Healthy male and female subjects between, and including 16 and 20 months of age at the time of booster vaccination, who were given the preservative-free (PF) formulation of Infanrix Hexa™ in the primary vaccination study 106786, additionally received a single booster dose of Infanrix Hexa™ vaccine, administered intramuscularly into the anterolateral quadrant of the right thigh.
89511671|NCT05149807|Placebo Comparator|Placebo + Tegafur Gimeracil Oteracil Potassium and Oxaliplatin|
89511672|NCT00679991|Active Comparator|PRT-201|
89511673|NCT00679991|Placebo Comparator|2|
89511674|NCT04459897||diagnosed or treated for granulomatous hepatitis fol|The cohort is composed by patient diagnosed or treated for granulomatous hepatitis followed in the internal medicine and / or Hepato-gastroenterology departments (Croix-Rousse Hospital, Edouard-Herriot Hospital, Lyon Sud Hospital Center).
89511675|NCT00678119|Experimental|1: AGS-003+sunitinib|Single arm study AGS-003 plus sunitinib
89511676|NCT03484585|Experimental|Rogaratinib (BAY1163877)|Healthy male subjects
89511677|NCT03487393|Experimental|Vitalflow treatment|The subject's exposure will be through a ramp model of increments in magnetic stimulation power delivered to the facial nerves bilaterally. Increases in magnetic stimulation will be 10% for 10 seconds from 10% to 60%. Subsequent to this will be evaluated for 5 minutes in the power of tolerability of the subject (60% 70%, 80% or 90%).
89511678|NCT02812667|Experimental|Nivolumab + Plinabulin|Nivolumab 240mg IV, day 1 and 15 until disease progression Plinabulin 3.5mg/m2, 20mg/m2, 30 mg/m2 or 40mg/m2 IV, day 1,8 and 15 until disease progression
89511679|NCT03495583|Experimental|Early introduction|Six commonly allergenic foods introduced (in a randomly assigned order) into the diets of exclusively breastfed infants from about 3 months of age.
89511680|NCT03495583|No Intervention|Standard introduction|Infants followed UK DoH standard advice for weaning
89511681|NCT02011321|Experimental|clevidipine|Four-hour infusion of low-dose intravenous clevidipine in patients with moderate vasospasm after aneurysmal subarachnoid hemorrhage
89511682|NCT03487315|Experimental|specific IgE|Different level of specific IgE and immunoblot
89511683|NCT03965377|Experimental|Home Safety Hero game play|Home Safety Hero is parental psychoeducational computer game to prevent childhood injuries
89511684|NCT01352585||JAK2 Positive Participants|
89511685|NCT01352585||JAK2 Negative Participants|
89511686|NCT02773355||Saxenda®|
89511687|NCT03484351|Experimental|Fall Monty Activity Programme (FallMAP)|A multifactorial falls prevention activity programme
89511688|NCT03495349||Diabetic foot infection|All of the patients followed for a diabetic foot infection in Hospices Civils of Lyon
89024266|NCT02323880|Experimental|Treatment (selinexor)|Patients receive selinexor PO on either a twice weekly (days 1, 3, 8, 10, 15, 17) or once weekly (days 1, 8, 15, and 22) schedule. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
89511689|NCT02744183|Active Comparator|Control Group|Maintain habitual habits
89511690|NCT02744183|Active Comparator|Fed Exercise|6 weeks of moderate intensity exercise with breakfast consumption
89511691|NCT02744183|Experimental|Fasted Exercise|6 weeks of moderate intensity exercise with breakfast omission
89511692|NCT03484195|Experimental|FOLFOXIRI|Patients received 4 cycles of neoadjuvant FOLFOXIRI chemotherapy before surgical resection.
89511693|NCT04526821|Experimental|Bovine Lactoferrin|Bovine Lactoferrin plus standard measures of personal protection.
89511694|NCT04526821|Placebo Comparator|Maltodextrin|Maltodextrin plus standard measures of personal protection.
89511695|NCT02690441|Experimental|CBT augmented with physical exercise|Patients receive 10 sessions of cognitive behavioural therapy for generalized anxiety disorder. Patients also receive 5 weeks of physical exercise pre-treatment, and 10 weeks of physical exercise alongside CBT. Both treatment and physical exercise is administered individually.
88959667|NCT02006082||COPD patients followed after TVC|All COPD patients living in the southern part of Rogaland county in Western Norway, with a habitual value of FEV1 < 50%, who were monitored at home by TVC following discharge after emergency hospitalization for COPD exacerbation at Stavanger University Hospital, or who had tele-monitoring at home under outpatient treatment for acute COPD deterioration during the pilot project period (16th April 2010 - 31st December 2011). The telemedicine equipment consisted of a computer with a web camera with a microphone, through which the patient at home and the specially trained nurse in hospital were able to communicate, and also comprised requisites to measure the patient's oxygen saturation and heart rate, and to perform a spirometry.
88959668|NCT02006173|Placebo Comparator|Normal saline|Participants will be randomly assigned to nasolabial or nasolabial&cheekbone group and receive control treatment (20mg/ml hyaluronic acid mixed with 0.175 ml normal saline) in one side of the face.
88959669|NCT02006173|Active Comparator|Lidocaine|Participants will be randomly assigned to nasolabial or nasolabial&cheekbone group and receive experiment treatment (20mg/ml hyaluronic acid mixed with 0.175 ml 2% lidocaine) in one side of the face.
88959670|NCT02006186|Experimental|Bicycle Train Intervention|The Bicycle Train intervention consists of research staff members who bike to and from school with enrolled participants. All participants, regardless of group assignment, each receive a bicycle, safety equipment, and take a bicycle safety course.
88959671|NCT02006186|No Intervention|Control|The control arm does not receive any intervention. All participants, regardless of group assignment, each receive a bicycle, safety equipment, and take a bicycle safety course.
88959672|NCT02006199|Experimental|relaxation with psychoeducation|after 8 weeks of relaxation with psychoeducation. subject take part in 8 weeks of the mindfulness meditation program
88959673|NCT02006199|Experimental|meditation|8 weeks of mindfulness meditation
89511696|NCT02690441|Active Comparator|CBT and placebo control|Patients receive 10 sessions of cognitive behavioural therapy for generalized anxiety disorder. Patients also receive 5 weeks of placebo control (15 minutes telephone follow-up call each week) pre-treatment, and 10 weeks of attention placebo alongside CBT. Both treatment and placebo control is administered individually.
89511697|NCT03487237|Experimental|All patient|Included patients will undergo a formal work up for pulmonary embolism: Ddimer testing, followed if positive by a computed tomography pulmonary angiogram or V/Q scan.
89511698|NCT02323243|Experimental|Allium BUS|Temporary urethral stent
89511699|NCT03487159|Other|Liver biopsy ,Elastography and MRE|Performance of routine Liver biopsy,Shear Wave Elastography and investigational MRE (Magnetic Resonance Elastography) in order to evaluate liver fibrosis stage.
89511700|NCT03487159|Other|Elastography and MRE|Performance of routine Shear Wave Elastography and investigational MRE (Magnetic Resonance Elastography) in order to evaluate liver fibrosis stage.
89511701|NCT02323399|Experimental|Phenylephrine|Phenylephrine Hydrochloride Injection, USP (United States Pharmacopeia) 10 mg/mL label claim
89511702|NCT03642769|Active Comparator|Lactated Ringer|Patients will receive fluid administration of Lactated Ringer's solution at a pre-determined volume algorithm that is the same for both arms
89511703|NCT03642769|Experimental|Normal Saline|Patients will receive fluid administration of Normal Saline solution at a pre-determined volume algorithm that is the same for both arms
89511704|NCT02616575||Silver link|Patients enrolled in NTUH hospital and its Behui branch
89511705|NCT02589197||Group 1 (Medial-Pivot)|Group 1 will be implanted with the EVOLUTION® MP System with Cruciate Sacrificing (CS) tibial inserts.
89511706|NCT02589197||Group 2 (Posterior-Stabilized)|Group 2 will be implanted with the Zimmer® NexGen® PS TKA system.
89511707|NCT02589197||Group 3 (Control Group)|Non-implanted control subjects
88959674|NCT02006212|Other|cadiac surgical patient; One arm|All patients undergoing first or redo cardiac surgery with or without cardiopulmonary bypass necessitating general and/or local anesthesia. If they present any EEG abnormality intraoperatively an immediate cerebral CT scan will be performed and the necessary measures will be taken to reduce the neurologic damage.
88959675|NCT02006225|Experimental|Plerixafor|The use of plerixafor as additive measurment for the conventional stem cell collection protocol.
88959676|NCT02006238|Experimental|Farabloc|The participants will sleep on Farabloc fabric nightly for a week.
88959677|NCT02006238|Placebo Comparator|Nylon Fabric|The participants will sleep on Nylon fabric nightly for week.
89511708|NCT03483805|Experimental|Treatment|Protalsafe product, daily, 12 weeks
89511709|NCT03483805|Placebo Comparator|Placebo|Placebo product, daily, 12 weeks
89511710|NCT04472741|Other|FUSE|wide angle colonoscope
89511711|NCT04472741|Other|HD Pentax i10 colonoscopes|SFV instrument
89511712|NCT04472741|Other|Endocuff|Cuff on SFV
89511713|NCT03438877|Experimental|Intervention group|Intervention group is intensive dosage of PD.
89511714|NCT03438877|Active Comparator|Control group|Control group is regular dosage of PD.
89511715|NCT02323477|Experimental|Allogeneic umbilical cord MSC group|Allogeneic human umbilical cord MSCs will be transplanted to 39 male patients (age 30-80) intramyocardially during CABG in chronic ischemic cardiomyopathy (EF<%45)
89511716|NCT02323477|Active Comparator|Autologous bone marrow-derived MNC group|Autologous bone marrow-derived MNCs will be transplanted to 20 male patients (age 30-80) intramyocardially during CABG in chronic ischemic cardiomyopathy (EF<%45)
89511717|NCT02323477|No Intervention|Control group|20 male patients (age 30-80) undergoing CABG in chronic ischemic cardiomyopathy (EF<%45) whom will not received any further transplantation
89511718|NCT04472819|Experimental|SHR2285 Part 1A|Participant received one of 7 dose levels of SHR2285 tablet as single-dose oral administration
89511719|NCT04472819|Placebo Comparator|Placebo Part 1A|Single ascending doses of placebo orally
89511720|NCT04472819|Experimental|SHR2285 Part 1B|Participant received one dose of SHR2285 tablet as single-dose oral administration
89511721|NCT04472819|Placebo Comparator|Placebo Part 1B|Single doses of placebo orally
89511722|NCT04472819|Experimental|SHR2285 Part 2|Participant received one of 4 dose levels of SHR2285 tablet as multi-dose oral administration
89511723|NCT04472819|Placebo Comparator|Placebo Part 2|Multiple ascending doses of placebo orally
89511724|NCT03294187|Experimental|Monitoring and Feedback|Subjects will use two wrist-worn wearables over a period of 6 weeks. Patients will receive multimodal (vibrotactile and visual) feedback.
88959678|NCT02006277|Experimental|Cohort 1|Cohort 1 will be an open label, randomized, 4 period, 4 treatment, 4 sequence, cross over sensory evaluation of three new prototype formulations (75 mg dose of crizotinib as prototypes 0.529 mg/mg, 0.470 mg/mg and 0.420 mg/mg Microspheres) and OS (75 mg dose of crizotinib)via use of a Crizotinib Taste Assessment - Questionnaire for Cohort 1 in healthy adults.
89511725|NCT03294187|Placebo Comparator|Monitoring|Study subjects will use identical devices over a period of 6 weeks. Patients will *not* receive multimodal feedback.
89511726|NCT00675623|Experimental|A|Dimebon, 5 mg orally three times daily
89511727|NCT00675623|Experimental|B|Dimebon 20 mg orally three times daily
89511728|NCT00675623|Placebo Comparator|C|Placebo orally three times daily for six months
89511729|NCT04473521|No Intervention|No Adhesive|No adhesive will be applied.
89511730|NCT04473521|Active Comparator|Super Poligrip Free (SPF)|The denture adhesive of 1.00grams (g) +/- 0.05g will be applied to only the maxillary denture in long, continuous strips manner that is controlled by weight for the maxillary dentures. Mandibular denture will be stabilised using this adhesive up to 2 times (maximum [max] 3 adhesive applications per day) at examiner's discretion.
89511731|NCT04473521|Experimental|Investigational Adhesive|The denture adhesive of 1.00g +/- 0.05g will be applied only to the maxillary denture only in long, continuous strips manner that is controlled by weight for the maxillary dentures. Mandibular denture will be stabilized using SPF adhesive up to 2 times (max 3 adhesive applications per day) at examiner's discretion.
89540752|NCT05917145|Experimental|Group C (Tumor Penetrance Treatments)|"One treatment of WSD0628 will be given prior to radiation and surgical resection will be performed on the same day. The two doses given will be determined by Group A and Group B. Patients will be randomized in a 1:1 fashion.~Dose level 1: minimally radiosensitizing concentration of WSD0628 will be achieved.~Dose level 2: selected based on a prediction that a maximally radiosensitizing concentration of WSD0628 will be achieved.~This portion of the study will open after Group A (Dose Escalation) is complete. This portion of the study will open to patients with recurrent high-grade glioma to further evaluate the efficacy, safety, tolerability, pharmacokinetics and biological activity of WSD0628 when combined with radiation therapy in specific patient subgroups"
89511732|NCT04473521|Experimental|Investigational Adhesive + Hot drink|The denture adhesive of 1.00g +/- 0.05g will be applied to only the maxillary denture in long, continuous strips manner that is controlled by weight for the maxillary dentures. Hot drinks will be provided within 1 hour of completing lunch and dinner and must be consumed within 30 minutes. Mandibular denture will be stabilized using SPF adhesive up to 2 times (max 3 adhesive applications per day) at examiner's discretion.
89511733|NCT04473287|Experimental|intervention group|Reflexology was applied to the intervention group during the procedure for 45 minutes.
89511734|NCT04473287|No Intervention|control group|Reflexology was not applied to the control group during the procedure. The control group received standard care and treatment.
88959679|NCT02006277|Experimental|Cohort 2|This cohort will be an open label, randomized, 5 period, 5 treatment, 4 sequence, cross over single dose bioavailability study employing administration of four crizotinib formulations Treatments E, F, G and H (Crizotinib 250 mg dose Formulated Capsule and 250 mg dose crizotinib as prototypes 0.529 mg/mg, 0.470 mg/mg and 0.420 mg/mg Microspheres, respectively) in the fasted state to healthy adult subjects (Periods 1-4). In addition, Treatment I (250 mg dose of crizotinib OS) will be administered at Period 5, for a taste evaluation only (no pharmacokinetic (PK) sample collection after the dose), in the period immediately following the completion of Period 4 of Cohort 2. A Crizotinib Taste Assessment - Questionnaire for Cohort 2 will be filled by all subjects.
88959680|NCT02006290|Experimental|1|
88959681|NCT02006290|Placebo Comparator|2|
89511735|NCT01352507|Experimental|Tadalafil then Sildenafil|"20 mg tadalafil taken orally, as needed, for 8 weeks, followed by 100 mg sildenafil taken orally, as needed, for an additional 8 weeks. There is a washout period of 7-10 days between treatments.~At the end of the two 8-week treatment periods, participants will be allowed to enter an 8-week extension phase on their preferred medication for erectile dysfunction (ED)."
89511736|NCT01352507|Active Comparator|Sildenafil then Tadalafil|"100 mg sildenafil taken orally, as needed, for 8 weeks, followed by 20 mg tadalafil taken orally, as needed, for an additional 8 weeks. There is a washout period of 7-10 days between treatments.~At the end of the two 8-week treatment periods, participants will be allowed to enter an 8-week extension phase on their preferred medication for ED."
89511737|NCT00672191|Experimental|1|
89511738|NCT02361346|Experimental|Part 1: Cohort 1 - 5 Micrograms/Kilogram/Dose (mcg/kg/Dose)|Part 1: MT-3724 5 mcg/kg/dose IV for 6 doses over 12 days, followed by dose escalations (Part 1) until recommended phase 2 dose of MT-3724 is determined
89511739|NCT02361346|Experimental|Part 1: Cohort 2- 10 mcg/kg/Dose|Part 1: MT-3724 10 mcg/kg/dose IV for 6 doses over 12 days, followed by dose escalations (Part) until recommended phase 2 dose of MT-3724 is determined
89511740|NCT02361346|Experimental|Part 1: Cohort 3- 20 mcg/kg/Dose|Part 1: MT-3724 20 mcg/kg/dose IV for 6 doses over 12 days, followed by dose escalations (Part 1) until recommended phase 2 dose of MT-3724 is determined
89511741|NCT02361346|Experimental|Part 1: Cohort 4- 50 mcg/kg/Dose|Part 1: MT-3724 50 mcg/kg/dose IV for 6 doses over 12 days, followed by dose escalations (Part 1) until recommended phase 2 dose of MT-3724 is determined
89511742|NCT02361346|Experimental|Part 1: Cohort 5- 100 mcg/kg/Dose|Part 1: MT-3724 100 mcg/kg/dose IV for 6 doses over 12 days, followed by dose escalations (Phase 1) until recommended phase 2 dose of MT-3724 is determined
88959682|NCT02006303|Active Comparator|Green light PVP|The KTP:YAG laser is based on the principle of passing Nd:YAG laser light through a KTP crystal. This halves the wavelength of the emitted laser to 532 nm and doubles its frequency. The emitted light is a visible green light, which is strongly absorbed by red tissues and hemoglobin; this renders a blood rich organ such as the prostate gland to be an excellent target. Prostate tissue is vaporized leaving an appropriate cavity for voiding.
88959683|NCT02006303|Active Comparator|Prostatic Artery Embolization|Prostatic artery embolization consists of gaining access into the patients arterial system via a common femoral artery puncture using a small needle and sheath. Once the access is established, a micro-catheter is navigated through the arterial system using X-ray guidance into the arteries feeding the prostate. There, small polyvynil alcohol plastic beads are injected to block the blood flow to the prostate. By doing so, the prostate undergoes an ischemic injury and there is reduction in gland size and relief of obstructive symtpoms.
88959684|NCT02006316||varicoceles|men with clinical varicoceles underwent microsurgical varicocelectomy due to causes other than infertility such as testicular pain, discomfort or scrotal mass
88959685|NCT02006329|Experimental|Intervention group - dietary consultation - Medit|
88959686|NCT02006329|No Intervention|Control group - dietary consultation - Mediterranean diet|
88959687|NCT02006355|Active Comparator|Continuous femoral nerve bloc|Continuous femoral nerve bloc
88959688|NCT02006355|Experimental|Continuous local anesthesia|Continuous local infiltration of local anesthetic in the operated knee.
88959689|NCT02006368|Experimental|Storage Age|
88959690|NCT02006381||Age 3-6|This will include 10 typically developing boys age 3-6
88959691|NCT02006381||Age 7-12|This will include 10 typically developing boys age 7-12
89207124|NCT03641547|Experimental|Stage A1, A2 & B|"The trial is a single arm study. Different populations are recruited to each stage and the stages run independently of each other. Stage A1 & A2 will commence before Stage B so that safety data can be obtained in the palliative setting prior to Stage B commencing. Stage A1 may be ongoing when Stage B begins. Each Stage has a separate eligibility criteria.~Stage A1: M6620 & palliative radiotherapy Stage A2: M6620 & palliative chemotherapy (Cisplatin & Capecitabine) Stage B: M6620 & definitive chemoradiotherapy"
88959692|NCT02006381||Age 13-17|This will include 10 typically developing boys age 13-17
88959693|NCT02006394|Experimental|Active Diet|Reduced glycemic index bread products, fish oil capsules, and polyphenol capsules.
89207125|NCT00851370|Experimental|Omalizumab|
89207126|NCT00851370|Placebo Comparator|Placebo|
89511743|NCT02361346|Experimental|Part 1: Cohort 6- 75 mcg/kg/Dose|Part 1b: MT-3724 75 mcg/kg/dose IV for 6 doses over 12 days of 21-Day cycle for up to 4 additional cycles to explore safety, tolerability and tumor response to repeat doses of MT-3724 (subject will continue with dose that was tolerated in the Part 1 portion of the study)
89511744|NCT02361346|Experimental|Part 2: Cohort 7- MTD Expansion Cohort|Part 2: MT-3724 IV for 6 doses administered within 14 days of 21-Day cycle up to 6 Cycles. If the Subject exhibits stable disease or PR after end of Cycle 6 and investigator determines ratio is favorable, treatment with MT- 3724 may be continued for up to additional 6 cycles.
89511745|NCT02361346|Experimental|Part 3: All MT-3724 Treated Participants|Part 3: MT-3724 IV 50 µg/kg/dose administered on Days 1, 3, 5, 8, 10, and 12 of each 21-day cycle. Treatment will continue until death, disease progression, unacceptable toxicity, withdrawal of consent, or another reason for withdrawal, or until study discontinuation
89511746|NCT02361346|Experimental|Part 4: All MT-3724 Treated Participants|Part 4: In this arm, subjects were planned to receive all doses of MT-3724 as IV infusion as confirmed in Part 3.
88959694|NCT02006394|Placebo Comparator|Placebo Diet|Market variety bread products, corn oil capsules, and corn starch capsules.
88959695|NCT02006433|Experimental|Deep Brain Stimulation|"Deep brain stimulation (DBS) for the alleviation of chronic neuropathic pain in patients with spinal cord injury (SCI). The stimulation will be applied bilaterally or unilaterally in the midbrain periaqueductal/periventricular gray region (PAG/PVG).~Extended participation in the study, which will last approximately 2 more years, precisely 104 weeks.The purpose of this extended portion of the study is to obtain long-term follow-up information on safety and efficacy, in subjects that have opted to receive continuing brain stimulation. Investigators label weeks in terms of original enrollment. Thus the surgery occurs in weeks 7 and 8 and the original study finishes in week 52, with the extension lasting from week 53 to week 156."
88959696|NCT02006446||VATES|men with altered spermograms (isolated teratozoospermia or oligo-astheno-teratozoospermia)
88959697|NCT02006485|Experimental|Ublituximab + TGR-1202|Ublituximab at a fixed IV infusion dose Days 1, 8 and 15 followed by maintenance infusions TGR-1202 oral daily dose
89207127|NCT00967629|Other|Sevelamer Carbonate crossover|Participants will be patients with stage II-IV CKD due to diabetic nephropathy randomized to start either with sevelamer carbonate or calcium carbonate
89207128|NCT00967629|Other|Calcium Carbonate crossover|Participants will be patients with stage II-IV CKD due to diabetic nephropathy randomized to start either with sevelamer carbonate or calcium carbonate
89511747|NCT04460963|Other|Biological evaluation|Adrenomedullin evaluation at diagnosis at first CR and 1 year of follow-up
89511748|NCT00873275|Experimental|Treatment (ursodiol, combination chemotherapy, bevacizumab)|Patients receive oral ursodiol twice daily on days 1-28 (days -6 to 28 of course 1), leucovorin calcium IV over 2 hours on days 1 and 15, fluorouracil IV over 46 hours on days 1-2 and 15-16, and oxaliplatin IV over 2 hours and bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
89511749|NCT04403243|Experimental|1. Colchicine|30 Patients with mild and severe COVID 19 Patients will get investigated therapy for ten days. Patients will be follow-up during 45 days after randomization
89511750|NCT04403243|Experimental|2. Ruxolitinib|10 Patients with mild and severe COVID 19 Patients will get investigated therapy for ten days. Patients will be follow-up during 45 days after randomization
89511751|NCT04403243|Experimental|3.Secukinumab|10 Patients with mild and severe COVID 19 Patients will get investigated therapy singly. Patients will be follow-up during 45 days after randomization
89511752|NCT04403243|Active Comparator|4.Standard treatment|-30 patients Patients with mild and severe COVID 19 Patients will get investigated therapy for ten days. Patients will be follow-up during 45 days after randomization
89511753|NCT00779519|Placebo Comparator|Placebo|
89511754|NCT00779519|Experimental|TTP435|
89207129|NCT00851448|Experimental|1|Oral nutritional supplement containing n-3 fatty acids, amino acids, antioxidants
89511755|NCT05648032|Experimental|PLT (lyophilized platelet) with steroid|PLT (30ng)+1.0 mL 1.0% Lidocaine+1.0 mL (10.0 mg/mL) Triamcinolone acetonide, once
89511756|NCT05648032|Experimental|PLT (lyophilized platelet)|PLT (30ng)+1.0 mL 1.0% Lidocaine+1.0 mL normal saline, once
89511757|NCT05648032|Active Comparator|Steroid|1.0 mL 1.0% Lidocaine+1.0 mL (10.0 mg/mL) Triamcinolone acetonide, once
89511758|NCT02272361|Other|laparoscopic sacrocolpopexy|laparoscopic sacrocolpopexy
89511759|NCT02272361|Other|vaginal mesh surgery|vaginal mesh surgery
89511760|NCT00774761|Experimental|1|
89511761|NCT00774761|Experimental|2|
89511762|NCT00774761|Active Comparator|3|
89511763|NCT00774761|Active Comparator|4|
89511764|NCT00774761|Active Comparator|5|
89511765|NCT02267278|Experimental|Ruxolitinib + Pracinostat|"Ruxolitinib starting dose 15 mg orally twice/day in 28-day cycle (dose assigned based on platelet count, if low platelet count gradual up-titration from a starting dose of 5 mg) - given alone for first 3 months, then Pracinostat added at starting dose 60 mg orally once/day for 3 alternating days every 3 weeks starting Day 1 of Cycle 4.~Dose of Ruxolitinib may be increased or decreased prior to initiation of Pracinostat. Quality of Life Questionnaire."
89511766|NCT04383509|Experimental|Cognitive control training|Cognitive Control Training (CCT) makes use of a very basic cognitive task that strongly loads on working memory and cognitive control processes, namely the adaptive Paced Auditory Serial Addition Task (aPASAT) where participants are given a number every 3 seconds and are asked to add the number they just heard with the number they heard before. Task difficulty is modified based on the participants current task performance, allowing training of cognitive control. Participants in the intervention group will start the CCT training after completion of ECT with a maximum time interval of 7 days. Training sessions will be performed on a tablet or computer and participants will complete five sessions per week (20 minutes per session) for a period of two weeks.
89511767|NCT04383509|Active Comparator|Active Control|Participants in the active control group will start placebo training after completion of ECT with a maximum time interval of 7 days. The placebo task consists of a task similar to the experimental condition but that does not train cognitive control. Prior research confirmed that this condition controls for non-specific effects of the training and motivational issues. Participants will perform the sessions on a tablet or computer and complete five sessions per week (20 minutes per session) for a period of two weeks.
89511768|NCT00772343|Placebo Comparator|Placebo Vaccine|0.9% Normal saline
89511769|NCT00772343|Experimental|Low dose|Low dose vaccine with adjuvant
89511770|NCT00772343|Experimental|High dose 1|High-dose vaccine with adjuvant
89511771|NCT00772343|Experimental|High dose 2|High-dose vaccine without adjuvant
89511772|NCT05647954|Experimental|HX008 Plus Transcatheter Arterial Chemoembolization(TACE)|
89511773|NCT05647954|Active Comparator|Temozolomide Plus Transcatheter Arterial Chemoembolization (TACE)|
89511774|NCT05647954|Active Comparator|Pembrolizumab|
89511775|NCT04874116|Experimental|Office Guidelines Applied to Practice (Office-GAP) + mobile phone text messaging|Participants receive Office Guidelines Applied to Practice (Office-GAP) + mobile phone text messaging for 12 months.
89511776|NCT04874116|Active Comparator|Mobile phone text messaging|Participants receive mobile phone text messaging alone for 12 months.
89511777|NCT00770081|Experimental|1|50mg qd vildagliptin
89511778|NCT00770081|Active Comparator|2|sitagliptin (25mg qd)
89511779|NCT02273843|Experimental|High-dose vitamin D|Will receive oral cholecalciferol (vitamin D3) in a single daily dose of 800 IU from the time of diagnosis of sepsis until discharge from the NICU
89511780|NCT02273843|Active Comparator|Conventional-dose vitamin D|Will receive oral cholecalciferol (vitamin D3) in a single daily dose of 400 IU from the time of diagnosis of sepsis until discharge from the NICU
89511781|NCT02273921|No Intervention|EEG|A non-invasive EEG recording
89511782|NCT00666497|Experimental|A|Azacitidine
89511783|NCT00666497|Experimental|B|MGCD0103
89207130|NCT00851448|Placebo Comparator|2|isocaloric, isonitrogenous
89207131|NCT00289783|Experimental|Menhibrix A Group|Subjects were primed with 3 doses of Menhibrix vaccine Lot A co-administered with Pediarix and boosted with 1 dose of Menhibrix vaccine, with co-administration of M-M-R II and Varivax. Subjects received vaccination at approximately 2, 4, 6 months and the fourth dose at 12-15 months of age. Menhibrix and Pediarix vaccines were administered intramuscularly in the right or left upper thigh, respectively. M-M-R II and Varivax vaccines were administered subcutaneously respectively in the upper left arm and the upper right arm.
89511784|NCT00666497|Experimental|C|Azacitidine + MGCD0103
89511785|NCT02274077|Active Comparator|EXPAREL|Bilateral, one time injections using 30ml of EXPAREL ((bupivacaine liposome injectable suspension) 1.3% ( 13.3mg/ml)) into the transverse abdominal plane at the time of abdominal component separation. A total of 60cc used with a Bupivacaine concentration of 0.44%.
88816146|NCT04341051||Case|we will observe the regional saturation of O2 through NIRS at the following time: T0(before peripheral anesthesia); T1 (5 minutes from the block); T2 (15 minutes from the block); T3 (30 minutes from the block); T4 (after revascularization); At each interval PA, SpO2 and NIRS were also recorded in the contralateral limb as control data.
89207132|NCT00289783|Experimental|Menhibrix B Group|Subjects were primed with 3 doses of Menhibrix vaccine Lot B co-administered with Pediarix and boosted with 1 dose of Menhibrix vaccine, with co-administration of M-M-R II and Varivax. Subjects received vaccination at approximately 2, 4, 6 months and the fourth dose at 12-15 months of age. Menhibrix and Pediarix vaccines were administered intramuscularly in the right or left upper thigh, respectively. M-M-R II and Varivax vaccines were administered subcutaneously respectively in the upper left arm and the upper right arm.
88959698|NCT02006485|Experimental|Ublituximab + TGR-1202 + ibrutinib|Ublituximab at a fixed IV infusion dose Days 1, 8 and 15 followed by maintenance infusions TGR-1202 oral daily dose ibrutinib oral daily dose
88959699|NCT02006485|Experimental|Ublituximab + TGR-1202 + bendamustine|Ublituximab at a fixed IV infusion dose Days 1, 8 and 15 followed by maintenance infusions TGR-1202 oral daily dose Bendamustine at a fixed IV infusion on Days 1 & 2
88959700|NCT05970900|Experimental|Preoperative Imatinib + local excision|"Following the attainment of the maximum treatment response through imatinib mesylate administration, typically occurring within 6-12 months, as evidenced by two consecutive imaging evaluations, the tumor exhibited no further reduction in size, thus necessitating the selection of surgical intervention.~According to the characteristics of the location of the tumor, the surgeon decides the surgical approach based on the existing literature and the availability of surgical equipment, including:~Local transanal resection (TA)~Local resection transsacralapproach~Local resection via perineal approach~Local resection transvaginal approach"
88959701|NCT05970848|Experimental|Group S|Group S patients will receive topical lidocaine anesthesia via the spray nozzle by the spray as-you-go technique during flexible bronchoscopy.
88959702|NCT05970848|No Intervention|Group C|Group C patients will receive topical lidocaine anesthesia with the conventional method by the spray as-you-go technique during flexible bronchoscopy.
88959703|NCT05970835|Active Comparator|Control group|"Firstly, all patients will be evaluated using Physical Performance Test, Saint George's Respiratory Questionnaire , and Geriatric Pain Measure and the MiniMental Satet Exam to fulfill the eligibility criteria. After that participants will be randomly assigned using the software www.randomizer.org. to control or intervention group. Outcome assessors and data analysts will remain blinded to participant´s allocation group.~Participants assigned to control group will receive the usual care provided by clinicians and physiotherapists from the Complexo Termal de Caldelas. They will have an educational session conducted by one of the researchers, and a paper sheet will be distributed with exercises and a written explanation of how to perform those exercises and the number of sets and repetitions."
88959704|NCT05970835|Experimental|Experimental group|Concerning patients from the intervention group will have an educational session given by one of the researchers, explaining how to use the HealthSmArt_ISAVE App. Then each patient will be given a unique code and password to log into the App and to start working with their smartphones. HealthSmArt_ISAVE App has three main components which are: evaluation (short, medium and long term); screening and intervention/rehabilitation.
88959705|NCT05970822|Experimental|BC3402+azacitidine|Subjects will receive azacitidine and BC3402 in a treatment cycle.
88959706|NCT05970783|Experimental|Jincaopian Tablets group|Patients receive Jincaopian Tablets 0.6g/day for 12 weeks.
88959707|NCT05970783|Placebo Comparator|Placebo group|Patients receive a placebo 0.6g/day for 12 weeks.
88959708|NCT05970757|Other|Extended MRI group|The MRI-scan time is extended with 15-20 minutes.
88959709|NCT05970705|Experimental|A: Regorafenib+TAS-102 combination therapy|Regorafenib 80mg ,orally, once a day, d1-28, every 28 days, TAS-102，35mg/m2, orally，twice a day, d1-5 & d15-19，every 28 days
88959710|NCT05970705|Active Comparator|B：Regorafenib monotherapy|Regorafenib, 120mg orally, once a day, d1-21, every 28 days (If the patient's body surface area is less than 1.5m2, the starting dose of regorafenib is 80mg)
88959711|NCT05970679|Experimental|DW1125|1 Ezetimibe/Atorvastatin 10/5 mg tablet orally once daily
88959712|NCT05970679|Experimental|DW1125A|1 Atorvastatin 5 mg tablet orally once daily
88959713|NCT05970679|Placebo Comparator|DW1125E|1 Ezetimibe 10mg tablet orally once daily
88959714|NCT05970679|Placebo Comparator|DW1125A-1|1 Atorvastatin 10mg tablet orally once daily
88959715|NCT05970627|Experimental|Chemotherapy+Toripalimab|"Toripalimab: 240 mg IV infusion on Day 1 of each 21 day cycle for 3 cycles prior to surgery and 3 cycles after surgery.~Chemotherapy: SOX(S-1+Oxaliplatin) Oxaliplatin,administered as a 2-hour intravenous infusion (130mg/m2) S-1, orally twice daily for 2 weeks followed by a 7-day rest period. The dose of S-1 was 80 mg/day for body surface area less than 1.25 m2, 100 mg/day for body surface area greater than or equal to 1.25 to less than 1.5 m2, and 120 mg/day for body surface area greater than or equal to 1.5 m2 Chemotherapy will be repeated each 21 day for 3 cycles prior to surgery and 3 cycles after surgery."
89207133|NCT00289783|Experimental|Menhibrix C Group|Subjects were primed with 3 doses of Menhibrix vaccine Lot C co-administered with Pediarix and boosted with 1 dose of Menhibrix vaccine, with co-administration of M-M-R II and Varivax. Subjects received vaccination at approximately 2, 4, 6 months and the fourth dose at 12-15 months of age. Menhibrix and Pediarix vaccines were administered intramuscularly in the right or left upper thigh, respectively. M-M-R II and Varivax vaccines were administered subcutaneously respectively in the upper left arm and the upper right arm.
89511786|NCT02274077|Placebo Comparator|Normal Saline|Bilateral, one time injections of 30ml normal saline into the transverse abdominal plane at the time of abdominal component separation.
89511787|NCT00765323|Active Comparator|1|84 mg octreotide implant for 6 months
88959716|NCT05970601|Experimental|high salt group|Intake of 9 g sodium chloride
88959717|NCT05970601|Active Comparator|low salt group|Intake of 6 g sodium chloride
88959718|NCT05970601|Active Comparator|substitution group|Intake of 6 g sodium chloride plus 3 g potassium chloride
88959719|NCT05970575|Experimental|Experimental Arm: NE3107|All participants will take 200mg BID (12 hours apart) of NE3107 for 6 months.
89024267|NCT02270814|Experimental|CACTUX: nab-paclitaxel, cisplatin (or carboplatin), cetuximab|"Up to 6 cycles of CACTUX may be given. The CACTUX regimen consists of:~nab-paclitaxel given intravenously over 30 minutes on an outpatient basis on Days 1, 8, and 15 of each 21-day cycle followed by~cisplatin given intravenously over 60 minutes on an outpatient basis OR carboplatin AUC5 given intravenously over 30 minutes on an outpatient basis on Day 1 of each 21-day cycle followed by~cetuximab given intravenously on an outpatient basis of Days 1, 8, and 15 of each 21-day cycle~Cisplatin or carboplatin may be given at the discretion of the investigator.~After the completion of 6 cycles of CACTUX, maintenance therapy will be given and consists of:~nab-paclitaxel given intravenously over 30 minutes on an outpatient basis on Days 1 and 8 of each 21-day cycle~cetuximab given intravenously on an outpatient basis on Days 1, 8, and 15 of each 21-day cycle"
89024268|NCT02228681|Experimental|Everolimus and Letrozole|Everolimus 10 mg daily and Letrozole 2.5 mg PO daily
89511788|NCT00765323|Active Comparator|2|Injections of Sandostatin LAR Depot(20, 30, 40 mg) every 4 weeks
89511789|NCT02274701|Experimental|Holistic Needs Assessment|Participants (patients) complete a self-reported paper assessment that asks them to indicate whether they have any emotional, practical, financial and/or clinical concerns. The patient then takes this completed assessment into their consultation. It is then given to the clinician where it informs a discussion based on the patient's needs and concerns as identified by them. A care plan is then written based on this assessment.
89511790|NCT02274701|No Intervention|Control|The control group entails standard care - routine consultation between the patient and clinician.
89511791|NCT04346459|Active Comparator|Group A- Fastrach (control group)|"Group of 40 patients scheduled for elective surgery under general anesthesia are planned to be intubated using intubating laryngeal mask airway Fastrach following blind intubating method through Fastrach"
89511792|NCT04346459|Active Comparator|Group B- I-gel|"Group of 40 patients scheduled for elective surgery under general anesthesia are planned to be intubated using I-gel supraglottic airway device as a conduit for tracheal intubation guided by a fiberoptic bronchoscope."
89511793|NCT04346459|Active Comparator|Group C- Protector|"Group of 40 patients scheduled for elective surgery under general anesthesia are planned to be intubated using the Protector laryngeal mask airway as a conduit for tracheal intubation guided by a fiberoptic bronchoscope."
89511794|NCT00760955|Experimental|TAK-583 5 mg QD|
89511795|NCT00760955|Experimental|TAK-583 50 mg QD|
89511796|NCT00760955|Experimental|TAK-583 100 mg QD|
89511797|NCT00760955|Placebo Comparator|Placebo QD|
89511798|NCT02276729|Experimental|Mirror Box Treatment Group|Participants in the intervention group will be required to perform two 20 minute sessions of Mirror Box Therapy, five days/week for the duration of their in-patient stay carried out under the direction of members of the OT stroke team as well as receiving their standard OT treatment for upper limb rehabilitation for the duration of their in-patient stay, which is 3-5 sessions per week of approximately 45 minutes duration. This classic rehabilitation treatment is based upon neurodevelopmental theory using the Bobath approach of postural control and repetitive task training.
89511799|NCT02276729|No Intervention|Conventional Therapy Control Group|Participants in the control group shall receive their standard OT treatment for upper limb rehabilitation for the duration of their in-patient stay, which is 3-5 sessions per week of approximately 45 minutes duration. This classic rehabilitation treatment is based upon neurodevelopmental theory using the Bobath approach of postural control and repetitive task training.
89511800|NCT02277587|Experimental|Plenadren|Plenadren (modified release hydrocortison) 20-25 or 30 mg oral tablets will be administered once-daily at 8.00 AM in the fasting state The dose is kept the same as patients had before entering the trial.
89511801|NCT02277587|Active Comparator|Conventional glucocorticoid therapy|"Hydrocortisone (dose range 10 to 30) mg will be continued as before entering the study. Cortisone Acetate (dose 25 to 37.5 mg) will be continued as before entering the study. The morning dose will be administered in the fasting state.~The total daily dose and timing is not changed during the study period."
89511802|NCT02277587|No Intervention|Healthy volunteers|Healthy volunteers will be enrolled as control group
88816147|NCT03011762|Other|Computer Controlled Mandibular Positioner|All study participants will undergo the computer controlled mandibular positioner test.
89540753|NCT05916664|Experimental|Intervention|"The intervention is a care coaching program that assists caregivers with their general caregiving goals and financial caregiving goals. Caregivers will attend a one-on-one care coaching session conducted via Zoom for 60-75 minutes with a care coach and will engage with their care coach through chat-based interactions after completing the session. If requested, up to two additional care coaching sessions will be scheduled.~Caregivers also will have the opportunity to attend up to 6 weekly support groups with other caregivers facilitated by a care coach and receive a variety of digital resources through the mobile app."
89540754|NCT05916664|No Intervention|Control|Control group that does not receive the Caregiver Support Intervention
89540755|NCT05913479|Experimental|Mucogyne treatment|"3 planned visits for each eligible patient:~Screening/Baseline visit: V0 at Day 0. Patient receive a box of Mucogyne Gel.~Phone call: V1 phone call at Day 10 ± 3~End-of-study visit: V2 at Day 35 ± 3"
89540756|NCT05912595|Active Comparator|EXOPULSE Mollii Suit Stimulation Active.|This will be the EXOPULSE Mollii Suit Active Stimulation. Stimulation will go on for 60 minutes while control unit is on for 60 minutes.
89024269|NCT02228681|Active Comparator|Hormonal Therapy|Tamoxifen 20 mg PO BID; on alternating weeks (even numbered) weeks, Medroxyprogesterone Acetate 200 mg PO daily with Tamoxifen 20 mg PO BID
89024270|NCT02213107|Experimental|Enzalutamide and dutasteride or finasteride|Use of either 1. Enzalutamide and dutasteride or 2. Enzalutamide and finasteride.
89024271|NCT02115282|Experimental|Arm A (exemestane, entinostat)|"Patients receive exemestane PO QD on days 1-28 and entinostat PO on days 1, 8, 15, and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI at baseline, at the end of cycle 3, every 3 cycles, at treatment discontinuation, and during follow-up, collection of blood samples at baseline and day 15 of cycle 1, and collection of archived tissue at baseline.~Pre/perimenopausal female patients and all male patients also receive goserelin acetate SC on day 1."
89540757|NCT05912595|Sham Comparator|EXOPULSE Mollii Suit Stimulation Sham.|This will be the EXOPULSE Mollii Suit Sham Stimulation. Stimulation will go on for 1 minute then it turns off while the control unit will remain on for total of 60 minutes.
89540758|NCT05910801|Experimental|Treatment (Tafasitamab, lenalidomide, venetoclax)|Patients receive tafasitamab IV, lenalidomide PO and venetoclax PO while on study. Patients may undergo lumbar puncture during screening. Patients undergo CT scan and blood sample collection and may undergo MRI and tumor biopsy on study and during follow-up. Patients undergo PET/CT, bone marrow biopsy, and bone marrow aspirate throughout the study.
89540759|NCT05898269|Experimental|Trendelenburg maneuver-EE OCC-EI OCC-Tidal volume challenge|"All enrolled patients will perform the 4 tests following a cross-over design and in a randomized sequence, separated by 1-min wash-out periods with return to hemodynamic baseline values, and concluded with the 500-ml fluid bolus.~There are 24 different possibilities of sequence"
89540760|NCT05898269|Experimental|Trendelenburg maneuver-EE OCC-Tidal volume challenge-EI OCC|"All enrolled patients will perform the 4 tests following a cross-over design and in a randomized sequence, separated by 1-min wash-out periods with return to hemodynamic baseline values, and concluded with the 500-ml fluid bolus.~There are 24 different possibilities of sequence"
89540761|NCT05898269|Experimental|Trendelenburg maneuver-Tidal volume challenge-EI OCC-EE OCC|"All enrolled patients will perform the 4 tests following a cross-over design and in a randomized sequence, separated by 1-min wash-out periods with return to hemodynamic baseline values, and concluded with the 500-ml fluid bolus.~There are 24 different possibilities of sequence"
88810932|NCT05052996|Experimental|B/F/TAF|"Participants will receive the following for at least 48 weeks:~bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) 50/200/25 mg once daily~After 48 weeks, participants will switch from B/F/TAF to ISL+LEN~Day 1: LEN oral 600 mg (2 x 300 mg) and ISL 2 mg (2 x 1 mg)~Day 2: LEN only oral 600 mg (2 x 300 mg)~Day 8 and weekly thereafter (ie, every 7 days): LEN oral 300 mg (1 x 300 mg) and ISL 2 mg~Participants who do not switch from B/F/TAF to ISL+LEN at Week 48 will be discontinued from the study."
89024272|NCT02115282|Placebo Comparator|Arm B (exemestane, placebo)|"Patients receive exemestane as in Arm A and placebo PO on days 1, 8, 15, and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI at baseline, at the end of cycle 3, every 3 cycles, at treatment discontinuation, and during follow-up, collection of blood samples at baseline and day 15 of cycle 1, and collection of archived tissue at baseline.~Pre/perimenopausal female patients and all male patients also receive goserelin acetate SC on day 1."
89024273|NCT02111941|Experimental|Treatment (vaccine therapy)|"INDUCTION PHASE: Patients receive folate receptor alpha peptide-loaded dendritic cell vaccine ID on day 1. Treatment repeats every 3 weeks for 5 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE PHASE: Patients receive folate receptor alpha peptide-loaded dendritic cell vaccine ID on day 1. Treatment repeats every 3 months for 7 courses in the absence of disease progression or unacceptable toxicity."
89024274|NCT01991977|Experimental|Diagnostic (PET, pMRI, DTI, IMRT, temozolomide)|Patients undergo 18F DOPA-PET, pMRI and DTI within 14 days before radiation therapy, 3-6 weeks after radiation therapy, and during follow-up. Patients also undergo IMRT over 30 fractions and receive temozolomide.
89024275|NCT01941277|Experimental|Intensive Exercise Group|Behavioral
89024276|NCT01941277|Experimental|Current Recommendations Exercise Group|Behavioral
89024277|NCT01938261|Experimental|Paracetamol effect on ductus|The first drug dose is given before 24 hours of age. Masked study drug is paracetamol infusion solution 10 mg/mL (PERFALGAN ®) or placebo, 0.45% saline solution. The loading dose is 20 mg/kg and the maintenance dose 7.5 mg kg every 6 hours for 4 days.
89024278|NCT01938261|Experimental|Paracetamol effect on pain|The first drug dose is given before 24 hours of age. Masked study drug is paracetamol infusion solution 10 mg/mL (PERFALGAN ®) or placebo, 0.45% saline solution. The loading dose is 20 mg/kg and the maintenance dose 7.5 mg kg every 6 hours for 4 days.
89024279|NCT01934582|Experimental|Open label extension|
89540762|NCT05898269|Experimental|Trendelenburg maneuver-Tidal volume challenge-EE OCC-EI OCC|"All enrolled patients will perform the 4 tests following a cross-over design and in a randomized sequence, separated by 1-min wash-out periods with return to hemodynamic baseline values, and concluded with the 500-ml fluid bolus.~There are 24 different possibilities of sequence"
89540763|NCT05898269|Experimental|Trendelenburg maneuver-EI OCC-Tidal volume challenge-EE OCC|"All enrolled patients will perform the 4 tests following a cross-over design and in a randomized sequence, separated by 1-min wash-out periods with return to hemodynamic baseline values, and concluded with the 500-ml fluid bolus.~There are 24 different possibilities of sequence"
89540764|NCT05898269|Experimental|Trendelenburg maneuver-EI OCC-EE OCC-Tidal volume challenge|"All enrolled patients will perform the 4 tests following a cross-over design and in a randomized sequence, separated by 1-min wash-out periods with return to hemodynamic baseline values, and concluded with the 500-ml fluid bolus.~There are 24 different possibilities of sequence"
89540765|NCT05898269|Experimental|EE OCC-EI OCC-Tidal volume challenge-Trendelenburg maneuver|"All enrolled patients will perform the 4 tests following a cross-over design and in a randomized sequence, separated by 1-min wash-out periods with return to hemodynamic baseline values, and concluded with the 500-ml fluid bolus.~There are 24 different possibilities of sequence"
89540766|NCT05898269|Experimental|EE OCC-EI OCC-Trendelenburg maneuver-Tidal volume challenge|"All enrolled patients will perform the 4 tests following a cross-over design and in a randomized sequence, separated by 1-min wash-out periods with return to hemodynamic baseline values, and concluded with the 500-ml fluid bolus.~There are 24 different possibilities of sequence"
89540767|NCT05898269|Experimental|EE OCC-Tidal volume challenge-Trendelenburg maneuver-EI OCC|"All enrolled patients will perform the 4 tests following a cross-over design and in a randomized sequence, separated by 1-min wash-out periods with return to hemodynamic baseline values, and concluded with the 500-ml fluid bolus.~There are 24 different possibilities of sequence"
89540768|NCT05898269|Experimental|EE OCC-Tidal volume challenge-EI OCC-Trendelenburg maneuver|"All enrolled patients will perform the 4 tests following a cross-over design and in a randomized sequence, separated by 1-min wash-out periods with return to hemodynamic baseline values, and concluded with the 500-ml fluid bolus.~There are 24 different possibilities of sequence"
89540769|NCT05898269|Experimental|EE OCC-Trendelenburg maneuver-Tidal volume challenge-EI OCC|"All enrolled patients will perform the 4 tests following a cross-over design and in a randomized sequence, separated by 1-min wash-out periods with return to hemodynamic baseline values, and concluded with the 500-ml fluid bolus.~There are 24 different possibilities of sequence"
89540770|NCT05898269|Experimental|EE OCC-Trendelenburg maneuver-EI OCC-Tidal volume challenge|"All enrolled patients will perform the 4 tests following a cross-over design and in a randomized sequence, separated by 1-min wash-out periods with return to hemodynamic baseline values, and concluded with the 500-ml fluid bolus.~There are 24 different possibilities of sequence"
88959720|NCT05970562|Experimental|Conversation Training Therapy with Ambulatory Voice Biofeedback|Conversation Training Therapy will be administered one time per week for 1 hour. Ambulatory Voice Monitoring with Biofeedback will be administered during the second therapy session and for 5 days between the second and third therapy sessions.
88959721|NCT05970562|Active Comparator|Conversation Training Therapy alone|Conversation Training Therapy will be administered one time per week for 1 hour.
88959722|NCT05970536|Experimental|Apple vinegar group|After hemostasis of the exposed pulp is achieved, Apple vinegar will be used for dentin conditioning for 5 mins then 1-2 mm thickness of MTA placed on the exposed pulp chamber.
88959723|NCT05970536|Active Comparator|EDTA 17% group|After hemostasis of the exposed pulp is achieved, EDTA 17 % will be used for dentin conditioning then 1-2 mm thickness of MTA placed on the exposed pulp chamber.
88959724|NCT05970432|Experimental|TQH2722 injection 300mg-150mg|Participants received subcutaneous injection of 300 mg TQH2722 injection + 600 mg placebo on day 1, followed by subcutaneous injection of 150 mg TQH2722 injection + 300 mg placebo on days 15, 29, 43, 57, 71, 85, 99.
88959725|NCT05970432|Experimental|TQH2722 injection 600mg-300mg|Participants received subcutaneous injection of 600 mg TQH2722 injection + 300 mg placebo on day 1, followed by subcutaneous injection of 300 mg TQH2722 injection + 150 mg placebo on days 15, 29, 43, 57, 71, 85, 99.
88959726|NCT05970432|Experimental|TQH2722 injection 900mg-450mg|Participants received subcutaneous injection of 900 mg TQH2722 injection on day 1, followed by subcutaneous injection of 450 mg TQH2722 injection on days 15, 29, 43, 57, 71, 85, 99.
88959727|NCT05970432|Placebo Comparator|TQH2722 injection matching Placebo|Subjects received 900mg placebo injection subcutaneously on day 1, followed by 450mg placebo injection on days 15, 29, 43, 57, 71, 85, 99.
88959728|NCT05970393|Experimental|Experimental|PMI represents the difference between plateau airway pressure and peak airway pressure (plateau - peak) during an end-inspiratory airway occlusion.
88959729|NCT05970367|Experimental|Intensive rehabilitation program|3 weeks of intensive rehabilitation --> follow-up 9 months standard care
88959730|NCT05970367|No Intervention|Standard care|Follow-up 9 months standard care --> 3 weeks of intensive rehabilitation
88959731|NCT05970315|Experimental|PPC|
88959732|NCT05970315|Active Comparator|Usual Care|
89511803|NCT02277899||Overweight school-age children|"Overweight 6-12 year-old children. Weight status will be measured and parents complete surveys at baseline and one year later. Pediatricians will complete surveys at baseline, and after index visit. Visits will be directly video-recorded.~The impact of pediatrician clinical practices and communication strategies on child's weight status will be evaluated at one year. Clinical practices (such as risk-factor screening) that occur during the 1-year interval between well-child visits also will be assessed. Specific clinical practice elements and communication strategies that will be examined include:~Communication regarding child's high weight status~Counseling regarding cardiovascular risk factor screening and assessment~Behavioral counseling~Interval follow-up to readdress weight, and~Patient-centeredness, scored as the ratio of patient to doctor-centered communication regarding weight topics."
89511804|NCT04320407|Experimental|Osia 2 System|Osia 2 Active Osseointegrated Implant System for Bone Conduction
88959733|NCT05970302|Experimental|XELOX +Bev +Tislelizumab|"Every 3 weeks as a cycle:~Tislelizumab: 200mg, iv, d1;~Bevacizumab: 7.5mg/kg, iv, d1;~Oxaliplatin: 130mg/m2, iv, d1;~Capecitabine: 1000mg/m2, bid, po, d1-d14; Re-evaluate patients every two cycles. If the patient has been treated for more than 8 cycles, they will enter maintenance therapy, and the regimen is capecitabine + BEV combined with tislelizumab."
89511805|NCT00758303|Active Comparator|1|Low Dose TRIA-662
89511806|NCT00758303|Active Comparator|2|High Dose TRIA-662
88959734|NCT05970250|Experimental|Whole body vibration group|In this group (the first study group) fifteen breast cancer patients after receiving chemotherapy within 3-6 months and complaining from osteoporosis were received the whole body vibration, 20 minutes 3 times per week for 2 months and drug therapy (vitamin D supplements and calcium).
88959735|NCT05970250|Experimental|Weight bearing exercises group|In this group (the second study group) fifteen breast cancer patients after receiving chemotherapy within 3-6 months and complaining from osteoporosis were received aerobic exercise on treadmill as form of weight bearing exercise 20 minutes 3 times per week for 2 months and drug therapy (vitamin D supplements and calcium).
88959736|NCT05970250|Other|drug therapy group|In this group (control group) fifteen breast cancer patients after receiving chemotherapy within 3-6 months and complaining from osteoporosis were received only drug therapy (vitamin D supplements and calcium. Measurements were conducted before starting the treatment as a first record, at end of the second month of treatment as second record and make follow up after 3 months as final record.
88959737|NCT05970211|Experimental|Hearing Intervention Group|Adults aged 55-75 with hearing loss who have little/no prior experience with hearing aids will be enrolled in the hearing intervention group.
88959738|NCT05970198|Active Comparator|Autologous hematopoietic stem cell transplantation|Porting method melphalan: recommended dose of 70 mg/m2/day with 2 consecutive days (days -2 and -1) intravenous (IV) for more than 30 minutes each prior to autologous hematopoietic stem cell transplantation (ASCT, day 0).
89024280|NCT01894854|No Intervention|Stem collar|The stem has two versions, one with and one without a collar. This arm will have stems with a collar. The classical Furlong HAC had a collar.
89024281|NCT01894854|Active Comparator|No Stem collar|The stem has two versions, one with and one without a collar. This arm will have stems without a collar. The classical Furlong HAC had a collar.
89511807|NCT00758303|Placebo Comparator|3|Matching Placebo for TRIA-662
89511808|NCT00664625|Experimental|1|"BMS-791325 (100 mg)~or~placebo match for (100 mg)"
89511809|NCT00664625|Experimental|2|"BMS-791325 (300 mg)~or~placebo match for (300 mg)"
89511810|NCT00664625|Experimental|3|"BMS-791325 (900 mg)~or~placebo match for (900 mg)"
89511811|NCT00664625|Experimental|4|"BMS-791325 (potential dose between 10-800 mg)~or~placebo match for (10-800 mg)"
89511812|NCT00663767|Placebo Comparator|Placebo|
89511813|NCT00663767|Experimental|Placebo, ARRY-371797|
89511814|NCT00663767|Experimental|ARRY-371797, Placebo|
89511815|NCT00663767|Experimental|ARRY-371797|
89511816|NCT00663767|Active Comparator|Celecoxib, Placebo|
89511817|NCT00663767|Experimental|Celecoxib, ARRY-371797|
89511818|NCT00662597|Experimental|ASA404|
89511819|NCT00662597|Placebo Comparator|ASA40 Placebo|
89511820|NCT02266888|Experimental|Rituximab Induction|Rituximab (Rituxan®) Induction Therapy Plus Standard of Care Immunosuppression (thymoglobulin induction, tacrolimus or equivalent, mycophenolate mofetil (MMF) or equivalent, and steroids)
89511821|NCT02266888|Placebo Comparator|Placebo Induction|Placebo Induction Therapy Plus Standard of Care Immunosuppression (Thymoglobulin® induction, tacrolimus or equivalent, mycophenolate mofetil (MMF) or equivalent, and steroids)
89511822|NCT00660959|Experimental|Active Comparator|lixivaptan
89511823|NCT00660959|Placebo Comparator|Placebo|placebo
89511824|NCT01641952||Rituximab|Participants who had an inadequate response or intolerance to one anti- tumor necrosis factor (anti-TNF) agent received rituximab (Mabthera) at a dose determined by the investigator, guided by the recommendation in the Summary of Product Characteristics.
89511825|NCT00757757|Experimental|MCS110|
89511826|NCT00660881|Experimental|EMAB|1200 mg epratuzumab given in 2 doses every other week in 12 week treatment cycles.
89511827|NCT02278835|Other|level1|Patients classified in level 1 were randomized in the breathing exercises group or incentive spirometry group
89511828|NCT02278835|Other|level2|Patients classified in level 2 were randomized in the Intermittent Positive Pressure Breathing group or Continuous Positive Airway Pressure group
89511829|NCT02359552|Placebo Comparator|Placebo|"Subjects will be randomized in 1:1 ratio to receive Rasagiline or the matching placebo 24-week double blind treatment.~Subjects will take one 0.5 mg Rasagiline tablet or the matching placebo once a day on Baseline (Day 1) through Week 4. The dose will be titrated up to one 1 mg tablet or the matching placebo once a day starting on Week 5 until the Week 28 (end of treatment visit)."
89511830|NCT02359552|Active Comparator|Rasagiline|"Subjects will be randomized in 1:1 ratio to receive Rasagiline or the matching placebo 24-week double blind treatment.~Subjects will take one 0.5 mg Rasagiline tablet or the matching placebo once a day on Baseline (Day 1) through Week 4. The dose will be titrated up to one 1 mg tablet or the matching placebo once a day starting on Week 5 until the Week 28 (end of treatment visit)."
89540771|NCT05898269|Experimental|EI OCC-Tidal volume challenge-EE OCC-Trendelenburg maneuver|"All enrolled patients will perform the 4 tests following a cross-over design and in a randomized sequence, separated by 1-min wash-out periods with return to hemodynamic baseline values, and concluded with the 500-ml fluid bolus.~There are 24 different possibilities of sequence"
89540772|NCT05898269|Experimental|EI OCC-Tidal volume challenge-Trendelenburg maneuver-EE OCC|"All enrolled patients will perform the 4 tests following a cross-over design and in a randomized sequence, separated by 1-min wash-out periods with return to hemodynamic baseline values, and concluded with the 500-ml fluid bolus.~There are 24 different possibilities of sequence"
89540773|NCT05898269|Experimental|EI OCC-Trendelenburg maneuver-EE OCC-Tidal volume challenge|"All enrolled patients will perform the 4 tests following a cross-over design and in a randomized sequence, separated by 1-min wash-out periods with return to hemodynamic baseline values, and concluded with the 500-ml fluid bolus.~There are 24 different possibilities of sequence"
89540774|NCT05898269|Experimental|EI OCC-Trendelenburg maneuver-Tidal volume challenge-EE OCC|"All enrolled patients will perform the 4 tests following a cross-over design and in a randomized sequence, separated by 1-min wash-out periods with return to hemodynamic baseline values, and concluded with the 500-ml fluid bolus.~There are 24 different possibilities of sequence"
89540775|NCT05898269|Experimental|EI OCC-EE OCC-Trendelenburg maneuver-Tidal volume challenge|"All enrolled patients will perform the 4 tests following a cross-over design and in a randomized sequence, separated by 1-min wash-out periods with return to hemodynamic baseline values, and concluded with the 500-ml fluid bolus.~There are 24 different possibilities of sequence"
89540776|NCT05898269|Experimental|EI OCC-EE OCC-Tidal volume challenge-Trendelenburg maneuver|"All enrolled patients will perform the 4 tests following a cross-over design and in a randomized sequence, separated by 1-min wash-out periods with return to hemodynamic baseline values, and concluded with the 500-ml fluid bolus.~There are 24 different possibilities of sequence"
89540777|NCT05898269|Experimental|Tidal volume challenge-EI OCC-EE OCC-Trendelenburg maneuver|"All enrolled patients will perform the 4 tests following a cross-over design and in a randomized sequence, separated by 1-min wash-out periods with return to hemodynamic baseline values, and concluded with the 500-ml fluid bolus.~There are 24 different possibilities of sequence"
89540778|NCT05898269|Experimental|Tidal volume challenge-EI OCC-Trendelenburg maneuver-EE OCC|"All enrolled patients will perform the 4 tests following a cross-over design and in a randomized sequence, separated by 1-min wash-out periods with return to hemodynamic baseline values, and concluded with the 500-ml fluid bolus.~There are 24 different possibilities of sequence"
89207134|NCT00289783|Experimental|Menhibrix Group|Subjects were primed with 3 doses of Menhibrix vaccine Lot A, B or C co-administered with Pediarix and boosted with 1 dose of Menhibrix vaccine, with co-administration of M-M-R II and Varivax. Subjects received vaccination at approximately 2, 4, 6 months and the fourth dose at 12-15 months of age. Menhibrix and Pediarix vaccines were administered intramuscularly in the right or left upper thigh, respectively. M-M-R II and Varivax vaccines were administered subcutaneously respectively in the upper left arm and the upper right arm.
89207135|NCT00289783|Active Comparator|ActHIB Group|Subjects were primed with 3 doses of ActHIB co-administered with Pediarix and boosted with 1 dose of PedvaxHIB, with co-administration of M-M-R II and Varivax. Subjects received vaccination at approximately 2, 4, 6 months and the fourth dose at 12-15 months of age. ActHIB, PedvaxHIB vaccines were administered intramuscularly in the right upper thigh and Pediarix vaccine in the left upper thigh. M-M-R II and Varivax vaccines were administered subcutaneously respectively in the upper left arm and the upper right arm.
88810933|NCT05042882|Experimental|Early enteral nutrition|Intervention group: enteral nutrition from the first postoperative night until 50% of caloric requirements are covered by oral nutrition. Enteral nutrition will start at a flow of 250 ml/12h. If tolerated, enteral nutrition will be increased to 500 ml/12h on postoperative day 1, 750 ml/12h on postoperative day 2, and 1000 ml/12h on postoperative day 3. A hypercaloric enteral nutrition will be used (Isosource Energy Fibre or similar).
88959739|NCT05970198|Experimental|Radiotherapy combined with autologous hematopoietic stem cell transplantation|"TMI radiation dose On the 5th day (-5 days) before transplantation, an irradiation dose of 8 Gy is given.~TMI uses a 6-18MV linear accelerator, the patient lies on his side in a single irradiation field, covered with a 1 cm thick plexiglass frame, and the radioactive source is 4 meters away from the body surface of the human side. The anterior and anterior positions were alternately irradiated, and the horizontal beam was irradiated in the opposite direction, and the actual irradiation dose was detected by the thermo-optical element of the 2570 roentgen dosimeter scale, and the irradiation dose of all parts of the body was adjusted to make the abdominal irradiation dose difference within 10%, the total dose was 8Gy, divided into 2 times a day, with an interval of 5 hours, and the dose rate was 4.99-6.96cGy/min.Porting method melphalan."
88959740|NCT05970133|Experimental|Laparoscopic surgery|The patients in this group will undergo laparoscopic surgery.
88959741|NCT05970133|Active Comparator|Robotic surgery|The patients in this group will undergo robotic surgery.
88959742|NCT05970055||PONV and Non PONV|PONV- patients who developed nausea and vomiting postoperatively Non PONV- patients who did not develop nausea and vomiting postoperatively
88959743|NCT05970029|Experimental|Enhanced communication|"In the enhanced communication study arm the nurse will say to the patient: I will now give you our first line analgesic medication, liquid Dipyrone. It is a very efficient treatment and based on my experience you will very soon feel significant pain relief."
89207136|NCT00851526||Coronary bifurcation lesion|
89540779|NCT05898269|Experimental|Tidal volume challenge-Trendelenburg maneuver-EE OCC- EI OCC|"All enrolled patients will perform the 4 tests following a cross-over design and in a randomized sequence, separated by 1-min wash-out periods with return to hemodynamic baseline values, and concluded with the 500-ml fluid bolus.~There are 24 different possibilities of sequence"
89511831|NCT05647720|Experimental|Third molar extraction group|After surgical extraction of unerupted upper third molars, the maxillary first molars were distalized using the infra-zygomatic gear distalizer, which is anchored to infra-zygomatic mini-implants inserted in the infra-zygomatic crest.
88959744|NCT05970029|Other|Normal communication|In the normal communication study arm the communication between the nurse and patients will be as usual in clinical practice - i.e. - no instruction are given to the nurses regarding on how to communicate with patients while administrating the treatment.
88959745|NCT05969990||case group|100 children with migraine are included into case group and we will collect the blood of them to investigate tryptophan metabolites plasma concentration
88959746|NCT05969990||control group|100 healthy children are included into control group and we will collect the blood of them to investigate tryptophan metabolites plasma concentration
88959747|NCT05969977|Experimental|PPI-1011|Single Ascending: PPI-1011 at 10, 25, 50, 75 and 100 mg/kg. Multiple Dose: PPI-1011 dose to be based on SAD; duration 14 days; one dose daily.
88959748|NCT05969977|Placebo Comparator|Placebo|Placebo arm.
88959749|NCT05969951||New scoring mode group|Patients were evaluated for VTE risk in the perioperative period using a new scoring system
89511832|NCT05647720|Experimental|Third molar presence group|Without extraction of unerupted upper third molars, the maxillary first molars were distalized using the infra-zygomatic gear distalizer, which is anchored to infra-zygomatic mini-implants inserted in the infra-zygomatic crest.
89511833|NCT02280005|Experimental|WAK Treatment|Use of experimental device.
89511834|NCT02280083|Experimental|Botulinum Toxin Type A for Injection|"HengLi002(Botulinum Toxin Type A for Injection,also known as HengLi®)"
89511835|NCT02280083|Placebo Comparator|placebo|excipient
89511836|NCT00752297|Active Comparator|1|Mentor Purified Toxin Botulinum Toxin Type A
89511837|NCT00752297|Placebo Comparator|2|Preservative-free Saline
89511838|NCT04472273||high-flow nasal cannula group|Group 1
89511839|NCT04472273||classic nasal cannula group|Group 2
89511840|NCT00656357|Placebo Comparator|A|SYN117 placebo and Ascending doses of cocaine (10, 20, 40 mg) and placebo
89511841|NCT00656357|Experimental|B|Ascending doses of SYN117 (placebo, 80 mg, 160 mg) and ascending doses of cocaine (10 mg, 20 mg, 40 mg) and placebo
89511842|NCT02280395|Experimental|RUT058-60|
89511843|NCT02280395|Placebo Comparator|Sterile Saline for Irrigation|
89511844|NCT00747929|Placebo Comparator|S-2367 Placebo|Placebo + reduced calorie diet
89511845|NCT00747929|Experimental|S-2367 800 mg|S-2367 800 mg q.d. + reduced calorie diet
89511846|NCT00747929|Experimental|S-2367 1600 mg|S-2367 1600 mg q.d. + reduced calorie diet
89511847|NCT02280551||Adolescents|1927 Grade 7 high school students
89511848|NCT02280551||Parent|A parent of each of the 1927 Grade 7 high school students
89511849|NCT00744731|Experimental|001|placebo placebo for 1 week
89511850|NCT00744731|Experimental|002|carisbamate 400 mg/day to 1,200 mg per day
89511851|NCT02280629|Experimental|LT-02|LT-02 1.6g twice daily AND mesalamine PLACEBO three-times daily
89511852|NCT02280629|Placebo Comparator|Placebo|LT-02 PLACEBO twice daily AND mesalamine PLACEBO three-times daily
89540780|NCT05898269|Experimental|Tidal volume challenge-Trendelenburg maneuver- EI OCC-EE OCC|"All enrolled patients will perform the 4 tests following a cross-over design and in a randomized sequence, separated by 1-min wash-out periods with return to hemodynamic baseline values, and concluded with the 500-ml fluid bolus.~There are 24 different possibilities of sequence"
88959750|NCT05969951||Caprini group|Patients were evaluated for VTE risk in the perioperative period using Caprini scoring system
88959751|NCT05969938||Treatment group|A total of 50 patients with stage II-III rectal cancer who plan to receive neoadjuvant chemoradiotherapy between the ages of 18-75 years old, and these patients have no distant metastasis, normal main organ function, and can receive long-term follow-up. simultaneously, these patients are required to provide sufficient ' colonoscopy collection ' tumor tissue samples for MRD customization, and sufficient whole blood samples are required for baseline MRD detection.
88959752|NCT05969899|Other|FOLFIRI+BEV|
89207137|NCT00840528|Experimental|Ozone exposure|Exposure to ozone at 0.4ppm
89207138|NCT00851604||1|Patients with malignant neuroendocrine tumors
89511853|NCT02280629|Active Comparator|Mesalamine|LT-02 PLACEBO twice daily AND 500mg mesalamine PLACEBO three-times daily
89511854|NCT03134573||Multiple Sclerosis|Women and men in Germany with the diagnosis of MS that are treated with Betaferon and use the myBETAapp
89511855|NCT00743795|Placebo Comparator|1|Peginterferon and ribavirin + placebo BID for 48 weeks + 24 weeks treatment-free follow-up (n = 50)
89511856|NCT00743795|Experimental|2|Peginterferon and ribavirin + GS 9190 40 mg BID for 48 weeks + 24 weeks treatment-free follow-up (n = 100)
89511857|NCT00743795|Experimental|3|Peginterferon and ribavirin + GS 9190 40 mg BID for 48 weeks + 24 weeks treatment-free follow-up. However, subjects who achieve RVR (HCV RNA undetectable at Week 4) and maintain that response through Week 24 will stop all study drugs at Week 24 and be followed for an additional 48 weeks (n = 50).
89511858|NCT04232033|Active Comparator|Fibroblast growth factor 21 infusion|Fibroblast growth factor 21 infusion
89511859|NCT04232033|Placebo Comparator|Placebo infusion (saline)|Saline infusion
89511860|NCT03134417|Experimental|Vitamin D and magnesium|Daily oral vitamin D (1000 IU) and magnesium (360 mg) supplement
89511861|NCT03134417|Active Comparator|Vitamin D|Daily oral vitamin D (1000 IU) supplement
89511862|NCT03134417|Placebo Comparator|Placebo|Daily oral placebo (cellulose)
89511863|NCT03135041|Experimental|Fiber-containing dietary supplement|2 x 200 ml of fiber-enriched UHT milk during 12 weeks of energy restriction
89511864|NCT03135041|Placebo Comparator|Placebo|2 x 200 ml of UHT milk with maltodextrin during 12 weeks of energy restriction
89511865|NCT03134261|Other|SPECT-CT|The participants will undergo two project scans: WB-MRI and SPECT-CT
89511866|NCT03134261|Other|Cholin-PET-CT|The participants will undergo two project scans: WB-MRI and Cholin-PET-CT
89511867|NCT03134261|Other|PSMA-PET-CT|The participants will undergo two project scans: WB-MRI and PSMA-PET-CT
89511868|NCT00649025|Experimental|1|FlutiForm 250/10ug
89511869|NCT00649025|Active Comparator|2|SKP Fluticasone 250ug
89511870|NCT00649025|Active Comparator|3|Flovent Fluticasone HFA
89511871|NCT02743793||Operationally Tolerant Kidney or Liver Allograft Recipients|"Operational tolerance at baseline is defined as:~An absence of any immunosuppressive therapy for ≥ 52 weeks prior to the screening visit;~No evidence of allograft rejection in the 52 weeks prior to the screening visit (Day 0), based on the participant's medical history; and~Normal and stable allograft function at screening visit defined as-~For liver transplant recipients: Liver function tests (ALT, GGT) both less than or equal to the upper limit of normal (ULN)~For kidney transplant recipients: Serum creatinine value corresponds to an estimated glomerular filtration rate (GFR) > 45 ml/min/1.73 m^2."
89511872|NCT00647231|Experimental|A, 2, II, HKT-500 Topical Patch|A Randomized, Multicenter, Double-Blind, Single Dose Study of the Analgesic Properties of HKT-500 and Placebo in Subjects With Pain Caused by Mild to Moderate Osteoarthritis of the Knee
89511873|NCT00647231|Placebo Comparator|Placebo Patch|Treatment with placebo patch
89511874|NCT00739739|Experimental|PD 0299685 15mg|
89511875|NCT00739739|Experimental|PD 0299685 30mg|
89511876|NCT00739739|Placebo Comparator|Placebo|
89511877|NCT00739349|Experimental|1|Cyclosporine 0.05%
89511878|NCT00739349|Experimental|2|Cyclosporine 0.1%
89511879|NCT00739349|Placebo Comparator|3|vehicle/placebo
89511880|NCT00627419|Experimental|1|IPI-504
89511881|NCT00152009|Experimental|SPD503 (Guanfacine HCl) (2 mg)|
89511882|NCT00152009|Experimental|SPD503 (3 mg)|
89511883|NCT00152009|Experimental|SPD503 (4 mg)|
89511884|NCT00152009|Placebo Comparator|Placebo|
89511885|NCT04182035|Experimental|Patient-tailored treatment group|Objectives & approach: The subjects in the PTT group will receive the individual tailored treatment program combining best evidence active and passive treatment strategies (manual therapy, individual exercises) in combination with education tailored to the individual situation of the patient and selected home exercises. 9 individual therapy sessions will be performed, in combination with 9 additional home exercise sessions.. NRS and NDI-scores will be monitored before every treatment. The therapist will register when the cut-off score of 30% NDI reduction is present in order to determine the evolution in pain/disability reduction. The importance of self-efficacy will be emphasized and tailored home-exercises will be monitored and adjusted every week.
89511886|NCT04182035|Active Comparator|Non patient-tailored treatment group|Objectives & approach: The NPTT will receive an individual (hands-off) treatment, which includes an active neck exercise program, non-tailored education and non-tailored home exercises, according to a previously published program with good results.53 The sessions will be performed once a week under supervision (9 therapy sessions, standard exercise program) and once a week by the patient at home (9 home exercise sessions, standard exercise program).
89511887|NCT04182035|No Intervention|Control group|The subjects randomized to the control group will not receive any intervention, if necessary medication use is permitted and will be monitored using the iMTAQ. Patients will be asked not to seek other treatment options (if possible). If this is not possible, patients will be considered lost to follow-up.
89511888|NCT02280707|Experimental|Intervention|
89511889|NCT02280707|No Intervention|Control|
89511890|NCT04473131||COVID-19 positive|"Inclusion criteria:~Male or female aged over 18 years~Admitted patients to ICU with a suspicious COVID19 infection~Tested positive for SARS-CoV-2~Exclusion criteria:~Burn and trauma~Any immunological diseases, or immunosuppressive medications~Other immune-related conditions (cancer, hematological malignancies, bone marrow diseases or transplant)~Sample collection time points: 4 to 5 (day 1-3, day 7, day 14, day 21, discharge day from ICU -between day 30-60- if possible)"
89511891|NCT04473131||COVID-19 negative|"Inclusion criteria:~Male or female aged over 18 years~Admitted patients to ICU~Tested negative for SARS-CoV-2~Exclusion criteria:~Burn and trauma~Any immunological diseases, or immunosuppressive medications~Other immune-related conditions (cancer, hematological malignancies, bone marrow diseases or transplant)~Sample collection time points: 4 to 5 (day 1-3, day 7, day 14, day 21, discharge day from ICU -between day 30-60- if possible)"
89511892|NCT04473131||Heathy volunteers|"Inclusion criteria:~Male or female aged over 18 years~Normal clinical examination~Exclusion criteria:~Person with an infectious syndrome during the last 90 days~Extreme physical stress within the last week~Person receiving within the last 90 days, a treatment based on: antivirals; antibiotics; antiparasitics; antifungals; non-steroidal anti-inflammatory drugs; immunosuppressive therapy; corticosteroids; therapeutic antibodies; chemotherapy~Person with history of: innate or acquired immune deficiency; hematological disease; solid tumor; severe chronic disease; surgery or hospitalization within the last 2 years; pregnancy within the last year; participation to a phase I clinical assay during the last year; participation to a phase I clinical assay during the last year; pregnant or breastfeeding women; a person with restricted liberty or under legal protection~Sample collection time points: 1 (day of blood sample donation)"
89511893|NCT02280785|Experimental|Brentuximab vedotin|"Brentuximab vedotin administered in 250ml of 0.9% saline by intravenous infusion over 30 minutes once every 3 weeks.~In the absence of infusion toxicities, the infusion rate for all patients must be calculated in order to achieve a 30-minute (approximate) infusion period.~Brentuximab Vedotin is dosed at 1.8mg/kg (capped at 100kg of body weight). Dosing is based on patients' weight according to the institutional standard; however, doses will be adjusted for patients who experience a ≥ 10% change in weight from baseline. Actual weight will be used except for patients weighing greater than 100 kg; dose will be calculated based on 100 kg for these individuals. The dose will be rounded to the nearest whole number of milligrams."
89511894|NCT02280941|Experimental|Single photon emission computed tomography|Myocardial blood flow (MBF) measurement will be analyzed using attenuation and scatter corrected dynamic single photon emission computed tomography (SPECT) imaging data. The data will be compared to MBF obtained from positron emission tomography (PET) imaging.
89511895|NCT04096937||Appalachian adults|Adults in Appalachia invested in well-being of youth.
89511896|NCT04096937||Appalachian youth|Youth from 7th through 12th grade.
89024282|NCT01854554|Experimental|Intensity Modulated Proton Radiotherapy (IMPT)|IMPT treatments delivered as once daily fractions, 5 days per week Monday - Friday for 30 treatments.
89024283|NCT01854554|Experimental|Intensity Modulated Radiotherapy (IMRT)|IMRT treatments delivered as once daily fractions, 5 days per week Monday - Friday for 30 treatments.
89024284|NCT01817959|Experimental|Reparixin group|Continuous iv infusion
89024285|NCT01817959|Placebo Comparator|Placebo group|Continuous iv infusion
88959753|NCT05969873|Experimental|Pilates Group|In this group patients will be treated with physical therapy treatment pilates exercise. Group A underwent 45 minutes of Pilates exercises in addition to the identical exercise programme as group A to improve the strength, coordination and flexibility of the lower limbs. Pilates movements were carried out ten times, with a two-minute break in between each repetition. For six weeks, both groups participated in the intervention programme three times per week. Starting the programme off with supine exercises of segmental motions that include using the trunk muscles to maintain a neutral posture is normal. To enhance shoulder girdle control, supine arm workouts were gradually added. The spine's ability to flex and extend was steadily increased.
88959754|NCT05969873|Active Comparator|Balance training group|In this group patients will be treated with PT treatment with balance training. Exercises for stability of posture on numerous surfaces and positions were performed by Group B, including exercises for the flexors and adductors of hip, flexors and extensors of knee, and calf muscle (15-second hold and five repetitions) for improving their flexibility. The lower extremity and trunk muscles were the focus of Group B. The postural control exercise included walking in every direction, moving past the point of stability in various postures like half-kneeling, standing on hard and soft surfaces, stepping down and up, walking and standing at the same time, and one leg standing with eyes open and closed. Each session started with a 5-minute warm-up and ended with a 5-minute cool-down in between each phase.
89511897|NCT04473209|Active Comparator|diabetic group|diabetic patients with chronic periodontitis
88959755|NCT05969847|Experimental|split-course hypofraction radiotherapy plus CAPOX and Envafolimab followed by local excision|"Patients diagnosed with locally advanced very low rectal cancer were chosen to undergo a total neoadjuvant therapy (TNT) regimen. This regimen consisted of preoperative fractionated radiotherapy (5×7Gy) combined with 6 cycles of CAPOX chemotherapy and enverolimab.~For patients who achieved clinical complete response (cCR) or near-clinical complete response (ncCR) after TNT, an organ-preserving strategy involving local full-thickness resection was implemented. Patients who achieve non-clinical complete response are subjected to traditional TME surgery."
88959756|NCT05969834||uHCG group|Trigger intramuscular (IM) administration of 10000 IU of uHCG
88959757|NCT05969834||rHCG group|Trigger with subcutaneous (SC) administration of 6500 IU of rHCG
88959758|NCT05969834||Dual trigger group|Combined SC administration of 0.1 mg of GnRHa and IM administration of 2500 IU of uHCG
88959759|NCT05969782||Endurant II|Patients with aortoiliac aneurysm submitted to EVAR with Endurant II.
88959760|NCT05969782||Zenith|Patients with aortoiliac aneurysm submitted to EVAR with Zenith.
89511898|NCT04473209|Active Comparator|non-diabetic group|non diabetic patients with chronic periodontitis
89511899|NCT02281019||Indeterminate strictures or undefined filling defects|
89511900|NCT02281019||Biliary stone cases|
89511901|NCT02281019||Other indications|
89511902|NCT02281253|Experimental|With metabolic syndrome|Before dietary therapy was initiated, in order to stabilise dietary patterns prior to intervention, patients were submitted to a 4-weeks run-in period of a caloric restriction of 500 Kcal to their usual diet. After this adaptation period, two intervention groups were evaluated: a calorie-restricted diet plus bread-enriched product that received 15.08 g of dietary fibre (9.49 g of insoluble fibre and 5.59 g of soluble fibre) plus 2325 mg of L-carnitine/day in 130 g of bread (enriched group) and a calorie-restricted diet plus placebo bread group whose diet included 130 g/day of not-enriched bread (placebo group).
89511903|NCT02281253|Experimental|Without metabolic syndrome|Before dietary therapy was initiated, in order to stabilise dietary patterns prior to intervention, patients were submitted to a 4-weeks run-in period of a caloric restriction of 500 Kcal to their usual diet. After this adaptation period, two intervention groups were evaluated: a calorie-restricted diet plus bread-enriched product that received 15.08 g of dietary fibre (9.49 g of insoluble fibre and 5.59 g of soluble fibre) plus 2325 mg of L-carnitine/day in 130 g of bread (enriched group) and a calorie-restricted diet plus placebo bread group whose diet included 130 g/day of not-enriched bread (placebo group).
89511904|NCT00734435|Active Comparator|1|Zonisamide SR 360 mg and olanzapine 10-20 mg daily
89511905|NCT00734435|Placebo Comparator|2|Placebo and olanzapine 10-20 mg daily
89511906|NCT02281331|Active Comparator|Supplement|Each day, participants in this group will receive a supplement that provides a total of protein, creatine monohydrate, calcium, vitamin D and carbohydrate. This supplement will be provided to participants in beverage format, twice daily.
89511907|NCT02281331|Placebo Comparator|Placebo|The placebo will provide participants with maltodextrin (carbohydrate) and sucrose.
89511908|NCT00624845|Experimental|Drug|
89511909|NCT00624845|Placebo Comparator|Vehicle|
89511910|NCT00728351|Experimental|vildagliptin + metformin|
89511911|NCT00728351|Active Comparator|metformin|
89511912|NCT00622193|Experimental|1 Active 50 mg|
89511913|NCT00622193|Experimental|2 Active 100 mg|
89511914|NCT00622193|Placebo Comparator|3 Placebo|
89511915|NCT00616811|Experimental|Vildagliptin|
89511916|NCT00616811|Active Comparator|Sitagliptin|
89511917|NCT02265952|Experimental|Open-label|Open-label REGN1500
89511918|NCT00615251|Experimental|1|
89511919|NCT00615251|Active Comparator|2|
89511920|NCT03946397|Experimental|Multisensory massage|
89511921|NCT03946397|No Intervention|Control|
89511922|NCT00614705|Experimental|1|
89511923|NCT00614705|Placebo Comparator|2|
89511924|NCT02265796|Active Comparator|Ranolazine|"Ranolazine 500 mg tablets~500mg tablet two times per day for 7 days then,~500mg tablet (1000mg) two times per day for 15 weeks"
89511925|NCT02265796|Placebo Comparator|Sugar pill|"Sugar pill that looks like the drug ranolazine 500mg tablet~500mg tablet two times per day for 7 days then,~500mg tablet (1000mg) two times per day for 15 weeks"
89511926|NCT05647642||low dose midazolam|0,025 mg/kg Midazolam
89024287|NCT01781728|Active Comparator|RT naive|
89024288|NCT01781728|Active Comparator|Previous RT|
89511927|NCT05647642||high dose midazolam|0,05 mg/kg Midazolam
89024289|NCT01755195|Experimental|Cabozantinib|60 mg tablets orally once a day in a 28-day cycle.
89024290|NCT01697384|Experimental|one histrelin acetate 50 mg implant|The test product was a histrelin acetate 50 mg hydrogel implant surgically placed subdermally into the inner aspect of the upper arm.
89024291|NCT01637987|Active Comparator|Unassisted vein visualization|The traditional technique of vein visualization and palpation will be used to identify veins during peripheral intravenous line (PIV) insertion procedures. This involves the use of a tourniquet to facilitate venous pooling to see the vein and prevent vein rupture during cannulation. Nurse may use heat application to facilitate vein identification.
89024292|NCT01637987|Active Comparator|Wee Sight Transilluminator|The Wee Sight® Transilluminator (Philips Children's Medical Ventures, Monroeville, PA) is a hand held, non-heat producing, light emitting diode (Class 2), battery operated device. The device assists in vein identification by being held adjacent to or under the subject's extremity to visualize the venous anatomy superficial veins absorb light and appear as dark lines against the surrounding illuminated tissues. This will be used to identify veins during peripheral intravenous line (PIV) insertion procedures.
89024293|NCT01637987|Active Comparator|Near Infra-red light (VeinViewer)|VeinViewer near infrared light views hemoglobin up to 10 mm beneath skin. Hemoglobin absorbs the light while surrounding tissue scatters it providing a suitable contrast between the vein & surrounding subcutaneous tissue. This data is captured, digitally processed by video camera, and projected back onto the skin as a visual image of venous anatomy. This will be used to identify veins during peripheral intravenous line (PIV) insertion procedures.
89024294|NCT01604512|Experimental|Pts with a brain tumor|The study will prospectively enroll patients who have increasing size and/or enhancement of brain lesion(s) after brain radiation therapy for a neoplasm (either primary or metastatic), where. it is unclear if a lesion represents radiation injury or progressive tumor. At the discretion of PI the RSI sequence may be repeated at SOC FDG or other radiotracer imaging carried out while the patient is still on study, if deemed clinically necessary.
89024295|NCT01541709|Experimental|Imatinib|
89024296|NCT01508897|Experimental|Phase 2 formulation|
89511928|NCT05647642||low dose dexmedetothymidine|0.5 mg/kg dexmedetothymidine 10 minute infusion
89511929|NCT05647642||high dose dexmedetothymidine|1mg/kg dexmedetothymidine 10 minute infusion
89511930|NCT04873726|No Intervention|Pre: pain AP|Pain assessment in the spinous processes of the spine with algometer anteroposterior pressure
89511931|NCT04873726|No Intervention|Pre: pain Pinch test|perceived pain over the paravertebral skin at each level of the spine using Pinch test
89511932|NCT04873726|No Intervention|Pre: pupil diameter|the pupil responses were measured with the fully automated Vorteq® system (Micromedical Technologies, Inc) to record the pupil reaction.
89511933|NCT04873726|Experimental|Post Exp: pain AP|Pain assessment in the spinous processes of the spine with algometer anteroposterior pressure
89511934|NCT04873726|Experimental|Post Exp: pain Pinch test|perceived pain over the paravertebral skin at each level of the spine using Pinch test
89511935|NCT04873726|Experimental|Post Exp: pupil diameter|the pupil responses were measured with the fully automated Vorteq® system (Micromedical Technologies, Inc) to record the pupil reaction.
89511936|NCT04873726|Placebo Comparator|Post Pla: pain AP|Pain assessment in the spinous processes of the spine with algometer anteroposterior pressure
89511937|NCT04873726|Placebo Comparator|Post Pla: pain Pinch test|perceived pain over the paravertebral skin at each level of the spine using Pinch test
89511938|NCT04873726|Placebo Comparator|Post Pla: pupil diameter|the pupil responses were measured with the fully automated Vorteq® system (Micromedical Technologies, Inc) to record the pupil reaction.
89511939|NCT02357368|Experimental|Depot medroxyprogesterone acetate (DMPA)|DMPA will be administered every 12 weeks at 150 mg by intramuscular (IM) injection at week 3 of study enrollment and repeated at week 15.
89511940|NCT02357368|Experimental|Etonogestrel implant (Eng-Implant)|A standard Nexplanon rod Implant will be placed at study week 3.
89511941|NCT02357368|Experimental|Levonorgestrel intrauterine device (Lng-IUD)|A standard Mirena IUD will be placed at study week 3.
89511942|NCT02357368|Experimental|ParaGard® T 380A Intrauterine Copper Contraceptive|A standard ParaGuard IUD will be placed at study week 3.
89511943|NCT05647486||EVAR|Patients with AAA, treated electively by EVAR. The 30-day postoperative outcome after elective EVAR and the role of possible predictors among patients' baseline characteristics were assessed.
89511944|NCT04873570|Experimental|Test Group|Subjects will be given one Mofest® 400mg (Moxifloxacin HCl) Tablet (1x400mg) manufactured by SAMI Pharmaceuticals (Pvt.) after at least 10 hours fast together with 240 mL of ambient temperature water at their scheduled dosing time-point. Blood samples will be taken up to 72.0 hours post-dose.
89511945|NCT04873570|Active Comparator|Reference Group|Subjects will be given one Avelox® 400mg (Moxifloxacin HCl) Tablet (1x400mg), manufactured by Bayer HealthCare, after at least 10 hours fast together with 240 mL of ambient temperature water at their scheduled dosing time-point. Blood samples will be taken up to 72.0 hours post-dose.
89511946|NCT05647408|Active Comparator|Intravenously DMX|Male and female volunteers received one dose of DXM. Drugs formulations employed were DXM phosphate injectable solution 8 mg/2 mL (Alin, Productos Farmaceuticos, Mexico). The drug was administered to 4 subjects intravenously (treatment A) according to a randomization list generated prior to the start of the clinical phase.
89511947|NCT05647408|Active Comparator|Intranasally DMX|Male and female volunteers received one dose of either DXM Drugs formulations employed were DXM phosphate injectable solution 8 mg/2 mL (Alin, Productos Farmaceuticos, Mexico). The drug was administered to 4 healthy subjects intranasally (treatment B). According to a randomization list generated prior to the start of the clinical phase.
89540781|NCT05898269|Experimental|Tidal volume challenge-EE OCC-Trendelenburg maneuver- EI OCC|"All enrolled patients will perform the 4 tests following a cross-over design and in a randomized sequence, separated by 1-min wash-out periods with return to hemodynamic baseline values, and concluded with the 500-ml fluid bolus.~There are 24 different possibilities of sequence"
89540782|NCT05898269|Experimental|Tidal volume challenge-EE OCC- EI OCC-Trendelenburg maneuver|"All enrolled patients will perform the 4 tests following a cross-over design and in a randomized sequence, separated by 1-min wash-out periods with return to hemodynamic baseline values, and concluded with the 500-ml fluid bolus.~There are 24 different possibilities of sequence"
89540783|NCT05898022|Other|N-of-1 Trial|Each individual N-of-1 trial will have 2 blocks. In each block patients will crossover between furosemide (plus potassium chloride) for 1 week and placebo (plus placebo electrolyte solution) for 1 week. The total arm length (length of the N-of-1 Trial/Crossover) is 28 days. Patients may receive furosemide (plus potassium chloride) and placebo (plus placebo electrolyte solution) in one of four different treatment order sequences, however, treatment order will not be analyzed for the primary outcomes of feasibility/responder status.
89540784|NCT05893888|Experimental|Open-Label, Single Arm Study of PRV211|PRV211 treatment application during standard of care tumor resection surgery. PRV211 system is comprised of two parts, a liquid permeation enhancer (PE) and cisplatin patch. The permeation is brushed onto the resected tumor bed and after 5 minutes the patch can be applied directly over the same area. Apply up to 2 layers of the PRV211 system to the tumor bed post-resection. The duration of the PRV211 treatment takes approximately 10-20 minutes and then the surgeon can continue as planned with the rest of the standard of care procedure. The proposed starting dose is 0.5 mg/cm2 of cisplatin on the tumor bed. This approach can be safe and effective in preventing locoregional recurrence after surgery and eliminating high-risk factors for local recurrence, such as dysplasia at the margins.
89540785|NCT05889286||Arm A: Symptomatic patient cohort|Arm A will consist of 20 patients who have suspected prosthetic infection and who are scheduled to undergo surgery debridement/removal.
89540786|NCT05889286||Arm B: Asymptomatic patient cohort|Arm B will consist of 10 asymptomatic normal control patients who have remotely placed total knee prosthesis without clinical or laboratory evidence of infection per inclusion criteria.
89540787|NCT05884957|Active Comparator|Patients Group (Nitric oxide Assesment)|Assessment of nitric oxide synthase gene polymorphism in diabetic patients with erectile dysfunction in 30 patients
89540788|NCT05884957|Placebo Comparator|Control Group|10 healthy people without erectile dysfunction
89540789|NCT05867225|Experimental|Biosynthetic absorbable mesh|Patients who have undergone hiatal surgery with use of a biosynthetic absorbable mesh
89540790|NCT05867225|Sham Comparator|No biosynthetic absorbable mesh|Patients who have undergone hiatal surgery without use of a biosynthetic absorbable mesh
89540791|NCT05845840|Experimental|BRII-297|Participants will receive a BRII-297 by Intramuscular injection
89540792|NCT05845840|Placebo Comparator|Placebo|Participants will receive placebo by Intramuscular injection
89540793|NCT05844735|Experimental|Part I SAR441566 Dose A|Participants will receive repeated low dose of SAR441566 for 7.5 days
89540794|NCT05844735|Experimental|Part I SAR441566 Dose B|Participants will receive repeated high dose of SAR441566 for 7.5 days
89540795|NCT05844735|Placebo Comparator|Part I Placebo|Participants will receive repeated SAR441566 matching placebo tablets for 7.5 days
89540796|NCT05844735|Active Comparator|Part II Ciprofloxacin|Participants will receive repeated ciprofloxacin 500 mg twice-daily (BID) for 5.5 days
89540797|NCT05844150|Experimental|PM8002+Etoposide＋platinum|Subjects will be administered with PM8002 plus Etoposide and platinum via intravenously (IV) Q3W for 4 cycles, followed by PM8002 until progression or for a maximum of 2 years.
89540798|NCT05844150|Active Comparator|Atezolizumab+Etoposide＋platinum|Subjects will be administered with Atezolizumab plus Etoposide and platinum via intravenously (IV) Q3W for 4 cycles, followed by Atezolizumab until progression or for a maximum of 2 years.
89540799|NCT05841706|Experimental|Arm I (Transfusion for Hgb less than 7 g/dL)|Patients undergo red blood cell transfusion if Hgb is less than 7 g/dL while on study. Patients undergo CT scan, x ray imaging, and blood sample collection throughout the study.
89540800|NCT05841706|Experimental|Arm II (Transfusion for Hgb less than 9 g/dL)|Patients undergo red blood cell transfusion if Hgb is less than 9 g/dL while on study. Patients undergo CT scan, x ray imaging, and blood sample collection throughout the study.
89540801|NCT05840250|Experimental|Continuous Glucose Monitoring and Education Support Group|Participants will be provided with a device to monitor their blood glucose (Abbott Free Style Libre2 Flash CGM system) along with educational materials to better understand and manage their diabetes and other supporting services. Pre and post intervention surveys will be implemented. Participants will be closely monitored for 3 months and then followed up for 3 more months for a total of 6-month participation.
89540802|NCT05838573|Experimental|Metformin group|The goal is to investigate whether adding metformin will benefit the cognitive impairment in individuals with schizophrenia.
89540803|NCT05838573|Placebo Comparator|Placebo group|The purpose of using placebo is to judge if the outcome is related to the study medication rather than other reasons.
88959761|NCT05969743|Experimental|Letermovir|Patients meeting the inclusion criteria will receive letermovir 480 mg per day. Patients receiving concomitant cyclosporine will receive 240 mg of letermovir. Letermovir will be given during 14 weeks or until prednisone dose is reduced below 0.2 mg / kg / day, whichever comes earlier.
88959762|NCT05969717|Experimental|GD-iExo-001 treatment|Group1 (low-dose group), 8 papatients are treated with 10 μg/mL GD-iExo-001. Group2 (high-dose group), 8 papatients are treated with 50 μg/mL GD-iExo-001. One drop (about 50 μL) of GD-iExo-001 was given to the affected skin area of 2-4 cm2 for 14 consecutive days, twice per day.
88959763|NCT05969717|Placebo Comparator|Normal saline control|Group1 (low-dose group), 2 papatients are treated with normal saline. Group2 (high-dose group), 2 papatients are treated with normal saline. One drop (about 50 μL) of normal saline was given to the affected skin area of 2-4 cm2 for 14 consecutive days, twice per day.
88959764|NCT05969639|Experimental|Intervention|The HEYA program is a 12-week app-delivered psychoeducational program that comprises of nutrition education, skills training on self-regulation, and weekly feedback.
88959765|NCT05969639|No Intervention|Control|
88959766|NCT05969613|Experimental|Regional Block|Bupivacaine 0.25%
88959767|NCT05969613|Active Comparator|Wound infilteration|Bupivacaine 0.25%
88959768|NCT05969613|Active Comparator|caudal block|Bupivacaine 0.25%
88959769|NCT05969600||relapse group|
88959770|NCT05969600||non-relapse group|
88959771|NCT05969561|Active Comparator|Ultrasound-guided femoral nerve block|Patients with hip fractures had underwent Ultrasound-guided femoral nerve block performed by emergency physicians.
88959772|NCT05969561|Sham Comparator|The liberal use of pain medication|Patients with hip fractures had given intravenous or intramuscular opioids or NSAID at the emergency department.
88959773|NCT05969522|Other|Control group-Low and medium risk group|"The children with AAGN admitted to all cooperating units during 2017.01.01 to 2022.12.31 were followed up for more than 6 months, and the case data were complete.~PARRG Classification (pediatric AAGN renal risk grade, pediatric AAV renal risk grade, PARRG) According to the PARRG grading method provided by the Affiliated Children's Hospital of Chongqing Medical University, the enrolled children with AAGN were classified into high risk group, medium risk group, low risk group, medium risk group, low risk combination and low risk group according to the two indexes of eGFR and percentage of glomerular sclerosis during renal biopsy.~PARRG risk grading criteria:~There are two risk factors for ESRD: (1) eGFR≤20ml/min/1.73m2 at renal biopsy; ② The proportion of glomerular sclerosis ≥30%; High risk resistance: meet 2 risk factors; Moderate risk group: only 1 risk factor; Low risk group: no above risk factors;"
88959774|NCT05969522|Other|Control group-High risk group|"The children with AAGN admitted to all cooperating units during 2017.01.01 to 2022.12.31 were followed up for more than 6 months, and the case data were complete.~PARRG Classification (pediatric AAGN renal risk grade, pediatric AAV renal risk grade, PARRG) According to the PARRG grading method provided by the Affiliated Children's Hospital of Chongqing Medical University, the enrolled children with AAGN were classified into high risk group, medium risk group, low risk group, medium risk group, low risk combination and low risk group according to the two indexes of eGFR and percentage of glomerular sclerosis during renal biopsy.~PARRG risk grading criteria:~There are two risk factors for ESRD: (1) eGFR≤20ml/min/1.73m2 at renal biopsy; ② The proportion of glomerular sclerosis ≥30%; High risk resistance: meet 2 risk factors; Moderate risk group: only 1 risk factor; Low risk group: no above risk factors;"
88959775|NCT05969522|Experimental|Experimental group-Low and medium risk group|"Newly diagnosed children with AAGN admitted to our partners during the period of 2023.01.01 to 2023.12.31.~All children with AAGN were PARRG risk graded before treatment with RTX and CTX:~PARRG Classification (pediatric AAGN renal risk grade, pediatric AAV renal risk grade, PARRG) According to the PARRG grading method provided by the Affiliated Children's Hospital of Chongqing Medical University, the enrolled children with AAGN were classified into high risk group, medium risk group, low risk group, medium risk group, low risk combination and low risk group according to the two indexes of eGFR and percentage of glomerular sclerosis during renal biopsy.~PARRG risk grading criteria:~There are two risk factors for ESRD: (1) eGFR≤20ml/min/1.73m2 at renal biopsy; ② The proportion of glomerular sclerosis ≥30%; High risk resistance: meet 2 risk factors; Moderate risk group: only 1 risk factor; Low risk group: no above risk factors;"
88959776|NCT05969522|Experimental|Experimental group-High risk group|"Newly diagnosed children with AAGN admitted to our partners during the period of 2023.01.01 to 2023.12.31.~All children with AAGN were PARRG risk graded before treatment with RTX and CTX:~PARRG Classification (pediatric AAGN renal risk grade, pediatric AAV renal risk grade, PARRG) According to the PARRG grading method provided by the Affiliated Children's Hospital of Chongqing Medical University, the enrolled children with AAGN were classified into high risk group, medium risk group, low risk group, medium risk group, low risk combination and low risk group according to the two indexes of eGFR and percentage of glomerular sclerosis during renal biopsy.~PARRG risk grading criteria:~There are two risk factors for ESRD: (1) eGFR≤20ml/min/1.73m2 at renal biopsy; ② The proportion of glomerular sclerosis ≥30%; High risk resistance: meet 2 risk factors; Moderate risk group: only 1 risk factor; Low risk group: no above risk factors;"
88959777|NCT05969509|Experimental|the group that performed relaxation exercises|patients' postoperative pain and bowel movements will be evaluated by applying relaxation exercise intermittently
88959778|NCT05969509|No Intervention|the group that did not do relaxation exercises|patients' postoperative pain and bowel movements will be evaluated
88959779|NCT05969483||sedated and ventilated pediatric critical care patients|All sedated and ventilated critically ill patients will be exposed to the Masimo Sedline® sensor. Its pEEG scores, including the PSI, will be registered by the patient primary nurse every 4 hours for the first 5 days of ventilation. At the same time, CBS will be evaluated by a specialized PICU nurse and by a critical-care expert physician, blinded to each other. In case of chemically paralyzed patients, a paralysis holiday will be performed when clinically possible . A CBS will be assessed when the paralytic agents will be considered washed out. The patient's analgosedation strategy and analgosedation protocol will not be standardized but will be decided by the treating physician based on the international recommendations.
88959780|NCT05969457|Experimental|Experienced group|Administration of Naropeine
88959781|NCT05969457|Placebo Comparator|Control group|Administration of a saline solution
88959782|NCT05969405||Laparoscopy|Laparoscopic staging group
88959783|NCT05969405||Robotic|Robotic staing group
88959784|NCT05969405||Laparotomic|Laparotomic group
88959785|NCT05969392|Experimental|Intradiscal Gelified Ethanol Arm|Patients who come with symptomatic cervical disc herniation or with cervical discogenic pain and meet the eligibility criteria.
88959786|NCT05969379||Patients with neurological immune-related adverse events (n-irAEs)|Patients developing neurological syndromes related to administration of any immune checkpoint inhibitors, including central nervous system disorders and neuromuscular toxicties
88959787|NCT05969366||patients 85 yearsold or orlder who hab total hip replacement with uncemented femoral stem|
88959788|NCT05969353|Sham Comparator|sham controlled arm|
88959789|NCT05969353|Active Comparator|battlefield acupunture|
88959790|NCT05969314|Experimental|Cannabis|Cannabis capsules containing 5 mg of THC and CBD each or 2.5 mg of THC and CBD each.
89024297|NCT01508897|Experimental|Phase 3 formulation|
89024298|NCT01454297||Newly diagnosed Multiple Myeloma|This is a prospective observational study in patients with symptomatic multiple myeloma who have not yet initiated therapy for their disease.
88959791|NCT05969249|Experimental|Experimental|"Each patient will go on a treatment with 24 sections, and each section is 60 minutes.~The experimental group received 30 minutes of effective vibration intervention with a vibration frequency of 30 Hz and an amplitude of 5 mm on the affected upper limb. The vibration duration was 1 minute, and there was also a 1-minute rest interval. After completion, 30 minutes of traditional clinical rehabilitation training was also performed."
88959792|NCT05969249|Active Comparator|Active Comparator:|"Each patient will go on a treatment with 24 sections, and each section is 60 minutes.~During the intervention, it is necessary to wear an upper limb vibration device on the affected limb, and perform a sham vibration intervention (sham vibration) with a vibration frequency of 1 Hz (excluding the effective vibration frequency range of 4-50 Hz proposed in previous studies) and an amplitude of 5 mm for 30 minutes. The duration of the vibration is 1 minute, and there is a rest interval of 1 minute. After completion, 30 minutes of traditional clinical rehabilitation training will be performed."
88959793|NCT05969210|Experimental|Group A|12 participants will be in experimental group giving them Toe strengthening exercise protocol along with running training for three weeks, measure all values before giving them protocol and after protocol.
88959794|NCT05969210|Experimental|Group B|12 participants will be in control group they will do only there running training.
88959795|NCT05969197|Experimental|Group A - Match Play Training|15 participants will be in Match play training group giving the Match play exercise protocol along with warm-up sessions for 6 weeks, measuring values before giving them protocol and after protocol.
88959796|NCT05969197|Experimental|Group B - Plyometric Training|15 participants will be in Plyometric training group giving isotonic exercise protocol along with warm-up sessions for 6 weeks, measuring values before giving them protocol and after protocol.
89511948|NCT03287245|Experimental|Idasanutlin|Two cohorts of ruxolitinib-naïve and ruxolitinib-resitant or intolerant participants will be enrolled to receive idasanutlin once daily for 5 days, every 28 days, until treatment discontinuation or end of study (up to 2 years).
88959797|NCT05969184|Experimental|four-drug treatment group|"CDK4/6 inhibitor (Qilu): 125mg, oral Qd from the 1st to the 21st day of the 28 day cycle Trastuzumab (Hanquyou): on the first day of the 21 day cycle, the initial dose was 8mg/kg, and the intravenous infusion was 90 minutes; Every 3 weeks thereafter, the dose is 6mg/kg, and the intravenous infusion is 30~90 minutes Pertuzumab: on the first day of the 21 day cycle, the initial dose was 840mg, intravenous infusion was 60 minutes, and then once every 3 weeks, the dose was 420mg, and the infusion time was 30-60 minutes.~Letrozole selected by the doctor: 2.5mg, oral Q24H or exemestane from the 1st to the 21st day of the 21 day cycle: 25mg, oral Q24H from the 1st to the 21st day of the 21 day cycle. The efficacy is evaluated every 2 months (CR, PR, SD, PD)."
89511949|NCT02323555|Experimental|Paramedic telephone consultation|"Establishment of a paramedic telephone consultation to the doctor to record the virtual early prescription or non-injectable cancer treatment before the arrival of the patient (Feasibility Process Optima), without changing the current practice of prescribing and dispensing of these treatments on the day of the coming of the patient."
89511950|NCT03487081|Experimental|Social regulation|Following the fMRI session, participants in the social regulation group will be asked to rate their mood twice a day for 3 weeks. Furthermore, every other day, they will receive one event written by another participant. They will be asked to help the other person use emotion regulation strategies to feel less negative. The participant will answer brief questions related to his/her feelings after receiving the event and after providing social emotion regulation.
89511951|NCT03487081|Active Comparator|Self regulation|Following the fMRI session, participants in the self regulation group will be asked to rate their mood twice a day for 3 weeks. Furthermore, every other day, they will write an event that caused them negative emotions. They will be asked to use emotion regulation strategies to decrease their negative emotions. The participant will answer brief questions related to his/her feelings after writing the event and after implementing the emotion regulation strategy.
89511952|NCT03483727|Experimental|Digital cognitive aid|The digital cognitive aid is designed as a smartphone app.
89511953|NCT03483727|Experimental|no digital cognitive aid|No cognitive aid in the hand of the leader during crises management.
89511954|NCT02323633|Active Comparator|tPCS group|Arm in which random noise oscillating frequencies will be produced for the duration of 20 minutes.
89511955|NCT02323633|Sham Comparator|Sham group|Arm in which no random noise oscillating frequencies will be produced for the duration of 20 minutes
89511956|NCT05984953||Statin|85 patients treated with statin
89511957|NCT05984953||Evolocumab|110 patients treated with evolocumab in addition to statin or evolocumab alone
89511958|NCT05984940|Active Comparator|GP and AH Plus sealer|Root canal obturation using gutta percha and AH Plus® bioceramic sealer.
89511959|NCT05984940|Experimental|Ortho MTA|Root canal obturation using Ortho MTA cement.
89511960|NCT05984914|Experimental|PSAI group|Participants are enrolled in the Pythagorean Self-Awareness Intervention (PSAI) where they receive weekly group sessions of 120 min for 8 weeks and they receive information about stress and lifestyle modifications and they are also instructed to practice the PSAI at bedtime and in the morning, every day, at home.
89511961|NCT05984914|Active Comparator|Control group|One day seminar where they receive information about stress and lifestyle modifications
89511962|NCT05984901|Other|The CAVA Multicentre Dizziness Trial (CAVA2)|CAVA 2 is a single arm study testing a diagnostic device to diagnose different inner-ear conditions appraised by calculating values for sensitivity and specificity. Head and eye movements recorded by the CAVA device will enable the computer algorithms (to be developed) to differentiate between the three target conditions.
89511963|NCT05984888|Experimental|MIND-BC Intervention Group|Individual, tailored, behaviorally based nutrition counseling provided by a Registered Dietitian Nutritionist (RDN) and dietetic interns.
88959798|NCT05969171|Experimental|Sofantinib in combination with abraxane and gemcitabine|Abraxane: 125mg/m2 intravenously, d1, 8; Gemcitabine: 1000mg/m2, intravenous infusion greater than 30min, d1, 8, every 3 weeks for a treatment cycle. Sofantinib capsules, 250mg orally, taken within 1 hour after breakfast, once a day for continuous administration, d1-d21, every 3 weeks for a treatment cycle. AG chemotherapy did not exceed a maximum of 6 treatment cycles, and soantinib was continued until disease progression (PD, RECIST 1.1) or death (while the patient was on treatment) or toxicity became intolerant or other criteria for discontinuation of study therapy were met in the protocol. Allow adjustment of dosage according to protocol requirements, including suspension, lowering of dosage or permanent discontinuation.
88959799|NCT05969171|Active Comparator|Abraxane combined with gemcitabine|Abraxane: 125mg/m2 intravenously, d1, 8; Gemcitabine: 1000mg/m2, intravenous infusion greater than 30min, d1, 8, every 3 weeks as a treatment cycle, treatment until toxicity intolerance or disease progression, death, or other criteria for termination of study therapy as specified in the protocol. AG chemotherapy should not exceed a maximum of 6 treatment cycles. Allow adjustment of dosage according to protocol requirements, including suspension, lowering of dosage or permanent discontinuation.
88959800|NCT05969158|Experimental|Hetrombopag|Hetrombopag 5mg/d
88959801|NCT05969132|Experimental|Digital workflow-based Protocol|Fully digital guided gingivectomy procedure
88959802|NCT05969132|Active Comparator|Mock-up workflow-based Protocol|Convectional guided gingivectomy procedure
88959803|NCT05969119|Experimental|Pyridostigmine|Parturients with postoperative PDPH and a VAS score of ≥5 will receive either 60 mg oral Pyridostigmine every 6 hours.
88959804|NCT05969119|Placebo Comparator|Placebo|Parturients with postoperative PDPH and a VAS score of ≥5 will receive placebo tablets similar in shape to pyridostigmine tablets every 6 hours.
88959805|NCT05969106||rtCGM + MDI|Real-time CGM Dexcom G6 used in parallel to Multiple Daily Injections (MDI)
88959806|NCT05969106||rtCGM + CSII|Real-time CGM Dexcom G6 used in parallel to freestanding Continuous Subcutaneous Insulin Infusion (CSII)
88959807|NCT05969106||Tandem Control-IQ|Realtime CGM Dexcom G6 used as part of the Automated Insulin Delivery (AID) system
88959808|NCT05969093||Healthy individuals|Participants will undergo the Tinel's Sign at different wrist positions while EMG activity and NCV are recorded.
89511964|NCT05984888|Active Comparator|General Health Curriculum (GHC) Control|Sessions of non-diet related health topic education.
89511965|NCT05984875||A|Newly diagnosed high grade serous or endometroid OC undergoing primary debulking surgery
89511966|NCT05984875||B|Newly diagnosed high grade serous or endometroid OC undergoing NACT followed by interval debulking surgery. This cohort also includes patients that will not be deemed suitable for interval debulking surgery following NACT
89511967|NCT05984875||C|Rare subtypes of epithelial OC (low grade serous, low grade endometrioid, clear cell, mucinous or carcinosarcoma) undergoing primary debulking surgery
89511968|NCT05984875||D|Rare subtypes of epithelial OC (low grade serous, low grade endometrioid, clear cell, mucinous or carcinosarcoma) undergoing NACT followed by interval debulking surgery. This cohort also includes patients with the selected histological subtypes that will not be deemed suitable to interval debulking surgery following NACT
89511969|NCT05984875||E|Women undergoing adnexectomy for benign pathology
89511970|NCT05984862|Experimental|Experimental: Treatment left|"A randomized side of the scalp will be covered with bandage, the other side with no bandage.~Intervention: Device: Treatment - Bandage"
89511971|NCT05984862|Experimental|Experimental: Treatment right|"A randomized side of the scalp will be covered with bandage, the other side with no bandage.~Intervention: Device: Treatment - Bandage"
89511972|NCT05984849|Experimental|HPV game group|parent-child dyads receive HPV game intervention
89511973|NCT05984849|Experimental|COVID game group|parent-child dyads receive COVID game intervention
89511974|NCT05984849|No Intervention|Usual care|parent-child dyads receive usual care (no intervention)
89511975|NCT05984797|Experimental|intervention arm|Integrated Short-term Palliative Rehabilitation + usual care
89511976|NCT05984797|No Intervention|control arm|usual care
89511977|NCT05984771|Active Comparator|Active group|10-element combination tablet (n=30) Superoxide Dismutase (SOD, 70 UI), Palmitoylethanolamide (PEA, 300 mg) Alpha Lipoic Acid (ALA, 300 mg), vitamins B6 (1.5 mg), B1 (1.1 mg), B12 (2.5 mcg), E (7.5 mg), Nicotinamide (9 mg) and minerals (Mg 30 mg, Zn 2,5 mg) in one tablet for 6 months
89511978|NCT05984771|Placebo Comparator|Placebo|usual care
89511979|NCT05984745|No Intervention|Control group|Patients will receive the standard conventional care which is mainly therapeutic life changes
89511980|NCT05984745|Experimental|Test Group|Patients will receive Coenzyme Q10 Forte® (MEPACO Pharmaceutical Company, Cairo, Egypt) capsules in a dose of 100 mg twice per day 1 capsule every 12 hours for twelve weeks, in addition to the standard conventional care.
89511981|NCT05984732|Experimental|Reminiscence with digital storytelling|Older adults in the intervention group will receive 10 sessions of life-review or reminiscence discussion with the trained young adult volunteers (1-1.5 hours each week for 10 weeks). At the end of the study, they create a digital storybook based on their previous discussion.
88959809|NCT05969080|Experimental|T-SIB|Participants randomized to the Treatment for Self-Injurious Behaviors (T-SIB) condition will receive nine sessions of T-SIB.
89024299|NCT01450020|Experimental|Arm I (PN and ACS material)|Participants receive 4 PN sessions tailored to their needs followed by a 6 month booster session and ACS materials.
89511982|NCT05984732|Sham Comparator|Social wellness with scrapbook or journal|Older adults in the control group will have general social wellness discussion with the young adult volunteers. At the end of the study, they will create a journal/scrapbook.
89511983|NCT05984719||New daily persistent headache (NDPH) group|Participants with NDPH will be administered an online survey.
89511984|NCT05984693|Experimental|Experimental group|Experimental group students determined by randomization will be shown videos containing examples of health education prepared by the researchers. After watching each video, the right and wrong aspects of health education will be critically evaluated, discussed with the group, and the group's suggestions for improving education will be taken.
89511985|NCT05984693|No Intervention|Control groups|Control group students will not receive any training other than theoretical training.
89511986|NCT05984641|Experimental|Group A|Active treatment CONAN® (Medical Device, Omikron Italia Srl) a proctological cream containing 2.5% glycerin macerate from horse chestnut buds (escin), 1% hesperidin, 0.1% hyaluronic acid, 0.1% centella asiatica and 2.5% glycerinic extract of mallow; Instrutction to an healthy diet including an adequate fibre intake and general advice for facilitating evacuation using stool softeners.
89511987|NCT05984641|No Intervention|Group B|No intervention. Instrutction to an healthy diet including an adequate fibre intake and general advice for facilitating evacuation using stool softeners.
88959810|NCT05969080|Active Comparator|Treatment As Usual|Participants randomized to the TAU condition will be provided with referrals to both Durham VA and local community mental health resources and offered a consult for Durham VA mental health services.
88959811|NCT05969067|Placebo Comparator|Dissection Technique|The peritoneum is incised superficially and opened longitudinally from the sacral promontory, downward to the posterior cul-de-sac and the posterior vaginal wall to create retroperitoneal space for the SCP mesh.
88959812|NCT05969067|Experimental|Tunneling Technique|A retroperitoneal tunnel is created by undermining the peritoneum with the robotic scissors and/or needle driver which is placed in the peritoneal opening over the sacral promontory. The tunnel is created just medial to the right uterosacral ligament and toward the posterior vaginal wall by using forward pressure and a sweeping motion to create a space within the retroperitoneum
88959813|NCT05969028|Active Comparator|Airway Strategy|Each of 28 first responder EMS agencies in King County will be randomly assigned to treat with either the BVM or i-gel for airway strategy
88959814|NCT05969028|Active Comparator|Compression Rate|Each of 28 first responder EMS agencies in King County will be randomly assigned with one of the three chest compression rates (100 vs 110 vs 120) at the outset.
88959815|NCT05969015|Experimental|Behavior-changing/Self-Management|This arm is composed by group-based interventions aiming to modify the self-management of the patients through the Prochaska and DiClemente transtheorical model. It is composed by weekly meetings, lasting up to 1 hour and a half, targeting eight patients per group. After the 12nd month of intervention, the meetings will be held each fifteen days untill the trial ending (18 months). The meetings will deal with lifestyle matters, such as nutrition, weight management, and physical activity, as well as medication adherence, blood glucose testing, and others. Whenever a care provider will be assigned to a group, he/she will go over untill the final of the trial, unless unexpected motivations appear. Patients achieving maintenance will receive green flag from the group-based interventions to avoid contamination. It is up to the care provider to perceive the readiness of the patient to another stage.
88959816|NCT05969015|No Intervention|Usual Care|Patients randomized to the usual care group will follow the same schedule of the experimental group for outcome assessment; however, the trial team will not intervene in the group - i.e., the group will continue their care routine in their primary care unit.
89511988|NCT05984615||Immunotherapy (IO) Cohort|
88959817|NCT05968976|Active Comparator|55 patients with essential tremor receive awake DBS|
88959818|NCT05968976|Experimental|55 patients with essential tremor receive asleep DBS|
88959819|NCT05968950|Experimental|Thoracic spine ultrasound localization|Single arm where patients undergo both types of skin localization Experimental ( Ultrasound ) correlating with standard of care which is Thoracic spine fluoroscopy
88959820|NCT05968885|Active Comparator|Intradetrusor onabotulinumtoxinA injection|The toxin produced by Clostridium botulinum binds to the nerves endings and inhibits the muscular contractions, help to treat overactivity of the bladder muscles.
88959821|NCT05968885|Experimental|Combination pharmacotherapy|Combine Mirabegron and Solifenacin.
88959822|NCT05968846|Experimental|Patients will receive a single IV injection of 124I-AT-01 radiotracer and PET/CT imaging|"124I-AT-01 (124I-p5+14, iodine-124I evuzamitide) is an iodine-124 (124I) labeled 45 L-amino acid peptide suitable for PET/CT imaging. The peptide binds many forms of amyloid through multivalent electrostatic interactions with the amyloid fibril and ubiquitous heparan sulfate proteoglycans.~124I-AT-01 has been evaluated previously in an open-label Phase 1/2 clinical trial, AMY1001, performed at the University of Tennessee Medical Center (IND# 132282; NCT T03678259).~In this repeat imaging study, patients previously enrolled in the AMY1001 study, in whom positive PET/CT imaging findings were observed will undergo repeat imaging to assess changes in radiotracer uptake in the liver, spleen, heart and kidneys."
89024300|NCT01450020|Active Comparator|Arm II (ACS material)|Participants receive ACS materials only.
89024301|NCT01429727||SCAD Registry|Individuals who have experienced at least one episode of spontaneous coronary artery dissection.
89511989|NCT05984615||Targeted Therapy (TT) Cohort|
89511990|NCT05984602|Experimental|Quadruplet regimen prior to resection for pancreatic cancer|Treatment of Canakinumab and Tislelizumab in Combination with Nab-Paclitaxel and Gemcitabine up to 4 cycles (4 months)
89511991|NCT05984537|Experimental|bivalirudin group|participants using bivalirudin during PCI
89511992|NCT05984537|Active Comparator|standard heparin group|participants using standard heparin during PCI
89511993|NCT05984498||COPD group|People with a spirometry confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD)
89511994|NCT05984498||Healthy Controls|Older adults over the age of 55 who do not have COPD
89511995|NCT05984485|Experimental|Primary total mesorectal excision|Patients with low-risk locally advanced rectal cancer received total mesorectal excision alone.
89511996|NCT05984485|Active Comparator|Neoadjuvant chemotherapy plus TME|Patients with low-risk locally advanced rectal cancer received neoadjuvant chemotherapy and total mesorectal excision.
89519430|NCT01998529|Experimental|Cisplatin|After cytoreductive surgery, possible pneumonectomy, and possible diaphragm resection, the chest cavity will be closed in layers, leaving inflow and outflow chest tubes in place. Catheters connected to an extracorporeal perfusion circuit. Starting dose of hyperthermic cisplatin 120 mg/m2. Perfusion continued for 60 minutes after adding the cisplatin at a target temperature of 41 C (+0.5 C). In order to limit the systemic toxicity of cisplatin, amifostine administered intravenously over 15 minutes beginning 30 minutes after cisplatin perfusion. Patient response to amifostine continuously monitored by anesthesiologist. Infusion may be stopped and/or restarted based on blood pressure.
89024302|NCT01394263|Active Comparator|Zoladex goserelin implant.|Zoladex goserelin implant: D, L-lactic and glycolic acids copolymer. Injected subcutaneously into the upper abdominal wall.
89024303|NCT01394263|Experimental|Histrelin Acetate implant|Histrelin hydrogel implant, 3 cm x 3.5 mm, containing 50 mg of histrelin acetate, surgically placed subdermally into the inner aspect of the upper arm.
89024304|NCT01347567|Experimental|BNP + Health Management|Subjects will provide information from home regarding weight,signs and symptoms, and will perform BNP self testing. This information including BNP results will be used by the investigator as an aid to treatment decisions. BNP results are blinded to subjects.
89024305|NCT01347567|Active Comparator|Health Management|Subjects will provide information from home regarding weight, signs and symptoms, and will perform BNP self testing . BNP results will be blinded to the investigator and subject; weight, signs and symptoms will be used by the investigator as an aid to treatment decisions
89024306|NCT01347567|Placebo Comparator|Control|Subject will provide information from home regarding weight, signs and symptoms and will perform BNP self testing. All these data will be blinded to the investigator. BNP results will be blinded to the subject.
89024307|NCT01263769|Experimental|Axitinib|Axitinib Starting dose: 5 mg by mouth twice each day for 12 weeks.
89024308|NCT01154764|Experimental|Group 1|Period 1: CG100649 will be administered alone on Day 1 -After washout period- Period 2: The combination of CG100649 and ketoconazole tabs together on Day 1 followed by ketoconzzole tabs
89024309|NCT01154764|Experimental|Group 2|"Period 1: The combination of CG100649 and ketoconazole tabs will be administered together on Day 1, followed by ketoconazole tabs for 4 days, for a total of 5 days.~-After washout period- Period 2: CG100649 alone"
89024310|NCT01153035|Other|Surgery followed by RFA|
89210531|NCT00627458|Experimental|INFANRIX HEXA PC GROUP|Healthy male and female subjects between, and including 16 and 20 months of age at the time of booster vaccination, who were given the preservative-containing (PC) formulation of Infanrix Hexa™ in the primary vaccination study 106786, additionally received a single booster dose of Infanrix Hexa™ vaccine, administered intramuscularly into the anterolateral quadrant of the right thigh.
89511997|NCT05984472|Active Comparator|Edelweiss Prefabricated Veneers|Edelweiss veneers (device 1) were randomly applied to patients. The teeth were evaluated in terms of color and size matching in order to select the correct veneers. Edelweiss sizing guide was used for size selection. Prefabricated veneers were adapted to the teeth' surfaces. Then, the inner surfaces of the prefabricated veneers were roughened to obtain better mechanical retention. Then the labial surfaces of the teeth were etched using 36% phosphoric acid. The etched surfaces were rinsed and dried. An adhesive system was applied to the teeth. Prefabricated veneers' inner surfaces were cleaned with alcohol, and Veneer Bond dental adhesive was applied. Edelweiss nanohybrid resin composite was placed on the inner surfaces of the veneers and transferred to the teeth. These restorations were light-cured for 40 s Gingival borders were adapted with contouring and polishing discs (intervention 1).
89511998|NCT05984472|Active Comparator|Ceram-X Duo SphereTec with U-Veneer|Direct resin composite restorations were randomly applied to patients. Ceram-X Duo SphereTec resin composite (device 2) was used for color selection. Then U-Veneer transparent templates were tried to select their correct size. After the preparation, the labial surfaces of the teeth were etched using 36% phosphoric acid. The etched surfaces were then rinsed and dried. An adhesive system was applied to the teeth. Then Ceram-X Duo SphereTec nanohybrid resin composite with dentin shade was placed on labial surfaces of teeth and was light-cured. After that Ceram-X Duo SphereTec nanohybrid resin composite enamel shade was placed on the inner surface of the transparent template and was transferred to the tooth. After that, the resin composite veneer was light-cured for 20 s from each surface. The transparent template was removed. Gingival borders were adapted with contouring and polishing discs. Then proximal surfaces were polished using proximal sandpaper strips (intervention 2).
89511999|NCT05984407||patients with vasoplegic shock|Application of cytokine hemadsorption therapy in patients with vasoplegic shock without microbiological findings
89512000|NCT05984394||AS patients with ILD|New diagnosis of patients with AS syndrome and ILD
89512001|NCT05984368|Experimental|Part 1|A single ascending dose (SAD) study divided into 7 dose groups: 2 mg (exploratory dose), 24 mg, 50 mg, 100 mg, 200 mg, and 300 mg, 400 mg (optional dose group), with 2 mg enrolling 2 subjects (all receiving the test drug) and the remaining 8 subjects in each group (6 test drug, 2 placebo).
89512002|NCT05984368|Experimental|Part 2|Multiple ascending dose (MAD) study, divided into 3 dose groups: 100 mg, 200 mg and 300 mg, each group included 8 healthy subjects (6 test drug, 2 placebo).
89512003|NCT05984355||People aged 65 and over|
89512004|NCT05984355||Naturals caregivers|
89512005|NCT05984355||Professionals|
89512006|NCT05984342|Experimental|Adjuvant Chemotherapy in Combination With Immunotherapy|Adjuvant Chemotherapy in Combination With Tislelizumab was used in patients with Lymph Node-Positive Esophageal Squamous Cell Carcinoma after surgery
89512007|NCT05984303|Experimental|Human Umbilical Cord-derived Mesenchymal Stem Cells|Standard of care (SOC) plus a multiple administration and dose-escalasion with 2 cohorts with 3 subjects/cohort who receive doses of 1 and 2 ×10E8 cells. Each person received 3 infusions, 1 week apart, Proceed from lower dose to higher dose if no safety concerns for each cohort.
89512008|NCT05984264|Experimental|Pridocaine cream|Pridocaine cream (lidocaine 2.5% and prilocaine 2.5%) will be applied at least 30 min before the pleurocentesis on the skin overlying the chosen aspiration site using ultrasound under occlusive dressing over a 5 × 5 cm area.
89519431|NCT02522663|No Intervention|Usual Care|Today, no post-discharge telephone support is offered as standard care from the hospital.
89519432|NCT02522663|Experimental|Intervention group|Experimental group is offered 24/7-telephone support during the first 1 month post-discharge, and patients are actively called at day 2 and day 9 day after discharge.
89519433|NCT03448861|Experimental|Polso Wearable watch|Polso Wearable watch for the purpose of NEWS measurement
89024311|NCT01035983|Experimental|Frovatriptan 2.5 mg|Frovatriptan 2.5 mg tablets administered orally 2 x 2.5 mg twice daily (loading dose) on day 1, followed by 2.5 mg twice daily days 2 to 6.
89024312|NCT01013025||Patients treated with Vantas implant|Patients were enrolled if they had had a Vantas implant placed for treatment of adenocarcinoma of the prostate, and if the patients were scheduled for explant of the implant, and the physician had difficulty locating the implant.
88959823|NCT05968729|Active Comparator|0.25 m/s asymmetric session first|Participants will perform three 15-minute sessions of walking with a 0.25 m/s asymmetric walking gait speed difference where one limb is set at 1.0 m/s and the other limb is set at 1.25 m/s. Each of these sessions will be followed by 5-minute de-adaptation sessions where they will perform a symmetric walking trial at 1.0 m/s.
89519434|NCT04455191|Experimental|Thawing Embryos in Advance|Thawing embryos one day in advance (16:00), 18h before embryos transfer (10:00).
89519435|NCT04455191|Experimental|Thawing Embryos on the Day of Transfer|Thawing embryos on the day of transfer (8:00), 2h before embryos transfer (10:00).
89519436|NCT04455971||OM Group|People who participate in the practice of orgasmic meditation (OM)
89519437|NCT05321797|Experimental|Aerobic Training Group|Cycling exercise group along with Conventional therapy
89519438|NCT05321797|Active Comparator|Conventional Physiotherapy|Strectching with ROM and gait training
89519439|NCT02521909||Tooth Extraction|Intervention is Tooth Extraction for Assessment of Different Apex Locators. All people in the study will contribute one or more teeth, which will be extracted for other clinical purposes, for device comparative testing
89519440|NCT04455113||Normo-phosphatemia|238 patients included in this group. Phosphorus level >2.5 mg/dl
89519441|NCT04455113||Hypophosphatemia|79 patients included in this group. Phosphorus level <2.5 mg/dl
89519442|NCT03448705|Experimental|Group 1 - Study drug 1 (i.e. 4Fluart ID 1 µg/0.1 ml QIV)|Vaccination of 12 subjects will be performed with the intradermal quadrivalent influenza vaccine containing 1 µg haemagglutinin per virus strain in 0.1 ml as a single dose.
89519443|NCT03448705|Experimental|Group 2 - Study drug 2 (i.e. 4Fluart ID 2 µg/0.1 ml QIV)|Vaccination of 12 subjects will be performed with the intradermal quadrivalent influenza vaccine containing 2 µg haemagglutinin per virus strain in 0.1 ml as a single dose.
89519444|NCT03448705|Active Comparator|Group 3 - Comparator drug (i.e. 3Fluart IM 6 µg/0.5 ml TIV)|Vaccination of 12 subjects will be performed with the intramuscular trivalent influenza vaccine containing 6 µg haemagglutinin per virus strain in 0.5 ml as a single dose.
89519445|NCT03857867|Experimental|Tactile Stimulation Glove|Patient will receive active stimulation for a minimum of 3 months and a maximum of 13 months
89519446|NCT04637425|Experimental|Ismigen|Treatment over 3 successive months with one daily tablet over 10 days followed by 20 days of rest.
89519447|NCT04637425|Placebo Comparator|Placebo|Treatment over 3 successive months with one daily tablet over 10 days followed by 20 days of rest.
89519448|NCT05128331|Experimental|Spermidine supplementation|Study participants are provided with spermidine supplementation
89519449|NCT05128331|Placebo Comparator|Placebo supplementation|Study participants are provided with a placebo supplementation
89519450|NCT03448627||Group 1: HSCT recipients|Pulmonary functions [spirometry], maximal exercise capacity [Modified-Incremental Shuttle Walk Test (ISWT)], inspiratory and expiratory muscle strength (MIP and MEP, respectively) [mouth pressure device] and peripheral muscle strength [hand-held dynamometer] were evaluated in allogeneic HSCT recipients (n=66).Vital signs, dyspnea and fatigue perception [Modified Borg Scale] were recorded as pre-post measurements of Modified-ISWT.
89519451|NCT03448627||Group 2: healthy individuals|Healthy individuals (n=50) were selected from individuals without known and diagnosed any chronic diseases. Similar measurements were applicated in healthy individuals.
89519452|NCT03448549|Experimental|Group A (TGOP-OX)|Colorectal cancer patients p-staged III are randomized and assigned with TGOP-OX (Tegafur，gimeracil and oteracil potassium+Oxaliplatin) as adjuvant chemotherapy.
89519453|NCT03448549|Active Comparator|Group B (XELOX)|Colorectal cancer patients p-staged III are randomized and assigned with XELOX (Xeloda+Oxaliplatin) as adjuvant chemotherapy.
89519454|NCT03679091|Experimental|low-dose ticagrelor|To observe the safety and efficacy of low-dose ticagrelor in Chinese patients with Stable Coronary Artery Disease
89519455|NCT03679091|Active Comparator|clopidogrel|To observe the safety and efficacy between low-dose ticagrelor and standard-dose clopidogrel.
89519456|NCT04627831|Experimental|CE-Iohexol|Subject is randomized to receive CE-Iohexol Injection
89519457|NCT04627831|Active Comparator|Omnipaque™ (Iohexol)|Subject is randomized to receive Omnipaque™ Iohexol Injection
89519458|NCT01628926|Experimental|SPM 962|SPM 962 transdermal patch
89519459|NCT01628926|Active Comparator|Ropinirole|Ropinirole tablet
89519460|NCT01628926|Placebo Comparator|Placebo|SPM962 placebo patch and Ropinirole placebo tab
89519461|NCT05321641|Experimental|Text SMS|Adherence messages presented in both text form.
89519462|NCT05321641|Experimental|Graphic SMS|Adherence messages presented in graphic form.
89519463|NCT05321641|Experimental|Both text and graphic|Adherence messages presented in both text and graphic form.
89519464|NCT05321641|Placebo Comparator|Control|Messages on public health promotion not related to epilepsy
89519465|NCT05313659|Experimental|group-K|At the end of surgery and immediately after the inhalational agent was discontinued, 2mL of normal saline containing 0.7 mg/kg racemic ketamine was administered intramuscularly to Group-K
89519466|NCT05313659|No Intervention|group-S|At the end of surgery and immediately after the inhalational agent was discontinued, 2 mL of normal saline was administered intramuscularly.
89519467|NCT03129373|Experimental|Pixie group|"Cryogenic treatment of wart (liquified nitrous oxide)~Maximum 3 application by the technician in charge of the study.~Apply between 15 to 20 sec on hand and 40 sec on feet."
89519468|NCT03129373|Active Comparator|Wartner group|"Cryogenic treatment of wart (dimethylether propane-based):~Maximum 3 application by the technician in charge of the study.~Apply between 15 to 20 sec on hand and 40 sec on feet."
89519469|NCT03129373|Active Comparator|Wortie group|"Cryogenic treatment of wart (dimethylether-based product):~Maximum 3 application by the technician in charge of the study.~Apply between 15 to 20 sec on hand and 40 sec on feet."
89519470|NCT05322187|Experimental|PLEN(PD-1/PD-L1 inhibitor and LENvatinib)|Treatment of PD-1/PD-L1 Inhibitor and LENvatinib would be employed in PLEN
89519471|NCT03129295|Experimental|MPC-SHRC|oral tablet four times a day for 3 days
88959824|NCT05968729|Active Comparator|0.50 m/s asymmetric walking session first|Participants will perform three 15-minute sessions of walking with a 0.50 m/s asymmetric walking gait speed difference where one limb is set at 1.0 m/s and the other limb is set at 1.5 m/s. Each of these sessions will be followed by 5-minute de-adaptation sessions where they will perform a symmetric walking trial at 1.0 m/s.
88959825|NCT05968716|No Intervention|Control (pre-implementation) arm|"Caregivers recruited from the pediatric hospital ward before the social needs screening and intervention protocol is implemented will compose the control group or pre-implementation group."
88959826|NCT05968716|Experimental|Intervention (post-implementation) arm|"Caregivers recruited from the pediatric hospital ward after the social needs screening and intervention protocol is implemented will compose the intervention group or post-implementation group."
88959827|NCT05968664|Active Comparator|Time Invariant Pulse(TIP) Stimulation|The control arm for this study will be the Time Invariant Pulse stimulation which is used in standard of care Spinal Cord Stimulation therapy. TIP tonic stimulation is delivered with fixed amplitude, pulse width, and frequency parameters.
89512009|NCT05984264|Active Comparator|Standardized local lidocaine infiltration|Anesthetize the skin over the insertion site with 1% lidocaine using the 5 ml syringe with a 25 or 27-gauge needle. Next, anesthetize the superior surface of the rib and the pleura. The needle is inserted over the top of the rib (superior margin) to avoid the intercostal nerves and blood vessels that run on the underside of the rib (the intercostal nerve and the blood supply are located near the inferior margin). As the needle is inserted, aspirate back on the syringe to check for pleural fluid. Once fluid returns, note the depth of the needle and mark it with a hemostat. This gives an approximate depth for the insertion of the thoracentesis needle. Remove the anesthetizing needle.
89512010|NCT05984251|Experimental|Cohort 1|During Period 1, participants will receive a single dose of CCX168 1 mg or placebo. During the second study period, participants will receive the same dose as during the first period but once daily (QD) for a period of 7 days continuously.
89512011|NCT05984251|Experimental|Cohort 2|During Period 1, participants will receive a single dose of CCX168 3 mg or placebo. During the second study period, participants will receive the same dose as during the first period but QD for a period of 7 days continuously.
89512012|NCT05984251|Experimental|Cohort 3|During Period 1, participants will receive a single dose of CCX168 10 mg or placebo. During the second study period, participants will receive the same dose as during the first period but QD for a period of 7 days continuously.
89512013|NCT05984251|Experimental|Cohort 4|During Period 1, participants will receive a single dose of CCX168 30 mg or placebo. During the second study period, participants will receive the same dose as during the first period or placebo twice daily (BID) for a period of 7 days continuously.
89512014|NCT05984251|Experimental|Cohort 5|During Period 1, participants will receive a single dose of CCX168 100 mg or placebo. During the second study period, participants will receive the same dose as during the first period or placebo BID for a period of 7 days continuously.
89512015|NCT05984225|Experimental|Physiotherapy students|Physiotherapy students of the 2nd course of the Grade of Physiotherapy of the University of Valencia.
89512016|NCT05984212|Experimental|dexmedetomidine infusion group|
89512017|NCT05984212|Placebo Comparator|normal saline infusion group|
89512018|NCT05984186||low flow on room air|
89512019|NCT05984186||low flow on oxygen|
89512020|NCT05984186||high flow on room air|
89512021|NCT05984186||high flow with oxygen|
89512022|NCT05984173|Experimental|study group|patients received vitamin E inside the socket after extraction (study group)
89512023|NCT05984173|No Intervention|control|patients didn't receive vitamin E after extraction (control group).
89512024|NCT05984160|Active Comparator|Paragastric neural block|Patients who were operated for sleeve gastrectomy were included in the study. Afterwards, they were divided into two groups. While pragastric neural block was applied to one group, no intervention was made to the other group.
89512025|NCT05984160|No Intervention|Control|Control grup
89512026|NCT05984134|Experimental|Middle Dose|12 hours after PCI: 0.5 ug/kg Recombinant Human Thymosin β4 （intravenous injection），Day2-Day7 after PCI：0.5 ug/kg Recombinant Human Thymosin β4 （intravenous injection）
89512027|NCT05984134|Experimental|High Dose|12 hours after PCI: 1.0 ug/kg Recombinant Human Thymosin β4 （intravenous injection），Day2-Day7 after PCI：1.0 ug/kg Recombinant Human Thymosin β4 （intravenous injection）
89512028|NCT05984134|Placebo Comparator|Placebo|Patients in this treatment group will receive placebo respective. Continuous administration for 7 days.
89512029|NCT05984108||Meningeal melanocytoma|
89512030|NCT05984108||Meningeal melanoma|
89512031|NCT05984108||Meningeal melanomatosis|
89512032|NCT05984108||Meningeal melanocytosis|
89512033|NCT05984043|Experimental|Biofeedback|
89512034|NCT05984043|Other|Waitlist|
89512035|NCT05984030|Experimental|STARR NC Intervention Condition|"Intervention arm will receive a multilevel intervention with three components: a PrEP Navigator to facilitate linkage to PrEP services and completion of applications for health insurance/drug assistance; a Digital Health Intervention (DHI) platform (HealthMpowerment); and referral to Telehealth PrEP services as an option for linking to PrEP care.~The Intervention Arm version of the DHI includes: Study Timeline and Calendar, publicly-available PrEP locator feature, Dried Blood Spot self-collection kit ordering, Educational Health Resource Center; Interactive skill-building health activities; social support newsfeed/group chat; Ask the Expert anonymous health question and answer; Medication Tracker; Health Behavior Tracker; Gamification features for participant engagement.~Intervention Arm participants will complete baseline and quarterly follow-up assessments.~Intervention Arm participants will complete two Dried Blood Spot self-collection kits at 3 and 6 months."
89512036|NCT05984030|Active Comparator|STARR NC Standard-of-Care Control Condition|"Standard-of-Care Control arm will receive the standard PrEP referral services available at the STI clinic setting where they were recruited. They will also receive study staff guided support to install the control arm version of the HealthMPowerment DHI platform.~The Control Arm version of the DHI includes: Study Timeline and Calendar, publicly-available PrEP locator feature, Dried Blood Spot self-collection kit ordering, Educational Health Resource Center.~Control Arm participants will complete baseline and quarterly follow-up assessments.~Control Arm participants will complete two Dried Blood Spot self-collection kits at 3 and 6 months."
89512037|NCT05983900|Experimental|BRIX 3000|brix 3000 used
88959828|NCT05968664|Experimental|Time Variant Pulse (TVP) Stimulation|The time variant pulse (TVP) stimulation will serve as the experimental arm for this study. There are two ways of delivering TVP stimulation to the spinal cord. TVP stimulation can either vary in intensity or it can vary rate, referred to as intensity-modulated TVP or rate-modulated TVP, respectively.
88959829|NCT05968651|Experimental|Clinical|This group consists of individuals with at least moderate symptoms of social anxiety disorder. This group will receive either an oxytocin or placebo administration (blind randomization).
88959830|NCT05968651|Placebo Comparator|Controls|This group consists of a healthy sample of individuals (no lifetime diagnoses of mania or psychotic disorders). This group will receive either an oxytocin or placebo administration (blind randomization).
89512038|NCT05983900|Active Comparator|Papacarie|papacarie duo used
89512039|NCT05983900|Active Comparator|Hand excavation|hand excavation used
89512040|NCT05983887|No Intervention|Control Group|The participants in this group continue their conventional intervention protocol without using the climbing instructions.
89512041|NCT05983887|Experimental|Climbing Group|The participants in this group continue their conventional intervention protocol plus an in-door climbing intervention protocol.
89512042|NCT05983874|Experimental|Group 1: BG505 SOSIP.664 gp140 Vaccine, Adjuvanted (3M-052 AF plus alum) Dosage|BG505 SOSIP.664 gp140 Vaccine, Adjuvanted (3M-052 AF plus alum)
89512043|NCT05983861||Multi drug resistant group|All critically ill adult patients (with no exclusion criteria) admitted to the ICU with microbiological confirmed diagnosis of infection at admission and multi drug resistant bacteria isolation :
89512044|NCT05983861||Multi sensible bacteria group|All critically ill adult patients (with no exclusion criteria) admitted to the ICU with microbiological confirmed diagnosis of infection at admission and multi drug sensible bacteria isolation :
89512045|NCT05983835|Experimental|combined segmentectomy|
89512046|NCT05983835|Placebo Comparator|lobectomy|
89512047|NCT05983796|Experimental|18F-HER2 PET|
89512048|NCT05983783|Experimental|Rezvilutamide+ADT+Docetaxel|"Rezvilutamide: 240 mg (3 tablets of 80 mg each) orally once daily (QD), can be taken with or without food.~Docetaxel 6 cycles"
89512049|NCT05983783|Active Comparator|Rezvilutamide+ADT|Rezvilutamide: 240 mg (3 tablets of 80 mg each) orally once daily (QD), can be taken with or without food.
89512050|NCT05983757|Active Comparator|Standard of Care Treatment|Standard medical management in patients who suffer a distal medium vessel occlusion
89512051|NCT05983757|Experimental|Endovascular Thrombectomy|Endovascular thrombectomy in patients who suffer a distal medium vessel occlusion.
89512052|NCT05983744|Experimental|Pulsatile perfusion therapy (PPT)|Application of oscillatory lower body negative pressure (LBNP) at specific target frequencies of interest.
89512053|NCT05983666||Patients undergoing scheduled and/or emergency surgery requiring orotracheal intubation.|
89512054|NCT05983653|Active Comparator|200 ml of normal saline lavage|in the first arm will be used 200 ml of normal saline lavage alone without PRP
89512055|NCT05983653|Active Comparator|200 ml arthrocentesis with PRP|in the second arm will be used 200 ml of normal saline arthrocentesis with PRP
89512056|NCT05983640|No Intervention|Control|Assessment without training or video prompt
89512057|NCT05983640|Experimental|Just in time video|Assessment with JiT video available
89512058|NCT05983640|Active Comparator|AHA Course|Assessment after completion of CPR training course
89512059|NCT05983627|Experimental|Human Umbilical Cord Mesenchymal Stem Cells|The trial was divided into three dose groups： Low-dose group: 1000000 cells/kg Medium-dose group: 2000000 cells/kg High-does group: 4000000 cells/kg
89512060|NCT05983601|Active Comparator|Active tDCS+Balance training|The current intensity will be 2mA and the duration of stimulation will be 20 minutes with direct current stimulation. In the beginning and end of the tDCS stimulation, there will be 30 second ascent and descent period.
89512061|NCT05983601|Sham Comparator|Sham tDCS+Balance Training|In sham stimulation, the current will increase to 2 mA in the first thirty second, following by 30 second active stimulation, then it will be dropped to 0 mA. Brief electric current will be given in order to create a tingling sensation under electrodes.
89512062|NCT05983549|No Intervention|Standard of care group|Patients will receive fluids according to clinical practice
89512063|NCT05983549|Active Comparator|Neutral balance|Patients will receive fluids aiming to a neutral balance
89512064|NCT05983536||Cancer patients|Cancer patints that confirmed by pathological examination
89512065|NCT05983536||Patients with blood diseases|Bone marrow aspiration and biopsy confirmed the blood disease
89512066|NCT05983523|Experimental|PEP07 Monotherapy|"The dose escalation stage of PEP07 monotherapy consists of an accelerated dose escalation followed by a standard 3+3 dose escalation. The accelerated titration will enroll 1 patient in each dose cohort until 1 patient experiences a DLT or a total of 2 patients experience any ≥ grade 2 PEP07-related AE during Cycle 1, and then the dose escalation will be switched to the 3+3 scheme to enroll 3 to 6 patients at the dose cohort where the DLT or the second ≥ grade 2 PEP07-related AE is observed.~To confirm the safety and evaluate the preliminary efficacy of PEP07, expansion cohorts with 12 patients will be opened for PEP07 monotherapy at RP2D once efficacy signal is observed in the dose escalation."
89512067|NCT05983497|Experimental|Experimental: Self-care skill Education|A total of 112 Participants will be assigned to the experimental group. Self-care skill educational intervention is administered to all the participants.
89512068|NCT05983497|No Intervention|No Intervention:|A total of 112 Participants will be assigned to the control group.No intervention will be received
88959831|NCT05968560|Experimental|Group and Family-Based Cognitive Behavioral Therapy (GF-CBT-TH)|GF-CBT via telehealth is an intervention consisting of three parts: 15 group sessions for young people, 15 individual sessions for young people, and 15 group sessions for families. The group sessions for young people and families focus on teaching CBT skills. The goal is to enhance reasoning, decision-making, and positive beliefs while reducing cognitive biases, distress, and isolation. The individual sessions personalize the CBT skills learned in the group, focusing on tailoring skills to personal goals. Family members also participate in group sessions to learn the same CBT skills and how to prompt and support their young family members in using these skills. All sessions are conducted via Telehealth
88959832|NCT05968560|Experimental|Family-Based Cognitive Behavioral Therapy (F-CBT-TH)|F-CBT via telehealth consists of two parts: 15 family sessions and 15 individual sessions for young people. The family sessions focus on teaching CBT skills to a family units. The individual sessions with youth personalize the CBT skills learned in the family sessions, focusing on tailoring skills to personal goals. All sessions are conducted via Telehealth.
88959833|NCT05968560|Active Comparator|Individual Cognitive Behavioral Therapy (I-CBT-TH)|I-CBT-TH via telehealth consists of two components: 15 CBT Skill Learning sessions and 15 follow-up session that personalizes the learned skills. All sessions are conducted via Telehealth.
88959834|NCT05968547||Glaucoma patients questionnaire|Questionnaire to understand patients driving needs and understanding of driving vision standards
88959835|NCT05968547||Visual acuity standards|DVLA vision standard estimated in the clinic is compared with standandard car number plate outside the clinic. We estimate the vision in the clinic using standard visual acuity chart and electronic number plate vision and compare with number plate vision estimated outside the clinic by the patient. Instruction to estimate number plate vision will be provided to the patient.
88959836|NCT05968391||Chronic kidney failure|No interventions for the purpose of the study. They will simply undergo two PET scans consecutively
88959837|NCT05968378|Active Comparator|Standard healthy eating advice|Subjects in this group will be counselled according to the Irish National Healthy Eating Guidelines.
88959838|NCT05968378|Experimental|eTRE plus Mediterranean diet|Subjects in this group will be asked to restrict their eating to 8-hours daily (8am - 4pm) and to adhere to a Mediterranean style diet.
88959839|NCT05968287||patient group|patients admitted to hospital with various infection conditions with or without sepsis
89512069|NCT05983471|Experimental|ME-015 (Suplatast Tosilate)|ME-015 (Suplatast Tosilate) 2 x 100 mg capsule t.i.d. (three times per day), for 2 weeks
89512070|NCT05983471|Placebo Comparator|Placebo|Identical placebo capsules 2 x t.i.d. (three times per day), for 2 weeks
89512071|NCT05983445|Experimental|Genakumab|Genakumab 200mg s.c
89512072|NCT05983445|Active Comparator|Diprospan|Diprospan 7mg im
89512073|NCT05983419|Experimental|intervantion|Complete resection of Barrett's esophagus harboring neoplasia with endoscopic submucosal dissection.
89512074|NCT05983406|Experimental|Intervention|Doppler endoscopic probe in the diagnosis of subepithelial gastrointestinal lesions
89512075|NCT05983328|Experimental|Healthy Volunteers dose 1|Evaluate tolerability, safety and pharmacokinetic properties of HUYPS-1 after 1 tablet oral administration in healthy subjects
89512076|NCT05983328|Experimental|Healthy Volunteer dose 2|Evaluate tolerability, safety and pharmacokinetic properties of HUYPS-1 after 9 tablets oral administration in healthy subjects
89512077|NCT05983315||CONECCT's classification assessment|Every patient who needs diagnostic colonoscopy because of digestive symptoms, medical or family history of colorectal cancer/polyps, positive colorectal screening test, acromegaly or referred by another gastroenterologist upon discovery of colorectal polyp after colonoscopy can join the cohort of this study and can get CONECCT's classification histological assessment of their neoplastic lesion by experienced endoscopist.
89512078|NCT05983289|Experimental|HSK7653|Single dose, oral
88959840|NCT05968287||control group|patients admitted to hospital with various non-infectious diseases and outpatients who admitted to the outpatient clinics
88959841|NCT05968248|Experimental|MLR-DBS（Deep brain stimulation of the mesencephalic locomotor region）|The arm will be switched on one month postoperatively for electrical stimulation therapy, exercise training rehabilitation and EMG-triggered neuromuscular stimulation. Specialist doctors will assess the patient's rehabilitation status through the telerehabilitation system every week, and provide guidance on rehabilitation training and electrical stimulation therapy.
88959842|NCT05968248|Sham Comparator|Conventional rehabilitation group|The arm will l also have DBS surgery and receive the same rehabilitation training under the face-to-face guidance of specialists except for the power-on (sham stimulation, power-on stimulation parameter is 0).
88959843|NCT05968235||Vitiligo|Patients diagnosed with vitiligo
88959844|NCT05968235||Healthy|Healthy volunteers with sex- and age-matched with vitiligo patients
89512079|NCT05983289|Placebo Comparator|Placebo|Single dose, oral
89512080|NCT05983146|Experimental|HRS-7053 Injection|
89512081|NCT05983120|Experimental|Training group|In the first five weeks, the experimental group was given training consisting of five modules, accompanied by power point presentations and applied social cognitive learning theory, then SMS reminders were sent every fortnight for seven weeks, and the study was completed at the end of the twelfth week. The control group received standard training from a diabetes nurse. Scale evaluations, metabolic and anthropometric measurements were made at the beginning and end of the study in the experimental and control groups. In addition, the scale evaluation was repeated in the fifth week for the experimental group. Data were evaluated using appropriate statistical methods.
89512082|NCT05983120|No Intervention|Control Group|The control group received standard training from a diabetes nurse.
89512083|NCT05983107|Experimental|cohort 1 PIK3CA Mutant|Everolimus combined with endocrine therapy
89512084|NCT05983107|Experimental|cohort 2 PIK3CA wild type|chidamide combined with endocrine therapy
89512085|NCT05983094|Experimental|cohort 1 Triple-negative breast cancer|Hormone Receptor(HR) negative, Human Epidermal Growth Factor Receptor 2(HER2 )negative breast cancer Drug: Utidelone in combination with carboplatin Utidelone injection 30mg/m2, on days 1-5 of each cycle; Carboplatin ,Area Under Curve(AUC)6, iv, was administered on day 1; One treatment cycle is 21 days, and there are 6 cycles in total.
89519472|NCT03129295|Placebo Comparator|Placebo|oral tablet four times a day for 3 days
89519473|NCT01628848|Experimental|SPM 962|SPM 962 transdermal patch
89519474|NCT01628848|Placebo Comparator|Placebo|Placebo transdermal patch
89540804|NCT05838573|Other|Cross-sectional participants|"Participants do not meet any of the diagnostic criteria for metabolic syndrome: 1)abdominal obesity (i.e. central obesity): waist circumference for male≥90 cm, for female ≥85 cm; 2)fasting blood glucose ≥110 mg/dl (6.1 mmol/l) and/or plasma glucose ≥140 mg/dl (7.8 mmol/l) after glucose load; 3)at fasting state, triglyceride ≥1.7 mmol/l; 4)at fasting state, HDL-C <1.04 mmol/L.~the other inclusion criteria and exclusion criteria are same as the intervention group."
89540805|NCT05838573|Other|Healthy volunteer|
89540806|NCT05833503|Experimental|Integrative Couple Treatment for Addiction (ICT-A)|"Inspired by the Alcohol Behavior Couple Therapy from Epstein & McCrady, the ICT-A will be offered over 12 to 16 sessions of 90 minutes. Typically, approximately the first half of each session is dedicated to GD/SUD problems,in a predominantly cognitive behavioral model. In the second part of each session, the clinician will help the couple to improve their communication,to reduce the reinforcements (non-voluntary) of the behaviors of GD/SUD and to increase marital pleasure situations incompatible with the use of GD/SUD.Particular attention will also be paid to feelings of betrayal and interpersonal attacks to restore trust. Plus,they will received a sefl-care guide."
89540807|NCT05833503|Active Comparator|Individual treatment as usually offered|"The usual treatment control group will receive individual treatment as already offered by the specialized centres in addiction.~For the person with GD/SUD, this treatment consists of 12 to 16 individual cognitive-behavioral sessions of 60 minutes. In general, the intervention aims to secure financial assets, awareness of erroneous thoughts and improvement of alternative skills to gambling in order to meet the normal demands of psychic and relational life. People undergoing this intervention will receive a self-care guide.~As for the partners randomized in this intervention, they will receive the services that are usually offered to members of the entourage of a person with GD/SUD. In groups or individually, these services are generally aimed at improving the partner's well-being and relationship with their spouse, which includes information about GD/SUD and the recovery process."
89540808|NCT05830721|Active Comparator|Standard of Care|This arm involves standard of care monitoring.
89540809|NCT05830721|Experimental|MY01 + standard of care group|This arm involves insertion of the MY01 device into the same leg as the arterial ECMO tubing to continuously monitor compartment pressures.
89540810|NCT05830721|Experimental|14-gauge slit catheter monitor + standard of care|This arm involves insertion of the 14g slit catheter into the same leg as the arterial ECMO tubing to continuously monitor compartment pressures.
89540811|NCT05821569||standard position during breastfeeding|Women who adopted, according to their preference and/or to the professional advice and support of the nursing staff the standard position (derived from UNICEF guidelines) to breastfeed
89540812|NCT05821569||biological nurturing|Women who adopted, according to their preference and/or to the professional advice and support of the nursing staff, the biological nurturing approach to breastfeed
89540813|NCT05810415||Renin group and lactate group|Renin group and lactate group
89540814|NCT05799079|Experimental|Treatment (Venetoclax, DEC-C)|Patients receive venetoclax PO daily for 28 days in a 28-day cycle. Patients receive DEC-C PO daily on days 1-5 of a 28-day cycle. Patients undergo bone marrow biopsy and aspiration and blood sample collection throughout the study.
89540815|NCT05789589|Experimental|Azeliragon and Stereotactic Radiosurgery (SRS)|"In the Phase 1 portion of the study, three treatment regimens will be systematically evaluated:~Azeliragon + SRS + loading corticosteroid dose (LD) + corticosteroid taper (CT)~Azeliragon + SRS + loading corticosteroid dose (LD)~Azeliragon + SRS~The starting cohort will receive Regimen #2, and depending on the tolerability, participants will be allocated to subsequent cohorts as follows: if Regimen #2 is not well tolerated, participants will be allocated to Regimen #1; if #2 is well tolerated, participants will be allocated to Regimen #3.~Once a Regimen has been identified as safe and tolerable, it will be used for the Phase 2 portion of the study."
89540816|NCT05785169|Experimental|First Cluster|"The intervention will be implemented across three steps with a total of 6 clinics (two clinics per step). The earliest roll-out of the intervention will be at the clinics randomized to Cluster 1.~The intervention consists of a mix of Workshops, Interactive Trainings and Learning Circles (virtual and in-person). In the first workshop, the investigators will present baseline findings to all clinic members to 1) raise awareness for the need for intervention to reduce Structural Racism and Discrimination (SRD) , 2) facilitate collaborative processes, 3) catalyze change for practice transformation, to 4) guide the intervention process. This workshop will be followed by a series of interactive trainings covering topics from the history of structural racism, to intersectional stigma and discrimination, bias, systems of accountability, and the creation of a manual to guide the implementation and sustainability of SRD reduction efforts."
89540817|NCT05785169|Experimental|Second Cluster|"The intervention will be implemented across three steps with a total of 6 clinics (two clinics per step). The earliest roll-out of the intervention will be at the clinics randomized to Cluster 1.~The intervention consists of a mix of Workshops, Interactive Trainings and Learning Circles (virtual and in-person). In the first workshop, the investigators will present baseline findings to all clinic members to 1) raise awareness for the need for intervention to reduce Structural Racism and Discrimination (SRD) , 2) facilitate collaborative processes, 3) catalyze change for practice transformation, to 4) guide the intervention process. This workshop will be followed by a series of interactive trainings covering topics from the history of structural racism, to intersectional stigma and discrimination, bias, systems of accountability, and the creation of a manual to guide the implementation and sustainability of SRD reduction efforts."
88959845|NCT05968222|No Intervention|Control group|Participants in the control group will undergo a determination of glycosylated hemoglobin, blood pressure, lipid profile, weight and height, as well as functional tests such as TUG, 10MWT, 5STS. Subsequently, they will be encouraged to continue their normal life insisting on the importance of glycemic controls before and after their daily physical exercise. In addition to continuing with the dietary measures recommended by their specialist.
88959846|NCT05968222|Experimental|Experimental group|"Participants in the intervention group will be subjected to the following tests:~At the beginning of the intervention, a determination of glycosylated hemoglobin, blood pressure, lipid profile, weight, height and TUG, 10MWT, 5STS, which will be repeated after 12 weeks of intervention.~Before each training session, participants will undergo a basal blood glucose and blood pressure measurement, which will be repeated after the end of the session.~Each training session on the vibrating platform is composed of 6 exercises with a duration of 60 seconds with 60-second pauses between exercises and a warm-up exercise."
88959847|NCT05968209|Active Comparator|Active group|
88959848|NCT05968209|Placebo Comparator|Placebo Group|
88959849|NCT05968196||FTC|Follicular thyroid carcinoma
88959850|NCT05968196||HCC|Hurthle cell carcinoma
88959851|NCT05968118|Experimental|investigational product|Patients in this treatment group will receive 8mg NL003 respective in D0、14、28
88959852|NCT05968118|Placebo Comparator|Placebo|Patients in this group will receive normal saline respective in D0、14、28
88959853|NCT05968040|Active Comparator|responder|
88959854|NCT05968040|Active Comparator|non responder|
89512086|NCT05983094|Experimental|cohort 2 HR positive, HER2 negative breast cancer|HR positive, HER2 negative, Immunohistochemical(IHC)0,1+; 2+, Fluorescence in situ hybridization(FISH)non-amplification breast cancer Drug: Utidelone in combination with Epirubicin Utidelone injection 30mg/m2, on days 1-5 of each cycle; Epirubicin 75mg/m2 was administered on day 1; One treatment cycle is 21 days, and there are 6 cycles in total.
89512087|NCT05983094|Experimental|cohort 3 HER2 positive (IHC 3+; IHC 2+,FISH amplification) breast cancer|"Drug: Utidelone in combination with carboplatin, trastuzumab and pertuzumab Utidelone injection 30mg/m2, on days 1-5 of each cycle; Carboplatin Area Under Curve(AUC)6, iv, was administered on day 1; One treatment cycle is 21 days, and there are 6 cycles in total. Trastuzumab 8mg/kg iv in first cycle on day 1, then 8mg/kg in the rest cycles; pertuzumab 840mg/kg iv in first cycle on day 1, then 420mg/kg in the rest cycles.~One treatment cycle is 21 days, and there are 6 cycles in total."
89512088|NCT05983081|Experimental|Injection Treatment|A- Experimental Group: Intra-articular Hyaluronic Acid Injection Treatment Regimen Patients in the experimental group received ultrasound-guided intra-articular injections of hyaluronic acid (Artibest, 60 mg/3 ml, 2%, manufactured by Kang Stem Biotech, Taiwan) into the affected shoulder joint. The injections were administered once a week for three consecutive weeks, totaling three injections per patient. The subjects were evaluated for shoulder function using the Shoulder Pain and Disability Index (SPADI) and Range of Motion (ROM) assessment at the following time points: before the treatment, 4 weeks after the treatment, 6 weeks after the treatment, and 8 weeks after the treatment.
89512089|NCT05983081|No Intervention|Physical Therapy|B- Control Group: Physical Therapy Patients in the control group underwent a 6-week physical therapy program, consisting of two sessions per week, with each session lasting approximately 30 minutes. The physical therapy program was conducted under the guidance and supervision of a physical therapist and included joint exercises, stretching, and muscle strengthening exercises.
89512090|NCT05983003||Control|"Following the efficacy assessment method outlined in the 2020 EPOS guidelines, the treatment outcomes of chronic sinusitis are categorized as controlled or uncontrolled. Clinical reference evaluation criteria include: nasal congestion, rhinorrhea, facial pain, reduced sense of smell, sleep disturbances, the need for ongoing medication maintenance and the abnormal nasal endoscopy findings, .If there are no three or more symptoms rated five or higher, the patient's chronic sinusitis is considered controlled."
89512091|NCT05983003||Uncontrol|"Following the efficacy assessment method outlined in the 2020 EPOS guidelines, the treatment outcomes of chronic sinusitis are categorized as controlled or uncontrolled. Clinical reference evaluation criteria include: nasal congestion, rhinorrhea, facial pain, reduced sense of smell, sleep disturbances, the need for ongoing medication maintenance and the abnormal nasal endoscopy findings, . The classification is based on the number and severity of these symptoms,and patients with three or more symptoms rated five or higher are considered to have uncontrolled disease"
89512092|NCT05982951|Active Comparator|Shoulder PENG block group|Ultrasound-guided peri-capsular nerve block of the shoulder with 20ml of 0.25% bupivacaine between the supraspinatus muscle and deltoid muscle.
89512093|NCT05982951|Active Comparator|Shoulder block|ultrasound guided axillary nerve block and suprascapular nerve block posterior approach with 10 ml 0.25% bupivacaine (total 20ml)
89512094|NCT05982925||MS Participant|Adults with multiple sclerosis
89512095|NCT05982925||Control Participant|Adults without neurologic disease
89512096|NCT05982925||Other Neuroinflammatory Participants|Adults with a neuroinflammatory disease that is not multiple sclerosis
89512097|NCT05982912||Patients that developed Invasive Pulmonary Aspergillosis|All patients sampled who later on developed IPA
89512098|NCT05982886||PIK3CA positive: HR+ Her2-|
89512099|NCT05982886||PIK3CA positive: HR- Her2-|
89512100|NCT05982886||PIK3CA positive: HR- Her2+|
89512101|NCT05982886||PIK3CA positive: HR+ Her2+|
89512102|NCT05982886||PIK3CA negative|
89512103|NCT05982834|Experimental|Disitamab Vedotin combined with fruquintinib and Tislelizumab|
89512104|NCT05982821||Training set|Patients with thyroid nodules underwent contrast-enhanced ultrasound and ultrasound-guided fine-needle aspiration during January 2018 and December 2020 in Sun Yat-sen Memorial Hospital Sun Yat-sen University.
89512105|NCT05982821||Internal test set|Patients with thyroid nodules underwent contrast-enhanced ultrasound and ultrasound-guided fine-needle aspiration during January 2021 and May 2023 in Sun Yat-sen Memorial Hospital Sun Yat-sen University.
89512106|NCT05982821||External test set|Patients with thyroid nodules underwent contrast-enhanced ultrasound and ultrasound-guided fine-needle aspiration during January 2022 and June 2023 in Houjie Hospital of Dongguan and Central People's Hospital of Zhanjiang.
89512107|NCT05982808|Experimental|Novel CLIF correction|ASD patients with novel CLIF correction
89512108|NCT05982808|Active Comparator|conventional correction strategy|ASD patients with conventional correction strategy
88959855|NCT05968027||Onco'nect pre-deployment|- Onco'nect pre-deployment (12 months): period covering the year prior to the actual implementation of the solution in each centre; patients receiving I.V. chemotherapy during the first 6 months of the period will be included, in order to assess the 6-month follow-up.
88959856|NCT05968027||Onco'nect post-deployment|-Onco'nect post-deployment (12 months): period covering the year following the implementation of the solution within the centre (installation, interoperability and parameterisation validated); patients with I.V. chemotherapy implemented during the first 6 months of the period will be included, in order to be able to evaluate the 6-month follow-up.
88959857|NCT05968001||Cohort 1|the younger cohort (aged ≥ 18 and < 60 years at the start of treatment)
88959858|NCT05968001||Cohort 2|the older cohort (aged ≥ 60 years at the start of treatment)
89512109|NCT05982795||CFTR-MT Group|"The cohort of adult cystic fibrosis patients that are currently on Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy (CFTR-MT) will be asked to complete the following research activities at baseline and every six months following for a two-year period.~Nasal endoscopy with microbiome swab and mucus collection through filter paper and sponge~The Sniffin' Sticks extended test kit and/or the University of Pennsylvania Smell Identification Test (UPSIT)~4 validated quality of life questionnaires:~Cystic Fibrosis Questionnaire Revised (CFQ-R)~Sino-Nasal Outcome Test-22 (SNOT-22)~Sinus Control Test (SCT)~Questionnaire of Olfactory Disorders"
89512110|NCT05982795||Non-CFTR-MT Group|"The cohort of adult cystic fibrosis patients that are not currently on Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy (CFTR-MT) will be asked to complete the following research activities at baseline and every six months following for a two-year period.~Nasal endoscopy with microbiome swab and mucus collection through filter paper and sponge~The Sniffin' Sticks extended test kit and/or the University of Pennsylvania Smell Identification Test (UPSIT)~4 validated quality of life questionnaires:~Cystic Fibrosis Questionnaire Revised (CFQ-R)~Sino-Nasal Outcome Test-22 (SNOT-22)~Sinus Control Test (SCT)~Questionnaire of Olfactory Disorders"
89512111|NCT05982756|Experimental|Test group: Induction treatment plan A|Bortezomib+DAG pre-excitation regimen
89512112|NCT05982756|Active Comparator|Control group: induction regimen B|DAG pre-excitation plan alone
89512113|NCT05982743|Experimental|Fermented milk drink|
89512114|NCT05982743|No Intervention|No drink|
89512115|NCT05982652||non-OH group|without orthostaric hypotension in spinal cord injuries
89512116|NCT05982652||symptomatic OH group|Symptomatic individuals in a patient population diagnosed with orthostatic hypotension (Symptom : dizziness, visual disturbance, nausea and headache)
89512117|NCT05982652||asymptomatic OH group|Asymptomatic individuals in a patient population diagnosed with orthostatic hypotension
89512118|NCT05981391||Tinnitus and PTSD (T+P)|Active duty service members and/or veterans with PTSD and tinnitus.
89512119|NCT05981391||Tinnitus Only (TO)|Active duty service members and/or veterans with only tinnitus/no PTSD.
89512120|NCT05981391||PTSD Only (PO)|Active duty service members and/or veterans with only PTSD/no tinnitus.
89512121|NCT05981391||Healthy Controls|Active duty service members and/or veterans with no PTSD and no tinnitus.
89512122|NCT05980351|Experimental|Study group|This group will receive exercise program
89512123|NCT05980351|No Intervention|Control group|This group will receive routine hospital care
89512124|NCT05980104|Experimental|Empowered Relief|Empowered Relief is a 2-hour one session pain relief skills intervention that is delivered to a group of patients by a certified instructor using a standardized treatment manual and electronic slide deck. Content includes completion of a pain survey, pain neuroscience education, information on pain and stress responses, experiential exercises, information on three core pain management skills, completion of a personalized plan for empowered relief, and receipt of a binaural app for daily use.
89512125|NCT05979870||Aortic valve disease-operation|"Surgery of the aortic valve:~Cardiac and blood flow changes assessed by advanced MRI methods before and after treatment."
89512126|NCT05979870||Aortic valve disease-intervention|"Interventional treatment of the aortic valve:~Cardiac and blood flow changes assessed by advanced MRI methods before and after treatment."
89512127|NCT05979870||Pulmonary valve disease-operation|"Surgery of the pulmonary valve:~Cardiac and blood flow changes assessed by advanced MRI methods before and after treatment."
89512128|NCT05979870||Pulmonary valve disease-intervention|"Interventional treatment of the pulmonary valve:~Cardiac and blood flow changes assessed by advanced MRI methods before and after treatment"
89512129|NCT05979649|Experimental|experimental group|"Throughout the intervention period, we will deliver weekly customized feeds to youths at a consistent time, covering stressful events, coping strategies, social support, and emotional intelligence, totaling eight deliveries.~After peer interveners (peer mentors) receive counseling credentials, every fifth participant will be randomly paired with a peer intervener. Over the next eight weeks, they will engage in individualized conversations via online video conferences biweekly.The intervention will last eight weeks, with four conversations in total.~After each personalized conversation, the interveners will collaboratively develop behavioral corrective tasks for the following two weeks from the To Do List, including at least one task from each category: social support, coping strategies, and emotional intelligence. During the next conversation, the interveners will inquire about the participants' completion status and personal experiences."
89512130|NCT05979649|Placebo Comparator|control group|Throughout the eight weeks of intervention, articles without professional psychological knowledge will be delivered to the control group participants once a week at a consistent time, totaling eight deliveries in total.
89512131|NCT05979649|Other|Peer intervener group|"Peer interveners will participate in a one-day course conducted by several instructors with backgrounds in psychology and medicine. They will be required to pass a standardized patient test after the course to obtain the qualification for intervention."
89512132|NCT05979428|Experimental|Part A Single ascending dose (SAD) cohorts in healthy participants:|Healthy participants, randomized in 3:1 ratio in each of the cohorts will receive single ascending dose of either NNC0491-6075 or placebo in 5 cohorts (Cohort A1, A2, A3, A4 and A5). In cohorts A1, A2 and A3, the participants will receive subcutaneous injection, whereas in cohorts A4 and A5 the administration will be performed intravenously.
89512133|NCT05979428|Experimental|Part B Multiple ascending dose (MAD) cohorts in dyslipidemia participants|Participants with dyslipidemia, randomized in the ratio 2:1 in each of the cohorts will receive multiple ascending dose of either NNC0491-6075 or placebo in 3 cohorts (Cohort B1,B2 and B3). Participants will receive subcutaneous injections of either NNC0491-6075 or placebo once weekly for 4 weeks.
89540818|NCT05785169|Experimental|Third Cluster|"The intervention will be implemented across three steps with a total of 6 clinics (two clinics per step). The earliest roll-out of the intervention will be at the clinics randomized to Cluster 1.~The intervention consists of a mix of Workshops, Interactive Trainings and Learning Circles (virtual and in-person). In the first workshop, the investigators will present baseline findings to all clinic members to 1) raise awareness for the need for intervention to reduce Structural Racism and Discrimination (SRD) , 2) facilitate collaborative processes, 3) catalyze change for practice transformation, to 4) guide the intervention process. This workshop will be followed by a series of interactive trainings covering topics from the history of structural racism, to intersectional stigma and discrimination, bias, systems of accountability, and the creation of a manual to guide the implementation and sustainability of SRD reduction efforts."
89540819|NCT05779475||Participants with Parkinson's disease|Participants will not receive any investigational treatment in this study. The participants will be treated with anti-Parkinson's disease medication according to local standard of care.
89540820|NCT05776121|Experimental|ZB001 for injection|Treat different dose cohorts with four intravenous injections of ZB001
89540821|NCT05772702|Experimental|Closed-loop tACS|Closed-loop individual alpha tACS daily for five consecutive days.
89540822|NCT05758896|Experimental|Isuzinaxib (APX-115)|4 x Isuzinaxib 88 mg calculated as free base (4 x 100mg APX-115(Isuzinaxib hydrocloride) capsules as salt form) administered QD, orally, for 5 consecutive days
89540823|NCT05758896|Placebo Comparator|Placebo|4 x Placebo capsules administered QD, orally, for 5 consecutive days
88959859|NCT05967988|Experimental|Atmospheric 3D video projection|Patients in the interventional arm will watch an immersive atmospheric video projection on the walls of their examination room.
88959860|NCT05967988|Sham Comparator|Atmospheric 3D color projection|Patients in the interventional arm will look at a neutral color of their choice projected on the walls of their examination room.
88959861|NCT05967936|Active Comparator|Paracervical block|10cc Bupivacaine 1% at 0.5-1 cm depth of the cervicovaginal junction at 5 and 7 o'clock positions (20cc in total).
88959862|NCT05967936|Experimental|Transcervical block|10cc Bupivacaine 1% through the endocervix using an 17-gauge epidural catheter
88959863|NCT05967923|Experimental|Group (a)|Patients in this group will receive shock wave therapy once a week for four weeks in addition to routine physical therapy program.
88959864|NCT05967923|Experimental|Group (b)|Patients in this group will receive low level lazer therapy three times per week for four weeks in addition to routine physical therapy program.
88959865|NCT05967923|Experimental|Group (c)|Patients in this group will receive only routine physical therapy program.
88959866|NCT05967897|Experimental|Blueberries|Freeze-dried blueberry powder
88959867|NCT05967897|Active Comparator|Blueberries and Whey Protein|Freeze-dried blueberry powder and whey protein
88959868|NCT05967897|Active Comparator|Blueberries and Pea Protein|Freeze-dried blueberry powder and pea protein
88959869|NCT05967897|Active Comparator|Blueberries and Hemp Protein|Freeze-dried blueberry powder and hemp protein
88959870|NCT05967884|Active Comparator|Arm A: Cemiplimab|Arm A: Cemiplimab (n=10), 350mg IV x 1 dose administered prior to surgery.
88959871|NCT05967884|Experimental|Arm B: Cemiplimab + Dupilumab|Arm B: Cemiplimab + Dupilumab (n=10), Cemiplimab 350mg IV x 1 dose + Dupilumab 600 mg SC x 1 dose administered prior to surgery.
88959872|NCT05967845|Active Comparator|Platelet rich fibrin augmented tympanoplasty|Platelet rich fibrin will be prepaired from the patient's own blood throud a centrifugation process and will be applied on the temproalis fascia graft to improve healing.
88959873|NCT05967845|Active Comparator|cartilage tympanoplasty|A piece of cartilage will be harvested from the concha and used as a graft for tympanoplasty
88959874|NCT05967793|Experimental|kinesio tape|Kinesio Tape will be applied on paraspinal trunk extensors muscles for 8 weeks, changed every 3 days.
88959875|NCT05967793|Active Comparator|Routine physical therapy program|routine physical therapy exercise
88959876|NCT05967767|Experimental|3 Session Repeated Sprint Training in Normobaric Hypoxia|Hypoxia group was exposed to normobaric hypoxia equal to 3420 m (FiO2: 13.5-13.6 %).
88959877|NCT05967767|Sham Comparator|3 Session Repeated Sprint Training in Normobaric Normoxia|Placebo group was exposed to normobaric normoxia equal to 162 m (FiO2: 20.9 %) through wearing the altitude generator mask.
88959878|NCT05967767|No Intervention|Control group|The control group was subjected to only pre and post-test.
88959879|NCT05967754|Other|Patients with Obstructive sleep Apnea|Patients with Obstructive sleep Apnea
88959880|NCT05967715|Experimental|Exercise training|high intensity interval training: thrice a week
88959881|NCT05967715|Active Comparator|Probiotics|VSL#3# probiotic: twice daily
88959882|NCT05967715|Placebo Comparator|Placebo|Comparator of the Probiotics arm
89540824|NCT05756660|Experimental|Stratum 1- Regimen CS|Cisplatin sensitive/no progression on cisplatin (when given at first diagnosis)
89540825|NCT05756660|Experimental|Stratum 2A- Regimen CSS|Cisplatin resistant or progressed on cisplatin after initial response (when given at first diagnosis)
89540826|NCT05756660|Experimental|Stratum 2B- Regimen CSS|Wilms tumor, GCT, Neuroblastoma
89540827|NCT05752279|Active Comparator|Plasma-Lyte® 148|Plasma-Lyte® 148 fluid 1L given intravenously for fluid replacement
89540828|NCT05752279|Active Comparator|0.9% sodium chloride|Normal saline fluid 1L given intravenously for fluid replacement
89540829|NCT05750498||Children and adolescents with Autoimmune Liver Disease|Pediatric patients with a diagnosis of autoimmune hepatitis, or primary sclerosing cholangitis.
89540830|NCT05743699|Experimental|Case management + Bright Horizons|Participants enrolled into the Bright Horizons intervention group will receive one 2-4 hour long session with an Research Program Assistant.
89540831|NCT05743699|Placebo Comparator|Case management|Participants in the control group will receive standard case management via the White Mountain Apache suicide and self-harm surveillance system.
89540832|NCT05740020|Experimental|Group (A)|Group (A) will receive virtual reality in addition to the traditional exercise program.
89540833|NCT05740020|Active Comparator|Group (B)|Group (B) will receive traditional exercise program.
89540834|NCT05731947|Experimental|Phase 1a: Dose Escalation|Participants will receive SNDX-5613 tablets or capsules three times a day (TID) or two times a day (BID) from Day 1 of each 28-day cycle.
89540835|NCT05731947|Experimental|Phase 1b: Signal-Seeking|Participants will receive SNDX-5613 tablets TID or BID from Day 1 of each 28-day cycle.
89540836|NCT05731947|Experimental|Phase 2: SNDX-5613|Participants will receive SNDX-5613 tablets TID or BID from Day 1 of each 28-day cycle.
89540837|NCT05731947|Active Comparator|Phase 2: Chemotherapy|Participants will receive chemotherapy from Day 1 of each 28-day cycle.
89540838|NCT05725603|Experimental|Shoulder MRI|Shoulder MRI will be performed at least 3 years after shoulder surgery
89540839|NCT05724849|Experimental|Venlafaxine|"Patients who screen negative or meet criteria for mild MDD are eligible for the randomized control trial (RCT) portion of this study in which patients are randomized into either the intervention (venlafaxine) arm or placebo. Participants randomized into the intervention group will be prescribed a starting dose of venlafaxine immediate release (IR) 75mg once daily. The dosing will be increased at the following rate:~Week 1: 75mg in AM~Week 2: 75mg BID~Week 3: 150mg in AM, 75mg in PM~Week 4: 150mg BID~For patients with hepatic impairment, severe renal impairment, or end stage kidney disease, the starting dose is 37.5 mg once daily, increased by increments of 37.5 mg per day to reach a maximum of 187.5 mg per day, given in two divided doses."
89540840|NCT05724849|Placebo Comparator|Placebo|Patients who screen negative or meet criteria for mild MDD are eligible for the randomized control trial (RCT) portion of this study in which patients are randomized into either the intervention (venlafaxine) arm or placebo. Participants randomized to the placebo group will receive a placebo capsule with the same dosing schedule as the intervention group.
89540841|NCT05724849|Other|Observation|Patients who screen positive for moderate, moderately-severe, or severe MDD are excluded from the RCT and will be enrolled in the study as an observation cohort. These patients will be offered initiation of venlafaxine and will be referred to our collaborating oncologic psychiatrist. Patients in cohort B will still complete the same patient-reported outcome measures (PROMs) as patients in cohort A, allowing us to collect data and better understand what effects venlafaxine has on patients who are already diagnosed with depression at the start of treatment for HNC.
89540842|NCT05723198|Experimental|Baricitinib High Dose|Participants will receive baricitinib high dose orally.
89540843|NCT05723198|Experimental|Baricitinib Low Dose|Participants will receive baricitinib low dose orally.
89540844|NCT05723198|Placebo Comparator|Placebo|Participants will receive placebo
89540845|NCT05722158|Placebo Comparator|Placebo|This group will be provided with a placebo solution for comparative purposes.
89540846|NCT05722158|Experimental|Collagen-based product CP1|This group will be provided with a the collagen-based product CP1, which will be compared to the placebo group.
89540847|NCT05722158|Experimental|Collagen-based product CP2|This group will be provided with a the collagen-based product CP2, which will be compared to the placebo group.
89540848|NCT05722158|Experimental|Collagen-based product CP3|This group will be provided with a the collagen-based product CP3, which will be compared to the placebo group.
89540849|NCT05722158|Experimental|Collagen-based product CP4|This group will be provided with a the collagen-based product CP4, which will be compared to the placebo group.
89540850|NCT05718557|Experimental|PYX-106 Dose Escalation|Participants will receive escalating doses of PYX-106 to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of PYX-106, and to determine the recommended dose(s).
89540851|NCT05712798||The children with primary ciliary dyskinesia|The children with primary ciliary dyskinesia
89540852|NCT05712798||Healthy controls|Healthy children
89540853|NCT05710848|Experimental|STM-416|STM-416
89540854|NCT05694884|Placebo Comparator|Placebo|Placebo loading dose equivalents at Baseline and Week 1, then placebo dose equivalents every week (QW) from Week 2 to Week 15
89024313|NCT01004978|Experimental|Arm I (sorafenib tosylate and TACE)|Patients receive sorafenib tosylate PO BID in the absence of disease progression or unacceptable toxicity. Beginning within 2 weeks after a stable dose of sorafenib tosylate is reached, patients undergo TACE comprising doxorubicin hydrochloride, mitomycin C, and cisplatin (closed to accrual as of 10/1/2010); conventional chemoembolization comprising doxorubicin hydrochloride only; or chemoembolization comprising doxorubicin-eluting beads. Treatment with TACE repeats approximately every 4 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and MRI on study.
89024314|NCT01004978|Active Comparator|Arm II (placebo and TACE)|Patients receive placebo PO BID in the absence of disease progression or unacceptable toxicity. Beginning within 2 weeks after a stable dose of placebo is reached, patients undergo TACE as in Arm I. Patients also undergo CT and MRI on study.
89024315|NCT00937001|Experimental|Biopsy/Ultrasound|
89024316|NCT00916903||1|Patients with genetic condition being studied.
89024317|NCT00916903||2|Matched controls
89540855|NCT05694884|Experimental|ASLAN004|Week 0, 1: LD of 600 mg; Week 2 through Week 15 QW: 400 mg dose
89540856|NCT05692388||Aim 1|Qualitative Aim
89540857|NCT05692388||Aim 2|Quantitative Aim
89540858|NCT05692388||Aim 3|Integrative Aim
89540859|NCT05683015|Experimental|Standard of care - tildrakizumab|Patients will continue to receive tildrakizumab according to the standard dosing schedule: subcutaneous injections at weeks 0 and 4, then every 12 weeks (100mg)
89540860|NCT05679674|Experimental|Stereotactic Ablative Body Radiation (SABR) and Tumor Treating Fields (TTF)|50 Gy in five fractions SABR (once per day for 5 days) and use of the TTF system for 18 hours per day starting on the first day of SABR and continuing until abdominal disease progression
89540861|NCT05674240||Cancer associated pain treated with conservative medical management (CMM) only|Subjects in this group are patients who opted for conservative medical management for their chronic pain that is cancer associated, including physical therapy, oral or transdermal medications and injections
89540862|NCT05674240||Cancer associated pain treated with Intrathecal Drug Delivery system (IDDs) along with CMM|Patients in this group are those that opted for targeted drug delivery along with conservative medical management of their cancer-associated pain
89540863|NCT05670158|Experimental|"Cochlear Implantation group"|50 patients with sensorineural hearing loss eligible for cochlear implantation surgery. The blood and perilymph sampling will be performed during surgery (visit V1). The blood sampling will be additionally done during the visits V2, V3 and V4. After the visit V4, this arm will be subdivided into 2 groups: group 1, 15 patients with the delayed residual hearing loss, and group 2,15 patients with preserved residual hearing. For these 30 patients, blood sampling will be also performed during the visit V5.
89540864|NCT05670158|Other|Control group|30 normally hearing patients who will undergo through an otological surgery other than cochlear implantation. A blood sampling will be performed during surgery (visit V1) as well as during the visits V2 and V3.
89024318|NCT00904540|Experimental|Lidoderm®|Commercially available Lidoderm (lidocaine patch 5%), up to four patches applied topically once daily (q24h) to the area of maximal peripheral pain
89024319|NCT00904202|Placebo Comparator|placebo capsules + placebo patch|Placebo to match lidocaine patch; up to four patches applied topically once daily (q24h) to the area of maximal peripheral pain AND Placebo capsules to match gabapentin for oral dosing
89024320|NCT00904202|Experimental|placebo capsules + Lidoderm patch (Lidocaine Group)|Lidoderm (lidocaine patch 5%), up to four patches applied topically once daily (q24h) to the area of maximal peripheral pain AND Placebo capsules to match gabapentin for oral dosing
89024321|NCT00904202|Active Comparator|Gabapentin capsules 1800 mg/day + placebo patch|Gabapentin 300 mg capsules for oral dosing at a dose of 1800 mg/day AND Placebo patch to match lidocaine patch; up to four patches applied topically daily (q24h) to the area of maximal peripheral pain
89024322|NCT00904202|Other|Gabapentin capsules 1800 mg/day + Lidoderm patch|Gabapentin 1800 mg/day AND Lidoderm (lidocaine patch 5%), up to four patches applied topically once daily (q24h) to the area of maximal peripheral pain
89024323|NCT00904020|Experimental|(1) Lidoderm|(1) Commercially available Lidoderm (lidocaine patch 5%) was provided to patients with up to four patches applied topically once daily (q24h) to the area of maximal peripheral pain.
89024324|NCT00719966||Group 1 (hormone receptor-positive)|Patients receive aromatase inhibition therapy for up to 6 months in the absence of unacceptable toxicity.
89024325|NCT00719966||Group 2 (hormone receptor-negative)|Patients do not receive adjuvant treatment.
89024326|NCT00671008||A|
89024327|NCT00671008||B|
89024328|NCT00644033|Active Comparator|1|
89024329|NCT00644033|Active Comparator|2|
89024330|NCT00644033|Placebo Comparator|3|
89024331|NCT00643604|Experimental|treprostinil sodium|all subjects had switched from IV epoprostenol to IV treprostinil sodium
89024332|NCT00585559|Placebo Comparator|Placebos for acetaminophen and N-acetylcysteine|Placebos for acetaminophen and N-acetylcysteine
89024333|NCT00585559|Active Comparator|Acetaminophen and N-acetylcysteine placebo|Acetaminophen 1 gm every 6 hours and N-acetylcysteine placebo
89024334|NCT00585559|Active Comparator|N-acetylcysteine and acetaminophen|N-acetylcysteine IV infusion at 0.5 gm hourly and acetaminophen placebo
89540865|NCT05664555|Active Comparator|Na Fluorescein 3mL Arm|Participants in this arm will receive Na Fluorescein 10% Inj 3mL (300mg) before taking fluorescein angiography.
89540866|NCT05664555|Experimental|Na Fluorescein 1mL Arm|Participants in this arm will receive Na Fluorescein 10% Inj 1mL (100mg) before taking fluorescein angiography.
89024335|NCT00585559|Active Comparator|Acetaminophen 1 Gram and N-acetylcysteine|Acetaminophen 1 gm every 6 hours, plus N-acetylcysteine IV infusion at 0.5 gm hourly
89024336|NCT00585559|Active Comparator|Acetaminophen 1.5 Gram and N-acetylcysteine|Acetaminophen 1.5 gm every 6 hours, plus N-acetylcysteine IV infusion at 0.5 gm hourly
89024337|NCT00486356|Experimental|Capecitabine, Epirubicin, and Carboplatin|Determine the recommended phase II dose of capecitabine when given together with epirubicin and carboplatin in treating patients with progressive, unresectable, or metastatic cancer.
89024338|NCT00471601|Experimental|Interviews/Questionnaires|The primary intervention in part 1 includes the interview for item generation with 50 women and the pilot-testing with a separate group of n = 30 women. The primary intervention in part 2 and 3 is the administration of the questionnaire. In part 3, along with the questionnaire being developed, the Body Image Scale (BIS), the Life Orientation Test-Revised (LOT-R), and the upcoming MSKCC BREAST-Q will be given to determine convergent and discriminant construct validity. No other therapeutic or diagnostic agents will be administered.
89024339|NCT00447382|Active Comparator|NN304|Individually adjusted dosage of insulin detemir produced by the NN304 process, administered sub-cutaneously (s.c.) 1-2 times daily + Individually adjusted dosage of insulin aspart, administered sub-cutaneously (s.c.) at meals for 52 weeks
89024340|NCT00447382|Experimental|NN729|Individually adjusted dosage of insulin detemir produced by the NN729 process, administered sub-cutaneously (s.c.) 1-2 times daily + Individually adjusted dosage of insulin aspart, administered sub-cutaneously (s.c.) at meals for 52 weeks
89024341|NCT00439946|Experimental|treprostinil|IV treprostinil continuous infusion via Crono Five infusion pump.
89540867|NCT05660395|Experimental|Arm A: Normal Hepatic Function|"Participants will receive loncastuximab tesirine 0.15 mg/kg once every 3 weeks (Q3W) for two cycles, then 0.075 mg/kg Q3W for subsequent cycles (1 cycle = 21 days).~Participants who have a toxicity meeting the criteria for dose reduction will have subsequent doses reduced by 50%. If the toxicity recurs, subsequent doses must be reduced by an additional 50%. A maximum of 2 dose reductions are allowed. Participants who have a toxicity meeting the criteria for dose reduction following Cycle 2 will receive the protocol-specified dose of 50% of initiate dose for Cycle 3, i.e., they will not have an additional dose reduction for Cycle 3."
89540868|NCT05660395|Experimental|Arm B: Moderate Hepatic Impairment|"Participants will receive loncastuximab tesirine in a standard 3+3 dose-escalation design. Initial dose will be 0.09 mg/kg Q3W for two cycles, then 0.045 mg/kg Q3W for subsequent cycles (1 cycle = 21 days). The highest dose possibly administered will be 0.15 mg/kg Q3W.~Participants who have a toxicity meeting the criteria for dose reduction will have subsequent doses reduced by 50%. If the toxicity recurs, subsequent doses must be reduced by an additional 50%. A maximum of 2 dose reductions are allowed. Participants who have a toxicity meeting the criteria for dose reduction following Cycle 2 will receive the protocol-specified dose of 50% of initiate dose for Cycle 3, i.e., they will not have an additional dose reduction for Cycle 3."
89540869|NCT05660395|Experimental|Arm C: Severe Hepatic Impairment|"Participants will receive loncastuximab tesirine in a standard 3+3 dose-escalation design. Initial dose will be 0.09 mg/kg Q3W for two cycles, then 0.045 mg/kg Q3W for subsequent cycles (1 cycle = 21 days). The highest dose possibly administered will be 0.15 mg/kg Q3W.~Participants who have a toxicity meeting the criteria for dose reduction will have subsequent doses reduced by 50%. If the toxicity recurs, subsequent doses must be reduced by an additional 50%. A maximum of 2 dose reductions are allowed. Participants who have a toxicity meeting the criteria for dose reduction following Cycle 2 will receive the protocol-specified dose of 50% of initiate dose for Cycle 3, i.e., they will not have an additional dose reduction for Cycle 3."
89540870|NCT05653661|Experimental|Treatment (AP160-complex)|Patients receive AP160-complex IV on study. Patients in the dose-escalation cohort undergo computed tomography/magnetic resonance imaging (MRI) scans, tissue biopsies, and collection of blood samples throughout the trial. Patients in the dose-expansion cohort undergo MRI scan during screening, collection of blood samples during screening and on study, and tissue biopsies throughout the trial.
89540871|NCT05649176|Active Comparator|Diet without soy|Participants receive a diet to moderate the blood glucose response that does not include soy
89540872|NCT05649176|Experimental|Diet with soy|Participants receive a diet to moderate the blood glucose response that includes soy
89540873|NCT05646537|Experimental|The group to which NLP techniques will be applied|"After the participant consented to participate in the study with the Informed Consent Form, her comfort level was measured with the Postpartum Comfort Scale.~A session of NLP (30 minutes) was applied to the participant. The patient was informed about the application. The mother was asked to sit or lie down i Before the discharge of the participant from the hospital, her comfort level was evaluated once again by using the Postpartum Comfort Scale"
89540874|NCT05646537|No Intervention|Control group|"After the participant consented to participate in the study with the Informed Consent Form, her comfort level was measured with the Postpartum Comfort Scale.~Without having any additional practice, the participant solely had the routine clinical protocol.~Before the discharge of the participant from the hospital, her comfort level was evaluated once again by using the Postpartum Comfort Scale."
89540875|NCT05646043|Active Comparator|Patients with cancer of the digestive system|Patients with cancer of the digestive system (oesophageal and stomach cancer) will be enrolled in this study arm.
89540876|NCT05646043|Active Comparator|Patients with cancer of the rectum|Patients with cancer of the rectum will be enrolled in this study arm.
89540877|NCT05642260|No Intervention|control group|"Patients in the control group will receive a conventional physiotherapy treatment (guided by the post-TKR protocol followed at Al-Razi Orthopedic Hospital). The treatment will be delivered by four allocated physiotherapists,The treatment will be delivered by four allocated physiotherapists, and will consist of:~Blood circulation exercise (i.e., ankle pumps)~Quadriceps isometric exercises (i.e., quad sets).~Knee ROM exercises (i.e., knee flexion and extension).~Lower limb strengthening exercises (e.g., straight leg raising, short/ long arch exercises)~Stretching exercises for the hamstring and calf muscles.~Gait training (with and without the assistive device).~Parallel bars exercises (e.g., standing hip abduction/adduction, knee flexion, squatting).~Ascending/descending stairs.~Home program."
89608409|NCT04146363|Experimental|Lebrikizumab 250 Q2W|"Induction Period (Baseline-Week 16):~500 milligram (mg) Lebrikizumab (2 x 250 mg) SC injections as a loading dose at Baseline and Week 2 visits followed by a single 250 mg Lebrikizumab injection Q2W from Week 4 until Week 14.~Maintenance Period (Week 16-Week 52):~One 250 mg Lebrikizumab SC injection Q2W until Week 50.~For participants who received placebo in the Induction Period, the maintenance loading dose is:~Two 250 mg Lebrikizumab SC injections on Week 16.~Two 250 mg Lebrikizumab SC injections on Week 18.~To maintain the blind, for participants who received Lebrikizumab in the Induction Period, the maintenance loading dose is:~One 250 mg Lebrikizumab SC injection and one placebo SC injection on Week 16.~One 250 mg Lebrikizumab SC injection and one placebo SC injection on Week 18."
89540878|NCT05642260|Experimental|intervention (treatment) group|"Patients in the experimental group will receive a comprehensive fall prevention program (described below) integrated into the conventional physiotherapy treatment. The fall prevention program will consist of:~Otago balance exercise for 12 weeks integrated with conventional physiotherapy treatment (described in the control group).~Individualized advice on assistive device usage based on the participant's Berg Balance Score (BBS) revised at the 3 data collection timepoints.~Environmental hazard checklist.~Advice on getting their eyes checked and the use of appropriate footwear to ensure the elimination of other risk factors.~Home program (consists of balance and strength training exercises).~The treatment will be delivered by four allocated physiotherapists. The physiotherapists will receive an introductory/training session on the fall prevention program prior to the commencement of the trial."
89540879|NCT05642156|Active Comparator|Sequential HD - Conventional HD|In sequence A patients will be treated with sequential HD first, for a total of 8 session and then switched to a conventional HD schedule for another 8 sessions.
89540880|NCT05642156|Active Comparator|Conventional HD - Sequential HD|In sequence A patients will be treated with conventional HD first, for a total of 8 session and then switched to a sequential HD schedule for another 8 sessions.
89540881|NCT05640908||Prospective|Participants who have scheduled spinal fusion with pelvic fixation/fusion using iFuse Bedrock Granite. These participants will be followed for 2 years.
89540882|NCT05640765|Active Comparator|Arm 1: (Standard of care + Educational material)|CGs receive the standard of care services assigned by the care team for their patient. Participants also receive additional educational and supportive material for health and wellness.
89540883|NCT05640765|Experimental|Arm 2: (Standard of care + BeWell360-CG)|CGs receive the standard of care services assigned by the care team for their patient and participate in the BeWell360-CG coaching sessions on study.
89540884|NCT05634720|Experimental|PDAC with HA Chemotherapy|On Day 1 of the treatment period, patients will undergo standard-of-care diagnostic laparoscopy to confirm the absence of metastatic disease not seen on staging imaging, as well as tissue acquisition (blood and liver biopsies) for pre-specified correlative scientific studies. On Day 2 (±1 day), patients will receive the interventional treatment, which is neoadjuvant HA chemotherapy. On Day 14 (±5 business days), patients will undergo standard-of-care resection of their primary tumor, as well as tissue acquisition (blood, liver biopsies, primary tumor, regional lymph nodes) for pre-specified correlative scientific studies.
89540885|NCT05632913|Experimental|DaRT Seeds|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seed
89540886|NCT05629702|Experimental|Standard Temozolomide with Nabiximols|"Temozolomide 150mg/m2 for cycle 1, increasing to 200mg/m2 for subsequent cycles, once daily for days 1-5, orally, at the start of each 28 day cycle, up to a maximum of 6 cycles.~Nabiximols up to 12 oromucosal sprays per day up to a maximum of 6 cycles; self titrated over days 1-14 in cycle 1."
89540887|NCT05629702|Placebo Comparator|Standard Temozolomide with Nabiximols-matched placebo|"Temozolomide 150mg/m2 for cycle 1, increasing to 200mg/m2 for subsequent cycles, once daily for days 1-5, orally, at the start of each 28 day cycle, up to a maximum of 6 cycles.~Nabiximols-matched placebo up to 12 oromucosal sprays per day up to a maximum of 6 cycles; self titrated over days 1-14 in cycle 1."
89540888|NCT05629572||Prospective subjects in Emergency Department (ED) with symptoms of acute coronary syndrome (ACS).|"Prospectively collected whole blood specimens from subjects presenting to the emergency department (ED) with chest discomfort or equivalent ischemic symptoms suggestive of acute coronary syndrome (ACS).~For this study's MI adjudication, a minimum of 2 samples are to be tested on the site's standard of care (SOC) instrument, one at baseline and one at another time point (T1, T2, T3). For each of the SOC test results, a corresponding research draw for testing on the i-STAT hs-TnI cartridge should be attempted, if feasible. For research, a minimum of 2 samples are to be tested on i-STAT instruments, one at baseline and one at an additional timepoint. Enrollment will be monitored throughout the clinical study."
89540889|NCT05626452|No Intervention|Usual Care|The current mechanisms used at each healthcare site to assess HIV risk/ take a sexual history, assess PrEP eligibility, identify PrEP ineligibility for otherwise PrEP eligible patients, provide PrEP education, offer PrEP, provide PrEP navigation, measure PrEP uptake, and measure PrEP persistence/retention.
88959883|NCT05967650|Active Comparator|HBV vaccination of Inflammatory bowel disease patients with stander regemin|"inflammatory bowel disease patient with negative HBVs AB will be vaccinated with standerd regemin HBV vaccination~st dose zero~nd dose after 2 months~rd dose after 6 months"
89540890|NCT05626452|Experimental|Intervention|Implementation of 1) Patient Education, 2) Provider PrEP training, 3) EMR optimization, and 4) PrEP navigation, and the effect of these intervention components on the ability of each site to assess HIV risk/take a sexual history, assess PrEP eligibility, identify PrEP ineligibility for otherwise PrEP-eligible patients, provide PrEP education, offer PrEP, provide PrEP navigation, measure PrEP uptake, and measure PrEP persistence/retention.
89540891|NCT05617846||Intervention group|Patients who received antiosteoporosis therapy after bone tumor resection
89540892|NCT05617846||Control group|Patients who underwent bone tumor resection without antiosteoporosis therapy
88959884|NCT05967650|Active Comparator|HBV vaccination of Inflammatory bowel disease patients with accelearetd regemin|"inflammatory bowel disease patient with negative HBVs AB will be vaccinated with standerd regemin HBV vaccination~st dose zero~nd dose after 1months~rd dose after 3 months"
88959885|NCT05967611||Healthy Adults|At least 30 healthy adult participants aged 18-45 years performing the Trendelenburg hip abduction test
88959886|NCT05967559|Experimental|Experiment group|The experimental group received online flipped learning training for six weeks.
88959887|NCT05967559|Other|Control groups|The control group received traditional learning training for 6 weeks.
88959888|NCT05967546||Experimental Group|ECG data and clinical data from this group of arrhythmia patients will be used to build a deep learning model.
88959889|NCT05967533|Experimental|Fermented wheat germ|Patients receive fermented wheat germ PO daily starting 3 days prior to the start of standard of care checkpoint inhibitor therapy on days 1-56 for 8 weeks. Patients undergo blood sample collection during screening, on days 1, 4, 15, 43 and at the end of treatment visit. Patients undergo stool sample collection during screening, day 1, 4 and at the end of treatment visit.
88959890|NCT05967442|Experimental|Magnesium|
88959891|NCT05967442|Active Comparator|Metoclopramide|Metoclopramide 10mg in 50ml D5W over 20 minutes
89512134|NCT05979428|Experimental|Part C: Single ascending dose (SAD) cohorts in healthy Japanese participants:|Healthy Japanese participants, randomized in the ratio 3:1 in each of the cohorts will receive single ascending dose of either NNC0491-6075 or placebo in 3 cohorts (Cohort C1,C2 and C3). The route of administration will be subcutaneous or intravenous.
89512135|NCT05979168|Experimental|Intervention arm|Hypertensive patients with uncontrolled BP in the intervention group will receive mobile phone text messages in the Nepali language and accept the phone call from the trained research nurse on their given mobile. They will also get the opportunity to ask questions and clarification during the phone call. However, text messaging would be only one way.
89512136|NCT05979168|No Intervention|Control arm|The control arm will receive the usual routine maintenance. In Nepal, hypertensive patients usually receive a prescription of antihypertensive medicine and advise for follow-up as the standard care. In addition, a pamphlet containing information about hypertension and required behavior modifications will be provided to all study participants, including the control arm.
89512137|NCT05979155|Experimental|Study arm (multiple doses of NWY001)|Part 1: dose-escalation of monotherapy NWY001
89512138|NCT05979155|Experimental|Study arm (RP2D of NWY001)|Part 2: dose-expansion of monotherapy NWY001
89512139|NCT05975372|Experimental|Blossom tissue expander|"The intervention group involves the placement of the Mentor Spectrum tissue expander coupled with Blossom Syringe Assist device inserted above the pectoralis major muscle in the usual fashion. The nature of the surgery remains identical to that employed for conventional breast tissue expander insertion for reconstruction or augmentation.~Postoperative follow-up will occur within 1 week of surgery. Weekly follow-ups with documentation of clinical data throughout will also take place until completion of the expansion, stabilization of surgical scars, and removal of all percutaneous drains. Tissue expansion will be automatic via the Blossom device until appropriate volume is achieved. Thereafter, follow-ups will be scheduled as needed (monthly) according to usual clinical practice in implant-based breast reconstruction in preparation for the second stage expander to definitive implant exchange."
89512140|NCT05975372|Active Comparator|Standard tissue expansion|The standard tissue expansion group will undergo the same procedure with placement of the Mentor Spectrum tissue expander inserted above the pectoralis major muscle in the usual fashion. Postoperative follow-up will occur within 1 week of surgery. Weekly follow-ups with documentation of clinical data throughout will also take place until completion of the expansion, stabilization of surgical scars, and removal of all percutaneous drains. Tissue expansion will be achieved via serial injections of sterile saline into the tissue expander during postoperative follow up visits. Thereafter, follow-ups will be scheduled as needed (monthly) according to usual clinical practice in implant-based breast reconstruction in preparation for the second stage expander to definitive implant exchange. The postoperative follow-up and subsequent surgery to exchange the device to a permanent implant is normal part of standard care.
89512141|NCT05974826|Experimental|Community Intervention (town: Cardona)|"The interventions aim to encourage a healthy lifestyle, including diet education, physical activity, and wellbeing.~The SI! Program for Secondary Schools: a four-year specially designed educational program for adolescents is applied.~The Fifty-Fifty Program implies two stages: 1) Training period; 2) a Peer-group intervention, designed to make the subjects participate actively in their healthcare"
89512142|NCT05974826|No Intervention|Community Control (town: Sallent)|The participants on the control group only receive general health recommendation at the end of each assessment.
89512143|NCT05973084||Natural infection cohort|Up to 200 symptomatic subjects (index cases) will be enrolled when they seek diagnosis for their symptoms of COVID-19 and have their SARS-CoV-2 infection confirmed. All their household contacts (anticipated 700) aged 5-75 years who provide consent (participants) will be examined for infection through two consecutive SARS-CoV-2 RT-PCR. Blood will be drawn from all participants who provide consent. Venous Blood will be drawn at the first visit (so called W0). A second collection is planned for 15 days after the first visit, a third collection at three months after the first visit, and subsequent collections are planned at six, nine, and 15 months after the first visit. At the visits one month, nine months and 15 months after the first visit, capillary blood will be collected. A stool sample will be collected for diagnosis of intestinal parasites.
89519475|NCT04396717|Experimental|Pritumumab|"Dose Escalation phase (3+3 patients):~Pritumumab administered sequentially as 1-hour IV infusion, on Day 1, 8, and 22 of each 28-day treatment cycle at: 1.6 mg/kg, 4.8 mg/kg, 8.0 mg/kg, 12.0 mg/kg, and 16.2 mg/kg, for a maximum of 6 cycles or progression or unacceptable toxicity.~Expansion phase (6-12 patients): Pritumumab administered as 1-hour IV infusion, on Day 1, 8, and 22 of each 28-day treatment cycle at or below MTD for a maximum of 6 cycles or progression or unacceptable toxicity."
88959892|NCT05967442|Active Comparator|Prochlorperazine|Prochlorperazine in 50ml D5W over 20 minutes
89207139|NCT02546466|Experimental|Functional Star-shape taping (FST)|For the Functional Star-shape taping (FST) procedure, four tapes will be applied in the form of an elastic ''I'' with the aim of facilitating muscle activation. The taping will be applied when the participant is in a seated position. The taping will be positioned covering the entire lumbar region and lower part of the thoracic region (T11, T12), and placed first at the center and then on the ends (Castro-Sanchez et al. 2012).The tension of the taping was 25%, this protocol being recommended by the Kinesio taping manual to facilitate muscle activation (Castro-Sanchez et al. 2012; Kase et al. 2003). The participant will remain for on week with FT.
89210532|NCT00627458|Active Comparator|CONTROL GROUP|Healthy male and female subjects between, and including 16 and 20 months of age at the time of booster vaccination, who were given the licensed formulation of Infanrix Hexa™ in the primary vaccination study 106786, additionally received a single booster dose of Infanrix Hexa™ vaccine, administered intramuscularly into the anterolateral quadrant of the right thigh.
89512144|NCT05973084||Vaccine cohort|Up to 600 subjects 18-75 years will be recruited when they attend a vaccination clinic at one of the study health centers in Blantyre to receive their 1st dose of the AstraZeneca (AZ) or the Johnson and Johnson (JJ) COVID-19 vaccines. Venous blood will be collected at that time. For AZ vaccinees, at their 2nd vaccine dose, about 90 days after the 1st dose, they will be given a stool sample container. JJ vaccinees will receive the stool sample container when they receive the first vaccine dose. Two weeks after completion of the primary regimen (2nd dose of the AZ [M3.5] and 1st dose of the JJ vaccines [M0.5]), venous blood draws will be repeated and stool containers will be collected. Subsequent visits/procedures will happen at one month thereafter (M4.5 for AZ and M1.5 for JJ), and 3, 6, 9, and 12 months after the primary regimen. Venous blood will be collected at the visit 1.5, 3, 6, and 12 months after the primary regimen and capillary blood will be collected at the other visits.
89512145|NCT05972811|Experimental|Cold application|"A frozen ice pack at -10 °C will be prepared for the patients in the experimental group. With these ice packs, the JP will be cooled to 13.6 °C, taking into account the literature, in order to create a local anesthetic effect on the drain outlet area before the drain is removed. Skin temperature will be measured intermittently with an infrared thermometer. When the skin temperature reaches 13.6 °C, the doctor will be informed and the drain will be removed. Before starting the cold application, immediately after the drain is removed, and after 15 minutes, considering the literature, pain will be measured with the Visual Analog Scale. By ensuring that the drain removal procedure is performed by the same physician, individual differences that may arise will be prevented."
89512146|NCT05972811|No Intervention|Control|No treatment will be applied to the patients in the control group. Pain measurement will be made with Visual Analog Scale before drain removal, immediately after drain removal, and 15 minutes later.
89512147|NCT05969626|Experimental|5-dose group of test vaccine|
89512148|NCT05969626|Active Comparator|5-dose group of control vaccine|
89512149|NCT05969626|Experimental|4-dose A group of test vaccine|
89512150|NCT05969626|Experimental|4-dose B group of test vaccine|
89512151|NCT05942183||CAM-ICU positive|delirium positive
89512152|NCT05942183||CAM-ICU negative|delirium negative
89512153|NCT05904106|Experimental|Ven+Aza arm|non-intensive treatment: venetoclax plus azacitidine
89512154|NCT05904106|Active Comparator|SOC arm|standard of care treatment: intensive chemotherapy plus gemtuzumab ozogamicin
89512155|NCT05882318|Experimental|Sensory|
89512156|NCT05882318|Experimental|Subsensory|
89512157|NCT05879042|Experimental|Group 1|Static Stretching
89512158|NCT05879042|Experimental|Group 2|Dynamic Stretching
89512159|NCT05879042|Experimental|Group 3|PNF Stretching
89512160|NCT05879042|Sham Comparator|Group 4|Sham stretching
89512161|NCT05859204|Experimental|OT-led Exercise Group on Inpatient Psychiatry Unit|Occupational therapist (OT) led group. Group includes education, warm-up, high intensity interval training cardio, strength, kick boxing, cool-down, yoga, and discussion. This group also receives the Treatment as Usual groups.
89512162|NCT05859204|Placebo Comparator|Treatment As Usual - OT Groups on Inpatient Psychiatry Unit|An occupational therapist (OT) will begin daily educational session about the topic of choice for that day.
89512163|NCT05853445||JAK inhibitor naive|JAK inhibitor naive patients
89512164|NCT05853445||JAK inhibitor pre-treated|JAK inhibitor pre-treated patients (Jakavi® or any other JAK inhibitor for ≥3 months)
89512165|NCT05850234|Experimental|GC012F|GC012F will be administrated in one infusion
89512166|NCT05841316||Sugammadex ED95%|"Sugammadex 0.6 mg/kg will be given in the first patient. The primary outcome is the success of recovery from deep (PTC:1-3) to superficial neuromuscular block (TOFR: 0.4) in 5 minutes after the administration of sugammadex.~In case of success, the next patient will be given the same or reduced dose of 0.2 mg/kg sugammadex according to the randomisation scheme.~In case of failure, the next patient will be given an increased dose of 0.2 mg/kg sugammadex."
89512167|NCT05831774|Placebo Comparator|Control - Standard IV administration of vancomycin|Patients will receive the Houston Methodist Hospital orthopedic surgeon's standard of care pre-operative antibiotic regimen for primary total shoulder arthroplasty patients. This includes IV abx (typically ancef or cefepime and vancomycin) will be started in the pre-operative period approximately 1 hour prior to incision (vancomycin dose weight-based at approximately 15mg/kg [6,7] generally 1000-1750mg in 500mL NS).
89512168|NCT05831774|Experimental|Intervention - Intraosseous (IO) administration of vancomycin|"IV antibiotics (per physician's standard of care): Typically ancef or cefepime is started in pre-op within 1 hour of incision~IO vancomycin is administered in the OR after sterile prep and draping has occurred (500mg in 100-150mL NS).~Injection will take place into the proximal humerus"
89512169|NCT05829395|Experimental|İntervention Group|Starting from the week following the pre-test application, online training will continue according to the Metaverse-based for a total of 3 weeks, two hours a week, for the intervention group. At the end of the 3 weeks, the Instructional Materials Motivation Scale and Academic Success Assessment (Quiz) will be re-administered as a post-test.
89519476|NCT03129217||Patients weaning from mechanical ventilation|
89512170|NCT05829395|No Intervention|Control Group|The subjects were explained by the instructor with the traditional e-teaching method. The subjects will be explained by the instructor with the traditional e-teaching method and as in the intervention group, the lectures were conducted online for two hours a week for 3 weeks. At the end of the 3 week, the post-tests of the Instruvtional Materials Motivation Scale and Academic Success Assessment (Quiz) will be apply in the control group simultaneously with the intervention group.
89512171|NCT05824299|Active Comparator|General Anesthesia|Patients in this group will receive general anesthesia during TURBT.
89512172|NCT05824299|Experimental|Spinal Anesthesia|Patients in this group will receive spinal anesthesia during TURBT.
89512173|NCT05822245|Experimental|Phase 1 Cohort A|Cohort A - Low Dose
89512174|NCT05822245|Experimental|Phase 1 Cohort B|Cohort B - High Dose
89512175|NCT05822245|Experimental|Phase 2 Cohort C|Cohort C - Low Dose or Sham
89512176|NCT05822245|Experimental|Phase 2 Cohort D|Cohort D - High Dose or Sham
89512177|NCT05817461|Experimental|AZD0780|In Part 1, one oral dose of AZD0780 and one intravenous dose of [14C]AZD0780. In Part 2, one oral dose of [14C]AZD0780
89512178|NCT05815173|Experimental|Advanced NSCLC Patients|Patients with KRASG12C mutant NSCLC will receive ladarixin and sotorasib in combination.
89512179|NCT05815004|Experimental|AVR-RD-02 Arm|Participants will have been on a stable prescribed ERT dose for at least 6 consecutive months at the time of Screening and willing to remain on the same ERT dose until 2 weeks prior to gene therapy infusion.
89512180|NCT05815004|Active Comparator|ERT Control Arm|"Participants on stable prescribed ERT dose for at least 6 consecutive months at the time of Screening.~Participants will have the opportunity to receive a gene therapy infusion of AVR-RD-02 after week 52 of Part 1."
89512181|NCT05809193|Experimental|Family-Focused Therapy|Bipolar Disorder and Psychotic Disorder
89512182|NCT05788107|Experimental|HLX51 Group|The initial dose of HLX51 is 0.3mg/kg, and 5 dose levels are designed: 0.3 mg/kg, 1 mg/kg , 2.5mg/kg, 5mg/kg, and 10mg/kg (Q3W). Patients with good tolerability and well controlled disease will receive the treatment until progressive disease (PD) without any clinical benefit, initiation of other anti-tumor therapies, death, intolerable toxicity, or withdraw the informed consent (whichever occurs first).
89512183|NCT05782972|Experimental|dapagliflozin (Forxiga) treatment|The participants received oral dapagliflozin (Forxiga) 10 mg/day for 24 weeks
89512184|NCT05751200||CARS group|In the CARS group, 3-0 polypropylene was used to suture the proximal end of aortic with the vascular grafts continuously, followed by one interrupted suture loop of 3-0 polypropylene for reinforcement.
89512185|NCT05751200||XJ-procedure group|In the XJ-procedure group, a 1.5-2cm wide bovine pericardial patch and graft ring were placed inside and outside the aortic root and against the aortic wall, respectively, and continuously sutured near the commissure using 5-0 polypropylene. Then an eversion about 15mm of vascular graft was intermittently sutured to full layers of aortic vascular with 2-0 pad polyester sutures. Finally, the eversion and aortic wall were continuously sutured together in one more turn.
89512186|NCT05741827|Experimental|Interventional group|Lifestyle intervention with focus on increased physical activity and healthy diet.
89512187|NCT05741827|No Intervention|Control group|No lifestyle intervention. No change in physical activity or diet.
89512188|NCT05736419|Experimental|Participants with Sickle Cell Disease or β-Thalassemia|Participants will have severe sickle cell disease or transfusion-dependent β-thalassemia.
89512189|NCT05729139|Experimental|Cemiplimab and Pegylated Interferon-alpha (PEG-IFN-alpha)|Cemiplimab administered at 350 mg intravenous (IV) every three weeks for up to 2 years. PEG-IFN-alpha administered subcutaneously weekly at doses of 45 mcg to 135 mcg for up to 1 year. Exact dosing will depend on when the participant is enrolled in the study and the number of serious adverse effects that have been encountered by previous participants, if any.
89512190|NCT05695846|Other|Patients with supra-esophageal gastroesophageal reflux disease|GERD patients with complaints of regurgitation and supra-esophageal symptoms
89512191|NCT05694260|Experimental|Cohort 1|Patients at 16 to <30 kg body weight at screening receiving once daily 60 mg bempedoic acid for 8 weeks followed by 90 mg bempedoic acid for 8 weeks.
89512192|NCT05694260|Experimental|Cohort 2|Patients at 30 to 60 kg body weight at screening receiving once daily120 mg bempedoic acid for 8 weeks followed by 150 mg bempedoic acid for 8 weeks.
89512193|NCT05694260|Experimental|Cohort 3|Patients at greater than 60 kg body weight at screening receiving once daily 180 mg bempedoic acid for 8 weeks.
89512194|NCT05690178|Experimental|DTM group|This group of participants (N=20) received Deep Tissue Massage therapy.
89512195|NCT05690178|No Intervention|Control group|This group of participants (N=20) did not receive any intervention.
89512196|NCT05688020|Experimental|Tranexamic acid|During the ER procedure, de-identified injectate solution will be introduced. Study group: 9 ml of standart solution for injection [Consisit of: 6 ml indigo carmine + 500 ml succinylated gelatin 4% (Gelofusine; B. Braun, Crissier, Switzerland)] + 1 ml (100mg) of TXA (tranexamic acid).
89512197|NCT05688020|Active Comparator|Epinephrine|During the ER procedure, de-identified injectate solution will be introduced. 9 ml of standart solution for injection [Consisit of: 6 ml indigo carmine + 500 ml succinylated gelatin 4% (Gelofusine; B. Braun, Crissier, Switzerland)] + 1 ml epinephrine 1:100,000 + 1 ml saline 0.9%.
89512198|NCT05672381||Lower leg Trauma|High-energy lower leg trauma at risk for Acute Compartment Syndrome
89512199|NCT05672381||Forearm Trauma|High-energy forearm trauma at risk for Acute Compartment Syndrome
89512200|NCT05668455|Experimental|HYDROCORTISONE|Topical corticosteroid : hydrocortisone
89512201|NCT05668455|Experimental|DEXAMETHASONE|Topical corticosteroid : dexamethasone
89512202|NCT05668455|Placebo Comparator|POVIDONE|Topical : tear substitute
89512203|NCT05653492|Active Comparator|Group 1|30-50 lbs; 1 tablet (30mg/d) 50-70 lbs; 2 tablets (60mg/d) 70-90 lbs; 3 tablets (90mg/d) >90 lbs; 4 tablets (120 mg/d)
89512204|NCT05653492|Active Comparator|Group 2|30-50 lbs; 1 tablet (30mg/d) 50-70 lbs; 1 tablet (30mg/d) 70-90 lbs; 2 tablets (60mg/d) >90 lbs; 2 tablets (60 mg/d)
89512205|NCT05653492|Active Comparator|Group 3|30-50 lbs; 1 tablet (30mg/d) 50-70 lbs; 1 tablet (30mg/d) 70-90 lbs; 1 tablet (30mg/d) >90 lbs; 1 tablet (30 mg/d)
89512206|NCT05649644|Active Comparator|Selective Trunk Block (SeTB)|Patient who scheduled an upper extremity surgery involving anywhere from the proximal humerus to distal hand or surgery involving any combination of these regions and randomized in SeTB group will receive a SeTB.It will be performed through two skin punctures and as three separate injections to the three trunks of the brachial plexus.
89512207|NCT05649644|Active Comparator|Supraclavicular Brachial Plexus Block (SC BPB)|Patient who scheduled an upper extremity surgery involving anywhere from the proximal humerus to distal hand or surgery involving any combination of these regions and randomized in SeTB group will receive a SC BPB. It will be performed using a single ultrasound window demonstrating the trunks and divisions of the brachial plexus in a superolateral position relative to the subclavian artery at the supraclavicular fossa.
89512208|NCT05640492|Experimental|MCT Group|Older adults (more than 59 years old) with depressive symptoms
89512209|NCT05640492|No Intervention|Control Group|
89512210|NCT05613257|Active Comparator|Free-hand/perfect circles|Patients in this group will have interlocking screw placement using a free-hand, perfect circles technique.
89512211|NCT05613257|Experimental|Distal targeting jig|Patients in this group will have interlocking screw placement using a proximally placed distal targeting jig
89512212|NCT05609357|Experimental|Head-up Cardiopulmonary Resuscitation|
89512213|NCT05565755|Experimental|Parents of adolescents who had a consultation with a group of IM-trained interns.|
89512214|NCT05565755|No Intervention|Parents of adolescents who have not had a consultation with a group of IM trained interns.|
89512215|NCT05564715|Active Comparator|Phase 1: Active Treatment|Participants will receive 10 sessions of active stimulation (1 mA anodal HD-tDCS targeting preSMA/dACC for 20 min) across 2 weeks. Word retrieval and other cognitive tasks will be completed at baseline, immediate follow-up after session 10, and a 2-month follow-up
89512216|NCT05564715|Sham Comparator|Phase 1: Sham Treatment|Participants will receive 10 sessions of sham stimulation across 2 weeks. Word retrieval and other cognitive tasks will be completed at baseline, immediate follow-up after session 10, and a 2-month follow-up
89512217|NCT05564715|Active Comparator|Phase 2: Active Treatment|For Phase 2, participants randomized into the sham group will have the opportunity to return after 2 months from completing Phase 1. They will receive the active treatment while being unblinded to their treatment condition. Following 10 active treatment sessions, word retrieval and other cognitive tasks will again be completed immediately following the last HD-tDCS session and then a 2-month follow-up.
89512218|NCT05529979||Intervention with the EPIONE® device|Patients treated by percutaneous CT-guided procedures in the abdomen with the EPIONE® device
89512219|NCT05520931||Hospitalization group|Previously hospitalized Covid-19 survivors who have been admittet to the hospital with or because of SARS-CoV-2 infection. Time from infection date start is > 6 months. The group is anticipated to encompass 2.182 privously hospitalized adult patients.
89512220|NCT05520931||PCR+ group|Non-hospitalized Covid-19 survivors that has previously testet positive in an Polymerase chain reaction test without being admittet to the hospital. Time from infection data start is > 6 months. The group will include almost the total population of adults who have tested positive in a Polymerase Chain Reaction test. Those with secret adresses and those without access to digital mail (information channel of the questionnaire) will be excluded being approcimatelyh 7% of 650.000 possible participants. The group encompasses 593.741 participants.
89512221|NCT05504395|Experimental|CSTI-500 10mg|All eligible subjects will be administered a single oral dose of CSTI-500 10 mg at Visit 2
89512222|NCT05502575|Experimental|Self-monitoring and individualized stress management|Self-monitoring and individualized stress management materials available on a smartphone.
89512223|NCT05502575|Active Comparator|Self-monitoring and general stress management|Self-monitoring and general stress management materials available on a smartphone.
89512224|NCT05492799|Experimental|single arm|AX 250 300 mg - open label
89512225|NCT05486377|Experimental|Remimazolam|General anesthesia with remimazolam-remifentanil TIVA.
89512226|NCT05486377|No Intervention|Desflurane|General anesthesia with maintaining with desflurane (induction:PPF, remifentanil CIV)
89512227|NCT05483517|Experimental|physiotherapy and high-PEMF|The patient receives physiotherapy under the physiotherapist's guidance and high-PEMF therapy for three weeks, following two sessions a week.
89512228|NCT05483517|Sham Comparator|physiotherapy and sham high-PEMF|The patient receives physiotherapy under the physiotherapist's guidance and sham high-PEMF therapy for three weeks, following two sessions a week.
89512229|NCT05476601|Experimental|CMAP Plus|CMAP Plus is comprised of an existing culturally adapted manually assisted problem-solving intervention (CMAP) integrated with CBT based Motivational Interviewing (MICBT) called (CMAP Plus). The TAU of intervention group participants will be continued along with study intervention.
89512230|NCT05476601|No Intervention|TAU alone|This will be comprised of standard care they will be receiving from participating centres at recruitment sites. The standard care for individuals with SUD in Pakistan usually includes a 2-3-week detoxification programme, followed by 2 months of weekly 1:1 session along with some family sessions, followed by a period of support groups programmes.
89512231|NCT05435729|Experimental|DSP-9632P 27.5 mg in Periods 3 of Part A|Single dose of DSP-9632P 27.5 mg in patients with levodopa-induced dyskinesia in Parkinson's disease
89512232|NCT05435729|Experimental|DSP-9632P 82.5 mg in Periods 4 of Part A|Single dose of DSP-9632P 82.5 mg in patients with levodopa-induced dyskinesia in Parkinson's disease
89512233|NCT05435729|Experimental|DSP-9632P 55.0 mg in Period 1 or 2 of Part B|Multiple dose of DSP-9632P 55.0 mg in patients with levodopa-induced dyskinesia in Parkinson's disease
89512234|NCT05430750|Active Comparator|Conventional' - N2O carrier gas group|Ventilation will be initiated with 2% Sevoflurane in O2-N2O (60 % FiO2) @3L/min to MAC 0.5. Once MAC reaches 0.5, the FGF will be decreased to 1.0L/min (Low flow) and allowed to reach MAC 1.0 before incision is allowed. At 20-minutes time point post induction if MAC 1.0 is not achieved at 2% sevoflurane then the sevoflurane vaporizer concentration will be adjusted to achieve MAC 1.0, before incision is allowed. Anaesthesia will be maintained at MAC 1.0 throughout. After surgery is over, the N2O - Sevoflurane will be stopped and FGF increased to 3.0L with 100% O2.
88959893|NCT05967429||Hepatocellular carcinoma receiving sorafenib|Patient with advanced stage HCC receiving sorafenib
88959894|NCT05967377|Active Comparator|Sorafenib - Period 1|Subjects were admitted to the clinical unit in the morning of Day 1, and dosed with 200 mg Sorafenib (Nexavar®) in the morning of Day 1 following an overnight fast of a minimum of 10 h. Subjects remained in clinical unit until 24 h post dose (Day 2) when they were discharged from the clinical unit, and then returned to the clinical unit at 48 h and 72 h post-dose (Days 3 and 4) for a PK blood sample.The minimum washout before the next dosing period was 10 days.
88959895|NCT05967377|Experimental|XS005 Sorafenib Capsule A - Period 1|Subjects were admitted to the clinical unit in the morning of Day 1, and dosed with 100 mg (2 x 50 mg) XS005 Sorafenib Capsule A in the morning of Day 1 following an overnight fast of a minimum of 10 h. Subjects remained in clinical unit until 24 h post dose (Day 2) when they were discharged from the clinical unit, and then returned to the clinical unit at 48 h and 72 h post-dose (Days 3 and 4) for a PK blood sample.The minimum washout before the next dosing period was 10 days.
88959896|NCT05967377|Experimental|XS005 Sorafenib Tablet A - Period 1|Subjects were admitted to the clinical unit in the morning of Day 1, and dosed with 100 mg XS005 Sorafenib Tablet A in the morning of Day 1 following an overnight fast of a minimum of 10 h. Subjects remained in clinical unit until 24 h post dose (Day 2) when they were discharged from the clinical unit, and then returned to the clinical unit at 48 h and 72 h post-dose (Days 3 and 4) for a PK blood sample.The minimum washout before the next dosing period was 10 days.
88959897|NCT05967377|Experimental|XS005 Sorafenib Capsule A - Period 2|Subjects were admitted to the clinical unit in the morning of Day 1, and dosed with 100 mg (2 x 50 mg) XS005 Sorafenib Capsule A in the morning of Day 1 following an overnight fast of a minimum of 10 h. Subjects remained in clinical unit until 24 h post dose (Day 2) when they were discharged from the clinical unit, and then returned to the clinical unit at 48 h and 72 h post-dose (Days 3 and 4) for a PK blood sample.The minimum washout before the next dosing period was 10 days.
89024342|NCT00325403|Active Comparator|UT-15C (oral treprositnil)|Subjects receive UT-15C (oral treprostinil) twice daily.
89024343|NCT00325403|Placebo Comparator|Placebo|Subjects receive placebo (sugar pill) twice daily.
89024344|NCT00278785|No Intervention|1|Control group to receive informational pamphlet on alcohol use and list of self referral agencies
89512235|NCT05430750|Active Comparator|'Streamed -in' N2O carrier gas group|Ventilation will be initiated with 2% Sevoflurane in O2 -Air (60 % FiO2) @3.0L/min to achieve a MAC of 0.5. Then, the FGF will be decreased to 1.0 L (low flow) and N2O will be 'streamed-in' @ 40 %. When MAC 1.0 is reached incision will be allowed. At 20-minutes time point post induction if MAC 1.0 is not achieved at 2% sevoflurane then the sevoflurane vaporizer concentration will be adjusted to achieve MAC 1.0, before incision is allowed. Anaesthesia will be maintained at MAC 1.0 throughout. After surgery is over, the N2O - Sevoflurane will be stopped and FGF increased to 3.0L with 100% O2.
89512236|NCT05430750|Active Comparator|Non-N2O group|Ventilation will be initiated with 2% Sevoflurane in O2-Air (60 % FiO2 @ 3.0L/min) till the time it reaches MAC 0.5. Once MAC 0.5 reached, the FGF is decreased to 1.0L (Low-flow). The incision is allowed when MAC 1.0 is achieved .At 20-minutes time point post induction if MAC 1.0 is not achieved at 2% sevoflurane then the sevoflurane vaporizer concentration will be adjusted to achieve MAC 1.0, before incision is allowed. Anaesthesia will be maintained at MAC 1.0 throughout. After surgery is over, the O2 - Sevoflurane will be stopped and FGF increased to 3.0L with 100% O2.
89512237|NCT05429593|Experimental|Part 1 sequence A|Semaglutide followed by Semaglutide/dapagliflozin
89512238|NCT05429593|Experimental|Part 1 sequence B|Semaglutide/dapagliflozin followed by Semaglutide
89512239|NCT05429593|Experimental|Part 2 sequence A|Dapagliflozin followed by Semaglutide/dapagliflozin
89512240|NCT05429593|Experimental|Part 2 sequence B|Semaglutide/dapagliflozin followed by dapagliflozin
89512241|NCT05428540|Experimental|Intervention group|Polyphenol-rich dietary supplement (3 capsules/day) + hypocaloric diet (1,200 kcal/day)
89512242|NCT05428540|Placebo Comparator|Control group|Placebo (3 capsules/day) + hypocaloric diet (1,200 kcal/day)
89512243|NCT05428098|Experimental|experiment group|In addition to standard care, patients will be given discharge training, planned within the framework of the Life model, one day before discharge. It is planned that the discharge training will be given by the researcher in the patient's room and by providing an accompanying person. Written training material will be delivered to the patients for their re-use after the training.
89512244|NCT05428098|No Intervention|control group|standard care will be applied
89512245|NCT05406310||Ablation-Index guided ablation group|This is the prospective study group that will undergo persistent atrial fibrillation ablation guided by Ablation Index.
89512246|NCT05406310||High-power, short-duration ablation Group|This is another prospective group of patients who will undergo persistent atrial fibrillation ablation by high-power, short-duration using QDOT Micro catheter.
89512247|NCT05398848|Experimental|Recombinant two-component COVID-19 vaccine (CHO cell)|Antigen: NTD-RBD-foldon protein, Adjuvant (BFA03)
89512248|NCT05398848|Placebo Comparator|Placebo|Adjuvant (BFA03)
89512249|NCT05397353|Experimental|Sleepio|Participants will receive the SleepioTM app
89210533|NCT00909168|Experimental|Efficacy of FLAIMy|
89512250|NCT05394350|Experimental|MK-1088|Participants will receive MK-1088 daily (QD) orally at specified dose on days 1-21 of each 21-day cycle for up to 35 cycles (up to ~24 months).
89512251|NCT05394350|Experimental|MK-1088 + Pembrolizumab|Participants will receive MK-1088 daily (QD) orally at specified dose on days 1-21 of each 21-day cycle plus pembrolizumab at 200 mg intravenous (IV) infusion every 3 weeks (Q3W), on Day 1 of each 21-day cycle for up to 35 cycles (up to ~24 months).
89512252|NCT05394168|Experimental|HLX53|
89512253|NCT05352048|Experimental|Intraoperative MMG vs EMG for cortical breach detection|Participants in this arm will be assessed with both MMG and EMG during their lower spine fusion surgery.
89540893|NCT05617833|Experimental|MLT+EPO|"Melatonin 3 mg/mL oral syringe enterally every evening. For neonates weighing less than 1200 g, divide the dose in half and administer each half 30 minutes apart.~High dose epoetin alfa epbx recombinant (1000 units/kg) syringe IV every 48 hours for 10 doses.~Low dose epoetin alfa-epbx recombinant (400 units/kg) subcutaneously or intravenously three times weekly on Monday, Wednesday, and Friday until age 33-6/7wk."
89540894|NCT05617833|Placebo Comparator|Placebo|"Placebo oral syringe enterally every evening.~Placebo syringe IV every 48 hours for 10 doses.~Placebo subcutaneously or intravenously three times weekly on Monday, Wednesday, and Friday until age 33-6/7wk."
89540895|NCT05616273||MMTT Visit 1, AST Visit 2|Mixed Meal Tolerance Test (MMTT) Visit 1 and Arginine Stimulated Test (AST) Visit 2
89540896|NCT05616273||AST Visit 1, MMTT Visit 2|Arginine Stimulated Test (AST) Visit 1 and Mixed Meal Tolerance Test (MMTT) Visit 2
89540897|NCT05616195||3D printed bone prosthesis replacement surgery|Patients undergoing 3D-printed bone prosthesis replacement surgery
89540898|NCT05600751|Experimental|Radiosurgery of Ganglion Stellatum|Patients will undergo radiosurgery of the ganglion stellatum (left one or both)
89540899|NCT05600088|Experimental|CTS Treatment Arm|active cryotherapy of a single suitable high-risk coronary plaque lesion with CTS device
89540900|NCT05598502|Experimental|REBOA|Addition of REBOA (Resuscitative Endovascular Occlusion of the Aorta)
89540901|NCT05598502|Active Comparator|National guidelines|Treatment according to Uganda national guidelines for post-partum hemorrhage.
89540902|NCT05591430|Active Comparator|Ganglion Impar Neurolysis|Block of ganglion impar using neurolytic
89540903|NCT05591430|Experimental|Bilateral S2, S3 and S4 Pulsed radiofrequency|Pulsed radiofrequency of S2-S4
89540904|NCT05591417|Active Comparator|Intravenous morphine|Patients will receive intravenous morphine 0.1 mg/kg
89540905|NCT05591417|Experimental|Bilevel erector spinae plane block|Patients will receive erector spinae plane block at 2 levels
89024345|NCT00278785|Experimental|2|Intervention group receives pamphlet on alcohol and self referral information in addition to brief motivational interview
89024346|NCT00147199|Experimental|Inhaled treprostinil|0.9 mg/mL treprostinil for inhalation supplied in 2.9mL ampoules for use in ultra sonic nebulizer
89024347|NCT00147199|Placebo Comparator|Placebo|Placebo inhalation solution for use in ultrasonic nebulizer
89540906|NCT05591417|Experimental|Bilevel erector spinae plane block with dexamethasone|Patients will receive erector spinae plane block at 2 levels with dexamethasone
89540907|NCT05591417|Experimental|Bilevel erector spinae plane block with dexmedetomidine|Patients will receive erector spinae plane block at 2 levels with dexmedetomidine
89540908|NCT05589415|Experimental|High Definition tDCS and rehabilitation|"10 sessions (2 hours/session) will be completed with high definition tDCS and upper limb rehabilitation.~Two times prior and two times after rehabilitation, upper limb weakness and neurophysiology will be assessed."
89540909|NCT05589415|Active Comparator|Conventional tDCS and rehabilitation|"10 sessions (2 hours/session) will be completed with conventional tDCS and upper limb rehabilitation.~Two times prior and two times after rehabilitation, upper limb weakness and neurophysiology will be assessed."
89540910|NCT05589402|Experimental|Lidocaine Cream 5%|"A topical anesthetic will be used to deliver temporary inactivation of muscle sensation. Specifically, due to its high safety profile, Lidocaine Cream 5% will be used in the current sub-study. Lidocaine cream (5%) is FDA-approved and available over-the-counter. The investigators will apply the lidocaine cream 5% following FDA guidelines and previously published protocol methodology. A test will be utilized to evaluate if the approach provides complete and temporary inactivation of sensation from the biceps. The von Frey filament test will be used with filaments ranging in size (1,65 to 6,65) to be placed on the biceps muscle every 15 minutes after lidocaine application.~Based on published work, and the current investigators' pilot data, it is anticipated that all sensations from the biceps should be blocked approximately 30 to 60 minutes after lidocaine application. Complete temporary inactivation will be defined at the point when all baseline sensation can no longer be achieved."
89540911|NCT05589402|Other|Rehabilitation Movement Training|"During temporary deafferentation, subjects will perform movement training. Similar to other single-session studies, the current investigators chose to pair the paradigm with movement training to bolster the effects of the approach.~A reaching task that is commonly performed in rehabilitation will be used. Task practice will be performed for 1 hour, with breaks given every 10 minutes. Past experiments in the current investigators' lab have adopted a similar protocol for task practice in SCI and found no adverse events. Movement training will also be assisted by the Bionik InMotion Arm/Hand robot, which has been studied in clinical and rehabilitative practices for over 20 years.~Movement training at 1 hour will be ceased due to issues with fatigue, as has been noted in previous SCI clinical studies. In addition, published work suggests that lidocaine has a half-life of one 1 hour. Thus, maximum benefits should be achieved at the 1-hour mark after application."
89024348|NCT00135668|Active Comparator|0.3 mcg/kg/min|Infusion of Sodium Nitroprusside began only after a 5-minute period of stable anesthesia or sedation (no changes in dosages). The infusion rate during the blinded study drug period was increased in a step-wise fashion to the full dose rate as follows: 5 ± 1 minutes at 1/3 of the full rate; 5 ± 1 minutes at 2/3 of the full rate; and 20 minutes at the full dose rate (ie, 30 minutes total). The full infusion rate was 0.6 mL/kg/hr; 2/3 of the full rate was 0.4 mL/kg/hr; and 1/3 of the full rate was 0.2 mL/kg/hr. After titration to the full dose of blinded study drug, blinded infusion dosage adjustments were not permitted during the blinded study drug administration period. The blinded infusion dosage continued for the 30 minutes unless clinical events demanded a change for safety reasons.
89024349|NCT00135668|Active Comparator|1 mcg/kg/min|Infusion of Sodium Nitroprusside began only after a 5-minute period of stable anesthesia or sedation (no changes in dosages). The infusion rate during the blinded study drug period was increased in a step-wise fashion to the full dose rate as follows: 5 ± 1 minutes at 1/3 of the full rate; 5 ± 1 minutes at 2/3 of the full rate; and 20 minutes at the full dose rate (ie, 30 minutes total). The full infusion rate was 0.6 mL/kg/hr; 2/3 of the full rate was 0.4 mL/kg/hr; and 1/3 of the full rate was 0.2 mL/kg/hr. After titration to the full dose of blinded study drug, blinded infusion dosage adjustments were not permitted during the blinded study drug administration period. The blinded infusion dosage continued for the 30 minutes unless clinical events demanded a change for safety reasons.
89024350|NCT00135668|Active Comparator|2 mcg/kg/min|Infusion of Sodium Nitroprusside began only after a 5-minute period of stable anesthesia or sedation (no changes in dosages). The infusion rate during the blinded study drug period was increased in a step-wise fashion to the full dose rate as follows: 5 ± 1 minutes at 1/3 of the full rate; 5 ± 1 minutes at 2/3 of the full rate; and 20 minutes at the full dose rate (ie, 30 minutes total). The full infusion rate was 0.6 mL/kg/hr; 2/3 of the full rate was 0.4 mL/kg/hr; and 1/3 of the full rate was 0.2 mL/kg/hr. After titration to the full dose of blinded study drug, blinded infusion dosage adjustments were not permitted during the blinded study drug administration period. The blinded infusion dosage continued for the 30 minutes unless clinical events demanded a change for safety reasons
89512254|NCT05346224|Experimental|Treatment group|HLX11 combined with trastuzumab and docetaxel will be adopted in the neoadjuvant treatment phase, and doxorubicin with cyclophosphamide will be administered in the adjuvant chemotherapy treatment phase, HLX11 combined with trastuzumab will be administered in the adjuvant treatment phase for HER-2 targeted.
89512255|NCT05346224|Active Comparator|Control group|Perjeta combined with trastuzumab and docetaxel will be adopted in the neoadjuvant treatment phase, and doxorubicin with cyclophosphamide will be administered in the adjuvant chemotherapy treatment phase, HLX11 or Perjeta combined with trastuzumab will be administered in the adjuvant treatment phase for HER-2 targeted.
89024351|NCT00135668|Active Comparator|3 mcg/kg/min|Infusion of Sodium Nitroprusside began only after a 5-minute period of stable anesthesia or sedation (no changes in dosages). The infusion rate during the blinded study drug period was increased in a step-wise fashion to the full dose rate as follows: 5 ± 1 minutes at 1/3 of the full rate; 5 ± 1 minutes at 2/3 of the full rate; and 20 minutes at the full dose rate (ie, 30 minutes total). The full infusion rate was 0.6 mL/kg/hr; 2/3 of the full rate was 0.4 mL/kg/hr; and 1/3 of the full rate was 0.2 mL/kg/hr. After titration to the full dose of blinded study drug, blinded infusion dosage adjustments were not permitted during the blinded study drug administration period. The blinded infusion dosage continued for the 30 minutes unless clinical events demanded a change for safety reasons
89024352|NCT00066703|Active Comparator|T+OFS|Ovarian function suppression (OFS) by triptorelin (GnRH analogue) 3.75mg by im injection q28 days for 5 years plus tamoxifen 20mg orally daily for 5 years. Tamoxifen (T) begins after the completion of adjuvant chemotherapy if given, or approximately 6-8 weeks after the initiation of triptorelin. Bilateral oophorectomy or ovarian irradiation was allowed after at least 6 months of triptorelin.
89024353|NCT00066703|Experimental|E+OFS|Ovarian function suppression (OFS) by triptorelin (GnRH analogue) 3.75mg by im injection q28 days for 5 years plus exemestane 25mg orally daily for 5 years. Exemestane (E) begins after the completion of adjuvant chemotherapy if given, or approximately 6-8 weeks after the initiation of triptorelin. Bilateral oophorectomy or ovarian irradiation was allowed after at least 6 months of triptorelin.
89024354|NCT00066690|Active Comparator|Tamoxifen|Tamoxifen 20mg orally daily for 5 years
89024355|NCT00066690|Experimental|T+OFS|Tamoxifen 20mg orally daily for 5 years plus ovarian function suppression (OFS; triptorelin (GnRH analogue) 3.75 mg by im injection q28 days for 5 years; or surgical oophorectomy; or ovarian irradiation)
89024356|NCT00066690|Experimental|E+OFS|Exemestane 25mg orally daily for 5 years plus ovarian function suppression (OFS; triptorelin (GnRH analogue) 3.75 mg by im injection q28 days for 5 years; or surgical oophorectomy; or ovarian irradiation)
89024357|NCT00469560|Experimental|Deferasirox|
89024358|NCT00469599|Active Comparator|1|alfacalcidol 16 weeks, 6 weeks wash out, paricalcitol 16 weeks
89024359|NCT00469599|Active Comparator|2|paricalcitol ´16 weeks, 6 weeks wash out, alfacalcidol 16 weeks
89024360|NCT00460980|Other|Virtual reality laparoscopic simulator|"Virtual reality laparoscopic simulator training:~Residents will participate in a structured approach to teaching laparoscopic skills to beginning surgeons with a virtual reality trainer will improve skills prior to actual operative experience."
89512256|NCT05318547|Experimental|standard-gamble technique|"Participants will be asked to imagine a scenario in which they are experiencing one of the 4 described conditions in the long-term. They will declare their preference between (a) keeping this long-term condition as is, or using a painless hypothetical cure that is associated with some risk of death, with the help of a visual aid on a laptop or tablet. A ping-pong technique will be applied until the point of equipoise is reached, when there is indecision whether to take the treatment or not. The utility will be calculated as 1 - the obtained risk of death of the point of equipoise. Health states will be evaluted in different orders across participants.~The elicitation of health state utilites by the standard-gamble technique is further clarified."
89512257|NCT05318547|Experimental|time trade-off technique|Participants will be asked to declare their preference between 50 years of life with the symptoms of 1 of the conditions, or 50-X years without these symptoms, with the help of a visual aid on a laptop or tablet. A ping-pong technique will be applied until the point of equipoise is reached, when there is indecision on the preference of the 2 choices. The utility will be calculated as the 50-x/50 obtained at this point of equipoise. Health states will be evaluted in different orders across participants.
89512258|NCT05302804|Experimental|Menthol gel application|Menthol gel will be applied to the skin prior to exercise in the heat
89512259|NCT05302804|Placebo Comparator|Hypoallergenic gel application|A hypoallergenic gel will be applied to the skin prior to exercise in the heat
89024361|NCT00429338|Experimental|AIR-MRSI|Endorectal MRSI with Air
89024362|NCT00429338|Experimental|PFC-MRSI|Endorectal MRSI with PFC
89024363|NCT00469638|Experimental|Agilis sheeth group|
89024364|NCT00469638|Active Comparator|Non-steerable sheeth group|
89512260|NCT05302791|Experimental|Muscle Cooling|The intervention will be applying a cooling wrap during the bilateral resistance exercise.
89024365|NCT00429455||Survey Participants|Female patients who had a hematopoietic stem cell transplantation between January 1987 and September 2004 at M. D. Anderson Cancer Center.
89512261|NCT05302791|Placebo Comparator|Control|There will be no temperature alteration for this leg during bilateral resistance exercise.
89512262|NCT05285696|Experimental|[68Ga]-NOTA-hGZP (CSB-111) Injection|Eligible participants will receive a single IV injection of CSB-111 up to 40 micro grams
89512263|NCT05285644|Experimental|AR 15512 Ophthalmic Solution (0.003%)|0.003% AR 15512 to be administered BID for 90 days. Both eyes will be treated.
89512264|NCT05285644|Placebo Comparator|Vehicle|AR-15512 vehicle to be administered BID for 90 days. Both eyes will be treated.
89512265|NCT05285215|Experimental|Integrated psychological program (IPP) group|Patients are assigned to have mindfulness training and music listening before and after delivery. Video counselling will be offered if patient is found to have Edinburgh Postnatal Depression Scale (EPDS) equal to or more than 10. Questionnaires on psychological and pain assessments will be administered before and after delivery, with the final time point being 2 months after delivery.
89512266|NCT05285215|No Intervention|Non- Integrated psychological program (IPP) group|Questionnaires on psychological and pain assessments will be administered before and after delivery, with the final time point being 2 months after delivery.
89512267|NCT05273723|Experimental|Intervention|Dose-finding study with 14 groups of 3 participants each. To identify the minimum effective dose (MED) to increase walking by 2,000 more steps per day between run-in and follow-up periods, the first group of 3 participants will receive a 5-week dose of the multi-BCT intervention. For the next subjects, the doses to administrate will vary between 1 and 10 weeks in length and will be determined using a modified version of the Time-to-Event Continual Reassessment Method (TiTE-CRM) according to the observed responses in the previous participants.
89512268|NCT05266430||Case Group|Patients with primary Choroidal Melanoma and Indeterminate Lesions who have received belzupacap sarotalocan (bel-sar; AU-011) in a previous Aura sponsored clinical trial
89512269|NCT05266430||Control Group|Patients who are planned to receive plaque radiotherapy for the treatment of IL/CM based on the expert judgment of the investigator
89512270|NCT05235906|Experimental|Surufatinib + Sintilimab|
89512271|NCT05223972|Experimental|Scoliosis Treatment Group|For the scoliosis group treatment include schroth theraphy
89512272|NCT05223972|Experimental|Lyon Treatment|For the scoliosis group treatment include Lyon theraphy..
89512273|NCT05208307|Experimental|Treatment (belantamab mafodotin, pomalidomide, dexamethasone)|Patients receive belantamab mafodotin IV over 30 minutes on day 1 of every other cycle, pomalidomide PO QD on days 1-21, and dexamethasone PO QD on days 1, 8, 15, and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89512274|NCT05184933|Experimental|Dipping vs non-dipping HTN|"Participants will wear an ambulatory blood pressure monitor (SpaceLabs, Inc.) which will take their blood pressure in 20-30-minute intervals for 24-48 hours to determine blood pressure dipping status.~All participants in this arm will complete the experiments in this order:~At-home polysomnography;~Constant Routine protocol;~Rested Wakefulness Trial AND Overnight Sleep Trial (Randomized crossover);~Sleep Regularization Trial"
89512275|NCT05169164||Single group|All adult patients (aged 18 years or older) undergoing elective or emergency surgery with a planned overnight stay. No interventions, only observational.
89512276|NCT05156658|Active Comparator|Group A: With HIV receiving Monthly CARLA: ENG subcutaneous implant|Participants with HIV-1 receiving monthly cabotegravir-long acting and rilpivirine-long acting (CARLA) (not provided by the study) will receive ENG implant immediately after enrollment.
89512277|NCT05156658|Active Comparator|Group B: Without HIV: ENG subcutaneous implant|Participants without HIV-1 will receive ENG implant immediately after enrollment.
89512278|NCT05136638|Active Comparator|Digital Sleep Hygiene and Self-Monitoring Control|Participants assigned to this condition will receive an app to track sleep and offers sleep hygiene recommendations
89512279|NCT05136638|Experimental|dCBTi without coaching|Participants assigned to this condition will receive a 6-module digital cognitive behavioral therapy for insomnia (dCBTi) with no coaching support
89512280|NCT05136638|Experimental|dCBTi with virtual coaching|Participants assigned to this condition will receive a 6-module digital cognitive behavioral therapy for insomnia (dCBTi) with a virtual coach in the form of a text-based force-choice conversation coach. The virtual coach will check participants' understanding of the treatment materials and lead them to come up with action plans to implement CBTi strategies.
89512281|NCT05136638|Experimental|dCBTi with non-therapist coaching support|Participants assigned to this condition will receive a 6-module digital cognitive behavioral therapy for insomnia (dCBTi) with the virtual coach. They will get additional support from a non-therapist support person who provides support after modules 1, 3, and 6 to address any questions or concerns.
89512282|NCT05136638|Experimental|dCBTi with therapist coaching support|Participants assigned to this condition will receive a 6-module digital cognitive behavioral therapy for insomnia (dCBTi) with the virtual coach. They will get additional support from a clinical psychology trainee who provides therapeutic support that aims to enhance the usage of CBTi treatment strategies.
89512283|NCT05095961|Experimental|Pre-operative oral steroids|Patients will be given a course of oral prednisone (30mg daily) for 5 days.
89512284|NCT05095961|No Intervention|Control|No pre-operative medication will be prescribed
89024366|NCT00461019|Experimental|Implantation of the CardioFit system|
89024367|NCT00461058|Active Comparator|Actos|
89024368|NCT00461058|Experimental|Aleglitazar|
89024369|NCT02957708|Experimental|mCIMT + SR|modified constraint-induced movement therapy plus self regulation
89024370|NCT02957708|Active Comparator|Control|conventional occupational therapy
89024371|NCT00429650|Experimental|1|Increased amount of exercise to maintain weight loss.
89024372|NCT00429650|Experimental|2|Combination of Exercise and Diet to maintain weight loss
89540912|NCT05588063|Experimental|Intervention Group|The intensity setting for pulse amplitude will be adjusted to the participant's tolerance (if a sensation is felt) to a maximum level of 3 on the dial indicator. The remaining settings will be stored in the device and will not need to be set for each treatment. Participants and guardians will be instructed to adjust intensity to highest level of tolerance each time the device is used and level will be logged.
89540913|NCT05588063|Sham Comparator|Sham Group|The sham device will be disabled internally so that electrical stimulation is not delivered, but the device will appear to function. Externally, the sham device will look identical to the taVNS device. The participant will be told to increase the intensity until tolerated if a sensation is felt, but will be asked to stop at a maximum level of 3. This inactive sham method was chosen because previous studies have shown that stimulation with placement of the ear clip on other parts of the ear such as the earlobe, although not innervated by the vagus nerve, results in some vagus nerve activity. Inactive sham methodology has been used in previous studies.
89540914|NCT05585762|Experimental|Ketone ester|Flavored ketone ester beverage 75 mL. Day 0 - 7: half of one bottle consumed daily. Day 8 to end (Week 12): one full bottle consumed daily.
89540915|NCT05585762|Placebo Comparator|Non-ketone placebo|Flavored beverage with bitter additive 75 mL. Matched for appearance, taste and calories. Day 0 - 7: half of one bottle consumed daily. Day 8 to end (Week 12): one full bottle consumed daily.
89540916|NCT05583942|Experimental|Intervention Group|The intensity setting for pulse amplitude will be adjusted to the participant's tolerance (if a sensation is felt) to a maximum level of 3.
89540917|NCT05583942|Sham Comparator|Sham Group|The sham device will be altered internally so that electrical stimulation is not delivered, but the device will appear to function. Externally, the sham device will look identical to the taVNS device. The participant will be told to increase the intensity until tolerated if a sensation is felt, but will be asked to stop at a maximum level of 3.
89024373|NCT00429650|Active Comparator|3|Use diet alone to maintain weight loss.
89024374|NCT00469872|Active Comparator|Child Focused|Occupational and physical therapy focused on improving child's skills and abilities through rehabilitation to improve child functioning
89540918|NCT05582447||Disease Cohort|Age greater than one year old Direct bilirubin level of >2 mg/dl. No known congenital red cell membrane defect
89540919|NCT05582447||Control|Age matched to disease cohort No evidence for cholestatic liver disease No known congenital red cell membrane defect
89540920|NCT05579327|Experimental|Tiratricol|
89540921|NCT05579327|Placebo Comparator|Placebo|
89540922|NCT05576948||Children with or at high risk of CP|Infants with a diagnosis of CP OR at high risk of CP as per the international Clinical Practice Guideline for early diagnosis of CP. In order to develop prognostic curves for motor function a minimum of 3 data points are required per participant. For this reason infants will be included if they are 12 months or younger (corrected age) at the time of enrolment.
89540923|NCT05570253|Experimental|SDX-7320 plus Eribulin (safety run-in period)|During the safety run-in period, the first 15 patients enrolled will be assigned to received study drug SDX-7320 plus Eribulin. Not randomized.
89540924|NCT05570253|Experimental|SDX-7320 plus Eribulin|Patients randomized to SDX-7320 plus Eribulin.
89540925|NCT05570253|Placebo Comparator|Eribulin Plus Placebo|Patients randomized to the control arm will receive placebo plus Eribulin.
89540926|NCT05561842||Participants with a solid mass on breast ultrasound|Participants will have a solid mass on breast ultrasound that is suspicious for breast cancer.
89024375|NCT00469872|Experimental|Context Focused|Occupational and physical therapy focused on improving child's skills and abilities through rehabilitation to change the task or environment around a child
89540927|NCT05557409|Experimental|AXS-05|Up to 5 weeks
89024376|NCT03271476|Experimental|Arms|Experimental: EMDR psychotherapy All the women will be in this arm and thus will receive the same intervention which is : 8 sessions (1 per week). The first session is an inclusion visit at Metz-Thionville Hospital, then 6 EMDR psychotherapy sessions and finally a last visit one month after for data recovery (questionnaire and semi-directive interview)
89024377|NCT03273738||postmenopausal diabetic women|50 female patients with T2DM who visited Assiut University Hospital Diabetes Clinic in Assiut, Egypt in these patients folate level measurement, B12 level and homocysteine are measured
89024378|NCT03273738||postmenopausal without diabetes|Another 50 participants will be volunteered in the study as control.n these subjects folate level measurement', B12 level and homocysteine are measured
89024379|NCT04704245|Experimental|epidermal growth factor (EGF) containing ointment group|"The subjects received one session of laser treatment with a Q-swithced (QS) 532-nm Nd:yttrium aluminum garnet (YAG) laser after enrollment.~The procedure parameters were as follows: 5-10-ns pulse duration, 3.5-mm spot size, 0.9-1.1-J/cm2 fluence, and 2-Hz frequency.~The end point of laser treatment for lentigines was immediate whitening. The subjects then applied the epidermal growth factor (EGF) ointment twice daily (morning and evening) to the lesion for 4 weeks after laser treatment."
89210534|NCT00905736|Experimental|current controlled|a current controlled microcurent device providing a primarily monophasic waveform of typical amplitude 40 microamps
89540928|NCT05557409|Placebo Comparator|Placebo|Up to 5 weeks
89540929|NCT05553418|Experimental|"In-Clinic wear first"|Participant will wear the devices first during 27 hr in-clinic wear first followed by injection, then a short-term wear period in-clinic followed by injection, and finally at home for 27 hrs followed by injection.
89540930|NCT05553418|Experimental|"Home wear first"|Participant will wear the devices at home first with return to clinic for injection, followed by a short-term wear period in-clinic for injection, and finally during a 27hr in-clinic stay for injection
89207140|NCT02546466|Sham Comparator|Sham Functional Taping (Sham-FT)|For the Sham-FT procedure, a single bandage 20 cm in length was positioned horizontally, passing through the spinous process of the second lumbar vertebra (Castro-Sanchez et al. 2012). The tension of the taping was 25%, this protocol being recommended by the Kinesio taping manual to facilitate muscle activation (Castro-Sanchez et al. 2012; Kase et al. 2003). The participant will remain for on week with FT.
89512285|NCT05087108|Experimental|Study arm|In this single arm study all enrolled subjects will the intervention by the investigational device, and both reference devices. Ultrasound will be used to measure the blood flow in the subject during the use of all three devices.
89512286|NCT05071677||Observational (survey, interview)|Patients participate in a standard of care treatment planning meeting over 3 hours with members of the multidisciplinary treatment team including, the oncologist, radiologist, oncology surgeon, and social worker. Patients then complete surveys over 20 minutes and within 30 days later. Some patients may participate in interviews over 30 minutes.
89512287|NCT05067556|Experimental|Intervention|Acceptance and Commitment Therapy for Chronic Pain (ACT-CP)
89512288|NCT05064371|Experimental|Eptinezumab|Participants will receive eptinezumab 100 milligrams (mg) at the Baseline visit (Week 0) and eptinezumab 100 mg or 300 mg (depending upon the treatment response) at Weeks 12, 24, 36, and 48 by intravenous (IV) infusions.
89512289|NCT05020275||Blood samples|Blood samples for further assays
89512290|NCT05004714||Head Start Staff|Head Start staff including teachers, family advocates, directors, and others
89512291|NCT05004714||Head Start Children with Asthma|Children enrolled in Head Start program with physician diagnosed asthma
89512292|NCT04998617|Experimental|Toothpaste Containing Curcumin|After screening, participants will be randomly assigned to receive toothpaste that contains 0.5% curcumin.
89512293|NCT04998617|Placebo Comparator|Toothpaste Without Curcumin|After screening, participants will be randomly assigned to receive toothpaste that does not contain curcumin.
89512294|NCT04965636|Experimental|Participants receiving mepolizumab|
89512295|NCT04949139|Active Comparator|Rapid intermittent bolus group|"A : males < 65 ; B : females < 65 or males ≥ 65 ; C : females ≥ 65 yrs~<During the first 3 h>~Primary treatment over 1h A: 5DW 8 B: 5DW 7 C: 5DW 6 mL/kg~If undercorrected, Repeat the 5DW amount infused during primary treatment after 3 h~<At 3-24 h> Modify protocol based on sNa at each time point (6/12/18/24 h)~Check U/S ratio at 0 h~undercorrection < 0.5: repeat the amount infused during primary treatment q 3 h~≥ 0.5: repeat the amount infused during primary treatment q 6 h~target correction < 0.5: repeat the amount infused during primary treatment q 6 h ≥ 0.5: stop the infusion~<At 24-48 h> Modify protocol based on sNa at each time point (30/36/42/48 h)~Check U/S ratio at 24 h~undercorrection < 0.5: repeat the amount infused during primary treatment q 3 h~≥ 0.5: repeat the amount infused during primary treatment q 6 h~target correction < 0.5: repeat the amount infused during primary treatment q 6 h ≥ 0.5: stop the infusion"
89512296|NCT04949139|Active Comparator|Slow continuous infusion group|"Participants will be divided into three groups same as above~<During the first 3 h>~Primary treatment A: 5DW 1.8 B: 5DW 1.57 C: 5DW 1.35 mL/kg/h~Modify protocol as described below based on sNa measurement at 3 h~undercorrection: maintain the infusion rate~target correction: stop the infusion~<At 3-24 h> Modify protocol based on sNa measurement at each time point (6/12/18/24 h)~Check U/S ratio at 0 h~• undercorrection~< 0.5: increase the infusion rate to twice that of the primary treatment~≥ 0.5: maintain the infusion rate~• target correction~< 0.5: maintain the infusion rate~≥ 0.5: stop the infusion~<At 24-48 h> Modify protocol based on sNa measurement at each time point (30/36/42/48 h)~Check U/S ratio at 24 h~• undercorrection~< 0.5: increase the infusion rate to twice that of the primary treatment~≥ 0.5: maintain the infusion rate~• target correction~< 0.5: maintain the infusion rate~≥ 0.5: stop the infusion"
89512297|NCT04944706|Experimental|Low dose group|The standard basic treatment is given according to the guidelines related to the underlying disease
89512298|NCT04944706|Experimental|High dose group|The standard basic treatment is given according to the guidelines related to the underlying disease
89512299|NCT04944706|Experimental|Placebo group|The standard basic treatment is given according to the guidelines related to the underlying disease
89512300|NCT04939246|Other|Single-fraction SABR|Patients will receive SABR in a single-fraction regiment treatment with one single dose of radiation therapy per lesion. Patients may be treated for up to a total of ten lesions. Each lesion will be treated in one fraction.
89512301|NCT04934163|Experimental|60 L/min arm|The flow rate of HFNC(high-flow nasal cannula) is set as 60 L/min after extubation.
89512302|NCT04934163|Experimental|40 L/min arm|The flow rate of HFNC(high-flow nasal cannula) is set as 40 L/min after extubation.
89512303|NCT04933916|Experimental|EMB-001 Active|720 mg metyrapone/24 mg oxazepam mg BID, for a total daily dose of 1440 mg metyrapone and 48 mg oxazepam
89512304|NCT04908449|Experimental|Rectus sheath block block with PIFB (experimental arm)|PIFB with local anesthetic with RSB with local anesthetic (bupivacaine)
89512305|NCT04908449|Placebo Comparator|Rectus sheath block with PIFB (placebo arm)|PIFB with local anesthetic with RSB placebo (saline)
89512306|NCT04889287|Experimental|Rosuvastatin and/or elinzanetant|The participants will receive each dose of rosuvastatin and/or elinzanetant together with 240 mL of non-sparkling water in total.
89512307|NCT04878094|Active Comparator|Arm A|Randomized to standard technique and assessment of anastomosis without the use of NIR angiography
89512308|NCT04878094|Experimental|Arm B|Randomized to additional assessment of proximal colonic stump and anastomotic perfusion using NIR angiography
89512309|NCT04845841|Experimental|Participants receive study medication on time point 1|Participants will receive two single doses of elinzanetant in two different treatments in a randomized sequence (Treatment A, Treatment B).
89512310|NCT04845841|Experimental|Participants receive study medication on time point 2|Participants will receive two single doses of elinzanetant in two different treatments in a randomized sequence (Treatment A, Treatment B).
89512311|NCT04821453|Placebo Comparator|Conventional Flow Triggered Mechanical Ventilation (CMV)|Subjects will be ventilated with conventional mechanical ventilation with data collected for the 5 day time frame to compare to the experimental arm
89540931|NCT05550207|Experimental|AXS-07 (meloxicam-rizatriptan)|Up to 8 weeks
88959898|NCT05967377|Experimental|XS005 Sorafenib Tablet A - Period 2|Subjects were admitted to the clinical unit in the morning of Day 1, and dosed with 100 mg XS005 Sorafenib Tablet A in the morning of Day 1 following an overnight fast of a minimum of 10 h. Subjects remained in clinical unit until 24 h post dose (Day 2) when they were discharged from the clinical unit, and then returned to the clinical unit at 48 h and 72 h post-dose (Days 3 and 4) for a PK blood sample.The minimum washout before the next dosing period was 10 days.
88959899|NCT05967377|Active Comparator|Sorafenib - Period 2|Subjects were admitted to the clinical unit in the morning of Day 1, and dosed with 200 mg Sorafenib (Nexavar®) in the morning of Day 1 following an overnight fast of a minimum of 10 h. Subjects remained in clinical unit until 24 h post dose (Day 2) when they were discharged from the clinical unit, and then returned to the clinical unit at 48 h and 72 h post-dose (Days 3 and 4) for a PK blood sample.The minimum washout before the next dosing period was 10 days.
89210535|NCT00905736|Experimental|voltage controlled|constant voltage amplitude delivering high frequency AC waveform
89512312|NCT04821453|Experimental|Neurally Adjusted Ventilatory Assist (NAVA)|Subjects will be ventilated on neurally adjusted ventilatory assist (NAVA) mode with data collected for the 5 day time frame to compare with placebo arm
89512313|NCT04796298|Experimental|Ballistic Hamstring Stretching Group|Ballistic Hamstring Stretching
89512314|NCT04796298|Experimental|Hamstring Extender Exercise Group|Hamstring Extender Exercise
89512315|NCT04796298|Experimental|Kinesiotape Group|Kinesiotape
89512316|NCT04729673|Active Comparator|Patient's normal canine occlusal relationship.|Before full mouth rehabilitation with stainless steel crowns for primary molars , the vertical dimension of occlusion from gingival zenith of upper and lower primary canines shall be determined at the right and left sides. The distance shall be determined using a digital caliper.(Shenzhen Jiabaili Electronic Commerce Co., Ltd), and the reading will be photographed by a digital camera (iPhone 11 dual 12 MP Ultra-Wide and wide camera,Apple Inc.).
89512317|NCT04729673|Sham Comparator|Canine occlusal relation after full mouth rehabilitation|After full mouth rehabilitation with stainless steel crowns for primary molars , the vertical dimension of occlusion from gingival zenith of upper and lower primary canines shall be determined at the right and left sides. The distance shall be determined using a digital caliper.(Shenzhen Jiabaili Electronic Commerce Co., Ltd), and the reading will be photographed by a digital camera (iPhone 11 dual 12 MP Ultra-Wide and wide camera,Apple Inc.).
89512318|NCT04712994|Experimental|PrEP Optimization Strategies|Four facilities will be assigned to the intervention group. The intervention group will receive a pre-identified package of interventions (PrEP video counselling, HIV Self-Testing, and optimized delivery and prescription processes).
89512319|NCT04712994|No Intervention|Comparator|Four facilities will be assigned to the comparator group.
89512320|NCT04680533|Experimental|TENS device|The device is worn on the upper calf right below the knee and secured by an elastic band. The device is controlled by an App and alternates between treatment periods and rest periods. Participants will be asked to wear the device 7-8 hours per day alternating legs.
89512321|NCT04640636|Experimental|Ketamine|Ketamine hydrochloride 0.5 mg/kg IM single injection
89512322|NCT04640636|Active Comparator|midazolam|Midazolam 0.06 mg/kg IM single injection
89512323|NCT04624659|Experimental|Double blind etavopivat Low Dose|Double blind etavopivat Low Dose
89512324|NCT04624659|Experimental|Double blind etavopivat High Dose|Double blind etavopivat High Dose
89512325|NCT04624659|Experimental|Double blind placebo|Double blind placebo
89512326|NCT04624659|Experimental|Open label etavopivat|Open label etavopivat
89512327|NCT04619602|Experimental|GSNO therapy|Intervention will be 30 minutes of inhaled GSNO agent in enrollment blocks of three subjects/dose (0.5 mL/kg of 0.25 mM, 0.5 mM, or 1 mM) to infants.
89512328|NCT04585607|Experimental|Expanded hemodialysis (HDx)|HDx therapies be implemented following current clinical practices guidelines and procedures at the hospital. No additional actions are required. General rules will be applied regarding dialysis prescription
89512329|NCT04585607|Active Comparator|Conventional hemodialysis|Conventional hemodialysis therapies be implemented following current clinical practices guidelines and procedures at the hospital. No additional actions are required. General rules will be applied regarding dialysis prescription
89512330|NCT04577326|Experimental|Engineered Autologous T Cells|Following eligibility screening and enrollment, patients will undergo leukapheresis for the collection of peripheral blood mononuclear cells (PBMCs), to enable generation of M28z1XXPD1DNR. Following successful M28z1XXPD1DNR CAR T-cell manufacturing, patients will be reevaluated for eligibility. A preconditioning regimen of one dose of intravenous (IV) cyclophosphamide 1.5 g/m2 will be administered 2-7 days before the infusion. A single dose of M28z1XXPD1DNR CAR T cells will be instilled into the pleural cavity via a pleural catheter or through an interventional radiology-guided needle. All patients will be monitored in the hospital for a minimum of 48 h following the administration of CAR T cells.
89512331|NCT04575766|Experimental|Dose escalation study of FT-7051|
89512332|NCT04573946|Placebo Comparator|Vitamin D placebo + fish oil placebo|
89512333|NCT04573946|Active Comparator|Vitamin D placebo + fish oil|
89512334|NCT04573946|Active Comparator|Vitamin D + fish oil placebo|
89512335|NCT04573946|Active Comparator|Vitamin D + fish oil|
89512336|NCT04570215|Active Comparator|Gotcha! Therapy Application|"Participants will receive the Gotcha therapy daily for six weeks.Participants are required to use the app everyday for a maximum of 45 minutes. After this time they enter a twelve week block with no therapy or maintenance of therapy (see Gotcha maintenance arm).~This aim of this arm is to invesitgate the efficacy of the Gotcha therapy for proper-noun anomia in mild-moderate patients with dementia (Alzheimer's disease, vascular dementia and mixed)"
89519477|NCT03448471||Group 1: severe-fatigued recipients|These recipients had Fatigue Severity Scale score ≥36. All recipients evaluated with similar methods. Meaurements were Pulmonary function tests, Respiratory muscle strength, Peripheral muscle strength, Functional exercise capacity, Dyspnea, Fatigue, Depression and Quality of life.
89519478|NCT03448471||Group 2: non-severe-fatigued recipients|These recipients had Fatigue Severity Scale score <36. All recipients evaluated with similar methods. Meaurements were Pulmonary function tests, Respiratory muscle strength, Peripheral muscle strength, Functional exercise capacity, Dyspnea, Fatigue, Depression and Quality of life.
89210536|NCT00906750|Experimental|1|
89210537|NCT00906750|Active Comparator|2|
89512337|NCT04570215|Active Comparator|Gotcha! Therapy Application: Maintenance|"Participants will receive the Gotcha therapy for six weeks as described in the Gotcha arm. After this time they enter a twelve week block of maintenance of therapy gains made in the initial six week therapy block.~The maintenance block consists of a weekly test of the Gotcha outcome measure to monitor the therapy gains made during the therapy block. If any previously correctly named person is incorrectly named during these weekly tests then the participant must complete a 'top-up' therapy session. They will then be tested again the following week.~The aim of this arm is to compare Gotcha maintenance with Gotcha, to see if extra testing and therapy is required to maintain gains made during an initial intense therapy block."
88959900|NCT05967377|Experimental|XS005 Sorafenib Tablet A - Period 3|Subjects were admitted to the clinical unit in the morning of Day 1, and dosed with 100 mg XS005 Sorafenib Tablet A in the morning of Day 1 following an overnight fast of a minimum of 10 h. Subjects remained in clinical unit until 24 h post dose (Day 2) when they were discharged from the clinical unit, and then returned to the clinical unit at 48 h and 72 h post-dose (Days 3 and 4) for a PK blood sample.The minimum washout before the next dosing period was 10 days.
89512338|NCT04558359|Active Comparator|Standard of Care Cohort|Patients in this group will receive standard of care treatment.
89512339|NCT04558359|Experimental|Angiotensin II Cohort|Patients in this group will receive angiotensin II.
89512340|NCT04538053|Active Comparator|Intervention|Children will receive high-dose oral cefalexin 37.5 mg/kg/dose (max 1.5 g) QID 1 to 7 days followed by oral cefalexin 45 mg/kg/dose (max 1.5 g) TDS for a total course of 3 weeks
89512341|NCT04538053|Active Comparator|Standard Therapy|Children will receive IV cefazolin 50 mg/kg/dose (max 2 g) three-times daily (TDS) or IV flucloxacillin 50 mg/kg/dise (max 2 g) four-times daily (QID) for 1 to 7 days followed by oral cefalexin 45 mg/kg/dose (max 1.5 g) three-times daily (TDS) for a total course of 3 weeks
89512342|NCT04529837||Pregnant individuals with Dilapan-S only|22 women received Dilapan-S rods without gauze at start of induction.
89512343|NCT04529837||Pregnant individuals with Dilapan-S plus gauze placement|22 women received Dilapan-S rods with 1 gauze at start of induction.
89512344|NCT04525794|Experimental|BRight DCB|
89512345|NCT04506879|Other|Popliteal Sciatic Nerve block|Patients will lie on their chest on the examination couch with both feet rested on the pillow to relax their lower extremity. Ultrasound scan of the nerves in popliteal fossa will be identified and then local anesthetic agents [1.5% lidocaine with 1:200,000 adrenaline and 0.5ml of 8.4% sodium bicarbonate (total 30ml)] will be injected close to the nerves (Common peroneal nerve and tibial nerve). The injections below the bifurcation near the two nerves are expected to produce quicker block than the injections above the bifurcation.
89512346|NCT04504344|Experimental|Active tDCS|Active tDCS
89512347|NCT04504344|Sham Comparator|Sham tDCS|Sham tDCS
89512348|NCT04495179|Experimental|Arm A: AZD4635 + durvalumab|AZD4635 plus durvalumab (Arm A) will consist of participants with mCRPC previously treated with one or more approved NHAs (eg, abiraterone acetate, enzalutamide, apalutamide and/or darolutamide), and one or more taxanes, or participants who are taxane ineligible.
89512349|NCT04495179|Experimental|Arm B: AZD4635 + durvalumab + cabazitaxel|AZD4635 plus durvalumab plus cabazitaxel (Arm B) will consist of participants with mCRPC previously treated with docetaxel and one prior NHA (either abiraterone acetate or enzalutamide but not both (prior apalutamide is not allowed in Arm B).
89512350|NCT04482777||ITP|Patient newly diagnosied with ITP
89512351|NCT04482777||Treated|Patients with ITP recived treatment
89512352|NCT04482777||Control|Healthy people
89512353|NCT04385290|Experimental|MODULE trial: dose escalation|Phase I (Trial part MODULE): The treatment plan combines increasing doses levels of midostaurin (25/50 mg BID) and gemtuzumab ozogamicin (3 mg/m^2 i.v. max 4.5 mg on day(s) 1, (4, 7)) with 7+3 standard chemotherapy scheme using cytarabine (200 mg/m^2 cont. inf. i.v. on days 1 to 7) and daunorubicin (60 mg/m^2 i.v. on days 1 to 3).
89512354|NCT04385290|Experimental|MAGNOLIA-trial: conventional chemotherapy+GO and midostaurin|Phase II (Trial part MAGNOLIA): midostaurin (recommended phase II dose, RP2D) is combined with treatment standard (7+3 standard chemotherapy scheme using cytarabine 200 mg/m^2 cont. inf. i.v. and daunorubicin 60 mg/m^2 i.v.) plus GO (recommended phase II dose, RP2D) in CBF AML
89512355|NCT04385290|Active Comparator|MAGNOLIA-trial: conventional chemotherapy+GO|Phase II (Trial part MAGNOLIA): treatment standard of CBF AML (7+3 standard chemotherapy scheme using cytarabine 200 mg/m^2 cont. inf. i.v. and daunorubicin 60 mg/m^2 i.v. plus GO (3 mg/m^2 i.v. max 4.5 mg) on days 1, 4, 7). No additional Midostaurin is given.
89512356|NCT04385290|Experimental|MAGMA-trial: conventional chemotherapy+midostaurin and GO|Phase II (Trial part MAGMA): GO (recommended phase II dose, RP2D) is combined with treatment standard (7+3 standard chemotherapy scheme using cytarabine 200 mg/m^2 cont. inf. i.v. and daunorubicin 60 mg/m^2 i.v.) plus Midostaurin (recommended phase II dose, RP2D) in FLT3 mutated AML
89512357|NCT04385290|Active Comparator|MAGMA-trial: conventional chemotherapy+midostaurin|Phase II Trial (MAGMA): treatment standard of FLT3 mutated AML (7+3 standard chemotherapy scheme using cytarabine 200 mg/m^2 cont. inf. i.v. and daunorubicin 60 mg/m^2 i.v plus midostaurin). No additional GO is given.
89512358|NCT04336241|Experimental|Dose escalation of RP2 - superficial tumors|Dose escalation of RP2 alone in 3 cohorts with IT injections in superficial tumors.
89512359|NCT04336241|Experimental|Dose escalation of RP2 - deep/visceral tumors|Dose escalation of RP2 alone in 3 cohorts with imaging guided IT injections in deep/visceral tumors.
89512360|NCT04336241|Experimental|Dose expansion of RP2 and nivolumab - superficial tumors|Doses of RP2 (IT) in superficial tumors with nivolumab (IV).
88959901|NCT05967377|Active Comparator|Sorafenib - Period 3|Subjects were admitted to the clinical unit in the morning of Day 1, and dosed with 200 mg Sorafenib (Nexavar®) in the morning of Day 1 following an overnight fast of a minimum of 10 h. Subjects remained in clinical unit until 24 h post dose (Day 2) when they were discharged from the clinical unit, and then returned to the clinical unit at 48 h and 72 h post-dose (Days 3 and 4) for a PK blood sample.The minimum washout before the next dosing period was 10 days.
89512361|NCT04336241|Experimental|Dose expansion of RP2 and nivolumab - deep/visceral tumors|Imaging guided doses of RP2 (IT) in deep/visceral tumors.
89512362|NCT04336241|Experimental|Seronegative cohort|Doses of RP2 (IT) in HSV seronegative participants.
89519479|NCT03448315|Active Comparator|real tDCS|motor cortex stimulation (2 mA, 20 min for 4 sessions)
89512363|NCT04328103||Cognitive Behavior Therapy (CBT)|Following established procedures at the Depression Evaluation Service (DES) at New York State Psychiatri Institute (NYSPI), 12 sessions of individual manual-driven CBT (Emery, 2000) will be conducted by highly trained master degree clinicians.
88959902|NCT05967377|Experimental|XS005 Sorafenib Capsule A - Period 3|Subjects were admitted to the clinical unit in the morning of Day 1, and dosed with 100 mg (2 x 50 mg) XS005 Sorafenib Capsule A in the morning of Day 1 following an overnight fast of a minimum of 10 h. Subjects remained in clinical unit until 24 h post dose (Day 2) when they were discharged from the clinical unit, and then returned to the clinical unit at 48 h and 72 h post-dose (Days 3 and 4) for a PK blood sample.The minimum washout before the next dosing period was 10 days.
88959903|NCT05967364|Experimental|Wingman Connect|Wingman-Connect (Wyman et al., 2020 & 2022) uses a network health theoretical framework to strengthen two suicide-protective functions of social networks: 1) Strengthening positive social bonds, and 2) Building healthy norms that incentivize adaptive coping.
88959904|NCT05967364|Active Comparator|Active Control|Active control is stress management training of cognitive and behavioral strategies.
88959905|NCT05967338||Group Direct|glottis visualization in direct lifting
88959906|NCT05967338||Group Indirect|glottis visualization in indirect lifting
89512364|NCT04328103||Nonspecific Supportive Therapy (PBO)|As a non-CBT intervention that includes warmth, genuineness and empathy (Linde et al., 2011), nonspecific supportive therapy (PBO) will be administered in a parallel format to CBT, also consisting of 12 individual sessions.
89512365|NCT04325035|Experimental|Istaroxime - Part A|Istaroxime IV infusion for 24 hours. Istaroxime administration can begin at 1.0 or 1.5 µg/kg/min; the target infusion rate is 1.5 µg/kg/min
89512366|NCT04325035|Placebo Comparator|Placebo - Part A|Placebo (lactose lyophilized powder) IV infusion for 24 hours
89512367|NCT04325035|Experimental|Istaroxime - Part B|Istaroxime IV infusion at 1.0 µg/kg/min for 6 hours, 0.5 µg/kg/min for 42 hours, 0.25 µg/kg/min for 12 hours.
89512368|NCT04325035|Experimental|Istaroxime and Placebo - Part B|Istaroxime IV infusion at 0.5 µg/kg/min for 48 hours, followed by placebo IV infusion for 12 hours.
89512369|NCT04325035|Placebo Comparator|Placebo - Part B|Placebo (lactose lyophilized powder) IV infusion for 60 hours.
89512370|NCT04313712||Participants|All study participants will be observed before and after they receive ibogaine-magnesium therapy.
89512371|NCT04294004|Experimental|KUR-113, Stage 1|During stage 1, subjects randomized to this arm will receive TGplPTH1-34 in fibrin (0.4mg/ml) that will be applied within and around a polyetheretherketone (PEEK) intervertebral cage. The maximum dose that will be applied is 4 mg of TGplPTH1-34 in 10mL KUR-113 Bone Graft.
89512372|NCT04294004|Active Comparator|Autologous Bone Graft|During stage 1 of the study, subjects randomized to this arm will receive local autologous bone graft. In the event of insufficient local autograft, Iliac crest bone graft may be used to supplement.
89512373|NCT04294004|Experimental|KUR-113, Stage 2|During stage 2, subjects will receive TGplPTH1-34 in fibrin that will be applied within and around a PEEK intervertebral cage at a concentration of 0.7mg/ml. The concentration received was selected by the DSMB based on the results of stage 1. The maximum dose that will be applied is 7 mg of TGplPTH1-34 in 10mL KUR-113 Bone Graft.
89512374|NCT04272242|Experimental|Arm 1: DTG + INH + RPT|"Participants will receive 50 mg of DTG orally twice daily (~12 hours apart). Participants will receive 300 mg of INH and 600 mg of RPT orally each morning for 4 weeks.~Participants will also receive 25 or 50 mg of pyridoxine (vitamin B6) with each dose of INH.~Participants will remain on DTG-based ARV treatment with 2 NRTIs (excluding TAF) during the study. Participants will take non-study supply of DTG for morning doses, and will take study-supplied DTG for evening doses."
89512375|NCT04272242|Experimental|Arm 2: DTG + INH + RPT|"Participants will receive 50 mg of DTG orally each morning. Participants will receive 300 mg of INH and 600 mg of RPT orally each morning for 4 weeks.~Participants will also receive 25 or 50 mg of pyridoxine (vitamin B6) with each dose of INH.~Participants will remain on once-daily DTG-based ARV treatment with 2 NRTIs (excluding TAF) during the study. DTG will be from non-study ARV supply.~NOTE: Arm 2 will only open based on assessment of DTG pharmacokinetics (PK) data from participants in Arm 1."
89519480|NCT03448315|Sham Comparator|sham tDCS|motor cortex stimulation (2 mA, 20 min for 4 sessions) but stimulation device is turned off without the participant knowledge
89519481|NCT03448237|Active Comparator|Speech therapy|Speech therapy adapted to the child,
89519482|NCT03448237|Experimental|Combined Treatment|Association of speech therapy and proprioceptive treatment, adapted to the child.
89519483|NCT02164318|No Intervention|Control group|Standard of care
89519484|NCT02164318|Experimental|Handgrip training group|Perform isometric handgrip exercises for 15 minutes twice per day for a total of 30 minutes
88959907|NCT05967312||Intervention:|Offered the Minuteful Kidney Test Kit
88959908|NCT05967312||Control|Continue as standard of care
89512376|NCT04261257|Experimental|Cardiac scanner|"As part of the usual care of patients hospitalized for stroke, the following examinations are carried out: a serum pregnancy test for women of childbearing age, a trans-thoracic cardiac ultrasound, a transesophageal cardiac ultrasound according to the needs of your care, an echo-doppler of the supraaortic trunks, a CT angiography of the supraaortic trunks (CT scan of the cerebral arteries), a transcranial Doppler, a biological assessment, a 24-hour holter or long-term holter.~Within 24 hours after admission: The cerebral artery scan, (usual care), is carried out and is supplemented by the additional examination of this research corresponding to a cardiac scanner (not requiring additional injection of contrast medium).~The following examinations of usual care are carried out within 3 days of inclusion: a trans-thoracic cardiac ultrasound, and a transesophageal cardiac ultrasound according to the needs of patient's care."
89512377|NCT04252209|Experimental|patients with sjogren's received natural mixture|"The intervention is a moisturizing gel containing 10% aloe vera jelly, 10% coconut oil, 3% peppermint essential oil, 3% carboxy methyl cellulose, 10% propylene glycol, and 0.1% potassium sorbate and water up to 100%.~applied topically in all surfaces of oral mucosa 4 times daily after eating and before sleep"
88959909|NCT05967273|Experimental|CirrhosisRx|Providers in this arm will have access to the CirrhosisRx CDS system, which aggregates and organizes clinical data, presents them in clinically relevant/intuitive fashion for cirrhosis care, and linked to order sets consistent with national guidelines.
88959910|NCT05967273|No Intervention|Usual Care|Providers in this arm will not have access to the CirrhosisRx CDS system.
88959911|NCT05967234|Experimental|Telehealth solution|Telehealth solution offered for breastfeeding education.
88959912|NCT05967208|Experimental|CONSORT referrals + Card referrals|Intervention arm
88959913|NCT05967208|Active Comparator|Card referrals alone|Control arm
89512378|NCT04252209|Active Comparator|patients with sjogren's recievrd CMC|"the control is a moisturizing gel containing 3% peppermint essential oil, 3% carboxy methyl cellulose, 10% propylene glycol, and 0.1% potassium sorbate and water up to 100%.~applied topically in all surfaces of oral mucosa 4 times daily after eating and before sleep"
89512379|NCT04248153|Experimental|Group A|BR55 will be performed in the early follicular phase first and in the late follicular phase thereafter.
89512380|NCT04248153|Experimental|Group B|BR55 will be performed in the late follicular phase first and in the early follicular phase thereafter.
89512381|NCT04241549|Experimental|Part 1 (Dose Finding): Cusatuzumab + Azacitidine|Participants with acute myeloid leukemia (AML) will receive cusatuzumab intravenously (IV) in combination with azacitidine subcutaneously (SC) or IV. The dose levels will be escalated based on the decisions of the Study Evaluation Team (SET) until the recommended Phase 2 Dose (RP2D) has been identified.
89512382|NCT04241549|Experimental|Part 2 (Dose Expansion): Cusatuzumab + Azacitidine|Participants with acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS) will receive cusatuzumab intravenously (IV) at the recommended Phase 2 dose (RP2D) determined in Part 1 in combination with azacitidine subcutaneously (SC) or IV.
89512383|NCT04240626|Active Comparator|Standard of Care|The group will receive the standard of care pain control protocol after index Bariatric Surgery which includes the use of a PCA (patient controlled analgesia) with Dilaudid or Morphine Sulphate, transitioning to oral narcotic based pain control medications.
89512384|NCT04240626|Experimental|Multi-Modal|Patients will receive Gabapentin pre-operatively on-call 120 minutes prior to surgery starting. Patients at the conclusion of surgery will have additional doses of Ofirmev (IV Tylenol) and Gabapentin via IV based on patients pre-operative weight. Post surgery the patient will be transitioned to oral pain medications (Tylenol and Gabapentin) with rescue medications available for breakthrough pain control.
89519485|NCT02164318|Experimental|Nitroglycerin ointment group|Apply 15mg of nitroglycerin ointment to the back of the hand of the surgical arm nightly
88959914|NCT05967156|Experimental|Empagliflozin|Heart failure dialysis patients will be treated with Empagliflozin
88959915|NCT05967130|Experimental|UC Positives|Stable Transplanted Patients with Positive UC
89512385|NCT04231318|Experimental|Cingal|Single injection of Cingal: 4 milliliter (mL) dose of 88 mg (22 mg/mL) of cross-linked sodium hyaluronate with 18 mg (4.5 mg/mL) of triamcinolone hexacetonide (TH). Manufactured by Anika Therapeutics.
89512386|NCT04231318|Active Comparator|Triamcinolone Hexacetonide (TH)|Single injection of Triamcinolone Hexacetonide (TH): 1 milliliter (mL) dose of 20 mg/ml TH. Manufactured by IntraPharm.
88959916|NCT05967104|Experimental|Experimental group|"Training to the intervention group was carried out in 3 sessions of 45 minutes each week, organized by the first author (AD). In each session, training was organized based on the PLISSIT framework.~Questionnaires (Introductory individual form, Gynecological cancer awareness scale and Sexual Attitudes and Beliefs Scale) were completed by students included in the intervention and control groups at the beginning and one month after the completion of the 3 training sessions."
88959917|NCT05967104|No Intervention|Control group|The students in the control group were not given any training within the scope of the study, and they only had knowledge about gynecological cancers and sexuality, which are included in the course content of gynecological diseases. However, in order to comply with ethical principles, training information was provided online to the control group after the study data collection process was completed.
88959918|NCT05967091|Experimental|Targeted Lung Denervation|Targeted lung denervation (TLD) with the Ryme Medical Lung Denervation System
89512387|NCT04231318|Placebo Comparator|Placebo|Single injection of Placebo: 4 milliliter (mL) dose of 0.9% saline. Manufactured by Anika Therapeutics.
89512388|NCT04230694|Active Comparator|Control Group|Control Group subjects will wear the CGM device during their hospitalization, up to 10 days, but glucose readings will NOT be continuously monitored. Control Group subjects will have their glucose management guided by routine standard of care finger sticks. The readings from the CGM device are recorded and reviewed retrospectively, but not used for glucose management during the hospital stay.
89512389|NCT04230694|Experimental|Treatment Group|Treatment Group subjects will wear the CGM device during their hospitalization, up to 10 days, and glucose readings WILL be continuously monitored. Treatment Group subjects will have their glucose management guided by readings from the CGM device and standard of care finger sticks.
89512390|NCT04222205|Active Comparator|Crossover sequence 1|"Cluster-randomization crossover sequence 1:~T-piece during odd-numbered months and inspiratory pressure augmentation during even-numbered months."
89512391|NCT04222205|Experimental|Crossover sequence 2|"Cluster-randomization crossover sequence 2:~T-piece during even-numbered months and inspiratory pressure augmentation during odd-numbered months."
89512392|NCT04201262|Experimental|Ravulizumab|"During the Primary Treatment Period, all participants will receive open-label ravulizumab via intravenous (IV) infusion starting on Day 1. The end of the Primary Treatment Period will be triggered when the last enrolled participant completes between 26 and 50 weeks in the study (depending on the number of adjudicated On-Trial Relapse observed).~After completion of the Primary Treatment Period, all participants will have the opportunity to continue receiving ravulizumab in the Long-Term Extension Period of the study. For each participant, the Long-Term Extension Period continues for up to 2 years, or until ravulizumab is approved and/or available (in accordance with country-specific regulations), whichever occurs first."
89512393|NCT04198909|Experimental|Cohort 1|
89512394|NCT04179669|Experimental|IBI306|Participants received IBI306 150 mg subcutaneously Q2W or 450mg Q4W for 12 weeks.
89512395|NCT04179669|Experimental|placebo|Participants received Placebo 150 mg subcutaneously Q2W or 450mg Q4W for 12 weeks.
89512396|NCT04158089|No Intervention|No intervention|"Participants in the No intervention group will receive treatment (e.g., prenatal care) as usual."
89512397|NCT04158089|Experimental|Attachment Exercises|"Participants in the Attachment Exercises group will receive daily texts over the 2-week intervention period with activities to do from home that are designed to increase feelings of attachment (e.g., read a children's book aloud; sing a nursery rhyme; picture giving the baby a bath; tell the baby a story; etc.)."
89512398|NCT04155489|Active Comparator|restrictive|In the restrictive blood transfusion group, if the hemoglobin value is less than 8 g /dL or if there are suspected symptoms of anemia such as dizziness or chest pain, headache, low on energy, blood transfusion is started.
89512399|NCT04155489|Experimental|Liberal|In the liberal transfusion group, If the hemoglobin value is less than 10 g /dL, blood transfusions begin.
89540932|NCT05544825|Experimental|Ice plant group|This group takes ice plant extract for 12 weeks.
88959919|NCT05967078|Experimental|Test group|The device under investigation is the ExerCube training software licence provided by Sphery (https://sphery.ch/exercube/). The ExerCube training software licence is an exergame training product that includes immersive mixed-reality training programs (or video games) for patients. Depending on the patient's training requirements, the therapists can choose from the training program repertoire. The ExerCube supporting material for safety consisting of a harness and an over-head gantry system ensures a safe training environment and prevents patients from falling.
88959920|NCT05967065|Other|Vestibular disorders|Patients uppfilling vestibular disorders diagnostic criterias
88959921|NCT05967065|Other|healthy control subjects|Patients without past or ongoing vestibular or balance disorders
88959922|NCT05967013|Experimental|4-period cross-over|"After a screening period of a maximum of 21 days, eligible subjects will be randomized in a 1:1:1:1 allocation ratio to one of the 4 treatment sequences (settings):~Sequence 1: A&B in Period 1 / C&D in Period 2~Sequence 2: D&A in Period 1 / B&C in Period 2~Sequence 3: C&D in Period 1 / A&B in Period 2~Sequence 4: B&C in Period 1 / D&A in Period 2~Setting definitions:~Setting B = volume 0.64mL of physiological serum with ZENEO® injector, setting GAMMA - Bare skin.~Setting A = volume 0.64mL of physiological serum with ZENEO® injector, setting GAMMA - Through Clothing.~Setting D = volume 0.64mL of physiological serum with ZENEO® injector, setting GAMMA low - Bare skin.~Setting C = volume 0.64mL of physiological serum with ZENEO® injector, setting GAMMA low - Through Clothing."
88959923|NCT05967000||Women at midlife|Women aged 45-65 years with risk factors or pre-existing CVD
88959924|NCT05966987|Experimental|i-PRF side: canine retraction|application of i-PRF with translation of maxillary canine that will be performed on intervention sides according to a standardized protocol
88959925|NCT05966987|No Intervention|i-prf side control side|i-PRF side:canine retraction control side
88959926|NCT05966987|Experimental|LLLT side canine retraction|translation of maxillary canine that will be performed with LLLT application according to a standardized protocol
89024380|NCT04704245|Placebo Comparator|Vehicle ointment group|"The subjects received one session of laser treatment with a Q-swithced (QS) 532-nm Nd:yttrium aluminum garnet (YAG) laser of their solar lentigines after enrollment.~The procedure parameters were as follows: 5-10-ns pulse duration, 3.5-mm spot size, 0.9-1.1-J/cm2 fluence, and 2-Hz frequency.~The end point of laser treatment for lentigines was immediate whitening. The subjects then applied the vehicle ointment twice daily (morning and evening) to the lesion for 4 weeks after laser treatment."
89540933|NCT05544825|Placebo Comparator|Placebo group|This group takes a placebo for 12 weeks.
89540934|NCT05543876|Experimental|intervention group|group watching video with virtual reality glasses
89540935|NCT05543876|No Intervention|control group|without any intervention
89540936|NCT05537441|Active Comparator|Standard Texts|"Patients randomized to this study arm will receive a standard text reminding them about the importance of influenza vaccination. The standard texts will include a clinic call back number and patient portal self-scheduling for patients to schedule their influenza vaccines:~#FirstName#, your flu shot is ready! Call your clinic at #ExternalRefNo# or visit the LA Health Portal at http://bit.ly/BookFluShot if you want this shot held for you."
89540937|NCT05537441|Experimental|Standard Texts with Transportation messaging|"Patients randomized to this study arm will receive standard texts plus transportation messaging including a phone number for patients to reserve transportation to a vaccination appointment based on MediCal health plan transportation resources:~#FirstName#, your flu shot is ready! Call your clinic at #ExternalRefNo# or visit the LA Health Portal at http://bit.ly/BookFluShot if you want this shot held for you. You can call #Health Plan Phone Number# to schedule a free ride for your flu shot through #HealthPlanName#."
89540938|NCT05524727|Experimental|Intervention Group|Usual care + concept-guided, personalized, motor-cognitive training by means of an exergame
89540939|NCT05524727|No Intervention|Control Group|Usual care only
89540940|NCT05524025||Control Cohort: Adult Male Without HPV-positive throat cancer|Participants will receive 1x Salivary TTMV-HPV DNA Test. If test is negative there will not be follow up, if test is positive participants will have repeat Salivary TTMV-HPV DNA Test, a blood test and head and neck exam.
89540941|NCT05524025||Case Cohort: Any Adult With HPV-positive throat cancer|Participants will receive 1x Salivary and Blood TTMV-HPV DNA Test(s).
89540942|NCT05516758|Experimental|Peresolimab Dose 1|Participants will be given peresolimab by subcutaneous injection.
89540943|NCT05516758|Experimental|Peresolimab Dose 2|Participants will be given peresolimab by subcutaneous injection.
89024381|NCT03271671|Active Comparator|PSV|Pressure support ventilation
89024382|NCT03271671|Experimental|NAVA|Neurally adjusted ventilator assist
89024383|NCT03271632|Experimental|Single arm|CAR T cells to treat MM
89024384|NCT00429806|Placebo Comparator|Placebo|Placebo suppository; once daily for 7 days.
89024385|NCT00429806|Experimental|DHEA 0.50%|DHEA 0.50% (6.5 mg) suppository; once daily for 7 days.
89024386|NCT00429806|Experimental|DHEA 1.0%|DHEA 1.0% (13 mg) suppository; once daily for 7 days.
89024387|NCT00429806|Experimental|DHEA 1.8%|DHEA 1.8% (23.4 mg) suppository; once daily for 7 days.
89024388|NCT03273660|Experimental|Aliaxin (new trademark - IBSA Farmaceutici Italia S.r.l.)|
89024389|NCT03271593||All children admitted|All children admitted to hospital
89540944|NCT05516758|Experimental|Peresolimab Dose 3|Participants will be given peresolimab by subcutaneous injection.
89540945|NCT05516758|Active Comparator|Placebo|Participants will be give placebo by subcutaneous injection.
89540946|NCT05508789|Experimental|Donanemab|Participants will receive donanemab intravenously (IV)
89024390|NCT00429962|Experimental|A|intravitreal ranibizumab used in combination with verteporfin photodynamic therapy
89024391|NCT00429962|Active Comparator|B|intravitreal ranibizumab
89024392|NCT03273504|Experimental|Actapil Corpo Spray (SHEDIR PHARMA Srl - Italy)|"Comparison within subjects of Actapil Corpo Spray versus Placebo. The study product will be applied twice a dayon the right or left leg (tibialis area) according to a randomisation list.~The placebo product will be applied in the same way, on the controlateral leg."
89024393|NCT04703894|Experimental|AYMES 'CARDIFF'|Patients established on an oral nutritional supplement (ONS), requiring nutritional supplementation of at least 300kcal/day will be changed onto an equivalent prescription of AYMES 'CARDIFF' for a period of 30 days.
89024394|NCT00461448|Active Comparator|1 Potassium supplement|Patients received an Enriched Grape Juice containing 234.5 mmol microcrystalline KCl (a total of 6000 mg of K in 2 EGJ, but split into 2 intakes daily)
89540947|NCT05508789|Placebo Comparator|Placebo|Participants will receive placebo IV
89540948|NCT05506982|Experimental|Supportive care (psilocybin, observation)|Patients receive psilocybin PO and undergo observation for up to 24 hours on day 14.
89540949|NCT05502861|Experimental|Intervention|The study's intervention is a prognostic-triggered EHR alert to nudge clinicians to provide generalist or specialist PC. The alert notifies the clinician that the patient is likely to benefit from PC, and requires clinicians to actively choose to provide generalist PC themselves, consult PC specialist, or to defer PC. If a clinician chooses to consult specialist PC, a second alert will fire that enables them to easily and quickly place the consult order. The alert will trigger for all patients with moderate or higher 6-month mortality risk on second full hospital day at 8AM.
89540950|NCT05502861|Active Comparator|Control/Usual Care|During the control phase, patients meeting eligibility criteria will be enrolled for study data collection but there will be no attempt to influence delivery of care. The length of the control phase will differ at each hospital dependent on the sequence in which hospitals are randomly assigned to switch to the intervention phase. All hospitals contribute a minimum of 15 weeks of outcomes data prior to adopting the intervention.
89540951|NCT05502042|No Intervention|Usual Care|Referral to a health facility (HC III, IV, or district hospital) that provide secondary antibiotic prophylaxis (every-28-day intramuscular benzathine benzylpenicillin G, BPG), receipt of a Ministry of Health secondary prophylaxis adherence booklet, and education for patient and family about the importance of SAP.
89024395|NCT00461448|Placebo Comparator|2 Grape Juice|Patients received same amount of grape juice for 28 days.
88959927|NCT05966987|No Intervention|LLLT side canine retraction control side|LLLT side canine retraction control side wihout intervention
88959928|NCT05966987|Experimental|I-PRF groupMolar distalization group inrervention side|Idistalization assisted with Injectable platelet-rich fibrin (i-PRF) according to a standardized protocol
89207141|NCT02546466|Active Comparator|Minimal Intervention Strategy (MIS)|The MIS group will receive an educational and counseling booklet (The Back Book) as recommend by Dupeyron et al. (2011) containing information about the low back pain clinical features, risk factors and prognosis, fear avoidance beliefs, how to deal with an acute pain crisis, the early resumption of normal or vocational activities, even when still experiencing pain, and the importance of improvement in functional activity levels and posture, not just pain relief (Delitto et al. 2012). Participants from this group will not receive FT intervention and the investigator will encourage participants to not receive any kind of treatment during the one month epoch after the initial assessment. They will be followed by one of the investigators that will make phone calls to clarify doubts and reinforce the counseling.
89207142|NCT00840606|Experimental|1|
89207143|NCT00840606|Active Comparator|2|
89207144|NCT03975127|No Intervention|Routine|women will routinely be invited to attend for cervical screening via the SCCRS application.
89207145|NCT03975127|Experimental|SMS|Women aged under 30 years will be identified to receive an SMS following cervical screening invitation using information from the CHI Broadcast
89207146|NCT00574080|Experimental|Arm A|DPACE Induction, Melphalan/DPACE Transplant 1, BEAM Transplant 2, DPACE Consolidation, Dexamethasone Maintenance with Interim dexamethasone between treatment phases
89207147|NCT00574080|Experimental|Arm B|DPACE Induction, Melphalan/DPACE + VTD Transplant 1, BEAM + VTD Transplant 2, DPACE Consolidation, Dexamethasone Maintenance with Interim dexamethasone between treatment phases
89207148|NCT00840762|Experimental|VircoType HIV-1|Genotypic HIV resistance testing results interpreted by VircoType HIV-1 algorithm
89207149|NCT00840762|Active Comparator|Local Expert review|Local Expert HIV genotypic review, as per Badri, S. et al CID 2003
89207150|NCT00845364|Experimental|Perhexiline|Pre-operative administration of Perhexiline tablets according to dosing schedule
89207151|NCT00845364|Placebo Comparator|Placebo|Pre-operative administration of placebo tablets according to dosing schedule
89207152|NCT04043052|Active Comparator|Treatment As Usual (TAU)|Evaluation of depression and anxiety disorders at 3 and 6 months post-stroke using psychological and functional examination
89512400|NCT04150887|Experimental|Experimental: Cohort 2: Cusatuzumab + Venetoclax|Participants enrolled in this cohort will receive venetoclax ramp-up to 400 mg orally (as background therapy) starting on Cycle 1 Day 1 and followed by 400 mg daily dosing starting on Cycle 1 Day 4 plus cusatuzumab IV on Day 3 and Day 17 of each 28-day cycle. Cohort 2 will not be enrolled in the US.
88959929|NCT05966987|No Intervention|I-PRF groupMolar distalization group control side|distalization without i-PRF intervention
88959930|NCT05966987|Experimental|LLLT group: distalization intervntion side|distalization will be commenced with application of LLLT according to a standardized protocol
88959931|NCT05966987|No Intervention|LLLT group: distalization control side|distalization will be commenced without application of LLLT according to a standardized protocol
88959932|NCT05966987|Experimental|i-PRF group: leveling and alignment|leveling and alignment assisted with Injectable platelet-rich fibrin (i-PRF) according to a standardized protocol
88959933|NCT05966987|Experimental|LLLT group: leveling and alignment|leveling and alignment be commenced with application of LLLT according to a standardized protocol
88959934|NCT05966987|No Intervention|leveling and alignment without intervention|leveling and alignment without intervention
89207153|NCT04043052|Experimental|EMA intervention assocuated to Treatment As Usual (EMA-TAU)|Evaluation of depression and anxiety disorders at 3 and 6 months post-stroke using psychological and functional examination in addition with Ecological Momentary Assessment (EMA) evaluation.
89207154|NCT00267865|Experimental|Rituximab, High-Dose Methotrexate & Leucovorin Treatment|Induction treatment cycles with rituximab, high-dose methotrexate and leucovorin will be administered every 2 weeks for 6 cycles. Two additional consolidation cycles of high-dose methotrexate without rituximab will be administered at 4 weeks and 8 weeks following completion of the combined therapy.
89207155|NCT00851760|Experimental|1 Combined Surgery|
89207156|NCT00851760|Active Comparator|2 consecutive surgery|
89207157|NCT00851838|Experimental|PD solution|
89207158|NCT01069237||OPTI-FREE Replenish|Multi-Purpose Solution for soft contact lenses
89207159|NCT01069237||Clear Care|Lens Care Solution for contact lenses
89207160|NCT00840918|Active Comparator|1|Intravenous Lidocaine group
89207161|NCT00840918|Placebo Comparator|Placebo|Intravenous placebo Group - Placebo is administered intravenously throughout surgery and during the 24 hours following surgery
89207162|NCT00546117|Experimental|Lansoprazole (Prevacid)|Prevacid SoluTab (15 or 30 mg tab) once daily for 2 months
89207163|NCT00546117|Placebo Comparator|Placebo|Placebo SoluTab once daily for 2 months
89207164|NCT01582165|Active Comparator|Angina. IMR. Statin.|
89207165|NCT01582165|Placebo Comparator|Angina. IMR. Placebo.|
89207166|NCT00851916|Other|CyberKnife Radiosurgery|Single arm study using CyberKnife radiosurgery to treat recurrent prostate cancer patients that have already received external beam radiotherapy.
89207167|NCT03975049|Active Comparator|5-Fu + RT|5Fu + RT for five weeks --- 6-8 weeks of interval --- TME --- mFOLFOX * 6-8
89207168|NCT03975049|Experimental|mFOLFOXIRI|mFOLFOXIRI * 4 --- TME --- mFOLFOXIRI * 4
89207169|NCT03975049|Experimental|mFOLFOX|mFOLFOX * 9 --- TME --- mFOLFOX * 3
89207170|NCT00841074|Experimental|1|Peridex mouthwash
89207171|NCT00841074|Placebo Comparator|2|Placebo mouthwash
89512401|NCT04150887|Experimental|Cohort 3: Cusatuzumab + Venetoclax + Azacitidine (CVA)|Participants enrolled at US sites will receive cusatuzumab 10 mg/kg and potentially escalate to 20 mg/kg IV in combination with azacitidine 75 mg/m^2 SC or IV plus venetoclax ramp-up to 400 mg orally (as background therapies). Participants enrolled from ex-US sites will receive cusatuzumab 20 mg/kg and potentially de-escalate to 10 mg/kg IV in combination with azacitidine 75 mg/m^2 SC or IV plus venetoclax ramp-up to 400 mg orally (as background therapies).
89512402|NCT04142047||HIV|Participants (ages 60 and above) with HIV
89512403|NCT04142047||Control|Participants (ages 60 and above) without HIV
88959935|NCT05966987|Experimental|I-PRF group: Intrusion|intrusion assisted with Injectable platelet-rich fibrin (i-PRF) according to a standardized protocol
88959936|NCT05966987|Experimental|LLLT group: Intrusion|intrusion assisted with application of LLLT according to a standardized protocol
88959937|NCT05966987|No Intervention|intrusion control group|intrusion without intervention
88959938|NCT05966974||Patients treated with AGN1 LOEP|
89512404|NCT04101695|Active Comparator|sham tDCS- washout period- anodal tDCS|"Ybrain tDCS System (Ybrain, Korea) is used. Anode of tDCS is placed over right cerebellar hemisphere (3cm lateral from the occipital protuberance) and cathode over the on ipsilateral buccinator muscle.~For Sham tDCS, total stimulation lasts 90 seconds: ramp up period of 30 seconds, stimultation for intensity of 2mA for 30 seconds, and ramp down period of 30 seconds. At least 7 days of washout period is in between two tDCS. For Anodal tDCS, 20 minutes of stimulation for intensity of 2mA."
89512405|NCT04101695|Active Comparator|anodal tDCS- washout period- sham tDCS|"Ybrain tDCS System (Ybrain, Korea) is used. Anode of tDCS is placed over right cerebellar hemisphere (3cm lateral from the occipital protuberance) and cathode over the on ipsilateral buccinator muscle.~For Anodal tDCS, 20 minutes of stimulation for intensity of 2mA. At least 7 days of washout period is in between two tDCS. For Sham tDCS, total stimulation lasts 90 seconds: ramp up period of 30 seconds, stimultation for intensity of 2mA for 30 seconds, and ramp down period of 30 seconds."
89207172|NCT00964197|Experimental|FemmeJock|The participant will be fitted with the girdle. The participant will use the girdle for the next 3 months. The girdle is only to be worn during the daytime during times of physical activity. The length of time you choose to wear it during the day is the patients choice. In two weeks the participant will be asked to fill out a 5 question survey in a follow up visit. The participant will be asked to return 3 months after wearing the FemmeJock girdle and to fill out a 5 question survey, as well as to complete a 20 question survey.
89512406|NCT04072445|Experimental|Treatment (trifluridine and tipiracil, irinotecan)|Patients receive trifluridine and tipiracil hydrochloride PO BID on days 1-5 and irinotecan hydrochloride IV over 90 minutes on day 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.
89512407|NCT04050540|Experimental|dPEP Intervention Arm|Participants assigned to dPEP will be instructed to take doxycycline 200 mg (two 100mg capsules) orally within 24 hours and up to 72 hours after each condomless sex act
88959939|NCT05966857|No Intervention|Control Group (CTL)|Patients who underwent standard treatment at the institution without any wearable monitoring.
88959940|NCT05966857|Experimental|Telemonitored Group (TLM)|Patients who received telemonitoring with a Samsung Galaxy smartwatch and FAPO SI³ platform, which is integrated with the hospital's electronic medical record system.
88959941|NCT05966818|Active Comparator|Dapagliflozin group and Standard therapy which include either ACEI or ARB|- The first group (45 patients) will receive Dapagliflozin (Diglifloz) 10 mg orally once daily at any time of day with or without food. Tablets are to be swallowed whole with half a cup of water for 24 weeks and standard therapy which include either angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB).
89512408|NCT04050540|No Intervention|Standard of Care Arm|Participants assigned to Standard of Care
89512409|NCT04046471|Other|Individual In-Person|
89207173|NCT00967707|Active Comparator|Gabapentin + venlafaxine|
89512410|NCT04046471|Other|Group Remote|
89512411|NCT04032197|Experimental|Semaglutide|Semaglutide injected once-weekly. Standard dose escalations every 4 weeks will be applied, until the maximum dose of 1.0 mg semaglutide is reached.
89512412|NCT04032197|Placebo Comparator|Placebo|Placebo injected once-weekly. Standard dose escalations every 4 weeks will be applied, until the maximum dose of 1.0 mg placebo is reached.
89512413|NCT04031950||test group|Test group will wear PSG
89512414|NCT04031950||Novel wearable device|THis group will wear the novel device
89512415|NCT04031742|Experimental|Part 1: IBI306|Participants receive open-label IBI306 150 mg subcutaneously Q2W or 450 mg Q4W for 12 weeks.
89512416|NCT04031742|Experimental|Part 2: IBI306|Participants receive open-label 450 mg Q4W subcutaneously for 12 weeks.
89512417|NCT04023526|Experimental|Azacitidine 75 mg/m^2 and Cusatuzumab 10 mg/kg|Participants will receive azacitidine 75 milligram per meter square (mg/m^2) subcutaneously (SC) or intravenously (IV) on Day 1 through Day 7 and cusatuzumab 10 milligram per kilogram (mg/kg) IV on Day 3 and Day 17 of each 28-day cycle in Part 1. Part 1 findings will be reviewed by a data review committee.
89512418|NCT04023526|Experimental|Azacitidine 75 mg/m^2 and Cusatuzumab 20 mg/kg|Participants will receive azacitidine 75 mg/m^2 SC or IV on Day 1 through Day 7 and cusatuzumab 20 mg/kg IV on Day 3 and Day 17 of each 28-day cycle in Part 1. Part 1 findings will be reviewed by a data review committee.
89512419|NCT03986164|Active Comparator|Guided surgery (GS)|Installation of dental implant with the aid of the virtually planned guide by means of specific software
89512420|NCT03986164|Active Comparator|Conventional surgery (CS)|Installation of dental implant performed freehand using a conventional surgical guide made by study models
89512421|NCT03957551|Experimental|Cabozantinib and pembrolizumab|Cabozantinib will be administered in the tablet form, at three dose levels: 40, 20 and 60 mg per day. Pembrolizumab will be administered as an intravenous infusion at a fixed dose of 200 mg once every 3 weeks.
89512422|NCT03893500|Experimental|Initiating a new PAH medication|Participants will start a new PAH medication
89512423|NCT03893500|Active Comparator|Continuing previous PAH medication regimen|Participants will continue the medication regimen that they were on prior to enrollment
89512424|NCT03862495|Experimental|Chlamydia Screening and Treatment|At the time of recruitment and prior to delivery, this group will have immediate testing for C. trachomatis and N. gonorrhoeae. Physicians will notify C. trachomatis positive results to pregnant women and suggest them and their spouses to get treated according to the national standard treatment plan for Chlamydia (Azithromycin 1g, single oral administration). Patients will be followed up to confirm cure of C. trachomatis in one month. Partner notification and treatment will be suggested for pregnant women who test positive for Chlamydia.
89519486|NCT02164318|Experimental|Combined handgrip training /Nitroglycerin ointment group|Perform isometric handgrip exercises for 15 minutes twice each day for a total of 30 minutes and apply 15mg of nitroglycerin ointment to the back of the hand of the surgical arm nightly
89519487|NCT03436199|Experimental|ADS-5102, 137 mg|ADS-5102, administered once daily at bedtime from Week 4 through Week 16
89540952|NCT05502042|Experimental|Peer Group + Case Manager|Usual care + an assigned village health team member to provide weekly short message (SMS) (weeks 1-3) and phone (week 4) support for attendance of SAP visits and a VHT (village health team member) led peer support group held at the assigned SAP clinic of participants, that includes games/peer support/education.
89540953|NCT05496465|Active Comparator|ARS-1 1mg|1 mg per 100 µL dose of ARS-1
89540954|NCT05496465|Active Comparator|ARS-1 2mg|2 mg per 100 µL dose of ARS-1
89540955|NCT05496465|Placebo Comparator|Placebo|Placebo (100 µL)
89540956|NCT05494801||Close Contacts|Close Contacts of EVD survivors, who were also previously in the PREVAIL III Neurology Substudy
89540957|NCT05494801||Patients (EVD Survivors)|Participants with a history of Ebola Virus Disease who were involved in the Neurology Substudy of the PREVAIL III Ebola Natural History Study
89540958|NCT05485194|No Intervention|Unassisted healing|The extraction sockets in the non-intervention group will be filled with blood clots only.
89207174|NCT00967707|Active Comparator|Gabapentin + donepezil|
89540959|NCT05485194|Experimental|Titanium bone screw (TBS)|One titanium bone screw (TBS) will be placed over the labial/buccal plate of the extraction socket in the TBS group on the same day of the extraction.
89540960|NCT05485194|Active Comparator|Alveolar ridge preservation (ARP)|The extraction socket will be filled with mineralized ground cortical allograft up to the level of the buccal and lingual/palatal bony plates. A resorbable membrane will be trimmed and adapted to cover the grafting material. The flaps will be secured with a monofilament suture.
89540961|NCT05483556|Experimental|Real tDCS|Five post-stroke patients will be allocated by the flip the coin method to the experimental group. Participants will receive anodal tDCS stimulation for 20 minutes
89540962|NCT05483556|Sham Comparator|Sham tDCS|Five participants will be allocated by the flip coin method to the sham comparator group. Participants will receive the tDCS stimulation for the 30s
89540963|NCT05479045|Experimental|NY-ESO-1 Peptide vaccine plus Nivolumab|
89540964|NCT05466721|Experimental|Hydrustoma C3|The participant will use the Hydrustoma C3 devices for 14 days and then switch into the control device for another 14 days.
89540965|NCT05466721|Other|Coloplast Alterna|The participant will use the control devices for 14 days and then switch into the Hydrustoma C3 devices for another 14 days.
89540966|NCT05463393|Experimental|Group Xn|Patients who received extract from Humulus lupus L rich in Xanthohumol (Hop-RXn™, BioActive-Tech Ltd, Lublin, Poland; http://xanthohumol.com.pl/) as an adjuvant therapy. Based on pharmacokinetics and bioactivity, Xn was administered enterally three times a day every 8 hours at a dose of 1.5 mg/kg body weight (4.5 mg/kg body weight/day) for 7 days. The first dose of Xn was administered within 4 hours after admission to the ICU.
88959942|NCT05966818|Active Comparator|Standard therapy which include either ACEI or ARB|- The second group (45 patients); will receive the standard therapy (ACEI or ARB).
89540967|NCT05463393|Placebo Comparator|Group C|Patients who received 0.9% NaCl at the oral volume 1 mL (similar to Xn volume) three times a day every 8 hours. The first dose of Xn was administered within 4 hours after admission to the ICU.
89540968|NCT05461885|Experimental|Vega Exercise Community|Participants will be offered one hour of tailored supervised, gym-based exercise training three times per week for a period of four months. In addition, participants are offered free-of-charge membership to the gym for six months and are invited to take part in training classes and use fitness equipment provided by the gym to regular members. The supervised program is tailored to meet the needs and requirements of this particular group of young adults and will include three weekly sessions of moderate-to-high intensity and mobility exercises.
88959943|NCT05966792|Experimental|SGLT2 inhibitors combined with metformin|Intervention with henggliflozin (5mg qd) and metformin (500mg bid) for 3 months
88959944|NCT05966792|Placebo Comparator|Placebo combined with metformin|Intervention with placebo (qd) and metformin (500mg bid) for 3 months
89207175|NCT00964275|Experimental|Arm I|Patients undergo diagnostic fludeoxyglucose F 18 PET in addition to standard methods.
89207176|NCT00964275|Active Comparator|Arm II|Patients only undergo standard diagnostic methods.
89207177|NCT00845598|Experimental|Azelastine Fluticasone|
89540969|NCT05461885|No Intervention|Usual care|Participants will receive treatment as usual and be informed of the official physical activity guidelines as part of the information on group allocation. Moreover, they will be advised to continue their daily living, as they normally would do, not guiding them to other interventions neither preventing them to do so. In addition, participants in the usual care group will be given a subsidized membership including access to the exercise classes for four months after the 12 months follow up.
89540970|NCT05442125|Experimental|PIMS group|Couples in the PIMS group will have up to 6 blastocysts screened with PIMS and a single euploid embryo with the optimal state of whole-genome DNA methylation and the highest morphologic score will be selected for the initial transfer. The optimal state of whole-genome DNA methylation includes methylation level closest to the optimal level (0.26 according to our preliminary results) and proper methylation state for some specific regions.
89540971|NCT05442125|Active Comparator|Conventional-IVF group|For women between 20 and 37 years of age,couples in the conventional-IVF group will have a single best blastocyst by morphologic criteria selected for the initial transfer.For women over 37 years old, couples in the PGT-A group will have up to 6 blastocysts tested with PGT-A and a single euploid embryo with the highest morphologic score will be selected for the initial transfer.
89540972|NCT05438563|Experimental|Treatment (MRI-guided TULSA)|Patients undergo MRI-guided TULSA. Patients may also undergo DRE, cystoscopy, biopsy, bone scan, PSMA PET, and/or mpMRI at screening.
89540973|NCT05436392|No Intervention|Control|
89540974|NCT05436392|Experimental|Peer Comparison Feedback|
89540975|NCT05436392|Experimental|Patient Informational Letter|
89207178|NCT00845598|Active Comparator|Fluticasone propionate|
89207179|NCT00251719|Experimental|Dexlansoprazole MR 60 mg QD|
89207180|NCT00251719|Experimental|Dexlansoprazole MR 90 mg QD|
89207181|NCT00251719|Active Comparator|Lansoprazole 30 mg QD|
89207182|NCT02547090||CP who underwent PSF by two attendings in 2012|
89540976|NCT05436392|Experimental|Peer Comparison Feedback plus Patient Informational Letter|
89540977|NCT05433012|Other|Isolated Acute Anterior Cruciate Ligament Injury with Ultrahigh Field MRI at 7T|
89540978|NCT05432622||Nivolumab Monotherapy|Participants who started adjuvant nivolumab
89540979|NCT05432622||Pembrolizumab Monotherapy|Participants who started adjuvant pembrolizumab
89540980|NCT05432622||Dabrafenib + Trametinib Combination Therapy|Participants who started adjuvant dabrafenib + trametinib combination therapy
89540981|NCT05432622||No Treatment of a Systemic Therapy|Participants with no systemic treatment during the study observation period until record of recurrence
89540982|NCT05429320|Experimental|Part I|In part I, 33 patients with metastatic NSCLC with: a) NR-VAF but b) without radiographic progression of disease, will be treated with LAT to determine if ablation to all sites of disease leads to acceptable rates of mean VAF reduction, thus indicating a discernible molecular/clinical response in this subgroup of patients with metastatic disease.
89540983|NCT05429320|Active Comparator|Part II - standard of care|If the appropriate criteria are met in part I,, in part II 60 patients with NR-VAF but without radiographic progression of disease will be randomized to one of two arms: continuation of systemic therapy (standard of care) vs. ablation to all sites of disease (experimental arm), with a primary endpoint of progression free survival.
89540984|NCT05429320|Experimental|Part II - ablation to all sites of disease (experimental arm)|If the appropriate criteria are met in part I,, in part II 60 patients with NR-VAF but without radiographic progression of disease will be randomized to one of two arms: continuation of systemic therapy (standard of care) vs. ablation to all sites of disease (experimental arm), with a primary endpoint of progression free survival.
89540985|NCT05423756|Active Comparator|Arm 1: Routine Care|Continuation of routine antibiotic stewardship strategies.
89540986|NCT05423756|Active Comparator|Arm 2: INSPIRE Stewardship Bundle|Use of computerized physician order entry (CPOE) smart prompts, clinician feedback, and activities to support CPOE adoption (including education and alignment of CPOE workflows) to guide empiric choice of antibiotics for skin/soft tissue infection in the first 3 days of hospitalization.
89540987|NCT05423743|Active Comparator|Arm 1: Routine Care|Continuation of routine antibiotic stewardship strategies.
89540988|NCT05423743|Active Comparator|Arm 2: INSPIRE Stewardship Bundle|Use of computerized physician order entry (CPOE) smart prompts, clinician feedback, and activities to support CPOE adoption (including education and alignment of CPOE workflows) to guide empiric choice of antibiotics for abdominal infection in the first 3 days of hospitalization.
89540989|NCT05423730|Experimental|WHITE WINE FOLLOWED BY WHITE GRAPE JUICE|"Participants will be randomized into one of the study drinking sequence groups: white wine followed by white grape juice or white grape juice followed by white wine.~The research study procedures include one screening visit to obtain informed consent, four study visits with blood draws, and ten weekly phone calls and online questionnaires over the ten weeks of the study.~-3 weeks of daily white wine followed by 3 weeks of daily white grape juice"
89540990|NCT05423730|Experimental|WHITE GRAPE JUICE FOLLOWED BY WHITE WINE|"Participants will be randomized into one of the study drinking sequence groups: white grape juice followed by white wine.~The research study procedures include one screening visit to obtain informed consent, four study visits with blood draws, and ten weekly phone calls and online questionnaires over the ten weeks of the study.~- 3 weeks of daily white grape juice followed by 3 weeks of daily white wine"
89540991|NCT05419869|Experimental|ALTO-100|ALTO-100 tablet PO ; twice daily dosing 8 weeks
89540992|NCT05419479|Experimental|LEAD-IN: DOSE DE-ESCALATION|The lead-in dose de-escalation cohort (Phase 1b) will enroll 6 patients (up to 12 patients in 2 dose levels if needed; 6 patients per DL) to receive zimberelimab, domvanalimab, and APX005M
89540993|NCT05419479|Experimental|ARM A: ZIMBERELIMAB + DOMVANALIMAB + APX005M|"Participants will be randomly assigned to one of two groups~Arm A will receive domvanalimab, zimberelimab, and APX005M every two weeks through an infusion."
89540994|NCT05419479|Active Comparator|ARM B: FOLFIRI|Arm B will receive leucovorin, fluorouracil, and irinotecan every two weeks through an infusion
89540995|NCT05419479|Experimental|CROSSOVER: ZIMBERELIMAB + DOMVANALIMAB + APX005M|Participants in Arm B (control arm) who experience disease progression (as defined by RECIST v1.1) will be given the option to crossover and receive domvanalimab + zimberelimab, + APX005M in the second-line setting, provided they meet eligibility criteria
89540996|NCT05416437|Active Comparator|Device arm|The patients in the device arm will get the Pneumocool device to channel medical air to their face to alleviate dyspnea
89540997|NCT05416437|Placebo Comparator|Standard of Care arm|The patients in the standard of care arm can get a fan or any other supportive care that is currently available in the hospital for alleviating dyspnea
89540998|NCT05415800|Experimental|Interventional Arm|Intervention
89540999|NCT05412212|Experimental|LTBI video intervention|Patients randomized to the intervention group will be sent an invitation with a link to watch a brief (~3 minute video) about the importance of taking and completing LTBI treatment.
89541000|NCT05412212|No Intervention|Standard care|Patients who are randomized to receive standard of care will not receive any messages or have any contact with the research team.
89541001|NCT05411939|Other|Control|Patients in the control arm of the study will watch a short video and then receive standard of care counseling with an orthopaedic surgeon.
89541002|NCT05411939|Experimental|Shared Decision-Making Tool|Patients in the treatment arm of the study will watch a short video and then receive standard of care counseling with an orthopaedic surgeon that includes discussion of the shared decision-making tool.
89541003|NCT05410977||Observational (biospecimen collection, record review)|Patients undergo collection of blood and stool samples no more than 90 days prior to or between 7-90 days after standard of care colonoscopy or flexible sigmoidoscopy. Patients' medical records are also reviewed.
89541004|NCT05399641|Experimental|Group A|Single day dosing, 300mg Ibrexafungerp BID for a total of 600mg a day.
89207183|NCT02547090||CP who underwent PSF by a single surgeon from 2008-2010|
89541005|NCT05399641|Experimental|Group B (3 Day dosing)|Three day dosing, 300 mg Ibrexafungerp BID for a total of 600mg a day.
89541006|NCT05399641|Experimental|Group b (7 Day dosing)|Seven day dosing, 300mg Ibrexafungerp BID for a total of 600mg a day
89541007|NCT05390983|Experimental|carotid endarterectomy|carotid endarterectomy with stent removal
88959945|NCT05966779||modified CDT physical therapy protocol, based on Godoy's Method|"A complete physical therapy assessment was done. All sociodemographic data were recruited as well as body mass index (BMI), the month of intervention, kind of surgery, extracted liters, psychological treatment, physical therapy sessions, pain, mobility, complications (seroma, wound infection, chafing or risk of ulcer, pain, fibrosis, genital edema), compression, smoking, satisfaction with the treatment received.~A modified CDT physical therapy protocol, based on Godoy's Method, was applied to all study participants. This protocol comprised of~Cervical Stimuli 15min~MLD based on Godoy~Mechanical lymphatic drainage with RA Godoy® device~Compression therapy with multilayer and multicomponent bandages during the mechanical lymphatic drainage.~Skin care - before and after the bandages- and therapeutic education.~Put on compression garments~Active movement if possible."
88959946|NCT05966714||Group 1|Nujiang (880m)
88959947|NCT05966714||Group 2|Kunming(1800m)
88959948|NCT05966714||Group 3|Lijiang(2500m)
88959949|NCT05966714||Group 4|Shangri-La (3500 m)
88959950|NCT05966701|Experimental|SSGJ-613|SSGJ-613，SC
88959951|NCT05966701|Placebo Comparator|Placebo|Placebo, SC
88959952|NCT05966571||PCOS women|Ovarian biopsy will be performed on PCOS women meeting the inclusion criteria undergoing surgery for other reasons . A sample of the ovarian tissue will be of a few millimeters in size and taken on only one of the ovaries.
88959953|NCT05965908|Experimental|liraglutide|Saxenda® starting dose is 0.6 mg per day for 1 week.1. Patients increase the dose by 0.6 mg each week until the full maintenance dose of 3 mg is reached
89207184|NCT00964587|Active Comparator|Usual Care|Packet of standard print patient education materials on CVD and diabetes from the American Heart Association (AHA) and the American Diabetes Association (ADA).
89207185|NCT00964587|Experimental|Self Study|One 90-minute educational session. Print materials and DVDs for self-study
89207186|NCT00964587|Experimental|Group Problem-Solving Training|One 90-minute education session. Group problem-solving training (eight, 90-minute sessions)
89512425|NCT03862495|Experimental|Control|This group will have testing after delivery (immediately following childbirth) or in the event of an adverse pregnancy outcome for C. trachomatis and N. gonorrhoeae. In the event of a positive test, patients will be informed of the positive test results the same way as the intervention group. Specific treatment options will be the same as the intervention group. Physicians will ask patients to return to Nanhai Hospital one month after treatment for test of cure. Partner notification and treatment will be suggested for pregnant women who test positive for Chlamydia.
89512426|NCT03831100|Experimental|BRIGHT|The BRIGHT intervention consists of 5 weekly, 60-minute, tablet-based, one-one telehealth sessions with a licensed therapist. BRIGHT Therapist: A licensed clinical psychologist with extensive experience managing pyscho-oncologic concerns in patients with HNC will deliver BRIGHT.
89512427|NCT03831100|Placebo Comparator|Active Control|The control intervention in this study will be matched to replicate the frequency, intensity, and delivery method of BRIGHT. AC consists of 5 weekly sessions of videos about HNC survivorship that are delivered using a telemedicine platform. Each AC session is a compilation of shorter videos featuring HNC survivors, caregivers, and oncologists discussing non-body image aspects of HNC survivorship.
89207187|NCT00964587|Experimental|Individual Problem-Solving Training|One 90-minute education session. Individual problem-solving training (eight, 60-minute sessions)
89207188|NCT00845754|Placebo Comparator|1|Placebo
89207189|NCT00845754|Active Comparator|2|Ketorolac
89207190|NCT00851994||1|Patients having surgery
89512428|NCT03831087|Other|TAVR-CMR|"All MR examinations will be performed with a 1.5-T clinical MR imaging unit (AVANTO_fit; Siemens, Erlangen, Germany). The MR protocol consists of a Navigator-gated free breathing 3D whole-heart coronary magnetic resonance angiography (MRA), axial 2D true fast imaging with steady-state free precession (true-FISP) during free breathing covering whole body trunk and a coronal 3D fast low-angle shot (FLASH) Gd-MRA."
89512429|NCT03831087|Other|TAVR-CT|All CT examinations will be performed on a 128-slice dual-source CT and high-pitch factor. Prospective electrocardiographic synchronization will be applied, triggered into the diastolic phase for the heart. An injected bolus of 70 to 110 mL of nonionic iodine contrast agent will be applied with 370 mg/mL iodine concentration, using an automatic injector at a flow rate of 5 mL/s, followed by 40 mL saline solution. Contrast agent volume for each patient will be calculated by scan time and body weight. Patients will be placed supine with arms overhead. The scan length range from supraaortic branches to the groins.
89512430|NCT03828825|Experimental|Patent Foramen Ovale Closure|The percutaneous closure of Patent Foramen Ovale is realized under trans-thoracic echocardiography control. If necessary, the operator will use trans-esophageal echocardiography to implant the prosthesis.
89512431|NCT03792633|Experimental|Newly Diagnosed VHR B-ALL or High-Risk Relapse of B|
89512432|NCT03792633|Experimental|Poor Response to Prior B Cell Directed Engineered cell therapy|
89512433|NCT03775577||HFpEF|Participants with Heart Failure with Preserved Ejection Fraction
89512434|NCT03775577||HFrEF|Participants with Heart Failure with Reduced Ejection Fraction
89512435|NCT03775577||Hypertensive Subjects|Participants with Hypertension
89512436|NCT03775577||Healthy Subjects|Participants without heart failure and without commodities
89512437|NCT03691662|Experimental|DE-117 Ophthalmic Solution|Topical DE-117 Ophthalmic Solution once daily and Vehicle once daily for 3 months
89512438|NCT03691662|Active Comparator|Timolol Maleate Ophthalmic Solution 0.5%|Topical Timolol Maleate Ophthalmic Solution 0.5% twice daily for 3 months
89519488|NCT03436199|Experimental|ADS-5102, 274 mg|ADS-5102, administered once daily at bedtime from Week 4 through Week 16
89519489|NCT03436199|Other|Placebo|placebo, administered once daily at bedtime from Week 4 through Week 16
89519490|NCT02131636|Experimental|AGN-199201|AGN-199201 applied to the face once daily for 29 days.
88959954|NCT05965908|Active Comparator|metformin|the patient is given Glucophage 1000 mg tab once daily after lunch for 1month
88959955|NCT05965908|No Intervention|control|not given any drug
88959956|NCT05960500|Active Comparator|Six implants in parallel distribution|patients received 6 implants in parallel distribution in anterior, premolar and molar region
89207191|NCT00964665|Experimental|Group 1 ABF656 900ug Q2w|
89207192|NCT00964665|Experimental|Group 2 ABF656 900ug Q4w|
89207193|NCT00964665|Experimental|Group 3 AB656 1200ug Q4w|
89541008|NCT05390983|Active Comparator|repeated angioplasty and stenting|percutaneous transluminal angioplasty with or without stenting
89512439|NCT03689244|Experimental|Selexipag DB|During the double blind treatment period, participants in this group will receive selexipag. Each participant will start with one oral tablet of selexipag 200 µg in the evening of Day 1 and will continue with 200 µg twice daily (b.i.d.) on Day 2. If this dose is well-tolerated, selexipag is up-titrated with weekly increments of 200 µg until reaching the individual maximal tolerated dose (iMTD) in the range of 200 to 1600 µg b.i.d. The up-titration period up to Week 12 is followed by a stable maintenance treatment period from Week 12 to Week 26, at the iMTD. After Week 26, further up-titration can be allowed (but not above 1600 µg b.i.d.).
89512440|NCT03689244|Placebo Comparator|Placebo DB|During the double-blind treatment period, participants in this group will receive the oral matching placebo, twice daily. A (mock) up-titration scheme will be followed.
89512441|NCT03689244|Experimental|Selexipag OL|All participants who completed the double-blind treatment period, whether they received placebo or selexipag during the double-blind period, will receive selexipag during the open-label extension period, using the same up-titration schedule as in the double-blind period.
89512442|NCT03649074|Experimental|AKL-T01|AKL-T01 digital treatment.
89512443|NCT03645239||Control|Questionnaires, Mechanical Temporal Summation assessment and preoperative pain assessment will be assigned to patient. Patients will be assigned to this group when they have a pain score of less than 3 (out of 10) at 6-10 post-delivery online/phone survey.
89512444|NCT03645239||Postoperative pain|Questionnaires, Mechanical Temporal Summation assessment and preoperative pain assessment will be assigned to patient. Patients will be assigned to this group when they have a pain score of equal or more than 3 (out of 10) at 6-10 post-delivery online/phone survey.
89512445|NCT03645239||Control (non-Headspace)|Questionnaires, Mechanical Temporal Summation assessment and preoperative pain assessment will be assigned to patient. Twenty five patients will be assigned to this group when they agree to participate in a sub-study on the use of a mindfulness exercise mobile app (Headspace). Patients will have a follow-up online/phone call survey at day 7-20 and 4-8 weeks after delivery.
89512446|NCT03645239||Experimental (Headspace)|Questionnaires, Mechanical Temporal Summation assessment and preoperative pain assessment will be assigned to patient. Fifty five patients will be assigned to this group when they agree to participate in a sub-study on the use of a mindfulness exercise mobile app (Headspace). Patients will have a follow-up online/phone call survey at day 7-20 and 4-8 weeks after delivery.
89512447|NCT03631225||Guided-Care Arm|Physicians will use the reported Vectra score to guide treatment decisions
89512448|NCT03631225||Usual Care Arm|Physicians will treat patient per standard of care without the use of the Vectra score
89512449|NCT03594175|Experimental|CUSA-081|Participants will receive 1 or 2 doses of CUSA-081, 0.7 milligrams (mg) (0.4 units) per 2 milliliter (mL) directly into the catheter lumen. Participants will receive the first dose at minute (min) 0, and the second dose, if needed, at min 90.
89512450|NCT03594175|Placebo Comparator|Placebo|Participants will receive 1 or 2 doses of placebo (normal saline) directly into the catheter lumen. Participants will receive the first dose at min 0, and the second dose, if needed, at min 90.
89512451|NCT03594175|Active Comparator|Alteplase|Participants will receive 1 or 2 doses of alteplase, 2 mg/mL, directly into the catheter lumen. Participants will receive the first dose at min 0, and the second dose, if needed, at min 90.
89512452|NCT03555552|Experimental|Anticoagulation and Thrombosis Point of Care Test (AT-POCT)|
89512453|NCT03555552|Active Comparator|Duke Central Automated Laboratory (DCAL)|
89512454|NCT03486327|Experimental|0.03mL/kg Dose Group|A group of up to 8 subjects to receive a single dose of BR55 at 0.03mL/kg.
89512455|NCT03486327|Experimental|0.05mL/kg Dose Group|A group of up to 8 subjects to receive a single dose of BR55 at 0.05mL/kg.
89512456|NCT03486327|Experimental|0.08mL/kg Dose Group|A group of 8 subjects to receive a single dose of BR55 at 0.08mL/kg.
89512457|NCT03473782||Voiding Diary|
89512458|NCT03473782||Urodynamics Correlation Study|
89541009|NCT05388929|Experimental|primary ventral hernia repair or inguinal hernia repair|"Primary ventral hernias, including umbilical, epigastric, and Spigelian hernias.~Primary or recurrent inguinal hernias."
89512459|NCT03415620|Experimental|Music listening|"Phase 1: Before and after surgery, 300 patients will be offered an ipod with earphone, in which the ipod is equipped with saved playlist of different music genres to select from pre-determined lists of music of different genres or patient choice. Patient will choose the desired playlist and listen to the music for about 30 minutes. Hospital Anxiety and Depression Scale (HADS) score, pain scores, analgesia usage, patient satisfaction, and quality of life measurement will be collected. Analysis of the type of music, duration of music listening, and the genre chosen will be analysed.~Phase 2: One hundred and ten women undergoing Caesarean delivery assigned to experimental (music listening) group will listen to the music before, during and after surgery. Pain and psychological assessments and demographic data collection will be conducted before and after surgery."
89512460|NCT03415620|No Intervention|No Music Listening|Phase 2: Patients assigned to this group (n=55) will only have pain, psychological assessments and demographic data collection conducted before and after surgery.
89512461|NCT03387813|Experimental|Randomized Arm - Treatment Group|"Management of subjects based on pulmonary artery (PA) pressure information derived from the CardioMEMS™ HF System.~All subjects will receive a CardioMEMS™ HF System."
89512462|NCT03387813|Experimental|Randomized Arm - Control Group|"Management of subjects per standard of care (signs, symptoms, weight etc.) without knowledge of PA pressure information derived from the CardioMEMS™ HF System.~All subjects will receive a CardioMEMS™ HF System."
89541010|NCT05388929|Experimental|open or robotic ventral hernia repair outpatient|Open repair of ventral incisional hernias. Robotic repair of ventral primary or incisional hernias.
89541011|NCT05388929|Experimental|open or robotic hernia repair inpatient|Open repair of ventral incisional hernias. Robotic repair of ventral primary or incisional hernias.
89207194|NCT00964665|Experimental|Group 4 ABF656 1500ug Q4w|
89207195|NCT00964665|Active Comparator|Group 5 Pegasys® 180µg qw|
89207196|NCT00841152||Hand lesions|Stratum I: comparison of three interventions (autograft, bioactive glass and beta-tricalcium phosphate)
89541012|NCT05378529|Other|Participants with history of ASCVD|Participants with history of ASCVD with known or unknown Lp(a) values.
89541013|NCT05371080|Other|LTFU Group|Participants who received at least one dose of the HZ/su vaccine in the ZOSTER-006/022 primary studies and are followed for long-term vaccine efficacy and safety in the current ZOSTER-101 study.
89541014|NCT05371080|Other|1-Additional Dose Group|Participants who received two doses of the HZ/su vaccine in the ZOSTER-006/022 primary studies and one additional dose of the HZ/su vaccine in the ZOSTER-049 study and are followed for persistence of immunogenicity and safety in the current ZOSTER-101 study.
89541015|NCT05371080|Other|Revaccination Group|Participants who received two doses of the HZ/su vaccine in the ZOSTER-006/022 primary studies and two additional doses of the HZ/su vaccine in the ZOSTER-049 study and are followed for persistence of immunogenicity and safety in the current ZOSTER-101 study.
89541016|NCT05371080|Other|Control Group|Participants who received two doses of the HZ/su vaccine in the ZOSTER-006/022 primary studies and no additional doses of the HZ/su vaccine in the ZOSTER-049 study, but who served as a control for the two groups that received 1 or 2 additional doses of HZ/su (1-Additional Dose and Revaccination groups). In the current ZOSTER-101 study, this Control group is used in the evaluation of the long-term vaccine efficacy, safety and as a control for persistence of immunogenicity to additional doses administered in ZOSTER-049 study.
89541017|NCT05365841||Severe asthma without CRSwNP|control group; n~20 of anti-IL5 naïve severe asthmatics
89207197|NCT00841152||Long-bone lesions|Stratum II: comparison of three interventions (bioactive glass, beta-tricalcium phosphate, allograft)
89207198|NCT02545686|Experimental|one|"this is a single arm study. All subjects treated the same way, and undergo four interventions:~Chest wall movement assessment without CPAP~Breath hold assessment without CPAP~Chest wall movement assessment with CPAP~Breath hold assessment with CPAP"
89207199|NCT00841230|Placebo Comparator|Lactose placebo|1x/day
89207200|NCT00841230|Experimental|Deanxit|
89541018|NCT05365841||Severe asthma with CRSwNP|n~40 of anti-IL5 naïve severe asthmatics
89541019|NCT05365841||subjects CRSwNP with mild or no asthma|~25;2nd control group
89541020|NCT05363670|Active Comparator|1 mg/100 µL dose of ARS-1|
89541021|NCT05363670|Active Comparator|2 mg/100 µL dose of ARS-1|
89541022|NCT05363670|Active Comparator|albuterol MDI (180 mcg)|
89541023|NCT05363670|Placebo Comparator|placebo|
89541024|NCT05361837|Active Comparator|Single level serratus anterior plane block|the allocated patients will receive single injection serratus anterior plane block at the level of third rib with local anesthetics only
89541025|NCT05361837|Experimental|Single level serratus anterior plane block with dexmedetomidine|the allocated patients will receive single injection serratus anterior plane block at the level of third rib with local anesthetics and dexmedetomidine
89541026|NCT05361837|Experimental|Bilevel serratus anterior plane block|the allocated patients will receive injection serratus anterior plane block at 2 levels, the level of third rib and the level of the fifth rib with local anesthetics only
89541027|NCT05361837|Experimental|Bilevel serratus anterior plane block with dexmedetomidine|the allocated patients will receive injection serratus anterior plane block at 2 levels, the level of third rib and the level of the fifth rib with local anesthetics and dexmedetomidine
89541028|NCT05343936||Active surveillance|This is a multicentric active surveillance prospective cohort study. The eligibility criteria defined are: low-risk prostate adenocarcinoma (clinical stage of cT1-T2a / Group Grade 1 (Gleason score less or equal to 6) / PSA less or equal to 10 ng/ml), transrectal prostate biopsy with at least 12 cores, estimated life expectancy over 10 years, clinical conditions for definitive treatment, multiparametric prostate MRI performed or planned.
89207201|NCT00841308|Active Comparator|Usual care|
89207202|NCT00841308|Active Comparator|Home blood pressure monitoring|
89207203|NCT00852072|Active Comparator|Single-operator cholangioscopy guided laser lithotripsy|Ability to clear the bile duct of all stones in one ERCP session using laser lithotripsy-based technique, including use of mechanical lithotripsy
89207204|NCT00852072|Active Comparator|Balloon sphincteroplasty|Ability to clear the bile duct of all stones in one ERCP session using large balloon sphincteroplasty-based technique, including use of mechanical lithotripsy
89207205|NCT00841386|Experimental|Cross-linking treatment|Topical anesthesia (lidocaine jelly 2%) will be used. The central 9 mm of corneal epithelium will be removed cautiously with an Amoils brush. Riboflavin 0.1% solution will be applied (10 mg riboflavin-5-phosphate in 10 ml dextran T-500 20% solution, supplied in a sterile, single dose container) to the cornea every 2-3 minutes for 15 minutes and then every 5 minutes thereafter. The UV source will be from the CBM VEGA X-linker (CSO, Florence, Italy). A wavelength of 370 nm will be used to direct 5.4 J/cm2 to the area of cornea debrided for 30 minutes. The distance from the UV source to the cornea will be 1.5 to 5.4 cm.
89207206|NCT00841386|Sham Comparator|Sham treatment group|Topical anesthesia (lidocaine jelly 2%) will be used. Differing from the treatment group, no epithelium will be debrided, but instead, this step will be skipped and a 2% methylcellulose solution combined with 1% fluorescein dye will be applied to the cornea every 5 minutes for 30 minutes. The patient will be placed under the UV device, but instead of the UV light, the LED aiming beam will be applied for 30 minutes.
89207207|NCT00848094|Other|arm 1|Arm I: tumor diameter more than 5 cm and less than 10 cm.
89207208|NCT00848094|Other|arm 2|Arm II: tumor diameter no less than 10 cm.
89541029|NCT05326750|Experimental|Real tACS|Four sessions (once a day, during four consecutive days) of gamma tACS (40 Hz) at 3 mA over the superior parietal cortex (Precuneus)
89541030|NCT05326750|Placebo Comparator|Sham tACS|Four sessions of sham tACS (once a day, during four consecutive days) over the superior parietal cortex (Precuneus)
88959957|NCT05960500|Active Comparator|Six implants according to all on six concept|patients recived four axially placed anterior Implants(*General system) in lateral and first premolar region and two distally tilted 30 degree posteriorly in molar region relative to the occlusal plane supporting screw retained maxillary single denture.
88959958|NCT05960422|Active Comparator|Popliteal Sciatic Nerve Block|Patients are in the group undergoing popliteal sciatic block
88959959|NCT05960422|Active Comparator|Adductor Canal Block|Patients are in the group undergoing popliteal sciatic block + adductor canal block
88959960|NCT05959993|Experimental|Intervention group|Intervention group participants underwent six interviews at two-week intervals, during which a hybrid and structured nursing intervention was administered.
88959961|NCT05959993|No Intervention|Control group|Control group participants were not subjected to a structured nursing intervention.
88959962|NCT05959876|Experimental|Training group|Face-to-face perineal care training will be given to the relatives of the patients in the training group in the determined common time period. During the trainings, the presentation prepared in the power point program and the content of perineum care will be conveyed by the researcher in two 30-minute sessions using plain lecture, case study and question and answer techniques.
88959963|NCT05959876|Active Comparator|Control group|The participants in the control group will not be interfered with by the researcher during the research.
88959964|NCT05956808|Experimental|New BTE hearing aid first, then legacy BTE hearing aid|All participants who complete speech intelligibility testing and subjective listening effort ratings with both devices, first with the new hearing aid, and then with the legacy hearing aid.
88959965|NCT05956808|Experimental|Legacy BTE hearing aid first, then new BTE hearing aid|All participants who complete speech intelligibility testing and subjective listening effort ratings with both devices, first with the new hearing aid, and then with the legacy hearing aid.
88959966|NCT05953155|Other|Control|The control group will be invited to attend 3 educational classes. In these sessions, participants will receive evidence-based information about self-management strategies and pain education.
88959967|NCT05953155|Experimental|Yoga|In addition to the invitation to attend the same 3 educational classes on evidence-based information about self-management strategies and pain education, the experimental group will participate in a 12-week, twice-weekly group-based yoga program.
89512463|NCT03387813|Experimental|Single Arm|"Management of subjects based on PA pressure information derived from the CardioMEMS™ HF System.~All subjects will receive a CardioMEMS™ HF System."
89512464|NCT03373916|Experimental|Peer Mentorship intervention|A Peer Specialist will be making weekly follow-up contact with study participants in the community or by telephone for 3 months following hospital discharge. The content of the peer mentorship interactions will be based on the manual developed by the study team and will address protective factors such as hope and belongingness.
89512465|NCT03373916|Active Comparator|Enhanced Usual Care (EUC)|"The EUC condition will consist of a caring message from the study team via e-mail or text message (based on the participant's preference) 24-72 hours after discharge. An example message is, We hope things are going well for you since you left the hospital. If you wish to reply, we'd be glad to hear from you. A list of local mental health resources will be available if participants reply and during the 3 and 6-month follow-up assessments. The EUC condition is modeled on prior studies of caring letters and brief contacts by health professionals after suicidal crisis and national recommendations to provide post-crisis follow-up contacts."
89512466|NCT03338959|Experimental|Treatment (pembrolizumab, radiation therapy)|Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 3 weeks for 3 months in the absence of disease progression or unacceptable toxicity. Patients also undergo radiation therapy daily for 5-6 weeks.
89512467|NCT03320226|Other|Probiotic 10 (Nature's Bounty)|The suggested dose will be two (2) pills of Probiotic 10 (Nature's Bounty) after dinner daily. Subjects will be asked to take probiotics for six (6) days after providing baseline fecal specimen. Subjects will self-report their daily GI function including the frequency of nausea, vomiting, and bowel movement(s). Then, the subjects will stop taking probiotics for two (2) days and resume taking probiotics for another six (6) days. This six (6)-day on and two (2)- day off cycle is repeated two (2) times.
89512468|NCT03278782|Experimental|Treatment (romidepsin, pembrolizumab)|Participants receive romidepsin IV over 4 hours on days 1 and 8 or day 8 of cycle 1 and days 1 and 8 of subsequent cycles and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 36 cycles in the absence of disease progression or unacceptable toxicity.
89512469|NCT03276793|Experimental|MRI and behavioral assessment for patients receiving TMS|Subjects will undergo an hour-long MRI scanning session, a marking for the site of planned clinical TMS stimulation and a behavioral testing battery before and after their TMS treatment course.
89512470|NCT03216720|Active Comparator|CABG with miniaturized ECC|Elective (CABG) with conventional miniaturized extracorporeal circulation (miECC)
89512471|NCT03216720|Active Comparator|CABG with conventional ECC|Elective CABG with conventional extracorporeal circulation (cECC)
89512472|NCT03144232|Experimental|Active rTMS|10 Hz rTMS applied to the left DLPFC
89512473|NCT03144232|Sham Comparator|Sham rTMS|Sham rTMS applied to the left DLPFC
89512474|NCT03106181|Active Comparator|Cataract surgery|Conventional phacoemulsification cataract surgery and intraocular lens implantation
89512475|NCT03106181|Experimental|Cataract surgery plus iStent inject®|Conventional phacoemulsification cataract surgery and lens implantation plus insertion of iStent inject®
88959968|NCT05951387|Active Comparator|dexmedetomidine plus ketamine|starting intravenous infusion dose of dexmedetomidine 0.5 µg/kg/h mixed with ketamine 0.5 mg/kg/h to 30 mechanically ventilated ARDS patient
88959969|NCT05951387|Active Comparator|high dose dexmedetomidine|dexmedetomidine at 0.5 µg/kg/h intravenous infusion only to be titrated to achieve full sedation to 30 mechanically ventilated ARDS patient
89024396|NCT00430079|Experimental|Diagnostic (etanidazole)|Patients receive etanidazole derivative EF5 IV over 1-2½ hours once within 1-2 days before surgical resection or biopsy. Tumor tissue, normal tissue, and/or tumor-infiltrated lymph node samples are collected during surgery and stained for biological markers. Fluorescent immunohistochemistry techniques are used to determine the presence, distribution, and levels of EF5 binding.
89024397|NCT00430118|Experimental|Induction Prot I/Dexa - reinduction Prot III|
89024398|NCT00430118|Experimental|Induction Prot I/Pred - reinduction Prot III|
89541031|NCT05323253|Experimental|DaRT seeds|DaRT source will be inserted using preplanned radiotherapy parameters and reassessed by volumetric imaging 2-3 weeks after placement and then removed. Objective Response Rate (ORR) will be determined based on confirmed BOR following DaRT insertion.
89541032|NCT05323123|Experimental|Intervention|Participants will receive PrEP
89541033|NCT05313009|Experimental|STAGE 1: SAFETY LEAD IN (n=6-18, depending on number of DLs explored)|SAFETY LEAD IN (n=6-18, depending on number of DLs explored) 3+3 design dependent on DLTs
89207209|NCT03952143|Experimental|LY900014|Participants received 100 units per milliliter (U/mL) LY900014 subcutaneously (SC) 0-2 minutes before each meal with either basal insulin glargine or insulin degludec given SC once daily.
89207210|NCT03952143|Active Comparator|Insulin Lispro|Participants received 100 U/mL insulin lispro (Humalog) given SC 0-2 minutes before each meal with either basal insulin glargine or insulin degludec given SC once daily.
89207211|NCT00968175|Active Comparator|Group 1: CPN + analgesic therapy|Receives ultrasound guided celiac plexus neurolysis (CPN) in addition to standard analgesic therapy
89207212|NCT00968175|No Intervention|Analgesic therapy alone|Will not receive ultrasound guided celiac plexus neurolysis (CPN); only standard analgesic therapy for pain management
89207213|NCT03071757|Experimental|Part 1A: Monotherapy Dose Escalation|Part 1A: ABBV-368 (various dose levels) intravenous administration every 2 weeks (Q2W). One cycle of treatment is 28 days, thus there will be 2 doses with ABBV-368 per cycle.
89024399|NCT00430118|Experimental|Induction Prot I/Dexa - reinduction Prot II|
89024400|NCT00430118|Active Comparator|Induction Prot I/Pred - reinduction Prot II|
89024401|NCT00430118|Experimental|Induction Prot I/Dexa - reinduction 2x Prot III|
89207214|NCT03071757|Experimental|Part 2A: Monotherapy Cohort Expansion|Part 2A: Additional participants (triple negative breast cancer [TNBC]) will be enrolled in a dose expansion cohort that will further evaluate ABBV-368 (various dose levels) intravenous administration Q4W.
89207215|NCT03071757|Experimental|Part 2B: Combination Therapy Cohort Expansion|Part 2B: Additional participants (with Head and Neck carcinoma) will be enrolled in a dose expansion cohort that will further evaluate ABBV-368 (various dose levels) intravenous administration Q4W plus ABBV-181.
89207216|NCT03071757|Experimental|Part 3A: 18F-AraG Imaging Substudy in TNBC Participants|Part 3A: Additional participants (with TNBC) will be enrolled in 18F-AraG Imaging Substudy that will further evaluate ABBV-368 intravenous administration Q4W plus ABBV-181.
89207217|NCT03071757|Experimental|Part 3B: 18F-AraG Imaging Substudy in HNSCC Participants|Part 3B: Additional participants (with HNSCC) will be enrolled in 18F-AraG Imaging Substudy that will further evaluate ABBV-368 intravenous administration Q4W plus ABBV-181.
89207218|NCT00968331|Experimental|REVLIMID plus RITUXIMAB|"Oral Lenalidomide is initiated on day 1 of cycle 1 at the dose of 20 mg daily for 21 days with 7 days rest (28 day cycle) for a total of 4 cycles.~Rituximab is administered on day 1 and day 21 of each cycle at the dose of 375 mg/m2 for a total of 4 cycles."
89207219|NCT00852228|Experimental|chronomodulated HAI chemotherapy|
89207220|NCT00852228|Experimental|conventional HAI chemotherapy|
89207221|NCT00267007|Experimental|001|PROCRIT 40 000 IU QW Epoetin alpha (PROCRIT) 40 000 IU every week (QW) for 18 weeks (IV or SC)
89207222|NCT00267007|Placebo Comparator|002|Placebo Equivalent volume to PROCRIT (1 mL) administered (QW) for 18 weeks (IV or SC)
89207223|NCT00841620|Active Comparator|1|Haemorrhoidectomy a.m. Milligan for grade 3-4 haemorrhoids
89541034|NCT05313009|Experimental|STAGE 2: EFFICACY (n=12)|EFFICACY (n=12)
89207224|NCT00841620|Active Comparator|2|Stapled anopexy for grade 3-4 haemorrhoids
89207225|NCT00964821||Flu vaccine|Patients and normal volunteers who have received a flu vaccine
89207226|NCT00964821||Non-vaccine|Patients and normal volunteers who have not received the flu vaccine
89207227|NCT00852306|Experimental|slow freeze|these recipients will have their first embryo transfer with oocytes frozen via the slow freeze method.
89207228|NCT00852306|Experimental|vitrification|these recipients will have their first attempt at an embryo transfer with oocytes frozen via the vitrification method.
89207229|NCT01071031|Experimental|Group 1|Low Dose HIV-v with water for injection
89207230|NCT01071031|Experimental|Group 2|Low Dose HIV-v with adjuvant
89207231|NCT01071031|Experimental|Group 3|High Dose HIV-v with water for injection
89024402|NCT00430118|Experimental|Induction Prot I/Pred - reinduction 2x Prot III|
89512476|NCT03104491|Experimental|Inotuzumab Ozogamicin|"Phase I:~A maximum of 4 cycles will be allowed and doses will be adjusted in 0.1mg/m2 increments using a dose escalation scale depending on tolerability. Total range of dose levels for participants is 0.1-0.6mg/m^2.~Phase II:~Participants will be enrolled until all Phase I participants have been followed and assessed for toxicity for at least 4 weeks after the fourth treatment dose of inotuzumab ozogamicin or 4 weeks after the participant goes off treatment, whichever comes first. Doses to be administered will be determined in the phase I portion of the study. The recommended phase 2 dose is 0.3mg/m2. Repeat cycles every 28 days for up to 4 cycles"
89512477|NCT03030612|Experimental|ARGX-110 with Azacytidine (AZA)|Phase 1: Participants will receive loading dose of ARGX-110 1 milligram per kilogram (mg/kg) body weight (cohort 1), 3 mg/kg body weight (cohort 2), 10 mg/kg body weight (cohort 3) or 20 mg/kg body weight (cohort 4) administered intravenously (IV) in combination with AZA standard dose of 75 milligram per meter square (mg/m^2) body surface area (BSA) administered subcutaneously (SC) / intravenously (IV). Phase 2: Participants will receive loading dose of ARGX-110 IV at a recommended dose for Phase 2 (RP2D) level from phase 1 in combination with AZA standard dose of 75 mg/m^2 BSA, administered SC/IV as per local practice.
89512478|NCT03030170|Experimental|Experimental|Stapling of the pancreas with ENDO GIA Reinforced reload
89512479|NCT03030170|Active Comparator|Control|Stapling of the pancreas with ENDO GIA X-tra Thick reload
89512480|NCT02977780|Active Comparator|Temozolomide|"Daily Radiation for a maximum of 49 days.~Temozolomide will be administered orally on a daily dosing schedule~Temozolomide will be administered approximately 2-3 hours before each session of radiotherapy~Temozolomide will also be administered post radiation for up to 6 cycles (5 days/cycle)"
89512481|NCT02977780|Experimental|Neratinib with Temozolomide|"Daily Radiation for a maximum of 49 days.~Temozolomide will be administered orally on a daily dosing schedule~Temozolomide will be administered approximately 2-3 hours before each session of radiotherapy~Neratinib will be taken post radiation at a daily oral pre-determine dose"
89512482|NCT02977780|Experimental|QBS10072S|"Daily Radiation for a maximum of 49 days.~QBS10072S will be administered on Day 1 of Radiation Treatment~QBS10072S will be administered post- radiation for up to 6 cycles"
89512483|NCT02804022|Experimental|VPIA analgesia system|Vital-signs-integrated patient-assisted intravenous opioid analgesia system (VPIA). The vital signs (oxygen saturation, respiratory rate, heart rate) will be close monitored when patients is using VPIA pump. The drug used is intravenous morphine (1mg per milligram) with bolus of 1 mg.
89512484|NCT02792413|Experimental|Denosumab|Denosumab 60 mg, subcutaneous injection every 6 months for 24 months
89512485|NCT02792413|Placebo Comparator|Placebo|NaCl 0.9% (1 mL), subcutaneous injection every 6 months for 24 months
89512486|NCT02714439|Experimental|High-Resolution Microendoscopy (HRME)|After standard colposcopy examination performed, participants undergo a high-resolution microendoscopy imaging procedure. Proflavine 0.01% is applied to the cervix, then high-resolution microendoscopy imaging procedure performed. Standard colposcopy procedure will then continue.
89512487|NCT02706262|No Intervention|Metabolically normal lean - Baseline testing only|"Metabolically normal lean - Lean individuals that have good glucose (sugar) control, normal plasma triglyceride (fat) levels and a low liver fat content.~Dietary intervention - None."
89519491|NCT02131636|Placebo Comparator|Vehicle|Vehicle to AGN-199201 applied to the face once daily for 29 days.
88959970|NCT05940467|Experimental|Sleep Loss|Participants will undergo a night shift work like schedule and be monitored with non-invasive devices while at-home (at set intervals) and during an in-lab phase (hourly) during a 97 continuous-hour protocol. During the in-lab phase, which is approximately 48 continuous hours, participants will undergo a 24-hour period of sleep loss, followed by a brief opportunity for an in-lab sleep opportunity of 5 hours, followed by another period of 19 hours of sleep loss before returning home for at-home monitoring. Measures of interest include arterial stiffness as measured by pulse wave velocity (PWV) and changes in subjective ratings (e.g., fatigue and sleepiness). Other measures include cognitive performance, total sleep during the protocol, and sleep depth during an in-lab sleep opportunity.
88959971|NCT05940220|Active Comparator|acetazolamid|We will administer injectable and oral furosemide in infusion ward based on the dosage determined by the specialist on day zero. After that, we continue oral furosemide administration for three days. The prescribed dose of injectable and oral furosemide is determined by the specialist based on previous visits and hospitalizations in such a way that the patient has the least symptoms. The intervention group will receive acetazolamide 500 mg on day zero, then 250 mg bd for two days and 250 mg on the third day. The control group will receive placebo equivalent to acetazolamide.
88959972|NCT05940220|Placebo Comparator|placebo|Acetazolamide placebo add-on a standard therapy of iv furosemide in one day and oral furosemide during three consecutive days will be used for the comparator arm.
88959973|NCT05939856|Other|1 Lymph node dissection before bladder resection|Lymph node dissection will be performed before bladder resection during radical cystectomy
88959974|NCT05939856|Other|2 Lymph node dissection after bladder resection|Lymph node dissection will be performed after bladder resection during radical cystectomy
89024403|NCT00430118|Experimental|Induction Prot I/Dexa - reinduction 3 HR courses + 3x Prot III|
89024404|NCT00430118|Experimental|Induction Prot I/Pred - reinduction 3 HR courses + 3x Prot III|
89024405|NCT00430118|Experimental|Induction Prot I/Dexa - reinduction 6 HR courses + Prot II|
88959975|NCT05935631|Experimental|Salt with folic acid and iodine|Intervention is intake of double fortified salt with folic acid and iodine (DFS). We will ask the participants to substitute their current salt with the study saltshaker and use it when preparing food or when eating out. We estimate minimum daily intake from salt consumption by participants will be 200 micrograms (µg) of folic acid per serving. Serving is 2g of salt. Participants will be given portion suggestions: 1/2 teaspoon or 2-3 pinches or 8-10 shakes/5 times a day. Containers (125g) will be weighted at the beginning and end of 1 month. We will ask each day if woman cooked/used the salt for herself only or to list number of people each day. Participants will also agree to complete either daily paper salt log. A commercially available salt that is fortified with folic acid has been provided by AlpenJodSalz produced by Sudwestdeutsche Salzwerk. For 30 participants, we will need 30 containers.
89207232|NCT01071031|Experimental|Group 4|High Dose HIV-v with adjuvant
89207233|NCT01071031|Placebo Comparator|Group 5|Control group: adjuvant only or water for injection only
89207234|NCT00968409|Other|FFNP-PET/CT Imaging|All subjects will receive an injection of F-18-FFNP followed by PET/CT imaging, laboratory testing and safety testing.
89512488|NCT02706262|No Intervention|Metabolically normal obese - Baseline testing only|"Metabolically normal obese - Persons with obesity that have good glucose (sugar) control, normal plasma triglyceride (fat) levels and a low liver fat content.~Dietary intervention - None."
89512489|NCT02706262|Experimental|Metabolically abnormal obese - Mediterranean diet|"Metabolically abnormal obese - Persons with obesity with glucose levels higher than recommended and a moderate to high amount of fat in the liver.~Dietary intervention - A nutritionally balanced diet that includes fruits, vegetables, fish, beans, whole grains, and olive oil with approximately 50% of daily calories coming from complex carbohydrates, 30% of calories from fat, and 20% of calories from protein."
89512490|NCT02706262|Experimental|Metabolically abnormal obese - Low carbohydrate ketogenic diet|"Metabolically abnormal obese - Persons with obesity with glucose levels higher than recommended and a moderate to high amount of fat in the liver.~Dietary intervention - A very-low-carbohydrate, adequate protein, high-fat diet containing 20 grams of carbohydrate or less per day (about 5% of calories), derived mainly from vegetables."
89512491|NCT02706262|Experimental|Metabolically abnormal obese - Plant-based very-low-fat diet|"Metabolically abnormal obese - Persons with obesity with glucose levels higher than recommended and a moderate to high amount of fat in the liver.~Dietary intervention - A plant-based diet high in complex carbohydrates and low in fat, protein, and sodium, with approximately 70% of daily calories from carbohydrates, 15% from fat, and 15% from protein."
89512492|NCT02586389||Non-hematological Cancer Cohort|Eligible subjects will have been previously diagnosed with a non-hematological cancer with tumor present at baseline blood draw.
89512493|NCT02298465|Active Comparator|Prone ESWL|ESWL for distal ureteric stone is performed in the traditional prone position
89512494|NCT02298465|Experimental|Supine ESWL|ESWL for distal ureteric stone is performed in the supine position, with the shockwave generator head placed at a 30 degree angle to the vertical at the patient's gluteal muscles. Thus, the shockwaves will travel via the greater and lesser sciatic foramina to reach the stone
89512495|NCT02133573|Experimental|Progesterone|Vaginal gel, 90mg twice a day (BID)
89512496|NCT02133573|Placebo Comparator|Vaginal Lubricant|Vaginal twice a day (BID)
89512497|NCT02057510||Patients receiving head and neck RT|No intervention
89512498|NCT01917916|Experimental|BI 655064 dose group 1 - 80 mg|
89512499|NCT01917916|Experimental|BI 655064 dose group 2 - 120 mg|
89512500|NCT01917916|Experimental|BI 655064 dose group 3 - 180 mg|
89512501|NCT01917916|Experimental|BI 655064 dose group 4 - 240 mg|
89512502|NCT01917916|Placebo Comparator|Placebo matching BI 655064|
89512503|NCT01889381|Experimental|Treatment (Transplantation)|Face transplantation in combination with a novel donor bone marrow cell-based therapy followed by single-drug immunosuppression with potential weaning.
89512504|NCT01878669|Placebo Comparator|saline|30 mg/kg/15 min intravenous bolus preprocedural and 50 mg/kg/8 h intravenous infusion during and after the procedure
89512505|NCT01878669|Experimental|n-acetyl cysteine|30 mg/kg/15 min intravenous bolus preprocedural and 50 mg/kg/8 h intravenous infusion during and after the procedure
89512506|NCT01878344|Experimental|n-acetyl cysteine|30 mg/kg/15 min intravenous bolus preprocedural and 50 mg/kg/8 h intravenous infusion during and after the procedure
89512507|NCT01878344|Placebo Comparator|Saline|30 mg/kg/15 min intravenous bolus preprocedural and 50 mg/kg/8 h intravenous infusion during and after the procedure
89512508|NCT01813539|Experimental|Dose Escalation: Cohort 1|Participants will receive ARGX-110 as an intravenous infusion (IV) at dose level 1.
89512509|NCT01813539|Experimental|Dose Escalation: Cohort 2|Participants will receive ARGX-110 as an IV infusion at dose level 2.
89512510|NCT01813539|Experimental|Dose Escalation: Cohort 3|Participants will receive ARGX-110 as an IV infusion at dose level 3.
89512511|NCT01813539|Experimental|Dose Escalation: Cohort 4|Participants will receive ARGX-110 as an IV infusion at dose level 4.
89512512|NCT01813539|Experimental|Dose Escalation: Cohort 5|Participants will receive ARGX-110 as an IV infusion at intermediate dose level at the conclusion of Cohort 4 prior to opening the safety expansion cohorts to participants enrolment.
89512513|NCT01813539|Experimental|Safety Expansion: Cohort 1|Participants with solid tumors will receive ARGX-110 as an IV infusion at a dose based on the safety, PD, and PK profiles of ARGX-110 as per the dose escalation part of the trial.
89512514|NCT01813539|Experimental|Safety Expansion: Cohort 2|Participants with hematological malignancies (all etiologies) will receive ARGX-110 as an IV infusion at a dose based on the safety, PD, and PK profiles of ARGX-110 as per the dose escalation part of the trial.
89512515|NCT01813539|Experimental|Safety Expansion: Cohort 3|Participants with cutaneous T-cell lymphoma (CTCL) will receive ARGX-110 as an IV infusion at dose level 2 followed by a maintenance therapy at dose level 2 or 3.
89512516|NCT01813539|Experimental|Safety Expansion: Cohort 4|Participants with peripheral T-cell lymphoma (PTCL) will receive ARGX-110 as an IV infusion at dose level 2 followed by a maintenance therapy at dose level 2 or 3.
89512517|NCT01813539|Experimental|Exploratory Efficacy: Cohort 5|Participants with relapsed/refractory CTCL will receive ARGX-110 as an IV infusion followed by a maintenance therapy at dose level 3.
89512518|NCT01704859|Placebo Comparator|Vitamin D placebo + fish oil placebo|
89512519|NCT01704859|Active Comparator|Vitamin D placebo + fish oil|
89024406|NCT00430118|Active Comparator|Induction Prot I/Pred - reinduction 6 HR courses + Prot II|
89024407|NCT00461487|Experimental|1|Participants will receive sex education information during the physical exam
89024408|NCT00461487|Active Comparator|2|Participants will receive information on hygiene and nutrition during the physical exam
89024409|NCT00461487|No Intervention|3|Passive control participants will not receive any additional information during the physical exam
89024410|NCT00461526|Experimental|125 mg crofelemer|
89024411|NCT00461526|Placebo Comparator|placebo|
89024412|NCT00461565|Active Comparator|Part A1|
89512520|NCT01704859|Active Comparator|Vitamin D + fish oil placebo|
89512521|NCT01704859|Active Comparator|Vitamin D + fish oil|
89512522|NCT01529944|Experimental|Low dose 33 mcg/kg/day|
89512523|NCT01529944|Experimental|High dose 66 mcg/kg/day|
89512524|NCT01459562|Experimental|NI-0501|
89512525|NCT01459562|Placebo Comparator|Placebo|
89512526|NCT01307384||Continuum Acetabular System|Patients receiving primary hip arthroplasty using the Continuum Metal on Polyethylene Acetabular System
89512527|NCT00869232|Experimental|MEL--VTD-PACE|Melphalan, Velcade, Thalidomide, Dexamethasone, Cisplatin, Adriamycin, Cyclophosphamide and Etoposide
89512528|NCT00765765|Experimental|Ixabepilone and hydroxychloroquine|
89512529|NCT00734877|Active Comparator|ARM A|The standard TT3 Regimen (S-TT3) will consist of 2 cycles of induction therapy with M-VTD-PACE and PBSC collection after the 1st cycle. MEL-based tandem transplant will be administered 6 weeks to 3 months apart, applying single dose MEL 200 mg/m2 with adjustments for age and renal function. Consolidation will consist of 2 cycles of dose-reduced VTD-PACE. Maintenance treatment will employ VRD for 3 years.
89512530|NCT00734877|Experimental|ARM B|The TT3-LITE Regimen (L-TT3) will employ only 1 cycle of induction therapy with MVTD- PACE
89512531|NCT00686595|Experimental|Infliximab 5 mg/kg|Infliximab 5 mg/kg intravenous (IV) infusion administered at Baseline (Week 0), Visit 3 (Week 2), Visit 4 (Week 6), Visit 6 (Week 14), and Visit 8 (Week 22).
89512532|NCT00640159|Experimental|Selegiline|Open label switch from current oral selegiline dose to orally disintegrating selegiline (Zelapar) titrated to a dose of 2.5 mg QD.
89024413|NCT00461565|Placebo Comparator|Part A2|
89512533|NCT00102011|Experimental|Study I- Arm I|Participants undergo baseline screening colonoscopy
89512534|NCT00102011|Other|Study I- Arm II|Participants receive standard care
89512535|NCT00102011|Experimental|Study II- Arm I|Participants undergo baseline screening colonoscopy. Participants are given individualized recommendations for further surveillance based on the results of the colonoscopy.
89512536|NCT00102011|Active Comparator|Study II- Arm II|Participants undergo a baseline fecal occult blood test (FOBT). Participants are given individualized recommendations for further surveillance based on the results of the FOBT. Participants with negative baseline FOBT undergo FOBT annually for up to 4 years in the absence of a positive FOBT.
89512537|NCT03483493|Experimental|Exposure Response Prevention for tics|10-weeks, online delivered, therapist supported exposure response prevention (ERP) therapy for tics
89024414|NCT00461565|Experimental|Part B1|
89024415|NCT00461565|Placebo Comparator|Part B2|
89024416|NCT00430391|Experimental|DVD patient high risk|Patients with a diagnosis of schizophrenia/schizoaffective disorder randomized to the DVD, high risk version
89024417|NCT00430391|Experimental|DVD patient low risk|Patient with a diagnosis of schizophrenia/schizoaffective disorder randomized to DVD consent, low risk version
89024418|NCT00430391|Experimental|DVD normal high risk|Participants with no psychiatric diagnosis randomized to DVD consent, high risk version
89024419|NCT00430391|Experimental|DVD normal low risk|Participants with no psychiatric diagnosis randomized to DVD consent, low risk version
89024420|NCT00430391|Experimental|Routine control high risk|Participants with no psychiatric diagnosis randomized to routine consent, high risk version
89024421|NCT00430391|Experimental|Routine control low risk|Participants with no psychiatric diagnosis randomized to routine consent, low risk version
89024422|NCT00430391|Experimental|Routine patient low risk|Participants with schizophrenia/schizoaffective disorder randomized to routine consent, low risk version
89207235|NCT00848406||1|30 individuals ≤ 40 years, who currently smoke ≥ 10 cigarettes/day and > 10 packyears
89512538|NCT03483493|Active Comparator|Active Control (Psychoeducation)|10-weeks, online delivered, therapist supported psychoeducation for tics
89512539|NCT03483415|Experimental|Grup L|"IV patient-controlled analgesia (PCA) morphine~+ Ultrasound guided Long thoracic nerve blockage with 5 ml % 0.25 bupivacaine"
89512540|NCT03483415|Active Comparator|Group P|IV patient-controlled analgesia (PCA) morphine
89512541|NCT03487003|Active Comparator|MR group|When the patients asleep, 0.3 mg/kg rocuronium is administered.
89512542|NCT03487003|Experimental|NMR group|When the patients asleep, 0.3 mg/kg saline is administered.
89512543|NCT03486925|Experimental|oxytocin group|
89512544|NCT03486925|Placebo Comparator|placebo group|
89512545|NCT03486847|Experimental|Repetitive recruitment with PEEP|One alveolar recruitment at before surgery and repetitive alveolar recruitment (once an hour) during surgery
89512546|NCT03486847|Active Comparator|One recruitment with PEEP|One alveolar recruitment at before surgery
89512547|NCT03495271||Hemodialysis Patients|"Inclusion Criteria:~Patient's undergoing hemodialysis.~Male and female of any race~18 years/ older.~Those with dysphagia were excluded.~In both participant groups, before each tasting protocol commences, sterile cotton dental rolls will be placed in the participant's mouth. This will be used to collect a saliva sample and determine salivary flow.~Tasting Protocol: The hemodialysis patients will taste each solutions twice, both before and after their dialysis session. An sensory questionnaire and an open ended comment box will be given for participants to type in other words to describe the sensations.~In dialysis patients only, blood will be drawn pre and post dialysis for serum ion concentrations."
89519492|NCT02131324|Active Comparator|Clobetasol Propionate Cream, 0.05%|applied twice a day for 15 days
89519493|NCT02131324|Experimental|DFD06 Cream|applied twice a day for 15 days
89519494|NCT02734693|Experimental|Dasotraline 4mg|Dasotraline capsule 4mg/day
89519495|NCT02734693|Placebo Comparator|Placebo|Placebo capsule
88810934|NCT05042882|No Intervention|Oral nutrition|Control group: patients will receive standardized oral nutrition. The night after the operation, patients will be allowed to have free drinks. On postoperative day 1, they will receive bouillons, creams, yogurts, and drinks >2 l. On postoperative day 2, they will receive a light diet. On postoperative day 3, they will receive half portion of normal diet and on postoperative day 4 normal diet.
89024423|NCT00430391|Experimental|Routine patient high risk|Participants with schizophrenia/schizoaffective disorder randomized to routine consent, high risk version
89024424|NCT00470340|Experimental|1|Oxaliplatin, gemcitabine, cisplatin, lipiodol
89024425|NCT00470340|Experimental|2|Oxaliplatin, gemcitabine, cisplatin, lipiodol
89024426|NCT00430430|Experimental|High MUFA|high monounsaturated fat background diet to portfolio diet
89024427|NCT00430430|Active Comparator|Low MUFA|low monounsaturated fat background diet to portfolio diet
89024428|NCT00461643|Active Comparator|Strategy A|clomiphene followed by clomiphene plus metformin followed by gonadotropins
89024429|NCT00461643|Active Comparator|Strategy B|metformin followed by metformin plus clomiphene followed by gonadotropins
89024430|NCT00461643|Active Comparator|Strategy C|metformin plus clomiphene followed by gonadotropins
89024431|NCT00430586|Experimental|20 U NT 201|
89512548|NCT03495271||Healthy Controls|"Inclusion Criteria~No tongue, lip, or cheek piercings~Over 18 years of age~Normal taste and smell function~No known issues with salivation or dry mouth~Willing to comply with study protocol (taste samples and provide saliva)~The above protocol will be mimicked in the healthy control group. The only difference is that instead of a pre/post dialysis tastings, the control population will have a 2-4 hour gap in between tastings in order to follow the approximate time-frame of the dialysis patients. Finally they will not be required to provide blood samples."
89512549|NCT03483259|Experimental|Arm A-Sulfatinib T capsule|The subjects in this arm will receive sulfatinib T capsules from Hutchison Whampoa Pharmaceutical (Suzhou) Co., Ltd.
89512550|NCT03483259|Experimental|Arm B-Sulfatinib R capsule|The subjects in this arm will receive sulfatinib R capsules from Beijing Yiling Bioengineering Technology Co., Ltd.
89512551|NCT02262754|Experimental|PF-06372865|Daily BID dosing for 4 weeks
89512552|NCT02262754|Placebo Comparator|Placebo|Daily BID dosing for 4 weeks
89512553|NCT02262754|Active Comparator|Naproxen|Daily BID dosing for 4 weeks
89512554|NCT03483181||Orthopedic surgery patient records|Medical records from patients aged 18 years or older with orthopedic surgeries during the hospitalization
89512555|NCT02323711|No Intervention|Control|This group would be receiving the standard of care. The subject would receive the standard dressing applied by a member of the surgical team in the standard fashion as follows: The closed incision will be covered first with a primary dressing consisting of a nonadherent, composite dressing (Telfa), which is covered with a secondary dressing consisting of an Army Battle Dressing (ABD), before removal of the sterile surgical drapes. This dressing is then held in place with an adhesive fabric tape, currently Mefix tape, which is typically applied by the surgical scrub tech.
89512556|NCT02323711|Experimental|2-octyl cyanoacrylate|This group would receive the experimental treatment. If allocated to coverage with glue, no dressing is placed. After closure of the incision with suture or staples, the incision is patted dry under sterile conditions. The incision is then covered longitudinally by a member of the surgical team with a thick layer of skin glue dispensed from 1 tube of surgical skin glue (2-octyl cyanoacrylate, currently using brand: Derma+Flex QS). The glue is then allowed to dry before the sterile surgical drapes are removed.
89512557|NCT03486769|Experimental|Dual Stimulation 1|i) anodal stimulation on ipsilesional primary motor cortex and cathodal stimulation on contralesional primary motor cortex, ii) anodal stimulation on ipsilesional premotor cortex and cathodal stimulation on contralesional supraorbital area.
89512558|NCT03486769|Experimental|Dual Stimulation 2|i) anodal stimulation on ipsilesional primary motor cortex and cathodal stimulation on contralesional primary motor cortex, ii) anodal stimulation on ipsilesional anterior intraparietal sulcus and cathodal stimulation on contralesional supraorbital area.
89512559|NCT03486769|Experimental|Single stimulation|anodal stimulation on ipsilesional primary motor cortex and cathodal stimulation on contralesional primary motor cortex
89512560|NCT03486691|Experimental|preoperative left lobe measurement|routine preoperative left lobe measurement
89512561|NCT03486691|Active Comparator|Control group|Control group without routine measurement of left lobe
89512562|NCT03486613|Other|Group AT|PROM registration via the DANBIO App on a smartphone and thereafter the touch screen solution
89512563|NCT03486613|Other|Group TA|PROM registration via the touch screen solution and thereafter the DANBIO App
89512564|NCT03483025|Other|Hair Cleansing product 1|Skin Testing of Hair cleansing products all pts will test 6 hair cleansing products, but site of testing will be randomized and blinded
89512565|NCT03483025|Other|Hair cleansing product 2|Skin Testing of Hair cleansing products all pts will test 6 hair cleansing products, but site of testing will be randomized and blinded
89512566|NCT03483025|Other|Hair cleansing product 3|Skin Testing of Hair cleansing products all pts will test 6 hair cleansing products, but site of testing will be randomized and blinded
89512567|NCT03483025|Other|Hair cleansing product 4|Skin Testing of Hair cleansing products all pts will test 6 hair cleansing products, but site of testing will be randomized and blinded
89512568|NCT03483025|Other|Hair cleansing product 5|Skin Testing of Hair cleansing products all pts will test 6 hair cleansing products, but site of testing will be randomized and blinded
89512569|NCT03483025|Other|Hair cleansing product 6|Skin Testing of Hair cleansing products all pts will test 6 hair cleansing products, but site of testing will be randomized and blinded
89512570|NCT02262364|Experimental|NStride APS|Subjects will receive an intra-articular injection of APS.
89024432|NCT00430586|Placebo Comparator|Placebo|
89024433|NCT00430586|Experimental|10 U NT 201|
89024434|NCT00430586|Experimental|30 U NT 201|
89541035|NCT05308004|No Intervention|Standard Care|Participants will receive the standard Medicare Skilled Nursing Facility care.
89512571|NCT02261974|Active Comparator|Active Viveve Treatment|Intervention in the active arm will be with the Viveve System using 90 Joules/cm2 active treatment with radiofrequency energy in the vaginal introitus
88810935|NCT05032235|Experimental|Group A|
89512572|NCT02261974|Placebo Comparator|Sham Viveve Treatment|Intervention in the sham arm will be with the Viveve System using ≤1 Joule/cm2 sham treatment with radiofrequency energy in the vaginal introitus
89512573|NCT02356588|Experimental|Sufentanil Tablet 30 mcg|A stratified randomization will be applied in this study with sex as a stratification factor. Patients who meet all inclusion and none of the exclusion criteria at screening, and following surgery, will be randomly assigned at a 2:1 ratio to treatment with ST 30 mcg or PT within one of two groups (male or female) at each study center. Patients may receive a dose of study medication no more frequently than once per hour. The study may last up to 48 hours.
88810936|NCT05032235|Experimental|Group B|
88810937|NCT05032235|Experimental|Group C|
88810938|NCT05028062|Active Comparator|XR-NTX 380 mg, intramuscular injection|Subjects will receive an injection of XR-NTX 380 mg (4 mL) repeated once after 4 weeks.
88810939|NCT05028062|Placebo Comparator|Inactive placebo intramuscular injection|Subjects will receive a placebo injection repeated once after 4 weeks.
88810940|NCT05024032|Experimental|10 Milligrams (mg) Tirzepatide|Participants received maintenance dose 10 mg with dose escalation starting from 2.5 mg, 5 mg, 7.5 mg, and then 10 mg tirzepatide administered subcutaneously (SC) once weekly (QW).
88810941|NCT05024032|Experimental|15 mg Tirzepatide|Participants received maintenance dose 15 mg with dose escalation starting from 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and then 15 mg tirzepatide administered SC QW.
88810942|NCT05024032|Placebo Comparator|Placebo|Participants received matching placebo SC QW.
88810943|NCT05005013|Experimental|Active tDCS + Mindfulness|
88810944|NCT05005013|Sham Comparator|Sham tDCS + Mindfulness|
88810945|NCT05004350|Experimental|Encorafenib and cetuximab|"Safety Lead-in (SLI) phase:~28 day cycles of encorafenib once daily (QD) 300 mg (4 x 75 mg oral capsule) and cetuximab 400 mg/m² initial dose (120-minute infusion), then 250 mg/m² (60-minute infusion) thereafter once weekly~Randomized (Phase II) phase:~28 day cycles of encorafenib once daily (QD) 300 mg (4 x 75 mg oral capsule) and cetuximab 400 mg/m² initial dose (120-minute infusion), then 250 mg/m² (60-minute infusion) thereafter once weekly"
88810946|NCT05004350|Experimental|Irinotecan and cetuximab or FOLFIRI and cetuximab|"Randomized (Phase II) phase: Either irinotecan and cetuximab or FOLFIRI and cetuximab in 28 day cycles.~Irinotecan and cetuximab:~irinotecan 180 mg/m² (90-minute intravenous infusion or to study site standards) every 2 weeks and~cetuximab 400 mg/m² initial dose (120-minute intravenous infusion), then 250 mg/m² (60-minute infusion) thereafter once weekly~OR~FOLFIRI and cetuximab:~irinotecan 180 mg/m² (90-minute intravenous infusion or to study site standards) every 2 weeks~Folinic acid 400 mg/m² (120-minute infusion or to study site standards) or maximal dose tolerated in a prior regimen every 2 weeks~5-FU 400 mg/m² initial dose bolus (not to exceed 15 minutes), then 1200 mg/m²/day × 2 days (total 2400 mg/m² over 46 to 48 hours) continuous infusion or maximal dose tolerated in a prior regimen every 2 weeks and~cetuximab 400 mg/m² initial dose (120-minute intravenous infusion), then 250 mg/m² (60-minute infusion) thereafter once weekly"
89512574|NCT02356588|Placebo Comparator|Placebo Tablet|A stratified randomization will be applied in this study with sex as a stratification factor. Patients who meet all inclusion and none of the exclusion criteria at screening, and following surgery, will be randomly assigned at a 2:1 ratio to treatment with ST 30 mcg or PT within one of two groups (male or female) at each study center. Patients may receive a dose of study medication no more frequently than once per hour. The study may last up to 48 hours.
88810947|NCT04990466|Experimental|Active Vaccine|IIBR-100 (VSV-ΔG) vaccine at 10 to the 8th strength in prime/boost separated by 28 days
88810948|NCT04990466|Active Comparator|Active Comparator|A currently approved vaccine for COVID-19 administered in prime/boost separated by 28 days
89512575|NCT04445389|Experimental|GX-19: Dose A|Dose A of GX-19 will be intramusculary administered via EP on day 1 and day 29.
89512576|NCT04445389|Experimental|GX-19: Dose B|Dose B of GX-19 will be intramusculary administered via EP on day 1 and day 29.
89512577|NCT04445389|Placebo Comparator|GX-19: Dose C|Dose C of GX-19 will be intramusculary administered via PharmaJet® Needle Free Delivery on day 1 and day 29.
89512578|NCT04445389|Placebo Comparator|Placebo: Dose A, B, or C|Placebo will be intramusculary administered on day 1 and day 29 via EP or PharmaJet® Needle Free Delivery
89512579|NCT03482947|Experimental|TAP|ultrasonography-guided transversus abdominis plane block administration of (1 mL/kg of bupivacaine 0.25% plus 1 μ/kg dexmedetomidine).
89512580|NCT03482947|Experimental|Caudal|Caudal epidural block administration of (1 mL/kg of bupivacaine 0.25% &1 μ/kg dexmedetomidine
89512581|NCT02323789|Experimental|Intervention arm|10 patients with RDEB will be selected to receive the intervention - mesenchymal stromal cells.
89512582|NCT03482869|Experimental|Diabetic patients|Patients referred for the equilibrium or diagnosis of diabetes mellitus will be proposed to participate and estimate their walking ability with the WELSH (Walking estimated limitation stated by History) based solely on images
89512583|NCT03486535||Diabetic patients|Diabetic patients will receive ultrasound-guided infraclavicular brachial plexus blocks (ICBs) with the mixture of 15 mL lidocaine 2% and 15 mL bupivacaine 0.5%.
89512584|NCT03486535||Non-diabetic patients|Nondiabetic patients will receive ultrasound-guided infraclavicular brachial plexus blocks (ICBs) with the mixture of 15 mL lidocaine 2% and 15 mL bupivacaine 0.5%.
89512585|NCT02324023|Experimental|Endoscopic ultrasound and pathology|Endoscopic ultrasound and contrast enhanced endoscopic ultrasound for staging and perfusion (preoperatively) compared to pathological stage and vessel density in the pathological specimen (postoperatively).
88811565|NCT01279187|Experimental|Teriparatide|demeclocycline HCl (150 mg, four times per day for 3d) followed by a 12 day intermission then 3 more days of demeclocycline HCl (150 mg, four times per day). One day after the last demeclocycline dosage, subjects will be instructed to self-administer teriparatide (or placebo) for 7 weeks. Twenty-five days after the last demeclocycline dosage, subjects will begin their second set of tetracycline labels:(250 mg, four times per day) for three days, followed by 12 days off, and then repeat another 3 days of tetracycline HCl (250 mg, four times per day). On day of the last teriparatide (or placebo) injection, subjects will present for bone core removal and dental implant placement.
88811967|NCT03439280|Experimental|Phase 2a: Mezagitamab|Mezagitamab, SC, once weekly for 8 weeks, then once every 2 weeks for 16 weeks, and then once every 4 weeks thereafter in a 28-day treatment cycle until PD, unacceptable toxicities or withdrawal due to other reasons. TAK-079 dose for this phase was to be determined based on review of the available safety, efficacy, pharmacokinetic, and pharmacodynamic data obtained from the Phase 1 portion of the study. However, Phase 2a of the study was not opened for enrollment due to changes in the Sponsor's overall clinical development plan.
89512586|NCT02355028|Experimental|LHA510|LHA510 ophthalmic suspension administered topically in the study eye as specified in the protocol for 84 days, with ranibizumab ophthalmic solution for IVT injection as standard of care rescue therapy.
89512587|NCT02355028|Placebo Comparator|Vehicle|LHA510 vehicle administered topically in the study eye as specified in the protocol for 84 days, with ranibizumab ophthalmic solution for IVT injection as standard of care rescue therapy.
89512588|NCT01595503|Experimental|fMRI-based targeting|
89512589|NCT01595503|Active Comparator|landmark-based targeting|
89512590|NCT05647330|Experimental|Hydroxychloroquine combined with gemcitabine|"Hydroxychloroquine sulfate tablets: twice a day, each time (600mg). Continuous oral administration. Until the disease progresses or becomes intolerable.~gemcitabine was administered intravenously at a dose of 1000mg/m2 for 30min,d1, 8, and every 3 weeks (21 days) until disease progression or intolerable toxicity, with a maximum duration of 2 years."
89512591|NCT04460755|Active Comparator|Control group|A group of participants that will be using toothpaste without tooth whitening ingredients.
89512592|NCT04460755|Experimental|Whitening toothpaste 1|A group of participants that will be using urea peroxide whitening toothpastes.
89512593|NCT04460755|Experimental|Whitening toothpaste 2|A group of participants that will be using hydrogen peroxide whitening toothpastes.
89512594|NCT04460755|Experimental|Whitening toothpaste 3|A group of participants that will be using whitening toothpastes that contain abrasive ingredients.
89512595|NCT04460755|Experimental|Whitening toothpaste 4|A group of participants that will be using whitening toothpastes that contain enzymes as whitening ingredients.
89512596|NCT04460755|Experimental|Whitening toothpaste 5|A group of participants that will be using toothpastes that contain an activated charcoal.
89512597|NCT02524093|Experimental|Intervention|Participants in this arm will be given the Positive Mental Training programme. This consists of twelve eighteen minute audio tracks. Each is listened to in turn every day, once a day for a week (or at least 5 days in a week). This means that to use the treatment properly the participant needs to spend 18 minutes a day for 12 weeks listening to it. Each track guides the listener through different instructions which aim to build skills and bring about positive change. The programme begins with simple relaxation, going on to support the creation of pictures in your head of safe places and a more positive future.
89512598|NCT02524093|Placebo Comparator|Control|Will receive treatment as usual for 12 weeks, when will be asked to complete rating scales again. They will then be given the Positive Mental Training programme.
89512599|NCT01643668|Experimental|BuClo RIC + SCT|Busulfan and Clofarabine (BuClo) reduced intensity conditioning (RIC) followed by allogeneic stem cell Transplantation (SCT)
89512600|NCT05388331||RIS/1-2 criteria|
89512601|NCT05388331||RIS/3-4 criteria|
89512602|NCT05388331||NON RIS/0 criteria|
89512603|NCT03495193|Active Comparator|Exercise Group|Subjects randomized to the exercise training group will complete 16 weeks of exercise training. Exercise training will be performed 3x/week.
89512604|NCT03495193|Active Comparator|No Exercise Group|Subjects randomized to the no-Ex group will receive a handout with tips for improving sleep hygiene. Additionally, study staff will provide the title page for a book on sleep relaxation techniques that is recommended for persons with sleeping difficulty.
89512605|NCT02260882|Experimental|Revaccination Group|0.5 mL intramuscular injection (deltoid or lateral mid-thigh) of PNEUMOVAX™ 23 vaccine on Day 1 for participants who received an initial vaccination at least 5 years prior
89512606|NCT02260882|Experimental|Primary Vaccination Group|0.5 mL intramuscular injection (deltoid or lateral mid-thigh) of PNEUMOVAX™ 23 vaccine on Day 1 for participants who have never received PNEUMOVAX™ 23 vaccination
89512607|NCT03482401|Experimental|Polyphenol group|Patients consumed a polyphenol-rich dietary supplement (commercial lemon, orange, pomegranate, olive, grape, cocoa, curcuma and broccoli extracts), mainly rich in simple phenolics such as hydroxytyrosol and the polyphenols procyanidins, hesperidin, eriocitrin, curcumin, resveratrol, punicalagin and ellagic acid. Cocoa extract also contains the methylxanthines theobromine and caffeine.
89512608|NCT03482401|No Intervention|Control group|Participating patients did not consume the supplement but provided biological samples to the trial
89512609|NCT04312789|Experimental|Treatment (avatrombopag)|Patients receive avatrombopag PO QD for up to 1 year in the absence of disease progression or unacceptable toxicity. Avatrombopag will be titrated weekly until platelet count of greater than or equal to 60,000/uL is achieved and persists for 7 consecutive days, and the patient remains free from platelet transfusion.
89512610|NCT05152225||Infective endocarditis|Infective endocarditis with systematic brain MRI and digital subtraction angiography (DSA) performed routinely.
89512611|NCT02260804|Experimental|CT-P10|CT-P10, intervention 375mg/m2, intravenous, 4 cycles in induction period and additional 12 cycles in maintenance period
89512612|NCT02260804|Active Comparator|Rituxan|Rituxan, 375mg/m2 intravenous, 4 cycles in induction period, Rituxan for the first 6 cycles and CT-P10 for the last 6 cycles in maintenance period.
89512613|NCT02324101|Experimental|Breast cancer|Detect plasma Hsp90α concentration of breast cancer patients
89512614|NCT03482323|Experimental|Exercise intervention|Exercise class will run twice a week for 12 weeks. Participants will be encouraged to maintain their exercise beyond the intervention. An exercise trainer will lead the classes. The main activity of the classes includes aerobic exercises of walking on treadmill, or out-doors depending on group preference and weather, at a set pace individually tailored for moderate intensity of exercise, determined by baseline physical functioning assessment and modified based on Rated Perceived Exertion (RPE), or cycling on a stationary bike, using a set resistance to the physical functioning assessment and RPE. A set of four strengthening exercises are included in one of the exercise classes each week. These exercises are chosen to increase strength in the leg, arm, abdomen and improve trunk stability. Weights for the strengthening exercise will be set to give participants a moderate level of intensity of exercise.
89512615|NCT03482323|Experimental|Tai-chi intervention|The classes will run twice a week for 12 weeks with each session lasting approximately 60 minutes. Classes will be taught by an experienced tai-chi master, who will explain the theory behind tai-chi and the principles of the techniques. The supervised session includes a warm up, self-massage and a guided run through of the movements, breathing techniques, and relaxation in tai-chi. The tai-chi master will guide participants to practice the tai-chi they learn in the classes at home each day. Upon completion of the 12 weeks course, participants will be encouraged to continue their tai-chi practice, given guidance on local services and programmes they may join if they wish to.
89512616|NCT03482323|No Intervention|Control group|Participants randomised to the control group shall receive written information on health levels of physical activity, which they can participate in at home (self-management) and continue to receive their usual care, participants will be followed up with an assessment at 12 weeks, 6 months and one year. At the end of the evaluation stage of the study, survivors in the control group will be invited to take part in an intervention of their choice.
89512617|NCT03495037|Experimental|Real World Strategy Training|Group intervention including education and strategy training to manage everyday functional difficulties.
89512618|NCT03495037|Active Comparator|Psychosocial Education|Group sessions including education on brain health.
89512619|NCT04460365|Active Comparator|Active|Softgel capsules: 10 mg Lutein, 2 mg zeaxanthin, 10 mg meso-zeaxanthin once a day with a meal for 18 months
89512620|NCT04460365|Placebo Comparator|Placebo|Identical capsule containing no active ingredients
89512621|NCT02260648|Experimental|Evacetrapib|130 milligrams (mg) evacetrapib and 10 mg atorvastatin administered PO once a day for 12 weeks.
89512622|NCT02260648|Active Comparator|Ezetimibe|10 mg ezetimibe and 10 mg atorvastatin administered PO once a day for 12 weeks as a reference arm.
89024435|NCT00461760|Active Comparator|1|Women with normal cytology at recruitment will be recalled for their next routine screen at 2 years and if negative again, for their exit screen at 4 years, all according to current provincial guidelines.
89024436|NCT00461760|Active Comparator|2|Women with abnormal cytology at recruitment or at the 2 year screen will be followed according to provincial guidelines based on their cytology results.
89024437|NCT01053962|Experimental|SP-304 0.3 mg|SP-304 0.3 mg tablet by mouth once daily for 14 consecutive days.
89512623|NCT02260648|Placebo Comparator|Placebo|Placebo and 10 mg atorvastatin administered PO once a day for 12 weeks.
89024438|NCT01053962|Experimental|SP-304 1.0 mg|SP-304 1.0 mg tablet by mouth once daily for 14 consecutive days.
89024439|NCT01053962|Experimental|SP-304 3.0 mg|SP-304 3.0 mg tablet by mouth once daily for 14 consecutive days
89024440|NCT01053962|Experimental|SP-304 9.0 mg|SP-304 9.0 mg tablet by mouth once daily for 14 consecutive days.
89024441|NCT01053962|Placebo Comparator|Placebo|Placebo tablet by mouth once daily for 14 consecutive days
89024442|NCT00461838||1|All women (n=56) who had undergone CO2 laser laparoscopic radical excision of deep infiltrating endometriosis with active involvement of colorectal surgeon and/or urologist were selected retrospectively from the list of all patients (n=more than 2000) operated at the Leuven University Fertility Centre (LUFc) between September 1996 and July 2004.
89024443|NCT00430703|Experimental|1|Patients with severe traumatic brain injury
89024444|NCT00430703|Experimental|2|Healthy volunteers
89024445|NCT00470379|Experimental|Immunization with NY-ESO-1b|Efficacy of maximal dose of topical resiquimod as immune adjuvant to intradermally administered NY-ESO-1b peptide vaccine.
89512624|NCT05151913||Previous ICP, recurrence|Pregnant women with at least one previously completed parturition with ICP and ICP during the present study
89512625|NCT05151913||Previous ICP, non-recurrence|Pregnant women with at least one previously completed parturition with ICP and no ICP during the present study
89512626|NCT05151913||No previous ICP|Pregnant women with at least one previously completed parturition with no previous ICP and no ICP during the present study
89024446|NCT00430742|Experimental|1|Arm 1: MK0364 0.5 mg capsule once daily
89024447|NCT00430742|Experimental|2|Arm 2: MK0364 1 mg capsule once daily
89024448|NCT00430742|Experimental|3|Arm 3: MK0364 2 mg capsule once daily
89024449|NCT00430742|Placebo Comparator|4|Arm 4: Pbo capsule once daily
89512627|NCT02324179||HIV positive|people with HIV diagnosis
89512628|NCT02324179||Control (HIV negative)|people without HIV
89512629|NCT02260492|Experimental|OT329 Solis|OT329 Solis (twice daily inhalation throughout the study)
89512630|NCT02260492|Active Comparator|Advair Diskus|Advair Diskus (twice daily inhalation throughout the study)
89512631|NCT02260492|Placebo Comparator|Placebo|Placebo (twice daily inhalation throughout the study)
89024450|NCT00430820||1|30 patients
89024451|NCT00430820||2|30 patients
89024452|NCT00430820||3|30 patients
89024453|NCT00430859|Experimental|1|BIAP
89024454|NCT00430859|Placebo Comparator|Placebo|Placebo, saline
89024455|NCT03271320||systemic sclerosis|patients with systemic sclerosis
89024456|NCT03271320||control|Healthy subjects
89024457|NCT03271164|Experimental|Treatment with FBPM10 system|One breast will be randomized to be treated with FBPM10 System.
89024458|NCT03271164|Active Comparator|Treatment with standard of care|One breast will be selected to be treated with massages with vitamin E cream.
89024459|NCT00430898|Placebo Comparator|1. Placebo|Placebo to mimic 40 mg of Simulect
89024460|NCT00430898|Experimental|2. 40 mg Simulect|40 mg of Simulect
89207236|NCT00848406||2|30 individuals ≤ 40 years, who have not smoked during the last year, have never smoked for as long as a year (i.e. at least one cigarette per day or one cigar per week, AND have < 0.5 packyear.
89207237|NCT00848406||3|30 individuals above 40 years, who currently smoke ≥ 10 cigarettes per day, and > 20 packyears.
89207238|NCT00848406||4|30 individuals above 40 years, who have not smoked during the last year, have never smoked for as long as a year, and have < 0.5 packyear.
89512632|NCT02260258|Experimental|Rocuronium|"Patients will receive a bolus dose of 1 mg/kg, then a continuous intravenous (IV) infusion as per standard intensive care unit practice.~Of note, protocol allows for use of cistatracurium in place of rocuronium for either reasons of drug-shortage or clinical conditions (if institutional preferences for dose adjustment in liver or renal insufficiency arise)."
89032953|NCT02944838|Active Comparator|Advocacy|"The Senior Change Makers Advocacy Program consists of weekly meetings, 1 hour each, for 8-weeks. The program will be led by graduate level students and will address topics such as how the environment affects walking, potential pedestrian hazards and solutions, how to conduct an audit of the walking environment, what advocates do, local examples of successful advocacy projects, creating an advocacy action plan, creating a fact sheet about the advocacy issue, writing letters to representatives, and making an advocacy presentation. The program will culminate with the presentation of the advocacy issue to a decision maker (e.g., a city planner, engineer, city council member, etc.)."
89512633|NCT02260258|Placebo Comparator|Usual Care|Patients will receive 100 mL of normal saline over 5-10 minutes at the beginning of the study in addition to usual care.
89512634|NCT02324257|Experimental|Part I: RO6958688|Participants will receive single dose of RO6958688 starting from a dose of 0.05, 0.15, 0.45, 1.3, and 2.5 mg in Part I of the study.
89512635|NCT02324257|Experimental|Part II: RO6958688 With/Without Obinutuzumab Pretreatment|Participants will receive RO6958688 with or without obinutuzumab pretreatment QW, Q3W, or according to a combined QW/Q3W step up dosing schedule. Doses will start at 40mg and increase with each administration up to the MTD or 1200mg, whichever is lower.
89512636|NCT05151289|Experimental|Patients consulting in one of the participating centers for intra uterine growth restriction.|All included patients
89512637|NCT03486145|Experimental|FVS (fruit and vegetable juice supplement)|The supplement contained ≈ 260-280 mg or 4 mmoles nitrate per two-ounce serving along with ≈ 51 mg total polyphenols. The FVS contains 7880 mg of a proprietary blend of beet root extract (Beta vulgaris), celery stem and leaf extract (Apium graveolens), red spinach leaf extract (Amaranthus dubius), stevia leaf extract (Stevia rebaudiana), and a fruit and vegetable extract blend (green tea leaf, red grape, white grape, bilberry, carrot, grapefruit, papaya, pineapple, strawberry, apple, apricot, cherry, orange, broccoli, green cabbage leaf, onion, garlic, black current, asparagus, tomato, olive and cucumber). Virtually all of the nitrates in FVS derive from the beet, celery, and red spinach extracts.
89512638|NCT03486145|Placebo Comparator|PRU (prune juice)|The placebo supplement was prune juice (Sunsweet brand 100% prune juice) (PRU). Prune juice was selected based on its very similar caloric and sugar content, its high antioxidant and phenolic profile, but low nitrate content. The prune juice contained <0.6 mg nitrates and 133 mg total polyphenols per two-ounce serving.
89512639|NCT05151055|Experimental|Lactezin|100 mg lactoferrin, 11 IU vitamin E (as alpha tocopherol), and 5 mg zinc (as zinc gluconate)
89512640|NCT05151055|Placebo Comparator|Placebo|
89512641|NCT03911089|Other|Open label|UCD Anamix Infant
89512642|NCT02260180|Active Comparator|A-101 40%|A-101 40% Topical Solution
89512643|NCT02260180|Active Comparator|A-101 32.5%|A-101 32.5% Topical Solution
89512644|NCT02260180|Placebo Comparator|A-101 Vehicle Topical Solution|A-101 0% Topical Solution (vehicle)
89512645|NCT03799393|Active Comparator|Control Group|"The control group will receive a brief tablet-based questionnaire followed by standard, paper discharge instructions on car safety. Children ≥13 years old and above will answer questions themselves. They will complete a questionnaire on the usefulness of their discharge education.~One week after discharge, participants will receive an automatic text message and/or email message with a link to a web-based survey that will assess: knowledge of appropriate car restraints and whether the parent/patient engaged in any behavioral changes regarding child car restraint."
89512646|NCT03799393|Experimental|Experimental/CIAS Group|"The Experimental/CIAS Group will receive a brief tablet-based questionnaire followed by the intervention - CIAS, an interactive tablet computer program that gives educational information customized to the patient's age and size. Children ≥13 years old will answer questions and interact with the program themselves. They will complete a questionnaire on the usefulness of their discharge education.~One week after discharge, participants will receive an automatic text message and/or email message with a link to a web-based survey that will assess: knowledge of appropriate car restraints and whether the parent/patient engaged in any behavioral changes regarding child car restraint."
89512647|NCT03796819|Experimental|lymphadenectomy|This group of patients would undergo routine hepatoduodenal lymphadenectomy combined with ICC resection
89512648|NCT03796819|No Intervention|No lymphadenectomy|This group of patients would not undergo hepatoduodenal lymphadenectomy when preoperative imaging and intraoperative exploration found no lymph node enlargement.
89512649|NCT02353468|Experimental|Enzyme inhibitor, biological therapy, chemotherapy|"CONSOLIDATION: Patients receive VLD therapy comprising bortezomib IV on days 1, 4, 8, and 11, lenalidomide PO QD on days 1-14, and dexamethasone PO or IV on days 1, 2, 4, 5, 8, 9, 11, and 12. Courses continue for 28 days and repeat every 3 months in the absence of disease progression or unacceptable toxicity.~In between courses of VLD, patients receive LD therapy comprising lenalidomide PO QD on days 1-21 and dexamethasone PO QD or IV every Monday (x3). Courses continue for 28 days.~MAINTENANCE: Starting in the third year of therapy, patients receive lenalidomide PO QD on days 1-14 and dexamethasone PO QD or IV every Monday (x2). Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity."
89512650|NCT04459741|Experimental|HIV+ Hypertensive|Participants receive 4 grams of dietary salt (equivalent of 1, 560 mg sodium) everyday for seven days followed by 9 grams (equivalent of 3, 510 mg sodium) of dietary salt for the following seven days
89512651|NCT04459741|Other|HIV+ Normotensive|Participants receive 4 grams of dietary salt (equivalent of 1, 560 mg sodium) everyday for seven days followed by 9 grams (equivalent of 3, 510 mg sodium) of dietary salt for the following seven days
89512652|NCT04459741|Experimental|HIV- Hypertensive|Participants receive 4 grams of dietary salt (equivalent of 1, 560 mg sodium) everyday for seven days followed by 9 grams (equivalent of 3, 510 mg sodium) of dietary salt for the following seven days
89512653|NCT04459741|Other|HIV- Normotensive|Participants receive 4 grams of dietary salt (equivalent of 1, 560 mg sodium) everyday for seven days followed by 9 grams (equivalent of 3, 510 mg sodium) of dietary salt for the following seven days
88816148|NCT02488317|Other|Intervention arm|These patients will receive the decision aid tool. Decision-making outcomes (e.g., self-efficacy) will be compared between patients who received and did not receive a decision aid. These arms were chosen because the current standard of care is for health care providers to discuss options with patients without using a decision aid.
89207239|NCT04010019|Experimental|Enhanced Facebook Condition|The enhanced Facebook group will be moderated by clinicians and offer psychosocial pain management techniques.
89207240|NCT04010019|Active Comparator|Control Facebook Condition|In the control condition, there will be no outside intervention; rather, the investigators will instruct participants to offer mutual support for the duration of the group and will not comment further.
89512654|NCT04459663|Experimental|JS001 combined with Axitinib|JS001 combined with Axitinib in the treatment of advanced non-small cell lung cancer without activated EGFR mutation, ALK fusion and ROS fusion after or during first-line chemotherapy
89512655|NCT02349412|Experimental|Arm 1|Patients receive early palliative care and standard oncology care. Patients and family caregivers will be asked to complete quality-of-life questionnaires at weeks 6, 12, and 24. Survival follow-up will be every 4 months from week 24 until death or up to 3 years.
89512656|NCT02349412|Experimental|Arm 2|Patients receive standard oncology care. Patient and family caregiver will be asked to complete self-report questionnaires at weeks 6, 12, and 24. Survival follow-up will be every 4 months from week 24 until death or up to 3 years. Palliative care visit only upon request from attending oncologist(s) or patient/family.
89512657|NCT04459975||AKI (-)|patients treated in ICU for COVID-19 infection and without occurrence of AKI (define as creatinine > 1,5x baseline according with KDIGO guidelines)
89512658|NCT04459975||AKI (+)|"patient treated in ICU for COVID-19 infection and with occurrence of AKI among which:~• Severe AKI patients (define as creatinine > 3x baseline or need for renal replacement therapy according with KDIGO guidelines) who will participate to biocollection and to post-mortem biopsy (if death)."
89512659|NCT02259400|Active Comparator|NSIPPV group|The NSIPPV is a conventional modality of mechanical ventilation delivered by the nasal ventilator device Giulia (Ginevri, Rome, Italy), that in noninvasive modality detects the inspiratory effort by means of a pneumotachograph, equipped with a fixed orifice (2 mm in diameter for LBW infants), positioned proximally to the nasal interface. Short bi-nasal prongs (NIV set, Ginevri, Rome, Italy), with different size according to infants'weight, will be used as interface.
89512660|NCT02259400|Active Comparator|BiPAP group|The BiPAP is a modality of noninvasive respiratory support that provides two alternate different levels of CPAP in which the babies can breath spontaneously. The BiPAP will be delivered by the Infant Flow-driver device (Infant Flow System, Vyasis Corp,Yorba Linda, California (CA),USA) and bi-nasal prongs as interface (Vyasis Corp,Yorba Linda, CA,USA) with different size according to infants' weight.
89512661|NCT03481855||Progressive bleeding simulation|The study intervention by a lower-body-low-pressure chamber is performed in this group of healthy volunteers with progressive increase of negative pressure by a step-wise approach (-15mmHg, -30mmHg, -45mmHg).
89512662|NCT03481855||Prolonged bleeding simulation|The study intervention by a lower-body-low-pressure chamber is performed in this group of healthy volunteers with prolonged exposure to a negative pressure of -15mmHg.
89512663|NCT03481699|Experimental|Incremental theory of personality|1 hour behavioral intervention (based on ITP) consisting on several tasks to be completed on paper individually.
89512664|NCT03481699|Other|Educational intervention|1 hour educational intervention (about the human brain) consisting on several tasks to be completed on paper individually.
89512665|NCT05150899||Tamsulosin 0.4mg|group A receive Tamsulosin 0.4mg in combination of NSAI drug if patient present with colic, if not in renal colic at bed time Tamsulosin 0.4mg with analgesic on demand.
89512666|NCT05150899||fexofenadine 180 mg in combination of Tamsulosin 0.4mg|group B receive pheniramine maleate 50mg injection every 12hr for 24 hr in combination of Tamsulosin 0.4mg and NSAI drug then fexofenadine 180 mg in combination of Tamsulosin 0.4mg and NSAI drug on demand if patient present with colic. if not in renal colic at bed time fexofenadine 180 mg in combination of Tamsulosin with NSAI on demand.
89512667|NCT01530997|Experimental|De-escalated Radiation and Chemotherapy|Patients will receive 54 to 60 Gy of Intensity Modulated Radiotherapy (IMRT) with concurrent weekly intravenous cisplatin (30 mg/m2). Diagnostic imaging (CT and/or MRI) will be obtained 4 to 8 weeks after completion of CRT to assess response. All patients will have surgical resection of any clinically apparent residual primary tumor or biopsy of the primary site if there is no evidence of residual tumor and will undergo a limited neck dissection to encompass at least those nodal level(s) that were positive pre-treatment, 4 to 14 weeks after CRT.
89512668|NCT00593905||Group 1|"GROUP 1~Patients have to be currently enrolled or previously enrolled in STRIDE FPH01, FPH01-XC FPH02, FPH02x, FPH03, FPH04 or FPH06.~WHO Group 1 Pulmonary arterial Hypertension: Idiopathic, Familial, Associated with (APAH) Collagen vascular disease, congenital systemic-to-pulmonary shunts, portal hypertension, Drugs and toxins (e.g., anorexigens, rapeseed oil, L-tryptophan, methamphetamine, and cocaine), other (thyroid disorders, glycogen storage disease, Gaucher disease, hereditary hemorrhagic telangiectasia, hemoglobinopathies, myeloproliferative disorders, splenectomy) Associated with significant venous or capillary involvement, Pulmonary veno-occlusive disease, Pulmonary-capillary hemangiomatosis."
89512669|NCT00593905||Group 2|"Group 2~Patients currently receiving bosentan or ambrisentan OR who have previously received bosentan or ambrisentan for greater than 4 (four) months.~WHO Group 1 Pulmonary Arterial Hypertension: Idiopathic, Familial, Associated with (APAH), collagen vascular disease, congenital systemic-to-pulmonary shunts, portal hypertension, drugs and toxins (e.g., anorexigens, rapeseed oil, L-tryptophan, methamphetamine, and cocaine), other (thyroid disorders, glycogen storage disease, Gaucher disease, hereditary hemorrhagic telangiectasia, hemoglobinopathies, myeloproliferative disorders, or splenectomy), associated with significant venous or capillary involvement, pulmonary veno-occlusive disease, or pulmonary capillary hemangiomatosis."
89512670|NCT03477253|Active Comparator|LC within 72 hours of disease onset|Immediate laparoscopic cholecystectomy within 72 hours of the onset of symptoms was performed in these patients
89512671|NCT03477253|Active Comparator|LC after 72 hours of disease onset|Late laparoscopic cholecystectomy after 72 hours of the onset of symptoms was performed in these patients
89512672|NCT03481621|Active Comparator|Group1a, Acupuncture on Vulvodynia|Focus on using the local points in pudendal nerve distribution area
89207241|NCT00841854|Active Comparator|PBMT7|pantoprazole 40mg bid, bismuth 300mg qid, metronidazole 500mg tid,tetracycline 500mg qid for 7 days
89541036|NCT05308004|Experimental|Palliative Care Consult|Participants will receive the standard Medicare Skilled Nursing Facility care plus a Palliative Care Consultation with a trained provider.
89541037|NCT05293626|Experimental|NR082 injection|"Potential doses at the dose-finding stage:~0.5E9 vg, 0.05 mL/eye/dose (low dose)~1.5E9 vg, 0.05 mL/eye/dose (starting dose)~3.0E9 vg, 0.05 mL/eye/dose (intermediate dose)~4.5E9 vg, 0.05 mL/eye/dose (high dose)"
89541038|NCT05293158|Experimental|HBIG treatment|
89541039|NCT05266469||Ofatumumab|Patients prescribed with Ofatumumab
89541040|NCT05266469||Ocrelizumab|Patients prescribed with Ocrelizumab
89541041|NCT05260957|Experimental|Combination CAR-T Cell Therapy, Mosunetuzumab + Polatuzumab|"Participants will receive study treatment in three phases: Induction Phase, CAR-T Treatment Phase and Consolidation Phase.~During the Induction Phase (Days -42, through -6), participants will receive Mosunetuzumab on Days -42, -35, -28, and -7; and Polatuzumab on Day -28. On Day -6, participants will be evaluated in clinic.~During the CAR-T Treatment Phase (Days -5, through Day 0), participants will receive lymphodepleting chemotherapy for three consecutive days beginning on Day -5, followed by CAR-T Cell therapy via infusion on Day 0.~During the Consolidation Phase (Days +1 through +90), participants will receive Mosunetuzumab on Day +14; and combination Mosunetuzumab and Polatuzumab on Days +35, +56 and +77."
89541042|NCT05243654|Experimental|Metformin 1000mg extended release (XR) once daily + standard-of-care MDT|Metformin hydrochloride 500mg XR tablets once daily by mouth for 2 weeks, escalating to a target dose of 1000mg XR once daily for another 22 weeks. Each participant will receive the same number of tablets made up of metformin and placebo to maintain the blinding.
89541043|NCT05243654|Placebo Comparator|Placebo + MDT|Matching metformin placebo tablets once daily by mouth for 2 weeks, escalating to two tablets for another 22 weeks. Each participant will receive the same number of tablets made up of metformin and placebo to maintain the blinding.
89541044|NCT05238376|Experimental|Patient|These are patients who are 90 (±30) days post-allogeneic hematopoietic stem cell transplant. Patients will complete 12 weeks of exercise training. Patients will also complete assessments to evaluate physical function, cognitive function, mental health, social support, nutrition and diet, symptoms, quality of life, and financial status. They will use devices to capture activity data and vital signs. They will collect bio-specimens to assess microbiota and biomarkers.
89541045|NCT05238376|Experimental|Caregiver|These are the assigned caregivers for the transplant patients. Caregivers will complete 12 weeks of exercise training. Caregivers will also complete assessments to evaluate physical function, caregiver support, and physical activity and exercise. They will collect bio-specimens to assess microbiota.
89541046|NCT05237492|Experimental|procoagulant effect on platelet function|LTA platelet function measurement on whole blood with addition of tramadol, demonstration of a dose-response relationship and determination of the effect of combination with other drugs.
88959976|NCT05931887|Active Comparator|SILQ ClearTract 100% Silicone 2-Way Foley Catheter|Subjects in this arm will receive the SILQ ClearTract 100% Silicone 2-Way Foley Catheter for approximately the first 3 month period of enrollment. In a subsequent period of approximately 3 months subjects in this arm will receive their current standard of care catheter.
89541047|NCT05236764|Experimental|Alpha beta+ T cell depleted CD34+ stem cells|The patient will be receiving a donor stem cell transplant with a preceding conditioning regimen (chemotherapy with, or without, radiation). The investigators will be specially treating the donor's blood cells used for the stem cell transplant.
89541048|NCT05215314|Experimental|Healthy Minds Program (HMP)|Fully remote, 4-week meditation intervention
88959977|NCT05931887|Active Comparator|Standard of Care Catheter|Subjects in this arm will receive their current Standard of Care Catheter for the first 3 month period of enrollment. In a subsequent period of approximately 3 months subjects in this arm will receive the SILQ ClearTract 100% Silicone 2-Way Foley Catheter
88959978|NCT05931172|Experimental|Dual tasking|Dual tasking utilizes a task-specific approach to balance training, applying repeated exposure to unpredictable mechanical perturbations that mimic balance disturbances experienced in daily life.
88959979|NCT05931172|Experimental|Proprioceptive neuromuscular facilitation|Proprioceptive neuromuscular facilitation (PNF) is a therapeutic approach that uses cutaneous, proprioceptive and auditory input to produce functional improvement in motor output.
88959980|NCT05928858|Experimental|Premixed Bio-ceramic MTA|Partial caries removal will be carried out then Premixed Bio-ceramic MTA will be applied as indirect pulp capping agent followed by Glass ionomer filling and composite restoration
88959981|NCT05928858|Active Comparator|Calcium hydroxide|Partial caries removal will be carried out then calcium hydroxide will be applied as indirect pulp capping agent followed by Glass ionomer filling and composite restoration
88959982|NCT05928845||Muscle thickness measurement|Rectus femoris and sternocleidomastoideus muscle thickness will be measured via ultrasonography
88959983|NCT05923476|Experimental|Intervention arm|Lithium and ECT will be administered concomitantly to the intervention group
88959984|NCT05923476|Placebo Comparator|Control arm|Placebo and ECT will be administered to the control group
88959985|NCT05923268|Experimental|The tested injected doses of [99mTc]Tc-G3-(G3S)3C 3000 μg|"At least five (5) evaluable subjects with HER2-positive status and at least five (5) subjects with HER2-negative status have to be enrolled in the study for each tested protein dose. The tested injected dose 3000 μg.~Subjects withdrawn from the study for any reason will be replaced."
88959986|NCT05912920|Experimental|gastric band|to do gastric banding use either round ligament or omental flap
88959987|NCT05912920|Active Comparator|sleeve gastrectomy|to do sleeve gastrectomy as standard
88959988|NCT05911789|Experimental|Online adaptive radiation therapy|Patients receive adaptive radiotherapy therapy and concurrent chemotherapy.
88959989|NCT05910788|Active Comparator|HFNC|The intervention group will receive HFNC therapy at induction of anesthesia. The intervention group will receive oxygen by 100% HFNC with a flow of 40 L.min-1 being increased to 70 L.min-1 during the period of apnea. A rapid sequence of orotracheal intubation will be performed, considering the time of apnea the moment of disappearance of the capnography line until the first ventilation after tube placement.
88959990|NCT05910788|No Intervention|Convencional oxygen therapy|Control group will receive conventional oxygen therapy by mask facial, with 100% oxygen and flow of 10 L.min-1.After surgery, patients who are extubated in the operating room or in theintensive care unit, will remain in the control and intervention groups and will receive therapy for conventional oxygen or HFNC, respectively.
89207242|NCT00841854|Active Comparator|PBMT14|pantoprazole 40mg bid, bismuth 300mg qid, metronidazole 500mg tid,tetracycline 500mg qid for 14 days
89541049|NCT05215314|No Intervention|Waitlist Control|Control participants will not complete the Healthy Minds Program during the study, but can use it after they have completed the study
88959993|NCT05903560|Experimental|the radial group|Patients with basilar artery occlusion within 24 hours of onset will be chosen to receive endovascular recanalization via radial approach randomly
88959994|NCT05903560|Active Comparator|the femoral group|Patients with basilar artery occlusion within 24 hours of onset will be chosen to receive endovascular recanalization via femoral approach randomly
88959995|NCT05899634|No Intervention|Group 1 - Recipes|Participants will receive healthy recipes (3 main meal + 1 snack/breakfast/lunch recipe per week of the two-week intervention).
88959996|NCT05899634|Experimental|Group 2 - Default|Participants will receive healthy recipes (3 main meal + 1 snack/breakfast/lunch recipe per week of the two-week intervention). In addition, in this group, participants' online grocery shopping carts will be pre-filled with ingredients corresponding to the provided recipes. They will be told that their cart has been filled with items that can be used to make recipes from the provided recipe cards, and that they can modify it as they like.
89207243|NCT05299281|Other|Glaucoma patients|Patients were enrolled from outpatient clinic with glaucoma during the period between January 2020 and July 2021
89024461|NCT00470613|Experimental|SGT-53|SGT-53 (2.4mg DNA/infusion) will be administered in a standard 3x3 dose escalation design in combination with docetaxel 40mg/m2 starting dose, cohort 1, cycle 1. This protocol will allow for both inter- and intra-patient dose escalations. SGT-53 will be administered weekly, day 1 except weeks 1, 4 & 7 when it will be administered biweekly on days 1 & 4. Docetaxel will be administered every 3 weeks (weeks 1, 4 & 7) on day 3. Patients completing cohort 1, cycle 1 without DLT at docetaxel 40mg/m2 will be allowed to dose escalate to 60mg/m2 in cycles 2 and 3. Cohort 2 (2.4mg DNA/infusion;75mg/m2 Docetaxel) will open 3 weeks after demonstration of 0/3 or ≤1/6 DLTs at docetaxel 60mg/m2. Cohort 3 (3.6mg DNA/infusion; 75mg/m2 Docetaxel) will open after demonstration of 0/3 or ≤1/6 DLTs at SGT-53 2.4mg DNA/infusion and docetaxel 75mg/m2. If necessary, the dose of docetaxel in cycle 2 and 3 may be reduced to 60mg/m2.
89024462|NCT03273465|Experimental|Fecal transplantation|Fecal transplantation of feces from healthy donor via capsules. Oral application.
89024463|NCT03273465|Placebo Comparator|Placebo|Placebo capsules
89024464|NCT02957409||sacubitril/valsartan|Patients diagnosed with HFrEF being treated with sacubitril/valsartan according to the Canadian product label and treatment initiation with sacubitril/valsartan within the last 3 months. The usual recommended starting dose is one tablet of 49 mg sacubitril / 51 mg valsartan taken twice daily. The target dose is one tablet of 97 mg sacubitril / 103 mg valsartan taken twice daily. Investigator/designated will document sacubitril/valsartan treatment adherence throughout the 3 years study period
89024465|NCT01053221|Experimental|MPA monotherapy|Subjects will discontinue calcineurin inhibitor (cyclosporine or tacrolimus) and remain on MPA (mycophenolate mofetil or mycophenolate sodium) monotherapy
89024466|NCT01053221|Active Comparator|Control: MPA and CNI|Subjects will continue with their current immunosuppressive regimen of MPA (mycophenolate mofetil or mycophenolate sodium) and calcineurin inhibitor (cyclosporine or tacrolimus)
89024467|NCT02956551|Experimental|cell_therapy|tumor neoantigen primed DC vaccines are administrated, 2-week interval, totally 5 times
89512673|NCT03481621|Active Comparator|Group1b, Acupuncture on Vulvodynia|Focus on traditional acupuncture using common meridian or distal points
89512674|NCT03481621|Active Comparator|Group2, Standard care or waiting lists|Standard care without acupuncture
89512675|NCT02948647|No Intervention|Control Group|Will receive standard of care, which is general dietary advice
89512676|NCT02948647|Experimental|Intervention Group|Will receive standard of care as well as sugar-reduction education
89512677|NCT03477097|No Intervention|Control group w/o social network intervention|Subjects did not receive any intervention of nutrition, physical activity and social network.
89512678|NCT03477097|Experimental|Control group w/ social network intervention|Subjects only received the intervention of social network.
89512679|NCT03477097|Experimental|Nutrition group 1 w/o social network intervention|Subjects only received the nutrition I intervention (e.g., food plate and multiple vitamin/ minerals powder).
89512680|NCT03477097|Experimental|Nutrition group 1 w/ social network intervention|Subjects received the nutrition I intervention (e.g., food plate and multiple vitamin/ minerals powder) and social network intervention as well.
89512681|NCT03477097|Experimental|Nutrition group 2 w/o social network intervention|Subjects only received the nutrition II intervention (e.g., food plate, multiple vitamin/ minerals powder, fruit/vegetable concentrate capsule, and fish oil).
89512682|NCT03477097|Experimental|Nutrition group 2 w/ social network intervention|Subjects received the nutrition II intervention (e.g., food plate, multiple vitamin/ minerals powder, fruit/vegetable concentrate capsule, and fish oil) and social network intervention as well.
89512683|NCT03477097|Experimental|Physical activity group w/o social network intervention|Subjects only received the personalized homed-based exercise prescription, which consisted of a combination of strength, flexibility, balance and endurance training.
89512684|NCT03477097|Experimental|Physical activity group w/ social network intervention|Subjects received the personalized homed-based exercise prescription, which consisted of a combination of strength, flexibility, balance and endurance training, and social network intervention as well.
89512685|NCT03477097|Experimental|Nutrition 1 + physical activity group w/o social network|Subjects received the nutrition I (e.g., food plate and multiple vitamin/ minerals powder) and exercise (e.g., personalized homed-based exercise plan) intervention.
89512686|NCT03477097|Experimental|Nutrition 1 + physical activity group w/ social network|Subjects received the nutrition I (e.g., food plate and multiple vitamin/ minerals powder), exercise (e.g., personalized homed-based exercise plan), and social network intervention.
89512687|NCT03477097|Experimental|Nutrition 2 + physical activity group w/o social network|Subjects only received the nutrition II (e.g., food plate, multiple vitamin/ minerals powder, fruit/vegetable concentrate capsule, and fish oil) and exercise (e.g., personalized homed-based exercise plan) intervention.
89512688|NCT03477097|Experimental|Nutrition 2 + physical activity group w/ social network|Subjects only received the nutrition II (e.g., food plate, multiple vitamin/ minerals powder, fruit/vegetable concentrate capsule, and fish oil), exercise (e.g., personalized homed-based exercise plan), and social network intervention.
89512689|NCT02259088|Experimental|Ranibizumab (RFB002)|3 initial intravitreal injections to the study eye at Day 1, Month 1 and Month 2, followed by as-needed intravitreal injections of ranibizumab 0.5 mg guided by VA stabilization, plus sham laser
89512690|NCT02259088|Active Comparator|Laser|Laser photocoagulation applied to the study eye at Day 1, followed by active laser photocoagulation at intervals no shorter than 3 months apart, plus sham injections
89024468|NCT00431054|Experimental|Perifosine + Docetaxel|
89024469|NCT00470652||1|Pre-intervention patients admitted to our ED in the month prior to the intervention, before the 'computer-assisted decision support' is turned on (the intervention)
89024470|NCT00470652||2|Short-term post-intervention cohort of patients admitted in the month following the initiation of the 'computer-assisted decision support' for pain management
89512691|NCT02880241|Experimental|Cohort 1A - P. vivax malaria|A single oral dose of up to 120mg MMV390048
89512692|NCT02880241|Experimental|Cohort 1B - P. falciparum malaria|A single oral dose of up to 120mg MMV390048
89512693|NCT02880241|Experimental|Cohort 2A - P. vivax malaria|A single oral dose (to be determined) of MMV390048
89512694|NCT02880241|Experimental|Cohort 2B - P. falciparum malaria|A single oral dose (to be determined) of MMV390048
89512695|NCT02880241|Experimental|Cohort 3A - P. vivax malaria|A single oral dose (to be determined) of MMV390048
89512696|NCT02880241|Experimental|Cohort 3B - P. falciparum malaria|A single oral dose (to be determined) of MMV390048
89512697|NCT02259010|Experimental|Part A: Alisertib 30 mg+Itraconazole; Part B: Alisertib 50 mg|All participants were to complete Part A prior to Part B. Part A: Alisertib 30 mg, tablets, orally, on Days 1 and 10 plus itraconazole, 200 mg, oral solution, once daily on Days 5 to 13. Part A and B were separated by a washout period of at least 10 days (and up to 4 weeks). Part B: Alisertib 50 mg, tablets, orally, twice daily, for 7 days in 21-day cycles until disease progression or unacceptable toxicity (up to 16 cycles).
89512698|NCT02329951||Epidural steroid injections|Patients will receive a single interlaminar epidural steroid injection with 60 mg depomethylprednisolone, 1.5 ml of 0.25% bupivacaine and 1.5 ml of saline or a transforaminal epidural steroid injection with 60 mg depomethylprednisolone, 1.5 ml of 0.25% bupivacaine and 0.5 ml of saline.
89512699|NCT02329951||Facet interventions|Patients will receive diagnostic medial branch (facet joint nerve) blocks with 0.5 ml of 0.5% bupivacaine. If they experience a positive block (> 50% pain relief lasting more than 3 hours), they will then receive radiofrequency denervation.
89512700|NCT02329951||Sacroiliac joint injections|Patients will receive a single SI joint injection on the affected side(s) with 40 mg depomethylprednisolone and 2 ml of 0.5% bupivacaine.
89512701|NCT05647018|Active Comparator|Deferred stenting in STEMI patients with high thrombus burden undergoing primary PCI|
89512702|NCT05647018|Active Comparator|Non-deferred stenting in STEMI patients with high thrombus burden undergoing primary PCI|
89512703|NCT02021773|Experimental|LBR-101 High Dose|Subcutaneous High Dose LBR-101 Administered Monthly x 3
89512704|NCT02021773|Experimental|LBR-101 Low Dose|Subcutaneous Low Dose LBR-101 Administered Monthly x 3
89512705|NCT02021773|Placebo Comparator|Placebo|Subcutaneous Placebo Administered Monthly x 3
89512706|NCT05153785|Experimental|Lidocaine arm|The experimental arm will receive a bolus of 1,5mg/kg Lidocaine before induction of anesthesia, immediately followed by an infusion of 1,5mg/kg/h until 1 hour post surgery.
89512707|NCT05153785|Placebo Comparator|Placebo arm|The placebo arm will receive the same amount of normal Saline.
89512708|NCT00151775|Experimental|Period 2|"For Cohorts A and B, olmesartan medoxomil suspension 2.5 mg to 40 mg in patients 6-16 years old, depending on weight.~For Cohort C, olmesartan medoxomil suspension 0.3 mg/kg to in patients 1-5 years old."
89512709|NCT00151775|Experimental|Period 3|Cohorts A, B, C - olmesartan medoxomil suspension or placebo taken once daily. Olmesartan medoxomil dose continued as in previous period.
89512710|NCT00151775|Experimental|Period 4|"Cohorts A and B: Open label olmesartan medoxomil suspension or tablets 10mg - 40 mg~Cohort C: Open label olmesartan medoxomil suspension 0.3 mg/kg - 0.6 mg/kg"
89512711|NCT02258464|Experimental|Radium 223 dichloride|Participants treated with a single hormonal agent as background therapy received 50 kBq/kg body weight (55 kBq/kg after implementation of National Institute of Standards and Technology [NIST] update) of Radium 223 dichloride intravenously for a maximum of 6 cycles at intervals of 4 weeks
89512712|NCT02258464|Placebo Comparator|Placebo|Participants treated with a single hormonal agent as background therapy received isotonic saline (0.9% sodium chloride solution for injection) intravenously for a maximum of 6 cycles at intervals of 4 weeks
89512713|NCT03476941|Experimental|Antibiotic Irrigation|The drain will be irrigated twice/day with the above antibiotic solution for 7 days maximum
89512714|NCT03476941|Placebo Comparator|Normal Saline Irrigation|The drain will be irrigated twice/day with normal saline
89512715|NCT03481153|Placebo Comparator|Sham tDCS|Participants will be participate in a 20-minute sham tDCS session. tDCS electrodes will be placed on the left (anodal positive polarity) and right (cathodal;negative polarity) dorsolateral prefrontal cortex. Sham stimulation will be applied.
89512716|NCT03481153|Active Comparator|tDCS|Participants will participate in a 20-minute tDCS session. tDCS electrodes will be placed on the left (anodal positive polarity) and right (cathodal;negative polarity) dorsolateral prefrontal cortex.
89512717|NCT03473119||Control|Healthy individuals
89512718|NCT03473119||Asthma|Asthma acute exacerbations
89512719|NCT03473119||Asthma with CAP|Asthma acute exacerbations with community-acquired pneumonia
89512720|NCT03473119||COPD|Acute exacerbations of chronic obstructive pulmonary disease
89512721|NCT03473119||COPD with CAP|Acute exacerbations of chronic obstructive pulmonary disease with community-acquired pneumonia
89512722|NCT03473119||CAP|Community-acquired pneumonia
89512723|NCT03476863|Experimental|Alveolar Recruitment Maneuver|
89512724|NCT03476863|Active Comparator|Conventional mechanical ventilation|
89512725|NCT00609323|Experimental|1|
89512726|NCT00609323|Placebo Comparator|2|
89512727|NCT00605735|Experimental|A1|
89512728|NCT00605735|Placebo Comparator|P1|
88959997|NCT05895344|Experimental|proton-therapy|Proton pencil-beam-scanning irradiation (50,4 Gy (RBE) in 28 fractions)
88959998|NCT05895344|Active Comparator|photon radiotherapy|Intensity modulated radiotherapy with or without stereotactic positioning (50,4 Gy in 28 fractions)
88959999|NCT05894941|Active Comparator|Corrective Exercises Group|The researcher will teach a total of 6 evidence-based corrective exercises and stretches. The participants will perform this for the prescribed time for a minimum of 3 and 5 times a week for a total of 6 weeks of the trial.
88960000|NCT05894941|Active Comparator|Postural Education Group|Postural guidelines for doing daily activity especially sitting for prolonged periods and using electronic devices like computers and other electronic devices.
88960001|NCT05894941|No Intervention|Control Group|This group will not receive either of the above mentioned treatments.
89512729|NCT02682901|Active Comparator|Cycloset (Bromocriptine-QR)|Subjects will be randomized in a 1:1 ratio to receive UDT (usual diabetes therapy) plus bromocriptine-QR. Following randomization subjects will be titrated to the maximum tolerated dose of the study drug over a four-week period. During these first 4 weeks, the daily dose of the study drug will be titrated up by one tablet (0.8 mg bromocriptine-QR) per day on a weekly basis until a maximal tolerated dose of at least two tablets (1.6 mg/day bromocriptine-QR) and no more than four tablets (3.2 mg/per day b-QR) is achieved. Subjects will be maintained at their maximum tolerated dose of between two to four tablets per day (1.6 to 3.2 mg bromocriptine-QR per day) for the duration of the study. Subjects will be seen at 4 weeks after randomization, at 12 weeks after randomization, and then at study end (week 24 or early termination).
89512730|NCT02682901|Placebo Comparator|Placebo|Subjects will be randomized in a 1:1 ratio to receive UDT (usual diabetes therapy) plus placebo. Following randomization subjects will be titrated to the maximum tolerated dose of the study drug over a four-week period. During these first 4 weeks, the daily dose of the study drug will be titrated up by one tablet (1 matching placebo tablet) per day on a weekly basis until a maximal tolerated dose of at least two tablets (2 placebo tablets) and no more than four tablets (4 placebo tablets) is achieved. Subjects will be maintained at their maximum tolerated dose of between two to four tablets per day (2 to 4 placebo tablets) for the duration of the study. Subjects will be seen at 4 weeks after randomization, at 12 weeks after randomization, and then at study end (week 24 or early termination).
88960002|NCT05887323||Left Bundle Branch Area Implant|Data included in this LBBAP data collection registry will be from subjects followed for 6 months (± 3 months) after attempted implant of LBBAP location. Data will be collected from previously occurring visits at pre-implant (baseline, required), implant (required), 6 months (±3 months, required), and 12 months (-2, +4months, optional).
89512731|NCT00603863|Experimental|multiple dose levels|1 of 3 different dose levels of 90Y-hPAM4 given once weekly for 3 weeks along with 4 weekly doses of gemcitabine.
89512732|NCT04472039||Studygroup|Retrospective analysis of OCT, IOP and distance corrected visual acuity from the patients history.
89512733|NCT04459195|Experimental|2 Minute Static stretching|Stretching applications will be applied to the first group for 2 minutes .
89512734|NCT04459195|Experimental|5 Minute Static stretching|Stretching applications will be applied to the first group for 5 minutes.
89512735|NCT04471961|Experimental|Children with cancer (Proband) with theirs parents|
89512736|NCT02258074|Experimental|Lanthanum carbonate + nicotinamide|One nicotinamide 750 mg capsule by mouth twice daily (1500 mg) for 12 months. Two lanthanum carbonate 500 mg capsules by mouth with each meal (3000 mg) for 12 months.
89512737|NCT02258074|Placebo Comparator|Lanthanum carbonate + nicotinamide placebo|Two lanthanum carbonate 500 mg capsules by mouth with each meal (3000 mg) for 12 months. One Placebo (for nicotinamide) 750 mg capsule by mouth twice daily (1500 mg) for 12 months.
89512738|NCT02258074|Active Comparator|Lanthanum carbonate placebo and nicotinamide|One nicotinamide 750 mg capsule by mouth twice daily (1500 mg) for 12 months. Two Placebo (for lanthanum carbonate) 500 mg capsules by mouth with each meal (3000 mg) for 12 months.
89512739|NCT02258074|Placebo Comparator|Lanthanum carbonate placebo and nicotinamide placebo|One Placebo (for nicotinamide) 750 mg capsule by mouth twice daily (1500 mg) for 12 months. Two Placebo (for lanthanum carbonate) 500 mg capsules by mouth with each meal (3000 mg) for 12 months.
89541050|NCT05212168|Active Comparator|Active Vaccine Arm|Subjects receiving Norovirus GI.1 Norwalk VP1 Vaccine, Oral E1-/E3-Deleted Replication Defective Recombinant Adenovirus 5 with dsRNA Adjuvant
88960003|NCT05884801|Experimental|QLS1103 Dose Escalation and Expansion|
88960004|NCT05878639|Experimental|Patients take Lactulose for bowel preparation|Patients take Lactulose for bowel preparation.
88960005|NCT05878639|Active Comparator|Patients take 3L-polyethylene glycol for bowel preparation|"Patients take 3L-polyethylene glycol for bowel preparation~."
88960006|NCT05876858|Experimental|PET/CT scans|Each subject will undergo a dynamic 18F-FDG PET/CT scan and a dynamic 11C-butanol PET/CT scan on the EXPLORER total-body PET/CT system
88960007|NCT05872490||Older 80 people|Semi-structured interviews were conducted for the qualitative research. In addition, a driving habits questionnaire was administered. To complete this questionnaire, medical data from the PROOF cohort were collected.The PROOF cohort is a prospective study for which enrollment began in 2001. The main objective is to evaluate the predictive value of Autonomic Nervous System (ANS) activity and its decline during follow-up on the occurrence of serious and cerebral events, and on all-cause mortality, in a general population of subjects of homogeneous age. Participants were included in the study if they were 65 years of age (plus or minus 2 years) at the time of inclusion and registered on the electoral list of the city of St Etienne, had not had a previous myocardial infarction or stroke and were non-insulin dependent.
88960008|NCT05872490||Attending physicians|Semi-structured interviews were conducted for the qualitative research
88960009|NCT05872490||law enforcement|Semi-structured interviews were conducted for the qualitative research
88960010|NCT05872490||certified driver's license physicians|Semi-structured interviews were conducted for the qualitative research
88960011|NCT05872490||geriatricians|Semi-structured interviews were conducted for the qualitative research
88960012|NCT05872490||driving instructors|Semi-structured interviews were conducted for the qualitative research
88960013|NCT05872490||personal assistance services|Semi-structured interviews were conducted for the qualitative research
88960014|NCT05871684|Experimental|The combination treatment group of CAR-T therapy|Patients dicided to receive CAR-T cell therapy will be divided into groups A and B according to their tumor burden. Group A was given a bridging regimen of BTKi (160 mg b.i.d. p.o.) + radiotherapy + chemotherapy, and group B was given a bridging regimen of BTKi (160 mg b.i.d. p.o.) + radiotherapy; BTKi (160 mg b.i.d. p.o.) was given continuously from D1 to D28 after the return of CAR-T after infusion; Based on the results of the first evaluation on day 28 after CAR-T cell infusion, CR patients were divided into groups A1 and B1, and both groups were given BTKi (160 mg b.i.d. p.o.) for 3 months maintenance; PR patients were divided into groups A2 and B2, and both groups were given BTKi (160 mg b.i.d. p.o.) for 3 months maintenance and PD-1 inhibitor (200mg q3w i.v.) for 2 years maintenance;
88960015|NCT05867953|Experimental|Biopsy Arm|Patients undergoing biopsy with the Ion Endoluminal System
89024471|NCT00470652||3|long-term post-intervention cohort of patients admitted on the 6th month following the initiation of the 'computer-assisted decision support' for pain management
89024472|NCT02956395|Active Comparator|Integrated care group|Integrated care intervention is implemented by a multidisciplinary team from the hospital and from the Primary Care in three healthcare sectors: Barcelona-Esquerra, Lleida and Badalona.
89024473|NCT02956395|No Intervention|Conventional care group|Patients assigned to the control group will be from other healthcare sectors in Catalonia with similar characteristics.
89024474|NCT00431210|Experimental|Biological/Vaccine|Epstein-Barr virus-specific adoptive T-cells immunotherapy given intravenously on Days 1 and 14
89024475|NCT00470691|Experimental|complete plaster cast|reduction and a complete plaster cast,
89024476|NCT00470691|Active Comparator|dorsal plaster splint|reduction and a dorsal plaster splint.
89512740|NCT03476785|Experimental|High Intensity Exercise|Subjects randomized to receive high intensity aerobic exercise will undergo exercise training for 1 year. A training program will be developed individually for each subject with the goal of increasing duration and intensity consistent with exercise training principles. Workouts will vary with respect to mode (walk, cycle) and duration (30 - 60 minutes). Each subject will be assigned an exercise physiologist and a heart rate monitor so that each session can be tracked and recorded.
89512741|NCT03476785|Placebo Comparator|Yoga|Subjects randomized to yoga will receive instructions on strength and flexibility exercises.
89512742|NCT04471571|Active Comparator|Resin infiltration group|Enamel lesions for this group will be treated only by resin infiltration.
89512743|NCT04471571|Experimental|Microabrasion + resin infiltration group|Enamel lesions for this group will be treated first by microabrasion followed by resin infiltration.
89512744|NCT03476707||Anemic|People with a preoperative hematocrit less than 0.39
89512745|NCT03476707||Non-anemic|People with a preoperative hematocrit greater than or equal to 0.39
89512746|NCT04472975||Multiple sclerosis (MS) cohort|Individuals with multiple sclerosis without any exposure to disease-mofidying drugs (DMDs) and with exposure to one or more DMDs.
89512747|NCT02281487|Active Comparator|Hysterectomy|standard hysterectomy
89512748|NCT02281487|Experimental|Hysterectomy plus tubectomy|Hysterectomy plus tubectomy
89512749|NCT01643044|Experimental|Alcohol intervention|Participants in this condition review tailored videos and normed feedback regarding their alcohol use and possible consequences of drinking. Next participants view a goal setting section describing possible ways to quit drinking alcohol and the participant is able to indicate a change goal (if any) and is helped through a specific change plan, should they set a change goal.
89512750|NCT01643044|Placebo Comparator|Control|Participants randomized into the control condition complete assessment and a time-matched interactive session on infant nutrition.
89512751|NCT02281643|Experimental|Early doxycycline administered|Early doxycycline administered - volunteers will be treated immediately with 200mg daily doxycycline for 6 weeks
89512752|NCT02281643|Active Comparator|Delayed doxycycline administered|Delayed doxycycline administered-volunteers will be treated six months after the early group has received treatment with 200mg daily doxycycline for 6 weeks
89512753|NCT02281721||Single Group; Surpass Flow Diverter(s)|Individuals using the Surpass Flow Diverter(s)
89512754|NCT01642732|Experimental|Everolimus with combined hormonal and radiation therapy|"Everolimus - there are five dose levels (2.5mg. every 48 hrs.,2.5mg./day, 5mg./day, 7.5mg./day, and 10mg./day) based on the initial expectations of toxicity and the incidence of toxicity of subjects already treated. Subjects will be on one dose level throughout the study. Subjects will receive everolimus starting on study day 1.~Radiation therapy will start on day 60-70 (44 treatments, at 5 treatments a week for a little longer than 8 weeks).~Bicalutamide (50 mg. tablets daily) will begin on study day 10-14, approximately 2 months prior to Radiation Therapy.~Lupron injections will begin on study day 10 to 25, approximately 2 months prior to Radiation Therapy. The typical dose schedule is either one injection (22.5 mg. dose)every 3 months for a total of 8 injections or one injection (30 mg. dose) every 4 months for a total of 6 injections.~Radiation, bicalutamide, and everolimus will end between study day 120-130. Lupron will end at 24 months on study."
89512755|NCT02283437|Experimental|Problem-solving Based Bibliotherapy|The Problem-solving Based Bibliotherapy Program (PSBPF) using a self-help manual based on problem-solving therapy defined by D'Zurilla and Nezu (2007) to be 'a self-directed cognitive-behavioral process by which a person attempts to identify/discover effective/adaptive solutions for specific problems encountered in everyday living' (p.11).
89512756|NCT02283437|Active Comparator|Behavioral Management and Education Program|The Behavioral Management and Education group program will be guided by a validated treatment protocol based on the research team's (Chien and Wong, 2007) psycho-education and McFarlane et al.'s (2003) family behavioral management programs for schizophrenia.
89512757|NCT02283437|No Intervention|Routine Outpatient Service|Participants in the control group (and 2 treatment groups) will receive routine psychiatric outpatient and family services.
89512758|NCT04872712|Active Comparator|Press Needles|The subjects/population of this study is Health Workers with insomnia symptoms who work at at Cipto Mangunkusumo Hospital treating COVID-19 patients. Subjects group with Press Needles treatment will be treated with 2-week needle retention, 20-second pressing 3 times a day and needle replacement performed every 5 days. The needles are inserted 0.9 mm deep at the acupuncture points HT7 Shenmen, PC6 Neiguan, ST36 Zusanli and SP6 Sanyinjiao.
89024477|NCT00431249|Other|one|
89024478|NCT00461955|Experimental|1|autologous peripheral blood stem cell transplantation
89024479|NCT00470886||Group 1|
89024480|NCT00431483|Other|Pharmaceutical counseling|
89024481|NCT00431561|Experimental|AP 12009 10 µM|
89024482|NCT00431561|Experimental|AP 12009 80 µM|
89024483|NCT00431561|Active Comparator|Chemotherapy|
89024484|NCT00431600|Experimental|1|12 healthy male subjects
89024485|NCT00431639|Active Comparator|Comparison|For the comparison condition, subjects will be asked to choose one of four topics that will be determined thatday with a recreational therapist for 20 minutes.
88960016|NCT05867940|Active Comparator|Children and adolescents with physical disabilities|20 children and adolescents with physical disabilities will participate in physical activity on prescription (PAP). They will be their own controls and will be compared with the other groups. Therefore, there is a baseline 1 and a baseline 2, with 3 months inbetween. After baseline 2, each participant will perform their PAP during 3 months. Assessments to evaluate the results will be performed directly after the 3 months PAP period, and after 6, 12 and 24 months.
88960017|NCT05867940|Active Comparator|Children and adolescents with intellectual disabilities|20 children and adolescents with intellectual disabilities will participate in physical activity on prescription (PAP). They will be their own controls and will be compared with the other groups. Therefore, there is a baseline 1 and a baseline 2, with 3 months inbetween. After baseline 2, each participant will perform their PAP during 3 months. Assessments to evaluate the results will be performed directly after the 3 months PAP period, and after 6, 12 and 24 months.
88960018|NCT05867940|Active Comparator|Children and adolescents with autism|20 children and adolescents with autism will participate in physical activity on prescription (PAP). They will be their own controls and will be compared with the other groups. Therefore, there is a baseline 1 and a baseline 2, with 3 months inbetween. After baseline 2, each participant will perform their PAP during 3 months. Assessments to evaluate the results will be performed directly after the 3 months PAP period, and after 6, 12 and 24 months.
89512759|NCT04872712|Active Comparator|Filiform Needles|The subjects/population of this study is Health Workers with insomnia symptoms who work at at Cipto Mangunkusumo Hospital treating COVID-19 patients. Subjects group with filiform needles treatment will be treated with 20-minute needle retention, 3 times a week for 2 weeks (total of 6 therapy sessions). The needles are inserted approximately 12 mm deep at the acupuncture points HT7 Shenmen and PC6 Neiguan and 25 mm deep at the ST36 Zusanli and SP6 Sanyinjiao.
89512760|NCT04892524|Experimental|Virtual multidisciplinary review|Participants in this arm will be reviewed in a virtual clinic by a multidisciplinary team
89512761|NCT04892524|No Intervention|Face-to-face review|Participants in this group will be reviewed in a face-to-face clinic
89512762|NCT02281799|Experimental|Open label|"10 patients diagnosed with IBD, treated previously with thiopurines and ceased treatment due to suspected thiopurine-induced pancreatitis.~Patients will be commenced on an alternative thiopurine to that used initially,. The medications will be commenced at standard dose (ie Azathioprine 2.5mg/kg/day, 6-MP 1.5mg/kg/day)."
89512763|NCT02281877|Experimental|Neuromuscular Electrical Stimulation|"Neuromuscular Electrical Stimulation (NMES) 48 hours after TKA, 5x/week, 2x/day, for 45 minutes/session.~Standard Rehabilitation Protocol"
89512764|NCT02281877|Active Comparator|Control|Standard Rehabilitation Protocol
89512765|NCT02283515|Active Comparator|group I - Rosuvastatin, 1.2 mg|Rosuvastatin- locally placed in intrabony defect sites.
89512766|NCT02283515|Placebo Comparator|group II - placebo|placebo-placed locally in intrabony defects.
89512767|NCT00600275|Experimental|BGT226|
88960019|NCT05867940|Active Comparator|Adults with physical or intellectual disabilities, or with autism|20 adults with physical or intellectual disabilities, or with autism will participate in physical activity on prescription (PAP). They will be their own controls and will be compared with the other groups. Therefore, there is a baseline 1 and a baseline 2, with 3 months inbetween. After baseline 2, each participant will perform their PAP during 3 months. Assessments to evaluate the results will be performed directly after the 3 months PAP period, and after 6, 12 and 24 months.
89024486|NCT00431639|Active Comparator|Treatment|The treatment condition will consist of a 20-minute visit by a therapy dog and its owner. Therapy dogowners will be instructed to limit conversation with the patient to topics of the therapy dog, thepatients pets, and pets in general.
89024487|NCT00470925|Experimental|Access [123I]MZINT and SPECT Imaging|
89024488|NCT00431678|Experimental|Arm 1|
89024489|NCT00431678|Active Comparator|Arm 2|
89512768|NCT00589823|Active Comparator|1|Immediate Release Morphine sulphate capsules taken at start of relevant BTCP episode. Each episode treated with either this medication OR the experimental comparator.
89512769|NCT00589823|Experimental|2|Nasalfent spray taken at start of relevant BTCP episode. Each episode to be treated with either this medication OR the active comparator (IRMS)
89512770|NCT02282033|Experimental|Treatment|"This is an unblinded, treatment only study in which each patient serves as his or her own control.~All patients who meet entry criteria will undergo implantation of the Moderato System. During the first month the pacemaker Performance will be evaluated and an additional 3 month period of treatment for studying the Moderato-HTN therapy effect."
89512771|NCT02257684|Experimental|Pegcrisantaspase|
89512772|NCT02283671|Experimental|Tolerogenic dendritic cells|"Somatic-cell therapy medicines: tolerogenic dendritic cells loaded with myelin peptides.~Patients will receive intravenous administration every two weeks (week 0 , 2 and 4 ) representing a total of three administrations per patient.~The dose escalation will occur as expected in the absence of limiting toxicity in the previous dosage level."
89512773|NCT04441697||continuous apomorphine delivery|apomorphine, subcutaneous administration, continuous delivery during 8 to 24 hours/day
89512774|NCT04441697||continous levodopa/carbidopa delivery|levodopa/carbidopa monohydrate, jejunal administration, continuous delivery during 8 to 24 hours/day
89512775|NCT04441697||deep brain stimulation|bilateral subthalamic electrical stimulation, intracranial neurosurgical electrodes, individual electrical parameters settings
89512776|NCT02282189|Other|Off/on for 4 weeks followed by on/off for 4 weeks|Subjects are randomized to either Oscillating Positive Expiratory Pressure device or no device for four weeks, then crossover for the following four weeks.
89512777|NCT02190721|Experimental|tbo-filgrastim|Patients will receive subcutaneous doses of tbo-filgrastim 5 μg/kg body weight daily; each daily dose, to be administered at the investigative site
89512778|NCT00581477|Experimental|Droxidopa|Patients with known or suspected Dopamine beta-Hydroxylase Deficiency were administered Droxidopa doses of 25 mg, 50 mg, 100 mg, 200 mg, 250 mg or 300 mg up to three times daily. Supine and upright blood pressures were subsequently measured 60 to 240 minutes post-dose.
89512779|NCT03134339|Experimental|saline 0.00mcg/kg/s|0.00 mcg/kg/s The day order will be randomized per day
89512780|NCT03134339|Experimental|0.24mcg/kg/s|0.24 mcg/kg/s The day order will be randomized per day
89512781|NCT03134339|Experimental|0.048mcg/kg/s|0.048 mcg/kg/s The day order will be randomized per day
89541051|NCT05212168|Placebo Comparator|Placebo Arm|Subject receiving Placebo oral tablets similar in appearance and number to active vaccine tablets
89541052|NCT05207865|Experimental|Rimegepant|rimegepant 75 mg ODT daily
89541053|NCT05199441|Experimental|Dihydroxydibutylether group|This group takes dihydroxydibutylether for 8 weeks.
89541054|NCT05199441|Placebo Comparator|Control group|This group takes placebo for 8 weeks.
89541055|NCT05182086|Experimental|Intervention group|Patients that are allocated to the intervention group will participate in a 12 week lifestyle intervention program consisting of group exercise therapy and dietary advice combined with dietary supplementation. The group exercise therapy will be guided by trained physical therapists. Patients will participate in this part of the intervention twice a week for one hour. The exercise therapy will combine cardiorespiratory with strength training. At the start of the intervention, patients will have an appointment with a nutritional scientist or doctor in which they will receive dietary advise and dietary supplements (ProSource®) to reach the advised caloric and protein intake as composed by the Dutch Centre for Nutrition (Voedingscentrum). Dietary supplements like ProSource® are extensively tested and often used as part of general practice to patients after ICU- or hospital-discharge following critical illness.
89541056|NCT05182086|No Intervention|Standard care|Standard care outpatient post-ICU clinic
88960020|NCT05866081|Other|Randomized cohort- No stent placement|"Participants that are eligible and consent for the randomization cohort of the trial will not have a stent placed.~If participants are found to be ineligible (see below) at the end of ureteroscopy the participants will not be randomized and taken off the study.~In randomization cohort, second stage eligibility criteria: ureteral perforation, unanticipated anatomic abnormality, greater than expected bleeding, ureteral dilation greater than 12 French, ureteral access sheath utilized, failed ureteroscopy, no or incomplete lithotripsy performed, unable to complete case due to medical or anesthetic event."
88960021|NCT05866081|Experimental|Randomized cohort- Stent placement|"Participants that are eligible and consent for the randomization cohort trial will have a stent placed.~If participants are found to be ineligible (see below) at the end of ureteroscopy the participants will not be randomized and taken off the study.~In randomization cohort, second stage eligibility criteria: ureteral perforation, unanticipated anatomic abnormality, greater than expected bleeding, ureteral dilation greater than 12 French, ureteral access sheath utilized, failed ureteroscopy, no or incomplete lithotripsy performed, unable to complete case due to medical or anesthetic event."
88960022|NCT05866081|Other|Observational participants - not randomized|Patients that do not consent to the randomization trial that elect to be on the observational cohort. Stent placement in the observational cohort will be decided by the surgeon intraoperatively, as per routine clinical practice.
88960023|NCT05856903||Severe hemophiliac patients under emicizumab|
88960024|NCT05856903||Healthy volunteers|
88960025|NCT05851365|Experimental|Pre-surgical participants with prostate cancer|The hyperpolarized 13C bicarbonate injection includes the administration of 35 mL injected intravenously (IV) at a rate of 5 mL/second followed by a 20 mL saline flush at 5 mL/second, followed by magnetic resonance (MR) imaging. The intervention will include routine and safety assessments 5 to 9 days after the injection.
88960026|NCT05845138|Experimental|SHR-A1811 combined with capecitabine|
88960027|NCT05842525|Experimental|study group|Fruquintinib combined with FOLFIRI
88960028|NCT05835258|Experimental|Melatonin with phenyl capsaicin|Participants will consume one capsule of 1 mg of melatonin with phenyl capsaicin
88960029|NCT05835258|Active Comparator|Melatonin without phenyl capsaicin|Participants will consume one capsule of 1 mg of melatonin without phenyl capsaicin
88960030|NCT05834296|Experimental|Active|ALZN002 (autologous DCs pulsed with E22W mutant peptide).
88960031|NCT05834296|Placebo Comparator|Placebo|Saline ID and IV administrations.
88960032|NCT05821998|Experimental|Thoracic block technique and designed chest physical therapy program|Manual compression on healthy lung for 20 seconds and rest for 20 seconds, total time 20 minutes and percussion, vibration and modified postural drainage on session time for 35 minutes every day for ten days
88960033|NCT05821998|Active Comparator|Designed chest physical therapy program|Percussion, vibration and modified postural drainage for 30 minutes every day for ten days
88960034|NCT05820126|Experimental|Cold-stored platelet concentrate|Cold-stored, pathogen-reduced platelet transfusion
88960035|NCT05820126|Other|Room temperature-stored platelet concentrate|Room temperature-stored, pathogen reduced platelet transfusion
88960036|NCT05818527|Experimental|vibrating device arm|the patients will use vibrating device 20 mins per day
89024490|NCT00471003||Arm 1|
89541057|NCT05180045|Experimental|LINKED-BP Program|"Patients in the LINKED-BP Program will be trained to measure their BP with an Omron 10 series device. Patients who have smartphones will download the patient facing app and receive a unique link from the study team. Patients who do not own a smartphone will be provided one with a data plan for the duration of the study. The primary care provider and CHW will be able to visualize the remotely transmitted data via the clinician portal.~CHWs will support patients by: (1) providing education on how to manage BP through self-monitoring and practicing dietary modification and exercise; (2) reinforcing positive BP self-management through follow-up encounters; (3) assisting with linkages to existing clinical and administrative services; and (4) link participants with community resources to address health-related social needs.~The staff in each participating community health center practice will be trained in blood pressure measurement best practices."
89541058|NCT05180045|No Intervention|Enhanced Usual Care|Patients in the Enhanced Usual Care Arm, will receive care as usual from thier primary care provider and will be trained to measure their BP with an Omron 10 series device. The staff in each participating community health center practice will be trained in blood pressure measurement best practices.
89541059|NCT05167110|Experimental|Treatment group|Children assigned to the groups (ASD/ADHD) will be randomly prescribed supplementation with two GABA- and dopamine-producing strains at a total of 1 x 10 (9) CFU/capsule for 12 weeks (probiotic subgroup).
89541060|NCT05167110|Placebo Comparator|Placebo group|Children assigned to the groups (ASD/ADHD) will be randomly prescribed placebo supplementation for 12 weeks (placebo subgroup).
89512782|NCT03134339|Experimental|0.024 mcg/kg/s|0.024 mcg/kg/s The day order will be randomized per day
89512783|NCT02282267|Experimental|Gefitinib|Patients with EGFR mutation in plasma detected by droplet digital PCR could receive Gefitinib 250mg every day until disease progression.
88960037|NCT05818527|No Intervention|control group|control group using no devices
88960038|NCT05813236|Experimental|Novosyn®|Novosyn® Quick is available in a range of gauge sizes and lengths, non-needled or attached to stainless steel needles of varying types and sizes: Novosyn® Quick sutures are available undyed in sizes USP 2 (5 metric) through USP 6-0 (0.7 metric).
88960039|NCT05813236|Active Comparator|Monosyn®|Monosyn® Quick is a sterile, synthetic, absorbable, monofilament surgical suture material made from a triblock copolymer comprising glycolide (72 %), ε-caprolactone (14 %) and trimethylene carbonate (14 %), which is only available undyed.
88960040|NCT05813067|Experimental|Test Product: JDS-HF3.0 Capsules|Dietary supplement containing a proprietary botanical blend with NK3R antagonistic activity
88960041|NCT05813067|Placebo Comparator|Placebo Capsules|"Placebo capsule containing:~Microcrystalline cellulose~Silicon dioxide micronized~Magnesium stearate"
88960042|NCT05812742|Active Comparator|Enhanced Usual Care|"For more details on the intervention, please go to the original registration of the RCT-study (NCT02337101) or the published article (PMID: 31891145).~Enhanced Usual Care (EUC) All patients had a brief clinical psychiatric and neurological assessment in order to determine eligibility, and they were provided with information and advice about typical post-concussional symptoms, the typical recovery process and the use of pain medication."
88960043|NCT05812742|Experimental|Enhanced Usual Care + Early intervention programme|"For more details on the intervention, please go to the original registration of the RCT-study (NCT02337101) or the published article (PMID: 31891145).~Behavioral: EUC + Early intervention programme All patients had a brief clinical psychiatric and neurological assessment in order to determine eligibility, and were provided with information and advice about typical post-concussional symptoms, the typical recovery process and the use of pain medication.~The early intervention programme was interdisciplinary and was provided by an occupational therapist and a physiotherapist under supervision of a neuropsychologist. It was based on psychoeducation and principles from Cognitive Behavioral Therapy and Graded Exercise Therapy and targeted to patients' individual goals.~Patients received 8 weekly treatment sessions (3 group based and 5 individual sessions). The intervention started approximately 4 months after the concussion."
88960044|NCT05812703||Behavioral Group Treatment (Cognitive Behavioral Therapy CBT + Movement)|Cognitive Behavioral Therapy Group led by a psychologist to learn pain coping skills, with gentle movement component of duration from 45 minutes to 60 minutes under a licensed Healthcare provider (PT or OT).
89512784|NCT03473041|Active Comparator|Hybrid sling|70 patients with stress urinary incontinence treated with surgeon tailored hybrid sling
89512785|NCT03473041|Active Comparator|TVT-O|70 patients with stress urinary incontinence treated with conventional TVT-O
89512786|NCT02283905|Other|Amphotericin-B and Voriconazole|Treatment with a 24 hour continuous infusion of amphotericin B deoxycholate at 1.0 mg/kg/day for a total dose of at least 1 g (i.e. ~ 14 days); and then the patient is stepped down to voriconazole 6 mg/kg i.v. q12h for 2 doses, then 4 mg/kg q12h either i.v. or orally as appropriate. The oral dose will be rounded for convenience to either the 200 mg or 400 mg tablet twice daily.
89512787|NCT04471025|Active Comparator|Group I|USG guided infraclavicular block with single operator jedi grip technique
89512788|NCT04471025|Active Comparator|Group 2|USG guided infraclavicular block with conventional double operator technique
89512789|NCT04471181||All patients with ruptured abdominal aortic aneurysms|"All patients will undergo CTA to confirm the diagnosis. The use of balloon for aortic clamp in case of haemodynamic instability can be used.~All patients included in the research study must undergo standard EVAR with a bifurcated graft or an aorto-uni-iliac and a femoral to femoral crossover. In aneurysms with short proximal neck down to 4mm, or in cases where completion angiography indicates type Ia endoleak, the Heli-FX EndoAnchor system is recommended to be used, as indicated. All patients will have plain abdominal x-rays on discharge. Participants will undergo CTA in 3months and annually post-op.. In case of an adverse event before the 3 months follow up CTA, a more urgent imaging might be requested and proceed to appropriate action according to the findings."
89512790|NCT00497159|Placebo Comparator|1|Placebo
89512791|NCT00497159|Experimental|2|Dimebon
89512792|NCT02523937||Group without PE or DVT|"PE or DVT have to be confirmed or discarded by combining Wells score clinical probability, D-Dimer, and imaging tests.~The criteria for exclusion of PE or DVT are:~low or intermediate clinical probability and D-dimer <0,50 µg/mL~low and moderate clinical probability and negative spiral computed tomography CT and/or proximal lower limb venous compression ultrasonography (US)~high clinical probability and negative CT and US.~Soluble Fibrin assay will be performed in comparison with D-dimer assays."
89512793|NCT02523937||Group with PE or DVT|"PE or DVT have to be confirmed or discarded by combining Wells score clinical probability, D-Dimer, and imaging tests.~The criteria for confirmation of PE or DVT are:~PE on spiral computed tomography (CT)~proximal deep vein thrombosis on ultrasonography (US).~Soluble Fibrin assay will be performed in comparison with D-dimer assays."
89512794|NCT03480997|Experimental|albuterol sulfate 100 mcg|albuterol sulfate 100 mcg Test MDI
89512795|NCT03480997|Active Comparator|albuterol sulfate 200 mcg|albuterol sulfate 200 mcg Reference MDI
89512796|NCT03480997|Experimental|albuterol sulfate and ipratropium bromide|albuterol sulfate 100 mcg and ipratropium bromide 20 mcg Test MDI
89512797|NCT00572585|Experimental|AEB071|
89512798|NCT00572585|Placebo Comparator|Placebo|
88960045|NCT05812703||Behavioral Group Treatment (ACT) only|Acceptance and Commitment Therapy Group led by a psychologist to learn skills to change their relationship with pain to decrease pain's impact on their life.
89512799|NCT04471259||Patients' injured side|The Biodex, AOFAS, VAS were tested on the patients' injured side
89512800|NCT04471259||Patients' uninjured side|The Biodex, AOFAS, VAS were tested on the patients' uninjured side
89512801|NCT05154877|Other|DMI5R|The DMI5R scanner is the standard of care PET/CT for this arm.
89512802|NCT05154877|Other|DIQ5R|The DIQ5R scanner is the standard of care PET/CT for this arm.
89512803|NCT00570635|Experimental|A|
89512804|NCT00570635|Experimental|B|
89024491|NCT04704128||Case group|women with primary stomatodynia
89024492|NCT04704128||Control group|women without oral disease
89024493|NCT00462267|No Intervention|Usual care|
89024494|NCT00462267|Experimental|Enriched lifestyle intervention|
89024495|NCT00471120|Experimental|P2x7 Assay|Compare assay results with biopsy
89024496|NCT02957669|Experimental|Practice Self-Regulation (PS-R)|Practice Self-Regulation (PS-R) is the treatment condition. PS-R is an in-person, individual-level, clinic-based intervention that aims to increase knowledge of sexual health and the impact of trauma on sexual decision-making.
89024497|NCT02957669|Active Comparator|Therapy Practice Group|Therapy Practice Group is the control counterfactual condition. It is an individual-level, therapy as usual in which the therapist addresses mental health concerns of the participant.
89512805|NCT02348008|Experimental|Arm A - Phase 1b Dose Escalation Cohort|"Cohort 1 will consist of 3-6 patients who will receive MK-3475 200mg and bevacizumab 10mg on day 1 of the 21-day cycle. The drugs are administered 15-30 minutes apart in separate intravenous infusions.~Cohort 2 will consist of 3-9 patients who will receive MK-3475 200mg and bevacizumab 15mg on day 1 of the 21-day cycle. The drugs are administered 15-30 minutes apart in separate intravenous infusions.~If none of the 3 subjects experience a dose limiting toxicity (DLT) during the first cycle of therapy, an additional 3 subjects will be enrolled at dose level 2. If all three subjects in dose level 2 complete the first cycle of therapy without DLT, 3 more subjects will be enrolled to ensure only 0-1 of 6 subjects have a DLT. There will be no further escalation beyond dose level 2."
89512806|NCT02348008|Other|Arm B - Phase II Investigational Treatment|The maximum safe dose of MK-3475 in combination bevacizumab (as determined in the phase 1b cohort) will be given on day 1 of each 21 day cycle.
89512807|NCT00569387|Experimental|Vaccine group|
89024498|NCT04703972|Experimental|Bipolar Patients with connected devices|Patients with bipolar disorder provided with connected devices (wristwatch and wristband)
89024499|NCT04703465|Experimental|tenofovir alafenamide|tenofovir alafenamide 25mg daily for 48 weeks
89512808|NCT05152693|Experimental|Low Variety Small Portion Without Beverage|Test meal with food components mixed together (low variety) with a small portion of food served without water
89512809|NCT05152693|Experimental|High Variety Small Portion Without Beverage|Test meal with food components separated on the plate (high variety) with a small portion of food served without water
89512810|NCT05152693|Experimental|Low Variety Small Portion With Beverage|Test meal with food components mixed together (low variety) with a small portion of food and water
89512811|NCT05152693|Experimental|High Variety Small Portion With Beverage|Test meal with food components separated on the plate (high variety) with a small portion of food and water
89512812|NCT05152693|Experimental|Low Variety Large Portion With Beverage|Test meal with food components mixed together (low variety) with a large portion of food and water
89512813|NCT05152693|Experimental|High Variety Large Portion With Beverage|Test meal with food components separated on the plate (high variety) with a large portion of food and water
89512814|NCT00569153|Experimental|Arm 1 (TAK-700)|
89512815|NCT00569153|Experimental|Arm 2 (TAK-700 at 400 mg & 5 mg prednisone)|
89512816|NCT00569153|Experimental|Arm 3 (TAK-700 at 600 mg & 5 mg prednisone)|
89512817|NCT00569153|Experimental|Arm 4 (TAK-700 at 600 mg)|
89512818|NCT05153005||Talaromycosis|Participants: AIDS patients complicated with Talaromycosis. Intervention(s): To use the specific antigen of taloromyces marneffei which is mannose protein (Mp1p), (1,3)- β- D-glucan (G antigen) and qPCR, dd-PCR and mass spectrometry identification in the diagnosis and efficacy evaluation of AIDS patients complicated with Talaromycosis.
89512819|NCT05153005||Pneumocystis pneumonia|Participants: AIDS patients complicated with Pneumocystis pneumonia Intervention(s)：To use (1,3)- β- D-glucan (G antigen) , qPCR, dd-PCR and mass spectrometry identification, to explore the methods of screening and early diagnosis strategies.
89512820|NCT05153005||Cryptococcus|Participants: AIDS patients complicated with Cryptococcus Intervention(s)：To use (1,3)- β- D-glucan (G antigen) and Cryptococcus capsular antigen(CrAg) serological detection, qPCR, DD PCR and mass spectrometry identification, to explore the methods of screening and early diagnosis strategies of disease.
89512821|NCT05944874|Experimental|HD- TDCS (inhibition)|Patients will perform a session (inhibition) of HD-TDCS of twenty minutes with intensity of 3 milliamps in the left temporal cortex. Before and after each session, patients will perform the six-minute walk test. Heart rate variability (HRV) will be evaluated throughout the protocol through Holter (3-channel). At the end, the perception of exertion and the level of dyspnea of the patient, distance covered and blood pressure will be evaluated.
89512822|NCT05944874|Experimental|HD- TDCS (stimulation)|Patients will perform a session (stimulation) of HD-TDCS of twenty minutes with intensity of 3 milliamps in the left temporal cortex. Before and after each session, patients will perform the six-minute walk test. Heart rate variability (HRV) will be evaluated throughout the protocol through Holter (3-channel). At the end, the perception of exertion and the level of dyspnea of the patient, distance covered and blood pressure will be evaluated.
89512823|NCT05944874|Experimental|HD- TDCS (shan)|Patients will perform a twenty-minute session (SHAN) of HD-TDCS with an intensity of 3 milliamps in the left temporal cortex. Before and after each session, patients will perform the six-minute walk test. Heart rate variability (HRV) will be evaluated throughout the protocol through Holter (3-channel). At the end, the perception of exertion and the level of dyspnea of the patient, distance covered and blood pressure will be evaluated.
89512824|NCT05944861|Experimental|Combined ultrasonography and flouroscopy guided injeciton|In 17 patients selected after randomization, the procedure will first be started with ultrasound and then continued with fluoroscopy.
89024500|NCT00462618|Active Comparator|CBT|
89024501|NCT00431795|Experimental|1|Epi
89024502|NCT00431795|Experimental|2|Cael
89024503|NCT03271203||Subjects participating in the CE and CD interview|Thirty adult subjects from the US with erosive HOA will be asked to participate in CE and CD interviews.
89024504|NCT03271203||Subjects participating in interview and real time data capture|Ten adult subjects from the US (n=5 with erosive HOA, n=5 with non-erosive HOA) of the thirty subjects who are participating in the CE and CD interviews, will be asked to participate in the real-time data capture app task
89024505|NCT00431912|Experimental|Single-arm, trinomial 2-stage design|
89024506|NCT01052012|Experimental|Active: SABER-Bupivacaine|SABER-Bupivacaine
89024507|NCT01052012|Active Comparator|Comparator: Bupivacaine HCl|Bupivacaine HCl
89024508|NCT01052012|Placebo Comparator|Placebo: SABER-Placebo|SABER-Placebo
89512825|NCT05944861|Active Comparator|Flouroscopy guided injection|In 17 patients selected after randomization, the procedure will be performed only through fluoroscopy.
89512826|NCT05944848|Experimental|1mg group|Single oral dose of 1 mg CL-197 capsules or CL-197 placebo
89512827|NCT05944848|Experimental|10mg group|Single oral dose of 10 mg CL-197 capsules or CL-197 placebo
89512828|NCT05944848|Experimental|30mg group|Single oral dose of 30 mg CL-197 capsules or CL-197 placebo
89512829|NCT05944848|Experimental|60mg group|Single oral dose of 60 mg CL-197 capsules or CL-197 placebo
89512830|NCT05944848|Experimental|100mg group|Single oral dose of 100 mg CL-197 capsules or CL-197 placebo
89512831|NCT05944809|Experimental|prophylactic TPO|Prophylactic TPO combined with BMS-IMRT in the esophageal cancer patients undergoing concurrent chemoradiotherapy
89512832|NCT05944783|Active Comparator|Liteda®|Dasatinib 100 mg tablets Lab. Tecnofarma Colombia S.A.S. Liteda®
89512833|NCT05944783|Active Comparator|Sprycel®|Dasatinib 100 mg tablets Lab. Bristol-Myer Squibb Sprycel®
89512834|NCT05944757|Experimental|PRP -plasma rich platelets group|Twenty patients (20) underwent 0.5 ml intrastromal injection of PRP plasma rich platelets (first group) every 2 weeks for one month
89512835|NCT05944757|Active Comparator|Autologous serum group|Twenty patients (20) underwent intrastromal injection of 0.5 ml of autologous serum (second group) every 2 weeks for 1 month
89512836|NCT05944744|Experimental|Intervention|The patient is given Cobamamide 2 x 3000 mg for 28 days.
89512837|NCT05944744|Placebo Comparator|Control|The patient is given placebo 2 x 1 capsule for 28 days.
89512838|NCT05944705||Symptomatic individuals using hemp or cannabis products for immune support|Individuals with symptomatic illness that utilize a proprietary hemp or cannabis product to aid in their recovery
89512839|NCT05944705||Symptomatic individuals not currently using hemp or cannabis products for immune support|Individuals without symptomatic illness that do not utilize the proprietary hemp or cannabis product to aid in their recovery
89512840|NCT05944679|Placebo Comparator|Group Xray|Xray at 1, 3, 6 and 12 months
89512841|NCT05944679|Active Comparator|Group No Xray|Xray at 12 months
89512842|NCT05944666|Experimental|Medical rehabilitation (MR) in acute period of IS-inpatient stage|"Devices Patients in acute period of IS receive a course of standart MR-program and in main group - rehabilitation with multimodal correction using and BFB-stabilometric training, cognitive-motor training in a virtual environment (VR), functional individually programmed stimulation of antagonist muscles of the lower limb (FES), subject-manipulative activity training to restore fine movements of the hand on a glove simulator, if moderate paresis of the upper limb - the neurointerface Exokist-2 with EEG registration."
89512843|NCT05944666|Experimental|MR in early recovery period of IS- inpatient stage|"Devices Patients in the early recovery period of IS receive a course of standart MR-program and in main group - rehabilitation with multimodal correction using and BFB-stabilometric training, cognitive-motor training in a virtual environment (VR), functional individually programmed stimulation of antagonist muscles of the lower limb (FES), subject-manipulative activity training to restore fine movements of the hand on a glove simulator, if moderate paresis of the upper limb - the neurointerface Exokist-2 with EEG registration."
89512844|NCT05944666|Experimental|MR in late recovery period of IS-inpatient stage|"Devices Patients in the late recovery period of IS receive a course of standart MR-program and in main group - rehabilitation with multimodal correction using and BFB-stabilometric training, cognitive-motor training in a virtual environment (VR), functional individually programmed stimulation of antagonist muscles of the lower limb (FES), subject-manipulative activity training to restore fine movements of the hand on a glove simulator, if moderate paresis of the upper limb - the neurointerface Exokist-2 with EEG registration."
89512845|NCT05944666|Experimental|MR in early recovery period of IS - outpatient stage|"Devices Patients in the early recovery period of IS receive a course of standart MR-program and in main group - rehabilitation with multimodal correction using and BFB-stabilometric training, cognitive-motor training in a virtual environment (VR), functional individually programmed stimulation of antagonist muscles of the lower limb (FES), subject-manipulative activity training to restore fine movements of the hand on a glove simulator, if moderate paresis of the upper limb - the neurointerface Exokist-2 with EEG registration."
89512846|NCT05944666|Experimental|MR in late recovery period of IS - outpatient stage|"Devices Patients in the late recovery period of IS receive a course of standart MR-program and in main group - rehabilitation with multimodal correction using and BFB-stabilometric training, cognitive-motor training in a virtual environment (VR), functional individually programmed stimulation of antagonist muscles of the lower limb (FES), subject-manipulative activity training to restore fine movements of the hand on a glove simulator, if moderate paresis of the upper limb - the neurointerface Exokist-2 with EEG registration."
89512847|NCT05944653||Women with hormonal contraception|
89512848|NCT05944653||Women without hormonal contraception|
89512849|NCT05944640||Patients with DR|Adult patients with T1DM or T2DM with any form of diabetic retinopathy and diabetic macular edema, indicated for ocular surgical procedure as standard of care. Blood samples and samples of intraocular fluids will bee taken during the ocular surgery.
89512850|NCT05944640||Patients without DR|Adult patients with T1DM or T2DM without any signs of diabetic retinopathy, indicated for ocular surgical procedure from other reasons as standard of care. Blood samples and samples of intraocular fluids will bee taken during the ocular surgery.
89512851|NCT05944640||Control group|Subjects without diabetes mellitus indicated for ocular surgery from other reasons (cataract, retinal detachment, macular hole, idiopathic epiretinal membrane) as standard of care. Blood samples and samples of intraocular fluids will bee taken during the ocular surgery.
89512852|NCT05944614||Marfan Syndrome patients|Marfan Syndrome patients age 18-50 with a pathological FBN1 mutation
89512853|NCT05944614||Healthy volunteers|Age and gender matched healthy control patients without a history of aortic disease.
89024509|NCT00432029|Other|1|IDDM
89512854|NCT05944588||Extubation Success|Patients who don't need a new intubation in the 7 days following the extubation
89024510|NCT00432029|Other|2|Hypercholesterolemia and/or Hypertension
89024511|NCT00432029|Other|3|age/sex matched healthy control subjects
88960046|NCT05812703||Behavioral Group Treatment (ACT + Movement)- Back in ACTion|Acceptance and Commitment Therapy Group led by a psychologist to learn skills to change their relationship with pain to decrease pain's impact on their life and improve willingness to engage in valued activities. Movement component to last from with intense and gentle movement sessions with a total movement time of 90 minutes - 2 hours led by licensed health care provider a PT or OT.
89512855|NCT05944588||Extubation Failure|Patients who need a new intubation in the 7 days following the extubation
89512856|NCT05944549|Experimental|Enhanced Intervention group|
89512857|NCT05944549|Active Comparator|lifestyle-intervention group|
89512858|NCT05944536|Active Comparator|Balance Exercise (BE)|Balance exercises; static standing on flat ground for 30 seconds, standing in tandem position for 30 seconds, standing on one foot for 30 seconds, standing on tiptoe for 30 seconds, looking left and right with one foot in the air, backward rotation with one foot in the air, rotation, squatting slightly in knee flexion with one foot in the air, squatting slightly in knee extension with one foot in the air, going on tiptoe and turning with the heel, multi-directional stretches on the balance board Each exercise will be performed with 10 repetitions for both lower extremities.
89512859|NCT05944536|Experimental|BE+Dual Task|"Cognitive and motor secondary tasks were given along with balance exercises. Cognitive tasks: color discrimination, counting city names, counting fruit and vegetable names, saying 3 numbers between 50-100, talking on a mobile phone, subtracting 3 and 7 in series, saying male names, counting backwards out loud, asking for a series of addition and subtraction operations.~Motor tasks: carrying a glass of water, carrying a glass on a tray, carrying an object, pressing a button, transferring money from hand to hand, rhythmic clapping"
89512860|NCT05944523|Active Comparator|Group 1|The group in which preemptive erector spina plane block was applied
89512861|NCT05944523|Active Comparator|Group 2|The group in which the end of the surgery was applied to the erector spina plane block
89512862|NCT05944484|Active Comparator|kegel exercises|"Kegel exercise program performed for 12 weeks( 3 sessions /week )~.• The first step is external observation, with the patient in the lithotomy position.And describe for each woman how to feel her muscle when she stops mid-stream urine.~The second step is vaginal examination, performed gently with one finger. - The digital exam served a double purpose: first to assess the development of the puboccocygeus muscle and second to verify that the patient was able to identify the correct muscle~The third stage main exercises quick flick : contract muscle as quickly as possible 10-20 times then relax then count 10 for relax then reapeat .( 50 repetitions) slow contraction: tighten the muscle as hard as you can for account of 10 -20 .relax for acount 10 then repeat ( 50 repetitions) sustained contraction: tighten the muscle halfway and hold 60 seconds .relax for account 20 then repeat (10 repetitions)"
89512863|NCT05944484|Active Comparator|low caloric diet|low caloric diet (800-1200) calories/day . According to each patient, diet should contain (carbohydrate protein, fats, minerals, vitamins),1200 calories in the first month, 1000 calories in the second month, and 800 calories in the third month. Every week, each woman will be allowed to change the types of food to avoid boarding.
89512864|NCT05944484|Active Comparator|ultrasound cavitation|ultrasound cavitation, for 30 minutes on abdomen with continuous emission and frequency of 40 KHz, 3-6 W/cm2, 60W with 10cm2 active surface, twice/ week with 3 days apart for 12 weeks.
89512865|NCT05944406||Audit Cycle 1|These are the patients included in the first cycle of the clinical audit. The study collected data from a sample of 256 patients who visited the Medical Unit I of Benazir Bhutto Hospital, Rawalpindi, during the specified period. The patients were triaged by the triage nurses using the Manchester Triage System (MTS). Their age, gender, registration time, time of consultation, triage category assigned by the triage nurse, and admission decision were recorded for analysis. The accuracy of triage and waiting times were assessed for these patients.
89512866|NCT05944406||Audit Cycle 2|These are the patients included in the second cycle of the clinical audit, conducted after an educational intervention for the triage nurses. The study collected data from a sample of 238 patients who visited the same Medical Unit I of Benazir Bhutto Hospital, Rawalpindi. Similar to audit cycle 1, these patients were triaged using the MTS, and their demographic information, triage category, and admission decision were recorded. The study aimed to evaluate any improvements in triage accuracy and waiting times compared to audit cycle 1 after the intervention and training of the triage nurses.
89512867|NCT05944393|Experimental|ESB block|Patients will receive preoperative ultrasound-guided bilateral single-injection ESP blocks at one or two levels before incision with 10 mL 0.2% ropivacaine per single injection. Using appropriate sterile precautions, under general anesthesia, an ultrasound (Mindrey TE9) equipped with either a linear 15-6 megahertz (MHz), or a curvilinear 5-2 MHz transducer (habitus-dependent) used to identify the erector spine, transverse process, and paravertebral space. A 22G 0,7x80 mm echogenic block needle (Stimuplex Ultra 360)) is inserted in-plane from the cranial to caudal direction until the needle tip contacts the transverse process. 1-3mL is injected to confirm the proper injection plane by visualizing the spread deep to the erector spinae muscles and superficial to the transverse process. Block is completed with 10mL of 0,2% Ropivacaine. The needle is withdrawn, and the needle entry site is wiped clean.
89512868|NCT05944393|Experimental|Placebo block|Patients will receive preoperative ultrasound-guided bilateral single-injection ESP blocks at one or two levels before incision with 10 mL 0,9% normal saline per single injection. Using appropriate sterile precautions, under general anesthesia, an ultrasound (Mindrey TE9) equipped with either a linear 15-6 megahertz (MHz), or a curvilinear 5-2 MHz transducer (habitus-dependent) used to identify the erector spine, transverse process, and paravertebral space. A 22G 0,7x80 mm echogenic block needle (Stimuplex Ultra 360)) is inserted in-plane from the cranial to caudal direction until the needle tip contacts the transverse process. 1-3mL is injected to confirm the proper injection plane by visualizing the spread deep to the erector spinae muscles and superficial to the transverse process. Block is completed with 10mL of 0,9% normal saline. The needle is withdrawn, and the needle entry site is wiped clean.
88960047|NCT05806580|Experimental|single arm|For patients who had undergone at least one disease assessment after the first treatment of Relmacabtagene Autoleucel injection and whose disease status was not complete remission, the investigators decided to give the patients a second treatment of Relmacabtagene Autoleucel injection based on clinical practice, and the specific dosage was determined by the investigators according to the patient's condition and dose reserve
88960048|NCT05804604||Level of bone intake proteins and muscle atrophy marker in patients after proximal femur fracture|Open reduction of femoral neck or pertrochanteric fracture and preoperative analysis of bone intake proteins and muscle atrophy marker serum concentration
88960049|NCT05804604||Level of bone intake proteins and muscle atrophy marker in patients without proximal femur fracture|Control group without a history of proximal femur fracture. Analysis of the bone intake proteins and muscle atrophy marker serum level
88960050|NCT05802901|Active Comparator|Spinal manipulation|Spinal manipulation of the lumbar spine only group.
88960051|NCT05802901|Active Comparator|Dry needling|Dry needling of the symptomatic side of the lumbar spine only group.
88960052|NCT05802901|Active Comparator|Spinal manipulation and dry needling|Combination of spinal manipulation and dry needling of the lumbar spine group
89512869|NCT05944380|Experimental|PENG with 20mL 0,5% Ropivacaine|Patients will receive a preoperative ultrasound-guided pericapsular nerve group block with 20 mL of 0.5% ropivacaine. Using appropriate sterile precautions and procedural sedation with up to 2 mg IV midazolam, an ultrasound (Mindrey TE9) equipped with either a linear 15-6 megahertz (MHz) or a curvilinear 5-2 MHz transducer (habitus-dependent) used to identify the anterior inferior iliac spine, iliopubic eminence, and psoas muscle. After spinal anesthesia, a 22g 80 mm echogenic block needle (Stimuplex Ultra 360) is advanced lateral to medial, in the plane with the ultrasound beam, beneath the psoas tendon to the iliopubic eminence. 20 mL 0.5% ropivacaine is injected beneath the psoas tendon and above the iliopubic eminence in 5 mL increments with a periodic aspiration to prevent intravascular injection. The needle is withdrawn, and the needle entry site is wiped clean.
88960053|NCT05802758|Active Comparator|Youngsters who get CFT + VR|yougsters, who get compassion-focused short intervention together with training in virtual reality together with general psychosocial rehabilitation offered by prisons and state residential schools
88960054|NCT05802758|No Intervention|Treatment as usual|youngsters, who get only general psychosocial rehabilitation offered by prisons and state residential schools
89512870|NCT05944380|Experimental|PENG block with 20mL 0,9% normal saline|Patients will receive a preoperative ultrasound-guided pericapsular nerve group block with 20 mL of 0.9% normal saline. Using appropriate sterile precautions and procedural sedation with up to 2 mg IV midazolam, an ultrasound (Mindrey TE9) equipped with either a linear 15-6 megahertz (MHz) or a curvilinear 5-2 MHz transducer (habitus-dependent) used to identify the anterior inferior iliac spine, iliopubic eminence, and psoas muscle. After spinal anesthesia, a 22g 80 mm echogenic block needle (Stimuplex Ultra 360) is advanced lateral to medial, in the plane with the ultrasound beam, beneath the psoas tendon to the iliopubic eminence. 20 mL 0.9% normal saline is injected beneath the psoas tendon and above the iliopubic eminence in 5 mL increments with a periodic aspiration to prevent intravascular injection. The needle is withdrawn, and the needle entry site is wiped clean.
89512871|NCT05944341|Experimental|Articaine|
89512872|NCT05944341|Active Comparator|Lidocaine|
89512873|NCT05944328|Experimental|intervention group|
89512874|NCT05944328|No Intervention|control group|
89512875|NCT05944315|Experimental|Teddy Bear Injury Prevention Clinic|receiving injury prevention education
89512876|NCT05944315|Active Comparator|Teddy Bear Hospital Education Clinic|receiving hospital based education
89512877|NCT05944289|Experimental|ACT|ACT Intervention Group
89512878|NCT05944289|Other|Support|Control Group - Caregiver support group
89512879|NCT05944211|Experimental|Hetrombopag|The study in a 1:1 randomization ratio (36 subjects to experimental group). The treatment group received Herteppa Ethanolamine tablets and platelet transfusion.
89512880|NCT05944211|No Intervention|Control|The study in a 1:1 randomization ratio (36 subjects to control group). The control group did not receive other platelet raising therapy except platelet transfusion.
89512881|NCT05944146|Experimental|cardiac surgery patients with thermodilution technique monitoring|
89512882|NCT05944094||Group 1: exposed patients|Group 1: pregnant women who received intravaginal chlorhexidine before 16 weeks of gestation Group 2: pregnant women who did not received intravaginal chlorhexidine e before 16 weeks of gestation
88960055|NCT05797103|Experimental|electrolyzed water spray group|Participants with bacteria E-coli and an attenuated human flu virus on their hands will receive one treatment with the novel electrolyzed water and complete the questionnaire.
88960056|NCT05797103|Experimental|untreated tap water group|Participants with bacteria E-coli and an attenuated human flu virus on their hands will receive one treatment with the untreated tap water and complete the questionnaire.
88960057|NCT05794685|Active Comparator|adductor canal block|adductor canal block : patients will receive an injection of 30 ml of .25% of Bupivacaine including 4mg of dexamethasone at a point anterior to the femoral artery, deep to the sartorius muscle
89512883|NCT05944068|Experimental|Early intervention group|This group will receive the intervention immediately after baseline.
89512884|NCT05944068|Other|Late intervention group|This group will receive the intervention 6 months after baseline, in psychological studies called the waiting list group
88960058|NCT05794685|Active Comparator|4 in one block|4 in one block : patients will receive an injection of 30 ml of .25% of Bupivacaine including 4mg dexamethasone at the adductor hiatus where the descending genicular artery branches from superficial femoral artery .
88960059|NCT05791903|Experimental|Experimental Group|In the application process, individuals in the experimental group will receive care based on Kolcaba's comfort theory and comfort behaviour checklist during their stay in the ICU.
89512885|NCT05944029|Experimental|Metabolic syndrome Patients|Pomegranate seed powder is administered for alleviating symptoms of metabolic syndrome
89512886|NCT05943925||Healthy control group|"The criteria for the recruitment will be:~Inclusion criteria: more than 60 years. Exclusion criteria: Significant neurology disease diagnosed, infectious treatment with antibiotics in the previous 6 months prior to providing the stool sample, corticosteroid use, immunosuppressors or immunostimulants treatment, illnesses of the gastrointestinal (GI) tract, large doses of commercial probiotics consumed (greater than or equal to 108 colony forming units (cfu) per organisms per day).~This control group were recruited from relatives of the patients enrolled or general population and interviewed at the hospital (relatives, University or their homes).~Neuropsychological, functional and neuropsychiatric assessment and stool sample."
88960060|NCT05791903|No Intervention|Control Group|In this study, the control group will receive standard care.
88960061|NCT05790109|Experimental|RF biopsy track cautery|This study is designed as an open-label, single arm study, wherein all study participants will undergo RF track cautery during percutaneous liver, kidney, or spleen biopsy.
88960062|NCT05786872|Experimental|dual-target deep brain stimulation|This is a single arm, prospective, open label clinical study, participants who fit inclusion/exclusion standards, completed physical anti-addiction treatments and surgical implantation standard will start DBS system stimulation and adjust parameters after 10-14 days of implantation. Then after stimulation for 9-32 weeks, they will be evaluated for treatment efficacies. This study is extendable, with agreements from participants, long term efficacy and safety follow-up study will be performed after 32 weeks ± 7 days of following, once every 2-3 months.
88960063|NCT05786625||Microwave ablation|Patients with a single or multiple soft tissue lung lesions that is medically inoperable or for which the patient has declined surgical resection.
89512887|NCT05943925||Alzheimer Disease (AD)|"The criteria for the recruitment will be:~Inclusion criteria: Alzheimer Disease (AD) diagnosed by the neurology service; more than 60 years.~Exclusion criteria: Comorbidity with other significant neurology disease, infectious treatment with antibiotics in the previous 6 months prior to providing the stool sample, corticosteroid use, immunosuppressors or immunostimulants treatment, illnesses of the GI tract, large doses of commercial probiotics consumed (greater than or equal to 108 colony forming units (cfu) per organisms per day).~Neuropsychological, functional and neuropsychiatric assessment and stool sample."
89512888|NCT05943925||Mild Cognitive Impairment (MCI)- amnesic|"The criteria for the recruitment will be:~Inclusion criteria: Mild Cognitive Impairment (MCI) amnesic, diagnosed by the neurology service; more than 60 years.~Exclusion criteria: Comorbidity with other significant neurology disease, infectious treatment with antibiotics in the previous 6 months prior to providing the stool sample, corticosteroid use, immunosuppressors or immunostimulants treatment, illnesses of the gastrointestinal (GI) tract, large doses of commercial probiotics consumed (greater than or equal to 108 colony forming units (cfu) per organisms per day).~Neuropsychological, functional and neuropsychiatric assessment and stool sample."
89512889|NCT05943925||Parkinson Disease Dementia (PDD)|"The criteria for the recruitment will be:~Inclusion criteria: Parkinson Disease Dementia (PDD) diagnosed by the neurology service; more than 60 years.~Exclusion criteria: Comorbidity with other significant neurology disease, infectious treatment with antibiotics in the previous 6 months prior to providing the stool sample, corticosteroid use, immunosuppressors or immunostimulants treatment, illnesses of the gastrointestinal (GI) tract, large doses of commercial probiotics consumed (greater than or equal to 108 colony forming units (cfu) per organisms per day).~Neuropsychological, functional and neuropsychiatric assessment and stool sample."
88960064|NCT05784532||STERN FIX|Patients undergoing cardiothoracic surgery through median sternotomy, once the main intervention is finished, will have their sternum closed using the sternal stabilization system STERN FIX in combination with wires according to the STERN FIX instructions for use.
88960065|NCT05783544|Active Comparator|COPD patients without any comorbidities|
88960066|NCT05783544|Active Comparator|COPD patients with chronic pulmonary aspergillosis|
88960067|NCT05783544|Active Comparator|COPD patients with ascariasis|
88960068|NCT05783544|Active Comparator|COPD patients with chronic pulmonary aspergillosis and ascariasis|
88960069|NCT05783544|Active Comparator|healthy control|
88960070|NCT05782231|Experimental|Experimental: GetActive+|A mind-body program focused on increasing physical and emotional function in older adults with chronic musculoskeletal pain
88960071|NCT05775315|Experimental|Action Observation Therapy|exercises of AO protocol
88960072|NCT05775315|Active Comparator|Visual feedback and Action Observation Therapy|Excercises of AO protocol infront of a mirror
89512890|NCT05943925||Lewy bodies dementia (LBD)|"The criteria for the recruitment will be:~Inclusion criteria: Lewy Body Dementia (LBD) diagnosed by the neurology service; more than 60 years.~Exclusion criteria: Comorbidity with other significant neurology disease, infectious treatment with antibiotics in the previous 6 months prior to providing the stool sample, corticosteroid use, immunosuppressors or immunostimulants treatment, illnesses of the gastrointestinal (GI) tract, large doses of commercial probiotics consumed (greater than or equal to 108 colony forming units (cfu) per organisms per day).~Neuropsychological, functional and neuropsychiatric assessment and stool sample."
89512891|NCT05943925||Frontotemporal Dementia (FTD)-behavioral variant|"The criteria for the recruitment will be:~Inclusion criteria: Frontotemporal Dementia (FTD)-behavioral variant diagnosed by the neurology service; more than 60 years.~Exclusion criteria: Comorbidity with other significant neurology disease, infectious treatment with antibiotics in the previous 6 months prior to providing the stool sample, corticosteroid use, immunosuppressors or immunostimulants treatment, illnesses of the gastrointestinal (GI) tract, large doses of commercial probiotics consumed (greater than or equal to 108 colony forming units (cfu) per organisms per day).~Neuropsychological, functional and neuropsychiatric assessment and stool sample."
89512892|NCT05943925||Alzheimer disease (AD)-control|"Inclusion criteria: Alzheimer Disease (AD) diagnosed by the neurology service; more than 65 years. Exclusion criteria: Comorbidity with other significant neurology disease, infectious treatment with antibiotics in the previous 6 months prior to providing the stool sample, corticosteroid use, immunosuppressors or immunostimulants treatment, illnesses of the gastrointestinal (GI) tract, large doses of commercial probiotics consumed (greater than or equal to 108 colony forming units (cfu) per organisms per day).~Neuropsychological, functional and neuropsychiatric assessment and stool sample at basal, 12 weeks and 24 weeks."
89519496|NCT04455269|Experimental|Full-Mouth Erythritol Powder Air-polishing Therapy (FM-EPAPT)|"The quadrants allocated to FM-EPAPT underwent the following steps:~Decontamination of soft tissues with air-polishing and erythritol powder;~Supra-gingival removal biofilm with air-polishing and erythritol powder;~Sub-gingival removal of biofilm with air-polishing and erythritol;~Calculus removal with a piezoceramic scaler."
89519497|NCT04455269|Active Comparator|Ultrasonic debridement and abrasive paste (US+P)|"The quadrants allocated to US+P treatment underwent the following steps:~Full-mouth ultrasonic debridement with piezoceramic scaler;~Plaque removal and polishing with soft rubber cup and low-RDA polishing paste"
89519498|NCT04749394|Experimental|Experimental Arm|Camrelizumab plus apatinib as consolidation therapy
88960073|NCT05771766|Experimental|Postural Drainage with Aerobic Training|The intervention group will undergo Postural Drainage and additional Aerobic Training thrice a week for two weeks as well along with postural drainage. Aerobic training will include a 5-step stair-climbing and 10-step walk during each session.
88960074|NCT05771766|Active Comparator|Postural Drainage|the group will receive postural drainage as baseline treatment thrice a week for two weeks.
88960075|NCT05764967|Experimental|Low Dye Taping|One Arm will be given Low Dye taping. The augmented low-Dye technique, involves applying a device consisting of a spur and mini-stirrups to the foot and then adding reverse sixes and calcaneal slings to an anchor on the distal one-third of the leg. A rigid 38-mm sports tape with zinc oxide adhesive will be used for all of the taping procedures. Prior to application of the tape, any hair in the region will be shaved and the foot and leg will be washed with soap and warm water to remove any dirt or oils that might decrease the adhesion of the tape. The Transverse Tibial Rotation (TTR) measurements will be repeated following application of tape.
88960076|NCT05764967|Active Comparator|Temporary Felt Insoles|other will be given temporary shoe insoles. A temporary orthosis will be fabricated from 7-mm orthopedic felt. The orthosis consist of two parts, a medial longitudinal buttress and a navicular/sustentaculum tali pad. The medial longitudinal buttress will extend from the posterior calcaneus to the first metatarsal head and from the medial border of the foot to the bisection of the calcaneus and calcaneal recess will be cut out. A navicular/sustentaculum tali pad will extend from the sustentaculum tali to the cuneiform.
88960077|NCT05764083||Inpatient Cohort|COVID-19-positive or -suspected inpatients: Eligible inpatient cohort participants include Veterans who receive inpatient care at VHA facilities and are tested for SARS-CoV-2. Members of this inpatient cohort include those with and without SARS-CoV-2 infection.
89512893|NCT05943925||Alzheimer disease (AD)-probiotic|"Inclusion criteria: Alzheimer Disease (AD) diagnosed by the neurology service; more than 65 years. Exclusion criteria: Comorbidity with other significant neurology disease, infectious treatment with antibiotics in the previous 6 months prior to providing the stool sample, corticosteroid use, immunosuppressors or immunostimulants treatment, illnesses of the gastrointestinal (GI) tract, large doses of commercial probiotics consumed (greater than or equal to 108 colony forming units (cfu) per organisms per day).~Neuropsychological, functional and neuropsychiatric assessment and stool sample at basal, 12 weeks and 24 weeks."
89512894|NCT05943912|Experimental|Single Vision Spectacle Lens|Participants who chose to correct myopia with single vision spectacle lenses.
89512895|NCT05943912|Experimental|Defocus Incorporated Multiple Segments (DIMS) Spectacle Lens|Participants who chose to correct myopia with DIMS spectacle lenses.
89512896|NCT05943873||Control|Conventional mastectomy
89512897|NCT05943873||Minimally invasive|robotic-assisted or endoscopic assisted mastectomies
89512898|NCT05943860|Experimental|Pantovigar vegan treatment|
89512899|NCT05943769|Experimental|MTA|Root end filling material is MTA without bone graft in the defect.
89512900|NCT05943769|Experimental|TotalFill|Root end filling material is TotalFill without bone graft in the defect.
89512901|NCT05943769|Experimental|MTA & bone|Root end filling material is MTA with the addition of composite bone graft in the defect.
89512902|NCT05943769|Experimental|TotalFill & bone|Root end filling material is TotalFill with the addition of composite bone graft in the defect.
89512903|NCT05943730|Experimental|Seismofit Validity|Participants will undergo a seismocardiography assessment, whilst supine, using the seismofit device. This will estimate their peak oxygen consumption. Participants will then undergo a maximal cardiopulmonary exercise test (CPET), where peak oxygen consumption will be measured. The Seismofit estimated peak oxygen consumption will be compared with CPET measured peak oxygen consumption (unless prespecified criteria for a maximal exercise test are not met).
89512904|NCT05943717||50 children and adolescents with end stage renal disease on regular hemodialysis|50 children and adolescents with end stage renal disease on regular hemodialysis for three times weekly
89512905|NCT05943704|Experimental|Children with cow milk allergy.|Beef introduction for children proven to have cow milk protein allergy
89512906|NCT05943652||Parkinson Disease|
89512907|NCT05943652||Idiopathic Dystonia|
89512908|NCT05943652||Essential Tremor|
89512909|NCT05943652||Functional Neurological Disorder|
89512910|NCT05943652||Functional Cognitive Disorder|
89512911|NCT05943652||Alzheimer Disease|
89512912|NCT05943639|Experimental|Experimental group|The Cultural Marginality Theory-Based Education program will be held in a face-to-face classroom environment for the students in the experimental group. This training program has been developed based on the concepts of Cultural Marginality Theory. The content and topics of the sessions in the program are arranged according to the conceptual structure and flow of the theory. The training program was created in a certain flow, based on the concepts of recognizing intercultural conflict (2 sessions), marginal living (2 sessions) and alleviating cultural tension (2 sessions). There are 6 sessions in the program and the frequency of sessions is 2 times a week, and each session lasts approximately 45 minutes. The training program will be applied to 33 foreign nursing students in the experimental group.
89512913|NCT05943639|No Intervention|Control group|There will be no training or intervention.
89512914|NCT05943613|Placebo Comparator|Group B|control group : will receive 2 ml (10 mg) of intrathecal hyperbaric Bupivacaine (0.5%) and another syringe containing 1 ml of Dextrose 5%.
89512915|NCT05943613|Active Comparator|Group BC|will receive 2 ml (10 mg) of intrathecal hyperbaric Bupivacaine (0.5%) and another syringe containing Clonidine (30 µg) diluted in Dextrose 5% to a total volume of 1 ml.
89512916|NCT05943613|Active Comparator|Group BN|will receive 2 ml (10 mg) of intrathecal hyperbaric Bupivacaine (0.5%) and another syringe containing Neostigmine (10 µg) diluted in Dextrose 5% to a total volume of 1 ml.
89512917|NCT05943600||Osteoporosis patients|Participants will fill out the self-report scales.
89512918|NCT05943587|Experimental|Chronic pain group|30-45 minute individual sessions of culture-sensitive PNE4kids training will be applied.
89512919|NCT05943587|Active Comparator|Control Group|30-45 minute individual sessions of standard education training will be applied.
89512920|NCT05943483||All subjects|Subjects who filled out our modified CCMQ questionnaire
89512921|NCT05943470|Active Comparator|daily|daily use of one exchange of icodextin as long dwell
89512922|NCT05943470|Experimental|alternative day|alternative day use of one exchange of icodextin as long dwell
89512923|NCT05943457|Experimental|Intervention (MK7) Arm|This corresponds to the sub-group of subjects who will receive the supplement (vitamin K2 or Menaquinone-7).
89512924|NCT05943457|Placebo Comparator|Control Arm|This corresponds to the sub-group of subjects who will receive placebo.
88960078|NCT05764083||Outpatient Cohort|COVID-19-positive or -suspected outpatients: Eligible outpatient cohort participants include Veterans who seek care in (1) VA medical center emergency departments, (2) VA medical center urgent care clinics, or (3) VA medical center COVID-19-specific testing sites, and who are tested for SARS-CoV-2 but do not require hospital admission at the time of evaluation. Members of this outpatient cohort include those with and without SARS-CoV-2 infection.
88960079|NCT05764083||Community Living Center Cohort|Community Living Center residents: Eligible Community Living Center cohort participants include all residents who reside in VA medical center-operated Community Living Centers. Members of this Community Living Center cohort include those with and without SARS-CoV-2 infection.
88960080|NCT05761379|Experimental|PBM therapy 1|PBM therapy was performed with a low-intensity laser (Airdoc, MPC Co.,Ltd., Beijing, China) with an irradiance of 0.6±0.2 mW, a wavelength of 650 nm±10 nm, and illumination of approximately 400 lux on average. The lighting spot for therapy is a dot. Only one eye will be treated with PBM therapy.
88960081|NCT05761379|Experimental|PBM therapy 2|PBM therapy was performed with a low-intensity laser (Airdoc, MPC Co.,Ltd., Beijing, China) with an irradiance of 0.3±0.2 mW, a wavelength of 650 nm±10 nm, and illumination of approximately 400 lux on average. Only one eye will be treated with PBM therapy.
89512925|NCT05943418|Experimental|Active Intervention|
89512926|NCT05943418|Active Comparator|Control arm|
89512927|NCT05943392||Healthy volunteers|EEG recordings; behavioural data (psychophysics)
89512928|NCT05943379|Experimental|cohort 1|BCG Naïve
89512929|NCT05943379|Experimental|cohort 2|BCG Unresponsive
89512930|NCT05943366|Experimental|KOKU-Nut|Participants will be helped to download KOKU-Nut onto their ipad or tablet during the baseline visit and will receive training. In cases where participants do not have the necessary devices or data to join the intervention, a tablet with KOKU-Nut installed will be provided for the duration of the intervention. Participants will be asked to engage with KOKU-Nut at least 3 times a week throughout the 12-week period.
89512931|NCT05943366|No Intervention|Usual care|Participants will continue with usual care and will receive a leaflet developed by Age UK about the importance of a healthy lifestyle including information on the importance of staying active and nutrition.
89512932|NCT05943353|Other|non-randomized trials|
89512933|NCT05943301|Experimental|Experimental group|Self-hypnosis/self-care intervention : It is an 8-week 2 hour-session (one session per week) of self-hypnosis/ self-care learning. Participants are given strategies to learn self-care (knowing your own needs, self-respect, communication, etc.), each strategie is discussed for participant to understand them and thus applie them correctly in daily living. An hypnosis exercice is also realised at the end of each session.
89512934|NCT05943301|No Intervention|Control group|The control goup has usual care and no intervention.
89512935|NCT05943262|Experimental|mesoscale nonlinear optical microscope + whole-mount H&E & IHC staining protocol|
89512936|NCT05943236||All patients|All patients
89512937|NCT05943223|Experimental|Piperacillin/tazobactam|
89512938|NCT05943223|Active Comparator|Ceftriaxone and metronidazole|
88960082|NCT05761379|Placebo Comparator|Control|Single vision spectacles correction only.
89512939|NCT05943210|Other|Single cohort|Eligible patients will receive short course radiation therapy (scRT) of 25Gy over 5 days (fractions) for their localized rectal cancer. Research bloods stool and tissue will be collected at three time points: Baseline, end of radiation therapy and at surgery.
89512940|NCT05943197|Experimental|20 patients with zirconia|patients who will receive crowns from zirconia
89512941|NCT05943197|Experimental|20 e-max patients|patients who will receive crowns from e-max
89512942|NCT05943197|Experimental|20 patients Cobalt-chromium alloy|patients who will receive crowns from Cobalt-chromium alloy
89512943|NCT05943197|Experimental|20 patients metal-ceramics|patients who will receive crowns from metal-ceramics
89512944|NCT05943184|No Intervention|Control group|
89512945|NCT05943184|Experimental|Observation group|
89512946|NCT05943171|Experimental|Digital RITch®CBT|(Digital RITch®CBT) is a Digital Avatar Assisted Interactive CBT Treatment
89512947|NCT05943171|Active Comparator|Standard CBT|Standard CBT is a human administered CBT Treatment
89512948|NCT05943158|Experimental|Myoinositol+folic acid group|This group is given myoinositol+folic acid (inofolic, ITF company, Italy) (myoinositol 4 gram+folic acid 400 micrograms)
89512949|NCT05943158|Experimental|Only folic acid group|This group is given only folic acid once a day (400 micrograms a day)
89512950|NCT05943132|Experimental|MISC-CBO|MISC-CBO is a year-long semi-structured, manualized video-feedback caregiver intervention that targets key components in caregiver-child interactions known to improve caregiving quality and child outcomes. These components include emotional and cognitive components shown to improve socio-emotional and cognitive developmental outcomes in children.
89512951|NCT05943132|Other|Treatment as Usual|TAU at CBOs include provision of meals, counselling services mostly focused on social support, financial assistance, and healthcare counseling - all which promote the mental health of OVC, but does not include a specific focus on caregiving quality.
89512952|NCT05943093||ALL patients|
89512953|NCT05943093||control group free from the disease|
89512954|NCT05942742||Cervical cancer|Patient treated with Linac MRI for their locally advanced cervical cancer
89512955|NCT05942729||Patients with hypokinetic cardiomyopathy.|The first arm includes patients with hypokinetic cardiomyopathy for whom echocardiographic data do not readily distinguish between a cause related to coronary artery disease or related to primary myocardial dysfunction, requiring invasive intervention, i.e., coronary angiography.
88960083|NCT05760677|Active Comparator|Pioglitazone group|All participants were treated with lifestyle intervention+ metformin(0.5g bid po)+ orlistat (0.12g bid po) (obese patients)+ pioglitazone (15mg qd po)
88960084|NCT05760677|Experimental|Chiglitazar group|All participants were treated with lifestyle intervention+ metformin(0.5g bid po)+ orlistat (0.12g bid po) (obese patients)+ Chiglitazar (32mg QD)
88960085|NCT05757453|Experimental|Experimental|MHealth group
88960086|NCT05756816|Experimental|SurePulse VS and VSP devices|All enrolled participants will undergo a controlled and stepwise reduction in oxygen blood levels, with both the SurePulse VS/SurePulse VSP placed on the volunteer.
88960087|NCT05744596||Incisura biopsy +|this arm has the incisura biopsy scored and added in the OLGA final stage
88960088|NCT05744596||Incisura biopsy -|this arm only has corpus and antrum biopsies scored for OLGA staging
88960089|NCT05733572|Experimental|active treatment group|active drug treatment group
88960090|NCT05733572|Placebo Comparator|placebo group|pacebo group
88960091|NCT05732207|Experimental|Cathodal cerebellar transcranial direct current stimulation (ctDCS)|For ctDCS, the cathodal (-) electrode will be positioned over the right cerebellum 1 cm below and 3 cm lateral to the inion, and the anodal (+) electrode will be placed on the contralateral supraorbital area (FP2 EEG location).
88960092|NCT05732207|Experimental|Anodal cerebellar transcranial direct current stimulation (atDCS)|For atDCS, anode/cathode locations are reversed from those of ctDCS..
88960093|NCT05732207|Sham Comparator|Sham cerebellar transcranial direct current stimulation (stDCS)|For stDCS, the electrodes will be configured randomly as atDCS 50% of the time, and as ctDCS 50% of the time.
88960094|NCT05731661|Experimental|Delivery of a Personalized Post-Cancer Plan (PPAC) with a day hospitalization in supportive care|
88960095|NCT05731661|Active Comparator|Delivery of a Personalized Post-Cancer Plan (PPAC) without day hospitalization in supportive care|
88960096|NCT05731661|Other|Observational cohort|
88960097|NCT05725031|Experimental|ER6|to receive rocuronium 0.6 mg/kg with ephedrine pretreatment
88960098|NCT05725031|Experimental|ER8|to receive rocuronium 0.8 mg/kg with ephedrine pretreatment
88960099|NCT05725031|Active Comparator|R12|to receive rocuronium 1.2 mg/kg with no pretreatment
88960100|NCT05724186|Experimental|Test myopia control lenses (CSL)|A pair of myopia control spectacle lenses (test lenses) will be given to subjects to wear for 12 months
88960101|NCT05718284|Experimental|HFNC|Administration of high flow nasal oxygen after extubation for 48 hours
88960102|NCT05718284|Other|STANDARD OXYGEN|Administration of oxygen through standard devices (nasal cannulae, venturi mask, none)
89512956|NCT05942729||Patients with left ventricular hypertrophy related to hypertension/infiltrative myocardial disease|The second arm includes patients with left ventricular hypertrophy, whose aetiology may be various and whose workup is particularly extensive and expensive.
88960103|NCT05716139|Active Comparator|Natural Cycle|In this,hCG trigger and Luteal Phase Support is monitored for the natural frozen embryo cycle procedure of IVF.
88960104|NCT05716139|Other|Artificial Cycle|In this, endometrial preparation and Luteal Phase Support is monitored for the artificial frozen embryo cycle procedure of IVF.
88960105|NCT05715333|Experimental|CM326 Low Dose|CM326 220 mg/2 mL or matched placebo, subcutaneous at low dose
88960106|NCT05715333|Experimental|CM326 Medium Dose|CM326 220mg/2 mL or matched placebo, subcutaneous at medium dose
88960107|NCT05715333|Experimental|CM326 High Dose|CM326 220mg/2mL or matched placebo, subcutaneous at high dose
88960108|NCT05715320|Experimental|Group A|CM310, subcutaneous
88960109|NCT05715320|Experimental|Group B|CM310, subcutaneous
88960110|NCT05707754|Active Comparator|High dose with unilateral administration|High dose (3ml) with unilateral administration of bupivacaine
88960111|NCT05707754|Active Comparator|High dose with bilateral administration|High dose (3ml) with bilateral administration of bupivacaine
89512957|NCT05941949|Experimental|Active|Softgel containing: Astaxanthin, Grape Juice Extract, and All Natural Vitamin E
89512958|NCT05941949|Placebo Comparator|Placebo|Softgel containing: Olive Oil and Sunflower Lecithin
89519499|NCT02193880|Other|Alpha-beta depleted T-cell infusion|Post-transplant alpha-beta depleted T-cell infusion after post-transplant cyclophosphamide.
88960112|NCT05707754|Active Comparator|Low dose with unilateral administration|Low dose (1ml) with unilateral administration of bupivacaine
88960113|NCT05707754|Active Comparator|Low dose with bilateral administration|Low dose (1ml) with bilateral administration of bupivacaine
88960114|NCT05707325|Experimental|Solid tumors after immunotherapy failure|In extension part， all patients will be administrated with recommend dose （WTX 212 IV infusion over 60 minutes on Day 1 of each cycle）confirmed by escalating part
88960115|NCT05707325|Experimental|Hematologic malignancies after immunotherapy failure|In extension part， all patients will be administrated with recommend dose （WTX 212 IV infusion over 60 minutes on Day 1 of each cycle）confirmed by escalating part
88960116|NCT05700760|Experimental|ROSE (Reach Out, Stay Strong, Essentials for mothers of newborns)|Evidence-based 5 session psychosocial intervention that has been found to prevent ~50% of postpartum depression among low-income, at risk women.
88960117|NCT05700760|Active Comparator|Enhanced Care as Usual (CAU)|Usual care at the study site does not include postpartum depression prevention. Instead, HFHS clinics try to screen for PPD that has already occurred and refer women for mental health care. Screening for existing PPD at these clinics primarily relies on the EPDS (10+), Perinatal women who score 10+ on the EPDS are referred for mental health services. Services received depends on follow-up, severity, and the mental health wait list. Our study will exclude women meeting criteria for likely current major depressive episode at baseline and assist them in obtaining mental health care. Enhanced CAU consists of usual care + monitoring and emergency referral, as is required to fulfill ethical obligations to trial participants.
88960118|NCT05699824|Experimental|Carvedilol at Day2 + Standard Medical Treatment|"Arm A- Carvedilol will be initiated on day 2, at a dose of 3.125mg twice a day (6.25mg/day), along with standard management as per institutional protocol for AVB.~All patients to receive Inj. Terlipressin, 1 mg at 4 hours along with standard management for acute variceal bleed as per institutional protocol"
89519500|NCT05321485|Experimental|MedicijnWijs|All participants will undergo the same intervention of using MedicijnWijs, and they will serve as their own control.
89519501|NCT05159219|Experimental|Oral Colchicine, 0.5mg once daily|Active colchicine tablet
88960119|NCT05699824|Active Comparator|Carvedilol at Day6 + Standard Medical Treatment|"Arm B- Carvedilol will be initiated on day 6, at a dose of 3.125mg twice a day (6.25mg/day), along with standard management as per institutional protocol for AVB.~All patients to receive Inj. Terlipressin, 1 mg at 4 hours along with standard management for acute variceal bleed as per institutional protocol"
88960120|NCT05699486|Experimental|Treatment with PDNO (placebo during baseline and washout observation periods before & after PDNO)|PDNO will be administered as an incremental intravenous infusion of respectively 15 minutes with the planned dosage: 3, 10, 30, 45 and 60 nmol/kg/min. If no effect on MPAP/PVR is seen at 60 nmol/kg/min in the first patients treated, further dose escalation up to 120 nmol/kg/min is possible, if recommended by the Internal Safety Review Committe (iSRC) following careful review of collected safety data. The iSRC will in any case review all collected data after 4, 8 and 12 patients (if applicable also after 16 and 20 patients). PDNO is administered together with a carrier buffer (NaHCO3-) flow into a central venous catheter. Placebo (NaCl, commercially available dilution solution for parenteral use, 9 mg/mL) will be administered during the baseline and washout observation periods before and after start of IMP infusion.
88960121|NCT05697679|Experimental|Usual management group|The intervention group is intervened with the TG
89512959|NCT05941260||Male patients above the age of 50|"All male patients aged 50 or more with benign prostatic hyperplasia who are scheduled for any planned endourological procedure will be included in our study.~Routine cystourethroscopy is a standard procedure in any endourological procedure, whatever the type of procedure.~With advanced imaging technology, it is possible through 3D scanning processes of analyzing photos and videos and digitally defining depth, to create 3D models of the tissues and channels, from endoscopy videos.~We are going to record this diagnostic cysto-urethroscopy of all patients, and we will send these videos for pre-processing and analysis by virtual computational reconstruction, so that an accurate model could be constructed with a digital model of the urethra geometry and a numerical model of the flow inside the urethra."
89512960|NCT05940636|Experimental|FES+TSCS (combined) neuromodulation group|For the combined neuromodulation with VFT group, the sub-motor threshold, open-loop TSCS will be coupled with closed-loop FES of ankle muscles during VFT. For this purpose, 2 electrical stimulators, one for each leg will stimulate SOL and TA muscles bilaterally while open-loop tonic lumbar TSCS will be applied at an intensity producing paresthesia in most of the lower-limb dermatomes
89512961|NCT05940636|Active Comparator|FES group|For the FES with VFT group, participants will receive visual feedback regarding their center of pressure location during four games with varying levels of difficulty and FES will be applied bilaterally to SOL and TA via a closed-loop system.
89512962|NCT05939622|Experimental|fMRI with subsequent injection of active drug (Ethyl methyl hydroxypyridine succinate + Meldonium)|Arm 1 (n=15) performed structural and functional MRI and received intramuscularly with the dosage regimen of 5 mL of solution (500 mg of ethyl methyl hydroxypyridine succinate + 500 mg of meldonium) once per day for 10 days
89512963|NCT05939622|Placebo Comparator|fMRI with subsequent injection of placebo|Arm 2 (n=15) performed structural and functional MRI and received Placebo in the same way.
89512964|NCT05939544|Experimental|Milk Fat Globule Membrane-enriched Powdered Ingredient|Participants will be provided with pre-weighed, foil sachets containing a ready-to-mix flavoured powdered supplement that is rich in milk fat globule membrane (and associated complex milk lipids). They will be asked to consume two sachets daily (mixed with water) during the 4-week study period. Sachets will be coded to maintain study blinding.
89512965|NCT05939544|Placebo Comparator|Control (Placebo) Powdered Ingredient|Participants will be provided with pre-weighed, foil sachets containing an energy- and macronutrient-matched ready-to-mix powdered placebo supplement that is devoid of milk fat globule membrane (and associated complex milk lipids). They will be asked to consume two sachets daily (mixed with water) during the 4-week study period. Sachets will be coded to maintain study blinding.
89512966|NCT05925699||All patients with new-onset cerebrovascular disease from January 1, 2016 to July 1, 2049|
89512967|NCT05922449|Experimental|Paravertebral block group (PV group)|This group of patients will undergo ultrasound-guided thoracic paravertebral nerve block in T4 and T7 thoracic paravertebral spaces before general anesthesia.
89512968|NCT05922449|No Intervention|Control group (C group)|This group of patients did not undergo any nerve block procedures before general anesthesia.
89512969|NCT05920213|Experimental|Lactulose AND LOLA|Lactulose which is the standard of care treatment will be administered with the experimental drug L-ornithine L-aspartate (LOLA).
89512970|NCT05920213|Experimental|Lactulose and PEG|Lactulose which is the standard of care treatment will be administered with the experimental drug polyethylene glycol (PEG).
89512971|NCT05920213|Active Comparator|Lactulose|This group will receive Lactulose only which is the standard of care treatment.
89512972|NCT05919056|Experimental|Intervention arm|The interventions include cardiovascular risk assessment, dynamic risk monitoring, and regular general practitioner (GP) visits. The frequency of risk assessment, risk monitoring, and automatic mobile texting will be once per month, while regular GP visits will be once per three months.
89512973|NCT05919056|No Intervention|Control arm|Current regular management (usual care) will be kept in the control arm. The management objectives are for patients with hypertension or diabetes mellitus. The frequency of follow-up is at least once per three months.
89512974|NCT05916118|Experimental|Exercise and Oxaliplatin-induced peripheral neuropathy|A single arm to evaluate the feasibility and acceptability of having patients exercise during oxaliplatin infusions in the infusion center. Arm will enroll patients receiving oxaliplatin-containing chemotherapy for gastrointestinal cancer or for cancer of unknown primary.
89512975|NCT05907005|Experimental|Intervention Group|Receive iCBT-based EMI with message content, delivery frequency and timing personalised to participants' preferences.
89512976|NCT05907005|No Intervention|Control Group|Receive general mental health information through instant message.
89512977|NCT05901714|Experimental|Part 1: Afimetoran followed by phenytoin + afimetoran|
89512978|NCT05901714|Experimental|Part 2: Midazolam followed by afimetoran + midazolam|
89512979|NCT05879510|Experimental|68Ga-NY104 PET/CT|Each patient will receive one dose of 68Ga-NY104 by intravenous route. Dedicated whole-body PET/CT imaging will be performed.
88960122|NCT05697679|Active Comparator|Goal-attainment-theory-based self-management group|The group is intervened with the CG
88960123|NCT05694767|Experimental|Intervention (CM313)|20 enrolled subjects: once a week x 8 doses
88960124|NCT05694637|Active Comparator|SBIRT|"Trained LHWs will oversee the screening and brief intervention procedures (i.e., the 5As). A culturally acceptable standardized form will be integrated into intake procedures within the HIV that will allow for the documentation and results of using the 5As. The first A will be the screening question where the LHW will Ask study participants about smoking. When a participant reports being a smoker, the LHW will proceed to the next 3 As (Advise, Assess, Assist). These 3As will constitute the brief intervention. The LHW will utilize motivational enhancing discussion between the study participant with a focus on increasing insight and awareness regarding smoking and motivation toward behavioral change. For those participants who are motivated for treatment, a referral will be made to a clinic nurse practitioner for evaluation for treatment with varenicline."
88960125|NCT05694637|No Intervention|Standard of Care|Trained LHWs will provide a brief motivation counseling and a brochure about smoking cessation.
88960126|NCT05687253|Experimental|BX1000 0.15 mg/kg|BX1000 0.15 mg/kg IV Bolus
88960127|NCT05687253|Experimental|BX1000 0.25 mg/kg|BX1000 0.25 mg/kg IV Bolus
88960128|NCT05687253|Experimental|BX1000 0.35 mg/kg|BX1000 0.35 mg/kg IV Bolus
88960129|NCT05687253|Active Comparator|Rocuronium 0.6 mg/kg|Rocuronium bromide 0.6 mg/kg IV Bolus
88960130|NCT05685264|Experimental|Ponsegromab low dose|
88960131|NCT05685264|Experimental|Ponsegromab high dose|
88960132|NCT05683821|Experimental|Enhanced outreach|Quarterly outreach via letter and applicable patient-preferred modalities, including e-mail and/or text messaging, offering both standard person-to-person treatment options (quitline referral, primary care provider referral, cessation counseling and treatment in a randomized clinical trial) and self-guided, remote treatment options (mailed nicotine replacement therapy samples and/or facilitated enrollment in a Smokefree.gov texting program). Patients in clinics assigned to this arm will also have the option to initiate treatment by phone or online. Patients may also receive outreach calls from Tobacco Care Managers offering the person-to-person treatments at their health systems 1-30 days following a visit to a participating clinic.
89024512|NCT03273348|Other|oncoplastic breast surgery|This study aim to evaluate the outcome on oncological side and patient satisfaction on the aesthetic side with skin-sparing mastectomy and immediate breast reconstruction for patients with early breast cancer .
89512980|NCT05879497|Experimental|68Ga-NY104 PET/CT|Each patient will receive one dose of 68Ga-NY104 by intravenous route. Dedicated whole-body PET/CT imaging will be performed.
89512981|NCT05876338|Experimental|CRCaSSM|CRCaSSM
89512982|NCT05876338|No Intervention|Control|
89512983|NCT05868707|Experimental|OH2|OH2: 10^7 CCID50/mL intratumoral injection, once every 2 weeks;
89512984|NCT05868707|Active Comparator|Salvage chemotherapy or best supportive care|Salvage chemotherapy (single or combined, including but not limited to dacarbazine, temozolomide, taxoid, or platinum) or best supportive care selected by the investigator
89512985|NCT05860283|Active Comparator|Core stabilization exercise group|Core muscle activation exercises will be done using the pressure biofeedback unit. The session will include visual, auditory & tactile biofeedback. Visual monitoring of the pressure gauge by the subjects during the exercise will be allowed and breath holding or compensatory movements will be avoided.
89512986|NCT05860283|Active Comparator|Diaphragmatic release group|The subjects will lay supine with relaxed limbs. Positioned at the head of the subjects, there will be manual contact with the pisiform, hypothenar region and the last three fingers bilaterally to the underside of the seventh to tenth rib costal cartilages, with the forearms aligned toward the subject's shoulders. In the inspiratory phase, a gentle pull will be given at the points of contact with both hands in the direction of the head and slightly laterally, accompanying the elevation of the ribs. During exhalation, a deepened contact will be given towards the inner costal margin, to resist the rebounding movement of the thoracic cage. In the subsequent respiratory cycles, there will be a progressive increase in the depth of contact inside the costal margin.
89512987|NCT05860283|No Intervention|Control group|The subjects in this group will receive traditional physical therapy program only.
89512988|NCT05857540|Experimental|Plyometric training group|Participants in this group will receive upper extremity plyometric training in body weight or with weight ball and strengthening exercises with band, dumbbell and barbell. The difficulty and intensity of the movement protocol will increase weekly. They will be trained 2 times per week for 6 weeks with an average duration of 50 min per session.
89512989|NCT05857540|Active Comparator|Strengthening training group|Participants in this group will receive upper extremity strengthening exercises with band, dumbbell and barbell. The intensity of the movement protocol will increase weekly. They will be trained 2 times per week for 6 weeks with an average duration of 50 min per session.
89512990|NCT05852249||Paper instruction|Participants in this group will use paper instructions to use Neutrocheck.
89512991|NCT05852249||App instruction|Participants in this group will use App instructions to use Neutrocheck.
89512992|NCT05838391|Experimental|Chemotherapy and Adaptive Radiation Treatment Planning|Subjects will receive concurrent chemotherapy and radiation as part of their treatment for anal cancer. Subjects will receive standard of care 54 Gy of radiation, 5 days a week for 6 weeks. In addition, subjects will receive standard of care chemotherapy, with mitomycin C (10mg/meters squared IV on Day 1) and 5-Fluorouracil (1000mg/meters squared via IV on days 1-4 and 29-32) or capecitabine (825 mg/meters squared in two divided doses by mouth on days of radiotherapy).
89512993|NCT05833230|Experimental|Individuals who use cannabis|Participants who are non-treatment seeking cannabis users (30 men, 30 women) ranging from once weekly use to multiple times daily. All participants will be recruited from the greater New Haven community and will complete four weeks of smartphone monitoring. During this monitoring period, they will also complete two three-consecutive days of intensive monitoring including more frequent smartphone surveys, saliva samples, heart rate monitoring, and an alcohol use monitor.
89512994|NCT05831618|Experimental|Interactive Visuo-Vestibular training|"Interactive Visuo-Vestibular training consists of exercises that stimulate saccadic movements during motor activities on the treadmill. Furthermore, a dynamic blindfolded training will be performed with the support and supervision of the physiotherapist.~Patients will perform 5 sessions, 1 session per week."
89512995|NCT05831618|Active Comparator|Vestibular rehabilitation training|"The conventional vestibular rehabilitation training will train the vestibular reflexes.~Patients will perform 5 sessions, 1 session per week."
89512996|NCT05815030|Experimental|Group A|experimental group, receiving 3 exposures to the kink-focused video intervention
89024513|NCT00432068|Experimental|Octreotide pamoate|
89024514|NCT03273309|Active Comparator|Vibratory Perineal Stimulus|It's thought that the vibratory perineal stimulation can produces afferent nerve impulses that goes to the sacral spinal cord (S2-S4) via the pudendal nerve and stimulates the sacral somatic response which will cause the pelvic muscle contraction.
89512997|NCT05815030|Other|Group B|control group, receiving no exposure to the kink-focused video, but seeing the generic / standard video
89512998|NCT05815030|Other|Group C|group that receives 1 exposure to the generic / standard video, and later 2 exposures to the kink-focused video
89512999|NCT05815030|Other|Group D|group that receives 2 exposures to the generic / standard video, and later 1 exposure to the kink-focused video
89513000|NCT05814900|Experimental|TPFM imaging of surgical margins|Patients will be imaged with TPFM
89513001|NCT05810272|Other|Habitual Activity|Following three days of habitual activity, a metabolic trial will be completed wherein participants (10M/10F) will be assessed for their anabolic response to a protein-carbohydrate meal.
89513002|NCT05810272|Experimental|Step-Reduction|Participants will undergo three days of reduced physical activity (<1,500 steps/day) prior to a metabolic trial to establish their anabolic response to a protein-carbohydrate meal.
89513003|NCT05801679|Experimental|Sugammadex|Single intravenous (IV) bolus of sugammadex at 2 mg/kg (Twitch count 2-4 of 4) or 4 mg/kg (twitch count less than 2 of 4).
89513004|NCT05801679|Placebo Comparator|Placebo|Single intravenous (IV) bolus of Placebo at 2 mg/kg (Twitch count 2-4 of 4) or 4 mg/kg (twitch count less than 2 of 4).
89513005|NCT05798806||Patients with diagnosis of cN+ breast cancer who underwent neoadjuvant treatment|Patients with diagnosis of cN+ breast cancer who underwent neoadjuvant treatment and then treated with lymph node biopsy or axillary lymphadenectomy
89513006|NCT05797259|Experimental|Danosumab|Danosumab 60mg subcutaneous once at diagnosis
89513007|NCT05797259|Placebo Comparator|Placebo|Similar Volume, and consistency placebo (Normal Saline) subcutaneous once at diagnosis
89513008|NCT05771714|Experimental|individuals ages 14 years and older|This kit is intended for non-prescription home use with self-collected direct anterior nares swab samples from individuals ages 14 years and older.
89513009|NCT05771714|Experimental|individuals aged 2 to 13 years|"This kit is intended for non-prescription home use with self-collected direct anterior nares swab samples.~If the subject is under the age of 14, an adult lay-user will collect the sample."
89513010|NCT05768360|Experimental|Drug cocktail/Savolitinib + Drug cocktail|Subjects will receive two different interventions in two periods (Periods 1 and 2). In Period 1, the subjects will receive a single-dose of Drug cocktail components (digoxin Dose B, furosemide Dose C, metformin hydrochloride Dose D, and rosuvastatin Dose E). During Period 2, the subjects will receive savolitinib dose A in combination with the Drug cocktail components.
89513011|NCT05765123||Healthy adults|Healthy male and female participants
89513012|NCT05764213|No Intervention|Screening Brief Intervention & Referral to Treatment (SBIRT)|This group will receive in-person screening and referral to treatment assessment.
89513013|NCT05764213|Experimental|Listening to Women & Pregnant & Postpartum People (LTWP)|This group will receive text-message-based SBIRT with phone-based assessment and referral to treatment. The SBIRT is a survey with 9 questions related to depression, anxiety, substance abuse (alcohol, cigarettes, and other drugs including prescription medication), and domestic violence.
89513014|NCT05756972|Experimental|PM8002+Chemotherapy|Subjects will be administered with PM8002 plus pemetrexed and carboplatin via intravenously (IV) Q3W for 4 cycles, followed by PM8002 and pemetrexed until progression or for a maximum of 2 years.
89513015|NCT05756972|Experimental|Placebo+Chemotherapy|Subjects will be administered with placebo plus pemetrexed and carboplatin via intravenously (IV) Q3W for 4 cycles, followed by placebo and pemetrexed until progression or for a maximum of 2 years.
89513016|NCT05755295|Experimental|horse therapy|
89519502|NCT05159219|Placebo Comparator|Oral matching placebo, once daily|Matching placebo tablet
89519503|NCT03590899||Healthy patients|Healthy volunteers without retinal disease, glaucoma, previous ocular surgery, laser photocoagulation, or optical media opacities that would disturb imaging.
89519504|NCT04453943|Experimental|Group A - SCI|Ten individuals with SCI at the T1-T10 level will be recruited (Group A). These individuals can have incomplete or complete paraplegia.
88811970|NCT00828074|Experimental|Treatment (vinorelbine tartrate and sorafenib tosylate)|Patients receive sorafenib tosylate PO twice daily on days 1-28 and vinorelbine ditartrate IV on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88811971|NCT01394003|Experimental|LY2584702|"Oral dose escalation starting at 25 milligrams (mg), daily for 28 day cycles in Part A; oral dose escalation starting at 50 mg, twice daily for 28 day cycles in Part B; oral dose with schedule determined by Parts A and B will be administered in Part C (dose confirmation).~Part A: Participants received 25 mg, 50 mg, 100 mg and 200 mg once daily (QD) and 300 mg twice daily (BID) of LY2584702 capsule, for a 28-day cycle during Part A of the study until the criteria for maximum tolerated dose (MTD) were met.~Part B: Participants received 50 mg, 75 mg and 100 mg LY2584702 orally as a capsule, twice daily (BID) for a 28-day cycle during Part B of the study until the criteria for maximum tolerated dose (MTD) were met."
88811972|NCT03434444|Active Comparator|Low Dose Oxytocin|The myometrial samples are bathed in an oxytocin solution at increasing concentrations (from 10 -12M to 10 -9M)
88811973|NCT03434444|Active Comparator|Propranolol|The myometrial samples are bathed in a propranol solution at 10 -6M
88811974|NCT03434444|Active Comparator|Propranolol + low dose oxytocin|The myometrial samples are bathed in an oxytocin solution at increasing concentrations (from 10 -12M to 10 -9M) plus propranol (10 -6M)
88811975|NCT03434444|Active Comparator|High Dose Oxytocin|The myometrial samples are bathed in an oxytocin solution (10 -5M), followed by increasing concentrations of oxytocin (from 10 -8M to 10 -5M)
88811976|NCT03434444|Active Comparator|High Dose Oxytocin, Propranolol-pretreated|The myometrial samples are bathed in an oxytocin solution (10 -5M) plus propranolol (10 -6M), followed by increasing concentrations of oxytocin (from 10 -8M to 10 -5M)
88811977|NCT03434444|Active Comparator|High dose oxytocin + propranolol|The myometrial samples are bathed in an oxytocin solution (10 -5M), followed by increasing concentrations of oxytocin (from 10 -8M to 10 -5M) plus propranolol (10 -6M)
89513017|NCT05743478|Experimental|Forging Hopeful Futures|Forging Hopeful Futures uses a group discussion format with activities that explore race, gender, class, identity, relationships, and multiple forms of violence. Forging Hopeful Futures is a 12 session curriculum for youth ages 14-19 that uses strengths-based and healing-centered approaches to critically examine structural forces that perpetuate racial and gender injustice, develop leadership skills in promoting gender equitable relationship norms, non-violent practices, and upstander skills, and enhance economic justice through job skills and employment opportunities. Through 12 sessions (3 hours/session) over a 6 to 12 week period, Forging Hopeful Futures combines racial, gender, and economic justice content with leadership development and workforce development opportunities.
89513018|NCT05743478|Active Comparator|Wellness Check-ins|Youth in neighborhoods randomized to the control group will receive individual wellness checks. This will occur through a strengths-based telephone conversation focused on wellness resources. Youth will be provided with tailored resources based on needs identified during the call. Youth will be offered the option for additional phone check-ins to coordinate access to community resources and connection to individualized behavioral health supports if desired.
89513019|NCT05708950|Experimental|KVA12123 Monotherapy Dose Escalation|Part A will consist of dose escalation with KVA12123 administered as a single agent in participants with advanced solid tumors.
89513020|NCT05708950|Experimental|KVA12123 Plus Pembrolizumab Dose Escalation|Part B will consist of dose escalation with KVA12123 administered in combination with a fixed dose of pembrolizumab.
89024515|NCT03273309|Active Comparator|Transvaginal Electrical Stimulation|Transvaginal electrical stimulation can produces direct and reflex responses of the pelvic floor muscles, being more effective in patients who can't voluntarily contract this musculature. In addition, it increases blood flow to the muscles, restores neuromuscular connections and improves muscle fiber function.
89513021|NCT05708950|Experimental|KVA12123 Monotherapy Dose Expansion|Part C will consist of dose expansion with KVA12123 administered as a single agent at the RP2D in participants with advanced solid tumors.
89513022|NCT05708950|Experimental|KVA12123 Plus Pembrolizumab Dose Expansion|Part D will consist of dose expansion with KVA12123 administered at the RP2D in combination with a fixed dose of pembrolizumab.
89513023|NCT05689827|Experimental|Ethyl methyl hydroxypyridine succinate + Meldonium|Arm 1 (n=80) received intramuscularly with the dosage regimen of 5 mL of solution (500 mg of ethyl methyl hydroxypyridine succinate + 500 mg of meldonium) once per day for 10 days; total number of injections for the treatment course is 10 and then orally with the dosage regimen of 2 capsules (500 mg of ethyl methyl hydroxypyridine succinate + 500 mg of meldonium) twice per day for 30 days; total number of capsules for the treatment course is 120. Second group received Placebo in the same way.
89513024|NCT05689827|Placebo Comparator|Placebo|Arm 2 (n=80) received Placebo in the same way.
89513025|NCT05680675|Experimental|Arm 1|Single-Tracer FDG (F18 Fluorodeoxyglucose) PET/CT exam + Single-Tracer Cu64-DOTATATE PET/CT
89513026|NCT05680675|Experimental|Arm 2|Single-Tracer FDG PET/CT exam + Single-Tracer Ga68-DOTATATE PET/CT exam
89513027|NCT05680675|Experimental|Arm 3|Single-Tracer FDG PET/CT exam + Single-Tracer PSMA (prostate-specific membrane antigen) PET/CT exam
89513028|NCT05651776|Experimental|Intervention of golf and rehab|2x/week x 6 weeks participation in a golf and PD rehab program
89513029|NCT05642884|Experimental|Teleprehab|The participants selected for the teleprehab arm will undergo a supervised 8-week multi-modal exercise program in a telehealth format (using doxy.me, a free telehealth platform) delivered by licensed physical or occupational therapists who have undergone cancer specific rehabilitation training within Select Medical's ReVital® cancer rehabilitation program. Participants will attend teleprehab sessions 2 times per week for a total of 16 sessions.
89513030|NCT05642884|Other|Attention Control|The participants randomized to the attention control arm will not undergo an exercise regimen, but will be contacted by the study staff on the phone once a week..
89513031|NCT05641155|Experimental|Adult Cochlear implant|Adult cochlear implant recipients receiving different combinations of alternative modes and, sound coding parameters
89513032|NCT05640076||2018-19 - Oncologic patients under home palliative care|Oncologic patients took over from the Metropolitan Palliative Care Service and receiving home palliative care within their last 90 days of life between 1/1/2018 and 31/12/2019
89513033|NCT05640076||2018-19 - Non-oncologic patients under home palliative care|Non-oncologic patients took over from the Metropolitan Palliative Care Service and receiving home palliative care within their last 90 days of life between 1/1/2018 and 31/12/2019
89513034|NCT05640076||2021-2022 - Oncologic patients under home palliative care|Oncologic patients took over from the Metropolitan Palliative Care Service and receiving home palliative care within their last 90 days of life between 1/1/2021 and 31/12/2022
89513035|NCT05640076||2021-2022 - Non-Oncologic patients under home palliative care|Non-oncologic patients took over from the Metropolitan Palliative Care Service and receiving home palliative care within their last 90 days of life between 1/1/2021 and 31/12/2022
89513036|NCT05624528|Experimental|Tolcapone|100mg of tolcapone twice daily for two weeks, then 200mg tolcapone twice daily for the remaining six weeks.
89513037|NCT05624528|Placebo Comparator|Placebo|100mg of placebo twice daily for two weeks, then 200mg of placebo twice daily for the remaining six weeks.
89513038|NCT05607290|Other|Treatment|Empirical supported psychotherapy for alcohol use disorder (Cognitive-Behavioral Therapy, Motivational Interviewing).
89513039|NCT05602818|Experimental|Soticlestat 300 mg|Participants will receive a single oral dose of soticlestat 300 milligrams (mg).
89513040|NCT05602818|Experimental|Soticlestat 600 mg|Participants will receive a single oral dose of soticlestat 600 mg.
89513041|NCT05602818|Experimental|Soticlestat 900 mg|Participants will receive a single oral dose of soticlestat 900 mg.
88811978|NCT04382300|Experimental|Treatment arm|pyrotinib 400mg p.o. qd, combined with thalidomide 200mg p.o. qd
88811979|NCT01394081|Experimental|Enhanced Engagement and Enrollment (EEE)|Enhanced Engagement and Enrollment (EEE) consists of the outreach worker (interventionalist) engaging the participant in education (about VA resources and medical care), navigating the patient through the VA eligibility, enrollment, and scheduling processes, and using motivational interview to focus on ambivalence about attending a VA appointment.
89513042|NCT05602818|Active Comparator|Alprazolam 2 mg|Participants will receive a single oral dose of over encapsulated alprazolam 2 mg.
89513043|NCT05602818|Placebo Comparator|Placebo|Participants will receive a single oral dose of matching placebo.
89024516|NCT00432107|Experimental|2-stage mono therapy of APO866|The treatment period consists of 3 consecutive 28 day cycles. Each cycle starts with a 4 day continuous infusion of the study medication followed by a 24 day break
89513044|NCT05599581|Experimental|Tu'Washindi intervention plus usual HIV prevention services|Participants in the intervention wards will receive the Tu'Washindi intervention plus access to evidence-based HIV prevention services offered throughout the county. These include PrEP delivery through ministry of health, which is accessible to all AGYW.
89513045|NCT05599581|No Intervention|Standard of care HIV (Usual) prevention services only|Participants in the non-intervention (control) wards will have access to evidence-based standard of care HIV prevention services offered throughout the county. These include PrEP delivery through Ministry of Health facilities, which is accessible to all AGYW.
89513046|NCT05594485||Retrospective collection of DICOM patient files for the period 15-17 August|To collect the CXR data for retrospective study, we addressed a municipal hospital in the Czech Republic that provides healthcare services to up to 130,000 residents of a medium-sized city (approximately 70,000 inhabitants) and the surrounding area. 127 anonymized CXR images were collected between August 15 and 17, 2022, and subsequently submitted to five independent radiologists of varying experience for annotation. The selected radiologists were asked to assess whether the CXR image shows any of the 12 abnormalities mentioned above. Pediatric CXR images (under 18 years of age), scans with technical problems (poor image quality, rotation), and images in lateral projection were excluded from the dataset.
89513047|NCT05588622|Experimental|Treatment Group|This single-arm study will enroll all 20 participants in the Meru Health Program.
89513048|NCT05579561|Experimental|Vegetarian ketogenic diet|Participants will be required to eat a diet that is very low in carbohydrates, moderate in vegetarian proteins, including fish and eggs, with added healthy fats
89513049|NCT05579561|Active Comparator|Omnivor ketogenic diet|Participants will be required to eat a diet that is very low in carbohydrates, moderate in animal protein, with added healthy fats.
89513050|NCT05574842|Experimental|Intervention|The intervention arm will be received the double duty intervention through nutrition behavior change communication approach using a Health Belief Model.
89513051|NCT05574842|No Intervention|Control|The control arm will not be received the double duty intervention, rather they receive the standard intervention given by the government.
89513052|NCT05568407||Patients with Advanced or Metastatic Urothelial Cancer|Patients with Advanced or Metastatic Urothelial Cancer
89513053|NCT05558514|Experimental|Place-based map|CIs will be mapped according to each participant's unique place-based map using MED-EL MAESTRO fitting software. Participants' audiological performance will be assessed in both the experimental and default programs at activation and at 6 months. At 1-month and 3-month visits, performance will be assessed in the participant's assigned program only. Following the 6-month testing interval, participants will listen to the alternative map than the one they were assigned for 1 additional month. At the 7-month visit, participants will be assessed in both programs. After the 7-month visit, participants will be given the choice to move forward with whichever map they prefer. The final assessment interval will take place at 1-year in the participant's chosen map.
89513054|NCT05558514|Active Comparator|Default map|CIs will be mapped according to the clinical default program using MED-EL MAESTRO fitting software. Participants' audiological performance will be assessed in both the experimental and default programs at activation and at 6 months. At 1-month and 3-month visits, performance will be assessed in the participant's assigned program only. Following the 6-month testing interval, participants will listen to the alternative map for 1 additional month from the one they were randomly assigned. At the 7-month visit, participants will be assessed in both programs. After the 7-month visit, participants will be given the choice to move forward with whichever map they prefer. The final assessment interval will take place at 1-year in the participant's chosen map.
89513055|NCT05553340|Experimental|Technology Educational|The intervention will be carried out by nurses and will consist of a virtual educational action through a massive, open and online course (MOOC) that seeks to equip the family caregiver to assist the elderly at home in care, such as hygiene, feeding, positioning and transfer, based on in the Guidance Manual for Family Caregivers of Elderly People with Stroke. A hotline will also be available for participants to contact if they have any questions.
89513056|NCT05553340|No Intervention|Usual|Control group participants will receive initial and final assessments, but will not have access to the course.
89513057|NCT05525780|Experimental|GB-5001|GB-5001 Suspension for intramuscular (IM) injection at three doses
89513058|NCT05525780|Placebo Comparator|Placebo|Placebo Suspension for intramuscular (IM) injection, Volume to be matched with the active drug in the respective cohort
89513059|NCT05525780|Active Comparator|Oral cohort|Aricept® tablet
89513060|NCT05511454|Experimental|Group of patients with periodontitis (cases)|Patients with periodontitis according to the Chicago 2018 classification criteria
89513061|NCT05511454|Other|Control group|Patients with periodontal health according to the 2018 Chicago Classification
89513062|NCT05511012|Other|motion control fault testing|"Each patient make six motion control fault tests in the same order :~waiters bow~pelvic tilt~one leg stance~sitting knee extension~rocking 4 point kneeling~prone knee bend~This tests are performed three times."
89513063|NCT05507866|Experimental|CSNEI|Schools randomized to receive the CSNEI intervention arm will receive help in addressing childhood obesity by modifying meal/menu items, changing school cafeteria environments, and making changes to purchasing and procurement practices.
89513064|NCT05507866|No Intervention|Control|Schools randomized to the control arm will follow their existing nutritional practices.
89513065|NCT05479201||Children 4-8 years of age|
89513066|NCT05479019|Experimental|Positive stimuli|Images/trials that contain a target
89513067|NCT05479019|Experimental|Negative stimuli|Images/trials that do not contain a target
89513068|NCT05472558|Experimental|CB CAR-NK019|All subjects were intravenously administrated with CAR-NK019
89513069|NCT05458830|Experimental|Intervention|After selecting a barrier in the barrier survey, participants receive tailored information with the purpose of addressing common concerns and misconceptions about the helpline.
89513070|NCT05458830|Other|Care as usual|Plain advisory text
89513071|NCT05452915||Chronic Pain|Patients with chronic pain, aged 18 - 50 years for the neuropsychological assessment and 18-45 years for the fMRI examination
89513072|NCT05452915||Healthy Controls|Healthy controls matched on group level in terms of gender, age, and educational level
89541061|NCT05159869|Experimental|Experimental|After participants are recruited, participants will undergo neuropsychological testing prior to randomization in order to establish baseline cognitive functioning and verify that the participants are indeed in the early stages of dementia. Persons randomized to the User-Led Meaningful Activity intervention group will begin the treatment protocol right after randomization. The intervention will consist of 3-4 sessions lasting 60-90 minutes each in which participants receive feedback from the neuropsychological assessment, identify the basis/topic of the activity plan, receive dementia psychoeducation, and map out an activity gradation plan. A brief cognitive screening tool will be re-administered at six months and 12 months. The neuropsychological battery that was administered at baseline will be re-administered 12 months later. Follow-up will also involve solicitation of feedback from the person with dementia and his or her caregiver regarding participants' participation in the study.
89541062|NCT05159869|Active Comparator|Wait-List Control|"After participants are recruited, participants will undergo neuropsychological testing prior to randomization in order to establish baseline cognitive functioning and verify that the participants are indeed in the early stages of dementia (i.e., mild dementia). Those who meet criteria will be randomly assigned. Persons randomized to the wait-list control group will begin the treatment protocol after four months' time."
89541063|NCT05155033|Experimental|1 - Pembro and IL-2|Course 1: pembrolizumab (200 mg IV) on Day 1 of each cycle with aldesleukin (600,000 IU/kg intravenous bolus every eight hours) continuing for up to 4 days (maximum 10 doses) for 2 cycles (each 21 days). Course 2: pembrolizumab (200 mg IV) on Day 1 of each cycle for 2 cycles (each 21 days).
89541064|NCT05144724|Experimental|Volume Targeted Ventilation|Positive pressure ventilation will be provided using a set tidal volume
89541065|NCT05144724|Active Comparator|Pressure guided Ventilation|Positive pressure ventilation will be provided using a set peak inflation pressure
88960133|NCT05683821|Active Comparator|Standard outreach|One mailed letter at study initiation outlining available person-to-person treatment options (quitline referral, primary care provider referral, cessation counseling and treatment in a randomized clinical trial) and how to initiate treatment by phone. Patients may also receive outreach calls from Tobacco Care Managers offering the person-to-person treatments at their health systems 1-30 days following a visit to a participating clinic.
88960134|NCT05680805|Experimental|PCOS|Participants with PCOS
88960135|NCT05671445|Experimental|CM326|CM326 injection, subcutaneous (SC)
88960136|NCT05669157|Experimental|Current practice: radiography request by physician|No interventions will be performed. There is no change in current practice.
88960137|NCT05669157|Experimental|Radiography request by the nurse|the intake and referral nurse will request a radiography if required according to the local cooperation protocol
88960138|NCT05667623|Experimental|1% OPA-15406 Ointment|The 1% formulation of OPA-15406 ointment will be administered twice-daily (approximately 12 hours apart between morning and night administration) for 4 weeks/24 weeks. The amount of IMP (g) per dose is 10 g/m2 BSA and calculated.
88960139|NCT05667623|Placebo Comparator|0% OPA-15406 Vehicle|The vehicle of OPA-15406 vehicle will be administered twice-daily (approximately 12 hours apart between morning and night administration) for 4 weeks/24 weeks. The amount of IMP (g) per dose is 10 g/m2 BSA and calculated.
88960140|NCT05665764||Veterans|Veterans will be the primary cohort for this study. Veterans who will be enrolled with have current insomnia and a history of traumatic brain injury.
88960141|NCT05665764||Caregivers|Caregivers of enrolled veterans will be an optional cohort for this study. If applicable and willing to participate, caregivers of enrolled Veterans will be asked to provide collateral information regarding the Veteran's experience with the study.
88960142|NCT05661968|Experimental|Online educational program|A 6-week educational program delivered online based on information and recommendations from international clinical practice guidelines for the management of back pain.
88960143|NCT05661968|No Intervention|Control group|The control group will receive no intervention and will be instructed to follow their clinical practice normally.
88960144|NCT05658796|Active Comparator|Control|No intervention (No RxWell). Subjects will receive standard of care and education regarding potential resources for anxiety and depression. Subjects will complete questionnaires via REDCap assessing primary and secondary outcomes
88960145|NCT05658796|Experimental|Intervention: RxWell|RxWell Intervention. Subjects will receive standard of care and digital cognitive behavioral intervention by using the application RxWell. Subjects will complete questionnaires via REDCap assessing primary and secondary outcomes and will complete GAD-7 (Generalized Anxiety Disorder Scale) and PHQ-8 (Patient Health Questionnaire for Depression) every 2 weeks within the RxWell application.
88960146|NCT05658796|No Intervention|Control (screen failures)|We will collect data on patient outcomes for patients that did not meet criteria for the RxWell intervention.
88960147|NCT05650528|Experimental|Part A|Five ascending dose levels (Cohort A1、Cohort A2、Cohort A3、Cohort A4 and Cohort A5) of SAD QG101-23-0 capsules (n=6) or placebo (n=2)
88960148|NCT05650528|Experimental|Part B|Three ascending dose levels (Cohort B1、Cohort B2、Cohort B3) of MAD QG101-23-0 capsules (n=6) or placebo (n=2)
89210538|NCT00816218|Experimental|Pioglitazone|Fifty type 2 diabetic patients (25 diet-treated and 25 treated with diet plus sulfonylurea) will have pioglitazone, 45 mg daily; added to their therapeutic regimen. All patients will be closely monitored and, in addition to periodic contacts and clinical visits, metabolic and vascular parameters will be assessed at the beginning and after 3 and 6 months of therapy. Euglycemic hyperinsulinemic clamp with muscle biopsies will be performed at the beginning and after 6 months of treatment.
88960149|NCT05650528|Experimental|Part C|Cohort A3 Group 1 (n=8) and Group 2 (n=6) will participate in the food effect study. The subjects will take QG101-23-0 capsules while under fasting or fed condition.
88960150|NCT05638282|Experimental|Cendakimab|
88960151|NCT05638282|Placebo Comparator|Placebo|
88960152|NCT05637970|Active Comparator|Perclose Only|Patients will have a PercloseTM device deployed at the arteriotomy. Manual pressure will be held for at least five minute, the beginning of which will correspond to time point zero. Patent hemostasis will be documented after device deployment. Any manual compression needed or per protocol under the disgression of the operator will count towards the time to hemostasis. After hemostasis is achieved in the cath lab the patient will be sent to the post-operative area for monitoring. If any additional bleeding is appreciated, manual compression will again be held. If any new bleeding from the puncture site or under the skin the patient will again lay supine and at least 10 minutes of manual pressure will be held. This will be continued until the patient has no bleeding.
89024517|NCT03273231|Experimental|ketamine group|Ketamine is administered intravenously with a loading dose of 0.25 mg/kg at 5 minutes before surgery, followed by an infusion rate of 0.05 mg/kg/h to the end of surgery.
89024518|NCT03273231|Placebo Comparator|control group|0.9% saline solution
89513073|NCT05452876|Experimental|ABCp|The patient sees MD that follows ABCp, patient then enrolls in ABCp intervention based on MD's categorization of low back pain.
89513074|NCT05452876|Active Comparator|Usual Care|"The patient receives usual care at the clinical site."
89513075|NCT05430399|Experimental|Arm A|utidelone
89513076|NCT05430399|Active Comparator|Arm B|docetaxel
89513077|NCT05422300|Experimental|Mid-Follicular Phase|7-10 days after the onset of menses, determined by self-reports and confirmed with ovulation test kits.
89513078|NCT05422300|Experimental|Mid-Luteal Phase|5-7 days after ovulation, determined by self-reports and confirmed with ovulation test kits.
89513079|NCT05398601|Active Comparator|MOBILIZATION WITH MOVEMENT|"MOBILIZATION with MOVEMENT~TENS, MWM techniques for Knee"
89513080|NCT05398601|Experimental|periosteal electrical dry needling|TENS, periosteal electrical dry needling 4 point technique for Knee
89513081|NCT05397171|Experimental|Substudy 1 - Parts A, B, and C|"Part A: AZD8853 monotherapy dose escalation~Part B1 and Part B2: AZD8853 monotherapy safety expansion at dose levels and indications determined to be safe in Part A~Part C1 and Part C2: AZD8853 monotherapy safety and preliminary efficacy expansion at dose levels and indications determined to be safe in Parts A and B"
89513082|NCT05397171|Experimental|Substudy 1 - Parts B1 and B2 with CD8+ PET|Sub-set of participants from Parts B1 and B2 will also receive investigational CD8+ T cell targeted radioactive tracer, Zirconium-89 crefmirlimab berdoxam with PET scans
89513083|NCT05386888|Experimental|treatment|GFH018 80mg 7-Day on/ 7-Day off and 4 doses of Toripalimab 240mg Q3W concurrently with standard chemo-radiotherapy, followed by GFH018 80mg 14-Day on/ 14-Day off and Toripalimab 3mg/kg Q2W for up to 48 weeks
89541066|NCT05144399|Experimental|Accelerated antibiotic treatment|Patients are treated shorter than usual
89024519|NCT00462891|Experimental|IT System|IT system to send reminder letters to patients overdue for breast cancer screening.
89024520|NCT00462891|No Intervention|Usual Care|
89024521|NCT00462969|Experimental|1|pre-surgical SHG
88960153|NCT05637970|Experimental|Perclose with Statseal Device|Patients will have a PercloseTM device deployed at the arteriotomy. A Statseal disc will applied and manual pressure will be held for at least five minute, the beginning of which will correspond to time point zero. Patent hemostasis will be documented after device deployment. Any manual compression needed or per protocol under the disgression of the operator will count towards the time to hemostasis. After hemostasis is achieved in the cath lab the patient will be sent to the post-operative area for monitoring. If any additional bleeding is appreciated, manual compression will again be held. If any new bleeding from the puncture site or under the skin the patient will again lay supine and at least 10 minutes of manual pressure will be held. This will be continued until the patient has no bleeding.
88960154|NCT05634200||Patients with haemoptysis and negative/non-diagnostic CT scan|Patients with haemoptysis and negative/non-diagnostic CT scan (i.e. with focal peripheral lung fibrosis, calcified parenchymal nodules with a maximum diameter <5 mm, linear subsegmental atelectasis, hilar-mediastinal lymph nodes with a short axis <1 cm, pleural thickening/pleural calcification and focal area of emphysema with a diameter <1 cm) for whom bronchoscopy is deemed necessary to obtain an aetiological diagnosis.
88960155|NCT05630716|Experimental|Non-Invasive Cardiac Output Monitor (NICOM)|adult inpatients with sepsis associated with acute hypotension and/or evidence of septic shock
88960156|NCT05619536|Experimental|Cohort 1|9 subjects randomized in a 7:2 ratio to receive either 50 mg CD388 SQ injection or matching placebo injection
89513084|NCT05382897|Experimental|Fasting-Mimicking Diet|Participants will be followed for 3 weeks for baseline assessment and then consume a plant-based fasting-mimicking diet for 5 days once a month for 3 months.
89513085|NCT05382897|Experimental|Caloric-Sufficient Diet|Participants will be followed for 3 weeks for baseline assessment and then consume a plant-based caloric-sufficient diet for 5 days once a month for 3 months.
89513086|NCT05358795|Experimental|Family Connections Intervention Arm|The intervention group sessions aim to 1) improve understanding of HIV among AYA and caregivers; 2) help AYA develop strategies for healthy living (e.g. ART adherence); 3) build AYA capacity to make informed decisions about their sexual and reproductive health; 4) build the capacity of caregivers to support AYA; and 5) help AYA develop life skills to communicate their HIV diagnosis effectively and to plan for their futures. Participants attend group sessions, with caregivers and AYA typically separated for sessions and then brought together sometimes during and sometimes at the end of the sessions, to share information and skills learned. The in-person group intervention will be held twice per month over a period of an estimated 6 months for a total of 10 sessions. Trained facilitators will deliver the intervention at the clinics. Health clinic staff will be available as technical experts to answer clinical questions.
89513087|NCT05358795|No Intervention|Standard of Care Comparison|The control group will receive the standard of care during the study for AYA living with HIV in these public health care facilities and communities. The 20 facilities included in the research have been trained to operate under the standard protocols endorsed by the Zambia Ministry of Health. There can be variations in how these standards are adhered to and if special programming is provided for youth, such as youth group meetings and special youth clinic hours. Standard of care services per the 2020 Zambia Consolidated Guidelines include routine clinical care for HIV treatment including laboratory testing (CD4, VL tests); adherence counseling, with enhanced adherence counseling for clients with unsuppressed viral loads; multi-month dispensing of ART including differentiated service delivery for stable clients; screening and treatment of sexually transmitted infections (STIs); prevention and screening for opportunistic infections; and clinical monitoring of kidney and liver function.
89513088|NCT05358132||ARM-ED group 1 - Acute toxicity group|Patients attending the Emergency Department with acute sedating drug toxicity
89513089|NCT05358132||ARM-ED group 2 - PSA group|Patients undergoing procedural sedation and analgaesia in the Emergency Department
89513090|NCT05354674||ARM A|Chemotherapy regimens are determined based on the clinical experience of specialists
89513091|NCT05354674||ARM B|Chemotherapy regimens are determined based on the multimodal deep learning signature
89513092|NCT05351424|Experimental|Audiovisual Intervention- Radiation Therapy Education|Audiovisual video will be provided to the subjects as educational material.
89513093|NCT05351424|Active Comparator|Written Brochure- Radiation Therapy Education|Written brochures will be provided to the subjects as educational material.
89513094|NCT05351424|Experimental|Audiovisual Intervention- Cancer Clinical Trials|Audiovisual video will be provided to the subjects as educational material.
89513095|NCT05351424|Active Comparator|Written Brochure- Cancer Clinical Trials|Written brochures will be provided to the subjects as educational material.
89513096|NCT05349565|Active Comparator|CONVENTIONAL PHYSICAL THERAPY|TENS , Open chain knee flexion and extension, Calf stretch , Quad set
89513097|NCT05349565|Experimental|MUSCLE ENERGY TECHNIQUE|MET ( isometric contraction with 6-10 sec )
89513098|NCT05347186|Experimental|Systematic corrective exercises and non-biomechanical functional exercises|
89513099|NCT05347186|Other|Non biomechanical functional exercises.|
89513100|NCT05337605||Hand driven tissue removal system|Endometrial polyp removed by hysteroscopic hand-driven tissue removal system in a previous study.
89513101|NCT05337605||Motor driven tissue removal system|Endometrial polyp removed by hysteroscopic motor-driven tissue removal system in a previous study.
89513102|NCT05334329|Experimental|Treatment (fludarabine, cyclophosphamide, COH06, atezolizumab)|Patients receive fludarabine IV on days -5 to -3, cyclophosphamide IV on days -5 to -3, and COH06 IV on days 0, 7, 14, and 21 in the absence of disease progression or unacceptable toxicity. Patients assigned to dose level 4 also receive atezolizumab IV over 60 minutes on days 0, 14, 28, and 42 in the absence of disease progression or unacceptable toxicity.
89513103|NCT05323409|Experimental|OPTIMISE|OPTIMISE components to facilitate Patient self-management support are: 1) a bilingual oncology nurse navigator (ONN) and care coordination; 2) distress screening; 3) tailored comorbidity self-management action planning, 4) tailored survivorship action planning, and 5) surveillance reminders and follow-up. OPTIMISE components to facilitate provider decision support are: 1) when the initial referral is made, the ONN will send the PCP treatment plan summary (based on the ASCO treatment plan template) and standardized fact sheets on treatment toxicities; 2) throughout treatment, there will be bi-directional and structured communication between oncologist and PCP facilitated by the ONN; 3) The ONN will send the SCP to the PCP describing surveillance guidelines and summary of late effects. Finally, OPTIMISE will adopt a risk-stratified shared care model of post-treatment survivorship care.
89541067|NCT05144399|Other|Standard length of antibiotic treatment|Patients are receiving the standard length of antibiotic treatment
88960157|NCT05619536|Experimental|Cohort 2|9 subjects randomized in a 7:2 ratio to receive either 150 mg CD388 SQ injection or matching placebo injection
88960158|NCT05619536|Experimental|Cohort 3|9 subjects randomized in a 7:2 ratio to receive either 450 mg CD388 SQ injection or matching placebo injection
88960159|NCT05618327|Experimental|JS203|
88960160|NCT05610579|Experimental|remedial exercises with compression bandage|
88960161|NCT05610579|Active Comparator|remedial exercises|
88960162|NCT05610423||Covid-19 vaccine associated myocarditis|No intervention
88960163|NCT05607771|Experimental|Manual|Oocytes will be prepared for vitrification using the manual protocol
88960164|NCT05607771|Experimental|Automated|Oocytes will be prepared for vitrification using Davitri device
88960165|NCT05603585|No Intervention|Control Group|Standard care as per current ICU feeding regime.
88960166|NCT05603585|Experimental|Interventional Group|Optimal protein supplementation to achieve 80% protein adequacy through optimised protein supplementation. The protein supplementation will be increased/decreased based on the previous day's intake to achieve 80% adequacy each day by the dietician.
88960167|NCT05585905|Experimental|Virtual Reality|The virtual reality system being used for research purposes is the RelievRx by AppliedVR which is an immersive virtual reality device that includes a goggle headset and remote control. The VR experience will be an immersive experience where the child will interact with the system and navigate their way through a game that will involve bright colors, cartoon-like characters, and settings with age-appropriate content.
88960168|NCT05585905|Active Comparator|Basic Behavior Guidance Techniques|The control sample will include basic behavior guidance techniques and is standard of care. The use of basic behavior guidance techniques is common in pediatric dentistry and is not unique to this study.
88960169|NCT05570955|Other|Intervention|50% of subjects will be randomized to a reporting tool designed to promote better adherence to treatment by having subjects report their progress on a weekly basis (the goal is not to test this tool but to help assure there is a broad range of adherence behavior including some positive adherence outliers)
88960170|NCT05570955|No Intervention|No Intervention|50% of subjects will not receive additional outreach to improve adherence
88960171|NCT05561933|Placebo Comparator|Choice Group|Participants assigned to the Choice group will receive a list of digital (i.e., links to TED talks) and hard-copy (i.e., books) resources that focus on the science of well-being and may support well-being. It is up to participants whether and to what extent they choose to engage with these resources. A study library with 10 copies of each recommended book will be accessible to participants should they wish to read any of the suggested books. After follow-up testing, Choice group participants will be provided free access to the HMP training.
88960172|NCT05561933|Experimental|Healthy Minds Program (HMP) Group|"Participants in the experimental arm will be assigned to the Healthy Minds Program Foundations training (HMP) which consists of 30-days of didactic and experiential content in a scientifically-derived model of well-being.~A second random assignment will occur among intervention participants in which participants will receive the standard Foundations training or the Foundations training plus once per day push notifications (i.e., a micro-interventions) that provide a very brief opportunity to practice with the HMP content of that day. HMP participants will not be made aware of this second assignment."
88960173|NCT05561543|Placebo Comparator|Placebo|Identical in taste and colour to the supplement juice, but with no peppermint content.
88960174|NCT05561543|Experimental|Peppermint oil|50 uL of peppermint oil, which will be diluted with 100 mL of water - taken twice per day.
88960175|NCT05555823|Experimental|Experimental: ATR-002|In the SAD part, study participants will receive IMP orally once (except for the first cohort), or twice (two single doses separated by an adequate washout period of at least 10 days for the FDI cohort, which will be conducted according to a two-period fixed-sequence design with all subjects receiving the treatment sequence 'fasted-fed'). In each of the periods of the MAD Part, study participants will receive the IMP for seven consecutive days. Dosing will start at 600 mg (SAD part) and 900 mg (MAD part) in the first cohort and follow the dose escalation schedule that is given in the study protocol.
88960176|NCT05555823|Placebo Comparator|Placebo Comparator: Placebo|"In the SAD part, study participants will receive IMP orally once (except for the first cohort), or twice (two single doses separated by an adequate washout period of at least 10 days for the FDI cohort, which will be conducted according to a two-period fixed-sequence design with all subjects receiving the treatment sequence 'fasted-fed'). In each of the periods of the MAD Part, study participants will receive the IMP for seven consecutive days.~In the DDI period with repaglinide two doses of ATR-002 will be given, and in the DDI period with celecoxib, four doses of ATR-002 will be given."
89519505|NCT04453943|Experimental|Group B - Subjects without disability|Twenty individuals without disability will be recruited (Group B). Individuals with SCI who have experience in using some kind of walking assistive devices in the recent past will be preferably recruited.
89519506|NCT05321329|Experimental|Single Arm|Capecitabine will be taken orally at dose of 1250 mg/m2 PO BID on days 1→14 every 3 weeks Cycles are to be repeated every 21 days for a total of 8 cycles
89519507|NCT02521831|Active Comparator|General Anesthesia|"Inhalational anesthesia with Isoflurane 1-2% in 50%/50% oxygen/air mixture.~This arm will receive the General Anesthesia (isoflurane) intervention exclusively."
89541068|NCT05138874|Experimental|Trending Feedback + Private Commitment|Clinicians receive both Trending Feedback + Private Commitment interventions.
89541069|NCT05138874|Experimental|Trending Feedback + Public Commitment|Clinicians receive both Trending Feedback + Public Commitment interventions.
89541070|NCT05138874|Experimental|Trending Feedback + Commitment Control|Clinicians receive Trending Feedback intervention + Commitment Control.
89541071|NCT05138874|Experimental|Benchmark Peer Comparison Feedback + Private Commitment|Clinicians receive both Benchmark Peer Comparison Feedback + Private Commitment interventions.
89541072|NCT05138874|Experimental|Benchmark Peer Comparison Feedback + Public Commitment|Clinicians receive both Benchmark Peer Comparison Feedback + Public Commitment interventions.
89541073|NCT05138874|Experimental|Benchmark Peer Comparison Feedback + Commitment Control|Clinicians receive Benchmark Peer Comparison Feedback intervention + Commitment Control.
89541074|NCT05138874|Experimental|Public Commitment + Feedback Control|Clinicians receive Public Commitment intervention + Feedback Control.
89541075|NCT05138874|Experimental|Private Commitment + Feedback Control|Clinicians receive Private Commitment intervention + Feedback Control.
89541076|NCT05138874|No Intervention|Commitment Control + Feedback Control|Clinicians receive no intervention.
89541077|NCT05136677|Experimental|Arm A|
89541078|NCT05136677|Experimental|Arm B|
89541079|NCT05133661||HPV positive women|"Women aged 25-49 years seeking offered HPV testing (either self-collection or clinician collection of samples) and treatment of precancerous lesions as part of service package in study facilities will be enrolled in the study and interviewed at different time points.~A subset of the women screened will be selected for in-depth interview to gather data on: ease of use of self-collection kits for cervical cancer screening, receipt of the test results, and treatment for precancer. Another subset of women will be selected after HPV screening to participate in client exit interview."
88960177|NCT05526378|Experimental|Group 1 (mother's voice)|"The mother called her baby between 40 and 60 decibels loudness. The intervention was continued 5 minutes before the heel blood collection and continued until the 5th minute after the procedure. NIPS score was saved in 5 minutes before the heel blood collection and continued until the 5th minute after the procedure.~Benetech brand GM1352 model decibel meter was used to measure the loudness."
88960178|NCT05526378|Experimental|Group 2 (mother's milk)|Breast milk was dripped onto the gauze in an amount to wet the entire 2,5cm*2,5cm sterile gauze. The gauze was then placed close to the baby's nose wings. The intervention was continued 5 minutes before the heel blood collection and continued until the 5th minute after the procedure. NIPS score was saved in 5 minutes before the heel blood collection and continued until the 5th minute after the procedure
88960179|NCT05526378|Experimental|Group 3 (skin to skin contact)|Skin-to-skin contact between mother and baby is provided. The intervention was continued 5 minutes before the heel blood collection and continued until the 5th minute after the procedure. NIPS score was saved in 5 minutes before the heel blood collection and continued until the 5th minute after the procedure
88960180|NCT05526378|No Intervention|Control group|
88960181|NCT05525663|Experimental|Rehabilitation Intervention|The Rehabilitation Intervention is a novel, progressive, multi-domain rehabilitation and exercise training intervention. The intervention will include strength, balance, endurance, and mobility training and the specific training exercises will be tailored based on participant performance in each of these domains. The intervention will begin as soon as possible after randomization during the hospitalization and will continue 3 times per week in an outpatient setting for 12 weeks.
88960182|NCT05525663|No Intervention|Attention Control|Attention control participants are contacted bi-weekly by study staff to maintain contact, collect information regarding health status, clinical events, and physical activity/exercise, and ensure retention; they do not receive any specific exercise recommendations.
88960183|NCT05523089|Placebo Comparator|Placebo (Arm 1)|In Cohort 1, up to 30 participants will be randomized to receive a single dose of placebo, administered by subcutaneous (SQ) injection, prior to being inoculated with the influenza challenge virus. Based on an interim analysis to be performed on data collected from the evaluation of Cohort 1 participants who have completed the inpatient phase at the time the interim analysis is performed, additional participants (of a number to be informed by the interim analysis) may be randomized into Cohort 2 in an extension of this Arm 1, to receive a single dose of placebo by SQ injection prior to viral challenge.
89541080|NCT05127161|Experimental|Early Intervention|The early intervention arm will begin receiving the intervention in study period 1.
89541081|NCT05127161|Other|Delayed Intervention (Control)|The delayed intervention (control) arm will begin receiving the intervention in study period 2. They will receive no intervention during period 1.
89541082|NCT05126966|Experimental|Ranibizumab|Subjects will have the implant (filled intra-operatively prior to implantation with approximately 20 µL of the 100-mg/mL formulation of ranibizumab [approximately 2-mg dose of ranibizumab]) surgically inserted in the study eye at the Day 1 visit following their randomization visit. Subjects will have their implant refilled with ranibizumab at weeks 36 and 72.
89541083|NCT05126966|Active Comparator|Aflibercept|Subjects will receive intravitreal injections of aflibercept (2mg) administered in the study eye per treat-and-extend. The decision to extend, maintain, or reduce the interval until next treatment will be per investigator judgment.
89541084|NCT05123365|Experimental|Dose Level 1 (DL1)|"Patients take N-Acetylcysteince 600 mg orally twice daily.~This is the starting dose level for the study."
89541085|NCT05123365|Experimental|Dose Level 2 (DL2)|"Patients take N-Acetylcysteince 1200 mg orally twice daily.~If DL1 is well tolerated, the next cohort will progress to this dose level."
89541086|NCT05123365|Experimental|Dose Level 3 (DL3)|"Patients take N-Acetylcysteince 1800 mg orally twice daily.~If DL2 is well tolerated, the next cohort will progress to this dose level."
89541087|NCT05116085|Experimental|Tislelizumab|Tislelizumab administered intravenously before surgery during the neo-adjuvant phase
88960184|NCT05523089|Experimental|CD388 High Dose (Arm 2)|In Cohort 1, up to 30 participants will be randomized to receive a single dose of 150 milligrams (mg) CD388, administered by SQ injection, prior to being inoculated with the influenza challenge virus. Based on an interim analysis to be performed on data collected from the evaluation of Cohort 1 participants who have completed the inpatient phase at the time the interim analysis is performed, additional participants (of a number to be informed by the interim analysis) may be randomized into Cohort 2 in an extension of this Arm 2, to receive a single dose of 150 mg CD388 by SQ injection prior to viral challenge.
88960185|NCT05523089|Experimental|CD388 Low Dose 1 (Arm 3)|In Cohort 1, up to 30 participants will be randomized to receive a single dose of 50 mg CD388, administered by SQ injection, prior to being inoculated with the influenza challenge virus. Based on an interim analysis to be performed on data collected from the evaluation of Cohort 1 participants who have completed the inpatient phase at the time the interim analysis is performed, additional participants (of a number to be informed by the interim analysis) may be randomized into Cohort 2 in an extension of this Arm 3, to receive a single dose of 50mg CD388 by SQ injection prior to viral challenge.
89541088|NCT05113927|No Intervention|Standard of Care|Lumpectomy with usual intraoperative margin assessment
89541089|NCT05113927|Experimental|Device|Imaging of all margins with investigational device
89541090|NCT05113745|Experimental|AXS-12 (reboxetine)|"Up to 24 weeks in open-label period~Up to 4 weeks in randomized double-blind period"
89541091|NCT05113745|Placebo Comparator|Placebo|Up to 4 weeks in randomized double-blind period
89541092|NCT05112484||Gilenya|Gilenya (fingolimod) - first registration 17 March 2011, last renewal 16 November 2020, selective immunosuppressant (ATC code L04AA27), sphingosine-1-phosphate receptor modulator
89541093|NCT05112484||Tecfidera|Tecfidera (dimethyl fumarate) - first registration 30 January 2014, last renewal 20 September 2018, cytostatic and immunomodulatory drug (ATC code L04AX07), an activator of the transcription pathway of nuclear factor Nrf2
89541094|NCT05112484||Mavenclad|Mavenclad (cladribine) - first registration 22/08/2017, selective immunosuppressant (ATC code L04AA40), nucleoside analogue of deoxyadenosine
88960186|NCT05523089|Experimental|CD388 Low Dose 2 (Optional Arm 4)|Based on an interim analysis to be performed on data collected from the evaluation of Cohort 1 participants who have completed the inpatient phase at the time the interim analysis is performed, participants (of a number to be informed by the interim analysis) may be randomized into Cohort 2 in this Optional Arm 4, to receive a single dose of CD388 lower than 150 mg (TBD based on PK results obtained in the first-in-human study CD388.IM.SQ.1.01, as well as the interim analysis), administered by SQ injection, prior to being inoculated with the influenza challenge virus.
88960187|NCT05523089|Experimental|CD388 Low Dose 3 (Optional Arm 5)|Based on an interim analysis to be performed on data collected from the evaluation of Cohort 1 participants who have completed the inpatient phase at the time the interim analysis is performed, participants (of a number to be informed by the interim analysis) may be randomized into Cohort 2 in this Optional Arm 5, to receive a single dose of CD388 lower than 150 mg (TBD based on PK results obtained in the first-in-human study CD388.IM.SQ.1.01, as well as the interim analysis), administered by SQ injection, prior to being inoculated with the influenza challenge virus.
88960188|NCT05523089|Experimental|CD388 Low Dose 4 (Optional Arm 6)|Based on an interim analysis to be performed on data collected from the evaluation of Cohort 1 participants who have completed the inpatient phase at the time the interim analysis is performed, participants (of a number to be informed by the interim analysis) may be randomized into Cohort 2 in this Optional Arm 6, to receive a single dose of CD388 lower than 150 mg (TBD based on PK results obtained in the first-in-human study CD388.IM.SQ.1.01, as well as the interim analysis), administered by SQ injection, prior to being inoculated with the influenza challenge virus.
88960189|NCT05522179|Experimental|NutraHeal|NutraHeal™ is a nutritional supplement that contains 7.5 micrograms (300 IU) of Vitamin D3, 80 mg of Calcium as Calcium Hydroxymethylbutyrate Monohydrate, 7.5 mg of Zinc, 600 mg of Calcium Hydroxymethylbutyrate Monohydrate, and 45 mg of Bromelain.
88960190|NCT05522179|Experimental|NutraHeal Plus|NutraHeal Plus™ is a nutritional supplement that contains 80 mg of Calcium as Calcium Hydroxymethylbutyrate Monohydrate, 7.5 mg of Zinc, 600 mg of Calcium Hydroxymethylbutyrate Monohydrate, 45 mg of Bromelain, and 7.5 mg of reduced Nicotinamide Adenine Dinucleotide (NADH).
88960191|NCT05522179|No Intervention|Standard of Care|Receive standard of care for 1 week prior to surgery and 3 weeks after foot surgery.
88960192|NCT05512858|No Intervention|phase 1|Data on restrictions and aggression events in the department will be collected throughout the two phases, and the participants will undergo an evaluation process.
88960193|NCT05512858|Experimental|phase 2|Data on restrictions and aggression events in the department will be collected throughout the two phases, and the participants will undergo an evaluation process. n addition, the subjects who participate in the intervention will wear an Empatica-E4 wristband to monitor autonomous metrics during their stay in the sensory stimulation room and will undergo a brief interview regarding their experience using the room.
88960194|NCT05502029|Active Comparator|Control|Translator in preoperative area
88960195|NCT05502029|Experimental|Intervention|Translator in preoperative area, continued through transport to the operating room, and in the operating room until the patient is under general anesthesia
88960196|NCT05501886|Experimental|Arm A - Patients Lacking PIK3CA Mutations (WT)|Gedatolisib + Palbociclib + Fulvestrant
88960197|NCT05501886|Experimental|Arm B - Patients Lacking PIK3CA Mutations (WT)|Gedatolisib + Fulvestrant
89541095|NCT05112484||Aubagio|Aubagio (teriflunomide) - first registration on 26 August 2013, last renewal on 28 May 2018, selective immunosuppressant (ATC code L04AA31), an inhibitor of the mitochondrial enzyme dihydroorotate dehydrogenase
88960198|NCT05501886|Active Comparator|Arm C - Patients Lacking PIK3CA Mutations (WT)|Fulvestrant
89513104|NCT05323409|No Intervention|Usual Medical Care (UMC)|UMC consists of standard oncologic care from point of diagnosis. Cancer patients with comorbidities are encouraged by their oncologist to follow up with their PCP regarding comorbidity management but no formal referral process is in place. At the end of cancer treatment (with standard, definitive therapies), patients meet with a nurse (Survivorship Nurse Practitioner, NP) to review the SCP, which is based on ASCO templates and populated from the EHR. The Survivorship NP also reviews therapies received, recommended surveillance, common late effects, and recommended lifestyle behaviors. Patients are given a printed copy of the SCP and are encouraged to share this information with their PCP. Cancer surveillance follows the traditional oncologist led model regardless of patient risk for recurrence.
89513105|NCT05309083|Experimental|Mindfulness Based Walking Therapy (MBWT)|Participants will participate in MBWT.
89513106|NCT05293041|Experimental|Argipressin|Patients will be treated with Empressin® 0.8 U/ml, 0.056 ml/kg/h during surgery.
89513107|NCT05293041|Placebo Comparator|Placebo|Patients will receive normal saline 0.056 ml/kg/h during surgery.
89513108|NCT05255653|Experimental|p53abn-RED trial: experimental|Adjuvant radiotherapy and chemotherapy followed by olaparib (lynparza), 300 mg twice daily, for two years
89513109|NCT05255653|Active Comparator|p53abn-RED trial: control|Adjuvant radiotherapy and chemotherapy
89513110|NCT05255653|Experimental|MMRd-GREEN trial: experimental|Adjuvant radiotherapy combined with and followed by durvalumab, 1500 mg intravenous once every 4 weeks for in total 1 year (13 cycles)
89513111|NCT05255653|Active Comparator|MMRd-GREEN trial: control|Adjuvant pelvic external beam radiotherapy
89513112|NCT05255653|Experimental|NSMP-ORANGE trial: experimental|Adjuvant radiotherapy followed by oral progestagens (medroxyprogesterone acetate or megestrol acetate) for two years
89513113|NCT05255653|Active Comparator|NSMP-ORANGE trial: control|Adjuvant radiotherapy and chemotherapy
89513114|NCT05255653|Other|POLEmut-BLUE trial: main cohort|"No adjuvant therapy in women with:~stage IA (not confined to polyp), grade 3, pN0, with or without LVSI~stage IB, grade 1 or 2, pNx/N0, with or without LVSI~stage IB, grade 3, pN0, without substantial LVSI~stage II (microscopic), grade 1 or 2, pN0, without substantial LVSI"
89513115|NCT05255653|Other|POLEmut-BLUE trial: exploratory cohort|"No adjuvant therapy or vaginal brachytherapy or pelvic external beam radiotherapy in women with:~stage IA (not confined to polyp), grade 3, pNx, with or without LVSI~stage IB, grade 3, pNx, with or with LVSI.~stage IB, grade 3, pN0, with substantial LVSI.~stage II (microscopic), grade 1 or 2, pNx, with or without LVSI.~stage II (microscopic), grade 1 or 2, pN0, with substantial LVSI.~stage II (microscopic), grade 3, pNx/N0, with or without LVSI.~stage II non-microscopic, any grade, pNx/N0, with or without LVSI.~stage III, any grade, pNx/N0-2, with or without LVSI."
89513116|NCT05249439|Experimental|I-SatPro|Patients in the I-SatPro group will attend I-SatPro patient group sessions and follow the I-SatPro weight loss programme
89513117|NCT05249439|Active Comparator|Control|Patients in the control group will attend NHS Tier 3 patient group sessions and follow the NHS Tier 3 weight loss programme
89513118|NCT05236894|Experimental|Aim 1: Arm I (lower dose nicotine pouch)|Patients receive lower dose nicotine pouch PO over 30 minutes at visits 1, 2, and 3.
89513119|NCT05236894|Experimental|Aim 1: Arm II (higher dose nicotine pouches)|Patients receive higher dose nicotine pouch PO over 30 minutes at visits 1, 2, and 3.
89513120|NCT05236894|Active Comparator|Aim 1: Arm III (cigarette smoking)|Patients smoke usual brand of cigarettes, taking one puff every 30 seconds over 5 minutes at visits 1, 2, and 3.
89513121|NCT05236894|Experimental|Aim 2: Arm I (3mg NP)|Patients receive nicotine pouch PO over 30 minutes at visits 1, 2, and 3.
89513122|NCT05236894|Experimental|Aim 2: Arm II (3mg NP)|Patients receive nicotine pouch PO over 30 minutes at visits 1, 2, and 3.
89513123|NCT05236894|Experimental|Aim 2: Arm III (3mg NP)|Patients receive nicotine pouch PO over 30 minutes at visits 1, 2, and 3.
89513124|NCT05229640|Other|Fibroscan|One study visit for fibroscan measurement of the liver.
89513125|NCT05225506|Experimental|Exercise|In this single group design, all participants will be provided with 6 months of twice weekly supervised group exercise.
89513126|NCT05224154|Experimental|Abstinent Contingent (AC) Re-Connect|Participants in this group will be able to unblock highly desired, but non-essential (e.g., social networking, shopping, games) applications contingent on meeting goals for smoking abstinence, as verified by meeting carbon monoxide goals (CO<=6ppm).
89513127|NCT05224154|Active Comparator|Submission Contingent (SC) Re-Connect|Participants in this group will also be able to unblock their applications, but contingent on submitting CO samples and independent of meeting CO goals for smoking abstinence.
89513128|NCT05220137|Active Comparator|1|Core Session 1, Core Session 2, Module Choice, Final Session
89513129|NCT05220137|Active Comparator|2|Core Session 1, Core Session 2, Modified A-B-C, Final Session
89513130|NCT05220137|Active Comparator|3|Core Session 1, Core Session 2, Challenging Questions, Final Session
89513131|NCT05220137|Active Comparator|4|Core Session 1, Core Session 2, Modified A-B-C, Challenging Questions, Module Choice, Final Session
89513132|NCT05220137|Active Comparator|5|Core Session 1, Core Session 2, Problematic Patterns, Final Session
89513133|NCT05220137|Active Comparator|6|Core Session 1, Core Session 2, Modified A-B-C, Problematic Patterns, Module Choice, Final Session
89513134|NCT05220137|Active Comparator|7|Core Session 1, Core Session 2, Challenging Questions, Problematic Patterns, Module Choice, Final Session
89513135|NCT05220137|Active Comparator|8|Core Session 1, Core Session 2, Modified A-B-C, Challenging Questions, Problematic Patterns, Final Session
89513136|NCT05220137|Active Comparator|9|Core Session 1, Core Session 2, Challenging Beliefs, Final Session
88960199|NCT05501886|Experimental|Arm D - Patients with PIK3CA Mutation (MT)|Gedatolisib + Palbociclib + Fulvestrant
88960200|NCT05501886|Active Comparator|Arm E - Patients with PIK3CA Mutation (MT)|Alpelisib + Fulvestrant
88960201|NCT05501886|Experimental|Arm F - Patients with PIK3CA Mutation (MT)|Gedatolisib + Fulvestrant
88960202|NCT05501691|Placebo Comparator|Placebo|Laser Simulation
88960203|NCT05501691|Experimental|445 nm|445 nm Diode Laser Wavelength (SiroLaser Blue)
88960204|NCT05501691|Experimental|660 nm|660 nm Diode Laser Wavelength (SiroLaser Blue)
88960205|NCT05501691|Experimental|970 nm|970 nm Diode Laser Wavelength (SiroLaser Blue)
88960206|NCT05500248|Experimental|Leave-In-Situ Arm|standard, high-definition colonoscopy with the use of Medtronic GI Genius module including both CADe and CADx. Polyps will be left in situ if diminutive (≤5 mm) in size, located in the rectum or sigma and optically diagnosed by the endoscopist using the system to be hyperplastic with high confidence, otherwise resected and sent to pathology.
88960207|NCT05500248|Active Comparator|Standard arm|standard, high-definition colonoscopy with the use of Medtronic GI Genius module including both CADe and CADx. All detected polyps regardless of size and optical diagnosis will be resected and sent to pathology.
88960208|NCT05498207|No Intervention|No Intervention|Participants will complete assessments at baseline, 3 months, 6 months, 9 months and 12 months. (this includes specimen collections, interviews, and surveys). Participants will also be asked to wear a Fitbit for 12 months.
88960209|NCT05498207|Experimental|Maya mobile app|
88960210|NCT05497960|Other|Vivo strength training|Participants will exercise virtually, 2 days a week for 12 weeks for a 45 minute live, interactive strength training workout.
88960211|NCT05493371|Experimental|Empagliflozin|
89513137|NCT05220137|Active Comparator|10|Core Session 1, Core Session 2, Modified A-B-C , Challenging Beliefs, Module Choice, Final Session
89513138|NCT05220137|Active Comparator|11|Core Session 1, Core Session 2, Challenging Questions, Challenging Beliefs, Module Choice, Final Session
89513139|NCT05220137|Active Comparator|12|Core Session 1, Core Session 2, Modified A-B-C, Challenging Questions, Challenging Beliefs, Final Session
89513140|NCT05220137|Active Comparator|13|Core Session 1, Core Session 2, Problematic Patterns, Challenging Beliefs, Module Choice, Final Session
89513141|NCT05220137|Active Comparator|14|Core Session 1, Core Session 2, Modified A-B-C, Problematic Patterns, Challenging Beliefs, Final Session
89513142|NCT05220137|Active Comparator|15|Core Session 1, Core Session 2, Challenging Questions, Problematic Patterns, Challenging Beliefs, Final Session
89513143|NCT05220137|Active Comparator|16|Core Session 1, Core Session 2, Modified A-B-C, Challenging Questions, Problematic Patterns, Challenging Beliefs, Module Choice, Final Session
89513144|NCT05199077|Placebo Comparator|placebo group|Topical administration of a drug-free placebo ointment daily for 28 days.
89513145|NCT05199077|Active Comparator|cohort A|Topical administration of a 2.5 % GM-XANTHO ointment daily for 28 days.
89513146|NCT05199077|Active Comparator|cohort B|Topical administration of a 5 % GM-XANTHO ointment daily for 28 days.
89513147|NCT05192499|Other|Case|"Patients aged to 1 to 3 years with severe asthma (i.e. resistant to inhaled corticosteroid doses less than or equal to 200μg fluticasone equivalent).~Severe asthma patients (cases) are defined by poor asthma control under doses of inhaled corticosteroids ≤200μg fluticasone equivalent."
89513148|NCT05192499|Other|Control|"Patients aged to 1 to 3 years with low or moderate asthma (controlled with mild to moderate doses of inhaled corticosteroids less than or equal to 200μg of fluticasone equivalent).~Mild to moderate asthma patients (controls) are defined by disease control by first-line treatment in asthma, i.e. corticosteroids inhaled at mild to moderate doses of ≤200 micrograms/day of fluticasone equivalent."
89513149|NCT05185453|Experimental|Strengthening Connections for Change|Strengthening Connections for Change uses a group discussion format with activities that explore identity, adolescent-adult relationships, social networks, and community engagement. Youth invite their self-identified key adult supports to jointly participate in programming and curriculum includes youth-focused, adult-focused and jointly focused activities designed to build leadership skills, enhance intergenerational networks, challenge attitudes towards violence and retaliation, and reduce violence involvement. Through 12 sessions (2 hours/session) delivered weekly, Strengthening Connections offers leadership development coupled with strengths-based youth violence prevention programming.
89513150|NCT05185453|Active Comparator|Job Readiness Training|Job Readiness Training uses a group discussion format to learn specific skills to prepare for employment including developing goals, seeking jobs, preparing for interviews, and so forth. Participants receive a 12 session job readiness training with linkages to businesses and employment opportunities. Discussions include a wide range of topics related to career exploration and job readiness.
89513151|NCT05181579|Experimental|Manuel therapy and exercise group|Patients in the manual therapy group will receive 5 sessions of sacroiliac joint manipulation once a week. And home exercises will be given and told. Each patient will do exercise 4 days a week for 4 weeks.
89513152|NCT05181579|Experimental|Sacroiliac injection and exercise group|"To patients in the injection group corticosteroid (1 ml 40 mg methylprednisolone) and local anesthetic (1 ml 1% lidocaine)will be injected into the sacroiliac joint using a 22 G spinal needle, guided by fluoroscopy (C-arm fluoroscopy).~And home exercises will be given and told. Each patient will do exercise 4 days a week for 4 weeks."
89513153|NCT05167032|Experimental|Cognitive Multisensory Rehabilitation (CMR) Group|"After the baseline testing, participants in the CMR group will receive 8 weeks of one-on-one, in-person therapy, 3 times a week, for 45 min. The CMR sessions will be recorded on video.~The participants will undergo clinical assessments and MRI scans at 3 time points: at baseline; a post-intervention after the first 8 weeks of CMR and a clinical assessment (no MRI) at 3 months."
89513154|NCT05167032|Active Comparator|Adaptive Fitness Group|"After the baseline testing, participants in the adapted fitness group will start with a fitness assessment and then complete a fitness program under supervision for 8 weeks, 3x/week, for 45 min. Staff at the Courage Kenny Rehabilitation Institute will monitor training adherence through a log sheet.~The participants will undergo clinical assessments and MRI scans at 3 times points: at baseline; a post-intervention after the first 8 weeks of adaptive fitness and a clinical assessment (no MRI) at 3 months."
89513155|NCT05109052|Experimental|Experimental|"Open label safety and tolerability assessment of PXS-5505:~(PXS-5505) 100-200mg BID (Atezolizumab) 1200mg every 3 weeks (Bevacizumab) 15mg/kg every 3 weeks"
89513156|NCT05092919|Other|Flavor|Either a sweet-flavored or a non-flavored cigarillo
89513157|NCT05073354||Pre-implementation|Patients experiencing shock without trauma prior to any SWOT model training or devices
88960212|NCT05492942|No Intervention|Clinician prompting and Decision Support, Best Practice Advisory (BPA)|Access to an existing BPA for risky alcohol use and alcohol use disorder.
88960213|NCT05492942|Experimental|BPA plus Population Health Management (BPA+PHM)|Access to the existing Epic BPA for risky alcohol use and alcohol use disorder + targeted support by a population health manager (PHM).
89541096|NCT05105308|Active Comparator|Family Assisted Diet (FAD)|This is a 20-session intervention with a child and the child's parents that consists of helping parents set goals around their child's renourishment; consider barriers to implementing proposed plans; thinking through strategies to avoid barriers; and providing ongoing support for plan implementation.
89541097|NCT05105308|Experimental|Feeling and Body Investigator_ARFID Division (FBI-ARFID)|This is a 20-session intervention with a child and the child's parents that consists of 4 components: 1) psychoeducation of somatic body sensations and sensory features of foods using playful characters (e.g., Aftertaste Anthony); 2) in-session exercises that expose family members to different body and food sensations so they can learn something new about their body and food; 3) body brainstorm worksheets that help them generalize what they learn in session to outside of treatment; and 4) Decision-tree practice worksheets that help them map body sensations to meanings and actions and to track explorations with food.
89541098|NCT05104697|Other|TMS at visit 1, Sham at visit 2|At visit 1, participants will receive active TMS using continuous theta burst over the preSMA. At Visit 2, participants will receive sham (fake) TMS in the same location.
89541099|NCT05104697|Other|Sham at visit 1, TMS at visit 2|At visit 2, participants will receive active TMS using continuous theta burst over the preSMA. At Visit 1, participants will receive sham (fake) TMS in the same location.
89541100|NCT05091307|Experimental|Group 1: Ad26.COV2.S + Quadrivalent (Q) Standard-dose (SD) Influenza Vaccine and Placebo|Participants aged greater than or equal to (>=) 18 years will receive a single intramuscular (IM) injection of Ad26.COV2.S and a seasonal Q SD influenza vaccine on Day 1 and placebo on Day 29.
89541101|NCT05091307|Placebo Comparator|Group 2: Placebo + Q SD Influenza Vaccine and Ad26.COV2.S|Participants aged >=18 years will receive a single IM injection of placebo and a seasonal Q SD influenza vaccine on Day 1 followed by Ad26.COV2.S on Day 29.
89541102|NCT05091307|Experimental|Group 3: Ad26.COV2.S + Q High-dose (HD) Influenza Vaccine and Placebo|Participants aged >=65 years will receive a single IM injection of Ad26.COV2.S and a seasonal Q HD influenza vaccine on Day 1 followed by placebo on Day 29.
89541103|NCT05091307|Placebo Comparator|Group 4: Placebo + Q HD Influenza Vaccine and Ad26.COV2.S|Participants aged >=65 years will receive a single IM injection of placebo and a seasonal Q HD influenza vaccine on Day 1 followed by Ad26.COV2.S on Day 29.
89541104|NCT05087992|Experimental|Phase 1a: BI 905711 + FOLFIRI + Bevacizumab|Phase 1a: Dose escalation in colorectal adenocarcinoma (CRC)
89541105|NCT05087992|Experimental|Phase 1b: BI 905711 + FOLFIRI|Phase 1b: Dose Expansion: Single arm cohort in 2nd line Pancreatic Ductal Adenocarcinoma (PDAC)
89541106|NCT05087992|Experimental|Phase 1b: BI 905711 + FOLFIRI + Bevacizumab|Phase 1b: Dose Expansion: Randomized cohort in 2nd line colorectal adenocarcinoma (CRC); Arm A.
89541107|NCT05087992|Experimental|Phase 1b: FOLFIRI + Bevacizumab|Phase 1b: Dose Expansion: Randomized cohort in 2nd line colorectal adenocarcinoma (CRC); Arm B.
88811566|NCT01279187|Placebo Comparator|Control|demeclocycline HCl (150 mg, four times per day for 3d) followed by a 12 day intermission then 3 more days of demeclocycline HCl (150 mg, four times per day). One day after the last demeclocycline dosage, subjects will be instructed to self-administer teriparatide (or placebo) for 7 weeks. Twenty-five days after the last demeclocycline dosage, subjects will begin their second set of tetracycline labels:(250 mg, four times per day) for three days, followed by 12 days off, and then repeat another 3 days of tetracycline HCl (250 mg, four times per day). On day of the last teriparatide (or placebo) injection, subjects will present for bone core removal and dental implant placement.
89541108|NCT05084677|Experimental|PD-1 arm|PD-1 concurrent with and subsequent after concurrent chemoradiotherapy
88811567|NCT01279265|Active Comparator|Nutramigen Lipil with Enflora|Formula with probiotics (Lactobaccillus Rhamnosus GG)
89541109|NCT05082116|Experimental|N8-GP prophylaxis|All patients will receive prophylaxis with 50 IU/kg N8-GP every 4 days for a treatment period of at least 28 weeks (with the possibility of switching to twice-weekly dosing during the treatment period at the discretion of the investigator).
89541110|NCT05082025|Experimental|Part 1: Dose confirmation|Up to 6 evaluable patients to confirm a single combination dose of copanlisib and fulvestrant
89541111|NCT05082025|Experimental|Part 2: Dose expansion:|The dose expansion part will enroll in 3 indication-specific cohorts with 13 to 26 patients
89541112|NCT05074537||MRI Participants|
89541113|NCT05074537||PET/CT Participants|
89541114|NCT05074537||CT Participants|
89541115|NCT05058612|Experimental|Midodrine|Midodrine 10 mg PO/NG q8h
89541116|NCT05058612|Placebo Comparator|Placebo|Microcrystalline cellulose PO/NG q8h
89541117|NCT05035732|Experimental|18F-ACBC|
89541118|NCT05024929||Prospective Cohort|Patients with differentiated thyroid cancer for whom oncogene-specific targeted therapy is planned from commercial supply or as part of a separate therapeutic trial
89541119|NCT05024929||Data Sharing Cohort|Patients with differentiated thyroid cancer enrolled on other oncogene-specific targeted therapy trials who undergo whole body thyroid scan approximately 28 days after beginning targeted therapy and agree to data sharing
89541120|NCT05022004|Experimental|BRIN-20-01|
88811568|NCT01279265|Placebo Comparator|Nutramigen A+|Hypoallergenic formula without probiotics (Lactobaccillus Rhamnosus GG)
88811569|NCT00848510|Experimental|EMD 525797|
88811570|NCT00848744|Experimental|topical salicylic acid 1.0% cream|
88811571|NCT03717974|Experimental|telemedecine's follow-up|Telemedecine follow-up after an intervention at home of the mobile team
88811572|NCT03717974|Active Comparator|mobile team's follow-up|Mobile team follow-up after an intervention at home of the mobile team
88811573|NCT03698708|Experimental|CARES Intervention- 12 sessions|Participants in the intervention will participate in 12 weekly group-based telemedicine intervention sessions (up to 60 minutes each) with other parents/caregivers of children with T1D. Intervention sessions focus on cognitive-behavioral therapy to treat depression, including identifying cognitive distortions, cognitive restructuring, behavioral activation, coping strategies, and learning diabetes management skills.
88811574|NCT03698708|Experimental|CARES Intervention- 8 sessions|Participants in the intervention will participate in 8 weekly group-based telemedicine intervention sessions (up to 60 minutes each) with other parents/caregivers of children with T1D. Intervention sessions focus on cognitive-behavioral therapy to treat depression, including identifying cognitive distortions, cognitive restructuring, behavioral activation, coping strategies, and learning diabetes management skills.
88960214|NCT05492942|Experimental|BPA plus Clinical Care Management (BPA+CCM)|Access to the existing Epic BPA for risky alcohol use and alcohol use disorder + targeted support by a clinician care manager (CCM).
88960215|NCT05492942|Experimental|BPA plus Population Health Management plus Clinical Care Management (BPA+PHM+CCM)|Access to the existing Epic BPA risky alcohol use and alcohol use disorder + targeted support by a population health manager (PHM) and clinician care manager (CCM)
88960216|NCT05492526|Other|Usual Cardiac Rehabilitation|Patients receive usual care and wear Ki monitor - doesn't receive any feedback during the cardiac rehabilitation period.
88960217|NCT05492526|Experimental|Intervention Arm - Usual Cardiac Rehabilitation plus contextualised Data feedback|Patient receives usual care and also wears Ki monitor and receives contextualised data feedback
89513158|NCT05073354||Partial-implementation|Patients experiencing shock without trauma after training and device deployment has been started but not fully implemented
89513159|NCT05073354||Full-implementation|Patients experiencing shock without trauma once all training is in place and devices are deployed
89513160|NCT05034718|Active Comparator|Control Arm|Completion of nurse powerform and data collection only.
89513161|NCT05034718|Experimental|Intervention Arm|Completion of nurse powerform, data collection and physician alert/powerform with score calculation and recommendations.
89513162|NCT05011396|Experimental|PH94B|3.2 micrograms PH94B intranasal spray (100 microliters to each nostril) one time
89513163|NCT05011396|Experimental|Placebo|Placebo intranasal spray (100 microliters to each nostril) one time
89513164|NCT05007483|Experimental|Group 1 (Modified paleolithic elimination diet).|Modified paleolithic elimination diet.
89513165|NCT05007483|Experimental|Group 2 (TROO)|Time Restricted Olive Oil Based (TROO) Ketogenic Diet
89513166|NCT05007483|Active Comparator|Group 3 Control|Usual diet with Dietary Guidelines for Americans Diet information
89513167|NCT04965792||HPV-positive oropharyngeal squamous cell carcinoma (HPV-OPC) Patients|Newly diagnosed HPV-positive oropharyngeal squamous cell carcinoma (HPV-OPC) patients will undergo blood testing for circulating tumor HPV DNA.
89513168|NCT04962022|Experimental|Period 1|PF-07321332/ritonavir orally
89513169|NCT04962022|Experimental|Period 2|Itraconazole + PF-07321332/ritonavir orally.
89513170|NCT04938167|No Intervention|Standard arm|target preductal SpO2 - 91 to 95%
89513171|NCT04938167|Experimental|Intervention arm|target preductal SpO2 - 95 to 99%
89513172|NCT04936594|Experimental|People Living with HIV/AIDS Who Smoke|Participants will be people living with HIV/AIDS who smoke. They will receive two interventions: iTBS and a sham comparator (TMS).
89513173|NCT04931836|Experimental|Experimental Group|Participants in this group will complete the physical activity intervention.
89513174|NCT04931836|No Intervention|Control Group|Participants in this group will be asked to maintain their normal level of physical activity.
89513175|NCT04929808|Active Comparator|Control group|Will receive the standard institutional skin care for acute radiodermatitis
89513176|NCT04929808|Experimental|Experimental group|Will receive the novel, self-prepared skin care product
89513177|NCT04910984|Experimental|Chatbot group|
89513178|NCT04910984|Placebo Comparator|TAU group|
89513179|NCT04910386|Experimental|Envafolimb|"Envafolimab plus Gemcitabine&Cisplatin Envafolimab: 300 mg on Day 1 of each cycle, subcutaneous injection. Every 21 days is a treatment cycle.~Gemcitabine (GEM): 1000 mg/m2 body surface area (BSA) administered on Days 1 and 8 of each cycle. Every 21 days is a treatment cycle with a maximum of 8 cycles.~Cisplatin (CIS): 25 mg/m2 body surface area (BSA) administered on Days 1 and 8 of each cycle. Every 21 days is a treatment cycle with a maximum of 8 cycles."
88960218|NCT05491096|Experimental|Proprioceptive Neuromuscular Training|It consists of 13 patients who will receive conventional exercises and proprioceptive training with 2 sessions per week for 8 weeks.
88960219|NCT05491096|Placebo Comparator|Conventional Physical Therapy|It consists of 13 patients who will receive conventional exercises i.e; strengthening exercises, 2 sessions per week for 8 weeks
88960220|NCT05489549||V122I TTR carriers|"Carriers and controls will undergo standardized, detailed CMRI assessments to test the hypothesis that V122I TTR carrier status will be associated with greater evidence of pathological amyloid progression in comparison with non-carriers.~In addition to the CMRI assessments, carriers and controls enrolled at UT Southwestern will undergo standardized exercise CMRI assessments during the same study visit.~V122I TTR carriers will undergo detailed biomarker assessments. These will be compared with controls and patients with symptomatic V122I hATTR-CA ."
88960221|NCT05489549||Age-, sex-, and race-matched non-carrier controls|"Carriers and controls will undergo standardized, detailed CMRI assessments to test the hypothesis that V122I TTR carrier status will be associated with greater evidence of pathological amyloid progression in comparison with non-carriers.~In addition to the CMRI assessments, carriers and controls enrolled at UT Southwestern will undergo standardized exercise CMRI assessments during the same study visit.~Controls will undergo detailed biomarker assessments. These will be compared with V122I TTR carriers and patients with symptomatic V122I hATTR-CA ."
89513180|NCT04910386|Active Comparator|Gemcitabine&Cisplatin|"Gemcitabine (GEM): 1000 mg/m2 body surface area (BSA) administered on Days 1 and 8 of each cycle. Every 21 days is a treatment cycle with a maximum of 8 cycles.~Cisplatin (CIS): 25 mg/m2 body surface area (BSA) administered on Days 1 and 8 of each cycle. Every 21 days is a treatment cycle with a maximum of 8 cycles."
89513181|NCT04898153|Experimental|aXess|Patients will be implanted with the Xeltis hemodialysis access graft (aXess)
89513182|NCT04895137|Experimental|mFOLFOX6+ Bevacizumab+PD-1 monoclonal antibody treatment combinations|mFOLFOX6+ Bevacizumab+PD-1 monoclonal antibody treatment combinations in patients with local advanced microsatellite stability colon and upper rectum cancer
89513183|NCT04891198|Experimental|Subjects with TMB-H/TMB-L|Subjects receive KN035 400 mg Subcutaneously on Day 1 and day 15 of cycle 1 and on day 1 of every subsequent 4-week cycle (Q4W)
89513184|NCT04873817||IonicRF Generator and compatible accessories|IonicRF Radiofrequency Generator, along with any country-specific market-released accessory (i.e. electrode, cannula, grounding pad, and adaptor cable) compatible with the IonicRF Generator will be used.
89513185|NCT04855474|Experimental|Low Protein|0.2 g/kg/day of protein provided as crystalline amino acid made after egg protein.
89513186|NCT04855474|Experimental|Moderate Protein|1.2g/kg/day of protein provided as crystalline amino acid made after egg protein.
89024522|NCT00432302|Experimental|Sagopilone|Subjects received 28 mg ZK 219477, containing 14 kBq/7.8 µg [14C]-ZK 219477 in the first infusion (Treatment course 1) followed by subsequent infusions (Treatment courses 2 to n [till disease progression]) of 16 mg/m2 ZK 219477 without radioactive label. Interval between the treatments was at least 21 days.
89024523|NCT00463086|Experimental|1.Isoniazid (INH)|A self-administered daily dose of 5mg/kg of Isoniazid (300mg if weight is more than or equal to 50kg and 200mg if weight is less than 50kg)
89024524|NCT00463086|Placebo Comparator|2. Placebo|A self-administered daily dose of 5mg/kg of placebo for 12months (300mg if weight is more than or equal to 50kg and 200mg if weight is less than 50kg)
89024525|NCT02957435|Experimental|eplerenone|(Single arm) Sequence 1: one eplerenone coated tablet 25 mg in fasting (period 1), one eplerenone coated tablet 50 mg in fasting (period 2) and two eplerenone coated tablets 50 mg (100 mg of eplerenone) in fasting (period 3)
89024526|NCT03271359|Experimental|Eye movement desensitization and reprocessing (EMDR) arm|
89024527|NCT03271359|Experimental|Progressive counting (PC) arm|
89024528|NCT02957591|Experimental|Probiotic Group|Over a period of 4 weeks, depressive patients will ingest a probiotic food supplementation (Vivomixx®) 4 times a day. Primary and secondary endpoints will be assessed before and after the intervention.
89024529|NCT02957591|Placebo Comparator|Placebo Group|Subjects in the placebo group will receive a placebo 4 times a day over 4 weeks. Primary and secondary endpoints will be assessed before and after the intervention.
89024530|NCT03271125|Experimental|Treadmill group|Participants in the experimental group received supervised treadmill training
88811575|NCT01280123|Experimental|15 mg pioglitazone|15 mg pioglitazone
88811576|NCT01280123|Experimental|45 mg pioglitazone|45 mg pioglitazone
88811577|NCT01280123|Placebo Comparator|Matching Placebo|Placebo
88811578|NCT04345640||Covid-19 with liver disease|Covid-19 with liver disease
89024531|NCT03271125|Active Comparator|Resistance group|Participants in the control group were treated with Resistance exercises.
89024532|NCT00471471|Experimental|Peptide Vaccine + GM-CSF + Pfizer 3512676 in-ISA Oil|"The water-in-oil emulsion will consist of peptide (100 mcg/0.1 mL), GM-CSF (80 mcg/0.16 mL using lyophilized 500 mcg/vial reconstituted with 1 mL of sterile water), Pfizer PF3512676 (0.6 mg/0.04 mL using 15mg/mL vial) and 0.20 mLl of sterile saline.~Vaccination will be given subcutaneously rotating truncal sites in the vicinity of the four nodal drainage groups of the four extremities, on days 1 and 15 of each cycle (1 cycle = 28 days) for a maximum of 13 cycles (1 year)."
89024533|NCT02273492|Experimental|Asasantin ER after a standardized breakfast|
89024534|NCT02273492|Active Comparator|Asasantin ER at fasted state|
89513187|NCT04855474|Experimental|High Protein|2.0 g/kg/day of protein provided as crystalline amino acid made after egg protein.
89513188|NCT04836871|Experimental|Double filtration plasmapheresis (DFPP) combined with chemotherapy|
89513189|NCT04805528|Experimental|Experimental: Acupuncture-Like Transcutaneous Electrical Stimulation (ALTENS) Therapy|Six (6) small electrodes will be placed on specific points of the body using adhesive pads. These electrodes are connected to the ALTENS device, which will send controlled, low-level electrical impulses through the skin and into the tissue underneath.
89024535|NCT00471510|Experimental|1|NEOSH101 2%
89024536|NCT00471510|Experimental|2|NEOSH101 1%
89024537|NCT00471510|Experimental|3|NEOSH101 0.5%
89513190|NCT04786730|Experimental|Open-label centanafadine|There will be multiple cohorts dosed with open-label centanafadine.
89513191|NCT04754594|Experimental|BNT162b2|2 doses
89513192|NCT04754594|Placebo Comparator|Placebo|2 doses
89513193|NCT04744545|Experimental|Meru Health Program plus adjunctive curcumin (MHP-CUR)|Meru Health Program (12 week program) with participants taking 2 turmeric supplements (1500mg/day) curcumin.
89513194|NCT04744545|Active Comparator|Meru Health Program (MHP-ONLY)|Meru Health Program (12 week program)
89513195|NCT04742751|Experimental|Treatment|Metformin is an antihyperglycemic agent which improves glucose tolerance in patients with type 2 diabetes mellitus, lowering both basal and postprandial plasma glucose. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization. With Metformin therapy, insulin secretion remains unchanged while fasting insulin levels and day-long plasma insulin response may decrease.
89513196|NCT04740905|Experimental|Arm A: Faricimab Q4W (Part 1), Faricimab PTI (Part 2)|In Part 1 (Day 1 through Week 24), participants randomly assigned to Arm A will receive faricimab 6 milligrams (mg) by IVT injection once every 4 weeks (Q4W) from Day 1 through Week 20 (a total of 6 injections). In Part 2 (from Week 24 to Week 72), participants will receive faricimab 6 mg by IVT injection according to a personalized treatment interval (PTI) dosing regimen. To preserve masking for Part 2, a sham procedure will be administered during study visits at which no faricimab treatment is administered (according to the PTI dosing regimen).
89513197|NCT04740905|Active Comparator|Arm B: Aflibercept Q4W (Part 1), Faricimab PTI (Part 2)|In Part 1 (Day 1 through Week 24), participants randomly assigned to Arm B will receive aflibercept 2 milligrams (mg) by IVT injection once every 4 weeks (Q4W) from Day 1 through Week 20 (a total of 6 injections). In Part 2 (from Week 24 to Week 72), participants will receive faricimab 6 mg by IVT injection according to a personalized treatment interval (PTI) dosing regimen. To preserve masking for Part 2, a sham procedure will be administered during study visits at which no faricimab treatment is administered (according to the PTI dosing regimen).
89513198|NCT04738084|Experimental|Meru Health Program|The Meru Health Program (MHP) is a 12-week online mobile digital mental health clinic delivered via Smartphone app that includes components of several evidence-based treatments (Cognitive Behavioral Therapy, Behavioral Activation Therapy, Mindfulness Meditation) and also several promising therapies (heart rate variability-biofeedback [HRVB], nutritional psychiatry, sleep training) and a group support component that is overseen by a licensed clinical therapist.
89513199|NCT04738084|No Intervention|Waitlist|12 week waitlist
89513200|NCT04737512|Experimental|Mindfulness-Based ADHD Treatment for Children|
89513201|NCT04737512|Active Comparator|Medication|
89513202|NCT04737512|Active Comparator|Combined (MBAT-C + medication)|
89513203|NCT04732936|Experimental|Device Usability|Device usability and safety will be evaluated.
89513204|NCT04732936|Experimental|Preliminary Efficacy|Preliminary treatment efficacy will be evaluated.
88811579|NCT04345640||Covid-19 without liver disease|Covid-19 without liver disease
88811580|NCT01280201|Experimental|Pazopanib|
88811581|NCT00851006|Experimental|Open-Label Creatine|Creatine Monohydrate 4 grams daily by mouth
88811582|NCT01364207|Experimental|Caffeinated Coffee 1st Visit, Decaffeinated Coffee 2nd Visit|Participants will be given an 8 oz cup of caffeinated coffee on their first visit and 8 oz cup of decaffeinated coffee on their second visit.
88811583|NCT01364207|Experimental|Decaffeinated Coffee 1st Visit, Caffeinated Coffee 2nd Visit|Participants will be given an 8 oz cup of decaffeinated coffee on their first visit and 8 oz cup of caffeinated coffee on their second visit.
89024538|NCT00471510|Placebo Comparator|4|
89513205|NCT04721327|Experimental|Pediatric Arm|Patient ages 1-17 years who are current cochlear implant (CI) users will receive CI programming in person for the first visit and remotely for the second visit.
89513206|NCT04721327|Experimental|Adult Arm|Patient ages 18-90 years who are current cochlear implant (CI) users will receive CI programming in person for the first visit and remotely for the second visit.
89513207|NCT04717440||Patients accepting palliative care|Patients included in an early phase trial and accepting palliative care
89513208|NCT04717440||Patients refusing palliative car|Patients included in an early phase trial but refusing palliative care
89513209|NCT04709783|Experimental|Implementation Arm|Participants will receive the 3-Step Workout for Life program and other rehabilitation services based on the plan of care.
89513210|NCT04678245|Experimental|Immediate Above the Influence-Vaping Intervention|School receives Above the Influence-Vaping (ATI-V) prevention program training after baseline assessment. Training and intervention continue over two school years (approximately 18 months). Surveys at baseline, 8 months (end 8th grade), 20 mo (end 9th grade), 28 mo (mid-10th grade).
89513211|NCT04678245|Active Comparator|Delayed Above the Influence-Vaping Intervention|Surveys at baseline, 8 months (end 8th grade), 20 mo (end 9th grade), 28 mo (mid-10th grade). ATI-V prevention program training after 4th assessment - after 28 months.
89513212|NCT04667117|Experimental|Cohort 1|RMS patients receiving a 2020-2021, 2021-2022, or 2022-2023 inactivated influenza vaccine at least two weeks prior to ofatumumab start
89513213|NCT04667117|Experimental|Cohort 2|RMS patients receiving a 2020-2021, 2021-2022, 2022-2023 inactivated influenza vaccine at least 4 weeks after ofatumumab start.
89513214|NCT04667117|Experimental|Cohort 3|RMS patients currently on iDMT receiving a 2020-2021, 2021-2022, or 2022-2023 an inactivated influenza vaccine
89513215|NCT04662879|Experimental|Intervention Arm|"Two interventions are performed:~Have Enriching New-onset Diabetes for Pancreatic Cancer (ENDPAC) score calculated, and if Score is >0,~Have abdominal imaging performed."
89513216|NCT04662879|No Intervention|Observation Arm|Passive follow-up by electronic medical record for study endpoints of pancreatic cancer diagnosis.
89513217|NCT04660994||Therapeutic education|Children with disordered breathing requiring CPAP or NIV and followed-up by the pediatric non-invasive ventilation and sleep unit of Necker-Enfants Malades hospital.
89513218|NCT04660994||Therapeutic education and Yapouni educational game|Children with disordered breathing requiring CPAP or NIV and followed-up by the pediatric non-invasive ventilation and sleep unit of Necker-Enfants Malades hospital.
89513219|NCT04643041|Experimental|watch and wait|patients with DNA mismatch repair-deficient or microsatellite instability-high distal rectal cancer accessed pathological complete response after 6 courses of PD-1 monoclonal antibody (200mg/Course/Q3W) therapy and start watch and wait.
89513220|NCT04639973|Experimental|Group 1 (First trimester ultrasound)|
89513221|NCT04639973|Active Comparator|Group 2 (Second trimester anatomy ultrasound)|
88811584|NCT03608696|Experimental|buprenorphine|"Buprenorphine 0.075 mg ml sublingual solution~Initial daily dose 24 mcg/kg/day Initial unit dose 8 mcg/kg q8 hours Maximum daily dose 75 mcg/kg/day Maximum unit dose 25 mcg/kg q8 hours Up-titration rate 33% Maximum # of up-titrations 4 Weaning rate 15% Cessation (bottom) dose < Initial dose Dosing interval until bottom dose (hrs) 8 Dose interval extension #1 at bottom dose (hrs) 12 Dose interval extension #2 at bottom dose (hrs) 24"
88811585|NCT04382690||India|People residing in India
88811586|NCT04382690||United Kingdom|People residing in the United Kingdom
88811587|NCT04382690||China|People residing in China
88811588|NCT04382690||Australia|People residing in Australia
88811589|NCT04382690||South Africa|People residing in South Africa
88811590|NCT04382690||Indonesia|People residing in Indonesia
88811591|NCT04382690||Saudi Arabia|People residing in Saudi Arabia
88811592|NCT01334723||Acute Urinary Retention|This subset of the Integrated Health Care Information Solutions (ICHIS) benign prostate hyperplasia (BPH) study population was used to assess acute urinary retention as a clinical outcome.
88811593|NCT01334723||Prostate Surgery|This subset of the ICHIS BPH study population was used to assess surgery as a clinical outcome.
88811594|NCT03451058||Mild TBI Group|History of head injury, Active Duty Service Member or Veteran, age 18-55, fluent in English
88811595|NCT03451058||Moderate to Severe TBI Group|History of head injury, Active Duty Service Member or Veteran, age 18-55, fluent in English
88811596|NCT03451058||Healthy Controls|No history of head injury, Active Duty Service Member or Veteran, age 18-55, fluent in English
88811597|NCT04311710|Experimental|Part 1 Arm A: mM, mUC, HCC|metastatic Melanoma (mM), metastatic Urothelial Carcinoma (mUC), and advanced Heptocellular Carcinoma (HCC)
88811598|NCT04311710|Experimental|Part 1: Arm B: mM|metastatic Melanoma (mM)
88811599|NCT04311710|Experimental|Part 2: Arm A: NSCLC|metastatic non small cell lung cancer (NSCLC)
89541121|NCT05022004|Active Comparator|Azopt®|
89541122|NCT05004259|Experimental|Arm 1|Six weekly doses of subcutaneous daratumumab 1,800mg and hyaluronidase 30,000U.
89519508|NCT02521831|Active Comparator|Spinal Anesthesia|"These infants will not receive any anesthetic gas prior to the spinal. These infants will be conscious for this procedure.~Spinal will be administered, containing 0.25% isobaric bupivacaine, 1 mg/kg (maximum 5mg), Clonidine, 1 µg/kg, and Epinephrine, 1:200,000.~This arm will receive the Spinal Anesthesia (bupivacaine) intervention exclusively."
89519509|NCT04455035|Active Comparator|Retrospective Group(Control)|
89519510|NCT04455035|Experimental|Prospective Group|
89519511|NCT03129763|Experimental|60mmHg Group|60mmHg capsule pressure expansion. This pressure depends on the ideal capsule pressure that previous study given.
88811600|NCT04311710|Experimental|Part 2: Arm B: RCC|advanced or metastatic renal cell carcinoma (RCC)
89519512|NCT03129763|Experimental|70mmHg Group|70mmHg capsule pressure expansion. This pressure gradient depends on the ideal capsule pressure that previous study given, and the regular expansion pressure in recent studies.
88811601|NCT01402427|Active Comparator|Verapamil|
88811602|NCT01402427|Placebo Comparator|Placebo|
88811603|NCT00813176|Active Comparator|Double Lumen Endotracheal Tube|We used a device called a double lumen tube ( DLT Broncho-Cath®). It is a bifurcated endotracheal tube designed to independently collapse the operated lung.
88811604|NCT00813176|Active Comparator|Arndt Bronchial Blocker|We used a device called a bronchial blocker (9 Fr Arndt® blocker) along with a standard single-lumen tracheal tube (8.0-9.0 mm ID). The Arndt bronchial blocker is a single device, with a distal balloon that is passed thru the single lumen endotracheal once the patient is intubated. The Arndt bronchial blocker is designed to collapse the operated lung.
88811605|NCT01335191|Experimental|TUTI-16 (1.0 mg)|Two subcutaneous injections of 1.0 mg at Day 0 and Week 3.
88811606|NCT01335191|Placebo Comparator|Placebo|Two subcutaneous injections of placebo at Day 0 and Week 3.
88811607|NCT01365611|Experimental|Ketorolac tromethamine|
88811608|NCT01403441|Experimental|Radiosurgical Neuromodulation|Bilateral Radiosurgical Neuromodulation using the Cyberknife
88811609|NCT01404611|Active Comparator|DF289|Ear drops
89519513|NCT03129763|Experimental|80mmHg Group|80mmHg capsule pressure expansion. This pressure gradient depends on the ideal capsule pressure that previous study given, and the regular expansion pressure in recent studies.
89519514|NCT03129763|Experimental|90mmHg Group|90mmHg capsule pressure expansion. This pressure gradient depends on the ideal capsule pressure that previous study given, and the regular expansion pressure in recent studies.
89519515|NCT03129763|Experimental|100mmHg Group|100mmHg capsule pressure expansion. This pressure gradient depends on the regular expansion pressure in recent studies.
89519516|NCT03447925|Experimental|Medicinal Plant X Salicylate|Treatment Group (TG) will receive topical treatment with medicinal plant and Salicylate Group (SG) will receive topical treatment with salicylate 10%, both once a day, for 30 consecutive days.
89519517|NCT03447925|Experimental|Medicinal Plant X Vaseline|Treatment Group (TG) will receive topical treatment with medicinal plant and Control Group (CG) will receive topical treatment with vaseline cream, both once a day, for 30 consecutive days.
89519518|NCT05399225||Platelets to lymphocytes ratio and procalcitonin|Platelets to lymphocytes ratio in patients with sepsis
89519519|NCT05399225||Procalcitonin group|Procalcitonin in patient with sepsis
89519520|NCT03447847|Experimental|Phase 1|A=oligomineral water, B=oligomineral water
89519521|NCT03447847|Experimental|Phase 2|A=oligomineral water, B=bicarbonate-rich water
89519522|NCT03447847|Experimental|Phase 3|A=bicarbonate-rich water, B=oligomineral water
89519523|NCT03447847|Experimental|Phase 4|A=bicarbonate-rich water, B=bicarbonate-rich water
89519524|NCT04928183|Sham Comparator|Room Air Rebreathe|Rebreathe protocol will be completed with a room air syringe rather than CO
89519525|NCT04928183|Experimental|CO Rebreathe|Rebreathe protocol will be completed with Carbon Monoxide
89519526|NCT05399147|Other|classic group (CL group)|20 patients will be enrolled to be intubated using the classic usual technique
89519527|NCT05399147|Other|tube 1st group (TF group)|20 patients will be enrolled to be intubated using the tube 1st technique
89519528|NCT05320861|Experimental|[14C]SJP-0008|
89519529|NCT04622189|Experimental|Action observation training for the upper limb rehabilitation|Neurorehabilitation training for the upper limb using AOT consists of watching videos related to every day actions. The subjects will be asked to reproduce, as accurately as possible, the actions proposed by the system, that will record their execution. In order to keep high motivation and participation in activities, simple games of skill will also be created that will involve the patient on both the motor and cognitive side. The training program includes 250 videos of every day transitive and intransitive actions: 20 consecutive sessions of 1 hour, five times a week over four weeks.
89519530|NCT05320783|Active Comparator|music intervention|Headphone was placed on the each patient. The classical music was started to the patients with individual comfortable volume.
89519531|NCT05320783|Placebo Comparator|control|Headphone was placed on the each patients, but the music player was not started.
89519532|NCT04453865|Experimental|Project EMPOWER|"Project EMPOWER is a web-based, self-administered SSI for parents that takes about 30 minutes to complete. The program includes 5 elements, based on current best-practices in SSI design (Schleider, Dobias, Sung, & Mullarkey, 2020) and existing interventions targeting accommodation (Lebowitz & Omer, 2014): (1) an introduction to the program's rationale; (2) psychoeducation around child anxiety and avoidance, along with how parental accommodation can inadvertently maintain child anxiety; (3) information on how parents can better identify children's patterns of avoidance and encourage brave behavior instead; (4) facilitating parents' creation of an action plan for promoting brave behavior and reduce avoidance in their own child; (5) a vignette exercise in which parents read about another family's difficulty managing their child's anxiety; parents identify the elements of the anxiety cycle and provide possible solutions to these parents based on what they learned."
89519533|NCT04453865|Other|Online Resources and Referrals (ORR)|Online Resources and Referrals (ORR) is an information sheet containing materials about the nature of child anxiety and a list of national resources related anxiety treatment. ORR does not include any psychoeducational components regarding parental accommodation.
89024539|NCT02273531|Experimental|Asasantin ER, new formulation|
89024540|NCT02273531|Active Comparator|Asasantin ER, present commercial formulation|
89024541|NCT01580345|Active Comparator|Docosa-hexaenoic Acid (DHA)|
89024542|NCT01580345|Placebo Comparator|Placebo|Corn-Soy Oil
89024543|NCT00432575|Placebo Comparator|1|
89024544|NCT00432575|Active Comparator|2|surinabant 2,5 mg/day
89024545|NCT00432575|Active Comparator|3|surinabant 5 mg/day
89024546|NCT00432575|Active Comparator|4|surinabant 10 mg/day
89024547|NCT00432614|Experimental|Group 1|SR58611A 350mg twice daily with escitalopram 10mg once daily
89024548|NCT00432614|Active Comparator|Group 2|placebo with escitalopram 10mg once daily
88811610|NCT01404611|Active Comparator|DF277|Ear drops
89513222|NCT04635722|Experimental|Weight Management Intervention|During a 12-month period, participants will attend a total of 22 diet improvement sessions, each of which will last approximately 1 hour. Twelve sessions will be held in the first 5 months and will be focused on safe and efficient weight loss. The participants will learn to create a personalized weight loss diet from their kitchen based on their diet practice and food preference. The next 10 sessions will be held in the last 7 months and will be focused on weight maintenance and healthy eating. The participants will build skills to select foods and create meals that prevent them from overeating. Participants will be followed by daily self-weighing for 1 year after intervention.
89513223|NCT04596163|Active Comparator|Intervention|Ultrasound guided Regional block using 0.25% levobupivacaine (local anaesthetic agent) 20ml (50mg) on each side of the sternum over 1-2 minutes after general anaesthesia before surgery.
89513224|NCT04596163|Placebo Comparator|Control|Ultrasound guided Regional block using 20ml of 0.9% normal saline on each side of the sternum after general anaesthesia before surgery.
89513225|NCT04594551|Experimental|Group 1: VRVg-2 + HRIG|"VRVg-2 4 injections: 2 at Day 0, 1 at Day 7, 1 at Day 21~+ HRIG at D0"
89513226|NCT04594551|Active Comparator|Group 2: Verorab + HRIG|"Verorab 4 injections: 2 at Day 0, 1 at Day 7, 1 at Day 21~+ HRIG at D0"
89541123|NCT04988555|Experimental|Phase 1 Arm A without Antifungals|Patients not taking antifungals within 7 days of study entry
88811611|NCT01404611|Experimental|DF289 plus DF277|Ear drops
88811612|NCT01365845|Active Comparator|1|Conventional photon plan
88811613|NCT01365845|Experimental|2|3D-Proton/Conventional plan or 3D-proton only
89024549|NCT00432614|Placebo Comparator|Group 3|placebo
89024550|NCT00463398||Patients operated at the LUFc|All patients operated at the Leuven University Fertility Centre (LUFc) between september 2006 and August 2008.
89024551|NCT01051817|Experimental|AIN457|
89024552|NCT01051817|Placebo Comparator|Placebo|
89024553|NCT04703660|Active Comparator|group A|This group will receive antero-posterior cervical mobilization at c5-6 grade III oscillation
89024554|NCT04703660|Active Comparator|group B|This group will receive lateral glide cervical mobilization at c5-6 grade III oscillation
89024555|NCT04703660|Active Comparator|group C|This group will receive postero-anterior cervical mobilization at c5-6 grade III oscillation
89024556|NCT01327846|Experimental|Canakinumab Dose 50 mg|"Pivotal Phase:~Blinded Canakinumab 50 mg quarterly subcutaneous + standard of care therapy.~Extension Phase:~Switched to open-label Canakinumab 150 mg quarterly subcutaneous + standard of care therapy"
89024557|NCT01327846|Experimental|Canakinumab Dose 150 mg|"Pivotal Phase:~Switched to open-label Canakinumab 150 mg quarterly subcutaneous + standard of care therapy"
89024558|NCT01327846|Experimental|Canakinumab Dose 300 mg|"Pivotal Phase:~Blinded Canakinumab 300 mg quarterly subcutaneous (with one additional dose at week 2) + standard of care therapy.~Extension phase:~Switched to open-label Canakinumab 150 mg quarterly subcutaneous + standard of care therapy"
89024559|NCT01327846|Placebo Comparator|Placebo|"Pivotal Phase:~Blinded matching placebo quarterly subcutaneous + standard of care therapy.~Extension Phase:~Switched to open-label Canakinumab 150 mg quarterly subcutaneous + standard of care therapy"
89024560|NCT00432926|Experimental|1|Five-session behavior change intervention that combines client-centered motivational interviewing and structured behavioral counseling (to address context of unsafe sex/drug use; condom use, safer sex negotiation; disclosure; and enhancement of social supports).
89513227|NCT04590170||Patients with Covid19 infection|Patients with Covid19 infection
89513228|NCT04590170||Control group|Asymptomatic group
89513229|NCT04585399|Experimental|Contingency Management|Participants in this arm of the study will receive financial incentives for attending their buprenorphine appointments and for being clean from other opioids. Participants in this group will also have up to two rides per week paid for to attend bup appointments.
89513230|NCT04585399|No Intervention|Standard Care|Participants in this group will be treatment as usual and will not receive any incentives for attending their bup appointments or for being opioid abstinent.
89513231|NCT04566367|Active Comparator|Standard White Light Imaging|In this group the participants will be examined by white light endoscopy first and secondly with blue laser imaging technique during the same gastroscopy.
89513232|NCT04566367|Experimental|Blue Light Imaging|In this group the participants will be examined by blue laser imaging technique first and secondly with standard white light during the same gastroscopy.
89513233|NCT04546867|Other|Sonography arm|Sonography is being performed by expericenced investigators to visualize a pancreatic stent in the pancreatic duct. If the stent is being visualized, an endoscopy will be performed to remove the stent. Otherwise, x-ray will be needed to confirm the sonographic finding of a dislodged pancreatic stent with no further need of intervention. If x-ray finds a pancreatic stent in situ opposingly to ultrasound, an endoscopy will be performed to confirm the stents position and eventually remove it.
89513234|NCT04510194|Experimental|Treatment Arm - Metformin Only Group|Participants in the treatment arm of the trial are those who test positive for SARS-COV-2 infection at the time of screening. Participants in this arm and group will receive the metformin alone.
89513235|NCT04510194|Placebo Comparator|Treatment Arm - Placebo Group|Participants in the treatment arm of the trial are those who test positive for SARS-COV-2 infection at the time of screening. Participants in this arm and group will receive the placebo.
89513236|NCT04510194|Experimental|Treatment Arm - Ivermectin Only Group|Participants in the treatment arm of the trial are those who test positive for SARS-COV-2 infection at the time of screening. Participants in this arm and group will receive the ivermectin alone.
89024561|NCT00432926|Experimental|2|Five-session behavior change intervention (identical to Arm 1) that combines client-centered motivational interviewing and structured behavioral counseling (to address context of unsafe sex/drug use; condom use, safer sex negotiation; disclosure; and enhancement of social supports) PLUS eight group-format safer sex maintenance counseling sessions, which utilize clinical strategies from relapse prevention to identify high risk situations and develop effective coping strategies.
89024562|NCT00432926|Active Comparator|3|An attention-control condition that is time-equivalent to Arm 2, and addresses diet, exercise, and HIV.
89024563|NCT00433043|Active Comparator|1|CRT and b-blocker uptitration to target dose
89513237|NCT04510194|Experimental|Treatment Arm - Fluvoxamine Only Group|Participants in the treatment arm of the trial are those who test positive for SARS-COV-2 infection at the time of screening. Participants in this arm and group will receive the fluvoxamine alone.
89513238|NCT04510194|Experimental|Treatment Arm - Metformin and Fluvoxamine Group|Participants in the treatment arm of the trial are those who test positive for SARS-COV-2 infection at the time of screening. Participants in this arm and group will receive metformin and fluvoxamine.
89513239|NCT04510194|Experimental|Treatment Arm - Metformin and Ivermectin Group|Participants in the treatment arm of the trial are those who test positive for SARS-COV-2 infection at the time of screening. Participants in this arm and group will receive metformin and ivermectin.
89513240|NCT04503174||Pump Naive|New to insulin pump use
89513241|NCT04503174||6-13 YO|Subjects between the age of 6-13 years old.
89513242|NCT04503174||14-17 YO|Subjects between the age of 14-17 years old.
89513243|NCT04503174||Adults (18+)|Subjects are 18 years old and older.
89513244|NCT04503174||CGM Naive|Subjects have not used CGM in the 30 days prior to enrollment.
89513245|NCT04503174||HbA1c more than or equal to 8.5%|Subjects have an HbA1c of more than or equal to 8.5% in the 3 months prior to enrollment.
89513246|NCT04503174||HbA1c less than or equal to 8.5%|Subjects have an HbA1c of less than or equal to 8.5% in the 3 months prior to enrollment.
89513247|NCT04502966|Experimental|Grazax® +Dupixent®|"Participants randomized to this assignment will receive the following during the initial 2-year period of the trial:~Once daily tablet of Grazax® sublingual immunotherapy and~Dupixent® administered every other week (e.g., biweekly) by subcutaneous injection"
89513248|NCT04502966|Experimental|Grazax® + Dupixent® Placebo|"Participants randomized to this assignment will receive the following during the initial 2-year period of the trial:~Once daily tablet of Grazax® sublingual immunotherapy and~Placebo for Dupixent® administered every other week (e.g., biweekly) by subcutaneous injection"
89513249|NCT04502966|Placebo Comparator|Grazax® Placebo +Dupixent® Placebo|"Participants randomized to this assignment will receive the following during the initial 2-year period of the trial:~Once daily tablet of placebo for Grazax® sublingual immunotherapy and~Placebo for Dupixent® administered every other week (e.g., biweekly) by subcutaneous injection"
89513250|NCT04482803|Experimental|Carbon nanoparticles labelled lymph nodes group|Carbon nanoparticles suspension injection will be injected into or around the cortex of the clinically assessed positive lymph nodes before NST.
89513251|NCT04465253|Experimental|Health services research (discussion, interview)|Patients participate in a discussion with an occupational therapist via videoconferencing over 15 minutes QW for 4 weeks about their experience with lymphedema and the occupational services they received. After 4 weeks, some patients may also participate in an interview with an occupational therapist via videoconferencing over 60 minutes. During the first week of the study, patients also receive occupational therapy per standard of care.
89513252|NCT04424914|Other|ATTR-CM positive|Participants diagnosed with ATTR-CM by scintigraphy
89513253|NCT04424914|Other|ATTR-CM negative|Participants who are scintigraphy negative for ATTR-CM
89513254|NCT04397822||COVID-19 GROUP Intensive care unit|Patients suffering from COVID-19 hospitalized in intensive care unit
89513255|NCT04397822||COVID-19 GROUP Standard care unit|Patients suffering from COVID-19 hospitalized in standard care unit.
89513256|NCT04390009|Other|Siemens Biograph Vision PET-CT scans|Parallel study arms defined by PET-CT scanners by different manufacturer and model
89513257|NCT04390009|Other|United Imaging uEXPLORER PET-CT scans|Parallel study arms defined by PET-CT scanners by different manufacturer and model
89024564|NCT00433043|Active Comparator|2|CRT and continuation of entry b-blocker dose to 6 month evaluation
89513258|NCT04376242|Experimental|virtual reality then standard technology|patients randomized to this arm will first use virtual reality (VR) during and oral food challenge and then use standard technology during a second oral food challenge
89513259|NCT04376242|Active Comparator|standard technology then virtual reality|patients randomized to this arm will first use standard technology during and oral food challenge and then use virtual reality during a second oral food challenge
89513260|NCT04357366|Experimental|Anakinra|Patients will receive 100mg of anakinra subcutaneously once daily for ten days. The drugs should be administered on the same time ± 2 hours every day. All other administered drugs are allowed. In case the patient is discharged home before the completion of 10 days of treatment, it is at the discretion of the investigator to suggest treatment continuation at home. In case such a decision is taken, the patient will be provided the required number of pre-filled syringes for daily self-injection. In this case, the patient should return the empty used syringes within 30 days.
89513261|NCT04346433|Experimental|Adolescents with Normal Weight|This group will be comprised of 30 adolescents with normal weight (BMI equal to or greater than the 5th percentile but less than the 85th percentile). Participants will be asked to engage in the sleep manipulation intervention.
89513262|NCT04346433|Experimental|Adolescents with Overweight or Obesity|This group will be comprised of 30 adolescents with overweight or obesity (BMI equal to or above the 85th percentile). Participants will be asked to engage in the sleep manipulation intervention.
89513263|NCT04335461|Placebo Comparator|Placebo|Placebo group, with no regional nerve blockade administered.
89513264|NCT04335461|Experimental|Fracture block|Patients will have an intrafragmentary fracture block using fluoroscopy guidance after surgical fixation with 30cc 0.25% marcaine
89513265|NCT04335461|Experimental|Fascia iliaca block|Fascia iliaca compartment blockade administered after surgical fixation using the loss of resistance technique with 30cc 0.25% marcaine
89541124|NCT04988555|Experimental|Phase 1 Arm B with Antifungals|Patients receiving anti-fungals that are moderate to strong cytochrome CYP3A4/5 inhibitors (i.e. Posaconazole, voriconazole, fluconazole, or isavuconazonium (prodrug of isavuconazole).
89541125|NCT04988555|Experimental|Phase 2 Arm A AML with MLL (KMT2A) gene rearrangements|Patients with R/R AML w/MLL (KMT2A) gene rearrangements
89541126|NCT04988555|Experimental|Phase 2 Arm B: AML with NPM1c mutations|Patients with R/R AML w/ NPM1c mutations
89541127|NCT04988503|Experimental|Second-generation hydrogel coil group|Treatment using second-generation hydrogel coils (had to constitute > 50% of the total coil length) for ruptured cerebral aneurysms
89541128|NCT04988503|Active Comparator|Bare platinum coil group|Treatment using bare metal coil only for ruptured cerebral aneurysms
88960222|NCT05489549||Patients with symptomatic V122I hATTR-CA|Patients with symptomatic V122I hATTR-CA will undergo detailed biomarker assessments. These will be compared with V122I TTR carriers and controls.
88960223|NCT05489354|Experimental|mHealth psychoeducational intervention|The intervention group will receive six weeks mHealth psychoeducational intervention (mPEI) delivered through a mobile application.
88960224|NCT05489354|No Intervention|Control Group|No psychoeducational intervention will be given.
88960225|NCT05488366|Experimental|A: Pembrolizumab + Radiation Therapy|Patients receive pembrolizumab 400 mg intravenous every 42 days; Radiation therapy in 1 to 10 fractions.
88960226|NCT05488366|Experimental|B: Radiation Therapy with or without standard of care checkpoint inhibitor immunotherapy|Patients who are currently receiving a checkpoint inhibitor immunotherapy regimen will be allowed to continue their regimen at their treating oncologist's discretion. Radiation therapy will be delivered in 1 to 10 fractions starting on Day 1.
88960227|NCT05481060|Experimental|Screen-based simulation|Screen-based simulation about intimate partner violence against women prepared by researchers will apply to nursing students.
88960228|NCT05481060|No Intervention|Control group|Online didactic education about intimate partner violence against women prepared by researchers will apply to nursing students.
88960229|NCT05477368|Experimental|Exogenous Ketone Supplement|Participants will be instructed to consume a total of 711 mL of the exogenous ketone supplement drink (for a total of 30 g of beta-hydroxybutyrate) per day (3 doses at 237 mL containing 10 g of beta-hydroxybutyrate each) for a period of 90 days.
88960230|NCT05477368|Placebo Comparator|Inert placebo|Participants will be instructed to consume an equivalent volume (711 mL) of taste- and volume-matched placebo per day (3 doses at 237 mL) for 90 days.
88960231|NCT05475132|Experimental|Exergaming|App based exercise games for dexterity will be used
88960232|NCT05475132|Active Comparator|Conventional Dexterity Exercises|Dexterity exercises used conventionally will be done in this.
88960233|NCT05474560|Experimental|Allopurinol group|Allopurinol (100 mg/day) plus lifestyle intervention
88960234|NCT05474560|Experimental|Febuxostat group|Febuxostat (40 mg/day) plus lifestyle intervention
88960235|NCT05474560|Active Comparator|lifestyle intervention|diet and exercise
88960236|NCT05471960||Observational Group|Each subject will attend eight testing sessions (MRI scanning, two TMS-motor test visits, two TMS-prefrontal test visits, motor assessments, neuropsychological testing, and overnight sleep testing (polysomnography - PSG).
88960237|NCT05469893|Active Comparator|Lenalidomide + Dexamethasone (LD)|"Each study treatment cycle lasts 28 days. Participants will be randomized into either Teclistamab arm or Lenalidomine + Dexamethoasone arm~Lenalidomine~Dexamethoasone"
88960238|NCT05469893|Experimental|Teclistamab|"Each study treatment cycle lasts 28 days. Participants will be randomized into either Teclistamab arm or Lenalidomine + Dexamethoasone arm~- Teclistamab-Per Protocol"
89024565|NCT00463593||2|children enrolled in formal schools and children not enrolled in formal schools
89024566|NCT01051739||Group 1|glaucoma
89024567|NCT01051739||Group 2|normal
89541129|NCT04985760|Experimental|Randomized Blinded Trimer 4571 Vaccine 100mcg|Six (6) participants will receive Trimer 4571 vaccine 100mcg with 500mcg alum adjuvant as a 1ml intramuscular injection at Day 0, Week 8 and Week 20.
89541130|NCT04985760|Placebo Comparator|Randomized Blinded Placebo for Trimer 4571 Vaccine 100mcg|Two (2) participants will receive the placebo control for Trimer 4571 vaccine 100mcg as a 1ml intramuscular injection at Day 0, Week 8 and Week 20.
89541131|NCT04985760|Experimental|Randomized Blinded Trimer 4571 Vaccine 500mcg|Eighteen (18) participants will receive Trimer 4571 vaccine 500mcg with 500mcg alum adjuvant as a 1.1ml intramuscular injection at Day 0, Week 8 and Week 20.
89541132|NCT04985760|Placebo Comparator|Randomized Blinded Placebo for Trimer 4571 Vaccine 500mcg|Six (6) participants will receive the placebo control for Trimer 4571 vaccine 500mcg as a 1.1ml intramuscular injection at Day 0, Week 8 and Week 20.
89541133|NCT04984304|Experimental|Mild cough|Mild cough only slightly worsening the quality of life (VAS 1-3)
88960239|NCT05468957|Active Comparator|Perclose Only|Patients will have a PercloseTM device deployed at the arteriotomy. Manual pressure will be held for at least one minute, the beginning of which will correspond to time point zero. Patent hemostasis will be documented after device deployment. Any manual compression needed or per protocol under the disgression of the operator will count towards the time to hemostasis. After hemostasis is achieved in the cath lab the patient will be sent to the post-operative area for monitoring. If any additional bleeding is appreciated, manual compression will again be held. Two hours after the patient has had the PercloseTM device deployed the patient will ambulate. If any new bleeding from the puncture site or under the skin the patient will again lay supine and at least 10 minutes of manual pressure will be held and the an ambulation trial will be attempted at least 30 minutes after the subsequent trial. This will be continued until the patient has no bleeding at the time of ambulation.
89513266|NCT04300192|Experimental|Group 1: Adacel Quadra vaccine|Adacel Quadra single injection at Day 0 in participants who received 4 doses of whole-cell pertussis (wP) vaccine during the first 2 years of life
88960240|NCT05468957|Experimental|Perclose with Statseal Device|Patients will have a PercloseTM device deployed at the arteriotomy. A Statseal disc will applied and manual pressure will be held for at least one minute, the beginning of which will correspond to time point zero. Patent hemostasis will be documented after device deployment. Any manual compression needed will count towards the time to hemostasis. After hemostasis is achieved in the cath lab the patient will be sent to the post-operative area for monitoring. If any additional bleeding is appreciated, manual compression will again be held. Two hours after the patient has had the PercloseTM device deployed the patient will ambulate. If any new bleeding from the puncture site or under the skin the patient will again lay supine and at least 10 minutes of manual pressure will be held and the an ambulation trial will be attempted at least 30 minutes after the subsequent trial. This will be continued until the patient has no bleeding at the time of ambulation.
89513267|NCT04300192|Experimental|Group 2: Adacel Quadra vaccine|Adacel Quadra single injection at Day 0 in participants who received 3 doses of wP followed by 1 dose of acellular pertussis (aP) vaccine during the first 2 years of life
89513268|NCT04300192|Experimental|Group 3: Adacel Quadra vaccine|Adacel Quadra single injection at Day 0 in participants who received 2 doses of wP vaccine followed by 2 doses of aP vaccine during the first 2 years of life
89513269|NCT04300192|Experimental|Group 4: Adacel Quadra vaccine|Adacel Quadra single injection at Day 0 in participants who received 1 dose of wP vaccine followed by 3 doses of aP vaccine during the first 2 years of life
89513270|NCT04300192|Experimental|Group 5: Adacel Quadra vaccine|Adacel Quadra single injection at Day 0 in participants who received 4 doses of aP vaccine during the first 2 years of life
89513271|NCT04300192|Experimental|Group 6: Adacel Quadra vaccine (HIV positive)|Adacel Quadra single injection at Day 0 in HIV + participants who received 4 doses of wP vaccine during the first 2 years of life
89513272|NCT04300192|Experimental|Group 7: Adacel Quadra vaccine (HIV positive)|Adacel Quadra single injection at Day 0 in HIV + participants who received 4 doses of aP vaccine during the first 2 years of life
89513273|NCT04286516|Experimental|Reaching with TMS|All participants enrolled in this group will receive TMS while performing reaching movements in a robotic system.
89513274|NCT04258761|Experimental|10XB-101 Solution for Injection 1.25%|Participants receive 10XB-101 Solution for Injection, 1.25% via subcutaneous injection up to 10 mL on Day 1 of subject participation.
89513275|NCT04258761|Experimental|10XB-101 Solution for Injection 2.0%|Participants receive 10XB-101 Solution for Injection, 2.0% via subcutaneous injection up to 10 mL on Day 1 of subject participation.
89513276|NCT04258761|Experimental|10XB-101 Solution for Injection 3.0%|Participants receive 10XB-101 Solution for Injection, 3.0% via subcutaneous injection up to 10 mL on Day 1 of subject participation.
89513277|NCT04258761|Experimental|10XB-101 Solution for Injection 4.5%|Participants receive 10XB-101 Solution for Injection, 4.5% via subcutaneous injection up to 10 mL on Day 1 of subject participation.
89513278|NCT04258761|Experimental|10XB-101 Solution for Injection 6.0%|Participants receive 10XB-101 Solution for Injection, 6.0% via subcutaneous injection up to 10 mL on Day 1 of subject participation.
89513279|NCT04226131|Other|Early Rheumatoid Arthritis (RA)|"Early RA defined as duration of disease/symptoms of less than 6 months (where duration denotes the length of time the patient has had symptoms/disease, not the length of time since RA diagnosis) AND prior to starting biologic Disease-modifying anti-rheumatic drugs (bDMARD) therapy"
89513280|NCT04226131|Other|Age-, Sex-, BMI-matched Healthy Controls|Healthy Controls.
89513281|NCT04210843|Experimental|Ligelizumab 72 mg LIVI -ligelizumab 120 mg PFS|Participants received 72 mg of ligelizumab liquid in vial (LIVI) subcutaneously every 4 weeks for the first 12 weeks. Thereafter, participants received 120 mg of ligelizumab pre-filled syringe (PFS) subcutaneously every 4 weeks for up to 92 additional weeks (continuous or interrupted if the participant entered the observation period 2).
89513282|NCT04210843|Experimental|Ligelizumab 120 mg LIVI -ligelizumab 120 mg PFS|Participants received 120 mg of ligelizumab liquid in vial (LIVI) subcutaneously every 4 weeks for the first 12 weeks. Thereafter, participants received 120 mg of ligelizumab pre-filled syringe (PFS) subcutaneously every 4 weeks for up to 92 additional weeks (continuous or interrupted if the participant entered the observation period 2).
89513283|NCT04202029|Other|pulseoxymetry arm|pulseoxymetry arm: standard monitoring: pulseoxymetry and non-invasive blood preassure monitoring
89513284|NCT04202029|Experimental|thoracic impedance monitoring arm|thoracic impedance monitoring arm: standard monitoring and additionally thoracic impedance measurement)
89513285|NCT04200196|Experimental|"Fabrique à histoire"|"Children 3 to 6 years in pediatric emergency needing to venous puncture and randomized in the fabrique à histoire (Lunii(R)) arm in addition to the routine anaesthetic cream patch."
89513286|NCT04200196|Active Comparator|Usual care|Children 3 to 6 years in pediatric emergency needing to venous puncture and randomized in the habitual care arm in addition to the routine anaesthetic cream patch.
89513287|NCT04188665|Experimental|MASL treated|Patients treated with lozenge containing MASL
89513288|NCT04188665|Placebo Comparator|Placebo treated|Patients treated with lozenge without MASL
89513289|NCT04064294||Statin Before Levodopa|Historical use of a statin BEFORE beginning levodopa
89513290|NCT04064294||Statin After Levodopa|Historical use of a statin AFTER beginning levodopa
89513291|NCT04064294||No Statin|No historical use of a statin
88960241|NCT05467397|Experimental|Patients will undergo [11C]acetate PET/CT|Patients will undergo a single [11c]acetate PET scan OR Patients will undergo an [11c]acetate PET scan, initiate treatment with rapamycin or rapalogs and receive a second [11c]acetate PET scan 3 or 4 months after starting the treatment.
88960242|NCT05460013|Placebo Comparator|Placebo Control|
89513292|NCT04042454|Experimental|Test Product|Cow's milk-based infant formula containing the thickener locust bean gum containing prebiotic oligosaccharides and postbiotics
89513293|NCT04042454|Active Comparator|Control Product|Cow's milk-based infant formula containing prebiotic oligosaccharides and postbiotics
89513294|NCT04029168||Pelvic floor surgery|The group will consist of females with pelvic floor disorders (pelvic organ prolapse, stress urinary incontinence) qualified for pelvic floor surgery
89513295|NCT04009044|Experimental|Treatment (afimoxifene)|Patients apply afimoxifene gel topically QD to both breasts for 3 to 5 weeks and then undergo core needle biopsies of both breasts.
89513296|NCT03865927|Experimental|GKT137831|GKT137831 will be administered orally, at a dose of 400 mg twice daily, for a total of 24 weeks.
89513297|NCT03865927|Placebo Comparator|Placebo Oral Tablet|Identically-appearing placebo oral tablets will be administered orally, twice daily, for a total of 24 weeks.
89513298|NCT03858998|Experimental|Case Management Intervention|A 90-day case management intervention to link hospitalized HIV-infected participants with local HIV clinics.
89513299|NCT03858998|Other|Control|Current routine HIV care in Tanzania.
89513300|NCT03759834|Experimental|Testing Arm|"There will only be one arm. The patient and investigator will initially be blinded to the on-off status of the electrode. The patient will thus serve as an internal control for testing. Once device integrity and possible benefit is confirmed, the patients will undergo non-tactile electrical stimulation to the bone of the inner ear (cochlear promontory) for short term relief of tinnitus via Cochlear promontory stimulation."
89513301|NCT03749551||Participants|diagnostic test - patients serving as their own controls
89513302|NCT03699319|Experimental|Standard Dose Cohort: CPI-613 + mFOLFIRINOX|"Novel drug and mitochondrial inhibitor, CPI-613 in conjunction with standard-of-care FOLFRINOX.~Consists of a Standard Dose Cohort and Dose escalation cohort using a standard 3 + 3 design starting at 750 mg/m^2 given at a rate of 4 ml/min (dose level (DL) 2). Participants receiving a dose of 1000mg/m^2 will be treated over 2 hours. In the absence of any DLT, the next DL will begin enrollment. If 1 DLT occurs, the DL will be expanded by 3 participants. If <33% of participants experience a DLT, the next DL will be opened and will proceed in similarly. Only 2 DLs are expected to be studied: 750 mg/m^2 and 1000 mg/m^2.~Participants may be enrolled in this cohort after the accrual goal of the standard cohort is met but prior to the completion of treatment of all patients in the standard dose cohort~Participants experiencing a DLT will be allowed to continue on the study at the standard DL of 500 mg or lower."
89513303|NCT03689907||Allogeneic Stem-Cell Transplant Recipients|"At day +14/15-post transplant - lineage-specific chimerism analysis will be performed on a peripheral blood sample drawn from the patient.~At day +30-post transplant, most participants will be in the outpatient setting and would undergo chimerism evaluation as part of the standard of care for transplant patients."
89513304|NCT03636919||experimental group|patient with pollen allergic rhinitis patients will filled an e-BOOK included questionnaires of life
89513305|NCT03618771|Experimental|Medacta GMK Sphere|Half of the patients will be implanted with the Medacta GMK Sphere total knee arthroplasty
89513306|NCT03618771|Experimental|DePuy Synthes Attune|Half of the patients will be implanted with the DePuy Attune total knee arthroplasty
89513307|NCT03594435|Experimental|Ibudilast|10mg delayed-release capsules, target dose 50mg BID (5 x 10mg capsules twice daily) for 12 weeks
89513308|NCT03594435|Placebo Comparator|Placebo Oral Capsule|matched to experimental drug
89513309|NCT03582566|Experimental|Phonological Awareness|Children will play games to practice their rhyming, sound sequencing, and letter-sound knowledge. These games are all implemented in the Earobics program.
89513310|NCT03582566|Experimental|Working Memory|Children will play games designed to help them hold and manipulate objects in memory. These games are implemented in Cogmed.
89513311|NCT03582566|Experimental|Phonological Awareness + Working Memory|Children will practice both their sound skills (Earobics) and their memory skills (Cogmed).
89513312|NCT03582566|Active Comparator|Active Control|Children will play games to practice their addition and subtraction skills (Splashmath).
89513313|NCT03566446|Experimental|36 aminoacid CALR exon 9 mutated peptide|15 vaccines, over the course of 1 year
89513314|NCT03563729|Experimental|B: Pembrolizumab (Prednisolone >10 mg)|Intravenous infusion of pembrolizumab 2 mg/kg every third week for up to two years.
89513315|NCT03563729|Experimental|C: Ipilimumab/nivolumab (Prednisolone 11-25 mg)|Intravenous infusion of ipilimumab 3 mg/kg and nivolumab 1 mg/kg four times every three weeks in the induction phase and nivolumab 480 mg every four weeks in the maintenance phase for up to two years.
89513316|NCT03563729|Experimental|D: Ipilimumab/nivolumab (Prednisolone >25 mg)|Intravenous infusion of ipilimumab 3 mg/kg and nivolumab 1 mg/kg four times every three weeks in the induction phase and nivolumab 480 mg every four weeks in the maintenance phase for up to two years.
89541134|NCT04984304|Experimental|Moderate and severe cough|Moderate and severe cough that significantly worsen the quality of life (VAS 4-10)
89541135|NCT04963920|Experimental|SoC+CytoSorb treatment|patients allocated to this group, will receive CytoSorb therapy in addition to the standard of care therapy according to applicable guidelines
89541136|NCT04963920|No Intervention|Standard of Care (SoC)|patients allocated to this group will receive only standard of care therapy according to applicable guidelines
88960243|NCT05460013|Experimental|Oral Nutritional Intervention|
89541137|NCT04954573|Other|Morphea|
89541138|NCT04954573|Other|Sclerotic graft-versus-host disease (GVHD)|
89541139|NCT04953507|Experimental|Thermal Radiofrequency|T2, T3 block by thermal radiofrequency lesioning at 80°c for 60-90 seconds
88960244|NCT05444751|Experimental|SA + ESP Block|Spinal Anesthesia: Patients will be provided with iv sedation, if desired, to facilitate placement of spinal anesthetic. Midazolam (2-5mg, iv), ketamine (up to 20 mg, lv) and/or propofol (0.1-0.2 mg/kg) will be permitted.
88960245|NCT05444751|Active Comparator|GA + ESP Block|General anesthesia: induction of general anesthesia to facilitate endotracheal intubation: fentanyl (up to 2μg.kg.min-1), propofol (1-2 mg.kg-1), vecuronium (1-2 mg.kg-1).
89541140|NCT04953507|Active Comparator|Chemical Neurolysis|T2, T3 block by chemical neurolysis using 2-3 ml of phenol in glycerin 6%
89541141|NCT04953208|Active Comparator|Active treatment|active tDCS (using the Neuroelectrics Starstim tCS 5G kit) and cognitive and emotional control video game
89541142|NCT04953208|Sham Comparator|Sham treatment|sham tDCS (using the Neuroelectrics Starstim tCS 5G kit) and non-active videogame
89541143|NCT04952610|Experimental|Etripamil NS 70 mg|Self- administration of a dose of 70 mg of etripamil. Patients will be provided with a maximum of 4 pre-filled devices at a time. If the symptoms of PSVT persist 10 minutes after the first dose of etripamil NS 70 mg, a second dose of etripamil NS 70 mg can be self-administered by the patient. A second dose of etripamil NS 70 mg should be taken not earlier than 10, and not later than 15 minutes after the first dose.
88960248|NCT05429944|Experimental|Motor Relearning Program|"MRP is a task- oriented approach to improve motor control, focusing on relearning of daily activities. Based on 4 steps~1.Analysis of task 2.Practice of missing component 3.Practice of task 4.Transference of learning"
88960249|NCT05429944|Experimental|Proprioceptive Neuromuscular Facilitation|Proprioceptive Neuromuscular Facilitation (PNF) is the neurophysiological approach in which impulses from the periphery are facilitated to the central nervous system through the stimulation of sensory receptors present in muscles and around the joints by stretch, resistance, traction, approximation and audiovisual command to the patient. The techniques administered included Rhythmic Initiation, Slow Reversal and Agonistic Reversal.
88960250|NCT05429944|Active Comparator|Conventional Physical Therapy|Electrotherapy includes TENS, Electrical stimulation and Heat therapy. ROM . Stretching and positioning Exercises Strengthening Exercises for the weak muscles. Sensory Interventions.
88960251|NCT05425199|Experimental|habituation exercises|head and eye movements first slowly then rapidly, head and body movements e.g., picking object from the ground standing and rotation in standing
88960252|NCT05425199|Experimental|proprioceptive training|Single leg stance (right side) + Single leg stance (left side) Lifting of right knee as high as comfortable and then alternative knee Tandem walking ,Toe walking ,Heel walking
88960253|NCT05425199|Active Comparator|Conventional vestibular therapy|Epley's Manuever
88960254|NCT05423587|Experimental|GAE Treatment|The genicular artery embolisation procedure identifies abnormal blood vessels in the knee via angiogram imaging. Through groin access and puncture of the femoral artery through a small sheath tiny microspheres (Embozene(TM)) will be injected into this area and reduce blood flow in order to reduce pain.
88960255|NCT05423587|Sham Comparator|Sham Procedure|In the control (sham) arm patients will not undergo the embolisation procedure with microspheres, instead they will have 2ml of saline injected into their knee artery supplying the abnormal area of the knee. The remainder of the procedure is otherwise identical between the two groups.
88960256|NCT05422534|Placebo Comparator|Observational + placebo|Participants will receive placebo with standard of care or regular activity for 12 weeks.
88960257|NCT05422534|Active Comparator|Observational+ CoQ10|Participants will receive CoQ10 1800 mg/day with standard of care or regular activity for 12 weeks.
88960258|NCT05422534|Placebo Comparator|HB HIIT +placebo|Participants will receive placebo and home based high intensity interval training for 12 weeks. Exercise will be performed on a non-dialysis day, it will be video-supervised exercise sessions, three days per week for 12 weeks. The three weekly sessions will include: 1 session of 1) body weight high-intensity interval training (bodyweight HIIT), 2) strength training, and 3) walking high-intensity interval training (walking HIIT).
89541144|NCT04947553|Experimental|AXS-05 (dextromethorphan-bupropion)|Up to 24 weeks
89541145|NCT04930965|Experimental|Intervention|
89541146|NCT04930965|No Intervention|Usual care|
89541147|NCT04928911||Adults receiving COVID-19 vaccine|Adults about to receive a COVID-19 vaccine fill out a questionnaire of potential predictors of side effect occurrence
89024568|NCT03273075|Active Comparator|Prasugrel + Cangrelor|If eligible, assigned to this arm and without contraindications to prasugrel administration, patients will receive a loading dose of prasugrel (60 mg) via nasogastric tube as soon as possible after arrival at the emergency department. Afterwards a 30 micrograms (mcg)/kg iv bolus of cangrelor followed immediately by a 4 mcg/kg/min iv infusion (lasting for at least 2 hours or for the duration of the revascularization procedure, whichever is longer) will be administered.
89513317|NCT03563729|Experimental|E: BRAF/MEK -> ipi/nivo (prednisolone >10 mg)|Induction treatment with BRAF/MEK inhibitors (either the combination of encorafenib/binimetinib or dabrafenib/trametinib) orally for 28 days followed by intravenous infusion of ipilimumab 3 mg/kg and nivolumab 1 mg/kg four times every three weeks in the induction phase and nivolumab 480 mg every four weeks in the maintenance phase for up to two years.
89513318|NCT03546413||LEAP Participants: Peanut Avoidance|Participants of the LEAP study who enrolled in the LEAP Trio study and were originally randomized to the Peanut Avoidance treatment arm upon entry into the LEAP study.
89513319|NCT03546413||LEAP Participants: Peanut Consumption|Participants of the LEAP study who enrolled in the LEAP Trio study and were originally randomized to the Peanut Consumption treatment arm upon entry into the LEAP study.
89513320|NCT03546413||Younger Siblings: Peanut Avoidance|Participants enrolled in the LEAP Trio study who are younger siblings of a LEAP Participant who was randomized to the Peanut Avoidance treatment arm upon entry into the LEAP study.
89513321|NCT03546413||Younger Siblings: Peanut Consumption|Participants enrolled in the LEAP Trio study who are younger siblings of a LEAP Participant who was randomized to the Peanut Consumption treatment arm upon entry into the LEAP study.
89513322|NCT03546413||Older Siblings: Peanut Avoidance|Participants enrolled in the LEAP Trio study who are older siblings of a LEAP Participant who was randomized to the Peanut Avoidance treatment arm upon entry into the LEAP study.
89513323|NCT03546413||Older Siblings: Peanut Consumption|Participants enrolled in the LEAP Trio study who are older siblings of a LEAP Participant who was randomized to the Peanut Consumption treatment arm upon entry into the LEAP study.
89513324|NCT03546413||Parents: Peanut Avoidance|Participants enrolled in the LEAP Trio study who are parents of a LEAP Participant who was randomized to the Peanut Avoidance treatment arm upon entry into the LEAP study.
89513325|NCT03546413||Parents: Peanut Consumption|Participants enrolled in the LEAP Trio study who are parents of a LEAP Participant who was randomized to the Peanut Consumption treatment arm upon entry into the LEAP study.
89513326|NCT03541525||Affected patients|Biological samples of blood for all patients. Biological samples of saliva, surgical remainder (skin, tumor, kidney,....), saliva, urine, hair.
89513327|NCT03541525||Non affected relatives|Biological samples of blood for all relatives.
89513328|NCT03539822|Experimental|Cabozantinib plus Durvalumab (Gastric & esophageal cancer cohort)|"Cabozantinib~By mouth (PO) once daily on days 1-28 of every 28 day cycle~Dose will be 40mg~Durvalumab~*Flat dose of 1500mg intravenous (IV) Infusion on day 1 of every 28 day cycle"
89513329|NCT03539822|Experimental|Cabozantinib plus Durvalumab (Colorectal cancer cohort)|"Cabozantinib~By mouth (PO) once daily on days 1-28 of every 28 day cycle~Dose will be 40mg~Durvalumab~*Flat dose of 1500mg intravenous (IV) Infusion on day 1 of every 28 day cycle"
89513330|NCT03539822|Experimental|Cabozantinib plus Durvalumab (Hepatocellular carcinoma cohort)|"Cabozantinib~By mouth (PO) once daily on days 1-28 of every 28 day cycle~Dose will be 40mg~Durvalumab~*Flat dose of 1500mg intravenous (IV) Infusion on day 1 of every 28 day cycle"
89513331|NCT03539822|Experimental|Cabozantinib plus Durvalumab plus Tremelimumab (Hepatocellular carcinoma cohort)|"Cabozantinib~By mouth (PO) once daily on days 1-28 of every 28 day cycle~Dose will be 40mg~Durvalumab *Flat dose of 1500mg intravenous (IV) Infusion on day 1 of every 28 day cycle~Tremelimumab~*Single dose of 300mg intavenous (IV) infusion on day 1 of cycle 1"
89513332|NCT03506633|Experimental|MitoQ-Placebo|Subjects will be tested on two different days, first day will be baseline and MitoQ and second day will be Placebo. Testing will take place forty-minutes after MitoQ/placebo intake. There will be a 2-week washout between testing days.
89513333|NCT03506633|Experimental|Placebo-MitoQ|Subjects will be tested on two different days, first day will be baseline and Placebo and second day will be MitoQ. Testing will take place forty-minutes after placebo/MitoQ intake. There will be a 2-week washout between testing days.
89513334|NCT03402854|Experimental|Active tDCS + bimanual training|In this arm, participants will engage in 120 min of bimanual training. Bimanual training involves using both hands to play with toys and games during the study. During the first 20 min of bimanual training, participants will receive active tDCS via sponges over the scalp.
89513335|NCT03402854|Experimental|Sham tDCS + bimanual training|In this arm, participants will engage in 120 min of bimanual training. Bimanual training involves using both hands to play with toys and games during the study. During the first 20 min of bimanual training, participants will wear the tDCS device that is worn by the active tDCS group, but in the sham group, participants will not receive stimulation during this 20 min period.
89513336|NCT03377205|Active Comparator|Plate|Compression screws and neutralization plate.
89513337|NCT03377205|Experimental|Intramedullary nail|Acumed Fibular Rod System
89513338|NCT03275636|Experimental|Haploidentical donor|Peripheral blood stem cells from Haploidentical donor
89513339|NCT03275636|Active Comparator|partially matched unrelated donor|Peripheral blood stem cells from unrelated donor with a single allele or antigen mismatch at HLA-A, -B, -C, or -DRB1 and no concurrent DQB1 mismatch (9/10) shown by confirmatory typing
89513340|NCT03257163|Experimental|Treatment (pembrolizumab, capecitabine, radiation therapy)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 2 courses in the absence of disease progression or unacceptable toxicity. Within 2-6 weeks, patients undergo surgery. Beginning up to 56 days after surgery, patients receive pembrolizumab IV over 30 minutes on day 1 and capecitabine PO BID on days 1-14. Treatment repeats every 21 days for up to 5 courses in the absence of disease progression or unacceptable toxicity. Within 2-6 weeks of resting, patients continue to receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 11 courses in the absence of disease progression or unacceptable toxicity. Beginning course 4, patients undergo radiation therapy over 15-30 minutes on days 1-5 for up to 5 weeks.
89513341|NCT03221660|Experimental|F-Composite 2 system|Tooth (teeth) affected by dental caries or with an existing defective filling will be restored using the F-Composite 2 system.
88960259|NCT05422534|Active Comparator|HB HIIT + CoQ10|Participants will received CoQ10 1800/day with home based high intensity interval training for 12 weeks. Exercise will be performed on a non-dialysis day, it will be video-supervised exercise sessions, three days per week for 12 weeks The three weekly sessions will include: 1 session of 1) body weight high-intensity interval training (bodyweight HIIT), 2) strength training, and 3) walking high-intensity interval training (walking HIIT).
88960260|NCT05422066|Experimental|Selinexor-R-CHOP|Selinexor po 60mg once weekly, Rituximab iv 375 mg/sqm on day 1, Cyclophosphamide iv 750 mg/sqm on day 1, Doxorubicin iv 50 mg/sqm on day 1, Vincristine iv 0.5 mg/kg on day 1, Prednisone po 100mg on days 1-5 in a 21 days per cycle.
89513342|NCT03177187|Experimental|Phase I|Increasing doses of AZD5069 in combination with a fixed dose of enzalutamide to establish the recommended phase II dose.
89513343|NCT03177187|Experimental|Phase II|"The Phase II part of the study will evaluate the recommended phase II dose identified in Phase I of the study in patients with metastatic castration resistant prostate cancer.~RECRUITING"
89513344|NCT03099005|Active Comparator|Low CBD session|In the morning, participants will inhale 8 puffs of vaporized cannabis containing 1.6% THC + 0.09 CBD. They will then undergo experimental testing as described below under Outcome Measures.
89513345|NCT03099005|Active Comparator|Medium CBD session|In the morning, participants will inhale 8 puffs of vaporized cannabis 4 puffs will contain 1.6% THC + 0.09 CBD and 4 puffs will contain 1.73% THC + 5.4% CBD. They will then undergo experimental testing as described below under Outcome Measures.
89513346|NCT03099005|Active Comparator|High CBD session|In the morning, participants will inhale 8 puffs of vaporized cannabis containing 1.73% THC + 5.4% CBD. They will then undergo experimental testing as described below under Outcome Measures.
88960261|NCT05419505|Experimental|Cohort 1: CCH-aaes Dose Evaluation|Participants will be administered CCH-aaes at different doses. Participants will receive CCH-aaes treatments in a split buttock arrangement, with the right buttock as the control, and the left buttock as the investigational treatment.
88960262|NCT05419505|Experimental|Cohort 2: CCH-aaes Concentration Evaluation|Participants will be administered CCH-aaes at different concentrations. Participants will receive CCH-aaes treatments in a split buttock arrangement, with the right buttock as the control, and the left buttock as the investigational treatment.
88960263|NCT05419505|Experimental|Cohort 3: CCH-aaes Injection Depth Evaluation|Participants will be administered CCH-aaes using different injection depths. Participants will receive CCH-aaes treatments in a split buttock arrangement, with the right buttock as the control, and the left buttock as the investigational treatment.
88960264|NCT05419505|Experimental|Cohort 4: CCH-aaes Injection Method Evaluation|Participants will be administered CCH-aaes using different injection methods. Participants will receive CCH-aaes treatments in a split buttock arrangement, with the right buttock as the control, and the left buttock as the investigational treatment.
88960265|NCT05419505|Experimental|Cohort 5: CCH-aaes and Diluent Additive Evaluation|Participants will be administered CCH-aaes and diluent additive. Participants will receive CCH-aaes treatments in a split buttock arrangement, with the right buttock as the control, and the left buttock as the investigational treatment.
89513347|NCT03071692|Experimental|Treatment Group|K-877 (pemafibrate) tablet twice daily.
89513348|NCT03071692|Placebo Comparator|Control Group|Matching K-877 placebo tablet twice daily.
89513349|NCT02991690|Experimental|Hypothermia|Intravascular hypothermia will be initiated within 24 hours post-injury and 33 degrees Celsius will be maintained for 48 hours.
89513350|NCT02991690|No Intervention|Control|Standard of care medical treatment, specific to each individual.
89513351|NCT02920788|Experimental|Veteran Mild TBI Group - GOALS Intervention|Veterans ages 18+ with chronic mild TBI, to undergo GOALS cognitive training as an intervention.
89513352|NCT02920788|Active Comparator|Veteran Mild TBI - Treatment as Usual|Veterans ages 18+ with chronic mild TBI, matched by demographic and clinical criteria to the GOALS group, to receive the standard clinical care.
89513353|NCT02920788|No Intervention|Veteran Non TBI - No Treatment|Veterans ages 18+ with no history of TBI, to undergo Neuropsychologic evaluation and MR Imaging with no intervention.
89513354|NCT02914964|Experimental|Swank Diet|Individuals randomized to this arm will follow a low saturated fat diet starting at week 12.
89513355|NCT02914964|Experimental|Wahls Elimination Diet|Individuals randomized to this arm will follow a modified paleolithic diet that eliminates all grains, dairy, eggs, legumes, and nightshade vegetables/spices starting at week 12.
89513356|NCT02861300|Experimental|CB-839 + capecitabine|Patients will receive CB-839 orally twice daily for 21 days (continuous administration) and capecitabine orally twice daily for 14/21 days. In the phase I portion of the study, patients will receive escalating doses of CB-839 and capecitabine and will have day 15 blood samples drawn and archived for as needed assessment of CB-839 pharmacokinetics. In the phase II portion of the study, patients will receiving 800mg CB-839 and 1000mg/m^2 capecitabine as were determined to be safe doses during the phase I portion of the study. They will also undergo pre-treatment and post-treatment blood samples and tissue biopsies for evaluation of pharmacodynamic biomarkers.
89513357|NCT02846922||catheter ablation group|atrial fibrillation patients with heart failure who received catheter ablation for rhythm control
89513358|NCT02846922||rate control group|atrial fibrillation patients with heart failure who received pharmacological approaches for rate control
89513359|NCT02825836|Experimental|TL-895 80/160 mg QD in R/R Participants|Participants received TL-895 80 mg powder in capsule (PiC) orally once daily (OD) for 3 days followed by TL-895 160 mg OD in fasted state for 28 days in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study.
89513360|NCT02825836|Experimental|TL-895 300 mg QD in R/R Participants|Participants received TL-895 300 mg PiC orally OD in fasted state for 28 days in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study.
89541148|NCT04923035||Case|"Children aged 5 years and below with clinically diagnosed pneumonia and attending the outpatient's department or admitted as a hospital inpatient at three sentinel sites. Pneumonia. Suspected pneumonia cases will be identified by a family physician or paediatrician based on medical history and clinical symptoms.~Pneumonia is defined as (WHO Fact Sheet 2019) patient with history of:~cough and/or~difficulty/rapid breathing and/or~intercostal recession,~with or without fever. and supported by chest x-ray findings."
88960266|NCT05419505|Experimental|Cohort 6: CCH-aaes Dose, Concentration, and Treatment Schedule Evaluation|Participants will be administered CCH-aaes using a different treatment schedule and different doses and concentrations. Participants will receive CCH-aaes treatments in a split buttock arrangement, with the right buttock as the control, and the left buttock as the investigational treatment.
88960267|NCT05419505|Experimental|Cohort 7: CCH-aaes and Antifibrinolytic Agent|Participants will be administered CCH-aaes and an antifibrinolytic agent. Participants will receive CCH-aaes treatments in a split buttock arrangement, with the right buttock as the control, and the left buttock as the investigational treatment.
88960268|NCT05418842|Experimental|Prehabilitation Group|In addition to standard medical care, the prehabilitation group will have three supervised exercise training sessions per week from diagnosis to start of radiotherapy (pre-treatment phase).
88960269|NCT05418842|No Intervention|Control Group|The control group will receive the standard medical care.
88960270|NCT05414552||ECP treatment arm|ECP treatment per prtocol
88960271|NCT05412381|Placebo Comparator|Control Arm|The control arm will receive a pre-op placebo injection of saline, and ACLR surgery with intra-op placebo injection
88960272|NCT05412381|Experimental|Investigational Arm|The investigational arm will receive a pre-op PRP injection, and ACLR surgery with PRP injection
88960273|NCT05404308|Experimental|Weekly follow-up by a medical radiography technician and weekly follow-up by the radiotherapist|
88960274|NCT05404308|Active Comparator|Standard weekly follow-up by the radiotherapist only|
88960275|NCT05391113|Experimental|Autism Spectrum Disorder|Characterized by two main diagnostic criteria: a socio-emotional deficit via a defect in communication and social reciprocity, and a behavioral deficit which manifests itself in repetitive behavioral patterns (stereotypes), restricted interests and/or activities.
88960276|NCT05391113|Active Comparator|Food Addictive Disorders|Characterized by regroup substance use disorders and behavioral addictions, are characterized in particular by the repeated occurrence of compulsive behavior and impaired social functioning
88960277|NCT05391113|Placebo Comparator|Healthy volonteers|Adult without neurological and psychiatric history, absence of progressive somatic pathologies or with vital risk.
88960278|NCT05387486|Active Comparator|ALT|
88960279|NCT05387486|Active Comparator|USG-Pre|
88960280|NCT05387486|Active Comparator|USG -RT|
88960281|NCT05384223|Experimental|RRFT (Risk Reduction through Family Therapy)|
88960282|NCT05384223|Active Comparator|Treatment as Usual (TAU): Encompass|
88960283|NCT05377346|Experimental|Paratracheal pressure group|After the induction of anesthesia, the i-gel is placed under the application of paratracheal pressure.
89513361|NCT02825836|Experimental|TL-895 600 mg QD in R/R Participants|Participants received TL-895 600 mg PiC orally OD in fasted state for 28 days in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study.
89513362|NCT02825836|Experimental|TL-895 300 mg BID in R/R Participants|Participants received TL-895 300 mg PiC orally twice daily (BID) in fasted state for 28 days in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study.
89513363|NCT02825836|Experimental|TL-895 900 mg QD in R/R Participants|Participants received TL-895 900 mg PiC orally QD in fasted state for 28 days in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study.
89513364|NCT02825836|Experimental|TL-895 100 mg BID in R/R Participants|Participants received TL-895 100 mg BID orally with food for 28 days in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study.
89513365|NCT02825836|Experimental|TL-895 150 mg BID in R/R Participants|Participants received TL-895 150 mg BID orally with food for 28 days in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study.
89513366|NCT02825836|Experimental|TL-895 150 mg BID in Treatment Naïve Participants|Participants received TL-895 150 mg BID orally with food for 28 days in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study.
89513367|NCT02825836|Experimental|TL-895 100 mg BID in Treatment Naïve Participants|Participants received TL-895 100 mg BID orally with food for 28 days in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study.
89513368|NCT02825836|Experimental|TL-895 150 mg BID & navtemadlin 240mg QD in R/R Participants without 17p(del)|Participants received navtemadlin 240 mg administered QD on Days 1-7 in combination with TL-895 150 mg BID orally with food for 28 days with in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study.
89513369|NCT02825836|Experimental|TL-895 150 mg BID & navtemadlin 240mg QD in Treatment Naïve Participants without 17p(del)|Participants received navtemadlin 240 mg administered QD on Days 1-7 in combination with TL-895 150 mg BID orally with food for 28 days with in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study.
89513370|NCT02825836|Experimental|TL-895 150 mg BID & navtemadlin 240mg QD in R/R Participants with 17p(del)|Participants received navtemadlin 240 mg administered QD on Days 1-7 in combination with TL-895 150 mg BID orally with food for 28 days with in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study.
89513371|NCT02750865|No Intervention|Control Usual Care|In this arm the subject receives usual care and just completes the baseline interview, monthly telephone surveys about their quality of life, and the exit interview at 6 months after enrollment.
89513372|NCT02750865|Experimental|Embodied Conversational Agent (ECA)|In this arm the subject is trained how to use a tablet device which they take home for the duration of the study. These subjects complete the baseline interview, monthly telephone surveys about their quality of life, and the exit interview at 6 months after enrollment.
89541149|NCT04923035||Control|Healthy children aged 5 years and below without any intercurrent respiratory illness and who is in good health as determined by a brief medical history and/or clinical judgement of the investigator whose parent/LAR is willing and able to give informed consent.
89541150|NCT04920006|No Intervention|Aim 1: Focus Groups|A series of three sequential focus groups will be used to gather ADRD caregiver feedback about EnACT intervention techniques, including frequency, duration, delivery, feasibility, acceptability, and relevance of the intervention. Between focus groups, we will refine and edit the EnACT intervention in an iterative process. Intervention scenarios and activities will be chosen and refined as part of Aim 1 in preparation for testing feasibility and acceptability.
89541151|NCT04920006|Experimental|Aims 2 & 3: Intervention|A Stage 1b pilot study will be conducted to test the feasibility and acceptability (Aim 2) of the EnACT intervention and potential mechanisms of change over time and their subsequent impact on proximal and distal outcomes (Aim 3). This arm will use a randomized waitlist control design.
89541152|NCT04916990|Active Comparator|CARES Intervention|All participants will complete surveys to assess Quality of Care and Patient Reported outcomes at baseline, 3 months and 6 months. The CARES intervention will include a maximum of 10 navigation and 10 counseling sessions delivered over approximately a 6- month period delivered by oncology nurse navigators and master's level counselors. Sessions will be scheduled to correspond with key transition points during treatment and may be held in person, virtually, or by phone.
89541153|NCT04916990|No Intervention|Usual Care|All participants will complete surveys to assess Quality of Care and Patient Reported Outcomes. Patients will receive a standardized list of resources.
89541154|NCT04911270|Experimental|Intervention Group- Computer Decision Support Tool|"Patients enrolled in the study will be started on IV vancomycin which will be dosed based on the LYV CDS tool, which will dose patients based on AUC24/MIC. Dosing will be adjusted based on vancomycin levels that will be drawn throughout the hospital stay.~All patients prospectively enrolled into this study will be in the intervention group. Results will be compared to the retrospectively matched historical controls."
89541155|NCT04911270|Other|Matched Historical Controls|Match historical controls are patients that were on IV vancomycin with dose adjustments based on vancomycin trough levels. Patients in this study arm will be retrospective patients that will be matched with the intervention group.
89541156|NCT04895943||Group with adjustable IGB|
89541157|NCT04895943||Group with non-adjustable IGB|
89541158|NCT04886895|Experimental|Let's Move Intervention|Let's Move intervention will be administered and videotaped for 20 infant/caregiver dyads. Therapy will occur weekly (30-60 minutes per session) for 16 weeks, alternating between clinic and home (video telehealth) sessions. Each month, there will be two clinic-based sessions followed by 2 telehealth-based sessions
89541159|NCT04886622|Experimental|DT2216|DT2216 will be administered by intravenous infusion over 30 minutes twice weekly on a continuous basis. Each treatment cycle will be 28 days in duration. The starting dose of DT2216 will be 0.04 mg/kg and will escalate by 100% increments for the first 5 treatment groups. Thereafter, if additional dose escalations are required, escalation will follow a modified Fibonacci scheme. Treatment may continue for up to 1 year.
89541160|NCT04883957|Experimental|Cohort A: R/R NHL|Participants with R/R NHL, including follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), marginal zone lymphoma (MZL), or transformed NHL, will receive oral BGB-11417 until the MTD (or maximum ascending dose [MAD]) and the RP2D can be determined.
89541161|NCT04883957|Experimental|Cohort B: R/R CLL/SLL (low tumor burden)|Participants with low tumor burden R/R CLL/SLL will receive oral BGB-11417 until the MTD (or MAD) and the RP2D can be determined.
89210539|NCT01562964|Experimental|Hypnotherapy|Hypnotherapy will be conducted at the Royal Brompton Hospital by a qualified practician (DF). Ten pain control hypnotherapy session will run for 50-60 minutes each. In the first session a thorough history will be taken of the patient's chest pain history together with both the sensory and affective components of their pain. If there is time, relaxation technique and self-hypnosis will be taught at this visit. In subsequent sessions, various techniques, including techniques that focus on direct suggestions and imagery work, will be applied and taught to the patient. The pain control techniques are all analgesic in nature - focusing on the reduction, but not the total removal of the pain. A small amount of pain is left behind to serve as a reminder that either something is wrong or that the patient needs to take it easy.
88960284|NCT05377346|Active Comparator|Cricoid pressure group|After the induction of anesthesia, the i-gel is placed under the application of cricoid pressure.
88960285|NCT05375929|Experimental|Abrocitinib 100 mg|Participants will receive abrocitinib 100 mg by mouth (QD).
88960286|NCT05375929|Experimental|Abrocitinib 200 mg|Participants will receive abrocitinib 200 mg QD.
88960287|NCT05374967|Other|Control group|The control group will receive the current standard of care: an informational brochure on how to cope with fatigue.
89513373|NCT02651675|Experimental|Cohort 1|2.5E12 (genome copies)/kg (kilogram) body weight (E means the exponential constant)
89513374|NCT02651675|Experimental|Cohort 2|7.5E12 GC/kg body weight
89513375|NCT02651675|Experimental|Cohort 2 Expansion|"7.5E12 GC/kg body weight~DSMB (Data Safety Monitoring Board) approved expansion of Dose 2 cohort, 3 additional subjects enrolled and received prophylactic corticosteroids"
89513376|NCT02611960|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 3-week cycle (Q3W) until progressive disease (PD) or unacceptable toxicity for a maximum of up to 35 cycles (up to approximately 2 years). Eligible participants who stop pembrolizumab with Stable Disease (SD) or better but progress after discontinuation may be able to initiate a second course of pembrolizumab 200 mg Q3W for up to 17 cycles (up to approximately 1 additional year).
89513377|NCT02611960|Active Comparator|Standard Treatment|Participants receive capecitabine 1000 mg/m^2 orally (PO) twice each day (BID) on Days 1-14 of each 3-week cycle, or gemcitabine 1250 mg/m^2 IV on Days 1 and 8 of each 3-week cycle, or docetaxel 75 mg/m^2 IV on Day 1 of each 3-week cycle until PD or unacceptable toxicity.
89513378|NCT02501993||Screening cohort|All participants will be tested for anti-EBV antibody by using serum samples. Participants are stratified into those having high, moderate and low antibody levels, those having moderate antibody levels are invited to retest annually in the following 3 years and those found to have high antibody levels on these occasions are referred to centers for diagnostic workup for NPC.
89513379|NCT02501980||Screening|All participants will be tested for HBsAg by using serum samples. Among those who are positive for HBsAg, further clinical work-ups including AFP test and ultrasonography for liver exam will be performed. Repeated check-ups will be performed in 6-months among HBsAg positive group and 3-years among HBsAg negative group.
88960288|NCT05374967|Experimental|Lifestyle intervention|Participants will undergo a multimodal lifestyle intervention, which focuses on nutrition, sleep, stress, and exercise. The lifestyle intervention includes digital lessons/webinars and online counseling by a nutritionist and a lifestyle coach.
88960289|NCT05365763||Medical oncologists|5 medical oncologists; trained in the serious illness conversation guide
88960290|NCT05365763||specialty palliative care|6 specialty palliative care physicians; trained in serious illness conversation guide
89513380|NCT02501980||Non-screening|All subjects in this arm will be followed by linkage to Cancer Register and Population Register.
89513381|NCT02358850|Active Comparator|Tonsillectomy and Norco|This represents patients who will be randomized (1:3 chance) to postoperative pain control with Norco (Hydrocodone and Acetaminophen)
89513382|NCT02358850|Active Comparator|Tonsillectomy and Percocet|This represents patients who will be randomized (1:3 chance) to postoperative pain control with Percocet (Oxycodone and Acetaminophen)
89513383|NCT02358850|Active Comparator|Tonsillectomy and Dilaudid + Tylenol|This represents patients who will be randomized (1:3 chance) to postoperative pain control with Dilaudid (hydromorphone) and Tylenol (Acetaminophen)
89513384|NCT02164019|Active Comparator|long-stem cemented hemiarthroplasty (LSCH)|"(LSCH), Hip, Ball, Rod and Cement Replace the ball of the hip joint with a metal ball and a rod that is placed inside the thigh bone with cement to keep the implant in place. The study participation period for each patient is 360 days from the date of surgery and includes 5 defined timepoints that include the suture removal visit at 3 weeks and follow-up clinical visits for radiographs and rehabilitation progress checks at 6 weeks, 12 weeks, 6 months, and 12 months after surgery. At each follow-up visit, a combination of questionnaires and physical tests will be administered to assess physical function, general health status, disability level, and pain control. Some patients may be in a rehabilitation center or on hospice care and will miss their follow-up appointments. To collect data for the primary endpoint, the 6 week and/or 12 week TESS can be done over phone if necessary."
89513385|NCT02164019|Active Comparator|intramedullary nailing (IMN)|"Intramedullary nailing (IMN), Rod and Screws A metal rod is placed inside your thigh bone and secured in place by metal screws just below the hip and above the knee. The study participation period for each patient is 360 days from the date of surgery and includes 5 defined timepoints that include the suture removal visit at 3 weeks and follow-up clinical visits for radiographs and rehabilitation progress checks at 6 weeks, 12 weeks, 6 months, and 12 months after surgery. At each follow-up visit, a combination of questionnaires and physical tests will be administered to assess physical function, general health status, disability level, and pain control. Some patients may be in a rehabilitation center or on hospice care and will miss their follow-up appointments. To collect data for the primary endpoint, the 6 week and/or 12 week TESS can be done over phone if necessary."
89513386|NCT02157025|Experimental|Cartoon Intervention|Cartoon video fixation target and cartoon character voice audio instructions during Humphrey perimetry
89513387|NCT02157025|Active Comparator|Usual Care|Usual care procedures for Humphrey perimetry in young children
89513388|NCT01845597||MAKOplasty® medial UKA|Patients knees that have received a MAKOplasty® robotically guided unicompartmental knee arthroplasty (UKA) and received a medial MCK onlay implant.
89513389|NCT01839396|Active Comparator|Medium continuous dose of stimulation|Subjects in this arm will receive stimulation settings at a medium continuous dose of Deep Brain stimulation that may have been effective in previous DBS patients.
88960291|NCT05363163|Experimental|Gana X|Participants will receive Gana X in both buttocks
88960292|NCT05347901||Health Control|Health children with age and sex paired with experimental group
88960293|NCT05347901||Kawasaki Disease|KD patients, with no congenital heart disease, metabolic disease or Immune deficiency disease.
88960294|NCT05346965|Experimental|Musical training programme|Participants in the experimental group received a weekly 1-hour musical training lesson for 6 months delivered by professionally qualified musicians. The participants will be assigned a particular musical instrument to learn, and this is based on their interests as well as their capabilities (i.e., fine motor skills), The training will begin at the lowest level (hitting simple notes) and end at the highest level (able to play an entire song).
88960295|NCT05346965|Active Comparator|Wait-list control group|To ensure equity of access to potentially effective intervention (i.e. musical training programme), participants in the wait-list control group will receive the same musical training programme as participants in the intervention group after the completion of all assessments.
88960296|NCT05345405|Active Comparator|Dyadic CARE|Participants will receive dyadic CARE following baseline and will complete self-report assessments at post-session-1, Month 1, Month 2, and Month 3.
89513390|NCT01839396|Sham Comparator|Low intermittent dose of stimulation|Subjects in this arm will receive stimulation settings at a lower intermittent dose of Deep Brain stimulation which is less likely to be effective.
89513391|NCT01827410||patients with a ventral hernia repair|All patients with a ventral hernia repair performed in Region Zealand and registered in The Danish Ventral Hernia Database during October 1st 2010 to October 1st 2011
89024569|NCT03273075|Active Comparator|Ticagrelor + Cangrelor|If eligible and assigned to this arm (i.e. patients who have contraindications against prasugrel (age >75years, weight <60kg, history of transient ischemic attack, ischemic stroke, intracranial bleeding, known allergy against prasugrel/Efient), patients will receive a loading dose of ticagrelor (180 mg) via nasogastric tube as soon as possible after arrival at the emergency department. Afterwards a 30 micrograms (mcg)/kg iv bolus of cangrelor followed immediately by a 4 mcg/kg/min iv infusion (lasting for at least 2 hours or for the duration of the revascularization procedure, whichever is longer) will be administered.
89024570|NCT03273075|Placebo Comparator|Prasugrel + Placebo|"If eligible, assigned to this arm and no contraindications to prasugrel, patients will receive a loading dose of prasugrel (60 mg) via nasogastric tube as soon as possible after arrival at the emergency department.~Afterwards a 30 micrograms (mcg)/kg iv bolus of placebo (0.9% NaCl) followed immediately by a 4 mcg/kg/min iv infusion of placebo (0.9% NaCl) (lasting for at least 2 hours or for the duration of the revascularization procedure, whichever is longer) will be administered."
89024571|NCT03273075|Placebo Comparator|Ticagrelor + Placebo|"If eligible and assigned to this arm (i.e. patients who have contraindications against prasugrel (age >75years, weight <60kg, history of transient ischemic attack, ischemic stroke, intracranial bleeding, known allergy against prasugrel/Efient), patients will receive a loading dose of ticagrelor (180 mg) via nasogastric tube as soon as possible after arrival at the emergency department.~Afterwards a 30 micrograms (mcg)/kg iv bolus of placebo (0.9% NaCl) followed immediately by a 4 mcg/kg/min iv infusion placebo (0.9% NaCl) (lasting for at least 2 hours or for the duration of the revascularization procedure, whichever is longer) will be administered."
89024572|NCT01051661|Experimental|Arepanrix 2D 6M-3Y Group|Subjects, male and female, aged 6 months (M) to 3 years (Y), received 2 doses (D) of the Arepanrix™ vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children <12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children <12 months of age, in the right anterolateral thigh.
89024573|NCT01051661|Experimental|Arepanrix 2D 3Y-10Y Group|Subjects, male and female, aged 3 years (Y) to 10 years, received 2 doses (D) of the Arepanrix™ vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).
89513392|NCT01784159|Placebo Comparator|Placebo|Placebo 1tb / day/ 7days
89513393|NCT01784159|Active Comparator|Aspirin|Intervention aspirin 200 mg/day for 7 days
89513394|NCT01749969|Experimental|SAR650984 (isatuximab)|"SAR650984 (isatuximab) (escalating dose) plus lenalidomide 25 mg on Days 1 to 21 plus dexamethasone 40 mg on Days 1, 8, 15, 22 in 28-day cycles for all cohorts up to disease progression.~For Q2W cohorts: SAR650984 (isatuximab) on Days 1 and 15 of every cycle. For QW/Q2W cohorts: SAR650984 (isatuximab) on Days 1, 8, 15, and 22 of first cycle and Days 1 and 15 of every subsequent cycle."
89513395|NCT01730170||Pregnant Women without Epilepsy|Women in their first trimester of pregnancy who are not diagnosed with epilepsy
89513396|NCT01730170||Nonpregnant Women with Epilepsy|Women diagnosed with epilepsy and not currently pregnant.
89513397|NCT01730170||Pregnant Women with Epilepsy|Women in their first trimester of pregnancy and diagnosed with epilepsy
89513398|NCT01665859||Danish Ventral Hernia Database|Patients registered in the Danish Ventral Hernia Database during January 1st 2007 to december 31st 2010
89513399|NCT01644669|Experimental|Intra-operative Radiation Therapy - IORT|Intra-operative Radiation Therapy
89513400|NCT01203020|Experimental|Allogeneic hematopoietic progenitor cell transplant|Intravenous busulfex 130mg/m2 on days -6 to -3 before transplant
89513401|NCT00919165||control and study group|severe carotid artery stenosis in asymptomatic patients defined as greater than 80% stenosis angiographically or greater than 400 cm/sec peak systolic velocity on carotid doppler evaluation
89513402|NCT00713206|Active Comparator|Dental implant (Osseotite)|Dental implants placed simultaneously with graft augmentation material.
89513403|NCT00713206|No Intervention|Control group|Dental implants placed into graft augmentation material that has four months to heal.
89513404|NCT00712751||1|usual care (UC) which is the standard care that patients receive
89513405|NCT00712751||2|Cancer Survivorship Intervention-Sexual Health (CSI-SH)plus Usual Care (US)
89513406|NCT00196742||Patients with Fabry disease|No experimental intervention is given. A patient with Fabry Disease will undergo clinical assessments and receive standard of care treatment as determined by the patient's physician.
89513407|NCT00196742||Pregnant women with confirmed diagnosis of Fabry|No experimental intervention is given. Pregnant women with confirmed diagnosis of Fabry that are participating in the Fabry Registry and consented to participate in the Fabry Sub-registry, regardless of whether she is receiving disease-specific therapy (such as ERT with agalsidase beta) and irrespective of the commercial product with which she may be treated.
89513408|NCT00495131|Active Comparator|Peginterfron and ribavirin (24 weeks)|Pegylated interferon alfa-2a (Pegasys, F. Hoffmann-LaRoche) 180 ug/week plus ribavirin (Robatrol, F. Hoffmann-LaRoche) 1000-1200 mg/day (<75 kg, 1000 mg/day; >= 75 kg, 1200 mg/day) for 24 weeks
89513409|NCT00495131|Active Comparator|Peginterferon and ribavirin (48 weeks)|Pegylated interferon alfa-2a (Pegasys, F. Hoffmann-LaRoche) 180 ug/week plus ribavirin (Robatrol, F. Hoffmann-LaRoche) 1000-1200 mg/day (<75 kg, 1000 mg/day; >= 75 kg, 1200 mg/day) for 48 weeks
89513410|NCT05103241|Experimental|[14C]GP681|Subject will receive single dose of orally [14C] GP681 .
89513411|NCT02257372|Experimental|UMEC (62.5 mcg)|Participants will self-administer blinded UMEC (62.5 mcg) each morning (once daily) as one inhalation from the double-blind DPI over a treatment period of 12 weeks. Participants will receive open labeled ICS/LABA medication through out duration of the treatment period as background treatment.
89513412|NCT02257372|Experimental|Placebo|Participants will self-administer blinded placebo each morning (once daily) as one inhalation from the double-blind DPI over a treatment period of 12 weeks. Participants will receive open labeled ICS/LABA medication through out duration of the treatment period as background treatment
89513413|NCT00566657|Experimental|Riferminogene pecaplasmid|4 administrations of riferminogene pecaplasmid 4 mg at 2-week intervals
89513414|NCT00566657|Placebo Comparator|Placebo|4 administrations of placebo (for riferminogene pecaplasmid) at 2-week intervals
89513415|NCT05059015|Active Comparator|CERVICAL HPV|Routine screening procedure based on HPV tests with cervical sampling by a health personnel
89513416|NCT05059015|Experimental|SELF SAMPLING HPV ARM 2|Screening based on HPV self-testing and colposcopic evaluation
89513417|NCT05059015|Experimental|SELF SAMPLING HPV ARM 3|Arm 3: screening based only on HPV self-testing
89513418|NCT05050747||Arm 1|Women with unexplained infertility undergoing ovulation induction following intrauterine adminstration of HCG on the day of trigger
89513419|NCT05050747||Arm 2|Women with unexplained infertility undergoing ovulation induction following endometrial injury by pipelle on day 8-9 of the same cycle of ovulation induction
89513420|NCT05050747||Arm 3|Women with unexplained infertility undergoing ovulation induction following intrauterine adminstration of placebo on the day of trigger
89513421|NCT02256982|Experimental|Resectable Disease|"Consent and Registration~3 cycles of gemcitabine + cisplatin~Evaluate for surgery* (weeks 10-15)~-- Patients who are eligible for surgery at restaging will receive surgery; patients not eligible for surgery at restaging will receive radiation therapy.~Proceed to surgery~Additional care as recommended; may include additional cycles of GEM + CDDP on a 21 day cycle and/or post-op radiation as recommended by treating medical oncologist and radiation oncologist"
89513422|NCT02256982|Experimental|Unresectable Disease|"Consent and Registration~3 cycles of gemcitabine + cisplatin~Evaluate for surgery* (weeks 10-15)~Patients who are eligible for surgery at restaging will receive surgery; patients not eligible for surgery at restaging will receive radiation therapy.~Proceed to radiation therapy with protons or photons, determined by available resources~Additional cycles of GEM + CDDP on a 21 day cycle as recommended by treating medical oncologist"
89513423|NCT05014867||Arm 1|Poor responders women undergoing frozen sequential embryo transfer on Day 3 and Day 5
89513424|NCT05014867||Arm 2|Poor responders women undergoing sequential fresh embryo transfer on Day 3 and Day 5
89513425|NCT05014867||Arm 3|Poor responders women undergoing sequential embryo transfer on Day 3 and Day 5 after performing PGS
89513426|NCT05014867||Arm 4|Poor responders women undergoing conventional frozen embryo transfer on Day 5
89513427|NCT03476629|Experimental|Combined Training|Combined Training with 2 types of physical activity
89513428|NCT03476629|Experimental|Standard Training|Physical activity with aerobic exercise
89513429|NCT03476629|Experimental|Respiratory Muscle Training|Respiratory muscle performance
89513430|NCT03480607|Active Comparator|Dexmedetomidine group|Dexmedetomidine in conjunction with bupivacaine for infra-orbital nerve block
89513431|NCT03480607|Active Comparator|Dexamethasone group|Dexamethasone in conjunction with bupivacaine f
89513432|NCT00492323|Placebo Comparator|002|placebo twice daily for 4 weeks
89513433|NCT00492323|Experimental|001|carisbamate 200 mg tablet twice daily for 4 weeks
89513434|NCT00489203|Experimental|Arm I|Patients receive oral beclomethasone dipropionate 4 times daily beginning at the start of the conditioning regimen and continuing through day 75 post-transplant. Patients also receive a standard immunosuppressive regimen comprising tacrolimus and methotrexate post-transplant.
88811980|NCT01394081|Active Comparator|Administrative Outreach (AO)|Administrative Outreach (AO) consists of the outreach worker giving the participants an application package to VA enrollment or phone number for the scheduling clerk. This intervention does not involve education, patient navigation (guidance through VA eligibility, enrollment, and scheduling processes) or motivational interviews (interviews focused on ambivalence about attending a VA appointment).
88811981|NCT04382534||Rehabilitation guidance group|1 to 2 times of rehabilitation instruction according to the rehabilitation instruction program, either online or in person.According to the rehabilitation instruction, the patient performed self-rehabilitation exercises in the isolation point.
88811982|NCT04382534||Systematic rehabilitation treatment|According to the systematic rehabilitation treatment program, the rehabilitation therapist entered the home for one-to-one rehabilitation treatment, once a day, for a total of 10 days.
88811983|NCT00880022|Active Comparator|arm compression only|Intervention of arm compression only by Flexitouch System
89513435|NCT00489203|Active Comparator|Arm II|Patients receive oral placebo 4 times daily beginning at the start of the conditioning regimen and continuing through day 75 post-transplant. Patients also receive a standard immunosuppressive regimen comprising tacrolimus and methotrexate post-transplant.
89513436|NCT03480529||Arthritis or lupus or CLS induced by a drug|Case reported in the World Health Organization (WHO) of arthritis or lupus, or Hepatitis, or capillary leak syndrome of patient treated by a drug, with a chronology compatible with the drug toxicity
89513437|NCT00563459|Experimental|001|carisbamate 400-1200 mg/day for 12 months
89513438|NCT00563459|Active Comparator|002|topiramate 200-400mg/day for 12 months
89513439|NCT00563459|Active Comparator|003|levetiracetam 1000-3000mg/day for 12 months
89513440|NCT05068921|Experimental|TQB2858|TQB2858 injection: once every 3 weeks, 1800mg each time, intravenous infusion. Until the disease progression or unbearable adverse events occur.
89513441|NCT00488267|Experimental|Thermoprofen|ThermoProfen™ (ketoprofen matrix/Controlled Heat Assisted Drug Delivery [CHADD™] patch)
89513442|NCT00488267|Placebo Comparator|Placebo Matrix|Placebo matrix with CHADD patch.
89513443|NCT00488267|Placebo Comparator|Ketoprofen matrix/placebo CHADD|Ketoprofen matrix with placebo CHADD patch (no heat)
89513444|NCT00560183|Experimental|1|
89513445|NCT00560183|Placebo Comparator|2|
89513446|NCT02736721|Experimental|Peginterferon alfa-2a|Participants will receive peginterferon alfa-2a subcutaneously in doses between 90 and 450 microgram (mcg) once weekly until medically indicated as judged by the treating investigator.
88811984|NCT00880022|Experimental|arm, trunk and chest compression|Intervention of arm, trunk and chest compression by Flexitouch System
88811985|NCT01430819|Experimental|Fluzone® Vaccine Group|Participants will receive the Influenza Virus Vaccine: Fluzone® 2011-2012 Formulation
88811986|NCT01430819|Active Comparator|Fluzone® High-Dose Vaccine Group|Participants will receive the Influenza Virus Vaccine, Fluzone® High-Dose 2011-2012 Formulation.
89513447|NCT00542633|Experimental|A|VIAject™
89513448|NCT00542633|Active Comparator|B|Regular Human Insulin
89513449|NCT02283983|Active Comparator|Standard cryoprotection|Proposal helmet without mittens and booties
89513450|NCT02283983|Experimental|Cryoprotection with mittens and booties|Standard cryoprotection with mittens and booties
89513451|NCT00485225|Experimental|Transdermal patch (EN3270) - Titration 1|
89513452|NCT00485225|Experimental|Transdermal patch (EN3270) - Titration 2|
89513453|NCT00485225|Experimental|Transdermal patch (EN3270) - Titration 3|
89513454|NCT00485225|Experimental|Transdermal patch (EN3270) - Titration 4|
89513455|NCT02523547|Experimental|Cavir|entecavir/0.5mg/day
89513456|NCT02523547|Active Comparator|Baraclude|entecavir/0.5mg/day
89513457|NCT00483977|Active Comparator|Oxycodone|
89513458|NCT00483977|Placebo Comparator|Placebo|
89513459|NCT00483977|Experimental|PF-00592379|
89513460|NCT04891549|Active Comparator|Tension band fixation|Surgical fixation of the patella fracture utilizing the AO principles using K-wires, screws, cerclage and sutures by surgeons choice.
89513461|NCT04891549|Experimental|Plate fixation|Surgical fixation of the patella fracture utilizing the AO principles and a locking plate with the number of screws by surgeons choice. Additional fixation by surgeons choice.
89513462|NCT00481325|Experimental|A1|
89513463|NCT00481325|Active Comparator|A2|
89513464|NCT00481325|Placebo Comparator|A3|
89513465|NCT04809025||the pathology of endoscopic biopsy|The histological type, histological grade, LAUREN type, HER-2 expression, MSI/dMMR status, and EBV status of gastric cancer testing on endoscopic biopsies
89513466|NCT04809025||the pathology of surgical resection specimen|The histological type, histological grade, LAUREN type, HER-2 expression, MSI/dMMR status, and EBV status of gastric cancer testing on surgical resection specimens
89513467|NCT00480701|Experimental|[123I]-IBVM|To assess [123I] IBVM and SPECT imaging
89513468|NCT04803409|Experimental|Ultrasound Group|Daily ultrasound application to the spleen of approximately 18 minutes for up to 7 days, in addition to standard clinical care.
89513469|NCT04803409|No Intervention|Control Group|Control Group
89513470|NCT02523703|Other|Healthy Volunteers|Healthy Volunteers
89513471|NCT02523703|Other|Multiple Sclerosis patient|Multiple Sclerosis patient
89513472|NCT00542009|Experimental|CE-326,597 100 mg QD|
89513473|NCT00542009|Experimental|CE-326,597 50 mg QD|
89513474|NCT00542009|Experimental|CE-326,597 25 mg QD|
89513475|NCT00542009|Placebo Comparator|Placebo|
89513476|NCT00542009|Experimental|CE-326,597 5mg QD|
89513477|NCT03480451|Other|Single Arm|"This project is being withdrawn. No revisions to ARM is available.~Patients will undergo consultation and education by members of a pre-determined multi-disciplinary team that aims to bring a predetermined set of services to the patient in a coordinated and scheduled manner in order to facilitate a comprehensive and through approach to the patient's entire well being"
89513478|NCT03480295|Experimental|HA0.4%+TAU0.5%|Patients had to administer 4 drops/day of an ophthalmic solution containing hyaluronic acid 0.4% and taurine 0.5% in addition to the ongoing glaucoma treatment
89541162|NCT04883957|Experimental|Cohort C: R/R CLL/SLL (high tumor burden)|Participants in this cohort will not be enrolled until the RP2D for Cohort B is established. Participants will be treated with the monotherapy ramp-up schedule and the RP2D established in Cohort B.
89541163|NCT04880109|Experimental|APX-115|Oral administration of APX-115 100mg, daily for 14 days
88811987|NCT00828542|Experimental|etonogestrel implant|Etonogestrel releasing contraceptive implant (Implanon®, NV Organon, Oss, The Netherlands) inserted 24-48 h after delivery. It is compounded by 68mg of etonogestrel, 3years of duration.
88811988|NCT00828542|Active Comparator|depot medroxyprogesterone acetate|At the 6th week postpartum, this group received intramuscular 150 mg of depot medroxyprogesterone acetate (Contracept®, EMS Sigma Pharma, Hortolandia, Brazil).
88811989|NCT01394159|Active Comparator|22G ProCore biopsy needle|Using the 22G ProCore needle for sampling pancreatic mass lesions, the tissue obtained will be compared to the standard FNA needle.
89513479|NCT03480295|Active Comparator|HA0.2%|Patients took 4 drops/day of an ophthalmic solution containing hyaluronic acid 0.2%
89513480|NCT02282423|Experimental|Lean Controls|"Lean controls will have BMI of 25 or less, gender specific normal body fat, and not be taking any medication that affects glucose metabolism.~Interventions include OGTT, Clamp, VO2 Max, Exercise Test and Muscle Biopsy"
89513481|NCT02282423|Experimental|Obese, Non-diabetic|"Obese nondiabetics will have a BMI between 30-50 and not be taking any medication that affects glucose metabolism.~Interventions include OGTT, Clamp, VO2 Max, Exercise Test and Muscle Biopsy"
89541164|NCT04880109|Placebo Comparator|Placebo|Oral administration of Placebo, daily for 14 days
88811990|NCT01394159|Active Comparator|22G standard FNA needle|Using the 22G standard fine needle aspiration needle (FNA) for sampling pancreatic mass lesions, the tissue obtained will be compared to the 22 G ProCore needle.
88811991|NCT03008759|Placebo Comparator|Placebo|Dentifrice without fluoride
88811992|NCT03008759|Active Comparator|Dentifrice standard|Dentifrice 1100 ppm sodium fluoride (NaF). Positive control
89024574|NCT01051661|Experimental|Arepanrix 1D 6M-3Y Group|Subjects, male and female, aged 6 months (M) to 3 years (Y), received 1 dose (D) of the Arepanrix™ vaccine followed by 1 dose of saline placebo at a 21-day interval at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children <12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children <12 months of age, in the right anterolateral thigh.
89024575|NCT01051661|Experimental|Arepanrix 1D 3Y-10Y Group|Subjects, male and female, aged 3 years (Y) to 10 years, received 1 dose (D) of the Arepanrix™ vaccine followed by 1 dose of saline placebo at a 21-day interval at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).
89024576|NCT01051661|Experimental|GSK2340273A 6M-3Y Group|Subjects, male and female, aged 6 months (M) to 3 years (Y), received 2 doses (D) of the GSK2340273A vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children <12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children <12 months of age, in the right anterolateral thigh.
89024577|NCT01051661|Experimental|GSK2340273A 3Y-10Y Group|Subjects, male and female, aged 3 years (Y) to 10 years, received 2 doses (D) of the GSK2340273A vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).
89024578|NCT01051466|Experimental|Duloxetine|
89024579|NCT01051466|No Intervention|Healthy Participants|
89024580|NCT01051349|Experimental|BIIB019|Participants received BIIB019, 150 mg subcutaneous injection every 4 weeks up to Week 288.
89513482|NCT02282423|Experimental|Diabetic|"Diabetic patients will have a BMI between 30-50. We will recruit patients with mild or newly diagnosed type 2 diabetes who are treated with diet, sulfonylureas, or other drugs working through enhanced insulin secretion. Patients taking metformin or TZDs will not be recruited due to the effects of those drugs on insulin action.~Interventions include OGTT, Clamp, VO2 Max, Exercise Test and Muscle Biopsy"
89513483|NCT02282423|Experimental|Non-diabetic|"Patients will be nondiabetic, although we will include patients with impaired glucose tolerance. Patients will meet criteria for treatment with fibrates to lower plasma triglyceride concentrations (triglyceride>300 mg/dl for nondiabetics, 250 mg/dl for patients with impaired glucose tolerance). We will aim at recruiting equal numbers of men and women. All participants will be between the ages of 30 and 59. Patients will have a BMI of 25-50 and not be taking any other medication that affects glucose metabolism. All participants will be sedentary (not reporting more than 10 minutes per day of light to vigorous leisure time physical activity.~Interventions include OGTT, Clamp, VO2 Max, Exercise Test and Muscle Biopsy"
89513484|NCT04564573||antidepressant treatment group|participants who had received systemic antidepressant (consecutive treatment with adequate antidepressants for 6 weeks at least)treatment in the early stage (from initial depressive onset to first manic/hypomani episode).
89513485|NCT04564573||non-antidepressant treatment group|participants who had not received systemic antidepressant (consecutive treatment with adequate antidepressants for 6 weeks at least)treatment in the early stage (from initial depressive onset to first manic/hypomani episode).
89513486|NCT02284061|Experimental|experimental|Immediate Program : the child follows the physical activity program for a period of 18 months, as soon as his medical condition permits.
89513487|NCT02284061|Other|Control|Delayed Program: the child does not participate to the program during the first 6 months, and he joins the delayed program late after 6 months.
89513488|NCT04379791||case cohort|Patients with a surgical site infection or a wound complication after surgical treatment of an ankle fracture. The time horizon for wound complication was set to maximally 4 weeks after surgery.
89513489|NCT04379791||control cohort|Patients without a surgical site infection or a wound complication (normal wound-healing and suture or staple removal) after surgical treatment of an ankle fracture.
89513490|NCT04458025|Active Comparator|Standard rehabilitation program|Standard postoperative 4 weeks immobilization rehabilitation program with a sling in adduction and internal rotation
89513491|NCT04458025|Experimental|Early rehabilitation program|Early rehabilitation program will start passive mobilization during second week after surgery, including controlled external rotation movements
89513492|NCT02282501|Active Comparator|intermittent feeding|Bolus infusion - The total daily feeding period was also 4-6 times a day.
89513493|NCT02282501|Active Comparator|continuous feeding|Continuous infusion - The daily desired amount was offered continuously for 20 hours a day.
89513494|NCT00473525|Placebo Comparator|Placebo|
89513495|NCT00473525|Experimental|PF-00734200 10 mg QD|
89513496|NCT00473525|Experimental|PF-00734200 20 mg QD|
89513497|NCT00473525|Experimental|PF-00734200 5 mg QD|
89513498|NCT00473525|Experimental|PF-00734200 2 mg QD|
89513499|NCT03472963|No Intervention|Pre- drug|Participants will not receive any drug. They will be asked to return 1-6 weeks after the screening visit for study procedures (blood collection, oral cheek swab, penile swabs, urethral swab, rectal swabs, urine sample, and rectal biopsy via rigid sigmoidoscopy.
89513500|NCT03472963|Experimental|Group A.1|Men will be dosed with Genvoya and Darunavir® on site (time of dose will be recorded) and asked to return in 2 hours, 24 hours (+/- 1 hour), and 72 hours (+/- 1 hour) after taking dose for study procedures (blood collection, oral cheek swab, penile swabs, urethral swab, and a urine sample). Participant will undergo rectal swabs and rectal biopsy via rigid sigmoidoscopy in 2 hours after dosing.
89541165|NCT04866017|Experimental|Arm A: ociperlimab + tislelizumab|ociperlimab combined with tislelizumab every 3 weeks
89541166|NCT04866017|Experimental|Arm B: tislelizumab|tislelizumab every 3 weeks
89541167|NCT04866017|Experimental|Arm C: durvalumab|durvalumab every 2 weeks or 4 weeks
89541168|NCT04860050|Experimental|TPG|76 participants who meet the eligibility criteria will be randomized under experimental arm and will receive Turmipure GOLD® product during 24 weeks
89541169|NCT04860050|Placebo Comparator|Control|76 participants who meet the eligibility criteria will be randomized under experimental arm and will receive placebo (colored acacia gum) product during 24 weeks
89541170|NCT04836975||SCLC|Patient Diagnosed with Small Cell Lung Cancer- (extensive or limited)
89541171|NCT04836975||NSCLC|Patient diagnosed with primary stage III Non-Small cell lung Cancer
89541172|NCT04816981|Experimental|EBUS-Elastography|
89541173|NCT04806334|Experimental|4D MRI of pelvis/bladder with genomic analysis of bladder tumor|Patients with sessile appearing bladder masses who are destined to undergo transurethral resection of the bladder tumor (TURBT) and are felt by the treating physician to harbor MIBC will be enrolled. Prior to TURBT, ALL subjects will undergo axial imaging for clinical staging in the form of contrast enhanced MRI of the abdomen and pelvis (standard of care). The pelvic MRI will be multiparametric (mp)-4D MRI incorporating high resolution diffusion weighted imaging (HR-DWI). Both the abdominal and pelvic MRI will have an official interpretation by a radiologist, thus both can be used in the care of the subject. Next, ALL subjects will undergo TURBT at which time, voided urine, blood and fresh frozen bladder tumor will be collected. Follow-up pathology will be collected.
89541174|NCT04794218|Experimental|Study Group 1|rVSV∆G-LASV-GPC Vaccine Dosage (pfu) intramuscularly Day 1 2 X 10^4 or Placebo
89541175|NCT04794218|Experimental|Study Group 2|rVSV∆G-LASV-GPC Vaccine Dosage (pfu) intramuscularly Day 1 2 X 10^5 or Placebo
89541176|NCT04794218|Experimental|Study Group 3|rVSV∆G-LASV-GPC Vaccine Dosage (pfu) intramuscularly Day 1 2 X 10^6 or Placebo
89541177|NCT04794218|Experimental|Study Group 4A|rVSV∆G-LASV-GPC Vaccine Dosage (pfu) intramuscularly Day 1 2 X 10^7 or Placebo
89541178|NCT04794218|Experimental|Study Group 5|rVSV∆G-LASV-GPC Vaccine Dosage (pfu) intramuscularly Day 1 2 X 10^5 or Placebo
89541179|NCT04794218|Experimental|Study Group 6|rVSV∆G-LASV-GPC Vaccine Dosage (pfu) intramuscularly Day 1 2 X 10^6 or Placebo
89024581|NCT04329208||Cerebral vasospasm|13 patients developed symptomatic cerebral vasospasm detected by CT angiography and TCD
89541180|NCT04794218|Experimental|Study Group 7|rVSV∆G-LASV-GPC Vaccine Dosage (pfu) intramuscularly Day 1 2 X 10^7 or Placebo
89541181|NCT04794218|Experimental|Study Group 4B|rVSV∆G-LASV-GPC Vaccine Dosage (pfu) intramuscularly Day 1 and Day 42 2 X 10^7 or Placebo
89541182|NCT04791527|Experimental|Mind-body Intervention arm|Online yoga, meditation, behavior change tips, and nutrition tips
89541183|NCT04785326|Experimental|DMB-3115|Patients randomized to receive DMB-3115 at the beginning of the study will continue to receive the same treatment
89541184|NCT04785326|Active Comparator|Stelara|Patients randomized to receive Stelara at the beginning of the study will be re-randomized at Week 28 in a 1:1 ratio to either continue on Stelara or will be transitioned to receive DMB-3115
89541185|NCT04780230|Experimental|real tDCS|A total of 60 Cantonese-speaking post-stroke patients who are suffering from dysarthria will be recruited and randomly divided into real tDCS and sham groups.
89541186|NCT04780230|Sham Comparator|sham tDCS|A total of 60 Cantonese-speaking post-stroke patients who are suffering from dysarthria will be recruited and randomly divided into real tDCS and sham groups.
88811993|NCT03008759|Experimental|Dentifrice 50% Nano-F|Dentifrice experimental with Fluoride being half of fluoride Nanoencapsulated and other half freeform of NaF
89541187|NCT04778046|Experimental|PAH:|Clinical diagnosis of PAH (Group 1 PH) in the absence of severe chronic lung disease, left heart disease, chronic thromboembolism, sarcoidosis, sickle cell disease or other causes of non-Group 1 PH.
89541188|NCT04778046|Experimental|COPD-noPH|Clinical diagnosis of COPD in the absence of precapillary PH.
89541189|NCT04778046|Experimental|COPD-PH|Clinical diagnosis of COPD with precapillary PH
89541190|NCT04778046|Experimental|IPF-noPH|Clinical diagnosis of IPF in the absence of precapillary PH
89541191|NCT04778046|Experimental|IPF-PH|Clinical diagnosis of IPF with precapillary PH
89541192|NCT04771416|Experimental|Part 1: Dose Escalation Cohorts designed to identify the optimal dose of PBKR03|"Cohort 1: Subjects aged >4 to <9 months Drug: PBKR03 1.5 x 10^11 GC/g* Single dose of PBKR03, via intra cisterna magna~Cohort 2: Subjects aged >4 to <9 months Drug: PBKR03 5.0 x 10^11 GC/g* Single dose of PBKR03, via intra cisterna magna~Cohort 3: Subjects aged >1 to <4 months Drug: PBKR03 1.5 x 10^11 GC/g* Single dose of PBKR03, via intra cisterna magna~Cohort 4: Subjects aged >1 to <4 months Drug: PBKR03 5.0 x 10^11 GC/g* Single dose of PBKR03, via intra cisterna magna~*GC/g: genome copiesy per gram of estimated brain weight"
89541193|NCT04771416|Experimental|Part 2: Expansion Cohort designed to confirm the safety and efficacy of PBKR03|"Cohort 5: Subjects aged >1 to <9 months Drug: PBKR03 Single dose of PBKR03, via intra cisterna magna Dose to be used for the confirmatory cohorts in Part 2 will be defined after a review of data from Part 1.~*GC/g: genome copiesy per gram of estimated brain weight"
89024582|NCT04329208||Non Vasospasm|27 patients without cerebral vasospasm
89541194|NCT04766125|Other|Standard adverse event information|
89541195|NCT04766125|Other|Elaborated adverse event information|
89541196|NCT04763447|Experimental|OMA withdrawal attempt|Patients will be told to stop abruptly (no progressive decrease of the dose) their Omalizumab treatment and they will not be prescribed new OMA
89541197|NCT04763447|Active Comparator|OMA continuation|Patients will be prescribed the same dosage of Omalizumab than they received before randomization
88811994|NCT03008759|Experimental|Dentifrice 100% Nano-F|Dentifrice experimental with fluoride 100% Nanoencapsulated
88811995|NCT01394705|No Intervention|Standard of Care|standard of care (office provider exercise counseling)
89024583|NCT04444531||Ozone autohemotherapy plus standard treatment|
89024584|NCT04444531||Standard treatment alone|
88960297|NCT05345405|Active Comparator|Supporter-Only CARE|Participants will receive supporter-only CARE following baseline and will complete self-report assessments at post-session-1, Month 1, Month 2, and Month 3.
88960298|NCT05345405|No Intervention|Waitlist Control|After completing baseline, participants will be invited to schedule a CARE session in 3 months (i.e., after the completion of all study assessments). The version of CARE received at that point will be selected by the survivor. Participants will complete self-report assessments at post-session-1, Month 1, Month 2, and Month 3.
88960299|NCT05339958|Experimental|Nutraceutical Dietary Supplement Capsule|The nutraceutical capsules are comprised of standardized, natural, medical-grade ingredients. Subject will be instructed to take four (4) capsules by mouth once daily with a substantial meal.
89513501|NCT03472963|Experimental|Group A.2|Men will be dosed with Genvoya and Darunavir® on site (time of dose will be recorded) and asked to return in 2 hours, 24 hours (+/- 1 hour), and 72 hours (+/- 1 hour) after taking dose for study procedures (blood collection, oral cheek swab, penile swabs, urethral swab, and a urine sample). Participant will undergo rectal swabs and rectal biopsy via rigid sigmoidoscopy in 24 hours after dosing.
89513502|NCT03472963|Experimental|Group A.3|Men will be dosed with Genvoya and Darunavir® on site (time of dose will be recorded) and asked to return in 2 hours, 24 hours (+/- 1 hour), and 72 hours (+/- 1 hour) after taking dose for study procedures (blood collection, oral cheek swab, penile swabs, urethral swab, and a urine sample). Participant will undergo rectal swabs and rectal biopsy via rigid sigmoidoscopy in 72 hours after dosing.
89513503|NCT03472963|Experimental|Group B.1|Men will be dosed with Genvoya and Darunavir® on site (time of dose will be recorded) and asked to return in 4 hours, 48 hours (+/- 1 hour), and 96 hours (+/- 1 hour) after taking dose for study procedures (blood collection, oral cheek swab, penile swabs, urethral swab, and a urine sample). Participant will undergo rectal swabs and rectal biopsy via rigid sigmoidoscopy in 4 hours after dosing.
89513504|NCT03472963|Experimental|Group B.2|Men will be dosed with Genvoya and Darunavir® on site (time of dose will be recorded) and asked to return in 4 hours, 48 hours (+/- 1 hour), and 96 hours (+/- 1 hour) after taking dose for study procedures (blood collection, oral cheek swab, penile swabs, urethral swab, and a urine sample). Participant will undergo rectal swabs and rectal biopsy via rigid sigmoidoscopy in 48 hours after dosing.
89513505|NCT03472963|Experimental|Group B.3|Men will be dosed with Genvoya and Darunavir® on site (time of dose will be recorded) and asked to return in 4 hours, 48 hours (+/- 1 hour), and 96 hours (+/- 1 hour) after taking dose for study procedures (blood collection, oral cheek swab, penile swabs, urethral swab, and a urine sample). Participant will undergo rectal swabs and rectal biopsy via rigid sigmoidoscopy in 96 hours after dosing.
89513506|NCT03472963|Experimental|Group C|Participants will be given a one- day supply of with Genvoya and Darunavir®. Participants return 8 hours (+/- 30min window), 24 hours (+/- 1 hr), and 48 hours (+/- 1 hour) after taking dose for study procedures (blood collection, oral cheek swab, penile swabs, urethral swab, and a urine sample). Participant will undergo rectal swabs and rectal biopsy via rigid sigmoidoscopy in 8 hours after taking the medication.
89513507|NCT02523079|Experimental|Cognitive Behavioral Group Therapy for Insomnia|Includes 6 group sessions (90 minutes each). The groups are led by trained psychologist or nurse of occupational health services. The manualized treatment is based on the general CBT-I model and includes components such as sleep hygiene, relaxation, stimulus control, sleep restriction and cognitive restructuring. In addition, participants receive information on how to schedule sleep, wake and light based on circadian principles while working differently timed shifts.
89513508|NCT02523079|Experimental|Cognitive Behavioral Self-help Therapy for Insomnia|Mainly computerized self-help intervention. Includes an individual session before and after the intervention (30 minutes each) led by trained psychologist or nurse of occupational health services. The self-help treatment is based on the general CBT-I model and includes components such as sleep hygiene, relaxation, stimulus control, sleep restriction and cognitive restructuring. In addition, participants receive information on how to schedule sleep, wake and light based on circadian principles while working differently timed shifts.
89513509|NCT02523079|Experimental|Sleep Hygiene Guidance|Includes one individual session (60 minutes) led by trained psychologist or nurse of occupational health services. The intervention is based on sleep hygiene guidance.
89513510|NCT02282579||Patient with metastatic renal cell carcinoma treated|Patient with metastatic renal cell carcinoma treated with Pazopanib
89513511|NCT02282657|Experimental|One single arm|Procedure: Baseline ventilator settings will be established per the EXPRESS protocol: VT = 6 mL/kg (ideal body weight); inspiratory flow will be set at 50-70 L/min resulting in an end-inspiratory pause of 0.2-0.5 sec, I:E ratio 1:1 to 1:3, PEEP set so that the plateau pressure (Pplat), measured during the end-inspiratory pause of 0.2 to 0.5 s, will be within the following limits: 28 cm H2O ≤ Pplat ≤ 30 cm H2O; Set RR to 20-35 to maintain approximately the same minute ventilation as before study initiation. Baseline ventilator settings will be maintained for a 2-hour run-in time (time to setup ECCO2R devices). Use heated humidifiers for gas humidification and minimize instrumental dead space. ECCO2R will be initiated during the 2-hour run-in time. Neuromuscular blocking agents (NMBA) will be used. EtCO2 will be monitored. RR will be kept what it was at Baseline. Sweep gas flow will be adapted. Ventilation will be adapted. Respiratory rate will be adapted.
89513512|NCT00465959|Experimental|400 mg TrIP|
89513513|NCT00465959|Experimental|800 mg TrIP|
89513514|NCT00465959|Placebo Comparator|Placebo|
89513515|NCT04458727||Patients who used supportive measures during home training|
89513516|NCT04458727||patients who did not use supp. measures during home training|
89513517|NCT00465803|Other|DuoTrav|One drop in the study eye(s) once daily at either 8 AM or 8 PM for twelve months, as recorded by dosing aid
89513518|NCT00465803|Other|Travatan/Timolol|One drop Timolol in the study eye(s) once daily at 8 AM; one drop of Travatan in the study eye(s) once daily at 8 PM. Both products dosed for twelve months, as recorded by separate dosing aid for each product.
89513519|NCT04176445|Other|Bedside Sitting followed by Orthostatic Board|Bedside sitting posture protocol followed by orthostatic board posture protocol.
89513520|NCT04176445|Other|Orthostatic Board followed by Bedside Sitting|Orthostatic board posture protocol followed by bedside sitting posture protocol.
88960300|NCT05339958|Placebo Comparator|Placebo Capsule|The placebo capsules contain no active ingredients. Subject will be instructed to take four (4) capsules by mouth once daily with a substantial meal.
88960301|NCT05336201|Experimental|C-READY (Cognitive-Remediation of Executive and Adaptive Deficits in Youth)|Self-management and goal-setting cognitive remediation
88960302|NCT05336201|Other|Wait-List Control Group|Will receive the same C-READY intervention after a 4-week wait period
88960303|NCT05332743|Experimental|Nutraceutical Dietary Supplement|Nutraceutical Dietary Supplement capsules are comprised of primary and secondary ingredients, designed to restore hair health from the inside out. In addition to the necessary vitamins, minerals, proteins to support the nutritional needs of hair.
89513521|NCT02282891|Active Comparator|Propofol|Induction of general Anesthesia using propofol 2mg/kg
89513522|NCT02282891|Experimental|Propofol/Ketamine (ketofol)|Induction of general anesthesia using a mixture of 1.5mg/kg:0.75mg/kg Propofol/ketamine
89513523|NCT00464633|Experimental|Alvocidib|Cycles with 4-week treatment with alvocidib followed by 2-week rest period for up to a maximum of 6 cycles
89513524|NCT03479983|Experimental|AMX160|500 mg (one capsule) x 2 times daily for 90 days
89513525|NCT03479983|Placebo Comparator|Placebo|500mg (one capsule) x 2 times daily for 90 days.
89513526|NCT00464555|Experimental|Islet Transfusion and LSF|Participants assigned to this group will receive an islet transfusion and an immunosuppressive medication regimen containing LSF.
89513527|NCT03476161|Other|Group 1|"upper left and lower right 3M Unitek Victory Series™ Superior Fit Buccal Tube with APC™ Flash-Free Adhesive~upper right and lower left 3M Unitek Victory Series™ Superior Fit Buccal Tube with APC™ II Adhesive"
89513528|NCT03476161|Other|Group 2|"upper right and lower left 3M Unitek Victory Series™ Superior Fit Buccal Tube with APC™ Flash-Free Adhesive~upper left and lower right 3M Unitek Victory Series™ Superior Fit Buccal Tube with APC™ II Adhesive"
89513529|NCT04471649||Experimental|Patient with rheumatoid arthritis using hydroxychloroquine as a part of their treatment regimen.
89513530|NCT04471649||Active Comparator|Patient with rheumatoid arthritis not using hydroxychloroquine as a part of their treatment regimen
89513531|NCT03479749|Experimental|RegenoGel-OSP - RegenoGel-OSP|First injection- the patients will receive RegenoGel-OSP; Second injection (after 3 months interval)- the patients will receive RegenoGel-OSP also
89513532|NCT03479749|Experimental|RegenoGel - RegenoGel|First injection- the patients will receive RegenoGel; Second injection (after 3 months interval)- the patients will receive RegenoGel also
89513533|NCT03479749|Placebo Comparator|Placebo - RegenoGel-OSP|First injection- the patients will receive Placebo; Second injection (after 3 months interval)- the patients will receive RegenoGel-OSP
89513534|NCT03479749|Placebo Comparator|Placebo - RegenoGel|First injection- the patients will receive Placebo; Second injection (after 3 months interval)- the patients will receive RegenoGel
89513535|NCT00464243|Experimental|Volinanserin|2 mg volinanserin tablets orally once daily
89513536|NCT00464243|Placebo Comparator|Placebo|tablets orally once daily
89513537|NCT02283047|Active Comparator|CONTROL GROUP-DIET|Hypocaloric diet intervention with no supervised exercise intervention
89513538|NCT02283047|Experimental|DIET & MODERATE CONTINUOUS TRAINING|Intervention with hypocaloric diet and supervised moderate continuous exercise training (60-80%HRpeak). High volume training (45 minutes in progression from 20 min)
89513539|NCT02283047|Experimental|DIET & HIGH VOLUME HIIT|Intervention with hypocaloric diet and supervised high intensity interval training (85-95%HRpeak). High volume training (45 minutes in progression from 20 min)
89513540|NCT02283047|Experimental|DIET & LOW VOLUME HIIT|Intervention with hypocaloric diet and supervised high intensity interval training (85-95%HRpeak). Low volume training (20 min)
89513541|NCT03336541|Experimental|Ketamine group|Low-dose ketamine (0.5 mg/kg in 100 ml normal saline) is intravenously infused in 40 minutes after childbirth during cesarean delivery.
89513542|NCT03336541|Placebo Comparator|Placebo group|Placebo (100 ml normal saline) is intravenously infused in 40 minutes after childbirth during cesarean delivery.
89513543|NCT03472729|Experimental|AGE-ON Workshop|Intervention participants will take part in a 6-week workshop to learn 1) basic features of the iPad; 2) how to use the internet; 3) how to take and view photos; 4) how to send and receive emails; and 5) other 'fun' functions.
89513544|NCT03472729|No Intervention|Wait-list control|Wait-list control group to be offered workshops after the study is complete
89513545|NCT03476083|Experimental|Group A|This is the experimental group. Participating mothers will receive Tenofovir Disoproxil Fumarate (TDF) 300 mg oral daily, starting at gestational weeks 14-16 and continue until delivery. The mothers will be followed together with their infants until postpartum week 28. Infants will receive hepatitis B vaccine at birth and additional hepatitis B (HBV) vaccine at the age of week 4 and week 24. HBIg will be omitted for the infants in this group.
89513546|NCT03476083|Active Comparator|Group B|This is the comparative group. Participating mothers will receive Tenofovir Disoproxil Fumarate (TDF) 300 mg oral daily, starting at gestational weeks 28 and continue until delivery. Patients in group B will have similar follow-up schedules as those in the experimental group. Infants will receive hepatitis B vaccine plus HBIg at birth and additional hepatitis B vaccine at the age of week 4 and week 24.
89513547|NCT02284139|Placebo Comparator|Placebo|Placebo ointment dose not contain EGF.
89513548|NCT02284139|Active Comparator|Arm EGF ointment 1ppm|Arm EGF ointment 1ppm will be treated with EGF ointment of 1 ppm concentration
89513549|NCT02284139|Active Comparator|Arm EGF ointment 20ppm|Arm EGF ointment 20ppm will be treated with EGF ointment of 20 ppm concentration
89513550|NCT02738203|Experimental|Experimental, IUD Insertion group|"If the subject is assigned to the experimental group (vaginal lidocaine jelly):~She will be given a pre-filled vaginal inserter with 10 ml of 2% lidocaine jelly) and will be asked to insert it vaginally 20-30 minutes prior to the start of her procedure. The subject will not know if she received the active drug or a placebo."
89513551|NCT02738203|Placebo Comparator|Control, IUD Insertion group|"If the subject is assigned to the control group (sterile, surgical lubricant jelly):~•She will be given a pre-filled vaginal inserter with 10 ml of surgical lubricant jelly and will be asked to insert it vaginally 20-30 minutes prior to the start of her procedure. The subject will not know if she received the active drug or a placebo."
89513552|NCT02284217|Experimental|Patients with invasive ICP monitor (EVD)|Hospitalized patients who have already been implanted with an invasive ICP monitor. Eligible patients will be enrolled into the study and HS-1000 headset portion of the device will be placed in their ears.
89513553|NCT03479359||Group 1|In this group, internship are given the pathology outcome of each prostate biopsy regularly twice a month.
89513554|NCT03479359||Group 2|In this group, internship are not given the pathology outcome of each prostate biopsy.
89513555|NCT00519389|Experimental|Low dose H5N1 VLP Vaccine|
89513556|NCT00519389|Experimental|Mid dose H5N1 VLP Vaccine|
89513557|NCT00519389|Experimental|High dose H5N1 VLP Vaccine|
89513558|NCT00519389|Placebo Comparator|Placebo|
89513559|NCT04459429|Experimental|NHF by smaller cannula|Nasal High Flow will be applied at 8 L/min (AIRVO 2) through the smaller cannula
89513560|NCT04459429|Experimental|NHF by larger cannula|Nasal High Flow will be applied at 8 L/min (AIRVO 2) through the larger cannula
89513561|NCT00458861|Experimental|BG9924|Subcutaneous administration of BG9924 given every other week for 12 weeks
89513562|NCT00458861|Placebo Comparator|Placebo|Subcutaneous administration of placebo given every other week for 12 weeks
89513563|NCT00457457|Active Comparator|Comparator|Tamsulosin 0.4 mg prolonged release
89513564|NCT00457457|Experimental|Treatment Arm|There are 5 possible UK-369,003 arms as follows: UK-369,003 MR (10mg, 25mg, 50mg & 100mg), UK-369,003 IR (40mg),
89513565|NCT04459039|Experimental|Fluid restriction|Within 12 h of surgery, the experimental group received 1000 mL 0.9% sterile saline intravenously.
89513566|NCT04459039|Placebo Comparator|Non-fluid restriction|Within 12 h of surgery, the control group received 250 mL 0.9% sterile saline intravenously
89513567|NCT03476005|Active Comparator|Proficiently Trained interns -|Provided with proficiency based progression training supported by technology enhanced learning
89513568|NCT03476005|No Intervention|Historical controls|no extra training provided
89513569|NCT00517439|Experimental|Group 1|Group 1 will receive triple combination treatment with HCV polymerase inhibitor pro-drug (1000 po bid) plus PEGASYS (180 micrograms sc weekly) plus Copegus (1000 or 1200mg po qd) for 24 weeks, followed by 24 weeks of open label Standard of Care (PEGASYS 180 micrograms sc weekly plus Copegus 1000/1200mg po qd).
89513570|NCT00517439|Experimental|Group 2|Group 2 will receive triple combination treatment with HCV polymerase inhibitor pro-drug (500 mg po bid) plus PEGASYS (180 micrograms sc weekly) plus Copegus (1000 or 1200mg po qd) for 24 weeks, followed by 24 weeks of open label Standard of Care (PEGASYS 180 micrograms sc weekly plus Copegus 1000/1200mg po qd).
89513571|NCT00517439|Experimental|Group 3|Group 3 will receive HCV polymerase inhibitor pro-drug 500mg po bid plus PEGASYS 180 micrograms sc weekly plus Copegus 1000/1200mg po qd for 24 weeks; after 24 weeks, those achieving a rapid virological response (RVR) will stop all medication, and non-RVR patients will remain on triple combination for an additional 24 weeks.
89513572|NCT00517439|Experimental|Group 4|Group 4 will receive triple combination treatment with HCV polymerase inhibitor pro-drug (1500 mg po bid) plus PEGASYS (90 micrograms sc weekly) plus Copegus (1000 or 1200mg po qd) for 24 weeks, followed by 24 weeks of open label Standard of Care (PEGASYS 180 micrograms sc weekly plus Copegus 1000/1200mg po qd).
89513573|NCT00517439|Experimental|Group 5|Group 5 will receive triple combination treatment with HCV polymerase inhibitor pro-drug (1000 mg po bid) plus PEGASYS (90 micrograms sc weekly) plus Copegus (1000 or 1200mg po qd) for 24 weeks, followed by 24 weeks of open label Standard of Care (PEGASYS 180 micrograms sc weekly plus Copegus 1000/1200mg po qd).
89513574|NCT00517439|Experimental|Group 6|Group 6 will receive triple combination treatment with HCV polymerase inhibitor pro-drug (500 mg po bid) plus PEGASYS (90 micrograms sc weekly) plus Copegus (1000 or 1200mg po qd) for 24 weeks, followed by 24 weeks of open label Standard of Care (PEGASYS 180 micrograms sc weekly plus Copegus 1000/1200mg po qd).
89513575|NCT00517439|Active Comparator|Group 7|Standard of care (SOC)
89513576|NCT02724085|Active Comparator|Cohort A|IV dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 0.15 mg/kg single dose, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
89513577|NCT02724085|Active Comparator|Cohort B|IV dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 0.45 mg/kg single dose, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
89513578|NCT02724085|Active Comparator|Cohort C|IV dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 1.0 mg/kg single dose, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
89513579|NCT02724085|Active Comparator|Cohort D|IV dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 2.0 mg/kg single dose, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
89513580|NCT02724085|Active Comparator|Cohort E|IV dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 3.0 mg/kg single dose, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
89513581|NCT02724085|Active Comparator|Cohort F|IV dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 4.0 mg/kg single dose, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
89513582|NCT02724085|Active Comparator|Cohort G|IV dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 5.0 mg/kg single dose, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
89513583|NCT03472651|Experimental|Cohort A1 Fasted condition|Subjects in cohort A1 will be administered the Investigational Medicinal Product in a fasted state, 30 subjects per cohort
89513584|NCT03472651|Experimental|Cohort A2 Fed condition|Subjects in cohort A2 will be administered the Investigational Medicinal Product in a fed state, 30 subjects per cohort
89513585|NCT05204849|Active Comparator|Active irrigation and aspiration|Patients randomized to IRRAflow will receive a ventricular catheter with active irrigation and aspiration.
89513586|NCT05204849|Active Comparator|Standard passive external ventricular drainage|Patients randomized to passive external ventricular drainage will receive a standard EVD.
89513587|NCT03131557|Experimental|Line extension of the Phonak Audéo B hearing aid|The line extension of the Phonak Audéo B product family will be fitted to the participants individual hearing loss.
89513588|NCT03131557|Active Comparator|Phonak Audéo B hearing aid|Phonak Audéo B will be fitted to the participants individual hearing loss.
89513589|NCT00517049|Experimental|1|
89513590|NCT03479125||Historical emricasan or placebo subjects|Subjects with liver fibrosis or cirrhosis who have received at least one dose of emricasan or placebo in a prior IDN-6556 study including IDN-6556-07, IDN-6556-12, IDN-6556-14 or IDN-6556-17.
89207244|NCT04043130|Experimental|Pulse Treatment App|The treatment app is a web-based mobile health app designed for Black & Latinx women ages 18-20. Through culturally and age-appropriate content, Pulse provides information on birth control, healthy relationships, sexual health, pregnancy, & utilization of clinical services to encourage users to choose effective birth control, seek reproductive health services, and prevent unplanned pregnancies. Users access Pulse autonomously and on their own terms. The app does not require users to follow a specific sequence of content viewed. Participants randomized to the intervention condition are given access to Pulse and receive Multimedia Messaging Service (MMS) messages related to sexual health several times a week for 6 weeks. Participants receive a baseline survey, 6-week follow-up survey, and 6-month follow-up survey via an electronic survey platform (6-month survey only administered to participants recruited between November 2018-March 2019).
89210540|NCT01562964|Active Comparator|Supportive therapy|Subjects in the Supportive therapy group will attend the Royal Brompton Hospital weekly for 10 weeks to meet with person of equal status to the hypnotherapist (e.g. a research assistant, not a medical practitioner) trained to provide counseling and support. Visits will last 50-60 min. Patients will be encouraged to talk about their physical symptoms and any emotional issues, and to discuss how these might be coped with in a better way.
88816149|NCT02488317|No Intervention|Control arm|These patients will not receive the decision aid tool and will be asked to test their knowledge without it. Decision-making outcomes (e.g., self-efficacy) will be compared between patients who received and did not receive a decision aid. These arms were chosen because the current standard of care is for health care providers to discuss options with patients without using a decision aid.
89210541|NCT00819728|Experimental|Taxotere/Irinotecan|
89210542|NCT00906828|Active Comparator|1. Duodopa, optimised dose|
89513591|NCT02283203|Active Comparator|APOTEL max|Active drug; water for injection at a volume of 100ml with added 1g of paracetamol and inactive ingredients (ΑPOTEL max®), infused within 15 minutes. Available in 100ml bags.
89513592|NCT02283203|Placebo Comparator|Placebo|Placebo; water for injection at a volume of 100ml with added inactive ingredients, infused within 15 minutes. Available in 100ml bags.
89513593|NCT00448721|Experimental|Perifosine|Perifosine will be administered orally at 100mg PO daily with food. One treatment cycle will consist of 42 days (6 weeks).
89513594|NCT02523313|Active Comparator|Nivolumab + Placebo|Nivolumab (3 mg/kg) i.v. every 2 weeks + Placebo instead of Ipilimumab on weeks 1, 4, 7 and 10 + Placebo instead of Nivolumab on weeks 4 and 10
89513595|NCT02523313|Experimental|Nivolumab + Ipilimumab|Nivolumab (1 mg/kg) and Ipilimumab (3 mg/kg) i.v. every 3 weeks for 4 doses. Both study drugs are administered on the same day over the first 12 weeks + Placebo instead of Nivolumab on weeks 3, 5, 9 and 11. After week 12: Nivolumab as maintenance and at a dose of 3 mg/kg IV every 2 weeks for up to 1 year after initial dosing (of the combination) or until PD.
89513596|NCT02523313|Placebo Comparator|Double Placebo Control|Placebo instead of Nivolumab and Placebo instead of Ipilimumab i.v. every 3 weeks for 4 doses. Both placebos are administered on the same day over the first 12 weeks + Placebo instead of Nivolumab on weeks 3, 5, 9 and 11. After week 12 Placebo instead of Nivolumab as maintenance and applied as IV every 2 weeks for up to 1 year after initial dosing (of the combination) or until PD.
89513597|NCT02452034|Experimental|3.5 mg/kg POS (2<7 years old)|Children 2 to less than 7 years of age will receive POS at 3.5 mg/kg by intravenous (IV) solution twice on Day 1, then once daily on Days 2-10. This will be followed by treatment with 3.5 mg/kg POS once daily by powder for oral suspension (PFS) for a minimum of 10 days; or, if they are unwilling or unable to tolerate POS PFS, continued treatment with POS IV.
89513598|NCT02452034|Experimental|4.5 mg/kg POS (2<7 years old)|Children 2 to less than 7 years of age will receive POS at 4.5 mg/kg by IV solution twice on Day 1, then once daily on Days 2-10. This will be followed by treatment with 4.5 mg/kg POS once daily by PFS for a minimum of 10 days; or, if they are unwilling or unable to tolerate POS PFS, continued treatment with POS IV.
89513599|NCT02452034|Experimental|3.5 mg/kg POS (7-17 years old)|Children 7 to 17 years of age will receive POS at 3.5 mg/kg by IV solution twice on Day 1, then once daily on Days 2-10. This will be followed by treatment with 3.5 mg/kg POS once daily by PFS for a minimum of 10 days; or, if they are unwilling or unable to tolerate POS PFS, continued treatment with POS IV.
89513600|NCT02452034|Experimental|4.5 mg/kg POS (7-17 years old)|Children 7 to 17 years of age will receive POS at 4.5 mg/kg by IV solution twice on Day 1, then once daily on Days 2-10. This will be followed by treatment with 4.5 mg/kg POS once daily by PFS for a minimum of 10 days; or, if they are unwilling or unable to tolerate POS PFS, continued treatment with POS IV.
89541198|NCT04759833|Experimental|Part A: Low Dose Group|Participants weighing less than (<) 50 kilograms (kg) will receive a daily dose of 0.04 milligrams per kilogram (mg/kg) prucalopride oral solution (will draw the required volume from one bottle of 0.4 milligram per milliliter [mg/mL] and one bottle of placebo oral solution to account for the daily dose assigned) once daily (QD) or participants weighing greater than or equal to (>=) 50 kg will receive a single dose of 2 milligram (mg) prucalopride oral tablet during 12 weeks of treatment period. Volume of the oral solution will be based on the participants body weight (BW) at the randomization visit.
89541199|NCT04759833|Experimental|Part A: High Dose Group|Participants weighing < 50 kg will receive a daily dose of 0.08 mg/kg prucalopride oral solution (will draw the required volume from two bottle of 0.4 mg/mL to account for the daily dose assigned) QD or participants weighing >= 50 kg will receive a two dose of 2 mg prucalopride oral tablet during 12 weeks of treatment period. Volume of the oral solution will be based on the participants BW at the randomization visit.
89541200|NCT04759833|Placebo Comparator|Part A: Placebo|Participants weighing < 50 kg will draw equal volumes from two bottles of matching placebo oral solution to account for the daily dose assigned or participants weighing >= 50 kg will receive two daily dose of matching placebo oral tablet during 12 weeks of treatment period.
89541201|NCT04759833|Experimental|Part B: Low Dose Group|Participants weighing < 50 kg will receive a daily dose of 0.04 mg/kg prucalopride oral solution (will draw the required volume from one bottle of 0.4 mg/mL and one bottle of placebo oral solution to account for the daily dose assigned) QD or participants weighing >= 50 kg will receive a single dose of 2 mg prucalopride oral tablet during 36 weeks of treatment period. Volume of the oral solution will be based on the participants BW at the randomization visit.
89541202|NCT04759833|Experimental|Part B: High Dose Group|Participants weighing < 50 kg will receive a daily dose of 0.08 mg/kg prucalopride oral solution (will draw the required volume from two bottle of 0.4 mg/mL to account for the daily dose assigned) QD or participants weighing >= 50 kg will receive two dose of 2 mg prucalopride oral tablet during 36 weeks of treatment period. Volume of the oral solution will be based on the participants BW at the randomization visit.
89210543|NCT00906828|Experimental|2. 80% Duodopa + entacapone|80% of optimised Duodopa dose + two tablets of entacapone at t=0 hours and at t= 6 hours
89210544|NCT00906828|Experimental|3. 80% Duodopa + tolcapone|80% of optimised Duodopa dose + two tablets of tolcapone at t=0 hours and at t= 6 hours
89210545|NCT00819806|Experimental|A|PF-3512676, and three MHC class I Montanide ISA 720 VG and the peptides NY-ESO-1 157-165V, NY-ESO-1 53-62 and NY-ESO-1 94-102 will be administered in three separate subcutaneous (under the skin) injections.
88960304|NCT05323539|Active Comparator|Patients with endometrioma|Patients having a prediagnosis of surgically planned endometrioma occured this group.
89541203|NCT04758676|Experimental|Nutritional and physiotherapy protocol, BIA|Study subjects randomized into this study arm will be indicated for nutritional and physiotherapy protocol, based upon the obtained results of the measurements, using bioimpedance analysis.
89541204|NCT04758676|Active Comparator|Standard of care|Study subjects randomized into this study arm will be provided the current standard of care.
89541205|NCT04749160||Rheumatoid arthritis (RA) with connected device|"RA with DAS28 ≥ 3.2 despite methotrexate therapy and initiating for the first time a bDMARD or a tsDMARD.~the physical activity and sleep quality measured with connected device"
89541206|NCT04748354|Active Comparator|Usual Care|Clinical care provided by geriatricians. Each participant will see the geriatrician at baseline and 6 months.
89541207|NCT04748354|Experimental|Usual Care with Exercise|Clinical care provided by geriatricians. Each participant will see the geriatrician at baseline and 6 months. In addition, they will receive the Otago Exercise Program, an individualized and home-based program of progressive strength and balance training exercises delivered by a physical therapist.
89541208|NCT04747847|Experimental|Atorvastatin and anakinra|Anakinra up to 8 mg/kg/day and atorvastatin at 0.75 mg/kg/day
89541209|NCT04740931|Experimental|Arm A: Faricimab Q4W (Part 1), Faricimab PTI (Part 2)|In Part 1 (Day 1 through Week 24), participants randomly assigned to Arm A will receive faricimab 6 milligrams (mg) by IVT injection once every 4 weeks (Q4W) from Day 1 through Week 20 (a total of 6 injections). In Part 2 (from Week 24 to Week 72), participants will receive faricimab 6 mg by IVT injection according to a personalized treatment interval (PTI) dosing regimen. To preserve masking for Part 2, a sham procedure will be administered during study visits at which no faricimab treatment is administered (according to the PTI dosing regimen).
89541210|NCT04740931|Active Comparator|Arm B: Aflibercept Q4W (Part 1), Faricimab PTI (Part 2)|In Part 1 (Day 1 through Week 24), participants randomly assigned to Arm B will receive aflibercept 2 milligrams (mg) by IVT injection once every 4 weeks (Q4W) from Day 1 through Week 20 (a total of 6 injections). In Part 2 (from Week 24 to Week 72), participants will receive faricimab 6 mg by IVT injection according to a personalized treatment interval (PTI) dosing regimen. To preserve masking for Part 2, a sham procedure will be administered during study visits at which no faricimab treatment is administered (according to the PTI dosing regimen).
89541211|NCT04711889|Experimental|Ulinastatin|Ulinastatin 10 0000 Units is taken intravenously three times a day.
88960305|NCT05323539|Active Comparator|Control group|Patients who had planned gynecological surgery for a reason (ovarian cycts) other than endometrioma
89210546|NCT00819806|Experimental|B|This vaccine injection contains all the same components of Arm A and will also be administered in 3 separate subcutaneous injections. However, 3 days prior to your 1st, 3rd, 5th, 7th, 9th and subsequent monthly vaccinations, you will have low-dose cyclophosphamide administered intravenously (through a vein in your arm). Cyclophosphamide is an agent that is thought to increase the anti-tumor response of vaccines.
88816150|NCT01168934|Experimental|1|Each subject will receive single oral and IV doses of crizotinib separated by at least 14 days.
88816151|NCT01170884|Active Comparator|Combigan® + Lumigan®|COMBIGAN® (fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution) adjunctive to LUMIGAN® (bimatoprost 0.03% ophthalmic solution)
88816152|NCT01170884|Active Comparator|Lumigan®|LUMIGAN® (bimatoprost 0.03% ophthalmic solution) plus Gen Teal® Mild (hypromellose 0.2% eye drops) used for masking purposes
88816153|NCT01171118|Experimental|Sedation & Physostigmine & Room Air|We are attempting to demonstrate a decrease in the frequency and severity of sedation-induced respiratory arrhythmias (central and obstructive apneas) with pharmacological pre-treatment in this pilot project and then eventually to understand the mechanisms behind this decrease. The efficacy and mechanisms of these treatments, while evaluated during sleep in OSA patients, have not been systematically studied during sedation in either normal subjects or OSA patients. The agent to be assessed in this study is physostigmine versus placebo.We are interested in the effect of breathing oxygen vs. room air on the regulation of respiratory control during moderate sedation.
88816154|NCT01171118|Placebo Comparator|Sedation & Placebo & Room Air|We are attempting to demonstrate a decrease in the frequency and severity of sedation-induced respiratory arrhythmias (central and obstructive apneas) with pharmacological pre-treatment in this pilot project and then eventually to understand the mechanisms behind this decrease. The efficacy and mechanisms of these treatments, while evaluated during sleep in OSA patients, have not been systematically studied during sedation in either normal subjects or OSA patients. The agent to be assessed in this study is physostigmine versus placebo.We are interested in the effect of breathing oxygen vs. room air on the regulation of respiratory control during moderate sedation.
89513601|NCT02452034|Experimental|6 mg/kg POS (2<7 years old)|Children 2 to less than 7 years of age will receive POS at 6 mg/kg by IV solution twice on Day 1, then once daily on Days 2-10. This will be followed by treatment with 6 mg/kg POS once daily by PFS for a minimum of 10 days; or, if they are unwilling or unable to tolerate POS PFS, continued treatment with POS IV.
89513602|NCT02452034|Experimental|6 mg/kg POS (7-17 years old)|Children 7 to 17 years of age will receive POS at 6 mg/kg by IV solution twice on Day 1, then once daily on Days 2-10. This will be followed by treatment with 6 mg/kg POS once daily by PFS for a minimum of 10 days; or, if they are unwilling or unable to tolerate POS PFS, continued treatment with POS IV.
89513603|NCT04471103|Experimental|Real-Time Delphi Method|The Real-Time Delphi Method involves a single-round Delphi survey rating the importance of outcomes for neonatal encephalopathy. Feedback on each outcome (participant's own rating score, rating of the outcome by stakeholder group and overall consensus results for that outcome) will be provided to the participant once they have rated an outcome. They can then modify how they rated the outcome based on this feedback if they wish. Participants can also re-visit and re-rate outcomes as many times as they wish when the survey is live. Duration will span approximately 5 weeks.
89513604|NCT04471103|Active Comparator|Multi-round Delphi Method|The Multi-Round Delphi Method involves a three-round Delphi survey rating the importance of outcomes for neonatal encephalopathy. Feedback on each outcome (participant's own rating score, rating of the outcome by stakeholder group and overall consensus results for that outcome) will be provided to the participant at the end of Round 1 and the end of Round 2. Participants can then modify how they rated the outcome based on feedback, in Rounds 2 and 3, if they wish. Each survey Round will run for 3 weeks approximately. In between survey Rounds, there will be a downtime of approximately 10 days before providing feedback and a further 7 days before starting the next round. Duration will span approximately 14 weeks.
89513605|NCT02283359|Experimental|Selinexor in Combination with Irinotecan|"The first study drug is called selinexor (KPT-330). This drug is taken by mouth on days 1, 3, 8 and 10 of each cycle. The starting dose of selinexor will be dependent on the cohort in which the patient is enrolled into. Level -1: 25 mg/m^2; Level 1: 40 mg/m^2; Level 2: 50 mg/m^2; Level 3: 65 mg/m^2.~The second drug is called irinotecan. This drug is given as intravenous (IV) infusion on days 1 and 8 of each cycle. Participants will receive the standard recommended dose: 125 mg/m^2."
89513606|NCT02284295||occupational COPD|"Consists of 2 subgroups~COPD patients with history of exposure to respirable silica dust~COPD patients with history of exposure to aromatic hydrocarbons"
89513607|NCT02284295||smokers with COPD and healthy control|"patients with COPD, history of tobacco smoke and no history of occupational exposure~healthy subjects"
89513608|NCT02284451|Active Comparator|English HIGH Health Literacy|Using a valid measure of health literacy, 300 participants will be randomized into this group. These participants will receive HIV/AIDS and HIV testing information either by video or pictorial brochure in two equal groups.
89513609|NCT02284451|Active Comparator|English LOW Health Literacy|Using a valid measure of health literacy, 300 participants will be randomized into this group. These participants will receive HIV/AIDS and HIV testing information either by video or pictorial brochure in two equal groups.
89513610|NCT02284451|Active Comparator|Spanish HIGH Health Literacy|Using a valid measure of health literacy, 300 participants will be randomized into this group. These participants will receive HIV/AIDS and HIV testing information either by video or pictorial brochure in two equal groups.
89513611|NCT02284451|Active Comparator|Spanish LOW Health Literacy|Using a valid measure of health literacy, 300 participants will be randomized into this group. These participants will receive HIV/AIDS and HIV testing information either by video or pictorial brochure in two equal groups.
89513612|NCT00513617|Active Comparator|Low Dose|0.05 g/kg/day Arginine
89513613|NCT00513617|Active Comparator|High Dose|0.10 g/kg/day Arginine
89513614|NCT00513617|Placebo Comparator|Placebo|No Arginine
89513615|NCT00511043|Experimental|All pts|PTK787
89513616|NCT00508625|Other|C|40 subjects will receive up to 6 cycles of carboplatin (AUC=6.0mg/ml.min) and paclitaxel (200mg/m2) on day 1 of each 21 day cycle plus Bevacizumab (15mg/kg) on day 1 of each 21 day cycle until disease progression, study drug intolerability or withdrawal of consent.
89513617|NCT00508625|Experimental|E|40 subjects will receive up to 6 cycles of carboplatin (AUC=6.0mg/ml.min) and paclitaxel (200mg/m2) on day 1 of each 21 day cycle plus Bevacizumab (15mg/kg) on day 1 and AMG 951 (rhApo2L/TRAIL) (20mg/kg) on days 1-2 per 21 day cycle until disease progression, study drug intolerability or withdrawal of consent.
89513618|NCT00508625|Experimental|B|40 subjects will receive up to 6 cycles of carboplatin (AUC=6.0mg/ml.min) and paclitaxel (200mg/m2) on day 1 of each 21 day cycle plus AMG 951 (rhApo2L/TRAIL) (8mg/kg) for 5 days per 21 days cycle until disease progression, study drug intolerability or withdrawal of consent.
89513619|NCT00508625|Other|A|40 subjects will receive up to 6 cycles of Carboplatin (AUC = 6.0mg/ml.min) and Paclitaxel (200mg/m2) only
89513620|NCT00508625|Experimental|D|40 subjects will receive up to 6 cycles of carboplatin (AUC=6.0mg/ml.min) and paclitaxel (200mg/m2) on day 1 of each 21 day cycle plus Bevacizumab (15mg/kg) on day 1 and AMG 951 (rhApo2L/TRAIL) (8mg/kg) on days 1-5 per 21 day cycle until disease progression, study drug intolerability or withdrawal of consent.
89513621|NCT02284529|Experimental|Orectalip® (Oxaliplatin)|High-risk Stage-Ⅱ Colorectal Cancer treatment with Oxaliplatin 85mg/m2 in D5W 250 ml IV drip 2hrs on D1, Leucovorin 100mg/m2 in N/S 100ml IV drip 2hrs on D1, follow by 5-FU 2400mg/m2 IV infusion 24hrs on D1 to execute 8~12 cycles
89513622|NCT02482298|Experimental|Dose A|
89513623|NCT02482298|Experimental|Dose B|
89513624|NCT02482298|Placebo Comparator|Placebo|
89513625|NCT02284607|Experimental|MHAA4549A higher dose|
89513626|NCT02284607|Experimental|MHAA4549A lower dose|
89513627|NCT02284607|Placebo Comparator|Placebo|
89513628|NCT02286479|Active Comparator|Incision and Drainage|In the incision and drainage group, the abscesses are incised, irrigated by sterile solutions and drained conventionally.
89541212|NCT04711889|Sham Comparator|Blank control|Blank control.
89541213|NCT04711655|Experimental|(ARMA) antireflux ablation of the cardiac mucosa|The ARMA (Ablation with electrocoagulation current or by argon gas fulguration) technique will be performed in patients assigned to this treatment arm.
89024585|NCT00472017|Experimental|Pediatric Diffuse Brainstem Glioma Patients|Patients with newly diagnosed diffuse brainstem gliomas receive vandetanib.
89541214|NCT04711655|Placebo Comparator|upper digestive endoscopy|Quality diagnostic upper gastrointestinal endoscopy will be performed without intervention in patients assigned to this treatment arm.
89541215|NCT04707690|Active Comparator|Intraurethral laser therapy|"Before treatment the vulva will be carefully inspected to rule out signs of infection or recent trauma. A local anesthetic fluid (Cathejell ®) will be applied to the urethral meatus. Before laser therapy, an intraurethral swab will be taken before treatment in order to determine the intraurethral microbiome.~Vulvovaginal laser therapies will be performed with the non-ablative 2940 nm Er:YAG laser (Smooth XS, Fotona, Slovenia) in the Incontinence mode according to the manufacturer's guidelines and recommendations. The spot size (diameter of the laser beam) is 7 mm, with a pulse at a frequency of 1.6 Hz, and a fluence (laser energy delivered per unit area) of 5.0 to 10.0 J/cm2."
89541216|NCT04707690|Placebo Comparator|Intraurethral SHAM laser therapy|"Clinical examination and preparations will be identical to the intervention group. Sham laser treatments will be performed with the same laser and the same device. However, a specially designed placebo probe, which blocks the emission of radiation, will be used. Women will therefore receive no therapeutic laser treatment. Before treatment, a study assistant, who is aware of the study allocation, will prepare the laser with the placebo probe, which looks identically to the normal probe. The treating physician will not be aware of the study allocation and the type of probe in use."
89541217|NCT04703101|Experimental|Treatment (IMRT, mFOLFOX6, CapeOX, TME)|Patients undergo SCRT in the form of IMRT over 5 fractions daily for 5 consecutive days. Beginning 11-18 days after the last day of radiation therapy, patients receive either oxaliplatin IV and leucovorin IV on day 1 and fluorouracil IV on days 1-3 (mFOLFOX6) or oxaliplatin IV on day 1 and capecitabine PO BID on days 1-14 (CapeOX). Treatment with mFOLFOX6 repeats every 2 weeks for up to 8 cycles, and treatment with CapeOX repeats every 3 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity. At 8-12 weeks after completion of all therapy, patients with residual tumor undergo TME. Patients with cCR undergo NOM.
89541218|NCT04681352|Experimental|Octave System|Single treatment of décolleté tissue.
89541219|NCT04664101|Experimental|REmotely Monitored, Mhealth (REMM) supported High Intensity Interval Training (HIIT)|REmotely Monitored, Mhealth (REMM) supported High Intensity Interval Training (HIIT) The intervention consists of high intensity interval training, consisting of a 30-minute exercise session that includes 10 x 1-minute intervals of high intensity 3x/week (e.g., Monday, Wednesday, Friday) and supplemented with 2 sessions per week of strength, balance, and mobility exercises (e.g., Tuesday, Thursday). Exercise will be supported by an activity tracker, which will allow study personnel to track patient heart rates during exercise on a daily basis, allowing them to provide individualized feedback and coaching.
89541220|NCT04664101|Other|Comparator|Patients randomized to the control arm will receive the same technology platform and education on exercise options, including HIIT, but will return home to exercise as they see fit without personalized instruction and coaching. They will be remotely monitored, but will not receive feedback unless any adverse events are noted
89541221|NCT04649905||Surgical Treatment|Patient's in this cohort will undergo surgical treatment for OCD of the knee.
89541222|NCT04649905||Nonoperative Treatment|Patient's in this cohort will undergo nonoperative treatment for OCD of the knee.
89541223|NCT04631718||MRI based abdominal QSM|Participants with known or suspected iron overload with past serum ferritin >500 will be recruited in this study.
89541224|NCT04609137|Experimental|Early drain removal|Participants will have an early drain removal (before postoperative day 3 (POD 3)) if specific conditions will be verified
89541225|NCT04609137|Active Comparator|Standard drain removal|Participants will receive the current standard of care at San Raffaele Hospital.
89541226|NCT04603196||Patients with Multiple Sclerosis with obstructive sleep apnea|Patients with Multiple Sclerosis with obstructive sleep apnea
89541227|NCT04603196||Patients with MS without obstructive sleep apnea|Patients with MS without obstructive sleep apnea
89541228|NCT04598477|Experimental|efgartigimod PH20 SC|patients receiving efgartigimod PH20 SC on top of prednisone
89541229|NCT04588428|Experimental|Part 1: INO-4700 Group A|Participants received one intradermal (ID) injection of 0.6 milligram (mg) of INO-4700 followed by electroporation (EP) using the CELLECTRA™ 2000 device on Day 0 and Week 4.
88960306|NCT05319899|Experimental|Sequence 1: ABC|"Participants received each treatment on 1 occasion:~Period 1 (Treatment A): ALXN1840 following an overnight fast. Period 2 (Treatment B): Omeprazole once daily in the morning of Days -5 to -1 following an overnight fast, omeprazole at Hour -1 on Day 1 following an overnight fast, and ALXN1840 at Hour 0 on Day 1, following an overnight fast. Period 3 (Treatment C): Omeprazole once daily in the morning of Days -5 to -1 following an overnight fast, omeprazole at Hour -1 on Day 1 following an overnight fast, and ALXN1840 at Hour 0 on Day 1, approximately 30 minutes after the start of a high-fat breakfast.~There was a washout period of at least 14 days between each ALXN1840 dosing."
88960307|NCT05319899|Experimental|Sequence 2: ACB|"Participants received each treatment on 1 occasion:~Period 1 (Treatment A): ALXN1840 following an overnight fast. Period 2 (Treatment C): Omeprazole once daily in the morning of Days -5 to -1 following an overnight fast, omeprazole at Hour -1 on Day 1 following an overnight fast, and ALXN1840 at Hour 0 on Day 1, approximately 30 minutes after the start of a high-fat breakfast. Period 3 (Treatment B): Omeprazole once daily in the morning of Days -5 to -1 following an overnight fast, omeprazole at Hour -1 on Day 1 following an overnight fast, and ALXN1840 at Hour 0 on Day 1, following an overnight fast.~There was a washout period of at least 14 days between each ALXN1840 dosing."
89024586|NCT02894203|Experimental|Mindfulness|
89024587|NCT02894203|Active Comparator|Hatha Yoga|
89024588|NCT02894203|No Intervention|Wait-list|
89024589|NCT00433121|Experimental|A|Discontinuation of neuroleptic or anti depressants
89210547|NCT00819806|Experimental|C|PF-3512676, Montanide ISA 720 VG and the peptides NY-ESO-1 157-165V, NY-ESO-1 53-62 and NY-ESO-1 94-102, NY-ESO-1 87-111, NY-ESO-1 119-143 and NY-ESO-1 157-170 will be administered in three separate subcutaneous injections.
89541230|NCT04588428|Experimental|Part 1: INO-4700 Group B|Participants received one ID injection of 1.0 mg of INO-4700 followed by EP using the CELLECTRA™ 2000 device on Day 0 and Week 4.
89541231|NCT04588428|Experimental|Part 1: INO-4700 Group C|Participants received one ID injection of 1.0 mg of INO-4700 followed by EP using the CELLECTRA™ 2000 device on Day 0 and Week 8.
89541232|NCT04588428|Experimental|Part 1: INO-4700 Group D|Participants received two ID injections (in an acceptable location on two different limbs) of 0.5 mg each of INO-4700 followed by EP using the CELLECTRA™ 2000 device on Day 0 and Week 8.
89541233|NCT04588428|Experimental|Part 1: INO-4700 Group E|Participants received two ID injections (in an acceptable location on two different limbs) of 1.0 mg each of INO-4700 followed by EP using the CELLECTRA™ 2000 device on Day 0 and Week 4.
89541234|NCT04588428|Placebo Comparator|Part 1: Placebo Group F|Participants received one ID injection of placebo followed by EP using the CELLECTRA™ 2000 device on Day 0 and Week 4.
89541235|NCT04588428|Placebo Comparator|Part 1: Placebo Group G|Participants received one ID injection of placebo followed by EP using the CELLECTRA™ 2000 device on Day 0 and Week 8.
89541236|NCT04588428|Placebo Comparator|Part 1: Placebo Group H|Participants received two ID injections (in an acceptable location on two different limbs) of placebo followed by EP using the CELLECTRA™ 2000 device on Day 0 and Week 8.
89541237|NCT04588428|Placebo Comparator|Part 1: Placebo Group I|Participants received two ID injections (in an acceptable location on two different limbs) of placebo followed by EP using the CELLECTRA™ 2000 device on Day 0 and Week 4.
89541238|NCT04588428|Experimental|Part 2: Parts 2A and 2B|Participants were planned to receive ID injection of INO-4700 based on optimal dose and regimen selection in Part 1 followed by EP using the CELLECTRA™ 2000 device on Day 0, Week 4 or Week 8 and a booster dose at Week 48 (only for Part 2B participants were planned to receive a third dose).
89541239|NCT04581564|Experimental|Rhythm intervention|
89541240|NCT04581564|Active Comparator|Non-rhythm intervention|
89541241|NCT04564157|Experimental|Adjuvant treatment + Adjuvant maintenance treatment|"Adjuvant treatment:~Paclitaxel: 200mg/m2 infusion over 3 hours~Carboplatin: AUC5 at the end of the Paclitaxel infusion~Nivolumab: 360 mg intravenous Q3W~It has to start within 3-10 weeks from surgery and the first administration has to be done within 1-3 days from randomization. 4 cycles will be administered at 21day intervals (QW3) after surgery. A CT-SAN must be done after the 4 cycles of adjuvant treatment. Patients must discontinue treatment if there is evidence of disease relapse.~After the 4 cycles of chemo-immunotherapy the patient will receive:~Adjuvant maintenance treatment: Nivolumab: 480 mg IV Q4W It will start after 4 weeks from day 1 cycle 4 of adjuvant treatment. 6 cycles will be administered every 28 days. A CT-SAN must be done within +/- 7 days from day 28 of the 3rd cycle of adjuvant maintenance treatment and within +/- 7 days at the end of the 6th cycle. Patients must discontinue treatment if there is evidence of disease relapse at 3rd cycle CT-SCAN."
89541242|NCT04564157|Active Comparator|Control arm: Adjuvant treatment|"Adjuvant treatment:~Paclitaxel: 200mg/m2 infusion over 3 hours~Carboplatin: AUC5 at the end of the Paclitaxel infusion Adjuvant treatment has to start within 3-10 weeks from surgery and the first administration and has to be done within 1-3 days from randomization. 4 cycles will be administered at 21-day (+/- 3 days) intervals (QW3) after surgery. A CT-SAN must be done after the 4 cycles of adjuvant treatment.~Observation: 2 observation visits will be done at 3 months and at 6 months from day 21 of cycle 4 of adjuvant treatment."
89541243|NCT04539366|Experimental|Treatment (GD2 CAR T)|"LYMPHODEPLETION CHEMOTHERAPY: Patients receive fludarabine phosphate IV daily on days -5 to -2 and cyclophosphamide IV daily on days -4 to -2.~GD2CART: Patients receive GD2CART cells IV on day 0.~Patients also undergo ECHO, MUGA or cardiac MRI scan during screening, blood sample collection throughout the trial, and tumor biopsies as clinically indicated. In addition, patients undergo standard imaging scans throughout the trial."
89541244|NCT04536350|Experimental|Aviptadil Treatment|Participants will receive standard care plus a dose of 67μg nebulized Aviptadil three times a day for ten days.
89541245|NCT04536350|Placebo Comparator|Placebo Treatment|Participants in the control group will receive an Inhalation of 0.9% NaCl solution three times a day for 10 days
88960308|NCT05319899|Experimental|Sequence 3: BAC|"Participants received each treatment on 1 occasion:~Period 1 (Treatment B): Omeprazole once daily in the morning of Days -5 to -1 following an overnight fast, omeprazole at Hour -1 on Day 1 following an overnight fast, and ALXN1840 at Hour 0 on Day 1, following an overnight fast. Period 2 (Treatment A): ALXN1840 following an overnight fast. Period 3 (Treatment C): Omeprazole once daily in the morning of Days -5 to -1 following an overnight fast, omeprazole at Hour -1 on Day 1 following an overnight fast, and ALXN1840 at Hour 0 on Day 1, approximately 30 minutes after the start of a high-fat breakfast.~There was a washout period of at least 14 days between each ALXN1840 dosing."
89541246|NCT04515212|Active Comparator|Healthy Volunteers|
89541247|NCT04515212|Experimental|Traumatic Brain Injury Patients|
89207245|NCT04043130|Active Comparator|Pulse Control App|The control app, also called Pulse, is a web-based mobile health app designed by the study team for young women ages 18-20. Although Pulse control and Pulse treatment apps look and feel similar aesthetically, they contain different content. Pulse control app provides information on general health topics, such as the importance of sleep, healthy eating, and friendships. Users access Pulse autonomously, on their own terms, and in their own time and place. The app does not require the user to follow a specific sequence of content viewed; however, all users receive a monetary incentive after completing a baseline survey and registering with the app. Control participants also receive MMS messages related to general health for six weeks. Participants receive a baseline survey and a six-week follow-up which are conducted online via an electronic survey platform.
89207246|NCT00968487|Experimental|Lyophilized Plasma|
88960309|NCT05319899|Experimental|Sequence 4: BCA|"Participants received each treatment on 1 occasion:~Period 1 (Treatment B): Omeprazole once daily in the morning of Days -5 to -1 following an overnight fast, omeprazole at Hour -1 on Day 1 following an overnight fast, and ALXN1840 at Hour 0 on Day 1, following an overnight fast. Period 2 (Treatment C): Omeprazole once daily in the morning of Days -5 to -1 following an overnight fast, omeprazole at Hour -1 on Day 1 following an overnight fast, and ALXN1840 at Hour 0 on Day 1, approximately 30 minutes after the start of a high-fat breakfast. Period 3 (Treatment A): ALXN1840 following an overnight fast.~There was a washout period of at least 14 days between each ALXN1840 dosing."
89207247|NCT00968487|Active Comparator|Fresh Frozen Plasma|
89207248|NCT00848562|Experimental|Nicorandil|
89207249|NCT02546154||CKD, iron deficiency anaemia|10% Iron Isomaltoside 1000 administered intravenously to Chronic Kidney Disease patients in doses at the doctor's discretion for treatment of iron deficiency anaemia.
89207250|NCT02546154||IBD, iron deficiency anaemia|10% Iron Isomaltoside 1000 administered intravenously to Inflammatory Bowel Disease patients in doses at the doctor's discretion for treatment of iron deficiency anaemia.
88960310|NCT05319899|Experimental|Sequence 5: CAB|"Participants received each treatment on 1 occasion:~Period 1 (Treatment C): Omeprazole once daily in the morning of Days -5 to -1 following an overnight fast, omeprazole at Hour -1 on Day 1 following an overnight fast, and ALXN1840 at Hour 0 on Day 1, approximately 30 minutes after the start of a high-fat breakfast. Period 2 (Treatment A): ALXN1840 following an overnight fast. Period 3 (Treatment B): Omeprazole once daily in the morning of Days -5 to -1 following an overnight fast, omeprazole at Hour -1 on Day 1 following an overnight fast, and ALXN1840 at Hour 0 on Day 1, following an overnight fast.~There was a washout period of at least 14 days between each ALXN1840 dosing."
88960311|NCT05319899|Experimental|Sequence 6: CBA|"Participants received each treatment on 1 occasion:~Period 1 (Treatment C): Omeprazole once daily in the morning of Days -5 to -1 following an overnight fast, omeprazole at Hour -1 on Day 1 following an overnight fast, and ALXN1840 at Hour 0 on Day 1, approximately 30 minutes after the start of a high-fat breakfast. Period 2 (Treatment B): Omeprazole once daily in the morning of Days -5 to -1 following an overnight fast, omeprazole at Hour -1 on Day 1 following an overnight fast, and ALXN1840 at Hour 0 on Day 1, following an overnight fast. Period 3 (Treatment A): ALXN1840 following an overnight fast.~There was a washout period of at least 14 days between each ALXN1840 dosing."
88960312|NCT05319665|No Intervention|Control|The control group will have the standard-of-care treatment.
88960313|NCT05319665|Experimental|Interventional|The interventional group will have a head-mounted display whilst still in the operating theatre airing a live video of their newborn filmed by a 2D 360° camera to enable a visual and auditory contact.
89207251|NCT03943095|Experimental|Test Dentifrice|Participants will be instructed to apply a strip of dentifrice (a full brush head) containing 5 % weight by weight (w/w) potassium nitrate and 0.454% w/w stannous fluoride (1100 parts per million [ppm] fluoride). Participants will brush their two selected 'test teeth' first, followed by the whole mouth for at least one timed minute, twice daily (morning and evening), and will be permitted to rinse with water post-brushing.
89513629|NCT02286479|Experimental|Loop drainage|In the loop drainage group, two small incision are made on each side of abscess. The pus are drained and septations are seperated by a forceps. Abscess cavitary irrigated by sterile solution. Sterile, non-powder, non-latex surgical gloves cuff is inserted in one incision and taken out from the other insicion. Then two tips of cuff are tied loosely.
89513630|NCT04470479|Experimental|Pilocarpine Hydrochloride|Patients with Sjögren's syndrome were allocated to receive oral pilocarpine 20mg per day, (5mg every 6 hours, for ten weeks.
89513631|NCT04470479|Placebo Comparator|placebo|Patients with Sjögren's syndrome were allocated to receive placebo administered in the same way (1 tablet every 6 hours), for ten weeks
89513632|NCT02286557|Experimental|Arm I|Arm 1 will undergo four weeks of treatment with MP extended-release (20 mg/day in the morning). Following the four weeks of treatment, all assessments performed at baseline will be repeated. To minimize practice effects, alternate versions of the neuropsychological tests will be used wherever available. A 7-day washout period will follow in which no medication will be administered. Following the washout period, Arm 1 will undergo four weeks of placebo. This will be followed by a final assessment consisting of measures of fatigue, cognitive functioning, and physical disability.
89513633|NCT02286557|Experimental|Arm II|Arm 2 will undergo four weeks of placebo (in the morning). Following the four weeks of placebo, all assessments performed at baseline will be repeated. To minimize practice effects, alternate versions of the neuropsychological tests will be used wherever available. A 7-day washout period will follow in which no medication will be administered. Following the washout period, Arm 2 will undergo four weeks of treatment with MP extended-release (20mg/day). This will be followed by a final assessment consisting of measures of fatigue, sleep quality, cognitive functioning, and physical disability.
89513634|NCT00383513|Experimental|Epratuzumab|
89513635|NCT00382811|Experimental|1|Daily Phenoxodiol + weekly carboplatin
89513636|NCT00382811|Active Comparator|2|Daily phenoxodiol placebo + weekly carboplatin
89513637|NCT02286635|Experimental|Cohort A Deflazacort and Rifampin|Subjects will recieve one 18 mg dose of deflazacort on Day 1, Period 1 and Day 10, Period 2; cohort A. Subjects will receive once daily dosing of rifampin on Day 1, Period 2 through Day 10, Period 2.
89513638|NCT02286635|Experimental|Cohort B Deflazacort and Clarithromycin|Subjects will recieve one 18 mg dose of deflazacort on Day 1, Period 1 and Day 4, period 2; cohort B. Subjects will receive twice daily dosing of clarithromycin on Day 1, Period 2 through Day 4, Period 2.
89513639|NCT00440531|Active Comparator|1|RECOMBIVAX HB™
89513640|NCT00440531|Experimental|2|Modified Process Hepatitis B Vaccine
89513641|NCT00440531|Active Comparator|3|ENGERIX-B™
89513642|NCT02286791|Experimental|Mindful Awareness Program|18 sessions of mindful awareness program teaching the elderly mindful awareness practice techniques
89513643|NCT02286791|Active Comparator|Health Education Program|18 sessions of health education program focusing on healthy living topics
89513644|NCT00437021|Active Comparator|Group C|Dryvax® vaccine or placebo on Day 0. This arm was discontinued from original protocol. Subjects already enrolled in this group will continue follow-up per protocol.
89513645|NCT00437021|Experimental|Group D|Standard dose IMVAMUNE® vaccine or placebo on Day 0 and Dryvax® vaccine or placebo on Day 7. This arm was discontinued from original protocol. Subjects already enrolled in this group will continue follow-up per protocol.
89513646|NCT00437021|Experimental|Group E|Dryvax® vaccine and standard dose IMVAMUNE® vaccine or 2 placebos on Day 0. This arm was discontinued from original protocol. Subjects already enrolled in this group will continue follow-up per protocol.
89513647|NCT00437021|Experimental|Group F|Standard dose IMVAMUNE® vaccine or placebo on Day 0.
89513648|NCT00437021|Experimental|Group B|Standard dose IMVAMUNE® vaccine or placebo on Days 0 and 28.
89513649|NCT00437021|Experimental|Group A|Standard dose IMVAMUNE® vaccine or placebo on Days 0 and 7.
89513650|NCT00375791|Experimental|Perifosine daily|Patients will take three 50 mg tablets of perifosine daily at bedtime with food. Patients will be examined every three weeks. If patients have no progression it is allowed to receive 8 cycles of perifosine
89513651|NCT00375791|Experimental|Perifosine daily + Dexa twice per week|Patients will take three 50 mg tablets of perifosine daily at bedtime with food until progression. If progressive disease is confirmed by a second measurement at least one week later the patient will receive a combination of 20 mg twice per week dexamethasone (dexa) and 150 mg perifosine daily at bedtime.
89513652|NCT00375401|Experimental|CP-945,598 Treatment A|
89513653|NCT00375401|Experimental|CP-945,598 Treatment B|
88960314|NCT05317481|Experimental|BE-SMART-DR|Participation will include research clinical/behavioral interviews and symptom self-ratings, magnetic resonance imaging (MRI) scanning, actigraphy wearables, and use of smart phones for ecological momentary assessment (EMA). Subjects will participate in 12 weekly sessions and 6-month in person follow-up.
88960315|NCT05317481|Active Comparator|control comparator condition|Matched for experimental, participation will include research clinical/behavioral interviews and symptom self-ratings, magnetic resonance imaging (MRI) scanning, actigraphy wearables, and use of smart phones for ecological momentary assessment (EMA). Subjects will participate in 12 weekly sessions and 6-month in person follow-up.
89513654|NCT00375401|Placebo Comparator|Placebo|
89513655|NCT02286869|Experimental|Pressure Controlled Ventilation|"INTERVENTION: respiratory trial in pressure controlled mode: (i) the inspiratory pressure is set up to obtain the same tidal volume than baseline, (ii) the imposed respiratory rate is the same respiratory rate than baseline.~The positive end expiratory pressure and fractional inspiratory oxygen are unchanged from the baseline.~After an acclimation period of 10 min, electrocardiographic, arterial pressure and respiratory waves are recorded for 30 min."
89513656|NCT02286869|Experimental|Pressure Support Ventilation|"INTERVENTION: respiratory trial in pressure support mode: (i) the inspiratory pressure is set up to obtain the same tidal volume than baseline, (ii) the inspiratory trigger is a flow-trigger with medium sensitivity.~The positive end expiratory pressure and fractional inspiratory oxygen are unchanged from the baseline. In this ventilatory mode the respiratory rate is not imposed because is driven by the patient's respiratory effort.~After an acclimation period of 10 min, electrocardiographic, arterial pressure and respiratory waves are recorded for 30 min."
89513657|NCT02286869|Experimental|Neurally Adjusted Ventilatory Assist|"INTERVENTION: respiratory trial in Neurally Adjusted Ventilatory Assist (NAVA) mode: (i) NAVA-level (gain) is set up to obtain the same tidal volume than baseline, (ii) the inspiratory trigger is a neural trigger set at 0.5 microVolt.~The positive end expiratory pressure and fractional inspiratory oxygen are unchanged from the baseline. In this ventilatory mode the respiratory rate is not imposed because is driven by the patient's respiratory effort.~After an acclimation period of 10 min, electrocardiographic, arterial pressure and respiratory waves are recorded for 30 min."
89513658|NCT02513732||XIENCE Xpedition 2.25 mm stent arm|Patients receiving XIENCE Xpedition 2.25 mm stent
89513659|NCT00432185|Active Comparator|1|One day treatment
89513660|NCT00432185|Active Comparator|2|Two day treatment
89513661|NCT02287103|Experimental|Skipping Breakfast (NoB)|The patients in No B will omit the breakfast and will continue the overnight fast until lunch. Will eat only lunch and dinner. In YesB will eat all three meals
89513662|NCT02287103|Active Comparator|Eating Breakfast (YesB):|The patients in YesB will eat all three mealswill consume three meals: breakfast, lunch and dinner
89513663|NCT00431873|Experimental|1|MGCD0103 administered orally three times per week.
89513664|NCT02287181|Active Comparator|remifentanil effect site concentration 0ng/ml|remifentanil run as an infusion using the minto TCI model, at an effect site concentration of 0 nano grams per millilitre, commenced from start of proposal infusion to point at which patient is anaesthetised and not responding to painful stimuli.
89513665|NCT02287181|Active Comparator|remifentanil effect site concentration 3ng/ml|remifentanil run as an infusion using the minto TCI model, at an effect site concentration of 3 nano grams per millilitre, commenced from start of proposal infusion to point at which patient is anaesthetised and not responding to painful stimuli.
89513666|NCT02287259|Experimental|Olanzapine|PO start with 2.5mg daily once for 7days, since then flexible dose.
89513667|NCT02287259|Active Comparator|Lithium|PO start with 400mg daily twice for 7days, since then flexible dose.
89513668|NCT00429923|Experimental|Difluprednate 0.05% BID|Difluprednate 0.05% 1 drop BID for 14 days.
89513669|NCT00429923|Experimental|Difluprednate 0.05% QID|Difluprednate 0.05% 1 drop QID for 14 days.
89513670|NCT00429923|Placebo Comparator|Placebo|Placebo for 14 days. Placebo was administered BID for 14 days and QID for 14 days. The outcomes of the 2 placebo groups were examined and were determined to be statistically indistinguishable so the placebo groups were pooled for comparison with the difluprednate groups.
89541248|NCT04494789|Active Comparator|Fludrocortisone dosing regime: 24hrs|Receive 50mcg doses of fludrocortisone every 24hrs
89541249|NCT04494789|Active Comparator|Fludrocortisone dosing regime: 12hrs|Receive 50mcg doses of fludrocortisone every 12hrs
89541250|NCT04494789|Active Comparator|Fludrocortisone dosing regime: 6hrs|Receive 50mcg doses of fludrocortisone every 6hrs
89541251|NCT04494789|Placebo Comparator|Control Arm|Receives standard treatment without fludrocortisone dosing regime
89541252|NCT04478747|Active Comparator|Transvaginal mesh|BSC mesh (A.M.I., Feldkirch, Austria) is attached to the sacrospinosus ligaments and to the apical part of the vagina.
89541253|NCT04478747|Active Comparator|Colposacropexy with the apical fixation only|EndoGYNious (A.M.I.) CSP mesh is attached laparoscopically to the apical part of the vagina.
89541254|NCT04478747|Active Comparator|Colposacropexy with the apical and the levator fixation|EndoGYNious (A.M.I.) CSP mesh is attached laparoscopically to the apical part of the vagina with fixation reaching to the level of the levator planes.
89541255|NCT04475640|Experimental|Screening (biospecimen collection)|Patients undergo collection of blood or saliva sample for genetic testing.
89541256|NCT04471428|Experimental|Atezolizumab + Cabozantinib|Participants received atezolizumab on Day 1 of each 21-day cycle and cabozantinib orally once daily on Days 1-21 of each cycle.
89541257|NCT04471428|Active Comparator|Docetaxel|Participants received docetaxel on Day 1 of each 21-day cycle.
89541258|NCT04446728|Active Comparator|Strategy I.Training|Sites randomized to Strategy I will receive a three hour training webinar in preparing for implementation of the PAT in their center.
89541259|NCT04446728|Active Comparator|Strategy II.Training+Implementation Enhanced Resources (TIER)|Sites randomized to Strategy II will identify a Champion for screening and will participate in a monthly consultation call in addition to completing the three hour training webinar for implementing the PAT in their center.
89541260|NCT04418661|Experimental|SAR442720 + Pembrolizumab|"Part 1:~SAR442720 (also known as RMC-4630) will be administered orally twice a week (BIW) followed by pembrolizumab which is given intravenously (IV) once every 3 weeks (Q3W). The dose of SAR442720 will be escalated or de-escalated depending on the emerging safety data of the combination."
89541261|NCT04418661|Experimental|SAR442720 + Pembrolizumab: Non-small cell lung cancer with Tumor proportion score > 50%|"Part 2:~SAR442720 dose will be administered orally in combination with Pembrolizumab which is given by IV infusion once every 3 weeks (Q3W) or once every 6 weeks (Q6W)"
89541262|NCT04418661|Experimental|SAR442720 + Pembrolizumab: Non-small cell lung cancer with Tumor proportion score 1-49%|"Part 2:~SAR442720 dose will be administered orally in combination with Pembrolizumab which is given by IV infusion once every 3 weeks (Q3W) or once every 6 weeks (Q6W)"
89541263|NCT04418661|Experimental|SAR444270 + adagrasib: Dose Escalation|Part 3A; SAR442720 and adagrasib will be administered orally on a continuous basis.
89541264|NCT04418661|Experimental|SAR444270 + adagrasib: Dose Expansion|"Part 3B:~Once SAR442720 dose is confirmed in Part 3A SAR442720 and adagrasib will be administered orally on a continuous basis."
89541265|NCT04418661|Experimental|SAR442720 + Pembrolizumab continuous|"Part 4:~SAR442720 will be administered orally in combination with Pembrolizumab which is given by IV infusion once every 3 weeks (Q3W) or once every 6 weeks (Q6W)"
89541266|NCT04400058|Experimental|Octagam 10%|Octagam 10%
89541267|NCT04400058|Placebo Comparator|Saline Solution|Placebo
89541268|NCT04390399|Active Comparator|Cohort A Control Treatment Arm|SBRT + gemcitabine + nab-paclitaxel
89541269|NCT04390399|Experimental|Cohort A Experimental Treatment Arm 1|SBRT + cyclophosphamide + gemcitabine + nab-paclitaxel + aldoxorubicin HCl + N-803
89541270|NCT04390399|Experimental|Cohort A Experimental Treatment Arm 2|SBRT + cyclophosphamide + gemcitabine + nab-paclitaxel+ aldoxorubicin HCl + N-803 + PD-L1 t-haNK
88960316|NCT05310695|Active Comparator|NSAC rapid: treatment at the NSAC at- or within 4 weeks|NSAC service delivered according to ordinary procedures, 4 weeks after referral.
89541271|NCT04390399|Active Comparator|Cohort B Control Treatment Arm|Irinotecan liposome + 5-FU/leucovorin
89541272|NCT04390399|Experimental|Cohort B Experimental Treatment Arm|SBRT + cyclophosphamide + gemcitabine + nab-paclitaxel+ aldoxorubicin HCl + N-803 + PD-L1 t-haNK
88960317|NCT05310695|Active Comparator|NSAC ordinary: treatment at the NSAC after 10-14 weeks|NSAC service delivered according to ordinary procedures, 10-14 weeks after referral, by and large equivalent to current waiting time
89207252|NCT03943095|Active Comparator|Control Dentifrice|Participants will be instructed to apply a strip of dentifrice (a full brush head) containing 0.454% w/w stannous fluoride (1100 ppm fluoride). Participants will brush their two selected 'test teeth' first, followed by the whole mouth for at least one timed minute, twice daily (morning and evening), and will be permitted to rinse with water post-brushing.
89541273|NCT04390399|Experimental|Cohort C Experimental Treatment Arm|SBRT + cyclophosphamide + gemcitabine + nab-paclitaxel + aldoxorubicin + N-803 + PD-L1 t-haNK
89541274|NCT04364620|Experimental|Arm AB-16B5 and Docetaxel|AB-16B5 at a dose of 12 mg/kg once weekly on Days 1, 8 and 15 combined with docetaxel at a dose of 75 mg/m2 once every 3 weeks on Day 1.
89541275|NCT04363320|Experimental|High-Dose NIATx Coaching & ECHO|"Attend an in-person Kick-Off Meeting with Study Team & Coaches~4-hour onsite visit (NIATx Training)~11 monthly (one-hour) NIATx coaching calls~Prescribers participate in 12 monthly (one-hour) ECHO video conference calls"
89541276|NCT04363320|Experimental|Low-Dose NIATx Coaching & ECHO|"Attend an in-person Kick-Off Meeting with Study Team & Coaches~One-hour conference call with Executive Sponsor~Two-hour NIATx webinar training with Change Leader/Team~Three (one-hour) coaching calls at months 4, 8, and 12 with Change Leader/Team~Prescribers participate in 12 monthly (one-hour) ECHO video conference calls"
89541277|NCT04363320|Experimental|High-Dose NIATx Coaching & No ECHO|"Attend an in-person Kick-Off Meeting with Study Team & Coaches~4-hour onsite visit~11 monthly (one-hour) NIATx coaching calls"
89541278|NCT04363320|Experimental|Low-Dose NIATx Coaching & No ECHO|"Attend an in-person Kick-Off Meeting with Study Team & Coaches~One-hour conference call with Executive Sponsor~Two-hour NIATx webinar training with Change Leader/Team~Three (one-hour) coaching calls at months 4, 8, and 12 with Change Leader/Team"
89541279|NCT04339413|Experimental|SCarlet RoAD|Participants enrolled from the open label extension (OLE) part of parent study WN25203, received gantenerumab, up to 1200 milligram (mg), subcutaneous (SC) injection, every 4 weeks (Q4W) for up to 129 weeks.
89541280|NCT04339413|Experimental|Marguerite RoAD|Participants enrolled from the OLE part of parent study WN28745, received gantenerumab, up to 1200 mg, SC injection, Q4W for up to 129 weeks.
89541281|NCT04333706|Experimental|Experimental: Phase I|A dose finding study of sarilumab plus capecitabine in patients with metastatic TNBC and metastatic HER2/neu-negative and hormone resistant breast cancer.
89541282|NCT04333706|Experimental|Phase 2 single arm study|Study of adjuvant sarilumab plus capecitabine in stage I to III TNBC with less than a pCR
89541283|NCT04333706|Other|Parallel Baseline Arm|Study of standard adjuvant capecitabine in stage I to III TNBC with less than a pCR. This Arm will be open in parallel with both Phases 1 and 2. Blood samples will be obtained during the course of the study. Bone marrow samples are optional.
89541284|NCT04327999|Experimental|Preservative free artificial tears|Day 1, patients will self-administer artificial tears every 15 minutes for 2 hours followed by every 30 minutes for at least 4 hours or until bedtime at night. On Day 2, patients will self-administer artificial tears every 1 hour for 12 hours. On Day 3, patients will self-administer artificial tears four times that day. On Day 4, patients will self-administer tears twice that day. Patients will be instructed to wear their contact lenses throughout their waking hours.
89541285|NCT04323202|Experimental|Permbrolizumab|Participants will undergo fine cut CT imaging (head and neck) followed by at least 4 doses of pembrolizumab q 3 weeks. After the 4th dose of pembrolizumab as appropriate, patients will undergo standard surgical resection, with all non-marginal tissue as well as the pre-op biopsy to be stored for collateral research. 2 weeks after initial flap or graft insert (which would be equivalent to stage 1 of a forehead flap) patients would continue for a total of approximately 1 year of pembrolizumab q 3 weeks (another 13 doses, thus 17 doses total).
89541286|NCT04313400|Experimental|Part 1 Dose Escalation: 3% to 70% of the BSA|Open-label, five (5) cohorts were sequentially enrolled. AMTX-100 CF 1.1% w/w, topically applied twice a day for 7 consecutive days to all treatable AD affected areas from 3% to 70% of the Body Surface Area (BSA) (3% BSA ≤ AD Affected Area ≤ 70% BSA)
89541287|NCT04313400|Experimental|Part 2 Group A: 1.1% w/w|AMTX-100 CF3 (1.1% w/w), topically applied twice a day for 28 consecutive days to all treatable AD affected areas
88960318|NCT05310695|Active Comparator|NSAC - active control|Monodisciplinary examination at the NSAC close to diagnosis-specific deadline for examination as suggested by guidelines (8-26 weeks, the majority at the end of this interval)
88960319|NCT05301959|Experimental|Experimental group|A single weekly intervention of low intensity galvanic currents will be applied in an ultrasound-guided manner.
88960320|NCT05301959|Sham Comparator|Simulated group.|The application of a single weekly intervention of low intensity galvanic currents will be simulated in an echogenic way, with the equipment turned off.
88960321|NCT05298956|Sham Comparator|Sham|Participants will receive sham laser to the right forehead.
88960322|NCT05298956|Active Comparator|Transcranial infrared laser stimulation|Participants will receive transcranial infrared laser stimulation to the right forehead.
88960323|NCT05291364|Active Comparator|Group 1|injection of ethanol and lidocaine with dexmedetomidine
88960324|NCT05291364|Active Comparator|Group 2|injection of ethanol and lidocaine Without dexmedetomidine
88960325|NCT05291221|Placebo Comparator|control|At the end of the operation by 15min, 5ml saline in a medical spray bottle was sprayed down the intratracheal tube of patients.
89207253|NCT00841932||Fractional Flow Reserve|Patients with suspected coronary artery disease undergoing FFR to assess physiological significance of stenosis
89541288|NCT04313400|Placebo Comparator|Part 2 Group B: Placebo|Placebo (Vehicle) (0% w/w), topically applied twice a day for 28 consecutive days to all treatable AD affected areas
89541289|NCT04293042|Experimental|BK cystitis and/or nephropathy|All patients with symptoms that are consistent with BK cystitis and/or nephropathy (frequency, dysuria, hematuria, elevated creatinine) will have serum quantitative DNA PCR for BK virus level measured in log copies per mL (results also expressed in copies per milliliter), performed in the Children's Hospital of Philadelphia Infectious Disease Diagnostics Laboratory
89541290|NCT04283227|Experimental|OTL-200 Gene Therapy|OTL-200 is an autologous CD34+ cell enriched population that contains hematopoietic stem and progenitor cells (HSPC) transduced ex vivo using a lentiviral vector encoding the human arylsulfatase A (ARSA) gene.
88960326|NCT05291221|Active Comparator|Dexmedetomidine|At the end of the operation by 15min, Dexmedetomidine (0.5µg/kg, diluted in 5mL saline in a medical spray bottle) was sprayed down the intratracheal tube of patients
88960327|NCT05291221|Active Comparator|Lidocaine|At the end of the operation by 15min, (5ml) 2% of lidocaine was sprayed down the intratracheal tube of patients.
88960328|NCT05288894||Repaired Tetralogy of Fallot|A patient affected by Tetralogy of Fallot (right ventricle outflow obstruction, right ventricle hypertrophy, ventricular septal defect, aortic overriding of the ventricular defect) that already underwent cardiac surgery for the correction.
88960329|NCT05281744|Experimental|Dementia Care Consultation program|The Dementia Care Consultation program provides an in-depth, personalized service for individuals and families facing ADRD.
88960330|NCT05281744|No Intervention|Routine Care|Members randomized into the control group will receive routine care.
89207254|NCT00852462|Experimental|SAMI|Patients and Health care providers use Symptom Assessment and Management Intervention: patient report symptoms by answering validated questionnaires in a secure online program. The system generates a report for providers that displays symptoms and customized suggestions for their clinical management.
89541291|NCT04271449|Experimental|Cerebellum tDCS|Cerebellum tDCS arm will be subdivided into two other arms according to the polarity of the stimulation (inhibitory vs excitatory stimulation). These two subgroups will be divided into two other subgroups according the the task exposed during prism exposure (pointing vs throwing).
89541292|NCT04271449|Experimental|Primary motor cortex|Primary motor cortex tDCS arm will be subdivided into two other arms according to the polarity of the stimulation (inhibitory vs excitatory stimulation). These two subgroups will be divided into two other subgroups according the the task exposed during prism exposure (pointing vs throwing).
89541293|NCT04271449|Sham Comparator|Sham tDCS|Sham tDCS arm will serve as a sham comparator for other experimental conditions. This arm will be subdivided into two groups depending on the localisation of the electrodes (cerebellum placement vs primary motor cortex placement).These two subgroups will be divided again in two subgroups depending on the task exposed (pointing vs throwing).
89541294|NCT04262206|Experimental|atorvastatin 40mg|40mg atorvastatin po qd from consent to study end
89541295|NCT04262206|Placebo Comparator|Placebo|matching placebo po qd from consent to study end
89541296|NCT04219800|Experimental|mHealth|"Activity tracker armband (Garmin Vivofit); warns of prolonged sitting and counts daily steps.~SMS text messages; reminds of activity breaks.~Mobile video instruction for standing pause gymnastics."
89541297|NCT04219800|Other|Control|Patient-centered counselling and written material regarding occupational sedentary behaviour, with telephone follow-ups after 1 and 5 weeks.
89541298|NCT04214249|Experimental|Arm I (cytarabine, idarubicin, daunorubicin, HSCT)|See Detailed Description.
89541299|NCT04214249|Active Comparator|Arm II (cytarabine, idarubicin, daunorubicin, HSCT)|See Detailed Description.
89541300|NCT04211337|Experimental|Selpercatinib|Selpercatinib given orally.
89541301|NCT04211337|Active Comparator|Cabozantinib or Vandetanib|Cabozantinib or vandetanib given orally.
89541302|NCT04210986|Experimental|Fisetin|Fisetin 100 mg capsules (~20 mg/ kg/ day) will be administered orally for two consecutive days (days 1 and 2) followed by 28 days off. A second course will be given for two consecutive days (days 31 and 32)
89541303|NCT04210986|Placebo Comparator|Placebo|Placebo capsules will be administered orally for two consecutive days (days 1 and 2) followed by 28 days off. A second course will be given for two consecutive days (days 31 and 32)
89541304|NCT04208984||Control|Patients randomized to this group will receive standard of care induction of anesthesia
89541305|NCT04208984||Study|Patients randomized to this group will receive induction of anesthesia using the Lullabreath game
88960331|NCT05277935|Active Comparator|Use of the WeCancer app combined with the smartwatch|The Wecancer app will be used in a way, combined with a smartwatch, similar to those used in professional fitness programs, with active measures, which may include, for example: notifications with personalized advice (via chat), feedback to the patient in the comments made, guidance on physical and eating exercises, reception and support from the Wecancer multidisciplinary team, consisting of a navigator nurse, psychologist, nutritionist and physiotherapist. During the survey period, participants should report their symptoms on the Wecancer app whenever possible, preferably daily.
88960332|NCT05277935|No Intervention|Using the WeCancer app|The Wecancer application similar to those used in professional fitness programs, with active measures, which may include, for example: notifications with personalized advice (via chat), patient feedback on the comments made, guidance on physical and dietary exercises, reception and support of the Multidisciplinary cancer team composed of a navigator nurse, a psychologist, nutritionist and physiotherapist. During the research period, participants must report your symptoms in the Wecancer app whenever possible, preferably daily.
88960333|NCT05274958|Experimental|Initial PROM plus monthly PROM plus educational video|These patients receive usual care plus monthly PROMs and educational video(s) while on the waitlist
88960334|NCT05274958|No Intervention|Usual Care|Patients will complete the initial bundle of PROMs, then no further PROMs while they remain on the waitlist
88960335|NCT05274269|Experimental|ELX/TEZ/IVA|Participants will receive ELX/TEZ/IVA in the morning and IVA in the evening.
88960336|NCT05274269|Placebo Comparator|Placebo|Participants will receive placebo matched to ELX/TEZ/IVA in the morning and placebo matched to IVA in the evening.
88960337|NCT05273307|Experimental|Miracle Fruit|Participants will receive 1 Miracle Fruit Farm miracle fruit cube by mouth three times a day before meals
88960338|NCT05273307|Placebo Comparator|Miracle Fruit Placebo|Participants will receive 1 placebo cube by mouth three times a day before meals
88960339|NCT05273268|Active Comparator|Control Arm|The control arm (target enrollment; n=180) will receive the US government-standard guidelines for dietary advice in the form of the USDA dietary recommendations digital leaflet.
88960340|NCT05273268|Experimental|Intervention Arm|The intervention arm (target enrollment; n=180) will receive personalized dietary guidelines created by machine learning algorithms using their personal anthropometric, gut, dietary and medical information as inputs. The guidelines will be delivered in the form of a smartphone/ smart device app.
89541306|NCT04208984||Music Video|Patients randomized to this group will receive induction of anesthesia using the music video game
89541307|NCT04204876||patients with GCA|All patients presenting with a new diagnosis of LV-GCA and all patients already treated for LV-GCA and planned for treatment termination
89541308|NCT04191746||Participants with critical limb disease|This registry will collect data from participants with critical limb disease from Duke University and approximately 40 sites in North America.
89541309|NCT04171765|Placebo Comparator|Fixed Dose: Placebo|Participants will receive a fixed dose of placebo matched to BFKB8488A.
89541310|NCT04171765|Placebo Comparator|Individualized Dose: Placebo|Participants will received a dose of placebo matched to BFKB8488A.
89541311|NCT04171765|Experimental|Fixed Dose: BFKB8488A Dose A|Participants will receive BFKB8488A.
89541312|NCT04171765|Experimental|Fixed Dose: BFKB8488A Dose B|Participants will receive BFKB8488A.
89541313|NCT04171765|Experimental|Fixed Dose: BFKB8488A Dose C|Participants will receive BFKB8488A.
89541314|NCT04171765|Experimental|Individualized Dose: BFKB8488A|Participants will receive increasing doses of BFKB8488A up to the highest tolerated dose .
89541315|NCT04163952|Experimental|Treatment (talimogene laherparepvec, panitumumab)|Patients receive talimogene laherparepvec IM on day 1. Patients then receive talimogene laherparepvec IM and panitumumab IV over 30-90 minutes on day 22. Treatment repeats every 2 weeks for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients may receive up to 3 additional cycles of treatment per physician discretion.
89541316|NCT04145037|Experimental|Switch Stable|Switch-stable arm: Subjects who had undergone ERT ≥15 U/kg and ≤60 U/kg every other week (or equivalent; i.e., any combination of infusions resulting in a total monthly ERT dose of >30 U/kg and <120 U/kg) for ≥24 consecutive months for Type 1 Gaucher disease at the time of Screening. Switch-stable subjects must have discontinued ERT at least 2 weeks before the scheduled AVR-RD-02 infusion. Switch-stable subjects who had been and substrate reduction therapy (SRT) must not have received SRT within 12 months of Screening.
89541317|NCT04145037|Experimental|Treatment-naïve|"Treatment-naïve arm: Subjects with Type 1 Gaucher disease who had never received either ERT or SRT for Gaucher disease or had not received either ERT or SRT for Gaucher disease within 12 months of Screening (i.e., treatment-naïve subjects). Enrollment followed a similar scheme as for the switch-stable subjects.~Note: No subjects enrolled in this arm."
89541318|NCT04143061|Experimental|Group 1|MenACYW conjugate vaccine, 1 vaccination, adults in India aged 18 to 55 years
89541319|NCT04143061|Active Comparator|Group 2|Menactra® conjugate vaccine, 1 vaccination, adults in India aged 18 to 55 years
89541320|NCT04143061|Experimental|Group 3|MenACYW conjugate vaccine, 1 vaccination, adults in India aged ≥ 56 years
89541321|NCT04143061|Active Comparator|Group 4|Quadri Meningo™, 1 vaccination, adults in India aged ≥ 56 years
89541322|NCT04143061|Experimental|Group 5|MenACYW conjugate vaccine, 1 vaccination, children and adolescents in India aged 2 to 17 years
89541323|NCT04143061|Active Comparator|Group 6|Menactra®, 1 vaccination, children and adolescents in India aged 2 to 17 years
89541324|NCT04143061|Experimental|Group 7|MenACYW conjugate vaccine, 1 vaccination, children and adolescents in RSA aged 2 to 17 years
89541325|NCT04143061|Active Comparator|Group 8|Menactra®, 1 vaccination, children and adolescents in RSA aged 2 to 17 years
89541326|NCT04143061|Experimental|Group 9|MenACYW conjugate vaccine and age-recommended routine pediatric vaccine(s), toddlers aged 12 to 23 months in India
89541327|NCT04143061|Active Comparator|Group 10|Age-recommended routine pediatric vaccine(s) (RPV) only, toddlers aged 12 to 23 months in India
89541328|NCT04128670|Experimental|Kinesiotape (KT)|Tape will be applied to the biceps muscle of the nondominant arm from approximately the shoulder to the elbow for up to 72 hours. For the KT group taping will be applied with a lymphatic application method according to the guidelines recommended by Kenzo Kase. This type of application is known to improve blood and lymphatic circulation which enhances the removal of metabolic products. The tape will be applied with a tension of 10-20%.
89541329|NCT04128670|Placebo Comparator|Placebo Kinesiotape|Tape will be applied to the biceps muscle of the nondominant arm from approximately the shoulder to the elbow for up to 72 hours. The placebo KT group will have 0% tension.
89541330|NCT04128670|No Intervention|No Tape|This group will not receive any intervention.
89541331|NCT04098250|Experimental|Erenumab|140 mg erenumab
89024590|NCT00591526|No Intervention|A|"Patients aged ≤ 60 years and with initial WBC ≤ 10000/mm3 Induction treatment~a) ATRA and chemotherapy ATRA 45 mg/m2/d until hematological CR first intensive chemotherapy course : DNR 60 mg/m2/d during 3 days AraC 200 mg/m2/d during 7 days~2) Consolidation treatment~First consolidation course (=2nd chemotherapy course) DNR 60 mg/m2/d d1-3 (intravenous bolus injection) AraC 200 mg/m2/d d1-7 (continuous infusion)~Second consolidation course AraC 1g/m2/12h d1-4 (1 hour infusion) Daunorubicin 45 mg/m2/d d1-3 (intravenous bolus injection) 3) Maintenance treatment~Consists of the combination of continuous low dose chemotherapy and intermittent ATRA, during 2 years~Continuous low dose chemotherapy~Intermittent ATRA"
89024591|NCT00591526|Experimental|B|Patients aged ≤ 60 years and with initial WBC ≤ 10000/mm3 (Group B) Same treatment as Group A but without AraC.
89024592|NCT00591526|No Intervention|C|"First consolidation course (=2nd chemotherapy course) DNR 60 mg/m2/d d1-3 (intravenous bolus injection) AraC 200 mg/m2/d d1-7 (continuous infusion)~Second consolidation course AraC 1g/m2/12h d1-4 (1 hour infusion) Daunorubicin 45 mg/m2/d d1-3 (intravenous bolus injection)~CNS prophylaxis : consists of 5 intrathecal (IT) injections of MTX 15mg and AraC 50 mg (12 mg/m2 maximum 15 mg, and 30mg/m2, maximum 50 mg, respectively, in children) + depomedrol IT. I~3) Maintenance treatment"
89024593|NCT00591526|No Intervention|D|"Patients aged >60 years and initial WBC ≤ 10000/mm3 Induction treatment~a) ATRA and chemotherapy ATRA 45 mg/m2/d until hematological CR first intensive chemotherapy course : DNR 60 mg/m2/d during 3 days (intravenous bolus injection) NO ARA C DURING THIS FIRST COURSE~2) Consolidation treatment~First consolidation course DNR 60 mg/m2/d d1-3 AraC 100 mg/m2/d d1-5 G-CSF~Second consolidation course DNR45 mg/m2/d d1-3 AraC 100 mg/m2/d d1-5 G-CSF~3) maintenance treatment: similar to other groups"
89024594|NCT02894008|Experimental|ChAd63- KH|Single intramuscular dose of ChAd63-KH, 1 x10(10)vp or, following safety review, 7.5 x 10(10)vp in adults
89541332|NCT04098250|Placebo Comparator|Placebo|placebo comparator
89541333|NCT04097028|Experimental|Treatment (TAS-102, oxaliplatin)|Patients receive oxaliplatin IV over 2 hours on day 1 and trifluridine and tipiracil hydrochloride PO BID on days 1-5. Treatment repeats every 14 days for 3 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care chemoradiation therapy followed by surgery.
89541334|NCT04063410|Experimental|Screening (pPCA)|Patients undergo standard of care CTA and undergo pPCA MRI for up to 60 minutes before surgery.
89541335|NCT04039607|Experimental|Nivolumab + Ipilimumab|
89541336|NCT04039607|Active Comparator|Sorafenib/lenvatinib|
89541337|NCT04026412|Experimental|Arm A: nivolumab + CCRT + ipilimumab|Concurrent chemoradiotherapy (CCRT)
89541338|NCT04026412|Experimental|Arm B: nivolumab + CCRT|Concurrent chemoradiotherapy (CCRT)
89541339|NCT04026412|Experimental|Arm C: CCRT + durvalumab|Concurrent chemoradiotherapy (CCRT)
89024595|NCT02894008|Experimental|ChAd63-KH|Single intramuscular dose of ChAd63-KH, 1x10(10)vp or, following safety review, 7.5 x 10(10)vp in adolescents
89541340|NCT04019522|Experimental|Hypoxia|During each session, study participants will receive a single sequence of AIH, consisting of 15 x 60-seconds periods of hypoxia alternating with 90-seconds of normoxia (21% O2), for a total of 30 minutes, whilst in a seated upright position. AIH will be applied by directing gas flow to a reservoir bag connected via plastic tubing to a non re-breathing facemask/respiratory valve system while the participants are in a seated position. Defined gas mixtures will be delivered by manual adjustment of one-way valves attached to a hypoxia generator.
89541341|NCT04015804|Other|Clinical database|
89541342|NCT03980561|Experimental|Varenicline|2 mg daily
89024596|NCT02893735|Active Comparator|Charisma-Diamond|Charisma Diamond was randomly applied for diastema closure.
89207255|NCT00852462|No Intervention|Usual Care|Symptom assessment and management follows customary procedures in each study site.
89207256|NCT02850939|Experimental|Mobile phone app + patient navigation|Patients assigned to the intervention group (60) will: 1) use the personalized mobile phone app in their preferred language for a duration of 6 months; and 2) receive assistance from a patient navigator. They will also continue to receive the usual EHT care provided at the MCC's breast clinic.
89541343|NCT03980561|Placebo Comparator|Placebo|2 mg daily
89541344|NCT03972306|Experimental|Group A: Cohorts A1-A4|"Participants (participants pretreated with ocrelizumab) will receive a single injection of subcutaneous (SC) ocrelizumab co-mixed with rHuPH20 in the abdomen. For every new dose level, recruitment will be staggered by enrolling 1 participant in each cohort followed by a 48-hour waiting period to review safety and tolerability data by the Safety Monitoring Committee (SMC) prior to enrolling subsequent participants in the same cohort. Currently, the planned dose escalation steps for patients who enroll in Group A are as follows:~Cohort A1: 40 mg of SC ocrelizumab~Cohort A2: 200 mg of SC ocrelizumab~Cohort A3: 600 mg of SC ocrelizumab~Cohort A4: 1200 mg of SC ocrelizumab"
89541345|NCT03972306|Experimental|Group A: Cohort A5|In the non-randomized subphase, participants will receive a single SC injection of ocrelizumab co-mixed with rHuPH20 in the abdomen.
89541346|NCT03972306|Experimental|Group A: Cohort AA|Participants will receive a single 600-mg dose ocrelizumab by intravenous (IV) infusion
89541347|NCT03972306|Experimental|Group B: Cohorts B1-B4|"Ocrelizumab treatment- naive participants will receive a minimum of 3 patients in Cohort B will receive a single SC injection of ocrelizumab co-mixed with rHuPH20 in the abdomen.~Cohort B1: 40 mg of SC ocrelizumab~Cohort B2: 200 mg of SC ocrelizumab~Cohort B3: 600 mg of SC ocrelizumab~Cohort B4: 1200 mg of SC ocrelizumab"
89541348|NCT03970967|Experimental|DaRT Seeds|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds
89541349|NCT03966807||Digital-based support|Digital support will consist of referral for the participant to visit https://smokefree.gov, a website which offers a menu of internet- and text-based support options.
89541350|NCT03966807||traditional-based support +nicotine replacement therapy(NRT)|Traditional support will consist of participant referral to the Indiana Tobacco Quitline (1-800-QUIT-NOW) which is a telephone hotline that connects participants to Indiana smoking cessation resources.
88960341|NCT05272267|Active Comparator|AI-assisted|AI-assisted models providing diagnosis and prognostic information
88960342|NCT05272267|Placebo Comparator|Usual care|usual care without AI-assisted models providing diagnosis and prognostic information
88960344|NCT05266924|Experimental|Test group|Foligraf 900 IU (66.0 μg) / 1.5mL Solution for Injection in Prefilled Pen Follicle Stimulating Hormone (Human Recombinant) manufactured by Bharat Serums and Vaccines Ltd
88960345|NCT05266924|Active Comparator|Reference group|Gonal-f Recombinant Human Follicle Stimulating Hormone
88960346|NCT05266196|Experimental|Single agent|Single agent seclidemstat, as assigned per parent protocol
88960347|NCT05266196|Experimental|TC Combination|Combination of seclidemstat with topotecan and cyclophosphamide, as assigned per parent protocol
88960348|NCT05244044|Active Comparator|Pulmonary rehabilitation group|The intervention group receives a 12 weeks pulmonary rehabilitation program supervised by a primary care physiotherapist consisting of maximum 36 sessions (3 sessions per week).
88960349|NCT05244044|No Intervention|Control group without rehabilitation|The control group will receive usual care that doesn't include pulmonary rehabilitation or a supervised physical activity program.
88960350|NCT05243472|No Intervention|Control group|Participants in the control group will not receive any intervention during the study period.
88960351|NCT05243472|Experimental|Protein nutritional supplement group|Participants in the intervention group will receive protein-enriched soups (24-30g of protein) per day for 12 weeks. Protein may come from either soy, bean or milk products.
88960352|NCT05241418||Patients with congenital heart disease undergoing a cardiac MRI with Gadolinium|Patients with congenital heart disease who are undergoing a clinically-ordered cardiac MRI and as part of that MRI the contrast agent, Gadolinium, will be administered.
88960353|NCT05235399||Preterm infants who are born before 32 weeks of gestation.|The study aims to recruit preterm infants who are born before 32 weeks of gestation.
89207257|NCT02850939|No Intervention|Usual care|Patients assigned to the control (usual care) group (60) will receive the usual EHT care and materials offered at the MCC's breast clinic.
89541351|NCT03953144|Experimental|Synapse 3D Lung Modelling + IC-GREEN Segmentectomy|Patients within this arm will undergo a high-resolution CT scan of the chest, which is required by Synapse 3D to create accurate 3D virtual model reconstructions. At the start of the operation, the 3D virtual model of the segmental pulmonary anatomy will be displayed on the da Vinci Robotic platform for operative planning. The model will be used as a guide to determine which vessels are involved in the segment and need to be removed. The surgeon will ligate the pulmonary vein and pulmonary artery of the broncho-pulmonary segment with the lung cancer nodule, isolating it from any blood supply, and mark the proposed segmental planes based on the 3D model. ICG will be prepared as a sterile solution (2.5 mg/10mL) for injection. After vascular ligation, an 8 mL bolus of ICG solution will be injected into the peripheral vein catheter, followed by a 10 mL saline solution bolus
89541352|NCT03936309|Experimental|Scar Deactivation Surface Release|Alternating placement of Spring Ten (0.30x40 mm) acupuncture needles to surround scar left in place for a treatment duration of 20 minutes. Needles will be placed at intervals of 1cm to 1.5 cm and will surround the scar with a maximum of 20 needles per treatment.
89541353|NCT03936309|Experimental|Scar Infiltration with 0.25-1% Lidocaine|Will consist of calculation of 3 mg/kg dose of 0.5-1% Lidocaine and a dermal followed by subcutaneous injection using 1.5 inch 25 G needle and syringe appropriate for volume based on calculated dose.
89541354|NCT03936309|Experimental|Physical Therapy|Will be a referral to physical therapy specifying McKenzie protocol treatment for the presenting complaint. The McKenzie protocol is a form of standard of care physical therapy in which the physical therapist tries to find a cause and effect relationship between the positions the patient usually assumes while sitting, standing, or moving, and the location of pain because of those positions or activities. The therapeutic approach requires a patient to move through a series of activities and test movement to gauge the patient's pain response. The approach then uses that information to develop an exercise program designed to centralize or alleviate the pain.
89513671|NCT02284685|Experimental|A (opt-out, loss, social norming)|Students in this intervention arm must opt-out of receiving linkage to eating disorder resources on their campus; messages include social norming (statistics comparing their rates of eating disorder symptoms to national averages on widely-used and clinically validated screening tools); and messages frame the negative consequences (losses) of not seeking-help for current disordered eating symptoms. The intervention ('A Novel Intervention Promoting Eating Disorder Treatment among College Students') is this version of the email messages (opt-out, loss, social norming).
89207258|NCT00848640|Experimental|Sorafenib|
89513672|NCT02284685|Experimental|B (opt-out, gain, social norming)|Students in this intervention arm must opt-out of receiving linkage to eating disorder resources on their campus; messages include social norming (statistics comparing their rates of eating disorder symptoms to national averages on widely-used and clinically validated screening tools); and messages frame the benefits of seeking-help for current disordered eating symptoms. The intervention ('A Novel Intervention Promoting Eating Disorder Treatment among College Students') is this version of the email messages (opt-out, gain, social norming).
89513673|NCT02284685|Experimental|C (opt-out, loss, no social norming)|Students in this intervention arm must opt-out of receiving linkage to eating disorder resources on their campus; messages do not include social norming (statistics comparing their rates of eating disorder symptoms to national averages on widely-used and clinically validated screening tools); and messages frame the negative consequences (losses) of not seeking-help for current disordered eating symptoms. The intervention ('A Novel Intervention Promoting Eating Disorder Treatment among College Students') is this version of the email messages (opt-out, loss, no social norming).
89513674|NCT02284685|Experimental|D (opt-out, gain, no social norming)|Students in this intervention arm must opt-out of receiving linkage to eating disorder resources on their campus; messages do not include social norming (statistics comparing their rates of eating disorder symptoms to national averages on widely-used and clinically validated screening tools); and messages frame the benefits of seeking-help for current disordered eating symptoms. The intervention ('A Novel Intervention Promoting Eating Disorder Treatment among College Students') is this version of the email messages (opt-out, gain, no social norming).
89513675|NCT02284685|Experimental|E (opt-in, loss, social norming)|Students in this intervention arm must opt-in to receiving linkage to eating disorder resources on their campus; messages include social norming (statistics comparing their rates of eating disorder symptoms to national averages on widely-used and clinically validated screening tools); and messages frame the negative consequences (losses) of not seeking-help for current disordered eating symptoms. The intervention ('A Novel Intervention Promoting Eating Disorder Treatment among College Students') is this version of the email messages (opt-in, loss, social norming).
89513676|NCT02284685|Experimental|F (opt-in, gain, social norming)|Students in this intervention arm must opt-in to receiving linkage to eating disorder resources on their campus; messages include social norming (statistics comparing their rates of eating disorder symptoms to national averages on widely-used and clinically validated screening tools); and messages frame the benefits of seeking-help for current disordered eating symptoms. The intervention ('A Novel Intervention Promoting Eating Disorder Treatment among College Students') is this version of the email messages (opt-in, gain, social norming).
89513677|NCT02284685|Experimental|G (opt-in, loss, no social norming)|Students in this intervention arm must opt-in to receiving linkage to eating disorder resources on their campus; messages do not include social norming (statistics comparing their rates of eating disorder symptoms to national averages on widely-used and clinically validated screening tools); and messages frame the negative consequences (losses) of not seeking-help for current disordered eating symptoms. The intervention ('A Novel Intervention Promoting Eating Disorder Treatment among College Students') is this version of the email messages (opt-in, loss, no social norming).
89024597|NCT02893735|Active Comparator|Filtek-Z550|Filtek-Z550 was randomly applied for diastema closure.
89207259|NCT00968565|Experimental|Citrate|Sodium citrate will be infused as the blood enters the ECMO circuit and calcium chloride will be infused as the blood leaves the ECMO circuit and enters the patient
89513678|NCT02284685|Experimental|H (opt-in, gain, no social norming)|Students in this intervention arm must opt-in to receiving linkage to eating disorder resources on their campus; messages do not include social norming (statistics comparing their rates of eating disorder symptoms to national averages on widely-used and clinically validated screening tools); and messages frame the benefits of seeking-help for current disordered eating symptoms. The intervention ('A Novel Intervention Promoting Eating Disorder Treatment among College Students') is this version of the email messages (opt-in, gain, no social norming).
89513679|NCT04470557||Patients with COVID-19|The patients will be subjected to to laboratory analyses, a number of hematological, immunological and biochemical parameters like total leucocytic count and differential count of CBC, ESR, D- dimer levels in plasma, CRP, serum urea and creatinine levels, serum levels of AST, ALT liver enzymes, serum ferritin levels Also, CT scan of chest, clinical assessment and the severity and course of the disease.
89513680|NCT00372437|Experimental|1|
89513681|NCT00369473|Experimental|1|350
89513682|NCT00369473|Experimental|2|350
89513683|NCT00425321|Experimental|RWJ-445380 100 mg|
89024598|NCT03271086|Experimental|Relaxation breathing training|Dyads of a parent and their child in this group will receive training on how to use breathing to relax with the StressEraser in the pediatric clinic and will then practice the breathing for about 4 weeks They will also complete a baseline questionnaire and two questionnaires one month after the training.
89024599|NCT03271086|Experimental|Technology-enhanced relaxation breathing|Dyads of a parent and their child in this group will receive technology-enhanced training on how to use breathing to relax with the StressEraser and the app Breathe2Relax in the pediatric clinic and will then practice the breathing for about 4 weeks and weekly receive weekly reminder text messages to practice their relaxation breathing. They will also complete a baseline questionnaire and two questionnaires one month after the training.
89207260|NCT04010331|Experimental|Nokyong Mixture Extract(CME-PI) group|2 times a day, 2 capsule for 1 time, after breakfast/dinner meal(1.4g/day, Nokyong Mixture Extract(CME-PI) 1 g/day)
89207261|NCT04010331|Placebo Comparator|Placebo group|2 times a day, 2 capsule for 1 time, after breakfast/dinner meal(1.4g/day, Nokyong Mixture Extract(CME-PI) 0 g/day)
89207262|NCT00965133|No Intervention|Normal daily activity|
89207263|NCT00848796|Other|Heparin|Compare two market brands of Heparin
89207264|NCT00968643|Active Comparator|Arm I (control)|Patients undergo radiotherapy to the area of spinal cord compression once daily for 5 days (total of 20 Gy).
89513684|NCT00425321|Experimental|RWJ-445380 200 mg|
89513685|NCT00425321|Experimental|RWJ-445380 300 mg|
89513686|NCT00425321|Placebo Comparator|Placebo|
89513687|NCT00422981|Active Comparator|AL-108 5 mg|5 mg QD
89513688|NCT00422981|Active Comparator|AL-108 15 mg|15 mg BID
89513689|NCT00422981|Placebo Comparator|Placebo|Placebo
89513690|NCT00360035|Experimental|GX15-070MS|Obatoclax mesylate 60mg
89513691|NCT02287337|Experimental|Manipulation|Patients will receive cervical manipulation on 2 visits and then a further 3 visits of therapeutic exercises
89513692|NCT02287337|Other|Exercise|Patients will receive 5 visits of therapeutic exercises
89513693|NCT00417287|Active Comparator|High dose|128 mg/m2
89513694|NCT00417287|Active Comparator|Low dose|54 mg/m2
89513695|NCT00356681|Placebo Comparator|Arm A Placebo|Blinded AMG 706 placebo plus paclitaxel
89513696|NCT00356681|Experimental|Arm B Experimental|Blinded AMG 706 plus paclitaxel
88960354|NCT05235126|Other|Treatment arm|All subjects receive treatment at V1 and option to receive touch-up at V2.
88960355|NCT05232760||SUPERA peripheral stent system|
89541355|NCT03930420|Active Comparator|Standard|Local health department staff in the standard arm will receive Connect to Wellness intervention materials, multiple real-time training sessions delivered via webinar, access to a web-based platform that includes all intervention and training materials and has features allowing them to communicate with each other and with research staff, and a monthly group technical assistance call.
89541356|NCT03930420|Experimental|Enhanced|Local health department staff in the enhanced arm will receive all the Connect to Wellness intervention materials, training, and support as described for the standard arm. In addition, the participants in the enhanced arm can telephone research staff at will to receive additional technical assistance. Research staff will also contact participants monthly, if they do not request assistance proactively.
89541357|NCT03929029|Experimental|Nivolumab+Ipilimumab+NeoVax plus Montanide|"Run in period will begin within 2 weeks of metastatic tissue biopsy, once the following criteria~Patients will receive Nivolumab at a flat dose I.V. infusion every 4 weeks (28 days)~Patients will receive Ipilimumab injection on weeks 12, 15, 18, and 21~Patients will receive NeoVax plus Montanide injection on weeks 12, 15, 18, and 21"
89541358|NCT03926299|Experimental|Laser|dual Fotona laser treatment (Nd:YAG and Er:YAG)
89541359|NCT03926299|Active Comparator|Topical steroid|clobetasol propionate 0.05% cream
89541360|NCT03917914|Active Comparator|Bisoprolol|1.25, 2.5 or 5mg of bisoprolol daily
89541361|NCT03917914|Placebo Comparator|Placebo|1.25, 2.5 or 5mg of matched placebo daily
89541362|NCT03912753|Experimental|Comunică|Comunică is delivered over eight 60-min live chat sessions, delivered by trained psychologists, on our mHealth study platform compatible with any mobile device (laptops, smartphones).
89541363|NCT03912753|Active Comparator|Education Attention Control (EAC)|"The EAC condition consists of eight self-administered modularized topics, content-matched with the Comunică sessions, which we have generated based on our HIV-prevention education with GBM in the US and Romania.Topics include 1) GBM identity, 2) HIV 101, 3) HIV/STI testing, 4) alcohol and the body, 5) the role of alcohol in HIV risk, 6) HIV-status disclosure and sexual health communication, 7) finding social supports, and 8) summary. EAC participants will receive five quiz questions after each module, with correct answers in a following screen."
89541364|NCT03912363|Active Comparator|Rotating fluids|Rotating fluids protocol will be initiated at the time of admission to Labor and Delivery.
89541365|NCT03912363|Active Comparator|Insulin infusion|Insulin infusion protocol will be initiated at the time of admission to Labor and Delivery.
89541366|NCT03902366||AUD+/HCV+|"With current Alcohol Use Disorder and with HCV~About to initiate DAA therapy for HCV"
89541367|NCT03902366||AUD-/HCV+|"Without current Alcohol Use Disorder and with HCV~About to initiate DAA therapy for HCV"
89541368|NCT03902366||AUD+/HCV-|-With Alcohol Use Disorder and without HCV
89541369|NCT03902366||AUD-/HCV-|-Without Alcohol Use Disorder and without HCV
89541370|NCT03892980|Experimental|Nipple Sparing Mastectomy|
88960356|NCT05229406|Experimental|5-minute app usage|Participants will be asked to use the HMP app for 5-minutes per day.
88960357|NCT05229406|Experimental|15-minute app usage|Participants will be asked to use the HMP app for 15-minutes per day.
88960358|NCT05223803|Active Comparator|Best systemic therapy (BST) + primary prostate radiation (XRT)|
88960359|NCT05223803|Active Comparator|BST + XRT + SABR metastasis-directed therapy (MDT)|
88960360|NCT05223179|Experimental|CODA-VAX H1N1|Live Attenuated Vaccine administered by Intramuscular Injection
88960361|NCT05223179|Active Comparator|Flucelvax Quad|Licensed Injectable Seasonal Influenza Vaccine
88960362|NCT05223179|Placebo Comparator|Saline|Normal Sterile Saline for Intramuscular Injection
88960363|NCT05216354|Experimental|Cohort 1 (healthy subjects)|8 subject with normal renal function will be administered 5mg (1 x 5 mg capsule) fruquintinib
88960364|NCT05216354|Experimental|Cohort 2 (severe renal impairment)|8 subjects with severe renal impairment will be administered 2 mg (2 x 1 mg capsules) fruquintinib
88960365|NCT05216354|Experimental|Cohort 3 (moderate renal impairment)|8 subjects with moderate renal impairment will be administered 5 mg (a x 5 mg capsule) fruquintinib
89207265|NCT00968643|Experimental|Arm II|Patients undergo a single fraction of radiotherapy to the area of spinal cord compression (total of 10 Gy).
88960366|NCT05215054|Experimental|Gana V versus Sculptra|Participants will receive both Gana V and Sculptra: one in each nasolabial folds
88960367|NCT05194592|Active Comparator|Dapagliflozin group|Dapagliflozin 10mg for 6 months.
88960368|NCT05194592|Placebo Comparator|Gemigliptin group|Gemigliptin 50mg for 6 months.
88960369|NCT05190562|Experimental|Zinc Sulphate|Zinc Sulphate 25 Mg once daily for one month
88960370|NCT05189366|Experimental|Experimental arm : Speech therapy + Sophrology|"In the experimental arm, patients will receive 6 sessions of sophrology. The sessions are individual and last approximately 50 minutes.~In addition to the sophrology sessions, patients will benefit from two speech therapy sessions per week for 6 months, lasting from 30 minutes to 1 hour depending on the patient's general condition."
88960371|NCT05189366|Active Comparator|Control arm : Speech therapy|Patients will benefit from two speech therapy sessions per week for 6 months, lasting from 30 minutes to 1 hour depending on the patient's general condition.
88960372|NCT05188729|Experimental|Part 1 LTX-315 Safety Run-in|Part 1: Starting total daily dose of LTX-315 will be 2 mg for the first subject. Subjects will receive ascending once daily doses increasing in 1 mg increments for up to 3 days in a 7-day treatment week until the first lesion is necrosed or a DLT occurs
89207266|NCT02545764|Experimental|Intervention|Strength and neuromuscular exercise programme
89207267|NCT02545764|No Intervention|Control|Control group will receive opportunity for the training programme after data capturing is finished
89541371|NCT03886168|Experimental|Immediate IGCIP|Immediate signal processing intervention of a biomedical device
89541372|NCT03886168|Active Comparator|Deferred IGCIP|Delayed signal processing intervention of a biomedical device
89541373|NCT03873402|Experimental|Nivolumab + ipilimumab|
89541374|NCT03873402|Experimental|Nivolumab + ipilimumab placebo|
89024600|NCT00463749|Active Comparator|1|High-dose N-Acetylcystein during percutaneous coronary intervention and for 2 days post intervention 2 x/day
89024601|NCT00463749|Placebo Comparator|2|Placebo (NaCl)
89541375|NCT03844802|Experimental|Local dry needling and exercise|The intervention protocol will combine a home-based neck and shoulder exercise program and the use of deep dry needling in the locus of active or latent myofascial trigger points of different neck-shoulder muscles. Patients will receive 1 dry needling session a week during 3 consecutive weeks (3 sessions in total). They will also undergo the neck exercise program at home during these three weeks, and for the next three months.
89541376|NCT03844802|Active Comparator|Distal dry needling and exercise|The intervention protocol will combine a home-based neck and shoulder exercise program and the use of deep dry needling in distant area from the location of active or latent myofascial trigger points of different neck-shoulder muscles. Therefore, dry needling will be applied in the same muscle but at a remote site from the locus of the myofascial trigger point, and, therefore, without evoking local twitch responses. Patients will receive 1 dry needling session a week during 3 weeks (3 sessions in total). They will also undergo the neck exercise program at home during these three weeks, and for the next three months.
89541377|NCT03844802|Active Comparator|Sham/placebo dry needling and exercise|"The intervention protocol will combine a home-based neck and shoulder exercise program and the use of deep dry needling in the locus of active or latent myofascial trigger points of different neck-shoulder muscles. Patients will receive 1 placebo dry needling session a week during 3 weeks (3 sessions in total). Therefore, participants in this group will receive simulated dry needling (with sham placebo needles, that will not actually penetrate the skin) in those neck muscles with active or latent myofascial trigger points. As formerly stated, the placebo needles evoke mechanical stimulation without piercing the skin; hence, patients experience a pressure sensation similar to that of a real needle.They will also undergo the neck exercise program at home during these three weeks, and for the next three months."
89541378|NCT03844802|Active Comparator|Neck Exercise|The intervention protocol will consist only a home-based neck and shoulder exercise program. Participants in this group will be also assessed for the presence of active or latent myofascial trigger points in the neck-shoulder muscles. As in the other groups, they will be advised to carry out the exercise protocol for three weeks and the following three months.
89541379|NCT03844620|Experimental|Arm I (ctDNA testing, regorafenib, TAS-102)|Patients will receive either regorafenib by mouth on days 1-21 every 28 day cycle or TAS-102 by mouth twice daily on days 1-5 and 8-12 every 28 day cycle. Patients in this arm will get ctDNA testing and will continue treatment beyond 1st cycle depending on ctDNA results. Beyond that patients will continue treatment in the absence of disease progression or unacceptable toxicity.
89541380|NCT03844620|Active Comparator|Arm II (SOC)|Patients will receive either regorafenib by mouth on days 1-21 every 28 day cycle or TAS-102 by mouth twice daily on days 1-5 and 8-12 every 28 day cycle as per standard of care. Patients in this arm will continue treatment in the absence of disease progression or unacceptable toxicity.
89541381|NCT03841357|Experimental|Abatacept and Usual Care (Part I)|Weekly abatacept injection at standard dosing for weight plus usual care with steroid joint injection and non-steroidal anti-inflammatory drugs per the discretion of the treating provider
89541382|NCT03841357|Active Comparator|Active Comparator: Usual Care (Part I)|Usual care includes steroid joint injections and treatment with non-steroidal anti-inflammatory drugs at the discretion of the treating provider
89541383|NCT03841357|Experimental|Abatacept and Usual Care (Part II)|Weekly abatacept injection at standard dosing for weight plus usual care with steroid joint injection and non-steroidal anti-inflammatory drugs per the discretion of the treating provider
89541384|NCT03838159|Experimental|Experimental: Neo-Adjuvant Immunotherapy|"Neoadjuvant treatment (200 mg/m3 Paclitaxel+ AUC5 Carboplatin+ 360 mg Nivolumab) will start within 1-3 days from randomisation. 3 cycles will be administered at 21-day (+/- 3 days) intervals (QW3) prior to surgery. Before surgery a tumor assessment will be done. Patients must leave the study if there is evidence of progression. Patients with stable disease or partial response may be considered for surgery.~Surgery: Surgery must be done within the 3rd-4th week (+7 days) from day 21 cycle 3 of neoadjuvant treatment (day 42-49 after day 1 of cycle 3) .~Adjuvant treatment:Nivolumab: 480 mg Q4W (+/- 3 days) for 6 months (6 cycles). Patients that are R0 confirmed by surgical pathology evaluation will receive the first adjuvant administration within the 3rd to 8th week (+ 7 days) from surgery and for 6 months."
89541385|NCT03838159|Active Comparator|Control: Neo-Adjuvant Chemotherapy|"Neoadjuvant treatment (200mg/m3 Paclitaxel+ AUC5 Carboplatin). It will start within 1-3 days from randomisation. 3 cycles will be administered at 21-day (+/- 3 days) intervals (QW3) prior to surgery. Before surgery a tumor assessment will be done. Patients must leave the study if there is evidence of progression. Patients with stable disease or partial response may be considered for surgery.~Surgery: Surgery must be done within the 3rd-4th week (+7 days) from day 21 cycle 3 of neoadjuvant treatment (day 42-49 after day 1 of cycle 3)"
89541386|NCT03835286|Experimental|Vitamin C|Vitamin C experimental group
89541387|NCT03835286|Placebo Comparator|Control|Placebos Controlled group
89541388|NCT03834363|Active Comparator|Morphine capsules and Placebo patch|Morphine retard 10 mg twice daily Placebo patch, change every three days.
89541389|NCT03834363|Experimental|Placebo capsules and Fentanyl patch|Placebo capsules twice daily Fentanyl patch 12 mcg/hr, change every three days
89541390|NCT03834363|Placebo Comparator|Placebo capsules and Placebo patch|Placebo capsules twice daily Placebo patch, change every three days
89024602|NCT00463827|Active Comparator|2|Atorvastatin 40
89024603|NCT00463827|Placebo Comparator|placebo|matched placebo
89024604|NCT00433316|Experimental|study|Receiving 10ml of 1% ropivacaine
89024605|NCT00433316|Placebo Comparator|Control|Receiving 10ml of saline
89024606|NCT00472095|Experimental|diabetes fotonovela|spanish language comic book describing diabetes care and consequences
89024607|NCT00472095|Placebo Comparator|placebo fotonovela|
89024608|NCT00433394|Experimental|Stratum 1: No Consent for personal identification|Data to be collected for this stratum include histology, primary site, treating hospital, and institutional principal investigator. Data will be coded using the North American Association for Central Cancer Registries (N.A.A.C.C.R.) data standards for cancer registries.
89207268|NCT05251155||Standard vision chart.|Best corrected visual acuity measured by standard chart projector.
89024609|NCT00433394|Experimental|Stratum 2: Consent for personal identification - No Contact|Data will be collected for this study include:child's name, parent's name, address, telephone number, child's date of birth, race, ethnicity, histology, primary site, treating hospital, and institutional principal investigator. Data will be coded using the North American Association for Central Cancer Registries (N.A.A.C.C.R.) data standards for cancer registries. No contact for future to ask me to consider taking part in Research Network approved studies
89513697|NCT00356681|Active Comparator|Arm C Comparator|Open-label bevacizumab plus paclitaxel
89513698|NCT02284763|Experimental|Change of EtCO2|Changes of rSO2 after adjustment of EtCO2 between 27-45 mmHg
89513699|NCT00417209|Experimental|Larotaxel (XRP9881)|
89513700|NCT00417209|Active Comparator|5-Fluorouracil or capecitabine|Each Investigator must choose either IV 5-FU or oral capecitabine regimen before the first participant begins the study and has to consistently use the chosen regimen throughout the study for all participants treated at her/his site.
89513701|NCT02284841|Experimental|Hilotherm cooling face mask|Use of Hilotherm cooling face mask post-operatively following surgical wisdom tooth removal to evaluate the incidence of pain and swelling
89513702|NCT02284841|No Intervention|No Hilotherm|No intervention following surgical wisdom tooth removal (same patient), therefore the patient is their own control.
89513703|NCT03789773|Experimental|Diagnostic (holographic mm-wave imaging)|Patients undergo holographic mm-wave imaging in radiotherapy treatment position after initial CT simulation.
89513704|NCT04470401|Placebo Comparator|Placebo|Abobotulinumtoxina 400 IU in 2cc of saline solution
89513705|NCT04470401|Experimental|Abobotulinumtoxina - 400IU|placebo (2cc of saline solution)
89513706|NCT00355355|Experimental|Litx|Drug: Talaporfin Sodium (1 mg/kg iv), Device: Interstitial Light Emitting Diodes (200 J/cm) 3 treatments within 6 months
89513707|NCT00355355|Active Comparator|Standard Care|The standard of care could include any one of the following treatment options: Percutaneous Ethanol Injection (PEI), Transcatheter Arterial Chemoembolization (TACE), Radio Frequency Ablation (RFA), Cryotherapy, Systemic Chemotherapy, or other modalities that may be used at a particular institution.
89513708|NCT00407303|Experimental|1|30mg obatoclax, 1.0mg/m2 bortezomib
89513709|NCT00407303|Experimental|2|obatoclax 30 mg, bortezomib 1.3 mg/m2
89513710|NCT00407303|Experimental|3|Obatoclax 45 mg, Bortezomib 1.3 mg/m2
89513711|NCT00351767|Experimental|1|
89513712|NCT00351767|Experimental|2|
89513713|NCT00351767|Experimental|3|
89513714|NCT00351767|Placebo Comparator|4|
89513715|NCT02287571|Active Comparator|Skin traction|Prior to hip fracture surgery, affected limb was wrapped with a special elastic bandage and pulled from the sole of the foot with a weight of 5-10% of total body weight of the patient (min 2.3 kg, max 4.5 kg).
89513716|NCT02287571|Experimental|Position splint|Prior to hip fracture surgery, position splint was applied to the affected limb in order to keep the extremity in the proper positon without any weight lifting.
89513717|NCT03134105|Experimental|Monthly Feedback|Sites will receive monthly reports of their patients enrolled in the study with data for each of their patients participating in the study along with summary data for their practice and all patients participating in the study.
89513718|NCT03134105|Active Comparator|End-of-study Feedback|Sites will only receive the report of their patients at the end of the 6 month follow-up period.
89513719|NCT02287649|Other|patients with rituximab treatment|blood sample intake
89513720|NCT00344045|Active Comparator|A|
89513721|NCT00344045|Placebo Comparator|B|
89513722|NCT02256436|Active Comparator|Control|Participants receive paclitaxel 175 mg/m^2 intravenously (IV) or docetaxel 75 mg/m^2 IV or vinflunine 320 mg/m^2 IV, on Day 1 of each 3-week cycle (Q3W). Eligible participants who experience disease progression may be able to switch over to receive pembrolizumab 200 mg Q3W for up to 35 treatment administrations (up to approximately 2 years).
89513723|NCT02256436|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg IV on Day 1 Q3W. Eligible participants who stop pembrolizumab with Stable Disease (SD) or better but progress after discontinuation may be able to initiate a second course of pembrolizumab 200 mg for up to 17 cycles (up to approximately 1 additional year).
89513724|NCT00343109|Experimental|Arm I|Patients receive HER-2/neu intracellular domain peptide-based vaccine mixed with GM-CSF intradermally once monthly for 6 months in the absence of disease progression or unacceptable toxicity.
89513725|NCT02287727|Experimental|Treatment (regorafenib)|Patients receive regorafenib PO QD on days 1-21. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
89513726|NCT00405743|Experimental|Arm A|CP4055, 2 and 4 hour IV infusion
89513727|NCT00405743|Experimental|Arm B|CP-4055, Continuous IV infusion
89513728|NCT00336713|Experimental|Saredutant 100 mg|Saredutant 100 mg once daily in the morning for a maximum of 64 weeks
89513729|NCT00336713|Placebo Comparator|Placebo|Placebo for Saredutant once daily in the morning during the maintenance phase for a maximum of 52 weeks
89513730|NCT00403169|Experimental|Lenalidomide for Advanced RCC|25 mg/day Lenalidomide for 21 days per cycle.
89513731|NCT00332657|Experimental|Anecortave Acetate, 15 mg|One 0.5 mL injection of 30 mg/mL Anecortave Acetate Sterile Suspension into the posterior juxtascleral depot (PJD) at 6-month intervals for 42 months.
89513732|NCT00332657|Experimental|Anecortave Acetate, 30 mg|One 0.5 mL injection of 60 mg/mL Anecortave Acetate Sterile Suspension into the posterior juxtascleral depot (PJD) at 6-month intervals for 42 months.
89513733|NCT00332657|Sham Comparator|Anecortave Acetate Vehicle|One sham injection at 6-month intervals for 42 months. Syringe and vehicle were not inserted into the eye.
89513734|NCT03133949||Patients with idiopathic inflammatory aortitis|
89513735|NCT03133949||a group of witnesses|
89513736|NCT00330473|Experimental|1|Treatment options available on the market plus the option of taking Human Insulin Inhalation Powder.
89513737|NCT00330473|Active Comparator|2|Treatment Options available on the market.
89513738|NCT00327743|Experimental|larotaxel + Capecitabine|
89513739|NCT02284997|Experimental|Treatment|Participants will be instructed to use a warming MGDRx® EyeBag for minimum of 10 minutes, twice a day
89513740|NCT02284997|No Intervention|Control|No treatment
89513741|NCT00326183|Active Comparator|1|Arm 1: vaccine
88960373|NCT05188729|Experimental|Part 2 VP-315 Regimen Finding|"Part 2: VP-315 once-daily dosing; total daily dose of 8 mg in up to 5 cohorts~Cohort 1: VP-315 once-daily dosing of 8 mg with half the target dose of 8 mg only on W1D1; all remaining doses will be the full target dose~Cohort 2: VP-315 once-daily dosing of 8 mg on all treatment days for up to 3 consecutive daily doses/week.~Cohort 3: has been removed, advance from Cohort 2 to 4 and 5.~Cohorts 4 and 5, the total daily dose of VP-315 (8.0 mg) will be divided into a split dose; the first dose is not to exceed 2.4 mg (30% of 8 mg dose), and the remaining dose will not exceed 5.6 mg (70% of 8 mg dose) and administered 15 minutes apart (not to exceed 30 minutes).~Cohort 4: (Two times weekly dosing) VP-315 once-daily dosing of 8 mg, administered on 2 consecutive days in one week.~Cohort 5: (Three times weekly dosing) VP-315 once-daily dosing of 8 mg, administered on 3 consecutive days in one week.~PK data will be collected in the Cohorts 4 and 5 expansion groups."
88960374|NCT05167279|Placebo Comparator|JS026/placebo 30 mg|4 patients will be enrolled in this arm.
88960375|NCT05167279|Placebo Comparator|JS026/placebo 100 mg|4 patients will be enrolled in this arm.
88960376|NCT05167279|Placebo Comparator|JS026/placebo 300 mg|8 patients will be enrolled in this arm.
89207269|NCT05251155||Mobile based vision chart.|Best corrected visual acuity measured by mobile based chart with screen mirroring over 24 inch monitor.
89207270|NCT00848874|Experimental|PVGS User|
89207271|NCT00968721||IBD patients|
89207272|NCT00965289|Experimental|HDT combined with rituximab before ASCT|The study treatment consisted on 2 courses of high-dose R-CHOP-like regimen, followed by a course of high-dose methotrexate with cytarabin. For patients who achieved at least a PR, ASCT started with a BEAM regimen.
89207273|NCT04042506|Experimental|Extracranial SBRT and Nivolumab|"Stereotactic body radiation therapy (SBRT) will be given to a single extracranial metastatic site in combination with nivolumab.~Patients will receive nivolumab 480mg intravenously (IV) every 4 weeks (1 cycle = 8 weeks), as well as SBRT dose of 8-10 Gy x 3 fractions (at maximum 3 doses per week) delivered to 1 extracranial site between days 1-14 of Cycle 1.~Nivolumab will be continued until confirmed progression, unacceptable toxicity, or total of 6 Cycles (whichever occurs first)."
89207274|NCT00251641|Experimental|Infliximab|
89207275|NCT00251641|Active Comparator|Methotrexate|
89207276|NCT03847662||Community Based Production and Access of Complimentary Foods|"Nine communes were randomly selected with the cluster inclusion criteria as having high levels of; agricultural production, childhood under-nutrition and food security. This was carried out in the three rural mountainous provinces of Lao Cai, Lai Chau, and Ha Giang. In each of these provinces, one district and three subsequent communes were selected, for a total of 9 communes. The districts of Bat Xat, Tam Duong, and Vi Xuyen were selected in Lao Cai, Lai Chau and Ha Giang province respectively. This second stage district sampling selected sites with similar characteristic of population density, area, number of women of reproductive age(15-35y), percentage of children(<2y), income primarily from agricultural production, poverty and climate data.~Changes were observed on food security and nutritional status with exposure to community based self reported purchasing local agricultural products and access to locally produced fortified complimentary foods."
89207277|NCT00842322|Experimental|High fluid intake|fluid intake of 4 litres per day
89207278|NCT00842322|Experimental|normal fluid intake|Fluid intake of 2 litres per day
89207279|NCT00250705|Other|Adolescent Conduct Disorder Males|All subjects were male and had a diagnosis of conduct disorder. All subjects were offered treatment with aripiprazole.
89207280|NCT00849030|Active Comparator|1|Arimidex 1mg + Nolvadex placebo
89207281|NCT00849030|Active Comparator|2|Arimidex placebo + Nolvadex 20mg
89207282|NCT00849030|Active Comparator|3|Arimidex 1mg + Nolvadex 20mg
89207283|NCT00852618||A|Participants undergoing treatment with raltegravir (RAL) in the main study
89207284|NCT00852618||B|Participants undergoing treatment with emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) in the main study
89207285|NCT00842478|Experimental|Raspall|
89207286|NCT00842478|No Intervention|Control|
89207287|NCT02545296|Other|In-vitro Diagnostics|All infants are recruited into the same arm.
89207288|NCT02545374|Experimental|Telemedicine|"In the telemedicine arm, all patients will be supported by Telemedicine protocol according to the development of telemedicine in the region.~The use of teleconsultation allows the couple expert doctor / nurse expert to perform a complex of wound assessment consultation and / or chronic. The use of telemedicine allows for acts of telecare, when the nurse applicant sought a remote support of an expert nurse (under the responsibility of a doctor) for the realization of an act. The use of tele-expertise enables physicians to remotely bring special expertise to improve patient care."
89207289|NCT02545374|Active Comparator|Control|"In the control arm, patient care depend on his home, as is currently the case:~If it is in the action zone of Cicat-LR network, then it will be supported by an expert nurse of the network that are physically visit the patient's home-lon is the protocols established by the network.~If not, then it will be supported by the customs of the attending physician and nursing teams who follow him."
89207290|NCT00266695|Experimental|Ruboxistaurin|
89207291|NCT00852774||1|Endometrial Cancer Patients Hysterectomy Robotic Surgery
89207292|NCT00852774||2|Endometrial Cancer Patient Hysterectomy Laparotomy Surgery
89207293|NCT00849264|Experimental|A|PLC patients with PVTT underwent hepatectomy and portal thrombectomy followed by portal vein chemotherapy with endostar
89207294|NCT00849264|Active Comparator|B|PLC patients with PVTT underwent hepatectomy and portal thrombectomy followed by portal vein chemotherapy with CBP and 5-FU
89207295|NCT00849264|Experimental|C|PLC patients with PVTT underwent hepatectomy and portal thrombectomy followed by portal vein chemotherapy with endostar, CBP and 5-FU
89207296|NCT00849342||A|
89207297|NCT00842556|Active Comparator|Dapagliflozin|
89207298|NCT00842556|Active Comparator|Glimepiride|
89207299|NCT00842556|Active Comparator|Dapagliflozin + Glimepiride|
89207300|NCT00842556|Active Comparator|Sitagliptin|
89207301|NCT00842556|Active Comparator|Dapagliflozin + Sitagliptin|
89207302|NCT00842634|Experimental|Cohort 1|Patients who have failed two more HAART regimens
89207303|NCT00842634|Experimental|Cohort 2|Patients doing well on a stable antiretroviral medication
89207304|NCT00842634|Experimental|Cohort 3|Patients who have an undetectable viral load on HAART who have exhibited suboptimal CD4+ T cell gains during long term antiretroviral therapy. This group will not participate in the structured treatment interruption.
89207305|NCT00620022|Experimental|Indacaterol 300 μg followed by placebo|Patients first received indacaterol 300 μg delivered via a single dose dry powder inhaler (SDDPI) once daily (od) in the morning for 3 weeks. After a 3-week washout period, patients received placebo delivered od via a SDDPI in the morning for 3 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
89207306|NCT00620022|Experimental|Placebo followed by indacaterol 300 μg|Patients first received placebo delivered via a single dose dry powder inhaler (SDDPI) once daily (od) in the morning for 3 weeks. After a 3-week washout period, patients received indacaterol 300 μg delivered od via a SDDPI in the morning for 3 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
89207307|NCT00852852|Experimental|Intervention|Patient participants in the intervention arm can access educational information about self-care strategies, track and share reports of their symptoms and quality of life issues over time, and receive coaching on how to discuss these issues with their care team.
89207308|NCT00852852|No Intervention|Control|Participants in the control arm access the ESRA-C from home or clinic to self-assess only.
89207309|NCT00849654|Experimental|PCI-32765|
89207310|NCT00849732|Experimental|1|V520 (1x10^9 vp/d)
89207311|NCT00849732|Experimental|2|V520 (1x10^10 vp/d)
89207312|NCT00849732|Placebo Comparator|3|Placebo to V520
89207313|NCT00849966|Experimental|A|Celebrex suspension
89207314|NCT00849966|Placebo Comparator|B|Placebo
89207315|NCT00853086||A|
89513742|NCT00326183|Active Comparator|2|Arm 2: Active comparator
89513743|NCT02285075|Other|temocillin PK/PD in haemodialysis|Pharmacokinetic study measuring total and free temocillin concentrations in patients treated with haemodialysis receiving 1 gram temocillin for a 1 day interval, 2 gram temocillin for a two day interval and 3 gram temocillin for a 3 day interval to the next dialysis session
89207316|NCT00853164|Experimental|aerobic exercise|Subjects who are randomly assigned to this arm will be assigned a walking program to participate in 3 times a week for eight weeks
89207317|NCT00853164|Experimental|resistence training|Subjects who are randomly assigned to this arm will be assigned a weight training program to participate in 3 times a week for eight weeks
89207318|NCT00853164|Active Comparator|Usual Care|Subjects who are randomly assigned to this arm will not participate in any exercise program and will continue with usual care treatment
89207319|NCT02545530|Active Comparator|transdermal clonidine+|apply one transdermal clonidine(2.5mg) each week for 4 weeks besides regular antihypertensive agents, reduce oral antihypertensive agents' dosage or type if blood pressure decreased.
89207320|NCT02545530|No Intervention|transdermal clonidine-|regular antihypertensive treatment
89207321|NCT00853320|Experimental|A|Oxycodone hydrochloride tablet 15 mg
89207322|NCT00853320|Active Comparator|B|Roxicodone™ tablet 15 mg
89207323|NCT00853398|Experimental|Minimal Invasive Surgery,|
89207324|NCT00853398|Active Comparator|Standard Surgical Technique|
89207325|NCT00547521|Experimental|Subcutaneous (SC) Abatacept + Methotrexate (MTX) Cohort|In the ST period, participants were administered a dose of 125 mg abatacept SC, once weekly, for 4 months. Participants were also administered a stable MTX dose of greater than or equal to 10 mg once weekly for at least 4 weeks prior to first injection of SC abatacept.
89207326|NCT00547521|Experimental|SC Abatacept Monotherapy Cohort|In the ST period, participants were administered a dose of 125 mg abatacept SC, once weekly, for 4 months. Participants did not receive MTX at screening i.e., MTX naive, or discontinued MTX due to lack of efficacy or tolerability at least 4 weeks prior to first injection of SC abatacept.
89207327|NCT02546310|Experimental|HTL0009936 high dose|high dose infusion
89207328|NCT02546310|Experimental|HTL0009936 low dose|low dose infusion
89207329|NCT02546310|Placebo Comparator|HTL0009936 matching placebo|matching infusion
89207330|NCT00850044|Active Comparator|1|ABT-450
89207331|NCT00850044|Placebo Comparator|2|Placebo for ABT-450
89207332|NCT00850044|Active Comparator|3|ABT-450/ritonavir
89207333|NCT00850044|Placebo Comparator|4|Placebo for ABT-450/placebo for ritonavir
89207334|NCT00266227|Experimental|Arm A: Rituximab Retreatment|1000 mg rituximab intravenous initial treatment on day 1 and day 15 plus 10-25 mg/week methotrexate followed by re-treatment during weeks 24 -40 consisting of two additional doses of 1000 mg rituximab 14 days apart plus 10-25 mg/week methotrexate.
89207335|NCT00266227|Placebo Comparator|Arm B: Placebo Retreatment|1000 mg rituximab intravenous initial treatment on day 1 and day 15 plus 10-25 mg/week methotrexate followed by retreatment during weeks 24 -40 consisting of two doses of placebo 14 days apart plus 10-25 mg/week methotrexate.
89207336|NCT00968877|Active Comparator|Cholecalciferol|
89207337|NCT00968877|Placebo Comparator|Placebo|
89207338|NCT02729727|Other|Single Arm|To evaluate safety and treatment effect of the CryoBalloon Ablation System for the Ablation of human esophageal epithelium in patients scheduled to undergo esophagectomy
89207339|NCT00965367|Experimental|Acustimulation|
89207340|NCT00965367|No Intervention|Standard treatment group|
89207341|NCT00287365|Experimental|1-ozone|Mildly asthmatic subjects with GSTM1 null genotype compared to GSTM1 sufficient subjects
89207342|NCT00850122|Experimental|Cefazolin|"Dosage Number of Infants~≤28 days of age 25 mg/kg IV q12 6 29-120 days of age 25 mg/kg IV q8 6"
89207343|NCT00968955|Active Comparator|Local infiltration with ropivacaine|Local infiltration with ropivacaine 0,2% (150 ML)
89207344|NCT00968955|Placebo Comparator|Local infiltration with saline|Local infiltration with saline (150 ML) (placebo)
89207345|NCT00843258|No Intervention|Active Sonographic surveillance|Follow-up at 1.5 and 3 months (Ultrasound,Clinical examination), at 6 and 12 months (clinical examination, pelvic X-ray)
89207346|NCT00843258|Experimental|Abduction treatment|Treatment (abduction splint) from 0-6 weeks, follow-up at 1.5 and 3 months (clinical examination and ultrasound) and at 6 and 12 months (clinical examination and pelvic x-ray)
89207347|NCT01072279|Experimental|Burundi: T24|
89207348|NCT01072279|Experimental|Burundi: TNFP|
89207349|NCT01072279|Experimental|Burundi: T18|
89207350|NCT01072279|No Intervention|Burundi: Control|
89541391|NCT03816735|Active Comparator|hyaluronic acid suppository therapy|"Women receive a vaginal suppository called Cikatridina manufactured by the company Angelini to treat women with GSM. Angelini Pharma Österreich GmbH's headquarters are located in Brigittenauer Lände 50-54, 1200 Wien, Austria. The suppositories contain ontain hyaluronic acid, tea tree oil, tigergras extract, and aloe vera."
89541392|NCT03816735|Active Comparator|Juliet feminine laser|The fractional microablative laser with 2940 nm wavelength has a high degree of absorption in water and selectively stimulates the synthesis of sub-mucosal collagen. The erbium-doped yttrium-aluminum-garnet (Er:YAG) laser has been successfully used in the field of plastic skin rejuvenation and reconstruction. The procedure is based on photothermic treatment of connective tissue: It has been established in animal and human studies that it affects collagen remodeling resulting in tightening of the supportive tissue.
89541393|NCT03802799|Experimental|ZYN002|ZYN002 - cannabidiol Transdermal Gel
89541394|NCT03749330|Other|CHOP CICU|CICU Team And Loved Ones Communicating (CICU TALC)
89541395|NCT03740737|Experimental|FE 999049 (Follitropin Delta)|
89541396|NCT03740737|Placebo Comparator|Placebo|
89541397|NCT03738618|Experimental|FE 999049 (Follitropin Delta)|
89541398|NCT03738618|Placebo Comparator|Placebo|
89541399|NCT03737643|Active Comparator|Arm 1|Platinum-based chemotherapy in combination with bevacizumab and durvalumab placebo (saline IV infusion) followed by maintenance bevacizumab, durvalumab placebo (saline IV infusion) and olaparib placebo (tablets).
89541400|NCT03737643|Experimental|Arm 2|Platinum-based chemotherapy in combination with bevacizumab and durvalumab followed by maintenance bevacizumab, durvalumab and olaparib placebo.
88960377|NCT05167279|Placebo Comparator|JS026/placebo 600 mg|8 patients will be enrolled in this arm.
88960378|NCT05167279|Placebo Comparator|JS026/placebo 1000 mg|8 patients will be enrolled in this arm.
88960379|NCT05167279|Placebo Comparator|JS026/placebo 300 mg + JS016/placebo1200 mg|8 patients will be enrolled in this arm.
88960380|NCT05167279|Placebo Comparator|JS026/placebo 600 mg + JS016/placebo 1200 mg|8 patients will be enrolled in this arm.
88960381|NCT05163574|Experimental|High dose|20 patients
88960382|NCT05163574|Active Comparator|Low dose|20 patients
88960383|NCT05157490|Experimental|Mindfulness training|Completion of guided meditations in the preoperative time period, at least 3 sessions per week, leading up to surgery
88960384|NCT05157490|No Intervention|Control|
88960385|NCT05152472|Experimental|Imatinib + Atezolizumab|Imatinib per os 400 mg daily continuously associated with intravenous administrations of atezolizumab at the fixed dose of 1 200 mg every 3 weeks (up to 12 months)
88960386|NCT05152472|Active Comparator|Imatinib alone|Imatinib alone, per os 400 mg daily continuously (up to 12 months)
88960387|NCT05138016|Experimental|Exercise testing with soft exosuit assistance|Progressive cardiovascular exercise testing on a treadmill with soft exosuit assistance.
88960388|NCT05138016|Active Comparator|Exercise testing without soft exosuit assistance|Progressive cardiovascular exercise testing on a treadmill.
89541401|NCT03737643|Experimental|Arm 3|Platinum-based chemotherapy in combination with bevacizumab and durvalumab followed by maintenance bevacizumab, durvalumab and olaparib.
89541402|NCT03737643|Experimental|tBRCAm cohort|Platinum-based chemotherapy in combination with bevacizumab and durvalumab followed by maintenance bevacizumab, durvalumab and olaparib. Bevacizumab is optional according to local practice.
89541403|NCT03730259|Experimental|WebTIPS|A Tailored Program for Perioperative Anxiety and Pain (WebTIPS) aims at reducing perioperative anxiety and pain in children via an internet and mobile platform with short message service (SMS) two-way communication between a healthcare provider and patient/parent. The Web-based Tailored Intervention Preparation for Surgery (WebTIPS) program is developed using the conceptual framework of the Triple Aim that evaluates the intervention within the context of clinical efficacy, improved child and parent surgical experience, and reduced resource utilization during the surgical episode.
89541404|NCT03730259|No Intervention|Control|Subjects in this attention control group, the Web-based Information (WebINFO) group will not be provided tailored content or access to two-way communication. Instead, this group will only receive basic information regarding the management of perioperative anxiety and postoperative pain via the internet and/or mobile platform.
88960389|NCT05135468|Experimental|CU-40102 Spray|0.25% (2.275mg/mL) Finasteride
88960390|NCT05135468|Placebo Comparator|Placebo for CU-40102 Spray|Placebo Spray
88960391|NCT05118269|Experimental|Treatment plus Optimal Medical Therapy|Patients will be treated with the InterVapor System and Optimal Medical Therapy
88960392|NCT05118269|Active Comparator|Optimal Medical Therapy (Control)|Patients will be treated according to Optimal Medical Therapy
88960393|NCT05114889|Experimental|Single Ascending Dose Healthy Volunteer|BSI-045B
88960394|NCT05114889|Experimental|Multiple Ascending Dose Healthy Volunteer|BSI-045B
88960395|NCT05114889|Experimental|Single Dose Atopic Dermatitis patients|BSI-045B
88960396|NCT05103670|Experimental|Patients undergoing a Ventilation/Perfusion PET/CT at inclusion and 3 months later|EOLE is an ancillary study which selects patients included in the RAMBO study. The RAMBO study is a 2-arm-parallel study which patients included in one arm will undergo a 3-month pulmonary rehabilitation, and the patients included in the other arm won't. The EOLE study will include specific patients in both arms of the RAMBO study, and all of the participants will undergo a PET/CT scan at the inclusion and 3 months later.
88960397|NCT05084768||Rejection of kidney transplant|Diagnostic test: measurement of regulatory T cell and donor-derived cell-free DNA
88960398|NCT05084768||No rejection of kidney transplant|Diagnostic test: measurement of regulatory T cell and donor-derived cell-free DNA
88960399|NCT05081817||ICU|ICU patients on insulin drip
88960400|NCT05081713|Other|Phase 1|Observational evaluations for 6 months followed by 3-4 months of high-intensity training (HIT)
88960401|NCT05081713|Other|Phase 2|Observational evaluations for 1 month followed by 3-4 months of high-intensity training (HIT)
88960402|NCT05081232|Experimental|Umbilical Cord Allograft Recipients|Male patients undergoing Robot Assisted Radical Prostectomy with bilateral nerve sparing technique will remain eligible to receive allograft during the surgery.
89513744|NCT00322517|Experimental|SU014813|
89513745|NCT02285231|Experimental|TEST|Arginyl-fructose Supplementation
88960403|NCT05077683|Active Comparator|DAPT|aspirin (≤100mg per day) and P2Y12 inhibitors (i.e. clopidogrel 75mg per day or ticagrelor 90mg twice a day), as per current guidelines
88960404|NCT05077683|Experimental|DAPT + Direct Oral AntiCoagulants (DOAC)|aspirin (≤100mg per day), clopidogrel (75mg per day) or ticagrelor (90mg twice daily) and rivaroxaban 2.5mg twice daily.
88960405|NCT05076942|Experimental|Chemoradiation|Inguinofemoral radiotherapy (48-50 Gy in 1.8 Gy daily fractions, with a boost dose to the involved inguinal site for a total equivalent dose of 56 Gy over 5-6 weeks, preferably with simultaneous integrated boost technique) combined with weekly cisplatin 40 mg/m2 intravenously on days 1, 8, 15, 22 and 29
88960406|NCT05062460|Other|1-hour post-prandial blood glucose monitoring Arm|Arm in which participants are randomized to blood glucose monitoring at 1 hour after eating.
88960407|NCT05062460|Other|2-hour post-prandial blood glucose monitoring Arm|Arm in which participants are randomized to blood glucose monitoring at 2 hours after eating.
88960408|NCT05061719|Experimental|Lumateperone 42 mg|
89513746|NCT02285231|Experimental|Placebo|Placebo Supplementation
89513747|NCT00321815|Experimental|A|Standard of Care chemotherapy plus experimental intervention (PF-3512676)
89513748|NCT00321815|Active Comparator|B|Standard of Care chemotherapy
89513749|NCT02287805||quantitative survey 1|parents of 300 patients with craniosynostosis diagnostic
89513750|NCT02287805||qualitative survey|"parents of 12 newly diagnosed patients, they will be seen 3 times (after the diagnosis, 3 months after surgery, 1 year after surgery~12 patients aged over 15 years, operated more than 10 years before"
89513751|NCT02287805||quantitative survey 2|"100 parents of patients 1 year after surgery~100 parents of patients, 5 years after the operation~100 patients aged over 15 years and operated over 10 years ago"
89513752|NCT00398879|Experimental|Arm 1: Perifosine + Capecitabine|Perifosine 50 mg/d qd + Capecitabine 825 mg/m^2 BID days 1 - 14 q 3 weeks until progression
89513753|NCT00398879|Placebo Comparator|Arm 2: Perifosine Placebo + Capecitabine|Perifosine Placebo 50 mg/d qd + Capecitabine 825 mg/m^2 BID days 1 - 14 q 3 weeks until progression
89513754|NCT00309179|Experimental|1|
89513755|NCT02481050|Experimental|Eribulin Mesylate|Participants with metastatic HER2-negative breast cancer previously treated with 2 to 5 chemotherapy regimens.
89513756|NCT00394199|Experimental|1|FlutiForm 100/10ug
89513757|NCT00394199|Experimental|2|Fluticasone 100
89513758|NCT00394199|Active Comparator|3|Formoterol 10
89513759|NCT02287961|Other|Subjects|"Standard proctologic examination with digital rectal examination and 2 anal swabs at initial inclusion visit, Month 12 and Month 24 follow-up visits and if applicable Month 6 and Month 18 control visits~High resolution anoscopy at initial inclusion visit, Month 12 and Month 24 follow-up visits and if applicable Month 6 and Month 18 control visits~Biopsy(ies) during High Resolution Anoscopy only if lesion suggestive of AIN detected during High Resolution Anoscopy~High Resolution Anoscopy biannually only if high-grade lesion (ASC-H, HSIL ou AIN2/3)"
88960409|NCT05051631|Experimental|Intervention plus 12 months maintenance|Clinics in this group will be in the control phase for 2 months, receive the 4 month intervention, and be in the maintenance phase for 12 months.
88960410|NCT05051631|Experimental|Intervention plus 10 months maintenance|Clinics in this group will be in the control phase for 4 months, receive the 4 month intervention, and be in the maintenance phase for 10 months.
88960411|NCT05051631|Experimental|Intervention plus 8 months maintenance|Clinics in this group will be in the control phase for 6 months, receive the 4 month intervention, and be in the maintenance phase for 8 months.
88960412|NCT05051631|Experimental|Intervention plus 6 months maintenance|Clinics in this group will be in the control phase for 8 months, receive the 4 month intervention, and be in the maintenance phase for 6 months.
88960413|NCT05051631|Experimental|Intervention plus 4 months maintenance|Clinics in this group will be in the control phase for 10 months, receive the 4 month intervention, and be in the maintenance phase for 4 months.
88960414|NCT05050773||Nicorandil group|Patients who are prescribed with Nicorandil with or without other concomitant medication
88960415|NCT05050773||Non-Nicorandil group|Patients who are prescribed with antianginal drugs except Nicorandil
89513760|NCT02511782|Experimental|Acute Graft versus Host Disease|This study arm includes patients who undergo allogeneic hematopoietic cell transplantation at CCHMC and develop acute graft versus host disease. Skin cell samples will be collected using the D-SQUAME Skin Sampling Discs. The first baseline skin sample will be obtained prior to the preparative regimen for stem cell transplant. Samples will be collected weekly after stem cell infusion until 8 weeks, if acute GVHD does not develop. If acute GVHD does develop, weekly samples will continue to be collected until resolution of acute GVHD or development of chronic GVHD, whichever occurs first. Blood samples will be collected at these same time points.
89513761|NCT02511782|Experimental|Chronic Graft versus Host Disease|This study arm includes patients who undergo allogeneic hematopoietic cell transplantation at CCHMC and develop chronic graft versus host disease. Skin cell samples will be collected weekly for 4 weeks using the D-SQUAME Skin Sampling Discs. Blood samples will be collected at these same time points.
89513762|NCT02511782|Active Comparator|Healthy Controls|This study arm includes healthy age matched controls as comparisons to study participants who develop graft versus host disease. These controls may be either healthy age matched siblings of patients who develop acute graft versus host disease or healthy age matched siblings of patients that are seen in the bone marrow transplant, oncology, or hematology clinics. A one-time single skin cell sample will be collected using a D-SQUAME Skin Sampling Disc. Blood samples will not be collected from the healthy controls.
89513763|NCT02480114|Active Comparator|Arm I Standard of Care|Patients receive standard of care consisting of oral health measures, oral rinsing, miracle mouthwash, nonsteroidal anti-inflammatories, and opioid analgesics. Patients also undergo an education session at the beginning of treatment to review foundations of oral care and pain management.
89541405|NCT03717415|Experimental|Part 1|Dose comparison between 50 or 100 mg BID of rebastinib orally (PO) dosed in 21-day cycles in combination with carboplatin administered by IV infusion at either AUC5 or AUC6 once every 3 weeks
88960416|NCT05038540|Experimental|Virtual reality application|Application of virtual reality glasses during scaling and root planning to a quadrant.
89207351|NCT01072279|Experimental|Guatemala: PROCOMIDA|
89541406|NCT03717415|Experimental|Part 2|"Dose expansion in the following tumor types at the recommended Phase 2 dose (RP2D) of rebastinib in combination with carboplatin~Triple-negative breast cancer~Platinum-sensitive Ovarian cancer~Mesothelioma"
89541407|NCT03708822|Experimental|Docetaxel and Cisplatin and Nimotuzumab|All eligible patients received intravenous nimotuzumab plus docetaxel and cisplatin every 3 weeks for a maximum of 6 cycles, or until disease progression, death, intolerable toxicity.
89541408|NCT03695042|Experimental|BFR THEN without BFR|Will perform exercises with BFR at the first visit and without BFR at the second visit
89541409|NCT03695042|Experimental|Without BFR THEN with BFR|Will perform exercises without BFR at the first visit and with BFR at the second visit
89541410|NCT03694249|Experimental|Group 1 (ifetroban)|ifetroban capsule (250mg) will be taken by mouth daily.
89541411|NCT03694249|Placebo Comparator|Group 2 (placebo)|Placebo capsule (250mg) will be taken by mouth daily.
89541412|NCT03677154|Experimental|Consolidation Therapy (Cohort A)|Participants with a partial response to first-line chemotherapy will receive mosunetuzumab up to the recommended consolidation dose (RCD).
89541413|NCT03677154|Experimental|Elderly/Unfit Previously Untreated Monotherapy (Cohort B)|Elderly/unfit participants with previously untreated DLBCL will receive mosunetuzumab at the previously determined recommended phase II dose (RP2D).
89541414|NCT03677154|Experimental|Elderly/Unfit Previously Untreated Combination Therapy (Cohort C)|Elderly/unfit participants with previously untreated DLBCL will receive mosunetuzumab in combination with polatuzumab vedotin.
89541415|NCT03644498||Adults treated with a CPI therapy for cancer|
89541416|NCT03581292|Experimental|Treatment (radiation therapy, veliparib, temozolomide)|"CHEMORADIOTHERAPY PHASE: Patients receive veliparib PO BID and undergo 30 daily fractions of radiation therapy 5 days per week for 6-7 weeks in the absence of disease progression or unacceptable toxicity.~MAINTENANCE CHEMOTHERAPY: Beginning 4 weeks after chemoradiotherapy phase, patients receive veliparib PO BID and temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 10 cycles in the absence of disease progression or unacceptable toxicity."
89541417|NCT03567018|Experimental|Healthy volunteer population|We plan to enroll 25 healthy volunteers.
89541418|NCT03567018|Experimental|Patient population|We plan to enroll 50 clinical patients who are receiving flap procedures at the Ohio State Medical Center.
89541419|NCT03556891|Experimental|eCoin Tibial Nerve Stimulation|
89541420|NCT03535506|Experimental|Group A|Patients enrolled to Group A will receive a 12-day course of Palbociclib before surgery. They will receive Palbociclib 100mg PO daily x 12 days.
89541421|NCT03535506|No Intervention|Group B|These patients will receive no pre-operative treatment. Core biopsies from diagnosis and material from definitive surgery will be collected for translational studies and tissue banking. They will also provide blood samples at screening and prior to definitive surgery.
88960417|NCT05038540|Active Comparator|No application|No application of virtual reality glasses during scaling and root planning to a quadrant.
88960418|NCT05028998||Veterans with Opioid Use Disorder receiving care through the Veterans Health Administration|"Pre-existing medical records data for these individuals will be part of our Aim 1 and Aim 2 large quantitative database.~Additionally, we will be recruiting 30 of these individuals to participate in our Aim 3 qualitative interviews."
88960419|NCT05028998||Veterans with Alcohol Use Disorder receiving care through the Veterans Health Administration|"Pre-existing medical records data for these individuals will be part of our Aim 1 and Aim 2 large quantitative database.~We will not be recruiting any of these individuals for Aim 3 qualitative interviews."
88960420|NCT05028998||Patients with Opioid Use Disorder for whom Market Scan Medicaid Claims data is available|"Pre-existing medical records data for these individuals will be part of our Aim 1 and Aim 2 large quantitative database.~We will not be recruiting any of these individuals for Aim 3 qualitative interviews."
88960421|NCT05028998||Patients with Alcohol Use Disorder for whom Market Scan Medicaid Claims data is available|"Pre-existing medical records data for these individuals will be part of our Aim 1 and Aim 2 large quantitative database.~We will not be recruiting any of these individuals for Aim 3 qualitative interviews."
88960422|NCT05028998||Patients with Opioid Use Disorder for whom Market Scan Commercial Insurance Claims data is available|"Pre-existing medical records data for these individuals will be part of our Aim 1 and Aim 2 large quantitative database.~We will not be recruiting any of these individuals for Aim 3 qualitative interviews."
88960423|NCT05028998||Patients with Alcohol Use Disorder for whom Market Scan Commercial Claims data is available|"Pre-existing medical records data for these individuals will be part of our Aim 1 and Aim 2 large quantitative database.~We will not be recruiting any of these individuals for Aim 3 qualitative interviews."
88960424|NCT05028998||Patients with Opioid Use Disorder receiving care outside of Veterans Health Administration|We will be recruiting 30 of these individuals to participate in our Aim 3 qualitative interviews.
88960425|NCT05028998||Opioid Use Disorder Treatment Providers who provide treatment in the Veterans Health Administration|We will be recruiting 15 of these individuals to participate in our Aim 3 qualitative interviews.
89541422|NCT03533283|Experimental|Atezolizumab|Participants will receive Glofitamab in combination with Atezolizumab up to the maximum tolerated dose (MTD).
89541423|NCT03533283|Experimental|Polatuzumab Vedotin|Participants will receive Glofitamab in combination with polatuzumab vedotin up to the MTD.
89541424|NCT03533283|Experimental|Imaging Sub-study|"Participants will undergo positive-emission tomography/computed tomography (PET/CT) at screening, followed by an Imaging Cycle, to replace Cycle 1 of the main study. Eligible participants will have the option roll-over to the atezolizumab arm of the main study from Cycle 2 onwards."
89541425|NCT03519659|Experimental|Sub-Study A|Patients receive PET/CT scan on Gemini Astonish PET/CT
89541426|NCT03519659|Experimental|Sub-Study B|Patients receive PET/CT scan on Biograph mCT
89541427|NCT03519659|Experimental|Sub-Study C|Patients receive PET/CT scan on Discovery PET/CT
89541428|NCT03519659|Experimental|Sub-Study D|Patients receive PET/CT scan on Vereos 128 digital PET/CT
89541429|NCT03519659|Experimental|Sub-Study E|Patients receive lower radiation dose on Vereos 128 digital PET/CT
89541430|NCT03519659|Experimental|Sub-Study F|Patients receive PET/SCAN using system that did not show equivalence in Sub-Study A-C
89541431|NCT03494335||Volunteer participants|Volunteer participants will participate in surveys assessing their perception of various imaging aspects.
89541432|NCT03491059|Experimental|Full Study - Radiation|
89207352|NCT01072279|Experimental|Guatemala: no family ration|
89207353|NCT01072279|Experimental|Guatemala: LNS|
89207354|NCT01072279|Experimental|Guatemala: Sprinkles|
89207355|NCT01072279|Experimental|Guatemala: reduced family ration|
89207356|NCT01072279|No Intervention|Guatemala: control|
89513764|NCT02480114|Experimental|Arm II Standard of Care Plus Gabapentin|Patients receive standard of care and undergo an education session as in Arm I. Patients also receive gabapentin PO three times a day throughout chemoradiation treatment (approximately 5-7 weeks) and until mucositis resolves and pain subsides.
89513765|NCT00309023|Experimental|dose escalation|
89513766|NCT05202041|Experimental|AccuFFRangio Group|NSTE-ACS patients with multiple lesions who met the requirements of the study were enrolled and received coronary angiography. First, the revascularization of the criminal vessel (PCI) was completed. The patients were randomly grouped and divided into AccuFFRangio Group and Angiography Group if the treatment results were good. The AccuFFRangio Group was defined as non-IRA of these patients who were treated with PCI after angio-FFR measurement with FFR≤0.8.
89513767|NCT05202041|Active Comparator|Angiography Group|The Angiography Group was defined as PCI treatment for non-IRA when diameter stenosis > 70% based on angiographic results.
89513768|NCT00303251|Experimental|TKI258|
89513769|NCT00299507|Experimental|15 mg Anecortave Acetate, 3 month intervals|Anecortave Acetate Sterile Suspension, 30 mg/mL, one 0.5 mL posterior juxtascleral depot injection at 3 month intervals (0, 3, 6, 9, 12, 15, 18 months).
89513770|NCT00299507|Experimental|15 mg Anecortave Acetate, 6 month intervals|Anecortave Acetate Sterile Suspension, 30 mg/mL, one 0.5 mL posterior juxtascleral depot injection at 6 month intervals (3, 9, 15, 21 months).
89513771|NCT00299507|Experimental|30 mg Anecortave Acetate, 6 month intervals|Anecortave Acetate Sterile Suspension, 60 mg/mL, one 0.5 mL posterior juxtascleral depot injection at 6 month intervals (3, 9, 15, 21 months).
89513772|NCT00299507|Sham Comparator|Anecortave Acetate Vehicle|One 0.5 mL sham injection of Anecortave Acetate Vehicle at 6 month intervals (3, 9, 15, 21 months).
89513773|NCT02285309||Cardiac surgery|
89513774|NCT02479880|Other|Tenofovir DF + increased bone/renal monitoring|Participants will receive tenofovir DF, plus laboratory bone biomarker testing and lumbar spine and whole-body DEXA scans every 24 weeks from baseline to Week 96 (5 scans), and monitoring of renal function at 4 and 12 weeks after baseline and every 12 weeks thereafter. With the exception of an enhanced monitoring protocol for bone and renal outcomes, participants will be managed according to local standards of care.
89513775|NCT02479880|Other|Tenofovir DF + prespecified bone monitoring|Participants will receive tenofovir DF, plus laboratory bone biomarker testing and lumbar spine and whole-body DEXA scans at baseline, Week 48, and Week 96. With the exception of pre-specified bone monitoring, participants will be managed according to local standards of care.
89513776|NCT00297401|Experimental|1|
89513777|NCT00297401|Placebo Comparator|2|
89513778|NCT02285387|Experimental|Rhythm control group|"Start AAD right after evaluating for LA size, EF, LA thrombus, and presence of CAD during anticoagulation~Cardioversion after 1 month~Rhythm FU schedule (2012 ACC/AHA/ESC guidelines)~If AF recur, RFCA"
89513779|NCT02285387|Active Comparator|Rate control group|"No AAD, just anticoagulation~HR control between 60~110bpm (with beta blocker, calcium channel blocker, digoxin)~Without the treatment about antiarrhythmia and rhythm control, deification of rate control, the subject will be drop out for study."
89513780|NCT00297089|Active Comparator|A|Pemetrexed + ABT-751
89513781|NCT00297089|Placebo Comparator|B|Pemetrexed + placebo
89513782|NCT02479802|Experimental|Albumin|Plasma exchange with Albumin
89513783|NCT00390845|Experimental|SB681323|Patients with pain associated with peripheral nerve injury and/or compression will be recruited for this study.
89513784|NCT00390845|Experimental|Placebo|Patients with pain associated with peripheral nerve injury and/or compression will be recruited for this study.
89513785|NCT00286793|Experimental|SIngle Arm Study of AT-101 in combination with Docetaxel|
89207357|NCT00965445||cardiac surgery with CPB|
89513786|NCT02285465|Experimental|ASP3700 multiple ascending dose cohort|
89513787|NCT02285465|Placebo Comparator|Placebo cohort|
89513788|NCT02288039|Experimental|Social Identity Goal-Based Intervention|Participants will receive collaborative goal-setting
88960426|NCT05028998||Opioid Use Disorder Providers who treat outside the Veterans Health Administration|We will be recruiting 15 of these individuals to participate in our Aim 3 qualitative interviews.
89513789|NCT02288039|No Intervention|Standard Care|Participants will receive usual standard treatment
89513790|NCT02285699|Other|SSRI treatment|The intervention only applies to Phase II of the proposed study. Individuals in the OCD group will be offered 12-weeks of standard SSRI treatment ti determine whether 12-weeks of treatment results in a change of the gut microbiota/inflammatory markers.
89513791|NCT02288351|Other|RYGB with mucosal abnormality on EGD|Subjects with Type 2 Diabetes undergoing a Roux-en-Y Gastric Bypass with a diagnosis of gastritis, esophagitis, ulcer, or other mucosal abnormality discovered at routine preoperative upper endoscopy, requiring follow-up endoscopy in the post-operative period.
89207358|NCT00850278|Experimental|FLT-PET imaging|Prior to surgical resection, patient will undergo [11C]MET PET imaging, [18F]FLT PET imaging, MRI, and spectroscopy imaging.
89207359|NCT05279625|Experimental|Interval exercise training|Interval exercise training using either elastic band, dumbbells, treadmill, cycling for 6 months
89207360|NCT05279625|Experimental|continuous exercise training|continuous exercise training using either elastic band, dumbbells, treadmill, cycling for 6 months
89207361|NCT05279625|Experimental|machine-assisted exercise training|machine-assisted exercise training for 6 months
89207362|NCT05279625|Active Comparator|traditional rehabilitation|traditional rehabilitation for 6 months
89207363|NCT00853554|Experimental|A|Hydromorphone Hydrochloride tablet 8 mg
89207364|NCT00853554|Active Comparator|B|Dilaudid® tablet 8 mg
89513792|NCT02288429||Colistin|"Patients ≥ 18 years old receiving intravenous colistimethate sodium for the treatment of infection~Have cystic fibrosis and/or are critically ill (admitted to a critical care unit)"
89513793|NCT03133637||Ceftriaxone Arm|
89513794|NCT00267371|Active Comparator|Test Arm with Premere investigational|PFO Closure with Premere investigational device.
89541433|NCT03491059|No Intervention|Dress Rehearsal Only - No Radiation|
89513795|NCT00267371|Active Comparator|Medical management/current medications|Patients in the control group arm will not receive the medical device and will continue medical management.
88960427|NCT05028998||Opioid Use Disorder Treatment and Policy Decision Makers|We will be recruiting 20 of these individuals to participate in our Aim 3 qualitative interviews.
89513796|NCT00254891|Experimental|A|Standard of care chemotherapy plus experiment intervention (PF-3512676)
89513797|NCT00254891|Active Comparator|B|Standard of care chemotherapy
89513798|NCT02479412|Experimental|Sequence 1|Placebo once daily for 14 days in Period 1, 58 µg AZD7594 once daily for 14 days in Period 2 and 250 µg AZD7594 once daily for 14 days in Period 3
89513799|NCT02479412|Experimental|Sequence 2|Placebo once daily for 14 days in Period 1, 250 µg AZD7594 once daily for 14 days in Period 2 and 800 µg AZD7594 once daily for 14 days in Period 3
89513800|NCT02479412|Experimental|Sequence 3|Placebo once daily for 14 days in Period 1, 800 µg AZD7594 once daily for 14 days in Period 2 and 58 µg AZD7594 once daily for 14 days in Period 3
89513801|NCT02479412|Experimental|Sequence 4|58 µg AZD7594 once daily for 14 days in Period 1, Placebo once daily for 14 days in Period 2 and 800 µg AZD7594 once daily for 14 days in Period 3
89513802|NCT02479412|Experimental|Sequence 6|250 µg AZD7594 once daily for 14 days in Period 1, Placebo once daily for 14 days in Period 2 and 58 µg AZD7594 once daily for 14 days in Period 3
89513803|NCT02479412|Experimental|Sequence 8|800 µg AZD7594 once daily for 14 days in Period 1, Placebo once daily for 14 days in Period 2 and 250 µg AZD7594 once daily for 14 days in Period 3
89513804|NCT02479412|Experimental|Sequence 5|58 µg AZD7594 once daily for 14 days in Period 1, 800 µg AZD7594 once daily for 14 days in Period 2 and Placebo once daily for 14 days in Period 3
89513805|NCT02479412|Experimental|Sequence 7|250 µg AZD7594 once daily for 14 days in Period 1, 58 µg AZD7594 once daily for 14 days in Period 2 and Placebo once daily for 14 days in Period 3
89513806|NCT02479412|Experimental|Sequence 9|800 µg AZD7594 once daily for 14 days in Period 1, 250 µg AZD7594 once daily for 14 days in Period 2 and Placebo once daily for 14 days in Period 3
89513807|NCT02285933|Experimental|VRT|sitting balance exercises delivered via virtual reality training
89513808|NCT02285933|Active Comparator|control|virtual reality training requiring limited arm movements and no challenge to sitting balance
89513809|NCT02286011|Experimental|MNC (Mononuclear cells)|"All patients included in the clinical trial will receive an intramuscular infusion of autologous mononuclear cells (MNC) of Bone Marrow (BM) in TA muscle of one of the lower limb (experimental group). The lower limb on the CMN infuse autologous BM will be determined randomly.~The average dose is 550 millions of cells (100-1200 million) diluted in 2 ml. saline"
89513810|NCT02286011|Placebo Comparator|Saline|All patients included in the clinical trial will receive an intramuscular infusion of 2 mL of saline (placebo) in the TA muscle of the contralateral limb (group control).
89513811|NCT00254579|Experimental|15 mg/kg CP-675,206|
89513812|NCT02288507|Experimental|sorafenib & Yttrium-90 radioembolization|Sorafenib dose de-escalation starting at 400mg PO BID starting on Day1 Yttrium-90 radioemoblization on Day 14
89513813|NCT02288585|Active Comparator|Plant sterols|Plant sterols
89513814|NCT02288585|Placebo Comparator|Placebo product|Placebo product
88960428|NCT05022147|Experimental|Alternating-Frequency DBS|In this single-arm study, all participants will receive all interventions in a crossover fashion.
88960429|NCT05017961|Active Comparator|Autograft|Following definitive fracture reduction a bone defect often remained in the substance of the calcaneus beneath the reduced posterior facet. In this group an autograft will be used to fill the void. For the purpose of autologous grafting, cancellous strips of bone will be harvested from the posterior superior iliac crest or proximal tibia. It shall be applied wherever bone loss exists as a result of the incident fracture or subsequent bone debridement(s). This will be the control arm.
88960430|NCT05017961|Other|Allograft only|Following definitive fracture reduction a bone defect often remained in the substance of the calcaneus beneath the reduced posterior facet. In this group a cryopreserved allograft bone (Musculoskeletal Tissue Foundation, New Jersey, NJ) will be used to fill the void. It shall be applied wherever bone loss exists as a result of the incident fracture or subsequent bone debridement(s).
89513815|NCT02286167|Other|Single arm diet|Intermittent, modified Atkins diet
89513816|NCT00231257|Experimental|1|Cypher Bx Velocity
89513817|NCT00231257|Active Comparator|2|Brachytherapy
89513818|NCT02286245|Experimental|1: focused Telephonic Medical Advice|The physician will implement a protocol of care to each patient call for an isolated fever and/or symptoms of gastroenteritis: medical advice, drug prescription by phone and supervisory board. Patients are invited to recall in case of worsening or onset of new symptoms and to get an appointment with their general practitioner during working hours.
89513819|NCT02286245|Active Comparator|2: Usual practice|The physician will decide for the same disease (isolated fever and/or symptoms of gastroenteritis) the need of telephone advice with or without drug prescription, home visit by a doctor, emergency department services with or without EMS system.
89513820|NCT00390533|Experimental|Saredutant 30 mg|Saredutant 30 mg once daily for a maximum of 8 weeks
89513821|NCT00390533|Experimental|Saredutant 100 mg|Saredutant 100 mg once daily for a maximum of 8 weeks
89513822|NCT00390533|Placebo Comparator|Placebo|Placebo for saredutant once daily for one week during the screening phase and for a maximum of 8 weeks during the acute phase
89513823|NCT00390143|Experimental|Group A|Subjects previously primed with meningococcal vaccine 134612.
89513824|NCT00390143|Active Comparator|Group B|Subjects previously primed with Mencevax™ ACWY.
89513825|NCT00206687|Experimental|Arm 1|
89513826|NCT00206687|Sham Comparator|Arm 2|
89513827|NCT00389675|Experimental|Darusentan|Darusentan capsules titrated to an optimal dose of 50 mg, 100 mg, or 300 mg administered orally once daily
89513828|NCT00389675|Active Comparator|Guanfacine|Guanfacine 1 mg capsules administered orally once daily
89513829|NCT02288663|Other|Freage group|only one group in this trial. All the participants will follow all the listed interventions.
89513830|NCT02286323|Experimental|Endotracheal intubation without chest compressions|Endotracheal intubation of mannikin during resuscitation without chest compressions.
89541434|NCT03491046|Experimental|Patient population with ACL injury or reconstruction|
89541435|NCT03491046|Experimental|Patient population without ACL injury or reconstruction|
89513831|NCT02286323|Experimental|Endotracheal intubation with uninterrupted chest compressions|Endotracheal intubation of mannikin during resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
89513832|NCT02288741|Experimental|A1: Induction chemotherapy|Anthracycline/dexamethasone-based induction chemotherapy Tumor-reduction chemotherapy and stem cell mobilization Stem cell apheresis Tandem high-dose chemotherapy Autologous peripheral blood stem cell transplantation
89513833|NCT02288741|Active Comparator|A2: No induction chemotherapy|Dexamethasone for control of symptoms Tumor-reduction chemotherapy and stem cell mobilization Stem cell apheresis Tandem high-dose chemotherapy Autologous peripheral blood stem cell transplantation
89513834|NCT02288741|Other|B: Observation|Tumor-reduction chemotherapy and stem cell mobilization Stem cell apheresis Tandem high-dose chemotherapy Autologous peripheral blood stem cell transplantation
89513835|NCT04470323||COVID19 patients|Patients admitted to Assiut university Hospitals diagnosed as COVID19 positive patients by PCR.
89513836|NCT04470323||healthy volunteer|as negative control for each sample
89513837|NCT04470245|Active Comparator|Healthy volunteers|
89513838|NCT04470245|Active Comparator|Patients undergoing surgery|We will include adults (over 18 years of age) undergoing surgical decompression of the ulnar nerve at the elbow for cubital tunnel syndrome.
89513839|NCT05726045|Active Comparator|HIIT morning|High-intensity interval training (HIIT) in the morning
89513840|NCT05726045|Experimental|HIIT evening|High-intensity interval training (HIIT) in the evening
89513841|NCT05726045|Active Comparator|HIIT morning + CRT|High-intensity interval training (HIIT) in the morning + cognitive remediation treatment (CRT)
89513842|NCT05726045|Experimental|HIIT evening + CRT|High-intensity interval training (HIIT) in the evening+ cognitive remediation treatment (CRT)
89513843|NCT02450552|Experimental|Oral ezogabine 600 mg/day|
89513844|NCT02450552|Experimental|Oral ezogabine 900 mg/day|
89513845|NCT02450552|Placebo Comparator|Placebo|
89513846|NCT02508428|Active Comparator|Crosslinked Marathon polyethylene|The crosslinked Marathon polyethylene liners used for the primary total hip replacements in this study were treated with 5 Mrad (50 kGy) of gamma irradiation to induce crosslinking and then heated above the melting temperature (150 degrees Celsius) to eliminate free radicals. This manufacturing process was designed to improve the polyethylene's resistance to wear through increased crosslinking and eliminate free radicals that render it susceptible to oxidative degradation. These liners were machined and terminally sterilized with gas plasma, a noncrosslinking chemical surface treatment. These liners did not have had free radicals at the time of implantation and did not incorporate antioxidants.
89513847|NCT02508428|Active Comparator|Noncrosslinked Enduron polyethylene|The standard, noncrosslinked Enduron polyethylene liners used for the primary total hip replacements in this study were manufactured from the same polyethylene resin as the crosslinked Marathon liners but never irradiated. Like the Marathon components, these liners were machined and terminally sterilized with gas plasma, a noncrosslinking chemical surface treatment. Based on the manufacturing methods, these liners would not have had free radicals at the time of implantation and did not incorporate antioxidants.
89210548|NCT00819806|Experimental|D|This vaccine injection contains all the same components of Arm C and will also be administered in 3 separate subcutaneous injections. However, 3 days prior to your 1st, 3rd, 5th, 7th, 9th and subsequent monthly vaccinations, you will have low-dose cyclophosphamide administered intravenously (through a vein in your arm).
89513848|NCT02448680|Active Comparator|Coagulation Factor VIIa (Recombinant): 75 µg/kg|75 µg/kg treatment regimen for 3 months
89513849|NCT02448680|Active Comparator|Coagulation Factor VIIa (Recombinant): 225 µg/kg|225 µg/kg treatment regimen for 3 months
89513850|NCT02448446|Active Comparator|Diabetic macular edema treatment group (Group 1)|Treatment using intravitreal ranibizumab 0.3mg based on the DRCR protocol I 4:2:7 strategy based on the presence of macular edema.
89513851|NCT02448446|Active Comparator|Diabetic macular edema and lipid treatment group (Group 2)|Continued treatment with intravitreal ranibizumab 0.3mg until, not only the macular edema is resolved, but also until the lipid exudate is resolved.
89513852|NCT02447744|Experimental|Mindfulness group|This arm receives an 8-week mindfulness based behavioral intervention program.
89513853|NCT02447744|Other|Waitlist control group|This arm waits while the mindfulness group receives their intervention, and then receives the mindfulness based intervention after their waiting period.
89513854|NCT04923386||Diabetics who receive mRNA COVID-19 vaccine|Patients that have a history of Diabetes Mellitus Type I or Type II who received Pfizer-N-Biotech or Moderna mRNA COVID-19 vaccines
89513855|NCT04200560|Experimental|Healthy Adult Subjects|Healthy adult subjects (18 - 30 years) will be assessed for markers of EC autophagy, eNOS activation, and NO generation before and after Rhythmic Handgrip Exercise
89513856|NCT04200560|Experimental|Healthy Older Adult Subjects|Healthy older adult subjects (> 60 years) will be assessed for markers of EC autophagy, eNOS activation, and NO generation before and after Rhythmic Handgrip Exercise and after Chronic Exercise Training.
89513857|NCT02478632|Active Comparator|CAR|Participants do not receive study medication in this study 202094. Participants group carried over from the parent study 201636 (SWORD-1) or 201637 (SWORD-2).
89513858|NCT02478632|Experimental|DTG 50 mg + RPV 25 mg|Participants do not receive study medication in this study 202094. Participants group carried over from the parent study 201636 (SWORD-1) or 201637 (SWORD-2)
89513859|NCT02478398|Experimental|Short ragweed pollen allergen extract|Participants receive one sublingual tablet containing 12 units of Ambrosia artemisiifolia major allergen number 1 (Amb a 1-U), once daily (QD) for up to 35 weeks. Participants may use study-provided rescue medication(s) as needed to treat rhinoconjunctivitis symptoms.
89513860|NCT02478398|Placebo Comparator|Placebo|Participants receive one placebo sublingual tablet, QD for up to 35 weeks. Participants may use study-provided rescue medication(s) as needed to treat rhinoconjunctivitis symptoms.
89513861|NCT02478164|Experimental|Ponatinib|Drug will be administered once daily per cycle through oral ingestion.
89513862|NCT02476994|Experimental|Clinolipid (lipid injectable emulsion, USP) 20%|Dosing schedule based on subject's age, weight, and medical condition and as per ESPEN-ESPHAN guidelines.
89541436|NCT03490812|Experimental|Prospective population|
89541437|NCT03490812|Experimental|Retrospective population|
88960431|NCT05017961|Other|Allograft combined with BMAC|Following definitive fracture reduction a bone defect often remained in the substance of the calcaneus beneath the reduced posterior facet. In this group a cryopreserved allograft bone (Musculoskeletal Tissue Foundation, New Jersey, NJ) combined with BMAC will be used to fill the void. For the purpose of BMAC preparation, bone marrow will be collected from iliac crest or proximal tibia. It shall be applied wherever bone loss exists as a result of the incident fracture or subsequent bone debridement(s).
88960432|NCT05017415|Experimental|Standard toilet chair (hip angle 90°)|uroflow measurement with subsequent post void residual measurement, conducted on a standard toilet chair.
88960433|NCT05017415|Experimental|Toilet chair with decreased hip angle|uroflow measurement with subsequent post void residual measurement, conducted on a toilet chair with decreased hip angle.
89513863|NCT02476994|Active Comparator|Intralipid 20% (lipid injectable emulsion, USP)|Dosing schedule based on subject's age, weight, and medical condition and as per ESPEN-ESPHAN guidelines.
89513864|NCT02508194|Active Comparator|Placebo + Inactivated Influenza Vaccine (IIV)|Participants received a single intramuscular (IM) injection of placebo (matched with MEDI7510) in one arm and single IM injection of (IIV) in the contralateral arm.
89513865|NCT02508194|Experimental|MEDI7510 + IIV|Participants received a single IM injection of MEDI7510 in one arm and single IM injection of IIV in the contralateral arm.
89513866|NCT02508116|Experimental|CYP2C19 Genotype guided|Prospective CYP2C19 genotyping to decide antiplatelet therapy.
89513867|NCT02508116|No Intervention|Control group|Antiplatelet therapy will be decided based on usual care
89513868|NCT01653782|Experimental|kUNDALINI YOGA|"Guided kundalini yoga sessions specific for low back pain for 1 hour, twice a week (120 minutes of instructor-led yoga) for 6 weeks. Cd recording for home practice recommended once per day.A written self care pamphlet The Back book"
89513869|NCT01653782|Active Comparator|Self care advice to stay active|Evidence based advice from caregiver to stay active and exercise
89513870|NCT01653782|Active Comparator|Exercise|"Guided exercise at a gym focusing on strength training. Twice a week during 6 weeks. A written self care pamphlet The Back book"
89513871|NCT02318329|Experimental|Part 1A: FPA144 Dose Escalation Solid Tumors|Dose escalation of FPA144 (0.3 mg/kg to 15 mg/kg)
89513872|NCT02318329|Experimental|Part 1B: FPA144 Dose Escalation Gastric Cancer|Dose escalation of FPA144 (3-10 mg/kg) in patients with gastric cancer
88960434|NCT05015153|Experimental|Intervention group|20 sessions of Pulmonary rehabilitation will be performed over a period of 3 months
88960435|NCT05015153|No Intervention|Control group|No Pulmonary rehabilitation
88960436|NCT05010759|Experimental|Ablation Arm|Subjects in this arm of the study will have focal ablation of the prostate cancer lesion with the NanoTherm technology. This ablation will be followed-up transperineal prostate biopsy at 4 months after treatment.
88960437|NCT05010538||Sarecycline|Eligible patients will be prescribed with commercially available sarecycline at a dosage of 1.5 mg/kg/day and followed for 12 weeks post initiation of treatment.
88960438|NCT05005351|Active Comparator|Digital Acceptance and Commitment Therapy (ACT)|
88960439|NCT05005351|Active Comparator|Digital Symptom Tracker|
88960440|NCT05005299|Experimental|Dose Level A|Subjects will receive receive short-course venetoclax on day -11 to -6 [venetoclax 100mg daily administered on day -11 to -6 (total venetoclax dose: 600mg)], followed by intravenous fludarabine 30mg/m2 daily (day -5 to -3) and intravenous cyclophosphamide 750mg/m2 daily (day -5 to -3). Allogeneic stem cell infusion will occur on day 0.
89207365|NCT02586597|Experimental|PAS 10: TMS and median nerve stimulation|Paired associative stimulation (PAS) is a new technique where one pairs a peripheral stimulation with centrally applied transcranial magnetic stimulation (TMS), and produces plasticity, as measured by TMS MEP's. Currently PAS is performed with median nerve stimulation. The interval between median nerve stimulation and TMS was chosen to be 10 ms, which is called PAS10. PAS 10: TMS and median nerve stimulation: 240 paired median nerve stimulation and TMS during 20 minutes.
89513873|NCT02318329|Experimental|Part 2: FPA144 Dose Expansion Gastric or Other Solid Tumors|Evaluation of objective responses in patients with tumors with various levels of FGFR2b overexpression
89513874|NCT02022631|Experimental|Alternative SoF|Investigators will compare one SoF table with alternative formats (Table A) against one SoF table with the current formats (Table B). In both tables, the clinical question in terms of patients and setting, intervention, comparator, and outcomes informed by the tables, and the complementary information included as footnotes will be the same. The only differences between the current and alternative SoF table formats will be different methods to either show the same data in a different way or to provide complementary data to the one showed in the current format (i.e. supplementary data as risk difference).
89513875|NCT02022631|Active Comparator|Current SoF|Investigators will compare one SoF table with alternative formats (Table A) against one SoF table with the current formats (Table B). In both tables, the clinical question in terms of patients and setting, intervention, comparator, and outcomes informed by the tables, and the complementary information included as footnotes will be the same. The only differences between the current and alternative SoF table formats will be different methods to either show the same data in a different way or to provide complementary data to the one showed in the current format (i.e. supplementary data as risk difference).
89513876|NCT03475849||RYGB subjects|Morbidly obese patients who has undergone an uncomplicated gastric bypass surgery more than 12 months before study start.
89513877|NCT03475849||Control subjects|Age, sex and BMI-matched healthy controls
89513878|NCT03475849||SG subjects|Morbidly obese patients who has undergone an uncomplicated sleeve gastrectomy surgery more than 12 months before study start.
89513879|NCT01962337|Experimental|1-FPA008/Placebo Randomize DoseLevels1-4|Single infusion at 4 different dose levels
89513880|NCT01962337|Experimental|2-FPA008/Placebo Randomize DoseLevels1-2|Dual Infusions at 2 different dose levels
89513881|NCT01962337|Experimental|3-FPA008 Open-Label DoseLevels 1-3|Dual infusions at 1 dose level AND Dual/Triple infusions at 2 different dose levels
89513882|NCT00687505|Experimental|1|Single ascending doses
89513883|NCT03472417|Active Comparator|Active partial rebreathing device|
89513884|NCT03472417|Sham Comparator|Dummy partial rebreathing device|
89513885|NCT05259007|Experimental|Group 1|Group 1 propolis with lactic acid extract on top of the treatment given by doctor
89513886|NCT05259007|Other|Group 2|Grorup 2 Lactic acid extract on top of the treatment by the doctor
89207366|NCT02586597|Experimental|PAS 25:TMS and median nerve stimulation|PAS 25: The interval between median nerve stimulation and TMS was chosen to be 25 ms, which is called PAS25. PAS 25:TMS and median nerve stimulation: 240 paired median nerve stimulation and TMS during 20 minutes.
89207367|NCT02586597|Sham Comparator|PAS100:TMS and median nerve stimulation|PAS Control Paradigm: The interval between median nerve stimulation and TMS was chosen to be 100 ms, which is called PAS100. PAS100:TMS and median nerve stimulation: 240 paired median nerve stimulation and TMS during 20 minutes.
89513887|NCT05259007|Placebo Comparator|Group 3|Group 3 the treatment given by the doctor and placebo treatment
89513888|NCT02255656|Experimental|Alemtuzumab|All Participants who completed the study CAMMS03409 (extension study of CAMMS223 [NCT00050778], CAMMS323 [NCT00530348], or CAMMS324 [NCT00548405]) and received alemtuzumab within 48 months prior to enrollment were included in this LPS13649 study. Participants received alemtuzumab, intravenous infusion of 12 milligram per day (mg/day) for 3 consecutive days, at the study investigators' discretion; and at least 12 months after the prior treatment course in the current study (LPS13649).
89513889|NCT00380653|Experimental|sapacitabine low dose|sapacitabine administered every 12 hours for 7 days followed by 14 days of rest or every 12 hours for 3 consecutive days per week for 2 weeks followed by 7 days of rest in patients with advanced leukemias or myelodysplastic syndromes The starting dose is (A) 75 mg twice daily x 7 days followed by 14 days of rest; Evaluated doses: 75mg, 100mg, 125mg, 175mg, 225mg, 275mg, 325mg and 375mg
89513890|NCT00380653|Experimental|sapacitabine high dose|"The starting dose is 375 mg twice daily x 3 consecutive days per week for 2 weeks followed by 7days of rest.~Evaluated doses: 375mg, 425mg and 475mg"
89513891|NCT04099537|Experimental|Approach cognitive training|This training is a single session training. Each session lasts about 30 minutes where participants are to pull the joystick toward (approach) them when seeing skin stimuli on a computer screen.
89513892|NCT04099537|Experimental|Avoidance cognitive training|This training is a single session training. Each session lasts about 30 minutes where participants are to push the joystick away (avoidance) from them when seeing skin stimuli on a computer screen.
89513893|NCT04099537|Placebo Comparator|Placebo cognitive training|This training is a single session training. Each session lasts about 30 minutes where participants are to push and pull the joystick towards or away from them (no rule) when seeing skin stimuli on a computer screen.
89513894|NCT03472339|Experimental|Group A|diclofenac sodium75 mg, intravenously, once
89513895|NCT03472339|Active Comparator|Group B|diclofenac sodium 100 mg, orally, once
89513896|NCT03472261|Experimental|Experimental Group|Patients treated by Botulinum toxin A and twister and specific home exercise program
89513897|NCT03472261|Active Comparator|Conventional Therapy Group|Patients treated by Botulinum toxin A and specific home exercise program
89513898|NCT03479047|Experimental|Ventilated patients|During a spontaneous breathing trial (SBT) we will simultaneously, for all included patient, assess diaphragmatic displacement (DD) using ultrasonography, respiratory rate (RR) and tidal volume (VT) on ventilator screen.
89513899|NCT03478813|Experimental|Intervention group|Voiding school (VS) is based on urotherapy guidelines for educating children with incontinence highlighting regular voiding habits and life-style advice. Learning by doing, understanding the body function by concrete example videos and pictures, and discussing are the main teaching methods.The intervention is delivered face-to-face in groups of 4-6 children. The VS includes three sessions one months apart. Duration of each VS session is three hours. The intervention is delivered with detailed manual. The intervention is provided by an urotherapist and a public-health nurse.
89513900|NCT03478813|No Intervention|Usual care group|The control group receives treatment according to the new 2016 guidelines of incontinence care in child welfare clinics in the city concerning. Treatment is carried out by public health nurse individually in consulting hours or by telephone.
89513901|NCT05369728|Other|First line coronary scanner group|The patient will benefit from a coronary CT scan in 1st line (evaluation of the coronary anatomy), then according to the result it will be managed according to the CAD-RADS decision algorithm.
89513902|NCT05369728|Other|First line functional test strategy group|The patient benefits from a functional test in 1st line (search for myocardial ischemia by myocardial scintigraphy: SPECT, stress echography, or MRI), then according to the result he will be managed in accordance with the European recommendations.
89513903|NCT03478735|Experimental|Ultrasound Guided GON Block at C2|Ultrasound Guided Greater Occipital Nerve Block at C2
89513904|NCT03478735|Active Comparator|Landmark based GON Block|Landmark-Based Greater Occipital Nerve Block
89513905|NCT03951025|Active Comparator|Melatonin oral administration|Consumption of one tablet with 1 mg of melatonin orally
89513906|NCT03951025|Experimental|Melatonin sublingual administration|Consumption of one tablet with 1 mg of melatonin sublingually
89513907|NCT02255500|Experimental|Bupivacaine FNB + EXPAREL Infiltration|Femoral nerve block with bupivacaine HCl 0.5% with epinephrine 1:200,000 within 2 hours of the surgical procedure. Infiltration of EXPAREL 266 mg just prior to wound closure.
89541438|NCT03490656|Experimental|Healthy volunteer population|
89541439|NCT03490656|Experimental|Patient population|
89207368|NCT00843336|Experimental|Electronic hormonal fertility monitoring|Use of an electronic hormonal fertility monitor that measures urinary estrogen and LH and provides users with low, high, or peak fertility readings.
89207369|NCT00843336|Active Comparator|Cervical mucus monitoring|Self-monitoring of externally observed cervical mucus to determine level of fertility.
89207370|NCT01071109|Experimental|Therapeutic Massage|
89207371|NCT01071109|No Intervention|No therapeutic massage|
89207372|NCT00853710|Experimental|rapid PSA assay on whole blood|
89513908|NCT03475693|Experimental|Treatment arm|Patients will receive PO magnesium 400 mg, Zofran 4 mgODT, and Tylenol 500 mg in the emergency department. They will then continue with 500 mg Tylenol BID and 400 mg MagOx tablets BID for the next 5 days. Symptom severity scores will be obtained and compared throughout this time as mentioned in the study design.
88960441|NCT05005299|Experimental|Dose Level B|Subjects will receive receive short-course venetoclax on day -11 to -6 [venetoclax 100mg daily administered on day -11, followed by 200mg daily administered on day -10 to -6 (total venetoclax dose: 1100mg)], followed by intravenous fludarabine 30mg/m2 daily (day -5 to -3) and intravenous cyclophosphamide 750mg/m2 daily (day -5 to -3). Allogeneic stem cell infusion will occur on day 0.
88960442|NCT05005299|Experimental|Dose Level C|Subjects will receive receive short-course venetoclax on day -11 to -6 [venetoclax 100mg daily administered on day -11, followed by 200mg daily administered on day -10, 400mg daily administered on day -9 and 600mg daily administered on day -8 to -6 (total venetoclax dose: 2500mg)], followed by intravenous fludarabine 30mg/m2 daily (day -5 to -3) and intravenous cyclophosphamide 750mg/m2 daily (day -5 to -3). Allogeneic stem cell infusion will occur on day 0.
88960443|NCT05005299|Experimental|Dose Level B'|Subjects will receive receive short-course venetoclax on day -11 to -6 [venetoclax 100mg daily administered on day -11, followed by 200mg daily administered on day -10 and 400mg daily administered on day -9 to -6 (total venetoclax dose: 1900mg)], followed by intravenous fludarabine 30mg/m2 daily (day -5 to -3) and intravenous cyclophosphamide 750mg/m2 daily (day -5 to -3). Allogeneic stem cell infusion will occur on day 0.
89513909|NCT03475693|Placebo Comparator|Placebo arm|Patients will receive PO Zofran 4 mgODT, and Tylenol 500 mg in the emergency department. They will then continue with 500 mg Tylenol BID for the next 5 days. Symptom severity scores will be obtained and compared throughout this time as mentioned in the study design.
89513910|NCT05258461|Experimental|The intervention group|The intervention group will receive conventional adverse event management and have access to the smartphone app during chemotherapy.
89513911|NCT05258461|Active Comparator|The control group|The control group will receive conventional adverse event management during chemotherapy. Chemotherapy-related adverse events in the control group will be managed with symptomatic treatment, dietary and lifestyle prescription according to the doctors' clinical experience.
89513912|NCT03475615|Experimental|SOXP|
89513913|NCT03475615|Active Comparator|SOX|
89513914|NCT03478501|Experimental|Decision Aid Group|Participants randomized to this arm will view the decision aid on a tablet in the emergency department.
89513915|NCT03478501|No Intervention|Control Group|Participants randomized to this arm will be asked to review general suicide prevention information on a tablet in the emergency department.
89513916|NCT03478423|Experimental|Codeine|"Patients will be provided with 30mg tablets of codeine, instructed to take 1 tablet every 4 hours as needed for moderate to severe pain if you continue to have pain despite taking acetaminophen.~Patients will also receive 500mg tablets of acetaminophen with instructions to take 1-2 tablets by mouth every 8 hours as needed for pain.~Patients will also receive 17g sachets of PEG, Dissolve in 120 to 240 mL (4 to 8 ounces) of beverage and drink. Use one sachet daily as needed to prevent constipation if you are taking the opioid study drug."
89513917|NCT03478423|Experimental|Oxycodone|"Patients will be provided with 5mg tablets of oxycodone, instructed to take 1 tablet every 4 hours as needed for moderate to severe pain if you continue to have pain despite taking acetaminophen.~Patients will also receive 500mg tablets of acetaminophen with instructions to take 1-2 tablets by mouth every 8 hours as needed for pain.~Patients will also receive 17g sachets of PEG, Dissolve in 120 to 240 mL (4 to 8 ounces) of beverage and drink. Use one sachet daily as needed to prevent constipation if you are taking the opioid study drug."
89513918|NCT03478423|Experimental|Hydromorphone|"Patients will be provided with 1mg tablets of hydromorphone, instructed to take 1 tablet every 4 hours as needed for moderate to severe pain if you continue to have pain despite taking acetaminophen.~Patients will also receive 500mg tablets of acetaminophen with instructions to take 1-2 tablets by mouth every 8 hours as needed for pain.~Patients will also receive 17g sachets of PEG, Dissolve in 120 to 240 mL (4 to 8 ounces) of beverage and drink. Use one sachet daily as needed to prevent constipation if you are taking the opioid study drug."
89513919|NCT03478345|Experimental|THRIVE Study|
88960444|NCT05003362|No Intervention|usual care|Subjects randomized to the usual care control group will continue using their usual medical care as prescribed by their physician.
88960445|NCT05003362|Active Comparator|ACT|An 8-week mindfulness-based group therapy.
88960446|NCT04999449|Experimental|Pharmacokinetic|Participants receive 1 dose of Scopolamine 0.4 mg delivered via a intranasal nebulizer developed by Creare LLC.
88960447|NCT04999449|Experimental|Chair|Participants receive 1 dose of Scopolamine 0.2 mg, 1 dose of Scopolamine 0.4 mg, and 1 dose of placebo saline delivered via the Creare LLC intranasal nebulizer. These dosages are all 1 week apart and the order is randomized.
88960448|NCT04988022|Experimental|Dupilumab|dupilumab 600mg loading dose at Baseline (given as two 300 mg injections) followed by one 300mg weekly subcutaneous injection through Week 52.
88960449|NCT04988022|Placebo Comparator|Placebo|matching placebo loading dose at Baseline (given as two injections) followed by one weekly subcutaneous injection through Week 24. Starting at Week 24, dupilumab 600mg loading dose (given as two 300 mg injections) followed by one 300mg weekly subcutaneous injection through Week 52.
88960450|NCT04971187|Experimental|Treatment (bintrafusp alfa, pemetrexed, carboplatin/cisplatin)|Patients receive bintrafusp alfa IV over 1 hour on day 1 and pemetrexed IV over 10 minutes on day 1. Patients also receive carboplatin IV over 15 minutes or cisplatin IV over 6-8 hours at the physician's discretion on day 1 of cycles 1-4. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
88960451|NCT04953442|Experimental|Intervention|Fitbit Device Self-Determination Theory Text Messages
88960452|NCT04953442|No Intervention|Wait List Control|Informational flyer of evidence-based strategies on engaging in healthy physical activity and sleep lifestyle habits.
89207373|NCT00969033|Experimental|CS-1008 with irinotecan|CS-1008 and irinotecan
89207374|NCT00969033|Active Comparator|irintoecan|irinotecan alone
89207375|NCT00965601|Active Comparator|CTB Group|Subjects will receive workbook assignments a series of six phone intervention interviews of Cognitive Behavioral Therapy (CBT)
89024610|NCT00433394|Experimental|Stratum 3: Consent for personal identification - Contact|Data will be collected for this study include:child's name, parent's name, address, telephone number, child's date of birth, race, ethnicity, histology, primary site, treating hospital, and institutional principal investigator. Data will be coded using the North American Association for Central Cancer Registries (N.A.A.C.C.R.) data standards for cancer registries Someone from the Childhood Cancer Research Network may contact me in the future to ask me to consider taking part in Research Network approved studies
89024611|NCT00472134|Active Comparator|Bupivicaine via Elastomeric pump|Bupivicaine via elastomeric pump
89024612|NCT00472134|Placebo Comparator|Placebo via elastomeric pump|Placebo via elastomeric pump
89513920|NCT03475537|Experimental|the treatment of transcranial direct current stimulation|Direct current was applied by a battery-driven constant current stimulator using saline-soaked surface sponge electrodes (7×5 cm) with the anode positioned over the left dorsolateral prefrontal cortex (F3 according to the 10-20 international system for EEG placement) and the cathode placed over the right supraorbital region. During real tDCS, the current was increased to 2 mA from the onset of stimulation and applied for 20 minutes.
89207376|NCT00965601|No Intervention|Usual Care|Subjects will not receive any type of intervention
89207377|NCT00573768|Active Comparator|1|
89513921|NCT03131011|Experimental|Arm 1 - UV ink|Radiotherapy tattoos will be applied using an invisible UV fluorescent ink that can only be detected while illuminated with a special ultraviolet flashlight.
89513922|NCT03131011|No Intervention|Arm 2 - Black ink|Radiotherapy tattoos will be applied using standard black ink.
89513923|NCT03130933|Active Comparator|The first tested subgroup|The tested subgroup from the main group without prior inflammation received a prophylactic single dose of 4 x Amoxicillin 500 Mg one hour prior the lower third molar surgery.
89513924|NCT03130933|Placebo Comparator|The first control subgroup|The control subgroup from the main group without prior inflammation received a placebo one hour prior the lower third molar surgery .
89513925|NCT03130933|Active Comparator|The second tested subgroup|The tested subgroup from the main group with prior inflammation received a prophylactic single dose of 4 x Amoxicillin 500 Mg one hour prior the lower third molar surgery .
89513926|NCT03130933|Placebo Comparator|The second control subgroup|The control subgroup from the main group with prior inflammation received a placebo one hour prior the lower third molar surgery .
89513927|NCT05155969|Experimental|Eskatamine group|Low-dose esketamine (0.3 mg/kg in 100 ml normal saline) is intravenously infused in 40 minutes before anesthesia induction
89513928|NCT05155969|Placebo Comparator|Placebo group|Placebo (40 ml normal saline) is intravenously infused in 40 minutes before anesthesia induction.
89513929|NCT03784417|Experimental|EUS-guided laser ablation|Laser ablation will be performed using a 1064-nm wavelength laser with the insertion of a 300-μm optical fiber through a 22-gauge needle under endoscopic ultrasonography guidance.
89513930|NCT03472183|Other|Patients with Alzheimer's disease|During the course of the colonoscopy that the patients should have in the context of their usual medical care, additional biopsies of colon will be removed to perform in vitro analysis for this study.
89513931|NCT03472183|Other|Patients with Parkinson's disease|During the course of the colonoscopy that the patients should have in the context of their usual medical care, additional biopsies of colon will be removed to perform in vitro analysis for this study.
89513932|NCT03472183|Other|Patients without neurodegenerative disease|During the course of the colonoscopy that the patients should have in the context of their usual medical care, additional biopsies of colon will be removed to perform in vitro analysis for this study.
89513933|NCT03472105|Other|Habitual diet|18 participants were on a habitual diet for 7 days
89513934|NCT03472105|Active Comparator|New Nordic Renal Diet|18 participants were given a New Nordic Renal Diet for 7 days
89513935|NCT02523157|Experimental|Intervention|Wellbeing Plan
89513936|NCT02523157|Active Comparator|Control|Control task. Information about physical health in pregnancy, matched for readability (Flesch score) and length/duration with the Wellbeing Plan
89513937|NCT05112913|Experimental|Inactivated SARS-CoV-2 vaccine Lot 1 of the workshop 2|360 Participants aged 3-17 years(including 52 children aged 3-5 years,154 children aged 6-11 years and 154 adolescents aged 12-17 years) will receive Inactivated SARS-CoV-2 vaccine Lot 1 of the workshop 2 according to 0,28-day immunization schedule.
89513938|NCT05112913|Experimental|Inactivated SARS-CoV-2 vaccine Lot 2 of the workshop 2|360 Participants aged 3-17 years(including 52 children aged 3-5 years,154 children aged 6-11 years and 154 adolescents aged 12-17 years) will receive Inactivated SARS-CoV-2 vaccine Lot 2 of the workshop 2 according to 0,28-day immunization schedule.
89513939|NCT05112913|Experimental|Inactivated SARS-CoV-2 vaccine Lot 3 of the workshop 2|360 Participants aged 3-17 years(including 52 children aged 3-5 years,154 children aged 6-11 years and 154 adolescents aged 12-17 years) will receive Inactivated SARS-CoV-2 vaccine Lot 3 of the workshop 2 according to 0,28-day immunization schedule.
89513940|NCT05112913|Experimental|Inactivated SARS-CoV-2 vaccine Lot 1 of the workshop 3|360 Participants aged 3-17 years(including 52 children aged 3-5 years,154 children aged 6-11 years and 154 adolescents aged 12-17 years) will receive Inactivated SARS-CoV-2 vaccine Lot 1 of the workshop 3 according to 0,28-day immunization schedule.
89207378|NCT00573768|Placebo Comparator|2|
89207379|NCT00573768|Active Comparator|3|
89207380|NCT00969189||Children|between 10 and 30 kgs
89207381|NCT00969189||Infants|between 5 - 10 kg
89207382|NCT04042428|Experimental|Treatment group|Subjects receive a 14-day treatment. A 450 mL blood sample is extracted 6 hours after the last administration (day 14).
89207383|NCT04042428|No Intervention|Control group|Subjects do not receive any treatment. A 450 mL blood sample is extracted at baseline.
89207384|NCT02546076|Active Comparator|Laser coagulation|Er:YAG laser treatment with coagulation modality
89207385|NCT02546076|Active Comparator|Laser w/o coagulation|Er:YAG laser treatment without coagulation modality
89207386|NCT02415387|Experimental|Arm I (inactive typhoid vaccine, placebo)|Patients receive inactive typhoid vaccine IM at visit 1 followed by placebo IM 30 days later at visit 2.
89207387|NCT02415387|Placebo Comparator|Arm II (placebo, inactive typhoid vaccine)|Patients receive placebo IM at visit 1 followed by inactive typhoid vaccine IM 30 days later at visit 2.
89207388|NCT00850356||Bariatric Surgery Patient (Sx)|Participants who are patients in an Adult Weight Management Clinic (AWMC) and undergo bariatric surgery.
88960453|NCT04938440||Prescribers of Instanyl®|Healthcare professionals (Oncologists, oncoradiologists, anaesthesiologists, pain management prescribers, palliative care prescribers, internal medicine prescribers, general practitioners and other specialties) who are current and potential prescribers of Instanyl® will be assessed before and after the distribution of the updated EMs via web-based survey questionnaire.
88960454|NCT04936451|Other|TENS / TENS ECOMODYN|Patients who have signed their consent receive, after randomization, the trial treatments assigned to them. Arm TENS / TENS ECOMODYN Patients first start with TENS during 2 months puis change with TENS ECOMODYN during 2 months with a wash-out period of 15 days
88960455|NCT04936451|Other|TENS ECOMODYN / TENS|Patients who have signed their consent receive, after randomization, the trial treatments assigned to them. Arm TENS ECOMODYN / TENS Patients first start with TENS ECOMODYN during 2 months puis change with TENS during 2 months with a wash-out period of 15 days
88960456|NCT04929379|Experimental|Fenofibrate|145 mg oral fenofibrate daily for 76 weeks. Dosage is decreased to 48 mg daily if iGFR is or is estimated to be below 30 ml/min/1.73 m2.
88960457|NCT04929379|Placebo Comparator|Placebo|Inactive tablets identical to fenofibrate
88960458|NCT04929080|Experimental|JS004 200mg, Q3W until to 2 years|Part A: phase I: 3-6; phase II: 66.
88960459|NCT04929080|Experimental|JS004 600mg, Q3W until to 2 years|Part A: phase I: 3-6; phase II: 66.
88960460|NCT04929080|Experimental|240mg JS001+100mg JS004, Q3W until to 2 years|Part B: phase I: 6; phase II: 68.
89207389|NCT00850356||Medical Treamtent (Mx)|Participants who are patients in the same AWMC as above and are currently undergoing a medical treatment program that includes intensive lifestyle counseling (diets, exercise, behavioral modification).
89513941|NCT05112913|Experimental|Inactivated SARS-CoV-2 vaccine Lot 2 of the workshop 3|360 Participants aged 3-17 years(including 52 children aged 3-5 years,154 children aged 6-11 years and 154 adolescents aged 12-17 years) will receive Inactivated SARS-CoV-2 vaccine Lot 2 of the workshop 3 according to 0,28-day immunization schedule.
89513942|NCT05112913|Experimental|Inactivated SARS-CoV-2 vaccine Lot 3 of the workshop 3|360 Participants aged 3-17 years(including 52 children aged 3-5 years,154 children aged 6-11 years and 154 adolescents aged 12-17 years) will receive Inactivated SARS-CoV-2 vaccine Lot 3 of the workshop 3 according to 0,28-day immunization schedule.
89513943|NCT05112913|Active Comparator|Inactivated SARS-CoV-2 vaccine Lot 1 of the workshop 1|360 Participants aged 3-17 years(including 52 children aged 3-5 years,154 children aged 6-11 years and 154 adolescents aged 12-17 years) will receive Inactivated SARS-CoV-2 vaccine Lot 1 of the workshop 1 according to 0,28-day immunization schedule.
89513944|NCT02523781|No Intervention|Control group|The control group does not receive the information pamphlet
89513945|NCT02523781|Experimental|Intervention group|The intervention group receives the information pamphlet
89513946|NCT03475459|Experimental|study drug|Study drug (NPC-15 and/or Placebo ) will be orally administered once with 200 ml of water at 20:00 on the first days of Period I, Period II and Period III.
89513947|NCT03478111|Experimental|CMAB008+MTX|"Drug: CMAB008 (recombinant chimeric anti-TNF-α monoclonal antibody injection) infusion of 3mg/kg in Week 0, 2, 6, 14, 22, 30.~Drug: MIX (methotrexate) will be oral administered at a dose of 7.5mg~15mg weekly from Week 0 to 38."
89513948|NCT03478111|Active Comparator|Remicade+MTX|"Drug: Remicade (recombinant chimeric anti-TNF-α monoclonal antibody injection) infusion of 3mg/kg in Week 0, 2, 6, 14, 22, 30.~Drug: MIX (methotrexate) will be oral administered at a dose of 7.5mg~15mg weekly from Week 0 to 38."
89513949|NCT03478033|Active Comparator|Rifampicin group|"Rifampicin group: Intensive treatment（4 types of anti-TB medicines）for 2 months, then isoniazid and rifampicin for 4 months of consolidation therapy.~isoniazid: 10-15mg/kg rifampicin: 10-20mg/kg pyrazinamide: 30-40mg/kg thambutol: 0.75(W<50kg)；1.0 g/d（W≥50kg）"
89513950|NCT03478033|Experimental|Rifabutin group|"Rifabutin group: Intensive treatment（4 types anti-TB medicines）for 2 months,then isoniazid and rifabutin for 4 months of consolidation therapy.~isoniazid: 10-15mg/kg rifabutin: 0.45g/d(W<50kg); 0.6g/d( W≥50kg） pyrazinamide: 30-40mg/kg thambutol: 0.75(W<50kg)；1.0 g/d（W≥50kg）"
89513951|NCT03477955|Active Comparator|Peek Group|Patients that received PEEK interspinous spacer
89513952|NCT03477955|Active Comparator|Silicon Group|Patients that received Silicon interspinous spacer and did not receive PEEK interspinous spacer
89513953|NCT03477955|Active Comparator|Control Group|Patients that did not receive PEEK interspinous spacer nor Silicon interspinous spacer
89513954|NCT03477877|Experimental|Indashyikirwa|Sectors which receive the full Indashyikirwa programme, including (1) couples training and activist training and support by RWAMREC, and (2) opinion leader training and establishment of women's spaces by the Rwanda Women's Network.
89513955|NCT03477877|Active Comparator|VSLA Only|Sectors that continue to receive only the village savings and loan association (VSLA) programmes offered by CARE Rwanda
89513956|NCT03477799|Active Comparator|Active|anodal stimulation over the right dlPFC
89513957|NCT03477799|Placebo Comparator|Sham|sham stimulation over the right dlPFC
89513958|NCT03477721||Group with cancer cachexia (CTB)|For diagnosis of cachexia it will be used the following criteria (Evans et al., 2008)
89513959|NCT03477721||Group without cancer cachexia (TB)|
89513960|NCT05231551||Single-group study|Patients having first trimester voluntary termination of pregnancy in Montpellier university hospital.
89513961|NCT03477643||Refractory Multiple Myeloma|Patients with relapsed and refractory multiple myeloma who have received treatment with pomalidomide, cyclophosphamide, and dexamethasone following the GEM-PETHEMA clinical practice guidelines between 01/01/2015 to 01/04/2018
89513962|NCT03477565|Experimental|Sperimental group|"Patients who belong to the sperimental group (SPER) will receive the standard treatment and Kinesio tape lymphatic drainage technique application.~The experimental group also receives the expected standard treatment, consisting in physiotherapeutic evaluation and physiotherapy counseling."
89207390|NCT00850356||Wait-List (Wx)|Participants who are on the Wait-List for the AWMC, and waiting to undergo medical treatment program and/or bariatric surgery.
89207391|NCT00969267|Experimental|Stimulation A|with needle A stimulation
89541440|NCT03486444|Experimental|Patient population|When a patient receives an ultrasound examination as part of standard of care or within another clinical research trial, such an examination may serve for an intra-individual comparator examination between conventional and new, ultra-portable ultrasound imaging. Patients will be identified in the clinical setting when appropriate and will be appropriately approached for consent for a combination of ultrasound with the physical exam, for medical student education, IV access, and novel application. Patients will be enrolled and accounted for in the appropriate sub-population.
89541441|NCT03486444|Experimental|Healthy volunteer population|The volunteer population will allow us to practice the use of this equipment and understand the limitations and applicability. The results will be the images acquired as well as surveys from the volunteers and those performing the scans, who will be enrolled in the staff population of this study.
89541442|NCT03486444|Experimental|Student and staff population|To understand the impact of ultraportable ultrasound, survey tools will be used to understand the workflow and clinical care applications and integration of these devices. All staff and student members will be appropriately consented; however, we anticipate that this portion of the study will be minimal risk.
89541443|NCT03484923|Experimental|Arm 1: LAG525 + PDR001 (randomized section)|Participnats randomized to receive LAG525 at a dosage of 600 mg administered intravenously every 4 weeks, in combination with PDR001 at a dosage of 400 mg administered intravenously every 4 weeks
89541444|NCT03484923|Experimental|Arm 2: INC280+PDR001 (randomized section)|Participants randomized to receive INC280 orally at a dosage of 400 mg twice daily, in combination with PDR001 intravenously at a dosage of 400 mg every 4 weeks
89541445|NCT03484923|Experimental|Arm 3: ACZ885 + PDR001 (randomized section)|Participants randomized to receive to receive ACZ885 at a dosage of 300 mg administered subcutaneously every 4 weeks, in combination with PDR001 at a dosage of 400 mg administered intravenously every 4 weeks
89541446|NCT03484923|Experimental|Arm 4: LEE011 + PDR001 (randomized section)|Participants randomized to receive LEE011 orally at a dosage of 600 mg once daily on Days 1-21 of a 28-day cycle, in combination with PDR001 intravenously at a dosage of 400 mg every 4 weeks
89541447|NCT03484923|Experimental|Arm 1A: LAG525 + PDR001 (non-randomized section)|LAG-3 positive participants received LAG525 at a dosage of 600 mg administered intravenously every 4 weeks, in combination with PDR001 at a dosage of 400 mg administered intravenously every 4 weeks
89541448|NCT03479502|Active Comparator|Methylprednisolone|Patients meeting the inclusion criteria will be randomized into either the control group of intra-articular injection of 40mg Methylprednisolone once every 2 two weeks for 4 weeks (day 1, week 2, week 4) with 20 patients in each group. Injections will be administered by the treating physician.
89541449|NCT03479502|Active Comparator|Doxycycline|Patients meeting the inclusion criteria will be randomized or the experimental group of intraarticular injection of 50 mg doxycycline once every 2 two weeks for 4 weeks (day 1, week 2, week 4), with 20 patients in each group. Injections will be administered by the treating physician.
89541450|NCT03471364|Experimental|Arm I (ketoconazole)|Participants apply ketoconazole topically BID on days 1-28.
89541451|NCT03471364|Placebo Comparator|Arm II (placebo)|Participants apply placebo topically BID on days 1-28.
89541452|NCT03461159|Experimental|H-reflex conditioning - Healthy|Operant conditioning of H-reflexes in healthy volunteers
89541453|NCT03461159|Experimental|H-reflex conditioning - Stroke|Operant conditioning of H-reflexes in people post-stroke
89541454|NCT03461159|Experimental|MEP conditioning - Healthy|Operant conditioning of motor evoked potentials in healthy volunteers
89541455|NCT03461159|Experimental|MEP conditioning - Stroke|Operant conditioning of motor evoked potentials in people post-stroke
89024613|NCT00433433|Active Comparator|Favorable - Standard - any PET outcome|ABVDx3 cycles + Involved node RT (IN-RT) 30 Gy (+boost of 6Gy to residual lesions); FDG-PET after two cycles of ABVD for comparison with the experimental arm will be performed but no treatment adaptation will take place.
89024614|NCT00433433|Experimental|Favorable - Experimental - PET negative|"ABVDx2 cycles; then FDG-PET evaluation:~PET negative: ABVDx2 without further RT (total of 4 cycles!)"
89024615|NCT00433433|Experimental|Favorable - Experimental - PET positive|"ABVDx2 cycles; then FDG-PET evaluation:~PET positive: presumed poor-risk: switch to escalated BEACOPPx2 + INRT30Gy (+boost 6Gy to residual lesions)."
89541456|NCT03456895|Experimental|Healthy volunteer population|"Healthy volunteer participants will have one of two options for participation:~completion of an electronic survey tool to assess the perception and preference of environmental factors (virtual participation)~completion of the above survey and participation in environmental experiences and providing feedback about their experience (physical participation)"
89541457|NCT03456895|Experimental|Patient population|Patient participants will complete a survey tool and either participate in specific environmental experience testing or may be exposed to an environmental experience during the imaging examination. The imaging exam will be assessed in regard to quality factors such as motion artifacts as an indicator of being relaxed during the examination.
89541458|NCT03456895|Experimental|Staff population|Staff participants who work in imaging-related healthcare environments will complete survey tools regarding their perception and preference of environmental factors and/or will participate in environmental experiences and provide feedback.
89541459|NCT03433469|Experimental|Treatment (osimertinib)|Participants receive 80mg osimertinib orally, once a day (PO QD) on days 1-28. Treatment repeats every 28 days for a minimum of 1 cycle prior to surgery in the absence of disease progression or unacceptable toxicity. Investigators will have the option to give a second cycle of study drug prior to surgery if clinically indicated. Depending on the timing of the final scans, patients may ultimately receive up to two weeks additional therapy with study drug beyond end of cycle 1 (or cycle 2) while awaiting surgery. Patients then undergo surgical resection of their cancer. No treatment with the study drug will be given after surgery.
89541460|NCT03427736||Drug of Interest|Individuals receiving anesthetics or analgesics per standard of care
89541461|NCT03397342|No Intervention|standard breath hold|"Breath-hold CT and 4D-CT without CPAP~Breath-hold MRI and 4D-MRI without CPAP a) T1-weighted, T2-weighted, Dixon fat/water, and ultra-short TE images"
89541462|NCT03397342|Experimental|CPAP intervention|"Breath-hold CT without CPAP~4D-CT with and without CPAP~4D-MRI with CPAP~T1-weighted, T2-weighted, Dixon fat/water, and ultra-short TE images"
89541463|NCT03387618|Experimental|Investigational Scan|new-generation digital PET/CT imaging technology
89513963|NCT03477565|No Intervention|Control group|"Patients who belong to the control group (CONTR) will receive only the standard treatment. Standard treatment consists in physiotherapy evaluation and counseling. The educational part, the demonstration of the exercises and the prosthesis mobilization are included in this treatment."
89513964|NCT03477487|Experimental|Lowest dose|The lowest dose of XT-150 in the escalation schedule
89513965|NCT03477487|Experimental|Second dose|The 2nd dose of XT-150 in the escalation sequence
89513966|NCT03477487|Experimental|Third dose|The 3rd dose of XT-150 in the escalation sequence
89513967|NCT03477487|Experimental|Highest dose|The highest dose of XT-150 in the escalation sequence
89513968|NCT03477409||Neonatal intensive care patients|The purpose of this biomonitoring study consists to evaluate the exposure of newborns and premature babies hospitalized in NICU to these plasticizers (DEHT and TOTM), by qualitative and quantitative measurement of their urinary metabolites
89513969|NCT05189197|Experimental|Experimental: Zanubrutinib + R-CHOP|"Zanubrutinib 160 mg bis in die（BID） administered by oral every day of each 21-day cycle. Rituximab 375 mg/m2, Cyclophosphamide 750 mg/m2, Doxorubicin 50 mg/m2 and Vincristine 1.4 mg/m2 (maximum total 2 mg) administered by IV infusion on Day 1 of each 21-day cycle.~Prednisone 100 mg administered by oral on Day 1-5 of each 21-day cycle. After 6 cycles of zanubrutinib and R-CHOP combination therapy, patients achieved complete response （CR）will continue to receive zanubrutinib 160mg BID for 1 year."
89513970|NCT03472027|Experimental|BCD-145 Monotherapy Dose Level 1|
89513971|NCT03472027|Experimental|BCD-145 Monotherapy Dose Level 2|
89513972|NCT03472027|Experimental|BCD-145 Monotherapy Dose Level 3|
89513973|NCT03472027|Experimental|BCD-145 Monotherapy Dose Level 4|
89513974|NCT03472027|Experimental|BCD-145 Monotherapy Dose Level 5|
89513975|NCT02505542|Other|Open-label Certolizumab Pegol|Certolizumab Pegol (CZP) 400 mg subcutaneous (sc) on Weeks 0, 2 and 4, followed by 200 mg CZP sc every 2 weeks (Q2W) from Week 6 to Week 48 (Part A). Subjects in sustained remission at Week 48 are eligible for randomization into Part B.
89513976|NCT02505542|Experimental|Double-blind Certolizumab Pegol 200 mg Q2W|Certolizumab Pegol (CZP) 200 mg subcutaneous (sc) every 2 weeks (Q2W) from Week 48 onwards.
89513977|NCT02505542|Experimental|Double-blind Certolizumab Pegol 200 mg Q4W|"Certolizumab Pegol (CZP) 200 mg subcutaneous (sc) every 4 weeks (Q4W) from Week 48 onwards.~At visits where CZP is not received, subjects receive one injection of Placebo to maintain the study blind."
89513978|NCT02505542|Placebo Comparator|Placebo|One placebo injection is administered every 2 weeks from Week 48 onwards.
89513979|NCT02505542|Other|Placebo to CZP 200 mg Q2W escape|Subjects randomized to Placebo who meet flare criteria receive CZP 400 mg subcutaneous (sc) every 2 weeks (Q2W) for the first 3 visits after flare has been confirmed. After that, CZP 200 mg is given every 2 weeks in open-label fashion.
89513980|NCT02505542|Other|CZP 200 mg Q4W to CZP 200 mg Q2W escape|Subjects randomized to CZP 200 mg Q4W who meet flare criteria receive CZP 200 mg subcutaneous (sc) every 2 weeks (Q2W) for all visits after flare has been confirmed. At the first 3 visits after flare has been confirmed, subjects receive one injection of 200 mg CZP and one injection of Placebo to maintain the study blind.
89513981|NCT02505542|Other|CZP 200 mg Q2W to CZP 200 mg Q2W escape|Subjects randomized to CZP 200 mg Q2W who meet flare criteria receive CZP 200 mg subcutaneous (sc) every 2 weeks (Q2W) for all visits after flare has been confirmed. At the first 3 visits after flare has been confirmed, subjects receive one injection of 200 mg CZP and one injection of Placebo to maintain the study blind.
89513982|NCT00701623|Experimental|1|patients treated with heparin
89513983|NCT00701623|Experimental|2|Patients treated with heparin
89513984|NCT00701623|Active Comparator|3|patients treated with folder water directly on the injured area
89513985|NCT03109483|Other|Geriatric Activation Program Pellenberg|intensive multicomponent physical therapy week program
89513986|NCT03471949|Experimental|CGM in a population with normal OGTT|A non-randomized, days 1-7 blinded, and days 8-14 non-blinded Dexcom G4 (CGM) trial. Each subject will sample capillary blood with the HemoCue meter and measure the concentration of glucose, minimum 3 times per day for 14 days.
89513987|NCT04589221||Degree of food processing and food texture|"Processed vs unprocessed foods based on NOVA classification~Soft and hard foods manipulated by cooking method"
89513988|NCT04456153|Experimental|standard of care therapy with atovaquone|The first treatment group will receive continued standard of care therapy together with an oral dose of 1500 mg atovaquone twice daily (administered with a meal or snack) for up to 10 days.
89513989|NCT04456153|Placebo Comparator|standard of care therapy with matching placebo|The second treatment group will receive continued standard of care therapy together with matching placebo.
89513990|NCT02475980||Adolescent girls|Adolescent post-menarchal girls ages 13-18 with Medicaid insurance presenting to a pediatric emergency department for a non-emergent complaint who receive comprehensive contraception counseling
89513991|NCT04403971|Experimental|0.12% chlorhexidine|Participants will be randomized to Chlorhexidine solution group, applied twice a day by care givers.
89513992|NCT04403971|Sham Comparator|Listerine|Participants will be randomized to Listerine solution group, applied twice a day by care givers.
89513993|NCT04403971|Placebo Comparator|Normal saline|Participants will be randomized to Normal saline group, applied twice a day by care givers.
89513994|NCT02447432|Experimental|10Pn_4d Group|Subjects received 10Pn-PD-DIT, in its investigational 4-dose presentation (4 doses in total with each single dose injected at Study Months 0, 1, 3 and 8), co administered with DTPw-HBV/Hib vaccine (3 doses injected at Study Months 0, 1 and 2).
89513995|NCT02447432|Active Comparator|10Pn Group|Subjects received 10Pn-PD-DIT, in its licensed 1-dose presentation (4 doses in total with each single dose injected at Study Months 0, 1, 3 and 8), co administered with DTPw-HBV/Hib vaccine (3 doses injected at Study Months 0, 1 and 2).
89513996|NCT02446886|Active Comparator|One Time Treatment|"MS patients enrolled in this study will be randomized into:~Intervention for Group A: 80 units/day ACTH (H.P. Acthar®)for 3-5 days (The dose could be adjusted based on the individual needs of the patients up to 80-120 units daily for 2-3 weeks.)"
89513997|NCT02446886|Experimental|Monthly Treatments|Intervention for Group B: 80 units/day ACTH (H.P. Acthar®) for 3-5 days (The dose could be adjusted based on the individual needs of the patients up to 80-120 units daily for 2-3 weeks.), followed by monthly 80 units/day ACTH for 3 days for 12 months of treatment.
89513998|NCT04351243|Experimental|Gimsilumab|Gimsilumab 400 mg on Day 1 Gimsilumab 200 mg on Day 8
89513999|NCT04351243|Placebo Comparator|Placebo|Normal saline on Day 1 Normal saline on Day 8
89514000|NCT04164121|Experimental|FLZ-150mg experimental|Oral administration was conducted on an empty stomach, and the drug or placebo was administered once a day on day 1 and 150mg each time from day 8 to day 17.
89514001|NCT04164121|Placebo Comparator|FLZ-150mg placebo|Oral administration was conducted on an empty stomach, and the drug or placebo was administered once a day on day 1 and 150mg each time from day 8 to day 17.
89514002|NCT04164121|Experimental|FLZ-600mg experimental|Oral administration was conducted on an empty stomach, and the drug or placebo was administered once a day on day 1 and 600mg each time from day 8 to day 17.
89514003|NCT04164121|Placebo Comparator|FLZ-600mg placebo|Oral administration was conducted on an empty stomach, and the drug or placebo was administered once a day on day 1 and 600mg each time from day 8 to day 17.
89514004|NCT04164121|Experimental|FLZ-900mg experimental|Oral administration was conducted on an empty stomach, and the drug or placebo was administered once a day on day 1 and 900mg each time from day 8 to day 17.
89514005|NCT04164121|Placebo Comparator|FLZ-900mg placebo|Oral administration was conducted on an empty stomach, and the drug or placebo was administered once a day on day 1 and 900mg each time from day 8 to day 17.
89514006|NCT04132141|Other|VR intervention|each subject will be own control. subjects breaks will be randomly assigned to VR or WT until they complete 3 for each type or a total of 6
89514007|NCT03475303|Experimental|early hospital discharge|women will be discharged early from hospital 12 hours postoperatively after elective cesarean sections.
89514008|NCT05008003|Active Comparator|Standard of care|This arm will receive the standard of care as per the hospital guidelines.
89514009|NCT05008003|Experimental|Investigational treatment|This arm will receive vitamin D3 supplement as add-on to the standard of care.
89514010|NCT03475225|Experimental|Experimental Arm|Drug resistant epilepsy patients with proved Vitamin D deficiency (Serum vitamin D level <30ng/ml) Cholecalciferol. 5 doses of cholecalciferol (100 000 IU) in 3 months than 1 dose of cholecalciferol (100 000 IU) per month during 6 months
89514011|NCT03475225|Placebo Comparator|Control Arm|Drug resistant epilepsy patients with proved Vitamin D deficiency (Serum vitamin D level<30ng/ml) Placebo than cholecalciferol. 5 doses of placebo in 3 months than 5 doses of cholecalciferol (100 000 IU) in 3 months than 1 dose of cholecalciferol (100 000 IU) per month during 3 months.
89514012|NCT03448939|Experimental|S5G4T-1|Participants will topically apply S5G4T-1 cream, once daily to face for 12 weeks.
89514013|NCT03448939|Placebo Comparator|S5G4T-2 Vehicle Cream|Participants will topically apply S5G4T-2 vehicle cream, once daily to face for 12 weeks.
89514014|NCT03433261|No Intervention|Normal Diet|The participant will eat their usual diet for at least 72 hrs prior to the experiment, document their diet during that time and be tested for ketone level immediately prior to the experiment.
89514015|NCT03433261|Experimental|Ketogenic Diet|The participant will follow a ketogenic diet for 72 hrs prior to the experiment and consume a ketone supplement 60 minutes prior to the experiment. They will document their diet and be tested for ketone level immediately prior to the experiment.
89514016|NCT03851107|Experimental|Community-based activity program|Engagement in 6-week community-based activity program
89514017|NCT02504294|Other|Epoetin Hospira|Epoetin Hospira Arm
89514018|NCT02504294|Other|Standard of Care|Standard of care arm
89514019|NCT02446418|Experimental|Fluticasone Furoate/Vilanterol|Subjects will receive FF/VI 92 micrograms (mcg)/22 mcg or FF/VI 184 mcg/22 mcg as decided by the investigator QD via ELLIPTA DPI for 24 weeks.
89514020|NCT02446418|Active Comparator|FP/S OR BUD/F|Subjects will receive FP/S (250 mcg/50 mcg or 500 mcg/50mcg) twice daily via DISKUS or BUD /F (200 mcg/6mcg or 400 mcg/12mcg one or two inhalations) twice daily via TURBUHALER DPI as decided by the investigator for 24 weeks.
89514021|NCT02445794|Experimental|RT001, oral, 1.8 g/day|RT001, oral, 1.8 g QD for 28 days or matching comparator
89514022|NCT02445794|Experimental|RT001, oral, 9 g/day|RT001, oral, 4.5 g BID for 28 days or matching comparator
89514023|NCT02475278|Experimental|NoV Vaccine|Norovirus GI.1/GII.4 bivalent Virus-Like Particle (VLP) vaccine (NoV Vaccine) (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP, adjuvanted with 500 µg aluminum hydroxide), intramuscular (IM) injection, once on Day 1.
89514024|NCT02254486|Experimental|NER1006, 2-Day Split-Dosing|NER1006:2-Day Split-Dosing Regimen (to commence in the evening of the day before the colonoscopy)
89514025|NCT02254486|Active Comparator|Trisulfate Solution, 2-Day Split-Dosing|Trisulfate Solution 2-Day Split-Dosing Regimen (to commence in the evening of the day before the colonoscopy)
89514026|NCT05556538||Those who had TFESI and whose subcutaneous fat index was above the cut-off value|Those who are above the subcutaneous fat index cut-off values (9.4 mm in men, 8.45 mm in women) will be included in this group.
89514027|NCT05556538||Those who had TFESI and whose subcutaneous fat index was below the cut-off value|Those who are below the subcutaneous fat index cut-off values (9.4 mm in men, 8.45 mm in women) will be included in this group.
89514028|NCT04859062|Placebo Comparator|control|no lidocaine gel 2% is applied
89514029|NCT04859062|Experimental|lidocaine group|the lidocaine gel 2% is applied to the operative eye preoperatively
89514030|NCT05538598|Experimental|Intramuscular Dry Needling|IMDN will be performed at the sacral multifidus and fibularis longus muscles.
89514031|NCT05645770||coronary artery disease|
89514032|NCT05645770||control|
89514033|NCT01641640|Experimental|Sofosbuvir+PEG+RBV|
89514034|NCT05644678|Active Comparator|Conventional treatment|Patients will be treated using the fixed appliances to track the impacted canines after opening the appropriate distance
89514035|NCT05644678|Experimental|Surgically-assisted treatment|Patients will be treated using fixed appliances assisted by minimally-invasive corticotomy (alveolar perforations and piezocision) to accelerate impacted canines' traction after opening the appropriate distance.
89514036|NCT05650762|Experimental|Cinnamon|
89514037|NCT04419922||Smartphone Contingency Management Arm|100 participants will be voluntarily recruited at BrightView's Colerain outpatient treatment center to participate in the Smartphone Contingency Management Intervention.
89541464|NCT03382548|Active Comparator|Short antibiotic treatment duration for VAP (7 days or less)|
89541465|NCT03382548|Active Comparator|Long antibiotic treatment duration for VAP ( 8 days or more)|
89541466|NCT03371225|Experimental|Active tDCS and Active Exercise|Active tDCS for 20 min Active exercise (60-70% max HR) for 30 min
89541467|NCT03371225|Active Comparator|Sham tDCS and Active Exercise|Sham tDCS for 20 min Active exercise (60-70% max HR) for 30 min
89541468|NCT03371225|Active Comparator|Active tDCS and Sham Exercise|Active tDCS for 20 min Sham exercise (within 10% baseline HR) for 30 min
89541469|NCT03371225|Sham Comparator|Sham TDCS and Sham Exercise|Sham tDCS for 20 min Sham exercise (within 10% baseline HR) for 30 min
89541470|NCT03370718|Experimental|Treatment (cabozantinib)|Patients receive cabozantinib PO QD in the absence of disease progression or unacceptable toxicity.
89541471|NCT03369821||Study 1: Existing EET1D (Case)|"Aged 0 to 70 years~Clinical diagnosis of diabetes <24 months (+ evidence of WHO diabetes criteria)~Negative genetic test for mutations causing non-autoimmune neonatal diabetes if diagnosed <12 months~Type 1 diabetes genetic risk score >50th centile of T1D reference group, or monogenic cause of T1D (e.g. STAT3 or FOXP3 mutation)."
89541472|NCT03369821||Study 1: T1D (Control)|"Age 0-70 years (matched to above)~Clinical diagnosis of T1D (diagnosed age 1-20 years)~Insulin treated from diagnosis."
88960461|NCT04929080|Experimental|240mg JS001+200mg JS004, Q3W until to 2 years|Part B: phase I: 6; phase II: 68.
89541473|NCT03369821||Study 2: Newly diagnosed EET1D (Case)|"Aged 0 to 24 months at recruitment~Clinical diagnosis of diabetes <24 months (+ evidence of WHO diabetes criteria)~Negative genetic test for mutations causing non-autoimmune neonatal diabetes~Type 1 diabetes genetic risk score >50th centile of T1D reference group, or monogenic cause of T1D (e.g. STAT3 or FOXP3 mutation)"
89541474|NCT03369821||Monogenic / NDM (Control)|"Diagnosis of diabetes <24 months~Age 0 to 24 months at recruitment~Diagnosis of Monogenic / NDM (confirmed by Exeter Molecular Genetics Laboratory)."
89541475|NCT03369821||Without diabetes (Control)|"Aged 0-6 years~Attending specified participating hospital sites for elective surgery, including but not limited to: inguinal hernia repair, umbilical/midline hernia repair, orchidopexy, gastrostomy insertion/change, hypospadias repair, cleft palate repair, excision of accessory digit, laryngoscopy, adenoidectomy, tonsillectomy, MRI under general anaesthesia, eye surgery.~Should recruitment be slower than anticipated, we would recruit children with congenital non-immune thyroid disease when they attend paediatric clinic for blood draw."
89207392|NCT00969267|Active Comparator|Stimulation B|with stimulation
88960462|NCT04923243||Delirium group|Group of patients with postoperative delirium
89207393|NCT00969267|Sham Comparator|Stimulation C|without needle
89207394|NCT00850434|Experimental|modified autoset|the modified AutoSet responds to different breathing patterns than the standard AutoSet, to treat OSA. Participants in this arm will trial the modified AutoSet for one night, and the standard AutoSet for one night, in a randomised order
88960463|NCT04923243||Non delirium group|Group of patients without postoperative delirium
88960464|NCT04922502|Active Comparator|Standard SPACE|12 one hour parent sessions over 12 weeks in which the therapist guides the parent to target anxious behaviors and support adaptive child behaviors.
88960465|NCT04922502|Active Comparator|Bibliotherapy, low therapist contact SPACE|"4 one hour parent sessions over 12 weeks in which the therapist supports the parent in understanding and implementing content reviewed in the book Breaking Free of Child Anxiety and OCD."
89024616|NCT00433433|Active Comparator|Unfavorable - Standard - Any PET outcome|ABVDx4 cycles + IN-RT 30Gy (+boost 6Gy to residual lesions). FDG-PET after two cycles of ABVD for comparison with the experimental arm will be performed but no treatment adaptation will take place.
89024617|NCT00433433|Experimental|Unfavorable - Experimental - PET negative|"ABVDx2 cycles; then FDG-PET evaluation:~PET negative: ABVDx 4 cycles, without RT (total of 6 cycles)"
89024618|NCT00433433|Experimental|Unfavorable - Experimental - PET positive|"ABVDx2 cycles; then FDG-PET evaluation:~PET positive: presumed poor-risk: switch to escalated BEACOPPx2 + INRT 30Gy (+boost 6Gy to residual lesions)."
89024619|NCT00463905|No Intervention|1|Current management for identifying postmenopausal women with osteoporotic vertebral fractures in primary care i.e. nothing
89207395|NCT00850434|Active Comparator|standard AutoSet|The standard autoset treat OSA by using pressure increases to overcome abnormal breathing patterns. Patients in this arm will use the standard AutoSet for one night and the modified AutoSet for one night, in a randomised order
89514038|NCT05650216|Experimental|Immunotherapy combined with Chemoradiotherapy|"A:Chemotherapy: nab-paclitaxel (80mg/m2), carboplatin (AUC=2)，on day 1,8,15,22,29;~B:Immunotherapy: camrelizumab (200mg)，IV on days 5 and 26;~C:Radiotherapy: Primary lesion and adjacent lymph nodes: 41.4Gy, 1.8Gy/23f; Abscopal lymph node 2Gy, 0.5Gy/4f.~D:Ivor-Lewis or McKeown esophagectomy~The participants will receive preoperative A+B+C. 4-6 weeks after completion of preoperative therapy ，D will be performed if there is no contraindication."
89514039|NCT05092672|Experimental|High traffic-related air pollution first|Participants will exercise in an environment with high levels of traffic-related air pollution first. Afterwards, participants will complete the same exercise in an environment with low levels of traffic-related air pollution.
89514040|NCT05092672|Experimental|Low traffic-related air pollution|Participants will exercise in an environment with low levels of traffic-related air pollution first. Afterwards, participants will complete the same exercise in an environment with high levels of traffic-related air pollution.
89514041|NCT04419610|Experimental|Patients with confirmed/suspected C19 given intervention|Intravenous infusion of either placebo or TRV027 at 12mg/hr. Treatment will continue until discharge or for 7 days (whichever is sooner).
89514042|NCT04419610|Placebo Comparator|Patients with confirmed/suspected C19 given no intervention|Saline infusion.
89514043|NCT05466526|Experimental|The participants who received HFDS|All participants in the arm were suffering from primary open-angle glaucoma and were indicated for surgery due to either progression of field defect and raised intraocular pressure above 21 mmHg in spite of maximum medical treatment or for patients who were not compliant patient to their medical treatment.
89514044|NCT05369650|Experimental|Lidocaine 1 group|After induction of anesthesia, 1% lidocaine 1.5mg/kg (ideal body weight, 10min pumped) was injected intravenously with a micro pump, and then 1% lidocaine 1mg/kg.h (ideal body weight) was continuously pumped until the end of the operation , connected to patient-controlled intravenous analgesia (PCIA) pump containing lidocaine 0.3-1.5mg/kg.h after operation to 72h after operation.
89514045|NCT05369650|Experimental|Lidocaine 1.5 group|After induction of anesthesia, 1% lidocaine 1.5mg/kg (ideal body weight, 10min pumped) was injected intravenously with a micro pump, and then 1% lidocaine 1.5mg/kg.h (ideal body weight) was continuously pumped until the end of the operation , connected to patient-controlled intravenous analgesia (PCIA) pump containing lidocaine 0.3-1.5mg/kg.h after operation to 72h after operation.
89514046|NCT05369650|Experimental|Lidocaine 2 group|After induction of anesthesia, 1% lidocaine 1.5mg/kg (ideal body weight, 10min pumped) was injected intravenously with a micro pump, and then 1% lidocaine 2mg/kg.h (ideal body weight) was continuously pumped until the end of the operation , connected to patient-controlled intravenous analgesia (PCIA) pump containing lidocaine 0.3-1.5mg/kg.h after operation to 72h after operation.
89514047|NCT05071612|Experimental|AD109 Dose 1|
89514048|NCT05071612|Experimental|AD109 Dose 2|
89514049|NCT05071612|Experimental|AD504 Dose 1|
89514050|NCT05071612|Experimental|AD504 Dose 2|
89514051|NCT05071612|Active Comparator|Atomoxetine 1|
89514052|NCT05071612|Active Comparator|Atomoxetine 2|
89514053|NCT05071612|Placebo Comparator|Placebo 1|
89514054|NCT05071612|Placebo Comparator|Placebo 2|
89514055|NCT01639144|Active Comparator|Receiving PRP and PPP.|Administration of PRP and PPP to surgical site.
89514056|NCT01639144|No Intervention|Control|Group not receiving autogenous PRP and PPP.
89514057|NCT01601626|Experimental|A: Standard-dose LPV/r w/RBT|"ART: lopinavir 400 mg/ritonavir 100 mg twice daily + two nucleoside reverse transcriptase inhibitors.~Anti-TB therapy: isoniazid 300 mg, rifabutin 300 mg, weight-based dosing for ethambutol and pyrazinamide, and pyridoxine 25 mg daily.~After completion of TB treatment through week 72: lopinavir 400 mg/ritonavir 100 mg twice daily + two nucleoside reverse transcriptase inhibitors (NRTIs)."
89514058|NCT01601626|Active Comparator|B: Double-dose LPV/r w/RIF|"ART: lopinavir 800 mg/ritonavir 200 mg twice daily + two nucleoside reverse transcriptase inhibitors.~Anti-TB therapy: isoniazid 300 mg, weight-based dosing for rifampin, ethambutol, and pyrazinamide, and pyridoxine 25 mg daily.~After completion of TB treatment through week 72: lopinavir 400 mg/ritonavir 100 mg twice daily + two nucleoside reverse transcriptase inhibitors (NRTIs)."
89207396|NCT00965835||DS|Those with Down syndrome
89514059|NCT01601626|Experimental|C: Standard-Dose LPV/r w/RBT + RAL|"ART: lopinavir 400 mg/ritonavir 100 mg twice daily + raltegravir 400 mg twice daily + two nucleoside reverse transcriptase inhibitors.~Anti-TB therapy: isoniazid 300 mg, rifabutin 300 mg, weight-based dosing for ethambutol and pyrazinamide, and pyridoxine 25 mg daily.~After completion of TB treatment through week 72: lopinavir 400 mg/ritonavir 100 mg twice daily + two nucleoside reverse transcriptase inhibitors (NRTIs)."
89207397|NCT00965835||Non-DS|Healthy controls
89514060|NCT05428150|Active Comparator|Regimen A|Esbriet® 801 mg (267 mg oral capsule x 3), three times daily (TID) with meals (6 hours apart) for 3 days, total daily dose of 2403 mg, given under fed conditions. Subjects will receive a single dose on Day 4 after breakfast.
89514061|NCT05428150|Experimental|Regimen B|EXCL-100, 1200 mg (600 mg oral tablet x 2), twice daily with meals (BID, every 12 hours) for 3 days, total daily dose of 2400 mg, given under fed conditions. Subjects will receive a single dose on Day 4 after breakfast.
89514062|NCT05643508|Experimental|(D) DWC202206 + DWC202207|
89514063|NCT05643508|Active Comparator|(P+D) DWC202206 + DWC202207|
89514064|NCT05643508|Active Comparator|(D+P) DWC202206 + DWC202207|
89514065|NCT05642728|Experimental|Case management group|
89514066|NCT05642728|No Intervention|Control group|
89514067|NCT02737501|Experimental|Randomized Phase: Brigatinib 90 mg QD/180 QD|Brigatinib 90 mg, tablets, orally, QD for first 7 days followed by 180 mg, orally, QD, in each 28-day cycle until PD, intolerable toxicity, consent withdrawal, or death (The median duration of exposure was 34.86 months).
89514068|NCT02737501|Active Comparator|Randomized Phase: Crizotinib 250 mg BID|Crizotinib 250 mg, tablets, BID in each 28-day cycle until disease progression, intolerable toxicity, consent withdrawal, or death (The median duration of exposure was 9.26 months).
89514069|NCT02737501|Experimental|Crossover Phase: Brigatinib 90 mg QD/180 mg QD|Participants who experienced PD as assessed by the BIRC or received radiotherapy to the brain while on 'Crizotinib 250 mg BID' therapy in Randomized Phase were crossed over. Following 10-day washout period, crossover participants received brigatinib 90 mg, tablets, orally, QD for first 7 days followed by 180 mg, tablets, orally, QD in each 28-day cycle up to end of the study (The median duration of exposure was 17.25 months).
89514070|NCT01640314|Experimental|Cell derived subunit trivalent nonadjuvanted vaccine|
89514071|NCT03471637|Experimental|Compassion-Focused Therapy|"Compassion-Focused Therapy 11 weeks of Compassion-Focused Therapy [based on Compassion-Focused Therapy for Dummies (Welford, 2016)]"
89514072|NCT03471559|Active Comparator|Reference formulation|Cannabidiol capsule, 200 mg
89514073|NCT03471559|Experimental|New formulation|Cannabidiol, intranasal gel (XX mg, dose need to be determined during the study)
89514074|NCT03475069|Experimental|Individual intervention|This exercise program was prepared specific to each patient in this group according to his/her physiotherapy assessment, functional performance tests and body analysis results. This exercise type focuses on patients' physical demands. Exercises were applied by a researcher physiotherapist.
89514075|NCT03475069|Experimental|Plates intervention|Plates exercises were applied as a group treatment. This exercise type contains non-impact exercises to develop strength, flexibility, balance, and inner awareness.Plates exercises were applied as a group treatment. Exercises were applied by a researcher physiotherapist.
89514076|NCT03475069|Experimental|Chalistenics intervention|These exercises included range of motion exercises of neck (flexion, extension, lateral flexion and rotation), shoulder (flexion, extension, abduction, adduction, internal and external rotation), elbow (flexion and extension), forearm (pronation and supination), wrist (flexion and extension), hip (flexion, extension, abduction and adduction, internal and external rotation), knee (flexion and extension), foot (dorsi and plantar flexion, pronation and supination) and trunk (flexion, extension, lateral flexion and rotation). Exercises were applied by a researcher physiotherapist.
89514077|NCT05052034||BAROQUE MUSIC|This group would listen to baroque music to control their anxiety level during their oral surgeries.
89514078|NCT05052034||CLASSICISM MUSIC|this group would listen to classical music to control their anxiety level during their oral surgeries.
89514079|NCT05052034||CONTROL GROUP|This group would not listen to music during their oral intervention, acting as a control group.
89514080|NCT05641480|Experimental|Subjective cognitive decline group|"Studies suggest that acupuncture point Shenting can reduce the levels of serum inflammatory factors IL-6 and TNF-α, and the activity of cholinesterase of these two inflammatory factors is increased, and the activity of cholinacetylase is inhibited, which leads to brain tissue damage, nerve damage and cognitive dysfunction. Shenting（DU24）, Benshen（BG13） and Tou Wei（ST8） are the acupoints on the forehead, which have the effect of awakening the brain. Moreover, after acupuncture, nerve and periosteum effects can be caused, so as to improve cognitive function.~Music therapy is a convenient and efficient method, and as a non-drug intervention, activate the memory to help people with Alzheimer's disease, trigger positive emotions, improve the symptoms of behavior, the moment of life in participants with Alzheimer's disease has great significance, is a good way to help participants with slow disease progression and improve the quality of life, increase happiness of life."
89519534|NCT03447691|Experimental|DES Group|"Desflurane will be administered via tracheal intubation tube at the level of 0.7-1.1 MAC. Remifentanil will be maintained intravenously by continuous infusion rate of 0.01-0.1 mcg / kg / min~DES Group's anesthetic depth will be adjusted to maintain the BIS (Bispectral index) between 40-60. Vital sign will be maintained within the range of ± 20% of the baseline MBP (Mean BP) and HR (Heart Rate)."
89519535|NCT03447691|Active Comparator|TIVA Group|"Propofol and remifentanil will be administered via intravenous, using an infusion pump capable of effect site target controlled infusion.~TIVA Group's anesthetic depth will be adjusted to maintain the BIS (Bispectral index) between 40-60. Vital sign will be maintained within the range of ± 20% of the baseline MBP (Mean BP) and HR (Heart Rate)."
89207398|NCT00855504||Subjects|All the consecutive primigravidae who register in the antenatal clinic before 20 weeks of gestation
89207399|NCT00969345|Sham Comparator|Control Group|Stretching exercises performed twice a day for 10 minutes (4 months)
89207400|NCT00969345|Active Comparator|Respiration Group|Respiratory Yoga exercises performed twice a day for 10 minutes (4 months)
89541476|NCT03367572|Experimental|Group I (netupitant/palonosetron hydrochloride, dexamethasone|Within 1 hour prior to chemotherapy, patients receive netupitant/palonosetron hydrochloride PO on day 1. Within 30 minutes prior to chemotherapy, patients also receive dexamethasone PO on days 1-4. Patients also receive placebo PO with chemotherapy Q8H on days 1-4.
89541477|NCT03367572|Experimental|Group II (net/pal hydro, dexa, prochlorperazine, placebo)|Patients receive netupitant/palonosetron hydrochloride and dexamethasone as in Group I. Patients also receive prochlorperazine PO Q8H and placebo PO with chemotherapy on days 1-4.
89541478|NCT03367572|Experimental|Group III (net/pal hydro, dexa, olanzapine, placebo)|Patients receive netupitant/palonosetron hydrochloride and dexamethasone as in Group I. Patients also receive olanzapine PO and placebo PO Q8H with chemotherapy on days 1-4.
89541479|NCT03332238|Placebo Comparator|Placebo|Patients will receive an injection of vehicle (Ringer's solution) into their supraspinatus muscle and tendon at the time of rotator cuff repair
89541480|NCT03332238|Active Comparator|Cell Therapy|Patients will receive an injection of stromal vascular fraction material suspended in vehicle (Ringer's solution) into their supraspinatus muscle and tendon at the time of rotator cuff repair
89541481|NCT03328091|Active Comparator|Traditional pre-test genetic counseling|"In-person consultation with licensed genetic counselor at the Center for Cancer Genetics and Prevention before genetic testing~Participant is given a pamphlet introducing prostate cancer genes, genetic testing~Participant is sent electronic family history tool~Participant is given the Genetic Testing Information for Decision Making packet. After the genetic counseling session, patient is asked if they would like to proceed with genetic testing."
89541482|NCT03328091|Experimental|Pre-test video education|"Participant is given a pamphlet that describes the basics of prostate cancer genes, genetic testing~Participant is sent electronic family history tool~Participant is approached in clinic by research staff at a pre-planned time~The patient is given the Genetic Testing Information for Decision Making packet~The pre-test video education is a short video. Information will be provided about the basics of genetics and mutations, the potential benefits, risks, and limitations of genetic testing, and the possible results the participant may receive"
89541483|NCT03323151|Experimental|Phase I: Ixazomib & Ibrutinib|Ixazomib and Ibrutinib will be given by mouth until progression or unacceptable toxicity.
89541484|NCT03323151|Experimental|Phase II: Ixazomib & BTK-Naive|Patients who are BTK-Naive will receive Ixazomib and Ibrutinib by mouth until progression or unacceptable toxicity.
89541485|NCT03323151|Experimental|Phase II: Ixazomib & BTK Pre-Treated (Closed 8/7/2020)|Patients previously treated with a BTK will receive Ixazomib and Ibrutinib by mouth until progression or unacceptable toxicity.
89541486|NCT03308578|Experimental|Atorvastatin|Subjects randomized to this arm will be started on a lower dose of atorvastatin 40 mg daily for the first 4 weeks. If they are tolerating this dose without significant problems, atorvastatin will be increased to 80 mg daily.
89541487|NCT03308578|Placebo Comparator|Placebo Oral Capsule|Subjects randomized to this arm will receive placebo capsules matching study drug.
89207401|NCT00850512|Experimental|CHOP21|4 cycles CHOP21-R plus Zevalin
89207402|NCT00969423|Experimental|5 mm equipment|5 mm videoscopic equipment
88960466|NCT04914572|Experimental|Therapeutic rainforest & MIndful walking|The first arm uses mindful walking through a 2km forest trail in Singapore. All Interventional and Control arms will conduct their walk between 8 am to 11 am for five occasions weekly. At the T1, participants will attend a Zoom orientation session to familiarize themselves with the route. During this session, participants will need to answer the self-report questionnaire and provide the first saliva sample for the baseline measurement. In T2, a pre-intervention and post-intervention saliva sample will be taken before the walk. This will follow by T3 the following week. At T4, participants will attend a 60 mins reflection session and answer the self-report questionnaire. On T5 and T6, the participants will continue with the therapeutic rainforest mindfulness walk. On T7, a pre-intervention and post-intervention saliva sample will be taken. On T8, participants will attend a 60 mins reflection session and answer the self-report questionnaire.
89541488|NCT03276832|Experimental|Treatment (pembrolizumab, imiquimod)|Patients receive pembrolizumab IV on day 1 and apply imiquimod cutaneously on days 1-5 (Monday - Friday). Cycles repeat every 21 days for up to 2 years (approximately 35 courses) in the absence of disease progression or unacceptable toxicity. Patients undergo biopsy at baseline, 6 weeks, and 12 weeks and CT, PET/CT, or MRI throughout the trial.
88960467|NCT04914572|Experimental|Therapeutic rainforest walk|The second arm of the intervention includes walking through a guided forest trail suggested by NParks Board. The collection of samples and answering of the self-report questionnaire will follow the same sequence as the 1st arm of the 3-arm RCT.
88960468|NCT04914572|Active Comparator|Campus green walk|The control for this study includes guided casual walking around the campus green trial conducted at the same intervals as per the interventions. The collection of samples and answering of the self-report questionnaire will also follow the same sequence as the 1 arm of the 3-arm RCT.
88960469|NCT04914195|Experimental|Leuprolide acetate 3.75 mg Depot (Luprodex)|Will be administered subcutaneously once a month for two cycles, on day 0 and on day 28/29
88960470|NCT04914195|Active Comparator|Leuprolide acetate 3.75 mg Depot (Lucrin)|Will be administered subcutaneously once a month for two cycles, on day 0 and on day 28/29
88960471|NCT04901299|Experimental|NERATINIB + FULVESTRANT|"After the screening procedures confirm participation in the research study.~- Each Cycle = 28 days~Neratinib (oral, once daily)~Fulvestrant, injection, on 2 days for cycle 1, then one time per cycle thereafter"
88960472|NCT04898075|Experimental|Remote Contingency Management (CM) for nicotine abstinence|Participants will be paid increasing amounts of payment for each negative saliva cotinine test.
88960473|NCT04898075|Placebo Comparator|Control|Participants will be paid for providing saliva nicotine test, regardless of whether the test is positive or negative.
89024620|NCT00463905|Experimental|2|Intervention arm: simple clinical assessment to identify high risk 30% (approximately) who will then be offered lateral thoraco-lumbar X-rays
89207403|NCT00969423|Experimental|10 mm|Use of standard 10 mm VATS equipment
89207404|NCT00850590|Experimental|Low Dose|NRL001 at 5, 7.5, and 10 mg administered in a dose escalating manner with placebo in a random position in the sequence. NRL001 is contained in either a 1 g or a 2 g slow release rectal suppository.
89210549|NCT00819806|Experimental|E|PF-3512676, Montanide ISA 720 VG and the NY-ESO-1 protein will be administered in three separate subcutaneous injections.
89541489|NCT03274258|Experimental|Treatment (nivolumab, ipilimumab)|Patients receive nivolumab IV over 60 minutes and ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients then receive nivolumab IV over 60 minutes on day 1. Courses repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
89541490|NCT03244475|Experimental|Transcranial Electrical Stimulation (TES)|mTBI Veterans blindly assigned to a 6 week of TES, either IASIS neurofeedback treatment or Nexalin, with 2-3 sessions per week.
89541491|NCT03244475|Placebo Comparator|Sham Treatment|mTBI Veterans blindly assigned to a sham treatment for 6 weeks with 2-3 sessions per week.
89541492|NCT03244475|No Intervention|Control|Veterans who are age-, gender-, education-, combat exposure-, and socioeconomically-matched. They will not undergo a treatment.
89541493|NCT03179917|Experimental|Pembrolizumab and Involved Site Radiation Therapy|Following a PET/CT simulation to evaluate the extent of disease, pembrolizumab 200mg IV will be given over 30 minutes on day 1 of each 21 day cycle for a total of 4 cycles. Fourteen to 21 days after the completion of therapy, a PET/CT simulation will be repeated. Pts with complete response will proceed to 20 Gy of ISRT. Pts without a PET CR, but improvement on CT scan will have a repeat biopsy. If the biopsy is negative for Hodgkin Lymphoma, these ps will receive 30 Gy of ISRT. If the biopsy is positive for Hodgkin Lymphoma, they will receive 36-40 Gy ISRT. Pts without a PET CR, but improvement on CT scan will have a repeat biopsy. If the biopsy is negative for Hodgkin Lymphoma, these pts will receive 30 Gy of ISRT. If the biopsy is positive for Hodgkin Lymphoma, they will receive 36-40 Gy ISRT. Pts with new sites of disease or progression on imaging will have a repeat biopsy, per treating physician's discretion & then be treated off study.
89541494|NCT03179631|Experimental|Ataluren|10, 20 milligrams per kilogram (mg/kg)
89541495|NCT03179631|Placebo Comparator|Placebo|10, 20 mg/kg
89541496|NCT03171246|Experimental|CD-TREAT (Solid food-based intervention)|"Solid food-based dietary intervention replicating composition of exclusive enteral nutrition (EEN).~Daily for up to 12 weeks."
89541497|NCT03146650|Experimental|Treatment (nivolumab, ipilimumab)|Patients receive nivolumab IV over 30 minutes on days 1, 15, 29, 43, 57, and 71 of course 1 and on days 1 and 15 of course 2, over 60 minutes on days 29 and 57 of course 2 and on days 1, 29, and 57 of subsequent courses. Patients also receive ipilimumab over 90 minutes on days 1 and 43. Courses repeat every 84 days in the absence of disease progression or unexpected toxicity.
89541498|NCT03132532|Experimental|Arm A (platinum doublet chemotherapy, lower dose PBT)|Patients receive platinum based doublet chemotherapy consisting of low dose carboplatin and paclitaxel, standard etoposide cisplatin or carboplatin or standard pemetrexed with cisplatin or carboplatin weekly for up to 6 weeks at the discretion of the treating medical oncologist. Patients also undergo lower dose proton beam radiation therapy daily for a total of 60 Gy for up to 30 weekdays in the absence of disease progression or unacceptable toxicity.
89541499|NCT03132532|Experimental|Arm C (platinum doublet chemotherapy, higher dose PBT)|Patients receive platinum based doublet chemotherapy consisting of low dose carboplatin and paclitaxel, standard etoposide cisplatin or carboplatin or standard pemetrexed with cisplatin or carboplatin weekly for up to 6 weeks at the discretion of the treating medical oncologist. Patients also undergo higher dose proton beam radiation therapy daily for a total of 72 Gy for up to 36 weekdays in the absence of disease progression or unacceptable toxicity.
89541500|NCT03131908|Experimental|GSK2636771 + Pembrolizumab|"Phase I: Participants receive the lowest dose level of GSK2636771. Each new group receives a higher dose of GSK2636771 than the group before it, if no intolerable side effects were seen. This will continue until the highest tolerable dose of GSK2636771 is found. Participants receive the same dose level of Pembrolizumab.~Phase II: Participants receive GSK2636771 at the highest dose that was tolerated in Phase 1. Participants receive the same dose level of Pembrolizumab."
89541501|NCT03128034|Experimental|Treatment (211^At-BC8-B10, PBSC)|Patients receive 211^At-BC8-B10 IV over 6-8 hours on day -7 and fludarabine phosphate IV over 30 minutes on days -4, -3 and -2. Patients undergo TBI and PBSC transplant on day 0. Patients also receive cyclosporine PO or IV every 12 hours on days -3 to 56 and then tapered to day 180, or continuing to day 96 and then tapered to day 150. Patients receive mycophenolate mofetil PO or IV (first dose to occur 4-6 hours after PBSC infusion) every 12 hours on days 0-27 (for patients with related donors) or every 8 hours on day 0 and then reduced to every 12 hours on days 30-150 then tapered to day 180 (for patients with unrelated donors).
89541502|NCT03111173|Other|Holter device|Holter device to be attached to a Singleton or twin pregnant women at 32 weeks gestation to full term
89541503|NCT03091192|Experimental|Savolitinib|See: intervention description
89541504|NCT03091192|Active Comparator|Sunitinib|See: intervention description
89541505|NCT03087760|Experimental|Single Arm|Single Arm, Open Label
89541506|NCT03084770||Active surveillance group|Advised surveillance strategy consists of imaging studies (MR or EUS or US), every 6 months for the first two years and yearly thereafter for five years in the absence of significant changes on imaging or symptoms appearance. During surveillance, a high-quality imaging technique (MRI or CT) is mandatory at least every 12 months. Determination of CgA during follow-up is at physician's discretion. During follow-up, the treating physician is responsible for patient management and decision-making.
89541507|NCT03084770||Surgical resection group|Timing and type of resection will be established by the treating physician. Follow up strategy after surgery consists of imaging studies (MR or CT), every 6 months for the first two years and yearly thereafter for five years. An high-quality imaging technique (MRI or CT) is mandatory at least every 12 months. Determination of CgA during follow-up is at physician's discretion. During follow-up, the treating physician is responsible for patient management and decision-making. Date of surgery does not change the timing of follow up which starts from the date of enrolment.
89541508|NCT03081689|Experimental|Arm 1|Nivolumab 360 mg IV Q3W + Paclitaxel 200mg/m2 + Carboplatin AUC 6 IV Q3W in resectable stage IIIA N2-NSCLC adult patients followed by adjuvant treatment for 1 year with Nivolumab 240 mg IV Q2W for 4 months and Nivolumab 480mg Q4W for 8 months
88960474|NCT04897009||Basic science (biospecimen collection)|Patients undergo blood sample collection at baseline (prior to first NAC treatment), after taxane and prior to first dose of A/C (for patients receiving a taxane), end of NAC, 1-4 weeks and 6 months post-surgery. Patients also undergo tissue collection at 1-4 weeks and 6 months post-surgery.
88960475|NCT04893655|Experimental|Dobutamine|dobutamine infusion will be started at 2mcg/kg/min after min 10 minutes dobutamine infusion will be raised to 5mcg/kg/min
89024621|NCT00433472|Other|MRI -|"MRI scan to be complete to look at RSR13 on measurement of T2 and T2* on MRI~Procedure/surgery magnetic resonance imaging (MRI)"
89024622|NCT00463983|Experimental|octreotide|octreotide SR 30 mg intra muscularly every 4 weeks
89024623|NCT03270813|Experimental|RAGE-Control|There are 6 research intervention sessions, which will involve Relaxation training plus RAGE-Control. The first session includes a 30-minute lesson on the relationship between physiological arousal and anger, introduction to the RAGE-Control videogame and 15 minutes of videogame play. The next 5 sessions include a 10-minute check in about symptoms and functioning, a brief presentation of a relaxation skill, and 15 minutes of videogame play.
89541509|NCT02980887||Controls|Healthy controls No intervention as this is an observational study
89541510|NCT02980887||Pulmonary Vascular Disease|Pulmonary Vascular Disease at risk for pulmonary hypertension
89024624|NCT03270813|Sham Comparator|Sham videogame|There are 6 research intervention sessions, which will involve Relaxation training plus Sham videogame. The first session includes a 30-minute lesson on the relationship between physiological arousal and anger, an introduction to the Sham videogame and 15 minutes of videogame play. The next 5 sessions include a 10-minute check in about symptoms and functioning, a brief presentation of a relaxation skill, and 15 minutes of videogame play.
89024625|NCT01050998|Experimental|Mavrilimumab 10 mg|Mavrilimumab (CAM-3001) 10 milligram (mg) injection subcutaneously every other week for 12 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) orally or parenterally.
89024626|NCT01050998|Experimental|Mavrilimumab 30 mg|Mavrilimumab (CAM-3001) 30 mg injection subcutaneously every other week for 12 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) orally or parenterally.
89024627|NCT01050998|Experimental|Mavrilimumab 50 mg|Mavrilimumab (CAM-3001) 50 mg injection subcutaneously every other week for 12 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) orally or parenterally.
89024628|NCT01050998|Experimental|Mavrilimumab 100 mg|Mavrilimumab (CAM-3001) 100 mg injection subcutaneously every other week for 12 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) orally or parenterally.
89024629|NCT01050998|Placebo Comparator|Placebo|Placebo matched to mavrilimumab injection subcutaneously every other week for 12 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) orally or parenterally.
89541511|NCT02980887||Pulmonary Hypertension|Those meeting WSPH/WHO group classifications 1-5 of pulmonary hypertension
89541512|NCT02941458||Non-small cell lung cancer|patients treated for a non small cell lung cancer
89541513|NCT02941458||Small cell lung cancer|patients treated for a small cell lung cancer
89541514|NCT02941458||Mesotelioma|patients treated for a mesotelioma
89541515|NCT02941458||timic cancer|patients treated for a timic cancer
89541516|NCT02941458||carcinoid cancer|patients treated for a carcinoid cancer
89541517|NCT02896699|Experimental|PrEP Intervention Group|Group training session including HIV Education, PrEP Education, Following the training session Booster phone calls HIv and syphillis testing
89541518|NCT02896699|Active Comparator|Control Group|Group HIV risk vignettes
89024630|NCT00472173|Active Comparator|Calcium hydroxide|
89024631|NCT00472173|Experimental|MTA|
89207405|NCT00850590|Experimental|High Dose|NRL001 at 10, 12.5, and 15 mg administered in a dose escalating manner with placebo in a random position in the sequence. NRL001 is contained in either a 1 g or a 2 g slow release rectal suppository.
89207406|NCT00965913|Experimental|Three Interventions on Lower Back|Three treatments were applied on the lower back, according to treatment sequence, daily for 21 days
89541519|NCT02871219|Experimental|Treatment (obinutuzumab, lenalidomide)|Patients receive obinutuzumab IV over 4-6 hours on days 1, 8, and 15 of course 1 and day 1 of cycles 2-6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, and 30. Treatment repeats every 28 days for up to 30 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive lenalidomide PO on days 1-21. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with CR or CRu may receive up to an additional 12 cycles of lenalidomide.
89541520|NCT02860000|Experimental|Arm I (alisertib)|Patients receive alisertib PO BID on days 1-3, 8-10, and 15-17. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression, may cross-over to Arm II.
89024632|NCT00472329|No Intervention|Fludarabine and 400cGY TBI|
89207407|NCT00853866|Experimental|1|reboxetine + tDCS verum
89207408|NCT00853866|Experimental|2|reboxetine + sham tDCS
89207409|NCT00853866|Experimental|3|placebo drug + verum tDCS
89207410|NCT00853866|Experimental|4|placebo drug + sham tDCS
89541521|NCT02860000|Experimental|Arm II (alisertib, fulvestrant)|Patients receive fulvestrant IM over 1-2 minutes on days 1 and 15 of course 1 and on day 1 of all subsequent courses. Patients also receive alisertib PO BID on days 1-3, 8-10, and 15-17. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89541522|NCT02829723|Experimental|BLZ945 single agent|BLZ945 administered as single agent
89541523|NCT02829723|Experimental|BLZ945 + PDR001|BLZ945 administered in combination with PDR001
89541524|NCT02815579|Experimental|Intervention|The Shamba Maisha Intervention includes: a) a loan (~$175) from a well-established Kenyan bank for purchasing agricultural implements and commodities; b) agricultural implements to be purchased with the loan including the KickStart treadle pump, seeds, fertilizers and pesticides; and c) education in financial management and sustainable farming practices occurring in the setting of patient support groups.
89541525|NCT02815579|No Intervention|Control|Participants in the control arm will receive the standard of care.
89541526|NCT02735824||patients with suspected PID|From included patients with suspected primary immunodeficiency (PID), i.e. patients with recurrent/unusual infection, immune dysregulation and/or susceptibility to malignancies from whom consent to participate was obtained, nucleated blood cells and/or fibroblasts from skin biopsy will be used for genetic testing and functional assays. Blood serum will be used for antibody and cytokine measurement.
89541527|NCT02735824||healthy relatives of patients with PID|From healthy relatives of patients with suspected PID from whom consent to participate was obtained, nucleated cells will be used for genetic testing in order to compare their genetic information with the one form their relatives with suspected PID.
89541528|NCT02735824||Healthy volunteers|From healthy volunteers from whom consent to participate was obtained, nucleated blood cells will be used for genetic testing and functional assays. Blood serum will be used for antibody and cytokine measurement. The data obtained will be compared to age matched patients with suspected PID.
89541529|NCT02735057|Experimental|Phase I|"for chemotherapy 3 levels: 50%, 75% and 100% of the standard Dutch dose (carboplatin AUC 2 and paclitaxel 50 mg/m2)~for radiotherapy 3 levels: 41.4 Gy/1.8 Gy/f; 45 Gy/1.8 Gy/f; 50.4 Gy/1.8 Gy/f basel level being : 41.4 Gy and 50% of standard CT doses The phase I is conducted with increasing doses of each component with 9 levels."
89541530|NCT02726906|Experimental|Moderate-aerobic walking|Participants will complete a 6-month home-based moderate-aerobic walking program of 150 minutes per week with the assistance of an interventionist.
89541531|NCT02726906|Placebo Comparator|Healthy Living Education|Participants will receive monthly topics on healthy living lifestyles for self-paced reading over 6 months with the assistance of an interventionist.
89541532|NCT02722616|Active Comparator|Pancreatic Cancer|"A 4D ultrasound scan of the pancreas will be acquired at the time at simulation and used as a reference ultrasound image for localizing tracking target. The ultrasound probe will be placed at the abdominal area to monitor the pancreas motion. The probe will remain in place during the CT scan. Patient setup and the ultrasound probe location will be recorded so that the same setup can be reproduced during treatment delivery. The ultrasound probe in the CT image will be contoured and radiation beams that directly pass through the ultrasound probe will be avoided.~On each treatment day, 4D ultrasound images will be acquired continuously during beam on time to monitor pancreas motion. Intra-fraction CBCT images acquired during treatment will be registered with reference CT images. Organ motion registered by ultrasound will be compared to motion recorded by CBCT and the accuracy of the ultrasound system will be evaluated."
89541533|NCT02722616|Active Comparator|Liver Cancer|"A 4D ultrasound scan of the liver will be acquired at the time at simulation and used as a reference ultrasound image for localizing tracking target. The ultrasound probe will be placed at the abdominal area to monitor the liver motion. The probe will remain in place during the CT scan. Patient setup and the ultrasound probe location will be recorded so that the same setup could be reproduced during treatment delivery.~On each treatment day, 4D ultrasound images will be acquired continuously during beam on time to monitor liver motion. The system will record all relevant images, but will not be used in clinical decision making. Intra-fraction CBCT images acquired during treatment will be registered with reference CT images. Organ motion registered by ultrasound will be compared to motion recorded by CBCT and the accuracy of the ultrasound system will be evaluated."
89541534|NCT02722616|Other|Healthy Volunteer|A reference ultrasound scan will be conducted on each subject during breath-hold. Subjects will be required to lie in supine position and engaged with ABC; an ultrasound probe will be placed at the abdomen area with minimal pressure applied. Continuous motion monitoring is achieved by acquiring 4D ultrasound images using a motorized 3D ultrasound probe to image the pancreas, liver and other intra-abdominal organs continuously. Several 4D ultrasound scans will be collected during subsequent breath-holds that serve as secondary images. Additional registration of ultrasound images will be performed with Velocity software to evaluate accuracy of automated registration software in the ultrasound system.
88960476|NCT04892823||Supportive care (EAR, questionnaires, biospecimen collection)|Participants will complete comprehensive assessments of social processes at 100 days and 1 year after HCT that combine reports of social support, strain, and isolation with a naturalistic observation tool, the Electronically Activated Recorder (EAR), which captures ambient sound bites to assess social interactions in survivors' daily lives. At each time point, participants will also provide reports of symptoms to characterize phenotypic aging, including cognitive, physical, and functional complaints, and blood samples to assess biological aging, including cellular senescence, DNA damage, SASP, and cellular stress using genome wide RNA sequencing. Relevant clinical information that could influence biological aging will also be collected from patients' medical records to consider as covariates.
88960477|NCT04890028|Experimental|F-DOPA PET/CT|Drug: 18 F-DOPA Radiation: F-DOPA PET CT
88960478|NCT04886986|Experimental|All Subjects|Patients enrolled in the study will receive the study drugs 225Ac-J591 and 177Lu-PSMA-I&T, along with 68Ga-PSMA-11.
89207411|NCT00855660|Active Comparator|Riociguat|Subjects received multiple doses of riociguat (thrice a day) with concomitant administration of ranitidine (once daily) for 14 days
89207412|NCT00855660|Placebo Comparator|Placebo|Subjects received placebo (thrice a day) with concomitant administration of ranitidine (once daily) for 14 days
89207413|NCT00853944|No Intervention|P|subjects take 1 tablet of placebo daily
89207414|NCT00853944|Experimental|S|subjects take 1 tablet of sitagliptin 100 mg daily
89541535|NCT02658487|Experimental|Treatment (vosaroxin, cytarabine)|Patients receive vosaroxin IV on days 1 and 4 and cytarabine IV continuously on days 1-7 (Induction I). Patients with residual leukemia and for whom a second course is indicated in the judgment of the investigator may undergo a second course of treatment (Induction II) 14-57 days after day 1 of Induction I.
89541536|NCT02607046|Experimental|Exercise|Exercise Training
88960479|NCT04882072|Experimental|Ustekinumab|"Double-blind (DB) Period: Participants will receive weight-ranged based ustekinumab (6 milligrams/kilogram[mg/kg]) as IV infusion at Week 0 followed by ustekinumab 90mg injection SC 8 weeks after initial IV dose, then every 8 weeks (q8w) thereafter until the end of the DB period with starting the protocol defined oral GC taper regimen from Week 2 visit.~Open Label Extension (OLE) period: Participants will receive ustekinumab SC injection at Week OL-0, followed by ustekinumab 90mg SC injection with oral GC taper at investigator's discretion for 52 weeks (Week OL-52) or until 32 weeks from first SC administration after end of DB period whichever is later.~Long-term Extension (LTE) Period: Participants who completed OLE period may be eligible to enter LTE and continue to receive ustekinumab 90mg SC injection q8w."
89541537|NCT02607046|Experimental|NMES|Neuromuscular Electrical Stimulation
89541538|NCT02604914|Experimental|ND0612L (LD/CD solution)|3 doses of the investigational ND0612L (LD/CD solution) for subcutaneous (SC) infusion 0.24ml per hour.
89541539|NCT02604914|Experimental|ND0612H (LD/CD solution)|3 doses of the investigational ND0612H (LD/CD solution) for subcutaneous (SC) infusion 0.64ml per hour.
89541540|NCT02604914|Active Comparator|LCIG (Levodopa-carbidopa intestinal gel)|Active Comparator: LCIG subjects who completed the ND0612H arm will be administered with 3 doses of LCIG, directly to the jejunum.
89541541|NCT02593175|Experimental|Treatment (panitumumab, paclitaxel, carboplatin)|Patients receive panitumumab IV over 30 minutes and paclitaxel IV over 30 minutes on days 1, 8, and 15. Patients also receive carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
89541542|NCT02579889|Experimental|Active group - CLS ON|Device will be programmed in a dual-chamber DDD pacing mode with the Closed Loop Stimulation (CLS) function ON; Intervention: DDD+CLS
89541543|NCT02579889|Active Comparator|Control group - CLS OFF|Device will be programmed in a dual-chamber DDD(R) pacing mode with the Closed Loop Stimulation (CLS) function OFF
89541544|NCT02570815|Experimental|indocyanine green|Non-toxic, fluorescent dye
89541545|NCT02568189|Experimental|Sepsis 1|Sepsis patients receiving SonoSite Maxx Series Ultrasound System ultrasound prior to clinical orders including medication and fluid orders being placed by the treating physician
89541546|NCT02568189|Active Comparator|Sepsis 2|Sepsis patients having SonoSite Maxx Series Ultrasound System ultrasound performed after clinical orders have been placed by the treating physician
89541547|NCT02568189|Experimental|Gastroenteritis 1|Patients with gastroenteritis receiving SonoSite Maxx Series Ultrasound System ultrasound prior to having orders placed by treating physician
89541548|NCT02568189|Active Comparator|Gastroenteritis 2|Patients with gastroenteritis having SonoSite Maxx Series Ultrasound System ultrasound after initial clinical orders are placed by treating physician
89541549|NCT02556099|Experimental|Hydroxyurea Treatment|Hydroxyurea will be administered once daily by mouth. Participants will be monitored monthly to maximum tolerated dose and quarterly thereafter with periodic clinical evaluations, laboratory tests, and transcranial doppler examinations every 6 months.
89541550|NCT02553460|Experimental|Treatment|"Participants who meet eligibility requirements will receive remission induction, consolidation treatment, reinduction, reintensification and maintenance therapy.~Interventions: ITMHA, dexamethasone, mitoxantrone, pegaspargase or asparaginase Erwinia chrysanthemi, bortezomib, vorinostat, cyclophosphamide, mercaptopurine, methotrexate, leucovorin calcium, cytarabine, etoposide, and vincristine."
89541551|NCT02525757|Experimental|Group 1: Chemotherapy + Radiation|"Participants receive standard chemotherapy and radiation for 6-7 weeks, followed by a 3-4 week rest period when they receive no chemotherapy or radiation.~Consolidation Phase: After the rest period, participants receive MPDL3280A in addition to chemotherapy for 2 cycles.~Maintenance Phase: After completing the consolidation period, participants continue to receive MPDL3280A alone for up to 1 year."
89541552|NCT02525757|Experimental|Group 2: MPDL3280A + Chemotherapy + Radiation|"Participants receive MPDL3280A, standard chemotherapy, and radiation therapy for 6-7 weeks. This will be followed by a rest period of 3-4 weeks, during which time participant receives 1 dose of MPDL3280A but no chemotherapy or radiation.~Consolidation Phase: After the rest period, participants receive MPDL3280A in addition to chemotherapy for 2 cycles.~Maintenance Phase: After completing the consolidation period, participants continue to receive MPDL3280A alone for up to 1 year."
89541553|NCT02470728|No Intervention|Control Group|Those randomized into the control group will receive the current standard of care for pain management. This standard care pathway involves a pain management specialist consultation only at the request of the primary admitting team. The pain management consultation can occur at any time during the patient's inpatient stay and care by these specialists ends at discharge.
89541554|NCT02470728|Experimental|Treatment Group|Subjects randomized into the treatment (early intervention) group will receive the New Clinical Pathway: pain management care coordinated by pain-management specialists from inpatient admission through 60 days after discharge.
89541555|NCT02453282|Experimental|Monotherapy|PD-L1 monoclonal Antibody monotherapy.
89541556|NCT02453282|Experimental|Combination Therapy|PD-L1+Tremelimumab combination therapy
89541557|NCT02453282|Active Comparator|Standard of Care|Standard of Care chemotherapy treatment
89541558|NCT02419976|Experimental|fasting breath analysis|Individuals consenting to participation of this study will be asked to provide a breath analysis using the Aeonose. Following their scheduled standard of care endoscopic procedure the patient will repeat the breath analysis
89541559|NCT02300766||Posterior fossa tumor patients|Children (0-18 years) with a tumour in the posterior fossa (cerebellum/4th ventricle/brainstem ) requiring surgery or open biopsy at one of the participating centres.
89541560|NCT02296125|Experimental|AZD9291+ placebo|AZD9291 (80 mg or 40 mg orally, once daily) plus placebo Erlotinib (150mg or 100mg orally, once daily) or placebo Gefitinib (250 mg orally, once daily), in accordance with the randomization schedule.
89541561|NCT02296125|Active Comparator|Standard of Care + placebo AZD9291|"Erlotinib (150 mg or 100 mg orally, once daily) or placebo Gefitinib (250 mg orally, once daily) plus placebo AZD9291 (80 mg or 40 mg orally, once daily), in accordance with the randomisation schedule.~Following objective disease progression according to RECIST 1.1, as per investigator assessment, patients who were randomized to Standard of Care arm may have the option to receive open-label AZD9291 (crossover to active AZD9291)."
89541562|NCT02287311|Experimental|Group A: MABEL CTLs|"Patients with 1st or subsequent relapse.~Three different dosing schedules will be evaluated. Two to four patients will be evaluated on each dosing schedule. Each patient will receive 2 injections, 14 days apart.~If the patient's level of circulating T cells is relatively high, s/he may require treatment with cyclophosphamide (Cytoxan) and Fludarabine before s/he receives MABEL CTLs."
89541563|NCT02287311|Experimental|Group B: MABEL CTLs|"Patients with persistent active disease despite therapy.~Three different dosing schedules will be evaluated. Two to four patients will be evaluated on each dosing schedule. Each patient will receive 2 injections, 14 days apart.~If the patient's level of circulating T cells is relatively high, s/he may require treatment with cyclophosphamide (Cytoxan) and Fludarabine before s/he receives MABEL CTLs."
89541564|NCT02287311|Experimental|Group C: MABEL CTLs|"Patients with active disease if immunosuppressive chemotherapy is contraindicated.~Three different dosing schedules will be evaluated. Two to four patients will be evaluated on each dosing schedule. Each patient will receive 2 injections, 14 days apart.~If the patient's level of circulating T cells is relatively high, s/he may require treatment with cyclophosphamide (Cytoxan) and Fludarabine before s/he receives MABEL CTLs."
89541565|NCT02286089|Experimental|OpRegen|Up to 12 legally blind subjects with best corrected visual acuity of 20/200 or less in first three cohorts and 12 subjects with best corrected visual acuity of 20/64 and 20/250 in fourth cohort
89541566|NCT02276443|Experimental|Arm A (predictive results given)|Patients undergo baseline molecular and IHC evaluation of their tumor biopsy, and receive the results. Patients then receive standard anthracycline-based chemotherapy and undergo standard ultrasound at baseline, after 2 cycles, after 4 cycles of treatment, and after completion of treatment (before surgery). Patients and physicians are notified of the results of the molecular evaluation. Patients may then choose to continue with standard taxane +/- platinum-based chemotherapy or participate in an experimental clinical trial designed to match the molecular profile and triple-negative subtype. Patients with tumors predicted to be insensitive to chemotherapy are advised to participate in a clinical trial treating their tumor subtype.
89541567|NCT02276443|Experimental|Arm B (predictive results given)|Patients undergo baseline molecular and IHC evaluation of their tumor biopsy, and receive the results. Patients then receive standard anthracycline-based chemotherapy and undergo standard ultrasound at baseline, after 2 cycles, and after 4 cycles of treatment. Patients and physicians are notified of the results of the molecular evaluation. Patients may then choose to continue with standard taxane +/- platinum-based chemotherapy or participate in an experimental clinical trial designed to match the molecular profile and triple-negative subtype. Patients with tumors predicted to be insensitive to chemotherapy are advised to participate in a clinical trial treating their tumor subtype.
89541568|NCT02276443|Experimental|Arm C (predictive results given)|Patients undergo baseline molecular and IHC evaluation of their tumor biopsy, and receive the results. Patients then receive standard anthracycline-based chemotherapy with immunotherapy and undergo standard ultrasound at baseline, after 2 cycles, and after 4 cycles of treatment. Patients and physicians are notified of the results of the molecular evaluation. Patients may then choose to continue with standard taxane +/- platinum-based chemotherapy or participate in an experimental clinical trial designed to match the molecular profile and triple-negative subtype. Patients with tumors predicted to be insensitive to chemotherapy are advised to participate in a clinical trial treating their tumor subtype
88960480|NCT04882072|Placebo Comparator|Placebo|"DB period: Participants will receive placebo intravenous (IV) infusion at Week 0 followed by placebo subcutaneous (SC) injection administration, 8 weeks after the initial IV dose, then q8w thereafter until the end of DB period with starting the protocol defined oral GC taper regimen from Week 2 visit.~OLE period: Participants will receive ustekinumab SC at Week OL-0, followed by SC administration of ustekinumab with oral GC taper at investigator's discretion for 52 weeks (Week OL-52) or until 32 weeks from the first SC administration after the end of DB period, whichever is later.~LTE Period: Participants who complete their participation in OLE period may be eligible to enter the LTE and continue to receive 90 mg SC ustekinumab q8w."
88960481|NCT04879641|No Intervention|1_Waiting List control|Randomized participants will only get the full intervention after study completion period (6 months since the randomization)
88960482|NCT04879641|Experimental|2_Exposure only|Randomized participants will only get the Exposure component
88960483|NCT04879641|Experimental|3_Attention Training only|Randomized participants will only get the Attention Training component
88960484|NCT04879641|Experimental|4_Exposure + Attention Training|Randomized participants will get Exposure + Attention Training components
88960485|NCT04879641|Experimental|5_Cognitive Restructuring only|Randomized participants will only get the Cognitive Restructuring component
88960486|NCT04879641|Experimental|6_Cognitive Restructuring + Exposure|Randomized participants will get Cognitive Restructuring + Exposure components
88960487|NCT04879641|Experimental|7_Cognitive Restructuring + Attention Training|Randomized participants will get Cognitive Restructuring + Attention Training components
88960488|NCT04879641|Experimental|8_Cognitive Restructuring + Attention Training + Exposure|Randomized participants will get Cognitive Restructuring + Attention Training + Exposure components
88960489|NCT04879641|Experimental|9_Psychoeducation only|Randomized participants will only get the Psychoeducation component
89514081|NCT05641480|Experimental|Mild cognitive impairment group|"Studies suggest that acupuncture point Shenting can reduce the levels of serum inflammatory factors IL-6 and TNF-α, and the activity of cholinesterase of these two inflammatory factors is increased, and the activity of cholinacetylase is inhibited, which leads to brain tissue damage, nerve damage and cognitive dysfunction. Shenting（DU24）, Benshen（BG13） and Tou Wei（ST8） are the acupoints on the forehead, which have the effect of awakening the brain. Moreover, after acupuncture, nerve and periosteum effects can be caused, so as to improve cognitive function.~Music therapy is a convenient and efficient method, and as a non-drug intervention, activate the memory to help people with Alzheimer's disease, trigger positive emotions, improve the symptoms of behavior, the moment of life in participants with Alzheimer's disease has great significance, is a good way to help participants with slow disease progression and improve the quality of life, increase happiness of life."
89514082|NCT05641480|Experimental|Mild dementia group|On the basis of the above two treatment options, oral donepezil hydrochloride tablets or carpalatine heavy tartrate tablets should be added.
89514083|NCT05037370|Experimental|LASIK refractive surgery|Contralateral Randomize Wave-Front Optimized (WFO) ablation vs Topography-guided ablation
89514084|NCT05037370|Experimental|PRK refractive surgery|Contralateral Randomize Wave-Front Optimized (WFO) ablation vs Topography-guided ablation
89514085|NCT05634304|Experimental|The mobile app self-management (mSM) program focusing on patients' needs in OA patients|An individualized mobile app self-management (mSM) program for managing OA patients' physical behavioral problems was applied for the intervention group. The program was based on the self-efficacy theory and the four resources were incorporated to emphasize patients' knowledge, skill, and responsibility in managing their OA situations.
89514086|NCT05634304|No Intervention|Control group for mSM program|The control group will receive with the usual care only and follow-up 6 months.
89514087|NCT03377803|Active Comparator|VP-102|VP-102 is contained within a single-use applicator. The VP-102 applicator consists of a plastic tube containing a sealed glass ampule and an applicator tip. One ampule contains 450 μL of VP-102 (0.7% [w/v] cantharidin) solution.
89514088|NCT03377803|Placebo Comparator|Placebo|Placebo is contained within a single-use applicator. The placebo applicator consists of a plastic tube containing a sealed glass ampule and an applicator tip. One ampule contains 450μl of placebo solution with the same color and consistency as VP-102.
89514089|NCT03474835|Other|ISCHEMIC HEART DISEASE and PROSTATE ADENOCARCINOMA|
89514090|NCT03474835|No Intervention|ISCHEMIC HEART DISEASE and PROSTATE hyperplasia|
89514091|NCT05013580|Experimental|Open Wound|After horizontal bone grafting, the wound where the graft was attached to the bone will be filled with a type of tissue (the amnion-chorion membrane) taken from a placenta and will be left partially open to heal.
89514092|NCT05013580|Active Comparator|Closed Wound|After horizontal bone grafting, the wound where the graft was attached to the bone will be filled with collagen tissue and stitched closed while it heals.
89514093|NCT03471325|Experimental|Plaque Disclosed with Air Flow (PDAF)|Plaque will be disclosed prior to polishing with the air flow system.
89514094|NCT03471325|Experimental|Plaque Disclosed with Rubber Cup (PD-RC)|Plaque will be disclosed prior to polishing with the rubber cup and fine grit prophylaxis paste.
89514095|NCT03471325|Experimental|Non Plaque Disclosed Air Flow (NPD-AF)|Air polishing system will be used to remove the plaque
89514096|NCT03471325|Placebo Comparator|Non Plaque Disclosed Rubber Cup (NPD-RC)|Rubber Cup polishing to remove plaque.
89514097|NCT04844164|Experimental|Cushing's Disease|
89514098|NCT04844164|Experimental|Acromegaly|
89514099|NCT04844164|Experimental|Diabetes Mellitus Type 1|
89514100|NCT04844164|Experimental|Primary Hyperparathyroidism|
89514101|NCT04844164|Experimental|Control group|
89514102|NCT03469921||15-17 years old|15-17 years old
89514103|NCT03469921||18-25 years old|18-25 years old
89514104|NCT03469921||26-30 years old|26-30 years old
89514105|NCT03469921||acute leukemia|acute leukemia
89514106|NCT03469921||non-Hodgkin's lymphoma|non-Hodgkin's lymphoma
89514107|NCT03469921||Hodgkin lymphoma|Hodgkin lymphoma
89514108|NCT03469921||pediatric therapeutic regimen administered|pediatric therapeutic regimen administered
89514109|NCT03469921||adult therapeutic regimen administered|adult therapeutic regimen administered
89514110|NCT03469921||patients included in clinical trials|patients included in clinical trials
88960490|NCT04879641|Experimental|10_Psychoeducation + Exposure|Randomized participants will get the Psychoeducation + Exposure components
89207415|NCT02545452|Experimental|BAY98-7196|Investigate the pharmacokinetics effect of a vaginally administered antimycotic (miconazole) during the use of an intra-vaginal ring (IVR) releasing anastrozole (ATZ) and levonorgestrel (LNG)
88960491|NCT04879641|Experimental|11_Psychoeducation + Attention Training|Randomized participants will get the Psychoeducation + Attention Training components
89514111|NCT03469921||patients not included in clinical trials|patients not included in clinical trials
89514112|NCT03474757||SPAF patients in Colombia_Rivaroxaban|First time users of rivaroxaban in the Audifarma database
89514113|NCT03474757||SPAF patients in Colombia_Dabigatran|First time users of dabigatran in the Audifarma database
89514114|NCT03474757||SPAF patients in Colombia_Apixaban|First time users of apixaban in the Audifarma database
89514115|NCT03110809|Placebo Comparator|BAT Positive Placebo|Participants will be confirmed positive for BAT activity, but on Placebo
89514116|NCT03110809|Placebo Comparator|BAT Negative Placebo|Participants will be confirmed negative for BAT activity, but on Placebo
89541569|NCT02152254|Active Comparator|Arm A: Targeted Therapy|Personalized treatment, targeted therapy against the alteration based on molecular profiling.
89541570|NCT02152254|Experimental|Arm B: Standard-of-Care Therapy|Standard-of-Care treatment not selected on basis of alteration analysis.
89541571|NCT02135744|No Intervention|Control|Group of patients undergo standard care as determined by the primary inpatient team
89541572|NCT02135744|Experimental|Bundle|Group of patients that receive the screening and educational tool
89541573|NCT02119065||Health Services Research (PET/CT scan)|Patients receive routine pre-therapy technetium Tc 99m-labeled macroaggregated albumin. Patients then undergo routine radioembolization with yttrium Y 90 resin microspheres. Within 36 hours after radioembolization, patients undergo PET/CT imaging.
89541574|NCT02096601|Experimental|ND0612|Levodopa and carbidopa SC solution
89541575|NCT02096601|Active Comparator|Oral levodopa and carbidopa|Oral levodopa and carbidopa
89541576|NCT02087423|Experimental|MEDI4736|see below
89541577|NCT02031419|Experimental|CC-122 + CC-223 +/- rituximab|CC-122 administered orally once daily at 2mg or 3 mg in combination with CC-223 administered orally once daily at 20mg or 30 mg with or without Rituximab administered by IV once every 28 days
89541578|NCT02031419|Experimental|CC-122 + CC-292 +/- rituximab|CC-122 administered orally once daily at 2mg or 3 mg in combination with CC-292 administered orally twice daily at 500 mg with or without Rituximab administered by IV once every 28 days
89541579|NCT02031419|Experimental|CC-292 + CC-223 +/- rituximab|CC-292 administered twice daily at 500 mg in combination with CC-223 administered orally once daily at 20mg or 30 mg with or without Rituximab administered by IV once every 28 days
89541580|NCT02031419|Experimental|CC-122 + rituximab|CC-122 administered orally once daily in combination with Rituximab.
89541581|NCT01997450||Q/LAIV|FluMist Quadrivalent
89541582|NCT01997450||Inactivated Influenza Vaccine|Inactivated Influenza Vaccine
89541583|NCT01954979|Experimental|Abatacept|Abatacept will be administered for a total of 6 doses. Doses 1-3 will be administered at two week intervals (+/-2 days). One month following Dose 3, abatacept will be administered, and given at four-week intervals (+/-2 days) for three doses (Doses 4-6.) Patients will be followed for toxicity for 28 days following last dose of Abatacept. Patients will then be seen monthly for six months.
89541584|NCT01883505|Experimental|ND0612|levodopa and carbidopa solution
89541585|NCT01883505|Placebo Comparator|Placebo|Saline
89541586|NCT01878617|Experimental|Stratum W1: Low Risk|Participants in stratum W1 will undergo reduced dose Craniospinal Irradiation with boost to the primary tumor site once daily 5 days a week for 6 weeks. Six weeks after completion of radiotherapy, patients receive one cycle of chemotherapy (cisplatin, vincristine, cyclophosphamide) once every 4 weeks for 4 cycles in absence of unacceptable toxicity. Some participants will complete aerobic training and/or neurocognitive remediation.
89541587|NCT01878617|Experimental|Stratum W2: Atypical|Participants in stratum W2 will undergo standard dose craniospinal radiation with boost to the primary tumor site once daily 5 days a week for 6 weeks. Six weeks after completion of radiotherapy, patients receive one cycle of chemotherapy (cisplatin, vincristine, cyclophosphamide) once every 4 weeks for 4 cycles in absence of unacceptable toxicity. Some participants will complete aerobic training and/or neurocognitive remediation.
89541588|NCT01878617|Experimental|Stratum W3: High Risk|Participants in stratum W3 will undergo high dose craniospinal radiation with boost to the primary tumor site once daily 5 days a week for 6 weeks. Six weeks after completion of radiotherapy, patients receive one cycle of chemotherapy (cisplatin, vincristine, cyclophosphamide) once every 4 weeks for 4 cycles in absence of unacceptable toxicity. Some participants will complete aerobic training and/or neurocognitive remediation.
89541589|NCT01878617|Experimental|Stratum S1: Standard Risk|Participants in stratum S1 will undergo standard dose craniospinal radiation with boost to the primary tumor site once daily 5 days a week for 6 weeks. Six weeks after completion of radiotherapy, patients receive one cycle of chemotherapy (cisplatin, vincristine, cyclophosphamide) once every 4 weeks for 4 cycles in absence of unacceptable toxicity. After completion of 4 cycles of chemotherapy, participants who are skeletally mature will receive maintenance chemotherapy with vismodegib. Some participants will complete aerobic training and/or neurocognitive remediation.
89541590|NCT01878617|Experimental|Stratum S2: High Risk|Participants in stratum S2 will undergo high dose craniospinal radiation with boost to the primary tumor site once daily 5 days a week for 6 weeks. Six weeks after completion of radiotherapy, patients receive one cycle of chemotherapy (cisplatin, vincristine, cyclophosphamide) once every 4 weeks for 4 cycles in absence of unacceptable toxicity. After completion of 4 cycles of chemotherapy, participants who are skeletally mature will receive maintenance chemotherapy with vismodegib. Some participants will complete aerobic training and/or neurocognitive remediation.
89541591|NCT01878617|Experimental|Stratum N1: Standard Risk|Participants in stratum N1 will undergo standard dose craniospinal radiation with boost to the primary tumor site once daily 5 days a week for 6 weeks. Six weeks after completion of radiotherapy, patients receive one cycle of chemotherapy (cisplatin, vincristine, cyclophosphamide) once every 4 weeks for 4 cycles in absence of unacceptable toxicity. Some participants will complete aerobic training and/or neurocognitive remediation.
89541592|NCT01878617|Experimental|Stratum N2: Intermediate Risk|Participants in stratum N2 will undergo standard dose craniospinal radiation with boost to the primary tumor site once daily 5 days a week for 6 weeks. Six weeks after completion of radiotherapy, patients receive standard chemotherapy (cisplatin, vincristine, cyclophosphamide) for 4 cycles intermixed with an additional 3 cycles of chemotherapy with pemetrexed and gemcitabine in absence of unacceptable toxicity. Some participants will complete aerobic training and/or neurocognitive remediation.
89541593|NCT01878617|Experimental|Stratum N3: High Risk|Participants in stratum N3 will undergo high dose craniospinal radiation with boost to the primary tumor site once daily 5 days a week for 6 weeks. Six weeks after completion of radiotherapy, patients receive standard chemotherapy (cisplatin, vincristine, cyclophosphamide) for 4 cycles intermixed with an additional 3 cycles of chemotherapy with pemetrexed and gemcitabine in absence of unacceptable toxicity. Some participants will complete aerobic training and/or neurocognitive remediation.
89541594|NCT01874353|Experimental|Olaparib 300mg tablets|Taken orally twice daily
89541595|NCT01874353|Placebo Comparator|Placebo tablets|Taken orally twice daily
89541596|NCT01802632|Experimental|Daily dose of AZD9291|Daily oral dose of AZD9291
89207416|NCT02545452|Experimental|Administered Antibiotic|Investigate the pharmacokinetics effect of a vaginally administered antibiotic (clindamycin) during the use of an IVR releasing ATZ and LNG
89514117|NCT03110809|Experimental|BAT Positive Capsinoid|Participants will be confirmed positive for BAT activity, but taking Capsinoids. Capsinoids are a derivative of sweet peppers that may activate and recruit BAT.
89514118|NCT03110809|Experimental|BAT Negative Capsinoid|Participants will be confirmed negative for BAT activity, but taking Capsinoids. Capsinoids are a derivative of sweet peppers that may activate and recruit BAT.
89514119|NCT02523625||Healthy volunteers|Age and gender matched to patient groups to undergo ultrasound of temporal and axillary arteries
89514120|NCT02523625||Patients with headache|Patients with new headache not due to GCA to undergo ultrasound of temporal and axillary arteries
89514121|NCT02523625||Patients with GCA (new)|Patients with new diagnosis of GCA to undergo ultrasound of temporal and axillary arteries
89514122|NCT02523625||Patients with GCA (flare)|Patients with apparent flare of GCA to undergo ultrasound of temporal and axillary arteries
89514123|NCT05368714|Experimental|Economic Empowerment (EE)|EE consists of a child development account (CDA) held in the child's name in a financial institution registered by the Central Bank (Bank of Uganda).
89514124|NCT05368714|Experimental|Multiple Family Group (MFG) - based Family Strengthening (FS) Intervention:|MFG-based consists of 16 sessions focused on building support for parents and families by providing opportunities for parents and children to communicate in a safe setting with other families who have shared experiences. Core components of MFG are known as 4Rs and 2S's: rules, responsibility, relationships, respectful communication, stress and social support.
89514125|NCT05368714|Experimental|Combined EE plus MFG-based FS|EE+ MFG-based FS combines both the child development account and 16 sessions of MFG.
89514126|NCT03000829|Experimental|Tele-intensivist consultation|Standardized consultation to on-site cardiac arrest response team by off-site intensivist via two-way audiovisual link using a mobile telemedicine cart
89514127|NCT03000829|Placebo Comparator|Control|"Simulated observation by ICU physician by displaying a silent, pre-recorded, non-interactive videotape of an ICU physician. The on-site participants will be told that an intensive care physician is observing the mock code."
89514128|NCT03469765||Group of patients after aortic surgery|with subanalysis of patients with/without supra-/infrarenal surgery
89514129|NCT04419844|Active Comparator|TAR with Botox|Evaluation of TAR technique in the treatment of huge abdominal wall hernia and large abdominal wall defect Botox injection .
89514130|NCT04419844|Active Comparator|TAR without Botox|Evaluation of TAR technique in the treatment of huge abdominal wall hernia and large abdominal wall defect without Botox injection .
89514131|NCT03469687|Other|Symax uncemented hip stem|The Symax hip stem is an uncemented design forged from Ti6Al4V alloy (Stryker EMEA). Primary mechanical stability is provided by anatomical metaphyseal geometry. The hip stem features a size dependent anteversion, neck length and offset, with a CCD angle of 128°. Secondary biological stability is accomplished by fast osseous integration due to the BONIT-HA coating on the metaphyseal part of the stem.
89514132|NCT05361538|Experimental|MTA Group|Use true circular microwave needle for ultrasound-guided thermal ablation in MSA （microwave spherical ablation） group.
89514133|NCT05361538|No Intervention|MWA Group|Use normal microwave needle for ultrasound-guided thermal ablation in MTA （microwave ablation） group.
89514134|NCT03474601||Acromegaly|Patients diagnosed with acromegaly
89514135|NCT03474601||Cushing's disease|Patients diagnosed with Cushing's disease
89514136|NCT03474601||Hyperprolactinemia/prolactinomas|Patients diagnosed with hyperprolactinemia/prolactinoma
89514137|NCT03474601||Pituitary stalk lesions|Patients diagnosed with pituitary stalk lesions
89514138|NCT03474601||Nonfunctioning pituitary adenomas|Patients diagnosed with nonfunctioning pituitary adenomas
89514139|NCT03474601||Central diabetes insipidus|Patients diagnosed with central diabetes insipidus
89514140|NCT03474601||Craniopharyngioma|Patients diagnosed with craniopharyngiomas
89514141|NCT03474601||Others|Patients diagnosed with other suprasellar/parasellar lesions
89514142|NCT04854772|Experimental|Mind Body Syndrome Therapy for Long Covid|"The participants will receive an initial one-on-one interview, followed by 1 to 2 hour biweekly group interactive, educational sessions for 12 weeks. This program also includes a day-long retreat at the end of the required course period. Participants will also be provided reading materials to study during the intervention period"
89514143|NCT05357248|Experimental|Intervention- BT-NCBT-00x|"The treatment, BT-NCBT-00x, consists of a software as a medical device developed by the study Sponsor, Better Therapeutics. It delivers treatment to participants with cardiometabolic disease, using behavioral therapy that targets individual behaviors related to improving dietary quality and physical activity. BT-NCBT-00x is accessed via the participants' smartphone after downloading from the phone's corresponding app store.~Participants will receive behavioral support by the Better Therapeutics patient services team in the form of phone calls as necessary or requested by the patient"
89514144|NCT05352880|Experimental|transplant recipients|They will be recruited from the Renal Transplantation Clinic at Alexandria Main University hospital
89514145|NCT05608954||Physical Therapy Modalities|Children diagnosed with cerebral palsy will be followed longitudinally in their therapies within the physiotherapeutic treatment.
89514146|NCT04984798|Experimental|Vitamin E Dose-Escalation|Subjects will take an oral Vitamin E (dl-alpha-tocopherol) supplement twice daily with a fat-containing meal for 6-9 weeks. The dose will be increased every 2-3 weeks over the course of the study (initial dose 600 IU twice daily, next dose 1,200 IU twice daily, final dose 2,400 IU twice daily). Formulations include softgel capsules in 200, 400, and 1,000 IU doses.
89514147|NCT04974658|Active Comparator|The block group (ISP)|After aseptic preparation of the injection area, the needle will be introduced in-plane through the skin and advanced into the fascial plane between the semispinalis cervicis and semispinalis capitis muscles. After negative aspiration for blood, 20 ml of 0.25% bupivacaine on each side will be injected for each block.
89514148|NCT04974658|Placebo Comparator|control group (C)|No block will be performed
89541597|NCT01782131|Experimental|Posaconazole (POS)|Participants received 300 mg posaconazole (POS) intravenous (IV) twice per day (BID) on Day 1, and then received 300 mg POS IV plus placebo IV once per day (QD) starting on Day 2 until clinically stable when participants transitioned to oral POS tablets plus oral placebo tablets QD for up to 12 weeks of treatment. Most participants were expected to initiate treatment with IV therapy and transition to oral therapy as clinically indicated, with some participants initiating treatment with oral therapy, per clinical judgment.
89541598|NCT01782131|Active Comparator|Voriconazole|Participants received 6 mg/kg voriconazole (VOR) IV twice per day (BID) on Day 1, and then received 4 mg/kg VOR IV BID on Day 2 until clinically stable when participants transitioned to oral therapy with VOR capsules or VOR placebo capsules BID for up to 12 weeks of treatment. Most participants were expected to initiate treatment with IV therapy and transition to oral therapy as clinically indicated, with some participants initiating treatment with oral therapy, per clinical judgment.
89541599|NCT01725802|Experimental|levodopa and carbidopa|levodopa and carbidopa solution
89541600|NCT01725802|Placebo Comparator|placebo to levodopa and carbidopa|saline
89541601|NCT01653093|Experimental|Diagnostic (3T MRI)|Patients undergo 3T MRI, including DCE-MRI, diffusion-weighted MRI, amide-proton-transfer MRI, and MR spectroscopy scans. Patients may undergo an additional 3T MRI scan at least 24 hours after the initial scan.
89541602|NCT01653080|Experimental|Dynamic contrast-enhanced MRI|Patients undergo Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI)
89541603|NCT01582191|Experimental|Treatment (vandetanib, everolimus)|Patients receive vandetanib PO QD and everolimus PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89541604|NCT01506674||criticall ill patients|
89541605|NCT01486628|Placebo Comparator|levodopa and carbidopa|
89541606|NCT01486628|Placebo Comparator|Placebo|Saline solution for subcutaneous administration
89541607|NCT01406184|Experimental|Durham Connects Eligible Group|From July 1, 2009 - December 31, 2010, all even-birth-date residential births in Durham County, North Carolina were randomly assigned to receive the Durham Connects nurse home visiting program.
89541608|NCT01406184|No Intervention|Control Group|From July 1, 2009 - December 31, 2010, all odd-birth-date residential births in Durham County, North Carolina were randomly assigned to a control group condition. These families were assigned to receive services as usual and served as the randomized comparison group for evaluating Durham Connects program impact.
89541609|NCT01189786|Experimental|Cohort 2: CD34+ cells as a top off|"Cohort 2 consists of patients needing additional CD34+ stem cells collected by 'CliniMACS CD34 Reagent system' as a topoff without the need for additional conditioning prior to the infusion. These patients who have already received SCT and are receiving CD34+ cells from their original donor for poor graft function, declining chimerism or disease relapse."
89541610|NCT01189786|Experimental|Cohort 1: CD34+ Cells for transplant|Cohort 1 consists of patients receiving CD34+ selected peripheral blood stem cell transplant with a preceding conditioning regimen (chemotherapy with, or without, radiation). The stem cells will then be separated out from the white blood cells by a special machine- called a CliniMACS CD34 Reagent System in the laboratory.
89541611|NCT00938145|Experimental|MRI+surgery|3 Tesla MRI/Cystectomy and Lymphadenectomy/Urinary Diversion/Specimen Ultra-High field MRI
89541612|NCT00938145|Experimental|MRI+surgery+chemotherapy|3 Tesla MRI/Cystectomy and Lymphadenectomy/Urinary Diversion/Specimen Ultra-High field MRI/chemotherapy
89541613|NCT00579124|Other|1. CliniMACS CD3+/CD19+ depletion|"6/6 or 8/8 matched (fully matched)~1 antigen or allele mismatched (mismatch at A or B or DRB1)~2 antigen or allele mismatched (mismatch ONLY at A and B but NOT at DRB1 plus either A or B).~Patients will receive grafts that have undergone CD3+ and CD19+ depletion. The CD3(-) fraction will be infused."
89541614|NCT00579124|Other|2. CliniMACS CD3+/CD19+ depletion|"Stratum 2. CliniMACS CD3+/CD19+ depletion:~Haploidentical match~2 antigen and/or allele mismatched where one of the mismatches includes DRB1~For patients in Stratum 2 we will perform CD3+ (T cell) and CD19+ (B cell) depletion. There will be no T cell add back in this stratum."
89541615|NCT03253055||Male Athletes|DEXA, pQCT, lifestyle questionnaire, muscular strength measurements, aerobic fitness, blood draw and finger prick test.
89541616|NCT03253055||Female Athletes|DEXA, pQCT, lifestyle questionnaire, muscular strength measurements, aerobic fitness, blood draw and finger prick test.
89541617|NCT03253055||Controls|DEXA, pQCT, lifestyle questionnaire, muscular strength measurements, aerobic fitness, blood draw and finger prick test.
89541618|NCT03252899||Therapists|Physiotherapists/occupational therapists experienced in working with stroke patients.
89541619|NCT03252899||Subacute stroke patients|Stroke patients less than 6 months after their stroke suffering from upper limb paresis.
89541620|NCT03252899||Chronic stroke patients|Stroke patients more than 6 months after their stroke suffering from upper limb paresis.
89541621|NCT01375205|Active Comparator|Standard of Care|Subjects will apply Johnson&Johnson moisturizer to their infant's skin as often as they wish. They will also use the Johnson&Johnson cleanser.
89541622|NCT01375205|Experimental|Cetaphil Restoraderm|Subjects will apply Cetaphil Restoraderm moisturizer once daily to infant's skin. They will bathe their infant with Cetaphil Restoraderm cleanser.
89541623|NCT03234959|Experimental|CareToy Intervention|Infants will perform individualized goal-directed activities for 30-45 minutes per day with CT system, while continuing SC. The CT training will be monitored and modified remotely by clinical staff, according to infants' developmental needs, abilities and progresses. It will last 8 wks.
89541624|NCT03234959|Active Comparator|Infant Massage|Infants and their caregivers will perform 4-5 sessions (around 1 hour every 2 weeks) of Infant massage conducted by an expert child therapist. The therapist will instruct the parent in the baby's massage and provide advises on promoting development. Parents will be invited to perform infant massage five days a week, for 8 weeks. Parent will take a diary in which will record the frequency of the IM.
89541625|NCT03229577|Experimental|Sudarshan Kriya Yoga|Sudarshan Kriya Yoga workshop is a nationally-recognized program focused on teaching yoga-based breathing techniques.
89541626|NCT03229577|Experimental|Mindfulness-Based Stress Reduction|Mindfulness-Based Stress Reduction (MBSR) is a nationally-recognized program focused on teaching mindfulness techniques.
89024633|NCT00464139||1|"The electronic files of all patients who consulted the LUFC since 2003 were searched to select women with at least 1 year of infertility, a regular cycle (variation 21 - 35 days), whose partner had normal sperm according to World Health Organization (WHO) criteria (n = 304).~After exclusion of 83 (27,3%) patients with a previous laparoscopic diagnosis of endometriosis before referral to our centre, 221 (72,7%) infertile women were included in our study."
89024634|NCT00433706|Experimental|Control position by 3DOBI daily|
89024635|NCT00433706|Active Comparator|Standard imaging|
89514149|NCT04843228|Experimental|Active Cognitive Bias Modification Group|This group of participants will receive 4 sessions of CBM targeting their interpretation biases for perfectionism and intolerance to uncertainty.
89514150|NCT04843228|Placebo Comparator|Placebo-Control Cognitive Bias Modification Group|This group of participants will receive 4 sessions of inactive CBM.
89514151|NCT04843072|Experimental|Evolut R/Pro bioprosthesis|Study subjects will receive a self-expanding-valve (either the Evolut R or PRO device)
89514152|NCT04843072|Active Comparator|Edwards Sapien S3/Ultra bioprosthesis|Study subjects will receive a balloon-expanding-valve (either the Edwards Sapien S3 or Ultra)
89514153|NCT03751007|Experimental|AG019 Cohort 1 - Low Dose/Adults|
89514154|NCT03751007|Experimental|AG019 Cohort 2 - High Dose/Adults|
89514155|NCT03751007|Experimental|AG019 Cohort 3 - Low Dose/Adolescents|
89514156|NCT03751007|Experimental|AG019 Cohort 4 - High Dose/Adolescents|
89514157|NCT03751007|Experimental|Combination Cohort 1 - Adults|
89514158|NCT03751007|Experimental|Combination Cohort 2 - Adolescents|
89514159|NCT05725967||Primary Obesity Endoscopic Procedures|Primary endoscopic procedures for treatment of obesity.
89514160|NCT05725967||Endoscopic Revision of Bariatric Surgical Procedures|Endoscopic revision of post-bariatric surgical complications.
89514161|NCT05725967||Bariatric Surgery Procedures|Bariatric surgical procedures.
89514162|NCT02230007|Experimental|MEOPA|ENTONOX (MEOPA)gas Duration of treatment of a subject according to the protocol: 60 MINUTES Inhalation use
89514163|NCT02230007|No Intervention|Without MEOPA|Physiotherapit care without MEOPA
89514164|NCT02230241||Cohort 1|Subjects of either gender and any race, aged ≥ 18 years, at moderate to very high CV risk, on lipid-lowering pharmacotherapy for at least 3 months (90 days), with no dose change for a minimum of 8 weeks (56 days). Before starting any study-related activities, the investigator should obtain written informed consent personally signed and dated by the subject.
89514165|NCT02230319|Experimental|Cryotherapy|Each patient will receive cryotherapy administered during weekly paclitaxel treatments by Elasto gel™ Hypothermia mitts and slippers. Patients will wear the mitts and slippers for 15 minutes prior to treatment start, for 60 minutes during treatment, and for 15 minutes following treatment completion, for a total of 90 minutes.
89514166|NCT04580537|Experimental|Laser-assisted Enstilar delivery|Ablative fractional laser (AFL) pre-treatment + daily use of Enstilar (cutaneous foam: 0.5 mg/g betamethasone dipropionate, 0.05mg/g calcipotriol)
89514167|NCT04580537|Active Comparator|Enstilar|Daily use of Enstilar (cutaneous foam: 0.5 mg/g betamethasone dipropionate, 0.05mg/g calcipotriol)
89514168|NCT04546841|Experimental|Vaccination|"A single vaccination with the IMP CoVac-1 (SARS-CoV-2 HLA-DR peptides, XS15 emulsified in Montanide ISA 51 VG) (500 µl) will be applied subcutaneously (s.c.) to the abdominal skin.~Part I: Age 18-55 at the time of screening, n=12~Part II: Age 56-74 years at the time of screening, n=12~Part III: Age ≥ 75 years at the time of screening, n=12"
89514169|NCT00112073|Experimental|0.15 mg/kg active bapineuzumab|
89514170|NCT00112073|Placebo Comparator|0.15 mg/kg placebo|
89514171|NCT00112073|Experimental|0.5 mg/kg active bapineuzumab|
89514172|NCT00112073|Placebo Comparator|0.5 mg/kg placebo|
89514173|NCT00112073|Experimental|1.0 mg/kg active bapineuzumab|
89514174|NCT00112073|Placebo Comparator|1.0 mg/kg placebo|
89514175|NCT00112073|Experimental|2.0 mg/kg active bapineuzumab|
89514176|NCT00112073|Placebo Comparator|2.0 mg/kg placebo|
89514177|NCT00141323|Experimental|lasofoxifene 0.5 mg/day|
89514178|NCT00141323|Placebo Comparator|placebo|
89514179|NCT00141323|Experimental|lasofoxifene 0.25 mg/day|
89514180|NCT00135395|Active Comparator|A|
89514181|NCT00135395|Active Comparator|B|
89514182|NCT05725889||DIABETES|Visual, finger tapping and auditory tests were performed regularly. The subjects' fasting plasma glucose and HbA1c levels, and the duration of their diabetes were recorded.
89514183|NCT05725889||CONTROL|Visual, finger tapping and auditory tests were performed regularly. The subjects' fasting plasma glucose and HbA1c levels were recorded.
89514184|NCT02230397|Other|plantaricin a (active product)|Volunteers applied the active product for an uninterrupted period of 8 weeks (on the right or on the left face side randomly) twice a day, in the morning and in the evening, with a mild massage.
88960492|NCT04879641|Experimental|12_Psychoeducation + Attention Training + Exposure|Randomized participants will get the Psychoeducation + Attention Training + Exposure components
88960493|NCT04879641|Experimental|13_Psychoeducation + Cognitive Restructuring|Randomized participants will get the Psychoeducation + Cognitive Restructuring components
88960494|NCT04879641|Experimental|14_Psychoeducation + Cognitive Restructuring + Exposure|Randomized participants will get the Psychoeducation + Cognitive Restructuring + Exposure components
88960495|NCT04879641|Experimental|15_Psychoeducation + Cognitive Restructuring + Attention Training|Randomized participants will get the Psychoeducation + Cognitive Restructuring + Attention Training components
88960496|NCT04879641|Experimental|16_full version (Psychoeducation + Cognitive Restructuring + Attention Training + Exposure)|Randomized participants will get the Psychoeducation + Cognitive Restructuring + Attention Training + Exposure components
88960497|NCT04865783|Active Comparator|Cryospray|Cryospray will be sprayed from a distance of 20-30 cm to the back of one hand.
88960498|NCT04865783|Placebo Comparator|Placebo|A saline solution will be sprayed from a distance of 20-30 cm to the back of the hand.
88960499|NCT04859907|Experimental|Clamp-like system|
88960500|NCT04859907|Active Comparator|Plates and screws|
89207417|NCT02545452|Experimental|Administered Spermicide|Investigate the pharmacokinetics effect of a vaginally administered spermicide (nonoxynol-9) during the use of an IVR releasing ATZ and LNG
88960501|NCT04840342|Experimental|Eplerenone Arm|We posit that individuals who carry the LSD1 risk allele have increased mineralocorticoid receptor activity, which results in hypertension. Thus, our mechanistic clinical study will assess whether hypertensive LSD1 risk allele carriers will show significantly greater reductions in blood pressure with a specific aldosterone mediated treatment approach (mineralocorticoid receptor blockade) than with a non-specific approach (amlodipine). To test this hypothesis, we will perform a randomized, double-blind, active controlled study in hypertensive carriers of the LSD1 risk allele using a novel two-limb, proof-of-principle study. Our primary outcome will be a liberal salt diet systolic blood pressure. Therefore, this mechanistic trial will provide support for using a genetic marker that identifies individuals who are uniquely responsive to mineralocorticoid receptor blockade--personalized, precision medicine.
89207418|NCT02545452|Experimental|Tampons|Investigate the pharmacokinetics effect of the concomitant use of tampons during the use of an IVR releasing ATZ and LNG; investigate the pharmacokinetics over an extended IVR wearing period of 35 days
89514185|NCT02230397|Other|placebo product|Volunteers applied the placebo product for an uninterrupted period of 8 weeks (on the right or on the left face side randomly) twice a day, in the morning and in the evening, with a mild massage
89514186|NCT02230553|Experimental|lapatinib + trametinib|lapatinib: oral tablets, once daily trametinib: oral tablets, once daily
89024636|NCT03270852|Experimental|Enhanced reality|"Patients are provided with occupational therapy and physical therapy (task-oriented OT 30 min, FES 20 min) daily for 50 minutes.~ER therapy is provided 2 times a day for 10 minutes for 2 weeks (10 days of treatment week), except for time of installation, calibration, and 3 minute breaks."
89207419|NCT00547365|Experimental|Human immune globulin intravenous (IGIV)|Analyze the therapeutic potential of human immune globulin intravenous (IGIV) when given to patients with cardiac-associated AL amyloidosis
89207420|NCT00854022||Healthy|Healthy adults, of any ethnicity, or sex, and with no previous history of cancer, except for non-melanoma skin cancer
89514187|NCT02259023|Experimental|Liquid: Sugar sweetened beverage consumption|Consumption of sugar-sweetened beverages
89514188|NCT02259023|Experimental|Solid: Grain based desserts and candy consumption|Consumption of grain based desserts and/or candy
89514189|NCT02230631||Part 1 (retrospective cross-sectional evaluation)|
89514190|NCT02230631||Part 2 (prospective observational evaluation)|
89514191|NCT02230709|Experimental|Dry needling|Dry needling treatment on the trigger point number 2 of the trapezius muscle.
89514192|NCT02230709|Active Comparator|"TENS and dry needling"|Application of TENS current after dry needling treatment.
89514193|NCT02230787|Active Comparator|Recession coverage without Emdogain|
89514194|NCT02230787|Experimental|Recession coverage with Emdogain|
89514195|NCT02230865||Surgery|Minimally invasive repair of pectus excavatum
89514196|NCT03530735|Experimental|Fingerprick Autologous Blood (FAB) for Use in Dry Mouth|"All patients recruited will receive a 10ml saline mouth wash. Half will produce a blood-saline mixture from this mouthwash (preparation details below) and the other half will only use standard saline mouthwash. Each group will use their respective mouthwash 4 times a day for 4 weeks. During the following 4 weeks, participants will use the other mouthwash treatment. In the final 4 weeks, neither group of patients will be using either mouthwash.~Patients will be assessed at week 0, 2, 4, 6, 8, 10 and 12. However only clinic visits 0, 4, 8 and 12 will require clinic visits. During weeks 2, 6, and 10 the patients will fill out the questionnaire at home."
89514197|NCT03530579|Experimental|Group 1|Participants will receive 6 two and a half hour educational group trainings over the course of 6 months.
89514198|NCT03530579|Active Comparator|Group 2|A community health worker will answer your questions about diabetes and refer participant if you need one.
89514199|NCT03530501|Placebo Comparator|Placebo|Very low calorie ketogenic diet followed by low calorie diet
89514200|NCT03530501|Experimental|Synbiotic1+synbiotic2|Very low calorie ketogenic diet supplemented with synbiotic 1 followed by low calorie diet supplemented with synbiotic2
89514201|NCT03530501|Experimental|placebo +synbiotic2|Very low calorie ketogenic diet supplemented with placebo followed by low calorie diet supplemented with synbiotic2
89514202|NCT04261049|Experimental|ZILRETTA Injection|All patients upon enrolling in the study will receive a single 5 mL injection of 32 mg ZILRETTA into the affected knee joint.
89514203|NCT03133715|Active Comparator|laparoscopic ventral hernia|laparoscopic ventral hernia repair
89514204|NCT03133715|Active Comparator|robot-assisted ventral hernia|robot-assisted ventral hernia repair
89514205|NCT00057473|Experimental|Arm A|
89514206|NCT00057473|Active Comparator|Arm B|
89514207|NCT04469777|Experimental|Systemic erythropoietin injections|20 patients diagnosed as late onset optic neuropathy that were attending Alexandria main university hospital.Systemic erythropoietin injections (eprax 10000 IU subcutaneous twice daily for three days).
89514208|NCT05372783|Experimental|STI-9199|4 mg, 10 mg or 20 mg STI-9199 administered intranasally
89514209|NCT05372783|Placebo Comparator|Placebo|Placebo administered intranasally
89514210|NCT03527849|Experimental|In-Person MBSR Course|
89514211|NCT03527849|Experimental|Online MBSR Course|
89514212|NCT03527849|Active Comparator|In-Person HEP|
89514213|NCT05708573|Experimental|Cohort 1|Participants will receive a single dose of rosuvastatin in the morning of Day 1 in Treatment Period 1. Following a washout period of 5 days, participants will receive ALXN2040 three times daily on Days 1 through 7 in treatment period 2.
89514214|NCT03530111||Sedentary|Sedentary individuals will be classified as achieving < 75 minutes of moderate-intensity or < 37 minutes of vigorous-intensity aerobic physical activity per week.
89024637|NCT03270852|Active Comparator|No Enhanced reality|Patients are provided with occupational therapy and physical therapy (task-oriented OT 30 min, FES 20 min) daily for 50 minutes.
89024638|NCT03273036|Active Comparator|epidural steroid injection|40 mg triamcinolone acetate 1 cc
89024639|NCT03273036|Placebo Comparator|placebo injection|no injection agent
89024640|NCT03270735|Experimental|Treatment|Snake venom thrombin
89024641|NCT03270735|Placebo Comparator|Placebo|Snake venom thrombin simulant
89024642|NCT01580384||Cohort|
89024643|NCT04702841|Experimental|CAR-γδT|Infusion,iv,0.2-5 ×10^6/ kg,once.
89024644|NCT04703114|Experimental|Symptomatic|40 symptomatic patients to COVID-19 infection
89541627|NCT03229577|Experimental|Emotional Intelligence|Emotional Intelligence is a program developed for university students that focuses on teaching the skills of emotional intelligence such as labeling, understanding, and regulating emotions.
89541628|NCT03229577|No Intervention|Control|The control group will receive no intervention.
89541629|NCT03235037|Other|Sinemet|The target dose of Sinemet is 2-10 mg per kilogram per day of levodopa. The initial dose will be determined by your weight and age and will start at a low dosage level, 1 mg per kilogram per day. The dose will be re-evaluated after the first 2 weeks and may be adjusted at each visit depending on your response to the drug.
89541630|NCT03229343|Experimental|Experimental|Supportive care, systematic and joint to pneumological consultation, monthly, starting at M0 and continuing up to M6.
89541631|NCT03229343|No Intervention|standard|pneumological consultation performed at M0, M3 and M6
89541632|NCT03229265|Experimental|Patiromer|
89541633|NCT03234803|Experimental|poly-amide|poly-amide is a thermoplastic material recently introduced to be used as a complete denture material, that provide excellent aesthetics and flexibility.
89541634|NCT03234803|Active Comparator|poly-methyl methacrylate|poly-methyl methacrylate has been commonly used as a material for constructing complete dentures and proved to have high success rate and considered to be gold standard.
89024645|NCT04703114|Experimental|Asymptomatic|40 asymptomatic patients to COVID-19 infection
89024646|NCT04053153|Experimental|Use of musical instrument|
89024647|NCT04053153|Sham Comparator|Use of sham musical instrument|
89024648|NCT04702685|Experimental|Ropivacaine|Ropivacaine 0.5% - 20 ml will be administered as erector spinae plane block under ultrasound guidance
89024649|NCT04702685|Placebo Comparator|Placebo|No injection. Bandage will be placed over the presumed site of injection
89024650|NCT00464373|Experimental|1|Botulinum Toxin Type A 200 U in 4ml NaCl 0.9%
89024651|NCT00464373|Placebo Comparator|2|4ml NaCl 0.9%
89024652|NCT00472368|Experimental|LBH589|
89024653|NCT00106028|Placebo Comparator|Placebo Daily|placebo tablet, once a day for one year then for two years open label risedronate
89024654|NCT00106028|Experimental|Risedronate Daily|risedronate tablet, once a day for one year then for two years open label risedronate once a day
89024655|NCT00464451|Experimental|1|Dexmedetomidine sedated pediatric patients undergoing EEG study.
89024656|NCT00464451|Active Comparator|2|Chloral hydrate sedated pediatric patients undergoing sedated EEG study.
89024657|NCT00433940||Infantile Hemangioma Patients|Infants with infantile hemangioma being treated clinically with oral prednisolone sodium phosphate suspensions.
89024658|NCT01050764|Experimental|T-reg Cell Infusion after Allogeneic Stem Cell Transplant|
89024659|NCT00434096|Experimental|1|
89024660|NCT00434096|Placebo Comparator|2|
89024661|NCT01050569|Active Comparator|VLNC Cigarette|Very Low Nicotine Content Cigarette. Dosage: 0.05 mg to 0.09 mg nicotine yield cigarette; Frequency: Daily; Duration: 6 weeks.
89024662|NCT01050569|Active Comparator|Nicotine Patch|21 mg nicotine patch. Dosage: 21 mg; Frequency: Daily; Duration: 6 weeks.
89024663|NCT01050569|Experimental|VLNC Cigarette plus Nicotine Patch|Very Low Nicotine Content Cigarette plus 21 mg Nicotine Patch. Patch Dosage: 21 mg; Cigarette Dosasge: 0.05 to 0.09 mg nicotine yield; Frequency: Daily; Duration: 6 weeks
89024664|NCT00464724|Experimental|3T MRSI Prostate|3T Magnetic Resonance Spectroscopic Imaging
89024665|NCT04702490|Experimental|MET409 A|MET409 Active (50mg)
89024666|NCT04702490|Placebo Comparator|MET409 P|MET409 Placebo (50mg)
89024667|NCT04702490|Experimental|MET409A +Open-Label Empagliflozin|MET409 Active (50mg) + Empagliflozin (10mg)
89024668|NCT04702490|Placebo Comparator|MET409P +Open-Label Empagliflozin|MET409 Placebo (50mg) + Empagliflozin (10mg)
89024669|NCT00464763|Experimental|Dexmedetomidine|
89024670|NCT00464763|Placebo Comparator|Placebo (PBO)|
89541635|NCT03229187||neoadjuvant chemotherapy|
89541636|NCT02452853|Experimental|HR combined with FOLFOX4|"HR ;~FOLFOX4 4 weeks after HR"
89541637|NCT00700271|Experimental|Morning Intake|After randomization, participants received a single daily oral dose of 5 mg amlodipine and 160 mg valsartan free combination therapy, taken in the morning between 6-10 am. At week 4, uncontrolled patients (msSBP >= 140 mmHg and/or msDBP >= 90 mmHg or msSBP >= 130 mmHg and/or msDBP >= 80 mmHg in the case of diabetes or renal insufficiency measured by using conventional methods) received amlodipine/valsartan 10/160 mg for 4 additional weeks. Patients who were controlled at Week 4 (msSBP < 140 mmHg and msDBP < 90 mmHg or msSBP < 130 mmHg and msDBP < 80 mmHg in the case of diabetes or renal insufficiency) continued their amlodipine/valsartan 5/160 mg treatment for the remaining 4 weeks of the study.
89541638|NCT00700271|Experimental|Evening Intake|After randomization participants received a single daily oral dose of 5 mg amlodipine and 160 mg valsartan free combination therapy, taken in the evening between 6-10 pm. At week 4, uncontrolled patients (msSBP >= 140 mmHg and/or msDBP >= 90 mmHg or msSBP >= 130 mmHg and/or msDBP >= 80 mmHg in the case of diabetes or renal insufficiency measured by using conventional methods) received amlodipine/valsartan 10/160 mg for 4 additional weeks. Patients who were controlled at Week 4 (msSBP < 140 mmHg and msDBP < 90 mmHg or msSBP < 130 mmHg and msDBP < 80 mmHg in the case of diabetes or renal insufficiency) continued their amlodipine/valsartan 5/160 mg treatment for the remaining 4 weeks of the study.
89541639|NCT03228797|Active Comparator|Group I|( 20 patients) will receive an ultrasound guided rectus sheath block by the end of the surgery using 15 ml ropivacaine 0.5% on either side.
89514215|NCT03530111||Very Physically Active|Very Physically Active individuals will be classified as achieving > 225 minutes of moderate-intensity or > 112 minutes of vigorous-intensity aerobic physical activity per week.
88811649|NCT01368653|Experimental|Very low nicotine cigarettes|In this condition, smokers from both the Standard treatment and the Standard treatment+practice quitting arms who have smoked in the last 7-days at a 4-week post-target-smoking-cessation-date follow-up interview may be randomly assigned to this group. Those assigned to this group will receive a 6-week supply of cigarettes that contain tobacco with very low levels of nicotine (in regular or menthol flavors) to smoke instead of regular cigarettes containing nicotine. This treatment is designed to help people stop smoking after slipping (returning to smoking) during an attempt to stop smoking
89514216|NCT04468295|Experimental|0.018-inch slot orthodontic bracket system|En-masse retraction using frictionless mechanics with 0.018-inch slot orthodontic bracket system.
89514217|NCT04468295|Active Comparator|0.022-inch slot orthodontic bracket system|En-masse retraction using frictionless mechanics with 0.022-inch slot orthodontic bracket system.
89514218|NCT03530033|No Intervention|Conventional surgery group|Induction of anesthesia according to conventional neuromuscular blockade dose, no neuromuscular blockade drug maintenance during lateral neck dissection.
89514219|NCT03530033|Experimental|Lidocaine group|Anesthesia induction was performed according to conventional nerve monitoring neuromuscular blockade doses and lateral neck dissection was performed. When local muscle tremors occur, lidocaine is injected locally to eliminate muscle tremors.
89514220|NCT03527771|No Intervention|unassisted CPR|unassisted CPR
89514221|NCT03527771|Active Comparator|T-CPR|telephone assisted CPR according to ERC Guidelines 2015
89514222|NCT03527771|Experimental|V-CPR|video-assisted CPR according to ERC Guidelines 2015
89514223|NCT03529721|Experimental|zumba dance group|females in this group will be instructed to engage into12 classes of 60-minute Zumba® fitness over an 8-week period of continuous dance movements to Latin music with varying intensity level throughout the sessions. Each session will be initiated with low-intensity movements for the ﬁrst 5 min, followed by an increasing intensity throughout the workout. At the end of the training session, the intensity will be gradually reduced.
89514224|NCT03529721|Placebo Comparator|non zumba dance group|the control group will be required to carry on doing their normal daily activities throughout the 8-week period.
89514225|NCT03529643|Experimental|Anesthesia with dexmedetomidine|"Anesthesia with sevoflurane-remifentanil-dexmedetomidine~Dexmedetomidine :Continuous infusion of dexmedetomidine with loading dose of 1.0 μg/kg (0.25 ml/kg) for 10 minutes, then followed by maintenance dose of 0.4 µg/kg/hr (0.1 ml/kg/hr)."
89514226|NCT03529643|Placebo Comparator|Anesthesia without dexmedetomidine|"Anesthesia with sevoflurane-remifentanil~Normal saline :Continuous infusion of normal saline with loading dose (0.25 ml/kg) for 10 minutes, then followed by maintenance dose (0.1 ml/kg/hr)."
89514227|NCT03529331|Active Comparator|Morphine Sulfate Immediate Release|ED patients at discharge will receive 15 mg Morphine Sulfate Immediate Release (MSIR) tablet 4 times a day for 5 days.
89514228|NCT03529331|Active Comparator|Oxycodone/Acetaminophen (Percocet),|ED patients at discharge will receive 5 mg of Oxycodone/Acetaminophen (Percocet) tablet 4 times a day for 5 days.
89514229|NCT03529331|Active Comparator|Hydrocodone/Acetaminophen (Vicodin)|ED patients at discharge will receive 5 mg of Hydrocodone/Acetaminophen (Vicodin) tablet 4 times a day for 5 days.
89514230|NCT04441541|Experimental|Treadmill with auditory feedback group|
89514231|NCT04441541|Experimental|Treadmill with visual feedback group|
89514232|NCT04441541|Experimental|Treadmill with auditory and visual feedback group|
89514233|NCT04441541|Active Comparator|Treadmill training group|
89514234|NCT03529253|Experimental|Intensive therapy group|Alirocumab group is Alirocumab75mg/2week plus Rosuvastatin10mg/daily.
89514235|NCT03529253|Active Comparator|Standard therapy group|The standard therapy group is Rosuvastatin10mg/daily alone.
89514236|NCT03532607|Experimental|Treatment|Participants will be asked to listen to pre-recorded music offered by the research team from an ipod for 30 minutes. After the 30 minutes have elapsed, the research staff will return and ask the patient to turn off the music. The patient then will be escorted to the clinic room to receive the botox injection.
89514237|NCT03532607|No Intervention|Control|After completing the consent form, the participants who are assigned to the control group will be asked to remain in the patient waiting area. The patient then will be escorted to the clinic room to receive the botox injection.
89514238|NCT03532529||experiencing the composit outcome|"Average values of LV longitudinal strain^ (Midesophageal 4 chamber view) in patients who developed the composite outcome including the following outcomes of interest:~death within 30 days from VA ECMO liberation~the necessity of new Mechanical Circulatory Support (VA-ECMO, Impella, LVAD) within 30 days from VA ECMO liberation~o Whether after VA ECMO liberation the patient still needs IABP or a RVAD support, this situation is not considered necessity of new Mechanical Circulatory Support. A necessity of new Mechanical Circulatory Support is defined when IABP or RVAD or VA ECMO or Impella are needed again after their removal~heart transplantation within 30 days from VA ECMO liberation"
89514239|NCT03532529||not experiencing the composit outcome|"Average values of LV longitudinal strain^ (Midesophageal 4 chamber view) in patients who did not develop the composite outcome including the following outcomes of interest:~death within 30 days from VA ECMO liberation~the necessity of new Mechanical Circulatory Support (VA-ECMO, Impella, LVAD) within 30 days from VA ECMO liberation~o Whether after VA ECMO liberation the patient still needs IABP or a RVAD support, this situation is not considered necessity of new Mechanical Circulatory Support. A necessity of new Mechanical Circulatory Support is defined when IABP or RVAD or VA ECMO or Impella are needed again after their removal~heart transplantation within 30 days from VA ECMO liberation"
89514240|NCT05725343|Experimental|Canakinumab|Eligible subjects will be randomized in a 3:2 ratio to receive either canakinumab s.c. at 200 mg or placebo every two months.
89514241|NCT05725343|Placebo Comparator|Placebo|Eligible subjects will be randomized in a 3:2 ratio to receive either canakinumab s.c. at 200 mg or placebo every two months.
89514242|NCT04469309|Experimental|Group I|Group I will receive Brandoff Exercises
89514243|NCT04469309|Active Comparator|Group II|Group II will receive Somersault exercises
89514244|NCT03529175|Active Comparator|Concomitant|Intravenous Abraxane125 mg/m2 30-minute infusion followed immediately by intravenous Gemcitabine 1000 mg/m2 30-minute infusion will be administered on days 1, 8 and 15 of a 4-week cycle.
88960502|NCT04840342|Experimental|Amlodipine Arm|We posit that individuals who carry the LSD1 risk allele have increased mineralocorticoid receptor activity, which results in hypertension. Thus, our mechanistic clinical study will assess whether hypertensive LSD1 risk allele carriers will show significantly greater reductions in blood pressure with a specific aldosterone mediated treatment approach (mineralocorticoid receptor blockade) than with a non-specific approach (amlodipine). To test this hypothesis, we will perform a randomized, double-blind, active controlled study in hypertensive carriers of the LSD1 risk allele using a novel two-limb, proof-of-principle study. Our primary outcome will be a liberal salt diet systolic blood pressure. Therefore, this mechanistic trial will provide support for using a genetic marker that identifies individuals who are uniquely responsive to mineralocorticoid receptor blockade--personalized, precision medicine.
89541640|NCT03228797|Active Comparator|Group II|( 20 patients) multiholed catheter will be inserted at the end of surgery and after the closure of the peritoneal layer, a10 ml bolus of ropivacaine 0.2% will be administered through the catheter and then connected to an elastomeric pump delivering a continuous fixed -rate of ropivacaine 5ml/h.
89541641|NCT03228797|Active Comparator|Group III|( 20 patients) a multiholed catheter will be inserted as in Group II and will receive also an ultrasound guided rectus sheath block as described for Group I.
89541642|NCT03234647|Experimental|AHF patients|AHF patient treatment with the Doraya catheter
89541643|NCT03044535||Group 1: Longitudinal assessment|Assessments will be performed pre-MCS, 3 months post-MCS and 6 months post-MCS. Participants in this group must be scheduled for MCS implant.
89541644|NCT03044535||Group 2: Cross-sectional assessment|A one-time assessment will be performed on participants who are post-MCS implant (between 3 months and 10 years post-implant). Participants in this group must already have an MCS device in place.
89541645|NCT02452541|Other|Prognostic evaluation|Prognostic tests/exams performed according to a determined schedule during the acute phase of care following admission in the intensive care unit.
89541646|NCT03046095|Experimental|Unilateral Resistance Exercise|One of the participant's legs will be randomized to a unilateral resistance training arm for 10 weeks in duration. The leg chosen to be trained will undergo resistance exercise three days per week (Monday, Wednesday, and Friday) for the entirety of the study.
89541647|NCT03046095|Experimental|Immobilization|One of the participant's legs will be chosen to be immobilized during the last two weeks of the study. Therefore, one leg will be resistance exercising from week 0-10 whereas the other leg will be immobilized during weeks 8-10.
88960503|NCT04839627||serum progesterone measurement|
88960504|NCT04832815|Experimental|Equine Therapy|
88960505|NCT04832815|No Intervention|Treatment as Usual (TAU)|
88960506|NCT04832815|Experimental|Therapeutic Horsemanship Program|
88960507|NCT04825366|Active Comparator|Standard educational program|Participants will be closely followed by a team of diabetes specialists. Participants will attend two education sessions to discuss the following topics: avoidance of hypoglycemia, causes of hypoglycemia, treatment (e.g. glucagon) of hypoglycemia, how to better recognize hypoglycemia symptoms, understand how to use a continuous glucose monitor (CGM) and understand CGM reports to adjust insulin doses.
89024671|NCT00434135|Experimental|A|Gemcitabine 1,250 mg/sqm days 1 and 8 + Alimta 500 mg/sqm day 8, every 3 weeks
89024672|NCT00434135|Active Comparator|B|Paclitaxel 120 mg/sqm days 1 and 8 + Gemcitabine 1,000 mg/sqm days 1 and 8, every 3 weeks
89024673|NCT01050530|Experimental|OPC-41061|
89541648|NCT03228641|Experimental|micro-excisional skin removal|Facial and neck wrinkles will be treated with micro-excisional skin removal
89024674|NCT01050530|Placebo Comparator|Placebo|
89541649|NCT03045939|Other|12 hours|This arm is the standard management that includes insertion of the DBD into the cervical canal according to manufacture guidelines, removal after 12 hours followed by artificial rupture of membranes and oxytocin infusion according to departments protocol. (a total of 10 units of oxytocin is infused, initiated with 10 cc/h, increased by 10cc every 20-30 min until 3-5 contractions are present, total of not more than 120 cc\h)
89024675|NCT03272880|Experimental|arts-based programming for cancer survivors and caregivers|This is a 8-week, arts-based, health, resilience, and well-being program.
89207421|NCT00854022||RCC|Adult patients with newly diagnosed (diagnosed within the year of enrollment) renal carcinoma (RCC) any ethnicity, or sex, who have not received prior chemotherapy or radiotherapy.
89207422|NCT00854178|Experimental|2|
89541650|NCT03045939|Active Comparator|6 hours|Removal of the DBD after 6 hours, followed by artificial rupture of membranes and oxytocin infusion according to departments protocol. (a total of 10 units of oxytocin is infused, initiated with 10 cc/h, increased by 10cc every 20-30 min until 3-5 contractions are present, total of not more than 120 cc\h)
89541651|NCT03228485||MyBPH Care|All patients enrolled in this study.
89541652|NCT04864197|Experimental|prf group|prf membrane placement over implant site for gingival thickening
89541653|NCT04864197|Experimental|control group|no prf placement
88960508|NCT04825366|Active Comparator|Standard educational program combined with high intensity interval training|"Participants will be closely followed by a team of diabetes specialists. Participants will attend two education sessions to discuss the following topics: avoidance of hypoglycemia, causes of hypoglycemia, treatment (e.g. glucagon) of hypoglycemia, how to better recognize hypoglycemia symptoms, understand how to use a continuous glucose monitor (CGM) and understand CGM reports to adjust insulin doses.~Each study participant will be asked to train 3 times per week following the home-based program that will be provided to them. Participants will be asked to perform at least 2 training sessions per week with the exercise specialist on a virtual platform. The training session will consist of a 3 to 5-minute low-intensity warm-up followed by 6 to 12 1-minute bouts of high-intensity exercise interspersed with 1-minute bouts of low-intensity exercise. Each session will end with a 3-minutes cool-down period."
88960509|NCT04816162|Placebo Comparator|Control group|21 ml of normal saline 0.9% will be I.V continuously infused fifteen minutes after induction of anesthesia up to two hours postoperatively.
88960510|NCT04816162|Active Comparator|ketofol group|21 ml of a mixture of (ketamine and propofol) will be I.V continuously infused fifteen minutes after induction of anesthesia up to two hours postoperatively
89541654|NCT02452619||Brain trauma|Patients with chronic brain injury that have been treated with Hyperbaric oxygen therapy and underwent MRI imaging and cognitive tests before and after the treatment
89541655|NCT03228251||Observation Group 1|all stroke patients receiving thrombolysis and/or thrombectomy in a time period of three months before stroke team simulation training
89541656|NCT03228251||Observation Group 2|all stroke patients receiving thrombolysis and/or thrombectomy in a time period of three months after stroke team simulation training
89541657|NCT03044379|Active Comparator|Dapivirine Gel|Participants will be randomized to receive a single dose of dapivirine gel rectally, followed by 7 daily doses of the same product to be administered under direct observation in the clinic.
89541658|NCT03044379|Placebo Comparator|Placebo Gel HEC|Participants will be randomized to receive the universal HEC placebo gel rectally, followed by 7 daily doses of the same product to be administered under direct observation in the clinic.
89541659|NCT04864509|Active Comparator|Melatonin 10mg|Nightly oral dose
89541660|NCT04864509|Placebo Comparator|Placebo|nightly oral dose
89541661|NCT04864353|Experimental|Experimental: Intervention|Participants will after baseline receive a guided intervention with weekly therapist support.
89541662|NCT04864353|No Intervention|Control: Waitlist|Participants will not receive intervention until 7 weeks after baseline.
89541663|NCT03228407|Active Comparator|Non-erosive reflux disease (NERD)|Patient's with GERD refractory to PPI with no evidence of erosive esophagitis on endoscopy. Confocal endomicroscopy, endoscopic biopsies and mucosal impedance (MI) will be performed.
89541664|NCT03228407|Active Comparator|Barrett's esophagus/erosive esophagitis|Patient's with Barrett's esophagus or with erosive esophagitis on endoscopy. Confocal endomicroscopy, endoscopic biopsies and mucosal impedance (MI) will be performed.
89541665|NCT03228407|Placebo Comparator|Control|Patient's with no h/o GERD or Barrett's esophagus who are undergoing endoscopy for non-GERD related indication. Confocal endomicroscopy, endoscopic biopsies and mucosal impedance (MI) will be performed.
89541666|NCT04863963||Milligan Morgan|Patients aged ≥18 years-old, with Goligher's grade III haemorrhoidal disease, who underwent elective Milligan-Morgan hemorrhoidectomy surgery.
88960511|NCT04816162|Active Comparator|dexmedetomidine group|21 ml of a mixture of (dexmedetomidine diluted with normal saline 0.9%) will be I.V continuously infused fifteen minutes after induction of anesthesia up to two hours postoperatively
88960512|NCT04813185|No Intervention|Treatment as usual|Adults who will not receive BTG services and will receive treatment as usual (TAU) in the hospital.
88960513|NCT04813185|Experimental|In-hospital intervention|Adults randomized to Bridging the Gap (BTG) services will receive a hospital-based violence prevention program with 6-months of community case management and a firearm counseling program.
89541667|NCT04863963||Dearterialization with mucopexy|Patients aged ≥18 years-old, with Goligher's grade III haemorrhoidal disease, who underwent elective Doppler-guided or non-Doppler guided HAL surgery associated with mucopexy
89541668|NCT03228329|Other|cardiometry|fluid boluses will be given when there will be hypovolemia assessed by presence of pulse pressure variations
89207423|NCT01783509||LGMD|Patients with GENETICALLY CONFIRMED limb girdle muscular dystrophy
89207424|NCT00850668|Active Comparator|EMP-123|Participants who are not allergic to peanuts will receive four escalating doses of study product on a weekly basis
89541669|NCT04864041||Patients hospitalised in ICU for vaso-occlusive crisis|
89541670|NCT03228095||Active Tuberculosis|Participants with Active Tuberculosis Disease Intervention: Diagnostic Test: VOC detection in breath and in skin headspace Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Diagnostic Test: Breath sampling Intervention: Headspace analysis for biological material
89541671|NCT03228095||Group of Control (Tuberculosis)|Participants Without Active Tuberculosis Disease Intervention: Diagnostic Test: VOC detection in breath and in skin headspace Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Diagnostic Test: Breath sampling Intervention: Headspace analysis for biological material
89541672|NCT03228095||Gastric cancer|Patients with histologically confirmed gastric cancer Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Upper endoscopy with biopsies Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Diagnostic Test: Feacal sampling Intervention: Headspace analysis for biological material Intervention: Procedure/Surgery: Histological examination of surgical speciment
89541673|NCT03228095||Gastric dysplasia|Patients without gastric adenocarcinoma but with histologically confirmed dysplasia (either high- or low-grade) of the stomach Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Upper endoscopy with biopsies Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Headspace analysis for biological material Intervention: Diagnostic Test: Fecal sampling Intervention: Procedure/Surgery: Histological examination of surgical specimen
88960514|NCT04808778||Participants with sickle cell anemia identified with neurological morbidity|"Successful completion of screening procedures inclusive of 1.) Cerebral blood flow velocity greater than or equal to 200 cm/sec measured twice or 2.) At least one measurement greater than or equal to 220 cm/sec in the middle cerebral artery or 3.) Two TCD measurements above 190 cm/sec within a three-month interval;~MRI showing cerebral infarcts with or without (based on Silent Cerebral Infarct Trial (SIT) criteria) neurological deficits on standard neurological examination;~Informed consent from a participant (> 18 years) or parent/legal guardian for participants (< 18 years) and assent of the participant completed;~Acceptance of hydroxyurea therapy for one year as standard care. After one year of therapy, the participant will have the option to continue therapy with follow-up visits to monitor adherence to therapy with his or her care provider."
89207425|NCT00850668|Experimental|EMP-123 in Peanut Allergics|Participants who are allergic to peanuts will receive weekly dose escalation of the study product for 10 weeks followed by administration every 2 weeks for 6 weeks
89514245|NCT03529175|Active Comparator|Sequential|Intravenous Abraxane 125 mg/m2 30-minute infusion will be administered on days 1, 8 and 15 of a 4-week cycle. Intravenous Gemcitabine 1000 mg/m2 30-minute infusion will be administered on days 2, 9 and 16 of a 4-week cycle. Gemcitabine must be delivered 24 +/- 2 hours after commencing Abraxane infusion.
89514246|NCT04469387|Active Comparator|NS Group|NS Group includes patients who simply receive responsible segments fused (L4-S1).
89514247|NCT04469387|Experimental|LD Group|LD Group includes patients who receive responsible segments fused (L4-S1) plus limited decompression at adjacent segment (L3/4).
89514248|NCT04468373|Experimental|WA-NG (NG-IMT) Telescope Prothesis|Implantable Miniature Telescope for end stage AMD (Age-related Macular Degeneration)
89514249|NCT03532061|Experimental|FamCare Group|Family caregivers who receive 6 in-person problem-solving skills training sessions (FamCare Program).
89514250|NCT03532061|Active Comparator|Caregiver Support Group|Family caregivers who receive 6 in-person caregiver support group sessions.
89514251|NCT03529097|Active Comparator|Fluids|Intervention: 2 liters of 0.9% NaCl IV during the ER stay with pain killers. For placebo purposes this arm participants will get an infusion with black cover so they could not tell if it drips or not
89514252|NCT03529097|Placebo Comparator|Placebo|No interventions, Only pain killers. For placebo purposes this arm participants will get an infusion with black cover so they could not tell if it drips or not
89514253|NCT03531749|Experimental|HIV+ MRPJ|Supplementation with microencapsulated (1g/d) for 90 days
89514254|NCT03531749|Experimental|HIV+ ascorbic acid|Supplementation with ascorbic acid (1g/d) for 90 days
89514255|NCT03531749|Experimental|HIV- MRPJ|Supplementation with microencapsulated (1g/d) for 90 days
89514256|NCT03531749|Experimental|HIV- ascorbic acid|Supplementation with ascorbic acid (1g/d) for 90
89514257|NCT03531749|No Intervention|HIV- Control|Unsupplemented
89514258|NCT03531749|No Intervention|HIV+ Control|Unsupplemented
89514259|NCT03531671|Experimental|Presence of age related cataract|Binocular-OCT used to assess the eye pre and post-operatively.
89514260|NCT03531593||US Elastography|All subjects will undergo one ultrasound elastography examination after consent.
89514261|NCT05583305||Patients diagnosed with APS|"Investigators shall recruit patients with the following criteria:~Diagnosed with APS who fulfilled the modified Sapporo criteria:~at least one clinical criterion (vascular thrombosis or pregnancy morbidity); and~laboratory criteria (aPL positivity twice, 12 weeks apart):~i. Lupus anticoagulant positivity requires screening, mixing, and confirmation test as per International Society of Thrombosis and Hemostasis guidelines (11).~ii. Anticardiolipin antibodies positivity requires a medium to high titer IgG and/or IgM level by ELISA assays.~iii. Anti-β2 glycoprotein antibodies positivity requires a >99th titer IgG and/or IgM level by ELISA assays.~Patients age ≥18 years~Patients who are able to provide an informed consent to study procedures"
89514262|NCT05583305||Controls|From the ongoing prospective Brain Health Longitudinal study which contained stroke- and dementia free participants (CREC Ref. No: 2018.148), investigators shall identify age- and gender-matched individuals without aPLs as controls
89514263|NCT03527459|Active Comparator|SPARC A|SPARC A is an existing clinical program which has a general focus on negative cognitions.
89514264|NCT03527459|Experimental|SPARC B|SPARC B includes all aspects of the SPARC A clinical program, but targets negative cognitions of perceived burdensomeness in some sessions.
89514265|NCT03528863|Experimental|Supportive Care (web-based mindfulness meditation)|Participants practice with web-based mindfulness meditation over 10-15 minute guided audio sessions for 5 days a week for 8 weeks. Participants also attend meditation webinars over 60 minutes once a week, for 8 weeks.
89514266|NCT03528785|Experimental|Single Arm|All patients will receive a treatment scheme of Irinotecan Liposomal Injection [Onivyde], oxaliplatin, Levofolinic Acid and 5-fluorouracil (5 -FU) on Day 1 and Day 15 of each 28 day cycles.
89514267|NCT03531437|Active Comparator|Zoely|Monophasic combined oral contraceptive pills 24 white active tablets and 4 yellow inactive tablets each active tablet contains 1.5 mg estradiol and 2.5 mg nomegestrol acetate 3 cycles
89514268|NCT03531437|Active Comparator|Minidoz|Monophasic combined oral contraceptive pills 24 active tablets and 4 inactive tablets each active tablet contains ethinylestradiol 15 µg and gestodene 60 µg 3 cycles
89514269|NCT03527381|Experimental|Nitric Oxide|Patients of this group receive treatment with exogenous gaseous nitric oxide supplied directly to the oxygenator in the cardiopulmonary bypass circuit during cardiac surgery.
89514270|NCT03527381|Placebo Comparator|Standard CPB|Patients of this group receive sham-treatment without supplying nitric oxide to the cardiopulmonary bypass circuit (Standard CPB) during cardiac surgery. Considering dilution of nitric oxide at a high ratio of 1 to 25,000 in the gas mixture of the cardiopulmonary bypass circuit (CPB), no addition of any inert gas to the CPB circuit is required in sham-treatment group.
89514271|NCT03527303|Experimental|Meditation Group|Participants in the intervention group will assigned to a digitally-based meditation intervention (Headspace app- Basics + Stress packs) and asked to use this for at least 10 minutes a day over the course of 8 weeks
89514272|NCT03527303|No Intervention|Waitlist Control Group|Waitlist control group participants will continue their normal activities and not add any form of meditation during the study period.
89514273|NCT03528707|Active Comparator|probiotic-omega|Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) of gel per day.
89514274|NCT03528707|Placebo Comparator|placebo|Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) of gel per day
89514275|NCT05246189||Patient with PXE working aged|Patient diagnosed with PXE on working age and followed up by the French Reference Center.
89514276|NCT04441151|Experimental|Experimental group|Pulmonary rehabilitation therapy
89514277|NCT04441151|No Intervention|Control group|Routine medical treatment
89514278|NCT05724407||Standard of care|Female patient diagnosed for breast cancer
89514279|NCT03527225|Experimental|Music|Patients randomized to the music intervention arm will select a preferred genre of music from an internet based resource.
89514280|NCT03527225|No Intervention|No Music|These patient's will have no music playing during the first radiotherapy session.
89514281|NCT04468997|Experimental|601 dose level 1 treatment|
89514282|NCT04468997|Experimental|601 dose level 2 treatment|
89514283|NCT04468997|Experimental|601 dose level 3 treatment|
89514284|NCT04468997|Experimental|601 dose level 4 treatment|
89514285|NCT04468997|Experimental|601 dose level 5 treatment|
89514286|NCT04468997|Experimental|601 dose level 6 treatment|
89514287|NCT04469153||SARS-COV 2 positive patient|57 SARS-COV-2 positive patients followed during the SARS-COV 2 epidemic in the internal medicine department of the Croix-Rousse hospital. For each patient ferritin and glycosylated ferritin was analysed one time (biological analysis) at the entry of the hospitalization.
89514288|NCT04468217||Subjects with positive test to SARS-COV2|Employees of critical services companies and healthcare workers with a positive test to SARS-COV2.
89514289|NCT04468217||Subjects with negative test to SARS-COV2|Employees of critical services companies and healthcare workers with a negative test to SARS-COV2.
89514290|NCT04441385|Experimental|Test arm|100 subjects will be randomly assigned to this arm. Patients in the test group will receive 300 mg of maraviroc BID for 14 days (added to standard care).
89514291|NCT04441385|Other|Control arm|100 subjects will be randomized in this arm and will be treated according to the standard care. The Ministry of Health has issued detailed guidelines for the management of COVID-19. Local Institutional Guidelines and Protocols for supportive management will also be implemented.
89514292|NCT03531359|Experimental|TIBD Tablet-based video distraction|Children will receive of tablet-based interctive games in preoperatory room
89514293|NCT03531359|Active Comparator|Midazolam|Children will be premedicated with usual treatmente (midazolam)
89514294|NCT03531281|Experimental|Arm I (goat milk, transplant conditioning/prophylaxis)|"CONDITIONING: Patients receive palifermin on days -10 to -8 and days 0 to 2, undergo FTBI on days -7 to -4, and receive cyclophosphamide on days -3 to -2 or etoposide on day -3 per COH SOP in the absence of disease progression or unacceptable toxicity.~HLZ: Patients receive human lysozyme goat milk PO TID on days -8 to 28 in the absence of disease progression or unacceptable toxicity.~TRANSPLANT: Patients undergo stem cell infusion on day 0.~GVHD PROPHYLAXIS: Beginning on day -2, patients receive tacrolimus and sirolimus daily per COH SOP in the absence of disease progression or unacceptable toxicity."
89514295|NCT03531281|Active Comparator|Arm II (transplant conditioning/prophylaxis)|"CONDITIONING: Patients receive palifermin on days -10 to -8 and days 0 to 2 per COH SOP, undergo FTBI on days -7 to -4, and receive cyclophosphamide on days -3 to -2 or etoposide on day -3 per COH SOP in the absence of disease progression or unacceptable toxicity.~TRANSPLANT: Patients undergo stem cell infusion on day 0.~GVHD PROPHYLAXIS: Beginning on day -2, patients receive tacrolimus and sirolimus daily per COH SOP in the absence of disease progression or unacceptable toxicity."
89514296|NCT03528629|Experimental|Safety Part Arm A (IMAB362 dose-1/2)|Participants will receive a loading dose-1 of IMAB362 on Cycle 1 Day 1 followed by a lower dose-2 in subsequent every 3 weeks.
89514297|NCT03528629|Experimental|Safety Part Arm B (IMAB362 dose-3)|Participants will receive a loading dose-3 of IMAB362 on Day 1 of each cycle (every 3 weeks).
89514298|NCT03528629|Experimental|Expansion Part (IMAB362 dose-1/2)|Participants will receive a loading dose-1 of IMAB362 on Cycle 1 Day 1 followed by a lower dose-2 in subsequent every 3 weeks.
89514299|NCT03528473|Experimental|Exercise|Patients involved in the 6 months-physical training group.
89514300|NCT03528473|No Intervention|Control|Patients in control group carry on their usual follow-up programme.
89514301|NCT05724251||Healthy|participants without periodontitis
89514302|NCT05724251||periodontitis|participants with stage-3 periodontitis
89514303|NCT05724017|Experimental|Street Games Intervention Group|Street Games Intervention Group
89514304|NCT05508191|Experimental|Secretome + Fractional CO₂ Laser|This clinical study uses a 4-fold concentrate of ADMSCs secretome developed by PT. Kimia Farma (Persero), Tbk. The secretome is extracted from stem cell line filtered through syringe with pore size of 0.22 µm to eliminate the debris, then concentrated with CorningⓇ Spin-XⓇ UF 500 µL centrifugator. Stabilization analysis is performed before utilization. As for fractional CO₂ laser, AMIⓇ device is used with this following settings: 15 mJ energy, 900 µs pulse duration, density level 15, and depth level 2.
89514305|NCT05508191|Experimental|Secretome + Microneedle|This clinical study uses a 4-fold concentrate of ADMSCs secretome developed by PT. Kimia Farma (Persero), Tbk. The secretome is extracted from stem cell line filtered through syringe with pore size of 0.22 µm to eliminate the debris, then concentrated with CorningⓇ Spin-XⓇ UF 500 µL centrifugator. Stabilization analysis is performed before utilization. As for microneedle, DrPenⓇ dermapen is used in this following direction and order: vertical, horizontal, and diagonal, with the depth of 150 µm.
89514306|NCT04468685|Experimental|Ondansetron|Ondansetron intraperitoneal in the gall bladder bed
89514307|NCT04468685|Placebo Comparator|Saline|Normal saline intraperitoneal in the gall bladder bed
89514308|NCT05099861||healthy volunteers|Healthy volunteers with no sign of internal disease. Age 18-50, both women and men.
89514309|NCT05099861||patients with internal disease|Patients with internal disease, both women and men.
89514310|NCT03528395|Experimental|Semi-immersive virtual reality|8 week protocol with semi-immersive virtual reality provided with the XBOX 360º video game console and its Kinect device. The commercial video games used will be: Kinect Sports I ®, Kinect Sport II ®, Kinect Joy Ride ® and Kinect Adventures ®.
89514311|NCT03528395|Active Comparator|Conventional Rehabilitation|Physical therapy and Occupational Therapy based on a task-oriented approach
89514312|NCT03528317|Experimental|Alternate day fasting|Alternate day fasting with a high protein diet
88960515|NCT04808778||Participants with sickle cell anemia identified to be without neurological morbidity|"Successful completion of screening procedures inclusive of cerebral blood flow velocity less than or equal to 199 cm/sec in the middle cerebral artery;~Normal MRI and MRA;~No focal neurological deficit on standard neurological examination;~Informed consent from a participant (> 18 years), or parent/legal guardian for participants (< 18 years) and assent from the participant;~Agreement to be followed for at least one year in the study."
88960516|NCT04808752|Experimental|Almonertinib high-dose group|Patients who meet the criteria for inclusion and exclusion will be included in the high-dose almonertinib treatment group and receive oral almonertinib 165 mg once a day
89210550|NCT00819806|Experimental|F|This vaccine injection contains all the same components of Arm E and will also be administered in 3 separate subcutaneous injections. However, 3 days prior to your 1st, 3rd, 5th, 7th, 9th and subsequent monthly vaccinations, you will have low-dose cyclophosphamide administered intravenously (through a vein in your arm).
89514313|NCT03531203|Experimental|With Soursop|Treatment group (with soursop group) was a group which receive soursop supplementation
88960517|NCT04792580|Experimental|Treatment|Subjects receive lifitegrast 5% ophthalmic solution twice a day for 4 weeks after a 2 week washout.
88960518|NCT04792580|Placebo Comparator|Placebo|Subjects receive the lifitegrast vehicle as placebo twice a day for 4 weeks after a 2 week washout.
88960519|NCT04785963|Experimental|Music with Suggestion|Active condition where participants will be provided with recordings of pre-determined music in addition to recorded suggestions instructing the participant on how to listen to the music.
88960520|NCT04785963|Active Comparator|Music|Control group where participants will be provided recordings of pre-determined music
89514314|NCT03531203|Placebo Comparator|Without Soursop|Control group (without soursop group) was a group which do not receive any intervention (placebo)
89514315|NCT05070299|Experimental|Psychosexual Educational Partners Program (PEPP)|Women and their partners will work through a three module workbook together, completing each module over a 2-week period (6 weeks total).
89514316|NCT03531047|Experimental|Refractive CXL|Tomography-customised CXL
89514317|NCT03109925|Experimental|Radio-opaque embolic arm|"Patients will undergo intervention in the form of prostate artery embolization with the new radio-opaque embolic Lumi-Bead developed by BTG plc."
89514318|NCT04440917|Experimental|Study group|Inductive therapy with Camrelizumab and Apatinib
89514319|NCT03526913|Experimental|PRP + STSG|autologous PRP treatments every week prior to graft placement (STSG)
89514320|NCT03526913|Active Comparator|STSG Split Thickness Skin Graft|skin graft (STSG) (intervention)
89514321|NCT03526757|Experimental|Standing Pilates protocol|Subjects will be submitted to a bi-weekly, 50-minute session of Pilates exercises focusing on orthostatic position, for twelve weeks. The following equipment will be used: The Cadillac, Reformer and Chair, emphasizing balance training in the orthostatic position.
89514322|NCT03526757|Active Comparator|Standard Pilates protocol|Subjects will be submitted to a bi-weekly, 50-minute session of the standard sequence of Pilates exercises (traditional sequence of the contemporary / classical method) for twelve weeks. The exercises will be performed using the same equipment used in the intervention group, but following the dorsal decubitus, sedestation and orthostasis, in a time-balanced distribution in each session.
89514323|NCT05455931||Patients with MF/SS|Adult patients with diagnosed MF/SS receiving Poteligeo treatment.
89514324|NCT02740049|Experimental|Astma patients|Participant undergoes a bronchoscopy to isolate epithelial cells
89514325|NCT05434481|Active Comparator|Aneurysm group|Patients operated for aneurysm of the ascending aorta according the guidelines on the diagnosis and treatment of aortic diseases (European Society of Cardiology - 2014).
89514326|NCT05434481|Active Comparator|Type A aortic dissection group|Patients operated for type A aortic dissection according the guidelines on the diagnosis and treatment of aortic diseases (European Society of Cardiology - 2014).
89514327|NCT05434481|Sham Comparator|Control group|Patients without aortic aneurysm or aortic dissection operated for aortic valve replacement (AVR) and/or coronary artery bypass with a saphenous vein graft for proximal aortic anastomosis to collect the aortic sample. For patients operated for AVR, an aortic sample will be collected before closing the aorta.
89514328|NCT03528083|No Intervention|Retrospective Controls|A retrospective control group of patients with a diagnosis of bronchiolitis and meeting inclusion criteria will be used as a comparison group. These patients received usual care for bronchiolitis at our institution.
89210551|NCT00909402|Experimental|All Subjects|
89210552|NCT00821366|Active Comparator|1|Households including ARV patients who receive the ARV treatment and associated support provided as part of government's ARV treatment programme - ARV treatment only group
89514329|NCT03528083|Experimental|Quality Improvement|All patients diagnosed with bronchiolitis and meeting inclusion criteria will undergo the intervention of a bronchiolitis quality improvement process to improve bronchiolitis care quality at our institution.
89514330|NCT03528005|No Intervention|Control|A regular health education program was provided by case managers only.
89514331|NCT03528005|Experimental|Intervention|Multi-domain intervention included exercise,cognitive training, diet education, and disease consultation was conducted for two hours twice per week in the first month, once per week in the second month, and once per month since third month.
89514332|NCT05387837|Experimental|Neovascular Age-related Macular Degeneration|"Cohort A1 - 0.25 mg/kg of D-4517.2~Cohort B1 - 0.5 mg/kg of D-4517.2~Cohort C1 - 1.0 mg/kg of D-4517.2~Cohort D1 - 2.0 mg/kg of D-4517.2"
89514333|NCT05387837|Experimental|Diabetic Macular Edema|"Cohort B2 - 0.5 mg/kg of D-4517.2~Cohort C2 - 1.0 mg/kg of D-4517.2~Cohort D2 - 2.0 mg/kg of D-4517.2"
89514334|NCT03526523|Experimental|Active Treatment|Mindfulness-based stress reduction
89514335|NCT03526523|No Intervention|Waitlist control|The active treatment will be received only after the outcomes monitoring period is complete.
89541674|NCT03228095||High-risk gastric lesions|Patients graded Stage III-IV according to OLGIM (Operative Link of Gastric Intestinal Metaplasia Assessment) staging system, Stage III-IV according to OLGA (Operative Link for Gastric Atrophy Assessment), and those with incomplete type of intestinal metaplasia, but excluding those with dysplasia Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Upper endoscopy with biopsies Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Diagnostic Test: Fecal sampling Intervention: Procedure/Surgery: Histological examination of surgical specimen Intervention: Headspace analysis for biological material
89541675|NCT03228095||Normal and low-risk gastric lesions|Staged 0-III according to OLGIM. Dysplasia should be excluded Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Upper endoscopy with biopsies Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Diagnostic Test: Fecal sampling Intervention: Headspace analysis for biological material
89541676|NCT03228095||Colorectal cancer|Patients with histologically confirmed colorectal cancer (adenocarcinoma) Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Colonoscopy with biopsies Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Diagnostic Test: Fecal sampling Intervention: Headspace analysis for biological material Intervention: Procedure/Surgery: Histological examination of surgical specimen
89541677|NCT03228095||Colorectal high-risk lesions|Patients without colorectal adenocarcinoma, but carrying high-risk adenomatous polyps being described by one of the following: 1) size≥1 cm; 2) high-grade dysplasia; 3) villous component. Prior to removal of the lesions Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Colonoscopy with biopsies Intervention: Headspace analysis for biological material Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Diagnostic Test: Fecal sampling Intervention: Procedure/Surgery: Histological examination of surgical specimen
89541678|NCT03228095||Colorectal low-risk adenoma|Patients without colorectal adenocarcinoma and without colorectal high-risk lesions Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Colonoscopy with biopsies Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Diagnostic Test: Fecal sampling Intervention: Headspace analysis for biological material
89541679|NCT03228095||Group of control (colorectal)|Patients having undergone colonoscopy without an evidence for colorectal lesions Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Colonoscopy with biopsies Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Diagnostic Test: Fecal sampling Intervention: Headspace analysis for biological material Intervention: Procedure/Surgery: Histological examination of surgical specimen
89541680|NCT03228095||Average risk general population|Average risk population of both genders aged 40-64 at the time of inclusion lacking alarm symptoms for gastrointestinal cancer Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Diagnostic Test: Fecal sampling Intervention: Headspace analysis for biological material
89541681|NCT03228095||Pancreatic cancer|Patients with histologically confirmed pancreatic cancer Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Headspace analysis for biological material
89541682|NCT03228095||Chronic pancreatitis|Patients with clinically and/or histologically and/or radiologically confirmed chronic pancreatitis Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Headspace analysis for biological material
89541683|NCT03228095||Liver cancer|Patients with histologically confirmed primary liver cancer Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Headspace analysis for biological material
89541684|NCT03228095||Chronic liver disease|Patients with histologically confirmed liver cirrhosis of viral or other ethiology Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Headspace analysis for biological material
89541685|NCT03228095||Upper respiratory tract acute infections|Patients with serologically confirmed infectious disease or individuals of high risk (e.g. population in season of flu epidemy). This group does not include tuberculosis Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Headspace analysis for biological material
89541686|NCT03228095||Oncological diseases of other locations|Patients with histologically confirmed oncological diseases, excluding gastric, colorectal, pancreatic and primary liver cancer Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Headspace analysis for biological material
89541687|NCT03044067|Experimental|Pain neuroscience education + Exercise|Pain neuroscience education can be defined as an educational session or sessions describing the neurobiology and neurophysiology of pain, and pain processing by the nervous system. It will be applied three times (at baseline, one week and one month after intervention). Exercise will be based on a set of 4 exercise implicating flexion, extension, lateral rotation and abduction of lower and upper extremities.
89541688|NCT03044067|Active Comparator|Exercise|Exercise will be based on a set of 4 exercise implicating flexion, extension, lateral rotation and abduction of lower and upper extremities. Participants will attend three appointments per week over three weeks. They will complete three sets of 10 repetitions, with the exercises progressed in difficulty at each appointment.
89541689|NCT03044301|Other|BMI < 25kg/m²|Subcutaneous high ZENEO® injection Intramuscular ZENEO® injection
89541690|NCT03044301|Other|27.5 > BMI > 25 kg/m²|Intramuscular ZENEO® injection
89541691|NCT03044301|Other|BMI > 27.5 kg/m²|Intramuscular ZENEO® injection
89541692|NCT03044301|Other|No special BMI|Subcutaneous low ZENEO® injection
89541693|NCT04875117||Intervention|Participants who are due to receive their first-ever hearing aid(s) as part of their routine audiological care.
89541694|NCT04875117||Control|Participants with hearing loss who have not experienced any change in hearing aid status for at least 1 year.
89541695|NCT03227783|Active Comparator|Real tDCS|"Constant weak electric currents through scalp via two electrodes will be delivered.~Current intensity: 2mA, 20min/day"
89541696|NCT03227783|Sham Comparator|Sham tDCS|"a 1 mA current, for 30 s giving an initial sensation of tDCS while minimizing stimulatory effects~Ramp up and ramp down was over 10 s. (Ref. Loo CK et al., Br J Psychiatry 2012;200:52-9)"
89541697|NCT04875039|Active Comparator|Perineural dexamethasone|Addition of dexamethasone 2mg to local anesthetics in infraclavicular brachial plexus block
89541698|NCT04875039|Experimental|Perineural dexamethasone plus dexmedetomidine|Addition of dexamethasone plus dexmedetomidine to local anesthetics in infraclavicular brachial plexus block
89541699|NCT03227939|Experimental|Combined Surgery Group|LSG + UPPP＆Adenoidectomy/Tonsillectomy
89541700|NCT03227939|Active Comparator|LSG Group|LSG only
89541701|NCT04874883|Active Comparator|Intervention Group|You will receive 6 grams of the symbiotic (association of fructooligosaccharides, prebiotics, and four probiotic strains: Lactobacillus casei, Lactobacillus rhamnosus, Lactobacillus Acidophilus, and Bifidobacterium bifidum) either enterally or twice a day.
89541702|NCT04874883|Placebo Comparator|Control Group|Will receive 6 grams of the maltodextrin placebo (carbohydrate easily absorbed and digested, not fermented by colonic bacteria and which does not interfere in the microbial ecology of the gastrointestinal tract or in the metabolism and function of the intestine), either enterally or orally in two sachets times a day
89541703|NCT04874727||Study Population|The five or six individual patients enrolled are the members of the sole group, the study population. These individuals all have been diagnosed with obstructive sleep apnea and have take a Cone-beam CT scan with and without the new bite technique.
89541704|NCT02452385|Experimental|CM082 tablet|Escalating dose of CM082 tablet starting at 25mg once a day
89541705|NCT04874649|Experimental|Balloon-blowing breathing|"Start by measuring the vital capacity using a balloon to determine. The width of the balloon diameter for each blow and used the value to make a balloon size control device to give to the sample group and parents to use it for home training.~Participant sit on a chair. Inhale fully through their nose and hold for a full 3 second inhalation, then exhale through their mouth into the balloon fully. By having the balloon inflate until their touch the balloon size control device and hold the exhalation period for 1 second, cover the balloon immediately with your fingers count as 1 breath cycle, then replace the balloon immediately. Do this for 3 consecutive rounds, counted as 1 set, in each training, do a total of 3 sets, rest between sets for 1 minute, which takes about 15 minutes, 5 times per week for 8 weeks"
89541706|NCT04874649|Experimental|Sustained maximal inspiration breathing|Participants sitting in a chair, back and head close to the wall. Inhale through their nose fully and hold for 3 seconds for a full breath, then slowly exhale through their mouth and hold for 1 second of exhalation, counted as 1 breathing cycle.Do this 3 times in a row for 1 set. Practice each time doing a total of 3 sets, with 1 minute rest between sets. Participants were required to complete breathing exercise 5 times per week for 8 weeks.
89541707|NCT03227627|Experimental|VitalStim|"One group of children (Group A) will receive 24 sessions of NMES for combined with traditional therapy including oral motor exercises and laryngeal exercises will be performed to the participants. The equipment to be used for NMES is VitalStim®. VitalStim is a product of Empi®. VitalStim® therapy involves the placement of electrodes to the muscles of the throat that is attached to a device that provides electrical stimulation. The intensity will be increased according to the subject's tolerance and when a therapeutic level is reached. Signs of reaching therapeutic level include changes in audible quality of swallows, triggers of swallows, and changes in quality of voice. This therapy is to be performed by a VitalStim® certified practitioner."
88960521|NCT04785963|Active Comparator|Pain Information|Non-arts group receiving structured attention and standard care
88960522|NCT04779866|Experimental|Self-Administered Hypnosis|Participants randomized to the self-administered hypnosis group will receive five audio-recordings of self-administered hypnosis, specifically targeting sleep improvement, which they will use for daily home practice.
88960523|NCT04779866|Active Comparator|White Noise Hypnosis Control|Participants randomized to the white noise hypnosis control will receive the same information and contact with the therapist, but will be provided with audio recordings that contain white noise as a sham hypnosis condition. These recordings include instructions and the use of white noise as a hypnotic induction.
88960524|NCT04779814||Cohort 1|Demipulse®/Aspire HC® (30 adult subjects)
88960525|NCT04779814||Cohort 2|Demipulse®/Aspire HC® (30 pediatric subjects)
88960526|NCT04779814||Cohort 3|Aspire SR® (30 adult subjects)
88960527|NCT04779814||Cohort 4|Aspire SR® (30 pediatric subjects)
88960528|NCT04779814||Cohort 5|SenTiva® (30 adult subjects)
88960529|NCT04779814||Cohort 6|SenTiva® (30 pediatric subjects)
88960530|NCT04776746|Experimental|Drug - trofinetide|trofinetide oral solution
88960531|NCT04775394|Experimental|Pilot Part: Healthy subjects|3-5 healthy ex-smokers with normal lung function to establish methods
88960532|NCT04775394|Experimental|Main Part: COPD patients and Healthy Controls|8 subjects with COPD stage II and III who are ex-smokers and have a history of chronic cough and sputum production and 5-8 healthy, age-matched controls
88960533|NCT04771611|Experimental|Treatment Group|Subjects will receive treatment drug Fisetin
88960534|NCT04771611|Placebo Comparator|Placebo|Subjects will receive placebo
88960535|NCT04770233|Active Comparator|Early ACL reconstruction|Early ACL reconstruction is performed within 12 weeks after ACL injury and is followed by rehabilitation led by a physiotherapist. ACL surgical technique and rehabilitation is pragmatic according to the routines at the including centre.
89210553|NCT00821366|Active Comparator|2|Households including ARV patients who receive the ARV treatment and associated support provided as part of government's ARV treatment programme - ARV treatment and ARV peer adherence support group
89541708|NCT03227627|Active Comparator|Traditional therapy|The other group (Group B) will be receiving 24 sessions of traditional dysphagia therapy.
89541709|NCT04874337|Experimental|Experimental group|Disaster nursing and management training will be given to students using Jenning's Disaster Nursing and Management Model.
89541710|NCT04874337|No Intervention|Control Group|
89541711|NCT03227393|No Intervention|No yoga training|This will be the control arm. The patients in this arm will not receive any yoga training. They will be continued on all their home, guideline-directed heart failure medications. They will undergo the same baseline and study completion evaluation as the treatment arm, including an I-123 MIBG scan, 24-hour holter monitoring and device interrogation.
89541712|NCT03227393|Experimental|Yoga training|The patients in this arm will receive yoga training. This includes weekly group yoga sessions consisting of breathing exercises, yoga poses, and relaxation and meditation lasting for about 80-90 minutes total. Patients will be asked to do home yoga practices at least twice a week and to document the date and time. Patients in this arm will have the same baseline and study completion evaluation as the control arm, including an I-123 MIBG scan, 24-hour holter monitoring and device interrogation.
89541713|NCT03045783|Experimental|Prophylactic use of antibiotics group|Prophylactic use of antibiotics during endoscopic treatment, cefotiam 2.0g intravenous
89541714|NCT03045783|No Intervention|On-demand group|Routine endoscopic examination and treatment. Antibiotics are not used during endoscopic treatment
89541715|NCT03227549|Experimental|Direct Superior Approach|The intervention being tested is the surgical approach.
89541716|NCT03227549|Active Comparator|Posterior Approach|
89541717|NCT04869033|Experimental|Farinelli's breathing group|Complete Farinelli's breathing exercise 5 times per week for 8 weeks.
89541718|NCT04869033|Other|Diaphragmatic breathing group (control group)|Complete Diaphragmatic breathing exercise 5 times per week for 8 weeks.
89541719|NCT01375049|Experimental|Aztreonam for Inhalation Solution (AZLI)|Participants will receive one 28-day course of AZLI, then will be followed for a 24-week period (through Day 196).
89541720|NCT04863807||Thoracic epidural for rib fracture management|Patients aged > 18 years of age presenting with traumatic rib fractures in a major trauma centre over the past 5 years that meet the criteria for the Imperial College Healthcare National Health Service (NHS) Trust 'Invasive rib fracture management pathway'
89541721|NCT04863807||Erector Spinae block for rib fracture management|Patients aged > 18 years of age presenting with traumatic rib fractures in a major trauma centre over the past 5 years that meet the criteria for the Imperial College Healthcare NHS Trust 'Invasive rib fracture management pathway'
89541722|NCT04863807||Serratus Anterior block for rib fracture management|Patients aged > 18 years of age presenting with traumatic rib fractures in a major trauma centre over the past 5 years that meet the criteria for the Imperial College Healthcare NHS Trust 'Invasive rib fracture management pathway'
89541723|NCT03227237||Case group|Introduction was given about research and researcher to participants. Got the assent from participants, consent from parents and collected baseline data (demographic variable, specific IPR variable) from the participants. Collected data about IPR on the basis of Modified Washington State Juvenile Court Assessment Scale from the participants.Participants were asked to fill out IPR related information of pre delinquent period with paper & pencil mode of technique. It took for each group of participants about 40 minutes. Collected data regarding conduct variables from parents with interview technique. On each day 8-16 participants were covered.
89541724|NCT03227237||Control group|Introduction was given about research and researcher to participants. Confirmed telephonic consent from Parents.Collected baseline data (demographic variable, specific IPR variable) from the participants.Collected data about IPR on the basis of Modified Washington State Juvenile Court Assessment Scale from the participants. Participants were asked to fill out IPR related information of their past life from before 2 years with paper & pencil mode of technique. It took for each group of participants about 40 minutes. On each day 8-20 participants were covered Got the written consent form parents and collected data regarding conduct variables from parents with interview technique.
89541725|NCT03120065|Other|MEMS follow up|Approximately 25% of the enrolled study population will have their adherence to medicines monitored by research personnel through the use of electronic dose monitoring caps (MEMS) for a period of 3 months. The participant's ART medication regimen will be dispensed in a bottle with a cap that monitors the time and date in which the cap is opened. Each month, the participant will bring the bottle with them on their clinic day for three months and the research personnel will extract the timing information from the cap.
89541726|NCT03120143|Experimental|Team sport and high protein group|This group participated in team sport based small-sided ball games with supplementation of a drink with a high content of protein after the training sessions
89541727|NCT03120143|Experimental|Team sport and low protein group|This group participated in team sport based small-sided ball games with supplementation of a drink low in protein content after the training sessions
89541728|NCT03120143|No Intervention|Control group|This group continued their usual life style without intervention
89541729|NCT03226925|Experimental|Healthy volunteers on ventilation|Dynamic MRI acquisition will be performed at two different time points with 10 healthy volunteers under non-invasive mechanically-assisted ventilation with a respirator. Different modes will be compared (spontaneous, physiologic, shallow, slow and jet ventilation).
89541730|NCT03226925|Experimental|Cancer patients on ventilation|Dynamic MRI acquisition will be performed at two different time points with 10 patients (intended for a radiation treatment of their thoracic or upper abdominal tumours) under non-invasive mechanically-assisted ventilation with a respirator. Different modes will be compared (spontaneous, physiologic, shallow, slow and jet ventilation).
89541731|NCT03226925|Experimental|Planning with patients on ventilation|Planning 4D-CT will be performed with 10 patients (intended for a radiation treatment of their thoracic or upper abdominal tumours) under non-invasive mechanically-assisted ventilation with a respirator. Different ventilation modes will be compared (spontaneous, physiologic, shallow, slow and jet ventilation).
89541732|NCT03226613|Experimental|Patients with suspected or known oropharyngeal cancer|Patients with either known or suspected oropharyngeal cancer will be asked to undergo a transcervical ultrasound and to provide a blood and oral rinse specimen.
89541733|NCT02452307|Experimental|Peptide vaccine|Subcutaneous application of Prostate-specific peptide vaccine compound emulsified in Montanide ISA-51
89541734|NCT02452307|Experimental|Peptide vaccine + GM-CSF|Subcutaneous application of Prostate-specific peptide vaccine compound emulsified in Montanide ISA-51 in combination with Granulocyte macrophage colony stimulating factor (GM-CSF)
89541735|NCT02452307|Experimental|Peptide vaccine + local hyperthermia|Subcutaneous application of Prostate-specific peptide vaccine compound emulsified in Montanide ISA-51 in combination with local hyperthermia
89541736|NCT02452307|Experimental|Peptide vaccine + Imiquimod|Subcutaneous application of Prostate-specific peptide vaccine compound emulsified in Montanide ISA-51 in combination with Imiquimod
89541737|NCT02452307|Experimental|Peptide vaccine + mRNA/Protamin|Subcutaneous application of Prostate-specific peptide vaccine compound emulsified in Montanide ISA-51 in combination with mRNA/Protamin
89541738|NCT02452151|Experimental|Infliximab-biosimilar|Infliximab-Biosimilar (Inflectra) (5mg/kg or 10mg/kg) by intravenous (IV) infusion administered as a 2-hour infusion per dose as treatment. In total 4 to 6 doses of the study drug will be administered while continuing patient's dosing intervals, ranging between 6 to 10 weeks.
89541739|NCT02452151|Active Comparator|Infliximab-Innovator|Infliximab-Innovator (Remicade) (5mg/kg or 10mg/kg) by intravenous (IV) infusion administered as a 2-hour infusion per dose as treatment. In total 4 to 6 doses of the study drug will be administered while continuing patient's dosing intervals, ranging between 6 to 10 weeks.
89541740|NCT04485299|Experimental|bifluorid 10 varnish|Bifluorid 10 (NaF and CaF) lead to reduce the dentin hypersensitivity, the sodium fluoride (NaF) dissociates and releases F ions, that diffuse through the tubules and then precipitates as calcium fluoride as a consequence of the high of calcium content in saliva and dentinal fluid ,The calcium fluoride (CaF) present in the varnish composition diffuses into the tubules and block the canal with a semi-permanent protective layer.The calcium fluoride is added to block the dentin tubules mechanically, by the combination with the calcium fluoride resulted from the sodium fluoride reaction to the calcium of dentin.
88960536|NCT04770233|Active Comparator|Primary ACL rehabilitation|"Primary ACL rehabilitation is active rehabilitaion led by a physiotherapist. Active rehabilitation will begin as early as possible after the ACL injury. The goal of rehabilitation is to stabilized the knee without an operation.~ACL reconstruciton is still an option after 6 months if the knee is unstable or do not allow adequat return to physical activity. If the patient sustain new knee injuries secondary to the ACL injury or has major instability, ACL reconstruction may be necessary before 6 months. The patients randomized to active rehabilitation will be routinely followed-up at his/her local hospital at 6 months."
89024676|NCT01050257|Experimental|Oseltamivir (TAMIFLU®) 100 mg|Oseltamivir (TAMIFLU®) 100 mg intravenous (IV) infused over 2 hours, two times a day (every 12 hours) for 5 days. At the discretion of the investigator after 3 days of treatment (6 doses), participants could either continue IV treatment or switch to 75 mg oral oseltamivir twice daily to complete the 5 days of treatment. If necessary, after completing the 5 days of treatment, participants could receive additional treatment with study drug (IV or oral) for up to 5 days.
89541741|NCT04485299|Active Comparator|sodium fluoride varnish|Topical application of varnish fluoride (sodium fluoride NaF) effect on exposed dentine as a desensitizing agent, the varnish fluoride process is caused by the reaction between NaF and calcium ions resulting in calcium fluoride crystals being deposited on the openings of the dentinal tubules that decrease pain.
89541742|NCT01594749|Experimental|Fosaprepitant Regimen|On Day 1, participants received fosaprepitant, 150 mg intravenous (IV) infusion, ~30 minutes prior to chemotherapy PLUS dexamethasone 12 mg, orally (PO) ~30 minutes prior to chemotherapy PLUS ondansetron 16 mg total dose: 8 mg PO ~30-60 minutes prior to chemotherapy, followed by 8 mg PO, 8 hours after first dose PLUS dexamethasone placebo, PO ~30 minutes prior to chemotherapy. On Days 2 and 3, participants received ondansetron placebo, PO every 12 hours. Rescue Therapy: For established cases of nausea or vomiting, medications may have been prescribed from these permitted choices: 5-HT3 antagonists (granisetron, dolasetron, tropisetron or ondansetron); phenothiazines (e.g. prochlorperazine, fluphenazine, perphenazine, thiethylperazine, or chlorpromazine); butyrophenones (e.g. haloperidol or droperidol); benzamides (e.g. metoclopramide or alizapride); benzodiazepines; corticosteroids; domperidone.
89541743|NCT01594749|Active Comparator|Control Regimen|On Day 1, participants received fosaprepitant placebo, 150 mL IV infusion, ~30 minutes prior to chemotherapy PLUS dexamethasone 20 mg, PO ~30 minutes prior to chemotherapy PLUS ondansetron 16 mg total dose: 8 mg PO ~30-60 minutes prior to chemotherapy; followed by 8 mg PO, 8 hours after the first dose. On Days 2-3, participants received ondansetron 8 mg, PO every 12 hours. Rescue Therapy: For established cases of nausea or vomiting, medications may have been prescribed from these permitted choices: 5-HT3 antagonists (granisetron, dolasetron, tropisetron or ondansetron); phenothiazines (e.g. prochlorperazine, fluphenazine, perphenazine, thiethylperazine, or chlorpromazine); butyrophenones (e.g. haloperidol or droperidol); benzamides (e.g. metoclopramide or alizapride); benzodiazepines; corticosteroids; domperidone.
89541744|NCT03226535|Experimental|Ultrasound-CT Fusion Guidance|The participants in this group (test group) will utilize the ultrasound-CT fusion system for guiding needle placement.
89541745|NCT03226535|No Intervention|CT Guidance|The participants in this group (control group) will receive the procedure with traditional CT methods and equipment, for guiding needle placement.
89541746|NCT03225911|Experimental|Insole group|This group will be treated via using lateral wedge insole. lateral wedge insole is an insole with higher lateral side than medial side. This insole is inserted in the participant shoes.
89541747|NCT03225911|Experimental|Sleeve group|This group will be treated via using simple knee sleeve. Simple knee sleeve is a knee support which has no metal support. This sleeve is wrapped around each participant knee.
89541748|NCT03225911|Experimental|insole + sleeve group|this group will have treated via using the later wedge insole and the sleeve together as combined treatment. lateral wedge insole is an insole with higher lateral side than medial side. This insole is inserted in the participant shoes. Simple knee sleeve is a knee support which has no metal support. This sleeve is wrapped around each participant knee.
89541749|NCT03226145|Active Comparator|Patients|"80 Patients : 40 FC 40 IBS-C~Will have MRI Motility and High Resolution Manometry~Then will have:~Bisacodyl 10mg once daily for 10 days, and matched placebo hyoscine butylbromide Buscopan 20mg three times daily for 10 days, and matched placebo~Both agents will have their matched placebo dispensed alongside the active product of the other agent.~All agents to be used in this study as tools for their known mechanisms of action, rather than to assess their effects."
89541750|NCT03226145|Active Comparator|Healthy Volunteers|40 HVs Will have MRI Motility and High Resolution Manometry No other interventions
89541751|NCT04863651||Securely Attached Parturients|Parturients who have a secure attachment style according to the Revised Adult Attachment Scale (Collins, 1996)
89541752|NCT04863651||Insecurely Attached Parturients|Parturients who have an insecure attachment style according to the Revised Adult Attachment Scale (Collins, 1996)
89541753|NCT03234725||LCI out group|The whitdrawal of the colonoscop happen in LCI mode.
89541754|NCT03234725||WL (white light) out group|The whitdrawal of the colonoscop happen in WL mode.
89541755|NCT04863183|Active Comparator|Group 1 (control-Triamcinolone acetonide)|Triamcinolone acetonide (10mg / mL) via intra-articular, 5 cc, one dose (zero time).
89541756|NCT04863183|Experimental|Group 2 (experimental- CELLISTEM-OA)|CELLISTEM-OA via intra-articular, doses of 2 x 106 mesenchymal stem cells in 5cc of saline solution, one dose (zero time).
88960537|NCT04764604|Experimental|Muscle Tension Group|"10 participants with a diagnosis of muscle tension dysphonia will carry out two experimental interventions, with a 30 minute vocal rest period in between interventions:~Three minutes of semi-occluded vocal tract exercise with both Acapella Choice~Three minutes of tube-in-water semi-occluded vocal tract exercise.~Aerodynamic, acoustic and electroglottographic baselines will be taken before each intervention and repeated immediately post-intervention as outcomes.~Participants will also provide a self-assessment of voice quality, perceived ease of voice production and perceived strength of voice before and after each intervention.~Participants will additionally answer qualitative questions following each intervention regarding their perceptions of the task: ease performing, pleasantness, effort, practicality and likelihood of carrying out the task on a daily basis as a form of therapy."
88960538|NCT04764604|Experimental|Vocal Fold Palsy Group|"10 participants with a diagnosis of (unilateral) vocal fold palsy will carry out two experimental interventions, with a 30 minute vocal rest period in between interventions:~Three minutes of semi-occluded vocal tract exercise with both Acapella Choice~Three minutes of tube-in-water semi-occluded vocal tract exercise.~Aerodynamic, acoustic and electroglottographic baselines will be taken before each intervention and repeated immediately post-intervention as outcomes.~Participants will also provide a self-assessment of voice quality, perceived ease of voice production and perceived strength of voice before and after each intervention.~Participants will additionally answer qualitative questions following each intervention regarding their perceptions of the task: ease performing, pleasantness, effort, practicality and likelihood of carrying out the task on a daily basis as a form of therapy."
88960539|NCT04764604|Experimental|Presbylaryngis Group|"10 participants with a diagnosis of presbylaryngis will carry out two experimental interventions, with a 30 minute vocal rest period in between interventions:~Three minutes of semi-occluded vocal tract exercise with both Acapella Choice~Three minutes of tube-in-water semi-occluded vocal tract exercise.~Aerodynamic, acoustic and electroglottographic baselines will be taken before each intervention and repeated immediately post-intervention as outcomes.~Participants will also provide a self-assessment of voice quality, perceived ease of voice production and perceived strength of voice before and after each intervention.~Participants will additionally answer qualitative questions following each intervention regarding their perceptions of the task: ease performing, pleasantness, effort, practicality and likelihood of carrying out the task on a daily basis as a form of therapy."
88960540|NCT04761224|No Intervention|control group|heated blanket + unheated NaCL instillation (operating room ambient temperature: around 17°C).
88960541|NCT04761224|Experimental|Heated group|heating blanket + instillation of NaCl at 38-39°C by Fluido® Irrigation fluid heating system
88960542|NCT04759599|Active Comparator|Group 1|Group 1 will undergo Shock Wave Lithotripsy (SWL) with focal size 2mm (F1), and 3000 shocks
88960543|NCT04759599|Active Comparator|Group 2|Group 2 will undergo Shock Wave Lithotripsy (SWL) with focal size 8mm (F3), and 3000 shocks
89514336|NCT05724641|Experimental|Healthy Volunteers|N = 10, who do not use contact lenses or eye glasses and have a recent evaluation of vision 10/10 ta participate in the repeatability study.
89514337|NCT05724641|Experimental|Chronic|N = 30 (10 patients with thyroid associated orbitopathy (TAO), 10 patients with inflammatory optic neuropathy (ION), 10 patients with ischemic neuropathy), all chronic patients followed in ophthalmology consultation, enlightened volunteers ta participate in the study, and presenting a decrease in residual visual acuity entering the TAO, inflammatory or ischemic frameworks.
89514338|NCT05724641|Experimental|Acute|N = 30 (10 patients with TAO, 10 patients with ION, 10 patients with ischemic neuropathy) all patients seen in the acute phase in ophthalmology consultation who will accept participation in the study, knowing the constraint of repeating the examination in the chronic phase.
89514339|NCT04468139|Experimental|Quercetin|Quercetin 500 g of quercetin Quercetin will be administered orally once daily, in the morning before breakfast for 5-10 days or patient improves or discharged
89514340|NCT03526445|Active Comparator|Glucagon|3 hours i.v. infusion of Glucagon (4 ng/kg/min).
89514341|NCT03526445|Placebo Comparator|Saline|3 hours i.v. infusion of saline
89514342|NCT04939649|Experimental|Ketamine|Participants will receive up to a four-week course of twice-weekly infusions of ketamine at 0.05mg/kg. All infusions will be administered by a consultant anaesthetist.
89514343|NCT04939649|Active Comparator|Midazolam|Participants will receive up to a four-week course of twice-weekly infusions of midazolam at 0.045mg/kg. All infusions will be administered by a consultant anaesthetist.
89514344|NCT04927949|Sham Comparator|patients without HPR|standard primary PCI
89514345|NCT04927949|Experimental|patients with HPR randomized to cangrelor|Cangrelor perfusion started before PCI
89514346|NCT04927949|Placebo Comparator|patients with HPR randomized to standard of care|standard primary PCI
89514347|NCT04589819|Active Comparator|Teriparatide|Study participants will be randomized into either the study medication arm or a placebo arm. The study medication Forteo (teriparatide [rDNA origin] injection) (El-Lilly, Indiana, USA), will be administered via an blinded injection pen in the abdominal wall or thigh as described in the product guide. Subjects in the teriparatide arm will receive a 20mg dose of the medication daily via self-injection.
89514348|NCT04589819|Placebo Comparator|Placebo|The placebo will be administered in a replica, blinded, injection pen in the same fashion. The study participant will self-administer the medication after being given a teaching session on medication administration by the study nurse.
89514349|NCT03526367|Experimental|hydration plus rosuvastatin therapy|"After randomized，hydration（3ml/kg/h, if patients had LVEF<40%, 1.5 ml/kg/h）last 12 hours;~After randomized，a loading dose of rosuvastatin 20mg then 10 mg daily followed for at least 7 days."
89514350|NCT03526367|Active Comparator|Standard therapy|No statin within 12 h after randomization, hydration at physicians' discretion, but no more than 1ml/kg/h.
89514351|NCT04467983|Active Comparator|Denosumab alone|3 injections of Denosumab at appropriate times, separated by no more than 7 months from the last treatment.
89514352|NCT04467983|Active Comparator|Combination therapy|3 injections of Denosumab at appropriate times, separated by no more than 7 months from the last treatment, with added abaloparatide 80 mcg subcutaneously daily, started within 6 months of the last denosumab treatment, for a total of 18 months.
89514353|NCT04839731|Placebo Comparator|Placebo group|10 patients will be divided into 7 and 14 day treatment groups with 5 patients each. They will apply Nourivan base cream from Pure Science Rx, twice per day for their designated time.
88960544|NCT04756154|Experimental|CHG/IPA Surgical skin preparation|Apply topically to the inguinal region for 2 minutes
88960545|NCT04756154|Active Comparator|CHG/IPA Film-Forming Surgical skin preparation|Apply topically to the inguinal region for 2 minutes
88960546|NCT04756154|Placebo Comparator|Normal saline|Apply topically to the inguinal region for 2 minutes
88960547|NCT04754529|Experimental|Supportive care (yoga)|Patients receive online yoga intervention QW for 12 weeks.
88960548|NCT04754217||Group 1|VAVGJ
88960549|NCT04754217||Group 2|CAVGJ
88960550|NCT04748666|Experimental|3 PST sessions and no boosters|
88960551|NCT04748666|Experimental|3 PST sessions with monthly boosters for 6 months|
88960552|NCT04748666|Experimental|6 PST sessions, no boosters|
88960553|NCT04748666|Experimental|6 PST sessions with monthly boosters for 6 months|
88960554|NCT04747249|Experimental|Psychological support|Monthly psychological support
88960555|NCT04742491|Experimental|Immediate Intervention Arm Descovy in the US|PrEP provision, STI screening and treatment, gender affirming hormonal therapy, peer-health management using strengths-based management using Descovy (emtricitabine 200 mg and tenofovir alafenamide 25mg, FTC/TAF) one tablet daily in the US
88960556|NCT04742491|Experimental|Deferred Intervention Arm Descovy in the US|0-6 months PrEP provision, STI screening and treatment. From months 6-18 gender affirming hormonal therapy, peer-health management using strengths-based management using Descovy (emtricitabine 200 mg and tenofovir alafenamide 25mg, FTC/TAF) one tablet daily in the US
88960557|NCT04742491|Experimental|Immediate Intervention Arm Truvada in Brazil|PrEP provision, STI screening and treatment, gender affirming hormonal therapy, peer-health management using strengths-based management using Truvada (emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg, FTC/TDF) one tablet daily in Brazil
88960558|NCT04742491|Experimental|Deferred Intervention Arm Truvada in Brazil|0-6 months PrEP provision, STI screening and treatment. From months 6-18 gender affirming hormonal therapy, peer-health management using strengths-based management using Truvada (emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg, FTC/TDF) one tablet daily in Brazil
88960559|NCT04742491|Experimental|Immediate Intervention Arm Truvada in the US|PrEP provision, STI screening and treatment, gender affirming hormonal therapy, peer-health management using strengths-based management using Truvada (emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg, FTC/TDF) one tablet daily in the US
88960560|NCT04742491|Experimental|Deferred Intervention Arm Truvada in the US|0-6 months PrEP provision, STI screening and treatment. From months 6-18 gender affirming hormonal therapy, peer-health management using strengths-based management using Truvada (emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg, FTC/TDF) one tablet daily in the US
88960561|NCT04741945|Experimental|Metformin|2000 mg/day metformin for 12 months.
88960562|NCT04736433||ACE Inhibitors|Reference group
88960563|NCT04736433||Sacubitril/Valsartan|Exposure group
88960564|NCT04735835|Experimental|Dietary Intervention|Dietary intervention using standardized test meals after which the postprandial metabolic response is measured.
88960565|NCT04735523||Warfarin|Reference group
88960566|NCT04735523||Dabigatran|Exposure group
88960567|NCT04734730|Experimental|Treatment (talazoparib, androgen deprivation therapy)|Patients receive talazoparib PO QD, abiraterone acetate PO QD, and prednisone PO QD on days 1-28. Patients also receive androgen deprivation therapy consisting of degarelix SC on day 1; leuprolide acetate IM on day 1 and bicalutamide PO QD on days 1-28 of cycle 1 and then leuprolide acetate IM on day 1 of subsequent cycles; leuprolide acetate IM on day 1 and bicalutamide PO QD on days 1-28 of cycle 1 and then leuprolide acetate IM on day 1 of cycles 2, 5, 8, and 11; or goserelin acetate SC monthly or every 3 months. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88960568|NCT04728620|Experimental|Intervention|Participants will have access to a new feature within an established patient portal native app on mobile devices. The new feature aims to address diabetes care gaps.
89210554|NCT00821366|Active Comparator|3|Households including ARV patients who receive the ARV treatment and associated support provided as part of government's ARV treatment programme - ARV treatment, ARV peer adherence support and nutritional support group
89514354|NCT04839731|Experimental|7 day medication group|The 7 day medication group will apply combination topical 5-fluorouracil 5% / calcipotriene 0.005% cream twice per day for 7 days.
89514355|NCT04839731|Experimental|14 day medication group|The 14 day medication group will apply combination topical 5-fluorouracil 5% / calcipotriene 0.005% cream twice per day for 14 days.
89514356|NCT03525509|Experimental|Epidural methadone|A single 4mg epidural bolus of methadone hydrochloride
89514357|NCT03525509|Active Comparator|Epidural morphine|A single 4mg epidural bolus of morphine sulfate
89514358|NCT04836923|Experimental|LIFT subgroup|PT evaluation, an individualized home exercise prescription (HEP), daily text message reminders to exercise and weekly telephone check-ins with team members.
89514359|NCT04836923|Experimental|LIFT + REAP subgroup|"PT evaluation, an individualized home exercise prescription (HEP), daily text message reminders to exercise and weekly telephone check-ins with team members. We will also employ Realistic Effort Action Planning (REAP), a form of personality-informed motivational interviewing in a subset of patients to potentially enhance patient engagement and adherence to the home-exercise prescription."
89514360|NCT03525353||Patients undergoing ERCP by formally trained Endoscopists|Patients who undergo ERCP (Endoscopic Retrograde Cholangio Pancreatography) performed by Endoscopists who are trained on minimum use of fluoroscopy.
89514361|NCT03525353||Patients undergoing ERCP by Endoscopists not formally trained|Patients who undergo ERCP (Endoscopic Retrograde Cholangio Pancreatography) performed by Endoscopists who have not received formal training on minimum use of fluoroscopy.
89514362|NCT04702451|Experimental|Tailored|Tailored ablation strategy
89514363|NCT04702451|Active Comparator|Anatomical|Anatomical ablation strategy
89514364|NCT03525275|Experimental|BFA with Physical Therapy|BFA + post-surgical protocol, intervention = battlefield acupuncture plus post-surgical protocol
89514365|NCT03525275|Active Comparator|Physical Therapy alone|Intervention = Post-surgical protocol
89514366|NCT04699721|Experimental|Arm 1|3 cycles of nivolumab+Paclitaxel (albumin-bound type)+ Carboplatin AUC5 (21 days/cycle); as well as BiFico (oral taking, 4 capsules/time, 2 times per day)
89541757|NCT03119909|Other|Learning of actions-events associations|Each subject will conduct 4 sessions, i.e. a training session and three fMRI sessions. The first session will consist in training the subject to carry out the different behavioral tasks that he will then have to perform during the sessions of fMRI.
89541758|NCT03119909|Other|Learning of action-event associations not linked to action|"This study is divided into two parts: a pilot behavioral study to determine the learning characteristics of non-action events and an fMRI study to study the neural networks involved in this type of learning.~30 subjects will participate in the behavioral study and 60 will participate in the fMRI study)"
89541759|NCT03234257|Other|patients with carotid stenosis.|asymptomatic patients with carotid stenosis.
89541760|NCT04874181|Experimental|Silverfit 3D|The subject will use SIlverfit 3D for rehabilitation of his/her shoulder/knee strength post stroke.
89541761|NCT04868955|Experimental|Intervention group|Usual care and oral screen (IQoro®) training.
89541762|NCT04868955|No Intervention|Control group|Usual care.
89541763|NCT03119987||UGIB|Those who was diagnosed as UGI bleeding at emergency department during the study periods. Red cell distribution widths wers checked at all patients.
89541764|NCT04873947||healthy adult volunteer|Subject is 18 to 50 years of age. Subject is a non-smoker or who has not smoked within 2 days prior to the study.
89541765|NCT04873791||Group 1|"Assessment Geriatric Individuals Living at Home were joined in Group 1.~Demographic and social characteristics, cognitive functions, balance, pain, depression, quality of life, and activities of daily living of elderly individuals living in a nursing home and home environment were evaluated.~Demographic information of all subjects (age, gender, educational status, occupation, body weight, height, body mass index), Standardized Mini-Mental Test (SMMT) score, Visual Analog Scale (VAS) score, Berg Balance Scale (BBS) score, Geriatric Depression Scale (GDS) score, Barthel Index score, Short Form-36 (SF-36) score were used for evaluations.~Assessments were made as described in section of outcome measures, in one session."
89541766|NCT04873791||Group 2|"Assessment Geriatric Individuals Living in Nursing Home were joined in Group 2. Demographic and social characteristics, cognitive functions, balance, pain, depression, quality of life, and activities of daily living of elderly individuals living in a nursing home and home environment were evaluated.~Demographic information of all subjects (age, gender, educational status, occupation, body weight, height, body mass index), Standardized Mini-Mental Test (SMMT) score, Visual Analog Scale (VAS) score, Berg Balance Scale (BBS) score, Geriatric Depression Scale (GDS) score, Barthel Index score, Short Form-36 (SF-36) score were used for evaluations.~Assessments were made as described in section of outcome measures, in one session."
89541767|NCT03225521|Experimental|HeartSteps intervention|"For activity suggestions, at each available decision time, each participant is randomly assigned to either receive an activity suggestion or not. The randomization probability is 0.6 for receiving a message and 0.4 for not receiving a message.~For activity planning, at each decision point, the participant is randomized to either receive evening planning or not at that decision time. The randomization probability for receiving planning is 0.5, and 0.5 for not receiving planning."
89541768|NCT04868487|Experimental|Intervention|The intervention group received four weekly training sessions of health literacy education. Each educational session lasted an average of 50 minutes. The students were divided into four groups with an average of 25 students in each group.
88960569|NCT04727879|Other|PMR|"Patients with PMR will be offered biopsy of the synovial membrane with puncture of synovial fluid during cortisone infiltration for analgesic purposes. In case of associated peripheric arthritis, the patient will also be offered a joint fluid sample during a cortisonic infiltration for analgesic purposes, performed as part of routine care~The study-specific examination that is not part of current practice is the synovial biopsy performed during the cortisonic infiltration procedure."
88960570|NCT04727879|Other|Control|Witnesses recruited into the orthopedic surgery department will be offered a synovial membrane biopsy during a shoulder surgery in the context of mechanical pathology.
88960571|NCT04725474|Experimental|Phase 1 (Part A; dose escalation): CTL-002 Monotherapy + Checkpoint Inhibitor Combination|Up to 5 dose levels with visugromab (CTL-002) administered as IV monotherapy and in combination with a CPI
88960572|NCT04725474|Experimental|Phase 2 (Part B; expansion): visugromab (CTL-002) + Checkpoint Inhibitor Combination|At defined dose level(s) with visugromab (CTL-002)
88960573|NCT04719052|Experimental|Mediterranean diet group|"1) The MD will be based on high consumption of unsaturated fat from vegetable sources (virgin olive oil and nuts) and minimally processed plant foods (vegetables, fruits, nuts, whole grains and legumes), low consumption of meat (especially red and processed meats) and sweets, and moderate consumption of fish and dairy products (mainly yoghurt and cheese). Accordingly, this diet will provide a high amount of mono and polyunsaturated fatty acids, fibre and phenolic compounds.~Adolescents in the MD group will replace the intake of conventional breads by sourdough bread consumption (2 servings of 50-60 g daily) and incorporate into their diet chickpeas (2 servings of 150 g/week chickpeas, minimum one of them in hummus format), and they will consume at least another serving of legumes which can be chickpeas or another legume), pomegranate juice (4 servings of 200ml/week) and mixed nuts (4 servings of 30 g/week)."
88960574|NCT04719052|Active Comparator|Low-fat diet group|2) The low-fat diet (control diet) will be based on low consumption of fats. A low-fat diet is the most used diet for obesity treatment in adolescents. This group will not receive any additional specific food by researchers. This diet will be based on the diet proposed as low-fat diet in the PREDIMED study
88960575|NCT04717713|Experimental|steroid group|patients receiving steroid injection for preventing postoperative dysphagia
88960576|NCT04717713|Placebo Comparator|placebo group|patients receiving saline injection for comparator
89541769|NCT04868487|No Intervention|Control|The control group had no educational interaction with the researcher after the pre-test. The control group was administered the one-week and three-month posttest THLS-32 by the researcher simultaneously with the intervention group.
89541770|NCT04379973|Experimental|Tubal flush with Lipiodol Ultra Fluide® after Hyfosy|
89541771|NCT04379973|No Intervention|No tubal flush after Hyfosy|
89541772|NCT02453009|Experimental|Arm A|Docetaxel 75 mg/m² intravenously on day 1 every 3 weeks for 8 cycles, plus oral prednisone 10 mg daily for 24 weeks plus oral enzalutamide 160 mg daily for 24 weeks
89541773|NCT02453009|Active Comparator|Arm B|Docetaxel 75 mg/m² intravenously on day 1 every 3 weeks for 8 cycles, plus oral prednisone 10 mg daily for 24 weeks
89541774|NCT03044457|Experimental|TKA by reversed gap technique|new operative technique of positioning the femoral and tibial component based on soft tissue tension and femoral 3D geometry.
89541775|NCT03044457|Active Comparator|TKA by gap technique|standard operative technique serving as control. tibia component positioning according to the mechanical axis, femoral component positioning according to the mechanical axis and soft tissue tension in flexion
89541776|NCT03225443||Particle Radiotherapy|The patients will receive particle radiotherapy before operation,and then radical hysterectomy, removal of pelvic lymph nodes and abdominal aorta lymph nodes would be conducted. Besides ovary reservation would be made according to the individual situation. Concurrent radiation and chemotherapy would be performed according to the clinical situation.
89541777|NCT03225443||Neoadjuvant Chemotherapy|The patients will receive NACT before operation,and then radical hysterectomy, removal of pelvic lymph nodes and abdominal aorta lymph nodes would be conducted. Besides ovary reservation would be made according to the individual situation. Concurrent radiation and chemotherapy would be performed according to the clinical situation.
89541778|NCT03225053|Experimental|MEP® technique|G1 (n = 15), referred to as LMF, will be submitted to the myofascial release technique consisting of: classic massage (superficial sliding, deep sliding, pumping-kneading, pulse and four-finger smear and sliding) Minutes. G2 (n = 15) will be applied to the MEP® technique, in which the needles will be introduced in three occasions during each session, in different points of the musculature of the most painful region, for a total of 3 minutes. The G3 (n = 15) will execute the two techniques above, being applied the first version Myofascial and later to the MEP®. G4 (n = 15) will be the control group, not performing any of the interventions. The reevaluations will occur immediately and after 48 hours of the intervention.
89541779|NCT04868331|Experimental|AIS girls|Girls between the ages of 10-16 will be recruited if they have a diagnosis of AIS.
89541780|NCT04868331|Active Comparator|Healthy Controls|Healthy adolescent girls matched in age and puberty maturity without spinal deformity
89541781|NCT03047811|Experimental|TCR - T cell therapy|Peripheral blood mononuclear cells collected: draw 100-150 ml of peripheral blood in patients and separate of the peripheral blood mononuclear cells, the total number of cells 1.5 * 10 ^ 7 / kg - 1 * 10 ^ 8 / kg Fludarabine 25 mg/m2 + NS 250 ml, ivgtt qdx5d, CTX 60 mg/kg + NS 250 ml, ivgtt qd x2d, should be in front of the TCR - T cells infusion of 4 days reinfusion the total number of T cells （1* 10 ^ 8 / kg - 10 * 10 ^ 8 / kg） in 3 days , infusion 10-15 minutes, should not be more than 20 minutes.
89541782|NCT04868175|Active Comparator|Group 1|control (hypromellose), then Timolol, then Travatan
89541783|NCT04868175|Active Comparator|Group 2|Timolol, then Travatan, Hypromellose
89541784|NCT04868175|Active Comparator|Group 3|Travatan, then Hypromellose, Timolol
89541785|NCT03225209|Experimental|OPTIFAST|"Subjects meeting inclusion criteria will be receive OPTIFAST meal replacement (MR) in the following manner:~WK1-WK12 (5 MR/DAY)~WK13-14 (4 MR/DAY)~WK 15 (3 MR/DAY)~WK 16 (2 MR/DAY)~WK 17-18 (1 MR/DAY)~WK 19-24 (No MR)"
89541786|NCT02452775|Experimental|Arm 1|Subjects in ARM 1 will receive the vaccination with OC-L alone
89541787|NCT02452775|Experimental|Arm 2|subjects in ARM 2 will receive vaccination with OC-L admixed with Montanide,
89541788|NCT02452775|Experimental|Arm 3|subjects in ARM3 will receive vaccination with OC-L admixed with 1 mg poly-ICLC (Hiltonol)
89541789|NCT02452775|Experimental|Arm 4|subjects in ARM 4 will receive vaccination with OC-L admixed with both Montanide and 1 mg poly-ICLC.
89541790|NCT03224975|Experimental|patients|Patient who was burned will have fMRI.
89541791|NCT03224975|Active Comparator|control group|Healthy volunteers (control group) will have fMRI.
88960577|NCT04717258|Experimental|Main FIREFLI trial: Intervention arm|Usual care from healthcare professionals; falls prevention leaflet; Safe and Well Visits (SWVs) offered by the Fire and Rescue Service (FRS) (either a firefighter, day duty safety advocate or home safety officer) once randomised.
88960578|NCT04717258|No Intervention|Main FIREFLI trial: Control arm|Usual care from healthcare professionals; falls prevention leaflet; Safe and Well Visits (SWVs) by the Fire and Rescue Service (FRS) (either a firefighter, day duty safety advocate or home safety officer offered 12 months post-randomisation)
88960579|NCT04717258|Experimental|Recruitment SWAT: Self-Determination Theory informed invitation letter|The recruitment pack to take part in the FIREFLI study will include an invitation letter informed by Self-Determination Theory.
88960580|NCT04717258|No Intervention|Recruitment SWAT: Standard invitation letter|The recruitment pack to take part in the FIREFLI study will include the University of York, York Trials Unit's standard invitation letter
88960581|NCT04717258|Experimental|Retention SWAT: Pen arm|A pen (which has the University of York logo on it) will be included with the first four-month reminder questionnaire.
88960582|NCT04717258|No Intervention|Retention SWAT: No pen|No pen will be included with the four-month reminder questionnaire.
88960583|NCT04715581|Experimental|Multicomponent prehabilitation group|Patients in the intervention group will receive nutritional optimization and exercise training before the surgery, exercise training after the surgery, and home-based rehabilitation after discharge.
88960584|NCT04715581|No Intervention|Control group|Patients in the control group will maintain normal diet and normal activity before surgery, normal activity after surgery, and normal activity after discharge.
89210555|NCT00821366|No Intervention|4|Randomly selected households from the general community served by the selected health facility, excluding households where someone is known to receive ARV treatment - comparison/control group
89210556|NCT02538120|Active Comparator|Diabetes type 1 patients|The intervention will be : Microvascular assessment with laser speckle contrast imaging
89541792|NCT03045705|Active Comparator|Labor+routine pain management|Women that will be treated by the medical team in the delivery room as if not part of a study regarding pain management.
89541793|NCT03045705|Active Comparator|Labor+experimental pain management|Women that will not be asked at all by the medical team in the delivery room regarding analgesia during labor but will be able to receive analgesia at wish at the time of choice.
89541794|NCT03224897|Active Comparator|Cathodal tDCS|
89541795|NCT03224897|Active Comparator|Anodal tDCS|
89541796|NCT03224897|Sham Comparator|Sham tDCS|
89541797|NCT03045627|Active Comparator|Experimental|"Ara-C, Aclarubicin Combined PEG-G-CSF~ARA-C subcutaneously in a 12-hour infusion on days 1 through 14, Aclarubicin(Acla) 5～7mg/m2/d，intravenously on days 1 through 8, PEG-G-CSF 6mg subcutaneously on days 0. One course includes 28 days."
89541798|NCT03045627|Active Comparator|Active comparator|"Ara-C, Aclarubicin Combined G-CSF~ARA-C subcutaneously in a 12-hour infusion on days 1 through 14, Aclarubicin(Acla) 5～7mg/m2/d，intravenously on days 1 through 8, G-CSF 200 μg·m-2·d-1, subcutaneously on days 0 through 14. G-CSF was postponed or interrupted in case of white blood cell (WBC) count greater than 20 × 109/L .~One course includes 28 days."
89541799|NCT03224663|Experimental|Module based learning|Module based learning is self-reading method using learner's guide module on FBNC provided by Department of Pediatrics
89541800|NCT03224663|Experimental|Mobile application based learning|"Mobile application based learning is learning method using android based mobile application on Facility Based Newborn Care provided by Division of Department of Pediatrics WHO-CC AIIMS FBNC deals with posters, videos, Modules."
88960585|NCT04701645|Experimental|Cohort 1: Primary cytoreduction|"Patients with a new or suspected diagnosis of ovarian cancer who are deemed surgical candidates for primary cytoreductive surgery (as per their surgical gynecologic oncologist) and who have not yet undergone surgery.~Participants will undergo percutaneous placement of several microdevices in a selected tumor deposit prior to surgery.~The microdevices will dwell in the tumor tissue for approximately 24 +/- 8 hours to allow time for tissue effects of the drugs in the microdevice reservoirs. Microdevices will then be removed by resection of the tumor mass during a previously planned, and clinically indicated, surgical procedure."
88960586|NCT04701645|Experimental|Cohort 2: Surgical assessment for primary surgery|"Patients with newly diagnosed ovarian cancers who are being considered for either primary surgery or neoadjuvant chemotherapy by their surgical gynecologic oncologist, and who require a laparoscopic procedure to determine their candidacy for surgery.~Participants will undergo percutaneous placement of several microdevices in a selected tumor deposit prior to surgery.~The microdevices will dwell in the tumor tissue for approximately 24 +/- 8 hours to allow time for tissue effects of the drugs in the microdevice reservoirs. Microdevices will then be removed by resection of the tumor mass during a previously planned, and clinically indicated, surgical procedure."
88960587|NCT04701645|Experimental|Cohort 3: Secondary cytoreduction|"Patients with recurrent ovarian cancer who are candidates for secondary cytoreduction, e.g.to confirm diagnosis of recurrent ovarian cancer and/or remove oligometastatic lesions.~Participants will undergo percutaneous placement of several microdevices in a selected tumor deposit prior to surgery.~The microdevices will dwell in the tumor tissue for approximately 24 +/- 8 hours to allow time for tissue effects of the drugs in the microdevice reservoirs. Microdevices will then be removed by resection of the tumor mass during a previously planned, and clinically indicated, surgical procedure."
88960588|NCT04701645|Experimental|Cohort 4: Interval debulking surgery following neoadjuvant chemotherapy|"Patients with newly diagnosed ovarian cancers who have undergone neoadjuvant chemotherapy and are deemed surgical candidates for interval debulking surgery (as per their surgical gynecologic oncologist) and who have not yet undergone surgery.~Participants will undergo percutaneous placement of several microdevices in a selected tumor deposit prior to surgery.~The microdevices will dwell in the tumor tissue for approximately 24 +/- 8 hours to allow time for tissue effects of the drugs in the microdevice reservoirs. Microdevices will then be removed by resection of the tumor mass during a previously planned, and clinically indicated, surgical procedure."
88960589|NCT04681820||flumatinib|flumatinib 600mg QD, fasting administration
88960590|NCT04681820||nilotinib|nilotinib 400mg BID, fasting administration
88960591|NCT04675788|Experimental|Postmenopausal women: Progesterone|Subjects will receive treatment with oral progesterone 400 mg once daily (two x 200 mg capsules) every evening for 7 days
88960592|NCT04675788|Placebo Comparator|Postmenopausal women: Placebo|Subjects will receive oral placebo, two capsules once daily every evening for 7 days
88960593|NCT04675788|Experimental|Men 65 years of age or older: Testosterone|Subjects will receive treatment with transdermal testosterone 1% (100 mg) every morning for 3 days
88960594|NCT04675788|Placebo Comparator|Men 65 years of age or older: Placebo|Subjects will receive treatment with transdermal placebo every morning for 3 days
88960595|NCT04669509||Group 1|Patients with normal ALT, AST and total bilirubin values
88960596|NCT04669509||Group 2|Patients whose ALT, AST or total bilirubin levels are up to 3 times upper limit of normal
88960597|NCT04669509||Group 3|Patients whose ALT, AST or total bilirubin levels are increased more than 3 times upper limit of normal
88960598|NCT04667572|Experimental|Pulsed 5mW/cm2|5mW/cm2, with pulsed mode, 10 seconds on, 10 second off, for 36 minute total treatment time
88960599|NCT04667572|Experimental|Pulsed 8mW/cm2|8mW/cm2, with pulsed mode, 10 seconds on, 10 second off, for 22 minute and 30 seconds total treatment time
88960600|NCT04656353|Experimental|Intervention Arm|Participants randomized to the Intervention Arm will be provided with the website link to the online psychosocial program and the questionnaire and distress survey. They will be asked to use the website within two weeks and then to complete the questionnaire and distress survey after using it and mail them back in a self-addressed stamped envelope. The participants will also be asked in the 3-month follow-up questionnaire if they are interested in attending a focus group to elaborate on their experience with the psychosocial self-help program. Those who have expressed an interest will be contacted.
88960601|NCT04656353|Experimental|Control Group|Participants randomized to the Control group will receive standard care (no intervention). They will be used as a baseline to compare groups and assess the effect of the intervention (i.e., the online psychosocial program). At the two weeks following randomization (T1) and the 3-month follow-up periods (T2), they will be asked to complete the questionnaire and distress survey and return them in a self-addressed stamped envelope. Participants will be given two weeks to complete the questionnaire and distress survey. The same documents will be administered at the 3-month follow-up period (T2). Once the 3-month follow-up is completed, each participant will be provided with the website link to view the self-help program.
89210557|NCT02538120|Active Comparator|Matched control-subjects|The intervention will be : Microvascular assessment with laser speckle contrast imaging
89541801|NCT04868019|Experimental|Group A|Groups A will receive solution A .i.e fenofibrate suspension
89541802|NCT04868019|Placebo Comparator|Group B|Group B will receive solution B i.e placebo.
89541803|NCT03233477||Posner-Schlossman Syndrome|"Inclusion criteria：~Clinical diagnosis of Posner-Schlossman Syndrome~Able to communicate with doctor and understand this study~Exclusion criteria:~Not be able to communicate with doctor and understand this study~One or more authorized investigators think he or she will suffer from any severe risks from the study"
89541804|NCT03233477||cataract|"Inclusion criteria：~Clinical diagnosis of age-related cataract~Prepare for cataract operation~Open angle and intraocular pressure is normally at anytime~No family history of glaucoma~Exclusion criteria:~Patients above 65 years old~With Secondary ocular hypertension~Have the history of receiving any ophthalmologic operation or anti-viral therapy~With diabetes mellitus~With autoimmune disease~Be receiving any therapy that can influence the virus-infection state and biochemical characteristics of serum and aqueous humor, or have received such therapy before one month"
89541805|NCT03233477||primary open-angle glaucoma|"Inclusion criteria：~Both eyes involved~Open angle~Progressive glaucomatous optic neuropathy~Specific visual field loss of glaucoma~Intraocular pressure above the up limit of normal people~Exclusion criteria:~Patients above 65 years old~With Secondary ocular hypertension~Have the history of receiving any ophthalmologic operation or anti-viral therapy~With diabetes mellitus~With autoimmune disease~Be receiving any therapy that can influence the virus-infection state and biochemical characteristics of serum and aqueous humor, or have received such therapy before one month"
89541806|NCT03047967|Experimental|PTSE|Prenatal tobacco smoke exposed newborns. Lung function test Nasal brushing
89541807|NCT03047967|Experimental|control|Prenatal tobacco smoke non exposed newborns Lung function test Nasal brushing
89541808|NCT03224741|Placebo Comparator|Information|
89541809|NCT03224741|Active Comparator|Active Choice|
89541810|NCT03224741|Experimental|Monetary incentive|
89541811|NCT04863105|Experimental|Conference-Abiraterone acetate tablet|Abiraterone acetate tablets(Zecke ® 250 mg,Batch number:VYCB manufactured by Patheon Inc.)
89541812|NCT04863105|Experimental|test-Abiraterone acetate tablet|Abiraterone acetate tablets(250 mg,Batch number:17F0023DD9 manufactured by Qilu Pharmaceutical Co., Ltd)
89541813|NCT02179918|Experimental|PF-05082566 +MK-3475|PF-05082566 +MK-3475
89541814|NCT03233321|Experimental|Experimental group|30 patients were selected in experimental group. Dry cold was applied to the subcutaneous injection site using ice bag filled with crushed ice with half table spoon of salt for 20 minutes after the administration of injection.Pain intensity was measured using numeric pain rating scale immediately after dry cold application and bruise size was assessed using bruise assessment scale after 12, 48 and 72 hrs of injection administration.
89541815|NCT03233321|No Intervention|Comparison group|No intervention was given. Pain intensity was measured using numeric pain rating after 20 minutes of subcutaneous injection and bruise size was assessed using bruise assessment scale after 12, 48 and 72 hrs of injection administration.
89541816|NCT04868253|Experimental|EMB-001|EMB-001 will be administered utilizing capsules which contain 240 mg of metyrapone and 8 mg of oxazepam (240/8 mg). Subjects will be prescribed 3 capsules (total of 720 mg metyrapone and 24 mg oxazepam) taken twice daily for a total of 12 weeks. After week 12, or if indicated and possibly for a subject who is being discontinued early, subjects will take one capsule of EMB-001, 240/8 mg, twice a day for one additional week (taper dose).
89541817|NCT04486157|Experimental|IN-A012|Intravenous administration of IN-A012
89541818|NCT04486157|Active Comparator|Akynzeo capsules|Single oral administration of Akynzeo capsules
88960602|NCT04652934|Experimental|Intervention group|The Upper Limb Neurodynamic Test (ULNT1) technique described by Butler will be performed on the affected limb. This technique consists of performing shoulder depression, 90º shoulder abduction, hand, wrist and forearm in a neutral position, external rotation of the shoulder and extension of the elbow. After positioning the limb in this position, wrist flexion-extension movements will be performed smoothly and rhythmically of 20 movements every minute, for 3 minutes, three times per session with 1 minute of rest between each series.
89541819|NCT02452073||CRE group|patients with chronic radiation enteritis
89541820|NCT02452073||malignancy group|patients with some kinds of malignant tumors but had not previously received radiotherapy
89541821|NCT02452073||control group|age-matched healthy volunteers
89541822|NCT02452229||Burn patients|The included patient are burn victims who sustained a burn of at least 1 % total body surface are (TBSA); with no restriction on age.
89541823|NCT04862637|Experimental|pull through group|the patients receiving the pull though method during the tongue cancer surgery
89541824|NCT04862637|Placebo Comparator|mandibular-lip split group|the patients receiving the traditional mandibular lip split method during the tongue cancer surgery
89541825|NCT03224273|Experimental|( proximal box design)|The proximal box at least ( 1mm wide and has 6◦ divergences, and extend 2 mm apical to the isthmus ﬂoor.
88960603|NCT04652934|Sham Comparator|Mimic group|The protocol used by Beneciuk et al. Will be used. This intervention consists of imitating NM without stressing the nervous system. It will be carried out as follow: a neutral cervical position will be maintained (0º of cervical inclination), 45º of shoulder abduction without depression, 45º of external rotation of the shoulder combined with 45º of elbow flexion with the forearm in pronation. Afterwards, 10 wrist flexion-extension movements will be performed at a rate of 6 seconds per cycle (3 seconds of flexion and 3 seconds of extension). The resistance that you will feel will stabilize when you change motion. Once the 10 cycles of movements have been carried out, a wrist flexion will be maintained for 10 seconds.
88960604|NCT04651166|Placebo Comparator|Placebo|100mL saline or lactated ringer without tranexamic acid added given intravenously over 10 minutes at start of procedure
88960605|NCT04651166|Active Comparator|Active Comparator|1g tranexamic acid mixed in 100mL saline or lactated ringer given intravenously over 10 minutes at start of procedure
88960606|NCT04642547|Experimental|Combination therapy with Lenvatinib and Gefitinib|First week: Gefitinib 125mg/day, Lenvatinib 8mg/day if body weight ≤ 60Kg and 12mg/day if body weight > 60Kg. If the patient is well tolerated, the dose of Gefitinib will be adjusted to 250 mg/day after one week, and the dose of Lenvatinib will remain the same (8mg/day for weight ≤ 60Kg and 12mg/day for weight > 60Kg). Route of administration: Oral.
88960607|NCT04630652|Experimental|Psoriasis treatment with risankizumab|Moderate-to-severe psoriasis treatment with risankizumab for 16 weeks
88960608|NCT04628013|Experimental|Noxious Electrical Stimulation (NxES)|The NxES intervention will be applied for a single treatment in Aim 1 and after a washout period, will be applied 3x/week for 2-weeks (6 sessions) for Aim 2.
89541826|NCT03224273|Active Comparator|( inlay shaped design)|The occlusal inlay has a preparation depth of 2.0 mm for the ceramic. The occlusal preparation ( 4 mm wide and extend 4mm for premolar and 6 mm for molar mesiodistally
89541827|NCT02153788|Active Comparator|temazepam|After screening, all subjects meeting entry criteria will be placed on the same single blind study drug treatment, asked to complete a daily sleep diary, and return one week later. After one week subjects randomized to temazepam will be given temazepam 15 mg for 12 weeks.
89541828|NCT02153788|Placebo Comparator|Placebo|After screening, all subjects meeting entry criteria will be placed on the same single blind study drug treatment, asked to complete a daily sleep diary, and return one week later. After one week subjects randomized to placebo will be given placebo for 12 weeks.
89541829|NCT03224117|Placebo Comparator|Placebo|SQ injection
89541830|NCT03224117|Experimental|DWJ211_0.5%|SQ injection with DWJ211 0.5%
89541831|NCT03224117|Experimental|DWJ211_1%|SQ injection with DWJ211 1.0%
89541832|NCT03224117|Experimental|DWJ211_2%|SQ injection with DWJ211 2.0%
89541833|NCT04862793|Experimental|Feedback|Feedback system through CoPS and CoRS
89541834|NCT04862793|No Intervention|Standard procedure|Performing the standard procedure in accordance with the departments usual conduct.
89541835|NCT04862559|Experimental|NovaCross|Subjects in this arm are treated with the investigational device, NovaCross micro-cetheter, to facilitate the opening of a chronic total occlusion (CTO)
89541836|NCT02451761||Sequencing|Blood sampling will be carried out in all patients ; molecular analysis and sequencing will be performed on these samples
89541837|NCT04867629|Experimental|Rapeseed oil|Participants asked to consume 20mL of rapeseed oil raw every day for 12 weeks
89541838|NCT04867629|Active Comparator|Sunflower oil|Participants asked to consume 20mL of sunflower oil raw every day for 12 weeks
89541839|NCT04867629|No Intervention|Habitual diet|Participants asked to maintain their habitual diet for 12 weeks
89541840|NCT03224429|Other|Decisional Needs Assessment|Caregivers and patients with sickle cell disease will participate in a semi-structured open ended interview regarding treatment decision making.
88960609|NCT04626674|Experimental|Delandistrogene Moxeparvovec|Participants will receive a single intravenous (IV) infusion of delandistrogene moxeparvovec on Day 1.
88960610|NCT04614246|Experimental|BAY1817080 150 mg|Participants will receive 150 mg of BAY1817080 twice daily over a 12-week intervention period
88960611|NCT04614246|Experimental|BAY1817080 75 mg|Participants will receive 75 mg of BAY1817080 twice daily over a 12-week intervention period
88960612|NCT04614246|Experimental|BAY1817080 25 mg|Participants will receive 25 mg of BAY1817080 twice daily over a 12-week intervention period
88960613|NCT04614246|Active Comparator|Elagolix|Participants will receive 150 mg of Elagolix once daily over a 12-week intervention period
88960614|NCT04614246|Placebo Comparator|Placebo|Participants will receive placebo matching BAY1817080 twice daily over a 12-week intervention period
88960615|NCT04612868|Experimental|AEYE Software Device|An AI software device (AEYE-DS) to be used as a diagnostic tool to assist primary care clinicians in screening for diabetic retinopathy using digital funduscopic images. The device automatically detects more than mild diabetic retinopathy (mtmDR) in adults diagnosed with diabetes who have not been previously diagnosed with diabetic retinopathy.
88960616|NCT04607226|Experimental|Active tVNS - 2 Hz|Expiratory-gated transcutaneous vagus nerve stimulation on the left auricle with 2 Hz stimulation frequency
88960617|NCT04607226|Experimental|Active tVNS - 8 Hz|Expiratory-gated transcutaneous vagus nerve stimulation on the left auricle with 8 Hz stimulation frequency
88960618|NCT04607226|Experimental|Active tVNS - 30 Hz|Expiratory-gated transcutaneous vagus nerve stimulation on the left auricle with 30 Hz stimulation frequency
88960619|NCT04607226|Experimental|Active tVNS - 100 Hz|Expiratory-gated transcutaneous vagus nerve stimulation on the left auricle with 100 Hz stimulation frequency
88960620|NCT04607226|Sham Comparator|Sham tVNS|Sham transcutaneous vagus nerve stimulation on the left auricle
88960621|NCT04601818|Experimental|Interventional arm|During our study period, transplants with a planned recipient anesthesia starting time between 10:00pm-6:00am will be allowed to move to a 6:00-8:00am start at the earliest. To be eligible, donor lungs cross clamp time have to occur between 6pm and 4am and lungs need to be suitable for transplantation without the need for ex vivo lung evaluation. Lungs meeting criteria for direct transplantation will be transported in the usual fashion in a cooler of ice at 4oC and upon arrival to Shands UF Health they will immediately be transferred to cold static preservation at 10oC within a specific refrigerator placed in the Shands UF Health OR. The maximum preservation time from donor cold flush (cross clamp) to recipient anesthesia start should be 12 hours and the recipient procedure should not start before 6am.
88960622|NCT04601818|No Intervention|Retrospective arm|Outcomes will be compared to conventional transplant patients matched by age, medical diagnosis, BMI, lung allocation score and donor type ( DCD vs. NDD) using a 1:2 matching.
88960623|NCT04593823|Experimental|Furoscix Infusor|Furoscix (furosemide injection, 8 mg/mL) administered subcutaneously over 5 hours via the Furoscix Infusor. The Infusor is applied to the abdomen via a medical grade adhesive and delivers a subcutaneous infusion of Furoscix through a pre-programmed, biphasic delivery profile with 30 mg (3.75 mL) administered over the first hour, followed by 12.5 mg (1.56 mL) per hour for the subsequent 4 hours (Total dose is 80 mg (10 mL) over 5 hours).
88960624|NCT04593823|No Intervention|Continued Medical Therapy|The subjects enrolled in this arm will receive treatment as usual
88960625|NCT04587700||Non-marijuana user|Has never consumed marijuana or has abstained for at least the past 12 months
88960626|NCT04587700||Chronic Marijuana User|Has used marijuana in any form at least once a week for the past 3 months
88960627|NCT04585919|Experimental|Paired Screening Intervention|
89210558|NCT02537964|Experimental|Chlorhexidine bath|Intervention: All infants in the NICU eligible for the study will be assigned for bathing three times a week with washcloths impregnated with 2% chlorhexidine gluconate
89514367|NCT04398407|Experimental|Coaching and Achievement of Peer Providers (CAPP)|"CAPP will consist of 16 individualized, one-on-one sessions using Zoom or other videoconferencing software and occurring over a 4-month period. Coaching meetings will take approximately one hour per week. The coach will tailor and individualize the modules and time spent on modules to meet the goals of each peer provider.~Modules:~Module 1: Establishing and solidifying the working alliance, understanding the work setting and role Module 2: Understand Generic drivers of burnout and role stress Module 3: Discuss specific sources of role stressors and burnout Module 4: Set SMART Goals Module 5: Overcome challenges for workplace success Module 6: Develop Skills for Workplace Success Module 7: Managing co-worker and supervisory relations in the workplace Module 8: Wrap-up sessions~During the first stage of research, the CAPP intervention will be further developed and refined, prior to the Randomized clinical trial."
89514368|NCT04398407|Active Comparator|Enhanced control|"The enhanced control condition will include 1 generic informational session conducted by a CAPP coach.During that session, the coach will introduce the key concepts under study and provide information about the drivers of burnout and role stress. The CAPP coach will discuss the need to set goals to overcome these challenges and will provide one article via email describing burnout and role stressors that is suitable for a lay person."
89210559|NCT02537964|No Intervention|Standard bathing|Standard bathing with water +/- mild soap according to age and gestational week
89514369|NCT03526289|Active Comparator|GIP infusion|5 hours of continuously GIP1-42 infusion
89514370|NCT03526289|Placebo Comparator|Saline|5 hours of continuously saline infusion
89514371|NCT03525197|Experimental|Whey protein-based supplement|Participants in the experimental condition will consume a supplement containing Whey Protein Isolate (20g) and other ingredients
89514372|NCT03525197|Active Comparator|Collagen protein-based supplement|Participants in the experimental condition will consume a supplement containing Collagen protein (20g) and other ingredients
89514373|NCT03526211|Experimental|Experimental|Patients with FES Cycling
89514374|NCT04257383|Experimental|Treatment|Families in the treatment cells will receive the Sugira Muryango treatment immediately after household identification and enrollment.
89514375|NCT04257383|Experimental|Waitlist Control|Families in the control cells will receive the Sugira Muryango treatment following the completion of the 12-month follow up on the original treatment group.
89514376|NCT03525977|No Intervention|Control|Patients in the control arm will receive pain control via traditional oral and intravenous pain medications such as opioids and non-steroidal anti-inflammatory medication as needed.
89514377|NCT03525977|Experimental|Fascia iliaca block|Patients in the intervention arm will receive the regional fascia iliaca block performed by the anesthesiologists on call.
89514378|NCT03525899||MH after diabetic pars plana vitrectomy|Recruited patients included, the persistent MH group, who had MH before the primary DV, and the newly-developed MH group, who developed MH after a successful primary DV
89514379|NCT03525821|Experimental|intranasal administration of ketamine|intranasal adminstration of ketamine combined with nitrous oxide befor reduction of fracture
89514380|NCT04623671|Active Comparator|CAP-1002|The active pharmaceutical ingredient in CAP-1002 is Cardiosphere-Derived Cells (CDCs). CDCs are known to secrete numerous bioactive elements (growth factors, exosomes) which impact the therapeutic benefits of the cell-based therapy. The mechanism of action is the composite ability to be immunomodulatory, anti-fibrotic and regenerative.
89514381|NCT04623671|Placebo Comparator|Placebo|Matching placebo solution
89514382|NCT04467047|Experimental|Intervention|Intravenous 1*10E6 MSCs/kg body weight Mesenchymal Stromal Cells infusion
89514383|NCT04467203|Experimental|Fadanafil fast to fat meal|"Seven subjects in group A will receive treatment in the following order:~At Day 1, a single dose of Fadanafil 100mg will be administered orally after overnight fasting-> At Day 8, a single dose of Fadanafil 100mg will be administered orally with high fat meal"
89514384|NCT04467203|Experimental|Fadanfil fat meal to fat|"Seven subjects in group B will receive treatment in the following order:~At Day1, a single dose of Fadanafil 100mg will be administered orally with high fat meal-> At Day 8, a single dose of Fadanafil 100mg will be administered orally after overnight fasting"
89514385|NCT04221035|Experimental|phase induction-R-I|R-I: induction regimens RAPID COJEC vs GPOH Assuming a baseline 3-year EFS of 40%, with a sample size of 686 patients (343 in each arm) and a two-sided alpha=5% this trial will have 90% power to demonstrate an improvement of 12% in 3-year EFS, within a recruitment period of 3 years and a minimum follow up of 1.5 years.
89514386|NCT04221035|Experimental|Phase high dose chemotherapy consolidation|R-HDC: consolidation regimen Bu-Mel vs Thiotepa + Bu-Mel The 3-year EFS in the Bu-Mel arm (with immunotherapy) is estimated to be 55%. This study aims to show an improvement of 12% for the Thiotepa + Bu-Mel arm (3-year EFS of 67%). With a recruitment of 448 patients (224 in each arm) over a period of 3 years and a minimum follow-up of 2 years, the power to show a 12% difference is 80% (two-sided logrank test and α=5%).
89514387|NCT04221035|Experimental|Phase of radiotherapy|R-RTx: 21.6 Gy radiotherapy vs 21.6 Gy + 14.4 Gy boost in patients with macroscopic residual disease
89514388|NCT01601704|Experimental|NB32|
89514389|NCT01601704|Placebo Comparator|PBO|
89514390|NCT04842682|Experimental|Active intervention|"Solo groups : CD40.HIVRI.Env vaccine (solution at 5.0 mg/ml) adjuvanted with Poly-ICLC (Hiltonol, solution at 1.8 mg/ml)~Combi groups : CD40.HIVRI.Env vaccine (solution at 5.0 mg/ml) adjuvanted with Poly-ICLC (Hiltonol, solution at 1.8 mg/ml) and combined with DNA-HIV-PT123 HIV-1 vaccine (solution at 4.0 mg/ml)"
89514391|NCT04842682|Placebo Comparator|Placebo|Commercial Sodium Chloride at 0.9% (NaCl 0.9%)
89514392|NCT04842214||Oncologic disorders|"All patients assigned for oncological rehabilitation with the diagnosis Cancer are included to this cohort."
89514393|NCT05304676|Experimental|KTT group|This group will receive neurodevelopmental treatment along with kinesotape and neuromuscular electrical stimulation. Children will be treated for 3 days a week over 4 weeks.
89514394|NCT05304676|Active Comparator|Conventional treatment|Group B will receive neurodevelopment treatment along with neuromuscular electrical stimulation.
89210560|NCT00819884|Experimental|1|twice daily during 4 days
89210561|NCT00819884|Experimental|2|once daily during 4 days
89210562|NCT00821444|Active Comparator|Geodon fed|Commercial Geodon (ziprasidone) capsules given with food
89514395|NCT05288920|Active Comparator|Radiofrequency group|Radiofrequency pulsed mode on dorsal root ganglion combined with transforaminal steroids injection
89514396|NCT05288920|Placebo Comparator|Steroids group|Transforaminal injection of Steroids alone
89514397|NCT05373940|Experimental|Heart failure optimal therapy alone (HFOT)|Heart failure Optimal therapy without implantable cardioverter defibrillator. This group will not undergo an ICD implantation. They will be treated according to the HFOT recommended in the latest guidelines.
89514398|NCT05373940|Active Comparator|Heart failure optimal therapy (HFOT) + Implantable cardioverter defibrillator (ICD)|Optimal medical therapy + implantable cardioverter defibrillator (HFOT+ICD). This group will undergo an ICD implantation (standard of care), any brand, CE marked, implantable (lifelong), available and reimbursed in the French market (the type and manufacturer at the discretion of the local investigator) in addition to heart failure medical therapy optimization.
89514399|NCT04419142|Experimental|Total infrapatellar fat pad excision group|Infrapatellar fat pad was totally excised during total knee arthroplasty in patients randomized to this group.
89514400|NCT04419142|Experimental|Partial infrapatellar fat pad excision group|Infrapatellar fat pad was partially excised during total knee arthroplasty in patients randomized to this group.
89514401|NCT04908046|Experimental|HMPL-295S1 open-label treatment arm|"During dose escalation, single-dose PK evaluation will be carried out firstly in each dose group.~At the first therapeutic dose level, the single-dose treatment period is 5 days; from the 2nd dose level, the sponsor can determine the adjustment of single-dose treatment period to 3-5 days based on the available PK profile. Subsequently, the patients will receive oral HMPL-295S1 QD continuously in a therapeutic cycle of 28 days (Day 1 - 28 of each cycle), until reaching the criteria on the end of treatment. The patients in RP2D extended cohort will enter the consecutive treatment period directly."
89514402|NCT05371444|Experimental|Controlled DoF|The treatment that this gruop will receive consist in a training with the exoskeleton that will restrict the DoF of the arm and trunk
89514403|NCT05371444|Active Comparator|Non controlled DoF|The treatment that this gruop will receive consist in a training with out the exoskeleton and without restriction of the DoF
89514404|NCT05371444|No Intervention|Conventional|This group will only recieve the conventional therapy that is given by the medical center
89514405|NCT05370976|Experimental|Experimental group|
89514406|NCT04890106|Experimental|Bimatoprost 0.01% Ophthalmic Solution|"Bimatoprost Pharmaceutical dosage form: Ophthalmic Solution Strength: 0.01% Manufactured by: Mankind Pharma Limited, India.~Intervention Drug: Test - Bimatoprost 0.01% Ophthalmic Solution"
89514407|NCT04890106|Active Comparator|LUMIGAN® 0.01% Ophthalmic Solution|"LUMIGAN® ( Contains Bimatoprost) Pharmaceutical dosage form: Ophthalmic Solution Strength: 0.01% Manufactured by: Allergan, Inc.,~Intervention Drug: Reference - Bimatoprost 0.01% Ophthalmic Solution"
89514408|NCT04833556||Postpartum haemorrhage|Patients undergoing cesarean delivery with postpartum haemorrhage (blood loss more than or equal to 1,000 ml.)
89514409|NCT04840654|Active Comparator|Caudal block|This group will receive the Caudal block during their operation (50 patients circumcision, 50 patients hypospadias). This group consist of 100 subjects
89514410|NCT04840654|Active Comparator|Pudendal Block|This group will receive the Pudendal block during their operation (50 patients circumcision, 50 patients hypospadias). This group consist of 100 subjects
89514411|NCT04840498||Magic Camp Session #1|Children ages 9-18
89514412|NCT04840498||Magic Camp Session #2|Children ages 9-18
89514413|NCT04833166|Experimental|Full glottic view on CMAC- D blade|Deliberately obtaining a full glottis view is deﬁned as negotiation and advancement of CMAC D blade tip positioned at the vallecula. Occasionally, external laryngeal pressure may be needed to assist in obtaining a full glottic view. The full glottic view is defined as a percentage of glottic opening (POGO) approximate 100%.
89514414|NCT04833166|Active Comparator|Partial glottic view on CMAC- D blade|The partial glottis view is deﬁned as a percentage of glottic opening <50%. This is achieved by deliberately position the CMAC D-blade tip proximally away from the vallecular.
89514415|NCT05356390|Experimental|Stabilization exercises|Group A performed stabilization exercises for 4 weeks. In stabilization exercises, floor bridging, heel prop and alternate arm and leg exercises were administered in iliopsoas, gluteal and hamstring groups.
89514416|NCT05356390|Active Comparator|Muscle energy techniques|Muscle energy techniques were given to group B. These techniques are active form of manual therapy in which patient uses its own energy on request to aid in treatment.
89514417|NCT05199298|Experimental|"Mandala Activity-Based Breastfeeding Program"|The group receiving Mandala Activity-Based Breastfeeding Program
89514418|NCT05199298|No Intervention|Control group|the group that did not receive any training/initiative
89514419|NCT05198362|Placebo Comparator|Placebo|Once-daily PO for 16 weeks during the double-blind period; then if eligible for OLE, once-daily dosing for 36 weeks of the highest tolerated Tesomet dose from the double-blind period
89514420|NCT05198362|Experimental|Tesomet Low Dose|Once-daily PO for 16 weeks during the double-blind period; then if eligible for OLE, once-daily dosing for 36 weeks of the highest tolerated dose from the double-blind period
89514421|NCT05198362|Experimental|Tesomet Medium Dose|Once-daily PO for 16 weeks during the double-blind period; then if eligible for OLE, once-daily dosing for 36 weeks of the highest tolerated dose from the double-blind period
89514422|NCT05198362|Experimental|Tesomet High Dose|Once-daily PO for 16 weeks during the double-blind period; then if eligible for OLE, once-daily dosing for 36 weeks of the highest tolerated dose from the double-blind period
89514423|NCT05355220|Experimental|silver spike point Therapy Group|One group will receive electrotherapy (silver spike point) for 10 mints along with conservative managment
89514424|NCT05355220|Active Comparator|Conservative treatment group|2nd group will receive strengthening, stretching and stabilization exercises for prlvic girlde
89514425|NCT05354206|Experimental|Evaluation of motor evoked potentials during non-invasive spinal cord stimulation and leg movements|This arm will receive the transcranial magnetic stimulation to evaluate the excitability of the corticospinal tract first then the arm will receive the loud auditory stimuli to evaluate the excitability of the reticulospinal track second.
89210563|NCT00821444|Experimental|B16 Fasted|Experimental reduced food effect formulation given without food
89541841|NCT03224429|Other|Beta Testing|Caregivers and patients with sickle cell disease will review the web-based Sickle Cell Decision Aid.
89541842|NCT04862403|Experimental|Intervention group I|In intervention group I - clamped at a distance of 2 cm - umbilical cord was measured 2 cm from the abdominal wall in the delivery room and clamped. This procedure was carried out by a single researcher using a 2 cm standard measuring tool (cut-to-size ruler) prepared before hand. In order to ensure standardization, this tool was cleaned with a disinfectant and used to measure the umbilical clamp distance of all newborns in the intervention group I.
89541843|NCT04862403|Experimental|Intervention group II|In intervention group II - clamped at a distance of 3 cm - umbilical cord was measured 3 cm from the abdominal wall in the delivery room and clamped. This procedure was carried out by a single researcher using a 3 cm standard measuring tool (cut-to-size ruler) prepared before hand. In order to ensure standardization, this tool was cleaned with a disinfectant and used to measure the umbilical clamp distance of all newborns in the intervention group II.
89541844|NCT04862403|No Intervention|Control group|Control group - clamped without measuring - no intervention was made in defining the distance at which the umbilical cord of the newborn would be clamped. Another healthcare workers measured the distance at which the umbilical cord had been clamped. The same researcher used a standard measuring tape to measure the distance between the umbilical cord to the clamping point.
89541845|NCT03224039|Experimental|Intranasal sufentanil|"Treatment arm to include~Sufentanil 0.7 mcg/kg intranasal (IN) x 1 dose~Normal saline 1ml intravenous (IV) push x 1 dose"
89541846|NCT03224039|Active Comparator|Intravenous morphine|"b. Treatment B:~Normal saline 0.3 mL IN x 1 dose~Morphine 0.1 mg/kg IV push x 1 dose"
89541847|NCT04862091|Experimental|Abiraterone Acetate Tablets (I)|
89541848|NCT04862091|Active Comparator|ZYTIGA®.|
89541849|NCT03119675|Other|Photorefraction of ages 1 to 6 years|Clinical Validation of GoCheck Kids Smartphone App
89541850|NCT04873635||Patients who had excised pathological jaw lesions and will receive implant rehabilitation|
89541851|NCT04485143||experimental group|Non-invasive Wearable Device
89541852|NCT03119441|Experimental|Dental water jet|Dental water jet (Jetpik JP210)
89541853|NCT03119441|Active Comparator|Dental floss|Dental floss
89541854|NCT03043833|Experimental|Wellbeing Course|Will receive the French-Canadian version of the Wellbeing Course consisting of five lessons based on cognitive behavior therapy delivered through the Internet over eight weeks.
89541855|NCT03043833|No Intervention|Waitlist-control|The Waitlist Control Group will receive the French-Canadian version of the Wellbeing Course once the treatment group will have completed treatment.
89541856|NCT03223961|Experimental|Early onset arm|Intervention: early onset of Eprex60000 IU/week , at patient inclusion
89541857|NCT03223961|Experimental|Delayed onset arm|Intervention: late introduction of Eprex60000 IU/week, whenever the patient reaches the level chosen RBC transfusions (based on age, comorbidities, anticipated tolerance of anemia).
89541858|NCT03045471||R-EPOCH|
89541859|NCT03045471||R-CHOP|
89541860|NCT03045315|Experimental|women included in a IVF program|
89210564|NCT00821444|Experimental|B16 Fed|Experimental reduced food effect formulation given with food
89541861|NCT03223571||Early post-stroke (<2 months)|Participants within 2 months of a first supra-tentorial ischeamic stroke, that show a motor deficit of the upper-limb (Fugl Meyer upper limb score < 30/66), older than 18yrs, without aphasie, cognitive troubles or hemineglect Post-stroke participants receive 6 week of motor rehabilitation training of the paretic upper-limb.
89541862|NCT03223571||Controls|Healthy people with no history of neurological pathologies
89210565|NCT00819962|Other|TAP|ksu
89210566|NCT00927342|Active Comparator|Vivostat|
89210567|NCT00927342|Active Comparator|BioGlue|
89541863|NCT04862169|Placebo Comparator|Control group|"In the control group, they will only receive electronic version of the modules. They are able to access the module on their own devices.~The observation arm will receive the link of eLOK at the end of data collection and follow-ups (week 14). With this link, then they are able to access modules, videos and case studies provide in SPARK."
89541864|NCT04862169|Experimental|Intervention group|The intervention on this RCT is an educational training program: SPARK (Strengthening PAlliative caRe in the community by enhancing nurses' Knowledge). This is an educational intervention using an online method with learning method system (LMS) eLOK hosted by Universitas Gadjah Mada Yogyakarta (Affiliation of authors' team). The intervention includes online discussions and access to eLOK for study materials (modules and videos) and some synchronous meetings.
89541865|NCT03223181||COMİSS|Measure of CoMiSS followed by two to four weeks eviction Cow's milk protein diet and second CoMiSS measurement
89541866|NCT03045549|Experimental|Experimental group|Home-based rehabilitation sessions performed with the digital biofeedback system. Patients will be instructed to perform exercise sessions at least 5 days a week, but compliance to this schedule is not mandatory.
89541867|NCT03045549|Active Comparator|Conventional rehabilitation group|Home-based rehabilitation sessions provided by a Physical Therapist, 3 times a week, each with 1h duration. Patients will be instructed to perform 2 additional unsupervised sessions per week, but compliance to these sessions is not mandatory.
89541868|NCT03223415|Experimental|Experimental arm|Detection and isolation of C. difficile carriers
89541869|NCT03223415|No Intervention|Control arm|No detection of C. difficile carriers upon admission and no implementation of contact isolation precautions for C. difficile carriers
89541870|NCT04861857|Experimental|Parmigiano Reggiano|participants will consume 50 g/die of the dietary supplement and undergo to eccentric exercise training 3 times/week
89541871|NCT04861857|Active Comparator|Whey Protein|participants will consume 20 g/die of the dietary supplement and undergo to eccentric exercise training 3 times/week
89541872|NCT03223259|Other|Injury Prevention Workshops|Subjects will attend two Injury Prevention Workshops
89541873|NCT04861701|Experimental|Stretching exercise group (SE)|All subjects will be assigned to the experimental or control group by randomization. Thus, there will be totally 2 groups : Stretching exercise group (SE) and Control group (CON).
89541874|NCT04861701|No Intervention|Control group (CON)|All subjects will be assigned to the experimental or control group by randomization. Thus, there will be totally 2 groups : Stretching exercise group (SE) and Control group (CON).
89514426|NCT05354206|Experimental|Reaction time evaluation during non-invasive spinal cord stimulation and leg movements|This arm will receive the loud auditory stimuli to evaluate the excitability of the reticulospinal tract first then the arm will receive the transcranial magnetic stimulation to excite the corticospinal tract second
88960628|NCT04585919|No Intervention|Usual Care Control|In this stepped wedge design, all sites have a period of being in usual care, and then providing the Paired Screening Intervention. Sites serve as their own controls in this design.
89514427|NCT04839484|Experimental|Lumina|Lumina Dermal Filler injected into 1 nasolabial fold. Optional Touch-up at 3 week visit with same.
89514428|NCT04839484|Active Comparator|Restylane Defyne|Restylane Defyne Dermal Filler injected into 1 nasolabial fold. Optional Touch-up at 3 week visit with same.
89514429|NCT04411264|No Intervention|Classic protocol for pain management|classic protocol for pain management during chronic wound dressing
89514430|NCT04411264|Experimental|Virtual reality for pain management|protocol associating virtual reality with the classic protocol for pain management during the treatment of chronic wound dressings
89514431|NCT04810156|Active Comparator|Cohort A: Steroids and MMF in grade 3-4 ir-hepatitis|Patients with ≥ 3 grade ir-hepatitis will be treated with high-dose steroids 2 mg/kg/day intravenously. A diagnostic liver biopsy will be taken. Patients with mixed or cholestatic liver injury patterns will be added UDCA. Treatment evaluation will be performed after 72 hours, patients in UDCA will be evaluated will be on day 7. Patients with sufficient steroid response defined as ≥ 20% reduction in ALT, AST, ALP or bilirubin at day 4 or day 7 will undergo steroid tapering with a transition to peroral steroids. Patients with initial insufficient treatment response, defined as less than < 20% reduction in ALT, AST, ALP, or bilirubin, are considered as having a steroid-refractory condition and will be added MMF. In case of no response or increase of ALT, AST, ALP, or bilirubin during treatment with steroids plus MMF a third-line treatment may be introduced according to the individual treating hepatologist.
89514432|NCT04810156|Active Comparator|Cohort B: Prednisolone versus MMF in steroiddependent ≥2 ir-hepatitis (randomized)|Patients who experienced relapse of ir-hepatitis of grade ≥2 during prednisolone tapering or within one months after ended tapering will be randomized to either 100% dose of current steroid dose or restart of steroid 0.5-1 mg/kg versus adding MMF (if the patient received prednisolone the tapering plan hereof is continued, prednisolone up to 25 mg can be added if clinical indicated). Treatment efficacy is evaluated after seven days, if sufficient response the patients continued treatment, in case of insufficient response a cross-over will be performed.
89514433|NCT04850092||Non-hypotensive|Mean blood pressure is maintained after positional change from supine to prone.
89514434|NCT04850092||Hypotensive|Mean blood pressure decrease < 20% after positional change from supine to prone.
89514435|NCT05176054|Experimental|Experimental group|Researchers will conduct the health service program for the experimental group.
89514436|NCT05176054|No Intervention|Contrast group|The contrast group will be receiving the routine care only.
89514437|NCT04411342||patients with type 2 diabetes|patients with type 2 diabetes and have normal range of albumine in urine and decline in renal functions
89514438|NCT04837924|Experimental|B (FICB)|Participants receiving fascia iliaca compartment block (FICB)
89514439|NCT04837924|Sham Comparator|A (PLACEBO)|Participants receiving sham injection matching fascia iliaca compartment block (FICB)
89514440|NCT04831996|Experimental|Treat Group 1 : Normal Renal Function|eGFR: ≥ 90 mL/min/1.73 m^2
89514441|NCT04831996|Experimental|Treat Group 2 : Mild Renal Impairment|eGFR: 60-89 mL/min/1.73 m^2
89514442|NCT04831996|Experimental|Treat Group 3 : Moderate Renal Impairment|eGFR: 30-59 mL/min/1.73 m^2
89514443|NCT04831996|Experimental|Treat Group 4 : Severe Renal Impairment|eGFR: 15-29 mL/min/1.73 m^2 and not on Hemo Dialysis
89514444|NCT04831996|Experimental|Treat Group 5 : Kidney Failure|eGFR: < 15 mL/min/1.73 m^2 on Hemo Dialysis
89514445|NCT05406466|Experimental|Cryoablation in combination with Tislelizumab plus lenvatinib|Cryoablation treatment starts at day 0. Tislelizumab plus lenvatinib will be initiated on day 14 after cryoablation. Tislelizumab will be administered at 200 mg i.v. every 3 weeks plus a lenvatinib (bodyweight ≥ 60 kg, 12 mg; < 60 kg, 8 mg) orally daily every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
89514446|NCT05152420|Experimental|Part 1 - Cohort 1|Single dose cohort
89514447|NCT05152420|Experimental|Part 1 - Cohort 2|Single dose cohort
89514448|NCT05152420|Experimental|Part 1 - Cohort 3|Single dose cohort
89514449|NCT05152420|Experimental|Part 1 - Cohort 4|Single dose cohort
89514450|NCT05152420|Experimental|Part 1 - Cohort 5|Single dose cohort
89514451|NCT05152420|Experimental|Part 1 - Cohort 6|Single dose cohort
89514452|NCT05152420|Experimental|Part 2 - Cohort 1|Single dose cohort of selected FXa DOAC anticoagulant in combination with VMX-C001
89514453|NCT05152420|Experimental|Part 2 - Cohort 2|Single dose cohort of selected FXa DOAC anticoagulant in combination with VMX-C001
89514454|NCT05152420|Experimental|Part 2 - Cohort 3|Single dose cohort of selected FXa DOAC anticoagulant in combination with VMX-C001
89514455|NCT05152420|Experimental|Part 2 - Cohort 4|Single dose cohort of selected FXa DOAC anticoagulant in combination with VMX-C001
89514456|NCT05152420|Experimental|Part 2 - Cohort 5|Single dose cohort of selected FXa DOAC anticoagulant in combination with VMX-C001
89514457|NCT05152420|Experimental|Part 2 - Cohort 6|Single dose cohort of selected FXa DOAC anticoagulant in combination with VMX-C001
89514458|NCT05152420|Experimental|Part 2 - Cohort 7|Single dose cohort of selected FXa DOAC anticoagulant in combination with VMX-C001
89514459|NCT01601470|Experimental|Period 1:Sildenafil;Period 2:LCZ696;Period 3:LCZ696+Sildenafil|During Treatment Period 1, on study Day 1, participants received a single dose of sildenafil followed by wash out on Day 2. In Period 2 (study Days 3-7), participants received LCZ696 once daily. In Period 3, on study Day 8, participants received LCZ696 , co-administered at the same time with a single dose of sildenafil.
89541875|NCT03223493||People with Obesity|General population, respondents are recruited via email and/or phone through an online panel company with which respondents have provided permission to be contacted for research
89541876|NCT03223493||Healthcare Providers|Health care professionals, respondents will be recruited via email, USPS mail, and/or phone through an online panel company with which respondents have provided permission to be contacted for research purposes or through the AMA Masterfile
89541877|NCT03223493||Employer representatives|Employers, respondents will be recruited via email, USPS mail, and/or phone through an online panel company with which respondents have provided permission to be contacted for research purposes
89541878|NCT02153398|Experimental|Group 1: D961H sachet 10 mg|Age: ≥1 year Weight: <20 kg
89541879|NCT02153398|Experimental|Group 2: D961H capsule 10mg|Age: ≥1 year to 11years Weight: ≥20 kg
89541880|NCT02153398|Experimental|Group 3: D961H capsule 20 mg|Age: ≥1 year to 11years Weight: ≥20 kg
89541881|NCT02153398|Experimental|Group 4: D961H capsule 10 mg|Age: 12 to 14 years Weight: ≥20 kg
89541882|NCT02153398|Experimental|Group 5: D961H capsule 20 mg|Age: 12 to 14 years Weight: ≥20 kg
89541883|NCT03045159|Experimental|Strong Families|parenting program
89541884|NCT03045159|Active Comparator|Strong Parents|self-care program
89541885|NCT03222947||Taybi-Linder index cases|Taybi-Linder index cases who have already consented for the (re)use of their DNA samples for medical research.
89541886|NCT03222947||Blood relatives of Taybi-Linder index cases|Blood relatives of Taybi-Linder index cases who have already consented for the (re)use of their DNA samples for medical research.
89541887|NCT03047499||Scar Length|
88960629|NCT04561570||Study Group: Vivity ACRYSOF IQ IOL|Subjects that were implanted with the Vivity ACRYSOF IQ extended depth of focus IntaOcular Lens
89541888|NCT03047499||Vancouver scar scale|
89541889|NCT03047499||Scar width|
89541890|NCT04867941|Experimental|Part1: Mild hepatic insufficiency|Participants with mild hepatic insufficiency will receive a single oral dose of 50 mg ACP-196 (2 x 25 mg capsules) on Day 1 of the study.
89541891|NCT04867941|Experimental|Part 1: Moderate hepatic insufficiency|Participants with moderate hepatic insufficiency will receive a single oral dose of 50 mg ACP-196 (2 x 25 mg capsules) on Day 1 of the study.
89541892|NCT04867941|Experimental|Part 1: Normal hepatic function|Participants with normal hepatic function will receive a single oral dose of 50 mgACP-196 (2 x 25 mg capsules) on Day 1 of the study.
89541893|NCT04867941|Experimental|Part 2: Severe hepatic insufficiency|Participants with sever hepatic insufficiency will receive a single oral dose of 50 mg ACP-196 (2 x 25 mg capsules) on Day 1 of the study.
89541894|NCT04873479|Experimental|test group|Participants in the test group received midazolam 0.05-0.1mg /kg, sufentanil 0.1-0.2ug/kg,Etomidate 0.1-0.2mg/kg, cisatracurium 0.15-0.3mg/kg, S-ketamine 0.125mg/kg (low dose) for Anesthesia induction, followed by an infusion of remifentanil 0.05-0.15ug/kg/min and S-Ketamine 0.125mg/kg/h (low dose) and continuous inhalation of sevoflurane at 2-3%.
89541895|NCT04873479|Other|control group|Participants in the control group received midazolam 0.05-0.1mg /kg, sufentanil 0.2-0.3ug/kg,Etomidate 0.2-0.3mg/kg, cisatracurium 0.15-0.3mg/kg, saline 0.125ml/kg for Anesthesia induction, followed by an infusion of remifentanil 0.1-0.3ug/kg/min and saline 0.125ml/kg/h and continuous inhalation of sevoflurane at 2-3%.
89541896|NCT03222557|Experimental|Electroacupuncture (EA)|Bilateral acupoints relevant to the treatment of abdominal pain, abdominal distension, and constipation, including Zusanli (stomach meridian ST-36), Sanyinjiao (spleen meridian SP-6), Hegu (large intestine meridian LI-4), and Zhigou (triple energizer meridian TE-6), will be used. Electric stimulation at a frequency of 50 Hz will be employed to the needles
89541897|NCT03222557|Sham Comparator|Sham Acupuncture (SA)|Sterile blunt-tip needles will be placed (without skin penetration) 20 mm away from the acupoints. The needle will be first inserted through a sterile plastic tube mounted on a foam block, and then pressed on the skin. The foam block compresses to give the impression that the needle is penetrating the skin, thus providing a SA effect. 'Pseudostimulation' will be given by deliberately connecting the needle to the incorrect output socket of the electroacupuncture device, thus there will be no flow of electric current.
89541898|NCT04861467|Experimental|Experimental: Camrelizumab|camrelizumab as maintenance therapy after Chemoradiation(evaluation results：PR/SD)
89541899|NCT04861467|No Intervention|observation|observation after Chemoradiation
89541900|NCT04861467|Experimental|Exploration：Camrelizumab|camrelizumab for maintenance after chemoradiation( evaluation results：CR)
89541901|NCT03222791|Experimental|Algorithm-based diet|Subjects randomized to this arm will receive personally tailored dietary recommendations based on their predicted glycemic responses according to the study algorithm.
89541902|NCT03222791|Other|Mediterranean-style low-fat diet|Subjects randomized to this arm will receive nutritional recommendations according to the standard Israeli dietary approach for treating pre-diabetes: Mediterranean-style low-fat diet.
89541903|NCT03222635|Experimental|Endoscopic follow-up|Patients treated with endoscopic resection (ER) for a submucosal or high-risk mucosal esophageal adenocarcinoma without lymphnode- or distant metastases (T1bN0M0 EAC) will undergo endoscopic follow-up.
88960630|NCT04561570||Control Group: ACRYSOF IQ IOL|Control Group: Subject that were implanted with the ACRYSOF IQ Monofocal IntaOcular Lens
88960631|NCT04560114|Experimental|Essential oils|Inhalation will be carried out via an inhaler stick containing essential oils (Mentha x Piperita; Citrus Limon; Zingiber Officinale)
88960632|NCT04556383|Placebo Comparator|PCP Placebo|PCP Placebo for oral administration for 36 weeks
88960633|NCT04556383|Experimental|PCP GB004 480 mg QD|PCP GB004 480 mg QD for oral administration for 36 weeks
88960634|NCT04556383|Experimental|PCP GB004 480 mg BID|PCP GB004 480 mg BID for oral administration for 36 weeks
88960635|NCT04556383|Experimental|Open-Label Extension (OLE) GB004 480 mg BID|OLE GB004 480 mg BID for oral administration for 24 weeks
88960636|NCT04554927|Experimental|WEB-application|
89541904|NCT04873167|Experimental|Low Fat Diet|subjects subjected to a low-fat dietary regime
89541905|NCT04873167|Experimental|Mediterranean Diet|subjects subjected to a mediterranean dietary regime
89541906|NCT03222479|Experimental|treatment arm|All individual is instructed to use the application we developed for 4 weeks
89541907|NCT03045237|Experimental|Intervention Group|The program consists in 3 physical exercise classes, one of them in the pool.
89541908|NCT03045237|No Intervention|Control Group|The control group has the basic information through health professionals.
89541909|NCT02451527|Experimental|Digoxin and PEX168|A single dose of 0.5mg digoxin administered on Day 1 followed by 5 weekly subcutaneous injections of a single dose of 200ug PEX168, followed by a further single dose of 0.5mg digoxin on Day 38.
89541910|NCT04872933|Other|Non-Waitlist|Patient will attend a total of 3 virtual assessments whilst in the study: at baseline, at 12 weeks then at 6 months. The online intervention will commence straight after completing the baseline visit.
89541911|NCT04872933|Other|Waitlist|Patient will be complete assessments at baseline and 12 weeks but will only start the online intervention after the 12-week assessment.
89541912|NCT04867239|Other|A two-day education program|During the camp, the multidisciplinary team provided disease information, lifestyle modification, nutrition, and exercise for metabolic syndrome. Participants visited at 3- and 6-month after camp for follow-up.
89541913|NCT03222401|No Intervention|Control Group|Control subjects will not receive an infusion or placebo
89541914|NCT03222401|Experimental|1 mg/kg single infusion of F598|1 mg/kg single infusion of F598
89541915|NCT03222401|Experimental|3 mg/kg single infusion of F598|3 mg/kg single infusion of F598
89541916|NCT03222401|Experimental|10 mg/kg single infusion of F598|10 mg/kg single infusion of F598
89541917|NCT04873011|Experimental|Quinine hydrochloride|The bitter tastant, quinine hydrochloride, will be acutely infused via a nasogastric feeding tube into the stomach. 320 mg of quinine hydrochloride is dissolved in 10 mL of water and all is infused.
89541918|NCT04873011|Placebo Comparator|Placebo|10 mL of water is infused via a nasogastric feeding tube into the stomach.
89541919|NCT02451605|Active Comparator|Femoral nerve blockade|In this group, patient will benefit of an ultrasound guided femoral nerve blockade with continuous catheter infusion as (initial bolus of 20ml of ropivacaine 0.75% follow with 7ml/hour of ropivacaine 0.2%) as analgesic nerve blockade for total knee replacement surgery.
89541920|NCT02451605|Active Comparator|Adductor canal blockade|In this group, patient will benefit of an ultrasound guided adductor canal blockade with continuous catheter infusion (initial bolus of 20ml of ropivacaine 0.75% follow with 7ml/hour of ropivacaine 0.2%) as analgesic nerve blockade for for total knee replacement surgery.
89541921|NCT02451605|Active Comparator|Subgluteal sciatic nerve blockade|In this group, patient will benefit of an ultrasound guided subgluteal sciatic nerve blockade with continuous catheter infusion (initial bolus of 20ml of ropivacaine 0.75% follow with 7ml/hour of ropivacaine 0.2%) as analgesic nerve blockade for total knee replacement surgery.
89541922|NCT04873089||RV3278A arm|RV3278A study product is applied twice a day (morning and evening) on the face during the whole study.
89541923|NCT04873089||Control Group|Subjects included in the control group did not receive the test product or other associated product
89541924|NCT03222323|Experimental|Perineural dexmedetomidine|Ulnar nerve block 4ml ropivacaine 5mg/ml + 1ml 100ug/ml dexmedetomidine perineurally
89541925|NCT03222323|Active Comparator|Systemic dexmedetomidine|Ulnar nerve block 4ml ropivacaine 5mg/ml + 1ml isotonic saline (placebo) perineurally + 100ug dexmedetomidine systemically (absorbed and redistributed from the opposite ulnar nerve block)
89541926|NCT03222323|Placebo Comparator|Placebo|Ulnar nerve block 4ml ropivacaine 5mg/ml + 1ml isotonic saline (placebo) perineurally
89541927|NCT03222323|Active Comparator|High dose Ropivacaine|Ulnar nerve block 4ml ropivacaine 7.5mg/ml + 1ml isotonic saline (placebo) perineurally
89541928|NCT03043677||Non-inflamed|
88960637|NCT04554927|Active Comparator|Standard accompaniment|
88960638|NCT04552548|No Intervention|Control group|the patients will receive regular analgesics (1 µg /kg fentanyl with induction and 15mg/kg paracetamol before extubation)
89541929|NCT03043677||Inflamed ulcerative colitis|
89541930|NCT03043677||inflamed Crohn´s disease|
88960639|NCT04552548|Active Comparator|TAP group|the patients will receive bilateral TAP block using (0.5 ml/ kg bupivacaine 0.25%) in each side + regular analgesics.
88960640|NCT04552548|Active Comparator|quadratus lumborum group|the patients will receive bilateral quadratus lumborum block using (0.5 ml/ kg bupivacaine 0.25%) in each side + regular analgesics.
88960641|NCT04539314|Placebo Comparator|Control group|TAP block will be performed using (0.5 ml/ kg bupivacaine 0.25%)
88960642|NCT04539314|Active Comparator|Dexmedetomidine 0.5 μg group|TAP block will be performed using (0.5 ml/ kg bupivacaine 0.25%) plus dexmedetomidine 0.5 μg / kg as an adjuvant
88960643|NCT04539314|Active Comparator|Dexmedetomidine 1 μg group|TAP block will be performed using (0.5 ml/ kg bupivacaine 0.25%) plus dexmedetomidine 1 μg / kg as an adjuvant
88960644|NCT04520711|Experimental|CDX-1140 + TCR-T + Pembro|Patients will receive CDX-1440, TCR-T, and pembrolizumab.
89541931|NCT03222089|Experimental|FOLFOXIGIL|"The FOLFOXIGIL chemoimmunotherapy regimen is composed by FOLFOXIRI chemotherapy and the immunotherapy of GM-CSF and IL-2.~FOLFOXIRI: Irinotecan 165 mg/m² + oxaliplatin 85 mg/m² + Levoleucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1, repeated every 2 weeks.~GM-CSF 150ug s.c. d3-7; Interleukin-2 100MIU s.c. d8-14 and d17-d28, Repeated every 4 weeks.~Treatment will be administered until progression, patients' withdrawal of consent, unacceptable toxicity."
89541932|NCT03222089|Active Comparator|FOLFOXIRI|"Irinotecan 165 mg/m² + oxaliplatin 85 mg/m² + Levoleucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1, Repeated every 2 weeks.~Treatment will be administered until progression, patients' withdrawal of consent, unacceptable toxicity."
89541933|NCT03043989|Active Comparator|Docetaxel and clarithromycin combination|"Docetaxel will be administered by intravenous infusion over 1 hour every 3 weeks on day 1 of each (3 week) cycle for a total of 18 weeks.~Clarithromycin will be administered orally at 500mg twice a day for 3 days per cycle on days -1, 1, and 2."
89541934|NCT03043989|Active Comparator|Cabazitaxel and clarithromycin combination|"Cabazitaxel will be administered by intravenous infusion over 1 hour every 3 weeks on day 1 of each (3 week) cycle for a total of 18 weeks.~Clarithromycin will be administered orally at 500mg twice a day for 3 days per cycle on days -1, 1, and 2."
89541935|NCT02451371|Experimental|tDCS|Patients with schizophrenia to receive tDCS treatment
89541936|NCT03044145|Experimental|Project 1: The Cultural Formulation Interview-Engagement Aid|The first project is creating the intervention through patient and clinician feedback at JHMC and expert consensus with the K23 mentoring team. The CFI-EA is a list of questions that clinicians can use to customize patient treatment plans based on a cultural competence assessment.
89541937|NCT03044145|Experimental|Project 2: The Cultural Formulation Interview-Engagement Aid|In this arm the study team will test the revised CFI-EA against treatment as usual in a pilot trial.
89541938|NCT03044145|Active Comparator|Project 2: Treatment as usual|Treatment as usual at JHMC consists of clinicians creating treatment plans for patients without any specific training in medical communication or treatment negotiation.
89541939|NCT03222167|Experimental|Elbasvir/ Grazoprevir|Elbasvir/ Grazoprevir 50/100 mg fixed dose combination for 12 weeks treatment aimed to evaluate SVR12 in treatment naïve patients with chronic hepatitis C (genotype 1b) infection, associated with metabolic syndrome, with or without severe fibrosis / compensated cirrhosis.
89541940|NCT04860999|Experimental|Somatic Dysfunction|This is the single study arm. All participants completed an osteopathic postural examination and an osteopathic manipulative treatment. Participants also completed a biomechanical assessment prior to and following the osteopathic manipulative treatment to evaluate effects of the treatment on the gait asymmetry.
89541941|NCT04867005|Active Comparator|Online traininig group. A|This arm included 5 primary care teams, that carried out a 10 hours online course.
89541942|NCT04867005|Experimental|online and face-to-face training group. B|This arm included 5 primary care teams, that carried out a 10 hours online course plus a 6h hours face-to-face course
89541943|NCT03221855|Active Comparator|Domperidone|Domperidone 10mg every 8 hours for 7 days.
89541944|NCT03221855|Placebo Comparator|Placebo|Placebo 10mg every 8 hours for 7 days.
89541945|NCT03043521|Experimental|CJ-12420 50mg|T1=CJ-12420 50mg QD evening (9PM)
89541946|NCT03043521|Experimental|CJ-12420 100mg|T2=CJ-12420 100mg QD evening (9PM)
89541947|NCT03043521|Experimental|CJ-12420 200mg|T3=CJ-12420 200mg QD evening (9PM)
89541948|NCT03043521|Active Comparator|Dexlansopazole 60mg|R=dexlansoprazole 60mg QD evening (9p.m)
89541949|NCT03221933|Experimental|Somatropin Injection low dose group|0.23mg/kg /wk，inject for seven divided doses.
89541950|NCT03221933|Experimental|Somatropin Injection high dose group|0.46mg/kg /wk，inject for seven divided doses.
89541951|NCT03047733|Active Comparator|continuously excimer laser treatment|"In this group, lesions treated twice weekly through out the whole trial length (9 months).~Application of topical tacrolimus 0.1% ointment through out the whole trial length (9 months)."
89541952|NCT03047733|Experimental|cyclic excimer laser treatment|"In this group, one cycle consists of a 2-month treatment period (on) and a consecutive 1-month intermission period (off).~Total 3 cycles of cyclic treatment through out the whole trial length (9 months). During the treatment period, lesions treated twice weekly.~Application of topical tacrolimus 0.1% ointment through out the whole trial length (9 months)."
89541953|NCT03222011|Active Comparator|Standard endoscopic therapy|Single endoscopic dilatation
89541954|NCT03222011|Experimental|Intensive endoscopic therapy|3 endoscopic dilatations 3 weeks apart and possible needle knife strictureplasty
89541955|NCT03119519|Experimental|Local Definitive Radiotherapy|Standard platinum-based doublet chemotherapy or EGFR-TKI (Gefitinib or Erlotinib) followed by 3D-CRT (three-dimensional conformal radiotherapy) or IMRT (intensity modulated radiotherapy) to primary thoracic foci or remediable oligometastatic focus.
89541956|NCT03119519|Active Comparator|No Local Definitive Radiotherapy|Standard platinum-based doublet chemotherapy or EGFR-TKI (Gefitinib or Erlotinib) alone, according to gene test.
89541957|NCT03221699|Placebo Comparator|control|Formula without ZnO
89541958|NCT03221699|Active Comparator|intervention|Formula with ZnO
89541959|NCT03221465|No Intervention|Usual Care|Usual care: dietary and exercise counseling only at baseline, no other intervention.
89541960|NCT03221465|Active Comparator|Usual Care + self-monitoring of physical activity|Tracking Device control: The intervention applied is usual care and self-monitoring of physical activity. Patients will receive a pedometer (e.g. Misfit brand wrist pedometer) to allow for self-monitoring of physical activity. They will be able to obtain daily feedback on step counts via the wearable device and their smartphones. They will also have a 2-week run-in period like the incentive arm.
89541961|NCT03221465|Experimental|Self-monitoring + incentives of physical activity|The intervention applied is self-monitoring of physical activity with incentives. Patients will receive a a pedometer (e.g. Misfit brand wrist pedometer) to allow for self-monitoring of physical activity. Participants will monitor daily step counts with automated feedback on goal attainment via text message. We will establish a baseline step count for each participant (during a 2-week run-in period) and then recommend a 15 percentage point increase in daily step goal every 2 weeks during the 12-week intervention period (weeks 3-14) with a maximum goal of 7,000 steps. Two health engagement questions will be sent per week to participants as well for the 12-week intervention period.
89541962|NCT02118766|Experimental|AN2728 Topical Ointment, 2%|AN2728 Topical Ointment, 2%, applied twice daily for up to 28 days
89541963|NCT02118766|Placebo Comparator|Matching vehicle control|Matching vehicle control, applied twice daily for up to 28 days
89541964|NCT03221543|Experimental|Resting Metabolic Rate Testing|All subjects will have the resting metabolic rate test. The ReeVue Indirect Calorimeter from Korr Medical will be used to obtain the resting metabolic rate.
89541965|NCT04484753|Other|Home Exercise Sheet|The participant took the sheet with the description of the exercises to his address.
89541966|NCT04484753|Other|Ipelvis mobile application|The participant received the app and performs home exercises guided by the app.
88960645|NCT04508894|Placebo Comparator|Control group|Supraclavicular Brachial Plexus Block using 20 ml 0.5%bupivacaine and 20 ml 0.9% normal saline
89514460|NCT05403346||SARS COv-2 RT-PCR AND Self collected CoviDx Covid-19 Antigen Self-Test|Sequentially enrolled symptomatic patients will have a nasal swab collected for high-sensitive SARS-CoV-2 RT-PCR testing as comparator and self collect a nasal swab for CoviDx™ Covid-19 Antigen self-testing. Order of tests will be performed following a randomization scheme.
88960646|NCT04508894|Active Comparator|Ketamine group|Supraclavicular Brachial Plexus Block using 20 ml 0.5%bupivacaine and 20 ml 0.9% normal saline plus 1 mg\kg ketamine
88960647|NCT04508894|Active Comparator|Dexmedetomidine group|Supraclavicular Brachial Plexus Block using 20 ml 0.5% bupivacaine and 20 ml 0.9% normal saline plus 1µg\kg dexmedetomidine
88960648|NCT04506125|Experimental|Liberal Group|transfusion of an erythrocyte concentrate in case of haemoglobin below 9.5 g/dL
88960649|NCT04506125|Active Comparator|Restrictive group|transfusion of an erythrocyte concentrate in case of haemoglobin below 7.5 g/dL
88960650|NCT04503473|Experimental|High Intensity Stepping Training|The primary goal will be to perform continuous stepping while maintaining HR within 70-85% maximum predicted HR (if patients are deconditioned, PTs will gradually increase intensity to desired levels as tolerated). We will also record Ratings of Perceived Exertion (RPE) every 3-5 minutes, with goals of 15-18. Sessions will be divided into ~10 minute increments (~25% of sessions) between speed-dependent treadmill training (described above for treadmill stepping), skill-dependent treadmill training, overground training, and stair climbing.
89514461|NCT04418986|Sham Comparator|Control (CCI Group)|The Participants will undergo phacoemulsification with on-axis incision
89514462|NCT04418986|Active Comparator|Study (OCCI Group)|The Participants will undergo phacoemulsification with opposite clear corneal incisions
89514463|NCT04418908|Active Comparator|GnRHant + E2|Participants in this arm received GnRHant and a transdermal estradiol patch (0.075 mg/day) for a period of 1 week.
89514464|NCT04418908|Placebo Comparator|GnRHant + PL|Participants in this arm received GnRHant and a placebo patch for a period of 1 week.
89514465|NCT04527328|Experimental|AKST1210|The AKST1210 column will be connected to the dialysis circuit during each dialysis session.
89514466|NCT04527328|Sham Comparator|Sham Control (No Intervention)|A covered surrogate object of similar size and shape as the investigational device
89514467|NCT05397808|Experimental|pilates group|Pilates training will be held for eight weeks, two days a week for 1 hour. The investigators divided the individuals in the pilates exercise group into groups of 12 or 13 to verify whether they did the exercises correctly. A program including 15 minutes of warm-up, 30 minutes of Pilates exercises, and 15 minutes of cooling and stretching exercises was arranged for the pilates group. The activities were performed in ten repetitions. The exercise program recommended by the Australian Pilates and Physiotherapy Institute during postpartum will be used in the training.
89514468|NCT05397808|Active Comparator|control group|The control group was given breathing and relaxation exercises, which they would do two days a week for eight weeks, in the form of a home program. Diaphragmatic breathing and respiratory control were given as breathing exercises.
89514469|NCT04747288||Sjögren's syndrome|Sjögren's syndrome patients were screened in the rheumatology outpatient departments and Center for Traditional Medicine at Taipei Veterans General Hospital, and were enrolled with the inclusion criteria: (1) aged between 20 and 75 years; (2) fulfilled the 2002 American-European Consensus Criteria for SS (AECG). Exclusion Criteria: NA.
89514470|NCT04747288||Systemic lupus erythematosus|Systemic lupus erythematosus patients were screened in the rheumatology outpatient departments and Center for Traditional Medicine at Taipei Veterans General Hospital, and were enrolled with the inclusion criteria: (1) aged between 20 and 75 years; (2) fulfilled the 1982 and 1997 revised Systemic lupus erythematosus criteria. Exclusion Criteria: NA.
89514471|NCT04747288||Dry eye syndrome|Dry eye syndrome patients were screened in the ophthalmology outpatient departments, rheumatology outpatient departments and Center for Traditional Medicine at Taipei Veterans General Hospital, and were enrolled with the inclusion criteria: (1) aged between 20 and 75 years; (2) Schirmer's test less than 10 mm/5 min. Exclusion Criteria: NA.
89514472|NCT04747288||non AIDDES Healthy Controls|Non AIDDES Healthy Controls were enrolled with inclusion criteria: (1) aged between 20 and 75 years; (2) without any Chronic disease. Exclusion Criteria: any Sjögren's syndrome, Systemic lupus erythematosus, or Dry eye syndrome.
89514473|NCT05304910|Experimental|Lu AG09222 Low Dose|Participants will receive a single dose of Lu AG09222 by subcutaneous (SC) injection on Day 1.
89514474|NCT05304910|Experimental|Lu AG09222 High Dose|Participants will receive a single dose of Lu AG09222 by SC injection on Day 1.
89514475|NCT05304910|Placebo Comparator|Placebo|Participants will receive a single dose of placebo matching LU AG0922 by SC injection on Day 1.
89514476|NCT04821934|Experimental|Telerehabilitation (TR) at home + Telesurveillance program (TSu)|These COVID-19 patients will enter the usual telesurveillance program together with a specific remote rehabilitation program on exercise activity.
89514477|NCT04821934|Active Comparator|Telesurveillance (TSu) alone|These COVID-19 patients will enter the usual remote telesurveillance program
89514478|NCT04466501|Experimental|ACR LAB for Professional User|
89514479|NCT03525041|Active Comparator|CABG+mitral valve annuloplasty|Participants will undergo CABG and mitral valve annuloplasty.
89514480|NCT03525041|Active Comparator|CABG|Participants will undergo CABG only.
89514481|NCT04831450|Experimental|Cemiplimab After CRT in HNSCC|Participants will receive Cemiplimab for 6 consecutive months (a total of 8 cycles) 14-42 days after completion of standard of care CRT.
89514482|NCT03248375|Other|Radiation Segmentectomy|Radiation Segmentectomy on Resectable HCC
89514483|NCT04830982|Experimental|Diazoxide|IV Diazoxide as additive to hypothermic hyperkalemic cardioplegia.
89514484|NCT04830982|Placebo Comparator|Placebo|Placebo as additive to hypothermic hyperkalemic cardioplegia.
89514485|NCT03524963|Experimental|Sequence A|Cilostan CR Tab. in phase 1 and Pletaal SR Cap. in phase 2
89514486|NCT03524963|Experimental|Sequence B|Pletaal SR Cap. in phase 1 and Cilostan CR Tab. in phase 2
89514487|NCT03524885|Active Comparator|Short implants|2 or 3 implant 4-5 mm length and 4 mm diameter (Syra Short, Sweden & Martina, Padua, Italy) will be positioned. The healing cap will be immediately connected and a vycril suture will be done after soft tissue reflection.
89541967|NCT04484753|Active Comparator|Home exercise sheet + Pelvic Physiotherapy|The participant did group physical therapy and used the exercise sheet at home on other days.
89541968|NCT04484753|Active Comparator|Ipelvis mobile application + Pelvic Physiotherapy|The participant did group physical therapy and used the mobile application on other days.
89541969|NCT03221231|Experimental|N-acetylcysteine|
89541970|NCT03221231|Placebo Comparator|Placebo|
89541971|NCT03221231|Active Comparator|Healthy controls|
89541972|NCT03221621|Active Comparator|Adalimumab Monotherapy|Adalimumab injections will be administered through subcutaneously in a weekly dose of 40mg from week 4 up to 24 months (V8), after an initial dose of 160mg at week 0 and a 80mg dose at week 2, continued for 2 years in total.
89541973|NCT03221621|Experimental|Adalimumab + Surgery|Patients will be treated with a combination of adalimumab and wide excision, with a maximum of three surgical interventions within the first year. Adalimumab will be administered through subcutaneous injections in weekly dose of 40mg from week 4 up to 24 months (V8), after an initial dose of 160mg at week 0 and a 80mg dose at week 2, continued until the last surgery.
89541974|NCT03221153|No Intervention|No Intervention|This is the control group. Participants in this group will take the usual course without simulation techniques.
89541975|NCT03221153|Experimental|Simulation|This is the intervention group. Participants in this group will to take the course with simulation techniques.
89541976|NCT03220997|Experimental|Interventional|Mothers will be given six sachets of carbohydrate powder to be mixed in water . Instructions will be given to have two sachets in 800ml water at 10pm the night before and one sachet in 400ml water at 6 am on the morning of surgery. The order of the list will be decided at 8.45am on the morning of surgery by the surgical team. Mothers scheduled to have surgery later than 11am will be given a further sachet at 9.30am. Mothers scheduled for surgery after 1pm will be given a sachet at 9am and 11am.
89541977|NCT03220997|No Intervention|Standard Care|"Standard fasting instructions will given to mother:~Food until midnight before surgery 800ml water at 10pm night before surgery 400ml water at 6 am morning of surgery The order of the list will be decided at 8.45am on the morning of surgery by the surgical team.~Mothers scheduled to have surgery later than 11am will be given a further 400ml water at 9.30am. Mothers scheduled for surgery after 1pm will be given 400ml water at 9am and 11am."
89541978|NCT02614287|Experimental|Galcanezumab 120 mg|Galcanezumab 240mg given as loading dose at first dosing visit followed by 120 mg given by subcutaneous (SC) injection once a month for up to 11 months by auto injector or pre-filled syringe.
89541979|NCT02614287|Experimental|Galcanezumab 240 mg|Galcanezumab 240 mg given by SC injection once a month for up to 12 months by auto injector or pre-filled syringe.
89541980|NCT03220919|Experimental|Weight-based|Weight-based insulin insulin titration regimen
89541981|NCT03220919|Placebo Comparator|Glucose level-based|Glucose level-based insulin titration regimen
89541982|NCT03220763||Thirds of number of restaurant meals|Respondent self-reports of # of times/week restaurant prepared meals were consumed. The respondents will be categorized into approximate thirds.
89541983|NCT03220841|Active Comparator|Standard drug therapy|Adalimumab monotherapy, Standard Dose induction (160mg at week 0, 80mg week 2 and 40mg fortnightly thereafter)
89541984|NCT03220841|Experimental|Intensive drug therapy|Adalimumab in combination with dose optimized thiopurine, Intensive induction (160mg weekly for 4 weeks then 40mg fortnightly). Anti-TNF dose may be increased if ongoing inflammation every 4 months until study endpoint.
89541985|NCT03047655|Active Comparator|Physical activity only|pedometers have to be used throughout all days; daily amount of steps is reported via App or website; 10000 steps are defined as daily goal
89541986|NCT03047655|Active Comparator|Physical activity + Dietary treatment|"pedometers have to be used throughout all days; daily amount of steps is reported via App or website; 10000 steps are defined as daily goal~additionally, subjects will be provided with one healthy muffin per day (450 kcal; low GI, high load of PUFA and isomaltulose) over 6 weeks"
88960651|NCT04503473|Active Comparator|Conventional Therapy|Participants provided conventional therapy will perform various standardized exercise tasks during 40 minutes of 1 hr sessions. The type of therapeutic activities is based on published normative data of typical activities performed during clinical physical therapy sessions with focus on strengthening activities (25% of session); balance activities (25%); locomotor activities (25%), and combined stretching exercises (10-15%) and transfers (10-15%). Intensity of activities will be targeted at 30-40% of their HR reserve in attempts to maintain consistent intensities between training groups.
88960652|NCT04495959||68Ga-HTK03149 PET/MRI DWB scan|"All participants will undergo the same procedures listed in Detailed Description in the protocol section."
88960653|NCT04487236|Experimental|ZN-A-1041 50mg|"Phase 1a:~Subjects will be given ZN-A-1041 orally 50mg Bid, for 21days as one cycle"
88960654|NCT04487236|Experimental|ZN-A-1041 100mg|"Phase 1a:~Subjects will be given ZN-A-1041 orally 100mg Bid, for 21days as one cycle"
88960655|NCT04487236|Experimental|ZN-A-1041 200mg|"Phase 1a:~Subjects will be given ZN-A-1041 orally 200mg Bid, for 21days as one cycle"
88960656|NCT04487236|Experimental|ZN-A-1041 400mg|"Phase 1a:~Subjects will be given ZN-A-1041 orally 400mg Bid, for 21days as one cycle"
88960657|NCT04487236|Experimental|ZN-A-1041 600mg|"Phase 1a:~Subjects will be given ZN-A-1041 orally 600mg Bid, for 21days as one cycle"
88960658|NCT04487236|Experimental|ZN-A-1041 800mg|"Phase 1a:~Subjects will be given ZN-A-1041 orally 800mg Bid, for 21days as one cycle"
88960659|NCT04487236|Experimental|ZN-A-1041 1000mg|"Phase 1a:~Subjects will be given ZN-A-1041 orally 1000mg Bid, for 21days as one cycle"
88960660|NCT04487236|Experimental|ZN-A-1041 level 1+Capecitabine 1000 mg/m2 + Trastuzumab 8 mg/kg iv. First Cycle|"Phase 1b:~ZN-A-1041 Level 1 (The previous dose of MTD) to be used in the combination therapy will be determined based on the MTD identified in the Phase 1a study.~Capecitabine will be given at the dose of 1000 mg/m2, BID (2000 mg/m2/day), during the first 2 weeks of the 21-day treatment cycle.~Trastuzumab (8 mg/kg in cycle 1 followed by 6 mg/kg beginning in cycle 2, administered as an IV infusion.~If intolerance, reduce Capecitabine dose to 750 mg/m2 for exploration"
89024677|NCT01050257|Experimental|Oseltamivir (TAMIFLU®) 200 mg|Oseltamivir (TAMIFLU®) 200 mg intravenous (IV) infused over 2 hours, two times a day (every 12 hours) for 5 days. At the discretion of the investigator after 3 days of treatment (6 doses), participants could either continue IV treatment or switch to 150 mg oral oseltamivir twice daily for 5 days. If necessary, after completing the 5 days of treatment, participants could receive additional treatment with study drug (IV or oral) for up to 5 days.
89541987|NCT03220607||Medical induced abortion|120 singleton nulliparous patients are planning to complete the study period. Study group constitute of second trimester pregnancies between 14-24 weeks of gestation. All participants were nulliparous and had no systemic illnesses. The uterocervical angle will be measured in all participants before the induction of labor.
89024678|NCT01050257|Experimental|Oseltamivir Open Label|Moderate/Severe renal impaired participants received open label oseltamivir IV or oseltamivir capsules at reduced doses for 5 days as per protocol. If necessary, after completing the 5 days of treatment, participants could receive additional treatment with study drug as per protocol.
89024679|NCT03272802|Experimental|Case group|"ALS patients who receive the usual treatment option (Riluzole) for this disease and Edaravone. Instructions:~Tab. Rilutek 50 mg PO q12hr on empty stomach.~Amp. Edaravone 60 mg per day IV infusion (in normal saline during 1 hour) for 14 days in the first 28 day cycle.~Amp. Edaravone 60 mg per day IV infusion (in normal saline during 1 hour) for 10 days in the following 28 day cycles after the first cycle (for 11 cycles)."
89024680|NCT03272802|Active Comparator|Control group|"ALS patients who receive the usual treatment option (Riluzole) for this disease.~Instructions:~1. Tab. Rilutek 50 mg PO q12hr on empty stomach."
89024681|NCT00472719|Experimental|1|Participants in this group will receive an injection of the adenoviral vector vaccine VRC-HIVADV027-00VP at study entry and an injection of VRC-HIVADV038-00-VP at Month 3. There will be 9 study visits for this arm.
89024682|NCT00472719|Experimental|2|Participants in this group will receive an injection of VRC-HIVADV038-00-VP at study entry and an injection of VRC-HIVADV027-00-VP at Month 3. There will be 9 study visits for this group.
89024683|NCT00472719|Experimental|3|Participants in this group will receive an injection of the VRC-HIVDNA044-00-VP vaccine at study entry and Months 1 and 2, followed by an injection of VRC-HIVADV027-00-VPat Month 6. There will be 13 study visits for this group.
89024684|NCT00472719|Experimental|4|Participants in this group will receive an injection of VRC-HIVDNA044-00-VP at study entry and Months 1 and 2, followed by an injection of VRC-HIVADV038-00-VP at Month 6. There will be 13 study visits for this group.
89024685|NCT01050062||Micombi® Combination Tablet AP|
89024686|NCT01050062||Micombi® Combination Tablet BP|
89024687|NCT00464841|Experimental|1|Tsui test for combined spinal-epidural
89024688|NCT00464841|Experimental|2|Tsui test for intrathecal catheter
89024689|NCT00464919|Experimental|A|
89024690|NCT00434174|Experimental|everolimus + Pemetrexed - daily|Daily treatment
89024691|NCT00434174|Experimental|everolimus + Pemetrexed - weekly|Weekly treatment
89024692|NCT00464958|Experimental|Sublingual tizanidine|Once nightly dosing of 12 mg sublingual tizanidine tablet
89024693|NCT01055912|Experimental|Lixivaptan|Capsule, 100mg Lixivaptan or matching placebo once daily.
89024694|NCT01055912|Placebo Comparator|Placebo|Patients will be screened for entry into the study and will be randomized (2:1) to lixivaptan or placebo.
89024695|NCT00472758|Active Comparator|1|MEDI 545
89024696|NCT00472758|Placebo Comparator|2|Placebo IV
89024697|NCT01055444|Experimental|Heated lidocaine/tetracaine topical patch|Patients will be instructed to apply one heated lidocaine 70 mg and tetracaine 70 mg topical patch to the affected shoulder every 12 hours starting on the evening of Day 1 through the morning of Day 14 (morning and evening applications) and to remove the patch after 2-4 hours.
89024698|NCT01055015|Experimental|1|Q8003, Flexible dose
89024699|NCT01055015|Experimental|2|Q8003, Low dose
89541988|NCT04866927||Adults|"Inclusion criteria: Healthy, non-pregnant women, adults aged 18-65 years, not taking any medication, including NSAIDs, not taking antibiotics within 4 weeks of study, BMI within 18-35 range.~Exclusion criteria: Children and elderly (over 65), pregnant women, individuals diagnosed with non-communicable or communicable disease, being under restrictive diet, antibiotics within 4 weeks of study, medications within 4 weeks of study."
89541989|NCT03045393|Experimental|Mirvetuximab Soravtansine|Participants will receive 2 doses of Mirvetuximab Soravtansine after neoadjuvant chemotherapy and before surgical resection of tumor.
89541990|NCT01374971|Other|Certolizumab Pegol (CZP)|Certolizumab Pegol (CZP) liquid formulation 200 mg sc -(initial loading dose of 400 mg sc at 0 (Baseline), 2, and 4 weeks), then 200 mg sc every 2 weeks at 6, 8, and 10 weeks with arthroscopic synovial tissue biopsy pre- and post-treatment.
89541991|NCT03220295|Experimental|Dose Escalation of VU319 - Dose 1|Dose Escalation of VU319
89541992|NCT03220295|Placebo Comparator|Placebo - Dose 1|Dose Escalation of Placebo
89541993|NCT03220295|Experimental|Single Dose of VU319 under Fed State|Single dose of VU319 (50% of the maximum tolerated dose) 30 minutes after a High Fat Standard Breakfast
89541994|NCT03220295|Placebo Comparator|Single Dose of Placebo under Fed State|Single dose of Placebo 30 minutes after a High Fat Standard Breakfast
89541995|NCT03220295|Experimental|Single Dose of VU319 under Fasted State|Single dose of VU319 (50% of the maximum tolerated dose) after overnight fast
89541996|NCT03220295|Placebo Comparator|Single Dose of Placebo under Fasted State|Single dose of placebo after overnight fast
89541997|NCT03220295|Experimental|Dose Escalation of VU319 - Dose 2|Dose Escalation of VU319
89541998|NCT03220295|Experimental|Dose Escalation of VU319 - Dose 3|Dose Escalation of VU319
88960661|NCT04487236|Experimental|ZN-A-1041 level 2+Capecitabine 1000 mg/m2+ Trastuzumab 8 mg/kg iv. First Cycle|"Phase 1b:~ZN-A-1041 Level 2 ( dose of MTD) to be used in the combination therapy will be determined based on the MTD identified in the Phase 1a study.~Capecitabine will be given at the dose of 1000 mg/m2, BID (2000 mg/m2/day), during the first 2 weeks of the 21-day treatment cycle.~Trastuzumab (8 mg/kg in cycle 1 followed by 6 mg/kg beginning in cycle 2, administered as an IV infusion.~If intolerance, reduce Capecitabine dose to 750 mg/m2 for exploration"
88960662|NCT04487236|Experimental|ZN-A-1041 MAD+Capecitabine 1000 mg/m2+Trastuzumab 8 mg/kg iv. First Cycle|"Phase 1b:~If the MTD is still not reached at the maximum dose level in Phase 1a study, the maximum dose level (MAD) of ZN-A-1041 in Phase 1a will be used in Phase 1b study.~If intolerance, reduce Capecitabine dose to 750 mg/m2 for exploration"
88960663|NCT04487236|Experimental|ZN-A-1041+Capecitabine+Trastuzumab|"Phase 1c:~The combined dose of ZN-A-1041 is based on the recommended combined dose in the Phase 1b and the possible changes in the dosage form and the results of the food effect study, which will be decided by the sponsor and the investigator after discussion"
88960664|NCT04480671|Other|Sacrocolpopexy|This group will only receive the sacrocolpopexy for their pelvic organ prolapse repair.
88960665|NCT04480671|Active Comparator|Sacrocolpopexy and concomitant level III support procedure|This randomized group will receive an additional vaginal repair for level III support at the conclusion of the sacrocolpopexy.
88960666|NCT04473664|Experimental|Participants with Moderate Hepatic Impairment|Participants with moderate hepatic impairment as defined by NCI-ODWG criteria who received a single, oral dose of quizartinib 30 mg on Day 1.
88960667|NCT04473664|Experimental|Control Participants with Normal Hepatic Function|Healthy participants with normal hepatic function matched as a group by sex, age (±10 years), and weight (±20%) who received a single, oral dose of quizartinib 30 mg on Day 1.
88960668|NCT04470024|Experimental|Arm 1|Vax + delayed anti-PD-1
88960669|NCT04470024|Experimental|Arm 2|Vax + anti-GITR + delayed anti-PD-1
88960670|NCT04460742|Experimental|CAPABLE Transitions|Older adults admitted to University of Rochester Medicine Home Care with and without dementia will receive care as usual as well as CAPABLE-trained occupational therapy, registered nurse, and handyman services delivered over 3-4 months.
88960671|NCT04460742|Active Comparator|Care As Usual|Older adults admitted to University of Rochester Medicine Home Care (a Medicare-certified home health agency) with and without dementia will receive care as usual.
88960672|NCT04459182|Active Comparator|Endothelial dysfunction (DE+)|obsese patient with OSA (AHI>15) and endothelial dysfunction
88960673|NCT04459182|Sham Comparator|No endothelial dysfunction (DE-)|obsese patient with OSA (AHI>15) and no endothelial dysfunction
88960674|NCT04458220||difficult airway|C-L≥Ⅲ grade
88960675|NCT04458220||none difficult airway|C-L<Ⅲgrade
88960676|NCT04444752|Experimental|CBP-201 Dose 1|CBP-201 Dose 1 subcutaneous (SC) injection
89541999|NCT03220295|Experimental|Dose Escalation of VU319 - Dose 4|Dose Escalation of VU319
89542000|NCT03220295|Experimental|Dose Escalation of VU319 - Dose 5|Dose Escalation of VU319
88960677|NCT04444752|Experimental|CBP-201 Dose 2|CBP-201 Dose 2 subcutaneous (SC) injection
88960678|NCT04444752|Experimental|CBP-201 Dose 3|CBP-201 Dose 3 subcutaneous (SC) injection
88960679|NCT04444752|Placebo Comparator|placebo|subcutaneous (SC) injection
88960680|NCT04436068|Experimental|Outpatients with known or suspected hydrocephalus|
88960681|NCT04436068|Experimental|Outpatients with other known or suspected neurological condition|
88960682|NCT04429022|Experimental|Prospective cohort|"Pre-Op:~Gabapentin 600mg PO PO x 1 prior to surgery (in pre-op)~Acetaminophen 1000mg PO x1 prior to surgery (in pre-op)~Intra-Op:~Paracervical block with local anesthetic (0.5% ropivacaine); 10 mL bilaterally (2 point) for total of 20mL~Local anesthetic (0.5% ropivacaine) at all laparoscopic port sites; another 10mL~Will operate at <15mmHg intra-abdominal pressure, with goal of <12mmHg~At end of procedure during closure of fascia, give 30mg ketorolac IV x 1~Post-Op:~Gabapentin 300mg PO BID for 7 days~Acetaminophen 1000mg PO q6h x 2 days then 1000mg q6h PRN~Celecoxib 200mg PO q 12h x 7d~Dilaudid 1mg IV PRN q3h while inpatient; oxycodone 12 x 5mg upon discharge (90MME) if patient did not use any opioids postoperatively while inpatient, will not prescribe opioid medication upon discharge"
89542001|NCT03220295|Placebo Comparator|Placebo - Dose 2|Dose Escalation of Placebo
89542002|NCT03220295|Placebo Comparator|Placebo - Dose 3|Dose Escalation of Placebo
89542003|NCT03220295|Placebo Comparator|Placebo - Dose 4|Dose Escalation of Placebo
89542004|NCT03220295|Placebo Comparator|Placebo - Dose 5|Dose Escalation of Placebo
89542005|NCT03220451|Experimental|Adhesive elastic taping|After a 4-week observation of the pressure ulcer under investigation, adhesive elastic tape is applied around it for a 4-week period (the tape is changed twice a week), according to a planned application protocol. The ulcer is then observed for a subsequent follow-up period of 4 weeks.
89024700|NCT03275051|Experimental|All subjects|Subjects who have received treatment with OTL-300 in and completed study TIGET-BTHAL will be included in this study. Subjects received OTL-300 injection administered intraosseously in TIGET-BTHAL study. No study treatment will be administered in this study (207757).
89024701|NCT00434447|Experimental|Zoledronic Acid|ZOL446
89024702|NCT00472953|Experimental|A|
89024703|NCT00472953|Active Comparator|B|
89514488|NCT03524885|Experimental|Bone regeneration with longer implants|"A horizontal and vertical regeneration following GBR technique will be performed using not-resorbable PTFE titanium reinforced membrane (Cytoplast Osteogenics, US) fixed by titanium pins or miniscrews to ensure the perfect stability (Pro-fix, Cytoplast Osteogenics, US).~The graft will be composed half autogenous bone harvested with a scraper (Meta, Firenze, Italy) by the same surgical site or by a second tunnel site in the mandibular ramus and half deproteinized bovine bone (Bio Oss Geislicht Pharma, Switzerland). The mucosal flaps will be sutured in a double layer with horizontal mattress and single gore-tex sutures (Cytoplast PTFE sutures 3.0, Cytoplast Osteogenics, US).~2 or 3 implant from 10 to 13 mm length putting the implant platform 2 or 3 mm apical to CEJ of the adjacent tooth will be inserted."
89514489|NCT04466423|Experimental|Small group intervention|Those randomized to the immediate intervention arm will be asked to meet approximately every other week for 6 months, covering 12 sessions. We will ask each group to meet in a relatively private setting (e.g., a restaurant near campus or a reserved meeting room), rather than more public spaces (e.g. river room, cafeteria) where interruptions are more likely.
89514490|NCT04466423|Placebo Comparator|Control|"Participants randomized to Arm 2 (delayed intervention) will be wait listed to begin sessions 6 months after the start of the study. This participation will be optional."
89514491|NCT03196115||Observation|Patients with Hyaline fibromatosis syndrome or high-grade suspicion for Hyaline fibromatosis syndrome
89514492|NCT04514848|Experimental|Individuals accessing screening for syphilis and HIV|Individuals at risk for syphilis and HIV (e.g. gay and bisexual men, indigenous communities experiencing a resurgence of syphilis, persons who inject drugs, etc) will undergo testing with both POCT and standard laboratory testing. Individuals testing positive for syphilis or HIV on the POCT will be informed that this is a preliminary positive and standard testing will be done. Individuals testing positive for syphilis on POCT may be offered treatment at the time of testing.
89514493|NCT04508140|Experimental|Single Arm|The study treatment consists of the combination of BO-112 given intratumorally inside the liver metastasis at the dose of 1gm in 1.2 mL in combination with intravenous pembrolizumab given at the fixed dose of 200 mg. This treatment will be given every 3 weeks, with a maximum duration of 35 cycles (2 years). Of note, during the first cycle, BO-112 will be administered on D1 and D8.
89514494|NCT04820452|Experimental|cohort 1 IBI302 treated with high dose level of IBI302|Drug: IBI302 4mg/eye;Intraocular injection
89514495|NCT04820452|Active Comparator|Aflibercept|Drug: Aflibercept 2mg/eye;Intraocular injection
89514496|NCT04820452|Experimental|cohort 1 IBI302 treated with low dose level of IBI302|Drug: IBI302 2mg/eye;Intraocular injection
89514497|NCT01637272|Experimental|SOM230|Subjects with dumping syndrome treated with pasireotide
89514498|NCT05224726|Experimental|PRP Treatment|PRP preparation will be applied on uterine incision after its closure.
89514499|NCT05224726|No Intervention|Control|Normal Cesarean delivery stages.
89514500|NCT03262558||Patients with ECC|No intervention
89514501|NCT03178864|Experimental|Rivaroxaban|Rivaroxaban
89514502|NCT03178864|Active Comparator|Standard of care|Unfractionated heparin Low-molecular weight heparin (dalteparin, enoxaparin, tinzaparin) Warfarin
89514503|NCT01636960|Experimental|Participants receiving PegIFN alfa-2b|Participants receive PegIFN alfa-2b 6 µg/kg subcutaneously (SC) on Day 1 of each week for 8 weeks (Induction) and then 3 µg/kg SC once weekly for up to 252 weeks (Maintenance).
89514504|NCT04827238||Patients with Elevated Gradients Post Transcatheter Aortic Valve Replacement|Patients who have an echocardiographic transaortic mean gradient ≥ 20mmHg OR VARC-3 criteria for ≥ moderate hemodynamic valve deterioration post TAVR on any TTE > 1 month post-TAVR
89514505|NCT04036708|Experimental|MISC and WTM|Wetting method (WTM)+ Mediational Intervention for Sensitizing Caregivers (MISC) bi-weekly for 12 months.
89514506|NCT04036708|Active Comparator|WTM only|WTM trainings only (recommended standard of care) bi-weekly for 12 months.
89514507|NCT04194970|Experimental|Group I (monitoring with live-feedback system)|WBM smart insole system is a product that can monitor the pressure under the foot and provide live feedback (if this option activated) to the user in case of exceeding the specified limits. Its components are insole with pressure sensors and mobile applications (IOS, Android). Post-operative patients (osteochondral lesion of the talus) will be monitored with the WBM smart insole system in case live feedback is turned on. We aimed to ensure the compliance of patients to specified weight bearing limits. We will follow up this grup for 6 weeks periods with WBM smart insole system. Pre-op. and post-op 6 week, we evaluate the patients in case of ankle function, pain with The American Orthopaedic Foot & Ankle Society (AOFAS) Scoring. Also we will monitor the compliance success of patients with WBM smart insole system during 6 week. The relationship with compliance to weight bearing success and AOFAS scores will be evaluate.
89514508|NCT04194970|Active Comparator|Group II (monitoring without live feedback)|"The post-operative patients (osteochondral lesion of talus), follow-up with product in live-feedback closed condition.~After surgery, we will educate the patients about weight bearing protocol on post-op first day and post op 3 week. The protocol is  first 3 weeks, %0 body weight bearing (BWB), second 3 weeks between %10-%20 BWB. Patients' compliance to BWB protocol will be monitored daily with the WBM smart insole system in case live-feedback is turned off. Pre-op and post-op 6 week, we evaluate the patients in case of ankle function, pain with The American Orthopaedic Foot & Ankle Society (AOFAS) Scoring. The relationship with compliance to weight bearing success and AOFAS scores will be evaluate."
89519536|NCT03524209|Other|Surgery|Patients with spondylodiscitis are operated by percutaneous instrumentation and receive an antibiotic treatment according to the bacterium evidenced in the initial diagnostic intervertebral disc puncture (6 weeks to 3 months according to CRP course)
89024704|NCT02957630|Experimental|15 mg E4/3 mg DRSP|15 mg estetrol/3 mg drospirenone combined oral contraceptive
89542006|NCT02506205|Experimental|LSVT LOUD|LSVT LOUD was developed based on concepts of neuroplasticity, motor learning, skill acquisition and motor speech. LSVT LOUD trains laryngeal and respiratory functions through loud and effortful phonatory tasks (Ramig, Sapir, Countryman, Pawlas, O'Brien, Hoehn, & Thomson, 2001). It targets vocal intensity via stimulation of effortful speech productions with multiple repetitions and through encouraging self-calibrations of loud voice by patients. LSVT LOUD cues patients to speak loud (e.g., Fox et al., 2002; Ramig et al., 2001; Sapir et al., 2007). Having a single cue may increase treatment effects, as it reduces cognitive load in adults with PD because some of them develop cognitive deficits when PD progresses (Fox et al., 2002). Treatment is intensive, consisting of 4 individual sessions a week for 4 weeks, with 16 sessions in one month.
89542007|NCT02506049|Other|S-LPC:Selective Laser Photocoagulation|S-LPC seals connecting vessels, normalizes flow between twins
89542008|NCT02505815||Regional Anesthesia|Patients with surgery in regional anesthesia.
89542009|NCT02505815||General Anesthesia|Patients with surgery in general anesthesia.
89542010|NCT04497545|Experimental|Study Group|A four-week rehabilitation program (Monday to Friday) involving the hour of individual therapy and 30 minutes of therapy on the Luna EMG device.
89542011|NCT04497545|Other|Control Group|A four-week rehabilitation program (Monday to Friday) involving one hour of individual therapy and 30 minutes on lower limb rotor
89542012|NCT02505737|Experimental|TH-CBT|The treatment works by teaching people with PD (PWP) the coping skills needed to manage their emotional reactions to the numerous challenges posed by the disease. Specifically, the treatment targets maladaptive thought patterns (e.g., I have no control; I am helpless) and behaviors (e.g., social isolation, lack of exercise, poor sleep habits, excessive worry), and critically, provides caregivers with the tools needed to encourage the PWPs' practice of their newly acquired coping skills. Treatment is administered over the phone and no travel is required.
89542013|NCT02505737|Other|Enhanced Usual Care|All participants will continue to receive their routine medical treatment under the supervision of their personal doctors (e.g., neurologists, psychiatrists, primary care physicians, therapists) while participating in the study. This routine treatment (e.g., usual care) will be further enhanced with the provision of written educational materials for effective coping with PD, the close clinical monitoring of depressive symptoms by study staff, and the provision of counseling resources in the local community.
89542014|NCT02505659|Experimental|EXPERIMENTAL GROUP|Sessions are aiming to neuromuscular and functional training. Each session starts with trunk muscle activation. Patients will then have to realize a neuromuscular training on Huber Motion Lab® followed by multiple exercises targeting functional stability and neuromuscular control. From the 4th session, a jump sequence will be added to the previous exercices. Exercises used in this protocol are based upon successful exercises of protocols already performed on patients with anterior cruciate ligament rupture.
89542015|NCT02505659|No Intervention|CONTRL GROUP|a control group (without preoperative reeducation)
89542016|NCT02505971|Active Comparator|Nadolol group|40 study participants will take Nadolol (oral liquid suspension)
89542017|NCT02505971|Active Comparator|Propranolol group|40 study paticipants will take Propranolol (oral liquid suspension)
88960683|NCT04429022|Active Comparator|Historical Control|Traditional post-operative opioid medication regimen: Dilaudid 1mg IV PRN q3h while inpatient; Percocets 12 x 5mg/325 (90MME) upon discharge
88960684|NCT04421625|Experimental|Diagnostic test for SARS-Cov2 for patients and health staff|"Blood test (rapid serology (immediate analysis), ELISA serology (differed analysis on frozen sample), genotyping of FCGR2A and FCGR3A gens)~Nasal swab test (only if the patient has symptoms)~Questionnaires"
88960685|NCT04420052|Experimental|OMT group|
88960686|NCT04420052|Placebo Comparator|Placebo group|
88960687|NCT04410367|Experimental|Patients|Single intravenous administration of 18F fluciclovine for PET Scan
88960688|NCT04401475|Experimental|Stage 1|Stage 1 (Phase II Study) For 80% power (β = 0.20), at a significance level of 5% (α =0.05) and a 1:1 randomization ratio, a total of 316 (EB05: 158, SOC: 158) evaluable patients will be required. Allowing for 20% attrition a total of 396 patients will be recruited.
88960689|NCT04401475|Experimental|Stage 2|Stage 2 (Phase III Study) For a 1:1 ratio of patients treated with EB05 vs. Placebo, a cumulative one-sided alpha of 2.5% and 90% power, to detect an Odds Ratio of 2.00, a total of 586 evaluable patients will be required for Stage 2 (Phase III study). 293 of these will be treated with EB05 + SOC and 293 treated with Placebo + SOC. Allowing for 10% attrition, a total of 644 patients will be enrolled in this Stage.
88960690|NCT04400838|Experimental|Group 1 a1|Volunteers will receive a single dose ChAdOx1 nCOV19 vaccine, 5x10^10vp (Abs 260)
88960691|NCT04400838|Experimental|Group 1 a3|Volunteers will receive two doses of ChAdOx1 nCoV19 vaccine: 5x10^10vp (Abs 260) prime and 0.5mL (3.5 - 6.5 × 10^10 vp, Abs 260) boost, minimum 4 weeks from prime
88960692|NCT04400838|Experimental|Group 1 b1|Volunteers will receive two dose ChAdOx1 nCOV19 vaccine, 5x10^10vp (Abs 260) prime and 2.2x10^10vp (qPCR) boost (4-6 weeks apart)
88960693|NCT04400838|Experimental|Group 2 a1|Volunteers will receive a single dose ChAdOx1 nCOV19 vaccine, 5x10^10vp (Abs 260)
88960694|NCT04400838|Experimental|Group 2 a3|Volunteers will receive two doses of ChAdOx1 nCoV19 vaccine: 5x10^10vp (Abs 260) prime and 0.5mL (3.5 - 6.5 × 10^10 vp, Abs 260) boost, minimum 4 weeks apart
88960695|NCT04400838|Experimental|Group 2 b1|.Volunteers will receive two dose ChAdOx1 nCOV19 vaccine, 5x10^10vp (Abs 260) prime and 2.2x10^10vp (qPCR) boost 4-6 weeks apart
88960696|NCT04400838|Experimental|Group 4 a1|Volunteers will receive a single dose ChAdOx1 nCoV19 vaccine, 5x10^10vp (Abs 260)
88960697|NCT04400838|Experimental|Group 4 b1|Volunteers will receive two dose ChAdOx1 nCOV19 vaccine, 5x10^10vp (Abs 260) prime and 2.2x10^10vp (qPCR) boost 4-6 weeks apart
88960698|NCT04400838|Experimental|Group 4 c1|Volunteers will receive two doses of ChAdOx1 nCOV19 vaccine, 5x10^10vp (Abs260) prime and 2.2x10^10vp (qPCR) boost*, at least 4 weeks apart
88960699|NCT04400838|Experimental|Group 5 a1|Volunteers will receive a single dose ChAdOx1 nCoV19 vaccine, 5x10^10vp, (Abs 260)
89542018|NCT02505503|Active Comparator|Unloading shoes|The unloading shoe will be a trainer-type shoe with a cosmetically-shaped rocker sole. The sole will have three circular curves whose arc centres are positioned at the anatomical ankle, hip and knee respectively; assuming a vertical lower limb. This is designed to influence the line of action of the ground reaction force to pass close to the anatomical joint centres and so reduce the moments needed to be generated for ambulation by the muscles acting across those joints in the lower limb. Additionally it is designed to place the ankle into a relatively plantarflexed position where the ankle plantarflexors use less energy than for instance when placed in dorsiflexion.
89542019|NCT02505503|Placebo Comparator|Unadapted control shoes|The control shoes will be similar in appearance to the unloading shoes, but they will not contain the altered sole.
89542020|NCT04497311||SARS-CoV-2|Patients with a SARS-CoV-2 polymerase chain reaction positive test upon admission to the emergency department.
89542021|NCT04497311||H1N1 influenza|Patients with an influenza H1N1 polymerase chain reaction positive test upon admission to the emergency department.
89542022|NCT02505581|Experimental|Oral + Parenteral prophylaxis|
89542023|NCT02505581|Active Comparator|Only Parenteral prophylaxis|
89542024|NCT03343847|Experimental|Romiplostim|the study in a 2:1 randomization ratio(108 subjects to romiplostim)
89542025|NCT03343847|Placebo Comparator|Placebo|the study in a 2:1 randomization ratio (54 subjects to placebo)
89542026|NCT02451293|Active Comparator|Melatonin (N-acetyl-5-methoxytryptamine)|Melatonin (N-acetyl-5-methoxytryptamine) 25 mg oral administration 1 hour before bedtime for 12 weeks.
89542027|NCT02451293|Placebo Comparator|Placebo|Comparable placebo pill, oral administration 1 hour before bedtime for 12 weeks.
89542028|NCT03343769||Patient|
89542029|NCT03343769||Control|
89542030|NCT02505191|Experimental|Test|St. John's wort prolonged-release tablet 500 mg
89542031|NCT02505191|Active Comparator|Reference|St. John's wort film coated tablets 250 mg (Remotiv N)
89542032|NCT04497077|Experimental|single dose tart cherry capsule|single dose tart cherry capsule
89542033|NCT04497077|Experimental|double dose tart cherry capsule|double dose tart cherry capsule
89542034|NCT04497077|Experimental|single dose tart cherry juice|single dose tart cherry juice
89542035|NCT04497077|Experimental|double dose tart cherry juice|double dose tart cherry juice
89542036|NCT04497077|Experimental|single placebo capsule|single placebo capsule
89542037|NCT04497077|Experimental|single placebo juice|single placebo juice
89542038|NCT02505035|Active Comparator|Default ordering of palliative consult|Hospitals randomized to the intervention arm will adopt a system whereby eligible patients are identified by the electronic health record, a consultation is ordered by default, and physicians may cancel the order after being alerted to it, and patients or family members may decline such services.
89542039|NCT02505035|No Intervention|Usual care|There will be no trial-driven approach to care. Inpatient palliative care consultative services will be actively requested by physicians as in usual care.
89542040|NCT03119753|Experimental|Group R|Rapid Prototyping method of fabrication of complete denture: the master casts will be scanned using DENTAL WINGS eco-scan 3, using laser technology for scanning, after spraying the stainless steel pins with scanning spray to be recorded into the denture base. Virtual model will be obtained for fabrication of denture bases. Denture base will be designed and modified on the virtual model, then it will be printed using ZENITH-3D Printer using Urethane acrylate oligomer based photo-polymerized resin.
89542041|NCT03119753|Active Comparator|Group C|Conventional method of fabrication of complete denture: Self-cured acrylic resin trial denture bases will be constructed on the obtained master casts, then processing of the final denture bases by conventional clamping method cured by long curing cycle (74º C for 8 hours) using heat-cured poly-methyl methacrylate (PMMA) resin material. The position of the pins will be recorded into the denture bases so that the linear changes could be measured.
89542042|NCT03220061|Experimental|experimental|music therapy was used in the study for 30 minutes
88960700|NCT04400838|Experimental|Group 5 a3|Volunteers will receive two doses of ChAdOx1 nCoV19 vaccine: 5x10^10vp (Abs 260) prime and 0.5mL (3.5 - 6.5 × 10^10 vp, Abs 260) boost, minimum 4 weeks from prime
88960701|NCT04400838|Experimental|Group 5 b1|Volunteers will receive a single dose ChAdOx1 nCoV19 vaccine, 5x1010vp, (qPCR)
89542043|NCT03220061|No Intervention|control|usual care was given to participant in control group
88960702|NCT04400838|Experimental|Group 5 c1|Volunteers will receive a single dose ChAdOx1 nCoV19 vaccine, 5x10^10vp, (qPCR)
88960703|NCT04400838|Experimental|Group 5 d1|Volunteers will receive two doses of ChAdOx1 nCoV19 vaccine, 0.5mL (3.5 - 6.5 × 10^10 vp, Abs 260)* 4-6 weeks apart
88960704|NCT04400838|Experimental|Group 5 e1|Two dose ChAdOx1 nCoV-19 0.5mL (Covishield 0.9 x 10^11 vp/mL), 4-6 weeks apart
88960705|NCT04400838|Experimental|Group 5 f1|Two dose ChAdOx1 nCoV-19 (Covishield 0.9 x 10^11 vp/mL), 0.25mL prime and 0.5mL boost 4-6 weeks apart
88960706|NCT04400838|Experimental|Group 6 a1|Volunteers will receive a single dose ofChAdOx1 nCoV19 vaccine, 5x1010vp (qPCR)
89024705|NCT02957630|Active Comparator|30 mcg EE/150 mcg LNG|30 mcg ethinylestradiol/150 mcg levonorgestrel combined oral contraceptive
89542044|NCT02505113||CTPV without Montelukast|Patients with CTPV do not receive the treatment of Montelukast.
89542045|NCT02505113||CTPV treated with Montelukast|Patients with CTPV treated with Montelukast (10mg, q.d., p.o.).
89542046|NCT02504957|Other|Photodynamic therapy|Patients who underwent photodynamic therapy for malignant biliary obstruction.
89542047|NCT03343691||Screening Population|"Cohort 1:Screening Population - Women presenting for routine XRM and / or breast US.~Participants will be followed for one year and the outcome of those who undergo an annual XRM / breast ultrasound will be recorded."
89542048|NCT03343691||Breast Cancer Population|Cohort 2:Breast Cancer Population - Women who were diagnosed with malignant breast tumors, as determined by biopsy, and have not yet begun any treatment for the disease.
89542049|NCT03219515|Experimental|Gongjin-dan|Participants will be orally administered Gongjin-dan pills of 3.75g, 1 pill/day, 8 weeks (56 days).
89542050|NCT03219515|Placebo Comparator|placebo|Participants will be orally administered placebo pills of 3.75g, 1 pill/day, 8 weeks (56 days).
89542051|NCT03216317|Active Comparator|Intervention Group|Subjects will perform three weekly sessions of isometric handgrip training consisting of four series (two in each arm) with two minutes of isometric contraction with intensity of 30% of maximum voluntary contraction with interval between the two-minute series under the guidance of the trained researcher.
89542052|NCT03216317|No Intervention|Control Group|Individuals randomized to Control Group will be encouraged to increase their level of general physical activity, but without specific recommendations on physical activity.
89542053|NCT02504801|Active Comparator|nebulized Budesonide 2mg/4mL|+terbutaline 5mg/2mL,BID+ipratropium 2 puff(40ug)BID
89542054|NCT02504801|Placebo Comparator|nebulized saline 4mL|+terbutaline 5mg/2mL,BID+ipratropium 2 puff(40ug)BID
89542055|NCT02504567|Other|Laser ablation|Ablation with laser catheter
89542056|NCT02504567|Other|RF ablation|Ablation with RF catheter
89542057|NCT02504411|Experimental|Device Assisted Colonoscopy|"Device assisted colonoscopy (DAC) is a technique of attaching disposable devices like Endocuff or Transparent cap at tip of colonoscope to improve mucosal visualization and stability."
89542058|NCT02504411|Active Comparator|Standard Colonoscopy|Standard colonoscopy is the endoscopic examination of the large bowel and the distal part of the small bowel with a camera on a flexible tube passed through the anus.
88811650|NCT01368653|No Intervention|Advice and encouragement only|In this condition, smokers from both the Standard treatment and the Standard treatment+practice quitting arms who have smoked in the last 7-days at a 4-week post-target-smoking-cessation-date follow-up interview may be randomly assigned to this condition. Those in this arm will receive advice and encouragement to try to stop smoking again after they have slipped (returned to smoking) during a stop smoking attempt.
88811651|NCT01407107|Experimental|Nitroglycerin|Dose escalation trial of Nitroglycerin
88811652|NCT01368809|Active Comparator|Fentanyl|Fentanyl (50 µg/ml) 2 ml at induction, 1-2 ml boluses as needed
88811653|NCT01368809|Placebo Comparator|Saline Solution|Saline Solution 2 ml at induction, 1-2 ml boluses as needed
88811654|NCT01369745|Active Comparator|Prednisolone|Prednisolone 2.7 mg daily for 12 weeks
88811655|NCT01369745|Active Comparator|dipyridamole|Dipyridamole 360 mg daily for 12 weeks
88811656|NCT01369745|Active Comparator|prednisone|Prednisone 5 mg daily for 12 weeks
88811657|NCT01369745|Experimental|Z102 (2.7/360)|Prednisolone 2.7 mg plus dipyridamole 360 mg daily for 12 weeks
88811658|NCT01369745|Placebo Comparator|placebo|Placebo daily for 12 weeks
88811659|NCT01475513|Active Comparator|African-American women|African-American women
88811660|NCT01475513|Active Comparator|Caucasian women|Caucasian women
88811661|NCT01407575|Experimental|Buprenorphine|0.2 to 1.6mg of buprenorphine sublingual over the course of 8 weeks
88811662|NCT01407575|Placebo Comparator|Placebo|matching placebo- sublingual- over the course of 8 weeks
88811663|NCT01409213||All Enrolled Participants|
88811664|NCT01476449|Active Comparator|Monthly Ranibizumab|Patients randomized to the Monthly Ranibizumab arm of the study will be administered intravitreal injections each month for their diabetic macular edema for the duration of the study.
88811665|NCT01476449|Experimental|Treat and Extend Ranibizumab|"Patients randomized to this arm of the study will receive intravitreal injections of ranibizumab until their maculae are anatomically dry, at which point the evaluation and injection interval will be extended."
88811666|NCT01370369|Experimental|Single Testosterone Dose (Inner Thigh)|Subjects received a single application of 2.50 mL (two strokes) of the testosterone gel 2% applied to the inner thigh followed by a seven day washout period.
88811667|NCT01370369|Experimental|Single Testosterone Dose (Abdomen)|Subjects received a single application of 2.50 mL (two strokes) of the testosterone gel 2% applied to the abdomen followed by a seven day washout period.
88811668|NCT01370369|Experimental|Single Testosterone Dose (shoulder/upper arm)|Subjects received a single application of 2.50 mL (two strokes) of the testosterone gel 2% applied to the shoulder/upper arm.
88811669|NCT01370369|Experimental|Testosterone 1.25|Subjects received testosterone gel 2% at dose of 1.25 mL (one stroke) applied once daily for 10 consecutive days to the shoulder/upper arm.
88811670|NCT01370369|Experimental|Testosterone 2.50|Subjects received testosterone gel 2% at dose of 2.50 mL (two strokes) applied once daily for 10 consecutive days to the shoulder/upper arm.
88811671|NCT01370369|Experimental|Testosterone 3.75|Subjects received testosterone gel 2% at dose of 3.75 mL (three strokes) applied once daily for 10 consecutive days to the shoulder/upper arm.
88811672|NCT01370837|Experimental|Healthy controls|
88811673|NCT01370837|Experimental|Diabetes|Patients with diabetes mellitus without polyneuropathy.
88811674|NCT01370837|Experimental|Polyneuropathy|Patients with diabetes and polyneuropathy.
88811675|NCT01477463|Experimental|Arm A: Vitamin D|4,000 IU oral vitamin D3
88811676|NCT01477463|Experimental|Arm B: Placebo + Vitamin D|Placebo + 4000 IU oral Vitamin D3
88811677|NCT01410773|Experimental|Intended Users of the System|Untrained subjects with diabetes (at least 70% of subjects will be insulin users) use an investigational blood glucose monitoring system (Ninja 2) to self-test capillary blood obtained from fingerstick and palm.
88811678|NCT01478009|Experimental|KRG Extract|
88811679|NCT01478009|Placebo Comparator|Placebo|
88811680|NCT02203565|Experimental|Supportive care (Dakin's solution, radiation therapy)|Patients apply Dakin's solution topically daily over 10 minutes within 60 minutes of radiation therapy for up to 6 weeks.
88811681|NCT01375127||Subjects from Study A3921009|
88811682|NCT01375127||Subjects from Study A3921030|
88811683|NCT02960204|Active Comparator|Emricasan (5 mg)|Subjects with Non-alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension will be administered orally with emricasan (5 mg) twice a day.
88811684|NCT02960204|Active Comparator|Emricasan (25 mg)|Subjects with Non-alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension will be administered orally with emricasan (25 mg) twice a day.
88811685|NCT02960204|Active Comparator|Emricasan (50 mg)|Subjects with Non-alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension will be administered orally with emricasan (50 mg) twice a day.
89542059|NCT02451059|Experimental|Intervention-WE CARE|"The WE CARE survey is used to identify unmet material needs; it will be administered with patient's developmental screening forms at all health supervision visits from birth to two years of age.~Providers will be trained to review the WE CARE survey at health supervision visits and generate our WE CARE community resource handouts (referrals) through the EMR.~A peer patient navigator will offer personalized guidance to families with accessing community resources. The patient navigator will be available for at least a 1/2 day per week at each intervention health center to meet with families and offer guidance. Providers can communicate the patient navigator to refer families via the electronic medical record and families will also have the opportunity to contact the peer navigator at any time via the hotline number listed on the referral information sheets."
89542060|NCT02451059|No Intervention|Control-Standard of Care|Participants in the delayed-intervention control group will receive standard pediatric care. However, since the health centers share a common EMR, and for ethical reasons, investigators will also embed the health IT referral mechanism into the EMR at the control sites. Control providers will be made aware of this prior to the start of the study. Although this may potentially reduce the effect size, the investigator's prior study found that the impact on referral rates of provider access to resource information was minimal. Families at control health centers will not receive the WE CARE surveys at health supervision visits and will not have access to the peer patient navigators
89542061|NCT02504255||Patients with Crohn's Disease|patients will have biological samplings (blood, urine and faecal sampling) and will fill questionnaires to assess their stress and adaptation
89542062|NCT02504177|Experimental|The group of keep medication NOAC|The randomization after scheduling of Ablation at clinic The explanation to stop taking medicine of NOAC 24 hours before the ablation
89542063|NCT02504177|Active Comparator|The group of stop medication NOAC 1 day|The randomization after scheduling of ablation at clinic. The explanation to stop taking medicine of NOAC day of ablation
89542064|NCT02450981|Experimental|BCD-021 group|BCD-021 (bevacizumab) at a dose of 1.25 mg, administered as single intravitreal injection every 28 days up to 12 months.
89542065|NCT02504021|Experimental|Family Consultation Condition|The family consultation will be one, 1-hour session conducted by trained, master's level therapists. The goals of the meetings are: a) Review patient and family understanding of events that caused the hospital admission; b) increase family awareness of the level of cognitive impairment that the patient is experiencing; c) discuss ways the family can get involved and help the patient with their medication and dialysis adherence; d) use motivational interviewing techniques as needed. This will be provided in addition to the usual care that inpatients receive in this unit.
89542066|NCT02504021|No Intervention|Treatment as Usual Control Condition|Standard of care for the nephrology unit.
89542067|NCT02451215|Experimental|Laser interstitial thermotherapy (LITT) treated patients|All patients enrolled on the trial will undergo LITT therapy per protocol. Side-effects and outcomes will be monitored and compared with disease matched historical controls.
89542068|NCT03215303|Experimental|Continuous Positive Airway Pressure (CPAP)|Participants in the intervention group will use CPAP device, for a period of 40 minutes, with the following parameters: PEEP of 10cmH2O and FiO2 0.21.
88960707|NCT04400838|Experimental|Group 6 b1|Volunteers will receive two doses of ChAdOx1 nCoV19 vaccine, 5x1010vp (Abs260) prime and 0.5mL (3.5 - 6.5 × 1010 vp, Abs 260)* boost* at least 4 weeks apart
88960708|NCT04400838|Experimental|Group 7 a1|Volunteers will receive a single dose ChAdOx1nCOV19 vaccine, 5x10^10vp (qPCR)
88960709|NCT04400838|Experimental|Group 7 b1|Volunteers will receive two doses of ChAdOx1nCOV19 vaccine, 5x10^10vp (qPCR)* 4-6 weeks apart
88960710|NCT04400838|Experimental|Group 8 a1|Volunteers will receive a single dose ChAdOx1nCOV19 vaccine, 5x10^10vp (qPCR)
88960711|NCT04400838|Experimental|Group 8 b1|Volunteers will receive two doses of ChAdOx1 nCoV19 vaccine, 0.5mL (3.5 - 6.5 × 10^10 vp, Abs 260)* 4-6 weeks apart
88960712|NCT04400838|Experimental|Group 9 a1|Volunteers will receive two doses of ChAdOx1 nCoV19 vaccine, 0.5mL (3.5 - 6.5 × 10^10 vp, Abs 260)* 4-6 weeks apart
88960713|NCT04400838|Experimental|Group 10 a1|Volunteers will receive two doses of ChAdOx1 nCoV19 vaccine, 0.5mL (3.5 - 6.5 × 10^10 vp, Abs 260)* 4-6 weeks apart
88960714|NCT04400838|Experimental|Group 11|Volunteers will receive two doses of ChAdOx1 nCoV19 vaccine, 0.5mL (3.5 - 6.5 × 10^10 vp, Abs 260)* 4-6 weeks apart
88960715|NCT04400838|Experimental|Group 12|Volunteers will receive two doses of ChAdOx1 nCoV19 vaccine, 0.5mL (3.5 - 6.5 × 10^10 vp, Abs 260)* 4-6 weeks apart
88960716|NCT04400838|Active Comparator|Single dose MenACWY|Groups 1 a2, 2 a2, 4 a2, 5 a2, 5 b2, 5 c2, 6 a2, 7 a2 & 8 a2 will receive a standard single dose of MenACWY vaccine
88960717|NCT04400838|Active Comparator|Two dose MenACWY 4 - 6 weeks|Groups 1 b2, 2 b2, 4 b2, 5 d2, 7 b2, 8 b2, 9 a2 & 10 a2 will receive two doses of MenACWY 4-6 weeks apart
89542069|NCT03215303|Placebo Comparator|CONTROL|Participants in the control group will use CPAP device, for a period of 40 minutes, with the following parameters: PEEP of 1cmH2O and FiO2 0.21.
89542070|NCT02503943|Experimental|"Liraglutide and Mitiglinide"|"Liraglutide(1.2mg/d) and Mitiglinide(50mg, 3/d)"
89542071|NCT02503943|Active Comparator|"Metformin and Mitiglinide"|"Metformin(500mg, 3/d) and Mitiglinide(50mg, 3/d)"
89542072|NCT02503943|Active Comparator|"Mitiglinide"|"Mitiglinide(50mg, 3/d)"
89542073|NCT02450825|Other|Mechanically ventilated patients|Mechanically ventilated patients who underwent a computed tomographic scan for dyspnea or hypoxemia will undergo a standardized lung ultrasound examination on Day 1 and Day 2 to 4. The GE Vivid ultrasound system will be used to perform the lung ultrasound examination.
89542074|NCT02450825|Other|Spontaneously breathing patients|Spontaneously breathing patients who underwent a computed tomographic scan for dyspnea or hypoxemia will undergo a standardized lung ultrasound examination on Day 1 only. The GE Vivid ultrasound system will be used to perform the lung ultrasound examination.
88960718|NCT04400838|Active Comparator|Two dose MenACWY minimum 4 weeks|Groups 1 a4, 2 a4, 4 c2, 5 a4, 6b2 will receive two doses of MenACWY at least 4 weeks apart
88960719|NCT04399941|Experimental|IVUS and venography group|Participants in the this group will receive venography/fistulogram, intravascular ultrasound (IVUS), and image processing.
88960720|NCT04396990||Group A Dextenza|Will receive Dextenza post-operative
88960721|NCT04396990||Group B Topical Prednisolone|Will receive standard of care prednisolone acetate 1% QID for 1 week, BID for 1 week
88960722|NCT04396366|Placebo Comparator|placebo|Placebo controlled arm
89542075|NCT02503631||Colorectal cancer patients|Subjects will be men and women, 40-90 years of age, inclusive, each with a colonoscopic biopsy-based diagnosis of colorectal cancer (CRC) and/or a pre-malignant colorectal lesion with large enough residual lesion to require subsequent surgical excision or complex colonoscopic polypectomy.
89542076|NCT02178592|Experimental|Dolutegravir|Twice-daily DTG 50 mg plus dual NRTI during RIF-containing TB treatment (isoniazid, RIF, pyrazinamide and ethambutol standard doses by the NTP under program conditions or acceptable alternative RIF-containing regimens) and for 2 weeks following discontinuation of TB treatment, then once-daily DTG 50 mg with the same NRTI through Week 52
89542077|NCT02178592|Active Comparator|Efavirenz|Once-daily EFV 600 mg plus dual NRTI through Week 52 along with TB treatment including isoniazid, RIF, pyrazinamide and ethambutol standard doses by the NTP under program conditions.
89542078|NCT04497233||Prospectively validation group|Two diagnosis methods will be used in the prospective validation section, one is traditional qualitative and quantitative method, the other is artificial intelligence prediction model based on videos to compare the diagnostic efficacy.
89542079|NCT03214445|Experimental|resin composite with nanofiller.|30 restorations of resin composite occlusal, molars or premolars, with values of 3 or 4 for the parameter marginal adaptation according to the FDI criteria randomized assigned in this group
89542080|NCT03214445|Active Comparator|sealant based on resin|30 restorations of resin composite occlusal, molars or premolars, with values of 3 or 4 for the parameter marginal adaptation according to the FDI criteria randomized assigned in this group
89542081|NCT03214445|No Intervention|Control|The restorations were evaluated without treatment about defective restoration that was considered clinically acceptable.
89542082|NCT02503397||Latent iron deficiency|Infants with cord serum ferritin levels ≤ 75 ng/mL
89542083|NCT02503397||Normal iron status|Infants with cord serum ferritin levels > 75 ng/mL.
89542084|NCT03213743|Other|before dexmedetomidine|We took blood samples before the administration of dexmedetomidine to determine exression level of microRNA in the subjects.
89542085|NCT03212495|Active Comparator|dexmedetomidine (D group)|intraarticular administration of dexmedetomidine at the end of surgery
89542086|NCT03212495|Active Comparator|neostigmine (N group)|intraarticular administration of neostigmine at the end of surgery.
89542087|NCT02503553|Experimental|Decision aid|"Option grid for cerebral aneurysm treatment~Patients will receive an option grid during the preoperative visit. They will be given the chance to ask questions. The interaction with the aneurysm surgeon will be voice recorded."
89542088|NCT02503553|Placebo Comparator|Control|Patients will receive the standard information booklet for cerebral aneurysms during the preoperative visit. They will be given the chance to ask questions. The interaction with the aneurysm surgeon will be voice recorded.
89542089|NCT03212183|Experimental|EPI-TAVIE|Patients assigned to this arm will be invited to complete a web-based nursing intervention called EPI-TAVIE.
89542090|NCT03212183|Other|Websites|Patients assigned to this arm will be invited to consult a validated list of predetermined conventional websites.
89542091|NCT04496843||Patients referred for an overnight in-lab PSG|Simultaneous assessment of SAS with Withings HWA09 Device and overnight PSG
89542092|NCT04496765||< 40 years|Patients with rectal cancer ageing 40 years or less
89542093|NCT04496765||> 40 years|Patients with rectal cancer ageing more than 40 years
89542094|NCT03211325|Experimental|Healthy|"Two sequences of ten healthy volunteers each will be performed :~During the first sequence, a biopsy of the gluteal area and another of the surrounding nail area of a finger will be sampled.Then, the cutaneous blood flux of the hand will be recorded at rest and during cooling and warming periods.~During the second sequence, two other biopsies of the surrounding nail area of two other fingers will be sampled."
89542095|NCT03211325|Experimental|Primary Raynaud's phenomenon|"Two sequences of ten primary Raynaud's syndrome each will be performed :~During the first sequence, a biopsy of the gluteal area and another of the surrounding nail area of a finger will be sampled.Then, the cutaneous blood flux of the hand will be recorded at rest and during cooling and warming periods.~During the second sequence, two other biopsies of the surrounding nail area of two other fingers will be sampled."
89542096|NCT03211325|Experimental|Secondary Raynaud's phenomenon|"Two sequences of ten patients each will be performed :~During the first sequence, a biopsy of the gluteal area and another of the surrounding nail area of a finger will be sampled.Then, the cutaneous blood flux of the hand will be recorded at rest and during cooling and warming periods.~During the second sequence, two other biopsies of the surrounding nail area of two other fingers will be sampled."
89542097|NCT02610777|Active Comparator|Azacitidine 75 mg/m^2|Azacitidine 75 mg/m^2, infusion, intravenously or subcutaneously, on Day 1 through Day 5, Days 8 and 9 in 28-day treatment cycles until unacceptable toxicity, relapse, transformation to AML (for participants with HR MDS or CMML), or progressive disease (for participants with low-blast AML).
89542098|NCT02610777|Experimental|Azacitidine 75 mg/m^2 + Pevonedistat 20 mg/m^2|Azacitidine 75 mg/m^2, infusion, intravenously or subcutaneously, on Day 1 through Day 5, Days 8 and 9 and pevonedistat 20 mg/m^2, infusion, intravenously, on Days 1, 3, and 5 in 28-day treatment cycles until unacceptable toxicity, relapse, transformation to AML (for participants with HR MDS or CMML), or progressive disease (for participants with low-blast AML).
89542099|NCT03210779|Active Comparator|L.reuteri|L. reuteri DSM 17938/ATCC PTA L. reuteri DSM 17938/ATCC PTA lozenges three times daily for 16 days + L. reuteri DSM 17938/ATCC PTA L. reuteri DSM 17938/ATCC PTA probiotic oil, topically, once daily for 8 days.
89024706|NCT02957630|Active Comparator|20 mcg EE/3 mg DRSP|20 mcg ethinylestradiol/3 mg drospirenone combined oral contraceptive
89542100|NCT03210779|Placebo Comparator|Placebo|Placebo lozenges three times daily for 16 days and placebo oil once daily for 8 days
89542101|NCT01628692|Experimental|Cohort 1: (Genotype 1b) Daclatasvir + Simeprevir|Participants with hepatitis C virus genotype 1b received daclatasvir, 30 mg, once daily with or without food + simeprevir, 150 mg, once daily with a meal for 12 weeks
89542102|NCT01628692|Experimental|Cohort 2: (Genotype 1b) Daclatasvir + Simeprevir + Ribavirin|Participants with hepatitis C virus genotype 1b received daclatasvir, 30 mg, once daily with or without food + simeprivir, 150 mg, once daily with a meal + ribavirin, twice daily with food (patients weighing <75 kg received a total ribavirin dose of 1000 mg per day; those weighing >=75 kg received 1200 mg per day) for 12 weeks.
89024707|NCT04702061|Active Comparator|Group E|Patients who receive general anesthesia after erector spina plane block
89024708|NCT04702061|Active Comparator|Group T|Patients who receive general anesthesia after thoracic epidural block
89024709|NCT00434525|Experimental|1 Sleeve gastrectomy with omentectomy|
89542103|NCT01628692|Experimental|Cohort 3: (Genotype 1a) Daclatasvir + Simeprevir + Ribavirin|Participants with hepatitis C virus genotype 1a received daclatasvir, 30 mg, once daily with or without food + simeprevir, 150 mg, once daily with a meal + ribavirin, twice daily with food (patients weighing <75 kg received a total ribavirin dose of 1000 mg per day; those weighing >=75 kg received 1200 mg per day) for 12 weeks.
89542104|NCT01628692|Experimental|Cohort 4: (Genotype 1a) Daclatasvir + Simeprevir + Ribavirin|Participants with hepatitis C virus genotype 1a received daclatasvir, 30 mg, once daily with or without food + simeprivir, 150 mg, once daily with a meal + ribavirin, twice daily with food (patients weighing <75 kg received a total ribavirin dose of 1000 mg per day; those weighing >=75 kg received 1200 mg per day.
89542105|NCT03209999||Fomally Employed|Mother engaged in formal employment. No intervention was assigned as this is a cross sectional study.
89542106|NCT03209999||Informally Employed|Mother engaged in informal employment. No intervention was assigned as this is a cross sectional study.
89542107|NCT03209999||Non-employed|Mother neither formally or informally employed. No intervention was assigned as this is a cross sectional study.
89542108|NCT02503007|Placebo Comparator|Placebo|A placebo similar in composition and appearance to the experimental treatment.
89542109|NCT02503007|Experimental|HMB-FA|Active treatment consisting of 3 g of HMB-FA per day.
89542110|NCT02503163|Experimental|KCT-0809|
89542111|NCT04496921|Active Comparator|Vitamin K supplement, dose #1|Vitamin K supplementation with dose #1
89542112|NCT04496921|Active Comparator|Vitamin K supplement, dose #2|Vitamin K supplementation with dose #2
89542113|NCT04860609|Active Comparator|Conventional Physiotherapy|It includes the pre-physiotherapy session by conventional physiotherapy
89542114|NCT04860609|Experimental|Lumber spinal decompression|It includes the pre-physiotherapy session iby lumber spinal decompression along with conventional therapy.
89542115|NCT03343613|Experimental|LY3381916 Escalation|LY3381916 administered orally.
89542116|NCT03343613|Experimental|LY3381916 + LY3300054 Escalation|LY3381916 administered orally and LY3300054 administered intravenously (IV).
89542117|NCT03343613|Experimental|LY3381916 Expansion|LY3381916 administered orally.
89542118|NCT03343613|Experimental|LY3381916 + LY3300054 Expansion B1|"Metastatic triple negative breast cancer (TNBC)~LY3381916 administered orally and LY3300054 administered IV."
89542119|NCT03343613|Experimental|LY3381916 + LY3300054 Expansion B2|"Metastatic non-small cell lung cancer (NSCLC)~LY3381916 administered orally and LY3300054 administered IV."
89542120|NCT03343613|Experimental|LY3381916 + LY3300054 Expansion B3|"Metastatic clear cell carcinoma renal cell carcinoma (RCC)~LY3381916 administered orally and LY3300054 administered IV."
89024710|NCT00434525|Active Comparator|2 Sleeve gastrectomy|
89024711|NCT00465153|Experimental|1|Flax oil
89542121|NCT03043287||BOTOX®|Participants who received 100 to 200 units (U) onabotulinumtoxinA (BOTOX®) as treatment for OAB. No study drug is administered in this study.
89542122|NCT02503241|Experimental|PEEP_Titration_INCREMENTAL|"The investigators will compare 3 levels of PEEP (BASELINE versus PEEP INCREMENTAL versus PEEP DECREMENTAL). Baseline PEEP is based in the standard of care PEEP used in the participant units. PEEP incremental value is based in transpulmonary pressure.~Intervention : PEEP INCREMENTAL"
89542123|NCT02503241|Experimental|PEEP_Titration_DECREMENTAL|"The investigators will compare 3 levels of PEEP (BASELINE versus PEEP INCREMENTAL versus PEEP DECREMENTAL). Baseline PEEP is based in the standard of care PEEP used in the participant units. PEEP decremental value is based in lung recruitment maneuver followed by a best compliance curve during PEEP decrements.~Intervention :PEEP DECREMENTAL"
89542124|NCT03043443|Placebo Comparator|Placebo|participants will receive placebo 1 capsule/day 1 hour before sleeping for 4 weeks
89542125|NCT03043443|Active Comparator|Melatonin|participants will receive melatonin 1 capsule (5mg)/day 1 hour before sleeping for 4 weeks
89542126|NCT02502929|Active Comparator|Social Services|Participants in this arm will receive referrals for social services as indicated.
89542127|NCT02502929|Experimental|Lifestyle|"Participants in this arm will receive lifestyle modification from community health workers using the manualized lifestyle intervention called Eat, Walk, Sleep. They will receive individual home visits, health activity group sessions, and supportive phone calls."
89542128|NCT02502929|Experimental|Lifestyle plus Medication Therapy Management|Participants in this arm will receive everything in the Lifestyle arm, plus Medication Therapy Management (MTM). Participants will receive MTM from a pharmacist via telemedicine with the assistance of a community health worker.
89542129|NCT04383795||Graves' disease patients|First diagnosed Graves' disease patients volunteered for stool collection
89542130|NCT04429737|Experimental|Experimental|The prediabetes patients in this arm will receive Clam protein capsules or Clam peptide plus Chlorella capsules with a dose for 2g/d (500mg/capsule, 2 capsules/time, 2 times/day at day and night ) for 6 months.
89542131|NCT04429737|Placebo Comparator|placebo|The prediabetes patients in this arm will receive placebo with similar appearance of Clam protein capsules or Clam peptide plus Chlorella capsules.
89542132|NCT03209843|Other|Successfully CTO recanalization|
89024712|NCT00465153|Placebo Comparator|2|corn oil
89024713|NCT02957552|Experimental|Treatment with Mesenchymal Stem Cells|"Two doses of 1 x 10^6 MSCs/kg body weight:~first administration intraoperatively via intraportal infusion~second infusion via intravenous infusion on postoperative day 2 (+/- 1 day)~Standard immunosuppressive treatment consisting of steroids, basiliximab and tacrolimus according to the center's pediatric liver transplantation protocol"
89024714|NCT03272646||Group 1 or NPS = 0|Patients undergoing surgery without alterations of the albumin and cholesterol levels, with normal NLR and LMR ratios.
89024715|NCT03272646||Group 2 or NPS >0 and < 3|Patients undergoing surgery with NPS between 1 or 2
89024716|NCT03272646||Group 3 or NPS > 2|Patients undergoing surgery with three or four alterations
89024717|NCT00473109|Experimental|Dialysis without systemic heparinization|Dialysis without systemic heparinization
89024718|NCT00473148|Experimental|1|BNP-guided treatment (Furosemide)
89024719|NCT00473148|No Intervention|2|
89542133|NCT03043131|Active Comparator|Ringer Lactate|patients randomized to this arm are given ringer's lactate solution for cardiopulmonary bypass prime, which is the standard practice
89542134|NCT03043131|Experimental|Plasmalyte A|patients randomized to this arm are given Plasma Lyte - A solution for cardiopulmonary bypass prime
89542135|NCT02502851|Active Comparator|Rotational Atherectomy|Calcified lesion preparation using rotational atherectomy followed by implantation of the ORSIRO sirolimus-eluting stent
89542136|NCT02502851|Active Comparator|Cutting/Scoring Balloon|Calcified lesion preparation using cutting/scoring balloon followed by implantation of the ORSIRO sirolimus-eluting stent
89542137|NCT03209765|Active Comparator|WhatsApp reminder|An interactive WhatsApp reminder to return to the centre for taking faecal tubes for screening
89542138|NCT03209765|No Intervention|No reminder|
89542139|NCT04866537||Pregnant women who received a fetal heart ultrasound between 2015 and 2019.|Pregnant women who received a fetal heart ultrasound between 2015 and 2019.
89542140|NCT03209453|Experimental|study group|children with developmental delays, under regular rehabilitation programs, participate the family work shop family work shop: 6 families in one course, 2 hours per session, one session per week, a total of 6 weeks
89542141|NCT03209453|No Intervention|control group|children with developmental delays, under regular rehabilitation programs, not participate the family work shop
89542142|NCT03047421||All patients included|For all patients scheduled for an anesthetic preoperative consultation, a comparison of accuracy of DES-OSA and P-SAP scores with PSG (polysomnography) will be performed.
89542143|NCT04866615||50 patients newly diagnosed SLE with no treatment|OCT & OCTA for newly diagnosed SLE patients
89542144|NCT04866615||50 patients SLE on treatment by (HCQ) at doses of less than 6.5 mg/kg per day for less than 5 years|OCT & OCTA for on treatment SLE patients
89542145|NCT04866615||50 normal subjects as control group of similar age and gender|OCT & OCTA for normal subjects
89542146|NCT02502773|Experimental|crystalloid group|The proposed Flash multicenter study will be conducted to assess if the use of HES or crystalloid solutions during an individualized GDT contribute to outcome differences in patients at moderate-to-high risk of postoperative complications after abdominal surgery
89542147|NCT02502773|Experimental|colloid group|The proposed Flash multicenter study will be conducted to assess if the use of HES or crystalloid solutions during an individualized GDT contribute to outcome differences in patients at moderate-to-high risk of postoperative complications after abdominal surgery
89542148|NCT04866225|Experimental|Study arm|One arm of healthy male participants administered a single oral dose of [14C]PF-06865571; followed by a single dose of unlabeled PF-06865571, and IV administration of [14C]PF-06865571 three hours later.
89542149|NCT03047187||ACLR patients|anterior cruciate ligament reconstruction patients
89024720|NCT00435032|Active Comparator|1|Early appendectomy
89024721|NCT00435032|Active Comparator|2|Interval appendectomy
89024722|NCT00435071|Active Comparator|1|
89024723|NCT00435071|Active Comparator|2|
89024724|NCT00435149|Active Comparator|1|
89542150|NCT03209297|Experimental|Direct treatment|Patients receive the TMD treatment immediately
89542151|NCT03209297|Experimental|Delayed treatment|No intervention in the first 9 weeks of the study. Afterwards, the patients receive the same treatment as the other group
89542152|NCT03042897|Experimental|Supportive Care (exercise and diet)|Patients undergo aerobic exercise thrice weekly over 95 minutes for up to 16 weeks. Patients also undergo multi-lifestyle interventions based on the DASH diet once weekly over 1 hour for up to 16 weeks.
89542153|NCT02502695||Cohort 1-VATS-associated best practices|"Data to be collected will include demographic data and information about the pre-operative workup, surgical procedure, postoperative course and early discharge course for these patients.~After the last patient completes the 30-day post surgery follow-up, the investigators will determine a set of best practices to implement at each of the sites for the quality improvement initiative. During the assessment period, no patients will be enrolled into the study."
89542154|NCT02502695||Cohort 2-VATS-associated best practices|-Once the set of VATS-associated best practices, an additional cohort of approximately 200 patients will be enrolled and followed in a manner identical to the first cohort.
89542155|NCT02502539|Experimental|autoimmune disease|to identify the mechanisms through which physical activity is liable to mediate inflammatory balance in autoimmune disease settings, and specifically in JIA patients.
89542156|NCT02612727|Experimental|Filtered-sunlight phototherapy|Infants will receive >= four hours per day of filtered-sunlight phototherapy for 1 to 10 days. The filtering will be done using Air Blue 80 window tinting film.
89542157|NCT02612727|Active Comparator|Intensive phototherapy|Infants will receive >= four hours per day of intensive phototherapy for 1 to 10 days.
89542158|NCT03209219|Experimental|Interferon Alpha 2A|Patients are treated with IFNα2a 3×10^IU α2a by subcutaneous injection or intramuscular injection daily for 4 weeks, and followed by every other day there after.
89542159|NCT03209219|Active Comparator|Cyclosporine|Patients are treated with oral CsA 100mg twice daily.
89542160|NCT04866381|Experimental|SHR-6390|SHR-6390
89542161|NCT04866381|Experimental|SHR-6390 combined with Camrelizumab (SHR-1210)|SHR-6390 combined with Camrelizumab (SHR-1210)
89542162|NCT04866381|Experimental|Camrelizumab (SHR-1210) combined with SHR-1020|Camrelizumab (SHR-1210) combined with SHR-1020
89024725|NCT00435149|Active Comparator|2|
89024726|NCT03272568|Experimental|Hemophilia A symptomatic female carriers|"Hemophilia A symptomatic female carriers with a baseline FVIII activity of ≤60% receive recombinant FVIII Fc fusion product Eloctate.~Some of participants will be taught to perform a hemoglobin check using a patient-operated diagnostic device for anemia AnemoCheck every other day during 2 consecutive menstrual cycles."
89024727|NCT03272568|Experimental|Hemophilia B symptomatic female carriers|"Hemophilia B symptomatic female carriers with a baseline FIX activity of ≤60% receive recombinant FIX Fc fusion product Alprolix.~Some of participants will be taught to perform a hemoglobin check using a patient-operated diagnostic device for anemia AnemoCheck every other day during 2 consecutive menstrual cycles."
89024728|NCT00435227|Experimental|Motavizumab|Participants will receive a single IM dose of 30 mg/kg of motavizumab on Day 0 of the study.
89024729|NCT00435227|Placebo Comparator|Placebo|Participants will receive a single IM dose of placebo matched to motavizumab on Day 0 of the study.
89542163|NCT03209141||Diastolic dysfunctional hypertension|Patients with confirmed arterial hypertension and diastolic dysfunction by echocardiographic diastolic function evaluation
89542164|NCT03209141||Non diastolic dysfunctional hypertension|Patients with confirmed arterial hypertension and without diastolic dysfunction by echocardiographic diastolic function evaluation
89542165|NCT04872231|Experimental|Voriconazole Inhalation Powder|Investigational drug will be supplied as capsules, each capsule contains 10 mg of Voriconazole Inhalation Powder. The capsules will be administered with the provided breath actuated Plastiape RS00 Model 8 Dry Powder Inhaler device.
89542166|NCT04872231|Placebo Comparator|Placebo|Placebo will be supplied as capsules, each capsule will contain no active ingredient. The capsules will be administered with the provided breath actuated Plastiape RS00 Model 8 Dry Powder Inhaler device.
89542167|NCT03044925|Experimental|Remote magnetic navigation|Persistent atrial fibrillation ablation with remote magnetic navigation
89542168|NCT03044925|Active Comparator|Cryoablation|Persistent atrial fibrillation ablation with cryoballoon
89542169|NCT04861389|Experimental|Distal transradial access (dTRA)|Distal transradial access for primary percutaneous coronary intervention in STEMI patients
89542170|NCT04861389|Active Comparator|Transradial access (TRA)|Transradial access for primary percutaneous coronary intervention in STEMI patients
89542171|NCT04860531|Active Comparator|Group (I) Platelet Rich Plasma|The participants are randomly assigned for intra-articular injection with autologous platelet rich plasma . The treated segments are determined by clinical signs and MRI detected facet joint synovitis .
89542172|NCT04860531|Active Comparator|Group (II) Corticosteroids|The participants are randomly assigned for intra-articular injection with corticosteroids(a mixture of 0.5% lidocaine and 5mg/ml of betamethasone) . The treated segments will be determined by clinical signs and MRI detected facet joint synovitis .
89542173|NCT01594827|Experimental|Inhaled Vanc and Oral Abx|In the experimental arm CF participants are randomized to 28 days of inhaled sterile vancomycin (250 mg twice a day) as well as 28 days of oral/skin antibiotics targeted to aggressively treat MRSA infection: oral rifampin, a second oral antibiotic (TMP/SMX or doxycycline, protocol determined), mupirocin intranasal cream and chlorhexidine body washes. Patients will be followed for 3 months after completion of the treatment protocol.
89542174|NCT01594827|Active Comparator|Inhaled Placebo and Oral Abx|In the active comparator arm CF participants are randomized to 28 days of inhaled sterile placebo (saline) and are treated with 28 days of oral/skin antibiotics targeted to aggressively treat MRSA infection: oral rifampin, a second oral antibiotic (TMP/SMX or doxycycline, protocol determined), mupirocin intranasal cream and chlorhexidine body washes. Patients will be followed for 3 months after completion of the treatment protocol.
89542175|NCT04858893||Subjects affected from Parkinsonims|Scores of MMSE, FAB MoCA were summarized to calculate the CoMDA scores, than they were used to develop the Neural Net 91 classificator
89542176|NCT04858893||Health Controls|CoMDA was administered and total score was calculate to develop the Neural Net 91 classificator
89542177|NCT03045003|Other|Arm A: Low Intensity|RESIL Intervention provided by nurses and oncologists of the outpatient oncology unit.
89542178|NCT03045003|Other|Arm B: High Intensity|RESIL Intervention provided by nurses and oncologists of the outpatient oncology unit plus 5 nurse-led consultations (3 face-to-face and 2 telephone consultations)
89542179|NCT03042585|Experimental|Dose Level 1|The participants will receive Palifermin on Day -10, -9 and -8. Total Body Irradiation 1.64 Gy per Fraction for a total of 8 Fractions. The total amount would be 13.12 Gy. The participants will receive total body irradiation twice a day for four days (Day -7, -6, -5, and Day -4). Over the following two days, the participants will receive cyclophosphamide (Day -3 and -2). The participants will receive stem cell infusion on Day 0 and G-CSF given daily until engraftment occurs. Participants will receive Palifermin on Day 0, +1 and +2.
89542180|NCT03042585|Experimental|Dose Level 2|The participants will receive Palifermin on Day -10, -9 and -8. Total Body Irradiation 1.76 Gy per Fraction for a total of 8 Fractions. The total amount would be 14.08 Gy. The participants will receive total body irradiation twice a day for four days (Day -7, -6, -5, and Day -4). Over the following two days, the participants will receive cyclophosphamide (Day -3 and -2). The participants will receive stem cell infusion on Day 0 and G-CSF given daily until engraftment occurs. Participants will receive Palifermin on Day 0, +1 and +2.
89542181|NCT03042585|Experimental|Dose Level 3|The participants will receive Palifermin on Day -10, -9 and -8. Total Body Irradiation 1.88 Gy per Fraction for a total of 8 Fractions. The total amount would be 15.04 Gy. The participants will receive total body irradiation twice a day for four days (Day -7, -6, -5, and Day -4). Over the following two days, the participants will receive cyclophosphamide (Day -3 and -2). The participants will receive stem cell infusion on Day 0 and G-CSF given daily until engraftment occurs. Participants will receive Palifermin on Day 0, +1 and +2.
89542182|NCT03042585|Experimental|Dose Level 4|The participants will receive Palifermin on Day -10, -9 and -8. Total Body Irradiation 2.00 Gy per Fraction for a total of 8 Fractions. The total amount would be 16 Gy. The participants will receive total body irradiation twice a day for four days (Day -7, -6, -5, and Day -4). Over the following two days, the participants will receive cyclophosphamide (Day -3 and -2). The participants will receive stem cell infusion on Day 0 and G-CSF given daily until engraftment occurs. Participants will receive Palifermin on Day 0, +1 and +2.
88811686|NCT02960204|Placebo Comparator|Matching Placebo|Subjects with Non-alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension will be administered orally with a matching placebo twice a day.
88811687|NCT02152826|Experimental|potassium oxalate gel|Professional application
88811688|NCT02152826|Active Comparator|Potassium oxalate liquid|Professional application
88811689|NCT02839148|Experimental|Dietary supplementation|In case of dietary supplementation, we will provide milk and egg 6 days a week for 3 months to stunted children.
88960723|NCT04396366|Active Comparator|QBW251|Active comparator drug arm
89542183|NCT04429191|Experimental|Blood Stem Cell Transplant w/ anti-CD117 conditioning|"The phase 1a portion of the study plans to assess approximately 3 planned dose cohorts of JSP191: 0.3 mg/kg, 0.6 mg/kg, and 1.0 mg/kg to determine the maximum tolerated dose for expansion. Subjects will receive a single dose of intravenous JSP191 antibody followed by monitoring for antibody clearance. Once the antibody has cleared below a certain level, patients will receive stem cell transplant and be monitored for hematopoietic recovery.~The phase 1b portion of the study will enroll additional subjects at the expansion dose in order to further explore the safety, feasibility, and PK of that dose."
89542184|NCT02610231|Experimental|Istradefylline 20 mg or 40 mg|Treatment for 52 weeks
89542185|NCT03042741|Experimental|V6 recipients|Arm will comprise 150 individuals with overweight problem or obesity randomly assigned to receive V6 - oral atherosclerosis vaccine administered once per day for one month
89542186|NCT03042741|Placebo Comparator|Placebo recipients|Arm will comprise 150 individuals with overweight problem or obesity randomly assigned to receive placebo pills given once per day as a single pill for one month
89542187|NCT04850157|Experimental|Tislelizumab+IMRT|
89542188|NCT04849533|Experimental|Group D Bela/EVR|rATG induction/belatacept/everolimus/early steroid withdrawal rATG 1.5mg/kg IV X 4 doses over 10 days belatacept 10mg/kg IV X 1 on POD 1, POD 5, weeks 2, 4, 8, and 12 then 5mg/kg IV X 1 on week 16 and then every 4 weeks thereafter Steroid taper x 5 days (500mg IV, 250mg IV, 125mg IV, 80mg po, 60mg po) Everolimus started within 24hours at 2mg BID and dosed to level 3-8ng/ml
89542189|NCT04849533|Active Comparator|Group E Bela/MMF|rATG induction/belatacept/mycophenolate/chronic steroidsrATG 1.5mg/kg IV X 4 doses over 10 days belatacept 10mg/kg IV X 1 on POD 1, POD 5, weeks 2, 4, 8, and 12 then 5mg/kg IV X 1 on week 16 and then every 4 weeks thereafter Steroid taper x 5 days (500mg IV, 250mg IV, 125mg IV, 80mg po, 60mg po) and then 5mg po daily thereafter MMF 1gm BID started pre-op and then continued throughout study
89542190|NCT03042663|Experimental|Intervention group|In patients meeting the inclusion criteria and with absence of any exclusion criteria, and after taking PI and Doppler Blood flow values hourly for 3 hours (control values), the procedure for administering the USG Stellate ganglion block on the side of the arterial cannula will be started
89542191|NCT03040635|Experimental|Risdiplam '2' Milligrams (mg)|A single dose of 2 mg Risdiplam will be administered to all participants randomized to this arm under fasted conditions as an oral drinking solution on Day 1.
89542192|NCT03040635|Experimental|Risdiplam '6' mg|A single dose of 6 mg Risdiplam will be administered to all participants randomized to this arm under fasted conditions as an oral drinking solution on Day 1.
89542193|NCT03040635|Experimental|Risdiplam '12' mg|A single dose of 12 mg Risdiplam will be administered to all participants randomized to this arm under fasted conditions as an oral drinking solution on Day 1.
89542194|NCT03040635|Placebo Comparator|Placebo|A single dose of placebo will be administered to all participants randomized to this arm under fasted conditions as an oral drinking solution on Day 1.
89542195|NCT02178358|Experimental|150 milligram (mg) Galunisertib Monotherapy|150 mg galunisertib administered orally, twice daily (BID) for 14 days followed by 14 days with no study drug (28 days cycle).
89542196|NCT02178358|Experimental|150 mg Galunisertib + 400 mg Sorafenib Therapy|"150 mg galunisertib administered orally, BID for 14 days followed by 14 days with no study drug (28 days cycle).~400 mg sorafenib administered orally BID for 28 days."
89542197|NCT02178358|Placebo Comparator|400 mg Sorafenib + Placebo Therapy|"Placebo administered orally BID for 14 days followed by 14 days with no study drug (28 days cycle).~400 mg sorafenib administered orally BID for 28 days."
89542198|NCT03042507|Other|Open Trial|This is a non-randomized open trial of a behavioral intervention for young children with tics
89542199|NCT01598896|Experimental|Dronabinol + Clonidine|Dronabinol titrated to 5 mg three times daily, Clonidine 0.1 mg twice daily
89542200|NCT01598896|Placebo Comparator|Placebo|Placebo
89542201|NCT03042195|Active Comparator|Intervention group|Supplementary parenteral nutrition
89542202|NCT03042195|No Intervention|Control group|The control group will receive standard nutritional care
89542203|NCT03042351|Other|Unique arm|Magic Kegel app
88960724|NCT04389437|Experimental|NCD patients (case)|Patient diagnosed with Alzheimer's disease or parkinsonian dementia / Lewy body dementia or other mild or severe NCD defined by international criteria.
88960725|NCT04389437|Other|Control patients with memory complaint|Normal neuropsychological evaluation during assessment
88960726|NCT04389437|Other|Control patients without memory complaint|MMS score and / or the Montreal Cognitive Assessment grid (MoCA) ≥26 / 30, No memory complaint
88960727|NCT04381299||Intervention|The cortex of selected ovary will be injected with 1 mL of autologous platelet rich plasma. Up to ten different sites will be injected under ultrasound guidance. In the surgical report, the surgeon will state how many punctures have been done.
88960728|NCT04381299||Control|The cortex of contralateral ovary will be injected with 1 mL of saline solution (SS). Up to ten different sites will be injected under ultrasound guidance. In the surgical report, the surgeon will state how many punctures have been done.
88960729|NCT04379401|Other|Biventricular Pacing deactivated|The primary objective of the study is to determine, whether short term activation/deactivation of biventricular pacing (BivP) of the CRT (during routine CRT interrogation) has an effect on vascular function
89024730|NCT02956512|Experimental|Dexibuprofen 300mg - Fed|Fed condition
89542204|NCT01598662|Active Comparator|1: IUD insertion 6 Weeks after delivery|"Device:Levonorgestrel-releasing intrauterine device marketed as Mirena.~Subjects randomized to interval placement will have their IUD placed in the office at six weeks postpartum or later. They must return for one visit within a month for a string check."
89542205|NCT01598662|Experimental|2: Immediate Post-placental insertion|"Device: Levonorgestrel-releasing intrauterine device marketed as Mirena~Subjects randomized to immediate post-placental placement within 10 minutes of delivery will have an IUD placed manually under sterile technique and with ultrasound guidance. An ultrasound will be performed within two days postpartum to verify proper placement and again at approximately six weeks postpartum."
89542206|NCT04849065|Experimental|MNC (Mononuclear cells)|"MNC (Mononuclear cells) (patients in which stem cells will be injected into the two muscles on one side and placebo -vehicle- in the two contralateral muscles).~This group would consist of 74 patients."
89024731|NCT02956512|Experimental|Dexibuprofen 300mg - Fasting|Fasting condition
89542207|NCT04849065|Placebo Comparator|Saline|(patients in which placebo -vehicle- will be injected into both muscles on both sides). This group would consist of 26 patients.
89542208|NCT01629706|Experimental|PV+ClearCare / PV+Renu (Phase 1)|Balafilcon A contact lens pre-soaked overnight in ClearCare cleaning and disinfecting system worn in 1 eye for two hours and four hours at a time, separate days, with Balafilcon A contact lens pre-soaked overnight in renu multi-purpose solution worn in the fellow eye
89542209|NCT01629706|Experimental|Habitual (Phase 2)|Phase 2: Habitual contact lenses worn bilaterally on a daily wear basis for 4 weeks with habitual lens care
89542210|NCT03042429|Experimental|experimental arm|Drug: Cycles N8, N5, and N6 Drug: topotecan, cyclophosphamide, and etoposide (N8 cycle) followed by Drug: cisplatin, etoposide, and vindesine (N5 cycle) and Drug: vincristine, dacarbacine, ifosfamide, and doxorubicine (N6 cycle) followed by myeloablative chemotherapy with autologous stem cell transplantation (melphalan, carboplatin, etoposide) and by 9 x retinoic acid cycles (6 months, 3 months break, 3 months)
89542211|NCT03042429|Active Comparator|standard arm|Drug: Cycles N5 and N6 Drug: cisplatin, etoposide, and vindesine (N5 cycle) and Drug: vincristine, dacarbacine, ifosfamide, and doxorubicine (N6 cycle) followed by myeloablative chemotherapy with autologous stem cell transplantation (melphalan, carboplatin, etoposide) and by 9 x retinoic acid cycles (6 months, 3 months break, 3 months)
89542212|NCT03040557|Active Comparator|Flexible footwear|The intervention with flexible footwear in women with plantar fasciitis (MFG), acute n=12 and chronic=15) will have a duration will be six months, for six hours a day, seven days a week (42 hours / week).
89542213|NCT03040557|Active Comparator|Orthopedic insole|The intervention with orthopedic insole in women with plantar fasciitis (COIG, acute n=14 and chronic=14) will have a duration will be six months, for six hours a day, seven days a week (42 hours / week).
89542214|NCT02153086||Ramelteon 8 mg Tablets|
89542215|NCT04849299|Experimental|AT-527 550 mg + cyclosporine (simultaneous)|n=12
89542216|NCT04849299|Experimental|AT-527 550 mg + cyclosporine (staggered)|n=12
89542217|NCT02117050|Experimental|Rebif® via Rebidose® auto-injector|
89542218|NCT03042273|Experimental|High Strength Cranberry|1 capsule of High Strength Cranberry (25,000mg Vaccinium macrocarpon) orally daily for 6 months
89542219|NCT03042273|Placebo Comparator|Placebo|1 capsule of Matching Placebo orally daily for 6 months
89542220|NCT04858659|Experimental|PK101 group|
89542221|NCT04858659|Active Comparator|PK101-002 group|
89542222|NCT04848987|Active Comparator|Etch-and-rinse (Variolink N) resin cement|For etch-and-rinse resin cement, 40 inlays were cemented by Variolink N resin cement.
89542223|NCT04848987|Placebo Comparator|Self-etch (Panavia F2.0) resin cement|Regarding self-etch resin cement, 40 inlays were cemented by Panavia F2.0 resin cement.
89024732|NCT04702334|Experimental|Hyaluronic acid|After application of local anesthetic, removal of plaque and polishing of the tooth surfaces was performed followed by the local administration of hyaluronic acid gel . This adjunctive treatment was performed at baseline and at the 3 months control.
89542224|NCT04848987|No Intervention|Self-adhesive (RelyX Unicem) resin cement|For self-adhesive resin cement, 40 inlays were cemented by RelyX Unicem resin cement.
89542225|NCT04858581|Other|Healthcare workers who had a diagnosis confirmed by a nasopharyngeal RT-PCR test with SARS-CoV-2|Survey, RT-PCR test and blood test.
89542226|NCT04859751|Experimental|VB4-845 Injection|"Induction - 30 mg of Vicinium in 50 mL of saline administered twice weekly (BIW) for 6 weeks followed by once weekly for 6 weeks, for a total of 12 weeks.~Maintenance - 30 mg of Vicinium in 50 mL of saline administered once weekly every other week for up to 104 weeks."
89542227|NCT04860063|Placebo Comparator|Placebo|Placebo three times daily for 6 months
89542228|NCT04860063|Experimental|Berberine|Berberine 500 mg three times daily for 6 months
89542229|NCT04860219|No Intervention|Control Group|None of the participants in the Control Group received lactoferrin
89542230|NCT04860219|Active Comparator|200 mg lactoferrin orally once daily Group|received 200 mg lactoferrin orally once daily
89542231|NCT04860219|Active Comparator|200 mg lactoferrin orally twice daily Group|received 200 mg lactoferrin orally twice daily
89542232|NCT04848207|Other|Digital impression technique|- 3D printed generic Scan bodies with unified shape and length replacing the traditional transfer copings will be press fitted on the trans-mucosal abutments and pickup cylinders that are screwed on the implants to capture their position and intra-oral scanning will be done.
89542233|NCT04848207|Other|Open tray impression technique|"Transfer copings will be screwed to the multiunit abutments on the existing implants, and splinted together using pre-cured printed resin splinting framework that will be fixed to the copings using flowable composite .~A one step impression technique using putty and light addition silicon will be made, where light impression material will be injected all around transfer copings and putty silicon will be loaded in tray and then will be seated intra-orally making sure to fully expose the screws of transfer copings through the impression material."
89542234|NCT02728895|Experimental|Cohort 1: Vedolizumab 75 mg|Vedolizumab 75 mg, injection, intravenously once on Days -1, 13 and 42.
89542235|NCT02728895|Experimental|Cohort 2: Vedolizumab 300 mg|Vedolizumab 300 mg, injection, intravenously once on Days -1, 13 and 42.
89542236|NCT02728895|Experimental|Cohort 3: Vedolizumab Dose 1|Vedolizumab first decided dose as determined from Cohort 1 or 2, injection, intravenously once on Days -1, 13 and 42.
89542237|NCT04848363|Experimental|Study group|patients receiving general anesthesia with propofol, fentanyl and cisatracurium for induction and sevoflurane, fentanyl and cisatracurium for maintaining anesthesia. Patients receiving postoperative multimodal intravenous analgesia with paracetamol, ketoprofen, tramadol, and trimeperidine. In this group, after induction of anesthesia before the operation, bilateral blockade of the square dorsi muscle is performed under ultrasound guidance using 20 ml of a solution of levobupivacaine 2.5 mg / ml.
89542238|NCT04848363|Placebo Comparator|Control group|patients receiving general anesthesia with propofol, fentanyl and cisatracurium for induction and sevoflurane, fentanyl and cisatracurium for maintaining anesthesia. Patients receiving postoperative multimodal intravenous analgesia with paracetamol, ketoprofen, tramadol, and trimeperidine. In this group, after induction of anesthesia before surgery, bilateral blockade of the square dorsi muscle is performed under ultrasound guidance using 20 ml of saline.
89542239|NCT04847895||Lucentis|Patients administered Lucentis by prescription
89542240|NCT02502227|Active Comparator|Mindfulness Training|Mindfulness training intervention consisting of eight weekly 2.5 hour group sessions, a day-long retreat in the sixth week, and daily home mindfulness meditation
89542241|NCT02502227|Active Comparator|Mindful Attention Only Training|Mindful attention only training intervention consisting of eight weekly 2.5 hour group sessions, a day-long retreat in the sixth week, and daily home mindfulness meditation
89542242|NCT02502227|No Intervention|No Treatment Control Condition|No treatment participants will be informed that their participation is important and that they are requested to not seek out similar treatments during this waiting period.
89542243|NCT04496531|Experimental|Active|Active group members use a device providing perceivable electrical stimulation
89542244|NCT04496531|Sham Comparator|Sham|Group members use a device providing a non-perceivable stimulus
89542245|NCT02502383|Experimental|ACTION PAC|
89542246|NCT02502383|Active Comparator|Comparison|
89542247|NCT03208829|Experimental|Group 1|Rehabilitation Exercises Group 1 will be submitted to an exercise protocol based on muscle strength training, with duration of 6 weeks and frequency of two weekly sessions, lasting 45 minutes.
89542248|NCT03208829|Active Comparator|Group 2|Postoperative guidance Group 2 will receive an orientation booklet and weekly links from researchers to address possible questions.
89542249|NCT04857957|Experimental|Cohort 1|300 mg oral dose TID
89542250|NCT04857957|Experimental|Cohort 2|600 mg oral dose TID
89542251|NCT04857957|Experimental|Cohort 3|800 mg oral dose TID
89542252|NCT04857957|Experimental|PDN cohort|Dose based on safety in healthy Cohorts 1-3
89542253|NCT02502305|Experimental|Intervention group|intervention group receives liveonline course training, 3 questionnaires at an interval of 6 weeks
89542254|NCT02502305|No Intervention|Control group|control group receives 3 questionnaires at an interval of 6 weeks
89542255|NCT04429269||mammography and ultrasound|mammography and ultrasound screening
89542256|NCT02450513||Single-group study|Subjects with active refractory Crohn's disease naïve to TNF antagonists starting adalimumab therapy.
89542257|NCT04859283|Active Comparator|DEX-group|intranasal dexmedetomidine 1 µg/kg
89542258|NCT04859283|Placebo Comparator|PLACEBO-group|intranasal saline 10 µL/kg
89542259|NCT03208751|Other|Exercise training|All patients were included in the exercise training group
89542260|NCT03208517|Experimental|Arm 1: Regular Contact Group (WHELD +)|Regular Contact Group (WHELD elearning package + regular supervision support) A research associate will provide one face-to-face training session with participating care staff in the care home on how to use the online modules, providing a walk-through demonstration to ensure all are comfortable with the programme and its technology. The research associate will provide light touch support by returning fortnightly throughout the intervention period to the care home to observe/troubleshoot around online programme.
89542261|NCT03208517|Experimental|Arm 2: Online Contact Group (WHELD only)|Online Contact Group (WHELD elearning package only) The e-learning modules will be emailed to the care home with clearly written instructions on how to access the course.
89542262|NCT03208517|No Intervention|Arm 3: Enhanced usual practice Control Group|"Arm 3: Enhanced usual practice Control Group (with information/signposting re high quality on line e-learning and educational materials).~This will consist of a 2-page written guidance sheet on the best freely available dementia e-learning programmes and a one-off meeting with a research associate in the care home to explain the information/signposting"
88960730|NCT04379401|Other|Biventricular Pacing activated|The primary objective of the study is to determine, whether short term activation/deactivation of biventricular pacing (BivP) of the CRT (during routine CRT interrogation) has an effect on vascular function
88960731|NCT04374136|Experimental|AL001|AL001 every 4 weeks
88960732|NCT04374136|Placebo Comparator|Placebo|Placebo every 4 weeks
89542263|NCT03343457|Experimental|Acceptance Commitment Therapy|Acceptance Commitment Therapy. Cognitive therapy
89542264|NCT03343457|Experimental|Multidisciplinary assessment|Assessment of a team. Cognitive therapy
89542265|NCT03343457|No Intervention|Control|Control group
89542266|NCT03208439|Experimental|EMG-driven NMES|subjects will receive EMG-driven NMES cycling exercise.
89542267|NCT03208439|Placebo Comparator|passive pre-programmed NMES|subjects will receive passive pre-programmed NMES during cycling exercise.
89542268|NCT04857879|Experimental|Good Life with Osteoarthritis (GLA:D) Program|Participants will attend 2 sessions aimed at providing disease-specific education followed by 12 sessions of neuromuscular exercises, each 1 hour in length, delivered twice a week over 6 weeks.
89542269|NCT04857879|Active Comparator|Control intervention group|Participants allocated to the control intervention will receive disease-specific education and training to learn home exercises in a 1-hour group session. They will receive a booster session 4-weeks after the first session.
89542270|NCT03208361|Experimental|Penicillin V|Penicillin V, 1600000 IU every 8h during 10 days.
89542271|NCT03208361|Active Comparator|Amoxicillin|Amoxicillin, 1 g every 8h during 10 days.
89542272|NCT04847115|Active Comparator|Operative|The patients in this arm will be treated operatively with intramedullar screw osteosynthesis. In addition to this, they will weight bear as tolareted in a walking boot orthosis for six weeks.
89542273|NCT04847115|Active Comparator|Non-operative|The patients in this arm will have non-operative treatment with a walking boot orthosis for six weeks. They will weight bear as tolerated
89542274|NCT02501915|Experimental|Kinesio Taping (GROUP A)|Received the application of KT from muscle Origin to Insertion
89542275|NCT02501915|Experimental|Kinesio Taping (GROUP B)|received the application of KT from muscle Insertion to Origen
89542276|NCT03041961|Placebo Comparator|Placebo|Formulation containing inert artificially colored maltodextrin, once daily, in a 1-hard capsule regimen (500 mg)
89542277|NCT03041961|Active Comparator|Aronia full spectrum|Formulation of an aronia full spectrum ingredient in a 1-hard capsule regimen (500 mg)
89542278|NCT03041961|Active Comparator|Aronia extract|Formulation of an aronia extract ingredient in a 1-hard capsule regimen (500 mg)
89542279|NCT03343379|Other|Healthy cohort|Core stability test
89542280|NCT04857567|Experimental|Three Self-Commitment (TSC) program|
89542281|NCT02501837|Experimental|Oxytocin|24 IU Oxytocin (Syntocinon spray), intranasal application 30 min prior to the experiment
89542282|NCT02501837|Placebo Comparator|Placebo|Intranasal application, containing all ingredients except for the peptide, 3 puffs per nostril
88960733|NCT04374136|Experimental|Open label - AL001|AL001 every 4 weeks
88960734|NCT04364555|Active Comparator|Active/active|The one bottle for use in the morning has clobetasol-oral gel, and so does the bottle fore use in the evening. The oral cavity will be rinsed with 5ml oral gel during 1 minute. Nystatin will be taken 1ml 4 times daily.
88960735|NCT04364555|Active Comparator|Placebo/active|The bottle for use in the morning contains placebo and one for use in the evening contains clobetasol oral gel. The oral cavity will be rinsed with 5ml oral gel during 1 minute. Nystatin will be taken 1ml 4 times daily.
88960736|NCT04364555|Placebo Comparator|Placebo/placebo|Both bottles, the one for the morning and the one for use in the evening, contains placebo. The oral cavity will be rinsed with 5ml oral gel during 1 minute. Nystatin will be taken 1ml 4 times daily.
88960737|NCT04360928|Experimental|Graymont X ERIS Knee Splint Degree Splinting Group|These patients will be randomized to receive the Graymont X ERIS Knee Splint. Patients will follow the same standardized postoperative rehabilitation protocol.
88960738|NCT04360928|Sham Comparator|Standard Hinged Knee Brace|These patients will be randomized to receive a standard hinged knee brace. Patients will follow the same standardized postoperative rehabilitation protocol.
88960739|NCT04360330|Experimental|Preoperative SABER|"Experimental: Preoperative Stereotactic Ablative Breast Radiotherapy (SABER). Phase I study testing up to 4 dose levels.~Non-experimental: Participants will undergo standard partial mastectomy and axillary surgery as per discretion of treating physician 4 to 6 weeks (+ at most 1 week delay) after preoperative SABER is completed."
89542283|NCT04859361|Experimental|Treatment with imiquimod|Colposcopy with PAP smear and punch biopsy is scheduled at 10 weeks to rule out progression, and at 20 weeks to evaluate treatment success. At 20 weeks, biopsies will be performed at the locations where lesions were previously present and additional biopsies will be performed on any visible lesions. At 20 weeks, in case of disease progression or persistence, treatment with LLETZ will be offered.
89542284|NCT04859361|Active Comparator|Treatment with LLETZ|Standard treatment will be scheduled after patients' first period.
89542285|NCT04840485|Experimental|Treatment group A|
89542286|NCT04840485|Experimental|Treatment group B|
89542287|NCT04840485|Placebo Comparator|Treatment group C|
89542288|NCT03207659|Experimental|Dusting|small stones will be left to pass spontaneously.
89542289|NCT03207659|Experimental|Basketing|stones will be actively extracted.
89542290|NCT04846725||Retrievable Inferior Vena Cava Filters (IVCF)|The population study includes patients with a Retrievable Inferior Vena Cava Filters (IVCF) inserted between April 2012 and November 2019. Follow up data is collected up to July 2020.
89542291|NCT03207971|Active Comparator|SCTG from palatal area with predominance of lamina propria|
89542292|NCT03207971|Active Comparator|SCTG from palatal area with predominance of submucosa|
89542293|NCT03039075|Active Comparator|Metformin SR Tablet|Metformin hydrochloride sustained-release tablets made in Conquer pharmaceutical co., LTD
89542294|NCT03039075|Active Comparator|Glucophage|The original drug of metformin
89542295|NCT03207893|Experimental|GEM+CGM|GEM lifestyle modification & continuous glucose monitoring
89542296|NCT03207893|Active Comparator|Routine Care|Subject's current t2d treatment
89542297|NCT03042039||Study group 'New Care'|Frail elderly receiving care within new organisational models delivering integrated healthcare (IHC) supported by ICT infrastructure (electronically shared-care platform) as provided by pilot sites individually.
89542298|NCT04857177|Experimental|CKD-701|Drug: CKD-701 (proposed ranibizumab biosimilar)
89542299|NCT04857177|Active Comparator|Lucentis®|Drug: Lucentis® (ranibizumab)
89542300|NCT02501681|Active Comparator|crystalloid|Group A (n=20); crystalloid as priming solution used in patients,
89542301|NCT02501681|Active Comparator|colloid|Group B (n=20); colloids as priming solution used in patients
89542302|NCT03207737|Experimental|MENTOR + Telehealth|This group will complete baseline testing, the MENTOR (Mindfulness, Exercise, and Nutrition To Optimize Resilience) program, and 5-days post baseline testing before beginning a one-year telehealth program.
89519537|NCT03524209|Other|Brace|Patients with spondylodiscitis are wearing a thoracolumbar brace for 3 months and receive an antibiotic treatment according to the bacterium evidenced in the initial diagnostic intervertebral disc puncture (6 weeks to 3 months according to CRP course)
88960741|NCT04351373|Experimental|Fluorescein sodium (FS) and YELLOW 560 nm microscope filter (YE560) during surgery|Subjects undergoing clinically planned vestibular schwannoma, Meningioma, Head and Neck Paraganglioma, or Head and Neck Schwannoma, removal surgery will have contrast agent fluorescein sodium administered intravenously after tumor exposure, and a special filter called YELLOW560 will be used on the operating microscope to see the fluorescent coloring of the contrast.
88960742|NCT04348266|Experimental|RFA|The assigned location will be treated with RFA at all lesion.
88960743|NCT04348266|No Intervention|Control|No treatment will not be performed at this location. However, if endoscopist detects any suspicious lesion during the scheduled endoscopy, the biopsy will be done and standard treatment will be performed accordingly.
88960744|NCT04341376|Experimental|Enhanced First Connections|Enhanced First Connections is a short-term risk assessment and response home visiting referral program. The goal of Enhanced First Connections is to identify family needs and link families to community resources, including evidence based home visiting models. Enhanced First Connections includes prenatal identification and engagement of women with an adversity or trauma history, and infant and early childhood mental health consultation. Women who enroll in Enhanced First Connections are expected to receive between four and eight home visits before being referred to other community resources.
89519538|NCT05398835|Experimental|Intervention|Online interventions promoting home-based HIV self-testing
89519539|NCT04601909|Active Comparator|FX-322|FX-322, 1 dose (N=24)
89519540|NCT04601909|Placebo Comparator|Placebo|Placebo, 1 dose (n=6)
89519541|NCT04923659|Experimental|LIFUS|Low Intensity Focussed ultrasound.
89519542|NCT05398679|Active Comparator|OPAT|Patients with infective endocarditis diagnostic, who have completed at least 10 days of intravenous therapy, and/ or seven days in the case of cardiac valvular surgery, and shown good clinical evolution and no clinical or echocardiographic signs of potential bad prognosis will be randomized. If assigned to this arm the patient will recieve parenteral antibiotics until the end of treatment.
89519543|NCT05398679|Experimental|Oral Therapy|Patients with infective endocarditis diagnostic, who have completed at least 10 days of intravenous therapy, and/ or seven days in the case of cardiac valvular surgery, and shown good clinical evolution and no clinical or echocardiographic signs of potential bad prognosis will be randomized. If assigned to this arm the patient will recieve oral antibiotics until the end of treatment.
89519544|NCT04817501||Breast cancer|At least eighty five subjects with breast cancer
89519545|NCT04817501||Ovarian cancer|At least 32 subjects with ovarian cancer
89519546|NCT04817501||Endometrial Cancer|At least 33 subjects with endometrial cancer
89519547|NCT04817501||Healthy control|30 healthy volunteers
89519548|NCT04817501||Suspected malignant tumor non-verified|Patients with suspected malignant tumor, which was not verified by biopsy. Nubmber of patients to be defined
89519549|NCT04867421||TANOs|Adult patients with osteosarcoma or chondrosarcoma
89519550|NCT05398133||COPD patients|
89519551|NCT05398133||asthma patients|
89519552|NCT05398133||control subjects|
89519553|NCT05398055|Experimental|A|Azithromycine group
89519554|NCT05398055|Placebo Comparator|B|Placebo group
89519555|NCT05397977|Experimental|mechanical traction group|use of device chattanooga tru trac
89519556|NCT05397977|Active Comparator|manual traction group|use of manual traction with physiotherapist hands
89519557|NCT04818281|Experimental|Low-Dose Group (Group A)|12 participants will receive 10 µg VLP vaccine (adjuvanted with alum and CpGODN-K3)
89519558|NCT04818281|Experimental|High-Dose Group (Group B)|12 participants will receive 40 µg VLP vaccine (adjuvanted with alum and CpGODN-K3)
89519559|NCT04818281|Placebo Comparator|Placebo Group|12 participants will receive 1 ml of 0.9% sodium chloride (NaCl)
89519560|NCT04388969||Gaucher disease patients|Patients with type 1,2,3 Gaucher disease.
89519561|NCT04388969||GBA carriers with Parkinson disease|Patients with Parkinson disease GBA related (carriers)
89519562|NCT04365101|Experimental|Phase I|CYNK-001 infusions on Days 1, 4, and 7
89519563|NCT04365101|Active Comparator|Phase II|Randomized, open label; CYNK-001 infusions on Days 1, 4, and 7 compared to Control Group: Best Supportive Care
89519564|NCT05397509|Experimental|Olive Leaf Tea|Olive Leaf Tea
89519565|NCT05397509|Placebo Comparator|Placebo tea|Placebo tea
89519566|NCT01378325|Experimental|Phenylephrine|PHenylephrine infusion started at 0.75 microgram per kg per mL started at spinal injection till delivery
89519567|NCT01378325|Placebo Comparator|Saline|Prophylactic variable rate of saline infusion where we adjusted the pump at a starting rate of 0.75 µg/kg/min, equivalent to 0.0075 mL/kg/min of saline
89519568|NCT05397275|Experimental|experimental group|progressive muscle relaxation exercises + breathing exercise
89519569|NCT05397275|Experimental|control group|only breathing exercise
89519570|NCT04298177|Experimental|QDOT-LAWT|"A QDOT® 3.5-mm open-irrigated contact force-sensing RF ablation catheter (Biosense Webster, Inc., Irvine, CA, USA) will be used.~The primary ablation mode for PVI will depend on the calculated LAWT at each atrial point, as follows:~**< 3.5-mm LAWT (red, and yellow colors): vHPSD ablation will be performed. If <1-mm LAWT (red color): Power 90 W; the duration of RF applications will be reduced to 2 seconds. If 1-3.5 mm LAWT (yellow color): Power 90 W; the duration of RF applications will be 4 seconds, according to the QDOT-FAST protocol.~**> 3.5-mm LAWT (green color): QMODE ablation will be performed. 50 W with AI target = 500"
89542303|NCT03207737|Active Comparator|Telehealth Only|This group will complete baseline and 5-days post baseline testing before beginning a one-year telehealth program.
89542304|NCT04496375||Institut Paoli Calmettes Outpatients|Patients with a solid tumor or an hematologic malignancy who will attend an appointement at IPC Outpatients clinic
89542305|NCT03207581|Experimental|Immediate Coaching Intervention|Immediate Coaching Intervention arm will receive professional coaching
89542306|NCT03207581|Active Comparator|Control/Delayed Coaching Intervention|Participants randomized to the Control/Delayed Coaching will receive no intervention for the first six months of the study, at which point they cross over and receive 6 professional coaching sessions
89542307|NCT03207269|Experimental|High protein no carbohydrate|Dietary. Two eggs will be consumed 30 minutes prior to bedtime. Energy content of dinner will be reduced to account for the calories in the bedtime snack.
89542308|NCT03207269|Active Comparator|High protein carbohydrate containing|Dietary. A low-fat yogurt will be consumed 30 minutes prior to bedtime. Protein will be matched to the high protein bedtime snack condition. Energy content of dinner will be reduced to account for the calories in the bedtime snack.
89542309|NCT03207269|No Intervention|Control no snack|No snack will be consumed prior to bed.
89542310|NCT02501447|Experimental|Guided audio-visual relaxation group|The guided relaxation (GR) intervention included a single 12-min GR video clip we administered to subjects at the baseline visit to determine the immediate effects of GR on stress and pain. The GR intervention also included six video clips, which ranged from 2 to 20 minutes in length to determine the short-term (2-week) effects of GR on stress and pain.
89542311|NCT02501447|No Intervention|Attention Control group|For the attention control group, subjects engaged in a 12-min computer-based discussion about their sickle cell disease (SCD) experience. The audio-taped questions and onscreen directions were programmed for self-administration. Subjects' responses were captured via the microphone so that Data Collectors were not involved in this discussion process, and it was equivalent to the guided relation activity.
89542312|NCT03207425|Experimental|Mild hepatic impairment group|
89542313|NCT03207425|Experimental|Moderate hepatic impairment group|
89542314|NCT03207425|Experimental|Matching healthy control group|Healthy control group will be matched with the hepatically impaired population with respect to age, sex and BMI
89542315|NCT03207113|Experimental|Ned Group|"Participants in the Ned case study (patients, caregivers, clinicians) will receive access to the Ned application.~Ned (No Evident Disease) is the first application to provide patients with access to individual-level prostate-specific antigen values streamed directly from the Ontario Laboratory Information System to their own smartphone. The application aims to promote self-care by informing patients directly of their PSA results and providing them with a personalised view of their own symptoms. It supports real-time clinical decision-making by providing clinicians with patient-reported outcomes collected in-app, and includes a curated educational feed and support group links."
89542316|NCT02606877|Experimental|Treatment naïve|Treatment naïve to pirfenidone
89542317|NCT02606877|Experimental|Pirfenidone-treated|Treatment before with pirfenidone
89542318|NCT03206957|Other|Study group|Down Syndrome children
88811690|NCT02839148|Experimental|psychosocial stimulation|In case of psychosocial stimulation, we well provide PS weekly for first month, fortnightly for 2nd and 3rd months and then monthly for next 3 months. The total number of visits will be 11 over a period of 6 months.
89542319|NCT03206957|Other|Control group n°1|Down Syndrome children's mothers
89542320|NCT03206957|Other|Control group n°2|Age and sex matched healthy children
89542321|NCT03206957|Other|Control group n°3|Down syndrome children's healthy siblings
89542322|NCT03206723|Active Comparator|Group 1|1. Standard care
89542323|NCT03206723|Active Comparator|Group 2|"Standard care~Bandage contact lens"
89542324|NCT04840407|Experimental|SHARP coach arm|The SHARP Peer Coach supports the direct care HHA and indirectly support the patient/family caregiver to enhance the patient's post-stroke recovery through two main pathways: 1) culturally sensitive, patient-centered reinforcement of rehabilitation regimens (prescribed physical/occupational exercises/training); and 2) early recognition and reporting of barriers to the rehabilitation therapist regarding adherence and recovery, including: a) environmental obstacles, b) family-related issues, c) psychological/clinical barriers (e.g., depression/anxiety).
89542325|NCT04840407|No Intervention|Usual care arm|
88811691|NCT00858494|Experimental|homeopathic cold remedy|
88811692|NCT00858962|Experimental|Bup/Ral|Buprenorphine and Raltegravir co-administration
88811693|NCT03839810|Experimental|stochastic resonance|stochastic resonance electrical stimulation is applied to the upper extremity during the subjects perform upper extremity motor function.
88811694|NCT03839810|Sham Comparator|sham stimulation|sham electrical stimulation (same electrode location, but no electrical current is applied) is applied to the upper extremity during the subjects perform upper extremity motor function.
88811695|NCT01376297|Experimental|Netupitant and Palonosetron plus dexamethasone|Oral netupitant/palonosetron (300 mg/0.50 mg) hard capsule (on Day 1) with oral dexamethasone prior to each scheduled chemotherapy cycle
88811696|NCT01376297|Active Comparator|Aprepitant and Palonosetron plus dexamethasone|Oral aprepitant hard capsule 125 mg (on Day 1) + 80 mg daily (for the following two days) and oral palonosetron soft capsule 0.50 mg (on Day 1) given with oral dexamethasone at each scheduled chemotherapy cycle.
88811697|NCT00859040|Experimental|SOM230C|Monthly SOM230C (pasireotide LAR) - 60 mg intramuscularly (Single-Arm Trial)
88811698|NCT00859508|Experimental|SyntheCel|
88811699|NCT00859508|Active Comparator|other FDA cleared dura replacements|
88811700|NCT01377467|Experimental|Denosumab|60 mg denosumab s.c. at baseline and after 6 months
88811701|NCT01377467|No Intervention|Control|No treatment
88811702|NCT02348762|Experimental|Glycine and N-acetylcysteine|Older subjects will be studied before and after taking oral cysteine (as n-acetylcysteine) and glycine for 6 months
88811703|NCT00859976|Active Comparator|Plasma-sprayed shell|Exceed ABT plasma-sprayed hydroxyapatite coated acetabular cup.
88811704|NCT00859976|Experimental|BoneMaster coated shell|Exceed ABT BoneMaster hydroxyapatite coated acetabular cup.
89542326|NCT03201185|Experimental|Ramipril|After transcatheter aortic valve implantation, patients will receive ramipril before discharge plus conventional treatment (in patients without ACEI).
89542327|NCT03201185|No Intervention|No intervention|Conventional treatment after transcatheter aortic valve implantation
89542328|NCT04840563|Experimental|Kalifilcon A lenses|Commercially available kalifilcon A lenses (Bausch + Lomb)
89542329|NCT04840563|Active Comparator|Dailies Total1|Dailies Total1 (Alcon)
89542330|NCT04840563|Active Comparator|Precision1|Precision1 (Alcon)
89542331|NCT04840251|Experimental|Intervention|The treatment group will have a physiotherapy well-being review and be referred for rehabilitation. They will be seen after 6 months for follow-up
89542332|NCT04840251|No Intervention|Control|The control group will have initial assessments then receive brief advice on exercise. They will also be followed up after 6 months
89542333|NCT04840251|Other|Qualitative|to understand how it feels to take part in the well-being review, we will interview some participants who have already had this kind of treatment and ask questions about their experiences of it and how it was for them. We are also interested to know what differences they felt it made so that we can help to decide about the things we want to measure as outcomes in the interventional of the study.
89542334|NCT03201263|Active Comparator|PSV group|Will be treated by standard of care for patients undergoing assisted mechanical ventilation (e.g., protective PSV settings, protocolized weaning, etc.).
89542335|NCT03201263|Experimental|PSV+Sigh group|Will be treated by standard of care for patients undergoing assisted mechanical ventilation (e.g., protective PSV settings, protocolized weaning, etc.) + Sigh (short cyclic recruitment breath once every minute) until death or spontaneous breathing trial and extubation.
89542336|NCT04856709|Other|study group|Women with stage 2 to 4 uterine prolapse. BMI from ≤ 35 kg\m2. Women of any parity including nulliparas will be included. Age of female patients ranges from 20 to 40 years.
89542337|NCT04857021|Active Comparator|GABA|Take GABA capsule once daily before sleep for 14 days.
89542338|NCT04857021|Placebo Comparator|Placebo|Take placebo capsule once daily before sleep for 14 days.
89542339|NCT03206567|Active Comparator|Nutrafol Supplement capsules|Subjects to take four (4) Nutrafol Supplement capsules by mouth daily for 180 days with a substantial meal
89542340|NCT03206567|Placebo Comparator|Placebo Capsules|Subjects to take four (4) Placebo capsules by mouth daily for 180 days with a substantial meal.
89542341|NCT04846023|Experimental|amplitude EEG (aEEG) via VEEGix|Amplitude-Integrated EEG can be achieved with a limited number of frontal electrodes.
89542342|NCT03038763||Mothers|Black or white mothers who have or have had hepatitis C and were born between 1945-1964. Participants must have at least one child over the age of 18.
89542343|NCT03038763||Adult Children|Adult children of Black or white mothers who have or have had hepatitis C and were born between 1945-1964. From speaking with these mothers, it must be possible that participants were exposed to hepatitis C virus while in the womb.
89542344|NCT03201341|Other|Behavioral protocol|To better understand the normal functioning of the brain within the framework of the representation of the body and of the space of action. During the experiment, physiological measurements will be recorded: electrical activity at the surface of the muscles (electromyography - EMG), scalp (electroencephalography - EEG) or skin (electrodermal response). Similarly, the movements of the arm will be recorded using an infrared kinematic system requiring simply the placement of markers at strategic points such as the tip of the thumb and forefinger, the wrist, the elbow ... Movements of the eyes can also be recorded, either with the aid of an electrooculograph (EOG) or with the aid of an infrared tracking device. Electrotactile stimulations of very low intensity and painless can also be administered.
89542345|NCT03201341|Other|Study in fMRI|To better understand the normal functioning of the brain in the representation of the body and the space of action, to identify the brain areas critical for these functions and to determine their functional roles. The examination will consist of several very short scans at the very beginning and then a scan of about ten minutes intended to take a detailed anatomical image of the brain. Then, the subject will carry out the experimental task during one or more scan (s) whose cumulative duration will not exceed 45 minutes. The task accomplished is explained in detail by the experimenter.
89542346|NCT03201341|Other|Study in MEG|To better understand the normal functioning of the brain in the representation of the body and the space of action, to identify the critical brain areas for these functions and to determine their functional roles and to study how They interact.The complete examination includes a magnetoencephalography (MEG) experiment followed by an MRI examination. The task accomplished is explained in detail by the experimenter.
88960745|NCT04341376|No Intervention|Treatment as Usual|Women who receive Treatment as Usual will follow the usual course of clinical care throughout their pregnancy and into the postpartum period, and will be eligible for the typical array of community services that may be offered to them.
88960746|NCT04331119|Experimental|Duvelisib Maintenance|"Duvelisib maintenance at 25 mg PO BID after count recovery (approximately 30 days after transplant) for one year. If the patient is in a complete remission at day +100, with no evidence of disease on PET/CT, then the dosing schedule of duvelisib may be changed to 25 mg BID for 14 days, then 14 days off in 28 day cycles (at the treating physician's discretion). If the patient has residual disease, duvelisib will continue at 25 mg BID until they have a negative PET CT. PET CTs will be completed every 3 months for patients with residual disease. Duvelisib maintenance will be continued for one year post-transplant.~Starting on 06/10/2021, all new participants will be enrolled to take 25 mg BID of duvelisib on days 1-14 of a 28 day cycle."
88960747|NCT04330391|No Intervention|Usual Care|Individuals randomized to the usual care group will receive standard care. This may include a physical therapist and/or nutritionist referral. Brigham and Women's Hospital offers several programs for patients interested in losing weight, including the Nutrition Wellness Service (NWS) and Program for Weight Management (PWM). Insurance coverage for these programs varies by patient insurance.
89024733|NCT04702334|Placebo Comparator|Lidocaine|After application of local anesthetic, removal of plaque and polishing of the tooth surfaces was performed followed by the local administration of anesthetic. This adjunctive treatment was performed at baseline and at the 3 months control.
89542347|NCT03201341|Other|Study in TMS|To better understand the normal functioning of the brain in the representation of the body and the space of action, to determine the functional role of the brain areas involved in these processes. Before the Transcranial magnetic stimulation (TMS) examination, MRI of the brain will be performed.The TMS review will consist of three distinct sessions separated from one another by at least one week, depending on the protocol, and which will differ simply at the site or type of stimulation.
89542348|NCT03201341|Other|Study in tDCS|To better understand the normal functioning of the brain in the representation of the body and the space of action, to determine the functional role of the cerebral areas involved in these processes. The transcranial Direct Current Stimulation (tDCS) exam will consist of three separate sessions separated from each other by at least one week and will simply differ at the stimulation site. The task accomplished is explained in detail by the experimenter.
89542349|NCT04856787|Experimental|SHR-1701 in combination with BP102 and XELOX（Phase 2）|
89542350|NCT04856787|Experimental|SHR-1701 in combination with BP102 and XELOX （Phase 3）|
89542351|NCT04856787|Placebo Comparator|placebo in combination with BP102 and XELOX|
89542352|NCT03206177|Experimental|Paclitaxel/Carboplatin + Galunisertib|
89542353|NCT04846179|Experimental|Ginkgo biloba extract group|Group receiving ginkgo biloba extract supplementation
89542354|NCT04856553|Experimental|Handgrip exercise (morning)|The handgrip exercise session will be executed with four series (two in each arm) of two minutes of isometric contraction at 30% of maximum voluntary contraction, with a one-minute interval between series in the morning.
89542355|NCT04856553|No Intervention|Control|In the control session, the participants will remain at rest for the same period of time as in the handgrip exercise protocol.
89542356|NCT04856553|Experimental|Handgrip exercise (afternoon)|The handgrip exercise session will be executed with four series (two in each arm) of two minutes of isometric contraction at 30% of maximum voluntary contraction, with a one-minute interval between series in the afternoon.
89542357|NCT04845789||Family caregivers|Family caregivers who were main caregiver to the person with dementia and who spent at least 10 hours a week providing care to the person with dementia.
89542358|NCT02606643|Active Comparator|Group 1 Catheter to slight traction|"For the Tension arm (research related), slight tension will be placed on the catheter, which will then be taped to the patient's inner thigh. The tension will be assessed and retaped as needed every 30 minutes by the research and/or the nursing staff.~Only slight tension will be applied to those catheters assign to the tension group. The catheter will be taped to the inner thigh so there is no sag in the catheter from the urethra to the tape. There is no method or device to measure the tension placed on these catheters, if the patient moves her leg it can lessen or increase the tension, these are known factors."
89542359|NCT02606643|Active Comparator|Group 2 Catheter to no traction|"Foley catheter to no traction placed as SOC No traction applied"
89542360|NCT04845867||Measurement and digital documentation|continuous measurement and digital documentation with alarms and display off
89542361|NCT04839939|Active Comparator|Control Group|Children in this group received conventional physical therapy program in form of Stretching for tight muscles, weak muscles Strengthening, Postural reactions training, Proprioceptive training, and Walking training were all part of the treatment plan, which was based on the neurodevelopmental approach.
89542362|NCT04839939|Experimental|AFO Group|Children in this group received the same conventional treatment plus they were provided with solid community-prescribed AFO with a wearing schedule of 6-12 hours per day. Parents were given a detailed demonstration about how to use the AFO probably and watching for areas of skin overpressure. AFO needs to be worn with a smooth, long sock underneath with the child's heel is right down in the AFO with the ankle strap and/or shoe fastened firmly.
89542363|NCT04839939|Experimental|Combination Taping Group|"Children in this group received the same conventional treatment plus the combination taping technique, which was performed by one qualified physical therapist with over five years of experience. The technique started with the application of two 5-cm wide Kinesio tape I straps. The first strap was applied from the lateral condyle of the tibia to the base of the first metatarsal bone with the ankle joint in plantar flexion. The tape was not stretched for 5 cm from the initial site and was then stretched up to 30% for the remaining parts15. The second I strap While the therapist holds the ankle in dorsiflexion, he applied the distal end of the tape 10 cm below the ankle joint. With almost 70% tension, the proximal end is applied 10 cm above the ankle joint. While one hand was holding each end of the tape, the child was asked to move the joint into plantar flexion. Finally, both hands moved towards the middle of the joint to apply the remaining tape."
89542364|NCT04845711|Placebo Comparator|Control group|patients will receive general anesthesia only.
89542365|NCT04845711|Experimental|Erector spinae plane block group|patients will receive general anesthesia and bilateral ultrasound guided erector spinae plane block (20ml Bupivacaine 0.25%)
88960748|NCT04330391|Experimental|Intervention|Intervention subjects will use the Nutrimedy mobile app and be connected at enrollment with a registered dietitian who will contact intervention participants weekly or bi-weekly via video calls and unlimited in-app text messaging for up to three months. The first week will include either one 55-minute video session or two 25-minute sessions. Weeks 2-4 will have weekly 25-minute video calls, and weeks 5-12 will have biweekly 25-minute sessions for a total of 8-9 sessions over 12 weeks. Together, participants and dietitians will come up with goals for the 12 weeks, and dietitians will check on progress toward these goals using in-app tools such as food logs and messaging between video calls. All patients will be encouraged to lose at least 20 pounds with a goal BMI<40 kg/m2 after 12 weeks. The intervention group will also receive all aspects of the usual care arm including the opportunity to have a physical therapist and/or nutritionist referral.
88960749|NCT04324944|Experimental|Collaborative Decision Skills Training|Collaborative Decision Skills Training (CDST) is the intervention group (experimental arm).
88960750|NCT04324944|Active Comparator|Leveling Up|Leveling Up is the active control arm.
88960751|NCT04324606|Experimental|Group 1a|Volunteers will receive a single dose of 5x10^10vp ChAdOx1 nCoV-19
88960752|NCT04324606|Active Comparator|Group 1b|Volunteers will receive a standard single dose of MenACWY vaccine
88960753|NCT04324606|Experimental|Group 1c|Volunteers will receive a single dose of 5x10^10vp ChAdOx1 nCoV-19 at week 0 and a boost dose of 5x10^10vp ChAdOx1 nCoV-19 9 months later
88960754|NCT04324606|Experimental|Group 1d|Volunteers will receive a standard single dose of MenACWY vaccine. 9 moths later they will receive two doses of 5x10^10vp ChAdOx1 nCoV-19 4-12 weeks apart
89542366|NCT04845711|Experimental|Quadratus lumborum block group|patients will receive general anesthesia and bilateral ultrasound guided quadratus lumborum block (20 ml Bupivacaine 0.25%)
89542367|NCT03042117||No Coronary Artery Disease (CAD)|Patients with no known cardiovascular disease.
89542368|NCT03042117||CAD without Myocardial Infarction (MI)|Patients with cardiovascular disease without a myocardial infarction.
89542369|NCT03042117||CAD with MI|Patients with cardiovascular disease with previous history of a myocardial infarction.
89542370|NCT04845633|Other|Healthy children using conventional toothbrush|
89542371|NCT04845633|Experimental|Healthy children using toothbrush with Customized Handle|
89542372|NCT04845633|Other|Children with Down syndrome using conventional toothbrush|
89542373|NCT04845633|Experimental|Children with Down syndrome using toothbrush with Customized Handle|
89542374|NCT04845243|Other|Emotion recognition training|All participants have to complete the online emotion recognition training E.V.A. as well as the pre- and post training tasks: GERT and social decision making task.
89542375|NCT04804995||Heathy participants|
89542376|NCT04804995||migraine patients|
89542377|NCT04845009|Experimental|progressive muscle relaxation|progressive muscle relaxation tape guided
89542378|NCT04845009|Placebo Comparator|usual care|usual care
89542379|NCT04856397|Other|Control group|"Responders will be in this category. These patients will be maintained on intravitreal anti-VEGF therapy for 1 year, with a monthly PRN (as needed) treatment regimen post 5 monthly loading doses."
89542380|NCT04856397|Experimental|Early switch|Suboptimal responders who are switched to intravitreal Ozurdex (monitored monthly and treated PRN at a potential 2-6 month interval) injections after the first 3 monthly loading intravitreal eylea.
88960755|NCT04324606|Experimental|Group 2a|Volunteers will receive a single dose of 5x10^10vp ChAdOx1 nCoV-19
88960756|NCT04324606|Active Comparator|Group 2b|Volunteers will receive a standard single dose of MenACWY vaccine
88960757|NCT04324606|Experimental|Group 2c|Volunteers will receive two doses of 5x10^10vp ChAdOx1 nCoV-19 at week 0 and week 8
88960758|NCT04324606|Experimental|Group 2d|Volunteers will receive a single dose of 5x10^10vp ChAdOx1 nCoV-19 at week 0 and a boost dose of 2.5x10^10vp ChAdOx1 nCoV-19 at week 8
88960759|NCT04324606|Active Comparator|Group 2e|Volunteers will receive two standard single doses of MenACWY vaccine at week 0 and week 8
88960760|NCT04324606|Experimental|Group 2f|Volunteers will receive a single dose of 5x10^10vp ChAdOx1 nCoV-19 at week 0 and a boost dose of ChAdOx1 nCoV-19 0.5mL (3.5-6.5x1010vp) a minimum of 4 weeks later
88960761|NCT04324606|Active Comparator|Group 2g|Volunteers will receive two standard single doses of MenACWY vaccine a minimum of 4 weeks apart
88960762|NCT04324606|Experimental|Group 3a|Volunteers will receive one dose of 5x10^10vp ChAdOx1 nCoV-19 at week 0 and one dose of 5x10^10vp ChAdOx1 nCoV-19 at week 4
88960763|NCT04324606|Experimental|Group 3b|Volunteers will receive a single dose of 5x10^10vp ChAdOx1 nCoV-19 at week 0, a boost dose of ChAdOx1 nCoV-19 0.5mL (3.5-6.5x1010vp) a minimum of 4 weeks later, and a third dose of ChAdOx1 nCoV-19 0.5mL (3.5-6.5x1010vp) at 9 months
88960764|NCT04324606|Experimental|Group 4a|Volunteers will receive a single dose of 5x10^10vp ChAdOx1 nCoV-19
88960765|NCT04324606|Active Comparator|Group 4b|Volunteers will receive a single dose of 5x10^10vp ChAdOx1 nCoV-19 delivered intramuscularly
88960766|NCT04324606|Experimental|Group 4c|Volunteers will receive a single dose of 5x10^10vp ChAdOx1 nCoV-19 at week 0 and a boost dose of ChAdOx1 nCoV-19 0.5mL (3.5-6.5x1010vp) a minimum of 4 weeks later
88960767|NCT04324606|Active Comparator|Group 4d|Volunteers will receive two standard single doses of MenACWY vaccine a minimum of 4 weeks apart
88960768|NCT04324606|Experimental|Group 5a|Volunteers will receive two doses of 5x10^10vp ChAdOx1 nCoV-19 ≤ 16 weeks apart, and a third dose of ChAdOx1 nCoV-19 0.5mL (3.5-6.5x1010vp) at 9 months
89542381|NCT04856397|Experimental|Late switch|Suboptimal responders who are switched to intravitreal Ozurdex (monitored monthly and treated PRN at a potential 2-6 month interval) injections after the first 6 monthly loading intravitreal eylea
89542382|NCT04856397|Other|Non-switch|Suboptimal responders who continue to receive monthly intravitreal anti-VEGF injections.
89542383|NCT04839471|Experimental|BI-754091 plus afatinib|BI-754091 plus afatinib
89542384|NCT04839237|Experimental|Liraglutide|Obese patients with HbA1C lower than 9.0%,receive Liraglutide alone for 3 months.
89542385|NCT04839237|Experimental|Liraglutide combined with metformin|Obese patients with HbA1C ≥9.0%, receive Liraglutide in combination with metformin for 3 months.
89542386|NCT04839159|Experimental|SCD Patient|
89542387|NCT04845087|Experimental|Trial Group|Patients from this group will receive treatment with ozonized water.
89542388|NCT04845087|Placebo Comparator|Placebo Group|Patients from this group will receive placebo with water.
89542389|NCT03038685|Experimental|prospective, multicenter cohort|A group of 175 patients will be recruited in 4 Belgian stroke centers during the six months period. All data will be collected prospectively and patients will be treated during six months period.
89542390|NCT03038685|No Intervention|historical, single center cohort|A historical cohort of Sint-Janhospital (2011 - Bruges, Belgium) with prospectively collected data will be used as comparator for the experimental arm. These data were published in Vanacker P, Couvreur T, Vanhooren G. Can we improve cerebrovascular risk reduction in real-life? A single centre's experience. Cerebrovasc Dis 2011;31(suppl 2):289
89542391|NCT03040245||intervention group|The intervention group was instructed to complete the questionnaires at least 48 hours after the intervention that is, after reading the information booklet
89542392|NCT03040245||control group|The same items were included as in the initial folder, with an additional questionnaire enabling the intervention group to qualitatively assess the information booklet. If there was no response, reminders were sent by email, then by telephone, and lastly by post.
89542393|NCT03038607|Active Comparator|Aspirin group|
89542394|NCT03038607|No Intervention|No intervention|
89542395|NCT03038529|Other|A: Classic approach|"Intradiscal O3 injection through classic postrolateral extraarticular percutaneous approach.~The participants will receive 10 ml of ozone oxygen mixture 30 ug O3/ml O2. The ozone-oxygen mixture was produced in real-time by a medical ozone generator (Ozonline E 80, Medica srl, Bologna Italy)."
89542396|NCT03038529|Active Comparator|B: Transforaminal approach (Yess approach )|"Participants will receive 10 ml of ozone oxygen mixture 30 ug O3/ml O2 through postrolateral transforaminal approach (Yess approach).~The ozone-oxygen mixture was produced in real-time by a medical ozone generator (Ozonline E 80, Medica srl, Bologna Italy)."
89542397|NCT03038451|Experimental|s-amlodipine besylate 2,5 and 5 mg tablets|
89542398|NCT03040401|Experimental|Cohort 1: Ceplene® and Proleukin®|"Enrolled subjects will receive histamine dihydrochloride (HDC; Ceplene®) and IL-2 (Proleukin®) subcutaneously (s.c.) twice daily (BID) in 3-week periods followed by 3 week rest periods for a total of 4 treatment cycles.~IL-2 will be administered s.c., 1 µg/kg (=16400 IU/kg) body weight twice daily (BID) during treatment periods. Ceplene® will be administered s.c. 0.5 mg BID after IL-2 injections.~Cohort 1 will receive only Ceplene® during the first treatment cycles and Ceplene® in combination with Proleukin® during treatment cycles 2-4."
89542399|NCT03040401|Experimental|Cohort 2: Ceplene® and Proleukin®|"Enrolled subjects will receive histamine dihydrochloride (HDC; Ceplene®) and IL-2 (Proleukin®) subcutaneously (s.c.) twice daily (BID) in 3-week periods followed by 3 week rest periods for a total of 4 treatment cycles.~IL-2 will be administered s.c., 1 µg/kg (=16400 IU/kg) body weight twice daily (BID) during treatment periods. Ceplene® will be administered s.c. 0.5 mg BID after IL-2 injections.~Cohort 2 will receive Ceplene® in combination with Proleukin® during all treatment cycles (1-4)."
89542400|NCT03040401|Experimental|Cohort 3: Ceplene® and Proleukin®|"Enrolled subjects will receive histamine dihydrochloride (HDC; Ceplene®) and IL-2 (Proleukin®) subcutaneously (s.c.) twice daily (BID) in 3-week periods followed by 3 week rest periods for a total of 4 treatment cycles.~IL-2 will be administered s.c., 1 µg/kg (=16400 IU/kg) body weight twice daily (BID) during treatment periods. Ceplene® will be administered s.c. 0.5 mg BID after IL-2 injections.~Cohort 3 will receive either only Ceplene® during treatment cycles 1-4 or Ceplene® in combination with Proleukin® during treatment cycles 1-4. Treatment will be decided by the study committee based on the safety profile of treatment administered to cohort 1 and 2."
89542401|NCT03038295|Experimental|oral propranol group|"Enrolled preterm newborns will receive oral propranolol 0.25mg/kg daily(every 24 hours).~The treatment will be started as soon as the diagnosis of stage 1 or 2 ROP without plus is made and will be continue until the development of retinal vascularization is completed, but no more than 90 days."
89542402|NCT03038295|Placebo Comparator|oral placebo group|Enrolled preterm newborns will receive oral normal saline 0.25mg/kg daily(every 24 hours) and other disposals will be done similarily to the oral propranol group.
89542403|NCT03038295|Experimental|eye drop propranol group|"Enrolled preterm newborns will receive propranolol as ophthalmic solution (0.2%). 3 microdrops of 6 microliters (μL) propranolol solution (= 6 μg propranolol/microdrop) will be topically applied with a calibrated pipette,in each eye, four times daily (every 6 hours) .~The treatment will be started as soon as the diagnosis of stage 1 or 2 ROP without plus is made and will be continue until the development of retinal vascularization is completed, but no more than 90 days."
89542404|NCT03038295|Placebo Comparator|eye drop placebo group|Enrolled preterm newborns will receive placebo as ophthalmic solution in the same way of eye drop propranolol and other disposals will be done similarily to the eye drop propranol group.
89542405|NCT03038217|Experimental|ACT group|Group of patients with pathologically confirmed Stage II-III colorectal cancer who receive postoperative treatment with chemotherapeutic agent (ACT) using Capecitabine +/- Oxaliplatin.
89542406|NCT03038217|Experimental|Non-ACT group|Group of patients with pathologically confirmed stage II colorectal cancer who receive no adjuvant chemotherapy.
89542407|NCT03038217|Experimental|LR group|Group of patients with clinically staged T1-2N0 rectal cancer who undergo local resection (LR)
89542408|NCT03038217|Experimental|RR group|Group of patients with clinically staged T1-2N0 rectal cancer who undergo radical resection (RR)
89207426|NCT04009473|Experimental|SEGOVA Intervention Group|Intervention group of 50-100 patients with ovarian failure would be subjected to a three-day procedure named SEGOVA: bone marrow derived StEm cell treatment, Growth factor incubation and Ovarian In Vitro Activation. After the procedure, one year follow up of hormones measurements (follicle stimulating hormone (FSH), luteinizing hormone (LH),estradiol (E2), progesterone (PG) and anti-mullerian hormone (AMH)) and follicle counts would be established. In patients with oocytes retrieved after SEGOVA procedure, standard In Vitro Fertilization protocol would be performed. The fertilization, cleavage and clinical pregnancy rate will be monitored.
89542409|NCT03038139|Experimental|Cervical exercises|"Group A= Cervical correction program The cervical exercise program consist of 3 strengthening exercises and 2 stretching exercises.~Applying exercises 3 times per week."
89542410|NCT03038139|Experimental|Lumbosacral exercises|"Group B= Cervical + Lumbosacral correction program The cervical exercise program consist of 3 strengthening exercises and 2 stretching exercises.~The lumbosacral exercise program consist of 2 strengthening exercises and 4 stretching exercises.~Applying exercises 3 times per week."
89542411|NCT02609607|Placebo Comparator|Placebo|Every other day placement of a placebo rectal suppository for 4 weeks
89542412|NCT02609607|Experimental|Bisacodyl|Every other day placement of a bisacodyl 10 mg rectal suppository for 4 weeks
89542413|NCT03040167|Placebo Comparator|Control group|PEC 1 block with injection of 0.4 mL/kg of normal saline under echoguidance.
89542414|NCT03040167|Active Comparator|Treatment group|PEC 1 block with injection of 0.4 mL/kg of 0.25% bupivacaine with 1/400 000 epinephrine under echoguidance.
89542415|NCT04838847|Experimental|Participants / Healthy Participants Aged ≥65 Years|Participants will be vaccinated with CVnCoV 12 μg mRNA on Day 1 and Day 29 in the deltoid area, preferably in the non-dominant arm.
88960769|NCT04324606|Experimental|Group 5b|Volunteers will receive two standard single doses of MenACWY vaccine ≤ 16 weeks apart, a dose of ChAdOx1 nCoV-19 0.5mL (3.5-6.5x1010vp) at 9 months then a second dose of ChAdOx1 nCoV-19 0.5mL (3.5-6.5x1010vp) 4-12 weeks later
88960770|NCT04316572|Experimental|mental health specialist video consultation|"The intervention group will receive five video consultations with psychotherapists directly in the GP's practice.~The consultations will be carried out via the web portal of a certified video service provider (arztkonsultation ak GmbH). The patient will be located in the GP's practice and the psychotherapist in his practice or another suitable room. Patients are scheduled for five sessions of 50 minutes."
89207427|NCT00850746|Placebo Comparator|A. Placebo|
89207428|NCT00850746|Experimental|B. Ym443 Lower Dose|
89542416|NCT04838847|Experimental|Participants / Healthy Participants Aged 18-45 Years|Participants will be vaccinated with CVnCoV 12 μg mRNA on Day 1 and Day 29 in the deltoid area, preferably in the non-dominant arm.
89542417|NCT03038061|Experimental|Experimental group|Patients undergoing Laparoscopic Surgery
89542418|NCT04843839|Experimental|Test Eye|These eyes will be given the Test drug, that is Nepafenac Eye Drops 0.1% w/v, at the dosage of 4 drops to be instilled in the eye 1 drop 4 times a day (every 4 hourly).That is at morning, afternoon, evening and at night. This is to be continued for a 6 months duration.
89542419|NCT04843839|Placebo Comparator|Control Eye|These eyes will be given the placebo, that is Carboxy-methylcellulose sodium lubricant eye drops 0.5%w/v, at the same dosage of 4 drops to be instilled in the eye 1 drop 4 times a day (every 4 hourly).That is at morning, afternoon, evening and at night. This is to be continued for a 6 months duration.
89542420|NCT04838691|Experimental|interpersonal relations counseling applied|8 sessions of interpersonal relations counseling, each lasting 40 minutes, were applied for 2.
89542421|NCT04838691|No Intervention|no application|No action taken.
89542422|NCT04838535|Other|PCOS follicular fluid|
89542423|NCT03037827|Active Comparator|Endovenous laser ablation (EVLA) 5W|One of three different regimens of endovenous laser ablation, the fiber pullback speed 0.7 mm/s, laser power 5 W, LEED 71 J/cm
89542424|NCT03037827|Active Comparator|Endovenous laser ablation (EVLA) 7W|One of three different regimens of endovenous laser ablation, the fiber pullback speed 1 mm/s, laser power 7 W, LEED 70 J/cm
89542425|NCT03037827|Active Comparator|Endovenous laser ablation (EVLA) 10W|One of three different regimens of endovenous laser ablation, the fiber pullback speed 1.5 mm/s, laser power 10 W, LEED 67 J/cm
89542426|NCT04838145|Active Comparator|Active treatment|Pleconaril: 5 mg/kg x2 times a day for 26 weeks up to 40 kg. Max dose 300mg x2. Ribavirin:15 (7.5) mg/kg/day divided in two doses daily for 26 weeks: Max dose 1000mg/24h if body weight<75kg and 1200mg if body weight>75kg.
89542427|NCT04838145|Placebo Comparator|Placebo|Receives placebo, on a double blind basis
89542428|NCT04837911|Other|Patients using the Spirobank Smart|Use of a portable spirometry
89542429|NCT03037749|Experimental|Distressed Violent Partners|Distressed violent partners engage in a placebo-controlled alcohol administration study with an emotion-regulation task.
89542430|NCT03037749|Experimental|Distressed Nonviolent Partners|Distressed nonviolent partners engage in a placebo-controlled alcohol administration study with an emotion-regulation task.
89542431|NCT04855539||wave 1|
89207429|NCT00850746|Experimental|C. YM443 Higher Dose|
89542432|NCT04855539||wave 2|
89542433|NCT04855149||WALANT|anesthesia performed with WALANT technique
89542434|NCT04855149||BAx|anesthesia performed with axillary block under ultrasound control
89542435|NCT04855071|Active Comparator|Interventional group|"The intervention will consist of supervised individualized sessions that will include application of exercises to balance the pelvis and their muscles, treatment of trigger points, teaching activation of the transverse abdominis with ultrasound biofeedback and teaching reflex activation exercises of the transverse abdominis and pelvic floor muscles in different body positions. In addition, standards of water, urination, food, defecation, postural hygiene and physical activity will be provided. It is also recommended different life habit advices related to tobacco use, constipation, etc.~Furthemore, active RF will be applied intracavitary, in monopolar application, reaching a temperature between 42-45ºC in the tissues (according to the patient's tolerance), and with a power of 50% until the desired temperature is reached. It will be applied with a dose of approximately between 3-4 KJ depending on the application time (20 minutes / session)."
89542436|NCT04855071|Sham Comparator|Comparator group|The intervention will be the same that in IG (exercises to balance the pelvis and their muscles, etc) an also standards of water, urination, food, defecation, postural hygiene and physical activity for their generalization at home and life habit advices. The application of RF in the control group will follow the same application procedure as in the intervention group with the only difference that no parameter is applied to the RF device (in terms of temperature, power, frequency and dose); that is, it remains off for the entire duration of the session.
89542437|NCT03041493|Experimental|Electronic cigarettes (EC) smokers|
89542438|NCT03041493|Experimental|traditional cigarette (TC) smokers|
89542439|NCT03041493|Active Comparator|nonsmokers|
89542440|NCT03041571||Medical Honors Students|The Medical Honors Program students will fill out the Patient Provider Orientation Scale (PPOS). MHP students will then interview a patient with a chronic or life limiting illness.
89542441|NCT03041571||Patients with chronic illnesses|The patients will fill out the PPOS scale. The patient will then have an Interview performed by MHP student
89542442|NCT03041259|Experimental|Rejuveinix Low Dose|Intravenous dosing of two doses per week of Rejuveinix
89542443|NCT03041259|Experimental|Rejuveinix High Dose|Intravenous dosing of two doses per week of Rejuveinix
89542444|NCT04429035|Experimental|Vitamin K2|Participants receive Vitamin K2 (Menaquinone) 100mcg tablet orally 3 times daily for 12 months.
89207430|NCT00850746|Active Comparator|D. Moxiflocxacin|
89207431|NCT00969735|Active Comparator|Cryoablation|Deflectable over-the-wire cryoablation balloon catheter (Arctic Front®, Cryocath Technologies)
89207432|NCT00969735|Active Comparator|Radiofrequency ablation|Open irrigation ablation catheter (Navistar® Thermo-cool®, Biosense Webster Inc).
89207433|NCT00850824|Experimental|Behavioral|Community Health Worker home visits
89207434|NCT00850824|Active Comparator|Usual Care|Usual Care, Wait List Control
89542445|NCT04429035|Placebo Comparator|Placebo|Participants receive Vitamin K2 (Menaquinone) placebo tablet matching Vitamin K2 (Menaquinone) orally 3 times daily for 12 months.
89542446|NCT03041337||Healthy subjects|Cohort of patients referred to our echocardiography laboratory to work assessment procedures and without any cardiovascular risk factor. They will underwent stress echocardiography.
89542447|NCT03041337||cardio-respiratory diseases|patients with any possible cardiovascular and respiratory condition. They will underwent stress echocardiography.
89542448|NCT04843449|Experimental|Inhibitor group|"ASC40 50mg, once daily on the 1st and 11th days before meal;~Itraconazole 200mg, once daily from the 6th day to the 15th day."
89542449|NCT04843449|Experimental|Inducer group|"ASC40 50mg, once daily on the 1st and 19th days before meal;~Rifampicin 600mg, once daily from the 6th day to the 19th day."
89542450|NCT03037593|Experimental|Intervention|4000 IU vitamin D3 +prenatal vitamin
89024734|NCT04702412|Experimental|Opal patient portal|Exposure to routine use of a patient portal (Opal) through which HIV patients are expected to complete a measure on barriers to ART adherence for screening purposes, before each HIV care visit.
89024735|NCT00435266|Experimental|1|Remote ischemic preconditioning
89542451|NCT03037593|No Intervention|Control|standard prenatal vitamin
89542452|NCT04838067|Experimental|Cefaly Intervention|Cefaly
89542453|NCT04843293|Experimental|Experimental Group: Olfactory stimulation group|Preterm newborns in the initiative group were sniffed the smell of breast milk before and during feeding, except for routine application
89542454|NCT04843293|No Intervention|Control Group|Premature newborns in the control group feeds gavage according to the routine of the clinic, and no attempt will be made during feeding.
89542455|NCT03041103|Experimental|Adult|Food Product 1:50 grams of fortified nutritious product from legumes administered to adults, for 2 weeks
89542456|NCT03041103|Experimental|Children|Food Product 1: 50 grams of fortified nutritious product from legumes administered to children 9-13 years of age, for 1 weeks
89542457|NCT04843215|Experimental|Experimental group/D2 radical gastrectomy with partial omentectomy|Partial omentectomy with preservation of the greater omentum at >3 cm from the gastroepiploic arcade.
89542458|NCT04843215|No Intervention|Control group/D2 radical gastrectomy with total omentectom|Control group with total omentectomy
89542459|NCT04803357|Experimental|Blinded Continuous Glucose Monitoring Devise|If you are in the control group, you will wear a continuous glucose monitor with the read out screen covered so you can not see your continuous glucose level. You will be taught how to test your blood sugar by pricking your finger and using a standard blood glucose meter as per the standard of care used by your provider in the obstetrics clinic.
89542460|NCT04837443|Experimental|Synchronous working group|
89542461|NCT04837443|Sham Comparator|Asynchronous working group|
89542462|NCT04842825|Experimental|kidney-tonifying and blood-regulating herbs treatment group|the treatment group will receive sequential treatment with the Chinese herbal formula for tonifying the kidney, nourishing the blood, and activating the blood 2 months before the proposed ET to regulate menstruation and improve ovarian reserve function. Treatment with the Chinese herbal formula will continue on the 5th day of menstruation after entering the super-ovulation cycle.
89542463|NCT04842825|Active Comparator|Western medicine group|The control group will be treated with conventional Western medicine
89542464|NCT04837599|No Intervention|Pentax i 10|Patient gets normal colonoscopy without Endocuff or activation of artifical intelligence
89542465|NCT04837599|Active Comparator|Pentax i 10 with artificial intelligence Discovery TM|Normal Pentax i 10 colonoscope with on the special monitor acitvated artificial intelligence
89542466|NCT04837599|Active Comparator|Pentax i 10 with Endocuff TM|Endocuff cap is mounted on the tip of the endoscope a cheap assistance device proven in former studies to increase adenoma detection rate.
89542467|NCT04837599|Active Comparator|Pentax i 10 with Endocuff TM and artificial intelligence Discovery TM|Endocuff cap is mounted on the tip of the endoscope and artificial intelligence is activated on the monitor. hypothesis is that probably artificial intelligence and Endocuff combined potentiate their effect.
89542468|NCT04854915|Active Comparator|Liverpool Overweight and Obesity Programme (LOOP) only|Patients will continue to follow the LOOP@ Alder Hey programme.
89542469|NCT04854915|Experimental|LOOP + mHealth technology assisted exercise counselling|Patients will continue to work with the LOOP MDT. However, exercise and physical activity advise will be taken over by an exercise specialist. Participants will co-develop a 3-month structured exercise and PA programme, with support from an exercise specialist. All participants will have 5 exercise consultations with their exercise specialist. The intervention will be supported by 3 mHealth elements; 1) a wrist worn fitness watch, 2) a smartphone app for patients, and 3) a coaching website for the exercise specialist. The 3 elements will be synced, allowing data to be transferred between platforms.
89542470|NCT04842903|Experimental|Experimental Group|Therapeutic touch and standard nursing care of the clinic (such as breathing exercise, postural drainage) was applied.
89542471|NCT04842903|No Intervention|Control Group|Only standard nursing care of the clinic (such as breathing exercise, postural drainage) was applied.
89542472|NCT04837287|Active Comparator|Static Stretching Exercise for 10 Seconds|After the participants are given one session of training, the participants do the exercises themselves at home.
89542473|NCT04837287|Active Comparator|Static Stretching Exercise for 30 Seconds|After the participants are given one session of training, the participants do the exercises themselves at home.
89542474|NCT04842669|Experimental|Low level laser therapy|Low level laser therapy
89542475|NCT04842669|Active Comparator|Conservative treatment|Conservative treatment
89542476|NCT02606253|Active Comparator|Metolazone|Metolazone 5mg tablet orally twice daily for 48 hours.
89542477|NCT02606253|Experimental|Chlorothiazide|Chlorothiazide 500mg intravenous infusion over 30 minutes twice daily for 48 hours
89542478|NCT02606253|Experimental|Tolvaptan|Tolvaptan 30mg tablet orally once daily for 48 hours
89542479|NCT03037125|Active Comparator|Control Arm|Split crest without PRF
89542480|NCT03037125|Experimental|Intervention Arm|Split crest with PRF
89542481|NCT03040947||Healthy Volunteer|Healthy Volunteers will undergo a cardiovascular magnetic resonance imaging scan.
89024736|NCT00435266|No Intervention|2|
89024737|NCT00473460|Experimental|Arm 1|
89024738|NCT00473460|Placebo Comparator|Arm 2|
89024739|NCT00465426||1|HIV Positive men and women 18-65 years of age
89024740|NCT00465426||2|HIV negative men and women 18-65 years of age
89024741|NCT00473499|Experimental|DEBlue stent|Paclitaxel coated balloon with CoCr stent mounted on it
89542482|NCT03040947||Diseased (Suspected or Known Cardiac Conditions)|Patients will undergo a cardiovascular magnetic resonance imaging scan.
89542483|NCT03040869||CHD Patients|coronary angioplasty confirmed coronary heart disease.
89542484|NCT03040869||non-CHD patients|coronary angioplasty confirmed no coronary heart disease.
89542485|NCT03040089|Experimental|picosecond laser & 2% hydroquinone cream|PICO+4 laser system and Neoquine Cream 2% (2% hydroquinone cream) for melasma
89542486|NCT03040089|Sham Comparator|2% hydroquinone cream|Only Neoquine Cream 2% (2% hydroquinone cream) for melasma
89542487|NCT04842357|Other|video - then self-study|Group A will be video recorded during the performance of the two skills on simulators (i.e. Donati suture and intraosseous venous access) (timepoint: T0). Then group A will watch a standardised video about the skills, then will be again video recorded during the performance of the two skills on simulators (timepoint: T1). After 1 to 2 weeks group A will do self-study, then will be again video recorded during the performance of the two skills on simulators (timepoint: T2).
89542488|NCT04842357|Other|self-study, then video|Group B will be video recorded during the performance of the two skills on simulators (i.e. Donati suture and intraosseous venous access) (timepoint: T0). Then group B will do self-study, then will be again video recorded during the performance of the two skills on simulators (timepoint: T1). After 1 to 2 weeks group B will watch the standardised video about the skills, then will be again video recorded during the performance of the two skills on simulators (timepoint: T2).
89542489|NCT04854759|Experimental|Study group|
89542490|NCT04854759|Placebo Comparator|Control group|
89542491|NCT04428957|Experimental|Telemonitoring group|3 months home-based telemonitoring
89542492|NCT04428957|No Intervention|Control group|3 months standard care
89542493|NCT04842435|Experimental|Stage 1. Group 1|Group 1 - 39 subjects who will receive a single intravenous infusion of COVID-globulin at a dose of 1 mL/kg in addition to standard therapy
89542494|NCT04842435|Experimental|Stage 1. Group 2|Group 2 - 39 subjects who will receive a single intravenous infusion of COVID-globulin at a dose of 2 mL/kg in addition to standard therapy
89542495|NCT04842435|Experimental|Stage 1. Group 3|Group 3 - 39 subjects who will receive a single intravenous infusion of COVID-globulin at a dose of 4 mL/kg in addition to standard therapy
89542496|NCT04842435|Placebo Comparator|Stage 1. Group 4|Group 4 - 39 subjects who will receive a single intravenous infusion of placebo at a dose of 1 mL/kg in addition to standard therapy
89542497|NCT04842435|Active Comparator|Stage 2. Group 1|Group 1 - 110 subjects who will receive a single intravenous infusion of COVID-globulin at a dose defined at Stage 1 in addition to standard therapy
89542498|NCT04842435|Placebo Comparator|Stage 2. Group 2|Group 2 - 110 subjects who will receive a single intravenous infusion of placebo at a dose equal to the COVID-globulin dose in addition to standard therapy
89542499|NCT04854681|Experimental|TQB2928 injection|Dose Escalation: intravenous (IV) infusion of TQB2928 as monotherapy
89542500|NCT02607735|Experimental|SOF/VEL/VOX (Primary Study)|SOF/VEL/VOX for 12 weeks
89542501|NCT02607735|Experimental|Placebo (Primary Study)|Placebo to match SOF/VEL/VOX for 12 weeks
89542502|NCT02607735|Experimental|SOF/VEL/VOX (Deferred Treatment Substudy)|SOF/VEL/VOX for 12 weeks for eligible participants initially randomized to receive placebo
89542503|NCT04772313|Experimental|Pegloticase plus Methotrexate (MTX)|Pegloticase (8 mg) intravenous (IV) every two weeks. Methotrexate (15 or 25 mg weekly) SC.
89024742|NCT00473499|Active Comparator|Cypher stent|
89542504|NCT04770285|Other|Digital Therapeutic A|Digital Therapeutic Version A
89542505|NCT04770285|Other|Digital Therapeutic B|Digital Therapeutic Version B
89542506|NCT04769973||Work Packages 1 - 3|"Work Package 1: Interviews with 15-20 people with Parkinson's and 15-20 caregivers.~Work Package 2: National Survey with up to 2000 participants~Work Package 3: Two to four Focus Groups with key stakeholders (6-10 participants per focus group)"
89542507|NCT04836663|Experimental|TQ-B3525 tablet|
89542508|NCT04836741|Experimental|Micro Hand S robot-assisted surgery|This group is consisted of 40 cases performed using the Micro Hand S robot by one single surgeon for rectal cancer
89542509|NCT04836741|Active Comparator|Laparoscopic surgery|This group is consisted of 65 cases performed using the laparoscope by one single surgeon for rectal cancer
89542510|NCT03040791|Experimental|Nivolumab|All patients will receive Nivolumab 240 mg every 14 days until progression or unacceptable toxicity
89542511|NCT04429113||G1 or Early Group|Patients treated before age 7 (Quad Helix on decidual second molars)
89542512|NCT04429113||G2 or Late Group|Patients treated between 7 and 13 years old (Quad Helix on first permanent molars)
89542513|NCT04854525||One Stage Reconstruction With pre-reconstruction Radiotherapy|
89542514|NCT04854525||Two Stage Reconstruction With pre-reconstruction Radiotherapy|
89542515|NCT04854525||Autologous Reconstruction With pre-reconstruction Radiotherapy|
89542516|NCT04854525||One Stage Reconstruction Without pre-reconstruction Radiotherapy|
89542517|NCT04854525||Two Stage Reconstruction Without pre-reconstruction Radiotherapy|
89542518|NCT04854525||Autologous Reconstruction Without pre-reconstruction Radiotherapy|
89542519|NCT03039855|Experimental|Treatment|Transcatheter mitral valve replacement with the TIARA valve and transapical delivery system
89542520|NCT04428879|Experimental|Phase I single arm trial|
89542521|NCT04836819|Active Comparator|Group L|IV lidocaine infusion (1-2 mg/kg/h) up to postoperative 12 hours.
88811705|NCT01377623|Placebo Comparator|Placebo group|Eligible subjects will be randomized to one of the two treatment group in1:1 ratio to receive either DEX or matching placebo (PBO, LR).
88811706|NCT01377623|Experimental|Dexmedetomidine group|Eligible subjects will be randomized to one of the two treatment group in1:1 ratio to receive either DEX or matching placebo (PBO, LR).
88811707|NCT01479725|Experimental|Ulcerative IC|HBOT for ulcerative IC
88811708|NCT01479725|Experimental|Non-Ulcerative IC|HBOT for non-ulcerative IC
88811709|NCT01481129|Experimental|Treatment (Akt inhibitor MK2206)|Patients receive Akt inhibitor MK2206 PO once weekly on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88811710|NCT03008447|Experimental|LEM5; LEM10; PBO; ZOL|Participants will receive LEM5 (one lemborexant [LEM] 5 milligram [mg] tablet and one zolpidem [ZOL]-matched placebo [PBO] tablet) in Treatment Period 1. In Treatment Period 2, participants will receive LEM10 (one LEM 10 mg tablet and one ZOL-matched PBO tablet). In Treatment Period 3, participants will receive PBO (one LEM-matched PBO tablet and one ZOL-matched PBO tablet). In Treatment Period 4, participants will receive ZOL (one LEM-matched PBO tablet and one ZOL 6.25 mg tablet).
88811711|NCT03008447|Experimental|LEM10; ZOL; LEM5; PBO|Participants will receive LEM10, ZOL, LEM5, and PBO in Treatments Periods 1, 2, 3, and 4, respectively.
88811712|NCT03008447|Experimental|ZOL; PBO; LEM10; LEM5|Participants will receive ZOL, PBO, LEM10, and LEM5 in Treatment Periods 1, 2, 3, and 4, respectively.
89542522|NCT04836819|Active Comparator|Group K|IV ketamine infusion (0.3-0.5 mg/kg/h) up to postoperative 12 hours.
89542523|NCT04836819|Active Comparator|Group D|IV dexmedetomidine infusion (0.3-0.5 mg/kg/h) up to postoperative 12 hours.
89542524|NCT04836507|Experimental|CRC01|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by investigational treatment, CRC01.
89542525|NCT03039933|Active Comparator|Fear of Hypoglycemia Intervention|Cognitive behavioral therapy based psychological intervention occurring every other week for 12 weeks.
89542526|NCT03039933|Other|Treatment As Usual|Control group completes questionnaires but does not receive any study intervention. Receives medical care as usual.
89542527|NCT04853745||sodium bicarbonate group|Sodium bicarbonate-based powder (CLASSIC®, EMS SA, Nyon, Switzerland) was used for air polishing the samples belonging to this group. All surfaces were numbered and application was made to the mesial and distal surfaces of the root, buccal and lingual surfaces of the crown to avoid repeated instrumentations. After device and samples were fixed, a metal plate with a 5 mm diameter hole was placed on the sample to limit the application area. Surfaces one and three were air-polished using the with a medium power setting (9 LED power setting), and surfaces two and four were air-polished using the with a maximum power setting (17 LED power setting). The distance between the handpiece and the tooth surface was kept constant at 5 mm, and the treatment angulation was adjusted to 60 degrees. In all applications, the application time was 5 seconds and the water setting was medium (6 LED). The powder chambers of the device were filled to the maximum level in each application.
89542528|NCT04853745||glycine group|Glycine-based powder (PERIO®, EMS SA, Nyon, Switzerland) was used for air polishing the samples belonging to this group. All surfaces were numbered and application was made to the mesial and distal surfaces of the root, buccal and lingual surfaces of the crown to avoid repeated instrumentations. After device and samples were fixed, a metal plate with a 5 mm diameter hole was placed on the sample to limit the application area. Surfaces one and three were air-polished using the with a medium power setting (9 LED power setting), and surfaces two and four were air-polished using the with a maximum power setting (17 LED power setting). The distance between the handpiece and the tooth surface was kept constant at 5 mm, and the treatment angulation was adjusted to 60 degrees. In all applications, the application time was 5 seconds and the water setting was medium (6 LED). The powder chambers of the device were filled to the maximum level in each application.
89542529|NCT04853745||erythritol group|Erythritol-based powder (PLUS®, EMS SA, Nyon, Switzerland) was used for air polishing the samples belonging to this group. All surfaces were numbered and application was made to the mesial and distal surfaces of the root, buccal and lingual surfaces of the crown to avoid repeated instrumentations. After device and samples were fixed, a metal plate with a 5 mm diameter hole was placed on the sample to limit the application area. Surfaces one and three were air-polished using the with a medium power setting (9 LED power setting), and surfaces two and four were air-polished using the with a maximum power setting (17 LED power setting). The distance between the handpiece and the tooth surface was kept constant at 5 mm, and the treatment angulation was adjusted to 60 degrees. In all applications, the application time was 5 seconds and the water setting was medium (6 LED). The powder chambers of the device were filled to the maximum level in each application.
89542530|NCT04836351|Experimental|Concentrated rehabilitation|3+ 1-2 day concentrated rehabilitation for patients with persistent symptoms post COVID-19.
89542531|NCT04372329|Experimental|CPAP4HealthySleep: System 1 (ABAB)|Participants in this group will first receive six tailored educational messages per week and weekly feedback messages notifying participants of their CPAP usage on the seventh day for two weeks (type A). Next, they will receive weekly feedback messages only (one message per week) notifying participants of their CPAP usage for two weeks (type B), re-introduction of type A for another two weeks, followed by re-introduction of type B for two weeks.
89542532|NCT04372329|Experimental|CPAP4HealthySleep: System 2 (BABA)|Participants in this group will first receive weekly feedback messages only (one message per week) notifying participants of their CPAP usage for two weeks (type B). Next, they will receive six tailored educational messages per week and weekly feedback messages notifying participants of their CPAP usage on the seventh day for two weeks (type A), re-introduction of type B for another two weeks, followed by re-introduction of type A for two weeks.
89542533|NCT04841733|Experimental|Protocol I: Foam Roller (FR) + Cold-Water Immersion (CWI)|Foam Roller (FR) Cold-Water Immersion (CWI)
89542534|NCT04841733|Experimental|Protocol II: Stretching (STR) + Cold-Water Immersion (CWI)|Stretching (STR) Cold-Water Immersion (CWI)
89542535|NCT04841733|Experimental|Protocol III: Foam Roller (FR) + Stretching (STR)|Foam Roller (FR) Stretching (STR)
89542536|NCT04841733|Experimental|Protocol IV: Foam Roller (FR) + Stretching (STR) + Cold-Water Immersion (CWI)|Foam Roller (FR) Stretching (STR) Cold-Water Immersion (CWI)
89542537|NCT04835883|Experimental|Assigned interventions|Subjects enrolled into the CS20AT04 with corticosteroid taper regimen arm will receive two infusions of CS20AT04 (2.0×10^6cell/kg), on 0 day and on 12 weeks post-enrollment.
89542538|NCT04841421|Experimental|89Zr-CD147 1mCi±10% 10mg dose group|The activity administered was 1mCi±10% and the mass of radiolabeled CD147 was 10 mg.
89542539|NCT04841421|Experimental|89Zr-CD147 3mCi±10% 10mg dose group|The activity administered was 3mCi±10% and the mass of radiolabeled CD147 was 10 mg.
89542540|NCT04841421|Experimental|89Zr-CD147 5mCi±10% 10mg dose group|The activity administered was 5mCi±10% and the mass of radiolabeled CD147 was 10 mg.
89542541|NCT04835259|Active Comparator|Group 1(treatment group)|"Topical application of a cream of a combination of antioxidants once daily at night for 6 months Name: Selenium ACE cream (Interpharma UK company, Egypt)~Ingredients:~Selenium (Selenium amino acid chelate) 0.5% Vitamin C (Sodium ascorbyl phosphate - stay C) %1 Vitamin E (Tocopheryl acetate) % 0.5 Vitamin A (Retinyl palmitate) %1 Emulsifiers ( Ceteareth 20 , Glycerol monostearate , Cetyl alcohol) Emollient(Caprylic capric triglycerides)"
89542542|NCT04835259|Active Comparator|Group 2 (positive control)|Topical application of a retinoid (tretinoin 0.05%) cream once daily at night for 6 months (Acretin 0.05% cream Jamjoom pharmaceuticals, Egypt)
88811713|NCT03008447|Experimental|PBO; LEM5; ZOL; LEM10|Participants will receive PBO, LEM5, ZOL, and LEM10 in Treatment Periods 1, 2, 3, and 4, respectively.
88811714|NCT01486043|Experimental|Metformin and insulin therapy|Up to 30-40 patients will be in the prospectively recruited treatment group, which will receive both metformin and insulin therapy for transient hyperglycemia
89542543|NCT04835259|Placebo Comparator|Group 3 (Negative control)|Topical application of a panthenol cream once daily at night for 6 months (panthenol 2% cream, El Nile company, Egypt)
89542544|NCT04853901|Experimental|Remdesivir|Remdesivir loading dose of 200 mg intravenously followed by 100 mg/day intravenously for 5 to 10days + Methylprednisolone 1-2mg/kg for 5-7 days
89542545|NCT04853901|Active Comparator|Standard of care therapy|Hydroxycoloroquine 400mg twice on day 1 then 200mg tab twice 2-10 days + Methylprednisolone 1-2mg/kg for 5-7 days
89542546|NCT04853823|Experimental|PDC-APB|Study duration for each subject is approximately 15 weeks (105 days) for Screening including patch testing, Treatment, and the initial 30-day post-treatment periods. Approximately 6 weeks after treatment, subjects will receive a second patch test. In addition, each subject will be followed from T1 for 6 months by monthly telephone follow-up to monitor adverse events. Subjects in Cohorts 2, 3 and 4 and, if applicable, additional cohorts, will not be dosed until all subjects from the prior cohort have completed the assessments after IP dosing and the Safety Review Committee has reviewed the results prior to Day T14. All subjects will be followed for 6 months after IP dosing for safety assessments, which will be carried out at monthly intervals via telephone.
89542547|NCT04853823|Placebo Comparator|Vehicle|Study duration for each subject is approximately 15 weeks (105 days) for Screening including patch testing, Treatment, and the initial 30-day post-treatment periods. Approximately 6 weeks after treatment, subjects will receive a second patch test. In addition, each subject will be followed from T1 for 6 months by monthly telephone follow-up to monitor adverse events. Subjects in Cohorts 2, 3 and 4 and, if applicable, additional cohorts, will not be dosed until all subjects from the prior cohort have completed the assessments after IP dosing and the Safety Review Committee has reviewed the results prior to Day T14. All subjects will be followed for 6 months after IP dosing for safety assessments, which will be carried out at monthly intervals via telephone.
89542548|NCT01668537|Experimental|Group 1|LF formulation of IMVAMUNE® 2 doses of 1 x 10E8 TCID50, s.c., 4 weeks apart
89542549|NCT01668537|Experimental|Group 2|FD formulation of IMVAMUNE® 2 doses of 1 x 10E8 TCID50, s.c., 4 weeks apart
89542550|NCT03039387|Active Comparator|anodal tDCS|transcranial direct current stimulation of the left dlPFC with 1mA
89542551|NCT03039387|Placebo Comparator|Sham stimulation|Double blind sham stimulation (stimulation will be ramped down after 30 sec.)
89542552|NCT04836039||Physiotherapists|Individuals between the ages of 22-65 who continue to work as a self-employed or employee physiotherapist.
89542553|NCT03039465|Experimental|Modified Trans-Esophageal Prosthesis|Patients satisfying the selection criteria would be subjected to the insertion of the TEP and evaluated at subsequent time points for the success of the procedure.
89542554|NCT04841031|Experimental|NET Treatment|Narrative Exposure Therapy (NET) Treatment: Treatment group consists of eligible individuals who are randomly assigned to receive NET treatment and are part of the study sample. Within each health center, treated individuals are randomly selected over several cohorts. In every cohort, the treatment group contained 6 individuals who received NET.
89542555|NCT04841031|Other|Control|This group contains eligible individuals who are randomly assigned to the control group and are part of the study sample. In every cohort, the control group contained 6 individuals.
89542556|NCT04834947||Prone position in non-intubated COVID19 , before and after.|Patients with non-intubated COVID19 pneumoniae for whom the clinician has decided to try prone positioning to increase the PaO2 in a context of hypoxemia with O2 requirement.
89542557|NCT04834791|Experimental|Letrozole|These patients were treated with letrozole (Femara®, Novartis New York, NY, USA) in a dose 2.5 mg (one tablet daily) orally began on the 3rd day to the 7th day of the cycle. If ovulation is not achieved dose is increased by 2.5 mg in next cycle till 3 cycles.
89542558|NCT04834791|Active Comparator|Gonadotropins|These patients were given urofollitropin (fostimon ®, IBSA, Lugano, Switzerland) in a dose of 75 IU/mL I.M from day 3rd to day 7th of the cycle beginning by one ampoule per day and the dose had been modulated according to response.
89542559|NCT04835181|Experimental|Electroacupuncture combined with umbilical moxibustion|
89542560|NCT04835181|Active Comparator|Electroacupuncture|
89542561|NCT03036969||Non-urgent emergencies|Outpatients in the Emergency Department with the MTS-Triage category blue, green or yellow
89542562|NCT03039231|Experimental|Freespira Breathing System (FBS)|The Freespira Breathing System (FBS) developed by Palo Alto Health Sciences, Inc, is a portable home device used for breathing biofeedback in adults with panic disorder (PD). FBS has received FDA clearance for the treatment of PD adults and is currently commercially available with more than 150 therapist providing the treatment nationally. FBS has not yet been tested for efficacy in an adult post traumatic stress disorder (PTSD) population. It has been suggested that there is overlap in the presence and persistence of symptoms between PD and PTSD patients. The primary goal of this study is to determine whether the FBS will produce similar benefit (both in quality and magnitude) in the defined population of patients with PTSD.
89542563|NCT04835025||Control group (radiotherapy group)|In non-small cell lung cancer, patients with brain metastases received radiotherapy for brain lesion (without limitation of dose and treatment method for radiotherapy) , but not receiving immunotherapy. Those patients would enter the control group. After patients experiencing disease progression(PD) in this group, follow-up treatment does not include immunotherapy until tumor progression again or death.
89542564|NCT03038919|Experimental|Anabolic patients|Intramuscular injection of testosterone cypionate 200mg every 15 days in addition to standard nutrition and physical therapy at ICU.
89542565|NCT03038919|Other|Control|Standard nutrition and physical therapy at ICU without administration of testosterone cypionate
89542566|NCT04852263|Other|Group I|Fiberoptic intubation was carried out without nasopharyngeal airway
88960771|NCT04316572|No Intervention|treatment as usual by the GP|Routine treatment by the GP, which may or may not include conversations about psychosocial problems and/or referral to specialised services (e.g., inpatient therapy, counseling, self-help).
89024743|NCT00473499|Placebo Comparator|Coroflex Blue stent|
89542567|NCT04852263|Other|Group II (NPA group)|Fiberoptic intubation was performed with a modified nasopharyngeal airway.
89542568|NCT04794153|Experimental|Pork|Locally sourced
89542569|NCT04794153|Experimental|Salmon|Locally sourced
89542570|NCT04794153|Experimental|Mycoprotein|Provided by Marlow Foods
89542571|NCT04794153|Experimental|Lentils|Red
89542572|NCT04794153|Experimental|Egg|Local supplier
89542573|NCT04794153|Active Comparator|Egg whites|Local Supplier
88960772|NCT04302727|Experimental|Med-South Weight Loss Intervention|The intervention will be delivered in 3 phases over 24 months: Phase I (4 months) provides a foundation for adopting and maintaining a healthful dietary pattern (Med-style, tailored for the southeastern United States); Phase II (8 months) focuses on weight loss; and Phase III (12 months) on maintenance of or continued weight loss, as appropriate.
89542574|NCT04852341||Corneal horizontal diameter ≤9.00mm group|
89542575|NCT04852341||Corneal horizontal diameter 9.00mm~9.50mm group|
89542576|NCT04852341||Corneal horizontal diameter 9.50mm~10.00mm group|
89542577|NCT04852341||Corneal horizontal diameter >10.00mm group|
89542578|NCT04833543|Active Comparator|Tilt Table|
89542579|NCT04833543|Experimental|Robotic Mobility Device (REX)|
89542580|NCT04834713||Mild patients|defined as patients who had kidney injury without oliguria and hypotension
89542581|NCT04834713||moderate patients|defined as patients who had uremia, effusion (bulbar conjunctiva), hypotension, hemorrhage (skin and mucous membranes), and AKI with typical oliguria
89542582|NCT04834713||severe patients|defined as patients who had severe uremia, effusion (bulbar conjunctiva and either peritoneum or pleura), hemorrhage (skin and mucous membranes), hypotension and AKI with oliguria (urine output of 50-500 mL/day) for ≤ 5 days or anuria (urine output of < 100 mL/day) for ≤ 2 days
89542583|NCT04834713||critical patients|defined as patients who usually had one or more of the following complications compared with the severe patients: refractory shock (≥ 2 days), visceral hemorrhage, heart failure, pulmonary edema, brain edema, severe secondary infection, and severe AKI with oliguria (urine output of 50-500 mL/day) for > 5 days or anuria (urine output of < 100 mL/day) for > 2 days
89542584|NCT04834713||healthy control|defined as people without HFRS
89542585|NCT04833621|Active Comparator|NMES GROUP|NMES TREATMENT AND PHYSICAL TREATMENT
89542586|NCT04833621|Active Comparator|CONTROL GROUP|JUST PHYSICAL TREATMENT
89542587|NCT03036891|Experimental|Study Group|Naloxegol 25 mg, oral tablet, daily for 4 weeks
89542588|NCT03036891|Placebo Comparator|Placebo Control|Placebo Oral Tablet, 25 mg, oral tablet, daily for 4 weeks
89542589|NCT04834323|Active Comparator|group (1)|included 42 patients who were subjected to distal mesogastric fixation after laparoscopic sleeve gastrectomy
89542590|NCT04834323|No Intervention|group (2)|included 42 patients who were subjected to laparoscopic sleeve gastrectomy alone without distal mesogastric fixation
89542591|NCT04851951||patients treated by one-shot PRP injection|
89542592|NCT04851561||Cases|Adults recovered from COVID-19 (diagnosed using a polymerase chain reaction test from a nasopharyngeal sample), cases will be defined as such if fulfill for the following criteria: individuals who report on lasting fatigue symptoms which appeared following COVID-19, while at least two months have elapsed since COVID-19 diagnosis and the lasting fatigue symptoms are present for at least six weeks.
89542593|NCT04851561||Controls|Adults recovered from COVID-19 (diagnosed using a polymerase chain reaction test from a nasopharyngeal sample), did not report fatigue symptoms at any time point following their diagnosis with COVID-19.
89542594|NCT01668147|Experimental|Control|Session 1: Control (no pretreatment) - IV 10-14 mCi of [11C] desmethyl-loperamide (dLop) with PET/CT imaging
89542595|NCT01668147|Active Comparator|Oral ritonavir|Session 2: Pretreatment with oral ritonavir for 3 days followed by IV 10-14 mCi of [11C]dLop with PET/CT imaging
89542596|NCT01668147|Active Comparator|Oral efavirenz|Session 3: Pretreatment with oral efavirenz for 14 days followed by IV 10-14 mCi of [11C]dLop with PET/CT imaging
89542597|NCT04851639|Experimental|Proof of principle|Proof of principle of the efficacy and utility of the WATapp
89542598|NCT04833777|Active Comparator|Lidocaine|Administration of subcutaneous lidocaine as local anesthetic prior to carpal tunnel release (lidocaine intervention)
89542599|NCT04833777|Experimental|Bupivacaine|Administration of subcutaneous bupivacaine + lidocaine as local anesthetic prior to carpal tunnel release (bupivacaine intervention)
89542600|NCT03037047|Placebo Comparator|Control group|patients will be treated by 0.9% sodium chloride injection on the basis of conventional therapy for 14 days.
89542601|NCT03037047|Experimental|Experimental group|patients will be treated by salvianolate injection on the basis of conventional therapy for 14 days.
89542602|NCT04323735|Active Comparator|Low Dosage|"For the LGG® instillation, participants will be instructed to mix the contents of 1 LGG capsule into 45 cc sterile 0.9% saline. After mixing, participants will draw up the 45cc liquid LGG mixture into a 60cc syringe and instill via the indwelling catheter (the catheter will not be changed as this would represent 2 interventions). Participants will be instructed the plug their catheter for 1 hour. Participants will receive 2 ]LGG capsules and will repeat this process the following day (Low dose). Subjects will remain in the study for up to 29 months, with participation ending after one completed intervention (2 doses) and post-intervention assessments are complete. If urinary symptoms do not occur warranting instillation during the ensuing 29 months, participants will be asked to return any remaining kits (including LGG®). Participants will be instructed to complete the USQNB-IDC weekly until study completion."
89024744|NCT00435383||Observational|Group 1 received a presurgical caudal block and group 2 received a intravenous narcotics.
89024745|NCT00465465|Active Comparator|1|Dose of 1 x 10^7
89542603|NCT04323735|Active Comparator|High dosage|"For the LGG® instillation, participants will be instructed to mix the contents of 1 LGG capsule into 45 cc sterile 0.9% saline. After mixing, participants will draw up the 45cc liquid LGG mixture into a 60cc syringe and instill via the indwelling catheter (the catheter will not be changed as this would represent 2 interventions). Participants will be instructed the plug their catheter for 1 hour. Participants will receive 4 LGG capsules and will repeat this process the following day twice for a total of four doses (High dose). Subjects will remain in the study for up to 29 months, with participation ending after one completed intervention (4 doses) and post-intervention assessments are complete. If urinary symptoms do not occur warranting instillation during the ensuing 29 months, participants will be asked to return any remaining kits (including LGG®). Participants will be instructed to complete the USQNB-IDC weekly until study completion."
89542604|NCT04833231||High eGFR group (eGFR ≥60 mL/ min/1.73 m2)|Patients with estimated glomerular filtration rate (eGFR) ≥60 mL/ min/1.73 m2 as high eGFR group
89542605|NCT04833231||Low eGFR group (eGFR <60 mL/min/1.73 m2)|Patients with estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2 as low eGFR group
89542606|NCT03036501|Experimental|[^14C]-Risdiplam|Participants will be administered with [^14C]-Risdiplam solution orally under fasted conditions on Day 1.
89542607|NCT03036345|Experimental|Surgery patients|Patients receiving shoulder surgery in the Beach Chair Position, and monitored by both INVOS and FORE-SIGHT monitors.
89542608|NCT03036189|Experimental|Intervention arm|There are no devices or drugs used in this trial. The treatment is the same for the intervention arm and the wait-list control arm. The treatment is group trial of 7 meetings designed to improve chronic illness self-management. The name of the treatment is baa nnilah.
89542609|NCT03036189|Experimental|Wait-list control arm|There are no devices or drugs used in this trial. The treatment is the same for the intervention arm and the wait-list control arm. The treatment is group trial of 7 meetings designed to improve chronic illness self-management. The name of the treatment is baa nnilah.
89542610|NCT04832997|Experimental|mpMRI plus Micro-US|Patients with a clinical suspicion of csPCa will receive mpMRI and Micro-US in two different visits (randomized sequence). The results of the diagnostic procedures will determine how many and which type of prostate biopsies patients will undergo.
89542611|NCT04834089|Experimental|Experimental product group (Stage A)|Anti-SARS-CoV-2 Serum Dose: 5 mL/dose or 10 mL/dose Administration Route: Intravenous
89542612|NCT04834089|Placebo Comparator|Placebo group (Stage C)|Saline solution Administration Route: Intravenous
89542613|NCT04834089|Experimental|Experimental product group (Stage B)|Anti-SARS-CoV-2 Serum Dose: 5 mL/dose or 10 mL/dose Administration Route: Intravenous
89542614|NCT04834089|Experimental|Experimental product group (Stage C)|Anti-SARS-CoV-2 Serum Dose: 5 mL/dose or 10 mL/dose Administration Route: Intravenous
89542615|NCT04834245|Experimental|hydrogel/nano silver-based dressing|hydrogel/nano silver-based dressing
89542616|NCT04851093|Experimental|TCM granule plus conventional drug|The experimental group will receive three types of TCM granule and conventional drug according to 2020 Global Initiative for Chronic Obstructive Lung Disease (GOLD) and Chinese Medicine Diagnosis Treatment Guidelines.
89542617|NCT04851093|Placebo Comparator|TCM placebo granule plus conventional drug|The control group will receive three types of TCM placebo granule and conventional drug according to 2020 Global Initiative for Chronic Obstructive Lung Disease (GOLD) and Chinese Medicine Diagnosis Treatment Guidelines.
89542618|NCT04851171|Active Comparator|Semi-rigid Ureteroscopy|Patient with upper ureteric stone who are randomized in this arm will undergo semi-rigid ureteroscopy for treatment of the stone.
88960773|NCT04302727|Active Comparator|Augmented Usual Care (WW)|The intervention that will be offered to control group participants is WW™ (formerly known as Weight Watchers). The study will provide access to the 'Workshop + Digital' option of WW™ during the 2 year intervention.
88960774|NCT04299646|Experimental|Steretactic radiotherapy plus systemic treatment|
88960775|NCT04299646|Active Comparator|Systemic treatment|
89542619|NCT04851171|Active Comparator|Flexible Ureteroscopy|Patient with upper ureteric stone who are randomized in this arm will undergo flexible ureteroscopy for treatment of the stone.
89542620|NCT04851015|Experimental|Reduced dose TMP-SMX|Trimethoprim-Sulfamethoxazole at a total dose of 10mg/kg/day. Oral or intravenous drug will be administered at discretion of treating team. This will be given as a dose of 10mg/kg/day open label with additional placebo tablets or intravenous placebo solution given to simulate 15mg/kg/day. All doses will be adjusted for obesity and renal function.
89542621|NCT04851015|Active Comparator|Standard dose TMP-SMX|Trimethoprim-Sulfamethoxazole at a total dose of 15mg/kg/day. Oral or intravenous drug will be administered at discretion of treating team. This will be given as 10mg/kg/day open label plus an extra masked 5mg/kg/day of tablets or intravenous solution. All doses will be adjusted for obesity and renal function.
89542622|NCT04365933|Experimental|Arm 1|EYP001a Dose A QD + ETV 0.5 mg QD + peg-IFN dosed per body surface area (180 µg, 135 µg or 90 µg) QW
89542623|NCT04365933|Experimental|Arm 2|EYP001a Dose A QD + peg-IFN dosed per body surface area (180 µg, 135 µg or 90 µg) QW
89542624|NCT04832451|Experimental|Intervention Group|"The Beck Depression Inventory[BDI] (inclusion criteria) was applied face to face to the students who constituted the population (n=385). After the BDI scores were evaluated, the students who met the inclusion criteria were randomly assigned to the intervention and control groups.~In a preliminary interview held with the intervention group (n=10), they were informed about the subject of the research, the duration and content of the implementation process, session rules, and that sessions would be audio-recorded. Informed consent forms were obtained from them, and pre-tests (BDI, Coping Styles Inventory[CSI]) were applied.~A total of 21 90-minute Interpersonal Relational Role Analysis (IRRA) sessions (two sessions a week) were held with the intervention group.~21 sessions of IRRA were applied to the intervention group, once the sessions were completed, post-tests (BDI, CSI) were applied. Three months later, a follow-up test (BDI, CSI) was applied to intervention group."
88960776|NCT04298606|Experimental|Prevention (recombinant human EGF-rP64K/montanide ISA 51)|"LOADING PHASE: Patients receive recombinant human EGF-rP64K/montanide ISA 51 vaccine IM at 0, 2, 4 and 6 weeks in the absence of disease progression or unacceptable toxicity.~MAINTENANCE PHASE: Patients receive recombinant human EGF-rP64K/montanide ISA 51 vaccine IM Q4W in the absence of disease progression or unacceptable toxicity."
88960777|NCT04275869|Experimental|Experimental Healthy Lifestyle|A 3-month internet-based program focusing on the promotion of healthy lifestyles. The treatment protocol comprises 9 modules which incorporate psychological strategies to promote healthy lifestyles by gradually changing eating and physical activity habits.
88960778|NCT04275869|No Intervention|Control Group|Control group will receive the standard treatment which consists of regular gynaecological visits; the Reproduction Service gynaecologists will recommend healthy lifestyle habits and give the patients a document detailing a specific diet they should follow for weight loss.
89542625|NCT04832451|No Intervention|Control Group|The students in the control group were informed about the research, informed consents were obtained from them, and pre-tests (Beck Depression Inventory, Coping Styles Inventory) were applied to them. No intervention was applied to the control group (n=10). Once the Interpersonal Relational Role Analysis sessions were completed, post-tests (Beck Depression Inventory, Coping Styles Inventory) were applied to the control group. Three months later, a follow-up test (Beck Depression Inventory, Coping Styles Inventory) was applied to control groups. After the follow-up test, the participants in the control group were referred to the psychological support unit of the university.
89542626|NCT04825119||MND patients|Patients with ''clinically definite ALS'' or ''clinically probable ALS'' or ''clinically probable ALS - laboratory supported'' according to the revised El Escorial diagnostic criteria or with the diagnosis of PMA or PLS will be included.
89542627|NCT04825119||SMA patients|SMA patients type I, II, III, and IV will be included.
89542628|NCT04824573|Experimental|Inspiratory Muscle Training (IMT)|The program of the IMT group (n=16) consists of individual sessions of approximately 20 minutes and the Powerbreathe device (IMT Technologies Ltd., Birmingham) was used for training.
89542629|NCT04824573|Experimental|Manual Therapy|In the manual therapy group (n=19), in addition to the approaches applied to the individuals in the IMT group, a total of eight sessions of manual therapy (manipulation, joint mobilization, and soft tissue mobilization) approaches, two days a week for four weeks and at least two days between sessions, were applied by an experienced physiotherapist in manual therapy. Manual therapy applications; included techniques targeting the cervical and thoracic regions. Techniques for the thoracic region; while it consists of manual diaphragm release, thoracic mobilization and High Velocity Low Amplitude (HVLA) thrust manipulation; the techniques applied to the cervical region consisted of soft tissue and joint mobilization.
89542630|NCT04824339|Experimental|Immediate Intervention Group|The intervention is an 8-week combined aerobic and resistance program, with virtual, group-based, supervised exercise sessions twice per week (60 min). The intervention also includes optional education on healthy eating.
89542631|NCT04824339|Experimental|Delayed Intervention Group|Usual lifestyle control for 8 weeks and then invited to participate in the exercise intervention.
89542632|NCT04824495||Patients with acute COVID-19|
89542633|NCT04378569|Active Comparator|ARQ-252 cream 0.3% QD (once daily)|Active Comparator
89542634|NCT04378569|Active Comparator|ARQ-252 cream 0.3% BID (twice daily)|Active Comparator
89542635|NCT04378569|Active Comparator|ARQ-252 cream 0.1% QD (once daily)|Active Comparator
89542636|NCT04378569|Placebo Comparator|Vehicle cream BID (twice daily)|Placebo Comparator
89542637|NCT04378569|Placebo Comparator|Vehicle cream QD (once daily)|Placebo Comparator
89542638|NCT04832217|Experimental|Pyrenees' beef group|"In the first period, 24 participants were randomly assigned to a beef (Pyrenees' beef group).~In the second period, 23 participants were randomly assigned to a beef (Pyrenees' beef group)."
89542639|NCT04832217|No Intervention|Conventional Chicken group|"In the first period, 23 participants were randomly assigned to a conventional chicken-based group (control group).~In the second period, 24 participants were randomly assigned to a conventional chicken-based group (control group)."
89542640|NCT04824261|Active Comparator|group 1|randomized 50 otomycosis patients will receive Clotrimazol solution 1%
89542641|NCT04824261|Active Comparator|group 2|randomized 50 otomycosis patients will receive 4%boric acid in distilled water
89542642|NCT04831905|Experimental|Pilote study|Micro-wave ablation of index lesion identified on MRi on prostate cancer
89542643|NCT04823793||Healthy group : Stool specimens from participants with healthy colon|"Stool specimens will be collected from participants before having a colonoscopy.~If the participant's colon has a healthy colon without any cancerous lesion, the stool specimen will be included in the healthy group."
89542644|NCT04823793||Disease group : Stool specimens from participants with adenoma/colorectal cancer|"Stool specimens will be collected from participants before having a colonoscopy.~If the participant's colon has precancerous lesion, such as adenoma, the stool specimen will be included in the disease group.~Also, specimens from confirmed colorectal cancer patients are included in the disease group."
88960779|NCT04274140||Obese Pregnant Women|obese, BMI 30-50
88960780|NCT04274140||Normal weight pregnant women|normal weight, BMI 18.5-25
88960781|NCT04266938|Active Comparator|Prospective RAPID|The prospective RAPID arm will include all patients who meet inclusion criteria and who start BIC/F/TAF within 7 days of HIV diagnos
88960782|NCT04266938|Active Comparator|Prospective Non- RAPID|The prospective non-RAPID arm will include all patients identified as having new HIV diagnosis per health department records, but who failed to establish care at the 550 Clinic and begin BIC/F/TAF within one week of diagnosis
88960783|NCT04266938|Active Comparator|Retrospective Non- RAPID|The retrospective Non-RAPID arm will include historic controls who enrolled in the treatment program from 2012, when universal ART guidelines were implemented, until prior to the implementation of RAPID start of ART.
88960784|NCT04266041|Experimental|High-density EEG localization in epilepsy|High-density EEG will be used for brain localization in epilepsy patients
88960785|NCT04266041|Active Comparator|High-density EEG localization in healthy controls|High-density EEG will be used for brain localization in healthy controls
89542645|NCT04850235|Experimental|TPX neoadjuvant chemotherapy +CCRT|Patients receive neoadjuvant chemotherapy with Nab-PTX (150/175/200/225/250 mg/m2, D1) , cisplatin (75 mg/m2, D1) and capecitabine (1000 mg/m2, BID, D1-14) every three weeks for three cycles before radiotherapy, then followed by concurrent IMRT and cisplatin (100 mg/m2) concurrent every three weeks during radiotherapy (D1, D22, D43 of RT)
89542646|NCT03036033|Experimental|SaeboGlove Therapy|All participants will be given a SaeboGlove for a 4-week period to use along side their routine functional based training program.
89542647|NCT04850001||Patient Group|Asymptomatic intracranial stenosis patients who receive standard medical treatment without stenting
89542648|NCT04850001||Healthy Control|Healthy control are free from intracranial stenosis
89542649|NCT04823715||TACE- hypofractionated radiation therapy|Patients will receive one course of transarterial chemoembolization followed 1 to 4 weeks later by hypofractionated radiation therapy up to a total dose of 45 to 60 Gy, 3 Gy per fraction, 5 fractions per week, for an overall treatment time of 3 to 4 weeks.
89542650|NCT04823715||Surgical resection|Surgical resection by open-laparotomy or laparoscopy of hepatocellular carcinoma
89542651|NCT04823559|No Intervention|Usual practice|Usual practice
89542652|NCT04823559|Experimental|Intervention|Receives educational workshop
89542653|NCT03036111|Sham Comparator|Hemorrhoidectomy|Patients will undergo Millgan-Morgan hemorrhoidectomy as classically described before
89542654|NCT03036111|Active Comparator|trimebutine|Patients will undergo Millgan-Morgan hemorrhoidectomy then triembutine suppository will be inserted in the anal canal intraoperatively and then every six hours for 24 hours.
89542655|NCT04823325||Surgery patients|Otherwise healthy patients with Skeletal Class III problem
89542656|NCT04823169|Experimental|podobarometry|podobarometric measures at day7 and day 30
89542657|NCT04823013|Experimental|high power pain threshold ultrasound which the dose was kept constant group (HPPT-US 1)|Participants in HPPT-US 1 group received one session of HPPT-US treatment which the dose was kept constant. The technique delivers sound waves directly to the myofascial trigger points and results in immediate pain relief.
89542658|NCT04823013|Experimental|high power pain threshold ultrasound which the dose reduced to one half group (HPPT-US 2)|Participants in HPPT-US 2 group received one session of HPPT-US treatment which the dose reduced to one half. The technique delivers sound waves directly to the myofascial trigger points and results in immediate pain relief.
89542659|NCT04823013|Experimental|ischemic compression group|Participants in IC group received one session of ischemic compression therapy. Ischemic compression is a therapy technique used in manual therapy, where blockage of blood in an area of the body is deliberately made, so that a resurgence of local blood flow will occur upon release.
89542660|NCT04816695|Experimental|VOC analysis|VOC analysis in exhaled air in patients hospitalised for COPD exacerbation
89542661|NCT05617365|Experimental|Treatment|All subjects in the Treatment group will receive OMT a minimum 4 times and a maximum of 8 times at the physician's (JJR) discretion (Jull et al., 2002). All subjects in the Treatment group will be taught the THE. This voluntary head retraction/protrusion exercise protocol engages the RCPm muscles in eccentric and isometric contractions that should strengthen the muscles and thereby increase CSA.
89542662|NCT05617365|No Intervention|Control|All subjects assigned to the Control group will be allowed to continue to receive conservative care. It is understood that any care that they receive will be prescribed on an individual basis. A participant could therefore receive any combination of medical, physio therapeutic and psychological care. It would also be expected that some form of pain management will be a priority for participants with moderate to severe symptoms. Subjects assigned to the Control group will not receive OMT and will not be taught the THE protocol.
89542663|NCT04830579|Other|Sequence TR|17 subjects assigned to the sequence TR will receive a single 120 mg dose of the test product Etoricoxib (1 x 120 mg tablet), marked as T in the sequence, in Period 1 and a single 120 mg dose of the reference product Arcoxia® (1 x 120 mg tablet), marked as R in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
89542664|NCT04830579|Other|Sequence RT|17 subjects assigned to the sequence RT will receive a single 120 mg dose of the reference product Arcoxia® (1 x 120 mg tablet), marked as R in the sequence, in Period 1 and a single 120 mg dose of the test product Etoricoxib (1 x 120 mg tablet), marked as T in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
89542665|NCT04428021|Active Comparator|Standard therapy protocol (STP)|STP is defined as the best evidence based therapy approved for treatment of COVID-19 patients by Regional Health System emergency committee. STP could be updated during the trial.
89542666|NCT04428021|Experimental|STP + Standard Plasma (SP)|STP + 3 units on day 1-3-5 of Standard Plasma collected in pre-COVID era (January-September 2019)
89542667|NCT04428021|Experimental|STP + COVID-19 Convalescent Plasma (CP)|STP + 3 units on day 1-3-5 of COVID-19 Convalescent Plasma containing neutralizing SARS-Cov-2 antibodies
89542668|NCT04816461|Experimental|SMC+ roommates screening with standard HRP2-RDT and treatment with DHAPPQ if positive|SMC+ roommates screening with standard HRP2-RDT and treatment with DHAPPQ if positive
89542669|NCT04816461|Experimental|SMC+ roommates screening with highly sensitive RDT and treatment with DHAPPQ if positive|SMC+ roommates screening with highly sensitive RDT and treatment with DHAPPQ if positive
89542670|NCT04816461|Active Comparator|SMC alone|No roommates screening and treatment
89542671|NCT04427865|Experimental|Lactoferrin prophylaxis|200 mg oral lactoferrin daily
89542672|NCT04427865|No Intervention|Control group|
89542673|NCT02600559|Experimental|0.1 mL OTO-201|Ciprofloxacin
89542674|NCT04427943||RIKA cohort|patients with periprosthetic knee joint infection scheduled for revision knee arthroplasty surgery
89542675|NCT04822857||1|AMH > cut-off point
89542676|NCT04822857||2|AMH < cut-off point
89542677|NCT04822779|Active Comparator|Active Group|"This group will receive ultrasound therapy.~Respondents will conduct individual medical-gymnastics: unloading pendular exercises if strength exercises cannot be started immediately, shoulder range exercises, and rotator cuff and scapula stabilizer exercises for 30 minutes per treatment."
89542678|NCT04822779|Sham Comparator|Control Group|"This group will receive sham ultrasound therapy.~Respondents will conduct the same individual medical-gymnastics, as in the active group: unloading pendular exercises if strength exercises cannot be started immediately, shoulder range exercises, and rotator cuff and scapula stabilizer exercises for 30 minutes per treatment."
89542679|NCT04830657|Experimental|Distant reiki group|The application will be carried out by the researcher who has received level 2 reiki training. Reiki energy will be sent to the individuals who have undergone hemodialysis with the intention of healing. The Reiki practitioner is enabled to send the Reiki remotely in a quiet and lonely room. The practitioner moves to the right side of the individual, imagining as if he is next to the individual, and his aura (the energy that exists around the body) is corrected 3 times from above and from the head to the feet. The practitioner's hands are held side by side. Starting from the beginning of the application, reiki energy is sent to the 7 main chakras in an average of 3 minutes, from top to bottom. Each session is approximately 21-25 minutes. After the session, the chakra equalization process is applied to help the frequencies of the chakras to work in harmony with each other. 15 minutes in total. Balancing is done.
88960786|NCT04266041|Experimental|High-density EEG localization in tumor patients|High-density EEG will be used for brain localization in tumor patients
89542680|NCT04830657|Other|Control|Patients will receive routine treatment in accordance with the institution policy without any intervention in the control group.
88960787|NCT04266041|Experimental|High-density EEG localization in peripheral nerve patients|High-density EEG will be used for brain localization in patients with peripheral nerve dysfunction
88960788|NCT04266041|Experimental|High-density EEG localization in stroke patients|High-density EEG will be used for brain localization in patients who have recently experienced a stroke
88960789|NCT04261686|Other|COVERA Vascular Covered Stent|COVERA Vascular Covered Stent for the treatment of stenotic lesions in the upper extremity venous outflow of the arteriovenous (AV) access circuit of hemodialysis subjects dialyzing with an AV fistula.
88960790|NCT04254081|Experimental|Buprenorphine 0.15mg + 1% lidocaine paracervical block|Paracervical block with 18mL of 1% lidocaine buffered with 2 mL 8.4% sodium bicarbonate plus 0.15mg of buprenorphine
88960791|NCT04254081|Placebo Comparator|1% lidocaine paracervical block|Paracervical block with 18 mL of 1% lidocaine buffered with 2 mL 8.4% sodium bicarbonate
89542681|NCT04830189|Experimental|shoulder slings|Patients were used shoulder sling in addition to conservative treatment.
89542682|NCT04830189|Active Comparator|forearm sling|Patients were used forearm sling in addition to conservative treatment.
89542683|NCT04427787|Experimental|Cabozantinib+lanreotide|Cabozantinib will be administered orally at a dose of 60 mg/day continuously in combination with Lanreotide 120 mg injection every 28 days. Both treatments will start the same day
89542684|NCT04815915|Experimental|Study Group|Graston tool was used to treat patients 3 times in a week according protocol for 6 weeks' treatment plan with extensions bised exercises protocol following pattern of APTA.
89542685|NCT04816071|Experimental|EAA - non-vaccinated|18 g/day
89542686|NCT04816071|Placebo Comparator|Placebo - non-vaccinated|18 g/day
89542687|NCT04816071|Experimental|EAA - vaccinated|18 g/day
89542688|NCT04816071|Placebo Comparator|Placebo - vaccinated|18 g/day
89542689|NCT04822623||MS|
89542690|NCT04822623||NMOSD|
89542691|NCT04822623||Control|
89542692|NCT04829253|Experimental|b-DBT (Brief Dialectical Behavioral Therapy)|3 months of and intensive modified DBT intervention.
89542693|NCT04829253|Active Comparator|s-DBT (standard Brief Dialectical Behavioral Therapy)|6 months of a standard DBT intervention (this is a shorter version of the original 12-month DBT, but includes all four active components delivered over 6 months)
88960792|NCT04250948|Active Comparator|XELOX or SOX|"XELOX: Oxaliplatin+Capecitabine; SOX: Oxaliplatin+S-1~Oxaliplatin: 130mg/m2, iv drip for 2h, d1, q3w;~S-1:40~60mg Bid, d1~14, q3w;~Capecitabine: 1000mg/m2 Bid, d1-14, q3w;~Neoadjuvant chemotherapy for 3 cycles, adjuvant chemotherapy for 5 cycles."
89542694|NCT04822233|Experimental|Hall Technique (HT)|
89542695|NCT04822233|Experimental|Modified Hall Technique (MHT)|
89542696|NCT04822233|Active Comparator|Conventional Technique (CT)|
88960793|NCT04250948|Experimental|JS001+XELOX or SOX|"XELOX: Oxaliplatin+Capecitabine; SOX: Oxaliplatin+S-1~JS001: 240mg, ivdrip, d1, q3w;~S-1:40~60mg Bid, d1~14, q3w;~Capecitabine: 1000mg/m2 Bid, d1-14, q3w;~Neoadjuvant chemotherapy for 3 cycles, adjuvant chemotherapy for 5 cycles."
88960794|NCT04249609|Experimental|High Carbohydrate Meals Around Exercise|On day 1, high CHO dinner meal will provide 35% of participants total daily energy requirements. Meal will consist of pasta, meat ball and orange juice. On the day 2, participants will exercise for 60 minutes and then in 60 minutes will consume morning meal, providing 30% of their total daily energy requirements. Morning meal will consist of oats, skimmed-milk, banana and seedless raisins.
88960795|NCT04249609|Experimental|Low Carbohydrate Meals Around Exercise|On day 1, low CHO dinner meal will provide 35% of participants total daily energy requirements. Meal will based on burger, cheese, mushroom, nuts, and butter.On the day 2, participants will exercise fro 60 minutes and then in 60 will consume morning meal, providing 30% of their total daily energy requirements. Meal will consist of white bread, egg, cheese, olive oil, nuts, and olives.
89024746|NCT00465465|Active Comparator|2|Dose of 1 x 10^8
89024747|NCT00465543|Placebo Comparator|II|Arm 2 receives 4 weeks of placebo mint tea (consumed twice a day) followed by 4 weeks of washout and then a further 4 weeks of treatment with study mint tea (consumed twice a day).
89542697|NCT04822077|Experimental|Proton radiotherapy|"Proton radiotherapy with RBE doses:~Patients with radical surgery and unfavourable histology (B2, B3, C) and/or Masaoka-Koga stage III, IVa: 2 Gy(RBE), once daily, five days a week to a total dose of 50 Gy(RBE).~Patients with non-radical surgery (R1 resection) regardless of stage and histology: 2.3 Gy(RBE), once daily, 5 days a week to a total dose of 57.5 Gy(RBE)~Inoperable patients regardless of stage and histology and patients with R2 non-radical resection: 2.5 Gy (RBE), once daily, 5 days a week to a total dose of 62.5 Gy(RBE)"
89542698|NCT04815837|Experimental|Intervention|"Participants received the following interventions:~Viewing a video promoting Human Papillomavirus (HPV) vaccination~Receiving discount coupons~Visiting the project webpage~Receiving follow-up reminders"
89542699|NCT04829487|Experimental|Vitamin D|Vitamin D 50,000 IU orally weekly for 8 weeks
89542700|NCT04829487|Placebo Comparator|Placebo|Placebo capsules orally weekly for 8 weeks
89542701|NCT04815603|Experimental|BGE-117|BGE-117 Capsules (4mg or 12mg) to be taken by mouth once a day for 84 days.
89542702|NCT04815603|Placebo Comparator|Placebo|Placebo Capsules to be taken by mouth once a day for 84 days.
89542703|NCT04815447||CCS group|Patients under 25 were recruited in the pediatric CPET laboratory of Montpellier University Hospital after a regular paediatric cardiology outpatient visit.
89542704|NCT04815447||Control|The control group consisted in children referred for a non-severe functional symptom linked to exercise (murmur, palpitation, or dyspnoea) or for a medical sports certificate. These children were classified in the control group only after a completely normal check-up, including physical examination, electrocardiogram, echocardiography, and spirometry.
89542705|NCT04821765|Experimental|Chemoradiotherapy Combined With PD-1 Antibody|The arm received chemoradiotherapy, 50-60Gy (BED) was given (1.8-2 Gy or 3-4Gy once daily , 5 days a week) to recurrent sites combined with chemotherapy（Cisplatin 75 mg/m2/day 1, and albumin paclitaxel 150 mg/m2/day 1 , every 3 weeks, 2 cycles ).PD-1 antibody (Tislelizumab) was performed simultaneously with concurrent chemoradiotherapy (Triprizumab 200mg，d1，every 3 weeks，2 cycles). After completion of chemoradiotherapy, PD-1 antibody was given continuously with 2-4 cycles of chemotherapy (the same regimen with concurrent chemotherapy) until 1 year or desease progression.
89542706|NCT04829097|Experimental|SIB-IMRT|1. New auxiliary TMZ period: oral TMZ 75mg/m2, qd, continued until the beginning of radiotherapy. 2. Concurrent radiotherapy and chemotherapy period: 4 weeks in total. Prior to treatment, radiotherapy positioning and planning were established, using SIB-IMRT technology, the irradiation range, the tumor residual area 60Gy/20f/4w, the tumor bed area 40Gy/20f/4w, 1 time/d, 5 times/w. During radiotherapy, TMZ will continue to be administered orally simultaneously, the specific dose: TMZ 75mg/m2 qd, until 42 days. 3. Intermediate rest period: 4 weeks in total. ;4. TMZ adjuvant chemotherapy period: 6 to 12 months in total. Cycle 1: TMZ 150mg/m2, d1-5, q28d; if the patient can tolerate it, cycles 2-12: TMZ 200mg/m2, d1-5, q28d; after cycles 3, 6, 9, and 12 of adjuvant chemotherapy Head functional magnetic resonance examination was performed to assess the size of residual lesions and edema.
89542707|NCT04829097|Active Comparator|CRT|1. Concurrent radiotherapy and chemotherapy period: 6 weeks in total. Radiotherapy positioning and planning before treatment, using CRT technology, irradiation range, tumor bed area, 60Gy/30f/6w, 1 time/d, 5 times/w, simultaneous TMZ oral administration on the first day of radiotherapy, specific dose: TMZ 75mg/m2 qd for 42 consecutive days; head functional magnetic resonance imaging was performed at the end of radiotherapy to assess the size of residual lesions and edema. 2. Intermediate rest period: 4 weeks in total. The patient will go to the hospital to recheck blood routine every week;3. TMZ adjuvant chemotherapy period: 6 to 12 months in total. Cycle 1: TMZ 150mg/m2, d1-5, q28d; if the patient can tolerate it, cycles 2-12: TMZ 200mg/m2, d1-5, q28d; head functional magnetic resonance imaging was performed after adjuvant chemotherapy in cycles 3, 6, 9, and 12 to assess the size of residual lesions and edema.
89542708|NCT04829019|Active Comparator|whole-brain irradiation (WBI) plus Osimertinib|Osimertinib plus WBI, with Osimertinib at a dose of 80 mg once per day.
89542709|NCT04829019|Active Comparator|Osimertinib|Osimertinib with WBI sequential therapy, with Osimertinib at a dose of 80 mg once per day.
89542710|NCT04828941|Experimental|Electronic Headache Diary|The electronic headache diary registers: total number of days with headache per month, number of days with migraine per month, number of days with tension headache per month, number of days taking SOS medication per month, number of days with incapacity for work per month, number of days in which patient goes to the emergency department.
89542711|NCT04828941|Active Comparator|Paper Diary|The paper headache diary registers: total number of days with headache per month, number of days with migraine per month, number of days with tension headache per month, number of days taking SOS medication per month, number of days with incapacity for work per month, number of days in which patient goes to the emergency department.
89542712|NCT04815759||Pre pandemic|
89542713|NCT04815759||Post pandemic|
89542714|NCT04814979|Experimental|Experimental Group|Low-intensity pulsed ultrasound along with routine physical therapy
89542715|NCT04814979|Active Comparator|Control Group|Routine physical therapy alone
89542716|NCT04815135||2020 group (COVID19 group)|Patients who were admitted to the surgical ward via the emergency department during the lockdown period due to the COVID19 pandemic
89542717|NCT04815135||2019 group (pre COVID19 group)|Patients who were admitted to the surgical ward via the emergency department during the similar period in 2019
89542718|NCT04815213|Experimental|Arm 1|Expanded autologous bone marrow-derived mesenchymal cells (BMMSCs), dose 20 million cells/ovary
89542719|NCT04820751|Experimental|Cyproheptadine and standard care|"Start Cyproheptadine 8mg three times a day during 5 days. Dose will be reduced to 4mg three times a day if GFR inferior to 30ml/min/1.73m²~Standard management of COVID-19 infection according to current international guidelines"
89542720|NCT04820751|No Intervention|Standard care|Standard management of COVID-19 infection according to current international guidelines
89542721|NCT05619393|Experimental|Mobilie Bi-planar X-ray Imaging system|
89542722|NCT04427553|Experimental|Percutaneous Peripheral Nerve Stimulation|"Participants assigned to this group will received two sessions (once per week) of ultrasound guided Percutaneous Peripheral Nerve Stimulation targeting the femoral nerve. We will apply a biphasic compensated electrical current at a frequency of 10 Hz, a pulse width of 240 µs and intensity allowed over a pain-free motor threshold (muscle contraction). Each participant will receive 10 repetitions of 10 seconds each one with 10 seconds rest- period between series (total treatment session 1.40 min).~After that participants will walk during 3 minutes."
89542723|NCT04427553|Placebo Comparator|Control|Participants in the control group will walk during 5 minutes, without receiving any intervention
89542724|NCT04827693||Immediate|implants are placed immediately after tooth extraction
89542725|NCT04827693||Delayed|implants are placed months after the tooth has been extracted
89542726|NCT04359927||SARS-CoV2/Covid-19 (cases)|Patients with detectable real-time reverse transcriptase-polymerase chain reaction for SARS-CoV2/Covid-19.
89542727|NCT04359927||No SARS-CoV2/Covid-19 (controls)|Patients with undetectable real-time reverse transcriptase-polymerase chain reaction for SARS-CoV2/Covid-19.
89542728|NCT01440777|Active Comparator|Go! to Sleep|Participants access and utilize the 6-week online program that provides a set of various psycho-educational materials and behavioral techniques to treat insomnia.
89542729|NCT01440777|No Intervention|Control Group|No intervention provided. These participants will receive the Go! to Sleep program after the research trial has been completed (10 weeks after registration).
89542730|NCT04815057|Experimental|Education|wellness education
89542731|NCT04820439|Experimental|recombinant monoclonal antibody against human epidermal growth factor receptor injection (HS627)|
89542732|NCT04820439|Active Comparator|Perjeta ®|
89542733|NCT05619315|Experimental|Charcoal -based whitening toothpaste.|The labial surface of anterior teeth will be brushed by the circular brushing technique twice daily (morning and after 6 hours) for at least 1 minute using charcoal containing toothpaste. Soft bristles toothbrushes will provided to all patients. After 1 month, re-evaluation of the stains will be performed and the data will be recorded.
89542734|NCT05619315|Active Comparator|Calcium carbonate /perlite containing whitening toothpaste.|The labial surface of anterior teeth will be brushed by the circular brushing technique twice daily (morning and after 6hours) for at least 1 minute using (calcium carbonate /perlite) containing toothpaste. Soft bristles toothbrushes will provided to all patients. After 1 month, re-evaluation of the stains will be performed and the data will be recorded.
89542735|NCT04814511|Other|Standard therapy with InfectoScab 5 % Creme|
89542736|NCT04814511|Experimental|Escalated therapy with InfectoScab 5 % Creme (arm E5)|
89542737|NCT04814511|Experimental|Escalated therapy with Permethrin 10 % Creme (arm E10)|
89542738|NCT04814511|Experimental|Escalated therapy with InfectoScab 5 % Creme in combination with Driponin 3 mg Tabletten (arm EK)|
89542739|NCT04814121|Experimental|Suxiao Jiuxin Pills|Suxiao Jiuxin Pills prescription (15 pills loading does, maintenance 6 pills each time, three times a day.) for 180 days
89542740|NCT04814121|Placebo Comparator|The placebo of Suxiao Jiuxin Pills|The placebo of Suxiao Jiuxin Pills prescription (15 pills loading does, maintenance 6 pills each time, three times a day.) for 180 days
89542741|NCT05619159||endometrial carcinoma smples|
89542742|NCT05619159||endometrial hyperplasia samples|
89542743|NCT04814043|Experimental|PD-1 antibody and lenvatinib plus TACE-HAIC|systemic PD-1 antibody (Sintilimab) and lenvatinib plus transarterial chemobolization and FOLFOX-based chemotherapy infusion
89542744|NCT04813965|No Intervention|Control|Participants in the control group received standard information on treatment side-effects.
89542745|NCT04813965|Experimental|Information without self-affirmation|Before completing the study's online baseline survey (pre-chemotherapy), participants in the information group received standard information with additional written information about potential chemotherapy-related cognitive symptoms.
89542746|NCT04813965|Experimental|Information with self-affirmation|Before completing the study's online baseline survey (pre-chemotherapy), participants in the information+SA group (SA=self-affirmation) received standard and additional written information about potential chemotherapy-related cognitive symptoms with a subsequent self-affirmative text.
89542747|NCT04814589|Experimental|ezetimibe Tablets|ezetimibe tablets test formulation at a single dose of 10 mg
89542748|NCT04814589|Active Comparator|ezetimibe tablets(Ezetrol ®)|ezetimibe tablets reference formulation at a single dose of 10 mg
89542749|NCT04819581|Experimental|SP-103 (1 topical system)|One topical system applied to the skin on the back for 12 hours.
89542750|NCT04819581|Experimental|SP-103 (2 topical systems)|Two topical systems applied to the skin on the back for 12 hours.
89542751|NCT04819581|Experimental|SP-103 (3 topical systems)|Three topical systems applied to the skin on the back for 12 hours.
89542752|NCT04819581|Active Comparator|ZTlido|Three topical systems applied to the skin on the back for 12 hours.
89542753|NCT04819347|Experimental|Early treatment of infection|"HIV-1 infected subjects initiated a stable combination antiretroviral therapy (ART) within 6 months of primary HIV infection (PHI), and had plasma HIV-1 RNA <50 copies/mL for at least 12 months.~Albuvirtide 0.32 g and 3BNC117 2 g every 2 weeks IV infusion for a total of 14 weeks."
89542754|NCT04819347|Experimental|Chronic period of infection treatment|"Chronically HIV-1 infected subjects initiated a stable combination antiretroviral therapy (ART) after 6 months of primary HIV infection (PHI), and had plasma HIV-1 RNA <50 copies/mL for at least 12 months.~Albuvirtide 0.32 g and 3BNC117 2 g every 2 weeks IV infusion for a total of 14 weeks."
89542755|NCT04813809|Experimental|BARRIER EasyWarm|This is an open, non randomised, single arm study
89542756|NCT04826679|Experimental|Experimental|"Camrelizumab + Cisplatin + Nab-paclitaxel~Camrelizumab (IV), dose= 200mg , day=1 , cycle length: 21 days. Cisplatin (IV), dose=60mg/m2, day= 1, cycle length: 21 days. Nab-paclitaxel (IV), dose=260mg/m2, day= 1, cycle length: 21 days."
89542757|NCT04813341|Experimental|Pilates training|Bridging, roll up, one leg circle (both ways); single straight leg stretches; double leg stretches; side kick up and down; side kick circles
89542758|NCT04813341|Active Comparator|Aerobic Training|"WALKING: 10 mint brisk walk excluding warm up and cool down in 5 days/ week STATIONARY CYCLE: for 10 mints, 5 days/ week~SITTING EERCISES:~Chest stretch: ask to hold for 5 seconds and perform 5 repetitions Upper body twist: ask to cross the arms against chest and hold for 5 seconds, perform 5 repetitions Hip marching: Ask the client to sit on chair with arm rest and lift each of her leg 5 times~BALANCE EXERCISES:~Sideways walking: ask to perform 10 steps on each way (side to side), 5 days/week.~Heel to Toe walk: perform at least 5 steps and increase gradually in each repetition, 5days/ week Step up and down: Ask to step up and down on given surface, 5 repetitions on each leg, 5 days/ week."
88960796|NCT04243122|Active Comparator|Aspirin and cytoreductive therapy (if applicable)|Patients who are randomized to this group will take a low-dose aspirin 81mg pill once per day (standard-of-care) for at least 6 months along with cytoreductive therapy, if applicable. Patients will then be treated and followed up as per standard of care at the discretion of his or her treating physician after the completion of the study.
88960797|NCT04243122|Experimental|Apixaban and cytoreductive therapy (if applicable)|Patients who are randomized to this group will receive apixaban 2.5mg twice daily for at least 6 months along with standard intervention, cytoreductive therapy, if applicable. Patients will then be treated and followed up as per standard of care at the discretion of their treating physician after the completion of the study.
88960798|NCT04239924|Experimental|Paramedic Coaching|The intervention is an adaptation of the evidence-based REACH program
89542759|NCT02601573|Experimental|Arm 1: HCV GT3 TN EBG/GZR+SOF+RBV 8 Weeks|TN HCV GT3 participants will take 1 fixed-dose combination (FDC) tablet containing EBR 50 mg+GZR 100 mg and 1 tablet containing SOF 400 mg once-daily (q.d.) with RBV (200 mg capsules; weight-based dosing) twice-daily (b.i.d.) for 8 weeks.
89542760|NCT02601573|Experimental|Arm 2: HCV GT3 TN EBG/GZR+SOF 12 Weeks|TN HCV GT3 participants will take 1 FDC tablet containing EBR 50 mg+GZR 100 mg and 1 tablet containing SOF 400 mg q.d. for 12 weeks.
89542761|NCT02601573|Experimental|Arm 3: HCV GT3 TE EBG/GZR+SOF 12 Weeks|TE HCV GT3 participants will take 1 FDC tablet containing EBR 50 mg+GZR 100 mg and 1 tablet containing SOF 400 mg q.d. for 12 weeks.
88960799|NCT04230109|Experimental|Sacituzumab Govitecan (monotherapy cohort)|"- The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits.~Sacituzumab govitecan via iv, predetermined dosage per protocol, IV, 2 days per each 21-day cycle, for 4 cycles.~This can be followed by standard chemotherapy at the discretion of treating physician."
89542762|NCT02601573|Experimental|Arm 4: HCV GT3 TE EBG/GZR+SOF+RBV 12 Weeks|TE HCV GT3 participants will take 1 FDC tablet containing EBR 50 mg+GZR 100 mg and 1 tablet containing SOF 400 mg q.d. with RBV (200 mg capsules; weight-based dosing) b.i.d. for 12 weeks.
89542763|NCT02601573|Experimental|Arm 5: HCV GT3 TE EBG/GZR+SOF 16 Weeks|TE HCV GT3 participants will take 1 FDC tablet containing EBR 50 mg+GZR 100 mg and 1 tablet containing SOF 400 mg q.d. for 16 weeks.
89542764|NCT04818879|Experimental|Interventional group|
89542765|NCT04818879|Sham Comparator|Control group|
89542766|NCT04813419|Active Comparator|right face|The right side of face of subjects
89542767|NCT04813419|Experimental|left face|The left side of face of subjects
89542768|NCT04826601|Experimental|Experimental|
89542769|NCT04813575|Experimental|Intervention arm|Experimental arm patients will have cryobiopsies for histological analysis of the ongoing pathology
89542770|NCT04813575|No Intervention|control group|This arm will be control group and will be observed prospectively
89608410|NCT04146363|Experimental|Lebrikizumab 250 Q4W|"Maintenance Period (Week 16-Week 52):~One 250 mg Lebrikizumab SC injection every 4 weeks (Q4W) on Weeks 20, 24, 28, 32, 36, 40, 44, and 48.~One placebo SC injection Q4W on Weeks 22, 26, 30, 34, 38, 42, 46, and 50.~For participants who received placebo in the Induction Period, the maintenance loading dose is:~Two 250 mg Lebrikizumab SC injections on Week 16.~Two placebo injections on Week 18.~To maintain the blind, for participants who received Lebrikizumab in the Induction Period, the maintenance loading dose is:~One 250 mg Lebrikizumab SC injection and one placebo SC injection on Week 16.~Two placebo injections on Week 18"
88960800|NCT04230109|Experimental|Sacituzumab Govitecan and Pembrolizumab (combination cohort)|"- The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits.~Sacituzumab govitecan via iv, predetermined dosage per protocol, IV, 2 days per each 21-day cycle, for 4 cycles.~Pembrolizumab via iv, predetermined dosage per protocol, IV, 1 day per each 21-day cycle, for 4 cycles.~This can be followed by standard chemotherapy at the discretion of treating physician."
88960801|NCT04221191||Standard of Care (SoC) Group|SoC neurologists will include and follow-up all study participants who receive DMF according to their standard of care practice (non-coached participants).
88960802|NCT04221191||OroSEP PSP (OPSP) Group|OPSP neurologists will include and follow-up all study participants who receive DMF according to their standard of care practice and the OroSEP PSP (coached participants).
88960803|NCT04209296||Major Depressive Disorder (MDD)|DSM-5 Diagnosis of MDD
88960804|NCT04209296||Bipolar Disorder|DSM-5 Diagnosis of Bipolar Disorder
88960805|NCT04209296||Obsessive Compulsive Disorder (OCD)|DSM-5 Diagnosis of OCD
88960806|NCT04209296||Post-traumatic Stress Disorder (PTSD)|DSM-5 Diagnosis of PTSD
88960807|NCT04208646|Experimental|Mesenchymal progenitor cells Dosage 1|Mesenchymal progenitor cells low-dose group
88960808|NCT04208646|Experimental|Mesenchymal progenitor cells Dosage 2|Mesenchymal progenitor cells high-dose group
88960809|NCT04208646|Placebo Comparator|No mesenchymal progenitor cells|No mesenchymal progenitor cells
88960810|NCT04203745|Experimental|Nonablative Fractional Diode Laser|Single Group - single arm study. Group was treated with Nonablative Fractional Diode Laser
88960811|NCT04192799|Experimental|Direct Admission|Referring providers contact the hospital to arrange for a child to be admitted directly into the pediatric hospital medicine unit.
88960812|NCT04192799|Active Comparator|ED Admission|Children initially present at the Emergency Department and are then admitted to the pediatric hospital medicine unit.
89542771|NCT04818723|Experimental|Montelukast Group|53 in Case Group (given montelukast 5mg at bed time). All patients were induced with prednisolone 2mg/kg single morning dose with breakfast for total 4 weeks. Patients who did not achieve remission after 4 weeks' full dose were labeled steroid resistant nephrotic syndrome (SRNS). Children with steroid sensitive nephrotic syndrome SSNS were further treated by prednisolone 1.5 mg/kg single morning dose with breakfast every other day for the next 4 weeks. Prednisolone was then tapered by reducing 25% dose fortnightly and completely stopped in 8 weeks. Patients in the Case Group continued taking montelukast after stopping steroids. All patients were followed up every 4-8 weeks for a minimum of 12 months to look for response to treatment, side effects of medications, other co-morbidities, and the number of relapses. Relapses were treated with repeat prednisolone doses according to the protocol of treatment for relapse.
88960813|NCT04188574|Experimental|BB2603-10|Treatment with topical spray twice-daily (BID) BB2603-10: 0.1% terbinafine
88960814|NCT04188574|Experimental|BB2603-3|Treatment with topical spray twice-daily (BID) BB2603-3: 0.03% terbinafine
88960815|NCT04188574|Experimental|BB2603-1|Treatment with topical spray twice-daily (BID)BB2603-1: 0.01% terbinafine
88960816|NCT04188574|Other|Vehicle Control|0.3% polyhexanide/ 20% ethanol/ water formulation.
88960817|NCT04180579|Experimental|Participants with Breast Cancer|Any adult woman with a new diagnosis of breast cancer, Stage I-III
88960818|NCT04175210|Experimental|ARM 1-4050cGY and boost to tumor bed of 4800cGY in 15fractions|Patients randomized to ARM 1 will receive whole breast radiotherapy of 4050cGY and a concomitant boost to the tumor bed of 4800cGY in 15 fractions
89542772|NCT04818723|Placebo Comparator|Placebo Group|Patients in this groups were induced with prednisolone 2mg/kg single morning dose with breakfast for total 4 weeks. Patients who did not achieve remission after 4 weeks' full dose were labeled steroid resistant nephrotic syndrome (SRNS). Children with steroid sensitive nephrotic syndrome SSNS were further treated by prednisolone 1.5 mg/kg single morning dose with breakfast every other day for the next 4 weeks. Prednisolone was then tapered by reducing 25% dose fortnightly and completely stopped in 8 weeks. Patients in the Case Group continued taking montelukast after stopping steroids. All patients were followed up every 4-8 weeks for a minimum of 12 months to look for response to treatment, side effects of medications, other co-morbidities, and the number of relapses. Relapses were treated with repeat prednisolone doses according to the protocol of treatment for relapse.
89542773|NCT04826445||Patients included in PENTOCLO protocol|We perform a prospective study with inclusions of all consecutive patients with osteoradionecrosis eligible for PENTOCLO.
88960819|NCT04175210|Experimental|ARM 2 - 3200cGY and boost to tumor bed of 4200cGY -10fractions|Patients randomized to ARM 2 will receive whole breast radiotherapy of 3200cGY and a concomitant boost to the tumor bed of 4200cGY in 10 fractions.
88960820|NCT04154904|Experimental|Aerobic exercise|
89542774|NCT04818411|Active Comparator|Routine physical therapy treatment with the Stabilization exercises|Stabilization exercises
89542775|NCT04818411|Experimental|Routine physical therapy treatment + High-velocity thrust manipulation|High-velocity thrust manipulation
89542776|NCT02601027|Experimental|0.125% Bupivacaine|0.125% bupivacaine infusion via transversus abdominis plane (TAP) catheter
89542777|NCT02601027|Placebo Comparator|Placebo|Saline infusion (sham) via transversus abdominis plane (TAP) catheter.
89542778|NCT04411875|Active Comparator|Amlodipine|amlodipine reference formulation at a single dose of 10 mg
89542779|NCT04411875|Experimental|Levamlodipine|levamlodipine test formulation at a single dose of 5 mg
89542780|NCT02600871|Experimental|Provodine|"Provodine patients will have standard care including incision and drainage. The contents of 1 packet of Provodine applied with a Q-tip to the walls and floor of the abscess cavity. The contents of a 2nd packet will be applied to the surrounding skin within 5 cm around the incision.~Provodine patients will return within 48-72 hours for a follow-up visit, have the packing removed and the contents of the packet reapplied to the abscess cavity and surrounding skin.~Provodine patients will be instructed to cleanse the abscess at home by soaking in water once a day and patting the wound dry. They will wash their hands with soap and water, pat dry, and apply the contents of 1 packet of Provodine to dorsum and palmar aspects of hands and fingers and rub together for 1 minute. They will apply the contents of a 2nd packet to the abscess cavity, and a 3rd packet to the surrounding skin. They will be then rinse their hands with water, pat dry, and cover the wound with 4x4 gauze."
89542781|NCT02600871|Active Comparator|Standard Care|"Standard care patients will have standard care including incision and drainage.~Standard care patients will return within 48-72 hours for a follow-up visit and have the packing removed.~Standard care patients will be instructed to cleanse the abscess at home by soaking in water once a day and patting the wound dry. They will cover wound with 4x4 gauze and wash hands with soap and water for 1 minute."
89542782|NCT04813029|Experimental|Straight Leg Raise|Patients perform straight leg raise maneuver at the end of High-resolution Manometry test
89542783|NCT04427631|Experimental|Single arm study|The family will complete questionnaires before and after each childs intervention. Therefore each child will act as their own control.
89542784|NCT04428255|Experimental|HBM9161 Dose A|Patients will be randomized in a 1:1:1 ratio to HBM9161 (Dose A or Dose B) or placebo
89542785|NCT04428255|Experimental|HBM9161 Dose B|Patients will be randomized in a 1:1:1 ratio to HBM9161 (Dose A or Dose B) or placebo
89542786|NCT04428255|Placebo Comparator|Placebo|Patients will be randomized in a 1:1:1 ratio to HBM9161 (Dose A or Dose B) or placebo
88960821|NCT04154904|Experimental|Resistance exercise|
88960822|NCT04154904|Experimental|High intensity interval exercise|
88960823|NCT04131413|Other|Vaccination Arm Level 1|The dose escalation of pNGVL4aCRTE6E7L2 will be conducted to evaluate the safety of three escalating doses; Level 1 dose of 0.3 mg
88960824|NCT04131413|Other|Vaccination Arm Level 2|The dose escalation of pNGVL4aCRTE6E7L2 will be conducted to evaluate the safety of three escalating doses; level 2 at dose 1.0 mg
88960825|NCT04131413|Other|Vaccination Arm Level 3|The dose escalation of pNGVL4aCRTE6E7L2 will be conducted to evaluate the safety of three escalating doses; level 3 dose of 3.0 mg
88960826|NCT04129450|Experimental|Mindfulness Pain Program + Usual PCP Care|Participants will undergo 8 weekly 90 minute sessions of Mindfulness-Based Stress Reduction in addition to receiving usual PCP care for chronic lower back pain.
89542787|NCT04818099|Experimental|routine supportive psychotherapy and votioxetine|On the basis of general psychotherapy, cognitive behavior therapy and supportive psychotherapy, the patients were given votioxetine 10mg/tablet, one tablet each time, once a day, for 2 months.
89542788|NCT04818099|Placebo Comparator|routine supportive psychotherapy and control|On the basis of general psychotherapy, cognitive behavior therapy and supportive psychotherapy, the patients were given placebo, one tablet each time, once a day, for 2 months.
89542789|NCT04817709||Arm 1|Patients view a video and read a workbook over 30 minutes about breast reconstruction surgery before their appointment. Patients also complete a questionnaire over 5-10 minutes before and after the video and after talking with the plastic surgeon. Patients' medical records are reviewed once they have made a decision about the type of reconstruction (if any).
89542790|NCT04817709||Arm 2|Patents receive an educational booklet about breast reconstruction surgery during appointment. Patients also complete a questionnaire over 5-10 minutes before and after talking with the plastic surgeon. Patients' medical records are reviewed once they have made a decision about the type of reconstruction (if any).
89542791|NCT05618847|Experimental|active cycle of breathing technique with acapella|"Sit up with good posture to use the Acapella. Take in a fairly deep breath and hold it for about 3 seconds. Place the Acapella mouthpiece in your mouth. Seal your lips tightly around the mouthpiece.~Exhale as much as possible (but not to forcefully) through the mouthpiece. Keep your cheeks as firm as possible when you exhale. Try not to inhale through the device.~Repeat this maneuver for 10 breaths. Try to resist coughing during this phase. After these 10 blows, perform 3 huffs, then a big cough to bring the sputum up and out. Try not to swallow the mucus"
89542792|NCT05618847|Active Comparator|active cycle of breathing technique|Ask patient to breathe in and out gently through nose if he/she can. If patient breathe out through their mouth. Ask patient to let go of any tension in body with each breath out. Gradually try to make the breaths slower. Ask patient to take a long, slow, deep breath in, through nose. Try to keep chest and shoulders relaxed. Repeat 3-5 times. Huff is exhaling through an open mouth and throat instead of coughing. It helps move sputum up in airways so that patient can clear it in a controlled way. To 'huff' ask patient to squeeze air quickly from lungs, out through open mouth and throat, as if trying to mist up a mirror or glasses. Ask to use abdominal muscles to help squeeze the air out, but do not force it so much that cause wheezing or tightness in chest. Huffing should always be followed by breathing control.
89542793|NCT05618769|Experimental|Intervention (LONG LOVE Framework)|"Consists of participants born in Franciscus Gasthuis (FG) and/or Vlietland (FV) and will be allocated to the intervention group, receiving additional (in addition to current standard of care) follow-up in accordance with our newly developed framework to identify modi able influencing factors compromising pulmonary health using validated questionnaires, weekly monitoring of respiratory symptoms as reported by parents using an app, in- and outdoor air quality measurements and non-invasive pulmonary function measurements based on impedance pneumatography.~In case of any modi able influencing factors, appropriate lifestyle and/or medical interventions will be undertaken."
89542794|NCT05618769|No Intervention|Control|"Consist of participants born in Maasstad Ziekenhuis (MSZ) and Albert Schweitzer Ziekenhuis (ASZ) and will receive standard of care follow-up.~Parents are requested to provide informed consent for the registration of outcome measurements and requested to complete validated questionnaires. Data on utilization of medical services will be inquired to avoid recall bias."
89542795|NCT04428099|Experimental|Intervention|Lifestyle change promotion program
89542796|NCT04428099|Active Comparator|Control 1|MBCT program
89542797|NCT04428099|Placebo Comparator|Control 2|Usual care
89542798|NCT02598297|Active Comparator|Ruxolitinib|Two tablets of ruxolitinib 5 mg were administered orally twice per day.
89542799|NCT02598297|Placebo Comparator|Ruxolitinib Placebo|Two tablets of 5mg placebo were administered orally twice per day.
89542800|NCT04812561|Experimental|Bronch™ group|2 times a day, 1 pill for 1 time, after breakfast/dinner meal(1,600 mg/day, 800 mg/day as Bronch™)
89542801|NCT04812561|Placebo Comparator|Placebo group|2 times a day, 1 pill for 1 time, after breakfast/dinner meal(1,600 mg/day)
89542802|NCT04812405|Other|Teeth|Occlusal examination
89542803|NCT04816929|Experimental|Bobath Method Group|The Bobath based exercises for 60 minutes will be formed according to the needs of the individual and will involve trunk exercises such as placing, stretching, functional reach, rotations, functional strengthening and, balance and walking exercises etc. It will be performed 3 days a week for 8 weeks.
89542804|NCT04816929|Active Comparator|Task-Oriented Approach Group|The task-oriented approach for 60 minutes will be formed according to the needs of the individual and involve exercises targeting functional tasks determined. It will be performed 3 days a week for 8 weeks.
89542805|NCT04825899||NGS Panel|patients who had NGS 481 gene mutation detected
89542806|NCT04816851||Ozaki group|Patients undergoing aortic valve reconstruction using autologous pericardium (OZAKI technique) at Assiut University Hospitals in conjunction with Al-Nas hospital in cairo.
89542807|NCT04807959||20Lighter Program Participants|All enrolled subjects will have completed a 20Lighter anti-obesity program prior to enrollment.
89542808|NCT04807569|Experimental|Experimental group|"10 sessions of non-invasive peripheral magnetic neuromodulation using the BTL Emsella magnetic stimulator according to the manufacturer's standard protocol: pelvic floor rehabilitation."
88960827|NCT04129450|Active Comparator|Usual PCP Care|Participants will receive usual PCP care for chronic lower back pain.
88960828|NCT04125147|Experimental|Montage Bone Hemostat|Use of Montage Settable Resorbable Hemostatic bone putty on the cut surfaces of bleeding bone at the osteotomy site
88960829|NCT04125147|No Intervention|Standard of Care: No bone hemostat|Use of no bone hemostat on the cut surfaces of bleeding bone at the osteotomy site
88960830|NCT04122196|Experimental|Pregabalin 300mg|Patient will receive a compounded version of 300mg pregabalin PO approximately one hour before surgery.
88960831|NCT04122196|Placebo Comparator|Placebo|Patient will receive a compounded version of inactive placebo PO approximately one hour before surgery.
88960832|NCT04106115|Experimental|Durvalumab + S-488210/S-488211|Trial treatment for up to 24 weeks of Durvalumab (1500 mg IV infusion every 4 weeks for up to 7 doses) in combination with S-488210/S-488211 vaccine (given as 2 subcutaneous injections of S-488210/Montanide and S-488211/Montanide starting day after first durvalumab dose, then weekly for the first 6 weeks, and then every 2 weeks for a further 9 doses).
89542809|NCT04807569|Experimental|Control group|one-month course of drug therapy with alpha-1-adrenoblocker according to the standard scheme
89542810|NCT04807491|Active Comparator|Kabat Technique's|Kabat exercises on Upper fulcrum, Intermediate fulcrum and lower fulcrum
89542811|NCT04807491|Experimental|Neuromuscular Re-Education:|For initiation, Facilitation, Movement control and movement control
89542812|NCT04807413|Experimental|Study Arm: The balloon will be opened to deliver nitric oxide at 40 ppm.|Nitric oxide balloon will be connected to the CPB machine. Participants randomized to this group will receive 40 ppm nitric oxide through the pump.
89542813|NCT04807413|Active Comparator|Control Arm: The balloon will be closed and no nitric oxide will be delivered.|Participants in this group will receive standard of care treatment. Participation in the trial will not affect surgery management in any way.
89542814|NCT05617053||DAART|Popliteal artery lesion treated by directional atherectomy with anti-restenotic therapy for the treatment of popliteal atherosclerotic lesions.
89542815|NCT05617053||ATP/Supera stenting|Angioplasty and Supera stent implantation for the treatment of popliteal atherosclerotic lesions.
89542816|NCT04825665|Experimental|Continuous force|A buccally directed continuous tipping force of 150 g is applied to the maxillary first premolar on one side
89542817|NCT04825665|Experimental|Intermittent force|A buccally directed tipping force of 150 g removed every 21 days for a 7-day rest period applied to the maxillary first premolar on one side
89542818|NCT04427319|Experimental|Experimental group|Product: β-Alanine Supplementation strategy: 5 g, four times a day with main meals, for 7 days after the initial evaluation and until the end of the study.
89542819|NCT04427319|Placebo Comparator|Placebo group|Product: wheat semolina Supplementation strategy: 5 g, four times a day with main meals, for 7 days after the initial evaluation and until the end of the study.
89542820|NCT04807335|Experimental|Investigational medicinal product CT001|intranasal dosage of CT001
89542821|NCT04807335|Active Comparator|Comparator 1|Ketamine 10mg iv
89542822|NCT04807335|Active Comparator|Comparator 2|Sufentanil 10mcg iv
89542823|NCT05616507|Experimental|Arm A|It is recommended to consume on an empty stomach, 2 servings per day, a total of 8 tablets, which can be eaten at one time or in divided doses. If it is difficult to swallow, the powder in the capsule can also be taken out and mixed with food or liquid food.
89542824|NCT05616507|No Intervention|Arm B|observation
89542825|NCT04806945|Experimental|HLX10|HLX10 + chemotherapy
89542826|NCT04806945|Placebo Comparator|Placebo|Placebo + chemotherapy
89542827|NCT04806711|Experimental|Menicon Z Night|The experimental arm consist of a group of Menicon Z Night orthokeratology contact lens wearers
89542828|NCT04806711|Active Comparator|Control|The active comparator arm consist of a control group of distance, single-vision glasses and contact lens wearers
89542829|NCT02596893|Experimental|GED0301 160mg x 12 weeks followed by periodic 160 mg GED0301|GED-0301 160 mg once daily (QD) for 12 weeks; followed by placebo QD for 4 weeks; followed by alternating GED-0301 160 mg QD for 4 weeks and placebo QD for 4 weeks, until the the Week 52 Visit
89542830|NCT02596893|Experimental|GED0301 160mg x 12 weeks followed by periodic GED0301 40mg|GED-0301 160 mg once daily (QD) for 12 weeks; followed by placebo QD for 4 weeks; followed by alternating GED-0301 40 mg QD for 4 weeks and placebo QD for 4 weeks, until the Week 52 Visit
89542831|NCT02596893|Experimental|GED0301 160mg x 12 weeks followed by continuous GED0301 40mg|GED-0301 160 mg once daily (QD) for 12 weeks; followed by continuous GED-0301 40 mg QD, until the Week 52 Visit
89542832|NCT02596893|Placebo Comparator|Placebo|Placebo once daily (QD) until the Week 52 Visit
89542833|NCT04806633|Active Comparator|Dapagliflozin|Patients who will be randomized to receive dapagliflozin following cardiac catheterization and PCI
89542834|NCT04806633|Placebo Comparator|Placebo|Patients who will be randomized to receive placebo following cardiac catheterization and PCI
88960833|NCT04105231|Experimental|Cannabidiol|"Cannabidiol (Epidiolex®) (oral suspension)100 mg/ml dosed as 3 ml in the morning for 4 days, then increased to 3 ml in the morning and 3 ml in the evening, equivalent to CBD 300 mg BID, with a total treatment duration of 7 weeks.~AND Risperione placebo, encapsulated tablet."
89542835|NCT05616897|Other|Medicine students|students with normal expected fitness
89542836|NCT05616897|Other|Physical education students|students with better expected fitness
89542837|NCT04427475|Other|pabolizumab|Baseline plasma samples were collected before the treatment, and the efficacy was evaluated once every two treatment cycles.
89542838|NCT04427475|Other|nafulizumab|Baseline plasma samples were collected before the treatment, and the efficacy was evaluated once every two treatment cycles.
89542839|NCT04797975|Experimental|KDS-1000|NK cells expanded ex vivo using PM21 membrane particles:
89542840|NCT04797975|Placebo Comparator|Control|0.9% Normal Saline
89542841|NCT04806477|Active Comparator|Adult patients with respiratory tract symptom - telemedicine before face-to-face evaluation|We included adults (≥18 years of age) who had at least one acute symptom compatible with Respiratory Tract Infection (sore throat, nasal obstruction, coryza, new or growing cough, sputum, hoarseness, dyspnea) with or without symptoms related to the infection (fever ≥ 38oC, chills, sweating, myalgia) who have undergone telemedicine consultation before face-to-face evaluation
88960834|NCT04105231|Active Comparator|Risperidone|"Risperidone (encapsulated tablet) dosed as 2 mg in the morning for 4 days, then increased with 2 mg in the morning and 2 mg in the evening, with a total treatment duration of 7 weeks~AND Cannabidiol placebo, oral suspension"
88960835|NCT04096755||DVT group|40 patients with a confirmed deep venous thrombosis (DVT) on Duplex ultrasound will be recruited into this group. All patients will have serum and urine samples for analysis.
88960836|NCT04096755||Control Group|40 volunteers without a DVT will be recruited for the control group. They will have urine and serum samples taken for analysis.
88960837|NCT04080115|Experimental|Attention Training Technique (ATT)|
88960838|NCT04080115|Active Comparator|Sham intervention control condition|
88960839|NCT04073745|Experimental|Treatment (SBRT)|Beginning at least 2 weeks after surgical resection, patients undergo 1 fraction (or 5 fractions every other day if R2 resection of central tumor) of SBRT.
89542842|NCT04806477|Active Comparator|Adult patients with respiratory tract symptom - only face-to-face evaluation|We included adults (≥18 years of age) who had at least one acute symptom compatible with Respiratory Tract Infection (sore throat, nasal obstruction, coryza, new or growing cough, sputum, hoarseness, dyspnea) with or without symptoms related to the infection (fever ≥ 38oC, chills, sweating, myalgia) who have undergone only face-to-face evaluation
89542843|NCT05616819|Active Comparator|Treatment Order A|Blue light treatment for 2 weeks, a 4-week washout period, and 2 weeks of placebo (amber) light treatment.
89024748|NCT00465543|Placebo Comparator|I|Arm 1 receives 4 weeks of treatment with mint tea high in rosmarinic acid, consumed twice a day. Treatment is followed by a 4 week wash-out phase. Subjects then enter a 4 week phase of placebo mint tea (low in rosmarinic acid), to be consumed twice a day.
89024749|NCT00435617|Experimental|A|Hand Mentor
89024750|NCT00435695|Active Comparator|GSK163090|one infusion only
89542844|NCT05616819|Placebo Comparator|Treatment Order B|Placebo light treatment for 2 weeks, a 4-week washout period, and 2 weeks of blue light treatment.
89542845|NCT04797819||Serum sST2 level < 14.5 ng/mL|
89542846|NCT04797819||14.5 ng/mL ≤ Serum sST2 level < 20.5 ng/mL|
89542847|NCT04797819||20.5 ng/mL ≤ Serum sST2 level < 25.9 ng/mL|
89542848|NCT04797819||Serum sST2 level ≥ 25.9 ng/mL|
89542849|NCT04806009|Experimental|'Mindful Living With Insomnia (MLWI)' Intervention via WeChat mini-program|Participants in the Intervention Group will receive the MLWI Intervention after follow the WeChat mini-program. The MLWI Intervention was developed and presented by the Principle Investigator (PI) who is a psychiatrist and have completed the Training of Mindfulness Facilitation (TMF) program at the Mindful Awareness Research Center of University of California, Los Angeles.
89542850|NCT04806009|Active Comparator|'Cognitive Behavioral Therapy for insomnia (CBT-I)'via WeChat mini-program|Participants in the Control Group will receive CBT-I after follow the WeChat mini-program. The CBT-I was developed and presented by a researcher who is a psychiatrist/psychologist and have many years' experiences in CBT.
89542851|NCT04806243|Experimental|Carelizumab Combined With Regorafenib arm|
89542852|NCT04805931|No Intervention|Control|Will receive a text message with standard messaging used to alert veterans that they are eligible for COVID-19 vaccine and offer scheduling embedded within the text message.
89542853|NCT04805931|Experimental|Scarcity|Will receive a text message with a behavioral scarcity message used to alert veterans that they are eligible for COVID-19 vaccine and offer scheduling embedded within the text message.
89542854|NCT04805931|Experimental|Social good|Will receive a text message with a behavioral social good message used to alert veterans that they are eligible for COVID-19 vaccine and offer scheduling embedded within the text message.
89542855|NCT04797507|Experimental|Treatment Group|SHR-1210 plus Anlotinib
89542856|NCT04811859|Experimental|Study Group|In the study group, Inspiratory Muscle Training will be applied with Threshold IMT device (Respironics, USA) at 40% of the maximum inspiratory pressure value for eight weeks, every day of the week, twice a day for 15 minutes. The patients will come for a control once a week, the maximum inspiratory pressure will be measured again and the new training intensity will be determined at 40% of the new maximum inspiratory pressure.
89542857|NCT04811859|Sham Comparator|Control group|In the control group, Inspiratory Muscle Training will be applied with Threshold IMT device (Respironics, USA) at 10% of the maximum inspiratory pressure value for eight weeks, every day of the week, twice a day for 15 minutes. The exercise workload will not be increased and will remain the same. It will run at 10% of maximum inspiratory pressure for eight weeks.
89542858|NCT04805697|Placebo Comparator|placebo group|subjects drank 50 ml , 1 bottle a day for 8 week
89542859|NCT04805697|Experimental|fermented grape drinks|subjects drank 50 ml , 1 bottle a day for 8 week
89542860|NCT04805853||type 2 diabetes without polycystic ovary syndrome|The treatment of type 2 diabetes is based on the Chinese Medical Association Diabetes Branch '2017 China Type 2 Diabetes Prevention Guidelines' for lifestyle adjustment and diabetes drug treatment.The research physician decides the diabetes treatment measures of the research object; the blood sugar control goal is that glycosylated hemoglobin is less than 7%.
89542861|NCT04805853||polycystic ovary syndrome without type 2 diabetes|The treatment of polycystic ovary syndrome is based on the '2018 Polycystic Ovary Syndrome Chinese Diagnosis and Treatment Guidelines' by the Endocrinology Group of the Obstetrics and Gynecology Branch of the Chinese Medical Association and the Guide Expert Group '2018 Polycystic Ovary Syndrome Expert consensus on diagnosis and treatment of endocrinology' for lifestyle and drug treatment.
89542862|NCT04805853||polycystic ovary syndrome with type 2 diabetes|Treatment is as above.
88811715|NCT03007901|Experimental|Pilot Cohort 1|This Pilot Study will be conducted to allow us to evaluate and test the various study processes, including: consent/enrollment, run-in-trial monitoring, measurement tools, outcome assessment, educational materials, and especially the mindfulness-based climate action trainings. The pilot study does not include a control group, and data will not be used for efficacy outcome analysis.
89024751|NCT00473616|Experimental|1|AZD7762 monotherapy followed by AZD7762 + irinotecan
88811716|NCT03008525|Experimental|obese patients (group OB)|patients with body mass index ≥ 35 kg/m²
88811717|NCT03008525|Active Comparator|non-obese patients (group NO)|patients with body mass index < 30 kg/m²
88811718|NCT01490723|Experimental|Yttrium-90 Ibritumomab + Chemo|Day -22 and -14, Rituximab 250 mg/m2 preceding 111In Ibritumomab and (90Y) ibritumomab tiuxetan administration, respectively. Day -22, -21 to -16, Imaging, repeated 3-6 hours later (including Single Photon Emission-Computed Tomography/Computed Tomography (SPECT/CT) scan of the abdomen). Day -14, (90Y) ibritumomab tiuxetan administration. Day -5, -4 and -3, Fludarabine and Bendamustine following Stem Cell Transplant (SCT) and CT. Fludarabine 30 mg/m2 intravenously followed by Bendamustine 130 mg/m2 intravenously. All patients receive Graft Versus Host Disease (GvHD) prophylaxis, infections disease prophylaxis, growth factors, blood and platelet transfusion and other supportive treatment.
89024752|NCT00481221||1|Screened pregnant women
89024753|NCT00435890|No Intervention|1|No triage liaison physician
89024754|NCT00481338|Experimental|Study specific procedure|X-rays, biological samples and medical information about osteoarthritis
89024755|NCT00473772|Active Comparator|Cypher Stent|
89024756|NCT00473772|Experimental|DEBlue Stent|
88960840|NCT04073615|Experimental|Rivoceranib|Participants will receive an oral dose of rivoceranib once per day on Days 1 through 28 of each 28-day cycle.
88960841|NCT04073615|Active Comparator|Trifluridine/tipiracil|Participants will receive an oral dose of Trifluridine/tipiracil twice per day with food, on Days 1 through 5 and Days 8 through 12 of each 28-day cycle.
89542863|NCT04805463|Experimental|control group|After gingivectomy and released into the secondary wound healing gingivoplasty group.
89542864|NCT04805463|Experimental|PRF group|The group in which PRF was applied to the wound surface after gingivectomy and gingivoplasty.
89542865|NCT04805463|Experimental|CGF group|The group in which CGF was applied to the wound surface after gingivectomy and gingivoplasty.
89542866|NCT04805463|Experimental|AFG group|The group in which AFG was applied to the wound surface after gingivectomy and gingivoplasty.
89542867|NCT04797351|Experimental|Experimental Group|"Pre-treatment session + 12 Sessions Group Intervention~TAU - Treatment as usual (Psychiatric support through Public health system)"
89542868|NCT04797351|No Intervention|Control Group|"TAU - Treatment as usual (Psychiatric support through Public health system)~Waiting list (will have access to the intervention program BI-REAL after the 3 month follow up assessment)"
89542869|NCT04811781||Cancer Patients with SARS-COV-2 infection.|
89542870|NCT04797663|Active Comparator|Nd-YAG laser|laser hair removal
89542871|NCT04797663|Experimental|TCA 20%|chemical peel
89542872|NCT04811547||Ankle-Brachial Index value|Valid participants were separated into 0-0.60, 0.61-0.90, 0.91-0.99, and 1.00-1.40 four ABI subgroups.
89542873|NCT04805229||Patients undergoing surgery|Retrospective cohort of patients who underwent surgery between 1/1/13 to 12/31/19 and were sampled from the Truven Health MarketScan Database.
89542874|NCT04812327||Prospective Observational Diagnostic Evaluation|Potential participants will be recruited at study sites where they are admitted/held for COVID-19 isolation. On the first day of isolation (ideally on the day they first test positive for SARS-CoV-2), potential participants will be asked to participate in the study. After consent (Study Day 0), two nasopharyngeal swabs (NP swabs) and one nasal swab will be collected. One NP swab will be tested via viral culture and the other nasal swab will be tested by RT-PCR for SARS-CoV-2. The nasal swab will be tested on the BD Veritor System. Specimen collection and testing will be repeated every 2 days for 6 days (Study Day 2, Day 4, and Day 6) or until the RT-PCR Ct value is >30, whichever comes first. Participants will be monitored for symptoms of COVID-19 throughout the study.
89542875|NCT04796805|Experimental|Essential oil application group|The experimental group received 20% black pepper essential oil in a base of aloe vera gel applied topically to the forearm using a rollerball 10 min before venipuncture. Twelve swipes were applied using the rollerball applicator. The maximum dose of the black pepper/aloe vera gel mixture was 3 mL. Sphygmomanometer cuff was placed on the right arm, and the cuff was inflated until it reached the patient's diastolic blood pressure level. When the pointer reached the desired value, the period was commenced by the researcher. The nurse determined the right vein. After selecting the right vein, the period was ended as the nurse successfully placed a catheter.
89542876|NCT04796805|No Intervention|Control group|Diastolic blood pressure and body temperature of the patients in the control group were measured. A sphygmomanometer cuff was placed on the arm that was not actively used by the patient. Until the cuff's pointer reached the diastolic blood pressure level of the patient, it was inflated. When the tip came to the desired value, the period was noted by the researcher. Without any extra attempts being made, the catheter was placed by the nurse. The period ended with the successful catheter placement by the nurse. Period of appropriate vein selection, the period of placing the catheter successfully, patient and nurse satisfaction were recorded.
89542877|NCT04426851|Experimental|Part 2: BI 1358894 (Test 2-Reference 2)|BI 1358894
89542878|NCT04426851|Experimental|Part 2: BI 1358894 (Reference 2-Test 2)|BI 1358894
89542879|NCT04426851|Experimental|Part 1: BI 1358894 (Test 1-Reference 1)|BI 1358894
89542880|NCT04796571|Experimental|Care Coordination Arm|Patients were assigned an IBD-focused care coordinator who facilitated a symptom-based monitoring algorithm and supported patient navigation to complement usual care.
89542881|NCT04796571|No Intervention|Usual Care|Participants in the usual care arm underwent symptom monitoring through regular push notifications to participants to complete a validated PRO instrument through the Epic EMR patient portal or telephone. These notifications were scheduled on a monthly basis. Results of the monthly PRO instrument were available to their treating IBD doctor with interventions at their discretion.
89542882|NCT04796571|No Intervention|passive control arn|To explore whether our usual care arm was influenced by the monthly PRO measurements required for examination of our primary outcome, we compared IBD charges, total charges, ED visits, hospitalizations, and medication utilization at 12 months in the usual care arm to a passive control arm consisting of patients who met eligibility criteria, but were not enrolled in the intervention or usual care arms.
88960842|NCT04073615|Experimental|Rivoceranib and trifluridine/tipiracil|Participants will receive a daily oral dose of rivoceranib on Days 1 through 28 and the recommended phase 2 dose (RP2D) of trifluridine/tipiracil twice per day between Days 1 to 5 and 8 to 12 of each 28-day cycle.
88960843|NCT04070521||Observational EEG Monitoring|
89542883|NCT04804683|Other|Cohort of patients with Fibromuscular Dysplasia|Intervention consists in blood/urine sampling
89542884|NCT04811157|Experimental|Test group|Healthy adults consuming test product
89542885|NCT04811157|Placebo Comparator|Control group|Healthy adults consuming control product
89542886|NCT04811391||Vaccinated participants|Participants who have received 2 doses of the pfizer Covid-19 vaccine or 1 or dose of the Astra Zeneca Covid-19 Vaccine
89542887|NCT04811391||Unvaccinated participants|Have not received any doses of any form of COVID-19 vaccine
88960844|NCT04067830|Active Comparator|Arm I (usual care)|Patients receive usual care consisting of physical therapy once weekly, receiving pre-surgical information, instruction on the use of a spirometer device, and wearing a Fitbit to track activity. Patients then undergo video-assisted thoracic surgery or laparoscopic surgery. Patients continue to track activity using the Fitbit for 3 months post-surgery.
89024757|NCT03272165|Placebo Comparator|Placebo|Participants will receive a single intravenous (IV) infusion of placebo matched to MEDI1341 and will be followed up for 13 weeks.
89024758|NCT03272165|Experimental|Cohort 1: MEDI1341 Dose 1|Participants will receive a single IV infusion of MEDI1341 Dose 1 and will be followed up for 13 weeks.
89542888|NCT04811313|Active Comparator|T group|each participant will receive 15 mg/kg of tranexamic acid diluted in a 10 mL syringe slowly over 10-15 minutes, 15 minutes before skin incision.
89542889|NCT04811313|Active Comparator|TC group|each participant will receive 10 mg/kg of tranexamic acid diluted in a 5 mL syringe slowly over 5 minutes, 15 minutes before skin incision, and A caudal epidural block with 1 mL/kg of 0.25% bupivacaine.
89542890|NCT04811313|Active Comparator|C group|each participant will receive a caudal epidural block with 1 mL/kg of 0.25% bupivacaine.
89542891|NCT04811313|Placebo Comparator|P group|participants will receive the regular standard care without adding tranexamic acid or caudal epidural block
89542892|NCT04810845|Experimental|Patients undergoing coronary angiography with planned PCI|Patients with a known coronary artery disease admitted for elective coronary angiography with planned PCI would be enrolled
89542893|NCT04810923|Experimental|i-PRF group|arthrocentesis procedure plus four consecutive intra-articular injection of i-PRF.
89542894|NCT04810923|Experimental|Control group|arthrocentesis procedure alone.
89542895|NCT04803981|Experimental|Standard diet with daily SpoonfulONE|Participants will receive one serving of SO (one of three possible forms of SO: mix-ins, puffs, or crackers) daily in addition to a standard diet. The SO form fed on a given day will be at the discretion of the parent/guardian.
89542896|NCT04803981|No Intervention|Standard diet|Participants will feed on a standard diet only, with no intervention, and complete questionnaires
89542897|NCT04352439|Experimental|Aspirin|Patients with a Khorana risk score of 1 receive 81 mg aspirin daily while receiving neoadjuvant chemotherapy for ovarian cancer.
89542898|NCT04351815|Experimental|Short prehabilitation|This arm will benefit from a 2 weeks prehabilitation program including a personalized dietetic and physical training program as well as psychological support.
89542899|NCT04351815|Other|No prehabilitation|This arm will not benefit from a prehabilitation program before surgery. Patients will be told to maintain a regular physical activity without support.
89542900|NCT04796025|Experimental|T-Double|TACE Combined With Sintilimab Plus Bevacizumab Biosimilar
89542901|NCT02592447|Experimental|Cognitive Behavior Therapy (CBT)|Cognitive Behavior Therapy for Targeted Therapy-related Fatigue (CBT-TTF) to help manage fatigue via FaceTime on an iPad, which will be provided to participants. Participants will meet with a trained therapist who will outline their therapy plan and will be taught how to use the iPad for upcoming therapy sessions.
89542902|NCT02592447|Other|Wait-List Control Condition (WLC)|Wait-List Control Condition (WLC) group will not receive therapy sessions and will continue usual care with their providers. This group will be offered the same cognitive behavior therapy as the group receiving the CBT-TTF intervention, after the 18 week study period.
89542903|NCT04810455|Experimental|Purrble -- Intervention design and logic model|"The intervention takes the form of an interactive plush toy, designed to be handed over to the child and support in-the-moment soothing; see (Theofanopoulou et al 2019, Slovak et al 2018) for the design and data from previous deployments.~The toy is introduced to the child as an anxious creature that needs kind attention from humans. When picked up, the toy emits a frantic heartbeat that slows down if the child uses calm stroking movements. If the toy is soothed for long enough, it transitions into a purring vibration indicating a calm, content state.~Logic model underlying the intervention:~Level 1: in-the-moment soothing support to children in emotional moments when they would attempt to calm down.~Level 2: mechanisms that facilitate long-term engagement with the intervention, building on positive subjective experience of Level 1.~Level 3: shift in children's ER practices and implicit beliefs about emotion, after repeated experience of Levels 1-2."
89542904|NCT04810455|Active Comparator|Non-interactive plush toy -- active control group|"The investigators argue that a comparison with a non-active control-such as waiting list / treatment-as-usual (i.e., nothing)-would not allow us to distinguish the hypothesised impact on in-the-moment soothing of interactivity vs. the emergence of new family routines; and would be also open to unequal social desirability bias.~However, from the perspective of the hypothesised logic model (Levels 1-3), it is not necessary for the active control to have exactly the same form factor as the active toy, as long as it is comparable in size, shape, and appeal. In fact, the investigators have explicitly decided not to use deactivated Purrble units as active controls due to the increased risk of unblinding, whereby the participants search for or come across Purrble online (or notice the plastic enclosure with electronics inside the toy), and assume their unit is malfunctioning."
89542905|NCT04795479|Experimental|Treatment Sequence 1|Participants will receive relacorilant 400 mg once daily (QD) for 5 days in Period 1, followed by relacorilant 800 mg QD for 5 days in Period 2, followed by placebo to relacorilant QD for 5 days in Period 3, followed by placebo to relacorilant QD for 4 days and moxifloxacin 400 mg on Day 5 in Period 4. Treatment periods will be separated by a washout of at least 10 days.
89542906|NCT04795479|Experimental|Treatment Sequence 2|Participants will receive relacorilant 800 mg QD for 5 days in Period 1, followed by placebo to relacorilant QD for 4 days and moxifloxacin 400 mg on Day 5 in Period 2, followed by relacorilant 400 mg QD for 5 days in Period 3, followed by placebo to relacorilant QD for 5 days in Period 4. Treatment periods will be separated by a washout of at least 10 days.
89542907|NCT04795479|Experimental|Treatment Sequence 3|Participants will receive placebo to relacorilant QD for 5 days in Period 1, followed by relacorilant 400 mg QD for 5 days in Period 2, followed by placebo to relacorilant QD for 4 days and moxifloxacin 400 mg on Day 5 in Period 3, followed by relacorilant 800 mg QD for 5 days in Period 4. Treatment periods will be separated by a washout of at least 10 days.
89542908|NCT04795479|Experimental|Treatment Sequence 4|Participants will receive relacorilant QD for 4 days and moxifloxacin 400 mg on Day 5 in Period 1, followed by placebo to relacorilant QD for 5 days in Period 2, followed by relacorilant 800 mg QD for 5 days in Period 3, followed by relacorilant 400 mg QD for 5 days in Period 4. Treatment periods will be separated by a washout of at least 10 days.
89542909|NCT04795479|Experimental|Treatment Sequence 5|Participants will receive relacorilant 800 mg QD for 5 days in Period 1, followed by placebo to relacorilant QD for 5 days in Period 2, followed by relacorilant 400 mg QD for 5 days in Period 3, followed by relacorilant QD for 4 days and moxifloxacin 400 mg on Day 5 in Period 4. Treatment periods will be separated by a washout of at least 10 days.
89542910|NCT04795479|Experimental|Treatment Sequence 6|Participants will receive placebo to relacorilant QD for 5 days in Period 1, followed by placebo to relacorilant QD for 4 days and moxifloxacin 400 mg on Day 5 in Period 2, followed by relacorilant 800 mg QD for 5 days in Period 3, followed by relacorilant 400 mg QD for 5 days in Period 4. Treatment periods will be separated by a washout of at least 10 days.
89542911|NCT04795479|Experimental|Treatment Sequence 7|Participants will receive relacorilant 400 mg QD for 5 days in Period 1, followed by relacorilant 800 mg QD for 5 days in Period 2, followed by placebo to relacorilant QD for 4 days and moxifloxacin 400 mg on Day 5 in Period 3, followed by placebo to relacorilant QD for 5 days in Period 4. Treatment periods will be separated by a washout of at least 10 days.
89542912|NCT04795479|Experimental|Treatment Sequence 8|Participants will receive placebo to relacorilant QD for 4 days and moxifloxacin 400 mg on Day 5 in Period 1, followed by relacorilant 400 mg QD for 5 days in Period 2, followed by placebo to relacorilant QD for 5 days in Period 3, followed by relacorilant 800 mg QD for 5 days in Period 4. Treatment periods will be separated by a washout of at least 10 days.
89542913|NCT04795479|Experimental|Treatment Sequence 9|Participants will receive placebo to relacorilant QD for 5 days in Period 1, followed by relacorilant 400 mg QD for 5 days in Period 2, followed by relacorilant 800 mg QD for 5 days in Period 3, followed by placebo to relacorilant QD for 4 days and moxifloxacin 400 mg on Day 5 in Period 4. Treatment periods will be separated by a washout of at least 10 days.
89024759|NCT03272165|Experimental|Cohort 2: MEDI1341 Dose 2|Participants will receive a single IV infusion of MEDI1341 Dose 2 and will be followed up for 13 weeks.
89542914|NCT04795479|Experimental|Treatment Sequence 10|Participants will receive relacorilant 400 mg QD for 5 days in Period 1, followed by placebo to relacorilant QD for 4 days and moxifloxacin 400 mg on Day 5 in Period 2, followed by placebo to relacorilant QD for 5 days in Period 3, followed by relacorilant 800 mg QD for 5 days in Period 4. Treatment periods will be separated by a washout of at least 10 days.
89542915|NCT04795479|Experimental|Treatment Sequence 11|Participants will receive relacorilant 800 mg QD for 5 days in Period 1, followed by placebo to relacorilant QD for 5 days in Period 2, followed by placebo to relacorilant QD for 4 days and moxifloxacin 400 mg on Day 5 in Period 3, followed by relacorilant 400 mg QD for 5 days in Period 4. Treatment periods will be separated by a washout of at least 10 days.
89542916|NCT04795479|Experimental|Treatment Sequence 12|Participants will receive placebo to relacorilant QD for 4 days and moxifloxacin 400 mg on Day 5 in Period 1, followed by relacorilant 800 mg QD for 5 days in Period 2, followed by relacorilant 400 mg QD for 5 days in Period 3, followed by placebo to relacorilant QD for 5 days in Period 4. Treatment periods will be separated by a washout of at least 10 days.
89542917|NCT04810533|Experimental|[14C] SH-1028|Volunteers will receive 200 mg [14C] SH-1028 containing a nominal 88 μCi activity, administered by mouth, as a solution.
89542918|NCT04803903||HPI + GDHT treatment|HPI + GDHT treatment using the FlowTraQ sensor and EV1000 monitor with the HPI algorithm incorporated following our protocol for hemodynamic treatment (fluids, vasopressors and inotropes) administered
89542919|NCT04803903||Control|Conventional treatment with invasive blood pressure monitoring. Administration of fluids and/or vasopressors are guided by standard hemodynamic parameters at the discretion of the attending physician.
89542920|NCT04803279||Ponto 3 SuperPower users|"Patients who are fitted either unilaterlaly or bilatterally on abutment since the device came to the market in 2016, and who have follwoed the clinics normal routine fitting and follow up visits.~They must also have undergone the normal procedures performed as part of the clinics routine for fitting and following up. Data will be collected from these routine visits."
89542921|NCT04795011|Active Comparator|control group|Standard rehabilitation protocol will be administered to the control group. In the standard rehabilitation protocol for the first three days after surgery, 3 sets of exercises will be applied as 10 repetitions. The treatment will be initiated for the patients with tolerable coughing and deep breathing exercises. Active dorsi-plantar flexion of the ankle, isometric contraction for the quadriceps, hamstrings and gluteus maximus, for the knee in the supine position on the bed; active heel shift exercises, straight leg raising and standing knee and hip flexion, active hamstring curling, and self-hamstring stretching will be performed. After the exercise, the morning treatment protocol will be completed with a walker at a tolerable distance. The patient will be given assignment in the form of walking and repetition of morning exercises at a tolerable level at least twice during the day.
89542922|NCT04795011|Experimental|manual lymphatic drainage group|manual lymphatic drainage (MLD) will be applied to the second group (MLD group) in addition to the standard rehabilitation protocol
89542923|NCT02595723|Experimental|Phenytoin, Then Megestrol|Participants first received pretreatment with Phenytoin 200 mg capsule twice/day for one day. Participants then received both Phenytoin (200 mg capsule twice/day) and liquid Megestrol (800 mg/day) for three consecutive days.
89542924|NCT02595723|Experimental|Placebo, Then Megestrol|Participants first received pretreatment with Placebo (matching Phenytoin 200 mg capsule) twice/day for one day. Participants then received both Placebo (matching Phenytoin 200 mg capsule) twice/day and liquid Megestrol (800 mg/day) for three consecutive days.
89542925|NCT02595723|Experimental|Placebo, Then Placebo|Participants first received pretreatment with Placebo (matching Phenytoin 200 mg capsule) twice/day for one day. Participants then received both Placebo (matching Phenytoin 200 mg capsule) twice/day and liquid Placebo (matching liquid Megestrol 800 mg/day) for three consecutive days.
89024760|NCT03272165|Experimental|Cohort 3: MEDI1341 Dose 3|Participants will receive a single IV infusion of MEDI1341 Dose 3 and will be followed up for 13 weeks.
89024761|NCT03272165|Experimental|Cohort 4: MEDI1341 Dose 4|Participants will receive a single IV infusion of MEDI1341 Dose 4 and will be followed up for 13 weeks.
88811719|NCT04351217|Experimental|Music|Music was Indian Classical Flute music, 23 minutes long. It was played on a speaker at equal volume to ensure uniformity.
88811720|NCT04351217|Experimental|Progressive Muscle Relaxation|Progressive Muscle Relaxation was recorded for uniformity of delivery, and was 22 minutes in length. It was played on a speaker at equal volume to ensure uniformity.
89024762|NCT03272165|Experimental|Cohort 5: MEDI1341 Dose 5|Participants will receive a single IV infusion of MEDI1341 Dose 5 and will be followed up for 13 weeks.
89542926|NCT04810065|Other|SingStrong for Pulmonary Fibrosis|"This arm of the project explores Singing as an intervention for people suffering from Pulmonary Fibrosis specifically.~It is a 10 week programme. All other aspects of the intervention are the same in terms of delivery and length of classes.~Different outcome measures, namely the St Georges Respiratory Questionnaire is used in this trial. This is a disease-specific instrument designed to measure impact on overall health, daily life, and perceived well-being in patients with airways disease. Scores range from 0 to 100, with higher scores indicating more limitations."
89542927|NCT01667679|Experimental|OPTINOSE SUMATRIPTAN and Placebo|20 mg OPTINOSE SUMATRIPTAN Powder Delivered Intranasally With the Bi-directional Device nasally and Placebo Tablet
89542928|NCT01667679|Active Comparator|100mg Sumatriptan and OPTINOSE Placebo|100 mg Sumatriptan Tablet and OPTINOSE Placebo delivered nasally
89542929|NCT04794933|Active Comparator|Conventional therapy (CT)|Cold pack (15 minutes); pulsed ultrasound therapy (1 watt/cm², 3 MHz, 1:2 pulsed mode; 3 minutes); transcutaneous electrical nerve stimulation (60-120 Hz; 20 minutes) and exercises (20 minutes). The exercises included stretching, strengthening and posture exercises.
89542930|NCT04794933|Experimental|CT+ PNF in extremity pattern|PNF in the extremity pattern, were instructed to actively move through the PNF flexion-abduction-external rotation diagonal pattern for 10 repetitions with manual facilitation and the treatment was performed within the range in which pain did not occur. Rhythmic stabilization and repeated contractions were applied from the PNF techniques.
89542931|NCT04794933|Experimental|CT+ PNF in extremity pattern+PNF in scapula and upper trunk patterns|PNF in scapula and upper trunk patterns in addition to PNF in the extremity pattern. The scapular pattern application was performed by positioning the affected extremity in a relaxed position above the stable side in the side-lying position. Rhythmic stabilization and repeated contractions were applied from the anterior-elevation position in the direction of posterior-depression. Extension, lateral flexion and rotation to the affected side were performed in the trunk patterns in rhythmic stabilization and repeated contractions.
89542932|NCT04286451|Experimental|Sleep Restriction|Women will undergo 4 nights of sleep restriction treatment.
89542933|NCT04286451|Experimental|Habitual Sleep|Women will undergo 4 nights of habitual sleep treatment.
89542934|NCT02597049|Experimental|1.5 mg Dulaglutide|1.5 milligrams (mg) given subcutaneously (SC) once a week for 24 weeks.
89542935|NCT02597049|Experimental|0.75 mg Dulaglutide|0.75 mg dulaglutide given SC once a week for 24 weeks.
89542936|NCT02597049|Placebo Comparator|Placebo|Placebo given SC once a week for 24 weeks.
89542937|NCT04809675|Active Comparator|HOS-HOS-FCM-FCM sequence|Use of a hard occlusal splint (HOS) for the first two weeks, followed by a week off, and a flexible customized mouthguard (FCM) for the fourth and fifth week.
89542938|NCT04809675|Active Comparator|FCM-FCM-HOS-HOS sequence|Use of a flexible customized mouthguard (FCM) for the first two weeks, followed by a week off, and a hard occlusal splint (HOS) for the fourth and fifth week.
89542939|NCT04809441|Experimental|Weight loss group|Participants were rigorously evaluated by the same endocrine doctor and podiatrist at baseline (Session 1) and at the end of the study after weight loss intervention (Session 2), when each participant had lost between 11-12% of its corporal weight. Therefore, we obtained 2 weight related with the two sessions: Session 1 - Weight 1; Session 2 - Weight 2.
89542940|NCT04427085|Experimental|Obese group|body mass index≥ 30 kg/m2
89542941|NCT04427085|Active Comparator|Non-obese group|BMI < 30 kg/m2
89542942|NCT04803045||Follow Up Email|Patients received a follow up email 3 months after an initial consult with a physician but did not return to care.
89542943|NCT04803045||No follow up|Patients who did not receive any follow up after their initial consult, following clinic standard of care.
89542944|NCT04802967|Experimental|KLS-GABA (part A and B)|"KLS-GABA 80 mg-34 mg capsules are administered once in the morning of Day 1 in Part A in Treatment Periods 1 and 2 in the fasted state, according to the randomisation schedule. Capsules are administered with 240 mL of water.~KLS-GABA (40 mg-17mg, 80 mg-34 mg, or 160 mg-68 mg) in Part B are administered as capsules once in the morning of Day 1 in the fasted state. Capsules are administered with 240 mL of water.~To maintain he blind, subjects assigned to receive 160 mg-68 mg KLS-GABA are administered two co-crystal KLS-GABA 114 mg (80 mg-34 mg) capsules, and subject assigned to receive 40 mg-17 mg KLS-GABA or 80 mg-34 mg KLS-GABA also receive a placebo capsule (dummy placebo)."
88960845|NCT04067830|Experimental|Arm II (RMT + usual care)|Patients use a power lung device to complete 3 sets of 15 RMT exercises over 30 minutes 6 days per week over 2-4 weeks for a minimum of 12 sessions prior to surgery. Patients also receive usual care consisting of attending physical therapy once weekly, receiving pre-surgical information, instruction on the use of a spirometer device, and wearing a Fitbit to track activity. Patients then undergo video-assisted thoracic surgery or laparoscopic surgery. Patients continue to track activity using the Fitbit for 3 months post-surgery.
88960846|NCT04050579|Other|OPIE in thin inverventricular septum|The Principal Investigator use the OPIE probe to measure the anterior basilar septal thickness. Myectomy will be performed and OPIE will be repeated.
88960847|NCT04050085|Experimental|Treatment (SD-101, radiation therapy, nivolumab)|Patients receive TLR9 agonist SD-101 intratumorally on days 1 and 8 of cycle 1 and day 1 of cycles 2-5. Treatment repeats every 2 weeks for up to 5 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo radiation therapy on days 1, 3, 5, 8, and 10 of cycle 1. Patients also receive nivolumab IV over 30 minutes on day 2. Cycles with nivolumab repeat every 2 weeks for 24 months in the absence of disease progression or unacceptable toxicity.
88960848|NCT04043403|Experimental|Device: Summit RC+S|"Open Loop DBS: Standard DBS therapy at a constant frequency and voltage~Adaptive (Closed Loop) DBS: DBS that responds to neural or kinematic features of patient's current state~Intermittent Open Loop DBS: Control for aDBS - DBS intensity or frequency changes in a manner that mimics aDBS but is pre-determined and open loop rather than being responsive to neural or kinematic signals."
88960849|NCT04043403|Experimental|Device: Percept PC|"Open Loop DBS: Standard DBS therapy at a constant frequency and voltage~Adaptive (Closed Loop) DBS: DBS that responds to neural features of patient's current state"
88960850|NCT04042558|Experimental|Cohort with Bevacizumab|"4 cycles of induction every 3 weeks with :~Carboplatin area under curve 6 mg/mL per minute per IV route or Cisplatin 75 mg/m² per IV route~Pemetrexed 500 mg/m² per IV route~Atezolizumab 1200 mg per IV route~Bevacizumab 15 mg/kg per IV route For patients without disease progression, treatment will be followed by maintenance therapy by Atezolizumab + Pemetrexed and Bevacizumab administered at the same dosage on 3-week cycles"
89542945|NCT04802967|Active Comparator|KLS (part A and B)|"KLS 80 mg capsules are administered once in the morning of Day 1 in Part A in Treatment Periods 1 and 2 in the fasted state, according to the randomisation schedule. Capsules will be administered with 240 mL of water.~In the part B KLS (40 mg, 80 mg or 160 mg) are administered as capsules once in the morning of Day 1 in the fasted state. Capsules are administered with 240 mL of water. To maintain the blind, subjects assigned to receive 160 mg KLS alone are administered two KLS 80 mg capsules and subjects assigned to receive either 40 mg KLS alone or 80 mg KLS alone also receive a placebo capsule (dummy placebo)."
89542946|NCT04802967|Active Comparator|Gabapentin (part B)|Gabapentin 300 mg are administered as capsules once in the morning of Day 1 in the fasted state. Capsules are administered with 240 mL of water.To maintain the blind, subjects assigned to receive 300 mg gabapentin also receive a placebo capsule (dummy placebo).
89542947|NCT04802967|Placebo Comparator|Placebo (part B)|To maintain the blind subjects assigned to receive placebo receive 2 placebo capsules. Capsules will be administered with 240 mL of water.
89542948|NCT04426617|Experimental|fentanyle|: patients will receive US guided unilateral Transversus abdominis plane block (25 ml bupivacaine 0.25% & fentanyl).
89542949|NCT04426617|Experimental|Midazolam|patients will receive us guided unilateral Transversus abdominis plane block (25 ml bupivacaine 0.25% & midazolam).
89542950|NCT04426617|Placebo Comparator|control|patients will receive us guided unilateral Transversus abdominis plane block (25 ml bupivacaine 0.25%).
89542951|NCT04263441|Experimental|NICE Intervention|The proposed intervention will engage clients in the health care enrollment and navigation process in-person, at the time of the HIV testing event. Subjects will be asked to share thoughts on the satisfaction survey.
88960851|NCT04042558|Experimental|Cohort without Bevacizumab|"4 cycles of induction every 3 weeks with :~Carboplatin area under curve 6 mg/mL per minute per IV route or Cisplatin 75 mg/m² per IV route~Pemetrexed 500 mg/m² per IV route~Atezolizumab 1200 mg per IV route For patients without disease progression, treatment will be followed by maintenance therapy by Atezolizumab + Pemetrexed administered at the same dosage on 3-week cycles"
88960852|NCT04040946|Other|TEMP-TDM with MIBI|Performing a MIBI scintigraphy, then, in the case of negativity, a F18-choline PET
88960853|NCT04040946|Other|F18-choline PET|Realization of F18-choline PET, then, in case of negativity, a MIBI scintigraphy
88960854|NCT04038099|Placebo Comparator|Water Based Lubricating Jelly|5ml of Water Based Lubricating Jelly
88960855|NCT04038099|Active Comparator|Lidocaine 2% Jelly|5ml of Lidocaine 2% Jelly
89542952|NCT04263441|No Intervention|Control Intervention|Subjects will be offered a handout on how to enroll in healthcare coverage This group will be provided with the site's standard healthcare enrollment and linkage to care, which is specific to the health care clinic they are visiting. Subjects will be followed for 1 year and information including lab tests and insurance coverage status will be collected. This information will be collected from medical record review. Subjects will be asked to share thoughts on the satisfaction survey.
89542953|NCT04802889|Experimental|cadaver eyes|The Central region of the retina and preretinal structures of cadaver eyes are examined
89542954|NCT05616117||High-dose intrauterine D3-vitamin|Children of mothers who received 90 µg vitamin D3 daily during pregnancy from 12 weeks to delivery.
89542955|NCT05616117||Low-dose intrauterine D3-vitamin|Children of mothers who received 10 µg vitamin D3 daily during pregnancy from 12 weeks to delivery
89542956|NCT04802421|Active Comparator|CPAP30|a 30 secondes 30 cmH2O continuous positive airway pressure applied after the orotracheal intubation will be checked and secured following induction of general anesthesia
89542957|NCT04802421|Active Comparator|STEP30|a stepwise increase (+5 cmH2O) in postivie airway pressure from +5 cmH2O to +30 cmH2O and decrease (-5 cmH2O) from +30 cmH2O to +5 cmH2O applied after the orotracheal intubation will be checked and secured following induction of general anesthesia
89542958|NCT05615961|Experimental|Probiotic Supplementation Arm|This group will receive the probiotic supplement for 4-weeks prior to their ironman race performance.
89542959|NCT05615961|Placebo Comparator|Placebo Arm|This group will receive the placebo capsules for 4-weeks prior to their ironman race performance.
88960856|NCT04037423||PE patients treated with CDT|Acute pulmonary embolism patients undergoing catheter-directed embolectomy.
88960857|NCT04034238|Experimental|1. Dose escalation|LMB-100 at escalating doses plus tofacitinib
88960858|NCT04034238|Experimental|2. Dose expansion|LMB-100 at optimal dose plus tofacitinib
88960859|NCT04034030|Experimental|Treatment Group|This study will be conducted over one year in 10 focal CSWS patients ranging in age from 3 to 21 years. The patients will be recruited from the large patient population that is served by the Children's Mercy Comprehensive Epilepsy Monitoring Unit (EMU) in Overland Park, Kansas. Subjects will be identified from these EMU patient population. Those meeting inclusion criteria will be approached for possible enrollment. Inclusion criteria will be defined by patients that were diagnosed with focal CSWS in accordance with the ILAE classification with SWI >85% during NREM sleep on their previous or most recent EEG. Patients and their parents/guardians will provide assent/consent for participation in the study after being briefed on the nature of the study, by reading and signing assent and assent/consent forms, respectively
88960860|NCT04018625|Experimental|Intervention|Participants (n = 30) will be randomized to receive the SMART Pregnancy stress management program via an online portal.
88960861|NCT04018625|Active Comparator|Treatment as usual|Participants (n = 30) will be randomized to receive treatment as usual, including referrals to community based support groups and individual mental health providers.
89542960|NCT02594163|Experimental|Brentuximab Vedotin|Subjects randomized to the brentuximab vedotin arm will receive IV infusions of brentuximab vedotin followed by bendamustine on day 1, and rituximab followed by bendamustine on day 2 of each 21 day cycle.
89542961|NCT02594163|Active Comparator|Rituximab,Bendamustine control|Subjects randomized to the control arm will receive IV infusions of rituximab on day 1 or day 2 and bendamustine on both days 1 and 2 of each 21 day cycle.
89542962|NCT04801875|Experimental|Violin Performers|Violin performers received three 40-45 minute exercise sessions each week for eight weeks. The selected exercise program designed to correct postural alignment.
89024763|NCT03272165|Experimental|Cohort 6: MEDI1341 Dose 6|Participants will receive a single IV infusion of MEDI1341 Dose 6 and will be followed up for 13 weeks.
88960862|NCT03994172|Experimental|teriparatide (TPTD) + the calcimimetic cinacalcet|Combination arm: Men randomized to this arm will take daily subcutaneous injections of teriparatide [PTH (1-34)] (20 mcg per day) and at the same time swallow a 30-mg tablet of cinacalcet. Men in both arms of the study will take a total of approximately 1000 mg elemental Ca through their diets and study provided Ca supplements (Ca citrate) and approximately 1000 IU vitamin D3. Men will be followed and assessed throughout the entire study using the clinical (vital signs, adverse events), laboratory (blood and urine tests) and densitometric procedures (DXA BMD and TBS) outlined in the study protocol.
89024764|NCT00473811|Active Comparator|ADA diet|Patients will be encouarged to consume foods consisted with ADA dietary recommendation
89542963|NCT04801875|Experimental|Ney Performers|Ney performers received three 40-45 minute exercise sessions each week for eight weeks. The selected exercise program designed to correct postural alignment.
89542964|NCT04801719|Experimental|Experimental arm - endoluminal RFA|standard treatment protocol for malignant biliary stenosis + endoluminal RFA prior metal stent insertion
89542965|NCT04801719|No Intervention|Control arm|standard treatment protocol for malignant biliary stenosis which includes metal stent insertion
89542966|NCT04801407|Active Comparator|radiofrequency group|it is the group that will be treated with Percutaneous Radiofrequency Rhizotomy
89542967|NCT04801407|Active Comparator|Microvascular decompression group|it is the group that will be treated with Microvascular decompression
89542968|NCT05615883|Experimental|AEP Group|First series of patients (10 pts) will be assigned to the Acute Exercise Protocol Group (AEP Group). The acute program consists in a single walking session on a treadmill lasting 80 minutes. The exercise session will begin with a 10-minute warm-up at the patient's self selected comfortable speed. On the ending of warm up, treadmill speed will be increased until reaching target HRR zone. Then the treadmill speed will be maintained stable throughout the exercise session. Cardiac workload will be monitored by a Sport-watch (Garmin Forerunner) and the walking biomechanics by a foot sensor (Garmin Running Dynamic Pod Sensore).
89542969|NCT05615883|Experimental|CEP Group|Second series of patients (10 pts) will be assigned to the Chronic Exercise Protocol Group (CEP Group). The chronic program consists in a walking session on a treadmill lasting 80 minutes (depending on the AEP results), repeated three time a week for three weeks. The walking intensity will be defined during a treadmill test performedbefore the beginning of the exercise program. Each exercise session will beginwith a 10-minute warm-up at the patient's self selected comfortable speed. On the ending of warm up, patients will increase treadmill speed until reaching target HRR zone.Then the treadmill speed will be maintained stable throughout the exercise session. The first training session will be organized in hospital with supervision of research staff. Cardiac workload will be monitored by a Sport-watch (Garmin Forerunner) and walking biomechanics by a foot sensor (Garmin Running Dynamic Pod Sensore).
89542970|NCT02712983|Experimental|Cohort A (3 capsules o.d.): TIP|Cohort A (3 capsules o.d.): Tobramycin inhalation powder (TIP)
89542971|NCT02712983|Experimental|Cohort A (3 capsules o.d.): TIP/PBO|Cohort A (3 capsules o.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical
89542972|NCT02712983|Placebo Comparator|Cohort A (3 capsules o.d.): PBO|Cohort A (3 capsules o.d.): Inhaled placebo (PBO)
89542973|NCT02712983|Experimental|Cohort B (5 capsules o.d.): TIP|Cohort B (5 capsules o.d.): Tobramycin inhalation powder (TIP)
89542974|NCT02712983|Experimental|Cohort B (5 capsules o.d.): TIP/PBO|Cohort B (5 capsules o.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical
89542975|NCT02712983|Placebo Comparator|Cohort B (5 capsules o.d.): PBO|Cohort B (5 capsules o.d.): inhaled placebo (PBO)
89542976|NCT02712983|Experimental|Cohort C (4 capsules b.i.d.): TIP|Cohort C (4 capsules b.i.d.): Tobramycin inhalation powder (TIP)
89542977|NCT02712983|Experimental|Cohort C (4 capsules b.i.d.): TIP/PBO|Cohort C (4 capsules b.i.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical
89542978|NCT02712983|Placebo Comparator|Cohort C (4 capsules b.i.d.): PBO|Cohort C (4 capsules b.i.d.): inhaled placebo (PBO)
89542979|NCT03201107|Experimental|Pilates group|This group receives physical training based on pilates exercises
89542980|NCT03201107|No Intervention|No intervention group|This group does not receive any treatment
89542981|NCT02449967|Experimental|HepaSphere|pancreatic cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
89542982|NCT02449967|No Intervention|control|pancreatic cancer patients did not receive any interventional therapy
89024765|NCT00473811|Experimental|Low-GI|a low GI dietary education
89542983|NCT03206255||9-17y (0,1,6m)|Participants in this arm have received 60μg of HPV 16/18 bivalent vaccine according to 3 doses of HPV 16/18 bivalent vaccine
89542984|NCT03206255||9-14y (0,6m)|Participants in this arm have received 60μg of HPV 16/18 bivalent vaccine according to 2 doses of HPV 16/18 bivalent vaccine
89542985|NCT03206255||18-26y (0,1,6m)|Participants in this arm have received 60μg of HPV 16/18 bivalent vaccine according to 3 doses of HPV 16/18 bivalent vaccine
89542986|NCT03200873|Active Comparator|high impulsivity|participants with high impulsivity (BIS >62), receiving active and sham repetitive transcranial magnetic stimulation [intermittent theta burst stimulation (iTBS)] in a randomised order
89542987|NCT03200873|Active Comparator|low impulsivity|participants with low impulsivity (BIS between 52 to 62), receiving active and sham repetitive transcranial magnetic stimulation [intermittent theta burst stimulation (iTBS)] in a randomised order
89542988|NCT03200951|Experimental|Bolus group|
89542989|NCT03200951|Active Comparator|Infusion group|
89542990|NCT03206021|Experimental|Phase I Dose-escalation|5'azacytidine will be administered on Days 1-7 at a dose of 75mg/m2/day, followed by escalating doses of Carboplatin on Day 14 in a rolling 6 design. Carboplatin will be dosed initially at AUC 4. Dose level -1 will reduce 5'azacytidine to 50mg/m2/day.
89542991|NCT03206021|Experimental|Posterior Fossa Ependymoma Expansion Arm|5'azacytidine will be administered on days 1-7 and carboplatin will be administered on day 14 at the maximum tolerated dose achieved in the Phase I dose escalation to 20 patients with recurrent/refractory posterior fossa ependymoma.
89542992|NCT03206021|Experimental|Recurrent Brain and Solid Tumour Expansion Arm|5'azacytidine will be administered on days 1-7 and carboplatin will be administered on day 14 at the maximum tolerated dose achieved in the Phase I dose escalation up to 12 patients with recurrent/refractory brain and solid tumour.
89542993|NCT03200795|Experimental|Rebound exercise group|Participants randomized to this group will be instructed on the proper techniques of the desired movements (hopping) on the rebounder.
89542994|NCT03200795|Experimental|Circuit training group|The circuit training for the participants in this group will be designed for each participant. Training will take place 3 times a week for 8 weeks. The participants will undergo 10 minutes warm up before and 10 minutes cool down after the training. Resistance exercises will be performed on weight machines. Throughout the resistance training program, participants will be alternating between the bench press, seated row, lateral pull down, biceps forward, front thigh, back thigh, leg press and rowing.
89542995|NCT03205631|Sham Comparator|Sham Natural Frequency Patch|
89542996|NCT03205631|Active Comparator|Active Natural Frequency Patch|
89542997|NCT03200639|Active Comparator|Physical training, CT|Combined Trained with no cancer (CT): Post menopausal women with no cancer submitted to 12 weeks of combined training (i.e. aerobic training plus resistance training)
89542998|NCT03200639|Active Comparator|Physical training, HIITBW|High intensity interval training with body weight with no cancer (HIITBW): Post menopausal women with no cancer submitted to 12 weeks of high intensity interval training with body weight (i.e. step climbing plus squats)
89542999|NCT03200639|Experimental|Physical training, CTc|Combined Trained with gynecological and/or breast cancer (CTc): Post menopausal women with with gynecological and/or breast cancer submitted to 12 weeks of combined training (i.e. aerobic training plus resistance training)
88960863|NCT03994172|Placebo Comparator|teriparatide (TPTD) + placebo|Monotherapy arm: Men randomized to this arm will take daily subcutaneous injections of teriparatide [PTH (1-34)] (20 mcg per day) and at the same time swallow a placebo tablet. Men in both arms of the study will take a total of approximately 1000 mg elemental Ca through their diets and study provided Ca supplements (Ca citrate) and approximately 1000 IU vitamin D3. Men will be followed and assessed throughout the entire study using the clinical (vital signs, adverse events), laboratory (blood and urine tests) and densitometric procedures (DXA BMD and TBS) outlined in the study protocol.
89543000|NCT03200639|Experimental|Physical training, HIITBWc|High intensity interval training with body weight with gynecological and/or breast cancer (HIITBWc): Post menopausal women with gynecological and/or breast cancer submitted to 12 weeks of high intensity interval training with body weight (i.e. step climbing plus squats)
89543001|NCT03200561|Active Comparator|S group|IVIG (2g/Kg in 12 hours)+oral prednisolone (2mg/Kg/day for 5 days)
89543002|NCT03200561|Placebo Comparator|I group|IVIG (2g/Kg in 12 hours)
89543003|NCT03200405|Experimental|DynaMeshVisible|the umbilical hernia will be fixed with a mesh, which is incorporated with Fe3O4 particles to become visible in MRI
89543004|NCT03200405|Active Comparator|DynaMeshCICAT|the umbilical hernia will be fixed with a Non-MRI-visible PVDF Mesh
89543005|NCT03118817|Experimental|HM95573|Single arm
89543006|NCT03118583|Experimental|Dietary supplement with carrageenan|300 mg/day of dietary supplement containing carrageenan
89543007|NCT02449811||Perindopril|Treatment period 1: Perindopril 5mg, oral, once daily, for 4 weeks Treatment period 2: Perindopril 10mg, oral, once daily, for 4 weeks
89543008|NCT02449811||Olmesartan|Treatment period 1: Olmesartan 20mg, oral, once daily, for 4 weeks Treatment period 2: Olmesartan 40mg, oral, once daily, for 4 weeks
89543009|NCT02449811||Amlodipine|Treatment period 1: Amlodipine 5mg, oral, once daily, for 4 weeks Treatment period 2: Amlodipine 10mg, oral, once daily, for 4 weeks
89543010|NCT02449811||Hydrochlorothiazide|Treatment period 1: Hydrochlorothiazide 25mg, oral, once daily, for 4 weeks Treatment period 2: Hydrochlorothiazide 50mg, oral, once daily, for 4 weeks
89543011|NCT03200093|Experimental|Oral vancomycin|"Oral vancomycin solution 125 mg in 2.5 mL, combined with 2.5 ml Ora-Sweet solution, to total 5 mL.~Taken by mouth once daily for:~If the total duration of systemic antibiotics is less than or equal to 14 days, oral vancomycin will be taken for the duration of the systemic antibiotics plus three days.~If the total duration of systemic antibiotics is greater than 14 days, oral vancomycin will be taken for the duration of the systemic antibiotics plus seven days."
89543012|NCT03200093|Placebo Comparator|Placebo arm|"Ora-Sweet 5 mL~Taken by mouth once daily for:~If the total duration of systemic antibiotics is less than or equal to 14 days, placebo will be taken for the duration of the systemic antibiotics plus three days.~If the total duration of systemic antibiotics is greater than 14 days, placebo will be taken for the duration of the systemic antibiotics plus seven days."
88960864|NCT03983291|Experimental|FaReWell Depression|Physiotherapeutic exercises for the relaxation of facial muscles associated with the expression of negative emotions and for the activation and strengthening of facial muscles associated with the expression of positive emotions 15 minutes daily
88960865|NCT03983291|Placebo Comparator|Resting exercise|Resting 15 minutes daily
88960866|NCT03980873|Experimental|Experimental|An experimental group. The psychological treatment includes 10 sessions of cognitive-behavioural treatment ESTEEM (Effective Skills to Empower Effective Men) is a 10-session intervention based on the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders
88960867|NCT03980873|No Intervention|Control|Three-month waitlist
88960868|NCT03978442|Experimental|CPT-SMART|COGNITIVE PROCESSING THERAPY with SMOKING ABSTINENCE REINFORCEMENT THERAPY (CPT-SMART) - an intervention that combines evidence-based PTSD treatment with guideline-concordant cognitive-behavioral smoking cessation counseling, bupropion, and intensive behavioral therapy through CM.
89024766|NCT02957474|Experimental|Treatment A = single oral dose GED 0301, fasted|Subjects will receive a single oral 160 mg dose of GED-0301 after a 10 hour overnight fast
89543013|NCT03200171||Group I|HCC patients who received DAAs for chronic HCV previously (either responders or not)
89543014|NCT03200171||Group II|HCC patients who are naive to DAAs.
89543015|NCT03200249|Experimental|Treatment|"- Treatment : concomitant preoperative radio-chemotherapy (during 5 weeks)~Chimiotherapy: Capecitabine 1600 mg/m2/j ; 5/7 days during the 5 weeks of radiotherapy~Radiotherapy RT + SIB-IMRT (5 weeks ; 5 sessions/week ; 25 sessions): Pelvic prophylactic dose of 45 Gy (1,8 Gy/session); boost with a dose of 60 Gy on the tumor PTV (2,4 Gy/session) - Total dose: 60 Gy in 25 sessions during 5 weeks.~- TME surgery (8 weeks after the end of treatment)"
89543016|NCT04485533|Experimental|VisuXL® Gel/HYLO®|Patients treated with VisuXL® ophthalmic gel for the first 30 days (1 treatment period) and with HYLO® for the second 30 days (2 treatment period).
88960869|NCT03978442|Active Comparator|Combined Contact Yoked Control|COMBINED CONTACT YOKED CONTROL (CCYC) - an intervention that is identical to CPT-SMART for PTSD and smoking treatment, except for using non-contingent payment (i.e., yoked CM) to control for compensation and monitoring.
88960870|NCT03958136|Experimental|Patients HR + and HER2-|"At each disease progression, patient will have specific interventions :~Metastasis biopsy~Biomarkers blood, urine and microbiota samples~Patient Reported Outcome (PRO)"
88960871|NCT03958136|Experimental|Patients HER2 + with or without HR+|"At each disease progression, patient will have specific interventions :~Metastasis biopsy~Biomarkers blood, urine and microbiota samples~Patient Reported Outcome (PRO)"
89514509|NCT05316298||PRESERVE protocol|"Treatment according to the PRESERVE protocol consists of 2 study phases. Phase 1 consists of standard-of-care non-surgical treatment, performed in accordance with current treatment guidelines, during which the research team performs observations.~After failed standard-of care non surgical treatment, subjects will be included in study phase 2 and undergo treatment by surgical debridement of the diabetic foot ulcer and underlying osteomyelitis, followed by bone void filling with gentamicin-loaded calcium sulfate-hydroxyapatite biocomposite and closure of soft tissues and skin, followed by postoperative treatment regimen including woundcare, 10 days of antibiotics and offloading."
89514510|NCT03061786||AKI|
88960872|NCT03958136|Experimental|Patients triple negative (HR- and HER2-)|"At each disease progression, patient will have specific interventions :~Metastasis biopsy~Biomarkers blood, urine and microbiota samples~Patient Reported Outcome (PRO)"
88960873|NCT03956966|Placebo Comparator|saline|bilateral quadratus lumborum block using 0.9% normal saline
89514511|NCT03061786||non-AKI|
89514512|NCT04808362|Experimental|OMO-103|OMO-103 will be administered intravenously as 30 min infusion once weekly
89514513|NCT03054142||AKI|
89514514|NCT03054142||non-AKI|
89514515|NCT04020484|Experimental|Intervention Group|Child-parent dyads will undergo a standardized 8-week course of Making Mindfulness Matter© (M3). The program will be delivered online using live, interactive sessions to groups of 4 to 8, for 1.5 hours each week for the parent group and 1 hour each week for the child group. Children and parents will attend separate on-line sessions and at the end of each child session, the parent will be asked to join their child on-line for a shared mindful exercise. Once 4 to 8 dyads are assigned to the intervention group, participants will be given the baseline questionnaires and start the intervention in the following week.
89514516|NCT04020484|Other|Waitlist Control|Child-parent dyads randomized to the control arm will continue treatment as usual. Once 4 to 8 dyads are assigned to the control group, participants will be given the baseline questionnaires, They will complete the Baseline and Immediate Follow-up questionnaire at comparable times to families in the intervention arm; they will not complete the Extended Follow-up questionnaire. These dyads will be provided with the intervention at the next scheduled session; the goal is to provide the intervention to controls as soon as possible to avoid differential attrition between the intervention and control arm. During the intervention sessions, they will complete all feasibility surveys pertaining to the intervention and their satisfaction with each intervention session.
89514517|NCT01636258|No Intervention|Arm A: Control group|These participants will continue to receive their usual care from their primary medical care team.
89514518|NCT01636258|Experimental|Arm B|Arm includes diet instruction, exercise, stress management, and culinary education
89514519|NCT04381624|Experimental|Transcutaneous Vagal Stimulation|TVS will be applied through a portable electrostimulation equipment during the whole session in each of the treatment sessions. The electrodes will be placed in the left ear, specifically in the auricular concha. The device will be programmed with a biphasic square current at an intensity that produces a clear tingling sensation that is neither uncomfortable nor painful, with pulses of 300 microseconds, at 25 Hertz, the stimulus will be present for 30 seconds and will be followed by a 30-second rest period repeating this for approximately one hour.
89514520|NCT04381624|Placebo Comparator|Sham Transcutaneous Vagal Stimulation|The device will be configured with the same parameters and intensity of the real TVS. However the device will be located in the left ear lobe.
89514521|NCT04009876|Experimental|Chemotherapy + Surgery|Treatment with 5-FU/LV + Oxaliplatin + nal-IRI for 8 cycles followed by standard chemoradiation (5 weeks) and surgical resection
89514522|NCT04009876|Experimental|Chemotherapy + Watch-and-wait|"Treatment with 5-FU/LV + Oxaliplatin + nal-IRI for 8 cycles followed by standard chemoradiation (5 weeks) and watch-and-wait surveillance protocol."
89514523|NCT05287516|Experimental|Breakfast meal with 460 kcal|
89514524|NCT05287516|Active Comparator|Breakfast meal with 230 kcal|
89514525|NCT04826302|Experimental|Myofascial treatment|4 sessions of myofascial intervention, 40 minutes per session, 1 session per week
89514526|NCT04826302|Sham Comparator|Sham myofascial treatment|4 sessions of sham myofascial intervention, 40 minutes per session, 1 session per week
89519571|NCT04298177|Active Comparator|CLOSE|"In the CLOSE arm, the use of MDCT-derived LAWT information will not be available for the operator. A ThermoCool® SmartTouch® 3.5-mm open-irrigated contact force-sensing RF ablation catheter (Biosense Webster, Inc., Diamond Bar, CA, USA) will be used. The ablation will be performed using a proprietary RF generator (SMARTABLATE®; Biosense Webster, Diamond Bar, CA, USA).~Ablation will be performed according to the CLOSE study settings: Power-controlled mode (without ramping) with 25 to 35 W (irrigation flow 30 ml/min). RF will be delivered until an AI of ≥ 400 at the posterior wall/roof and ≥ 550 at the anterior wall are reached."
88960874|NCT03956966|Active Comparator|Bupivacaine|bilateral quadratus lumborum block using Bupivacaine hydrochloride 0.25%
88960875|NCT03956966|Active Comparator|Bupivacaine and dexamethasone|bilateral quadratus lumborum block using Bupivacaine hydrochloride 0.25% and dexamethasone
88960876|NCT03956056|Experimental|Neoantigen Peptide Vaccine|The schedule for vaccination will be Days 1, 4, 8, 15, and 22 (delays of up to 96 hours are allowed for each dose based on the adverse events experienced). Additional vaccinations will be given on Days 50 and 78 (+/- 2 weeks). The first vaccine dose may be administered following confirmation of disease-free status and within 90 days following date of repeat imaging. All study injections will be given subcutaneously and co-administered with poly-ICLC by a trained healthcare provider.
88960877|NCT03954041|Experimental|BIIB093 3 mg|Participants will be administered BIIB093 3 milligrams per day (mg/day) as a IV bolus followed by rapid and slow intravenous (IV) infusions for 96 hours.
88960878|NCT03954041|Experimental|BIIB093 5 mg|Participants will be administered BIIB093 5 mg/day as a IV bolus followed by rapid and slow IV infusions for 96 hours.
89514527|NCT05309902|Experimental|Sequence 1: (Regimen A + Regimen B + Regimen C + Regimen D)|Regimen A (soticlestat 300 milligram [mg] tablets + soticlestat placebo-matching tablets + moxifloxacin placebo-matching capsule), orally, in fasting condition once on Day 1 of Treatment Period 1, followed by at least 7 days washout period, followed by Regimen B (soticlestat 900 mg tablets + moxifloxacin placebo-matching capsule), orally, in fasting condition once on Day 1 of Treatment Period 2, followed by at least 7 days washout period, followed by Regimen C (soticlestat placebo-matching tablets + moxifloxacin 400 mg over-encapsulated tablet), orally, in fasting condition, once on Day 1 of Treatment Period 3, followed by at least 7 days washout period, followed by Regimen D (soticlestat placebo-matching tablets + moxifloxacin placebo-matching capsule), orally, in fasting condition once on Day 1 of Treatment Period 4.
89514528|NCT05309902|Experimental|Sequence 2: (Regimen B + Regimen D + Regimen A + Regimen C)|Regimen B (soticlestat 900 mg tablets + moxifloxacin placebo-matching capsule), orally, in fasting condition once on Day 1 of Treatment Period 1, followed by at least 7 days washout period, followed by Regimen D (soticlestat placebo-matching tablets + moxifloxacin placebo-matching capsule), orally, in fasting condition once on Day 1 of Treatment Period 2, followed by at least 7 days washout period, followed by Regimen A (soticlestat 300 mg tablets + soticlestat placebo-matching tablets + moxifloxacin placebo-matching capsule), orally, in fasting condition, once on Day 1 of Treatment Period 3, followed by at least 7 days washout period, followed by Regimen C (soticlestat -matching tablets + moxifloxacin 400 mg over-encapsulated tablet), orally, in fasting condition once on Day 1 of Treatment Period 4.
89514529|NCT05309902|Experimental|Sequence 3: (Regimen C + Regimen A + Regimen D + Regimen B)|Regimen C (soticlestat placebo-matching tablets + moxifloxacin 400 mg over-encapsulated tablet), orally, in fasting condition once on Day 1 of Treatment Period 1, followed by at least 7 days washout period, followed by Regimen A (soticlestat 300 mg tablets + soticlestat placebo-matching tablets + moxifloxacin placebo-matching capsule), orally, in fasting condition once on Day 1 of Treatment Period 2, followed by at least 7 days washout period, followed by Regimen D (soticlestat placebo-matching tablets + moxifloxacin placebo-matching capsule), orally, in fasting condition, once on Day 1 of Treatment Period 3, followed by at least 7 days washout period, followed by Regimen B (soticlestat 900 mg tablets + moxifloxacin placebo-matching capsule), orally, in fasting condition once on Day 1 of Treatment Period 4.
89514530|NCT05309902|Experimental|Sequence 4: (Regimen D + Regimen C + Regimen B + Regimen A)|Regimen D (soticlestat placebo-matching tablets + moxifloxacin placebo-matching capsule), orally, in fasting condition once on Day 1 of Treatment Period 1, followed by at least 7 days washout period, followed by Regimen C (soticlestat placebo-matching tablets + moxifloxacin 400 mg over-encapsulated tablet), orally, in fasting condition once on Day 1 of Treatment Period 2, followed by at least 7 days washout period, followed by Regimen B (soticlestat 900 mg tablets + moxifloxacin placebo-matching capsule), orally, in fasting condition, once on Day 1 of Treatment Period 3, followed by at least 7 days washout period, followed by Regimen A (soticlestat 300 mg tablets + soticlestat placebo-matching tablets + moxifloxacin placebo-matching capsule), orally, in fasting condition once on Day 1 of Treatment Period 4.
89514531|NCT05369026|Experimental|Fortetropin|Foretetropin, which is non-thermal pasteurized, freeze-dried fertilized egg yolk, per day
89514532|NCT05369026|Placebo Comparator|Placebo|Cheese powder, which is isonitrogenous, isoenergetic, and macronutrient-matched with Fortetropin
89514533|NCT02983240|Experimental|60 Minute Study|After a 20-minute pre-intervention control period the electrical inhibition will be used intermittently, only when there is monitored contraction, during the 20-minute intervention study period. At the end of the intervention period there will be a 20-minute post-intervention control period. The FHR patterns, tocogram, EMG and EHG, and fECG recordings will be compared to before and after the use of the electrical uterine pacemaker device.
89514534|NCT02983240|Experimental|80 Minute Study|After a 20-minute pre-intervention control period the electrical inhibition will be used intermittently, only when there is monitored contraction, during the 40-minute intervention study period. At the end of the intervention period there will be a 20-minute post-intervention control period. The FHR patterns, tocogram, EMG and EHG, and fECG recordings will be compared to before and after the use of the electrical uterine pacemaker device.
89514535|NCT02983240|Experimental|120 Minute Study|After a 20-minute pre-intervention control period the electrical inhibition will be used intermittently, only when there is monitored contraction, during the 80-minute intervention study period. At the end of the intervention period there will be a 20-minute post-intervention control period. The FHR patterns, tocogram, EMG and EHG, and fECG recordings will be compared to before and after the use of the electrical uterine pacemaker device.
89514536|NCT02504216|Experimental|Rivaroxaban|Rivaroxaban 2.5 mg orally twice daily (5 mg cumulative daily dose)
89514537|NCT02504216|Placebo Comparator|Placebo|Rivaroxaban-placebo orally twice daily
89514538|NCT04355650|Experimental|Clinical decision tool|Launch of clinical decision support tool at baseline visit with study clinician.
89514539|NCT05277922|Experimental|C21|15 µg C21 (infusion rate 3 µg/min) 50 µg C21 (infusion rate 10 µg/min) 150 µg C21 (infusion rate 30 µg/min) 500 µg C21 (infusion rate 100 µg/min) 1000 µg C21 (infusion rate 200 µg/min)
88960879|NCT03954041|Placebo Comparator|Placebo|Participants will be administered BIIB093 matching placebo as a IV bolus followed by rapid and slow IV infusions for 96 hours.
88960880|NCT03950154|Experimental|Arm 1|"Bevacizumab & Oxaliplatin & Capecitabine & PD1-T cells~Bevacizumab, 7.5mg/kg, intravenous infusion, d1; Oxaliplatin, 130mg/m2, intravenous infusion, d1; Capecitabine, 1g/m2, oral administration, d1-14; PD1-T cells, 1x10^10 (10 billion), intravenous infusion, d17; Q3W, 6 cycles. After 6 cycles, Bevacizumab, 7.5mg/kg, intravenous infusion, d1; Capecitabine, 1g/m2, oral administration, d1-14; Q3W, maintenance treatment."
88960881|NCT03950154|Active Comparator|Arm 2: Control|"Bevacizumab & Oxaliplatin & Capecitabine~Bevacizumab, 7.5mg/kg, intravenous infusion, d1; Oxaliplatin, 130mg/m2, intravenous infusion, d1; Capecitabine, 1g/m2, oral administration, d1-14; Q3W, 6 cycles. After 6 cycles, Bevacizumab, 7.5mg/kg, intravenous infusion, d1; Capecitabine, 1g/m2, oral administration, d1-14; Q3W, maintenance treatment."
88960882|NCT03948867|Experimental|Elevated Initial Screening TCD|Those who have an elevated initial screening TCD (either conditional or abnormal TAMV) and will be a treatment cohort that receives open-label hydroxyurea therapy as per the dosing and administration schedule.
89543017|NCT04485533|Active Comparator|HYLO®/VisuXL® Gel|Patients treated with HYLO® for the first 30 days (1 treatment period) and with VisuXL® ophthalmic gel for the second 30 days (2 treatment period).
89543018|NCT03205787|Experimental|Trifolium pratense|Red clover extract; 2 gelatin capsules (398 mg extract) per day for 14 days
89543019|NCT02450435||Control|Use Flow cytometry (FCM) and RT-PCR to test peripheral blood mononuclear cells(PBMCs) from healthy volunteer.
89543020|NCT02450435||Cryosurgery group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received cryosurgery only, 1 day before and 2 days after the cryosurgery.
89543021|NCT02450435||DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received DC-CIK treatment only, 1 day before and 2 days after the DC-CIK treatment.
89543022|NCT02450435||Cryosurgery with DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients received cryosurgery and DC-CIK treatment both, 1 day before and 2 days after the cryosurgery with DC-CIK treatment.
89543023|NCT03205397|Experimental|Accompanying and information procedure|Preparation for anesthesia (explanations, film, booklet), the presence of a relative in the operating room and the awakening of the child.
89543024|NCT03205397|Other|Usual care|Consultation of anesthesia and the care of the child without parental presence
89543025|NCT03205319|Experimental|Intervention arm / e-learning|Patients will receive e-learning instead of upper GI endoscopy.
89543026|NCT03205319|No Intervention|Control arm / upper GI endoscopy|Patients will receive the upper GI endoscopy, i.e. standard of care
88960883|NCT03948867|Experimental|Normal Initial Screening TCD|Those who are found to have a normal TCD at enrolment are a part of the observation/control cohort and will undergo repeat TCD every 12 months after enrolment. If the TCD at 12 months has changed to an elevated velocity (conditional or abnormal), the study participant will be reassigned to the elevated initial screening TCD arm and can begin study treatment (hydroxyurea), but will not be included in the primary endpoint analysis.
88960884|NCT03939741|Experimental|Group A|"Participants having a harvested total Adipose Derived Stem Cell (ADSC) count (in 5 ml SVF solution) more than 1 x 10^6.~Genetic: SVF containing Autologous Non Expanded ADSC."
88960885|NCT03936829|Experimental|Interventional|Drug:Cyclophosphamide Dosage form: intravenous infusion Dosage: 500 mg/m2 of BSA Frequency: every 4 weeks Duration: 24 weeks
88960886|NCT03936023||2nd Generation SUs|Reference Group
89543027|NCT03205241|Experimental|n-3 PUFA|Omega-3 polyunsaturated fatty acid - 5.7g/ day for 4 weeks
89543028|NCT03205241|Placebo Comparator|Placebo|Olive Oil - 6g/ day for 4 weeks
89543029|NCT03205085|Experimental|CTEPH PATIENTS|Patients undergoing pulmonary endarterectomy for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH).
89543030|NCT03205085|Experimental|PAH PATIENTS|patients with pulmonary arterial hypertension (PAH) undergoing lung transplantation
89543031|NCT03204929|Experimental|Cu(II)ATSM|Cu(II)ATSM dosed once daily
89543032|NCT03204851|Active Comparator|Venous Stasis Ulcer|Venous Stasis Ulcer
89543033|NCT03204851|Active Comparator|Pressure Ulcers|Pressure Ulcers
89543034|NCT03204851|Active Comparator|Diabetic Foot Ulcers|Diabetic Foot Ulcers
89543035|NCT03204851|Active Comparator|Wounds from a variety of etiologies|Wounds from a variety of etiologies
89543036|NCT02596971|Experimental|Atezo-G-Benda (Safety Run-In and Expansion Phases)|Safety run-in phase: Participants with previously untreated or relapsed or refractory FL will receive obinutuzumab (G) and bendamustine during Cycle 1 (28-day cycle) and atezolizumab, obinutuzumab, and bendamustine during Cycles 2-6, during induction treatment, followed by atezolizumab (once monthly) and obinutuzumab (every other month [q2m]) for 24 months, during maintenance treatment. Expansion phase: Participants with previously untreated FL will receive same treatment regimen as described for safety run-in phase.
89543037|NCT02596971|Experimental|Atezo-G-CHOP (Safety Run-In Phase)|Safety run-in phase: Participants with previously untreated or relapsed or refractory FL will receive obinutuzumab and CHOP during Cycle 1 (21-day cycle) and atezolizumab, obinutuzumab, and CHOP during Cycles 2-6, during induction treatment, followed by atezolizumab (once monthly) and obinutuzumab (q2m) for 24 months, during maintenance treatment.
89543038|NCT02596971|Experimental|Atezo-R-CHOP (Expansion Phase)|Participants with previously untreated DLBCL will receive rituximab and CHOP during Cycle 1 (21-day cycle) and atezolizumab, rituximab, and CHOP during Cycles 2-8 (atezolizumab and rituximab for 8 cycles and CHOP for either 6 or 8 cycles, as determined by the investigator), during induction treatment, followed by atezolizumab from Cycles 9-25 during consolidation treatment.
88960887|NCT03936023||Saxagliptin|Exposure Group
88960888|NCT03926195|Experimental|Filgotinib|Participants received filgotinib 200 milligrams (mg) tablet, orally, once daily up to Week 13 in the double-blind (DB) phase. At Week 13, participants who were arthritis responders, were unblinded and received open-label (OL) treatment filgotinib 200 mg, tablet, orally, once daily up to approximately 143 weeks (until Week 156) in the extension (EXT) phase and participants who were arthritis nonresponders discontinued blinded study drug and started standard of care (SOC) treatment in the EXT phase. Participants on DB treatment or OL filgotinib who entered the monitoring phase (if their sperm parameters met ≥50% decrease threshold in pre-specified semen parameters) discontinued the study drug and started SOC for up to 52 weeks.
88960889|NCT03926195|Placebo Comparator|Placebo|Participants received placebo (matched to filgotinib) tablet, orally, once daily up to Week 13 in the DB phase. At Week 13, participants were unblinded and started SOC treatment in the EXT phase for up to approximately 143 weeks (until Week 156). Participants who entered the monitoring phase (if their sperm parameters met ≥50% decrease threshold in pre-specified semen parameters) continued on SOC treatment.
88960890|NCT03908476|Experimental|Subjects using BurstDR SCS systems|Spinal cord stimulation with a Burst waveform.
89543039|NCT03205007|Experimental|Health promotion nutrition program|Health promotion nutrition program
89543040|NCT03204773||HSP patients|Patients with hereditary spastic paraplegia regardless of their genetic mutation
89543041|NCT03204773||Healthy controls|healthy controls (spouses, relatives, or other healthy controls)
89543042|NCT03204461||PCOS-NIH|
89543043|NCT03204461||PCOS-Rotterdam|
89543044|NCT03204461||Controls|
89543045|NCT03204617|Experimental|DDDMM + CCM|DNA.HTI 0.5mL at weeks 0, 4 and 8 + MVA.HTI 0.5mL at weeks 12 and 20. At least 24 weeks since second MVA.HTI administration (week 20), administration of ChAdOx1.HTI 0.5mL at weeks 0 and 12 + MVA.HTI 0.5mL at week 24.
89514540|NCT05277922|Experimental|Control group|4 µg nitroprusside (infusion rate 0.8 µg/min) 8 µg nitroprusside (infusion rate 1.6 µg/min) 16 µg nitroprusside (infusion rate 3.2 µg/min)
89514541|NCT02941666||Collapse ON group|This group will consist of patients who have concentrations of Mesenchymal Stem Cells in with post collapse osteonecrosis.
89514542|NCT02941666||Pre-collapse group|This group will consist of patients who have concentrations of Mesenchymal Stem Cells in with pre-collapse osteonecrosis.
89514543|NCT02941666||FAI group|This control group will be selected in patients undergoing hip arthroscopy for femoral/acetabular impingement.
89514544|NCT04354870|Experimental|HCQ Group|Approximately 300 Health Care Workers (HCW) who choose to be provided HCQ
89514545|NCT04354870|No Intervention|Control Group|approximately 50 HCW who choose not to be provided HCQ
89514546|NCT04816552|Experimental|CHoBI7 mHealth program Arm|The first arm will receive the CHoBI7 mHealth program and a general message on oral rehydration solution (ORS) (CHoBI7 mHealth program Arm) .
89514547|NCT04816552|Active Comparator|Standard Recommendation Arm|The second arm will serve as a Control Arm and only receive a general message on oral rehydration solution (ORS).
89514548|NCT04419298||Acute CO poisoning with myocardial injury|"A diagnosis of CO poisoning was made according to medical history and carboxyhaemoglobin >5% (>10% in smokers).~Myocardial injury was defined as elevated high-sensitivity TnI level above the upper limit (> 0.046 ng/mL) when measured in the emergency department (ED) or repeatedly within 24 hours after ED arrival."
89514549|NCT02473952|Experimental|IGIV-C|"IGIV-C: Immune Globulin Injection (Human), 10%, Caprylate/Chromatography Purified.~An initial loading dose of 2 g/kg of body weight will be administered at Baseline (Week 0, Visit 1) followed by maintenance doses of 1 g/kg of body weight administered every third week through Week 21 (Visit 8)."
89514550|NCT02473952|Placebo Comparator|Placebo|Placebo: Sterile 0.9% sodium chloride injection or equivalent. Placebo will be infused at the Baseline/Week 0 Visit (Visit 1) using the same volume as would be required for the IGIV-C loading dose. Subsequent placebo maintenance doses will be matched in volume to the IGIV-C maintenance doses and administered every third week until Week 21 (Visit 8).
89514551|NCT04194424|Experimental|Multidisciplinary program|Multidisciplinary weight loss program
89514552|NCT04194424|Other|Control|Standard care
88960891|NCT03908476|Experimental|Subjects using DRG systems|Dorsal root ganglion stimulation.
88960892|NCT03901547|Other|Education and Documentation (Tier 1)|Education only. Participants who do not wish to enroll in the behavioral observation group are followed in the education only. This includes participation in a two week palliative medicine elective which is a part of the medical trainees training and training in the serious illness communication guide (SICG). Participants can opt out of the pre and post training confidence surveys, and simulated patient encounters. Electronic documentation of the SICG by these trainees will be monitored prospectively. Participants will be provided reminders and profile information on their own documentation rate of the SICG via email and have the ability to opt out of receiving emails if they wish.
88960893|NCT03901547|Other|Priming and additional measures (Tier 2)|Education and behavioral observation cohort. These participants must sign an informed consent to participate in this part of the study. In addition to all of Tier 1 activities, participants also complete psychological inventories at three time points to measure emotion regulation and burnout, and participate in a semi-structured interview.
89514553|NCT02863978|Experimental|Digi-NewB Cohort|Multimodal signal acquisitions
89514554|NCT02473640|Experimental|150 mg SYN-004|There will be 2 in-house treatment periods: in Treatment Period 1, subjects will receive 2 oral doses of 150 mg SYN-004 (two 75 mg capsules) and 1g ceftriaxone, and in Treatment Period 2, subjects will receive 2 oral doses of 150mg SYN-004 (two 75 mg capsules) and 1g ceftriaxone in the presence of steady-state esomeprazole; Treatment Periods 1 and 2 will be separated by a 5- to 7-day run-in phase, during which subjects will self-administer 40 mg of esomeprazole once daily (QD) in the morning, at home.
89514555|NCT03895996|Experimental|AVT001 (Treatment)|Infusion of AVT001 (treatment)
89514556|NCT03895996|Placebo Comparator|Matched placebo|Infusion of AVT001-matched placebo
89514557|NCT01637584|Experimental|Prazosin|Active medication arm. Prazosin is an FDA approved medication, originally designed as an anti-hypertension medication. Side effects of the medication in some include sleepiness and once asleep, sustained sleep.
89514558|NCT01637584|Placebo Comparator|Placebo|A placebo is a sugar pill, which will be used to compare with the results of the active medication
89514559|NCT03883906|Experimental|Viral Specific T-cells (VSTs)|
88960894|NCT03890068|Experimental|anlotinib|anlotinib for maintenance treatment a dose of 12 mg once daily (day1-14 PO) in 21-day cycles
88960895|NCT03883126|Active Comparator|Group A|Group A will receive nearly immediate monetary payments over the internet each day they remotely provide negative breathalyzer samples, but will not receive the payments if they provide positive samples or fail to provide samples in a timely manner for the first 3 weeks of the intervention. For the remaining 9 weeks they will continue to receive incentives for submitting negative samples.
88960896|NCT03883126|Active Comparator|Group B|Group B will receive nearly immediate monetary payments over the internet each day they remotely provide negative breathalyzer samples, but will not receive the payments if they provide positive samples or fail to provide samples in a timely manner for the first 3 weeks of the intervention.For the remaining 9 weeks they will not be required to submit breathalyzer samples.
88960897|NCT03883126|Sham Comparator|Group C|Group C will receive nearly immediate monetary payments over the internet each day they remotely provide breathalyzer samples regardless of the alcohol content, but will not receive the payments if they fail to provide samples in a timely manner for the first 3 weeks of the intervention. For the remaining 9 weeks they will continue to receive incentives for submitting on time samples regardless of alcohol content.
89543046|NCT03204617|Placebo Comparator|Placebo|0.9% sterile normal saline solution at weeks 0, 4, 8, 12 and 20. At least 24 weeks since fifth placebo administration, administration of 0.9% sterile normal saline solution at weeks 0, 12 and 24.
89543047|NCT04808895|Active Comparator|Acetylsalicylic acid|Tablets of 100 mg acetylsalicylic acid (one 100 mg daily dose. On the first day a loading dose of 300 mg will be administered)
89543048|NCT04808895|Placebo Comparator|Placebo|Tablets of placebo, identical to active comparator (one tablet daily dose. On the first day 3 tablets will be administered)
89543049|NCT04485689|Experimental|Capsaicin - alone|5x7 cm2 capsaicin patch
89543050|NCT04485689|Placebo Comparator|Placebo - alone|5x7 cm2 placebo patch alone
89543051|NCT04485689|Experimental|Capsaicin - ice|5x7 cm2 capsaicin patch - plus ice
89543052|NCT04485689|Placebo Comparator|Placebo - ice|5x7 cm2 placebo patch - plus ice
89543053|NCT04808661|Experimental|Intervention group|Thoracic endovascular aortic repair plus optimal medical therapy
89543054|NCT04808661|Active Comparator|Conservative group|Optimal medical therapy
88960898|NCT03883126|Sham Comparator|Group D|Group D will receive nearly immediate monetary payments over the internet each day they remotely provide breathalyzer samples regardless of the alcohol content, but will not receive the payments if they fail to provide samples in a timely manner for the first 3 weeks of the intervention. For the remaining 9 weeks they will not be required to submit breathalyzer samples.
88960899|NCT03883126|No Intervention|Group E|Group E will have no intervention, they will only complete assessment sessions.
88960900|NCT03875547||Patients with haemophilia B|Both patients who have not previously been exposed to Refixia® and patients previously exposed to Refixia® in one of the clinical trials can be included.
88960901|NCT03859024|Active Comparator|Standard Protocol|Patients will receive the historical standard for pain management, which may include narcotics during and after surgery. Postoperative prescriptions ibuprofen 800 mg, and acetaminophen 1000 mg to be taken on a scheduled basis then as needed. Another prescription for oxycodone will be given to be used only if needed.
88960902|NCT03859024|Experimental|Enhanced Recovery Protocol|A combination regimen of acetaminophen, Celebrex and gabapentin pre-op, with 30 mL of 0.5% bupivacaine and 4 mg of dexamethasone given as a perineal nerve block at the time of urethroplasty surgery. Narcotics will be administered judiciously and ass seen fit by the anesthesia and/or surgical teams. Postoperative prescriptions ibuprofen 800 mg, and acetaminophen 1000 mg to be taken on a scheduled basis then as needed. Another prescription for oxycodone will be given to be used only if needed.
88960903|NCT03840577|No Intervention|Sedation guided by Clinical Scales|Sedative guided by RASS (Richmond Agitation-Sedation Scale) score. Target RASS: -4 / -5.
88960904|NCT03840577|Experimental|Sedation guided by Bispectral Index|Sedation guided by the Bispectral Index (BIS). Target BIS between 40 to 60.
88960905|NCT03832504|Experimental|38°C and 60% RH + No intervention|The participant will enter an environmental chamber maintained at 38°C and 60% relative humidity. The participant will remain within the environmental chamber and will rest in a seated position for 3 hours.
88960906|NCT03832504|Experimental|38°C and 60% RH + Fan|The participant will enter an environmental chamber maintained at 38°C and 60% relative humidity. The participant will remain within the environmental chamber and will rest in a seated position for 3 hours.
88960907|NCT03832504|Experimental|38°C and 60% RH + Skin wetting|The participant will enter an environmental chamber maintained at 38°C and 60% relative humidity. The participant will remain within the environmental chamber and will rest in a seated position for 3 hours.
88960908|NCT03832504|Experimental|38°C and 60% RH + Fan + Skin wetting|Tthe participant will enter an environmental chamber maintained at 38°C and 60% relative humidity. The participant will remain within the environmental chamber and will rest in a seated position for 3 hours.
88960909|NCT03832504|Experimental|46°C and 10% RH + No intervention|The participant will enter an environmental chamber maintained at 46°C and 10% relative humidity.
88960910|NCT03832504|Experimental|46°C and 10% RH + Skin wetting|The participant will enter an environmental chamber maintained at 46°C and 10% relative humidity. The participant will remain within the environmental chamber and will rest in a seated position for 3 hours.
88960911|NCT03830866|Experimental|Durvalumab (intravenous infusion)|durvalumab + standard of care concurrent chemoradiation therapy(SoC CCRT) followed by durvalumab monotherapy up to 24 months or until PD from the date of randomization
88960912|NCT03830866|Placebo Comparator|Placebo (matching placebo for intravenous infusion)|placebo + standard of care concurrent chemoradiation therapy(SoC CCRT)
89543055|NCT03204227|Experimental|JECEVAX|JECEVAX - VABIOTECH Vietnam Liquid form Composition: 0.5 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 28-34 days
89543056|NCT03204227|Active Comparator|JEVAX|JEVAX - VABIOTECH Vietnam Liquid form Composition: 1,0 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 28-34 days
89543057|NCT03204149|Experimental|Treatment group|"The treatment group will be treated with the MC-8XL laser device, emitting 808 nm laser beam with a green laser beam.~Intervention: MC-8XL low level laser device and Standard wound care"
89543058|NCT03204149|Sham Comparator|Control group|"The control group will receive treatment with a sham laser device, emitting a low power green light with inactive Infrared (IR) laser for indication only.~Intervention: Sham laser device and Standard wound care"
89543059|NCT04801563|Other|SINGLE ARM|
89543060|NCT03119051|Experimental|online cognitive training|Patients will receive 3-4 times of 20-30 minutes' training game every week
89543061|NCT03119051|No Intervention|no training|Patients will not undergo preoperative cognitive training.
89543062|NCT03119051|Experimental|Cognitive training and physical exercise|Patients will receive 3-4 times of 20-30 minutes' training game every week and 2 times of 60 minutes' Tai Chi Training
89543063|NCT03119207|Experimental|Naptime Participants|The participants will undergo the Naptime Protocol. The study team will provide a 4 hour period nightly during which patient room activity, light levels and noise levels will be decreased. The team will monitor the changes in the number and quality of these disruptions and to monitor the changes in patient sleep and outcome following our intervention.
89543064|NCT03119207|No Intervention|Control Participants|Naptime will not be enforced. Patient room activity, light levels and noise levels are monitored. Standard care will be provided. During the intervention period patients are randomized to either control or naptime.
88960913|NCT03804424|Experimental|Cohort 1: Pilot 64Cu-LLP2A Imaging|"16 adult individuals (6-8 patients with known MM; 6-10 healthy volunteers)~All subjects who enter the study in Cohort 1 will be injected with up to 11 mCi of 64Cu-LLP2A and will undergo body imaging at least twice within 0-30 hrs following administration of 64Cu-LLP2A to study tracer biodistribution and calculate human dosimetry~6 subjects will also undergo dynamic study for 60 mins immediately after administration of 64Cu-LLP2A."
88960914|NCT03804424|Experimental|Cohort 2: Quantitative 64Cu-LLP2A Imaging|"20 patients with MM will be recruited~Subjects who enter on study in Cohort 2 will undergo a 60-min dynamic imaging over the known site of disease (OR pelvis and lower lumbar spine, if no site of disease is known). Following a simple DIXON MRI or low dose CT scan for attenuation correction, subjects will be injected with a dose of up to11 mCi of 64Cu-LLP2A and a list mode dynamic imaging acquisition will begin for a total of 60 mins. Following the dynamic study, or at the optimal time point determined from cohort 1 imaging, after a simple DIXON or low dose CT scan for body (top of the head to below the knees) attenuation correction, emission scans (2-5 min per bed position) will be performed"
89543065|NCT03119207|No Intervention|Baseline Participants|Prior to the intervention period, baseline patients under usual care are monitored. Naptime will not be enforced. Patient room activity, light levels and noise levels are monitored.
89543066|NCT03204071|Placebo Comparator|Group 1|Placebo gel without active ingredient to be delivered at baseline, 6 and 12 months.
89543067|NCT03204071|Active Comparator|Group 2|Aloe vera gel to be delivered at baseline, 6 and 12 months.
89543068|NCT03204071|Active Comparator|Group 3|1% metformin gel to be delivered at baseline, 6 and 12 months.
89543069|NCT03203915|Experimental|Group 1|"Order of treatments:~A: Chardonnay grape marc powder high polyphenol dose B: Chardonnay grape marc powder low polyphenol dose C: Placebo"
89543070|NCT03203915|Experimental|Group 2|"Order of treatments:~A: Chardonnay grape marc powder high polyphenol dose C: Placebo B: Chardonnay grape marc powder low polyphenol dose"
89543071|NCT03203915|Experimental|Group 3|"Order of treatments:~B: Chardonnay grape marc powder low polyphenol dose C: Placebo A: Chardonnay grape marc powder high polyphenol dose"
89543072|NCT03203915|Experimental|Group 4|"Order of treatments:~B: Chardonnay grape marc powder low polyphenol dose A: Chardonnay grape marc powder high polyphenol dose C: Placebo"
89543073|NCT03203915|Experimental|Group 5|"Order of treatments:~C: Placebo A: Chardonnay grape marc powder high polyphenol dose B: Chardonnay grape marc powder low polyphenol dose"
89543074|NCT03203915|Experimental|Group 6|"Order of treatments:~C: Placebo B: Chardonnay grape marc powder low polyphenol dose A: Chardonnay grape marc powder high polyphenol dose"
89543075|NCT04801017|Experimental|OT-101 + Artemisinin + Standard of Care|"OT-101 - Days 1 to 7: 140 mg/m2 daily intravenous (i.v.) infusion for 7 continuous days.~Artemisinin: Days 1 to 5: 500 mg per day for 5 days by oral"
89543076|NCT04801017|Placebo Comparator|Placebo + Artemisinin + Standard of Care|Artemisinin: Days 1 to 5: 500 mg per day for 5 days by oral
89543077|NCT03203837||HCC patients|HCC patients treated with radioembolization. Plasma collection will be performed at 7 timepoints in relation to treatment.
89543078|NCT04801251|Other|Resident|Full history.complete systemic and cardiac physical examination
89543079|NCT04801251|Other|Assistant Lecturer|Echocardiographic examination
88960915|NCT03794388|Experimental|Arm CAPSAICINE topical|"Application of capsaicin patches at 8% on the painful area~1 to 2 patches will be administered during the consultation. If necessary, a second application will be realized 3 months later."
88960916|NCT03794388|Active Comparator|Arm PREGABALINE|"Pregabalin tablets will be initiated at a dose of 50 mg / day taken in 2 doses Depending on the tolerance, the dose will be increased to 100 mg / day and then to 150 mg / day to reach a maximum dose of 600 mg / day.~An interval of 3 to 7 days must be observed between each dose increase."
89543080|NCT03233165|Experimental|Patients with diagnosed leukoplakia 1|"Patients who meet the conditions of pathohistological diagnosis of leukoplakia and clinical criteria for diagnosis of non-homogeneous leukoplakia.~Intervention using Er:YAG laser"
89543081|NCT03233165|Experimental|Patients with diagnosed leukoplakia 2|"Patients who meet the conditions of pathohistological diagnosis of leukoplakia and clinical criteria for diagnosis of non-homogeneous leukoplakia.~Intervention using Er,Cr:YSGG laser"
89543082|NCT04800705||Premature ovarian insufficiency (POI)|POI is a clinical syndrome defined by loss of ovarian activity before the age of 40 years. POI is characterized by menstrual disturbance (amenorrhea or oligomenorrhea) with raised gonadotropins and low estradiol.
89543083|NCT04800705||Control group|The study population will be consisted of 70 women with POI as the study group and 70 patients with normal healthy women as the control group. A volunteer group of healthy women who will be visited the gynaecology clinic for routine examinations and women who will be admitted for pre-pregnancy tests will be invited randomly to this research as a control group.
89543084|NCT03203759|Active Comparator|Inpatient hospitalization|Control / usual care arm. Patients are admitted per usual to an inpatient service. Patients' medical records will be closely monitored. Patients will wear a vital sign and activity monitor whose data is used only retrospectively. On discharge and 30 days after discharge, they will be interviewed regarding their hospitalization and health.
89543085|NCT03203759|Experimental|Home hospitalization|Intervention arm. Patients will return home after triage, diagnosis, and the beginning of treatment in the emergency department with a set of specialized patient-tailored services (listed above). On discharge and 30 days after discharge, they will be interviewed regarding their hospitalization and health.
89543086|NCT03203213|Experimental|Interventional arm|"Sampling of a few additional drops of blood and sending this sample for analysis and identification of a possible toxic cause by psychoactive substance in relation to the clinical picture presented by the patient~Oriented hair removal is also carried out if possible (small wick cut and not torn the size of a pencil mine of paper taken at the level of the occipital region). This technique has been used many times, and evaluates the previous consumption (memory consumption)~A urine sample is taken if possible."
89543087|NCT04786665|Experimental|Strawberry powder|Participants consume 1 package of standard strawberry powder (26 g) daily for 8 weeks
89543088|NCT04786665|Placebo Comparator|Placebo group|Participants consume 1 package of placebo powder (26 g) daily for 8 weeks
89543089|NCT03233087||Top third of subjects based levels of selected biomarker.|
89543090|NCT03233087||Middle third of subjects based levels of selected biomarker.|
89543091|NCT03233087||Bottom third ofsubjects based levels of selected biomarker.|
89024767|NCT02957474|Experimental|Treatment B = single oral dose GED 0301, fed|Subjects will receive a single oral 160 mg dose of GED-0301 after a 10 hour overnight fast, and within 30 minutes of completely consuming a high fat meal.
89024768|NCT02957474|Experimental|Treatment C = single oral dose GED 0301 fasted|Subjects will receive an oral dose of 160 mg of GED-0301 given as 4 tablets of 40 mg, after a 10 hour overnight fast
89024769|NCT02957474|Experimental|Treatment D = oral omeprazole and GED-0301|Subjects will receive one oral dose of 40 mg omeprazole once a day for 6 days. On the 5th day, a single oral 160 mg dose of GED-0301 will be given together with omeprazole.
89024770|NCT00465231|Active Comparator|1|Epidural
89514560|NCT03860584|Experimental|MFGM-enriched full-fat dairy milk|Participants in this arm will receive MFGM-enriched full-fat dairy milk (3 servings/d) that contains MFGM at 10% phospholipid (relative to total lipid content) delivering MFGM at ~10-times that in full-fat dairy milk.
89024771|NCT00465231|Placebo Comparator|2|Epidural - saline solution
89024772|NCT00436241|Experimental|1|
89024773|NCT00481455|Experimental|1|
89514561|NCT03860584|Placebo Comparator|Soy phospholipid/lecithin milk|Participants in this arm will receive a matched dairy milk that instead contains soy phospholipid/lecithin.
89514562|NCT04816396|Experimental|experimental|For 8 weeks, Reminiscence Therapy based on Roy Adaptation Model will be applied
89514563|NCT04816396|No Intervention|No İntervention|No intervention will be applied to this group.
89514564|NCT05207488|Experimental|Exercise + Prebiotic|The Exercise + Prebiotic intervention group will consume 10 g/d of fructo-oligosaccharides (FOS). Additionally, they will perform 6 wk. of supervised progressive multi-component exercise training consisting of moderate to vigorous aerobic and strength-based exercises (3x/wk).
89514565|NCT05207488|Placebo Comparator|Exercise + Placebo|The Exercise + Placebo group will consume 10 g/d of a placebo (maltodextrin) powder every day. Additionally, they will perform 6 wk. of supervised progressive multi-component exercise training consisting of moderate to vigorous aerobic and strength-based exercises (3x/wk).
89514566|NCT04806646|Experimental|Single Arm Treatment|"One cycle of therapy is defined as 28 days of sonidegib. The patient will start with TS1 schedule.~TS1: assumption 14 days on and 14 days off. TS1 may be temporary interrupted for any grade 2 or 3 toxicity (excluding alopecia) until return to grade 1. If the patient experiences any grade 3 or 2 side effects lasting for more than 28 days, at treatment resumption they will start the TS2 schedule.~TS2: assumption 7 days on and 21 days off. TS2 may be temporary interrupted for any grade 2 or 3 toxicity (excluding alopecia) until return to grade 1. If the patient experiences any grade 3 or 2 side effects lasting for more than 28 days, he/she is discontinued from the study.~If progression of disease is observed (during TS1 or TS2) the patient is discontinued from the study."
89514567|NCT02503202|Experimental|V920 Consistency Lot A|Participants received a 1.0 mL intramuscular injection of V920 on Day 1
89514568|NCT02503202|Experimental|V920 Consistency Lot B|Participants received a 1.0 mL intramuscular injection of V920 on Day 1
89514569|NCT02503202|Experimental|V920 Consistency Lot C|Participants received a 1.0 mL intramuscular injection of V920 on Day 1
89514570|NCT02503202|Experimental|V920 High-dose Lot|Participants received a 1.0 mL intramuscular injection of V920 on Day 1
89514571|NCT02503202|Placebo Comparator|Placebo to V920|Participants received a 1.0 mL intramuscular injection of placebo on Day 1
89514572|NCT02502734|Experimental|Sequence 1: Fluticasone furoate 50 μg and then placebo|Subjects will receive oral inhalation of FF 50 μg administered via ELLIPTA, once daily (OD) for 14 days +/- 4 days in Period 1 followed by oral inhalation of placebo administered via ELLIPTA, OD for 14 days +/- 4 days in Period 2. The two treatment periods will be separated by a two-week wash-out period. Additionally all subjects will be provided salbutamol inhaler to be used for symptomatic relief of asthma symptoms during both the run-in and treatment periods as needed.
89514573|NCT02502734|Experimental|Sequence 2: Placebo and then fluticasone furoate 50 μg|Subjects will receive oral inhalation of placebo administered via ELLIPTA OD for 14 days +/- 4 days in Period 1 followed by receive oral inhalation of FF 50 μg administered via ELLIPTA, OD for 14 days +/- 4 days. The two treatment periods will be separated by a two-week wash-out period. Additionally all subjects will be provided salbutamol inhaler to be used for symptomatic relief of asthma symptoms during both the run-in and treatment periods as needed.
89514574|NCT04193878|Placebo Comparator|Placebo|4 ml aerosolized 0.9% saline every 12 hours x 10 doses
89514575|NCT04193878|Active Comparator|Intervention|aerosolized formoterol (20 mcg/2 ml) and budesonide (1.0 mg/2 ml) every 12 hours x 10 doses
89514576|NCT02473250|Experimental|Bipolar depressed|Bipolar depressed subjects will have neuroimaging and treatment with fluoxetine in combination with a mood stabilizer (valproate)
89514577|NCT04821778|Placebo Comparator|Definitive Chemoradiation|This arm received chemoradiation without immunotherapy/targeting agents as definitive treatment.
89514578|NCT04821778|Experimental|Chemoradiation Combined With Immunotherapy/targeting agents|This arm received chemoradiation with immunotherapy/targeting agents as definitive treatment.
89514579|NCT03825952|Experimental|Participants using MERM device|Participants will use an electronic medication monitor to measure their adherence to ART in routine clinical care.
89514580|NCT02706730|Experimental|OTO-104|12 mg dexamethasone
89514581|NCT04419220||Observational|Doppler Ultrasound will be performed in all subjects.
89514582|NCT04825210|Experimental|Integrated Behavioral Health - Prevention (IBH-P)|The IBH-P intervention addresses four areas: 1) assessment of emotional and behavioral adjustment, 2) parental education on important supports for emotional and behavioral health, 3) modeling and guidance on nurturing and responsive parenting, and 4) addressing parental concerns about and promoting child self-regulation. The primary focus of IBH-P is promoting infant self-regulation by teaching mothers how to soothe and calm their baby. Trauma-informed and relationship building methods are emphasized to acknowledge maternal experiences with violence and adversity and the desire to establish a strong working alliance. IBH-P is distinguished from Bright Futures through its emphasis on experiential learning, modeling of effective parenting skills, in-session practice and feedback, and proactive problem-solving. Families in IBH-P will receive all standard care elements of the well-child visit including pediatrician implementation of Bright Futures curriculum.
88960917|NCT03779906|Experimental|ISOVUE|Isovue will be given to all subjects per the standard of clinical care.The specific iodine concentration and volume of ISOVUE used during the radiologic procedure will depend on the type of procedure and the standards in place at the site where the procedure is performed.
88960918|NCT03748563|Experimental|ds-MCE and EGD|All the enrolled participants will undergo the examination of detachable string magnetically maneuvered capsule endoscopy (ds-MCE) first, followed by EGD within 48 hours.
88960919|NCT03745898|Active Comparator|Nocturnal Oxygen Therapy|Active nocturnal oxygen therapy
88960920|NCT03745898|Sham Comparator|Sham Nocturnal Oxygen Therapy|Sham nocturnal oxygen therapy (room air)
88960921|NCT03725761|Experimental|Sacituzumab Govitecan Treatment|Subjects enrolled in this study will receive Sacituzumab Govitecan in addition to their single agent ARSI as treatment for Castrate-Resistant Prostate Cancer. Dose will be calculated per protocol in milligrams based on the subject's body weight at the beginning of each cycle or more frequently if weight changes >10%. Subjects will be treated on days 1 and 8 in a 21-day cycle, minimum 3 cycles.
88960922|NCT03699007|Experimental|Graded Exposure Therapy (GET Living)|GET Living is jointly delivered by a pain psychologist and a physical therapist. The GET Living treatment was based on a published graded in-vivo exposure treatment manual for adults with adaptations to target a pediatric audience.
88960923|NCT03699007|Active Comparator|Multidisciplinary Pain Management (MPM)|MPM is a treatment intervention that is representative of current standards of care in a multidisciplinary pain clinic setting. It consists of Cognitive Behavioral Therapy (CBT) and Physical Therapy (PT) sessions, delivered separately by a pain psychologist and a physical therapist.
88960924|NCT03689595||Specimen Collection|"Samples of blood (2-4 tablespoons) from 3 tubes will be collected~Analysis will be performed on the blood to test for multiple myeloma precursor conditions once sent to outside labs at Mayo Clinic and the Broad Institute"
88960925|NCT03682094|Experimental|Probiotic|The treatment will consist of VSL#3, 3 grams (g), taken orally once a day for 4 weeks. The VSL#3 will be delivered in the form of a sachet of freeze-dried powder. Participants will be instructed to mix the sachets with water to consume. Those participants taking thickened liquids will mix the sachet with liquids thickened to the level (nectar versus honey) prescribed by their clinician. In order to facilitate delivery of the probiotic solution throughout the oral cavity, participants will be instructed to swish the solution in the mouth for up to 10 seconds (as tolerated) prior to each swallow.
88960926|NCT03679949|Placebo Comparator|Placebo|Participants will receive 0 mg oxycodone (oral) and placebo cannabis (vaporized)
88960927|NCT03679949|Experimental|Oxycodone|Participants will receive 2.5 mg oxycodone (oral) and placebo cannabis (vaporized)
88960928|NCT03679949|Experimental|Cannabis (THC:CBD = ~1:0)|Participants will receive 0 mg oxycodone (oral) and cannabis with high THC concentrations (vaporized)
88960929|NCT03679949|Experimental|Cannabis (THC:CBD = ~ 0:1)|Participants will receive 0 mg oxycodone (oral) and cannabis with high CBD concentrations (vaporized)
88960930|NCT03679949|Experimental|Cannabis (THC:CBD = ~ 1:1)|Participants will receive 0 mg oxycodone (oral) and cannabis with equal CBD and THC concentrations (vaporized)
88960931|NCT03679949|Experimental|Cannabis (THC:CBD = ~1:0) + Oxycodone|Participants will receive 2.5 mg oxycodone (oral) and cannabis with high THC concentrations (vaporized)
88960932|NCT03679949|Experimental|Cannabis (THC:CBD = ~ 0:1) + Oxycodone|Participants will receive 2.5 mg oxycodone (oral) and cannabis with high CBD concentrations (vaporized)
88960933|NCT03679949|Experimental|Cannabis (THC:CBD = ~ 1:1) + Oxycodone|Participants will receive 2.5 mg oxycodone (oral) and cannabis with equal concentrations of THC and CBD (vaporized)
88960934|NCT03676218||Elderly cancer patients|
88960935|NCT03630666|Active Comparator|IADT|one injection of IADT. The overall duration of IADT will be six months.
88960936|NCT03630666|Experimental|IADT+ radiotherapy|One injection of IADT. The overall duration of IADT will be six months. Irradiation three months after injection of IADT. The overall duration of radiotherapy will be three months.
88960937|NCT03625947||Hemoptysis patients|Hemoptysis patients caused by endobronchial malignancies
88960938|NCT03614507|Experimental|FreeO2 group|Automatic oxygen flow titration
88960939|NCT03614507|Active Comparator|Manual group|Manual oxygen flow titration
88960940|NCT03610815|Experimental|mSBIRT|Mobile Screening, Brief Intervention, Referral to Treatment (mSBIRT)
88960941|NCT03610815|Active Comparator|SBIRT-CTS),|Screening, Brief Intervention, Referral to Treatment Conventional Training and Supervision strategy
88960942|NCT03607175|Active Comparator|Steroid-eluting implant (Propel)|Mometasone furoate implant. 370ug of mometasone furoate with each application. One application to be used at the conclusion of surgery and left in place for 1 month or less depending on if it requires removal during office debridement.
88960943|NCT03607175|Experimental|Triamcinolone-impregnated CMC foam|Applied to one nostril at end of case through randomization. Experimental drug is triamcinolone-acetonide 40mg/mL. 2mL will be combined with 5mL sterile water and mixed with carboxymethylcellulose foam and placed in the nares at the conclusion of the surgery. This will only be applied once and will remain in the nares until it dissolves or 7 days.
88960944|NCT03581188|Experimental|Patient-led surveillance|Participants receive a mobile dermatoscope that attaches to their smartphone to take photos of skin lesions for teledermatology, instructions on skin self-examination from the ASICA skin checker App, text and email reminders to perform self-examination every 2 months, an educational booklet 'Your guide to early melanoma', and scheduled visits to their clinician as required.
88960945|NCT03581188|Active Comparator|Clinician-led surveillance|Participants receive an educational booklet 'Your guide to early melanoma' and scheduled visits to their clinician as required.
88960946|NCT03576365|Experimental|VOICE Intervention Arm|Participants participate in the online VOICE program to learn about perceived control and stress reduction to improve voice outcomes.
88960947|NCT03576365|Sham Comparator|Information-Only Arm|Participants participate in the information only program to learn about voice problems, anatomy and physiology.
88960948|NCT03576131|Experimental|GEN1029 (HexaBody®-DR5/DR5)|
88960949|NCT03573024|Experimental|Azacitidine and Venetoclax|Azacitidine will be given intravenously for 7 days. Venetoclax will be given orally. The patient will start out with 100mg and progress to 600mg. Once 600mg is reached, the patient will stay at this dose until the 28 day cycle is finished.
88960950|NCT03569228|Experimental|Study 1 (In-the-Ear) Group|Experienced users of in-the-ear (ITE) hearing aids will receive replacement ITE hearing aids that are fitted and verified in a test box coupler, then mailed to the patient for a 4-week field trial.
88960951|NCT03569228|Experimental|Study 1 (Behind-the-Ear) Group|Experienced users of behind-the-ear (BTE) hearing aids will receive replacement BTE hearing aids that are fitted and verified in a test box coupler, then mailed to the patient for a 4-week field trial.
88960952|NCT03569228|No Intervention|Study 2 (Open-Fit corrections)|Participants with hearing loss will be fitted monaurally with 12 stock non-custom, receiver in the canal (RIC) or receiver in the aid (RITA) hearing aids using the standard in-situ approach and test box measures will be made of each fitting to develop correction factors for these styles.
88960953|NCT03569228|Active Comparator|Study 3 (open-fit comparison)|This group will serve as the active comparator group for experienced hearing aid user receiving replacement receiver in the canal (RIC) or receiver in the aid (RITA) hearing aids with OPEN coupling using the standard of care approach, then undergoing a 4-week field trial.
88960954|NCT03569228|Active Comparator|Study 3 (closed-fit comparison)|This group will serve as the active comparator group for experienced hearing aid user receiving replacement receiver in the canal (RIC) or receiver in the aid (RITA) hearing aids with CLOSED coupling using the standard of care approach, then undergoing a 4-week field trial.
88960955|NCT03569228|Experimental|Study 3 (experimental open-fit)|Experienced hearing aid user receiving replacement receiver in the canal (RIC) or receiver in the aid (RITA) hearing aids with OPEN coupling that are fitted and verified in a test box coupler, then mailed to the patient for a 4-week field trial.
88960956|NCT03569228|Experimental|Study 3 (experimental closed-fit)|Experienced hearing aid user receiving replacement receiver in the canal (RIC) or receiver in the aid (RITA) hearing aids with CLOSED coupling that are fitted and verified in a test box coupler, then mailed to the patient for a 4-week field trial.
89514583|NCT04825210|Active Comparator|Bright Futures: Guidelines for Health Supervision of Infants, Children, and Adolescents, 4th Edition|The Bright Futures control condition consists of standard of care in addressing emotional and behavioral health as provided by pediatricians. Pediatricians will follow the 4th edition of the Bright Futures: Guidelines for Health Supervision of Infants, Children, and Adolescents [pocket guide]. Guidelines are provided for topics to discuss and anticipatory guidance at each well-child visit. In contrast to IBH-P, there is an emphasis on didactic presentation, teaching mothers about developmental milestones, and responding to questions and concerns. These include discussions of crying, soothing, and feeding, although self-regulation is not a unifying theme.
89514584|NCT02611024|Experimental|Lurbinectedin Escalation Group|Irinotecan 75 mg/m^2 as a 90-min (-5-min/+30-min) intravenous (i.v.) infusion, followed by Lurbinectedin with starting dose of 1.0 mg/m^2 as a 60-min (-5-min/+20-min) i.v. infusion followed by Irinotecan alone on Day 8 (at the same dose as Day 1 and as a 90-min [-5-min/+30-min] i.v. infusion)
89514585|NCT02611024|Experimental|Irinotecan Escalation Group|Starting dose of Irinotecan 15 mg/m^2 as a 90-min (-5-min/+30-min) i.v. infusion, followed by Lurbinectedin 3.0 mg/m^2 as a 60-min (-5-min/+20-min) i.v. infusion followed by Irinotecan alone on Day 8 (at the same dose as Day 1 and as a 90-min [-5-min/+30-min] i.v. infusion).
89514586|NCT02611024|Experimental|Intermediate Escalation Group|Starting dose of Irinotecan 50 mg/m^2 as a 90-min (-5-min/+30-min) i.v. infusion, followed by Lurbinectedin 2.6 mg/m^2 as a 60-min (-5-min/+20-min) i.v. infusion. No Irinotecan dose will be administered on Day 8 in this group.
89514587|NCT02443688|Experimental|50 mg CTX-4430|Once daily oral capsule for 48 weeks
89514588|NCT02443688|Experimental|100 mg CTX-4430|Once daily oral capsule for 48 weeks
89514589|NCT02443688|Placebo Comparator|Matching Placebo|Once daily oral capsule for 48 weeks
89514590|NCT04419376||Patients with pARDS|Within 7 days of known clinical insult Respiratory failure not fully explained by cardiac failure or fluid overload chest imaging findings of new infiltrate(s) consistent with acute pulmonary parenchymal disease patients with an oxygenation index (OI) ([FIO2 × mean airway pressure × 100]/PaO2) above 4
89514591|NCT04419376||Patients with non-pARDS|non-pARDS patients who received mechanical ventilation support due to respiratory failure.
89514592|NCT02602756|Active Comparator|A|Protontherapy : 4 sessions of 13 Gy, total dosis 52 Gy
89514593|NCT02602756|Experimental|B|Protontherapy : 8 sessions of 6.5 Gy, total dosis 52 Gy
89514594|NCT02443298|Experimental|Risankizumab|Patients received subcutaneous injection of 1 milliliter (mL) prefilled syringe with 90 milligram/ milliliter (mg/mL) risankizumab once every 4 weeks (weeks 0, 4, 8, 12, 16, 20).
89514595|NCT02443298|Placebo Comparator|Placebo|Patients received subcutaneous injection of 1 milliliter (mL) prefilled syringe consisting of matching placebo to risankizumab once every 4 weeks (weeks 0, 4, 8, 12, 16, 20).
89514596|NCT02500706|Experimental|Mealtime faster-acting insulin aspart and insulin degludec|
89514597|NCT02500706|Active Comparator|Mealtime NovoRapid® and insulin degludec|
89514598|NCT02500706|Experimental|Postmeal faster-acting insulin aspart and insulin degludec|
89514599|NCT02442830|Experimental|Early Video Capsule Endoscopy|The intervention for subjects in this arm will be to have a video capsule deployed as soon as possible after presentation to the emergency department. Information from the video capsule will be obtained and reviewed to determine location of bleeding. Once that information has been obtained a decision will be made on which endoscopic test is most pertinent in finding and treating the source of bleeding.
89514600|NCT02442830|No Intervention|Standard of Care Workup Group|"In this arm, patients will receive standard of care workup for non-hematemesis gastrointestinal bleeding. This could include upper endoscopy, colonoscopy, and additional capsule or small bowel enteroscopy depending on the subject's presentation and the results of the workup performed by the gastroenterology team. For patients requiring a video capsule endoscopy as part of standard of care workup the patients will be given the same Olympus video capsule that is used in the Early Capsule group."
89514601|NCT04201496|Experimental|Empagliflozin + Control-IQ x 4 wks then Basal-IQ x 2 wks|Control-IQ x 4 weeks (CiQ-EMPA) then Basal-IQ x 2 weeks (BiQ-EMPA)
89514602|NCT04201496|Experimental|Empagliflozin + Basal-IQ x 2 wks then CiQ x 4 wks|Basal-IQ x 2 weeks (BiQ-EMPA) then Control-IQ x 4 weeks (CiQ-EMPA)
89514603|NCT04201496|Active Comparator|No Empagliflozin + Control-IQ x 4 wks then Basal-IQ x 2 wks|Control-IQ x 4 weeks (CiQ-NO EMPA) then Basal-IQ x 2 weeks (BiQ-NO EMPA)
89024774|NCT02957396|Active Comparator|Adult formulation: Finerenone tablet_Fasting|Single oral dose of 20 mg intact finerenone tablet fasting
89024775|NCT02957396|Experimental|Adult formulation: Finerenone crushed tablet_Fasting|Single oral dose of 20 mg crushed and resuspended finerenone tablet fasting
89024776|NCT02957396|Experimental|Pediatric formulation: Finerenone suspension_Fasting|Single oral dose of 20 mg finerenone suspension fasting
89024777|NCT02957396|Experimental|Pediatric formulation: Finerenone suspension_Fed|Single oral dose of 20 mg finerenone suspension fed; 30 minutes after start of an American breakfast
89024778|NCT00436319|No Intervention|1|In the control group (group 1) the initiation of the ovarian stimulation will be realized according to the typical long luteal protocol, two weeks after the initiation of the GnRH agonist administration.
89024779|NCT00436319|Other|2|In the study group (group 2) the initiation of the ovarian stimulation will be effectuated on the second day of the menstrual period.
89024780|NCT00436358||Group A|IS case deemed children
89024781|NCT00436358||Group B|LRTI-related post-neonatal deaths deemed Children
89024782|NCT00436358||Group C|A random sample of children from an annual birth cohort within the electronic IMSS dataset
89024783|NCT00436358||Group D|All children from a single annual birth cohort with IS identified in their electronic IMSS data
89024784|NCT00436358||Group E|A sample of children from the electronic IMSS dataset selected to match the selected IS cases on age, gender, and hospital of birth.
89024785|NCT00481572|Experimental|1|Terlipressin
89024786|NCT00481572|Experimental|2|Vasopressin
89024787|NCT00481572|Active Comparator|3|titrated norepinephrine
89024788|NCT00436592|Experimental|1|
89024789|NCT00473967|Experimental|10 mcg Na-ASP-2/Alhydrogel|Na-ASP-2 Hookworm Vaccine
89024790|NCT00473967|Active Comparator|Butang hepatitis B vaccine|Hepatitis B Vaccine - comparator vaccine
89024791|NCT04701554|Experimental|Qigong program|The experimental group participated in the Qigong program during 2 months, 16 sessions with a total of 16 hours.
89024792|NCT04701554|Active Comparator|Active comparator group|The control group received information on healthy lifestyles, physical exercise and dietary recommendations.
89514604|NCT04201496|Active Comparator|No Empagliflozin + Basal-IQ x 2 wks then Control-IQ x 4 wks|Basal-IQ x 2 weeks (BiQ-NO EMPA) then Control-IQ x 4 weeks (CiQ-NO EMPA)
89024793|NCT00474006|Active Comparator|arm I|Cytarabine 200 mg/m2/d civ x 7 days Daunorubicin 45 mg/m2/d civ x 3 days
89024794|NCT04697745|Active Comparator|dexamethasone intrathecal|
89024795|NCT04697745|Active Comparator|dexmedetomidine intrathecal|
89514605|NCT02500550|Experimental|ATIR101|
89514606|NCT04824040||Study group|Patients with a genetically confirmed dysferlinopathy.
89514607|NCT04824040||Control group|Healthy Volunteers
89514608|NCT02446366|Experimental|Treatment (hypofractionated SBRT)|Patients undergo 5, 10, or 15 fractions of hypofractionated SBRT daily over 1-3 weeks.
89514609|NCT04797286|Experimental|Sildenafil|Sildenafil 20 mg by mouth three(3) times each day
89514610|NCT04797286|Placebo Comparator|Placebo|Placebo by mouth three(3) times each day
89514611|NCT03696628|Other|Healthy children|Blood test with generated hiPSC-cardiomyocytes Physical Examination. Electrocardiogram. Echocardiography.
89514612|NCT03696628|Other|Cardiomyopathic children|Blood test with generated hiPSC-cardiomyocytes Physical Examination. Electrocardiogram. Echocardiography.
89514613|NCT03682276|Experimental|Treatment Group|Ipilimumab, solution for infusion, 1 milligram per kilogram body weight, once every 3 weeks, for 3 weeks; Nivolumab, solution for infusion, 3 milligrams per kilogram body weight, once every 3 weeks, for 6 weeks
89514614|NCT04797130|No Intervention|Control group|All subjects eligible for inclusion in this study receive usual care physiotherapy as prescribed by the physician. The number of treatment sessions and content of physiotherapy treatment sessions will depend on the diagnosis and needs of the individual patient. This study will not interfere with the content of the usual care physiotherapy treatment. Patients in the control group will receive an accelerometer, measuring PA, which is applied by the physiotherapist during the first treatment. They receive no other additional intervention. Usual care physiotherapy sessions will take approximately 20-30 minutes per session.
89514615|NCT04797130|Experimental|Intervention group|Patients in the intervention group will receive usual care physiotherapy and use Hospital Fit 2.0 (HF) additionally. After the last treatment session (max. 7 days), the therapist will remove the accelerometer and participation in the study will end.
89514616|NCT02167906|Experimental|hand oa patients|assess the carotid-femoral arterial stiffness determined by measuring the PWV
89514617|NCT02167906|Active Comparator|without Hand OA patients|assess the carotid-femoral arterial stiffness determined by measuring the PWV
89024796|NCT00436631|Experimental|diet|
89024797|NCT00481728|Experimental|Tolterodine|
89024798|NCT00436865|Other|PCOS|PCOS women receiving weight loss intervention
89024799|NCT00436865|Other|Control|Non-PCOS women receiving weight loss intervention
89024800|NCT00436943||A|Smokers
89024801|NCT00437060||Ancillary/Correlative (neurocognitive assessment, biomarkers))|"Patients complete neurocognitive tests to assess thinking, memory, attention, and concentration. The baseline test is administered during the consolidation phase of chemotherapy and further tests are done at 1 year from baseline and 1 year after* the completion of study therapy.~Patients undergo blood and cerebrospinal fluid collection periodically for biomarker, genotypic polymorphisms, and pharmacokinetic analysis. Patients undergo MRI diffusion-tensor imaging to correlate imaging with neuropsychological outcomes."
89024802|NCT00437099|Experimental|1|subjects with BPD receiving Omacor 1.680 mg/d
89024803|NCT00437099|Experimental|2|BPD patients randomized to Omacor 3.360 mg/d
89024804|NCT00437099|Placebo Comparator|3|patients with BPD randomized to Placebo
89024805|NCT00481884|Experimental|RadiaPlexRx Gel|RadiaPlexRx Gel for application to one half of irradiated breast skin, determined by a randomization process.
89024806|NCT00481884|Active Comparator|Aquaphor Gel|Aquaphor Gel for application to one half of irradiated breast skin, determined by a randomization process.
89024807|NCT00437372|Experimental|Sunitinib plus Radiation|Sunitinib plus Radiation
89024808|NCT00482118||Cases|Non smoking women with lung cancer
88960957|NCT03560960|Experimental|Probable AD|Participants with probable AD with positive imaging AD pathology will receive the pramlintide challenge test.
88960958|NCT03560960|Active Comparator|Amnestic MCI|Participants with amnestic MCI with or without positive AD imaging pathology will receive the pramlintide challenge test.
88960959|NCT03560960|Active Comparator|Control- Normal Cognition|Participants with normal cognition without any memory complaints will receive the pramlintide challenge test.
88960960|NCT03543124|Active Comparator|Water exchange (WE)|This group will have the air in the colon removed and replaced with water to guide the insertion of the colonoscope.
88960961|NCT03543124|Experimental|WE plus cap(WECAC)|The procedure of this group is similar with WE group, except a cap will be fitted onto the end of the colonoscope.
88960962|NCT03538587|Active Comparator|Arm 1 Enhanced Mindfulness Intervention (EMI) - Immediate Group|Participate in an in-person session followed by a series of at-home assignments, and two booster sessions.
88960963|NCT03538587|Active Comparator|Arm 2 Control Group - Psychoeducation Group|Participants will briefly meet with a member of the research team who will assess parent and child coping, and provide the child- caregiver dyad educational material about coping with cancer
89024809|NCT00482118||Controls|Non smoking women without lung cancer
89024810|NCT00437411|Experimental|Workshop|Affective Self Awareness intervention
89514618|NCT04813198|Active Comparator|TIPSTART|Following baseline testing, the study orientation and randomization, the TIPSTART group will engage in 5.5 hours (30 minutes, on 11 separate occasions, over 10 weeks) of training delivered through Zoom and supported by instructional and communication apps, and that is further supervised by our TIPSTART study navigators who will provide motivational support and detailed lifestyle behavioral prescriptions (150 to 300 minutes per week of aerobic and strength training, with mental practice of material discussed each week). Participants will also be asked to complete approximately 3 total hours of repeated testing that occurs online via surveys and face-to-face interviews for the 12-week study.
89514619|NCT04813198|No Intervention|Wait-list Control|Following baseline testing, the study orientation and randomization, the wait-list control group will be asked to continue living life as usual until their delayed TIPSTART program is initiated. Participants will be asked to complete repeated online surveys and face-to-face interviews during the first 12 weeks, concurrently, with participants assigned to the TIPSTART intervention.
89514620|NCT05652946|Experimental|Inpatient Rehabilitation with ART|Inpatient rehabilitation with advanced rehabilitation technology
89514621|NCT05652946|Active Comparator|Inpatient Rehabilitation without ART|Inpatient rehabilitation without advanced rehabilitation technology
89514622|NCT04418752|Other|Psychological therapy|Narrative Exposure Therapy will be delivered to all participants in the study except carer participants recruited to complete informant measures.
89514623|NCT02499770|Experimental|trilaciclib + carboplatin/etoposide|All patients in part 1 will receive trilaciclib (G1T28) prior to standard chemotherapy- carboplatin and etoposide. Patients will have PK assessments completed on days 1 and 3 in cycle 1 only. All patents will be monitored for safety and tumor response based on RECIST version 1.1. Safety surveillance reporting of AEs and concomitant medications commences at the time that informed consent is obtained and continues through the Post Treatment Visit.
89514624|NCT02499770|Experimental|trilaciclib/placebo + carboplatin/etoposide|All patients enrolled in part 2 will be randomized to receive either trilaciclib (G1T28) or placebo administered prior to standard chemotherapy- carboplatin and etoposide. All patents will be monitored for safety and tumor response based on RECIST version 1.1. Safety surveillance reporting of AEs and concomitant medications commences at the time that informed consent is obtained and continues through the Post Treatment Visit.
89514625|NCT05652712||Immunotherapy Regimen|Patients receiving different treatment regimens of Toripalimab in each center were consecutively enrolled from January 1, 2019 to December 31, 2022
89514626|NCT04418674|Experimental|Ketamine|Patient will be given Ketamine 0.3mg/kg intravenously before sitting positioning for subarachnoid block.
89514627|NCT04418674|Active Comparator|Fentanyl|Patient will be given Fentanyl 1.5mcg/kg intravenously before sitting position for subarachnoid block.
89514628|NCT02442284|Experimental|3-DAA ± RBV for 12 or 24 weeks|3-DAA (ombitasvir/paritaprevir/ritonavir [25 mg/150 mg/100 mg once daily] and dasabuvir [250 mg twice daily]) with or without weight-based ribavirin (± RBV; dosed 1,000 or 1,200 mg daily divided twice a day) for 12 or 24 weeks, dosed as per label based on genotype and presence of cirrhosis.
89514629|NCT03781960|Experimental|Abemaciclib & Nivolumab|Subjects will receive abemaciclib monotherapy 150mg twice daily for seven days then will initiate nivolumab 480mg IV every 28 days while continuing twice daily abemaciclib.
89514630|NCT04795882|Experimental|Cohort 1: BCMA CAR T cells|Treatment with Advanced Therapy Investigational Product (ATIMP): BCMA CAR T-cells
89514631|NCT04795882|Experimental|Cohort 2: BCMA/CD19 CAR T cells|Treatment with Advanced Therapy Investigational Product (ATIMP): BCMA/CD19 CAR T-cells
89514632|NCT02442206|Experimental|Treatment sequence 1|QVA149 from day 1 to day 15 followed by Placebo from day 29 to day 43
89514633|NCT02442206|Experimental|Treatment sequence 2|Placebo from day 1 to day 15 followed by QVA149 from day 29 to day 43
89514634|NCT05182450|Experimental|Active capsule|Colored capsule containing 300 mg mango leaf extract (Zynamite®) standardized to contain ≥ 60% mangiferin. Supplied by PLT Health Solutions, Inc.
89514635|NCT05182450|Placebo Comparator|Placebo capsule|Colored capsule, appearance-matched to the active experimental capsule
89514636|NCT04794868||Culprit vessel of acute coronary syndrome|Culprit vessel of acute coronary syndrome
89514637|NCT04794868||Non-culprit vessel of acute coronary syndrome|Non-culprit vessel of acute coronary syndrome
89514638|NCT05652244|Experimental|Retraction with mini-implants|Mini-implants will be used as an anchor unit.
89514639|NCT05652244|Active Comparator|Retraction with transpalatal arches|Transpalatal arches will be used as an anchor unit.
89514640|NCT02499146|Experimental|Cohort 1|Combination therapy of palbociclib and letrozole
89514641|NCT03544138|Other|Hummingbird Tympanostomy Tube System (H-TTS)|"The Hummingbird Tympanostomy Tube System (H-TTS) is a disposable surgical tool designed to deliver a tympanostomy tube (ear tube) into the tympanic membrane of patients during a tympanostomy tube placement procedure."
89514642|NCT03542344|Experimental|BI 1015550|
89514643|NCT03542344|Placebo Comparator|Placebo|
89543092|NCT04800549|Experimental|METHOD|The power of the test in the study was calculated by using G*Power 3.1 program. While Type I error is 0.05 and the power of the test is 0.80 (α= 0.05, 1-β= 0.80), minimal sample size was calculated as 62 children (31 children in each group). By considering the losses that may occur from the sample during the study due to any reason, it was planned to include 40 children in both experimental and control groups. Follow-up lost occurred in 5 patients from experimental group and 6 patients in the control group during the study. The study was completed with 69 paediatric patients including 34 in the experimental group and 35 in the control group.
89543093|NCT03203369|Experimental|Part 1: Dose Escalation|A single intravenous administration of UCART123. Dose escalation in Part 1 will include 3 doses ranging from 6.25 x 10^5 cells/kg to 6.25 x 10^6 cells/kg and continue until the Recommended Phase 2 Dose (RP2D) is identified.
89543094|NCT03203369|Experimental|Part 2: Dose Expansion|A single intravenous administration of UCART123 at the RP2D. 2 Cohorts: Patients with Relapsed/Refractory BPDCN and Newly Diagnosed BPDCN.
89543095|NCT04794855||preganant women|observation from 6-8 weeks.
89543096|NCT02450357||Control|Use Flow cytometry (FCM) and RT-PCR to test peripheral blood mononuclear cells(PBMCs) from healthy volunteer.
89543097|NCT02450357||Cryosurgery group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received cryosurgery only, 1 day before and 2 days after the cryosurgery.
89543098|NCT02450357||DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received DC-CIK treatment only, 1 day before and 2 days after the DC-CIK treatment.
89543099|NCT02450357||Cryosurgery with DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients received cryosurgery and DC-CIK treatment both, 1 day before and 2 days after the cryosurgery with DC-CIK treatment.
89543100|NCT04794309|Experimental|Experimental Group|The participants will receive circuit training exercise and dietary intervention.
89543101|NCT04794309|Active Comparator|Control group|The participants will be only involved in dietary intervention.
89543102|NCT03107429|Active Comparator|Placebo and Trendelenburg Position|"Volunteers received placebo medication and placed in Trendelenburg.~IOP will be measured. Participants will then be administered with a placebo and after 2.5 hours will be placed in 17 degrees head-down position for a minimum of 1 hour and maximum 4 hours. Repeat IOP measure will be taken whilst still in the Trendelenburg position after 5 mins and then every 30 minutes."
89543103|NCT03107429|Experimental|Acetazolamide and Trendelenburg Position|"Volunteer given acetazolomide and placed in Trendelenburg position and IOP measured.~IOP will be measured. Participants will then be administered with acetazolamide and after 2.5 hours placed in 17 degrees head-down position for a minimum of 1 hour and maximum 4 hours. Repeat IOP measure will be taken whilst still in the Trendelenburg position after 5 mins and then every 30 minutes."
89543104|NCT04794231|Active Comparator|Standard dressing group|Patients were randomly assigned to one of two dressings, both of which were being actively used as part of standard care.
89543105|NCT04794231|Active Comparator|Chlorhexidine gluconate -impregnated dressing group|Patients were randomly assigned to one of two dressings, both of which were being actively used as part of standard care.
89543106|NCT02450201|Experimental|Part 1: Reproducibility|Pyruvate injection followed by an MRI scan. 2-3 weeks after imaging #1: a second pyruvate injection followed by an MRI scan.
89543107|NCT02450201|Experimental|Part 2: Treatment Response|Pyruvate injection followed by an MRI scan. 2 months after imaging #1: a second pyruvate injection followed by an MRI scan.
89543108|NCT04800081|Experimental|Sacubitril/Valsartan|receive once-daily treatment with 100-400 mg of Sacubitril/Valsartan
89543109|NCT04800081|Active Comparator|Valsartan|receive once-daily treatment with 80-320 mg of Valsartan
89543110|NCT03202979|Experimental|Group 1|Trazodone 20 mg
89543111|NCT03202979|Experimental|Group 2|Trazodone 10 mg
89543112|NCT03202979|Placebo Comparator|Group 3|Placebo
89543113|NCT04799925||Intervention group|Hyperuricemic group will be treated with uric acid lowering drug (febuxostat 80 mg once daily for 6 months).
89543114|NCT04799925||Placebo group|Hyperuricemic group will take placebo pills.
89543115|NCT03232775|Other|Treatment|Treatment: Physical Exam with Visual Pedagogy and Structure
89543116|NCT03232775|Other|Control|Control: Physical Exam without Visual Pedagogy and Structure
89543117|NCT04786431||Controls, CVD, IS, SLE|"Control (n = 85) were taken from the population of the Coimbra and Lisbon, Portugal, regions. They satisfied the criterion that they had never had any CVD- or SLE-related health complaints.~The CVD patients (n = 238) were divided into 6 groups. CVD1 (n = 61) contains individuals who went to the hospital with chest pain but had no indicators for stable angina pectoris, unstable angina pectoris or myocardial infarction.~Acute ischemic stroke (IS) (n = 21) were patients admitted at the emergency room of the Centro Hospitalar de Lisboa Ocidental, Lisbon, Portugal, who suffered from acute ischemic stroke.~The SLE cohort (n = 104) were patients from Hospital Dr. Fernando Fonseca, Amadora, Portugal."
88960964|NCT03534323|Experimental|Duvelisib +Venetoclax,|"Duvelisib will be given alone for the first seven days. On day 8 Venetoclax will be added.~Duvelisib will be administered orally twice daily~Venetoclax will be administered orally daily~All patients will be admitted for administration of the initial dose of venetoclax at each dose escalation"
88960965|NCT03530852|Experimental|Relizorb treatment|Patients will have tube feeds placed through chamber and evaluate wean from parenteral nutrition
88960966|NCT03525587|Active Comparator|Ongoing r-hGH therapy|"Patients on long-term r-hGH therapy.~Intervention: Use of MAGHD App/MAGHD Framework"
88960967|NCT03525587|Active Comparator|Previous r-hGH therapy|"Patients previously treated with r-hGH, who had stopped the treatment for any reason (age, concomitant adverse reactions, contraindications or personal will).~Intervention: Use of MAGHD App/MAGHD Framework"
88960968|NCT03525587|Active Comparator|Never treated|"Patients never treated for any reason (according to age, contraindications or lack of patient's consent).~Intervention: Use of MAGHD App/MAGHD Framework"
88960969|NCT03522597||Normal weight|Normal weight (BMI) women and their infants
88960970|NCT03522597||Obese|Obese (BMI) women and their infants
88960971|NCT03522597||Diabetic|Women with gestational diabetes and their infants
88960972|NCT03520842|Experimental|Treatment (regorafenib, methotrexate)|Participants receive regorafenib PO QD on days 1-21, and methotrexate PO twice weekly with 2-3 days apart on a 3 week on/ 1 week off cycle. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88960973|NCT03512080||Stable International Normalised Ratio|Consenting adult patients with either venous thromboembolism (VTE), atrial fibrillation (AF) on warfarin with a target International Normalised Ratio (INR) (INR range 2-3) or valvular heart disease with a target INR (INR range 3-4).
88960974|NCT03493464|Experimental|Treatment|Subjects will receive a single dose of BR55 at 0.03 mL/kg or 0.05 mL/kg.
88960975|NCT03491020||Respiratory syncytial virus (RSV)|Patients seen at the Emergency Department or admitted to the hospital with respiratory symptoms and diagnosed with a respiratory pathogen. A nasopharyngeal swab will be obtained to identify RSV.
88960976|NCT03491020||Enteroviruses|Patients seen at the Emergency Department or admitted to the hospital with respiratory symptoms and diagnosed with a respiratory pathogen. A nasopharyngeal swab will be obtained to identify enterovirus.
88960977|NCT03491020||Adenoviruses|Patients seen at the Emergency Department or admitted to the hospital with respiratory symptoms and diagnosed with a respiratory pathogen. A nasopharyngeal swab will be obtained to identify adenovirus.
88960978|NCT03491020||Coronaviruses|Patients seen at the Emergency Department or admitted to the hospital with respiratory symptoms and diagnosed with a respiratory pathogen. A nasopharyngeal swab will be obtained to identify coronavirus.
88960979|NCT03491020||Metapneumoviruses|Patients seen at the Emergency Department or admitted to the hospital with respiratory symptoms and diagnosed with a respiratory pathogen. A nasopharyngeal swab will be obtained to identify metapneumovirus.
88960980|NCT03491020||Chlamydia pneumoniae|Patients seen at the Emergency Department or admitted to the hospital with respiratory symptoms and diagnosed with a respiratory pathogen. A nasopharyngeal swab will be obtained to identify chlamydia pneumoniae.
88960981|NCT03491020||Mycoplasma|Patients seen at the Emergency Department or admitted to the hospital with respiratory symptoms and diagnosed with a respiratory pathogen. A nasopharyngeal swab will be obtained to identify mycoplasma.
88960982|NCT03491020||Parainfluenza|Patients seen at the Emergency Department or admitted to the hospital with respiratory symptoms and diagnosed with a respiratory pathogen. A nasopharyngeal swab will be obtained to identify parainfluenza.
88960983|NCT03491020||Neisseria meningitides|Patients seen at the Emergency Department or admitted to the hospital with respiratory symptoms and diagnosed with a respiratory pathogen. A nasopharyngeal swab will be obtained to identify neisseria meningitides.
88960984|NCT03491020||Bordetella pertussis|Patients seen at the Emergency Department or admitted to the hospital with respiratory symptoms and diagnosed with a respiratory pathogen. A nasopharyngeal swab will be obtained to identify bordetella pertussis.
88960985|NCT03491020||Rhinovirus|Patients seen at the Emergency Department or admitted to the hospital with respiratory symptoms and diagnosed with a respiratory pathogen. A nasopharyngeal swab will be obtained to identify rhinovirus.
88960986|NCT03479554|Experimental|Early antihypertensive treatment group|BP-lowering treatment will start immediately after randomization in the early antihypertensive treatment group.
88960987|NCT03479554|Active Comparator|Delayed antihypertensive treatment group|All home antihypertensive medications will be discontinued in the first seven days after randomization. Study participants will receive antihypertensive treatment on day eight after randomization.
88960988|NCT03477435|Experimental|Opt-in clinical reminder|As the investigators have done previously, the reminder will be self-explanatory, and will walk staff through each step of referral. The reminder will include the following domains: normative advice, referral to treatment, handout
88960989|NCT03477435|Experimental|Opt-out tobacco treatment|The investigators will directly change the treatment status quo by implementing a clinical reminder that automatically initiates tobacco treatment referral at the time the reminder is activated.
89543118|NCT03232697|Other|Healthy subjects|Subjects will be submitted to both the full version of the Montreal Cognitive Assessment and of the 5-minutes version of the Montreal Cognitive Assessment
89543119|NCT03232697|Other|Alzheimer patients|Patients will be submitted to both the full version of the Montreal Cognitive Assessment and of the 5-minutes version of the Montreal Cognitive Assessment
89543120|NCT03232697|Other|Parkinson and Huntington patients|Patients will be submitted to both the full version of the Montreal Cognitive Assessment and of the 5-minutes version of the Montreal Cognitive Assessment
89543121|NCT03232697|Other|Diabetic patients|Patients will be submitted to both the full version of the Montreal Cognitive Assessment and of the 5-minutes version of the Montreal Cognitive Assessment
89543122|NCT04793997|Active Comparator|Verum Microbiome spray group|Daily use of microbiome spray for two weeks
89543123|NCT04793997|Placebo Comparator|Placebo spray group|Daily use of placebo spray for two weeks
89543124|NCT04793997|No Intervention|Household member group|No use of spray
89543125|NCT03107351|Sham Comparator|repeatability measures|In this arm, healthy subjects will undergo repeated measures at different times of the day.
89543126|NCT03107351|Experimental|Contractility changes measures|In this arm, healthy subjects will have their cardiac contractility increased in a controlled way and assessed with both HK and echocardiography.
89543127|NCT04786509||ECG sensor|All subjects performed shuttle run (SR), Cooper 2400 m (C), and 100 m sprint test (S), once wearing the sensor attached to self-adhesive skin electrodes, additionally fixed with self-adhesive tapes, and secondly with the sensor attached to Polar belt and strapped around the chests.
89543128|NCT03107273||Diagnostic patient|
89543129|NCT03107273||Control|
89543130|NCT04800003||Dry human mandibles, selected for evaluation|51 dry mandibles with posterior region endetulism and sufficient bone integrity to make the necessary measurements were evaluated. CBCT images of the 51 dry human mandibles included in the study were obtained using the Planmeca Promex-3D (Helsinki, Finland) device in our faculty Dentomaxillofacial Radiology department. Gonial angle was measured on CBCT images as the angle between the tangent line drawn posterior to the border of the ramus of the mandible and the tangent line drawn to the lower border of the mandible. While determining the depth of the submandibular fossa, a line was drawn to connect the most dislocated upper and lower points on the inner surface of the mandible in the coronal plane sections obtained with CBCT, and the length of the line drawn at a right angle from the deepest point of the fossa to this line was measured as the depth of the submandibular fossa.
89543131|NCT03202823||Diabetics|
89543132|NCT03202823||Non-diabetics|
89543133|NCT04794465||Asymptomatic IBD diagnosed during the colorectal cancer screening|
89543134|NCT03203057||control group|10 individuals get randomised to control group.
89543135|NCT03203057||short ischemic time|10 individuals get randomised to a controlled coronary occlusion for 30 seconds
89543136|NCT03203057||intermediate ischemic time|10 individuals get randomised to a controlled coronary occlusion for 60 seconds
89543137|NCT03203057||long ischemic time|10 individuals get randomised to a controlled coronary occlusion for 90 seconds
89543138|NCT03202745|No Intervention|Control|The control arm will not receive any communications as a result of this study.
89543139|NCT03202745|Experimental|Patient Consequences|The patient consequences arm prescribers receive an initial patient consequences letter followed by 2 followup letters at approximately 3 month intervals. The letters focus on the consequences of inappropriate prescribing for patients.
89543140|NCT03202745|Experimental|Prescriber Consequences|The prescriber consequences arm prescribers receive an initial prescriber consequences letter followed by 2 followup letters at approximately 3 month intervals. The letters focus on the consequences of inappropriate prescribing for prescribers.
89543141|NCT04799457|No Intervention|Classical caesarean group|Care providers are applying standard caesarean procedure for participants.
89543142|NCT04799457|Experimental|Study caesarean group|Care providers are applying additional sutures to standard caesarean procedure for participants.
89543143|NCT04799613|No Intervention|Natural walking|
89543144|NCT04799613|Experimental|fast walking|
89543145|NCT04799613|Experimental|normal walking passing through narrow pathway|
89543146|NCT04799613|Experimental|fast walking passing through narrow pathway|
89543147|NCT04799613|Experimental|Natural walking with dual task|
88960990|NCT03454711|Experimental|Patient with food addcitions|"Patients (20) will be selected from the Yale Food Addiction Scale (YFAS): a validated screening of FA questionnaire.~Three clinical visits will be realized in less than two months"
88960991|NCT03454711|Experimental|Patients without food addictions|"Patients (20) will be selected from the Yale Food Addiction Scale (YFAS): a validated screening of FA questionnaire.~Three clinical visits will be realized in less than two months"
88960992|NCT03454529|Experimental|Treatment (simvastatin)|Patients receive simvastatin PO daily for 2-4 weeks in the absence of disease progression or unacceptable toxicity.
88960993|NCT03439735|Experimental|Cohort A: Participants with untreated metastatic disease receiving ET and a CDK 4/6|Participants will undergo blood collection (intervention) at time of initiating treatment with endocrine therapy and palbociclib, at 4 weeks after initiating this treatment, and every 3-4 months while on treatment. If a participant progresses on this treatment, they will have a blood collection at that time.
88960994|NCT03439735|Experimental|Cohort B: Participants initiating a CDK 4/6 i after progression on ET.|Participants will undergo blood collection (intervention) at time of initiating treatment with endocrine therapy and palbociclib, at 4 weeks after initiating this treatment, and every 3-4 months while on treatment. If a participant progresses on this treatment, they will have a blood collection at that time.
88960995|NCT03419689|Experimental|Sample Collection|"The following samples may be collected during the study:~Tumour tissue samples~Blood samples~Ascites samples~Other fluids requiring drainage"
88960996|NCT03418844|Other|Interest group (patients treated with chemotherapy)|Patients will complete several self-questionnaires on living conditions and quality of life. They will also perform a cardiac, pulmonary, auditory and biological assessment
88960997|NCT03418844|Other|Patient control group (patients not treated with chemotherapy)|Patients will complete several self-questionnaires on living conditions and quality of life. They will also perform a cardiac, pulmonary, auditory and biological assessment
88960998|NCT03418844|Other|Healthy volunteers|Healthy volunteers will complete several self-questionnaires on living conditions and quality of life.
88960999|NCT03414658|Experimental|Trastuzumab + Vinorelbine|"Trastuzumab is administered intravenously twice per cycle~Vinorelbine is administered intravenously 3 times per cycle"
88961000|NCT03414658|Experimental|Trastuzumab + Vinorelbine + Avelumab|"Trastuzumab is administered intravenously twice per cycle~Vinorelbine is administered intravenously 3 times per cycle~Avelumab is administered intravenously twice per cycle~Antihistamine and with acetaminophen is mandatory 30 to 60 minutes prior to each dose of avelumab"
88961001|NCT03414658|Experimental|Trastuzumab + Vinorelbine + Avelumab + Utomilumab|"Trastuzumab is administered intravenously twice per cycle~Vinorelbine is administered intravenously 3 times per cycle~Avelumab is administered intravenously twice per cycle~Antihistamine and with acetaminophen is mandatory 30 to 60 minutes prior to each dose of avelumab~Utomilumab is administered intravenously once per cycle"
88961002|NCT03414658|Experimental|Trastuzumab + Avelumab + Utomilumab|"This is a crossover arm~Avelumab is administered intravenously twice per cycle~Antihistamine and with acetaminophen is mandatory 30 to 60 minutes prior to each dose of avelumab~Utomilumab is administered intravenously once per cycle~Trastuzumab is administered intravenously twice per cycle"
89543148|NCT04799613|Experimental|fast walking with dual task|
89543149|NCT04799613|Experimental|Natural walking passing through narrow pathway and during cognitive dual task|
89543150|NCT04799613|Experimental|fast walking passing through narrow pathway and during cognitive dual task|
89543151|NCT04799613|Experimental|Natural walking reducing the best side|
89543152|NCT04799613|Experimental|fast walking reducing the best side|
89543153|NCT04799613|Experimental|Natural walking reducing the best side passing through narrow pathway|
89543154|NCT04799613|Experimental|fast walking reducing the best side passing through narrow pathway|
89543155|NCT04799613|Experimental|Natural walking reducing the best side with cognitive dual task|
89543156|NCT04799613|Experimental|fast walking reducing the best side with cognitive dual task|
89543157|NCT04799613|Experimental|Natural walking reducing the best side passing through narrow pathway and during cognitive dual task|
89543158|NCT04799613|Experimental|fast walking reducing the best side passing through narrow pathway and during cognitive dual task|
89543159|NCT03202433|Experimental|Virtual Reality Distractor|The objective is to apply a technique, using virtual reality lenses, with relaxing audio-visual contents of no more than ten minutes, to reduce stress before and during the blood donation process and to respond to the level of pain perceived during donation, either post-puncture and withdrawal of the needle
89543160|NCT03202433|No Intervention|Traditional Blood Donation Process|The objective is to respond to the level of pain perceived during donation, either post-puncture and withdrawal of the needle, without virtual reality support
88961003|NCT03409731|Other|Absorb GT1 BVS|Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.
88961004|NCT03400215|Active Comparator|Breast cancer confirmed by biopsy|Cases will be women first diagnosed with invasive breast cancer confirmed by biopsy
88961005|NCT03400215|Active Comparator|Women without any history of breast cancer|No known malignancy confirmed by at least 1-year follow up exams.
88961006|NCT03398148|Experimental|Substudy 1, Induction 1: Double-blind Risankizumab Dose 1|Participants randomized to receive risankizumab dose 1 administered by intravenous (IV) infusion.
88961007|NCT03398148|Experimental|Substudy 1, Induction 1: Double-blind Risankizumab Dose 2|Participants randomized to receive risankizumab dose 2 administered by intravenous (IV) infusion.
88961008|NCT03398148|Experimental|Substudy 1, Induction 1: Double-blind Risankizumab Dose 3|Participants randomized to receive risankizumab dose 3 administered by intravenous (IV) infusion.
88961009|NCT03398148|Placebo Comparator|Substudy 1, Induction 1: Double-blind Placebo|Participants randomized to receive placebo for risankizumab administered by intravenous (IV) infusion.
88961010|NCT03398148|Experimental|Substudy 1, Induction 1: Open-label Risankizumab Dose 1|Participants receive risankizumab dose 1 administered by intravenous (IV) infusion.
89514644|NCT01634854|Active Comparator|Vaginal Misoprostol|Dosage: 25 µg every 4 hours up to a maximum of 4 doses until cervical change is consistent with a diagnosis of active labor Route of administration: Intravaginal
89514645|NCT01634854|Active Comparator|Intravenous Oxytocin|"2 miu per minute increased in increments of 1-2 miu per minute every 30 minutes to establish an effective contraction pattern.~Route of administration: intravenous"
89514646|NCT05173792|Experimental|AK119|Subjects will receive escalating doses of AK119 every 2 or 3 weeks.
89514647|NCT03542188|Active Comparator|Primary Stroke Center (PSC)|Transport to a primary stroke center for early IV-thrombolysis followed by a secondary transport to a comprehensive stroke center for EVT if needed.
89514648|NCT03542188|Experimental|Comprehensive Stroke Center (CSC)|Direct transport to a comprehensive stroke center for IV-trombolysis and early EVT.
89514649|NCT03541408|Placebo Comparator|Control|Subjects will receive anesthesia
89514650|NCT03541408|Experimental|Preventative Delirium Protocol|"Consider regional block if applicable~Minimized fentanyl usage intraoperatively~Intubation + GA adjunct total: 1-2 mcg/kg~Sedation: 0-0.25 mcg/kg~Post-op: 0.5-1 mcg/kg~Avoid morphine~Avoid ketamine~Avoid diphenhydramine, dexamethasone, scopolamine, metoclopramide, and promethazine~Avoid H2-blockers (cimetidine, ranitidine, famotidine)~Avoid polypharmacy intraoperatively if possible (i.e. >5 new medications)~Fluid repletion based on maintenance and losses"
89514651|NCT04811794||Group A (largest part of the cohort)|Children, adolescents, and adults who are still in follow-up care (data are collected retrospectively until 2016 at the most)
89514652|NCT04811794||Group B (very small part of the cohort)|Children, adolescents, and adults who left follow-up care (data are collected retrospectively until 2016 at the most)
89514653|NCT02469896|Placebo Comparator|Placebo|8 subjects will receive matching IV placebo every 4 weeks for 3 months.
89514654|NCT02469896|Active Comparator|Active drug|14 subjects will receive 8mg/kg of IV tocilizumab every 4 weeks for 3 months.
89514655|NCT05651698|Experimental|HeartMan Intervention group|80 patients are in the intervention group (40 in Belgium and 40 in Italy).
89514656|NCT05651698|No Intervention|Control group|40 patients are in the intervention group (20 in Belgium and 20 in Italy). Standard care consists of optimal medical treatment according to the international guidelines. In addition, written and oral education on heart failure disease and its management is provided by the heart failure nurse at the moment a patient has been diagnosed with heart failure or whenever he is rehospitalized for heart failure if necessary. Further support after discharge is possible by giving the patient the opportunity to call with the heart failure nurse in case he has questions about his treatment or health condition. Regular visits with the treating physician are scheduled several times per year.
89514657|NCT05651464|Active Comparator|Intervention: Prophylactic antibiotic treatment|Application of 15-20 mg per kgKG Vancomycine I.V. prior to ECMO liberation
89514658|NCT05651464|No Intervention|Control Arm: No prophylactic antibiotic treatment|Control group - no intervention.
89514659|NCT02441114|Experimental|Inhalation of HCP0910 and HGP1011|"Single, twice and triple inhalation of HCP0910 and HGP1011 (open-label, single-arm, dose-escalation) at period 1, 2, and 3, respectively.~The periods were separated with a washout period of 14 days."
89514660|NCT03461848|Experimental|CYPHP Evelina London Model|Practice clusters across Lambeth and Southwark have been randomised to introduce either the CYPHP Evelina London model of care, or Enhanced Usual Care.
89514661|NCT03461848|Active Comparator|Enhanced Usual Care Model|Practice clusters across Lambeth and Southwark have been randomised to introduce either the CYPHP Evelina London model of care, or Enhanced Usual Care.
89514662|NCT02498678|No Intervention|control group|After verifying the absence of sevoflurane through the gas analyzer, TOF monitor mode starts with stimuli every 12 to 15 seconds. After 1 minute (min) stimulation, calibration and supramaximal stimulation will be ensured by the built-in calibration function (CAL 2) of the TOF-Watch®. The stability of the response will be documented by at least 2 to 5 min [< 5% variation in the first response (T1) in the TOF]. Monitoring of neuromuscular junction will be held until recovery of the TOF ratio to 0.9 (90%), an expected average of 60 minutes.
89514663|NCT02498678|Experimental|tetanus group|After verifying the absence of sevoflurane through the gas analyzer, a 50-Hz tetanic stimulation will be applied for 5 s and followed after 1 min by TOF stimulation every 15 s. After 1 minute (min) calibration and supramaximal stimulation will be ensured by the built-in calibration function (CAL 2) of the TOF-Watch®. The stability of the response will be documented by at least 2 to 5 min [< 5% variation in the first response (T1) in the TOF]. Monitoring of neuromuscular junction will be held until recovery of the TOF ratio to 0.9 (90%), an expected average of 60 minutes.
89514664|NCT04793698|Experimental|Compassion meditation|Compassion meditation is a contemplative meditation practice that fosters compassion through contemplation of common humanity.
89514665|NCT04793698|Active Comparator|Applied relaxation|Veteran.calm is an applied relaxation program that exposes participants to a variety of relaxation strategies and their application.
89514666|NCT02441036|Active Comparator|Group 1 - 1-3 hours prior|Subjects will receive Ultherapy treatment 1-3 hours prior to tissue resection.
89514667|NCT02441036|Active Comparator|Group 2 - 1 day prior|Subjects will receive Ultherapy treatment 1 day prior to tissue resection.
89024811|NCT00437411|No Intervention|Control|Waiting-list control.
89024812|NCT01240668||Hyponatremia Patients|Euvolemic or hypervolemic hyponatremia with serum sodium ≤130 mmol/L
89024813|NCT04701710|Experimental|Experimental Group|"The EG received Ivermectin orally 2 drops of 6 mg = 12 mg every 7 days, and Iota-Carrageenan 6 sprays per day for 4 weeks.~Standard biosecurity care"
89543161|NCT03232619|Experimental|CD19-CART with a murine scFv|All enrolled patients in this arm will receive CD19-CART with a murine scFv.
89543162|NCT03232619|Experimental|humanized CD19-CART|All enrolled patients in this arm will receive humanized CD19-CART.
89543163|NCT04261959||myoActivation only|Participants who receive one or more sessions of myoActivation. They may receive 1:1 counselling also, but will not receive physiotherapy or group counselling
89543164|NCT04261959||Physiotherapy only|Participants who receive one or more sessions of physiotherapy. They may receive 1:1 counselling also, but will not receive myoActivation or group counselling
89543165|NCT04261959||myoActivation and Physiotherapy|Participants who receive one or more sessions of myoActivation AND one or more sessions of physiotherapy. They may receive 1:1 counselling also, but will not receive group counselling
89543166|NCT03232385|Experimental|MR-US Fusion Arm|Clear Guide SCENERGY, MR-US
89543167|NCT03232385|Active Comparator|EM Fusion or No Fusion Arm|
89543168|NCT04793763|Placebo Comparator|group A|"placebo Comparator Group A~: twenty patients were received traditional Physical Therapy agents"
89543169|NCT04793763|Experimental|group B|experimental Group B Group B: twenty patients were received traditional Physical Therapy agents plus isometric, stretching, scapulothoracic exercises and deep neck flexors exercises;
89543170|NCT04793763|Experimental|group C|"Experimental Group C~Group C: twenty patients were received traditional Physical Therapy agents plus isometric, stretching, scapulothoracic exercises and Mckenzie technique."
89543171|NCT03232307|Experimental|Treatment (ibrutinib, rituximab, lenalidomide, dexamethasone)|Participants receive ibrutinib PO on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Participants also receive rituximab IV on days 1, 8, 15 and 22 in course 1 and 2, on day 1 of course 3-8, and then on day 1 of every other 28-day course, lenalidomide PO on days 1-21, and dexamethasone PO weekly. Treatment with rituximab repeats every 28 days for 2 years, with lenalidomide for 1 year, and with dexamethasone for up to 2 courses in the absence of disease progression or unacceptable toxicity.
89543172|NCT05615727|Experimental|Dexmedetomidine|
89543173|NCT05615727|Active Comparator|Zolpidem|
89543174|NCT05615727|Placebo Comparator|Placebo|
89543175|NCT03232229||Tennis players|
89543176|NCT03202355|Experimental|Group 1 (Control)|Subjects assigned to this group receive fixed appliance orthodontic treatment only
89543177|NCT03202355|Experimental|Group 2 (OP1)|Subjects assigned to this group receive fixed appliance orthodontic treatment in conjunction with receiving daily OrthoPulse™ treatments.
89543178|NCT04785729|Experimental|almonertinib|
89543179|NCT04785885||Transcatheter Aortic Valve Replacement|Patients receive 100U/Kg of IV heparin. An arterial sample activated clotting time (ACT) will be checked by iStat and hemochron
89024814|NCT04701710|No Intervention|Control Group|Standard biosecurity care
89024815|NCT01240707|Other|LF tests, Fiberoptic bronchoscopy|Spirometry, Peak Expiratory Flow (PEF). Bronchoscopic assessment of soot in central airways.
89024816|NCT00437567|Active Comparator|Prebiotics|Babies randomized to this arm will receive galacto-oligosaccharide supplements
89024817|NCT00437567|Placebo Comparator|Placebo|Babies randomized to this arm will receive placebo
89543180|NCT04785885||Cardiac Valve Annuloplasty|Patients receive 300U/kg of IV heparin. An arterial sample activated clotting time (ACT) will be checked by iStat and hemochron
89543181|NCT02450279|Active Comparator|Nebulization with a vibrating-mesh nebulizer|Nebulization performed with a vibrating-mesh nebulizer
89024818|NCT02274129|Experimental|Use of Healing cap II|Single arm study using a new healing cap as intervention
89024819|NCT00437606|Experimental|1|
89024820|NCT00437606|Experimental|2|
89024821|NCT00437606|Experimental|3|
89024822|NCT00482313|Experimental|Methylphenidate|PR OROS Methylphenidate given orally once daily for 5 weeks. The dosage was as follows: 36 mg per day from day 1-3, 54 mg per day from day 4-7 and 72 mg per day from day 8 until end of 5th week.
89543182|NCT02450279|Active Comparator|Nebulization with a jet nebulizer|Nebulization performed with a jet nebulizer
89543183|NCT03231839|Placebo Comparator|Caloric restriction (control)|daily reduction of caloric intake aimed at 400 kcal/day
89543184|NCT03231839|Active Comparator|No red meat|daily reduction of caloric intake aimed at 400 kcal/day plus no red meat intake
89543185|NCT03231839|Active Comparator|Increased fiber intake|daily reduction of caloric intake aimed at 400 kcal/day plus increased fiber intake (aim: 40gr/day)
89543186|NCT03231761|Experimental|Service user testimonial videos|Videos with service user testimonials about depression and psychosis
89543187|NCT03231761|Active Comparator|mhGAP didactic video|The intervention in the active comparator arm includes two didactic videos with instruction about depression and psychosis based on the World Health Organization mental health Gap Action Programme (mhGAP) modules for those conditions
89543188|NCT03231761|No Intervention|No video|Participants do not observe any videos prior to the assessment
89543189|NCT04786041||underwent Appendectomy during march-april of 2019|all patients who underwent Appendectomy during the period of march-april of 2019
89543190|NCT04786041||underwent Appendectomy during march-april of 2020 (during covid pandemic)|all patients who underwent Appendectomy during the period of march-april of 2020 (during the COVID19 pandemic lockdown)
89543191|NCT03231683|Active Comparator|Esketamine|Esketamine and remifentanil to be given alongside with propofol through target control infusion pump.
89543192|NCT03231683|Placebo Comparator|Control|Saline and remifentanil to be given alongside with propofol through target control infusion pump.
89543193|NCT04346979|Experimental|Study Group|Telerehabilitation based yoga and mindfulness training will be given to the study group.
89543194|NCT04346979|Experimental|Control Group|Yoga and mindfulness training will be provided by sending a video recording to the control group.
89543195|NCT03202277|Experimental|BeWell24 smartphone app|Smartphone app, linked with commercial activity monitor, to support lifestyle changes in physical activity, sleep, sedentary behavior, and dietary intake.
89024823|NCT00482313|Placebo Comparator|Sugar pill|Placebo given orally once daily for 5 weeks.
89024824|NCT00437684|Experimental|A|LPV/r: LPV/r monotherapy and anti HCV drugs for 12 months. All the patients will be followed-up for six months after the end of anti-HCV drugs for the evaluation of Sustained Virological Response (SVR). At the end of the co-treatment for HCV/HIV, each subject will be treated for HIV infection according to physician decisions.As anti-HCV drugs the patients will receive PEG-IFNa 2a 180 mcg/week + Ribavirin 1-1.2 g/day .At the end of the third month of combined therapy, only patients who reach an early virological response will continue anti-HCV drugs.
89024825|NCT00437684|Active Comparator|B|LPV/r+ selected NUCS and anti HCV drugs for 12 months. All the patients will be followed-up for six months after the end of anti-HCV drugs for the evaluation of Sustained Virological Response (SVR). At the end of the co-treatment for HCV/HIV, each subject will be treated for HIV infection according to physician decisions.As anti-HCV drugs the patients will receive PEG-IFNa 2a 180 mcg/week + Ribavirin 1-1.2 g/day .At the end of the third month of combined therapy, only patients who reach an early virological response will continue anti-HCV drugs.
89543196|NCT03202277|Active Comparator|Health education smartphone app|Smartphone app with basic health education content, designed to control for non-specific treatment effects and match for smartphone app novelty.
89543197|NCT03231605|Experimental|Group 1|Group 1 is experimental group which used the Hepatitis A Vaccine product by Changchun Institute of Biological Co.,Ltd
89543198|NCT03231605|Active Comparator|Group 2|Group 2 is control group which used the Hepatitis A Vaccine product by Changchun Changsheng Life Sciences Limited
89543199|NCT04798599|Experimental|Intervention|In the intervention group there will be the application of the intervention - use of telemonitoring and teleorientation applied to children in primary care in Dentistry.
89543200|NCT04798599|Active Comparator|Waiting list|In the control group, children waiting to be booked to the intervention (in implementation in the unit because of the pandemic) will be evaluated for the outcomes. Only after the evaluation, the control group's children will be invited to perform the teleconsultation (proposed intervention).
89543201|NCT03202199|Experimental|PET/MRI|PET/MRI examination
89543202|NCT04793451|Experimental|Group A|Endurance training
89543203|NCT04793451|Experimental|Group B|Endurance-strength training
89024826|NCT00437723|Experimental|1|
89024827|NCT00437723|No Intervention|2|
89024828|NCT00482430|Other|1|MK0557 10mg tablet qd, crossing over to MK0557 Pbo tablet qd.
89024829|NCT00482430|Other|2|MK0557 Pbo tablet qd, crossing over to MK0557 10mg tablet qd.
89024830|NCT00437762|Experimental|1|Botulinum Toxin A Injection
89024831|NCT00437762|Placebo Comparator|2|Placebo injection
89024832|NCT00437840|Experimental|Treatment Arm A|In Arm A dosing subject will receive Placebo in Week 1, 10 milligram (mg) of GSK598809 in Week 2, 25 mg of GSK598809 in Week 3, 75 mg of GSK598809 in Week 4. Subjects will have a wash-out of period of one week before receiving another dose.
89024833|NCT00437840|Experimental|Treatment Arm B|In Arm B dosing subject will receive 10 mg of GSK598809 in Week 1, Placebo in Week 2, 25 mg of GSK598809 in Week 3, 75 mg of GSK598809 in Week 4. Subjects will have a wash-out of period of one week before receiving another dose.
89024834|NCT00437840|Experimental|Treatment Arm C|In Arm C dosing subject will receive 10 mg of GSK598809 in Week 1, 25 mg of GSK598809 in Week 2, Placebo in Week 3, 75 mg of GSK598809 in Week 4. Subjects will have a wash-out of period of one week before receiving another dose.
89024835|NCT00437840|Experimental|Treatment Arm D|In Arm D dosing subject will receive 10 mg of GSK598809 in Week 1, 25 mg of GSK598809 in Week 2, 75 mg of GSK598809 in Week 3, Placebo in Week 4. Subjects will have a wash-out of period of one week before receiving another dose.
89024836|NCT00482586||Image-guided Therapy|Patients undergoing Image-guided Therapy of Hepatic Neoplasms.
89543204|NCT03202121||insomnia group|After screening according to inclusion and exclusion criteria, patients were assigned to insomnia group that contained 25 cases.
89543205|NCT03202121||non-insomnia group|After screening according to inclusion and exclusion criteria, patients were assigned to non-insomnia group that contained 25 cases.
89543206|NCT03202121||normal control|persons without stroke or insomnia served as normal controls that contained 25 cases.
89543207|NCT03201887|Experimental|Sub-optimal Traumatic Brain Injury|Sub-optimal effort
89543208|NCT03201887|Experimental|Sub-optimal effort Chronic pain|Sub-optimal effort
89024837|NCT00482742|Other|Lifestyle counseling|
89024838|NCT00482742|Other|Metformin|
89024839|NCT00437957|Experimental|Temazolomide, Valproic Acid and Radiation|Temazolomide, Valproic Acid and Whole Brain Radiation Therapy
89024840|NCT03270176|Experimental|Debio 1143 and Avelumab|"Part A: Participants will receive Debio 1143 100 to 250 milligram (mg) capsule orally at an escalating dose levels for 10 days every 2 weeks along with avelumab 10 milligrams per kilogram (mg/kg) as an intravenous (IV) infusion every 2 weeks.~Part B: Participants will receive Debio 1143 capsules orally at a recommended phase 2 dose (RP2D) of 200 mg/day (days 1-10 and 15-24 every 28 days ([q4w]) in combination with avelumab IV infusion at the standard dose unless disease progression or unacceptable toxicity occurs, as judged by investigators up to 26 cycles (each cycle is of 28 days)."
89543209|NCT03201887|No Intervention|Traumatic Brain Injury|optimal effort
89543210|NCT03201887|No Intervention|Chronic pain|optimal effort
89543211|NCT02593773|Experimental|interferon γ-1b|Subcutaneous (SC) doses of ACTIMMUNE® TIW for a total of 26 weeks.
89543212|NCT01526681||RANGER: Avance Nerve Graft|Processed Human Nerve Graft
89543213|NCT01526681||Historical Control for Standard Treatment|Literature review for outcomes from standard treatments, i.e. Autogenous Nerve Graft.
89543214|NCT01526681||MATCH Arm: Contemporary Control|Addendum 1: Autogenous Nerve Graft and Nerve Tube Conduit
89543215|NCT01526681||Sensation-NOW Arm: Breast Neurotization|Addendum 2: Post-mastectomy autologous breast reconstruction with or without neurotization
89543216|NCT04798443|Active Comparator|Subureteral endoscopic injection|The endoscopic procedure was done under general anesthesia, and all patients received antibiotic prophylaxis. We used the subureteral injection technique (STING), as described by O'Donnell and Puri (1984). The volume of Dx/HA was injected until ureteral orifice collapse in all patients. The needle was held for 30 s.
89207435|NCT00966069|Active Comparator|Healthcare worker visit|"Healthcare worker performs home visit when study child has acute respiratory illness to collect a respiratory swab (nasopharyngeal swab).~At the healthcare worker home visit, the HCW will collect the nasopharyngeal swab, and a parent will collect an anterior nasal swab. The HCW swab is to be returned immediately to the laboratory, and the parent collected swab was placed in a post box for return to the laboratory by surface mail."
89543217|NCT04798443|Active Comparator|open ureteral reimplantation (lich-gregoir)|extravesical ureteral reimplantation (lich-gregoir) by open surgery
89543218|NCT03201731||Cases|Those diagnosed with a non-organic, non-affective psychotic disorder for the first time after age 60, recruited from a Community Mental Health Team.
89543219|NCT03201731||Controls|Those aged 60 and above in contact with the same Community Mental Health Team for another mental health problem aside from a psychotic disorder or dementia.
89543220|NCT05234333||Patients presenting a malaise after the vaccination by any vaccine|
89543221|NCT05234333||Patients presenting any other adverse event after the vaccination by any vaccine|
89543222|NCT02450045|Active Comparator|Femoral nerve block|Patients will receive a pre-operative continuous femoral nerve block.
89543223|NCT02450045|No Intervention|Control|Patients will receive standard care without a continuous femoral nerve block.
89543224|NCT03201653|Active Comparator|Conventional|Stump closure as our institute routine, using interrupted silk mattress suture and continuous prolene sutures.
89543225|NCT03201653|Experimental|Surgicel|Stump closure modified from our institute routine, using interrupted silk mattress suture and continuous prolene sutures with NU-KNIT SURGICEL overlying for reinforcement.
89543226|NCT03201497||patients with PJP|PJP patients in ICU with or without HIV infection
89543227|NCT02593539|Experimental|Participants recieving nemiralisib|
89543228|NCT00919763|Experimental|CD2027 Ointment 3 mcg/g, twice daily|Participants applied 3 mcg/g CD2027 Ointment (up to 10 gram per application) topically, twice daily (at least 8 hours apart) over 4 weeks on atopic dermatitis lesions.
89543229|NCT00919763|Placebo Comparator|Vehicle Ointment, twice daily|Participants applied Vehicle Ointment (up to 10 gram per application) topically, twice daily (at least 8 hours apart) over 4 weeks on atopic dermatitis lesions.
89543230|NCT05615571||Patients with NBIA who remain without molecular diagnosis|A group of 40 patients with NBIA, who remain without molecular diagnosis
89543231|NCT05615571||Patients with NBIA with identified mutations in genes|A group of patients with 2 frequent forms of NBIA, carrying mutations in genes (already studied in the CHU molecular diagnostic laboratory)
89543232|NCT00306917|Active Comparator|1|DuoFix HA
89543233|NCT00306917|Active Comparator|2|Porocoat porous coated
89543234|NCT05615493|Active Comparator|Group I|Will receive rESWT once weekly for one month
89543235|NCT05615493|Sham Comparator|Group II|Will receive Sham rESWT once weekly for one month
89543236|NCT03119129|Experimental|Cohort 1|Four middle or intermediate schools receiving the Ho'ouna Pono curriculum in Quarter 2, Academic Year (AY) 2016-2017
89543237|NCT03119129|Experimental|Cohort 2|Three middle or intermediate schools receiving the Ho'ouna Pono curriculum in Quarter 3, AY 2016-2017
89543238|NCT03119129|Experimental|Cohort 3|Three middle or intermediate schools receiving the Ho'ouna Pono curriculum in Quarter 2, AY 2017-2018
89543239|NCT03119129|Experimental|Cohort 4|Three middle or intermediate schools receiving the Ho'ouna Pono curriculum in Quarter 3, AY 2017-2018
89543240|NCT02593305|Experimental|Beetroot crystals (nitrate), then placebo|Participants will receive a nitrate rich beetroot powder (10g/day) for 4 weeks. After a washout period of 4 weeks, they will then receive the placebo (beetroot powder, no nitrate) for 4 weeks.
89543241|NCT02593305|Experimental|Placebo, then beetroot crystals (nitrate)|Participants will receive a beetroot powder placebo (no nitrate) for 4 weeks. After a 4 week washout period, they will receive the nitrate rich beetroot powder for 4 weeks.
89543242|NCT02593305|No Intervention|Young Comparison|Young control group, used for age-related comparisons. This group did not go through any intervention.
89543243|NCT03118973|Experimental|Goff|For patients in whom biliary cannulation is difficult to achieve, Goff trans-pancreatic septotomy will be performed to facilitate biliary cannulation.
89543244|NCT03118973|Experimental|Double wire|For patients in whom biliary cannulation is difficult to achieve, double wire technique will be used to facilitate biliary cannulation.
89543245|NCT02593149|Experimental|Treatment|ClearGuard HD End Cap
89543246|NCT02593149|No Intervention|Control|Tego® connector with the CurosTM for Tego disinfecting port protector
89543247|NCT02448173|Experimental|OncoVAX and Surgery|Autologous Specific Immunotherapy given intradermally following surgical resection of Stage II colon cancer
89543248|NCT02448173|Active Comparator|Surgery|Surgical resection of Stage II colon cancer
88961011|NCT03398148|Experimental|Substudy 1, Induction 2: Double-blind Risankizumab Dose 1(a)|Participants who received placebo with inadequate response in Induction 1 receive risankizumab dose 1 administered by intravenous (IV) infusion in Induction 2.
88961012|NCT03398148|Experimental|Substudy 1, Induction 2: Double-blind Risankizumab Dose 1(b)|Participants who received risankizumab with inadequate response in Induction 1 randomized to receive risankizumab dose 1 administered by intravenous (IV) infusion in Induction 2.
89543249|NCT04389411|Experimental|Montelukast|10mg Oral Montelukast once daily for 60 days
89543250|NCT04389411|Placebo Comparator|Placebo|Placebo.
89207436|NCT00966069|Experimental|Parent collection|Home collection of respiratory swab (anterior nose) and mailed return when study subject has an acute respiratory illness.
89207437|NCT00850902|Active Comparator|Moderate Humidity (MH)|
89207438|NCT00850902|Experimental|High Humidity|
89207439|NCT04041882|Experimental|68Ga-DOTATATE PET/CT|Inject 68Ga-DOTATATE and then perform PET/CT scan
89543251|NCT03231527||Total Arterial coronary CABG|Total Arterial revascularization
89543252|NCT03231527||Saphenous vein based CABG|Saphenous vein based revascularization
89543253|NCT02448251|Experimental|single dose per day (QD)|Phase I Arm 1: AC0010MA orally taking once daily, starting from 100 mg per day.
89543254|NCT02448251|Experimental|two doses per day (BID)|Phase I Arm 2: AC0010MA orally taking twice daily, starting from 200 mg per day (100 mg BID). Arm 2 will be initiated once the drug plasma t1/2 is 10 hours or below in the first dose cohort (100 mg QD).
89543255|NCT04792593|Experimental|Senl-h19 CAR-T|Patients will be treated with Senl-h19 CAR-T cells
89543256|NCT03195569||Experimental group|QL1101 + paclitaxel/carboplatin:subjects are given 15 mg/kg QL1101 on Day 1 of each cycle with every 3 weeks as a cycle, respectively combined with paclitaxel/carboplatin for 6 cycles.
89543257|NCT03195569||Control group|Avastin® + paclitaxel/carboplatin:subjects are given 15 mg/kg Avastin® on Day 1 of each cycle with every 3 weeks as a cycle, respectively combined with paclitaxel/carboplatin for 6 cycles.
89543258|NCT04792671||Perinatal group|females who are pregnancy
89543259|NCT04792671||postpartum group|female who get delivery(from day 1 up to 1 year)
89543260|NCT04785495||Cancer Patients Exposed to Highly Emetogenic Chemotherapy|Patients who will start chemotherapy with a high-grade emetogenic scheme and who have received adequate antiemetic prophylaxis.
89543261|NCT02448017|Active Comparator|The Herbst appliance|Orthodontic functional appliance
89543262|NCT02448017|Active Comparator|Twin block appliance|Orthodontic functional appliance
89543263|NCT04792827||analgosedation group|analgosedation concept
89543264|NCT04792827||historical group|standard historical concept
89543265|NCT02447939|Experimental|Dabrafenib and Trametinib|Subject will be assigned in 2 cohorts, in cohort A, subjects will be administered dabrafenib (150 mg BID) monotherapy from Day1 to Day 21 (first part), followed by dabrafenib (150 mg BID) and trametinib (2mg QD) combination (second part, starting from day 22). After the last subject in cohort A has finished the last pharmacokinetic sampling(1st part ), another 10 subjects will be enrolled in cohort B with administration of dabrafenib (150 mg BID) in combination with oral trametinib (2mg QD).
89543266|NCT04785183|Experimental|Melatonin Group|
89543267|NCT04785183|Placebo Comparator|Control Group|
89543268|NCT03195725||Year 2013|Participant's notes will be reviewed from the year 2013
89543269|NCT03195725||Year 2015|Participant's notes will be reviewed from the year 2015
89543270|NCT04297917|Experimental|Healthy Volunteers with low dose vaccination|5 Healthy Volunteers receiving low dose vaccination
89543271|NCT04297917|Experimental|Healthy Volunteers with high dose vaccination|5 Healthy Volunteers receiving high dose vaccination
89543272|NCT04297917|Experimental|Chronic Hepatitis B participants with low dose vaccination|6 participants with Chronic Hepatitis B infection receiving low dose vaccination
89543273|NCT04297917|Experimental|Chronic Hepatitis B participants with high dose vaccination|6 participants with Chronic Hepatitis B infection receiving high dose vaccination
89543274|NCT04297917|Experimental|Healthy Volunteers who have had COVID-19 AZD1222 vaccine|15 participants who have had 2 doses of COVID-19 AZD1222 vaccine
89543275|NCT04297917|Experimental|Healthy Volunteers who have had Pfizer/Moderna mRNA COVID 19 vaccine|15 participants who have had Pfizer/Moderna mRNA COVID 19 vaccine
88961013|NCT03398148|Experimental|Substudy 1, Induction 2: Double-blind Risankizumab Dose 2|Participants who received risankizumab with inadequate response in Induction 1 randomized to receive risankizumab dose 2 administered by subcutaneous (SC) injection in Induction 2.
88961014|NCT03398148|Experimental|Substudy 1, Induction 2: Double-blind Risankizumab Dose 3|Participants who received risankizumab with inadequate response in Induction 1 randomized to receive risankizumab dose 3 administered by subcutaneous (SC) injection in Induction 2.
88961015|NCT03398148|Experimental|Substudy 2, Induction 1: Double-blind Risankizumab Dose 1|Participants randomized to receive risankizumab dose 1 administered by intravenous (IV) infusion.
89543276|NCT03195803|Experimental|MCI with WMH|Computerized Cognitive Stimulation was administered to this group, twice a week.
89543277|NCT03195803|Active Comparator|MCI without WMH|Computerized Cognitive Stimulation was administered to this group, twice a week.
89543278|NCT03195491|Experimental|Monotherapy|Nivolumab administered every two weeks
89543279|NCT03195413|Experimental|Nerve Block Arm|This group of patients will receive an ultrasound-guided forearm block intervention by the study team. The nerve block will be achieved with a solution of 1% lidocaine without epinephrine and 0.5% bupivacaine without epinephrine (mixed in a 1:1 volume ratio) dosed once. A second dose will be given only in the case of complete block failure.
89543280|NCT03195413|No Intervention|Control Arm|This group will receive the standard of care in our emergency department, as determined by their primary team. If a patient here receives a nerve block from the primary team, they will be handled with intention-to-treat analysis.
89543281|NCT03195335||Children with cerebral palsy|Children who diagnosed as cerebral palsy by a pediatric neurologist
89543282|NCT02447861||3q29 deletion|Individuals with 3q29 deletion
89543283|NCT02447861||3q29 duplication|Individuals with 3q29 duplication
89543284|NCT02447861||Unaffected siblings|Unaffected siblings of 3q29 deletion or duplication individuals
89543285|NCT02447861||Healthy Controls|Unrelated age-matched controls without 3q29 deletion or duplication
89543286|NCT04792983||Older (≥ 65 years of age)|Older surgical patients presenting for elective spine surgery.
89543287|NCT02447783|Placebo Comparator|Control, Flavanol-free intervention|Intake of flavanol-free, macro- and micro-nutrient matched control capsules
89543288|NCT02447783|Active Comparator|CF intervention|Intake of capsules containing Mars Cocoa Extract Capsules manufactured by the Cocoapro® process and providing 500 mg of cocoa flavanols per capsule
89543289|NCT02447705|No Intervention|Lamivudine group|continue Lamivudine
89543290|NCT02447705|Experimental|Telbivudine group|Telbivudine replaces Lamivudine
89543291|NCT02447627||Part A|Cohort 1- Participants with severe SCD (4-10 VOC/year) Cohort 2- Participants with milder SCD (<4-10 VOC/year) Cohort 3- Healthy volunteers Part A and B can occur in parallel
89543292|NCT02447627||Part B|Adults with SCD receiving chronic red blood cell exchange transfusion Part A and B can occur in parallel
89543293|NCT04792125|Experimental|External electrical stimulation (EES) added to pelvic floor muscle training (PFMT) group|This arm is going to include the patients who are performed external electrical stimulation (EES) added to pelvic floor muscle training (PFMT).
89543294|NCT04792125|Other|External electrical stimulation (EES) group|This arm is going to include the patients who are performed external electrical stimulation (EES).
89543295|NCT04792125|Active Comparator|Pelvic floor muscle training (PFMT) group|This arm is going to include the patients who are performed pelvic floor muscle training (PFMT).
89543296|NCT03195257|Placebo Comparator|Hypoglycemia-saline|
89543297|NCT03195257|Experimental|Hypoglycemia-GIP|
89543298|NCT03195257|Active Comparator|Hypoglycemia-GLP-1|
89543299|NCT03195257|Experimental|Hyperglycemia-GIP|
89543300|NCT03195257|Placebo Comparator|Hyperglycemia-Saline|
89543301|NCT03195101|Experimental|patients with orbital tumors|patients with orbital tumors will be managed by excisional or incisional biopsy via the transconjunctival orbitotomy approach
89543302|NCT02447393|Other|levocetirizine|Study Drug
89543303|NCT02447393|Other|cetirizine|Study Drug
89543304|NCT02447393|Other|placebo|Study Drug
89543305|NCT04785105||patient with isolated SMA stenosis|patient with isolated SMA stenosis on initial scanner
89543306|NCT04785105||patient with both SMA stenosis and CA or/and IMA stenosis|patient with both SMA stenosis and CA or/and IMA stenosis on initial scanner
89543307|NCT02447549|Active Comparator|WBRT|Standard dose whole bladder radiotherapy
89543308|NCT02447549|Experimental|SART|Standard dose Adaptive tumour focused radiotherapy (SART)
89543309|NCT02447549|Experimental|DART|Dose escalated Adaptive tumour boost radiotherapy (DART)
88961016|NCT03398148|Placebo Comparator|Substudy 2, Induction 1: Double-blind Placebo|Participants randomized to receive placebo for risankizumab administered by intravenous (IV) infusion.
88961017|NCT03398148|Experimental|Substudy 2, Induction 2: Double-blind Risankizumab Dose 1(a)|Participants who received placebo with inadequate response in Induction 1 randomized to receive risankizumab dose 1 administered by intravenous (IV) infusion in Induction 2.
88961018|NCT03398148|Experimental|Substudy 2, Induction 2: Double-blind Risankizumab Dose 1(b)|Participants who received risankizumab with inadequate response in Induction 1 randomized to receive risankizumab dose 1 administered by intravenous (IV) infusion in Induction 2.
88961019|NCT03398148|Experimental|Substudy 2, Induction 2: Double-blind Risankizumab Dose 2|Participants who received risankizumab with inadequate response in Induction 1 randomized to receive risankizumab dose 2 administered by subcutaneous (SC) injection in Induction 2.
89207440|NCT00969813|Experimental|Normal hepatic function|
89543310|NCT04792359|Experimental|Equinometer|Measurement with Equinometer
89543311|NCT04792437||glioma patients|glioma patients with routine surgery
89543312|NCT02447471||study group|all participants
89543313|NCT02447315|Experimental|Treatment Sequence ABCDD|Subjects receive a single dose out of 4 oral doses of study drug (pilocarpine or matching placebo) per day for 5 subsequent days in the sequence ABCDD. Treatment A: pilocarpine low dose, Treatment B: pilocarpine medium dose, Treatment C: pilocarpine high dose, Treatment D: Placebo
89543314|NCT02447315|Experimental|Treatment Sequence BDACC|Subjects receive a single dose out of 4 oral doses of study drug (pilocarpine or matching placebo) per day for 5 subsequent days in the sequence BDACC. Treatment A: pilocarpine low dose, Treatment B: pilocarpine medium dose, Treatment C: pilocarpine high dose, Treatment D: Placebo
89543315|NCT02447315|Experimental|Treatment Sequence CADBB|Subjects receive a single dose out of 4 oral doses of study drug (pilocarpine or matching placebo) per day for 5 subsequent days in the sequence CADBB. Treatment A: pilocarpine low dose, Treatment B: pilocarpine medium dose, Treatment C: pilocarpine high dose, Treatment D: Placebo
89543316|NCT02447315|Experimental|Treatment Sequence DCBAA|Subjects receive a single dose out of 4 oral doses of study drug (pilocarpine or matching placebo) per day for 5 subsequent days in the sequence DCBAA. Treatment A: pilocarpine low dose, Treatment B: pilocarpine medium dose, Treatment C: pilocarpine high dose, Treatment D: Placebo
89543317|NCT04792515|Experimental|treatment group|Patients were treated with camrelizumab combined with SOX/ or apatinib
89543318|NCT04792047||Lesions with perivasular FAI greater than ≥-70.1|
89543319|NCT04792047||Lesions with perivasular FAI greater than <-70.1|
89543320|NCT02447237|Experimental|liquid food|dietary counselling in fulfilling need of protein and energy through liquid food
89543321|NCT02447237|Other|solid food|dietary counselling in fulfilling need of protein and energy through solid food
89543322|NCT04791657||Patients without complications|Patients with uneventful recovery
88961020|NCT03398148|Experimental|Substudy 2, Induction 2: Double-blind Risankizumab Dose 3|Participants who received risankizumab with inadequate response in Induction 1 randomized to receive risankizumab dose 3 administered by subcutaneous (SC) injection in Induction 2.
88961021|NCT03386604|Experimental|Whey protein + Rehabilitation|Pulmonary rehabilitation will last 8 weeks covering 3 weekly sessions of supervised exercise and a weekly educational session. Patients will receive whey protein and will be instructed to take it daily for breakfast, diluted in milk or water (if they do not drink milk).
88961022|NCT03386604|Placebo Comparator|Placebo + Rehabilitation|Pulmonary rehabilitation will last 8 weeks covering 3 weekly sessions of supervised exercise and a weekly educational session. Patients will receive placebo (maltodextrin) and will be instructed to take it daily for breakfast, diluted in milk or water (if they do not drink milk).
88961023|NCT03386604|No Intervention|Control|Patients without pulmonary rehabilitation nor whey protein supplementation.
89543323|NCT04791657||Patients with complications|Patients experiencing complications within 30 days postoperatively
89543324|NCT03118193|Experimental|Depressive patient|olfactive tests ; blood test ; optional: Tissue Pulsatility imaging ; optional: Collection of faeces
89543325|NCT04784793|No Intervention|Phase1: Design and development|"We conducted focus group meetings to discuss the content, features and design of the app.~The focus group consisted of physiotherapists and young adults. The focus group members discussed the variety of topics in subgroups (login parameters, self-monitoring, exercises content, video or animation types, exercise diary, reminders, encouragement, method, etc)."
89543326|NCT04784793|No Intervention|Phase 2: Testing the app|We tested the prototype version app interface in the 2nd phase. All participants downloaded the prototype app and used the app for one week.
89543327|NCT04784793|No Intervention|Phase 3: Usability evaluation|"We conduct a think-aloud interview and evaluate the quantitative usability in the third phase.~The quantitative usability was assessed by the System Usability Scale (SUS), and the adapted Usability, Satisfaction and Ease to Use (USE) Questionnaire."
89543328|NCT04784793|Active Comparator|Phase 4: Pilot randomized controlled trial/ The app-based group|"The app-based group:~Participants in the intervention group received their smartphone-based- home exercise program."
89543329|NCT04784793|Experimental|Phase 4: Pilot randomized controlled trial/ The control group|"The control group:~Participants in the control group received their home exercise programs as a paper handout."
88961024|NCT03375164|Experimental|Cohort A: Delandistrogene Moxeparvovec|Participants will receive a Single IV infusion of delandistrogene moxeparvovec on Day 1.
89543330|NCT02447159|Experimental|Intervention|Each participant in the intervention arm will receive conditional cash transfers when she: (1) registers pregnancy, (2)picks up her medication in the first two months after her first visit, (3) delivers at the health clinic, and (4) receives early infant diagnosis test for newborn. Eight to ten weeks after delivery, the participant will also be asked to participate in an endline survey and will be compensated for her time.
89543331|NCT02447159|No Intervention|Control|Antenatal care utilization data will be extracted from the administrative records. Eight to ten weeks after delivery, the participant will also be asked to participate in an endline survey and will be compensated for her time.
89543332|NCT04784949|Experimental|Portland cement|pulpotomy with PRF and white Portland cement
89543333|NCT04784949|Experimental|Mineral trioxide aggregate|pulpotomy with PRF and Mineral trioxide aggregate
89543334|NCT04784949|Experimental|Biodentine|pulpotomy with PRF and Biodentine
89543335|NCT02446535|Experimental|BIA DW assessment|All patients have undergone a Clinical DW assessment. Then, they undergo HD sessions in which BIA DW is determined reducing body weight (kg): when flattening of the BIA resistance occurs, the BIA DW is achieved and compared with the Clinical DW
89543336|NCT02446379||EnLightTM and LightPathTM Imaging Systems arm|"Patients will first be injected intravenously with 2-5 MBq/kg, up to a maximum 300 MBq of the marketed product 18F-fluorodeoxyglucose (FDG) and after this undergo tumour excision surgery according to standard of care.~The surgical cavity will be imaged by the EnLightTM system and the tumour excision specimen will be imaged by both the EnLightTM and LightPathTM Imaging Systems. The EnLightTM and LightPathTM Imaging Systems results will not influence any surgical or clinical decision-making. The tumour excision specimen will be analysed according to standard of care pathology. Patients will be followed-up (Visit 3) 2-14 days after the end of surgery for adverse events (AEs)."
88961025|NCT03375164|Experimental|Cohort B: Delandistrogene Moxeparvovec|Participants will receive a Single IV infusion of delandistrogene moxeparvovec on Day 1.
88961026|NCT03318406||BTVA treated patients|Patients with heterogeneous upper lobe emphysema undergoing Bronchoscopic Thermal Vapor Ablation treatment
89543337|NCT03194945|Active Comparator|Linagliptin plus metformin|CSII followed by Linagliptin 5 mg Qd + Metformin 0.5 g bid for 48 weeks
89543338|NCT03194945|Active Comparator|Linagliptin|CSII followed by Linagliptin 5mg Qd for 48 weeks
89543339|NCT03194945|Active Comparator|Metformin|CSII followed by Metformin 0.5 bid for 48 weeks
88961027|NCT03285152|Experimental|Ketogenic Diet (KD)|The KD cohort will receive a rotating 7 day meal plan prepared by the Clinical Translational Science Center (CTSC) at Weill Cornell Medical Center (WCMC) with weekly food pick-up. The meal plan will provide a 3:1 fat to net carbohydrate ratio and calories for weight maintenance (30kcals /kg for a BMI< 30kg/ m2 and 25 kcal/kg for a BMI.30 kg/ m2.
88961028|NCT03285152|Active Comparator|Standard Diet (SD)|Patients randomized to the SD group will consume their normal diet plan. They will meet with the dietitian from the CTSC at WCMC weekly and receive standard nutritional counseling from the CTSC. Average intake will be documented through analyzing a 3 day intake pre and post the 4 week period.
88961029|NCT03284502|Experimental|Stage 1|Dose-escalation
88961030|NCT03284502|Experimental|Stage 1b|Dose-escalation
88961031|NCT03284502|Experimental|Stage 2 (Cohort I and II)|Dose-expansion
88961032|NCT03284502|Experimental|Stage 2 (Cohort III)|Dose-expansion
88961033|NCT03284333|Experimental|other|no arm
88961034|NCT03281499|Experimental|da Vinci Surgical System Model IS4000|Transoral robotic surgery, followed by tailored radiotherapy
88961035|NCT03277482|Experimental|Phase I Safety Lead-In|"A modified 3+3 design will be used in this trial Lead-in phase with Durvalumab* and radiation therapy~*q4 weeks durvalumab for 13 cycles or until progression"
89543340|NCT03194945|Active Comparator|Lifestyle alone|No OHA is given after CSII
88961036|NCT03277482|Experimental|Phase I Radiation Dose Evaluation|"Durvalumab~Tremelimumab* -- Start radiation dose from safety lead-in (level 0 or level -1) *q4 weeks durvalumab / tremelimumab for 4 cycles and continue durvalumab for 13 cycles or until disease progression"
89543341|NCT04791501||Hypoxemic Respiratory Failure|Consecutive intubated patients receiving invasive mechanical ventilation with a PaO2/FiO2 ≤300 mmHg under a PEEP of 5 cmH2O or more and FiO2 of 0.3 or more.
89543342|NCT03195023|Active Comparator|RAS Blockers|Patients in this arm will receive Lisinopril 20mg/day
89543343|NCT03195023|Active Comparator|Non RAS Blockers|Patients in this arm will receive Amlodipine 10mg/day or Lercanidipine 20mg/day +/- diuretics
89543344|NCT03194711||Patients with stable CAD|
89543345|NCT02446301|Experimental|Period I (reference drug)|Before administration of investigational products, subjects should be fasted for 10 hours. On the dosing day, subjects will be confined after administration and won't be discharged until after completion of sample collections for 24 hours following dosing in Period I (Bain® IM injection).
89543346|NCT02446301|Experimental|Period II (Test drug)|Subjects will be back to the clinical site to join Period II (SDE IM injection) and will be discharged after completion for sample collections for 24 hours post drug administration.
88961037|NCT03277469|Experimental|MRI Guided BRACHYTHERAPY with Tracker|"Standard pelvic MRI sequences will be obtained~MRI Tracker is used during catheter positioning with serial MR imaging during implant~All patients will undergo 3D-based image acquisition for brachytherapy treatment planning per standard clinical practice~The brachytherapy modality to be used is high-dose-rate brachytherapy using an iridum-192 stepping source"
88961038|NCT03277469|Experimental|MRI Guided BRACHYTHERAPY without Tracker|"Standard pelvic MRI sequences will be obtained~Standard process is used with serial MR imaging to evaluate catheter position during implant~All patients will undergo 3D-based image acquisition for brachytherapy treatment planning per standard clinical practice~The brachytherapy modality to be used is high-dose-rate brachytherapy using an iridum-192 stepping source"
88961039|NCT03267186|Experimental|Prevention (ibrutinib)|Beginning 60-90 days after allogeneic HCT, patients receive ibrutinib PO QD for up to 18 months post-transplant in the absence of disease progression or unacceptable toxicity.
88961040|NCT03249142|Experimental|ARM A Durvalumab/chemotherapy association|
89207441|NCT00969813|Experimental|Mild hepatic impairment|
89207442|NCT00969813|Experimental|Moderate hepatic impairment|
89207443|NCT00854256|Experimental|Canaloplasty|
88961041|NCT03249142|Experimental|ARM B Durvalumab/Tremelimumab/chemotherapy association|
89207444|NCT00854256|Active Comparator|Trabeculectomy with mitomycin C|
89207445|NCT00966147|Experimental|Lidco group|All patients monitored by the lidco system and treated to optimize oxygen delivery
89207446|NCT04042662||Meropenem Failure ( Treatment failure)|
89514668|NCT02441036|Active Comparator|Group 3 - 3 days prior|Subjects will receive Ultherapy treatment 3 days prior to tissue resection.
89514669|NCT02441036|Active Comparator|Group 4 - 7 days prior|Subjects will receive Ultherapy treatment 7 days prior to tissue resection.
89514670|NCT02441036|Active Comparator|Group 5 - 45 days prior|Subjects will receive Ultherapy treatment 45 days prior to tissue resection.
89514671|NCT02498444|Experimental|Treprostinil|The subcutaneous continuous treprostinil infusion will start at a dose of 2 ng/kg/min. The dose will be increased over the first 24 hours to goal 10 ng/kg/min through day five. On postoperative day six, the dose will be decreased by 2 ng/kg/min every 8 hours with plans for discontinuation on postoperative day seven.
89514672|NCT02498444|Placebo Comparator|Saline|Saline administration via subcutaneous infusion
89514673|NCT04792372|Other|Periodontitis patients|Single-group receiving periodontal treatment. The data will be evaluated according to the healing potential of individuals in the group and also site-specifically.
89514674|NCT05235256|Active Comparator|SPGB Group|patients will receive bilateral sphenopalatine ganglion block using 3ml mixture of 2ml 2% lidocaine plus 1ml dexamethasone 4mg (on each nostril).
89514675|NCT05235256|Active Comparator|GONB Group|patients will receive bilateral greater occipital nerve block using a mixture of 3ml of 2ml 2% lidocaine plus 1ml dexamethasone 4mg (on each side of the occipital region).
89514676|NCT04792216|Experimental|Wild Salmon|Wild salmon fillets in a raw form
89514677|NCT04792216|Experimental|Farmed Salmon|Farmed salmon fillets in a raw form
89514678|NCT02497976|Active Comparator|Group 1: Experimental|Biological: Certolizumab pegol (Cimzia) 400 mg loading dose given subcutaneously at week 0, 2, and 4 followed by a maintenance dose at week 8
89514679|NCT02497976|Placebo Comparator|Group 2: Placebo Comparator|Placebo: given subcutaneously at week 0, 2, 4, and week 8
88961042|NCT03192254|Active Comparator|Self-Monitoring Control|Daily tracking of fruit and vegetable consumption
89207447|NCT04042662||Meropenem Success ( Treatment Success)|
89207448|NCT00969891||AML patients in induction treatment|
89207449|NCT00966225|Experimental|One gram LIP-01 per day|One gram LIP-01 per day for 12 weeks
89207450|NCT00966225|Experimental|Two grams LIP-01 per day|Two grams LIP-01 per day for 12 weeks
89207451|NCT00966225|Experimental|0.333 grams LIP-01 per day|0.333 grams LIP-01 per day for 12 weeks
89207452|NCT00854334||1.|Children with both obesity and obstructive sleep apnea
89207453|NCT00854334||2|Children without the presence of both obesity and obstructive sleep apnea
89207454|NCT00966303|Experimental|Cardiac Rehabilitation|9 patients with cardiomyopathy in functional class III or IV, submitted to an 8-week program with exercises and respiratory muscle training.
89207455|NCT00619866|Placebo Comparator|Placebo|Participants received placebo tablets once a day for 12 weeks. At the end of 12 weeks participants were re-randomized to receive one of the two doses of elagolix (150 mg or 250 mg) QD for 12 weeks.
89207456|NCT00619866|Experimental|Elagolix 150 mg|Participants received elagolix 150 mg tablets once a day for 12 weeks. At the end of 12 weeks participants continued to receive elagolix 150 mg QD for an additional 12 weeks.
89207457|NCT00619866|Experimental|Elagolix 250 mg|Participants received elagolix 250 mg tablets once a day for 12 weeks. At the end of 12 weeks participants continued to receive elagolix 250 mg for an additional 12 weeks.
89514680|NCT05651386|Other|Six food elimination diet|The six food elimination diet will be performed in all subjects.
89514681|NCT03347188|Experimental|Fremanezumab|Participants will receive fremanezumab 675 milligrams (mg) administered as 3 subcutaneous (SC) injections (225 mg/1.5 milliliters [mL] each) at randomization (Week 0), Weeks 4, and 8 during the DB treatment period. Participants who complete the DB treatment period and continue into the OL treatment period will receive fremanezumab 675 mg administered as 3 SC injections (225 mg/1.5 mL each) at Weeks 12, 16, and 20 during the OL treatment period.
89514682|NCT03347188|Placebo Comparator|Placebo|Participants will receive placebo matching to fremanezumab administered as 3 SC injections (1.5 mL each) at randomization (Week 0), Weeks 4, and 8 during the DB treatment period. Participants who complete the DB treatment period and continue into the OL treatment period will receive fremanezumab 675 mg administered as 3 SC injections (225 mg/1.5 mL each) at Weeks 12, 16, and 20 during the OL treatment period.
89514683|NCT03347032|Experimental|Intervention|This group will undergo remote ischemic preconditioning with serial inflations of the blood pressure cuff to 200 mmHg followed by deflation for reperfusion for a period of 5 minutes each for a total of 4 cycles.
89514684|NCT03347032|Sham Comparator|Control|This group will undergo serial inflations of the blood pressure cuff to 40 mmHg followed by deflation for a period of 5 minutes each for a total of 4 cycles.
89514685|NCT04596826|Experimental|healthy subjects|
89514686|NCT04596826|Experimental|glaucoma patients|
89514687|NCT04596826|Placebo Comparator|healthy volunteers|
89514688|NCT04596826|Placebo Comparator|Glaucoma patients|
89514689|NCT02440568|Experimental|Cohort 1: Omacetaxine at Dose level at 0.625mg/m^2|Patients will receive Omacetaxine at Dose level 0.625mg/m^2, Cytarabine and Idarubicin as part of the treatment plan. Study participants will follow in outpatient clinic at least every 2 months for a total of 6 months. A final study visit will occur 6 months (+/-1 week) after the last dose of Omacetaxine. This visit will end study participation unless there is ongoing toxicity that is at least possibly related to study treatment. In this case, the patient will be followed as medically appropriate until resolution or stabilization of the adverse event.
89519572|NCT04288193||Trinity Health LIFE New Jersey PACE|Participants enrolled in Trinity Health LIFE New Jersey PACE facility who received an antipsychotic medication for the treatment of BPSD or insomnia
89024841|NCT03270696|Experimental|simultaneous administration of propofol and rocuronium|"In this group, the investigator will administrate propofol (2ml/kg) and rocuronium (0.6mg/kg) simultaneously, and start facemask ventilation after patient loss consciousness to induce general anesthesia.~The investigator will measure the mean tidal volume (TV) applied during facemask ventilation for 1 minute."
89543347|NCT04791345|Experimental|Methylprednisone single-dose|Subjects receive a single dose treatment. Urine samples will be collected until 5 days after administration in 10 fractions: 0-4h, 4-8h, 8-12h, 12-24h, 24-36h, 36-48h, 48-72h, 72-96h, 96-120h post-administration. Blood samples will be collected until 6 days after administration in 5 fractions: pre-administration and 24h, 48h, 72h and 120h post-administration.
89543348|NCT04791345|Experimental|Methylprednisone multiple-dose|Subjects receive a multiple dose treatment. Urine samples will be collected until 7 days after administration in 20 fractions.
89543349|NCT04791345|Experimental|Deflazacort single-dose|Subjects receive a single-dose treatment. Urine samples will be collected until 5 days after administration in 10 fractions: 0-4h, 4-8h, 8-12h, 12-24h, 24-36h, 36-48h, 48-72h, 72-96h, 96-120h post-administration. Blood samples will be collected until 6 days after administration in 5 fractions: pre-administration and 24h, 48h, 72h and 120h post-administration.
89024842|NCT03270696|Experimental|ordinal administration of propofol and rocuronium|"In this group, the investigator will administrate propofol (2ml/kg) first, and follow injection of rocuronium (0.6mg/kg) after patient loss consciousness and confirming facemask ventilation.~The investigator will measure the mean tidal volume (TV) applied during facemask ventilation for 1 minute."
89024843|NCT03278600|Experimental|site-specific therapy|standard treatments of sites of origin
89543350|NCT04791345|Experimental|Dexamethasone single-dose|"Subjects receive a single-dose treatment. Urine samples will be collected until 13 days after administration in 11 fractions: 0-4h, 4-8h, 8-12h, 12-24h, 24-36h, 36-48h, 48-72h, 72-96h, 96-120h, 120-144h post-administration.~Blood samples will be collected until 9 days after administration in 6 fractions: pre-administration and 24h, 48h, 72h, 120h and 192h post-administration."
89543351|NCT04791345|Experimental|Dexamethasone multiple-dose|Subjects receive a multiple dose treatment. Urine samples will be collected until 10 days after administration in 34 fractions. Blood samples will be collected until 13 days after the first administration.
89543352|NCT02445989|Active Comparator|Cyclic NuvaRing CVR Use|CVR use for 3 weeks, remove for 1 week, then replace
89543353|NCT02445989|Experimental|Continuous NuvaRing CVR Use|CVR use for 4 weeks, then replace
89543354|NCT04483895|Active Comparator|The OHL method|the ETT insertion depth was estimated according to the OHL method.
89543355|NCT04483895|Active Comparator|The 7-8-9 method|the ETT insertion depth was estimated according to the 7-8-9 method.
89543356|NCT03711435||Training set|The training set is composed of 30 IPF patients and 15 controls. The group is designed to identify differential metabolites between IPF and control groups.
89543357|NCT03711435||Validation set|The validation set is composed of 15 IPF patients and 15 controls. The group is designed to validate differential metabolites identified in the previous groups.
89543358|NCT03231137|Experimental|PRGF/ATV|Included 10 patients undergoing single tooth extraction and platelet rich in growth factors fibrin scaffold loaded with Atorvastatin powder (PRGF/ATV) were placed to fill the extraction socket.
89543359|NCT03231137|Experimental|ATV gel|Included 10 patients undergoing single tooth extraction and Atorvastatin gel were placed to fill the extraction socket.
89543360|NCT03231137|Experimental|PRF|Included 10 patients undergoing single tooth extraction and platelet rich fibrin (PRF) were placed to fill the extraction socket.
89543361|NCT03231137|Experimental|PRGF|Included 10 patients undergoing single tooth extraction and plasma rich in growth factors (PRGF) were placed to fill the extraction socket.
89543362|NCT03231137|No Intervention|Control|Spontaneously healed socket
89024844|NCT03278600|Active Comparator|standard empiric chemotherapy|standard empiric chemotherapy
89024845|NCT03270579|Experimental|Part A: [18F]JNJ-64511070|Participants will receive an intravenous (IV) bolus injection of [18F]JNJ-64511070 at a dose of 185 megaBecquerel (MBq) on Day 1 of Part A to investigate the total body biodistribution and measure the radiation dosimetry of [18F]JNJ-64511070.
89207458|NCT00851058|Experimental|Counseling|Four session of group counseling and six hours of guided observation of the emergency and trauma services at a busy urban hospital
89543363|NCT03674853|Experimental|Wuling Capsule group|Patients who were treated with Wuling Caspule
89543364|NCT03674853|Active Comparator|Oryzanol group|Patients who were treated with oryzanol
89543365|NCT02446067|No Intervention|Healthy control|No Repetitive Transcranial Magnetic Stimulation (rTMS)
89543366|NCT02446067|Active Comparator|Active rTMS group|Active Repetitive Transcranial Magnetic Stimulation (rTMS)
89543367|NCT02446067|Sham Comparator|Sham rTMS group|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)
89543368|NCT03231215|Placebo Comparator|controlled group|Group І (control group): the patients received 15 ml epidural plain bupivacaine (0.5%) +2 ml normal saline Group (BS).
89543369|NCT03231215|Active Comparator|dexamethasone group|Group II (dexamethasone group):- the patients received 15 ml epidural plain bupivacaine (0.5%) + 8mg dexamethasone (2ml) Group (BD)
89543370|NCT04784481|Experimental|Experimental Group|"The EG received Ivermectin orally 4 tablets of 6 mg = 24 mg every 7 days for 4 weeks.~All participants were evaluated by physical examination COVID-19 diagnosed with positive RT-PCR at the beginning, and final of the protocol"
89543371|NCT04784481|No Intervention|Control Group|Conventional treatment. All participants were evaluated by physical examination COVID-19 diagnosed with positive RT-PCR at the beginning, and final of the protocol
89543372|NCT04790877|Active Comparator|First sub-study: Glucose beverage|This intervention entails the intake of a beverage including 25 g of glucose.
89543373|NCT04790877|Experimental|First sub-study: Regular alcohol-free beer|This intervention entails the intake of regular alcohol-free beer including 25 of carbohydrates.
89543374|NCT04790877|Experimental|First sub-study: Alcohol-free beer with modified composition (isomaltulose + maltodextrin)|This intervention entails the intake of an alcohol-free beer with modified composition in which the maltose has been almost completely eliminated and enriched with isomaltulose (2.5 g/100 mL) and a resistant maltodextrin (0.8 g/100 mL) (IMB). This beverage included 25 g of carbohydrates.
89543375|NCT04790877|Experimental|First sub-study: Alcohol-free beer with modified composition (++ maltodextrin)|This intervention entails the intake of an alcohol-free beer with modified composition in which the maltose has been almost completely eliminated and enriched with a resistant maltodextrin (2.0 g/100 mL) (MB). This beverage included 25 g of carbohydrates.
89543376|NCT04790877|Active Comparator|Second sub-study: White bread + Water|This intervention entails the intake of white bread (providing 50 g of carbohydrates) and water.
89543377|NCT04790877|Experimental|Second sub-study: White bread + Regular alcohol-free beer|This intervention entails the intake of white bread (providing 50 g of carbohydrates) and regular alcohol-free beer (providing 14.3 g of carbohydrates).
89543378|NCT04790877|Experimental|Second sub-study: White bread+Alcohol-free beer enriched with isomaltulose+maltodextrin)|This intervention entails the intake of white bread (providing 50 g of carbohydrates) and an alcohol-free beer with modified composition in which the maltose has been almost completely eliminated and enriched with isomaltulose (2.5 g/100 mL) and a resistant maltodextrin (0.8 g/100 mL) (IMB). This beverage included 14.3 g of carbohydrates.
89543379|NCT04790877|Experimental|Second sub-study: White bread + Alcohol-free beer enriched with ++ maltodextrin|This intervention entails the intake of white bread (providing 50 g of carbohydrates) and an alcohol-free beer with modified composition in which the maltose has been almost completely eliminated and enriched a resistant maltodextrin (2.0 g/100 mL) (MB). This beverage included 14.3 g of carbohydrates.
89543380|NCT04790877|Active Comparator|Second sub-study: Extra-White bread + Water|This intervention entails the intake of white bread which provides 64.3 g (50 g + 14.3 g) of carbohydrates and water. This intervention would be the comparator in carbohydrates-equally conditions.
89543381|NCT03231059||Experimental treatment strategy|All patients in the treatment group received acetylsalicylic acid (ASA) and ticagrelor for 1 month followed by 23 months of ticagrelor monotherapy
89543382|NCT03231059||Reference treatment strategy|"Acute Coronary Syndrome (ACS) patients incl. unstable angina (UA) patients: ASA and ticagrelor for 12 months followed by 12 months of ASA monotherapy.~Stable Coronary Artery Disease (CAD) patients: ASA and clopidogrel for 12 months followed by 12 months of ASA monotherapy."
89543383|NCT02445833|Experimental|Lifestyle on-line intervention|"The self-applied on-line intervention will received acces to the web and the Vivir mejor modules."
89543384|NCT03230825|Experimental|Oral contraceptives|Oral contraceptive agent, given for free, for 3 weeks and a follow up visit a week after treatment withdrawal.
89543385|NCT03230825|Sham Comparator|Expectant management|Expectant management for 3 weeks and a follow up visit a week later.
89543386|NCT05473221|Experimental|CD33 CAR-T|"Dose Escalation:After enrollment ,Participants complete the PBMC apheresis,then complete the Lymphocyte clearance,and then receive the dose climning test: 3×10e6/kg，6 ×10e6/kg，9×10e6/kg.~Dose Expansion:Participants receive a single dose (at the MTD determined)."
89543387|NCT05234489|Active Comparator|Low Dosage Group|This group will receive the lower dose (75mg) of the investigational product.
89543388|NCT05234489|Active Comparator|High Dosage Group|This group will receive the higher dose (150mg) of the investigational product.
89543389|NCT02445677|Experimental|Active TENS|Receiving active transcutaneous electrical nerve stimulation (TENS) treatments during the rehabilitation sessions (only the first half of the rehabilitation period, i.e. 4 to 6 weeks.
89543390|NCT02445677|Placebo Comparator|Simulated TENS|Receiving simulated transcutaneous electrical nerve stimulation (TENS) treatments during the rehabilitation sessions (only the first half of the rehabilitation period, i.e. 4 to 6 weeks.
88961043|NCT03192254|Experimental|Daily Incentives|Incentives for fruit and vegetable consumption delivered daily
88961044|NCT03192254|Experimental|Delayed Lump Sum Incentives|Incentives for fruit and vegetable consumption delivered in a lump sum at the end of the intervention
88961045|NCT03168347|Active Comparator|Anecdotal Evidence|Scenario describes a medication's (biologic's) therapeutic effect results based on anecdotal evidence.
89543391|NCT03526185|Experimental|Cohort 1|"Subjects will receive a non-myeloablative lymphocyte depleting preparative regimen of cyclophosphamide (60 mg/kg/day IV) on days -7 and -6 and fludarabine (25 mg/m2/day) on days -5 through -1.~Prophylactic antibiotics will be administered as medically indicated until recovery of ANC to > 500 and recovery of ALC to > 400~On day 0 subjects will receive the infusion of autologous TIL and one hour later (but can be delayed up to 24 hours) will begin low-dose aldesleukin (IL-2) (72,000 IU/kg IV every 12 hours for up to 10 doses)."
88961046|NCT03168347|Active Comparator|Research Study Evidence|Scenario describes a medication's (biologic's) therapeutic effect results based on research study evidence.
88961047|NCT03168347|Active Comparator|Anecdotal + Research Study Evidence|Scenario describes a medication's (biologic's) therapeutic effect results based on research study evidence and anecdotal evidence.
88961048|NCT03168347|Placebo Comparator|No Evidence|Scenario describes a medication's (biologic's) therapeutic effect with no mention on anecdotal nor research study evidence.
88961049|NCT03149770|Experimental|1|Naloxone, then placebo
88961050|NCT03149770|Placebo Comparator|2|Placebo, then Naloxone
88961051|NCT03111875|Active Comparator|Routine thermal management|Patients assigned to routine thermal management will not be pre-warmed and ambient intraoperative temperature will be maintained near 20°C per routine. Only transfused blood will be warmed. An Multi-Position Upper Body Warming Blanket forced-air cover will be positioned over an appropriate non-operative site, but will not initially be activated. Should core temperature decrease to 35.5°C, the warmer will be activated as necessary to prevent core temperature from decreasing further.
89024846|NCT03270579|Experimental|Part B: [18F]JNJ-64511070|Participants will receive an IV bolus injection of [18F]JNJ-64511070 at a dose of 185 MBq on Day 1 of Part B to measure the uptake, binding, distribution, and washout of [18F]JNJ-64511070 and to model the tissue specific kinetics of [18F]JNJ-64511070 in the human brain with the appropriate arterial IF.
89543392|NCT03526185|Experimental|Cohort 2|"Subjects will receive a non-myeloablative lymphocyte depleting preparative regimen of cyclophosphamide (60 mg/kg/day IV) on days -7 and -6 and fludarabine (25 mg/m2/day) on days -5 through -1.~Prophylactic antibiotics will be administered as medically indicated until recovery of ANC to > 500 and recovery of ALC to > 400~On day 0 subjects will receive the infusion of autologous TIL and one hour later (but can be delayed up to 24 hours) will begin low-dose aldesleukin (IL-2) (72,000 IU/kg IV every 12 hours for up to 10 doses).~Within 1 week post discharge subjects will be treated with Nivolumab 1 mg/kg and Ipilimumab 3 mg/kg every 3 weeks for 4 doses. Following this, patients will receive Nivolumab 480 mg every 4 weeks. Adjuvant Nivolumab will continue until evidence of disease progression or inability to tolerate treatment."
89543393|NCT02445599|Experimental|Diclofenac group|"Diclofenac 100 mg tablet were administered orally and Midazolam 5 mg + Atropine 0.5 mg were administered intramuscularly as premedication, 60 minutes before surgical interventions.~Every patient recieved additional thoracic epidural analgesia during and after the surgery.~As rescue medication patients get nalbuphine 10-20mg, diclofenac 75 mg + orphenadrine 30 mg (NEODOLPASSE infusion), metamizole-sodium 2g, tramadol 50-100mg as needed postoperatively."
89543394|NCT02445599|Experimental|Control group|"Midazolam 5 mg + Atropine 0.5 mg were administered intramuscularly as premedication 60 minutes before surgical interventions.~Every patient recieved additional thoracic epidural analgesia during and after the surgery.~As rescue medication patients get nalbuphine 10-20mg, diclofenac 75 mg + orphenadrine 30 mg (NEODOLPASSE infusion), metamizole-sodium 2g, tramadol 50-100mg as needed postoperatively."
89543395|NCT03515733|Experimental|PF-04995274|PF-04995274, three x 5mg tablet (15mg total), once daily for 7-9 days
89543396|NCT03515733|Placebo Comparator|Placebo|3 placebo tablets, once daily for 7-9 days
89543397|NCT03194633||Nifedipine controlled-release tablets(Nifedipine GITS, ADALAT, BAYA1040)|Male and female patients with a diagnosis of CKD and hypertension (age, 18-70 years) was enrolled.
89543398|NCT03230903|Experimental|Home Telerehabilitation|The physical telerehabilitation group will receive an exercise plan, exercise equipment, a computer, and access to a daily individualized exercise plan. Participants in this group will follow the exercise plan that is sent to their computer via the telerehabilitation software. Participants will have interactions with a physical therapist and an exercise physiologist throughout training intervention.
89543399|NCT03230903|Sham Comparator|Usual Care|The usual care group will receive an individualized exercise program at baseline however participants will not receive the home telerehabilitation system or exercise equipment. Participants assigned to the usual care group will also not have access to the study physical therapist or exercise physiologist during the intervention.
89543400|NCT03194399|Experimental|Breast cancer patients|
89207459|NCT00851058|Active Comparator|Community Counseling|Four session of group counseling and six hours of volunteering in a local not for profit community agency.
89543401|NCT04791189||Patients with juvenile rheumatoid arthritis aged from 18 to 45 years|"Major male or female patient [18 to 45 years of age] with juvenile idiopathic arthritis reported before the age of 16.~- Able to understand and complete the questionnaire online (speaking and reading French, with an internet connection for completion via RedCap°). ¬~- Able to give informed consent to participate~- Involving one's parents in the survey is not a prerequisite for inclusion."
89543402|NCT04791189||Parents of patients with juvenile rheumatoid arthritis aged from 18 to 45 years|"Parents of adult patients with JIA~- Parents able to understand and complete the questionnaire online (speaking and reading French, having an internet connection for completion via Red Cap°).~- Able to give informed consent to participate~- The parents must have been in charge of the patient as a teenager."
89543403|NCT03194555|Experimental|Low-Dose Naltrexone and Acetaminophen Combination|
89543404|NCT03194555|Placebo Comparator|Placebo|
89543405|NCT03230669|No Intervention|Control|this arm receives treatment as usual and no intervention.
88961052|NCT03111875|Experimental|Aggressive thermal management|"Patients assigned to aggressive warming will be pre-warmed with a full-body Bair Hugger or Bair Paws cover for ≈30 minutes before induction of anesthesia. The warmer will initially be set to high which corresponds to ≈43°C. It will be subsequently adjusted to make patients feel warm, but not uncomfortably so. Patients will be aggressively warmed during surgery to a target intraoperative core temperature between 37 and 37.5°C, using an Multi-Position Upper Body and Full Access Underbody Warming Blankets forced-air covers when clinically practical. All intravenous fluids will be warmed to body temperature."
88961053|NCT03095235|Experimental|Treatment with riboflavin|Patients will take 400 mg dietary riboflavin per day and go outside without sunglasses for 15 minutes per day to evaluate the effects of riboflavin B2 and natural UV light from sun exposure on cornea cross linking and stabilization of ectatic disease.
88961054|NCT03012971|Experimental|Dexmedetomidine group|Dexmedetomidine supplemented morphine analgesia is provided for patients in this group in the form of patient-controlled intravenous analgesia. The formula contains a mixture of morphine (0.5 mg/ml) and dexmedetomidine (1.25 ug/ml), diluted with normal saline to a total volume of 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time from 6 to 8 minutes.
88961055|NCT03012971|Placebo Comparator|Control group|Morphine analgesia is provided for patients in this group in the form of patient-controlled intravenous analgesia. The formula contains morphine (0.5 mg/ml), diluted with normal saline to a total volume of 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time from 6 to 8 minutes.
88961056|NCT02988817|Experimental|Enapotamab vedotin (HuMax-AXL-ADC)|Participants in all cohorts of the trial (both in escalation and expansion phase) will be administered enapotamab vedotin (HuMax-AXL-ADC) intravenously (IV).
88961057|NCT02960659|Active Comparator|Metformin|Standard release metformin (500 mg tablets) was initiated and titrated to maximum dose of metformin 1000 mg twice daily over 3 weeks and continued for 12 weeks
88961058|NCT02960659|Experimental|Metformin and liraglutide|Standard release metformin (500 mg tablets) and liraglutide (0.6mg) were initiated and titrated to maximum dose of metformin 1000 mg twice daily, and liraglutide 1.8 mg daily over 3 weeks and continued for 12 weeks
88961059|NCT02957214|Experimental|Pain education|The patient education provides a basic set of information that includes the explanation of possible pathophysiological mechanisms involved in the development of chronic pain. The main objective is to reduce pain threatening and alarmist interpretation. The patient must understand that the pain is not necessarily a sign of injury, but the consequence of a maladaptive central sensitization. One element of this therapeutic strategy is to help the patient to perform physical activities that involve a gradual exposition to stimuli associated with their pain and promote physical recovery exposure. Pain education also aims to reduce fear-avoidance behavior and the patient's disability.
88961060|NCT02943083|Experimental|Coached Intervention|Perform prenatal relaxation exercise in the lab with a coach and at home
88961061|NCT02943083|Active Comparator|Home Intervention|Only perform relaxation exercise at home
88961062|NCT02943083|No Intervention|Control Group|Never performs relaxation routine, attends prenatal assessment sessions
88961063|NCT02943083|No Intervention|Postpartum Only|Only attends visits postpartum, never receives prenatal assessments
88961064|NCT02936622|Experimental|Stent 1|Zilver® PTX Stent
88961065|NCT02936622|Experimental|Stent 2|Zilver® Paclitaxel-Eluting Peripheral Stent with slower-dissolving polymer-free paclitaxel coating
88961066|NCT02936622|Experimental|Stent 3|Zilver® Paclitaxel-Eluting Peripheral Stent with higher-dose polymer-free paclitaxel coating
88961067|NCT02916771|Experimental|Ixazomib|"Cycles 1-9~Ixazomib is administered orally on days 1, 8, 15 on a 28 days cycle~Lenalidomide is administered orally on days 1-21 on a 28 days cycle~Dexamethasone is administered orally on days 1, 8, 15, 22 on a 28 days cycle~Cycle 10-24~Ixazomib is administered orally on days 1, 8, 15 on a 28 days cycle~Lenalidomide is administered orally on days 1-21 on a 28 days cycle~Supportive measures consistent with optimal patient care may be given throughout the study"
88961068|NCT02913196|Experimental|All patients|Apalutamide, 120 mg (cohort 1), 240 mg (cohort 2), 180 mg (cohort 3) Abiraterone Acetate 1000mg Prednisone 10mg Docetaxel 75 mg/m2
88961069|NCT02895230||Men with prostate cancer with androgen-deprivation therapy|Using the French Health Reimbursement Agency database and French hospital discharge database, the investigators will identify all men with prostate cancer who had either, at least one dispensation in a 1.5-year period (1st July 2010 to 31st December 2011) of an androgen-deprivation therapy or a hospitalization for orchiectomy. The French Health Insurance System covers the entire French population (65.3 million inhabitants in 2012).
88961070|NCT02893774|Experimental|cancer quality of life|All patients with breath cancer or melanoma will have quality of life assessment 1, 6, 12, 24, 48 and 60 months after the initial cancer diagnosis
89514690|NCT02440568|Experimental|Cohort 2: Omacetaxine at Dose level at 1.25mg/m^|Patients will receive Omacetaxine at Dose level 1.25mg/m^2, Cytarabine and Idarubicin as part of the treatment plan. Study participants will follow in outpatient clinic at least every 2 months for a total of 6 months. A final study visit will occur 6 months (+/-1 week) after the last dose of Omacetaxine. This visit will end study participation unless there is ongoing toxicity that is at least possibly related to study treatment. In this case, the patient will be followed as medically appropriate until resolution or stabilization of the adverse event.
89514691|NCT02440568|Experimental|Cohort 3: Omacetaxine at Dose level at 2.0mg/m^|Patients will receive Omacetaxine at Dose level 2.0mg/m^2, Cytarabine and Idarubicin as part of the treatment plan. Study participants will follow in outpatient clinic at least every 2 months for a total of 6 months. A final study visit will occur 6 months (+/-1 week) after the last dose of Omacetaxine. This visit will end study participation unless there is ongoing toxicity that is at least possibly related to study treatment. In this case, the patient will be followed as medically appropriate until resolution or stabilization of the adverse event.
89514692|NCT02440568|Experimental|Cohort 4: Omacetaxine at Dose level at 3.0mg/m^|Patients will receive Omacetaxine at Dose level 3.0mg/m^2, Cytarabine and Idarubicin as part of the treatment plan. Study participants will follow in outpatient clinic at least every 2 months for a total of 6 months. A final study visit will occur 6 months (+/-1 week) after the last dose of Omacetaxine. This visit will end study participation unless there is ongoing toxicity that is at least possibly related to study treatment. In this case, the patient will be followed as medically appropriate until resolution or stabilization of the adverse event.
89514693|NCT05643664|Active Comparator|Standart technology|the zone of aortic and main artery clamping is determined by the surgeon intraoperatively.
89514694|NCT05643664|Experimental|Artificial intellect|"The multispiral computed tomography data is evaluated using artificial intelligence and the definition of safe zones of aortic and main artery clamping is performed. Intraoperatively, clamping is performed in the settlement zones."
89514695|NCT04783090|Experimental|1st cohort|MT1013 injection at 2.5 mg.
89514696|NCT04783090|Experimental|2nd cohort|MT1013 injection at 5 mg.
89514697|NCT04783090|Experimental|3rd cohort|MT1013 injection at 10 mg.
89514698|NCT04783090|Experimental|4th cohort|MT1013 injection at 15 mg.
89514699|NCT04783090|Experimental|5th cohort|MT1013 injection at 20 mg.
89514700|NCT04790734|Experimental|Remimazolam|Patients in the remimazolam group received remimazolam besylate at an initial infusion rate of 0.15 mg/kg/h and adjusted to maintain a RASS score of -3 to 0.
89514701|NCT04790734|Active Comparator|Propofol|Patients in the propofol group received propofol at an initial infusion rate of 2.0 mg/kg/h and adjusted to maintain a RASS score of -3 to 0.
89514702|NCT04789954|Experimental|AryoSeven 10 μg/kg|Single dose, intravenously
89514703|NCT04789954|Experimental|AryoSeven 30 μg/kg|Single dose, intravenously
89514704|NCT04789954|Experimental|AryoSeven 90 μg/kg|Single dose, intravenously
89514705|NCT04789954|Experimental|AryoSeven 270 μg/kg|Single dose, intravenously
89514706|NCT04789954|Active Comparator|NovoSeven 30 μg/kg|Single dose, intravenously
89514707|NCT04420624|Experimental|Colchicine|colchicine and standard therapy
89514708|NCT04420624|No Intervention|Comparator|standard therapy
89514709|NCT03090191|Experimental|Clostridium difficile vaccine|
89514710|NCT03090191|Placebo Comparator|Placebo|
89514711|NCT04782778|Active Comparator|Costoclavicular Block|US-guided lateral approach costoclavicular block with 1 mg/kg Bupivacaine (%0,25)
89514712|NCT04782778|Active Comparator|Ultrasound Guided Supraclavicular Block|US-guided supraclavicular block with 1 mg/kg Bupivacaine (%0,25)
89514713|NCT04782544|Active Comparator|Treatment|5 grams of buttermilk powder daily for 10 weeks, oral.
88961071|NCT02893202|Experimental|Ride On Center for Kids (ROCK) facility|8-week therapeutic horseback riding
88961072|NCT02893202|Experimental|Triple H Equitherapy Facility|8-week therapeutic horseback riding
88961073|NCT02893202|Experimental|Rainer Therapeutic Riding facility|8-week therapeutic horseback riding
88961074|NCT02893202|Experimental|REACH Therapeutic Riding facility|8-week therapeutic horseback riding
88961075|NCT02893202|Experimental|Courtney Cares Riding facility|8-week therapeutic horseback riding
89514714|NCT04782544|Placebo Comparator|Placebo|5 grams of milk powder (10% buttermilk powder, 90% anhydrous milk fat) daily for 10 weeks, oral.
88961076|NCT02890082|Experimental|Tamoxifen stim in early follicular phase|Day cycle of the patient when ovarian stimulation begin (early follicular phase) = D1 to D3
89514715|NCT00543712|Experimental|PRO95780|
89514716|NCT00434434|Experimental|1|
89514717|NCT00434434|Experimental|2|
88961077|NCT02890082|Other|Tamoxifen stim in late follicular phase|Day cycle of the patient when ovarian stimulation begin (late follicular phase) = D4 to D14
89514718|NCT00434434|Placebo Comparator|3|
89514719|NCT03524807|Experimental|Electrophysiologic therapy group|apply electrophysiologic therapy after surgery
89514720|NCT03524807|No Intervention|non-electrophysiologic therapy group|do not apply electrophysiologic therapy after surgery
89514721|NCT04020107|Active Comparator|Compressive garment associated with physical therapy|
89514722|NCT04020107|Placebo Comparator|Low compressive garment associated with physical therapy|
89514723|NCT03046511|Experimental|Intraperitoneal|One single dose of intraperitoneal Cefazolin 1000 mg via the recently inserted peritoneal catheter
89514724|NCT03046511|Active Comparator|Intravenous|One single dose of intravenous Cefazolin 1000 mg one hour before catheter insertion
89514725|NCT03522857||Teesside University|nursing, midwifery, physiotherapy, occupational therapy, diagnostic radiography, paramedics
89514726|NCT03522857||Glasgow Caledonian University|nursing, midwifery, physiotherapy, occupational therapy, diagnostic radiography, paramedics
89514727|NCT03522857||Northumbria University|nursing, midwifery, physiotherapy, occupational therapy
89514728|NCT03522857||University of Nottingham|Physiotherapy, nursing and midwifery
89514729|NCT03522857||Curtin University|Physiotherapy
89514730|NCT03522857||Notre Dame University|Physiotherapy
89514731|NCT03522857||University College Dublin|Physiotherapists
89514732|NCT03522857||Leeds Beckett University|Physiotherapists
89514733|NCT03522857||University College Cork|Physiotherapists
89514734|NCT03522857||Robert Gordon University|OT, Physio, Midwifery, Nursing, Diagnostic radiography
89514735|NCT03522857||University of Ulster|Physiotherapy
89514736|NCT03522857||University of Limerick|OT, Physio, Midwifery, Nursing, Diagnostic radiography, paramedic
88961078|NCT02890082|Other|Tamoxifen stim in luteal phase|Day cycle of the patient when ovarian stimulation begin (luteal phase) = D15 to D28
88961079|NCT02858336|Active Comparator|Control|All participants will receive the NEA availability to act as their own control to the experimental DEA intervention.
88961080|NCT02858336|Experimental|Experimental|All participants will be in the experimental arm and receive the DEA intervention.
88961081|NCT02855489|Experimental|Attitudes Only|The attitudes condition targeted cognitive and affective attitudes by pairing attitudinal messages with pictures, and included an evaluative conditioning task.
88961082|NCT02855489|Experimental|Norms Only|The norms condition utilized a group-affirmation exercise, personalized feedback, and group norms in an attempt to greater condom use norms.
89024847|NCT04701125|Experimental|Study group|Players receive selective head-neck cooling after concussion
89514737|NCT03956537||Pedicle screw system alone|
89514738|NCT03956537||Pedicle screw system with cages|
89514739|NCT03522779|Placebo Comparator|High-fat meal + placebo|Participants will complete a high-fat meal challenge with a placebo beverage.The placebo will be designed to match the tart cherry juice for volume and macronutrient content, but without the phytonutrient content of the tart cherries.The high-fat breakfast meal will consist of 2 Sausage Biscuits (McDonalds Corporation). Blood draws will then be obtained at 1, 2 and 3 hours postprandially for antioxidant and oxidative stress measurements.
89514740|NCT03522779|Experimental|High-fat meal + tart cherry|Participants will complete a high-fat meal challenge with a tart cherry juice concentrate. 60 mL of montmorency tart cherry concentrate will be diluted with 100 mL of water.The high-fat breakfast meal will consist of 2 Sausage Biscuits (McDonalds Corporation). Blood draws will then be obtained at 1, 2 and 3 hours postprandially for antioxidant and oxidative stress measurements.
89514741|NCT03522779|Placebo Comparator|Exercise + high-fat meal + placebo|Participants will perform an acute bout of submaximal aerobic exercise 15 hours prior to the high-fat meal test. The exercise will consist of 30 minutes of treadmill running at 70% of each participants' calculated heart rate reserve. The following morning participants will complete a high-fat meal challenge with a placebo beverage.The placebo will be designed to match the tart cherry juice for volume and macronutrient content, but without the phytonutrient content of the tart cherries.The high-fat breakfast meal will consist of 2 Sausage Biscuits (McDonalds Corporation). Blood draws will then be obtained at 1, 2 and 3 hours postprandially for antioxidant and oxidative stress measurements.
89514742|NCT03522779|Experimental|Exercise + high-fat meal + tart cherry|Participants will perform an acute bout of submaximal aerobic exercise 15 hours prior to the high-fat meal test. The exercise will consist of 30 minutes of treadmill running at 70% of each participants' calculated heart rate reserve.The following morning participants will complete a high-fat meal challenge with a tart cherry juice concentrate. 60 mL of montmorency tart cherry concentrate will be diluted with 100 mL of water.The high-fat breakfast meal will consist of 2 Sausage Biscuits (McDonalds Corporation). Blood draws will then be obtained at 1, 2 and 3 hours postprandially for antioxidant and oxidative stress measurements.
89514743|NCT03522623||IBD|Children and families with IBD will be surveyed
89514744|NCT02439320|Experimental|Lasmiditan 100 mg|Oral tablet. Lasmiditan 100 mg plus placebo (to match 200 mg tablet). One dose for acute treatment of migraine. Second dose for rescue or recurrence of migraine allowed within 24 hours.
89514745|NCT02439320|Experimental|Lasmiditan 200 mg|Oral tablet. Lasmiditan 200 mg plus placebo (to match 100 mg tablet). One dose for acute treatment of migraine. Second dose for rescue or recurrence of migraine allowed within 24 hours.
89024848|NCT04701125|No Intervention|control group|Players receive the standard sport-related concussion management
89514746|NCT02439320|Placebo Comparator|Placebo|Oral tablet. Placebo tablets match lasmiditan 100 mg and lasmiditan 200 mg. One dose for acute treatment of migraine. Second dose for rescue or recurrence of migraine allowed within 24 hours.
89514747|NCT04936256||Bilateral implantation of the Clareon monofocal IOL|Clareon monofocal intraocular lens (IOL)
89514748|NCT02469038|Experimental|AccuCath catheter|We use the AccuCath catheter with ultrasound guidance for IV access for patients in the experimental group.
89514749|NCT02469038|Active Comparator|Control|We will use ultrasound-guided conventional IV for patients in the control group.
89514750|NCT02468648|Experimental|Combination of sofosbuvir and GS-5816|Combination of sofosbuvir and GS-5816 agent into a single pill will be used.
89514751|NCT02468414|Experimental|MDGN201 TARGTEPO secreting EPO|MDGN201 TARGTEPO secreting EPO
89514752|NCT02466386|Experimental|SPD489|Participants will receive 5 milligrams (mg) of SPD489 capsule orally once daily in the morning and titrated in a step-wise fashion up to either 10 mg, 15 mg, 20 mg, or 30 mg until an optimal dose was reached within 52 weeks.
89514753|NCT04936100|Experimental|"Visual acuity assessment using Vision Screening module of Easy Vision application"|
89514754|NCT04936100|Experimental|"Visual acuity assessment using Test Yourself module of Easy Vision application"|
89514755|NCT04936100|Experimental|"Visual acuity assessment using Peek Acuity application"|
89514756|NCT04936100|Other|Visual acuity assessment using the conventional methods|
89514757|NCT01633060|Experimental|BKM120 100mg + Fulvestrant|BKM120 100 mg per day and fulvestrant given until progression or as described in the protocol.
89514758|NCT01633060|Placebo Comparator|Placebo + Fulvestrant|BKM120 matching placebo daily and fulvestrant given until progression or as described in the protocol.
89514759|NCT03522467|Experimental|MRCP001|MRCP001 administered per protocol dose titration regimen (beginning at 1 capsule daily, titrated to a maximum of 3 capsules BID)
89514760|NCT03914495|Placebo Comparator|Placebo|Participants will receive powdered maltodextrin to provide equivalent calories and macronutrients without any fiber.
89514761|NCT03914495|Active Comparator|Inulin|Participants will receive inulin, 10 grams TID for 28 days with titration as follows: 10 grams QD for 3 days, 20 grams BID for 4 days with the remaining 21 days at 10 g TID.
89514762|NCT03906695|Experimental|10-Day Schedule|"10-Day Schedule~Investigational Medicinal Products (IMP) will be administered for 10 days in total per 4 weeks, i.e. a 28-day cycle."
89514763|NCT03906695|Experimental|5-Day Schedule A|"5-Day Schedule A~IMP will be administered for 5 days in total per 4 weeks, i.e. a 28-day cycle."
89514764|NCT03906695|Experimental|5-Day Schedule B|"5-Day Schedule B~IMP will be administered for 5 days in total per 4 weeks, i.e. a 28-day cycle."
89514765|NCT03906695|Experimental|5-Day Schedule C|"5-Day Schedule C~IMP will be administered for 5 days in total per 4 weeks, i.e. a 28-day cycle."
89514766|NCT03906695|Experimental|7-Day Schedule|"7-Day Schedule~IMP will be administered for 7 days in total per 4 weeks, i.e. a 28-day cycle."
89514767|NCT03524651|Active Comparator|Ferrous sulfate|Patients will take every day for 12 weeks two oral capsules of 150 mg ferrous sulfate delivering 47 mg of active elemental iron. Capsules should be taken orally either two hours before meal or two hours after meal. The same patients will take every day on exactly the same time for 12 weeks two placebo vials of 15 ml volume with excipients contained in the commercially available formulation Fe-Asp Omalin (Uni-Pharma SA).
89514768|NCT03524651|Active Comparator|Fe-ASP|Patients will take every day for 12 weeks two oral placebo capsules. Capsules should be taken orally either two hours before meal or two hours after meal. The same patients will take every day on exactly the same time for 12 weeks two vials of 15 ml volume of the Fe-Asp preparation Omalin (Uni-Pharma SA) delivering 40 mg of elemental iron.
89514769|NCT03852329|Experimental|Navigated|Lateral skull base navigation intervention is applied
89514770|NCT01632904|Experimental|ruxolitinib and hydroxyurea (HU)-placebo|
89514771|NCT01632904|Active Comparator|HU and ruxolitinib-placebo|
89514772|NCT05473000|Experimental|Ozone (O3)|Participants of the experimental group will perform sub-maximal exercise (power output associated with 10% below anaerobic threshold for 30 minutes) and maximal exercise (time-to-exhaustion test at 5% above previously determined maximal power output) on a cycle ergometer while inhaling 170ppb ozone delivered continuously during each exercise session.
89514773|NCT05473000|Sham Comparator|Room air|Participants of the sham group will perform sub-maximal exercise (power output associated with 10% below anaerobic threshold for 30 minutes) and maximal exercise (time-to-exhaustion test at 5% above previously determined maximal power output) on a cycle ergometer while inhaling room air during each exercise session.
89514774|NCT03834779|Other|DOORS-CHW Intervention|"The type of intervention is behavioral.~Participants randomized to the intervention arm will meet with the Community Health Worker (CHW) and a staff member from Unlocking DOORS. The Unlocking DOORS broker will complete a needs assessment, generate an individualized re-entry plan and make referrals to providers in the extensive Unlocking DOORS network. The CHW will assist the participant in navigating these referrals, specifically with regards to HIV care, substance use treatment and mental healthcare."
89514775|NCT03834779|No Intervention|Treatment As Usual|TAU participants will receive standard of care, which involves passive referral by jail medical staff to the outpatient HIV clinic.
89514776|NCT03522389|Experimental|AOT with gait training group|Action observation training with gait training
89514777|NCT03522389|Active Comparator|Gait training group|Gait training
89514778|NCT03522389|Other|Control group|Education
89514779|NCT04467125|Experimental|EMLA|Subjects randomized to EMLA receive one inch of EMLA cream placed at the removal site and then have an occlusive dressing placed. One hour later they have the Nexplanon device removed.
89024849|NCT00474357|Experimental|1|Bipolar patients participating in psychoeducation intervention
89024850|NCT00474357|No Intervention|2|bipolar patients who do not participate in psychoeducation group
89024851|NCT00474357|No Intervention|3|Therapists will complete questionnaires regarding myths about bipolar patients, no intervention
89514780|NCT04467125|Active Comparator|Subcutaneous Lidocaine|Subjects randomized to subcutaneous lidocaine have 1% lidocaine injected at the removal site and then undergo Nexplanon removal.
89024852|NCT04701242|Active Comparator|Atorvastatin-Ezetimibe combination|Eligible patients randomized to this arm will receive combination of Atorvastatin 80mg plus Ezetimibe 10mg
89024853|NCT04701242|No Intervention|Atorvastatin monotherapy|Eligible patients randomized to this arm will receive Atorvastatin 80mg as monotherapy for LDL-C reduction. They can be upgraded to combination (adding Ezetimibe 10mg) if found in follow-up that they had not achieve recommended LDL-C targets.
89024854|NCT03270267||Patients with IBD|
89024855|NCT03279965||Cystic fibrosis|Patients with known cystic fibrosis
89024856|NCT03279965||Primary ciliary dyskinesia|Patients with known primary ciliary dyskinesia
89207460|NCT00851058|Placebo Comparator|Prototypic Community Service|Four hours of education about road safety and 16 hours volunteering at a local not for profit community service.
89207461|NCT02544906|No Intervention|Control|No drugs will be given. the emergence agitation will be monitored and recorded
89514781|NCT03726437|Experimental|RealConsent|A 3-hour web-based program designed to teach female college freshmen strategies to reduce their risk of sexual violence victimization.
89514782|NCT03726437|Placebo Comparator|Stress and Mood Management|A 3-hour general mental health web-based program.
89514783|NCT02465528|Experimental|Inflammatory myofibroblastic tumor (IMT)|Patients diagnosed with IMT with a confirmed translocation involving the ALK gene
89514784|NCT02465528|Experimental|Anaplastic large cell lymphoma (ALCL)|Patients with a diagnosis of ALCL histologically or cytologically confirmed to be ALK-positive
89514785|NCT02465528|Experimental|Glioblastoma (GBM)|Patients with GBM with a translocation involving the ALK gene
89514786|NCT02465528|Experimental|Any other ALK-positive tumor|Patients with any other ALK-positive tumor. Patients in this arm included adenocarcinoma (n= 2), sarcoma (1) and other (2).
89514787|NCT02438384|No Intervention|Usual care|Pts will receive education and follow-up based on judgment of emergency provider.
89514788|NCT02438384|Experimental|Video|Patients will watch 10 minute educational video
89514789|NCT02438384|Experimental|Video plus Phone Follow-up|Patients will watch 10 minute educational video and receive phone call follow-up at 3 days to assess pain symptoms. Patients with a pain score of 4 or more will receive another call with advice from a geriatric pain specialist.
89514790|NCT02463032|Experimental|GTx-024 9 mg|Drug: GTx-024 GTx-024 softgel capsules will be administered once daily to a total dose of 9 mg
89514791|NCT02463032|Experimental|GTx-024 18 mg|Drug: GTx-024 GTx-024 softgel capsules will be administered once daily to a total dose of 18 mg
89514792|NCT02545205|Experimental|Hybrid Assistive Limb (HAL)|
89514793|NCT02545205|Active Comparator|Conventional gait training|
89514794|NCT02298647||Observation|Patients with GM1/GM2-Gangliosidosis or high-grade suspicion for GM1/GM2-Gangliosidosis
89514795|NCT03524261|Experimental|Cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
89514796|NCT03524261|Active Comparator|Cryotherapy & Activated CIK and bispecific antibody|the maximum tumor length≥2cm, use cryotherapy. the maximum tumor length<2 cm,Biological/Vaccine:Activated CIK and bispecific antibody CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
89514797|NCT03524261|No Intervention|Conventional therapy|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
89514798|NCT02496884|Experimental|M-CKD DS-5565 7.5 mg BID|Patients with moderate chronic kidney disease (M-CKD) randomized to receive DS-5565 BID during the treatment period.
89514799|NCT02496884|Experimental|S-CKD DS-5565 7.5 mg QD|Fibromyalgia patients with severe chronic kidney disease (S-CKD) randomized to receive a DS-5565 7.5 mg tablet once per day (QD), and a placebo tablet (no drug) QD, for a total of 7.5 mg DS-5565
89514800|NCT02496884|Placebo Comparator|M-CKD Placebo|Patients with M-CKD randomized to receive placebo twice daily (BID) during the treatment period.
89514801|NCT02496884|Placebo Comparator|S-CKD Placebo|Patients with S-CKD randomized to receive placebo once daily (QD) during the treatment period.
89514802|NCT03133091|Active Comparator|PIEB (Patient Intermittent Epidural Bolus)|"PIEB: The boluses are programmed every 30 minutes. The patient can ask for another extra bolus in between if she wishes.~The dosis per hour are equivalent to the PCEA. We make a comparison between PCEA vs PIEB."
89514803|NCT03133091|Active Comparator|PCEA (Patient continuous Epidural Analgesia)|"PCEA: There is a continuous infusion and the patient can order extra boluses every 15 minutes.~The dosis per hour are equivalent to the other arm to the PIEB. We make a comparison between PCEA vs PIEB."
89514804|NCT04466813|Experimental|Deep Dry Needling|Intervention-Dry Needling: Deep Dry Needing into the latent trigger point of the upper trapezius muscle
89514805|NCT04466813|Sham Comparator|Sham Dry Needling|Control-Dry Needling: Sham Dry Needling into the latent trigger point of the upper trapezius muscle
89514806|NCT03501095||patients|patients who must undergo general and/or urology surgery of an elective type
89514807|NCT03386721|Experimental|Cohort A (Part I)|Checkpoint Inhibitor (CPI)-Naïve Participants with non-small-cell lung cancer (NSCLC) who have not received CPI therapy previously will receive simlukafusp alfa intravenous (IV) infusion once in a week (QW) for first 5 doses, and once in 2 weeks (Q2W) for remaining doses up to maximum 36 months. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered in combination Q2W at a dose of 840 mg. Tumor biopsies: collection of fresh tumor biopsies (at baseline and on-treatment) will be optional.
89514808|NCT03386721|Experimental|Cohort B (Part I)|CPI-Experienced Participants (NSCLC) who have received CPI therapy previously will receive simlukafusp alfa intravenous (IV) infusion once in a week (QW) for first 5 doses, and once in 2 weeks (Q2W) for remaining doses up to maximum 36 months. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered in combination Q2W at a dose of 840 mg. Tumor biopsies: 2 mandatory fresh tumor biopsies, one at baseline and one on-treatment, will be collected. Additional on-treatment biopsies will be optional.
89519573|NCT03855995||Active surveillance (DTP sub-Group)|Children enrolled in the active surveillance (AS), <18 months of age who were identified at any administration of DTP/HepB/Hib (usually given at 6, 10 and 14 weeks of age) or at hospitalisation before administration of 3rd dose of DTP/HepB/Hib and vaccinated with at least one dose of DTP/HepB/Hib; including both RTS,S/AS01E vaccinated and unvaccinated children (from exposed or unexposed clusters), living in the HDSS area are eligible for enrolment in the DTP sub-group of active surveillance.
88961083|NCT02855489|Experimental|Perceived Behavioral Control Only|The PBC condition included a condom application video, lubrication instructions, condom negotiation videos, and a detailed description regarding purchasing condoms.
88961084|NCT02855489|Experimental|Intentions Only|The intentions condition utilized implementation intentions in order to create condom use intentions.
88961085|NCT02855489|Experimental|Three Constructs|A three construct condition, which included attitudes, norms, and perceived behavioral control represented the core components of the TPB that are thought to work through intentions to result in behavior change.
88961086|NCT02855489|Experimental|Four Constructs|"A four construct condition (i.e., attitudes, norms, PBC, and intentions) was designed to represent the full TPB model intervention which we expected would be more successful than either the three-construct intervention or any of the single construct interventions."
88961087|NCT02855489|No Intervention|No-Treatment, Control|A no-treatment control condition, which solely consisted of pretest and posttest assessments, was included. This allowed us to obtain important information about how the theoretical constructs in the TPB change over time (or do not) in the absence of an experimental manipulation.
88961088|NCT02844933|Experimental|Cannabidiol|Cannabidiol oral solution (40 milligram/kilogram/day [40 mg/kg/day]) divided into two daily doses with a standard meal
88961089|NCT02844933|Placebo Comparator|Placebo|Matching placebo solution divided into two daily doses with a standard meal
88961090|NCT02797470|Experimental|Treatment (anti-HIV gene transduced CD34+ cells)|Patients receive BEAM regimen administered as standard of care comprising carmustine on day -6, cytarabine BID on days -5 to -2, etoposide BID on days -5 to -2, and melphalan on day -1. Patients undergo infusion of lentivirus vector CCR5 shRNA/TRIM5alpha/TAR decoy-transduced autologous CD34-positive hematopoietic progenitor cells over 1 hour.
88961091|NCT02744690|Experimental|MMC Injection|Intervention: At the intended surgical site and about 6mm from the limbus, 0.2ml of 0.2mg/ml of mitomycin-C (MMC) will be injected subconjunctivally before peritomy
88961092|NCT02744690|Active Comparator|MMC Sponge Application|Intervention: After peritomy, three half-sponges soaked in 0.2mg/ml mitomycin-C (MMC) will be placed posterior to the area of intended filtration. After 2 minutes, the sponges will be removed
88961093|NCT02735668|Active Comparator|Shoulder Conventional Exercises|"The protocol consists in:~Flexibility and Strengthening Exercises of the shoulder muscles conventionally performed in shoulder pathology treatment.~Therapeutic Education about chronic shoulder pain.~The treatment duration is 1 day per week during 6 weeks."
89207462|NCT02544906|Experimental|Propofol group|Propofol at dose of 1 mg/kg over 5 minutes will be started before extubation. the emergence agitation will be monitored and recorded
89514809|NCT03386721|Experimental|Cohort C (Part I)|"This is a mandatory biopsy cohort based on the treatment's safety and preliminary activity analysis to enroll CPI-Naive Participants. Participants (NSCLC) will receive simlukafusp alfa intravenous (IV) infusion once in a week (QW) for first 5 doses, and once in 2 weeks (Q2W) for remaining doses up to maximum 36 months. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered in combination Q2W at a dose of 840 mg.~Tumor biopsies: 2 mandatory fresh tumor biopsies, one at baseline and one on-treatment, will be collected. Additional on-treatment biopsies will be optional."
89514810|NCT03386721|Experimental|Cohort D Arm I (Part I)|"CPI Experienced Participants (NSCLC) who were previously treated with platinum and docetaxel.~Participants will receive simlukafusp alfa intravenous (IV) infusion once in a week (QW) for first 5 doses, and once in 2 weeks (Q2W) for remaining doses up to maximum 36 months. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered in combination Q2W at a dose of 840 mg.~Tumor biopsies: 2 mandatory fresh tumor biopsies, one at baseline and one on-treatment, will be collected. Additional on-treatment biopsies will be optional."
89514811|NCT03386721|Experimental|Cohort D Arm 2 (Part I)|"CPI Experienced Participants (NSCLC) who were previously treated with platinum and docetaxel.~Participants will receive simlukafusp alfa intravenous (IV) infusion once in 3 weeks (Q3W) up to maximum 36 months. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered in combination Q3W at a dose of 1200 mg.~Tumor biopsies: 2 mandatory fresh tumor biopsies, one at baseline and one on-treatment, will be collected. Additional on-treatment biopsies will be optional."
89514812|NCT03386721|Experimental|Cohort D Arm 3 (Part I)|"CPI Experienced Participants (NSCLC) who were previously treated with platinum and docetaxel will receive a single-agent gemcitabine or vinorelbine as per approved protocol.~Tumor biopsies: 2 mandatory fresh tumor biopsies, one at baseline and one on-treatment, will be collected. Additional on-treatment biopsies will be optional."
89514813|NCT03386721|Experimental|Cohort E Arm I (Part II)|"This cohort will enroll participants (NSCLC) with High-Tumor PD-L1 Expression who have not received any prior systemic therapy. Participants will receive simlukafusp alfa intravenous (IV) infusion once in a week (QW) for first 5 doses, and once in 2 weeks (Q2W) for remaining doses up to maximum 36 months. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered in combination Q2W at a dose of 840 mg.~Tumor biopsies: 2 mandatory fresh tumor biopsies, one at baseline and one on-treatment, will be collected. Additional on-treatment biopsies will be optional."
89514814|NCT03386721|Experimental|Cohort E Arm 2 (Part II)|"This cohort will enroll participants (NSCLC) with High-Tumor PD-L1 Expression who have not received any prior systemic therapy. Participants will receive simlukafusp alfa IV infusion in combination with atezolizumab Q3W. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered at a dose of 1200 mg.~Tumor biopsies: 2 mandatory fresh tumor biopsies, one at baseline and one on-treatment, will be collected. Additional on-treatment biopsies will be optional."
89514815|NCT03386721|Experimental|Cohort F (Part I)|"CPI-experienced, docetaxel naive participants (NSCLC) who experienced disease progression during or following treatment with a platinum - containing regimen. Participants will receive combination of simlukafusp alfa and atezolizumab in a Q3W schedule. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered at a dose of 1200 mg.~Tumor biopsies: one mandatory fresh tumor biopsy will be collected at baseline. Additional on-treatment biopsies will be optional."
89543406|NCT03230669|Experimental|CBT4CBT|This arm receives treatment as usual and in addition are given access to an online therapy, cbt4cbt. If placed in this group, individuals are asked to use the online therapy for a minimum of 30 minutes each week for the trial duration of 8 weeks.
89543407|NCT03194243||Patients admitted for acute dyspnea|Patients admitted for acute dyspnea in the emergency department
89207463|NCT02544906|Experimental|dexmedetomedine group|dexmedetomedine at dose of .5 mic/kg over 5 minutes will be started before extubation. the emergence agitation will be monitored and recorded
89543408|NCT03230591||Fabry's disease|Fabry's disease patients who were confirmed by enzyme assay and gene study
89543409|NCT04790643||Stage 1 - Development of the new cardiac risk stratification protocol|This will be a prospective cohort study, in which individuals attending cardiac rehabilitation programs will be assessed by clinical and physical variables that will be used to guide the elaboration of the cardiac risk stratification protocol. After this initial evaluation, the volunteers will be followed for 2 months during their habitual cardiac rehabilitation routine for the evaluation and registry of the occurrence of minor adverse events, defined as signs and symptoms (arrhythmias, blood pressure alterations, tachypnea, pallor, chest pain, cramps, muscle pain, fatigue, and nausea). The cardiac rehabilitation program in which the volunteers will be recruited is based on moderate-intensity aerobic exercise.
89543410|NCT04790643||Stage 2 - Reproducibility and efficiency of the new protocol|"This will be a prospective cohort study, in which a new sample of individuals attending cardiac rehabilitation programs will be assessed by clinical and physical variables and stratified in one of the three following risk classes: low risk, moderate risk, and high risk accordingly to the new risk stratification protocol. After that, the sample will be followed for 2 months of rehabilitation to the evaluation of the occurrence of signs and symptoms. The cardiac rehabilitation program from where the volunteers will be recruited is based on moderate-intensity aerobic exercise and resistance training. With these data, the reproducibility and efficiency of the protocol will be evaluated."
89543411|NCT04790643||Stage 3 - Protocols´ agreement between evaluators|This will be a cross-sectional observational study in which a new sample of participants will be evaluated by two independent physiotherapists for clinical and physical variables, and based on these data will be stratified by the new protocol by the same evaluators independently. After these procedures, the protocol´s agreement between evaluators will be analyzed.
89543412|NCT03230513|Active Comparator|Self Epley Manoeuvre|Self Epley Manoeuvre.
89543413|NCT03230513|Active Comparator|Brandt-Daroff Exercise|Brandt-Daroff Exercise.
89543414|NCT02445521||PKU (low phe-level)|A subject diagnosed with phenylketonuria (PKU) with low phenylalanine levels, defined as 1-5 mg/dL
89543415|NCT02445521||PKU (mid phe-level)|A subject diagnosed with phenylketonuria (PKU) with middle phenylalanine levels, defined as 6-10 mg/dL
89543416|NCT02445521||PKU (high mid phe-level)|A subject diagnosed with phenylketonuria (PKU) with high middle phenylalanine levels, defined as 11-15 mg/dL
89543417|NCT02445521||PKU (high phe-level)|A subject diagnosed with phenylketonuria (PKU) with high phenylalanine levels, defined as 16-20+ mg/dL
89543418|NCT02445521||Control|A normal subject without phenylketonuria (PKU)
89543419|NCT02445209|Active Comparator|EOX|"Epirubicin 50mg/m2 IV on day 1; Oxaliplatin 130mg/m2 IV on day 1; Capecitabine 625mg/m2/day PO BID days 1-21; Cycled every 21 days. Cycled every 3 weeks for a maximum of 8 cycles initially (24 weeks of treatment).~Patients who experienced a long term response to the initial 8 cycles of EOX chemotherapy, could be rechallenged with the same regimen."
89543420|NCT02445209|Active Comparator|mDCF|"Docetaxel 40 mg/m2 IV od day 1; Leucovorin 400 mg/m2 IV on day 1; 5fluorouracyl 400 mg/m2 IV on day 1; 5fluorouracil 1000 mg/m2/d IV continuous infusion days 1-2; Cisplatin 40 mg/m2 IV on day 3; Cycled every 2 weeks for a maximum of 12 cycles initially (24 weeks of treatment).~Patients who experienced a long term response to the initial 12 cycles of mDCF chemotherapy, could be rechallenged with the same regimen"
89543421|NCT05613699|Other|supervised, group-based, online-social media exercise program|
89543422|NCT05613699|Other|unsupervised individual home-based training with an online-training app|
88961094|NCT02735668|Experimental|Multimodal Physiotherapy|"The protocol consists in:~Dry Needling in active myofascial trigger points.~Neurodynamic techniques.~Scapular exercises.~Therapeutic Education about chronic shoulder pain.~The treatment duration is 1 day per week during 6 weeks."
88961095|NCT02735668|Experimental|Scapular exercises|"The protocol consists in:~Scapular exercises~Therapeutic Education about chronic shoulder pain.~The treatment duration is 1 day per week during 6 weeks."
88961096|NCT02706652||all patients|all eligible patients
88961097|NCT02705820|Experimental|single arm study|experimental treatment with maintenance pembrolizumab
88961098|NCT02701543|Active Comparator|Ranger Drug Eluting Balloon|Intervention with Over the Wire (OTW) Percutaneous transluminal angioplasty (PTA )balloon catheter with a semi-compliant balloon coated with a formulation of 2μg/mm2 paclitaxel and acetyl tri-n-butyl citrate (ATBC) as carrier substance
88961099|NCT02701543|Active Comparator|In Pact Drug Eluting Balloon|Intervention with Over the Wire (OTW) peripheral balloon catheter. The balloon surface is coated with a formulation of 3μg/mm2 paclitaxel and urea as carrier substance.
88961100|NCT02680821|Other|Isolated ACL-revision|The standard operation with an isolated Anterior cruciate ligament.
88961101|NCT02680821|Other|Combined ACL and ALL surgery|An operation with an Anterior cruciate ligament combined with an anterolateral ligament.
89207464|NCT00861276|Experimental|1|Arm instructed to use spray at least once an hour when awake.
89207465|NCT00861276|Active Comparator|2|Ad libitum: patients were instructed to use NNS when craving appears.
89207466|NCT02544828|Experimental|Experimental group|Iron Sucrose 200mg
89207467|NCT02544828|Placebo Comparator|Control Group|placebo
89207468|NCT00861432|Active Comparator|additive homeopathic treatment|These patients receive additive homeopathic treatment during conventional cancer treatment.
89207469|NCT00861432|No Intervention|no additive homeopathic treatment|These patients do not receive additive homeopathic treatment during conventional cancer treatment.
89207470|NCT01095003|Experimental|Vinflunine plus Capecitabine|"Patients received (in combination with capecitabine)~• Vinflunine at the dose of 280 mg/m² and as a 20-minute IV. infusion on day 1 of each cycle repeated every 3 weeks."
89543423|NCT05613699|Other|supervised, in-person exercise program close to place of residence|
89543424|NCT02445365|Experimental|Active RIC|Daily remote ischemic conditioning for 10 days. Remote ischemic conditioning is induced by placing a blood pressure cuff around the right or left arm. The cuff is inflated to 200 mmHg and the pressure is kept for 5 minutes. Hereafter the cuff is deflated for 5 minutes completing one cyclus. This cyclus is repeated 4 times.
89543425|NCT02445365|Sham Comparator|Sham|As above with a cuff pressure of 20 mmHg
89514816|NCT03386721|Experimental|Cohort G (Part III)|CPI-naïve SCC of the head and neck (SCCHN) (20 response-evaluable participants), mandatory biopsies. Participants in cohort G Part III will receive simlukafusp alfa Q3W in combination with atezolizumab Q3W. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered at a dose of 1200 mg. Tumor biopsies: one mandatory fresh tumor biopsy will be collected at baseline. Additional on-treatment biopsies will be optional. Biopsies are not applicable to participants presenting with a single target lesion and absence of any non-target lesion.
89514817|NCT03386721|Experimental|Cohort H (Part III)|Previously treated, CPI-experienced squamous cell carcinoma head and heck cancer (20 response evaluable participants), mandatory biopsies. Participants in cohort H Part III will receive simlukafusp alfa Q3W in combination with atezolizumab Q3W. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered at a dose of 1200 mg. Tumor biopsies: one mandatory fresh tumor biopsy will be collected at baseline. Additional on-treatment biopsies will be optional. Biopsies are not applicable to participants presenting with a single target lesion and absence of any non-target lesion.
89514818|NCT03386721|Experimental|Cohort I (Part III)|Previously treated, CPI-naïve squamous esophageal cancer (20 response evaluable participants), mandatory biopsies. Participants in cohort I Part III will receive simlukafusp alfa Q3W in combination with atezolizumab Q3W. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered at a dose of 1200 mg. Tumor biopsies: one mandatory fresh tumor biopsy will be collected at baseline. Additional on-treatment biopsies will be optional.
89514819|NCT03386721|Experimental|Cohort J (Part III)|Previously treated, CPI-naïve squamous cervical cancer (20 response evaluable participants): mandatory biopsy. Participants in cohort J Part III will receive simlukafusp alfa Q3W in combination with atezolizumab Q3W. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered at a dose of 1200 mg. Tumor biopsies: one mandatory fresh tumor biopsy will be collected at baseline. Additional on-treatment biopsies will be optional.
89514820|NCT03386721|Experimental|Cohort K (Part III)|CPI-naïve SCC of the head and neck (SCCHN) (20 response-evaluable participants), mandatory biopsies. Participants in cohort K Part III will receive simlukafusp alfa QW in combination with atezolizumab Q2W for 4 weeks followed by simlukafusp alfa in combination with atezolizumab Q2W. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered at a dose of 840 mg. Tumor biopsies: one mandatory fresh tumor biopsy will be collected at baseline. Additional on-treatment biopsies will be optional. Biopsies are not applicable to participants presenting with a single target lesion and absence of any non-target lesion.
89514821|NCT03386721|Experimental|Cohort L (Part III)|Previously treated, CPI-experienced squamous cell carcinoma head and neck cancer (20 response evaluable participants), mandatory biopsies. Participants in cohort L Part III will receive simlukafusp alfa QW in combination with atezolizumab Q2W for 4 weeks followed by simlukafusp alfa in combination with atezolizumab Q2W. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered at a dose of 840 mg. Tumor biopsies: one mandatory fresh tumor biopsy will be collected at baseline. Additional on-treatment biopsies will be optional. Biopsies are not applicable to participants presenting with a single target lesion and absence of any non-target lesion.
89514822|NCT03386721|Experimental|Cohort M (Part III)|Esophageal SCC participants will receive simlukafusp alfa QW in combination with atezolizumab Q2W for 4 weeks followed by simlukafusp alfa in combination with atezolizumab Q2W. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered at a dose of 840 mg. Tumor biopsies: one mandatory fresh tumor biopsy will be collected at baseline. Additional on-treatment biopsies will be optional.
89514823|NCT03386721|Experimental|Cohort N (Part III)|Cervical SCC participants will receive simlukafusp alfa QW in combination with atezolizumab Q2W for 4 weeks followed by simlukafusp alfa in combination with atezolizumab Q2W. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered at a dose of 840 mg. Tumor biopsies: one mandatory fresh tumor biopsy will be collected at baseline. Additional on-treatment biopsies will be optional.
89514824|NCT02462720|Experimental|Varithena®, then Radiofrequency Ablation|Varithena (polidocanol injectable foam) supplied as polidocanol solution 180 mg/18 mL (10 mg/mL) to be activated before use. Once activated, Varithena is a white injectable foam delivering a 1% polidocanol solution. Each milliliter of Varithena injectable foam contains 1.3 mg of polidocanol. Up to 5 mL per injection or 15 mL per treatment session could be used. This was followed by RFA treatment.
89514825|NCT02462720|Active Comparator|Radiofrequency ablation then Varithena|RFA procedures were conducted in accordance with the physician's standard of care and according to the manufacturer's instructions for use. This was followed by treatment with Varithena.
89514826|NCT03524105|Active Comparator|Thrive Professional Learning plus ParentCorps|
89514827|NCT03524105|Active Comparator|Thrive Professional Learning track|
89514828|NCT03524027|Experimental|Congenital Thoracolumbar Kyphoscoliosis|Correction of Adolescent Thoracolumbar Congenital Kyphoscoliosis (CKS) Spinal Deformity by Posterior Vertebral Column Resection (PVCR) Surgical Technique
89514829|NCT02246218|Experimental|RAVICTI|RAVICTI Oral Liquid should be administered just prior to breastfeeding or intake of formula or food. The recommended dosing regimen is 3-6 times per day depending on feeding schedule and at the discretion of the Investigator.
89514830|NCT05393661||Patients undergoing inpatient rehabilitation poststroke|Inpatient rehabilitation poststroke
89514831|NCT03523949|Experimental|PNE.|Procedure: This educational intervention is based in the latest evidence of pain neuroscience education, used in multiple rehabilitation programs. Its aim is to change the subject's pain understanding, teaching them the biological processes underneath the pain construct, as a mechanism to reduce itself and its related maladaptive thoughts and behaviors.
89514832|NCT05085093||Study Group|HPV vaccine group
89514833|NCT05085093||Control group|non HPV vaccine group
89514834|NCT03522155|Experimental|Intervention Arm|"Intervention: (1) Subjects will be provided with patient-specific LE estimates, (2) counseling physicians will receive talking points to assist in meaningful communication of life expectancy, and (3) subjects will complete a computer-based conjoint analysis exercise prior to counseling."
89514835|NCT03522155|No Intervention|Standard-of-care Arm|Patients in the standard-of-care arm will not receive an intervention and will receive the usual standard of care for treatment counseling.
89514836|NCT05084781|Experimental|Coblation Debridement|FLOW 90 / WEREWOLF debridement of rotator cuff footprint.
89543426|NCT05613621||training cohort|Consisting of 4 sub-groups: HBV (+) steatosis (+), HBV (-) steatosis (+), HBV (+) steatosis (-) and HBV (-) steatosis (-). HBV (+) is defined as either: (a) HBsAg (+) or (b) HBsAg (-) anti-HBc (+) and HBV DNA detectable in blood or tumor tissue. Steatosis is defined by histology. We will enroll 400 patients who had sufficient tissue for testing in the training cohort.
89543427|NCT05613621||validation cohort|For the validation cohort, the clinical and pathological information will be obtained retrospectively by TCOG and will take 6 months to identify eligible patients for the 4 sub-groups listed above.
89543428|NCT02444975|Experimental|Increased water intake+coaching program|Women in the intervention group will be asked to increase their mineral water intake of 1.5L/day
89543429|NCT02444975|Other|No intervention|No intervention
89543430|NCT03230357|Experimental|PICC guided by EDUG|PICC(Peripherally Inserted Central Catheter)guided by ECG Doppler ultrasonic Guidance（EDUG),EDUG is a combination device which can be used for selecting the right vein and precise positioning for the catheter tip during the PICC cathetering.
89543431|NCT04790331|Experimental|verapamil group|verapamil group who will receive verapamil 80 mg PO 3 hours preoperative
89543432|NCT04790331|Experimental|Ditiazim|Diltiazim group will receive Diltiazim 90mg PO 3 hours preoperative
89543433|NCT04790331|Experimental|placebo group|Placebo oral tablet
89543434|NCT03230201|No Intervention|Blank control|do not receive Lymph node dissection during surgery.
89543435|NCT03230201|Experimental|Lymph node dissection|will receive Lymph node dissection during radical nephroureterectomy.
89543436|NCT05613465|Experimental|intervention|Codonopsis pilosula Nnannf
89543437|NCT05613465|Placebo Comparator|Control group|Placebo
89543438|NCT03230279|Active Comparator|Sacroiliac joint fusion|The subject will receive a sacroiliac joint fusion
89543439|NCT03230279|Active Comparator|Sacroiliac radio frequency ablation|The subject will receive a sacroiliac joint radiofrequency ablation
89543440|NCT03230123|Experimental|Green banana biomass|The intervention group is constituted diet counseling plus 4.5 g of resistant starch from green banana biomass, per day, during six months.
89207471|NCT01095003|Active Comparator|Capecitabine single-agent|Capecitabine at the dose of 825mg/m² per os twice per day each morning and each evening for 14 consecutive days beginning on day 1 of each cycle repeated every 3 weeks (self-administered).
89543441|NCT03230123|Placebo Comparator|Diet alone|The control group will receive diet counseling during six months.
89543442|NCT04790097|Experimental|Simultaneous In-Field Boost on FET-PET positive target volumes|
89543443|NCT03230045|Experimental|Acupoint stimulation|Acupoint Zhongfu and Zusanli are stimulated by transcutaneous electrical stimulation
89543444|NCT03230045|Sham Comparator|no treatment|Electrodes are attached to Acupoint Zhongfu and Zusanli, but no stimulation is given
89543445|NCT04789941|Experimental|Single arm of patients with locally advanced cancer cervix|"Single arm study to assess the efficacy and safety of use of neoadjuvant cisplatin and irinotecan in treatment of patients with locally advanced cancer cervix.~A combined regimen of intravenous infusion of cisplatin 80mg/m2 on day 1 with irinotecan 60mg/m2 on day 1 and day 8 of every 21- day cycle for 3 cycles.~Then, MRI pelvis will be used for assessment of disease response. According to RECIST criteria, patients who will develop at least stable disease, will be sent for radical hysterectomy. Afterwards, 6 weeks after the surgery, another 3 cycles of the same regimen will be given to the participants as adjuvant treatment."
89543446|NCT02444819|Experimental|HM61713|Subjects who entered the study will be administered HM61713 800 mg per day.
88961102|NCT02611427|Active Comparator|Education/Self-efficacy|Booklet about physical activity, movement monitoring device, encouragement
88961103|NCT02611427|Active Comparator|Education|Booklet about physical activity
88961104|NCT02594319|Active Comparator|Control|Daily reporting of fruit and vegetable consumption
88961105|NCT02594319|Experimental|Daily reward|Incentives for fruit and vegetable consumption delivered daily
88961106|NCT02594319|Experimental|Delayed reward|Incentives for fruit and vegetable consumption delivered in a lump sum at the end of the intervention
88961107|NCT02582775|Experimental|CLOSED TO ACCRUAL Arm A: HCT with 300 cGy of TBI|Epidermolysis bullosa patients treated per study regimen with chemotherapy and stem cell transplant without mesenchymal stem cell infusions.
88961108|NCT02582775|Experimental|CLOSED TO ACCRUAL Arm B: HCT plus MSC, 300 cGy of TBI|Epidermolysis bullosa patients treated per study regimen with chemotherapy and hematopoietic stem cell transplant with mesenchymal stem cell infusions using 300 cGY of TBI.
89207472|NCT00854568|Experimental|CEOP regimen|CEOP regimen
89543447|NCT03079089|Other|Relapsed or refractory lymphoid hematological disorders|Patients in refractory or relapses with an indication of allo-HSC used the combination of an SET followed by the RIC with the PDLI
88961109|NCT02582775|Experimental|Arm C: Re-Transplant with 300 cGy of TBI|Epidermolysis bullosa patients treated regardless of original transplant arm with re-transplant using 300 cGy of TBI.
89024857|NCT04701320|Experimental|Glass carbomer|Nano hydroxyapatite Reinforced Glass Ionomer that results in chemical bond formation with tooth structure mimic that of enamel tissue
89543448|NCT02444897|Experimental|Epidural PCA group|Epidural patient-controlled analgesia group
89543449|NCT02444897|Active Comparator|IV PCA group|Intravenous patient-controlled analgesia
89543450|NCT03193775|Active Comparator|chronic HBV with persistent HBsAg|"inactive carriers (n=100). Group II: CHB exposed to nucleos(t)ides (n=120) till 6 months after HBe seroconversion and HBV DNA disappearance in HBeAg positive (n=60) or DNA disappearance in HBeAg negative patients (n=60). All showed persistent HBs antigenemia.~they were given 30 µg of HBV vaccine initiated 6 months after HBe seroconversion and disappearance of HBV DNA."
89543451|NCT03193775|No Intervention|control group|A control group (n=100) did not receive HBV vaccine
89543452|NCT03229733|Experimental|Experimental group|Patients randomized to the experimental group participate in exergames training with Kinect. The supervised OT chooses different games according to the patient's needs and abilities. During therapy patients are at sitting position. The game program will be adjusted when patients got improvement. After 30 minutes of exergames training, participants will receive a 30-minutes of traditional occupational therapy.
89207473|NCT00854568|Active Comparator|CHOP regimen|CHOP regimen
89514837|NCT05084781|Active Comparator|Mechanical Debridement|Standard mechanical debridement of rotator cuff footprint.
89543453|NCT03229733|Active Comparator|Control group|Patients in the control group will receive individually tailored traditional occupational therapy consisting of the similar movement and dose as the experimental group doing by using the traditional equipment, such as climbing bar.
89024858|NCT04701320|Active Comparator|Fuji ix|Conventional Glass Ionomer cement fluoride-releasing restorative system that combines fluoride release of glass ionomer cement and acceptable esthetics, a wear resistant, self-adhesive
89024859|NCT03270423|Active Comparator|Intervention SG|Therapy during 6 months with PathMate2 design. 6 therapy visits + PathMate2 over 6 months
89024860|NCT03270423|No Intervention|Control SG|Therapy during 6 months with usual care. 10 therapy visits over 6 months
89024861|NCT03270423|Active Comparator|Intervention VD|Adapted sport session 1h/week + PathMate-S during 6 months
89024862|NCT03270423|No Intervention|Control VD|Adapted sport session 1h/week during 6 months
89024863|NCT00438113|Active Comparator|Aggressive Blood Pressure control|"The experimental arm will receive open label therapy to achieve a target systolic blood pressure less than or equal to 120 mmHg.~If the average BP is found to be > 120 mmHg at the baseline, telephone or clinic followup visits, treatment will be recommended based on the following regimen (For details, please see Appendix 4):~Step 1 - Accupril, titrated to maximum tolerated dose, beginning at 20 mg po od followed by 40 mg successively Step 2 - combination of Accupril with Hydrochlorothiazide 12.5 mg po od. Step 3 - Addition of Atenolol 50 mg po od. Step 4 - Addition of Norvasc 2.5-10 mg po od. Step 5 - Addition of Terazosin 1 mg po od."
89024864|NCT00438113|No Intervention|Standard Blood Pressure control|Treatment will be carried out as per the CHEP guidelines. These patients may require ACEi or ARBs for their treatment. No changes to their drug regimen will be made as long as BP measurements are congruent with current guidelines. These modifications will be made as per standard practice by the physician who is primarily involved with their care (this may be a family physician or a specialist, depending on the patient). Patients with diabetes in the standard arm will be treated to a target BP of <130/80 as per the CHEP guidelines.
89024865|NCT00438152|Active Comparator|Invirase® tablets|
89024866|NCT00438152|Active Comparator|Kaletra® tablets|
89024867|NCT03279926|Experimental|PLAY|Preschoolers & their teachers will get activity trackers and the child care program/providers will get some basic information on the use of the trackers and how to integrate their use in the curriculum. A PLAY Champion will be identified to help support PLAY related activities.
89024868|NCT03279926|Experimental|PLAY Parents|Everything in Arm 1 plus one parent per child will receive an activity tracker and will get reports to help with physical activity goal setting for the family.
89024869|NCT03279926|Experimental|PLAY Teachers|Everything in Arm 1 plus an enhanced focus on teacher wellness, specifically with regard to active lifestyles for them.
89024870|NCT00474552|Experimental|1|Experimental-Placebo Comparator
89024871|NCT03279809|Experimental|Intervention|Intervention : aspirin medication Case with aspirin medication for 6 months after stenting
89024872|NCT03279809|Placebo Comparator|Control|Control : placebo medication Case with placebo medication for 6 months after stenting
89024873|NCT00474825|Active Comparator|1|Hyperbaric Oxygen twice weekly (Monday & Friday) with Radiation and Chemotherapy
89024874|NCT00474825|Active Comparator|2|Hyperbaric Oxygen three times per week (Monday, Wednesday & Friday) with Radiation and Chemotherapy.
89024875|NCT00474825|Active Comparator|3|Hyperbaric Oxygen Five times per week (Monday through Friday) with Radiation and Chemotherapy
89024876|NCT00438308||1|Subjects who begin therapy immediately after fracture.
89024877|NCT00438308||2|Subjects delay therapy for 3 weeks after injury.
89024878|NCT00438347||group 1|Intervention Group- aerobic exercise
89024879|NCT00438347||group 2|Control Group- stretching and toning
89024880|NCT00474981|Experimental|1|IMNCI
89024881|NCT00474981|No Intervention|2|Control
89024882|NCT00475059|Experimental|1|patients who received cimétidine
89024883|NCT00438425|Experimental|Intensive Portfolio|The portfolio dietary advice will conform to current therapeutic diets appropriate for hypercholesterolemic subjects (<7% of energy saturated fat, <200 mg/d cholesterol) plus the combination of viscous fibers, soy protein, plant sterols and nuts. The portfolio diet plan will include foods which contribute 9.8 g/1000 kcal viscous fiber as B-glucan (oats, barley, oat bran breads and soups) and psylliium (cereal), 0.94 g plant sterol/1000 kcal diet (in sterol margarine), 22.5 g soy protein/1000 kcal (soy burgers, dogs, links, other meat analogues, milks, yogurts and cheese) and 22.5 g nuts/1000 kcal. Participants received 7 visits during a 6-month period with the study dietitian.
89024884|NCT00438425|Experimental|Routine Portfolio|The portfolio dietary advice will conform to current therapeutic diets appropriate for hypercholesterolemic subjects (<7% of energy saturated fat, <200 mg/d cholesterol) plus the combination of viscous fibers, soy protein, plant sterols and nuts. The portfolio diet plan will include foods which contribute 9.8 g/1000 kcal viscous fiber as B-glucan (oats, barley, oat bran breads and soups) and psylliium (cereal), 0.94 g plant sterol/1000 kcal diet (in sterol margarine), 22.5 g soy protein/1000 kcal (soy burgers, dogs, links, other meat analogues, milks, yogurts and cheese) and 22.5 g nuts/1000 kcal. Participants received 2 visits during a 6-month period with the study dietitian.
89514838|NCT05084703|Experimental|Patients operated for previous shoulder instability|Different functionnal test to be done
89514839|NCT05084703|Active Comparator|Healthy volunteer|Different functionnal test to be done
89514840|NCT05081739|Active Comparator|Prospera Surveillance|Subjects will undergo Prospera testing in accordance with the institution's Control Group EMB surveillance standard of care schedule, which is expected to be approximately every other week months 2 and 3, then monthly through months 4 through 6, then every 1-3 months during months 7 through 12. Prospera test results will be provided to investigators. Prospera cfDNA level < 0.15 % will be interpreted as negative, and screening EMB will be omitted. EMB will be performed for cfDNA level ≥ 0.15 %. At any time, the clinical team may perform for cause EMB for standard clinical indications (e.g., evidence of graft failure) as per the treating team's discretion. Additional research blood samples will be collected for research purposes; the results of testing performed on research samples will not be provided to investigators.
89543454|NCT03229655|Experimental|Sequential stent addition|ERCP with sphincterotomy and stent placement is initially performed, then additional stents are placed across the stricture during sequential ERCPs, without stent removal/exchange or stricture dilation.
89543455|NCT03229655|Active Comparator|Incremental Dilation & Stent Exchange|ERCP with sphincterotomy and stent placement is initially performed, with subsequent ERCPs involving removal of previously placed stents, stricture dilation and balloon sweeps to extract stone debris/sludge.
89543456|NCT05472285|Active Comparator|Verum|2 capsules per day during 8 weeks
89543457|NCT05472285|Placebo Comparator|Placebo|2 capsules per day during 8 weeks
89543458|NCT03229889|Active Comparator|Flomax + Placebo|Patients will be prescribed Flomax 0.4Mg Capsule and given a bottle of placebo. They will be instructed to take 1 of each pill for the seven days prior to their surgery.
89543459|NCT03229889|Active Comparator|Cialis + Placebo|Patients will be prescribed Cialis 5Mg tablet and given a bottle of placebo. They will be instructed to take 1 of each pill for the seven days prior to their surgery.
89543460|NCT03229889|Active Comparator|Cialis + Flomax|Patients will be prescribed .4mg of Flomax and 5mg of Cialis. They will be instructed to take 1 of each pill for the seven days prior to their surgery.
89543461|NCT03229889|Placebo Comparator|Placebo + Placebo|Given 2 bottles of placebo. They will be instructed to take 1 of each pill for the seven days prior to their surgery.
89543462|NCT04789629|Active Comparator|low level laser , physiotherapy|Instrumentation Diode laser device will use for biostimulation of the muscle fiber . The device has a wavelength of 808 nm and a power output 0-250 mW. parameters of laser : Wavelength 808 nm Power output 100 mW Spot size 0.0314 cm2 Power density 3,18 W/cm2 Treatment time per point 40 s Energy density per point 4,77 J/cm2 Energy per point 4 J 12 sessions for one month with traditional physiotherapy ( stretching , strenghthing exercises , trunk control , balance training , standing exercises , gait training .)
89543463|NCT04789629|Active Comparator|physiotherapy|traditional physiotherapy ( stretching , strenghthing exercises , trunk control , balance training , standing exercises , gait training ) for one hour
89543464|NCT02444585|Experimental|Denosumab|Drug for prevention of bone loss
89543465|NCT02444585|Placebo Comparator|Control|Hip Replacement Patient without Drug
89543466|NCT03120221||First trimester pregnant women|
89543467|NCT05472129||Cases|"Cases were defined, with respect to bowel, bladder or prolapse symptoms using the question: How much do your symptoms bother you? and the following choice of answers: Not applicable - I do not have symptoms, not at all, a little, quite a lot and very much."
89543468|NCT05472129||Control|"Controls were identified as women answering Not applicable - I do not have symptoms or not at all, otherwise patients were defined as cases."
89543469|NCT03193073|Active Comparator|CKD patients with different stages|"Full clinical history and through clinical examination.~Full blood count at time of diagnosis and 3 months after initiation of treatment with iron and erythropoietin Stimulating agents.~Iron study at time of diagnosis and 3 months after treatment .~Serum calcium , phosphorus, intact Parathrmone hormone. 5-24- urinary proteins or Albumin Creatinine ratio every month (for 3 months )then every 3 months (1 st year), then annually.~6- Lipid profile . 7-Estimated glomerular filtration rate by MDRD equation ."
89543470|NCT03193073|Active Comparator|Newly renal transplanted patients .|"Full clinical history and through clinical examination.~Pre transplant Serum calcium , phosphorus , I Parathrmone hormone , serial measures every / 3 months for 2 years.~Pre-transplant full blood count serial measures every / 3 months for 2 years.~Pre transplant serum Iron study and annually for 2 years.~24- urinary proteins or albumin-creatinine ratio every month (for 3 months )then every 3 months (1 st year), then annually.~Post-transplant serum FGF-23 (as independent risk factor) at 6months.~Different immunosuppressive protocols.~Pre-transplant panel reactive antibody,donor-specific antibody"
89543471|NCT02444507|Active Comparator|Reference Drug: Nexium|Name: Nexium powder for injection and infusion 40 mg, Active substance: Esomeprazole 40 mg, Each single dose of esomeprazole 40 mg will be administrated as intravenous infusion over 30 minutes.
88961110|NCT02582775|Experimental|Arm D: HCT with 200 cGy BID of TBI|HLA-matched epidermolysis bullosa patients treated with hematopoietic cell transplant alone using 200 cGY BID of TBI (400 cGy total).
88961111|NCT02582775|Experimental|Arm E: HCT plus MSC, 200 cGy BID of TBI|HLA-matched epidermolysis bullosa patients treated with hematopoietic cell transplant plus serial MSC infusions using 200 cGY BID of TBI (400 cGy total)
88961112|NCT02582775|Experimental|Arm F: HCT Alone, 200 cGy BID of TBI|HLA-mismatched epidermolysis bullosa patients treated with hematopoietic cell transplant alone using 200 cGy BID of TBI (400 cGy total) + addition of low dose busulfan for recipients of HLA-mismatched bone marrow
88961113|NCT02582775|Experimental|Arm G: HCT plus MSC, 200 cGy|HLA-mismatched epidermolysis bullosa patients treated with hematopoietic cell transplant plus serial MSC infusions using 200 cGy BID of TBI (400 cGy total) + addition of low dose busulfan for recipients of HLA-mismatched bone marrow
88961114|NCT02561221|Experimental|Lifestyle Counseling|Patients in the Lifestyle Counseling Arm attended weekly (16 in-person) sessions in the first six months, followed by monthly sessions for the remaining 18 months. The behavioral intervention was delivered by a trained health coach embedded in the primary care clinic. Primary Care Practitioners in the experimental arm received a series of webinars on obesity science to help them manage and treat patients with obesity.
88961115|NCT02561221|No Intervention|Usual Care|Patients assigned to the usual care arm continued to interact with their Primary Care Practitioners according to their usual schedule, and received a series of newsletters on topics of interest, including importance of sleep for health, brain and memory health, goal setting, smoking cessation, etc. Primary Care Practitioners in the usual care arm received a webinar describing the current Centers for Medicare and Medicaid (CMS) approach to reimbursing for obesity treatment, and a reminder informational brochure was sent to the Primary Care Practitioners each year.
88961116|NCT02515760|Experimental|Lung cancer group|Bone marrow puncture in patients with non-small cell lung cancer
88961117|NCT02515760|Experimental|Control group (healthy donors)|Bone marrow puncture in healthy donors
88961118|NCT02506517|Experimental|Afatinib|Afatinib, orally, at a dose of 40 mg once a day, every day of each 28 day cycle.
88961119|NCT02499835|Experimental|Arm I (pTVG-HP plasmid DNA vaccine, concurrent pembrolizumab)|Patients receive pTVG-HP plasmid DNA vaccine ID every other week on days 1, 15, 29, 43, 57, and 71 and pembrolizumab IV over 30 minutes every 3 weeks on days 1, 22, 43, and 64.
89024885|NCT00438425|Active Comparator|Control|Advice focused on low-fat dairy and whole grain cereals together with fruit and vegetables as part of a low fat vegetarian diet, and avoidance of the specific portfolio components.
89024886|NCT00475098|Active Comparator|A|
89024887|NCT00475098|Experimental|B|
89024888|NCT00475137|Experimental|Lamotrigine Plus Antidepressant|Subjects will be randomized to one of two study arms at baseline. Those in the first treatment arm will be prescribed lamotrigine in addition to the antidepressant medication they were prescribed prior to study entry.
89024889|NCT00475137|Active Comparator|2. Lamotrigine Monotherapy|Subjects in the second treatment arm will discontinue their antidepressants and will be prescribed lamotrigine monotherapy. Lamotrigine will be initiated at 25mg daily for two weeks, then increased to 50mg daily for one week, and then increased to 100 mg daily. The dose may then be adjusted upward or downward by 50-100mg weekly, at the investigator's discretion, provided that it remains within the protocol defined range of 100mg - 400mg daily.
89024890|NCT00438698|Experimental|Low Glycemic Index Diet|Diet with low glycemic index carbohydrates
89024891|NCT00438698|Active Comparator|High Fiber Diet|Diet with high cereal fibre choices
89024892|NCT00475293|Experimental|1|
89024893|NCT00475371|Experimental|1|MKC253 Inhalation Powder
89024894|NCT00438776|Active Comparator|olanzapine|active zyprexa (olanzapine)
89024895|NCT00438776|Placebo Comparator|sugar pill|Placebo (fake pill)
89024896|NCT00475410|Experimental|ASCs|
89024897|NCT00475410|Experimental|ASCs+fibrin glue|
89024898|NCT00475410|Active Comparator|Fibrin glue|
89024899|NCT00438893|Other|A portfolio of cholesterol-lowering foods|Dietary advice to consume a dietary portfolio of cholesterol-lowering foods
89024900|NCT00475527|No Intervention|iron only|Only iron therapy
89024901|NCT00475527|Experimental|iron + HP therapy|Iron + 'omeprazole,clarithromycin,amoxicillin (or metronidazole)
89514841|NCT05081739|No Intervention|EMB Surveillance|Subjects will undergo surveillance EMB per the institution's standard clinical care, which is expected to be approximately every other week months 2 and 3, then monthly through months 4 through 6, then every 1-3 months during months 7 through 12. Research blood samples will be obtained at the time of each EMB. At any time, the clinical team may perform for cause EMB for standard clinical indications (e.g., evidence of graft failure) as per the treating team's discretion. Research blood samples will be collected for research purposes; the results of testing performed on research samples will not be provided to investigators.
89514842|NCT03523637|Experimental|Pain Education/Interoceptive Exposure|This study will evaluate the effects of IE and will briefly comprises of: education session explaining the rationale behind IE practice, teaching of the technique, supervised IE practice and self-monitored home practice twice daily for the period of two weeks.
89514843|NCT02244580|Experimental|MammaTyper™|MammaTyper™ kit will be used tio assess tumor material of patients enrolled into the FinHer trial.
89514844|NCT05073939|Experimental|Oral Oxytocin|Oxytocin orally (24 IU)
89514845|NCT05073939|Placebo Comparator|Oral Placebo|Placebo orally (identical ingredients, except the active agent)
89514846|NCT05065125||LDLT cohort|Living-donor liver transplatation (LDLT) patients with anastomotic biliary stricture
89514847|NCT03521843|Experimental|balloon dilation only|The balloon dilation only will be used to treat the femoropopliteal in-stent restenosis.
89514848|NCT03521843|Experimental|balloon dilation+local drug delivery|The balloon dilation and local drug delivery will be used to treat the femoropopliteal in-stent restenosis.
89514849|NCT02244424|Experimental|Tools for Teen Moms Intervention Group|Tools for Teen Moms intervention group will receive daily challenges focusing on: 1) Maternal-Infant Feeding Interaction; and 2) Feeding Practices Challenges. The challenges will cycle through a pre-determined schedule where they are automatically updated each day at midnight. Participants will have a 24-hour period to complete each challenge. The intervention will provide a new daily challenge over six weeks, a time frame selected to provide participants with enough opportunities to form the habit of visiting the website daily. Participants will continue to receive usual MIHP care during the intervention.
89024902|NCT00475566|Other|1|This is a prospective, non-randomized, single-arm, multi-center study. A projected 100 patients will receive the stent(s) in this study at approximately 10-15 European sites. The primary objective is to evaluate the safety and performance of the Dynalink®-E everolimus eluting peripheral stent system for the treatment of patients with atherosclerotic de novo or restenotic native superficial femoral or proximal popliteal lesions.
89024903|NCT00475605||1. Protopic Exposure|Pediatric subjects whose ages are/were <16 years at the time of first tacrolimus ointment exposure
89024904|NCT00439166|Experimental|1 AD combined doxycycline + rifampin|Doxycycline 100 mg b.i.d. plus rifampin 300 mg o.d. for 12 months.
89024905|NCT00439166|Experimental|2 AD Doxycycline only|Doxycycline 100 mg b.i.d. plus placebo matched to rifampin o.d. for 12 months.
89024906|NCT00439166|Experimental|3 Rifampin only|Rifampin 300 mg o.d. plus placebo matched to doxycycline b.i.d. for 12 months.
89024907|NCT00439166|Placebo Comparator|4 Double Placebo|Placebo matched to Doxycycline b.i.d. plus placebo matched to rifampin o.d. for 12 months.
89024908|NCT00439205||MDM + FastEEM4|Multispectral digital microscope (MDM) + FastEEM4 Systems
89024909|NCT00475683|Sham Comparator|regular measurments|Mouth wash with chlorexidin
89024910|NCT00475683|Experimental|Curucmol|mouth wash with curcumol and mouth wash with chlorexidin
89024911|NCT00439322||Group 1|
89024912|NCT00475839|Active Comparator|Tension-free Vaginal Tape|
89024913|NCT00475839|Active Comparator|Monarc Sub-fascial hammock|
89024914|NCT00439361|Experimental|Bortezomib + ICE|"Bortezomib + ICE (Ifosfamide, Carboplatin, Etoposide):~Bortezomib 1.0 mg/m^2 intravenous (IV) over 5 Seconds on Days 1 and 4; + ICE (Ifosfamide 5 Gm/m^2 IV continuous infusion on Day 1, Carboplatin 5 AUC IV over 1 Hour Day 1, Etoposide 100 mg/m^2 IV over 2 Hours Days 1-3) + Mesna 5 mg/m^2 IV continuous infusion Day 1; 2 Gm/m^2 IV continuous infusion over 12 Hours."
89024915|NCT00475917|Experimental|1|
89024916|NCT00474669|Experimental|Docetaxel|Intraperitoneal Docetaxel administered with heat
89024917|NCT00439400|Active Comparator|A|
89024918|NCT00439400|Placebo Comparator|B|
89024919|NCT00475956|Experimental|1|AZD2171 Monotherapy
89024920|NCT00475956|Experimental|2|AZD2171 + AZD0530
89024921|NCT00439439|Sham Comparator|A|Sham Procedure
89024922|NCT00439439|Active Comparator|B|Verum Beamer ablation of heterotopic gastric mucosa
89024923|NCT00439595|Experimental|1|Hemocue 210 meter
89024924|NCT00439595|Experimental|2|Copack HBCS
89024925|NCT00439595|No Intervention|3|Control
89514850|NCT02244424|No Intervention|MIHP standard care|MIHP care consists of voluntary home visits: one week postpartum, at six weeks, and six months, and on-going as needed provided by a RN, licensed social worker, RD, infant mental health specialist and/or paraprofessional. Content includes a flexible plan of care with visits based on identified domains for both the mother and the infant.
89514851|NCT03523481||NHF use|
89514852|NCT04206982|Experimental|Marshall Plan arm|Patients will undergo (1) the destruction of Marshall bundles by ethanol infusion followed by ablation of the distal coronary sinus bundles, the ridge and the saddle; (2) the standard pulmonary veins sleeves isolation; (3) and finally the ablation of the mitral, the roof, and the cavo-tricuspid isthmus.
89514853|NCT04206982|Active Comparator|Pulmonary vein isolation arm|
89514854|NCT03521765|Experimental|OT intervention group|The OT intervention group were given a consultation based on a CRC education handbook by an occupational therapist for discharge preparation and on 1-month, 3-month follow-up clinic.
89514855|NCT03521765|No Intervention|non-intervention group|The non-intervention group participants were given a CRC education handbook (the same handbook) only for discharge preparation.
89514856|NCT05254301|Experimental|Personalized multimodal treatment|A combination of biometric parameter oriented nutritional counseling and a tailored physical training program.
89514857|NCT05254301|Active Comparator|Standard care|Physiotherapy with standard care advice for gradual cardiorespiratory and resistance training. (In this standard care setting, nutritional screening nor counseling is included.)
89514858|NCT05433610|Experimental|Constant Treadmill Load Test (CTLT) using non-invasive ventilation (NIV)|Exercise capacity testing using PS in HF patients
89514859|NCT05433610|Experimental|Constant Treadmill Load Test (CTLT) using NIV|Exercise capacity testing using CPAP in HF patients
89514860|NCT05433610|Active Comparator|Constant Treadmill Load Test (CTLT) without NIV|Exercise capacity testing without NIV in HF patients
89514861|NCT04192630|Experimental|CVisc50 Ophthalmic Viscosurgical Device (OVD)|CVisc50 OVD will be carefully injected into the anterior chamber using standard aseptic technique, during the surgical procedure. The duration of the treatment is anticipated to be approximately 15-20 minutes for the surgical procedure. The OVD may also be used to coat surgical instruments prior to Intraocular Lens (IOL) implantation (for example, the internal surfaces of an IOL inserter are typically filled and/or coated with the OVD to provide lubricity during IOL compression and delivery into the eye). Additional OVD of the same product, may be injected as needed throughout surgery to keep the anterior chamber fully formed and to re-inflate the capsular bag following cataract removal. At the end of the surgical procedure it is recommended that OVD be removed from the eye as completely as practical by thoroughly irrigating and aspirating with a sterile irrigating solution.
89514862|NCT04192630|Active Comparator|ProVisc OVD|ProVisc OVD will be carefully injected into the anterior chamber using standard aseptic technique, during the surgical procedure. The duration of the treatment is anticipated to be approximately 15-20 minutes for the surgical procedure. The OVD may also be used to coat surgical instruments prior to IOL implantation (for example, the internal surfaces of an IOL inserter are typically filled and/or coated with the OVD to provide lubricity during IOL compression and delivery into the eye). Additional OVD of the same product, may be injected as needed throughout surgery to keep the anterior chamber fully formed and to re-inflate the capsular bag following cataract removal. At the end of the surgical procedure it is recommended that OVD be removed from the eye as completely as practical by thoroughly irrigating and aspirating with a sterile irrigating solution.
89514863|NCT00159783|Experimental|Asenapine|Asenapine 5-10 mg twice daily for 40 weeks
89514864|NCT00159783|Active Comparator|Olanzapine|Olanzapine 5-20 mg once daily for 40 weeks
89514865|NCT04682067|Experimental|Contingency Management|Participants in the contingency management (CM) treatment arm will receive the usual care (UC) treatment program offered at the Tobacco Treatment Research Program (TTRP) and will be eligible to earn gift cards at each weekly visit on their quit date up until four weeks post-quit for proof of abstinence. They will earn $20 in gift cards for quitting on the specified quit day (i.e., one week after the orientation visit), and this amount will increase by $5 with each successive weekly abstinent visit (i.e., up to $40 in gift cards at 4 weeks post-quit; up to $150 total).
89514866|NCT04682067|Placebo Comparator|Usual Care|Participants in the usual care (UC) group will receive the standard smoking cessation treatment offered at the Health Promotion Research Center's Tobacco Treatment Research Program (TTRP) at the University of Oklahoma. This includes at least 4 treatment sessions of counseling and the opportunity to use nicotine replacement therapy or medications.
89514867|NCT01023737|Experimental|Hydroxychloroquine and Vorinostat|Oral administration of Vorinostat will be begin on Cycle 1 Day 1 at 300mg and will be continued daily and HCQ will be administered starting on Day 2 of Cycle 1 and both will be continued daily thereafter until progression of disease or unacceptable toxicity develops.
89514868|NCT03523403|Experimental|Acute phase - intervention|Participants will be asked to consume 3 whole apples and a high-fat meal (a mixture of commercially available whipping cream and milk, providing 1 g of fat per kg of body weight) within 30 minutes.
89514869|NCT03523403|No Intervention|Acute phase - control|Participants will be asked to consume a high-fat meal (a mixture of commercially available whipping cream and milk, providing 1 g of fat per kg of body weight) within 30 minutes.
89514870|NCT03523403|Experimental|Chronic phase - intervention group|Participants will be asked to consume 3 whole apples per day for 6 weeks.
89024926|NCT00476112|Experimental|1|Atrial flutter duration of 3 hours to <45 days
89024927|NCT00476268|Experimental|beclometasone /formoterol|beclomethasone dipropionate 100 µg plus formoterol 6 µg pMDI
89024928|NCT00476268|Active Comparator|Beclomethasone|Beclomethasone dipropionate (BecotideTM) 250 µg/unit dose pMDI aerosol via CFC propellant.
89024929|NCT00476268|Active Comparator|Formoterol powder 12 µg/unit dose|Formoterol powder 12 µg/unit dose (Foradil™)
89024930|NCT00105989|Experimental|A|duloxetine 60-120 mg every day (QD), by mouth (PO) for 34 weeks followed by duloxetine 60-120 mg QD, PO for up to 54 weeks
89024931|NCT00105989|Placebo Comparator|B|duloxetine 60-120 mg every day (QD), by mouth (PO) for 34 weeks followed by placebo QD, PO for up to 54 weeks
89514871|NCT03523403|No Intervention|Chronic phase - control group|Participants will be asked to consume no apples per day for 6 weeks.
89514872|NCT04136314|Experimental|Gain-Frame Survey [A]|
89024932|NCT00476346|Active Comparator|Calcium|Daily calcium supplementation Intervention: Calcium 2000mg / daily
89024933|NCT00476346|Experimental|Vitamin D|Daily Calcium and Vitamin D supplementation Intervention: Vitamin D 800IU / daily
89024934|NCT00476385|Experimental|somatropine|
89024935|NCT00476424|Active Comparator|1|400 mg EFV
89514873|NCT04136314|Experimental|Loss-Frame Survey [B]|
89514874|NCT00646204|Experimental|1-Active study drug|memantine 10 mg bid
89514875|NCT00646204|Placebo Comparator|2-placebo comparator|2 tabs bid
89514876|NCT03140007|Other|Control arm - ERCP arm|Control arm- If a patient is randomized to the Control arm, then the procedure will consist of the following: ERC with recording of ERC-based impression of malignancy .ERC-guided biopsies will be collected, consisting of 6 macroscopically visible biopsies. The biopsy forceps / brush will be selected per investigator preference. ERC-guided brushing will be performed, consisting of 10 through-and-fro passes through the target lesion. After this a biliary stent will be placed under ERC-guidance if needed. A biliary sphincterotomy will be performed as needed
89514877|NCT03140007|Active Comparator|Study arm - cholangioscopy arm|If patient is randomized to the Study arm, then the procedure will consist of the following in order: Cannulation and sphincterotomy per standard of practice. POCS with recording of POCS-based impression of malignancy (yes/no/indeterminate). POCS will be performed using the Spy DS system. POCS-guided biopsies will be collected, consisting of 6 macroscopically visible biopsies. The POCS-guided biopsy forceps will be the SpyBite forceps.
89514878|NCT04128904|Active Comparator|Standard in vitro fertilisation (IVF)|"Oocytes are fertilised with standard IVF. For details please see Project Description."
89514879|NCT04128904|Active Comparator|Intracytoplasmic sperm injection (ICSI)|"Oocytes are fertilised with ICSI. For details please see Project Description."
89514880|NCT02936323|Experimental|Phase 1: Dose Escalation|"Cohort 1 will consist of two (2) participants who will receive PEN-221 at the starting dose of 1.0 mg. The first participant will be followed for at least 7 days for safety and dose limiting toxicity (DLT). If PEN-221 is tolerated, the second participant will be enrolled into the cohort. The two (2) participants will be followed for safety and DLTs for at least a 4-week observation period. The Safety Review Committee (SRC) will determine the initiation of cohort 2.~Cohort 2 and each subsequent dose escalation cohort will consist of 3 to 6 participants who will be treated at each dose level of PEN-221 as determined by the SRC and will be followed for safety and DLTs for at least a 3-week observation period. Each dose escalation level and cohort initiation will be determined by the SRC.~Dose escalation will continue until the Maximum Tolerated Dose (MTD) of PEN-221 is determined and the Recommended Phase 2a Dose (RP2D) is established by the SRC."
89514881|NCT02936323|Experimental|Phase 2a: Dose Expansion (GI mid-gut NET)|Gastrointestinal mid-gut NET Cohort
89514882|NCT02936323|Experimental|Phase 2a: Dose Expansion (PNET)|Pancreatic NET Cohort
89514883|NCT02936323|Experimental|Phase 2a: Dose Expansion (SCLC)|Small Cell Lung Cancer Cohort
89514884|NCT04596891|Experimental|Intervention|Remotely delivered psychotherapy combining exposure therapy with mindfulness
89514885|NCT04590573|Experimental|CBCT|Cognitive behavioural couple therapy (CBCT), 5-session
89514886|NCT04590573|Experimental|EFCT|Emotion focused couple therapy (EFCT), 5-session
89514887|NCT04590573|Active Comparator|Control|Social activity wait-list groups (Control), 5-session
89514888|NCT05044221||Interviews: Past ICU patients and caregivers|Former ICU patients and their families that meet the following criteria: Adults > 18 years and above who required at least 48 hours of invasive mechanical ventilation and were in the ICU at least 4 days with an ICU admission in the past five years; and able to participate in a workshop in English.
89514889|NCT05044221||Interviews: Health care professionals|Active working health professionals with prior experience working directly in the ICU setting and/or care for ICU patients in their own clinical rea (acute, subacute and/or community settings).
89514890|NCT04770064|Experimental|High-dose/short-duration Fisetin (FIS-hi)|
89514891|NCT04770064|Experimental|Low-dose/sustained duration Fisetin (FIS-lo)|
89514892|NCT04770064|Placebo Comparator|Placebo|
89514893|NCT05393349|Experimental|Intervention Group|
89514894|NCT05393349|No Intervention|Standard Group|
89514895|NCT03474523|Experimental|Experimental or Diathermy-Radiofrecuency|All patients are given a Combined Physiotherapy Protocol (CPP) consisting of: Diathermy-Radiofrecuency (manual 70% intensity of about 40-43º resistive modality for about 30 minutes and authomatic capacitive modality for about 10 minutes) and application of Presotherapy (intensity 35%, compression 35seg, pause 15 seg, speed 9, for about 30 minutes). Non-invasive treatment
89514896|NCT03474523|Active Comparator|Control or Cavitation|All patients are given a Combined Physiotherapy Protocol (CPP) consisting of: Cavitation (plane electrode for about 30 minutes and focal electrode for about 10 minutes) at 70% intensity and application of Presotherapy (intensity 35%, compression 35seg, pause 15 seg, speed 9, for about 30 minutes). Non-invasive treatment
89514897|NCT03584477|Active Comparator|Conventional rehabilitation|5 sessions / week of 1 hour of occupational therapy
89514898|NCT03584477|Active Comparator|Robotic rehabilitation with assistance|5 sessions / week of 1 hour of rehabilitation of the upper limb with 30 min of conventional rehabilitation and 30 min of robotic rehabilitation with assistance.
89514899|NCT03584477|Active Comparator|Non-assistance robotic rehabilitation|5 sessions / week of 1 hour of rehabilitation of the upper limb including 30 min of conventional rehabilitation and 30 min of robotic rehabilitation without assistance.
89514900|NCT02243176|Experimental|Saxagliptin|The dose of saxaglitpin will be 5mg oral qd. An estimated total of 480 patients (240 per treatment arm) will be randomized in a 1:1 ratio to the active treatment arm and the active comparator arm. So estimated 240 patients will be allocated to this arm.
89514901|NCT02243176|Active Comparator|Acarbose|Patients who take acarbose will begin with 50mg tid for 7 days then be titrated to 100mg tid till the end of the study. A call visit (V5) will be performed at Week 1 for adverse event and reminding patients the dose titration of acrabose. An estimated total of 480 patients (240 per treatment arm) will be randomized in a 1:1 ratio to the active treatment arm and the active comparator arm. So estimated 240 patients will be allocalted to this arm.
89024936|NCT00476424|Active Comparator|2|600 mg EFV
89543472|NCT02444507|Active Comparator|Test Drug: Esomelone|Name: Esomelone Powder for Solution for Injection / Infusion 40 mg Active substance: Esomeprazole 40 mg, Each single dose of esomeprazole 40 mg will be administrated as intravenous infusion over 30 minutes.
89543473|NCT03118271|Active Comparator|lumbar traction|Treatment with lumbar traction is via an OPD base. It comprised a 20 min. treatment session over a period of 2 months. If the symptoms subside before the end of 2 months' treatment, lumbar traction will be discontinued, and the treatment duration and number of treatment session will be recorded. The frequency of treatment is 3 times per week. Treatment method is according to the common clinical guidelines, starting from 25% of the subject's body weight and steadily increasing to 50% of body weight. Before traction, heat therapy will be applied to the low back of the subject, and electric therapy will also be given to the painful areas. The treatment will be conducted by the same physiotherapist.
89543474|NCT03118271|Active Comparator|spinal manipulation|Spinal manipulation will be performed by a spinal manipulator (Dr. Tso-Liang Wang) who was graduated from Los Angeles College of Chiropractic. Before performing spinal manipulation, he will exam the patient's whole body throughly, especially focusing on the lumbo-pelvic-hip region. What he exams includes pelvic and spinal alignment, tension of soft tissues, tissue texture, joint mobility, movement patterns, and muscle power. The manipulation is started with release of the hypertonic myofascial structures and thus normalize the myofascial tension of the lumbo-pelvic-hip region. Then he will align the lumbar spine, pelvis and hip joint three-dimensionally according to the findings of his examination on the same day. The manipulation will be performed up to 8 times within one month (no more than 2 manipulations a week). If the symptoms subside before the end of one-month' treatment, the manipulation is discontinued and the number of treatment session will be recorded.
89543475|NCT03118271|Active Comparator|surgery|General anesthesia, the patient will be put in the prone and abdomen-free position. A 4-cm midline longitudinal incision will be made over the spinous processes of the L3-5 levels. It will be deepened through the fat and fascia in line with the skin incision to reach the spinous processes.The paraspinous muscles will be dissected subperiosteally down the spinous processes and along the lamina to the facet joints. Laminectomy will be done carefully at the herniated disc level for posterior decompression. The ligamentum flavum will be excised to expose the dural sac.Using blunt dissection, the investigators carefully continue down the lateral side of the dura to the floor of the spinal canal; the investigators retract the dura and its nerve root medially. After the posterior aspect of the disc space is revealed, the affected disc will be removed and discotomy will be performed.The wound will be closed in the routine fashion after meticulous hemostasis and normal saline irrigation.
89543476|NCT03118427|Experimental|Zero-fluoroscopy implantation|Pacemaker implantation performed for all patients in this group with zero-fluoroscopy 3D navigation.
89543477|NCT03118427|Active Comparator|Conventional fluoroscopy implantation|Pacemaker implantation performed for all patients with conventional x-ray navigation.
89543478|NCT05472051||Young girls housekeepers|Malian young girls migrating from rural areas towards Bamako to seek for a job as housekeepers. Include young girls aged at least 12 years.
89543479|NCT02444195|Experimental|Guided Imagery|Guided Imagery With Audio Media
89543480|NCT02444195|No Intervention|Routine Postoperative Care|Subjects will receive routine pre-operative, intra-operative, post-operative, chemotherapy, and radiation care as dictated by pathologic diagnosis.
89543481|NCT04789317||Stable CAD or stabilized NSTEMI (ACS) with significant epicardial lesions defined as FFR≤0.80.|The PPG Global Registry an investigator-initiated, observational, multicenter study of patients with an indication for PCI based on coronary angiography and FFR ≤0.80. After confirmation of intention to treat with PCI, a manual pullback with PPG analysis will be performed. A second level of decision making is then performed concerning PCI, coronary artery bypass grafting (CABG) or medical therapy (OMT). Patients will undergo PCI at operator discretion and post-PCI FFR will be measured. Clinical follow-up will be performed at 1, 2 and 3 years.
89543482|NCT02177812|Experimental|Dose Escalation Phase (Part 1)|The safety and PK/PD data will be reviewed prior to the dose decision, and the dose escalation will be guided by the Neuenschwander -continuous reassessment method (N-CRM).The dose escalation will complete when RP2D is determined. The RP2D will be the MTD or a lower dose that provides adequate PK exposure and biologic activity with superior tolerability.
89543483|NCT02177812|Experimental|Expansion Phase (Part 2)|Once the MTD and/or RP2D has been determined in Part 1, an expansion cohort of up to 30 subjects will be enrolled in order to characterize the clinical activity and safety profile of the RP2D. Subjects may continue treatment in the study until disease progression, unacceptable toxicity, or withdrawal of consent.
89543484|NCT02203305|Experimental|Cochlear Implant|Cochlear implantation of the affected ear
89543485|NCT02203305|Other|Control Group|A control group without the study intervention (cochlear implantation) will complete the test battery.
89543486|NCT02203305|Experimental|Cochlear Implant: Asymmetric hearing loss|Cochlear implantation of the poorer hearing ear
89207474|NCT00854646|Experimental|ON 01910.Na|The starting dose is 650 mg/m2 per day for 3 continuous days every 2 weeks. In successive courses, infusion time may be increased by 1 day up to 7 days every two weeks and/or drug dose may be increased (650, 1050, 1700 mg/m2/day, etc.). After 4 2-week cycles, cycle length may be extended to 3 or 4 weeks. Treatment continues until evidence of disease progression, intolerable adverse events or withdraw of consent.
89207475|NCT00856362|Experimental|1|
89543487|NCT01626352|Experimental|Bendamustine/Ofatumumab|All patients in this study will receive ofatumumab and bendamustine as an IV infusion for 6 cycles (a cycle is defined as 21 days in length). Patients will receive as an IV infusion of bendamustine Days 1 and 2 of Cycles 1-6, ofatumumab Days 1 and 8 during Cycle 1 only and on Day 1 of Cycles 2-6.
89024937|NCT00439712|Experimental|Treatment Group 1|
89024938|NCT00439712|Placebo Comparator|Treatment Group 2|
89024939|NCT00476463|Active Comparator|1|AZT+FTC+EFV
89024940|NCT00476463|Active Comparator|2|TDF+FTC+EFV
89024941|NCT00439751|Other|Immediate ADT|
89024942|NCT00439751|Other|Deferred ADT|
89024943|NCT00438243|Placebo Comparator|1|1 drop affected eye twice daily.
89024944|NCT00438243|Experimental|2|Bromfenac (Xibrom) 1 drop to affected eye twice a day.
89024945|NCT00439829|Experimental|1|Initiation of ovarian stimulation therapy on day 1 (i.e., first day of menses)
88961120|NCT02499835|Experimental|Arm II (pTVG-HP plasmid DNA vaccine, sequential pembrolizumab)|Patients receive pTVG-HP plasmid DNA vaccine ID as in Arm I and pembrolizumab IV over 30 minutes every 3 weeks on days 85, 106, 127, and 148.
89514902|NCT03432715|Experimental|Wellness Champions for Change + Students|Schools randomized to the WCC+S arm will receive both the Teacher Intervention and the Student Wellness Champion Intervention.
89514903|NCT03432715|Experimental|Wellness Champions for Change|Schools randomized to the WCC+S arm will receive only the Teacher Intervention.
88961121|NCT02499835|Experimental|Extended Treatment Arm III|pTVG-HP (100 μg) with rhGM-CSF (208 μg) administered intradermally (i.d.) every 3 weeks, for a maximum of 16 doses. Pembrolizumab 2 mg/kg, with a maximum dose of 200 mg, administered intravenously every 3 weeks, for a maximum of 16 doses, beginning on day 1 after the first pTVG-HP vaccination.
88961122|NCT02499835|Experimental|Extended Treatment Arm IV|pTVG-HP (100 µg) with rhGM-CSF (208 µg) administered intradermally (i.d.) every 2 weeks, for a maximum of 24 doses Pembrolizumab 2 mg/kg, with a maximum dose of 200 mg, administered intravenously every 4 weeks, for a maximum of 12 doses, beginning on day 1 after the first pTVG-HP vaccination
88961123|NCT02460497|Experimental|Treatment|
88961124|NCT02460289|Experimental|Treatment|
89514904|NCT03432715|No Intervention|Control|The control group will not receive either intervention. Schools will be given a modified SWC curriculum as well as the teacher training at the end of the data collection period.
89514905|NCT04551261|Experimental|Part A|Subjects will receive GLS4 and RTV on Day 1, TAF on Day 5-14, GLS4 and RTV and TAF on Day15.
89514906|NCT04551261|Experimental|Part B|Subjects will receive TAF on Day 1, GLS4 and RTV on Day 5-14, GLS4 and RTV and TAF on Day15.
88961125|NCT02405221|Experimental|TA-CIN administration via thigh|Each dose of TA-CIN vaccine is fixed, 100µg. Patients will receive 3 doses of the TA-CIN 4 weeks apart (Weeks 1, 5, and 9), administered in the thigh. Patients will be followed for 2 years after the 1st dose is given.
88961126|NCT02405221|Experimental|TA-CIN administration via arm|Each dose of TA-CIN vaccine is fixed, 100µg. Patients will receive 3 doses of the TA-CIN 4 weeks apart (Weeks 1, 5, and 9), administered in the arm. Patients will be followed for 2 years after the 1st dose is given.
88961127|NCT02384317|Experimental|CCX168 (Avacopan)|CCX168 (Avacopan) plus stable dose of RAAS blocker
88961128|NCT02354651||Patients With Pompe Disease Eligible for Diaphragm Pacing|Patients will receive tests of breathing pattern, phrenic nerve stimulation, maximal inspiratory pressure (MIP), forced expiration, and EMG.
88961129|NCT02332460||Infliximab|Patients treated with Infliximab
89514907|NCT04690387|Experimental|0.1 mg antigen, 0 mcg GM-CSF|Dendritic cells previously incubated with 0.1 mcg antigen
89514908|NCT04690387|Experimental|0.33 mg antigen, 0 mcg GM-CSF|Dendritic cells previously incubated with 0.33 mcg antigen
89514909|NCT04690387|Experimental|1.0 mg antigen, 0 mcg GM-CSF|Dendritic cells previously incubated with 1.0 mcg antigen
89514910|NCT04690387|Experimental|0.1 mg antigen, 250 mcg GM-CSF|Dendritic cells previously incubated with 0.1 mcg antigen, admixed with 250 mcg GM-CSF
89514911|NCT04690387|Experimental|0.33 mg antigen, 250 mcg GM-CSF|Dendritic cells previously incubated with 0.33 mcg antigen, admixed with 250 mcg GM-CSF
89514912|NCT04690387|Experimental|1.0 mg antigen, 250 mcg GM-CSF|Dendritic cells previously incubated with 1.0 mcg antigen, admixed with 250 mcg GM-CSF
89514913|NCT04690387|Experimental|0.1 mg antigen, 500 mcg GM-CSF|Dendritic cells previously incubated with 0.1 mcg antigen, admixed with 500 mcg GM-CSF
89514914|NCT04690387|Experimental|0.33 mg antigen, 500 mcg GM-CSF|Dendritic cells previously incubated with 0.33 mcg antigen, admixed with 500 mcg GM-CSF
89514915|NCT04690387|Experimental|1.0 mg antigen, 500 mcg GM-CSF|Dendritic cells previously incubated with 1.0 mcg antigen, admixed with 500 mcg GM-CSF
89514916|NCT03534401|No Intervention|Standard Contraceptive Counseling|Providers at control clinics receive no additional training; clients receive standard contraceptive counseling services.
89514917|NCT03534401|Experimental|ARCHES Kenya Intervention in Contraceptive Counseling|Providers at intervention clinics receive training on ARCHES strategies integrated into contraceptive counseling; clients receive the ARCHES Kenya intervention integrated within standard contraceptive counseling services.
89514918|NCT05392725||Normal renal function group|Observe survival time
89514919|NCT05392725||Renal dysfunction group|Observe survival time
89514920|NCT03474367||Unplanned Peritoneal Dialysis|CKD patients stage 5 (eGFR < 15 ml/min/1,73m²) or stages 4 with abrupt worsening renal function requiring dialysis treatment immediately, followed or not by nephrologists prior to renal replacement therapy (RRT) indication, that agree to initiate peritoneal dialysis (PD) in less than 48 hours after implantation of the peritoneal catheter, without family training or adequacy of the home. The patient must not have any absolute contraindications to initiate PD, which include: presence of recent abdominal surgery (less than 30 days); multiple previous abdominal surgery (more than two); presence of fibrosis or peritoneal adhesions; fungal peritonitis; severe respiratory insufficiency (FiO2> 70%); abdominal infections; severe hyperkalemia with changes characteristic in ECG; and acute pulmonary edema. These patients will be treated with HD.
89514921|NCT03474367||Unplanned Hemodialysis|CKD patients stage 5 (eGFR < 15 ml/min/1,73m²) or stages 4 with abrupt worsening renal function requiring dialysis treatment immediately, followed or not by nephrologists prior to renal replacement therapy (RRT) indication, that agree to initiate HD without a functional arteriovenous fistula, ie, with a central venous catheter (nontunneled or tunneled).
88961130|NCT02286154|Experimental|Hydroxyurea|"All enrolled participants will receive hydroxyurea, but upon enrollment, participants will be identified as part of the New Cohort or Old Cohort New Cohort participants include those who are not receiving hydroxyurea therapy upon study entry. Old Cohort participants include those who are already receiving hydroxyurea therapy upon study entry. New Cohort participants will have starting dose predicted using PK/PD data and Old Cohort participants will continue dosing per clinical guidelines."
89024946|NCT00439829|Active Comparator|2|Initiation of ovarian stimulation therapy on day 4 (day 1= first day of menses)
89514922|NCT04769830||AGI group|Collect the characteristic data of intestinal sound, such as 24-hour average intestinal rate, duration of gastrointestinal sound, amplitude, maximum frequency, average frequency, etc., and detect citrulline, intestinal fatty acid binding protein and so on.
89543488|NCT04789473||Control Normal Glycemic Pregnancy|Cohort of control adults who are currently pregnant or have been pregnant within the last year, but were not diagnosed with gestational diabetes.
89543489|NCT04789473||Gestational Diabetic Cohort|Cohort of adults who are currently pregnant or have been pregnant within the last year, but were diagnosed with gestational diabetes.
89543490|NCT01626118|Experimental|Indomethacin 40 mg TID|
89543491|NCT01626118|Experimental|Indomethacin 40 mg BID|
89543492|NCT01626118|Placebo Comparator|Placebo|
89543493|NCT01626118|Experimental|Indomethacin 20 mg TID|
89543494|NCT05471583||Main group|There is only one group in the study. It is observational.
89543495|NCT04789005|Active Comparator|Phenylephrine group|Phenylephrine 100mcg was administered manually by the anaesthesiologist every time the SBP was 20% lower than baseline and the HR ≥60 bpm.
89543496|NCT04789005|Experimental|Norepinephrine group|Norepinephrine 8mcg was administered manually by the anaesthesiologist every time the SBP was 20% lower than baseline and the HR ≥60 bpm.
89543497|NCT04788849||Women referred to colposcopy|Three sample types (urine, vaginal and cervical) will be collected from all enrolled women.
88961131|NCT02274779|Experimental|Hight dose IMRT, ELIGARD|"PTV1 PTV5 to 66 Gy in 30 fractions of 2.2 Gy~PTV Pelvis: 54 Gy in 30 fractions of 1.8 Gy~PTV Loge 60 Gy in 30 fractions of 2 Gy 6 Gy A complement of 3 in two additional fractions Gy may be delivered across the lodge PTV.~PTV Relapse Lodge: In addition to treating the PTV Lodge, additional radiation of 6 Gy in 3 fractions of 2 Gy may be made to bring the total dose of 72 Gy in 36 fractions of 2 Gy."
88961132|NCT02269592||Specimen Collection|Patients' tumor tissue including bone marrow, blood, buccal swab or mouthwash, lymph node, urine or other specimens will be collected from patients who consent to the protocol
88961133|NCT02255331||Retrieval Analysis|"You qualify for this Retrieval Analysis study if you:~Have a total hip replacement with a ceramic component undergoing revision for any reason, including recurrent dislocation.~Have a metal-on-polyethylene total hip replacement and have repeated dislocation, or~Have a metal-on-polyethylene total hip replacement greater than 1 year old, or~Have an infected total hip replacement (any surface bearing)~You do not qualify for this arm of the study if you:~Have occupational exposure to cobalt or chromium~Presence of a metal-on-metal (MOM) implant, or a recalled implant~Have had a prior revision of your total hip~Standard contra-indications to MRI (e.g. cardiac pacemaker, etc.)"
88961134|NCT02255331||Longitudinal Evaluation|"You qualify for this arm of the study if you:~Have a total hip replacement with a ceramic component~Have a metal-on-polyethylene total hip replacement.~Have your original or revised total hip replacement.~You do not qualify for this arm of the study if you:~Have occupational exposure to cobalt or chromium~Have cemented components.~Presence of a metal-on-metal (MOM) implant, or a recalled implant~Standard contra-indications to MRI (e.g. cardiac pacemaker, etc.)"
88961135|NCT02253316|Experimental|Consolidation: Ixazomib, Lenalidomide, & Dexamethasone|Consolidation therapy will begin between Day 80 and Day 120 following ASCT and will consist of four 28-day cycles of IRD (ixazomib, lenalidomide, & dexamethasone). Barring dose modifications for toxicity, 4 mg of ixazomib and 40 mg of dexamethasone will be administered on Days 1, 8, and 15, and 15 mg of lenalidomide will be administered on daily on Days 1-21.
89207476|NCT00854802|Experimental|Debio 025 600 mg + peg-IFNα2a + ribavirin - 48 weeks|Participants receive Debio 025 600 mg orally twice daily for 7 days (loading dose) followed by Debio 025 600 mg orally once daily for 47 weeks + peg-IFNα2a 180 µg subcutaneously (sc) once weekly for 48 weeks + ribavirin 1000 or 1200 mg (weight based) orally daily for 48 weeks.
89543498|NCT02152384|Experimental|Insulin peglispro (LY2605541, with Insulin Lispro)|Insulin peglispro (LY2605541) once daily subcutaneous (SC) injection at bedtime. Insulin lispro given SC prandially or as bolus as required
89543499|NCT02152384|Active Comparator|Insulin Glargine (with Insulin Lispro)|Insulin glargine once daily SC injection at bedtime. Insulin lispro given SC prandially or as a bolus as required
89543500|NCT05469243||psychedelics|50 non active military participants not under the care of Dr. Gupta will be recruited through word of mouth and advertising to self-identify as having used psychedelic medicine for non recreational purposes (Appendix B recruitment letter). In addition to demographic information, they will be asked to complete the PGIC and anxiety, mood, pain and disability subscales, PEG, HADS and DI, provide information on their past medical history, nature/indications for use, and adverse events. This data will be collected once per participant and they will be able to speak with a research associate if further clarification if necessary at anytime.
89543501|NCT02177266|Placebo Comparator|Placebo|A placebo pill (identical to the study drug Colchicine) will be given in a double-blinded fashion to study participants randomized to placebo.
89543502|NCT02177266|Experimental|Colchicine|Colchicine 0.6mg bid will be given to study participants randomized to the study drug arm beginning at 48-72 hours prior to the planned cardiac surgery and then continued for a total of 30 days.
89543503|NCT05468229|Active Comparator|dorzagliatin|Dorzagliatin 50 mg single dose
89543504|NCT05468229|Placebo Comparator|placebo|matching placebo
89543505|NCT04788381||Participants with CRC or lung cancer was performed unexpected operation|This is an observational study; thus, no intervention or treatment is required by the protocol. During the study, enrolled patients may be eligibled if bevacizumab was discontinued within 6 weeks prior to unexpected operation.
89543506|NCT05475249|Placebo Comparator|white yttria-stabilized zirconia abutment|white yttria-stabilized zirconia abutment (PYRCA; BioHorizons, Birmingham, EEUU) without immersion in fluorescent liquid
89543507|NCT05475249|Experimental|fluorescence white yttria-stabilized zirconia abutment|white yttria-stabilized zirconia abutment (PYRCA; BioHorizons, Birmingham, EEUU) with immersion in fluorescent liquid
89543508|NCT05466591|Experimental|Pre-hospital rule-out strategy|Patients undergo a point-of-care troponin T measurement. If troponin is low, an acute coronary syndrome is considered ruled-out and the care for the patient is transferred to the general practitioner. If troponin is elevated, the patient is immediately transported to the emergency department.
89543509|NCT05466591|No Intervention|Emergency department rule-out strategy|According to standard care, the patients are immediately transported to the emergency department.
89543510|NCT04342377|Experimental|Selective Targeted Sampling|"During patients' Endobronchial Ultrasound (EBUS) procedure, they will first undergo:~Selective Targeted Sampling - endosonographic assessment of at least 3 mediastinal lymph node stations (4R, 4L, and 7) using the four criteria of the Canada Lymph Node Score (predictor of nodal disease during Endobronchial Ultrasound). Each lymph node will be assigned a CLNS ranging from 0 to 4. Triple Normal lymph nodes will be defined as those that appear normal on CT (diameter < 1 cm), AND normal on PET (SUV < 2.5), AND normal on EBUS (CLNS < 2). Lymph nodes that are found to be Triple Normal will be marked as Not for Biopsy, whereas all other lymph nodes will be biopsied."
89543511|NCT04342377|Active Comparator|Systematic Sampling|"Upon completion of Systematic Targeted Sampling, all patients will crossover and receive the standard of care:~Systematic Sampling - all lymph nodes previously marked as Not for Biopsy will be biopsied.~At the conclusion of the EBUS procedure, all nodal stations would have been sampled as is mandated by current guidelines."
89543512|NCT04787913|No Intervention|controlgeneric|No intervention provided. Participant answers outcome questions about an unnamed vaccine-preventable disease. English and French.
89543513|NCT04787913|No Intervention|controlmeasles|No intervention provided. Participant answers outcome questions about measles. English and French.
89543514|NCT04787913|No Intervention|controlpertussis|No intervention provided. Participant answers outcome questions about pertussis. English and French.
89543515|NCT04787913|No Intervention|controlflu|No intervention provided. Participant answers outcome questions about flu. English and French.
89543516|NCT04787913|Experimental|herdimmgeneric|Web-based application (main intervention) provided. Participant answers outcome questions about an unnamed vaccine-preventable disease. English and French.
89543517|NCT04787913|Experimental|herdimmmeasles|Web-based application (main intervention) provided. Participant answers outcome questions about measles. English and French.
89543518|NCT04787913|Experimental|herdimmpertussis|Web-based application (main intervention) provided. Participant answers outcome questions about pertussis. English and French.
89543519|NCT04787913|Experimental|herdimmflu|Web-based application (main intervention) provided. Participant answers outcome questions about flu. English and French.
89543520|NCT04787913|Active Comparator|robertkochgeneric|Web-based application (comparator) provided. Participant answers outcome questions about an unnamed vaccine-preventable disease. English only.
89543521|NCT04787913|Active Comparator|sbsnewsgeneric|Video (comparator) provided. Participant answers outcome questions about an unnamed vaccine-preventable disease. English only.
89543522|NCT04787913|Active Comparator|guardianmeasles|Video (comparator) provided. Participant answers outcome questions about measles. English only.
89543523|NCT04787913|Active Comparator|theotheredmundmeasles|Video (comparator) provided. Participant answers outcome questions about measles. English only.
88961136|NCT02253316|Experimental|Maintenance Arm 1: Ixazomib|Ixazomib will be administered on Days 1, 8, and 15 of a 28-day cycle at a starting dose of 4 mg until patient progresses or experiences an unacceptable toxicity.
88961137|NCT02253316|Experimental|Maintenance Arm 2: Lenalidomide|Lenalidomide will be administered daily continuously for a 28-day cycle at a starting dose of 10 mg. If lenalidomide is tolerated well (i.e. no dose modification required) during the first three cycles, lenalidomide dose will be increased to 15 mg daily and will continue until patient progresses or experiences an unacceptable toxicity.
88961138|NCT02214160|Experimental|UX007|Participants previously treated with UX007 or treatment-naive participants will begin or continue treatment with daily open-label UX007 while maintaining their other dietary restrictions.
88961139|NCT02169089|Experimental|Spironolactone|Spironolactone
88961140|NCT02169089|Placebo Comparator|Placebo|Placebo
88961141|NCT02130453|Experimental|ReSTE Cardiac Imaging|Echocardiography strain measurement performed taking about 10 minutes. After resting strain measurement done, first set of nuclear images performed. Once these images are completed, participant given Regadenoson 0.4 mg by vein over about 10 seconds. Within 2 to 4 minutes of receiving the Regadenoson, measurements repeated. These measurements will take about 2 minutes to complete.
88961142|NCT02130453|Other|SPECT Cardiac Imaging|After resting strain measurement done, first set of nuclear images taken. Once these images are completed, participant given Regadenoson 0.4 mg by vein over about 10 seconds. Within 2 to 4 minutes of receiving Regadenoson, measurements repeated. These measurements take about 2 minutes to complete. At about 30 minutes after Regadenoson given, participant will have final images for the nuclear portion of the testing.
88961143|NCT02059265|Experimental|Treatment (dasatinib)|Patients receive dasatinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88961144|NCT02032628|Experimental|High Intensity/Longer Duration|Exercise at higher intensity (~75% of VO2max) for 40 minute bouts 4 times per week
88961145|NCT02032628|Experimental|High Intensity/Lower Duration|Exercise at high intensity (~75% of VO2max) for 20 minute bouts 4 times per week
88961146|NCT02032628|Experimental|Lower Intensity/Higher Duration|Exercise at lower intensity (~55% of VO2max) for 40 minute bouts 4 times per week
88961147|NCT02032628|Experimental|Low Intensity/Low Duration|Exercise at lower intensity (~55% of VO2max) for 20 minute bouts 4 times per week
88961148|NCT01868711|Active Comparator|*Cognitive behavior therapy|Depressed patients will receive 12 virtual sessions of cognitive behavior therapy (CBT) for depression. CBT Includes behavior activation, correcting distorted thoughts, and other tools to reduce symptoms.
88961149|NCT01868711|Other|Supportive psychotherapy|Supportive psychotherapy aims to strengthen the patient's ability to cope effectively with various life stressors. Specifically, in our study, supportive psychotherapy will be geared towards reducing or alleviating symptoms of depression. The sessions will be administered virtually.
89543524|NCT04787913|Active Comparator|publichealthagencycanadaflu|Video (comparator) provided. Participant answers outcome questions about flu. English and French.
89543525|NCT05613231|Experimental|Aerobic plus Muscle-Strengthening Activity Intervention|Participants will receive access to a web-based, individually tailored, theory-driven aerobic moderate-to-vigorous physical activity (MVPA) intervention that was enhanced with content on muscle-strengthening activity.
89543526|NCT05613231|Active Comparator|Original Physical Activity Intervention|Participants will receive access to a web-based, individually tailored, theory-driven aerobic moderate-to-vigorous physical activity (MVPA) intervention
89543527|NCT05474937|Active Comparator|inhalational Sevoflurane|In the field of pediatric gastroenterology, upper gastrointestinal endoscopy has established itself as a diagnostic and therapeutic tool. In order to increase patient tolerance during this procedure, deep sedation is essential. Children are at a higher risk of serious adverse effects from procedural sedation; thus, their safety is a primary issue throughout this procedure. Multiple studies have been done to find the ideal method for procedural sedation in terms of ease of administration, quality, safety of sedation and recovery profile, but the consensus seems lacking. In this study we will compare between nasal inhalation of sevoflurane versus intravenous ketamine, midazolam and propofol for pediatrics undergoing upper gastrointestinal endoscopy.
89543528|NCT05474937|Active Comparator|Intravenous Ketamine, Midazolam and Propofol group|Preoxygenation with 100% O2 for 1 minute, by proper sized face mask. Patients in Ketamine -midazolam -propofol (KMP) group will receive 1-1.5 mg/kg IV ketamine and 0.05mg/kg IV Midazolam and 1mg/kg IV Propofol as induction dose then followed by incremental doses of 0.5 mg/kg IV Propofol alone for maintenance and if procedure is prolonged propofol infusion at 100 μg/kg/min is given for maintenance of sedation. Induction dose will be considered as adequate if adequate jaw relaxation for endoscope insertion and Modified Ramsay Sedation Score (MRSS) ≥7 occurs with maintenance of spontaneous respiration. Induction time will be considered as time from beginning of IV agent to achievement of MRSS ≥7. After endoscope insertion, maintenance of oxygenation by nasal cannula at flow twice the minute ventilation of the patient.
89543529|NCT04788225||Patients with ATFL repair by arthroscopic method|Patients who have passed at least 1 year after the operation Unilateral arthroscopic ATFL repair Between the ages of 18-65 Volunteer to participate in the study Without any orthopedic conditions, neuromuscular disease, balance disorder, cognitive disorder No history of fracture and surgical operation of the lower extremity
89543530|NCT04788225||Control group|Between the ages of 18-65 Volunteer to participate in the study Healthy individuals with no disease
89543531|NCT04787601|Experimental|Cognitive training|Cognitive-based neuromuscular exercises will be applied to the experimental group for a total of 8 weeks.
89543532|NCT04787601|Other|Control|The control group will only do the classic training.
89543533|NCT05474547|Experimental|Meditation|Meditation for 30 min 10 days
89543534|NCT02177032|Experimental|4-sites, 1-week without HRIG|"PCEC rabies vaccine, administered ID according to the 4-sites, 1-week regimen"
89543535|NCT02177032|Experimental|4-sites, 1-week with HRIG|"PCEC rabies vaccine, administered ID to adults, according to the 4-sites, 1-week regimen plus HRIG"
89543536|NCT02177032|Active Comparator|2-sites, TRC without HRIG|"PCEC rabies vaccine, administered ID according to the 2-sites, TRC regimen"
89543537|NCT02177032|Active Comparator|2-sites, TRC with HRIG|"PCEC rabies vaccine, administered ID to adults , according to the 2-sites, TRC regimen plus HRIG"
89543538|NCT05135325|Experimental|No-blood-type message|This group will receive a message that does not mention the patient's blood type, or that the patient's blood type is in short supply.
89543539|NCT05135325|Experimental|Blood-type message|This group will receive a message that mentions the patient's blood type and that states their blood type is in short supply.
89543540|NCT05135325|No Intervention|Shortage control|This group will not receive a message.
89543541|NCT05135325|No Intervention|No-shortage control|This group will not receive a message.
89543542|NCT04426305|Experimental|Intervention arm|psychosocial support
89543543|NCT04426305|Active Comparator|control arm|care as usual
89543544|NCT05474157||Study group|15 patients Patients followed in the Intensive Care Unit due to COVID-19 infection
89543545|NCT05474157||Control group|15 patients Patients who admitted to the 'Physical Medicine and Rehabilitation' clinic for other reasons during the pandemic period
89543546|NCT05316753|Experimental|Schiller Defigard HD- 7 - DGHD7|Device: Cardioversion with a pulsed biphasic waveform Cardioversion is performed by a pulsed biphasic (Multipulse Biowave®) waveform (Schiller Defigard HD- 7 - DGHD7, Schiller Medical, France) with adult pads (0-21-0003 Schiller) following an energy protocol of 3 consecutive shocks with escalating selected energy: 150J, 200J, 200J. The third shock is combined with MAP (Manual Pressure Application). The protocol is stopped at successfull cardioversion (sinus rhythm at 1 min post-shock), otherwise after the 3rd shock Other Name: DGHD7
89543547|NCT05316753|Active Comparator|LIFEPAK 15, Physio-Control - LP15|"Device: Cardioversion with a biphasic truncated exponential waveform Cardioversion is performed by a biphasic truncated exponential waveform (LIFEPAK 15, Physio-Control Inc., Redmond, WA, USA) with recommended by the manufacturer adult pads (Redipak QUICK COMBO, Physio-Control) following an energy protocol of 3 consecutive shocks with escalating selected energy: 150J, 360J, 360J. The third shock is combined with MAP (Manual Pressure Application). The protocol is stopped at successfull cardioversion (sinus rhythm at 1 minute post-shock), otherwise after the 3rd shock.~Other Name: LP15"
88961150|NCT01719744|Experimental|ENMD-2076|ENMD-2076 capsules, 275 mg once daily, by mouth.
88961151|NCT01661647|Experimental|3D knee kinematic assessment|3D knee kinematic assessment under local anesthesia
88961152|NCT01508390|Experimental|Boost|CyberKnife Boost 21 Gy in 7 Gy per day, 3 fractions, Every other day
88961153|NCT01253213|Experimental|BR55|
88961154|NCT01244737|Experimental|New diagnosis of brain tumor|In children with a new diagnosis of central nervous system tumor, a PET scan will be performed using [18F] FLT.
88961155|NCT01244737|Experimental|Possible recurrent brain tumor|In children in whom there is concern for recurrent central nervous system tumor, a PET scan will be performed using [18F] PET.
88961156|NCT01244737|Experimental|Brain tumor response to chemotherapy|"In children with a newly diagnosed central nervous system tumor who will be treated with post-operative chemotherapy, a PET scan will be performed using [18F] FLT before the start and after two cycles of chemotherapy.~Despite much effort and working with referring physicians at multiple hospitals, enrollment in this arm remained low, and it seemed unlikely that meaningful enrollment would be accomplished. A revised study plan was submitted to the granting agency and FDA, and this arm was closed to further enrollment."
88961157|NCT00820456||Colorectal Cancer, Hepatic Metastasis|Eligible participants in Arm A enrolled in this imaging study will: be older than 18, have metastatic colorectal cancer with at least one hepatic lesion, and be treated with FOLFOX in combination with bevacizumab.
89543548|NCT02176642|Active Comparator|Oxybutynin plus PTNS|Oxybutynin extended release (blinded tablet) 5mg by mouth daily for 6 weeks, Posterior Tibial Nerve Stimulation utilizing the Urgent PC neuromodulation system administered weekly in the office setting for a total of 6 weeks.
89543549|NCT02176642|Placebo Comparator|Placebo plus PTNS|Placebo (blinded tablet) taken daily for 6 weeks. Posterior Tibial Nerve Stimulation utilizing the Urgent PC neuromodulation system administered weekly in the office setting for a total of 6 weeks.
89543550|NCT05612997||Relative Validation Arm|
89543551|NCT05473845|Experimental|Acupressure|Acupressure intervention
89543552|NCT05473845|Experimental|Reiki|Reiki intervention
89543553|NCT05473845|No Intervention|Control|No intervention.
89543554|NCT02116660|Experimental|Raltegravir plus Nevirapine plus Lamivudine|Raltegravir 400 mg oral twice daily for 96 weeks; plus nevirapine 200 mg oral once daily for 14 days followed by nevirapine 200 mg oral twice daily, plus lamivudine 150 mg oral twice daily for 96 weeks
89543555|NCT02116660|Active Comparator|Protease Inhibitor/Ritonavir plus tenofovir/emtricitabine|Tenofovir/emtricitabine 300/200 mg oral once daily plus 1) lopinavir/ritonavir 400/100 mg oral twice daily or 800/200 mg oral once daily, or 2) atazanavir/ritonavir 300/100 mg oral once daily, or 3) darunavir/ritonavir 800/100 mg oral once daily or 600/100 mg oral twice daily
89543556|NCT02589405|Experimental|Benzaknen treatment regimen|Benzac® 5% Gel (once daily) + Dermotivin® Soft Liquid soap (twice daily) + Cetaphil® Dermacontrol Moisturizer SPF30 (once daily)
89543557|NCT02176018|Active Comparator|Nuedexta|One capsule will be taken (dextromethorphan HB and quinidine sulfate, 20 mg/10 mg) daily for seven days. On the eight day and for the remainder of the study 2 capsule will be taken twice a day. Medication will be taking daily for a total of 3 months.
89543558|NCT02176018|Placebo Comparator|Placebo|One capsule will be taken of placebo to match daily for seven days. On the eight day and for the remainder of the study 2 capsule will be taken twice a day. Medication will be taking daily for a total of 3 months.
89543559|NCT05612919|Experimental|Patients exclusively transfused with UCB-RBC|Interventional group infants arm will receive UCB-RBC bag when RBC transfusion is indicated as per standard practice, and when UCB-RBC is available within the first 6 hours of the request.
89543560|NCT05612919|Active Comparator|Patients exclusively transfused with AB-RBC|Standard treatment group infants arm will receive AB-RBC when RBC transfusion is indicated as per standard practice, and compatible UCB-RBC bag is not available.
89543561|NCT05612919|No Intervention|Non transfused patients|Patients with no indications for RBC transfusion. Their clinical management will be the usual in our neonatal unit.
89543562|NCT05612841||non metastatic castration resistant prostate cancer|
89543563|NCT05612841||metastatic castrare naïve prostate cancer|
89543564|NCT05612763|Experimental|Method of fit|Devices are fit using either a clinician completed fitting process or a patient completed fitting process. Then the alternate fitting method is used to repeat the process. The order of which method used is counterbalanced.
89543565|NCT05465967|Sham Comparator|Group I: Control Group|Patients in this group will receive ipsilateral sham ultrasound-guided block via subcutaneous injection of 1 ml of normal saline after surgery.
89543566|NCT05465967|Active Comparator|Group II:( transverse trans muscular Quadratus lumborum group).|patients in this group will receive an ipsilateral single-shot of paraspinous sagittal approach of Quadratus lumborum BLOCK(30 ml of plain bupivacaine 0.25%) after surgery using ultrasonographic guidance.
89543567|NCT05465967|Active Comparator|Group III : paraspinous sagittal approach of Quadratus lumborum BLOCK|patients in this group will receive an ipsilateral single-shot of paraspinous sagittal approach of Quadratus lumborum BLOCK (30 ml of plain bupivacaine 0.25%) after surgery using ultrasonographic guidance.
89543568|NCT05465889|Experimental|OSS group|Bowel preparation for colonoscopy was performed using oral sulfate solution as laxative
89543569|NCT05465889|Active Comparator|Polyethylene glycol group|Bowel preparation for colonoscopy was performed using polyethylene glycol as laxative
89543570|NCT02116582|Experimental|Enzalutamide|Participants received 160 mg of enzalutamide orally once daily until they experienced an adverse event, disease progression, started new anti-cancer therapy, withdrew consent, or other protocol-specified criteria.
89543571|NCT05611827|Experimental|Quercetin LipoMicel (250 mg)|Each participant receives their treatment of Quercetin LipoMicel at a total dose of 250 mg quercetin. Treatments are consumed with a glass of water (approx. 200 mL), but with no food (4hr fasting condition). Capillary whole blood samples are collected at time points 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24hrs following a single-dose administration of quercetin and at 25, 47, 48, 71 and 72hrs after a repeated oral total dose of 250 mg LipoMicel (once daily for 72hrs). A washout period of at least 7 days between each treatment will be used.
89543572|NCT05611827|Experimental|Quercetin LipoMicel (500 mg)|Each participant receives their treatment of Quercetin LipoMicel at a total dose of 500 mg quercetin. Treatments are consumed with a glass of water (approx. 200 mL), but with no food (4hr fasting condition). Capillary whole blood samples are collected at time points 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24hrs following a single-dose administration of quercetin and at 25, 47, 48, 71 and 72hrs after a repeated oral total dose of 500 mg LipoMicel (once daily for 72hrs). A washout period of at least 7 days between each treatment will be used.
89543573|NCT05611827|Experimental|Quercetin LipoMicel (1000 mg)|Each participant receives their treatment of Quercetin LipoMicel at a total dose of 1000 mg quercetin. Treatments are consumed with a glass of water (approx. 200 mL), but with no food (4hr fasting condition). Capillary whole blood samples are collected at time points 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24hrs following a single-dose administration of quercetin and at 25, 47, 48, 71 and 72hrs after a repeated oral total dose of 1000 mg LipoMicel (once daily for 72hrs). A washout period of at least 7 days between each treatment will be used.
89543574|NCT05611827|Experimental|Regular/standard Quercetin (500 mg)|Each participant receives their treatment of standard/raw Quercetin at a total dose of 500 mg quercetin. Treatments are consumed with a glass of water (approx. 200 mL), but with no food (4hr fasting condition). A standardized lunch and dinner are served after 4h and 8h of product administration. Capillary whole blood samples are collected (after a 10hr overnight fast) at time points 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24hrs following a single-dose administration of quercetin. A washout period of at least 7 days between each treatment will be used.
89543575|NCT04936425|Experimental|OTSC Stentfix|
89543576|NCT04936425|No Intervention|Stent Suturing|
89543577|NCT05612607|Other|IGRT discontinuation|Participants will be tested to determine Switched memory B cells (SMB) levels. If SMB cells are ≥ 2%, IGRT will be discontinued. If SMB cells are < 2%, the patient will remain on IGRT and a maximum of 40 mL of blood will be drawn again in 3-6 months to reassess SMB levels and eligibility for IGRT discontinuation.
89543578|NCT02589639|Experimental|empagliflozin 10 mg|
88961158|NCT00820456||Primary Tumor Undefined, Hepatic Metastasis|Eligible participants in Arm B enrolled in this imaging study will: be older than 18, must have prior histological documentation of any types of cancer with metastasis to the liver, and must be in stable treatment conditions prior to and between scans.
89543579|NCT02589639|Experimental|empagliflozin 25 mg|
88961159|NCT00655967|Experimental|1|Acamprosate(Campral)
88961160|NCT00601198|Experimental|Treatment Period|The chemotherapy regimen will be given for 2 consecutive days. On day #1, pt. will be premedicated with drugs to prevent nausea and vomiting in addition to intravenous fluids. Then they will receive amifostine intravenously followed by oxaliplatin, 5FU and leucovorin. This will be followed by an infusion of 5FU given in a pump over 22 hours. If the doctor decides on giving the pt. Avastin, this will be given on day #1. On day #2, they will receive the same treatment except for oxaliplatin.
88961161|NCT00415805|Experimental|1|
89543580|NCT02589639|Placebo Comparator|placebo|
89543581|NCT05611749|Placebo Comparator|control group receiving a placebo|The study medication (either placebo or Duloxetine) will be continued throughout the duration of hospitalization. The balance of the remaining pills will be provided to the patient as a discharge prescription to allow for 10 days total treatment.
89543582|NCT05611749|Experimental|treatment group receiving 60 mg Duloxetine|The study medication (either placebo or Duloxetine) will be continued throughout the duration of hospitalization. The balance of the remaining pills will be provided to the patient as a discharge prescription to allow for 10 days total treatment.
89543583|NCT05614713|Experimental|Study group|received a modified selected physical therapy program to increase sensory input.
89543584|NCT05614713|Active Comparator|Control group|received a selected physical therapy
89543585|NCT05611515||TORS|Patients operated by Trans-oral Robotic Surgery (TORS)
89543586|NCT05611515||TLM|Patients operated by Trans-oral Laser Microsurgery (TLM)
89543587|NCT05611515||IMRT|Patients treated by Intensity Modulated Radiation Therapy (IMRT)
89543588|NCT05612451|Experimental|non-setting calcium hydroxide|Regenerative Endodontic Procedure utilizing non-setting calcium hydroxide as intracanal medicament
89543589|NCT05612451|Experimental|modified triple antibiotic paste|Regenerative Endodontic Procedure utilizing modified triple antibiotic paste as intracanal medicament
89543590|NCT05611359|Experimental|Thermal Ablation|In the patients with liver oligometastasis after pancreatic ductal adenocarcinoma (PDAC) surgery, thermal ablation and chemotherapy are administered.
89543591|NCT05611359|Active Comparator|Chemotherapy|In the patients with liver oligometastasis after pancreatic ductal adenocarcinoma (PDAC) surgery, chemotherapy is administered.
89543592|NCT04334811|Other|Arm|No arm
89543593|NCT02151682|Active Comparator|Morphine prolonged-release (Part 1)|"10 milligram (mg) or 30 mg tablets were taken orally twice daily. Starting doses varied from 10 to 40 mg morphine PR twice daily depending on participant's weight; if necessary, doses were gradually increased up to a maximum dose defined per weight group.~The highest dose defined for participants weighing 55 kg and more was 200 mg per day."
89543594|NCT02151682|Experimental|Tapentadol prolonged-release (Part 1)|"25 mg or 100 mg tablets were taken orally twice daily. Starting doses varied from 25 to 100 mg tapentadol PR twice daily depending on participant's weight. If necessary, doses were gradually increased up to a maximum dose defined per weight group.~The highest dose defined for participants weighing 55 kg and more was 500 mg per day."
89543595|NCT02151682|Experimental|Tapentadol in Part 2 after Tapentadol or Morphine in Part 1|Participants on tapentadol PR in Part 1 of the study continued on the current dose of tapentadol PR in Part 2 and if necessary could modify their tapentadol PR dosage. Participants who were randomized to morphine PR in Part 1 of the study were rotated to tapentadol PR in Part 2 with 70 percent of their current morphine equivalent dose or lower. The dosage could be increased gradually up to approximately 4.5 mg/kg body weight tapentadol PR twice daily.
89543596|NCT02151682|No Intervention|Observation Period after Tapentadol in Part 1|Participants who completed tapentadol PR in Part 1 of the study or discontinued tapentadol treatment early in Part 1 could continue directly in the observation period in Part 2 for up to 12 months (with standard-of-care treatment if needed).
89024947|NCT03278769|Experimental|Ventilator setting|Positive end-expiratory pressure , Tidal volume
89543597|NCT02151682|No Intervention|Observation Period after Morphine in Part 1|Participants who completed morphine PR treatment in Part 1 of the study or discontinued early from morphine treatment in Part 1 could continue directly in the observation period in Part 2 (with standard-of-care treatment if needed).
89543598|NCT02151682|No Intervention|Observation Period after Tapentadol in Part 2|Participants who completed tapentadol PR or morphine PR treatment in Part 1 of the study could enter the Observation Period for up to 12 months (with standard-of-care treatment if needed) after they had discontinued from tapentadol PR treatment in Part 2.
89543599|NCT04331691|Active Comparator|Spironolactone|After randomization, this group will receive 12.5 mg of spironolactone daily. Subjects who did not reach the target blood pressure after 4 weeks of treatment should be increased to 25 mg of spironolactone. After 12 weeks of treatment, study will be end.
89543600|NCT04331691|Experimental|Amiloride|After randomization, this group will receive 5 mg of amiloride daily. Subjects who did not reach the target blood pressure after 4 weeks of treatment should be increased to 10 mg of amiloride. After 12 weeks of treatment, study will be end.
88961162|NCT00415805|Active Comparator|2|
88961163|NCT02006498|Experimental|Sillymarin|Active component study medication
88961164|NCT02006498|Placebo Comparator|Placebo|Placebo capsules
88961165|NCT02006524|Active Comparator|Screening with MyDiagnostick|All patients eligible for influenza vaccination are screened for atrial fibrillation with the MyDiagnostick, an easy to use and patient friendly device.
88961166|NCT02006537|Experimental|Cohort 1|Cohort 1 will enrol 8 healthy male volunteers, who will receive a single 10 mg dose of GSK225694 in the fasted state.
89024948|NCT00439868|Experimental|Treatment Group 1|Subjects in Period 1 of treatment group 1 will receive oral doses of extended release WELLBUTRIN XL tablets for 2 weeks, from Days 1-3 subject will receive 150 milligram (mg) tablets once daily (QD) and from Days 4-14 300 mg QD. In Period 2 subject will receive placebo for 2 weeks.
89024949|NCT00439868|Experimental|Treatment Group 2|Subjects in Period 1 of Treatment group 2 will receive Placebo for 2 weeks and in Period 2 subject will receive oral doses of extended release WELLBUTRIN XL for 2 weeks, from Days 1-3 subject will receive 150 milligram (mg) tablets once daily (QD) and from Days 4-14 300 mg QD.
89024950|NCT03279653||SleeveGastrectomy|Sleeve Gastrectomy will be performed. Preoperative and Postoperative pancreatic enzyme sufficiency (with steatocrit or fecal elastase) will be compared.
89024951|NCT03277248|Experimental|Ublituximab + Oral Placebo|Participants received ublituximab intravenous (IV) infusion, 150 milligrams (mg) over 4 hours (h) on Day 1 followed by 450 mg over 1 h on Days 15, 168, 336 and 504 (Week 72) along with the oral placebo tablet, once daily (QD) from Day 1 up to the last day of Week 95.
89543601|NCT04756635|Experimental|Experimental Group|Measures taken before and after the defined IF periods. Two groups of participants will be included in this project: 1) resistance trained group (tested for neuromuscular function, anaerobic capacity and body composition); 2) endurance trained group (tested for aerobic and anaerobic capacity and body composition). Experimental condition: pre- and post-4 weeks of IF. Measurements will be taken during the morning period (between 07:00 and 11:00 am) in the fasted state. Neuromuscular function and anaerobic capacity will be assessed on separate days (with at least a 48- hour interval) to ensure full recovery.
89024952|NCT03277248|Active Comparator|Teriflunomide + IV Placebo|Participants received teriflunomide 14 mg tablet, orally, QD from Day 1 up to the last day of Week 95 along with the placebo IV infusion on Days 1, 15, 168, 336 and 504 (Week 72).
89024953|NCT03279614|Experimental|SOX|OXA：130mg/m2 ，iv drip for 180min d1, S-1 40-60mg p.o. bid d1-14, q3W
89543602|NCT04756635|Other|Control Group|Participants of each group serving as their own controls. Control condition: pre- and post4 weeks of normal diet. Measurements will be taken during the morning period (between 07:00 and 11:00 am) in the fasted state. Neuromuscular function and anaerobic capacity will be assessed on separate days (with at least a 48-hour interval) to ensure full recovery.
89543603|NCT02174848|Experimental|Deferiprone|All patients will receive deferiprone oral solution.
89543604|NCT05612217||patients with CVD|20 patients per 1 center: patients with CVD C1 class 4 patients with CVD C2 class; 2 patients with CVD with classes other than C1-C2 (C4-C6); 8 patients with either C0s CVD or with skin pathologic conditions of lower extremities other than CVD;
89543605|NCT02151058|Other|Negative Control, 035000513007|Colgate® Regular Cavity Protection
89543606|NCT02151058|Experimental|Experimental Mouth Rinse, 19545-118|
89543607|NCT02151058|Active Comparator|Active Comparator: Mouth Rinse 037000089872|Crest® 3D White Multi-Care Whitening Rinse, Glamorous White, Fresh Mint
89024954|NCT00439907|Active Comparator|End-to-end|End-to-end repair
89024955|NCT00439907|Active Comparator|Overlap|Overlap repair
89024956|NCT03279822||Group|
89543608|NCT04744389|Experimental|Hypothermic Machine Perfusion|uDCD and cDCD after Normothermic Regional Perfusion matching the inclusion criteria, ECD matching the inclusion criteria, uDCD and cDCD exceeding the inclusion criteria.
89543609|NCT04744389|Experimental|Normothermic Machine Perfusion|uDCD and cDCD after Normothermic Regional Perfusion matching the inclusion criteria, ECD matching the inclusion criteria, uDCD and cDCD exceeding the inclusion criteria.
89543610|NCT04699695||Biologic Treatment|Subjects prescribed a biologic agent per standard of care
89024957|NCT00439985|Other|Behavioral: Cognitive Behavior Therapy|
89024958|NCT03279783|No Intervention|WLI (White light Imaging)|Colonoscope withdrawal was performed in the right colon evaluating the mucosa using standard white light.
89543611|NCT04699695||Other Treatments|Subjects prescribed other treatment modalities exclusive of biologic therapy per standard of care
89543612|NCT05614479|Other|Intervention group|Use of the MAHA mobile application
89543613|NCT02149810|Experimental|Automatic Self Transcending Meditation and Treatment as Usual|Participants in the ASTM group will undergo ASTM training in groups of four .This involves participating in four, 90-120 minutes sessions each of four consecutive days. This will be followed by once weekly 45-60 minute follow up sessions for 12 weeks. In addition participants will be asked to practice ASTM at home for 20 minutes twice daily over the study period (24 weeks). Participants will be asked to log practice frequency and any other noteworthy observations in the log sheet provided to them.
89543614|NCT02149810|No Intervention|Treatment as Usual|Participants randomized to control arm (TAU) will continue to receive their treatment as usual including antidepressant medications and/or psychotherapy
89543615|NCT05205759|Experimental|Bamlanivimab Etesevimab|Bamlanivimab 700 mg + Etesevimab 1400 mg administered in 250 mL prefilled 0.9% sodium chloride injection infusion solution over one hour
89543616|NCT05205759|Experimental|Sotrovimab|Sotrovimab 500 mg administered in 100 mL prefilled 0.9% sodium chloride injection infusion solution over 1/2 hour
89543617|NCT05205759|Active Comparator|Casirivimab Imdevimab|Casirivimab 600 mg + Imdevimab 600 mg administered in 250 mL prefilled 0.9% sodium chloride injection infusion solution over one hour
89024959|NCT03279783|Active Comparator|LCI (Linked Color Imaging)|Colonoscope withdrawal was performed in the right colon evaluating the mucosa using LCI (Linked Color Imaging).
89024960|NCT00440024|Experimental|Cell A|Study controlled daily skin care regimen during 'rest period' consisting of Dove Mild Cleanser, Dove Facial Moisturizer with SPF 15 followed by Tazorac
89024961|NCT00440024|Placebo Comparator|Cell B|Subject controlled normal skin care regimen during 'rest period, followed by study controlled daily skin care regime consisting of Dove Mild Cleanser, Dove Facial Moisturizer with SPF 15 followed by Tazorac
89024962|NCT00476502||1|patients involved in structured interruption therapy
89024963|NCT00438282|No Intervention|1|Control group
89024964|NCT00438282|Experimental|2|Paraprofessional home visits
89024965|NCT00438282|Experimental|3|Nurse home visitation
89024966|NCT00440102|Active Comparator|1|ketamine
89024967|NCT00440102|Active Comparator|2|Etomidate
89024968|NCT00476541|Experimental|1|Gemtuzumab 5 mg / m2 two courses with three week interval
89024969|NCT00476541|No Intervention|2|No further therapy
89543618|NCT04621851||Retrospective cohort|Patients who discontinued before the opening of this study will contribute to the retrospective cohort.
88961167|NCT02006537|Experimental|Cohort 2|Cohort 2 will enrol 20 healthy elderly male and female volunteers (10 males and 10 females), who will receive a single 10 mg dose of GSK225694 in the fasted or fed state according to the randomization schedule.
88961168|NCT02006589|Experimental|Arm 1 Test then Reference|Subjects will be randomized and receive the following two treatments administered orally in a fasting state A= Single dose of candesartan cilexetil (Test formulation) 8mg; B = Single dose of candesartan cilexetil (Reference treatment) 8mg. The two treatment periods will be separated by a washout period of at least 7 days and no more than 14 days.
88961169|NCT02006589|Experimental|Arm 2 Reference then Test|Subjects will be randomized and receive the following two treatments administered orally in a fasting state: A=Single dose of candesartan cilexetil (Reference treatment) 8mg; B= Single dose of candesartan cilexetil (Test formulation) 8mg. The two treatment periods will be separated by a washout period of at least 7 days and no more than 14 days.
88961170|NCT02006602|Experimental|Arm 1 reference then test|Subjects will be randomized and receive the following two treatments administered orally in a fasting state: A=Single dose of candesartan cilexetil (Reference treatment) 16mg; B= Single dose of candesartan cilexetil (Test formulation) 16mg. The two treatment periods will be separated by a washout period of at least 7 days and no more than 14 days.
88961171|NCT02006602|Experimental|Arm 2 test then reference|Subjects will receive the following two treatments administered orally in a fasting state: A= Single dose of candesartan cilexetil (Test formulation) 16mg. B=Single dose of candesartan cilexetil (Reference treatment) 16mg. The two treatment periods will be separated by a washout period of at least 7 days and no more than 14 days.
88961172|NCT02006615|Experimental|High frequency rTMS plus fNIRS|rTMS with neuroimage assessment of functional near infrared spectroscopy
88961173|NCT02006615|Sham Comparator|Sham rTMS|Sham stimulation
88961174|NCT02006615|Experimental|High frequency rTMS|High frequency rTMS to modulate brain areas
89543619|NCT04621851||Prospective cohort|Patients who will discontinue after it will contribute to the prospective cohort.
89543620|NCT04621851||Retrospective/Prospective cohort|Patients who discontinued before the opening of this study but will continue their discontinuation after it, will contribute to both cohorts.
89543621|NCT05558163|Other|PPI through traditional penoscrotal approach|cases of erectyl dysfunction who underwent PPI throug penoscrotal approach
89543622|NCT05558163|Other|PPI through novel transverse scrotal approach|cases of erectyl dysfunction who underwent PPI throug novel transverse scrotal approach
89543623|NCT04971447|Experimental|Group: transgender men|
89543624|NCT04971447|No Intervention|Groupe: control cis-gender women|
89543625|NCT04971447|Experimental|Group: transgender women|
89543626|NCT04971447|No Intervention|Groupe: control cis-gender men|
89543627|NCT04394715|Experimental|Intervention|Providers will see an electronic alert for eligible patients who are at very high risk for future ASCVD events upon opening of the patient's order entry screen in the medical record.
89543628|NCT04394715|No Intervention|Control|Providers will not see an electronic alert for any patients and will provide usual care. Silent alerts will be generated that will be sent to study team members.
89543629|NCT02149420|Experimental|VAY736 3 mg/kg|single dose iv of VAY736 at a dose of 3mg/kg
88961175|NCT02006680||Children with Central Precocious Puberty|Children with Central Precocious Puberty will have hormonal testing of markers of puberty up to 30 days prior to placement of a Supprelin LA insert and 28-97 days after placement of the Supprelin LA insert.
88961176|NCT02006745|Other|Ribavirin|ARM 1: PEG-IFN and weight-based ribavirin (RBV)
88961177|NCT02006745|Other|Telaprevir|ARM 2: PEG-IFN and weight-based RBV plus telaprevir (TPV)
88961178|NCT02006771|Experimental|Southern Chinese meal|White rice (1 bowl), stir fried Choi sum (0.5 bowl) and stir fried lean pork (0.5 bowl) cooked with maize oil
88961179|NCT02006771|Experimental|Northern Chinese meal|Noodles (1 bowl) and shredded pork with sweet bean sauce (0.5 bowl) cooked with blend oil
88961180|NCT02006771|Experimental|American meal|Hamburger with cheese (1 piece), French fries (117 g) cooked with canola blend oil plus Coca-cola classic (21 fluid ounces)
88961181|NCT02006771|Experimental|South Indian meal|Basmati rice (1 bowl), chicken curry dish (0.5 bowl), dry vegetable dish (i.e. green beans mixed with herbs) (0.5 bowl), yogurt made with milk powder mainly (0.5 bowl), pickle made with lemon, salt, chilli powder, Asafoetida and vegetable based oil (1 tablespoon)
89543630|NCT02149420|Experimental|VAY736 10 mg/kg|single dose iv of VAY736 at a dose of 10mg/kg
88961182|NCT02006797|Experimental|intervention|patients with reconciliation procedure at discharge and included in the exchange process
89543631|NCT02149420|Placebo Comparator|Placebo|single dose iv of Placebo. At Week 24 patients were offered to receive open label VAY736 10 mg/kg.
89543632|NCT05557773|Active Comparator|Control Group|The control group will be given home based traditional scoliosis exercise training for 8 weeks, 5 days a week for 45 minutes.
88961183|NCT02006797|No Intervention|control|usual care
89543633|NCT05557773|Experimental|Training Group|In addition to conventional home based traditional scoliosis exercises, patients in this group will also receive core stabilization exercise training for 45 minutes, 5 times in a week for 8 weeks. Every two sessions will be supervised in a clinic per week.
89543634|NCT04337307||standard decontamination|incubators decontaminated with antiseptic molecules, healthcare workers involved in this decontamination, patients housed in these incubators
89543635|NCT04337307||steam pulverization|incubators decontaminated with steam pulverization, healthcare workers involved in this decontamination, patients housed in these incubators
89543636|NCT05557383|Experimental|use peanut ball|Registered nurses were educated by the investigators on the study protocol, and standard care was given to both the intervention and control groups.The peanut ball was placed between the legs of a woman in the intervention group immediately after she received her epidural and consented to participate in the study.
89543637|NCT05557383|No Intervention|usual care|usual nursing care.
89543638|NCT02149264|Experimental|Testosterone gel (FE 999303)|Subjects received at least one dose of testosterone gel (23 mg), which was further titrated, if needed (upto three doses [69 mg]), based on serum testosterone concentrations. Testosterone gel was delivered using an applicator to the contralateral shoulder/upper arm.
89514923|NCT04769830||non-AGI group|Collect the characteristic data of intestinal sound, such as 24-hour average intestinal rate, duration of gastrointestinal sound, amplitude, maximum frequency, average frequency, etc., and detect citrulline, intestinal fatty acid binding protein and so on.
89514924|NCT04534257|Experimental|Angioplasty with SELUTION Sirolimus DCB|Subjects with infra-inguinal occlusive lesions will be treated with SELUTION Sirolimus DCB
89514925|NCT04528953|Experimental|interval group|
89514926|NCT04528953|Experimental|Qigong exercise|
89514927|NCT04528953|Active Comparator|continuous walking|
89514928|NCT04946955|Experimental|Application and website with promotion|Development of an application and a website to de-stigmatise mental health and support the user in seeking help
89514929|NCT04946955|Other|Application and website without promotion|
89514930|NCT05392647|Experimental|Single arm|Hetrombopag
89514931|NCT04922619|Active Comparator|Cochlear Implant (CI) with default fitting then tonotopy based fitting|Cochlear Implant with default fitting first during 6 weeks then with tonotopy based fitting during 6 weeks
89514932|NCT04922619|Active Comparator|Cochlear Implant (CI) with tonotopy based fitting then default fitting|Cochlear Implant with tonotopy based fitting during 6 weeks then with default fitting during 6 weeks
89514933|NCT03523013|Experimental|CPAP pressure (determied by DISE)|
89514934|NCT03523013|Active Comparator|CPAP pressure (determined by physician)|
89514935|NCT04476927|Experimental|DiaNose procedure|all subjects will be required to undergo the DiaNose exhalation test.
89514936|NCT04444323|Experimental|3D Telemedicine|Single arm. All patient seen face-to-face and then with 3D telemedicine.
89514937|NCT03522935|Experimental|Elafin 0.03 mg/kg|5 subjects will be administered with 0.03 mg/kg of Elafin subcutaneously once daily for 7 days.
89514938|NCT03522935|Experimental|Elafin 0.06 mg/kg|5 subjects will be administered with 0.06 mg/kg of Elafin subcutaneously once daily for 7 days.
89514939|NCT03522935|Experimental|Elafin 0.10 mg/kg|5 subjects will be administered with 0.10 mg/kg of Elafin subcutaneously once daily for 7 days.
89514940|NCT03522935|Experimental|Elafin 0.15 mg/kg|5 subjects will be administered with 0.15 mg/kg of Elafin subcutaneously once daily for 7 days.
89514941|NCT03522935|Experimental|Elafin 0.18 mg/kg|5 subjects will be administered with 0.18 mg/kg of Elafin subcutaneously once daily for 7 days.
89514942|NCT03522935|Placebo Comparator|Placebo Drug|5 subjects will be administered with placebo drug subcutaneously once daily for 7 days.
89514943|NCT03110445|Experimental|rVV-740CTA vaccine|
89514944|NCT03138681|Placebo Comparator|Placebo|
89514945|NCT03138681|Experimental|ATP|
89514946|NCT03138681|Experimental|phosphocreatine|
89514947|NCT04839861|Active Comparator|Mightier Online Games|6 weeks of use ad-libitum. Parents will be encouraged to have their children play Mightier online games at least 3 times a week for the 6 week duration.
89514948|NCT04839861|Experimental|Mightier Online Plus Offline Family Games|6 weeks of use ad-libitum. Parents will be encouraged to have their children play Mightier online games at least 3 times a week for the 6 week duration. Parents will be encouraged to play Mightier offline Family Games at least once a week for the 6 week duration.
89514949|NCT04796103|Active Comparator|Dextrose Prolotherapy Group|Patients diagnosed with chondromalacia patella
89514950|NCT04796103|Placebo Comparator|Serum Physiological Group|Patients diagnosed with chondromalacia patella
89514951|NCT04376853||COVID-19|Patients with COVID-19, who have cardiovascular diseases or receive medication with arrhythmogenic risk.
89514952|NCT05392491||Control group (without coronary lesions)|Cohort control group. No interventions.
89514953|NCT05392491||Coronary Lesion < 30%|Participants with coronary lesion under 30%. No interventions.
89514954|NCT05392491||Coronary Lesion > 30% and < 50%|Participants with coronary lesions greater than 30% and under 50%. No interventions.
89514955|NCT05392257|Experimental|Arms|
89514956|NCT00002663|Experimental|EBV+ PTLD-HCT R/R Rituximab (Tab-cel Only)|Patients with Epstein-Barr virus positive (EBV+) posttransplant lymphoproliferative disorders (PTLD) following hematopoietic cell transplant (HCT) who were relapse/refractory (R/R) to rituximab will receive IV infusion of tabelecleucel (tab-cel) at 1-5 × 10^6 T-cells/kg on Days 1, 8, and 15 and will be observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.
89514957|NCT00002663|Experimental|EBV+ PTLD-SOT R/R Rituximab + Chemo (Tab-cel Only)|Patients with EBV+ PTLD following solid organ transplant (SOT) who were R/R to rituximab and chemotherapy will receive IV infusion of tabelecleucel at 1-5 × 10^6 T-cells/kg on Days 1, 8, and 15 and will be observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.
89514958|NCT00002663|Experimental|EBV+ AID-LPD (Tab-cel Only)|Patients with EBV+ acquired immunodeficiency (AID) lymphoproliferative disorder (LPD) will receive IV infusion of tabelecleucel at 1-5 × 10^6 T-cells/kg on Days 1, 8, and 15 and will be observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.
89514959|NCT00002663|Experimental|EBV+ LMS (Tab-cel Only)|Patients with EBV+ leiomyosarcoma (LMS) will receive IV infusion of tabelecleucel at 1-5 × 10^6 T-cells/kg on Days 1, 8, and 15 and will be observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.
89514960|NCT00002663|Experimental|EBV+ NPC (Tab-cel Only)|Patients with EBV+ nasopharyngeal carcinoma (NPC) will receive IV infusion of tabelecleucel at 1-5 × 10^6 T-cells/kg on Days 1, 8, and 15 and will be observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.
89543639|NCT05557149|Sham Comparator|Neutral VR|Ten minutes virtual reality exposure to neutral stimuli (e.g. neutral picture frames)
89543640|NCT05557149|Experimental|Cocaine VR|Ten minutes virtual reality exposure to cocaine use-related stimuli (i.e. peers using cocaine, cocaine paraphernalia, cocaine use preparing, cocaine use, etc.)
89024970|NCT00476580||Sri Lankan Sinhalese|Sri Lankan Sinhalese adults (18 years of age or older) living in the greater Houston area, but born in Sri Lanka.
89024971|NCT00476580||Siblings or Cousins in Sri Lanka|Siblings or the first cousins of the study participants living in Sri Lanka of same sex and of an age plus or minus 10 years.
89543641|NCT05557149|Other|Relaxation|Ten minutes respiratory relaxation (eyes closed and sitted on a chair)
89543642|NCT04417738|Active Comparator|Active|Patients will receive the active treatment.
89543643|NCT04417738|Sham Comparator|Sham|Patients will receive the sham treatment (the identical LED covered by aluminum foil).
89543644|NCT02115256|Active Comparator|Intravenous Terbutaline|0.25 mL of Intravenous Terbutaline
89543645|NCT02115256|Active Comparator|Intravenous Nitroglycerine|IV nitroglycerine 100 micrograms three minutes before beginning the procedure, then followed by a second dose 3 minutes later just after the start of the procedure for a total of 200 micrograms.
89543646|NCT02173054|Placebo Comparator|Adapalene gel|"Evening~Wash face by prepared facial foam and dry your face~Apply adapalene gel all over the face"
89543647|NCT02173054|Placebo Comparator|Adapalene gel with placebo moisturizer|"Morning~Wash face by prepared facial foam and dry their face~Apply placebo cream all over the face~Evening~Wash face by prepared facial foam and dry your face~Apply adapalene gel all over the face~Apply placebo cream all over the face"
89543648|NCT02173054|Active Comparator|Adapalene gel with Eucerin|"Morning~Wash face by prepared facial foam and dry their face~Apply Eucerin cream all over the face~Evening~Wash face by prepared facial foam and dry your face~Apply adapalene gel all over the face~Apply Eucerin cream all over the face"
89543649|NCT04741906||Patient with osteoporosis - antiresorptive treatment > 4 years. Previous tooth extraction|Patient with osteoporosis - antiresorptive treatment > 4 years who have had previous tooth extraction without development of MRONJ
89543650|NCT04741906||Patient with osteoporosis - antiresorptive treatment > 4 years. Previous resection|Patient with osteoporosis - antiresorptive treatment > 4 years who have lost teeth due to having previous osteonecrosis of the jaw which has been successfully surgically treated and healed for at least 3 months without recurrence
89543651|NCT04741906||Patient with osteoporosis - antiresorptive treatment > 4 years. Simultaneously with resection|Patient with osteoporosis - antiresorptive treatment > 4 years with ongoing osteonecrosis of the jaw to be surgically treated with block resection of the lower jaw and insertion of a titanium reconstruction plate. Simultaneous insertion of dental implants, or resection of the upper jaw where there is sufficient remaining bone volume to have implants inserted simultaneously (without bone augmentation)
89543652|NCT04741906||Patient with cancer - adjuvant dose antiresorptive treatment. Previous tooth extraction|Patient with cancer (breast, prostate or multiple myeloma) - adjuvant dose antiresorptive treatment who have had previous tooth extraction without development of MRONJ
89543653|NCT04741906||Patient with cancer - adjuvant dose antiresorptive treatment. Previous resection|Patient with cancer (breast, prostate or multiple myeloma) - adjuvant dose antiresorptive treatment who have lost teeth due to having previous osteonecrosis of the jaw which has been successfully surgically treated and healed for at least 3 months without recurrence
89543654|NCT04741906||Patient with cancer - adjuvant dose antiresorptive treatment. Simultaneously with resection|Patient with cancer (breast, prostate or multiple myeloma) - adjuvant dose antiresorptive treatment with ongoing osteonecrosis of the jaw to be surgically treated with block resection of the lower jaw and insertion of a titanium reconstruction plate. Simultaneous insertion of dental implants, or resection of the upper jaw where there is sufficient remaining bone volume to have implants inserted simultaneously (without bone augmentation)
89543655|NCT04741906||Cancer patient treated with high dose antiresorptive treatment. Previous tooth extraction|Cancer patient treated with high dose antiresorptive treatment who have had previous tooth extraction without development of MRONJ
89543656|NCT04741906||Cancer patient treated with high dose antiresorptive treatment. Previous resection|Cancer patient treated with high dose antiresorptive treatment who have lost teeth due to having previous osteonecrosis of the jaw which has been successfully surgically treated and healed for at least 3 months without recurrence
89543657|NCT04741906||Cancer patient treated with high dose antiresorptive treatment. Simultaneously with resection|Cancer patients (breast, prostate or multiple myeloma) treated with high dose antiresorptive treatment with ongoing osteonecrosis of the jaw to be surgically treated with block resection of the lower jaw and insertion of a titanium reconstruction plate. Simultaneous insertion of dental implants, or resection of the upper jaw where there is sufficient remaining bone volume to have implants inserted simultaneously (without bone augmentation)
89543658|NCT04741828|Experimental|Vi-DT Typhoid Conjugate Vaccine|Participants receive 1 dose (0.5ml) Vi-DT Typhoid Conjugate Vaccine, intramuscularly.
89543659|NCT04225221|Experimental|Sequence A: estradiol followed by progesterone|"Participants are randomly assigned to treatment Sequence A: after achieving hormone suppression using Lupron, participants begin the addback period and take study medications for 8 weeks. During the 8 week period, participants will take placebo or estradiol or progesterone. Participants will not know when or for how long they are on active medication (i.e., estradiol or progesterone) or inactive (i.e., placebo) medication. When active medication is administered, participants randomized to treatment sequence A will receive estradiol addback first, followed by progesterone.~Estradiol and progesterone are never given simultaneously. Participants are on active medication for a total of 4 weeks."
88961184|NCT02006810|Experimental|lipids|The study will be randomized (on the order of taking the products: a single dose of lipids or a single dose of flavonoids), single-blinded, cross-over for each population (healthy and metabolic syndrome).
89024972|NCT00440141|Experimental|1|
89024973|NCT00440141|Active Comparator|2|
89543660|NCT04225221|Experimental|Sequence B: progesterone followed by estradiol|"Participants are randomly assigned to treatment Sequence B: after achieving hormone suppression using Lupron, participants begin the addback period and take study medications for 8 weeks. During the 8 week period, participants will take placebo or estradiol or progesterone. Participants will not know when or for how long they are on active medication (i.e., estradiol or progesterone) or inactive (i.e., placebo) medication. When active medication is administered, participants randomized to treatment sequence B will receive progesterone first followed by estradiol.~Estradiol and progesterone are never given simultaneously. Participants are on active medication for a total of 4 weeks."
89543661|NCT04187625|Experimental|Intervention|Patients will be given autologous endothelial progenitor cells
89543662|NCT04024371||HV|Humans aged 20-55 without a diagnosis of a psychiatric and neurological disorder.
89543663|NCT04024371||SZ|Humans aged 20-55 with a primary Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5) diagnosis of Schizophrenia.
89543664|NCT04024371||MDD|Humans aged 20-55 with a primary Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5) diagnosis of MDD.
89543665|NCT04675593|Experimental|iTAB-CV + Self Monitoring|Receives iTAB-CV intervention plus self-monitoring (SM), blood pressure home monitoring, eCAP, and weekly mood rating
89543666|NCT04675593|Active Comparator|Self Monitoring|Receives self-monitoring (SM), blood pressure home monitoring, eCAP, and weekly mood rating
89543667|NCT04675593|Experimental|iTAB-CV + Self Monitoring - High Intensity Booster|Following the 4-month assessment, subjects in the iTAB-CV group will be re-randomized to receive either a high intensity booster or low intensity booster. Those in the high intensity booster group will start off receiving 1 reminder per day and taper down to 1 reminder per week over 2 months, in addition to self monitoring.
89543668|NCT04675593|Experimental|iTAB-CV + Self Monitoring - Low Intensity Booster|Following the 4-month assessment, subjects in the iTAB-CV group will be re-randomized to receive either a high intensity booster or low intensity booster. Those in the low intensity booster group will receive 1 reminder per week for 2 months, in addition to self monitoring.
89543669|NCT05556369||Single Arm Study|The study involves the execution of a genetic analysis using a panel of 54 genes conducted on blood obtained from peripheral venous sampling, the collection of clinical / instrumental / biological data in a dedicated prospective register in the form of a pseudo-anonymized database and the follow-up clinical up over time of patients. The study also provides for the execution of: a cardiological examination with electrocardiogram, Echocardiogram-color doppler and Basic blood tests: CBC, renal function, electrolytes, hepatic profile, NT-proBNP, lipid profile.
89543670|NCT05556213|Active Comparator|Patients|
89543671|NCT05556213|Active Comparator|Control|
89543672|NCT05556135||group1|NAFLD patients
89543673|NCT05556135||group 2|non NAFLD patients
89543674|NCT03977961||DDD Patients|All patients presenting to the neurosurgical department of the Kantonsspital St. Gallen (KSSG) with a diagnosed DDD fulfilling the inclusion criteria and scheduled for surgery will be considered for this study.
89543675|NCT04425993|Experimental|Rectal indomethacin and sublingual nitrate|"All patients without contraindications should receive sublingual isosorbide dinitrate within 5 min before ERCP.~All patients without contraindications should receive rectal indomethacin within 30 min before ERCP."
89543676|NCT04425993|Active Comparator|Rectal indomethacin and sublingual placebo|"All patients without contraindications should receive sublingual placebo within 5 min before ERCP.~All patients without contraindications should receive rectal indomethacin within 30 min before ERCP."
89543677|NCT04425993|Active Comparator|Rectal placebo and sublingual nitrate|"All patients without contraindications should receive sublingual isosorbide dinitrate within 5 min before ERCP.~All patients without contraindications should receive rectal placebo within 30 min before ERCP."
88961185|NCT02006810|Other|flavonoids|The study will be randomized (on the order of taking the products: a single dose of lipids or a single dose of flavonoids), single-blinded, cross-over for each population (healthy and metabolic syndrome).
88961186|NCT02006849|Other|Acthar 40 units|Acthar 40 units subcutaneously three times a week for patients with sub-nephrotic proteinuria.
88961187|NCT02006849|Other|Acthar 80 units|Acthar 80 units subcutaneously twice a week for patients with nephrotic proteinuria.
89543678|NCT04425993|Placebo Comparator|Rectal placebo and sublingual placebo|"All patients without contraindications should receive sublingual placebo within 5 min before ERCP.~All patients without contraindications should receive rectal placebo within 30 min before ERCP."
89543679|NCT03971643|Experimental|vilobelimab 800 mg Q2W|"Dose finding with a total of 15 doses of vilobelimab.~Vilobelimab: IV infusions of vilobelimab diluted in sodium chloride.~All patients received vilobelimab 800 mg three times during the first week (Days 1, 4, and 8).~Starting at Day 15:~Group 1 (N=6) continued to receive vilobelimab 800 mg every 2 weeks (Q2W), with option to increase dose from Day 57 to 1600 mg every Q2W."
89543680|NCT03971643|Experimental|vilobelimab 1600 mg Q2W|"Dose finding with a total of 15 doses of vilobelimab.~Vilobelimab: IV infusions of vilobelimab diluted in sodium chloride.~All patients received vilobelimab 800 mg three times during the first week (Days 1, 4, and 8).~Starting at Day 15:~Group 2 (N=6) received vilobelimab 1600 mg every 2 weeks (Q2W), with option to increase dose from Day 57 to 2400 mg every Q2W."
88961188|NCT02006862||olanzapine, schizophrenia|
88961189|NCT02006875|Experimental|real rTMS|Experimental included the a daily real rTMS session for 15 mins followed by a physical therapy for 45 mins.
88961190|NCT02006875|Sham Comparator|sham rTMS|the control interventions included a daily sham rTMS session for 15 minutes followed by a physical therapy for 45 minutes.
88961191|NCT02006901||microdecompression|surgical microdecompression using a bilateral or unilateral approach depending on the surgeon's preference and the individual patient's anatomy and symptoms.
88961192|NCT02006901||laminectomy|the spinous process and the laminae of the involved level(s) as well as the medial aspects of the facet joints are resected
88961193|NCT02005185||6-11y/o anesthetized at 0-2y/o for >2hrs|6-11yr olds anesthetized for more than120 minutes before the age of 2.
88961194|NCT02005185||6-11y/o anesthetized @ 0-2y/o for <30min|6-11 year olds anesthetized for < 30min before the age of 2.
88961195|NCT02005185||6-11y/o anesthetized at 4-7y/o for >2hrs|6-11 year olds anesthetized for more than 120 min between the ages of 4-7.
89024974|NCT03279575|Experimental|Night Shift|Night Shift is an adventure video game with the transformational goal of teaching physicians key characteristics of patients with non-representative severe injuries - injuries classified by the American College of Surgeons as life-threatening or critical but that do not fit the archetype of injuries typically requiring treatment at a trauma center. Players take on the persona of Andy Jordan, a young emergency physician who moves home after the disappearance of his estranged grandfather (Robert Jordan) and takes up a job in the local Emergency Department (ED). In the preamble, players learn they have two explicit objectives. First, they must diagnose and treat patients who present to their ED. Second they must solve the mystery of Robert's disappearance: was he murdered or has he simply chosen to disappear?
89024975|NCT03279575|Experimental|Graveyard Shift|Graveyard Shift is a puzzle video game with the transformational goal of helping physicians derive key triage decision principles for themselves. They complete a three-step game loop to obtain case information, compare cases to determine similarities and differences between cases, and then explicitly state the decision principle that should drive decision making.
89207477|NCT00854802|Experimental|Debio 025 600 mg + peg-IFNα2a + ribavirin - 24 weeks|Participants receive Debio 025 600 mg orally twice daily for 7 days (loading dose) followed by Debio 025 600 mg orally once daily for 23 weeks + peg-IFNα2a 180 µg sc once weekly for 24 weeks + ribavirin 1000 or 1200 mg (weight based) orally daily for 24 weeks.
89514961|NCT00002663|Experimental|EBV+ PTLD-HCT R/R Rituximab (EBV-CTLs Only)|Patients with EBV+ following PTLD HCT who were R/R to rituximab or rituximab naive will receive IV infusion of transplant donor-derived EBV-cytotoxic T lymphocytes (CTLs) at 1-5 × 10^6 T-cells/kg on Days 1, 8, and 15 and will be observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.
89514962|NCT00002663|Experimental|EBV+ PTLD-SOT R/R Rituximab + Chemo (EBV-CTLs Only)|Patients with EBV+ PTLD following SOT who were R/R to rituximab and chemotherapy will receive IV infusion of transplant donor-derived EBV-CTLs at 1-5 × 10^6 T-cells/kg on Days 1, 8, and 15 and will be observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.
89514963|NCT00002663|Experimental|EBV+ Viremia (EBV-CTLs Only)|Patients with EBV+ viremia will receive IV infusion of transplant donor-derived EBV-CTLs at 1-5 × 10^6 T-cells/kg on Days 1, 8, and 15 and will be observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.
89514964|NCT00002663|Experimental|EBV+ PID-LPD (Tab-cel or EBV-CTLs)|Patients with EBV+ primary immunodeficiency (PID) LPD will receive IV infusion of tabelecleucel or transplant donor-derived EBV- CTLs at 1-5 × 10^6 T-cells/kg on Days 1, 8, and 15 and will be observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.
89514965|NCT00002663|Experimental|EBV+ Lymphoma (Tab-cel or EBV-CTLs)|Patients with EBV+ lymphoma will receive IV infusion of tabelecleucel or transplant donor-derived EBV-CTLs at 1-5 × 10^6 T-cells/kg on Days 1, 8, and 15 and will be observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.
89514966|NCT02240680|Experimental|linagliptin 5 mg|patient to receive a tablet of linagliptin 5 mg each day
89514967|NCT02240680|Placebo Comparator|placebo|patient to receive a tablet of placebo matching linagliptin 5 mg
89514968|NCT05391867|Experimental|Lenvatinib group (Group-A)|Patients diagnosed as hepatocellular carcinoma will be randomly assigned for treatment with Lenvatinib. Cap. Lenvatinib will be given at doses of 4 mg 12 hourly.
89514969|NCT05391867|Experimental|Sorafenib group (Group-B)|Patients diagnosed as hepatocellular carcinoma will be randomly assigned for treatment with Sorafenib. Tab. Sorafenib will be given at doses of 200 mg 12 hourly.
89514970|NCT02288975||CytoSorb|Patients with septic shock will get routine ICU care supported by CytoSorb® treatment.
89514971|NCT02288975||Control|Patients with septic shock will get routine ICU care.
89514972|NCT03110679|Experimental|autologous bone marrow concentrate|concentration of bone marrow taken from the patient's right tibia using Bio-MAC® suction catheter, company Biologic Therapies, Inc., and concentrated by centrifuge Bio.SPINTM Magellan®, company Biologic Therapies , Inc., and its injection in the intra-articular.
89514973|NCT03110679|Experimental|hyaluronic acid.|single injection of intra-articular hyaluronic acid 60mg (4 cc), and serve as a control.
89514974|NCT02290067|Active Comparator|Omnitest 3|Blood glucose monitoring system
89514975|NCT02290067|Experimental|Omnitest 5|Blood glucose monitoring system
89514976|NCT02290067|Experimental|Omnitest 5D|Blood glucose monitoring system
89514977|NCT02289053||Positive Family History|"Eligible participants with a family history of colorectal cancer or polyps will be grouped into the subjects group."
89514978|NCT02289053||Average Risk Patients|"Eligible participants without a family history of colorectal cancer or polyps will be grouped into the control group."
89514979|NCT02289131|Experimental|Frequency of Once a Day|Tooth Brushing Protocol to be provided at 8:00 am (+/- 1.5 hours)
89514980|NCT02289131|Experimental|Frequency of Twice a Day|Tooth Brushing Protocol to be provided at 8:00 am (+/- 1.5 hours) Tooth Brushing Protocol to be provided at 1:00 pm (+/- 1.5 hours)
89514981|NCT02289131|Experimental|Frequency of Three Times a Day|Tooth Brushing Protocol to be provided at 8:00 am (+/- 1.5 hours) Tooth Brushing Protocol to be provided at 1:00 pm (+/- 1.5 hours) Tooth Brushing Protocol to be provided at 6:00 pm (+/- 1.5 hours)
89514982|NCT05391789|Experimental|normal dose|Patients would be given 400000 units of ulinastatin (specification: 100000 units / vial) dissolved in 50 ml of 0.9% normal saline intravenously for at least 1 hour, once every 8 hours. It is evaluated by the attending doctor every day. When the patient does not have systemic inflammatory response syndrome (SIRS), halve the dose and continue to use it for 2 days, with a total course of treatment of at least 3 days
89514983|NCT05391789|Experimental|high dose|Patients would be given 800000 units of ulinastatin (specification: 100000 units / vial) dissolved in 50 ml of 0.9% normal saline intravenously for at least 1 hour, once every 8 hours. It is evaluated by the attending doctor every day. When the patient does not have systemic inflammatory response syndrome (SIRS), halve the dose and continue to use it for 2 days, with a total course of treatment of at least 3 days
89514984|NCT05391789|Placebo Comparator|placebo|Patients would be given 50 ml of 0.9% normal saline intravenously for at least 1 hour once every 8 hours.It is evaluated by the attending doctor every day. When the patient does not have systemic inflammatory response syndrome (SIRS), continue to use it for 2 days, with a total course of treatment of at least 3 days.
89514985|NCT02240368||Group 1|Children age between 1 month to 12 months
89514986|NCT02240368||Group 2|Children age between 13 months and 36 months
89514987|NCT02240368||Group 3|Children age between 37 months to 144 months
88961196|NCT02005185||6-11 y/o healthy control|6-11 year olds that have never received general anesthesia.
88961197|NCT02006914||Chromium Picolinate|Subjects who are HIV+ and insulin resistant
89514988|NCT02290301||Type 2 Diabetes Mellitus|
89514989|NCT04699071|Experimental|patients with recurrent clear cell carcinoma of gynecological origin (CCGC)|Recurrent clear cell carcinoma of gynecological origin (ovarian and endometrial primary) after progression on chemotherapy.
89514990|NCT02289287|Experimental|Self-Management group-intervention|Participants will receive Self-Management group-intervention + Standard Care
89514991|NCT02289287|Active Comparator|Standard Care|Participants will receive Standard Care only
89514992|NCT02239978||Parkinsons disease|Individuals with Parkinsons disease
89514993|NCT02239978||Control|Age-matched healthy adults
89514994|NCT02290379|Experimental|TNX-201 35 mg|Drug: TNX-201 35 mg
89514995|NCT02290379|Experimental|TNX-201 70 mg|Drug: TNX-201 70 mg
89514996|NCT02290379|Experimental|TNX-201 140 mg|Drug: TNX-201 140 mg
89514997|NCT02290379|Active Comparator|Racemic isometheptene 70 mg|Comparator: Racemic Isometheptene 70 mg
89514998|NCT02290379|Placebo Comparator|Placebo|Drug: Placebo
89514999|NCT04688307|Experimental|Lifestyle modification and smoking reduction failure|Obtaining ideal body weight by calorie restriction diet and programmed physical activity and the amount of cigarette smoking reduction is not more than 50% of the baseline
89515000|NCT04688307|Experimental|Lifestyle modification and smoking reduction|Obtaining ideal body weight by calorie restriction diet and programmed physical activity and the amount of cigarette smoking reduction is 50% of the baseline or more
89515001|NCT02290457|Experimental|CSTS|core strength training performed on stable surfaces
89515002|NCT02290457|Experimental|CSTU|core strength training performed on unstable surfaces
89515003|NCT03139851|Other|Cyclophosphamide and Pembrolizumab|"The treatments received are:~cyclophosphamide (50 mg/day, daily, per os)~pembrolizumab (200 mg every 3 weeks, intravenously [IV]). On days 1, cyclophosphamide should be taken first and pembrolizumab infusion initiated within 1 hour after cyclophosphamide intake."
89515004|NCT02289365|Placebo Comparator|Group I|Totally 3000 mg of PEG-400 per day. 3 capsules of 500 mg PEG-400 per time, twice a day.
89515005|NCT02289365|Experimental|Group II|Totally 2000 mg of JBM-TC4 per day. 2 capsules of 500 mg JBM-TC4 plus 1 capsule of 500 mg PEG-400 per time, twice a day.
89515006|NCT02289365|Experimental|Group III|Totally 3000 mg of JBM-TC4 per day. 3 capsules of 500 mg JBM-TC4 per time, twice a day.
89515007|NCT04636281|Experimental|Passive static stretching exercise|Group 1 will receive passive static stretching. All subjects will be assessed before the intervention through likert muscle soreness scale, Numeric Rating Pain Scale and range of motion for Shoulder, elbow, and wrist by a Goniometer. After that all subjects will perform eccentric exhaust weight exercises in the gym of all mentioned joints, three sets at each joint. Before giving the intervention they will assess of all mentioned parameters.
89515008|NCT04636281|Experimental|Active static stretching|Group 2 will receive active static stretching. All subjects will be assessed before the intervention through likert muscle soreness scale, Numeric Rating Pain Scale and range of motion for Shoulder, elbow, and wrist by a Goniometer. After that all subjects will perform eccentric exhaust weight exercises in the gym of all mentioned joints, three sets at each joint. Before giving the intervention they will assess of all mentioned parameters.
89515009|NCT03521609|Experimental|Emotional Intelligence Intervention|Patient's emotional abilities will be stimulated by means of a brief intervention in a group format (nine sessions). In these sessions we will use both projective and guided-fantasy techniques for the emotional diagnosis, as well as psychoeducational workshops of both emotional education and emotional intelligence development.
89515010|NCT02289443||Simplified|Complete denture fabricated by simple way than the textbook traditional method.
89515011|NCT02289443||Traditional|Complete denture fabricated by textbook discribed traditional method.
89543681|NCT03971643|Experimental|vilobelimab 2400 mg Q2W|"Dose finding with a total of 15 doses of vilobelimab.~Vilobelimab: IV infusions of vilobelimab diluted in sodium chloride.~All patients received vilobelimab 800 mg three times during the first week (Days 1, 4, and 8).~Starting at Day 15:~Group 3 (N=7) received vilobelimab 2400 mg every Q2W."
88961198|NCT02006914||Placebo|HIV+ and insulin resistant
88961199|NCT02006940|Experimental|Alveoflex, in vivo imaging miniprobe|All the patients will be examined using confocal laser endomicroscopy during bronchoscopy with a special minirobe Alveoflex before and after the treatment. Records will be done and analyzed prospectively with the included software for endomicroscopic system.
88961200|NCT02006953|Active Comparator|Bolus|"Bolus: Total volume of feedings is determined by the amount of formula required to meet calorie and protein needs, which is determined by a Registered Dietitian. Volume of each bolus is determined by dividing the total volume of feeding by the desired number of feedings per day:~If child is less than 6 months: 8 feeds/day If child is 6-12 months 6 feeds/day If child is 12 months or greater: 5 feedings/day Rate of feeds is determine by the rate needed to infuse each bolus over 1 hour. Patient to remain NPO. Once at goal, if able to take PO, may offer orally first with remainder of goal volume over the remainder of the hour."
88961201|NCT02006953|Active Comparator|Continuous|Continuous: Total volume of feedings is determined by the amount of formula required to meet calorie and protein needs, which is determined by a Registered Dietitian. Rate of feeds is determined by dividing total volume of feedings by 24 hours. Patient is to remain NPO. Once at goal, if able to take PO, may offer hourly amount orally, but only 2x per day.
88961202|NCT02006966|Experimental|Group L|Intravenous lidocaine infusion group
88961203|NCT02006966|Active Comparator|Group C|Intravenous normal saline infusion - control group
88961204|NCT02006992|Active Comparator|RTF Infant Formula 1|a ready to feed (RTF) extensively hydrolyzed infant formula fed ad lib.
89543682|NCT03971175|Active Comparator|Forceps group|
89543683|NCT03971175|Experimental|Cryobiopsy group|
89543684|NCT03961113||assessment by questionnaire|
89543685|NCT04512885||Patients with type 1 diabetes|
89543686|NCT04512885||Health professionals|
89543687|NCT04480749|Other|Routine Testing|Among men in the control group, they will receive a list of local clinics that can provide free syphilis testing.
89543688|NCT04480749|Experimental|Self-Testing|In the intervention arm we will provide a treponemal rapid syphilis test kit to all individuals in the intervention arm of the pilot, delivered through MSM community facilitators. This is similar to existing rapid treponemal test kits that are available at many clinical facilities. Kits will be accompanied by simplified pictorial instructions on finger prick blood sample collection.
89543689|NCT02149108|Experimental|Nintedanib (BIBF 1120) + BSC|
89543690|NCT02149108|Placebo Comparator|Placebo + BSC|
89543691|NCT02148952|Experimental|Intervention Health Facility|WHO Safe Childbirth Checklist Program
89543692|NCT02148952|No Intervention|Control Health Facility|Matched control facilities providing comparison for intervention facilities
89543693|NCT04421859|Experimental|EyeCU App|"Augmented reality mobile application called EyeCU which simulates glaucoma progression and enhances understanding about the disease and its course. It is a bilingual (English/Spanish) application that is free-to-download on the Android and Apple app store. It will be delivered on a hospital owned tablet device and patients will be instructed to complete two sections, taking approximately 10 minutes."
89543694|NCT03569007|Active Comparator|Larazotide 0.25 mg|Larazotide 0.25 mg capsules TID
89543695|NCT03569007|Active Comparator|Larazotide 0.50 mg|Larazotide 0.50 mg capsules TID
89543696|NCT03569007|Placebo Comparator|Placebo|Matching placebo capsules TID
89543697|NCT02148718|Experimental|Adalimumab|Participants received adalimumab for 12 weeks (160 mg at Week 0; 80 mg at week 2; then adalimumab 40 mg every other week starting at Week 4).
89543698|NCT03397953|Experimental|Vinorelbine monotherapy treatment|Patients will be treated by Vinorelbine. Four weeks as a course. There are 20 courses in total.
89543699|NCT05549973|Experimental|Anlotinib Hydrochloride Capsule|Anlotinib Hydrochloride Capsule, 21 days as a treatment cycle.
89543700|NCT02148250|Experimental|100 Syringe Units, then 200|Participants randomized to first receive 100 syringe units of U-500 regular insulin, then 200 units
89543701|NCT02148250|Experimental|200 Syringe Units, then 100|Participants randomized to first receive 200 syringe units of U-500 regular insulin, then 100 units
89543702|NCT03321747|Experimental|Phase 1/Dose Level 1|11 Gy will be given in 5 fractions for a total dose of 55 Gy
89543703|NCT03321747|Experimental|Phase 1/Dose Level 2|12 Gy will be given in 5 fractions for a total dose of 60 Gy
89543704|NCT03321747|Experimental|Phase 1/Dose Level 3|13 Gy will be given in 5 fractions for a total dose of 65 Gy
89543705|NCT03321747|Experimental|Phase 1/Dose Level 4|14 Gy will be given in 5 fractions for a total dose of 70 Gy
89543706|NCT03321747|Experimental|Phase 2|The maximum tolerated radiation dose determined during Phase 1 (i.e. 11, 12, 13, or 14 Gy) will be given in 5 fractions for a total dose of 55, 60, 65, or 70 Gy.
89543707|NCT03285789|Experimental|Dyslexics with reduced visual attention span|21 subjects diagnosed dyslexics with reduced visual attention span
89543708|NCT03285789|Experimental|Dyslexics with normal visual attention span|
89543709|NCT03285789|Active Comparator|controls|
89543710|NCT02147626|Active Comparator|Information and Screening Group|Intervention: The patient website will include the American Heart Association (AHA) Class I Lifestyle recommendations (translated to an 8th grade reading level and with a link to the publication), a link to the online National Institutes of Health (NIH) Dietary Approaches to Stop Hypertension (DASH) website, and the NIH smoking cessation website
89543711|NCT02147626|Experimental|HH4M Intervention Arm|Intervention: The HH4M patient website will include information and tools. These resources are customized to help new mothers achieve the AHA Class I Lifestyle recommendations for women with a history of preeclampsia.
89543712|NCT04870359|Active Comparator|Pre-emptive Treatment (Prednisolone and/or AZA/MMF)|"Increase prednisolone to 0.4-0.5 mg/kg/day; taper by 5 mg every 2 weeks to reach 15mg/day; then further reduce by 2.5 mg every 2 week and aim to reach 5-7.5 mg/day after 12 weeks.~Adjustment of the 2nd agent would be as follows:~For patients who receive AZA <75mg/day; increase the dose of AZA to 75 mg/day.~For patients who receive MMF <1g/day, increase the dose of MMF to 1g/day."
89543713|NCT04870359|No Intervention|Control|Current immunosuppressive regimen and dosage should remain unchanged until the development of renal or extra-renal flares which required increase/change in immunosuppression.
88961205|NCT02006992|Experimental|Powder Infant Formula 2|a powdered extensively hydrolyzed infant formula fed ad lib.
88961206|NCT02007005|Experimental|Dose escalation|intravesical instillation of abnobaVISCUM Fraxini
88961207|NCT02007018|Experimental|Negative Pressure Wound Therapy|This group will receive the usual care of surgical wound AND Negative Pressure Wound Therapy (NPWT). The Prevena™ Incision Management System (PIMS) is placed in a sterile fashion over the closed surgical site prior to leaving the operating room. The PIMS is to remain in place until the completion of therapy at five days.
88961208|NCT02007018|Active Comparator|Usual Care of Surgical Wound|This group will receive the usual care of a surgical wound.
89543714|NCT05549817|Experimental|Synchronous Telerehabilitation Group|The exercise program was applied to groups that include three participants of the synchronous group 3 days per week by video conference method on an online platform (Zoom) with the supervision of a physiotherapist. The time of the group session was organized according to the availability of participants in that group and the physiotherapist using shared calendar availability (Doodle). The physiotherapist sent a reminder to participants one hour prior to each session including the video conference meeting link. Each exercise session lasted approximately 40 minutes. For 8 weeks, a total of 24 exercise sessions were performed. The physiotherapist demonstrated the exercises as needed, supervised the group by giving real-time feedback, and progressed the exercise program according to the needs of each group.
89543715|NCT05549817|Active Comparator|Asynchronous Telerehabilitation Group|The exercise program was prescribed and followed up 3 days per week via the mobile application (FizyoTr). A notification was sent to participants' phones via mobile application prior to each session and attendance to the exercise program was recorded. For 8 weeks, a total of 24 exercise sessions were performed. The physiotherapist progressed the exercise program according to the assessment at 4 weeks and the needs of each participant.
89543716|NCT05549583|Experimental|Reference group|Thirty minutes after the start of the breakfast, a single dose of the Reference formulation was administered with approximately 240 mL of water at ambient temperature
89207478|NCT00854802|Experimental|Debio 025 600 mg + peg-IFNα2a + ribavirin - 24 or 48 weeks|Participants receive Debio 025 600 mg orally twice daily for 7 days (loading dose) followed by Debio 025 600 mg orally once daily for 23 or 47 weeks + peg-IFNα2a 180 µg sc once weekly for 24 or 48 weeks + ribavirin 1000 or 1200 mg (weight based) orally daily for 24 or 48 weeks. Participants who achieve a rapid viral response, defined as having undetectable hepatitis C virus RNA at week 4, are treated for 24 weeks; other patients are treated for 48 weeks.
89543717|NCT05549583|Experimental|Test group|Thirty minutes after the start of the breakfast, a single dose of the Test formulation was administered with approximately 240 mL of water at ambient temperature
89543718|NCT05554809|Experimental|Dynamic stretching|
89543719|NCT05554809|Experimental|Static stretching|
89543720|NCT05554809|Active Comparator|Controll|
89543721|NCT02172664|Active Comparator|Adhese Universal with self etch enamel etching|patients will receive one restoration on randomly selected study tooth utilizing the self-etch universal adhesive (Adhese Universal, Ivoclar Vivadent) with no separate enamel etching
89543722|NCT02172664|Experimental|selective etch protocol followed by Adhese Universal|patients will receive one restoration on randomly selected study tooth utilizing a 37% phosphoric acid solution followed by application of self-etch universal adhesive (Adhese Universal, Ivoclar Vivadent)
89543723|NCT05554731|Experimental|New balloon catheter for Endotracheal hemostasis + Traditional Therapy|"Haemoptysis clinic for regular haemoptysis after treatment and life safety safeguard measures;~Balloon closure after informed consent (it can be blocked in emergency);~CTA (can be performed as an emergency prior to balloon blockage);~Artery interventional therapy (if necessary);~Surgery (if needed)."
89543724|NCT05554731|Active Comparator|Traditional Therapy|"Haemoptysis clinic for regular haemoptysis after treatment and life safety safeguard measures;~CTA (can be performed as an emergency prior to balloon blockage);~Artery interventional therapy (if necessary);~Surgery (if needed)."
89543725|NCT02172040|Experimental|Amlodipine+Celecoxib|Over-encapsulated 10 mg amlodipine besylate tablet + over-encapsulated 200 mg celecoxib capsule once a day for two weeks
89543726|NCT02172040|Active Comparator|Amlodipine+Placebo|Over-encapsulated 10 mg amlodipine besylate tablet + matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks
89543727|NCT02172040|Placebo Comparator|Placebo+Celecoxib|Matched placebo capsule for over-encapsulated amlodipine besylate tablet + over-encapsulated 200 mg celecoxib capsule once a day for two weeks
89543728|NCT02172040|Sham Comparator|Placebo+Placebo|Matched placebo capsule for over-encapsulated amlodipine besylate tablet + matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks
89543729|NCT02367105|Active Comparator|Testosterone plus Lifestyle Therapy|Testosterone replacement in combination with behavioral diet to induce ~10% weight loss + supervised aerobic and exercise training
89543730|NCT02367105|Placebo Comparator|Placebo plus Lifestyle Therapy|Placebo in combination with behavioral diet to induce ~10% weight loss and supervised aerobic and exercise training
89543731|NCT05554575|Experimental|BT-007 CD7 CAR-T cells in R/R T-LBL|Subjects will receive BT-007 CD7 CAR-T cells infusion on Day 0 : 100% of total dose.
89543732|NCT05549349||Cholecystectomy during hospitalization|In this group, patients will have their cholecystectomy during the initial hospitalization. We will look at the mode of feeding between the biliary crisis and the cholecystectomy.
89543733|NCT05549349||Delayed cholecystectomy|In this group, patients will have their cholecystectomy deferred from their initial hospitalization for various reasons. They will be seen again 3 months after leaving hospital. They will or will not have been cholecystectomized during this interval. Their mode of feeding as well as biliary events will be studied.
89543734|NCT05549271||Obese patients who underwent a Laparoscopic One Anastomosis Gastric Bypass (OAGB) 5 years ago|Patients (BMI > or = 35kg/m2 +/- co-morbidities) who have been operated on using the Gastric bypass procedure built with an Omega loop of 200 cm and a unique gastro-jejunal anastomosis
89543735|NCT05549271||Obese patients who underwent a Laparoscopic Roux-en-Y Gastric ByPass (RYGBP) 5 years ago|Patients (BMI > or = 35kg/m2 +/- co-morbidities) who have been operated on using the Roux-en-Y gastric bypass which consists in a small gastric pouch (30cc), a 150cm alimentary limb and a 50cm biliary limb. Mesenteric defects were closed.
89543736|NCT05549193|Experimental|Mild and Moderate-Severe Urinary Incontinence Group|10 sets of pelvic floor muscle training and 2 sets of abdominal muscle strengthening training were given every day for 6 weeks. All analyzes were conducted at the beginning and end of the 6-week training. The same training program was applied to both groups ( Group 1 (mild urinary incontinence) and Group 2 (moderate-severe urinary incontinence), and the effects were compared according to the severity of incontinence.
89207479|NCT00854802|Placebo Comparator|Debio 025 placebo + peg-IFNα2a + ribavirin - 48 weeks|Participants receive Debio 025 placebo orally twice daily for 7 days followed by Debio 025 placebo orally once daily for 47 weeks + peg-IFNα2a 180 µg subcutaneously (sc) once weekly for 48 weeks + ribavirin 1000 or 1200 mg (weight based) orally daily for 48 weeks.
89207480|NCT00969969|Active Comparator|Arthrodesis|Fusion
89207481|NCT00969969|Experimental|Cartiva|Synthetic Cartilage Implant
89024976|NCT03279575|Active Comparator|Educational program|The educational module consists of two separate apps, both commercially available. myATLS includes a review of each chapter of the Advanced Trauma Life Support (ATLS) textbook, a series of videos demonstrating common trauma procedures, and clinical resources including checklists for use at the bedside. Trauma Life Support MCQ Review includes 550 multiple-choice questions with correct answers and explanations. The investigators will ask physicians to review the myATLS app and then com
89024977|NCT03279575|Placebo Comparator|Control|Physicians in this arm will not be asked to complete any intervention.
89515012|NCT02289521|Active Comparator|Anodal Transcranial Direct Current Stim.|"Transcranial Direct Current Stimulation~Anodal (A-tDCS): Active anodal electrode over F3 (EEG system) and return electrode over right supraorbital area. A 1.5mA current will flow between the electrodes for 20 min. To decrease current-induced injuries, at the beginning the current reaches from 0 to 1.5mA during 30 seconds (fade-in), and decreases from 1.5mA to 0 in 15 seconds at the end (fade-out)."
89515013|NCT02289521|Sham Comparator|Sham Transcranial Direct Current Stim.|"Transcranial Direct Current Stimulation~Sham: The parameters mimics the A-tDCS (electrode placement, fade-in and current intensity), except the stimulation duration: the current will reach 1.5mA in 30 sec (fade-in) and lasts only for 30 sec (to give the initial sensation of stimulation).~After the stimulation, language performance and EEG will be recorded. Order of interventions (anodal - sham) will be randomised across subjects."
89515014|NCT02290535||Patients|Children and Teenager of 5-18 years with obstructive pulmonary disease (asthma, cystic fibrosis, immotile-cilia-syndrome, obstructive bronchitis, obstructive pneumonia).
89515015|NCT02290535||Probands|Children and Teenager of 5-18 years without known obstructive pulmonary diseases
89515016|NCT03962062|Experimental|Cohort 1: 12-17 years|Moxidectin 8mg per oral, single dose
89515017|NCT03962062|Experimental|Cohort 2: 8-11 years|Moxidectin 8mg (or lower dose) per oral, single dose
89515018|NCT03962062|Experimental|Cohort 3: 4-7 years|Moxidectin single dose, determined by population pharmacokinetic modelling including data from Cohorts 1 and 2
89515019|NCT02289599|Experimental|Part A: 1 mg E2307 (young cohort)|E2307 (1 x 1 mg E2307 capsule) or placebo (1 x 1 E2307 matching placebo capsule)
89515020|NCT02289599|Experimental|Part A: 3 mg E2307 (young cohort)|E2307 (3 x 1 mg E2307 capsules) or placebo (3 x 1 E2307 matching placebo capsules)
89515021|NCT02289599|Experimental|Part A: 10 mg E2307 (young cohort)|E2307 (1 x 10 mg E2307 capsule) or placebo (1 x 1 E2307 matching placebo capsule)
89515022|NCT02289599|Experimental|Part A: 30 mg E2307 (young cohort)|E2307 (3 x 10 mg E2307 capsules) or placebo (3 x 1 E2307 matching placebo capsules)
89515023|NCT02289599|Experimental|Part A: 100 mg E2307 (young cohort)|E2307 (1 x 100 mg E2307 capsule) or placebo (1 x 1 E2307 matching placebo capsule)
89515024|NCT02289599|Experimental|Part A: 200 mg E2307 (young cohort)|E2307 (2 x 100 mg E2307 capsules) or placebo (2 x 1 E2307 matching placebo capsules)
89515025|NCT02289599|Experimental|Part A: 300 mg E2307 (young cohort)|E2307 (3 x 100 mg E2307 capsules) or placebo (3 x 1 E2307 matching placebo capsules)
89515026|NCT02289599|Experimental|Part B: Elderly cohort|One dose level below MTD from Part A
89515027|NCT03140085|Active Comparator|Anbiotica|
89515028|NCT03140085|Active Comparator|Bacteriophages|
89515029|NCT03140085|Placebo Comparator|Placebo|
89515030|NCT02289677|Experimental|Intubation during chest compression|Intubation during mannequin chest compressions. Chest compression was performed using LUCAS-2 (Physio-Control, Redmond, WA, USA).
89024978|NCT00438321|Placebo Comparator|Placebo|Placebo injection, gel and pill
89024979|NCT00438321|Active Comparator|Testosterone only|Zoladex 3.6 mg IM injection Testosterone 7.5 g gel (AndroGel) transdermally daily Anastrozole 10 mg (Arimidex) orally daily
89024980|NCT00438321|Active Comparator|Testosterone and Estrogen|Zoladex 3.6 mg IM injection Testosterone 7.5 g gel (AndroGel) transdermally Placebo pill orally daily
89024981|NCT00476619|Placebo Comparator|Erythropoeitin|Subjects will receive a one-time dose of either placebo, or EPO 40,000 U intravenously 30 to 240 minutes prior to intravenous contrast administration.
89024982|NCT03279536|Experimental|Oral Lactoferrin|Group A is 120 mg of Oral lactoferrin for 4 weeks Intervention: The participants 66 will receive oral Lactoferrin 120mg for 4 weeks
89515031|NCT05391399|Experimental|group A Interlocking detachable coils system|The coil is designed with mechanical release, which can be recovered and repositioned at any time when the release process meets certain conditions.
89515032|NCT05391399|Active Comparator|group B Interlock Fibered IDC Occlusion System|The coil adopts the design of mechanical release, and can be recovered, repositioned and released at any time when the release process meets certain conditions.
89515033|NCT02239510|Active Comparator|Senna|1 capsule (50 mg) Senna daily for 12 weeks
89515034|NCT02239510|Active Comparator|Linzess|1 capsule (145 mcg) once daily for 12 weeks
89515035|NCT02290847|Active Comparator|In-Home Therapy|Cognitive Processing Therapy (CPT-C) will be delivered to participants face to face in their homes by a certified therapist.
89515036|NCT02290847|Active Comparator|In-Office Therapy|Cognitive Processing Therapy (CPT-C) will be delivered to participants face to face in a mental health clinic office setting by a certified therapist.
89515037|NCT02290847|Active Comparator|Telebehavioral Health|Cognitive Processing Therapy (CPT-C) will be delivered to participants over the internet using video conferencing software by a certified therapist.
89515038|NCT02291003||Healthy controls|Healthy controls -observational, no intervention administered.
89515039|NCT04426929|Experimental|Conventional Group|Electrotherapy program will be applied to all individuals. conventional exercise therapy will be applied to this group.
89543737|NCT04426227|Experimental|Group Gaze|The gaze-trained group will be shown a video, derived from the eye tracker, of an expert's visual control whilst performing the ultrasound task. Participants will be made aware of the target-focused gaze strategy (lengthy and stable fixations on the needling target), and the manner in which the gaze shifted from target to tools (hands, needle and transducer) in a fast, smooth fashion. They will then be advised to try to mimic the gaze strategy of the expert while undertaking the needling task as their first training task. After completion of this training task, participants will be shown their own video data, as captured by the eye tracker. Participants will be asked to comment on differences between their own video and the expert video they had previously seen. This feedback process will be replicated a further four training task attempts. Participants in this group will therefore undergo a total of five training attempts of the needling task.
89543738|NCT04426227|Active Comparator|Group Discovery|The discovery learning group will be given no video feedback and will be instructed to perform five training attempts at the needling task without further training or feedback.
89543739|NCT05554185|Experimental|group A|aspirin 100mg and probiotics 1 bag
89543740|NCT05554185|Placebo Comparator|group B|aspirin 100mg and placebo1 bag
89543741|NCT05554029|Experimental|Study group|Patients with rheumatic diseases
89543742|NCT05548959|Experimental|Microshunt patients|Pneumatonometry of the intraocular pressure was performed on patients who have undergone previous microshunt implantation.
89543743|NCT05548959|Experimental|Ab interno trabeculectomy patientes|Pneumatonometry of the intraocular pressure was performed on patients who have undergone previous ab interno trabeculectomy.
89543744|NCT05558631||Residents of the municipality of Leiria aged 18 years or more.|
89543745|NCT02112994|Experimental|Sebelipase Alfa|Pediatric and adult participants initiated IV treatment with sebelipase alfa at a dose of 1 mg/kg qow. Participants were considered for a dose adjustment at the discretion of the Investigator and in consultation with the Sponsor. Dose escalation to 3 mg/kg qow was considered if pre-defined dose-escalation criteria were met. If these criteria continued to be met, a subsequent dose escalation to 3 mg/kg every week (qw) was considered. Dose decreases as low as 0.35 mg/kg qow were permitted based upon evidence of intolerance to sebelipase alfa treatment. Participants who completed the 96-week treatment period were permitted to continue receiving sebelipase alfa in an expanded treatment period for up to 48 weeks, pending local drug availability and study participation status.
89543746|NCT04325841|Experimental|Autologous Murine Anti-CD19 CAR-T treatment|
89543747|NCT05558397|Active Comparator|Control Group (Oral Morphine)|The control group will be composed of 15 patients who will receive oral drug treatment according to the Clinical Protocol and Therapeutic Guidelines for Chronic Pain of the Brazilian Ministry of Health. The drugs included in the treatment plan are morphine (60 mg/day), pregabalin (150 mg/day) and duloxetine (60 mg/day), available free of charge to the participating patients. The treatment will be carried out orally in a home environment.
89543748|NCT05558397|Experimental|Interventional Group (Epidural morphine)|The intervention group will be composed of 15 patients who will undergo a surgical procedure for subcutaneous implantation of a catheter (Celsite ST304-19BBraun) that allows epidural administration of morphine and ropivacaine drugs. The treatment plan for such patients includes Patient Controlled Analgesia (PCA). Patients in this group will receive, via catheter, an anesthetic solution containing 2.0 mL of morphine (1.0 mg/mL), 3.0 mL of ropivacaine (7.5 mg/mL) and 5.0 mL of distilled water. For 24 hours after this application, if the patient continues to have pain, they may use a rescue dose of oral morphine of 10 mg.
89543749|NCT05558319|Active Comparator|Control arm (A)|"INDUCTION: Isatuximab + VRD, 4 cycles. Isatuximab (IV) 10 mg/Kg, 1st cycle D: 1,8,15, 22. Cycles 2-4: D 1,15. Bortezomib (SC) 1.3 mg/m2, D:1, 4, 8, 11. Lenalidomide (PO) 25mg, D:1-21. Dexamethasone (PO) 40 mg, D: 1-4, 9-12.~ASCT. The conditioning regimen is melphalan 200 mg/m2.~CONSOLIDATION: Isatuximab + VRD, 2 cycles. Isatuximab (IV) 10 mg/Kg. D 1-15. Bortezomib (SC) 1.3 mg/m2, D:1, 4, 8, 11. Lenalidomide (PO) 25mg, D:1-21. Dexamethasone (PO) 40 mg, D: 1-4, 9-12.~CONTINUOUS TREATMENT: Lenalidomide and monthly Isatuximab until progression, unacceptable toxicity, patient withdrawal, loss to follow up or death. During continuous treatment, dexamethasone 40 mg is used as a standardized premedication for Isatuximab."
89543750|NCT05558319|Experimental|EXPERIMENTAL ARM (B): Extended VRD and Early Rescue Intervention|"INDUCTION: Includes two experimental lines:~VRD extended to 18 cycles: Induction (VRDx6): Bortezomib (SC) 1.3 mg/m2, D: 1, 4, 8, and 11 (Q4W). Lenalidomide 25 mg (PO), D: 1-21 (Q4W). Dexamethasone 40 mg (PO) D 1 to 4 and 9 to 12 (Q4W). Isatuximab (IV) 10 mg/kg, D: 1, 8, 15, and 22 (Q4W) and D: 1-15 in subsequent cycles.~Early detection of treatment failure and Early Rescue Intervention (ERI): Isatuximab-Iberdomide-Dexamethasone in continuous treatment. Isatuximab (IV) 10mg/kg Cycle 1: Days 1, 8, 15, and 22 (Q4W). Cycles 2 onwards: Days 1 and 15 (Q4W). Isatuximab will be infused monthly after 1 year treatment (Day 1 Q4W) including ASCT. Iberdomide (PO) 1,6 mg. D: 1-21 (Q4W). Dexamethasone (PO) 40 mg. D: 1, 8, 15, and 22 (Q4W).~ASCT. The conditioning regimen is melphalan 200 mg/m2. CONSOLIDATION (VRDx2)- Extended VRD: VDx10, followed by lenalidomide plus dexamethasone maintenance.~CONTINUOUS TREATMENT: Lenalidomide 15 mg, D: 1-21, and dexamethasone 20 mg, D: 1-4 (Q4W)."
89543751|NCT05558319|Experimental|EXPLORATORY ARM (C)|"INDUCTION: Iberdomide plus Isatuximab, bortezomib and dexamethasone (four cycles). Isatuximab (IV) 10 mg/kg D 1, 8, 15, and 22 in the first Q4W; and days 1-15 in subsequent cycles. Iberdomide (PO) at 1.6 mg on days 1-21 of every 4-week cycle. Bortezomib (SC) at 1.3 mg/m2 on days 1, 4, 8, and 11 of every 4-week cycle. Dexamethasone 40 mg (PO) D 1-4, 9-12 (Q4W).~ASCT. The conditioning regimen is melphalan 200 mg/m2.~CONSOLIDATION: two cycles (Q4W) of Isatuximab, Iberdomide, Bortezomib and Dexamethasone, as in induction, starting approximately 2 months after hospital discharge or 3 months after transplantation. Isatuximab will be infused monthly since the start of continuous therapy (after the second cycle of consolidation).~CONTINUOUS TREATMENT: Iberdomide and monthly Isatuximab until progression, unacceptable toxicity, patient withdrawal, loss to follow up or death. During continuous treatment, dexamethasone 40 mg is used as a standardized premedication for Isatuximab."
89543752|NCT05700825|Active Comparator|In-person|
89543753|NCT05700825|Experimental|Telehealth|
89024983|NCT03279536|Active Comparator|Total dose infusion (TDI) iron dextran|Group B is a parenteral total dose infusion (TDI) of LMW iron dextran 20mg/kg body weight for 4 weeks Intervention: The participants 33 will receive parental iron 20mg/kg body weight for 4 weeks
89207482|NCT00966459|Other|1|
89207483|NCT00958503|Placebo Comparator|Placebo|Placebo
88961209|NCT02007057|Active Comparator|Interscalene nerve block|"Interscalene block is performed preoperatively with ultrasound guidance and neurostimulation 0.8 milliampere. The block is performed using in-plane approach with a needle of 50 mm for a neurostimulation. During the injection, it is verified that the diffusion extends to the anterior and posterior space. If the posterior distribution is limited, the needle is remobilized to obtain an overall diffusion: a bolus of 20 mL of ropivacaine 0.75% is made by the anesthetist. The effectiveness of the nerve block is checked before the start of surgery."
89207484|NCT00958503|Active Comparator|Thiamphenicol|Active comparator
89515040|NCT04426929|Experimental|Closed Chain Exercise Group|An exercise program consisting of 3 phases that runs from simple to difficult and includes closed kinetic chain exercises and proprioceptive exercises will be implemented in this group.
89515041|NCT04426929|Experimental|Video Based Exercise Group|Video based exercise program will be applied to the this group.
89515042|NCT03521453||Before|Conventionnel written information
89515043|NCT03521453||After, with PEPPER|Written information + presence of a robot (PEPPER) in the waiting room, who will give informations.
89515044|NCT03521297|Placebo Comparator|Placebo group|Placebo (three times per day, one pack each time) and UDCA (13-15mg/kg/day), orally, 6 months
89515045|NCT03521297|Experimental|Probiotics group|Probiotics (three times per day, one pack each time) and UDCA(13-15mg/kg/day), orally, 6 months
89515046|NCT04393701|Experimental|neonates tested in Normandie, France|All neonates will be tested in Normandie
89515047|NCT03521375|Experimental|VATS lobectomy|VATS lobectomy is undertaken through one to four keyhole incisions without rib spreading. The use of 'rib spreading' is prohibited as this is the key intra-operative manoeuvre which disrupts tissues and causes pain (and is used in open surgery). The procedure is performed with videoscopic visualisation without direct vision. The hilar structures are dissected, stapled and divided. Endoscopic ligation of pulmonary arterial branches may be performed. The fissure is completed and the lobe of lung resected. Lymph node management is the same as described for open surgery. The incisions are closed in layers and may involve muscle, fat and skin layers. This definition of VATS lobectomy is a modification of CALGB 39802.
89515048|NCT03521375|Active Comparator|Open lobectomy|Conventional open surgery is undertaken through a single incision +/- rib resection and with rib spreading. The operation is performed under direct vision with isolation of the hilar structures (vein, artery and bronchus) which are dissected, ligated and divided in sequence and the lobe of lung resected. The procedures may be undertaken using ligatures, over sewing or with staplers. Lymph node management is undertaken in accordance with the International Association of the Study of Lung Cancer (IASLC) recommendations where a minimal of 6 nodes / stations are removed, of which 3 are from the mediastinum that includes the subcarinal station. The thoracotomy is closed in layers starting from pericostal sutures over the ribs, muscle, fat and skin layers.
89515049|NCT03140163|Experimental|Subjects suffering from pneumonia|CXR ULD-CT
89515050|NCT02289911|Active Comparator|Class|Traditional learning form
89515051|NCT02289911|Active Comparator|Web|Didactic training using internet
89515052|NCT02291159|Experimental|Intervention-DNHS technique|Dry needling of Myofascial Trigger Points
89515053|NCT02291159|Sham Comparator|Control-Sham Dry Needling|Sham Dry Needling of Myofascial Trigger Points
89515054|NCT02291315||Test meal ingestion|On the morning of the absorption study, fasted women received 2 mg of 42Ca intravenously (in 5 ml of isotonic saline) over 5 minutes before being randomly assigned to receive either the milk or cassia meal first for breakfast and the milk or cassia meal second for lunch. The milk meal consisted of approximately 100 mg of fresh ultrahigh temperature (UHT) milk to which 2 mg of 44Ca was added and allowed to equilibrate for 12 h prior to ingestion and the cassia meal consisted of 142 g of cooked cassia to which 1 mg of 43Ca was extrinsically added.
89515055|NCT02294123|Experimental|Diabetes (3 tortillas and white bread)|"Each participants (n=27) receive in random order the following foods: 1) a whole corn tortilla (white criollo corn= 5.3% fiber), 2) a whole corn tortilla (white hybrid corn= 7.9%), 3) a traditional corn tortilla (3.9% fiber), and 4) white bread (reference food containing 2.2% of fiber)."
89515056|NCT02294123|Experimental|Overweight (3 tortillas and white bread)|"Each participants (n=27) receive in random order the following foods: 1) a whole corn tortilla (white criollo corn= 5.3% fiber), 2) a whole corn tortilla (white hybrid corn= 7.9%), 3) a traditional corn tortilla (3.9% fiber), and 4) white bread (reference food containing 2.2% of fiber)."
89515057|NCT02294123|Experimental|Healthy (3 tortillas and white bread)|"Each participants (n=27) receive in random order the following foods: 1) a whole corn tortilla (white criollo corn= 5.3% fiber), 2) a whole corn tortilla (white hybrid corn= 7.9%), 3) a traditional corn tortilla (3.9% fiber), and 4) white bread (reference food containing 2.2% of fiber)."
89515058|NCT03139695||Critically ill patients|High resolution ultrasound of the diaphragm and intercostal muscle
89515059|NCT03984539|Active Comparator|CBT-E|Participants will be randomly assigned to one of two conditions (CBT-E or CBT-T). CBT-E will occur over the course of 25 weeks and be delivered as it typically is in the clinic setting of the investigators.
89515060|NCT03984539|Experimental|CBT-T|Participants will be randomly assigned to one of two conditions (CBT-E or CBT-T). Participants who agree to participate will receive 10 weeks of CBT-T.
89207485|NCT00970047||Pregnant females|Women who are pregnant and between 6 and 16 weeks of gestation and who are 18 to 64 years of age.
89515061|NCT03140241|Experimental|PDR measurement|Two measurements of PDR perioperatively before and after opioid administration
89515062|NCT02291393|Other|Patient|Patients with previously confirmed Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)
89515063|NCT02291393|Other|Healthy volunteers|Aged and gender matched healthy controls.
89515064|NCT03139773|Experimental|Normal Weight|Received control breakfast beverage and breakfast beverage supplemented with omega-3 fatty acids.
89515065|NCT03139773|Experimental|Overweight/Obese|Received control breakfast beverage and breakfast beverage supplemented with omega-3 fatty acids.
89515066|NCT02291471|Experimental|T0001|
89515067|NCT03899961|Active Comparator|Oxytocin|Oxytocin 2.5 U i.v.
89515068|NCT03899961|Experimental|Carbetocin|Carbetocin 100 µg i.v.
89515069|NCT02294201|Placebo Comparator|Placebo|Placebo Repellent product with no active ingredient
89515070|NCT02294201|Active Comparator|Intervention|Spatial Repellent product with active ingredient
89543754|NCT05700513|Active Comparator|Capsules containing the combination products|Capsules containing dog-rose, Cranberry leaves, Cranberry Berries, Alfalfa, Fenugreek, Lemon Beebrush, Urtica, and Sumac
89543755|NCT05700513|Placebo Comparator|Placebo|Placebo capsules containing maltodextrin
89543756|NCT05543343|Experimental|Ntaphylococcus albicans tablets|Participants received High-dose Staphylococcus albicans tablets (0.3 mg/tablet, 8 tablets each time, 3 times a day, Qilu Pharmaceutical Co., Ltd., course of treatment 90 days) or Normal-doseStaphylococcus albicans tablets (0.3 mg/tablet, 4 tablets each time, 3 times a day, Qilu Pharmaceutical Co., Ltd., course of treatment 90 days)+ placebo (4 tablets each time, 3 times a day, Qilu Pharmaceutical Co., Ltd., course of treatment 90 days).
89543757|NCT05543343|Placebo Comparator|Placebo|Participants received placebo (8 tablets each time, 3 times a day, Shandong Qilu Pharmaceutical Co., Ltd., course of treatment 90 days).
89543758|NCT05553717|Active Comparator|group 1|33 patients who will receive aspirin 150mg + carvedilol 12.5mg twice daily plus other traditional therapy of ischemia for three months.
89543759|NCT05553717|No Intervention|group 2 control|33 patients who will receive aspirin 150mg + Captopril 12.5mg twice daily plus other traditional therapy of ischemia for three months.
89543760|NCT05543031|Experimental|Study group|"There are 9 (35,8%) female and 14 (64,2%) male preschool cochlear implant users in the study group.~Children ranging in age from 5 to 7 who also have 5-6 years old language skills."
89543761|NCT05543031|Experimental|Control group|"There are 9 (35.8%) female and 14 (64,2%) male preschool children with normal hearing in the control group.~Children ranging in age from 5 to 6 who also have age-appropriate language skills."
89543762|NCT05553483|Experimental|pranayama and acupoint stimulation by laser|"for 6 weeks,This 30-children group will receive 2-session per-week laser stimulation to some selected acupoints and daily pranyama exercises (nearly every session will be one hour), the stimulated bilateral acupoints will be (LI 19, LI 20, ST2, and ST4. ST6, ST7, ST17, ST36, SI18, BL2, GB14, GV24 and EXHN5). Every acupoint will be stimulated with laser power of 100 mw that will be used on a spot area of 1 cm2 for 1 minute.~this group will receive also pranayama session (applied daily, one hour approximately, for six weeks) will be (alternate nostril pranayama, diaphragmatic pranayama, rapid abdominal pranayama, Bhramari pranayama)"
89543763|NCT05553483|Active Comparator|acupoint stimulation by laser|for six weeks, This 30-children group will receive 2-session per-week laser stimulation to some selected acupoints. The stimulated bilateral points will be (LI 19, LI 20, ST2, and ST4. ST6, ST7, ST17, ST36, SI18, BL2, GB14, GV24 and EXHN5). Every acupoint will be stimulated with laser power of 100 mw that will be used on a spot area of 1 cm2 for 1 minute.
89543764|NCT05542953|Experimental|Alzheimer's Disease|AD subjects will undergo PET imaging using [18F]APN-1607.
89543765|NCT05542953|Experimental|Mild Cognitive Impairment Due to Alzheimer's Disease|MCI subjects will undergo PET imaging using [18F]APN-1607.
89543766|NCT05542953|Experimental|Healthy Volunteers|Healthy control subjects will undergo PET imaging using [18F]APN-1607.
89543767|NCT05542875|Experimental|Group A (Thrust Manipulation)|Participants will be randomly allocated to Group A which will recieve Thrust manipulation treatment in addition to standard treatment protocol. Prone thoracic extension manipulation technique will be applied from T2 - T6 to participants for 4 sessions on alternate days
89543768|NCT05542875|Experimental|Group B (Non-Thrust Manipulation)|Participants will be randomly allocated to group B which, in addition to standard treatment protocol, will recieve Maitland grade III or IV manipulation from T1 to T6. Posterior to anterior glide over spinous process will be maintained for 30 seconds. Participants will recieve 4 sessions on alternate days
89543769|NCT05700123||Video|
89543770|NCT05700123||Music|
89543771|NCT05700123||Vocal-Local|
89543772|NCT05542797|Experimental|Micronised progesterone|Micronized progesterone will be given to 70 pregnant women with threated miscarriage.
89543773|NCT05542797|Experimental|Dydrogesterone|Dydrogesterone will be given to 70 pregnant women with threated miscarriage.
89543774|NCT02147158|Experimental|UPA 5 mg:Placebo|Ulipristal Acetate (UPA) 5 mg tablet plus matching placebo 10 mg tablet, orally, once daily for 12 weeks in Treatment Course 1; followed by a 2 menses drug-free interval; followed by matching placebo tablets (5 mg and 10 mg), orally, once daily for 12 weeks in Treatment Course 2.
89543775|NCT02147158|Experimental|UPA 10 mg:Placebo|UPA 10 mg tablet plus matching placebo 5 mg tablet, orally, once daily for 12 weeks in Treatment Course 1; followed by a 2 menses drug-free interval; followed by matching placebo tablets (5 mg and 10 mg), orally, once daily for 12 weeks in Treatment Course 2.
89543776|NCT02147158|Experimental|UPA 5 mg:UPA 5 mg|UPA 5 mg tablet plus matching placebo 10 mg tablet, orally, once daily in both Treatment Course 1 and Treatment Course 2. There was a 2 menses drug-free interval in between courses.
89543777|NCT02147158|Experimental|UPA 10 mg:UPA 10 mg|UPA 10 mg tablet plus matching placebo 5 mg tablet, orally, once daily in both Treatment Course 1 and Treatment Course 2. There was a 2 menses drug-free interval in between courses.
89543778|NCT02147158|Experimental|Placebo:UPA 5 mg|Matching placebo tablets (5 mg and 10 mg) orally, once daily for 12 weeks in Treatment Course 1; followed by a 2 menses drug-free interval; followed by UPA 5 mg tablet plus matching placebo 10 mg tablet, orally, once daily for 12 weeks in Treatment Course 2.
89543779|NCT02147158|Experimental|Placebo:UPA 10 mg|Matching placebo tablets (5 mg and 10 mg), orally, once daily for 12 weeks in Treatment Course 1; followed by a 2 menses drug-free interval; followed by UPA 10 mg tablet plus matching placebo 5 mg tablet, orally, once daily for 12 weeks in Treatment Course 2.
89543780|NCT05553093|Experimental|Tirzepatide|Tirzepatide 5、10、15mg
89543781|NCT05553093|Active Comparator|Insulin Glargine|Insulin Glargine 6 international unit (IU)
89543782|NCT05542719||frequency of dyslipidemias|To describe the frequency of dyslipidemias in high-risk and very high-risk patients with atherosclerotic cardiovascular disease and analyze the impact of using an application to achieve dyslipidemia treatment goals at one-year follow-up.
89543783|NCT04757740|Active Comparator|Platelet rich fibrin Group|Platelet rich fibrin. Group P
89543784|NCT04757740|Active Comparator|Methylprednisolone acetate|Group S
89543785|NCT05552937|Experimental|Tafasitamab and Lenalidomide|Tafasitamab and lenalidomide will be coadministered for up to 12 cycles (28 days per cycle).followed by tafasitamab monotherapy (in participants with stable disease or better) until treatment withdrawal criteria are met.
89543786|NCT02112448|Active Comparator|Continuous infusion|Patients in this group will received morphine/midazolam drips at 0.3 mg/kg/hour each. They will be given doses of morphine 0.05 mg/kg/dose every 2 hours as needed for pain score 4 or more. Midazolam will also be given as needed (0.05 mg/kg/dose every 1 hour)
89543787|NCT02112448|Active Comparator|As needed dosing|Patients in this arm will be given doses of morphine 0.05 mg/kg/dose every 2 hours as needed for pain score 4 or more. Midazolam will also be given as needed (0.05 mg/kg/dose every 1 hour)
89543788|NCT02171260|Experimental|Eribulin Mesylate|Eribulin mesylate will be administered intravenously on Days 1 and 8 of each 21-day cycle. A cycle of therapy is considered to be 21 days. The starting dose for eribulin mesylate will be at 1.1 milligram per square meter (mg/m^2) (Dose Level 1), which is approximately 80% of the adult MTD, and will be escalated up to no more than 2.2 mg/m^2.
89543789|NCT02110732|Active Comparator|Lactobacillus rhamnosus GG|Lactobacillus rhamnosus GG 8-9 x 10 -9 pmy 2x2 for 3 weeks
89543790|NCT02110732|Placebo Comparator|Crystalline cellulose|Crystalline cellulose
89543791|NCT02109562|Experimental|RBP-7000 90 mg|Risperidone tablets given during the screening period to check for sensitivity. RBP-7000 administered as a 90 mg subcutaneous injection on Days 1 and 29 for a total of two injections.
89543792|NCT02109562|Experimental|RBP-7000 120 mg|Risperidone tablets given during the screening period to check for sensitivity. RBP-7000 administered as a 120 mg subcutaneous injection on Days 1 and 29 for a total of two injections.
89543793|NCT02109562|Placebo Comparator|Placebo|Risperidone tablets given during the screening period to check for sensitivity. Placebo administered by subcutaneous injection on Days 1 and 29 for a total of two injections.
89543794|NCT02109484|Experimental|Cohort A P2-VP8 30 mcg|Cohort A toddlers (24-35 mo) receiving P2-VP8 Subunit Vaccine (30 mcg)
89543795|NCT02109484|Placebo Comparator|Cohort A Placebo|Cohort A toddlers (24-35 mo)
89543796|NCT02109484|Experimental|Cohort A P2-VP8 60 mcg|Cohort A toddlers (24-35 mo) receiving high dose P2-VP8 Subunit Vaccine (60mcg)
89543797|NCT02109484|Experimental|Cohort B P2-VP8 10mcg|Cohort B infants receiving P2-VP8 Subunit Vaccine (10mcg)
89543798|NCT02109484|Placebo Comparator|Cohort B placebo|Cohort B infants aged 6 to < 8 weeks receiving placebo
89543799|NCT02109484|Experimental|Cohort B P2-VP8 30mcg|Cohort B infants aged 6 to < 8 weeks receiving P2-VP8 Subunit Vaccine (30mcg)
89543800|NCT02109484|Experimental|Cohort B1 P2-VP8 60mcg|Cohort B1 Infants aged 6 to < 8 weeks receiving P2-VP8 Subunit Vaccine (60mcg)
89543801|NCT02109484|Experimental|Cohort A P2-VP8 10mcg|Cohort A toddlers (24-35 mo) receiving P2VP8 Subunit Vaccine (10mcg)
89543802|NCT05134792|No Intervention|No intravenous immunoglobulin (IVIG)|The control group are burn patients with inclusion criteria that did not receive IVIG.
89543803|NCT05134792|Experimental|Intravenous immunoglobulin (IVIG) group|Pediatric burn patients between 1and 5 years with 10% or greater burn area of TBSA within 24 hours of onset of burn will receive intravenous immunoglobulin.
89543804|NCT05177692|Active Comparator|Intervention group - Vguard|Intervention group will be fitted with a Vguard system Patients will have double ICP monitoring using the intraventricular drainage and and intraparenchymal ICP monitoring device
89543805|NCT05177692|No Intervention|Control group - regular intra-ventricular drainage|Control group will be fitted with a standard system for drainage of ventricular fluid Patients will have double ICP monitoring using the intraventricular drainage and and intraparenchymal ICP monitoring device
89543806|NCT04737850|Experimental|PartA, open-label|Hetrombopag plus standard of care
89543807|NCT04737850|Experimental|PartB, double-blind treatment group|Hetrombopag plus standard of care
89543808|NCT04737850|Placebo Comparator|Placebo Comparator|Placebo plus standard of care Part B, double-blind treatment group
89543809|NCT02105974|Experimental|Fluticasone Furoate/Vilanterol 100/25 Inhalation Powder|Inhaled corticosteroid (ICS)/long-acting beta2-agonist (LABA)
89543810|NCT02105974|Experimental|Vilanterol 25 Inhalation Powder|Long-acting beta2-agonist (LABA)
89543811|NCT02105662|Experimental|Grazoprevir+Elbasvir|Participants receive a fixed-dose combination (FDC) of grazoprevir 100 mg plus elbasvir 50 mg once daily for 12 weeks and are followed-up for 24 weeks.
89207486|NCT00861588|Experimental|isoflavones|Subjects who met the inclusion and exclusion criteria would be randomly assigned (concealment of allocation) to receive isoflavones
89207487|NCT00861588|Placebo Comparator|starch|Subjects who met the inclusion and exclusion criteria would be randomly assigned (concealment of allocation) to receive placebo
89543812|NCT02143102||Training set|Data from subjects in the training set will be utilized to further develop the vascuCAPTM classifiers.
89543813|NCT02143102||Testing set|Data from subjects in the testing set will be used to assess the study endpoints.
89543814|NCT02143024|Experimental|Family-based depression intervention|The family-focused component will consist of up to up to 10 joint (i.e. older man alone and/or with family members) sessions that will cover specific topics related to family support of men's depression care provided by a clinic-based social worker
89543815|NCT02143024|Active Comparator|Usual care plus educational materials|Control subjects will receive usual care in the clinic enhanced by a single depression psychoeducation session.
89543816|NCT02142712|Active Comparator|Pantoprazole|Pantoprazole intravenous 40mg q daily as part of standard of care for stress ulcer prophylaxis along with current standard of care.
89543817|NCT02142712|Active Comparator|Famotidine|Famotidine 40 mg intravenous BID (maximum dose of 80 mg/day) for 4 days as part of standard of care for stress ulcer prophylaxis along with current standard of care.
89207488|NCT00970125|Experimental|Cancer subjects|
89543818|NCT02142712|Experimental|Dextromethorphan|"Dextromethorphan 60 mg QID orally (maximum dose of 240 mg/day) for 2 days (total of 4 doses) along with current standard of care.~If the drug can't be given orally, then feeding tube (G-tube, NG Tube or DHT) will be used for drug administration."
89543819|NCT02142712|Experimental|Diphenhydramine|Diphenhydramine 12.5 mg BID intravenous or 25 mg BID oral for 4 days along with current standard of care.
89543820|NCT02105272|Experimental|OPC-1085EL ophthalmic solution|Once daily
89543821|NCT02105272|Active Comparator|Latanoprost ophthalmic solution|Once daily
89543822|NCT02141854|Experimental|FS MDPI 200 / 12.5 mcg|Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate 200 mcg (for a total daily dose of 400 mcg) and salmeterol 12.5 mcg (for a total daily dose of 25 mcg) for 12 weeks.
89543823|NCT02141854|Experimental|FS MDPI 100 / 12.5 mcg|Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate 100 mcg (for a total daily dose of 200 mcg) and salmeterol 12.5 mcg (for a total daily dose of 25 mcg) for 12 weeks.
89543824|NCT02141854|Experimental|Fp MDPI 200 mcg|Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate (Fp) for a total daily dose of 400 mcg for 12 weeks.
89543825|NCT02141854|Experimental|Fp MDPI 100 mcg|Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate (Fp) for a total daily dose of 200 mcg for 12 weeks.
89543826|NCT02141854|Placebo Comparator|Placebo MDPI|Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of placebo for 12 weeks.
89543827|NCT02587221|Experimental|aQIV|MF59-adjuvanted Quadrivalent Influenza Vaccine (aQIV)
89543828|NCT02587221|Placebo Comparator|Non-influenza Comparator Vaccine|Non-influenza comparator vaccine
89543829|NCT02141620|Placebo Comparator|Placebo|Subjects will be maintained on oral placebo.
89543830|NCT02141620|Experimental|n-Acetylcysteine|Subjects will be maintained on oral n-acetylcysteine.
89543831|NCT05548257||All patients were reviewed|
88961210|NCT02007057|Experimental|Suprascapular nerve block|The suprascapular block is performed at the end of surgery when the incisions are closed but before the removal of the surgical drapes. The material used is a compound of a 10 cc syringe sterile equipment, a green intramuscular needle (14 gauge) and a bulb 10 cc of 0.75% Ropivacaine. The injection of 10 cc is realized by the technical princeps
88961211|NCT02007083|Active Comparator|Bilateral laminotomy (BL)|The multifidus muscles is detached from the spinous process bilaterally.The decompression of the spinal canal is performed by first doing a flavectomy. Thereby performing a laminotomy (about 1/3) of the the lower part of the superior lamina, and a laminotomy of the upper part (about 1/4) of the inferior lamina. This is performed bilaterally.
88961212|NCT02007083|Active Comparator|Unilateral laminotomy with crossover (UL)|The multifidus muscles is detached from the spinous process unilaterally. The laminotomy is first performed ipsilaterally. The decompression of the spinal canal is performed by first doing a flavectomy. Then, performing a laminotomy (about 1/3) of the the lower part of the superior lamina, and a laminotomy of the upper part (about 1/4) of the inferior lamina. Dura is then retracted, and the decompression is performed contralaterally.
89543832|NCT02106910|Experimental|Participants with Barrett's and No History of Ablation|Participants with a diagnosis of BE, presenting for routine care endoscopy for surveillance or treatment of their BE.
89543833|NCT02106910|Experimental|Participants with Barrett's and a History of Ablation|Participants with Barrett's Esophagus (BE) with low grade dysplasia (LGD) or high grade dysplasia (HGD) and achieved complete eradication of BE via radiofrequency ablation (RFA).
89543834|NCT05698953|Experimental|Reiki Group|Reiki is applied to the Reiki group for 20-30 minutes for three consecutive days.
89543835|NCT05698953|Placebo Comparator|Placebo Group|Placebo group is applied to the sham Reiki group for 20-30 minutes for three consecutive days Placebo Reiki group is applied to the sham Reiki by an independent nurse during the same application period.
89543836|NCT05698953|No Intervention|Control Group|No intervention is made in the control group. Standard care was used
89543837|NCT01664949|Experimental|Carboxymethylcellulose Based Eye Drop Formulation A|Carboxymethylcellulose Based Eye Drop Formulation A 1-2 drops in each eye as needed at least 2 times daily for 90 days.
89543838|NCT01664949|Active Comparator|OPTIVE™|Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops (OPTIVE™) 1-2 drops in each eye as needed at least 2 times daily for 90 days.
89543839|NCT05548101|No Intervention|Conventional Insemination|Oocytes will be fertilized via conventional insemination: Oocytes will be washed with multipurpose handling medium (MHM) plus 0.5% human serum albumin (HSA). Excess cumulus cells and blood will be trimmed. Oocytes will be transferred to a dish containing Irvine Scientific Continuous Cell Culture Complete Medium with two oocytes per dish. The dish will then be transferred to the incubator. Insemination will occur 4-6 hours post-retrieval. Sperm will be collected as a fresh specimen and washed with Irvine Scientific Continuous Single Culture-NX. Sperm concentration and motility will be assessed before and after washing according to WHO 6th edition criteria. Sperm will be prepared to achieve a concentration of 200,000 sperm per 100 microliter drop. 6 drops of prepared sperm will be added to each dish.
89543840|NCT05548101|Active Comparator|Intracytoplasmic Sperm Injection (ICSI)|Oocytes will be fertilized via ICSI: Oocytes will be washed with multipurpose handling medium (MHM) plus 0.5% human serum albumin (HSA). Excess cumulus cells and blood will be trimmed. Oocytes will be transferred to a dish containing Irvine Scientific Continuous Cell Culture Complete Medium with two oocytes per dish. The dish will then be transferred to the incubator. Oocytes will be immediately exposed to hyaluronidase to strip the cumulus and coronal cells. Embryologists will assess the maturation status under inverted microscopy. ICSI will be performed on all mature metaphase II oocytes 4 hours after retrieval. Injected oocytes will then be placed in a fresh culture dish and returned to the incubator.
88961213|NCT02007083|Active Comparator|Spinous process osteotomy (SPO)|The multifidus muscles is detached from the spinous process unilaterally. An osteotomy of the superior spinous process is performed at the basis, in the actual level. The spinous process with intact interspinal and supraspinal ligaments is then retracted to the contralateral side. The decompression is first performed in the midline. Then one goes laterally on both sides too perform the decompression. About 1/3 of the lower part of the superior lamina is removed, and about 1/4 of the upper part of the inferior lamina is removed.
88961214|NCT02007135||Healthy|Healthy persons, without non-specific low back pain
88961215|NCT02007148|Experimental|micado|CAPECITABINE 500 mg twice a day, orally, continuously DOCETAXEL 60 mg/sqm i.v. over 1 hr on day 1 cycles repeated every 3 weeks Duration of treatment: Chemotherapy should be continued until: progressive disease; unacceptable toxicities; patients' refusal; or upon investigator's judgement is in the best interest for the patient.
88961216|NCT02007161|Active Comparator|Nutritional State|"Fed vs. Fasted State~Diclofenac potassium 50 mg"
89543841|NCT02587143|Active Comparator|Control|Alcohol -based spray as placebo will be administrated before arterial puncture.
89543842|NCT02587143|Experimental|Ethyl chloride|Ethyl choride will be administrated before arterial puncture.
89207489|NCT00966615|Experimental|Balance group|peritoneal dialysis with neutral peritoneal dialysis solution with minimal glucose-degradation-product
89515071|NCT04079673|Active Comparator|Patient controlled epidural analgesia|Use of patient controlled epidural analgesia (PCEA) for postoperative pain control
89515072|NCT04079673|Sham Comparator|Intravenous patient controlled analgesia|Use of intravenous patient controlled analgesia(IVPCA) for postoperative pain control
89515073|NCT02291627|Experimental|intubation with immobilized cervical spine|endotracheal intubation with immobilized cervical spine
89515074|NCT02462486|Experimental|Abicipar Pegol 2 mg (2Q8)|Abicipar pegol 2 mg was administered to the study eye by intravitreal injection on Day 1, Week 4, and Week 8, followed by injections every 8 weeks through Week 96. Scheduled visits occurred every 4 weeks. To maintain masking, sham was administered to the study eye at scheduled visits where abicipar was not administered.
89515075|NCT02462486|Experimental|Abicipar Pegol 2 mg (2Q12)|Abicipar pegol 2 mg was administered to the study eye by intravitreal injection on Day 1, Week 4, and Week 12, followed by injections every 12 weeks through Week 96. Scheduled visits occurred every 4 weeks. To maintain masking, sham was administered to the study eye at scheduled visits where abicipar was not administered.
89515076|NCT02462486|Active Comparator|Ranibizumab (rQ4)|Ranibizumab (Lucentis®) was administered to the study eye by intravitreal injection every 4 weeks from Day 1 through Week 96.
89515077|NCT05370963|Active Comparator|hyalase group|Bupivacaine 5 mg (1 mL) + Triamcinolone 40 mg (1 mL) + Saline solution (2 mL) + Hyaluronidase 1,500 IU reconstituted in 1 mL distilled water (HYL)
89515078|NCT05370963|Active Comparator|dexmedtemodine group|Bupivacaine 5 mg (1 mL) + Triamcinolone 40 mg (1 mL) + Saline solution (2 mL) + Dexmedetomidine 0.5 mic/kg
89515079|NCT03521219|Experimental|Apatinib|Apatinib 500mg, once a day, oral of each 28 day cycle. Number of cycle: until progression or unacceptable toxicity develops.
89515080|NCT05318157|Experimental|Sublingual Immunotherapy group|
89515081|NCT05318157|Experimental|Drugs treatment group|
89515082|NCT02294279|Experimental|Active|4 weeks of corticosteroid treatment with QVAR (100mcg), 400 mcg daily; two puffs twice daily
89515083|NCT02294279|No Intervention|Placebo|Blinded placebo inhaler
89515084|NCT03136653|Experimental|Single arm Study MP0250 plus BOR + DEX|Single arm study of MP0250 plus bortezomib + dexamethasone
89515085|NCT03110237|Active Comparator|Control Balance Training (BT) class|Group based circuit training class, 30 minute session, twice a week for three weeks
89515086|NCT03110237|Experimental|Fallproof Balance Training (BT) class|Group based balance training class based on the FallProof(TM) approach, 30 minute session , twice a week for three weeks
89515087|NCT03110289|Experimental|Superdonor FMT|Fecal microbiota transplantation from a healthy donor that was selected based on a fecal/blood screening, medical interview and on abundance of taxa of the investigators their interest
89515088|NCT03110289|Sham Comparator|Autologous FMT|Fecal microbiota transplantation derived from feces from the patient her/himself.
89515089|NCT03880539|Other|BEZLO + SOC taper|Single arm of patients treated with BEZLO + SOC oral VAN pulse/taper.
89515090|NCT03518021|Experimental|Naloxone, intranasal|
89515091|NCT03518021|Active Comparator|Naloxone, intramuscular|
89515092|NCT03518021|Placebo Comparator|placebo, intranasal|
89515093|NCT03518021|Placebo Comparator|placebo, intramuscular|
89515094|NCT02495948|Other|AOA then ULTRA|Lotrafilcon B contact lenses worn first, followed by samfilcon A contact lenses. Each product worn bilaterally (in both eyes) for a minimum of 5 days/week, 8 hours/day for 30 days in a daily wear modality.
89515095|NCT02495948|Other|ULTRA then AOA|Samfilcon A contact lenses worn first, followed by lotrafilcon B contact lenses. Each product worn bilaterally for a minimum of 5 days/week, 8 hours/day for 30 days in a daily wear modality.
89515096|NCT03734289|Active Comparator|Immediate Coaching|Immediately following randomization, online coaching sessions will occur weekly for 6 weeks. Web-based courses containing instructional materials that deal with preventing and reducing care resistant behavior (CRB) within intimate care (dressing, bathing, toileting) and treatment regimens (medication, therapeutic activities) after the initial study visit. The NeuroNS-Care intervention is an innovative distance-learning , internet based, family caregiver coaching program; one for the caregivers of persons with dementia and one for the caregivers of persons recovering from TBI. It will be delivered using Instructure's Canvas™ web-based platform.
89515097|NCT03734289|Active Comparator|Delayed Coaching|6 weeks following the initial visit, online coaching sessions will occur weekly for 6 weeks. Web-based courses containing instructional materials that deal with preventing and reducing care resistant behavior (CRB) within intimate care (dressing, bathing, toileting) and treatment regimens (medication, therapeutic activities) after the initial study visit. The NeuroNS-Care intervention is an innovative distance-learning , internet based, family caregiver coaching program; one for the caregivers of persons with dementia and one for the caregivers of persons recovering from TBI. It will be delivered using Instructure's Canvas™ web-based platform.
89515098|NCT03132935||Telemedicine group|Telemedical care of acute coronary syndromes in the prehospital phase. Paramedics were supported by a physician in a tele consultation centre.
89515099|NCT03132935||Control group|Conventional on-scene care of acute coronary syndromes by a physician. No telemedicine system was available during this control period.
89515100|NCT02461628|Experimental|Malaria RDT & conditional voucher|In the intervention arm, trained community health volunteers (CHVs) will offer eligible household members a free malaria rapid diagnostic test (RDT) and a voucher allowing the purchase of a qualified artemisinin combination therapy (ACT) at a reduced fixed price in the retail sector conditional on a positive test.
89515101|NCT02461628|No Intervention|Comparison Arm|Individuals in the comparison arm will only receive standard community health volunteer (CHV) visits.
88961217|NCT02007161|Active Comparator|Use of a PPI|"Nexiam (esomeprazole) 40 mg~Diclofenac potassium 50 mg"
88961218|NCT02007174||Bevacizumab injection|Three subconjunctival intralesional injections of bevacizumab. Bevacizumab injections were 2.5 mg/0.05 ml, subconjunctivally applied near to the pterygium recurrence. Application of bevacizumab was performed three times: basal, 2 and 4 weeks.
89207490|NCT00966615|Active Comparator|Control group|conventional PD solution
89543843|NCT02106832|Experimental|Ciprofloxacin DPI 28 Days on/off (Cipro 28)|Subjects received ciprofloxacin (BAYQ3939) 32.5 milligram (mg) corresponding to 50 mg dry powder for inhalation (DPI) administered twice daily (BID) (every 12 hours); a treatment cycle consisted of a 28-day on-treatment phase followed by a 28-day off-treatment phase (48 weeks treatment phase = 6 active cycles).
89543844|NCT02106832|Experimental|Ciprofloxacin DPI 14 Days on/off (Cipro 14)|Subjects received ciprofloxacin 32.5 mg corresponding to 50 mg DPI administered BID (every 12 hours); a treatment cycle consisted of a 14-day on-treatment phase followed by a 14-day off-treatment phase (48 weeks treatment phase = 12 active cycles).
89543845|NCT02106832|Placebo Comparator|Placebo 28 Days on/off (Placebo 28)|Subjects received placebo matched to ciprofloxacin 32.5 mg powder (containing 40 mg dry powder) administered BID (every 12 hours); a treatment cycle consisted of a 28-day on-treatment phase followed by a 28-day off-treatment phase (48 weeks treatment phase = 6 cycles).
89543846|NCT02106832|Placebo Comparator|Placebo 14 Days on/off (Placebo 14)|Subjects received placebo matched to ciprofloxacin 32.5 mg powder (containing 40 mg dry powder) administered BID (every 12 hours); a treatment cycle consisted of a 14-day on-treatment phase followed by a 14-day off-treatment phase (48 weeks treatment phase = 12 cycles).
89543847|NCT05542329|No Intervention|Control|Standard of care
89543848|NCT05542329|Experimental|Tele-Medecine|The experimental group will be given a case of connected devices dedicated to telemedicine allowing them to closely monitor their state of health during the 3 months following discharge from hospital
89543849|NCT05547945|Other|health promotion program|The health promotion program included knowledge guidance on ADHD disease, physical activity, diet nutrition, parental training/stress adjustment, related social welfare resources, mindfulness relaxation, and yoga.
89543850|NCT05547945|No Intervention|Control group|The control received as usual care.
89543851|NCT05698797|Experimental|Experimental group 1|In this group participants received hip abductor and external rotator strengthening exercises in addition to conventional physical therapy.
89543852|NCT05698797|Active Comparator|Experimental group 2|In this group participants received proprioceptive training and conventional physical therapy.
89543853|NCT05698797|Active Comparator|Control group|In this group participants received conventional physical therapy alone.
89543854|NCT05552625|Active Comparator|TADIOS + Standard of care treatment|4 tablets of 300 mg each will be administered to the subjects twice daily (1200 mg in the morning and 1200mg in the evening making it 2400 mg/day) for a maximum of 10 days. The subject can consume standard of care treatment as per prescribed by the physician.
89543855|NCT05552625|Placebo Comparator|Placebo + Standard of care treatment|4 tablets of 300 mg each will be administered to the subjects twice daily (1200 mg in the morning and 1200mg in the evening making it 2400 mg/day) for a maximum of 10 days. The subject can consume standard of care treatment as per prescribed by the physician.
89543856|NCT05552391|Placebo Comparator|bupivacaine|Group bupivacaine(Control) (B) received 0.5 ml/kg bupivacaine 0.25% diluted with isotonic saline (total volume15 ml).
89543857|NCT05552391|Active Comparator|bupivacaine - ketamine|Group bupivacaine - ketamine (K) received 0.5 ml/kg bupivacaine 0.25% with ketamine 2 mg/kg, diluted with isotonic saline (total volume15 ml).
89543858|NCT05552391|Active Comparator|bupivacaine - Dexametomedine|Group bupivacaine - Dexametomedine (D) received 0.5 mL/kg bupivacaine 0.25% with dexmedetomidine 1 µg/kg. diluted with isotonic saline (total volume 15ml).
89543859|NCT02106442||Sodium Risedronate 75 mg|75 mg of sodium risedronate is administered orally with a sufficient volume (approximately 180 mL) of water once monthly after waking. Participants receive sodium risedronate 75 mg as part of routine medical care.
89543860|NCT05552313|Experimental|kinesio taping with thoracic manipulation and conventional treatment|experimental group will be given kinesio taping with thoracic manipulation and conventional treatment
89543861|NCT05552313|Sham Comparator|sham kinesio taping with thoracic manipulation and conventional treatment|control group will be given sham kinesio taping with thoracic manipulation and conventional treatment
89543862|NCT05551923||Acute cerebral hemorrhage|intestinal flora disturbance To observe the clinical prognosis of acute cerebral hemorrhage after enterobacterial disorder
89543863|NCT05551923||The group without stroke|The group without stroke
89543864|NCT02105116|Experimental|Standard chemotherapy followed by allogenic therapy|INDUCTION CHEMOTHERAPY: Patients receive standard induction chemotherapy with fludarabine phosphate IV over 1 hour QD for 5 days and cytarabine IV over 4 hours for 5 days. G-CSF 5 mcg/kg will be started at day14 if day14 bone marrow does not have >5% leukemic blasts. Treatment may continue for 1 or 2 courses at the discretion of the treating physician. If the patient enters a complete remission they are eligible for ALLOGENEIC CELLULAR THERAPY: Patients eligible for the experimental therapy undergo irradiated Donor Lymphocyte Infusion (DLI) of 3 x 10^8 CD3+ cells/kg at 8 weeks. Patients with stable disease may repeat irradiated DLI every 8-12 weeks in the absence of disease progression or unacceptable toxicity.
89543865|NCT05551767|Experimental|Experimental arm|3 cycles of induction immunochemotherapy with platinum (cisplatin 75 mg\m2, 5-FU 1000 mg/m2/day 96-hour infusion and pembrolizumab 200 mg) followed by (chemo)radiation. Effect of induction therapy will be assesed by PET/CT and by endoscopic evaluation with biopsy of suspected residual tumor. Managemant of any residual tumor will be performed according with local rules and standards.
89543866|NCT05551689|Active Comparator|ADHD monitoring as usual|ADHD patient monitoring as usual based on psychostimulant prescription and follow up
89543867|NCT05551689|Experimental|FOCUS ADHD|ADHD patient monitoring as usual based on psychostimulant prescription and follow up plus the indication to use the FOCUS ADHD app as a treatment monitoring tool
89543868|NCT05551689|Experimental|FOCUS ADHD and the elegibility for discount concession on treatment purchase|ADHD patient monitoring as usual based on psychostimulant prescription and follow up plus the indication to use the FOCUS ADHD app as a treatment monitoring tool. In this arm patients are also eligible for a discount of at least 25% of the drug cost (after the first month of treatment) if they register and maintain at least 80% of their treatment adherence on the FOCUS ADHD app. The discount is granted after week 4 until the end of the follow up period.
89543869|NCT05547789||Study group|
89543870|NCT05547789||Control group|
89543871|NCT05698719||STEMI patients undergoing physiological assessment of a non-culprit lesion|vFFR, FFR, RFR, dPR, CFR and IMR
89543872|NCT05698641||HFNC|Patients treated with HFNC
89543873|NCT05698641||NIV|Patients treated with NIV
89543874|NCT05547711|Active Comparator|Patients with depression|
89543875|NCT05547711|Active Comparator|Healthy controls|
89543876|NCT05547555||INVASIVE PGT-A|Women who proceed to embryo transfer after invasive PGT-A embryo selection.
89543877|NCT05547555||NON INVASIVE PGT-A|Women who proceed to embryo transfer after non- invasive PGT-A embryo selection.
89543878|NCT05542095|Experimental|topical nasal simvastatin - 0.1 mg dose|"topical nasal simvastatin - 0.1 mg dose~Subjects are entered into the study in groups of 3. This first cohort will receive the lowest dose of simvastatin (0.1mg) via nasal irrigation for 4 weeks. If none of the 3 subjects report toxicity, the next group of 3 subjects enrolled will receive the consecutive higher dose of simvastatin for 1 month. If >2 of the 3 subjects enrolled in the first group report toxicity then the dose is considered toxic or MTD is exceeded. If 1 of the first 3 reports toxicity, then the next group of 3 enrolled subjects will receive the same dose as group 1. When 6 subjects receive the same dose, and <1 of them report toxicity, the consecutive group of 3 subjects will receive the successive higher dose. If >2 of the 6 subjects on the same dose report toxicities, then MTD is exceeded. Intra-patient dose escalation will not be performed."
89543879|NCT05542095|Experimental|topical nasal simvastatin - 0.25 mg dose|"topical nasal simvastatin - 0.25 mg dose~Subjects are entered into the study in groups of 3. This 2nd cohort will receive the 0.25mg simvastatin via nasal irrigation for 4 weeks. If none of the 3 subjects report toxicity, the next group of 3 subjects enrolled will receive the consecutive higher dose of simvastatin for 1 month. If >2 of the 3 subjects enrolled in the first group report toxicity then the dose is considered toxic or MTD is exceeded. If 1 of the first 3 reports toxicity, then the next group of 3 enrolled subjects will receive the same dose as group 1. When 6 subjects receive the same dose, and <1 of them report toxicity, the consecutive group of 3 subjects will receive the successive higher dose. If >2 of the 6 subjects on the same dose report toxicities, then MTD is exceeded. Intra-patient dose escalation will not be performed."
89543880|NCT05542095|Experimental|topical nasal simvastatin - 0.5 mg dose|"topical nasal simvastatin - 0.5 mg dose~Subjects are entered into the study in groups of 3. This 3rd cohort will receive the 0.5mg simvastatin via nasal irrigation for 4 weeks. If none of the 3 subjects report toxicity, the next group of 3 subjects enrolled will receive the consecutive higher dose of simvastatin for 1 month. If >2 of the 3 subjects enrolled in the first group report toxicity then the dose is considered toxic or MTD is exceeded. If 1 of the first 3 reports toxicity, then the next group of 3 enrolled subjects will receive the same dose as group 1. When 6 subjects receive the same dose, and <1 of them report toxicity, the consecutive group of 3 subjects will receive the successive higher dose. If >2 of the 6 subjects on the same dose report toxicities, then MTD is exceeded. Intra-patient dose escalation will not be performed."
89543881|NCT05542095|Experimental|topical nasal simvastatin - 1 mg dose|"topical nasal simvastatin - 1 mg dose~Subjects are entered into the study in groups of 3. This 4th cohort will receive the 1mg simvastatin via nasal irrigation for 4 weeks. If none of the 3 subjects report toxicity, then the drug will be considered tolerated at the maximum tested dose. If >2 of the 3 subjects enrolled in the first group report toxicity then the dose is considered toxic or MTD is exceeded. If 1 of the first 3 reports toxicity, then the next group of 3 enrolled subjects will receive the same dose as group 1. When 6 subjects receive the same dose, and <1 of them report toxicity, then this maximum dose is considered tolerable. If >2 of the 6 subjects on the same dose report toxicities, then MTD is exceeded. Intra-patient dose escalation will not be performed."
89543882|NCT05551221|Active Comparator|Tamsulosin Hydrochloride Capsules combine with Ningmitai Capsules placebo|Patients take tamsulosin hydrochloride capsules (1 tablet each time, once daily) and Ningmitai capsules placebo (0.38 g/capsule, 4 capsules/time, tid.)
89543883|NCT05551221|Experimental|Silodosin Capsules combine with Ningmitai Capsules placebo|Patients take Silodosin Capsules ( Qianweitai®, 4mg/capsule, 1 capsule/time, bid, after breakfast and dinner) and Ningmitai capsules placebo (0.38 g/capsule, 4 capsules/time, tid).
89543884|NCT05551221|Experimental|Silodosin Capsules combine with Ningmitai Capsules|Patients take Silodosin Capsules ( Qianweitai®, 4mg/capsule, 1 capsule/time, bid, after breakfast and dinner) and Ningmitai capsules (Ningmitai®, 0.38 g/capsule, 4 capsules/time, tid).
89543885|NCT05551143|Experimental|LiftKit Intervention|All participants will have access to the LiftKit that provides them with a set of tools that should reduce the physical demands experienced by EMS providers when lifting and moving patients in their homes, thereby reducing the risk of musculoskeletal disorders (MSDs).
89543886|NCT02104804|Experimental|Saxagliptin 5mg|Saxagliptin 5mg, administered to subjects with Type 2 diabetes inadequately controlled with insulin alone or with insulin plus metformin
89543887|NCT02104804|Placebo Comparator|Placebo|Placebo administered to subjects with Type 2 diabetes inadequately controlled with insulin alone or with insulin plus metformin
89543888|NCT05541783|Active Comparator|Laparoscopy-assisted distal gastrectomy|The patients who are assigned to LADG group undergo extracorporeal anasto- mosis for gastrointestinal reconstruction.
89543889|NCT05541783|Experimental|Totally laparoscopic distal gastrectomy|The patients who are allocated to TLDG group undergo intracorporeal anastomosis for the recovery of gastrointes- tinal continuity after gastrectomy.
89543890|NCT05547009|Experimental|Blended-learning group|The BL program included paced, asynchronous online learning modules and scheduled online activities with strategic face-to-face lectures.
89543891|NCT05547009|Active Comparator|Face-to-face learning group|Face-to-face classes.
89543892|NCT02075008|Experimental|QGE031 every 4 weeks (q4w)|QGE031 240 mg subcutaneously q4w
89543893|NCT05541549|Placebo Comparator|Placebo|
89543894|NCT05541549|Experimental|CE-VST01-JC|
89543895|NCT05550441|Placebo Comparator|Placebo group|
89543896|NCT05550441|Experimental|Dapagliflozin group|
89543897|NCT05550285|Experimental|Orbital Volume After Using Guided Calvarial Graft in Floor Recontsruction|
89024984|NCT03279497|Experimental|Health game|Health game intervention consists of 20 minutes guided training session with the mobile health game at school and 4 weeks free usage of the game via own smart phone during free time. Smart phones are tracking the actual physical activity (steps) of the participants via activity sensors and the tracked steps work as In-App Currency enabling the participants to play the game and proceed in it.
89207491|NCT00861666|Other|Forgiveness-based Writing|
89207492|NCT00861822|Active Comparator|RBC|Advance RBC transfusion' (ART) group
89207493|NCT00861822|Other|Standard Care|Standard-of-care RBC transfusion (SRT) group
89543898|NCT05550285|Experimental|Orbital Volume After Using 3D Printed Titanium mesh in Floor Recontsruction|
89543899|NCT04321941|Experimental|CTE (Computerised Tomography Enterography)|CTE examination performed with experimental contrast agent, Lumentin.
89543900|NCT04321941|Active Comparator|MRE (Magnetic Resonance Enterography)|Comparative diagnostic method performed with the contrast agent Movprep®
89543901|NCT05540925||Low-risk for MVI|Using the sequencing data of cfDNA, a nomogram to predict MVI was constructed using genomic mutations. We designed to stratify early-stage HCC into two sub-stages with nomogram-estimated high or low risks of MVI, respectively, using an optimal cutoff value of 90. The MVI low-risk group refers to patients with score ≤ 90.
89543902|NCT05540925||High-risk for MVI|Using the sequencing data of cfDNA, a nomogram to predict MVI was constructed using genomic mutations. We designed to stratify early-stage HCC into two sub-stages with nomogram-estimated high or low risks of MVI, respectively, using an optimal cutoff value of 90. The MVI low-risk group refers to patients with score > 90.
89543903|NCT05535699|Experimental|scapular muscle strengthening exercises|Group A (n=22): will receive a program of scapular muscle strengthening exercises for 18 sessions (3 sessions per week for six weeks)
89543904|NCT05535699|Experimental|PNF exercise|Group B (n=22): will receive a scapular PNF exercise program for the same frequency as in group A
89543905|NCT05535699|No Intervention|control|Group C (n=22): will be a control group who will not receive any treatment during the study period.
89543906|NCT05540769|Experimental|case group|
89543907|NCT05535543||Baseline slope of phase iii|Severe ARDS patients who are intubated and mechanically ventilated and will undergo prone positioning
89543908|NCT05546619|Experimental|Treating with a Design Protocol|
89543909|NCT05540379|Active Comparator|Group A: Ob/Gyn physicians|It is about 51 participants whom had performed less than 50 diagnostic hysteroscopies and hysteroscopic polypectomy.
89543910|NCT05540379|Active Comparator|Group B: Ob/Gyn physicians|It is about 51 participants whom had performed at least 50 diagnostic hysteroscopies and hysteroscopic polypectomy.
89543911|NCT05535465|Experimental|Intervention arm|Heath system strengthening with additional trained mobile health care worker to help community health workers
89543912|NCT05535465|No Intervention|Standard of care|National strategy to control malaria
89543913|NCT05540301|Experimental|Modified Sleeper Stretch Group|Modified sleeper stretch was performed for four weeks.
89543914|NCT05540301|Active Comparator|Modified Cross-Body Adduction Stretch Group|Modified cross-body adduction stretch was performed for four weeks.
89543915|NCT05698017|Active Comparator|Low dose hOMSC300|Single IT administration of low dose hOMSC300
89543916|NCT05698017|Active Comparator|High dose hOMSC300|Single IT administration of high dose hOMSC300
89543917|NCT05698017|Other|Sham Procedure|Lumbar puncture only
89543918|NCT05546541||subjects normal weight undergo to PRP treatment|subjects with body mass index (BMI) considered normal weight (≥18.5 and ≤25) undergo to Platelet-Rich Plasma (PRP) treatment.
89543919|NCT05546541||subjects overweight undergo to PRP treatment|subjects with BMI values that exceed the normal weight range (BMI>25) undergo to PRP treatment.
89543920|NCT05546541||subjects with normal weight undergo to microfragmented adipose tissue treatment|subjects with BMI within the considered normal weight range (≥18.5 e ≤25) and undergo to microfragmented adipose tissue treatment.
89543921|NCT05546541||subjects overweight undergo to microfragmented adipose tissue treatment|subjects with BMI values that exceed the normal weight range undergo to microfragmented adipose tissue treatment. (BMI>25).
89543922|NCT05546463|Experimental|Intervention group|"During the suture procedure, the children in the intervention group played digital games.~Children began playing digital games about one minute before the local anesthesia procedure, continued to play digital games throughout the suturing procedure."
89543923|NCT05546463|Experimental|Control group|During the suture procedure, the children in the control group did not play digital games.
89543924|NCT05699577||metastatic breast cancer|
89543925|NCT05699577||non metastatic breast cancer|
89543926|NCT05699421||CITEMB project participants|This is a single cohort, observational prospective multicenter study. The participating centers of the Barcelona Northern Metropolitan Area are primary attention centers - ASSIR Muntanya, ASSIR Esquerra, ASSIR Santa Coloma de Gramenet, ASSIR Badalona-Sant Adrià and hospitals - Vall d'Hebron University Hospital in Barcelona, BCNatal, Hospital Clínic /Hospital Sant Joan de Déu University of Barcelona and Trias i Pujol University Hospital.
89543927|NCT05592327|Experimental|Citric acid abutment|"Antimicrobial-coated abutments (citric acid) will be allocated to the test group.~Permanent Vega® (Klockner Implant System, Barcelona, Spain) will be used. The interface between implant and abutment is platform switching. The abutment height will be of 2 mm. It will be placed the day of the implant surgery and tighten to 25 N"
89543928|NCT05592327|Placebo Comparator|Control non coated abutment|Non- coated abutments (citric acid) will be allocated to the control group. Permanent Vega® (Klockner Implant System, Barcelona, Spain) will be used. The interface between implant and abutment is platform switching. The abutment height will be of 2 mm. It will be placed the day of the implant surgery and tighten to 25 N
89543929|NCT05539755|Experimental|Non-surgical therapy of peri-implantitis|Subjects over 18 years old were consecutively included in the study if they present at least one implant in function for more than 1 year diagnosed with peri-implantitis following the case definition of the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions (Berglundh et al., 2018).
89543930|NCT05592171|Other|Occlusafe assisted MWA+ DEB-TACE|
89543931|NCT05592171|Other|Occlusafe assisted MWA|
89543932|NCT05592171|Other|MWA+ DEB-TACE|
89543933|NCT05539677||Melanoma|
89543934|NCT05539677||Soft tissue sarcoma|
89543935|NCT05539677||Kidney cancer|
89543936|NCT05539677||Primary brain tumors|
89543937|NCT05539677||Malignant neoplasms|
89543938|NCT05539677||Prostate cancer|
89543939|NCT05539677||Colorectal cancer|
89543940|NCT05546307|Experimental|one relaxation session before the examination|
89543941|NCT05546307|Active Comparator|No relaxation session before the examination|
89543942|NCT05539521|Experimental|Remimazolam Besylate|Patients in the remimazolam group received remimazolam besylate at an initial infusion rate of 0.3 mg/kg/h and adjusted to maintain a Narcotrend index between 13 and 64.
89543943|NCT05539521|Active Comparator|Propofol|Patients in the propofol group received propofol at an initial infusion rate of 3.0 mg/kg/h and adjusted to maintain a Narcotrend index between 13 and 64.
89543944|NCT05546229||Controls|Subjects not taking medications for opioid use disorder
89543945|NCT05546229||Methadone|Subjects taking methadone for opioid use disorder
89543946|NCT05546229||Buprenorphine|Subjects taking buprenorphine for opioid use disorder
89543947|NCT05591937|Active Comparator|Symptom Severity Decision-Making|Using current symptom severity level to guide triaging and adapting level of care.
89543948|NCT05591937|Experimental|Data-Driven Decision-Making|Using data-driven algorithm that considers social determinants of mental health, early life adversity/stress, predisposing, enabling and need influences upon health services use, and comprehensive mental health status to guide triaging and adapting level of care.
89543949|NCT05591781|Experimental|Vest Airway Clearance System|Thirty patients (Group A) received high frequency chest wall oscillation with vest system in addition to their prescribed medication, 3 times per week for three successive weeks and the total duration of each session was 15-30 minutes
89543950|NCT05591781|Active Comparator|Lung flute (OPEP)|Thirty patients (Group B) received Lung flute (OPEP) in addition to their prescribed medication, 3 times per week twice a day
89543951|NCT05538975|Experimental|Group A|home based plan of aerobic exercises, strengthening exercises of upper and lower limbs and huffing and coughing
89543952|NCT05538975|Placebo Comparator|Group B|Supervised aerobic exercises, strengthening exercises of upper and lower limbs and huffing and coughing
89543953|NCT05545995||TIME LAPSE|Women who proceed to embryo transfer after time lapse assisted embryo selection.
89543954|NCT05545995||NI-PGT-A|Women who proceed to embryo transfer after non-invasive PGT-A assisted embryo selection.
89543955|NCT05545917|Experimental|APP care|The experimental arm will receive advanced practice physiotherapy care.
89543956|NCT05545917|Active Comparator|Usual physician care|The control arm will receive usual ED physician care delivered only by an ED physician.
89543957|NCT04426149|Experimental|interventional|supplement: trehalose
89543958|NCT05591469|Experimental|Noncontact Respiration monitoring group|
89543959|NCT05591469|Experimental|Contact Respiration monitoring group|
89543960|NCT05591391|Experimental|Mallya|Patients use Mallya cap to record the time and dosage of insulin injection
89543961|NCT05591391|Active Comparator|Standard care|Patients receive standard care.
89543962|NCT05538507|Active Comparator|Group I severe AD|Patients over 40 years of age and eligible for NIA-AA 2011 probable severe AD will be given donepezil 10 mg, memantine 20 mg and smart soup
89543963|NCT05538507|Sham Comparator|Group II severe AD|Patients over 40 years of age and eligible for NIA-AA 2011 probable severe AD will be given donepezil 10 mg, memantine 20 mg and placebo
89543964|NCT05538507|Active Comparator|Group III Mild or moderate AD|Patients over 40 years of age and eligible for NIA-AA 2011 probable mild or moderate AD will be given donepezil 10 mg and smart soup
89543965|NCT05538507|Sham Comparator|Group IV Mild or moderate AD|Patients over 40 years of age and eligible for NIA-AA 2011 probable mild or moderate AD will be given donepezil 10 mg and placebo
89543966|NCT05538507|Active Comparator|Group V MCI|Patients over 40 years of age and eligible for NIA-AA 2011 probable MCI will be given smart soup
89543967|NCT05538507|Sham Comparator|Group VI MCI|Patients over 40 years of age and eligible for NIA-AA 2011 probable MCI will be given placebo
89543968|NCT05538429|Experimental|ESPB&SAPB|erector spinal plane block combined with serratus anterior plane block
89543969|NCT05538429|Active Comparator|TPVB|thoracic paravertebral block
89543970|NCT05591235|Active Comparator|Metformin|
89543971|NCT05591235|Active Comparator|Fixed-dose combination of metformin and pioglitazone (500mg metformin plus 15mg pioglitazone)|
89543972|NCT05591235|Active Comparator|Dapagliflozin|
89543973|NCT04425837|Active Comparator|Standard care alone|
89543974|NCT04425837|Experimental|SARS-CoV-2 convalescent plasma treatment plus standard care|
89543975|NCT05589519|Experimental|Partial rehabilitation using PEEK|A 3-unit implant-supported fixed prosthesis using PEEK polymer in its composition for the rehabilitation of the partial edentulous.
89543976|NCT05538195|Experimental|Intravenous of CEA-targeted CAR-T|Infusion of CEA-targeted CAR-T cells by dose of 3-10x10^6 cells/kg
89543977|NCT05538195|Experimental|intraperitoneal injection of CEA-targeted CAR-T|Infusion of CEA-targeted CAR-T cells by dose of 1-10x10^6 cells/kg
89543978|NCT05523063||Breast cancer patients followed at CAMI|The trial population concerns all adult patients with breast cancer followed at the Croix-Rousse hospital, who have been under care for less than 3 months or who are going to be treated at the CAMI.
89543979|NCT05537805|Experimental|proximal tubal occlusion|Infertile patients that were referred to our unit for uni or bilateral proximal tubal occlusion demonstrated by HyFoSy or hysterosalpingography.
89543980|NCT05537649|Active Comparator|Oatmeal porridge|Cold-stored oatmeal porridge (38 g oats) and stored for 24 h at 4 degrees Celsius
89543981|NCT05537649|Active Comparator|Oatmeal porridge treated with amylomaltase|Cold-stored oatmeal porridge (38 g oats) treated with 30 enzyme units/g oats of amylomaltase and stored for 24 h at 4 degrees Celsius
89543982|NCT01666119|Experimental|BEMA Buprenorphine NX films|BEMA Buprenorphine NX films (3.5/0.6 mg and 5.25/0.9 mg buprenorphine/naloxone)will be provided in 3.361 and 5.447 cm2 film sizes, respectively.
89543983|NCT05389839|Experimental|Wechat program guidance group|Wechat program guidance group using insulin dose calculator
89543984|NCT05389839|Active Comparator|clinical experience treatment group|clinical experience treatment group using physician experience
89543985|NCT04425681|Experimental|Osimertinib With Bevacizumab group|Osimertinib 80 mg oral daily; and bevacizumab 7.5 mg/kg intravenous every 3 weeks
89543986|NCT05545059|Experimental|sacubitril/valsartan group|The experimental group will be sacubitril/valsartan group. Patients assigned to this group will receive sacubitril/valsartan 200mg added to existing medication regimens before randomization including amlodipine 10mg per day, hydrochlorothiazide 25 mg per day, spironolactone 20 mg per day. The initial dose of sacubitril/valsartan will be 100mg per day and will be doubled to 200mg per day after 2 weeks then maintain until the end of the 8-week treatment period.
89543987|NCT05545059|Active Comparator|valsartan group|The control group will be valsartan group, which patients will receive valsartan 160mg added to existing medication regimens before randomization including amlodipine 10mg per day, hydrochlorothiazide 25 mg per day, spironolactone 20 mg per day. The initial dose of valsartan will be 80mg per day and will be doubled to 160mg per day 2 weeks later and then maintain until the end of the 8-week treatment period.
89543988|NCT05536947|Active Comparator|Standard-milled Wholegrain|Bread rolls prepared using standard-milled Wholegrain (75 g per bread roll, containing stable isotopes of Fe and Zn), with butter and strawberry jam.
89543989|NCT05536947|Experimental|Micro-milled Wholegrain|Bread rolls prepared using Micro-milled Wholegrain (75 g per bread roll, containing stable isotopes of Fe and Zn), with butter and strawberry jam.
89543990|NCT05536947|Active Comparator|White flour fortified with standard milled Aleurone|Bread rolls prepared using a white flour and standard-milled aleurone mix (75 g per bread roll, containing stable isotope of Fe), with butter and strawberry jam.
89543991|NCT05536947|Experimental|White flour fortified with micro-milled Aleurone|Bread rolls prepared using a white flour and micro-milled aleurone mix (75 g per bread roll, containing stable isotope of Fe), with butter and strawberry jam.
88961219|NCT02007174||Medical Treatment|In order to reduce the patient bias, the control eye received a sham laser treatment, under slit lamp, topical anesthesia using 0.5% tetracaine hydrochloride eye drops (Ponti-Ofteno, Laboratorios Sophia, Jalisco, Mexico) and topical 1 mg fluorescein Sodium staining (Bio-Glo, Hub Pharmaceuticals, Rancho Cucamonga CA). Post sham laser care treatment included topical eyedrops of 0.3% tobramycin and 0.1% dexamethasone (Trazidex, Laboratorios Sophia) three times daily, and 0.5 carboxymethylcellulose lubricating eye drops (Refresh-Tears, Allergan, Irving, California, USA). Topical antibiotics and corticosteroids were tapered and discontinued after two weeks.
88961220|NCT02007174||Argon Laser Treatment|Argon laser therapies were performed on an outpatient basis only by one ophthalmologist. Under slit lamp, topical anesthesia using 0.5% tetracaine hydrochloride eye drops (Ponti-Ofteno, Laboratorios Sophia, Jalisco, Mex) and topical 1 mg fluorescein Sodium staining (Bio-Glo, Hub Pharmaceuticals, Rancho Cucamonga CA) was applied. Argon laser was applied along the vessels of the pterygium apex with power between 450mW to 780 mW, spot size of 100 u with 10 milliseconds duration. Additional grill pattern treatment was given to pterygium body using a 200 microns spot size. Treatments were given in one only session. Post laser care treatment included topical eyedrops of 0.3% tobramycin and 0.1% dexamethasone (Trazidex, Laboratorios Sophia) three times daily, and 0.5 carboxymethylcellulose lubricating eye drops (Refresh-Tears, Allergan, Irving, CA, USA). Topical antibiotics and corticosteroids were tapered and discontinued after two weeks.
88961221|NCT02007187|Experimental|Danhong injection|Based on the standard medical care, 40ml of Danhong injection, added into 250ml of 0.9% saline, given by continuous IV infusion at 2.5ml/min within 2-3 hours every day for 7 days.
88961222|NCT02007187|Placebo Comparator|Placebo|Based on the standard medical care, placebo was 40ml of 0.9% saline, added into 250ml of 0.9% saline, given by continuous IV infusion at 2.5ml/min within 2-3 hours every day for 7 days.
88961223|NCT02007265||TIA and SPC outpatients|All consecutive patients attending outpatient TIA and Stroke Prevention Clinics at three regional stroke centres will be eligible to be screened.
88961224|NCT02007304|Experimental|Herbs|participants assigned to experimental arm will take 300mg panax ginseng and 300mg salvia miltiorrhiza extracts in capsules for 12 weeks along with eccentric exercise training
88961225|NCT02007304|Placebo Comparator|Placebo|parcipants in this group will take placebo capsule containing microcrystalline cellulose
88961226|NCT02007317|Experimental|Oshadi D and Oshadi R|Anti tumor agents
88961227|NCT02007330|Experimental|Group L|Intravenous lidocaine infusion group
89543992|NCT05696925|Experimental|motor imagery, observation of the action, and execution of the action (GE1)|in the sitting position, the participant will watch the recorded video to observe the action, for two minutes. Soon after, they will close their eyes, and receive the description of the action, through recorded audio of the same action, to imagine it, for two minutes. In the sitting or standing position, depending on the action to be performed, the participant must execute the same action imagined previously, for two minutes. Each session will have five different actions that will be repeated twice, totaling 60 minutes of intervention.
89543993|NCT05696925|Experimental|motor imagery and execution of the action (GE2)|in the sitting position, the participant will close his eyes and will receive the description of the action, through recorded audio, to imagine it, for two minutes. Then, in the sitting or standing position, depending on the action to be performed, the participant must execute the same action imagined previously, for two minutes. Each session will have five different actions that will be repeated twice, totaling 40 minutes of intervention.
89543994|NCT05696925|Experimental|action observation and action execution (GE3)|in the sitting position, the participant will watch the recorded video to perform the action observation, which will last two minutes. Then, in the sitting or standing position, depending on the action to be performed, the participant must execute the same action observed previously, for two minutes. Each session will have five different actions that will be repeated twice, totaling 40 minutes of intervention.
89543995|NCT05696925|Experimental|motor imagery, execution of the action, and exoskeleton (GE4)|in the sitting position, the participant will perform the exoskeleton protocol for 40 minutes. Then, the participant will close his eyes and will receive the description of the action, through recorded audio, to imagine it, for two minutes. In the sitting or standing position, depending on the action to be performed, the participant must execute the same action imagined previously, for two minutes. Each session will have five different actions that will be repeated twice, totaling 80 minutes of intervention.
89543996|NCT05696925|Experimental|observation of the action, execution of the action, and exoskeleton (GE5)|"in the sitting position, the participant will perform the exoskeleton protocol for 40 minutes.~Then, the participant will watch the recorded video to observe the action, for two minutes. Then, in the sitting or standing position, depending on the action to be performed, the participant must execute the same action observed previously, for two minutes. Each session will have five different actions that will be repeated twice, totaling 80 minutes of intervention."
89543997|NCT05536869|Active Comparator|Patient with intraperitoneal caesarean section|
89543998|NCT05536869|Experimental|patient with extraperitoneal caesarean section|Faucs technique
89543999|NCT05128773|Experimental|Amcenestrant with tamoxifen-matching placebo arm|Amcenestrant dose, once daily, continuously. Tamoxifen-matching placebo, once daily, continuously.
89544000|NCT05128773|Active Comparator|Tamoxifen with amcenestrant-matching placebo|Tamoxifen dose, once daily, continuously. Amcenestrant-matching placebo, once daily, continuously.
89544001|NCT05536635|Experimental|breathing techniques|The patients in the intervention group will be taught and practiced breathing technique. Breathing techniques will be taught face-to-face by the researcher to the patients in the intervention group. The participant will breathe through one nostril at a natural rate and depth, while the other nostril will be closed with the thumb or forefinger. After the act of breathing, it will open the closed nostril, close the open nostril and breathe naturally. As explained later, they will continue the cycle with the act of breathing. This process is described as a loop.
89544002|NCT05536635|No Intervention|treatment as usual|The control group will continue his/her usual treatment as advised by the physician.
89544003|NCT05699187|Experimental|Face Transplant Recipient|The procedure will be carried out simultaneously by two teams of transplant surgeons for each face transplanted in the operation. The teams will be divided between the functions of tissue recovery (donor operation) and transplant surgery (recipient operation). In most cases the facial graft will include the entire nose; the soft tissues of the mid-face, including all its blood vessels, muscles, and nerves; and a significant portion of the mid-facial skeleton.
89544004|NCT05536479|Experimental|Autogenous stored mineralized dentin graft (ASMDG)|Autogenous stored mineralized dentin graft (ASMDG) particles will be prepared by immersing tooth particles in basic ethanol for 10 min for disinfection, then washed twice in saline and dried using sterile gauze The disinfected particles will then be stored at room temperature for 21 days in a sterile container. After 21 days, a second extraction will be performed followed by mixing the stored graft with a few drops of sterile saline to be packed in a socket after extraction
88961228|NCT02007330|Placebo Comparator|Group C|Intravenous normal saline infusion - control group
88961229|NCT02007343||Patients with gram-negative infections|"Sample (5/week/hospital) of all patients in a hospital that meet all of the following:~meeting the criteria of at least one infection entity based on (modified) definitions of the Center for Disease Control and Infection Prevention (CDC; Am J Infect Control 2008;36:309-32) (restricted to infections that have septic potential);~a culture with a gram-negative isolate (Enterobacteriaceae / Pseudomonas aeruginosa / Acinetobacter spp. / Stenotrophomonas maltophilia) with minimal inhibitory concentration (MIC) results from an automated system available that can be used to identify such an infection entity according to these criteria;~receipt of antibiotics (oral, intravenous or intramuscular) for this infection, the choice of which is determined by the culture with the gram-negative (i.e. this isolate is seen as the causative pathogen);~were admitted to the hospital during (part of) the infection episode.~Date of entry into cohort: date of index culture of infection episode"
88961230|NCT02007343||Non-infected patients|"Matched sample of all patients that (1) were admitted to the hospital and (2) did not have a gram-negative infection according to the 4 criteria set out in the other group on the date used for matching. Selected by matching 1:1 to patients with gram-negative infections on (1) hospital, (2) length of hospital stay on the date the index culture for the infected patient was obtained, and (3) age.~Date of cohort entry: date of index culture of matched infected patient"
88961231|NCT02007395||colonoscopy population|
88961232|NCT02007408|Placebo Comparator|Placebo group|
88961233|NCT02007408|Active Comparator|Paracervical block plus lidocaine spray|Lidocaine injection+Lidocaine spray received PCB with 2 ampoules of lidocaine solution plus 2 pumps (20 mg=2 pumps) of 10% lidocaine spray
88961234|NCT02007408|Active Comparator|paracervical block plus isotonic saline spray|2 ampoules of lidocaine solution (20 mg Lidocaine HCl+0.0125 mg epinephrine/ml) plus isotonic spray
88961235|NCT02007408|Active Comparator|only lidocaine spray|paracervical block with saline solution plus 10% lidocaine spray
88961236|NCT02007421|Other|HIV positive homosexual men|"Therefore, it is proposed we conduct a longitudinal study of the epidemiology of low risk and high risk HPV infection and related low grade and high grade anal cancers in HIV negative and HIV positive homosexual men who are 35 years or older. Participants are asked questions about recent experiences of anal intercourse in the last six months.~At baseline, all men (both HIV positive and HIV negative)will undergo a behavioural questionnaire, and anal swabs which will be tested for HPV and cytology. An HRA will also be performed on all men. Blood will be collected for HIV testing for HIV negative participants, syphilis and storage. Participants will be followed up for three years with one six-monthly visit in the first year then annually. A 6th study visit to discuss all study results will take place 2-3 months after the 5th study visit. A behavioural questionnaire, an anal swab, and HRA will be administered at all follow up interviews."
88961237|NCT02007421|Other|HIV negative homosexual men|"Therefore, it is proposed we conduct a longitudinal study of the epidemiology of low risk and high risk HPV infection and related low grade and high grade anal cancers in HIV negative and HIV positive homosexual men who are 35 years or older. Participants are asked questions about recent experiences of anal intercourse in the last six months.~At baseline, all men (both HIV positive and HIV negative)will undergo a behavioural questionnaire, and anal swabs which will be tested for HPV and cytology. An HRA will also be performed on all men. Blood will be collected for HIV testing for HIV negative participants, syphilis and storage. Participants will be followed up for three years with one six-monthly visit in the first year then annually. A 6th study visit to discuss all study results will take place 2-3 months after the 5th study visit. A behavioural questionnaire, an anal swab, and HRA will be administered at all follow up interviews."
88961238|NCT02007447|Active Comparator|OCYTOCINA - SPRAY NASAL|OCYTOCINA - SPRAY NASAL - 24Ui twice per day for 8 weeks
88961239|NCT02007447|Placebo Comparator|Placebo|Placebo - twice per day for 8 weeks
88961240|NCT02007460|Experimental|Exercise leg|
88961241|NCT02007460|No Intervention|Control leg|
89544005|NCT05536479|Active Comparator|Autogenous fresh mineralized dentin graft (AFMDG)|Autogenous fresh mineralized dentin graft (AFMDG) particles will be prepared by immersing tooth particles in basic ethanol for 10 min for disinfection, then washed twice in saline and dried using sterile gauze
89544006|NCT05544435|Experimental|Motivational Interviewing|Intervention In addition to the care they always received, MI sessions were conducted by the researcher for the participants in the experimental group. This intervention was conducted as 30-45 minutes of 12 sessions in total for each patient for a period of 3 months by the academic nurse. In these sessions, the agenda was created in accordance with the nature of MI intervention, efforts were made to resolve the ambivalent feelings in the patient, the patient's change phase was determined, the patient's self-confidence for change was determined, it was questioned how much the patient cared for change and the patient was helped in determining the change plan. In addition, during the sessions, the problems patients experienced about self-care activities, the causes of these problems and the barriers in maintaining self-care activities were discussed and efforts were made to create awareness in patients.
89544007|NCT04744467|Experimental|PODEYE TORIC IOL Implantation experimental|Mono- or bilateral implantation of toric intraocular lenses PODEYE TORIC
89544008|NCT04677855|Experimental|PCUR-101 Dose Escalation|PCUR-101 dosed orally once per day in 28 day cycles. Patients will be enrolled into escalating dose levels during the dose escalation phase
89544009|NCT04677855|Experimental|PCUR-101 Dose Expansion Cohort 1|PCUR-101 dosed orally once per day in 28 day cycles
88961242|NCT02007473||Patients requiring transfusion with plasma|Recipients, who have received a transfusion with Methylene Blue plasma produced using the THERAFLEX MB-Plasma procedure from MacoPharma.
88961243|NCT02007486||Heart Failure: NYHA functional class I|Ambulatory and clinically-stable patients with New York Heart Association Functional Class I heart failure and a left ventricular ejection fraction (LVEF) on echocardiography of <45%.
88961244|NCT02007486||Heart Failure: NYHA functional class II|Ambulatory and clinically-stable patients with New York Heart Association Functional Class II heart failure and a left ventricular ejection fraction (LVEF) on echocardiography of <45%.
88961245|NCT02007486||Heart Failure: NYHA functional class III|Ambulatory and clinically-stable patients with New York Heart Association Functional Class III heart failure and a left ventricular ejection fraction (LVEF) on echocardiography of <45%.
88961246|NCT02007486||Healthy Control Subjects|Healthy, sedentary, non-smoking, age- and sex-matched control subjects.
88961247|NCT02007499||Cardiac Arrest, Out of hospital|Pre-arrival Cardiopulmonary Resuscitation (CPR) instruction for bystander.
88961248|NCT02007525|Experimental|Yoga intervention|
88961249|NCT02007525|No Intervention|Wait list control|
88961250|NCT02007538||Thin Prep|Samples obtained from this group will be tested with thin prep
88961251|NCT02007538||Control Group|Samples obtained from this group will be tested with conventional procedure.
88961252|NCT02007551|Experimental|Mealtime Intervention|The mealtime intervention group will receive a trained peer volunteer to their home once weekly for 8 weeks to prepare and share a meal with them.
88961253|NCT02007564|Experimental|LIFE Intervention|RSVs received intensive training in the manualized intervention, including practice opportunities. The manual and accompanying workbook consist of instructions about using the steps of problem solving to decide on a period of life and creative activity project; constructing a project; evaluation of the activity; and additional questions. With the help of the RSV, dyads narrow the focus to one time period in the patients' life that could be adequately represented in one tangible project (scrapbook, audiotapes). The RSV and dyad brainstormed ways to portray the life story and then narrowed the focus to one meaningful project. The dyad gathered all necessary materials (such as pictures) and actively worked on completing a portion of the project between sessions.
88961254|NCT02007564|No Intervention|Supportive Telephone Contact Control|Patients and caregivers each received three separate, structured emotional support telephone calls with research staff (M duration = 13 minutes; SD = 6.5 minutes) to minimize differential drop-out with the RSV intervention group. Control callers asked questions of participants and then engaged in supportive conversations using empathic listening and reflection. Topics discussed included family, intergenerational ties, and important aspects of the patient's life, but structured reminiscence and the creative and therapeutic nature of legacy activities were not discussed.
88961255|NCT02007590|Experimental|Aerosure 25 Hz|All subjects receive an active device, sham device (disabled) and no device in a randomised sequence.
88961256|NCT02007590|Sham Comparator|Aerosure sham|All subjects receive an active device, sham device (disabled) and no device in a randomised sequence.
88961257|NCT02007590|No Intervention|No device|All subjects receive an active device, sham device (disabled) and no device in a randomised sequence.
88961258|NCT02007603|Experimental|Ampicillin / sulbactam|Patients are randomized to the ampicillin / sulbactam arm. Pharmacokinetic samples will be taken during multiple hemodialysis sessions.
88961259|NCT02007603|Experimental|Amoxicillin / clavulanic acid|Patients are randomized to the amoxicillin / clavulanic acid arm. Pharmacokinetic samples will be taken during multiple hemodialysis sessions.
88961260|NCT02007616|Experimental|Non-action video game training|20 1-hour sessions of non-action video game training
89544010|NCT04677855|Experimental|PCUR-101 Dose Expansion Cohort 2|PCUR-101 in combination with dutasteride dosed orally once per day in 28 day cycles
89544011|NCT04677855|Experimental|PCUR-101 Dose Expansion Cohort 3|PCUR-101 dosed orally once per day in combination with abiraterone (once per day) and prednisone (twice per day) in 28 day cycles
89544012|NCT05696223||Early fetal growth restriction|Fetal growth restriction diagnosed before 32 SA
89544013|NCT05696223||Late fetal growth restriction|Fetal growth restriction diagnosed after 32 SA
89544014|NCT05544279|Experimental|Intervention group that given education|"7 interviews are held. 3 meaurements are explored. In the first measurement (first interview) Personal information form, Zarit Burden Interview (ZBI), STAI-S and STAI-T are filled in preoperatively within 24-48 hours, and the planned training and booklet are given. Second measurement (4th interview) is done on the phone within the 1st week after discharge. Third measurement (7th interview) is explored within the 4th week after discharge. In the interim interviews, the training is repeated and the questions about the places that were not understood are answered."
88961261|NCT02007616|No Intervention|Control|Participants in the control group did not receive non-action video game training
89024985|NCT03279497|Sham Comparator|Sport and fitness application|Sport and fitness application intervention consists of 20 minutes guided training session with the app at school and 4 weeks free usage of the app via own smart phone during free time. Sport and fitness application, when turned on, tracks the physical activity (running, cycling and every-day training) of the participant.
89515102|NCT03110211|Experimental|Physical Therapist Evaluation|Patients are randomized to have an initial appointment with a physical therapist for a musculoskeletal complaint. The intervention is an initial evaluation and treatment recommendations by a physical therapist.
89515103|NCT03110211|Experimental|Primary Care Physician Evaluation|Patients are randomized to have an initial appointment with a primary care physician for a musculoskeletal complaint. The intervention is an initial evaluation and treatment recommendations by a primary care physician.
89515104|NCT02294513||AD_HI|This group will consist of participants with Alzheimer's disease who receive treatment (Standard audiologic rehabilitation (incl. HI)) immediately and are followed over a three-month intervention period.
89515105|NCT02294513||NC_HI|This group will consist of participants with normal cognition (i.e., no diagnosis of Alzheimer's disease) who receive treatment (Standard audiologic rehabilitation (incl. HI)) immediately and are followed over a three-month intervention period.
89515106|NCT02294591|Active Comparator|NAC group|Receiving N-acetylcysteine as add-on treatment
89515107|NCT02294591|Placebo Comparator|Placebo group|Receiving placebo as add-on treatment
89515108|NCT03110367|Active Comparator|Pain Reframing Intervention|"Participants will be randomized into this group:~- Memory reframe with parent facilitated by researcher:~Parents and youth in the intervention group will receive instructions about adaptive ways of reminiscing about the in-hospital and post-surgery periods. The intervention will draw from existing narrative-based interventions that have taught parents to reminisce with their children about past negative events in more elaborative and emotion-rich ways."
89515109|NCT03110367|Sham Comparator|Attention Control Group|"Participants will include 90 youth scheduled for a pectus repair or a spinal fusion surgery, surgeries associated with high levels of post-surgical pain, and their parents. They will be recruited at the Alberta Children's Hospital. The timelines and measures to be administered to parents and children are listed below. The timelines will include a baseline assessment (1-3 weeks pre-op), in hospital assessment for several days, 1-2 weeks post-op (acute recovery phase), the 2-4 week post-op clinic visit (memory reframing intervention) and 6 weeks post-op.~Participants will be randomized into this group:~- Attention control (watch video [Planet Earth] for same amount of time): Parents and youth in the attention control group will watch a neutral 20-minute video that is not related to surgery (Planet Earth). Importantly, they will not talk about pain or the past surgery experience."
89515110|NCT03110367|No Intervention|Normal Reminiscing|"Participants will include 90 youth scheduled for a pectus repair or a spinal fusion surgery, surgeries associated with high levels of post-surgical pain, and their parents. They will be recruited at the Alberta Children's Hospital. The timelines and measures to be administered to parents and children are listed below. The timelines will include a baseline assessment (1-3 weeks pre-op), in hospital assessment for several days, 1-2 weeks post-op (acute recovery phase), the 2-4 week post-op clinic visit (memory reframing intervention) and 6 weeks post-op.~Participants will be randomized into this group:~- Normal Reminiscing: Parents and youth in the normal reminiscing group will be instructed to reminisce with their children about the in-hospital and post-surgery periods as they normally would."
89515111|NCT03521063|Experimental|Poractant alfa/budesonide|A mixture of poractant (200mg/kg) and budesonide (0.25 mg/kg) will be instilled intratracheal
89515112|NCT03521063|Active Comparator|Poractant alfa/saline|A mixture of poractant (200mg/kg) and saline (1 ml/kg) will be instilled intratracheal
89515113|NCT02294669|Experimental|Turris Facet Fuser|
89515114|NCT04056273|Experimental|Guide sheath group|Transbronchial biopsy with a guide sheath
89515115|NCT04056273|Active Comparator|Conventional group|Transbronchial biopsy without a guide sheath
89515116|NCT03520985|Experimental|Pomalidomide|The treatment in this trial consists of oral pomalidomide on alternate days (ad) plus Low-Dose Dexamethasone (adPOM + LD-DEX)
89515117|NCT04010721|Other|Experimental : experiment 1,2 and 3|"One user included participates all experiments:~Visit 1 : experiment 1~Visit 2 : experiment 2~Visit 3 : experiment 3"
89515118|NCT03517943|Experimental|Test treatment|Healthy adult subjects under fed conditions
89515119|NCT03517943|Active Comparator|Reference treatment|Healthy adult subjects under fed conditions
89515120|NCT04005495|Experimental|Teaching kitchen program|The teaching kitchen model is an innovative, multidisciplinary approach for motivating and establishing healthful habits and behaviors. The program combines didactic information with experiential learning in nutrition, culinary arts, exercise, yoga, and mindfulness.
89515121|NCT02294747|Active Comparator|SHS without TSP|Patients with AO 31 A2 trochanteric fractures operated with sliding hip screw without trochanteric stabilization plate.
89515122|NCT02294747|Active Comparator|SHS with TSP|Patients with AO 31 A2 trochanteric fractures operated with sliding hip screw with trochanteric stabilization plate.
89515123|NCT03541005|Experimental|Obex|a nutritional supplement Obex® 8 g daily by oral route divided into two doses of 4g (between 15 and 20 minutes before lunch and dinner) diluted in water or juice for 6 months. Patients will be recommended to comply with a healthy lifestyle through diet and exercise.
89515124|NCT03541005|Placebo Comparator|Placebo|Placebo 8 g daily by oral route divided into two doses of 4g (between 15 and 20 minutes before lunch and dinner) diluted in water or juice for 6 months. Patients will be recommended to comply with a healthy lifestyle through diet and exercise.
89515125|NCT02291783|Experimental|HTL0009936|HTL0009936 single and multiple ascending oral doses.
89515126|NCT02291783|Placebo Comparator|HTL0009936 Placebo|HTL0009936 matching placebo
89515127|NCT03445923|No Intervention|Morphology|Embryos for transfer will be selected based on standard morphological evaluation.
89515128|NCT03445923|Active Comparator|TLM|Embryos for transfer will be selected base on standard morphological evaluation and information from time-lapse monitoring.
89515129|NCT02291939||Parotidectomy|Patients with an indication for surgical intervention for a parotidectomy.
89515130|NCT03138993|Active Comparator|Patient decision aid|
89544015|NCT05544279|No Intervention|Control group|"1. Interview (pre-test): 1st interview: Personal information form, ZBI, STAI were filled in preoperatively within 24-48 hours. They receive routine care at the hospital 2nd interview (on the phone within the 1st week after discharge): ZBYÖ, STAI-S and Education follow-up form are filled.~3rd interview (post-test): ZBYÖ, STAI-S and Education follow-up forms were filled on the phone within the 4th week after discharge. A pdf format of the training material was sent to the mothers in the control group via whatsapp application."
89544016|NCT01665807|Experimental|Nurse-administered IM|Nurse-administered intramuscular influenza vaccine (Vaxigrip, 0.5 mL)
89544017|NCT01665807|Experimental|Self-administered intradermal|Self-administered intradermal influenza vaccine (Intanza 0.1 mL)
89544018|NCT01665807|Active Comparator|Repeat self-administration intradermal|Self-administration of intradermal influenza vaccine (Intanza 0.1 mL) by participants who self-administered an intradermal vaccine in our 2010 study
89544019|NCT04585113||People with hand OA awaiting surgery|Patients with hand OA awaiting hand surgery of a joint with OA will be considered eligible. All IP joints in the hands are eligible (thus both IP, PIP and DIP) if in- and exclusion criteria are fulfilled.
89544020|NCT05699109||Aranesp group|Aranesp group: patients received darbepoetin alpha prefilled syringe subcutaneously once weekly or biweekly
89544021|NCT05699109||Eprex group|Eprex group: patients received epoetin alpha prefilled syringe subcutaneously one to three times per week
89544022|NCT04448535|Experimental|Gingko Biloba|oral intake of gingko biloba for 4 weeks
89544023|NCT05695989|Experimental|Dual Robotic Arm Accessory (DRAA)|
89544024|NCT02584959|Experimental|Experimental/Placebo|Subjects will be randomized to receive C1 Esterase Inhibitor in the 1st Treatment period and then switch to Placebo in the 2nd treatment period.
89544025|NCT02584959|Experimental|Placebo/Experimental|Subjects will be randomized to receive a placebo treatment in the 1st Treatment period and then switch to receive C1 Esterase Inhibitor in the 2nd treatment period.
89544026|NCT02584959|Experimental|Experimental/ Experimental|Subjects will be randomized and receive C1 Esterase Inhibitor in both 1st as well as the 2nd treatment period
89544027|NCT05543889||Patients|100 patient participants will be recruited for limbal anterior chamber depth image capture. These images will be used to develop the clinical vignette database
89544028|NCT05543889||Optometrists|50 optometrists will be recruited to undertake the clinical vignette assessment
89544029|NCT05695833|Experimental|Radiofrequency|Device
89544030|NCT05695833|Active Comparator|Nd Yag Laser|Device
89544031|NCT02584257|Placebo Comparator|Placebo dose|Placebo dose: 1 actuation each from 2 different placebo ProAir HFA inhalation aerosols and one actuation each from 2 different placebo Lupin albuterol HFA MDI inhalation aerosols
89544032|NCT02584257|Active Comparator|90 mcg ProAir HFA|90 mcg of ProAir HFA: 1 actuation each from ProAir HFA inhalation aerosol and the placebo ProAir HFA inhalation aerosol and 1 actuation each from 2 different placebo Lupin albuterol HFA MDI inhalation aerosols
88961262|NCT02007629|Experimental|Riociguat|Subjects received riociguat film coated immediate-release (IR) tablet 3 times a day (tid) with or without food at a starting dose of 1.0 milligram (mg) and increased by 0.5 mg increments at 2-weekly intervals to a maximum of 2.5 mg tid, until Week 8 (titration phase). An optimal dose was determined based on systolic blood pressure (SBP) and well-being. Thereafter, riociguat continued at the optimal individual dose until Week 24 (Main phase). Dose reductions or stop of study medication for safety reasons were allowed at any time. Increases or re-increases in 0.5 mg steps (maximum dose 2.5 mg) were possible at the investigator's discretion weighing the benefit with potential risks implied. Subjects were offered participation in EDSP and received riociguat 2.5 mg film coated IR tablet 3 tid with or without food for 18 months or until reimbursement.
88961263|NCT02007642||No study treatment|
88961264|NCT02007668|Experimental|Kinesio Taping|Patients will receive an application of Kinesio taping in their lumbar spine.
88961265|NCT02007668|Placebo Comparator|Kinesio Taping Placebo|Patients will receive an application of medical adhesive tape in their lumbar spine.
88961266|NCT02007668|No Intervention|Control|This participants will not receive intervention
88961267|NCT02007681|Experimental|Lifestyle change|One 5-10 minute break per hour during the work day using a software that alert the participant, and perform 6000 steps above the baseline number of steps/day (previously evaluated), by adopting several domain specific strategies, during 7 days.
88961268|NCT02007681|No Intervention|Control|Regular free week with no changes performed
88961269|NCT02007694|Active Comparator|VRET plus Yohimbine|Virtual Reality Exposure Therapy combined with the administration of yohimbine.
89544033|NCT02584257|Active Comparator|180 mcg ProAir HFA|180 mcg of ProAir HFA: 1 actuation each from 2 different ProAir HFA inhalation aerosols and 1 actuation each from 2 different placebo Lupin albuterol HFA MDI inhalation aerosols
89544034|NCT02584257|Experimental|90 mcg Lupin albuterol HFA MDI|90 mcg of Lupin albuterol HFA MDI product: 1 actuation each from the Lupin albuterol HFA MDI inhalation aerosol and the placebo Lupin albuterol HFA MDI inhalation aerosol and 1 actuation each from 2 different placebo ProAir HFA inhalation aerosols
88961270|NCT02007694|Active Comparator|VRET plus propranolol|Virtual Reality Exposure Therapy combined with the administration of propranolol
88961271|NCT02007694|Placebo Comparator|VRET plus placebo|Virtual Reality Exposure Therapy combined with the administration of a non-active placebo pill
88961272|NCT02007707|Experimental|Tobacco LHW|Quit Smoking For a Healthy Family - family-based psycho-education intervention using lay health worker (LHW) outreach.
88961273|NCT02007707|Active Comparator|Healthy Eating|Eating Healthy and Physically Active for You and Your Family - This is a attention-control comparison group using a family-based psycho-education intervention delivered through lay health worker (LHW) outreach.
88961274|NCT02007746||Subjects with sickle cell disease and iron overload|Patients will have blood tests done to evaluate liver function and general health, then have FibroScan and Ferriscan. A blinded (no access to laboratory parameters or available data) radiologist will interpret the Ferriscan. Liver biopsy will be also obtained (if not done within the previous year). Otherwise, the results of the recent liver biopsy will be collected.
89544035|NCT02584257|Experimental|180 mcg Lupin albuterol HFA MDI|180 mcg of Lupin albuterol HFA MDI: 1 actuation each from 2 different Lupin albuterol HFA MDI inhalation aerosols and 1 actuation each from 2 different placebo ProAir HFA product inhalation aerosols
89544036|NCT05543655|Experimental|simulated|The 'Simulation training', using high fidelity simulation with a simulated patient, is composed of 2 training sessions of 3 hours each. The training will include a high-fidelity scenario whose events will be adapted to medication administration in conventional care services. This scenario is developed by a multidisciplinary team of healthcare professionals, experts in simulation and risk management
89544037|NCT05543421|Active Comparator|rTMS active|
89544038|NCT05543421|Sham Comparator|rTMS sham|
89544039|NCT05543421|Experimental|iTBS active|
89544040|NCT05543421|Sham Comparator|iTBS sham|
89544041|NCT04272099||PG1 (patients with diabetes 0-25 years of age)|Patients 0 to 25 years of age, with a diagnosis of diabetes that are either followed at Kay Mackenson Pediatric Clinic, Haiti, or who are of Haitian ancestry, defined as both maternal and paternal grandparents being born in Haiti, and attend one of the three diabetes clinics in Montreal.
89544042|NCT04272099||PG2 (patient's principal caregiver)|The patient's principal caregiver (a parent of legal guardian).
89544043|NCT04254783|Experimental|Cytochrome P450 (CYP) + Risankizumab|In Period 1, participants will receive single oral dose of Cytochrome P450 (CYP) substrates on Day 1. In Period 2, three IV doses of risankizumab on Days 1, 29 and 57, followed by single oral dose of CYP substrates on Day 64 will be administered.
89544044|NCT04090203|Experimental|Boiled Peanut Powder|Boiled Peanut Powder
89544045|NCT04062201|Experimental|Study Strategy|
89544046|NCT04062201|Active Comparator|Control Strategy|
89544047|NCT05696457|Experimental|AML-E|Acute myeloblastic leukemia - experimental
89544048|NCT05696457|No Intervention|AML-C|Acute myeloblastic leukemia - control
89544049|NCT05696457|Experimental|AlloSCT-E|Allogeneic stem cell transplantation - experimental
89544050|NCT05696457|No Intervention|AlloSCT-C|Allogeneic stem cell transplantation - control
89544051|NCT05696457|Experimental|AutoSCT-E(I)|Autologous stem cell transplantation - experimental (inpatient)
89544052|NCT05696457|No Intervention|AutoSCT-C(I)|Autologous stem cell transplantation - control (inpatient)
89544053|NCT05696457|Experimental|AutoSCT-E(O)|Autologous stem cell transplantation - experimental (outpatient)
89544054|NCT05696457|No Intervention|AutoSCT-C(O)|Autologous stem cell transplantation - control (outpatient)
89544055|NCT02583477|Experimental|MEDI4736 +nab-paclitaxel + gemcitabine|MEDI4736 in combination with nab-paclitaxel + gemcitabine chemotherapy regimen via IV infusion
89544056|NCT02583477|Experimental|MEDI4736+AZD5069|MEDI4736 via IV infusion and oral AZD5069
89544057|NCT05696379||STEMI with high Angio-IMR|Patients with ST segment elevation myocardial infarction and high Angio-IMR
89544058|NCT05696379||STEMI with low Angio-IMR|Patients with ST segment elevation myocardial infarction and low Angio-IMR
89544059|NCT05696379||NSTEMI with high Angio-IMR|Patients with non-ST segment elevation myocardial infarction and high Angio-IMR
89544060|NCT05696379||NSTEMI with low Angio-IMR|Patients with non-ST segment elevation myocardial infarction and low Angio-IMR
89544061|NCT02583399|Experimental|Ibuprofen|Ibuprofen, 10 mg/kg
89544062|NCT05468463|Active Comparator|Living Donor Navigator Program In-person|The LDN program is designed to help transplant candidates find potential donors, and guide potential living donors through the evaluation/ donation process. The LDN program consists of four educational sessions, with each session building on the last. Each educational session lasts approximately 2 hours and is held once every other week for two months. Each LDN session will be conducted by a living donor navigator. As potential living donors are identified, the living donor navigators will work closely with the potential donors to guide them through each step of the evaluation/donation process to ensure streamlined medical services and a personalized experience. Individuals randomized to LDN in-person will receive the program locally at the transplant center.
89544063|NCT05468463|Active Comparator|Living Donor Navigator Program Tele-health|The LDN program is designed to help transplant candidates find potential donors, and guide potential living donors through the evaluation/ donation process. The LDN program consists of four educational sessions, with each session building on the last. Each educational session lasts approximately 2 hours and is held once every other week for two months. Each LDN session will be conducted by a living donor navigator. As potential living donors are identified, the living donor navigators will work closely with the potential donors to guide them through each step of the evaluation/donation process to ensure streamlined medical services and a personalized experience. Individuals randomized to LDN tele-health will receive the program virtually at a local health department within the Alabama Department of Public Health's tele-health network.
89544064|NCT05679297||Patients with thalamic CPSP (central post-stroke pain)|Patients with CPSP of thalamic origin due to stroke.
89544065|NCT05679297||Patients with thalamic stroke without CPSP|Patients with thalamic stroke at least 2 years ago, but without CPSP or other chronic pain disorders
89544066|NCT05679297||Patients with migraine|Patients with migraine (other central pain disorder)
89544067|NCT05679297||Healthy controls|Age- and gender-matched healthy control subjects
89544068|NCT05679219|Active Comparator|Structured Pes Planus Exercise Group|23 individuals will be included in this group. Structured pes planus exercise group; short foot exercise, towel picking exercise, toe walking, heel walking, tandem walking, eccentric gastrosoleus stretching at the edge of the stairs, picking objects from the ground with the toes, balance exercises on one foot. The purpose of all these exercises; The aim is to increase the medial longitudinal arch by contracting the intrinsic muscles of the foot, and to improve the balance at the same time. Walking exercises will be performed in the form of 10 meters and 10 rounds, other exercises will be performed with 30 repetitions for both feet and the whole session will be 40 minutes in total.
89024986|NCT00476697|Experimental|UVA1 Irradiation|UVA1 irradiaton up to 5 times per week, for up to 16 weeks using German manufactured UVA1 emitting light system. UVA1 dose will be applied with up to 130 J/cm2.
89024987|NCT00440219|Experimental|Prednisone group|Prednisone 50 mg daily for 10 days immediately pre-op
89544069|NCT05679219|Active Comparator|Wii Based Exergame Group|23 individuals will be included in this group. Wii-based exergame group, Nintendo wii game console balance games; In the literature, frequently used ones in different disease groups will be selected and played. In this context, Penguin Slide, Tightrople Tension, Tilt Table, Soccer Heading and Balance Bubble games will be played in each session under the supervision of an expert physiotherapist (executive), each game will be 8 minutes and the session will be 40 minutes in total. The motion sensor will be placed directly opposite the Balance Board. All games are played in a standing upright position on a double-footed Balance Board.
89544070|NCT05679219|Active Comparator|Wii Based Serious Game Group|23 individuals will be included in this group. The lower extremity strengthening and balance exercises within the Becure Balance System, developed in cooperation with the Physiotherapist, Academician and Engineer, will be performed by the Wii-based serious game group through the Wii Balance Board. Three games, Balance Surf, Balance Adventure and Balance Maze, which are among the balance games within the Becure Balance System application, will be played for 40 minutes in each session under the supervision of an expert physiotherapist (executive). The Wii Balance Board will be connected via Bluetooth from the menu in the Becure application. Then the Person will stand on the Balance Board and transfer weight in four directions in line with the instructions of the game on the screen.
89544071|NCT05454657|Experimental|Heart rate variability biofeedback + treatment as usual|The experimental group will participate in 8 weeks of heart rate variability biofeedback practice using the Lief heart rate variability biofeedback Smart Patch and smartphone app + treatment as usual. Participants will be asked to, 1) wear the Lief Smart Patch for at least 8 hours per day, 2) do 15mins of scheduled heart rate variability biofeedback practice daily, and 3) use it as needed in response to negative affect in-the-moment.
89544072|NCT05454657|Active Comparator|Treatment as usual only|The control group will participate in 8 weeks of treatment as usual only.
89544073|NCT05678985|Experimental|Choose to Move|"CTM (Phase 4) is a 3-month, flexible, choice-based program for low active older adults that can be delivered in-person or online.~CTM includes~One-on-One Consultation: Participants meet 1-on-1 with their activity coach at the start of the program to set goals and develop an action plan tailored to their abilities, interests and resources. Older adults can choose to participate in individual or group-based activities.~Group Meetings: Over the 3-months, participants will attend eight, 1-hour group-based meetings (up to 12 participants total) led by their activity coach. Meetings cover a discussion topic (health-related) and provide time and space for social connection between participants. Group meetings are held in person or online as public health restrictions and community preference dictate."
89544074|NCT02580591|Experimental|Empagliflozin low dose|
89544075|NCT02580591|Experimental|Empagliflozin high dose|
89544076|NCT02580591|Experimental|Empagliflozin medium dose|
89544077|NCT02580591|Placebo Comparator|Placebo|
89544078|NCT05695677|Other|Tecar treatment sucess|
89544079|NCT05561439||Cardiology: Coronary/Valvular|
89544080|NCT05561439||Cardiology: Rhythmology|
89544081|NCT05561439||Cardiology: Mixed|
89544082|NCT05561439||Radiology: Simple Vascular|
89544083|NCT05561439||Radiology: Complex Vascular|
89544084|NCT05561439||Radiology: Mixed Vascular|
89544085|NCT05561439||Radiology: Simple Osteoarticular|
89544086|NCT05561439||Radiology: Complex Osteoarticular|
89544087|NCT05561439||Radiology: Mixed Osteoarticular|
89544088|NCT05561439||Radiology: Simple Neuroradiology|
89024988|NCT00440219|Placebo Comparator|Placebo group|Placebo pill for 10 days immediately pre-operative
89024989|NCT00438477|Experimental|Injection Methods|One injection site with radioactive tracer intraparenchymal/peritumoral (around the tumor), and other subareolar (around the nipple)
89544089|NCT05561439||Radiology: Complex Neuroradiology|
89544090|NCT05561439||Radiology: Mixed Neuroradiology|
89544091|NCT05561439||Radiology: Mixed|
89544092|NCT05561439||Radiology: Simple Oncology|
89544093|NCT05561439||Radiology: Complex Oncology|
89544094|NCT05561439||Radiology: Mixed Oncology|
89544095|NCT05557461||Group-1|"group with fluid responsiveness in passive leg raise test After the patients are in a semi-sitting position (at least 2 minutes), two healthcare professionals will take the supine position and then lift their legs 45 degrees, wait for 2 minutes and return to the initial position.~10% change in stroke volume will be considered positive and patients will be divided into 2 groups as fluid-responsive and non-responsive."
89544096|NCT05557461||Group-2|"group with no fluid response in passive leg raise test After the patients are in a semi-sitting position (at least 2 minutes), two healthcare professionals will take the supine position and then lift their legs 45 degrees, wait for 2 minutes and return to the initial position.~10% change in stroke volume will be considered positive and patients will be divided into 2 groups as fluid-responsive and non-responsive."
89544097|NCT05556057|Experimental|mindfulness meditation(MM)|
89544098|NCT05556057|Active Comparator|Health Education|
89544099|NCT05555043|Active Comparator|Control group|Participants receive passive ultrasonic irrigation for endodontic irrigation treatment and will be followed for 12 months after treatment to assess radiographic healing of the periapex and clinical healing of the tooth.
89544100|NCT05555043|Experimental|GentleWave group|Participants receive GentleWave System for endodontic irrigation treatment and will be followed for 12 months after treatment to assess radiographic healing of the periapex and clinical healing of the tooth.
89024990|NCT00438516|No Intervention|1|Control group
89024991|NCT00438516|Experimental|2|Nurse home visitation
89544101|NCT05555043|Experimental|Waterlase group|Participants receive Waterlase iPlus for endodontic irrigation treatment and will be followed for 12 months after treatment to assess radiographic healing of the periapex and clinical healing of the tooth.
89544102|NCT04261725||Squamous Cell Lung Cancer|Genetic analysis for searching EGFR mutation
89515131|NCT03138993|Sham Comparator|General sleep education|
89515132|NCT03138525||Multiple Sclerosis|Subjects with multiple sclerosis (MS) initiating treatment with ocrelizumab
89515133|NCT03138525||Healthy|Healthy individuals serving as controls to the subjects with MS
89515134|NCT02294903|Experimental|ProRAFT|Procedure/Surgery: Coiled Bipolar Radiofrequency Ablation
89515135|NCT03383211||HIV+|Pregnant women diagnosed with HIV infection during pregnancy. No intervention beyond the standard care provided for such cohort.
89515136|NCT03383211||LTBI|Pregnant women diagnosed with Latent form of TB infection (LTBI). No intervention beyond the standard of care provided for such cohort.
89515137|NCT03383211||HV+/LTBI|Pregnant women diagnosed with HIV and LTBI co-infection. No intervention beyond the standard of care provided for such cohort.
89515138|NCT03383211||Healthy Control|Healthy pregnant women without HIV or LTBI. No intervention beyond the standard of care provided for such cohort.
89515139|NCT03823521|Experimental|Cardioplexol™- Cardioplegia Solution|Cardioplexol™ will be used as cardioplegic solution in cardiac surgery
89515140|NCT03520907|Experimental|Transversalis Fascia Plane Block|receive transversalis fascia plane block with 0.4 ml/kg of 0.25% levobupivacaine after establishment of general anesthesia.
89515141|NCT03520907|Active Comparator|Ilioinguinal/iliohypogastric Nerve Block|receive ilioinguinal/iliohypogastric nerve block with 0.1 ml/kg of 0.25% levobupivacaine after establishment of general anesthesia.
89515142|NCT03136341|Active Comparator|Abobotulinum toxin A|
89515143|NCT03136341|Placebo Comparator|Placebo|
89515144|NCT04465175|Active Comparator|Second dose magnesium sulphate|Second dose magnesium sulphate 50 mg/kg infused over one hour
89515145|NCT04465175|Placebo Comparator|Placebo|Normal saline (2.5 ml/kg) infused over one hour
89515146|NCT03158883|Experimental|Non-responders|"Patients who initially progress at first response assessment on a PD-1 inhibitor will be enrolled to the non-responder arm.~Avelumab: 10 mg/kg administered by IV infusion q2w (1 cycle = 14 [±2] days).~Stereotactic ablative radiotherapy (SAR): the prescription dose will be 50 Gy over 5 fractions of 10 Gy each on an every 2 day basis (i.e., 2-3 treatments per week, with a minimum of 40 hours and a maximum of 96 hours between treatments) and completed within 1.5-2 weeks. SAR treatment will not be repeated."
89515147|NCT03158883|Experimental|Progressors|"Patients who initially present with PR, CR, or SD to a PD-1 inhibitor but subsequently progress will be enrolled to the progressor arm.~Avelumab: 10 mg/kg administered by IV infusion q2w (1 cycle = 14 [±2] days).~Stereotactic ablative radiotherapy (SAR): the prescription dose will be 50 Gy over 5 fractions of 10 Gy each on an every 2 day basis (i.e., 2-3 treatments per week, with a minimum of 40 hours and a maximum of 96 hours between treatments) and completed within 1.5-2 weeks. SAR treatment will not be repeated."
89515148|NCT02292017|Experimental|Embolization of intracranial aneurysm|Embolization with Target Coils
89515149|NCT03041649|Active Comparator|GT button change - Mic-Key|Subjects randomized to the Mic-Key arm will have the Mic-Key button placed initially at surgery, and at the first gastrostomy change in the clinic at 2 months, will change to the Mini One button. At the routine 4-month visit, parents will be asked which button they prefer to keep.
89515150|NCT03041649|Active Comparator|GT button change - Mini One|Subjects randomized to the Mini One arm will have the Mini One button placed initially at surgery, and at the first gastrostomy change in the clinic at 2 months, will change to the Mic-Key button. At the routine 4-month visit, parents will be asked which button they prefer to keep.
89515151|NCT03520829||Patient treated for Gamma Knife|
89515152|NCT02292095|Experimental|TAPB group|Participants in this group will receive transverse abdominis plane block combined with patient controlled intravenous analgesia.Transverse abdominis plane block will be guided by ultrasound and 0.75% 20 ml ropivacaine will be injected with the sonographic view at the end of the surgery.Participants in this group will also receive patient controlled intravenous analgesia after surgery,the regimens of patient controlled intravenous analgesia are included tramadol 800 mg, flurbiprofenaxetil 100 mg, and dexamethasone 5 mg with saline added up to a volume of 80 ml in total
89515153|NCT02292095|Active Comparator|PCIA group|Participants in this group will only receive patient controlled intravenous analgesia after surgery.The formula of the PCIA included tramadol 800 mg, flurbiprofenaxetil 100 mg, and dexamethasone 5 mg with saline added up to a volume of 80 ml in total, they received a loading dose of 2 ml followed by an infusion rate of 1 ml/h with bolus of 2 ml, the lock time was set at 15 min
89515154|NCT03138447|Experimental|Prospective Cohort|
89515155|NCT03138447|No Intervention|Retrospective Cohort|
89515156|NCT03517709|Other|Conventional|
89515157|NCT03517709|Other|Blood Pressure Monitor|
89515158|NCT03136575|Active Comparator|Qigong|Patients in the Qigong group receive Qigong,a mind-body exercise, 3 times a week, for 6 weeks during radiotherapy course. The participants are given a DVD contains Qigong program, and they attend the Qigong class in a health education room at the radiation oncology department to assure their attendance.
89515159|NCT03136575|Placebo Comparator|wait-list control|Patients who are assigned to the wait-list control are told to have some exercise by their own but no actually attend the the class in fact.
89515160|NCT03109899|Experimental|Intervention|Participants in this arm will have access to the Sex Pro mobile app and support for HIV/STI testing and PrEP uptake.
89515161|NCT03109899|No Intervention|Control|Participants in this arm will be given the local standard of care for HIV/STI testing and PrEP access.
89515162|NCT03109977|Experimental|Zr-DFO-pertuzumab (89Zr-DFO-pertuzumab) PET/CT|Zr-DFO-pertuzumab (89Zr-DFO-pertuzumab) PET/CT will be performed in patients with known HER2-positive malignancy. Patients with multifocal disease, as demonstrated on cross-sectional imaging studies, will be preferentially recruited.
89515163|NCT03520673|Other|Development of Clinical Decision Support Tool|All men will receive the same series of simple index tests which will be compared with the results of the urodynamics reference test to identify which index tests give the best prediction of the urodynamic results. The data from the first cohort will develop the clinical decision support tool.
89515164|NCT03520595|Active Comparator|Arnica Group|Study group 1 CLP with ostectomy Arnica 200 drug 3 pills,3 times daily for 3 days
89515165|NCT03520595|Active Comparator|Diclofenac Sodium group|Study group 2 CLP with ostectomy Diclofenac Sodium 50mg twice daily after meals with plain water
89515166|NCT03520595|Placebo Comparator|Placebo Group|Study group 3 CLP with ostectomy Placebo pills and distilled water 3 pills,3 times daily
89515167|NCT03517553|Experimental|EMS users in ESRD|Subjects then initiate passive electrical muscle stimulation (EMS) delivered by a commercially available FDA approved neuromuscular stimulator (EMPI 300PV or its replacement, EMPI Continuum device obtained from EMPI, Inc., St Paul MN) 3 times a week to the quadriceps muscle groups (15 minutes on each side, 30 minutes total) while on hemodialysis. The duration of training will last for 4 months. Subjects will be monitored at regular intervals during the training to make sure they are doing the training correctly and they are not experiencing any problems.
89515168|NCT02295137|Experimental|pre-procedure image guidance|
89515169|NCT02295215|No Intervention|Sedentary Group|The patients will not do exercise training
89515170|NCT02295215|Experimental|Trained Group|The patients will do exercise training for sixteen weeks.
89515171|NCT03520439|Experimental|study group|mifepristone tablets ，10mg，One tablet daily, oral treatment
89515172|NCT03520439|Placebo Comparator|control group|placebo，10mg，One tablet daily, oral treatment
89515173|NCT04542993|Active Comparator|Resveratrol and Zinc Picolinate combination therapy|Resveratrol and Zinc Picolinate combination therapy
89515174|NCT04542993|Placebo Comparator|Resveratrol Placebo and Zinc Placebo combination therapy|Placebo Resveratrol and Placebo Zinc combination therapy
89515175|NCT03520361|Experimental|Oral sulfate solution (OSS) taking group|On the evening before colonoscopy, drink 177ml of OSS (Suclear®) (473ml including water in container), additionally allow another 946 ml of water. On the day of colonoscopy, drink 177ml of OSS (473ml including water in container), additionally allow another 946 ml of water.
89515176|NCT03520361|Active Comparator|2L PEG/Asc taking group|On the evening before colonoscopy, drink 1L of 2L PEG/Asc (Haprep®) solution, additionally allow another 500 ml of water. On the day of colonoscopy, drink 1L of 2L PEG/Asc solution, additionally allow another 500 ml of water.
89515177|NCT03517397|Experimental|Mobile Contingency Management|
89515178|NCT03002415|Experimental|Guided water intake|"Verbal and written guidelines will be given for the patient to ingest the daily volume of water calculated by the weight (30 ml / kg / day) for 14 days. Patients will receive an acrylic glass with a mark in 200 ml and will be instructed to take the number of glasses a day corresponding to the calculated volume (30 ml / kg). Patients will also receive a leaflet indicating how many glasses of water they will need to take. They will also be instructed to mark with an X the number of glasses of water that they actually drank daily during the fourteen days of intervention.~Patients are asked to note on a food record food and liquids and quantities consumed throughout the day. Patients are advised to make a four-day food diary out of the 14 days."
89515179|NCT03002415|Placebo Comparator|Placebo - free demand water intake|Patients are instructed to drink water and other liquids on demand. Patients are asked to note on a food record food and liquids and quantities consumed throughout the day. Patients are advised to make a four-day food diary out of the 14 days.
89515180|NCT02292173|Experimental|Trametinib plus Sorafenib|"Dose Escalation Followed by Dose Expansion.~Trametinib: Daily (To start on day 8 during cycle 1 and on day 1 from cycle 2 onwards), according to dose level upon entry.~Sorafenib: Twice daily, according to dose level upon entry.~Each cycle is repeated every 28 days."
89515181|NCT02000869||wait-listed kidney transplant candidates|
89515182|NCT02295293|Experimental|Rhus|500 mg of Rhus Coriaria L. (Rhus) powder in capsule: 1 capsule twice daily for 6 weeks
89515183|NCT02295293|Placebo Comparator|Placebo|Placebo capsule: 1 capsule twice daily for 6 weeks
89515184|NCT03520205|Active Comparator|Quadratus Lumborum Block|Patient will receive quadratus lumborum block
89515185|NCT03520205|Active Comparator|Continuous Epidural|Patient will receive epidural anesthesia
89515186|NCT03517319|Placebo Comparator|Placebo|Normal Saline 0.9% 1.2 ml will be injected to finger flexor muscles
89515187|NCT03517319|Experimental|Treatment dose 15|Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 15 U will be injected to finger flexor muscles
89515188|NCT03517319|Experimental|Treatment dose 30|Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 30 U will be injected to finger flexor muscles
89515189|NCT03517319|Experimental|Treatment dose 50|Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 50 U will be injected to finger flexor muscles
89515190|NCT03517319|Experimental|Treatment dose 70|Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 70 U will be injected to finger flexor muscles
89515191|NCT03133169||on chelation|"patients with B-thalassemia major samples of which will be examined for renal and liver function, Erythrocyte Glutamine level, ferritin level and complete blood picture. Also Echo will be done for measuring the Tricuspid regurge velocity.~group 1: cases on chelation: deferasirox 500mg oral tablet with initial dose 20 mg/kg guided by ferritin level~Diagnostic Test: blood sample~Diagnostic Test: Tricuspid regurge velocity"
89515192|NCT03133169||No chelation|"group 2: cases without chelation~Diagnostic Test: blood sample~Diagnostic Test: Tricuspid regurge velocity"
89515193|NCT03133169||splenectomy|"group 3: cases with splenectomy~Diagnostic Test: blood sample~Diagnostic Test: Tricuspid regurge velocity"
89515194|NCT03133169||no splenectomy|group 4: cases without splenectomy Diagnostic Test: blood sample Diagnostic Test: Tricuspid regurge velocity
89515195|NCT03517241||Geographic atrophy secondary to AMD|20 patients clinically diagnosed with geographic atrophy (GA) secondary to AMD.
89515196|NCT03517241||Stargards disease|20 patients clinically and genetically diagnosed with Stargards disease (STGD)
89515197|NCT03517241||Branch retinal artery occlusion|20 patients clinically diagnosed with branch retinal artery occlusion (BRAO)
89515198|NCT03517241||Full thickness macular hole|20 patients clinically diagnosed with acute full thickness macular hole (FTMH) before and after macular surgery
89515199|NCT03517241||Healthy controls|20 healthy control subjects. Visual acuity of 20/16- 20/32
89515200|NCT03520127||Females, 18 years of age or older|Females, 18 years of age or older, who will undergo the Intact procedure
89515201|NCT02295371||Patients with an incident|Patients undergoing a safety incident while being treated with drugs
89515202|NCT02292251|Active Comparator|Device-assisted therapy|30 hours of therapy with the ArmeoPower device, a commercially available device for arm rehabilitation
89515203|NCT02292251|Active Comparator|Therapy-based occupational therapy|30 hours of conventional occupational therapy that emphasizes task-oriented training.
89515204|NCT02295449|Experimental|1|
88961275|NCT02007746||control patients with sickle cell disease|Patients 10 years and older with sickle cell disease without history of chronic transfusions (less than 4 transfusions in a lifetime) and without obvious liver disease. Will have liver function blood tests and general health check ups. Then will have FibroScan performed. No liver biopsy will be performed in control patients.
88961276|NCT02007759|Experimental|VitalStim|This group will be assigned to the active VitalStim unit.
89515205|NCT03517007|Experimental|Opt-Out Protocol|Should an eligible patient pass the safety screen and be randomized to the intervention arm of the trial, the designated pharmacist will approach the patient's primary provider in charge of antibiotic decision-making The pharmacist will inform the provider the patient's antibiotics can be de-escalated unless the provider opts out.
89515206|NCT03517007|No Intervention|Standard of Care|Provider continues routine, standard of care on the patient.
89515207|NCT03516929|Active Comparator|high risk group|history of stroke or TIA, carotid bruit, left main stem disease, other peripheral vascular disease
89515208|NCT03516929|Sham Comparator|low risk group|No history or stroke,TIA. NO left main stem disease
89515209|NCT03516851|Active Comparator|Precision bypass group|Using ICG with Flow800 software and multimodal neuronavigation to choose the recipient vessel
89515210|NCT03516851|No Intervention|Empirical group|choosing the recipient vessel by the surgeon's own experience
89515211|NCT02295527|Experimental|Home-based physical exercise|Participants randomized to the Intervention Group (IG) will be submitted to a physical exercise program involving a progressive and challenging balance training and a neuromuscular and functional training of the lower limbs, conducted at home by physiotherapists, once a week, lasting about one hour, in the first, second and third month after randomization and will be oriented to perform exercises, twice a week, through a booklet. Visits to follow up exercises progression will be conducted once a month, from de fourth to the sixth month and each two months until the end of the follow up at the 12th month, summing up 18 sessions. Participants will receive monthly phone calls to increase exercise adherence.
89515212|NCT02295527|Other|Control Group Usual Care|This group will receive usual care and the booklet regarding bone health information.
89515213|NCT03520049|Experimental|Oseltamivir|Oseltamivir capsule administered orally at 75 mg twice daily for five consecutive days.
89515214|NCT03520049|Placebo Comparator|Placebo|Placebo capsule administered orally twice daily for five consecutive days.
89515215|NCT02292329|Active Comparator|150g of acai fruit|150g of acai fruit in fruit smoothie form
89515216|NCT02292329|Placebo Comparator|Placebo control|The control will be a smoothie-like drink matched for major macro- and micro-nutrients
89515217|NCT03517631|Experimental|No busulfan preconditioning|shRNA-modified CD34+ cells without busulfan preconditioning.
89515218|NCT03517631|Experimental|Low dose busulfan preconditioning|shRNA-modified CD34+ cells, with a single dose of 1 mg/kg busulfan administered every 6 hours for 4 times as preconditioning for transplantation.
89515219|NCT03517631|Experimental|High dose busulfan preconditioning|shRNA-modified CD34+ cells, with a single dose of 1 mg/kg busulfan administered every 6 hours for 8 times as preconditioning for transplantation.
89515220|NCT02295605|Experimental|Land-based exercises|Land-based muscle strengthening exercises protocol
89515221|NCT02295605|Experimental|Water-based exercises|Water-based muscle strengthening exercises protocol
89515222|NCT02292407|Experimental|LigaSure Precise instrument|ALND with use of LigaSure Precise instrument, closure of dead space, omission of a postoperative drain.
89515223|NCT02292485||Physicians - Texas Academy of Family Physicians|Physicians attending Texas Academy of Family Physicians event asked to fill out an anonymous survey to better understand their readiness to implement lung cancer screening programs in their practice settings. Surveys administered to physicians attending the TAFP education events in Houston, Texas, October 17-19, 2014 and in Dallas, Texas, November 7-9, 2014.
89515224|NCT03516773|Experimental|Treatment A|Intervention: EB612 (EBP05) 2.25 mg orally (PO) four times a day (QID) (approximately 5 hours apart) for 4 doses, for a total dose of 9 mg per day
89515225|NCT03516773|Experimental|Treatment B|Intervention: EB612 (EBP05) 2.25 mg PO twice a day (BID) (approximately 10 hours apart) for 2 doses, for a total dose of 4.5 mg per day
89515226|NCT03516773|Active Comparator|Treatment C|Intervention: NATPARA/NATPAR PTH(1-84) 100 μg subcutaneous injection once daily (single dose)
89515227|NCT03516773|Experimental|Treatment D|Intervention: EB612 (EBP05) 2.25 mg PO TID (dose 1 and dose 2 approximately 10 hours apart; dose 2 and dose 3 approximately 5 hours apart- TID schedule option 2), for a total dose of 6.75 mg per day
89515228|NCT03516773|Experimental|Treatment E - EB612 (EBP05)|Intervention: EB612 (EBP05) 0.75 mg PO TID (dose 1 and dose 2 approximately 10 hours apart; dose 2 and dose 3 approximately 5 hours apart- TID schedule option 2), for a total dose of 2.25 mg per day
89515229|NCT05187455|Experimental|Renal transplantation(S group)|n=17,CLCR≤30ml/min
89515230|NCT05187455|Experimental|the control group|n=17, CLCR≥80ml/min
89515231|NCT02295761|Active Comparator|Lifestyle counseling|12-weeks
88961277|NCT02007759|Sham Comparator|Sham VitalStim|This group will be assigned to the sham VitalStim unit.
88961278|NCT02007772|Active Comparator|BiPAP breathing support|BiPAP is used over a period of 6 weeks (outpatient)
88961279|NCT02007772|Experimental|nHF / TNI breathing support|nasal high-flow is used over a period of 6 weeks (outpatient)
89024992|NCT03276780|Experimental|In vivo|Will receive 4 types of short-acting NRT medication to use in combination with the nicotine patch in each counseling session for four sessions. At the fifth session, participants will select their short acting NRT to use with the patch to make a cessation attempt.
89515232|NCT02295761|Active Comparator|Lifestyle counseling + activity watch|12-weeks
89515233|NCT03519815|Active Comparator|Ectoin Eye Spray|"Eye Spray to be applied 3 times per day for the duration of 10 +/-3 days Ectoin® Eye Spray - Colloidal (EES09; bitop AG) - CE marked medical device~Ingredients: Ectoin®, Soy-Lecithin, Vitamin A, Vitamin E, water, physiological buffer system Indication: to treat mild to moderate dry eye disease"
89515234|NCT03519815|Active Comparator|Liponit Eye Spray|"Eye Spray to be applied 3 times per day for the duration of 10 +/-3 days~Liposomal eye spray: Tears Again® (TA, Optima Medical Swiss AG) - CE marked medical device Ingredients: Soy-Lecithin, Sodium Chloride, Ethanol, Phenoxyethanol, Vitamin A-Palmitate, Vitamin E, Aqua purificata Indication: to treat mild to moderate dry eye disease"
89544103|NCT02580357|Sham Comparator|Low Level Laser therapy (LLLT) Sham|The patients allocated to the control group received sham irradiation. For this, black rubber protection was placed at the tip of the laser device, which did not allow the light to reach the tissue. The applications were performed by a different operator (CAS) from the one who measured the study parameters. During irradiation, the tip of the laser probe was placed perpendicularly with slight contact on the area. Laser therapy was initiated in the immediate postoperative period (just after sutures) and was repeated by six more applications performed every other day, with a total of 7 laser applications.
89544104|NCT02580357|Experimental|GaAlAs Laser therapy (LLLT) 60 J/cm²|The irradiation was performed with a GaAlAs diode laser that continuously emitted a wavelength of 660 nm with a power of 30 mW. The patients allocated for the group 60 received the following protocol for laser application: Two (2) points of irradiation were performed using a total energy density (fluence) of 60 J/cm2 and a time of 60 seconds (30 J/cm2 per point and an application time of 30 seconds per point). During irradiation, the tip of the laser probe was placed perpendicularly with slight contact on the area. Laser therapy was initiated in the immediate postoperative period (just after sutures) and was repeated by six more applications performed every other day, with a total of 7 laser applications. The power of the equipment was calibrated prior to each application.
89544105|NCT02580357|Experimental|GaAlAs Laser therapy (LLLT) 30 J/cm²|The irradiation was performed with a GaAlAs diode laser that continuously emitted a wavelength of 660 nm with a power of 30 mW. The patients allocated for the group 30 received the following protocol for laser application: Two (2) points of irradiation were performed using a total energy density (fluence) of 30 J/cm2 and a time of 30 seconds (15 J/cm2 per point and an application time of 15 seconds per point). During irradiation, the tip of the laser probe was placed perpendicularly with slight contact on the area. Laser therapy was initiated in the immediate postoperative period (just after sutures) and was repeated by six more applications performed every other day, with a total of 7 laser applications. The power of the equipment was calibrated prior to each application.
89544106|NCT05680311|Active Comparator|Breast Cancer Patients|Group of patients with verified breast cancer diagnosis
89544107|NCT05680311|Sham Comparator|Non-Cancer patients|Group of healthy patients with no verified any type of cancer.
89544108|NCT05678751||case group|patients with infertility
89544109|NCT05678751||control group|women that are capable of spontaneous intrauterine pregnanc
89544110|NCT05404191|Experimental|burn wound receiving low level laser therapy|
89544111|NCT05678517||Patients|Patients with AMD
89544112|NCT04079439|Other|Intervention|Tailored e-heath support for physical activity with a focus on communication and rewards, using commercial accelerometers for measurements
89544113|NCT04079439|No Intervention|Control group|Standard care
89544114|NCT04425369|No Intervention|inner side approaches for iliac crest bone graft|An anterior approach was used to expose the inner table of the ilium.
89544115|NCT04425369|Experimental|two-sided approaches for iliac crest bone graft|both sides of the ilium were totally exposed of the ilium.
89544116|NCT05542563|Experimental|Mindfulness Intervention plus Standard of Care|The Foundations and Awareness modules of the HMP app require a minimum of 133 and 253 minutes, equating to less than 5 and less than 10 minutes per day on average, respectively. Date, duration, and content of usage will be recorded for each participant through the app. Participants will have access to the entire contents of the app for the full duration of the study.
89544117|NCT05542563|No Intervention|Standard of Care|Control group receives standard of care only
89544118|NCT04012749|Active Comparator|Advance directive|Messaging and advance directive distribution. All arms receive physician advance care planning education at the clinic level.
89544119|NCT04012749|Active Comparator|Advance directive and Prepare|Messaging and advance directive distribution plus introduction to the Prepare For Your Care website. All arms receive physician advance care planning education at the clinic level.
89544120|NCT04012749|Active Comparator|Advance directive, Prepare and Facilitator|Messaging and advance directive distribution, introduction to the Prepare For Your Care website, plus patient engagement from a trained facilitator who also can interact with the primary care physician. All arms receive physician advance care planning education at the clinic level.
89544121|NCT04716777|Experimental|Brief Transdiagnostic GCBT|Participants receive Brief Transdiagnostic group cognitive-behavioral treatment. Eight weekly sessions.
89544122|NCT04716777|No Intervention|Waitlist|Participants receive an 8-week waitlist condition with some attentional-control via monitoring for clinical deterioration. After a post-waitlist assessment, participants in this condition are offered the Brief Transiagnostic GCBT for eight weeks.
89544123|NCT05319249|Experimental|NK cells combined with PARP inhibition|Combination of NK cell therapy and PARP inhibition by Talazoparib after immunosuppression with cyclophosphamide and fludarabine
89544124|NCT05539131|Active Comparator|active transcranial direct current stimulation (tDCS)|daily active transcranial direct current stimulation (tDCS) use for 6 weeks
89544125|NCT05539131|Sham Comparator|sham transcranial direct current stimulation (tDCS)|daily active transcranial direct current stimulation (tDCS) use for 3 weeks + daily sham transcranial direct current stimulation (tDCS) use for 3 weeks
89544126|NCT05678361|Experimental|Sleep after exposure|Participants take a nap during 90 min following three exposure (WET) sessions.
89544127|NCT05678361|No Intervention|Wake after exposure|Participants watch a 90 min documentary following three exposure (WET) sessions.
89544128|NCT03849885|No Intervention|Standard Skin Prep|"Patients will undergo a skin cleansing protocols using 4% Chlorhexidine gluconate (CHG) cloths.~After the skin prep, three 3-mm punch (Acu-Punch, Acuderm, Fort Lauderdale, FL) skin biopsies will performed for both an anterior-based hypothetical incision, and for a more lateral/posterior incision, for a total of 6 biopsies taken per subject."
89024993|NCT03276780|Active Comparator|Standard of care|Will receive 4 sessions of behavioral counseling around their smoking. At the fifth session, participants will select their short-acting NRT to use with the nicotine patch based on a product description of each product to make a cessation attempt.
89515235|NCT03133013|Experimental|Individuals with Untreated Depression|32 participants diagnosed with Major Depressive Disorder by a psychiatric specialist of this research according to MINI screening and Diagnostic and Statistical Manual (DSM-5) criteria, and defined as a score of 15 or higher on the clinician-administered Hamilton Rating Scale for Depression, Beck Depression Inventory, and Patient Health Questionnaire for Depression (PHQ-9). The participants will be attached to the SLEEPSCOPE device.
89515236|NCT03133013|Other|Healthy Participants|32 healthy participants with absence of mental disorders, including but not limited to depression and sleep disorders, by a psychiatric specialist according to MINI screening and Diagnostic and Statistical Manual (DSM-5) criteria, and negative Hamilton Rating Scale for Depression, Beck Depression Inventory, and Patient Health Questionnaire for Depression (PHQ-9). The participants will be attached to the SLEEPSCOPE device.
89515237|NCT02461160|Placebo Comparator|SRD Cohorts 1-3: Placebo|TAK-915 placebo-matching suspension, orally, once on Day 1.
89515238|NCT02461160|Experimental|SRD Cohort 1 TAK-915 30 mg|TAK-915 30 mg suspension, orally, once on Day 1.
89515239|NCT02461160|Experimental|SRD Cohort 2: TAK-915 100 mg|TAK-915 100 mg suspension, orally, once on Day 1.
89515240|NCT02461160|Experimental|SRD Cohort 3: TAK-915 200 mg|TAK-915 200 mg suspension, orally, once on Day 1.
89515241|NCT02461160|Placebo Comparator|MRD Cohorts 4-6|TAK-915 placebo-matching suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 placebo-matching suspension, orally, once on Days 8 to 14.
89515242|NCT02461160|Experimental|MRD Cohort 4: TAK-915 30 mg|TAK-915 30 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 30 mg suspension, orally, once on Days 8 to 14.
89515243|NCT02461160|Experimental|MRD Cohort 5: TAK-915 100 mg|TAK-915 100 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 100 mg suspension, orally, once on Days 8 to 14.
89515244|NCT02461160|Experimental|MRD Cohort 6: TAK-915 200 mg|TAK-915 200 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 200 mg suspension, orally, once on Days 8 to 14.
89515245|NCT02461160|Experimental|DDI Cohort 7: TAK-915 + Midazolam 2 mg|Midazolam 2 mg suspension, orally, once on Day 1, followed by TAK-915 100 mg, suspension, orally, once on Day 3, followed by a 7-day washout period, followed by TAK-915 100 mg, suspension, orally, once, daily on Days 10 to 16 and Midazolam 2 mg solution, orally, once, on Day 16 (within 15 minutes after last dose of TAK-915).
89515246|NCT02461160|Experimental|BA/FE Cohort 8 Group 1: A,B,C|Regimen A: TAK-915 50 mg, suspension, orally, under fasted conditions once on Day 1 of Period 1, followed by Regimen B: TAK-915 50 mg, tablet, orally, under fasted conditions once on Day 1 of Period 2, followed by Regimen C: TAK-915 50 mg, tablet, orally under fed conditions once on Day 1 of Period 3. Each period was separated out by a 6 to 14-day washout period.
89515247|NCT02461160|Experimental|BA/FE Cohort 9 Group 1: B,C,A|Regimen B: TAK-915 50 mg, tablet, orally, under fasted conditions once on Day 1 of Period 2, followed by Regimen C: TAK-915 50 mg, tablet, orally under fed conditions once on Day 1 of Period 3 followed by Regimen A: TAK-915 50 mg, suspension, orally, under fasted conditions once on Day 1 of Period 1. Each period was separated out by a 6 to 14-day washout period.
89515248|NCT02461160|Experimental|BA/FE Cohort 10 Group 1: C,A,B|Regimen C: TAK-915 50 mg, tablet, orally under fed conditions once on Day 1 of Period 3 followed by Regimen A: TAK-915 50 mg, suspension, orally, under fasted conditions once on Day 1 of Period 1 followed by Regimen B: TAK-915 50 mg, tablet, orally, under fasted conditions once on Day 1 of Period 2. Each period was separated out by a 6 to 14-day washout period.
89515249|NCT02461160|Experimental|ESSD Cohort 11: TAK-915 50 mg|TAK-915 50 mg, suspension, orally, under fasted conditions, once on Day 1 in participants aged 65 to 75 years.
89515250|NCT02295839|No Intervention|Usual care|
89515251|NCT02295839|Experimental|Sleep Hygiene and Relaxation Education|
89515252|NCT02292563|Experimental|endoscopist only|Single inspection by endoscopist during colonoscopy
89515253|NCT02292563|Experimental|nurse participation|Dual inspection by both an endoscopist and an experienced nurse during colonoscopy
89515254|NCT03516539|Experimental|Group ML|Mcgrath videolaryngoscopy
89515255|NCT03516539|Active Comparator|Group DL|direct Macintosh laryngoscope
89515256|NCT01653704|Experimental|active management of crises scenario|participants assigned to actively manage a crisis scenario
89515257|NCT01653704|Active Comparator|Observer role in crisis scenario|Observational role in management of crises scenario
89515258|NCT03519737|Sham Comparator|Control group (tPA + sham TUS)|Control group (tPA + sham TUS) During the primary phase of the study, subjects will be randomized 1:1
89515259|NCT03519737|Active Comparator|Treatment group (tPA + TUS)|Treatment group (tPA + TUS): Lead-in phase and Primary phase
89515260|NCT03516461|Experimental|Selective Microbiota Transplant (SMT)|Patients undergo once SMT a day for three consecutive days.
89515261|NCT03516461|Experimental|Fecal Microbiota Transplantation (FMT)|Patients undergo FMT on day 1. If they fail to benefit from single FMT, repeat FMTs (no more than 3 times) would be performed.
89515262|NCT03516383||Experimental|"ABI < 0.6, confirmed PAD~50 - 90 years of age~In-patients or out-patients~Participants who understand the study and are able to give consent~Participants who can be followed by the same investigating team for the whole period of their participation in the study"
89515263|NCT03516383||Control|"ABI of 0.9 < ABI < 1.2~50 - 90 years of age~Participants who understand the study and are able to give consent~Participants who can be followed by the same investigating team for the whole period of their participation in the study"
89515264|NCT02292875||TG002 Subjects|Subjects previously randomised in study TG002
89515265|NCT02293031|Experimental|"Gene-activated matrix Nucleostim"|"Implantation of gene-activated matrix Nucleostim into the bone defects or sites of bone atrophy"
89515266|NCT02296073|Experimental|Midazolam|midazolam 3～5μg/kg•min for maintenance of sedation.
89515267|NCT02296073|Experimental|Dexmedetomidine1|Dexmedetomidine 0.5μg/kg intravenous bump for 15 min，then 0.2～1.4μg/(kg.h) for maintenance of sedation；
89515268|NCT02296073|Experimental|Dexmedetomidine2|Dexmedetomidine 0.25μg/kg intravenous bump for 15 min，then 0.2～1.4μg/(kg.h) for maintenance of sedation；
89515269|NCT02296073|Experimental|Dexmedetomiding3|Dexmedetomidine 0.2～1.4μg/(kg.h) for maintenance of sedation；
89515270|NCT02296151|Placebo Comparator|Group A|Four iliotibial band stretches; to be completed 3 days per week.
88961280|NCT02007785|Experimental|CO-OP treatment protocol|Participants with Parkinson's disease will be participating in up to 12 one-on-one treatment sessions with 2 sessions per week, for up to 6 weeks. Each session will last 45-60 minutes. During these treatment sessions, each participant will be taught a problem-solving strategy that teaches individuals to monitor and adjust their own actions. Participants will be guided by the principal investigator to select 5 individual treatment goals to work on during treatment. Sessions will continue until all 5 treatment goals have been met or until 12 sessions have been completed, whichever occurs earlier. Initially, each participant's respective primary caregiver will be required to attend treatment sessions, so that the caregiver may be familiar with the treatment strategy in order to coach the participant with Parkinson's disease when you he or she uses the strategy at home.
88961281|NCT02007798|Experimental|low-dose group|S group : dexmedetomidine is infused intravenously at a dose of 0.4 ug/kg
88961282|NCT02007798|Experimental|middle-dose group|M group: dexmedetomidine is infused intravenously at a dose of 0.8 ug/kg
88961283|NCT02007798|Experimental|control group|P group: normal saline is infused intravenously
88961284|NCT02007811|Experimental|allogeneic donor derived B-lymphocytes|
88961285|NCT02007824|Experimental|ULSD-12D|ultrasound surgical device made by Ultech.
88961286|NCT02007824|Active Comparator|SONOCA-180|ultrasound surgical device made by Soering
88961287|NCT02007837|Experimental|Combined aspirin and multinutrient supplement|In a single capsule, the following will be combined: 80mg low-dose aspirin, 1.2 grams calcium, 600 IU vitamin D, 5mg folic acid and 1000 ug vitamin B12
89515271|NCT02296151|Active Comparator|Group B|Four conventional hip exercises (Hip abductor, gluteus medius strengthening); to be completed 3 days per week.
89515272|NCT02296151|Experimental|Group C|Four conventional hip exercises progressed during the 8-weeks, totalling 16 exercises over the 8-week period (Hip abductor, gluteus medius strengthening). Exercises to be completed 3 days per week.
89515273|NCT03516149|Experimental|Foam Rolling Group|The participants in this group will receive foam rolling exercise.
89515274|NCT03516149|No Intervention|Control Group|The participants in this group will receive no foam rolling. They will only be evaluated.
89515275|NCT03519425|No Intervention|Group 1 (Standard of care)|"Participants will be directed to the clinic waiting area to be seen by facility health workers who will direct all further care without any further input from the study team. Available to facility health workers will be:~Routine HIV testing and counselling, provided by Facility HIV Testers using a rapid fingerprick kit-based algorithm.~Routine TB screening, with both sputum smear microscopy and Xpert MTB/Rif testing available onsite.~Routine linkage to the onsite HIV clinic, where patients are registered and assessed for initiation onto antiretroviral therapy by facility HIV Care Clinic health workers. Malawi guidelines recommend universal treatment for HIV. HIV Care Clinic health workers will additionally have access to TB screening tests as described above.~Routine linkage to the onsite TB clinic, where patients are registered and initiated onto anti-TB treatment. Malawi guidelines recommend universal HIV testing for all patients with confirmed TB."
89515276|NCT03519425|Active Comparator|Group 2 (Optimised HIV screening and linkage to care)|"Participants will be directed to the study room located in a separate building. After identity validation participants will be offered a supervised HIV self-testing intervention. Participants will be given brief pre-test instructions and will be asked to self-test in a private area using the OraQuick 1/2 (OraSure Technologies) oral fluid HIV kit. Participants will be supported to read their HIV test result by study Research Assistants, and provided with confirmatory HIV testing by the trained Research Assistants.~HIV-positive participants will be supported by Research Assistants to register at the onsite HIV care clinic, and all further care (including TB screening) will be directed by facility health workers without any further study input.~HIV-negative participants will be referred to the clinic waiting area (with a copy of their HIV test results) to be seen by the facility health workers who will direct all further investigations without further study input."
89515277|NCT03519425|Active Comparator|Group 3 (Optimised HIV and TB screening and linkage to care)|"Participants will be directed to the Study Room. After identity validation, they will be offered the HIV self-testing and linkage intervention as described above for Group 2. Additionally, they will be offered a TB screening intervention comprising of:~A digital chest x-ray using the study MinXray unit.~Chest x-rays will be immediately classified by the CAD4TB software running on the MinXray unit laptop as either high probability of TB, or low probability of TB.~Participants whose chest x-rays have a low probability of TB will be referred to facility health workers (at either the onsite HIV care clinic if HIV-positive, or the clinic waiting area), with copies of their results for further routine care, and without further study input.~Participants whose chest x-ray x-ray show a high probability of TB will submit a single spot sputum sample for Xpert testing (done in the clinic). Those with confirmed TB will be linked to register at the onsite TB clinic."
89515278|NCT03132779|Experimental|One armed|One group of patient will take Intralipid for all
89515279|NCT02293187|Active Comparator|vitamin D3|Vitamin D3, 800 IU will be given initially; after 4 months if D level < 70 nmol/L, increase dose to 1600 IU for remainder of study.
89515280|NCT02293187|Placebo Comparator|Placebo|Placebo, microcrystalline cellulose
89515281|NCT03519191|Other|Healthy Relationships Education (HRE)|Social-behavioral intervention Participants will receive employment support services and Healthy Relationships Education interventions.
89515282|NCT03519191|Other|HRE+Technology Bootcamp|Social-behavioral intervention + technology bootcamp (associated economic pathways for participants) Participants will receive employment support services, Healthy Relationships Education, and Technology Bootcamp interventions.
89515283|NCT02296385|Experimental|Supplementation|Supplementation
89515284|NCT03519113|Experimental|Test group 1|GC1102 80,000 IU
89515285|NCT03519113|Experimental|Test group 2|GC1102 100,000 IU
89515286|NCT03519113|Active Comparator|Control group|I.V HBIG
89515287|NCT03519035||Borderline personality disorder Patient|"Patients will be recruited in the different services. They have to respect inclusion criteria which are : patient with BPD (clinical diagnosis), patients 18 years of age or older, patients who can give their consent.~In this study, patients will have to pass different questionnaires (DIB-R, DES II, THQ, PCL-S, PSAS, qualitative questionnaire) in order to compare the characteristics between BDL patients with and without hallucinations."
89515288|NCT03518957|Experimental|Exercise intervention|Patients who are randomised to this arm will be enrolled to the exercise programme.
89515289|NCT03518957|No Intervention|Non-exercise|Patients who are randomised to the non-exercise group can continue their daily and physical activities as they normally would.
89515290|NCT03516071|Experimental|Brivanib 800 mg, QD + BSC|
89515291|NCT03516071|Experimental|Brivanib 400 mg, BID + BSC|
89515292|NCT02296463|Experimental|Treatment Group A|Day 0: RSV F Vaccine with adjuvant, Day 28: RSV F Vaccine with adjuvant
89515293|NCT02296463|Experimental|Treatment Group B|Day 0: RSV F Vaccine with adjuvant, Day 28: Hepatitis A Vaccine
89515294|NCT02296463|Experimental|Treatment Group C|Day 0: RSV F Vaccine, Day 28: RSV F Vaccine
89515295|NCT02296463|Experimental|Treatment Group D|Day 0: RSV F Vaccine, Day 28: Hepatitis A Vaccine
89515296|NCT02296463|Placebo Comparator|Treatment Group E|Day 0: Placebo, Day 28: Hepatitis A Vaccine
89515297|NCT02293265|Other|Non-drug interventional group|All enrolled participants will provide a blood sample, spirometry , and feedback on their severe asthma symptoms via questionnaires, and health related quality of life and burden of illness through response to self-administered questionnaires. No investigational product will be administered to participants.
89515298|NCT02293343||control group|healthy subjects
89515299|NCT02293343||IgE positive|patients with high IgE level in serum
89515300|NCT02293343||IBS patients|patients with afflictions, but no high IgE level and suspicion on histamine intolerance
89515301|NCT02296541|Experimental|Group 1: DNA Nat-B env and MVA-CMDR|Participants will receive a single injection of DNA Nat-B env at Months 0, 1, and 2. They will receive a single injection of MVA-CMDR at Months 4 and 8.
89515302|NCT02296541|Placebo Comparator|Group 1: Placebo vaccines for DNA Nat-B env and MVA-CMDR|Participants will receive a single injection of placebo for DNA Nat-B env at Months 0, 1, and 2. They will receive a single injection of placebo for MVA-CMDR at Months 4 and 8.
89515303|NCT02296541|Experimental|Group 2: DNA CON-S env and MVA-CMDR|Participants will receive a single injection of DNA CON-S env at Months 0, 1, and 2. They will receive a single injection of MVA-CMDR at Months 4 and 8.
89515304|NCT02296541|Placebo Comparator|Group 2: Placebo vaccines for DNA CON-S env and MVA-CMDR|Participants will receive a single injection of placebo for DNA CON-S env at Months 0, 1, and 2. They will receive a single injection of placebo for MVA-CMDR at Months 4 and 8.
89515305|NCT02296541|Experimental|Group 3: DNA Mosaic env and MVA-CMDR|Participants will receive a single injection of DNA Mosaic env at Months 0, 1, and 2. They will receive a single injection of MVA-CMDR at Months 4 and 8.
89515306|NCT02296541|Placebo Comparator|Group 3: Placebo vaccines for DNA Mosaic env and MVA-CMDR|Participants will receive a single injection of placebo for DNA Mosaic env at Months 0, 1, and 2. They will receive a single injection of placebo for MVA-CMDR at Months 4 and 8.
89515307|NCT03518879|Experimental|ASTHMA-Educator arm|The ASTHMA-Educator mobile application for patient-centered asthma education. The application is administered via on-site iPad (tablet).
89515308|NCT02495168|Experimental|Generic Budesonide/Formoterol Fumarate Dihydrate|After a 2-week Run-in Period of administering 2 inhalations twice daily via a generic placebo pMDI device, participants will administer 2 inhalations twice daily via a generic budesonide/formoterol fumarate dihydrate (80 μg/4.5 μg) pMDI for up to 50 days.
89515309|NCT02495168|Active Comparator|Symbicort (Budesonide/Formoterol Fumarate Dihydrate)|After a 2-week Run-in Period of administering 2 inhalations twice daily via a generic placebo pMDI device, participants will administer 2 inhalations twice daily via a Symbicort budesonide/formoterol fumarate dihydrate (80 μg/4.5 μg) pMDI for up to 50 days.
89515310|NCT02495168|Placebo Comparator|Placebo|After a 2-week Run-in Period of administering 2 inhalations twice daily via a generic placebo pMDI device, participants will administer 2 inhalations twice daily via a generic placebo pMDI for up to 50 days.
89515311|NCT03518645|Experimental|OPN strategy|The OPN NC Super High Pressure PTCA Balloon will be used as the study device for lesion preparation for BVS Absorb implantation - OPN strategy of lesion preparation. This balloon has a twin layer balloon construction, which allows a very high pressure resistance of 35 bar. The balloon has a 0.016'' lesion entry profile and is available in sizes between 1.5 and 4.5 mm and lengths of 10, 15 and 20 mm.
89515312|NCT03518645|Active Comparator|standard strategy|Predilatation with standard coronary balloon will be performed for lesion preparation for BVS Absorb implantation - standard strategy of lesion preparation.
88961288|NCT02007837|Placebo Comparator|Placebo|5mg folic acid, cellulose filler
88961289|NCT02007850|Placebo Comparator|ropivacaine continuous mode|0.2% ropivacaine 8 ml/hr through femoral nerve block catheter for 2 days and they have patient controlled intravenous fentanyl
88961290|NCT02007850|Active Comparator|ropivacaine patient controlled mode|0.2% ropivacaine patient controlled mode, basal rate 4 ml/hr, bolus 4 ml, lockout 60 minutes through femoral nerve block catheter for 2 days and they have patient controlled intravenous fentanyl
89024994|NCT04700930|Experimental|CBD|Patients receive CBD cigarettes additionally to standard psychiatric care including neuroleptic medication
89515313|NCT02293421|Other|STOP BANG|STOP BANG screening questionnaire and a snore question
89515314|NCT04934072|Experimental|FKS518|
89515315|NCT04934072|Active Comparator|US-licensed Prolia|
89515316|NCT03518489|Experimental|Experimental|Lappaconitine Adhesive Patch Lappaconitine Adhesive Patch is administered every radiation day, until the end of radiotherapy.
89515317|NCT03518489|Active Comparator|Control|Patients will be given standard care when oral pain is reported
89515318|NCT02296619|Experimental|TAP Block|Using real time ultrasound imaging, bilateral, 20 ml 0,25% bupivacaine inject into the area between the internal oblique and transverse abdominis muscle
89515319|NCT02296619|Sham Comparator|Control|A sham band-aid will be applied to the abdomen of subjects who are randomized to the no intervention group.
89515320|NCT02296697|Active Comparator|Low-level laser therapy AlGaInP|AlGaInP 660 nm laser and dose of 6 J / cm 2 with point application on the edges of the lesion and sweep up application in the center.
89024995|NCT04700930|No Intervention|Non-CBD|Patients recieve standard psychiatric care including neuroleptic medication
89515321|NCT02296697|Active Comparator|High-frequency therapy with O3 formation|High frequency generator, spherical electrode. Direct spark technique will be used, in which the electrode is positioned millimeters away from the skin of the patient, causing the formation of sparks, with increasing intensity up to 80 to 100% for ozone formation.
89024996|NCT00438555|Experimental|Parent's group|3 months workshop of parents intervention, guided by dietician and phycologist
89024997|NCT00438555|Experimental|Parents and children group|3 months workshops of parents and children intervention, guided by dietician and phycologist
89024998|NCT00438555|No Intervention|Control group|control group, no intervention, medical follow up only
89515322|NCT02296697|Placebo Comparator|Wound dressing with saline solution|Wound dressing with hygiene of the pressure ulcer with warm saline and after applying the bandage will be held will be held.
89515323|NCT02494778|Experimental|Pridopidine|The mode of administration is oral. Capsules will be swallowed whole with water. One capsule should be taken in the morning and 1 in the afternoon, 7 to 10 hours after the morning dose. Study drug can be taken irrespective of meals.
89515324|NCT04465019||TBI Group|Subjects in the TBI group included patients who suffered a TBI and who used the EKSO® bionic exoskeleton during their rehabilitation treatment from 01/01/2017 to 04/30/2020.
89515325|NCT04465019||CVA Group|Subjects in the CVA group included all patients in the hospital that used the EKSO® during their rehabilitation process during their rehabilitation treatment from 01/01/2017 to 04/30/2020.
89515326|NCT04464941|Experimental|oral health promotion program|"The oral health promotion program was a composite intervention with both group and individual components. The group intervention consisted of:~1. Group oral health education 2. Display of Bass tooth-brushing methods 3. Broadcasting of songs as tooth-brushing reminders; The individual interventions included:~1. Instruction in the Bass tooth-brushing method 2. Individual behavioral modification method"
89515327|NCT04464941|No Intervention|Usual care group|
89515328|NCT04933838|Placebo Comparator|Control Group|1% licocaine 3 mL + Normal saline 3 mL mixture
89515329|NCT04933838|Experimental|Atelocollagen group|1% lidocaine 3 mL + atelocollagen 3 mL mixture
89515330|NCT03518411|Experimental|Medical Students|Cognitive Behavioral Therapy Protocol
89515331|NCT04933526|Active Comparator|Flumatinib|600mg QD orally form 1 to 12 months
89515332|NCT04933526|Placebo Comparator|Dasatinib|100mg QD orally form 1 to 12 months
89515333|NCT02293733||Patients NSCLC EGFR mutated|This is an observational study, there is no intervention.
89515334|NCT03518333|Experimental|ARM 1|Injection of adipose derived cells into penis followed six months later with sham control saline injection procedure
89515335|NCT03518333|Experimental|ARM 2|Sham control saline injection procedure followed six months later by injection of adipose derived cells into penis
89515336|NCT03515759||hypertensive patients|60 pregnant women with singleton living fetus between 34 -38 wks gestation known to have severe hypertension in the current pregnancy were included
89515337|NCT03518255|No Intervention|Control group|This control group will not receive an intervention.
89515338|NCT03518255|Experimental|Nature video|A pre-validated nature images video will be shown to the patient during their chemotherapy session. After thirty minutes of the start of the chemotherapy session, the patient you will receive a notebook (specific to the study and blocked for other functions) that he can watch a presentation of nature images. It will be four videos with fifteen minutes each one.
89515339|NCT02293889|Experimental|Vitamin D|Vitamin D3 2000IU/daily 3 months
89515340|NCT02293889|Experimental|Physical Activity|PA intervention People with Osteoarthritis Walking Programme
89515341|NCT02293889|Experimental|Vitamin D and Physical Activity|Vitamin D3 2000IU/daily 3 months PA intervention People with Osteoarthritis Walking Programme
89515342|NCT02293889|Placebo Comparator|Placebo|Placebo capsule: edible oil
89515343|NCT02293967|Experimental|MT-1303|[14C] MT-1303 after a single oral dose
89515344|NCT03518177|Experimental|Hospital-based PR group|The patient will receive an 8-week supervised Pulmonary Rehabilitation Exercise Program at hospital
89515345|NCT03518177|Experimental|Home-based PR group|The patient will receive an 8-week Pulmonary Rehabilitation Exercise Program at home
89515346|NCT02297009||Volunteers|30 volunteers, half men and half women Buccal swab
89024999|NCT00440414|Experimental|1|Alimta
89025000|NCT00440414|Experimental|2|Tarceva
89025001|NCT00440453|No Intervention|1|Normal hospital food
89025002|NCT00440453|Experimental|2|Nutritional treatment
89025003|NCT00438594|No Intervention|Control group|Control group
89025004|NCT00438594|Experimental|Paraprofessional home visits|home visitation by Paraprofessional
89025005|NCT00438594|Experimental|Nurse home visits|home visitation by Nurse
89025006|NCT00476775|Experimental|After school ethnic dance and home-based screen time reduction|After school ethnic dance classes and home-based screen time reduction intervention
89515347|NCT02297087|Other|Pilot|Obtain the necessary tumor biopsies to yield sufficient DNA and RNA for Genome-Wide Sequencing (GWS).
89515348|NCT02297165|Experimental|Program|olfactory stimulation program
89515349|NCT02297165|No Intervention|Control|normal follow-up
89515350|NCT03514745|Active Comparator|GlideScope group|After the induction of anesthesia, endobronchial intubation is performed using the GlideScope.
89515351|NCT03514745|Experimental|Lighted stylet group|After the induction of anesthesia, endobronchial intubation is performed using a lighted stylet.
89515352|NCT02298335|Experimental|prednisone|First,full-dose induction period, then protracted tapering period.
89515353|NCT03514667|Active Comparator|intervention group|80 mg nanomicielle curcumin capsules once a day for 12 weeks
89515354|NCT03514667|Placebo Comparator|control group|placebo capsules once a day for 12 weeks
89515355|NCT03515525||Hematoma side|Drain secretion volume prior to revision surgery on the breast side affected by hematoma.
89515356|NCT03515525||Non-hematoma side|Drain secretion volume prior to revision surgery on the breast side not affected by hematoma.
89515357|NCT02297243|Experimental|Sinopsys Lacrimal Stent|The Sinopsys Lacrimal Stent is indicated for use to create a transcaruncular ethmoid sinus access.
89515358|NCT02298569|No Intervention|Phase 1 (before multi-pronged program)|400 low-risk mothers having given birth without any complication to a healthy newborn are to be recruited in the 5 maternity wards of a French perinatal network consecutively, whatever the duration of their hospital stay
89025007|NCT00476775|Active Comparator|Health and Nutrition Education|Health and nutrition education active placebo control intervention
89025008|NCT03270462|Other|Envarsus XR|A form of the anti-rejection drug, tacrolimus, for people who have had a kidney transplant.
89025009|NCT00440609|Active Comparator|0.5mg transitioning to 2.0mg|Ranibizumab-intravitreal injection
89025010|NCT00440609|Active Comparator|1.0 mg transitioning to 2.0mg|Ranibizumab-intravitreal injection
89025011|NCT00440648|Other|1|sevelamer carbonate w(1-8) sevelamer hydrochloride w(9-16)
89515359|NCT02298569|Experimental|Phase 2 (after multi-pronged program)|400 low-risk mothers having given birth without any complication to a healthy newborn are to be recruited in the 5 maternity wards of the same French perinatal network 3 months after the intervention (introduction of the multi-pronged program) consecutively, whatever the duration of their hospital stay
89515360|NCT02297321|Experimental|DeScribe patch|Comparison of the number of passes achieved using the Describe patch plus laser compared to laser along
89515361|NCT02297399|Experimental|PEG-ascorbate 2L|Subjects will take 2 liters of a polyethylene glycol 3500 (sodium sulphate, sodium chloride, postassium chloride), ascorbic acid and sodium ascorbate solution.
89515362|NCT02297399|Active Comparator|PEG 4L|Subjects will take 4 liters of a polyethylene glycol 4000 (sodium sulphate, sodium chloride, postassium chloride and sodium bicarbonate) solution.
89515363|NCT02493764|Experimental|IMI/REL|Imipenem 500 mg + relebactam 250 mg + cilastatin 500 mg as a FDC administered intravenously (IV) every 6 hours for a minimum of 7 days, up to 14 days. At study entry open label linezolid 600 mg will also be administered by IV every 12 hours for up to 14 days.
89515364|NCT02493764|Active Comparator|PIP/TAZ|Piperacillin 4000 mg + tazobactam 500 mg as a FDC administered IV every 6 hours for a minimum of 7 days, up to 14 days. At study entry open label linezolid 600 mg will also be administered by IV every 12 hours for up to 14 days.
89515365|NCT02297477|Active Comparator|atovaquone-proguanil (AP)|A standard fixed-dose 3 day regimen of Atovaquone-proguanil (AP) for treatment of uncomplicated P. falciparum malaria.
89515366|NCT02297477|Active Comparator|artesunate-atovaquone-proguanil (ASAP)|A standard fixed-dose 3 day regimen of Atovaquone-proguanil (AP) plus 3 days of artesunate (200mg per day) for treatment of uncomplicated P. falciparum malaria.
89515367|NCT02298725|Experimental|DGA Diet Plan|A nutrient-adequate, balanced diet providing energy to maintain body weight, and macronutrient composition falling within the acceptable range, as recommended by the Institute of Medicine. The foods provided in this diet will be closely aligned with food group recommendations set in the 2010 Dietary Guidelines for Americans. All foods and beverages will be provided to enrolled subjects during the intervention period.
89515368|NCT02298725|Experimental|NHANES Diet Plan|"A nutrient-adequate, balanced diet providing energy to maintain body weight, and macronutrient composition falling within the acceptable range, as recommended by the Institute of Medicine. The foods provided in this diet plan will be closely aligned with the NHANES What We Eat In America report. All foods and beverages will be provided to enrolled subjects during the intervention period."
89515369|NCT02298881||Dry eye group|People with dry eye symptoms
89515370|NCT02298881||Non-dry eye group|People with no dry eye symptoms
89515371|NCT03515447||Before period|During this period no patient received Romiplostim.
89515372|NCT03515447||After period|"Application of the transfusion saving strategy protocol through Romiplostim treatment.~The first subcutaneous injection of 1.5 to 2 µg/kg of romiplostim was administered in the post-operative periods. An algorithm based on patient weight and platelet count was established to determine romiplostim doses. One injection per week was performed. Romiplostim posology was adjusted between 2 and 5µg/kg every week according to platelet count with a maximum of 4 administrations in the ICU."
89515373|NCT02460380|Active Comparator|Vitamin D3|Women allocated to vitamin D3 group received one capsule 50.000 IU of vitamin D3 once weekly for eight weeks.
89515374|NCT02460380|Placebo Comparator|Placebo|Women in the placebo group received once capsule of placebo once weekly for eight weeks.
89515375|NCT02297555|No Intervention|Conventional medical therapy|Conventional medical therapy is defined as the use of the latest lifestyle guidelines to optimize weight loss and glycaemic management, frequent home monitoring/titration strategies, use of latest approved drug therapy for treatment of hyperglycaemia and restoration of pancreatic B cell function, also for dyslipidemia and hypertension in addition to regular follow-up visits to a medical doctor from a multidisciplinary team
89515376|NCT02297555|Experimental|ENDOBARRIER®|The interventional therapy will be the device ENDOBARRIER® over conventional medical therapy
89515377|NCT02297633||Stability in patients with COPD|Those patients diagnosed COPD according to the GOLD guideline and without acute exacerbation within one month.
89515378|NCT02297633||AECOPD|the diagnosis of an exacerbation relies exclusively on the clinical presentation of the patient complaining of an acute change of symptoms (baseline dyspnea, cough, and/or sputum production) that is beyond normal day-to-day variation.
89515379|NCT02297633||Healthy persons without smoking|The healthy people who do not smoke
89515380|NCT02297633||Healthy persons with smoking|Healthy persons who smoke
89515381|NCT03514511|Experimental|Cohort 1 in healthy subjects|LEO 138559 (dose regiment 1) or LEO 138559 placebo
89515382|NCT03514511|Experimental|Cohort 2 in healthy subjects|LEO 138559 (dose regiment 2) or LEO 138559 placebo
89544129|NCT03849885|Experimental|Experimental Skin Prep with BPO|"Patients will undergo a skin cleansing protocols using 4% Chlorhexidine gluconate (CHG) cloths.~Following the CHG wipes, patients will be prepped with 5% BPO gel applied directly to the biopsy site.~After the skin prep, three 3-mm punch (Acu-Punch, Acuderm, Fort Lauderdale, FL) skin biopsies will performed for both an anterior-based hypothetical incision, and for a more lateral/posterior incision, for a total of 6 biopsies taken per subject."
89544130|NCT05678283|Experimental|Part 1: CC-90010 followed by [14C]CC-90010|
89544131|NCT05678283|Experimental|Part 2: CC-90010|
89544132|NCT01664091|Experimental|TE-ADM with PMRT|Participants received immediate breast reconstruction using a sub-muscular tissue expander (TE) and acellular dermal matrix (ADM) sling placed during the same surgery. This was followed by post-mastectomy radiation therapy (PMRT) no sooner than a minimum of 6 weeks and optimally 6 months, if adjuvant chemotherapy was required. The prescribed chest-wall dose was 50 -50.4 gray (Gy) in 25-28 fractions given once daily over 5-7 weeks with a 0.5-centimeter (cm) bolus to the scar every other day. Permanent reconstruction was performed at least 5 months after completion of PMRT.
89544133|NCT02577315|Experimental|Test - Empagliflozin/Metformin|fixed dose combination of 2 tablets of 12.5 mg Empagliflozin and 500 mg Metformin, oral with 200 mL of water uder fed conditions
89544134|NCT02577315|Experimental|Reference - Empagliflozin + Metformin|free combination of 1 tablet of 25 mg Empagliflozin and 1 tablet of 1000 mg of Metformin, oral with 200 mL of water under fed conditions
89544135|NCT05220657||Low active subjects|No intervention
89544136|NCT05220657||Moderately active subjects|No intervention
89544137|NCT05220657||Elite soccer players|No intervention
89544138|NCT05220657||Elite cyclists|No intervention
89544139|NCT05211297||Exposed cohort:|Children whose mothers suffered a suspected preterm labour during pregnancy.
89544140|NCT05211297||Unexposed cohort|Children born at term (> 37 weeks) whose mothers did not suffer a suspected preterm labour during pregnancy.
89544141|NCT05210283||Stage ll or lll|Patients with stage ll or lll colorectal cancer
89544142|NCT05509413|No Intervention|Control Arm|Wait-and-see approach.
89544143|NCT05509413|Experimental|DEFLAGYN Arm|Application of DEFLAGYN vaginal gel for 3x 28days (as per instructions provided by the manufacturer)
89544144|NCT03526887|Experimental|Cohort 1|Patients who experienced progression disease while on treatment progression disease < 12 weeks after stopping treatment. After that the patients took chemotherapy ≥ 4 cycles and progressed again. After the last progression the patient is included in the study to be retreated with Pembrolizumab 200mg
89544145|NCT03526887|Experimental|Cohort 2|Stop treatment and progression > 12 weeks after stopping treatment. After the last progression the patient is included in the study to be retreated with Pembrolizumab 200mg
89025012|NCT00440648|Other|2|sevelamer hydrochloride w(1-8) sevelamer carbonate w(9-16)
89544146|NCT03505983|Active Comparator|ESR Prosthetic Foot First|Subject will start with an energy storing and returning (ESR) prosthetic foot first for 1 week, then will complete an additional week with an articulating ESR prosthetic foot, and a powered prosthetic foot for 1 week. During the final 4 weeks of the study, all prosthetic feet will be available and subjects can self-select which foot to use.
89544147|NCT03505983|Active Comparator|Articulating ESR Prosthetic Foot First|Subjects will start with an Articulating ESR prosthetic foot first for 1 week, then will complete an additional week with the ESR prosthetic foot, and a powered prosthetic foot for 1 week.The final 4 weeks, all prosthetic feet will be available for use and subjects will self-select which foot to use for daily activities.
89544148|NCT03505983|Active Comparator|Powered Prosthetic Foot First|Subjects will start with a powered prosthetic foot first for 1 week, then will complete an additional week with an articulating ESR prosthetic foot and an ESR prosthetic foot for 1 week. The final 4 weeks, all prosthetic feet will be available for use and subjects will self-select which foot to use for daily activities.
89544149|NCT03496779|Experimental|Experimental|"Patients treated with gemcitabine will receive Brentuximab Vedotin-induction for 4 cycles of induction.~Patients who will obtain partial or complete response and who will be eligible for transplant will receive autologous or allogeneic stem cell transplantation.~Patients who will obtain partial or complete response and who will not be eligible for transplant will receive maintenance therapy with Brentuximab Vedotin-maintenance every 3 weeks for 12 infusions."
89544150|NCT02711345|Experimental|Escalation|
89544151|NCT02711345|Experimental|Expansion Group 1|
89544152|NCT02711345|Experimental|Expansion Group 2|
89544153|NCT02711345|Experimental|Expansion Group 3|
89544154|NCT02711345|Experimental|Expansion Group 4|
89544155|NCT03398655|Experimental|Arm 1|VB-111 + Paclitaxel
89025013|NCT03271047|Experimental|Phase 1b / Arm 1A|binimetinib + nivolumab
89025014|NCT03271047|Experimental|Phase 1b / Arm 1B|binimetinib + nivolumab + ipilimumab
89025015|NCT03271047|Experimental|Phase 2 / Arm 2A|binimetinib + nivolumab
89025016|NCT03271047|Experimental|Phase 2 / Arm 2B|binimetinib + nivolumab + ipilimumab
89025017|NCT00440765||001|bortezomib dose as determined (observational study) by treating physician
89025018|NCT03276936|Experimental|Minocycline Foam 1.5%|FMX-103
89025019|NCT00440843|Experimental|OLZ|
89025020|NCT00440843|Active Comparator|Typicals|
89544156|NCT03398655|Active Comparator|Arm 2|Placebo + Paclitaxel
89544157|NCT03873623||Kidney Transplant Recipients|
89544158|NCT05695287|Other|Propofol|Anesthesia
89544159|NCT05695287|Other|Isofluran|Anesthesia
89544160|NCT05695287|Other|Sevofluran|Anesthesia
89544161|NCT03772691|Experimental|lateral suspension|All operations will be performed with patient in loyd davies position, sterilization of the perineum then sterilization of the vagina
89544162|NCT03772691|Active Comparator|sacropexy|Our ﬁrst passage is the peritoneum incision overlying the sacral promontory (L5-S1) to expose the anterior longitudinal ligament, which is the anchorage point of the mesh on the sacrum. We create a tunnel under the peritoneum on the right side through the cul-de-sac of Douglas till reach the cervix or vaginal cuff (after hysterectomy).
89544163|NCT05501067|Active Comparator|tai chi group|patients will receive tai chi exercise program
89544164|NCT05501067|Active Comparator|control group|no intervention
89544165|NCT03118115|Experimental|Impedance|Measurement of the flap bioimpedance before and after clamping of the artery or the vein. For information: All patients will have the vein and the arterial section simulating venous or arterial thrombosis.
89544166|NCT05097495|Experimental|Control group (Only NNS)|NNS will be started 5 minutes before diaper change. The use of NNS will continue during diaper change and up to 5 minutes after the application.
89544167|NCT05097495|Experimental|Experimental Group (NNS Combined with Breast Milk)|NNS combined with breast milk will be started 5 minutes before diaper change. The use of NNS combined with breast milk will continue during diaper change and up to 5 minutes after the application.
89544168|NCT03662009||Parkinson Disease|Observation of individuals with idiopathic Parkinson disease performing a multilimb dual task using the arm and the leg.
89544169|NCT03662009||Control|Observation of healthy age-matched individuals will perform a multilimb dual task using the arm and the leg.
89544170|NCT05497869|Experimental|Experimental interventional group|Active Release Technique (ART)
89544171|NCT05497869|Active Comparator|active control group|conventional group
89544172|NCT00591227|Active Comparator|aspart detemir|these subjects will be treated with insulin aspart every 2 hours if blood glucose is more than 200 mg/dl during their ER evaluation. If they are admitted to hospital then they will receive a weight-based dose of insulin detemir immediately prior to admission and then every 24 hours thereafter combined with mealtime doses of insulin aspart if they are eating.
89544173|NCT00591227|No Intervention|usual care|these subjects will receive no insulin per protocol during their ER stay or during a possible inpatient admission. The care for their diabetes will be solely determined by the physician(s) in the ER and by the physician(s) caring for them in the hospital if they are admitted. They may receive no therapy, oral agents or insulin per primary physician preference.
89544174|NCT03193697|Experimental|control group|Old patients with unstable intertrochanteric fractures underwent total hip arthroplasty. Forty-four patients in the control group received a cemented SPII prosthesis (Link, Germany).
89544175|NCT03193697|Experimental|trial group|Old patients with unstable intertrochanteric fractures underwent total hip arthroplasty. Forty-two patients in the trial group received cementless Wagner prosthesis (Zimmer, USA).
89544176|NCT00189293|Experimental|1|Imiquimod 5% cream
89544177|NCT00189293|Other|2|vehicle cream
89544178|NCT03194009|Active Comparator|Lifestyle Intervention|The prediabetic individuals from the primary care centres that belong to this arm, will receive only recommendations for lifestyle modifications (physical activity and diet).
89544179|NCT03194009|Active Comparator|Metformin|The prediabetic individuals from the primary care centres that belong to this arm, will receive metformin treatment and lifestyle modifications recommendations (physical activity and diet).
89544180|NCT03192761|Active Comparator|ACL-reconstruction hamstrings|ACL reconstruction hamstrings
88961291|NCT02007876|Experimental|Mobility and Activity Training|"Pre-operative: Participants will receive weekly sessions of higher level, task-specific transfer training. All MAT participants will learn the GCS set of exercises chosen to activate core muscles and lessen decline in core strength. These sessions will be supplemented by a home-based walking and physical activity enhancement program of the participants' choosing, focusing on attaining a safe community-based rate of perceived exertion. A pedometer and home exercise log will be used to encourage compliance and advance activities.~Post-operative: Participants will be screened by physical therapy for standard physical therapy with focus on early mobilization. The GCS exercises taught pre-operatively will be reinstituted.~Post-discharge/home: Participants will continue the GCS program and begin to return to elements of their pre-operative home-based MAT program. The program physical therapist will call weekly to review progress."
88961292|NCT02007876|No Intervention|Normal activity|"Pre-operative: Participants will be given the National Institute on Aging guide to home-based exercise but no further instruction or incentive for walking or physical activity enhancement.~Post-operative: Participants will be screened by in-hospital physical therapy for standard physical therapy with focus on early mobilization. Those who do not receive physical therapy will not be given any additional training, as is standard for reimbursed hospital services.~Post-discharge: Program nurse will call weekly to provide health education but no instruction or incentives for mobility or physical activity enhancement."
88961293|NCT02007889|Active Comparator|L-carnitine|50 mg/kg/day carnitine in divided 2-3 times/day (maximum 3 g/day) in addition to antibiotic regimens
88961294|NCT02007889|No Intervention|Control|control group received just antibiotic regimens without L-carnitine
88961295|NCT02007902||Very preterm babies|Observational model: cohort
88961296|NCT02007915|Experimental|Pamidronate Disodium|
89025021|NCT00438828|Experimental|Dexamethasone|8mg Dexamethasone PO on days 0 (prior to radiation treatment), and days 1, 2, and 3 following radiation treatment.
89544181|NCT03192761|Active Comparator|ACL-reconstruction patella tendon|ACL reconstruction patella tendon
89544182|NCT03192761|Active Comparator|ACL-reconstruction iliotibial tract|ACL reconstruction iliotibial tract
89544183|NCT02581995|Experimental|Arm 1 / Quality of Life|Aflibercept treatment in subjects with diabetic macular edema (DME)
89544184|NCT03193385||Closed reduction|
89544185|NCT03192605|Experimental|Blueberry|150 grams wild blueberries
89544186|NCT03192605|Placebo Comparator|Placebo|Placebo control
89544187|NCT03192683|Active Comparator|Regular sling|
89544188|NCT03192683|Experimental|Cast-sling|
89544189|NCT02910843|Experimental|Regorafenib & Capecitabine|"Regorafenib dose level 1-3: day 1 to 14 and day 22 to 35 (2 weeks on 1 week off, 2 weeks on, including Saturday and Sunday) at a daily dose according to the escalation table.~Regorafenib dose level -1: day 1 to 5, day 8 to 12, day 22 to 26 and day 29 to 33 (5 days on and 2 days off during week 1, 2, 4 and 5; week 3 off) at a daily dose according to the escalation table.~Capecitabine: day 1 to 38 (5 weeks and 3 days, including Saturday and Sunday) according to dose escalation table. The intake stops in the evening of the last day of RT.~External beam Radiotherapy~Surgery"
89544190|NCT03192527|Experimental|Arm A|KN015, Triptorelin
89544191|NCT03192527|Placebo Comparator|Arm B|placebo, Triptorelin
89544192|NCT02444351|Active Comparator|control group|
89544193|NCT02444351|Experimental|botox group|
89515383|NCT03514511|Experimental|Cohort 3 in healthy subjects|LEO 138559 (dose regiment 3) or LEO 138559 placebo
89515384|NCT03514511|Experimental|Cohort 4 in healthy subjects|LEO 138559 (dose regiment 4) or LEO 138559 placebo
89515385|NCT03514511|Experimental|Cohort 5 in healthy subjects|LEO 138559 (dose regiment 5) or LEO 138559 placebo
88961297|NCT02007928|Other|rispéridone, aripiprazole, olanzapine...|"Study:~We propose a prospective, interventional multicenter study.~Method:~Both in and out patients may be included in the study Patients will be recruited over a period of 24 months. They will be followed up for 12 months. Each patient will receive one year of therapeutic monitoring after the introduction of the antipsychotic drug.~The therapeutic monitoring will include clinical, electrocardiographical, and laboratory assessments. These assessments are performed at baseline (before prescribing treatment) and at 1 month (M1), at 3 months (M3), 6 months (M6), 9 months (M9), and at 12 months (M12) after the first prescription of the antipsychotic drug."
89515386|NCT03514511|Experimental|Cohort 6 in healthy subjects|LEO 138559 (dose regiment 6) or LEO 138559 placebo
89515387|NCT03514511|Experimental|Cohort 7 in healthy subjects|LEO 138559 (dose regiment 7) or LEO 138559 placebo
89515388|NCT03514511|Experimental|Cohort 8 in subjects with atopic dermatitis|LEO 138559 (dose regiment 8) or LEO 138559 placebo
89515389|NCT03514511|Experimental|Cohort 9 in subjects with atopic dermatitis|LEO 138559 (dose regiment 9) or LEO 138559 placebo
89515390|NCT02493062|Experimental|single-arm study|This single-arm study is described by women who have undergone prenatal fetal open (uterus was opened to perform a fetal intervention/surgery) surgery and cesarean section delivery. These women will undergo sonohysterogram.
89515391|NCT02299115|Experimental|Prednisolone|Single center, prospective, observational, open trial using high-dose oral prednisolone as first-line treatment for newly diagnosed Infantile Spasms (non-Tuberous Sclerosis)
89515392|NCT02299115|Active Comparator|Vigabatrin|Retrospective controls composed of our cohort of non-Tuberous Sclerosis Infantile Spasms patients from January 2010- September 2013 who received Vigabatrin as first-line treatment.
89515393|NCT04932356|Other|Therapeutic Education by phone|Therapeutic education in diabetes mellitus (pharmacological, nutritional, physical exercise, social adherence ... etc) on face-to-face visit and then reinforcement each 15 days over the weak points of this visit.
89515394|NCT04932356|Other|Traditional Therapeutic Education|Therapeutic education in diabetes mellitus (pharmacological, nutritional, physical exercise, social adherence ... etc) on face-to-face visit.
89515395|NCT02297711|Experimental|Total ExtraPeritoneal|Total ExtraPeritoneal (TEP) technique in general anesthesiacanal from behind
89515396|NCT02297711|Active Comparator|Open minimal suture repair|Open minimal repair (OMR) technique in local or spinal anesthesia
89515397|NCT02297789|Experimental|Headgear 1|Full Face Mask with Headgear 1
89515398|NCT02297789|Experimental|Headgear 2|Full Face Mask with Headgear 2
89515399|NCT02297867|Experimental|ADSCs|One milliliter of cell suspension will be injected intrahepatically under sonographic guidance using a gauge-18 needle.
89515400|NCT03515291|Experimental|iMP cell injection|iMP cells injected in to the epicardial surface of the heart during coronary artery bypass graft surgery.
89515401|NCT03515291|Placebo Comparator|Control injection|Control (cell suspension solution) injected in to the epicardial surface of the heart during coronary artery bypass graft surgery.
89515402|NCT02297945|Experimental|Metyrapone|Metyrapone will be administered orally in an open-label fashion. Two possible initiation doses will be used depending on the severity of hypercortisolism, dose will then be adjusted (up or down-titrated) during the first month on an individual basis according to clinical tolerance and cortisol levels achieved.
89515403|NCT02492984|Experimental|Intravenous infusions of Xyntha|Enrolled subjects will be treated with intravenous infusions of Xyntha for: • On-Demand treatment, • Surgical Prophylaxis at a dose and frequency prescribed by the subject's treating physician in accordance with the Xyntha label and will be adjusted solely according to medical and therapeutic necessity.
88961298|NCT02007941|Experimental|End Stage Renal Disease(ESRD)|"CKD-501 will be administered to patients who have required dialysis and non-dialysis eGFR(estimate glomerular filtration rate ) is Less than 15.~First, ESRD Patient and normal renal function Subjects are conducted. After the interim analysis, Determine whether early termination or renal impaired subject's progress"
88961299|NCT02007941|Active Comparator|normal renal function|"CKD-501 will be administered to normal renal function subject who have eGFR(estimate glomerular filtration rate ) of 90 or more.~First, ESRD Patient and normal renal function Subjects are conducted. After the interim analysis, Determine whether early termination or renal impaired subject's progress"
88961300|NCT02007941|Experimental|Mild renal impairment|CKD-501 will be administered to patients who have eGFR(estimate glomerular filtration rate ) is 60 to 89 that.
88961301|NCT02007993|Active Comparator|Group 1|Treatment with a tongue scraper
89515404|NCT03515135|Experimental|Intervention group|"Subjects in this group will receive the Metacognitive Executive Function Training (MEFP) program in aiming to reduce ADHD symptoms and improve the executive function."
89515405|NCT03515135|No Intervention|Waiting group|Subjects in this group will not receive the MEFP program during the study period.
89515406|NCT03514355|Experimental|Intervention|Mindfulness-Based Stress Reduction (MBSR) is a program intended to draw upon the group's shared experiences to facilitate the development of mindfulness. MBSR is offered in 2.5-h classes on a weekly basis for 8 consecutive weeks, with a retreat day in between classes 6 and 7. This day involves guided meditations, allowing for continuity in practice. Classes include specific exercises (e.g. identifying thoughts, emotions and body sensations associated with illness); these are then extended as homework and discussed in the subsequent class. The curriculum themes and content are arranged week by week to reflect these principles.
89515407|NCT03514355|No Intervention|Control|The control group will receive usual care, with no treatment restrictions. Treating physicians will be informed of CES-D results. Patients will be asked to fulfill the same clinical assessment and questionnaires, and to provide the same biosamples than those patients in the intervention.
89515408|NCT03132623|Active Comparator|Experimental group|andrographolide sulfonate(Xiyanping injection) 10-20ml/d, With 0.9% normal saline 100ml-250ml diluted intravenous drip (not with other drugs in the same container mixed use), control drip speed per minute of 30-40 drops.
89515409|NCT03132623|Placebo Comparator|control group|andrographolide sulfonate simulation(0.9% normal saline) 10-20ml/d, The treatment method is the same as the experimental group.
88961302|NCT02007993|Experimental|Group 2|PDT wavelength = 660 nm Fluency = 320 J/cm2 Power = 100 milliwatt Energy = 9 J Time = 90 s
88961303|NCT02007993|Experimental|Group 4|Tongue scraper + PDT wavelength = 660 nm Fluency = 320 J/cm2 Power = 100 milliwatt Energy = 9 J Time = 90 s
88961304|NCT02007993|Experimental|Group 3|PDT wavelength = 660 nm Fluency = 428 J/cm2 Power = 100 milliwatt Energy = 12 J Time = 120 s
88961305|NCT02007993|Experimental|Group 5|Tongue scraper + PDT wavelength = 660 nm Fluency = 428 J/cm2 Power = 100 milliwatt Energy = 12 J Time = 120 s
88961306|NCT02008006|Experimental|BeEAM|"High Dose Chemotherapy (HDT) containing :~Bendamustine~Etoposide~Cytarabine~Melphalan~HDT will be followed by an Autologous Stem Cell Transplantation"
88961307|NCT02008019|No Intervention|No treatment|No Everolimus treatment before surgery
88961308|NCT02008019|Experimental|Everolimus 2,5 mg/day|Everolimus treatment at 2,5 mg/day for 30 days
88961309|NCT02008019|Experimental|Everolimus 10 mg/day|Everolimus treatment at 10 mg/day for 30 days
88961310|NCT02008032|Experimental|All patients|Stationary Breast Tomosynthesis
89025022|NCT00441038|Active Comparator|1|Education on postural hygiene and handout of The Back Guide
89515410|NCT03514199|Experimental|Mediterranean-type diet|Recommends high consumption of whole grains, vegetables, nuts, fruits, vegetables and olive oil as the main source of fat used for salads. Moderate to high fish consumption and low consumption of red and processed meats. Poultry and dairy products (such as yogurt or cheese) will be consumed in small quantities and moderate consumption of alcohol, usually in the form of red wine, will be recommended with meals for usual drinkers.
89515411|NCT03514199|Active Comparator|Low fat diet|It recommends reducing the intake of foods rich in fats, especially those saturated and hydrogenated.
89515412|NCT03515057|Experimental|Atrial Fibrillation Spot-Check|For eligible patients from primary care clinics randomly selected for the Atrial Fibrillation Spot-Check arm, practice medical assistants will screen assenting patients for undiagnosed AF during regularly scheduled office visits using a single-lead handheld electrocardiogram (ECG). Single-lead handheld electrocardiogram readings detecting AF will be confirmed during the same office visit with a standard 12-lead ECG at the discretion of the primary care physician. If AF is detected, the patient's PCP will be able to address the condition with them during the clinic visit and initiate appropriate follow-up to manage the AF.
89515413|NCT03515057|No Intervention|Usual Care|For eligible patients from primary care clinics randomly selected for the Usual Care arm, they will receive standard care during outpatient visits without change.
89515414|NCT03514979|Experimental|AAV patients treated with rituximab|Pneumococcal Polysaccharide Conjugate vaccination at Month 0 and then Pneumococcal Polysaccharide Vaccination at Month 6.
89515415|NCT03514979|Experimental|AAV patients - never received rituximab|Pneumococcal Polysaccharide Conjugate vaccination at Month 0 and then Pneumococcal Polysaccharide Vaccination at Month 6.
89515416|NCT03514979|Experimental|Healthy controls|Pneumococcal Polysaccharide Conjugate vaccination at Month 0 and then Pneumococcal Polysaccharide Vaccination at Month 6.
89515417|NCT03513965|Experimental|Symptoms as Side Effects Mindset|Both arms are given identical treatment instructions at their first clinic visit, including practical strategies for taking doses and managing symptoms. Families are given comprehensive instructions for recognizing life-threatening symptoms and administering epinephrine when appropriate. However, information about the implications of non-life-threatening symptoms differs between arms. At the first clinic visit, families are given verbal (e.g., provider explanations) and written information (e.g., brochures on symptom management) informing them about symptoms in different ways. In this arm, families are informed that these non-life-threatening symptoms are an unfortunate part of treatment that must be endured, similar to side effects from common medications.
89515418|NCT03513965|Experimental|Symptoms as Positive Signals Mindset|Both arms are given identical treatment instructions at their first clinic visit, including practical strategies for taking doses and managing symptoms. Families are given comprehensive instructions for recognizing life-threatening symptoms and administering epinephrine when appropriate. However, information about the implications of non-life-threatening symptoms differs between arms. At the first clinic visit, families are given verbal (e.g., provider explanations) and written information (e.g., brochures on symptom management) informing them about symptoms in different ways. In this arm, families are informed that symptoms are a sign that that their bodies are gradually increasing desensitization, similar to having sore muscles after a difficult workout.
89515419|NCT02298101|Active Comparator|Aeroneb Solo Adapter|Subjects inhaled radiolabelled aerosol via the Aeroneb Solo Adapter
89515420|NCT02298101|Active Comparator|Standard Jet Nebulizer|Subjects inhaled radiolabelled aerosol via a standard jet nebulizer, the Opti-Mist Plus Nebulizer
89515421|NCT01680159|Experimental|TA-650|
89515422|NCT02299193|Experimental|Cognitive Behavioral Therapy|online sessions on how behaviors and thoughts that can affect sleep.
89515423|NCT02299193|Sham Comparator|Healthy Sleep Habits|online sessions about healthy sleep practices
89515424|NCT02491892|Experimental|Pertuzumab 1050 mg|Participants will not receive a loading dose, but will receive pertuzumab 1050 milligrams (mg) via intravenous (IV) infusion every 3 weeks until unacceptable toxicity or disease progression.
89515425|NCT02491892|Experimental|Pertuzumab 420 mg|Participants will receive a loading dose of 840 mg via IV infusion at the first infusion of pertuzumab, followed by a maintenance dose of 420 mg every 3 weeks until unacceptable toxicity or disease progression.
89515426|NCT03513887||Group/Cohorts|we will prospectively collect patients with liver cirrhosis who fulfill all inclusion criterias and will be treated in the Department of Gastroenterology of the Second Affiliated Hospital of Xi'an Jiaotong University.
89515427|NCT03476811|No Intervention|Control Group|Normal treatment paradigm (no anesthetic pump) with pain medications, only.
89515428|NCT03476811|Active Comparator|Marciano Group|Subcutaneous pain control with OnQ pump (0.25% Marcaine at 2ml/hr) and pain medications.
89515429|NCT03476811|Placebo Comparator|Placebo Group|OnQ pump with placebo (normal saline at 2ml/hr) and pain medications.
89515430|NCT03514823|Experimental|IMT Group|
89515431|NCT03514823|Sham Comparator|No IMT Group|
89544194|NCT03193463|Experimental|Predominantly enhancing mass with volume of 8 cc or less|Only 1 Cleveland Multiport Catheter (CMC) will be placed and CED will be performed intra-operatively only in a magnetic resonance imaging (MRI) equipped Operating Room. Topotecan infusion will be performed over a 4-hour period, with the goal of complete tumor coverage. The initial rate will be 1.20 ml/hour and infusion will be monitored by intermittent MRI imaging. The rate may be adjusted upwards during the infusion, in the event of incomplete tumor coverage, or downwards, if new mass effect is apparent. Following completion of the 4-hour infusion, the CMC will be removed. The initial rate for each subsequent patient may be adjusted upwards in increments of up to 1.20 ml/hour based upon the tumor coverage and safety characteristics of the previously treated patients.
89544195|NCT03193463|Experimental|Predominantly enhancing mass with volume of > 8 cc|2 Cleveland Multiport Catheter (CMCs) will be placed and the total infusion rate of Topotecan per CMC to be used for the first 24 hours for the first patient will be 0.834 ml/hour (3.48 microliters/minute/microcatheter). The rate used for the second 24 hours of the infusion will be 1.668 ml/hour. If the first patient does not experience rate-limiting toxicity, then the patient #2's initial infusion rate will start at the highest tolerated rate for patient #1, and the second 24-hour rate for that patient will be increased by 0.834 ml/hour. Each subsequent patient will undergo rate escalation in a similar manner until we observe either: 1) complete coverage of the enhancing tumor by the infused Gadopentetic acid (Gd-DTPA), or 2) rate-limiting toxicity.
89544196|NCT03193463|Experimental|Predominantly non-enhancing mass|The total infusion rate of Topotecan per Cleveland Multiport Catheter (CMC) to be used for the first 24 hours for the first patient will be 0.29 ml/hour. The rate used for the second 24 hours of the infusion will be 0.58 ml/hour. If the first patient does not experience rate-limiting toxicity, then the patient #2's initial infusion rate will start at the highest tolerated rate for patient #1, and the second 24-hour rate for that patient will be increased by 0.29 ml/hour. Each subsequent patient will undergo rate escalation in a similar manner until we observe either: 1) complete coverage of the non-enhancing tumor by the infused Gd-DTPA, or 2) rate-limiting toxicity.
89544197|NCT02444273|No Intervention|Control Group|Subjects will receive standard care both pre and post transplant.
89544198|NCT02444273|Experimental|Exercise Group|Subjects will receive a personalized home exercise program and regular phone calls from a therapist to monitor and promote activity.
89544199|NCT02577003|Experimental|Ipragliflozin + Sitagliptin|Ipragliflozin once daily for 24 weeks in addition to sitagliptin, diet, and exercise.
89544200|NCT02577003|Active Comparator|Placebo + Sitagliptin|Placebo to ipragliflozin once daily for 24 weeks in addition to sitagliptin, diet, and exercise.
89544201|NCT03193229|Experimental|MapTrek|Patients in the intervention group receive a Fitbit and MapTrek, an interactive text-messaging platform. The only equipment needed is a Fitbit (we provide) and a smartphone (required prior to enrollment). Each week, patients are assigned to a virtual walking route. Each day, they receive a text message with a link to the current route. The link will take them to a map where they can see their progress and the progress of others. A leaderboard provides information on how many steps each participant has taken. MapTrek also supports Street View on Google Maps, so patients can explore what they would see if they were in that location. Throughout each race, patients will randomly receive challenge text messages. Completing a challenge awards bonus steps to propel their character along the map.
89544202|NCT03193229|Active Comparator|Fitbit Only|Patients randomized to the control group will receive a Fitbit only. This will allow us to determine if changes in physical activity are due to MapTrek or simply by giving the patients a Fitbit.
89544203|NCT05487417|Experimental|Minocycline treatment group|Patients were given minocycline 200mg/d orally from the day of admission for 5 days. At the same time, the patient received mechanical thrombectomy and other standard treatments for acute ischemic stroke.
89544204|NCT05487417|No Intervention|Routine treatment group|Patients were given mechanical thrombectomy and other standard treatment for acute ischemic stroke, without minocycline treatment.
89544205|NCT03471611|Experimental|Subjects with Endothelial Dysfunction|Subjects will be treated with Granulocyte Colony-Stimulating Factor (G-CSF) for 5 days at a dose of 5 mg/kg twice daily. When count of CD34+ cells is sufficient, the CD34+ cells will be collected by apheresis. Autologous CD34+ cells will be injected into the subjects at a rate of 10 ml/min.
89544206|NCT03281057|Experimental|Individual CRAFT|Individual CRAFT is offered to 135 participants and each participants are going to get 6 sessions.
89544207|NCT03281057|Experimental|Group CRAFT|Open group CRAFT is offered to 135 participants in 6 sessions.
89544208|NCT03281057|Experimental|Self-help materials|Self-help materials (control group) are going to be offered a self-help book, because it is unethically not to offer any intervention, as the CRAFT intervention in early studies have shown to be very effectful
89544209|NCT03192917|Experimental|Active treatment|This group of participant will receive low intensity shock wave treatment accounted on their penile shaft once every week for 5 weeks.
89544210|NCT03192917|Placebo Comparator|Placebo group|this group of participant will meet up for treatment. The treatment given will be the exact same as the active group, but the transducer used for shock wave treat will me capped, meaning that no shock waves are transmitted to their penis.
89544211|NCT03200327|Active Comparator|laparoscopic promontofixation|
89544212|NCT03200327|Experimental|Anterior vaginal sacrospinofixation|
89544213|NCT03192839|Experimental|Low dose PUFA|
89544214|NCT03192839|Experimental|High dose PUFA|
89544215|NCT03192839|Placebo Comparator|Placebo|
88961311|NCT02008058||Single Arm|Surveys, diaries, clinical assessments of men with metastatic castrate-resistant prostate cancer
88961312|NCT02008071|Experimental|Daily step goal financial incentive|
88961313|NCT02008071|Active Comparator|Control, Standard of Care|
88961314|NCT02008084|Sham Comparator|TRIA-662 single-blind baseline|Baseline, 6 to 8-week, dietary lead-in period
88961315|NCT02008084|Experimental|TRIA-662|Following successful completion of the Baseline randomized to active drug
88961316|NCT02008084|Placebo Comparator|Placebo|Following successful completion of the Baseline randomized to placebo drug
88961317|NCT02008097|Experimental|Liver transplant without a stent|Liver Transplant patients without a stent who are referred for liver ultrasound will have will have a B-Flow ultrasound exam using the GE LOGIQ E9 Ultrasound System .
89544216|NCT05174741|Active Comparator|Conventional Chest Physiotherapy|Diaphragmatic Breathing exercise 15 repetition ACBT *3 sets/session*TD Walk (10-15 minutes) * BD
89544217|NCT05174741|Experimental|Aerobic Training group|"Supervised Conventional chest physiotherapy+ Aerobic training Conventional chest physiotherapy supervised (1st week) Then non supervised for 2nd to 6th week Warm-up (5 minutes) Breathing exercise and stepping Diaphragmatic Breathing exercise *15 Reps* TD~Aerobic training on cycle ergometer:~between 50% and 70% Vo2max, perceived exertion up to 11 on Borg scale 20-30 min/session/day Cool down (5 minutes) AROM +Body stretch"
89544218|NCT03098693||Sero-discordant Couple Cohort|We will enroll and track a cohort of 60 serodiscordant couples (120 individuals). The HIV-positive couple members will be offered anti-retroviral therapy (ART) and the HIV-negative couple members will be offered pre-exposure prophylaxis (PrEP). We will monitor monthly clinic visits for the couple and will conduct in-depth behavioral surveys at baseline, 6-, 12-, and 18-months.
89544219|NCT04484129||Close contacts of MDR-TB patients|"Close contacts of MDR-TB who met the inclusion and exclusion criteria were enrolled. Routine follow-up is scheduled at week 8, 20, 32, and 80. During the visit, participants with suspected tuberculosis symptoms will have detailed clincial assessent, weight measurement, sputum smear, sputum culture and drug sensitivity examination, imaging examinations, etc. For patients diagnosed with TB, the trial ends. Proper treatment will be started. For all paricipants who are not diagnosed with tuebrculosis in previous follow-up, the last follow-up of this study is all face-to-face visits. Sputum smear, sputum culture and chest imaging screening will be performed when necessary to exclude the possibility of tuberculosis infection. In addition, If the participants has suspected TB symptoms or is diagnosed with TB in another hospital, the researchers can be contacted for follow-up at any time."
89544220|NCT02866487||Asthmatics|"0-5 years of age: Intermittent cough, wheeze, chest symptoms AND one or more of the following: Eczema Eosinophilia Elevated total IgE Positive family history~6-17 years of age: Physician diagnosis Current treatment with one or more asthma medications Recurrent episodes of cough, wheeze, chest discomfort, pain"
89544221|NCT02866487||Age-Similar Non-asthmatic Controls|Age-similar controls will undergo diagnostic bronchoscopy for clinical indications in the absence of known asthma, including recurrent pneumonia, congenital lung anomalies, prolonged cough, suspected laryngeal abnormalities, and suspected aspiration syndromes. Inclusion in the final set to be determined post-procedure based on BAL granulocyte profiles. To be included as a control, participants must have pauci-granular BAL counts (less than 2 percent eosinophils and less than 4 percent PMN), no positive allergen sensitization, and no positive viral or bacterial studies from analysis of BAL fluid.
89544222|NCT05470335|No Intervention|physician insertion|radial sheath insertion is performed by physicians
89544223|NCT05470335|Experimental|nurse insertion|radial sheath insertion is performed by nurses
89544224|NCT05674305|Experimental|Radiotherapy alone|Patients with undectable plazma EBV DNA after first cycle neoadjuvant chemotherapy using GP regimen (gemcitabine 1000mg/m2 d1,8+ cisplatin 25mg/m2 d1-3) and without rebound during the course of second and third cycle received definitive radiotherapy to head and neck region.
89544225|NCT05674305|Active Comparator|Concurrent chemoradiotherapy|Patients with undectable plazma EBV DNA after first cycle neoadjuvant chemotherapy using GP regimen (gemcitabine 1000mg/m2 d1,8+ cisplatin 25mg/m2 d1-3) and without rebound during the course of second and third cycle received definitive radiotherapy to head and neck region plus two cycles of concurent chemotherapy （cisplatin 80mg/m2）
89544226|NCT02443649|Experimental|Sleep hypnosis plus sleep hygiene|Those randomized into this group will receive the sleep hygiene program plus hypnosis.
89544227|NCT02443649|Active Comparator|Sleep hygiene only|Those randomized into this group will receive the Optimizing Sleep Hygiene program during the intervention visit and hypnosis recording after the follow-up visit.
89544228|NCT03192449|Experimental|Albendazole 400mg p.o. single dose|Volunteers receive 1 tablet albendazole 400mg (GSK) fasting.
89544229|NCT05666973|Active Comparator|Group 1: Scalpel|"Skin Incision for inguinal hernia repair will be given by Stainless steel blade no.10.~Open Mesh Hernioplasty"
89544230|NCT05666973|Experimental|Group 2 : Electrocautery|"Open Mesh Hernioplasty~Skin Incision for inguinal hernia repair will be given by following:~Cautery machine: Erbe VIO 300 S~Cut setting: Cut:30 Coagulate:30~Cautery tip (tip pointed)~Mode: Monopolar"
89544231|NCT04308057||Aquatic Exercise|General inclusion criteria included being over 55 years of age and normotensive (e.g., <140/90 mm Hg). Specifically for this group, we include participants engaging in swimming or other aquatic, primarily aerobic-based, training regimes for more than 2 times a week, for more than 6 months, at the time of the assessments.
89544232|NCT04308057||Land-based exercise|General inclusion criteria included being over 55 years of age and normotensive (e.g., <140/90 mm Hg). Specifically for this group, we include participants engaging in land-based, primarily aerobic training regimes (e.g. aerobic exercise) for more than 2 times a week, for a period longer than 6 months, at the time of the assessments.
89544233|NCT04308057||Mixed exercise|General inclusion criteria included being over 55 years of age and normotensive (e.g., <140/90 mm Hg). Specifically for this group, we include participants engaging in both land-based and aquatic, primarily aerobic, exercise regimes on an equal basis, for more than 6 months.
89544234|NCT04308057||Sedentary.|General inclusion criteria included being over 55 years of age and normotensive (e.g., <140/90 mm Hg). Specifically for this group, we include participants who are sedentary (e.g., defined as undertaking less than 60 min of structured/planned physical activity per week), for a period longer than 6 months.
89544235|NCT02443415||Healthy Controls|Non-diabetic subjects
89544236|NCT02443415||Diabetics without DKA|Diabetic subjects (recent(< 1 year) diagnosis of diabetes) without a history of diabetic ketoacidosis (DKA)
89544237|NCT02443415||First episode of DKA|Diabetic subjects that just had their primary event of diabetic ketoacidosis (DKA)
89544238|NCT02443415||Three or more DKA episodes|Diabetic subjects who have had three or more diabetic ketoacidosis (DKA) episodes
89544239|NCT02443259||late preterms from pre eclamptic mothers|late preterms born to pre eclamptic mothers
89544240|NCT02443259||late preterms|late preterm neonates
89544241|NCT05691933|Active Comparator|Block group|Patients will be subjected to bilateral external oblique intercostal plane block
89544242|NCT05691933|Active Comparator|Opioid group|Patients will be subjected to morphine infusion at a rate of 0.03mg/kg/h
89544243|NCT02443493|Experimental|Treatment group|Treatment group (receives low-level laser therapy (2x/week) in combination with standard skin care starting from day 1 of radiotherapy)
89544244|NCT02443493|Sham Comparator|Control group|Control group (receives sham laser (2x/week) in combination with standard skin care starting from day 1 of radiotherapy)
89544245|NCT00977483|Experimental|Drug: Thioctic Acid|600mg tablet Thioctic Acid (alpha-lipoic acid) once daily throughout the trial
89544246|NCT00977483|Placebo Comparator|Drug: Placebo|1 tablet once daily throughout the trial
89544247|NCT02439905|Experimental|Dexmedetomidine group|
89544248|NCT02439905|Placebo Comparator|Normal saline group|
89544249|NCT03190421|Experimental|Expanded Urinary Culture (EQUC)|Participants in this arm will receive the expanded urine culture
89544250|NCT03190421|Active Comparator|Standard Urine Culture (SUC)|Participants in this arm will receive the standard urine culture
89544251|NCT03192371|Experimental|Zagreb 2-1-1 Group|4 doses of Rabipur vaccine, administered intramuscularly according to the Zagreb (2-1-1) regimen (i.e., 2 doses of vaccine administered on Day 1 and 1 dose of vaccine administered on Days 8 and 22).
89544252|NCT03192371|Experimental|Essen 1-1-1-1-1 Group|5 doses of Rabipur vaccine, administered intramuscularly according to the Essen (1-1-1-1-1) regimen (i.e., 1 dose of vaccine administered on Days 1, 4, 8, 15, and 29).
89544253|NCT02439983|Placebo Comparator|Placebo|
89544254|NCT02439983|Experimental|Proprietary Nutritional Supplement|
89544255|NCT02446899|Experimental|Anifrolumab|Anifrolumab 300 mg intravenous infusion (IV) administered every 4 weeks for a total of 13 doses.
89544256|NCT02446899|Placebo Comparator|Placebo|Placebo intravenous infusion (IV) administered every 4 weeks for a total of 13 doses.
89544257|NCT02709785|Experimental|Group 1 SmartMouth|24 subjects with plaque and gingival inflammation
89544258|NCT02709785|Experimental|Group 2 Chlorhexidine|28 subjects with plaque and gingival inflammation
89544259|NCT02709785|Placebo Comparator|Group 3 Placebo|28 subjects with plaque and gingival inflammation
89544260|NCT02440061|Active Comparator|Study Group: Type 2 Diabetes Mellitus (T2DM)|Subjects with Type 2 Diabetes Mellitus (T2DM). Subjects will receive AG and saline infusions, but the order of which they receive will be random and they will not be told which one they are receiving on each given visit. Arginine will be used at both study visits.
89544261|NCT02440061|Active Comparator|Control Group|Control group of healthy subjects. Subjects will receive AG and saline, but the order of which they receive will be random and they will not be told which one they are receiving on each given visit. Arginine will be used at both study visits.
89544262|NCT02439827|Experimental|"Fortaleça sua Saúde program"|The intervention program was structured into four main components: (i) training and activities in general curriculum; (ii) training and activities in Physical Education classes; (iii) active opportunities in the school environment; (iv) health education in school community.
89544263|NCT02439827|No Intervention|Control|Schools from the control group carried out one semester with the regular and conventional activities of a full-time school. In general, the control schools had two weekly Physical Education classes that include content and activities according to the perspective of their teachers. The conventional Programa Saúde na Escola were also performed in these schools.
89544264|NCT02442947|Experimental|Research arm|"1 day which will include: physician examination,ECG,anthropometric measurements and Vo2max test.~6 acclimatization days carried out by a standard protocol including a daily 2 hour effort performed in a climatic chamber, which include walk on a treadmill at 5 Km/h on a 2% incline under heat conditions (40 deg. centigrade & 40% HR) and when dressed in shorts.At the sixth day, the subjects will be dressed in a standard work uniform as a baseline exposure. Core (rectal) and skin temperature and heart rate will be monitored continuously.~4 experiment days carried out by the following protocol: 2 hour walk on a treadmill (5 Km/h,2% incline) under heavy heat stress conditions (30 deg. centigrade,60% RH) and when dressed each time with different clothing out of 4 options:~NBC protective garment (charcoal base).~combat garment.~2 different types of work uniforms. physiological stress will be examined based on rectal temperature and heart rate measurements."
89544265|NCT02443025|Experimental|Intervention|Classes receive anti-tobacco presentations from Teens Against Tobacco Use members
89544266|NCT02443025|No Intervention|Wait list control|Classes continue as usual without receiving anti-tobacco presentations from Teens Against Tobacco Use members until the end of the year, when data collection is complete.
89544267|NCT05632341|Experimental|GCWB1176|1 capsule once a day
89544268|NCT05632341|Active Comparator|Placebo|1 capsule once a day
89544269|NCT02439671|Experimental|Immediate intervention|Participant assigned to McGill Transition Support Program in next available session
89544270|NCT02439671|No Intervention|Waiting List control|Participant assigned to waiting list for one session prior to receiving McGill Transition Support Program in following session
89544271|NCT02442791|Experimental|GLP-1|"Half of the participants will receive the study drug, that will be given as follows:~250 mL isotonic sodium chloride added 1.5 mL of 20% Human Albumin added 25 microg Byetta (Lilly, Exenatide).~The study drug infusion is initiated as soon as possible at rate of 72ml/hour (0.12 μg/min) for 15 min (set volume at 18 ml), followed by 26ml/hour (0.043 μg/min) to be continued for 6 hours (set volume at 156 ml). This concludes the pharmacological intervention."
89025023|NCT00441038|Active Comparator|2|Education on active management and handout of The Back Book
89025024|NCT00441038|Active Comparator|3|Education on cardiovascular and general health
89025025|NCT00438867|Experimental|1|
89025026|NCT00438867|Experimental|2|
89025027|NCT00438867|Placebo Comparator|3|
89025028|NCT00441155|Experimental|Monotherapy: AMN107|initial dose of imatinib (dose level 1) was 400 mg bid was administered orally on a continuous daily schedule and was not escalated during the study
89025029|NCT00441155|Active Comparator|Combination Therapy: AMN107 + Imatinib|six possible doses of Nilotinib (100 mg once daily (qd), 200 mg qd, 400 mg qd, 200 mg bid, 300 mg bid, and 400 mg bid). four possible doses of Imatinib (0 mg, 400 mg qd, 600 mg qd, and 400 mg bid).the initial dose of nilotinib (dose level 1) was 200 mg qd and could have been escalated up to 400 mg bid
89025030|NCT00106002|Experimental|A|
89025031|NCT00476853|Active Comparator|1|NVP 400 mg
89025032|NCT00476853|Active Comparator|2|NVP 600 mg
89515432|NCT02972853|Experimental|Mindfulness Training for Primary Care|"For intervention description see Mindfulness Training for Primary Care (MTPC) in the study MINDFUL-PC: Integrating Mindfulness Into the Patient-Centered Medical Home - A Pilot Study. For the Mindfulness Training for Primary Care (MTPC) fMRI - arm, we acquire pre-/post-intervention neuroimaging measures from subjects enrolled in this additional pilot fMRI study."
89515433|NCT03513809||Acute hypoxemic respiratory failure|Patients with acute hypoxemic respiratory failure breathing spontaneously with no requirements of immediate intubation connected to thoracic electrical impedance tomography.
89515434|NCT04931888|Experimental|Intervention|The intervention arm will receive the EMPOWER curriculum between the pre- and post-evaluations.
89515435|NCT04931888|Other|Waitlist|"The waitlist control arm will receive the EMPOWER curriculum after the evaluations. They will receive a second set of evaluations at the same time as the post evaluations of the control arm."
89515436|NCT02302313|Other|painful stimuli|"No drug and no placebo will be used in this study. The study participants will only rate their pain on a numerical scale (EN) following cutaneous painful stimulation (6 for each phase) of variable intensity, delivered by a CO2 laser. ANI (Analgesia Nociception Index) will be raised simultaneously by the ANI monitor. This sequence will be performed on subjects at rest and in a state of hypnosis by the technique of remembering a pleasant memory and the ideo-sensory technique of protective glove."
89515437|NCT03435315|Active Comparator|Treadmill exercise|
89515438|NCT03435315|Experimental|Treadmill exercise with behavioral techniques|
89515439|NCT02299271|Active Comparator|ropivacaine block|Ropivacaine 0.375% as a one-time 60 milliliter injection.
89515440|NCT02299271|Placebo Comparator|saline block|Sodium chloride 0.9% as a one-time 60 milliliter injection.
89515441|NCT02302391||Midazolam/fentanyl: PK analysis|Pediatric intensive care patients under analgosedation with midazolam and fentanyl.
89025033|NCT00441311|Experimental|Academic Detailing|The academic detailing intervention will involve multiple components some of which are standardized across physicians (i.e. self-learning packets, newsletters). Detailing will also be customized to each physician, although the frequency of the detailing visits will be routinized across all participants to reduce cost and to maximize its potential for dissemination.
89515442|NCT02302469|Other|revlimid|a dose-escalation of revlimid
89515443|NCT02664597|Sham Comparator|Standard strategy|In control group, the complex adnexal mass will be managed according to the standard strategy and treatment plan routinely used by the multidisciplinary team.
89515444|NCT02664597|Experimental|ADNEXMR SCORING|In the intervention group, patients will undergo a pelvic MR imaging as routinely performed, including morphological sequences and functional sequences. Prospectively, the radiologist will classify the mass using ADNEXMR SCORING system and the patient will be managed according to the score.
89515445|NCT02302547|Active Comparator|triple therapy|Tenofovir Disoproxil Fumarate (nucleotide reverse transcriptase inhibitor) + Emtricitabine (nucleoside reverse transcriptase inhibitor) + third agent (boosted protease inhibitor or unboosted protease inhibitor or integrase inhibitor or celsentri or non-nucleoside reverse transcriptase inhibitor).
89515446|NCT02302547|Experimental|dual therapy|"Truvada®245mg:oral administration Tenofovir Disoproxil Fumarate (nucleotide reverse transcriptase inhibitor) + Emtricitabine (nucleoside reverse transcriptase inhibitor)"
89515447|NCT03515369|Experimental|Hepatectomy plus Babaodan|Surgical removal of all lesions and take Babaodan oral capsule after operation
89515448|NCT03515369|Placebo Comparator|Hepatectomy plus Placebo|Surgical removal of all lesions and take Placebo oral capsule after operation
89515449|NCT02634411|Experimental|8 days of effective antibiotic treatment|Antibiotic treatment should be started just after realization of bacteriological sampling, and then converted into a narrow-spectrum therapy, based on culture results, for a total duration of effective antibiotic therapy against PA of 8 days.
89025034|NCT00441311|No Intervention|Service-as-Usual|Control Arm
89025035|NCT00476892|Other|1|"It consists of five outpatient appointments (weeks 0, 2, 6, 11 and 16) with a local trial physiotherapist at a trial centre. At the first appointment a standardised history is taken from the woman, anatomy and function of the pelvic floor muscles are taught, and types of prolapse described, using diagrams and a model pelvis. Women are taught how to contract the muscles, and also how to contract and hold prior to an event that increases intra-abdominal pressure (the Knack). Pelvic floor muscles are assessed by vaginal examination and recorded on a dedicated form at each appointment thus determining the content of a single set of exercises for each woman. At least three sets of exercises daily is recommended. Women use an exercise diary to record compliance. Tailored advice is given on ways of reducing intra-abdominal pressure, e.g. advice on weight loss, chronic cough, heavy lifting and general exercise."
89025036|NCT00476892|No Intervention|2|Women allocated to the control group will be sent a lifestyle advice leaflet only, and will have no planned contact with the centre until their consultant review appointment at six months. The leaflet gives instructions on seeking advice where appropriate about weight loss, constipation, and avoidance of heavy lifting, coughing and high impact exercise, with a view to minimising increases in intra-abdominal pressure which may cause prolapse to worsen.
89515450|NCT02634411|Sham Comparator|15 days of effective antibiotic treatment|Antibiotic treatment should be started just after realization of bacteriological sampling, and then converted into a narrow-spectrum therapy, based on culture results, for a total duration of effective antibiotic therapy against PA of 15 days.
89515451|NCT03513575|Active Comparator|Group 1: no intervention|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva. The subject is then given 100 ml of test flavored milk drink, Amul Kool® milk, (Gujarat Cooperative Milk Marketing Federation Ltd.) to drink. The subject will sip, swish and swallow the drink within 2 minutes.~Unstimulated saliva samples are collected from the subject to measure the pH of saliva after 5, 15, 30, 45 and 60 minutes of consumption of the test flavored milk drink."
89515452|NCT03513575|Experimental|Group 2: tap water gargle|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva. The subject is then given 100 ml of test flavored milk drink, Amul Kool® milk, (Gujarat Cooperative Milk Marketing Federation Ltd.) to drink. The subject will sip, swish and swallow the drink within 2 minutes.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test flavored milk drink.~The subject will use 10 ml of tap water as mouth rinse to swish for 60 seconds and spit. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention."
89515453|NCT03513575|Experimental|Group 3: 0.2% chlorhexidine|"The subject collects unstimulated saliva in a sterile glass dish for measurement of baseline pH of saliva. The subject is then given 100ml of test flavored milk drink, Amul Kool® milk, (Gujarat Cooperative Milk Marketing Federation Ltd.) to drink. The subject will sip, swish and swallow the drink within 2 minutes.Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test flavored milk drink.~The subject will use 10 ml of 0.2% Chlorhexidine mouthrinse (Rexidine®, Indoco Remidies Ltd, Mumbai, India) to swish for 60 seconds and spit. Unstimulated saliva samples are collected thereafter to measure and record the pH of saliva at 15, 30 and 45 minutes after subject completes the gargle as an intervention."
89515454|NCT03513575|Experimental|Group 4: fluoridated tooth paste|"The subject collects unstimulated saliva in a sterile glass dish for measurement of baseline pH of saliva. The subject is then given 100 ml of test flavored milk drink, Amul Kool® milk, (Gujarat Cooperative Milk Marketing Federation Ltd.) to drink. The subject will sip, swish and swallow the drink within 2 minutes. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test flavored milk drink.~The subject will brush with fluoridated toothpaste (Colgate Total®, Colgate-Palmolive Co., Mumbai, India) for 2 minutes using soft brush. Unstimulated saliva samples are collected thereafter to measure and record the pH of saliva at 15, 30 and 45 minutes after subject completes the brushing as an intervention."
89515455|NCT03513575|Experimental|Group 5: Polyol containing gum|"The subject collects unstimulated saliva in a sterile glass dish for the measurement of baseline pH of saliva. The subject is then given 100 ml of test flavored milk drink, Amul Kool® milk, (Gujarat Cooperative Milk Marketing Federation Ltd.) to drink. The subject will sip, swish and swallow the drink within 2 minutes. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test flavored milk drink.~The subject will chew polyol containing gum (Orbit®, Wrigley Company) for 5 minutes and spit. Unstimulated saliva samples are thereafter collected from to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the chewing gum as an intervention."
89515456|NCT03513575|Experimental|Group 6: 1% sodium bicarbonate solution|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva. The subject is then given 100 ml of test flavored milk drink, Amul Kool® milk, (Gujarat Cooperative Milk Marketing Federation Ltd.) to drink. The subject will sip, swish and swallow the drink within 2 minutes.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test flavored milk drink.~The subject will use 10 ml freshly prepared 1% sodium bicarbonate w/v solution to swish for 60 seconds and spit.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention."
89515457|NCT02302625|Experimental|Cognitive behavior therapy|Cognitive behavior therapy based on exposure and response prevention. The treatment also incorporates mindfulness training as a means to increasing tolerance for aversive thoughts and emotions associated with AD. The treatment is delivered by a licensed psychologist and comprises 10 individual weekly sessions.
89515458|NCT03334461|Experimental|high concentration enamel remineralisation agent|first month brushing teeth three times per day: twice per day with high-fluorides gel (Mirafluor K gel cola 6150 ppm F pH 5.1) and once per day without toothpaste and fluoride gel next two months brushing teeth three times per day with toothpaste containing low concentration of fluorides (1450 ppm)
89515459|NCT03334461|Experimental|oral antiseptic|first month brushing teeth without toothpaste three times per day and using oral antiseptic chlorhexidine mouthwash (Curasept ADS 212 a 200ml 0,12%) twice per day next two months brushing teeth three times per day with toothpaste containing low concentration of fluorides (1450 ppm)
89515460|NCT03334461|No Intervention|Control|regular oral hygiene without exposure to oral antiseptic or high concentration enamel remineralisation agent three months brushing teeth three times per day with toothpaste containing low concentration of fluorides (1450 ppm)
89515461|NCT02302703|Active Comparator|the low FODMAP diet|
89515462|NCT02302703|Active Comparator|Gluten free diet|
89515463|NCT03513419|Experimental|AMOR Method|The AMOR Method: The parent resilience training involves a series of eight weekly 90-minute group sessions, as well as three individual sessions. Group session content includes training in mindfulness, grief and loss processing, acceptance and committed actions, optimistic thinking, and resilience through the use of didactic training, group discussions, and homework assignments. Individual session content will center on additional and individualized training in grief and loss processing, optimistic thinking, and maintaining resilience over time.
89515464|NCT03513419|No Intervention|Wait List|Participants assigned to the waitlist will continue stable treatments and will be offered the opportunity to participate in the treatment after completion of the 8-week trial.
89515465|NCT04542525|Experimental|PanOptix Toric Trifocal IOL|ACRYSOF IQ PanOptix Toric Trifocal IOL Model TFNT20 implanted in the capsular bag in the posterior chamber following cataract surgery. At least one eye will be implanted.
89515466|NCT03513341||Maastricht University First Year Students|Maastricht University 2017-2018 undergraduate first year students are invited to participate in the study. The participants are invited to complete a demographics questionnaire, wear an ActivPAL accelerometer for 7 days, and to complete daily diaries (modified International Physical Activity Questionnaire) for 7 days.
89515467|NCT02582619||Rehabilitation Professionals|Focus group consisting of rehabilitation professionals that will inform the study on vocational rehabilitation interventions rendered during acute to in-patient rehabilitation in KwaZulu-Natal.
89515468|NCT02582619||People living with Spinal Cord Injuries (PLWSCI)|"Focus group consisting of PLWSCI that will inform the study on the perspective of the patient on vocational rehabilitation needs or desires during acute care and in-patient rehabilitation.~This group will inform the study on the employment rate amongst people living with spinal cord injuries as well as factors that influence employment.~This group will also inform the study on the perceived barriers and facilitators of employment"
89515469|NCT02582619||Stakeholders|"Representatives from the following departments or organisations will be invited to participate in the interviews and focus groups:~Government Departments:~Education Social Development Health Labour Transport~Private Companies:~Insurance Companies and Health Risk Management companies Non-profit Organisations QASA DPSA"
89515470|NCT02582619||Experts|A delphi technique will be used to get an expert opinion and consensus on the aspects of the model to be developed.
89515471|NCT02302781||Subfertile couples|Couples referred to one of the four participating hospitals with any type of subfertility for work up and/ or treatment will be screened for inclusion. Couples have not visited only other clinic yet.
89515472|NCT02302937|Active Comparator|group A: Standard TEP|Group A will undergo laparoscopic TEP inguinal hernia repair with 3 ports (10 mm , and 2 ports of 5 mm ).
89515473|NCT02302937|Active Comparator|Group B: LESS Port|Group B will undergo laparoscopic TEP inguinal hernia repair with a single port (12 to 15 mm transumbilical).
89515474|NCT04464551|Experimental|[14C]D-0316|To investigate the absorption properties, as well as to evaluate the mass balance and elucidate the pathways of biotransformation after a single oral dose (75mg, 50µCi) of [14C]D-0316 to healthy Chinese male subjects
89515475|NCT02299583|Experimental|Preventive intervention|In this arm HCPs will conduct a trauma-informed early intervention with children and families after exposure to potentially traumatic events (PTE).
89515476|NCT02299583|No Intervention|Control group|There will be no intervention in this arm. The outcome will show the efficiency of usual care.
89515477|NCT03252093|Experimental|Angiotensin-(1-7)|Intervention: Drug: 200 mcg/kg/day injected subcutaneously once daily for 21 days
89515478|NCT03252093|Placebo Comparator|Placebo for Angiotensin-(1-7)|Intervention: Placebo for Angiotensin-(1-7) injected subcutaneously once daily for 21 days
89515479|NCT02299661|Experimental|7.5mg DS-1093a|DS-1093a, single oral dose of 7.5 mg
89515480|NCT02299661|Experimental|25mg DS-1093a|DS-1093a, single oral dose of 25 mg
89515481|NCT02299661|Experimental|50mg DS-1093a|DS-1093a, single oral dose of 50 mg
89515482|NCT03510767|Experimental|TQ-B3525|
89515483|NCT02436356|Active Comparator|Distal Radius Fracture Operative Group|Fracture group patients will undergo DXA and MRI scans, along with Osteoprobe indentation.
89515484|NCT02436356|Active Comparator|Healthy Volunteers (Non Fracture Group)|Healthy volunteers will undergo DXA and MRI scans.
89515485|NCT02436356|Active Comparator|Distal Radius Fracture Non-operative Group|Fracture group patients will undergo DXA and MRI scans, but will not undergo Osteoprobe indentation.
89515486|NCT03510611|Experimental|Period 1: fed control → Period 2: fasted control|Period 1: administration of Ensartinib 225mg at 7:30am, 30 minutes after the breakfast；Period 2: administration of Ensartinib 225mg at 7:30am, without the breakfast
89515487|NCT03510611|Experimental|Period 1: fasted control → Period 2: fed control|Period 1: administration of Ensartinib 225mg at 7:30am, without the breakfast；Period 2: administration of Ensartinib 225mg at 7:30am, 30 minutes after the breakfast
89515488|NCT02436200|Experimental|Intervention|Patients receiving neuromuscular electrical stimulation.
89515489|NCT02299817|Active Comparator|Denosumab|Patients will receive a dose of 60 mg denosumab (1 ml solution) for a total of 6 doses with start on day one and every 6 months with last treatment at 30 months.
89515490|NCT02299817|Placebo Comparator|Placebo|Patients will receive a dose of placebo (1 ml solution) for a total of 6 doses with start on day one and every 6 months with last treatment at 30 months.
89515491|NCT01679613|Experimental|1 Nintedanib (Reference)|single dose, oral with 240 ml water
89515492|NCT01679613|Experimental|2 Nintedanib + Ketoconazole (Test)|Nintedanib single dose, Ketoconazole steady state, oral with 240 ml water
89515493|NCT01679613|Experimental|3 Nintedanib (Reference)|single dose, oral with 240 ml water
89515494|NCT01679613|Experimental|4 Nintedanib + Ketoconazole (Test)|Nintedanib single dose, Ketoconazole steady state, oral with 240 ml water
89515495|NCT02489630|Experimental|Ketamine|0.1 mg/kg ketamine + opiate analgesic
89025037|NCT00438984|Experimental|Treatment (chemotherapy, immunosuppressive, lymphocytes)|"All patients receive high-dose cyclophosphamide IV on days -3 and -2 and autologous antigen-specific cytotoxic CD8+ T-lymphocyte clones IV over 30-60 minutes on day 0.~COHORT I: Beginning within 6 hours of T cell infusion, patients receive low-dose aldesleukin SC twice daily on days 0-14.~COHORT II: Beginning within 6 hours of T cell infusion, patients receive high-dose aldesleukin IV 3 times daily on days 0-5."
89515496|NCT02489630|Placebo Comparator|Placebo|0.1 mL/kg normal saline + opiate analgesic
89025038|NCT04700852|Experimental|allergic rhinitis|Puressentiel protective nasal spray
89025039|NCT00476970|Experimental|Patient Navigation Intervention|Participants randomized to this arm will receive language-concordant patient navigation in the form of an introductory letter with educational material followed by phone or in-person contact to provide individually tailored interventions.
89515497|NCT03513263|Active Comparator|Scaling and polishing plus oral hygiene instruction|This arm will contain RA participants with PD who will continue with their treatment for RA and also receive the intervention of scaling and polishing plus oral hygiene instructions
89515498|NCT03513263|Sham Comparator|only oral hygiene instructions|This arm will contain rheumatoid arthritis (RA) participants with periodontitis who will continue with their treatment for (RA) and also receive only oral hygiene instructions
89515499|NCT03138213|Experimental|TLPD|Ttotal laparoscopic pancreaticoduodenectomy
89515500|NCT03138213|Experimental|OPD|Open pancreaticoduodenectomy
89515501|NCT02739347|Experimental|Active Stimulation|Active stimulation group will receive 20 min of 2 mA direct current stimulation.
89515502|NCT02739347|Sham Comparator|Sham Stimulation|This will be an active sham involving brief (15 msec) low current (0.11 mA) pulses every 550 ms.
89515503|NCT05089773||group 1|The only group in this retrospective study includes patients diagnosed with transposition of the great arteries receiving arterial switch operation in children's hospital of fudan university and shanghai children's medical center.
89515504|NCT02435966|Experimental|Manual therapy + Dry needling|Manual therapy + Dry needling: 2 sessions, after a 7 days interval
89515505|NCT02435966|Other|Manual therapy + Sham Dry needling|Manual therapy + Sham Dry needling: after a 7 days interval
89515506|NCT02435966|No Intervention|Untreated control|Natural history of the condition
89515507|NCT00590265|Experimental|1|
89515508|NCT00590265|Placebo Comparator|2|
89515509|NCT05089539|Experimental|HFpEF with ARNI treatment|Sacubitril/valsartan (ARNI, 100mg bid)
89515510|NCT05089539|Placebo Comparator|Control group|placebo (100mg bid)
89515511|NCT02299973|Placebo Comparator|Placebo group (FMT with own stool)|Fecal microbiota transplantation with patient's own stool
89515512|NCT02299973|Experimental|Treatment group (FMT with donor stool)|Fecal microbiota transplantation with healthy donor stool
89515513|NCT05089383||combined progesterone group|patients will receive vaginal plus subcutaneous or per os progesterone
89515514|NCT05089383||Vaginal progesterone group|patients will receive vaginal progesterone
89515515|NCT02300051|Experimental|STPGP and RPGT|16 weekly sessions of 90 minutes of Short-Term Psychodynamic Group Psychotherapy (STPGP) followed by 8 weekly sessions of 90 minutes of Relapse Prevention Group Therapy (RPGT)
89515516|NCT02300051|Active Comparator|TAU|Treatment as usual (TAU) will be introduced through psychiatric follow up, in which the three first visits will occur at intervals of 30 days and the followings will occur with an interval of 60 days. The medication protocol includes serotonin reuptake inhibitors (fluoxetine 20 - 80 mg/day, paroxetine 20 - 60 mg/day, sertraline 50 - 200 mg/day) or mood stabilizers (topiramate 25 - 200 mg/day, divalproex sodium (500 - 1500 mg/day, oxcarbazepine (300 - 1200 mg/day, and lamotrigine 50 - 200 mg/day).
89515517|NCT02300051|Experimental|STPGP and RPGT + TAU|Participants undergo both interventions: 1) 16 weekly sessions of 90 minutes of Short-Term Psychodynamic Group Psychotherapy (STPGP) followed by 8 weekly sessions of 90 minutes of Relapse Prevention Group Therapy (RPGT); 2)Treatment as usual (TAU) will be introduced through psychiatric follow up, in which the three first visits will occur at intervals of 30 days and the followings will occur with an interval of 60 days. The medication protocol includes serotonin reuptake inhibitors (fluoxetine 20 - 80 mg/day, paroxetine 20 - 60 mg/day, sertraline 50 - 200 mg/day) or mood stabilizers (topiramate 25 - 200 mg/day, divalproex sodium (500 - 1500 mg/day, oxcarbazepine (300 - 1200 mg/day, and lamotrigine 50 - 200 mg/day).
89515518|NCT02303249|Experimental|Intervention|Review of discharges and cross-sectoral video conferencing immediately after discharge
89515519|NCT02303249|No Intervention|Control|Standard health care services
89515520|NCT05088993|Experimental|Antigravity Treadmill Group|This group received antigravity treadmill training 100% weight bearing and conventional exercise program.
89515521|NCT05088993|Active Comparator|Conventional Exercise Group|This group received the conventional exercise program only.
89515522|NCT03510533|Experimental|Eating disorders patients|first clinical visit in nutrition department of CHU de Rouen for eating disorders (anorexia nervosa, hyperphagia or bulimia) according to the classification DSM-V
89515523|NCT03510533|Other|healthy volunteers|Volunteers with negative SCOFF test (No active or history of eating disorders)
89515524|NCT03513185||Patients with SSD|Patients are diagnosed with SSD by physician according to DSM-5,and will be treated with Deanxit, SSRI or SRNI on the basis of severity assessment by physician.
89515525|NCT03513185||Patients with non-SSD|No SSD is diagnosed by physician according to DSM-5
89515526|NCT04464395|Experimental|CPI-006 Dose Escalation|CPI-006 + Standard of Care
89515527|NCT04464395|Other|Control Arm|Standard of Care Only
89515528|NCT01679301|Active Comparator|Continuous dose|Users will be randomized to either receive oxygen via continuous dose oxygen or pulsed dose ('sleep' mode) for the first part of the night and will switch for the second part of the night using the SimplyGo Portable Oxygen Concentrator.
89515529|NCT01679301|Experimental|Pulse dose ('sleep mode')|Users will be randomized to either receive oxygen via continuous dose oxygen or pulsed dose ('sleep' mode) for the first part of the night and will switch for the second part of the night using the SimplyGo Portable Oxygen Concentrator
89515530|NCT03513029|Experimental|Study Device|VytronUS Ablation System
89207494|NCT00970437|Active Comparator|CBASP|CBASP as the experimental intervention will follow a manual (McCullough, 2000; German version: Schramm et al., 2006). The approach is specifically tailored for the treatment of chronic forms of depression, particularly with early-onset by focusing on the problems resulting from an inhibition of maturation in early childhood and by using the therapeutic relationship in a personal, disciplined way as well as other specific techniques (e.g. Interpersonal Discrimination Exercise, Situation Analysis). CBASP integrates behavioural, cognitive, and interpersonal strategies.
89207495|NCT00970437|Placebo Comparator|SYSP|The comparator for CBASP is SYSP, a system of supportive psychotherapy, an active but less specific, manualized control treatment. SYSP - defined as non-interpersonal and non-cognitive-behavioral therapy - resembles supportive clinical management, client-centered therapy, counseling, and psychoeducation about depression. There is no specific explanatory mechanism for treatment effect offered to the patient and it does not focus on specific themes.
89207496|NCT02545218|Active Comparator|Perineorraphy.|Secondary surgical repair of the perineal body. Operation is performed by a urogynecologist in an operation theater in local anesthesia. The operation aims to re-create the anatomy in the injured perineum using 2-4 sutures.
89207497|NCT02545218|Active Comparator|Pelvic floor exercise.|Tutored pelvic floor exercise. A trained physio therapist evaluate the pelvic floor musculature and helps the patient to perform proper pelvic floor exercises using biofeedback. The patient receives a training scheme and meets the therapist regularly every second week during 4 months.
89207498|NCT00966771||IUD|Women presenting for emergency contraception who select the copper IUD
89207499|NCT00966771||Oral levonorgestrel|Women presenting for emergency contraception who select oral levonorgestrel
89207500|NCT00856440||1|SCI
89207501|NCT00856440||2|Able-bodied
89207502|NCT00958659||Ancillary-Correlative (gene expression profiling)|Previously collected samples are analyzed for 59 prognostic genes by real-time quantitative PCR-based gene expression profiling.
89207503|NCT00958815||HIV-seronegative with no CVD risk factors|Healthy, 35-60 yr old HIV-seronegative men and women with no CVD risk factors (normal fasting glucose tolerance, normal fasting lipid/lipoprotein levels, normotensive, waist circumference <102cm (men) and <88cm (women).
89207504|NCT00958815||HIV+ with CVD risk factors|35-60 yr old HIV-infected men and women with insulin resistance, dyslipidemia, hypertension, and central adiposity.
89207505|NCT00856596|Other|Males and females with athlete's foot|Male and female subjects with athlete's foot inbetween their toes without nail involvement
89207506|NCT00970515|Experimental|Laparoscopic approach|group A: Laparoscopic approach
89207507|NCT00970515|Active Comparator|Open approach|group B: Open anterior approach
89207508|NCT04042350||CKD patients on dialysis|Data will be analyzed from CKD patients on dialysis that participated in the AURORA study.
89207509|NCT00966927||subjects with spina bifid|subjects with spina bifid between 14 and 21 years old referred to Unit for Care of Spina Bifid Hospital of Parma
89207510|NCT00855114|Experimental|Patients Treated with Everolimus|Breast cancer patients treated with Everolimus by mouth, 5 mgs/day x 7 days, followed by surgery.
89207511|NCT00855192|Experimental|mindfulness-based therapy|mindfulness-based meditation
89207512|NCT00855192|Experimental|interpersonal therapy|psycho-educational
89207513|NCT00856752|Experimental|T1|Pre-treatment with rifampicin
89207514|NCT00856752|Experimental|T2|Pre-treatment with cyclosporin
89207515|NCT00856752|Experimental|Reference|Administration of NRL001 alone: no pre-treatment
89207516|NCT04042272||Healthy volunteers|Healthy volunteers group; Kidney donor groups; Course of the research: Blood samples from all groups shall be taken for S100β, NSE, and GFAP in the preoperative period, in the operating room and after 1st, 7th day and the first following month in the postoperative period. Mortality and morbidity of the patients shall be recorded. Neurological damage and its effect on prognosis shall be examined within the patients with S100β, NSE, and GFAP. Patients' demographic data, accompanying diseases, American Society of Anesthesiology classification, main etiology, preoperative laboratory values shall be recorded accordingly. In addition, routinely taken anesthetics, duration of the operation, duration of anesthesia, duration before the reperfusion, duration of postperfusion, graft hot and cold ischemia durations, first measured central venous pressure, volume replacement therapy, blood component transfusion, and immunosuppressive drugs are given during the operation shall be recorded.
89207517|NCT04042272||Living kidney graft recipients|Kidney transplant group; Course of the research: Course of the research: Blood samples from all groups shall be taken for S100β, NSE, and GFAP in the preoperative period, in the operating room and after 1st, 7th day and the first following month in the postoperative period. Mortality and morbidity of the patients shall be recorded. Neurological damage and its effect on prognosis shall be examined within the patients with S100β, NSE, and GFAP. Patients' demographic data, accompanying diseases, American Society of Anesthesiology classification, main etiology, preoperative laboratory values shall be recorded accordingly. In addition, routinely taken anesthetics, duration of the operation, duration of anesthesia, duration before the reperfusion, duration of postperfusion, graft hot and cold ischemia durations, first measured central venous pressure, volume replacement therapy, blood component transfusion, and immunosuppressive drugs are given during the operation shall be recorded.
89207518|NCT04041960|Experimental|SMG|Brain region targeted with transcranial magnetic stimulation: superamarginal gyrus
89207519|NCT04041960|Experimental|MTG|Brain region targeted with transcranial magnetic stimulation: middle temporal gyrus
89207520|NCT04041960|Active Comparator|Vertex|Brain region targeted with transcranial magnetic stimulation (none associated): Vertex
89207521|NCT00855270|Placebo Comparator|saline|An IV injection of saline will be administered to the control group in a double blind, randomized manner.
89207522|NCT00855270|Experimental|Hydrocortisone|IV hydrocortisone will be given in a double blind random manner as the active treatment group
89207523|NCT03937479|Experimental|RPL554 0.375 mg twice daily|RPL554 0.375 mg twice daily
89207524|NCT03937479|Experimental|RPL554 0.75 mg twice daily|RPL554 0.75 mg twice daily
89207525|NCT03937479|Experimental|RPL554 1.5 mg twice daily|RPL554 1.5 mg twice daily
89207526|NCT03937479|Experimental|RPL554 3.0 mg twice daily|RPL554 3.0 mg twice daily
89207527|NCT03937479|Placebo Comparator|Placebo twice daily|Placebo twice daily
89025040|NCT00476970|No Intervention|Usual Care|Participants randomized to this arm will receive no additional navigation beyond the usual care for the duration of the 9-month intervention. Participants will be offered navigation services after the completion of the intervention period.
89025041|NCT00477009|Experimental|1|Adjustable mandibular repositioning appliance
89025042|NCT00477009|Placebo Comparator|2|Placebo device in upper jaw
89025043|NCT02957162|Other|Blood samples and Atorvastatin 80mg|All participants are given Atorvastatin 80mg as part of their standard care. The main study intervention is blood samples at days 1-2, 3-4 and 7-8.
89515531|NCT05088837|Experimental|muscle energy technique|muscle energy technique was performed in the form of post-isometric relaxation technique for iliopsoas, hamstrings, and erector spinae and quadratus lumborum muscles, it was done 3 times per session for 12 sessions.
89515532|NCT05088837|Experimental|ice and heat packs|Alternating ice and heat (20 min , 10 heat,10 cold),3times per week for 12sessions.
89515533|NCT03512951|Experimental|Normal hearing|A control group including ten normal-hearing participants. These participants are recruited because they can be considered as a reference when compared to hearing-impaired patients. They usually provide homogeneous results that are expected to be significantly different than those obtained with hearing-impaired patients. In this study, normal-hearing participants are expected to provide better and more consistent performance of auditory distance estimation.
89515534|NCT03512951|Experimental|10 experienced hearing impaired|A group of ten (expected sample size) severe-to-profound hearing-impaired patients who have a past and/or present experience of more than 6 months with remote microphone systems. These patients are expected to be aware of the drawbacks of the current remote microphone technology with respect to sound localization, auditory distance estimation, and audio-visual fusion.
89515535|NCT03512951|Experimental|10 naive hearing impaired|A group of ten severe-to-profound hearing-impaired patients with no past or current experience with remote microphone systems. They are referred to as naïve patients. These patients must have similar profiles to the patients in the experienced group as regards the degree of hearing loss, origin of hearing loss (congenital, pre- or post-lingual disability), age, gender, and hearing aid technology. They will be selected and recruited on the basis of the patients included in experienced group
89515536|NCT02951559|Experimental|Brushing|Patients will undergo nasal brushing as further described additionally to other gold standard practices according to the suspected aetiology (brain MRI, lumbar puncture, plasma tests, etc.)
89515537|NCT04464239|Experimental|Part A: Cohort 1: TS-142 10 mg|Single dose of TS-142 10 mg or placebo in a fasted condition
89515538|NCT04464239|Experimental|Part A: Cohort 2: TS-142 30 mg|Single dose of TS-142 30 mg or placebo in a fasted condition.
89515539|NCT04464239|Experimental|Part B: Cohort 4: TS-142 20 mg|Daily doses of 20 mg TS-142 or placebo for 7 days before bedtime.
89515540|NCT02300207|No Intervention|Control group|Subjects were in a resting, flat, head-down position -6° from the horizontal. The entire bed rest period was composed of the 4-day head-down bed rest and 2-day period of data collection (before and after the bed rest period). During all of these periods, there was intensive care monitoring. All dining, washing, urination, and defecation were carried out in the bedridden state. Changing position around the body axis was permitted. Dietary intake was 2300-2500 kcal/day, and water intake was 1.0-1.5 L/day. Urine samples (24 h) were collected every day throughout the study. Body weight, heart rate (HR), and blood pressure (BP) were measured in the morning before breakfast.
89515541|NCT02300207|Experimental|Electroacupuncture group|During the bed rest phase, subjects in the Electroacupuncture(EA) groups received 30 min of EA treatment, while subjects in the Con group did not receive any treatment.EA was performed using small-sized (1.5 cm) cutaneous electrode pads placed bilaterally at the PC-6 points of the forearms. The intensity of the electrical stimulation was adjusted to produce the most intense tolerable electrical sensation without muscle contractions or uncomfortable feelings at a frequency of 50 Hz using the Hwato electronic acupuncture treatment instrument (Model No. SDZ-II; Suzhou Medical Appliances Co, Ltd, Suzhou, China).
89515542|NCT05088447||Stable Disease|"15 control stable disease participants"
89515543|NCT05088447||Frequent Exacerbation Cohort|"15 experimental frequent exacerbation cohort"
89515544|NCT03512873|Experimental|Tranilast|
89515545|NCT01678911|Placebo Comparator|Placebo then Gralise|Subjects may receive a pill with no medicine (placebo) for phase 1. Subject washout, then cross over to Gralise in Phase 2.
89515546|NCT01678911|Active Comparator|Gralise then Placebo|Subjects recieve Gralise (a long acting gabapentinoid) for phase 1.Subject washout, then cross over to placebo in Phase 2.
89515547|NCT03510377|Experimental|Aquatic physical intervention|Aquatic physical intervention: Ai-Chi
89515548|NCT03510377|Experimental|On-land physical intervention|On-land physical intervention: Tai-Chi
89515549|NCT03510377|Experimental|Non physical intervention|Non physical intervention: Guided imagery
89515550|NCT03132701|Active Comparator|Magnesium group|Mg is administered with dose of 30 mg/kg for 10 minutes and then 10 mg/kg/hr until 5 minutes before surgery ends
89515551|NCT03132701|Placebo Comparator|Control group|Saline is administered with same volume of Mg of magnesium group until 5 minutes before surgery ends
89515552|NCT02322099|Active Comparator|Alendronate|Alendronate 70 mg plus calcium/vitamin D (1250 mg/400iu) plus Truvada®
89025044|NCT00439101|Experimental|1|
89025045|NCT00439101|Placebo Comparator|2|Placebo
89025046|NCT00441740|Experimental|1|VG
89025047|NCT00441740|Experimental|2|DG
89025048|NCT02274012|Experimental|Afatinib and weekly Paclitaxel|In addition to the standard chemotherapy, afatinib 40 mg orally once daily will be administered starting on the first day of paclitaxel. Translational studies to assess circulating tumor cells at the start of therapy and then at several later time points, including at the time of progression. These studies will assess the correlation of circulating tumor cell numbers with radiographic response and pilot studies will also be conducted to assess HER2 expression, HER2 genomic amplification, HER2 pathway activation and secondary genetic changes in the HER2 coding sequence as well as other pathway components.
89025049|NCT00441779||1|Traumatic injury
89025050|NCT00441779||2|Elective orthopedic surgery
89025051|NCT00441779||3|Burn injury
89025052|NCT00477048|Other|1|Replace Indinavir with SQV in patients with indinavir toxicity
89025053|NCT00477126|Active Comparator|1|start generic product cross over to reference product
89515553|NCT02322099|Placebo Comparator|Placebo|Placebo to alendronate 70mg plus calcium/vitamin D (1250 mg/400iu) plus Truvada®
89515554|NCT02487446|Experimental|First QVA149, then Umeclidinium/vilanterol|Participants received QVA149 27.5/12.5 ug via inhalation twice daily (b.i.d.) for 12 weeks. Then after 3 weeks washout, participants received Umeclidinium/vilanterol 62.5/25 ug via inhalation once daily for 12 weeks.
89515555|NCT02487446|Experimental|First Umeclidinium/vilanterol, then QVA149|Participants received Umeclidinium/vilanterol 62.5/25 ug via inhalation once daily for 12 weeks. Then after 3 weeks washout, participants received QVA149 27.5/12.5 ug via inhalation twice daily (b.i.d.) for 12 weeks.
89515556|NCT05081349|Experimental|Hydra+L-Carnitine|Hydroxycarbamide+ L-Carnitine+supportive treatment
89515557|NCT05081349|Active Comparator|Hydra only|Hydroxycarbamide+ supportive treatment
89515558|NCT05081349|Active Comparator|L-Carnitine only|L-Carnitine+ supportive treatment
89515559|NCT05081349|No Intervention|Supportive measures|Supportive only
89515560|NCT03512717|Experimental|Potenfill|
89515561|NCT03512717|Active Comparator|Powerfill|
89515562|NCT03132545||PCOS|
89515563|NCT03132545||controls|
89515564|NCT05071599|Experimental|Twin arch brackets|the malocclusion for this group will be treated using fixed appliance which utilize twin arch brackets system.
89515565|NCT05071599|Experimental|Conventional brackets|"the malocclusion for this group will be treated using fixed appliance which utilize conventional pre-adjusted edgewise brackets system."
89515566|NCT02303327|Other|ADT+EBRT+ HDR brachytherapy boost|Standard fractionation radiotherapy: 46 Gy in 23 fractions (EBRT) and a 15-Gy HDRB boost in conjunction with 28 months of androgen deprivation therapy (ADT).
89515567|NCT02303327|Active Comparator|ADT+Hypofractionated Dose Escalation RT|Hypofractionated dose escalation radiotherapy: 68 Gy in 25 fractions in conjunction with 28 months of androgen deprivation therapy (ADT).
89515568|NCT03510299|Placebo Comparator|Control group|
89515569|NCT03510299|Experimental|McGrath group|
89515570|NCT03136419|Placebo Comparator|Control|Placebo capsules bis in die for 8 weeks
89515571|NCT03136419|Experimental|Experimental|Lactobacillus casei DG capsules bis in die for 8 weeks
89515572|NCT03510221|Active Comparator|Antioxidants|Subjects received 3 antioxidant capsules (1 capsule of blueberry + 1 capsule of cranberry + 1 capsule pomegranate - a day) during 4 weeks.
89515573|NCT03510221|Placebo Comparator|Placebo|Subjects received 3 placebo capsules during 4 weeks.
89515574|NCT05068089||Nissen fundoplication surgery and Enteral nutrition|The cohort population retrospectively enrolled in the study is represented by pediatric patients with severe motor and intellectual disabilities (with progressive e non- progressive neurological disease) followed-up at Nutrition Unit of Ospedale Pediatrico Bambino Gesù between January 2009 to January 2020.
89515575|NCT03510143|No Intervention|Control|No use of Neoveil in the neck node dissection area
89515576|NCT03510143|Experimental|Neoveil|Use of Neoveil in the neck node dissection area
89515577|NCT04541511|Experimental|Healthy subject|"Healthy subject will be asked to performed two 6-minutes walking test : one in a corridor and one on the non-motorized treadmill.~Oxygen saturation, heart rate and Borg score will be collected before and after each test."
89515578|NCT04541511|Experimental|Patients|Patients will be asked to to performed a 6-minutes walking test on the non-motorized treadmill and to answer a questionnaire regarding the acceptability and ease of use of the new method.
89515579|NCT03509987|Other|hb analysis with Hemacue|Hb analysis with Hemacue and with arterial blood gas analyser in geriatric ill patients requiring intensive care
89515580|NCT03509831|Other|INT2150-A|
89515581|NCT03509831|Other|INT2150-B|
89515582|NCT05065827||Normal oxygenation|Normal oxygenation based on the BERLIN criteria for ARDS
89515583|NCT05065827||Mild deficit in oxygenation|Mild deficit in oxygenation based on the BERLIN criteria for ARDS
89515584|NCT05065827||Moderate deficit in oxygenation|Moderate deficit in oxygenation based on the BERLIN criteria for ARDS
89515585|NCT05065827||Severe deficit in oxygenation|Severe deficit in oxygenation based on the BERLIN criteria for ARDS
88961318|NCT02008097|Experimental|Liver transplant with a stent|Liver transplant patients who are referred for angioplasty and stenting, or who have had angioplasty and stenting and are referred for liver ultrasound will have a B-Flow ultrasound exam using the GE LOGIQ E9 Ultrasound System.
88961319|NCT02008097|Experimental|Renal artery disease without a stent|Patients with hypertension or impaired renal function who are referred for renal ultrasound will have a B-Flow ultrasound exam using the GE LOGIQ E9 Ultrasound System.
88961320|NCT02008097|Experimental|Renal artery disease with a stent|Patients who are referred for angioplasty and stenting, or who have had angioplasty and stenting and are referred for renal ultrasound will have a B-Flow ultrasound exam using the GE LOGIQ E9 Ultrasound System.
88961321|NCT02008097|Experimental|Pregnancy, Normal|Pregnant women referred for an obstetrical ultrasound to evaluate a normal pregnancy; for example, to determine gestation or gestational age will have a B-Flow ultrasound exam using the GE LOGIQ E9 Ultrasound System.
89515586|NCT02303483|Placebo Comparator|Placebo|lime tablets
89515587|NCT02303483|Experimental|Nicotinamide riboside (NR, Vit B3)|NIAGEN (ChromaDex) 1 g x 2 orally per day
89515588|NCT05046327|Experimental|20 mg Avatrombopag daily|Avatrombopag
89515589|NCT03509753|Experimental|High Fiber|Per 10 ounces of feed: 4 g oat-soy fiber with 45% short-chain fructooligosaccharides, 296 kCal, 19 g protein, 8 g fat, and 39 g carbohydrates. Feed rate/duration individualized for each patient.
89515590|NCT03509753|Active Comparator|Low Fiber|Per 10 ounces of feed: 0 g fiber, 296 kCal, 19 g protein, 8 g fat, and 39 g carbohydrates. Feed rate/duration individualized for each patient.
89207528|NCT00855348||Adults > 50 Years Scheduled for Colonscopy|Average to increased risk adults older than 50 years without symptoms indicative of CRC and designated for colonoscopy.
89207529|NCT00967083||family caregivers of lung cancer patients|In this 2-year pilot study, we plan to screen family caregivers of lung cancer patients within 4 to 6 weeks after the a new visit to the thoracic clinic. We will screen spouses, adult children, and other family members using the HAD-18 to determine their level of anxiety and depressive symptoms at enrollment.
89207530|NCT00967161|Experimental|Evolution Medial Pivot Knee|20 Patients will receive the EMP Knee Implant
89207531|NCT00967161|Active Comparator|Triathlon PS Knee|20 Patients will receive the Triathlon PS Knee
89515591|NCT05378061|Experimental|PACAP-38|A time- and volume-controlled infusion pump is used to administer PACAP-38 by intravenous infusion over 20 minutes.
89515592|NCT05378061|Placebo Comparator|Placebo (isotonic saline)|A time- and volume-controlled infusion pump is used to administer placebo (isotonic saline) by intravenous infusion over 20 minutes.
89515593|NCT02303561|Experimental|CHAMP|Families assigned to this arm will receive tailored asthma education and behavioral skills focused on improving asthma and weight management.
89515594|NCT02303561|Active Comparator|Health education|Families assigned to this arm will receive tailored asthma education and general health education on a variety of topics.
89515595|NCT02303639|Experimental|Radiofrequency catheter ablation|Radiofrequency catheter ablation using open-irrigated ablation catheter and 3D electroanatomical mapping
89515596|NCT02303639|Active Comparator|Antiarrhythmic drug therapy|Amiodarone (or sotalol) tablet by mouth for the duration of the study
89515597|NCT02303717|Active Comparator|Xience|Percutaneous coronary intervention utilising a cobalt chromium everolimus eluting stent with durable polymer (Xience) plus oral dual antiplatelet therapy (DAPT) for 12 months. DAPT will be aspirin 75-100mg daily plus either clopidogrel 75mg daily or prasugrel 5-10mg daily or ticagrelor 90mg twice daily.
89515598|NCT02303717|Experimental|Synergy|Percutaneous coronary intervention utilising a platinum chromium everolimus eluting stent with bioresorbable polymer (Synergy) plus oral dual antiplatelet therapy (DAPT) for 4 months. DAPT will be aspirin 75-100mg daily plus either clopidogrel 75mg daily or prasugrel 5-10mg daily or ticagrelor 90mg twice daily.
89515599|NCT03509597|Experimental|Aerobic Exercise|This program consists of an exercise dosage of 180 min/week administered in 3 sessions of 60 minutes. Each session includes 10 minutes of warm-up exercise before the main exercise and 10 minutes of cool-down afterwards.the principal exercise section includes 20 minutes of aerobic exercise and 20 minutes of resistance and strength exercises. The exercise intensity will be regulated according to the heart rate measured by a pulsimeter throughout the exercise. The target intensity level will be individualized according to the heart rate to set the moderate intensity level (HR values between ventilatory thresholds) and high intensity level (HR values from 2nd. ventilatory threshold to the peak threshold).
89515600|NCT03509597|Experimental|Cognitive Training|The CT group participates in a cognitive remediation program. This program consists of 3 sessions of 60 minutes per week. CT will be administered in groups of 5-8 subjects. The cognitive domains involved in the CT are attention/concentration, memory/learning, language, executive functions, social cognition, social skills, daily living activities and psychoeducation. Cognitive Remediation will be provided by using REHACOP, a cognitive remediation training tool designed and validated for Spanish patients with schizophrenia.
89515601|NCT03509597|Sham Comparator|Treatment as usual|The TaU Group receives the usual treatment that patients with schizophrenia in Spain enriched with occupational activities administered 3 times a week with a duration of 60 minutes each session.
89515602|NCT03509519|Experimental|NMES-Millicurrent Group|NMES-millicurrent group will receive the NMES experimental treatment. Stimulating electrodes will be applied to the quadriceps muscle of each leg 3 times a week for 4 weeks (12 sessions) for 40min on each leg.
89515603|NCT03509519|Sham Comparator|NMES-Microcurrent Group|The NMES-microcurrent group will receive the Sham Treatment. The Sham Treatment will consist of electrode pad application for 40 mins on each leg, but electrical current will not be delivered. Otherwise all procedures will be the same as the NMES-millicurrent experimental group. Participants will be informed they are receiving microcurrent stimulation which is typically not felt by patients. Microcurrent stimulation is an actual type of electrical stimulation that is used therapeutically and is typically not felt by patients, however, participants will not receive this treatment. Participants will be informed of the actual treatment received at the study conclusion. Those in the Sham Group will be given the opportunity to receive the treatment at the conclusion of the study.
89515604|NCT02303873|Experimental|an open label, prospective, self-controlled study|Children or adolescents under the age of 18 years old with minor trauma fracture were recruited from 30 provinces of China. The diagnosis of OI was made by endocrinology department of Peking Union Medical College Hospital(PUMCH).
89515605|NCT03138135|Experimental|Intervention|The Intervention group will receive the HOME Study intervention.
89515606|NCT03138135|Active Comparator|Control|The Control group will receive standard of care.
89515607|NCT04506099|Active Comparator|TINS Active|Electrical stimulation will be applied to the T6-T11 levels of intercostal nerves, as close to the level directly below the level of injury as possible. For example, a T7 level of injury will have TINS applied to the T8 level. A T2 level of injury will have TINS applied to the T6 level. Electrodes 2 inch by 4 inch will be placed according to anatomic landmarks with the negative electrode applied to the lateral ribcage and the positive electrode applied to the ventral aspect, verified with contraction of the rectus abdominis. The intensity level will be set to the amperage immediately under the threshold for motor contraction. If there is no contraction seen, patients will be excluded. In addition, if the patient perceives pain, the intensity will be lowered until comfortable. Stimulation frequency of 20 Hz and pulse width of 200ms in continuous mode will be used.
89515608|NCT04506099|Sham Comparator|Sham protocol|Electrical stimulation will be applied to the T6-T11 levels of intercostal nerves, as close to the level directly below the level of injury as possible until contraction is seen in the rectus abdominis. Stimulation frequency of 20 Hz and pulse width of 200ms in continuous mode will be used. Electrodes 2 inch by 4 inch will be placed according to anatomic landmarks with the negative electrode applied to the lateral ribcage and the positive electrode applied to the ventral aspect. The intensity level will be set to 1mA . If there is no contraction seen, patients will be excluded. In addition, if the patient perceives pain, the intensity will be lowered until comfortable.
89515609|NCT02739269|Active Comparator|AMH group|Serum AMH measurement
89544272|NCT02442791|Placebo Comparator|Placebo|"Half of the participants will receive placebo, that will be given as follows:~250 mL isotonic sodium chloride added 1.5 mL of 20% Human Albumin. The placebo infusion is administered exactly the same way as the study drug infusion."
89544273|NCT03190655|Experimental|Aluminaid|Treatment group: Aluminaid wound dressing
89544274|NCT03190655|Active Comparator|Hydrogel|Hydrogel wound dressing (Trademark: Burnshield)
89544275|NCT04771221|Experimental|Main group|Patients with complaints of sore throat, coughing, burning sensation in the throat, cough, frequent sore throat, difficulty swallowing, lump in the throat, feeling of a foreign body in the throat, voice change, heartburn, belching.
89544276|NCT04771221|Experimental|Control group 1|Patients with an early diagnosis of Gastroesophageal reflux disease
89544277|NCT04771221|Experimental|Control group 2|Patients without complaints of sore throat, coughing, burning sensation in the throat, cough, frequent sore throat, difficulty swallowing, lump in the throat, feeling of a foreign body in the throat, voice change, heartburn, belching.
89544278|NCT02442557|Active Comparator|single dose 4 mg|a single intravenous injection of 4 mg DC-TAB
89544279|NCT02442557|Active Comparator|single dose 12.5 mg|a single intravenous injection of 12.5 mg DC-TAB
89544280|NCT02442557|Active Comparator|single dose 25 mg|a single intravenous injection of 25 mg DC-TAB
89544281|NCT02442557|Active Comparator|single dose 37.5 mg|a single intravenous injection of 4 mg DC-TAB
89544282|NCT02442557|Placebo Comparator|single dose placebo|a single intravenous injection of placebo
89544283|NCT02442557|Active Comparator|multiple dose 10 mg|three consecutive daily intravenous injections of 10 mg DC-TAB
89544284|NCT02442557|Active Comparator|multiple dose 25 mg|three consecutive daily intravenous injections of 25 mg DC-TAB
89544285|NCT02442557|Active Comparator|multiple dose 37.5 mg|three consecutive daily intravenous injections of 37.5 mg DC-TAB
89544286|NCT02442557|Placebo Comparator|multiple dose placebo|three consecutive daily intravenous injections of placebo
89544287|NCT04756557|Experimental|Tooth Brushing HAP Toothpaste|"Experimental: Tooth Brushing HAP HAP-Toothpaste Tooth Brushing HAP Prophylactic cleaning of all teeth using a standardized electric tooth brush and a non-fluoridated toothpaste containing microcrystalline hydroxylapatite two x daily over the duration of the study (18 months).~Procedure: Tooth Brushing HAP"
89544288|NCT04756557|Active Comparator|Tooth Brushing F Toothpaste|Cleaning teeth using a standardized electric tooth brush and a fluoridated tooth paste containing amino fluoride (1450 ppm F-), (two x daily over the duration of the study (18 months).
88961322|NCT02008097|Experimental|Pregnancy, High Risk|Pregnant women referred for an obstetrical ultrasound to evaluate a high risk pregnancy due to a medical condition present before or during pregnancy for either the mother or the baby will have a B-Flow ultrasound exam using the GE LOGIQ E9 Ultrasound System. Examples of risk factors include placenta previa, vaginal bleeding, suspected multiple gestation, suspected uterine abnormality, suspected fetal growth abnormality, advanced maternal age, a prior C-section, prior low birth weight baby, and prior preterm birth.
89544289|NCT02442635|Experimental|Condition 1|Yoga Breathing
89544290|NCT02442635|Experimental|Condition 2|Static Yoga
89544291|NCT02442635|Experimental|Condition 3|Flowing Yoga
89544292|NCT02442713|Experimental|fluvoxamine|fluvoxamine: 50-300mg/day
89544293|NCT03190187|Active Comparator|Spinal manipulation|Spinal manipulation to the spine will be applied to participants enrolled in this group.
89544294|NCT03190187|Sham Comparator|Sham manipulation|Sham technique wich mimic the intervention manipulation with less force and different body location will be applied.
89544295|NCT03189953|Experimental|68Ga-NODAGA-exendin PET/CT|68Ga-NODAGA-exendin PET/CT
89544296|NCT02356887|Experimental|sitting position|The volunteers were kept comfortable in the sitting position. The cricoid cartilage (representing the C6 level) was used as a landmark. A horizontal straight line drawn across the volunteer's neck at the cricoid level and intersecting the IJV on both sides of the neck marked the initial scanning points. The second scanning point was along the IJV at the highest accessible point on the neck. Internal jugular vein cross-sectional area and blood velocity were measured using 2D ultrasound and Doppler (Philips CX50, Andover, MA, USA), respectively, with a 12-3 MHz transducer (Philips L12-3, Andover, MA, USA)
89544297|NCT02442479|Active Comparator|HHH3|High-resistance concentric-eccentric training (H) 3 d/wk (HHH3).
89544298|NCT02442479|Experimental|HLH3|3 d/wk mixed model consisting of high-resistance concentric-eccentric training 2 d/wk separated by 1 bout of low-resistance, high-velocity, concentric only training (L) (HLH3).
89544299|NCT02442479|Experimental|HH2|High-resistance concentric-eccentric training 2 d/wk (HH2).
89544300|NCT02442479|Experimental|HL2|2 d/wk mixed model consisting of high-resistance concentric-eccentric training 1 d/wk and low-resistance, high-velocity, concentric only training 1 d/wk (HL2).
89544301|NCT02204085|Experimental|GO-203-2c|"Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.~GO-203-2c given daily on predetermined schedule of a 28-day treatment cycle"
88961323|NCT02008123|Experimental|Primidone|Participants will receive primidone in addition to their clopidogrel regimen. For the first 3 days of the study, participants will take 125 mg of primidone (one-half tablet). After 3 days of 125 mg, the primidone dose will be increased to 250 mg (1 tablet) taken at bedtime for the next 17-25 days. The participant will then be asked to return and be retested.
89544302|NCT02204085|Experimental|GO-203-2c + Decitabine|"Dose escalation will occur for GO-203-2c using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.~GO-203-2c given daily on predetermined schedule of a 28-day treatment cycle. Decitabine will be administered at a dose of 20mg/m2 on days 8-12 of a 28-day treatment cycle."
89544303|NCT02439593|Active Comparator|Chemoradiotherapy (CTRT) (Control Group)|"Intervention type:~Drug and Radiation~Intervention name:~Drug (Gemcitabine) Radiation (Loco-regional radiotherapy by SIB-IMRT)~Intervention description:~Radiotherapy: 5 days a week (Days 1 to 5) of each week for 5.5 weeks (28 fractions), Total dose: 50.4 Gy at 1.8 Gy /fr. over 5.5 weeks Chemotherapy: Gemcitabine (400 mg / sq. m) would be administered weekly 24 hours after hyperthermia on Day 2 and after radiotherapy every week on D2"
89515610|NCT02739269|Sham Comparator|AFC group|AFC measurement
89515611|NCT04757493|Active Comparator|Prucalopride group (A)|"Prucalopride 2 mg tablet, once daily in morning before breakfast will use as intervention in arm A."
89515612|NCT04757493|Placebo Comparator|Placebo group (B)|"Placebo will be given at the same time and same dose in arm B . Both active drug and placebo have packed in the same type of strip."
89515613|NCT03509363|Experimental|Intervention|Participants allocated to the intervention group will be prescribed a set of exercise video with QR code provided in home exercise pamphlets and they have to perform the prescribed exercises under the guidance of video.The content of home exercise program in both groups is the same and is based on the recommendations from the National Stroke Foundation Clinical Guidelines, including mobilization exercise, strengthening exercise and balance training which is tailor-made for different mobility level of stroke patients. Suitability of participating home exercise program will be assessed by physiotherapists based on environmental risk, fall risk and competence of patients or carers in performing exercise with patients. The number of exercises prescribed, frequency and intensity of exercise varies from participants and will be determinated by physiotherapists
89515614|NCT03509363|No Intervention|Control|Participants in control group will be given instructions for their home exercise program in a traditional pamphlet includes photographs and instructions of exercise demonstration.
89515615|NCT02303951|Experimental|vemurafenib + cobimetinib + atezolizumab|"Run-In (week 1-4):~Day 1-21: vemurafenib 960 mg bid orally + cobimetinib 60 mg od orally~Day 22-28: vemurafenib 720 mg bid orally~Triple-Treatment (week 5 ongoing):~atezolizumab 840 mg Q2W i.v. + vemurafenib 720 mg bid orally + cobimetinib 60 mg od 21/7 orally (vemurafenib: daily intake; cobimetinib: 3 weeks on drug, 1 week off)"
89515616|NCT04406415|Experimental|10 mg|10 mg nafamostat three times a day (t.i.d., approximately q8h) for up to 5 days
89515617|NCT04406415|Experimental|50 mg|50 mg nafamostat three times a day (t.i.d., approximately q8h) for up to 5 days
89515618|NCT04406415|Experimental|100 mg|100 mg nafamostat three times a day (t.i.d., approximately q8h) for up to 5 days
89515619|NCT04406415|Experimental|200 mg|200 mg nafamostat three times a day (t.i.d., approximately q8h) for up to 5 days
89515620|NCT04406415|Placebo Comparator|Placebo|Placebo administered three times a day (t.i.d., approximately q8h) for up to 5 days
89515621|NCT02304029|Experimental|assessment of a innovative MRI|Sodium MRI will be performed at CEMEREM, CHU Timone, the only site with this technique, with a Siemens Verio 3T MRI using a dedicated coil and a sequence already developed locally, in 90 patients with partial drug -resistant epilepsy
89515622|NCT02304107|Active Comparator|FSH|70 women will receive urinary purified FSH (Fostimon® IBSA, Switzerland) 75IU daily for 7 days starting from the 3rd day of menstruation or progesterone withdrawal bleeding. If the follicle does not exceed 9 mm the dose will be increased by 37.5 IU every 7 days.
89515623|NCT02304107|Active Comparator|Letrozole|70 women will receive Letrozole (Femara®, Novartis, Switzerland) 2.5mg twice daily for 5 days starting from the 3rd day of menstruation or progesterone withdrawal bleeding.
89515624|NCT03137823|Other|patients|each patient will be reviewed twice - first time culture from the tonsills and the second culture from the bucal surface.
89515625|NCT02304185|Experimental|gp140, 50 mcg|
89515626|NCT02304185|Experimental|gp140, 50 mcg + Adjuvant|
89515627|NCT02304185|Placebo Comparator|Placebo 1|
89515628|NCT02304185|Experimental|gp140, 250 mcg|
89515629|NCT02304185|Experimental|gp140, 250 mcg + Adjuvant|
89515630|NCT02304185|Placebo Comparator|Placebo 2|
89515631|NCT03195855|Experimental|Ankle and big toe mobilisations combined with home stretches|"Intervention group (n=29):~This group will undertake talocural and 1st MTP joint mobilisations (x1/week for 6 weeks) and a 6 week home programme of stretching exercises.~Mobilisations: In our study, a traction intervention consisting of two, 2-min sets of Maitland grade II joint traction will precede 2-min sets of Maitland grade III mobilisations with one minute rest in between sets. Four sets will be performed for the ankle and two for the MTP. This protocol has been used previously (19, 43). The direction of mobilisation force will be parallel to the treatment plane and perpendicular to the treatment plane during traction (75).~Home Program: There will be 3 stretches prescribed (gastrocnemius, soleus and plantar fascia). Participants will be recommended to undertake three consecutive static stretches for 20-30s with a 1 minute rest period (76). Stretches will occur in standing."
89515632|NCT03195855|No Intervention|Control group of usual care including podiatry|"Control group (n=29):~Usual care including regular monitoring of foot health by podiatrists as indicated by NICE (NG19) guidelines (78). A review of current clinical practice within the podiatry clinic indicates that people with moderate/intermediate risk are reviewed every 3 months. Interventions include nail care, callus debridement and foot care advice.~In both groups, interventions delivered by podiatrists in the study period will be determined from the clinic notes."
89515633|NCT02304263||Younger (18-35 years old)|iohexol
89515634|NCT02304263||Older (>60 years old)|iohexol
89515635|NCT04376619|Experimental|KDIGO guidelines|Part 1 of study, those identified as high risk for AKI then will have Kidney Disease Global Improving outcomes guideline implemented to see if this reduces incidence of AKI
89515636|NCT04376619|Experimental|RIPC|part 2 of study, those identified as high risk of AKI will have Kidney Disease Improving Global Outcomes guidelines and RIPC implemented to see if this reduces incidence of AKI compared to part 2 of study
89515637|NCT03509285|Placebo Comparator|Qualification Y|Placebo; administered orally as a single dose of 2 x 100 mg lactose tablets, over-encapsulated (alprazolam placebo)
89515638|NCT03509285|Active Comparator|Qualification Z|Alprazolam 2.0 mg; administered orally as a single dose of 2 x 1.0 mg alprazolam tablets, over-encapsulated
89515639|NCT03509285|Placebo Comparator|Treatment A|Placebo; administered orally as a single dose of 4 x cenobamate-matched placebo tablets and 3 x 100 mg lactose tablets, over-encapsulated (alprazolam placebo)
89515640|NCT03509285|Active Comparator|Treatment B|Alprazolam 1.5 mg; administered orally as a single dose of 3 x 0.5 mg alprazolam tablets, over-encapsulated and 4 x cenobamate-matched placebo tablets
89515641|NCT03509285|Active Comparator|Treatment C|Alprazolam 3.0 mg; administered orally as a single dose of 3 x 1.0 mg alprazolam tablets, over-encapsulated and 4 x cenobamate-matched placebo tablets
89515642|NCT03509285|Experimental|Treatment D|Cenobamate, 200 mg; administered orally as a single dose of 2 x 100 mg cenobamate tablets, 2 x cenobamate-matched placebo tablets, and 3 x 100 mg lactose tablets, over-encapsulated (alprazolam placebo)
89515643|NCT03509285|Experimental|Treatment E|Cenobamate, 400 mg; administered orally as a single dose of 4 x 100 mg cenobamate tablets and 3 x 100 mg lactose tablets, over-encapsulated (alprazolam placebo)
89515644|NCT05738109|Experimental|Self-guided journaling Intervention|Participants assigned to the waitlist group complete a 2wk, 1mo, 2mo and 3mo survey over the 91-day study period. After the 91-days they will also complete a follow-up survey and exit interview
89515645|NCT05738109|No Intervention|Waitlist Control|Participants assigned to the waitlist group complete a 2wk, 1mo, 2mo and 3mo survey over the 91-day study period. After the 91-days they receive access to the 91-day Self-Talk Journal for their own personal use.
89515646|NCT03509129|Active Comparator|TECH (Technology)|Participants will receive a theory-based physical activity program. They will enroll in the study as part of a self-selected group of 3-8 individuals. They will be provided with a personal step goal and Fitbit Alta HR for self-monitoring physical activity. They will also have access to a study website that will be accessible across conventional and mobile platforms. They will be asked to visit the website each week to receive behavior change information and guidance.
89515647|NCT03509129|Experimental|TECH+COMP (Technology + Competition)|Participants will receive the same intervention components as the TECH goup, as well as a study designed team competition.
89515648|NCT02300363|Experimental|Treatment A|10 mg oral rosuvastatin administration
89515649|NCT02300363|Experimental|Treatment B|400 mg oral LX4211 qd administration
89515650|NCT02300363|Experimental|Treatment C|10 mg oral rosuvastatin administration + 400 mg oral LX4211 qd administration
89515651|NCT02304341||intermediate units|Children admitted to the paediatric inpatient unit in 7 regional hospitals French
89515652|NCT03318523|Placebo Comparator|Placebo|"Year 1: Participants will receive matching placebo to BIIB054 on Day 1 and then every 4 weeks.~Year 2: Participants who received placebo in year 1 will be randomized into one of the active treatment arms in year 2 and will receive BIIB054 intravenous (IV) infusion on Week 52 and then every 4 weeks."
89515653|NCT03318523|Experimental|BIIB054 250 mg|Participants will receive BIIB054 250 milligrams (mg) intravenous (IV) infusion on Day 1 and then every 4 weeks.
89515654|NCT03318523|Experimental|BIIB054 1250 mg|Participants will receive BIIB054 1250 mg IV infusion on Day 1 and then every 4 weeks.
89515655|NCT03318523|Experimental|BIIB054 3500 mg|Participants will receive BIIB054 3500 mg IV infusion on Day 1 and then every 4 weeks.
89515656|NCT03135951|Experimental|SPI-2012|"SPI-2012 (13.2 mg/0.6 mL fixed dose, equivalent to 3.6 mg G-CSF per cycle)~Supplied in 1 mL prefilled, single-use syringes for subcutaneous injection~Administered on Day 2 of each cycle after TC administration"
89515657|NCT03509051|Experimental|B vaccination|One intramuscular injection of Bexsero (multicomponent B vaccine) from 6 months after transplant. A second similar dose will be given 2 months later.
89515658|NCT02300519||Volunteers|Blood sampling : 1 blood punction of 36.5 ml for each volunteer
89515659|NCT03508973|Experimental|Sculptra|Sculptra, an injectable implant containing microparticles of ply-L-lactic acid, carboxymethylcellulose, non-pyrogenic mannitol and sterile water, will be injected into the decolletage.
89515660|NCT03512639|Active Comparator|Study|Patients in the study group were given homeopathic medication (Arnica montana C30 and Bellis perennis C30) .
89515661|NCT03512639|Placebo Comparator|control|Patients in the control group were given placebo medication. The placebos and the active medication were indistinguishable in appearance, taste and smell
89515662|NCT04120701|Experimental|Chemotherapy|
89515663|NCT04120701|No Intervention|Follow-up within the study|
89515664|NCT04120701|No Intervention|Follow-up outside the study|
89515665|NCT02304419|Experimental|Galunisertib|150 milligrams galunisertib given orally twice daily (BID) for 14 days followed by 14 days with no study drug (28 day cycles). Treatment is expected to last for 6 cycles. Participants may receive additional cycles if they are deriving clinical benefit.
89515666|NCT02304497||DM-CTRL|Diabetes mellitus patients with periodontally healthy Platelet Rich Fibrin obtained
89515667|NCT02304497||DM-CP|Diabetes mellitus patients with chronic periodontitis Platelet Rich Fibrin obtained
89515668|NCT02304497||CP|Chronic periodontitis patients with systemically healthy Platelet Rich Fibrin obtained
89515669|NCT02304497||CTRL|Periodontally and systemically healthy subject Platelet Rich Fibrin obtained
89515670|NCT03135795|Experimental|patients undergoing pancreatectomy|patients undergoing pancreatectomy received dexmedetomidine 1μg/Kg，sufentanil 0.5μg/Kg， propofol 2mg/Kg，rocuronium 0.6mg/Kg for induction.And received sevoflurane(1-2%), remifentanil(0.1-0.2ug/kg/min) and propofol(0.3-0.6mg/kg/h) for maintenance. Parecoxib 40mg was given single intravenously before incision. And PCA with sufentanil 1ug/ml was started immediately after surgery.
89515671|NCT03471169|Experimental|Desirable TEG|Patients receiving antiplatelet medication and desirable thrombelastogram(TEG) test results.
89515672|NCT03471169|Sham Comparator|Undesirable TEG|Patients receiving antiplatelet medication and undesirable thrombelastogram(TEG) test results.
89515673|NCT02300597|Experimental|Internet based support and coaching|Young people between age 15 and 25 with ADHD and/or autism spectrum disorders are offered internet-based support and coaching during eight weeks (chat and e-mail). Data is collected before and after the intervention and six months after end of treatment using self-report questionnaires pertaining to sense of coherence, self-esteem, quality of life, depressive and anxiety symptoms and socioeconomic status. Parents complete an assessment scale for the next of kin. After treatment the young people are interviewed regarding the quality of the intervention.
89515674|NCT02300597|No Intervention|Treatment as usual (TAU)|A comparison group matched for age, gender and neuropsychiatric diagnosis is offered treatment as usual and is assessed at the same time points as the intervention group.
89515675|NCT03474289|Experimental|Escalation|SHR-1316 administrated intravenously(IV) at protocol defined dose levels
89515676|NCT03474289|Experimental|Expansion|SHR-1316 administrated IV in advanced solid tumors and selected tumor type
89544304|NCT02439593|Experimental|Thermochemoradiotherapy (CTRTHT)|"Intervention type:~Drug, Radiation and Hyperthermia~Intervention name:~Drug (Gemcitabine) Radiation (Loco-regional radiotherapy by SIB-IMRT) Hyperthermia (Loco-regional hyperthermia),~Intervention description:~Radiotherapy: 5 days a week (Days 1 to 5) of each week for 5.5 weeks (28 fractions), Total dose: 50.4 Gy at 1.8 Gy /fr. over 5.5 weeks Chemotherapy: Gemcitabine (400 mg / sq. m) would be administered weekly 24 hours after hyperthermia on Day 2 and after radiotherapy every week on D2 Hyperthermia: Weekly Local hyperthermia before radiotherapy on D1 of every week, 41-43°C for 60 mins, once every week"
89544305|NCT02067741|Experimental|Stratum A - HER2neg BC RD - CR1447|Stratum A - patients with endocrine responsive-HER2neg BC
89544306|NCT02067741|Experimental|Stratum B - ARpos B - CR1447|Stratum B - patients with triple-negative and confirmed ARpos BC
89544307|NCT02442401|Experimental|NPWT group|Negative pressure wound therapy was used to prevent donor site seroma formation
89544308|NCT02442401|No Intervention|Control group|Conventional method was used to the donor site
89544309|NCT02439359|Placebo Comparator|Placebo|Placebo
89544310|NCT02439359|Experimental|CF-301|CF-301
89544311|NCT02442323|Experimental|Walking Intervention|Intervention patients will receive a 12-week home-based walking program, which includes a personalized instruction booklet and pedometer. The walking program consists of 3 phases and will be individualized for each patient based on their physical condition and baseline assessment. Patients are instructed to walk 3 to 5 times each week at home or other safe environment. Patients will be instructed on a gradual increase in walking time over the course of the intervention.
89544312|NCT02442323|No Intervention|Usual Care|Usual care patients will receive standard of care. They will not receive any instruction on walking or other physical activity other than what is normally provided by their physician or clinical staff.
89544313|NCT02439437|Active Comparator|Psychosocial Intervention|Telephone-based psychosocial intervention involving Eight telephone encounters. Each encounter will focus on strategies for dealing with pain and stress, and how to apply these strategies to patients own experiences.
89544314|NCT02439437|No Intervention|Treatment as usual|Treatment as usual
89544315|NCT03192293|Experimental|Metformin/Simvastatin/Fulvestrant|"7 days Lead-in period:~Metformin: 850mg (one tablet) twice a day~Simvastatin: 20mg (one tablet) once every night~Once the doctor has deemed that patients have tolerated Simvastatin and Metformin well, patients will receive Fulvestrant at standard doses:~Cycle 1: 500mg (in the form of two injections, 1 in each buttock) at Day 1 and Day 15. Each cycle comprises of 28 consecutive days starting from Day 1.~Cycle 2 and beyond: 500mg at Day 1 of each 28-day cycle."
89544316|NCT02442089|No Intervention|No Intervention|The intervention arm subjects will not receive the automated interactive voice reminder before their appointment.
89544317|NCT02442089|Experimental|Intervention|The intervention arm subjects will receive the automated interactive voice reminder before their appointment.
89544318|NCT02442245|Placebo Comparator|Placebo|Placebo group will receive microcrystalline cellulose
89544319|NCT02442245|Active Comparator|Treatment|Treatment group will get 2 g daily of XSurge in microcrystalline cellulose
89544320|NCT02442245|Sham Comparator|Control Group|The control group will be included to quantify or describe the effects of the acute exercise training but will not receive any supplement
89544321|NCT02439515|Experimental|Biofeedback training|"It consists of 15 daily sessions of voluntary cycling training augmented by functional electrical stimulation (FES) followed by 15 daily sessions of balance training (multimodal biofeedback training). Both cycling and balance training are supported by a visual biofeedback and last about 20 minutes.~In addition to cycling or balance training, subjects perform standard physical therapy in order to reach 90 minutes of training per day."
89544322|NCT02439515|Active Comparator|Usual Care|It consists of 30 daily sessions of standard physical therapy. Each session last about 90 minutes.
88961324|NCT02008136|Experimental|botulinum toxin injected|Because this is an open label study, all subjects will receive one of two botulinum toxins based on their symptoms. Those will cervicalgia will receive Botox (botulinum toxin A) and those with lumbago or low back pain will receive Myobloc (botulinum toxin B)
88961325|NCT02008162||Bronchodilators|"Patients with severe heterogeneous emphysema selected as potential candidtes for lung volume reduction surgery.~Bronchodilators employed for the study include albuterol 200µg and tiotropium bromide 18 µg administered by puffs following a first spirometry and plethysmography performed after a washout period of 48h from all bronchodilators and subsequently repeated within 30 min after bronchodilators administration."
89544323|NCT02439203|Experimental|JM-010|JM-010
89544324|NCT02439203|Placebo Comparator|Placebo|Placebo
89544325|NCT02439125|Experimental|Eltoprazine HCl 2.5 mg|Eltoprazine HCl 2.5 mg capsules to be taken orally b.i.d. (ie, 5 mg/day) for 3 weeks
89544326|NCT02439125|Experimental|Eltoprazine HCl 5.0 mg|Eltoprazine HCl 5.0 mg capsules to be taken orally b.i.d. (ie, 10 mg/day) for 3 weeks
89544327|NCT02439125|Experimental|Eltoprazine HCl 7.5 mg|Eltoprazine HCl 7.5 mg capsules to be taken orally b.i.d. (ie, 15 mg/day) for 3 weeks
89544328|NCT02439125|Placebo Comparator|Placebo|Placebo capsules to be taken orally b.i.d. for 3 weeks
89544329|NCT02441933|Active Comparator|control group|
89544330|NCT02441933|Experimental|carboplatin group|
89544331|NCT01604265|Placebo Comparator|Placebo|Placebo control.
89544332|NCT01604265|Experimental|Sativex|Active treatment.
88961326|NCT02008175|Experimental|Conventional CXL|Crosslinking was done according to the standard protocol using hypo-osmolar riboflavin to saturate the cornea following epithelial debridement and ultra - violet light of 370nm with energy density of 3 milliwatts/sq.cm with riboflavin and distilled water alternated every 2 minutes was used for the procedure.
88961327|NCT02008201|Experimental|Vitamin D dose 1|Vitamin D dose 1
88961328|NCT02008201|Experimental|Vitamin D dose 2|Vitamin D dose 2
88961329|NCT02008201|Experimental|Vitamin D dose 3|Vitamin D dose 3
88961330|NCT02008201|No Intervention|observational|No dose
88961331|NCT02008214|Experimental|PTX|IFN 180 micrograms subcutaneous weekly RBV 400 mg each 12 h, oral PTX 400 mg each 12 h, oral
88961332|NCT02008214|Placebo Comparator|Placebo|IFN 180 micrograms subcutaneous weekly RBV 400 mg each 12 h, oral Placebo oral daily
89025054|NCT00477126|Active Comparator|2|start reference product cross over to generic product
89515677|NCT04958967|Experimental|treated subjects will receive Furmonertinib 240mg/day,|treated subjects will receive Furmonertinib 240mg/day, QD, PO, under fasted state, until progressive disease, death or intolerability.
89515678|NCT04958967|Experimental|treated subjects will receive Furmonertinib 160mg/day|treated subjects will receive Furmonertinib 160 mg/day, QD, PO, under fasted state, until progressive disease, death or intolerability.
89025055|NCT03279419||Liver disease|"15 patients with acute or chronic liver disease of any aetiology. Serial static images to be taken at up to 3 time points using thermal imaging camera. Video images using thermal camera will be used to capture warming of one hand after cooling.~Patient may or may not be receiving terlipressin therapy."
89515679|NCT02304575||Testicular cancer survivors|Patients treated for testicular cancer, will receive questionnaires and hormonal function measurement.
89515680|NCT02304575||Surgery for benign testicular problems|Patients treated for benign testicular conditions, will receive questionnaires and hormonal function measurement.
89515681|NCT02304575||Healthy males|Healthy volunteers, will receive questionnaires and hormonal function measurement.
89515682|NCT03469531|Experimental|experimental group|Patients receive nimotuzumab combined with cisplatin and undergo external-beam radiation and brachytherapy as the patients in experimental group.
89515683|NCT03469531|Active Comparator|control group|Patients receive cisplatin and undergo external-beam radiation and brachytherapy as the patients in control group.
89515684|NCT05737953||Mucinous tumour group|
89515685|NCT05737953||Non-mucinous tumour group|
89515686|NCT05737719||Prehab|Patients awaiting a knee surgical procedure, and after the surgery
89515687|NCT05737719||Control|Patients after the surgery
89515688|NCT03512483|No Intervention|Usual Care|Control group participants will be notified of their assignment and will continue their usual care with the AF clinic receiving onsite care. Participants will be contacted at 3 time points (baseline, 3 months, and 6 months)
89515689|NCT03512483|Experimental|Virtual Atrial Fibrillation Clinic|Participants in the intervention group can expect to receive between 1 and 4 telehealth appointments over a 6 month period, as well as being contacted by the research team at 3 time points for data collection (baseline, 3 months, and 6 months). Telehealth appointments will consist of remote interactions with clinicians. Telehealth appointments will take place in participants' homes, using their personal computer/tablet/smartphone. Participants will also receive an orientation to the website and will be encouraged to visit often and utilize the resources. To promote and encourage website interaction, emails will be sent to participants once semi-monthly for the duration of the intervention with highlights and important messages from the website.
89515690|NCT05159011|No Intervention|Usual Care|Virtual Genetic Counseling
89515691|NCT05159011|Other|Chatbot|computer program that that uses machine learning to provide tailored counseling to patients
89515692|NCT02300675|No Intervention|control arm|Patients follow the classic support prescription of hormonotherapy
89515693|NCT02300675|Experimental|therapeutic education program|Patients follow the 4 sessions of PEP hormonotherapy. The therapeutic education prgram is led by a trained educational team, inside a prevention center : Hygée centre.
89515694|NCT03133143|Experimental|Cognifit|Participants are instructed to play CogniFit 45-60 minutes, 5 days/week. A minimum of 50 gaming hours will be acquired to ensure observable neuroplasticity in the brain after gaming.
89515695|NCT03133143|Active Comparator|SIMS 4 (Maxis, Inc)|Participants are instructed to play SIMS 4 45-60 minutes, 5 days/week. A minimum of 50 gaming hours will be acquired to ensure observable neuroplasticity in the brain after gaming.
89515696|NCT03133143|No Intervention|Treatment as usual|No specific intervention will be offered to those who receive treatment as usual according to their treatment schedule. The participants are encouraged not to play video games during the study period.
89515697|NCT03508817|Experimental|Atropine Sulfate 0.01% Eye Drops Group|Intervention group will receive atropine sulphate eye drops 0.01% once nightly for 2 years.
89515698|NCT03508817|No Intervention|Control group|Control group will not receive any medication.
89515699|NCT02961517||Patients|All patients with type 2 diabetes and/or cardiovascular disease who will complete the questionnaire
89515700|NCT03508583||Participation|"Parents will complete the The Measure of Processes of Care 56- 20 (MPOC 56-20) questionary~Service providers will complete The Measure of Processes of Care for Service Providers (MPOC-SP)"
89515701|NCT03469453|Experimental|Internet-delivered CBT|Internet-delivered Cognitive Behavioral Therapy (ICBT) for GAD, 10 weeks. Patients and their parents work with separate programs via the Internet. Both have contact with a therapist. Participants practice awareness of worry through daily worry monitoring. They identify their own behaviors that reinforce worry, i.e. control and avoidance behaviors. The program gives a rationale for behavior change, which is then implemented. Participants practice problem solving and exposure to uncertainty inducing situations and thoughts. Parents receive support and psycho education about worry. They practice alternative parental behaviors, which decrease focus on worry while validating the child's feelings. Treatment contains planning for maintenance of treatment gains for both patients and parents.
89515702|NCT02300831||NSCLC|The eligible patient population of this study will comprise of advanced 2nd line NSCLC patients who are screened for two randomised clinical trials (RCTs) sponsored by AstraZeneca (AZ): SELECT-1 and SELECT-2 trials, but who do not meet eligibility criteria for those trials
89515703|NCT01678209|Active Comparator|fMRI scans|Healthy Control Group: will receive initial evaluation, and 2 fMRI (functional magnetic resonance imaging) scans each 6-8 weeks apart
89515704|NCT01678209|Experimental|Atomoxetine arm|These subjects will receive initial evaluation and baseline fMRI scan, flexible dose titration with atomoxetine for 6-8 weeks, and fMRI postscan, with optional post study stabilization visits.
89515705|NCT01678209|Experimental|Methylphenidate arm|Subjects will receive initial evaluation, baseline fMRI scan, flexible dose titration with methylphenidate (Concerta) for 6-8 weeks, and fMRI scan post treatment.
89515706|NCT03474211||vaccinated|
89515707|NCT03474211||non vaccinated|
89515708|NCT02239120|Experimental|dabigatran etexilate 110 or 150 mg|Patients will be assigned Dabigatran 150 mg b.i.d. (unless they are 75 years or older, or have a Creatinine Clearance (CrCl) of greater than or equal to 30 to less than 50ml/min (or experience GI bleed during trial), in which case they will receive Dabigatran 110 mg b.i.d.). All patients in this arm will also receive ASA placebo (q.d.)
89515709|NCT02239120|Active Comparator|ASA 100 mg|All patients will receive blinded ASA 100 mg q.d. and dabigatran placebo 150 mg b.i.d. (unless they are 75 years or older, or have a CrCl of greater than or equal to 30 to less than 50ml/min (or experience GI bleed during trial), in which case they will receive placebo Dabigatran 110 mg b.i.d
89515710|NCT04091893|Active Comparator|Usual care/wait list|
89515711|NCT04091893|Experimental|Art Rx|
89515712|NCT04091893|Experimental|Artful Meditation|
89515713|NCT04091893|Experimental|Art Rx + Artful Meditation|
89515714|NCT02304731|Experimental|Exercise and Pollution Groups|Physical Exercise performed in a clean environment and in a polluted environment.
89515715|NCT04013269|Active Comparator|CytoSorb-Therapy|Therapy of septic shock using guideline directed standard of care, including continuous renal replacement therapy in combination with haemadsorption using CytoSorb-Adsorber
89515716|NCT04013269|No Intervention|Standard of care|Therapy of septic shock using guideline directed standard of care, including continuous renal replacement therapy
89515717|NCT04464863||Cases|Acute stroke patients during the first week of evolution
89515718|NCT04464863||Control|Age and sex 1:1 healthy participants
89515719|NCT05158699|Active Comparator|topical bromfenac & dexamethasone|bromfenac 0.09% eye drops twice daily starting two days before surgery and continuing 2 weeks postoperatively & dexamethasone 0.1% eye drops four times daily starting two days before surgery and continuing four times daily during the first postoperative week and one drop less per day every following week.
89515720|NCT05158699|Active Comparator|subconjunctival triamcinolone acetonide|one subconjunctival injection of 10 mg triamcinolone acetonide during cataract surgery (TA, Triesence/Vistrec) in the inferotemporal quadrant, 6mm from the limbus.
89515721|NCT05158699|Active Comparator|intracameral ketorolac|intracameral injection of ketorolac tromethamine solution during cataract surgery (Omidria). A 4ml vial of Omidria (ketorolac concentration 2.88mg/ml) is added to 500ml of the irrigation solution used during cataract surgery, resulting in a ketorolac concentration of 0.023mg/ml. At the end of the surgery, the anterior chamber will be filled with the ketorolac solution.
89515722|NCT05158699|Active Comparator|subconjunctival triamcinolone acetonide & intracameral ketorolac|one subconjunctival injection of 10 mg triamcinolone acetonide & intracameral injection of ketorolac tromethamine solution (Omidria; 0.023mg/mL) during cataract surgery.
89515723|NCT05158465|Experimental|Motivational Interviewing and Assessments|Two 1 hour assessments. At each assessment, participant will complete a survey, supply a saliva sample, do a toothpick test, and take a plaque photo. Three one-on-one, half hour educational and skill-building MI sessions will address: proper oral hygiene technique, bacteria and dental caries process, and nutrition. Intervention group adolescents will also receive three calls over one month reinforcing their hygiene behavior goals.
89515724|NCT05158465|No Intervention|Assessments Only|Two 1 hour assessments. At each assessment, participant will complete a survey, supply a saliva sample, do a toothpick test, and take a plaque photo.
89515725|NCT02304887||Bisphosphonate|
89515726|NCT02304887||Selective estrogen receptor modulator|
89515727|NCT02304887||Teriparatide|
89515728|NCT02304887||Senosumab|
89515729|NCT03474133|Experimental|Brentuximab|Brentuximab vedotin 1,8 mg/kg, every 21 days, up to 16 cycles
89515730|NCT02300909|Experimental|dHACM|Lumbar Decompression Surgery or Microdiscectomy Surgery with Application of Dehydrated Human Amnion/Chorion Membrane (dHACM)
89515731|NCT02300909|Other|Surgery without dHACM|Control Group - Lumbar Decompression Surgery or Microdiscectomy Surgery without application of dHACM
89515732|NCT03474055|Experimental|LBRV-PV Lot A|The study participants in this arm will receive one of the three liquid rotavirus vaccine lots (LBRV-PV Lot A).
89515733|NCT03474055|Experimental|LBRV-PV Lot B|The study participants in this arm will receive one of the three liquid rotavirus vaccine lots (LBRV-PV Lot B).
89515734|NCT03474055|Experimental|LBRV-PV Lot C|The study participants in this arm will receive one of the three liquid rotavirus vaccine lots (LBRV-PV Lot C).
89515735|NCT03474055|Active Comparator|ROTASIIL|The study participants in this arm will receive ROTASIIL, the licensed lyophilized rotavirus vaccine in India.
89515736|NCT03512171|Experimental|Amphetamine|One oral dose of dextroamphetamine (0.43 mg/kg) up to a maximum dose of 45mg. The dose is administered in 10mg and 2.5mg capsules prepared by the Vanderbilt Investigational Drug Services (IDS). Note: We are not testing the effect of dextro-amphetamine on a symptom. Rather it is part of the diagnostic intervention that is used to measure dopamine release assessed as the decline in [18F]fallypride binding relative to baseline.
89515737|NCT03512171|Placebo Comparator|Placebo|One oral placebo dose, with capsules prepared by the Vanderbilt Investigational Drug Services (IDS). This provides the baseline against which dopamine release is measured.
89515738|NCT03512171|Experimental|[18F]-FE-PE2I|[18F]-FE-PE2I is a radioligand for measuring dopamine transporters with positron emission tomography (PET). All participants complete this arm. The arm does not include administration of amphetamine or placebo.
89515739|NCT03512327|Experimental|Autoimmune protocol (AIP) diet|Adult patients with active Crohn's disease or ulcerative colitis, undergoing 11 week autoimmune protocol diet, to examine therapeutic efficacy
89515740|NCT02757235|Active Comparator|Irrigation fluid of body temperature|During burr hole evacuation of the chronic subdural hematoma the irrigation fluid used will be of body temperature (approximately 37 degrees Celsius)
89515741|NCT02757235|Active Comparator|Irrigation fluid of room temperature|During burr hole evacuation of the chronic subdural hematoma the irrigation fluid used will be of room temperature (approximately 22 degrees Celsius)
89515742|NCT02304965|Experimental|Daily physical activity|Eligible subjects will be included in the feasibility study to conduct an individualized and structured training program with defined walking and cycling on a bicycle ergometer for 2 months.
89515743|NCT05157763|Experimental|EscharEx 5%|The powder of EX-02 (4 g per vial) should be reconstituted with 10 ml water for injection (WFI) to obtain 5% EX-02 gel. The EX-02 powder and the WFI are to be mixed up to 15 min prior to use. EX-02 5% gel will be topically applied in a thick layer of 2-3 mm on the lesion surface including margin of 5-10 mm for 8-12 hours (preferable over-night) and covered with an occlusive dressing. A new vial should be used for each application. Each patient will be treated with 7 applications.
89515744|NCT04457869|Experimental|Single arm|
89515745|NCT03739099|Active Comparator|Closed-loop insulin delivery 24/7, day and night|Closed-loop subcutaneous insulin infusion driven by continuous glucose monitoring through an algorithm
89515746|NCT03739099|Other|Closed-loop insulin delivery 7/7, dinner and night|Closed-loop subcutaneous insulin infusion driven by continuous glucose monitoring through an algorithm
89515747|NCT03512093||Retrospective chart review|
89515748|NCT03512093||Focus Group Discussion (FGD) of the medical staff|
89515749|NCT03512093||Interviews of mothers|
89515750|NCT02305199|Active Comparator|Hartmanns' solution|"All the participants went on a fast at midnight and 1 L of 5% dextrose fluid containing 10 units of regular insulin (RI) and 40 mEq of potassium was administered intravenously.~On participant's arrival to the operation room, fluid from the ward was immediately removed and replaced it with 1 L of unknown fluid completely sealed in black bag. Neither the participant nor the researcher were aware of the type of the fluid.~After the fluid change, general anesthesia was induced. Intraoperative blood glucose was checked every one hours and 20% dextrose was injected if the number was below 100 and RI was injected if the number was checked over 200."
89515751|NCT02305199|Active Comparator|Normal saline|"All the participants went on a fast at midnight and 1 L of 5% dextrose fluid containing 10 units of RI and 40 mEq of potassium was administered intravenously.~On participant's arrival to the operation room, fluid from the ward was immediately removed and replaced it with 1 L of unknown fluid completely sealed in black bag. Neither the participant nor the researcher were aware of the type of the fluid.~After the fluid change, general anesthesia was induced. Intraoperative blood glucose was checked every one hours and 20% dextrose was injected if the number was below 100 and RI was injected if the number was checked over 200"
89515752|NCT03469375||LAPC patients with mFOFLRINOX-based neoadjuvant therapy|LAPC patients were enrolled prospectively and diagnosed by MDT group in our hospital. These patients further received the neoadjuvant therapy with mFOLFIRINOX, the Overall survival, Progression survival, response to mFOLFIRINOX, chemo-related Toxicities, Postoperative complications and Histopathologic staging were measured.
89515753|NCT03512015|Experimental|LuCApp + Standard Care|"LuCApp (Lung Cancer App) is an application developed by researchers and lung cancer clinicians to gather symptom data in real time and to share it with healthcare professionals.~LuCApp allows daily monitoring and grading of a list of symptoms which trigger alerts to the physicians in case predefined severity thresholds are met."
89515754|NCT03512015|Active Comparator|Standard Care|Usual care will consist of standard procedures currently available at participating centers for monitoring and documenting symptoms. These therapeutical procedures are based on the guidelines developed by the National Comprehensive Cancer Network (NCCN) and the Associazione Italiana di Oncologia Medica (AIOM). Symptoms for control arm patients will be discussed and registered during scheduled clinical visits with the oncologists. Standard-of-care patients will fill out their PROMs following the same schedule identified for LuCApp patients with paper questionnaires during clinic visits, or at home (having received paper questionnaires during the previous visit) or via telephonic interviews with the research team.
89515755|NCT02301065||Stem Cell Donors|Allogeneic hematopoietic stem cell transplant (HSCT) donors. Blood samples for phenotypes research will be collected once from donors, prior to apheresis for collection of donor stem cells.
89515756|NCT02301065||Stem Cell Recipients|Allogeneic hematopoietic stem cell transplant (HSCT) recipients. Blood samples will be drawn prior to transplantation and every two weeks, up to day 100 post-transplantation.
89515757|NCT01603407|Experimental|Daily prednisone|daily prednisone (0.75 mg/kg/day)
89515758|NCT01603407|Experimental|Intermittent prednisone|intermittent prednisone (0.75 mg/kg/day, 10 days on, 10 days off)
89515759|NCT01603407|Experimental|Daily deflazacort|daily deflazacort (0.9 mg/kg/day
89515760|NCT05302570|Experimental|Hypofractionated Proton Beam Therapy|5 fractions of 5 Gy of PBT to clinical tumor volume +/- an additional simultaneous 1 Gy per fraction to any pre-determined at-risk margin (for a total of 6 Gy per fraction x 5 fractions for at-risk margins as a simultaneous integrated boost (SIB)).
89515761|NCT02305355|Experimental|Omega-3-acids ethylesters 90 4g, any statin|
89515762|NCT02305355|Active Comparator|any statin|
88961333|NCT02008240|Experimental|Needle aspiration of hydrosalpinx|Aspiration of hydrosalpingeal fluid under ultrasound guidance
88961334|NCT02008240|Active Comparator|salpingectomy|Surgical removal of hydrosalpinx
88961335|NCT02008253||INTRASTROMAL CORNEAL RING SEGMENT|Forty-two eyes of 26 patients, 14 men and 12 women, with ectasia after refractive surgery were studied in a nonrandomized, retrospective, observational case series.
89515763|NCT03469219||Study group|patients with psoriasis vulgaris. measuring serum granulysin level for all patients and tissue granulysin level in lesional and perilesional skin for a number of patients using Enzyme Linked Immunosorbent Assay.
89515764|NCT03469219||Control group|Healthy volunteers. measuring serum granulysin level for all healthy volunteers and tissue granulysin level for a number of them using Enzyme Linked Immunosorbent Assay.
89515765|NCT02305511|Experimental|Peripheral venous catheterization|Peripheral venous catheterization during pediatric resuscitation
89515766|NCT02305511|Experimental|intraosseous access|Intraosseus access using intraosseous access devices during resuscitation
89515767|NCT03511859||Control Group|Mammography/ultrasonography confirmed no findings.
89515768|NCT03511859||Cancer Group|The biopsy result is breast cancer.
89515769|NCT03511703|Experimental|Apatinib|
89515770|NCT03511703|Other|TACE|
89515771|NCT03495661|Active Comparator|Surgical (Decompression)|Central decompression of the stenotic segment(s) with undercutting of the lateral recesses.
89515772|NCT03495661|No Intervention|Non-surgical|"Physical therapy according to the Östersund model: training on stationary bicycle 30 min, 3 times/week under 4 months."
89515773|NCT05157373||Group 1|Patients with any type of endometrial cancer
89515774|NCT05157373||Group 2|Patients with hyperplastic endometrial lesion (all type of endometrial hyperplasia and endometrial polyps). In this group will be included the breast cancer survivors under tamoxifen.
89515775|NCT05157373||Control group|A random sample of women without any endometrial pathology.
89515776|NCT02305667|Placebo Comparator|Macintosh|Double lumen tube intubation using Macintosh laryngoscope
89515777|NCT02305667|Active Comparator|Glidescope®|Double lumen tube intubation using Glidescope® videolaryngoscope
89515778|NCT02305667|Active Comparator|Airtraq®|Double lumen tube intubation using Airtraq® videolaryngoscope
89515779|NCT02305667|Active Comparator|King Vision™|Double lumen tube intubation using King Vision™ videolaryngoscope
89515780|NCT05157295|Experimental|Experimental Group|100 U of onabotulinumtoxinA toxin diluted in 10 mL of saline cystoscopically injected into approximately 4 different detrusor muscle sites along the posterior bladder wall and dome.
89515781|NCT05157295|Active Comparator|Control Group|100 U of onabotulinumtoxinA toxin diluted in 10 mL of saline cystoscopically injected into approximately 20 different detrusor muscle sites along the posterior bladder wall and dome.
89515782|NCT03771898|Experimental|SHP611|Participants will receive 150 milligrams (mg) of SHP611 intrathecally (IT) via intrathecal drug delivery device (IDDD) or lumbar puncture (LP) once weekly for 106 weeks.
89515783|NCT02301221|Experimental|Fecal microbiota transplantation (FMT)|Patients included will receive standard FMT, and then will be followed up for 24 weeks.
88961336|NCT02008266||Patients with Rheumatoid Arthritis|
88961337|NCT02008279|Experimental|Group 1A|100 mg CNTO 3157 or placebo in healthy male Japanese participants
89515784|NCT03339141|Placebo Comparator|supine position|Patients are placed in the supine position at 0° from arrival in the room until intubation
89515785|NCT03339141|Active Comparator|25° head-up position|Patients are placed in the 25° head-up position (half-seat or whole body proclive) from arrival in the room until intubation.
89515786|NCT02305745||Preeclampsia- observational|45 women with preeclampsia
89515787|NCT02305745||No preeclampsia- observational|10 women without preeclampsia
89515788|NCT03288363|Experimental|tDCS|20 sessions tDCS (DC-Stimulator Plus -Neuroconn) during 2 Weeks on temporal cortex - each session : 30 minutes - 2 mA - 2 sessions per day - evaluation at 12 weeks post-treatment
89515789|NCT03288363|Sham Comparator|sham stimulation|the same parameters of stimulation as with real current stimulation (time, parameters to be seen on the apparatus screen) 20 sessions during 2 Weeks on temporal cortex - each session : 30 minutes - 2 sessions per day.
89515790|NCT03511547|Active Comparator|Intervention group 1: Pitch-Patch|Reconstruction with patch augmentation using a synthetic patch
89515791|NCT03511547|Active Comparator|Intervention group 2: ArthroFlex|Reconstruction with patch augmentation using a biological human dermis patch
89515792|NCT03511547|No Intervention|Control|
89515793|NCT03122431|Other|SLE/cutaneous lupus with thalidomide|This subproject includes only one arm of lupus patients with active and refractory cutaneous disease and eligible for Thalidomide 100mg/day for 12 months.
89515794|NCT03122431|Active Comparator|Inactive SLE with standard dose of HCQ|This subproject includes one arm of lupus patients with inactive disease, in which will be maintained on standard dose of Hydroxychloroquine (400mg/day).
88961338|NCT02008279|Experimental|Group 1B|100 mg CNTO 3157 or placebo in healthy male Caucasian participants
89515795|NCT03122431|Active Comparator|Inactive SLE with reduced dose of HCQ|This subproject includes one arm of lupus patients with inactive disease: in which the dose will be reduced to 400mg 3 times a week (Hydroxychloroquine reduced).
89515796|NCT03263637|Experimental|Arm A: (Cohort 1-3)|dose level 1-3 in subjects with relapsed or refractory haematological malignancies excluding AML/ALL/high-risk MDS/CMML/CLL.
89515797|NCT03263637|Experimental|Arm B: (Cohort 1-3)|dose level 1-3 in subjects with relapsed or refractory AML, ALL, high-risk MDS, CMML, CLL and Richter's syndrome.
89515798|NCT03736018|Active Comparator|CTCA + ICA|Computed Tomography Cardiac Angiography (CTCA) performed prior to invasive coronary angiogram (ICA).
89515799|NCT03736018|No Intervention|ICA only|Invasive coronary angiogram (ICA) performed only.
89515800|NCT03511469|Experimental|Control Group|Patients in this group will only received standardized rehabilitation protochol after Bankart surgery
89515801|NCT03511469|Experimental|Isokinetic Group|Patients in this group will receive concentric training for rotator cuff muscles with isokinetic device in addition the the standart rehabilitation protocol.
89515802|NCT02990481|Experimental|Arm 1 - TRK-950|"Solid tumor~TRK-950 (Three dose levels will be explored during Arm 1)"
89515803|NCT02990481|Experimental|Arm 2 - TRK-950|"Colon cancer~TRK-950 (Low dose and High dose)"
89515804|NCT02990481|Experimental|Arm 3 -TRK-950|"Cholangiocarcinomas~TRK-950 (Low dose)"
89515805|NCT05248360|Experimental|Experimental group|Hydrogen-oxygen mixed gas(H2-O2, 66.6% hydrogen, 33.3% oxygen) inhalation, 900ml/min, 2h/d
89515806|NCT05248360|Placebo Comparator|Control group|Air inhalation, 900ml/min, 2h/d
88961339|NCT02008279|Experimental|Group 2A|300 mg CNTO 3157 or placebo in healthy male Japanese participants
89515807|NCT03511313|Experimental|Renal denervation|Renal angiography and renal denervation (with sterile irrigated deflectable ablation catheter in renal artery), and maintaining anti-hypertensive medications
89515808|NCT03511313|Sham Comparator|Renal angiography|Renal angiography and maintaining anti-hypertensive medications
89515809|NCT02506465|Experimental|iTind arm|iTind implant is implant during the study for 5-7 days.
89515810|NCT02506465|Sham Comparator|Sham arm|Foley catheter is used during the study
89515811|NCT05092425||with CPPV|Group 1 is childrens with contralateral patent processus vaginalis.
89515812|NCT05092425||without CPPV|Group 2 is childrens without contralateral patent processus vaginalis.
89515813|NCT02235454|Other|Glaucoma arm|Consecutive patients with glaucoma will undergo non-invasive OCT imaging
89515814|NCT02305823|Active Comparator|Aripiprazole|Oral, dose range 5-30 mg/day, once or twice a day, during study duration
89515815|NCT02305823|Active Comparator|Quetiapine|Oral, dose range 100-600 mg/day, once or twice a day, during study duration
89515816|NCT02305823|Active Comparator|Ziprasidone|Oral, dose range 40-160 mg/day, once or twice a day, during study duration
89515817|NCT03471091|Experimental|Intervention group|"Intervention group subjects will use NIV with the integrated tele-monitoring management program as home therapy and accomplish the following tasks via mobile COPD Butler APP: 1) upload daily NIV usage data， blood pressure, oxygen saturation, and heart rate measurement; 2) daily medication taken recording; 3) regular self-reported health questionnaire and symptom recording; 4) read health education materials.~Information collected from the intervention group by the APP will be monitored by physician team from the leading hospital through physician web portal. The physician team will provide regular health report, and once an alert is generated due to the abnormality in NIV usage or vital sign data etc., physicians will take action accordingly."
89515818|NCT03471091|No Intervention|Control group|Control group subjects will only use NIV according to their treatment plan at home. NIV usage data will be read from the NIV secure digital memory card for the control group.
89515819|NCT05376189|Active Comparator|Control Group|This group will be given standardized tuberculosis drug with 400 IU of oral Vitamin D3
89515820|NCT05376189|Experimental|Moderate Dose|This group will be given standardized tuberculosis drug with 5000 IU of oral Vitamin D3
89515821|NCT05376189|Experimental|High Dose|This group will be given standardized tuberculosis drug with 10000 IU of oral Vitamin D3
89515822|NCT02235298|Experimental|Dapagliflozin and Metformin Group|Participants in this group will receive Dapagliflozin in addition to Metformin for 6 months.
89515823|NCT02235298|Active Comparator|Metformin and Placebo Group|Participants in this group will receive Metformin and Placebo for 6 months.
89515824|NCT02305901|Experimental|Repaglinide + Bupropion + BI 187004|repaglinide tablets and bupropion tablets with and without concomitant administration of BI 187004
89515825|NCT03473899|Active Comparator|rESWT + RP|Device: rESWT
89515826|NCT03473899|Placebo Comparator|sham-rESWT + RP|Device: sham-rESWT
89515827|NCT04657263||Person at risk of infection according to French 2019 immunization|Person at risk of infection according to French 2019 immunization
89515828|NCT05136391|Experimental|XTR003|Administration and investigation of myocardial fatty acid radiotracer
89515829|NCT04619199|Experimental|Idiopathic Pulmonary Fibrosis|Blood sample were performed during the study for all patients.
89515830|NCT02234596|Experimental|Nintedanib|
89515831|NCT02305979||Treatment with Loratadine|Treatment with Loratadine
89515832|NCT02306057||Pre BCPC|Children undergoing catheterization before Bidirectional CavoPulmonary Connection (BCPC) procedure
89515833|NCT02306057||BCPC surgery|Children undergoing surgical BCPC procedure
89515834|NCT02306057||Pre TCPC|Children undergoing catheterization before Total CavoPulmonary Connection (TCPC )procedure
89515835|NCT02306057||TCPC surgery|Children undergoing surgical TCPC procedure
89515836|NCT05737407|Experimental|LUS-guided Peep|"After induction of anesthesia and intubation, patients will be briefly turned onto their side and LUS will be performed in the posterior areas of the lung; PEEP will be adjusted in increments of 1 cmH20/minute starting from zero while maintaining visual inspection of LUS up to the point where signs of eventual subpleural consolidations and/or multiple B lines are not present anymore.~FiO2 will be chosen as the minimum necessary to maintain SpO2 of 97-98%."
89515837|NCT05737407|Active Comparator|Standard setting of Peep|"After induction, patients will be similarly scanned with LUS on their side but PEEP will be set at 4 cmH2O independently from results of LUS.~FiO2 will be chosen as the minimum necessary to maintain SpO2 of 97-98%."
89515838|NCT04539951|Active Comparator|serotonin treatment|In experimental phase I, all recruited subjects provide written informed consent before any related procedures. Participants will receive sertraline, initially at 50mg/d, with a weekly 50mg/d further increase, to the maximum recommended dosage (200mg/d) or to the maximum tolerated dosage (less than 200mg/d). Patients will be on their maximum dose by week 4, so allowing an assessment of response at 12 weeks
89515839|NCT04539951|Active Comparator|sequenced treatment alternatives|If participants in In Experimental phase I do not achieve remission, they will be will be randomly assigned to the second-step treatment (Experimental phase II). The second-step therapy will consist of five treatment options including higher-than-usual-maximal dosage of sertraline, switching to fluvoxamine, switching to venlafaxine, augmentation with memantine, and augmentation with aripiprazole.
89515840|NCT02306213|Experimental|Hydroxyethylstarch 6% 130/0.4|These patients have received Hydroxyethylstarch 6% 130/0.4 intraoperatively or postoperatively in addition to standard volume therapy.
89515841|NCT02306213|Active Comparator|No Hydroxyethylstarch 6% 130/0.4|These patients have not received Hydroxyethylstarch 6% 130/0.4 at any time point. Only standard volume therapy has been used.
89515842|NCT03508349|Experimental|IST using RDT|Women presenting for their first ANC visit to facilities will be consecutively enrolled after providing informed consent. Women in the intervention group (IST+ routine care) will be tested for malaria at the health center during their ANC visits with an RDT. If positive, they will be treated with artemisinin-based combination therapy (ACT) in second or third trimester or quinine in the first trimester.
88961340|NCT02008279|Experimental|Group 2B|300 mg CNTO 3157 or placebo in healthy male Caucasian participants
89515843|NCT03508349|No Intervention|Routine Antenatal Care|Women presenting for their first ANC visit to facilities will be consecutively enrolled after providing informed consent. Women in the comparison group (routine care) will receive routine antenatal care services per the national guidelines. They will not be tested for malaria at each antenatal care visit unless they are symptomatic for malaria.
89515844|NCT02234362|Experimental|open-label vortioxetine|flexible-dose vortioxetine of 5-20 mg depending on tolerability
89515845|NCT04434807|Experimental|Minimally invasive hematoma evacuation|Patients randomized to minimally invasive hematoma evacuation will have neurosurgery followed by standard medical therapy in a stroke care unit or intensive care unit, as appropriate to the patients clinical condition.
89515846|NCT04434807|No Intervention|Standard care (medical therapy)|Patients randomized to medical management will receive the standard medical therapies for the treatment of intracerebral hemorrhage in a stroke care unit or intensive care unit, as appropriate to the patients clinical condition, with no planned surgical intervention.
89515847|NCT02301455|No Intervention|Control, Not hypertensive|Participants who after 3 weeks do not have high blood pressure or are not responsive to text messages.
89515848|NCT02301455|Experimental|Text messages, hypertensive|Participants who after 3 weeks have high blood pressure and are responsive to text messages, who are then randomized to receive text messages.
89515849|NCT02301455|No Intervention|No text messages, hypertensive|Participants who after 3 weeks have high blood pressure and are responsive to text messages, who are then randomized to not receive text messages.
89515850|NCT02301533|Experimental|Shikamana Intervention|The Shikamana Intervention consists of provider support (modified Next Step Counseling) and peer support (trained peer navigator) to promote adherence to antiretroviral therapy
89515851|NCT02301533|Other|Standard Care|The standard care arm will receive adherence counseling per standard Kenyan Ministry of Health guidelines, along with the recommendation to disclose to a family member or friend in order to obtain support
89515852|NCT04415541|Experimental|Psychodynamic Psychotheray|Following Coordinated Specialty Care, we will offer weekly psychodynamic psychotherapy and medication management sessions which will be conducted solely by the PI, Keith Gallagher, in the initial pilot period. Consent will be obtained to record audio and video of the sessions
89515853|NCT04415541|Active Comparator|Treatment as Usual|Following Coordinated Specialty Care, patients will be referred to general mental health providers in the community, which would typically include less intensive and frequent psychotherapy by a social worker or psychologist as well as medication management by a psychiatrist who may not be a specialist in psychotic disorders.
89515854|NCT03508271||Elderly individuals with NVAF and HF who are taking OAC's|
89515855|NCT05092113|Experimental|Group A|a compound glutamine capsule was taken orally in the first cycle of chemotherapy, and a compound glutamine capsule simulated placebo was taken in the second cycle of chemotherapy. All patients take drugs orally on the first day of each cycle of chemotherapy, 3 tablets 3 times a day, and the course of the treatment was 3 weeks.
89515856|NCT05092113|Experimental|Group B|in the first cycle of chemotherapy, a compound glutamine capsule simulated placebo was given ,and in the second cycle, a compound glutamine capsule was taken at the same time of chemotherapy. All patients take orally from the first day of chemotherapy, 3 times a day after meals, 3 tablets each time, and the course of treatment was 3 weeks.
89515857|NCT02234284|Experimental|Health Coaching|Patients randomized to the health coaching intervention would work with a trained health coach who would provide patient education self-management support, use action planning to help patient make changes to reach goals, as well as help coordinate patient care between the primary care provider and pulmonary specialist, identify gaps in care, and help patient access needed services
89515858|NCT02234284|No Intervention|Usual care|Usual care was chosen as the comparison group to provide maximum generalizability of the study, as usual care is the practical alternative for the target population. Usual care includes patient education classes, smoking cessation classes, psychosocial medicine and nutritional counseling.
89515859|NCT05737251|Experimental|PoET Group|Participants received two sessions of PoET and filled out the questionnaires.
89515860|NCT05737251|No Intervention|Control Group|Participants only filled out the questionnaires.
89515861|NCT02301689||Heart Failure patients|
89515862|NCT02306369|No Intervention|Treatment as usual|A wait-list control.
89515863|NCT02306369|Experimental|Internetdelivered exposure-based CBT|10 sessions of ICBT during 10 weeks for the adolescents. 5 session of parent training during 10 weeks for parents. Therapist support is provided at least once weekly through the platform developed for the purpose. Therapists are trained CBT-psychologists.
89515864|NCT02301845|Experimental|Suspended Diatoms|Suspended diatom shells (10 mg/ 10 ml of saline) will be instilled in the oral cavity of the study subject every 12 hours for the first three study days. The total amount of amorphous silica administered will be 20 mg/day, which is the average daily intake of amorphous silica in normal human diet (0.3 mg/kg body weight/day)
89515865|NCT05091411|Experimental|Population Ⅰ|3 doses of experimental vaccine (pilot scale batch) were given at day 0, 30 and 60.
89515866|NCT05091411|Experimental|Population Ⅱ|3 doses of experimental vaccine (process validation lot 1) at day 0, 30 and 60;
89515867|NCT05091411|Experimental|Population Ⅲ|3 doses of experimental vaccine (process validation lot 2) at day 0, 30 and 60;
89515868|NCT05091411|Experimental|Population Ⅳ|3 doses of experimental vaccine (process validation lot 3) were given at day 0, 30 and 60.
89515869|NCT03508037|Experimental|Experimental group|The subject receives the Functional Electrical Stimulation (FES) when he or she has the intention to move. It is obtained through electroencephalography.
89515870|NCT03508037|Active Comparator|Control group|The subject receives the Functional Electrical Stimulation (FES) after o before (0.5 seconds) when he or she has the intention to move. It is obtained through electroencephalography.
89515871|NCT04309305|Experimental|Stroke RE|After discharge from the acute rehabilitation facility, participants in the stroke RE group will participate 3 days a week for 10 weeks in robotic exoskeleton gait training provided by a trained, licensed physical therapist. Participants will be permitted to participate in additional prescribed standard physical therapy on their own.
88961341|NCT02008279|Experimental|Group 3A|600 mg CNTO 3157 or placebo in healthy male Japanese participants
89515872|NCT04309305|Active Comparator|Stroke SOC|After discharge from the acute rehabilitation facility, participants in the stroke SOC group will participate 3 days a week for 10 weeks in standard of care gait training provided by a licensed physical therapist. Participants will be permitted to participate in additional prescribed standard physical therapy on their own.
89515873|NCT04309305|Other|Healthy Control|Participants in the healthy control group will not participate in any gait training. Healthy control participants will only be asked to complete 3 testing sessions.
89515874|NCT02306447|Experimental|rPMS and rTMS|"rPMS Stimulation of the neck muscles in five medial-lateral movements starting from the neck: left and right trapezius and deltoid muscle, trapezius and lattissimus dorsi muslce, and over the backbone. 20 stimuli per movement with 2s inter-train interval; four repetitions for each of the five movements; the first 20 trains with a frequency of 5Hz, the second 20 trains at 20Hz; stimulation at individual comfortable level (20-30% stimulator output); round coil.~rTMS 20Hz stimulation with 2000 stimuli over the left dorso-lateral prefrontal cortex at 110% motor threshold; followed by 1Hz stimulation with 2000 stimuli over the left temporo-parietal cortex; stimulation intensity 110% motor threshold; butterfly coil.~For stimulation we use MagPro X100 (Medtronic, Denmark)."
89515875|NCT05737173|Experimental|Leukocyte-rich platelet-rich plasma|Leukocyte-rich PRP: Centrifuge at 300 G for 5 min, separate the plasma and buffy coat layers, and then centrifuge at 700 G for 17 min with calcium chloride at the ratio of 1:5 to PRP by volume.
89515876|NCT05737173|Experimental|Leukocyte-poor platelet-rich plasma|Leukocyte-poor PRP: Centrifuge at 123 G for 15 min, separate the plasma and buffy coat layers, and then centrifuge at 448 G for 10 min. Calcium chloride was added 1:5 to PRP by volume.
89515877|NCT05737173|Experimental|Corticosteroid|Corticosteroid: 1 ml of triamcinolone acetonide (40mg/ml) mixed with 0.9% NaCl to a total volume of 4 ml.
89515878|NCT02301923||CPAP compliant (C)|Patients confirmed with obstructive sleep apnea and succeeded to pursue treatment with CPAP
89515879|NCT02301923||CPAP noncompliant (NC)|Patients confirmed with obstructive sleep apnea but did not succeed to pursue treatment with CPAP
89515880|NCT03510923||Patients who underwent an appendectomy|Patients of all ages who underwent an appendectomy in the elective or non-elective setting.
89515881|NCT03510923||Patients who underwent a cholecystectomy|Patients of all ages who underwent a cholecystectomy in the elective or non-elective setting.
89515882|NCT05091177||the patience group|underwent the following examinations: serum acetylcholine receptor antibody, erythrocyte deposition rate, hypersensitive C protein, neostigmine test, chest CT, low frequency repetitive nerve stimulation (orbicularis oculi muscle, levator palpebrae muscle, frontalis muscle), thyroid function and color ultrasound.
89515883|NCT05091177||the normal group|underwent the following examinations: serum acetylcholine receptor antibody, erythrocyte deposition rate, hypersensitive C protein, neostigmine test, chest CT, low frequency repetitive nerve stimulation (orbicularis oculi muscle, levator palpebrae muscle, frontalis muscle), thyroid function and ultrasound.
89515884|NCT02302001|Experimental|Primary Breast Augmentation|
89515885|NCT05737095||Premature infants|premature infants born between 32 and 36 weeks of amenorrhea + 6 days hospitalized for respiratory distress
89515886|NCT03507959|Experimental|OLP scientifically-objective|Participants are informed that they are about to take a placebo. The rationale for the effectivity of placebos is explained in a scientifically-objective manner.
89515887|NCT03507959|Experimental|OLP personally-affective|Participants are informed that they are about to take a placebo. The rationale for the effectivity of placebos is explained in a personally-affective manner.
89515888|NCT03507959|Experimental|DP scientifically-objective|Participants are informed that they are about to take an effective antidepressant. The rationale for the effectivity of the antidepressant is explained in a scientifically-objective manner.
89515889|NCT03507959|Experimental|DP personally-affective|Participants are informed that they are about to take an effective antidepressant. The rationale for the effectivity of the antidepressant is explained in a personally-affective manner.
89515890|NCT03507959|No Intervention|Control group|This group does not take the nasal spray.
89515891|NCT02469285|Experimental|Modified pork|Pork with modified fatty acid composition, more unsaturated fat. 160 g pork or pork products daily for 4 weeks, consumption of other red meat is prohibited
89515892|NCT02469285|Active Comparator|Normal pork|Normal pork 160 g pork or pork products daily for 4 weeks, consumption of other red meat is prohibited
89515893|NCT02469285|Experimental|Normal pork and berries|Normal pork and berries (strawberry, raspberry, wild blueberry, lingonberry, cloudberry, blackcurrant) 160 g pork or pork products daily for 4 weeks, consumption of other red meat is prohibited
88961342|NCT02008279|Experimental|Group 3B|600 mg CNTO 3157 or placebo in healthy male Caucasian participants
88961343|NCT02008279|Experimental|Group 4|300 mg CNTO 3157 in healthy male Caucasian participants
89515894|NCT03507881||Ennovate|Implantation of an Ennovate® internal fixation
89515895|NCT04217577|Experimental|Dried Plums|Consume dried plums daily.
89515896|NCT02306525||Ptt. with Femoracetabular Impingement|Enrollment anticipated: 60 Arthroscopic surgery of the hip joint
89515897|NCT02306525||Healthy volunteers|Enrollment anticipated: 30
89515898|NCT03507803|Experimental|Gait Biofeedback|This group will receive audiovisual feedback about the position of their foot during walking. Feedback will be provided over 8 total sessions.
89515899|NCT03507803|No Intervention|Control|This arm will not receive any audiovisual feedback about the position of their foot during walking.
89515900|NCT04122261|Experimental|experimental group|MicroHand S robotic surgery group
89515901|NCT04122261|Experimental|control group|da Vinci robotic surgery group
88961344|NCT02008305|Experimental|protocol of optimization ALARA|protocol of optimization ALARA protocol of optimization of doses
88961345|NCT02008305|Active Comparator|protocol of opimization Philips|protocol of optimization Philips usual protocol of optimization of doses
88961346|NCT02008331|Experimental|SYNBIOTIC|Patients of this group assumed Probinul-Neutro® po 5g three times a day for 30 days
88961347|NCT02008331|Placebo Comparator|PLACEBO|patients of this group received 5g of placebo 3 times a day for 30 days
88961348|NCT02008383|Experimental|Cabozantinib and Panitumumab|60 mg Cabozantinib PO daily and 6 mg/kg Panitumumab IV every 2 weeks.
88961349|NCT02008383|Experimental|Cabozantinib|60 mg Cabozantinib PO daily.
89515902|NCT05158439|Experimental|Treatment Group (AlloRx)|Single intravenous infusion of 100 million cells
89515903|NCT05091099|Active Comparator|On time Zoledronate|Zoledronate would be given (one dose for one year) after the completiong of denosumab on time
89515904|NCT05091099|Experimental|Alendronate and Zoledronate|Alendronate would be given one month before the the completiong of denosumab and the following 3 months (Total four months). After the completion of Alendronate, Zoledronate would be given (one dose).
89515905|NCT03505151|Experimental|All subjects|
89515906|NCT02306681||SAQ-Self-Assessment Questionnaire|
89515907|NCT02232880|Active Comparator|abatacept|"Subjects randomized to abatacept weighing 60 to 100 kg will receive 750 mg, and those >100 kg will receive 1000 mg abatacept by intravenous infusion at 0 [randomization], 2, and 4 weeks and then every 4 weeks thereafter for a total of 24 weeks.~All subjects will be treated with chlorthalidone 25 mg/day, lisinopril 20 mg/day [Patients with a history of adverse reaction to lisinopril will be treated with losartan 50 mg/day], amlodipine 5 mg/day and spironolactone 25 mg bid as standardized treatment of hypertension prior to randomization and throughout the active treatment phase."
89515908|NCT02232880|Placebo Comparator|placebo|"Subjects randomized to placebo will receive 100 ml normal saline by intravenous infusion at 0 [randomization], 2, and 4 weeks and then every 4 weeks thereafter for a total of 24 weeks.~All subjects will be treated with chlorthalidone 25 mg/day, lisinopril 20 mg/day [Patients with a history of adverse reaction to lisinopril will be treated with losartan 50 mg/day], amlodipine 5 mg/day and spironolactone 25 mg bid as standardized treatment of hypertension prior to randomization and throughout the active treatment phase."
89515909|NCT02896855|Active Comparator|Arm A: Placebo + Trastuzumab + Docetaxel|Placebo matched to pertuzumab, trastuzumab (8-milligrams per kilogram [mg/kg] loading dose for Cycle 1, followed by 6 mg/kg for subsequent cycles), and docetaxel (75-milligrams per square meter [mg/m^2]) were administered by intravenous (IV) infusion every 3 weeks until disease progression or unacceptable toxicity.
89515910|NCT02896855|Experimental|Arm B: Pertuzumab + Trastuzumab + Docetaxel|Pertuzumab (840-mg loading dose for Cycle 1, followed by 420 mg for subsequent cycles), trastuzumab (8-mg/kg loading dose for Cycle 1, followed by 6 mg/kg for subsequent cycles), and docetaxel (75-mg/m^2) were administered by IV infusion every 3 weeks until disease progression or unacceptable toxicity.
89515911|NCT03504995|Experimental|IRE patients|patients who will underwent 'Focal irreversible electroporation of the prostate cancer'
89515912|NCT02311439|Experimental|FOLFIRINOX + CRT|FOLFIRINOX regimen, consisted of oxaliplatin, irinotecan, leucovorin and fluorouracil (5-FU), for 4 cycles, followed by consolidation radiotherapy concurrent with capecitabine 625mg/m2 BID in non-progressed cases, in treating patients with locally advanced cancer pancreas.
89515913|NCT02311517|Experimental|ropivacaine group|45 patients will be randomly allocated into ropivacaine group with 0.4 ml/kg of 0.375% ropivacaine after induction of anesthesia.
89515914|NCT02311517|Placebo Comparator|saline group|40 patients are randomly allocated into saline group with 0.4 ml/kg saline after induction of anesthesia.
89515915|NCT02232802|Experimental|Enoxaparin Sodium Chemi|Enoxaparin Sodium Chemi and Clexane will be administered to healthy subjects. Each subject will receive each treatment over two separate treatment periods under fasting conditions.
89515916|NCT02232802|Experimental|Clexane|Enoxaparin Sodium Chemi and Clexane will be administered to healthy subjects. Each subject will receive each treatment over two separate treatment periods under fasting conditions.
89515917|NCT04463459|No Intervention|Chemotherapy + Placebo|Patients receiving chemotherapy This group will be received chemotherapy and placebo
89515918|NCT04463459|Active Comparator|Chemotherapy + Vitamin C + Vitamin E|Patients receiving vitamin C and E with Chemotherapy This group will be received vitamin C (500 mg) twice daily and vitamin E (400 mg) once daily with chemotherapy for 6 weeks
89515919|NCT04463381||Group 1|sharp choledochotomy by a scalpel or scissor
89515920|NCT04463381||Group 2|choledochotomy by a diathermy hook
89515921|NCT04463381||Group 3|choledochotomy by an ultrasonic device
89515922|NCT05736783|Experimental|plyometric exercises|performing plyometric exercises for 6 weeks
89515923|NCT05736783|Experimental|strenghtening of quadriceps and hamstring|performing strengthening of quadriceps and hamstring for 6 weeks
89515924|NCT02762773|Experimental|Experimental|Patients will undergo non-dissection of the inferior rectus sheath at time of primary cesarean delivery
89515925|NCT02762773|Placebo Comparator|Control|Patients will undergo standard practice which is dissection of the superior and inferior rectus sheath at time of cesarean delivery
89515926|NCT03534375||Female Early Adolescents|
89025056|NCT03279419||Normal|"15 patients without liver disease, and without any other disease or drug known to affect the peripheral circulation.~Serial static images to be taken at up to 3 time points using thermal imaging camera. Video images using thermal camera will be used to capture warming of one hand after cooling."
89515927|NCT03534375||Male Early Adolescents|
89515928|NCT03507335||Atrial fibrillation|Patients with atrial fibrillation during measurements
89025057|NCT00439257||Group 1|
89515929|NCT03507335||Sinus|Patients with sinus rhythm during measurements
89515930|NCT02289313|Experimental|Youth Healthy Living Program|Youth attending the Rochester Alternative Learning Center (ALC) will be enrolled in a youth healthy living program at the ALC.
89515931|NCT02825355||Patients with cervical cancer|All patients receive sentinel node mapping as the conventional treatment.
89515932|NCT02825355||Patients with endometrial cancer|All patients receive sentinel node mapping as the conventional treatment.
89515933|NCT04457011|Experimental|High dose group|High dose Susu Xiao'er Zhike Granules, 1 bag, bid
89515934|NCT04457011|Experimental|Middle dose group|Middle dose Susu Xiao'er Zhike Granules, 1 bag, bid
89515935|NCT04457011|Placebo Comparator|Extremely-low dose group|Extremely-low dose Susu Xiao'er Zhike Granules, 1 bag, bid
89515936|NCT02311595|Experimental|reduced port|gastric cancer patients go through reduced port laparoscopic distal gastrectomy with D2 lymph node dissection
89515937|NCT05735223|Experimental|Stretched flaccid penile length (SFPL) following RALP.|Stretched flaccid penile length (SFPL) was measured by a single male assessor at preoperative visit, and at the time of catheter removal (10 days post-surgery).
89515938|NCT04456855||Locoregional surgery|
89515939|NCT04456855||No surgery|
89515940|NCT02306837|Experimental|Consolidation chemo|Patients recieved 3 cycles of consolidation chemotherapy post-auto-HSCT: mini-Bu-Cy-E regimen
89515941|NCT04778644|Experimental|Patients with psychosis|People who are part of a dimensionally-organized psychosis sample spanning several serious mental illness diagnoses including schizophrenia, schizoaffective disorder, or psychotic bipolar I disorder. Eligible participants will be scheduled for two dose visits where they will receive a 600mg CBD dose on one day and a placebo dose on the other day. Doses will be randomized and double-blind. Doses will be administered via oral gel capsules.
89515942|NCT04778644|Experimental|Healthy controls|People who do not have a diagnosis of schizophrenia, schizoaffective disorder, or psychotic bipolar I disorder. Eligible participants will be scheduled for two dose visits where they will receive a 600mg CBD dose on one day and a placebo dose on the other day. Doses will be randomized and double-blind. Doses will be administered via oral gel capsules.
89515943|NCT02434328|Experimental|Brolucizumab 6 mg|Single intravitreal (IVT) injection of brolucizumab at Day 0, Week 4, and Week 8, followed by 1 injection every 8 weeks/1 injection every 12 weeks (q8w/q12w) maintenance regimen until study exit
89515944|NCT02434328|Active Comparator|Aflibercept 2 mg|Single IVT injection of aflibercept ophthalmic solution at Day 0, Week 4, and Week 8, followed by q8w maintenance regimen until study exit
89515945|NCT02307071|Experimental|Cefaly Kit Arnold|Occipital transcranial stimulation is implemented in occipital region at 16 mA of intensity, for 20 minutes, everyday for 3 months, in 20 chronic migraine patients.
89515946|NCT04785274||SpHb|
89515947|NCT04785274||Control|
89515948|NCT04457791|Experimental|Intervention phase|From week 5-8, participants will receive the intervention, namely personalized dietary advice.
89515949|NCT04457791|No Intervention|Observational phase|From week 1-4, participants will not receive any intervention, but just will be observed, to form as their own control
89515950|NCT02311751|Active Comparator|Active rTMS|"Active treatment will be delivered at an intensity that is 90% of the resting motor threshold (RMT). Stimulation will be delivered at 20 Hz with 25 simulation trains of 30 stimuli each (i.e., 750 stimuli) and an intertrain interval of 30 sec. Treatment will be applied in sequential order bilaterally to the left and right dorsolateral prefrontal cortex (DLPFC). The order of bilateral stimulation (i.e. right then left or left than right) will be held constant for all 20 treatments.~Intervention: Device: Repetitive Transcranial Magnetic Stimulation"
89515951|NCT02311751|Sham Comparator|Sham rTMS|"Sham stimulation will be delivered using the same stimulation parameters and at the site of active treatment, but with only the side-edge resting on the scalp. The coil will be angled 45 degrees way from the skull in a single-wing tilt position. This method produces sound and some somatic sensation (e.g. contraction of scalp muscles) similar to those of active stimulation, but with minimal direct brain effects.~Intervention: Device: Repetitive Transcranial Magnetic Stimulation"
89515952|NCT04778176|Experimental|DopaFuse Delivery System 50mg LD/hr or 68mg LD/hr flow rate|Either 50mg/13mg LD/CD per hour or 68mg/17mg LD/CD per hour flow rate based upon Subject's standard levodopa (LD) dose. Subjects will routinely wear each container for approximately 5 hours (3 containers per day).
89515953|NCT04457635|Experimental|Brief psychotherapy (brief PsT)|The focus was on normalizing, accepting and coping with their present mental health complaints and their hindrance for work participation. Primarily, there was no intention to process previous pathogenic experiences. The standard duration was set on six sessions.
89515954|NCT04457635|Active Comparator|Short psychotherapy (short-PsT)|With more extended focus, there was besides coping of mental health and challenges concerning WP, an emphasis on both an extensive anamnesis and possibility to establish a so-called central theme based on previous or current challenging issues such as trauma, difficult childhood conditions, and personality-related issues. Additional aims of the intervention could include reducing symptoms and problematic behaviour and an improvement of home situation, with deeper focus on cognitive maladaptive coping strategies or dynamic repetitions. The number of sessions was aimed to be 20 on average
89515955|NCT03507179|Placebo Comparator|conventional dentures|a complete denture made through conventional processing technique
89515956|NCT03507179|Active Comparator|3d printed dentures|a complete denture made through 3D printing
89515957|NCT05110027|Experimental|Period 1: Enpatoran + [14C]enpatoran microtracer|
89515958|NCT05110027|Experimental|Period 2: Enpatoran + [14C]enpatoran microdose|
89515959|NCT02311829|Experimental|Telephone follow-up device (DST)|"An external independent clinical psychologist is responsible for calling regular the patient included in DST-arm.~Telephone follow-up device(DST) consists of telephone calls at 15 day, 2 month and then every 2 months until 12 months. The clinical psychologist is designed to inform the patient about its pathology, promote acceptance of diagnosis, support the patient in his approach to care encouraging psychiatric observation. The device does not replace psychiatric counseling recommended."
89515960|NCT02311829|No Intervention|Group control ; usual care|"- Usual care: After diagnosis of PNES: orientation psychiatric care or CMP liberal and meeting biannually with the neurologist~- For patients in both groups: in addition, quotation questionnaires of quality of life and evaluation by a neuropsychologist biannual for 24 months after the appointment with the neurologist."
89515961|NCT05089513|Experimental|Robotic surgery|Robotic surgery in both live donor and recipient
89515962|NCT05076253|Active Comparator|Ivermectin|Ivermectin 12 mg per day for 5 plus standard care
89515963|NCT05076253|Placebo Comparator|Placebo|Placebo plus standard care
89515964|NCT02311985|Active Comparator|Coagulogram-based protocol|Arm based on standard coagulation tests protocol to guide blood transfusion before central venous catheterization. The possible components to be used include fresh frozen plasma, platelets (random or aphaeresis) and or cryoprecipitate.
89515965|NCT02311985|Experimental|Thromboelastometry-based protocol|Arm based on rotational thromboelastometry (ROTEM(R)) protocol to guide blood transfusion before central venous catheterization. The possible components to be used include fresh frozen plasma, platelets (random or aphaeresis) and or cryoprecipitate.
89515966|NCT02311985|Experimental|Restrictive strategy|Arm based on a restrictive protocol strategy based on INR/PT and platelets count. The possible components to be used include fresh frozen plasma and/or platelets (random or aphaeresis).
89515967|NCT03473587|Experimental|Motivational Interview|Subjects will engage in a brief motivational interview to establish an action plan and discuss follow-up interviews a 3 and 6 months post ED visit
89515968|NCT03473587|Active Comparator|Standard of Care|Subjects will be provided a standard of care colorectal cancer screening brochure at the time of ED visit
89515969|NCT03504761|Experimental|ClariCore System|ClariCore System study designed to obtain prostate biopsies utilizing real-time tissue classification with the ClariCore Optical Biopsy System.
89515970|NCT05077839|Experimental|experimental group|In the experimental group, the treatment regimen is trifluridine/tipiracil 35mg/m2 orally taken on d1-5 and d8-12, oxaliplatin 85mg/m2 and bevacizumab 5mg/kg intravenously infused on d1 and d15 every 4 weeks, up to 6 cycles. Then patients will be given trifluridine/tipiracil and bevacizumab maintenance treatment.
89515971|NCT05077839|No Intervention|control group|The control group was XELOX plus bevacizumab regimen, bevacizumab 7.5mg/kg, d1 oxaliplatin 130mg/m2, d1, capecitabine 1000mg/m2, orally, bid (half an hour after breakfast and dinner), d1-14, every 3 weeks, up to 8 cycles. Then patients will be given capecitabine and bevacizumab maintenance treatment.
89515972|NCT03132233|Active Comparator|Verum|Receives the investigational medicine product (IMP; Beta-hydroxybutyrate calcium and magnesium salt).
89515973|NCT03132233|Placebo Comparator|Placebo|Receives a matched placebo powder to the IMP.
89515974|NCT04565977||Retrospective Cohort|All patients with hypercoagulable states identified by ICD-9/ICD-10 codes from January 1st, 2015 to December 31st, 2019
89515975|NCT03471013||Patients and caregivers|Patients suffering from schizophrenia accompanied by their caregiver
89515976|NCT02678715|Experimental|Sequence SB-CA-SM|Solubrux®+ Customized Appliance + Somatics®
89515977|NCT02678715|Experimental|Sequence SB-SM-CA|Solubrux®+Somatics®+Customized Appliance
89515978|NCT02678715|Experimental|Sequence CA-SB-SM|Customized Appliance+Solubrux®+Somatics®
89515979|NCT02678715|Experimental|Sequence CA-SM-SB|Customized Appliance+Somatics®+Solubrux®
89515980|NCT02678715|Experimental|Sequence SM-SB-CA|Somatics®+Solubrux®+Customized Appliance
89515981|NCT02678715|Experimental|Sequence SM-CA-SB|Somatics®+ Customized Appliance+Solubrux®
89515982|NCT02307227|Experimental|Locally advanced HER2+ breast cancer pts|"HER2 positive (defined as 3+ at Herceptest or FISH/CISH positive):~treatment with Trastuzumab 4mg/kg first time, then 2 mg/kg weekly with concomitant paclitaxel 80 mg/mq weekly (one cycle corresponding to 4 weeks) for 12 weeks (3 cycles). Clinical and instrumental evaluation, in responding patients continue for additional 12 weeks (total 6 cycles), then surgical excision"
89515983|NCT02307227|Experimental|Locally advanced HER2- breast cancer pts|"HER2 negative:~treatment with Epirubicin 90 mg/mq and docetaxel 75 mg/mq every 3 weeks for 4 cycles. Clinical and instrumental evaluation, in responding patients continue for additional 12 weeks (total 8 cycles), then surgical excision."
89515984|NCT03473509|Experimental|Chronic Kidney Disease (CKD) Registry|The CKD registry provided primary care practice teams with point-of-care data about patient-specific CKD status, recent ambulatory clinic blood pressure (BP) readings, status of Angiotensin Converting Enzyme inhibitor (ACEi) or Angiotensin Receptor Blocker (ARB) prescription, and quantification of albuminuria (UACR). It also provided data about diabetes care, immunization status, and data pertinent to age appropriate cancer screening, to align with usual care. Point-of-care decision support reminded primary care providers (PCPs) about guideline concordant care for individuals with CKD. Quarterly feedback to practice teams and individual PCPs identified patients with CKD and BP >140/90 mmHg, those not prescribed an ACEi/ARB, and those with albuminuria.
89515985|NCT03473509|No Intervention|Usual Care Registry|Usual care consisted of an electronic registry that was in use before trial implementation. It provided practice teams with point-of-care data about diabetes care, age-appropriate cancer screening and immunizations, but no CKD-related data. Medical assistants were encouraged to use the usual care registry to identify patients who were due for cancer screening or immunizations. Quarterly feedback was not provided for practice teams randomized to receive usual care.
89515986|NCT02307305|Experimental|Duloxetin group|"Phase I (preemptive): 2 hour before surgery (30mg for 1 day)~Phase II (titration): POD#1~6 (30mg for another 6 days)~Phase III (maintenance): POD#7~13(60mg for 7 days)~Phase IV (tapering-1): POD#14~20 (30mg for 7 days)~Phase V (tapering-2): POD#21~27 (30mg another every day for 7 days)~plus routine pain control (celecoxib, naproxen/esomeprazole, acetaminophen/tramadol, oxycodone/naloxone)"
89515987|NCT02307305|Active Comparator|routine pain control group|"Preemptive analgesia : celebrex, Patient controlled analgesia (postop. 28 hours), During admission : celebrex BP or vimovo BP +ultracet ER BP, targin HS, Discharge medication: celebrex BP or vimovo BP, ultracet ER BP(PRN)~Other name of drugs: celecoxib, naproxen/esomeprazole, acetaminophen/tramadol, oxycodone/naloxone"
89515988|NCT05118451|Experimental|3d reconstruction visualization model to guide preoperative planning and surgery|All patients in this study were operated by the medical team whose main members were the medical team leader, and all patients underwent anatomic hepatectomy. The main points of anatomic hepatectomy are summarized as follows :(1) determine and mark the boundary of liver segment according to ischemia line or staining. (2) The postoperative liver section should fully expose the iconic veins and vessels. (3) The initial part of Glisson's pedicle of the target liver segment was severed. Tissue was taken from the surgical margins of all patients and sent to frozen sections for examination. Routine pathological examinations were performed on all resected liver after surgery. Postoperative patients were treated with relevant perioperative symptomatic treatment, and blood routine examination, liver function and coagulation function were detected on the 1st, 3rd and 5th day after surgery.
89515989|NCT05118451|No Intervention|Based on high-quality thin slice CT images to guide preoperative planning and surgery.|All patients in this study were operated by the medical team whose main members were the medical team leader, and all patients underwent anatomic hepatectomy. The main points of anatomic hepatectomy are summarized as follows :(1) determine and mark the boundary of liver segment according to ischemia line or staining. (2) The postoperative liver section should fully expose the iconic veins and vessels. (3) The initial part of Glisson's pedicle of the target liver segment was severed. Tissue was taken from the surgical margins of all patients and sent to frozen sections for examination. Routine pathological examinations were performed on all resected liver after surgery. Postoperative patients were treated with relevant perioperative symptomatic treatment, and blood routine examination, liver function and coagulation function were detected on the 1st, 3rd and 5th day after surgery.
89515990|NCT02660229|Experimental|Oxycodone Hydrochloride|Brand Name: OxyNorm® Generic name: Oxycodone hydrochloride
89515991|NCT02660229|Active Comparator|Morphine Sulphate|Brand name: BC Morphine sulfate Generic name: Morphine sulfate
88961350|NCT02008409|Experimental|EndoLift Liver Retractor|"During surgery, the surgeon will use the new internal liver retractor device. The device will retract the subject's liver out of the way and help the surgeon see better during the surgery. The device is placed inside the abdomen during the surgery. It is clipped onto 2 safe surfaces inside the abdomen. The device is removed before the surgery ends."
89515992|NCT02307383|Experimental|Lactitol and Lactobacillus|"Lactitol monohydrated 10g (Emportal®), 1 sachet dissolved in water, three times a day for 21 days.~Lactobacillus acidophilus, 1 x 109 UFC and Lactobacillus Biphidus 1 x 109 UFC, (Infloran Berna), 2 tablets by mouth, three times a day for 21 days."
89515993|NCT04719247|Experimental|Turmeric|Turmeric extract will be used as a dental pulp dressing material after pulpotomy and compared with Formocresol
89515994|NCT04719247|Experimental|Thymus Vulgaris|Thymus Vulgaris extract will be used as a dental pulp dressing material after pulpotomy and compared with Formocresol
89515995|NCT04719247|Experimental|Nigella Sativa|Nigella Sativa extract will be used as a dental pulp dressing material after pulpotomy and compared with Formocresol
89515996|NCT04719247|Experimental|Aloe Vera|Aloe Vera extract will be used as a dental pulp dressing material after pulpotomy and compared with Formocresol
89515997|NCT04719247|Active Comparator|Formocresol|Formocresol will be used as a dental pulp dressing material after pulpotomy to be compared with other materials.
89515998|NCT02232178|Experimental|2 100mg Xaracoll implants|Bupivacaine HCl implant
89515999|NCT02232178|Experimental|3 100mg Xaracoll implants|Bupivacaine HCl implant
89516000|NCT02232178|Active Comparator|150mg Bupivacaine HCl injection|Bupivacaine HCl
89516001|NCT05094921|Experimental|Group A (Halliwick method group)|Under water exercise program according to halliwick concept which will be applied as three sessions per week for three successive months. Underwater exercises will be performed under the supervision of a certified aquatic therapist. This practitioner will instruct the child in proper techniques for performing exercises while ensuring child's safety by using flotation devices, body boards or float belts when necessary. Also the pool where the children will perform underwater exercises will be equipped with ramps, chair lifts, stairs, and handrails to facilitate a child's ability to access the pool.
89516002|NCT05094921|Active Comparator|Group B (conventional physical therapy group)|Conventional selected exercise program for 60 minutes , three sessions per week for three successive months aiming to improve the motor functions of the children in form of: (1) Neuro-developmental technique, (2) Back and abdominal exercises, (3) improving postural responses, (4) Flexibility exercises, (5) Strengthening exercise (particularly knee extensors, hip abductors and the ankle dorsi-flexors muscles) and (6) Improving standing, weight transfer and shift and finally facilitation of normal walking pattern .
89516003|NCT02307461|Experimental|Part 1 Cohort 1|IPI-145 test formulation (capsule) high single dose and IPI-145 reference formulation (capsule) high single dose
89516004|NCT02307461|Experimental|Part 1 Cohort 2|IPI-145 test formulation (capsule) low single dose and IPI-145 reference formulation (capsule) low single dose
89516005|NCT02307461|Experimental|Part 2 Cohort 3|IPI-145 test formulation (capsule) high single dose administered under fasted and fed conditions
89516006|NCT04457323|Experimental|Test|S-Metoprolol XR 25 mg Film Coated Tablets (first four weeks) S-Metoprolol XR 50 mg Film Coated Tablets (second four weeks)
89516007|NCT04457323|Active Comparator|REFERENCE|Beloc® (Metoprolol) Zok 50 mg Controlled Release Film Tablets (first four weeks) Beloc® (Metoprolol) Zok 100 mg Controlled Release Film Tablets (second four weeks)
89516008|NCT04768036|No Intervention|Usual Medical Care|As per standard of care
89516009|NCT04768036|Experimental|"SMART on FHIR application of the IMPROVE DD VTE CPR"|"This study will be a multicenter clustered randomized trial of patients in hospitals in which a universal SMART on FHIR platform-based EHR-embedded IMPROVE VTE CPR with electronic order entry has been incorporated into required admission and discharge EHR workflow versus hospitals following UMC for VTE risk assessment of medically ill patients.~Health outcomes and health resource utilization will be assessed for the duration of patient hospitalization until 90 days post-discharge by review of health records.~2 hospitals will be randomized to the experimental arm and 2 hospitals will be randomized to the No Intervention arm."
89516010|NCT04448431|Experimental|Vortioxetine|8 weeks treatment
89516011|NCT04448431|Active Comparator|Desvenlafaxine|8 weeks treatment
89516012|NCT02307539|Experimental|Supportive care (PCPI intervention)|"Patients receive a handbook titled Supporting You During Cancer Treatment with educational material on QOL issues. Patients undergo 2 education sessions on handbook material in-person or by telephone, with session 1 focusing on physical and social well-being issues and session 2 focusing on psychological and spiritual well-being issues. At the beginning of each session, patients select 3 priority topics from a list, and content is tailored to patient needs."
89516013|NCT04784962|Sham Comparator|Control Arm|Sham device
89516014|NCT04784962|Experimental|Intervention Arm|Standard rehabilitation care including physiotherapy + Adjunctive Neuromuscular Stimulation Device Usage
89516015|NCT05094765|Experimental|FMT|60 capsules per day for 2 day
89516016|NCT03507023|Placebo Comparator|Placebo Control|2 capsules per day, each with 400 mg Cellulose microcrystalline, for 6 weeks.
89516017|NCT03507023|Experimental|Dietetic Supplement Group|2 Capsules per day of Metabolaid® (each capsule contains 250 mg Metabolaid®, 150 mg cellulose microcrystalline), for 6 weeks.
89516018|NCT05713149||Subjects with osteomyelitis-associated pressure ulcers|Subjects with neuromotor disability and admitted for the treatment of osteomyelitis-associated pressure ulcers
89516019|NCT02307617||Group 2|Adolescent participants who plan to start selective serotonin reuptake inhibitor (SSRI) treatment for their depression. Data will be collected prior to the start of the medication and again 6 weeks after the start of the medication.
89516020|NCT02307617||Medication Responders|Adolescent participants who have responded to SSRI treatment for their depression.
89516021|NCT02307617||Medication Non-Responders|Adolescent participants with depression that has not responded to SSRI treatment.
89516022|NCT02307617||Healthy Controls|Adolescent participants who have no current or past mental health diagnoses.
89516023|NCT04428931||PD patients|Patients with Asymmetric Parkinson's disease
89516024|NCT02307695|Experimental|insulin+Saxagliptin|Patients who have diagnosed type 1 diabetes are assigned to receive Saxagliptin tablets 5 mg and insulin for 24-week.
89516025|NCT02307695|Active Comparator|insulin|Patients who have diagnosed type 1 diabetes only use insulin.
89207532|NCT00967317|Experimental|Auris-Sedina|"Drip 2 drops of the medication with the head tilted and protect with a cotton swab. Repeat the process one at a time until the pain relief. Continue the administration of medication every 3 hours until the pain ceases.~The medication should be used for a maximum of 3 days when they should return to the doctor."
89544333|NCT02439047|Experimental|Biological samples collection|"-Peritoneal samples : will be collected during abdominal surgery~A biopsy from 1 to 2 cm2 will be performed in healthy peritoneum~-Adipose tissue samples : will be collected during surgery for breast reconstruction"
89544334|NCT02441855||pneumonia|patients with community-acquired pneumonia
89544335|NCT02441855||control|patients admitted to emergency department with shortness of breath
89544336|NCT03190031|Experimental|Endurance respiratory muscle training|The intervention consists in performing isocapnic hyperpnea at 70-80% of maximal voluntary ventilation for 20 min, 5 times a week, for 8 weeks
89544337|NCT03190031|Active Comparator|Resistance inspiratory muscle training|The intervention consists in performing inspiratory resistive breathing at 70-80% of maximal inspiratory pressure for 20 min, 5 times a week, for 8 weeks
89544338|NCT04705233|Experimental|Sputum chart|Use of the 5 point sputum colour chart, adapted from Bronkotest® a self-management (SM) plan and rescue pack (RP) containing 5 days supply of antibiotic and steroid treatment
89544339|NCT04705233|No Intervention|Control|Use of the plan and rescue pack alone (best usual care)
89544340|NCT04483427|Experimental|OSA patients after multilevel surgery|
89544341|NCT02438735||Endometrioma|Reproductive aged women diagnosed with endometrioma. Conservative follow up for six months.
89544342|NCT02438735||Healthy Controls|"Women with regular menstrual cycles and without ovarian pathology will be recruited from physicians, nurses and other staff of the same hospital.~Controls will be matched for age with the women in the endometrioma group. They will be conservatively followed up for six months."
89544343|NCT02438735||Historical controls who underwent surgical excision|20 women who underwent surgical excision of endometrioma in the same clinic had serum AMH levels measured preoperatively and on post operative sixth month. Their values will be compared with that of endometrioma group. These data were priorly published in detail (Uncu et al. 2013).
89544344|NCT01664247|Experimental|IDeg + Lira|
89544345|NCT01664247|Experimental|Placebo + Lira|
89544346|NCT02441699||Intervention group|Rural villages in which Gram Vikas has fully implemented its water supply and sanitation (Mantra) intervention. Intervention villages must: 1) be within 3 hours travel to the study office in Brahmapur, 2) have started the intervention by January 2003, and 3) have completed the intervention by January 2013.
89544347|NCT02441699||Control group|Rural villages that have been matched with intervention villages on demographics and other criteria. The sampling frame for control villages is limited to those: 1) within 3 hours travel to the study office in Brahmapur, and 2) within Gram Panchayats which do not include an intervention village and are not adjacent to an intervention village, to minimize spillover effects. In addition, both intervention and control villages must appear in the Government of India Census in 2001.
89544348|NCT02441465|Experimental|Vemurafenib|Participants will receive oral vemurafenib BID from Day 1 to Day 28 and a single IV infusion of 14C-labeled vemurafenib on Day 21.
89544349|NCT02438657|Experimental|median nerve block|"An ultrasound-guided nerve block with dextrose 5% hydrodissection is performed in each case. The first patient will receive a 2 mL local anesthetic solution. For following patients, the volume of local anesthetic depends on the clinical result of the previous patient:~increase of the volume (0.5 mL) in case of failure,~no change or decrease (0.5 mol) in case of success; a randomization is made in this case (BCD method, Stylianou M, Flournoy N. Dose finding using the biased coin up-and-down design and isotonic regression. Biometrics 2002;58:171-7)"
89544350|NCT02441621|Other|Passive leg raising|
89544351|NCT02441621|Other|premedication|
89544352|NCT02441621|Other|intubation and mechanical ventilation|
89544353|NCT02441621|Other|central venous catheter|
89544354|NCT02441621|Other|arterial catheter|Continuous monitoring is performed including electrocardiogram, radial arterial pressure catheter
89544355|NCT02441621|Other|transesophageal echocardiography|
89544356|NCT02441621|Other|transpulmonary thermodilution catheter|
89544357|NCT03189797|Experimental|study group|"After defining the individual patient's likelihood risk status and the diagnosis for each lesion, ICCMS presents a management element to build a comprehensive patient care plan as follow:~In the study group they were given a preventive program as homecare program including tooth brushing 2/day with a fluoride toothpaste( 5000 ppm F) following the instructions in addition to fluoride mouth rinse. For the clinical approach motivational engagement was done by discussing with patients how to improve oral health behavior including amount of sugar, fibrous food and junk food. This in addition to pits and fissures sealant, F- varnish 2 times /year. and application of fluoride varnish every 6 months and dietary intake interventions."
89544358|NCT03189797|No Intervention|control group|In the Control group participants assigned to the control condition will be advised to maintain their existing lifestyles. For ethical reasons, if the program shows its effectiveness, it will be made available to all groups at the end of the study.
89544359|NCT02441387||Antidepressant treatment|"According to their previous treatment history and clinical presentation, patients may take:~Sertraline 50-250mg/day for 1 year or Escitalopram 10-20mg/day for 1 year or Mirtazapine 15-45mg/day for 1 year or Venlafaxine 37,5-300mg/day for 1 year or Lithium 300-900mg/day for 1 year."
89544360|NCT02441387||Antidepressant treatment & Psychoeducation intervention|Antidepressant treatment and psych education program (10 weekly sessions).
89544361|NCT01441947|Experimental|Cabozantinib plus fulvestrant|Combination therapy with cabozantinib 60 mg daily plus fulvestrant 500 mg monthly Intramuscularly (IM)
89544362|NCT03192059|Experimental|experimental arm|Pembrolizumab, immune modulatory cocktail composed of Vitamin D, Lansoprazole Teva, Cyclophosphamide and Aspirine, radiation and Curcumin
89207533|NCT00967317|Active Comparator|Otosynalar®|Drip 3 drops in the ear 2 times a day. The medication should be used by more than 3 days after which the patient must return to the doctor.
89207534|NCT00959127|Experimental|ARRY-438162 (MEK 162)|
89207535|NCT00970749||history of chlamydia infection|Women who self-reported a history of cervical infection with Chlamydia trachomatis
89516026|NCT05161975|Placebo Comparator|Placebo|Food supplement tablets do not contain vitamin K2
89516027|NCT05161975|Experimental|Vitamin K2|Food supplement tablets contain vitamin K2
89516028|NCT05712291|Other|total knee arthroplasty using the active robotic system|Total knee arthroplasty using the active robotic surgical system TSolution One TCAT, and system for planning TPlan
89516029|NCT05712291|Other|total knee arthroplasty using the standard manual technic|Primary total knee arthroplasty using the standard recommended set of instruments
89516030|NCT03504605|Experimental|Self-compassion intervention|Participants will be asked to recall and write (in an online text-box) about a parenting event during which they felt shame. They will then receive the online self-compassion intervention as detailed in Sirois, Bögels and Emerson (in revision). This involves parents in the experimental condition being given a validated set of instructions asking them to reflect on the event and write self-compassionate responses (see intervention).
89516031|NCT03504605|No Intervention|Control|Participants will be asked to recall and write (in an online text-box) about a parenting event during which they felt shame. Those in the control condition will be asked to re-read the account of the event and make notes about factual information (e.g. time of day, who was there, etc.). It should be noted that if the SCI is found to reduce state shame and increase state self-compassion, it will be offered to participants in the control group.
89516032|NCT02523391|Experimental|Treatment Period 1|Either 5mg TA-8995 Capsule or Tablet
89516033|NCT02523391|Experimental|Treatment Period 2|Either 5mg TA-8995 Capsule or Tablet
89516034|NCT03135639|Experimental|Sham Stim followed by Alpha Stim|"20 minutes of sham stimulation (sham stim) is followed by a washout period of 20 minutes. 20 minutes of alpha stimulation (alpha stim) is applied next.~Sham stimulation mimics the physical effects of stimulation, with up to 1 minute of stimulation during the session. Sham stimulation is delivered using the NeuroConn Plus Stimulator Sham.~Participants will receive 2 mA alternating current stimulation at their individual alpha frequency (8-12 Hz, as determined by the 2 minute resting state EEG) for 20 minutes. Alpha stimulation is delivered using the NeuroConn Plus Stimulator tACS."
89516035|NCT03135639|Experimental|Alpha Stim followed by Sham Stim|"20 minutes of alpha stimulation (alpha stim) is followed by a washout period of 20 minutes. 20 minutes of sham stimulation (sham stim) is applied next.~Participants will receive 2 mA alternating current stimulation at their individual alpha frequency (8-12 Hz, as determined by the 2 minute resting state EEG) for 20 minutes. Alpha stimulation is delivered using the NeuroConn Plus Stimulator tACS.~Sham stimulation mimics the physical effects of stimulation, with up to 1 minute of stimulation during the session. Sham stimulation is delivered using the NeuroConn Plus Stimulator Sham."
89516036|NCT03469141|No Intervention|Control Group|The control group will continue to have the WC sensor system for measurement only and will not receive biofeedback after receiving instructions on the importance of pressure relief (PR) maneuvers for skin care, as well as training regarding the three pressure relief maneuvers. Materials (including fact sheets, etc.) will be incorporated in the educational content of the project.
89516037|NCT03469141|Experimental|Intervention Group|The intervention group will receive biofeedback via the smartphone app.
89516038|NCT03504527|Experimental|triple combinations|Budesonide/Fermotil inhalant 160ug/4.5ug bid; Tiotropium bromide inhalants 18ug qd
89516039|NCT03504527|Active Comparator|double combinations|Fermotil inhalants 4.5ug bid; Tiotropium bromide inhalants 18ug qd
89516040|NCT02307773||Case Group|Treated with additional 2 puffs of the 10% lidocaine spray on the tip of endoscope before intubation with conventional pharyngeal anesthesia
89516041|NCT02307773||Control Group|Treated with conventional pharyngeal anesthesia without further treatment.
89516042|NCT03504449|Experimental|surgery without neoadjuvant chemoradiotherapy|For T3N1-2M0 rectal cancer with negative circumferential resection margin based on MRI assessment, recieve surgery without neoadjuvant chemoradiotherapy.
89516043|NCT03504449|Experimental|surgery with neoadjuvant chemoradiotherapy|For T3N1-2M0 rectal cancer with negative circumferential resection margin based on MRI assessment, recieve surgery following neoadjuvant chemoradiotherapy.
89516044|NCT01678131|Experimental|Vaniprevir 600 mg|Participants received 600 mg vaniprevir only on days 1-7, and had postdose liver biopsy done by FNA and CNB from Day 7 up to Day 10.
89516045|NCT01678131|Experimental|Vaniprevir 600 mg + Peg-IFN + RBV|Participants received 600 mg vaniprevir on Days 1-7; Peg-IFN alpha-2b once a week, RBV daily from Day 1 up to Day 21; and had postdose liver biopsy done by FNA and CNB from Day 7 up to Day 10.
89516046|NCT01678131|Experimental|Vaniprevir 300 mg + Peg-IFN + RBV|Participants received 300 mg vaniprevir from Days 1-7; Peg-IFN alpha-2b once a week, RBV daily from Day 1 up to Day 21; and had postdose liver biopsy done by FNA and CNB from Day 7 up to Day 10.
89516047|NCT04579783|Active Comparator|Ultrasound intracarpal corticosteroid injection|"Twice ultrasound-guided hydro-dissection of median nerve at carpal tunnel level.~1st injection (0 week): 40mg triamcinolone acetonide (40mg/mL ) with 4mL normal saline, 2nd injection (6 week): 5 mL normal saline"
89516048|NCT04579783|Active Comparator|Ultrasound guided intracarpal dextrose hydro-dissection|"Twice ultrasound-guided hydro-dissection of median nerve at carpal tunnel level.~Group B: 1st injection (0 week): 5 mL 5% dextrose, 2nd injection (6 week): 5 mL 5% dextrose"
89516049|NCT03504371|Active Comparator|bilateral erector spinae block|The patient placed in a lateral position and ultrasound transducer placed 3 cm lateral to the T7 spinous process. Three muscles will be identified: trapezius, rhomboid major, and erector spinae. 8-cm 22-gauge block needle will be inserted in a cephalad-to-caudad direction until the tip lay in the interfascial plane between rhomboid major and erector spinae muscles, as evidenced by visualization of local anesthetic spreading in a linear pattern between erector spinae and the bony shadows of the transverse processes. 20 mL of 0.25% bupivacaine will be injected then it will be repeated on the other side in the same way without changing the position of the patient to achieve sensory block T5-T10 .
89544363|NCT02441075|Experimental|70% Ethanol|The study will use 70% ethanol lock in the CVLs. A 2ml 70% ethanol lock will be instilled into the white lumen of the CVL for 2 hours. At the end of 2 hours, the ethanol will be withdrawn; the CVL lumen flushed with normal saline, and the CVL would be available for normal use for that day.
89544364|NCT02441153||Group 1(Extended Timing)|Surgery will be performed at 10-11 weeks after the completion of chemoradiotherapy.
89544365|NCT02441153||Group 2 (Non-extended timing)|Surgery will be performed at 6-7 weeks after completion of chemoradiotherapy.
89516050|NCT03504371|Sham Comparator|Thoracic epidural anesthesia|an epidural catheter placed at the T7-8 interspace after proper sterilization and positioning of the patient in the sitting position then standard technique of application will be applied, then a test dose consists of 3 ml of 1.5% preservative free lidocaine will be injected followed by 5-6 ml of bupivacaine 0.25%
89516051|NCT02231164|Placebo Comparator|Docetaxel and placebo|patients to receive backbone chemotherapy and placebo
89516052|NCT02231164|Experimental|Docetaxel and Nintedanib|patients to receive backbone chemotherapy and nintedanib
89516053|NCT02457182|Experimental|Mindfulness-based Stress Reduction|Mindfulness-based Stress Reduction (MBSR)
89516054|NCT02457182|Placebo Comparator|Usual Care|Usual medical therapy
89516055|NCT03506789|Active Comparator|Treatment A:|24 mg dexamethasone i.v. perioperatively and 24 mg dexamethasone i.v. on the first postoperative day
89516056|NCT03506789|Active Comparator|Treatment B:|24 mg dexamethasone i.v. perioperatively and placebo (isotonic saline) i.v. on the first postoperative day
89516057|NCT03506789|Placebo Comparator|Placebo|Placebo (isotonic saline) i.v. perioperatively and placebo (isotonic saline) i.v. on the first postoperative day
89516058|NCT02523001||Naïve-S|Patients with hypercholesterolemia starting statin treatment for primary or secondary prevention of cardiovascular diseases.
89207536|NCT00970749||no history of chlamydia infection|Women who self-reported no history of cervical infection with Chlamydia trachomatis
89516059|NCT02523001||ONC-S|Patients with hypercholesterolemia who had been treated with statin for at least one year and continued their previous therapy during the study period
89516060|NCT02523001||Naïve-MC|Patients with mild hypercholesterolemia either refusing initial statin treatment or intolerant to standard statin treatment and starting with monacolin K
89516061|NCT02523001||Naïve-Diet|Patients refusing an initial pharmacologic treatments and choosing the hypolipidic diet
89516062|NCT02312297|Experimental|Test|Minocycline hydrochloride extended release tablets 135 mg
89516063|NCT02312297|Active Comparator|Reference|Solodyn Extended Release Tablets 135 mg
89516064|NCT03473431|Experimental|ketamine|single infusion of 0.5 mg / kg ketamine
89516065|NCT03473431|Sham Comparator|control|physiological solution at 0.9 % with the same physical characteristics of ketamine solution,
89516066|NCT03681704|Experimental|HuangQi Decoction|HuangQi Decoction 150ml by mouth ,twice a day for 24 weeks
89516067|NCT03681704|Placebo Comparator|HuangQi Decoction placebo|HuangQi Decoction placebo 150ml by mouth, twice a day for 24 weeks
89516068|NCT03377452|Experimental|Behavioral Education Intervention I|Manual-based education program focusing on sleep and sleep apnea provided in individual sessions.
89516069|NCT03377452|Experimental|Behavioral Education Intervention II|Manual-based education program focusing on sleep and sleep apnea provided in individual sessions.
89516070|NCT02307929||Chronic Disease Management|Aging population with the need of Chronic Disease Management
89516071|NCT05161585|Experimental|ctDNA dynamic monitoring + routine postoperative follow-up|"ctDNA is detected before operation, before chemotherapy, and then every three months for 2 years, 10 times in total. At the same time, routine postoperative follow-up is given.~To be pointed out, after the completion of the adjuvant chemotherapy, if the ctDNA test indicates positive, patients will immediately perform chest, abdominal and pelvic CT and other imaging tests to determine whether there is recurrence /metastasis. If it is not confirmed, repeat the imaging review every two months, and continue to perform ctDNA test every three months. If the following ctDNA test is negative for two consecutive times, the above imaging reexamination will return to the routine follow-up frequency. In addition, during the follow-up, the following situations may occur: the imaging examination has found recurrence/metastasis, but the ctDNA test is still negative. At this time, the patient will be informed and treated in time of the recurrence/metastasis."
89516072|NCT05161585|No Intervention|routine postoperative follow-up|Only routine postoperative follow-up is given as follows: Physical examination and CEA were performed every 3-6 months for the first 2 years, every 6 months within the third to fifth year, and then annually. Chest/abdominal/pelvis computed tomography was performed annually for up to 5 years, and colonoscopy was performed for proper patients the first year after treatment and repeated in the third year if no advanced adenoma was found and then every 5 years.
89207537|NCT00959205|Active Comparator|Angiography|Conventional fluoroscopically guided activation mapping
89207538|NCT00959205|Experimental|CARTO 3D|CARTO (3D Electroanatomic imaging)
89516073|NCT04930250|Experimental|Oat bran fibre processed with method A|Beverage powder with 12% oat bran processed with method A
89516074|NCT04930250|Experimental|Oat bran fibre processed with method B|Beverage powder with 12% oat bran processed with method B
89516075|NCT04930250|Experimental|Oat bran fibre processed with method C|Beverage powder with 12% oat bran processed with method C
89516076|NCT04930250|Active Comparator|Minimally-processed oat bran (positive control)|Beverage powder with minimally-processed oat bran (Positive Control)
89516077|NCT04930250|Placebo Comparator|Readily-digestible carbohydrate (negative control)|Beverage powder with readily digestible carbohydrate (Negative Control)
89516078|NCT02378805||no-T: untreated patients|untreated patients, typically uncles or grandfathers of present patients. No Intervention (means no therapy until CKD stage V, on renal replacement therapy)
89516079|NCT02378805||T-III: late therapy in patients|patients treated with RAAS-Blockade after onset of renal failure (GFR below 60 ml/min) (starts at patients with CKD stages III and IV).
89516080|NCT02378805||T-II: early therapy in patients|therapy starts at patients with proteinuria >0.3 g/day or per gCreatinine
89516081|NCT02378805||T-I: very early tharpy in patients|starts at patients with microhematuria only (usually at birth) or microalbuminuria (30-300 mg protein per day or per gCreatinine in children).
89516082|NCT02378805||no therapy in heterozygous carriers|heterozygous carriers without therapy
89516083|NCT02378805||therapy in heterozygous carriers|heterozygous carriers with RAAS-blockade
89516084|NCT02230384|Experimental|Active JNJ Drug|200 mg (100 mg b.i.d.) Active JNJ Drug used to assess quitting for one week, as part of crossover design. This JNJ experimental compound has NO name, just a company number.
89516085|NCT02230384|Experimental|Placebo Pill|Placebo pill used for one week quit attempt, as part of crossover design.
89544366|NCT04687683|Experimental|Post Isometric Relaxation Group|The participants in this group will receive post isometric relaxation stretching in modified cross body position.
89544367|NCT04687683|Experimental|Isolytic Stretching Group|The participants in this group will receive isolytic stretching in modified cross body position.
89544368|NCT04687683|Experimental|Static Stretching Group Group|The participants in this group will receive static stretching in modified cross body position.
89544369|NCT02438579|Experimental|Nasal Irrigation & Gargling|"Videos on how to collect nasal swabs, prepare and perform hypertonic saline nasal irrigation and gargling (HSNIG) are shown. A nasal swab is collected. Participant chooses the highest concentration of hypertonic saline he/she is comfortable with (from 1.5, 2.0, 2.5 and 3.0%) and performs HSNIG under observation. Nasal swabs are to be collected first thing in the morning on 4 consecutive days and posted using the Royal Mail Safebox. Daily diaries are to be completed (online / paper form) until they document not unwell for two consecutive days; or a maximum of 14 days or if they need medical attention for the URTI. Swabs are tested in parallel to detect change in viral shedding."
89544370|NCT02438579|No Intervention|Control|"The control group are advised to manage the URTI as they normally do. A video on how to collect nasal swabs is shown. A nasal swab is collected. Nasal swabs are to be collected first thing in the morning on 4 consecutive days and posted using the Royal Mail Safebox. Daily diaries are to be completed (online / paper form) until they document not unwell for two consecutive days; or a maximum of 14 days or if they need medical attention for the URTI. Swabs are tested in parallel to detect change in viral shedding."
89544371|NCT04664751||Patients scheduled for general surgery with anesthesia|Patients scheduled for general surgery with anesthesia, receiving Nil-per-Oral order.
89544372|NCT02441231|Experimental|Probiotic Group|Visbiome probiotic group (900 billion bacteria daily; 2 sachets daily)
89544373|NCT02441231|Placebo Comparator|Placebo Group|Placebo comparator group
89544374|NCT02438501|Experimental|LD-IFRT group|Chemotherapy / Low-dose involved-field radiotherapy
89544375|NCT02438501|Active Comparator|IFRT group|Chemotherapy / Involved-field radiotherapy
89544376|NCT02440997|Placebo Comparator|foot bath only|10 minute foot bath with addition of jojoba only
89544377|NCT02440997|Experimental|foot bath and aromatherapy|10 minute foot bath with addition of jojoba with added Mentha piperita
89544378|NCT02438345|Active Comparator|Treatment Arm 1|PRO 140: one SC dose, 350 mg, weekly for 24 weeks
89544379|NCT02438345|Placebo Comparator|Treatment Arm 2|PRO 140: one SC dose, placebo, weekly for 24 weeks
89544380|NCT02438189|Active Comparator|Hyperglycemia Minimization Algorithm|The hyperglycemia minimization algorithm will be running actively on the study laptop during the night and dose insulin if the algorithm predicts hyperglycemia. If hypoglycemia is predicted, the system will suspend the pump.
89544381|NCT02438189|No Intervention|Predictive Low Glucose Suspend|The control algorithm will run passively and not dose additional insulin. If hypoglycemia is predicted, the system will suspend the pump.
88961351|NCT02008422|Experimental|Oxaliplatin & Endostar injection|Oxaliplatin, 130 mg/m2 , iv, 3-4h, d1; Gimeracil and Oteracil Potassium Capsules, 40 mg/m2, po., Bid., d1-14; Endostar injection, 7.5 mg/m2/d, 2 mL/h continuous pumping into vein, d1-10; 21 d as a cycle.
88961352|NCT02008422|Active Comparator|Oxaliplatin|Oxaliplatin, 130 mg/m2 , iv, 3-4h, d1; Gimeracil and Oteracil Potassium Capsules, 40 mg/m2, po., Bid., d1-14, 21 d as a cycle.
88961353|NCT02008435|Experimental|Enriched GLB|This arm aims to increase the effectiveness of the Group Lifestyle Balance (GLB) program by integrating habit formation techniques, namely if-then plans and their mental practice, into the program.
88961354|NCT02008435|Active Comparator|Standard GLB|This arm is the standard Group Lifestyle Balance (GLB) program, which is the group version of the Diabetes Prevention Program developed by the NIH.
88961355|NCT02008448|Active Comparator|PVI+LL|Circumferential PVI was accomplished and then additional ablation lines were created by connecting the left inferior PV to the mitral annulus (mitral isthmus) and the LA between the two superior PVs (roof). Finally, patients underwent cavo-tricuspid isthmus ablation in the right atrium.
88961356|NCT02008448|Active Comparator|PVI+LL+BT injection|"Circumferential PVI was accomplished and then additional ablation lines were created by connecting the left inferior PV to the mitral annulus (mitral isthmus) and the LA between the two superior PVs (roof). Finally, patients underwent cavo-tricuspid isthmus ablation in the right atrium.~Injection of the botulinum toxin is performed in main anatomical zones of ganglionated plexuses of left atrium using Myostar catheter (Biosense Webster)."
88961357|NCT02008461|Active Comparator|RFA|Mapping and radiofrequency ablation are performed by using standard methods.
88961358|NCT02008461|Active Comparator|RFA+BT injection|"Mapping and radiofrequency ablation are performed by using standard methods.~Injection of the botulinum toxin is performed in main anatomical zones of ganglionated plexuses of left atrium using Myostar catheter (Biosense Webster)."
88961359|NCT02008474|Active Comparator|Online weight loss + Incentives for behavior 3 months|
88961360|NCT02008474|Active Comparator|Online weight loss + Incentives for weight loss 3 months|
88961361|NCT02008474|Active Comparator|Online weight loss + Incentives for behavior 12 months|
88961362|NCT02008474|Active Comparator|Online weight loss + Incentives for weight loss 12 months|
89544382|NCT05245851|Experimental|Opportunistic screening for low BMD|Outpatients aged over 50 years undergoing x-ray of the thoracic spine, lumbar spine, chest, pelvis, hand or knee will have their x-rays screened for low BMD by the software-as-a-medical device. If low BMD is identified by the software, a radiologist reviewing the x-ray may choose to incorporate this as an incidental finding in their report to the referring physician.
89544383|NCT02438267||Non-NC group|Enrolled subjects who did not have evidence of NC on renal ultrasound
89544384|NCT02438267||NC group|Enrolled subjects who did have evidence of NC on renal ultrasound
89544385|NCT03191981|Experimental|Treatment|Cyclophosphamide and lenalidomide combined with fixed dose pembrolizumab
89544386|NCT05534997|Experimental|Group A|will receive the post covid protocol conventional treatment in form of medication and 24 sessions of combined rehabilitation exercise program in the form of Graded exercise therapy (GET) and cognitive behavioral therapy (CBT). Patients will attend two sessions per week for 12 weeks. Sessions will be taken at Modern university for technology and information physical therapy rehabilitation center . A home exercise program will be prescribed on at least five days a week. Patients will be contacted by phone daily for the 12 weeks treatment sessions, for following up the home exercise program.
89516086|NCT04286113|Active Comparator|Control group|Participants will receive non-personalized information (one-size-fits-all) diet, sleep and physical activity recommendations via messaging delivered by app.
89516087|NCT04286113|Experimental|Intervention Group|Participants will receive personalized messages about achieving healthy diet, physical activity and sleep as well as summary of their performance for the week and month. They will also receive personalized content about research volunteerism and altruistic activities.
89516088|NCT05094375|Experimental|Vaginal Misoprostol 600 mcg|"All patients will receive three doses of vaginal misoprostol every four hours. The first dose of misoprostol 600 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of the second dose will be given upon sending home.~Two doses of misoprostol 600 mcg each (3 tablets of 200 mcg per dose).~Paracetamol, eight hourlies, will be provided as analgesic or antipyretic.~A specimen bottle to collect the POC if passed out.~Two pairs of disposable gloves.~Pre-filled histopathological examination form to be sent to the laboratory together with the products of conception"
89516089|NCT05094375|Active Comparator|Vaginal Misoprostol 800 mcg|"All patients will receive three doses of vaginal misoprostol every four hours. The first dose of misoprostol 800 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of the second dose will be given upon sending home.~Two doses of misoprostol 800 mcg each (four tablets of 200 mcg per dose).~Paracetamol, eight hourlies, will be provided as analgesic or antipyretic.~A specimen bottle to collect the POC if passed out.~Two pairs of disposable gloves.~Pre-filled histopathological examination form to be sent to the laboratory together with the products of conception"
89516090|NCT04458181|Experimental|Treatment Group|Participants in this group will complete the intervention, Positive Peer Journaling (PPJ), while also continuing to attend intensive outpatient treatment for addiction.
89516091|NCT04458181|No Intervention|Control Group|There will be no intervention for those randomized to the control group. However, they will complete assessment instruments throughout the study period while also continuing to attend intensive outpatient treatment for addiction.
89516092|NCT02738801|Experimental|GLPG1690 600 mg once daily (QD)|
89516093|NCT02738801|Placebo Comparator|Placebo QD|
89516094|NCT04345861|Active Comparator|monotherapy hydroxychloroquine|Hydroxychloroquine 800mg (Day 1), 600mg (from Day 2 to Day 10) + placebo from Day 1 to Day 5
89516095|NCT04345861|Experimental|combination hydroxychloroquine + azithromycin|Hydroxychloroquine 800mg (Day 1), 600mg (from Day 2 to Day 10) and azithromycin 500mg (Day 1 ), 250 mg (from day 2 to Day 5)
89516096|NCT02067819|Experimental|Active Oral Orthotic Treatment|Active treatment group will receive an occlusal splint adjusted to the appropriate therapeutic height (based on an initial fitting). Participants will be instructed to wear the orthotic 24/7 (or as close as possible) for the duration of the study.
89516097|NCT02067819|Placebo Comparator|Placebo Oral Orthotic Treatment|Control participants will receive an identical sham splint to the active condition, but not adjusted to the recommended height for the given participant. Participants will be asked to wear the orthotic 24/7 for the duration of the study.
89516098|NCT03506711|Active Comparator|T1DM Children and adolescents|Children and adolescents with Type 1 Diabetes Mellitus
89516099|NCT03506711|Active Comparator|Healthy Children and adolescents|Healthy community-dwelling children on no medication
89516100|NCT03504059|No Intervention|Control|The usual educational program is applied
89516101|NCT03504059|Active Comparator|Short Intervention|A two-year specially designed educational program is applied. This program aims to encourage a healthy lifestyle through gamification, including diet education, physical activity and self esteem.
89516102|NCT03504059|Active Comparator|Long Intervention|A four-year specially designed educational program is applied. This program aims to encourage a healthy lifestyle through gamification, including diet education, physical activity and self esteem.
89516103|NCT04438473|Experimental|Pectin|sequential supplementation with combination of 90ml pectin and 500ml enteral nutrition formula for 7 days
89516104|NCT04438473|Placebo Comparator|Control|standard formula enteral nutrition feeding without pectin for 7 days
89516105|NCT02230306|Experimental|Cobimetinib in Combination with Vemurafenib|"Vemurafenib (960 mg twice a day) will be taken on Days 1 - 28 of each 28-day treatment cycle. The first dose of vemurafenib should be taken in the morning, and the second dose should be taken in the evening. Vemurafenib can be taken with or without a meal and should be taken with a glass of water.~Cobimetinib (60 mg once a day) will be taken on Days 1 - 21 of each 28-day treatment cycle. The cobimetinib tablet should be taken at approximately the same time each day in the morning with the vemurafenib dose, but no later than 4 hours after the scheduled time. Cobimetinib can be taken with or without a meal and should never be chewed, cut, or crushed and should be taken with a glass of water."
89516106|NCT04266379|Experimental|Closed-Loop Control (CLC)|Closed-loop subcutaneous insulin infusion driven by continuous glucose monitoring through an algorithm
89516107|NCT04266379|Active Comparator|Sensor Augmented Pump (SAP)|Closed-loop subcutaneous insulin infusion and continuous glucose monitoring manage by patient
89516108|NCT02308319|Active Comparator|PROMPT|Prompt therapy with Tenofovir disoproxil fumarate (Viread(R)) 300mg p.o
89516109|NCT02308319|Other|Watchful monitoring|Wait and treat with Tenofovir disoproxil fumarate (Viread(R)) when active liver disease is present [defined as HBV DNA >2,000 IU/ml and abnormal ALT (>40 IU/ml)]
89516110|NCT05095545|Experimental|Group 1|"AV5080 80 mg/day (80 mg in the morning + placebo in the evening)"
89516111|NCT05095545|Experimental|Group 2|"AV5080 160 mg/day (80 mg in the morning + 80 mg in the evening)"
89516112|NCT05095545|Placebo Comparator|Group 3|"Placebo (placebo in the morning + placebo in the evening)"
89516113|NCT02312375|Experimental|Fimasartan|Expreimental drug is fimasartan.
89516114|NCT02312375|Active Comparator|Amlodipine|Active comparator is amlodipine.
89516115|NCT05062174||mifepristone + surgery|Mifepristone is taken orally as a one-time only dose between 48 and 56 hours before your planned prophylactic mastectomy surgery
89516116|NCT05095467|Experimental|Group A|"patients with locally resectable GC (cT4aNxM0, P0)~1 cycle HIPEC+S-1 chemotherapy, sequential 3 cycles of chemotherapy (AS plan, Q21d × 3), surgery+HIPEC, sequential 3 cycles of chemotherapy ( AS plan, Q21d × 3)"
88961363|NCT02008487|Other|Wound powder|In both hospice settings, a registered nurse establishes the wound protocol per principles of wound care and agency guidelines. The cover dressing will be removed and the wound cleansed according to agency protocol (usual care) or as needed. The RGN107 powder, contained in a small squirt bottle, will be squeezed/sprinkled on the wound at each dressing change after cleansing or until a crust is formed. Once formed, the powder will be applied only minimally to reinforce crust integrity. The peri-wound skin will receive care and the cover dressing will be applied. Minimal manipulation of the crusted area will ensue once it has formed. Frequency of dressing changes depends on wound characteristics such as exudate.
88961364|NCT02008500|Placebo Comparator|Placebo Mouthwash Group|Group 1 (placebo mouthwash group) contained 51 individuals
88961365|NCT02008500|Active Comparator|Herbal Mouthwash Group|Group 2 ( Herbal mouthwash) contained 52 individual
89544387|NCT05534997|No Intervention|Group B|will receive the post covid protocol conventional treatment in form of medication and specialist medical care provided by doctors with specialist experience in CFS. All patients will be given a leaflet explaining the illness and the nature of this treatment. Treatment will consist of an explanation of chronic fatigue syndrome, generic advice such as to avoid extremes of activity and rest, specific advice on self-help and symptomatic pharmacotherapy (especially for insomnia, pain and mood) .
89544388|NCT05530941|Experimental|Intervention group|Participants in this group (all participants) were asked to complete a questionnaire and then received access to the online prevention campaign during three days, after which they were asked to complete another questionnaire.
89544389|NCT05534841||Pathological complete response|Patients with a complete response to the neoadjuvant therapy on the definitive anatomopathology study.
89544390|NCT05534841||Non pathological complete response|Patients without complete response to the neoadjuvant therapy on the definitive anatomopathology study.
89544391|NCT05428761|Experimental|TP1|Participants will receive TP1 during one experimental trial.
89544392|NCT05428761|Experimental|TP2|Participants will receive TP2 during one experimental trial.
89544393|NCT05428761|Placebo Comparator|Placebo|Participants will receive placebo during one experimental trial.
89544394|NCT05530785|Experimental|treatment group|radiotherapy combined with sintilimab and bevacizumab biosimilar
89544395|NCT05425173|Active Comparator|Conventional treatment|Chest Physical Therapy
89544396|NCT05425173|Experimental|Limb Range of Motion Exercises + Chest Physical Therapy|Limb Range of Motion Exercises + Chest Physical Therapy
89544397|NCT05530629|Experimental|High intensity of resistance training|"The intensity of 75-80% 1RM is used for high intensity resistance training group. The number of repetitions of each set is relatively few, only 6-8 times. The rest time between sets is relatively long, 2-3 minutes, so that the participants can better adapt to this intensity.~chest press, lat pull down, shoulder press and square, which are all trained through the multi-functional Smith machine.~Bicep curl and triceps extension are operated by purchasing dumbbells with different weights.~Leg extension and Leg curl use leg extension and curl machine Abdominal crunches and lower back exercises just do it by body weight training in yoga mat with abdominal curl and Lower back bridge"
89544398|NCT05530629|Experimental|Moderate intensity of resistance training|"The intensity of 60-65% 1RM is used for moderate intensity resistance training group. The repetition times of each set are relatively moderate, 10-12 times. The rest time between sets is relatively moderate, 1-2 minutes. The relative exercise volume of this group was consistent with that of other experimental groups chest press, lat pull down, shoulder press and square, which are all trained through the multi-functional Smith machine.~Bicep curl and triceps extension are operated by purchasing dumbbells with different weights.~Leg extension and Leg curl use leg extension and curl machine Abdominal crunches and lower back exercises just do it by body weight training in yoga mat with abdominal curl and Lower back bridge"
89544399|NCT05530629|Experimental|Low intensity of resistance training|"The intensity of 40-45% 1RM is used for low intensity resistance training group. The repetition times of each set are relatively more, 16-18 times. The rest time between groups is short, only about 1 minute, so that the participants can still maintain sufficient total exercise load under low intensity.~chest press, lat pull down, shoulder press and square, which are all trained through the multi-functional Smith machine.~Bicep curl and triceps extension are operated by purchasing dumbbells with different weights.~Leg extension and Leg curl use leg extension and curl machine Abdominal crunches and lower back exercises just do it by body weight training in yoga mat with abdominal curl and Lower back bridge"
89544400|NCT05530629|Other|Normal P.E. course|Carry out general teaching content according to the college syllabus.
88961366|NCT02008500|Sham Comparator|Non Herbal Mouthwash Group|Group 3 (Non Herbal mouthwash) contained 50 individuals
88961367|NCT02008513|Active Comparator|Group 1|AFF006 Placebo groups receive 6 AFFITOPE® AD02 vaccinations
88961368|NCT02008513|Active Comparator|Group 2|AFF006 verum groups receive 3 Placebo injections then followed by 3 AFFITOPE® AD02 vaccinations
89544401|NCT04655703|Experimental|DJO X4 Brace with Motion Intelligence Platform: Home discharge|Patients randomized to this group will be provided with the X4 brace and trained on the use of Motion Intelligence platform.
89544402|NCT04655703|No Intervention|Control group: Home discharge|Patients randomized to this group will serve as the control group. There will be no changes to the standard of care recovery for a TKA patient.
88961369|NCT02008539|Experimental|treatment arm|
88961370|NCT02008578|Experimental|Intravenous hyperimmune immunoglobulin (Flu-IVIG)|Adults with confirmed Influenza A or B and evidence of ongoing viral replication (as demonstrated by positive rapid Ag or PCR preferably within 24 hours and no later than 6 days from symptom onset) will receive 0.25g Flu-IVIG/kg of actual body weight, to a maximum dose of 25g Flu-IVIG.
88961371|NCT02008578|Placebo Comparator|Placebo|Adults with Influenza A or B and evidence of ongoing viral replication (as demonstrated by positive rapid Ag or PCR preferably within 24 hours and no later than 6 days from symptom onset) will receive placebo for Flu-IVIG (a comparable volume of saline).
89544403|NCT04655703|Experimental|DJO X4 Brace with Motion Intelligence Platform: Discharge to rehabilitation center|Patients randomized to this group will be provided with the X4 brace and trained on the use of Motion Intelligence platform.
89544404|NCT04655703|No Intervention|Control group: Discharge to rehabilitation center|Patients randomized to this group will serve as the control group. There will be no changes to the standard of care recovery for a TKA patient.
89544405|NCT05637255|Experimental|SYL1801 ophthalmic solution Low Dose once daily|42 treatment days
89544406|NCT05637255|Experimental|SYL1801 ophthalmic solution Middle Dose once daily|42 treatment days
89544407|NCT05637255|Experimental|SYL1801 ophthalmic solution High Dose once daily|42 treatment days
89544408|NCT04692441|Other|Intervention|All participants undergo the same intervention: Drinking heavy cream and undergoing MRI.
89544409|NCT05407701|Experimental|Cranberry|100% juice active: water, cranberry juice concentrate.
89544410|NCT05407701|Placebo Comparator|Placebo|100% juice placebo: water, fructose, dextrose, citric acid, malic acid, natural flavors, pectin, cherry colorant, sucralose.
89544411|NCT05400057||group 1|Oral Lichen Planus patients. Patients will be diagnosed clinically and histologically.
89544412|NCT05400057||Group 2|Healthy patients. Patients without any systemic or oral lesions, not taking drugs for at least the the last 6 months
89544413|NCT05400057||Group 3|Oral Squamous Cell Carcinoma
89544414|NCT03191903|Experimental|Cingal|Cingal is a combination product consisting of 88 milligrams of cross-linked HA (hyaluronic acid) with 18 milligrams of TH (triamcinolone hexacetonide) in a 4 milliliter (mL) intra-articular injection.
89544415|NCT03191903|Active Comparator|Monovisc|Monovisc is a device that consists of 88 milligrams of cross-linked HA (hyaluronic acid) in a 4 milliliter (mL) intra-articular injection.
88961372|NCT02008110|Experimental|CA125 guided strategy|In this group, physician will be encouraged to maximize all treatment measures aimed to keep CA125≤35 U/ml (normal values).
88961373|NCT02008110|Active Comparator|Standard treatment strategy|Therapy is based on established european current guidelines
88961374|NCT02008591|Active Comparator|Epidural Technique|Bupivacaine 0.125% with Fentanyl 2 mcg/mL, 15 mL load over 5 min
88961375|NCT02008591|Active Comparator|Combined Spinal Epidural Technique|Bupivacaine 2.5 mg with Fentanyl 25 mcg
88961376|NCT02008591|Active Comparator|Dural Puncture Epidural Technique|Bupivacaine 0.125% with Fentanyl 2 mcg/mL, 15 mL load over 5 min
88961377|NCT02008604||Stroke patients|
88961378|NCT02008604||TIA patients|patients with a transient ischemic attack (control group)
88961379|NCT02008630|Experimental|Animal-assisted activity|30 minutes group session with animal-assisted activity twice a week for 12 weeks in groups of 4-6 participants.
88961380|NCT02008630|Experimental|Animal-assisted therapy|30 minutes group session with animal-assisted therapy twice a week for 12 weeks in groups of 4-6 participants
88961381|NCT02008630|No Intervention|Control|Control group with treatment as usual
89544416|NCT03191903|Active Comparator|Triamcinolone Hexacetonide (TH)|Triamcinolone hexacetonide (TH) is a corticosteroid supplied in a 20 milligram per 1 milliliter (20 mg/mL) intra-articular injection.
89544417|NCT05530239||Healthy subjects|Subjects with no documented hematological pathology (neither constitutional nor acquired). From the recruitment of living kidney donors, transplantation unit of Grenoble Alpes University Hospital
89544418|NCT05530239||SCD patients|Patients with SCD
89544419|NCT05530239||Control patients|With a constitutional non-sickle cell disease of the red blood cell, or an acquired red blood cell disease.
89544420|NCT05530161||trauma induced coagulopathy|patients with INR>1.2
89544421|NCT05530161||non-trauma induced coagulopathy|patients with INR≤1.2
89544422|NCT05534685|Experimental|intratracheal administration of surfactant/budesonide on the incidence of bronchopulmonary dysplasia|Group A will be given surfactant (beractant, lung phospholipids of bovine origin. Injectable suspension 1ml contains 25mg) at a dose of 100mg/kg or 4ml/kg and budesonide (budesonide, nebulized suspension 2ml contains 0.500mg) at a dose of 0.250 mg/kg or 1 ml/kg.
89544423|NCT05534685|Experimental|intratracheal administration of surfactant on the incidence of bronchopulmonary dysplasia|Group B will receive surfactant alone (beractant, lung phospholipids of bovine origin. Injectable suspension 1ml contains 25mg) administered at a dose of 100mg/kg or 4ml/kg.
89544424|NCT02437877||Mouth Breather|Mouth Breathers Children from 7 to 13 years old
89544425|NCT02437877||Nasal Breather|Nasal breathers children from 7 to 13 years old
89544426|NCT05530083|Experimental|group education|The investigators will provide experimental groups with group education of smoking cessation, including lectures in groups of 50 to 100 people and panel discussion in groups of 5 to 10 people.
89544427|NCT05530083|Other|conventional smoking cessation management|The investigators will provide control groups with conventional smoking cessation management, including regular follow-up of smoking status and giving advice of smoking cessation.
89544428|NCT03191825|Active Comparator|Standard web-application|Endre: a digital smoking cessation counsellor
89544429|NCT03191825|Experimental|Web-based lapse management system|Endre: a digital smoking cessation counsellor + Lapse management system triggered from web-page
88961382|NCT02008643|Experimental|children with food allergy|Chidren aged 8-18 year with food allergy
88961383|NCT02008643|Active Comparator|children with chronic diseases|
89544430|NCT03191825|Experimental|SMS & web-based lapse management system|Endre: a digital smoking cessation counsellor + Lapse management system triggered by SMS-textmessage
89544431|NCT02437955|Experimental|FESO4+T|Ferrous sulfate fortified bread with tea
89544432|NCT02437955|Experimental|FESO4+W|Ferrous sulfate fortified bread with water
89544433|NCT02437955|Experimental|FeFu+T|Ferrous fumarate fortified bread with tea
89544434|NCT02437955|Experimental|FeFu+W|Ferrous fumarate fortified bread with water
89544435|NCT05530005|Active Comparator|Hands on|Patients with shoulder impingement syndrome. Age 18-50 years. Shoulder pain lasting from 3 months to 1 year, No surgery and injection intervention in the shoulder joint and surrounding area in the history of the disease. - Ailments in scales I and II according to Neer.
89544436|NCT05530005|No Intervention|Hands off|Patients with shoulder impingement syndrome. Age 18-50 years. Shoulder pain lasting from 3 months to 1 year, No surgery and injection intervention in the shoulder joint and surrounding area in the history of the disease. - Ailments in scales I and II according to Neer.
89544437|NCT03191435|Experimental|Inspiratory muscle training|Patients will perform the inspiratory muscle training using a load moderate of 30% of maximal inspiratory pressure (MIP 30%).
89544438|NCT03191435|Placebo Comparator|Placebo inspiratory muscle|Patients will perform the inspiratory muscle training using a load of 2% of maximal inspiratory pressure (MIP 2%).
89544439|NCT03191591|Experimental|First 1,000 Days Program|
89544440|NCT02438033|Experimental|Treatment Arm|All patients will be implanted with the investigational device in an open-label fashion
89544441|NCT02437799||Caesarean section spinal anaesthesia|Dicrotic Wave analysis of pulse oximeter of Women undergoing planned caesarean section under spinal anaesthesia.
89544442|NCT05534217|Experimental|debridement+traditional treatment|The experimental group receives debridement of the abrasion wound before receiving traditional treatment including evofloxacin eye drops + befushu QID * for 14 days, four times a day, and the corneal contact lens was worn for 2 weeks.
89544443|NCT05534217|Active Comparator|traditional treatment|The traditional group receives evofloxacin eye drops + befushu QID * for 14 days, four times a day, and the corneal contact lens was worn for 2 weeks.
89544444|NCT02437643|Placebo Comparator|WL-LoEX|10% Weight loss diet plus low intensity exercise (protein ~0.8g/kg). Participants will be provided one serving of dairy protein daily.
89544445|NCT02437643|Active Comparator|Pro-WL-LoEX|Protein-enhanced 10% Weight loss diet plus low intensity exercise (protein ~1.2 g/kg with > 30g per meal and >60% as dairy). Participants will be provided at least 8 servings of dairy protein daily.
89544446|NCT05534139||Healthy controls|Partner/spouse of a patient not at risk of HD OR sibling with genetic test results available that show a normal CAG repeat length for both HTT alleles (<36); No other known cognitive, neurological or psychiatric disorders.
89544447|NCT05534139||Premanifest HD expanded gene carrier|HDGEC before clinical onset: TMS <5, DCL <4, TFC = 13. No other major comorbidity.
89544448|NCT05534139||Early Manifest HD patient|HDGEC after clincial onset: TMS >5, DCL = 4. Early stage of disease: TFC 11-13. No other major comorbidity.
89544449|NCT05534139||Moderate Manifest HD patient|HDGEC after clincial onset: TMS >5, DCL = 4. Moderate stage of disease: TFC 7-10. No other major comorbidity.
88961384|NCT02008643|Active Comparator|witnesses|"Inclusion criteria Age between 8-18 year old Children attending schools of Nice City Signed informed consent of the two parents Signed informed consent of the child Health insurance recipient~Non inclusion criteria Association with another medical or psychiatric chronic disease No signed consent"
89544450|NCT02437721|Active Comparator|infant formula containing folic acid|Infant formula including folic acid within the range stipulated by European legislation on infant formula
89544451|NCT02437721|Experimental|infant formula containing MTHF|Infant formula including MTHF instead of folic acid
89544452|NCT02437721|No Intervention|Breast milk|non randomized reference group
89544453|NCT02437565|Active Comparator|Control|Placement of stainless steel crown under general anesthesia without the use of an occlusal template
89544454|NCT02437565|Experimental|Impression|Placement of stainless steel crown under general anesthesia with the use of an occlusal template prepared after making an impression of the teeth using a fast setting polyvinyl siloxane material
89544455|NCT02437331||advanced heart failure|the patients was diagnostic on Chronic heart failure with NYHA class 3 and 4, AHA stage D, or LVEF<40%.
89544456|NCT05533983|Experimental|Preparation of Frozen Stool Suspensions for FMT|The study will enroll patients with advanced, unresectable, or metastatic solid cancer who have progressed during anti-PD-(L)1 therapy.
89544457|NCT02436863||Surgical perfomance (Laminoplasty)|After the lesions inside the spinal canal were surgical removed by laminectomy, the lamina and spinous process were replanted with titanium plates and screws.
89544458|NCT02436863||Surgical perfomance (Internal fixation)|After the lesions inside the spinal canal were surgical removed by laminectomy, the pedicle screws (Thoracic and lumbar vertebra) or lateral mass (Cervical vertebra) and sticks were used for internal fixation.
89544459|NCT05533827|Experimental|Kaleidoscope|Kaleidoscope
89544460|NCT05533827|Experimental|Music|Music listening
89544461|NCT05533827|Experimental|Virtual reality glasses|Virtual reality glasses
88961385|NCT02008669||Multiple Sclerosis cases|"All patients will undergo the following interventions~Gustatory sensitivity test using Taste strips~Blood sampling~Questionnaires"
88961386|NCT02008695|Active Comparator|Youth microfinance only|Youth receive loan
89544462|NCT05533827|No Intervention|Control|Control
89544463|NCT05533749|Experimental|GILL eHealth module|Patients will perform the GILL eHealth. This eHealth contains two modules focusing on systematic somatic screening and lifestyle behaviors.
89544464|NCT05533749|No Intervention|Care as usual|Patients will receive usual care and have unrestricted access to mental care and treatment.
89544465|NCT03189407|Other|Moringa oleifera tea in T2DM patients|The study was a pre/post design for type 2 diabetes mellitus patients on metformin in which each patient acted as his/her control. Intervention of twice daily pre-packed 400g dried Moringa oleifera leaves to be prepared as tea by the patients was done. Evaluation of the effect of the tea on metformin steady state concentrations and blood glucose measurements were done.
88961387|NCT02008695|Active Comparator|youth and adult micro finance|youth and adult receive loan
88961388|NCT02008695|Active Comparator|adult microfinance|adults receive loan
89516117|NCT05095467|Experimental|Group B|"patients with peritoneal metastasis stage P1a or P1b (cTxNxM1, P1a or P1b)~1 cycle HIPEC+S-1 chemotherapy, sequential 3 cycles of chemotherapy (AS plan, Q21d × 3), surgery+HIPEC, sequential 3 cycles of chemotherapy ( AS plan, Q21d × 3)"
88961389|NCT02008708|Experimental|Livestock microfinance|Participants randomized to the microfinance intervention receive a female pig loan with ongoing support to manage health and care of the pig by trained agents.
88961390|NCT02008708|Active Comparator|Delayed Control Group|Participants randomized to delayed control group receives pig loan 12 months after the intervention group
88961391|NCT02007031||Hypertensive subjects|Hypertensive subjects are exposed to brief cold exposure (-15 C for 15 min) mainly subjected to their facial region during which their cardiovascular responses are registered.
88961392|NCT02007031||Normotensive subjects|Normotensive subjects are exposed to brief cold exposure (-15 C for 15 min) mainly subjected to their facial region during which their cardiovascular responses are registered.
88961393|NCT02008734|No Intervention|Control|
88961394|NCT02008734|Experimental|PD0332991|Patients will be randomized 3:1 to be treated with PD0332991 125mg/day orally for a total duration of 14 days (or 100 mg/day for a total duration of 21 days depending on results of interim analysis) with last treatment taken the day previous to the surgical procedure.
88961395|NCT02008747|Active Comparator|Magnesium sulphate|"The patients in this group underwent general anaesthesia with total intravenous anesthesia containing Remifentanyl (0,3 mg/kg ideal body weight/h), Propofol (4 mg/kg ideal body weight/h) and Atracurium.~They also received 40mg/kg ideal body weight magnesium sulphate by bolus injection before the operation started, followed by a continuous application of 10mg/kg ideal body weight/hour for 24 hours."
89516118|NCT05095467|Experimental|Group C|"group C is patients with peritoneal metastasis stage P1c (cTxNxM1, P1c)~1 cycle HIPEC+S-1 chemotherapy, sequential 3 cycles of chemotherapy (AS plan, Q21d × 3), HIPEC+S-1 chemotherapy, sequential 3 cycles of chemotherapy ( AS plan, Q21d × 3)"
89516119|NCT02312453|Experimental|Posterior approach|All patients were given a single shot ultrasound-guided posterior parasagittal in-plane approach infraclavicular brachial plexus block under aseptic technique. The blocks were performed using a 21G, 100 mm insulated short bevel needle (Stimuplex A, B Braun, Melsungen, Germany) without nerve stimulation. A 25-ml local anaesthetic admixture [Lignocaine 2% (100mg) plus Ropivacaine 0.75% (150mg)] was administered. We used an ultrasound machine (Sonosite M-Turbo; Sonosite®, Bothell, WA, USA) with HFL38x/ 13-6 MHz linear transducer probe.
89516120|NCT02312531|Experimental|HBIG group|Mothers in HBIG group received 'Hepatitis B immunoglobulin' (HBIG 200 IU, S20023028, Hualan Biological Engineering Inc.) injection at gestational weeks 20, 24, 28, 32, 34, 36, 38, 39, and 40.
89516121|NCT02312531|No Intervention|Control group|Mothers in control group had no HBIG injection during pregnancy.
89516122|NCT04234477|Experimental|Beta-blocker strategy|MICU patients assigned to Team Blue will receive an intravenous (IV) beta-blocker strategy to manage AF with RVR
89516123|NCT04234477|Experimental|Calcium channel blocker strategy|MICU patients assigned to Team Red will receive an intravenous (IV) calcium channel blocker strategy to manage AF with RVR
89516124|NCT04234477|Active Comparator|Physician preference strategy|MICU patients assigned to Team Green will receive a physician preference strategy with usual/standard of care interventions to manage AF with RVR
89516125|NCT02449031||TOBI® PODHALER® cohort|
89516126|NCT02449031||non-TOBI® PODHALER® cohort|Approximately 250 patients treated with other FDA-approved inhaled antipseudomonal antibacterial drugs at enrollment
89516127|NCT04232449|Active Comparator|Intervention group|"Identically looking, numbered and marked medication glass jars with 5 daily doses of 40 mg (2 tablets of 20 mg) of prednisone (intervention group) are provided by General Physicians (GPs) to participants. PREDNISON Galepharm Tabl. 20 mg are manufactured according to Good Manufacturing Practice (GMP)-guidelines.~The prednisone medication is manufactured by Galepharm AG, 8700 Küsnacht (ZH) and packaged and labelled by the Hospital Pharmacy of the University Hospital Basel. The PREDNISON tablets' active substance is Prednisonum; the tablets also contain Excipiens pro compresso. Swissmedic authorization 50821"
89516128|NCT04232449|Placebo Comparator|Control group|"Identically looking, numbered and marked medication glass jars with 5 daily doses of placebo (control group) are provided by General Physicians (GPs) to participants.~The content of the placebo tablets is as follows: Lactose monohydrate 140 mg, microcrystalline cellulose 68 mg, Croscarmellose sodium 5 mg, Magnesium stearate 2mg. The placebo tablets were manufactured by Apotheke Hotz, Zürichstrasse 176, CH- 8700 Küsnacht."
89516129|NCT03469063|Experimental|AferBio|Daily oral AferBio (20 g/day, in sachets)
89516130|NCT03469063|Placebo Comparator|Placebo|Daily oral placebo (20 g/day, in sachets)
89516131|NCT01680861|Experimental|Tacrolimus and Everolimus|"Patients in both arms will receive reduced tacrolimus dosing (rTd), 0.1 mg/kg PO divided in two daily doses - beginning when serum Cr decreases to a level of <4 mg/dl (i.e., acceptable renal transplant function) postoperatively. Target tacrolimus trough levels during the first year post-transplant and thereafter will be 5-8 ng/ml.~Everolimus initiated within 24 hours post-transplant (i.e., immediately following randomization) at 0.75mg PO BID and will be adjusted in order to achieve target everolimus trough levels of 3-8 ng/ml."
89516132|NCT01680861|Active Comparator|Tacrolimus and Enteric-Coated Mycophenolate Sodium (EC-MPS)|"Patients in both arms will receive reduced tacrolimus dosing (rTd), 0.1 mg/kg PO divided in two daily doses - beginning when serum Cr decreases to a level of <4 mg/dl (i.e., acceptable renal transplant function) postoperatively. Target tacrolimus trough levels during the first year post-transplant and thereafter will be 5-8 ng/ml.~EC-MPS will be initiated at 720 mg PO BID starting on the first post-operative day."
89516133|NCT04182607||hand-assisted kidney transplant|Kidney donors and recipients who underwent a hand-assisted kidney transplant
89516134|NCT04182607||robotic kidney transplant|Kidney donors and recipients who underwent a robotic kidney transplant
89516135|NCT02308397|Experimental|Group 1|Begins with Normal gluten containing bread
89516136|NCT02308397|Experimental|Group 2|Begins with Bread with reduced gliadins content
89516137|NCT02308397|Experimental|Group 3|Begins with Bread with reduced ATIs content
89516138|NCT02308397|Experimental|Group 4|Begins with Bread with reduced overall protein content
89544466|NCT02437097|Experimental|Aerobic Exercise|Participants will perform 30 minutes of cycling at an intensity of 60 to 70% of maximum heart rate based on 220 - their age. The aerobic exercise will utilize a Monarch 818E Monarch Lower Body Ergometer (Monark Exercise, Stockholm, Sweden). Participant's heart rate will be monitored using Polar heart rate monitor.
89544467|NCT02437097|Experimental|Video Gaming|Participants will play Brain Age: Train Your Brain in Minutes a Day! on Nintendo 3DS for 30 minutes in a seated resting position.
89544468|NCT02437097|Experimental|Aerobic Exercise and Video Gaming|Participants will perform 30 minutes of cycling at an intensity of 60 to 70% of maximum heart rate based on 220 minus their age on a Monarch ergometer while playing Brain Age: Train Your Brain in Minutes a Day! on a Nintendo 3DS. Participant's heart rate will be monitored using Polar heart rate.
89544469|NCT02437097|Placebo Comparator|Control|Participants will sit quietly for 30 minutes
89544470|NCT02436551||Pregnant women in Tajikistan|
89544471|NCT02436629|Active Comparator|Nitrate-rich concentrated beetroot juice|Dietary supplement: 800 mg of nitrate in 140 mL of concentrated beetroot juice (Beet-IT)
89544472|NCT02436629|Placebo Comparator|Nitrate-depleted conc. beetroot juice|Placebo: 140 mL of nitrate-depleted concentrated red beetroot juice
89544473|NCT02436785|Active Comparator|Music Therapy|The music therapy group will run for approximately an hour (twice a week) and will involve in-vivo relaxation where the live music is manipulated in terms of speed and intensity to bring on a state of relaxation. There will be a brief therapist-led discussion before and after the relaxation portion to increase a sense of group cohesion. Procedures that will be used are based on evidence-based practice for trained Music Therapists.
89544474|NCT02436785|Active Comparator|Music Listening|The control group will also run for approximately an hour (twice a week) and will involve listening to relaxing music on a CD player.
89207539|NCT00967395|Experimental|Healing|patients receive healing while blindfolded and with hearing protector. The healer is behind a screen and not allowed to speak with the subject.
89544475|NCT02436473|Experimental|Test fluoride toothpaste|Participants will apply 1.5 weighed g (± 0.1 g) of the study toothpaste to a wet toothbrush and brush their natural teeth twice daily for one timed minute. Participants will wear their mandibular partial denture with test specimens while brushing and continuously for 24 hours a day during each of the 4-week treatment periods
89544476|NCT02436473|Placebo Comparator|Fluoride free (0ppm F) reference control toothpaste|Participants will apply 1.5 weighed g (± 0.1 g) of the study toothpaste to a wet toothbrush and brush their natural teeth twice daily for one timed minute. Participants will wear their mandibular partial denture with test specimens while brushing and continuously for 24 hours a day during each of the 4-week treatment periods.
89544477|NCT02436473|Active Comparator|Low dose fluoride (250ppm F) reference control toothpaste|Participants will apply 1.5 weighed g (± 0.1 g) of the study toothpaste to a wet toothbrush and brush their natural teeth twice daily for one timed minute. Participants will wear their mandibular partial denture with test specimens while brushing and continuously for 24 hours a day during each of the 4-week treatment periods.
89544478|NCT02436473|Active Comparator|Fluoride (1150ppm F) reference control toothpaste|Participants will apply 1.5 weighed g (± 0.1 g) of the study toothpaste to a wet toothbrush and brush their natural teeth twice daily for one timed minute. Participants will wear their mandibular partial denture with test specimens while brushing and continuously for 24 hours a day during each of the 4-week treatment periods.
89544479|NCT02436161|Experimental|"Care management program PROMIC"|care management program provided by a multidisciplinary team that optimizes care with the main role of nurses acting as coaches of patients and carers, within the primary care teams
89544480|NCT02436161|No Intervention|Usual care|Patients in the control group belongs to different Primary health care centres from the intervention group and are treated as usual by their Primary Care team and by cardiologists different from the intervention group
89544481|NCT05233553||post-COVID-patients|
89544482|NCT02436395|Experimental|Group A (povidone-iodine group)|"The surgical incision is washed by the mixed solution with 400ml 9% normal saline and 100ml 5% povidone-iodine solution.~We declare that we have no conflicts of interest."
89544483|NCT02436395|Experimental|Group B (normal saline group)|"The surgical incision is washed by the 500ml 0.9% normal saline.~We declare that we have no conflicts of interest."
89544484|NCT02436317|Experimental|Study group|"All patients included in intervention group will be examined with an ultrasound machine with cardiac probe and vascular probe [Saote/ Mylab 5/ Italy] using both 2 dimensional and color Doppler imaging modalities according to our local point of care ultrasonography protocol.~Including demographic and medical data collection. Also, a wellbeing questionnaire will be filled by the investigator."
89544485|NCT02436317|No Intervention|Control group|All patients included in the control group won't be examined with an ultrasound machine. Participation including demographic and medical data collection. Also, a wellbeing questionnaire will be filled by the investigator.
89544486|NCT02436083|No Intervention|control|no antibiotics
89544487|NCT02436083|Active Comparator|experimental group|drug administration (antibiotic)
89544488|NCT03189017|Experimental|ICP-022|"There are 5 cohorts in the Part 1 phase of the trial. Three quarters of subjects will be randomized to receive ICP-022 in a double-blind fashion. Five dose levels will be evaluated; dose escalation steps may be modified based on the safety from the previous dose. Cohort 4 will return on Day 8 and receive a single dose of ICP-022 under fed conditions.~In Part 2 phase of the trial,three quarters of subjects will be randomized to receive the ICP-022 in a double-blind fashion in 3 cohorts. ICP-022 will be administered once a day for 14 consecutive days."
89544489|NCT03189017|Placebo Comparator|Placebos|"In part 1 phase of the trial, one quarter of subjects will be randomized to receive placebo in a double-blind fashion. Cohort 4 will return on Day 8 and receive a single dose of placebo under fed conditions.~In Part 2 phase of the trial,one quarter of subjects will be randomized to receive placebo in a double-blind fashion. Placebo will be administered once a day for 14 consecutive days."
89544490|NCT05599815|Experimental|ADX-629|
89544491|NCT03189095|Experimental|Intervention|
89207540|NCT00967395|Sham Comparator|Sham healing|Same design of room as with the healing, while in this case a student is behind the screen
89207541|NCT00967395|No Intervention|Control|Business as usual in the third arm
89207542|NCT00970827|Active Comparator|1|Leg postconditioning
89207543|NCT00970827|Active Comparator|2|Arm postconditioning
89544492|NCT03189095|No Intervention|Wait-List Control|
89544493|NCT05207631|No Intervention|Control cohort|Participants in the control cohort received standard care.
89544494|NCT05207631|Active Comparator|Cohort with intervention|Participants included in the intervention cohort receive a systematic and standardised assessment of their inhaler on admission to our department. Their inhalers are adapted in accordance with a prescribing guide.
89544495|NCT03117335|Active Comparator|Vinorelbine plus Cisplatin With placebos|The control group
89544496|NCT03117335|Experimental|Vinorelbine plus Cisplatin With Sulijia|The treatment group
89544497|NCT05533515||RP Treatment cohort|We will use participants who have been deemed eligible for radical prostatectomy based on the current European Urology Association classification system, and who have been scheduled for surgery to completely remove the cancer in the prostate gland.
89544498|NCT05533437|Experimental|Dry needling|During dry needling, a practitioner inserts several filiform needles into your skin. Filiform needles are fine, short, stainless steel needles that don't inject fluid into the body.
89544499|NCT05533437|Active Comparator|kinesio taping|The Kinesio Taping Method is a therapeutic taping technique which alleviates pain and facilitates lymphatic drainage by microscopically lifting the skin. This lifting affect forms convolutions in the skin increasing interstitial space and allowing for decreased inflammation in affected areas. Based upon research and years of clinical use, The Kinesio Taping Method specifically applies Kinesio tape based on evaluation and assessment to dictate a specific application.
89544500|NCT02435927|Experimental|ASLAN001 + CAPOX|ASLAN001 + CAPOX: ASLAN001 twice daily in combination with oxaliplatin 130 mg/m2 intravenously on day 1 and capecitabine 850 mg/m2 orally twice daily on days 1 to 14 every 3 weeks
89544501|NCT02435927|Experimental|ASLAN001 + mFolfox6|ASLAN001 + mFolfox6: ASLAN001 twice daily in combination with mFolfox6 (oxaliplatin 85 mg/m2 intravenously on day 1 and 5-FU bolus 400mg/m2 i.v on day 1 and as a continuous infusion 2400mg/ m2 over 46h and leucovorin 400mg/2 i.v on day 1) every 2 weeks
89544502|NCT02435771|Experimental|BMI <25|Normal BMI
89544503|NCT02435771|Experimental|BMI 25-35|Overweight and obese by BMI
89544504|NCT02435771|Experimental|BMI >35|Obese by BMI
89544505|NCT02440763||Spinocerebellar ataxia type 1,2,3 and 6|Spinocerebellar ataxias (SCA) are autosomal dominantly inherited progressive ataxia disorders. An epidemiological study performed in the Netherlands found a prevalence of 3.0 : 100,000 (van de Warrenburg et al. 2002). The SCA´s are genetically and clinically heterogeneous disorders with SCA1, SCA2, SCA3 and SCA6 being the most frequent genotypes worldwide. While SCA1, SCA2 and SCA3 have a complex phenotype, SCA6 patients usually present with pure cerebellar ataxia (Schols et al. 2004). Although precise knowledge of the rate of disease progression is a prerequisite for the biometrical design of future therapeutical trials, prospective studies of the natural history of SCA´s have not been performed. Similarly, the occurrence and evolution of accompanying non-ataxia symptoms have not been studied prospectively.
89544506|NCT02435693|Experimental|PHARMACEUTICAL CARE programe|The pharmaceutical care program was characterized by face to face monthly visits to collect information, register information, prepare plan of care for every health problem; identification of drug therapy problems, communication to prescribers the drug therapy problems identified and education of participants to resolve the drug therapy problems.
89544507|NCT02435693|Other|control|without pharmaceutical care programe (control)
89544508|NCT02440607|Experimental|Electronic aid|The dynamic aid will consist of a centralized electronic aid embedded within a simulated EMR.
89544509|NCT02440607|Active Comparator|Static Cognitive aid|The static aid represents the standard algorithm put forth by a leading clinical care organization.
89544510|NCT02440841|Experimental|fedovapagon and itraconazole|Two daily doses of fedovapagon and once daily doses of itraconazole
89544511|NCT02440841|Experimental|fedovapagon and rifampicin|Two daily doses of fedovapagon and once daily doses of rifampicin
89544512|NCT02435615|Experimental|Study group|There is one group of patients which are those presenting to the hospital with suspected clinical case of dengue fever for diagnosis. This group will have oral fluid collected via the SaniSal oral fluid collector and a pipette, and blood collected via venipuncture.
89544513|NCT02576145|Experimental|Group A (With Daclizumab Therapy)|Participants who were receiving a full course of 5 doses of daclizumab (1 milligram per kilogram [mg/kg]) with Day 1 vaccine administered immediately prior to the fifth dose.
89544514|NCT02576145|Active Comparator|Group B (Post Daclizumab Therapy)|Participants who completed a full course of daclizumab therapy in the previous 4 to 18 months.
89544515|NCT02435537|Active Comparator|Intrathecal Bupivacaine|intrathecal injection of 10 mg hyperbaric bupivacaine 0.5% in 2 ml volume and 1ml of saline 0.9%
89544516|NCT02435537|Active Comparator|Intrathecal Morphine|intrathecal injection of 10mg bupivacaine 0.5% in 2ml volume intrathecal injection of 0.5 mg morphine in 1ml volume
88961396|NCT02008747|No Intervention|No treatment|The patients in this group underwent general anaesthesia with total intravenous anesthesia containing Remifentanyl (0,3 mg/kg ideal body weight/h), Propofol (4 mg/kg ideal body weight/h) and Atracurium. They received no additional medication.
89544517|NCT02435537|Active Comparator|Intrathecal Morphine-Dex|intrathecal 10mg bupivacaine 0.5% in 2 ml volume intrathecal 0.5 mg morphine intrathecal 5 µg of dexmedetomidine in 1ml volume .
89207544|NCT00970827|Placebo Comparator|3|Control group
89544518|NCT02440685|Experimental|Part A ASN002 Dose Escalation|Multiple ascending doses of ASN002 will be administered to determine the maximum tolerated dose (MTD). Arm Closed
89544519|NCT02440685|Experimental|Part B ASN002 Recommended dose (RD)|ASN002 administered at the recommended dose
89544520|NCT03191513|Experimental|Interesterified|Interesterified blend of palm kernal and plam stearin. 50g fat.
89544521|NCT03191513|Active Comparator|Un-interesterified|Un-interesterified blend of palm kernal and plam stearin. 50g fat.
88961397|NCT02008760|Placebo Comparator|vegetable oil with betacarotene|4 capsules vegetable oil with betacarotene
88961398|NCT02008760|Active Comparator|krill and vitamin D3|krill and vitamin D3. (72 mg), four capsules daily
88961399|NCT02008799|Experimental|Bone marrow stem cell injection|through special butterfly inject stem cell in testicular artery and inside tubules
88961400|NCT02008812|Experimental|Ad sensor|virus detection
88961401|NCT02008825|Experimental|ViSiGi|Utilization of ViSiGi calibration tube
88961402|NCT02008825|Active Comparator|Usual standard of care|Usual non suction Bougie
89544522|NCT03191513|Active Comparator|Control|Rapeseed oil. 50g fat.
89544523|NCT02576067|Experimental|Low dose methotrexate|average dose of 15-20 mg po/weekly
89544524|NCT02576067|Placebo Comparator|Placebo|matching placebo
89544525|NCT02435459|Placebo Comparator|No lining|No lining material placed under amalgam dental restoration
89544526|NCT02435459|Active Comparator|Calcium hydroxide cement|Placement of calcium hydroxide cement under amalgam dental restorations
89544527|NCT02435459|Active Comparator|Bonding agent|Placement of Resin bonding agent under amalgam dental restorations
89544528|NCT02435459|Active Comparator|RMGI cement|Placement of rmgi lining under amalgam dental restorations
89544529|NCT05199909|Experimental|Intervention ( zanubrutinib)|10 enrolled patients are picked up to take zanubrutinib at the indicated dose.
89544530|NCT02435303|Experimental|Sildenafil|Sildenafil 20mg tid for six months (* consider open-label extension study for 1 year)
89544531|NCT02435303|Placebo Comparator|Placebo|Placebo tablets do not contain an active ingredient but are identical in shape with each active tablet of Sildenafil
89544532|NCT05529615|Other|stage II with high risk and stage III with low risk（T1-3N1）|ctDNA will be detected at 7 days after surgical treatment. If，ctDNA(-)-> observation； ctDNA(+)-> 1:1 randomized as Capeox chemotherapy 3 months and observation. CtDNA will be detected at 4 months after surgical treatment.
89544533|NCT05529615|Other|stage III with high risk（T4 or N2 or both）|"ctDNA will be detected at 7 days after surgical treatment. All the stage III with high risk will receive Capeox chemotherapy 3 months. ctDNA will be detected after the completion of Capeox chemotherapy 3 months. If，ctDNA(-) -> observation； ctDNA(+) -> 1:2 randomized as Capeox chemotherapy 3 monthsand second line treatment（decided by physician）.~CtDNA will be detected at 7 months after surgical treatment."
89544534|NCT02435225|Experimental|Mindfulness group|Participation in a 12 week mindfulness therapy group.
89544535|NCT05533047|Active Comparator|Bipolar TURP|Patients thats will undergo bipolar TURP
89544536|NCT05533047|Active Comparator|Monopolar TURP|Patients thats will undergo monopolar TURP
89544537|NCT02434991|Experimental|Barostat|The barostat (a thin tube, with a deflated balloon attached at the end) will be placed through your mouth down your esophagus (swallowing tube) to where your stomach and esophagus meet. The 10-cm long balloon will then be inflated with step by step pressure increases of 4mmHg for 30 seconds each to a maximum pressure of 50mmHg. The patient will rate discomfort during each step of inflation
89544538|NCT05363787|Experimental|The effect of therapeutic touch on sleep patterns of elderly patients|The important effects of the therapeutic approach made by the researcher to the elderly patients hospitalized in the intensive care unit will be evaluated.
89544539|NCT05363787|No Intervention|Determining the sleep pattern of the Control Group|It will be evaluated whether there is a change in sleep patterns without intervention in the control group.
89544540|NCT02434835|Experimental|[14C]KWA-0711|
89544541|NCT02575911|Experimental|LenSx|LASIK surgery in both eyes using LenSx® Femtosecond Laser System
89544542|NCT02434757|Experimental|Acthar 40 U|Acthar 40 U (0.5mL)
89544543|NCT03189329|Active Comparator|Group L|Patients undergoing block with 2% lidocaine hydrochloride
89544544|NCT03189329|Active Comparator|Group LB|Patients undergoing block with 0.5% levobupivacaine
89544545|NCT03188939|Active Comparator|G s|20 guage 10cm block needle inserted in the supraclavicular fossa guided by portable ultrasound machine using in plane method and lateral to medial direction, local anesthetic (30 ml bupivacaine) is injected at the point where the subclavian artery meets the first rib
89544546|NCT03188939|Active Comparator|G ic|20 guage 10cm block needle inserted in the supraclavicular fossa guided by portable ultrasound machine using in plane method and lateral to medial direction,the local anesthetic(30 ml bupivacaine) is injected inside main and satellite neural cluster.( Circumferential administration of local anesthetic rather than creating a single point injection )
89544547|NCT03188939|Active Comparator|G d|20 guage 10cm block needle inserted in the supraclavicular fossa guided by portable ultrasound machine using in plane method and lateral to medial direction,half the volume of local anesthetic(15 ml bupivacaine) is injected at intersection of first rib and subclavian artery and another half(15 ml bupivacaine) is injected supero- lateral to subclavian artery to assure spread of the local anesthetic solution in all planes containing brachial plexus
89544548|NCT02575833|Placebo Comparator|Placebo|Participants received a single dose of placebo administered by intravenous infusion on day 1.
89544549|NCT02575833|Experimental|Erenumab|Participants received a single dose of erenumab 140 mg administered by intravenous infusion on day 1.
89544550|NCT03188783|Experimental|Cohort 1: GDC-0853 Low Dose|Japanese subjects will receive a single low dose of GDC-0853 or matching placebo by mouth.
89544551|NCT03188783|Experimental|Cohort 2: GDC-0853 Intermediate Dose|Japanese subjects will receive a single intermediate dose of GDC-0853 or matching placebo by mouth. Subsequently, participants will receive twice-daily intermediate doses of GDC-0853 or matching placebo by mouth for 4 days followed by a single intermediate dose of GDC-0853 or matching placebo by mouth.
89544552|NCT03188783|Experimental|Cohort 3: GDC-0853 Intermediate Dose|Caucasian subjects will receive a single intermediate dose of GDC-0853 or matching placebo by mouth. Subsequently, participants will receive twice-daily intermediate doses of GDC-0853 or matching placebo by mouth for 4 days followed by a single intermediate dose of GDC-0853 or matching placebo by mouth.
89544553|NCT03188783|Experimental|Cohort 4: GDC-0853 Low Dose|Japanese subjects will receive a single high dose of GDC-0853 or matching placebo by mouth.
89544554|NCT05532969||Observation group of newly diffuse astrocytoma patients with high-level psychological stress|The patients had high threshold levels of perceived psychological stress, fear, anxiety, and depression as assessed by psychologists
88961403|NCT02008838|Active Comparator|Synbiotic|Each synbiotic capsule (Protexin, UK) contained 2 × 108 CFU of seven strains of friendly bacteria (Lactobacillus casei, Lactobacillus rhamnosus, Streptococcus thermophilus, Bifidobacterium breve, Lactobacillus acidophilus, Bifidobacterium longum, Lactobacillus bulgaricus), prebiotics (FOS [Fructooligosaccharide]), and probiotics culture (Magnesium stearate [source: mineral and vegetable], and vegetable capsule [hydroxypropyl methyl cellulose])
88961404|NCT02008838|Placebo Comparator|Placebo|250 mg Maltodexterin
88961405|NCT02008851|Experimental|Implantation of Neo-kidney Augment|Patients receiving one dose (implant) of NKA into the left kidney
89516139|NCT02229214|Experimental|VI-0521 (Qsymia)|"Days 1-3: VI-0521 (Phentermine/Topiramate 3.75 mg/23 mg)~Days 4-6: VI-0521 (Phentermine/Topiramate 7.5 mg/46 mg)~Days 7-9: VI-0521 (Phentermine/Topiramate 11.25 mg/69 mg)~Days 10-28: VI-0521 (Phentermine/Topiramate 15 mg/92 mg)"
89516140|NCT02229214|Placebo Comparator|Sugar pill|Days 1-28: Placebo
89516141|NCT03470779|Experimental|Treatment group|Participants randomly assigned to the treatment group will participate in an interdisciplinary treatment program in which local Kurdish psychotherapists and physiotherapists provide a 10-week intervention program. Treatment will consist of group physiotherapy and group psychotherapy
89516142|NCT03470779|No Intervention|Wait-list group|Participants randomly assigned to the wait-list group will not receive treatment but will participate in outcome data collection for comparison purposes.
89516143|NCT02308553|Experimental|Nintedanib + Paclitaxel|Nintedanib (150 or 200mg BID) for up to 48 weeks combined with paclitaxel 90mg/m2 BSA day 1, 8, 15 q28 days for a maximum of 6 courses
89516144|NCT02308553|Placebo Comparator|Nintedanib-Placebo + Paclitaxel|Placebo (150 or 200mg BID) for up to 48 weeks combined with paclitaxel 90mg/m2 BSA day 1, 8, 15 q28 days for a maximum of 6 courses
89516145|NCT04458415|Experimental|TPR Arm|Surgeon will use the Traxi Panniculus Retractor to retract the panniculus during cesarean section.
89516146|NCT04458415|Active Comparator|Silk Tape Arm|Surgeon will use silk tape to retract the panniculus during cesarean section.
89516147|NCT05094063|Experimental|experimental group|Training will be given to the patients in the experimental group.
89516148|NCT05094063|No Intervention|control group|untrained patient group
89516149|NCT03503981||Anxiety unit|Patients have anxiety as a primary diagnose. Receive treatment for anxiety (CBT and MCT).
89516150|NCT03503981||Eating disorder unit|Patients have eating disorder as primary diagnose. Receive treatment for their eating disorder (CBT and compassion-focused therapy).
89516151|NCT03503981||Depression unit|Patients have depression as primary disorder. Receive treatment for their depression (Short-term dynamic therapy, existential therapy and relational psychodynamic therapy).
89516152|NCT03503981||Family unit|One of the members of the family has a psychological disorder. The treatment is focused towards the family and family dynamics.
89516153|NCT03503981||Trauma unit|Patients have PTSD and relational trauma as primary diagnosis. Receive stabilizing treatment and exposure therapy.
89516154|NCT04458493|Experimental|control|no supplement will be provided on the day of the experiment
89516155|NCT04458493|Experimental|Generation UCAN|carbohydrates - protein (Generation UCAN supplement, 400ml, 20% solution)
89516156|NCT05094999|Experimental|Intervention group|Vibration treatment will last eight weeks for each patient, with 4 sessions per week, 30 minutes per session. Subjects of the intervention group will receive proprioceptive stimulations set to create illusions of movement.
89516157|NCT05094999|Sham Comparator|Control group|Vibration treatment will last eight weeks for each patient, with 4 sessions per week, 30 minutes per session. Subjects of the control group will receive sham stimulations.
89516158|NCT03503903|Experimental|Wet Cupping|One armed self-controlled study. Individuals in this arm will receive three concecutive WCT application
89516159|NCT05093985|Experimental|Neuromuscular electrical stimulation with blood flow restriction|This is the intervention condition
89516160|NCT05093985|No Intervention|No intervention|This is the control condition
89516161|NCT03523663||Control|healthy children without ADHD or other mental health issues
89516162|NCT03523663||ADHD|children diagnosed with ADHD
89516163|NCT03503825|Experimental|Healthy Volunteers|Healthy volunteers will be administered [Tc-99m]-RPI-T-087 Injection, single IV dose of 555 MBq and will be monitored for safety, knee image evaluation, and radioactivity biodistribution and dosimetry.
89516164|NCT03503825|Experimental|Osteo Arthritis of the knee|Subjects with knee osteoarthritis will be administered [Tc-99m]-RPI-T-087 Injection, single IV dose of 555 MBq and will be monitored for safety and knee image evaluation.
89516165|NCT03470701|No Intervention|Control - usual care|This arm will receive usual care.
89516166|NCT03470701|Experimental|Mailed Urinalysis Smartphone Kit|This arm will receive a mailed urinalysis smartphone kit if they do not complete albuminuria screening after the initial reminder to do so.
89516167|NCT02308631|Experimental|Colostomy with colopexy by endoscopy|Colostomy with colopexy by endoscopy. 5 porks underwent endoscopic assisted colostomy with percutaneous colopexy. Animals were evaluated in post-operative days 1, 2, 5 and 7 Procedure/Surgery: ENDOSCOPICALLY ASSISTED COLOSTOMY WITH COLOPEXY
89516168|NCT05093907|Experimental|BEY1107 + Capecitabine|Administer BEY1107 in combination with Capecitabine, 3-weeks as 1 cycle.
89516169|NCT03793543|Experimental|18F-DCFPyL Injection|9±1 mCi (333±37 MBq) IV injection of 18F-DCFPyL
89516170|NCT02228980|Experimental|Subjects aged 6 to 35 months (Group 1)|Participants aged 6 months to 35 months will receive two 0.25 mL doses of SP Shz TIV given 28 days apart.
89516171|NCT02228980|Experimental|Subjects aged 3 to 17 years (Group 2)|Participants aged 3 years to 17 years will receive a single 0.5 mL dose of SP Shz TIV
89516172|NCT02228980|Experimental|Subjects aged 18 to 60 years (Group 3)|Participants aged 18 years to 60 years will receive a single 0.5 mL dose of SP Shz TIV
89516173|NCT02228980|Experimental|Subjects aged 61 years or older (Group 4)|Participants aged 61 years or older will receive a single 0.5 mL dose of SP Shz TIV
89516174|NCT03506555|Active Comparator|the arm A (Veress needle)|a standard reusable Veress needle technique was performed for laparoscopic entry
89516175|NCT03506555|Active Comparator|the arm B (Hasson)|the standard open Hasson technique was performed for laparoscopic entry
89516176|NCT05093751||Meningioma patients|
88961406|NCT02008864|Placebo Comparator|Placebo|Wheat
88961407|NCT02008864|Active Comparator|Senna|Senna
88961408|NCT02008929|Other|MG4101|Ex vivo expanded allogeneic NK cell
88961409|NCT02008955|Experimental|lysine intake at different levels of intake|all subjects will receive all 7 of the lysine test levels, assigned in random order.
89516177|NCT03783091|Experimental|Hydroxocobalamin|Single IV infusion administered over a 10-15 minute period
89516178|NCT03783091|Placebo Comparator|Saline Placebo|Single IV saline administered over a 10-15 minute period.
89516179|NCT05057481|Active Comparator|MMF arm|
89516180|NCT05057481|Active Comparator|Rituximab arm|
89516181|NCT02312609|Experimental|Test|Minocycline hydrochloride extended release tablets 135 mg
89516182|NCT02312609|Active Comparator|Reference|Solodyn Extended Release Tablets 135 mg
89516183|NCT03470623|Experimental|bioabsorbable screws|hallux valgus treated with chevron osteotomy using bioabsorbable screws
89516184|NCT03470623|Experimental|steel screws|hallux valgus treated with chevron osteotomy using steel screws
89516185|NCT05374707|Experimental|The motivational interviewing group|"The data of the study were collected through online questionnaires. An motivational interviewing lasting 30 minutes on average, both online and face-to-face, was carried out with the experimental group. Four reminder text messages were sent to the experimental group in a one-month period.~One month after the interview was carried out and Questionnaire on Smoking Urges and Smoking Cessation Success Prediction Scale were completed as a pretest for the experimental group, the scales were completed again as a post-test."
89516186|NCT05374707|No Intervention|The group in which no motivational interviews were conducted|The control group, on the other hand, were asked to fill in Questionnaire on Smoking Urges and Smoking Cessation Success Prediction Scale as a pretest, and again a month later as a post-test.
89516187|NCT03506399|Experimental|Oral Contraceptive (OC)|Ethinyl estradiol and levonorgestrel administered as a single dose, orally
89516188|NCT03506399|Experimental|Lanabecestat|Single oral dose of lanabecestat
89516189|NCT03506399|Experimental|Lanabecestat and OC|A single oral dose of oral contraceptive and single daily doses of lanabecestat
89516190|NCT04993911|Experimental|Balance training + conventional exercises|"Assessment will be performed pre and post of intervention. Intervention will be given 3 days a week for 8 weeks. Each session will include a 5-min warm-up on a fitness bike or treadmill before commencement of the program and a 5-min cool period. Participants of this group will receive balance training with conventional treatment. Participants will perform between 2 sets of 5 and 7 repetitions of each exercise.~Single leg balance~Walking forward Walking backward Side stepping Walk heel to toe Static exercises with eyes close or open~CONVENTIONAL EXERCISE PROGRAM :~TENS for 15 minutes Hot pack for 15 minutes~Participants will perform between 2 sets of 7 and 10 repetitions of each exercise:~Quadriceps/hamstring isometric exercises. ROM and active stretching of the hamstring and quadriceps muscle. Active ankle pump. Squats,step-up, sit to stand, calf raises Straigh leg raising exercise in crook lying position"
89516191|NCT04993911|Active Comparator|Only conventional|"CONVENTIONAL EXERCISE PROGRAM :~TENS for 15 minutes Hot pack for 15 minutes~Participants will perform between 2 sets of 7 and 10 repetitions of each exercise:~Quadriceps/hamstring isometric exercises. ROM and active stretching of the hamstring and quadriceps muscle. Active ankle pump. Squats,step-up, sit to stand, calf raises Straigh leg raising exercise in crook lying position"
89516192|NCT02228590|Other|APL-130277|open label baseline comparison
89516193|NCT03503279|No Intervention|Macintosh Laryngoscope|
89516194|NCT03503279|Active Comparator|McGrath MAC® Video Laryngoscope|
89516195|NCT04489537|Experimental|MarzAA|Coagulation Factor VIIa variant, 60 µg/kg by subcutaneous route, administered on-demand during bleeding episodes for a maximum of 3 doses as needed for hemostasis
89516196|NCT04489537|Active Comparator|Standard of Care|Standard of care administered on-demand during bleeding episodes
89516197|NCT05374629|Experimental|The Intervention group had Shared Decision Making of smoking cessation.|The intervention group had the shared decision-making of smoking cessation which was guided by the smoking cessation health educator, and it containing the nicotine addiction, the impact of smoking on health, the methods and difficulties about smoking cessation, and the way of decision.
89516198|NCT05374629|No Intervention|The control group received routine smoking cessation health education|The control group received routine smoking cessation health education by another smoking cessation health educator, and it containing the harm of smoking, the benefits of quitting smoking, smoking cessation methods, and second-generation smoking cessation .
89516199|NCT04932057|Experimental|Self-Action Observation (s-AO Group)|Participants will watch their own actions during an upper extremity functionality test.
89516200|NCT04932057|Experimental|Action Observation (AO Group)|Participants will watch a person while performing an upper extremity functionality test.
89516201|NCT04932057|Active Comparator|Action Practice|Participants will perform an upper extremity task 4 more times.
89516202|NCT04932057|Placebo Comparator|Observation|Participants will watch a slide show which will only contain landscapes.
89516203|NCT04932057|No Intervention|Control|Participants will wait without any performance till the second assesment.
89516204|NCT02308865|No Intervention|Control arm|Patient supported by the onco respiratory service for the treatment of their disease by chemotherapy and for the treatment of complications.
88961410|NCT02008968|Active Comparator|Uric acid ≥7 mg/dL|This arm will receive allopurinol treatment. 50 subjects will be recruited.
88961411|NCT02008968|Active Comparator|Uric acid ≥6 and <7|This arm will not receive allopurinol. 50 subjects will be recruited.
89516205|NCT02308865|Experimental|intervention arm|Multi disciplinary palliative care monthly consultations with a doctor, a nurse, a psychologist and posibility of a physical therapist and a chaplain in addition to standard onco-pneumologic care.
89516206|NCT03374371||S. epidermidis Infection (CASE)|Patients with confirmed infection at S. epidermidis
89516207|NCT03374371||S. epidermidis Contamination (CONTROL)|Patients with confirmed contamination at S. epidermidis
88961412|NCT02008968|Placebo Comparator|Normouricemic|This arm is healthy controls. 30 subjects will be recruited.
88961413|NCT02008981|Active Comparator|Angelica sinensis|Angelica sinensis in capsule form will be given with actual or placebo aspirin, each for a 3 week period. Clotting profile and platelet function test will be done before and after.
88961414|NCT02008981|Active Comparator|Curcuma longa|Curcuma longa in capsule form will be given with actual or placebo aspirin, each for a 3 week period. Clotting profile and platelet function test will be done before and after.
88961415|NCT02008981|Active Comparator|Siwu Tang|"TCM formulation Siwu Tang consisting of 4 herbs ( Ligustici chuangxiong, Angelicae sinensis, Rehmanniae praeparata and Paeoniae alba) in tablet form will be given with actual or placebo aspirin, each for a 3 week period. Clotting profile and platelet function test will be done before and after."
89025058|NCT03279380|Experimental|Single-nucleotide polymorphisms (SNPs)|In the first part the Case-control study design will be used to estimate the association between multiple single-nucleotide polymorphisms (SNPs) and the endurance/power athlete status.
89207545|NCT00970905|Experimental|Aprepitant & Ondansetron|
89207546|NCT00619476|Placebo Comparator|Placebo|placebo
89516208|NCT02309021|Other|Sport Group|Participants randomised to the exercise condition will receive 12 weeks of physical exercise training. Once they have been assigned to this group, they will be informed about the training programme and its content. Training will be carried out in groups (two groups of ten or four groups of five, depending on scheduling, sport preferences, available materials) to ensure that individual attention can be paid to each participant.
89516209|NCT02309021|Other|Control Group|The control group will not receive any exercise training. In order to control, as far as possible, for the potentially therapeutic effects of extra contact time with investigators, and the potentially motivational elements of participation in an intervention, the C group will have equal contact time with an investigator and participate in a leisure program without physical activity component. This time will be filled with group mealtimes, games, films, painting, handcrafts, stretching or relaxation exercises.
89516210|NCT05163379||INTENSIVE CARE PATIENTS|EARLY MOBILIZATION OF INTUBE PATIENTS
89516211|NCT04831827|Experimental|IVR Reminder|Participants will receive an interactive voice reminder
89516212|NCT04831827|Active Comparator|Personalized Phone Call Reminder|Participants will receive a personalized phone call
89516213|NCT04831827|Active Comparator|Portal Message Only|Participants will receive a online patient portal message reminder
89516214|NCT03503201|Active Comparator|treatment|patients receive chromium supplementation as capsules of 200 micrograms of chromium picolinte (Arab company for pharmaceuticals and medicinal plants) for 2 months before Intracytoplasmic sperm injection cycle
89516215|NCT03503201|No Intervention|No treatment|patients will not receive chromium supplementation before Intracytoplasmic sperm injection cycle
89516216|NCT05093283|Experimental|Workgroup|The probes will be fixed by giving the left lateral position for NST to the pregnant women in the intervention group by the researcher. After providing internet connection with a smart phone for the image, by clicking on youtube.com link, Relaxation (https://www.youtube.com/watch?v=H1iboKia3AQ) nature video watching virtual reality glasses will be provided. The name and surname of the pregnant woman will be written on the NST trace and the trace will be photographed. After the NST process is completed, the NST traces will be evaluated by the researchers.
89516217|NCT05093283|No Intervention|Control|Unlike the study group, only video monitoring will not be applied to the pregnant women included in the control group. Other applications will be done in the same way.
89516218|NCT02312843|Active Comparator|High-Intensity Program-aerobic exercises|This exercise program will consist of walking or running on a treadmill or elliptical trainer, or spinning on a stationary bicycle. The goal of the program will be for participants to exercise at a moderate to high level of intensity, defined as 70-80% (American College of Sports Medicine guidelines) of heart rate reserve (HRR), for 45-60 minutes 4 days per week. At the start of each training session and following a 5-minute warm-up, subjects will exercise at 50% HRR (0.5[HRmax-HRrest] +HRrest) and intensity will gradually be increased to the individualized target heart rate training zone. Exercise facilitators will use a pre-specified computerized program. This program provides guidelines for the individualized progression of exercise based on age and resting heart rate. Subjects will wear a digital heart rate monitoring device for the duration of the training session to ensure they are exercising safely at the specified level of intensity.
89516219|NCT02312843|Placebo Comparator|Low-intensity Program-Stretching|The low-intensity activity program will consist of an individualized and organized series of stretching and balance activities for the whole body, specifically designed for older adults. Consistent with the high-intensity protocol, subjects will complete the prescribed 45-60 minute stretching routine 4 days per week at the exercise facility. All stretching routines will include warm-up and cool-down activities, and will be within each subject's range of motion. Each stretch will be held for 20-30 s and repeated 5-10 times. Subjects will wear a digital heart rate monitoring device to ensure they are stretching safely and at an intensity below 35% HRR. The activity log completed during each stretching session will include HR, stretching duration, and mean HR during stretching. Subjects will also have the option to participate in structured pre-approved (by the exercise facilitator) stretching classes at the exercise facility when available.
89516220|NCT05095077|Experimental|Tadalafil|Subjects are randomized to either 40 mg tadalafil on study day 1 and placebo on study day 2, or placebo on study day 1 and 40 mg tadalafil on study day 2.
89516221|NCT05095077|Placebo Comparator|Placebo|Subjects are randomized to either 40 mg tadalafil on study day 1 and placebo on study day 2, or placebo on study day 1 and 40 mg tadalafil on study day 2.
89516222|NCT05376033|Experimental|Premixed Sealer + Single cone|Premixed flowable hydraulic calcium silicate sealer was applied with a a K File #15 that was inserted into the canal to reach the WL - 3mm and gently moved around the root canal walls. Then, gutta-percha points were gently inserted at the WL -0.5mm and compacted with lateral condensation/vertical condensation.
89516223|NCT05376033|Experimental|Premixed Sealer + Thermafil|Premixed bioceramic sealer was applied and previously described. Pre-heated carrier was inserted in the canal at WL-0.5mm. The carrier excess was removed with a Thermacut bur.
89544555|NCT05532969||Observation group of newly diffuse astrocytoma patients with low-level psychological stress|The patients had lower than threshold levels of perceived stress, psychological distress, fear, anxiety, and depression as assessed by psychologists
89516224|NCT05376033|Other|Sealer + Thermafil|Epoxy-resin-based sealer was mixed and immediately inserted into the root canal using a K File #15. Pre-heated carrier was inserted in the canal at WL -0.5mm. The carriers excess was removed with a bur.
89516225|NCT02312921||PREDICT|"Delivery system changes where a team of dental providers (dentists, dental hygienists, case managers, community outreach workers and others) within Advantage Dental Services, LLC provide evidence-based screening, risk assessment and primary and secondary preventive care in non-conventional community settings (WIC, Head Start and similar settings) and seamless, timely and appropriate evidence-based care in dental clinics.~Payment plan model based on global budgeting and Alternative Quality Contract (pay-for-performance) for dental providers within Advantage Dental Services, LLC (Advantage) with the goal of incentivizing implementation of delivery system changes aimed at reducing disparities in dental care utilization and oral health for low-income mothers and children.."
89516226|NCT02312921||Control|Usual care
89516227|NCT03602833|Experimental|Compound 451238|To assess the safety and tolerability of combining radiotherapy with compound 451238, treating advanced STS.
89516228|NCT05087355||Influenza|
89516229|NCT05087355||Covid 19|
89516230|NCT05087355||Control group|hospitalisation due to other disease (not influenza or Covid 19)
89516231|NCT02309177|Experimental|nab-Paclitaxel and Nivolumab in Pancreatic Cancer|nab-paclitaxel 125 mg/m2 on Days 1, 8 and 15, and nivolumab on Days 1 and 15 of each 28 day cycle.
89516232|NCT02309177|Experimental|nab-Paclitaxel, Gemcitabine and Nivolumab in Pancreatic Cancer|nab-paclitaxel 125 mg/m2 on Days 1, 8 and 15, gemcitabine 1000 mg/m2 on Days 1, 8 and 15, and nivolumab on Days 1 and 15 of each 28-day cycle.
89516233|NCT02309177|Experimental|nab-Paclitaxel, carboplatin and nivolumab Cycle 1 in NSCLC|nab-paclitaxel 100 mg/m2 on Days 1, 8 and 15 and carboplatin AUC 6 on Day 1 (Cycles 1 to 4 only) of each 21 day cycle; nivolumab on Day 15 of each 21 day cycle starting in Cycle 1.
89516234|NCT02309177|Experimental|nab-Paclitaxel, carboplatin and nivolumab Cycle 3 in NSCLC|nab-paclitaxel 100 mg/m2 on Days 1, 8 and 15 and carboplatin AUC 6 on Day 1 (Cycles 1 to 4 only) of each 21 day cycle; nivolumab on Day 15 of each 21 day cycle starting in Cycle 3.
89516235|NCT02309177|Experimental|nab-Paclitaxel 100 mg/m2 and Nivolumab in MBC|nab-paclitaxel 100 mg/m2 on Days 1, 8 and 15 of each 28 day cycle, plus nivolumab on Days 1 and 15 starting in Cycle 3.
89516236|NCT02309177|Experimental|nab-Paclitaxel 260 mg/m2 and Nivolumab in MBC|nab-paclitaxel 260 mg/m2 on Days 1 of each 21 day cycle, plus nivolumab on Days 15 starting in Cycle 3.
89516237|NCT05060835||Breast Cancer|patients diagnosed with breast cancer at any stage.
89516238|NCT05060835||Prostate cancer|patients diagnosed with prostate cancer at any stage
89516239|NCT02227108|Experimental|Moxetumomab Pasudotox 40 mcg/kg|Participants received 6 doses of moxetumomab pasudotox 40 microgram per kilogram (mcg/kg) intravenous infusion over 30 minutes every other day (Days 1, 3, 5, 7, 9, and 11) in 21-day treatment cycles until completion of a maximum of 6 cycles of therapy.
89516240|NCT03564145|Experimental|S5G4T-1|Participants will topically apply S5G4T-1 cream, once daily to face for 40 weeks.
89516241|NCT02309255||coronary heart disease patients|
89516242|NCT05388253|Experimental|Static Stretching Among Plantar Fasciitis Patients|Using Static Stretching exercises
89516243|NCT05388253|Experimental|Deep Kneading Massage Among Plantar Fasciitis Patients|Using Deep Kneading Massage technique
89516244|NCT02312999|Experimental|Volulyte|A baseline crystalloid infusion (plasmalyte®) will be set by the attending physician at 3 cc/kg/hr (standard patient care) for each of the randomized groups. The patient will receive fluid management via a closed loop (automated) system that will use an infusion pump (Q-Core) and a controller (a computer run index and algorithm developed by Sironis) to standardize the way fluids are administered intra-operatively and eliminate variation between clinical providers. The liquid perfused will be bolus amounts of volulyte.
89516245|NCT02312999|Active Comparator|Plasma-Lyte|A baseline crystalloid infusion (plasmalyte®) will be set by the attending physician at 3 cc/kg/hr (standard patient care) for each of the randomized groups. The patient will receive fluid management via a closed loop (automated) system that will use an infusion pump (Q-Core) and a controller (a computer run index and algorithm developed by Sironis) to standardize the way fluids are administered intra-operatively and eliminate variation between clinical providers. The liquid perfused will be bolus amounts of plasma-lyte.
89516246|NCT04863261|Active Comparator|Intervention|Clinics randomized to the intervention. A notification will be sent to the provider when a patient on CAB+RPV LA needs to be scheduled for their injections or when an appointment needs to be confirmed. Alerts are sent out to the provider when a patient is due or overdue for their injections.
89516247|NCT04863261|No Intervention|Control|Clinics randomized to the control group. No alerts or notification will be sent. The providers will manage their CAB+RPV LA patients using standard of care in their clinic.
89516248|NCT02313077|Experimental|Group 1|Participants will receive MVA-BN-filo/ Ad26.ZEBOV (Day 1 /Day 29) or Placebo (Day 1/Day 29).
89516249|NCT02313077|Experimental|Group 2|Participants will receive MVA-BN-filo/Ad26.ZEBOV (Day 1 /Day 57) or placebo ( Day 1/Day 57).
89516250|NCT02313077|Experimental|Group 3|Participants will receive Ad26.ZEBOV/ MVA-BN-filo (Day 1/Day 29) or placebo (Day 1/Day 29).
89516251|NCT02313077|Experimental|Group 4|Participants will receive Ad26.ZEBOV/ MVA-BN-filo (Day 1/Day 57) or placebo (Day 1/Day 57).
89516252|NCT02313077|Experimental|Group 5|Participants will receive Ad26.ZEBOV/ MVA-BN-filo (Day 1/Day 15).
89516253|NCT03423355|Active Comparator|Dapagliflozin (Forxiga®)|Treatment with the SGLT2 inhibitor dapagliflozin 10 mg once daily for 28 days.
89516254|NCT03423355|Placebo Comparator|Placebo matching Dapagliflozin|Treatment with the Dapagliflozin matching placebo once daily for 28 days.
89516255|NCT03423355|Other|Hydrochlorothiazide|Treatment with the Hydrochlorothiazide 25 mg once daily for 28 days
89516256|NCT04481997||Diabetic patients with CAD submitted to PCI|Individuals with type 2 Diabetes mellitus (previously diagnosed or diagnosed at index admission) submitted to PCI
89516257|NCT02226562|Experimental|Potassium nitrate and sodium fluoride|3.0% weight by weight (w/w) potassium nitrate mouthwash with 0.02% sodium fluoride
89516258|NCT02226562|Other|Standard fluoride dentifrice|Standard fluoride dentifrice containing 1000 ppm fluoride as sodium monofluorophosphate (SMFP)
89516259|NCT04430985|Experimental|FOLFOX + Immunotherapy|"8 cycles of FOLFOX every 2 weeks with intrahepatic administration of oxaliplatin in cycles 1-4, thereafter (cycles 5-8) oxaliplatin i given i.v.; starting from cycle 3 this is combined with i.v. administration of nivolumab (cycle 3-8) and ipilimumab (cycle 3 + 6)~Immunotherapy:~Starting from cycle 3: Nivolumab 3 mg/kg i.v. on day 3 (every 2nd week, total of 6 administrations), Ipilimumab 1 mg/kg i.v. on day 3 (every 6th week, total of 2 administrations)"
89516260|NCT03506243|Experimental|Test group|Follitrope PFS
89516261|NCT03506243|Active Comparator|Control group|Gonal-F pen
89516262|NCT03365635|Experimental|Genotype 1a -Rx naive -no NS5A polymorph|Genotype 1a - treatment naive without NS5A polymorphism - Drug Intervention : Oral administration Elbasvir (50mg)/Grazoprevir (100mg) one tablet per day for 12 weeks
89516263|NCT03365635|Experimental|Genotype 1a, Rx naive + NS5A polymorph|Genotype 1a - treatment naiive with NS5A polymorphism - Oral administration of Elbasvir/Grazoprevir one tablet daily and ribavirin (200 mg) daily for 16 weeks weeks
89516264|NCT03365635|Experimental|Genotype 1b - Rx naive|Genotype 1b-treatment naive - Oral administration of Elbasvir/Grazoprevir one daily for 12 weeks
89516265|NCT03365635|Experimental|Genotype 1a/1b -prior INF or NS3/4A|Genotype 1a or 1b - prior treatment with INF or HCV NS3/4A protease inhibitor - oral administration of Elbasvir/Grazoprevir and ribavirin each once daily for 12 weeks
89516266|NCT03365635|Experimental|Genotype4 - treatment naive|(e) Genotype 4 - treatment naive - oral administration of Elbasvir/Grazoprevir one daily for 12 weeks
89516267|NCT03365635|Experimental|Genotype 4- prior treatment|Genotype 4 -prior treatment - oral administration of Elbasvir/Grazoprevir and ribavirin each once per day for 16 weeks
89516268|NCT04774497|Experimental|Oxygen inhalation treatment group|"Patients receive chemotherapy for breast cancer.~Patients are randomly divided into inhalation treatment group. Oxygen inhalation is started on the first day of chemotherapy, and the oxygen inhalation volume is 2 L / min, 8 hours / day for 3 consecutive days.（d1，d2，d3）.~Blood samples are collected before and after chemotherapy（d0，d3）.~CIS and BFI are measured before chemotherapy（d0, d3 chemotherapy regimen/ d0, d3， chemotherapy regimen）."
89516269|NCT04774497|Placebo Comparator|Oxygen non-inhalation treatment group|"Patients receive chemotherapy for breast cancer.~Patients are randomly divided into non-inhalation treatment group.~Blood samples are collected before and after chemotherapy（d0，d3）.~CIS and BFI are measured before chemotherapy（d0, d3，chemotherapy regimen/ d0, d3， chemotherapy regimen）."
89516270|NCT04413357|Active Comparator|Balanced Nutritional Drink|The study interventions contain protein, carbohydrate and fat and are intended for use as Supplemental Nutrition.
89516271|NCT04413357|Active Comparator|Balanced Nutritional Drink - DMA|The study interventions contain protein, carbohydrate and fat and are intended for use as retail Supplemental Nutrition for people living with diabetes.
89516272|NCT04413357|Active Comparator|Balanced Nutritional Drink - DMB|The study interventions contain protein, carbohydrate and fat and are intended for use as Supplemental Nutrition for people living with diabetes.
89516273|NCT04030585|Experimental|robot-assisted exercise|Robot-assisted exercise program will applied by patients with upper limb amputation using myoelectric prosthesis
89516274|NCT04030585|Active Comparator|Home exercise|Home exercise program will applied by patients with upper limb amputation using myoelectric prosthesis
89516275|NCT04410549|Experimental|COVID-19 patient with pulmonary thrombosis|"patients with COVID-19, high D-dimer levels and contrast CT scan negative for pulmonary thrombosis~patients with contrast CT scan positive for pulmonary embolism in areas where contrast CT scan was negative."
89516276|NCT04456231||QR Code|Patients will drink 1 Liter of Plenvu and 1 Liter of water or tea in preparation for endoscopy according to endoscopy Guidelines. In Addition, this Group will receive a health app for better preparation and more Information regarding preparation and endoscopy itself.
89516277|NCT04456231||no QR Code|Patients will drink 1 Liter of Plenvu and 1 Liter of water or tea in preparation for endoscopy according to endoscopy Guidelines. This Group will have no app and will have to receive Information in traditional ways.
89516278|NCT04658277|Active Comparator|Treatment|Patients will be given one tab of Clarithromycin 250mg daily.
89516279|NCT04658277|Placebo Comparator|usual care|Patients will receive usual medical care
89516280|NCT03506165|Experimental|Rheumatoid Arthritis with Periodontitis|Rheumatoid Arthritis patients with Periodontitis diagnosed after oral examination then treated with Periodontal treatment
89516281|NCT03506165|No Intervention|Rheumatoid without Periodontitis|Rheumatoid Arthritis patients without Periodontitis diagnosed after oral examination with. No interventions
89516282|NCT04456777|Experimental|1group|patients with vortioxetine
89516283|NCT04456777|Placebo Comparator|2 group|patients without vortioxetine
89516284|NCT02874430|Experimental|Treatment (metformin hydrochloride, doxycycline)|Patients receive metformin hydrochloride orally daily on days 1-3 and twice a day starting on day 4. Patients also receive doxycycline orally every 12 hours starting on day 1. Treatment repeats every 7 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
89516285|NCT04336371||Anxiety level|patient's psychological experience the anxiety level
89516286|NCT03506087|Experimental|Coaching|Receives printed advance care planning (ACP) materials. Receives advance care planning coaching session. May receive followup coaching session, typically by telephone.
89516287|NCT03506087|Active Comparator|Enhanced Control|Receives printed advance care planning materials only.
89516288|NCT04650633|Experimental|SHR-1701|R/M SCCHN subjects failure after 1 lines of platinum based chemotherapy or after anti PD-1/PD-L1 antibody therapy.
89516289|NCT04055103|Active Comparator|Intervention Group|Half of the participating hospitals will be in the intervention group for the first 6 months. The intervention will switch to the control group after the 6 months.
89516290|NCT04055103|No Intervention|Control Group|Half of the participating hospitals will be in the control group for the first 6 months. The control group will undergo the intervention in the second 6 months.
89516291|NCT05162989|Experimental|iCare HOME2 vs iCare IC200|Measurement of intraocular pressure (IOP) with iCare IC200 reference tonometer compared to iCare HOME2 test tonometer. Measurement will be performed to categorize each subject as having Low IOP (7 to 16 mmHg), Medium IOP (>16 to <23 mmHg), or High IOP (≥23 mmHg).
89516292|NCT02444039||Any Willing and Able Person for Ocular Imaging|Any Willing and Able Person for Ocular Imaging
89516293|NCT04621071|Experimental|Probiotics|Two probiotic strains will constitute the experimental arm (Probiotics). Patients will take two capsules a day (one closed capsule to swallow and one open capsule mixed with maple syrup) from Day 1 to Day 10 and one closed capsule to swallow from Day 11 to Day 25.They will stop the treatment if they are admitted to the hospital. The treatment will last a maximum of 25 days.
89516294|NCT04621071|Placebo Comparator|Placebo|Potato starch and magnesium stearate will constitute the comparator arm (Placebo). Patients will take two capsules a day (one closed capsule to swallow and one open capsule mixed with maple syrup) from Day 1 to Day 10 and one closed capsule to swallow from Day 11 to Day 25.They will stop the treatment if they are admitted to the hospital. The treatment will last a maximum of 25 days.
89516295|NCT05160727|Experimental|Treatment group|"Concurrent Chemoradiotherapy:~Radiation: The dose is determined according to the treatment site and the purpose of treatment.~Irinotecan: 80mg/m2/w (UGT1A1*28 and *6: 6/6+GG) or 65mg/m2/w (UGT1A1*28 and *6: 6/7+GG or 6/6+GA) or 50mg/m2/w (UGT1A1*28 and *6: 7/7+GG or 6/6+AA or 6/7+GA) Tislelizumab: 200mg ivgtt d1 q3w~Consolidation therapy: 2 weeks after the completion of chemoradiotherapy. Irinotecan: 200mg/m2 ivgtt d1 q3w. Tislelizumab: 200mg ivgtt d1 q3w. Efficacy assessment every 3 cycles."
89516296|NCT03506009|Experimental|Argatroban combined with rt-PA|
89516297|NCT03506009|Active Comparator|rt-PA|
89516298|NCT04538157|Experimental|Comprehensive Geriatric Assessment|Specialist co-ordinated care (known as comprehensive geriatric assessment, or CGA) was developed to address medical, social, mental health, and physical needs with the help of a skilled multi-disciplinary team.
89516299|NCT04538157|No Intervention|Usual Care|Usual Care
89516300|NCT03130855|Experimental|inferior alveolar nerve block with 4% articaine|inferior alveolar nerve block using 4% articaine anesthetic solution
89516301|NCT03130855|Active Comparator|buccal infiltration with 4% articaine|buccal infiltration using 4% articaine anesthetic solution
89516302|NCT04463927|Experimental|Intervention Group|The non-nutritive sucking is applied to the group during the examination for retinopathy of prematurity
89516303|NCT04463927|No Intervention|Control Group|The non-nutritive sucking is not applied to the control group.
89516304|NCT04456543|Experimental|Pressure monitoring group|In the pressure monitoring group, garment pressures were monitored using the portable pressure measuring device and the compression garment was adjusted so that the pressure was maintained at the therapeutic range of 15 - 25 mmHg for 2 months. Subjects were instructed to wear the garment 23 hours per day, removing them only for bathing.
89516305|NCT04456543|Active Comparator|conventional treatment group|In the conventional treatment group, non-surgical standard treatment of burn scars except for pressure monitoring was performed in the same manner. Subjects were instructed to wear the garment 23 hours per day, removing them only for bathing.
89516306|NCT02309801|Experimental|Daidzin and alcohol|"Daidzin 80 mg, single dose, oral administration (4 capsules of Super-Absorbable Soy Isoflavones®).~Alcohol 0.5 g/kg (vodka diluted in lemon-flavoured water), single dose, oral administration. Solution of 150 ml."
89516307|NCT02309801|Active Comparator|Alcohol|Alcohol 0.5 g/kg (vodka diluted in lemon-flavoured water), single dose, oral administration. Solution of 150 ml.
89516308|NCT04860349|Experimental|High Intensity Interval Training|20 minutes of High Intensity Interval Training for experimental group.
89516309|NCT04860349|No Intervention|Control|No intervention for the control group.
89516310|NCT04537845||with cancer pain|
89516311|NCT04537845||without cancer pain|
89516312|NCT03505931||Eluvia|Patients treated with Eluvia stent
89516313|NCT02456636|Active Comparator|Fee-for-Service Model (FFS, In clinic individual visits)|Participants will receive individual counseling from their physician or other healthcare professional during regular clinic visits.
89516314|NCT02456636|Active Comparator|Patient Centered Medical Home (PCMH, In clinic group visits)|Participants will take part in group weight-management counseling during in-person group visits; later sessions may be conducted via group telephone calls if the group prefers.
89516315|NCT02456636|Active Comparator|Disease Management (DM, Phone group visits)|Participants will take part in group weight-management counseling by telephone.
89516316|NCT02226172|Experimental|Arm A|Oral daily dose of glasdegib (PF-04449913) 100 mg tablet in a continuous regimen of 28-day cycles.
89516317|NCT02226172|Placebo Comparator|Arm B|Oral daily dose of placebo 100 mg tablet in a continuous regimen of 28-day cycles.
89516318|NCT03505853|Experimental|Givosiran with 5-probe cocktail|
89516319|NCT05388019|Experimental|Prospective interventional cohort of newly-implanted patients|This cohort will consist of patients who recently underwent LVAD implantation at Massachusetts General Hospital, and their caregivers. These patients will receive only multidisciplinary team care from the time of their implant.
89516320|NCT05388019|Experimental|Prospective interventional cohort of previously-implanted patients|This cohort will consist of patients who have previously undergone LVAD implantation at Massachusetts General Hospital who are being followed-up with standard-of-care VAD clinic visits, and their caregivers. These patients will receive a hybrid of multidisciplinary team care and standard-of-care visits.
89516321|NCT05388019|No Intervention|Retrospective control cohort|The historical control cohort will consist of retrospective data collection on patients who have undergone LVAD implantation in the past and no longer have an LVAD implanted (due to transplant, death, explant, etc.).
89516322|NCT05388019|Experimental|Primary caregiver cohort|This cohort will consist of primary caregivers of VAD patients from the two interventional cohorts. They will be administered a questionnaire at two timepoints. Each VAD patient will be associated with only one primary caregiver for the duration of the study.
89516323|NCT02309879|Active Comparator|Remifentanil group|Patients in remifentanil group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous remifentanil infusion of 0,1 mcg/kg/min.
89516324|NCT02309879|Active Comparator|Lidocaine group|Patients in lidocaine group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous lidocaine infusion of 3 mg/kg/hr.
89516325|NCT02309879|Active Comparator|Magnesium group|Patients in lidocaine group received an intravenous bolus injection of 50 mg/kg magnesium sulphate followed by a continuous magnesium sulphate infusion of 15 mg/kg/hr.
89516326|NCT02309879|Active Comparator|Magnesium and Lidocaine group|Patients received an intravenous bolus injection of 2 mg/kg lidocaine plus 50 mg/kg magnesium sulphate followed by a continuous lidocaine infusion of 3 mg/kg/hr plus 15 mg/kg/hr magnesium sulphate
89516327|NCT01676961|Experimental|Supportive care (romiplostim)|Patients receive romiplostim SC once weekly for up to 6 weeks. Patients achieving a platelet count > 50 x 10^9 then receive romiplostim once weekly during 1 course of chemotherapy and may continue for as long as benefit is seen..
89516328|NCT03874351|Experimental|Active tDCS|Twenty minutes of direct current at intensity of 1.5 milliamperes (mA).
89516329|NCT03874351|Sham Comparator|Sham tDCS|Thirty seconds of direct current at 1.5 mA, followed by 0 mA for the remaining time of the 20-minute stimulation period.
89516330|NCT05015998||Non-dialysis dependent patients with CKD stage 3-5|A cohort of patients will be created from the Stockholm CREAtinine Measurement (SCREAM) cohort based on the eligibility criteria.
89516331|NCT02309957||BioMatrix CRD|All patients will receive BioMatrix CRD to repair an articular cartilage lesion or osteochondral defect.
89516332|NCT05081115||ABCDE-Stress Echo in Coronary Artery Disease (SECAD project)|All patients with known or suspected CAD will be evaluated with ABCDE-SE. Patients will be referred according to existing 2020 guidelines indication; status post heart transplant; pediatric patients and congenital heart disease ; peri-partum cardiomyopathy. Information on demographics, lifestyle and other risk factors and ongoing therapy will be collected. Data related to carotid disease and cardiac calcification will be collected. All patients will enter a regular clinical follow-up program with annotation of cardiovascular and non-cardiovascular endpoints, such as cancer or neurodegenerative disease, characterized by endothelial dysfunction (step D positivity) and autonomic dysfunction (step E positivity). A sample size of about 2 430 patients with a 5-year follow-up is required to provide 90% power with an alpha error of 5% to detect a difference for the primary endpoint of all-cause mortality among those with positive versus negative SE also considering a 20% drop-out.
89516333|NCT05081115||ABCDE-Stress Echo in Diastolic Heart failure (SEDIA project)|Patients with dyspnea and known or suspected heart failure with preserved ejection fraction by 2019 European Society of Cardiology criteria will be enrolled and studied with cycle-ergometer in semi-supine SE (or treadmill). A score of at least 1 according to the criteria proposed by Pieske et al. is required for inclusion. In patients unable to exercise or did not allow sampling of CFVR, pharmacological test (vasodilator or dobutamine) is recommended. Assuming that the hypothesis of proportionality of hazard holds, as required for Cox proportional hazards regression, with a power of 90%, an attrition rate of 10% and a 5-year follow-up period of a sample size of 181 patients is required.
89516334|NCT05081115||ABCDE-Stress Echo in Hypertrophic Cardiomyopathy (SEHCA project)|The primary aim is to evaluate the feasibility of comprehensive ABCDEFG-SE in the evaluation of HCM. The secondary aim is to assess the value of each of obtaained parameters in predicting response to specific therapy and other interventions. The tertiary aim is to assess the prognostic value of SE indices for prognostic stratification in the medium-long-term. HCM diagnosis will be based on existing guidelines. All patients will be followed-up. In patients and first-degree relatives with genetic characterization different phenotypes will be correlated with specific genotypes. Non-imaging or routine imaging non-ultrasound exams will be collected and analyzed with neural network analysis developed in project 5. We assume that a sample size of 338 patients is required.
89516335|NCT05081115||ABCDE-Stress Echo post-Radiotherapy (SERA project)|Radiation-induced heart disease is associated with a significantly higher morbidity and mortality in cancer patients. The most frequent forms treated with chest radiation therapy are breast, lung, and esophageal cancers or lymphoma. The chances of developing radiation-induced heart disease increase with higher cumulative doses (>30 Gray) in anterior or left sided irradiation, concomitant chemotherapy, presence of cardiovascular risk factors, and increased distance from time of irradiation. The estimated incidence of major cardiac events related to ischemic heart disease is 30% at 10 years post-treatment in female patients with radiotherapy post-breast cancer. The resulting epicardial artery stenosis, low grade inflammation , myocardial fibrosis, microvascular injury , alterations in autonomic balance, valve leaflets, and accelerated calcification can lead to significant alteration of all SE steps. A sample size of 507 patients is required and will be enrolled.
89516336|NCT05081115||ABCDE- Artificial Intelligence Stress echo (AI-SEE)|The project have 2 separate aims: AI-SEE images: To make SE reading operator-independent for each of the essential reading steps (from A to E). AI-SEE data: To identify the links between clinical imaging and stress variables and develop a tailored personalized model for risk prediction. For each parameter assessment (positivity versus negativity), the area under the receiver-operating characteristic curve produced by the deep learning algorithm will be compared to that produced by the experienced cardiologist (cross-sectional analysis). AI-SEE images: a set of images from 1 250 patients from at least 10 laboratories will be sufficient to develop the algorithm (modeling set) subsequently prospectively tested on a different set of 1250 patients (validation set). AI-SEE data: a set of data from 2 500 patients from at least 10 laboratories will be sufficient to develop the algorithm (modeling set) subsequently tested on a different set of 2 500 patients (validation set).
89516337|NCT05081115||ABCDE- Environmental Stress Echocardiography, air pollution and medical radiation (ESTER project)|The primary aim is to assess the inter-patient correlation between SE results and outdoor air pollution levels in patients matched for clinical, coronary anatomy (if available) and resting functional features. Secondary aim is to assess the effects of air quality and cumulative medical radiation exposure in prognostic modeling using traditional risk factors and SE results. All patients enrolled in projects 1 to 4 have information on house residency and work place in the data bank. The air epidemiology unit will obtain same day local air quality data from publicly available data sets from regional authority of environmental protection. For each patient and each test of the same patient, the values of 2 particulate and 4 gaseous pollutants will be collected when available. Data on medical radiation exposure will also be systematically collected. Of the 2 430 tests recruited in protocol 1, at least 600 will have access to geo-referenced air quality data.
89516338|NCT05081115||SETOF Stress Echo in operated Tetralogy of Fallot.|The primary aim is to evaluate the feasibility of right ventricular SE in patients with repaired Tetralogy of Fallot. The secondary aim is to assess the presence and amount of right ventricular contractile reserve and its correlation with indices of functional severity (NYHA class, cardiac natriuretic peptides, peak VO2, 6-min walking test, etc.). The tertiary aim is to assess the prognostic value of SE indices for prognostic stratification in the medium and long-term. Patients with repaired Tetralogy of Fallot or Fallot-like pathology evaluated at least 1 year after the last surgical or percutaneous procedure, will be recruited by regional reference centers for congenital heart disease. Additional inclusion criteria are age>10 years, height>140 cm, NYHA class I or II. Data on medical radiation exposure will also be systematically collected. A sample size of about 250 patients is required to detect a significant stress-induced increase in tricuspid annular plane systolic excursion.
89516339|NCT05081115||Stress Echo for surveillance post-COVID-19 (SECOV).|Cardiovascular abnormalities are observed in half of all COVID-19 patients and may range from RWMA to interstitial lung disease with alveolar capillary distress, global contractile dysfunction, coronary microvascular abnormalities and cardiac autonomic dysfunction. In addition, pulmonary hypertension and valves abnormalities are a possible consequence. The primary aim is to assess the feasibility of an integrated ABCDEFG approach in post-COVID 19 patients. Secondary aim is to prevalence of abnormalities of different SE parameters in populations stratified according to severity of COVID-19. Tertiary aim is to assess the prognostic value of individually considered or combined SE indices in prognostic modeling using traditional risk factors and COVID-19 variables. The relevant parameters related to COVID-19 infection will be collected .SE will be performed from 3 months to 3 years after infection. A sample size of 406 patients is required.
89516340|NCT05081115||RESURGE: Recovery by stress echo of conventionally unfit donor good hearts.|The primary aim is to recruit hearts from donation which are currently excluded by conventional criteria as aged hearts in patients > 55 years and ≤ 55 years with multiple risk factors. Secondary aim is to assess outcome in SE-driven transplantation compared to hearts transplanted in the same cardiac surgery centers on the basis of conventional criteria. Tertiary aim is to assess the additional prognostic value of other signs not used for decision-making. These aspects may include diastolic function, preload reserve, coronary microvascular function, and residual innervation of the intrinsic cardiac autonomic system through assessment of HRR in donor heart. In case of donor with age >55 years o ≤ 55 years but with concomitant ≥ 3 risk factors (diabetes, hypertension, smoking, obesity, hypercholesterolemia) or history of cardiac arrest, the protocol will be applied.
89516341|NCT05081115||SEMIR- Stress echo in ischemic mitral regurgitation|The value of SE testing as an indicator of outcome will be assessed in patients with resting moderate mitral regurgitation (effective regurgitant orifice 0.2-0.39 cm2, and regurgitant volume 30-59 ml) of ischemic origin and angiographically documented CAD, and will enter a regular clinical follow-up program with annotation of cardiovascular and non-cardiovascular endpoints. Patients undergoing CABG with or without mitral repair or PCI with or without mitral valve intervention will be separately analyzed. A sample size of 173 patients per arm (CABG or PCI) is required. The primary hypothesis is that patients with moderate mitral regurgitation worsening of ≥ 1 grade during exercise have worse outcome on medical therapy and greater benefit from valve correction. The secondary hypothesis is that patients with worse SE pre-surgery parameters will have worse prognosis independent of regurgitation severity and treatment (medical therapy or valve repair).
89516342|NCT05081115||SEVA: Stress Echocardiography in Valvular Heart Disease|SE is recommended in valvular heart disease in patients characterized by a mismatch between resting transthoracic echocardiography findings and symptoms during exercise or activities of daily living: 1. Severe valve disease without symptoms; 2. Non-severe single- or multi-valve disease with symptoms; and 3. Symptomatic valve disease of indeterminate severity in context of low flow. The primary aim is to evaluate the feasibility of ABCDEFG-SE plus L (left atrium), P (pulmonary vascular reserve) and R (right ventricular function) in these patients. The secondary aim is to assess the correlation of each SE parameter with indices of functional severity (NYHA, cardiac natriuretic peptides, peak oxygen consumption, etc.). The tertiary aim is to assess the prognostic value of SE for prognostic stratification in the long-term. A sample size of about 217 patients per sub-group is required to evaluate the tertiary endpoint with 90% power and an alpha error of 5% .
89516343|NCT05081115||SESPASM - SE for coronary vasospasm|The primary aim is to evaluate the feasibility and safety of hyperventilation and exercise ABCDE-SE in patients with angiographically normal coronary arteries and an intermediate-to-high pre-test probability of coronary vasospasm of epicardial arteries or microvasculature. The secondary aim is to assess the positivity rate of A and D criteria in these patients, compared to standard ECG criteria. The tertiary aim is to assess the prognostic value of the different responses of SE leading to SE-driven therapies. Only patients with strong (Class 1) indication to vasospasm testing according to the recent guidelines will be initially considered. Patients prepared for exercise testing will undergo vasospasm testing in the morning with hyperventilation. If negative or equivocal at 5 minutes after the end of hyperventilation, the patient will start exercise with the usual protocol. A sample size of 513 patients is required with a 5-year follow-up for the composite endpoint.
89516344|NCT03505775|Other|23Na-MRI|A 23Na magnetic resonance imaging of the calf (muscle and skin) was performed in every participating patient after clinical and laboratory examinations.
89516345|NCT03505697|Experimental|IMT+PR Group|Patients received a 3-month standard hospital-based Pulmonary Rehabilitation included aerobic and strength training. In addition standard pulmonary rehabilitation, patients received inspiratory muscle training.
89516346|NCT03505697|Experimental|PR group|Patients received a 3-month standard hospital-based Pulmonary Rehabilitation included aerobic and strength training.
89025059|NCT03279380|Active Comparator|High Intensity Interval Training (HIIT)|"High intensity interval exercise on the cycling ergometer (Velodyn, Racermate ™, USA).~Protocol: 8 x 5 min at 80% PPO (between intervals 1.5 min at 75 W). Baseline measurements will include the V̇O2peak test and peak power output. Monitoring of physiological responses with spirometry and analysis of expired air (oxygen and carbon dioxide output) (Quark, Cosmed, Rim, Italy)."
89207547|NCT00619476|Experimental|GEn 1200mg/day|gabapentin enacarbil 1200mg/day, maintenance treatment 14 weeks
89516347|NCT03942627|Experimental|Mindfulness Program|The intervention consists of an introductory video in which a mindfulness expert explains the program's approach and models practices to increase women's comfort with the material, four audio-recorded mindfulness practices for mothers' use when the baby is in the NICU, each available in 5- and 10-minute versions, and a brief video and four additional audio mindfulness practices (each available in briefer and longer versions) for use by mothers during and following the transition home with the baby.
89516348|NCT03942627|Placebo Comparator|Infant Health Education Program|The intervention consists of an introductory video explaining the program's approach, four audio recordings providing education about infant health and development, each available in 5- and 10-minute versions, and a brief video and four additional educational recordings (each available in briefer and longer versions) for use by mothers during and following the transition home with the baby.
89516349|NCT03505619|Experimental|ASSIST 1.0|A ten-week intervention program using a person-centred approach to support the older person to set up goals to perform daily activities that he/she wants or needs to do. The activity goals will target improvements in quality of life, physical health, mental well-being, and conditions for social community. The focus will be on supporting the older person's activities in everyday life that are considered meaningful for the individual. During the intervention, a specially designed application will send reminders and feedback related to the older adults' activity goals of doing their prioritized everyday activities both to the older adults and to the home care providers via mobile phones, tablet etc. The home care providers will participate in coaching sessions supporting the intervention held by the team of researchers.
89516350|NCT03505619|No Intervention|Ordinary home care services|The home care providers in the control group (CG) will provide services as usual to older adults participating in the control group. They will however, identify potential older persons to participate in the control group according to the same procedure and criteria as the intervention group.
89516351|NCT03876483|No Intervention|Standard of Care|Youth enrolled in care at control facilities will receive current standard of care related to HIV care and transition to adult care.
89516352|NCT03876483|Experimental|Virtual peer support group|Youth enrolled in care at intervention facilities will be invited to participate in a virtual peer support program
89516353|NCT02820961|Active Comparator|Cohort 1|Cohort 1 will evaluate exemestane's effect on the PK of entinostat. Each treatment cycle is 28 days.
89516354|NCT02820961|Active Comparator|Cohort 2|Cohort 2 will enroll when Cohort 1 enrollment is complete. Cohort 2 will evaluate entinostat's effect on the PK of exemestane. Each treatment cycle is 28 days.
89516355|NCT04430673|Experimental|Home-School based VR trial|The VR system will be provided to each participant for a 2-week home- or school- based trial. No additional interventions.
89516356|NCT04658173|Experimental|remimazolam-alfentanil combination|Group remimazolam-alfentanil combination received 10 µg/kg alfentanil and 0.3mg/kg remimazolam over 30 seconds, followed by an infusion of remimazolam at 0.2 to 1 mg/kg/hr and alfentanil at 0 to 1ug/kg/min. In case of the sudden patient movement, and difficulty in maneuvering the endoscope, remimazolam 0.1mg/kg was used in the form of bolus, as rescue drugs, and alfentanil 5ug/kg when additional analgesia is needed
89516357|NCT04658173|Active Comparator|propofol-alfentanil combination|Group propofol-alfentanil combination received 10 µg/kg alfentanil and 1.5 to 2mg/kg propofol over 30 seconds followed by an infusion of propofol at 2 to 6 mg/kg/hr and alfentanil at 0 to 1ug/kg/min. In case of the sudden patient movement, and difficulty in maneuvering the endoscope, propofol 0.5 mg/kg was used in the form of bolus, as rescue drugs, and alfentanil 5ug/kg when additional analgesia is needed
89516358|NCT03505541||Control group|Healthy, term, non-obese (BMI < 30) pregnant women with a singleton gestation scheduled for CS delivery at 37-41 weeks of gestation.
89516359|NCT03505541||Study group 1|Term pregnant, non-obese (BMI <30), diagnosed with gestational diabetes, scheduled for CS delivery between 37-41 weeks of gestation.
89516360|NCT03505541||Study group 2|Term pregnant, obese (BMI >30), non-diabetic and scheduled for CS delivery between 37-41 weeks of gestation
89516361|NCT03636165|Experimental|MP plus RP group|Patients in RP/MP group will receive a peri-incisional scalp infiltration with 0.125% methylprednisolone and 0.2% ropivacaine and normal saline miscible liquids. The assigned solution will be injected subcutaneously by surgeons along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigators.
89516362|NCT03636165|Active Comparator|RP group|Patients in RP group will receive peri-incisional scalp infiltration with 0.2% ropivacaine alone. The assigned solution will be injected subcutaneously by surgeons along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigators.
89516363|NCT02310113||Hematologic outpatients|Chronic anaemic outpatients who are planed to get transfusion RBC
89516364|NCT03635151|Experimental|TASK III Group|The Telephone Assessment and Skill-Building Kit (TASK III) group
89516365|NCT03635151|Active Comparator|ISR Group|The Information, Support, and Referral (ISR) group
89516366|NCT02310191||Stenting|Carotid stenting
89516367|NCT03769519|No Intervention|Control (Group 1)|This group is considered the control group. This group will have scheduled texts and emails for the monthly surveys after the participant completes the baseline questionnaires.
89207548|NCT00619476|Experimental|GEn 2400mg/day|gabapentin enacarbil 2400mg/day, maintenance treatment 14 weeks
89516368|NCT03769519|Experimental|ARICA Intervention (Group 2)|This group is considered the intervention group. Participants in this group will receive weekly texts and emails containing asthma facts and myths. They will also complete monthly surveys and participate in asthma education sessions.
89516369|NCT02310347|Experimental|Marinol|"generic name: dronabinol~dosage: 0.1 mg/kg~frequency: 2 times a single dose~duration: acute adminstration"
89516370|NCT02310347|Placebo Comparator|Placebo|Empty hard gelatin capsules
89516371|NCT02310425|Active Comparator|The study group|The study group received S. boulardii supplementation, 50 mg/kg twice daily, compared to no intervention in the control group.
89516372|NCT02310425|Placebo Comparator|The control group|A prospective, Placebo Comparator,randomized case-controlled trial was conducted in infants with a gestational age of 30 to 37 weeks and a birth weight between 1500 to 2500 g.
89516373|NCT03124875|Experimental|Treatment|Treated with the LimFlow Stent Graft System
89516374|NCT02310503||Mohs surgery|Patients treated using Mohs surgery. Other exposures considered include patient characteristics, preoperative care and technical variants.
89516375|NCT02310659||lower calcificant score group|patients with coronary artery calcificant score <400
89516376|NCT02310659||higher calcificant score group|patients with coronary artery calcificant score ≥400
89516377|NCT05374161|Experimental|Brief ACT-based intervention|A 6- week ACT intervention for depression and physical pain will be delivered.
89516378|NCT05374161|Other|Waitlist control group (WL)|The WL control group will receive treatment as usual, just like women in the experimental condition.
89516379|NCT02310737|Active Comparator|sharp incision|the patients who were included as the control group (Group 1) with sharp fascia incision
89516380|NCT02310737|Active Comparator|blunt incision|the patients who were included as the another group (Group 2) with blunt fascia incision
89516381|NCT02310893|Active Comparator|Contingency Management only|Participants assigned to this arm will receive payments for attending regular HIV medical appointments at the clinic and filling prescribed HIV medications at the pharmacy
89516382|NCT02310893|Active Comparator|Peer Navigation only|Participants in this arm will be assigned a peer navigator to assist them in accessing and remaining in HIV care
89516383|NCT02310893|Experimental|Combined Contingency Management and Peer Navigation|Participants in this arm will be assigned a peer navigator to assist them in accessing and remaining in HIV care and will be eligible to receive incentives for attending HIV care visits/refilling prescriptions.
89516384|NCT02310893|No Intervention|Usual care|Participants in this arm will receive the care that they would usually get in their clinic in the absence of this study.
89516385|NCT01391949|Experimental|Detailed feedback|Subjects will pedal on the UCFit with a goal of 30 total minutes of daily exercise.
89516386|NCT01391949|Active Comparator|Basic feedback|Subjects will pedal on the UCFit with a goal of 30 total minutes of daily exercise.
89516387|NCT03505463||Injured participants|
89516388|NCT03505463||Healthy participants|
89516389|NCT04429425|Other|EA group|patients with colorectal surgery that willl be performed epidural anesthesia
89516390|NCT04429425|No Intervention|non -EA group|patients with colorectal surgery that willl be performed only general anesthesia
89516391|NCT03502889|Active Comparator|Adductor Canal Block Alone|Control arm to receive Adductor Canal Block without additional interventions Intervention: ropivacaine 0.5% 15cc injected under ultrasound guidance
89516392|NCT03502889|Experimental|SPANK Block Plus Adductor Canal Block|Experimental arm to receive Adductor Canal Block plus SPANK Block (Sensory Posterior Articular Nerves of the Knee) without additional interventions Intervention: ropivacaine 0.5% 15cc injected under ultrasound guidance into the adductor canal plus 20cc ropivacaine 0.5% injected into the posterior tissues of the knee
89516393|NCT04533477|Experimental|Routine surgery with reconstructing FCS|The participants undergo FCS reconstruction during the routine standardized surgery.
89516394|NCT04533477|Active Comparator|Routine surgery|The participants undergo routine standardized surgery.
89516395|NCT02310971|Experimental|Biologic/Vaccine|Cvac will be administered via intradermal injection, every 4 weeks for the first 3 doses and thereafter every 12 weeks for 3 additional doses for a total of 6
89207549|NCT00619476|Experimental|GEn 3600mg/day|gabapentin enacarbil 3600mg/day, maintenance treatment 14 weeks
89516396|NCT04463537|Experimental|experiment group|"Firstly, patients selected with convenience sampling. In the sampling method, the order of the patients' enrollment to the emergency room was used. Then, patient's age, sex and presence of otitis media were recorded in the Personal Information Form.~After recording, measurements were carried out on the patients in the study firstly by not changing the position of the auricle. The duration was measured by stop watch and the results were recorded in the data form. The levels of patients' discomfort were evaluated by the Visual Comparison Scale.~The measurement was then repeated after a minute, this time by changing the position of the auricle. The duration was measured for this position and the results were recorded in the data form. The levels of patients' discomfort were evaluated by the Visual Comparison Scale. The auricle on the same side was used during both measurements."
89516397|NCT01676727||CoreValve aortic valve|Implantation of CoreValve aortic valve via direct aortic approach
89516398|NCT05375487|Experimental|Carbonated Natural Mineral Water|750 mL/day of carbonated natural mineral water, with high content of bicarbonate, calcium and magnesium.
89516399|NCT05375487|Placebo Comparator|Low Mineral Water|750 mL/day of low mineral water.
89516400|NCT05375409||Postoperative Delirium (+)|
89516401|NCT05375409||Postoperative Delirium (-)|
89516402|NCT05375409||Healthy Control|
89516403|NCT05098353|Experimental|Quetiapine 25-75 mg|"There is one arm in this study. Patients will take quetiapine in dose 25-75 1-3 times a day.~Dose and its frequency can be adjusted by researcher during first 2 weeks (till visit 2), after that patients will take stable dose of quetiapine till week 6 (visit 3)."
89516404|NCT04437849|Experimental|Telemonitoring|
89516405|NCT04437849|No Intervention|Usual Care|
89516406|NCT02738879|Experimental|Sitagliptin|Sitagliptin 100 mg, oral, once daily for 30 weeks
89516407|NCT02738879|Placebo Comparator|Placebo|Placebo to sitagliptin, 100 mg, oral, once daily for 30 weeks
89516408|NCT03587493|Experimental|EXPERIMENTAL GROUP|"110 adults, on national waiting list for a first lung transplantation in the centers of Marseille and Strasbourg, whatever the lung disease, and who will be transplanted and benefit immunosuppressive induction therapy that specifically targets T lymphocytes will be included.~Blood sample analysis will be performed"
89516409|NCT04815681|Experimental|Common Elements Toolbox (COMET)|
89516410|NCT04815681|Active Comparator|Active Control Condition|
89516411|NCT03502811||MitraClip NTR/XTR System|Percutaneous mitral valve repair using the MitraClip NTR and XTR system
89516412|NCT04456309||Atrial fibrillation|stroke patients with atrial fibrillation
89516413|NCT04456309||Intracardiac thrombus|stroke patients with intracardiac thrombus
89516414|NCT03502655|Other|Intervention message (first phase)|Standardized message The intervention will consist in the delivery of a message with a positive content regarding the insertion of the peripheral venous catheter. The message will be delivered through an audio record
89516415|NCT03502655|Active Comparator|Control message (first phase)|Standardized message The intervention will consist in the delivery of a control message, whose content is based upon the usual caregiver-patient communication prior to the insertion of a peripheral venous catheter. The message will be delivered through an audio record.
89516416|NCT03502655|Other|Intervention message (second phase)|Standardized message The intervention will consist in the delivery of message with a positive content regarding the insertion of the peripheral venous catheter. The message will be delivered by the health providers themselves before inserting the catheter.
89516417|NCT03502655|Active Comparator|Control message (second phase)|Standardized message In this arm, the patient will be delivered a control message, which content is based upon the usual caregiver-patient communication prior to the insertion of a peripheral venous catheter. The message will be delivered by the caregivers themselves before inserting the catheter.
89516418|NCT03470389|Experimental|HVPG|Each patient's computed tomography, blood tests, Doppler ultrasound and HVPG measurement will be performed within 30 days and treatments that may affect HVPG value will be avoided during this period.
89516419|NCT05097417|Experimental|traditional Chinese medicine combined with thermal or cold ablation|
89516420|NCT05097417|Active Comparator|thermal or cold ablation|
89516421|NCT05097339||Patients with type 1 diabetes|Patients with type 1 diabetes perform a morning Symptom Limited Maximal Exercise Test (CPET) or a 60-minute morning Aerobic Test (AEX) at 60% VO2peak
89516422|NCT04289311|Experimental|Intervention arm|Single group study; all participants are in the intervention arm and receive the intervention
89516423|NCT03253913|Experimental|Treatment Arm|"Resveratrol 250mg daily for the first 8 weeks, followed by 250mg twice daily for the next 8 weeks, and then 500mg twice daily for the last 8 weeks.~Patients will be on a stable background therapy of sirolimus prior to enrolling and will continue on that regimen throughout the study."
89516424|NCT03397719|Active Comparator|Control Group|This group will receive treatment as usual. Each participant will receive three hours of in-vivo parent coaching per week for 6 months.
89516425|NCT03397719|Experimental|Treatment Condition|This group will receive an additional component which will involve videotaping parent/child interactions at home for thirty minutes a week. Each week, the therapist will select sections of the video to review with the parent during one of the parent coaching sessions.
89516426|NCT04455919|Experimental|Yoga|Yoga classes once a week for eight weeks
89516427|NCT04455919|Other|Wait-list control|The delayed intervention group was to benefit from the intervention after week 8.
89516428|NCT03237819|Placebo Comparator|Placebo|Glucose serum (3 ampoules)
89516429|NCT03237819|Experimental|Magnesium Sulfate|20/5000 magnesium sulfate (4 ampoules, 1,5g each)
89516430|NCT03468907|Experimental|Early cessation|Pregnant mothers who opted for antiviral therapy would start on oral LDT 600 mg or TDF 300 mg (as per patients' wishes) daily between gestational weeks 24 and 28. Antiviral therapy was discontinued in intrapartum.
89207550|NCT00970983|Active Comparator|QUART|Patients in this arm will receive quadrantectomy, axillary dissection and radiotherapy (the current standard therapy).
89516431|NCT03468907|Experimental|Late cessation|Pregnant mothers who opted for antiviral therapy would start on oral LDT 600 mg or TDF 300 mg (as per patients' wishes) daily between gestational weeks 24 and 28. After delivery, mothers ceased antiviral treatment at postpartum 6 weeks.
89516432|NCT03468907|No Intervention|Control|Eligible patients who refused antiviral therapy but consented to the study were assigned to the control arm.
89516433|NCT03505385|Experimental|Co-created intervention|"The Get Ready (GR) intervention was delivered one-to-one with the care home resident and a relevant family member during a 12-week period:~The familiarisation stage aimed to build a rapport with two long-term achievement goals to sit less and move more with the resident and the family member and consisted of two sessions, one in week 1 (50-60minutes) and the other in week 3 (30-40 minutes).~The ramping up stage aimed to review the rapport and reach an achievable consensus with the resident and the family member. It consisted of two sessions, one in week 5 and the other in week 7 (20-30 minutes each).~The maintenance stage aimed at integrating behaviours and included two sessions, one in week 9 and the other at week 12 (20-30 minutes each). Sessions 5 and 6 were used to understand how the resident was getting on with their short-term GR goals, facilitating some problem-solving discussions."
89516434|NCT03505385|No Intervention|Usual care|
89516435|NCT05356221||Ponto Users|Users that have been fitted with a Bone Anhcored Sound Processor, Ponto
89516436|NCT02313467|Active Comparator|1.5% Butenyl ALA|Topical application of 1.5% Butenyl ALA per every other day around acne lesions in the face
89516437|NCT02313467|Sham Comparator|Control|Topical application of sham control per every other day around acne lesions in the face
89516438|NCT05089851|Active Comparator|Peptide Antiaging Serum|"Dosage Form: Serum composed of water, thickener, and bioactive ingredients including peptides and antioxidants.~Frequency of Dosage: Twice daily. Subjects will be asked to pump 1x and apply to assigned facial side (left or right) corresponding to randomization.~Study Duration: 12 weeks"
89516439|NCT05089851|Placebo Comparator|Placebo Serum|"Dosage Form: Serum composed of water and thickener~Frequency of Dosage: Twice daily. Subjects will be asked to pump 1x and apply to assigned facial side (left or right) corresponding to randomization.~Study Duration: 12 weeks"
89516440|NCT00515671|Experimental|Arm 1_IMR|Illness Management and Recovery was offered in small groups (less than 8), co-facilitated by either an experienced masters level clinician or a doctoral level psychologist and by a doctoral student in clinical psychology. Facilitators used the IMR curriculum, incorporating psychoeducation, cognitive-behavioral approaches, relapse prevention, social skills training, and coping skills training. Facilitators worked with groups to set personal recovery goals and address progress towards those goals throughout the intervention. Home assignments helped participants apply newly learned skills and/or make progress on goals. Groups were open to rolling admission across the study period
89516441|NCT00515671|Placebo Comparator|Arm 2_PS|Problem Solving was the active control condition (also offered in groups weekly for 9 months). Participants were encouraged to discuss current concerns and receive group support; we did not use structured problem solving tasks. These groups were led by the same facilitators described above, who helped establish group expectations (attendance, confidentiality), encouraged participation, and provided process-oriented observations; there was no formal curriculum, goal setting, or homework assignments.
89516442|NCT02311127|Experimental|SecurAcath|Subcutaneous securement
89516443|NCT02311127|Active Comparator|StatLock|Adhesive securement
89516444|NCT04657809|Experimental|Insulin fast dissolving film|Formulated bioadhesive fast dissolving film contains 100IU of insulin
89516445|NCT04657809|Placebo Comparator|Plain fast dissolving film|Formulated bioadhesive fast dissolving film contains no drug
89516446|NCT02313545|Experimental|Experimental - IZN-6NVS Cream|Eligible women of 3 groups will be assigned to receive IZN-6NVS (IP) - 2.5 g of cream/day for the first 14 days, followed by 3 applications per week for the next 4 weeks.
89516447|NCT04457167|Experimental|Robotic surgery|Robotic surgery for breast mastectomy with conservation of areolo-nipple plate and immediate or delayed reconstruction by latissimus dorsi flap,
89516448|NCT04457167|Active Comparator|Non robotic surgery|Non-robotic surgery for breast mastectomy with conservation of areolo-nipple plate and immediate or delayed reconstruction by latissimus dorsi flap,
89516449|NCT05350917|Experimental|Tislelizumab Combined With DisitamabVedotin and Pyrotinib Maleate|One arm study
89516450|NCT02313701|No Intervention|Vaginal hysterectomy counseling|Standard verbal counseling to consent for vaginal hysterectomy in terms of what the procedures involves, other treatment options, risks, benefits, and what to expect in the pre-op and post-op periods. At the end of the clinic visit, participants will receive a survey to evaluate their understanding of their procedure, pre-operative and post-operative expectations, and satisfaction with their experience. A similar survey will be repeated before their surgery and at their post-operative clinic visit at approximately 1-2 weeks following the surgery.
89516451|NCT02313701|Experimental|Vaginal hysterectomy visual aid|In addition to standard verbal counseling, intervention will include a standardized visual presentation for vaginal hysterectomy. Time spent viewing the visual presentation will be recorded to assess for the efficiency of this quality improvement intervention. At the end of the clinic visit, participants will receive a survey to evaluate their understanding of their procedure, pre-operative and post-operative expectations, and satisfaction with their experience. A similar survey will be repeated before their surgery and at their post-operative clinic visit at approximately 1-2 weeks following the surgery.
89516452|NCT02313701|No Intervention|Robotic sacrocolpopexy counseling|Standard verbal counseling to consent for robotic sacrocolpopexy in terms of what the procedures involves, other treatment options, risks, benefits, and what to expect in the pre-op and post-op periods. At the end of the clinic visit, participants will receive a survey to evaluate their understanding of their procedure, pre-operative and post-operative expectations, and satisfaction with their experience. A similar survey will be repeated before their surgery and at their post-operative clinic visit at approximately 1-2 weeks following the surgery.
89516453|NCT02313701|Experimental|Robotic sacrocolpopexy visual aid|In addition to standard verbal counseling, intervention will include a standardized visual presentation for robotic sacrocolpopexy. Time spent viewing the visual presentation will be recorded to assess for the efficiency of this quality improvement intervention. At the end of the clinic visit, participants will receive a survey to evaluate their understanding of their procedure, pre-operative and post-operative expectations, and satisfaction with their experience. A similar survey will be repeated before their surgery and at their post-operative clinic visit at approximately 1-2 weeks following the surgery.
89516454|NCT02313701|No Intervention|Sub-urethral sling counseling|Standard verbal counseling to consent for sub-urethral sling in terms of what the procedures involves, other treatment options, risks, benefits, and what to expect in the pre-op and post-op periods. At the end of the clinic visit, participants will receive a survey to evaluate their understanding of their procedure, pre-operative and post-operative expectations, and satisfaction with their experience. A similar survey will be repeated before their surgery and at their post-operative clinic visit at approximately 1-2 weeks following the surgery.
89516455|NCT02313701|Experimental|Sub-urethral sling visual aid|In addition to standard verbal counseling, intervention will include a standardized visual presentation for sub-urethral sling. Time spent viewing the visual presentation will be recorded to assess for the efficiency of this quality improvement intervention. At the end of the clinic visit, participants will receive a survey to evaluate their understanding of their procedure, pre-operative and post-operative expectations, and satisfaction with their experience. A similar survey will be repeated before their surgery and at their post-operative clinic visit at approximately 1-2 weeks following the surgery.
89516456|NCT03019497|Experimental|CBT-E|CBT-E refers to Cognitive Behavioral Therapy with specific modules. In the CBT-E condition and following the identification of the needs identified during the evaluation, additional strategies will be added to the CBT strategies for PTSD to address one or more of the seven related problem types that emerged as a result of the traumatic event: 1) major depression, 2) sleep disorders, 3) pain, 4) stressors, 5) inadequate social support, 6) substance use disorder, and 7) anxiety disorder.
89516457|NCT03019497|Active Comparator|CBT-C|CBT-C refers to Cognitive Behavioral Therapy without specific modules. CBT-C participants will be offered only cognitive-behavioral intervention strategies to alleviate the symptoms of each of the PTSD diagnostic criteria.
89516458|NCT02311205|Experimental|TACE+sorafenib|Concurrent Conventional Transarterial Chemoembolization (TACE) and Sorafenib
89516459|NCT05064657|Experimental|Experimental Group|"Experimental Group (ball squeezing) The group were used a ball squeezing method during the blood collection process.~The children were given a ball during the blood draw and told to tighten and loosen it."
89516460|NCT05064657|Active Comparator|Active Comparator|Active Comparator ( bubble blowing) The group were used a bubble blowing method during the blood collection process. During the blood collection process, the children were asked to blow bubbles by giving the apparatus inside the foam bubble to their free arm.
89516461|NCT05064657|No Intervention|Control Group|No intervention
89516462|NCT02313779|Placebo Comparator|Neutral|Reading passage about brain function which is masked as a news article.
89516463|NCT02313779|Experimental|Lovingkindness Meditation (LKM)|Lovingkindness guided meditation experienced in the laboratory and 6 additional LKM meditations taken home on the iPod.
89516464|NCT02313779|Placebo Comparator|Mindfulness Meditation|Mindfulness guided meditation experienced in the laboratory and 6 additional Mindfulness meditations taken home on the iPod.
89516465|NCT02313779|Experimental|Positivity|Reading passage about prioritizing positive emotions which is masked as a news article.
89516466|NCT05390749|Experimental|POR-ROMTX|The experimental arm will be treated with 4 cycles of POR regimen （Pomalidomide 4mg d1-d14, Orelabrutinib 150mg d1-d21, Rituximab 375mg/m2 d1, 21 days per cycle). The response will be evaluated every 2 cycles. The patients with PD will drop out of the study.Patients with CR/PR/SD after 4 cycles of POR treatment will be treated with 2 cycles of RO-MTX regimen（methotrexate 3.5g/m2 civ d1, Orelabrutinib 150mg d1-d21, Rituximab 375mg/m2 d1, 21 days per cycle).
89516467|NCT02313857|Experimental|Viralym-C|"Partially HLA-matched Viralym-C cells will be thawed and given by intravenous injection. Patients will receive 2 x 10^7 partially HLA-matched Viralym-C/m2 as a single infusion.~If a patient has a partial response they are eligible to receive up to 4 additional doses at biweekly intervals. These doses would come from the original infused line if sufficient vials were available but may come from another line if there are insufficient cells in the original line."
89516468|NCT04936113|Experimental|FB-401|FB-401 applied topically
89516469|NCT03468829|Experimental|ALX-0171 Dose 1|
89516470|NCT03468829|Experimental|ALX-0171 Dose 2|
89516471|NCT03468829|Placebo Comparator|Placebo|
89516472|NCT02313935|Experimental|LLM|LLM training Participants use the FitForAll exergaming computer platform as the physical training component (PTC); Participants use the language adapted Version of the BrainFitness Program as the cognitive training component (CTC)
89516473|NCT02313935|Experimental|PTC|Physical training only. Participants use the FitForAll exergaming computer platform as the physical training component (PTC).
89516474|NCT02313935|Experimental|CTC|Cognitive training only. Participants use the language adapted Version of the BrainFitness Program as the cognitive training component (CTC)
89516475|NCT02313935|No Intervention|Passive|Passive Control Participants do not receive an intervention serving as passive controls
89516476|NCT02313935|Active Comparator|Active|Active Control Participants receive an alternative cognitive training scheme; software was built on purpose by the AUTH team. The software is called VideoGrade and uses YouTube documentaries.
89516477|NCT04912791||Women in labor undergoing anesthesia care|Women in labor undergoing anesthesia care
89516478|NCT05334927||Medicine Overuse Headache/New Daily Persistent Headache|The first 18 months were followed up once a month,then followed up once at the 24th month,follow-up visits were made annually after 24 months
89516479|NCT05334927||Chronic Migraine|The patients were followed up at 1, 2, 3, 6, 9, 12, 18 and 24 months,then follow-up visits were made annually
89516480|NCT05334927||Patients with other types of primary headache|The patients were followed up at 3, 6, 9months
89516481|NCT02316197|Experimental|MSC2490484A 100 mg QD|Participants received MSC2490484A capsules 100 milligram (mg) orally, once daily (QD) from Day 1 to Day 21 of each treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent, and/or occurrence of any criterion for withdrawal from study or M3814.
89516482|NCT02316197|Experimental|MSC2490484A 200 mg QD|Participants received MSC2490484A capsules 200 mg orally, QD from Day 1 to Day 21 of each treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent, and/or occurrence of any criterion for withdrawal from study or M3814.
89516483|NCT02316197|Experimental|MSC2490484A 150 mg BID|Participants received MSC2490484A capsules 150 mg orally, twice daily (BID) from Day 1 to Day 21 of each treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent, and/or occurrence of any criterion for withdrawal from study or M3814.
89516484|NCT02316197|Experimental|MSC2490484A 200 mg BID|Participants received MSC2490484A capsules 200 mg orally, BID from Day 1 to Day 21 of each treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent, and/or occurrence of any criterion for withdrawal from study or M3814.
89516485|NCT02316197|Experimental|MSC2490484A 300 mg BID|Participants received MSC2490484A capsules 300 mg orally, BID from Day 1 to Day 21 of each treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent, and/or occurrence of any criterion for withdrawal from study or M3814.
89516486|NCT02316197|Experimental|MSC2490484A 400 mg BID|Participants received MSC2490484A capsules 400 mg orally, BID from Day 1 to Day 21 of each treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent, and/or occurrence of any criterion for withdrawal from study or M3814.
89516487|NCT02316197|Experimental|MSC2490484A 400 mg BID RP2D|Participants received MSC2490484A capsules 400 mg recommended Phase II dose (RP2D) orally, BID from Day 1 to Day 21 of each treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent, and/or occurrence of any criterion for withdrawal from study or M3814.
89516488|NCT04010851|Experimental|Peer co-led educational group|The intervention delivered in a group format is added to treatment as usual. After the parents participate in the one day-intervention, they can continue in self-help groups, which meet once a week for a 2-hour evening session. User representatives lead these weekly self-help groups, which do not require user-fees and aim to offer practical tools, support and information to increase the parent's skills, knowledge and confidence.
89207551|NCT00970983|Experimental|QURT (SN-)|Patients will receive quadrantectomy, sentinel node investigation and radiotherapy. Selective axillary dissection will be performed if sentinel node is positive.
89207552|NCT04009083|Other|Standard of Care|
89207553|NCT04009083|Experimental|18F-Fluciclovine PET Scan|
89207554|NCT00971061|Experimental|MSPI|Molteno single-plate implant
89516489|NCT04010851|Other|Control group|The control goup will receive treatment as usual.
89516490|NCT02314013|Active Comparator|Cephalosporin + Metronidazole|intravenous antibiotics injection (3rd generation cephalosporin + metronidazole) and then change to oral antibiotics (3rd generation cephalosporin+ metronidazole) (an expected average 10 days)
89516491|NCT02314013|No Intervention|No antibiotic|bowel rest and then, discharge until tolerable soft diet.
89516492|NCT01677195|Active Comparator|ACCS100 High Dose|Participants will receive a total daily dose of 3 grams of ACCS100; 1 gram three times a day with meals.
89516493|NCT01677195|Active Comparator|ACCS100 Low Dose|Participants will receive a total daily dose of 1.5 grams of ACCS100; 500 mgs three times a day with meals.
89516494|NCT01677195|Placebo Comparator|Placebo|Participants will receive placebo capsules shown not to absorb mycotoxins three times a day with meals.
89516495|NCT03468751|Experimental|HLX10, Dose Finding Cohort|Each cycle of treatment consists of 4 weeks. Patients who enroll into this study will receive an infusion of assigned dose of HLX10 once every two weeks. No intra-patient dose escalation is allowed. The proposed dose escalation sequence is 0.3, 1.0, 3.0, and 10 mg/kg, starting from 0.3 mg/kg.
89516496|NCT03468751|Experimental|HLX10, Dose Expansion Cohort (200 mg )|Each cycle of treatment consists of 4 weeks. Patients who enroll into this expansion cohort will receive an infusion of assigned dose of HLX10 at 200 mg once every two weeks.
89516497|NCT02314091|Experimental|Onlay|Onlay mesh repair group
89516498|NCT02314091|Experimental|sublay|Sublay mesh repair group
89516499|NCT03130465||Aripiprazole Once Monthly (AOM)|Schizophrenia patients who initiated maintenance treatment with AOM during a schizophrenia-related hospitalisation or during the first three months after this hospitalisation.
89516500|NCT03130465||Daily oral atypical AP|Schizophrenia patients who initiated maintenance treatment with any daily oral atypical AP during a schizophrenia-related hospitalisation or during the first three months after this hospitalisation.
89516501|NCT02316275|Active Comparator|Standard post-operative activity restriction|As a traditional method, patients will be restricted from activity for six weeks after sling surgery.
89516502|NCT02316275|Experimental|No post-operative activity restrictions|Patients are to resume regular activity immediately after mid-urethral sling surgery.
89516503|NCT04470063|Experimental|group A|
89516504|NCT04470063|Experimental|group B|
89516505|NCT04470063|Experimental|group C|
89516506|NCT05331807|Experimental|Group (A)|Participants will be received daily omega-3 fatty acid (two capsules of 1000mg fish oil daily). Each soft gel capsule contains 300 mg of omega-3 fatty acids in the bioactive triglyceride (TG) and 180mg EPA and 120 mg DHA. (Omega3 complex, Jamieson Laboratories, Canada)
89516507|NCT05331807|Experimental|Group (B)|Participants will be received only vitamin D (one capsule of 50,000IU weekly). Each film coated tablet of vitamin D contains 50,000 IU Vitamin D3 (Cholecalciferol). (J-Dee, Jerusalem Pharmaceutical Company, West bank, Palestine).
89516508|NCT05331807|Experimental|Group (C)|Participants will be received both omega-3 fatty acids capsules and vitamin D3 capsule. (one capsule of D3 50,000 IU weekly + two omega-3 fatty acids capsules daily (each capsule contains 300 mg of omega-3 fatty acids)
89516509|NCT05331807|No Intervention|Group (D)|Participants will not be received any supplements and just receive oncology treatment as an usual oncology patient.
89516510|NCT05390593|Experimental|iTBS-1800|The active group will receive 1800 pluse of intermittent theta-bursts in the left dorsolateral prefrontal cortex.
89516511|NCT05390593|Experimental|iTBS-1200|The active group will receive 1200 pluse of intermittent theta-bursts in the left dorsolateral prefrontal cortex.
89516512|NCT02316509|Experimental|Part I: Dose Escalation - GDC-0927|Participants will receive GDC-0927 orally as a single dose on Day -7. Continuous daily dosing will commence on Day 1. Depending on safety and tolerability, participants will be assigned sequentially to escalating doses of GDC-0927 with use of a standard 3 + 3 design. The starting dose will be 600 milligrams per day (mg/day), followed by dose escalation in 400 milligrams (mg) increments.
89516513|NCT02316509|Experimental|Part II: Dose Expansion - GDC-0927|Participants in the expansion cohorts will receive GDC-0927 at MTD/RP2D starting from Day 1 of Cycle 1 (cycle length: 28 days) up to disease progression, unacceptable toxicity, participant withdrawal of consent or study termination.
89516514|NCT02314325|Active Comparator|Standard prophylaxis|Advate [Antihemophilic Factor(Recombinant)] 20-40 IU/kg 5-7 infusions per 14days
89516515|NCT02314325|Experimental|Pharmacokinetic tailored prophylaxis|Advate [Antihemophilic Factor(Recombinant)] dose determined by individual patient pharmacokinetics and infusions administerd on alternate days
89516516|NCT02680171|Experimental|Prism adaptation treatment|Prism Goggles with ten-degree rightward deviating prism lenses will be used to implement prism adaptation treatment, in addition to standard care.
89516517|NCT02680171|Sham Comparator|Sham prism adaptation treatment|Non-Shifting Goggles (sham) will be worn by patients in the control condition. These goggles do not shift the patients visual field.
89516518|NCT03502499|Experimental|Half-normal saline|
89516519|NCT03502499|Active Comparator|Normal saline|
89516520|NCT04402827||Cases|HCW highly exposed (defined as more than 15 days of continued personal attention in ICU, anaesthesia, or Infectious Diseases wards) to patients with a diagnosis of COVID-19 (PCR confirmed), who remained asymptomatic and with a negative serology (IgM and IgG negative). Transient entry or stay in the zone (kitchen personnel, rehab members,...) will be not included.
89207555|NCT00971061|Active Comparator|AVI|Ahmed valve implant
89516521|NCT04402827||Controls|HCW highly exposed to PCR-confirmed patients with a diagnosis of COVID-19, as defined above, matched by age and sex, who had suffered confirmed SARS CoV-2 disease (positive PCR or after, positive IgG)
89516522|NCT02547337||Type 1 diabetes|
89516523|NCT02547337||Healthy subjects|
89516524|NCT02316665|Experimental|continuous positive airway pressure|Patients will receive continuous positive airway pressure during three months
89516525|NCT02316665|Sham Comparator|Sham-continuous positive airway pressure|Patients will receive sham-continuous positive airway pressure during 3 months
89516526|NCT03501641|Experimental|image-based virtual reality learning|The participants will undergo 10-minute image-based virtual reality learning for history taking and physical examination of otolaryngology.
89516527|NCT03501641|Active Comparator|video-based learning|The participants will undergo 10-minute video-based learning for history taking and physical examination of otolaryngology.
89516528|NCT05101941|Experimental|immediate dental implants|
89516529|NCT05160337|Other|Healthy Volunteers|Healthy Volunteers will be recruited into the study
89516530|NCT04437771||Subjects with Fanconi Anaemia Subtype A (FA-A)|Subjects treated with ex vivo lentiviral gene therapy product in FANCOLEN-I trial and agree to participate in this long-term follow-up (LTFU) study
89516531|NCT04437459|Experimental|Abbreviated Fat Tolerance Test|
89516532|NCT04437459|Active Comparator|Oral Glucose Tolerance Test|
89516533|NCT02316743|Experimental|Levothyroxine|Levothyroxine supplementation
89516534|NCT04428567|Experimental|Treadmill Exercise + Cognitive Training (Dual-Task)|The Dual-Task group will be provided with treadmill training with added simultaneous cognitive training during treadmill exercise training.
89516535|NCT04428567|No Intervention|Control Group|The control group will be assessed as the intervention group at the same time intervals without the intervention.
89516536|NCT03502421|Experimental|Ketamine|Continuous infusion of Ketamine 0.3 to 0.5 mg/kg per hour PCA Dilaudid 2.0-2.5 mg
89516537|NCT03502421|No Intervention|Opioid Only|Patient-controlled analgesia Dilaudid 2.0-2.5 mg
89516538|NCT03502343|Experimental|Modified Gemcitabine plus nab-Paclitaxel|The intervention group
89516539|NCT03501563||Case Group|"Participants with ASA 1-2, aged 18-60 years, undergoing hypotensive anesthesia in the operation of the septoplasty in Recep Tayyip Erdoğan University Medical Faculty Training and Research Hospital. Participants with uncontrolled hypertension, diabetes mellitus, cerebrovascular disease, cogulopathy, morbid obesity (BMI ≥35) and renal disease will not be taken.~Participants were first pre-medicated with an infusion of midazolam 0.05 mg/kg, fentanyl 1 µg/kg, lidocaine 1 mg/kg. Induction of anesthesia was achieved with an infusion of propofol 1-2 mg/kg and vecuronium bromide 0.6 mg/kg and after 2 to 3 minutes participants were intubated with the appropriate tube size. Anesthesia was maintained with an infusion of remi fentanyl (0.05 - 1 µg/Kg/min), with oxygen (O2) in air with desflurane."
89516540|NCT04345887||Spironolactone|2 x 100 mg spironolactone
89516541|NCT04345887||Placebo|2 x 1 placebo
89516542|NCT03818971|Experimental|alcohol consumption with alcohol use disorder (AUD)|subjects with regular alcohol consumption with AUD according to the DSM 5 without any other substance use disorder (except alcohol) without psychiatric, neurologic or ophthalmologic disease in progress with a negative drug check and Breathalyzer the day of the inclusion - only one visit is planned for this study : an electroretinogram will be realized
89516543|NCT03818971|Other|alcohol consumption without alcohol use disorder|subjects with regular alcohol consumption without AUD according to the DSM 5 without any other substance use disorder without psychiatric, neurologic or ophthalmologic disease in progress with a negative drug check and Breathalyzer the day of the inclusion - only one visit is planned for this study : an electroretinogram will be realized
89516544|NCT03818971|Other|no alcohol consumption|subjects without alcohol consumption without any other substance use disorder without psychiatric, neurologic or ophthalmologic disease in progress with a negative drug check and Breathalyzer the day of the inclusion - only one visit is planned for this study : an electroretinogram will be realized
89516545|NCT03132311|Experimental|HIV positive subjects|"300 HIV positive adults with CD4 > 200 cells/mm3, stratified in 3 groups (100 patients in each group) according to CD4 counts (200-350; 351-500, >500 cells/mm3).~Assigned intervention: Yellow fever vaccination (17 DD Biomanguinhos)"
89516546|NCT03132311|Active Comparator|HIV negative subjects|"100 HIV negative adults.~Assigned intervention: Yellow fever vaccination (17 DD Biomanguinhos)"
89516547|NCT05374083|Experimental|Alveolar ridge preservation using autogenous demineralized dentin block graft|Atraumatic extraction of non-restorable teeth, then the extracted tooth will be prepared and demineralized using hydrochloric acid (HCL) acid as demineralized dentin block graft and inserted in the extraction socket and covered then suturing
89516548|NCT05374083|Active Comparator|Alveolar ridge preservation using particulate deproteinized bovine bone graft|Atraumatic extraction of non-restorable teeth, then the socket will be packed by particulate deproteinized bovine bone graft and covered then suturing
89516549|NCT01989949|Experimental|TP-434 (Eravacycline) via IV infusion|TP-434 (Eravacycline) reconstituted and administered via IV infusion at a dose of 1 mg/kg, every 12 hours, for 7 doses over 4 days.
89516550|NCT02314715||Knee Osteoarthritis|Participants with diagnosed knee osteoarthritis
89516551|NCT02314715||Controls|Participants without knee osteoarthritis
89516552|NCT05390437|Placebo Comparator|control group|starch (placebo) 4 grams per day for 60 days
89516553|NCT05390437|Experimental|Interventional group|Prebiotics (GOS) Galactooligosaccharides 4 gram per day for 60 days
89516554|NCT02316821|Experimental|bardoxolone methyl|bardoxolone methyl capsules, dosage To Be Determined, once daily for 16 weeks
89516555|NCT02316821|Placebo Comparator|Placebo|Placebo capsules, once daily for 16 weeks
89516556|NCT02316899|Experimental|ASP0456 (Period I)|Up to 12 weeks
89516557|NCT02316899|Placebo Comparator|Placebo (Period I)|Up to 12 weeks
89516558|NCT02316899|Experimental|ASP0456 (Period II)|From 12 weeks to 52 weeks
89516559|NCT01727011|Experimental|IPAS|Once the patient recorded in the trial, and after completion of a post-implant dosimetry scanner to analyze the dose distribution within the target volume and organs at risk, the patient is treated by irradiation and partial accelerated breast brachytherapy using high dose rate, delivering a total dose of 16 Gy in one fraction
89516560|NCT02314793|Experimental|Part 1: Single Ascending Dose ASP2205 (Fasting)|Young male and female subjects will receive single doses of ASP2205 in a dose escalation format.
89516561|NCT02314793|Placebo Comparator|Part 1: Single Ascending Dose Placebo (Fasting)|Young male and female subjects will receive single doses of matching placebo in a dose escalation format.
89207556|NCT00973557||Taking Bevacizumab|Patients who are currently being treated for cancer by the drug Bevacizumab.
89207557|NCT00973635|No Intervention|Traditional training|"Patients of subjects with no detailed curriculum for handoff skills during non-intervention months.~Learners provided a brief outline of how to perform discharge summaries (handout).~Learners given two core articles describing some of the communication issues regarding handoff safety.~Handoff teaching left to discretion of the subintern's team (typically the see one, do one, teach one method).~No feedback given to these subinterns on their performance of their handoff skills."
89516562|NCT02314793|Experimental|Part 1: Single Ascending Dose ASP2205 (Fed)|Young male and female subjects will receive a single dose of ASP2205
89516563|NCT02314793|Experimental|Part 2: Multiple Ascending Dose ASP2205, Young females|Young female subjects will receive multiple dosing of ASP2205 for 14 days: single doses on days 1 and 14 and depending on the dosing regimen (based on emerging data from Part 1) either once or twice daily dosing from days 2 to 13.
89516564|NCT02314793|Placebo Comparator|Part 2: Multiple Ascending Dose Placebo, Young females|Young female subjects will receive matching placebo for 14 days: single doses on days 1 and 14 and depending on the dosing regimen (based on emerging data from Part 1) either once or twice daily dosing from days 2 to 13.
89516565|NCT02314793|Experimental|Part 2: Multiple Ascending Dose ASP2205, Elderly females|Elderly female subjects will receive multiple dosing of ASP2205 for 14 days: single doses on days 1 and 14 and depending on the dosing regimen (based on emerging data from Part 1) either once or twice daily dosing from days 2 to 13.
89516566|NCT02314793|Placebo Comparator|Part 2: Multiple Ascending Dose Placebo, Elderly females|Elderly female subjects will receive matching placebo for 14 days: single doses on days 1 and 14 and depending on the dosing regimen (based on emerging data from Part 1) either once or twice daily dosing from days 2 to 13.
89516567|NCT00928447|Experimental|rHuPH20|Participant's upper back will be divided into 2 equal spaces and will receive Regimen 1 and 2 in 4 spaces respectively. In Regimen 1, a single row of 4 patches, each with the nickel sulfate concentration (NSC) (1, 2.5, or 5%) determined at screening, will be applied to the upper space at Day 1. After 48 hours, the patches will be removed and the reactions will be graded on the ICDRG scale. An ID injection containing rHuPH20 (3,000 Units [U]) will be administered once daily (QD) for 5 days at the center of each area of reaction. In Regimen 2, a single row of 4 sites in the lower space will be injected intradermally with drug rHuPH20 (3,000 U) at Day 1. Ten minutes after the injections, patches with the NSC (1, 2.5, or 5%) determined at screening will be applied to the injection sites. After 48 hours, the patches will be removed and the reactions will be graded on the ICDRG scale. As during pretreatment, an ID injection containing rHuPH20 will be then administered QD for 5 days.
89516568|NCT00928447|Placebo Comparator|Placebo|Participant's upper back will be divided into 2 equal spaces and will receive Regimen 1 and 2 in 4 spaces respectively. In Regimen 1, a single row of 4 patches, each with the NSC (1, 2.5, or 5%) determined at screening, will be applied to the upper space at Day 1. After 48 hours, the patches will be removed and the reactions will be graded on the ICDRG scale. An ID injection containing placebo will be administered QD for 5 days at the center of each area of reaction. In Regimen 2, a single row of 4 sites in the lower space will be injected intradermally with placebo at Day 1. Ten minutes after the injections, patches with the NSC (1, 2.5, or 5%) determined at screening will be applied to the injection sites. After 48 hours, the patches will be removed and the reactions will be graded on the ICDRG scale. As during pretreatment, an ID injection containing placebo will be then administered QD for 5 days.
89516569|NCT02314871|Active Comparator|Epidural|Patients will receive perioperative epidural analgesia. Drugs: bupivacaine 1.25 mg/ml and sufentanil 0.5 mcg/ml Form and frequency: continuous infusion Dosage: 4 - 14 ml/h with boluses 2 - 4 ml based on pain assessment Duration: as long as required
89516570|NCT02314871|Active Comparator|Piritramide|Patients will receive postoperative analgesia with piritramide. Drugs: piritramide 1.0 mg/ml Form and frequency: continuous infusion Dosage: 0 - 4 ml/h with boluses 2 - 4 ml based on pain assessment Duration: as long as required
89516571|NCT02314871|Active Comparator|Morphine|Patients will receive postoperative analgesia with morphine. Drugs: morphine 1.0 mg/ml Form and frequency: continuous infusion Dosage: 0 - 4 ml/h with boluses 2 - 4 ml based on pain assessment Duration: as long as required
89516572|NCT05159635|Experimental|Active Living programme and wearable technical aids|Active Living programme and wearable technical aids
89516573|NCT05159635|Active Comparator|Wearable technical aids|Wearable technical aids
89516574|NCT02317055|Other|Patient|Imaging
89516575|NCT02317055|Other|healthy subject|Imaging
89516576|NCT02224846|Experimental|2.5 mg/5 mg tadalafil|2.5 mg tadalafil orally once daily for 3 months (Period 1) and then 5 mg tadalafil orally once daily for 21 months (Period 2).
89516577|NCT02224846|Experimental|5 mg tadalafil|5 mg tadalafil orally once daily for 24 months (Period 1 and Period 2).
89516578|NCT03569761|Experimental|Decision Aid Video Intervention|Participants randomized to the intervention group will view the AI culturally-adapted CRC screening decision aid in a private room at a RHCC clinic. The video will be viewed on an electronic tablet or laptop computer.
89516579|NCT03569761|Active Comparator|Control|Participants randomized to the control group will view an attention-control video about food safety in a private room at a RHCC clinic. The video will be viewed on an electronic tablet or laptop computer. The investigators chose the attention-control video so that the structure of the control arm mirrors the intervention arm. The food safety topic was chosen to provide information that is reasonably salient to the control arm participants but that would not be likely to affect encounters with healthcare providers.
89516580|NCT02317133||HSP: acute episode|"Patients in this group are going through an acute episode of Henoch Schönlein Purpura.~Intervention: Blood samples Intervention: Stool samples"
89516581|NCT02317133||HSP: remission|"Patients in this group have had Henoch Schönlein Purpura in the past but currently have no symptoms.~Intervention: Blood samples Intervention: Stool samples"
89516582|NCT02317133||Control group|"Control patients recruited from elective surgery candidates at the participating hospitals.~Intervention: Blood samples Intervention: Stool samples"
89516583|NCT02522923|Experimental|Physical Therapist|Participants randomized to this arm will receive care from a physical therapist first.
89207558|NCT00973635|Experimental|Intervention|Group that receives educational intervention.
89207559|NCT00861978|Placebo Comparator|1|
89207560|NCT00861978|Experimental|2|
89207561|NCT00971139|Experimental|Access to an OPPC service|Access to an Internet-based messaging system where patients can ask questions and receive advice and support from care providers at the hospital and social counsellors
89207562|NCT00971139|No Intervention|Control group|Patients receiving usual care
89207563|NCT00862056||Cardiac CT|All participants will undergo a coronary artery CT angiogram
89207564|NCT00959361|Experimental|pharmaceutical care|consultation with the pharmacists
89207565|NCT00959361|No Intervention|control|usual care without consultation with the pharmacists
89207566|NCT04040712|Experimental|Donor FMT|Fecal microbiota transplantation using stools from healthy donors
89207567|NCT04040712|Sham Comparator|Sham FMT|Sham fecal microbiota transplantation
89207568|NCT00973713|Experimental|RAD001 10mg/d|
89207569|NCT00857142|Experimental|1|Oxymorphone hydrochloride 40 mg extended release tablets (Sandoz)
89207570|NCT00857142|Active Comparator|2|Opana 40 mg extended release tablets
89207571|NCT00971217|Experimental|Exercise|"Participants will engage in 2 exercise sessions each week for 10 weeks. Each session will last 50 minutes and will commence with a 5 minute warm up on the bike or treadmill and conclude with a 5 minute cool down. The participants will be required to exercise on their own without interference from others. Participants will wear heart rate monitors to ensure that they are exercising to moderate intensity (70-80% of age predicted maximum heart rate).~Exercise: Aerobic exercise on the bike/cross trainer/ rower/ treadmill and resistance exercise on the weights machines."
89207572|NCT00971217|Experimental|Online Cognitive Behavioural Therapy|Participants will be asked to log-on to a web-site specifically aimed at young men once per week and complete the set cognitive-behavioural tasks.
89207573|NCT00971217|Experimental|Combined Exercise/Online CBT|Participants will simultaneously par-take in both the exercise and the online CBT conditions already outlined.
89207574|NCT00971217|No Intervention|Control|Individuals will be advised that the start of their intervention will be delayed by 10 weeks. After 10 weeks individuals in the control condition will be given the opportunity to avail of an induction session in the gym and subsequently use the gym facilities for three sessions if they so desire. Participants will be asked to refrain from exercise for the 10 week study period.
89207575|NCT00865176|Experimental|1|Eplerenone 50mg Tablets
89207576|NCT00865176|Active Comparator|2|INSPRA 50mg Tablets
89207577|NCT00973791|Active Comparator|Prior crystalloid|Crystalloid (Ringer's Lactate) was given before spinal anesthesia
89207578|NCT00973791|Active Comparator|Posterior crystalloid|Crystalloid (Ringer's Lactate) was given after spinal anesthesia
89516584|NCT02522923|Active Comparator|Primary Care Provider|Participants randomized to this arm will receive care from a primary care provider first.
89207579|NCT00973791|Active Comparator|Prior colloid|Colloid (6% hydroxyethyl starch) was given before spinal anesthesia
89207580|NCT00973791|Active Comparator|Posterior colloid|Colloid (6% hydroxyethyl starch) was given after spinal anesthesia
89207581|NCT00865254|Experimental|Traditional Contingency Management|Standard treatment plus prize based contingency management.
89207582|NCT00865254|Experimental|Early Enhanced Contingency Management|Prize based contingency management with enhanced magnitude early in treatment and reduced magnitude later in treatment.
89207583|NCT00865254|Active Comparator|Standard Treatment|Counseling and monitoring of smoking cessation.
89207584|NCT02544672|Experimental|Myoelectric Elbow-Wrist-Hand Orthosis|
89207585|NCT00959439|Experimental|1|Naproxen Delayed Release Tables, 375 (Gevena Pharmaceuticals, Inc.)
89207586|NCT00959439|Active Comparator|2|Naproxen (EC-Narosyn) Delayed Release Tables, 375 (Syntex (USA), Inc.)
89207587|NCT04041492|Experimental|Group 1|Vitamin D3 1000UI + Placebo (Calcined Magnesia).
89207588|NCT04041492|Experimental|Group 2|Vitamin K2 100 mcg + Placebo (Calcined Magnesia).
89207589|NCT04041492|Active Comparator|Group 3|Vitamin D3 1000UI + Vitamin K2 100 mcg
89207590|NCT00971373|Experimental|Exp Scrubs|antimicrobial impregnated scrubs
89207591|NCT00971373|No Intervention|Non-antimicrobial scrubs|Non-antimicrobial scrubs
89207592|NCT00862212|Experimental|Brief Alcohol Intervention|Half of the subjects will be randomly assigned to receive a brief physician-delivered alcohol intervention designed by the NIAAA to be delivered by primary care and mental health providers.
89207593|NCT00862212|No Intervention|Control Group|
89516585|NCT02314949||intestinal transplantation|all performed intestinal transplants underwent the same Leuven intestinal transplant protocol
89516586|NCT04463303||group 1|patient who will develop weaning induced pulmonary adema
89516587|NCT04463303||group 2|patient who will nor develop weaning induced pulmonary adema
89516588|NCT03470077|Experimental|Group A|40 randomly allocated Patients undergoing repair of rupture globe will receive IV nalbuphine 0.1 mg/kg with induction of anesthesia.
89516589|NCT03470077|Experimental|Group B|40 randomly allocated Patients undergoing repair of rupture globe.will receive IV nalbuphine 0.1 mg/kg at the end of surgery just before discontinuation of anesthesia.
89516590|NCT04463147|Other|new residents|new residents in ultrasound-guided central vascular catheterization.
89516591|NCT04463147|Other|experienced residents or ICU practitioners|experienced residents or ICU practitioners in ultrasound-guided central vascular catheterization.
89516592|NCT01632280|Active Comparator|Active tDCS|In this arm, participants will receive active tDCS (2mA, 20 min per session). The anode electrode will be placed over the right inferior frontal gyrus, defined as F8 (10-20 EEG system), with the cathode electrode placed over the contralateral supraorbital area, above the left eyebrow. During each session they will also perform a computerized task designed to engage the inhibitory control circuit when confronted with food stimuli.
89025060|NCT03279380|Active Comparator|Low Intensity Continuous Training|"Low intensity continuous exercise on the cycling ergometer (Velodyn, Racermate ™, USA).~Protocol: continuous 60 min cycling at 50% PPO. Baseline measurements will include the V̇o2peak test and peak power output. Monitoring of physiological responses with spirometry and analysis of expired air (oxygen and carbon dioxide output) (Quark, Cosmed, Rim, Italy)."
89516593|NCT01632280|Sham Comparator|Sham tDCS|Participants will receive sham tDCS sessions with the same duration and electrode montage as in the real tDCS arm. In this case, current will be applied for 30 s only according to standard procedures, and participants will perform a control task where they will observe and provide responses for the same food and non-food pictures as in the active group task, but without requirement of inhibitory control for performance.
89516594|NCT02315105|Experimental|Morbid Obese patients|This purpose of this study is to find out more about the safety and effectiveness of the Laparoscopic Greater Curvature Plication (LGCP) for Morbid Obese Patients with related problems such as diabetes, hypertension, high cholesterol, mild obstructive sleep apnea and joint problems.
89516595|NCT04455763|Experimental|SVF|Thumb carpometacarpal injection with adipose-derived SVF combined with splinting
89516596|NCT04455763|Active Comparator|Splint|Thumb carpometacarpal osteoarthrosis treated with splinting only
89516597|NCT03502109|Experimental|Intervention group|Medication review with follow-up every 2 months, conducted by a trained pharmacist.
89516598|NCT03502109|No Intervention|Control group|Usual care by physicians, nurses and dietitians.
89516599|NCT05159323|Experimental|Diffusion Spectrum Imaging|All participants accept diffusion spectrum imaging, the quantitative parameters of the diffusion spectrum imaging are obtained. The quantitative parameters are compared in different subgroups based on the pathologic examination results.
89516600|NCT02317211|Placebo Comparator|control|placebo 320 mg daily for twelve weeks
89516601|NCT02317211|Experimental|anthocyanins treatment|anthocyanin supplement 320mg daily for twelve weeks
89516602|NCT02317367||adult women|Women who drink seven or more drinks per week
89516603|NCT02317367||adults a|Individuals who eat fewer than five servings of fruits and vegetables per day, on average, based on an NCI screener for fruit and vegetable consumption.
89516604|NCT02317367||adults b|Individuals who exercise (moderate or vigorous intensity) less than 75 minutes per week.
89516605|NCT05159167|Experimental|Intervention group|Participants in the intervention group received two months of Baduanjin exercise training provided by the specialist coach 3 days per week in Hubei Cancer Hospital, and they were also required to do Baduanjin exercise at home for the remaining 4 days each week for at least 20 min per day. All the participants are requested to monitor and record adverse effects during their exercise sessions.
89516606|NCT05159167|Placebo Comparator|Control group|Participants in the control group were requested to maintain their original daily physical activity for no less than 20 min per day over the following 6-month period and record their daily activity at home by themselves. These data were collected by a researcher during the participants' time in the study and at the 6-month follow-up at the hospital. After the 6-month follow-up, the participants were provided with 1-month professional Baduanjin exercise guidance by the trial's specialist coach for free if they wished.
89516607|NCT02224690|Experimental|GWP42003-P 20 mg/kg/day Dose|Participants received GWP42003-P 20 mg/kg/day administered orally, half in the morning and half in the evening. Participants titrated GWP42003-P to 20 mg/kg/day over 11 days and remained at this dose for the 12-week maintenance period. If the participant did not immediately enter the OLE study, the maintenance period was followed by a 10-day taper (10% per day) period.
89516608|NCT02224690|Placebo Comparator|Placebo|Participants received placebo (0 mg/mL CBD), volume matched to the 20 mg/kg/day dose, administered orally, half in the morning and half in the evening. To maintain the blinded aspect of the study, participants titrated the placebo dose over 11 days and remained at this dose for the 12-week maintenance period. If the participant did not immediately enter the OLE study, the maintenance period was followed by a 10-day taper (10% per day) period.
89516609|NCT03501407||Erythema migrans|Patients for whom a diagnosis of acute phase of Lyme disease is done on the basis of the existence of an erythema migrans and a tick bite history in the days preceding the occurrence of erythema (before and after antibiotics treatment) will be recruited
89516610|NCT03501407||No-erythema migrans|"Patients with unspecific symptoms (the most common symptoms being:~headache, arthralgia, myalgia, febrile episode) appearing within 3 months after a tick bite will be recruited"
89516611|NCT05390281||Pre-diabetic group|Patients with preoperative HbA1c 5.7-6.4% (group A) (prediabetics)
89516612|NCT05390281||Diabetic group|Patients with preoperative HbA1c > or = 6.5% till 7% or > 7% in case of emergency surgery or rapidly progressive cases with no time for long-term glycemic control (group B) (diabetics)
89516613|NCT03501329||Outpatients in Community Psychiatry|"Treatment with consultations, social support, psychological and psychopharmacological treatment. This is routine psychiatric care.~Treatment was not changed as a result of the investigation in itself."
89516614|NCT03501251|Experimental|Moxidectin 8 mg|A single tablet of 8 mg of moxidectin
89516615|NCT03501251|Experimental|Moxidectin 8 mg + Albendazole|A single tablet of 8 mg of moxidectin plus a single tablet of albendazole (400 mg)
89516616|NCT03501251|Experimental|Moxidectin 16 mg|Two tablets of 8 mg of moxidectin ( = 16 mg)
89516617|NCT03501251|Experimental|Moxidectin 16 mg + Albendazole|Two tablets of 8 mg of moxidectin ( = 16 mg) plus a single tablet of albendazole (400 mg)
89516618|NCT03501251|Experimental|Moxidectin 24 mg|Three tablets of 8 mg of moxidectin ( = 24 mg)
89516619|NCT03501251|Experimental|Moxidectin 24 mg + Albendazole|Three tablets of 8 mg of moxidectin ( = 24 mg) plus a single tablet of albendazole (400 mg)
89516620|NCT03501251|Placebo Comparator|Placebo|A single tablet of placebo
89516621|NCT05163691|Experimental|Group A - 6 mg single-dose|A single, inhaled dose of GH001 6 mg or placebo (randomized as 8 active and 2 placebo subjects)
89516622|NCT05163691|Experimental|Group B - 12 mg single-dose|A single, inhaled dose of GH001 12 mg or placebo (randomized as 8 active and 2 placebo subjects)
89516623|NCT05163691|Experimental|Group C - 18 mg single-dose|A single, inhaled dose of GH001 18 mg or placebo (randomized as 8 active and 2 placebo subjects)
89516624|NCT05163691|Experimental|Group D - Individualized Dosing Regimen, 1-hour interval|Administration of up to 3 inhaled doses of GH001 within a single day (6 mg, followed by 12 mg, followed by 18 mg) with a 1-hour dose interval (8 subjects)
89544556|NCT02709083|Experimental|Treatment-dasatinib, nilotinib, imatinib|Patients receive dasatinib orally (PO) once a day (QD) or nilotinib PO twice a day (BID) at the discretion of the treating hematologist. Patients achieving either a 1 log reduction at 3 months or a 2 log reduction at 6 months in their breakpoint cluster region-abelson murine leukemia viral oncogene homolog 1 (BCR-ABL1) transcript levels may switch to imatinib mesylate PO QD.
89544557|NCT05528991||mesangial hypercellularity, M|the histopathology was graded based on the revised Oxford Classification system as follows: M absent (M0) or M present (M1)
89544558|NCT05528991||endocapillary hypercellularity, E|E absent (E0) or E present (E1)
89544559|NCT05528991||segmental glomerulosclerosis, S|S absent (S0) or S present (S1)
89544560|NCT05528991||tubular atrophy/interstitial fibrosis, T|T ≤ 25% (T0) or T 26%-50% (T1), or T > 50% (T2)
89544561|NCT05528991||crescents, C|C absent (C0) or C present ≥ 1 glomerulus (C1) or C > 25% glomeruli (C2)
89544562|NCT02709005|Experimental|5% Monolaurin Vaginal Gel|80 subjects will receive 5% Monolaurin Gel twice daily for three successive days for a total of 6 doses
89544563|NCT02709005|Placebo Comparator|Vehicle Placebo|40 subjects will receive placebo Gel twice daily for three successive days for a total of 6 doses
89544564|NCT02434445||Hepatorenal syndrome group|Patients with advanced cirrhosis who develope hepatorenal syndrome
89544565|NCT02434445||Non-hepatorenal syndrome group|Patients with advanced cirrhosis who do not hepatorenal syndrome
89544566|NCT03188315|Experimental|cases|HPV detection HPV Genotyping HPV Oncogenes and oncoproteins
89544567|NCT03188315|Active Comparator|control|HPV detection HPV Genotyping HPV Oncogenes and oncoproteins
89544568|NCT03188471|Experimental|GnRH antagonist|Vitamin C (1 tablet daily) as placebo of aspirin GnRH antagonist 0.25mg daily from the day of oocyte retrieval for seven days
89544569|NCT03188471|Active Comparator|aspirin|aspirin (100 mg daily, plus saline as placebo of GnRH antagonist ) for seven days.
89544570|NCT03188549|Active Comparator|Departments of Branch A|Intervention: AniosGel Respiratory ICU Pediatric Cardiac Surgery, NICU Hemato-Oncology, Oncology Internal A, C, D, E, F Surgery C, Vascular Surgery and Chest Surgery Pediatric B South Imaging Orthopedics B
89544571|NCT03188549|Active Comparator|Departments of Branch B|Intervention: Softaman Neurosurgery ICU Cardiac Surgery, Cardiac ICU, Pediatric ICU Pediatric Hemato-Oncology Internal B and I, Geriatric C and D Surgery B Pediatric B North Emergency Room Orthopedics A and Hand
89544572|NCT03188549|Active Comparator|Branch C|Control Intervention - Septol without any changes All patients hospitalized in the 29 departments in Sheba, including two of the branches, during the year of the study
89025061|NCT03277521|Active Comparator|Neurologically Normal|Neurologically normal subjects (i.e., nonimpaired) will be recruited for participation in three sessions of intermittent theta burst stimulation (iTBS), each consisting of sham iTBS applied to the hotspot of the target muscle and active iTBS; sham iTBS always be will administered first to minimize the potential for carry over effects. Sessions will be separated by at least 3 days to minimize the potential for carry over effects. Before and 10, 20 and 30 minutes after each iTBS session, motor evoked potentials (MEPs) will be recorded in order to quantify changes in corticomotor excitability.
89025062|NCT03277521|Active Comparator|Quadriplegia|Individuals with quadriplegia will be recruited for participation in three sessions of intermittent theta burst stimulation (iTBS), each consisting of sham iTBS applied to the hotspot of the target muscle and active iTBS; sham iTBS always be will administered first to minimize the potential for carry over effects. Sessions will be separated by at least 3 days to minimize the potential for carry over effects. Before and 10, 20 and 30 minutes after each iTBS session, motor evoked potentials (MEPs) will be recorded in order to quantify changes in corticomotor excitability.
89207594|NCT00973947|Other|Control|Immobilisation: Standard headrest plus individual customised mask (orfit)
89207595|NCT00973947|Other|TRial Arm|Immobilisation: Customised headrest plus individual customised mask (orfit)
89544573|NCT05528679|Experimental|Treatment group A|610 100 mg administered subcutaneously every 4 weeks
89544574|NCT05528679|Experimental|Treatment group B|610 300 mg administered subcutaneously every 4 weeks
89544575|NCT05528679|Placebo Comparator|placebo Arm Type：no inter|placebo administered subcutaneously every 4 weeks
89544576|NCT02434601|Other|Treatment of Dentin Surface|Treatment of Dentin Surface: Restoration made following the protocol recommended by the manufacturer of the materials.
89544577|NCT02434601|Experimental|Dentin Surface|Treatment of Dentin Surface: Increased etching dentin for 15 seconds to 30 seconds
89544578|NCT02434601|Experimental|Treatment|Treatment of Dentin Surface: Intervention with the cavity prophylaxis probe ultrasound blunt applied for 30 seconds in Surface hypermineralized non-carious dentin cervical lesions. Therefore, the restoration was done following the protocol recommended by the manufacturer of the material.
89544579|NCT04650087|Active Comparator|Apixaban|Drug: Apixaban 2.5 MG Participants will be given study medication at the time of discharge from the hospital. Participants will take Apixaban 2.5 MG twice a day, once in the morning and once in the evening, for 30 days. Participants will be contacted (electronic or telephone) 2 days after starting the study medication and contact will continue up to day 90 after starting study treatment. Follow up will be through electronic and/or telephone contact depending on the participant's preference, compliance, and medication adherence. Participants will be queried for any clinically relevant endpoints, especially major bleeding or a need to seek healthcare attention for any reason. Follow-up will occur from the time of discharge and through the 30 day study period, with contacts 2 days, 10 days, 20 days, and 30 days after discharge. Two additional study contacts will take place 45 days and 90 days after discharge.
89207596|NCT00857298|Active Comparator|HIV-MS|HIV-positive obese women with metabolic syndrome will be studied before and after losing 6-8% of body weight
89207597|NCT00857298|Active Comparator|MS only|HIV-negative obese women with metabolic syndrome will be studied before and after losing 6-8% of body weight
89207598|NCT00971451|Experimental|knee joint cryotherapy|20 minutes of knee joint cryotherapy - ice bag application
89516625|NCT05163691|Experimental|Group E - Individualized Dosing Regimen, 2-hour interval|Administration of up to 3 inhaled doses of GH001 within a single day (6 mg, followed by 12 mg, followed by 18 mg) with a 2-hour dose interval (8 subjects)
89516626|NCT03501017|Experimental|Intervention group|The 12-week physical activity program was implemented under the guidance of nurse, in outdoors with the group, 5 days a week with warm up and cooling down for 10 minutes and normal walking tempo at a moderate pace for 30-45 minutes (3-6 km/hour).
89516627|NCT03501017|Active Comparator|Control Group|As routine practice, a brochure provided from the Public Health Directorate on protection from CVD was delivered to the individuals in the control group.
89516628|NCT01634152|Placebo Comparator|Placebo QD|
89516629|NCT01634152|Experimental|Tiotropium low dose QD|
89516630|NCT01634152|Experimental|Tiotropium medium dose QD|
89516631|NCT05391217||Transgender people with history of cancer|Self-reported cancer history and/or treatment for cancer within the last 5 years.
89516632|NCT05391217||Transgender people without history of cancer|People living with other chronic conditions
89516633|NCT02315417|Experimental|gevokizumab|Solution for subcutaneous injection (Part 1, Group B)
89516634|NCT02315417|Placebo Comparator|Placebo|Solution for subcutaneous injection (Part 1, Group A)
89516635|NCT02315417|Experimental|gevokizumab open-label|Solution for subcutaneous injection (Part 2, Open-label)
89516636|NCT05120323|Experimental|vDOT Intervention Group|The VDot group will submit videos via app to Emocha to have their inhaler technique graded to assess their inhaler technique.
89516637|NCT05120323|No Intervention|Standard Asthma Care Group|Participants in the standard asthma care group will receive standard of care asthma education conducted by a respiratory therapist in the specialty clinics at Arkansas Children's Hospital at the baseline visit. Education will include standard of care instruction on the participant's prescribed asthma medications, how to use an asthma action plan, as well as training and demonstration of proper inhaler technique. They will not have any additional study activities until the 3-month visit. They will be instructed to take their medications as prescribed.
89516638|NCT03501953|Experimental|Nature Exposure|6-week physical activity course in a natural environment
89516639|NCT03501953|Active Comparator|Urban Exposure|6-week physical activity course in an urban environment
89516640|NCT05390125||4B ward staff|Multidisciplinary staff members from a surgical ward in Cork University Hospital.
89516641|NCT05390125||Cedar ward staff|Multidisciplinary staff members from the Cedar ward in University Hospital Waterford with a similar case mix of patients to ward 4B in CUH.
89516642|NCT02317523|Experimental|Behavioral Activation|Behavioral Activation (BA) emphasize self-monitoring as an aid for increasing one's engagement in self-reinforcing activities while simultaneously reducing negative avoidant coping responses. The intervention consists of 6 total face-to-face sessions lasting 60 minutes each.
89516643|NCT02317523|Active Comparator|Information and Support|Information and Support (IS) consists of providing education on Alzheimer's disease, coping with specific stresses prevalent in caregiving, and community-based services available for caregivers. Caregivers choose information most relevant to their current circumstances, and can discuss this with their counselor during the sessions. In addition, the IS condition encompasses elements of supportive therapy including empathy and active listening. The intervention consists of 6 total face-to-face sessions lasting 60 minutes each.
89516644|NCT04338555|Experimental|TEAS group|Patients in the TEAS group will receive electrical stimulation of acupoints at Neiguan and Shenmen points for 30min every hour. The stimulation will repeat until the end of surgery.
89516645|NCT04338555|No Intervention|control group|In patients from the control group, the electrodes will only be attached to the corresponding sites, with no TEAS electrical stimulation given during the operation.
89516646|NCT02315495|Experimental|5 mg saxagliptin + 100 mg acarbose|"Acute dosing:~5 mg saxagliptin is given with water, 60 min before a test meal 100 mg acarbose is given with a test meal"
89516647|NCT02315495|Experimental|5 mg saxagliptin|"Acute dosing:~5 mg saxagliptin is given 60 min before a test meal,"
89516648|NCT02315495|Experimental|100 mg acarbose|"Acute dosing:~100 mg acarbose is given with a test meal"
89516649|NCT02315495|No Intervention|control|
89516650|NCT04286139|Experimental|SHAPE Intervention|This group will receive the online group based self-management course develop self-management skills in areas including decision making, symptom management and social interaction and to provide information on the disease process and the development of healthy behaviours in a supportive learning environment to prevent problems that are common in the later stages of the disease. Key themes of the intervention will include positive actions to improve and maintain health, how to talk about the impact of the disease on the life of the person with dementia, fear of losing independence and how to tackle and solve other sensitive issues. Running in parallel there will be an e-learning resource available to the carers which covers the similar material covered in the group sessions for the person with dementia, as well as some additional resources and signposting to help them in their role supporting the person with dementia.
89516651|NCT04286139|No Intervention|Treatment as usual|Participants in the TAU arm will receive normal services such as clinical reviews, psychiatric appointments and other services when needed. With TAU as the comparator condition ensures that participants receive any needed services and enable comparison between current best practice and the new intervention of SHAPE
89516652|NCT02317601|Active Comparator|Methylprednisolone sodium succinate|125 mg iv, as single dose, preoperative.
89516653|NCT02317601|Placebo Comparator|physiological saline|5 mL of Sodium-Chloride 9 mg/ml, Fresenius Kabi
89207599|NCT00971451|Experimental|TENS|continuous TENS for duration of the 1 hour exercise session
89207600|NCT00971451|No Intervention|No intervention|no modality intervention; just exercise
89207601|NCT00857376|Placebo Comparator|placebo|Placebo 2 tabs three times daily
89516654|NCT03862807|Experimental|Patisiran|Participants received patisiran 0.3 milligrams/kilogram (mg/kg) via intravenous (IV) infusion once every 3 weeks (q3w) for 12 months. Dosing was based on actual body weight. For participants weighing 100 kg or more, patisiran was administered at a total dose of 30 mg IV q3w.
89207602|NCT00857376|Experimental|Alpha lipoic acid 1|Alpha lipoic acid 600 mg daily
89207603|NCT00857376|Experimental|Alpha lipoic acid 2|Alpha Lipoic acid 1200 mg daily
89207604|NCT00857376|Experimental|Alpha lipoic acid 3|Alpha lipoic acid 1800 mg daily
89516655|NCT04274751||Transaxillary|TAVI, transaxillary approach
89516656|NCT04274751||Transfemoral|TAVI, transfemoral approach
89516657|NCT03501875|Experimental|CAC Score|CAC Score evaluated by the Agatston method
89516658|NCT03500861|Experimental|Dry Needling|While the patient was sitting, the therapist firstly cleaned the area with alcohol. Then, DN was applied into the active TrPs on the basis of the technique described by Hong (19). The needle remained in the trigger points for 20 minutes. Upon removal of the needle, the area was compressed firmly with a cotton swab for 60 secs. The DN procedure used sterile stainless-steel acupuncture needles of 0.25x40 mm and 0.25x 25 mm dimensions (Hua Long ®). DN was applied three times a week for 2 weeks, in previously diagnosed active trigger points located in the musculature of the head and the neck.
89516659|NCT03500861|Sham Comparator|Sham Dry Needling|In the Sham Dry Needling (SDN) group, three times a week for 2 weeks, the SDN procedure was applied into the adipose tissue located at any area where an active TrPs was absent.
89516660|NCT04262895|Experimental|TTI-0102 2 mg/day|TTI-0102 2 mg/day
89516661|NCT04262895|Experimental|TTI-0102 4 mg/day|TTI-0102 4 mg/day
89516662|NCT04262895|Placebo Comparator|Placebo|Placebo
89516663|NCT02522455|Other|Preterm infants with RDS|
89516664|NCT05101785|Active Comparator|Lidocaine|Lidocain hydrochloride 2 %with epinephrine 1:100000
89516665|NCT05101785|Experimental|Articaine|Articaine chloride 4% with epinephrine 1:100000
89516666|NCT02315573|Experimental|Lidocaine with epinephrine|"Wrist block anesthesia with Lidocaine 1% with epinephrine; 10cc.~Group 1 will receive the same treatment as group 2, except that the wide-awake carpal tunnel release surgery will be performed under Lidocaine anesthesia instead of Bupivacaine anesthesia."
89516667|NCT02315573|Experimental|Bupivacaine with epinephrine|"Wrist block anesthesia with Bupivacaine 0.25% with epinephrine; 10cc.~Group 2 will receive the same treatment as group 1, except that the wide-awake carpal tunnel release surgery will be performed under Bupivacaine anesthesia instead of Lidocaine anesthesia."
89516668|NCT02724241|Experimental|nicotine|use of an e-cigarette filled with liquid with nicotine
89516669|NCT02724241|Experimental|no nicotine|Use of an e-cigarette filled with liquid without nicotine
89516670|NCT02724241|Sham Comparator|sham comparator|Use of empty e-cigarette (sham control)
89516671|NCT02315651|Experimental|Coenzyme Q10|30 children aged 6-12 will consume daily a snack containing 60 mg of CoQ10 for 8 weeks.
89516672|NCT02315651|Placebo Comparator|Placebo|30 children aged 6-12 years will consume an identical snack without CoQ10 for 8 weeks
89516673|NCT06230042|Experimental|Parylene-Coated Catheter|The type of catheter used during a patient's indwelling urinary catheterization is Parylene-Coated Catheter
89516674|NCT06230042|Active Comparator|Silicone Catheter|The type of catheter used during a patient's indwelling urinary catheterization is Silicone Catheter
89516675|NCT06229990|Experimental|Protocol based-furosemide stress test|Furosemide at 1.5 mg/kg intravenously
89516676|NCT06229990|No Intervention|Standard care|Standard CRRT care without furosemide use during treatment.
89516677|NCT06229977|Experimental|PEA plus Treatment as Usual (TAU)|
89516678|NCT06229977|Placebo Comparator|Placebo plus Treatment as Usual (TAU)|
89516679|NCT06229951|Experimental|Collagen supplement group|Patients who have taken 480 mg of hydrolyzed collagen and 20 mg of undenatured type II collagen (in one tablet) twice a day
89516680|NCT06229951|Placebo Comparator|Control group|Control patients will take placebo twice a day
89516681|NCT06229938||Elderly perioperative population|All patients included in the study (minimum 70 years of age on day of surgery)
89516682|NCT06229873|Experimental|App-Based Inspiratory Muscle Strength Training|Using a handheld device, participants will perform 30 breaths a day, six days a week, for six weeks. Training will be guided by a smartphone application.
89516683|NCT06229873|Active Comparator|Clinic-Based Inspiratory Muscle Strength Training|Using a handheld device, participants will perform 30 breaths a day, six days a week, for six weeks. Training will be guided by researchers.
89516684|NCT06229808|Experimental|Multifunctional Birthing Ball group|"Massages will be applied to the experimental group in the first stage of labor for 30 minutes each at the end of the latent, active and transition phases (cervical dilatation 3-4 cm, 5-7 cm, 8-10 cm), respectively.~Perineal heating application is planned to be performed at least twice until the delivery occurs as 20 minutes of application and 20 minutes of tissue rest periods when the second stage of labor begins (the duration of this stage may reach 2 hours in primiparous women)."
89516685|NCT06229808|No Intervention|Control group|No intervention will be applied
89207605|NCT00974025|Experimental|Vitamin C|High-dose Vitamin C in 4 age-based doses will be given in two-daily doses for four weeks
89207606|NCT00974025|Placebo Comparator|Placebo|Placebo will be given in two-daily doses for four weeks
89516686|NCT06229795|Experimental|Intervention|Metformin 500 mg tablet twice daily and Green tea 300 mg film coated tablet three times daily.
89516687|NCT06229795|Active Comparator|Control|Metformin 500 mg tablet twice daily
89516688|NCT06229756||EDOF Toric|Patient submitted to bilateral implantation of Asqelio EDOF Toric IOL
89516689|NCT06229730||Healthy children without hearing or balance problems|Healthy children in the age of 6 months to 10 years, without any known hearing or balance problems and with normal gross motor development are recruited in local nurseries, kinder gardens, and schools.
89516690|NCT06229717||Children with sensorineural hearing loss|Children in the age of 3-10 years with either unilateral or bilateral sensorineural hearing loss is recruited at The Audiologic Clinic at Viborg Regional Hospital, Denmark
89516691|NCT06229704||Children with delayed gross motor development and/or with dizziness/balance problems|Children in the age of 6 months to 10 years with delayed gross motor development and/or with dizziness/balance problems are recruited at The Pediatric Department at Gødstrup Hospital, Denmark.
89207607|NCT00618072|Placebo Comparator|A: Study diet|EMPOWIR dietary intervention food exchange program; 40-45% carbohydrates, 35-40% protein, and 20% fat AND 4 week dosage escalation of placebo metformin, 500 mg/day to a total dose of 2000mg/day; starting dose of placebo rosiglitazone 2mg/day added at weeks 3 and weeks 4 to a total dose of 4 mg/day.
89207608|NCT00618072|Active Comparator|B: Study diet plus Metformin|"Metformin and Rosiglitazone Placebo~EMPOWIR dietary intervention food exchange program; 40-45% carbohydrates, 35-40% protein, and 20% fat AND 4 week dosage escalation of metformin, 500 mg/day to a total dose of 2000mg/day; starting dose of placebo rosiglitazone 2mg/day added at weeks 3 and weeks 4 to a total dose of 4 mg/day."
89207609|NCT00618072|Active Comparator|C: Study diet plus metformin and avandia|"Metformin and Rosiglitazone~EMPOWIR dietary intervention food exchange program; 40-45% carbohydrates, 35-40% protein, and 20% fat AND 4 week dosage escalation of metformin, 500 mg/day to a total dose of 2000mg/day; starting dose of rosiglitazone 2mg/day added at weeks 3 and weeks 4 to a total dose of 4 mg/day."
89207610|NCT00959517|Experimental|CQ|
89207611|NCT00959517|Experimental|CQ+PQ|
89207612|NCT00959517|Experimental|CQ + AS|
89207613|NCT00959517|Experimental|SP|
89207614|NCT00959517|Experimental|SP + PQ|
89207615|NCT00959517|Experimental|SP + AS|
89207616|NCT04008771|Experimental|Severe Disease|Subjects with baseline BCVA between 20/16000 and hand motion (HM). Subjects received 2.0 μM concentration intravitreal injections on each Day 0 and Day 21.
89207617|NCT04008771|Experimental|Moderate to Severe Disease|Subjects with baseline BCVA from 20/60 to 20/16000. The first five (5) to receive 2.0 μM concentration intravitreal at each Day 0 and Day 21, the subsequent five (5) to receive 0.2 μM intravitreal injection at each Day 0 and Day 21, additional subjects (up to ten [10]) to receive one of the dosing options (either 2.0 μM or 0.2 μM) at each Day 0 and Day 21, at the discretion of the Investigator and Sponsor.
89207618|NCT00959595|Experimental|EMLA cream|
89207619|NCT00959595|Placebo Comparator|Placebo cream|A placebo cream identical in appearance and consistency to the experimental cream
89207620|NCT00666926|Experimental|1|
89207621|NCT00666926|Experimental|2|
89207622|NCT00666926|Experimental|3|
89207623|NCT00666926|Experimental|4|
89207624|NCT00862290||sepsis group|Patients who develop sepsis in the ICU
89207625|NCT00862290||SIRS group|Patients who develop SIRS after cardiac surgery with cardiopulmonary bypass
89207626|NCT00862290||control group|normal healthy volunteers
89207627|NCT00974103|Experimental|Chiropractic treatment, exercise|Chiropractic treatment and exercise
89207628|NCT00974103|Experimental|Exercises|Exercise advise
89207629|NCT00971529||lifestyle|70 volunteers were double-blinded, placebo-controlled and randomized into 2 groups (smoking with tea filters or regular filters).
89516692|NCT06229691|Experimental|Healthy|
89516693|NCT06229691|Experimental|Knee osteoarthritis|
89516694|NCT06229665|Experimental|Photobiomodulation (PBM)|The Valeda Light Delivery System will deliver two alternating and sequential treatments of 590 nm and 850 nm for 35 seconds, or a total of 70 seconds; and 660 nm for 90 seconds, or a total of 180 seconds.
89207630|NCT00971529||tea filter|The investigators then recruited 59 volunteers with longer smoking history and stronger desire for quitting smoking for smoking cessation test using the tea filter.
89207631|NCT00865410|Experimental|A|Abrika Bupropion 150 mg Extended-Released Tablet, single dose
89207632|NCT00865410|Active Comparator|B|Wellbutrin SR® 150 mg Extended-Release Tablet, single dose
89207633|NCT00974181|Active Comparator|Conor Medsystems COSTAR™ stent (10 µg Paclitaxel)|Conor Medsystems COSTAR™ stent loaded with the antiproliferative compound paclitaxel (10 µg), pre-mounted on a rapid exchange, percutaneous transluminal coronary angioplasty balloon catheter.
89207634|NCT00974181|Active Comparator|Conor Medsystems COSTAR™ stent (30 µg Paclitaxel)|Conor Medsystems COSTAR™ stent loaded with the antiproliferative compound paclitaxel (30 µg), pre-mounted on a rapid exchange, percutaneous transluminal coronary angioplasty balloon catheter.
89207635|NCT00857610||1|Subjects using 0.1% retinol one day per week
89207636|NCT00857610||2|Subjects using 0.1% retinol three days per week
89207637|NCT00857610||3|Subjects using 0.1% retinol seven days per week
89207638|NCT00857610||4|Subjects using 0.5% retinol one day per week
89207639|NCT00857610||5|Subjects using 0.5% retinol three days per week
89207640|NCT00857610||6|Subjects using 0.5% retinol seven times per week
89207641|NCT00971607|Active Comparator|1|Sevoflurane
89207642|NCT00971607|Placebo Comparator|2|Oxygen
89207643|NCT00865488|No Intervention|1|patients who will be treated in accordance with standard of care
89207644|NCT00865488|Experimental|2|patients for which Adhexil will be applied to prevent/reduce adhesions
89207645|NCT00974337||Shock|"Preterm VLBW infants with shock (BP <3rd centile for gestation and birth weight with at least one of the following:~Prolonged capillary refill time (>3sec)~Reduced urine output (<1 mL/kg/hr)~Metabolic acidosis (Base deficit >5)"
89207646|NCT00974337||No shock|Hemodynamically stable infant with normal blood pressure, capillary refill time, and urine output
89210568|NCT00542919|Experimental|T-Cell|T-Cell (TCL): Peripheral and cutaneous T-cell lymphoma (PTCL, CTCL). Participants received enzastaurin 1125 milligram (mg) loading dose then 500 mg, oral, daily until progressive disease or predefined criteria for discontinuation is met. Participants who progress within the first 28 days may remain on study treatment, provided that the participant is not in need of immediate treatment with another anticancer therapy. Study treatment occurs in cycles. 1 cycle = 28 days
89516695|NCT06229626|Experimental|the reeducation group|"The population included in the reeducation group will benefit, in addition to their usual physiotherapy care (at least 1 session per week), from :~1 group physiotherapy session per week at the ICM or by videoconference from home for 6 weeks~2 sessions per week at home with video support sent by e-mail for 6 weeks~These 3 additional video or group sessions will last 30 min. These sessions will be created and adjusted by a physiotherapist and a Physical and Rehabilitation Medicine doctor. They will include exercises such as :~Stretching~posture~Muscle strengthening~Proprioception~And will be performed in standing, sitting and lying positions."
89516696|NCT06229626|No Intervention|The control group|usual physiotherapy care (at least 1 session per week)
89516697|NCT06229600||Group A|"Patients with an established diagnosis according to the DSM-5 classification (DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS - FIFTH EDITION, 2014) and possible drug therapy (24).~Schizophrenia spectrum disorders and other psychotic disorders~Bipolar disorder and related disorders~Depressive disorders~Anxiety disorders~Obsessive-compulsive disorder and related disorders~Disorders related to traumatic and stressful events~Dissociative disorders~Somatic symptoms and related disorders~Nutrition and eating disorders~Evacuation disorders~Sleep-wake disorders~Sexual dysfunctions~Gender dysphoria~Disruptive behaviour, impulse control and conduct disorder~Substance-related and addiction disorders~Personality disorders~Paraphilia disorders~Autism spectrum disorders~ADHD"
89516698|NCT06229600||Group B|Patients on medication (psychotropic drugs) without a reported/reported specific psychiatric diagnosis in their clinical history.
89516699|NCT06229600||Group C|Patients without a history/reported psychiatric disorder and without specific psychopharmacological therapy.
89516700|NCT06229600||Group D|Patients with a history of diagnosed neurocognitive disorder.
89516701|NCT06229600||Group E|"Patients in the practice without a history/report of psychiatric disorders and without specific psychopharmacological treatment on admission who are diagnosed during admission.~This is a subgroup of the C group."
89516702|NCT06229600||Group F|"Patients in the practice without a history/report of psychiatric disorders and without specific psychopharmacological therapy on admission who are diagnosed during admission for suspected psychiatric/neurocognitive pathology and are discharged with indications for further investigation at the territorial services.~This is a subgroup of the C group."
89516703|NCT06229587|Experimental|furlow with buccinator arm|
89516704|NCT06229561|Experimental|ADM and SCTG|ADM and SCTG
89516705|NCT06229561|Experimental|Acellular Dermal Matrix and soft tissue graft|12participatent in two groups
89516706|NCT06229548|Experimental|SYH2053 SAD experimental group|Subjects in SAD experimental groups will receive a single subcutaneous injection of SYH2053 on Day 1.
89516707|NCT06229548|Placebo Comparator|Placebo SAD group|Subjects in SAD placebo groups will receive a single subcutaneous injection of placebo on Day 1.
89516708|NCT06229509|Experimental|Effective noninvasive ventilation|Alleviate dyspnea (lower Borg Score by 2 points)
89516709|NCT06229509|Sham Comparator|Sham noninvasive ventilation|
89516710|NCT06229496|Experimental|GAS regimen-dose level 1|
89516711|NCT06229496|Experimental|GAS regimen-dose level 2|
89516712|NCT06229496|Experimental|GAS regimen-dose level 3|
89516713|NCT06229457|Experimental|Girls PLAY program|
89516714|NCT06229379|Experimental|"Digital twin patient + Real patient"|"The test was completed in 5 days: the students in the Digital twin patient + Real patient group were trained in history taking using a digital twin patient on Monday, and then took a 15-minute clinical questioning exam using the digital twin patient on Tuesday. After that, they were trained in history taking using a real patient on Wednesday, and then took a 15-minute clinical questioning exam using a digital twin patient on Thursday. Finally, they were tested regards clinical questioning skills using a real patient on Friday."
89516715|NCT06229379|Other|"Real patient + Digital twin patient"|"The test was completed in 5 days: the students in the Real patient + Digital twin patient group were trained in history taking using a real patient on Monday, and then took a 15-minute clinical questioning exam using the digital twin patient on Tuesday. After that, they were trained in history taking using a digital twin patient on Wednesday, and then took a 15-minute clinical questioning exam using a digital twin patient on Thursday. Finally, they were tested regards clinical questioning skills using a real patient on Friday."
89516716|NCT06229366|Experimental|BCR|Patients with BCR prostate cancer, after definitive surgery or radiation therapy, who have PSMA-positive disease and have not yet initiated lifelong hormone therapy.
89516717|NCT06229366|Experimental|mCRPC|Patients with PSMA-positive mCRPC who have exhausted all satisfactory or available approved treatment options.
89516718|NCT06229340|Experimental|Group 1|Leflunomide
89516719|NCT06229340|Experimental|Group 2|Combination of MEK Inhibitor and Hydroxychloroquine ( Plaquenil)
89516720|NCT06229340|No Intervention|historical control group|standard therapy
89516721|NCT06229301||Experienced-nomogram Group|Patients who underwent Small incision lenticule extraction (SMILE) from March 2014 to October 2018 in Refractive Surgery Center of Tianjin Eye Hospital and had at least three months of postoperative follow-up were included in this group. The Nomogram were based on experience of the surgeon.
89516722|NCT06229301||AI-nomogram Group 1|Patients who underwent Small incision lenticule extraction (SMILE) from November 2018 to May 2021 in Refractive Surgery Center of Tianjin Eye Hospital and had at least three months of postoperative follow-up were included in this group. AI-predicted nomogram was obtained and used on patients who underwent surgery.
89516723|NCT06229301||AI-nomogram Group 2|Patients who underwent Small incision lenticule extraction (SMILE) from January 2023 in Refractive Surgery Center of Tianjin Eye Hospital and had at least three months of postoperative follow-up were included in this group. The datasets used to train AI(Artificial Intelligence) models have been continuously updated for better accuracy since 2018, the newest AI-predicted nomogram was obtained and used on patients who underwent surgery.
89516724|NCT06229301||Good Surgical Effect and Changes of Biological Parameters|-0.50D < spherical equivalent (SE) < 0.50D
89516725|NCT06229301||Poor Surgical Effect and Changes of Biological Parameters|spherical equivalent (SE) <-0.50D or >0.50D
89516726|NCT06229288|Experimental|Amoxicillin|"Amoxicillin is an antibiotic treatment approved in France and in many countries.~The investigational medicinal products (IMPs) are:~- Amoxicillin capsules : Formulated as a 500 mg capsules for PO administration (commercially available). Description in IMP file.~Amoxicillin capsules contain compendial excipients listed in the Summary Product Characteristics (SmPC), current version, and are kept in a cool dry place where the temperature stays at 15- 25°C.~- Amoxicillin IV vials : Formulated as a 1000 mg vial for IV administration (commercially available). Description in IMP file.~Amoxicillin IV vials contain compendial excipient listed in the Summary Product Characteristics (SmPC), current version, and are kept in a cool dry place where the temperature stays at 15-25°C."
89516727|NCT06229288|Active Comparator|Amoxicillin/clavulanate|"Amoxicillin/clavulanate is recommended by French and European guidelines for the treatment of patients aged 65 years or older, and hospitalized in a non-ICU ward, as reported above.~The active comparators (IMPs) are:~- Amoxicillin/clavulanate tablets: Formulated as a tablet for PO administration (commercially available). Description in IMP file. Tablets contain 500 mg of amoxicillin trihydrate and 62.5 mg of clavulanate. Amoxicillin/clavulanate tablets contain compendial excipients listed in the Summary Product Characteristics (SmPC), current version, and are kept in a cool dry place where the temperature stays at 15-25°C.~- Amoxicillin/clavulanate vials Vials contain 1000 mg of amoxicillin and 200 mg of clavulanate. Description in IMP file.~Amoxicillin/clavulanate vials contain compendial excipients listed in the Summary Product Characteristics (SmPC), current version, and are kept in a cool dry place where the temperature stays at 15-25°C"
89516728|NCT06229275|Experimental|Pap smear collection using the Personal Pap Smear (PPS) Device|
89516729|NCT06229275|Active Comparator|Pap smear collection using the Rovers Cervex-Brush|
89516730|NCT06229262|Active Comparator|Mango Group|Participants in the Mango group will consume 1.5 cups of mangos for 12 weeks
89516731|NCT06229262|No Intervention|control group|The control group will receive no dietary intervention. they will follow usual diet and abstain from eating mangos
89516732|NCT06229249|Experimental|Experimental group|The participants in this group received carpal ligament self-myofascial stretching along with conventional physical therapy.
89516733|NCT06229249|Active Comparator|Control group|The participants in this group received conventional physical therapy.
89516734|NCT06229197|Experimental|Billroth II with Braun Reconstruction|
89516735|NCT06229197|Active Comparator|Billroth II Reconstruction|
89516736|NCT06229171|No Intervention|usual practice|
89516737|NCT06229171|Experimental|vocal assistant|
89516738|NCT06229132|Other|LGBTQ-affirmative CBT treatment|LGBTQ-affirmative CBT includes client case conceptualizations to personalize treatment delivery and functional relevance. Modules raise awareness of the impact of sexual minority stress on mental, behavioral, and sexual health; instill cognitive flexibility toward minority stress cognitions; and reduce maladaptive avoidance tendencies rooted in minority stress. The treatment is guided by six principles: (1) normalizing mood and anxiety as a common response to LGBTQ-related stress; (2) challenging persistent, inflexible LGBTQ-related stress-induced cognitions; (3) encouraging assertive behavior and open self-expression in safe situations to effectively cope with the consequences of LGBTQ-related stress; (4) validating LGBTQ clients' unique strengths; (5) building authentic relationships as an essential resource for LGBTQ people's mental health; and (6) recognizing intersectional identities as a source of stress and resilience. The intervention consists of 16 sessions delivered on Zoom.
89516739|NCT06229106|Active Comparator|Symfony IOL|The Symfony IOL is a lens designed to provide high quality vision up tp 26 inches reducing the need for glasses after routine cataract surgery in patients with or without astigmatism.
89516740|NCT06229106|Active Comparator|Vivity IOL|The Vivity IOL is a lens that provides extended range of vision ranging from distance to near reducing the need for glasses after routine cataract surgery in patients with or without astigmatism.
89516741|NCT06229067|Experimental|adebrelimab + VEX|Adebrelimab at a dose of 1200 mg via intravenous infusion every three weeks, in combination with metronomic oral vinorelbine 20 mg every other day + cyclophosphamide 50 mg daily + capecitabine 500 mg three times daily
89516742|NCT06229067|Active Comparator|VEX|Metronomic oral vinorelbine 20 mg every other day + cyclophosphamide 50 mg daily + capecitabine 500 mg three times daily
89516743|NCT06229041|Experimental|Total Neoadjuvant Treatment ＋Immunotherapy|
89516744|NCT06229041|No Intervention|Total Neoadjuvant Treatment|
89516745|NCT06229028|Experimental|verbal explanation group|The treatment by the diagnosis will be explained under the guidance of the therapist and will be repeated at each appointment to the first group.
89516746|NCT06229028|Experimental|patient information and exercise forms group|Treatment by the diagnosis will be provided with patient information and exercise forms containing visual and written information in addition to an explanation under the guidance of the therapist for the second group.
89516747|NCT06229028|Experimental|video recording group|Treatment by diagnosis will be provided with patient information containing visual and written information, exercise forms, and video recording, in addition to narration under the guidance of the therapist for the third group.
89516748|NCT06228989|Experimental|Extraction therapy|"Patients exclusive treated with extraction therapy of any first permanent molars due to severe MIH.~Affected first permanent molars were dignosed with MIH degree 4-6."
89544580|NCT04650087|Placebo Comparator|Placebo|Drug: Placebo Participants will be given study medication at the time of discharge from the hospital. Participants will take the Placebo twice a day, once in the morning and once in the evening, for 30 days. Participants will be contacted (electronic or telephone) 2 days after starting the study medication and contact will continue up to day 90 after starting study treatment. Follow up will be through electronic and/or telephone contact depending on the participant's preference, compliance, and medication adherence. Participants will be queried for any clinically relevant endpoints, especially major bleeding or a need to seek healthcare attention for any reason. Follow-up will occur from the time of discharge and through the 30 day study period, with contacts 2 days, 10 days, 20 days, and 30 days after discharge. Two additional study contacts will take place 45 days and 90 days after discharge.
89544581|NCT02434367|Experimental|Arm A|Women randomized to the WWE program will receive a workbook, and a daily walking log, the latter to be completed during the study.
89544582|NCT02434367|No Intervention|Arm B|Patients randomized to the usual care arm will receive a document with information on exercise to improve fatigue during radiotherapy
89544583|NCT02434289|Experimental|Resistance exercise and protein products|Practice intervention trial including resistance exercise training and intake of dietary protein products in (frail) elderly, implemented by health care professionals.
89544584|NCT02434211|Experimental|Questionnaire and Focus group|The children complete the questionnaire to better know their knowledge and cancer individual conceptions. Then, they will be interviewed during one hour in groups for the pre-testing phase. And after, for the testing phase, they just complete the questionnaire.
89544585|NCT03188159|Experimental|IV Vinorelbine|IV Vinorelbine 25mg/m2
89544586|NCT05528601|Experimental|users|app users
89544587|NCT05528601|No Intervention|non-users|app non-users
89544588|NCT05532579|Experimental|Invasive Physiotherapy|
89544589|NCT05532579|Placebo Comparator|Sham Group|
89544590|NCT03191669||MS patients|Single group of patients with MS attending an outpatient MS clinic or hospitalization
88961416|NCT02008994|Experimental|Genomic and Proteomic Profiling|"Reverse Phase Protein Microarray will be used to determine how often there are specific proteins that could make your tumor susceptible or resistant to treatment.~Immunohistochemistry will look for specific markers of disease in your DNA.~RNA sequencing will be used to help doctors and scientists understand how your genes are working.~Low pass whole genome and exome sequencing will be used to help identify variants in your DNA."
88961417|NCT02009007|Experimental|dopamine|dopamine is administered to maintain systolic blood pressure in the range of 80-120% of baseline during operation
88961418|NCT02009007|Experimental|phenylephrine|Phenylephrine is administered to maintain systolic blood pressure in the range of 80-120% of baseline during operation
88961419|NCT02009033|Experimental|Ringer's lactate|Fluid therapy during operation
89544591|NCT05532501|Active Comparator|Oral Oxytocin|Administer oxytocin (24 IU) orally
89544592|NCT05532501|Active Comparator|Intranasal Oxytocin|Administer oxytocin (24 IU) intranasally
89544593|NCT05532501|Placebo Comparator|Oral placebo|Administer placebo orally (identical ingredients, except the active agent)
89544594|NCT05532501|Placebo Comparator|Intranasal placebo|Administer placebo intranasally (identical ingredients, except the active agent)
89544595|NCT03188237|Experimental|AfyaJamii facility|Facilities using AfyaJamii
89544596|NCT03188237|No Intervention|Referent facility|Facilities using Focused Antenatal Care Individual Model
89544597|NCT05524857|Experimental|Fedratinib 300 mg|Cohort 1: 300 mg of Fedratinib by mouth, once daily during each 28-day cycle
88961420|NCT02009059||Non-invasive temperature in hypothermia|Adult patients undergoing elective thoracic surgery in deep hypothermia
88961421|NCT02009072|Experimental|Sutured limbal conjunctival autograft|Sutured limbal conjunctival autograft was done for patients of group 2 after pterygium excision
88961422|NCT02009072|Experimental|Suturless and glue free Limbal conjuctival autograft|Sutureless and glue free Limbal conjunctival autograft was done for patients of group 1 after pterygium excision
88961423|NCT02009085||Individuals undergoing skin excision.|Skin lesions are under suspicion for skin cancer.
89544598|NCT05524857|Experimental|Fedratinib 400 mg|Cohort 2: 400 mg of Fedratinib by mouth, once daily during each 28-day cycle
89544599|NCT05524779|Experimental|BTL-785-7 Treatment|Treatment of wrinkles with the BTL-785-7 applicator to the BTL-785F system.
89544600|NCT03191357||TBI/no PH|"Active and reserve component SMs along with others who are eligible for care in the DoD healthcare system, who have experienced traumatic brain injury (TBI) without psychological health (PH) concerns.~no intervention/Observational"
89544601|NCT03191357||TBI with PH|"Active and reserve component SMs along with others who are eligible for care in the DoD healthcare system, who have experienced traumatic brain injury (TBI) and also have psychological health (PH) concerns.~no intervention/Observational"
89544602|NCT03191357||PH only|"Active and reserve component SMs along with others who are eligible for care in the DoD healthcare system, who have experience psychological health (PH) concerns.~no intervention/Observational"
89544603|NCT03191357||Controls|"Control participants may include (i) those with exposure to primary blast without the development of TBI, (ii) those with physical injuries without experiencing head injury, and (iii) healthy participants (non-injured, non-TBI, non-PH).~no intervention/Observational"
89544604|NCT05528523|Other|Writing a clinical narrative|The participants had to write a clinical narrative regarding a significant encounter with a patient.
89544605|NCT03188003|Experimental|Stabilization|"This group will undergo 10 Pilates sessions with a focus on lumbo-pelvic stabilization exercises approach.~Intervention administered: Exercise Movement Techniques (Pilates Exercise) based on stabilization"
89544606|NCT03188003|Experimental|Mobilization|"This group will undergo 10 Pilates sessions with a focus on lumbo-pelvic mobilization exercises approach.~Intervention administered: Exercise Movement Techniques (Pilates Exercise) based on mobilization"
89544607|NCT05528445||Patients|Patients who are assessed by the clinical staff using Mini-Mental State Exam (MMSE) and Montreal-Cognitive-Assessment-Test(MoCA)
89544608|NCT02440529|Active Comparator|(Intervention Group)|The discussion about how smoking cigarettes impacts patient orthopaedic management plus aid
89544609|NCT02440529|Active Comparator|(Control Group)|The discussion about how smoking cigarettes impacts patient orthopaedic management.
88961424|NCT02009098|Active Comparator|præoperativ antibiotic|iv Cefuroxime 1,5g administered 15-60 minutes before incision
88961425|NCT02009098|Active Comparator|postoperativ antibiotic|iv Cefuroxime 1,5g administered after umbilical cord clamping
88961426|NCT02009111|Experimental|Couple CARE for Parents|Couple CARE for Parents is a couple-focused intervention that addresses interpersonal processes within relationships and promotes healthy relationship and parenting skills among couples with a newborn. Couple CARE for Parents uses a highly disseminable model (i.e., home-visitation and video- and telephone-assisted skills training) developed in Australia.
88961427|NCT02009111|Other|Wait-list control|The control group will be wait-listed until after the 24-month assessment, at which point they are eligible to receive Couple CARE for Parents (tailored for their children's ages).
88961428|NCT02009124|Experimental|Stem cell|autologous bone marrow mononuclear cell transplantation
88961429|NCT02009124|No Intervention|Control|Stem cell therapy is not done for this group of spinal cord injury patients
88961430|NCT02009137|Experimental|EVERA|EVERA- korean ESTES system, apply for 12 weeks
88961431|NCT02009137|Active Comparator|ESTES|ESTES apply for 12 weeks
88961432|NCT02009150||Women at high risk for breast cancer|Proven carriers of deleterious BRCA1 or BRCA2 mutations Or Women that were found to have a lifetime risk of developing breast cancer greater or equal to 20% based on Tyrer-Cuzick, Gail or Clause risk models.
88961433|NCT02009189|Placebo Comparator|Control|Saline flush
88961434|NCT02009189|Active Comparator|2% Taurolidine lock|Catheter lock with 2% Taurolidine
88961435|NCT02009189|Active Comparator|1.35% Taurolidine with citrate|Catheter lock with 1.35% Taurolidine + citrate
88961436|NCT02009202|Active Comparator|picosulphate|Picosulphate is given orally
88961437|NCT02009202|Active Comparator|polyethylene glycol|Polyethylene glycol is given orally
88961438|NCT02009215|Experimental|Intermittent preventive treatment (IPT)|Dihydroartemisinin-piperaquine (DP)
89516749|NCT06228989|Experimental|Restorative therapy|"Patients exclusive treated with restorative therapy of any first permanent molars due to severe MIH.~Affected first permanent molars were dignosed with MIH degree 4-5."
89516750|NCT06228989|Experimental|Extraction therapy and Restorative therapy|"Patients undergoing combined treatment of both extraction therapy and restorative therapy of their first permanent molars due to MIH.~Affected first permanent molars treated with extraction therapy were dignosed with MIH degree 6.~Affected first permanent molars treated with restorative therapy were dignosed with MIH degree 4-5."
89516751|NCT06228989|No Intervention|Control patients|Patients devoid of any enamel developmental defects, attending the Public Dental Service in Region Västra Götaland, constituted a basis for the control patients. These controls were matched in terms of gender, age, and socio-economic factors, with each study patient paired with seven potential control patients.
89516752|NCT06228976|Experimental|Intervention Arm|One or two tailored messages will be sent to participants everyday at designated time for 12 weeks
89516753|NCT06228976|Active Comparator|Education Arm|One tailored message will be sent to participants everyday at designated time for 12 weeks
89544610|NCT05524701|Experimental|Sleep Restriction Condition|Participants will be asked to restrict their sleep duration to a maximum of four hours per night (3 am to 7 am) for the two nights prior to the measurement day.
89544611|NCT05524701|Experimental|Normal Sleep Condition|Participants will be asked to sleep for at least eight hours per night (11 pm to 7 am) for two nights prior to the measurement day.
89544612|NCT02434133||Case (Group A)|Group A (Immunomodulator) currently taking azathioprine or 6- mercaptopurine (Blood Draw)
89544613|NCT02434133||Case (Group B)|"Group B (Biologic group) currently taking anti-TNF therapy (infliximab, golimumab, adalimumab, or certolizumab).~(Blood Draw)"
89544614|NCT02434133||Case (Group C)|Group C (Combination therapy) currently taking anti-TNF therapy and an immunomodulator (including methotrexate) (Blood Draw)
89544615|NCT02434133||Control|"Individuals will be obtained from patients without an IBD diagnosis coming to Digestive Health Center for endoscopic procedures or clinic visits.~(Blood Draw)"
89544616|NCT03191045||Healthy participants|A group of 21 healthy adult participants studied twice (test-retest)
89544617|NCT05327439|Experimental|Electronic Cigarette|Participants in this experimental condition will be provided with a 4th generation electronic cigarette device and disposable cartridges.
89544618|NCT05327439|Experimental|Nicotine Pouch|Participants in this experimental condition will be provided with nicotine pouches.
89544619|NCT05327439|No Intervention|Smoking As Usual|Participants in this assessment-only condition will continue smoking as usual.
89544620|NCT05528367|Experimental|CRT with Tirelizumab|"Chemotherapy+Tirelizumab:PS regimen:S-1:BSA <=1.25 m2 ,80 mg daily; 1.25 m2 <BSA <1.5 m2,100 mg daily; BSA>=1.5 m2 ,120 mg daily.~Nab-PTX:preoperation：130mg/m2,d1，8，q3w；adjuvant:100mg/m2,d1，8，q3w； Tirelizumab：200mg d1 q3w.~Concurrent Chemoradiotherapy:~Radiation: 45-50Gy/25Fx;During radiation: Nab-PTX:100mg qw,Tirelizumab：200mg d1 q3w.~Chemotherapy+Tirelizumab:PS regimen:S-1:BSA <=1.25 m2 ,80 mg daily; 1.25 m2 <BSA <1.5 m2,100 mg daily; BSA>=1.5 m2 ,120 mg daily.~Nab-PTX:preoperation：130mg/m2,d1，8，q3w； Tirelizumab：200mg d1 q3w.~We will evaluate whether the tumor could be resectable through CT scan and Endoscope after two cycles of Chemotherapy+Tirelizumab and CRT.If it could be resctable,three cycles of adjuvant chemotherapy+Tirelizumab will be arranged;If not,another three cycles of chemotherapy+Tirelizumab will be arranged，then evaluate again."
89544621|NCT03191279||First aid correct|Patient has received first aid according to local guidelines for all indicated first aid measures from bystanders on scene of accident when the first ambulance arrives
89544622|NCT03191279||First aid attempted|Bystanders have attempted first aid for indicated first aid measures, but measures have been incorrectly performed according to local guidelines
89544623|NCT03191279||No first aid|Indicated first aid measures have not been carried out when the first ambulance arrives on scene
89544624|NCT05528289|Active Comparator|HFNC 30 L/min with conventional symmetric nasal cannula|The patients will be asked to breathe with HFNC at flow of 30 L/min with standard interface
89544625|NCT05528289|Active Comparator|HFNC 30 L/min with new asymmetric nasal cannula|The patients will be asked to breathe with HFNC at flow of 30 L/min with the new asymmetric nasal cannula
89544626|NCT02433821|Experimental|Pilates Group|The group will realize 2 classes per week, lasting one our, of Pilates under supervision of a trained instructor. The training program will last 3 months.
89544627|NCT02433821|No Intervention|Control group|The patients will keep the drug treatment and will be keep in a waiting list. After the 180 days of study the will be invited to realize the Pilates training.
89544628|NCT03187691|Experimental|CAMB 200 mg|200 mg CAMB (MAT2203) Oral Amphotericin B
89544629|NCT03187691|Experimental|CAMB 400 mg|400 mg CAMB (MAT2203) Oral Amphotericin B
89544630|NCT03187691|Experimental|CAMB 800mg|800 mg CAMB (MAT2203) Oral Amphotericin B
89544631|NCT02433899|Experimental|Test - Microsurgical semilunar flap|"Semilunar coronally repositioned flap performed under magnification with a surgical microscope.~SLI was carried out following the outline of the gingival margin with a microsurgical blade under (8x) magnification. An ISI was performed mid-facially. Then, a split-thickness dissection was performed from the initial incision coronally until connecting to the ISI. The mid-facial tissue was completely released, positioned coronally to the CEJ and held in place against the tooth. A cyanoacrilate adhesive (CAA) was applied over the post-surgical gingival margin and tooth enamel to stabilize the flap."
89544632|NCT02433899|Active Comparator|Control - Conventional Semilunar flap|Semilunar coronally repositioned flap performed without magnification. A semilunar incision (SLI) was carried out with a 15c surgical blade. An ISI was performed mid-facially. Then, a split-thickness dissection was performed from the initial incision coronally until connecting to the ISI. The mid-facial tissue was completely released, positioned coronally to the CEJ and held in place against the tooth. A cyanoacrilate adhesive (CAA) was applied over the post-surgical gingival margin and tooth enamel to stabilize the flap.
89544633|NCT03191123|Active Comparator|Hepatic resection|Indications for Hepatic resection were the presence of appropriate residual liver volume determined by volumetric computed tomography and lack of hepatic encephalopathy.
89544634|NCT03191123|Experimental|Transarterial Chemoembolization(TACE)|Transarterial Chemoembolization is performed in less than one week after clinical diagnosis.
89544635|NCT05184855|Experimental|Blueberry|26 g freeze-dried blueberry powder per day or approximately one cup fresh blueberries equivalent; two weeks intake.
89544636|NCT05184855|Placebo Comparator|Placebo|26 g placebo powder per day matched for color, taste, aroma; two weeks intake.
89544637|NCT05532267|Experimental|Test Product (T)|subjects were administered a single film-coated tablet of 750 mg Ciprofloxacin with approximately 240 ml water after an overnight fast of 10 hours
89544638|NCT05532267|Active Comparator|Reference Product (R)|subjects were administered a single film-coated tablet of 750 mg Ciprofloxacin with approximately 240 ml water after an overnight fast of 10 hours
89544639|NCT03191201|Active Comparator|Ferric carboxymaltose arm|Ferric carboxymaltose (FCM), 1000 mg iron element will be administered once by drip infusion (Intravenous route). FCM will be diluted in 250 mL of a commercially available sterile 0.9% sodium chloride solution prior to administration. Infusion time will be 15 minutes.
89516754|NCT06228976|Active Comparator|Control arm|One tailored message will be sent to participants everyday at designated time for 12 weeks
89516755|NCT06228963|Experimental|Experimental group|Triple therapy for eradication of Helicobacter Pylori+Orelabrutinib
89516756|NCT06228963|Active Comparator|Control group|Triple therapy for eradication of Helicobacter Pylori
89516757|NCT06228950|Experimental|Intervention Group|A structured MBSR training for this study will be given to the intervention group of students with visual impairment. The intervention will include body scan, sitting meditation, yoga, breathing exercises, guided mindfulness, loving kindness, etc exercises to improve the emotional and behavioural problems of students with visual impairment.
89516758|NCT06228950|No Intervention|Wait-list Control Group|The Wait-list control group will receive no intervention. This group will serve as a comparison group to evaluate the specific effect of the mindfulness based intervention.
89516759|NCT06228898||patients with type 2 diabetes with improved HbA1c|Participants with type 2 diabetes with a reduction in HbA1c ranging from 5% to 11.6% in three months time (n=56)
89516760|NCT06228898||patients with type 2 diabetes with a better HbA1c|Group 2 comprised individuals with type 2 diabetes who exhibited a decline in HbA1c levels ranging from 2.8% to 4.9% in three months time (n=56).
89516761|NCT06228898||patients with type 2 diabetes with little or no HbA1c change|Group 3 comprised 58 participants who exhibited a decrease in HbA1c levels ranging from 2.7% to 0%, in addition to an increase ranging from 0.1% to 3.4%.
89516762|NCT06228885||Children with Autism Spectrum Disorder|
89516763|NCT06228885||Typical developed children|
89516764|NCT06228872|Experimental|Experimental Group|Participants will receive Computerized Cognitive Training and anodal tDCS daily for one month. Stimulation will consist of 20 min of anodal 2mA tDCS stimulation over the DLPFC, followed by 15 min of computerized cognitive training.
89516765|NCT06228872|Sham Comparator|Control Group|Participants will receive Computerized Cognitive Training and sham tDCS daily for one month. Sham stimulation will consist of 60 seconds of anodal 2mA tDCS stimulation over the DLPFC, followed by 19 mins of no current delivery. The same 15 min of computerized cognitive training will be provided after the end of the Sham Stimulation.
89516766|NCT06228859|Experimental|Group I (LOA): Patients were given overdentures with locator attachments.|locater groups or overdenture attachment
89516767|NCT06228859|Experimental|Group II (TIA): Patients were given overdentures with TITACH attachment.|TITACH groups for overdenture attachment
89516768|NCT06228833|Experimental|Test group|
89516769|NCT06228833|Active Comparator|Control group|
89516770|NCT06228820|Experimental|Aspirin Arm|Healthy patients will then undergo at least a 2-week course of 81mg of Bayer Aspirin per oral daily, followed by platelet function testing. The patients will then undergo a washout period of 2 weeks, followed by another 2-week course of 81mg Vazalore Aspirin per oral daily, followed by a second round of platelet function testing.
89516771|NCT06228794||Newly diagnosed multiple myeloma cohort|Participants who meet the multiple myeloma diagnostic criteria of IMWG are eligible.
89516772|NCT06228781|Experimental|Hematopoietic Stem Cell Transplantation|Patients will undergo stem cell transplantation for the treatment of refractory MS
89516773|NCT06228755|Experimental|Training, Coaching, and Orientation|Clinic personnel will receive training for delivering integrative medicine group visits (IMGV) and ongoing coaching in delivering IMGV for patients with chronic pain. Clinic patients will participate in orientation and the 9-week IMGV.
89516774|NCT06228716|Experimental|Experimental|Subcutaneous biological drug self-administration training was given by the researcher in two stages, theoretical and practical, face to face. Power point presentation and training brochure were used in theoretical training. The practical training given after the theoretical training was given using the Hybrid simulation method. The Wearable Subcutaneous Injection Hybrid Simulator developed by the researcher was worn by the individuals after being informed about its purpose and function. A medicine pen similar to their own medicine pens (demo pen without medicine), dry cotton, alcohol swab (similar to the ones that come in medicine pen boxes), and a small notepad and pen were left in a clean medicine tray on a clean table. Afterwards, they were expected to apply the subcutaneous application step by step as explained to them. Each application step they made incorrectly was corrected and repeated with the support of the researcher.The training took approximately 40 minutes.
89516775|NCT06228716|Other|Kontrol Group|Subcutaneous biological drug self-administration training was given theoretically face to face by the researcher using a power point presentation and training brochure. The training lasted approximately 25 minutes and was given in the same room where the experimental group received training.
89516776|NCT06228690|Experimental|Gold Fish exercises|Gold Fish exercises for the flexibility of TMJ that will target the Jaw muscles.
89516777|NCT06228690|Experimental|Cervico-thoracic postural correction training.|Cervico-thoracic postural correction training for upper thoracic and neck muscles.
89516778|NCT06228690|Active Comparator|Conventional PT treatment|Conventional PT including Hot Pack for 10mins, Active-Passive neck Stretching Exercise + jaw Isometric Exercises.
89516779|NCT06228677||Adrenal Venous Sampling Group|Adrenal veinous sampling in patients with primary aldosteronism who underwent percutaneous selective adrenal artery embolization
89516780|NCT06228677||Peripheral Venous Sampling Group|Peripheral veinous sampling in patients with primary aldosteronism who underwent percutaneous selective adrenal artery embolization
89516781|NCT06228651|Active Comparator|Tourniquet|The leg with the tourniquet which was inflated during surgery
89516782|NCT06228651|Active Comparator|Control|The leg without the tourniquet which was not inflated during surgery
89516783|NCT06228612|Active Comparator|group I:vacuum therapy|group I:vacuum therapy VT:patients who were diagnosed with TMJ osteoarthritis. The patients received Isolated vacuum therapy VT
89516784|NCT06228612|Active Comparator|group II: maxillary stabilization splint (MSS)|group II, patients who were diagnosed with TMJ osteoarthritis. The patients received stabilization splint therapy (STT)
89516785|NCT06228612|Active Comparator|group III: vacuum therapy VT and maxillary stabilization splint (MSS)|group III: patients who were diagnosed with TMJ osteoarthritis. The patients received combined VT and SST.
89516786|NCT06228599|Experimental|Molecular Tumor Board (MTB)-recommended matched therapy|The MTB, a multidisciplinary group composed of medical oncologists (including those with expertise in precision oncology), surgical oncologists, and a pathologist, convenes periodically to discuss and recommend an individualized treatment plan that targets specific molecular alterations (e.g., genomic mutations) found in the patient's cancer while considering patient clinical and laboratory factors.
89516787|NCT06228547||POI|Woman aged 18 years and older, diagnosed with POI following ESHRE 2016 criteria
89516788|NCT06228534|Experimental|tunneling technique with connective tissue|GRUPO TEST: THE RECIPIENT BED OF THE CONNECTIVE GRAFT, THE TUNNELING TECHNIQUE IS PREPARED.
89516789|NCT06228534|Experimental|coronal advancement flap technique|GRUPO CONTROL: THE RECIPIENT BED OF THE CONNECTIVE GRAFT, THE CORONAL ADVANCEMENT FLAP TECHNIQUE IS PREPARED
89516790|NCT06228495|Experimental|Social Support|This version of the intervention prompted users to engage in social support which is thought to buffer against the negative effects of stress. This effect is present in occupational settings, with several studies indicating that social support plays an important role in preventing burnout among nurses. Furthermore, interventions targeting social support in the workplace suggest that these have positive effects on mental health. Sample strategies included asking for help from co-workers, listening with compassion, and sharing authentic emotions.
89516791|NCT06228495|Active Comparator|Physical Activity|This version of the interventions promoted an increase of physical activity in daily life. Physical activity is well-known to improve various health outcomes similar to our outcomes of interest, for instance reducing stress and burnout symptoms. Additionally, physical activity interventions in the workplace are widely used and have been found effective in many studies. Sample strategies included taking walks, going to the gym, and using the stairs instead of the elevator.
89516792|NCT06228495|Active Comparator|Psychological Strategies|This version of the intervention promoted a variety of psychological strategies for stress reduction. Sample strategies included sleep quality improvement tips, mindfulness, and work detachment - evidence-based strategies that have a positive effect on outcomes of interest. Workplace interventions targeting these kinds of strategies have been found to be effective.
89516793|NCT06228443|Experimental|Leflunomide 20 mg Tablets (Test Drug)|Leflunomide 20 mg Tablets ,1 x 20 mg, single dose fasting.
89516794|NCT06228443|Active Comparator|ARAVA® 20 mg Tablets (Reference Drug)|ARAVA™ 20 mg Tablets,1 x 20 mg, single dose fasting.
89516795|NCT06228430|Experimental|Acyclovir 800 mg (Test Drug)|Generic Acyclovir 800 mg Tablet
89516796|NCT06228430|Active Comparator|ZoviraxTM 800 mg Tablet (Reference Drug)|ZoviraxTM 800 mg Tablet
89516797|NCT06228404|Experimental|Enhanced autologous PSMA-CAR T:|Enhanced autologous PSMA-CAR T is an electrotransfer system based on non-viral transposons that integrates the CAR gene into the genome of host cells by electrotransfer using PMSA as a target, while this CAR vector co-expresses enhanced factors and plays a strong regulatory role in innate and adaptive immunity.
89516798|NCT06228391|Experimental|Ketamine|Twice a week ketamine IV 0.5 mg/kg
89516799|NCT06228391|Active Comparator|Midazolam|Twice a week midazolam IV 0.045 mg/kg
89516800|NCT06228378|Experimental|Unstable ankle|Unstable ankle
89516801|NCT06228378|Active Comparator|Stable ankle|
89516802|NCT06228365|Active Comparator|usual neuroleptanalgesic treatment|- Group 1: local anaesthesia by tumescence + neuroleptanalgesia
89516803|NCT06228365|Experimental|use of a device incorporating virtual reality software|- Group 2: local anaesthesia by tumescence with virtual reality software
89516804|NCT06228352||Ulcerative colitis flare-up|Patient with ulcerative colitis, whatever the extent, except isolated proctitis (<5 cm), diagnosed for more than 3 months, presenting with a flare of UC defined by a Pediatric Ulcerative Colitis Activity Index (PUCAI) score between 35 and 65.
89516805|NCT06228352||Ulcerative colitis remission|Patient with ulcerative colitis, whatever the extent, except isolated proctitis (<5 cm), diagnosed for more than 3 months and in clinical remission defined by a Pediatric Ulcerative Colitis Activity Index (PUCAI) score under 10.
89516806|NCT06228352||Controls|Paediatric patients (<18 years) without chronic liver disease or chronic digestive disease (celiac disease, inflammatory bowel disease, chronic diarrhea) and hospitalized for an endoscopic examination to investigate abdominal pain, gastroesophageal reflux or polyposis.
89516807|NCT06228339|Experimental|Alfuzosin Hydrochloride 10 mg Prolonged-release Tablets|Alfuzosin Hydrochloride 10 mg Prolonged-release Tablets (Test Drug)
89516808|NCT06228339|Active Comparator|Xatral® XL 10 mg|Xatral® XL 10 mg (Alfuzosin Hydrochloride 10 mg Prolonged-release Tablets)(Reference Drug)
89516809|NCT06228274||ARTHRUM 2.5% single injection|
89516810|NCT06228235|Experimental|Active rTMS|There is a single arm in this open-label pilot study. All participants will receive active rTMS paired with different types of behavioral priming (upregulation of craving, downregulation of craving, no regulation of craving).
89516811|NCT06228222||patients|patients with lupus nephritis who will be admitted to Rheumatology and Nephrology Units, Internal Medicine Department, Assuit university hospitals, Egypt. (classified according to the 1997 American College of Rheumatology or Systemic Lupus Collaborating Clinics criteria) with biopsyproven LN (classified according to The revised ISN/RPS 2018mhistopathological classification system).
89516812|NCT06228131||subjects who provided early pregnancy urine samples|
89516813|NCT06228092|Active Comparator|neostigmine/glycopyrrolate group|neostigmine/glycopyrrolate 50 mikrogr/kg
89516814|NCT06228092|Active Comparator|Sugammadex group|Sugammadex 2 mg/kg
89207647|NCT00862368|Experimental|PAM -Enhanced/Asthma|The PAM-Enhanced/Asthma group: 2 in-home visits that included asthma education consistent with NIH recommendations (NIH, NAEPP, 1997) and smoking cessation counseling. Consistent with Motivational Interviewing (MI), smoking was broached in a non-judgmental manner and as another trigger for asthma. Feedback was given on expired air Carbon Monoxide (CO) levels of the smoker (to increase personal perception of risk) and the amount of smoke exposure to the child (to increase risk perception to the child). 6 phone calls were then provided over the next 4 months that focused on asthma education, a second round of feedback on the child's ETS exposure, and smoking cessation counseling. MI was used at all contacts. Free nicotine patch tx was given if they were ready to quit within 30 days.
89516815|NCT06228079|No Intervention|The control group|Patients in the control group would go through observation and follow-up after recurrent endoscopic surgery.
89516816|NCT06228079|Experimental|The experimental group|Patients in the experimental group would be implemented with adjuvant therapy including chemotherapy and immunotherapy after endoscopic surgery.
89516817|NCT06228053|Experimental|SX-682 + enzalutamide|
89516818|NCT06227988||patients with liver disease who undergoing surgery|"For each patient and surgery, we will be collecting detailed pre-operative data regarding demographics (age, sex, body mass index, surgery category, comorbidities (diabetes mellitus, hypertension), and pertinent laboratory values (sodium, creatinine, total bilirubin, the international normalized ratio [INR], albumin, platelet count.) The etiology of liver disease will be classified.~To ensure that laboratory data accurately reflected the pre-operative state, only those from within 30 days prior to surgery will be considered For each patient VOCAL PENN score, MELD score, and Mayo score will be calculated using an online calculator."
89516819|NCT06227988||patients with liver disease who do not undergoing surgery|"For each patient and surgery, we will be collecting detailed pre-operative data regarding demographics (age, sex, body mass index, surgery category, comorbidities (diabetes mellitus, hypertension), and pertinent laboratory values (sodium, creatinine, total bilirubin, the international normalized ratio [INR], albumin, platelet count.) The etiology of liver disease will be classified.~To ensure that laboratory data accurately reflected the pre-operative state, only those from within 30 days prior to surgery will be considered For each patient VOCAL PENN score, MELD score, and Mayo score will be calculated using an online calculator."
89516820|NCT06227962||Retinoblastoma Survivors|Children and adults who survived retinoblastoma (8-35 years of age)
89516821|NCT06227962||Retinoblastoma Risk Carriers|Children and adults who (might) carry a genetic risk to develop retinoblastoma (8-35 years of age)
89516822|NCT06227962||Parents|Parents of Rb patients, Rb survivors, or Rb risk carriers (6 months-12 years of age)
89516823|NCT06227949|No Intervention|Control|subcutaneous injection of Gonal-F (FSH)
89516824|NCT06227949|Experimental|Intervention|subcutaneous injection of Luveris in addition to Gonal-F (FSH)
89516825|NCT06227923|Experimental|Intervention group|Participants are transferred from the hospital ward to a small apartment with a technological assessment and monitoring established inside the hospital setting.
89516826|NCT06227923|No Intervention|Control group|Participants remain in the hospital ward and receive normal clinical practice.
89516827|NCT06227897|Experimental|Aumolertinib|Aumolertinib 110 mg once daily (110 mg per day) orally for 36 months.
89516828|NCT06227884||Patients with APN intervention|Participants with a schedule of a MD consultation (within approximately 2 to 12 months) + an APN intervention halfway between day hospitalization et MD consultation
89516829|NCT06227884||Patients without APN intervention|Participants with a MD consultation only, within approximately 2 to 12 months
89516830|NCT06227871||Penetrating intra-abdominal injury|Patients diagnosed with a pancreatic injury secondary to penetrating intra-abdominal injury subdivided by pancreatic injury grade
89516831|NCT06227871||Blunt intra-abdominal injury|Patients diagnosed with a pancreatic injury secondary to blunt intra-abdominal injury subdivided by pancreatic injury grade
89516832|NCT06227806|Experimental|Tibial Tubercle Transfer surgery|Tibial Tubercle Transfer surgery followed by a home exercise program.
89516833|NCT06227806|Active Comparator|Home Exercise Program|A home exercise program.
89516834|NCT06227793|Experimental|intervention|With health education
89516835|NCT06227793|No Intervention|control|Without health education
89516836|NCT06227754|Active Comparator|Angiography-guided PCI|The PCI procedure in this group will be performed as standard procedure.
89516837|NCT06227754|Experimental|Optical coherence tomography-guided PCI|Use of OCT will be allowed at any step of PCI (pre-PCI, during PCI and post-PCI), but OCT after stent implantation will be mandatory. In this group, the recommendations for selecting reference segment, selecting appropriate size of stent, and stent optimization are as follows. OPTIS imaging catheter (Abbott Vascular) will be used for the imaging arm according to MLD MAX algorithm.
89516838|NCT06227741|Experimental|concept mapping|utility of concept mapping as a learning tool for problem solving. As well, examine the effect of using concept mapping as a tool for problem based learning on students' Metacognitive Awareness, problem solving skills, , and self -directed learning at Zagazig Faculty of Nursing
89516839|NCT06227741|No Intervention|traditional learning experience|utility of traditional learning experience as a learning tool
89516840|NCT06227715|Other|selective etch|In SLE mode, only enamel margin was etched for 15 seconds, washed for 15 seconds and dried, and the adhesive was applied to the dentin and enamel by rubbing for 20 seconds.
89516841|NCT06227715|Other|Total etch|Each mode of the universal adhesive used in the mouth of each of the patients evaluated was applied to at least two teeth. In accordance with the recommendations of the manufacturer; in TE mode, enamel and dentin were etched with 37% orthophosphoric acid for 15 seconds, washed for 15 seconds, and after air-drying, the adhesive was applied to enamel and dentin by rubbing for 20 seconds.
89516842|NCT06227715|Other|self etch|In SE mode, the adhesive was applied to the dentin and enamel by rubbing for 20 seconds.
89516843|NCT06227689|Experimental|HPV Chatbot Intervention group|In this arm, participants will receive a vaccine chatbot intervention. They will be invited to use the HPV vaccine chatbot online through WeChat or any web browsers, where they can ask any questions related to the HPV vaccine and get immediate answers from the chatbot. The intervention lasts two weeks, with invitations sent every four days to reinforce the intervention.
89516844|NCT06227689|No Intervention|Control group|The control group will not use the chatbot during the intervention duration.
89516845|NCT06227676|Placebo Comparator|Granola Bites|This snack contains no known spices or nutrients that have been shown to help with spasmodic or congestive dysmenorrhea. It is the same shape and size as the active comparator.
89516846|NCT06227676|Active Comparator|Cramp Bites|This snack contains spices and ingredients that have been shown to help with both spasmodic and congestive dysmenorrhea. It is the same shape and size as the placebo comparator.
89516847|NCT06227663|Experimental|Access to the KOALOU(®) digital application|
88961439|NCT02009215|No Intervention|Control|No intermittent preventive treatment (IPT) with dihyroartemisinin-piperaquine (DP) will be given.
89207648|NCT00862368|Active Comparator|PAM-Asthma|The PAM-Asthma arm received the same in-home counseling visits as PAM-Enhanced/Asthma. The 6 counseling phone calls were different from those received by PAM-Enhanced/Asthma, and included only an asthma follow-up and discussion of a child wellness topic. Smoking cessation was not discussed and additional feedback on ETS samplers was not provided. Motivational Interviewing approaches were used in all in-home and phone counseling. Free nicotine patch tx was given if they were ready to quit within 30 days.
89516848|NCT06227663|No Intervention|No access|
89516849|NCT06227637|Active Comparator|Group (A) (Muscle Energy Techniques )|Muscle Energy Techniques
89516850|NCT06227637|Active Comparator|Group( B) (Local Muscle Vibration)|Local Muscle Vibration
89516851|NCT06227624|Other|combined oral zinc salts with phototherapy|neonates received combination therapy which is phototherapy and oral zinc sulfate in a dose of 5 mg every 12 hours using a calibrated dropper provided with the bottle, during the period of NICU admission of neonates on phototherapy
89516852|NCT06227624|No Intervention|phototherapy group|neonates receiving phototherapy alone
89516853|NCT06227572|Experimental|Intervention Group|The CATNAP MI intervention consists of 3 Motivational Interviewing sessions to address obstructive sleep apnea (OSA), positive airway pressure (PAP) adherence, and risk of Alzheimer's disease and related dementias (ADRD) in American Indians and electronic messaging to support PAP adherence, and usual care. Data will be collected at baseline, 3-months, and 9-months.
89516854|NCT06227572|No Intervention|Waitlist Control Group|Usual care, consisting of an in-service on how to operate the PAP machine, and a mask fitting to select the most comfortable, effective mask for the individual. After 4-6 weeks of use, the participant will be contacted by Missouri Breaks Durable Medical Equipment to review objective adherence data and address any challenges or barriers to therapy such as treatment-emergent central apneas. Data will be collected at baseline, 3-months, and 9-months.
89516855|NCT06227546|Experimental|MCG018|
89516856|NCT06227533|Experimental|PRF group|Five ml blood will be drawn from the patient's right median cubital vein into a test tube without the addition of an anticoagulant and centrifuged immediately at 3000 rpm for 10 minutes
89516857|NCT06227533|Experimental|CGF group|Ten ml of intravenous blood sample from the patient will be obtained and placed in centrifuge tubes without anticoagulants; accelerated for 30 seconds; centrifuged at 2700 rpm for 2 min, 2400 rpm for 4 min, 2700 rpm for 4 min, and 3000 rpm for 3 min; and decelerated for 36 secs to stop
89516858|NCT06227520|Experimental|Dermgen|Application of Dermgen
89516859|NCT06227507|Experimental|No icon|"Participants will be shown 3 frozen meals at once; each product will be high in 1, 2, or 3 nutrients of concern (added sugar, sodium, and/or saturated fat) and will be labeled as such with a rectangular high in front-of-package label. The label will solely contain high in and nutrient text with no icon."
89516860|NCT06227507|Experimental|Magnifying glass|"Participants will be shown 3 frozen meals at once; each product will be high in 1, 2, or 3 nutrients of concern (added sugar, sodium, and/or saturated fat) and will be labeled as such with a rectangular high in front-of-package label. The label will contain high in and nutrient text, along with a magnifying glass icon."
89516861|NCT06227507|Experimental|Exclamation Mark|"Participants will be shown 3 frozen meals at once; each product will be high in 1, 2, or 3 nutrients of concern (added sugar, sodium, and/or saturated fat) and will be labeled as such with a rectangular high in front-of-package label. The label will contain high in and nutrient text, along with an exclamation mark icon."
89516862|NCT06227507|Experimental|Exclamation Mark with multiple labels|"Participants will be shown 3 frozen meals at once; each product will be high in 1, 2, or 3 nutrients of concern (added sugar, sodium, and/or saturated fat) and will be labeled as such with 1, 2, or 3 rectangular high in front-of-package labels, one for each specific nutrient of concern. Each label will contain high in and nutrient text, along with an exclamation mark icon."
89516863|NCT06227507|Experimental|Exclamation Mark with Black Background|"Participants will be shown 3 frozen meals at once; each product will be high in 1, 2, or 3 nutrients of concern (added sugar, sodium, and/or saturated fat) and will be labeled as such with a rectangular high in front-of-package label. The label will contain high in and nutrient text, along with an exclamation mark icon. The background of the high in text will be black, and the high in text will be white."
89516864|NCT06227481|Active Comparator|Subcision plus platelet rich plasma|3 sessions of scar subcision with platelet rich plasma injection at the same session with one month interval
89516865|NCT06227481|Active Comparator|Subcision plus Polydioxanone mono threads|3 sessions of scar subcision followed by the insertion of Polydioxanone mono threads after the last session
89516866|NCT06227481|Active Comparator|Subcision plus fractional carbon dioxide laser|3 sessions of scar subcision with Fractional carbon dioxide laser at the same session with one month interval
89516867|NCT06226857|Active Comparator|A|All patients will recieve chemotherapy FOLFOX (oxaliplatin 85 mg/m2 + folinic acid 400 mg/m2 + FU 400 mg/m2 bolus and FU 2400 mg/m2 46-hour insusion q2w) + anti-EGFR monoclonal antibody (cetuximab 500 mg/m2 q2w or panitumumab 6 mg/kg q2w) until disease progression or unacceptable toxicity. It is permited to withdraw oxaliplatin after 8 cycles.
89516868|NCT06226857|Experimental|BC|"All patients will recieve chemotherapy FOLFOX (oxaliplatin 85 mg/m2 + folinic acid 400 mg/m2 + FU 400 mg/m2 bolus and FU 2400mg/m2 46-hour insusion q2w). Monoclonal antibody will be added to chemotherapy after 1-2 cycles based on molecular profile results: anti-EGFR (cetuximab 500 mg/m2 q2w or panitumumab 6 mg/kg q2w) for hyperselected wild type tumors or bevacizumab 5 mg/m2 q2w for mutant profile.~Patients will recieve therapy until disease progression or unacceptable toxicity. It is permited to withdraw oxaliplatin after 8 cycles."
89516869|NCT06226623|Experimental|Intervention|Participants were given 4-week healthy nutrition training. Participants' basal metabolic rates were calculated according to gender and body weight (kg) using the Schofield equation. The appropriate equation for each participant's age was used. The daily energy requirement of the participants was calculated by adding an activity factor of 1.3 to the calculated basal metabolic rate. A healthy nutrition program was prepared according to the calculated daily energy needs of the participants. While preparing this program, WHO and Turkey-Specific Healthy Nutrition Guide (TÜBER) were used. In the individual healthy nutrition program, 55% carbohydrates, 15% protein and 30% fat macronutrients were provided. Total cholesterol of the nutrition program was kept at 300 mg and below. The intervention group was asked to consume 50 g of fresh coconut daily in addition to the healthy nutrition program.
89516870|NCT06226623|No Intervention|Control|Participants were given 4-week healthy nutrition training. Participants' basal metabolic rates were calculated according to gender and body weight (kg) using the Schofield equation. The appropriate equation for each participant's age was used. The daily energy requirement of the participants was calculated by adding an activity factor of 1.3 to the calculated basal metabolic rate. A healthy nutrition program was prepared according to the calculated daily energy needs of the participants. While preparing this program, WHO and Turkey-Specific Healthy Nutrition Guide (TÜBER) were used. In the individual healthy nutrition program, 55% carbohydrates, 15% protein and 30% fat macronutrients were provided. Total cholesterol of the nutrition program was kept at 300 mg and below. The control group was given only a healthy nutrition program.
89516871|NCT06226259|Experimental|GABA supplement group|"The experimental group was given a kind of GABA supplement already on the market, with 100mg of GABA in the unit package.~Take orally every night before sleep for 14 days."
89516872|NCT06226259|Placebo Comparator|placebo group|Placebo ,Take orally every night before sleep for 14 days.
89516873|NCT06225947||Lemborexant(LEM)|Subjects will be administered with Lemborexant(LEM). The dosage of LEM is 5 mg or 10mg taken no more than once per night during the study.
89516874|NCT06225492|Experimental|DaxibotulinumtoxinA 20 units|Subjects will receive 20 units of daxibotulinumtoxinA per platysmal band, up to 2 anterior bands and 2 lateral bands.
89516875|NCT06225492|Experimental|DaxibotulinumtoxinA 15 units|Subjects will receive 15 units of daxibotulinumtoxinA per platysmal band, up to 2 anterior bands and 2 lateral bands.
89516876|NCT06225336|Experimental|AUR-201|AUR-201
89516877|NCT06224140|Active Comparator|Heparin Anticoagulation|
89516878|NCT06224140|Experimental|Regional Anticoagulation Procedure (RAP)|
89516879|NCT06223919|Experimental|Immediate vaccination|"This vaccin is a yellowish-yellow dry preparation containing live vaccinia virus (strain LC16m8). When the accompanying solvent is added, it dissolves rapidly to form a clear or slightly cloudy yellowish-red or reddish liquid. The ingredients of this vaccin are contained in 0.5 mL of a solution of this product dissolved in 0.5 mL of the accompanying solvent (20 vol% glycerin-added water for injection).~Just one dose of vaccine will be administered according to standardized operating procedure (SOP). Briefly, the vaccine is dissolved with 0.5 mL of a diluent provided. The reconstituted vaccine is usually administered percutaneously at a dose of approximately 0.025 mL by the multiple puncture technique using a bifurcated needle. The number of punctures will be 15 times. Procedures for vaccine administration are described in detail in the SOP. The participant must be observed at the vaccination site for 30 minutes after vaccine administration to observe possible immediate reactions."
89516880|NCT06223919|Active Comparator|Delayed vaccination|The use of placebo as a control group is essential to scientifically assess the efficacy of vaccines in clinical trials and to obtain reliable evidence in preventing the onset of disease. However, the use of a placebo is unethical. Subjects are at high risk of mpox and must not be given a placebo. Therefore, a design was applied in which the immediate treatment group was evaluated with the delayed group as a control group. A period of six weeks was set aside between the immediate and delayed treatment groups to be used for logistics, such as preparations and delivery of the vaccine in the delayed treatment group. It is ethical, for the same reason, because it prevents inequities based on the abovementioned reasons.
89516881|NCT06223724||Cochlear implant electrode insertion depth estimation|Electrode insertion depth estimation using impedance telemetry data measured during cochlear implantation and at three regular follow-up visits
89516882|NCT06222060||Parents|Couples of parents of newborns
89516883|NCT06208293|Experimental|KPZ Program (KPZ)|Participants in this group will receive the KPZ program in addition to EUC. This group will receive the culturally adapted suicide prevention package (KPZ) of services delivered by trained Peers. The KPZ package includes a culturally adapted approach to a co-designed safety plan. The assigned Peers will provide safety planning and Brief Contact Follow-Up. Contact follow up sessions will occur at the household level. A Peer will be assigned an eligible mother and visit her within no less than 48 hours of enrollment. The first session will be delivered within two days of detection, and follow up contacts conducted by a trained Peer at 24 hours, every two days (for one week), weekly (for 1 month), and monthly (for 5 months), totaling 13 KPZ sessions in all. Contact assesses how the participant is coping, if the safety plan is helpful, adjustments to the safety plan, assessment of the suicide ideation and depression, and providing basic motivational interviewing and referral as needed.
89516884|NCT06208293|Active Comparator|Enhanced Usual Care (EUC)|Participants in this group will receive usual care enhanced by Lady Health Workers (LHWs) trained in WHO Mental Health Gap Action Programme (mhGAP) that will link at-risk women with the primary care facility based medical officer. The LHWs will follow the mhGAP protocol for imminent or low risk of suicide including ensuring the participant is safe, removing or reducing means, assigning a family member to ensure safety (if appropriate), providing psychoeducation, and referring and accompanying the individual to their primary care health center where a mhGAP trained doctor is staffed to resume care or make a referral to specialized care. Additionally, all women and healthcare workers are provided a 24 hour hotline number (hosted by a Pakistani based mental health organization called Taskeen) and are briefed on exactly what will happen if participant calls.
89516885|NCT06205615|Experimental|BXP154B/Right Leg Period 1; Placebo/Left Leg Period 2|Single topical application of BXP154B 6ml (right leg), treatment period 1; single topical application of Placebo 6ml (left leg), treatment period 2
89516886|NCT06205615|Experimental|Placebo/Right Leg Period 1; BXP154B/Left Leg Period 2|Single topical application of Placebo 6ml (right leg), treatment period 1; single topical application of BXP154B 6ml (left leg), treatment period 2
89516887|NCT06205615|Experimental|BXP154B/ Left Leg Period 1; Placebo/Right Leg Period 2|Single topical application of BXP154B 6ml (left leg), treatment period 1; single topical application of Placebo 6ml (right leg), treatment period 2
89516888|NCT06205615|Experimental|Placebo/Left Leg Period 1; BXP154B/Right Leg Period 2|Single topical application of Placebo 6ml (left leg), treatment period 1; single topical application of BXP154B 6ml (right leg), treatment period 2
89516889|NCT06201390|Experimental|Stable sleep|Participants will be asked to maintain a consistent sleep pattern for two weeks.
89516890|NCT06201390|No Intervention|Habitual Sleep|Participants will be asked to maintain their usual sleep pattern for two weeks.
89516891|NCT06192186|Experimental|Adebrelimab combined with SOX regimen|Adebrelimab combined with SOX regimen preoperatively used 3 cycles(stop adebrelimab and S-1/oxaliplatin after 3 cycles and evaluate tumor staging)→ radical surgery (D2) →Postoperative selection of continued medication or cessation of treatment will base on the patient's pathological reports. Surgery should be performed within 3-6 weeks after 3 cycles of preoperative neoadjuvant therapy.
89516892|NCT06192186|Active Comparator|Placebo combined with SOX (S-1/oxaliplatin) regimen|Placebo combined with SOX (S-1/oxaliplatin) regimen preoperatively used 3 cycles(stop placebo and S-1/oxaliplatin after 3 cycles and evaluate tumor staging)→ radical surgery (D2) →Postoperative selection of continued medication or cessation of treatment will base on the patient's pathological reports. Surgery should be performed within 3-6 weeks after 3 cycles of preoperative neoadjuvant therapy.
89516893|NCT06188065||Participants with severe exacerbation of COPD and eosinophils < 0.05 x 10^9/L|Participants to be included in the co-primary outcomes for the time to recovery from eosinopenia analysis as well as the analysis to identify independent factors associated with eosinopenia on admission in patients with a severe exacerbation of COPD. This group of participants will also be included in all secondary outcomes.
89516894|NCT06188065||Participants with severe exacerbation of COPD and eosinophils >= 0.05 x 10^9/L|Participants will be included in the co-primary outcome to identify independent factors associated with eosinopenia on admission in patients with a severe exacerbation of COPD. This group of participants will also be included in some of the secondary outcomes.
89516895|NCT06184594|Experimental|eNav intervention|Subjects assigned to this arm will receive a link to the eNav website.
89516896|NCT06184594|Placebo Comparator|Usual Care Group|Subjects assigned to this arm will not receive the link to the website and will receive standard clinical care.
89516897|NCT06178003|Experimental|intravitreal injection of Tpdelansbsalbac in malignant pleural and abdominal effusions|the safety and efficacy of intravitreal injection of Tpdelansbsalbac in the treatment of malignant pleural and abdominal effusions
89516898|NCT06170281|Active Comparator|Random - ME|participants will be randomized to an intervention involving regular mealtime and regular timed exercise
89516899|NCT06170281|Active Comparator|Random - MS|participants will be randomized to an intervention involving regular mealtime and regular sleep
89516900|NCT06170281|Active Comparator|Random - SE|participants will be randomized to an intervention involving regular sleep and regular timed exercise
89516901|NCT06170281|Active Comparator|Choice - ME|this arm belongs to participants who choose the intervention involving regular mealtime and regular timed exercise
89516902|NCT06170281|Active Comparator|Choice - MS|this arm belongs to participants who choose the intervention involving regular mealtime and regular sleep
89516903|NCT06170281|Active Comparator|Choice - SE|this arm belongs to participants who choose the intervention involving regular sleep and regular timed exercise
89516904|NCT06164431|Experimental|ZSP1273 Sequence 1|Single oral dose of 200mg ZSP1273 tablet administered under fasting conditions in first period and 200mg granules in second period，then 200mg ZSP1273 tablet administered under fasting conditions in third period and 200mg granules in fourth period.
89516905|NCT06164431|Experimental|ZSP1273 Sequence 2|Single oral dose of 200mg ZSP1273 granules administered under fasting conditions in first period and 200mg tablet in second period，then 200mg ZSP1273 granules administered under fasting conditions in third period and 200mg tablet in fourth period.
89516906|NCT06158971|Experimental|Flexible Microwave Ablation|Soft tissue ablation will be performed using the phenoWave flexible Microwave Ablation System and Accessories on lesions in the peripheral lung. The image-guided ablation procedure may utilize a combination of the radial EBUS and conebeam CT to confirm the lesion, position of the device relative to lesion and monitor the ablation progress.
89516907|NCT06158464|No Intervention|Care-as-usual|In standard care, persons on sick leave/work disability are invited by the medical advisor for a consultation. If the patient is allocated to the control group (or if the patient did not agree to participate in the study), the medical advisor takes decisions based on the information at his disposal, e.g. start a return-to-work trajectory, to temporarily prolong sickness absence and disability, or to confirm definitive work disability. If they agree to participate, they are asked to complete four questionnaires: at baseline, at 3 months, 6 months, and 9 months.
89516908|NCT06158464|Experimental|Care-as-usual supplemented by a Functional Capacity Evaluation|"In the intervention group, participants are referred to an occupational therapist to receive an FCE. Afterwards, the occupational therapist completes a standardized FCE-template, and conveys these recommendations to the medical advisor. This template includes a list of ICF categories important to the work context. The conclusion of the FCE includes: 1) The facilitators and barriers related to work-related physical, cognitive or psychological functioning, or related to environmental and/or psychosocial factors. 2) A recommendation on the current or last occupation or a reference occupation with or without adaptation and/or on reorientation, training, coaching.~Based on the FCE results, the medical advisor can adapt his advice and communicate to the person on sick leave/work disability to advise him/her, or refer the person on sick leave/work disability to other partners (such as VDAB, FOREM, Actiris, or the RTW-coordinator)."
89516909|NCT06154980|Active Comparator|Preoperative Ultrasound TLIP Group|Participant will receive TLIP in preop with 20cc of 0.2% ropivacaine administered bilaterally, 40cc total. Blocks will be performed under ultrasound guidance with an in-plane technique by a single study investigator.
89516910|NCT06154980|Active Comparator|Intraoperative TLIP Group|Participants will receive TLIP with 20cc of 0.2% ropivacaine bilaterally, 40cc total. Blocks will be performed intraoperatively under direct surgical visualization.
89516911|NCT06153446||CDL PJI Database|Patients tested for PJI through the PJI Panel at CD Laboratories (CDL)
89516912|NCT06150989||Observational Group|Black women enrolled in this study will complete a series of lab-based assessments that evaluate their vascular health, followed by a 10-day free-living monitoring period with mobile and wearable devices.
89516913|NCT06146335|Experimental|Kono-S anastomosis (KSa)|Randomized enrollment of preoperative patients undergoing surgical resection for Crohn's ileitis or ileocolitis
89516914|NCT06146335|Active Comparator|side-to-side anastomosis (SSa)|Randomized enrollment of preoperative patients undergoing surgical resection for Crohn's ileitis or ileocolitis
89516915|NCT06145347||Acute kidney injury group|Patients developed acute kidney injury.
89516916|NCT06145347||Non-Acute kidney injury group|Patients didn't develope acute kidney injury.
89516917|NCT06142383|Placebo Comparator|Arm 1|Placebo Treatment
89516918|NCT06142383|Experimental|Arm 2|XXB750 Low Dose
89516919|NCT06142383|Experimental|Arm 3|XXB750 Medium Dose
89516920|NCT06142383|Experimental|Arm 4|XXB750 High Dose
89516921|NCT06142383|Active Comparator|Arm 5|Sacubitril/valsartan, open label tablet
89516922|NCT06142292|Experimental|Clients|"All participants will be asked to complete the following:~participate in 12 individual mental health counseling sessions participate in 3 group counseling sessions receive information on community resources related to their social and mental health needs/challenges"
89516923|NCT06139445|Experimental|Study Group|
89516924|NCT06139445|Placebo Comparator|Plasebo Group|
89516925|NCT06131853|Experimental|prostate group|
89516926|NCT06131853|Active Comparator|control group|
89516927|NCT06121349||OCR|Patients under treatment with Ocrelizumab (OCR) for at least 1 year prior to study start.
89516928|NCT06121349||OMB|Patients under treatment with ofatumumab (OMB) for at least 6 months prior to study start
89516929|NCT06115031|Experimental|Remimazolam|General anesthesia using continuous infusion of intravenous remimazolam and remifentanil. Remimazolam will be used for maintenance of general anesthesia and adjusted between 0.6-2mg/kg/hr until the end of surgery.
89516930|NCT06115031|Active Comparator|Propofol|General anesthesia using target-controlled infusion of intravenous propofol and remifentanil. Propofol will be adjusted maintaining the BIS between 40-60 until the end of surgery.
89516931|NCT06111729|Experimental|HabitAware Participants|Patients will be asked to wear the HabitAwareness bracelet for 12 weeks. The bracelet provides the attention stimulus of gentle vibration when the motion of nail biting is sensed.
89516932|NCT06108102||Post-stroke epilepsy|Stroke patients aged ≥18 years, with ischemic or hemorrhagic stroke, presenting with early or late onset post-stroke seizures.
89516933|NCT06108102||No post-stroke epilepsy|Stroke patients aged ≥18 years, with ischemic or hemorrhagic stroke, presenting with no post-stroke seizures.
89516934|NCT06101251|No Intervention|Control|"Participants will have the Way to Drive app monitoring in the background throughout the intervention period for overall driving score, handheld phone use, speeding, hard braking, and fast acceleration. They will not receive feedback, driving tips or UBI-like behavioral incentives.~Participants will also receive payment or non-adherence messages as needed for having the app functioning."
89516935|NCT06101251|Active Comparator|Standard Feedback + UBI-like Behavioral Incentive|Participants will have the Way to Drive app monitoring in the background, and will receive payment or non-adherence messages as needed, but will also receive, Standard Feedback, Study Dashboard, Driving Tips, and UBI-like Behavioral Incentive
89516936|NCT06101251|Active Comparator|Assigned Goal with UBI-like Behavioral Incentive|Participants will have the Way to Drive app monitoring in the background, and will receive payment or non-adherence messages as needed, but will also receive Assigned Focus Area Feedback, Driving Tips, a Study Dashboard, and UBI-like Behavioral Incentive
89516937|NCT06101251|Active Comparator|Self-Chosen Goal with UBI-like Behavioral Incentive|Participants will have the Way to Drive app monitoring in the background, and will receive payment or non-adherence messages as needed, but will also receive Self-Chosen Focus Area Feedback, Driving Tips, Study Dashboard, and UBI-like Behavioral Incentive.
89516938|NCT06092281|Experimental|Control Arm|Patients after ESD are informed on follow-up instructions by doctors about the follow-up requirements before discharge, and complete a questionnaire without compliance-related education.
89516939|NCT06092281|Experimental|Questionnaire Arm|In addition to receiving the same follow-up instructions as the control group, patients need to complete a questionnaire on compliance-related education before discharge. Based on the responses, nurses provide feedback and guidance.
89516940|NCT06084702|Placebo Comparator|Water|Plain Water
89516941|NCT06084702|Experimental|Low Carb drink|Roaring Water
89516942|NCT06081946|Experimental|Sleep fragmentation|This subproject will be conducted in two sessions separated by three nights of sleep fragmentation. Each session will last approximately 2 hours. At the beginning of the first visit and after the last visit, 9 ml of blood will be drawn, and plasma will be isolated. After plasma isolation, the CRP concentration will be analyzed. In each forearm of the participant, a 4x4 cm area will be selected as Area of Interest (AOI). In these selected areas, itch will be induced in both sessions using histamine and cowhage and several tests will be conducted.
89516943|NCT06073496|No Intervention|Control|The Patient are cancer patient that experience cancer pain that only receive analgetic drug treatment according to WHO Stepledder of Pain
89516944|NCT06073496|Experimental|Electroacupuncture and standard Therapy|The Patient are cancer patient that experience cancer paint that receive analgetic drug treatement according WHO stepledder of pain and receive electroacupuncture
89516945|NCT06070363|No Intervention|Control|The Patient are cancer patient that experience cancer pain that only receive analgetic drug treatment according to WHO Stepledder of Pain
89516946|NCT06070363|Experimental|Manual acupuncture and standard Therapy|The Patient are cancer patient that experience cancer paint that receive analgetic drug treatement according WHO stepledder of pain and receive manual acupuncture
89516947|NCT06070077||On ground CPR|Quality of CPR provided on the ground in a standard environment. (n=6)
89516948|NCT06070077||Via ferrata CPR|Quality of CPR provided on the via ferrata place. (n=6)
89516949|NCT06059963||Average risk|Patients aged between 45 and 84, who are at average risk of developing colorectal cancer, and are scheduled for a standard-of-care screening colonoscopy.
89516950|NCT06047847|Experimental|TOTUM-448|"10 healthy men will consume an acute intake of 4.284g of TOTUM-448 on three separate occasions.~Phase 1: once per galenic form (capsule and powder). Phase 2: once (capsule only)."
89516951|NCT06046287|Experimental|Daratumumab and hyaluronidase-fihj|
89516952|NCT06043557|Active Comparator|left side lateral and right side medial|left side lateral and right side medial
89516953|NCT06043557|Active Comparator|right side lateral with left side medial|right side lateral with left side medial
89516954|NCT06039644|Experimental|Probiotic group|Subjects received two probiotic sachets per day
89516955|NCT06039644|Placebo Comparator|Placebo group|Subjects received two placebo sachets per day
89516956|NCT06037603|Experimental|Intervention|The intervention group will be asked to visit the UNLV study site three times to evaluate baseline (T1), post-intervention (T2), and at 1-month post-intervention (T3) for functional assessments and saliva collection. Each participant will complete the BraW-Day program between baseline (T1) and post-intervention (T2). The program consists of 15-minute-long daily cognitive-walking tasks for 14 consecutive days. The program will be delivered on the Uplode mobile app. Each participant will be asked to perform three different 5-minute-long cognitive tasks (e.g., subtracting numbers or remembering long phrases) and one physical task (tandem walking or 8-shape walking) either indoors or outdoors at the same time for 15 minutes every day, which they will repeat daily for the next 13 days (2 weeks in total).
89516957|NCT06037603|Active Comparator|Wait-list Control|The wait-list control group will be will be asked to visit the UNLV study site four times to evaluate pre-baseline (T0), baseline (T1), post-intervention (T2), and at 1-month post-intervention (T3) for functional assessments and saliva collection. Each participant will complete the BraW-Day program between baseline (T1) and post-intervention (T2). The program consists of 15-minute-long daily cognitive-walking tasks for 14 consecutive days. The program will be delivered on the Uplode mobile app. Each participant will be asked to perform three different 5-minute-long cognitive tasks (e.g., subtracting numbers or remembering long phrases) and one physical task (tandem walking or 8-shape walking) either indoors or outdoors at the same time for 15 minutes every day, which they will repeat daily for the next 13 days (2 weeks in total).
89516958|NCT06032143|Experimental|Intervention Doulas|Doulas randomized to the intervention group will engage in a one-hour online course about exposure to phthalates and the relationship with reproductive health.
89516959|NCT06032143|Sham Comparator|Control Doulas|Doulas randomized to the control group will access a worksheet about an alternative environmental exposure and the relationship with reproductive health.
89516960|NCT06032143|Experimental|Intervention Pregnant Individuals|Pregnant individuals working with intervention doulas will be asked to have a conversation with their doulas about environmental chemicals (phthalates).
89516961|NCT06032143|Sham Comparator|Control Pregnant Individuals|Pregnant individuals working with control doulas will be asked to have a conversation with their doulas about environmental chemicals (distinct from phthalates).
89516962|NCT06030193|Experimental|QLS-111 ophthalmic solution|Qlaris' investigational product, QLS-111 ophthalmic solution, provided in 2 concentrations for this study (0.15% and 0.03%), single use vials, masked, and preservative free (PF).
89516963|NCT06030193|Placebo Comparator|QLS-111 ophthalmic vehicle solution|Inactive control. QLS-111 ophthalmic vehicle solution, single use vials, masked, PF.
89516964|NCT06021678|Experimental|EX103 injection|From Cycle 0 to Cycle 2, the subject will receive the preset dose of EX103 once a week (QW), and from Cycle 3, the subject will receive the preset dose of EX103 once every two weeks (Q2W). The recommended dose is MTD or OBD, and a cycle of treatment is 28 days.
89516965|NCT06016777|Experimental|PVB+PCIA group|
89516966|NCT06016777|Experimental|ESB+PCIA group|
89516967|NCT06016777|Active Comparator|PCIA group|
89516968|NCT06006000||Older adults returning home post-ICU|Community-dwelling older adults who return home (either directly or after a stay in short-term rehab (STR)) after an ICU hospitalization.
89516969|NCT05997901|Experimental|Varenicline healthbot|While the exact healthbot features will be based on results from the rapid review, interviews and Wizard of OZ testing, the investigators know from the existing literature on medication adherence, and behaviour change interventions, that the healthbot will provide: 1) reminders for varenicline dosing and schedule; 2) information and suggestions on managing known side effects (the most frequently cited reason for varenicline non-adherence is experiencing side effects); 3) answers to questions about medication use (e.g., what to do if a dose is missed); and 4) support to increase participants' motivation to continue their quit attempts. During the next 12 weeks, participants will be reminded by the healthbot to take their varenicline at the appropriate times, and will be able to interact with the healthbot when they want.
89516970|NCT05997823|Active Comparator|home exercises|
89516971|NCT05997823|Experimental|sham-KT and home exercises|
89516972|NCT05997823|Experimental|dorso-volar KT and home exercises|
89516973|NCT05993364|Active Comparator|Control group|The control group receive a standard rehabilitative treatment to improve the secretions management and the respiratory function. Besides, the control group receives a traditional rehabilitative treatment carried out by the speech and language pathologist.
89516974|NCT05993364|Experimental|Experimental group|The experimental group receives the same standard rehabilitative treatment performed with the control group. In addition, sessions with the EFA technology are provided.
89516975|NCT05991284|Active Comparator|Intervention arm|Sacubitril-Valsartan (target dose 97/103 mg twice daily) on top of standard of care (including SGLT-2 inhibitor and MRA)
89516976|NCT05991284|Placebo Comparator|Control arm|Standard of care (including SGLT-2 inhibitor and MRA)
89516977|NCT05974111||Ischemic Stroke|"Patients presenting at emergency department / Intensive Care unit with ischemic stroke~registration of baseline clinical data~registration of baseline blood parameters (in context of standard of clinical care)~additional blood sampling at 5 time points during 1st week with the purpose of full coagulation testing and cell free DNA methylation"
89516978|NCT05974111||Haemorrhagic stroke|"Patients presenting at emergency department / Intensive Care unit with haemorraghic stroke (spontaneous intracranial bleeding, no trauma)~registration of baseline clinical data~registration of baseline blood parameters (in context of standard of clinical care)~additional blood sampling at 5 time points during 1st week with the purpose of full coagulation testing and cell free DNA methylation"
89516979|NCT05974111||Aneursmal Subarachnoid Haemorrhage|"Patients presenting at emergency department / Intensive Care unit with aneurysmal subarachnoid haemorrhage~registration of baseline clinical data~registration of baseline blood parameters (in context of standard of clinical care)~additional blood sampling at 5 time points during 1st week with the purpose of full coagulation testing and cell free DNA methylation"
89516980|NCT05963113|Experimental|Control, then Swallowing Exercises + Protein|"Participants randomized to 12 weeks of swallowing exercises with protein supplementation, after completing an initial 12-week period of usual activity."
89516981|NCT05963113|Active Comparator|Control, then Swallowing Exercises|"Participants randomized to 12 weeks of swallowing exercises without protein supplementation, after completing an initial 12-week period of usual activity."
89516982|NCT05959109|Experimental|Peresolimab (Test 1)|Peresolimab administered subcutaneously (SC).
89516983|NCT05959109|Experimental|Peresolimab (Test 2)|Peresolimab administered SC.
89516984|NCT05959109|Experimental|Peresolimab (Test 3)|Peresolimab administered SC.
89516985|NCT05959109|Experimental|Peresolimab (Reference)|Peresolimab administered SC.
89516986|NCT05954624|Experimental|Experimental 1|"All participants will receive the following oral doses of study drugs following an overnight fast in the fixed-sequence below:~Period 1: 1 × 0.25-mg digoxin tablet, 1 × 10-mg rosuvastatin tablet Period 2: 8 × 600-mg ZSP1273 tablet+1 × 0.25 mg digoxin tablet, 1 × 10-mg rosuvastatin tablet"
89516987|NCT05954624|Experimental|Experimental 2|"All participants will receive the following oral doses of study drugs following an overnight fast in the fixed-sequence below:~Period 1: 600-mg ZSP1273 tablet Period 2: 5× 500mg Probenecid tablet BID+600-mg ZSP1273 tablet Period3: （Day1）200mg Itraconazole Capsule BID，（Day2-7）200mg Itraconazole Capsule QD+600-mg ZSP1273 tablet"
89516988|NCT05954000|Experimental|Intervention|Dose-finding study with 14 groups of 3 participants each. To identify the minimum effective dose (MED) to increase medication adherence by 20% between run-in and follow-up periods, the first group of 3 participants will receive a 5-week dose of the multi-BCT intervention. For the next subjects, the doses to administrate will vary between 1 and 10 weeks in length and will be determined by the modified Time-to-Event Continual Reassessment Method (TiTE-CRM) according to the observed responses in the previous subjects.
89516989|NCT05953051|Experimental|ACLr with bone/PrP-composite|"During surgery, the drilled bone debris is collected in a sterile filtered chamber.~Then the bone debris is mixed with PrP. After fixation of the graft the composite is inserted into the drilled tunnel at the interface between tendon to bone. The intraarticular aperture sites are sealed by use of fibrin that is previously gathered out of the PrP as well."
89516990|NCT05953051|Active Comparator|ACLr standard|No insertion of additional material after ACL graft fixation.
89516991|NCT05952492|Experimental|Cognitive-Behavioral Stress Management and Health Education|Participants will attend group sessions with a trained facilitator held over videoconference. Sessions will each last 2 hours and be held once weekly for 10 weeks. Sessions will include Cognitive-Behavioral Stress Management and health education content.
89516992|NCT05948670|Experimental|DISC-MVP|Participants randomized to the experimental condition, DISC-MVP, will be asked to download and use the BUILD study application. They will have access to the app throughout the 2 week study.
89516993|NCT05948670|Active Comparator|DISC-CON|Participants randomized to the digital control condition, DISC-CON, will be asked to download and use the BUILD study application. They will have access to the app throughout the 2 week study.
89516994|NCT05948579|Experimental|Intervention B Vilazodone|
89516995|NCT05948579|Placebo Comparator|Intervention B Placebo|
89516996|NCT05948553|Experimental|Intervention A: Fluoxetine HCl|
89516997|NCT05948553|Placebo Comparator|Intervention A Placebo|
89516998|NCT05948540|Experimental|Intervention C Daridorexant|
89516999|NCT05948540|Placebo Comparator|Intervention C Placebo|
89517000|NCT05947344|Experimental|STI-8591 in Advanced Acute Myeloid Leukemia (AML)|Subjects with Advanced primary AML or MDS secondary to AML or AML-MR.
89517001|NCT05924672|Experimental|Treatment (NaF PET/CT/MDP, Ra-223, PSMA PET)|Patients undergo NaF PET/CT or MDP scan within 45 days prior to cycle 1 day 1. Patients then receive standard of care Ra-223 IV on day 1 of each cycle. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo PSMA PET/CT over 45-60 minutes between 30-60 days after the last dose of Ra-223. Patients also undergo collection of blood samples during screening, on day 1 of every Ra-223 cycle, and at 30 days after the last dose of Ra-223. Patients may also undergo NaF PET/CT or MDP scans during Ra-223 treatment as clinically indicated, and/or CT scans during screening and Ra-223 treatment as clinically indicated.
89517002|NCT05910632|Experimental|Eccentrically strengthened resistance exercise|Women who will be part of the eccentrically reinforced resistance group will perform using the multi-gym equipment with flywheel. Each workout will involve upper and lower extremities.
89517003|NCT05910632|Active Comparator|Traditional resistance training|The control group (traditional resistance program) will carry out their interventions on gym machines for the lower limbs and free weights for the upper extremities.
89517004|NCT05899608|Experimental|Arm A - Ivonescimab and chemotherapy|Subject will receive ivonescimab and chemotherapy
89517005|NCT05899608|Active Comparator|Arm B - Pembrolizumab and chemotherapy|Subject will receive pembrolizumab and chemotherapy
89517006|NCT05893628||study group|
89517007|NCT05885945||dysmenorrhea|primary dysmenorrhea
89517008|NCT05885945||control|control not pain
89517009|NCT05882708|No Intervention|standard treatment group|"Standard treatment refers to that patients received active anti-infection and treatment of primary diseases according to the 2016 International Guidelines for the Management of Sepsis and septic shock. In addition, adequate volume resuscitation and vasoactive drug support can be given to maintain MAP≥65mmHg, and life support technologies such as ventilators and CRRT were given as needed.~The target of heart rate control not mentioned in the above guidelines, was not mandatory for this group of patients with sinus tachycardia, so pharmacologic intervention was not administered."
89517010|NCT05882708|Experimental|Ivabradine group|Standard treatment for sepsis plus enteral ivabradine.
89517011|NCT05879666|Experimental|Reproductive Health Professionals - EHL|All participants will complete a pre-course survey, engage in the online educational intervention, then complete 2 post-course surveys. They have the option to provide urine samples before and after the intervention.
89517012|NCT05872932|Experimental|Only gastric balloon|After analgesia endoscopy will be performed. After diagnostic endoscopy if there is no any gastric pathology that would be contraindication for balloon placement a gastric balloon will be placed. For first day standard medication will be provided. Starting from first hour until 1 week, patient nausea -vomiting and retching scores, re-admission to hospital, quality of life scores will be documented. After analgesia endoscopy will be performed. After diagnostic endoscopy if there is not any gastric pathology that would be contraindication for balloon placement a gastric balloon will be placed. For first day standard medication will be provided. Starting from first hour until 1 week, patient nausea -vomiting and retching scores, re-admission to hospital, quality of life scores will be documented.
89517013|NCT05872932|Experimental|sequential botulinum toxin A injection and then gastric balloon|After analgesia endoscopy will be performed. After diagnostic endoscopy if there is not any gastric pathology that would be contraindication for Botox injection and balloon placement, 200 U of botulinum toxin A will be injected to the antrum and the fundus. After 24 hour or 1 week the second procedure (placement of gastric balloon) will be performed. And Starting from first hour until 1 week, patient's nausea-vomiting and retching scores, re-admission to hospital, quality of life scores will be documented.
89517014|NCT05840718||Control group|Septic shock patients treated according surviving sepsis campaign 2021 guidelines
89517015|NCT05840718||Intervention group|Septic shock patients treated according surviving sepsis campaign 2021 guidelines supplemented with thiamin 200 mg in 50 ml 5% dextrose twice daily for 7 days.
89517016|NCT05837624|Experimental|Women with an ovarian endometrioma who will take drospirenone / estetrol|Women 18 years of age or older with endometriosis who have at least one ovarian endometrioma, of at least 3 cm in diameter, who will take oral Drospirenone / Estetrol treatment for 6 months
89517017|NCT05824910|Experimental|Small group zoom meeting|2 groups of 6 participants will be asked to follow the exercise program with their peers in a zoom meeting 3 times a week for 45 min each time. This time includes 5 min before and 10 min after for free talk and chat between participants. There will also be a weekly zoom education session for 30min.
89517018|NCT05820009|Experimental|GORE® VIABIL® Biliary Endoprosthesis|GORE® VIABIL® Biliary Endoprosthesis
89517019|NCT05819385||All participants|All participants must be diagnosed with rheumatic disease (connective tissue disease (CTD)) and intestinal lung disease (ILD) and fulfil all inclusion and no exclusion criteria. Information about participants will be obtained from electronic and physical medical records for existing data collection (over the past ten years, from 2012 to 2022) and/or from medical consultations for newly collected data (for the next three years, from 2023 to 2026). The participants' observation time varies and can be over the whole study duration (from 2012 to 2023), over the past ten years only (existing data) or over the next three years (new data).
89517020|NCT05795894||patents|Questionnaires
89517021|NCT05780242||TCA|interviews based on a questionnaire established beforehand evoking the history of eating disorders and the experience of the participant
89517022|NCT05769218|Experimental|CHORUS+|The baseline questionnaire for participants in this arm will be followed by a 30-minute motivational interviewing (MI) session with the peer recovery coach (PRC), and will assess readiness for change and provide information about PrEP. The PRC will also assess readiness for MOUD, and this will be further explored during subsequent visits.
89517023|NCT05769218|Active Comparator|Usual care- control|Participants in this arm will receive passive referral for care. there will be no PRC MI session and they will not be offered PrEP or MOUD.
89517024|NCT05766371|Experimental|Pembrolizumab, 177Lu-PSMA-617|Participants will receive an infusion of 7.4 gigabequerel (GBq) (+/- 10%) of 177Lu-PSMA-617 on Cycle 1 Day 1 (of a 28 day cycle), and at every PSA progression for up to a maximum of 6 doses. Beginning Cycle 2 Day 1 (Day 29), participants will receive 400 mg of Pembrolizumab every 6 weeks.
89517025|NCT05757843|Experimental|Consolidation to Durvalumab|All subjects will receive consolidation Durvalumab approximately every 4 weeks. Prior to the 5th cycle the first mandatory ctDNA test will be done. If it's negative and the subsequent test 4 weeks later prior to cycle 6 is negative, then Durvalumab will be stopped otherwise subject will continue consolidation durvalumab until 2 negative ctDNA analyses performed approximately 4 weeks apart or up to 1 year of consolidation per standard medical practice is complete.
89517026|NCT05757752|Other|Intervention|Participants meeting eligibility criteria will participate in the Mind Body Program for Vascular Disease, working in-person or via telehealth with a study interventionist for an hour weekly in 6-8 week cycles learning problem-solving techniques targeting mood/distress and enhancing disease management strategies. Participants will be assessed at baseline, 3-months, and 6-months.
89517027|NCT05754255|Active Comparator|Group A: standard care with a nasal cannula.|Group A will be given the standard nasal cannula during sedation. The cannula prongs will be inserted into the patient's nose to provide oxygen to the patient.
89517028|NCT05754255|Active Comparator|Group B: SuperNO2VA™EtCO2|Group B will be given a nasal oxygen to deliver gas, create a seal, and provide positive pressure. The mask will be placed over a patient's nose and connected to either an anesthesia circuit or hyperinflation bag during respiratory, anesthesia, and resuscitation procedures.
89517029|NCT05751577|Experimental|EXPERIMENTAL ARM: TAVI WITHOUT ON-SITE SURGERY|After randomization, study TAVI operators of the participating center will schedule the patient for TAVI within 7-10 days in their hospital without on-site surgery
89517030|NCT05751577|Active Comparator|CONTROL ARM: TAVI WITH ON-SITE SURGERY|After randomization, the patient will immediately be placed on the waiting list of the referring center with on-site cardiac surgery. Study TAVI operators of the participating center will perform the TAVI procedure in the hospital with on-site surgery according to the waiting list schedule of the latter
89517031|NCT05746195|Experimental|Text message intervention|Adaptive 12-week text message intervention using reinforcement learning to increase whole grain and reduce refined grain intake. Participants will also complete semi-structured follow-up interviews and study related questionnaires.
89517032|NCT05701982|Experimental|Every Step Counts-Tai Chi|The intervention is ESC-TC which is a web-based platform (Every Step Counts) to promote walking combined with pain management content, an online Tai Chi video library, and synchronous Tai Chi classes led by an instructor via teleconference. The intervention is delivered remotely.
89517033|NCT05701982|Active Comparator|Usual Care|Usual Care
89517034|NCT05686135|Experimental|90Second IBD|Participants will receive 90SecondIBD weekly at no charge via text message or email linked to a website.
89517035|NCT05670990|Experimental|Equine assisted therapy|"once a week during 10 weeks the children will come to Humlamaden which is a horse farm with special trained horses and employees with specialist education in psychiatric care. During the time at the farm the child will go through a structured program that starts at the first time with just resting on the horse back under blankets"
89517036|NCT05670990|No Intervention|Control|This group will receive treatment as usual and consist of those who is randomized to control group.
89517037|NCT05669976|Experimental|Safety Planning Intervention with Navigation Services|A patient navigation (PN) intervention for SGM youth/emerging adults designed to target mechanisms (i.e., decreasing thwarted belongingness and increasing suicide-related coping skills) that theoretically underlie suicide. The proposed intervention integrates a single-session, empirically supported, suicide prevention intervention (Safety Planning Intervention; SPI) with PN services (PN+SPI). The patient navigator will deliver the SPI and continue frequent contact for the purpose of providing motivational enhancement, problem-solving, reinforcing coping strategies, and connecting participants to mental health and social support resources (e.g., SGM-specific support groups within the community).
89517038|NCT05669976|Active Comparator|Safety Planning Intervention|The Safety Planning Intervention (SPI) is a single-session, empirically supported, suicide prevention intervention. The patient navigator will deliver the SPI.
89517039|NCT05664204|Experimental|Systematic ECMO|VA-ECMO will be implanted before the first pulmonary artery cross-clamp, in a systematic manner
89517040|NCT05664204|Active Comparator|On-demand ECMO|"VA-ECMO will be implanted intraoperatively, in an unplanned manner if the hemodynamic and respiratory indices meet pre-planned criteria at different time-points:~a PaO2/FiO2 ratio<100 mmHg or a respiratory acidosis, with pH< 7.2, PaCO2>60 mmHg, a mean pulmonary arterial pressure>50mmHg (or 2/3 of MAP) and/or an acute pulmonal core at trans-esophageal echography monitoring an acute left ventricular dysfunction at trans-esophageal echography monitoring"
89517041|NCT05658536|Active Comparator|6-Week Self-Management Group|6-week telemedicine group-based intervention designed to improve symptom management and coping in adults with Post-COVID. The intervention consists of six weekly group sessions that are 1.5 hours long. Group size is 8-10 participants.
89517042|NCT05658536|No Intervention|6-Week Waitlist Group|6-week waitlist period during which participants will complete study assessments. After completing the study, waitlist participants will be offered the active intervention.
89517043|NCT05652686|Experimental|Dose Escalation|An accelerated titration design will be employed, and 1 patient will be enrolled initially at each of the lower dose levels: 0.2 mg/kg, 0.6 mg/kg and 2 mg/kg. The starting dose to be evaluated in the dose escalation study is 0.2 mg/kg weekly (QW). Additional provisional dose levels include: 6 mg/kg QW, 12 mg/kg QW.
89517044|NCT05652686|Experimental|Dose Expansion|"There will be two Dose Expansion Cohorts:~Cohort 1: RP2D, with a focus on SCLC patients. Cohort 2: RP2D minus 1 dose level, with a focus on all neuroendocrine cancer patients (limit of n=5 that are not SCLC)."
89517045|NCT05647096|Experimental|NucleoCapture Treatment|Participants in the NucleoCapture treatment arm will receive Standard of Care plus three treatment sessions with the NucleoCapture treatment device. The device consists of 100ml NucleoCapture selective adsorber.
89517046|NCT05647096|No Intervention|Standard of Care|Participants in the Standard of Care arm will receive standard medical care alone.
89517047|NCT05637710|Experimental|Group 1|Investigational group: FDC levocetirizine 5mg / pseudoephedrine 240mg from Eurofarma Laboratórios S.A.
89517048|NCT05637710|Active Comparator|Group 2|Comparator group: Levocetirizine 5mg (Zina® - comparator drug)
89517049|NCT05634395|Experimental|Intervention with activity tracker|Women allocated to the intervention arm will used an activity tracker
89517050|NCT05618925|Experimental|Arm A|Subjects in both cohorts will initially receive lymphodepleting chemotherapy followed by a single 4-week cycle of the CD19 t-haNK single-agent regimen. Following a 1-week rest period, subjects will then receive lymphodepleting chemotherapy followed by a single 4-week cycle of CD19 t-haNK in combination with rituximab
89517051|NCT05618925|Experimental|Arm B|Subjects in both cohorts will initially receive lymphodepleting chemotherapy followed by a single 4-week cycle of the CD19 t-haNK single-agent regimen. Following a 1-week rest period, subjects will then receive lymphodepleting chemotherapy followed by a single 4-week cycle of CD19 t-haNK in combination with rituximab (cohort A) or in combination with rituximab and N-803 (cohort B).
89517052|NCT05610826|Other|Arm 1- Control Arm - Standard Of Care - no peptide receptor radionuclide therapy|Arm 1 is the control arm, which will undergo standard of care cytoreductive surgery (for the tumor). Participants in this arm will not receive peptide receptor radionuclide therapy (PRRT).
89517053|NCT05610826|Experimental|Arm 2 (peptide receptor radionuclide therapy + cytoreductive surgery)|Arm 2 will undergo four cycles of peptide receptor radionuclide therapy (PRRT) before cytoreductive surgery.
89517054|NCT05607004|Experimental|PK Cohort|"(Z)-endoxifen capsules orally once daily for 4 weeks. Initial (Z)-endoxifen dose evaluated will be 40 mg with an option to evaluate 20 mg or 80 mg.~The PK Cohort participants may extend treatment based on Ki-67% at Week 4.~If Ki-67 ≤ 10% at Week 4, participant will be offered option to continue on this treatment for up to 6 cycles/Week 24. Each cycle is 28 days.~If Ki-67 > 10% at Week 4, participant will be withdrawn and go on to surgery."
89517055|NCT05607004|Experimental|Treatment Cohort Arm 1 Initial Regimen|"(Z)-endoxifen capsules orally once daily for 4 weeks. Dose will be based on the results of the PK Cohort.~If Ki-67 ≤ 10% at Week 4, continue on this treatment for up to 6 cycles/Week 24. Each cycle is 28 days.~If Ki-67 > 10% at Week 4, participant will be offered modified regimen or be withdrawn and go on to surgery."
89517056|NCT05607004|Active Comparator|Treatment Cohort Arm 2 Initial Regimen|"Exemestane 25 mg orally once daily for 4 weeks + goserelin 3.6 mg by subcutaneous implant approximately every 28 days.~If Ki-67 ≤ 10% at Week 4, continue on this treatment for up to 6 cycles/Week 24. Each cycle is 28 days.~If Ki-67 > 10% at Week 4, participant will be offered modified regimen or be withdrawn and go on to surgery."
89517057|NCT05607004|Experimental|Treatment Cohort Arm 1 Modified Regimen|"(Z)-endoxifen capsules orally once daily for 4 weeks + goserelin 3.6 mg by subcutaneous implant approximately every 28 days. (Z)-endoxifen dose will be based on the results of the PK Cohort.~If Ki-67 ≤ 10% after 4 weeks of modified regimen, continue on this treatment for up to 6 total treatment cycles/Week 24. Each cycle is 28 days.~If Ki-67 > 10% after 4 weeks of modified regimen, participant will be withdrawn and go on to surgery."
89517058|NCT05607004|Experimental|Treatment Cohort Arm 2 Modified Regimen|"(Z)-endoxifen capsules orally once daily for 4 weeks + goserelin 3.6 mg by subcutaneous implant approximately every 28 days. (Z)-endoxifen dose will be based on the results of the PK Cohort.~If Ki-67 ≤ 10% after 4 weeks of modified regimen, continue on this treatment for up to 6 total treatment cycles/Week 24. Each cycle is 28 days.~If Ki-67 > 10% after 4 weeks of modified regimen, participant will be withdrawn and go on to surgery."
89517059|NCT05607004|Experimental|PK Cohort 80 mg|"(Z)-endoxifen 80 mg capsules orally once daily for 4 weeks.~The PK Cohort participants may extend treatment based on Ki-67% at Week 4.~If Ki-67 ≤ 10% at Week 4, participant will be offered option to continue on this treatment for up to 6 cycles/Week 24. Each cycle is 28 days.~If Ki-67 > 10% at Week 4, participant will be withdrawn and go on to surgery."
89517060|NCT05607004|Experimental|PK Cohort 80 mg + OFS|"(Z)-endoxifen 80 mg capsules orally once daily for 4 weeks + goserelin 3.6 mg by subcutaneous implant approximately every 28 days.~The PK Cohort participants may extend treatment based on Ki-67% at Week 4.~If Ki-67 ≤ 10% at Week 4, participant will be offered option to continue on this treatment for up to 6 cycles/Week 24. Each cycle is 28 days.~If Ki-67 > 10% at Week 4, participant will be withdrawn and go on to surgery."
89517061|NCT05605964|Experimental|Relugolix|Oral relugolix 120 mg once daily with a loading dose of 360 mg on Day 1
89517062|NCT05605964|Active Comparator|Leuprolide Acetate|Subcutaneous or intramuscular leuprolide acetate 22.5 mg 3-M depot or 45 mg 6-M injection or Leuprolide acetate injectable emulsion (42 mg injectable emulsion is not allowed)
89517063|NCT05589285|Experimental|Treatment group|Chronic plantar fasciitis patients who will receive autologous whole blood injection.
89517064|NCT05589285|Sham Comparator|Control group|Chronic plantar fasciitis patients who will receive normal saline injection.
89517065|NCT05587179|Experimental|Lateral side-lying recovery position with extended arm|The lateral side-lying recovery position with extended arm is directly based on the revised 2021 ERC guidelines recommending to extend the dependent arm and placing it next to the creased upper lying arm, which supports the head.
89517066|NCT05587179|Active Comparator|Lateral side-lying recovery position with bent arms|In the lateral side-lying recovery position with bent arms, the elbow of the dependent arm will now be bent with palm up and the far knee still flexed.
89517067|NCT05556746|Experimental|BCZD|Bedaquiline 200 mg for 12 weeks + pyrazinamide 1000 - 2000 mg (according to weight) for 12 weeks + clofazimine 300 mg for 2 weeks, followed by 100 mg for 10 weeks + delamanid 200 mg for 12 weeks, all given once daily.
89517068|NCT05556746|Active Comparator|Standard TB Treatment|Rifampin, isoniazid, ethambutol and pyrazinamide for 8 weeks, followed by rifampin and isoniazid for 18 weeks; given daily in fixed dose combinations at standard weight-based doses.
89517069|NCT05555914|Experimental|Neurostimulation|Implantation of 3 multicontact cuff electrodes in the upper limb of patients with tetraplegia
89517070|NCT05550311|Experimental|Robot group|In addition to conventional treatment, an upper extremity robot-assisted rehabilitation program will be applied for 45 minutes a day, two days a week.
89517071|NCT05550311|Active Comparator|Control Group|Participants in this group will be included in a conventional rehabilitation program
89517072|NCT05549518|Experimental|Core stabilization + Traditional Physical Therapy|In addition to the traditional physical therapy training, core stabilization exercises will be applied in this group.
89517073|NCT05549518|Active Comparator|Traditional Physical Therapy|This group will continue the traditional physical therapy program.
89517074|NCT05539872|Experimental|Insulin Aspart, I004|Participants who were dosed with I004
89517075|NCT05539872|Active Comparator|NovoLog|Participants who were dosed with NovoLog
89517076|NCT05534919|Experimental|Nefecon active treatment|Nefecon 16mg once daily for 9 months.
89517077|NCT05528380|Experimental|Open Trial Intervention|Participants will receive a Fitbit to track activity levels and participate in a 6-session lifestyle physical activity intervention over the course of 12 weeks. The intervention consists of 20-25 minute phone or video-delivered session to: (a) review PA progress and re-evaluate current step-count goals, (b) problem-solve barriers to incorporating PA into their daily lives, (c) address difficulties utilizing the Fitbit, (d) encourage the use of bouts of PA as a coping strategy, and e) engage the participant in brief discussions focused on increasing and maintaining PA.
89517078|NCT05526079|Experimental|Watchful Waiting|"Six cycles of FOLFOX (infusional fluorouracil, leucovorin, and oxaliplatin) will be administered every two weeks according to protocol. After a 3 week recovery period, this will be followed by conventional concurrent radiation and 5FU/capecitabine.~Patients will be re-staged two to three weeks after completion of induction FOLFOX therapy to ensure no disease progression. The patients will be re-staged again at least 7-11 weeks post completion of nCRT. Patients with restaging results showing either complete or near complete response, will be allocated to watchful waiting."
89517079|NCT05512247|Experimental|Meal Delivery|Behavioral intervention program designed to improve diet quality and promote healthy weight gain in women with overweight/obesity through meal delivery and behavioral strategies during pregnancy.
89517080|NCT05512208|Experimental|Avutometinib (VS-6766) + Defactinib|"Avutometinib (VS-6766): will be administered at 3.2 mg orally twice a week~Defactinib: will be administered at 200 mg orally twice a day (BID)."
89517081|NCT05505942|Experimental|Lifestyle Physical Activity (LPA)|The LPA arm will receive 7 LPA sessions with a trained interventionist to assist in adding LPA to the participant's routine.
89517082|NCT05505942|Active Comparator|Fitbit Only|The Fitbit only arm will receive only brief check in phone calls and only related to assisting with any Fitbit functioning issues.
89517083|NCT05503173|Experimental|Motivational and Cognitive-Behavioral Management for Alcohol and Pain Intervention (MCBMAP)|Participants randomized to this arm will receive MCBMAP which utilizes a self-regulation framework to integrate evidence-based approaches for chronic pain and unhealthy drinking.
89517084|NCT05503173|Active Comparator|Brief Advice and Information|Participants randomized to this arm will be provided treatment as usual for their conditions.
89517085|NCT05479734|Experimental|mHealth Intervention + EMA|When families are in the mHealth intervention condition, the mHealth app will deliver parenting tips and strategies daily for 14 days. Furthermore, we plan to administer brief surveys via the mHealth app twice once a day at a pre-determined time. These surveys will ask parents to provide information about where they are and with whom, their emotional state, any recent parent-child interactions, and any current stressors or challenges. Parents will receive these daily surveys and the parenting tips for every day for two weeks. Then they will switch to EMA Only + Services As Usual.
89517086|NCT05479734|No Intervention|EMA Only+ Services As Usual|In the EMA only condition, families will continue to receive services utilizing the home visiting model for the program they are enrolled in, including modules on healthy parent-child interaction and promoting parenting skills in high-risk families, but they will not receive parenting tips via the mHealth app during this period (2 weeks). Then, they will switch to mHealth Intervention + EMA.
89517087|NCT05463848|Experimental|Cohort 1 (Safety Lead In): pembrolizumab plus olaparib and temozolomide|"Following a 3 + 3 dose escalation design 6-18 participants will receive:~Olaparib 2x daily on Days 1-7 of each 21-day study cycle.~Temozolomide 1x daily on Days 1-7 of each 21-day study cycle.~Pembrolizumab on Day 1 of every other 21-day cycle (once every 6 weeks)."
89517088|NCT05463848|Experimental|Cohort 2 (Surgical Cohort): Arm A - Pembrolizumab plus olaparib and temozolomide|"Cohort 2 participants will be randomized into either group a or b (1:1):~Group A participants will receive pembrolizumab, olaparib, and temozolomide before and after surgery.~Olaparib 2x daily on Days 1-7 of each 21-day study cycle.~Temozolomide 1x daily on Days 1-7 of each 21-day study cycle.~Pembrolizumab on Day 1 of every other 21-day cycle (once every 6 weeks)."
89517089|NCT05463848|Experimental|Cohort 2 (Surgical Cohort): Arm B - Pembrolizumab monotherapy|"Cohort 2 participants will be randomized into either group a or b (1:1):~Group B participants will receive pembrolizumab monotherapy before and after surgery.~Pembrolizumab Before Surgery: Day 1 of the pre-surgical treatment cycle.~Pembrolizumab After Surgery: Day 1 of every other 21-day cycle (once every 6 weeks)."
89517090|NCT05458258||Adults (age 60+) with Newly Diagnosed AML|This group will consist of participants age 60+ who will be assessed for malnutrition and sarcopenia. Participants in this group will undergo chemotherapy and/or receive cancer drugs (as part of standard care). Participants in this group will receive different assessments when they start induction therapy to measure their nutritional health and the severity of their sarcopenia.
89517091|NCT05458258||Healthy Control Group: Adults with AML (age 60+) in Good Health|This group will also consist of participants age 60+ who will be assessed for malnutrition and sarcopenia. Participants in this group will undergo induction therapy and/or receive cancer drugs to treat their AML (as part of standard care). Participants in this group will also receive different assessments when they start induction therapy to measure their nutritional health and the severity of their sarcopenia. Participants in this group will receive the same assessment as participants in the first study group -- the only difference is that participants in this group have been determined to be healthier than those in the first study group according to clinical assessments.
89517092|NCT05456490|Experimental|Liposomal Bupivacaine 13.3|"Cohort 1 subjects will be dosed 2 mL (26.6 mg) of Liposomal Bupivacaine 13.3.~Cohort 2 subjects randomized to the Liposomal Bupivacaine 13.3 arm will be dosed 3 mL (39.9 mg) of Liposomal Bupivacaine 13.3.~Cohort 3 subjects randomized to the Liposomal Bupivacaine 13.3 arm will be dosed 4 mL (53.2 mg) of Liposomal Bupivacaine 13.3."
89517093|NCT05456490|Active Comparator|Bupivacaine IT|"Cohort 1 subjects randomized to the bupivacaine arm will be dosed 2 mL (7.5 mg/ 1 mL) of 0.75% bupivacaine.~Cohort 2 subjects randomized to the bupivacaine arm will be dosed 2 mL (7.5 mg/ 1 mL) of 0.75% bupivacaine mixed with 1 mL of preservative free normal saline to create a total volume of solution administered of 3 mL.~Cohort 3 subjects randomized to the bupivacaine arm will be dosed 2 mL (7.5 mg / 1 mL) of 0.75% bupivacaine mixed with 2 mL of preservative free normal saline to create a total volume of solution administered of 4 mL."
89517094|NCT05456490|Placebo Comparator|Placebo|"Cohort 1 subjects randomized to the placebo arm will be dosed 2 mL of preservative free normal saline.~Cohort 2 subjects randomized to the placebo arm will be dosed 3 mL of preservative free normal saline.~Cohort 3 subjects randomized to the placebo arm will be dosed 4 mL of preservative free normal saline."
89517095|NCT05444894|Experimental|EDIT-301|EDIT-301 (autologous gene edited (CD)34+ hematopoietic stem cells) will be administered as a one-time intravenous infusion.
89517096|NCT05441163|Experimental|APA and nutrition program|
89517097|NCT05441163|No Intervention|control group|
89517098|NCT05431322|Experimental|Total intravenous anesthesia (TIVA) + Dexmedetomidine|Total intravenous anesthetic drug is propofol. Dexmedetomidine is infused continuously.
89517099|NCT05431322|No Intervention|Total intravenous anesthesia (TIVA)|Total intravenous anesthetic drug is propofol. The ordinary pain is controlled mainly by opioids.
89517100|NCT05427435|Experimental|Marshall ethanolisation with specific catheter|Patients will undergo the destruction of Marshall bundles by ethanol infusion with the specific catheter
89517101|NCT05422612|Experimental|Intervention A: Fluoxetine HCl|
89517102|NCT05422612|Placebo Comparator|Intervention A Placebo|
89517103|NCT05422612|Experimental|Intervention B Vilazodone|
89517104|NCT05422612|Placebo Comparator|Intervention B Placebo|
89517105|NCT05422612|Experimental|Intervention C Daridorexant|
89517106|NCT05422612|Placebo Comparator|Intervention C Placebo|
89544640|NCT03191201|Placebo Comparator|Placebo arm|"A commercially available sterile, 250 mL, 0.9% sodium chloride solution will be administered by drip infusion (Intravenous route). Infusion time will be 15 minutes.~At the end of the randomised part of the study, participants initially randomised to the placebo group will be included in a non-blinded open-label extension part and receive a FCM 1000 mg injection."
89207649|NCT00862368|Active Comparator|PAM-Healthy|The PAM-Healthy arm received the same in-home counseling visits as PAM and PAM Enhanced but asthma information was replaced with child wellness topics. The 6 counseling phone calls were the same timing and duration as the other two groups (six, 15 minutes calls, over four months) focused on a child wellness topic. Smoking cessation or sampler feedback was not discussed. Motivational Interviewing approaches were used in all in-home and phone counseling. Free nicotine patch tx was given if they were ready to quit within 30 days.
89207650|NCT00971685|Experimental|Lenalidomide plus Dexamethasone|RD regimen: Lenalidomide 25 mg/die for 21 days every month for 6 cycles, with once-weekly dexamethasone (40 mg).
89207651|NCT03861052|Experimental|5 mg Tirzepatide|Participants received 5 milligram (mg) tirzepatide administered subcutaneously (SC) once weekly for 52 weeks.
89207652|NCT03861052|Experimental|10 mg Tirzepatide|Participants received 10 mg tirzepatide administered SC once weekly for 52 weeks.
89207653|NCT03861052|Experimental|15 mg Tirzepatide|Participants received 15 mg tirzepatide administered SC once weekly for 52 weeks.
89207654|NCT03861052|Active Comparator|0.75 mg Dulaglutide|Participants received 0.75 mg dulaglutide administered SC once weekly for 52 weeks.
89207655|NCT00790634||Parkinson's Disease|Patients with idiopathic Parkinson's disease
89207656|NCT00790634||Obsessive-compulsive disorder|Individuals with a diagnosis of obsessive-compulsive disorder
89207657|NCT00790634||OCD controls|Healthy controls, matched in age and number to obsessive-compulsive group
89207658|NCT00790634||PD controls|Healthy controls, matched in age and number to Parkinson's disease group
89207659|NCT00971763|Experimental|R-GCVP|"Up to 6 x 21 day cycles of R-GCVP:~Gemcitabine 750mg/m^2 days 1 & 8 (increasing to 875mg/m^2 for cycle 2 & 1g/m^2 for subsequent cycles if tolerated satisfactorily)~Cyclophosphamide 750mg/m^2 day 1~Vincristine 1.4mg/m^2 day 1 (capped at 2mg)~Prednisolone 100mg/day days 1-5~Rituximab 375mg/m^2 day 1~Neulasta 6mg day 9"
89207660|NCT04018170|Experimental|JW1601|tablet formulation
89207661|NCT04018170|Placebo Comparator|Placebo|tablet formulation identified with JW1601
89207662|NCT00785252|Experimental|1|EZIO
89207663|NCT00785252|Experimental|2|Central line
89207664|NCT00857688|Experimental|1 - Test|Patients will recieve the association.
89207665|NCT00857688|Placebo Comparator|2|Placebo: Menthol, saccharin sodium, propylene glycol, sodium hydroxide, glycerol, ethyl alcohol, water
89207666|NCT00959829|Placebo Comparator|silence|"The control group listened silence and was evaluated the same things."
89207667|NCT00781196|Experimental|1|Oral folic acid
89207668|NCT00781196|Placebo Comparator|2|placebo
89207669|NCT00865644|Experimental|Imiquimod|
89207670|NCT00785330|Other|A|Patients receiving no rituximab as GVHD prophylaxis after allogeneic SZT and only standard GVHD prophylaxis (tacrolimus with aimed serum level of 10 ng / ml and mycophenolat mofetil 2 x 1 g p.o. day 1 to 28 after allogeneic SZT
89207671|NCT00785330|Experimental|B|rituximab in addition to standard GVHD prophylaxis
89207672|NCT00974649|No Intervention|Included in questionnaire study|
89207673|NCT02555150|Active Comparator|PRC-063|Titration during which subjects will be titrated from a starting dose of 45 mg/day (dosed once daily) of PRC-063 oral capsules up to his/her final dose (45, 70 or 100 mg/day of PRC-063). This phase will be 10 to 21 days long.
89207674|NCT02555150|Active Comparator|lisdexamfetamine dimesylate|Titration during which subjects will be titrated from a starting dose of 30 mg/day of lisdexamfetamine up to his/her final dose (30, 50 or 70 mg/day of LDX). This phase will be 10 to 21 days long.
89207675|NCT02555150|Placebo Comparator|Placebo|Subjects will be dosed once daily with a placebo oral capsule for 10 to 21 days.
89207676|NCT00790946|Active Comparator|Valsartan|Valsartan 80 to 160mg
89207677|NCT00790946|No Intervention|standard therapy|
89207678|NCT05263102|Experimental|Treatment Arm|Treatment duration: 8 weeks Twice treatments per week
89207679|NCT05179239|Experimental|SHR-1701 + paclitaxel + cisplatin/carboplatin + BP102|
89207680|NCT05179239|Experimental|SHR-1701 + paclitaxel + cisplatin/carboplatin ± BP102|
89207681|NCT05179239|Placebo Comparator|Placebo + paclitaxel + cisplatin/carboplatin ± BP102|
89207682|NCT04046666|Other|COPD group|This group will include 40 patients with chronic obstructive pulmonary disease (COPD).
89207683|NCT04046666|Other|Healthy group|This group will include 40 healthy volunteers.
89207684|NCT04046666|Other|Healthy intervention group|This group will include 40 healthy volunteers, who will receive moxibustion intervention.
89207685|NCT04527874|Experimental|Intervention|Clusters in the intervention arm receive the VITAL intervention (see intervention)
89207686|NCT04527874|No Intervention|Control|Clusters in the control arm continue standard of care.
89207687|NCT00972075|Experimental|Circadin|Circadin is 2 mg of prolonged release melatonin
89207688|NCT00972075|Placebo Comparator|Placebo|
89207689|NCT00974727|Experimental|Gardening Program|
89207690|NCT00974727|No Intervention|Control|Subjects received the standard of care for the summer.
89207691|NCT00785408|Experimental|1|
89207692|NCT00785408|Experimental|2|
89207693|NCT00785408|Experimental|3|
89207694|NCT00785408|Placebo Comparator|4|
89207695|NCT00785408|Placebo Comparator|5|
89207696|NCT00785408|Placebo Comparator|6|
89207697|NCT01565122||Cohort|
89207698|NCT00974805|Experimental|Seretide 500 Accuhaler|Seretide 500 Accuhaler one inhalation BD
89207699|NCT00781352|Active Comparator|group 1|Colorectal surgery with 65% nitrous oxide administration
89207700|NCT00781352|Active Comparator|group 2|Colorectal surgery with nitrogen administration
89207701|NCT00960219|Experimental|DAAOI-1|
89207702|NCT00960219|Placebo Comparator|placebo|
89207703|NCT02555774|Experimental|cognitive training|Cognitive training programs 2 times a week for 3 months (totally 24 sessions) for 90 minutes per session. Lifestyle modification is educated first, then weekly phone call for lifestyle modification is done by investigators.
89207704|NCT02555774|Active Comparator|lifestyle modification|This group receives only lifestyle modification for 3 months. Lifestyle modification is educated at the first, then weekly phone call for lifestyle modification is done by investigators. The method of lifestyle modification is same with the first arm.
89517107|NCT05418725|Experimental|PEF Arm|PEF is a non-thermal ablation modality using extremely short high voltage pulses to induce cell death, with tissue selectivity, cardiomyocytes being much more sensitive to this energy than Phrenic nerve or Esophageal cells. Energy (2000 V) will be delivered 8 times per vein with 2 different catheter configurations and rotations. Linear lesion will be delivered using 8 deliveries using 2000 V at the posterior left atrium
89517108|NCT05418725|Active Comparator|Pulmonary vein isolation and linear lesion using Contact Force RF|The PVI strategy using RF is very standard. The CARTO© platform will be used, with a contact force catheter (SmartTouch), aiming at an ablation index value of 300 to 400 on the posterior wall, and at least 500 on the anterior wall. Power will be limited to 35/45 W, with a distance between consecutive deliveries of 6 mm or less (CLOSE protocol). Linear lesion will be delivered at the posterior left atrium.
89517109|NCT05414370|Active Comparator|Liquid medical oxygen|Liquid medical oxygen will be administered using high-flow nasal cannula delivery system.
89517110|NCT05414370|Placebo Comparator|Synthetic medical air|Synthetic medical air will be administered using high-flow nasal cannula delivery system.
89517111|NCT05406622|Experimental|MOTIV Sirolimus-Eluting Bioresorbable Scaffold|Participants who receive the MOTIV device will be included in this arm
89517112|NCT05406622|Active Comparator|Percutaneous Transluminal Angioplasty (PTA)|Participants who receive PTA treatment will be included in this arm
89517113|NCT05390502|Experimental|Integrated|Participants will have their home blood pressure readings sent directly to their participating health systems. Participants will also receive a wrap-around intervention.
89517114|NCT05390502|Active Comparator|Manual|Participants will record their own blood pressures and report them to their health care system as per usual care.
89517115|NCT05388318|Experimental|Prolonged nightly fasting (PNF)|
89517116|NCT05388318|Active Comparator|Health Education Control (HEC)|
89517117|NCT05378425|Experimental|Part 1 - Dose Escalation Phase (Monotherapy)|NTX-1088 administered as a 60-minute IV infusion at escalating doses as a monotherapy. NTX-1088 will be administered on Day 1 of a 21-day cycle.
89517118|NCT05378425|Experimental|Part 1 - Dose Escalation Phase (Combination Therapy)|"NTX-1088 administered as a 60-minute IV infusion in escalating doses in combination with pembrolizumab. NTX-1088 will be administered on Day 1 of a 21-day cycle.~Pembrolizumab will be administered as a 30-minute IV infusion, within 2 hours prior to NTX-1088 administration, at a dose of 200 mg on Day 1 of every 21-day cycle."
89517119|NCT05378425|Experimental|Part 2 - Dose Expansion (Monotherapy)|NTX-1088 administered at the RP2D as a 60-minute IV infusion as a monotherapy.
89517120|NCT05378425|Experimental|Part 2 - Dose Expansion (Combination Therapy)|NTX-1088 administered at the RP2D as a 60-minute IV infusion in combination with pembrolizumab at the standard labeled dose.
89517121|NCT05366660|Experimental|CIED's interrogation/programming|All the patients will be included in this single arm to interrogate/programm their CIED
89517122|NCT05359042|Experimental|ePRO Assessment Tool|Participants will receive either a text message or an email inviting them to engage in the health chat. Participant assessments including HRQOL and user experience will be administered via the platform. Participants will also be able to participate in short, interactive patient education modules related to the infusion and side effect management.
89517123|NCT05359042|No Intervention|Standard of Care|Participants in the standard of care arm will report symptoms via standard of care messaging through UCSF MyChart or telephone calls throughout the study period, and complete standard of care HRQoL surveys.
89517124|NCT05358353|Experimental|Bare Temporary Spur Stent System|Treatment with the Temporary Bare Spur Stent System (Spur Stent System).
89517125|NCT05351138|Experimental|TENS Group|Transcutaneus electric nerve stimulation intervention will be done for a total of 12 weeks, 2 sessions of 20 minutes per week.
89517126|NCT05351138|Experimental|Masaj Group|Massage intervention will be done in the form of massage practise to the abdominal region, 2 sessions of 20 minutes per week.
89517127|NCT05303051|Experimental|Study Population|The investigators will conduct an electronic medical record (EMR) query of individuals in the University of California, San Francisco (UCSF) primary care clinics without a prior diagnosis of DM and who are undergoing, or who have recently undergone, a lab measured HBA1c before or after 1 month of enrollment. sample size estimation for testing the estimated AUROC in the validation sample vs. the null value of AUC 0.7. The investigators will target an enrollment of 5006 subjects in order to obtain a pre-specified AUROC 95% confidence interval width of 0.07 (i.e. AUROC = 0.76 [95%CI 0.725, 0.795]). The investigators assume that ~4% of the cohort will have undiagnosed diabetes based on national prevalence estimates.
89517128|NCT05303051|Experimental|Alternative Sample Group|The investigators also aim to perform a sensitivity analysis to estimate the DNN performance in a target general population without a diabetes diagnosis. The investigators will recruit patients from the UCSF EHR system without a history of diabetes, no prior HBA1c measured, and no history of known diabetic risk factors. The investigators will target an enrollment of 1000 subjects in order to obtain a pre-specified AUROC 95% confidence interval width of 0.18 (i.e. AUROC = 0.76 [95%CI 0.67, 0.85]). The investigators assume that ~3% of the cohort will have undiagnosed diabetes based on national prevalence estimates.
89517129|NCT05297695|Experimental|Study group|Children with drug-resistant idiopathic generalized epilepsy and positive H. pylori stool antigen test who will receive H. pylori eradication therapy.
89517130|NCT05297695|No Intervention|Control group|Children with drug-resistant idiopathic generalized epilepsy and positive H. pylori stool antigen test who will not receive H. pylori eradication therapy.
89517131|NCT05281510|Experimental|VRC07523LS + CAP256V2LS + Vesatolimod (VES)|Participants will receive VES 6 mg (or up to 8 mg) every 2 weeks, for a total of 10 doses + VRC07-523LS and CAP256V2LS 20 mg/kg each on Day 7.
89207705|NCT02555774|No Intervention|No intervention|This group receives no intervention.
89207706|NCT00972231||Thalassemia Group|Patients suffering from Thalassemia Major and patients with Thalassemia Intermedia
89207707|NCT00972231||Sickle Cell Group|Patients with Sickle Cell Anemia and Sickle Cell Thalassemia
89207708|NCT00791024|Experimental|single arm|
89517132|NCT05275478|Experimental|Dose Escalation|Participants with MTAP-deleted solid tumors will receive escalating doses of TNG908 to estimate the MTD
89517133|NCT05275478|Experimental|Dose Expansion in NSCLC|Participants with MTAP-deleted NSCLC (squamous and non squamous) will receive TNG908 at the identified RP2D
89517134|NCT05275478|Experimental|Dose Expansion in Mesothelioma|Participants with MTAP-deleted mesothelioma will receive TNG908 at the identified RP2D
89517135|NCT05275478|Experimental|Dose Expansion in Pancreatic Ductal Adenocarcinoma|Participants with MTAP-deleted pancreatic ductal adenocarcinoma will receive TNG908 at the identified RP2D
89207709|NCT00974883||Suspected GCA|Patients who present with new onset of headache and suspected diagnosis of GCA. They will all require a temporal artery biopsy to assist in the diagnosis
89207710|NCT00974883||Training cohort|Patients with any condition or healthy volunteers who are willing to consent ot have their temporal and axillary arteries examined using ultrasound, for training purposes
89517136|NCT05275478|Experimental|Dose Expansion in Sarcoma|Participants with MTAP-deleted sarcoma (soft tissue and bone) will receive TNG908 at the identified RP2D
89517137|NCT05275478|Experimental|Dose Expansion in solid tumors|Participants with other MTAP-deleted solid tumors will receive TNG908 at the identified RP2D
89517138|NCT05275478|Experimental|Dose Expansion in Glioblastoma|Participants with MTAP-deleted relapsed/refractory glioblastoma will receive TNG908 at the identified RP2D
89517139|NCT05271318|Experimental|TILT-123 and pembrolizumab|"Patients will receive multiple administrations of TILT-123 and pembrolizumab.~Escalation to the next dose of TILT-123 level will occur when the safety data has been evaluated for all patients in the preceding dose level."
89517140|NCT05266066|Experimental|Clinical observation without antibiotic therapy for VAT|Patients will receive standard care and no antibiotic therapy for VAT. Antibiotics will be prescribed if other infections and/or organ dysfunction ensues (especially shock) or there is progression to pneumonia
89517141|NCT05266066|Active Comparator|7 day antibiotic course for VAT|Patients will receive standard care and 7 day course of antibiotic therapy for VAT.
89517142|NCT05256745|Experimental|Cohort 1: TTP488 (Azeliragon) co-administered with dose dense paclitaxel (ddAC/ddT)|Cohort 1: On day 7 of cycle 3, twelve capsules of azeliragon taken daily for 6 days, and then four capsules of Azeliragon each day continuously through the end of that cycle of chemotherapy, extending into Cycle 4 Day 2 (C4D2).
89517143|NCT05256745|Experimental|Cohort 2: TTP488 (Azeliragon) co-administered with TC|"TC: docetaxel and cyclophosphamide~Cohort 2a (6 cycles): Cycle 5 Day 14 (C5D14), take twelve capsules of azeliragon daily for 6 days, then four capsules of Azeliragon each day continuously through the end of that cycle of chemotherapy, extending into Cycle 6 Day 2 (C6D2).~Cohort 2b (4 cycles): Cycle 3 Day 14 (C3D14), take twelve capsules of azeliragon daily for 6 days, then four capsules of Azeliragon each day continuously through the end of that cycle of chemotherapy, extending into Cycle 4 Day 2 (C4D2)."
89517144|NCT05256745|Experimental|Cohort 3: TTP488 (Azeliragon) co-administered with TCHP|TCHP: docetaxel, carboplatin, trastuzumab, and pertuzumab Cohort 3: Cycle 5 Day 14 (C5D14), take twelve capsules of azeliragon daily for 6 days, then four capsules of Azeliragon each day continuously through the end of that cycle of chemotherapy, extending into Cycle 6 Day 2 (C6D2).
89517145|NCT05256745|Experimental|Cohort 4: TTP488 (Azeliragon) co-administered with chemotherapy regimen that includes ddAC|"given at the end of the chemotherapy plan [can include: (1)weekly carboplatin + paclitaxel + pembrolizumab followed by pembrolizumab + dose dense doxorubicin and cyclophosphamide; (2) weekly carboplatin + paclitaxel followed by dose dense doxorubicin and cyclophosphamide; (3) weekly or dose dense paclitaxel followed by dose dense doxorubicin and cyclophosphamide]~Cohort 4: On day 7 of cycle 3, twelve capsules of azeliragon taken daily for 6 days, and then four capsules of Azeliragon each day continuously through the end of that cycle of chemotherapy, extending into Cycle 4 Day 2 (C4D2)."
89517146|NCT05242627|No Intervention|DGSOM Class of 2023|
89517147|NCT05242627|Experimental|DGSOM Class of 2024|
89517148|NCT05241847|Experimental|Pediatric liver transplant recipients|"As this is a single arm trial, all eligible liver transplant recipients and their caregivers will be enrolled in this arm.~Eligible participants are children who received a liver transplant at least 1 year prior to enrollment at a participating SNEPT center and continue to receive their post-transplant care at that center."
89517149|NCT05240612|Experimental|MT-3921|Intravenous (IV)
89517150|NCT05240612|Placebo Comparator|Placebo|Intravenous (IV)
89517151|NCT05238701|Experimental|LPM3770164|LPM3770164 sustained-release tablets will be administrated with single dose from 0.5mg to 60mg
89517152|NCT05238701|Placebo Comparator|Placebo|LPM3770164 sustained release tablet simulant will be administrated with single dose
89517153|NCT05237284|Experimental|SAR443820|twice daily (BID) oral SAR443820
89517154|NCT05237284|Placebo Comparator|Placebo|twice daily (BID) oral placebo
89517155|NCT05225311||Patients with Fetal Ebstein's Anomaly or Tricuspid Valve Dysplasia|Patients will be followed for life-long outcomes.
89207711|NCT00664742|Experimental|Fluvastatin XL® Treatment|80 mg once daily, at bedtime.
89519574|NCT03855995||Active surveillance (Catch-up sub-Group)|Children enrolled in the active surveillance (AS), <18 months of age who were identified at 1st RTS,S/AS01E dose administration and who either received all DTP/HepB/Hib doses before study start or received at least one dose of DTP/HepB/Hib and are older than the age corresponding to the 3rd DTP/HepB/Hib dose at study start; including only RTS,S/AS01E vaccinated children from exposed clusters who could not be recruited at the time of DTP/HepB/Hib administration because the study had not yet started, living in the HDSS area are eligible for enrolment in the Catch-up sub-group of active surveillance.
89544641|NCT05528055|Experimental|Dose escalation|Participants will receive SCR-6920 capsule orally at escalating doses, till the maximum tolerated dose level is reached, and the recommended phase 2 dose(RP2D) will be determined.
89544642|NCT05528055|Experimental|Dose expansion: non small cell lung cancer(NSCLC)|Participants will receive SCR-6920 capsule orally at the recommended phase 2 dose
89207712|NCT04046354|Experimental|Group A|The group will use microwave ablation equipment to treat benign thyroid nodules.
89207713|NCT04046354|Active Comparator|Group B|The group will use radiofrequency ablation equipment to treat benign thyroid nodules.
89207714|NCT00781430|Experimental|1|
89207715|NCT00511342|Experimental|NOMAC-E2|Nomegestrol Acetate (NOMAC) and Estradiol (E2), 2.5 mg NOMAC and 1.5 mg E2 monophasic COC
89517156|NCT05200442|Experimental|Phase 1(Dose-Finding Arm): Group 1 - Dose Level 1 (Starting Dose)|"This study will use two dose levels (a starting dose at level 1 and a second dose highest dose at level 2) of the VS-6766 and cetuximab regimen. If participants in group 1 don't experience severe negative side effects to the starting dose of the regimen, then more participants will be assigned to group 2 at a higher dose until the safest/ most tolerable dose is found. If participants show toxic side effects to the first pre-determined dose, the dose will be decreased to the next lower dose level.~Group 1/ Dose Level 1:~Participants in group 0 will receive the starting dose of study drugs (below):~VS-6766 (2.4mg) orally twice a week~cetuximab (500mg) via intravenous (IV) needle in vein every 2 weeks~During phase 1, VS-6766 and cetuximab will be given in 28-day cycles (a period of time when participants receive study drugs). Participants in this portion of the study will receive 12 cycles of VS-6766 and cetuximab."
89517157|NCT05200442|Experimental|Phase 1(Dose-Finding Arm): Group 2- Dose Level 2 (Second Highest Dose)|"This study will use two dose levels (a starting dose at level 1 and a second dose highest dose at level 2) of the VS-6766 and cetuximab regimen. If participants in group 1 don't experience severe negative side effects to the starting dose of the regimen, then more participants will be assigned to group 2 at a higher dose until the safest/ most tolerable dose is found. If participants show toxic side effects to the first pre-determined dose, the dose will be decreased to the next lower dose level.~Participants in group 2 will receive the second highest dose of study drugs (below):~VS-6766 (3.4mg) orally twice a week~cetuximab (500mg) via intravenous (IV) needle in vein every 2 weeks~During phase 1, VS-6766 and cetuximab will be given in 28-day cycles (a period of time when participants receive study drugs). Participants in this portion of the study will receive 12 cycles of VS-6766 and cetuximab."
89517158|NCT05200442|Experimental|Phase 1(Dose-Finding Arm): Group 3 - Lower Dose Level 1|"Participants in this group will received a lower dose of the VS6766 and cetuximab regimen. Inclusion in this group is optional and based on whether the participant reports serious side effects in response to a higher dose of the regimen.~If participants are included in this group, they will receive:~VS-6766 (2.4mg) orally twice a week~cetuximab (400mg) via intravenous (IV) needle in vein every 2 weeks"
89517159|NCT05200442|Experimental|Phase 1(Dose-Finding Arm): Group 4 - Lower Dose Level 2|"Participants in this group will received the second lowest dose of the VS6766 and cetuximab regimen. Inclusion in this group is optional and based on whether the participant reports serious side effects in response to a higher dose of the regimen.~If participants are included in this group, they will receive:~VS-6766 (2.4mg) orally twice a week~cetuximab (300mg) via intravenous (IV) needle in vein every 2 weeks"
89517160|NCT05200442|Experimental|Phase 2 (Efficacy Arm/ Expansion Cohort)|"Participants in this arm will help test the efficacy of the VS-6766 and cetuximab dose established in phase 1 of the study. Participants will take the same two drugs ( VS-6766 and cetuximab) at the best tolerated dose that was found during the first phase of the study.~Participants in this group will also keep a pill diary. This helps you keep track of when you take your pills. The study team at your doctor's office will show you how to use this diary. Each time you visit the clinic, you must bring the pill diary, any remaining pills, and the pill bottle."
89517161|NCT05185999|Experimental|Intervention|Intraperitoneal infusion with 500 mL of sodium-free 30% Icodextrin/ 10% Dextrose solution
89517162|NCT05185258|Experimental|Enstilar|Participants will need to have two separate clinically healed psoriasis plaques. At baseline (visit 2), one target lesion (plaque # 1) will be actively treated with once-daily cutaneous application of Enstilar® foam and one target lesion (plaque # 2) will be treated with placebo-vehicle. Participants will then simultaneously be treated three-weekly with full-body NB-UVB for 8 weeks (or a minimum of 20 sessions in total). After 4 weeks of Enstilar® and emollient, treatment application will be changed to twice-weekly until EOT (visit 5). First dose of IMP will be administered by trained personal. Subsequent doses will be administered by the participant. Study visits will occur at Screening, Baseline (Week 0), Weeks 8, 13, and 18. At baseline, week 8, week 13, and week 18 two skin punch biopsies will be acquired from each target lesion.
89517163|NCT05185258|Placebo Comparator|Placebo-vehicle|Placebo-vehicle will be given as explained for the arm description under Enstilar.
89517164|NCT05179005||RibFix Advantage|Underwent surgical stabilization of rib fractures
89517165|NCT05176925|Experimental|Tislelizumab combined with sitravatinib|
89517166|NCT05159492|Experimental|PEF Arm|PEF is a non-thermal ablation modality using extremely short high voltage pulses to induce cell death, with tissue selectivity, cardiomyocytes being much more sensitive to this energy than Phrenic nerve or Esophageal cells. Energy (2000 V) will be delivered 8 times per vein with 2 different catheter configurations and rotations
89517167|NCT05159492|Active Comparator|Pulmonary vein isolation using Contact Force RF|The PVI strategy using RF is very standard. The CARTO© platform will be used, with a contact force catheter (SmartTouch), aiming at an ablation index value of 300 to 400 on the posterior wall, and at least 500 on the anterior wall. Power will be limited to 35/45 W, with a distance between consecutive deliveries of 6 mm or less (CLOSE protocol).
89517168|NCT05157932|Experimental|Talk Test|Virtual Cardiac Rehab + Exercise prescription based on the Talk test.
89517169|NCT05157932|Experimental|Cardiopulmonary Exercise Test|Virtual Cardiac Rehab + Exercise prescription based on the CPET results.
89517170|NCT05147272|Experimental|Phase 1 Dose Escalation|Multiple dose levels of RP-6306 and gemcitabine
89517171|NCT05145478||Shockwave Intravascular Lithotripsy (IVL)|Patients with calcified common-femoral artery disease, who are eligible to receive IVL per the FDA indications.
89517172|NCT05120895||Mevalotin|Korean menopausal women aged 50 years or more who required treatment of dyslipidemia and received Mevalotin® tablets.
89517173|NCT05106764||Retrospective Database Analysis|Data from patient's hospital records of the last 10 years will be collected/extracted retrospectively using epidemiological methods to test the forecasting power of the algorithm.
89517174|NCT05091203|Sham Comparator|control|Control group in which vitamin D was not administrated.
89517175|NCT05091203|Active Comparator|Study group|Study group in which Vitamin D was administered
89517176|NCT05087641|Experimental|IAB System|Patients will be treated with IAB(s)
89517177|NCT05079919|Experimental|Olezarsen|Olezarsen will be administered once every 4 weeks by subcutaneous (SC) injection from Week 1 through Week 49.
89517178|NCT05079919|Placebo Comparator|Placebo|Olezarsen-matching placebo will be administered once every 4 weeks by SC injection from Week 1 through Week 49.
89517179|NCT05077787|Experimental|Experimental Group|Neonates recruited in experimental group will receive massage therapy and kinaesthetic stimulation for 15 minutes along with phototherapy for consecutive days . It will be given in three phases first massage therapy will be given for 5 minutes, followed by movement of limbs for 5 minutes and then again massage therapy will be repeated for 5 minutes.
89517180|NCT05077787|No Intervention|Control Group|Neonates recruited in control group will receive phototherapy alone along with regular care
89517181|NCT05031065||Women undergoing radiation treatment after lumpectomy for breast cancer.|There is no specific study intervention being used. Samples will be collected from participants undergoing standard of care radiotherapy at pre-specified timepoints.
89517182|NCT05028634|Experimental|Cohort 1 - Ozanimod|"Comprises of participants received oral ozanimod will be administered tetanus, diphtheria, and acellular pertussis vaccine (Tdap), pneumococcal polysaccharide vaccine (PPSV23), and the seasonal inactivated influenza vaccine~-Enrollment is closed for this cohort"
89517183|NCT05028634|Experimental|Cohort 1 - non-pegylated interferon-β or no disease modifying therapy|"Comprises of participants received either non-pegylated interferon-β (IFN-β) or no disease modifying therapy (DMT) will be administered tetanus, diphtheria, and acellular pertussis vaccine (Tdap), Pneumococcal polysaccharide vaccine (PPSV23), and the seasonal inactivated influenza vaccine~-Enrollment is closed for this cohort"
89517184|NCT05028634|Experimental|Cohort 2 - Ozanimod|Comprises of participants received oral ozanimod will be administered tetanus, diphtheria, and acellular pertussis vaccine (Tdap), and pneumococcal polysaccharide vaccine (PPSV23).
89517185|NCT05028634|Experimental|Cohort 2 - non-pegylated interferon-β or no disease modifying therapy|Comprises of participants received either non-pegylated interferon-β (IFN-β) or no disease modifying therapy (DMT) will be administered tetanus, diphtheria, and acellular pertussis vaccine (Tdap) and Pneumococcal polysaccharide vaccine (PPSV23).
89517186|NCT05026385|Experimental|Intervention|"The intervention group will receive initial nutrition and exercise consultations with a Registered Dietitian (RD) and Clinical Exercise Physiologist (CEP) to personalize the study protocol and recommendations to their needs. The intervention period (3 months) includes: a) whole-body resistance training exercise sessions completed three-times per week (at-home with loaned equipment and/or in-person at the research gym); b) biweekly nutrition education provided through video conferencing; and c) biweekly OA self-management support provided through video conferencing.~After the 3 month intervention, participants will receive bimonthly phone calls from a study staff member to encourage continued behavior changes during the 6 month maintenance phase."
89517187|NCT05026385|No Intervention|Usual Care|The control group will follow standard care procedures, which includes their usual activities. The control group will receive bimonthly contact during the study period through phone calls with a study staff member to encourage retention. However no recommendations or advice on nutrition, exercise or self-management will be provided.
89517188|NCT05019976|Experimental|Dose-Finding Group 0 - Dose Level 0|"High-energy radiation will be delivered to a focused area of your body using a treatment machine called a linear accelerator. Radiation will be delivered through an IV. A mold will also be customized to fit your body, so you don't move during the radiation process. The actual time on the radiation treatment machine will be 30-60 minutes. The mold will be removed after the treatment.~The longest possible treatment will be 14 radiation treatments over a course of 3 weeks. The shortest possible treatment will be 3 treatments in duration or less than 1 week. The amount of time required for radiation treatment depends on the dose group your are assigned.~Participants will receive radiation to at least 1 but no more than 5 lesions (areas of body with cancer)."
89517189|NCT05019976|Experimental|Dose-Finding Group 1 - Dose Level 1|"High-energy radiation will be delivered to a focused area of your body using a treatment machine called a linear accelerator. Radiation will be delivered through an IV. A mold will also be customized to fit your body, so you don't move during the radiation process. The actual time on the radiation treatment machine will be 30-60 minutes. The mold will be removed after the treatment.~The longest possible treatment will be 14 radiation treatments over a course of 3 weeks. The shortest possible treatment will be 3 treatments in duration or less than 1 week. The amount of time required for radiation treatment depends on the dose group your are assigned.~Participants will receive radiation to at least 1 but no more than 5 lesions (areas of body with cancer)."
89517190|NCT05019976|Experimental|Dose-Finding Group 2 - Dose Level 2|"High-energy radiation will be delivered to a focused area of your body using a treatment machine called a linear accelerator. Radiation will be delivered through an IV. A mold will also be customized to fit your body, so you don't move during the radiation process. The actual time on the radiation treatment machine will be 30-60 minutes. The mold will be removed after the treatment.~The longest possible treatment will be 14 radiation treatments over a course of 3 weeks. The shortest possible treatment will be 3 treatments in duration or less than 1 week. The amount of time required for radiation treatment depends on the dose group your are assigned.~Participants will receive radiation to at least 1 but no more than 5 lesions (areas of body with cancer)."
89517191|NCT05019976|Experimental|Dose-Finding Group 3 - Dose Level 3|"High-energy radiation will be delivered to a focused area of your body using a treatment machine called a linear accelerator. Radiation will be delivered through an IV. A mold will also be customized to fit your body, so you don't move during the radiation process. The actual time on the radiation treatment machine will be 30-60 minutes. The mold will be removed after the treatment.~The longest possible treatment will be 14 radiation treatments over a course of 3 weeks. The shortest possible treatment will be 3 treatments in duration or less than 1 week. The amount of time required for radiation treatment depends on the dose group your are assigned.~Participants will receive radiation to at least 1 but no more than 5 lesions (areas of body with cancer)."
89207716|NCT00511342|Active Comparator|LNG-EE|Levonorgestrel (LNG) and Ethinyl Estradiol (EE), 0.150 mg LNG and 0.030 mg EE monophasic COC
89207717|NCT03931785|Experimental|MD-7246 300 μg|1 MD-7246 300-μg oral tablet and 3 matching placebo oral tablets
89517192|NCT05019976|Experimental|Dose-Finding Group 4 - Dose Level 4|"High-energy radiation will be delivered to a focused area of your body using a treatment machine called a linear accelerator. Radiation will be delivered through an IV. A mold will also be customized to fit your body, so you don't move during the radiation process. The actual time on the radiation treatment machine will be 30-60 minutes. The mold will be removed after the treatment.~The longest possible treatment will be 14 radiation treatments over a course of 3 weeks. The shortest possible treatment will be 3 treatments in duration or less than 1 week. The amount of time required for radiation treatment depends on the dose group your are assigned.~Participants will receive radiation to at least 1 but no more than 5 lesions (areas of body with cancer)."
89207718|NCT03931785|Experimental|MD-7246 600 μg|2 MD-7246 300-μg oral tablets and 2 matching placebo oral tablets
89207719|NCT03931785|Experimental|MD-7246 1200 μg|4 MD-7246 300-μg oral tablets
89517193|NCT05014178||Adult CKD stage 1-5 participants|"Age greater than or equal to 18 years~Estimated GFR < 90 mL/min/1.73m²"
89517194|NCT05014178||Adult transplanted participants|• Age greater than or equal to 18 years
89517195|NCT05014178||Adult dialysis participants|"Age greater than or equal to 18 years~More than 3 months duration of therapy"
89517196|NCT05014178||Adult ADPKD|• Age greater than or equal to 18 years
89517197|NCT05014178||Adults treated for nephrolithiasis|• Age greater than or equal to 18 years
89517198|NCT05014178||Adult healthy controls including kidney donors|"Age greater than or equal to 18 years~Lack of kidney disease, heart failure, liver cirrhosis and peripheral"
89517199|NCT05011721|Experimental|Intervention with activity tracker|Women allocated to the intervention arm will used an activity tracker
89517200|NCT04977622||Primary Progressive MS (PPMS)|Clinically definite MS patients with identified primary-progressive disease onset, within 10 years of diagnosis
89517201|NCT04977622||Non-neurological controls (HC)|Age and sex matched to the PPMS patients
89517202|NCT04972734|Experimental|NEC|premature newborns developing a NEC
89517203|NCT04972734|Active Comparator|Healthy control|premature newborns without NEC
89517204|NCT04959695|Experimental|Prolonged exposure with PE Coach|The mobile application will be incorporated into each PE psychotherapy session and used to support homework between sessions.
89517205|NCT04959695|Active Comparator|Prolonged exposure without PE Coach|Standard PE treatment protocol without PE Coach
89517206|NCT04953715||1 - This is a multicenter microbiome and pharmacokinetic study.|A prospective, observational microbiome study of adult kidney transplant recipients receiving mycophenolate mofetil and tacrolimus maintenance immunosuppression. Participants will be studied post-transplant for mycophenolate pharmacokinetics and microbiome samples collected. Clinically measured tacrolimus trough concentrations will also be evaluated. Associations among mycophenolic acid enterohepatic recycling and metabolite formation, tacrolimus troughs, immunosuppression adverse effects, diarrhea and microbiome will be studied. To assess the relationship between kidney graft outcomes and stool, oral, nasal and urine microbiome diversity. To assess the relationship between transplant graft outcomes and urinary transcriptome.
89517207|NCT04950764|Experimental|Seladelpar 10 mg|Part A: Single oral dose 10 mg
89517208|NCT04950764|Experimental|Seladelpar 10 mg or less|Part B: Multiple oral dose of 10 mg or less
89517209|NCT04950608|Experimental|PATH|"The research study procedures include screening for eligibility, and study intervention including preparation, evaluations, one psilocybin session and follow up visits.~-The treatment regimen consists of a single administration of psilocybin 25 mg orally combined with a supportive psychotherapy including 2 preparation sessions and 2 integration sessions"
89517210|NCT04947462|Experimental|Chronically Implanted Neural and Muscular Interface|6 eligible participants will be chronically implanted with neural and muscular interfaces to characterize proprioceptive sensations using Functional Electrical Stimulation (FES).
89517211|NCT04940065||Kesimpta|Patients treated with Kesimpta
89517212|NCT04915768|Experimental|Group 1:Treatment|CH505 TF chTrimer 300 mcg admixed with (5 mcg) 3M-052-AF + (500 mcg) Aluminum Hydroxide suspension, administered at months 0, 2, 4, 8 and 12.
89517213|NCT04915768|Experimental|Group 2: Treatment|CH505 TF chTrimer 300 mcg admixed with (3 mcg) 3M-052-AF administered at months 0, 2, 4, 8 and 12.
89517214|NCT04915768|Experimental|Group 3: Treatment|CH505 cTrimer, 300 mcg admixed with (3 mcg) 3M-052-AF + (500 mcg) Aluminum Hydroxide Ssuspension (Alum) administered at months 0, 2, 4, 8 and 12.
89517215|NCT04915768|Experimental|Group 4: Treatment|CH505 chTrimer 300 mcg admixed with (5 mcg) 3M-052-AF administered at months 0, 2, 4, 8 and 12.
89517216|NCT04906499|Experimental|Physical Activity Promotion Group|Participants will receive a text message each morning with a personalized, daily step count goal and a link used to confirm receipt of the goal. The preceding 10 days of step data will be rank ordered and the 60th percentile step count will be set as the goal for the next day.
89517217|NCT04884256|Placebo Comparator|CBT-004|
89517218|NCT04884256|Experimental|0.05% CBT-004|
89517219|NCT04884256|Experimental|0.075% CBT-004|
89544643|NCT05528055|Experimental|Dose expansion: NHL|Participants will receive SCR-6920 capsule orally at the recommended phase 2 dose on a continuous basis
89544644|NCT05528055|Experimental|Dose expansion: solid tumors|Participants will receive SCR-6920 capsule orally at the recommended phase 2 dose on a continuous basis
89544645|NCT03187457|Other|Treatment group|Metronidazole 400 mg 3 times daily for 5 days for Bacterial Vaginosis (BV) infection
89207720|NCT03931785|Placebo Comparator|Placebo|4 matching placebo oral tablets
89517220|NCT04857528||Retrospective (Participants Who Have Already Been Treated for HPV-Related Cancer Before Study)|This group will use medical records from participants who have already received chemoradiation for their HPV-related anal or cervical cancer at a time before this study started. Because they have already received treatment, these participants will provide previous blood/tumor tissue samples that contain detectable HPV DNA as well as at least one post-treatment sample that their doctor collected before the study. Data from these previously collected samples will be compared to current samples from participants who are actively enrolled in this study in present day (chart review).
89544646|NCT03187457|Other|Control group|Healthy women without Bacterial Vaginosis and without treatment
89544647|NCT05524155|Experimental|Sintilimab Combined With Regorafenib and HAIC|Sintilimab Combined With Regorafenib and HAIC
89544648|NCT03187223|Active Comparator|Arm A (Mel)|Melphalan 100mg/m2/day iv days -2 and -1
89032954|NCT02944838|Active Comparator|Physical Activity|The Senior Change Makers Physical Activity Program consists of weekly meetings, 1 hour each, for 8 weeks. The program provides participants with information about safe physical activity, strategies to increase physical activity, and guided walks. Topics will focus on walking, but we will also include information and activities relating to strength training, flexibility, and balance. Behavioral skills such as goal setting, addressing barriers, and social support will also be addressed.
89517221|NCT04857528||Prospective (Participants Who Will Receive Radiation Treatment for HPV-Related Cancer During Study)|This group is for participants who plan to receive radiation treatment (with or without chemotherapy) for their HPV-related anal or cervical cancer during the time this study will be conducted. Participants in this group will sign a consent form allowing researchers to collect their blood samples and analyze/compare them to the samples from the retrospective group of participants.
89517222|NCT04855656|Experimental|Phase 1: RP-6306 Single-Agent, Dose Escalation and Food-effect Study|Patients receive RP-6306 orally until disease progression, unacceptable toxicity, or investigator/patient decision. Dose escalation will proceed until a maximum tolerated dose is identified.
89517223|NCT04855656|Experimental|Phase 1: RP-6306 in combination with RP-3500, Dose Escalation Study|Patients receive RP-6306 with RP-3500 orally until disease progression, unacceptable toxicity, or investigator/patient decision. Dose escalation will proceed until a maximum tolerated dose is identified.
89517224|NCT04847011|Experimental|RA - longitudinal arm|
89517225|NCT04847011|Experimental|PD - longitudinal arm|
89517226|NCT04847011|No Intervention|RA - crosssectional arm|
89517227|NCT04847011|No Intervention|PD - crossectional arm|
89517228|NCT04847011|No Intervention|Healthy controls - crosssectional arm|
89517229|NCT04827030|Active Comparator|Ropivacaine hydrochloride injected by Erector Spinae block|The injection will be performed with Ropivacaine hydrochloride 0.6 ml/kg of solution at 5 mg/ml up to 30 ml
89517230|NCT04827030|Active Comparator|Ropivacaine hydrochloride injected by Paravertebral block|The injection will be performed with Ropivacaine hydrochloride 0.6 ml/kg of solution at 5 mg/ml up to 30 ml
89517231|NCT04804553|Experimental|Apremilast|Participants will receive apremilast in the double-blind 16 week treatment phase. Then the participants will continue to receive apremilast in the active 36 weeks treatment phase.
89517232|NCT04804553|Placebo Comparator|Placebo to Apremilast|Participants will receive the matching placebo in the double-blind 16 week treatment phase. Then the participants will receive apremilast in the active 36 weeks treatment phase.
89517233|NCT04801641|Placebo Comparator|Placebo|Placebo
89517234|NCT04801641|Experimental|Low-Dose Nabilone|pms-nabilone titrated to 2 mg daily
89517235|NCT04801641|Experimental|High-Dose Nabilone|pms-nabilone titrated to 6 mg daily
89517236|NCT04796012|Experimental|Feasibility Cohort: Patients with relapsed or refractory solid tumors|Six (6) participants with relapsed or refractory solid tumor will be enrolled. Atezolizumab will be administered in combination with vincristine, irinotecan, and temozolomide for up to 2 years or until the participant experiences disease progression or an unacceptable toxicity.
89517237|NCT04796012|Experimental|Rhabdomyosarcoma (RMS) Cohort: Patients with rhabdomyosarcoma|Seventeen (17) participants with RMS, including the six participants from the Feasibility Cohort, will be enrolled. At least 8 of the RMS participants must have a tumor that expresses the protein PD-L1. Atezolizumab will be administered in combination with vincristine, irinotecan, and temozolomide for up to 2 years or until the participant experiences disease progression or an unacceptable toxicity.
89517238|NCT04781972|Experimental|Methylphenidate first|Single oral dose of methylphenidate (10mg or 15 mg) and then matching placebo after washout period of one week.
89517239|NCT04781972|Placebo Comparator|Placebo first|Matching placebo and then single oral dose of methylphenidate (10mg or 15 mg) after washout period of one week.
89517240|NCT04757649|Experimental|Safety Planning Intervention with Navigation Services|A patient navigation (PN) intervention for SGM youth/emerging adults designed to target mechanisms (i.e., decreasing thwarted belongingness and increasing suicide-related coping skills) that theoretically underlie suicide. The proposed intervention will integrate a single-session, empirically supported, suicide prevention intervention (Safety Planning Intervention; SPI) with PN services (PN+SPI). The patient navigator will deliver the SPI and continue frequent contact for the purpose of providing motivational enhancement, problem-solving, reinforcing coping strategies, and connecting participants to social support and mental health resources (e.g., SGM-specific support groups within the community).
89517241|NCT04735016||Treatment Arm|Patients enrolled and treated with the DiamondTemp™ Ablation System
89517242|NCT04721652||Hemodialysis Patients (nondiabetic)|Nondiabetic adult hemodialysis patients
89517243|NCT04701684|Experimental|Direct tot Angiography Suite (DTAS) triage workflow|
89517244|NCT04701684|Active Comparator|Conventional CT/MR triage workflow|
89517245|NCT04679389|Experimental|Acetazolamide|Acetazolamide administered via capsule or liquid suspension. Capsule would be 250 mg oral capsules encapsulated by gelatin capsule and filled with lactose to match placebo. Liquid suspension would be 25 mg/mL oral suspension but adding 125 mg Acetazolamide tablets to suspending agent Ora-blend
89517246|NCT04679389|Placebo Comparator|Placebo|Placebo administered via capsule or liquid suspension. Capsule would be a gelatin capsule filled with lactose powder to match Acetazolamide. Liquid suspension would be Ora-blend.
89517247|NCT04670900|Active Comparator|Operative|Patients will be operated according to Orthopedic Trauma Association (OTA) principles with either tension band wiring or plate fixation with an anatomical precontoured plate.
89517248|NCT04670900|Experimental|Non-operative|Patients will be offered a plaster cast for 1-2 weeks
89517249|NCT04653038|Experimental|Unresectable, recurrent or metastatic melanoma|Cohort1: patients with unresectable, recurrent or metastatic melanoma who have failed prior immune checkpoint inhibitor therapy
89517250|NCT04653038|Experimental|Untreated mucosal or acral lentiginous melanoma|Cohort2: patients with untreated, unresectable recurrent or metastatic, mucosal or acral lentiginous melanoma
89517251|NCT04649489||Arm A (experimental arm)|hepatic resection with post-operative atezolizumab 1200mg and bevacizumab 15mg/kg, both administered by IV infusion on Day 1 of each 21-day cycle
89517252|NCT04649489||Arm B (control arm)|atezolizumab 1200mg and bevacizumab 15mg/kg, both administered by IV infusion on Day 1 of each 21-day cycle
89544649|NCT03187223|Experimental|Arm B (BenMel)|Melphalan 100mg/m2/day iv days -2 and -1 Bendamustine 200mg/m2/day iv days -4 and -3
89544650|NCT05184075|Active Comparator|Reverse hybrid coronary revascularization (HCR)|Patients will undergo reverse hybrid coronary revascularization. Moreover, quality of life is assessed at baseline, 14 days, 30 days, 90 days, 6 months and 1 year.
89544651|NCT05184075|Active Comparator|Standard hybrid coronary revascularization (HCR)|Patients will undergo standard hybrid coronary revascularization. Moreover, quality of life is assessed at baseline, 14 days, 30 days, 90 days, 6 months and 1 year.
89544652|NCT03187145||diabetic patients|
89544653|NCT03187145||healthy control|
89544654|NCT05532111|Experimental|RT-R Group|Rituximab combined with tacrolimus induction + rituximab maintenance
89544655|NCT05532111|Experimental|RT-T Group|Rituximab combined with tacrolimus induction + tacrolimus maintenance
89544656|NCT05532111|Experimental|PC-C Group|Glucocorticoid combined with cyclophosphamide induction + maintenance
89544657|NCT03187067||Mozambique, cases|
89544658|NCT03187067||Mozambique, controls|
89544659|NCT03187067||Pakistan, cases|
89544660|NCT03187067||Pakistan, controls|
89032955|NCT02923284||Imaged renal mass cohort|Subjects undergoing surgery for an kidney tumor identified radiologically.
89544661|NCT03186599|No Intervention|high adherence control group|-Patients on continuous MEMS monitoring with usual care.
89544662|NCT03186599|No Intervention|low adherence control group|-Patients on continuous MEMS monitoring with usual care.
89544663|NCT03186599|Experimental|low adherence intervention group|"Patient with the WALKON mobile application.~Patient with monthly feedback call~Patients on continuous MEMS monitoring."
89544664|NCT05527899|Placebo Comparator|Placebo|½ RDA of micronutrients including 5 mg/d Zn
89544665|NCT05527899|Experimental|Zinc 30 mg|½ RDA of micronutrients including 30 mg/d Zn
89544666|NCT05527899|Experimental|Zinc 60 mg|½ RDA of micronutrients including 60 mg/d Zn
89544667|NCT03117959|Placebo Comparator|Stryker Triathlon Custom Fit Knee|implanted in standard fashion
89544668|NCT03117959|Experimental|Stryker shape match|no longer RCT
89544669|NCT05524077|Experimental|Ablation|"Patients will be expected to have a catheter ablation procedure within 2 weeks post randomisation and no longer than 30 days post randomisation.~Medical therapy can be used as a temporising measure before catheter ablation, as is standard of care. If there is breakthrough VT during the period before the clinical procedure, standard practice will be followed in stabilising the ventricular tachycardia (VT) including intravenous short acting anti-arrhythmic drugs (AAD), admission to hospital, internal or external cardioversion. However, preference will be given to scheduling the procedure within 24-48 hours in this situation."
89544670|NCT05524077|Active Comparator|Anti-arrhythmic drugs (AAD)|Patients managed with medical therapy alone by their usual medical practitioners. A protocol aligned with standard clinical care/current clinical guidelines will be provided for guidance, the objective being that the control arm replicates what would constitute standard of care for patients with ventricular tachycardia managed with a non-interventional approach.
89544671|NCT03186833||Group A|males or females aged > 70 years without major systemic comorbidities (resting blood pressure <140/90 mmHg, no history diabetes mellitus according to WHO criteria).
89544672|NCT03186833||Group B|males or females aged >70 years with hypertension, defined as a documented blood pressure of Systolic Blood Pressure (SP >140 mmHg or >90mmHg Diastolic Blood Pressure) without diabetes mellitus and HF defined as: a) relevant symptoms/signs/radiographic findings as indicated by Boston criteria b) need for diuretic therapy.
89544673|NCT03186833||Group C|male or female aged > 70 years with diabetes mellitus (defined according to the World Health Organization (WHO)) AND hypertension, without HF defined as: a) relevant symptoms/signs/radiographic findings as indicated by Boston criteria38 b) need for diuretic therapy.
89544674|NCT03186833||Group D|male or female aged >70 years with HFPEF, defined as signs and symptoms of HF with LVEF>50% and raised natriuretic peptides (BNP>35pg/ml or NT-proBNP>125pg/ml) along with one other criteria: i) structural heart disease (left atrial enlargement or left ventricular hypertrophy) on TTE, ii) evidence of LV diastolic dysfunction based on ESC Guidelines 2016, or iii) hospitalization with heart failure within 12 months prior to study entry.
89544675|NCT03186833||Group E|male or female aged >70 years with HFREF, defined as HF with LVEF <40% on TTE)
89544676|NCT02433743|No Intervention|Control|Control group (n=33) didn't received intervention. The received the standard hospital diet
89544677|NCT02433743|Experimental|Ready-to-use therapeutic food (RUTF)|RUTF group (n=32) received the standard hospital diet combined with 100 g/day of RUTF
89032956|NCT02923284||control cohort|Subjects undergoing surgery for any kind of cancer other than kidney.
89032957|NCT00529256|No Intervention|2|No intervention
89032958|NCT00529295|Experimental|1|Titrated oral misoprostol
89032959|NCT00529295|Active Comparator|2|Vaginal misoprostol
89544678|NCT04299867||< 34 weeks gestational age|"Metronidazole will be given per standard of care prior to incision. Intraoperative plasma samples will be obtained from pre-existing vascular access catheters at end of bolus, 30, 60, 90 minutes, at time of intestinal excision(s), and at the end of the case in ethylenediaminetetraacetic acid microcontainers, exceeding no more than approximately 5 mL total.~At the time of intestinal excision, the surgeon will cut at least 500 mg of intestine from the specimen, ensuring all layers of bowel are included. If more than one intestinal sample is taken during the surgery, such as in the case of multiple strictures removed, each sample will be obtained and labeled appropriately."
89544679|NCT04299867||34 weeks gestational age|"Metronidazole will be given per standard of care prior to incision. Intraoperative plasma samples will be obtained from pre-existing vascular access catheters at end of bolus, 30, 60, 90 minutes, at time of intestinal excision(s), and at the end of the case in ethylenediaminetetraacetic acid microcontainers, exceeding no more than approximately 5 mL total.~At the time of intestinal excision, the surgeon will cut at least 500 mg of intestine from the specimen, ensuring all layers of bowel are included. If more than one intestinal sample is taken during the surgery, such as in the case of multiple strictures removed, each sample will be obtained and labeled appropriately."
89544680|NCT05531877|Experimental|Patients undergoing Penile Implant Surgery|"All intraoperative measurements are documented in real time. Measurements recorded are as follows:~Preoperative Pre-ICI penile length and circumference, both in relaxed and stretched states. Preoperative post-ICI penile length and circumference, both in relaxed and stretched states. Postoperative penile length and circumference. Penile implant length and girth."
89025063|NCT03277521|Active Comparator|Quadriplegia with upper limb reconstruction|Individuals with quadriplegia and upper limb reconstruction will be recruited for participation in three sessions of intermittent theta burst stimulation (iTBS), each consisting of sham iTBS applied to the hotspot of the target muscle and active iTBS; sham iTBS always be will administered first to minimize the potential for carry over effects. Sessions will be separated by at least 3 days to minimize the potential for carry over effects. Before and 10, 20 and 30 minutes after each iTBS session, motor evoked potentials (MEPs) will be recorded in order to quantify changes in corticomotor excitability.
89025064|NCT03279341|Active Comparator|polyethylene glycol, osmotic laxitive|13.8g polyethylene glycol 3350 with sodium bicarbonate, sodium chloride, and potassium chloride, mixed with 125mL of water administered twice orally as a solution
89025065|NCT03279341|Active Comparator|bisacodyl, stimulant laxative|10 mg bisacodyl once daily oral administration with 125mL of water
89025066|NCT03279341|Active Comparator|prucalopride, prokinetic|2mg prucalopride, film-coated tablets (prucalopride succinate eq. 2mg), once daily oral administration with 125mL of water
89025067|NCT02957370||Diagnosed Urinary Bladder Neoplasms|Patients who are being monitored for bladder cancer will be the experimental group to test the electro-phage and aptamer approach to following bladder cancer biomarkers
89544681|NCT05527821|Experimental|Surufatinib Combined With Sintilimab and SCRT|
89544682|NCT05527743|Experimental|Invasive Physiotherapy|
89544683|NCT05527743|Placebo Comparator|Sham Group|
89544684|NCT02440217||DCM-AGT|Subjects with both dilated cardiomyopathy (DCM) and abnormal glucose tolerance (AGT, either impaired glucose tolerance or type 2 diabetes).
89544685|NCT02440217||DCM-NGT|Subjects with dilated cardiomyopathy (DCM) and normal glucose tolerance (NGT).
89025068|NCT02957370||Non-Urinary Bladder Neoplasms|Patients being treated for hematuria will provide a negative control to provide data from testing for biomarkers in patients being treated for other diseases.
89544686|NCT02440217||N-AGT|Subjects without dilated cardiomyopathy (N) with abnormal glucose tolerance (AGT, either impaired glucose tolerance or type 2 diabetes).
89544687|NCT02433587|Experimental|Short Term|The short term group will continue Aspirin 81mg and Clopidogrel 75mg for 1 month after the intervention. After that, they will continue Aspirin 81mg only.
89544688|NCT02433587|Experimental|Long Term|The long term group will continue Aspirin 81mg and Clopidogrel 75mg for 6 months after the intervention. After this time, they will continue on Aspirin 81mg only.
89544689|NCT04299009|Experimental|Retimer bright light therapy glasses|active bright light therapy in the green/blue spectrum range
89544690|NCT04299009|Sham Comparator|sham-Retimer bright light therapy glasses|bright light therapy with light in the red spectrum (not active)
89544691|NCT02433431|Active Comparator|Mindfulness Training|14-lesson audio-guided mindfulness training program instructing present-moment attention and an orientation of acceptance
89544692|NCT02433431|Active Comparator|Mindful Attention Only Training|14-lesson audio-guided mindfulness training program instructing present-moment attention only
89544693|NCT02433431|Active Comparator|Analytic Thinking Training|14-lesson audio-guided analytic thinking program encouraging reflection on one's thoughts, feelings, and behaviors, but not instructing mindfulness
89544694|NCT05527665||Patient group|"Women over 90 years of age Women who have received a suburethral sling at CHUGA in the gynecology or urology departments between January 2015 and June 2020.~Women who agreed to complete the PPSSQ"
89544695|NCT05527665||Healthy volunteers group|"-Adult women under 90 years of age, matched on age and menopausal status to the patient group Women who have never had surgery for stress urinary incontinence with a sub-urethral sling.~Women who agreed to complete the PPSSQ"
89544696|NCT02433353|Experimental|EMDR + Venlafaxine XR|Participants will receive 12 one-hour sessions of EMDR while taking venlafaxine XR 150mg or 225mg for the duration of the 6 month study.
89544697|NCT02433353|Placebo Comparator|EMDR + Placebo|Participants will receive 12 one-hour sessions of EMDR while taking placebo 150mg or 225mg for the duration of the 6 month study.
89544698|NCT03190733|Experimental|ATG 10.0mg/kg|ATG 10.0mg/kg group refers to treatment with ATG in the total dose of 10.0mg/kg.
89544699|NCT03190733|Active Comparator|ATG 12.5mg/kg|ATG 12.5mg/kg group refers to treatment with ATG in the total dose of 12.5mg/kg.
89544700|NCT04648605|Experimental|Questionary|Questionary for all parents
89544701|NCT03190499||Children with childhood cancer|Children with childhood cancer that are having medical treatment will be assessed with family based questionnaires.
89544702|NCT02433119|Experimental|Amlodipine orotate & Valsartan|Amlodipine orotate 6.91mg (5mg as amlodipine) and Valsartan 160 mg, tablet, once a day for 8 weeks
89544703|NCT02433119|Active Comparator|Valsartan & Hydrochlorothiazide|Valsartan 160mg and Hydrochlorothiazide 12.5mg, tablet, once a day for 8 weeks
89544704|NCT05178459||Diabetic|Patient diagnosed with diabetes
89544705|NCT05178459||Neuropathic without diabetes|Patient diagnosed with neuropathy without diabetes
89544706|NCT04425135|Experimental|Camrelizumab +apatinib mesylate+Pemetrixed + Carboplatin|Camrelizumab combined with apatinib mesylate,Pemetrixed and Carboplatin in the treatment（4-6 cycle）of effective (CR, PR, SD) patients continued to be treated with Camrelizumab combined with apadine mesylate until PD, toxicity intolerance, and other reasons that the researcher thinks need to stop the research treatment.
89544707|NCT03186911|Other|E-liquid Group|Participants will sample two different e-liquids.
89544708|NCT02429999|Active Comparator|Letrozole plus FSH|letrozole, 10 mg daily from day 3-7 and FSH 75 international unit(IU) /day from day 5 continuously and GnRH antagonist (orgalutran 0.25) is given when the follicle size equal to 14 mm till human chorionic gonadotrophin (hCG) injection.
89544709|NCT02429999|Active Comparator|Standered protocol for induction of ovulation|0.1 decapeptyl from day 21 in the previous cycle and continuously stimulated by FSH (150-225 international unit/day) from day 2. We will give them at first 225 international unit FSH for 5 days.
89544710|NCT02430155|Active Comparator|Bakri balloon group|The women in this group will be managed by Bakri balloon
89207721|NCT00666536|Active Comparator|Aggressive treatment regimen (5/320 mg to 10/320 mg)|Valsartan + Amlodipine, daily: 320 mg + 5 mg (2 weeks); Valsartan + Amlodipine, daily: 320 mg + 10 mg (2 weeks); Valsartan + Amlodipine and Hydrochlorothiazide, daily: 320 mg + 10 mg and 12.5 mg (4 weeks); Valsartan + Amlodipine and Hydrochlorothiazide, daily: 320 mg + 10 mg and 12.5 mg or 25 mg (optional titration) (4 weeks)
89207722|NCT00666536|Active Comparator|Moderate treatment regimen (5/160 mg)|Valsartan + Amlodipine, daily dose: 160 mg + 5 mg (4 weeks); Valsartan + Amlodipine and Hydrochlorothiazide, daily: 160 mg + 5 mg and 12.5 mg (4 weeks); Valsartan + Amlodipine and Hydrochlorothiazide, daily: 160 mg + 5 mg and 12.5 mg or 25 mg (optional titration) (4 weeks)
89207723|NCT00519532|Experimental|Rotigotine|Rotigotine Transdermal Patch
89207724|NCT00666458|Experimental|1|saxagliptin add-on to metformin
89544711|NCT02430155|Active Comparator|Condom loaded Foley's catheter group|The women in this group will be managed by condom loaded Foley's catheter
89544712|NCT02573883|Experimental|Prior Clobetasol Exposure|Patients with biopsy proven lichen sclerosus previously treated with clobetasol propionate
89544713|NCT02573883|Active Comparator|No Prior Clobetasol Exposure|Patients with biopsy proven lichen sclerosus never previously treated with clobetasol propionate.
89544714|NCT02432885|Experimental|ACE inhibitor|ACE inhibitor (enalapril up to 20mg BID), in patients with preserved EF (LVEF grater than 50%) and with detectable delayed enhancement (myocardial fibrosis) in cardiac magnetic resonance, randomized to therapy or not.
89544715|NCT02432885|No Intervention|Control|Patients with preserved EF (LVEF grater than 50%) and with no detectable delayed enhancement (myocardial fibrosis) in cardiac magnetic resonance
89544716|NCT02433041|Active Comparator|Haloperidol|Haloperidol 0.005mg/kg at induction of anesthesia
89544717|NCT02433041|Active Comparator|Ketamine|Ketamine 1mg/kg at induction of anesthesia
89544718|NCT02433041|Active Comparator|Haloperidol + Ketamine|Combination of Haloperidol + Ketamine in same dosage at induction of anesthesia
89544719|NCT02433041|Placebo Comparator|Saline solution (NaCl 0.9%)|Placebo
89544720|NCT02429921|Experimental|low-Se lentils|50 mg of low-selenium lentils per person consumed as soups
89544721|NCT02429921|Experimental|high-Se lentils|50 mg of high-selenium lentils per person consumed as soup
89544722|NCT02575365|Experimental|Fingolimod arm|0.5 mg p.o fingolimod daily
89544723|NCT02707991|No Intervention|Enhanced Usual Care|Usual clinic appointment process plus receipt of the Centers for Disease Control and Prevention (CDC) Hepatitis C Fact Sheet
89544724|NCT02707991|Experimental|Nurse Case Management|Nurse-initiated hepatitis C clinic referral, strengths-based education, patient navigation, appointment reminders, and care coordination of HIV/hepatitis C drug-drug interaction prevention
89544725|NCT05527431|Active Comparator|high flow nasal cannula|
89544726|NCT05527431|Active Comparator|noninvasive mechanical ventilation|
89544727|NCT02432807|Experimental|Vancomycin 1.1%|Vancomycin hydrochloride ophthalmic ointment 1.1% dosed approximately 1 cm of ointment QID for 7 days
89544728|NCT02432807|Placebo Comparator|Placebo|Vehicle (placebo) ophthalmic ointment dosed approximately 1 cm of ointment QID for 7 days
89544729|NCT05527353||Women with PCOS|Women born in Northern Finland during 1985-1987 fulfilling ≥2 Rotterdam criteria.
89544730|NCT05527353||Controls|Women born in Northern Finland during 1985-1987 who are PCOM negative with no other diagnostic features of PCOS according to the Rotterdam criteria.
89544731|NCT02429843|Experimental|Standard treatment + TRC105|In addition to standard treatment of paclitaxel, carboplatin, and bevacizumab, dosing of TRC105 will begin at 8 mg/kg. However a lower dose level has also been included (6 mg/kg) and will be enrolled if 8 mg/kg is found to exceed the maximum tolerated dose. Following the appropriate pre-medication regimen, the first weekly TRC105 dose (cycle 1 day 8) will be split into two doses whereby 3 mg/kg is administered on cycle 1 day 8 and the balance (e.g., 5 mg/kg for Dose Level 1) is administered on cycle 1 day 11. Beginning with cycle 1 day 15 and thereafter, the full TRC105 dose will be administered intravenously each week during the 21-day cycle. Intra-patient dose reductions are allowed beginning in cycle 2.
89544732|NCT05527275|Experimental|Mitoxantrone Hydrochloride Liposome Injection Combined With Chidamide|
89544733|NCT02429765|Active Comparator|ACL/FOR|The evening dose of twice-daily dual bronchodilator medication will consist of aclidinium/formoterol 400/12mcg . After 2-weeks of treatment with twice-daily aclidinium/formoterol 400/12mcg, subjects will be randomized to receive an evening dose consisting of active drug or placebo.
89544734|NCT02429765|Placebo Comparator|Placebo|The evening dose of twice-daily dual bronchodilator medication will consist of a placebo inhaler. After 2-weeks of treatment with twice-daily aclidinium/formoterol 400/12mcg, subjects will be randomized to receive an evening dose consisting of active drug or placebo.
89544735|NCT03186053|Experimental|sodium creatine phosphate|5g creatine phosphate was dissolved in 50ml saline solution. After induction of anesthesia, the patients were first given a load dose of 1g, 20min (30ml / h) , And then pumped at a rate of 1 g / h (10 ml / h).
89544736|NCT03186053|Placebo Comparator|Control|The control group was treated with saline in the same manner.
89544737|NCT02429219|Active Comparator|Transurethral Resection|Transurethral Resection of the Prostate in Saline irrigation with ethanol
89544738|NCT02429219|Experimental|Photoselective vaporisation|Photoselective vaporisation of the Prostate in Saline irrigation with ethanol
89544739|NCT05531409|Experimental|Intervention Arm|Students from 6th and 7th grades from two schools were randomized to receive the RBYC curriculum. The RBYC curriculum has eight core content sessions, each of which lasts approximately 45 minutes. These include sessions that address: 1) Developmental differences between children versus teenagers; 2) Perspective-taking of and empathic responding to younger children; 3) and 4) Healthy versus unhealthy teenage-younger child relationships; 5) Misconceptions versus facts about child sexual abuse and legal ramifications; 6) Why adolescents may engage in harmful sexual behaviors; 7) Peer sexual harassment, what it is and how to avoid or address it; and 8) Being a good bystander or upstander when you have concerns that another child or peer has been or may be harmed. The RBYC curriculum was integrated into each school's existing health education curriculum.
89544740|NCT05531409|No Intervention|Waitlist Control|Students from 6th and 7th grades from the two schools that were randomized to the waitlist control condition received the RBYC curriculum once the study was completed (i.e., baseline and post-assessment data were collected).
89544741|NCT02429531|Experimental|Healthy controls|Healthy volunteers who consented to participate in the study will be immunized with both Pneumovax 23 and Typhim Vi .
89544742|NCT02429531|Experimental|Patients|Patients presenting for immune evaluation because of recurrent ENT/lung infection or invasive infection with encapsulated bacteria, in whom evaluation of pneumococcal antibody response is indicated, will be immunized with both Pneumovax 23 and Typhim Vi .
89544743|NCT04483193||Critically ill patients|Critically ill patients hospitalised at the intensive care unit.
89544744|NCT02429141|Experimental|US-guided periarterial techique|Axillary brachial plexus block by an ultrasound-guided periarterial technique
89544745|NCT02429141|Experimental|US-guided multi-injection technique|Ultrasound-guided multi-injection perineural technique for axillary brachial plexus
89544746|NCT02429453|Active Comparator|Fresh Frozen Plasma|Administration of a single dose of fresh frozen plasma based on INR per the following regimen: 2U for INR of 2-2.5; 3U for INR of 2.5-3; 4U for INR of 3-3.5; 5U for INR of 3.5-4; 6U for INR of 4+
89544747|NCT02429453|Experimental|Four Factor Prothrombin Complex Concentrate|Administration of a single dose of four factor prothrombin complex concentrate per the following dosing regimen: 25 U/kg for INR of 2-4; 35 U/kg for INR of 4-6; 50 U/kg for INR of 6+; maximum dosing weight of 100kg, patients may be dispensed +/- 10% of ordered dose
89544748|NCT02429297|Experimental|Patient Only - HITCM-only|Patients enrolling without a CarePartner receive weekly Health Information Technology/Care Manager (HITCM) automated assessment and self-care support calls with feedback to the clinical team.
89544749|NCT02429297|Experimental|Patient & CarePartner - HITCM-only|Patients enrolling with a CarePartner receive weekly Health Information Technology/Care Manager (HITCM) automated assessment and self-care support calls with feedback to the clinical team.
89544750|NCT02429297|Experimental|Patient & CarePartner - HITCM+CP|Patients enrolling with a CarePartner receive weekly Health Information Technology/Care Manager (HITCM) automated assessment and self-care support calls with feedback to the clinical team plus updates to their CarePartner via phone or email.
89544751|NCT05526963|Experimental|Intervention Group|Medication review (STOPP/START-criteria) + telephone-based adherence support measure (motivational interviewing)
89544752|NCT05526963|No Intervention|Control Group|Usual care
89207725|NCT00666458|Active Comparator|2|sitagliptin add-on to metformin
89544753|NCT02428751|Active Comparator|R-CHOP|This group received R-CHOP regimen as the first-line chemotherapy. Rituximab, 375mg/m2, iv, d0; Cyclophophamide, 750mg/m2, iv, d1; Doxorubicin, 50mg/m2, iv, d1; Vincristine, 2mg/m2 (max 2mg), iv, d1; Prednisone, 100mg, po, d1-5. Repeat every 21 days for 6-8 cycles or until the criteria of terminating treatment was met.
89544754|NCT02428751|Experimental|R-CDOP|This group received R-CDOP regimen as the first-line chemotherapy. Rituximab, 375mg/m2, iv, d0; Cyclophophamide, 750mg/m2, iv, d1; Pegylated liposomal doxorubicin, 30mg/m2, iv, d1; Vincristine, 2mg/m2 (max 2mg), iv, d1; Prednisone, 100mg, po, d1-5. Repeat every 21 days for 6-8 cycles or until the criteria of terminating treatment was met.
89544755|NCT05526807|Experimental|Ursodeoxycholic acid|Only one arm - subjects receiving ursodeoxycholic acid
89544756|NCT02428829|Experimental|Intervention|Intervention group will be seen by a physiotherapist to attempt walking from 4 hours post operatively, on the day of their surgery.
89544757|NCT02428829|Active Comparator|Control|Control group will receive standard physiotherapy in line with current hospital protocol including first walking approximately 24 hours post operatively
89544758|NCT05531331|Experimental|Intervention Group|After discharge, the individuals in the experimental group were given training by the researcher through training booklets prepared by the Association of Wound Ostomy Incontinence Nurses and video conference in four interviews. The first interview was done on the 5th day after discharge, the second on the 10th day, the third on the 15th day, and the fourth on the 2nd month.
89544759|NCT05531331|No Intervention|Control Group|Individuals with stoma in the control group received the training of the company representative that sells stoma materials routinely in the hospital.
89544760|NCT03184961|Experimental|lung recruitment maneuver|"Heart rate, mean arterial pressure, stroke volume, pulse pressure variations, pleth variability index, and photoplethysmographic waveform were recorded before lung recruitment maneuver (application of continuous positive airway pressure of 25 cm H2O for 20 s), during lung recruitment maneuver when stroke volume reached its minimal value.~Cardiac index measured before and after volume expansion (10ml/kg saline, 0.9%, infused during 10 min). Patients were considered as responders to fluid administration if cardiac index increased greater than or equal to 15%."
89544761|NCT04644783|Experimental|Blood test with assays|Ten patients with FPIES exhibiting reactions to 2-3 foods, and up to 10 exhibiting FPIES reactions to 4 or more foods will be recruited.
89544762|NCT03184883|Experimental|single conventional denture|patients with mandibular edentulous arch by using acrylic resin denture with soft linner
89207726|NCT00974961|Active Comparator|Levobupivacaine|Lumbar puncture with Levobupivacaine for spinal anesthesia
89207727|NCT00974961|Active Comparator|Bupivacaine|Lumbar puncture with Bupivacaine for spinal anesthesia
89544763|NCT03184883|Active Comparator|single flexible denture|patients with mandibular edentulous arch by using flexible lower denture
89544764|NCT04639947|Experimental|EyeCheck|EyeCheck pressures will be measured with contact lens in place
89544765|NCT04639947|Active Comparator|Traditional Tonometer (Goldmann and Tonopen)|Pressures will be measured with both Goldmann and Tonopen (both traditional tonometers to take the intraocular pressure (IOP) measurements of the eye).
89544766|NCT03185195|Experimental|AQX-1125 Oral Tablet|AQX-1125 - Oral Tablet
89544767|NCT03185195|Experimental|[14C]-AQX-1125 IV|Radiolabelled AQX-1125 - Intravenous
89544768|NCT03185195|Experimental|[14C]-AQX-1125 Oral Solution|Radiolabelled AQX-1125 - Oral Solution
89544769|NCT03185039|Experimental|kidney cancer|Localized, oligometastatic or metastatic
89544770|NCT03186365|Experimental|8-week arm|patients receiving 8 weeks of elbasvir 50 mg/grazoprevir (Zepatier Oral Product)100 mg daily
89544771|NCT03186365|Active Comparator|12-week arm|patients receiving 12 weeks of elbasvir 50 mg/grazoprevir 100 mg (Zepatier Oral Product) daily
89544772|NCT05531175|Experimental|İntervention Group|A total of 10 sessions of reiki were applied to the patients in the intervention group twice a week for 5 weeks, lasting 40-45 minutes during dialysis. The scales were administered to the individuals in the intervention groups three times in total.
89544773|NCT05531175|No Intervention|Control Group|No treatment was applied to the control group. The scales were administered to the individuals in the control groups three times in total.
89544774|NCT02432651|Other|6 mg xanthohumol per day vs. placebo|All participants take 6 mg xanthohumol daily and placebo in a crossover design with a washout period.
89544775|NCT02432651|Other|12 mg xanthohumol per day vs. placebo|All participants take 12 mg xanthohumol daily and placebo in a crossover design with a washout period.
89544776|NCT02432651|Other|24 mg xanthohumol per day vs. placebo|All participants take 24 mg xanthohumol daily and placebo in a crossover design with a washout period.
89544777|NCT04628091|Experimental|Test group|Test group is composed of 20 women of reproductive age devoid of any pathology coming to the hospital for a salpingectomy for contraceptive purposes or for a total hysterectomy.
89544778|NCT02428517||Young/MSD|Patients who are <55 years old, and will receive alloHCT for Young/MSD
89544779|NCT02428517||Young/MUD&FMD|Patients who are <55 years old, and will receive alloHCT for Young/MUD&FMD
89032960|NCT00529334|Experimental|1|CyberKnife Partial Breast Irradiation (PBI)
89207728|NCT00975039|Experimental|WST11|Treatment with WST11-mediated VTP
89544780|NCT02428517||Old/MSD|Patients who are >=55 years old, and will receive alloHCT for Old/MSD
89544781|NCT02428517||Old/MUD&FMD|Patients who are >=55 years old, and will receive alloHCT for Old/MUD&FMD
89544782|NCT05522985|Experimental|Treprizumab combined with TP|"treprizumab injection: 240mg once, intravenous infusion, D1, once every 3 weeks, a total of 3 cycles.~paclitaxel for injection (albumin binding type) 260 mg / m2, intravenous drip, D1, every 3 weeks as a cycle, a total of 3 cycles; cisplatin: 75mg / m2, intravenous drip, D1, once every 3 weeks, a total of 3 cycles; Treprizumab was infused before and at least 60 minutes apart from chemotherapy; The intravenous infusion time of treprizumab shall be at least 60 minutes. Intravenous bolus or single rapid intravenous injection is not allowed."
89544783|NCT05522985|Active Comparator|TP（paclitaxel +cisplatin）|paclitaxel for injection (albumin binding type) 260 mg / m2, intravenous drip, D1, every 3 weeks as a cycle, a total of 3 cycles; cisplatin: 75mg / m2, intravenous drip, D1, once every 3 weeks, a total of 3 cycles;
89544784|NCT05526339|Experimental|High-flow nasal oxygenation combined with nasopharyngeal airway|High-flow nasal oxygenation combined with nasopharyngeal airway was used in obese patients who are scheduled to undergo gastrointestinal endoscopy procedures sedated with propofol.
89544785|NCT05526339|Active Comparator|Regular nasal cannula combined with nasopharyngeal airway|Regular nasal cannula combined with nasopharyngeal airway was used in obese patients who are scheduled to undergo gastrointestinal endoscopy procedures sedated with propofol.
89544786|NCT02707757|Active Comparator|Iron sucrose|Iron sucrose 200mg for 5 doses
89544787|NCT02707757|Active Comparator|Neorecormon|Incremental increase in dose along following parameters: 1000-2000-3000-4000-6000-8000-12000
89544788|NCT05522907||Neoadjuvant|From the beginning of the project for the past five years to the next three years, underwent prostate cancer biopsies at the First Affiliated Hospital of Xi'an Jiaotong University before neoadjuvant therapy, and underwent radical prostatectomy after 3-6 months of neoadjuvant therapy.
89544789|NCT05522907||CRPC|Patients with CRPC-diagnosed prostate cancer after initial continuous ADT therapy, with serum testosterone reaching castration levels (<50ng/dl or <1.7nmol/L) but with progressive disease, and who were diagnosed with CRPC at Xi'an Jiaotong University The First Affiliated Hospital did a prostate cancer biopsy.
89544790|NCT02432573|No Intervention|Standard care|Postpartum patients that receive physician rounding at current time
89544791|NCT02432573|Experimental|Delayed rounding|Postpartum patients that receive physician rounding at a delayed time
89544792|NCT05522829|Experimental|Cohort 1: Group SCTV01E-1|3 doses of SCTV01E-1
89544793|NCT05522829|Active Comparator|Cohort 1: Group SCTV01E|3 doses of SCTV01E
89544794|NCT05522829|Experimental|Cohort 2: Group SCTV01E-1|2 doses of SCTV01E-1
89032961|NCT04218903|Experimental|Combined Training 4 times per week (CT4)|The CT4 group will perform four sessions per week of combined exercise program. This intervention will last 12 weeks.
89544795|NCT05522829|Active Comparator|Cohort 2: Group SCTV01E|2 doses of SCTV01E
89544796|NCT02432495||Anterior screw fixation|Patients aged 65 years or older with an ASA score of 2 or higher who had undergone anterior screw fixation of type II odontoid fractures
89544797|NCT02432495||Halo immobilization|Patients aged 65 years or older with an ASA score of 2 or higher who had undergone of halo immobilization of type II odontoid fractures
89544798|NCT02432339|Experimental|mycophenolate mofetil (MMF)|Mycophenolate Mofetil (MMF) 500 mg tablet twice a day for 7 1/2 days.
89544799|NCT02432339|Placebo Comparator|Placebo|Placebo (sugar pill) in the same size capsule that the MMF is used in - twice a day for 7 1/2 days.
89544800|NCT03184805|Active Comparator|Continuing aspirin|Patients in the group may continue the administration of aspirin during perioperative period.
89544801|NCT03184805|Experimental|Stopping aspirin|Patients in the group may stop medication of antiplatelet drugs during perioperative period.
89207729|NCT00511108|Experimental|1|Arm 1: drug
89207730|NCT00511108|Active Comparator|2|Arm 2: active comparator
89207731|NCT00511108|Experimental|3|Arm 3: drug + active comparator
89207732|NCT00511108|Placebo Comparator|4|Arm 4: placebo comparator
89207733|NCT00785642|Experimental|1|Dermacyd PH_DETINLYN Tangerine Mix (Lactic Acid)
89207734|NCT00781586|Experimental|Arm 1|
89207735|NCT00781586|Active Comparator|Arm 2|
89207736|NCT00781586|Placebo Comparator|Arm 3|
89207737|NCT00785720|Experimental|1|Dermacyd PH_DETINBACK (Lactic Acid)
89207738|NCT00781664|Experimental|A|AN2718 Cream SF Vehicle
89207739|NCT00781664|Experimental|B|AN2718 Cream SF, 0.3%
89207740|NCT00781664|Experimental|C|AN2718 Cream SF, 1%
89207741|NCT00781664|Experimental|D|AN2718 Gel Vehicle
89207742|NCT00781664|Experimental|E|AN2718 Gel, 1.5%
89207743|NCT00781664|Experimental|F|AN2718 Gel, 2.5%
89207744|NCT00781664|Experimental|G|AN2718 Gel, 5%
89207745|NCT00781664|Experimental|H|AN2718 Gel, 7.5%
89207746|NCT00781664|Active Comparator|I|Sodium Lauryl Sulfate, 0.5%
89207747|NCT00785876|No Intervention|1|Control Sites
89207748|NCT00785876|Experimental|2|Intervention Sites
89207749|NCT02554916||Dual-belt Exercise|The participants assigned to this group will use the dual-belt treadmill 3 times a week for 16 weeks.
89207750|NCT02554916||Treadmill Exercise|The participants assigned to this group will use the treadmill 3 times a week for 16 weeks.
89207751|NCT02554916||Usual Care|The participants assigned to this group will not use the treadmills.
89207752|NCT00791570|Experimental|A|
89207753|NCT00510952|Experimental|Lispro|Insulin Lispro protamine suspension: Patient adjusted dose, once daily (QD) or twice daily (BID), injected subcutaneous (SC) x 24 weeks
89207754|NCT00510952|Active Comparator|Glargine|Insulin glargine: Patient adjusted dose, once daily (QD), injected subcutaneous (SC) x 24 weeks
89207755|NCT00617604|Placebo Comparator|Placebo|Participants received placebo administered intra-operatively as an intravenous (IV) bolus on Day 0, another IV bolus on Day 3 and weekly subcutaneous injections thereafter for 12 weeks. Participants also received tacrolimus, mycophenolate mofetil (MMF) and steroid treatment.
89207756|NCT00617604|Experimental|Alefacept|Participants received 7.5 mg alefacept administered intra-operatively as an IV bolus on Day 0, another 7.5 mg IV bolus on Day 3, and weekly subcutaneous injections of 15 mg alefacept thereafter for 12 weeks. Participants also received tacrolimus, MMF and steroid treatment.
89207757|NCT00865722|Active Comparator|RemotePostConditioning|Patients will receive pPCI and treatments according to guidelines for STEMI PLUS extrinsic cuff compression to the lower limb for 5 ' followed by 5' reperfusion for three cycles (30' in total) starting with myocardial reperfusion
89207758|NCT00865722|Sham Comparator|Controls|pPCI and treatments according to guidelines for STEMI
89544802|NCT05518383|Experimental|R1: stage I and II|R1: resection status: complete, stage I and II
89544803|NCT05518383|Experimental|R2: incomplete, stage I and II|R2: resection status: incomplete, stage I and II
89207759|NCT00857844||Group 1|Normal GFR (>90ml/min/1.73m2). Stage I CKD
89207760|NCT00857844||Group 2|GFR between 30-59ml/min/1.73m2. Stage III CKD
89207761|NCT00857844||Group 3|GFR between 15-29ml/min/1.72m2. Stage IV CKD
89207762|NCT02544594|Active Comparator|Extra-Corporal Life Support (ECLS)|Standard treatment plus Extra-Corporal Life Support (ECLS) (from Sorin) in patients with cardiogenic shock due to myocardial infarction.
89207763|NCT02544594|No Intervention|Standard treatment|Standard treatment alone without Extra-Corporal Life Support (ECLS) in patients with cardiogenic shock due to myocardial infarction.
89207764|NCT00858000||Group A|No intervention
89207765|NCT02544438|Experimental|Astarabine|Astarabine
89207766|NCT00865878|Active Comparator|1|Topical Levulan Kerastick containing 20% aminolevulinic acid HCL (ALA) will be applied to the entire scalp OR both forearms 90 +/- 30 minutes prior to blue light treatment for 16 minutes and 40 seconds.
89207767|NCT00865878|Placebo Comparator|2|Kerastick containing vehicle ingredients only (VEH) will be applied to the entire scalp OR both forearms 90 +/- 30 minutes prior to blue light treatment for 16 minutes 40 seconds.
89207768|NCT00661622|Experimental|Immunoembolization|Liver embolization treatment with injection of GM-CSF.
89207769|NCT00661622|Active Comparator|Plain embolization|Liver embolization with normal saline injected in place of GM-CSF
89207770|NCT00791726||1|Patients with noninfectious uveitis and macular edema
89207771|NCT00781820|Placebo Comparator|Arm 2|
89207772|NCT00781820|Experimental|Arm 1|
89207773|NCT00786110|Experimental|1 arm only|"One arm only with Sorafenib plus Paclitaxel Patients enrolled will undergo strict follow-up~Intervention: Sorafenib plus Paclitaxel"
89207774|NCT00781976|Placebo Comparator|1|
89207775|NCT00781976|Active Comparator|2|
89207776|NCT00782054|Active Comparator|Active|moisturizer with endopeptidases
89207777|NCT00782054|Placebo Comparator|Placebo|moisturizer without endopeptidases
89207778|NCT00791804|Experimental|Single Arm|
89207779|NCT00791882|Experimental|1|"Group of behaviors by which someone express feelings, attitudes, wishes,opinions and rights , in an adequate manner regarding situation and context.~Social skills are the substrate for social competence, which is the ability to find and legitimate relevant and personal goals"
89207780|NCT00791882|No Intervention|2|Control group will attend the same number of sessions, but without intervention of the therapists
89207781|NCT02544516|Experimental|Patients|patients suffering schizophrenic disorders and who will perform cognitive tasks + PANSS+ IQ
89207782|NCT02544516|Active Comparator|control group|healthy patients who will perform cognitive tasks
89207783|NCT00791960|Active Comparator|Dimenhydrinate|Dimenhydrinate
89207784|NCT00791960|Placebo Comparator|Placebo|Placebo
89207785|NCT00792038||1|OCD patients
89207786|NCT00792038||2|Normal Controls
89207787|NCT00792194|Experimental|training group|supervised training program 3 times a week with coach.
89207788|NCT00792194|No Intervention|group without training|a control group, where subjects are asked to continue their normal daily activities and physiotherapy regime.
89544804|NCT05518383|Experimental|R3: incomplete, stage III and LDH < 2 x ULN|R3: resection status: incomplete, stage III and LDH < 2 x ULN
88961440|NCT02009228|Active Comparator|Single-port laparoscopy|The three-channel single-port: a 1.5-cm horizontal intraumbilical skin incision, a 1.5-cm to 2-cm rectus fasciotomy to open the peritoneal cavity, and the insertion of an Alexis small wound retractor (Applied Medical, Rancho Santa Margarita, CA). The wrist portion of a size 6.5 surgical glove was fixed to the outer ring of the wound retractor. A 12-mm trocar was inserted through a small hole made in one of the fingertips of the glove and advanced into the abdominal cavity. Two additional holes for the accessory channels were made in another fingertip of the glove, and two conventional 5-mm trocars were inserted through the holes.
88811721|NCT01491113|Experimental|Group A: Normal renal function|"Subjects who have normal renal function (CLcr >80 mL/min/1.73 m^2). Subjects will be orally administered Levetiracetam (LEV) 500 mg once. After LEV administration, safety assessments and blood and urine samplings will be taken through to Day 4 during the Treatment Period, and safety follow-up assessments will be performed on Day 8 according to the schedule of study assessments.~Blood samples for Pharmacokinetics (PK): Predose (Baseline), and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours postdose~Urine samples for PK: 0 - 6, 6 - 12, 12 - 24, 24 - 48, 48 - 72 hours postdose"
88961441|NCT02009228|Active Comparator|Conventional laparoscopy|The 12-mm main troca was inserted via subumbilical incision after fully insufflation by verness needle and other 3 working 5-mm trocas were inserted under vision at right middle abdominal, left middle abdominal and suprapubic incisions.
89207789|NCT00792350||Group 1|
88961442|NCT02009241|Active Comparator|Pulmonary Rehabilitation|The intervention group will perform a 12 week pulmonary rehabilitation program consisting of 30 minutes of treadmill aerobic exercise training and 30 minutes of muscle strength training.
88961443|NCT02009241|No Intervention|Control|
88961444|NCT02009254|Experimental|Mashed Potatoes (as produced)|
88961445|NCT02009254|Experimental|Mashed Potatoes (with no added butter during production)|
88961446|NCT02009254|Experimental|glucose control (50 g)|
88961447|NCT02009267||Patient controlled analgesia|Use of patient controlled analgesia (PCA) for the management of postoperative pain after the Nuss procedure.
89517253|NCT04638829|Other|Avatrombopag|Avatrombopag 20 mg oral tablet formulation for 90 days
89517254|NCT04634097|Experimental|Experimental group|"Clusters will be proposed LE DECLIC EPRI intervention, which is a complex intervention, associating 3 components,:~A. DECLIC program set up in the centers, open to concerned patients.~B. 3 training sessions :~one public of primary care physicians in order to give them the opportunity to be involved in the medical care in charge of the patient suffering from cancer pain.~one public of cancer physicians, leaders of opinions in each cancer centers participating to the study and one public of health professionals in order to train them to be educators (team building).~for healthcare professionals in order to train them as educators in this program.~C. The collaboration of one primary care network, specialized in pain management, in order to reinforce the patient care pathway."
89517255|NCT04634097|Other|Standard group|Standard follow-up patient related to pain. Specific to each center : with or without existing local ETP program (standard care).
89517256|NCT04622267|Active Comparator|Standard suture|Standard antimicrobial suture (vicryl) - control arm
89517257|NCT04622267|Experimental|Barbed suture|Barbed suture type is STRATAFIX Symmetric PDS Plus Knotless Tissue
89517258|NCT04619004|Experimental|Study Group 1: Patritumab deruxtecan 5.6 mg/kg|Study Group 1 will be participants with metastatic or locally advanced NSCLC with an EGFR-activating mutation randomized to receive patritumab deruxtecan 5.6 mg/kg IV every 3 weeks (Q3W)
89517259|NCT04619004|Experimental|Study Group 2: Patritumab deruxtecan Up-Titration|Study Group 2 will be participants with metastatic or locally advanced NSCLC with an EGFR-activating mutation randomized to receive patritumab deruxtecan up-titration IV every 3 weeks (Q3W)
89517260|NCT04583735|Other|TEPEZZA|8 infusions of TEPEZZA (10 mg/kg for the first infusion and 20 mg/kg for the remaining 7 infusions) with a final visit at Week 24 (Treatment Period)
89517261|NCT04583735|Placebo Comparator|Placebo|Placebo once every 3 weeks
89517262|NCT04572633|Experimental|HistoSonics System|
89517263|NCT04570332|Experimental|Single Arm|Patients will be treated with the combination of BO-112 and pembrolizumab. IT administration of BO-112 will be performed once weekly (QW) for the first 7 weeks and then once every three weeks (Q3W); pembrolizumab Q3W will be administered IV. The order of administration should be pembrolizumab then IT BO-112. BO-112 will be administered IT at a total dose of 1-2 mg at each administration to 1-8 tumor lesions using tuberculin (TB) syringes (or equivalent) with 20- to 25-gauge needles.
89517264|NCT04547777|Experimental|D2C7-IT + 2141-V11|Single D2C7-IT intratumoral infusion (4613.2 ng/mL in 36 mL) over 72 hours followed by single 2141-V11 infusion (5 dose levels) over 7 hours
89517265|NCT04541381|No Intervention|Control Group|Participants assigned to the control group will receive standard chemotherapy without their doctors receiving any genetic information based on the participants' pharmacogenetic results. DNA (Deoxyribonucleic acid) samples for participants in this group will be stored and tested for genotyping six months later after treatment (or earlier if the participant experiences side effects).
89517266|NCT04541381|Experimental|Pharmacogenomics Group|Participants enrolled in the pharmacogenomics group will give a DNA (deoxyribonucleic acid) sample for immediate pharmacogenomic genotyping. Once the genotyping results are in, cancer doctors caring for each participant will have immediate access to clinical decision support based on the participant's genetic results and can make dosing decisions/changes to the participant's chemotherapy prescription.
89517267|NCT04518228||Component 1: Arm 1.1: Bictegravir (BIC) 50 mg q.d.|Women ≥ 20 weeks gestation not receiving TB drugs and receiving bictegravir (BIC) 50 mg once daily (q.d.), and their infants
89517268|NCT04518228||Component 1: Arm 1.2: Doravirine (DOR) 100 mg q.d.|Women ≥ 20 weeks gestation not receiving TB drugs and receiving doravirine (DOR) 100 mg q.d., and their infants
89517269|NCT04518228||Component 1: Arm 1.3: Tenofovir alafenamide (TAF) 10 mg q.d.|Women ≥ 20 weeks gestation not receiving TB drugs and receiving tenofovir alafenamide (TAF) 10 mg q.d. boosted with cobicistat, and their infants
89517270|NCT04518228||Component 1: Arm 1.4: TAF 25 mg q.d. without boosting|Women ≥ 20 weeks gestation not receiving TB drugs and receiving TAF 25 mg q.d. without boosting, and their infants
89517271|NCT04518228||Component 1: Arm 1.5: TAF 25 mg q.d. with boosting|Women ≥ 20 weeks gestation not receiving TB drugs and receiving TAF 25 mg q.d. boosted with cobicistat or ritonavir, and their infants
89544805|NCT05518383|Experimental|R4: stage III and LDH ≥ 2 x ULN, stage IV/B-AL and CNS negative; CNS +|R4: resection status: incomplete, stage III and LDH ≥ 2 x ULN, stage IV/B-AL and CNS negative; CNS +
89544806|NCT02432027|Experimental|IMP 1|C-82 Topical Gel, 1%
89544807|NCT02432027|Placebo Comparator|IMP 2|C-82 Topical Gel, placebo
89544808|NCT02432027|Active Comparator|IMP 3|Daivonex cream
89544809|NCT02432027|Active Comparator|IMP 4|Diprosis gel
89544810|NCT02428439||Increased suicidality|Increase in suicidal ideation after taking the standardized pharmacotherapy (bupropion or lamotrigine) during 8 weeks.
89544811|NCT02428439||Non-increased suicidality|Non-increase of suicidal ideation after taking the standardized pharmacotherapy (bupropion or lamotrigine) during 8 weeks.
89544812|NCT05526183|Experimental|Low dose arm|Low dose (5x1010 VP, i.m.); CoVacHGMix (with equal amounts of CoVacHGA1320, CoVacHGB420, CoVacHGC720 and CoVacHGD1480 adenoviral vector mix, as 0.5 solution) Intramuscular injection, two injections 28 days apart
89544813|NCT05526183|Experimental|High dose arm|High dose (1x1011 VP, i.m.); CoVacHGMix (with equal amounts of CoVacHGB420, CoVacHGC720 and CoVacHGD1480 adenoviral vector mix, as 1.0 solution) Intramuscular injections, two injections 28 days apart
89544814|NCT03186443|Active Comparator|pregabalin|experiment group: pregabalin 300mg,q12h for 6 months
89544815|NCT03186443|Experimental|gabapentin|compared to pregabalin effect on herpetic neuralgia
89544816|NCT05526027|Other|ETI|pwCF which are CFTR-modulator naive and pwCF previously treated with a CFTR-modulator (i.e. tezacaftor-ivacaftor or lumacaftor-ivacaftor) will undergo standard-of-care examinations as well as examinations in the context of this trial (i.e. CFQ-R, PHQ-9, GAD-7 and SNOT-22 questionnaires, fecal elastase measurement)
89544817|NCT02428361|Experimental|Pouchitis patients receiving FMT|Pouchitis patients receiving biologically active human fecal material sourced from OpenBiome.The physician will administer 250 mL of the fecal suspension in aliquots of 50-60 mL through the endoscope. The material will be delivered to the most proximal point of insertion.
89544818|NCT05517993|Experimental|Group A|Gui-Lu-Er-Xian-Jiao-Wan (GLEXJW) 3g orally twice daily for 12 weeks.
89544819|NCT05517993|No Intervention|Group B|No intervention.
89544820|NCT02428673|Other|Load-measuring platform|A load-sensing platform will be placed under each foot of the subject to record the time course of load borne by each of the lower extremities during weight-bearing training in an assisted standing device.
89544821|NCT03186131|Active Comparator|Oral Ibandronate alone|Monthly Oral Intake of Ibandronate
89544822|NCT03186131|Active Comparator|Oral Ibandronate and Vitamin D|Monthly oral intake of Ibandronate and daily oral intake of Vitamin D
89544823|NCT02572401|Experimental|HIV Risk Reduction Only|STAND HIV Risk Reduction Intervention. Participants will not receive the Text Messaging Intervention.
89544824|NCT02572401|No Intervention|No-Intervention No-Text Message Control|Participants do not receive the STAND HIV Risk Reduction Intervention or the Text Messaging Intervention.
89544825|NCT02572401|Experimental|HIV Risk Reduction and Text Messaging|STAND HIV Risk Reduction Intervention and Text Messaging Intervention. Participants will receive the intervention and text messages.
89544826|NCT02572401|Experimental|Text Messaging Only|Text Messaging Intervention. Participants will receive the text messages but not the STAND HIV Risk Reduction Intervention.
89544827|NCT03186287|Experimental|Eccentric training group|The participants in this group will actively perform eccentric phase of resistive shoulder exercises. Additionally they will receive standard physiotherapy.
89544828|NCT03186287|Experimental|Concentric training group|The participants in this group will actively perform concentric phase of resistive shoulder exercises. Additionally they will receive standard physiotherapy.
89544829|NCT03186287|Active Comparator|Control group|The participants in this group will receive only standard physiotherapy.
89544830|NCT03185975|Placebo Comparator|Control arm|Each participant will receive an at-home test kit and will be asked to test and return results to investigator.
89544831|NCT03185975|Active Comparator|Intervention Arm|Each participant will receive an at-home test kit and will be asked to take the test in conjunction with an online Motivational interviewing/certified testing and referral (MI/CTR).
89544832|NCT03184649|Experimental|intervention arm|Ibuprofen suspension (Ibufen®, 100 mg/5 mL; fruit flavored, orange colour, Abbott) will be given 30 min before injection of local anesthesia. Then pain scores will be recorded from 0-4.
89544833|NCT03184649|Experimental|intervention|Paracetamol (Calpol™, 250 mg/5 mL; fruit flavored, orange color, GlaxoSmithKline) will be given 60 min before injection of local anesthesia.Then pain scores will be recorded from 0-4.
89544834|NCT03184649|Placebo Comparator|comparator|A fruit-flavored orange color placebo solution will be given 60 min before injection of local anesthesia.Then pain scores will be recorded from 0-4.
89544835|NCT05517915|Experimental|IMT group|IMT training with 70% threshold was given.
89544836|NCT05517915|Sham Comparator|Sham group|unloaded IMT training was given.
89544837|NCT02432261|Experimental|Group 1|5.0 mL of the 1.62% Nestorone® /testosterone gel (containing 8.3 mg NES + 62.5 mg T) applied each day on the arms and shoulders
89544838|NCT02432261|Experimental|Group 2|4.4 mL of the 1.62% Testosterone only gel (AndrogelTM) (containing 62.7 mg T) applied each day to the arms and shoulders
89544839|NCT03184415|Experimental|DWC20155/DWC20156 Combination Therapy|
89544840|NCT03184415|Active Comparator|DWC20155 Monotherapy|
89544841|NCT03184415|Active Comparator|DWC20156 Monotherapy|
89544842|NCT05522595|Experimental|Standard of care arm|The patient is his own comparator. During the intervention, the eyes movements measurements will be performed using the standard of care and the medical device S360.
89544843|NCT02431949||Controls|Participants without a psychosis disorder diagnosis.
89544844|NCT02431949||Patients|Participants with a psychosis disorder diagnosis- recruited from the BC Psychosis Program.
89544845|NCT02428283|Experimental|Nerve block|Scalp nerve block was performed with 0.25% ropivacaine.
89544846|NCT02428283|Active Comparator|Control|Remifentanil was administered intravenously.
89544847|NCT02428127|Experimental|Test|20g Carbohydrate powder fortified with multiple micronutrients, reconstituted as a beverage in 200mL lukewarm water. This will be administered twice a day
88811722|NCT01491113|Experimental|Group B: Mild renal impairment|"Patients who have mild renal impairment (50<CLcr <80 mL/min/1.73 m^2). Subjects will be orally administered (Levetiracetam) LEV 500 mg once. After LEV administration, safety assessments and blood and urine samplings will be conducted through Day 5 during the Treatment Period, and safety follow-up assessments will be performed on Day 8 according to the schedule of study assessments.~Blood samples for Pharmacokinetics (PK): Predose (Baseline), and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96 hours postdose~Urine samples for PK: 0 - 6, 6 - 12, 12 - 24, 24 - 48, 48 - 72, 72 - 96 hours postdose"
88961448|NCT02009267||Continuous thoracic epidural infusion|Continuous thoracic epidural infusions (TE) for the management of postoperative pain after the Nuss procedure.
88961449|NCT02009267||Continuous paravertebral blockade|Continuous paravertebral blockade (PVB) for the management of postoperative pain after the Nuss procedure.
88961450|NCT05778890|Experimental|Intervention group|The physiotherapy program consisted of 1 session per day for 3 weeks, a total of 15 sessions. Intervention group included Ultrasound for 5 minutes to both TMJ, TENS on both TMJ for 20 minutes, exercise for 30 minutes and patient education. The intervention group was also taught home exercises program and asked to do 6 repetitions 6 times a day. This exercise program was given to the patients in brochure form. These exercises were not given to the control group.
88961451|NCT05778890|Active Comparator|control group|Control group is physiotherapy program consisted of 1 session per day for 3 weeks, a total of 15 sessions. This group included Ultrasound for 5 minutes to both TMJ, TENS on both TMJ for 20 minutes, exercise for 30 minutes and patient education.
89032962|NCT04218903|Active Comparator|Combined Training 2 times per week (CT2)|The CT2 group will perform two sessions per week of combined exercise program. This intervention will last 12 weeks.
89032963|NCT02945306|Experimental|Adenotonsillectomy|Removal of tonsils and adenoids under a general anaesthetic
89544848|NCT02428127|Active Comparator|Calorie matched protein powder|20g Calorie matched protein powder with 80% protein, reconstituted as a beverage in 200mL lukewarm water. This will be administered twice a day
89544849|NCT02428127|Placebo Comparator|Control|200mL lukewarm water given twice a day
89544850|NCT02427971||Perseus|Use of Perseus® A 500 with VaporView® mode that gives the evolution of inspired (Fi) and end-tidal (Fe) fractions of halogenated agents for 20 minutes based on the delivered fraction (Fd). FGF remains adjusted manually by the practitioner. This mode also makes it possible to maintain a low FGF (0.5 L/min)
89544851|NCT02427971||Aysis|Use of Aysis® Cs2 ventilator with automated control of end-tidal inhalation anesthetic concentration, EtControl® mode.
89544852|NCT03185585||Adults 60 yrs and older|Participants will be asked to take the full MNA and COAST tools, separately .They will take a hand grip strength test to evaluate their functional status and five times Sit to Stand test as part of the COAST screening tool. Moreover, their weight, height, mid-arm circumference and calf circumference, will be measured as part of the MNA screening tool.
89544853|NCT02427893|Active Comparator|Cohort 1|Ten patients begin Vemurafenib monotherapy, after 10 days, begin combination therapy by adding Cobimetinib.
89544854|NCT02427893|Active Comparator|Cohort 2|Ten patients begin Cobimetinib monotherapy, after 10 days, begin combination therapy by adding Vemurafenib.
89544855|NCT03184493|Experimental|Celebrex|Patients will receive celebrex (1 piece/day, 0.2mg/piece, Pfizer Pharmaceuticals Ltd) until obvious side effects.
89544856|NCT03184493|Experimental|Metformin|Patients will receive metformin (1 piece/bid, 250 mg/piece) until obvious side effects.
89544857|NCT03184493|Active Comparator|Celebrex plus Metformin|Patients will receive celebrex (1 piece/day, 0.2mg/piece, Pfizer Pharmaceuticals Ltd) until obvious side effects. In addition, patients will receive metformin (1 piece/bid, 250 mg/piece) until obvious side effects.
89544858|NCT03184493|No Intervention|Empty control group|This group patients will not receive any postoperative adjuvant therapy.
89544859|NCT03184337|Active Comparator|Active Control|Participants in the active control group will receive 8 group sessions of the CDC's PreventT2 program.
89544860|NCT03184337|Experimental|Experimental|Participants in the experimental group will receive 8 group sessions of the CDC's PreventT2 Program with Added Sleep Content designed to extend and improve sleep.
89544861|NCT02431481|Experimental|Normal renal function|Normal renal function; matched demography to renal impariment cohorts
89544862|NCT02431481|Experimental|Severe renal impairment|Severe decrease in GFR (15-29 ml/min)
89544863|NCT02431481|Experimental|End Stage Renal Disease|End stage renal disease not on dialysis; GFR <15 ml/min
89544864|NCT02431481|Experimental|Mild renal impairment|Mild decrease in GFR (60-89 ml/min)
89544865|NCT02431481|Experimental|Moderate renal impairment|Moderate decrease in GFR (30-59 ml/min)
89544866|NCT02431403|Experimental|ESHAP-Imatinib 100mg|"Imatinib 100 mg combined with ESHAP~* ESAHP D1-4 Etoposide 40mg/m2 D1-4 Cisplatin 25mg/m2 D5 Cytarabine 2000mg/m2 D1-5 Methylprednisolone 250mg/m2 D6 Pegfilgrastim 6mg"
89544867|NCT02431403|Experimental|ESHAP-Imatinib 200mg|"Imatinib 200 mg combined with ESHAP~* ESAHP D1-4 Etoposide 40mg/m2 D1-4 Cisplatin 25mg/m2 D5 Cytarabine 2000mg/m2 D1-5 Methylprednisolone 250mg/m2 D6 Pegfilgrastim 6mg"
89544868|NCT02431403|Experimental|ESHAP-Imatinib 400mg|"Imatinib 400 mg combined with ESHAP~* ESAHP D1-4 Etoposide 40mg/m2 D1-4 Cisplatin 25mg/m2 D5 Cytarabine 2000mg/m2 D1-5 Methylprednisolone 250mg/m2 D6 Pegfilgrastim 6mg"
89544869|NCT02431403|Experimental|ESHAP-Imatinib 300mg|"Imatinib 300 mg combined with ESHAP~* ESAHP D1-4 Etoposide 40mg/m2 D1-4 Cisplatin 25mg/m2 D5 Cytarabine 2000mg/m2 D1-5 Methylprednisolone 250mg/m2 D6 Pegfilgrastim 6mg"
89544870|NCT02431325|Experimental|Teduglutide|Teduglutide, subcutaneous injection, 0.05 mg/kg/day, 6 months duration
89544871|NCT02431325|Placebo Comparator|Placebo|Placebo, subcutaneous injection, 6 months duration
89544872|NCT03184025|Other|patients have class I caries|patients have received four restorations which included HEMA containing and HEMA-free dentin adhesive with or without surface sealing
89544873|NCT02103478|Experimental|Phase 1 Dose Escalation|Starting cohort was administered 40 mg oral cedazuridine and 20 mg oral decitabine. Participants were enrolled into successive cohorts in which either the cedazuridine or decitabine oral dose was varied in Course 1 Day 2 through Course 1 Day 5 for comparison with a single dose of IV decitabine at 20 mg/m^2 administered on Day 1 by continuous IV infusion over 1 hour (28 days per course).
88811723|NCT01491113|Experimental|Group C: Moderate renal impairment|"Patients who have moderate renal impairment (30<CLcr < 50 mL/min/1.73 m^2). Subjects will be orally administered Levetiracetam (LEV) 250 mg once. After LEV administration, safety assessments and blood and urine samplings will be conducted through Day 6 during the Treatment Period, and safety follow-up assessments will be performed on Day 8 according to the schedule of study assessments.~Blood samples for Pharmacokinetics (PK): Predose (Baseline), and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours postdose~Urine samples for PK: 0 - 6, 6 - 12, 12 - 24, 24 - 48, 48 - 72, 72 - 96, 96 -120 hours postdose"
88961452|NCT05778773||TAVR|"Patients undergoing aortic valve replacement through the Transcatheter Aortic Valve Replacement procedure.~For all the patients a set of clinical, anatomical, and procedural details will be obtained and registered. The outcome at the hospital discharge and at the 12-month follow-up will be collected, as well. The quality of life questionnaire will be administered to all the patients at the hospital discharge, at the 12-month follow-up (mandatory), and then at annual base (facultative)."
88961453|NCT05778773||AVR|"Patients undergoing aortic valve replacement through conventional open-heart surgery (sternotomy and biological valve implantation).~For all the patients a set of clinical, anatomical, and procedural details will be obtained and registered. The outcome at the hospital discharge and at the 12-month follow-up will be collected, as well. The quality of life questionnaire will be administered to all the patients at the hospital discharge, at the 12-month follow-up (mandatory), and then at annual base (facultative)."
88961454|NCT05778682|Experimental|Suction based protocol|Weaning protocol based on suctioning frequency. Once the weaning of mechanical ventilation, the patients in this arm will be on high-flow nasal canula. The canula will be remove if the decannulation conditions are met (if the patient require less than 2 aspirations in 8 hours for 24 consecutive hours)
88961455|NCT05778682|Other|Usual care|Usual care will mainly base on the capping trial.
89544874|NCT02103478|Experimental|Phase 2 Dose Confirmation|Participants were randomized in a 1:1 ratio to receive either oral cedazuridine (E7727) (100 mg) + decitabine (35 mg) capsules Dailyx5 in Course 1 followed by IV decitabine (20 mg/m^2) Dailyx5 in Course 2 (28 days per course) or the converse. In Courses ≥ 3, participants received cedazuridine and decitabine capsules Dailyx5 in 28-day courses until disease progression, unacceptable toxicity, withdrawal of consent or withdrawal from the study.
88961456|NCT05778669||Cohort Group: Longitudinal follow-up intervention|Monitoring of medical, health and psychosocial conditions through questionnaires, on-site assessments and medical record checking.
88961457|NCT05778630|Other|Group A. Focus group|Individuals will participate in one or several, semi-structured focus group meetings.
88961458|NCT05778630|Other|Group B. Individual|Individuals will participate in a semi-structured qualitative interview.
88961459|NCT05778604|Experimental|Physio-fEedback Exercise pRogram (PEER) Group|In week 1 participants will receive the first technology-based physio-feedback, cognitive reframing based on the fall risk appraisal matrix and develop a personal goal setting and action plan. From week 1 to week 8, participants will receive tailored exercise training. Participants will perform peer-led exercises (60 mins/week) and individual exercise at home for at least 30 minutes twice per week. Exercise training consists of four sets of exercise: a) warm-up (seated); b) strength upper and lower body (seated and standing); c) balance (standing and moving); and d) stretch lower and upper body. Participants will receive an exercise booklet (English or Spanish version) with illustrations that highlight steps for each set of exercise and provide a wide variety of exercises to integrate into daily activity such as cooking. Finally, in week 8, participants will receive the second physio-feedback and printed BTracks Balance System (BBS) results.
88961460|NCT05778604|Experimental|Attention Control (AC) Group|Participants in the AC group will receive an information pamphlet about falls, Simple Exercises for Improving Balance and Preventing Falls in Older Adults, (English or Spanish version) that was developed by the CDC Stopping Elderly Accidents, Deaths, and Injuries (STEADI)-Older Adult Fall Prevention. The topics contain information on fall risk, how to prevent falls, check for safety, postural hypotension and chair rise exercise included what you can do to prevent falls, check for safety, postural hypotension, and chair rise exercise. The control group will be encouraged to discuss fall prevention with a primary care provider and continue normal activities (treatment-as-usual) for 6 months. Participants will be offered the PEER intervention when the study concludes.
88961461|NCT05778552||Home-based pelvic muscle training devices group|Patients underwent pelvic muscle training by home-based device and at home.
88961462|NCT05778552||Traditional pelvic muscle training devices group|Patients underwent traditional pelvic muscle training at hospital
89544875|NCT02103478|Experimental|Phase 2 Fixed-Dose Combination|Participants were randomized in a 1:1 ratio to receive either the fixed-dose combination (FDC) tablet (100 mg cedazuridine (E7727)/35 mg decitabine) Dailyx5 in Course 1 followed by IV decitabine (20 mg/m^2) Dailyx5 in Course 2 (28 days per course) or the converse. In Courses ≥ 3, all participants received the FDC tablet Dailyx5 in 28-day courses until disease progression, unacceptable toxicity, withdrawal of consent or withdrawal from the study.
89544876|NCT02431013|Experimental|Simvastatin+Cilostazol|Simvastatin 40 mg on Day 1. Cilostazol 100 mg twice a day for 6 days. Simvastatin 40 mg and Cilostazol 100 mg twice a day on Day 8.
89544877|NCT02431013|Active Comparator|Pravastatin+Cilostazol|Pravastatin 20 mg on Day 1. Cilostazol 100 mg twice a day for 6 days. Pravastatin 20 mg and Cilostazol 100 mg twice a day on Day 8.
89544878|NCT02427503||Asthma with NP and require surgery|Patients receiving standardized treatment for nasal polyposis, according to the POLINA guidelines and for persistent asthma who will undergo FESS-BP.
89544879|NCT02427503||Asthma with NP and NOT require surgery|Patients receiving standardized treatment for nasal polyposis, according to the POLINA guidelines and for persistent asthma who will NOT undergo FESS-BP.
89544880|NCT02430857|Experimental|OMT-Group|The OMT-group will get an osteopathic treatment once a week for 1 hour for 5 weeks. The blood will be screened again after the treatment.
89544881|NCT02430857|No Intervention|Controll Group|This group will receive no treatment. A blood screening is made again after 5 weeks.
89544882|NCT02427659|Other|Virtual Reality Distraction|The subjects will receive a 20-minute Virtual Reality Distraction (VRD) during their wound care procedure. The nurse will be doing their wound care.
89544883|NCT02427659|Other|Audio (sounds of nature)|"The subjects will listen to an audio recording called Sounds of Nature during their wound care. The nurse will be doing the wound care."
89544884|NCT02427659|Other|control standard nurse wound care|The subjects will receive their standard care during wound care. The nurse will be doing the wound care.
89544885|NCT02427425|Experimental|TENS group|It was applied conventional TENS with FIV effect, frequency of 100 Hertz, a pulse width of 60μs and intensity adjusted according to the individual baseline for each patient without causing muscular contraction. The electrodes were arranged in a cross shape in the paravertebral region (levels T12-L1 and L5 - S1). Treatment consisted of 10 sessions (2x / week / 5 weeks), with each session lasting 30 '.
89544886|NCT02427425|Placebo Comparator|Placebo group|In Placebo group the same procedures of the TENS group were adopted, but did not occur electrical stimulus.
89544887|NCT02102464|Experimental|LipiFlow|Single 12-minute LipiFlow treatment
89544888|NCT02102464|No Intervention|Untreated Control|Untreated Control (No Intervention)
89544889|NCT02102464|Experimental|Crossover LipiFlow Treatment|Crossover LipiFlow treatment of the untreated control group after 3 months
89544890|NCT02427347|Experimental|Intervention group|Intervention including acupuncture treatment and healthy education.
89544891|NCT02427347|Other|Control group|Healthy education is given as a baseline treatment.
89544892|NCT03183947|Experimental|fMRI Neurofeedback regulation of left PFC|Study related procedures included: PANAS, BDI-II, ERQ (questionnaires or evaluations)
89544893|NCT03183947|Experimental|fMRI Neurofeedback of right PFC|Study related procedures included: PANAS, BDI-II, ERQ (questionnaires or evaluations)
89544894|NCT02430935|Experimental|Cognitive Adaptation Training|Cognitive Adaptation Training (CAT) is a standardized approach to the use of environmental supports for improving multiple domains of adaptive functioning including adherence to medication, grooming, and activities of daily living in patients with schizophrenia.
89544895|NCT02430935|Active Comparator|Action Based Cognitive Remediation|ABCR is applied in once weekly 2 hour sessions in small groups (6-8 per group). In these group sessions, simulated bridging activities are done immediately following computerized cognitive activation to increase the chance that participants retain the strategies just developed in a real life environment.
89544896|NCT02430779|Experimental|IRE Group|irreversible electroporation for Unresectable Renal Pelvic and Ureteral Neoplasms
89544897|NCT02430779|No Intervention|Control|The patients without treatment
89544898|NCT03185429|Experimental|Experimental|"Drug:Cyclophosphamide~Biological/Vaccine:Tumor Specific Antigen-loaded Dendritic Cells"
89544899|NCT02427191|Experimental|AmnioFix® Injectable|1 mL injection of 40 mg Micronized dehydrated human amnion/chorion membrane (dHACM)
89544900|NCT02427191|Placebo Comparator|Saline Injection|Injection of 1mL 0.9% Sodium Chloride Injection, USP
89544901|NCT03185507|Experimental|Cryotherapy|Participants received superficial cryotherapy using the Cryohelmet(TM)
89544902|NCT03185507|No Intervention|Control|Participants sat quietly for 20 minutes
89544903|NCT03117413|Other|Asymmetric hearing loss|Asymmetric hearing loss treated with a cochlear implant will undergo positron emission tomography scan.
89544904|NCT03117413|Other|Normal hearing subjects|Normal hearing subjects will undergo positron emission tomography scan.
89544905|NCT03184259|Experimental|Robotic ankle system|Subjects will wear the Ankle Robot during 20-session gait training, power assistance will be provided from the motor to the ankle joint.
89544906|NCT03184259|Experimental|Robotic knee system|Subjects will wear the Knee Robot during 20-session gait training, power assistance will be provided from the motor to the knee joint.
89544907|NCT03184259|Placebo Comparator|Ankle Sham group|Subjects will wear the Ankle Robot during 20-session gait training, but no power assistance will be provided from the motor to the ankle joint.
89544908|NCT03184259|Placebo Comparator|Knee Sham group|Subjects will wear the Knee Robot during 20-session gait training, but no power assistance will be provided from the motor to the knee joint.
89544909|NCT03184259|No Intervention|Health Control|Healthy subjects will wear the Ankle Robot and/or Knee Robot during walking tasks (with or without power assistance), to collect control data for investigating if there are any effects of the robotic assistance on normal gait pattern.
89544910|NCT03117491|Active Comparator|GGNB injection technique|In GGNB group, every patient received two1.8-mL cartridges of 2% lidocaine with 1:80,000 epinephrine using the GGNB technique
89544911|NCT03117491|Active Comparator|IANB injection technique|In IANB group, every patient received two 1.8-mL cartridges of 2% lidocaine with 1:80,000 epinephrine using the IANB technique
89544912|NCT03117491|Active Comparator|GGNB + IANB injection technique|In IANB + GGNB group, every patient received one 1.8-mL cartridges of 2% lidocaine with 1:80,000 epinephrine using the IANB technique and one 1.8-mL cartridges of 2% lidocaine with 1:80,000 epinephrine using the GGNB technique
89544913|NCT02430701|Experimental|IRE Group|irreversible electroporation for Unresectable Esophageal Neoplasms
89544914|NCT02430701|No Intervention|Control|The patients without treatment
89544915|NCT02430545|Experimental|Glasdegib, Rifampin|Subjects receive a 100mg oral dose of glasdegib under fasted conditions with washout, then single 100mg oral dose of glasdegib under fasted following dosing to steady state with rifampin
89544916|NCT03117725|Experimental|melatonin administration group|"Total 50 patients are to be randomized into this group, 25 of which are poor responder and the others are normal responders. After randomization, participants are to under go melatonin administration intervention from the time of controlled ovarian hyperstimulation(COH) to the date of oocyte retrieval. If pregnancy is not confirmed in the first cycle, all subjects are to enter the second cycle after 1-2 months of recovery period.~For the second cycle, the procedure will be repeated same as the first cycle with doubling of the drug dosage . It should also be administered for 2 weeks until the date of oocyte retrieval."
89544917|NCT03117725|Placebo Comparator|placebo comparator|"Total 50 patients are to be randomized into this group, 25 of which are poor responder and the others are normal responders. Participants for placebo comparator are advised to take the drug (placebo) from the time of COH to the date of oocyte retrieval. If pregnancy is not confirmed in the first cycle, all subjects are to enter the second cycle after 1-2 months of recovery period.~For the second cycle, the procedure will be repeated same as the first cycle with doubling of the drug dosage . It should also be administered for 2 weeks until the date of oocyte retrieval."
89544918|NCT03185351|Active Comparator|BUPIVACAINE|"patients will receive 20 ml of 0.5% bupivacaine + 5 ml normal saline (0.9%) using supraclavicular BPB.~."
88961463|NCT05778539|Experimental|Lateral retinacular release group|During the implantation of a total knee arthroplasty a lateral retinacular release is performed
89544919|NCT03185351|Active Comparator|BUPIVACAINE and midazolam|patients will receive 20 ml of 0.5% bupivacaine + midazolam 0.03 mg/kg dissolved in 5 ml normal saline (0.9%) using supraclavicular BPB.
89544920|NCT03185351|Active Comparator|BUPIVACAINE and i.v midazolam|patients will receive 20 ml of 0.5% bupivacaine + 5 ml normal saline (0.9%) using supraclavicular BPB + 0.03 mg/kg of midazolam by I.V. route at the same time of the block
89544921|NCT02427035|Experimental|Low|A low dose of either CSL112 or placebo is to be administered as a single intravenous (IV) infusion. The placebo will be administered at the same frequency, volume and duration as the CSL112 infusion.
89544922|NCT02427035|Experimental|High|A high dose of either CSL112 or placebo is to be administered as a single intravenous (IV) infusion. The placebo will be administered at the same frequency, volume and duration as the CSL112 infusion.
89544923|NCT02427113|Active Comparator|Self-Select Music|Participants will be randomized to two groups. Self-select music will be used as treatment for managing pain. They will be required to listen to their preferred songs for 30 minutes per 7 days, recommended 5, for 3 weeks.
89544924|NCT02427113|Active Comparator|Sound Oasis Vibrating Chair|Participants will be randomized to two groups. Vibroacoustic therapy will be administered in the form of a vibrating chair. They will be required to listen to their preferred songs for 30 minutes per 7 days, recommended 5, for 3 weeks.
89544925|NCT02707601|Experimental|E/C/F/TAF + LDV/SOF|"Part 1: Participants will switch from 2 nucleoside reverse transcriptase inhibitors (NRTI) plus a third agent to E/C/F/TAF.~Part 2: After 8 weeks of E/C/F/TAF treatment, the participants maintaining HIV-1 RNA < 50 copies/mL will start receiving LDV/SOF for 12 weeks and continue their HIV treatment until the end of the study."
89544926|NCT02707601|Experimental|F/R/TAF + LDV/SOF|"Part 1: Participants will switch from 2 NRTI plus a third agent to F/R/TAF.~Part 2: After 8 weeks of F/R/TAF treatment, the participants maintaining HIV-1 RNA < 50 copies/mL will start receiving LDV/SOF for 12 weeks and continue their HIV treatment until the end of the study."
89544927|NCT02426957|Experimental|Motivational Enhancement Therapy|The 60-90 minute intervention consists of the following components: establishing rapport, assessing motivation for change, enhancing motivation for change, envisioning the future, establishing goals, and completing goals, strategies, and change plan worksheets. Personalized feedback for the intervention will be derived from the assessment battery and will be provided in both written and graphic formats. In addition to the 60-90 minute MI intervention delivered to the adolescent, a 30-45 minute intervention will be conducted with the adolescent and parent(s) the following day, in which the adolescent will review the goals, strategies, and change plan worksheets with the parent(s), facilitated by the therapist.
89544928|NCT02426957|No Intervention|Treatment As Usual|Treatment As Usual on inpatient psychiatric unit
89544929|NCT02430623|Experimental|IRE Group|irreversible electroporation for Unresectable Urinary Bladder Neoplasms
89544930|NCT02430623|No Intervention|Control|The patients without treatment
89544931|NCT02707055|Experimental|PF-05190457, then placebo|Participants with alcohol use disorder received PF-05190457 100 mg twice a day for a maximum of 14 days followed by a minimum of 2-day washout period, then placebo twice a day for a maximum of 14 days.
89544932|NCT02707055|Placebo Comparator|Placebo, then PF-05190457|Participants with alcohol use disorder received placebo twice a day for a maximum of 14 days followed by a minimum of 2-day washout period then PF-05190457 100 mg twice a day for a maximum of 14 days.
89544933|NCT03183635|Experimental|Kinect based Rapid Movement Therapy|Kinect based Rapid Movement Therapy (RMT) training requires participants to move their limbs very rapidly to reach-to-grasp or step towards a virtual target appear suddenly on a screen, which is designed to their range of motion as well as response speed.
89544934|NCT03183635|Placebo Comparator|Conventional balance training|Conventional balance training involves some slow and low-impact muscle strengthening and mobilizing exercises.
89544935|NCT03183557|Active Comparator|ZA alone|
89032964|NCT02945306|Active Comparator|Watchful waiting with supportive care|Reassurance with active medical treatment of conditions associated with Sleep Disordered Breathing such as otitis media with effusion and allergic rhinitis
89544936|NCT03183557|Active Comparator|ZA plus VD|
89544937|NCT03183479|Experimental|Treatment group|The patients in treatment group will receive Fibrinogen Concentrate Human administration.
89544938|NCT03183479|Placebo Comparator|Control group|The patients in control group will be administered with normal saline solution as placebo.
89544939|NCT02425397||patients with grade 3 or 4 Brock ototoxicity|
89544940|NCT02425397||patients controls with no signs of ototoxicity|
89544941|NCT02425475||Mole|Patients with suspicious moles
89544942|NCT05526495|Experimental|De-implementation|"A multi-behaviour technique will be used along with theoretical domains framework.~Clinicians will be provided with continuing multi-behaviour component intervention to increase accountability for preoperative test ordering in patients having low risk surgeries."
89544943|NCT05526495|No Intervention|Comparator|Standard of care
89544944|NCT02425319||patients with CapFlex-PIP© implant|
89544945|NCT02425319||patients with silicone implant|
89544946|NCT02425319||patients with healthy PIP joints|
89544947|NCT02426723|Experimental|CWP232291|"Phase 1a: single administration of CWP232291 ,~Phase 1b: CWP232291 combination with Lenalidomide and Dexamethasone"
89544948|NCT03182699|Experimental|Etelcalcetide|Patients will receive Etelcalcetide i.v. 3 times per week after dialysis Dose titration will take plac every 4 weeks in the first 16 weeks Dose adaptation is based on PTH, SerumCa++, SerumPhosphate, T-50-time
88961464|NCT05778539|No Intervention|Non-release group|No aditional gesture in the lateral retinaculum is performed during the implantation of a total knee arthroplasty
88961465|NCT05778513||Cases|Male subjects with obesity
88961466|NCT05778513||Controls|Male subjects without obesity
88961467|NCT05778487|No Intervention|Control Group|"Standard of care for dietary instructions only.~The control group will consist of retrospectively recruited participants who have recently undergone a successful elective spine surgery, and followed the preoperative nutrition standards for their surgery, as outlined by the research institution's fasting dietary guidelines. Recruitment will include the most recent spine surgeries that meet the inclusion criteria and match prospective patient demographics."
88961468|NCT05778487|Experimental|Carbohydrate Group|"Standard of care for dietary instructions + carbohydrate loading.~The carbohydrate (CHO) group will consist of prospectively recruited patients scheduled to undergo an elective spine surgery. These participants will also follow the preoperative nutrition standards, however, in addition, they will be instructed to consume 710ml of a simple, commercial carbohydrate sports drink on the day of their procedure up to 2 hours prior to surgery."
88961469|NCT05778461|Experimental|L-ornithine L-Aspartate|LOLA will be administered via continuous intravenous infusion at a dosage of 0.75g/kg/day for 72h (maximum 30g/day). High volume plasma exchange (2x plasma volume) will be started at least 8 hours after initiation of LOLA, and will be completed within 4-5 hours depending on the volume of exchange. Three consecutive cycles of HVPE will be performed, starting at 8h, 32h and 56h respectively.
88961470|NCT05778461|Placebo Comparator|Placebo|Placebo will be administered via continuous infusion for 72h, along with HVPE (2x plasma volume) starting at 8h, 32h and 56h respectively.
88961471|NCT05778435|Experimental|wireless fetal monitoring group|wireless fetal monitoring system was applied to the experimental group
88961472|NCT05778435|No Intervention|Control group|Standard wired fetal monitoring system was applied to the control group.
89544949|NCT03182699|Active Comparator|Alfacalcidol|Patients will receive Alfacalcidol i.v. 3 times per week after dialysis Dose titration will take plac every 4 weeks in the first 16 weeks Dose adaptation is based on PTH, SerumCa++, SerumPhosphate, T-50-time
89544950|NCT02426879|Other|surgery|esophagectomy with three-field lymphnode dissection
89544951|NCT02426801|No Intervention|Control|Patients in this arm were given no intervention. Their self-reported medication adherence was assessed at the baseline (week 0) and follow-up (week 12) visits but during the study period they did not receive any intervention.
89544952|NCT02426801|Sham Comparator|Medication Sensor Only|"These patients received the medication use sensor (sham intervention) and downloaded a sham version of the mobile app. Thus, the medication use from these patients was able to be recorded but the patients did not receive reminders or incentives or the ability to see their medication use via the real mobile app.~Intervention: inhaler sensor"
89544953|NCT02426801|Experimental|Medication Sensor and Mobile App|"These patients received the medication use sensor and the mobile app with reminders (intervention arm).~Interventions: inhaler sensor and mobile application for asthma adherence"
89544954|NCT02426567|Experimental|Healthy Adult Participants A|Participants who will get two interventional diets, for 7 days each, but allocated to start with Exclusive Enteral Nutrition (EEN)
89544955|NCT02426567|Experimental|Healthy Adult Participants B|Participants who will get two interventional diets, for 7 days each, but allocated to start with Crohn's Disease TReatment-with-EATing diet (CD-TREAT diet)
89544956|NCT03183011|Other|Post-CRT MRI|This study has a single arm. Enrolled patients will follow the protocol as described, including evaluation with MRI, echocardiography, and cardiopulmonary exercise testing.
89544957|NCT03182777|Active Comparator|Lidocaine with epinephrine|Application of local dental anesthesia with two cartridges (3,6 mL) of lidocaine 2% with epinephrine 1:100.000 for dental restorative procedures in patients with cardiac channelopathies.
89544958|NCT03182777|Active Comparator|Lidocaine|Application of local dental anesthesia with two cartridges (3,6 mL) of lidocaine 2% without vasoconstrictor for dental restorative procedures in patients with cardiac channelopathies.
89544959|NCT02425085|Experimental|multi-endodiathermy retinectomy group|Patients receive multi-endodiathermy retinectomy
89544960|NCT02425085|Active Comparator|relaxing retinectomy|Patients receive relaxing retinectomy
89544961|NCT02425241|Experimental|CPHPC|"CPHPC infusion over 26 hours to deplete SAP at weeks 0,4 and 8. pSG2.HIVconsv DNA vaccine 4 mg at weeks 0, 4 and 8 after 24 hours of CPHPC infusion.~ChAdV63.HIVconsv booster vaccine 5 x 10^10 vp at week 12. MVA.HIVconsv booster vaccine 2 x 10^8 pfu at week 20"
89544962|NCT02425241|Placebo Comparator|0.9% w/v saline solution|"Placebo (normal saline) infusion over 26 hours at weeks 0,4 and 8. pSG2.HIVconsv DNA vaccine 4 mg at weeks 0, 4 and 8 after 24 hours of placebo infusion.~ChAdV63.HIVconsv booster vaccine 5 x 10^10 vp at week 12. MVA.HIVconsv booster vaccine 2 x 10^8 pfu at week 20"
89544963|NCT02425007|Experimental|Spiro|Incentive spirometry
89544964|NCT02425007|No Intervention|Control|Control group
89544965|NCT02426411|Experimental|EMA401 200 mg|2 X 50 mg capsules BID
89544966|NCT02426411|Experimental|EMA401 600 mg|2 X 150 mg capsules BID
89544967|NCT02426411|Placebo Comparator|Placebo|Placebo to match 2 capsules BID
89544968|NCT02425163|Active Comparator|suspicious for Prostate Cancer|"PSA >4ng/ml or PSA-Velocity >0.75ng/ml/a or suspicious rectal examination or Status after external beam therapy of the prostate in prostate cancer.~Patients who are able for transrectal ultrasound examination. Transrectal shear wave elastography of the prostate for Transrectal random biopsy of the prostate."
89544969|NCT02426489|No Intervention|Diagnostic accuracy with MRI alone|The MRI of the breast lesion will be examined. Measures of performance accuracy will be evaluated, including diagnostic sensitivity (true positives divided by true positives and false negatives), diagnostic specificity (true negatives divided by true negatives and false positives), and diagnostic accuracy, defined as the number of correct assessments divided by the number of all assessments.
89544970|NCT02426489|Experimental|Diagnostic accuracy with MRI + PEM image|The combined PEM/MRI image will be examined.
89544971|NCT03182855|Active Comparator|Prehospital ticagrelor|"Ticagrelor 180 mg orally administered in the ambulance as soon as possible after inclusion and before coronary angiography. The two pills are chewed and swallowed with a glass of water.~In both groups heparin and bivalirudin will be administered as part of routine therapy. In hemodynamically compromised patients with a high thrombus load a glycoprotein IIb/IIIa inhibitor may be used as bail-out therapy (these patients will be excluded). These drugs are not deemed to be study medication."
89544972|NCT03182855|Active Comparator|Inhospital cangrelor tetrasodium|"Ticagrelor 180 mg orally in combination with cangrelor intravenously (bolus 30 μg/kg within 1 minute followed by infusion (4 μg/kg/minute) for two hours) both administered immediately after coronary angiography, when PPCI is indicated.~In both groups heparin and bivalirudin will be administered as part of routine therapy. In hemodynamically compromised patients with a high thrombus load a glycoprotein IIb/IIIa inhibitor may be used as bail-out therapy (these patients will be excluded). These drugs are not deemed to be study medication."
89544973|NCT02426333||Abiraterone Acetate|abiraterone treatment, 1000mg, tablets, once daily, treatment is not adapted for the study
89544974|NCT02424929|Other|Awake|"Original surgery intervention.~Patient will have DBS surgery done in the normal fashion. Asleep for the drilling of the burr holes, then awakened for the placement of the electrodes. No intervention will be given."
89544975|NCT02424929|Other|Asleep|"Sedation intervention.~Surgical intervention, anesthesia will be administered during entire placement of the system. Patient will not be awake at any point during procedure. All other aspects of surgery will be conducted normally."
89544976|NCT02426177|Active Comparator|group A|tab.labetalol is given to the patient with postpartum hypertension in dose of 100 mg 6 hourly increased to maximum 600 mg in 24 hours
89544977|NCT02426177|Active Comparator|group B|tab.nifedipine is given to the patient with postpartum hypertension in the dose of 10 mg twice a day to maximum dose of 60 mg per 24 hours
89544978|NCT02426099|Experimental|Low dose Spironolactone|Add-on low dose 25 mg Spironolactone to current hypertension treatment
89544979|NCT02426099|Active Comparator|Routine|Routine intensification of anti hypertensive treatment based on existing guidelines
89544980|NCT03182621|Experimental|THINK|The Translational Health in Nutrition and Kinesiology (THINK) program will have education and fitness sessions lasting two hours, five times a week for a total of 10 weeks. Sessions will include theory, clinical laboratory activities, and physically active games to facilitate a fun environment to enhance physical and health-related fitness, improve nutrition and exercise knowledge and behaviors, and exercise enjoyment and self-confidence.
89544981|NCT03182621|Active Comparator|SPARK|This The Sports, Play, and Active Recreation for Kids (SPARK) group will receive the traditional YMCA SPARK after-school program. They will undergo the same pre and post testing protocol as the intervention group, but will not receive the THINK program.
89544982|NCT02426021|Experimental|Cohort J1: MLN1202 (75 mg)|Single subcutaneous administration of MLN1202 (75 mg) in 6 healthy Japanese male adults
89544983|NCT02426021|Experimental|Cohort J1: placebo|Single subcutaneous administration of placebo in 2 healthy Japanese male adults
89544984|NCT02426021|Experimental|Cohort J2:MLN1202 (105 mg)|Single subcutaneous administration of MLN1202 (105 mg) in 6 healthy Japanese male adults
89544985|NCT02426021|Experimental|Cohort J2: placebo|Single subcutaneous administration of placebo in 2 healthy Japanese male adults
89544986|NCT02426021|Experimental|Cohort J3: MLN1202 (150 mg)|Single subcutaneous administration of MLN1202 (150 mg) in 6 healthy Japanese male adults
89544987|NCT02426021|Experimental|Cohort J3: placebo|Single subcutaneous administration of placebo in 2 healthy Japanese male adults
89544988|NCT02426021|Experimental|Cohort J4: MLN1202 (450 mg)|Single subcutaneous administration of MLN1202 (450 mg) in 6 healthy Japanese male adults
89544989|NCT02426021|Experimental|Cohort J4: placebo|Single subcutaneous administration of placebo in 2 healthy Japanese male adults
89544990|NCT02426021|Experimental|Cohort C1: MLN1202 (75 mg)|Single subcutaneous administration of MLN1202 (75 mg) in healthy Causacian male adults
89544991|NCT02426021|Experimental|Cohort C2: MLN1202 (150 mg)|Single subcutaneous administration of MLN1202 (150 mg) in healthy Causacian male adults
89544992|NCT03182543|Experimental|AM1|Mango pulp beverage
89544993|NCT03182543|Experimental|AM2|Mango pulp and peel beverage
89544994|NCT03182543|Placebo Comparator|Control|Control beverage
89544995|NCT02425709|Active Comparator|Diclofenac|women will receive oral diclofenac 50 mg 1 hour before the procedure.
89544996|NCT02425709|Active Comparator|Tramadol|Women will receive oral tramadol 50 mg 1 hour before the procedure.
89544997|NCT02425709|Placebo Comparator|Placebo|Women will receive a placebo 1 hour before the procedure.
89544998|NCT03182153||Enrolled subjects|Subjects who are diagnosed with HCM and require routine extended cardiac monitoring for risk stratification of sudden cardiac death. All subjects will receive 28 days of external cardiac monitoring.
89544999|NCT03183089|Experimental|Active|
89545000|NCT03183089|Active Comparator|Active Comparator|
89545001|NCT02073682|Experimental|Edoxaban group|After 5 days of low molecular weight heparin (LMWH), patients receive edoxaban treatment daily - tablet for oral use
89545002|NCT02073682|Active Comparator|Dalteparin group|Participants receive Dalteparin treatment daily -solution for subcutaneous injection
89545003|NCT03181919|Experimental|Step Up group|includes females taking Letrozole 5 mg tablets in a step-up protocol 5 mg in day one, 7.5 in day 2, 10 mg in days 3, 12.5 mg in day 4 and 15 in day 5 started in day 3 to day 7 of menstrual cycle.
89545004|NCT03181919|No Intervention|Control group|includes females taking Letrozole 5 mg tab orally once daily started in day 3 to day 7 of menstrual cycle.
89545005|NCT02072980|Other|16hrs/15mins|Delefilcon A contact lenses worn bilaterally (in both eyes) for 16 waking hours (1 day) in Period 1, followed by 15 minutes in Period 2. A fresh pair of lenses was dispensed for Period 2.
89545006|NCT02072980|Other|15mins/16hrs|Delefilcon A contact lenses worn bilaterally for 15 minutes in Period 1, followed by 16 waking hours (1 day) in Period 2. A fresh pair of lenses was dispensed for Period 2.
89545007|NCT02706899|Experimental|33A + azacitidine|Vadastuximab talirine plus azacitidine
89545008|NCT02706899|Active Comparator|Placebo + azacitidine|placebo plus azacitidine
89545009|NCT03107039|Experimental|Exercise|This arm will use a resistance exercise curriculum.
89545010|NCT03107039|Active Comparator|Health Education|This arm will use health education curriculum.
89545011|NCT03106883|Experimental|Affective training|"One happy and three sad faces selected from the NimStim Set of Facial Expressions~Five five-minute blocks separate by 90-second rest periods"
89545012|NCT03106883|Sham Comparator|Sham training|"Neutral, non-affective, non-social photos of objects (i.e., cars)~Five five-minute blocks separate by 90-second rest periods"
89545013|NCT03181997||TAVI Patients with active cancer|Patients with active cancer undergoing transcatheter aortic valve implantation (TAVI) with native aortic valves.
89545014|NCT03181997||TAVI patients without cancer|Patients with no active cancer undergoing transcatheter aortic valve implantation (TAVI) with native aortic valves.
89545015|NCT02425553||Faculty and Delegates of Ascona II Meeting|
89545016|NCT02424773|Active Comparator|Venturi group|Venturi group : Oxygen is delivered using oxygen Venturi mask FiO2 is started at 60% (15l/min) and modified to maintain SpO2 over 94%.
89545017|NCT02424773|Experimental|HFNC group|HFNC group : Oxygen is delivered using HFNC. HFNC is started with FIO2 =1 and modified to maintain SpO2 over 94%, flow is settled at 40-50l/min.
89545018|NCT02421575|Experimental|Group I, Arm I (lower dose hydroxychloroquine)|Patients receive hydroxychloroquine PO QD for 14 days and then undergo prostatectomy.
89545019|NCT02421575|Experimental|Group I, Arm II (higher dose hydroxychloroquine)|Patients receive hydroxychloroquine PO TID for 14 days and then undergo prostatectomy.
89545020|NCT02421575|Experimental|Group II (mid-dose hydroxychloroquine)|Patients receive hydroxychloroquine PO QD. Treatment continues until the beginning of local therapy or for up to 1 year.
89545021|NCT02424695|Experimental|Single Gabapentin Enacarbil Arm|"Gabapentin Enacarbil (Gen) 600 mg will be administered once daily for 4 weeks~Matching placebo will be administered once daily for one week prior initiation of treatment with GEn"
89545022|NCT02422277|Active Comparator|LI-ESWT group|Intervention include that patients will undergo penile low-intensity extracorporeal shock wave therapy, 6-12 sessions, 1500 shocks per session, two sesssions per week for 3 weeks then 3 weeks break and then 2 sessions per week for 3 weeks.
89545023|NCT02422277|Active Comparator|PDE-5 inhibitors group|"Intervention include that patients will intke oral tablets of PDE-5 inhibitors :~- Oral intake of 50 mg once daily for 6 months."
89545024|NCT02422277|No Intervention|Control group|Patients will be only followed up without any therapy for assisting erection.
89545025|NCT02422121|Experimental|RNS60|RNS60, 4 ml twice daily
89545026|NCT02422121|Placebo Comparator|Placebo|Normal Saline, 4 ml twice daily
89545027|NCT02424305|Experimental|face: LEO 43204 gel 0.018%|3 days treatment (once daily) on face: LEO 43204 gel 0.018%
89545028|NCT02424305|Experimental|arm: LEO 43204 gel 0.1%|3 days treatment (once daily) on arm: LEO 43204 gel 0.1%
89545029|NCT02424305|Experimental|scalp: LEO 43204 gel 0.037%|3 days treatment (once daily) on scalp: LEO 43204 gel 0.037%
89545030|NCT02424227||Kidney Transplant Recipients|Adult living and deceased donor kidney transplant recipients will be eligible to participate in this study.
89545031|NCT02421107|Other|all patients|all patients
89545032|NCT02424461|Active Comparator|7 day-antimicrobial treatment|"Ceftriaxone : 1 injection 1 g per day for 2 days~Ofloxacine : 400 mg/jour (200 mg/ jour in case of renal failure) for seven days~Placebo of ofloxacine for 7 days"
89545033|NCT02424461|Active Comparator|14-day antimicrobial treatment|"Ceftriaxone : 1 injection 1 g per day for 2 days~Ofloxacine : 400 mg/jour (200 mg/ jour in case of renal failure) for 14 days"
89545034|NCT02072824|Experimental|Study Drug Level 1|
89545035|NCT02072824|Experimental|Study Drug Level 2|
89545036|NCT02072824|Placebo Comparator|Placebo|
89545037|NCT04440605||cI|clincal TNM stage I
89545038|NCT04440605||cII|clinical TNM stage II
89545039|NCT04440605||cIII|clinical TNM stage III
89545040|NCT02421185|Experimental|Part 1: Dose Escalation and Part 2: Dose Expansion|"Part 1: First, participants will receive 8 milligram (mg) (starting dose) tablet of JNJ-42756493 (erdafitinib) orally once daily from Day 1 to 7, then Day 15 to 21 of 28 days cycle or 8 mg orally once daily from Day 1 to 21 of 28 days cycle (intermittent dosing). After recommended Phase 2 dose (RP2D) is identified, enrollment of continuous dosing schedule will be open, starting at 8mg. In this cohort, participants will receive 8mg (starting dose) tablet of JNJ42756493 (erdafitinib) orally once daily from Day 1 to Day 28 in a 28-day cycle. Dose of the study medication will be escalated sequentially till the dose limiting toxicity is achieved to determine RP2D.~Part 2: Participants will receive RP2D JNJ-42756493 (erdafitinib) dose determined in Part 1. Participants who are tolerating study drug treatment and achieve clinical responses or stable disease will continue to receive study drug at the same dose until disease progression, unacceptable toxicity, or withdrawal of consent."
89545041|NCT03117257|Experimental|the treatment group|docetaxel plus lobaplatin induction chemotherapy combined with lopoplatin chemoradiotherapy
89545042|NCT03117257|Active Comparator|the control group|TPF induction chemotherapy combined with cisplatin chemoradiotherapy
89545043|NCT02072668|Other|Rivaroxaban for 4 wks, Placebo for 4 wks|Subject will receive rivaroxaban 20mg PO daily for 4 weeks and then matching placebo 1 PO daily for 4 weeks, with a 2-week wash out period in between the two treatment phases. Both of the two treatments will be in capsule form.
89545044|NCT02072668|Other|Placebo for 4 wks, rivaroxaban for 4 wks|Subject will receive placebo 1 PO daily for 4 weeks, then rivaroxaban 20mg PO daily for 4 weeks, with a 2-week wash out period in between the two treatment phases. Both of the two treatments will be in capsule form.
89545045|NCT03179267|Experimental|SNAP40 monitor|All participants in the study will be fitted with the SNAP40 ambulatory monitoring device as well as usual monitoring as standard care
89545046|NCT04750876|Active Comparator|Conventional support|
89545047|NCT04750876|Experimental|Specific care, including the intervention of a psychologist and a physical therapist.|
89545048|NCT03181841|Experimental|Active dose 1|Single dose of PF-06412562 in low dosage strength
89545049|NCT03181841|Experimental|Active dose 2|Single dose of PF-06412562 in medium dosage strength
89545050|NCT03181841|Experimental|Active dose 3|Single dose of PF-06412562 in higher dosage strength
89545051|NCT03181841|Placebo Comparator|Placebo|Single dose of placebo
89545052|NCT03116789|Active Comparator|VGA-1(Probiotics)|Lactobacillus rhamnosus and Lactobacillus acidophilus.
89545053|NCT03116789|Active Comparator|VGA-2(Probiotics)|Lactobacillus rhamnosus and Lactobacillus plantarum.
88961473|NCT05778409|Experimental|Cordyceps Cicadae extract group|500 mg/ day for 1 month
88961474|NCT05778383|No Intervention|Standars of Care|Standard of Care of treatment for SARS-coV-2 infection
88961475|NCT05778383|Experimental|Zinc Supplementation +Standard of Care|Standard of care + ( 240mg zinc acetate Zinc (75mg Zn element) +NM QD) during 14 days
88961476|NCT05778370||Group 1|will include 15 patients (30 eyes) of age matched non-diabetic candidates (control group)
88961477|NCT05778370||Group 2|will include 15 patients (30 eyes) of diabetic patients with good glycemic control (HbA1c ≤7%),
88961478|NCT05778370||Group 3|will include 15 patients (30 eyes) of diabetic patients with poor glycemic control (HbA1c <7% (
88961479|NCT05778357||Evaluation of neuromotor development of healthy infants|75 healthy infants were included. Neuromotor development was evaluated with the Denver II Developmental Screening Test and Alberta Infant motor scale.
88961480|NCT05778331||Group A : POSEIDON group 3|"Age : < 35~AFC: < 5~AMH : < 1.2~Planning for IVF"
88961481|NCT05778331||Group B: POSEIDON group 4|"Age : ≥ 35 years old~AFC : < 5~AMH : < 1.2~Planning for IVF"
88961482|NCT05778305|Active Comparator|Dexmedetomidine group|patients will have loading Dexmedetomidine( 1ug/kg) over 10 minutes followed by continuous infusion of (0.5ug/kg/hr) from the initiation of anaesthesia up to extubation in the ICU. Patients will not be extubated until completely awake and have no sign of arrhythmias and bleeding
88961483|NCT05778305|Placebo Comparator|control group|patients will receive the same volume of 0.9% saline infusion as loading and maintenance infusion.
88961484|NCT05778253||Patients with lung Squamous Cell Carcinoma receiving neoadjuvant chemoimmunotherapy|
88961485|NCT05778240|Experimental|Status quo bias and implementation intention bias|Participants' families in this arm were informed about prophylaxis program and provided a schedule additionally called two days before appointments (status quo bias) and were asked to plan the appointment day (implementation intention).
89545054|NCT03181685|Active Comparator|Treatment S (Subcutaneous)|Progesterone 25 mg subcutaneous (a single administration per day) from the day of oocyte retrieval. Controlled ovarian stimulation (COS) will be performed with recombinant FSH and cetrorelix acetate.
89545055|NCT03181685|Active Comparator|Treatment V (Vaginal)|Micronized progesterone 200 mg (3 vaginal administrations per day) from the day of oocyte retrieval. Controlled ovarian stimulation (COS) will be performed with recombinant FSH and cetrorelix acetate.
89545056|NCT03116711|Active Comparator|Positive CIQ plus High Carbohydrate Diet|Positive Carbohydrate Intolerance Questionnaire (CIQ) plus 30% carbohydrate, 45% protein, 25% fat diet
89545057|NCT03116711|Active Comparator|Positive CIQ plus High Protein Diet|Positive Carbohydrate Intolerance Questionnaire (CIQ) plus 20% carbohydrate, 45% protein, 35% fat diet
89545058|NCT03116711|Active Comparator|Negative CIQ plus High Carbohydrate Diet|Negative Carbohydrate Intolerance Questionnaire (CIQ) plus 30% carbohydrate, 45% protein, 25% fat diet
89545059|NCT03116711|Active Comparator|Negative CIQ plus High Protein Diet|Negative Carbohydrate Intolerance Questionnaire (CIQ) plus 20% carbohydrate, 45% protein, 35% fat diet
89545060|NCT03116633||Arm A|1st line setting-approx. 150 patients. collect tissue biopsy per standard of care & one blood draw (40ml)
89545061|NCT03116633||Arm B|1st line setting- approx. 100 patients one blood draw (40ml)
89545062|NCT03116633||Arm C|Approx. 10 patients tissue collection optional 3 blood draws (40ml) over 5 days
89545063|NCT03181373||Traumatic brain injury population|Defined population : traumatic brain injury population
89545064|NCT02140762|Experimental|MenABCWY|Subjects received one dose of MenABCWY vaccine at day 1 and a second dose after 2 months
89545065|NCT02140762|Active Comparator|Placebo/MenACWY|Subjects received one dose of placebo at day 1 and one dose of MenACWY vaccine after 2 months
89545066|NCT03106727|Active Comparator|Zalewa|Household Model Intervention introduced first - March 2017
89545067|NCT03106727|Active Comparator|Ligowe and Magaleta|Household Model Intervention to be introduced in June 2017
89545068|NCT03106727|Active Comparator|Neno District Hospital and Neno Parish|Household Model Intervention to be introduced in September 2017
89545069|NCT03106727|Active Comparator|Matope|Household Model Intervention to be introduced in December 2017
89545070|NCT03106727|Active Comparator|Matandani and Nsambe|Household Model Intervention to be introduced in March 2018
89545071|NCT03106727|Active Comparator|Luwani, Nkula, and Midzemba|Household Model Intervention to be introduced in June 2018
89545072|NCT02424071|Active Comparator|Melatonin group|Patients will receive a pill containing 5mg of melatonin on the evening before the surgery. Patients will receive another pill containing 5mg of melatonin two hours prior to surgery.
89545073|NCT02424071|Placebo Comparator|Placebo group|Patients will receive a pill containing placebo on the evening before the surgery. Patients will receive another pill containing placebo two hours prior to surgery.
89545074|NCT02101294|Experimental|Interossei Lumbricals Neuro Interface|Comparison of report of symptoms of carpal tunnel syndrome when typing with standard QWERTY keyboard to report of symptoms of carpal tunnel syndrome when typing with Interossei Lumbricals Neuromuscular Technology Interface Therapy device.
89545075|NCT03179111|Experimental|Low Pressure Group|Participants will undergo elective bariatric surgery. Participants under this group will be given intra-abdominal pressure of 8-10mmHg. The number of subjects anticipated for this arm will be 47. Participants in this low pressure group are expected to encounter lesser shoulder tip pain and abdominal pain. Operating field for surgeons also expected to be better.
89545076|NCT03179111|Experimental|Standard Pressure Group|Participants will undergo elective bariatric surgery. Participants under this group will be given intra-abdominal pressure of 12-15mmHg. The number of subjects anticipated for this arm will be 47. Participants in this group are expected to have an increased amount of shoulder tip pain and higher pain score postoperatively compared to low pressure group. Operating fields for surgeons are expected to be less clear.
88961486|NCT05778240|Experimental|Availability bias and social norm|Participants' families in this arm were informed about prophylaxis program and provided a schedule and were received messages biweekly informing about benefits of program and adherence rate (availability bias and social norm).
88961487|NCT05778240|Experimental|Control|Participants' families in this arm were informed about prophylaxis program and provided a schedule
88961488|NCT05778214|Experimental|Interventional Robotic System Assisted Surgery|Experimental group underwent cerebral angiography using the vascular interventional surgical control system
89545077|NCT01598506|Experimental|Hydromorphone|Laboring patients receive ED50 of hydromorphone one time intrathecally
89545078|NCT02423915|Experimental|Phase I: Fucosylated T-reg Cells + Chemotherapy|"Rituximab 375 mg/m2 by vein on Day -12 for for participants with CD20+ malignancies.~Fludarabine 40 mg/m2 by vein on Days -8 to -5.~Cyclophosphamide 50 mg/kg by vein on Day -8.~Mesna administered on Day -8 immediately following completion of the Fludarabine.~Total body radiation 2 Gy delivered on Day -4.~3rd party CB Treg infusion on Day -1.~Three (3) participants treated at cell dose level 1: 1 x 10^6/kg fucosylated T-reg cells. The cells are infused on Day -1.~Cord blood transplant, MRD, or MUD transplant on Day 0.~Mycophenolate 15 mg/kg by vein or mouth from Day -3 to Day +100 in the absence of GVHD.~Sirolimus 12 mg by mouth load followed by 4 mg by mouth daily from Day -3 to Day +180 in the absence of GVHD.~G-CSF 5 mcg/kg/day subcutaneously beginning on D+0 for CORD blood stem cell transplant and D+7 for allogeneic stem cell transplant, and continuing until the absolute neutrophil count (ANC) is > 500 x 10/L for 3 consecutive days."
89545079|NCT02423915|Experimental|Phase I: Non-Fucosylated T-reg Cells + Chemotherapy|"Rituximab 375 mg/m2 by vein on Day -12 for for participants with CD20+ malignancies.~Fludarabine 40 mg/m2 by vein on Days -8 to -5.~Cyclophosphamide 50 mg/kg by vein on Day -8.~Total body radiation 2 Gy delivered on Day -4.~3rd party CB Treg infusion on Day -1.~Ten (10) participants treated with non-fucosylated T-reg cells at dose level 2: 1 x 10^7/kg T-reg cells. The cells are infused on Day -1.~Cord blood transplant, MRD, or MUD infused on Day 0.~Mycophenolate 15 mg/kg (actual body weight with a maximum dose of 1 gram twice daily) by vein or mouth from Day -3 to Day +100 in the absence of GVHD.~Sirolimus 12 mg by mouth load followed by 4 mg by mouth daily from Day -3 to Day +180 in the absence of GVHD.~G-CSF 5 mcg/kg/day subcutaneously beginning on D+0 for CORD blood stem cell transplant and D+7 for allogeneic stem cell transplant, and continuing until the absolute neutrophil count (ANC) is > 500 x 10/L for 3 consecutive days."
89545080|NCT02423915|Experimental|Phase II: Fucosylated T-reg Cells + Chemotherapy|"Rituximab 375 mg/m2 by vein on Day -12 for for participants with CD20+ malignancies.~Fludarabine 40 mg/m2 by vein on Days -8 to -5.~Cyclophosphamide 50 mg/kg by vein on Day -8.~Total body radiation 2 Gy delivered on Day -4.~Seventeen (17) participants treated with Fucosylated T-reg cells at dose level 2: 1 x 10^7/kg. The cells are infused on Day -1.~Cord blood transplant, MRD, or MUD infused on Day 0.~Mycophenolate 15 mg/kg (actual body weight with a maximum dose of 1 gram twice daily) by vein or mouth from Day -3 to Day +100 in the absence of GVHD.~Sirolimus 12 mg by mouth load followed by 4 mg by mouth daily from Day -3 to Day +180 in the absence of GVHD.~G-CSF 5 mcg/kg/day subcutaneously beginning on D+0 for CORD blood stem cell transplant and D+7 for allogeneic stem cell transplant, and continuing until the absolute neutrophil count (ANC) is > 500 x 10/L for 3 consecutive days."
89545081|NCT02423915|Experimental|Phase II: Non-Fucosylated T-reg Cells + Chemotherapy|"Rituximab 375 mg/m2 by vein on Day -12 for for participants with CD20+ malignancies.~Fludarabine 40 mg/m2 by vein on Days -8 to -5.~Cyclophosphamide 50 mg/kg by vein on Day -8.~Total body radiation 2 Gy delivered on Day -4.~Seventeen (17) participants treated with Non-Fucosylated T-reg cells at dose level 2: 1 x 10^7/kg. The cells are infused on Day -1.~Cord blood transplant, MRD, or MUD infused on Day 0.~Mycophenolate 15 mg/kg (actual body weight with a maximum dose of 1 gram twice daily) by vein or mouth from Day -3 to Day +100 in the absence of GVHD.~Sirolimus 12 mg by mouth load followed by 4 mg by mouth daily from Day -3 to Day +180 in the absence of GVHD.~G-CSF 5 mcg/kg/day subcutaneously beginning on D+0 for CORD blood stem cell transplant and D+7 for allogeneic stem cell transplant, and continuing until the absolute neutrophil count (ANC) is > 500 x 10/L for 3 consecutive days."
89545082|NCT03178877||IBS|IBS group is medical student who filled Rome IV criteria for IBS
89545083|NCT03178877||Non IBS|Non-IBS group is non IBS medical student based on Rome IV criteria
89545084|NCT02140060|Experimental|TravA/Brinz|Dose Level A / Brinzolamide 1% ophthalmic suspension (fixed combination), 1 drop twice daily in the treated eye(s) morning and night, with travoprost solution vehicle, 1 drop once daily in the treated eye(s) at night, for 6 weeks
89545085|NCT02140060|Experimental|TravB/Brinz|Dose Level B / Brinzolamide 1% ophthalmic suspension (fixed combination), 1 drop twice daily in the treated eye(s) morning and night, with travoprost solution vehicle, 1 drop once daily in the treated eye(s) at night, for 6 weeks
89545086|NCT02140060|Experimental|TravC/Brinz|Dose Level C / Brinzolamide 1% ophthalmic suspension (fixed combination), 1 drop twice daily in the treated eye(s) morning and night, with travoprost solution vehicle, 1 drop once daily in the treated eye(s) at night, for 6 weeks
89545087|NCT02140060|Active Comparator|AZOPT|Brinzolamide 1% ophthalmic suspension, 1 drop twice daily in the treated eye(s) morning and night, with travoprost solution vehicle, 1 drop once daily in the treated eye(s) at night for 6 weeks
89545088|NCT02140060|Active Comparator|TRAV Z|Brinzolamide suspension vehicle, 1 drop twice daily in the treated eye(s) morning and night, with travoprost 0.004% ophthalmic solution, 1 drop once daily in the treated eye(s) at night, for 6 weeks
89545089|NCT02140060|Active Comparator|TRAV Z + AZOPT|Brinzolamide 1% ophthalmic suspension, 1 drop twice daily in the treated eye(s) twice daily morning and night, with travoprost 0.004% ophthalmic solution, 1 drop once daily in the treated eye(s) at night, for 6 weeks
89545090|NCT03181295|No Intervention|Usual care|Standard periodic health review (PHR) appointment. [As patients will get a survey about PA levels prior to their PHR, this may affect their likelihood of addressing PA during their PHR.]
89545091|NCT03181295|Experimental|Usual care plus intervention|Standard PHR appointment plus personalized exercise Rx and resources
89545092|NCT03178721||1|Systemic lupus erythematosus with atherosclerosis
89545093|NCT03178721||2|Systemic lupus erythematosus without atherosclerosis
89545094|NCT02421029|Experimental|edetate calcium disodium|Subjects who had a gadolinium-enhanced MRI within 1-4 weeks or within 3-6 months before enrollment will receive a single dose of edetate calcium disodium to evaluate levels of gadolinium in their urine, pre and post infusion.
89545095|NCT03181217|Experimental|water 22, water 0, glucose 0, glucose 22|Subjects consume 300 ml water at 22 ºC, 300 ml water at 0 ºC, 300 ml water at 0 ºC containing 75 grams glucose and 300 ml water at 22 ºC containing 75 grams glucose sequentially with a one-week washout between consumptions
88961489|NCT05778214|No Intervention|Traditional Manual Surgery|The control group process the traditional manual operation for cerebral angiography
88961490|NCT05778201|Experimental|Baby Drink group|1 package/ day for 1 month
89545096|NCT03181217|Experimental|water 0, glucose 22, water 22, glucose 0|Subjects consume 300 ml water at 0 ºC, 300 ml water at 22 ºC containing 75 grams glucose, 300 ml water at 22 ºC and 300 ml water at 0 ºC containing 75 grams glucose sequentially with a one-week washout between consumptions
89545097|NCT03181217|Experimental|glucose 22, glucose 0, water 0, water 22|Subjects consume 300 ml water at 22ºC containing 75 grams glucose, 300 ml water at 0 ºC containing 75 grams glucose, 300 ml water at 0 ºC and 300 ml water at 22 ºC sequentially with a one-week washout between consumptions
89545098|NCT03181217|Experimental|glucose 0, water 22, glucose 22, water 0|Subjects consume 300 ml water at 0 ºC containing 75 grams glucose, 300 ml water at 22 ºC, 300 ml water at 22 ºC containing 75 grams glucose and 300 ml water at 0 ºC sequentially with a one-week washout between consumptions
89545099|NCT02139982|Other|group MC(phase 1)|specific nerve block:musculocutaneous nerve block
89545100|NCT02139982|Other|group UL( phase 1)|specific nerve block:ulnar nerve block
89545101|NCT02139982|Other|group RA (phase 1)|specific nerve block:radial nerve block
89545102|NCT02139982|Other|group ME (phase 1)|specific nerve block:median nerve block
89545103|NCT02139982|Experimental|group A(phase 2)|30ml ropivacaine 0.125%
89545104|NCT02139982|Experimental|group B(phase 2)|30ml ropivacaine 0.2%
89545105|NCT02139982|Experimental|group C(phase 2)|30ml ropivacaine 0.25%
89545106|NCT02139982|Experimental|group D(phase 2)|30ml ropivacaine 0.375%
89545107|NCT02139982|Experimental|group E(phase 2)|30ml ropivacaine 0.5%
89545108|NCT02139982|Experimental|group F(phase 2)|30ml ropivacaine 0.75%
89545109|NCT03181139||pre-ERAS|Patients cared for prior to the implementation of the Enhanced Recovery after surgery for total mastectomy pathway
89545110|NCT03181139||post-ERAS|patients cared for after the implementation of the Enhanced Recovery after surgery for total mastectomy pathway. Pathway included preoperative acetaminophen and gabapentin, Pec blocks, multimodal analgesia postoperatively and aggressive PONV treatment.
89545111|NCT03180983|Other|INTERVENTIONAL GROUP|The intervention group will receive a blended-learning intervention.
89545112|NCT03180983|No Intervention|CONTROL GROUP|No intervention
89545113|NCT02139826|Experimental|IX-01 Capsule while Fasting|Singe oral dose of 800 milligrams of IX-01 as a capsule, while fasting, in 1 of 3 treatment periods
89545114|NCT02139826|Experimental|IX-01 Aqueous Dispersion while Fasting|Single oral dose of 800 milligrams IX-01 as an aqueous dispersion, while fasting in 1 of 3 treatment periods
89545115|NCT02139826|Experimental|IX-01 Capsule after Food|Single oral dose of 800 milligrams IX-01 as a capsule, after food, in 1 of 3 treatment periods
89545116|NCT02420561|Experimental|Motivational Interviewing|"The motivational interviewing (MI) intervention consisted of one 45-minute in-person MI session followed by two 15-minute telephone booster sessions"
89545117|NCT02420561|Active Comparator|Control|Participants received a brochure on alcohol and drug use risks.
89545118|NCT02420483|Experimental|Patients|Cardiopulmonary resuscitation with measurement of tidal volume, airway pressure and flow by a pneumotachograph and airway, oesophageal pressure sensors
89545119|NCT02139592||brentuximab vedotin (recombinant) Intravenous infusion|Intravenous infusion of 1.8 mg/kg (body weight) of brentuximab vedotin (recombinant) administered once every three weeks
89545120|NCT02139280|Active Comparator|Arm 2: Cyclophosphamide 3 gms/m(2)|Patients will receive intravenous mesna 15 minutes prior to cyclophosphamide and again at 4 and 8 hours afterwards. Each infusion will be given over 15 minutes. Oral mesna can be substituted for the two post-cyclophosphamide doses. Oral mesna will be administered at 2 and 6 hours after the start of cyclophosphamide. Cyclophosphamide will be administered intravenously over one hour at the dose of 3 gms/m(2).
89545121|NCT02139280|Experimental|Arm 1: 1.5 gms/m(2) Cyclophosphamide|Patients will receive intravenous mesna 15 minutes prior to cyclophosphamide and again at 4 and 8 hours afterwards. Each infusion will be given over 15 minutes. Oral mesna can be substituted for the two post-cyclophosphamide doses. Oral mesna will be administered at 2 and 6 hours after the start of cyclophosphamide. Cyclophosphamide will be administered intravenously over one hour at the dose of 1.5 gms/m(2).
89545122|NCT02072434|Experimental|Edoxaban|Edoxaban oral tablet, 60 mg-once daily (QD), reduced to 30 mg based on protocol-defined parameters, for up to 49 days
89545123|NCT02072434|Active Comparator|Warfarin|"Participants naïve to anticoagulation, taking anticoagulants other than a Vitamin K antagonist (VKA) or taking a VKA but with a prothrombin time (PT) international normalized ratio (INR) of less than 2.0 receive enoxaparin until they reach a PT INR of at least 2.0, before taking warfarin.~All participants in this arm receive warfarin oral tablet QD at their doctor's prescribed dose, for up to 49 days."
89545124|NCT04725994|Other|Group 1|
89545125|NCT04725994|Other|Group 2|
89545126|NCT02101060|Experimental|exercise|16-week progressive aerobic and resistance exercise training
89545127|NCT02101060|No Intervention|control|usual care controls
89032965|NCT02945618|Experimental|Neurocryostimulation|"CRYOFOS will be applied on the ankle at the end of each of the 8 sessions (in accordance to the protocol established). The treatment time with the CRYOFOS will take between 1 and 2 minutes, and will be pain-free.~Both groups will also receive the same conventional program consisting of: compression, bracing, early mobilization (including manual therapy), strengthening (isometric and isotonic using elastic bands) and proprioception (using proprioception boards) exercises, according to the grade of the sprain and the stage of biological ligament healing."
89545128|NCT02139124|Placebo Comparator|Placebo|Placebo Arm
89545129|NCT02139124|Experimental|PRC-063 25 mg|PRC-063 25 mg
89545130|NCT02139124|Active Comparator|PRC-063 45 mg|PRC-063 45 mg
89545131|NCT02139124|Active Comparator|PRC-063 70 mg|PRC-063 70 mg
89545132|NCT02139124|Active Comparator|PRC-063 100 mg|PRC-063 100 mg
89545133|NCT02139046|Active Comparator|Febuxostat IR 40 mg|Febuxostat Immediate Release (IR) 40 mg over-encapsulated tablet, orally, once daily, and colchicine 0.6 mg tablet, orally, every day (for participants with estimated glomerular filtration rate (eGFR) ≥ 60 mL/min) or every other day (if eGFR ≥ 15 - ≤ 59 mL/min), or, alternatively, if colchicine is not tolerated and the subject's eGFR is ≥ 50 mL/min, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.
89545134|NCT02139046|Active Comparator|Febuxostat IR 80 mg|Febuxostat IR 80 mg over-encapsulated tablet, orally, once daily, and colchicine 0.6 mg tablet, orally, every day or every other day, or, alternatively, if colchicine is not tolerated and the subject's eGFR is ≥ 50 mL/min, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.
89545135|NCT02139046|Experimental|Febuxostat XR 40 mg|Febuxostat Extended Release (XR) 40 mg over-encapsulated capsule, orally, once daily, and colchicine 0.6 mg tablet, orally, every day or every other day, or, alternatively, if colchicine is not tolerated and the subject's eGFR is ≥ 50 mL/min, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.
89545136|NCT02139046|Experimental|Febuxostat XR 80 mg|Febuxostat XR 80 mg over-encapsulated capsule, orally, once daily, and colchicine 0.6 mg tablet, orally, every day or every other day, or, alternatively, if colchicine is not tolerated and the subject's eGFR is ≥ 50 mL/min, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.
89545137|NCT02139046|Placebo Comparator|Placebo|Febuxostat placebo-matching capsule, orally, once daily, and colchicine 0.6 mg tablet, orally, every day or every other day, or, alternatively, if colchicine is not tolerated and the subject's eGFR is ≥ 50 mL/min, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.
89545138|NCT02138890|Experimental|APS injection|Autologous Protein Solution
89545139|NCT02138890|Placebo Comparator|Control|Saline
89545140|NCT04725526|No Intervention|usual clinical practice|A group of pluripatological patients with heart failure and complex needs of health will be tratad per standard of care on site
89545141|NCT04725526|Experimental|mHealth intervention plus usual clinical practice|A group of pluripatological patients with heart failure and complex needs of health will be tratad per standard of care plus mHealth intervention on site
89545142|NCT02100670|Experimental|1% diclofenac sodium plus 3% menthol|1% diclofenac sodium plus 3% menthol gel supplied in 30 gram (g) tubes sufficient for each subject to apply 4g of gel to the injured ankle region four times daily for up to 10 days.
89545143|NCT02100670|Experimental|1% diclofenac sodium plus 0.09% menthol|1% diclofenac sodium plus 0.09% menthol gel supplied in 30g tubes sufficient for each subject to apply 4g of gel to the injured ankle region four times daily for up to 10 days.
89545144|NCT02100670|Experimental|3% menthol|3% menthol gel supplied in 30g tubes sufficient for each subject to apply 4g of gel to the injured ankle region four times daily for up to 10 days.
89545145|NCT02100670|Placebo Comparator|Placebo with 0.09% menthol gel|Placebo with 0.09% menthol gel supplied in 30g tubes sufficient for each subject to apply 4g of gel to the injured ankle region four times daily for up to 10 days.
89545146|NCT02070484|Experimental|NuCel|Stemcell allograft
89545147|NCT02070484|Active Comparator|Demineralized Bone Matrix (DBM)|Demineralized Bone Matrix (DBM) bone graft substitute
89545148|NCT02100514|Experimental|Bococizumab (PF-04950615; RN316)|Bococizumab (PF-04950615; RN316)
89545149|NCT02100514|Placebo Comparator|placebo|
89545150|NCT02069392|Active Comparator|Cognitive remediation training with nicotine|Participants will complete daily sessions of Posit Science cognitive remediation training for 10 weeks. Twice a week, participants will consume a 2 mg (for non-smokers) or 4 mg (for smokers) nicotine polacrilex lozenge prior to the training.
89545151|NCT02069392|Placebo Comparator|Cognitive remediation training without nicotine|Participants will complete daily Posit Science cognitive remediation training for 10 weeks. Twice a week, participants will consume a placebo lozenge prior to the training.
89545152|NCT02047318|Experimental|LUM001 (Maralixibat)|LUM001 also known as Maralixibat (MRX) administered orally up to twice each day
89545153|NCT05517681|Placebo Comparator|non-ICG Group|Laparoscopic radical resection of rectal cancer was performed routinely without ICG injection
89517272|NCT04518228||Component 2: Arm 2.1: CAB LA|Women ≥ 24 weeks gestation who received at least one dose of long-acting injectable formulation of cabotegravir (CAB LA) any dose during pregnancy, and their infants
89517273|NCT04518228||Component 3: Arm 3.1: Dolutegravir (DTG) 50 mg|Women ≥ 20 weeks gestation receiving first-line TB treatment with at least two of the following TB treatment drugs: isoniazid (INH), rifampin (RIF), rifabutin (RFB), ethambutol (EMB), pyrazinamide (PZA), moxifloxacin (MFX), and receiving dolutegravir (DTG) 50 mg twice daily (b.i.d.) when combined with RIF or 50 mg q.d. if RIF is not part of the TB regimen, and their infants
89517274|NCT04518228||Component 3: Arm 3.2: ATV/r or DRV/r|Women ≥ 20 weeks gestation receiving first-line TB treatment with at least two of the following TB treatment drugs: isoniazid (INH), rifampin (RIF), rifabutin (RFB), ethambutol (EMB), pyrazinamide (PZA), moxifloxacin (MFX), and receiving atazanavir/ritonavir (ATV/r) ≥ 300/100 mg q.d. or darunavir/ritonavir (DRV/r) ≥ 600/100 mg b.i.d., and their infants
89545154|NCT05517681|Experimental|ICG Group|ICG was injected preoperatively via anoscope or anal dilator in the mucosal layer around the tumor, and surgical treatment was performed after visualization. The surgical approach was performed by laparoscopic radical rectal cancer with an intermediate approach step.The IMA root is treated with low ligation of the IMA, while lymph node dissection is performed while preserving the autonomic nerves around the IMA
89545155|NCT05525793|Experimental|Transitional care|This group is the actual intervention group.
89545156|NCT05525793|No Intervention|Usual care|This group is the routine treatment (control) valid in the clinical practice.
89545157|NCT05525715|Experimental|Phase Ib Cohort 1（2mg QY201 tablets or 2mg QY201 placebo）|8 subjects use 2mg QY201 tablets，2 subject uses 2mg QY201 placebo ，BID，29 days
89545158|NCT05525715|Experimental|Phase Ib Cohort 2（5mg QY201 tablets or 5mg QY201 placebo）|8 subjects use 5mg QY201 tablets，2 subject uses 5mg QY201 placebo ，BID，29 days
89545159|NCT05525715|Experimental|Phase Ib Cohort 3（10mg QY201 tablets or 10mg QY201 placebo）|8 subjects use 10mg QY201 tablets，2 subject uses 10mg QY201 placebo，QD，29 days
89545160|NCT05525715|Experimental|Phase Ib Cohort 4（10mg QY201 tablets or 10mg QY201 placebo）|8 subjects use 10mg QY201 tablets，2 subject uses 10mg QY201 placebo，BID，29 days
89545161|NCT05525715|Experimental|Phase Ib Cohort 5（15mg QY201 tablets or 15mg QY201 placebo）|8 subjects use 15mg QY201 tablets，2 subject uses 15mg QY201 placebo，BID，29 days
88811996|NCT01394705|Experimental|Intervention|The intervention group received a personalized exercise prescription (using the FITT principles) and wore an accelerometer up to 7days/week (most waking hours) and logged their activity by regularly (3 times a week) uploading the device for a period of 3 months, use of the internet was supervised by a parent or guardian. Their activity was monitored via the online BodyMedia site on a regular basis by study personnel and feedback was provided at least once a week through email and/or phone calls
89545162|NCT05525715|Experimental|Phase Ib Cohort 6（20mg QY201 tablets or 20mg QY201 placebo）|8 subjects use 20mg QY201 tablets，2 subject uses 20mg QY201 placebo，BID，29 days
89545163|NCT05525715|Experimental|Phase II Cohort1 (5mg QY201 tablets)|50 subjects use 5mg QY201 tablets twice daily for 12 weeks
89545164|NCT05525715|Experimental|Phase II Cohort2 (10mg QY201 tablets)|50 subjects use 10mg QY201 tablets twice daily for 12 weeks
89545165|NCT05525715|Experimental|Phase II Cohort3 (20mg QY201 tablets)|50 subjects use 20mg QY201 tablets twice daily for 12 weeks
89545166|NCT05525715|Experimental|Phase II Cohort4 (QY201 placebo)|50 subjects use QY201 placebo twice daily for 12 weeks
89545167|NCT02100124|Experimental|Reproductive Life Planning (RLP)|RLP is an online adaptation of the Centers for Disease Control and Prevention (CDC) reproductive life planning toll that guides women to identify their reproductive goals and individual requirements for contraception.
89545168|NCT02100124|Experimental|Reproductive Life Planning Plus (RLP+)|RLP+ additionally includes contraceptive action planning, aimed at helping women select solutions for potential problems they may encounter with contraceptive adherence.
89545169|NCT02100124|Active Comparator|Information-only control|The information-only control will deliver on-line information about their contraceptive benefits coverage and information about all FDA-approved contraceptive methods.
89545170|NCT05522283||CMV colitis|Patients with the detection of either cytomegalic cells or IHC-CMV cells were diagnosed with CMV colitis.
89545171|NCT05522283||Non-CMV colitis|Symptomatic patients were not detected with either cytomegalic cells or IHC-CMV cells.
89545172|NCT05522283||Healthy volunteers|Asymptomatic patients underwent colonoscopy for screening.
89545173|NCT02068768||Operated Subjects|Subjects scheduled to receive an Avenue® L Interbody Fusion System (LDR Spine) for fusion of the lumbar spine from L2-S1
89545174|NCT05015049||Neonatal population - hypertensive disorder of pregnancy|All babies born to a woman with a hypertensive disorder of pregnancy (HDP) and admitted to a neonatal unit in England and Wales between 1st January 2012 and 31st December 2020
89545175|NCT05015049||Neonatal population - no hypertensive disorder of pregnancy|All babies born to a woman without a hypertensive disorder of pregnancy (HDP) and admitted to a neonatal unit in England and Wales between 1st January 2012 and 31st December 2020
89545176|NCT02046616|Experimental|Tocilizumab Alone or Combined with Methotrexate or Other DMARD|All participants will receive tocilizumab as a single fixed dose (monotherapy) or in combination with methotrexate or other non-biologic DMARDs, irrespective of body weight, for 24 weeks.
89545177|NCT05525559|Experimental|Dose Escalation|Oral capsules taken in escalating levels to determine MTD/RP2D. Each treatment cycle will be 21 days in duration with ET0038 administered, once daily (QD).
89545178|NCT04425057|Experimental|Interval training|Physiotherapy program during two months: Interval training at a high intensity, inlcuding a warm-up and a cool-down. Aerobic exercises, resistance exercises, stretching
89545179|NCT04425057|No Intervention|Control group|No physiotherapy
89545180|NCT05525481|Experimental|Intervention arm|This is a single-arm trial. We only have one experimental arm. The control arm will be provided by another study.
89545181|NCT02099344|Active Comparator|Artegraft|Artegraft® vs Gore® Propaten®. Approximately 50 eligible patients with End Stage Renal Disease (ESRD) requiring hemodialysis will be randomized to receive one of these two grafts as part of their standard care.
89545182|NCT02099344|Active Comparator|Propaten|Artegraft® vs Gore® Propaten®. Approximately 50 eligible patients with End Stage Renal Disease (ESRD) requiring hemodialysis will be randomized to receive one of these two grafts as part of their standard care.
89545183|NCT02068222|Experimental|ABT-450/r and ABT-530 plus RBV|ABT-450/r (150 mg/100 mg) once daily (QD) co-administered with ABT-530 (120 mg) once daily (QD) plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks.
89545184|NCT05517213|Experimental|Etoposide|Etoposide1.2g/m2(Pump continuously for 24h)+G-CSF10ug/kg.
89545185|NCT05517213|Experimental|Cyclophosphamide|Cyclophosphamide 3.0g/m2+Grh-CSF10ug/kg.
89545186|NCT05517135||Arm 1|Arm 1: EBV DNA <4000 copies/mL AND T3N0-2 or T4N0 (TNM AJCC/UICC 8th edition)
89545187|NCT05517135||Arm 2|Arm 2: EBV DNA ≥4000 copies/mL OR N3 OR T4N+ (TNM AJCC/UICC 8th edition) AND EBV DNA undetectable after 2-3 cycles of induction chemotherapy (IC)
89545188|NCT05517135||Arm 3|Arm 3: EBV DNA ≥4000 copies/mL OR N3 OR T4N+ (TNM AJCC/UICC 8th edition) AND EBV DNA detectable after 2-3 cycles of IC
89545189|NCT05517135||Group 1|Group 1: Recurrent/metastatic NPC, EBV DNA <4000 copies/mL
89545190|NCT05517135||Group 2|Group 2: Recurrent/metastatic NPC, EBV DNA ≥4000 copies/mL
89545191|NCT05517057||success of the medical management|Patients that recovered flatus and stools, and that tolerated solid food within the 3 days after the admission
89545192|NCT05517057||failure of the medical management|Patients that did not recover flatus and stools, and that did not tolerate solid food within the 3 days after the admission. These patients had an indication for surgery.
89545193|NCT05512455||virtual articulator mounting using an average facebow|indirect virtual mounting in MS VA by using an average facebow
89545194|NCT05512455||virtual articulator mounting by using average values|virtual mounting in MS VA by using average values;
89545195|NCT05512455||virtual articulator mounting by using professional facial scanner|virtual mounting in MS VA by using professional facial scanner
89545196|NCT05512455||virtual articulator mounting by using smartphone facial scanner|virtual mounting in MS VA by using smartphone facial scanner
89545197|NCT05512455||virtual articulator mounting by using CBCT located in Bergstrom's point|virtual mounting in MS VA by using CBCT located in Bergstrom's point
89545198|NCT05512455||virtual articulator mounting by using CBCT located in the medial poles of the condyle|virtual mounting in MS VA by using CBCT located in the medial poles of the condyle
89545199|NCT05512455||virtual articulator mounting by using JMA|virtual mounting in CA VA by using JMA,as the group to compare with the other mounting procedures.
89545200|NCT05516901|Experimental|The erector spinae plane block group|The erector spinae plane block group: Patients will receive general anesthesia plus bilateral ultrasound guided ESP block.
89545201|NCT05516901|Placebo Comparator|Control group|Control group (group І): Patients will receive general anesthesia alone.
89545202|NCT05516823||Group: Psychedelics-only Group|"A group of participants who reported using in their past psychedelic substances only (both classical and non-classical psychedelics are included). Specifically, in the current study this group included reports on the following substances:~Psilocybin (magic mushrooms, truffles) LSD (acid) Mescaline (peyote, San Pedro) Dimethyltryptamine (DMT) Ayahuasca 5-MeO-DMT 3-MMC Ibogaine Salvia Phenethylamines (2C family)"
89545203|NCT05516823||Group: Stimulants-only Group|"A group of participants who reported using in their past drugs identified as stimulating compounds only (both recreational and prescribed usages are included). Stimulating compounds are considered, in the context of the current study, substances that increase the overall activity of the central nervous system. Specifically, in the current study this group included reports on the following substances:~Cocaine Crack Amphetamines Methamphetamines Prescription stimulants (e.g., Adderall, Ritalin, Concerta)"
89545204|NCT05516823||Depressants-only Group|"A group of participants who reported using in their past drugs identified as depressing compounds only (both recreational and prescribed usages are included). Depressing compounds are considered, in the context of the current study, substances that decrease the overall activity of the central nervous system. Specifically, in the current study this group included reports on the following substances:~Benzodiazepines Opiates (recreational use of heroin, opium, hydrocodone, oxycodone, oxymorphone, codeine, fentanyl) Prescription opioids"
89545205|NCT05516823||Cannabinoids Group|"A group of participants who reported using in their past cannabinoids compounds only (both recreational and prescribed usages are included). Specifically, in the current study this group included reports on the following substances:~THC (cannabis, marijuana) CBD Medical Cannabis (both THC and CBD)"
89545206|NCT05516823||Psychedelic and Non-psychedelic Substances Group|"A group of participants who reported using in their past drugs identified as psychedelics and stimulants and/or depressants (both recreational and prescribed usages are included). In this group participants will be included who reported using at least one non-psychedelic drug additionally to a psychedelic one. Specifically, the following options were provided:~Psychedelic compounds:~Psilocybin (magic mushrooms, truffles) LSD (acid) Mescaline (peyote, San Pedro) Dimethyltryptamine (DMT) Ayahuasca 5-MeO-DMT 3-MMC Ibogaine Salvia Phenethylamines (2C family)~Non-psychedelic compounds:~THC (cannabis, marijuana) CBD Medical Cannabis (both THC and CBD) MDMA (ecstasy) Ketamine Cocaine Crack Amphetamines Methamphetamines Prescription stimulants (e.g., Adderall, Ritalin, Concerta) Benzodiazepines Opiates (e.g., heroin, opium, hydrocodone, oxycodone, oxymorphone, codeine, fentanyl) Prescription opioids"
89545207|NCT05516823||Substance-naive Group|"A group of participants who reported no past experience with any of the substances listed in the current study nor reported using other substances (excluding alcohol and nicotine). Participants will be assigned to this group if and only if they choose the None of the above option from the Substance Use Survey (item 1)."
89545208|NCT05512299||PD with resting tremor|Parkinson's disease patient with pure resting tremor.
89545209|NCT05512299||PD with postural tremor|Parkinson's disease patient with postural tremor.
89545210|NCT05512299||Cerebellar degeneration with intention tremor|Cerebellar degeneration patient with intention tremor.
89545211|NCT05521971|Other|Before group|In the usual care cohort, there was no systematic clinical pharmacist involvement regarding deprescribing of hypnotics.
89545212|NCT05521971|Experimental|After group|In the intervention cohort a pharmacist-led intervention was implemented comprising the four following components: 1) education of health care personnel; 2) access to standardized discontinuation regimens; 3) patient education; 4) support of transitional care.
89545213|NCT05521893|Experimental|Telemedicine group|
89545214|NCT05521893|Active Comparator|Standard care group|
89545215|NCT05077761|Experimental|High-intensity laser therapy|77 participants will receive active high-intensity laser therapy interventions on hamstring muscle to improve the flexibility of muscle
89545216|NCT05077761|Sham Comparator|Sham High-intensity laser therapy|77 participants will receive sham high-intensity laser therapy on hamstring muscle
89545217|NCT05516745|Experimental|arm with intervention (AioCare spirometry)|50 participants with DMD aged 7-17 years, subjected to home electronic monitoring
89545218|NCT05516745|Experimental|arm with intervention (AioCare spirometry with telerehabilitation)|50 participants with DMD aged 7-17 years, subjected to home electronic monitoring with the AioCare device and pulmonary rehabilitation exercises
89545219|NCT05516745|Experimental|arm with intervention (telerehabilitation)|50 participants with DMD aged 7-17 years, subjected to pulmonary rehabilitation exercises
89545220|NCT05516745|No Intervention|control arm (no intervention)|50 participants with DMD aged 7-17 years, subject to a standard of care
89545221|NCT02099110|Experimental|Ertugliflozin 5 mg + sitagliptin 100 mg|Ertugliflozin 5 mg + sitagliptin 100 mg, oral, once daily for 52 weeks
89545222|NCT02099110|Experimental|Ertugliflozin 15 mg + sitagliptin 100 mg|Ertugliflozin 15 mg + sitagliptin 100 mg, oral, once daily for 52 weeks
89545223|NCT02099110|Experimental|Ertugliflozin 5 mg|Ertugliflozin 5 mg, oral, once daily for 52 weeks
89545224|NCT02099110|Experimental|Ertugliflozin 15 mg|Ertugliflozin, oral, once daily for 52 weeks
89545225|NCT02099110|Active Comparator|Sitagliptin 100 mg|Sitagliptin 100 mg, oral, once daily for 52 weeks
89545226|NCT02098876|Active Comparator|Resolute Integrity DES|Resolute Integrity zotarolimus eluting stent
89545227|NCT02098876|Active Comparator|Xience Xpedition DES|Xience Xpedition everolimus eluting stent
89545228|NCT01624090|Experimental|1/mithramycin|Single agent intravenous (IV) mithramycin
89545229|NCT02571777|Experimental|QVM149 150/50/160 µg o.d.|QVM149 150/50/160 μg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device
89545230|NCT02571777|Experimental|QVM149 150/50/80 µg o.d.|QVM149 150/50/80 μg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device
88961491|NCT05778149|Experimental|Treatment|single arm,Treatment plan: Aumolertinib 110mg p.o QD; Anlotinib 12mg, oral for 2 weeks, three weeks a cycle, until disease progression.
89032966|NCT02945618|Active Comparator|Conventional program with ice|The control group will receive the same conventional program (as the experimental group) consisting of: compression, bracing, early mobilization (including manual therapy), strengthening (isometric and isotonic using elastic bands) and proprioception (using proprioception boards) exercises, according to the grade of the sprain and the stage of biological ligament healing. Ice will be applied to the ankle for 15 minutes at the end of each of the 8 sessions.
89032967|NCT02922933|Active Comparator|Omeprazole|"Treatment A: 5mg entinostat on Day 1~Treatment B: 20mg omeprazole for 5 days with 5mg entinostat on Day 1"
89545231|NCT02571777|Active Comparator|QMF149 150/320 µg o.d.|QMF149 150/320 μg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device
89545232|NCT02571777|Active Comparator|QMF149 150/160 µg o.d.|QMF149 150/160 μg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device
89545233|NCT02571777|Active Comparator|Salmeterol/fluticasone 50/500 μg b.i.d.|Salmeterol xinafoate /fluticasone propionate 50/500 μg twice daily (b.i.d.) delivered via Accuhaler®
89545234|NCT05516355|Experimental|Group 1 (MBSR + CCT)|Group 1 will begin the retreat with a 3-day MBSR intervention. On day 4 of the retreat, they will crossover and begin a 3-day CCT intervention.
89545235|NCT05516355|Experimental|Group 2 (CCT + MBSR)|Group 2 will begin the retreat with a 3-day CCT intervention. On day 4 of the retreat, they will crossover and begin a 3-day MBSR intervention.
89545236|NCT05521659|Experimental|Standardized oral care protocol|Intervention: Patients in experimental group were given oral care 3 times a day at certain hours (06-14-22) with oral care set including chlorhexidine gluconate.
89545237|NCT05521659|No Intervention|Control Group|Routine oral care (usual oral care with the same appliances and solution but applied twice a day without following a protocol)
89545238|NCT05521581|Experimental|intervention|Hand massage will be applied to primiparous mothers who gave birth by cesarean section
89545239|NCT05521581|No Intervention|control|Routine care will be given to mothers who have given cesarean section and hand massage will not be applied.
89545240|NCT05511831|Experimental|ketotifen|Ketotifen was added to the standard treatment within 24 hours after the completion of primary PCI for 3 months, taking 1 mg each time, 1-2 times a day according to the patient's tolerance.
89545241|NCT05511831|Sham Comparator|Control group|Standard treatment according to guidelines
89545242|NCT02571075|Experimental|Group 1 - Receives auricular acupuncture|"Receives Battlefield Acupuncture (BFA) as soon a anesthesia is initiated and needles removed right before they are extubated and awakened."
89545243|NCT02571075|No Intervention|Group 2 don't receive anything|They do not receive any any acupuncture only standard of care.
89545244|NCT02705105|Experimental|Dose-Finding Cohort|"Cycle 1 Days 1, 8, 15, and 22: Dose Level 1 of Mogamulizumab + Nivolumab Subsequent Cycles Days 1 and 15: Dose Level 1 of Mogamulizumab + Nivolumab~If >1 patient has a DLT at first dose level, then the following cohort will be enrolled:~Cycle 1 Days 1, 8, 15, and 22: Optional Dose Level of Mogamulizumab + Nivolumab Subsequent Cycles Days 1 and 15: Optional Dose Level of Mogamulizumab + Nivolumab"
89545245|NCT02705105|Experimental|Expansion Cohort|"Cycle 1 Days 1, 8, 15, and 22: Maximum Tolerated Dose of Mogamulizumab + Nivolumab Subsequent Cycles Days 1 and 15: Maximum Tolerated Dose of Mogamulizumab + Nivolumab~Subjects will be separated further into cohorts by tumor type"
89545246|NCT05521425|Experimental|Intervention Group|"Training + Helping Hands provided for CAPD bag exchange procedures at home"
89545247|NCT05521425|No Intervention|Control Group|"Training alone (without Helping Hands provided to assist in bag exchange procedures)"
89545248|NCT05511753|Experimental|pure tone audiometry improving|Pure tone audiometry: observe changes in hearing ability Evaluation time: Before acupuncture treatment, 2 weeks, 4 weeks, 6 weeks after treatment, and 2 weeks after acupuncture treatment, pure-tone audiometry was performed. The pure tone audiometry measures the hearing thresholds of 2KHz, 4KHz and 8KHz respectively.
89545249|NCT05521347|Experimental|caffeine|capsules with 3 mg/kg of caffeine
89545250|NCT05521347|Placebo Comparator|placebo|The placebo capsule contained flour
89545251|NCT02097472|Experimental|Adult Cohort 1, PATH-wSP, 600 mcg|A single injection of 600 mcg PATH-wSP in one arm, followed 4 weeks later by a single injection of 600 mcg PATH-wSP in the alternate arm.
89545252|NCT02097472|Placebo Comparator|Adult Cohort 1, Saline|A single injection of saline in one arm, followed 4 weeks later by a single injection of saline in the alternate arm.
89545253|NCT02097472|Experimental|Adult Cohort 2, PATH-wSP, 1000 mcg|A single injection of 1000 mcg PATH-wSP in one arm, followed 4 weeks later by a single injection of 1000 mcg PATH-wSP in the alternate arm.
89545254|NCT02097472|Placebo Comparator|Adult Cohort 2, Saline|A single injection of saline in one arm, followed 4 weeks later by a single injection of saline in the alternate arm.
89545255|NCT02097472|Experimental|Toddler Cohort 1 PATH-wSP 300 mcg+Active control|A single injection of PATH-wSP 300 mcg in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 300 mcg in the left thigh 8 weeks later.
89545256|NCT02097472|Experimental|Toddler Cohort 1 PATH-wSP 300 mcg+Saline|A single injection of PATH-wSP 300 mcg in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 300 mcg in the left thigh 8 weeks later.
88961492|NCT05778097|Experimental|Apalutamide+ADT|Apalutamide (240 mg once daily) in combination with ADT for 12 cycles (28 days of each cycle)
88961493|NCT05778084|Other|Heart failure patients with reduced and mildly reduced ejection fraction|"One paired test group described as Heart Failure patients with reduced and mildly reduced ejection fraction are indicated for Empagliflozin.~Blood samples will be collected as a baseline before Empagliflozin administration to test for N-terminal Pro-B-type Natriuretic Peptide,~Followed by administration of empagliflozin for 6 months.~Then retest the N-terminal Pro-B-type Natriuretic Peptide after 6 months."
89545257|NCT02097472|Active Comparator|Toddler Cohort 1: Active Control Only|A single injection of saline in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of saline in the left thigh 8 weeks later.
89545258|NCT02097472|Experimental|Toddler Cohort 2 PATH-wSP 600 mcg+Active control|A single injection of PATH-wSP 600 mcg in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 600 mcg in the left thigh 8 weeks later.
89545259|NCT02097472|Experimental|Toddler Cohort 2 PATH-wSP 600 mcg+saline|A single injection of PATH-wSP 600 mcg in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 600 mcg in the left thigh 8 weeks later.
89545260|NCT02097472|Active Comparator|Toddler Cohort 2: Active Control Only|A single injection of saline in the left thigh and a single injection of each of the two active comparator vaccines in the right thigh. These 3 injections are followed by a single injection of saline in the left thigh 8 weeks later.
89545261|NCT03180671|No Intervention|Group 1 Control|Counselling with explanation of preventive procedures.
89545262|NCT03180671|Active Comparator|Group 2 deprogramer Sliding Guide|Intervention using the Deprogrammer Sliding Guide for 12-15 minutes.
89545263|NCT03180671|Active Comparator|Group 3 deprogrammer Dawson B-Splint|Intervention using the Dawson B-Splint for 7 days with breaks for eating/drinking and oral hygiene procedures.
89545264|NCT03180671|Active Comparator|Group 4 deprogrammer Kois|Intervention using the Kois deprogrammer for 14 days with breaks for eating/drinking and oral hygiene procedures.
89545265|NCT02420249|Experimental|Qigong training group|Participants assigned to the Qigong group will receive Qigong training. The Qigong training programme will be run for 3 months with two supervised 1-hour sessions per week. Participants will learn the 18 Forms of Tai Chi Internal Qigong. The training sessions will be conducted by a qualified Qigong instructor from the Natural Health Qigong Association. Participants in the control group will receive no Qigong training during the study period. They will receive an 18 Forms of Tai Chi Internal Qigong training package after the study.
89545266|NCT02420249|No Intervention|Control group|Participants in the control group will receive no Qigong training.
89545267|NCT02420171|Active Comparator|In Vitro culture media with insulin|We will add insulin to the single step culture media to monitor the embryogenesis
89545268|NCT02420171|No Intervention|In Vitro culture media without insulin m|The embryos will be cultured in the media without insulin and compare this arm as the control arm with the interventional one.
89545269|NCT05516121|Experimental|patients|Each patient takes 100 mg single dose, after wash-out period 200 mg single dose, then, after wash-out period 200 mg single dose two following days
89545270|NCT03180593|Active Comparator|Valsartan Arm|Valsartan 80mg randomly assigned for 8 weeks to asses BP control with office and 24-hour ABPM and reduction of LVH
89545271|NCT03180593|Active Comparator|Nebivolol/Valsartan|Nebivolol/Valsartan 5/80mg randomly assigned for 8 weeks to asses Blood Pressure control with office and 24-hour Ambulatory Blood Pressure Monitoring and reduction of Left Ventricular Hypertrophy
89545272|NCT03180437|Active Comparator|Group A|In this group, the patients will receive IRE surgery to control the local tumor under CT .
89545273|NCT03180437|Experimental|Group B|In this group, the patients will receive multiple high-activity γδ T cell immunotherapies and IRE surgery
89545274|NCT02423759|Active Comparator|ciprofloxacin|standard chemoprophylaxis [500mg ciprofloxacin twice daily for 3 days]
89545275|NCT02423759|Experimental|ciprofloxacin and gentamycine|Augmented Chemoprophylaxis [standard chemoprophylaxis plus 160mg]
89545276|NCT02423759|Experimental|culture based chemoprophylaxis|Patients will receive antibiotic according to rectal swab culture at time of biopsy and then after for 3 days.
89545277|NCT02420405|Placebo Comparator|Routine gene testing|Routine gene testing of EGFR, ROS1 and ALK will be performed on those diagnosed with nonsquamous NSCLC.
89545278|NCT02420405|Experimental|Next-generation sequencing|Routine gene testing was performed in those diagnosed with nonsquamous NSCLC. NGS will be performed on these that have adequate rest tissues.
89545279|NCT02419781|Active Comparator|Group with endovascular treatment|Group with additional endovascular treatment
89545280|NCT02419781|Active Comparator|Group without endovascular treatment|Group without additional endovascular treatment
89545281|NCT01623310|Experimental|OPN-375 400 μg BID|OPN-375 400 μg BID for 12 months
89545282|NCT03178565|Experimental|Intervention Group|Respiratory physiotherapy using a mechanical insufflation-exsufflation device (CoughAssist)
89545283|NCT03178565|Active Comparator|Control Group|Respiratory physiotherapy according standard of care - without the use of a mechanical insufflation-exsufflation device.
89545284|NCT03180125|Experimental|sodium hyaluorinate ultrasound guided|median nerve hydro-dissection using 1% lidocain followed by low molecular weight sodium hyaluronate (Hyalgan) injection ultrasonographically guided
89545285|NCT03180125|Placebo Comparator|corticosteroid with ultrasound guided|median nerve hydro-dissection using 1% lidocain followed by injection of corticosteroid Ultrasonographically guided
89545286|NCT02046226|Experimental|OxyGenesys(TM) Dissolved Oxygen Dressing|OxyGenesys(TM) Dissolved Oxygen Dressing
89545287|NCT02046226|No Intervention|Standard Wound Care|Standard wound care using gauze dressings per institutional standard of care.
89545288|NCT02423603|Active Comparator|Paclitaxel + AZD5363|Paclitaxel was administered as a once-per-week intravenous infusion of 90 mg/m2 over approximately 1 hour on days 1, 8, and 15 of each 28-day treatment cycle. Capivasertib 400 mg was administered orally twice per day on an intermittent weekly dosing schedule, with treatment on days 2 to 5 of weeks 1, 2, and 3 within each 28-day cycle.
89545289|NCT02423603|Placebo Comparator|Paclitaxel + Placebo|Paclitaxel was administered as a once-per-week intravenous infusion of 90 mg/m2 over approximately 1 hour on days 1, 8, and 15 of each 28-day treatment cycle. Placebo was administered orally twice per day on an intermittent weekly dosing schedule, with treatment on days 2 to 5 of weeks 1, 2, and 3 within each 28-day cycle.
89545290|NCT03178409||cHCC-MFCCC|Patients affected by combined HCC-MFCCC
89545291|NCT03178409||HCC|Patients affected by classical HCC
89545292|NCT03178409||MFCCC|Patients affected by classical MFCCC
89545293|NCT03178253||3|
88961494|NCT05778058|Experimental|Unilateral Stimulation|"After evaluating with 7 different parameters on the first, second, third and fourth days of the protocol, the participants in all groups will be asked to do cycling exercise with maximum performance for 30 minutes under the same wattage load.~It will be re-evaluated after the cycling exercise application. After the assessment is complete, stimulation will be given with Vagustim non-invasively for 30 minutes. After vagus nerve stimulation, a re-evaluation will be made and the protocol for that day will be terminated.~With the Vagustim device, vagus nerve stimulation will be applied in one ear for 20 minutes, with a frequency of 10 Hz, a pulse width of 300 μs in Modulation mode, and a constant current that the participant will feel the current comfortably."
88961495|NCT05778058|Experimental|Bilateral Stimulation|"After evaluating with 7 different parameters on the first, second, third and fourth days of the protocol, the participants in all groups will be asked to do cycling exercise with maximum performance for 30 minutes under the same wattage load.~It will be re-evaluated after the cycling exercise application. After the assessment is complete, stimulation will be given with Vagustim non-invasively for 20minutes. After vagus nerve stimulation, a re-evaluation will be made and the protocol for that day will be terminated.~With the Vagustim device, vagus nerve stimulation will be applied in bilateral ear for 20 minutes, with a frequency of 10 Hz, a pulse width of 300 μs in Modulation mode, and a constant current that the participant will feel the current comfortably."
89032968|NCT02922933|Active Comparator|Famotidine|"Treatment C: 5mg entinostat on Day 1~Treatment D: 20mg famotidine on Days -1 and 1 with 5mg entinostat on Day 1"
89032969|NCT02922933|Active Comparator|Acidic Beverage|"Treatment E: 20mg omeprazole for 5 days with 5mg entinostat on Day 1 taken with water~Treatment F: 20mg omeprazole for 5 days with 5mg entinostat on Day 1 taken with an acidic beverage"
89545294|NCT03180203|Experimental|INTELLiVENT-ASV|INTELLiVENT-ASV is a full closed-loop ventilation mode,available on the mechanical ventilator S1 of Hamilton.
89545295|NCT03180203|Active Comparator|Conventional modes|Volume controlled continuous mandatory ventilation (CMV) mode with pressure support mode on the Hamilton S1 Device.
89545296|NCT03180281|Experimental|DPP4 group|DPP4 inhibitor,1 pill qd
89545297|NCT03180281|Experimental|insulin group|insulin,glargine or detemir，0.2U/Kg,qd
89545298|NCT03180281|Placebo Comparator|SU group|SU,Glimepiride，1-2mg qd
89545299|NCT02419703||Patients receiving Targeted Radiofrequency Ablation (t-RFA)|
89545300|NCT03178175|Experimental|"acupuncture with De Qi"|all participants in this group will receive the standard procedure of acupuncture.
89545301|NCT03178175|Sham Comparator|Sham acupuncture|In this group, all participants will receive acupuncture needle insertion but not exact acupoint's location and depth.
89545302|NCT03116945|Experimental|Drug; 68Gallium Citrate|Procedure: PET/CT Imaging
89545303|NCT03117023|Experimental|dexmedetomidine group|sufentanil + dexmedetomidine
89545304|NCT03117023|No Intervention|control group|sufentanil + saline
89545305|NCT02046148|Experimental|GBS Group|Healthy pregnant women, between and including 18-40 years of age, at 24 0/7 through 34 6/7 weeks of gestation, with the intent to breastfeed, who received a single dose of Group B Streptococcus (GBS) trivalent vaccine, injected intramuscularly. (Pregnant women are referred to as maternal subjects as the study period spans from pregnancy to Day 180 postpartum).
89545306|NCT02046148|Active Comparator|Placebo Group|Healthy pregnant women, between and including 18-40 years of age, at 24 0/7 through 34 6/7 weeks of gestation, with the intent to breastfeed, who received a single dose of Placebo, injected intramuscularly. (Pregnant women are referred to as maternal subjects as the study period spans from pregnancy to Day 180 postpartum).
89545307|NCT03117101|Experimental|Dose escalation/ Dose extension of Lucitanib|"Dose escalation: Dose Level -1: 5 mg.Dose Level 1:.10 mg.Dose Level 2: 15 mg.Dose Level 3: 20 mg.~Dose extension: Once the MTD was reached, the MTD-5 mg dose level was to be extended in order to enrol up to 12 patients (number of patients was to be determined regarding safety data) to better assess the toxicity profile, PK profile and antitumor activity."
89545308|NCT03178019||Euglycemia group|Normoglycemic/normotolerant subjects
89545309|NCT03178019||Prediabetes group|Subjects with prediabetes
89545310|NCT03178019||Diabetes group|Subjects with type 2 diabetes mellitus
89545311|NCT03107585|Experimental|bilateral cervical plexus block (GP1)|arm intervention GP1 : after skin disinfection and oral premedication , ultrasound guided cervical bilateral bloc ,with10 ml of bupivacaine 0.25 was realized in each side of deep cervical space; then general anesthesia was performed with local protocol
89545312|NCT03107585|Placebo Comparator|control(GP2)|GP2 control no specific intervention only general anesthesia was performed with local protocol
89545313|NCT02097238|Experimental|Treatment (eribulin mesylate)|Patients receive eribulin mesylate IV over 2-5 minutes on days 1 and 8. Courses repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
89545314|NCT04703764|Experimental|HSG4112 480 mg|60 mg HSG4112 tablet, 8 tablets, once-daily, 14-day multiple oral administration
89545315|NCT04703764|Placebo Comparator|Placebo 480 mg|60 mg placebo tablet, 8 tablets, once-daily, 14-day multiple oral administration
89545316|NCT04703764|Experimental|HSG4112 720 mg|60 mg HSG4112 tablet, 12 tablets, once-daily, 14-day multiple oral administration
89545317|NCT04703764|Placebo Comparator|Placebo 720 mg|60 mg placebo tablet, 12 tablets, once-daily, 14-day multiple oral administration
89545318|NCT02704091|Active Comparator|Smecta|2 sachets, three times a day (TID), during 5 to 9 days
89545319|NCT02704091|Placebo Comparator|Smecta placebo|2 sachets of placebo, TID, during 5 to 9 days
89545320|NCT03179813|Experimental|Hydrocortisone group|Intraoperative topical use of hydrocortisone as a irrigation solution in third molar surgery.
89545321|NCT03179813|Placebo Comparator|Control Group|Intraoperative irrigation with saline solution.
89545322|NCT02419625|Other|subgroup-specific HEV in Israel|The study will involve patient interviews using questionnaires
89545323|NCT03179735|Experimental|Essential oils mouthwash|Essential-oils group will rinse with an alcohol-free mouthwash (twice daily use; 20 ml/30 s) containing a fixed combination of four essential oils (eucalyptol 0.092%, menthol 0.042%, methyl salicylate 0.060%, thymol 0.064%)
89545324|NCT03179735|Experimental|Cetylpyridinium mouthwash|Cetylpyridinium chloride group will rinse with an alcohol-free mouthwash (twice daily use; 20 ml/30 s) containing cetylpyridinium chloride 0.7 mg/ml
89545325|NCT03179735|Placebo Comparator|Placebos mouthwash|Placebo group will rinse with an alcohol-free placebo solution (twice daily use; 20 ml/30 s)
88961496|NCT05778058|Sham Comparator|Bilateral Sham Stimulation|"After evaluating with 7 different parameters on the first, second, third and fourth days of the protocol, the participants in all groups will be asked to do cycling exercise with maximum performance for 30 minutes under the same wattage load. Bisiklet egzersiz uygulaması sonrasında tekrar değerlendirilecektir.~It will be re-evaluated after the cycling exercise. After the assessment is complete, sham stimulation with Vagustim for 20 minutes will be given non-invasively. After vagus nerve stimulation, a re-evaluation will be made and the protocol for that day will be terminated."
88961497|NCT05778019||Case Scenarios|No personal patient information is shared. The circulated case scenarios within the network will be constructed cases from the clinical practice, to serve representatively
88961498|NCT05777954||Systemic Sclerosis patients|
88961499|NCT05777954||Healthy subjects|
88961500|NCT05777928|Experimental|Sleeve gastrectomy group|Subjects with obesity candidates for sleeve gastrectomy
89545326|NCT02419859|Experimental|PaQ® Insulin Delivery Device|The intervention is continuous subcutaneous U 100 Insulin, Asp(B28)-rapid-acting insulin, at a constant basal rate of either 20, 24, 32, 40 or 50 U per day over 3 days and and bolus insulin as needed at meals in 2 U increments.
89545327|NCT02419391|Experimental|Group 1|18-49 year old healthy subjects, receiving either 1x10E7TCID50 MVA BN RSV or Placebo
89545328|NCT02419391|Experimental|Group 2|18-49 year old healthy subjects, receiving either 1x10E8TCID50 MVA BN RSV or Placebo
89545329|NCT02419391|Experimental|Group 3|50-65 year old healthy subjects, receiving either 1x10E8TCID50 MVA BN RSV or Placebo
89545330|NCT03116867||patients receiving hysteroscopic tubal occlusion|This group will have sonosalpingography done for them one month after the tubal occlusion.
89545331|NCT03177941|Experimental|Skin Self-Examination|"Melanoma patients (n=300) and their first-degree relatives (n=300) that are between 16-70 years old will participate in the study. Participants will be randomized to receive the intervention or the control group. Participants randomized to the control group will have access to the app later.~Assigned Interventions Behavioral: Skin self-examination structure training First-degree relatives download a mobile application onto their smart phone (n=150). This is the skin self-examination training intervention used in the original RCT (MoleScore). Participants will perform a Skin Self-Examination with partner assistance each month during the study. Participants will take a picture of one of their moles using their smart phone and upload to the application one image of a mole/freckle with a decision about their mole/freckle."
89545332|NCT03177941|Active Comparator|Active Control|"Participants (n=150) will complete web-based surveys at baseline and 4-months. Control participants do not initially receive training; however, after completing the 4-month survey they will be given access to the training.~Assigned Interventions~Behavioral: Skin self-examination structured training Training will be provided via a mobile application. After completing the 4-month survey, the control participants may request the link to download the application."
89545333|NCT02423681|Active Comparator|Heated humidification as first intention (HH1st)|Subjects receive heated humidification as first intention with ThermoSmart
89545334|NCT02423681|Placebo Comparator|Non-heated humidification|Subjects will receive no humidification. However they can be switched to the humidification group if patients complains of nasal dryness, congestion, nose bleed or if they had significant leak that cannot be resolved by two changes of mask.
89545335|NCT02423369|Experimental|neonates and infants requiring surgery|neonates and infants in whom blood samples for measurement of S-100 B protein in serum and NSE protein in serum are taken pre-operatively and 1-st, 2-nd and 3-rd post-operatively. During anesthesia cerebral near infrared spectroscopy is continuously applied until the wound closure.
89545336|NCT02419157|Active Comparator|Clearfil SE Bond Etch (CSE-E)|"CSE-E (n=28): After shade selection, teeth were restored under relative isolation. Lesions were cleaned with pumice and water in a rubber cup followed by rinsing and drying. An enamel bevel of 1-2 mm was prepared with a diamond bur operated in a high-speed handpiece under air-water spray. Enamel margins were selectively etched with 36% phosphoric acid for 15s and subsequently thoroughly rinsed and air-dried. Adhesive system was applied according to manufacturers' instructions and light-cured with an LED for 10s. NCCLs were restored incrementally with a microhybrid composite resin. Increments were light cured for 20s. Afterwards, retraction cord was removed and finishing and polishing were performed with rubber points.~Selective enamel etching with 36% phosphoric acid"
89545337|NCT02419157|Active Comparator|Xeno V+ Etch (XV-E)|"XV-E (n=28): After shade selection, teeth were restored under relative isolation. Lesions were cleaned with pumice and water in a rubber cup followed by rinsing and drying. An enamel bevel of 1-2 mm was prepared with a diamond bur operated in a high-speed handpiece under air-water spray. Enamel margins were selectively etched with 36% phosphoric acid for 15s and subsequently thoroughly rinsed and air-dried. Adhesive system was applied according to manufacturers' instructions and light-cured with an LED for 10s. NCCLs were restored incrementally with a microhybrid composite resin. Increments were light cured for 20s. Afterwards, retraction cord was removed and finishing and polishing were performed with rubber points.~Selective enamel etching with 36% phosphoric acid"
89545338|NCT02419157|Active Comparator|Clearfil SE Bon Non-etch (CSE-NE)|"CSE-NE (n=28): After shade selection, teeth were restored under relative isolation. Lesions were cleaned with pumice and water in a rubber cup followed by rinsing and drying. An enamel bevel of 1-2 mm was prepared with a diamond bur operated in a high-speed handpiece under air-water spray. Adhesive system was applied according to manufacturers' instructions and light-cured with an LED for 10s. NCCLs were restored incrementally with a microhybrid composite resin. Increments were light cured for 20s. Afterwards, retraction cord was removed and finishing and polishing were performed with rubber points.~No selective enamel etching with 36% phosphoric acid"
88961501|NCT05777928|Experimental|OverStitch™ Endoscopic Suturing System group|Subjects candidates for a revision bariatric surgery with Overstitch endoscopic
88961502|NCT05777902|Experimental|Patient|
89032970|NCT00529412|No Intervention|control|no Seprafilm
89545339|NCT02419157|Active Comparator|Xeno V+ Non-etch (XV-NE)|"XV-NE (n=28): After shade selection, teeth were restored under relative isolation. Lesions were cleaned with pumice and water in a rubber cup followed by rinsing and drying. An enamel bevel of 1-2 mm was prepared with a diamond bur operated in a high-speed handpiece under air-water spray. Adhesive system was applied according to manufacturers' instructions and light-cured with an LED for 10s. NCCLs were restored incrementally with a microhybrid composite resin. Increments were light cured for 20s. Afterwards, retraction cord was removed and finishing and polishing were performed with rubber points.~No selective enamel etching with 36% phosphoric acid"
89545340|NCT02419235|Placebo Comparator|20% Ethanol|Ten drops of unmedicated 20% ethanol must be administered under the tongue, three times per day, thirty minutes before or after meals, for six weeks.
89545341|NCT02419235|Experimental|Homoeopathic complex|Ten drops of 20% ethanol medicated with Amylenum nitrosum 6cH, Crataegus oxyacantha 6cH, Natrum muriaticum 6cH and Scutellaria lateriflora 6cH will be administered under the tongue, three times per day, thirty minutes before or after meals, for six weeks.
89545342|NCT02423135|Experimental|Blood bags without DEHP|Intervention : Autologous blood transfusion
89545343|NCT02423135|Experimental|Blood bags with DEHP|Intervention : Autologous blood transfusion
89545344|NCT02422901||Vit C deficiency in acute diseases|Patients with vitamin C deficiency due to a acute underlying disease treated with Pascorbin® 7.5 g
89545345|NCT02422901||Vit C deficiency in chronic diseases|Patients with vitamin C deficiency due to a chronic underlying disease treated with Pascorbin® 7.5 g
89545346|NCT02418767|Experimental|Low dose|7 Japanese and 7 Caucasian subjects (randomized 6:1) administered a single dose of MOD-4023/Placebo
89545347|NCT02418767|Experimental|Mid dose|7 Japanese and 7 Caucasian subjects (randomized 6:1) administered a single dose of MOD-4023/Placebo
89545348|NCT02418767|Experimental|High dose|7 Japanese and 7 Caucasian subjects (randomized 6:1) administered a single dose of MOD-4023/Placebo
89545349|NCT02422823|Experimental|injection of 1.8mL|injections of 1.8 mL of 4% articaine with 1:100,000 epinephrine Intervention: inferior alveolar nerve block injection
89545350|NCT02422823|Experimental|injection of 3.6mL|injections of 3.6 mL of 4% articaine with 1:100,000 epinephrine Intervention: inferior alveolar nerve block injection
89545351|NCT04440683||Antler plate group|Antler plate group
89545352|NCT03179501|Experimental|NP001|NP001
89545353|NCT03179501|Placebo Comparator|Placebo|Normal saline
89545354|NCT03179423|Experimental|GNbAC1|Monthly IV repeated dose
89545355|NCT03179423|Placebo Comparator|Placebo|Monthly IV repeated dose
89545356|NCT03179579|Experimental|Experimental group|"HIPEC with paclitaxel 135 mg/m^2+HIPEC with cisplatin 75 mg/m^2±HIPEC with Raltitrexed 3 mg/m^2 intraperitoneally in succession~2 cycles of neoadjuvant chemotherapy: S-1 40-60 mg/m^2, d1-d14, Bid p.o.+ oxaliplatin 130 mg/m^2, d1, IV, every 3 weeks~Cytoreductive surgery~HIPEC with paclitaxel 135 mg/m^2+HIPEC with cisplatin 75 mg/m^2±HIPEC with Raltitrexed 3 mg/m^2 intraperitoneally in succession~4-6 cycles of adjuvant chemotherapy: S-1 40-60 mg/m^2, d1-d14, Bid p.o.+ oxaliplatin 130 mg/m^2, d1, IV, every 3 weeks"
89545357|NCT03179579|Active Comparator|Control group|"3 cycles of neoadjuvant chemotherapy: S-1 40-60 mg/m^2, d1-d14, Bid p.o.+ oxaliplatin 130 mg/m^2, d1, IV, every 3 weeks~Cytoreductive surgery~4-6 cycles of adjuvant chemotherapy: S-1 40-60 mg/m^2, d1-d14, Bid p.o.+ oxaliplatin 130 mg/m^2, d1, IV, every 3 weeks"
89545358|NCT02422589|Experimental|Ceritinib|
89545359|NCT02422199|Experimental|pyrotinib plus capecitabine|pyrotinib(400 mg once daily) + capecitabine (2000 mg/m^2 daily, 1000 mg/m^2 BID)
89545360|NCT02422199|Active Comparator|lapatinib plus capecitabine|lapatinib (1250 mg once daily) + capecitabine (2000 mg/m^2 daily, 1000 mg/m^2 BID)
89545361|NCT02421965|Experimental|FOCUS (Smartphone Application)|FOCUS is a smartphone application system designed to improve illness self-management and facilitate recovery in individuals with serious mental illness. It delivers both system initiated (i.e. pre-programmed) and patient initiated (i.e. on demand) real-time assessment to individuals in their own environment.
89545362|NCT02421965|Active Comparator|WRAP (Wellness Recovery Action Planning)|WRAP is a clinic-based intervention designed to improve illness self-management and facilitate recovery in individuals with serious mental illness. It is conducted in group sessions that are delivered by trained facilitators with lived experience, using lecture, group discussion, and exercises.
89545363|NCT02421653|Experimental|MNP90 + INERT OIL|Daily micronutrient powders (14 micronutrients) containing 90 µg iodine as potassium iodate plus one inert oil capsule without iodine at the study start;
89545364|NCT02421653|Experimental|MNP45 + INERT OIL|Daily micronutrient powders (14 micronutrients) containing 45 µg iodine as potassium iodate plus one inert oil capsule without iodine at the study start;
89545365|NCT02421653|Experimental|IODISED OIL + INERT MNP|Daily inert powder (maltodextrin, no micronutrients) plus one oral dose of 200 mg iodine as iodised poppy seed oil at the study start
89545366|NCT02421653|Active Comparator|NON-IODISED MNP + INERT OIL|Daily micronutrient powders (14 micronutrients) without iodine plus one inert oil capsule without iodine at the study start.
89545367|NCT02421809||NCWS patients|Consecutive adult patients with an irritable bowel syndrome (IBS)-like clinical presentation, according to Rome II criteria, and a definitive diagnosis of NCWS.
89545368|NCT02421809||CD patients|Sex- and age-matched subjects with CD, diagnosed according to standard criteria during the same study period and enrolled as first control group.
89545369|NCT02421809||IBS patients|Sex- and age-matched subjects with IBS unrelated to NCWS or other food 'intolerance', diagnosed according to standard criteria during the same study period and enrolled as second control group.
89545370|NCT02416739|Experimental|Nicotinamide|"Nicotinamide with EGFR-TKI:~gefitinib (250mg tab) or erlotinib (150mg tab) - per oral, once a day~nicotinamide (500mg tab) - per oral, twice a day, until the event or censoring occurs"
89032971|NCT00529412|Active Comparator|Seprafilm|
89545371|NCT02416739|Placebo Comparator|Placebo|"Placebo tablet with EGFR-TKI:~gefitinib (250mg tab) or erlotinib (150mg tab) - per oral, once a day~placebo tablet - per oral, twice a day, until the event or censoring occurs"
89545372|NCT02416583|Active Comparator|Oxytocin & Membrane sweeping|"Women assigned to Concurrent oxytocin with membrane sweeping had their cervix swept by inserting the examining finger as high as possible past the internal cervical os, followed by oxytocin infusion the next day"
89032972|NCT00529490|Experimental|HL|Hypertonic lactate group
89545373|NCT02416583|Active Comparator|Oxytocin & Dinoprostone|"For women assigned to Concurrent oxytocin with dinoprostone vaginal insert: The 10mg dinoprostone vaginal insert were placed in the posterior fornix for cervical ripening, followed by oxytocin infusion the next day"
89545374|NCT02416427|Experimental|Arm A|Atorvastatin 80 mg/day for 3 weeks
89545375|NCT02416427|No Intervention|Arm B|Observation
89545376|NCT02416349|Active Comparator|Respiratory Muscles Stretching|Respiratory Muscles Stretching Neck stretching, upper chest stretching, pectoralis major stretching and lateral chest stretching.
89545377|NCT02416349|Placebo Comparator|Control Group|All volunteers will be positioned at rest in a comfortable in a chair during 20 minutes.
89545378|NCT02416271|Experimental|Teriparatide|20 micrograms per day teriparatide subcutaneous (SC) injection plus oral placebo for 18 months.
89545379|NCT02416271|Active Comparator|Alendronate|10 milligrams/day alendronate orally plus SC injection placebo for 18 months.
89545380|NCT02702609|Experimental|Moldable beta-TCP grafting system|Device: easy-graft CLASSIC (beta-Tricalcium Phosphate)
89545381|NCT02702609|Active Comparator|Allograft|Device: Freeze-Dried Bone Allograft (FDBA) with collagen plug
89545382|NCT02416505|No Intervention|Verbal Discussion: Control Group|"In this group, participants will receive a 10 minute Verbal Only Knee Osteoarthritis Steroid Injection Informed Consent discussion.~This discussion will cover the relevant topics of Knee OA causes, relevant anatomy, symptoms, diagnosis, and treatment options. This discussion will also include the risks, benefits, and alternatives to a steroid injection."
89545383|NCT02416505|Active Comparator|Verbal+Anatomic Model|"This intervention group will receive a 10 minute Knee Osteoarthritis Steroid Injection Informed Consent discussion with the aid of a Knee Model.~This discussion will cover the relevant topics of Knee OA causes, relevant anatomy, symptoms, diagnosis, and treatment options. This discussion will also include the risks, benefits, and alternatives to a steroid injection."
89545384|NCT02416505|Active Comparator|Verbal+Video Presentation|"This intervention group will receive a 10 minute Knee Osteoarthritis Steroid Injection Informed Consent discussion with the aid of a Video.~This discussion will cover the relevant topics of Knee OA causes, relevant anatomy, symptoms, diagnosis, and treatment options. This discussion will also include the risks, benefits, and alternatives to a steroid injection."
89545385|NCT02416115|Active Comparator|R group|Thirty minutes before end of surgery, patients in R group (n=30) received 0.3 mg ramosetron. In the post anesthetic care unit, patients in R group received PCA morphine 1 mg/ml
89545386|NCT02416115|Active Comparator|N group|Thirty minutes before end of surgery, patients in N group (n=30) received normal saline. In the post anesthetic care unit, group N received PCA mixture of naloxone 1μg/ml and morphine 1 mg/ml.
89545387|NCT02416115|Experimental|RN group|Thirty minutes before end of surgery, patients in Ramosetron and naloxone (RN) group (n=30) received 0.3 mg ramosetron. In the post anesthetic care unit, group RN received PCA mixture of naloxone 1μg/ml and morphine 1 mg/ml.
89545388|NCT02416037|Experimental|Prone Proseva|
89545389|NCT02416037|Active Comparator|Prone Talmor|
89032973|NCT00529490|Active Comparator|RL|Ringer's lactate
89032974|NCT02923089|Experimental|Small Green Lentil Muffin|Muffin: 25g available carbohydrate from small green lentil
89032975|NCT02923089|Experimental|Split Red Lentil Muffin|Muffin: 25g available carbohydrate from split red lentil
89545390|NCT02415881|Experimental|Panitumumab IRDye 800|Patients will receive Panitumumab IRDye800 prior to their scheduled surgery.
89545391|NCT02415803|Experimental|low-dose ticagrelor|To observe the safety and efficacy of low-dose ticagrelor in Chinese patients with non-ST-elevation acute coronary syndrome
89545392|NCT02415803|Active Comparator|conventional-dose ticagrelor|To observe the different safety and efficacy between low-dose ticagrelor and conventional-dose ticagrelor.
89545393|NCT02415803|Active Comparator|clopidogrel|To observe the different safety and efficacy between low-dose ticagrelor and conventional-dose clopidogrel.
89545394|NCT02415725|Experimental|lymphofluoroscopy|Indocyanine Green intradermal injection before surgery, and after 3, 6 and 12 monthes
89545395|NCT04482881|Active Comparator|women receiving isosorbide mononitrates lower dose|women who will receive isosorbide mononitrates lower dose
89545396|NCT04482881|Active Comparator|women receiving isosorbide mononitrates higher dose|women who will receive isosorbide mononitrates higher dose
89545397|NCT04482881|Active Comparator|Women receiving misoprostol|Women who will receive misoprostol
89545398|NCT02415647||Child Proband with Psychiatric Disorder|Affected group of child probands with psychiatric disorders (ages 6-12 years).
89545399|NCT02415647||Normal Comparison Group|Non-disordered psychiatrically normal comparison group (ages 6-12 years).
89545400|NCT02415569|Experimental|group1|Subjects whose bristol stool forms are type 1 or 2, will receive standard bowel prep (2L PEG-ELP) the same-day of procedure.
89545401|NCT02415569|Experimental|group2|Subjects whose bristol stool forms are type 1 or 2, will be asked to take standard bowel prep (2L PEG-ELP) the same-day of procedure and 10mg bisacodyl the day before procedure. ( 2L PEG-ELP and 10mg bisacodyl )
89545402|NCT02415569|Active Comparator|group3|Subjects whose bristol stool forms are type 3 to 7, will receive standard bowel prep (2L PEG-ELP) the same-day of procedure.
89545403|NCT02415491|Experimental|ASO group|ASO group:Evaluation of Correlation of Heart Magnetic Resonance Imaging at rest and stress with Cardiopulmonary stress test for long term assessment after ASO and recommendation of physical activity of young adults after TGA
89545404|NCT02415335|Placebo Comparator|Placebo|Injection of 2 ml isotonic NaCl intravenously minimum 30 minutes preoperative.
89545405|NCT02415335|Experimental|dexamethasone|Injection of 2 ml 4 mg/ml dexamethasone phosphate intravenously minimum 30 minutes preoperative.
89545406|NCT02415257|Experimental|Gentamicin treated|"Installation of gentamicin in the middle ear 6 weeks prior to surgery + rehabilitation exercises before and after both treatment and surgery.~Rehabilitation exercises are not considered to be an intervention since their benign impact on vestibular/postural compensation is well documented and exclusion from exercises would not be approved by the ethical board"
89545407|NCT02415257|No Intervention|Non-gentamicin|Rehabilitation exercises before and after both treatment and surgery Rehabilitation exercises are not considered to be an intervention since their benign impact on vestibular/postural compensation is well documented and exclusion from exercises would not be approved by the ethical board
89545408|NCT02415179|Experimental|Inhaled Mometasone/formoterol|Inhaled Mometasone/Formoterol (100/5 microgram) 2 puffs twice daily delivered by using metered dose inhaler for 6 weeks
89545409|NCT02415179|Active Comparator|Inhaled Fluticasone/Salmeterol|Inhaled Fluticasone/Salmeterol (125/25 microgram) 2 puffs twice daily delivered by using metered dose inhaler for 6 weeks
89545410|NCT02415101|Active Comparator|Resective surgery after 4-6 weeks|Resective surgery 4-6 weeks after completed chemoradiotherapy (CRT)
89545411|NCT02415101|Active Comparator|Resective surgery after 10-12 weeks|Resective surgery 10-12 weeks after completed chemoradiotherapy (CRT)
89545412|NCT02415023|Experimental|fruquintinib+paclitaxel|fruquintinib combined with paclitaxel. Fruquintinib treatment: administration for 3 weeks followed by 1-week break, and administration every day for the first 21 days.Paclitaxel is administered once weekly in the first three weeks of each cycle.
89545413|NCT02414945|Experimental|Tumor Infiltrating lymphocytes (TILs)|"Lymphodepleting preparative regimen: Cyclophosphamide, intravenously, at 60mg/kg/day x 2 days, and Fludarabine, intravenously at 25mg/m2/day x 5 days~Autologous tumor infiltrating lymphocytes (TILs): Intravenously at 1x10^10 - 1.6x10^11 cells~Low-dose interleukin-2: Subcutaneously at 125,000 IU/kg per day, for 2 weeks (2 days rest between each week)."
89545414|NCT02414555|Active Comparator|NaCl 0.9% BBraun (normale saline)|154mmol/l sodium, 154mmol/l chloride
89545415|NCT02414555|Active Comparator|Elo-Mel Isoton (balanced acetat-based infusate)|sodium 140mmol/l, potassium 5.0mmol/l, calcium 2.5mmol/l, magnesium 1.5mmol/l, chlorid 108mmol/l, acetate 45mmol/l
89545416|NCT02414711|Other|No depressed|"If the result of the HSCL25 scale is inferior than 1.75, then the patient is considered as no depressed.~50 of these patients have to have a psychological interview with the PSE9 questionary to validate the result of the HSCL25 scale."
89545417|NCT02414711|Other|Depressed|"If the result of the HSCL25 scale is superior or equal to 1.75, then the patient is considered as depressed.~50 of these patients have to have a psychological interview with the PSE9 questionary to validate the result of the HSCL25 scale."
89545418|NCT02414087|Active Comparator|study group|ICB Medical Insoles
89545419|NCT02414087|Placebo Comparator|control group|without ICB Medical insoles
89545420|NCT02046070|Experimental|Ixazomib 4.0 mg + CYC 300 mg/m^2 + DEX 40 mg (NDMM)|Ixazomib 4.0 mg, capsules, orally, on Days 1, 8, 15 of a 28-day cycle until progressive disease (PD)/death or unacceptable toxicity [13 cycles in the Induction Phase continuing in the Maintenance Phase for up to 36 Months] and cyclophosphamide (CYC) 300 mg/m^2, tablets, orally, on Days 1, 8 and 15 of a 28-day cycle for 13 cycles or until PD/death or unacceptable toxicity and dexamethasone (DEX) 40 mg, tablets, orally, on Days 1, 8, 15 and 22 (dose reduced to 20 mg for patients >75 years) of a 28-day cycle for 13 cycles or until PD/death or unacceptable toxicity in participants with NDMM.
89545421|NCT02046070|Experimental|Ixazomib 4.0 mg + CYC 400 mg/m^2 + DEX 40 mg (NDMM)|Ixazomib 4.0 mg, capsules, orally, on Days 1, 8, 15 of a 28-day cycle until PD/death or unacceptable toxicity [13 cycles in the Induction Phase continuing in the Maintenance Phase for up to 36 Months] and cyclophosphamide (CYC) 400 mg/m^2, tablets, orally, on Days 1, 8 and 15 of a 28-day cycle for 13 cycles or until PD/death or unacceptable toxicity and dexamethasone (DEX) 40 mg, tablets, orally, on Days 1, 8, 15 and 22 (dose reduced to 20 mg for patients >75 years) of a 28-day cycle for 13 cycles or until PD/death or unacceptable toxicity in participants with NDMM.
89545422|NCT02046070|Experimental|Ixazomib 4.0 mg + CYC 300 mg/m^2 + DEX 40 mg (RRMM)|Ixazomib 4.0 mg, capsules, orally, on Days 1, 8, 15 of a 28-day cycle and cyclophosphamide 300 mg/m^2, tablets, orally, on Days 1, 8 and 15 of a 28-day cycle and dexamethasone (DEX) 40 mg, tablets, orally, on Days 1, 8, 15 and 22 (dose reduced to 20 mg for patients >75 years) of a 28-day cycle until PD/death or unacceptable toxicity in participants with RRMM.
89545423|NCT04483037|Active Comparator|split dose, day before, colonoscopy in the morning (Observation Group)|routine bowel preparation before colonoscopy in the morning
89545424|NCT04483037|Active Comparator|split dose, day before, colonoscopy in the afternoon (Random)|routine bowel preparation before colonoscopy in the afternoon
88811997|NCT01395329|Active Comparator|Nebivolol|Systolic and Diastolic blood pressure will be measured before and after randomization to12 weeks of Nebivolol. Forearm blood flow will be measured in response to 100 nmol/min of BQ-123, BQ-123+BQ788 (50 mol/min), Acetylcholine (4.0, 8.0, 16.0 ug/100 mL tissue/min), Sodium Nitroprusside (1.0, 2.0, 4.0 ug/100 mL tissue/min) and BQ-123+BQ-788+Acetylcholine (same doses as above) will be measured before and after the 12 weeks of nebivolol.
89545425|NCT04483037|Experimental|two dose in the same day, colonoscopy in the afternoon (Random)|experimental group
89545426|NCT01663857|Experimental|Phase 1b (Cohort 1) LY2228820 200 milligrams (mg)|"Cohort 1: Cycles 1-6 (21 day cycles)- LY2228820 200 mg administered orally every 12 hours on days 1-10. Gemcitabine 1000 milligrams per square meter (mg/m^2) administered intravenously (IV) over 30 minutes on days 3 and 10. Carboplatin dose Area Under Curve (AUC) 4 (maximum dose 600 mg) administered IV over 30 minutes on day 3..~Cohort 1: Cycles 7+ (28 day cycles)- LY2228820 300 mg administered orally every 12 hours on days 1-14."
89545427|NCT01663857|Experimental|Phase 1b (Cohort 2) LY2228820 300 mg|"Cohort 2: Cycles 1-6 (21 day cycles)- LY2228820 300 mg administered orally every 12 hours on days 1-10. Gemcitabine 1000 mg/m^2 administered IV over 30 minutes on days 3 and 10. Carboplatin dose Area Under Curve (AUC) 4 (maximum dose 600 mg) administered IV over 30 minutes on day 3.~Cohort 2: Cycles 7+ (28 day cycles)- LY2228820 300 mg administered orally every 12 hours on days 1-14."
89032976|NCT02923089|Placebo Comparator|Wheat Muffin|Muffin: 25g available carbohydrate from wheat
89545428|NCT01663857|Experimental|Phase 2 (Arm A) LY2228820 200 mg|"Arm A: Cycles 1-6 (21 day cycles)- LY2228820 200 mg administered orally every 12 hours on days 1-10. Gemcitabine 1000 mg/m^2 administered IV over 30 minutes on days 3 and 10. Carboplatin dose Area Under Curve (AUC) 4 (maximum dose 600 mg) administered IV over 30 minutes on day 3.~Arm A: Cycles 7+ (28 day cycles)- LY2228820 300 mg administered orally every 12 hours on days 1-14."
89545429|NCT01663857|Placebo Comparator|Phase 2 (Arm B) Placebo|"Arm B: Cycles 1-6 (21 day cycles)- Placebo administered orally every 12 hours on days 1-10. Gemcitabine 1000 mg/m^2 administered IV over 30 minutes on days 3 and 10. Carboplatin dose Area Under Curve (AUC) 4 (maximum dose 600 mg) administered IV over 30 minutes on day 3.~Arm B: Cycle 7+ (28 day cycles)- Placebo administered orally on days 1-14 to maintain blind."
89545430|NCT02414165|Experimental|Toca 511/Toca FC|"Resection followed by administration of 4 mL Toca 511 (vocimagene amiretrorepvec). Toca 511 is administered by injection into the wall of the subject's tumor resection cavity on Day 1 (approximately 40 injections of 0.1 mL)~Toca FC is an extended-release formulation of flucytosine. Toca FC will be administered at 220 mg/kg/day orally for 7-day courses beginning at least 6 weeks after resection and repeated approximately every 6 weeks."
89545431|NCT02414165|Active Comparator|Lomustine, Temozolomide, or Bevacizumab|"Investigator selects one of the following:~Bevacizumab: Beginning 6 weeks after tumor resection, bevacizumab will be administered by IV infusion at 10 mg/kg and repeated every 2 weeks. Refer to the prescribing information and to institutional guidelines for details on the administration procedure.~Lomustine: Beginning 6 weeks after tumor resection, lomustine will be administered as a single oral dose of 110 mg/m2 and repeated every 6 weeks. Refer to the prescribing information and to institutional guidelines for details regarding the administration procedure.~Temozolomide: Beginning 6 weeks after tumor resection, temozolomide will be administered per 1 of 2 options:~at a dose of 50 mg/m2 PO once daily continuously, or~at an initial dose of 150 mg/m2 IV or PO once daily for 5 consecutive days per 28-day treatment cycle that may be raised to 200 mg/ m2 once daily for 5 consecutive days in the following 28-day treatment cycles"
89545432|NCT02094898|Experimental|Ketamine infusion|This trial was conducted in 2 phases. During the acute-phase, i.v. ketamine was administered thrice-weekly for up to 2 weeks.Those who achieved depressive symptom remission received continuation-phase treatment that consisted of once-weekly i.v. ketamine infusions for 4 additional weeks. Remission could occur after any of the 6 acute-phase infusions, at which point the next infusion was the first (of four) continuation-phase infusions. Individuals who remitted during acute-phase and completed continuation-phase treatment had 4 additional weekly post-continuation follow-up visits.
89545433|NCT02414009|Experimental|CAPTEM|Patients in Arm A will receive capecitabine at the oral dose of 1500 mg/mq/die bid from day 1 to day 14 every 28 days plus temozolomide 150 mg/mq/die bid starting on day 10 to 14 every 28 days. Treatment will continue for up to 6 cycles or up to disease progression, unacceptable toxicity or informed consent withdrawal.
89545434|NCT02414009|Active Comparator|FOLFIRI|"Patients in Arm B will receive FOLFIRI chemotherapy starting Day~1 q2w (every cycle) starting on Day 1 of Cycle 1. FOLFIRI consists of irinotecan (starting dose of 180 mg/m2) on day one only; 5-FU 7 (starting bolus and 22-hour infusional doses of 400 mg/m2 and 600 mg/m2, respectively), and leucovorin (racemic, starting dose of 200 mg/m2 or L-form, starting dose of 100 mg/m2) for two consecutive days. Treatment will continue for up to 12 cycles in Arm B or up to disease progression, unacceptable toxicity or informed consent withdrawal."
89545435|NCT02413697|Active Comparator|Two-dimensional ultrasound|Two-dimensional ultrasound guided embryo transfer
89545436|NCT02413697|Experimental|Three-dimensional ultrasound|Three-dimensional ultrasound guided embryo transfer
89545437|NCT02413853|Experimental|Arm I (PRI-724, mFOLFOX6/bevacizumab)|Patients receive CBP/beta-catenin antagonist PRI-724 IV continuously on days 1-7, bevacizumab IV over 30 minutes, leucovorin calcium IV over 2 hours, oxaliplatin IV over 2 hours, and fluorouracil IV over 46 hours on day 8. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
89545438|NCT02413853|Experimental|Arm II (mFOLFOX6/bevacizumab)|Patients receive bevacizumab, leucovorin calcium, oxaliplatin, and fluorouracil as in Arm I. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
89545439|NCT05515965|Experimental|Kinesiotape|The patients in the Kinesiotape group were taped with the mechanical correction method.
89545440|NCT05515965|Sham Comparator|Control|In the patients in the Control group were taped with tensionless gluing of the I tape.
89545441|NCT02413931||Patients with MDR-TB|Patients with multidrug-resistant tuberculosis admitted for treatment at the Marius Nasta Institute will be included
89545442|NCT04598295|Experimental|microbial consortia (DS-01)|DS-01 is a rationally defined microbial consortia consisting of 24 strains across 12 species, with polyphenolic and phenolic prebiotic bioactive compounds. Participants will be instructed to take 2 capsules daily for the duration of the trial.
89545443|NCT04598295|Placebo Comparator|placebo|Placebo capsules for DS-01 will contain rice flour matched for color and texture in an identical outer capsule shell. Participants will be instructed to take 2 capsules daily for the duration of the trial.
89545444|NCT02413619|Active Comparator|Start cataract|Patients start having cataract surgery. After one month they undergo vitrectomy
89545445|NCT02413619|Active Comparator|start vitrectomy|Patients start having vitrectomy. After one month they undergo cataract surgery.
89545446|NCT02413619|Active Comparator|combined surgery|Combined cataract surgery and vitrectomy at the same time
89032977|NCT02923089|Experimental|Small Green Lentil Soup|Soup: 25g available carbohydrate from small green lentil
89545447|NCT00704483|Experimental|1|1g tid
89545448|NCT00704483|Active Comparator|2|Sevelamer HCl
89545449|NCT00704483|Experimental|3|SBR759 1.5 g tid
89545450|NCT00704483|Active Comparator|4|Sevelamer HCl
89545451|NCT04596189|Experimental|Dupilumab|Sterile Dupilumab 150 mg/mL will be provided in pre-filled syringes (2.25 total volume) to deliver 300 mg in 2 mL.
89545452|NCT04596189|Placebo Comparator|Placebo|Sterile placebo for Dupilumab will be provided in identically matching pre-filled syringes to deliver 2 mL.
89545453|NCT03176537|Placebo Comparator|Placebo|Gel, daily
89545454|NCT03176537|Experimental|TRT|Testosterone Replacement Therapy
89545455|NCT05511441|Experimental|Surgery Without Aspirin Withdraw|Routine Minimally Invasive Thoracic Surgery Without Aspirin Withdraw
89545456|NCT03176147||Pregnant women|Pregnant women are included during the ultrasound of T1. Written consent will be sought after delivery of the information notice.
89545457|NCT05515809|Experimental|interventional arm|the experimental arm will receive the parasternal block with injection of locoregional anesthesia
89545458|NCT05515809|Active Comparator|control arm not requiring loco-regional anesthesia.|the control arm will receive a standard treatment, without locoregional anesthesia
89545459|NCT02413307|Experimental|Intervention Group|Self-practice compassion focused therapy intervention following written or audio scripts. This includes instructions, an explanation of compassion and aims of the intervention. It includes several exercises designed to increase self-compassion including breathing exercises and compassionate imagery exercises focused on self and others
89545460|NCT02413307|No Intervention|Waiting List Control|Participants on the waiting list for trauma specific therapy. These will be participants who have consented to engaging in the research project but their intervention phase has a delayed start.
89545461|NCT05515731|Experimental|Autologous platelet-rich plasma eye drops|Autologous platelet-rich plasma eye drops are derived from treatment of patients plasma using special process.
89545462|NCT02413385|Experimental|HealtheSteps Program|6 month evidence-based lifestyle Rx program: receive lifestyle Rx's for exercise, physical activity (step counts) and healthy eating and set goals around Rx's (in person sessions at set time points during 6-month period); take part in self-directed healthy living activities to achieve Rx's (Months 0-6); access to a suite of health technology support options for additional support and coaching (Months 0-6).
89545463|NCT02413385|No Intervention|Usual-care wait-list control|No active intervention (usual care).
89545464|NCT02413541|Experimental|High EAA and use Polymyxin-B Hemoperfusion|EAA level > 0.6 or EAA = 0.6 and use Polymyxin-B Hemoperfusion
89545465|NCT02413541|Experimental|High EAA and not use Polymyxin-B Hemoperfusion|EAA level > 0.6 or EAA = 0.6 and not use Polymyxin-B Hemoperfusion
89545466|NCT02413541|Active Comparator|Low EAA|EAA level < 0.6 and not use Polymyxin-B Hemoperfusion
89545467|NCT02412995|Experimental|Meal sequence 1-2-3|The three meals, sea buckthorn puree, strawberry puree, or placebo (sugar drink) were allocated a number (1-3) in a blinded fashion and given to the participants in the order 1-2-3
89545468|NCT02412995|Experimental|Meal sequence 1-3-2|The three meals, sea buckthorn puree, strawberry puree, or placebo (sugar drink) were allocated a number (1-3) in a blinded fashion and given to the participants in the order 1-3-2
89545469|NCT02412995|Experimental|Meal sequence 2-3-1|The three meals, sea buckthorn puree, strawberry puree, or placebo (sugar drink) were allocated a number (1-3) in a blinded fashion and given to the participants in the order 2-3-1
89545470|NCT02412995|Experimental|Meal sequence 2-1-3|The three meals, sea buckthorn puree, strawberry puree, or placebo (sugar drink) were allocated a number (1-3) in a blinded fashion and given to the participants in the order 2-1-3
89032978|NCT02923089|Experimental|Split Red Lentil Soup|Soup: 25g available carbohydrate from split red lentil
89545471|NCT02412995|Experimental|Meal sequence 3-1-2|The three meals, sea buckthorn puree, strawberry puree, or placebo (sugar drink) were allocated a number (1-3) in a blinded fashion and given to the participants in the order 3-1-2
89545472|NCT02412995|Experimental|Meal sequence 3-2-1|The three meals, sea buckthorn puree, strawberry puree, or placebo (sugar drink) were allocated a number (1-3) in a blinded fashion and given to the participants in the order 3-2-1
89545473|NCT03176069|Active Comparator|Group A - women diagnosed with vaginismus|"All patients will be submitted to anamnesis, physical examination, examination of the pelvic floor. The algometry will be performed with patient will be lying in a supine position (belly up), with the pelvis in a neutral position, back at 45º and feet supported in stirrups, for the verification the perineal pain threshold.~The available treatment tools are educational, behavioral and rehabilitating. The physiotherapeutic treatment will consist of the following features:~Kinesiotherapy Manual therapy Electrotherapy (electric electrostimulation, ultrasound) Behavioral therapy"
89545474|NCT03176069|Active Comparator|Group B - women without a diagnosis of vaginismus|All patients will be submitted to anamnesis, physical examination, examination of the pelvic floor. The algometry will be performed with patient will be lying in a supine position (belly up), with the pelvis in a neutral position, back at 45º and feet supported in stirrups, for the verification the perineal pain threshold.
89545475|NCT02045836|Experimental|Co-Ad Group|Subjects received one dose of the GSK1437173A study vaccine and one dose of the Pneumovax™ 23 vaccine at Day 0 and a second dose of GSK1437173A study vaccine at Month 2. GSK1437173A vaccine was administered intramuscularly, in the deltoid region of the non-dominant arm. Pneumovax™ 23 was administered intramuscularly, in the deltoid region of the dominant arm.
89545476|NCT02045836|Active Comparator|Control Group|Subjects received one dose of the Pneumovax™ 23 vaccine at Day 0, one dose of the GSK1437173A study vaccine at Month 2 and a second dose of the GSK1437173A study vaccine at Month 4. GSK1437173A vaccine was administered intramuscularly, in the deltoid region of the non-dominant arm. Pneumovax™ 23 was administered intramuscularly, in the deltoid region of the dominant arm.
89545477|NCT02413073|Sham Comparator|Sham of Whole Body Vibration|This group will receive placebo treatment on the platform we'll use a little engine that will produce a very small vibration stimulus in the platform.
89545478|NCT02413073|Experimental|Whole body vibration Group|This group will be a training na vibratory platform with 12 weeks (3 months), held twice a week on alternate days
89545479|NCT02412917|Experimental|FV-100 400 mg QD|FV-100 400mg QD
89032979|NCT02923089|Placebo Comparator|Potato Soup|Soup: 25g available carbohydrate from potato
89032980|NCT02923089|Experimental|Small Green Lentil Chili|Chili: 25g available carbohydrate from small green lentil
89545480|NCT02412917|Experimental|FV-100 400mg BID|FV-100 400mg BID(total daily dose of 800mg)
89545481|NCT02412917|Active Comparator|valacyclovir|valacyclovir 1000mg TID
89545482|NCT02412839||Group 20-39|Patients aged from 20 to 39 years old. 30 males and 30 females.
89545483|NCT02412839||Group 40-59|Patients aged from 40 to 59 years old. 30 males and 30 females.
89545484|NCT02412839||Group 60-79|Patients aged from 60 to 79 years old. 15 males and 15 females.
89545485|NCT02412605||Fertile embryo biopsy|Fertile couples requesting sex selection for family balancing
89545486|NCT02412605||Infertile embryo biopsy|Infertile women having embryo biopsy
89545487|NCT02412605||IVF/ICSI|Infertile women undergoing IVF/ICSI without embryo biopsy
89545488|NCT02412527||Primary insomnia|Primary insomnia patients, without combined any other sleep disorders
89545489|NCT02412527||Periodic limb movement in sleep|Patients have periodic limb movement in sleep, without combined any other sleep disorders
89545490|NCT02412527||Simple snores|Simple snore patients, without combined any other sleep disorders
89545491|NCT02412527||Obstructive sleep apnea|Obstructive sleep apnea patients, including mild, moderate and severe types, without combined any other sleep disorders or CPAP treatment during PSG study
89545492|NCT04482101|Experimental|Ah-Plus sealer|"Root canal sealer which is a resin-based formula with excellent radiopacity , low shrinkage , low solubility and outstanding flow characteristics .~It features a 1:1 , paste-to-paste mixing system for fast , easy preparation and less waste . It is biocompatible and silver free ."
89545493|NCT04482101|Experimental|Endosequence BC sealer|"It is a root canal sealer which is premixed ready-to-use injectable bioceramic cement paste developed for permanent root canal filling and sealing applications.~It is insoluble , radiopaque and aluminum-free material based on calcium silicate composition , which requires the presence of water to set and hardens . It does not shrink during setting and demonstrate excellent physical properties ."
89545494|NCT02569437|Experimental|Doxycycline|Doxycycline plus oral methylprednisolone and nasal saline sprays
89545495|NCT02569437|Placebo Comparator|Sugar pill|placebo pill plus oral methylprednisolone for three weeks. After this, maintenance therapy which includes nasal saline sprays and daily nasal steroid sprays.
89545496|NCT02412449|Experimental|Treatment A|AKB-6548
89545497|NCT02412449|Experimental|Treatment B|AKB-6548
89545498|NCT02412449|Experimental|Treatment C|AKB-6548
89545499|NCT02412293|Experimental|Intervention|"Health Education & Promotion: LHWs and CHWs will delivered the package via community awareness sessions and two one-to-one counselling sessions to pregnant women during third trimester and five newborn assessment visits in the neonatal period in intervention areas.~Training of Health Workers: The LHWs and CHWs will receive trainings on IMNCI-based training package.~Community Mobilization: For community mobilization and education, two types of tools will be used one group session by use of flip charts and group session by use of video."
89545500|NCT02412293|No Intervention|Control|Control areas will continue to receive the routine standard health services of governmental and non-governmental organizations in the area.
89545501|NCT02412059|Experimental|Prednisolone|Pred Forte (prednisolone acetate ophthalmic suspension, USP) 1% sterile
89545502|NCT02412059|No Intervention|Control|Patients in control group will not be given a corticosteroid as per usual standard of care.
89545503|NCT02045212|Experimental|RPh201|3/6 month treatment schedule, consisting of bi-weekly SC administration of the RPh201
89545504|NCT02045212|Placebo Comparator|Placebo|3/6 month treatment schedule, consisting of bi-weekly SC administration of the Placebo
89545505|NCT02412215|Experimental|Toric Nanoflex IOL|Phacoemulsification with toric Nanoflex IOL implantation
89545506|NCT02412137|Experimental|Counseled Patients|The counseled cohort will have their brace wear compliance documented on the Brace Progress Report after the Orthotist downloads the time/temperature data onto a laptop from the sensor reader (A piece of computer hardware which the sensor clips into and is attached to the laptop via the USB port). The Orthotist will then reset the temperature logger discs and reinstall them into the padding in the inside front of the brace in order to monitor the next period of brace wear. This group will then be counseled for about 10 minutes or less regarding their brace-wear using the Brace Progress report as a checklist.
89032981|NCT02923089|Experimental|Split Red Lentil Chili|Chili: 25g available carbohydrate from split red lentil
89032982|NCT02923089|Placebo Comparator|Rice Chili|Chili: 25g available carbohydrate from rice
89032983|NCT00527891||Signa Excite 3.0 T MRI Scan|Signa Excite 3.0 T MRI Scan
89545507|NCT02412137|Placebo Comparator|Non-counseled patients|The non-counseled cohort will have their brace wear compliance documented on the Brace Progress Report after the Orthotist downloads the time/temperature data onto a laptop from the sensor reader (A piece of computer hardware which the sensor clips into and is attached to the laptop via the USB port). The Orthotist will then reset the temperature logger discs and reinstall them into the padding in the inside front of the brace in order to monitor the next period of brace wear. This group will not be counseled, and will only receive standard clinical care.
89545508|NCT03175991||ovarian masses patients|women of different age groups diagnosed as having an ovarian mass or accidentally discovered ovarian mass in non-complaining female by ultrasonography or Patients known to have primary that may give metastasis to the ovaries.
89545509|NCT03175679|Experimental|Autologous iNKT Cells + Tegafur +Interleukin-2(IL-2)|Autologous in vitro expanded iNKT cells in conjunction with IL-2 and along with lymphodepleting chemotherapy (Tegafur) will be administered to patients with advanced HCC.
89545510|NCT05520645|Experimental|Eto 0.15mg/kg|Etomidate 0.15mg/kg for anesthesia induction
89545511|NCT05520645|Experimental|Eto 0.2mg/kg|Etomidate 0.2mg/kg for anesthesia induction
89545512|NCT05520645|Experimental|Eto 0.25mg/kg|Etomidate 0.25mg/kg for anesthesia induction
89545513|NCT05520645|Active Comparator|Propofol 2mg/kg|propofol 2mg/kg for anesthesia induction
89545514|NCT03175757|Experimental|Cholesterol Health Formulation|Turmeric and black cumin seed preparation
89545515|NCT03175757|Placebo Comparator|Placebo|Placebo
89545516|NCT03175835|Experimental|Rosuvastatin 20 mg & CKD-519 200 mg|"Period 1: Treatment A(Rosuvastatin 20 mg(20 mg X 1 tablet))~Period 2: Treatment B(CKD-519 200 mg(100 mg X 2 tablets))~Period 3: Treatment C(Rosuvastatin 20 mg(20 mg X 1 tablet), CKD-519 200 mg(100 mg X 2 tablets))"
89545517|NCT05515185|Experimental|KT095 CAR-T|KT095 CAR-T injection Intravenous infusion
89545518|NCT02044822|Experimental|Idelalisib + rituximab|Participants will receive rituximab for 8 weeks and Idelalisib continuously throughout the study (up to 10 years).
89545519|NCT05511051|Experimental|Fruquintinib + HAIC|Fruquintinib: 5 mg orally once daily for 21 days on followed by 7 days off (q4w); HAIC: oxaliplatin 100 mg/m2, leucovorin calcium 200 mg/m2, fluorouracil 2000 mg/m2 24-hour drip, q4w, 2 cycles; HAIC treatment was administered during fruquintinib rest; HAIC was discontinued 1 day before surgery, on the day of completion of surgery, and 5 days after surgery;
89545520|NCT05511051|Active Comparator|Fruquintinib|Fruquintinib: 5 mg orally once daily for 21 days on followed by 7 days off (q4w);
89545521|NCT03116555|Experimental|Irinotecan plus apatinib|"Irinotecan: 180mg/m2, ivgtt,given on the first day; Apatinib: initial dose: 250mg,oral,once a day, after meal ( try to take the medicine at the same time each day).~Repeat the therapeutic schedule every 3 weeks till progressive disease or intolerable toxicities."
89025069|NCT00439452|Active Comparator|Telemedicine-Based Collaborative Care|Telemedicine-Based Collaborative Care - Off-site depression care team (telephone nurse care manager, telephone pharmacist, tele-psychologist and tele-psychiatrist) works collaboratively with on-site primary care providers. Telephone nurse care manager activities include promoting patient activation and self management, assessing symptoms and comorbidities, and monitoring adherence, side-effects and treatment response. Telephone pharmacist activities include documenting medication histories and conducting medication management. Tele-psychologist activities include providing cognitive behavioral therapy via interactive video. Tele-psychiatrist activities include conducting patient consultation via interactive video.
89032984|NCT02923050|No Intervention|Waitlist control|
89545522|NCT03175913|Experimental|Vapocoolant spray group|vapocoolant spray was applied for 10 second
89545523|NCT03175913|Active Comparator|Local infiltration group|3 ml of 2% lidocaine infiltrated subcutaneously
89545524|NCT03175445||mandible CBCT scans in males|74 males CBCT scan by planmeca promax 3D Mid machine using 90 kVp, 10 mA, 14 seconds and 200×60 mm FOV with a 0.2 mm voxel size.
89545525|NCT03175445||mandible CBCT scans in female|74 females CBCT scan by planmeca promax 3D Mid machine using 90 kVp, 10 mA, 14 seconds and 200×60 mm FOV with a 0.2 mm voxel size
89545526|NCT02044510|Experimental|Mirabegron|Patients randomised to this arm start with mirabegron 25mg PO daily for two weeks, and then at 2 weeks titrate to 50mg PO daily, and maintain that dose for the duration of the study (8 additional weeks).
89545527|NCT02044510|Placebo Comparator|Placebo|Inert placebo pill, matching active treatment pill.
89545528|NCT02411981|Other|Autogenic drainage|"The autogenic drainage will be the chest physiotherapy technique used for this study.~Autogenic drainage is an airway clearance technique that attempts to obtain the optimal airflow to evacuate the secretions. This technique uses modulation of inspiratory and expiratory airflow at different breathing level within the vital capacity."
89545529|NCT02411903|Active Comparator|atorvastatin and Clopidogrel|80 patients will be taking atorvastatin 40mg/d plus clopidogrel 75mg/d for 9 months。
89545530|NCT02411903|Experimental|rosuvastatin and Clopidogrel|80 patients will be taking rosuvastatin 20mg/d plus clopidogrel 75mg/d for 9 months。
89545531|NCT02411669||Health care professionals|Physicians, nurses and managerial staff
89545532|NCT02411825|Experimental|SAR425899 (healthy subjects)|Once daily SC doses of SAR425899
89545533|NCT02411825|Placebo Comparator|Placebo (healthy subjects)|Once daily SC doses of placebo
89545534|NCT02411825|Experimental|SAR425899 (T2DM Patients)|Once daily SC doses of SAR425899 and two up titration steps in each dose cohort with metformin as background therapy
89545535|NCT02411825|Placebo Comparator|Placebo (T2DM Patients)|Once daily SC doses of placebo and two up titration steps in each dose cohort with metformin as background therapy
89545536|NCT02411513|Experimental|Active|60 minutes of CEFALY stimulation as acute treatment of an on-going attack
89545537|NCT02411435|Experimental|Treatment A(CAB 30mg)+B (RIF 600mg)+C (CAB 30mg and RIF 600mg)|Subjects will receive a single dose of CAB 30 mg on day 1. Subjects will then receive RIF 600 mg once daily on days 8-28 with co-administration of a single dose of CAB 30 mg on day 21.
89545538|NCT05520489|Active Comparator|treatment as usual, physiotherapy|Exercises were performed by using different objects for task orientated movements. The therapist provided assistance as needed and encouraged participants to complete the tasks. Training was divided to 3 sessions for fine motor training and complex training and 1 session for shoulder girdle and complex training per week for 3 weeks, in addition to usual care. Each session lasts 1 hour and estimated time is 2-5 min to each exercise section
89545539|NCT05520489|Active Comparator|Transcranial magnetic stimulation|"Participants received 15 sessions (15 daily session - Monday to Friday) of active rTMS over the 'hotspot M1 area of the unaffected hemisphere leading to a response in the contralateral thenar muscle using Visor2-navigation system and MagstimRapid -magnetic stimulator. Low frequency rTMS was applied at 80-90% resting motor threshold (rMT) intensity, 1 Hz, 600+600 pulses, inbetween 10 minutes break. Intensity was increased after each 2-3 treatment to keep motor threshold 90%."
89545540|NCT05520489|Active Comparator|robot assisted training|"This was delivered using the Diego and Pablo (Tyromotion GmBH) robotic gym system. Participants receive robot-assisted training for up to 60 min per day, four days per week for 3 weeks, in addition to usual care. Robotic devices enable 3D interactive exercising, using weight reducing system in Diego and fine motor training in Pablo. Exercises can be one- or two-handed and/or symmetrical. Patient performs 150-400 repetitions in one therapy session. Estimated time is 2-3 minutes per one exercise section. Standard minimum program includes 4 games: swimming, shooting, ship and apple orchard. The therapist instructs the patient and assure the position of trunk and shoulder girdle."
89545541|NCT02411279||Groupe 1: experimental group|Equiped group with telemedicine systems
89545542|NCT02411279||Groupe 2: control group|Non equiped group with telemedicine systems
89032985|NCT02923050|Experimental|10-week family meals program|
89545543|NCT02411123|Experimental|IDgenetix Neuropsychiatric Test Panel Intervention|The medical provider for the IDgenetix Neuropsychiatric Test Panel-guided group will make treatment recommendations based on test results. Patient outcomes will be measured throughout the duration of the study.
89545544|NCT02411123|No Intervention|control|The medical provider for the control group will not receive IDgenetix Neuropsychiatric Test Panel results and will make treatment recommendations as usual. Patient outcomes will be measured throughout the duration of the study.
89545545|NCT03175289|Active Comparator|Arm I (standard of care, home exercises)|Patients receive standard of care comprising of written patient education materials focusing on oral care, signs/symptoms of dysphagia/aspiration, and trismus. Patients participate in a therapy session conducted by a speech pathologist over 30 minutes once per week for 6 weeks during chemoradiation therapy. Patients also perform prescribed exercises at home daily for 3 sets of 10 repetitions.
89545546|NCT03175289|Experimental|Arm II (standard of care, home exercises, EMST)|Patients receive standard of care comprising of written patient education materials focusing on oral care, signs/symptoms of dysphagia/aspiration, and trismus. Patients participate in a therapy session conducted by a speech pathologist over 30 minutes once per week for 6 weeks during chemoradiation therapy. Patients perform prescribed exercises at home daily for 3 sets of 10 repetitions. Patients also participate in an EMST session over 30 minutes comprising of 5 sets of 5 repetitions daily for 5 days per week for 6 weeks during chemoradiation therapy
89545547|NCT02411045|Active Comparator|Group 1: Control|Ask participants to take a picture of themselves
89545548|NCT02411045|Experimental|Group 2: Dress for Success|Ask participants to take a picture of themselves while wearing their workout gear
89545549|NCT02411045|Experimental|Group 3: Exercise for Success|Ask participants to take a picture of themselves while wearing their workout gear and complete a 30-minute workout
89545550|NCT02410889||Patients with Epilepsy|A group of patients with a variety of types of epilepsy.
89545551|NCT03175211|Experimental|BI 456906|
89545552|NCT03175211|Placebo Comparator|Placebo|
89545553|NCT03175055|Experimental|Phoenix|Phoenix
89545554|NCT03174899|Experimental|Stage1:eGFR; ≥90 mL/min/1.73 m2 .|All MRI examinations will be performed with a 1.5-T scanner (Acheiva, Philips, and Netherland). All MRI scans will be obtained with the following parameters: Repetition time (TR); 1580 MS, echo time (TE); 60 MS, slice thickness; 1-5 mm, receiver bandwidth; 1158 kHz/pixel, field of view (FOV); 40 cm, matrix size; 164 × 159. . ADC value of the kidneys will be calculated with Diffusion weighted magnetic resonance imaging gradient b-values of 0 and 1000s/mm2. In the axial ADC map, a region of interest (ROI) will be placed for measurement of ADC values on the renal parenchyma of both kidneys, without any preference for cortex or medulla. Three circular ROIs of size 1 cm2 will be placed-one each at the upper pole, inter-polar region, and lower pole of both kidneys-and 6 total ROIs from bilateral kidneys will be averaged for each patient. The mean ADC values will be recorded for each patient and the relationship of ADC values with CKD stage will be evaluated.
89545555|NCT03174899|Experimental|Stage 2: eGFR; 60-89 mL/min/1.73 m2 .|All MRI examinations will be performed with a 1.5-T scanner (Acheiva, Philips, and Netherland). All MRI scans will be obtained with the following parameters: Repetition time (TR); 1580 MS, echo time (TE); 60 MS, slice thickness; 1-5 mm, receiver bandwidth; 1158 kHz/pixel, field of view (FOV); 40 cm, matrix size; 164 × 159. ADC value of the kidneys will be calculated with Diffusion weighted magnetic resonance imaging gradient b-values of 0 and 1000s/mm2. In the axial ADC map, a region of interest (ROI) will be placed for measurement of ADC values on the renal parenchyma of both kidneys, without any preference for cortex or medulla. Three circular ROIs of size 1 cm2 will be placed-one each at the upper pole, inter-polar region, and lower pole of both kidneys-and 6 total ROIs from bilateral kidneys will be averaged for each patient. The mean ADC values will be recorded for each patient and the relationship of ADC values with CKD stage will be evaluated.
89545556|NCT03174899|Experimental|Stage 3:eGFR; 30-59 mL/min/1.73 m2|All MRI examinations will be performed with a 1.5-T scanner (Acheiva, Philips, and Netherland). All MRI scans will be obtained with the following parameters: Repetition time (TR); 1580 MS, echo time (TE); 60 MS, slice thickness; 1-5 mm, receiver bandwidth; 1158 kHz/pixel, field of view (FOV); 40 cm, matrix size; 164 × 159. ADC value of the kidneys will be calculated with Diffusion weighted magnetic resonance imaging gradient b-values of 0 and 1000s/mm2. In the axial ADC map, a region of interest (ROI) will be placed for measurement of ADC values on the renal parenchyma of both kidneys, without any preference for cortex or medulla. Three circular ROIs of size 1 cm2 will be placed-one each at the upper pole, inter-polar region, and lower pole of both kidneys-and 6 total ROIs from bilateral kidneys will be averaged for each patient. The mean ADC values will be recorded for each patient and the relationship of ADC values with CKD stage will be evaluated.
89545557|NCT03174899|Experimental|Stage 4:eGFR; 15-29 mL/min/1.73 m2 .|All MRI examinations will be performed with a 1.5-T scanner (Acheiva, Philips, and Netherland). All MRI scans will be obtained with the following parameters: Repetition time (TR); 1580 MS, echo time (TE); 60 MS, slice thickness; 1-5 mm, receiver bandwidth; 1158 kHz/pixel, field of view (FOV); 40 cm, matrix size; 164 × 159. ADC value of the kidneys will be calculated with Diffusion weighted magnetic resonance imaginggradient b-values of 0 and 1000s/mm2. In the axial ADC map, a region of interest (ROI) will be placed for measurement of ADC values on the renal parenchyma of both kidneys, without any preference for cortex or medulla. Three circular ROIs of size 1 cm2 will be placed-one each at the upper pole, inter-polar region, and lower pole of both kidneys-and 6 total ROIs from bilateral kidneys will be averaged for each patient. The mean ADC values will be recorded for each patient and the relationship of ADC values with CKD stage will be evaluated.
89545558|NCT03174899|Experimental|Stage 5:eGFR; < 15 mL/min/1.73 m2.|All MRI examinations will be performed with a 1.5-T scanner (Acheiva, Philips, and Netherland). All MRI scans will be obtained with the following parameters: Repetition time (TR); 1580 MS, echo time (TE); 60 MS, slice thickness; 1-5 mm, receiver bandwidth; 1158 kHz/pixel, field of view (FOV); 40 cm, matrix size; 164 × 159. ADC value of the kidneys will be calculated with Diffusion weighted magnetic resonance imaging gradient b-values of 0 and 1000s/mm2. In the axial ADC map, a region of interest (ROI) will be placed for measurement of ADC values on the renal parenchyma of both kidneys, without any preference for cortex or medulla. Three circular ROIs of size 1 cm2 will be placed-one each at the upper pole, inter-polar region, and lower pole of both kidneys-and 6 total ROIs from bilateral kidneys will be averaged for each patient. The mean ADC values will be recorded for each patient and the relationship of ADC values with CKD stage will be evaluated.
89545559|NCT03175133|Experimental|Strength training|Strength exercises for ankle PF, hip abduction, and trunk muscles. Exercises will be done in three standard positions of supine, sidelying, prone, seated, and standing. Exercises during the initial 4 weeks will be completed 2x week with supervision of a physical therapist and 2x week at home, for a total of 4x week. For the final 4 weeks of the intervention will be completed 1x week with supervision and 3x week at home.
89545560|NCT02410655|Active Comparator|Conventional standard of care|Traditional administration of oxytocin at Lutheran Medical Center involves the use of two 20 IU / 1000 mL bags hung sequentially at a flow rate of 125 mL / hour each after the delivery of the anterior shoulder. This will total no more than 16 hours.
89545561|NCT02410655|Active Comparator|Evidence based protocol|The proposed evidence based protocol involves utilizing a single 30IU / 500mL bag of oxytocin. After the delivery of the anterior shoulder, an initial rapid infusion bolus of 50mL of the 30IU / 500mL at 999mL / hour. Three minutes after rapid infusion, uterine tone should be assessed. If inadequate uterine tone persists, a second rapid infusion at the same dose and rate as above should be given. If inadequate uterine tone persists, a third rapid infusion may be given. If adequate uterine tone is achieved after any rapid infusion, the remainder of the bag should be administered at a rate of 100mL / hour until finished. If adequate tone is not achieved, the remainder of the bag should be administered at 100mL / hour and additional uterotonic agents should be considered.
89545562|NCT02410499|Placebo Comparator|Placebo|MLN1202 placebo-matching solution, subcutaneous injection (SC), once, on Day 1 (loading dose), followed by MLN1202 placebo-matching solution, SC, once, weekly, on Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78.
89545563|NCT02410499|Experimental|MLN1202 75 mg|MLN1202 450 mg, solution, SC injection, once, on Day 1 (loading dose), followed by MLN1202 75 mg, solution, SC, once, weekly, on Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78.
89545564|NCT02410499|Experimental|MLN1202 105 mg|MLN1202 450 mg, solution, SC injection, once, on Day 1 (loading dose), followed by MLN1202 105 mg, solution, SC, once, weekly, on Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78.
89545565|NCT02410499|Experimental|MLN1202 150 mg|MLN1202 450 mg, solution, SC injection, once, on Day 1 (loading dose), followed by MLN1202 150 mg, solution, SC, once, weekly, on Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78.
89545566|NCT04859127||Patient Group|"The criteria for inclusion in the study were determined as voluntary patients between the ages of 18-65 with neck pain lasting more than 3 months who were clinically diagnosed with chronic neck pain by a specialist physician.~Within the scope of the evaluation for the assessment of pain by visual analog scale (VAS), standard evaluation posture Postural Analysis, range of motion for the evaluation of Elektrogonyometer, Nov stabilizer and force evaluation for a hand-held Dynamometer, Nov for brevity, brevity reviews left internal rotator muscles of the pectoral muscles with standard, fear of movement kinezyofobi Tampa scale for the assessment of the neck in apology etc."
89545567|NCT04859127||Control Group|Asymptomatic individuals between the ages of 18-65 who have not experienced neck pain during the last 1 year will be included in the control group. Within the scope of the evaluation for the assessment of pain by visual analog scale (VAS), standard evaluation posture Postural Analysis, range of motion for the evaluation of Elektrogonyometer, Nov stabilizer and force evaluation for a hand-held Dynamometer, Nov for brevity, brevity reviews left internal rotator muscles of the pectoral muscles with standard, fear of movement kinezyofobi Tampa scale for the assessment of the neck in apology etc.
89545568|NCT02410421|Experimental|Individualized rTMS protocol|"The target region will be defined by comparing the rCBF scan of the patient to a control population (n = 80). rCBF will be measured using the QUIPS2 arterial spin labeling sequence on a Siemens 3T Verio.~The therapeutic protocol will be design to correct the rCBF anomaly first by defining each point where to deliver the stimulation than the stimulation protocol for each point (180% of active motor threshold, 4-second 10 Hz train duration, with 26-second intertrain interval for a total of 3000 pulses). The whole target will be homogeneously stimulated.~The active motor threshold will be assessed. The programmed protocol will be delivered while a figure of eight coil will be positioned by a robotic device (Axilum Robotics).~The procedure will be repeated twice a day for 10 days over 2 weeks."
89545569|NCT02410421|Active Comparator|High frequency rTMS as usual|"rTMS will be performed as usual using a figure-eight coil: Defining the active motor threshold. For each session positioning the coil 5 cm ahead of the abductor pollicis brevis muscle, stimulating at 180% of active motor threshold (10 Hz, 4-second train duration, and 26-second intertrain interval) for 37.5 minutes (3000 pulses per session), twice a day for 10 days over 2 weeks.~Coil and stimulator will remain the same between individualized and as usual proceedures."
89207790|NCT04046198|Experimental|İntervention group|Nurses working at Akdeniz University Hospital became the intervention group. The nurses who accepted to participate in the study were divided into groups of 5-15 people. Pre-test was applied to nurses who accepted the research. Nurses were given 4-hour group trainings. A booklet on the subject prepared by the researchers was given. Three interim interviews were conducted in the subsequent 3-month period. Six separate posters were posted in the clinics. Weekly reminder messages were sent via WhatsApp. At the end of the third month, post-test data were collected from the nurses.
89545570|NCT02410421|Active Comparator|Trans-cranial direct current stimulation (tDCS)|tDCS will be performed as usual: After controlling for skin healthiness, the anode and the cathode will be respectively placed over F3 and F4. A commercial devices (MagStim), will deliver a constant current of 2 mA through 25 cm2 saline-soaked rubber sponges for 20 min per session. The procedure will be repeated twice a day for 10 days over 2 weeks.
89545571|NCT05514249|Experimental|Single patient|Single dose of CRD-TMH-001 administered by IV
89545572|NCT05510505|Active Comparator|ATG arm (control group)|"4.2.1 Matched sibling donor 1) ATG arm (control group) Fludarabine 30mg/m2/d×6d（-7d ~ -2d）+ Cyclophosphamide 50mg/kg/d×2d （-4d ~ -3d）+ ATG 2.5mg/kg/d×5d（-8d ~ -4d）~4.2.2 Unrelated donor and haploidentical donor~1) ATG arm (control group) Busulfan 3.2 mg/kg/d（0.8 mg/kg，q6h）×2d（-7d ~ -6d） + Cyclophosphamide 50mg/kg/d×4d （-5d ~ -2d）+ ATG 2.5mg/kg/d×4d（-5d ~ -2d）"
89545573|NCT05510505|Experimental|ATG + CD20 monoclonal antibody (test arm)|"4.2.1 Matched sibling donor 2) ATG + CD20 monoclonal antibody (test arm) Fludarabine 30mg/m2/d×6d（-7d ~ -2d） + Cyclophosphamide 50mg/kg/d×2d （-4d ~ -3d）+ ATG 2.5mg/kg/d×5d（-8d ~ -4d）+ CD20 monoclonal antibody 375mg/m2, -1d~4.2.2 Unrelated donor and haploidentical donor 2) ATG + CD20 monoclonal antibody (test arm) Busulfan 3.2 mg/kg/d（0.8 mg/kg，q6h）×2d（-7d ~ -6d） + Cyclophosphamide 50mg/kg/d×4d （-5d ~ -2d）+ ATG 2.5mg/kg/d×4d（-5d ~ -2d）+ CD20 monoclonal antibody 375mg/m2, -1d"
89545574|NCT05514171||Neoadyuvant therapy|Patients with borderline or resectable ADK subjected to neoadyuvant therapy
89545575|NCT05514171||Upfront surgery|Patients with borderline or resectable ADK who undergo upfront surgery
89545576|NCT04987385|Other|single arm: Phase 1: protein supplementation, Phase 2: Urea|
89545577|NCT05510349|Experimental|All the patients|Sonographic measure of placental elasticity and viscosity
89545578|NCT05514015|Experimental|Intervention arm|Rituximab combined with steroid treatment group
89545579|NCT05514015|Active Comparator|Control arm|Cyclophosphamide-steroid alternating cycle treatment
89545580|NCT03174821|Experimental|Insulin pump therapy|The total requisite amount=0.44×weight (Kg); The preprandial and basal amount respectively took up 50% of integral dose.15 minutes before meal the preprandial insulin was equally given by 3 times. The basal insulin was pumped at 00:00-3:00，3:00-8:00，8:00-14:00，14:00-20:00，20:00-24:00.
89545581|NCT03174821|No Intervention|Normal control|The subjects were asked to maintain normal diet and lifestyle until the end of the observation period.
89545582|NCT05520021|Active Comparator|Magnesium sulfate treatment|A total of 30 pregnancies with preterm labor threats will be treated with Magnesium sulfate.
89545583|NCT05520021|Active Comparator|Nifedipine treatment|A total of 30 pregnancies with preterm labor threats will be treated with Nifedipine.
89545584|NCT05520021|No Intervention|Healthy pregnant women|A total of 30 pregnancies without preterm labor threat will be included.
89545585|NCT02410031||Cyproterone acetate 2mg/ethinylestradiol 35 μg (Diane-35)|Prescribers of Diane-35 who agree and fulfill the criteria inclusion to participate in the survey
89545586|NCT02410109|Experimental|SCRIPT intervention|
89545587|NCT02410109|No Intervention|Historical Control|
89545588|NCT02410187|Active Comparator|Arm 1|systemic therapy+palliative RT
89545589|NCT02410187|Experimental|Arm 2|systemic therapy+SBRT
89545590|NCT02410265|Experimental|Lantern: Guided self-help program|"Subject assigned to the Lantern intervention will receive 3-month access to a web-based, CBT-based guided self-help intervention for GAD. In the program, they receive psycho-education about GAD and the management of symptoms of GAD along with access to an e-coach who can monitor their progress in the program and provide feedback and encouragement via messaging and one voice call."
89545591|NCT02410265|Experimental|Mental Health Online: Self-help program|Subject assigned to the Mental Health Online (MHO) intervention will receive 3-month access to a web-based, CBT-based self-help intervention for GAD. In the program, they receive psycho-education about GAD and the management of symptoms of GAD.
89545592|NCT02410265|No Intervention|Delayed Program|Subject assigned to this arm will receive one of the online programs in 9 months.
89545593|NCT05055453|Experimental|Experimental Study Group|"It is a prospective study to investigate whether the MyPhonak Junior app can improve speech understanding in children with hearing aids, by evaluating the use of the volume, noise reduction and directional microphone using the MyPhonak Junior App.. The study is linked to randomized patient and test allocation carried out.~Introduction to the MyPhonak Junior app. There are measurements of speech understanding of sentences Carried out in background noise with the Oldenburg sentence test (OLSA). The language test is hard of hearing children and adolescents known from routine clinical practice. Various everyday situations / noise scenarios are played out. Questionnaire (E-HAK, also known from routine) and interview of the children regarding the use of the app in everyday life."
89545594|NCT02409953|Experimental|Bath|
89545595|NCT02409953|Placebo Comparator|Bed|
89545596|NCT04842981|Experimental|Interleukin 6 receptor antibody|Tocilizumab, 162 mg subcutaneous, once every week OR Sarilumab, 200 mg subcutaneous, once every two weeks.
89545597|NCT03174587|Experimental|CS20AT04|Test group : CS20AT04 (allogenic bone marrow derived mesenchymal stem cells.)
89545598|NCT02409875||Risk groups|"For families that both parents have BMI>=24 or at least one of them BMI>=28, then calculated as high-risk group.~For families that both parents have BMI<24 or one parents with BMI<24 and one with 24<=BMI<28, then grouped as low-risk group."
89545599|NCT03174509|Active Comparator|Positive Pressure Extubation|Positive pressure extubation is used for patients in this group.
89545600|NCT03174509|Active Comparator|Traditional Extubation|Traditional extubation is used for patients in this group.
89545601|NCT02409641|Experimental|30 healthy male and female subjects|30 healthy male and female subjects , age 18-35 years
89545602|NCT04839705|Other|WEB Aneurysm Embolization Device|WEB Aneurysm Embolization Device The WEB is an intra-aneurysmal device intended for use in endovascular embolization of intracranial aneurysms. The intended therapeutic effect of the WEB device is to line the neck of the aneurysm with a metallic structure that disrupts the inflow of blood, causing hemostasis within the aneurysm sac, and leading to thrombus formation within the implant.
89025070|NCT00439452|Active Comparator|Practice Based Collaborative Care|One-site nurse care manager works collaboratively with on-site primary care providers. Nurse care manager activities include promoting patient activation and self management, assessing symptoms and comorbidities, and monitoring adherence, side-effects and treatment response.
89025071|NCT03279302|Experimental|Group A|1 mg glepaglutide once daily, given as single SC injections on Days 1 to 7
89025072|NCT03279302|Experimental|Group B|5 mg glepaglutide once daily, given as single SC injections on Days 1 to 7
89025073|NCT03279302|Experimental|Group C|5 mg glepaglutide once weekly, given as single SC injections on Days 1, 8, 15, 22, 29, and 36
89025074|NCT03279302|Experimental|Group D|10 mg glepaglutide once weekly, given as single SC injections on Days 1, 8, 15, 22, 29, and 36
89025075|NCT03279302|Experimental|Group E|1 mg glepaglutide, given as an IV infusion at a rate of 4 mg/h for 15 minutes on Day 1
89207791|NCT04046198|Other|Control group|The nurses working in the University of Health Sciences Antalya Training and Research Hospital constituted the control group. Pre-test was applied to nurses who accepted the research. Post test applied 3 months later. A booklet on the subject prepared by the researchers was given after the post test. Group training was conducted to nurses.
89545603|NCT02409797|Experimental|Flexion-Distraction spinal manipulation|Participants will receive Flexion-Distraction treatment from a licensed doctor of chiropractic. During the procedure the participant lies prone on a specially designed treatment table. The table is equipped with a movable lower body section, which can be directed by the study doctor to lower the participants legs, move them from side to side, or in a traction motion. Table movements can occur in combination with other motions, depending on the diagnosis and characteristics specific to the participant's condition. During this procedure, the doctor will also touch the lower or upper part of the participants back or neck with their hands to direct treatment toward specific spinal regions.
89545604|NCT05519943|Experimental|group cognitive behavioral therapy intervention|
89545605|NCT05519943|Experimental|Treatment as usual (TAU)|
89545606|NCT02067676|Experimental|CJCV1 2 μg / Alum 0 μg (1A)|Two vaccinations (one on Day 0 and one on Day 28) with an intramuscular dose of Capsule-Conjugate Campylobacter Vaccine (CJCV1) equivalent to 2 μg of polysaccharide and 0 μg of Alhydrogel®, aluminum hydroxide adjuvant (Alum)
89545607|NCT02067676|Experimental|CJCV1 2 μg / Alum 125 μg (1B)|Two vaccinations (one on Day 0 and one on Day 28) with an intramuscular dose of Capsule-Conjugate Campylobacter Vaccine (CJCV1) equivalent to 2 μg of polysaccharide and 125 μg of Alhydrogel®, aluminum hydroxide adjuvant (Alum)
89545608|NCT02067676|Experimental|CJCV1 5 μg / Alum 0 μg (2A)|Two vaccinations (one on Day 0 and one on Day 28) with an intramuscular dose of Capsule-Conjugate Campylobacter Vaccine (CJCV1) equivalent to 5 μg of polysaccharide and 0 μg of Alhydrogel®, aluminum hydroxide adjuvant (Alum)
89545609|NCT02067676|Experimental|CJCV1 5 μg / Alum 125 μg (2B)|Two vaccinations (one on Day 0 and one on Day 28) with an intramuscular dose of Capsule-Conjugate Campylobacter Vaccine (CJCV1) equivalent to 5 μg of polysaccharide and 125 μg of Alhydrogel®, aluminum hydroxide adjuvant (Alum)
89545610|NCT02067676|Experimental|CJCV1 10 μg / Alum 0 μg (3A)|Two vaccinations (one on Day 0 and one on Day 28) with an intramuscular dose of Capsule-Conjugate Campylobacter Vaccine (CJCV1) equivalent to 10 μg of polysaccharide and 0 μg of Alhydrogel®, aluminum hydroxide adjuvant (Alum)
89545611|NCT02067676|Experimental|CJCV1 10 μg / Alum 125 μg (1A)|Two vaccinations (one on Day 0 and one on Day 28) with an intramuscular dose of Capsule-Conjugate Campylobacter Vaccine (CJCV1) equivalent to 10 μg of polysaccharide and 125 μg of Alhydrogel®, aluminum hydroxide adjuvant (Alum)
89545612|NCT03174665||Patients with Pain|"Patients who had upper limb surgery or other trauma with a history of persistent spontaneous and/or evoked pain with duration of at least 3 months.~Patients will be recruited to the study by using a postal follow up questionnaire. Patients who judge their pain at least moderate and/or affecting daily life by will be eligible and asked to participate. Patients will visit the Pain Clinic once. Oral and written information about the study will be provided, informed consent obtained. The affected nerve will be identified and the anatomy verified by ultrasound when needed."
89545613|NCT03174665||Patients with no pain|Patients operated with nerve suture surgery after a lesion of the nerves of upper extremity will be recruited to the study by using a postal follow up questionnaire. Patients with no pain will be asked to participate. Patients will visit the Pain Clinic once. Oral and written information about the study will be provided, informed consent obtained. The affected nerve will be identified and the anatomy verified by ultrasound when needed.
89545614|NCT03174743|Placebo Comparator|Convential Ventilation 1|Intraoperatively ventilated patients with a tidal volume (VT) of 10 ml/kg of ideal body weight, the level of PEEP at 0 cmH2O and a FiO2 of 60%.
89545615|NCT03174743|Placebo Comparator|Convential Ventilation 2|Intraoperatively ventilated patients with a tidal volume (VT) of 10 ml/kg of ideal body weight, the level of PEEP at 0 cmH2O and a FiO2 of100%.
89025076|NCT03279263|Experimental|MLR-1023 25mg QD|MLR-1023 25mg QD Tablet
89025077|NCT03279263|Experimental|MLR-1023 50mg QD|MLR-1023 50mg QD Tablet
89025078|NCT03279263|Experimental|MLR-1023 100mg QD|MLR-1023 100mg QD Tablet
89025079|NCT03279263|Placebo Comparator|Placebo|Placebo QDTablet
89025080|NCT03276741|No Intervention|Control Group|Routine care during labor (authorized clear liquid diet).
89207792|NCT00792584|Experimental|1|patients treats with etravirine for 6 weeks
89207793|NCT00792584|Experimental|2|patients treats with efavirenz for 6 weeks
89207794|NCT00782366||Genetic Testing Group|Those who will receive predictive genetic risk assessments
89207795|NCT00782366||Control|Those who will receive standard of care
89207796|NCT02556086|Experimental|Daclatasvir + Sofosbuvir|Daclatasvir 30, 60, 90 mg tablet (dose is dependent on cART regimen) + Sofosbuvir 400 mg tablet oral dosing once daily for 8 weeks
89545616|NCT03174743|Active Comparator|Protective ventilation 1|Intraoperatively ventilated patients with a tidal volume (VT) of 6 ml/kg of ideal body weight, the level of PEEP at 6 cmH2O and a FiO2 of 60% with lung recruitment maneuvers.
89545617|NCT03174743|Active Comparator|Protective ventilation 2|Intraoperatively ventilated patients with a tidal volume (VT) of 6 ml/kg of ideal body weight, the level of PEEP at 6 cmH2O and a FiO2 of 100% with lung recruitment maneuvers.
89545618|NCT01623154|Other|BreathTek UBT|Comparison of Urea hydrolysis rate (UHR) values derived from Delta over Baseline (DOB)values obtained from the POCone and UBiT-IR300
89545619|NCT03116243||MSHS children and families|"Cohort includes:~children (1272)~parents (1272)~teachers (159)~teaching assistants (159)~program and center directors (253)"
89545620|NCT03174431|Active Comparator|Continence Pessary|Participants randomized to the continence pessary will be fitted for a pessary by a clinician at enrollment and they will be taught how to remove and reinsert the device. Per usual clinical practice they will be instructed to call with any concerns and scheduled for a return visit in 2 weeks for a follow-up to assess fit and comfort and undergo refitting if necessary.
89545621|NCT03174431|Active Comparator|Disposable Intravaginal Device|Participants randomized to the intravaginal device will be given a sizing kit in the office, asked to select a size and provided with a 2-week supply of the appropriately sized devices. In accordance with manufacturer guidelines, participants will be instructed that the device is to be used for no more than 8 hours per 24-hour period and that each device is single use only. Participants will return in 2 weeks for a follow-up visit to assess fit and comfort, undergo resizing as necessary and receive an additional 2 week supply of the appropriately sized devices.
89545622|NCT04417816|Experimental|Exercise training + adipose tissue cavitation|
89545623|NCT04417816|Sham Comparator|Exercise training + sham procedure|
89545624|NCT02409407|Experimental|Oral Misoprostol|oral misoprostol ( prostaglandins E1 analogue) will be administered at a dose of 600 µg (200 µg every 8 hours), starting 24 hours before office hysteroscopy.
89545625|NCT02409407|Experimental|Vaginal Misoprostol|vaginal misoprostol ( prostaglandins E1 analogue)will be administered at a dose of 400 µg (200 µg 12 hours apart, starting 24 hours before office hysteroscopy)
89545626|NCT02409407|Placebo Comparator|Placebo|oral placebo (one pill every 8 hours) will be administered starting 24 hours before the office hysteroscopy.
89545627|NCT05510037||HER2-0|
89545628|NCT05510037||HER2-LOW|
89545629|NCT05510037||HER2-POSITIVE|
89545630|NCT02409563|Experimental|Budesonide nasal (100 mcg bid)|The study will be randomized, controlled parallel group. After 1 week of phase baseline screening (Visit 1), patients will be randomized (1:4) with the assignment of a code (B-200_da 01 to 08, B-100_ 01 to 31) (day 0, Visit 2) in 2 groups: N1 (n = 8) = Budesonide nasal spray 100 mcg, 2 v / d; Patients return to control after the 1st week (day 7, Visit 3), after the 2nd week (day 14, Visit 4) and one week after the end of the treatment period (day 21, Visit 5). It will give a tolerance of ± 3 days for the timing of planned visits. In the phase of follow-up, (3 days after the last dose of drug) will be recorded the occurrence of adverse effects (Adverse Event, EA)
89545631|NCT02409563|Experimental|Budesonide nasal (50 mcg bid)|The study will be randomized, controlled parallel group. After 1 week of phase baseline screening (Visit 1), patients will be randomized (1:4) with the assignment of a code (B-200_da 01 to 08, B-100_ 01 to 31) (day 0, Visit 2) in 2 groups: ; N2 (n = 31) = Budesonide nasal spray 50 mcg, 2 v / d. Patients return to control after the 1st week (day 7, Visit 3), after the 2nd week (day 14, Visit 4) and one week after the end of the treatment period (day 21, Visit 5). It will give a tolerance of ± 3 days for the timing of planned visits. In the phase of follow-up, (3 days after the last dose of drug) will be recorded the occurrence of adverse effects (Adverse Event, EA)
89545632|NCT02409485|Experimental|Couples Skill-Training (CST)|CST provides education about acute and long-term side-effects of HNC and teaches: 1) self-management skills to control/prevent side-effects; 2) communication skills to facilitate coordination of care; and, 3) strategies to improve communal coping and confidence in the ability to work as a team.
89545633|NCT02409485|No Intervention|Usual Medical Care (UMC)|Patients receive standard symptom management education by their health care team.
89545634|NCT02409017|Active Comparator|Protocol A|Our current standard during labor
89545635|NCT02409017|Active Comparator|Protocol B|Another commonly accepted alternative for insulin drip management during labor
89207797|NCT00782522|Experimental|1|Eccentric training program
89207798|NCT00782522|Active Comparator|2|Traditional training program
89207799|NCT00782600|Experimental|50 mg oral suspension|once daily for one day
89207800|NCT00782600|Experimental|50 mg CR Type 1|once daily for one day
89207801|NCT00782600|Experimental|50 mg CR Type 2|once daily for one day
89207802|NCT00782600|Experimental|50 mg SR Type 3|once daily for one day
89207803|NCT00786266|Active Comparator|NIOSH shiftwork booklet|
89207804|NCT00786266|Experimental|Sleep Enhancement Training System|
89207805|NCT04093752|Experimental|5 mg Tirzepatide|Participants received 5 milligrams (mg) tirzepatide administered subcutaneously (SC) once weekly (QW).
89545636|NCT05513079|No Intervention|Control group|"Individuals in the control group agreed to participate in the study after being explained about the research.~Verbal and written consent will be obtained from individuals who do so. Initial interview with individuals who agreed to participate in the study Introductory Information Form, Trait Anxiety Scale, Dermatological Quality of Life Scale, Urticaria Activity Score will be applied. Patients in this group have routine chronic No application will be made other than the treatment of urticaria. 5 months after the pre-test Trait State Anxiety Scale, Dermatological Quality of Life Scale, Urticaria Activity Score will be applied. After the study is completed, individuals in the control group can also request it.~counseling will be provided."
89545637|NCT05513079|Experimental|Intervention Group|Positive psychotherapy counseling sessions, specialist psychiatry who completed positive psychotherapy training will be done by the nurse. The first one face-to-face with each individual in the intervention group. A total of 8 sessions will be held, theothers being online. Audio and video with attendees Other sessions will be completed through a program that allows sharing (WhatsAap, zoom etc.). Each session will be applied once a week, lasting 45-50 minutes. Interviews with individuals No audio or video recording will be taken during the recording.
89545638|NCT05519553|Experimental|Experimental group|30 MS (Multiple sclerosis, relapsing-remitting) patients
89545639|NCT05519553|No Intervention|Control group|30 MS (Multiple sclerosis, relapsing-remitting) patients
89545640|NCT05512845||Double factor group|"Patients treated with full arch implant supported prostheses based on the All-on-four® concept. All implants were placed using the double factor computer assisted surgery technique, which involves combination of the static and dynamic computer assisted surgery protocols."
89545641|NCT00702689|Experimental|Imatinib mesylate in patients with cGVHD|"Cohort 1 - Pts 1-8:Adults: 400mg imatinib mesylate daily; Children: 260mg/m^2 daily (400mg maximum), followed by dose de-escalation for adverse events.~Cohort 2 - Pts 9-20:Adults - 100 mg oral dose daily (increase to 200 mg daily after 28 days if well tolerated). Children - 65 mg/m^2 oral dose daily (increase to 130 mg/m^2 daily after 28 days if well tolerated)"
89545642|NCT02409251|Experimental|Education and feedback|The intervention consisted of a one-hour, small group educational session. During this session information on rational ANA testing was provided and feedback on current ANA testing was provided to the rheumatologists. A booster session with the same components was held 6 months after the first session.
89545643|NCT02409095|Experimental|DISPOSABLE-SYRINGE JET INJECTOR (DSJI)|Subjects in this arm will be given three deep intramuscular doses, 0.5 mL each dose 4 weeks apart, of Serum Institute of India Ltd.'s DTP-HB-Hib vaccine (Brand name: Pentavac) via Disposable Syringe Jet Injector (Brand Name:Stratis) of Pharmajet Inc
89545644|NCT02409095|Active Comparator|NEEDLE & SYRINGE (N-S)|Subjects in this arm will be given three deep intramuscular doses, 0.5 mL each dose 4 weeks apart, of Serum Institute of India Ltd.'s DTP-HB-Hib vaccine (Brand name: Pentavac) via conventional needle and Syringe
89545645|NCT05512533|Experimental|BF-UC290F for diagnosing PPLs|Thin EBUS endoscope is inserted and used to visualize peripheral pulmonary lesions, and biopsies will be conducted by EBUS-TBNA.
89545646|NCT02409173|Experimental|Noninvasive Ventilation and Surgery|Noninvasive positive airway pressure flow generator device by full face or nasal mask and bariatric surgery.
89545647|NCT02409173|No Intervention|Control Group|
89207806|NCT04093752|Experimental|10 mg Tirzepatide|Participants received 10 mg tirzepatide administered SC QW.
89545648|NCT02065570|Experimental|Induction: Standard Induction Dose|Participants randomized to receive received blinded adalimumab 160 mg at Baseline and matching placebo at Week 1, adalimumab 80 mg and matching placebo at Week 2, matching placebo at Week 3, and then adalimumab 40 mg every other week (eow) starting at Week 4 through Week 12.
89545649|NCT02065570|Experimental|Induction: Higher Induction Dose|Participants randomized to receive blinded adalimumab 160 mg at Baseline, Week 1, Week 2, and Week 3. At Week 4, participants receive adalimumab 40 mg eow through Week 12.
89545650|NCT02065570|Experimental|Maintenance: Clinically Adjusted (CA) Regimen|Participants randomized to the CA regimen receive adalimumab 40 mg eow beginning at Week 12. The adalimumab dose will be escalated to every week (ew) starting as early as Week 14 and up to Week 54 based on Crohn's Disease Activity Index (CDAI) or high-sensitivity C-reactive protein (hs-CRP) values, using results from the prior or current study visit. Once participants in the CA regimen are escalated, they remain on adalimumab 40 mg ew dosing.
89545651|NCT02065570|Experimental|Maintenance: Therapeutic Drug Monitoring (TDM) Regimen|At Weeks 14, 28 and 42, the adalimumab dose for participants randomized to the TDM will be determined by protocol-established dose adjustment criteria. Doses will be determined using blinded serum concentrations at the prior visit (Weeks 12, 26 and 40, respectively) as well as the CDAI or hs-CRP values from the current or prior study visit. Participants who meet criteria for dose escalation at Weeks 14, 28 or 42 will receive 40 mg ew.
89545652|NCT02408705|Active Comparator|Liraglutide|3-month treatment of liraglutide
89545653|NCT02408705|Placebo Comparator|Placebo|3-month treatment of placebo
89545654|NCT04804449||Rheumatoid arthritis and psoriatic arthritis|Patients with rheumatoid arthritis or psoriatic arthritis, who require an intra-articular corticosteroid injection
89545655|NCT02408627|Active Comparator|conventional EEG-registration type 1|conventional EEG-registration with wet bridge electrodes and conductive gel
89545656|NCT02408627|Active Comparator|conventional EEG-registration type 2|conventional EEG-registration with wet cup electrodes and collodion
89545657|NCT02408627|Experimental|EEG-registration with dry electrodes|EEG-registration with dry electrodes
89545658|NCT05507697|Experimental|Experimental|MSCs Participants will received i. m. HUC-MSCs both lower extremities
89545659|NCT05507697|Placebo Comparator|Comparator|The control group will receive i.v Lipoic Acid Injection
89545660|NCT04292223|Experimental|Drug - Pimavanserin|Pimavanserin 34 mg administered orally
89545661|NCT03174119|Active Comparator|Real light exposition by the mean of Luminette®|All patients will be exposed to a real light (1500 lux, 470 nm) during the treatment phase, 3 times per day (morning, afternoon and evening) for 60 minutes each via goggles providing light at the eyes level. Meanwhile, different assessments will be performed in order evaluating the potential effects of provided light in comparison to placebo ligh. Patients will be given behavioral assessments (Coma Recovery Scale-Revised, Nociception Coma Scale-Revised, brainstem reflexes,...), physiological (body core temperature, saliva, urine, heart rate, blood sample), neuroimaging and neurophysiological tools (PET, fMRI, TMS-EEG, resting-state and auditory paradigm EEG) before, during and after treatment.
89545662|NCT03174119|Placebo Comparator|Placebo light exposition by the mean of Luminette®|All patients will also be exposed to a placebo light (80 lux, 470 nm) during the treatment phase, 3 times per day (morning, afternoon and evening) for 60 minutes each via goggles providing light at the eyes level. Meanwhile, different assessments will be performed in order evaluating the potential effects of provided light in comparison to placebo light. Patients will be given behavioral assessments (Coma Recovery Scale-Revised, Nociception Coma Scale-Revised, brainstem reflexes,...), physiological (body core temperature, saliva, urine, heart rate, blood sample), neuroimaging and neurophysiological tools (PET, fMRI, TMS-EEG, resting-state and auditory paradigm EEG) before, during and after treatment.
89545663|NCT05509491|Experimental|Postural Awareness Program with Exercises in people with neck pain|Postural education, bad posture, good posture, awareness, their effects in daily life
89545664|NCT03116321|Experimental|Test 1 - TBM (Treatment A - 1 × 800 mg tablet)|"single oral dose of 800 mg (1 × 800 mg tablet) of Eslicarbazepine acetate (ESL) as tablets, on each of three separate occasions, under fasting conditions.~Route of administration:Oral."
89545665|NCT03116321|Experimental|Test 2 - TBM (Treatment B - 2 × 200 mg tablet)|"single oral dose of 800 mg (4 × 200 mg tablet) of Eslicarbazepine acetate (ESL) as tablets, on each of three separate occasions, under fasting conditions.~Route of administration:Oral."
89545666|NCT03116321|Active Comparator|Reference Product - MF (Treatment C - 1 × 800 mg tablet)|"single oral dose of 800 mg (1 × 800 mg tablet) of Eslicarbazepine acetate (ESL) as tablets, on each of three separate occasions, under fasting conditions.~Route of administration:Oral."
89545667|NCT03174041|Experimental|Part 1|Participants will receive a single dose of midazolam followed by multiple doses of GDC-0853 coadministered with a single dose of midazolam.
89545668|NCT03174041|Experimental|Part 2|Participants will receive a single dose of rosuvastatin followed by multiple doses of GDC-0853 coadministered with a single dose of rosuvastatin.
89545669|NCT03174041|Experimental|Part 3|Participants will receive a single dose of simvastatin followed by multiple doses of GDC-0853 coadministered with a single dose of simvastatin.
89545670|NCT03174041|Experimental|Part 4|Participants will receive a single dose of GDC-0853 followed by multiple doses of itraconazole coadministered with a single dose of GDC-0853.
89545671|NCT02566005|Active Comparator|misoprostol group|The women in the misoprostol only group will receive 25mcg of misoprostol per vagina every 4hours per the standard hospital protocol. Once the cervix becomes favorable or if the patient is in active labor, or if there is no progress for 24 hours, misoprostol administration will be discontinued. Further management of labor will depend on the labor team. (25mcg tablets are not available commercially; a 100mcg table is cut into fourths by the hospital pharmacist
88961503|NCT05777876|No Intervention|non-TRD|Patients with first episode or relapse of untreated depression group are treated with escitalopram for 8 weeks, and if effective, they are included in the n-TRD group. If ineffective, Venlafaxine is used for full treatment for 8 weeks; if effective, the patients are included in the non-TRD group. The subjects get clinical evaluation, blood sample collection, magnetic resonance scanning, and electrophysiological monitoring.
88961504|NCT05777876|Experimental|TRD Target stimulation A|Patients do not respond favorably to two antidepressants. The subjects get clinical evaluation, blood sample collection, magnetic resonance scanning, and electrophysiological monitoring. Regimen: Receiving TIS intervention with target A (Characteristic abnormal brain region targets based on data-driven exploration) for 10 times, once a day (except weekends and holidays) for 2 weeks. Stimulation（130Hz, 2mA total current intensity, each stimulation lasts for 30 minutes, 15 seconds respectively for import and exit).
89032986|NCT02945267|Experimental|Nimotuzumab plus S1|Nimotuzumab Injection:400 mg/w, Intravenous infusion, Infusion time ≥ 60 min, d1, once every two weeks; S1:40 mg (Body surface area<1.5 m2) or 60mg (Body surface area>1.5 m2) ,oral,d1-d14, every three weeks for a cycle
89545672|NCT02566005|Active Comparator|misoprostol and foley bulb group|Women in the combination group will receive vaginal misoprostol per standard protocol. In addition, a foley bulb will be inserted digitally or by direct visualization with the use of a sterile speculum. The foley will be inserted through the internal os and filled with 60cc of normal saline. The catheter will be taped to the patient's inner thigh under gentle traction. When the foley bulb has fallen out (spontaneous expulsion), further management of labor depends on the labor team. If this does not occur, the catheter will be deflated and removed after 24 hours. Oxytocin will be initiated in those patients who were not in labor after expulsion or removal of the catheter.
89545673|NCT02408393|Placebo Comparator|Placebo|Saline (30 mL maximum)
89545674|NCT02408393|Experimental|Ropivacaine|Ropivacaine 7.5 mg/mL (0.35 mL/kg of solution)
89545675|NCT05519163||Patients with type 2 diabetes|Patients with type 2 diabetes who were hospitalized in The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital between January 1, 2016 and December 31, 2021.
89545676|NCT02408237|Active Comparator|tDCS Ambulatory & Sham|Active tDCS Ambulatory: 1 mA of current of active tDCS applied for 20 minutes, single session of stimulation. Sham tDCS Ambulatory: applied for 20 minutes, single session of stimulation.
89545677|NCT02408237|Active Comparator|tDCS home use & Sham|Active tDCS home use: 11 active tDCS sessions: single session in the hospital and the remaining 10 in the subject's home, with duration of each active tDCS session of 20 min. Sham tDCS home use: 11 sessions of tDCS: single session in the hospital and the remaining 10 in the subject's home, with duration of each sham tDCS session of 20 min.
89545678|NCT03173885|Experimental|PGS (genetic screening)|Intent to transfer single cryopreserved embryo, selection based on euploid status (after preimplantation genetic screening) and standard morphological assessment
89545679|NCT03173885|No Intervention|no PGS (no genetic screening)|Intent to transfer single cryopreserved embryo, selection based on standard morphological assessment
89545680|NCT03173807|Active Comparator|dietary and exercise counseling|The duration of study in Arm A will be 24 months, with study assessments and interventions (review of diet, food diary, and guidance from the dietician; review of activity journal, assessment of body composition, tests for gait, balance and muscle strength, and new assignment from the exercise trainer) done at baseline, 3 months, 6 months, 12 months and 24 months.
89545681|NCT03173807|Active Comparator|standard of care|The duration of study in Arm B will be 24 months, with study assessments and interventions (review of diet, food diary, and guidance from the dietician; review of activity journal, assessment of body composition, tests for gait, balance and muscle strength, and new assignment from the exercise trainer) done at baseline, 12 months, 15 months, 18 months and 24 months. At 12 months, participants in Arm B will be offered the same intervention that Arm A received during months 1-12.
89545682|NCT02408159|Experimental|Varicella Zoster Vaccine|Sterile, lyophilized white to off-white compact crystalline plug in a single-dose vial. Each vial contains one dose of lyophilized vaccine (approximately 0.65 mL when reconstituted as directed). The diluent (0.7 mL) is a sterile, clear, colorless fluid supplied separately in a 3 mL single-dose vial. A single dose will be administered to subjects at baseline.
89545683|NCT02408159|Placebo Comparator|0.9% Sodium Chloride|"United States Pharmacopeia (USP), preservative free for injection supplied in a single dose vial.~A single dose will be administered to subjects at baseline."
89545684|NCT05507619|Active Comparator|Control|
89545685|NCT05507619|Experimental|Intervention|
89545686|NCT02408081|No Intervention|Treatment as usual|Pharmacological treatment, patient information and counselling according to international and national guidelines by health professionals specialized in elderly medical patients.
89545687|NCT02408081|Experimental|Family Focused Nursing|Family Focused Nursing and treatment as usual
89545688|NCT02407925||Endoscopists|Approximately 35 endoscopists whom are certified to perform colonoscopies on FIT-positive patients in the Dutch population screening program
89545689|NCT02407925||Colonoscopies|Colonoscopies on FIT-positive patients in the Dutch population screening program
89545690|NCT02407925||Device|Olympus colonoscopes with Narrow Band Imaging
89545691|NCT05507463|Experimental|KBP-7072|Proposed dose levels for Part A: 25, 50, 100, 150 and 200mg KBP-7072. Proposed dose levels for Part B: 50 and 100mg. Administration route is intravenous infusion.
89545692|NCT05507463|Placebo Comparator|Placebo|Placebo for intravenous infusion.
89545693|NCT03173963|Active Comparator|Drug|Empagliflozin 10mg once a day
89545694|NCT03173963|Placebo Comparator|Placebo|1 placebo tablet a day
89545695|NCT02407847|No Intervention|General Practitioners Care|Usual medical care provided by General Practitioners at the Primary Out-of-Hours Service.
89545696|NCT02407847|Experimental|Nurse Practitioners Care|Medical care provided by both Nurse Practitioners and General Practitioners at the Primary Out-of-Hours Service.
89545697|NCT05507229|Experimental|Arm 1|Hillchol®(BBV131) vaccine - (Lot-I ) administered to 450 subjects on day 0 and 14.
89545698|NCT05507229|Experimental|Arm 2|Hillchol®(BBV131) vaccine - (Lot-II) administered to 450 subjects on day 0 and 14.
89545699|NCT05507229|Experimental|Arm 3|Hillchol®(BBV131) vaccine - (Lot-III ) administered to 450 subjects on day 0 and 14 .
89545700|NCT05507229|Active Comparator|Arm 4|Shanchol Vaccine administered to 450 subjects on day 0 and 14
89545701|NCT03173651|Experimental|Group W|This group was intubated by Fiberoptic bronchoscope assisted by Modified Williams airway as a conduit
89545702|NCT03173651|Experimental|Group G|This group was intubated by Fiberoptic bronchoscope assisted by Modified Guedle's airway as a conduit
89545703|NCT03173651|Experimental|Group M|This group was intubated by Fiberoptic bronchoscope assisted by LMA MADgic airway as a conduit
89545704|NCT03173417|Experimental|IM19 CART|All patients will be treated with fludarabine and cyclophosphamide for 3 days,then,CAR-T cells expressing CD19 CAR will be infused 24-96 hours later.
89545705|NCT03173573|Experimental|Part 1 SAD FDL176 level 1 to 6|Part 1: Single dose of FDL176 test formulation Level 1 to 6 on healthy males.
89545706|NCT03173573|Placebo Comparator|Part 1 SAD Placebo|Part 1: Single dose of Placebo for FDL176.
89545707|NCT03173573|Experimental|Part 2 SAD FDL176 at fasted state|Part 2: single dose of FDL176 test formulation, fasted state.
89545708|NCT03173573|Experimental|Part 2 SAD FDL176 at fed state|Part 2: single dose of FDL176 test formulation, fed state
89545709|NCT03173573|Experimental|Part 3 SAD FDL176 test formulation|Part 3: Single dose of FDL176 test formulation on healthy females.
89545710|NCT03173573|Placebo Comparator|Part 3 SAD placebo|Part 3: Single dose of Placebo for FDL176.
89545711|NCT03173573|Experimental|Part 4 MAD FDL176 Level 1 to 3|Part 4: Dose escalation of FDL176 test formulation Level 1 to 3.
89545712|NCT03173573|Placebo Comparator|Part 4 MAD Placebo|Part 4: Dose escalation of Placebo for FDL176 Level 1 to 3.
89545713|NCT03173573|Experimental|Part 5 SAD FDL176 test formulation|Part 5: Single dose of FDL176 test formulation.
89545714|NCT03173495|Experimental|FRUCTOSE|Day 0, 45 min in rest position. Day 1, High Fat Meal (HFM) consisted of macronutrients (50% fat, 40% carbohydrate and 10% protein) with a fructose-rich beverage (0.5 g / kg). Day 2, High Fat Meal (HFM) consisted of macronutrients (50% fat, 40% carbohydrate and 10% protein) with a dextrose-rich beverage (0.5 g / kg).
89545715|NCT03173495|Placebo Comparator|DEXTROSE|Day 0, 45 min in rest position. Day 1, High Fat Meal (HFM) consisted of macronutrients (50% fat, 40% carbohydrate and 10% protein) with a dextrose-rich beverage (0.5 g / kg). Day 2, High Fat Meal (HFM) consisted of macronutrients (50% fat, 40% carbohydrate and 10% protein) with a dextrose-rich beverage (0.5 g / kg).
89545716|NCT03173495|Active Comparator|FRUCTEX|Day 0, 45 min of 60%VO2peak aerobic exercise . Day 1, High Fat Meal (HFM) consisted of macronutrients (50% fat, 40% carbohydrate and 10% protein) with a fructose-rich beverage (0.5 g / kg). Day 2, High Fat Meal (HFM) consisted of macronutrients (50% fat, 40% carbohydrate and 10% protein) with a dextrose-rich beverage (0.5 g / kg).
89545717|NCT05508945|Experimental|Surgical Incision|Abdominoplasty Surgical Incision, Breast Reduction Surgical Incision, Mastopexy Surgical Incision, or Belt Lipectomy Surgical Incision
89545718|NCT03173339|Active Comparator|Low remifentanil and high sevoflurane|Remifentanil was administered as 0.1 mcg/kg/min. Sevoflurane was started as 0.5 MAC. Sevoflurane dose was adjusted to maintain blood pressure (20% of preoperative blood pressure) and bispectral index (40-60) by 0.2 %.
89545719|NCT03173339|Experimental|High remifentanil and low sevoflurane|Sevoflurane was administered as 0.5 MAC. Remifentanil was started as 0.25 mcg/kg/min. Remifentanil dose was adjusted to maintain blood pressure (20% of preoperative blood pressure) and bispectral index (40-60) by 0.05 mcg/kg/min.
89545720|NCT03173261|Other|tuberculous pleural effusion|diagnosis of tuberculous pleural effusion and genitourinary tuberculosis by Genexpert by urine and pus and pleural fluid aspirate
89545721|NCT03173183|Experimental|genuine regional Rhizoma Atractylodis|"Granules of genuine regional Rhizoma Atractylodis:~Maozhu granule, 9g per bag, manufactured by Guangdong Yifang Pharmaceutical Co., Ltd., orally administration, 9g per time, 3 times a day."
89545722|NCT03173183|Active Comparator|non-genuine regional Rhizoma Atractylodis|"Granules of non-genuine regional Rhizoma Atractylodis (Luotian, Hubei province) :~Luozhu granule, 9g per bag, manufactured by Guangdong Yifang Pharmaceutical Co., Ltd., orally administration, 9g per time, 3 times a day."
89545723|NCT03173183|Placebo Comparator|placebo|placebo granules: Simulants (granule), 9g per bag, manufactured by Guangdong Yifang Pharmaceutical Group Co., Ltd., orally administration, 9g per time, 3 times a day.
89545724|NCT04757805|Experimental|Spinal anesthesia|Infants receiving spinal anesthesia for standard of care procedure
89545725|NCT03172871|Experimental|Aripiprazole IM Depot|"Aripiprazole IM depot group (Aripiprazole IM Depot):~The first 2 weeks of the acute treatment phase IM Injection 400 mg every 4 weeks + Aripiprazole tablets 10-20 mg per day After the first two weeks of the acute treatment phase IM Injection 400/300 mg every 4 weeks + placebo（tablets）(once a day)"
89545726|NCT03172871|Active Comparator|Aripiprazole tablet|"Oral aripiprazole group (Aripiprazole tablet):~The first 2 weeks of the acute treatment phase Placebo (Injection) every 4 weeks + Aripiprazole tablets 10-20 mg per day After the first two weeks of the acute treatment phase Placebo (Injection) every 4 weeks + Aripiprazole tablets 10-20 mg per day"
89545727|NCT05506995||Vitiligo vulgaris|A serial of vitiligo patients under treatment with UVB-NB
89545728|NCT02065336|Experimental|ARC-520 Cohort 1|a single intravenous (IV) dose of double-blind ARC-520 Injection 1.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection
89545729|NCT02065336|Placebo Comparator|ARC-520 Cohort 2|a single IV dose of double-blind ARC-520 Injection 2.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection
89545730|NCT02065336|Experimental|ARC-520 Cohort 3|a single IV dose of double-blind ARC-520 Injection 3.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection
89545731|NCT02065336|Experimental|ARC-520 Cohort 4|a single IV dose of double-blind ARC-520 Injection 4.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection
89545732|NCT02065336|Experimental|ARC-520 Cohort 5|a single IV dose of double-blind ARC-520 Injection 4.0 mg/kg in combination with entecavir administered to participants with HBeAg-positive immune active chronic HBV infection
89545733|NCT02065336|Experimental|Placebo Normal Saline Cohorts 1-5|a single IV dose of double-blind normal saline in combination with entecavir administered to participants with HBeAg-negative or -positive immune active chronic HBV infection
89545734|NCT02065336|Experimental|ARC-520 Cohort 6|two IV doses of open-label ARC-520 2.0 mg/kg administered to participants with HBeAg-positive immune active chronic HBV
89545735|NCT02065336|Experimental|ARC-520 Cohort 7|a single IV dose of open-label ARC-520 4.0 mg/kg administered to treatment-naïve, HBeAg-negative or -positive participants with chronic hepatitis B (CHB)
89545736|NCT02065336|Experimental|ARC-520 Cohort 8|open-label multi-dose extension cohort: multiple IV doses of open-label ARC-520 (4.0 mg/kg every [Q]4 weeks) administered to HBeAg-negative participants with CHB receiving chronic entecavir therapy who completed Cohorts 1 through 4
89545737|NCT02065336|Experimental|ARC-520 Cohort 9|open-label multi-dose extension cohort: multiple IV doses of open-label ARC-520 (4.0 mg/kg Q6 weeks or Q8 weeks) administered to HBeAg-positive participants with CHB receiving chronic entecavir therapy who completed Cohorts 5 or 6
89545738|NCT02065336|Experimental|ARC-520 Cohort 10|open-label multi-dose extension cohort: multiple IV doses of open-label ARC-520 (4.0 mg/kg Q4 weeks) administered to a mixed cohort (HBeAg-negative and -positive participants) who were naïve (within the last 6 months) to entecavir treatment and completed Cohort 7
89545739|NCT02065336|Experimental|ARC-520 Cohort 11|a single IV dose of open-label ARC-520 5.0 mg/kg administered to treatment-naïve, HBeAg-positive participants with CHB
89545740|NCT02065336|Experimental|ARC-520 Cohort 12|a single IV dose of open-label ARC-520 6.0 mg/kg administered to treatment-naïve, HBeAg-positive participants with CHB
89545741|NCT02408003|Experimental|Levosimendan|"st dose: 12 µg/kg iv bolus for 10 min followed by 0,1 µg/kg/min for 20 min.~nd dose: 12 µg/kg iv bolus for 10 min followed by 0,2 µg/kg/min for 20 min."
89545742|NCT02408003|Experimental|Milrinone|"st dose: 48 µg/kg iv bolus for 10 min followed by 0,4 µg/kg/min for 20 min.~nd dose: 48 µg/kg iv bolus for 10 min followed by 0,8 µg/kg/min for 20 min."
89545743|NCT02407769|Experimental|Branched chain amino acids|The patients will drink a Enterex Hepatic bag (500 Kcal, 18.6g of proteins of which 8.63g are branched chain amino acids, 71.7g of carbohydrates and 15.4g of lipids) during the late evening (after 19:00 hours) daily by two months.
89545744|NCT02407769|Sham Comparator|Late evening snack|The patients will eat a snack with similar nutrimental facts that food supplement (480 Kcal, 19g of proteins and they were based in casein and vegetable proteins; 17g of lipids and 63g of carbohydrates) during the late evening (after 19:00 hours) daily by two months.
89545745|NCT04790409|Experimental|Sintilimab with anlotinib|Patients received sintilimab (anti-PD-1) combined with anlotinib (multi-target anti-angiogenesis).
89545746|NCT02407535|Experimental|Endometrial carcinoma patient|
89545747|NCT02407379|Active Comparator|PAPD+SRP Quadrant|This quadrant, randomly selected in each patients, undergoes treatment with PAPD+ SRP
89545748|NCT02407379|Sham Comparator|Sham-laser + SRP|This quadrant, randomly selected in each patients, undergoes treatment with sham-laser + SRP
89545749|NCT02407301||Laryngeal function in cough|cough airflow measure, vocal tasks, true vocal fold movement, spirometry test, and maximum expiratory pressure (MEP) assessment will be performed in this group.
89545750|NCT05506917|Experimental|Periodontal treatment group|Patients will receive an intensive (non surgical) regimen of scaling and root planing of the root surfaces under local analgesia (depending on the severity in one session or two sessions within 2 days). Any tooth that from the baseline examination is defined as hopeless or irrational to treat will be extracted at the oral hygiene visit. After the 2 months re-assessment individuals if presenting with at least one periodontal pocket of 6 mm in depth will undergo additional corrective periodontal therapy consisting of periodontal surgery and re-instrumentation under local analgesia. If surgical periodontal therapy is not indicated, appropriate re-instrumentation of the sites will be performed.
89545751|NCT05506761|No Intervention|Group I|This group includes patients with rib fractures receiving patient-controlled analgesia.
89545752|NCT05506761|Experimental|Group II|This group includes patients with rib fractures receiving continuous ultrasound-guided erector spinae plane block.
89545753|NCT05506761|Experimental|Group III|This group includes patients with rib fractures receiving continuous ultrasound-guided rhomboid intercostal block combined with sub-serratus plane block.
89545754|NCT02407067|Active Comparator|Voice Amplifier|Participant will be fit with a voice amplifier (ChatterVox) and it will be used during speech testing and during regular conversations over a one week period.
89545755|NCT02407067|Experimental|Personal Communication System|Participant will be fit with a personal communication system (Easy Listener FM system) and it will be used during speech testing and during regular conversations over a one week period.
89545756|NCT02406989|Experimental|MS-553|MS-553 oral tablet BID x 14 days
89545757|NCT02406989|Placebo Comparator|Placebo|Placebo oral tablet BID x 14 days
89545758|NCT05508711||Group 1|"st cardiac output measurement (horizontal supine position): Transesophageal echocardiographic cardiac output measurements, data recorded and in the meantime the data of the FloTrac system (© Edwards Lifesciences) monitor recorded also.~nd cardiac output measurement (Trendelenburg position): The operating table was then tilted in - 30 ° Trendelenburg (head-down) position. Echocardiographic measurements and FloTrac system (© Edwards Lifesciences) data were recorded.~rd cardiac output measurement: The patients were positioned from Trendelenburg to reverse-Trendelenburg, the above-described data were recorded again."
89025081|NCT03276741|Active Comparator|Experimental Group|"Patients in the experimental group will have a gastric soft/bland diet available, which will include lean protein, fruits, vegetables, and low-fat dairy. This will be ordered in the electronic medical record (EMR) and is a standard non-select meal, referred to as a gastric/soft bland diet that is not based on patient's preferred menu selections."
89025082|NCT03279146|Active Comparator|Regimen A|Immediate release tablet Tenofovir exalidex (TXL)
89025083|NCT03279146|Experimental|Regimen B|New Formulation 1 Tenofovir exalidex (TXL)
89025084|NCT03279146|Experimental|Regimen C|New formulation 2 Tenofovir exalidex (TXL)
89545759|NCT05508711||Group 2|"st cardiac output measurement (horizontal supine position): Transesophageal echocardiographic cardiac output measurements, data recorded and in the meantime the data of the FloTrac system (© Edwards Lifesciences) monitor recorded also.~nd cardiac output measurement (reverse Trendelenburg position): The operating table was then tilted in + 30 ° reverse Trendelenburg (head-up) position. Echocardiographic measurements and FloTrac system (© Edwards Lifesciences) data were recorded.~rd cardiac output measurement: The patients were positioned from reverse Trendelenburg to Trendelenburg, the above-described data were recorded again."
89545760|NCT02406911|Experimental|Ticagrelor 90 mg|After randomization, an initial loading dose of ticagrelor (180 mg) was given and low dose ticagrelor (ticagrelor 90 mg once a day) was treated for 14 days.
89545761|NCT02406911|Active Comparator|Ticagrelor 180 mg|After randomization, an initial loading dose of ticagrelor (180 mg) was given and usual dose ticagrelor (ticagrelor 90 mg twice a day) was treated for 14 days.
89545762|NCT02406833|Experimental|TGF-β2 antisense oligonucleotide|"Core Study: Administered intravitreally at the time of trabeculectomy at escalating doses~Post-Study Follow-up: until 1 year after administration"
89545763|NCT03173027|Experimental|Experimental group|Drug: Fangji Huangqi pill 4g, twice a day, one month, oral Drug: Mobic 7.5mg, once a day, one month, oral participants should administrate both pill and Mobic
89545764|NCT03173027|Placebo Comparator|Placebo group|Drug: Fangji Huangqi pill placebo 4g, twice a day, one month, oral Drug: Mobic 7.5mg, once a day, one month, oral participants should administrate both pill placebo and Mobic
89545765|NCT03173105|Active Comparator|Group 1 (G1)|active tDCS + dynamic proprioceptive exercises
89545766|NCT03173105|Sham Comparator|Group 2 (G2)|sham tDCS + dynamic proprioceptive exercises
89545767|NCT03173105|Active Comparator|Group 3 (G3)|active tDCS + static proprioceptive exercises
89545768|NCT03173105|Sham Comparator|Group 4 (4)|sham tDCS + static proprioceptive exercises
89545769|NCT03172793|Experimental|Telavancin injection Dose 1 (7.5mg/kg)|The pharmacokinetics and tolerability of telavancin 7.5mg/kg q24h will be measured in 6 participants.
89545770|NCT03172793|Experimental|Telavancin injection Dose 2 (10mg/kg)|After completion and analysis of 7.5mg/kg group, the next 6 participants will receive 10mg/kg q24h, and pharmacokinetics and tolerability will be measured.
89545771|NCT03172793|Experimental|Telavancin injection Dose 3 (TBD)|The third arm will enroll 6 participants to receive the following dose of telavancin q24h: 7.5, 10, 12.5, or 15 mg/kg. The final dose will be selected based on pharmacokinetic studies from first 12 participants, tolerability, and pharmacodynamic modeling.
89545772|NCT03116087|Active Comparator|Testosterone patch|Testosterone patches
89545773|NCT03116087|Placebo Comparator|Placebo|Placebo patches
89545774|NCT03116165|Experimental|Modified prolonged exposure therapy|Participants will receive three sessions of modified prolonged exposure therapy.
89545775|NCT03116165|Placebo Comparator|Attention control|Participants will receive three sessions of supportive counselling and psychoeducation
89545776|NCT03116009|Active Comparator|Screening for diabetes with 1-hour GCT and HbA1|Participants in this group will do 1-hour GCT before 20 weeks of gestation. Those with positive test will undergo 3-hours OGTT. Diabetes will be diagnosed if they have two or more abnormal values out of the 4 values and they will be treated accordingly based on the institutional protocol. They will also have HbA1C done.
89545777|NCT03116009|Experimental|Early screening with only HbA1C|Participants in this group will only have HbA1C done before 20 weeks but will do the standard diabetes screening at 24 - 28 weeks. Those who have abnormal values will also be treated based on the institutional protocol.
89025085|NCT00441935||Interstim Neuromodulation|Subjects undergoing implantation of an Interstim device for neuromodulation.
89025086|NCT03275571|Experimental|cCBT intervention|Over the course of 9 weeks, 30 min online sessions, once per week, with a fictive therapist.
89545778|NCT02406755|No Intervention|Control|This control group will not receive an intervention.
89545779|NCT02406755|Active Comparator|one-sensory self care|Daily moisturizing body care with an odorless moisturizer (Todo Dia® - Natura) for 30 days.
89545780|NCT02406755|Active Comparator|bi-sensory self care|Daily moisturizing body care with a moisturizer with cotton fragance (Todo Dia® - Natura) for 30 days.
89025087|NCT00477243||Palliative Care Clinic Patients|Department of Symptom Control and Palliative Care Center Patients
89025088|NCT00442091|Other|10 ml of dandelion juice twice daily|
89025089|NCT00477282|Experimental|Karenitecin|
89545781|NCT02406755|Active Comparator|multisensory self care|Daily moisturizing body care with a moisturizer with cotton fragance (Todo Dia® - Natura) for 30 days, and will watch a video with music and images of nature during self-care.
89545782|NCT02406599|Other|SOC + Device|The surgeon will perform routine standard of care lumpectomy with adjunctive MarginProbe device use on the main ex-vivo lumpectomy specimen.
89545783|NCT02406599|Other|SOC + Additional Inspection|The surgeon will perform routine standard of care lumpectomy with additional inspection on the main ex-vivo lumpectomy specimen.
89545784|NCT03172637||Group A|50 female end stage renal disease patients
89545785|NCT03172637||Group B|50 normal female patients
89545786|NCT04482023||Nurses COVID 19|Nurses from any unit of the Consortium Parc Taulí Corporation who have been in direct care of patients diagnosed with COVID 19 between March 9, 2020 and May 15, 2020
89545787|NCT03172559|Experimental|Stereotactic body radiotherapy|Stereotactic body radiotherapy (SBRT) treatment will be individualized with the dose based on baseline liver function, effective liver volume irradiated and proximity to other normal tissues. The recommended dose will be 30 gray (Gy) in 5 fractions. The treatment will be administered in 5 alternative days. Patients will come every other day to the hospital to be treated and will not need to be admitted. Patients will not receive further SBRT on the treated tumor.
89545788|NCT03172559|No Intervention|No intervention|Follow-up will be carried out every 3 months and a computed tomography (CT) scan of the chest and abdomen or an magnetic resonance imaging (MRI), and blood work with liver function test and alpha-fetoprotein (AFP) value will be done until the patient is transplanted or drops-out of the waiting list.
89545789|NCT02701985|Placebo Comparator|Placebo|Matching-placebo capsules will be administered orally, 2 times a day, for up to 12 weeks.
89545790|NCT02701985|Experimental|RO5459072|RO5459072 at a dose of 100 milligrams (as capsules) will be administered orally, 2 times a day, for up to 12 weeks.
89545791|NCT03172169||Healthy control group|no intervention
89545792|NCT03172169||Difficult withdrawal group|The mechanical ventilation time was >48 hours and the first SBT failure
89545793|NCT03172169||Mechanical ventilation control group|Elective and expected postoperative control of mechanical ventilation time greater than 12h after cardiothoracic surgery
89545794|NCT02064868|Experimental|Serelaxin + Standard of Care|Serelaxin (30 µg/kg/day) as continuous 48 hour intravenous infusion plus standard of care.
89545795|NCT02064868|Other|Standard of Care (SOC)|All patients were required to receive standard of care background heart failure (HF) management during the study, according to local guidelines/international standards. This treatment can include but is not limited to intravenous and/or oral diuretics, angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor antagonists, beta blockers and aldosterone receptor antagonists, etc.
89545796|NCT03171935|Experimental|High-Flow Nasal Cannula Oxygenation|
89545797|NCT03171935|Experimental|Noninvasive Positive Pressure Ventilation|
89025090|NCT00477282|Active Comparator|Topotecan|
89207807|NCT04093752|Experimental|15 mg Tirzepatide|Participants received 15 mg tirzepatide administered SC QW.
89545798|NCT03171935|Active Comparator|Conventional Weaning|
89545799|NCT03172013||Cirrhotic ascitic patients with SBP,|Cirrhotic ascitic patients with SBP,
89545800|NCT03172013||cirrhotic ascitic patients without SBP,|cirrhotic ascitic patients without SBP,
89545801|NCT03172013||Healthy volunteers|Healthy individuals
89545802|NCT03172091|Experimental|Acute rejection|Pulmonary transplant patients with acute rejection
89545803|NCT03172091|Other|Control group|Pulmonary transplant patients without acute rejection
89545804|NCT02406521|Experimental|Arm A: Pazopanib with Radium-223|"No prior targeted therapy~Pazopanib oral, daily and at predetermined dosage per cycle~Radium-223 predetermined dosage via IV, per cycle"
89545805|NCT02406521|Experimental|Arm B: Sorafenib with Radium-223|"At least one line of prior targeted therapy:~Sorafenib at predetermined dosage, mouth twice daily~Radium-223 predetermined dosage via IV, per cycle"
89545806|NCT02406287|Experimental|Active|Netarsudil (AR-13324) Ophthalmic Solution
89545807|NCT02406287|Placebo Comparator|Placebo|Netarsudil (AR-13324) Ophthalmic Solution Placebo
89545808|NCT02406365|Experimental|Standard of care plus imaging with research devices|"Eligible patients who consent to participate in the research study will receive their standard of care colposcopy or treatment with the Loop Electrosurgical Excision Procedure (LEEP). Additionally, cervical images will be taken using the diagnostic imaging aid. The cervical images will be compared to the histopathology from the biopsies taken as part of the patients' standard of care for colposcopy. If the patient is presenting for the LEEP procedure, then she will be asked if one or two biopsies can be obtained prior to the procedure but after anesthesia has been administered.~The imaging device is not being used to make a diagnosis, but rather to develop an algorithm to make more efficacious and timely diagnoses of cervical neoplasias in the future."
89545809|NCT02406131|No Intervention|Control Group:|This group will be getting all the routine work up including Duplex scan . we will add request for inflammatory and coagulation markers in their blood samples before and after intervention . The pre-op blood sample will be collected within the 24 hours before intervention and the post intervention in the 24 hrs after (second RIPC window). The repeated duplex scan will be schedule after 6 months.
89545810|NCT02406131|Active Comparator|RIPC Group|Remote Ischemic Preconditioning Group (RIPC):This group will have all the tests as for the control group with the additional component will be preconditioning. One hour prior to procedure candidates in this group will have structured intermittent periods of induced remote ischaemic preconditioning using standard blood pressure cuffs. The cuff will be inflated to 200 mmHg applied for 5 minutes alternating with 5 minutes rest to the total of 4 cycles, which needs 40 minutes.
89545811|NCT02405975|No Intervention|Control|These participants will not receive the educational intervention
89545812|NCT02405975|Experimental|Intervention|"These participants will receive the online educational intervention SCRIPT"
89545813|NCT02405897|Experimental|Cup forceps|4 biopsies (transbronchial lung biopsy) with Cup forceps
89545814|NCT02405897|Active Comparator|Alligator forceps|4 biopsies (transbronchial lung biopsy) with Alligator forceps
89545815|NCT02406053||OSAS|Obstructive sleep apnea syndrome
89545816|NCT02406053||COPD|Chronic obstructive pulmonary disease
89545817|NCT02406053||LC|Lung cancer
89545818|NCT02406053||HC|Healthy controls
89545819|NCT02064166|Experimental|Insulin|40 IU of intranasal insulin daily
89545820|NCT02064166|Placebo Comparator|Placebo|Placebo arm using intranasal normal saline
89545821|NCT04482335||Main Study|Participants complete questionnaires and agree to have their retrospective and prospective medical data used as part f this research project. All participants will take part in this arm.
89545822|NCT04482335||Biosample Sub-Study|A subset of the participants will take part of this. Participants will agree to have blood samples taken at regular intervals or at the point of a flare or when their treatment changes. They might also be asked to provide urine samples.
89545823|NCT04482335||Synovial Biopsy and Synovial Fluid Sub-Study|A subset of the participants will take part of this. Participants will agree to synovial biopsies at regular intervals or at the point of a flare or when their treatment changes. They might also be asked to donate waste synovial fluid.
89545824|NCT02405819|Other|Patient Directed|We will collect baseline data, including sociodemographic information for the patients and an assessment of each patient's baseline supportive care needs and knowledge about survivorship care. Sociodemographic information will be self completed. All other data collection will be interviewer administered. The instruments used at baseline and follow-up are adapted from previously published surveys (Hodgkinson et al, 2007; Sprague et al, 2013; Griggs et al). The research team will direct patients to their assigned condition by providing a hand-out directing them to the planning tool. After 2 months, we will re-contact all randomized patients to determine whether the survivorship care planning occurred as intended.
89545825|NCT02405819|Other|Clinician Directed|We will collect baseline data, including sociodemographic information for the patients and an assessment of each patient's baseline supportive care needs and knowledge about survivorship care. Sociodemographic information will be self completed. All other data collection will be interviewer administered. The instruments used at baseline and follow-up are adapted from previously published surveys (Hodgkinson et al, 2007; Sprague et al, 2013; Griggs et al). The provider will be provided a hand-out with their patient's assigned condition and is responsible for implementing the survivorship care plan process. After 2 months, we will re-contact all randomized patients to determine whether the survivorship care planning occurred as intended.
89545826|NCT03171701||maturation of arteriovenous fistula|
89545827|NCT02405663|Experimental|manual removal group|Group will be assigned for manual removal of the placenta as the surgeon will introduce his hand into the uterine cavity to cleave the placenta from the decidua basalis as soon as possible after the delivery of the baby by caesarean section
89545828|NCT02405663|Experimental|cord traction group|Group will be assigned for controlled cord traction as the surgeon do external uterine massage and gentle traction on the exposed umbilical cord to facilitate placental delivery after the delivery of the baby by caesarean section
89545829|NCT03171467|Experimental|Salpingectomy|Opportunistic salpingectomy at the time of laparoscopic cholecystectomy
89545830|NCT03171779||Usual practice|
89545831|NCT03171779||IPEM|Interprofessional Training in Early Identification and Multidimensional Evaluation (IPEM) of patients' palliative needs
89545832|NCT03171779||IPEM and PAS|Interprofessional Early Identification Training and Multidimensional Assessment (IPEM) of patients' palliative needs, and to the Early Care Planning (SAP)
89025091|NCT00442130|Experimental|GM-K562 Vaccine|"Biological/Vaccine: GM-K562 vaccine The vaccine will be administered over 1 cycle of 7 weeks, that begins 1 month after stem cell transplant. The vaccine will be given 6 times over 2 months -- once a week for three weeks then every other week for 3 vaccines.~Procedure/Surgery: stem cell transplantation Participants will be admitted to the hospital for approximately 8 days to receive chemotherapy and stem cell transplantation"
89545833|NCT03171623|Experimental|SY-004 2mg|SY-004 (globalagliatin hydrochloride) 2mg by mouth, single dose
89545834|NCT03171623|Placebo Comparator|SY-004 20mg&placebo|SY-004 (globalagliatin hydrochloride) 20mg or placebo by mouth, single dose
89545835|NCT03171623|Placebo Comparator|SY-004 40mg&placebo|SY-004 (globalagliatin hydrochloride) 40mg or placebo by mouth, single dose
89545836|NCT03171623|Placebo Comparator|SY-004 80mg&placebo|SY-004 (globalagliatin hydrochloride) 80mg or placebo by mouth, single dose
89545837|NCT03171623|Placebo Comparator|SY-004 120mg&placebo|SY-004(globalagliatin hydrochloride) 120mg or placebo by mouth, single dose
89545838|NCT03171389|Experimental|Cohort A|patients with primary c-KIT mutations and with either no detectable or non-exon13-secondary mutations (as measured by plasma sequencing); failure of imatinib treatment (only) Treatment with oral ponatinib 30MG (milligram) daily until progression or intolerable side effects.
89545839|NCT03171389|Experimental|Cohort B|GIST patients with primary c-KIT mutations and secondary c-KIT mutations in Exon 13; failure of imatinib treatment (only) Treatment with oral ponatinib 30MG daily until progression or intolerable side effects.
89545840|NCT03171389|Experimental|Cohort C|"GIST patients with KIT-mutations and treatment failure of imatinib, sunitinib and regorafenib.~Treatment with oral ponatinib 30MG daily until progression or intolerable side effects."
89545841|NCT02405507|Experimental|wheat bread with wheat germ|wheat bread with wheat germ supplementation
89545842|NCT02405507|Placebo Comparator|wheat bread without wheat germ|wheat bread without wheat germ supplementation
89545843|NCT02405273|Experimental|Interventional Group|Pulmonary rehabilitation
89545844|NCT02405273|Active Comparator|Control Group|Standard Care
89545845|NCT02565615||Atorvastatin dose titration (single-arm)|Judged by investigators, patients in cardiology department who are using atorvastatin can be included into this study, if they are eligible. During the study, the dose can be titrated based on the judgement of investigator
89545846|NCT02405117|Experimental|LiveWell System|For 16 weeks, participants will be asked to carry a mobile phone and wear a wrist-worn device for measuring activity. Participants in this arm will receive the psychosocial intervention via a smartphone and context-dependent feedback based on self-report and behavioral data. Providers whose patients are randomized to this arm will also be asked to enroll in order to receive information and notifications about patient status for the duration of the study.
89545847|NCT02405117|No Intervention|Treatment As Usual|For 16 weeks, participants will be asked to carry a mobile phone and wear a wrist-worn device for measuring activity. Participants in this arm will be asked to provide limited self-report data via the phone.
89545848|NCT03170999||Subjects included in Focus groups|Approximately 45 subjects with COPD will participate in the focus group interviews for item identification. The group may contain subjects who are functionally illiterate and at least one third women will be recruited.
89545849|NCT03170999||Subjects included in cognitive interviews|Approximately 9 subjects with COPD will be involved in cognitive interviews and will be asked to respond to all of the items in the draft item set.
89545850|NCT03170999||Subjects included in candidate item set|Approximately 150 subjects with COPD will respond to the questions in candidate item set.
89545851|NCT03171077|Active Comparator|Virtual Rehabilitation|"A virtual rehabilitation program (G0) based on the use of the NW for a period of two months, with sessions two times a week for 50 minutes (a total of 16 sessions).All treatment groups prior to perform the study interventions,stretches of upper and lower limbs for 10 minutes.~The G0 treatment program consists of the following protocols: a) protocol 1 games (Balance Bubble Plus and Tennis); b) protocol 2 games (Rhythm Parade and Boxing)."
89545852|NCT03171077|Experimental|PNF Method|A program of therapeutic exercises (G1) based on the PNF method for a period of two months, with sessions two times a week for 50 minutes (a total of 16 sessions).All treatment groups prior to perform the study interventions,stretches of upper and lower limbs for 10 minutes. The G1 treatment program consists of the following protocols: a) protocol 1 : 30 minutes diagonal exercise upper limb (flexion-abduction-external rotation and extension-abduction-internal rotation), and 10 minutes diagonal exercise scapula (anterior and posterior elevation); b) protocol 2: 20 minutes diagonal exercise lower limb (flexion-abduction-external rotation and flexion-abduction-internal rotation),10 minutes diagonal exercise pelvis (anterior and posterior depression), and 10 minutes gait cycle training;
89545853|NCT03171077|Active Comparator|Virtual Rehabilitation and PNF Method|In G2 program will be performed 20 minutes G0 protocol (1 or 2, used alternately between sessions a week) and 20 minutes G1 protocol (1 or 2, used alternately between sessions a week), taking the time of the performed activities halved in both protocols.
89545854|NCT05508633|Experimental|Low dose Alverine|Alverine 60mg (1 capsule), orally
89545855|NCT05508633|Experimental|High dose Alverine|Alverine 120mg (2 capsules), orally
89545856|NCT04482257|Experimental|T-R|Subjects will receive Irinotecan Liposome Injection (CSPC) 70mg/m2 plus 5-FU/LV, followed by Irinotecan Liposome Injection (Ipsen) 70mg/m2 plus 5-FU/LV
89545857|NCT04482257|Experimental|R-T|Subjects will receive Irinotecan Liposome Injection (Ipsen) 70mg/m2 plus 5-FU/LV, followed by Irinotecan Liposome Injection (CSPC) 70mg/m2 plus 5-FU/LV
89545858|NCT02701361|Active Comparator|Education group|A care condition in which an educational program relevant to critical illness is presented in a web-based format similar to the other arms. Telephone calls will be used to answer questions and assist with web content.
89545859|NCT02701361|Experimental|Standard mindfulness|Receives audiovisual mindfulness content via internet plus 1 call per week from a trained mindfulness expert.
89545860|NCT02701361|Experimental|Mobile mindfulness|Receives audiovisual mindfulness content via web-app. Will receive at least 1 call from a trained mindfulness expert, though up to 4 total calls based on symptoms / request.
89545861|NCT05506527|Experimental|study group 1|Study group A: will receive combined plyometric exercises and sensorimotor program
89545862|NCT05506527|Experimental|study group 2|Study group B: will receive sensorimotor program alone
89545863|NCT02404727|Active Comparator|cup fixation cemented|30 of the 60 patients will be randomized to cemented cup fixation
89545864|NCT02404727|Active Comparator|cup fixation cementless|30 of the 60 patients will be randomized to cementless cup fixation
89545865|NCT05508555|Active Comparator|HITHOC group|the group that will receive HITHOC after pleurectomy decortication
89545866|NCT05508555|No Intervention|pleurectomy decortication without HITOC|the group who received pleurectomy decortication without HITHOC
89545867|NCT02404883|No Intervention|control group|care as usual (fertility preservation counseling)
89545868|NCT02404883|Experimental|intervention group|Intervention: use of an online decision-aid tool after fertility preservation counseling
89545869|NCT05502705|Experimental|Lidocaine|Intravenous bolus of 1.5 mg/kg of lidocaine followed by a continuous infusion of 3.0 mg/kg for the first hour, 1.5 mg/kg for the second hour, 0.7 mg/kg until the end of the surgery.
89545870|NCT05502705|Placebo Comparator|Normal saline|Normal saline administered as a bolus and an infusion with identical volume and rate changes as the treatment group.
89545871|NCT05508477|Experimental|Vaksin Merah Putih - UA SARS-CoV-2 (Vero Cell Inactivated) 5 µg|Study product are provided in the form of liquid in vial single dose (0.5 ml). The vaccine will be given twice with 28 days interval.
89545872|NCT05508477|Active Comparator|CoronaVac Biofarma COVID-19 Vaccine|Control vaccine is CoronaVac Bio Farma vaccine, supplied by Ministry of Health of Indonesia, in the form of two doses vial. The vaccine will be given twice with 28 days interval.
89545873|NCT02404961||Control (no vulvodynia)|Clinically-confirmed as a woman with no history of vulvodynia.
89025092|NCT00477321|Experimental|CYT107|CYT107 vs Placebo (4:1 ratio)
89545874|NCT02404961||Vulvodynia Case|Clinically-confirmed as a woman with vulvodynia.
89545875|NCT02405039|Active Comparator|Active Comparator: EBI-005|Drug: EBI-005 The investigational drug EBI-005, is an intervention to one of two study arms: 5 mg/mL topical administered 3 times per day
89545876|NCT02405039|Placebo Comparator|Placebo or Vehicle control Comparator|One of two study arms: placebo or vehicle control topical administered 3 times per day
89545877|NCT03171233|Active Comparator|Group mobilization with movement|Techniques to improve ankle mobility that possibily will to cause changes in the biomechanical motion of the lower limb. The patient does the movement actively, but is assisted by the therapist to mobilize.
89545878|NCT03171233|Active Comparator|Group Self mobilization with movement|Techniques to improve ankle mobility that possibily will to cause changes in the biomechanical motion of the lower limb. The patient performs the movement and the mobilization in an independently way without receiving help from the therapist
89545879|NCT05506293||paravalvular leak|patients referred for percutaneous paravalvular leak closure
89545880|NCT05508321|Experimental|Patients with confirmed or suspected telomeropathy|Patients with idiopathic pulmonary fibrosis, adult or pediatric medullar dysplasia or myelodysplasia, unexplained liver cirrhosis or unexplained liver regenerative nodular hyperplasia.
89545881|NCT05508321|Other|Controls|Age and sex-matched control participants
89545882|NCT05502627||Experimental group|scaling was done along with intervention (0.25% lemongrass mouthwash was given)
89025093|NCT03279107|No Intervention|Control beverage with glucose powder|Standard glucose beverage with 50 g of glucose powder
89545883|NCT05502627||control group|only scaling was done
89545884|NCT05506137|Experimental|Treatment|
89545885|NCT05506137|Placebo Comparator|Placebo|
89545886|NCT04742283|Experimental|DE-126 Opthalmic Solution 0.002% QD and Vehicle QD|DE-126 Ophthalmic Solution 0.002% is administered once daily (QD)
89545887|NCT04742283|Active Comparator|Timolol Maleate Opthalmic Solution 0.5% BID|Timolol Maleate Ophthalmic Solution 0.5% is administered twice daily (BID)
89545888|NCT04289805|Active Comparator|standard-stimulated cohort|this cohort includes all newly diagnosed breast cancer patients who are candidates to receive (neo)adjuvant chemotherapy and wish to preserve their fertility by undergoing oocyte/embryo cryopreservation at the French participating centres.
89545889|NCT04289805|Experimental|letrozole-stimulated cohort|this cohort includes all newly diagnosed breast cancer patients who are candidates to receive (neo)adjuvant chemotherapy and wish to preserve their fertility by undergoing oocyte/embryo cryopreservation at the Belgian participating centres.
89545890|NCT04289805|No Intervention|non-stimulated cohort|this cohort includes all newly diagnosed breast cancer patients who are candidates to receive (neo)adjuvant chemotherapy and who have access to the Fertility Clinics in all the participating centres but are not willing to preserve their fertility by undergoing oocyte/embryo cryopreservation.
89545891|NCT05508165|No Intervention|Cohort 1a: in-person clinical assessment of LUTS/BPH|COHORT 1a: Subjects randomized to undergo in-person initial clinical workup of Lower Urinary Tract Symptoms (LUTS) / Benign Prostatic Hyperplasia (BPH) and in-person clinical follow-up after 3 months of clinical intervention. In-person clinical workup at both the initial and Month 3 follow-up timepoint includes International Prostate Symptom Score (IPSS), and standard of care uroflowmetry, post void residual (PVR), and urinalysis (UA) assessments.
89545892|NCT05508165|Experimental|Cohort 1b: virtual (telehealth) clinical assessment of LUTS/BPH|COHORT 1b: Subjects randomized to undergo virtual initial clinical workup of Lower Urinary Tract Symptoms (LUTS) / Benign Prostatic Hyperplasia (BPH) and virtual clinical follow-up after 3 months of clinical intervention. Virtual clinical workup at both the initial and Month 3 follow-up timepoint includes at home completion of International Prostate Symptom Score (IPSS), at home uroflowmetry assessment through use of the Stream Dx device, at home assessment of post void residual (PVR) through use of the DFree device, and at home urinalysis (UA) through use of the TestCard device.
89545893|NCT05508165|Other|Cohort 2: Validation Cohort|COHORT 2: Non-randomized subjects who will attend a single, clinically scheduled, in-person follow-up appointment to directly compare the standard of care assessments/devices to the experimental assessments/devices. Prior to the in-person appointment, patients will complete at home uroflowmetry assessment through use of the Stream Dx device. At the in-person appointment, the clinic staff will perform standard of care uroflowmetry, post void residual (PVR), and urinalysis (UA). At this visit, clinic staff will also obtain PVR measurements through use of the DFree device and urinalysis through the TestCard device.
89545894|NCT05505981|Experimental|Immediate Functional Progression Group|Athletes randomized to this group will start Physical Therapy immediately (with 7 days of diagnosis). Once in PT, Athletes will perform phase I (neutral spine) of the program and progress to phase II (functional motion) as able without an increase in pain and without compensations noted in function. The athlete will be assessed at each session to determine if they meet the criteria to begin the next step of functional progression program. Once the athlete has met the criteria of phase II, they will progress into the final phase of the functional progression program for return to sport activity. As these athletes progress through the third phase, and are able to meet the return to sport criteria, they will be released to return to sport. Athletes will not be released to return to sport prior to their first physician follow-up visit at 4 weeks.
89545895|NCT05505981|Active Comparator|Rest until pain resolves Group|Athletes with an active spondylolysis randomized into the control group will rest from all activity until their pain has resolved. Physicians will assess pain resolution at each visit which occurs every four weeks. Once the pain has resolved, the patient will be referred to physical therapy (PT) two times per week. The time, frequency, and exercise progression will be the same as the IFPP group. Since the pain has resolved in these participants be-fore initiating PT, the criteria to progress through phases will be time-based, not pain and function-based.
89545896|NCT04782921|Experimental|Gel 40|Application of Gel 40
89545897|NCT04782921|Active Comparator|Gen-Os|Application of Gen-Os
89545898|NCT05502471|Other|ADHD|Children with ADHD
89545899|NCT05502471|Other|Control|Children without any psychiatric disorder
89545900|NCT05502393|Experimental|JS107|
89545901|NCT05502393|Experimental|JS107 combination with Toripalimab|
89545902|NCT05449431|Experimental|TLC1_TM6|Patient doing 1-minute chair lift test (TLC1) before 6-minute Walk Test (TM6).
89545903|NCT05449431|Experimental|TM6_TLC1|Patient performing 6-minute Walk Test (TM6) before 1-minute chair lift test (TLC1)
89545904|NCT05505591||High bleeding risk|Patients treated with cangrelor who met the Academic Research Consortium (ARC) definition of high bleeding risk (HBR)
89545905|NCT05505591||Non-high bleeding risk|Patients treated with cangrelor who did not meet the Academic Research Consortium (ARC) definition of high bleeding risk (HBR)
89545906|NCT05448807|Experimental|participants receiving oraverse injection after local anaesthetic administration|participants receive phentolamine mesylate (Oraverse) injection after the completion of their dental procedures with ratio 1:1 to LA in children weighed 30 kg and more while in children less than 30 kg only half of the amount of the cartridge is administrated.
89545907|NCT05448807|No Intervention|participants with no drug after local anaesthetic administration|participants don't receive any reversal agent or placebo after the completion of their dental procedures.
89545908|NCT05402631||New patient with lower back pain|
89545909|NCT05402631||known patient with lower back pain|
89025094|NCT03279107|Experimental|Beverage with soluble corn fiber|Beverage with soluble corn fiber (50 gram of total carbohydrate)
89545910|NCT01662999|Experimental|A-B-C: Saxagliptin-Dapagliflozin-(Saxagliptin+Dapagliflozin)|Treatment A: Saxagliptin 5mg, Tablet, Oral; Single dose Treatment B: Dapagliflozin 10mg, Tablet, Oral; single dose Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral; single dose
89545911|NCT01662999|Experimental|A-C-B: Saxagliptin-(Saxagliptin+Dapagliflozin)-Dapagliflozin|Treatment A: Saxagliptin 5mg, Tablet, Oral, single dose; Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral, single dose; Treatment B: Dapagliflozin 10mg, Tablet, Oral, single dose
89545912|NCT01662999|Experimental|B-A-C: Dapagliflozin-Saxagliptin-(Saxagliptin+Dapagliflozin)|Treatment B: Dapagliflozin 10mg, Tablet, Oral, single dose. Treatment A: Saxagliptin 5mg, Tablet, Oral, single dose; Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral, single dose
89545913|NCT01662999|Experimental|B-C-A: Dapagliflozin-(Saxagliptin+Dapagliflozin)-Saxagliptin|Treatment B: Dapagliflozin 10mg, Tablet, Oral, single dose; Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral, single dose; Treatment A: Saxagliptin 5mg, Tablet, Oral, single dose
89545914|NCT01662999|Experimental|C-A-B: (Saxagliptin+Dapagliflozin)-Saxagliptin-Dapagliflozin|Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral, single dose; Treatment A: Saxagliptin 5mg, Tablet, Oral, single dose; Treatment B: Dapagliflozin 10mg, Tablet, Oral, single dose
89545915|NCT01662999|Experimental|C-B-A: (Saxagliptin+Dapagliflozin)-Dapagliflozin-Saxagliptin|Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral, single dose; Treatment B: Dapagliflozin 10mg, Tablet, Oral, Once daily, single dose; Treatment A: Saxagliptin 5mg, Tablet, Oral, single dose
89545916|NCT05366283|Experimental|Cohort 1 (Part 1)|Single dose of 250 microgram (mcg) sargramostim IV over 2 hours
89545917|NCT05366283|Experimental|Cohort 2 (Part 1)|Single dose of 25 mcg sargramostim SC
89545918|NCT05366283|Experimental|Cohort 3 (Part 1)|Single dose of 125 mcg sargramostim SC
89545919|NCT05366283|Experimental|Cohort 4 (Part 1)|Single dose of 250 mcg sargramostim SC
89545920|NCT05366283|Experimental|Cohort 5 (Part 1)|Single dose of 500 mcg sargramostim SC
89545921|NCT05366283|Experimental|Cohort 6 (Part 1)|Single dose of 250 mcg sargramostim IH
89545922|NCT05366283|Experimental|Cohort 7 (Part 2)|Two doses of 500 mg sargramostim SC, weekly
89545923|NCT05319951|Experimental|Oral Rehydration Salts Power (iii)|Dissolve 2 packs of Oral Rehydration Salts Power (iii) (5.125g/pack) in 500ml water and let the subjects drink it up in 20 minutes prior to donation.
88961505|NCT05777876|Experimental|TRD Target stimulation B|Patients do not respond favorably to two antidepressants. The subjects get clinical evaluation, blood sample collection, magnetic resonance scanning, and electrophysiological monitoring. Regimen: Receiving TIS intervention with target B (Characteristic abnormal brain region targets based on data-driven exploration) for 10 times, once a day (except weekends and holidays) for 2 weeks. Stimulation（130Hz, 2mA total current intensity, each stimulation lasts for 30 minutes, 15 seconds respectively for import and exit).
88961506|NCT05777876|Experimental|TRD Target stimulation C|Patients do not respond favorably to two antidepressants. The subjects get clinical evaluation, blood sample collection, magnetic resonance scanning, and electrophysiological monitoring. Regimen: Receiving TIS intervention with target C (Characteristic abnormal brain region targets based on data-driven exploration) for 10 times, once a day (except weekends and holidays) for 2 weeks. Stimulation（130Hz, 2mA total current intensity, each stimulation lasts for 30 minutes, 15 seconds respectively for import and exit).
89545924|NCT05319951|Experimental|water with white granulated sugar|Dissolve 2 packs of Taikoo white granulated sugar (5g/pack) in 500ml water and let the subjects drink it up in 20 minutes prior to donation.
89545925|NCT05319951|Placebo Comparator|recommended water intake|Recommend the subjects to drink up 500ml water in 20 minutes prior to donation.
89545926|NCT02565381|Active Comparator|Control (N=25)|"Transdermal nicotine patch~In-person smoking cessation counseling"
89545927|NCT02565381|Experimental|Financial rewards (N=25)|"Transdermal nicotine patch~In-person smoking cessation counseling~Contingent financial rewards for smoking abstinence"
89545928|NCT02565381|Experimental|Text messaging (N=25)|"Transdermal nicotine patch~In-person smoking cessation counseling~Text messages to support smoking abstinence"
88961507|NCT05777876|Sham Comparator|TRD sham stimulation|Patients do not respond favorably to two antidepressants. The subjects get clinical evaluation, blood sample collection, magnetic resonance scanning, and electrophysiological monitoring. Regimen: sham stimulation for 10 times, once a day (except weekends and holidays) for 2 weeks. Stimulation（130Hz, 2mA total current intensity, each stimulation lasts for 30 seconds, total wearing the instrument for 30 minutes)
89545929|NCT02063854|Active Comparator|NE-58095 IR 2.5 mg Once Daily on Awakening|NE-58095 immediate release (IR) 2.5 mg tablet, orally, once, daily, at time of wakening + NE-58095 delayed release (DR) placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.
89545930|NCT02063854|Experimental|NE-58095 DR 25 mg Once Monthly on Awakening|NE-58095 DR 25 mg tablet, orally, once, monthly, at time of wakening + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.
89545931|NCT02063854|Experimental|NE-58095 DR 25 mg Once Monthly Following Breakfast|NE-58095 DR 25 mg tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.
89545932|NCT02063854|Experimental|NE-58095 DR 25 mg Once Monthly 30 Min. After Breakfast|NE-58095 DR 25 mg tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.
88961508|NCT05777876|Experimental|TRD closed-loop stimulation|Patients do not respond favorably to two antidepressants. The subjects get clinical evaluation, blood sample collection, magnetic resonance scanning, and electrophysiological monitoring. Patients receive closed-loop stimulation guided by EEG phase, and the stimulation target is the effective deep brain region target verified in this study. Regimen: stimulation for 10 times, once a day (except weekends and holidays) for 2 weeks. Stimulation（130Hz, 2mA total current intensity, each stimulation lasts for 30 minutes, 15 seconds respectively for import and exit)
88961509|NCT05777876|Experimental|HC experimental stimulation|The subjects get clinical evaluation, blood sample collection, magnetic resonance scanning, and electrophysiological monitoring. HC will receive TIS intervention in the exercise area for one time, the stimulation scheme adopted 20 Hz and 2mA total current intensity, and each stimulation lasted for 30 minutes (15 seconds respectively for lead-in and withdrawal)
89025095|NCT03279107|Experimental|Beverage with maltodextrin|Beverage with maltodextrin (50 gram of total carbohydrate)
89545933|NCT02063854|Experimental|NE-58095 DR 37.5 mg Once Monthly on Awakening|NE-58095 DR 37.5 mg tablet, orally, once, monthly, at time of wakening + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.
89545934|NCT02063854|Experimental|NE-58095 DR 37.5 mg Once Monthly Following Breakfast|NE-58095 DR 37.5 mg tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.
89545935|NCT02063854|Experimental|NE-58095 DR 37.5 mg Once Monthly 30 Min. After Breakfast|NE-58095 DR 37.5 mg tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.
89545936|NCT02063698|Experimental|Arm I (auranofin)|Patients receive auranofin PO on day 2.
89545937|NCT02063698|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO on day 2.
89545938|NCT02062450||Primary surgery with Dual Mobility Cup|Patients having a Primary Hip acetabular replacement, using a Dual Mobility Cup.
89545939|NCT02062450||Revision surgery with Dual Mobility Cup|Patients having a Revision Hip acetabular replacement, using a Dual Mobility Cup.
89545940|NCT02561247|Experimental|Prismaflex HF20 CRRT|Patients included in this arm will be treated for a minimum period of 20 of the first 24 hours and up to 72 hours with each Prismaflex® HF 20 Set with BUN, creatinine and bicarbonate being measured for statistical analysis at 12 hour intervals during CRRT treatment.
89545941|NCT02061592|Active Comparator|Etafilcon A Control Lens|etafilcon A
89545942|NCT02061592|Experimental|Etafilcon A Test Lens|etafilcon A
89545943|NCT04701034|Active Comparator|Active treatment group|"Intravenous immunoglobulin(IVIg) and prednisolone. IVIG is administered at the time of embryo/blastocyst transfer (ET) (5 days before to 2 days after ET) and if the participant becomes pregnant, the infusion (same dose) is repeated in gestational week 5, 6, and 7.~Participants with pre-pregnancy weight ≤70 kg will receive 25 g immunoglobulin (250 ml), participants with weight 70-85 kg will receive 30 g immunoglobulin (300 ml), and participants with weight ≥85 kg will receive 35 g immunoglobulin (350 ml) at each infusion, which will approximate 0.4 g IVIg per kg body weight.~Prednisolone, tablets, 5mg. 1 tablet daily started within first 3 days of menstrual cycle and until ET. On the day of ET, the participant will double her dose to 2 tablets daily until a negative pregnancy test, the time of biochemical loss/miscarriage, or pregnancy week 8+0, whichever comes first. Gradual discontinuation four days with one tablet before completing cessation."
89545944|NCT04701034|Placebo Comparator|Passive treatment group|"Human albumin infusion and placebo tablets.~Human albumin, 5%, (CLS Behring). Participants with pre-pregnancy weight ≤70 kg will receive 250 ml, participants with weight 70-85 kg will receive 300 ml, and participants with weight ≥85 kg will receive 350 ml at each infusion. Administration is planned at the time of ET (5 days before to 2 days after ET) and if the participant becomes pregnant, the infusion is repeated in the same volume in gestational week 5, 6, and 7.~Placebo tablets: contain 85 mg of lactose monohydrate, 86 mg potato starch, 8.1 mg talc, 3 mg gelatine, and 0.9 mg magnesium stearate. 1 tablet daily started within first 3 days of menstrual cycle and until ET. On the day of ET, the participant will double her dose to 2 tablets daily until a negative pregnancy test, the time of biochemical loss/miscarriage, or pregnancy week 8+0, whichever comes first. Gradual discontinuation four days with one tablet before completing cessation."
89545945|NCT04700956|Active Comparator|the primary suture group|The linea alba will be closed to a ratio of 5mm / 5mm. Only the fascia will be sutured ; fat or muscle tissue will be avoided. Subcutaneous tissue will be closed with polyglactin 3/0 suture. The skin will be closed with a stapler.
89545946|NCT04700956|Experimental|mesh group|After the fascia was closed with the same method, 5 cm of subcutaneous tissue will be dissected around the incision. The mesh will be placed in the supra-aponeurotic area (onlay) to a distance of laterally and cranial-caudally 5 cm from the fascia margins. The mesh used will be partially absorbable, light and large porous. After this procedure, the borders of the mesh will be fixed circumferentially on the abdominal wall using polypropylene suture to prevent the intestines from herniating on the mesh. Two subcutaneous drainage catheters will be placed in all patients with mesh.
89545947|NCT01663623|Placebo Comparator|Placebo plus azathioprine|Placebo IV plus oral azathioprine 2 mg/kg/day; placebo administered on Days 0, 14, 28, and then every 28 days until the end of the study. If the results in the double-blind period show that belimumab is safe and effective, then participants have the option to receive treatment with belimumab in a 6-month open-label extension phase. Placebo patients who opt to participate in the extension will receive belimumab 10 mg/kg IV every 28 days plus oral azathioprine 2 mg/kg/day for an additional 6 months.
89025096|NCT03279107|Experimental|Snack with soluble corn fiber|snack with soluble corn fiber (50 gram of total carbohydrate)
89025097|NCT03279107|Experimental|Snack with maltodextrin|Snack with maltodextrin (50 gram of total carbohydrate)
89545948|NCT01663623|Experimental|Belimumab 10 mg/kg plus azathioprine|Belimumab 10 mg/kg IV plus oral azathioprine 2 mg/kg/day; belimumab administered on Days 0, 14, 28, and then every 28 days until the end of the study. If the results in the double-blind period show that belimumab is safe and effective, then participants have the option to continue treatment with belimumab in a 6-month open-label extension phase. Patients who opt to participate in the extension will continue to receive belimumab 10 mg/kg IV every 28 plus oral azathioprine 2 mg/kg/day days for an additional 6 months.
89545949|NCT02042950|Experimental|Carfilzomib|Carfilzomib given at a dose of 20*/56 mg/m^2 (* CFZ 20 mg/m2 by vein on Days 1 and 2 in Cycle 1 followed by 56 mg/m^2 for each subsequent dose thereafter) on days 1 and 2, 8 and 9, 15 and 16 of a 28-day cycle (following cycle 12 carfilzomib given on days 1 and 2 and 15 and 16 only).
89545950|NCT02042404|Experimental|Mild to severe hearing impairment|Sound amplification provided via the EarLens System assistive hearing device.
89545951|NCT04582305|Active Comparator|Bleomycin jet-injections|This study consists of a split-lesion design in which the keloid scar will receive three consecutive treatments with an interval of 4 weeks of: 1) bleomycin and 2) placebo (NaCl 0,9%), administered with an electronic pneumatic jet injector. A single injection of 100 μL will be given per 1 cm2, with a maximum of 20 injections per treatment. The maximum dosage of bleomycin per treatment will be 2 mL, corresponding to 2 USP-E (units) of bleomycin. The maximum cumulative dosage of bleomycin will be 6 USP-E in this study.
89545952|NCT04582305|Placebo Comparator|Placebo jet-injections|This study consists of a split-lesion design in which the keloid scar will receive three consecutive treatments with an interval of 4 weeks of: 1) bleomycin and 2) placebo (NaCl 0,9%), administered with an electronic pneumatic jet injector. A single injection of 100 μL will be given per 1 cm2, with a maximum of 20 injections per treatment. The maximum dosage of normal saline per treatment will be 2 mL.
89545953|NCT02042014|Experimental|QTI571|Participants will receive QTI571 during 3 years.
89545954|NCT04700410|Experimental|Pure-Vu|All patients willing to participate will receive a limited bowel preparation (2-days of dietary restrictions + 2x 150ml picoprep) followed by intra-procedural bowel cleansing with the Pure-Vu System (single arm)
89545955|NCT05504967|Active Comparator|dexamethasone|"12.5mg dexamethasone + saline solution peramygdalin infiltration in each loca (25mg in total).~Single dosage pre-incisional."
89545956|NCT05504967|Active Comparator|ropivacain|"18.75 mg ropivacain + saline solution peramygdalin infiltration in each loca (37mg in total).~Single dosage pre-incisional."
89545957|NCT05504967|Experimental|ropivacain + dexamethasone|"18.75mg ropivacain + 12.5mg dexamethasone peramygdalin infiltration (in each loca).~Single dosage pre-incisional."
89545958|NCT05504967|Placebo Comparator|placebo|Saline solution (NaCl 0.9%) peramygdalin infiltration (in each loca). Single dosage pre-incisional. 4 syringes must be prepared, two for each of the tonsil sites.
89545959|NCT02041702|Experimental|Cardiac MRI Scan Group|
89545960|NCT02041702|No Intervention|Control Group|
89545961|NCT02565147|Experimental|PPCI with Bivalirudin|Bivalirudin was administered as a bolus (0.75 mg/kg) and an infusion (1.75 mg/kg/h) for the duration of the PPCI and continued for the first 4 h after completion of the procedure.
89545962|NCT02565147|Active Comparator|PPCI with Heparin|UFH was administered as a bolus according to standard of care for completion of PPCI per site. An ACT ≥250 s at the end of the procedure was recommended.
89545963|NCT02061280|Experimental|MICT Trial Design|"Participants randomized to MICT will complete study procedures using an iPad for data entry and FaceTime visits rather than coming into the study site for onsite visits. Participants will perform spirometry at home using a handheld spirometer, EasyOne Plus.~Randomized to one of 3 study treatments:~fluticasone/salmeterol 250/50 Dry Powder Inhaler one inhalation twice daily, or fluticasone/salmeterol 100/50 Dry Powder Inhaler one inhalation twice daily, or fluticasone 100mcg Dry Powder Inhaler one inhalation twice daily"
89545964|NCT02061280|Active Comparator|LASST Trial Design|"Participants randomized to LASST will complete study procedures in the traditional format in which all study visits are conducted at the study site, all questionnaires are completed by pen/paper, and all spirometry is performed at the clinic site.~Randomized to one of 3 study treatments:~fluticasone/salmeterol 250/50 Dry Powder Inhaler one inhalation twice daily, or fluticasone/salmeterol 100/50 Dry Powder Inhaler one inhalation twice daily, or fluticasone 100mcg Dry Powder Inhaler one inhalation twice daily."
89545965|NCT05150925|Experimental|Immediate mobilization after distal radius fracture treated with volar locking plate|
89545966|NCT05150925|Active Comparator|2 weeks cast immobilization after distal radius fracture treated with volar locking plate|
89545967|NCT02061202|Experimental|Mometasone Furoate|1 puff daily (220mcg) for 16 weeks
89545968|NCT02061202|Placebo Comparator|Placebo|1 puff daily for 16 weeks. Training inhaler that does not contain any medication (placebo).
89545969|NCT05112172|Experimental|Oxygen Therapy|Oxygen Therapy in patients developing an altitude related adverse health effect (ARAHE) during 30h exposure to 2500m of high altitude
89545970|NCT02059408|No Intervention|Usual Care|The patients in this arm will receive normal primary care.
89545971|NCT02059408|Active Comparator|Screen-Educate|Education program to improve blood pressure control among hypertensive non-diabetic persons. The Screen and Educate arm recommends using creatinine, cystatin C and albuminuria for detection and risk stratification, followed by guideline-concordant CKD management appropriate for CKD stage.
89545972|NCT02059408|Active Comparator|Screen-Educate and Intensify Treatment|Education and treatment program to improve blood pressure control among hypertensive non-diabetic persons. The Screen-Educate and Intensify Treatment adds a pharmacist-led CKD management program and attempts to improve BP management and patient-centered outcomes among persons with newly stratified higher risk CKD based on creatinine, cystatin c and albuminuria.
89545973|NCT05504811|Experimental|Experimental: FitMi AD Exercise Program|Participants will perform exercises by interacting with FitMi pucks, as described and monitored on a tablet computer. Participants will be asked to exercise at least 30 minutes per day for 3 months.
89025098|NCT00439686|Experimental|Single Arm|
89545974|NCT05504811|Active Comparator|Active Comparator: Conventional booklet of exercise program|Participants will perform exercises described in a booklet similar to what is typically provided to individuals. Participants will be asked to exercise at least 30 minutes per day for 3 months.
89545975|NCT05504733|Experimental|Layperson Audiovisual Assist Tourniquet (LAVA TQ)|For participants in the experimental arm, the Layperson Audiovisual Assist Tourniquet (LAVA TQ) is the first tourniquet applied to their leg as the intervention.
89025099|NCT00477360|Experimental|1|C.A.P
89025100|NCT03278990|Experimental|Future Self - Value Affirmation|This is a behavioral intervention whereby participants write (Value Affirmation and Future Selves Combination) for 5 minutes about 1-2 values that are important to them, as well as about a time in their life when they were particularly important. Next, for five minutes, they write a letter to themselves in 20 years.
89025101|NCT03278990|Sham Comparator|Control|In this sham comparator, participants will also write (Control Writing Exercise) --similar to the intervention above. However, the content of the writing exercise is different. Participants write for five minutes about what they did that day. Next, for five minutes, they write a letter to themselves next week.
89545976|NCT05504733|Active Comparator|Combat Application Tourniquet (CAT)|For participants in the control/active comparator arm, the Combat Application Tourniquet (CAT) is the first tourniquet applied to their leg as the intervention.
89545977|NCT04698850|Active Comparator|aflibercept|Patients with RAP who will be receiving aflibercept.
89545978|NCT04698850|Experimental|brolucizumab|Patients with RAP who will be receiving brolucizumab.
89545979|NCT04698226|Active Comparator|ILM peel|Patients who will undergo 25-gauge pars plana vitrectomy with complete internal limiting membrane peeling and SF6 tamponade.
89545980|NCT04698226|Experimental|Inverted flap|Patients who will undergo 25-gauge pars plana vitrectomy with inverted flap technique and SF6 tamponade.
89545981|NCT05504577|Experimental|QCG group|After the prosthesis are all implanted, apply the QCG (Quikclot Z-fold hemostatic gauze, Z-Medica, Wallingford, CT, USA) into the joint space. Compress the knee joint by elastic bandage. Deflate the tourniquet for 10 minutes, then remove the QCG from the knee joint and throughout check bleeders before closure of the joint capsule. Tranexamic acid 1g is intravenously injected at 10 mins before tourniquet deflation
89545982|NCT05504577|Active Comparator|Surgical gauze group|After the prosthesis are all implanted, apply the surgical gauze into the joint space. Compress the knee joint by elastic bandage. Deflate the tourniquet for 10 minutes, then remove the gauze from the joint and throughout check bleeders before closure of the joint capsule. Tranexamic acid 1g is intravenously injected at 10 mins before tourniquet deflation
89545983|NCT05504577|Placebo Comparator|Control group|fter the prosthesis are all implanted, we close the joint capsule directly. Tranexamic acid 1g is intravenously injected at 10 mins before tourniquet deflation. .
89545984|NCT05504499|Experimental|Single Arm|A Prospective, Open-Label, Non-Randomized, Multi-Center Study Measuring Functional Outcomes In a Novel Interspinous Fusion Device In Subjects With Low Back Pain A Prospective, Observational, Open-Label, Non-Randomized, Multi-Center Study Measuring Functional Outcomes In a Novel Interspinous Fusion Device In Subjects With Low Back Pain
89545985|NCT05501535||pseudophakic patients before and after having ND YAG laser|
89545986|NCT05501457|Experimental|The gastrocnemius group|The patients in the first group (n=15) were given a pulmonary rehabilitation program and additionally 20 minutes of Neuromuscular electrical stimulation (Group 1) to the gastrocnemius muscle,
89545987|NCT05501457|Experimental|The quadriceps femoris group|The second group was given a pulmonary rehabilitation program and an additionally 20 minutes of neuromuscular electrical stimulation to the quadriceps femoris muscle (Group 2),
89545988|NCT05501457|Experimental|The control group|The third group, which was the control group, was given only a pulmonary rehabilitation program (Group 3).
89545989|NCT05016297|Experimental|baricitinib 4mg per day + HCQ 200mg twice a day|On the basis of the HCQ treatment before, patients in this group will be added on baricitinib 4mg once a day.
89545990|NCT05016297|Active Comparator|HCQ 200mg twice a day|Patients in this group will be given HCQ 200mg twice a day for 12 weeks. Patients who has no response to HCQ treatment alone at week 12 will be switched to baricitinib + HCQ group and added on baricitinib 4mg per day until the end of the study (week 24).
89545991|NCT05504265|Other|Postoperative NSAIDs|
89545992|NCT05504265|Experimental|Preemptive analgesia followed by Postoperative NSAIDs|
89545993|NCT05504265|Experimental|Postoperative patient-controlled analgesia pump|
89545994|NCT01625338|Experimental|SOF+RBV 12 Weeks|SOF+RBV for 12 weeks
89545995|NCT01625338|Experimental|SOF+RBV 24 Weeks|SOF+RBV for 24 weeks
89545996|NCT01625338|Experimental|SOF+RBV+Peg-IFN 12 Weeks|SOF+RBV+Peg-IFN for 12 weeks
89545997|NCT05504109|Active Comparator|Group A|patients who will undergo mitral valve replacement through full sternotomy approach
89545998|NCT05504109|Active Comparator|Group B|patients who will undergo mitral valve replacement through right mini thoracotomy approach
89545999|NCT05504031|Experimental|Hybrid Group|Revascularization in the form of a combined MIDCAB (LIMA-LAD graft trough a minimal invasive left anterior thoracotomy) and PCI (of all non-LAD stenoses)
89546000|NCT05504031|Active Comparator|CABG Group|Conventional CABG through a sternotomy
89025102|NCT03279744|Experimental|Single-Arm|Radion™-pdt
89546001|NCT05503953|Experimental|AGSAVI|
89546002|NCT05503953|Active Comparator|AGLS|
89546003|NCT04698148||CDI patients|Patients with Clostridium Difficile Infection
89546004|NCT04698148||MDRO patients|Patients with Multi Drug Resistant Organisms infection
89546005|NCT04698148||IBD patients|Patients with Chronic Inflammatory Bowel Disease
89546006|NCT04698148||IBS patients|Patients with Irritable Bowel Syndrome
89546007|NCT04698148||Hepatic Encephalopathy patients|Patients with Hepatic Encephalopathy
89546008|NCT04698148||healthy volunteers|healthy volunteers
89546009|NCT02560623|Experimental|Phase 1: Sponge on a String 25 mm 10 pores/inch|In phase 1 of the study, subjects will be assigned to swallow a capsule sponge device 25 mm 10 pores/inch to collect cells and cellular material from the mucosa in the esophagus prior to scheduled for a clinically indicated upper endoscopy
89546010|NCT02560623|Experimental|Phase 1: Sponge on a String 25 mm 20 pores/inch|In phase 1 of the study, subjects will be assigned to swallow a capsule sponge device 25 mm 20 pores/inch to collect cells and cellular material from the mucosa in the esophagus prior to scheduled for a clinically indicated upper endoscopy
89546011|NCT02560623|Experimental|Phase 2: Cases - Barrett's Esophagus|In phase 2 of the study, additional subjects will be assigned to swallow a capsule sponge device 25 mm 10 pores/inch to collect cells and cellular material from the mucosa in the esophagus prior to scheduled for a clinically indicated upper endoscopy
89546012|NCT02560623|Experimental|Phase 2: Controls - No Barrett's Esophagus|In phase 2 of the study, additional subjects will be assigned to swallow a capsule sponge device 25 mm 10 pores/inch to collect cells and cellular material from the mucosa in the esophagus prior to scheduled for a clinically indicated upper endoscopy
89546013|NCT05501223|Other|Intervention|Standard care + medication review
89546014|NCT05501223|Other|Control|Standard care
89546015|NCT04740099|Experimental|SOONER Training (Intervention)|Arm receives video training and kit designed by SOONER team.
89546016|NCT04740099|Other|Standard of care training (control)|Participant referred to standard of care (community based Naloxone training)
88961510|NCT05777876|Sham Comparator|HC sham stimulation|The subjects get clinical evaluation, blood sample collection, magnetic resonance scanning, and electrophysiological monitoring. Electrode placement, current intensity and intervention times are consistent with those of TIS regimen. 20 Hz, 2mA total current intensityis used, but only lasted for 30 seconds, and then the current is 0 for a total of 30 minutes.
88961511|NCT05777876|No Intervention|HC observation|Collect data on healthy controls without stimulation. The subjects get clinical evaluation, blood sample collection, magnetic resonance scanning, and electrophysiological monitoring.
89546017|NCT05503563||tetra modal bladder preservation|
89546018|NCT04535115|Experimental|Group 1|Starting LRM (Lung Recruitment Maneuver)
89546019|NCT04535115|Experimental|Group 2|Starting VtC (Tidal Volume Challenge)
89546020|NCT02560389|Placebo Comparator|Placebo|Placebo administered in pill form once by mouth
88961512|NCT05777850|Active Comparator|Conventional ablation|CTI ablation with electroanatomic navigation system using individual 25-40 W applications of unlimited duration until achieving in each application the minimum value of one of the currently accepted and used lesion markers: Ablation Index >500 at the anterior half of the CTI and >400 at the posterior half with de CARTO 3 system. Minimum contact force required is 5 grams. Maximum distance between applications must be 6 mm.
88961513|NCT05777850|Experimental|High-power short-duration ablation|CTI ablation with electroanatomic navigation system using individual high power (90W) short duration (4 seconds) applications in a catheters' stable position with a minimum contact force of 15-30 g at the anterior half and 10-25 g at the posterior one. Maximum distance between applications is settled at 4 mm.
88961514|NCT05777837|Active Comparator|Laparoscopic Excision of Large Cesarean Scar Niche|
88961515|NCT05777837|Active Comparator|Combined Hysteroscopic and Laparoscopic Repair without Excision of Large Cesarean Scar Niche|
88961516|NCT05777785|Experimental|Active|VIZO Glasses- personalized
88961517|NCT05777746|Experimental|An online 12 week plant-based dietary program|
88961518|NCT05777746|Other|Usual Diet|
88961519|NCT05777707|Experimental|Neoadjuvant PD-1 Blockade Plus Chemotherapy|PD-1 blockade, 200 mg, IV., every 3 weeks, 2-3 cycles； Albumin paclitaxel, 300 mg/m2, IV., every 3 weeks, 2-3 cycles； Carboplatin/Nedaplatin, area under the curve = 5, IV., every 3 weeks, 2-3 cycles.
88961520|NCT05777694|Active Comparator|Group 1: 25 gauge spinal needle|Group 1: Patients who underwent cesarean section under spinal anesthesia with 25 gauge spinal needle ( Pencan® 0.42 × 88 mm- G27 × 3½, B. Braun, Melsungen, Germany)
88961521|NCT05777694|Active Comparator|Group 2: 26 gauge spinal needle|Group 2: Patients who underwent cesarean section under spinal anesthesia with 26 gauge spinal needle ( Atraucan® 0.42 × 88 mm- G27 × 3½, B. Braun, Melsungen, Germany)
88961522|NCT05777694|Active Comparator|Group 3: 27 gauge spina needle|Group 3: Patients who underwent cesarean section operation under spinal anesthesia with 27 gauge spinal needle ( Pencan ® 0.42 × 88 mm- G27 × 3½, B. Braun, Melsungen, Germany)
88961523|NCT05777668||Head and neck cancer patients undergoing radiotherapy|
89546021|NCT02560389|Active Comparator|100mg L-DOPA|100mg levodopa administered in pill form once by mouth
89546022|NCT02560389|Active Comparator|200mg L-DOPA|200mg levodopa administered in pill form once by mouth
89546023|NCT04653051||Patients who received DVR Plating System|
89546024|NCT05500989||Short track controls|"Controls are women (18 years or older) with an uncomplicated pregnancy (i.e no foetal or maternal placental complications, such as pregnancy induced hypertension, preeclampsia or HELLP-syndrome, or small for gestational birth infancies).~Follow up roughly 18 months postpartum."
88961524|NCT05777655|Experimental|Medication management app|Standard of care (statin prescription, targeted monitoring of individual LDL-C values by primary care physician) + medication management app and follow-up visits at our institution at 6 and 18 months
89546025|NCT05500989||Short track early PE with IUGR|"These cases consist of women (18 years or older) with preeclampsia (PE) and/or HELLP syndrome in the current pregnancy (PE is defined as hypertension (systolic blood pressure ≥ 140 mmHg and/or diastolic BP ≥ 90 mmHg) developed after 20 weeks of pregnancy with de novo proteinuria (≥ 300 mg/ 24 hours)) Cases will be subdivided into early and late PE, with or without IUGR (Early PE is defined as the occurence of PE < 34 weeks of gestation, whereas late PE is defined as the occurence of PE ≥ 34 weeks of gestation. IUGR is defined as birthweight below the 10th percentile).~Follow up roughly 18 months postpartum."
88961525|NCT05777655|No Intervention|Standard of care|Statin prescription, targeted monitoring of individual LDL-C values by primary care physician and follow-up visits at our institution at 6 and 18 months
88961526|NCT05777642|Experimental|Oxygen Nanobubble First|"In this arm, the oxygen nanobubbles drink will be provided as the first drink. The oxygen nanobubbles mixture will be mixed with water and oxygenated and provided as a one-time 200ml drink 10 minutes before the start of the 2000m row.~The placebo will be provided as the second drink, 2-4 days after the first drink. The placebo mixture will be mixed with water and oxygenated and provided as a one-time 200ml drink 10 minutes before the start of the 2000m row."
88961527|NCT05777642|Placebo Comparator|Placebo First|"In this arm, the placebo drink will be provided as the first drink. The placebo mixture will be mixed with water and oxygenated and provided as a one-time 200ml drink 10 minutes before the start of the 2000m row.~The oxygen nanobubbles will be provided as the second drink, 2-4 days after the first drink. The oxygen nanobubbles mixture will be mixed with water and oxygenated and provided as a one-time 200ml drink 10 minutes before the start of the 2000m row."
88961528|NCT05777577|Experimental|Rheumatoid Arthritis Probiotic (RAP)|patients with RA 30-50 yers old, who have 4 or more swollen and painful joints, who did not take probiotic and other drugs that affect the microbiome
88961529|NCT05777577|Active Comparator|Rheumatoid Arthritis Probiotic1 (RAP1)|closest relatives (brothers and sister, children, parents) living in the same living area and corresponding to the age group, without RA, who did not take probiotic and other drugs that affect the microbiome
88961530|NCT05777499|Experimental|Music Therapy|See Intervention section
88961531|NCT05777499|Active Comparator|Control Therapy|See Intervention section
88961532|NCT05777434|Active Comparator|Group A (Conventional Physical Therapy)|"Patients in this group will recieve conventional physical therapy including hot pack and TENS for pain relief, axial elongtion exercises to correct posture, cervical isometrics and cervical stabilization exercises (cervical bracing with deep neck flexor activation followed by extremity ROM) along with general flexibility exercises.~Each exercise would be performed with a hold time of 5-10 sec and 8-12 reps. A total of 12 sessions would be conducted over a period of 4 weeks."
88961533|NCT05777434|Experimental|Group B (Scapulothoracic Stabilization Exercises)|"Patients will recieve scapulothoracic stabilization exercises in addition to the convential physical therapy including hot pack, TENS, axial elongation, cervical isometrics and cervical stabilization exercises. SSE would include scapular adduction and shoulder external rotation, B/L shoulder extension with scapular retraction, Eccentric scapular retraction, Brügger exercise and Forward punch. Exercises would be given using latex Thera-Band, or acc. to patient strength for mild to moderate resistance.~Each exercise would be performed with a hold time of 5-10 sec and 8-12 reps. A total of 12 sessions would be conducted over a period of 4 weeks."
88961534|NCT05777421|Active Comparator|Conventional Physical Therapy Regime for Knee Osteoarthrithis|"Pt will receive conventional therapy targeting stretching and stretching of knee musculature in combination with electrotherapy for pain modulation.~Frequency : 2-3 times for a duration of 6 weeks Pt will be guided home plan based exercises."
88961535|NCT05777421|Experimental|Virtual reality Based Therapeutic Exercise Regimes|"VR-based therapeutic exercise regimes utilizing Xbox, that focus on different activities like Partial squatting, lunges, side lunge, calf raises, and hamstring curls.~Gaming exercises begin will an easy warm up round and get challenging with different rounds of each game as the patient progresses to week 6.~Frequency: 2-3 times for a duration for 6 weeks Pt will be guided home plan based exercises"
88961536|NCT05777408|Active Comparator|Control Group|"Participants of this group will receive the conventional physical therapy protocol mentioned above. In addition to this, they will receive Natural apophyseal glides 3 sets of 10 repetitions.~Frequency: 3 times a week for 2 weeks. 6 sessions in total.~Mobilizations will be performed in Grade 1 initially and then progressed to Grade 2 and 3 depending on the patients pain status and compliance."
89546026|NCT05500989||Short track early PE without IUGR|"Cases consist of women (18 years or older) with preeclampsia (PE) and/or HELLP syndrome in the current pregnancy (PE is defined as hypertension (systolic blood pressure ≥ 140 mmHg and/or diastolic BP ≥ 90 mmHg) developed after 20 weeks of pregnancy with de novo proteinuria (≥ 300 mg/ 24 hours)) Cases will be subdivided into early and late PE, with or without IUGR (Early PE is defined as the occurence of PE < 34 weeks of gestation, whereas late PE is defined as the occurence of PE ≥ 34 weeks of gestation. IUGR is defined as birthweight below the 10th percentile).~Follow up roughly 18 months postpartum."
89546027|NCT05500989||Short track late PE with IUGR|"Cases consist of women (18 years or older) with preeclampsia (PE) and/or HELLP syndrome in the current pregnancy (PE is defined as hypertension (systolic blood pressure ≥ 140 mmHg and/or diastolic BP ≥ 90 mmHg) developed after 20 weeks of pregnancy with de novo proteinuria (≥ 300 mg/ 24 hours)) Cases will be subdivided into early and late PE, with or without IUGR (Early PE is defined as the occurence of PE < 34 weeks of gestation, whereas late PE is defined as the occurence of PE ≥ 34 weeks of gestation. IUGR is defined as birthweight below the 10th percentile).~Follow up roughly 18 months postpartum."
89546028|NCT05500989||Short track late PE without IUGR|"Cases consist of women (18 years or older) with preeclampsia (PE) and/or HELLP syndrome in the current pregnancy (PE is defined as hypertension (systolic blood pressure ≥ 140 mmHg and/or diastolic BP ≥ 90 mmHg) developed after 20 weeks of pregnancy with de novo proteinuria (≥ 300 mg/ 24 hours)) Cases will be subdivided into early and late PE, with or without IUGR (Early PE is defined as the occurence of PE < 34 weeks of gestation, whereas late PE is defined as the occurence of PE ≥ 34 weeks of gestation. IUGR is defined as birthweight below the 10th percentile).~Follow up roughly 18 months postpartum."
89546029|NCT05500989||Long term follow up track controls|"Controls are women (18 years or older) with an uncomplicated pregnancy (i.e no foetal or maternal placental complications, such as pregnancy induced hypertension, preeclampsia or HELLP-syndrome, or small for gestational birth infancies).~Follow up 10 to 20 years postpartum."
89546030|NCT05500989||Long term follow up track cases|"Cases consist of women (18 years or older) with preeclampsia (PE) and/or HELLP syndrome in the current pregnancy (PE is defined as hypertension (systolic blood pressure ≥ 140 mmHg and/or diastolic BP ≥ 90 mmHg) developed after 20 weeks of pregnancy with de novo proteinuria (≥ 300 mg/ 24 hours)) Cases will be subdivided into early and late PE, with or without IUGR (Early PE is defined as the occurence of PE < 34 weeks of gestation, whereas late PE is defined as the occurence of PE ≥ 34 weeks of gestation. IUGR is defined as birthweight below the 10th percentile).~Follow up roughly 18 months postpartum."
89546031|NCT05500911|Active Comparator|NINA- MultiNeO NH|After the sinus lift procedure (performed with OSSIX® BONE on all study subjects) treatment group will be treated with a bioactive surfaced implant (NINA MultiNeO NH)
89546032|NCT05500911|Active Comparator|MultiNeO CS|After the sinus lift procedure (performed with OSSIX® BONE on all study subjects) control group will be treated with a traditional implant surface (MultiNeO CS)
89546033|NCT02564211|Experimental|Ipragliflozin|Ipragliflozin one 50 mg tablet co-administered with one 50 mg sitagliptin once daily (QD) for 52 weeks in addition to diet and exercise therapy.
89025103|NCT03278951|No Intervention|Control Group|The control group received the mHealth devices but no health coaching or feedback. Participants in this group completed the same pre- and post-intervention measurements.
89546034|NCT04596579||Participants age 18-34|Up to 300 participants age 18-34 who received an invitation by mail and are free of fever at time of interview.
89546035|NCT04596579||Participants age 35-54|Up to 300 Participants age 35-54 who received an invitation by mail and are free of fever at time of interview.
89546036|NCT04596579||Participants age 55-64|Up to 300 participants age 35-54 who received an invitation by mail and are free of fever at time of interview.
89546037|NCT04596579||Participants 65 and over|Up to 300 participants age 35-54 who received an invitation by mail and are free of fever at time of interview.
89546038|NCT04465461|Experimental|Treatment|Patients exhibiting baseline collateral ventilation by Chartis® balloon catheter assessment who undergo video-assisted thoracoscopic surgery (VATS) fissure completion surgery, confirmation of fissure completion by computerized tomography (CT) scan and confirmation of conversion to collateral ventilation negative by Chartis® balloon catheter assessment post VATS surgery and subsequent Zephyr Valve insertion.
89546039|NCT04619901||Parents only|
89546040|NCT04619901||Children and Parents|
89546041|NCT04465383|Experimental|Digital Sedation|Digital Sedation with rescue intravenous sedation (propofol) if needed upon patient request
89546042|NCT04465383|Active Comparator|Intravenous sedation|Control arm with conventional Intravenous sedation
89546043|NCT04388865|Experimental|Control|Usual Care
89546044|NCT04388865|Experimental|Clinical Hovering|Remote monitoring with feedback to social support
89546045|NCT05500677|Active Comparator|Lidocaine|10% lidocaine spray was applied on the broken rib from a distance of 10 cm, 1-2 puffs. Each puff contains 10 mg of lidocaine.
89546046|NCT05500677|Active Comparator|Tramadol|100 mg of tramadol hydrochloride was placed in 150 cc isotonic saline and given as a 15-minute intravenous infusion.
89546047|NCT05500677|Active Comparator|Fentanyl|50 mcg of fentanyl citrate was given as a 15-minute intravenous infusion in 150 cc isotonic.
89546048|NCT04331535|Experimental|Polygenic risk score (PRS) - high risk stratum|Patient-participants in the PRS-high arm and their providers will receive their high-PRS results at baseline, along with educational resources about the results.
89546049|NCT04331535|Active Comparator|Usual care (UC) - high risk stratum|Patient-participants in the UC-high arm and their providers will receive their high-PRS results after a 24-month observation period, along with educational resources about the results.
89546050|NCT04331535|Experimental|Polygenic risk score (PRS) - average risk stratum|Patient-participants in the PRS-average arm and their providers will receive their average-PRS results at baseline, along with educational resources about the results.
89546051|NCT04331535|Active Comparator|Usual care (UC) - average risk stratum|Patient-participants in the UC-average arm and their providers will receive their average-PRS results after a 24-month observation period, along with educational resources about the results..
89546052|NCT04411563||Group I-Mild|The patients who have these mild symptoms are low-grade fever (not more than 38 degrees celsius), dry cough, fatigue, sore throat, headache, the new loss of taste, and smell. Patients with normal or mild pneumonia findings of radiological imaging and blood lymphocyte count ≥800 / µl and serum CRP≤40 mg /l, ferritin ≤500ng/ml, D-Dimer ≤1000 ng/ml will be included in group I.
89546053|NCT04411563||Group II-Moderate|The patients who have these moderate symptoms are fever of about 38,5-39 degrees celsius, chills, deep cough, fatigue and body aches, muscle pain, the general feeling of being unwell. Patients with bilateral diffuse pneumonia findings of radiological imaging or blood lymphocyte count <800 / µl or serum CRP> 40 mg / l or ferritin> 500ng / ml or D-Dimer> 1000 ng / ml will be included in group II.
89546054|NCT04411563||Group III-Severe|The patients who have these severe symptoms are all the common symptoms mentioned above along with shortness of breath, chest discomfort, confusion/unresponsiveness, bluish face/lips, possible gastrointestinal issues, like diarrhea or nausea. Patients with ICU (intensive care unit) admission criteria, such as confusion or tachycardia (> 125 / min) or respiratory distress or tachypnea (> 22 / min) or hypotension <90/60 mmHg or SPO2 <93%will be included in group III. Also, patients with the central nervous system and heart involvement will be directly included in the severe case group
89608641|NCT04149561||Cerebral Palsy|100 patients over 2 years of age with a diagnosis of cerebral palsy will be included in the study. Demographic information form prepared for the study in terms of demographic information such as age, gender, clinical type of cerebral palsy, drugs used, comorbid diseases will be completed. Communication Function Classification System and Functional Communication Classification System will be used to evaluate patients' communication skills. In addition, patients; The Gross Motor Function Classification System for cerebral palsy and based on child-initiated movements with emphasis on sitting, displacement and mobility, and to hold objects during the daily activities of children with cerebral palsy. The Manual Ability Classification System, which classifies how they use their hands, will also be completed.
88961537|NCT05777408|Experimental|Experimental Group|"Participants of this Group will receive the conventional physical therapy protocol mentioned above. In addition to this, they will receive Natural apophyseal glides and cranial base release.~Frequency: 3 times a week for 2 weeks. 6 sessions in total.~Cranial base release would be given for around 1-4minutes until the tissues relax and would be given once daily"
89546055|NCT02093026|Experimental|Rituximab|Participants will receive rituximab 1 gram intravenously (IV) on Days 1 and 15 of each course of retreatment. In addition, participants will receive methotrexate 10-25 milligrams per week (mg/week) orally or parenterally, methylprednisolone 100 mg IV 30 minutes prior to both rituximab infusions, and a stable dose of folic acid greater than or equal to (>=) 5 mg/week or equivalent. Participants will receive retreatment (next course of rituximab repeat treatment) within 2 weeks of meeting the retreatment criteria as defined in the protocol (minimum of 24 weeks after the first [Day 1] infusion of the last course of rituximab). Repeat treatment will be based on the investigator's decision of prior clinical response to rituximab, clinical need and evidence of active disease (Disease Activity Score in 28 joints >=2.6). Retreatment with rituximab will be continued until withdrawal of consent or study treatment completion on 31 December 2011, whichever is sooner.
89546056|NCT04698070|Active Comparator|Standard|RUTF 130-200 kcal/kg/day for children with nutritional edema or MUAC < 115 mm or WHZ <-3 and RUSF 500 kcal/d for children 6-23 months with WHZ between -2 and -3 Z and MUAC 115-124 mm.
89546057|NCT04698070|Experimental|OptiMA|RUTF 170 kcal/kg/d for children with nutritional edema or MUAC < 115 mm; 125 kcal/kg/d for MUAC 115-119 mm and 75 kcal/kg/d for MUAC 120-124 mm.
88961538|NCT05777395|Experimental|Maitland + Conventional PT Group|"Participants of this group will receive the conventional physical therapy protocol mentioned above. In addition to this, they will receive Maitland oscillatory mobilizations. 3 sets of 15 repetitions. Each set is of 30 seconds and each repetition is given in 2 seconds.~Frequency: 3 times a week for 2 weeks. 6 sessions in total.~Mobilizations will be performed in Grade 1 initially and then progressed to Grade 2 and 3.~Techniques used are postero-anterior unilateral vertebral pressure and Maitland rotation."
89025104|NCT03278951|Experimental|Video Conferencing Health Coaching|The video conferencing group participants met via the eClinicalWorks® app using their smartphone, and met 12 times with the registered dietitian (RD) and 12 times with the exercise physiologist to discuss exercise and diet goals.
89546058|NCT04698070|Experimental|ComPAS|RUTF 1000 kcal/d for children with nutritional edema or MUAC < 115 mm and 500 kcal/day for MUAC 115-124 mm.
89546059|NCT02040844|Other|Cat-PAD Treatment 1|Received Cat-PAD Treatment 1 in Study CP007 [NCT01620762].No further treatment received in CP007A
89546060|NCT02040844|Other|Cat-PAD Treatment 2|Received Cat-PAD Treatment 2 in Study CP007 [NCT01620762].No further treatment received in CP007A.
89546061|NCT02040844|Other|Cat-PAD Treatment 3|Received Cat-PAD Treatment 3 in Study CP007 [NCT01620762]. No further treatment received in CP007A.
89546062|NCT02059174|Experimental|MK-1293 / EU-Lantus™ / MK-1293 / EU-Lantus™|MK-1293 or EU-Lantus™ 0.4 units/kg administered subcutaneously on Day 1 in 2 out of 4 study periods in a replicate crossover design with a minimum of 7 days between each treatment period
89546063|NCT02059174|Experimental|EU-Lantus™ / MK-1293 / EU-Lantus™ / MK-1293|MK-1293 or EU-Lantus™ 0.4 units/kg administered subcutaneously on Day 1 in 2 out of 4 study periods in a replicate crossover design with a minimum of 7 days between each treatment period
89546064|NCT02092324|Experimental|Treatment (ruxolitinib phosphate)|Patients receive ruxolitinib phosphate PO every other day, QD, or BID on days 1-28. Each patient will be followed for a maximum of 96 weeks (24 cycles, 1 cycle is 4 weeks long). If the study drug continues to be effective, the patient may be eligible to continue on study drug past 24 cycles.
89546065|NCT04417582||life syte modification only|obese patients followed with life style modification
89546066|NCT04417582||medical teatment with antiobesity drugs|patients prescribed antiobesity drugs
89546067|NCT04417582||bariatric surgery|patients undergone bariatric surgery
89546068|NCT02040766|Experimental|BDP 80 mcg BAI|"Beclomethasone dipropionate (BDP) was administered via a breath-actuated inhaler (BAI) twice daily (40 mcg twice a day).~Placebo MDI twice daily for blinding.~Albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) at 90 mcg ex-actuator) or equivalent was used as rescue medication throughout the study."
89546069|NCT02040766|Experimental|BDP 160 mcg BAI|"Beclomethasone dipropionate (BDP) was administered via a breath-actuated inhaler (BAI) twice daily (80 mcg twice a day).~Placebo MDI twice daily for blinding.~Albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) at 90 mcg ex-actuator) or equivalent was used as rescue medication throughout the study."
89546070|NCT02040766|Active Comparator|BDP 80 mcg MDI|"Beclomethasone dipropionate (BDP) was administered via a metered-dose inhaler (MDI) twice daily (40 mcg twice a day).~Placebo BAI twice daily for blinding.~Albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) at 90 mcg ex-actuator) or equivalent was used as rescue medication throughout the study."
89546071|NCT02040766|Active Comparator|BDP 160 mcg MDI|"Beclomethasone dipropionate (BDP) was administered via a metered-dose inhaler (MDI) twice daily (80 mcg twice a day).~Placebo BAI twice daily for blinding.~Albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) at 90 mcg ex-actuator) or equivalent was used as rescue medication throughout the study."
89546072|NCT02040766|Placebo Comparator|Placebo BAI and MDI|"Placebo was administered via breath-actuated inhaler (BAI) twice daily. Additionally placebo was administered via metered-dose inhaler (MDI) twice daily.~Albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) at 90 mcg ex-actuator) or equivalent was used as rescue medication throughout the study."
89546073|NCT02040532|Experimental|Open-label gabapentin|Dose titration of 100mg for 1 week, 300mg for 3 weeks, and 600mg for 3 weeks.
89546074|NCT02039908|Active Comparator|Methylphenidate 7-day dosing|During the school year, children in this arm will receive 7-day dosing of medication.
89546075|NCT02039908|Active Comparator|Methylphenidate 5-day dosing|During the school year phase, these children will receive 5-day dosing with weekend holidays.
89608642|NCT04149483|Experimental|Atorvastatin|Atorvastatin tablets, 20mg once a day, for six months.
89608643|NCT04149483|Placebo Comparator|Placebo|Same color and size coated tablet, 20mg once a day, for six months.
89025105|NCT03278951|Experimental|In Person Health Coaching|The in person group participants met 12 times with the registered dietitian (RD) and 12 times with the exercise physiologist over the course of the study to discuss both diet and exercise regimens.
88961539|NCT05777395|Experimental|Kaltenborn + Conventional PT Group|"Participants of this Group will receive the conventional physical therapy protocol mentioned above. In addition to this, they will receive Kaltenborn sustained stretch mobilizations. 3 sets of 15 repetitions for 3 seconds.~Frequency: 3 times a week for 2 weeks. 6 sessions in total.~Mobilizations will be performed in Grade 1 and then progressed to 2 and 3.~Kaltenborn technique used will be atlas-axis rotation."
88961540|NCT05777369|Experimental|R-CMOP|R-CMOP：Rituximab, Cyclophosphamide, Mitoxantrone hydrochloride liposomes, Vincristine or Vindesine, Prednisone
88961541|NCT05777239|Experimental|Dental Implant Approach for Crestal Sinus Elevation|
88961542|NCT05777213|Experimental|Conditioned Medium Wharton's Jelly-derived mesenchymal stem cells (CM-WJMSCs)|Conditioned Medium Wharton's Jelly-derived mesenchymal stem cells (CM-WJMSCs) made as much as 0.1cc / 1cm intracutaneously with a flexpen device in the wound area every 2 weeks.
88961543|NCT05777148|Experimental|postdilution online hemodiafiltration|hemodialysis by using post dilution online HDF technique
88961544|NCT05777148|Experimental|super high-flux hemodialysis|hemodialysis by using super high-flux dialyzer
89546076|NCT04695730|Active Comparator|Active physical therapy|Active intervention (including both pain education and home exercises). A 60-minutes education session will be provided, concerning pain mechanisms and management and a demonstration of the exercises to perform individually at home. Home exercises will be performed daily. To support patients during the treatment, a booklet will be created. One 30-minutes booster session will be planned after 4 weeks. Patients will follow this active intervention for 8 weeks.
89546077|NCT04695730|Experimental|Active physical therapy plus manual therapy|"Participants in the Group 2 will receive active intervention plus 8 Pompage technique sessions (1 session/week). In these sessions (30 minutes each), Pompage technique will be performed by a physical therapist."
89546078|NCT04417270|Other|Freestyle Libre 14-day CGM|The FreeStyle Libre 14 day system is a continuous glucose monitoring system consisting of a handheld reader and a sensor worn on the back of the upper arm.
89546079|NCT04417270|Other|Accuchek Inform II meter|ACCU-CHEK INFORM II system quantitatively measures glucose in fresh venous, arterial, neonatal heel stick and capillary whole blood from the finger and is used as an aid in monitoring the effectiveness of glucose control
89546080|NCT04417348|Active Comparator|Retinoic Acid|patients with melasma treated with 0.05% retinoic acid plus UV-Visible light filter
89546081|NCT04417348|Placebo Comparator|Sunscreen|patients with melasma treated with UV-Visible light filter alone
89546082|NCT02058940|Experimental|Exenatide|
89546083|NCT02058628|Experimental|Arm 1|A total of 110 subjects will receive clindamycin + BPO once daily in the evening for 12 weeks as per the randomization schedule.
89546084|NCT02058628|Experimental|Arm 2|A total of 110 subjects will receive azelaic acid twice daily (1 in the morning and 1 in the evening) for 12 weeks as per the randomization schedule.
89546085|NCT02058160|Experimental|Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC)|FRC once daily (QD) for 30 weeks. Dose individually adjusted.
89546086|NCT02058160|Active Comparator|Insulin glargine|Insulin glargine 100 U/mL QD for 30 weeks. Dose individually adjusted.
89546087|NCT02090764|Experimental|Ozenoxacin|ozenoxacin cream 1%
89546088|NCT02090764|Placebo Comparator|Placebo|Placebo cream
89546089|NCT04718506|Experimental|Exercise|Supervised exercise training
89546090|NCT04718506|Experimental|Inspiratory muscle training|Non-supervised inspiratory muscle training protocol
89546091|NCT04718506|Active Comparator|Controls|Non-supervised WHO exercise guidelines
89546092|NCT04730830|Experimental|Only experimental arm|Only experimental arm. Patients filling out questionnaires.
89546093|NCT02057692|Experimental|LUM001|LUM001 for oral administration
89546094|NCT02057692|Placebo Comparator|Placebo|Placebo administered orally once each day
89546095|NCT02038036|Experimental|Ruxolitinib|Ruxolitinib was administered at a starting dose of 10 mg twice a day (bid). Dose was adjusted based on efficacy and safety parameters up to a maximum dose of 25 mg bid.
89546096|NCT02038036|Active Comparator|Best Available Therapy (BAT)|Best Available Therapy as selected by the investigator from: Hydroxyurea, Pegylated-Interferon (IFN/PEG-IFN), pipobroman, anagrelide, IMIDs, or observation. Participants randomized to BAT who did not respond by Week 28 were eligible to crossover and start treatment with ruxolitinib.
89546097|NCT02037568|No Intervention|Caregiver Self-Directed|Orientation class; laboratory biomarker analysis; questionnaire administration; survey administration; treatment as usual psychosocial care; caregiver workbook.
89546098|NCT02037568|Experimental|Caregiver Intervention|Orientation class; laboratory biomarker analysis; questionnaire administration; survey administration; Psychoeducation and Relaxation (fPER), which included one-on-one psychoeducation, and stress management intervention.
89546099|NCT02088034|Experimental|Promotora-led Intervention|The Promotora-led Intervention consists of a core curriculum or 12 group sessions of 90 minute duration over a 12-week period and will be followed by a maintenance phase of 10 biweekly and then monthly 90-minute sessions during months 4 through 12. One promotora will lead each session in Spanish, exploring such topics as being active, low-fat diets, portion control, self monitoring, problem solving and life-style changes.
89546100|NCT02088034|Active Comparator|Usual care|One physician visit at Puentes de Salud or Congreso Health Center to discuss healthy lifestyle behaviors that promote weight loss and diabetes prevention. During that visit, UC participants will also receive standard educational materials in Spanish from the NIDDK Weight-control Information Network covering the same topics. UC participants will receive another physician visit upon completion of 1-year follow-up to review laboratory assessments.
89546101|NCT02088034|Active Comparator|Metformin Therapy|Participants randomized to the metformin arm of the study will receive this medication from months 1 through 12 after randomization. Subjects will receive 850 mg daily for 1 month and increase to 850 mg twice daily thereafter if no side effects are experienced.
88961545|NCT05777122|Experimental|group A|lignocaine gel every 8 hours
88961546|NCT05777122|Experimental|group B|chewing gum every 8 hours 5-10 mins chew
88961547|NCT05777083|Experimental|Inferior STEMI group|Patients who undergo emergent coronary angiography for ST-elevation myocardial infarction.
88961548|NCT05777083|Active Comparator|Control group|Patients who undergo elective coronary angiography to differentiate angina symptom. ST-elevation myocardial infarction will be excluded.
89025106|NCT03279705|Experimental|Two-channel group|The colonoscopy was done with the new designed colonoscopy that integrated a separate water jet channel for infusing water. The dirty water was removed through other accessory channel.
89025107|NCT03279705|Active Comparator|One-channel group|The colonoscopy was done with the traditional colonoscopy. Water exchange was done by using the accessory channel for both infusing and suctioning of water.
89546102|NCT02037256|Experimental|A Treatment (bortezomib and filgrastim)|GROUP A: Bortezomib administered in the evening after comploetion of G-CSF collection or on day 6 of mobilization with G-CSF.
89546103|NCT02037256|Experimental|B Treatment (bortezomib and filgrastim)|GROUP B: Bortexomib administered on days 4 & day 7, before administration of filgrastim.
89546104|NCT02035696|Experimental|TIVc-High Dose|Subjects (6 to <48 months old) received two doses of 0.75 mL of TIVc vaccine
89546105|NCT02035696|Experimental|TIVc-Full Dose|Subjects(6 to <48 months old) received two doses of 0.50 mL of TIVc vaccine
89546106|NCT02035696|Experimental|TIVc- Half Dose|Subjects (6 to <48 months old)received two doses of 0.25 mL of TIVc vaccine
89546107|NCT02035696|Active Comparator|TIVe|Subjects (6 to <48 months old) received two doses of TIVe vaccine(IM/0.25mL -for ages 6 to <36 months and IM/ 0.5 mL -for ages 36 to <48 months)
89546108|NCT02057458|Experimental|Acute Study: Sildenafil first, then Placebo|In randomized order, on two separate days, endothelial function and exercise capacity will be determined 1 hour following a single dose of sildenafil (50 mg) or placebo.
89546109|NCT02057458|Experimental|Acute Study: Placebo first, then Sildenafil|In randomized order, on two separate days, endothelial function and exercise capacity will be determined 1 hour following a single dose of sildenafil (50 mg) or placebo.
89546110|NCT02057458|Experimental|Sub-Chronic Study Sildenafil|Following the acute study, patients will be instructed to take 20 mg of sildenafil, three times a day, for 4 weeks. Endothelial function will be determined within 48 hours following the last dose.
89546111|NCT02057068|Experimental|SLEEP-E Dyads Intervention|"SLEEP-E Dyads Six-Week Tele-Health Intervention~. Daily core video modules on sleep education, sleep hygiene and behavioral and environmental factors influencing sleep.~. Daily and on-demand video modules designed to promote and provide guided instruction for daily Move Out time consisting of activity enhancement and exercise.~. Daily and on-demand video modules designed to promote and provide guided instruction for daily Stand Down time (meditation, therapeutic breathing and self-care).~. SLEEP-E Dyads book~. Two tele-video conferences to discuss evaluation results, obtain buy-in for the prescribed intervention and address dysfunctional beliefs and attitudes about sleep. The second call involves checking-in, encouragement, reinforcement and coaching"
89546112|NCT02057068|No Intervention|Usual Care Group|During the intervention period there is no data collection or contact with research staff other than for scheduling outcomes visits.
89546113|NCT02056834||chronOS Inject|Closed proximal tibial fractures of type Schatzker I - VI, AO-OTA 41, AO-OTA 42 with bone defect
89546114|NCT02087176|Experimental|AZD 1775, antimitotic, pegfilgrastim|AZD 1775, antimitotic agent + pegfilgrastim 21 day Cycle, maximum of 4 cycles
89546115|NCT02087176|Placebo Comparator|Placebo + antimitotic + pegfilgrastim|Placebo + antimitotic+pegfilgrastim 21 day cycle, maximum of 4 cycles
89546116|NCT02056288|Active Comparator|Ultrasound Guided Supraclavicular block|Patients randomized to the supraclavicular block group will receive an ultrasound guided nerve block with 0.2 ml/kg ropivacaine 0.5% (maximum 10 ml), using the technique described by Marhofer et al. In order to decrease variance in success rates, the ultrasound guided nerve block will be performed by 1 of the 4 anesthesiology co-investigators, each of whom have successfully performed over 100 ultrasound guided blocks in the past. Supraclavicular blocks were performed using the higher frequency of the probe and placing it in a coronal-oblique-plane in the supraclavicular fossa.
89546117|NCT02056288|Active Comparator|IV Opioids|Patients randomized to the systemic analgesia group will receive 1mcg/kg of fentanyl IV after induction.
89546118|NCT02086162|Experimental|Behavioral intervention|Web-based motivational decision support system
89546119|NCT02086162|Active Comparator|Educational intervention|Computerized version of the National Cancer Institute (NCI) Educational Pamphlet
89546120|NCT02404571|Experimental|GDP chemotherapy|GDP chemotherapy: gemcitabine (1000mg/m2 intravenously over 30 minutes on days 1 and 8), cisplatin (25mg/m2 intravenously over 60 minutes on days 1-3), and dexamethasone (20mg/d orally on days 1-4 and days 11-14), which was administered every 21 days.
89546121|NCT03115697|Active Comparator|Lactulose with Rifaximin|
89546122|NCT03115697|Experimental|Plasmapheresis|Plasmapheresis will be added to the standard medical care therapy.(Maximum of 3 sessions once in 24 hours/or alternate days with an follow up for 5 days)
89546123|NCT03115775|Active Comparator|Conjugated linoleic acid (Tonalin)|Conjugated linoleic acid (4000 mg Tonalin FFA 80 per day)
89546124|NCT03115775|Active Comparator|Vitamin D|Vitamin D3 (2000 IU per day)
89546125|NCT03115775|Active Comparator|Conjugated linoleic acid and Vitamin D|Conjugated linoleic acid (4000 mg Tonalin FFA 80) and Vitamin D (2000 IU) per day
89546126|NCT03115775|Placebo Comparator|Placebo|Corn oil (4000 mg per day)
89546127|NCT02404259|Other|non-nucleoside reverse transcriptase inhibitor (NNRTI)|Efavirenz
89025108|NCT03278834|Experimental|Intervention Group|"Neuromuscular muscle stimulation machine - Muscle stimulation machine to be used on glutes and abductors on disuse atrophy setting.~Twice per day for 45 minutes.~Exercise - Home exercises programme once per day with 10 exercises."
89025109|NCT03278834|Placebo Comparator|Placebo Group|"Neuromuscular muscle stimulation- Muscle stimulation machine to be used on glutes and abductors on TENS setting. Twice per day for 45 minutes.~Exercise - Home exercises programme once per day with 10 exercises."
89546128|NCT02404259|Other|ritonavir-boosted protease inhibitor|lopinavir/ritonavir atazanavir/ritonavir
89546129|NCT03171155|Experimental|XPro System|Implantation of XPro System during percutaneous vascular closure
89546130|NCT03170921|Experimental|Angola|The rhythm performance had duration of 90 seconds. During recovery period (post- intervention) in the moments 1, 3, 5, 7, and 9 minutes was measured the physiological and the perceptual variables of the study.
89546131|NCT03170921|Experimental|Benguela|The rhythm performance had duration of 90 seconds. During recovery period (post- intervention) in the moments 1, 3, 5, 7, and 9 minutes was measured the physiological and the perceptual variables of the study.
89608644|NCT04149639|Experimental|NeuroQ|Directions: take 2 capsules at the same time daily
89546132|NCT03170921|Experimental|São Bento|The rhythm performance had duration of 90 seconds. During recovery period (post- intervention) in the moments 1, 3, 5, 7, and 9 minutes was measured the physiological and the perceptual variables of the study.
89546133|NCT03170765|Experimental|GROUP A|measles vaccine at 6 months and 9 months of age
89546134|NCT03170765|Experimental|GROUP B|measles vaccine at 7.5 months and 9 months of age
89546135|NCT03170765|Active Comparator|GROUP C|measles vaccine at 9 months of age (current practice)
89546136|NCT03170687|Experimental|foot cast|
89546137|NCT03170687|Active Comparator|short leg cast|
89546138|NCT03170531||Custom MR spine coil|
89546139|NCT02403947|Experimental|Mesenchymal stem cells|At week 0 a single infusion of either ex-vivo expanded autologous MSC or suspension media will be administered intravenously at a dose of 1-2 x 1000000 MSC/Kg body weight. At week 24, another infusion will be performed for cross-over re-treatment: at week 24 treatments will be reversed compared to week 0
89546140|NCT02403947|Placebo Comparator|Suspension media|At week 0 a single infusion of either ex-vivo expanded autologous MSC or suspension media will be administered intravenously at a dose of 1-2 x 1000000 MSC/Kg body weight. At week 24, another infusion will be performed for cross-over re-treatment: at week 24 treatments will be reversed compared to week 0
89546141|NCT04481633|Other|Patient treated with Hydroxy-chloroquine|patients treated with Hydroxy-Chloroquine (HC) with or without immunosuppressants (IS)(HC+ group, n=400)
89546142|NCT04481633|Other|Patient without treatment with Hydroxy-chloroquine|patients without treatment with Hydroxy-Chloroquine with or without immunosuppressants
89546143|NCT03170063||Parkinson's Disease Subjects|Up to 30 Parkinson's Disease patients will be enrolled.
89546144|NCT03170063||Healthy Controls|Up to 20 healthy controls will be enrolled.
89546145|NCT03169907|Experimental|Rh isoimmunized patients|Patients will be selected from Rh isoimmunized patients (positive titre of indirect coomb's test) who are scheduled to have intrauterine blood transfusion. This intrauterine blood transfusion is due to fetal anemia, and it is detected when the measurement of PSV (peak systolic velocity) of middle cerebral artery is more than 1.5 MoM (multiple of the median) according to Fetal Medicine unit of Cairo University protocol. All fetuses are free of structural and functional Fetal and echocardiographic anomaly scan.
89546146|NCT03169751||PNES Cohort|Participants who experience a non-epileptic event with upper extremity motor involvement, while enrolled in the trial
89546147|NCT03169751||Epileptic Cohort|Participants who experience an epileptic event with upper extremity motor involvement, while enrolled in the trial
89546148|NCT03169829|Experimental|Hemodialysis Patients|Phosphorus and potassium homeostasis will be assessed based on the concentrations of phosphorus and potassium in blood samples collected in fasting, post-prandial, mid-afternoon, pre-dialysis states, as well as the concentrations of phosphorus-regulatory factors, calcitriol, parathyroid hormone and fibroblast growth factor-23. The participants will be transitioned gradually to a plant-rich diet
89546149|NCT04481867|Active Comparator|intervention arm :densah bur group|at the maxillary molar area for implant placement ,,just after making initial drilling perforation close to the sinus floor, the direction of the drill is reversed and the cutting speed is raised to 1200 rpm, then 2 successive densah burs are used to elevate sinus membrane 2 mm and to prepare implant hole to the selected implant size .for both groups the selected implant size, 4.2 mm width and 10 mm. length
89546150|NCT04481867|Other|control group :osteotome group|at the maxillary molar area for implant placement .a set of concave osteotomes with different dimensions sequentially used to widen the osteotomy site by surgical mallet. Osteotome 2.5 mm is inserted into the osteotomy firstly to a depth of 1 mm away from the sinus floor with light malleting by the nylon cap mallet then 3 mm osteotome is used to fracture up the sinus floor and finally 3.5 mm osteotome is tapped gently to elevate the sinus floor to the desired depth of the implant in the maxillary sinus.
89546151|NCT02403791|Experimental|Lung Ultrasound|In infants allocated to this arm Lung ultrasound for detection of ARDS will be performed before chest radiography.
89546152|NCT02403791|Active Comparator|Chest Radiography|In infants allocated to this arm chest radiography will be performed for the detection of indirect signs of ARDS without ultrasound evaluation.
89546153|NCT02403713|Experimental|Test Treatment|Fluticasone/formoterol 125/5 µg BAI
89546154|NCT02403713|Active Comparator|Active Comparator 1|Fluticasone/formoterol 125/5 µg pMDI with spacer
89546155|NCT02403713|Active Comparator|Active Comparator 2|Fluticasone/formoterol 125/5 µg pMDI without spacer
89546156|NCT02403713|Active Comparator|Active Comparator 3|Fluticasone/formoterol pMDI (125/5 μg) without spacer, low dose
89546157|NCT02403713|Active Comparator|Active Comparator 4|Formoterol (12 µg) without spacer
89546158|NCT02700815|Experimental|Diclofenac and capsaicin|Fixed dose combination
89546159|NCT02700815|Active Comparator|Diclofenac|
89546160|NCT02700815|Active Comparator|Capsaicin|
89546161|NCT02700815|Placebo Comparator|Placebo|
89025110|NCT00477477|Experimental|1|Low glycemic load diet
89025111|NCT00477477|Active Comparator|2|Low fat diet
89546162|NCT02403557|Experimental|Tailored Internet-delivered CBT|Tailored Internet-delivered CBT during 8 weeks.
89546163|NCT02403557|Active Comparator|Waitlist|Weekly check-up.
89546164|NCT02403401|Experimental|Levonorgestrel (BAY98-7196)|Vaginal ring containing 170 mg levonorgestrel
89546165|NCT02403245|Experimental|Psychosocial stimulation|One session of a social stimulation
89025112|NCT00439764|Active Comparator|1|Routine clinical practice and talk on general health
89025113|NCT00439764|Active Comparator|2|Talk on back health and handout of The Back Book
89546166|NCT02403245|No Intervention|Control group|Residents are in a social controlled condition but without direct stimulation.
89546167|NCT02403011|Experimental|Soft tissue mobilization group|soft tissue mobilization was applied three times in a week and home program exercises were recommended which consisted of positioning the neck and head, handling strategies, stretching exercises, strengthening exercises according to babies neurodevelopmental level and environmental adaptations
89546168|NCT02403011|Experimental|Home program controlled once six weeks|Home program which consisted of positioning the neck and head, handling strategies, stretching exercises, strengthening exercises according to babies neurodevelopmental level and environmental adaptations were recommended
89546169|NCT02402855|Experimental|Group Intervention: Financial support|
89546170|NCT02402855|Active Comparator|Group Control: no financial support|
89546171|NCT02402621|Active Comparator|Conventional analgesic group|fentanyl
89546172|NCT02402621|Experimental|Model based analgesic group|fentanyl
88961549|NCT05775250|Experimental|giomer varnish|Giomer varnish containing surface pre-reacted glass-ionomer (PRG) filler, will be administrated once.
88961550|NCT05775250|Active Comparator|fluoride varnish|5% NaF fluoride varnish, it will be administrated once.
89025114|NCT00439764|Active Comparator|3|Routine clinical practice, talk on back health, handout of The Back Book and back exercise
89546173|NCT04481789|Experimental|Rosuvastatin, Sildenafil, and MT-1186|"Group 1 of Cohort 1:~A single-sequence study in which healthy male subjects receive a single dose of rosuvastatin on Day 1 followed by a single dose of sildenafil on Day 4. MT-1186 will be administered from Day 6 to 13 with co-administration of rosuvastatin and sildenafil on Day 9 and 12, respectively."
89546174|NCT04481789|Experimental|Furosemide and MT-1186|"Group 2 of Cohort 1:~A single-sequence study in which healthy male subjects receive a single dose of furosemide on Day 1. MT-1186 will be administered from Day 3 to 7 with co-administration of furosemide on Day 6."
89546175|NCT04481789|Experimental|MT-1186|"Cohort 2:~A three-way crossover study in which Japanese healthy male subjects receive a single dose of MT-1186 under several dosing condition on Day 1, 4, and 7 according to their treatment sequence with 3-day wash out between doses. Caucasian healthy male subjects receive a single dose of MT-1186 at the same period with Japanese subjects under the corresponding condition on Day 1, 4, or 7 according to their treatment schedule."
89546176|NCT02402387|Active Comparator|Neutral|The patient's head will be in neutral position.
89546177|NCT02402387|Experimental|Flexed|The patient's head will be flexed.
89546178|NCT02402387|Experimental|Extended|The patient's head will be extended.
89546179|NCT02402387|Experimental|Rotated|The patient's head will be rotated.
89546180|NCT02402465|Placebo Comparator|Placebo|Placebo nasal spray that is similar to Dymista in all respects except the active ingredient
89546181|NCT02402465|Experimental|Fluticasone propionate|Fluticasone propionate nasal spray provided in a bottle similar to placebo and dymista
89546182|NCT02402465|Experimental|Dymista (fluticasone/azelastine)|Dymista is also provided as a nasal spray in bottles similar to the other two agents
89546183|NCT04481711|Experimental|Study group|Twenty-nine patients (female/male: 24/5) with grade 4 osteoarthritis were included in the study group. These patients underwent total knee arthroplasty
89546184|NCT04481711|No Intervention|Control group|Twenty-two patients (female/male:13/9) with <grade 4 osteoarthritis were included in the control group.
89546185|NCT02402231|Experimental|Omalizumab|Omalizumab is given to protect the study object from severe allergic reactions while they are going through oral immunotherapy with peanuts. There wïll be only one arm. The study objects are their own controls by also having allergy to airborne allergens. The dose is calculated by the study objects body mass and number of total IgE antibodies.
89546186|NCT02402543|Placebo Comparator|Control Arm|In pre-op, the subject is administered four placebo pills PO containing confectioners sugar, which are matched in color, size, and shape to the active pills.
89546187|NCT02402543|Experimental|Experimental Arm|In pre-op, the subject is administered four pills PO containing a total of 1000 mg of acetaminophen and 600 mg of gabapentin, which are matched in color, size, and shape to the placebo pills.
89546188|NCT02402075||Brain tumor|patients with glioma
89546189|NCT02401841||Sugammadex|Patients treated with Sugammadex
89546190|NCT02401841||Neostigmine|Patients treated with Neostigmine
89546191|NCT02401919|Experimental|Tell-us Card Intervention|Patients in the experimental arm will receive a Tell-us Card on a daily basis during their stay in the hospital. With this card patients are invited to state what is important to them for that day or before discharge from the ward.
89546192|NCT02401919|No Intervention|Care as usual|In the control arm, patients will receive care as usual.
88961551|NCT05774730||Emphysema quantitative analysis softwarebased on chest image AI technology|
88961552|NCT05774730||artificial analysis|
88961553|NCT05774730||imported Chartis detection system|
88961554|NCT05774483|Active Comparator|Sentinel node biopsy|
88961555|NCT05774483|Experimental|Limited elective neck dissection|
89546193|NCT02401763||Nasopharyngeal carcinoma and salivary gland tumor|patients diagnosed and treated in National Taiwan University Hospital
89546194|NCT04481477||Patients COVID-19|Patients over the age of 18 who were admitted with a diagnosis of COVID-19 to any CCSPT unit between March 13, 2020 and April 30, 2020 and were discharged with a recovery result
88961558|NCT05770440||Group 1|Patient with COPD and at least 1 SARS-Cov2 Infection
88961559|NCT05770440||Group 2|Patient with COPD and no SARS-COV2 Infection
88961560|NCT05764551|Experimental|DNA methylation|The enrolled individuals with HCC would receive serum DNA methylation test before their treatment (including all kinds of recommened HCC treatment). Then regularly serum DNA methylation test would be done at 4th~8th weeks, 16th week, 32th week and 48th week. If the enrolled patients did not have HCC recurrence during at 48th week. The regular check of serum DNA methylation would be canceled. The enrolled patients would be observed till 96th week. If there is any recurrence during 48~96th week, one time of serum DNA methylation would be checked at the time of recurrence. The observation and intervention would be completed at 96th week.
89546195|NCT02401373|Experimental|low dose|30 participants will be firstly recruited and assigned to receive the low dose of Recombinant Human Type 5 Adenovirus Vector Based Ebola Vaccine (Ad5-EBOV).
89546196|NCT02401373|Experimental|High dose|After the safety of the low dose vaccination is confirmed, another 30 participants will be recruited and assigned to receive the high dose of Recombinant Human Type 5 Adenovirus Vector Based Ebola Vaccine (Ad5-EBOV).
89608645|NCT04141371|Active Comparator|Molar Sodium Lactate|
89608646|NCT04141371|Placebo Comparator|physiological serum|
89608647|NCT04140981||group 1|difficult intubation according to antropometric measurements
89608648|NCT04140981||group 2|not difficult intubation according to antropometric measurements
89608649|NCT04140981||group 3|difficult intubation according to ultrasound measurements
89608650|NCT04140981||group 4|not difficult intubation according to ultrasound measurements
89546197|NCT05232305|Experimental|People with type 2 diabetes who eat bread with pomegranate crust - Experimental Group|"Individuals with type 2 diabetes who met the inclusion criteria and participated in the study will divided into two groups by Specialist Akkız Zuhal ÖZTAŞ and Specialist Doctor Emel ŞENOL, and they will be asked to consume the breads produced (in the preliminary study) produced as a standard (n=15) and with the addition of pomegranate peel (n=15) for eight weeks.~The individuals participating in the study will be asked not to change their eating habits, physical activity habits, and drug treatments during the study period. Each individual participating in the study will be provided with the required amount of bread during the study and will be contacted weekly by Zeynep ÇAMLIK, a specialist dietitian, to verify whether they consume bread regularly."
89546198|NCT05232305|No Intervention|No intervention - Control Group|Individuals with type 2 diabetes will not eat pomegranate crust bread
89546199|NCT02401295|Experimental|ATRA/celecoxib/itraconazole|"All maintenance drugs will be given on days 1-21 of each cycle, followed by 14 days off treatment. Cycles will be repeated every 35 days (+/- 3 days) for a total of five cycles.~Each patient enrolled will receive ATRA 20mg twice per day by mouth. Dose modifications are not allowed unless excessive toxicity occurs. In this case, ATRA will be de-escalated by 50% to 10mg twice per day by mouth.~The dose of celecoxib for all patients enrolled will be 400 mg twice per day by mouth. If creatinine level increases to more than 2 mg/dl and cannot be corrected by increased oral fluid intake or other measures, the dose of celecoxib will be decreased by 50%. If creatinine level does not drop below 2 mg/dl on the reduced dose, celecoxib will be discontinued.~The dose of itraconazole for all patients enrolled will be 200 mg twice per day by mouth. Dose modifications are not allowed."
89546200|NCT02401451|Experimental|ECG acquisition|"ECG acquisition using the standard ECG machine~Intervention: An ECG will be performed on every participant using the novel device called the 'RhythmPadGP'"
89546201|NCT04897763|Experimental|89Zr-TLX250 PET/CT|Pretherapeutic 89Zr-TLX250 PET/CT
89546202|NCT03169517||Peripheral nerve block group|patients scheduled for elective upper or lower limb surgery with peripheral nerve block will receive LSCI measurements and pinprick sensory tests at 5 min before the block and at 5-min intervals till 30 min after the block.
89546203|NCT03169439|Other|hepatic focal lesions and pancreatic masses|
89546204|NCT03169205||preexisting Diabetes mellitus type 1|
89546205|NCT03169205||preexisting Diabetes mellitus type 2|
89546206|NCT03169205||Gestational Diabetes mellitus|
89546207|NCT02401061|Experimental|PRTX-100|Patients will be assigned to consecutive PRTX-100 interventions as they are enrolled into the study. Between two and six patients will be enrolled per intervention level. Intervention levels range from one (1) to twenty four (24) micrograms of PRTX-100 per kilogram of patient weight. Patients may receive up to four weekly infusions of PRTX-100 over the study treatment period. PRTX-100 doses ≤ 500 μg will be infused intravenously over 30 minutes. PRTX-100 doses > 500 μg will be infused over 60 minutes. Patients will remain under observation for 4 hours after completion of PRTX-100 dosing for safety management.
89546208|NCT02401217|Experimental|Phase 1-Arm 1 Infant Formula|Milk-based infant formula manufactured by an alternative method. Non-commercially available formula. To be fed ad libitum.
89546209|NCT02401217|Active Comparator|Phase 2- Arm 2 Infant Formula|Milk-based infant formula using current manufacturing and ingredients. Non-commercially available formula. To be fed ad libitum.
89546210|NCT02401217|Experimental|Phase 2- Arm 3 Infant Formula|Milk-based infant formula using a new protein. Non-commercially available formula. To be fed ad libitum.
89546211|NCT03106649|Experimental|Gr (E)|The group in which the proposed algorithm for prevention and treatment of spinal hypotension will be tested with regard to fluid and vasopressor use, by means of echocardiography.
89546212|NCT03106649|No Intervention|Gr (S)|The control group in which the anesthesia (fluid and vasopressor) management will be decided by the attending anesthesiologist
89546213|NCT00708305|Experimental|NaF toothpaste (1450 parts per million [ppm] fluoride [F])|Participants brushed for one timed minute with 1.6g of NaF/silica and 0.4 percent carbopol toothpaste containing 1450ppmF as NaF. Participants then swished the slurry around their mouth for 10 seconds, expectorated, then rinsed with water for 10 seconds.
89546214|NCT00708305|Active Comparator|NaF toothpaste (1400ppmF)|Participants brushed for one timed minute with 1.6g of NaF toothpaste containing 1400ppmF as NaF. Participants then swished the slurry around their mouth for 10 seconds, expectorated, then rinsed with water for 10 seconds.
89546215|NCT00708305|Active Comparator|Sodium monofluorophosphate (NaMFP)/ NaF toothpaste (1450ppmF))|Participants brushed for one timed minute with 1.6g of NaMFP/NaF toothpaste containing 1450ppmF from NaMFP and NaF. Participants then swished the slurry around their mouth for 10 seconds, expectorated, then rinsed with water for 10 seconds.
89546216|NCT00708305|Placebo Comparator|Placebo toothpaste (0ppmF)|Participants brushed for one timed minute with 1.6g of fluoride free toothpaste. Participants then swished the slurry around their mouth for 10 seconds, expectorated, then rinsed with water for 10 seconds.
89546217|NCT03169049|Experimental|High-Frequency|"Transcutaneous application of high frequency electrical current over the arm for a 20 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold."
89546218|NCT03169049|Sham Comparator|Sham stimulation|Electrodes are placed over the arm for a 20 minutes in the same manner as experimental group but will be applied a sham electrical stimulation increasing the current intensity of an unconnected channel
89546219|NCT03169127|Experimental|Experimental Group Ibuprofen 600mg|Two Hundred healthy volunteers underwent removal of one lower third molar, will be treated to control pain, swelling and trismus with ibuprofen 600mg. Therefore, these 200 patients will be genotyped and phenotyped for these genes and their postoperative records with all data collected will be compared with the haplotypes found in the Brazilian population.
89546220|NCT03115307|Experimental|Gonapeptyl|In the intervention group the patient will get the advice to using triptorelin (Gonapeptyl®) in the eight day after the injection of hCG (Pregnyl®) in the insemination cycle.
89546221|NCT03115307|No Intervention|Control group|In the control group, there are no luteal phase medications in the insemination cycle.
89546222|NCT03169283|Experimental|Cereal 1|A cereal high in viscous dietary fiber B glucan
88961561|NCT05755672||Synchronous mCRC patients|Patients diagnosed with synchronous metastatic colorectal cancer with planned treatment with curative intent at Skåne University Hospital (Malmö and Lund), who have accepted the study invitation (agreeing to participation - informed consent)
88961562|NCT05743998||Hemodialysis patients|They will fill 2 questionnaires and ill do some functional tests.
88961563|NCT05743998||Peritoneal dialysis patients|They will fill 2 questionnaires and ill do some functional tests.
88961564|NCT05740995||Neoadjuvant Anti-PD-1 Plus Chemotherapy Group|Patients with locally advanced resectable ESCC (cT3-4aN0-1M0) who receive neoadjuvant anti-PD-1 plus chemotherapy and donate biological samples
88961565|NCT05726214|Other|Control Group|The control group will receive general recommendations for maintaining physically active and reducing sedentary behaviors. This will be done verbally and through written material.
88961566|NCT05726214|Experimental|Intervention Group|"The intervention group will receive the same recommendations as the control group. In addition, they will participate in a 6-month multicomponent physical exercise program consisting of a) 1 face-to-face weekly multicomponent session (Rodriguez-Larrad et al. BMC Geriatrics (2017) 17:60), and b) 2 autonomous sessions at home following the Vivifrail program (https://vivifrail.com/es/inicio/).~Face-to-face supervised sessions will last 1 hour and include strength, balance, and flexibility exercises (50%-75% of the 1 repetition maximum for strength exercises). The volume, intensity and difficulty of the exercises will be individualized based on the initial performance of each participant, and will progress as the participants' physical capacity evolves.~At-home training will follow the Vivifrail program."
89546223|NCT03169283|Active Comparator|Cereal 2|A cereal without B glucan
88961568|NCT05668858|Experimental|Study treatment|Participants will receive treatment during the first cycle. Participants with clinical benefits received more cycles of additional therapy. Administration will be discontinued due to disease progression or occurrence of intolerable toxicity or other reasons.
88961569|NCT05640687||aPAP|
89546224|NCT02418533|Experimental|Mono-menotropin protocol|Stimulation Group 1: Mono-Menotropin Protocol Fifty patients will undergo the standard of care COS for IVF using Menopur only. Patients will receive 300 IU of Menopur injected subcutaneously daily for the first five days of stimulation. Thereafter, Menopur may be adjusted (to optimize ovarian response by patient's physician) in 75 IU increments up to a total of 450 IU Menopur daily up to and including day of hCG trigger.
88961570|NCT05640687||healthy control|
88961571|NCT05639374|Experimental|BASICS_HealthyClassroom|"Students assigned to the IG will receive the peer-led preventive program. The preventive program consists of a single face-to-face session, lasting about 45-50 minutes. First, the participant will receive, from the Research Staff in Training, the individualized feedback sheet prepared from the baseline information obtained through the BASICS_HealthyClassroom Questionnaire. Subsequently, they will have a motivational interview with the counsellor. The content of the intervention will be adapted to the interests and level of motivation of each participant."
88961572|NCT05639374|No Intervention|Control Group|Students assigned to the CG will not receive any type of intervention, they will only receive the usual information and messages that students receive in their daily environments and at the University.
88961573|NCT05638386||Patients who underwent a robotic-assisted total knee arthroplasty with the use of bone plugs|
88961574|NCT05638386||Patients who underwent a robotic-assisted total knee arthroplasty without the use of bone plugs|
88961575|NCT05635487|Experimental|SHR-A1811+Pyrotinib|
89546225|NCT02418533|Experimental|rFSH protocol|Stimulation Group 2: Recombinant follicle stimulating hormone (rFSH) Protocol Fifty patients will undergo the standard of care COS for IVF using Gonal-f (EMD Serono, USA) Protocol. Patients will receive Gonal-f (300 IU) administered subcutaneously daily for the first five days of stimulation. Thereafter, Gonal-f may be adjusted (to optimize ovarian response by the patient's physician) in 75 IU increments up to a total of 450 IU daily up to and including day of hCG trigger.
89546226|NCT02418377||Obese children|"The obese subject must meet all of the following inclusion criteria to participate in this study:~Ideal body weight for height (WFH) of at least 140% or BMI for age above 97th percentile~Overweight before 10 years of age~Informed consent from both obese children subject and legal representative e.g. parents"
89207808|NCT04093752|Active Comparator|Insulin Glargine|Participants received insulin glargine administered once daily (QD) SC. The starting dose of insulin glargine was 6 Insulin Units (IU)/day at bedtime, titrated to a fasting blood glucose (FBG) between 72-100 milligrams per Deciliter (mg/dL), following a treat-to-target (TTT) algorithm.
89207809|NCT00865956|Experimental|Care Management|Care Management plus voucher incentives for adherence to primary care appointments.
89546227|NCT02418377||Family members of obese children|"Family member must meet all of the following inclusion criteria to participate in this study:~Must be parent or direct sibling of obese subject~Informed consent from both subject and parent is subject is below 21 years of age"
89546228|NCT03168893|Experimental|Deep brain stimulation ON|Surgical procedure is necessary.In surgery, two cerebral electrodes (either in the Subgenual cingulate or in the Accumbens Nucleus) are connected to a subcutaneous generator at abdominal fat level, under general anesthesia. The patient will initiate the stimulation prior to discharge . At 6 months follow up, Deep brain stimulation continue 3 months more activated, patient and psychiatrist don´t know
89207810|NCT00865956|No Intervention|Usual care|Usual care
89546229|NCT03168893|Experimental|Deep brain stimulation OFF|Surgical procedure is necessary.In surgery, two cerebral electrodes (either in the Subgenual cingulate or in the Accumbens Nucleus) are connected to a subcutaneous generator at abdominal fat level, under general anesthesia. The patient will initiate the stimulation prior to discharge . At 6 months follow up, Deep brain stimulation is stopped during 3 months , patient and psychiatrist don´t know
89546230|NCT02400593|Experimental|Lovingkindness|A six-week formal meditation workshop for 1 hour per week.
89546231|NCT02400593|Placebo Comparator|Mindfulness|A six-week formal meditation workshop for 1 hour per week.
89546232|NCT02418299|Experimental|IncontiLase Er:YAG laser treatment|Er:YAG laser treatment for stress and mixed urinary incontinence
89546233|NCT02418221|Experimental|DAOSiN®/ Placebo & ProvokAmin® Ingestion|A sample of blood is drawn from Patient, blood pressure & pulse are recorded. Patient will ingest 2 capsules of either DAOSiN® or Placebo, followed by 2 tablets of ProvokAmin 20 minutes later. After an additional 40 minutes blood pressure and pulse are recorded and another sample of blood is drawn. Patient is handed a questionaire for self-evaluation to record any symptoms for the following After between 7 and 15 days the whole cycle is repeated switching between active treatment and Placebo.
89546234|NCT02400827||cryopreservation|
89546235|NCT02401997|Active Comparator|sexual abstinence period group I|The subjects participated in the study are divided into three groups according to the male partners sexual abstinence period during the day of sperm preparation for intrauterine insemination. Group I male partners have sexual abstinence period of 2 days or less.
89546236|NCT02401997|Active Comparator|sexual abstinence period group II|The subjects participated in the study are divided into three groups according to the male partners sexual abstinence period during the day of sperm preparation for intrauterine insemination. Group II male partners have sexual abstinence period of 2 to 4 days.
89546237|NCT02401997|Active Comparator|sexual abstinence period group III|The subjects participated in the study are divided into three groups according to the male partners sexual abstinence period during the day of sperm preparation for intrauterine insemination. Group II male partners have sexual abstinence period of more than 4 days
89546238|NCT02417909||Healthy volunteers|This group is composed of healthy teenagers that volunteered to participate in the trial and that will answer questionnaires about quality of life. Parents will anwser questionnaires too.
89546239|NCT02417909||Obese teenagers|This group is composed of obese teenagers that have been recruited to participate in the trial and that will answer different questionnaires quality of life. Parents will anwser questionnaires too.
89546240|NCT02418065|Experimental|treated group|testosteron, oral nutritional supplementation, n3 polyunsaturated fatty acid, training on ergonomic bicycle
89546241|NCT02418065|Other|control group|oral nutritional supplementation
89546242|NCT02417987|Active Comparator|High Volume injection|"A total volume of 50 ml:~10 mls 0.5% bupivacaine hydrochloride and~20 mg of Depomedrol (hydrocortisone)~40 mls saline (NaCl) HVI is injected one time at baseline and thereafter the group received sham treatment at 2 weeks, 4 weeks and after 6 weeks."
89546243|NCT02417987|Active Comparator|Autologous conditioned plasma (ACP)|"Whole blood was drawn from the patients using arthrex system (total of 10 mls whole blood). After that the whole blood is spined for 5 minutes and ACP with platelets and growth factors is separated from the red and white blood cells (4 mls).~The ACP is injected 4 times (at baseline, 2 weeks, 4 weeks and after 6 weeks)"
89546244|NCT02417987|Sham Comparator|Placebo|A few drops of saline is injected in the soft tissue away from the tendon.
89546245|NCT02400515|Other|Moderate Exercise|Aerobic physical exercise was applied during 3 months, 3x/week on women with type 2 diabetic. The evaluation occurred before and after exercise in the same (and only) group, considering that this is a quasi-experimental study.
88961576|NCT05620355|Experimental|BG2109 100mg group|One tablet of BG2109 100mg + one tablet of placebo for BG2109 + one tablet of placebo for add-back therapy, oral, once-daily.
88961577|NCT05620355|Experimental|BG2109 200mg+ABT group|Two tablets of BG2109 100mg + one tablet of add-back therapy, oral, once-daily.
89517275|NCT04518228||Component 3: Arm 3.3: Lopinavir/ritonavir (LPV/r) 800/200 mg|Women ≥ 20 weeks gestation receiving first-line TB treatment with at least two of the following TB treatment drugs: isoniazid (INH), rifampin (RIF), rifabutin (RFB), ethambutol (EMB), pyrazinamide (PZA), moxifloxacin (MFX), and receiving lopinavir/ritonavir (LPV/r) 800/200 mg b.i.d., and their infants
88961578|NCT05620355|Placebo Comparator|Placebo group|Two tablets of placebo for BG2109 + one tablet of placebo for add-back therapy, oral, once-daily.
89546246|NCT03168581|Experimental|CN-105|All eligible subjects will receive study drug, CN-105
89546247|NCT05058443|Experimental|Denosumab|Denosumab 60 mg were injected subcutaneously every 6 months (Q6M)
89546248|NCT05058443|Placebo Comparator|Placebo|Equal volume of saline (0.9%) as placebo were injected subcutaneously every 6 months (Q6M)
89546249|NCT02417519|Experimental|Sequence A|The meal study was performed with dark roast coffee (DAR), light roast coffe (LIR), or water (CTR) in a random sequence. Sequance A was DAR-LIR-CTR
89546250|NCT02417519|Experimental|Sequence B|The meal study was performed with dark roast coffee (DAR), light roast coffe (LIR), or water (CTR) in a random sequence. Sequance B was DAR-CTR-LIR
89546251|NCT02417519|Experimental|Sequance C|The meal study was performed with dark roast coffee (DAR), light roast coffe (LIR), or water (CTR) in a random sequence. Sequance C was LIR-DAR-CTR
89546252|NCT02417519|Experimental|Sequence D|The meal study was performed with dark roast coffee (DAR), light roast coffe (LIR), or water (CTR) in a random sequence. Sequance D was LIR-CTR-DAR
89546253|NCT02417519|Experimental|Sequence E|The meal study was performed with dark roast coffee (DAR), light roast coffe (LIR), or water (CTR) in a random sequence. Sequance E was CTR-DAR-LIR
89546254|NCT02417519|Experimental|Sequence F|The meal study was performed with dark roast coffee (DAR), light roast coffe (LIR), or water (CTR) in a random sequence. Sequance F was CTR-LIR-DAR
89546255|NCT02400125||1|Patients underwent isolated or combined coronary artery bypass grafting surgery
89546256|NCT02400125||2|Patients underwent isolate or combined surgical treatment for heart valve disease
89546257|NCT02055976|Experimental|Population A|A total of 9 groups in two population. Population A comprises hypercholesterolemic Japanese subjects whose LDL-C is not controlled by a stable dose of atorvastatin. A subject who is receiving a stable dose of atorvastatin will be randomized into one out of 5 dose groups.
89546258|NCT02055976|Experimental|Population B|A total of 9 groups in two population. Population B comprises hypercholesterolemic Japanese subjects who are naïve for a treatment by lipid lowering drug and whose fasting LDL-cholesterol is not controlled. A subject who is treatment naïve will be randomized into one out of 4 dose groups.
89546259|NCT02055898|Experimental|Placebo first, then sodium oxybate|Subjects received a single dose of placebo comparator (fresh potable water) at bedtime on 4 nights during an inpatient stay of 5 days in the research centre. This was followed by an interval of at least 2 weeks. They were then admitted again and received a single dose of sodium oxybate (3.0g as liquid) at bedtime for 4 nights
89546260|NCT02055898|Experimental|Sodium oxybate first, then placebo|Subjects received a single dose of sodium oxybate (3.0g as liquid) at bedtime on 4 nights during an inpatient stay of 5 days in the research centre. This was followed by an interval of at least 2 weeks. They were then admitted again and received a single dose of placebo comparator (fresh potable water) at bedtime for 4 nights
89546261|NCT02564055|Experimental|GSK2894512 1% cream twice daily|Subjects will apply a thin layer of GSK2894512 1% (10 milligram per gram [mg/g]) topical cream twice daily (morning and evening) for 12 weeks, to all atopic dermatitis lesions (except on the scalp).
89546262|NCT02564055|Experimental|GSK2894512 1% cream once daily|Subjects will apply a thin layer of GSK2894512 1% (10 mg/g) topical cream once daily (evening) for 12 weeks, to all atopic dermatitis lesions (except on the scalp).
89546263|NCT02564055|Experimental|GSK2894512 0.5% cream twice daily|Subjects will apply a thin layer of GSK2894512 0.5% (5 mg/g) topical cream twice daily (morning and evening) for 12 weeks, to all atopic dermatitis lesions (except on the scalp).
89546264|NCT02564055|Experimental|GSK2894512 0.5% cream once daily|Subjects will apply a thin layer of GSK2894512 0.5% (5 mg/g) topical cream once daily (evening) for 12 weeks, to all atopic dermatitis lesions (except on the scalp).
89546265|NCT02564055|Placebo Comparator|Vehicle cream twice daily|Subjects will apply a thin layer of vehicle topical cream twice daily (morning and evening) for 12 weeks, to all atopic dermatitis lesions (except on the scalp).
89546266|NCT02564055|Placebo Comparator|Vehicle cream once daily|Subjects will apply a thin layer of vehicle topical cream once daily (evening) for 12 weeks, to all atopic dermatitis lesions (except on the scalp).
89546267|NCT02563899|Experimental|Umeclidinium|Subjects will receive umeclidinium once daily before bedtime for 14 days.
89546268|NCT02563899|Placebo Comparator|Vehicle|Subjects will receive vehicle once daily before bedtime for 14 days.
89546269|NCT04406259|Other|Verapamil|administration of verapamil to treat cluster headache
89546270|NCT05500521||Patients with severe-to-profound hearing loss|Patients with severe-to-profound hearing loss will undergo investigation with caloric irrigation, video head impulse test and vestibular evoked myogenic potential. Patients will complete the Dizziness Handicap Inventory-questionnaire.
89546271|NCT05500521||Controls|Controls will undergo investigation with caloric irrigation, video head impuls test and vestibular evoked myogenic potential. Controls will complete the Dizziness Handicap Inventory-questionnaire.
88961579|NCT05616390|Experimental|experimental group|Sintilimab Combined With Bevacizumab and Liver Protective Support Therapy
88961580|NCT05614817|Experimental|[Treatment Period 1]Group 1-Dose1|CBP-201 600 mg (4 mL) SC on Day 1 (Week 0 visit) visit followed by 300 mg (2 mL) SC Q2W starting at Week 2 with the last dose at Week 14.
88961581|NCT05614817|Placebo Comparator|[Treatment Period 1]Goup 2-Placebo1|Placebo (4 mL) SC on Day 0 (Week 0) visit followed by placebo (2 mL) SC Q2W starting at Week 2 with the last dose at Week 14
88961582|NCT05614817|Experimental|[Treatment Period 2] Group 1-Dose2|CBP-201 300 mg SC Q2W starting at Week 16 with the last dose at Week 50 Treatment Period 2 (Group 1 Dose 1 responder pts that rerandomize to Dose 2, Dose 3, or PBO 2)
88961583|NCT05614817|Experimental|[Treatment Period 2] Group 1-Dose3|CBP-201 300 mg SC Q4W starting at Week 16, alternating with placebo SC Q4W starting at Week 18 with the last dose of CBP-201 at Week 48 and placebo at Week 50
88961584|NCT05614817|Placebo Comparator|[Treatment Period 2] Group 1-Placebo2|Placebo Q2W SC starting at Week 16 with the last dose at Week 50
89546272|NCT05500287|Experimental|Virtual Care Group|Children in virtual care group (VCG) were given distance asthma education for the first month. The education was given in groups of 5-6 children. Also, short videos were taken by the researcher on how to use medications and nebulizers and were shown in Zoom meetings. The education and videos were prepared by scanning the current literature and expert opinion was obtained from 2 experts in nursing education, 2 experts in pediatric nursing and a expert in the pediatric allergy field. Children and families sent asthma diaries to the researcher every 4 weeks. At the end of the first, third and sixth months, data from asthma diaries were collected via Google Forms. The Pediatric Asthma Child Quality of Life Scale score was also collected through Google Forms at the beginning and end of the sixth month. The patients received support from the researcher on case management via telephone or video call 24/7. Case management was multidisciplinary (a nurse and a specialist).
89546273|NCT05500287|No Intervention|Control Group|Children and families who in the control group (CG), sent asthma diaries to the researcher every 4 weeks. At the end of the first, third and sixth months, data from asthma diaries were collected via Google Forms. The Pediatric Asthma Child Quality of Life Scale score was also collected through Google Forms at the beginning and end of the sixth month. In the CG, the education routinely given by the physician during the outpatient clinic visits continued in the same way. In the name of equality of opportunity, training presentations and videos were shared with the CG at the end of the study. Also, the training presentation was converted into a booklet (videos were added to the booklet in the form of QR codes) and delivered to the clinic in printed form.
89546274|NCT02699099|Experimental|Coad group|Children randomized received Vitamin A at 6 months of age, SB257049 vaccine at 6, 7.5 and 9 months of age, and Yellow Fever (YF) vaccine and a combined measles and rubella vaccine at 9 months of age. Subjects received a booster dose of SB257049 vaccine at 18 months post Dose 3 (i.e. at 27 months of age).
88961585|NCT05614817|Placebo Comparator|[Treatment Period 2] Group 2-Placebo|PBO 1 pts responders that continue PBO 1
89546275|NCT02699099|Experimental|RTS,S group|Children randomized received Vitamin A at 6 months of age, SB257049 vaccine at 6, 7.5 and 9 months of age, and Yellow Fever (YF) vaccine and a combined measles and rubella vaccine at 10.5 months of age. Subjects received a booster dose of SB257049 vaccine at 18 months post Dose 3 (i.e. at 27 months of age).
89546276|NCT02699099|Experimental|Control group|Children randomized received Vitamin A at 6 months of age and Yellow Fever (YF) vaccine and a combined measles and rubella vaccine at 9 months of age. These children received SB257049 vaccine at 10.5, 11.5 and 12.5 months of age plus a booster dose 17.5 months post Dose 3 (i.e. at 30 months of age).
89546277|NCT03928587|Experimental|Active|A lozenge containing 2 billion CFU in total of the two strains Lactobacillus paracasei subsp. paracasei and Lactobacillus rhamnosus and arginine 2% to be taken once daily
89546278|NCT03928587|Placebo Comparator|Placebo|An identical lozenge except for the absence of probiotics and arginine to be taken once daily.
88961586|NCT05614817|Experimental|[Treatment Period 2] Group 3-Dose|Dose 1 and PBO 1 Non-responders, and Group 1 and 2 Non-responders that get open-label Dose 4 or 5 (LD 300 mg or 600 mg, biweekly 300 mg thereafter)
88961587|NCT05593471|Experimental|High intensity exercises|The first group (HG) received a High-intensity exercise program consisting of progressive resistance training for 30 min using dumbbells, sandbags, and TheraBand with different colors. The exercised muscles were (knee extensors, elbow flexors, chest muscles, hip adductors, abductors, abdominal muscles, back muscles, and hand grip muscles) (references). The intensity of exercise was determined by the load which was kept at 65% of the 10-repetition maximum throughout the program duration. The repetitions of each exercise were kept at a fixed value of 2 sets of 10 - 12 repetitions per session (exercises stopped if the patient reached fatigue level). For progression, the 10-repetition maximum test was performed on a weekly schedule and the amount of load was adjusted accordingly. Exercises were done in a cyclic manner where half of the selected muscles were exercised per session and the other half were exercised in the next session.
88961588|NCT05593471|Experimental|low intensity aerobic exercises|The second group (LG) received a low-intensity aerobic exercise program consisting of an arm ergometer, and a bicycle ergometer to train both upper and lower body muscles. Additionally, 5 minutes of regular treadmill walking was added at the beginning and the end of the exercises session as warming up and cooling down respectively. Exercises were performed in a cyclic manner where the arm and bicycle ergometers were used alternatively. The rate of perceived exertion (RPE) scale was used to monitor the intensity of the exercises to be at 3 -4 level. The actual working out time was 20 minutes plus 10 minutes for the warming up and cooling down. Sessions were performed 3 times per week for six weeks.
88961589|NCT05592236|Experimental|Study group|Dynamic compression garments for 2 hours a day in addition to standard therapy twice a week (1 session of 45 minutes) for a total of 6 weeks
89546279|NCT02399969|Experimental|Battlefield Acupuncture Plus Standard of Care|Patients with low back pain that will receive ear acupuncture based on the Battlefield Acupuncture protocol.
89546280|NCT02399969|No Intervention|Standard of Care Alone|Patients with low back pain that will receive standard of care without study intervention.
89546281|NCT05500131||Experimental group|All participants allowed three practice trials for each test in this order: the Weight-bearing lunge test and the Single-leg squat test. Both of them were evaluated through the Leg Motion system (LegMotion, your MOtion®, Albacete, Spain)
89546282|NCT02399891||Retrospective|MI prior to December 11, 2011
89546283|NCT02399891||Prospective|MI on or after December 11, 2011
89546284|NCT02417597|Experimental|Experimental Group|Participants in this arm are aged over 65 years and would receive three doses of Recombinant Hepatitis E Vaccine (Escherichia Coli)(Hecolin®) at o,1,6 month.
89546285|NCT02417597|Active Comparator|Immunogenicity Control Group|Participants in this arm are aged beteen 18-65 years and would receive three doses of Recombinant Hepatitis E Vaccine (Escherichia Coli)(Hecolin®) at o,1,6 month.
89546286|NCT02417597|No Intervention|Safety Control Group|Participants in this arm are aged over 65 years.
89546287|NCT05497479|Experimental|Treatment with Schirmer test with no anesthetic|Both eyes will be treated.
88811724|NCT01491113|Experimental|Group D: Severe renal impairment|"Patients who have severe renal impairment (CLcr <30 mL/min/1.73 m^2). Subjects will be orally administered Levetiracetam (LEV) 250 mg once. After LEV administration, safety assessments and blood and urine samplings will be conducted through Day 7 during the Treatment Period, and safety follow-up assessments will be performed on Day 8 according to the schedule of study assessments.~Blood samples for Pharmacokinetics (PK): Predose (Baseline), and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144 hours postdose~Urine samples for PK: 0 - 6, 6 - 12, 12 - 24, 24 - 48, 48 - 72, 72 - 96, 96 -120, 120 - 144 hours postdose"
89546288|NCT05497479|Experimental|Treatment with Schirmer test with anesthetic|Both eyes will be treated.
89546289|NCT03177785|Experimental|Intervention|6-weeks of telephone-delivered sessions, moderated by a trained clinician offering EverydayMatters MS.
89546290|NCT03177785|No Intervention|Control|Wait-list control
89546291|NCT02400047|Experimental|Dexamethasone 0.2 mg/kg|Single injection of DXM (Mylan Dexamethasone® 20 mg/5 ml or 4 mg/1 ml injection ampoule solution) at 0.2 mg / kg after general anesthesia induction and before surgery incision.
89546292|NCT02400047|Experimental|Dexamethasone 0.4 mg/kg|Single injection of DXM (Mylan Dexamethasone® 20 mg/5 ml or 4 mg/1 ml injection ampoule solution) at 0.4 mg / kg after general anesthesia induction and before surgery incision.
89546293|NCT02400047|Active Comparator|Ketoprofen 1 mg/kg|Single injection of ketoprofen (Medac ketoprofen ® 100 mg/4 ml injection ampoule solution) at 1 mg /kg after general anesthesia induction and before surgery incision.
89546294|NCT02698865|Experimental|MONOVISC|MONOVISC High Molecular Weight Hyaluronan
89546295|NCT02698865|Placebo Comparator|Saline|Physiologic saline
89546296|NCT03842319|Experimental|Control|In patients allocated to the control group, the currently used Spanish Mediterranean diet will be recommended as part of a standard high-quality secondary prevention program, where the patient is invited to participate in a single 45 minute nutritional educational group session. Interventions: Microbiota analysis, Immunological analysis, Proteome analysis, Metabolome analysis, Clinical evaluation
89546297|NCT03842319|Experimental|High-intensity MedDiet|Patients allocated to the interventional group will be individually evaluated by a dietitian and will participate in dedicated individual and group sessions at baseline, and at 3, 6, 9 and 12 months. In the interventional group, a personalized MedDiet will assess chemical and nutritional composition and total energy intake will be adapted to participant's weight, age, and requirements, and the dietitian's tailored advice to his/her individual needs. A 14-item dietary screen for adherence to the Mediterranean diet will be used to personalize the intervention and negotiate dietary changes. Furthermore, free virgin olive oil, recipes, shopping list and designed weekly menus will be provided to maximize the differences between groups. Interventions: MedDiet, Microbiota analysis, Immunological analysis, Proteome analysis, Metabolome analysis, Clinical evaluation, Diet evaluation
89546298|NCT04497597||Participants receiving Upadacitinib|Participants receiving Upadacitinib for moderate to severe rheumatoid arthritis (RA).
89546299|NCT02698787|Experimental|Group 1|All patients will be receiving commercially available Cochlear™ Nucleus® CI24RE with Contour Advance™ Electrode or Cochlear™ Nucleus® CI512 cochlear implant with Contour Advance™ Electrode for this study. Group 1 will be receiving the FAST (experimental) sound coding strategy at initial activation and use it for the first three months.At the three month interval subjects in Group 1 will be switched to the commercially available ACE (control) sound coding strategy.
89546300|NCT02698787|Experimental|Group 2|All patients will be receiving commercially available Cochlear™ Nucleus® CI24RE with Contour Advance™ Electrode or Cochlear™ Nucleus® CI512 cochlear implant with Contour Advance™ Electrode for this study. Group 2 will be the commercially available ACE (control) sound coding strategy at initial activation and use it for the first three months.At the three month interval subjects in Group 2 will be switched to the receiving intervention of the FAST (experimental) sound coding strategy. The experimental sound coding strategy will be used from 3-6 months post activation.
89546301|NCT03755349|Experimental|Intervention group|Both burr-holes are covered by burr-hole covers in patients with unilateral cSDH. In patients with bilateral cSDH, both burr-holes of the intervention side are covered by burr-hole covers.
89546302|NCT03755349|Active Comparator|Control group|None of the burr-holes are covered by burr-hole covers in patients with unilateral cSDH. In patients with bilateral cSDH, both burr-holes on the control side are left uncovered.
89546303|NCT02417051|Experimental|Resiliency Training|Intervention: Disaster Worker Resiliency Training (DWRT) Program.
89546304|NCT02417051|No Intervention|Waitlist|Waitlist control: Participants to be offered the program after completion of the trial.
89546305|NCT05499897|Placebo Comparator|Group general anesthesia|(Patients who will be operated under general anesthesia): Standard ASA monitoring, induction with 2 mg/kg propofol, 0.6mg/kg rocuronium bromide, 1µcg/kg fentanyl. Maintenance with 2MAC sevoflurane + 40% air mixture. Flow 2L/min. Before extubation, 1 mg/kg tramadol and 15 mg/kg paracetamol will be administered iv. Paracetamol will be repeated at 8 hour intervals.
89546306|NCT05499897|Experimental|Group interscalene|(Patients who will undergo surgery with interscalen block): 20 ml of 0.25% bupivacaine for anesthesia. Before being taken to the postoperative unit, 1 mg/kg tramadol and 15 mg/kg paracetamol will be administered iv. Paracetamol will be repeated at 8 hour intervals.
89546307|NCT02417675|Active Comparator|Standard of Care (SOC)|"Women who choose the SOC will receive postpartum antiretroviral therapy (ART) services at their nearest primary care clinic, following the Standard of Care for Mothers. Details are provided in the intervention description.~Infants receive the same care in each arm, according to the Standard of Care for Infants."
89546308|NCT02417675|Experimental|Intervention (AC)|"Women who choose the Community-based Adherence Clubs (AC) will receive postpartum antiretroviral therapy (ART) services at an AC, rather than at their nearest primary care clinic as in the SOC arm. Details are provided in the intervention section.~Infants receive the same care in each arm, according to the Standard of Care for Infants."
89546309|NCT02417207|Sham Comparator|Entecavir combined long-term low-dose HBIG group intramuscular|HBIG scheme is: the use of intraoperative muscle injection of 800 IU HBIG, postoperative week 1 intramuscular injection HBIG 400 IU 1 times a day, 1 week after intramuscular injection HBIG 400 IU 2 times per week, dosage and time interval according to the HBsAb drops in patients with degree of level adjustment, target drops for 3 months or more after 500 IU/mL, 3 ~ 6 months or 300 IU/mL, after six months of 100 IU/mL or more.
88961590|NCT05592236|Active Comparator|Control Group|Standard therapy twice a week (1 session of 45 minutes) for a total of 6 weeks
89207811|NCT02545062|Experimental|group of type 1 and 2 diabetics|"A group of type 1 and 2 diabetes patients who meets the inclusion criteria will be done the MoCa test. A fingertip blood glucose will be made previous to the begin with the test in order to avoid doing it on a hypoglycemia event. The participants are instructed to do or respond the items in a organized manner. For each items there's a score. If the participant has 12 years of education or fewer, a point is added to his total score. At the end of the test the investigator will sum all sub items scores listed on the right side of the test paper. The maximum score is 30.~The MoCa test will be done in a control group, no diabetics, that meets the inclusion criteria."
89207812|NCT02545062|Experimental|control group|The MoCa test will be done in a control group, no diabetics, that meets the inclusion criteria.
89546310|NCT02417207|Active Comparator|Entecavir combined HBIG group short-term high-dose intravenous|Preoperative HBV DNA level is less than 1000 IU/ml, intraoperative intravenous drip of 2500 IU HBIG static note type, postoperative 1 and 15 days respectively to give 2500 IU HBIG static note type, a total of three times, then no longer apply. Preoperative HBV DNA level greater than 1000 IU/ml, the use of HBIG solution for: intraoperative intravenous drip of 5000 IU HBIG static note type, postoperative day 1, 15 days and 30 days respectively to give 2000-2500 IU HBIG static note type, a total of four times, since then no longer apply. Preoperative HBV DNA level of the unknown, preoperative immediate detection of DNA, intraoperative intravenous drip of 5000 iu HBIG static note type, choose according to test results after dosing frequency.
89546311|NCT02399501|Experimental|uterine lesion ultrasound, hysteroscopy|evaluation of female with proved uterine lesion by two dimensional ultrasound, three dimensional ultrasound, saline sonohysterography and hysteroscopy
89546312|NCT02698475|Experimental|Ustekinumab Group|Participants will receive 1 of the following dose levels depending on their weight: participants weighing less than (<) 60 kg will receive Ustekinumab 0.75 milligram per kilogram (mg/kg); participants weighing greater than or equal to (>=) 60 kg to less than or equal to (<=) 100 kg will receive ustekinumab 45 mg; participants weighing >100 kg will receive ustekinumab 90 mg, at Weeks 0 and 4 followed by every 12 weeks dosing with the last dose at Week 40. Eligible participants who enter the long-term extension (LTE) period will continue receiving ustekinumab every 12 weeks (q12w) beginning at Week 56 up to Week 248.
89546313|NCT02399657|Experimental|Intravitreal dexamethasone implant|Intravitreal dexamethasone 0.7mg implant (Ozurdex)
89546314|NCT03177707|Experimental|Immediate start|Patients begin the Mindfulness-based Therapy Group for Couples treatment group immediately after enrollment
89546315|NCT03177707|Other|Delayed start|Patients begin the Mindfulness-based Therapy Group for Couples after a delay post-study enrollment (approximately 6 months)
89546316|NCT02399579|Experimental|HypoScore|Provocation test. Recording symptoms of cat allergic participants with the cat owner's cat: Before and after petting the cat.
89546317|NCT03177629|Experimental|Treatment arm: H. pylori eradication|treatment arm: H. pylori eradication at visit 1(0 month)
89546318|NCT03177629|No Intervention|Control arm -1st stage|At visit 1(0 month) no intervention, observation only from visit 1 to visit 3
89546319|NCT03177629|Active Comparator|Control arm - 2nd stage|Same patients group with control arm 1st stage. After observation for 3 months during stage 1, the patients of control arm will be treated with same regimen for H. pylori eradication at visit 4 (2nd stage).
89546320|NCT02559687|Experimental|Pembrolizumab 200 mg|Participants will receive pembrolizumab 200 mg, intravenously (IV), every 3 weeks (Q3W) for up to 35 treatments (approximately 2 years). Eligible participants who stop pembrolizumab with Stable Disease (SD) or better but progress after discontinuation may be able to initiate a second course of pembrolizumab for up to 17 cycles (up to approximately 1 additional year) at the investigator's discretion.
89546321|NCT03177551||Developement Cohort|Development the Predictive Nomogram for mCRPC in Patients with Prostate Cancer
89546322|NCT03177551||Validation Cohort|Validation the Predictive Nomogram for mCRPC in Patients with Prostate Cancer
89546323|NCT04279119|Experimental|ARQ-151 cream 0.3%|Open label study of ARQ-151 cream 0.3% applied once daily for 2 weeks
89546324|NCT02399735|Experimental|Arm A|Received conventional treatment and NK cells once per two-week for the first two-month, at a dose of 5×10E9 NK cells.
89546325|NCT02399735|Experimental|Arm B|Received conventional treatment and NK cells once per two-week for the first two-month, at a dose of 1×10E10 NK cells.
89546326|NCT02399735|Experimental|Arm C|Received conventional treatment and NK cells once per two-week for the first four-month, at a dose of 1×10E10 NK cells.
89207813|NCT00866112|Experimental|1|Intervention group to promote physical activity
89546327|NCT03177317|Experimental|Elderly patients (>= 70 years of age)|Dexamethasone 8mg intravenously before chemotherapy
89546328|NCT03177239|Experimental|Nivolumab and Ipilimumab|"Part 1: nivolumab 240mg IV q2w for a maximum of 12 months.~Part 2; nivolumab 240mg IV q3w in addition to ipilimumab 1mg/kg q3w x 4 cycles Then nivolumab 240mg q2w for a maximum of 12 months."
89546329|NCT02399267|Active Comparator|Once daily screening|In the 'once daily screening arm', RTs will screen invasively ventilated patients between approximately 06:00 - 08:00 hours daily. If a screening period is missed inadvertently or due to an investigation or intervention (operation/procedure) necessitating absence from the ICU, it may be conducted later on the same day and ideally within 6 hours of the scheduled screening period. Regardless of group assignment, if the SBT screening assessment is passed, an SBT will be conducted as per protocol.
89546330|NCT02399267|Experimental|At least twice daily screening|In the 'at least twice daily' screening arm patients will be screened at a minimum between approximately 06:00 - 08:00 hours and 13:00 - 15:00 hours daily. If a screening period is missed inadvertently or due to an investigation or intervention (operation/procedure) necessitating absence from the ICU, it may be conducted later on the same day and ideally within 6 hours of the scheduled screening period. Additional screening trials in the 'at least twice daily' screening arm will be permitted at the discretion of the clinical team (RTs and physicians). Regardless of group assignment, if the SBT screening assessment is passed, an SBT will be conducted as per protocol.
89546331|NCT02399267|Active Comparator|PS SBTs|In the 'PS SBTs arm', RTs will conduct SBTs using only PS =< 8 cm H2O with PEEP =< 5 cm H2O. Regardless of group assignment, if the SBT screening assessment is passed, an SBT will be conducted as per protocol.
89546332|NCT02399267|Active Comparator|T-piece SBTs|In the 'T-piece SBTs arm', RTs will conduct SBTs using only T-piece. Regardless of group assignment, if the SBT screening assessment is passed, an SBT will be conducted as per protocol.
89546333|NCT04480775|Experimental|bupivacaine group|28 Patients will receive 18 ml of bupivacaine 0.5 % plus 1ml 0.9% saline in TAP block divided equally on both sides
89546334|NCT04480775|Active Comparator|triamicinolone group|28 Patient will receive 18 ml of bupivacaine 0.5 % plus (20 mg of triamcinolone in 1ml 0.9% saline divided equally on both sides in TAP block
89546335|NCT04480775|Active Comparator|methylprednisolone group|28 Patient will receive 18 ml of bupivacaine 0.5 % plus (40 mg of methylprednisolone in 1ml 0.9% saline ) on both sides in TAP block.
89546336|NCT02399033|No Intervention|the control group|Patients in Control group were not received Xihuang Capsules.
89546337|NCT02399033|Experimental|Xihuang Capsules group|Patients in Xihuang Capsules group were received Xihuang Capsules (2g, bid), Continuously taking to cancer recurrence or death.
89546338|NCT02417363||Group A|the control group,healthy individuals
89546339|NCT02417363||Group B|patients with 1-4 stage K/DOQI (Kidney Disease Outcome Quality Initiative) chronic kidney disease, but healthy periodontium
89546340|NCT02417363||Group C|patients with periodontitis, but healthy renal conditions
89546341|NCT02417363||Group D|patients with 1-4 stage K/DOQI (Kidney Disease Outcome Quality Initiative) chronic kidney disease and periodontitis
89546342|NCT02416817|Experimental|Blood Products only.|This arm will receive 1:1:1 Red blood cells : Fresh Frozen Plasma : Platelets upon a major trauma triggers. 1:1:1 Ratio for packs of blood products. The patient will be re-evaluated every hour again for the major bleeding triggers and another 1:1:1 intervention may or may not occur.
89546343|NCT02416817|Experimental|Point of care guided|This arm will receive Red blood cells, Human Fibrinogen and Prothrombinic complex concentrates (PCC) based on thromboelastometry. The dosis of each drug will be determined by the analyses of the thromboelastometry curves.
89546344|NCT02416661||Participants diagnosed with Gaucher disease|Participants with genetically confirmed diagnosis of Gaucher disease type 1 older than 6 months old
89546345|NCT02399189|Experimental|R-MT followed by auto-HSCT|"R-MT followed by auto-HSCT Rituximab 375 mg/m2 d1 MTX 3.5g/m2 d2(0.5g/m2 15min,3g/m2 3h） TMZ 100 mg/m2 d2-6 Q21d*4cycles~Auto-HSCT conditioning regimen:~BCNU 400mg/m2 d1; Thiotepa 5mg/kg q12h，d2-3"
89546346|NCT03106493||Primary|Singletons and 1 twin of each pair
89546347|NCT03106493||Secondary|Twin sibling of children enrolled in primary cohort
89546348|NCT03106493||Tertiary|Higher order multiples and siblings
89546349|NCT03177161|Experimental|Postal Questionnaire|
89546350|NCT03177161|Experimental|Online Questionnaire|
89546351|NCT03177161|Experimental|Face-to-face Questionnaire|
89546352|NCT03177161|Experimental|Telephone Questionnaire|
89546353|NCT03176849|Experimental|Single, high dose oral vitamin D3|Patients will take a single oral dose of vitamin D3 based on age and initial vitamin D level. A patient will be classified as sufficient, insufficient, or deficient at the start of therapy. Following this dose, patients will also be given standard vitamin D3 supplementation according to current Endocrine Society Guidelines.
89546354|NCT03176849|Active Comparator|Standard Vitamin D Supplementation|Patients will be given standard vitamin D3 supplementation during transplant in accordance with standard of care per Endocrine Society Guidelines. This supplementation is based on a patient's initial vitamin D level.
89546355|NCT03106571|Experimental|Pomaglumetad methionil Low + Methamphetamine|Pomaglumetad 40 mg orally twice daily x 9 days with intravenous methamphetamine challenges
89546356|NCT03106571|Experimental|Pomaglumetad methionil Mid + Methamphetamine|Pomaglumetad 40 mg orally twice daily x 1 day then pomaglumetad 80 mg orally twice daily x 8 days with intravenous methamphetamine challenges
89546357|NCT03106571|Experimental|Pomaglumetad methionil High + Methamphetamine|Pomaglumetad 40 mg orally twice daily x 1 day then pomaglumetad 160 mg orally twice daily x 8 days with intravenous methamphetamine challenges
89546358|NCT03106571|Placebo Comparator|Control + Methamphetamine|1-4 placebo tabs orally twice daily x 9 days (to match pomaglumetad dosing in each cohort) with intravenous methamphetamine challenges
89546359|NCT02398955||Study cohort|All comers patients with coronary artery disease treated with percutaneous coronary intervention and at least one Biomime stent
89546360|NCT03177083|Active Comparator|peginterferon beta-1a|
89546361|NCT03177083|Active Comparator|Current Therapy|
89546362|NCT02398721|Other|FNAC|patients will then be randomized routine FNAC strategy
89207814|NCT00866112|Other|2|Minimal contact control group
89207815|NCT00862602|Experimental|1|Stepping Up to Health
89207816|NCT00862602|No Intervention|2|Usual care group
89207817|NCT00858312|Experimental|1|Diet with 3-4 servings of dairy-rich foods/day
89207818|NCT00858312|Placebo Comparator|2|Low Dairy < 1 serving of dairy food/day
89207819|NCT00862680||Diagnostic (4D PET/CT)|Participants undergo 4D PET/CT scan over up to 12 minutes.
89207820|NCT02544282|Active Comparator|Pecs II|General anesthesia followed by a Pecs II block and opioids if required
89207821|NCT02544282|Placebo Comparator|Placebo|General anesthesia followed by a placebo Pecs II block and opioids if required
89207822|NCT00866190|Experimental|Cohort 1|SQ109 dose 75 mg or placebo once daily for 14 days.
89207823|NCT00866190|Experimental|Cohort 3|SQ109 dose 150 mg or placebo once daily for 14 days.
89207824|NCT00866190|Experimental|Cohort 2|SQ109 dose 150 mg or placebo once daily on Days 1-5, 9, and 14.
89207825|NCT05227482|Active Comparator|Standard dosimetric approach for 90Y activity calculation|The radionuclide activity to be injected is calculated with standard dosimetric approach such as body surface area (BSA) method or Medical Internal Radiation Dose (MIRD) monocompartmental method.
89207826|NCT05227482|Experimental|Personalized voxel-based dosimetric method for 90Y activity calculation|The radionuclide activity to be injected is calculated with voxel-based approach based on pre-treatment simulation with the injection of 99mTc-MAA and the acquisition of SPECT/CT images.
89207827|NCT04041804|Active Comparator|Every week RPE activation|Non-surgical semi-rapid maxillary expansion (SRME) with the time intervals activation every week until getting the require expansion needed
89207828|NCT04041804|Active Comparator|Every four days RPE activation|Non-surgical semi-rapid maxillary expansion (SRME) with the time intervals activation every four days until getting the require expansion needed
89207829|NCT00858546|Experimental|Active repetitive transcranial Stimulation|Active repetitive transcranial Stimulation
89207830|NCT04041648|Placebo Comparator|placebo|placebo group
89546363|NCT02398721|No Intervention|No FNAC|patients will be randomized to watchful observation strategy (no FNAC)
89546364|NCT02398643|Other|Early Pulmonary Education (EPE)|Patients randomized to EPE will receive focused education sessions by a Certified Respiratory Educator. Education sessions will start within two weeks of discharge from hospital.
89546365|NCT02398643|Other|Usual Care|Patients randomized to usual care will receive general education sessions by a Certified Respiratory Educator within the month of being discharged.
89546366|NCT02398799|No Intervention|control|The dyads in the control group received care as usual including traditional care in hospital and outpatient education and support. The care is mainly focused on the patient's needs. The partner is not systematically involved in the follow-up focusing on education and psychosocial support.
88961591|NCT05587751|Experimental|Pulmonary Function in Transgender and Gender Diverse Patients|Transgender and gender diverse (TGD) patients undergoing masculinizing or feminizing hormone therapies will have breathing tests to evaluate their lung function
89207831|NCT04041648|Experimental|L606 Liposomal inhalation solution|Liposomal inhalation solution
89207832|NCT02544360|Experimental|Intervention|"Schools in this arm receive a photoaging mobile app promoting poster campaign revealing the effects of smoking on the users face via a self portrait (i.e. a selfie)."
89207833|NCT02544360|No Intervention|Control|The control group consists of schools participating in the survey but not receiving the intervention.
89207834|NCT03928821|Experimental|Group 1: PGT121 + VRC07-523LS|Participants will receive PGT121 and VRC07-523LS administered sequentially in this order at Day 0.
89207835|NCT03928821|Experimental|Group 2: PGDM1400 + VRC07-523LS|Participants will receive PGDM1400 and VRC07-523LS administered sequentially in this order at Day 0.
89207836|NCT03928821|Experimental|Group 3: 10-1074 + VRC07-523LS|Participants will receive 10-1074 and VRC07-523LS administered sequentially in this order at Day 0.
89207837|NCT03928821|Experimental|Group 4: PGDM1400 + PGT121 + VRC07-523LS|Participants will receive PGDM1400, PGT121, and VRC07-523LS administered sequentially in this order at Day 0 and Month 4.
89207838|NCT00666224|Experimental|Glatiramer acetate|Glatiramer acetate 20 mg once daily by subcutaneous injection is administered in both the double-blind and open label periods.
89207839|NCT00666224|Placebo Comparator|Placebo (DB) to GA (OL)|Placebo matching glatiramer acetate once daily by subcutaneous injection during the double-blind period (DB). Glatiramer acetate (GA) 20 mg once daily by subcutaneous injection during the open-label period (OL).
89207840|NCT00866268|Experimental|Low suction drainage|In the experimental group the drainage catheter was connected to a modified DRENOFAST® system. This system consisted of a sterile plastic bottle with a holding capacity of 600 mL of fluid and a negative pressure of 700mmHg. It was hermetically closed and had two connections. The DRENOFAST® modification consisted of establishing an open connection between the bottle and a wall vacuum source (normally used to administer oxygen) placed next to the patient's bed. The 50 mmHg constant negative pressure of the bottle was maintained by the wall vacuum source and verified by flow meter.
89207841|NCT00866268|Active Comparator|High suction drainage|The standard DRENOFAST® system was used in the control group, and the initial negative pressure was 700 mmHg.
89207842|NCT00866346|Experimental|PR1-CTL|"Two infusions of PR1-specific T lymphocytes (donor immune cells) 60 days apart.~Starting infusion dose 1 x 106 nucleated cells/kg."
89207843|NCT00866424|Experimental|A,2, II|
89207844|NCT00663962|Experimental|Perioperative pregabalin|Pregabalin 150mg administered one hour prior to surgery and 12 hours after surgery, then continued BID until day 7 post-operatively (n=3) or Pregabalin 300mg administered one hour prior to surgery and 12 hours after surgery, then continued BID until day 7 post-operatively (n=4).
89546367|NCT02398799|Experimental|Psycho edcuactional support|The intervention psychoeducational support to the patient-partner dyads was delivered in 3 sessions through nurse-led face-to-face counseling, a computer-based CD-ROM program and other written teaching materials. All sessions lasted at least 60 minutes and were conducted in the dyads' homes or in the heart failure clinic. The first session 2 weeks after discharge and the two remaining sessions 6- and 12-weeks following discharge. Each session included education on heart failure and development of problem- solving skills to assist the dyads in recognizing and modifying factors that contribute to psychological and emotional distress. The intervention focused on changing thoughts and behaviors and implementing strategies for self-care.
89546368|NCT03629925|Experimental|Sintilimab+ gemcitabine plus platinum|Sintilimab combination arm: Sintilimab in combination with gemcitabine plus cisplatin or carboplatin
89546369|NCT03629925|Placebo Comparator|Placebo+gemcitabine plus platinum|Placebo combination arm: Placebo in combination with gemcitabine plus cisplatin or carboplatin
89546370|NCT04295811|Experimental|EsoCheck and EsoGuard vs. EGD with or without biopsies|All subjects will undergo both the EsoGuard lab assay run on distal esophageal cells collected with EsoCheck (non-invasive esophageal cell sample collection) device followed by Esophagogastroduodenoscopy (EGD) with or without biopsies
89546371|NCT04294719||Inpatient Clients|Have a chart diagnosis of a schizophrenia spectrum illness, capacity to consent or availability of a substitute decision-maker to consent with the assent of the participant and is residing on a CAMH inpatient forensic unit (general security)
89546372|NCT02703311|Other|Cardioband procedure|Mitral valve repair with Cardioband implanted via transcatheter procedure under transesophageal echocardiography (TEE) and fluoroscopy guidance
89546373|NCT02416895||Army recruits|Army recruits at the start of basic training will complete an in vivo immunity model
89546374|NCT04280133|Experimental|Educational Video Tool|Patients randomized to the intervention arm will watch a 3-minute video educational tool about CAR-T cell therapy prior to admission for CAR-T cell therapy.
89546375|NCT04280133|No Intervention|Standard Care|Patients randomized to the control arm will receive usual care per the treating team. Any questions regarding CAR-T cell therapy will be directed to the patient's medical team
89546376|NCT02398565||Cohort|"Patients with a history of ventral hernia repair (umbilical/epigastric and incisional) with subsequent pregnancy~Ventral hernia repair - perioperative factors of interest:~- mesh vs sutured repair, age, planned vs emergency repair, open vs laparoscopic approach,~Pregnancy and delivery - factors of interest:~- vaginal vs caesearan section, single vs multiple pregnancy~Subgroup of patients with mesh repair:~- subanalysis on main attributes~Subgroup of patients with sutured repair:~- mono- vs multifilament, slowly vs rapidly absorbable"
89546377|NCT05499819|Experimental|Black beans|Canned black beans, drained and rinsed
89546378|NCT05499819|Experimental|Red kidney beans|Canned red kidney beans, drained and rinsed
89546379|NCT05499819|Experimental|Extra-lean ground beef|Extra-lean ground beef, pan-fried
89546380|NCT02398877|Experimental|Depression with early trauma|stress
89546381|NCT02398877|Experimental|Depression without early trauma|stress
89546382|NCT02398877|Experimental|Healthy with early trauma|stress
89546383|NCT02398877|Experimental|Healthy without early trauma|stress
89546384|NCT03595995|Experimental|Cohort 1|"Placebo (volume equivalent to 2.5 mg/kg UB-621)~2.5 mg/kg UB-621"
88961592|NCT05548270|Experimental|DPI-386|Each 0.12 gram of the gel contains0.2 mg of scopolamine HBr
89546385|NCT03595995|Experimental|Cohort 2|"Placebo (volume equivalent to 5 mg/kg UB-621)~5 mg/kg UB-621"
89546386|NCT02398487|Active Comparator|Personal Vaporizer|Personal Vaporizer loaded with nicotine
89546387|NCT02398487|Active Comparator|Cigalike|Cigalike loaded with nicotine
89546388|NCT02398487|No Intervention|Usual smoking|
89546389|NCT02396927|Placebo Comparator|2D HD laparoscopy|Elective laparoscopic cholecystectomy performed with the use of Olympus ENDOEYE FLEX in the 2DHD viewing mode
89546390|NCT02396927|Active Comparator|3D HD laparoscopy|Elective laparoscopic cholecystectomy performed with the use of Olympus ENDOEYE FLEX in the 3DHD viewing mode
89546391|NCT05497245|Experimental|intervention group|mobile app-based breastfeeding education
89546392|NCT05497245|No Intervention|control group|rutin health care
89546393|NCT04480619|Experimental|Ga-68-PEG-Αvβ3-IAC PET/CT|Companion Ga-68 PET diagnostic for tumor targeted therapy
89546394|NCT03371745|Active Comparator|PGS-FET|The PGS-FET arm involves deferred transfer of embryos following cryopreservation at the blastocyst stage following pre-implantation genetic screening. This arm will culture embryos to day 5/6/7 (blastocyst stage). The embryos will be cryopreserved following trophectoderm biopsy. A subsequent frozen embryo transfer cycle will be performed during which 1 euploid (chromosomally normal) embryo will be thawed and transferred.
89546395|NCT03371745|Active Comparator|FET|"The Freeze only arm involves the deferred transfer of embryos following cryopreservation. In this arm embryos will be cryopreserved. A subsequent frozen embryo transfer cycle will be performed during which one or more embryos will be thawed and transfered based on local clinical site, age-specific embryo number transfer guidelines."
88961593|NCT05548270|Placebo Comparator|Placebo|Placebo Nasal Gel (0.12 g)
89546396|NCT03371745|Active Comparator|Fresh|The Fresh arm will have an immediate embryo(s) transfer based on local clinical site, age-specific embryo number transfer guidelines within the stimulation cycle.
89546397|NCT02398253|Experimental|CBT + Hypo-energetic Diet|
89546398|NCT02398253|Experimental|Hypo-energetic Diet only|
89546399|NCT05497167|Experimental|Period Kit|This is a single arm interventional study wherein the subjects enrolled will all participate in the study in the same way by being asked to answer pre-study survey questions concerning their attitudes towards menarche, receiving a period kit to explore on their own for two weeks, and then being asked to answer post-study survey questions.
89546400|NCT02398097|Active Comparator|Agripal|28 trivalent subunit inactivated intramuscular vaccine (Agripal) recipients: one vaccine injection administered on Day 0
89546401|NCT02398097|Active Comparator|IDflu9μg|30 reduced-content intradermal split vaccine (IDflu9μg) recipients: one vaccine injection administered on Day 0
88961594|NCT05546450|No Intervention|Control Group|Among those who applied to the clinic, those who do not want to follow their diet will be randomized into this group.
89546402|NCT02398097|Active Comparator|IDflu15μg|28 standard-content intradermal split vaccine (IDflu15μg) recipients: one vaccine injection administered on Day 0
89546403|NCT03348345|Experimental|Eat Breathe Thrive Intervention|A manualized program designed to prevent eating disorders using psychoeducation, group work, and yoga.
89546404|NCT03348345|No Intervention|Wait-List|Participants are placed on a wait-list receiving no intervention.
89546405|NCT02396615|Active Comparator|Active|Satin pineapple. Active juice with fibre and ginseng
89546406|NCT02396615|Placebo Comparator|Control|SATIN pineapple control. Control juice - normal juice prpoducts without added active ingredients
89546407|NCT03250299|Experimental|Dose Finding|Fixed 3+3 dose escalation of BAL101553 (7 days per week), combined with RT days 1-5 for 6 weeks followed by 4 week rest.
89546408|NCT02697617|Placebo Comparator|Placebo Arm|Subject will be on placebo
89546409|NCT02697617|Active Comparator|Pioglitazone Arm|Subject will be on pioglitazone
89546410|NCT05499429|Active Comparator|active stimulus group|Patients were assigned into active stimulus group according to random number table
89546411|NCT05499429|Sham Comparator|sham stimulus control group|Patients were assigned into sham stimulus control group according to random number table
89546412|NCT02398331|Experimental|arm|Standardised information and education on sexuality in women with spinal cord injury
89546413|NCT02398331|No Intervention|Control arm|Usual care (no structured information or education on sexuality)
89546414|NCT02396771|Experimental|Massage|Women allocated to the uterine massage group will be provided with 2 minutes of trans-abdominal uterine massage starting promptly after placental delivery.
89546415|NCT02396771|Experimental|Compression|Women allocated to the uterine compression group will be provided with 2 minutes of sustained trans-abdominal uterine compression starting promptly after placental delivery.
89546416|NCT02396693|Experimental|NIPPV|NIPPV - Newborns randomized to this group underwent NIPPV, in noninvasive ventilation support intermittent, in TIME mode of the respirator.
89546417|NCT02396693|Placebo Comparator|Bubble NCPAP|Bubble NCPAP - Newborns randomized to this group bubble NCPAP, in noninvasive ventilation continuous, in bubble NCPAP.
89546418|NCT02396693|Placebo Comparator|Ventilator NCPAP|Ventilator NCPAP - Newborns randomized to this group ventilator NCPAP, in noninvasive ventilation continuous, in NCPAP mode of the respirator.
89546419|NCT05496699|Experimental|mckenzie group|Mckenzie exercise protocol will be applied to the participants in this group. It will be applied to the participants for 4 weeks and 5 days a week for 30 minutes. The exercise program will be performed by the patient under the supervision of a physiotherapist.
89546420|NCT05496699|Experimental|mullgian group|Mulligan exercise protocol will be applied to the participants in this group. It will be applied to the participants for 4 weeks and 5 days a week for 30 minutes. The exercise program will be performed by the patient under the supervision of a physiotherapist.
89546421|NCT02396225|Experimental|Inhaled voriconazole|12 patients inhale voriconazole 40 mg b.i.d for two days
89546422|NCT02396225|Active Comparator|Oral Voriconazole|12 patients ingest voriconazole tablets 400 mg b.i.d for one day followed by 200 mg b.i.d for one day
89546423|NCT02398175||Pediatric polytraumatized patients with thoracic injuries|Pediatric polytraumatized patients (age < 18), (ISS > 16) with thoracic injuries
89546424|NCT02396303|Experimental|Patient receiving carbetocin|Experimental group subjects will receive intravenous Carbetocin during third stage of labour.
89546425|NCT02396303|Active Comparator|Patient receiving oxytocin|Comparator group subjects will receive intramascular Oxytocin during third stage of labour.
89546426|NCT05496621|Experimental|Musculoskeletal Diseas|Questionnaires will be asked for the validity of the Turkish version of the Keel Start Tool.
89546427|NCT05564247|Experimental|Experimental Group (WSTP)|Participants will complete 12, 45-minute weekly sessions of WSTP delivered by clinicians with >5 years of experience working with children who use MWC. Trainers will customize each session based on the age group (child or adolescent) and training goals of each child as determined in session one. Subsequent sessions will begin with a 5-minute review of progress and socializing, followed by a 10-minute warm-up (random practice of the previously learned skills); 20 minutes of attempting new skills (training on each skill will be carried to next session until the skills are learned or until the trainer and participant mutually agree that training should be abandoned; the trainer will periodically ask the participant to practice newly learned skills to incorporate variability of practice); 10 minute cool-down, during which the participant will practice skills in a self-controlled environment. Age-appropriate considerations are incorporated into training materials
89546428|NCT05564247|No Intervention|Control Group (Attention)|Participants will be attention-matched to mimic time and contacts ‬of‭ ‬the‭ experimental‭ ‬group. The control group will receive 12, 45-minute weekly sessions of 'Games and Activities' facilitated by healthcare professionals (e.g., occupational therapy/rehabilitation students) who will not be involved in the intervention or any other aspect of the study. The control group facilitator will mimic the same type of attention as the training at each site (i.e., sessions will be held at healthcare facilities and in the community (e.g., libraries, shopping centres, museums, parks). Facilitators will be equipped with current popular games and activities (according to social media and websites of popular children's stores) kits that include various board and card games, hand-eye coordination games, active games, cognitive activities, and arts and crafts suitable for children and adolescents to ensure interest and acceptability for all participants.
89546429|NCT02698241|Other|Diagnostic & Medication Management|Enrolled subjects will be managed using integrated device diagnostics combined with a clinical medication plan.
89546430|NCT01292421|Placebo Comparator|Arm I|Participants consume placebo HBV-EPV on days 0, 14, 28, and 56.
89546431|NCT01292421|Experimental|Arm II|Participants consume HBV-EPV expressing HBsAg on days 0 and 28 and placebo HBV-EPV on days 14 and 56.
89546432|NCT01292421|Experimental|Arm III|Participants consume HBV-EPV expressing HBsAg on days 0, 28, and 56 and placebo HBV-EPV on day 14.
89546433|NCT01292421|Experimental|Arm IV|Participants consume HBV-EPV expressing HBsAg on days 0, 14, 28, and 56.
89546434|NCT02396069|Experimental|JPI-289|Each cohort, volunteers will be infused JPI-289 for 60 min. (6 volunteers per each cohort, total 3 cohort)
89546435|NCT02396069|Placebo Comparator|Placebo|Each cohort, volunteer will be infused placebo for 60 min. (2 volunteers per each cohort, total 3 cohort)
89546436|NCT04440215|Other|Control|Usual rehabilitation care (no telerehabilitation, interdisciplinary meetings not systematically organized and/or not involving a complete team of professionals)
89032987|NCT02945267|Active Comparator|Placebo plus S1|Placebo:400 mg/w, Intravenous infusion, Infusion time ≥ 60 min, d1, once every two weeks; S1:40 mg (Body surface area<1.5 m2) or 60 mg (Body surface area>1.5 m2) ,oral,d1-d14, every three weeks for a cycle
89546437|NCT04440215|Experimental|Telerehabilitation|A mix of home or rehabilitation center visits, telerehabilitation and interprofessional shared decision making process.
89546438|NCT03168503|Experimental|LGG+Promitor™|LGG:10^12 CFU/g Lactobacillus rhamnosus GG (commercialised as LGG) combined with Promitor™:12g fibres/delivered of Soluble Corn Fibre (SCF) as dry powders to be consumed as 250 ml beverages at breakfast.
89546439|NCT03168503|Experimental|Promitor™|Promitor™:12g fibres/delivered of Soluble Corn Fibre (SCF) as dry powders to be consumed as 250 ml beverages at breakfast.
89546440|NCT03168503|Experimental|LGG-PB12+Promitor™|LGG-PB12:10^12 CFU/g of a pilus-less derivative L. rhamnosus GG combined with Promitor™:12g fibres/delivered of Soluble Corn Fibre (SCF) as dry powders to be consumed as 250 ml beverages at breakfast.
89546441|NCT03168503|Placebo Comparator|Maltodextrin|Maltodextrin (an oligosaccharide without prebiotic effect) 12g delivered and served as dry powders to be consumed as 250 ml beverages at breakfast.
89546442|NCT02397941||non-pregnant women|20 non-pregnant women, BMI < 30 kg/m2, Nulligravidas, no abdominal pre-operations, aged 20-45 years, measurement of the abdominal muscles and interrectal distance by ultrasound
89546443|NCT02397941||pregnant women|40 pregnant women, BMI < 30 kg/m2 before pregnancy, Primigravidas, no abdominal pre-operations, aged 20-45 years, measurement of the abdominal muscles and interrectal distance by ultrasound, consecutive measurement during the course of pregnancy
89546444|NCT02397941||women who deliverd|20 pregnant women, BMI < 30 kg/m2 before pregnancy, Primiparas, no abdominal pre-operations, aged 20-45 years, measurement of the abdominal muscles and interrectal distance by ultrasound, measurement after delivery (10 after spontaneous delivery, 10 after elective cesarean section)
89546445|NCT04282473||with mesh|Placement of lightweight (<50g/m2) monofilament mesh during colostomy formation
89546446|NCT04282473||no mesh|colostomy without mesh placement
89546447|NCT03168113||AD and Peanut Food Allergy|"Participants with active Atopic Dermatitis (AD) and food allergy to peanut.* Twenty participants ages 4 to 17 years of age will be enrolled in this group.~*Peanut skin prick test wheal ≥ 8 mm."
89546448|NCT03168113||AD and No Food Allergy|"Participants with active Atopic Dermatitis (AD) and no food allergy.* Twenty participants ages 4 to 17 years of age will be enrolled in this group.~*Negative skin prick test (wheal < 3 mm) to peanut, milk, egg, wheat, soy, shellfish mix, tree nuts, and sesame seed."
89546449|NCT03168113||Non-Atopic Health Control|"Participants that are non-atopic, healthy controls*. Twenty participants ages 4 to 17 years of age will be enrolled in this group.~*Negative for Atopic Dermatitis (AD), asthma, or allergic rhinitis; negative for food allergy; and negative by skin prick test to peanut, milk, egg, wheat, soy, shellfish mix, tree nuts, and sesame seed, and negative to environmental allergens - cat, dog, dust mite, cockroach, and local trees/grasses/weeds/molds."
88961595|NCT05546450|Experimental|Cornus mas L. and Diet Group|Among those who applied to the clinic, those who want to follow their diet will be randomized into this group. Patients in this group will be followed by a personalized diet and will receive 30 g/day lyophilized Cornus mas L. fruit powder for their one portion of fruit a day.
89546450|NCT05496387|Experimental|Study Group One|Sciatic nerve neuromobilization techniques (tension) was applied to the dominant side lower extremities of all participants in the study.
89546451|NCT05496387|Experimental|Study Group Two|Sciatic nerve neuromobilization techniques (sliding) was applied to the dominant side lower extremities of all participants in the study.
89546452|NCT05496387|Sham Comparator|Control Group|No application was applied to the sham group
89546453|NCT02395757|Experimental|Microperimetry|Microperimetry exam performed in addition to the usual ophthalmological examinations for monitoring AMD.
89546454|NCT02398019|Experimental|CPB-OXIRIS®|Non emergent cardiac surgery patients with CPB requirement.
89546455|NCT02398019|No Intervention|CPB-Standard|Non emergent cardiac surgery patients with CPB requirement.
89546456|NCT01097733||Pre-procedural cardiac CT|CRT patients will undergo pre-procedural cardiac CT to assess for dyssynchrony, scar, and coronary venous anatomy. The CT venogram will be randomize to pre-knowledge to implanting physician or blinded. The CT dyssynchrony and scar assessment will remain blinded to caregivers and patients.
89546457|NCT04480229|Experimental|Intervention Group|After the first treatment, every week the patients were called and consulted by telenursing. During the next there chemotherapy treatments, Edmonton Symptom Assessment System and General Comfort Questionnaire were filled. The study ended with the fourth cycle chemotherapy. A total of six telephone calls and 3 face-to-face follow-ups were done with each of the intervention group patients. Face-to-face follow-up with patients during chemotherapy treatments lasted for about 20-30 minutes, and patients were evaluated three times in terms of symptom severity and comfort level.
89546458|NCT04480229|No Intervention|No Intervention: Control Group|"During their first treatment the Patient Identification Form was filled and they were trained, which is the routine practice of the clinic. Patients were informed about the Symptom follow-up form, asked to mark the symptoms and signs they experienced due to the disease and treatment in the form between the two chemotherapy treatments and to note when they experienced and how they resolved this symptom. When the patients came to the second treatment, the first follow-up of the patients was done. The investigator filled Edmonton Symptom Assessment System and General Comfort Questionnaire forms via face-to-face interviews. The Symptom Follow-up Form given to the patients in the previous chemotherapy treatment was collected and the same new form was given. They were requested to bring this form in their next treatment. The same protocol was followed during the third and fourth chemotherapy treatment"
89546459|NCT03168035|Experimental|NC-4016|"Dose Escalation Group: NC-4016 will be administered as 2-hour intravenous infusion once every 3 weeks. Initial dose level 15 mg/m2. The dose level of NC-4016 in subsequent cohorts determined by the toxicity profile of the previous cohort, and dose level increased to 25, 30, 40, 60, and 80 mg/m2 or higher at each subsequent cycle until the highest dose level is reached or DLT prohibits further dose-level escalation. Dose level 1 will be the starting dose level (DL). If 2 out of the first 3 patients enrolled at DL1 experience a DLT during Cycle 1 or Cycle 2,then the next cohort of patients will be enrolled at DL0 (10 mg/m2).~Dose Expansion Group: Maximum tolerated dose from Dose Escalation Group"
89546460|NCT02397395|Experimental|Simeprevir Co-administered with Daclatasvir|All participants will receive Simeprevir (SMV) 150 milligram (mg) capsule co-administered with Daclatasvir (DCV) 60 mg tablet, orally, once daily for a duration of 12 weeks. Participants should take the study drugs (SMV and DCV together) orally and once daily with food.
89546461|NCT02397551|Active Comparator|Small doses of HCG|Supplementing the luteal phase with three small doses (500 IU) of HCG after trigger with GnRH agonist in antagonist IVF/ICSI cycles in high responders
89546462|NCT02397551|Active Comparator|Booster HCG dose|Booster HCG dose GnRH agonist only to trigger final maturation followed by a booster dose of 1500 IU of HCG on the day of ovum pickup
89546463|NCT02395913|Active Comparator|R|
89546464|NCT02395913|Experimental|T1|
89546465|NCT02395913|Experimental|T3|
89546466|NCT02395913|Experimental|T4|
88961596|NCT05546450|Experimental|Diet Group|Among those who applied to the clinic, those who want to follow their diet will be randomized into this group. Patients in this group will be followed by a personalized diet.
89546467|NCT02395679|Experimental|MesoCancerVac|Autologous dendritic cells loaded with a mixture of 5 allogenic mesothelioma tumor cell lysates 3 to 5 vaccinations with 10x10e6, 25x10e6 or 50x10e6 loaded dendritic cells i.d. and i.v. administration every two weeks
89546468|NCT02395835||Normal weight (NW) pregnant women|"Pregnant women with Body Mass Index (BMI) > = 30. Body weight and height were measured in an overnight fasting status using an adult scale (Seca, Hamburg, Germany). Prepregnancy BMI was calculated as weight in kg divided by height in meters squared based on the prenatal chart or on the self-reported weight of women with no prenatal chart.~Dietetic treatment was calculated according to height, weeks of gestation, and weight, considering an energy intake of 30 kcal/kg of ideal weight and a macronutrient distribution of: 55-65% carbohydrates, 10-20% fat, and the remainder as proteins."
89546469|NCT02395835||Overweight (OW) pregnant women|"Pregnant women with Body Mass Index (BMI) < 30. Body weight and height were measured in an overnight fasting status using an adult scale (Seca, Hamburg, Germany). Prepregnancy BMI was calculated as weight in kg divided by height in meters squared based on the prenatal chart or on the self-reported weight of women with no prenatal chart.~Dietetic treatment was calculated according to height, weeks of gestation, and weight, considering an energy intake of 30 kcal/kg of ideal weight and a macronutrient distribution of: 55-65% carbohydrates, 10-20% fat, and the remainder as proteins."
89546470|NCT03168191|Experimental|E-cigarette flavor|In this arm, subjects will receive an experimental flavor. Participants will be randomly assigned to low or high dose of nicotine.
89546471|NCT03168191|Experimental|Menthol Flavor|In this arm, subjects will receive a menthol flavor. Participants will be randomly assigned to low or high dose of nicotine.
89546472|NCT03168191|Placebo Comparator|No Flavor|In this arm, subjects will receive no flavor. Participants will be randomly assigned to low or high dose of nicotine.
89546473|NCT04440293|Experimental|Group BBAT / CT|Group BBAT / CT started treatment with BBAT and received 2 days a week for 6 weeks. After the interval of 5-week, group BBAT / CT was treated with CT twice a week for 6 weeks.
89546474|NCT04440293|Experimental|Group CT / BBAT|Group CT / BBAT started treatment with CT and received 2 days a week for 6 weeks. After the interval of 5-week, group CT / BBAT was treated with BBAT twice a week for 6 weeks.
89546475|NCT02395445|Active Comparator|Totaltrack|Indirect laryngoscopy
89546476|NCT02395445|Active Comparator|Macintosh Laryngoscope|Direct laryngoscopy
89546477|NCT02397317|Experimental|Multi-fraction SABR|All participants will receive Multi-Fraction SABR; 36.25 Gy (PTV D95) in 5 Fractions within 2-5 weeks
89546478|NCT02395523|Experimental|Proton Beam Therapy|"Definition of target volume:~Gross tumor volume (GTV) = gross tumor defined using a treatment planning CT scan~Clinical target volume (CTV) = GTV + internal target volume~Planning target volume (PTV) = CTV + 5 - 7 mm of lateral, craniocaudal, and anteroposterior margins.~Radiation dose and planning~Prescription dose to PTV: 70 GyE /10 fx, 7GyE fraction dose, 5 days/week~Dose prescription : 95% isodose volume of prescribed dose encompassed PTV"
89546479|NCT05564013|No Intervention|Phase 1 - Patient feedback and needs analysis|To facilitate the development of virtual reality application that is suitable for perioperative care management, a survey will be conducted in 100 subjects to gather patient preference and feedback with needs analysis.
89546480|NCT05564013|Experimental|Phase 2 - Evaluation of prototype efficacy|Comparison of pre-operative anxiety and post-operative pain in 60 patients before and after intervention using the developed virtual reality application.
89546481|NCT05563935|Active Comparator|OCD group|OCD patients will receive rTMS treatment for 6 weeks.
89546482|NCT05563935|No Intervention|HC group|Health control will not receive any treatment.
89546483|NCT05496153|Experimental|Cardiovascular diseases Patients|Subjects were recruited from outpatients with CVDs, under 18 years of age. All pa-tients have been verified the willingness of participating before the experiment. Patients was excluded if having abnormal blood pressure response, unstable angina pectoris, acute heart failure, congenital heart disease, and severe musculoskeletal diseases limiting.
89546484|NCT05499351|Experimental|Adult group in immunogenicity and safety study of combined immunization|300 participants will be randomly divided into 3 subgroups of 100 people per group, each subject will receive 1 dose of COVID-19 vaccine, 1 dose of influenza vaccine and 1 dose of pneumonia vaccine
89546485|NCT05499351|Experimental|Elderly group in immunogenicity and safety study of combined immunization|300 participants will be randomly divided into 3 subgroups of 100 people per group, each subject will receive 1 dose of COVID-19 vaccine, 1 dose of influenza vaccine and 1 dose of pneumonia vaccine
89546486|NCT05499351|Experimental|Adult group in safety observation study of combined immunization|1200 participants will be randomly divided into 2 subgroups of 600 people per group, each subject will receive 1 dose of COVID-19 vaccine, 1 dose of influenza vaccine and 1 dose of pneumonia vaccine
89546487|NCT05499351|Experimental|Elderly group in safety observation study of combined immunization|1200 participants will be randomly divided into 2 subgroups of 600 people per group, each subject will receive 1 dose of COVID-19 vaccine, 1 dose of influenza vaccine and 1 dose of pneumonia vaccine
89546488|NCT05495919|Experimental|Control Group|No intervention was performed to reduce anxiety in the control group
89546489|NCT05495919|Experimental|video interaction group|Before the training, the students took videos and during the lesson, the videos were evaluated and feedback was given.
89546490|NCT05495919|Experimental|Flipped Training|Before the training, educational materials were given to the students, and they were discussed with the students in the lesson.
89546491|NCT05563623||progression group|
89546492|NCT05563623||non-progression group|
89546493|NCT04280055|Experimental|Psilocybin|
89546494|NCT05495685||Cancer arm|Participants with new diagnosis of pancreatic cancer, from whom a blood sample will be collected.
89207845|NCT00663962|Placebo Comparator|Placebo control|An identical placebo administered one hour prior to surgery and 12 hours after surgery, then continued BID until day 7 post-op. (N=8)
89207846|NCT00866502|Experimental|sNN0031|Continuous ICV infusion for two weeks at one of three dose levels
89546495|NCT05495685||Benign disease arm|Participants with benign pancreatic diseases, from whom a blood sample will be collected.
89546496|NCT05495607||Patients|We have included 25 neonates and small infants having received CARPEDIEM® machine in France in a multicentric experience
89546497|NCT05499195||ESD group|ESD was performed by a highly experienced endoscopist who underwent systemic training. First, the endoscopist carried out chromoendoscopy by spraying 1.25% Lugol's iodine solution to identify the lesion and made dots with a dual-knife outside the margin of the lesion. Next, a forward-viewing endoscope was introduced with a transparent cap attachment on its tip. A saline solution with methylene blue and epinephrine was injected into the submucosa with an injection needle to create a liquid cushion separating the lesion and the muscle layer. Then, a mucosal incision at the periphery of the marking dots was performed with a dual-knife. After that, the submucosal connective tissue beneath the lesion was dissected using the same dual-knife, and the lesion was totally removed through dissection.
89546498|NCT05499195||ESD+adjuvant radiotherapy group|The process of ESD was the same as that of ESD group. A total dose of 41.4-60.0 Gy in common fractionation based on three-dimensional conformal radiotherapy or intensity modulated radiotherapy technology was prescribed.
89546499|NCT04424823|Experimental|LED|LED photobiomodulation therapy for the non-specific LBP working nurse
89546500|NCT04424823|Sham Comparator|Sham|Shame group. The all procedure was same as the LED group but the LED ped was upside down without direct treatment.
89546501|NCT04265781|Experimental|Dose escalation BAY1817080|Participants receive dose 1 to 3 of BAY1817080 as a single dose on Day 1.
89546502|NCT04265781|Experimental|Dose expansion BAY1817080|Participants receive the highest dose 3 of BAY1817080 twice daily (BID) from Day 1 until Day 13 and a single dose on Day 14.
89546503|NCT04265781|Placebo Comparator|Dose escalation Placebo|Participants receive placebo tablets orally as a single dose on Day 1.
89546504|NCT04265781|Placebo Comparator|Dose expansion Placebo|Participants receive placebo tablets as BID multiple doses from Day 1 until Day 13 and as a single dose on Day 14.
89546505|NCT05495529||Patients|Patients with single liver tumor traited by thermoablation with high iatrogenic risk, with biliary or digestive protection by ambiant air interposition
89546506|NCT05499117|Active Comparator|Antidepressant and light treatment group|
89546507|NCT05499117|Placebo Comparator|Antidepressants and pseudo-light therapy|
89546508|NCT05495373||healthy cases|healthy children at ages between 4-12
89546509|NCT05563311|Experimental|high-intensity interval training|High-intensity interval training describes physical exercise that is characterized by brief, intermittent bursts of vigorous activity, interspersed with periods of rest or low-intensity exercise
89546510|NCT05499039|Active Comparator|Group A1 (NIVMV on hypoxemic)|Use of NIV on acute hypoxemic respiratory failure patients
89546511|NCT05499039|Experimental|Group A2 (HFNC on hypoxemic)|Use of HFNC on acute hypoxemic respiratory failure patients
89546512|NCT05499039|Active Comparator|Group B1 (NIVMV on hypercapneic)|Use of NIV on acute hypercapneic respiratory failure patients
89546513|NCT05499039|Experimental|Group B2 (HFNC on hypercapneic)|Use of HFNC on acute hypercapneic respiratory failure patients
89546514|NCT05495295|Experimental|Advanced Solid Tumours|"First-in-human clinical trial of the acetylglucosaminyltransferase V inhibitor PhOx430 in patients with advanced solid tumours. The trial includes two parts, a dose escalation phase (part I) which will enroll patients with non-selected tumour types, followed by a cohort expansion phase (part II) in selected tumour types:~Glioblastoma Multiforme (GBM)~Triple Negative Breast Cancer (TNBC)~Selected solid tumours"
89546515|NCT05495217|Experimental|Gasless Laparoscopy-assisted Gastrectomy|Patients receive Gasless Laparoscopy-assisted Gastrectomy with D2 Lymphadenectomy for Distal Gastric Cancer.
89546516|NCT05495217|Other|Conventional Laparoscopy-assisted Gastrectomy|Patients receive Conventional Laparoscopy-assisted Gastrectomy with D2 Lymphadenectomy for Distal Gastric Cancer.
89546517|NCT05495139|Experimental|A single arm study, only investigational product|To evaluate the preliminary effectiveness and safety of the Gastric Bypass Stent System in treating nonalcoholic fatty liver disease.
89546518|NCT05498805|Experimental|experimental group|PD-1 inhibitor combined with radiotherapy, whether PD-1 inhibitor was used alone or in combination with other drugs was determined by the investigator. According to the lesion sties, SBRT or hyperfractionated radiotherapy was used.
89546519|NCT05498805|Active Comparator|controlled group|PD-1 inhibitor without radiotherapy, whether PD-1 inhibitor was used alone or in combination with other drugs was determined by the investigator.
89546520|NCT05498571||Schizophrenia Patients|We collect relevant information, review cardiovascular events in schizophrenia patients.
89546521|NCT05494827|Experimental|Borjomi|Healthy volunteers (N16, 8 males and 8 females) 30.63±1.04 y.o. with BMI 22.17±0.75 kg/m2 were randomly allocated to Borjomi group. Participants received 30 bottles (500 ml) of natural mineral water Borjomi® for daily 1000 ml (2 bottles) water consumption for 14 days (from visits 1 and 2). Participants drank the first bottle on the visit 1 after the first study Wingate test and the last bottle on the visit 3 before the second study Wingate test
89546522|NCT05494827|Active Comparator|Smart Spring|Healthy volunteers (N16, 8 males and 8 females) 28.56±1.61 y.o. with BMI 23.14±0.60 kg/m2 were randomly allocated to Smart Spring group. Participants received 30 bottles (500 ml) of processed drinking water Smart Spring® for daily 1000 ml (2 bottles) water consumption for 14 days (from visits 1 and 2). Participants drank the first bottle on the visit 1 after the first study Wingate test and the last bottle on the visit 3 before the second study Wingate test.
89546523|NCT05494827|Placebo Comparator|Control group|Healthy volunteers (N16, 8 males and 8 females) 30.69±1.74 y.o. with BMI 22.67±0.51 kg/m2 were randomly allocated to Control group. Participants received 30 bottles (500 ml) of steal drinking water Святой Источник® for daily 1000 ml (2 bottles) water consumption for 14 days (from visits 1 and 2). Participants drank the first bottle on the visit 1 after the first study Wingate test and the last bottle on the visit 3 before the second study Wingate test.
89546524|NCT04424433|Other|Normoxaemia First|Patients will undergo TEE imaging at normoxaemia (FiO2=0.3) first, and hyperoxia (FiO2=0.8) will be targeted second.
89546525|NCT04424433|Other|Hyperoxia First|Patients will undergo TEE imaging at hyperoxia (FiO2=0.8) first, and normoxaemia (FiO2=0.3) will be targeted second.
89517276|NCT04518228||Component 4: Arm 4.1: Second-line TB treatment drugs|"Women ≥ 20 weeks gestation receiving at least one of the following second-line TB treatment drugs, and their infants:~Levofloxacin (LFX) 750mg - 1000mg q.d.~Clofazimine (CFZ) 100mg q.d.~Linezolid (LZD) 300mg - 600mg q.d.~Bedaquiline (BDQ) 200mg three times per week (t.i.w.)~Delamanid (DLM) 100mg b.i.d.~Moxifloxacin (MFX) 400mg or 800mg q.d., and at least one other second-line TB treatment drug under study"
89517277|NCT04518228||Component 5: Arm 5.1: ATV/r|Women post-delivery receiving ATV/r, and their infants
89546526|NCT05494515|Experimental|the early swallowing rehabilitation program|swallowing problem eveluated by high resolution impedance manometry (HRIM). The early swallowing rehabilitation program based on the results of HRIM evaluation
89546527|NCT05494515|No Intervention|the routine care group|patients recieve swallowing education
89546528|NCT05494359||ESCA group|"40 patients of ESCA were included through the diagnosis of gastroscopic biopsy positive.~Age, gender, esophageal cancer staging, tumor biomarkers and other laboratory test indicators, CT and other imaging examinations results, gastroscope and pathological examinations results have been collected."
89546529|NCT05494359||Health control|"40 healthy people who experienced negative gastroscopy and tumor biomarkers were included as healthy control.~Age, gender, gastroscope, tumor biomarkers and other laboratory test results have been collected."
89546530|NCT05494359||Reflux esophagitis|40 patients of reflux esophagitis were included. Age, gender, tumor markers and other laboratory test indicators, gastroscope and pathological examinations results have been collected.
89546531|NCT05498337|Other|Examiner|Examiner
89546532|NCT05498337|No Intervention|Patient|Patient
89546533|NCT01663233|Experimental|LCZ696 and amlodipine|Participants, first treated with 5 mg of amlodipine for 4 weeks to determine if they were not adequately responding to amlodipine (had an office msSBP ≥145 mmHg and <180 mmHg) and who met all inclusion and exclusion criteria), were randomized to receive 200mg of LCZ696 in combination with 5 mg of amlodipine for 8 weeks.
89207847|NCT00866502|Placebo Comparator|Placebo|Continuous ICV infusion
89546534|NCT01663233|Active Comparator|Amlodipine|Participants, first treated with 5 mg of amlodipine for 4 weeks to determine if they were not adequately responding to amlodipine (had an office msSBP ≥145 mmHg and <180 mmHg) and who met all inclusion and exclusion criteria), were randomized to receive 5 mg of amlodipine and placebo to LCZ696 for 8 weeks.
89546535|NCT04064151|Experimental|"My Guide (psychoeducation & self-management program)"|Smartphone-based program plus standard clinical care.
89546536|NCT04064151|No Intervention|Standard Medical Care|Standard clinical care with no smartphone intervention.
88961597|NCT05546450|Experimental|Cornus mas L. Group|Among those who applied to the clinic, those who do not want to follow their diet will be randomized into this group. Patients in this group will receive 30 g/day lyophilized Cornus mas L. fruit powder
88961598|NCT05546450|No Intervention|Healthy Control Group|This group included healthy individuals who were not diagnosed with Metabolic Associated Fatty Liver.
89546537|NCT04046055|Experimental|Sham and Experimental Sessions|"50% of participants will have a unilateral cerebellar montage with the anode (active electrode) three cm lateral to the inion on the side ipsilateral to the more PD-affected side and the cathode (return electrode) on the ipsilateral cheek. 50% of participants will have a bilateral cerebellar tDCS will have both electrodes placed 3 cm to either side of the inion, with the anode assigned to the most PD-affected side and the cathode assigned to the less PD-affected side. Stimulation is turned (2 mA) on for the 30 seconds at the beginning and the end of the trial, but it turned to 0 mA in the intervening time.~A unilateral cerebellar montage will be applied. tDCS intensity will be 2 mA. Bilateral cerebellar tDCS will be applied. tDCS intensity will be 2 mA. A unilateral cerebellar montage will be applied. tDCS intensity will be 4 mA. Bilateral cerebellar tDCS will be applied. tDCS intensity will be 4 mA."
89546538|NCT05494281|Experimental|Placebo|
88961599|NCT05534347||Juvenile Idiopathic Arthritis|Patients seen in a specialized rheumatology consultation for the management of juvenile idiopathic arthritis in an adult service, after information and collection of their non-opposition.
88961600|NCT05524597|Experimental|Writing about Experiences|Participants will be asked to write about experiences with familiar individuals in their lives.
88961601|NCT05524597|Placebo Comparator|Writing about Places|Participants will be asked to write about experiences with familiar places in their lives.
89207848|NCT00975117|Placebo Comparator|Placebo|
89207849|NCT00975117|Experimental|Spermotrend|
89207850|NCT00786344|Experimental|Lifestyle Redesign|
89517278|NCT04518228||Component 5: Arm 5.2: DRV/r|Women post-delivery receiving DRV/r, and their infants
89546539|NCT05494281|Experimental|Serratus anterior plane block|
89546540|NCT05494203||spa|Untreated patients meeting the revised AS New York diagnostic criteria or the ASAS classification criteria for axial SpA. Exclusion criteria: ① Patients with rheumatoid arthritis, scleroderma, systemic lupus erythematosus and other diseases of the immune system; ② Patients who have received head and neck radiation therapy; ③ Those who have a history of using antidepressants and parasympathetic stimulants; ④ Known infection with human immunodeficiency virus (HIV) or hepatitis C virus; ⑤ Patients with sarcoidosis or tuberculosis infection. According to the existing ethical approval documents, the patients signed the informed consent.
89546541|NCT05494203||HC|healthy control. Exclusion criteria: ① Patients with rheumatoid arthritis, scleroderma, systemic lupus erythematosus and other diseases of the immune system; ② Patients who have received head and neck radiation therapy; ③ Those who have a history of using antidepressants and parasympathetic stimulants; ④ Known infection with human immunodeficiency virus (HIV) or hepatitis C virus; ⑤ Patients with sarcoidosis or tuberculosis infection. According to the existing ethical approval documents, the patients signed the informed consent.
89546542|NCT05486091|Experimental|App-Enhanced Brief Cognitive-Behavioral Therapy|Up to 4 in-person sessions
89546543|NCT05494047|Experimental|Tetravalent influenza vaccine developed by Sinovac Biotech Co.|The group will be formed by 800 individuals. 200 from 3 to 8 years old, 200 from 9 to 17 years old, 200 from 18 to 64 years old and 200 subjects 65 years and older. They will receive an unique dose of the tetravalent influenza vaccine developed by Sinovac Biotech Co.(H1N1, H3N2 and 2 strains of influenza B). Subjects 3 to 8 years will receive 2 doses of influenza vaccine unless they have receipt of 2 previous doses of any influenza vaccine or they have an history of previous influenza.
89546544|NCT05494047|Active Comparator|Vaxigrip Tetra TM|The group will be formed by 800 individuals. 200 from 3 to 8 years old, 200 from 9 to 17 years old, 200 from 18 to 64 years old and 200 subjects 65 years and older. They will receive an unique dose of the tetravalent influenza vaccine Vaxigrip Tetra TM(H1N1, H3N2 and 2 strains of influenza B). Subjects 3 to 8 years will receive 2 doses of influenza vaccine unless they have receipt of 2 previous doses of any influenza vaccine or they have an history of previous influenza.
89546545|NCT05493969|Other|DTG/3TC|Subjects will switch to dolutegravir (DTG) plus lamivudine (3TC) or fixed dose combination DTG/3TC for 48 weeks.
89546546|NCT05491629||surgical team members|The aim of this study is to determine with a deep understanding the perceptions of the operating room nurses' competence and the surgical team's views on the competence of nurses and the factors affecting them. In the research, parallel data type in convergent parallel mixed design (convergent parallel) was used to obtain rigorous, valid and reliable data with survey questions and individual interviews. In the quantitative dimension of the study, it was aimed to determine the perceptions of the operating room nurses about their competencies, and in the qualitative aspect, the thoughts/opinions of the entire surgical team about the competency of the operating room nurses and the factors affecting them.
89546547|NCT05491473||Control|Patients who did not receive the application of iNPWT at the donor site.
89546548|NCT05491473||Negative pressure|Patients who received the application of iNPWT at the donor site.
89546549|NCT05493813|Active Comparator|Intubated Sevoflurane-GA group|After preoxygenation for 3 minutes with 100% oxygen, anesthesia is induced with intravenous injection of propofol (1.5-2 mg/kg), remifentanil infusion (Ce value around 1-1.5 ng/kg), and cisatracurium (0.15-0.2 mg/kg), and followed by endotracheal intubation. General anesthesia is maintained with cisatracuirum (0.03 mg/kg every 45-50 min), remifentanil (Ce value around 1-1.5 ng/kg) and sevoflurane inhalation. Sevoflurane concentration will be adjusted to keep BIS value within the range of 40-60. Mechanical ventilation will be processed at volume-controlled mode with fraction of inspired oxygen (FiO2) 60%, tidal volume 6 ml/kg, and respiratory rate 9-12/min to keep normocapnia and avoid desaturation during the EVT procedure.
89546550|NCT05493813|Active Comparator|Non-intubated TIVA-propofol group|With the application of Optiflow nasal high flow set at a flow rate of 20 L/min and 60% FiO2, total intravenous anesthesia is induced with target-controlled infusion of propofol (effect site (Ce) concentration around 1.5-2 μg/ml) and remifentanil (Ce value around 1.0-1.5 ng/ml), and adjusted as required.
89546551|NCT05491395|Experimental|Post Mastectomy Hypofractionated Radiotherapy Arm|Post Mastectomy Hypofractionated Radiotherapy Arm
89546552|NCT05491395|No Intervention|Post Mastectomy Conventional Radiotherapy|Post Mastectomy Conventional Radiotherapy
89546553|NCT05493579|Experimental|Complete denture then complete implant supported overdenture|
89546554|NCT05485545|Other|Fallot group|Patient with Fallot Tetralogy operated
89546555|NCT05485545|Other|Control group|Patient benefiting from electrophysiological exploration for a healthy heart arrhythmia
89546556|NCT05485389|Experimental|Study group|At the beginning, knowledge test, individualized care perception and attitude scale to the elderly will be applied to the participants in the pre-test. Then, 6-hour theoretical course on the care of the elderly patient will be given to the participants included in the study. After the theoretical course, the knowledge test will be re-applied. After that, experience will be provided within the scope of first, second and third level simulation-based learning, one week apart. After the simulation experiences knowledge test, individualized care perception and attitude scale to the elderly will be applied to the participants in the post-test 1. Post-tests will be administered in the first (Post-test 2) and third (Post-test 3) months of the simulation experience.
89546557|NCT04277091|No Intervention|Control|No exercise
89546558|NCT04277091|Experimental|High-intensity interval exercise|10 x 60 s intervals at 80% peak power output (interspersed with 60 s recovery intervals at 10% peak power output)
89546559|NCT04277091|Experimental|Moderate-intensity continous exercise|50% peak power output (duration determined to elicit same energy expenditure as high-intensity interval exercise condition)
89546560|NCT05493267|Experimental|Vγ2Vδ2 T lymphocyte-based immunotherapy +Treatment regimens for MDR-TB|Treatment was based on the principles of the WHO guidelines for the treatment of drug-resistant tuberculosis, with the addition of immunotherapy：zoledronic acid and recombinant human interleukin 2
89546561|NCT05493267|Active Comparator|Treatment regimens for MDR-TB|Treatment regimens was based on the principles of the WHO guidelines for the treatment of drug-resistant tuberculosis.
89025115|NCT03278756|Experimental|Cognitive Control Training|A cognitive control training, consisting of 10 sessions of 15 minutes each, will be administered. The task in this training is an adaptive paced auditory serial addition task, where participants need to click on the sum of the last two heard digits.
89546562|NCT04239261|Active Comparator|Nutritional therapy|Serum-derived bovine immunoglobulin/protein isolate (SBI) 10.0 grams once daily
89517279|NCT04518228||Component 5: Arm 5.3: LPV/r|Women post-delivery receiving LPV/r, and their infants
89517280|NCT04507243|Experimental|Active - HD tDCS|Participants randomized to this arm will receive 12 sessions of high definition tDCS (HD-tDCS) stimulation (Soterix Medical) delivered to the left dorsolateral prefrontal cortex for 20-30 minutes.
89517281|NCT04507243|Sham Comparator|Sham - HD tDCS|Participants randomized to this arm will receive 12 sessions of sham HD tDCS stimulation (Soterix Medical) delivered to the left dorsolateral prefrontal cortex for 20-30 minutes.
89517282|NCT04506086|Experimental|Blinatumomab|
89517283|NCT04491682|Experimental|MA + Rosuvastatin|"Patients will receive MA 160 mg and rosuvastatin 10 mg by mouth daily for at least 6 months.Then every 3 months, hysteroscopy will be used to evaluate the endometrial condition, and findings will be recorded.~Due to personal reasons, it may not be possible to accept hysteroscopic evaluation every three months, then the longest duration will be 8 months."
89517284|NCT04491643|Experimental|MA + Rosuvastatin|"Patients will receive MA 160 mg and rosuvastatin 10 mg by mouth daily for at least 6 months. Then every 3 months, hysteroscopy will be used to evaluate the endometrial condition, and findings will be recorded.~Due to personal reasons, patients may not accept hysteroscopic evaluation every three months, then the longest duration will be 8 months."
89517285|NCT04454203|Experimental|Mepivacaine Block Group|Infiltration of local anesthetic (mepivacaine) above and beside the femoral artery through a perineural catheter.
89517286|NCT04454203|Placebo Comparator|Saline Sham Group|Infiltration of salt water (saline) above and beside the femoral artery through a perineural catheter.
89517287|NCT04393779|Other|HARPOON™ MVRS|Subjects who were treated with the HARPOON MVRS.
89517288|NCT04359914||NCoV-A-COVID|"adult patients of every age~admission to hospital with suspected COVID-19 disease~confirmed SARS-CoV-2 infection within 48 hours after admission"
89517289|NCT04359914||NCoV-A-CONTROL|"adult patients of every age~admission to hospital with suspected COVID-19 disease~exclusion of SARS-CoV-2 infection within 48 hours after admission"
89517290|NCT04359914||NCoV-P-COVID|"pediatric patients~admission to hospital with suspected COVID-19 disease~confirmed SARS-CoV-2 infection within 48 hours after admission"
89517291|NCT04359914||NCoV-P-CONTROL|"pediatric patient~admission to hospital with suspected COVID-19 disease~exclusion of SARS-CoV-2 infection within 48 hours after admission"
89517292|NCT04327063|Placebo Comparator|Placebo|Saline (30 mL maximum)
89517293|NCT04327063|Experimental|Ropivacaïne|Ropivacaïne 5 mg/mL (not to exceed 3 mg/kg and 30 ml of maximal volume)
89517294|NCT04302207|Experimental|High use hospitals|patients 1-23 months with Bronchiolitis seen in emergency department, urgent care or admitted patients will be included; provider surveys measuring the acceptability, appropriateness, feasibility, and perceived burden of piloted strategies; review of patient data extracted from electronic health record to include baseline, intervention and post-intervention data
89517295|NCT04302207|No Intervention|Low use hospital (Children's Hospital Colorado)|patients 1-23 months with Bronchiolitis seen in emergency department, urgent care or admitted patients will be included; review of patient data extracted from electronic health record to include data over the same time periods as the experimental groups' baseline, intervention, and post-intervention data
89517296|NCT04293809|Experimental|Cohort 1 - EXPAREL|A total of 15 subjects will be enrolled in this cohort. Subjects in this cohort will receive 20mL EXPAREL (266mg) with 30mL of saline
89517297|NCT04293809|Experimental|Cohort 2 - EXPAREL|A total of 15 subjects will be enrolled. Subjects in this cohort will receive 20mL EXPAREL (266mg) with 30mL of 0.5% bupivacaine HCl (150mg)
89517298|NCT04230356|Experimental|VSTs to Prevent|VSTs are given through an IV infusion 21-30 days after transplant to see if the VSTs will help prevent a viral infection.
89517299|NCT04230356|Experimental|VSTs to Treat|VSTs will be given only if a viral infection develops.
89517300|NCT04226950|Active Comparator|Recombinant Interferon Alpha|Recombinant Interferon Alpha, with an initial dose of 300 wu twice a week. Other interferons that have been listed can be used if Recombinant Interferon Alpha (300 wu) is not available, and the specific dose will be determined by the researchers.
89517301|NCT04226950|Experimental|Pegylated Interferon Alfa-2b|Pegylated Interferon Alfa-2b, with an initial dose of 135 ug once a week (body surface area < 1.73 m2) or 180 ug once a week ( body surface area≥1.73 m2).
89517302|NCT04209504||Continuous Perineural Catheter|Placement of preoperative continuous perineural catheter using 25 milliliters (mL) 0.5% ropivacaine with 1:400,000k ropivacaine for initial block and 0.2% ropivacaine for continuous infusion.
89517303|NCT04209504||10 mL Liposomal Bupivacaine Single Shot|Placement of preoperative single shot using 10mL liposomal bupivacaine (Exparel; n=20) plus 5 mL 0.5% bupivacaine
89517304|NCT04209504||20 mL Liposomal Bupivacaine Single Shot|Placement of preoperative single shot using 20mL liposomal bupivacaine (Exparel; n=20) plus 5 mL 0.5% bupivacaine
89517305|NCT04170855|Other|Furosemide Injection|"Patients with diuretic resistance:~The presence of diuretic resistance, defined as having clinical signs of fluid overload despite diuretic therapy (this information is routinely collected at each clinical visit). Fluid overload is defined as the presence of at least two of the following clinical features:~Peripheral or sacral oedema~Jugular venous distension ≥ 7 cm~Radiographic pulmonary oedema or pleural effusion~Enlarged liver or ascites~Pulmonary rales, paroxysmal nocturnal dyspnoea, or orthopnoea~Point of Care UltraSound (POCUS) evidence of congestion. Inferior Vena Cava diameter >2.5 cm and/or failure to collapse at least 50% with sharp inspiration"
89517306|NCT04160494|Experimental|D2C7-IT (6920 ng/mL) + Atezolizumab|Single D2C7-IT convection-enhanced delivery (CED) infusion (6920 ng/mL) plus atezolizumab (1200 mg) intravenous (IV) infusions every three weeks for up to two years
89207851|NCT00786344|No Intervention|No Treatment Control|The no treatment control arm did not receive the intervention during the first six-month period. However the intervention, which has been proven to be beneficial, was administered to the control arm immediately following the 6 month assessment.
89546563|NCT04239261|Placebo Comparator|Placebo|Hydrolyzed gelatin 10.0 grams once daily
89546564|NCT05485311||retrospective analysis|A retrospective analysis of disease histories for the period from 2014 to 2021 was carried out. Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury.
89546565|NCT05485311||prospective study|Recruitment of patients for the prospective study was carried out in the period from 02.24.2022 to 05.24.2022
89546566|NCT02556255|Experimental|B-Laser™ Atherectomy Catheter|Percutaneous Transluminal Angioplasty (PTA) for treatment of infrainguinal arteries in patients with Peripheral Artery Disease (PAD), that the atherectomy part of the PTA will include an experimental atherectomy catheter, B-Laser™.
89546567|NCT05485233||Presencial|At day 3th and 10th after surgery, each patient will undergo face-to-face examination of their surgical wound by a physician or a nurse, who will confirme the presence or absence of complications and they will fill in the questionnarie to compare the reponses with the aplication
89546568|NCT05485233||Telematic|At day 3th and 10th after surgery, each patient will upload an image of the surgical wound via RedScar© aplication using their own smartphone device. RedScar© aplication will evaluate the risk of complications of the surgical wound and will assign patients to 2 different groups: potential complications requiring new consultation or satisfactory evolution and discharge.
89546569|NCT05490849|Experimental|68Ga-HX01 PET scanning|Determine if 68Ga-HX01 PET is safe and effective method for imaging of malignant tumors
89546570|NCT05485077||Positive group|All the subjects who completed colorectal cancer polygene methylation test at baseline completed colonoscopy within 3 months. Colorectal cancer diagnosed by colonoscopy, adenoma or polyp lesions found after treatment will reach the end of the study. The tumor history of family members was tracked for patients who met the end point of the study. The positive subjects who did not reach the end point of the study underwent three center visits at 12, 36 and 60 months after enrollment respectively, including history taking, colonoscopy, FIT test and blood CEA test. Another telephone follow-up was conducted at 24 and 48 months, respectively.
89546571|NCT05485077||Negative group|The subjects who completed colorectal cancer polygene methylation test at baseline, and those with negative test results (n= 500, direct extraction method) completed colonoscopy within 3 months. The end points and follow-up were the same as those in the positive group. The negative group was compared with the positive group to observe the difference of negative predictive value and survival outcome.
89546572|NCT05492487|Experimental|Mirena Arm|The patients in the Mirena arm will have a Mirena inserted at time of recruitment of the study. An endometrial biopsy will be performed to assess for disease progression, regression or persistence after 3 months. The endometrial biopsy will be performed via bedside endometrial sampling or hysteroscopic biopsy. As Mirena can be used for treatment of atypical hyperplasia as well as endometrial protection (decreases the risk of endometrial hyperplasia recurrence), the option of keeping or changing the Mirena during biopsy will be discussed with the patient.
89546573|NCT05492487|Experimental|Megace Arm|The patients in the megace arm will have be prescribed 3 months of oral megace at time of recruitment of the study. An endometrial biopsy will be performed to assess for disease progression, regression or persistence after 3 months. The endometrial biopsy will be performed via bedside endometrial sampling or hysteroscopic biopsy.
89207852|NCT00858624|Active Comparator|Chronic Cough Patients|
89546574|NCT02556801|Placebo Comparator|SUBLIVAC FIX Phleum Prat. 0 AUN/ml|42 subjects received placebo (SUBLIVAC FIX Phleum Pratense 0 AUN/ml) sublingually. Subjects will start with one drop and add one drop each consecutive day until the maintenance dose of 5 drops per day is reached. Next treatment at maintenance dose is continued during 10 months.
89546575|NCT02556801|Experimental|SUBLIVAC FIX Phleum Prat. 10,000 AUN/ml|42 subjects received SUBLIVAC FIX Phleum Pratense 10,000 AUN/ml) sublingually. Subjects will start with one drop and add one drop each consecutive day until the maintenance dose of 5 drops per day is reached. Next treatment at maintenance dose is continued during 10 months.
89546576|NCT02556801|Experimental|SUBLIVAC FIX Phleum Prat. 40,000 AUN/ml|40 subjects received SUBLIVAC FIX Phleum Pratense 40,000 AUN/ml sublingually. Subjects will start with one drop and add one drop each consecutive day until the maintenance dose of 5 drops per day is reached. Next treatment at maintenance dose is continued during 10 months.
89546577|NCT02556801|Experimental|SUBLIVAC FIX Phleum Prat. 80,000 AUN/ml|40 subjects received SUBLIVAC FIX Phleum Pratense 80,000 AUN/ml sublingually. Subjects will start with one drop and add one drop each consecutive day until the maintenance dose of 5 drops per day is reached. Next treatment at maintenance dose is continued during 10 months.
89207853|NCT00858624|Active Comparator|Healthy Volunteers|
89207854|NCT04008459||Degenerative musculoskeletal spinal conditions|Participants are included who are enrolled in a 6-week physiotherapy exercise class aimed at improving function in people with degenerative spinal conditions.
89546578|NCT02556177|Active Comparator|mTBI patient group (Segment 1)|"1.5T or 3.0T MRI brain scanning with research sequences at 3 to 4 intervals in the acute period, with psychological cognitive evaluations at each MR visit~Patients in the acute period following recent diagnosis of mild traumatic brain injury (mTBI)"
89546579|NCT02556177|Active Comparator|non-TBI patients (Segment 2)|Control subjects with no recent mild traumatic brain injury. 1.5T or 3.0T MRI brain scanning with research sequences at 3 to 4 intervals in the acute period, with psychological cognitive evaluations at each MR visit
89546580|NCT05492019|Experimental|Doxycyline- Patients receiving Doxycycline .|Drug generic name: Doxycycline Dosage form- oral capsule Dosage- (50mg) one capsule Frequency- twice daily Duration- 8 weeks.
89546581|NCT05492019|Placebo Comparator|Control- Patients receiving placebo|Patient will receive one capsule of placebo twice daily
89546582|NCT05484921||traumatic brain injury group|(1) age 18-80 years, (2) admission due to isolated head injury, (3) unconsciousness at the time of injury. Isolated head trauma was defined as CT scan-confirmed brain injury without other major extracranial injuries, such as pelvis fractures, femur fractures, and severe invasive abdominal or thoracic injuries. Other exclusion criteria for patients were infection within the most recent month, previous head trauma, neurological diseases including ischemic and hemorrhagic stroke, use of antiplatelet or anticoagulant medications, and other prior systemic diseases including uremia, liver cirrhosis, malignancy, chronic heart disease, and chronic lung disease.
89546583|NCT04170777||Arm A|The CBCT imaging involved for Arm A is considered part of the study treatment. Pre and post treatment images will be acquired of the patient treated on Perfexion Gamma Knife using the 'Leksell Coordinate Frame'.
89546584|NCT04170777||Arm B|Arm B will be undergoing standard treatment on Gamma Knife Perfexion for Stereotactic Radiosurgery using the 'relocatable mask'. Patients with lesions that are >3 cm at the largest diameter will be treated with the relocatable mask for which a hypo fractionated approach may be beneficial.
89546585|NCT05484843|Experimental|Stroke patients_intervention group|"Inclusion criteria for the study:~Being over 18 years old~Being of all genders, male and female~Being able to communicate in Turkish~Having had a hemorrhagic or ischemic stroke~Not more than one month after the stroke event.~Being oriented to person, place and time~Not being aphasic~Having a score of 21 or above on the Montreal Cognitive Assessment Scale (MOBİD)~Not having serious vision and hearing problems~Not having a psychiatric history~Being open to communication and cooperation~To be willing and voluntarily to participate in the study."
89546586|NCT05484843|Experimental|stroke patients_control group|"Inclusion criteria for the study:~Being over 18 years old~Being of all genders, male and female~Being able to communicate in Turkish~Having had a hemorrhagic or ischemic stroke~Not more than one month after the stroke event.~Being oriented to person, place and time~Not being aphasic~Having a score of 21 or above on the Montreal Cognitive Assessment Scale (MOBİD)~Not having serious vision and hearing problems~Not having a psychiatric history~Being open to communication and cooperation~To be willing and voluntarily to participate in the study."
89546587|NCT05491941|Active Comparator|Hour-1 Bundle|If the patient meets 2+ SIRS and chief complaint criteria, a second BPA may be triggered, which displays to the provider. The second alert identifies patients who progress to organ failure based on lab results, or who have a recorded instance of hypotension. When this alert appears, an automatic counter will begin and serve as our Sepsis Time Zero. The provider will receive sepsis order sets and guided to the Sepsis Navigator. The navigator will allow them to review relevant patient data, reference sepsis guidelines, and keep tabs on a live-updating sepsis checklist to ensure they complete each element in order and on time. Following identification in the ED, both study arms will receive the same bundle (see below). The only difference will be the timing: For the Hour-1 bundle, all interventions in the bundle must be initiated within 1 hour.
89546588|NCT05491941|Active Comparator|3-Hour Bundle|If the patient meets 2+ SIRS and chief complaint criteria, a second BPA may be triggered, which displays to the provider. The second alert identifies patients who progress to organ failure based on lab results, or who have a recorded instance of hypotension. When this alert appears, an automatic counter will begin and serve as our Sepsis Time Zero. The provider will receive sepsis order sets and guided to the Sepsis Navigator. The navigator will allow them to review relevant patient data, reference sepsis guidelines, and keep tabs on a live-updating sepsis checklist to ensure they complete each element in order and on time. Following identification in the ED, both study arms will receive the same bundle (see below). The only difference will be the timing: For the 3-hour bundle, all elements must be completed by 3 hours.
89546589|NCT05491863|Active Comparator|conservative physiotherapy plan|Postural and Proprioceptive facilitation,walking ,jumping and staircase activity
89546590|NCT05491863|Experimental|Trunk stability exercise plan|Trunk stability exercises including proprioception,balance and stability.
89546591|NCT05491785|Experimental|Cebranopadol 600 µg|3 x 200 µg cebranopadol tablets
89546592|NCT05491785|Experimental|Cebranopadol 800 µg|4 x 200 µg cebranopadol tablets
89546593|NCT05491785|Experimental|Cebranopadol 1000 µg|5 x 200 µg cebranopadol tablets
89546594|NCT05491785|Active Comparator|Oxycodone 30 mg|3 x 10 mg Oxycodone tablets
89546595|NCT05491785|Active Comparator|Oxycodone 60 mg|3 x 20 mg Oxycodone tablets
89546596|NCT05491785|Placebo Comparator|Cebranopadol placebo tablets/ Oxycodone placebo capsules|Cebranopadol placebo tablets/ Oxycodone placebo capsules
89546597|NCT05490147|Experimental|conventional tidal volume (tidal volume [ml]= ideal body weight [kg]* 10~12) group|In the conventional tidal volume group, patients are ventilated with a tidal volume [ml]= ideal body weight [kg]* 10~12 throughout the surgery.
89546598|NCT05490147|Experimental|low tidal (tidal volume [ml]= ideal body weight [kg] * 6~8) volume|In the low tidal volume group, patients are ventilated with a tidal volume [ml]= ideal body weight [kg]* 6~8 throughout the surgery.
89546599|NCT05484609|Experimental|OUD scenario|
89546600|NCT05484609|Active Comparator|Diabetes scenario|
89546601|NCT04424589|Experimental|Myofascial release|"Myofascial release or induction (MFR) is a widely used manual therapy treatment involving specifically guided, low-load, long-lasting mechanical forces to manipulate the myofascial complex, aimed at restoring optimal length, decreasing pain, and improving function. Manual therapists often use their hands using their knuckles, elbows, or other instrumental tools to slowly penetrate the layers of the fascia, using applied pressure with a few kilograms of force that can strain the restricted fascia, this implies a guided gentle stretch.~The experimental group will receive 1 examination session and 6 myofascial release sessions carried out by a physiotherapist specialized in orthopedic manual therapy, superficial and deep techniques will be applied in the cervical region, for the spinal at the level of the quadratus lumborum, sacroiliac region and upper trapezius. 2 sessions per week over the course of 3 weeks."
89207855|NCT00782990|Active Comparator|tvt group|Surgical treatment for incontinence: TVT
89207856|NCT00782990|Active Comparator|Burch group|Surgical treatment for incontinence: Colposuspension
89207857|NCT00960453|Other|Sitagliptin 25mg|Repeated administrations for 4 days
89207858|NCT00960453|Other|Sitagliptin 50mg|Repeated administrations for 4 days
89207859|NCT00960453|Other|Sitagliptin 100mg|Repeated administrations for 4 days
89207860|NCT00265759|Experimental|Arm I|Patients receive oral exemestane once daily for up to 16-18 weeks.
89207861|NCT00265759|Experimental|Arm II|Patients receive oral letrozole once daily for up to 16-18 weeks.
89207862|NCT00265759|Experimental|Arm III|Patients receive oral anastrozole once daily for up to 16-18 weeks.
89207863|NCT00786500|Active Comparator|Gynostemma pentaphyllum tea|
89207864|NCT00786500|Placebo Comparator|Placebo tea|
89207865|NCT00972387|Active Comparator|Order 1|Supplement order for each time trial run, 1-4 respectively: CHO, CHO-P, CHO-CHO, PLA
89207866|NCT00972387|Active Comparator|Order 2|Supplement order for each time trial run, 1-4 respectively: CHO-P, CHO-CHO, PLA, CHO
89207867|NCT00972387|Active Comparator|Order 3|Supplement order for each time trial run, 1-4 respectively: CHO-CHO, PLA, CHO, CHO-P
89207868|NCT00972387|Active Comparator|Order 4|Supplement order for each time trial run, 1-4 respectively: PLA, CHO, CHO-P, CHO-CHO
89207869|NCT00866580|Experimental|Group A|
89207870|NCT00866580|Experimental|Group B|
89207871|NCT00744263|Placebo Comparator|Placebo|
89207872|NCT00744263|Experimental|13-valent pneumococcal conjugate vaccine|
89207873|NCT00862914||1|benign melanocytic naevi
89207874|NCT00862914||2|dysplastic melanocytic naevi
89207875|NCT00862914||3|cutaneous malignant melanoma
89207876|NCT00975273|Experimental|Breathing Training|Patients will receive biofeedback assisted breathing training
89546602|NCT04424589|Sham Comparator|Sham Therapy|The control group will receive 1 examination session and 6 simulated myofascial releasesessions, where a physiotherapist will apparently apply the same techniques and maneuvers of myofascial release, however, they will not follow the basic principles of technique execution, which does a procedure with a placebo effect.
89546603|NCT05484531||CLEAR|Adult subjects suffering from myopia AND/OR astigmatism treated with CLEAR.
89546604|NCT05484453||GoCheckKids screening|GoCheckKids screening at the Child And Family Agency at the age of 12-15 months (+- 1 month) are invited to undergo a complete eye examination by an ophthalmologist for evaluation of amblyopia risk factors.
89546605|NCT05484375|Experimental|Capecitabine plus toripalimab maintenance therapy|capecitabine and toripalimab were used as maintenance therapy every 3 weeks until toxicity was unacceptable, disease progression, consent withdrawal, or withdrawal was determined by the investigator, or a maximum of 2 years of treatment had been reached.
88961602|NCT05521516|Active Comparator|Active Percutaneous Auricular Neuromodulation with NSS-2 Bridge|Application of 5 days of percutaneous auricular Neuromodulation with NSS-2 Bridge device
89207877|NCT00975273|Active Comparator|Breathing Awareness|Patients will receive biofeedback assisted breathing awareness training.
89207878|NCT00783068|Active Comparator|GTS-21|Subjects will be randomized to oral pre-treatment with GTS-21 (150 mg tid 3 days before LPS injection and an oral dose of 150 mg GTS-21 on the morning of the day of the experiment (07:00 AM). Subjects will then receive an oral dose of 150 mg GTS-21 or placebo at 08:00 AM and another oral dose of 150 mg GTS-21 or placebo at 1 hour before LPS administration (t=0).
89207879|NCT00783068|Placebo Comparator|Placebo|Subjects will receive placebo 3 day before injection of LPS (150 mg tid) and a single oral dose of 150 mg of placebo the morning of LPS injection (07:00 AM). Subjects will then receive an oral dose of 150 mg placebo at 08:00 AM and another oral dose of 150 mg placebo at 1 hour before LPS administration (t=0).
89207880|NCT00866736|Experimental|dasatinib|
89207881|NCT02532049|Active Comparator|Group 1|ChAd63 Pfs25-IMX313 (5x10^9 vp)
89207882|NCT02532049|Active Comparator|Group 2A|ChAd63 Pfs25-IMX313 (5x10^10 vp)
89207883|NCT02532049|Active Comparator|Group 2B|ChAd63 Pfs25-IMX313 (5x10^10) and MVA Pfs25-IMX313 (1x10^8 pfu) 8 weeks later
89207884|NCT02532049|Active Comparator|Group 2C|ChAd63 Pfs25-IMX313 (5x10^10) and MVA Pfs25-IMX313 (2x10^8 pfu) 8 weeks later
89207885|NCT04008849||Subjects treated with MGTA-456|MGTA-456 is an investigational expanded CD34+ cell therapy
89207886|NCT00792818|Experimental|curcuma domestica|1,500 mg/day (oral) divided into 3 times for 28 days
89207887|NCT00792818|Active Comparator|Ibuprofen|1,200 mg/day (oral) divided into 3 times for 28 days
89207888|NCT00975351|Experimental|IV dose of 5-methyltetrahydrofolic acid|IV test dose of 13C5-labelled 5-methyltetrahydrofolic acid to all eligible volunteers, followed by regular blood samplings over 2hr period taken via a cannula.
89207889|NCT00786578||1|overweight runners (BMI>25)
89207890|NCT00786578||2|lean runners (BMI<24)
89207891|NCT01071187|Experimental|Varenicline|Treatment with varenicline with 0,5mg daily on day 1-3, 1mg daily on day 4-7 and 2mg daily on day 8-84.
89207892|NCT01071187|Placebo Comparator|Placebo|
89207893|NCT04008693|Active Comparator|Kyolic® Hi-Po Formula - Kyolic|Aged garlic extract
89207894|NCT04008693|Placebo Comparator|Placebo|Maltodextrin
89207895|NCT00792896|Experimental|1|Family conference + education materials
89207896|NCT00792896|No Intervention|2|education materials
89207897|NCT01071265|Placebo Comparator|Sham RIPC|Inflation of thigh pneumatic tourniquet to <15 mmHg
89207898|NCT01071265|Active Comparator|Active RIPC|300 mmHg inflation of thigh pneumatic tourniquet for three cycles of 5 minutes each with 5 minutes of no inflation between cycles.
89207899|NCT00792974||COPD by GOLD-criteria III and IV|
89207900|NCT00858936|Experimental|IK-1001|6 escalating dose levels of 0.2, 0.5, 0.75, 1.0, 1.25, and 1.5 mg/kg/hr infusion for 6 hours
89207901|NCT00858936|Placebo Comparator|Normal Saline|6 escalating dose levels of 0.2, 0.5, 0.75, 1.0, 1.25, and 1.5 mg/kg/hr infusion for 6 hours
89207902|NCT03974893||Vegetarian Diet|Includes children following a vegetarian diet.
89207903|NCT03974893||Non-Vegetarian Diet|Includes children following a non-vegetarian diet.
89207904|NCT00917345||aldosteronism, hypertension|
89207905|NCT00917345||hypertension|
89207906|NCT00793052|Experimental|A|
89207907|NCT00859092|Experimental|Thickening of feeds|
89207908|NCT00859092|No Intervention|Removal of thickener|
89546606|NCT05480007|No Intervention|Control|did not take medicine
88961603|NCT05521516|Sham Comparator|Sham Treatment|Application of 5 days of a nonfunctional sham device
89546607|NCT05480007|Experimental|DPPVI|received sitagliptin treatment (100mg per day)
88961604|NCT05517226|Experimental|Cohort 1|Participants in each cohort will receive Dose A cotadutide subcutaneously.
89546608|NCT05480007|Experimental|metformin|received metformin (500mg three times per day)
89546609|NCT05480007|Experimental|metformin +DPPVI|received sitagliptin (100mg per day) and metformin (500 mg three times per day)
89546610|NCT05479929||Patients with Respiratory Symptoms|The Canadian Triage Assessment Scale (CTAS) will be assessed via patient survey form and electronic chart review.
89546611|NCT05484063|Experimental|Intervention|Intervention group will receive a multicomponent, mobility-focused intervention during the course of inpatient admission.
89546612|NCT05484063|No Intervention|Control|The control group will receive usual care as per current ward practice.
89546613|NCT05489601||Participants|"Adults between 21 and 59 years of age.~Males and females; women must practice an effective form of birth control (condoms, diaphragm, birth control pill, IUD).~Subjects have taken an opioid prescription for pain management within the prior 24 months and have not used any opioids during the preceding 30 days.~Subjects are required to have a negative urine drug test. At any point during the study, If a subject is found to have a positive drug test, the subject will be discontinued from the study."
89546614|NCT05489367||Pre-vaccine ovarian reserve and fertility status|Before vaccination, ovarian reserve tests and fertility status of 64 women will be examined and results will be recorded.After 2 doses of vaccination, ovarian reserve and fertility status of same 64 women will be examined and results will be recorded
89546615|NCT05483985|No Intervention|Traditional Morphology|The embryo selection will be based on standard of care traditional morphology only.
89546616|NCT05483985|Experimental|Device: Hera System|For the Hera, the embryologist will use the consider both the standard morphology grade and the Hera System score on embryos that were already deemed suitable for transfer or freeze based on the standard morphology assessment to determine the most suitable embryo for transfer.
89546617|NCT05483829|Experimental|Long COVID prospective group|
89546618|NCT04424121|No Intervention|Standard of care plus ECG Stress Testing|Participants will be approached and randomized to receive standard care plus ECG-stress testing
89546619|NCT04424121|No Intervention|Standard of care plus ECG Stress Testing and CACS|Participants will be approached and randomized to receive standard care plus ECG-stress testing and coronary artery calcium scoring
89546620|NCT04424121|Active Comparator|Standard of care plus CCTA|Participants will be approached and randomized to receive standard care plus ≥ 64 multidetector coronary computed tomography angiography
89546621|NCT05479695|Experimental|Patient who use spinal orthoses and insoles|Spinal Orthoses: Devices that used in spinal deformities. Insoles: Devices that used in foot deformities.
89546622|NCT05479695|Other|Patient who use only spinal orthoses|Spinal Orthoses: Devices that used in spinal deformities.
89546623|NCT05479539|Experimental|AOT|
89546624|NCT05479539|No Intervention|Control|
89546625|NCT05489289|Active Comparator|AK104|AK104 IV every three weeks
89546626|NCT05489289|Placebo Comparator|placebo|Placebo IV every three weeks
89546627|NCT05479227||Patients with bile duct injuries during laparoscopic cholecystectomy|The data concerning 241 patients´ BDI emergence, severity, management, and outcomes was analyzed
89546628|NCT05479071||SLE patients WITH cardiovascular disease|Relation of antibodies against LDL to disease activity in pt with cardiovascular disease
88961605|NCT05517226|Experimental|Cohort 2|Participants in each cohort will receive Dose A cotadutide subcutaneously.
88961606|NCT05517226|Experimental|Cohort 3|Participants in each cohort will receive Dose A cotadutide subcutaneously.
88961607|NCT05517226|Experimental|Cohort 4|Participants in each cohort will receive Dose A cotadutide subcutaneously.
88961608|NCT05510193|Experimental|Aktio|Use of the prosthesis for 2 weeks, after a 3-session training
88961609|NCT05510193|No Intervention|Control|Non-use of the prosthesis
88961610|NCT05507749|Experimental|a group of participants receive implantable loop recorder before cryoballoon ablation|Following enrollment, an implantable loop recorder is implanted in all participants for the purpose of arrhythmia (any atrial fibrillation or atrial tachycardia) detection (Reveal LINQ, Medtronic, Minneapolis, MN).
89546629|NCT05479071||SLE Patients without cardiovascular disease|Relation of antibodies against LDL to disease activity in pt without cardiovascular disease
89546630|NCT02554929|Experimental|Taming Sneaky Fears Group|An 11 week (introduction plus 10 week) manualized treatment protocol utilizing cognitive behavioral strategies specifically developed for children 4 to 7 years of age with social anxiety disorder and/or selective mutism. Parent and child groups run separately but concurrently.
89546631|NCT02554929|Active Comparator|Parent Psychoeducation and Child Socialization Group|An 11 week (introduction plus 10 week) manualized treatment protocol focusing on parent psychoeducation and child socialization in children 4 to 7 years of age with social anxiety disorder and/or selective mutism. Parent and child groups run separately but concurrently.
89546632|NCT05489055|Experimental|BBT-CM (basic body temperature) group|BBT-CM (basic body temperature) group received contrast media warmed to body temperature (37°C[99°F]) before coronary CTA.
89546633|NCT05489055|Active Comparator|RT-CM (room temperature) group|RT-CM (room temperature) group received contrast media at room temperature (~23°C [~73°F]) before coronary CTA.
89546634|NCT04423965|Experimental|mFOLFOXIRI|Patients receive 6 cycles of mFOLFOXIRI
89546635|NCT04423965|Experimental|Chemoradiotherapy(CRT)|Patients receive standard chemoradiotherapy
89546636|NCT03766035||Consented, enrolled PSC patients undergoing ERCP + SpyGlass|Patients with PSC who have been consented and enrolled in the study will undergo ERCP with the addition of SpyGlass as indicated by their treating physician.
89546637|NCT03972501|Placebo Comparator|AZR-MD-001 Vehicle|AZR-MD-001 Vehicle will be dosed up to once daily.
89207909|NCT02555852||Users of PPIs|Exposure to proton pump inhibitors (PPIs) will be defined as a prescription for a PPI (esomeprazole, omeprazole, pantoprazole, lansoprazole, rabeprazole, and combinations) on the same day as the cohort entry defining prescription for an NSAID.
89207910|NCT02555852||Users of H2RAs|Exposure to histamine-2 receptor antagonists (H2RAs) will be defined as a prescription for a H2RA (cimetidine, ranitidine, famotidine, nizatidine, niperotidine, roxatidine, ranitidine bismuth citrate, lafutidine, cimetidine combinations, and famotidine combinations) on the same day as the cohort entry defining prescription for an NSAID.
89546638|NCT03972501|Experimental|AZR-MD-001 Active Dose|AZR-MD-001 Active Dose will be dosed up to once daily.
89546639|NCT05488899|Experimental|Half iodine - Spectral CT group|Patients receive half dosage of iodine contrast agent, and Spectral CT acquisition with Virtual Monoenergetic Images at 40 and 50 kiloelectronVolts (keV).
89546640|NCT05488899|Active Comparator|Standard iodine - Conventional CT|Patients receive standard dosage of iodine contrast agent, and conventional 120 kiloVolts (kV) polychromatic CT images
89546641|NCT05483439|Experimental|Immunotherapy and neoadjuvant therapy|Traditional herbal medicine twice daily combined with neoadjuvant therapy recommended by the guidelines every 3 weeks, for 6 or 8 cycles.
89546642|NCT05483439|Other|neoadjuvant therapy|Only received neoadjuvant therapy recommended by the guidelines every 3 weeks, for 6 or 8 cycles.
89546643|NCT04275375||hyperbaric bupivacaine|The dosage of hyperbaric bupivacaine decided by the clinical anesthesiologist. This study is an observational study.
89546644|NCT04275375||plain bupivacaine|The dosage of plain bupivacaine decided by the clinical anesthesiologist. This study is an observational study.
89546645|NCT04058301|No Intervention|Handout|Participants receive a generic handout about resources in Boston
89546646|NCT04058301|Experimental|Text message|Participants receive a generic handout about resources in Boston and a text message with a geographically proximate resource
89546647|NCT05488821|Experimental|QLH11906|QLH11906 Tablets
89546648|NCT05488743||7th and 8th grade students (children age 12-15 years) from the elementary school|
89546649|NCT05478057|Experimental|PD patients with speech disturbance treated with 10 Hz rTMS|
89546650|NCT05478057|Sham Comparator|PD patients with speech disturbance treated with sham rTMS|
89546651|NCT05478057|Experimental|PD patients without speech disturbance treated with 10 Hz rTMS|
89546652|NCT05478057|Sham Comparator|PD patients without speech disturbance with sham rTMS|
89546653|NCT05483361||smart phone addiction group|Smart phone addiction will be assessed using the Smart Phone Addiction Scale short version (SAS-SV) evaluation of pulmonary functions and functional capacity evaluation craniovertebral angle
89546654|NCT05488587||hepatocellular carcinoma|
89546655|NCT05488587||liver cirrhosis|
89546656|NCT05488587||healthy individuals|
89546657|NCT05488353|Experimental|Single Arm|Disitamab Vedotin for Injection, 2.0 mg/kg, given as an IV infusion on day 1, and Penpulimab Injection, 200 mg, on every 21 days On day 1 of the cycle, it is given as an intravenous infusion. Order of use: Disitamab Vedotin for Injection → Penpulimab Injection.
89546658|NCT05488275|Active Comparator|MPFL static|Medial Patellofemoral Ligament reconstruction with hamstring graft - static procedure
89207911|NCT02555852||Unexposed group (Reference)|Patients that are considered to be unexposed will be defined as patients not prescribed a PPI or H2RA on the same day as the cohort entry defining prescription for an NSAID.
89546659|NCT05488275|Active Comparator|Campbell|Medial Patellofemoral Ligament reconstruction using non-anatomic reconstruction (quadriceps femoris plasty - Campbell method)
89546660|NCT05488275|Active Comparator|MPFL dynamic|Medial Patellofemoral Ligament reconstruction with hamstring graft - dynamic procedure
89546661|NCT04543305|Experimental|PRT1419|PRT1419 will be administered orally
89546662|NCT05488197||Group 1 participants with gestational diabetes|
89546663|NCT05488197||Group 2 participants without gestational diabetes|
89207912|NCT04091009|Active Comparator|Continue Group|Those who continue taking their standard dose of buprenorphine before, during and after surgery.
89546664|NCT05488041|Experimental|UC patients with anorectal symptoms|Patients with ulcerative colitis in remission who have anorectal symptoms will undergo an anal manometry test to characterize these symptoms.
89546665|NCT05488041|Active Comparator|UC patients without anorectal symptoms|Patients with ulcerative colitis in remission without anorectal symptoms will undergo an anal manometry test to characterize their anorectal function and to compare to those with symptoms
89546666|NCT05477745||The group that the sagittal flexion angle of the femoral component less than 4°|The patients' knees were taken on the X-ray examination after the total knee arthroplasty on the medial-lateral position. The flexion (positive degree) or extension (negative degree) angle of the femoral component according to the anterior femoral cortex was measured. The patients with the sagittal flexion angle of the femoral component less than 4° were categorized into this group.
89546667|NCT05477745||The group that the sagittal flexion angle of the femoral component over 4°|The patients' knees were taken on the X-ray examination after the total knee arthroplasty on the medial-lateral position. The flexion (positive degree) or extension (negative degree) angle of the femoral component according to the anterior femoral cortex was measured. The patients with the sagittal flexion angle of the femoral component over 4° were categorized into this group.
89546668|NCT05487963|Experimental|CGB-500 topical ointment, 1% tofacitinib|
89546669|NCT05487963|Placebo Comparator|Vehicle topical ointment|
89546670|NCT05487729||Young adults|Young adults without neurological and serious structural condition.
89546671|NCT05483049||grey zone 1|HBeAg (+), HBV DNA >20 but < 10000000IU/mL, ALT ≤40 U/L
89546672|NCT05483049||grey zone 2|HBeAg (-), HBV DNA > 2000 IU/mL, ALT ≤40 U/L
89546673|NCT05477667|Active Comparator|control group|the patients with non-malignant hematological diseases
89546674|NCT05477667|Active Comparator|the cases (A)|NHL .
89546675|NCT05477667|Active Comparator|the cases (B)|acute leukemia
89546676|NCT05487495|Experimental|CD5 CAR T (CT125B)|All patients who receive CD5 CAR T (CT125B) cell infusion.
89546677|NCT05477355|Experimental|Intervention Arm|Participants will be provided the 5 session intervention.
89546678|NCT05477355|Active Comparator|Wait list control arm|Participants will not be provided Group PM+ in Phase 1 but will be provided the intervention after all participants in the initial intervention arm receive Group PM+.
89546679|NCT05482659|Experimental|Experimental|Health education on healthy nutrition and regular physical activity based on the transtheoretic model was given to overweight university students in the experimental group once a week (every 4 weeks) using the online education method.
89546680|NCT05482659|No Intervention|control group|No attempt was made to the students in the control group during the intervention process. When the intervention process of the experimental group was finished, the materials used in health education were shared with the students.
89546681|NCT04274985||1|Patients with temporomandibular disorders
89546682|NCT05477043||group of study|Patients ≥ 18 years old subjected to uterosacral ligaments suspension surgical procedures for pelvic organs prolapse.
89546683|NCT04274595|Experimental|Psoriasis patients|
89546684|NCT04274127|Other|children aged 16 to 24|estimate the positive predictive value of an early detection kit composed of 2 questionnaires (M-CHAT-R + CSBS-ITC) followed by a confirmation of the detection with a phone call by a neuropsychologist, in children aged 16 to 24 months seen by their usual general practitioner or pediatrician or child care centers or attending nurseries.
89546685|NCT05486871|Active Comparator|renal cell carcinoma stages T1|laparoscopic partial nephrectomy in renal cell carcinoma stage T1
89025116|NCT03278756|Active Comparator|Active Control Training|An active control training, consisting of 10 sessions of 15 minutes each, will be administered. The task in this training is an adaptive low load cognitive task, where participants need to click on the last heard digit.
89546686|NCT05486871|Active Comparator|renal cell carcinoma stages T2a|laparoscopic partial nephrectomy in renal cell carcinoma stage T2a
89517307|NCT04160494|Experimental|D2C7-IT (4613.2 ng/mL) + Atezolizumab|Single D2C7-IT convection-enhanced delivery (CED) infusion (4613.2 ng/mL) plus atezolizumab (1200 mg) intravenous (IV) infusions every three weeks for up to two years
89517308|NCT04143711|Experimental|Monotherapy DF1001 Dose Escalation|Dose escalation cohorts of DF1001 in sequential ascending order.
89517309|NCT04143711|Experimental|Monotherapy DF1001 Safety/PK/PD Expansion|Expansion cohorts of monotherapy DF1001 in multiple dose levels after evaluation for safety in Monotherapy Dose Escalation arm. Additional pharmacokinetic (PK) and pharmacodynamic (PD) samples included in this arm.
89517310|NCT04143711|Experimental|Monotherapy DF1001 Expansion in Urothelial Bladder Cancer|Monotherapy expansion cohort enrolling up to 20 patients with urothelial bladder cancer using the recommended phase 2 dose (RP2D) identified in the Monotherapy Dose Escalation arm.
89517311|NCT04143711|Experimental|Monotherapy DF1001 Expansion in Metastatic Breast Cancer (HER2 Low)|Monotherapy expansion cohort enrolling up to 20 patients with metastatic breast cancer with documented low expression of HER2 using the recommended phase 2 dose (RP2D) identified in the Monotherapy Dose Escalation arm.
89546687|NCT05476965|Experimental|Arm 1|De-escalation radiation following induction therapy and surgery Drug: Cisplatinum Drug: Paclitaxel Drug: Sintilimab Surgery: Surgery Radiation: De-escalation radiotherapy
89546688|NCT05476965|Active Comparator|Arm 2|Arm 2 Standard radiation following induction therapy and surgery Drug: Cisplatinum Drug: Paclitaxel Drug: Sintilimab Surgery: Surgery Radiation: Standard radiotherapy
89546689|NCT05482503|Experimental|Atrial Fibrillation|
89546690|NCT05482503|Experimental|Premature beats|
89546691|NCT05482503|Experimental|Sinus Rhythm|
89546692|NCT04424043|Experimental|neo-TACE-HAIC with surgery|transartery chemoembolization with lipiodol and EADM, FOLFOX (Oxa 85mg/m2 2h+CF 400mg/m2 2h +5FU 400mg/m2 10min+5FU 1200mg/m2 23h)-based artery infusion chemotherapy, followed by hepatic resection
89546693|NCT04424043|Active Comparator|surgery alone|hepatic resection remove the liver tumors
89546694|NCT05486715||65 rheumatoid arthritis patient|Vitamin d effect on rheumatoid arthritis activity on 65 rheumatoid arthritis patients and 65 healthy population
89546695|NCT05486715||65 healthy population|Vitamin d effect on rheumatoid arthritis activity on 65 rheumatoid arthritis patients and 65 healthy population
89546696|NCT03560895||Group I|Patients will be anesthetized using high-volume low-pressure cuffed endotracheal tube (Flexicare-UK) ) with its outer diameter determined by ultrasonography.
89207913|NCT04091009|Active Comparator|Reduce Group|Those who are placed on a lower dose of buprenorphine starting one day before surgery and during the time period after surgery until the pain from the surgery has decreased. Once the pain from the surgery has decreased, you will be put back on your full dose of buprenorphine.
89546697|NCT03560895||Group II|Patients will be anesthetized using uncuffed endotracheal tube (Flexicare-UK) with its outer diameter determined by ultrasonography.
89546698|NCT05486637|Experimental|Vocal emotion communication by children and adults with cochlear implants or normal hearing|Participants will be native speakers of American English and include pediatric cochlear implant recipients with unilateral or bilateral devices aged 6-19 years, children with normal hearing aged 6-19 years, postlingually deaf adults with cochlear implants, and adults with normal hearing. In Aim 1 participants will listen to emotional speech sounds and identify the talker's intended emotion. In Aim 2 participants will be invited to produce emotional speech by reading out scripted materials or in a more naturalistic conversational setting.
89546699|NCT05476731||case|
89546700|NCT05476731||control|
89546701|NCT05482113|Active Comparator|Control - Standard Bupivacaine|After proper positioning and local infiltration, a linear high-frequency ultrasound transducer will be placed on the anteromedial aspect of the neck, approximately 2 cm above the clavicle, and the interscalene brachial plexus will be identified between the anterior and middle scalene muscles. After sterile preparation of the skin, a 22-gauge needle will be inserted in-plane from the lateral aspect of the transducer and directed through the middle scalene muscle. The needle will be advanced until the tip is observed just lateral to the brachial plexus sheath. After negative aspiration, 20mL of 0.5% bupivacaine will be injected in 5mL increments, followed by 20mL of 0.25% bupivacaine injected in 5mL increments. The injection will be administered slowly with periodic aspiration, with the needle being adjusted using ultrasound guidance as the ISB is injected to surround the brachial plexus trunks (upper, middle and lower) that are seen at the interscalene level of injection.
89546702|NCT05482113|Experimental|Experimental - Liposomal Bupivacaine (Exparel)|After proper positioning and local infiltration, a linear high-frequency ultrasound transducer will be placed on the anteromedial aspect of the neck, approximately 2 cm above the clavicle, and the interscalene brachial plexus will be identified between the anterior and middle scalene muscles. After sterile preparation of the skin, a 22-gauge needle will be inserted in-plane from the lateral aspect of the transducer and directed through the middle scalene muscle. The needle will be advanced until the tip is observed just lateral to the brachial plexus sheath. After negative aspiration, 20mL of 0.5% bupivacaine will be injected in 5mL increments, followed by 20mL of Exparel injected in 5mL increments. The injection will be administered slowly with periodic aspiration, with the needle being adjusted using ultrasound guidance as the ISB is injected to surround the brachial plexus trunks (upper, middle and lower) that are seen at the interscalene level of injection.
89546703|NCT05482035|Experimental|Blood pressure measured by wrist blood pressure monitor and mercury sphygmomanometer|
89546704|NCT05476653|Experimental|MRI exam|"Patients will be asked to perform a pulmonary MRI in addition to the usual chest CT can.~The chest CT scan will be performed according to the usual protocol of standard practices. No difference is expected for this research protocol."
89546705|NCT05476575|Experimental|Hydrogen inhalation group|Patients allocating to this group received hydrogen inhalation (4% hydrogen given via nasal cannula) with other normal intraoperative care throughout the whole procedure.
89546706|NCT05476575|No Intervention|Traditional care group|Patients allocating to this group received traditional intraoperative care.
89546707|NCT05486325|Experimental|Bariatric Surgery|Up to twenty participants meeting inclusion criteria will undergo laparoscopic or robotic sleeve gastrectomy using the Endolumik Gastric Calibration Tube instead of the standard bougie calibration tube. Up to ten participants meeting inclusion criteria will undergo laparoscopic gastric bypass using the Endolumik Gastric Calibration Tube instead of the standard calibration tube.
89546708|NCT05481957|Experimental|vortioxetine|participants given 5~10mg per day for 16 weeks
89546709|NCT05481957|Active Comparator|Sodium valproate|participants given 500~1000mg per day for 16 weeks
89546710|NCT05475561|Active Comparator|Group (P)|
89546711|NCT05475561|Active Comparator|Group (E)|
89546712|NCT05475405|Experimental|Scapulothoracic mobilization along with conventional physical therapy for mechanical neck pain.|"conventional physical therapy:~Scapulothoracic mobilization:~Patient in prone lying position. The left hand of the physical therapist lifts the scapula to distract from the thoracic wall while the right hand mobilizes and stretches the inferior muscle groups attached to the scapula."
89546713|NCT05475405|Active Comparator|IASTM with conventional physical therapy for mechanical neck pain|"Conventional Physical Therapy:~IASTM (Instrument Assisted Soft Tissue Technique):~Patient sitting or prone lying Restrictions and myofascial adhesions assessed prior to treatment fanning strokes at 45 degree angles to skin be applied using the tool"
89546714|NCT05476341|Experimental|Bevacizumab injection|On the first day, bevacizumab injection was given, 3mg/kg each time, diluted to 100ml of 0.9% sodium chloride injection, mixed evenly, and then intravenous infusion for 90 minutes (±15 minutes).
89546715|NCT05476341|Active Comparator|Bevacizumab injection（Avastin）|On the first day, Avastin injection was given, 3mg/kg of which was diluted to 100ml of 0.9% sodium chloride injection. After mixing evenly, it was infused intravenously for 90 minutes (±15 minutes).
89546716|NCT05481723|Active Comparator|Control group|The control group will be treated according to the usual protocol of the department (standard group)
89546717|NCT05481723|Experimental|pulmonary ultrasound group|the experimental group follows an algorithm incorporating the number of B-lines occurring after a filling test (pulmonary ultrasound group).
89546718|NCT05481567||Stage III|Patients diagnosed with periodontitis stage III
89546719|NCT05481567||Stage IV|Patients diagnosed with periodontitis stage IV
89546720|NCT05474703||AUK with Dydrogestrone|Patients who applied for abnormal uterine bleeding and received oral dydrogesterone therapy for at least 6 months
89025117|NCT00477516|Experimental|1|
89207914|NCT00866892|Active Comparator|irrigation|
89207915|NCT00866892|Experimental|no irrigation|
89546721|NCT05474703||AUK with Levonorgestrel releasing intrauterin device|Patients who applied for abnormal uterine bleeding and were administered levonorgestrel-releasing intrauterine device at least 6 months ago
89546722|NCT04272021|Experimental|ADHD sample|Children with a diagnosis of ADHD
89546723|NCT04423887|Active Comparator|Control|
89546724|NCT04423887|Experimental|Creatine Supplementation|
89546725|NCT05474313|Experimental|PrEP-3D|Use of Alto Pharmacy, PrEP-3D mobile app and home laboratory testing.
89546726|NCT05474313|Other|Control Arm|Participants in the control arm will receive standard of care PREP navigation.
89546727|NCT02697773|Placebo Comparator|Placebo|placebo administered subcutaneously at day 0 and week 8
89546728|NCT02697773|Experimental|Tanezumab 2.5 mg|tanezumab 2.5 mg administered subcutaneously at day 0 and week 8
89546729|NCT02697773|Experimental|Tanezumab 2.5mg/5mg|tanezumab 2.5 mg administered subcutaneously at day 0 and tanezumab 5 mg administered subcutaneously at week 8
89546730|NCT02395289|Experimental|Cognitive-Based Compassion Training (CBCT)|HIV-1 positive subjects on antiretroviral therapy (ART) will be randomized to receive an 8-week program of Cognitive-Based Compassion Training (CBCT).
89546731|NCT02395289|Active Comparator|Health Discussion Control|HIV-1 positive subjects on antiretroviral therapy (ART) will be randomized to attend a health discussion group for 8 weeks.
89546732|NCT02395211|Active Comparator|Usual Physiotherapy|
88961611|NCT05502094||Group 1|Participants who experienced Post-Covid 19 syndrome were involved in this group.
88961612|NCT05502094||Group 2|Participants who fully recovered after Covid-19 were involved in this group.
88961613|NCT05502094||Group 3|Participants who had never had Covid-19 were involved in this group.
89546733|NCT02395211|Experimental|Gloreha device|
89546734|NCT02394977|Experimental|Compression with Feedback|CPR performed according to established international standards with chest compressions performed with the assistance of the Cardio First Angel™ (CFA; INOTECH, Nubberg, Germany) compression feedback device.
89546735|NCT02394977|Active Comparator|Standard chest compression|CPR performed according to established international standards with standard manual chest compression
89546736|NCT02397239||Six cycles|Maintenance pemetrexed 500 mg/m2 every 3 weeks for six cycles
89546737|NCT02397239||Until disease progression|Maintenance pemetrexed 500 mg/m2 every 3 weeks until disease progression
89546738|NCT02394899|No Intervention|Control|The control dyad will receive usual care.
89546739|NCT02394899|Experimental|Intervened|Parents receive training in problem solving skills and play therapy with their infants.
89546740|NCT02397005|Active Comparator|ZL-2102|Planned to be administrated in an ascending manner: 5,20,60,150,300,500,750mg
89546741|NCT02397005|Placebo Comparator|Placebo|Placebo matching ZL-2102
88961614|NCT05472441|Active Comparator|Mid Ohio Food Farmacy|The Food Farmacy arm receives weekly produce through a consortium of local food banks at the direction of the Mid-Ohio Food Collective.
89025118|NCT03278639|Experimental|Rhythmic auditory stimulation|Each patient will receive training for 4 weeks, 3 times per week. Each training session will last 30 minutes. Training will be performed by music therapists board-certified in RAS.
89546742|NCT02394821|Experimental|Metronidazole|metronidazole 0.8% solution - topical
89546743|NCT02394821|Experimental|Polihexanide|Polihexanide 2%
89546744|NCT02394587|Experimental|Mindfulness-Based Stress Reduction|Subjects assigned to the experimental group will participate in a MBSR foundation program, which includes weekly telephonic, group-based, 60-minute MBSR sessions for 6 weeks. The foundation program will introduce subjects to the concept of mindfulness with each week focusing on a different facet. Modeled after Kabat-Zinn's original program, breath awareness (focus on breath and observing thoughts without fighting or following them), body scan (promoting mindfulness of sensations in different parts of body), walking meditation (walking as form of meditation), loving kindness (projection of friendliness and kindness towards oneself and others), and choiceness awareness (awareness of all sensations with equal interest) will be taught.
89546745|NCT02394587|Other|Wait-listed control group|Subjects assigned to the wait-listed control group will not receive the MBSR program, but will receive weekly reminders of their study participation, be asked to complete the same questionnaires (per telephone script) once every three weeks, and receive the same financial incentives as the MBSR group. Upon completion of the 6-week session, the wait-list control group will be offered the same MBSR program. At that time, a new series of MBSR sessions will be scheduled and offered to the wait-listed control patients. Subjects who elect to participate in MBSR will receive the same packet of materials and measures received by the intervention group and be asked to complete the measures again at baseline, 1, 3, and 6 weeks.
89546746|NCT02394743||eGFR > 90|group whose eGFR is more than 90
89546747|NCT02394743||60 < eGFR <90|group whose eGFR is between 60 and 90
88961615|NCT05472441|Experimental|Mid-Ohio Food Farmacy + Cooking for Diabetes|The Food Farmacy + Cooking for Diabetes Arm receives weekly produce through a consortium of local food banks at the direction of the Mid-Ohio Food Collective and Cooking for Diabetes, a 6-week diabetes self-management education and support and culinary education intervention.
89546748|NCT02394743||eGFR < 60|group whose eGFR is less than 60
89546749|NCT02397161|Experimental|AT-NMT|AT-NMT group - will receive a 12-week EEG biofeedback mental attention-neuromuscular training
89546750|NCT02397161|Experimental|NMT alone|NMT group - will receive a 12-week neuromuscular training
89546751|NCT02397161|Experimental|AT alone|AT group - will receive a 12-week EEG biofeedback mental attention training
89546752|NCT02397161|No Intervention|Control|Control group - no intervention for 12 weeks
89546753|NCT02394509|Experimental|HOBSCOTCH-IP (in person)|Participants will receive the HOBSCOTCH intervention consisting of a first session conducted in-person, 3 weekly followed by 3 bi-weekly telephone coaching sessions, and a final session conducted in-person.
89546754|NCT02394509|Experimental|HOBSCOTCH-V (virtual)|Participants will receive the HOBSCOTCH intervention consisting of a first session conducted virtually, 3 weekly followed by 3 bi-weekly telephone coaching sessions, and a final session conducted virtually.
89546755|NCT02394509|Other|Control|Participants will be wait listed and given an option whether they prefer to enroll into HOBSCOTCH-IP or HOBSCOTCH-V. Subjects in Group 3 will receive HOBSCOTCH following a 6 month wait period.
89546756|NCT02394431||Sickle cell disease patients|Sickle cell disease patients
89546757|NCT02394431||Healthy patients|This is the control group for the sickle cell disease patients: each sickle cell disease patient will be matched with a healthy patient of the same sex and of similar age.
89546758|NCT05745857|Experimental|Oral bevacizumab-800CW|Dose finding of oral bevacizumab-800CW and extend optimal dose group (n = 5 - 10)
89546759|NCT05745857|Experimental|Oral cetuximab-800CW and combined oral cetuximab-800CW and bevacizumab-800CW|"Dose finding of oral cetuximab-800CW in first five patients and combined oral bevacizumab-800CW and cetuximab-800CW if the investigators see good results with cetuximab-800CW. If not, they will add a control group of non-dysplastic BE patients and administer oral bevacizumab-800CW.~(n = 15)"
89546760|NCT05745857|Experimental|Combined topical tracer administration bevacizumab-800CW and cetuximab-800CW|"This arm will only be part of the study when oral administration is not feasible or safe.~Compare single topical tracer administration of bevacizumab-800CW with combined topical tracer administration of bevacizumab-800CW and cetuximab-800CW. Extend combined group when lesion detection is increased or add control group with non-dysplastic BE patients if not.~(n = 20)"
89546761|NCT05476185|Experimental|READY4Life Programming - classroom instruction|The intervention is an 16-hour classroom-based relationship education program taught by project staff. This instruction will strengthen and promote healthy marriages among young refugees and immigrants through education and comprehensive case management that will support an overall goal of helping youth build healthy relationship skills while supporting positive socio-emotional development and promoting successful transitions to young adulthood.
88961616|NCT05472441|Experimental|Mid-Ohio Food Farmacy + Health Impact Ohio Pathways Hub|The Food Farmacy + Health Impact Ohio Pathways Hub Arm receives weekly produce through a consortium of local food banks at the direction of the Mid-Ohio Food Collective and has social needs address through a community health worker model at the direction of Health Impact Ohio. The community health worker meets with participants, evaluates and addresses non-medical, health-related social needs.
88961617|NCT05472441|Experimental|Mid-Ohio Food Farmacy + Cooking for Diabetes + Health Impact Ohio Pathways Hub|The Food Farmacy + Cooking for Diabetes + Health Impact Ohio Pathways Hub Arm receives all 3 interventions. Participants receive weekly produce through a consortium of local food banks at the direction of the Mid-Ohio Food Collective, Cooking for Diabetes, a 6-week diabetes self-management education and support and culinary education intervention and has social needs addressed through a community health worker model at the direction of Health Impact Ohio. The community health worker meets with participants, evaluates and addresses non-medical, health-related social needs.
88961618|NCT05423522|Experimental|NanoLithium® NP03|"Description: Homogeneous yellow oily liquid. Dosage: One administration of 3 mL per day (1.8 mg/day) by depositing 1.5 mL in the gingivo-jugal groove of each cheek with the graduated pipette.~Duration of treatment: Approximately one year (12 weeks for the double-blind period and 36 weeks for the subsequent open-label period)."
89546762|NCT05476185|No Intervention|No Intervention: Control|The control group does not receive any part of the classroom instruction that the intervention group receives. Like the intervention group, however, the control group does have access to case management.
89546763|NCT02394353|Active Comparator|Sleeve Gastrectomy|Patients undergoing the sleeve gastrectomy surgery
89546764|NCT02394353|Active Comparator|Gastric Bypass|Patients undergoing the gastric bypass surgery
89546765|NCT05745779||Gingivitis|0% interdental bone loss
89546766|NCT05745779||Stage 1 periodontitis|0-15% interdental bone loss
89546767|NCT05745779||Stage 2 Periodontitis|15-33% interdental bone loss
89546768|NCT05745779||Stage 3 Periodontitis|>33% interdental bone loss with potential for additional tooth loss
89546769|NCT05745779||Stage 4 Periodontitis|>%33 interdental bone loss with potantial for loss of dentition
89207916|NCT03972839||D-Dimers patients|population recruited in Brest for a period of 1 year: patients for whom a dose of VIDAS D-dimers is prescribed (approximately 3700 patients)
89546770|NCT02394197|Active Comparator|14-day treatment (T14)|"The operational treatment-dose was administered by mouth. The number of tablets of Chloroquine phosphate of 150 mg for three days (x-x-x/ number of tablets of Primaquine (15mg or 5 mg)), daily during 14 days. For 1 year old subjects only chloroquine (1-½-½/ ½ of 5 mg); for 2-5 years old (1-¾-1/ 1 of 5 mg); 6-12 years old (2-1-2/ 2 of 5 mg); 13 years old and over with about 60 kg of body weight (3-2-2/ 1 of 15 mg) and above 60 kg of body weight (4-3-3 / 1 of 15 mg).~According to the age group as indicated by the Mexican guidelines for vector borne diseases control (http://www.salud.gob.mx/unidades/cdi/nom/032ssa202.html) (Table 10)"
89546771|NCT02394197|Experimental|Intermittent single doses (ISD)|"The single dose medication was administered orally according to age group as the operational table: (number of tablets of chloroquine phosphate of 150 mg / number of tablets of primaquine (15mg or 5 mg)): for 1 year old (½ / 1 of 5 mg); for 2¬-5 years old (1 / 2 of 5 mg); 6-12 years old (2 / 4 of 5 mg); 13 years old and over of about 60 kg of body weight (3 / 2 of 15 mg), and above 60 kg of body weight (4 / 3 of 15 mg).~It is administered on Days 0 (after the detection of infection by microscopy), and Days 30, 60, 180, 210, 240 and 360 as indicated in the National guidelines for vector borne diseases control (http://www.salud.gob.mx/unidades/cdi/nom/032ssa202.html)."
89546772|NCT02394119|Experimental|Ofatumumab|"Drug Name: Ofatumumab~Why: Anti-body/antigen interaction results in cell apoptosis and reduced CD20 positive cell related activities~Procedures: methylprednisolone 2 mg/kg infused in 30' IV diluted in 100 ml of normal saline (NaCl 0,9%); oral paracetamol 15 mg/kg ; cetirizine 0,4 mg/kg IV infused slowly in 5 ml of normal saline (NaCl 0,9%) prior to Ofatumumab infusion to reduce common reactions~How: Ofatumumab IV: 1500 mg/1.73m2 at 12 ml/hour in the first 30'. Thereafter, the infusion rate can be doubled every 30 minutes up to a maximum of 200 ml/hour.~When and how much: once; diluted in 1000 ml of normal saline."
89546773|NCT02394119|Active Comparator|Rituximab|"Drug Name: Rituximab (RTX)~Why: Anti-body/antigen interaction results in cell apoptosis and reduced CD20 positive cell related activities~Procedures: the same as for Ofatumumab Arm~How: Rituximab IV: 375 mg/m2; for dosage between 100 and 250 mg RTX will be diluted in 100 ml of normal saline and administered at 2 ml/h for the first 30'; 3 ml/h for the second 30'; 6 ml/h for the third 30'; 15 ml/h until the end. For dosage between 260 and 500 mg RTX will be diluted in 250 ml of normal saline and administered at 6 ml/h for the first 30'; 9 ml/h for the second 30'; 18 ml/h for the third 30'; 36 ml/h until the end. For dosage between 510 and 1000 mg RTX will be diluted in 500 ml of normal saline and administered at 9 ml/h for the first 30'; thereafter, the infusion rate can be doubled every 30 minutes up to a maximum of 72 ml/h.~When and how much: once; diluted in 100/250/500 ml of normal saline for dosage respectively between 100-250 mg, 260-500 mg, 510-1000 mg."
89546774|NCT03167333|Experimental|PRP group|the patients received PRP(platelet-rich-plasma) injection twice at 2-week intervals
89546775|NCT03167333|Active Comparator|HA group|the patients received HA(hyaluronic acid) injection twice at 2-week intervals
89207917|NCT00859170|Experimental|Accordion use|Use of an Accordion device during the lithotripsy.
89546776|NCT02394041|Experimental|acupuncture|"The first session of acupuncture treatment will be performed at the inclusion visit, 2 additional acupuncture sessions will be scheduled as 1 session per week for the next 2 weeks.~One or more additional session will be performed in the delivery room."
89546777|NCT02394041|Sham Comparator|Sham acupuncture|The same as active arm but with sham needles.
89546778|NCT02394041|No Intervention|control group|Standard care, no acupuncture session.
89546779|NCT02393729|Other|children with DCD|Children with Developmental Coordination Disorder (DCD) will have neuropsychological assessment and MRI study
89546780|NCT02393729|Other|children with DD|Children with Developmental Dyslexia (DD) will have neuropsychological assessment and MRI study
89025119|NCT03278639|Active Comparator|Kinesiology|Each patient will receive training for 4 weeks, 3 times per week. Each training session will last 30 minutes. Training will be performed by board-certified kinesio therapists. The objectives of the training sessions will match those of RAS.
89025120|NCT00477711|Experimental|C225+Chemotherapy|
89025121|NCT03278561||Early onset asthma|Sputum induction according to the European Respiratory Society (ERS) protocol. A blood sample of 100ml will be taken.
89025122|NCT03278561||Late onset asthma|Sputum induction according to the ERS protocol. A blood sample of 100ml will be taken.
89546781|NCT02393729|Other|children with DCD + DD|Neuropsychological assessment and MRI study
89546782|NCT02393729|Other|control children|Neuropsychological assessment and MRI study
89546783|NCT03167567|Experimental|intervention|These women will have a medical clown present in the room during their labor
89546784|NCT03167567|No Intervention|Control|These women will not have a medical clown in the room during their labor
89546785|NCT02393963|Experimental|Tranexamic Acid|Intra-articular administration of low dose Tranexamic acid
89546786|NCT02393963|Placebo Comparator|Placebo|Sodium Chloride
89546787|NCT03115385|Placebo Comparator|Placebo|Inactive ingredients include maltose, lemon flavoring (or corn starch if unflavored), and silicon dioxide.
89546788|NCT03115385|Active Comparator|VSL#3|VSL#3 is classified as a medical food that is specially formulated and processed to provide a precise mixture of 8 strains of bacterial species with potential synergistic relationships. These strains include Streptococcus thermophilus, Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasei, and Lactobacillus delbrueckii subsp. bulgaricus.
89025123|NCT03278561||No pulmonary disease|Sputum induction according to the ERS protocol. A blood sample of 100ml will be taken.
89025124|NCT00439803|Active Comparator|T1|
89025125|NCT00439803|Placebo Comparator|C1|
89025126|NCT00439803|Active Comparator|T2|
89025127|NCT00439803|Placebo Comparator|C2|
89025128|NCT00439803|Active Comparator|T3|
89207918|NCT00859170|No Intervention|Control Group|Patients who will not have an Accordion device used during lithotripsy.
89207919|NCT02597231|Experimental|Melatonin Group|Patients in this group will receive melatonin 3mg orally at 9pm.
89546789|NCT02393807|Experimental|Open label single dose crossover study of PF-06260414|This will be a Phase 1, open label, randomized, single dose, 3 period, 3 way crossover study to evaluate the relative bioavailability of solid dose formulation of PF 06260414 under fasted conditions compared to the nanosuspension under fasted conditions
89546790|NCT02393651|Placebo Comparator|Sham|Motor training of the affected upper extremity combined with sham tDCS.
89546791|NCT02393651|Experimental|tDCS|Motor training of the affected upper extremity combined with dual transcranial direct current stimulation (tDCS).
89546792|NCT03115619||Participants With IPF|Observational data of participants with IPF under treatment with pirfenidone will be collected from the medical records as a part of their routine clinical visits at 12-week interval until study completion or early withdrawal (up to Week 52).
89546793|NCT05745623|Experimental|ICP-723|
89546794|NCT02393495|Experimental|Ultrasound guided group|the female will be asked to be full bladder. the trans-abdominal probe will be placed by an assistant on the suprapubic region. under speculum examination, the intrauterine device IUD (TCu 380A) will be placed till it reaches the fundus of the uterus and then released.
89546795|NCT02393495|Experimental|Non ultrasound guided group|the intrauterine device TCu 380A will be inserted in the conventional method, and checked afterwards by transvaginal ultrasound.
89546796|NCT02393573|Active Comparator|Metformin|Metformin will be administered as pills to be taken orally with an initial dose of 850 mg on the first day; the dose will be increased to 850 mg every 12 hours and 850mg every 8 hours respectively on the second day and then on the days to follow up to the morning of the surgery. Metformin will be discontinued on the day of surgery and will be restarted immediately after surgery.
89546797|NCT02393573|Placebo Comparator|Placebo|Placebo will be administered exactly in the similar way to Metformin
89546798|NCT02393261|Experimental|A 2500mlGroup|use 2-3 bags of 2500ml Huaren dialysate in the daytime and keep 1 bag of 2500ml Huaren dialysate in the night
89546799|NCT02393261|Active Comparator|B 2000mlGroup|use 3-4 bags of normal 2000ml dialysate in the daytime and keep 1 bag of 2000ml dialysate in the night
89546800|NCT02393105||Breast cancer survivor|Females finished primary breast cancer treatment including surgical operation, radiation therapy and chemotherapy.
89546801|NCT02693171||Dinutuximab administered for 5 cycles|High-risk neuroblastoma patient treated with Unituxin as standard of care
89546802|NCT02392949|Experimental|Experimental group|Passive mobilization on cervical spine
89546803|NCT02392949|Placebo Comparator|Control|Placebo exercise on arms
89546804|NCT03167021||Students|Students of the Auvergne Rhone Alpes region will be contacted by email thanks to the student associations and scholarity departments. Answer to the survey will be done online.
89546805|NCT02393027|Experimental|patients|10 idopathic parkinson disease
89546806|NCT02393027|Active Comparator|controls subjects|10 healthy controls (no parkinson disease)
89546807|NCT02392793|Active Comparator|Arm A: Talazoparib Plus Irinotecan|"Talazoparib will be administered orally on day 1 either once or twice per day depending on the dose level of the enrolled patient. Both oral talazoparib and IV irinotecan will then be administered daily, on days 2-6. Each cycle will last 21 days. Filgrastim or peg-filgrastim will be given following the last dose of chemotherapy.~Arm A is closed to enrollment."
89546808|NCT02392793|Active Comparator|Arm B: Talazoparib Plus Irinotecan Plus Temozolomide|Once the maximum tolerated doses (MTDs) for talazoparib and irinotecan are determined, a second arm of the study will open administering talazoparib, irinotecan and temozolomide. Talazoparib will be given orally, days 1-6. Intravenous irinotecan and oral temozolomide will be given days 2-6. Filgrastim or peg-filgrastim will be given following the last dose of chemotherapy.
89546809|NCT05745155|Experimental|Senti-Wear with Senti-AI|Participants will wear the Senti-Wear smart garment up to twice per day (as tolerated) and complete a study journal detailing issues with the device and changes to their respiratory illness.
89546810|NCT03166943|Experimental|study group|Systolic function by echocardiography to100 Hepatitis C virus infected patients on continuous regimen ( sofosbuvir and daclatasvir )
89546811|NCT03166943|Active Comparator|Control group|Diastolic function by echocardiography age and sex matched group of 30 patients with Hepatitis C virus who did not receive antiviral treatment ( sofosbuvir and daclatasvir )
89546812|NCT02392715|Experimental|Intervention cohort|"36 sessions of 60 - 75 minutes with a frequency of 3x/week~30' endurance training, 15' strength training, 15' inspiratory muscle training with Threshold by Respironics~Inspiratory muscle training intensity: 15% of maximal inspiratory pressure (PiMax) during the first week. Then increment of 5% each session until 60% of PiMax after the first month. The PiMax will be reassessed after 12 and 24 sessions in order to readjust the 60% of PiMax."
89546813|NCT02392715|Sham Comparator|Control cohort|"36 sessions of 60 - 75 minutes with a frequency of 3x/week~30' endurance training, 15' strength training, 15' sham inspiratory muscle training with Threshold by Respironics~Sham inspiratory muscle training intensity : 5 centimeters of water (cmH20)"
89546814|NCT03167801||spinal cord injury|spinal cord injury all scores AIS
89546815|NCT03167801||Healthy volunteers|Healthy volunteers for whom melatonin profiles have been taken and stored in the Lyon endocrinology laboratory's database. No healthy volunteers will be directly recruited for the study.
89546816|NCT02692703|Experimental|Glecaprevir/Pibrentasvir|Glecaprevir/pibrentasvir (300 mg/120 mg) coformulated once daily (QD) for 12 weeks.
89546817|NCT02392325|Experimental|rDEN1Δ30 and rDEN2Δ30-7169|Participants will receive the rDEN1Δ30 vaccine at Day 0. They will receive the rDEN2Δ30-7169 vaccine at Day 270.
89546818|NCT02392325|Experimental|Placebo and rDEN2Δ30-7169|Participants will receive placebo vaccine at Day 0. They will receive the rDEN2Δ30-7169 vaccine at Day 270.
89546819|NCT03167177|Experimental|NANT Melanoma Vaccine|"A combination of agents will be administered to subjects in this study:~avelumab, bevacizumab, capecitabine, cisplatin, cyclophosphamide, 5-fluorouracil, leucovorin, nab-paclitaxel, nivolumab, omega-3-acid ethyl esters, stereotactic body radiation therapy, ALT-803, ETBX-011, ETBX-051, ETBX-061, GI-6207, GI-6301, and haNK."
89546820|NCT03166709|Active Comparator|Treatment As Usual|Intensive Outpatient Program (IOP) addiction treatment
89546821|NCT03166709|Experimental|Experimental|Secondary Prevention Intervention (PARS) plus Treatment as Usual
89546822|NCT02392091||critically ill patients|critically ill patients at the age ≥18, expected to stay in the ICU for ≥24h, with the clinical necessity for a urinary catheter and the absence of anuria
89546823|NCT02392013|Experimental|Home Modification Group|A tailored home-modification (home-hazard removal) intervention delivered in the home by occupational therapists over three visits and with a booster session at six months.
89546824|NCT02392013|No Intervention|Usual Care Group|Usual care by an Area Agency on Aging
89025129|NCT00439803|Placebo Comparator|C3|
89546825|NCT02391857|Experimental|EGDgroup|Intervention (gastric decompression by naso(oro)-gastric tube insertion) was performed
89546826|NCT03166865|Experimental|Intervention group|Intraarticular injection of 2×10~7 Umbilical-cord mesenchimal stem cells with plateler Rich Plasma(5ml)
89546827|NCT03166865|Other|Control group|Intraarticular injection of hyaluronic acid
89546828|NCT03166787|Experimental|Myocardial Blood Flow|Myocardial contrast echocardiography will be used to measure regional myocardial perfusion .
89546829|NCT03166787|Experimental|Assess Coronary Endothelial Function|young hookah smokers will be randomized to have coronary endothelial function assessed before and after inhaling Carbon Monoxide or room air from a Douglas bag.
89546830|NCT03166787|Experimental|Test coronary endothelial function|Test coronary endothelial function before after hookah smokers smoke charcoal-heated hookah and before and after age-matched cigarette smokers smoke 2 cigarettes. In the same subjects, we will test for acute smoking-induced changes in LV wall strain by speckle tracking. Finally, in a subset of subjects we will repeat the MCE and speckle tracking studies after pretreatment with either i.v. vitamin C or one dose of oral tadalafil.
89546831|NCT02692235|Experimental|carnitine|24 weeks l-carnitine-l-tartrate supplementation
89546832|NCT02692235|Placebo Comparator|placebo|24 weeks isonitrogenous supplementation
89546833|NCT03166241|Experimental|study group|measure serum interleukin 21 level in patients with severe adverse drug reaction who show change in serum interleukin 21 before and after therapy the following investigation will be done at the begning of the study to patients: Complete Blood Picture Erythrocyte Sedimentation Rate Random blood sugar Liver function tests Kidney function tests
89546834|NCT03166241|Placebo Comparator|control group|compare serum interleukin 21 level in patients with severe adverse drug reaction and healthy control subjects
89546835|NCT03167645|Experimental|Human albumin|Substitution of human albumin until serum albumin >30g/l; dosage: (30 g/l - serum albumin [g/l] ) x 0,04 l/kg x body weight [kg] x 2
89546836|NCT03167645|No Intervention|Control|Standard clinical care
89546837|NCT03166553|Experimental|Elemene +Oxaliplatin|the group treated with the Elemene Injection/Elemene Oral Emulsion in Combination with Systematic Chemotherapy including Oxaliplatin
89546838|NCT03166553|No Intervention|Oxaliplatin|the group treated with Systematic Chemotherapy including Oxaliplatin
89546839|NCT03167957|Experimental|CAMB 200 mg|200 mg CAMB Oral Amphotericin B
89546840|NCT03167957|Experimental|CAMB 400 mg|400 mg CAMB Oral Amphotericin B
89546841|NCT03166397|Experimental|ACT TIL|"Reduced Intensity, non-myeloablative, lymphodepleting induction regimen using Cyclophosphamide 30mg/kg/day with Fludarabine (25 mg/m2/d) followed by 3 consecutive days of Fludarabine 25mg/m2/d..~Preparation and administration of TIL~Bolus high-dose (720,000 IU/kg) IL-2 will be administered to each patient every 8 hours, to tolerance. A maximum of 10 doses will be administered per patient."
89546842|NCT03166397|Experimental|ACT TIL + Anti PD-1|"Single dose of Nivolumab 480 mg fixed dose~Reduced Intensity, non-myeloablative, lymphodepleting induction regimen using Cyclophosphamide 30mg/kg/day with Fludarabine (25 mg/m2/d) followed by 3 consecutive days of Fludarabine 25mg/m2/d..~Preparation and administration of TIL~Bolus high-dose (720,000 IU/kg) IL-2 will be administered to each patient every 8 hours, to tolerance. A maximum of 10 doses will be administered per patient.~Second dose of Nivolumab 480 mg fixed dose (at least 4 weeks from the first dose)"
89546843|NCT03166397|Experimental|ACT TIL FMT + Anti CTLA4|"FMT loading dose given via colonoscopy~FMT 12 oral capsules as maintenance - given 2 times~Single dose of Ipilimumab 1mg/kg up to 100 mg~Reduced Intensity, non-myeloablative, lymphodepleting induction regimen using Cyclophosphamide 30mg/kg/day with Fludarabine (25 mg/m2/d) followed by 3 consecutive days of Fludarabine 25mg/m2/d..~Preparation and administration of TIL~Bolus high-dose (720,000 IU/kg) IL-2 will be administered to each patient every 8 hours, to tolerance. A maximum of 10 doses will be administered per patient."
89546844|NCT05744609||children hospitalized with community-acquired pneumonia|
89546845|NCT04480073|Other|edentulous patients with atrophic jaws|patients presenting with severely atrophic edentulous sites in the upper and lower jaw, and requesting implant-supported prosthetic restorations, will be enrolled in this study.
89546846|NCT05744531|Experimental|education group|The healthy pregnant women and their spouses meeting the inclusion criteria were determined by randomization according to the order of application to the antenatal clinic. A guide to providing access to internet-based education, training booklet and attachment diary was given to the pregnant women and their spouses in the education group .Internet-based Parenting education based on the Information-Motivation-Behavioral Skills (IMB) Model was given to the pregnant women and their spouses in the education group , once a week between 31 and 34 weeks of gestation, for a total of 4 times. . Internet-based counseling was given to the pregnant women and their spouses in the education group as part of the motivation step of the model,
89025130|NCT00439803|Active Comparator|T4|
89546847|NCT05744531|No Intervention|control group|The healthy pregnant women and their spouses meeting the inclusion criteria were determined by randomization according to the order of application to the antenatal clinic. A guide to providing access to internet-based education, training booklet and attachment diary was not given to the pregnant women and their spouses in the control group. No training was given to the pregnant women and their spouses in the control group.Counseling was not provided to the pregnant women and their spouses in the control group. .
89025131|NCT00439803|Placebo Comparator|C4|
89025132|NCT00442442|No Intervention|1|No treatment control
89546848|NCT05746169||Pregnant women and their children|The DREAM cohort will recruit from University of California, San Francisco (UCSF) Mission Bay, Zuckerberg San Francisco General Hospital, and Fresno Community Medical Center locations to enroll an economically, geographically, ethnically and racially diverse cohort of pregnant women and their children for long term follow-up.
89025133|NCT00442442|Active Comparator|2|LLIN Nets
89025134|NCT00442442|Experimental|3|Mosquito Coils
89025135|NCT00442442|Experimental|4|Mosquito coils & LLIN
89546849|NCT04480151||IMPELLA™ alone as bridge to LVAD|patients assisted by IMPELLA™ pump alone during the days preceding the implantation of long term LVAD (at least 48 hours for patients for whom an ECLS was previously used)
89546850|NCT04480151||ECLS alone or with IMPELLA™ as bridge to LVAD|patients assisted by ECLS (ExtraCorporeal life support) alone or simultaneously with IMPELLA™ until the implantation of LVAD
89546851|NCT05744453|Experimental|Olive Leaf Extract|Olive leaf extract supplementation
89546852|NCT05744453|Placebo Comparator|Control|Cellulose Supplementation
89546853|NCT03166475|Experimental|Palatal pedicle flap (Group 1)|On patients of this group were performed the palatal pedicle subepithelial connective tissue flap after the extraction, following the technique described by Khoury & Happe (2000), which consists of total detachment of the palatal flap followed by division of the flap to release the connective tissue, maintain a pedicle and sliding it to cover the fresh socket by primary intention. The sutures were removed seven to ten days of postoperative.
89546854|NCT03166475|Experimental|Graft + palatal pedicle flap (Group 2)|On patients of this group were performed the palatal pedicle flap like the group 1, however, the sockets were previously filled with a graft of synthetic bone substitute (Bone Ceramic®, Straumann, Switzerland) and then recovered with the connective flap and sutured by primary intention. The sutures were removed seven to ten days of postoperative.
89546855|NCT03166475|Experimental|Provisional ovoid pontic (Group 3)|On patients of this group, after the extraction of the tooth, were made a provisional ovoid pontic with acrylic resin or with the crown of the removed tooth itself, cut and sealed with composite resin. The pontics were placed to seal the entire gingival margin of the socket and penetrating 2 to 3 mm into it, stabilized laterally by the adjacent teeth with orthodontic and composite resin or acrylic resin. No sutures were made.
89546856|NCT05746013|Placebo Comparator|No Fat meal|
89546857|NCT05746013|Experimental|SFA meal|
89546858|NCT05746013|Experimental|MUFA meal|
89546859|NCT05746013|Experimental|PUFA meal|
89546860|NCT03106103||Women with urinary incontinence|The patients were randomized in four groups: Group A received 500mg of levofloxacin, group B received placebo, group C received 80mg trimethoprim and 400mg sulfamethoxazole (SMZ-TMP) and group D received 100mg of nitrofurantoin.
89546861|NCT03115229|No Intervention|Control Group|The control group of the RCT was composed of 35 students randomly assigned to the control group who are BMI was between 25.0-29.9 or BMI was between 18.5-24.9 and they were in the risk group in terms of obesity according to the risk rating scales.
89546862|NCT03115229|Experimental|Intervention Group|The selected students were associated with obesity risk factors about obesity (owerveight or normal weight and they were in the risk group in terms of obesity according to the risk rating scales, and between 19-24 years old) and randomly assigned to the experimental group to Protective Nursing Interventions for Reduction Obesity Risk
89546863|NCT03106259||Non-Interventional Study|Subjects participating in this observational study originally participated in study FURESTEM-RA Inj.[NCT02221258]
89546864|NCT02552121|Experimental|Tisotumab vedotin (HuMax-TF-ADC)|
89546865|NCT03488355|Experimental|Modified Reporting|Modified laboratory report
89546866|NCT03488355|No Intervention|Standard Reporting|Standard laboratory report
88961619|NCT05423522|Placebo Comparator|Placebo|"Description: Homogeneous yellow oily liquid. Dosage: One administration of 3 mL per day (1.8 mg/day) by depositing 1.5 mL in the gingivo-jugal groove of each cheek with the graduated pipette.~Duration of treatment: 12 weeks during the double-blind period."
88961620|NCT05421143||Quantitative study with medication reconciliation|The data collection will continue consecutively until the goal of 150 patients is reached. If it is feasible, we will try to reach 200 patients. We think 150-200 patients will give good insight into different types of medication discrepancies, since studies have shown that up to 90% of patients have at least one medication discrepancy in primary care.
89207920|NCT02597231|Placebo Comparator|Placebo Group|Patient in this group will receive a matching placebo pill orally at 9pm.
89546867|NCT03484143|Active Comparator|Active Neuro RX Gamma device|Neuro RX Gamma device delivers low-energy near-infrared light, through 5 diodes, to the brain transcranially and intranasally
89546868|NCT03484143|Sham Comparator|Sham Neuro RX Gamma device|Sham Neuro RX Gamma device is identical in appearance and sound as the active Neuro RX Gamma device but does not emit low-energy near infrared light
89546869|NCT05473611||closed reduction percutaneous fixation method|Patients with closed reduction percutaneous sacroiliac screw fixation of posterior pelvic ring due to unstable pelvic injury
89546870|NCT05473611||open reduction anterior sacroiliac approach|Patients with fixation of the posterior pelvic ring by open reduction anterior approach due to unstable pelvic injury
89546871|NCT05473611||open reduction posterior sacroiliac approach|Patients with fixation of the posterior pelvic ring by open reduction posterior approach due to unstable pelvic injury
89546872|NCT05476107|Experimental|AMT-126|oral AMT-126
89546873|NCT05476107|Placebo Comparator|Placebo|oral placebo
89546874|NCT05476107|Other|Radioactive Tablet (Part 2 only)|oral radioactive tablet for scintigraphic analysis
89546875|NCT03415035||Patients with Chronic Lymphocytic Leukemia (CLL)|Patients with diagnosed CLL and eligible to venetoclax as per label
89546876|NCT02552355|Experimental|Metformin/Carbohydrate|Daily oral administration of Metformin with a 12-week exercise training program consisting of 3 days per week of aerobic exercise training. The dose of Metformin will begin as one 500 mg tablet for the first week and will increase by 500 mg/day/week until reaching 2000 mg/day by week 4. Supervised aerobic exercise 3 days per week followed by a carbohydrate drink along with daily oral administration of Metformin.
89207921|NCT00866970|Experimental|1|ALD518
89546877|NCT02552355|Placebo Comparator|Placebo/Carbohydrate|Daily oral administration of matching placebo with a 12-week exercise training program consisting of 3 days per week of aerobic exercise training. The dose of matching placebo will begin as one tablet for the first week and will increase by one tablet/day/week until reaching 4 tablets by week 4. Supervised aerobic exercise 3 days per week followed by a carbohydrate drink along with daily oral administration of matching placebo.
88961621|NCT05421143||Qualitative semi-structured interviews with patients and next of kin|A selection of patients from the quantitative study described above will be chosen purposively and step by step along the way to ensure the informational strength in the selection. When possible, we will include next of kin in the interviews together with the patient. We aim to include around 20-30 patients, without counting in next of kin. The part will be accomplished together with the quantitative part. Every new interview will be compared with previous interviews to identify similarities and differences. Characteristics it is important to ensure variability for; women and men, different ethnicities, education type, spread in age, number of medications and help from next of kin/homecare nurses or not. It is also important to ensure variability in number and type of medications and diagnoses.
88961622|NCT05421143||Qualitative semi-structured interviews with HCP|HCP will be recruited purposively along the quantitative study to ensure the informational strength in the selection. We aim to include around 15-20 HCP. The HCP recruited are involved in the patients medication regime or management, this to ensure that they have knowledge about patients with multiple long term conditions. Every new interview will be compared with previous interviews to identify similarities and differences. Characteristics it is important to ensure variability for; woman and men, physicians and homecare nurses, spread in age, years of working experience, different ethnicities and number of medications the patients they care for use.
88961623|NCT05416060|Experimental|Dulce Digital|Patients will participate in a text-based diabetes self-management educational and support (DSME/S) program and receive ongoing support via text messages designed to improve knowledge, health beliefs, self-management behaviors and clinical outcomes.
88961624|NCT05416060|Experimental|Project Dulce Telehealth DSME/S|Patients will participate in live a peer-led Telehealth diabetes self-management education and support program.
88961625|NCT05416060|Experimental|Project Dulce Live DSME/S|Patients will participate in live a peer-led Telehealth diabetes self-management education and support program.
88961626|NCT05410158|Other|Pecs block group|"The Pecs block will be performed while the patient in the supine position with the ipsilateral upper limb abducted 90 degree with an 80 mm 21 G needle (Pajunk®SonoPlex Stim cannula U.S.A) using linear array ultrasound probe of high frequency (Sonosite®, Inc. U.S.A) starting from the lateral third of the clavicle and moving distally and laterally to the mid axillary line .~Patients will be given ultrasound guided, modified Pecs block with 30 mL of 0.25% bupivacaine hydrochloride (Markyrene ®Sigma Tec, Egypt) plus ketamine hydrochloride (1 mg/kg) (Ketamine® Sigma-Tec, Egypt) injected between the pectoralis minor and the serratus anterior muscles , and skin incision will be performed 15 minutes after the block was given."
88961627|NCT05410158|Other|Topical instillation group:|After surgical hemostasis before wound closure Patients will receive 1 mg/kg ketamine hydrochloride plus 30 mL of 0.25% bupivacaine hydrochloride which will be put in asterile syringe and irrigated onto the surgical field at the end of surgery .
89207922|NCT00866970|Experimental|2|ALD518
89546878|NCT02552355|Active Comparator|Metformin/Protein|Daily oral administration of Metformin with a 12-week exercise training program consisting of 3 days per week of aerobic exercise training. The dose of Metformin will begin as one 500 mg tablet for the first week and will increase by 500 mg/day/week until reaching 2000 mg/day by week. Supervised aerobic exercise 3 days per week followed by a protein drink along with daily oral administration of Metformin
89546879|NCT02552355|Active Comparator|Placebo/Protein|Daily oral administration of Metformin with a 12-week exercise training program consisting of 3 days per week of aerobic exercise training. The dose of Metformin will begin as one 500 mg tablet for the first week and will increase by 500 mg/day/week until reaching 2000 mg/day by week. Supervised aerobic exercise 3 days per week followed by a protein drink along with daily oral administration of placebo.
89546880|NCT02551731|Experimental|Cannabidiol Oral Solution: 20 or 40 mg/kg/day BID|The dose of Cannabidiol Oral Solution will begin at 20 mg/kg/day [10 mg/kg twice per day (BID)], will be adjusted at any time if the investigator feels the safety or well-being of the participant is at risk, and will be titrated up or down according to protocol-stipulated parameters and at the investigator's discretion after Day 14 to enhance efficacy. Dose will not exceed 40 mg/kg/day.
89546881|NCT04479657|Experimental|QingFei Granule+Cefuroxime group|Cefuroxime：30mg/kg/d,bid QingFei Granule: tid
89546882|NCT04479657|Active Comparator|Cefuroxime group|Cefuroxime：30mg/kg/d,bid
89546883|NCT05476029||Sepsis complicated with ARDS group|Blood samples and alveolar lavage fluid were collected within 24h after admission to ICU. After blood samples were collected, they were placed in static stratification at 4°C and centrifuged at 3000×g for 10 min. Serum samples and alveolar lavage fluid samples were transferred to a cleaning tube and stored in a refrigerator at -80°C for exosome sorting, identification, differential miRNAs, and analysis of serum oxidation and inflammatory indicators.
89546884|NCT05476029||control group|Blood samples and alveolar lavage fluid were collected. After blood samples were collected, they were placed in static stratification at 4°C and centrifuged at 3000×g for 10 min. Serum samples and alveolar lavage fluid samples were transferred to a cleaning tube and stored in a refrigerator at -80°C for exosome sorting, identification, differential miRNAs, and analysis of serum oxidation and inflammatory indicators.
89546885|NCT05475951|Experimental|Normal Weight Pregnant Women|The women who had term pregnancy and had normal BMI.
89546886|NCT05475951|Experimental|Overweight Pregnant Women|The women who had term pregnancy and had BMI values between 25-30.
89546887|NCT05475951|Experimental|Obese Pregnant Women|The women who had term pregnancy, and had BMI values more than 30.
89546888|NCT05475795|Active Comparator|Metapex group|Obturation of primary molars with calcium hydroxide and iodoform paste
89546889|NCT05475795|Experimental|Endoflas group|Obturation of primary molars with calcium hydroxide, eugenol and iodoform paste
89546890|NCT04270305|Experimental|orientation|Orientation training with GRAIL
89546891|NCT04270305|Active Comparator|walking|Walking training with GRAIL
89546892|NCT05481099|Experimental|Intervention|Cognitive-behavioural-based intervention combined with mindfulness, psychoeducation, and relaxation techniques
89546893|NCT05481099|No Intervention|Control|Care as usual
89546894|NCT05480787|Experimental|Remimazolam 0.1mg/kg/h|Participants were first induced with 5mg in 1-min intravenous injection and then maintained at 0.1 mg/kg/h.
88961628|NCT05383885||Observational cohort|"The study is an observational study on a single cohort of consecutive out-of-hospital cardiac arrest patients.~All patients in the cohort will be monitored with a non-invasive pletismograph. No intervention will be administered to any patient and no decision on treatment will be based on the collected informations. Treating physicians will be blinded to collected values of perfusion index during the study"
88961629|NCT05352347|Active Comparator|NuSepin® 0.2 mg/kg|NuSepin® 0.2 mg/kg in 100mL NS bid
88961630|NCT05352347|Active Comparator|NuSepin® 0.4 mg/kg|NuSepin® 0.4 mg/kg in 100mL NS bid
88961631|NCT05352347|Placebo Comparator|Placebo|Normal saline (NS) 100mL bid
88961632|NCT05337293|Experimental|COPE-HF Partnership Intervention|Working with a trained registered nurse interventionist, participants in this arm were trained to use a 4-step problem-solving process to manage identified problems related to heart failure. Heart failure self-care education and materials were provided as indicated based on specific identified problems.
88961633|NCT05337293|Sham Comparator|Attention|Participants in this arm received telephone calls from a trained research assistant on the same schedule as the intervention group. During these calls basic data were collected on several key areas of heart failure self-care. No intervention or patient education took place during these calls.
88961634|NCT05337293|No Intervention|Usual Care|Participants in this arm received usual care from their healthcare providers and facility designated heart failure discharge education only.
88961635|NCT05333211|Experimental|Investigational Arm with Ortho-R/PRP|Using a double row, Trans-osseous Equivalent Rotator Cuff Repair Technique (TOE) with Ortho-R/PRP combination
89546895|NCT05480787|Experimental|Remimazolam 0.3mg/kg/h|Participants were first induced with 5mg in 1-min intravenous injection and then maintained at 0.3 mg/kg/h.
89546896|NCT05480787|Experimental|Remimazolam 0.5mg/kg/h|Participants were first induced with 5mg in 1-min intravenous injection and then maintained at 0.5 mg/kg/h.
89546897|NCT05471661|Experimental|Penta-STs|Patients will receive penta-STs in a single infusion. If they have a partial response or receive therapy post-infusion which could ablate the infused T cells they are eligible to receive up to 2 additional doses from 28 days after their first dose.
89546898|NCT05480631|Active Comparator|Group A|group A- autograft
89546899|NCT05480631|Experimental|group B|group B- concentrated growth factor with autograft
89546900|NCT05480631|Experimental|Group C|group C- concentrated growth factor with xenograft
89546901|NCT05471193||Instability|
88961636|NCT05333211|No Intervention|Control Arm Standard of Care without Ortho-R/PRP|Using the Trans-osseous Equivalent Rotator Cuff Repair Technique (TOE) without Ortho-R/PRP combination
88961637|NCT05331222|Experimental|Jantar-1 (JT-1), 7% (w/w) aqueous solution|Dosing regimen: ad libitum between at least 2 doses, in the morning and in the evening, and at most 10 doses per day. A dose corresponds to two strokes of 100ul each per nostril.
88961638|NCT05317442|Experimental|Pressure Injury in Sacrum Wound|"Name: Fespixon Cream~Dosage form: Topical cream, 15 g ointment per tube~Active ingredients: 1.25% extracts of Plectranthus amboinicus (PA-F4, 0.25%) and Centella asiatica (S1, 1%)~Dose(s): Apply 1 cc per 5 cm^2 ulcer size (not exceeding 2 mm in thickness)~Dosing schedule: Apply once a day~Duration: up to 16 weeks"
88961639|NCT05305391|Experimental|A2 milk + placebo|A2 whole milk, 3.5% fat, heat-treated; placebo capsule without enzyme
89207923|NCT00866970|Experimental|3|ALD518
89546902|NCT05471193||No Instability|
89546903|NCT05480397|Experimental|• Group (1) will receive (TENS , cryotherapy and conventional physical therapy program).|
89546904|NCT05480397|Experimental|•Group (2) receive (distractive techniques , cryotherapy and conventional physical therapy)|
89546905|NCT05480397|Experimental|• Group (3) will receive (cryotherapy and conventional physical therapy program).|
89546906|NCT05458869||Observational (survey, HPV self-collection, interview)|Participants complete a survey, use an HPV self-collection kit, and attend an interview over 30 minutes.
89546907|NCT02542605|Other|PACAP-38 Challenge Agent|In Part A, 4 cohorts of 2 to 5 participants sequentially received an intravenous infusion of 10 picomol/kilogram/minute (pmol/kg/minute) PACAP-38 for 2.5, 5, 7.5 and 10 minutes each in order to determine the dose for Part B.
89546908|NCT02542605|Placebo Comparator|Placebo|Participants were randomized to receive matching erenumab placebo by intravenous administration over 30 minutes on day 1. On day 8 participants were administered the dose of PACAP-38 determined from Part A of the study (100 pmol/kg) and were followed up for 11 weeks.
89546909|NCT02542605|Experimental|Erenumab|Participants were randomized to receive 140 milligrams (mg) erenumab by intravenous administration over 30 minutes on day 1 in Part B. On day 8 participants were administered the dose of PACAP-38 determined from Part A of the study (100 pmol/kg) and were followed up for 11 weeks.
89546910|NCT05480241|Experimental|Pancreatic Enzyme Replacement Therapy|Pancreatic Enzyme Replacement Therapy (PERT) 50000 Ph.U./meal + 25000 Ph.U./snack + Omeprazole 20mg once daily on fasting
89546911|NCT05480241|Placebo Comparator|Placebo|Placebo + Omeprazole 20mg once daily on fasting
89546912|NCT02550873|Experimental|PRM-151 10mg / kg|Dosing Every 4 Weeks
89546913|NCT02550873|Placebo Comparator|Placebo|Dosing Every 4 weeks
89546914|NCT05480163|Experimental|Measurement records in COPD patients|"The subject is informed of the procedure, his or her rights, and the use of the data collected (including the video recording of the session)~Pre-session clinical assessment by the physiotherapist~Installation of the Sybille waistcoat on the patient~First measurement phase: Recording of spirometry parameters, acoustics, movements (thoracic volumetry) for forced vital capacity (FVC) and LVC manoeuvres.~Second phase of measurements:~Treatment: the physiotherapist performs the session in the classical way. Recording of acoustic parameters, movements (thoracic volumetry).~Third phase of measurements: Recording of spirometry, acoustics and movement parameters (thoracic volumetry) for FVC and LVC manoeuvres.~Removal of measurement devices~Post session evaluation by the physiotherapist."
89546915|NCT05480163|Other|Measurement records in control subject|"The subject is informed of the procedure, his or her rights, and the use of the data collected (including the video recording of the session)~Clinical assessment by the physiotherapist The subject answers the questionnaire~Installation of the Sybille waistcoat on the patient~Measurement phase: Recording of spirometry, acoustics, movements (thoracic volumetry) for FVC and LVC manoeuvres.~Removal of measurement devices"
89546916|NCT02702115|Experimental|Cohort 1: SB-318: Starting Dose 1.00E+13 vg/kg|A single dose of each of the three components of SB-318 [zinc finger nucleases (ZFN1, ZFN2, and hIDUA Donor)] administered via intravenous (IV) infusion.
89546917|NCT02702115|Experimental|Cohort 2: SB-318 at Next Ascending Dose 5.00E+13 vg/kg|A single dose of each of the three components of SB-318 [zinc finger nucleases (ZFN1, ZFN2, and hIDUA Donor)] administered via intravenous (IV) infusion.
89546918|NCT02702115|Experimental|Cohort 3: SB-318 at Next Ascending Dose 1.20E+14 vg/kg|A single dose of each of the three components of SB-318 [zinc finger nucleases (ZFN1, ZFN2, and hIDUA Donor)] administered via intravenous (IV) infusion.
89546919|NCT05455905||Main Study Cohort|"A web-based audio recording tool will be used to record voice sample answering the prompt, How are you feeling today? Participants are asked to speak for 1-minute. Following the recording, participants are asked to complete the Patient Health Questionnaire-9 and Generalized Anxiety Disorder-7 questions."
89546920|NCT05455905||Selected Self-Reported Depression Cohort|The Researcher will review Patient Health Questionnaire-9 scores of all the participants and select the subset that self-reported a scored greater than 20, on a scale from 0 to 27. Participants will be approached via email to complete an additional administration of the Patient Health Questionnaire-9 and Generalized Anxiety Disorder-7 questionnaires and be offered resources for depression and anxiety and how to set up an appointment with a mental health professional.
89546921|NCT02550795|Placebo Comparator|Control|administration of 0.9% normal saline 10ml
89546922|NCT02550795|Active Comparator|Dexmedetomidine|administration of 0.5ug/kg of dexmedetomidine (5ml)
89546923|NCT02550795|Active Comparator|Dexmedetomidine and dexamethasone|administration of 0.5 ug/kg of dexmedetomidine and dexamethasone 5mg (total 5ml)
88961640|NCT05305391|Experimental|A2 milk+ lactase enzyme|A2 whole milk, 3.5% fat, heat-treated; lactase capsule
88961641|NCT05305391|Experimental|Protein-hydrolyzed A1 milk + placebo|Protein-hydrolyzed lactose-free milk, 3% fat, heat-treated; placebo capsule without enzyme
88961642|NCT05301439|Experimental|Restoration Group|Participants in this group will receive the universal adhesive restorative procedure combined with condensable bulk fill resin, for the restoration of the cavited teeth.
89207924|NCT00866970|Placebo Comparator|4|No ALD518
89207925|NCT00545571|Experimental|Mircera in Renal Anemia|Participants will receive intravenous Mircera every 4 weeks for a total of 52 weeks in this single-arm study. The first dose of 120, 200, or 360 mcg will be determined by the dose of ESA received prior to administration of study treatment, while subsequent doses will be adjusted to maintain hemoglobin within a country-specific target range.
89546924|NCT02541903|Experimental|Gilotrif|Gilotrif will be administered orally at 40 mg dosage once daily. Continuous administration of 4 weeks is considered one cycle. Therapy will continue until progression of the disease or severe toxicities. Labs will be monitored with routine blood collections every cycle and a CT scan will be done every two cycles (8 weeks).
89546925|NCT02541669|Experimental|TAK-491 40 mg (Open Label)|TAK-491 40 milligram (mg), tablet, orally, once daily on Day 1 and Days 4 to 10 as an open-label treatment.
89546926|NCT02541669|Experimental|TAK-491 80 mg (Open-label)|TAK-491 80 mg, tablet, orally, once daily on Day 1 and Days 4 to 10 as an open-label treatment.
89546927|NCT02541669|Experimental|TAK-491 40 mg (Double-blind)|TAK-491 40 mg, tablet, orally, once daily and TAK-491 80 mg placebo-matching tablet, orally, once daily on Day 1 and Days 4 to 10 in double-blind manner.
89207926|NCT00783380|Experimental|Virosomal influenza vaccine|
89207927|NCT00783380|Active Comparator|Subunit influenza vaccine|
88811998|NCT01395329|Active Comparator|Metoprolol|Systolic and Diastolic blood pressure will be measured before and after randomization to12 weeks of Metoprolol. Forearm blood flow will be measured in response to 100 nmol/min of BQ-123, BQ-123+BQ788 (50 mol/min), Acetylcholine (4.0, 8.0, 16.0 ug/100 mL tissue/min), Sodium Nitroprusside (1.0, 2.0, 4.0 ug/100 mL tissue/min) and BQ-123+BQ-788+Acetylcholine (same doses as above) will be measured before and after the 12 weeks of Metoprolol.
88961643|NCT05301439|Experimental|Hall Technique Group|Participants in this group will receive the Hall Technique with steel crowns for the restoration of the cavited teeth.
88961644|NCT05301439|Experimental|Steel Crown with Conventional Technique Group|Participants in this group will receive steel crowns with conventional technique for the restoration of the cavited teeth.
88961645|NCT05280665||The non-specialized group|"Patients who were operated by a non-specialized surgeon. Non-specialized surgeons were defined as general surgeon who does not have the characteristics of a specialized gastric cancer surgeon.~The non-specialized group will be divided into two subgroups (high-volume vs low-volume) for further analysis."
89207928|NCT00793130|Other|Coltect|Coltect contains natural compounds: curcumin, green tea and selenium which are approved as food supplements by the Ministry of Health in Israel. Curcumin and green tea are widely used in the food industry.
89207929|NCT00863070||Bladder Exstrophy Patients|Patients who receive follow-up care at Connecticut CMC urology clinic for bladder exstrophy.
89546928|NCT02541669|Experimental|TAK-491 80 mg (Double-blind)|TAK-491 80 mg, tablet, orally, once daily and TAK-491 40 mg placebo-matching tablet, orally, once daily on Day 1 and Days 4 to 10 in double-blind manner.
89546929|NCT02541669|Placebo Comparator|Placebo|TAK-491 40 mg placebo-matching tablet, orally, once daily and TAK-491 80 mg placebo-matching tablet, orally, once daily on Day 1 and Days 4 to 10.
89546930|NCT04423809||caregivers of adult patients hospitalized in psychiatry|a face-to-face interview with a nurse and self-assessment scales.
89546931|NCT02549859|Experimental|Deep Brain Stimulation (DBS)|All patients were treated and assessed under three conditions (60 Hz DBS, 130 Hz DBS and no DBS) at Visit 1 (V1), were then treated with 60 Hz DBS for at least 6 months (14.5 months on average), and were finally reassessed during a second visit (V2) under the same three conditions as V1. The order of treatment/assessment under the three conditions was randomized at each visit.
89546932|NCT02688647|Experimental|Belumosudil-R|"Subjects receive two 200 mg tablets of belumosudil (400 mg) PO QD for 24 weeks. Subjects may also continue treatment with belumosudil 400 mg PO QD after 24 weeks.~No subject may receive more than 96 weeks of treatment with belumosudil"
89546933|NCT02688647|Active Comparator|BSC-R|Subjects receive best supportive care as determined by the physician. Subjects may later crossover to treatment with belumosudil 400 mg PO QD. No subject may receive more than 96 weeks of treatment with belumosudil.
89546934|NCT04469127|Experimental|Arm 1|"Single Arm study Lu-177-DOTAGA-PEG-IAC (intracutaneous)~Dosage and Dose Escalation Frequency:~Cohort 1: 75 mCi x 3 (maximum cumulative administered activity, 225mCi) + 100 μgr IAC Cohort 2: 150 mCi x 3 (maximum cumulative administered activity, 450mCi) + 100 μgr IAC Cohort 3: 200 mCi x 3 (maximum cumulative administered activity, 600mCi) + 100 μgr IAC~Three cycles each 8 weeks apart."
89546935|NCT02687607||WEB Aneurysm Embolization System|Subjects aged ≥ 18 years, but ≤ 80 years requiring treatment for single ruptured intracranial aneurysms.
89546936|NCT04479839||Microcuff ETT|Patients intubated with microcuff ETT
89546937|NCT04479839||Non-microcuff ett|Patients intubated with regular ETT
89546938|NCT03165851||CAMS-2005 trial|The induction course was Daunorubicin(DNR) + Cytarabine(Ara-C) or Homoharringtonine(HHT) + Ara-C or HHT + DNR + Ara-C. There are 5 consolidation course after complete remission (CR).
89546939|NCT03165851||CAMS-2009 trial|The induction course was MAE(Mitoxantrone + Cytarabine + Etoposide) or IAE(Idamycin + Cytarabine + Etoposide). Risk-stratified therapy and dose-dense intensive chemotherapy were adopted in the consolidation therapy. After the second course of therapy, patients in remission were stratified into three risk groups: low-risk children were defined as those with t(8;21) and a white blood cell count lower than 50,000/L, inv(16), or an age younger than 2 years without any high-risk factors; high-risk children were those with CR after consolidation course 1 or induction C , or with abnormalities of monosomy 7, 5q-, t(16;21), t(9;22)(Philadelphia chromosome [Ph1]); intermediate-risk children were those who were not in either a low-risk or high-risk group. Hematopoietic stem cell transplantation (HSCT) was indicated for only relapsed patients in the second CR.
89546940|NCT05453799|Experimental|Treatment (vudalimab)|Patients receive vudalimab IV over 1 hour on days 1 and 15 of each cycle. Cycles repeat every 28 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
89546941|NCT05453487|Experimental|Co-Ad group|"A total of 120 participants received one dose of inactivated COVID-19 vaccine and three doses of rabies vaccine.~Participants received one dose of inactivated COVID-19 vaccine and rabies vaccine on Day 0, and one dose of rabies vaccine on Day 7 and Day 28.~Blood sampling was performed on Day 0, Day 28 and Day 42."
89546942|NCT05453487|Experimental|COVID-19 vaccine group|"A total of 120 participants received one dose of inactivated COVID-19 vaccine on Day 0.~Blood sampling was performed on Day 0 and Day 28."
89546943|NCT05453487|Experimental|Rabies vaccine group|"A total of 120 participants received three doses of rabies vaccine on Day 0, Day 7 and Day 28.~Blood sampling was performed on Day 0 and Day 42."
89546944|NCT03968601||cohorte 1|Severe primary chronic mitral regurgitation with preserved left ventricular ejection fraction.
89546945|NCT05738525||Automated peritoneal dialysis with remote patient management (APD-RPM)|APD mode is recommended but not limited to continuous circulating peritoneal dialysis (CCPD). Dialysis dose ranges from 5 to 10 liters per day and glucose concentration starts from low concentration (1.5%).
89546946|NCT05738525||Continuous ambulatory peritoneal dialysis (CAPD)|(1) Dialysis dose ranges from 5 to 10 liters per day at the run-in period. For those with regular peritoneal dialysis, the original dose can be used according to the volume status and solute clearance effect in the past 3 months; (2) Exchange time and abdominal retention time is generally 2-5 times and 1 time at daytime and night, separately; (3) Glucose concentration includes 1.5%, 2.5% or 4.25%; (4) The treatments can be adjusted according to the change of residual renal function, peritoneal transport characteristics, volume status, solute clearance, clinical status and peritonitis.
89546947|NCT01662063|Experimental|SC TCZ QW|Participants who received IV TCZ in the previous trial will be switched to SC TCZ 162 mg QW, and those who received SC TCZ will continue at their same dosage of SC TCZ 162 mg QW. Tocilizumab will be given for an additional 96 weeks in this open-label extension study.
89207930|NCT04008225||ARDS group|Inpatients hospitalized in medical intensive care with a table of ARDS defined according to the Berlin criteria and requiring an BAL for a diagnostic purpose under a suspicion of pneumopathy acquired under mechanical ventilation.
89207931|NCT04008225||Control group|The control group will be made up of patients with an BAL considered normal (endoscopy patients from the pneumology department). The normality of the BAL is defined by a normocellular wash with cellularity: < 150,000 to 200,000 cells/mL Cell composition (formula): macrophages: 80-90%, lymphocytes 5 to 10% (< 20%), neutrophils: < 5%, eosinophils: < 2%.
89207932|NCT00748709|Experimental|BIBW 2992 (Afatinib)|BIBW 2992 (Afatinib) for patients FISH positive for/or harboring EGFR or HER2 Mutation
89546948|NCT01662063|Experimental|SC TCZ Q2W|Participants who received SC TCZ will continue at their same dosage of SC TCZ 162 mg Q2W. Tocilizumab will be given for an additional 96 weeks in this open-label extension study.
89546949|NCT05627999||patients candidate to the haemorrhoidal artery embolization|Consecutive patients assessed at the Division of General Surgery 1, Treviso Regional Hospital, from October to December 2021 and candidate to the haemorrhoidal artery embolization were included in the study. Indications to the procedure were symptomatic hemorrhoidal disease (French bleeding score [FBS] > 4), Goligher's classification score II or III, age >18 years, failure of non-operative management (change life style, dietary modification, supplemental fibers for constipation, over-the-counter treatments). Signed informed and research consents were obtained. Exclusion criteria were age < 18 years, Goligher prolapse score IV, pregnancy, previous haemorrhoidal surgery, inflammatory bowel disease. Use of anticoagulant or antiaggregant was not considered an exclusion criteria [stecca].
89546950|NCT05431725|Experimental|Sinovac-QIV group|800 subjects aged 3 years and older will receive one dose of Sinovac-QIV for vaccine-primed subjects or two doses of Sinovac-QIV for vaccine-unprimed subjects.
89546951|NCT05431725|Active Comparator|Vaxigrip Tetra-QIV group|800 subjects aged 3 years and older will receive one dose of Vaxigrip Tetra-QIV for vaccine-primed subjects or two doses of Vaxigrip Tetra-QIV for vaccine-unprimed subjects.
89546952|NCT02548455|Experimental|Treatment|Subjects implanted with the Quartet 1457Q LV lead
89546953|NCT02691455|Active Comparator|Second Aqueous Shunt|"Second Aqueous Shunt~Either a Baerveldt Glaucoma Implant 350-mm2 BG101-350 or an Ahmed Model FP7 Flexible Plate must be used for all participants unless there is insufficient space, in which case a Baerveldt Glaucoma Implant 250-mm2 BG103-250 may be used."
89546954|NCT02691455|Active Comparator|Transscleral Cyclophotocoagulation|Transscleral Diode Laser Cyclophotocoagulation
89546955|NCT04264845||Provider Focus Group|All heart failure providers at the participating centers will be screened as potential participants.
89546956|NCT04264845||Patient Interview Group|Patients with heart failure who are seen in the heart failure outpatient clinics at the participating centers will be screened for this study. The Principal Investigator will confirm the presence of heart failure based on established and agreed criteria. A real world, diverse population ranging from patients with milder forms of HF to the most advanced disease will be included in this study and allow the researchers to validate the prognostic models in larger, regionally diverse populations to better define the comparative effectiveness of alternative treatments in patients with different risk profiles.
89546957|NCT04264845||PROs/Clinical Data Integration Group|"Patients with heart failure who are seen in the heart failure outpatient clinics at the participating centers will be screened for this study. The Principal Investigator will confirm the presence of heart failure based on established and agreed criteria. A real world, diverse population ranging from patients with milder forms of HF to the most advanced disease will be included in this study and allow the researchers to validate the prognostic models in larger, regionally diverse populations to better define the comparative effectiveness of alternative treatments in patients with different risk profiles.~This group includes a sub-study of patients providing blood samples."
89546958|NCT05451615|Experimental|Abatacept|D2T RA patients receive Abatacept
89546959|NCT05451615|Experimental|JAK inhibitor|D2T RA patients receive JAKi
89546960|NCT03166007|Experimental|Optimised bowel care + abdominal massage|In addition to optimised bowel care as described below for the control group, the Intervention Nurse will teach the participant and/or their carer in the intervention arm how to deliver the abdominal massage. This will include viewing the massage DVD and the abdominal massage training booklet, as well as the demonstration of the technique on the participant by the Intervention Nurse.
89546961|NCT03166007|Active Comparator|Optimised bowel care|During a 1 hour outpatient appointment, the participants' existing bowel care routine will be reviewed and optimised. For example, explaining the necessity of adequate fluid intake. No change in medication will be advocated.
89546962|NCT02534883|Active Comparator|Group 1|Group 1 will received 200ug of misoprostol, to be placed into the posterior vaginal fornix 12 hours and 2 hours before their scheduled surgery (a total of 400ug of misoprostol).
89546963|NCT02534883|Placebo Comparator|Group 2|Group 2 will received placebo (empty gelatin capsule), to be placed into the posterior vaginal fornix 12 hours and 2 hours before their scheduled surgery.
89546964|NCT02685995|Active Comparator|Palindrome TDC|TDC insertion with Palindrome will be in accordance with its FDA-approved indication under moderate sedation or general anesthesia with local anesthesia using 1% lidocaine in per institutional protocol. Following TDC insertion, the catheter may be used immediately. The goal of HD is typically to achieve a target effective blood flow of 300mL/min within the first 3 hemodialysis sessions. The dialysis records from each of the first three HD sessions will be reviewed by the study coordinator for (A) Blood flow rate (QB), (B) Arterial and venous lumen pressures, (C) Kt/V, and (D) Urea reduction ratio (URR). Additionally, need and use of thrombolytic infusion (ie t-PA) (other than single dose injection) to restore or improve patency and/or need for catheter exchange.
89546965|NCT02685995|Active Comparator|VectorFlow TDC|TDC insertion with VectorFlow will be in accordance with its FDA-approved indication under moderate sedation or general anesthesia with local anesthesia using 1% lidocaine in per institutional protocol. Following TDC insertion, the catheter may be used immediately. The goal of HD is typically to achieve a target effective blood flow of 300mL/min within the first 3 hemodialysis sessions. The dialysis records from each of the first three HD sessions will be reviewed by the study coordinator for (A) Blood flow rate (QB), (B) Arterial and venous lumen pressures, (C) Kt/V, and (D) Urea reduction ratio (URR). Additionally, need and use of thrombolytic infusion (ie t-PA) (other than single dose injection) to restore or improve patency and/or need for catheter exchange.
89546966|NCT02548143|Experimental|Coagulation Factor VIIa (Recombinant)|A dose of 75 μg/kg (minor surgery or invasive procedure) or 200 μg/kg (major surgery or major invasive procedure) of LR769 will be administered as an initial intravenous (IV) bolus dose of LR769 within ≤2 minutes before the surgical incision or start of the invasive procedure. For both minor and major procedures, the initial dose will be followed by repeated administration of 75 µg/kg of LR769 every 2 hours (±5 minutes) for the first 48 hours after completion of the procedure and then as per the dosing schedules in the protocol for major or minor surgeries or invasive procedures. The minimum duration of LR769 treatment for major procedures will be 5 days, and for minor procedures 2 days except for certain procedures that may not require this duration of treatment.
89546967|NCT03165149|Active Comparator|Group (A)|patients will receive 1mg / kg of Ketamine diluted by 20 ml saline (0.9 % )
89546968|NCT03165149|Active Comparator|Group (B)|patients will receive 2 mg /kg of Ketamine diluted by 20 ml saline (0.9 %) a
89546969|NCT03165149|Active Comparator|Group (C)|patients will receive 3 mg / kg of Ketamine diluted by 20 ml saline (0.9 %)
89546970|NCT03165227|Experimental|BI 685509 Dose 1|
89546971|NCT03165227|Experimental|BI 685509 Dose 2|
89546972|NCT03165227|Experimental|BI 685509 Dose 3|
89546973|NCT03165227|Placebo Comparator|Placebo|
89546974|NCT03165305|Experimental|Sustained Inflation Group|Includes the infants who administered sustained inflation for 5 seconds with a pressure of 30cm H20 immediately after the delivery.
89546975|NCT03165305|No Intervention|No Intervention group|Includes routine neonatal care in the delivery room
89546976|NCT02547441|Experimental|Treatment|CLS001 (Omiganan) gel applied once daily
89546977|NCT02547441|Placebo Comparator|Vehicle Gel|Vehicle gel applied once daily
89546978|NCT05430009|Experimental|Arm 1|This is an open-label, single-arm, single center clinical trial to evaluate the feasibility of liver SBRT (up to 4 metastases) during the first cycle of physician's choice ICI for NSCLC.
89546979|NCT05429697|Experimental|Pembrolizumab+SMT-NK inj.|"Experimental:~Pembrolizumab + SMT-NK inj. Participants will be randomized to receive 200 mg pembrolizumab followed by 3*10^6cells/kg SMT-NK inj.~Interventions:~Drug: SMT-NK inj. Drug: Pembrolizumab"
89546980|NCT05429697|Placebo Comparator|Pembrolizumab|"Placebo Comparator: Pembrolizumb Participants will be randomized to receive 200 mg pembrolizumab.~Intervention:~Drug: Pembrolizumab"
89546981|NCT02540265|Experimental|N1539 30mg|N1539 (Intravenous meloxicam) 30mg every 24 hours for up to 3 doses.
89546982|NCT02540265|Experimental|N1539 60mg|N1539 (Intravenous meloxicam) 60mg every 24 hours for up to 3 doses.
89546983|NCT02540265|Placebo Comparator|IV Placebo|IV Placebo every 24 hours for up to 3 doses.
89546984|NCT02547363|Experimental|LEO 43204|Treatment once daily for 3 days
89546985|NCT02547363|Placebo Comparator|Vehicle gel|Treatment once daily for 3 days
89546986|NCT02539797|Experimental|tDCS anodal stimulation|anodal stimulation
89546987|NCT02539797|Active Comparator|tDCS cathodal stimulation|cathodal stimulation
89546988|NCT02539797|Sham Comparator|Sham stimulation|Sham stimulation. Termination of electrical stimulation following 30 seconds
89546989|NCT02684357|Placebo Comparator|Placebo (Part A)|Participants were randomized to receive double-blind (DB) placebo by subcutaneous (SC) injection at Weeks 0 and 4 (Part A).
89546990|NCT02684357|Active Comparator|Ustekinumab (Part A)|Participants randomized to receive double-blind (DB) ustekinumab 45 or 90 mg (based on screening weight) by subcutaneous (SC) injection at Weeks 0 and 4 (Part A).
89546991|NCT02684357|Experimental|Risankizumab (Part A)|Participants randomized to receive double-blind (DB) risankizumab 150 mg by subcutaneous (SC) injection at Weeks 0 and 4 (Part A).
89546992|NCT05586191|Experimental|Action Observation therapy at home|In action observation therapy, patient will not come to hospital for treatment. He will see a video at home in which therapist will perform different activities then patient will also perform the same movements.
88811999|NCT01395329|Placebo Comparator|Placebo|Systolic and Diastolic blood pressure will be measured before and after randomization to12 weeks of placebo. Forearm blood flow will be measured in response to 100 nmol/min of BQ-123, BQ-123+BQ788 (50 mol/min), Acetylcholine (4.0, 8.0, 16.0 ug/100 mL tissue/min), Sodium Nitroprusside (1.0, 2.0, 4.0 ug/100 mL tissue/min) and BQ-123+BQ-788+Acetylcholine (same doses as above) will be measured before and after the 12 weeks of placebo.
89546993|NCT05586191|Active Comparator|Action Observation therapy at hospital|In action observation therapy, patient will come to hospital for treatment. He will see a video in which therapist will perform different activities then patient will also perform the same movements.
89546994|NCT02684279|Experimental|Dasotraline|4, 6, 8 mg flexibly dosed
89546995|NCT05578703|Experimental|Gastric Fundic Ablation plus Endoscopic Sleeve Gastroplasty|Subjects will undergo fundic mucosal ablation followed by endoscopic sleeve gastroplasty
89546996|NCT03115073|Experimental|0,2% Candiplus|Candiplus® 0.2%
89546997|NCT03115073|Experimental|0,3% Candiplus|Candiplus® 0.3%
89546998|NCT03115073|Experimental|0,4% Candiplus|Candiplus® 0.4%
89546999|NCT03115073|Active Comparator|Clotri mono|Clotrimazole mono
89547000|NCT03166163|Experimental|Azadirachta indica (Neem extract)|its herbal mouthwash that will be given to a group a Egyptian children twice a day(10 ml each) for 3 weeks
89547001|NCT03166163|Active Comparator|chlorhexidine mouthwash|its an antimoicrobial, antiplaque mouthwash that will be given to a group of Egyptian children twice daily(10 ml each) for 3 weeks
89547002|NCT03165929|Active Comparator|flurbiprofen-free gingival graft|
89547003|NCT03165929|Placebo Comparator|placebo-free gingival graft|
89547004|NCT03165929|Active Comparator|flurbiprofen-connective tissue graft|
89547005|NCT03165929|Placebo Comparator|placebo-connective tissue graft|
89547006|NCT03165773|Experimental|Oatmeal|87 grams oatmeal
89547007|NCT03165773|Active Comparator|Corn grits|67 grams corn grits
89547008|NCT03165695|Experimental|Ramelteon Arm|Ramelteon tablet 8 mg orally at 21:00 for 7 days or until discharge whichever comes first.
89547009|NCT03165695|Placebo Comparator|Placebo Arm|Sugar pill manufactured to mimic Ramelteon 8 mg tablet orally at 21:00 for 7 days or until discharge whichever comes first.
89547010|NCT02534493|Experimental|Carpal Tunnel Medical Device (CTMD)|Carpal Tunnel Tissue Manipulation Device (CTMD)
89547011|NCT02547129|Active Comparator|Static Antibiotic Spacer|Patient with prosthetic joint infection of their knee will have a two stage joint replacement surgery with the Static Antibiotic Spacer Surgical Implant being used to treat the joint infection until the second stage of surgery which will replace the joint after the infection is treated.
89547012|NCT02547129|Active Comparator|Articulating Antibiotic Spacer|Patient with prosthetic joint infection of their knee will have a two stage joint replacement surgery with the Articulating Antibiotic Spacer Surgical Implant being used to treat the joint infection until the second stage of surgery which will replace the joint after the infection is treated.
89547013|NCT05448729|Sham Comparator|Strain ratio Elastography EUS|The solid pancreatic lesion will be assessed by using strain ratio elastography EUS
89547014|NCT05448729|Active Comparator|Shear Wave Elastography EUS|The solid pancreatic lesion will be assessed by using shear wave elastography EUS
89547015|NCT04423653|Experimental|Tele-coaching group|This group will receive exercises videos, 2 sessions a week to be done on participant's own and the 3rd session will be live video conference session for training, supervision, and consultation purposes.
89547016|NCT04423653|Active Comparator|Self-monitored group|This group will receive exercises videos, 3 sessions a week to be done on participant's own with out any supervision.
89547017|NCT05446935|Other|HITOC|HITOC group contains all patients who undergo HIROC in this study.
89547018|NCT05465811|Experimental|Baseline|Before the intervention period, the following tests will be applied: SARC-F, Short Physical Performance Battery, hand-grip dynamometry, Geriatric Anxiety Inventory, Geriatric Depression Scale and Pittsburgh Sleep Quality Index.
89547019|NCT05465811|Experimental|Follow-up|After the intervention period, the following tests will be applied: SARC-F, Short Physical Performance Battery, hand-grip dynamometry, Geriatric Anxiety Inventory, Geriatric Depression Scale and Pittsburgh Sleep Quality Index.
89547020|NCT02419989||CF patients|Male and female subjects with CF age 6 years and older who meet diagnostic criteria for NTM disease through participation in the PREDICT (Part A) study who are being offered NTM treatment.
89547021|NCT02546193|Experimental|Outpatient Foley catheter (Randomized & Prospective)|"This arm reflects enrolled women who were (A) randomized to the outpatient Foley catheter group (RCT design) or (B) chose the outpatient Foley catheter group (Modified Prospective study design).~Participants underwent basic history review, fetal nonstress testing, ultrasound for presentation and amniotic fluid index, and cervical exams the evening before their scheduled induction in the Family Birth Center. A Foley catheter was placed for cervical ripening. After fetal monitoring, they were dismissed to home, to return to the Family Birth Center in the morning for continuation of their labor inductions in the inpatient setting."
88812000|NCT00882206|Experimental|Decitabine / Vorinostat|This is a therapeutic trial investigating the combination of decitabine 15 mg/m2 and vorinostat 230 mg/m2 (maximum daily dose not to exceed 400 mg) in relapsed/refractory ALL/LL patients prior to induction chemotherapy.
88812001|NCT00831272|Experimental|Naltrexone|50mg/day of naltrexone
88812002|NCT00831272|Placebo Comparator|Placebo|Placebo
88812003|NCT00831428||Scottish swimming team|
88812004|NCT00832130|Experimental|Manual Mini System|Treatment with experimental Manual Mini System
88812005|NCT00832130|Active Comparator|Warm Compress Therapy|Control group receiving warm compress therapy in first study phase and crossover Manual Mini System treatment in second study phase
89547022|NCT02546193|Active Comparator|Inpatient usual care (Randomized & Prospective)|"This arm reflects enrolled women who were (A) randomized to the inpatient usual care group (RCT design) or (B) chose the inpatient usual care group (Modified Prospective study design). No participants in the modified Prospective study design were accrued due to screen failure.~Participants presented to the Family Birth Center in the evening for their scheduled induction of labor. They underwent basic history review, fetal nonstress testing, ultrasound for presentation and amniotic fluid index, and cervical exam. Cervical ripening commenced with either a Foley catheter or vaginal misoprostol per the discretion of the managing obstetric team. They remained in the inpatient setting throughout their entire labor induction course."
89547023|NCT02538471|Experimental|Arm 1 - Study Drug & Radiation therapy|"Study Drug: Enrolled patients will receive 300 mg/day of LY2157299. LY2157299 will be administered as an oral drug tablet.~The study drug will be administered orally on a 28-day cycle (1 cycle=28 days), every 2 weeks, or 14 days on / 14 days off. Blood samples will be obtained at baseline, and weeks 2, 6 and 15 for immune monitoring.~Radiation therapy : Patients will receive Radiation therapy to a metastatic site at a dose of 7.5 Gy, given consecutively on days 1, 3 and 5, during Week 1 of their treatment."
89547024|NCT05465421|Active Comparator|socket preservation with platelet rich fibrin PRF alone the implant placement 3 months after|after extraction socket preservation will be done by using PRF only in the socket and closed the socket by flap advancement.
89547025|NCT05465421|Experimental|socket preservation with BMMNCs of bone marrow aspirated of maxillary tuberosity|after extraction socket preservation will be done by using bone marrow mononuclear cell layer seeded on PRF in the socket and close the socket by flap advancement
89547026|NCT01661595|Active Comparator|Sildenafil / Placebo|50 mg/day Sildenafil: (Other Name: Viagra, Revatio) for weeks 0-4. Placebo for weeks 5-8.
89547027|NCT01661595|Active Comparator|Tadalafil / Placebo|10 mg/day Tadalafil: (Other Name: Cialis, Adcirca) for weeks 0-4. Placebo for weeks 5-8.
89547028|NCT01661595|Active Comparator|Placebo / Sildenafil|Placebo for weeks 0-4. 50 mg/day Sildenafil: (Other Name: Viagra, Revatio) for weeks 5-8.
89547029|NCT01661595|Active Comparator|Placebo / Tadalafil|Placebo for weeks 0-4. 10 mg/day Tadalafil: (Other Name: Cialis, Adcirca) for weeks 5-8.
89547030|NCT02213133|Experimental|Cohort 1: Head and Neck-SCC|Participants with advanced squamous cell carcinoma (SCC) of head and neck, who had relapsed or had metastasis following chemotherapy, received a fixed dose of 60 milligram (mg) selinexor oral tablets twice weekly on Days 1 and 3 of a 28-day cycle (8 doses in 4 weeks) until disease progression or development of unacceptable toxicities. After completion of Cycle 2, for participants with absence of any grade 2 toxicity and thrombocytopenia (platelets less than [<] 100*10^9 per litre [/L]), dose may be increased to 80 mg selinexor oral tablets twice weekly as assessed by investigator in a 28-day cycle until disease progression or development of unacceptable toxicities.
89547031|NCT02213133|Experimental|Cohort 2: Lungs-SCC|Participants with advanced SCC of lungs, who had relapsed or had metastasis following chemotherapy, received a fixed dose of 60 mg selinexor oral tablets twice weekly on Days 1 and 3 of a 28-day cycle (8 doses in 4 weeks) until disease progression or development of unacceptable toxicities. After completion of Cycle 2, for participants with absence of any grade 2 toxicity and thrombocytopenia (platelets <100*10^9/L), dose may be increased to 80 mg selinexor oral tablets twice weekly as assessed by investigator in a 28-day cycle until disease progression or development of unacceptable toxicities.
89547032|NCT02213133|Experimental|Cohort 3: Esophagus-SCC|Participants with advanced SCC of esophagus, who had relapsed or had metastasis following chemotherapy, received a fixed dose of 60 mg selinexor oral tablets twice weekly on Days 1 and 3 of a 28-day cycle (8 doses in 4 weeks) until disease progression or development of unacceptable toxicities. After completion of Cycle 2, for participants with absence of any grade 2 toxicity and thrombocytopenia (platelets <100*10^9/L), dose may be increased to 80 mg selinexor oral tablets twice weekly as assessed by investigator in a 28-day cycle until disease progression or development of unacceptable toxicities.
89547033|NCT02684981||Cohort A - VKA to Pradaxa switcher|Patients with non-valvular atrial fibrillation (NVAF), currently on Vitamin K Antagonist (VKA) therapy, who are switched to Pradaxa.
89547034|NCT02684981||Cohort B - newly assigned to treatment|Newly diagnosed NVAF patients who are treated with VKA or Pradaxa (VKA : Pradaxa = 1:1).
89547035|NCT02146833|Experimental|Selinexor Dosing Regimen 1|80 mg twice weekly for 4 weeks (8 doses per 28-day cycle)
89547036|NCT02146833|Experimental|Selinexor Dosing Regimen 2|80 mg once weekly for 4 weeks (4 doses per 28-day cycle)
89547037|NCT02146833|Experimental|Selinexor Dosing Regimen 3|60 mg twice weekly for 2 weeks, then 1 week off (4 doses per 21-day cycle)
89547038|NCT05445999|Experimental|tES treatment|The stimulation type is cathode direct current stimulation and alternating current stimulation. The maximum stimulation current of a single channel is not more than 3mA. The frequency of electrical stimulation was 0-10Hz; DLPFC was preferentially selected for electrical stimulation, and other candidate brain regions were: orbitofrontal cortex premotor cortex, motor cortex, sensorimotor cortex, auditory cortex, posterior parietal cortex, and cerebellar cortex. The brain state changes caused by each stimulus parameter combination were compared with sleep state to determine the optimal stimulus parameters. Each cycle of stimulation was 2 weeks, once a night on weekdays, a total of 10 times
89547039|NCT04262661|Experimental|NNC0472-0147 Part 1|Part 1: Each cohort will consist of 8 healthy subjects - 6 subjects will receive a single subcutaneous (s.c., under the skin) dose of NNC0472-0147.
89547040|NCT04262661|Placebo Comparator|Placebo Part 1|Part 1: Each cohort will consist of 8 healthy subjects - 2 subjects will receive a single s.c. dose of placebo.
89547041|NCT04262661|Experimental|NNC0472-0147 Part 2|Part 2: Each cohort will consist of 12 subjects with T2DM. 9 subjects will receive once daily s.c. doses of NNC0472-0147 for 14 days
89547042|NCT04262661|Active Comparator|Insulin glargine Part 2|Part 2: Each cohort will consist of 12 subjects with T2DM - 3 subjects will receive once daily s.c. doses of insulin glargine for 14 days.
89547043|NCT02957097|Experimental|Medication - Gabapentin|Participants of this group will be administered either Gabapentin 900 milligram PO 2-3 hours prior to the surgical procedure.
88812006|NCT00885092|Other|FID 114675A / RepleniSH|FID 114675A in Period 1; RepleniSH in Period 2. Each solution was used for 7 days for cleaning, rinsing, conditioning, disinfecting, and storing silicone hydrogel contact lenses, per protocol-specified instructions. A new pair of silicone hydrogel contact lenses was dispensed at the start of each period and worn bilaterally on a daily wear basis.
89547044|NCT02957097|Placebo Comparator|Medication - Placebo|Participants of this group will be administered either Placebo PO 2-3 hours prior to the surgical procedure.
89547045|NCT02690207|Experimental|HZ/su Group|Subjects received Herpes Zoster subunit vaccine, administered intramuscularly (IM) in the deltoid of the non-dominant arm
89547046|NCT02689349|Experimental|Esteem Implant Prospective Subjects|Subjects followed through 1 year for both Safety and Efficacy endpoints
89547047|NCT02689349|Other|Esteem Implant Retrospective Chart Review Subjects|Subjects providing Safety-only endpoint data through retrospective chart review, to be added to Prospective Subjects' Safety data
89547048|NCT03165383|Active Comparator|Transversus Abdominis Plane (TAP) Block Group|Intervention - At the end of surgery Ultrasound guided Transversus Abdominis Plane block was given with 20 ml 0.25 % bupivacaine bolus and repeated every 8 hourly upto 24 hours.
89547049|NCT03165383|Placebo Comparator|Control Group (No TAP Block)|The Transversus Abdominis Plane Block was not performed. Intravenous PCA Morphine was given as rescue analgesic upto 24 hours.
89547050|NCT03114839|Experimental|Dietary Supplement: Lactobacillus casei strain Shirota (LcS)|
89547051|NCT03165539||Thoracic surgery patient|Pre-operatively, patients will have baseline cognitive assessment done using the Mini-mental status test and MOCA test. Intra-operatively patients' baseline cerebral saturation (%) will be measured, and continuously monitored throughout the procedure. Post-operatively, patients will be assessed for delirium using the CAM score.
89547052|NCT03162575|Experimental|Mindfulness-Based Cognitive Therapy|The intervention consists of 8 weekly sessions of MBCT. Each session will be administered in a group and will last 2.5 hours
89547053|NCT03162575|No Intervention|Waiting List Control|Patients assigned to the waiting list condition will receive no intervention for three months and afterwards will receive MBCT
89547054|NCT02679287|Experimental|Group A|"Order of intervention will be 1) SAP; 2) USS + SAP(d); 3) USS +CLC (d); 4) USS + SAP(d)~SAP=sensor-augmented pump only~USS+SAP (d)= Evening and Overnight Closed-Loop Control=SAP during day and CLC starting at dinner and continuing overnight~USS+CLC (d)= 24/7 Closed-Loop Control=24-hour Day and Night Closed Loop Control"
89547055|NCT02679287|Experimental|Group B|"Order of intervention will be 1)USS + SAP(d) ; 2)USS +CLC (d); 3) USS + SAP(d); 4) SAP~SAP=sensor-augmented pump only~USS+SAP (d)= Evening and Overnight Closed-Loop Control=SAP during day and CLC starting at dinner and continuing overnight~USS+CLC (d)= 24/7 Closed-Loop Control=24-hour Day and Night Closed Loop Control"
89547056|NCT05357261|Active Comparator|Daily home delivered meals|A lunch-time meal delivered to participants' homes five days per week with wellness check and socialization.
89547057|NCT05357261|Experimental|Frozen, Drop-shipped Meals|Ten frozen meals that are mailed to participants every two weeks.
89547058|NCT03162185|Experimental|Interventional group|Half of the participants (n = 30) will receive 20mg of the SSRI Escitalopram.
89547059|NCT03162185|Placebo Comparator|Control group|Half of the participants ( n= 30) will receive the placebo.
89547060|NCT03162029||study group|CBCT imaging of patients with end stage renal failure, undergoing hemo-dialysis
89547061|NCT03162029||control group|CBCT imaging of medically-free participants
89547062|NCT02544633|Experimental|Arm 1|MGCD265 in patients with MET activating mutations in tumor tissue
89547063|NCT02544633|Experimental|Arm 2|MGCD265 in patients with MET gene amplifications in tumor tissue
89547064|NCT02544633|Experimental|Arm 3|MGCD265 in patients with MET activating mutations in blood (circulating tumor DNA)
89547065|NCT02544633|Experimental|Arm 4|MGCD265 in patients with MET gene amplifications in blood (circulating tumor DNA)
89547066|NCT03162263|Experimental|Ekso training|All patients underwent twenty-four Ekso sessions, scheduled 3 times a week. Each session lasted about 1h, and included transferring into the device arranged on an office chair; donning, standing, walking, sitting, doffing; and transferring out of the exoskeleton.The user can stand up, sit down, and walk with help of a front-wheeled walker and with the exoskeleton attached to a ceiling rail tether. A physical therapist initially provides assistance to maintain the user's center of mass over the base of support to prevent falling.
89547067|NCT03162263|Active Comparator|Overground training|Conventional gait training overground; before the training 10 min lower limb muscular exercises and stretching were performed by the physiotherapist. The overground training had the same duration of the Ekso training.
89547068|NCT03161951||Neuroinfections|Patients with acute neuroinfections of bacterial and viral ethology.
89547069|NCT03161951||Intestinal Infectious Diseases|Patients with acute intestinal infectious diseases of bacterial and viral ethology.
89547070|NCT03161951||Control group|Control group of healthy persons
89547071|NCT02678351|Experimental|68Ga-PSMA PET/MRI|Patients receive 68Ga-PSMA-11 IV. Patients then undergo PET/MRI after 45 minutes of administration of radiopharmaceutical injection.
89547072|NCT03161717|Experimental|Epidural electrical stimulation (EES)|n=20
89547073|NCT03161717|Active Comparator|Loss of resistance (LOR)|n=20
89547074|NCT04440527|Experimental|Microshunt|Patients will be treated with Preserflo / Innfocus Microshunt (Santen Pharmaceutical Co., Ltd.).
89547075|NCT04440527|Active Comparator|Trabeculectomy|Patients will be treated with trabeculectomy.
89547076|NCT03161639|No Intervention|Operator 1|Perform the pulpectomies except the working length measurement
89547077|NCT03161639|No Intervention|Operator 2|Perform the electronic length measurement of the pulpectomies
89547078|NCT03161639|Active Comparator|Operator 3|Perform radiographic length measurement and final evaluation of the pulpectomies
89025136|NCT00439842|Experimental|HF group clinic appointments|HF group clinic appointments Heart failure multidisciplinary group clinic appointments (Arm 1 - HFcareGroup) includes 6 teaching sessions with patients led by nurse practitioner.
89547079|NCT05442099|Experimental|Iso-principle music playlist|Participants listen to the iso-principle music playlist for 30 minutes.
89547080|NCT05442099|Sham Comparator|Generic calm music playlist|Participants listen to the generic music playlist for 30 minutes.
89547081|NCT03161561|Other|capacity of primary phagocytes|capacity of primary phagocytes isolated from COPD patients' blood to carry out key host defence functions and compare these to similar cells isolated from age and sex-matched non-smokers or smokers without COPD as controls.
89547082|NCT05554289|Experimental|Experimental group|Conventional Treatment + Depression Auxiliary Intervention Treatment Software.A software used to treat depression, used frequently once a day.
89547083|NCT05554289|Placebo Comparator|control group|Conventional treatment + auxiliary intervention treatment software for depression (placebo software)
89547084|NCT03160937|Experimental|Manual therapy Foam|The subjects included rolled the foam roller down their quadriceps using short kneading-like motions until it was just above their patellae, and then rolled it back to its initial position in one fluid motion. The subjects repeated this motion for 1 min, rested for 30 s, and then repeated it again for 5 sets
89547085|NCT03160937|Active Comparator|Manual therapy Nerve|The subjects was positioned lying on his/her side with a pillow underside leg (without fully flexing it) and the cervical and thoracic spines flexed. The investigator flex the knee and the hip extended and then put it back to its initial position in one fluid motion. The subjects repeated this motion for 1 min, rested for 30 s, and then repeated it again for 5 sets
89547086|NCT02683187|Active Comparator|Sitagliptin|The infusion procedures performed during study visits 2 and 3 are identical except that the oral medicine Sitagliptin will only be administered at one of the two visits, with order of Sitagliptin administration determined at random by study staff. In this arm, Sitagliptin will be administered.
89547087|NCT02683187|Placebo Comparator|Non-Sitagliptin|The infusion procedures performed during study visits 2 and 3 are identical except that the oral medicine Sitagliptin will only be administered at one of the two visits, with order of Sitagliptin administration determined at random by study staff. In this arm, placebo will be administered
89547088|NCT05515601|Experimental|Mirikizumab Solution (Reference)|Mirikizumab administered subcutaneously (SC) via an autoinjector (AI) at 3 different injection sites (arm, thigh, and abdomen).
89547089|NCT05515601|Experimental|Mirikizumab Solution (Test)|Mirikizumab administered SC via an AI at 3 different injection sites (arm, thigh, and abdomen).
89547090|NCT02683109|Experimental|FDC of tiotropium + olodaterol|Fixed Dose Combination of tiotropium + olodaterol
89547091|NCT02683109|Active Comparator|Free combination tiotropium + olodaterol|
89547092|NCT02544321|Active Comparator|Bromocriptine QR|4 weeks of investigational drug Bromocriptine QR
89547093|NCT02544321|Placebo Comparator|Placebo|4 weeks of placebo
89547094|NCT05195723|Experimental|WP1122|"Each study group consists of 10 volunteers randomized in a 4:1 ratio to receive WP1122 or placebo. In the first part of the study (Single Ascending Dose [SAD]) in each group (up to 4), 8 volunteers will receive WP1122 and 2 volunteers will receive placebo, one time orally. A total of up to 40 volunteers will be enrolled into the SAD portion of the study.~The second part of the study (Multiple Ascending Dose [MAD]) will begin when the third group in the SAD part of the study has completed dosing. In this part of the study (MAD) in each group (up to 4), 8 volunteers will receive WP1122 and 2 volunteers will receive placebo, 2 times per day (12 hours apart) orally for 7 days. A total of up to 40 volunteers will be enrolled into the MAD portion of the study.~Up to 80 volunteers will be enrolled into the study entirely."
89547095|NCT05195723|Placebo Comparator|Placebo|"Each study group consists of 10 volunteers randomized in a 4:1 ratio to receive WP1122 or placebo. In the first part of the study (Single Ascending Dose [SAD]) in each group (up to 4), 8 volunteers will receive WP1122 and 2 volunteers will receive placebo, one time orally. A total of up to 40 volunteers will be enrolled into the SAD portion of the study.~The second part of the study (Multiple Ascending Dose [MAD]) will begin when the third group in the SAD part of the study has completed dosing. In this part of the study (MAD) in each group (up to 4), 8 volunteers will receive WP1122 and 2 volunteers will receive placebo, 2 times per day (12 hours apart) orally for 7 days. A total of up to 40 volunteers will be enrolled into the MAD portion of the study.~Up to 80 volunteers will be enrolled into the study entirely."
89547096|NCT02533401|Experimental|Rituximab + Fludarabine + Cyclophosphamide|Participants will receive rituximab (375 milligrams per meter-squared [mg/m^2] intravenously [IV]) on Cycle 1 Day 1, followed by fludarabine (25 mg/m^2 once daily IV) and cyclophosphamide (250 mg/m^2 once daily IV) for Days 2 to 4 of Cycle 1. Then rituximab (500 mg/m^2 IV) will be administered on Day 1 of Cycles 2 to 6, followed by IV fludarabine (25 mg/m^2 once daily IV) and cyclophosphamide (250 mg/m^2 once daily IV) on Days 1 to 3 of Cycles 2 to 6. Each cycle will be 28 days or 4 weeks in length, and the overall duration of treatment will be approximately 6 months.
89547097|NCT05497037|Sham Comparator|Sham Control Group|Subject receiving fake stimulation (no stimulation but same device procedure with PRF group)
89547098|NCT05497037|Active Comparator|PRF Group|Subject receiving 500 KHz PRF stimulation for 15 min
89547099|NCT05441709|No Intervention|Standard of care|Standard lactation care is provided by postpartum RNs on the inpatient unit and RNs who are board certified in lactation (IBCLCs).Postpartum RNs provide support to all patients post delivery with direct breastfeeding, breast pump use, and addressing routine breastfeeding concerns. IBCLCs provide direct lactation care for more complicated lactation problems and is delivered in a dosed manner based on the nature of the lactation problem, with low-risk patients often having no encounters.
89547100|NCT05441709|Active Comparator|ci-BPC with Standard of Care|"In addtion to normal standard of care (as described above), patients will also receive clinically-integrated breastfeeding peer counseling (ci-BPC) from a Peer Counselor at four timepoints throughout the perinatal period. The encounters will take place either in person or virtually and include: an intake encounter between 2- and 30 weeks gestation, a dedicated prenatal infant feeding education encounter, at least one inpatient encounter post-delivery during the delivery admission, and at least one postpartum encounter. Patients will also have access to a warmline that will include phone follow up by the next business day."
89547101|NCT03164837|Experimental|68Ga-NOTA-RM26 PET/CT|The patients were injected with 111-148 MBq of 68Ga-NOTA-RM26 in one dose intravenously and underwent PET/CT scan 15-30 min later.
89547102|NCT02370927|Placebo Comparator|Control|100% Wheat Flour
89547103|NCT02370927|Experimental|Cereal w/ pea protein|Pea protein
89547104|NCT02370927|Experimental|Cereal w/ pea starch|Pea starch
89547105|NCT02370927|Experimental|Cereal w/ pea starch + pea fibre|Pea starch + pea fibre: 5g
89547106|NCT02370927|Experimental|Cereal w/ pea protein + pea starch|Pea protein + pea starch: 10g
89547107|NCT02370927|Experimental|Cereal w/ pea protein + pea fibre + pea starch:|Pea protein + pea fibre + pea starch: 20g
89547108|NCT05441475|Experimental|ABSK-011 180 mg QD combined with atilizumab 1200 mg q3w.|During part a, all subjects will receive continuous oral administration of absk-011 once a day (QD) or twice a day (bid) with an initial dose of 180 mg, and intravenous infusion (IV) of 1200 mg of atilizumab every 21 days (q3w). After the first subject (sentinel subject) in each dose cohort completed the first combined medication, follow-up subjects were administered at least 7 days later
89547109|NCT03164915|Experimental|LIV-GAMMA SN Inj.|
88961646|NCT05280665||The specialized group|"Patients who were operated by a specialized gastric cancer surgeon. Specialized gastric cancer surgeons were defined as surgeons who meet all of the criteria for a specialized gastric cancer surgeon.~Who had undergone professional training in gastric cancer surgery in specialized gastric cancer centers (in Japan or Korea),~Who identified themselves as primarily gastric surgeons during the study period~Whose annual gastric cancer surgery volume is more than 21"
89547110|NCT04440137|No Intervention|Control Group|Mother of children will receive a brochure with a standard of care info (with only essential information regarding the harmful effect of bottle feeding) and kid toothbrush and toothpaste (1000ppm of fluoride).
89547111|NCT04440137|Experimental|Intervention group|Mother of the children will be provided with intervention brochure (which include detailed information regarding the harmful effect of bottle feeding), kid toothbrush and toothpaste (1000ppm of fluoride) and a sippy cup.
89547112|NCT04777565|Experimental|CI surgery|cochlear implant surgery
89547113|NCT02536833|Experimental|0.03 mg SM04690|Single intra-articular injection of SM04690 0.03 mg in 2 mL injectable suspension
89547114|NCT02536833|Experimental|0.07 mg SM04690|Single intra-articular injection of SM04690 0.07 mg in 2 mL injectable suspension
89547115|NCT02536833|Experimental|0.23 mg SM04690|Single intra-articular injection of SM04690 0.23 mg in 2 mL injectable suspension
89547116|NCT02536833|Placebo Comparator|Placebo|Single intra-articular injection of SM04690 0 mg in 2 mL phosphate buffered saline
89547117|NCT02680847|Experimental|ALO-02|One arm, open label, active
89547118|NCT03164603|Experimental|NLG8021 Dose Escalation|Approximately 6 to 36 participants will be enrolled and treated at escalating doses of NLG802. Treatment may continue until unacceptable toxicity or disease progression. Successive groups of at least 3 participants will be evaluated during a 28-day window for DLTs, which will determine the enrollment and dosing for subsequent cohorts in the dose-escalation stage.
89547119|NCT05146973|Experimental|Single administration of 177Lu-DOTA-TLX591|Two single IV infusions of 76 mCi (2.8 GBq) each (equivalent to a 45 mCi/m2 administered activity in a standard 1.7m2 individual) of 177Lu-DOTA-TLX591, given 14 days apart.
89547120|NCT03164213|Experimental|Experimental tDCS|TDCS stimulation at the left M1 region followed by naming therapy. The intervention will be given daily for duration of two weeks (5 days/week).
89547121|NCT03164213|Sham Comparator|sham tDCS|Sham tDCS at the left M1 region followed by naming therapy. The intervention will be given daily for duration of two weeks (5 days/week).
89547122|NCT02532855|Experimental|Sitagliptin|Participants receive sitagliptin 100 mg once daily plus matching placebo for dapagliflozin 5 mg once daily for 4 weeks followed by sitagliptin 100 mg once daily plus matching placebo for dapagliflozin 10 mg once daily for 20 weeks. Participants continue pre-study metformin (at least 1500 mg daily) alone or in combination with a sulfonylurea agent (at a dose of ≥ 50% maximum labeled dose in the country of the investigational site) throughout the duration of the study.
89547123|NCT02532855|Active Comparator|Dapagliflozin|Participants receive dapagliflozin 5 mg once daily plus matching placebo for sitagliptin 100 mg once daily for 4 weeks followed by dapagliflozin 10 mg once daily plus matching placebo for sitagliptin 100 mg once daily for 20 weeks. Participants continue pre-study metformin (at least 1500 mg daily) alone or in combination with a sulfonylurea agent (at a dose of ≥ 50% maximum labeled dose in the country of the investigational site) throughout the duration of the study.
89517312|NCT04143711|Experimental|Monotherapy DF1001 Expansion in Cancers with Erbb2 Amplification|Monotherapy expansion cohort enrolling up to 40 patients with solid tumors showing documented erbb2 amplification using the recommended phase 2 dose (RP2D) identified in the Monotherapy Dose Escalation arm.
89547124|NCT05438667|Experimental|TCR-T treatment group|Within 3 - 5 days after pretreatment, subjects will receive a single TCR-T infusion with an infusion dose of about 1 × 10⁹～1 × 10¹⁰.Once every 12 hours within 24 hours after TCR-T cell infusion, recombinant human interleukin-2 will be injected intravenously for 14 days .After 3 months of treatment, the patient's condition was evaluated. If the subject did not occur tumor progression and did not occur adverse events (AEs) of level 3 or higher, a second TCR-T cell reinfusion can be performed .
89547125|NCT04262427|Experimental|Single Group Assignment|Cyclophosphamide 50mg PO OD for 3 weeks as monotherapy followed by cyclophosphamide 50mg PO OD with pembrolizumab 200mg IV every 3 weeks
89547126|NCT04262349|Experimental|intervention|"Every week because of differences in the number of pregnant women who attended the school participating women were divided into two groups using a random number table created in the program via the computer itself. The purpose of the study was explained to pregnant women, informed consent form and data collection tools of the study were collected by face to face interview technique. In the first interview to all pregnant women; Personal Information Form, Course Information Form, Pittshburg Sleep Quality Index (PUKI) and General Self-Efficacy Scale were applied. Pregnant women in the intervention group were given a two-session training program to improve sleep quality and Sleep Guide and Safe Baby Sleep Conditions Brochure."
88961647|NCT05271682|Experimental|Part 1: 0.4 mg|FHND6091, 0.4 mg, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period
89207933|NCT00793208|Experimental|Vaccine|vaccine composed of lethally irradiated semi-allogeneic human fibroblasts transfected with genomic tumor DNA from the patient's own tumor
89517313|NCT04143711|Experimental|Combination Therapy with DF1001 and Nivolumab|Combination dose escalation of DF1001 in combination with nivolumab in patients with select solid tumors.
89517314|NCT04143711|Experimental|Combination Therapy with DF1001 and Nab-paclitaxel|Combination dose escalation of DF1001 in combination with nab-paclitaxel in patients with select solid tumors.
89517315|NCT04143711|Experimental|Combination Therapy with DF1001 and Nivolumab Safety/PK/PD Expansion|Expansion cohort of DF1001 in combination with nivolumab after evaluation for safety in the Combination Therapy with DF1001 and nivolumab Dose Escalation arm. Additional pharmacokinetic (PK) and pharmacodynamic (PD) samples included in this arm.
88961648|NCT05271682|Experimental|Part 1: 0.8 mg|FHND6091, 0.8 mg, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period
89547127|NCT04262349|No Intervention|control|"Pregnant women in the control group were subjected to routine practice without any training given by the researcher. Four weeks after the completion of the sleep training, all pregnant women were contacted by telephone and the data collection tools were applied for the second time and the final test applications were completed. After completion of the data collection process made a new plan for training to improve the quality of sleep to pregnant women in the control group and the Sleep Guide and Safe Baby Sleep Conditions Brochure is given."
89547128|NCT02530125|Experimental|Treatment (pidilizumab)|Patients receive pidilizumab IV over approximately 5 hours on day 1. Treatment repeats every 42 days for 3 courses in the absence of disease progression or unacceptable toxicity.
89547129|NCT05436873|Experimental|Treatment Arm|This is a single arm study
89547130|NCT05421585|Active Comparator|QL2 block|Posterior QLB process After aseptic conditions are provided, the convex US probe will be covered with a sterile sheath, and an 80-100 mm block needle will be used. After imaging the abdominal muscles with the anterior approach, the needle will be advanced in the Petit triangle and 1-2 ml of saline will be injected into the posterior border of the quadratus lumborum muscle. After the block location is confirmed, 20 ml of local anesthetic infiltration at a concentration of 0.25% will be applied. The same procedure will be applied to the other side. A total of 30 ml of local anesthetic solution will be used.
89547131|NCT05421585|Active Comparator|TLIP block|Classic TLIP block After providing aseptic conditions, the high frequency linear US probe will be covered with a sterile sheath, and a 50 mm block needle will be used. The ultrasound probe will be placed vertically at the level of the L3 vertebra. After visualizing the guiding point spinous process and interspinal muscles, the probe will be moved laterally to visualize the longissimus and multifidus muscles. By using the in-plane technique, the block needle will be directed from medial to lateral, and after reaching the interfacial area between the longissimus and multifidus muscles, the block area will be confirmed by administering 5 ml of serum physiologically. Then, 20 ml of 0.25% local anesthetic will be administered. The same procedure will be applied to the other side. A total of 40 ml of local anesthetic solution will be used.
89547132|NCT01661205|Experimental|AtriCure Bipolar System combined with a catheter ablation|Minimally invasive procedure using the AtriCure Bipolar System plus a catheter ablation performed approximately 1-10 days apart
89547133|NCT05436171||All deliveries conducted from 2011 to 2021 in Prince of Wales Hospital|"All deliveries conducted from 2011 to 2021 in Prince of Wales Hospital~The target sample size will be about 67,000 women who had delivered in our unit from 2011 to 2021. Among them, it is expected that 75-80% had vaginal deliveries, either normal vaginal delivery or instrumental delivery. 53,600 will be recruited in study site."
89547134|NCT02055820|Experimental|Venetoclax + G-CHOP Arm|Phase I: Participants will receive 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle will consist of 21 days. Phase II: Participants will receive 6 cycles of CHOP and 8 cycles of venetoclax (at dose determined in Phase I) + obinutuzumab. Each cycle will consist of 21 days. For both phase I and II, participants with ongoing response without excessive toxicity may receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
89547135|NCT02055820|Experimental|Venetoclax + R-CHOP Arm|Phase I: Participants will receive 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle will consist of 21 days. Phase II: Participants will receive 6 cycles of CHOP and 8 cycles of venetoclax (at dose determined in Phase I) + rituximab. Each cycle will consist of 21 days. For both phase I and II, participants with ongoing response without excessive toxicity may receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
89547136|NCT04258215|Experimental|Positive pressure achieved with PSA|Maximum airway inflation pressure achievable before a significant leak occurs.
89547137|NCT01975233||WEB Aneurysm Embolization System|Subjects aged ≥ 18 years, but ≤ 75 years requiring treatment for intracranial aneurysms.
89547138|NCT02055352|Experimental|Budesonide/indacaterol|Participants will receive a fixed combination of fluticasone and salmeterol during 4 weeks followed by a free combination of budesonide and indacaterol for the remainig of study.
89547139|NCT02055352|Active Comparator|Fluticasone / salmeterol|Fixed combination of fluticasone and salmeterol
89547140|NCT02034916|Experimental|talazoparib|"Cohort 1) Subjects with a documented PR or CR to a prior platinum-containing regimen for metastatic disease with disease progression > 8 weeks following the last dose of platinum~Cohort 2) Subjects who have received > 2 prior chemotherapy regimens for metastatic disease and who have had no prior platinum therapy for metastatic disease"
89547141|NCT01374425|Experimental|Bevacizumab + mFOLFOX6|Participants will receive bevacizumab plus mFOLFOX6 by intravenous (IV) infusion on Day 1 of each 2-week cycle until disease progression or unacceptable toxicity. Participants may be transitioned to oral capecitabine in the event of unacceptable toxicity to oxaliplatin, with bevacizumab continued in 3-week cycles.
89547142|NCT01374425|Experimental|Bevacizumab + FOLFIRI|Participants will receive bevacizumab plus FOLFIRI by IV infusion on Day 1 of each 2-week cycle until disease progression or unacceptable toxicity. Participants may be transitioned to oral capecitabine in the event of unacceptable toxicity to irinotecan, with bevacizumab continued in 3-week cycles.
89547143|NCT03161015|Experimental|GBT440 Dose 1: Severe Renal Impairment|eGFR < 30 mL/min/1.73m2, not on dialysis
89547144|NCT03161015|Experimental|GBT440 Dose 1: Moderate Renal Impairment|30 mL/min/1.73m2 = or < eGFR < 60 mL/min/1.73m2
89547145|NCT03161015|Experimental|GBT440 Dose 1: Mild Renal Impairment|60 mL/min/1.73m2 = or < eGFR < 90 mL/min/1.73m2
89547146|NCT03161015|Experimental|GBT440 Dose 1: Normal Renal function|eGFR > or = 90 mL/min/1.73m2
89547147|NCT02085460|Placebo Comparator|Placebo|6 times daily
89547148|NCT02085460|Experimental|2% Rebamipide liquid|6 times daily
89547149|NCT02085460|Experimental|4% Rebamipide liquid|6 times daily
88961649|NCT05271682|Experimental|Part 1: 1.4 mg|FHND6091, 1.4 mg, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period
88961650|NCT05271682|Experimental|Part 1: 2.0 mg|FHND6091, 2.0 mg, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period
88961651|NCT05271682|Experimental|Part 1: 2.8 mg|FHND6091, 2.8 mg, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period
88961652|NCT05271682|Experimental|Part 1: 3.6 mg|FHND6091, 3.6 mg, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period
89547150|NCT03164291|Experimental|Rifabutin|Treatment of adults with chronic Mycobacterium avium-intracellulare complex lung infections or other NTM disease who fail therapy with other drugs ( i.e., rifampin)
89547151|NCT02084134|Active Comparator|steroid treatment arm|Receives intravenous hydrocortisone 100mg and following surgery intravenous dexamethasone 0.5mg
89547152|NCT02084134|No Intervention|non-steroid treatment|Subjects will not receive any steroids at the time of surgery or after surgery unless symptoms of adrenal insufficiency develop (i.e. nausea, vomiting, dizziness, or low blood pressure).
89547153|NCT03164135|Experimental|CCR5 gene modification|CD34+ hematopoietic stem/progenitor cells from donor are treated with CRISPR/Cas9 before transplantation into the patient.
88961653|NCT05271682|Experimental|Part 2: lower dose expansion|FHND6091, a lower dose, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period
88961654|NCT05271682|Experimental|Part 2: MTD pr MTD-1 dose expansion|FHND6091, MTD or MTD-1 dose, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period
89547154|NCT03163901|Active Comparator|Treatment groups|To recruit and organize patients with TBI enrolled in a standard rehabilitation program into three groups ((a) treatment group receiving OMT; (b) control group A receiving sham treatment; and (c) control group B receiving neither OMT nor sham treatment) in order to assess the feasibility and adherence to the protocol and determine participation and attrition rates in preparation for a larger study.
89547155|NCT03163901|Other|Effect of OMT on clinical outcome measures|Clinical outcome measures including Neurocom Balance Manager assessments (Modified Clinical Test of Sensory Interaction and Balance; Stability Evaluation Test; Rhythmic Weight Shift; Limits of Stability), Vestibular Oculomotor Screen, Motion Sensitivity Test, as well as questionnaires such as the Headache Impact Test (HIT-6), Dizziness Handicap Inventory, and the more general quality of life measures (dressing; bathing; medication management, etc. as assessed by the SF 36 QOL questionnaire).
89547156|NCT03163901|No Intervention|Anti-inflammatory Biomarkers|to analyze urine and plasma samples collected from the three groups of participants: urine and plasma samples one hour before, plasma samples one hour after and 48 hours after treatment for alterations in the levels of low molecular weight compounds or protein components to identify potential biomarkers that may correlate with the TBI condition and/or the OMT.
89547157|NCT03163901|No Intervention|Infrastructure development|to establish the infrastructure for the recording, management, and extraction of clinical data and to estimate effect sizes and variability in key outcome measures so that a larger, longer term study can be planned with sufficient statistical power to identify significant results.
89547158|NCT02034058|Other|Wingspan Stent System|Placement of the Wingspan Stent
89547159|NCT01374269|Experimental|Excercise|One group will be assigned to protocolized back pain exercise, three times a week for 4 weeks. This program is carried out by physiotherapists from participating institutions who wish to participate in research and who will be given a training which will standardize the intervention programs Exercise program includes: physical agents, massage of myofascial points, stretching and strengthening exercises, cycloergometer or band aerobic exercises. Treatment, type of exercises, exercise tolerance and adverse reactions will be registered
89547160|NCT01374269|Active Comparator|NSAID|Naproxen 500 mg per day by 10 days or Celecoxib 200 mg per day by 10 days and Acetaminophen 1,5 a 2 g as rescue
89547161|NCT03163823|Placebo Comparator|Standard Communication|Standard of Care communication styles will be used. Patients will receive the standard communication protocol identified by the hospital.
89547162|NCT03163823|Experimental|iPad with Speech App|Use of application Proloquo2Go on iPad device. The application being used is called Proloquo2Go which is the intervention portion. The iPad is the device used to access the application.
89547163|NCT03163979|Active Comparator|PET/CT and Comet assay guided IMRT|18F-FDG PET/CT and Comet assay guide IMRT Based on FDG-PET/CT and comet analysis, higher doses of irradiation can be delivered to low sensitivity tumor region, so as to achieve individualized treatment.
89547164|NCT03163979|Active Comparator|PET/CT and Comet assay guided RapidArc|"18F-FDG PET/CT and Comet assay guide RapidArc:~1.A Rapid-Arc plan for cancer of the cervix uteri improved the sparing of organs at risk (OARs) with uncompromised target coverage. 2.Based on FDG-PET/CT and comet analysis, higher doses of irradiation can be delivered to low sensitivity tumor region, so as to achieve individualized treatment."
89547165|NCT03163979|Active Comparator|RapidArc|"RapidArc:~A maximum DR of 600 MU/min was set for comparing the 7f-IMRT treatment time. Two 360° coplanar arcs (one clockwise arc rotated from 181° to 179° and the other counter-clockwise arc rotated from 179° to 181°) sharing the same isocentre were used."
89547166|NCT03163979|Sham Comparator|7f-IMRT|seventy-five patients received IMRT. The 7f-IMRT gantry angles were 0°, 51°, 102°, 153°, 204°, 255° and 306°, with 20 intensity levels and a dose rate of 400 monitor units (MU)/min. Doses were delivered using the step-and-shoot method.Conventional fractionation was used in all patients for a total dose 45-50.4 Gy with 6 MV high-energy photons.
89547167|NCT03114761|Experimental|CTA-IH|
89547168|NCT03114605|Experimental|Mindfulness|Mindfulness-based Intervention (8 sessions - 2 hours each- 1 session/week)
89547169|NCT03114605|No Intervention|Control|Waiting List
89547170|NCT03160781|Experimental|Platelet Rich Plasma|Combination of Intraarticular and Intraosseous Administraion of Platelet Rich Plasma
89547171|NCT03163745||Asymptomatic spontaneous bacterial peritonitis|"All the included patients will be subjected to:~Full medical History and physical examination~Laboratory investigations: Complete blood picture , kidney function tests, liver function tests ,prothrombin time and concentration~Abdominal Ultrasound~Ascitic fluid paracentesis will be done to test for total leucocyte count and polymorphonuclear count , total protein and albumin levels. Testing for cytological analysis and culture will be done."
89547172|NCT03163589|Experimental|study group|Within 4 to 6 hours after birth all cases with moderate to severe hypoxic ischemic encephalopathy will be enrolled in therapeutic hypothermia using total body cooling and temperature and Receive erythropoietin (1000 U/kg intravenously) on days 1, 2, 3, 5 ,7 and 9 (six doses,first two doses will be daily from the first day and last 4 doses will be every 2 days)
89547173|NCT03163589|Placebo Comparator|control group|Within 4 to 6 hours after birth cases with moderate to severe hypoxic ischemic encephalopathy enrolled in therapeutic hypothermia using total body cooling and temperature and Receive normal saline on days 1, 2, 3, 5 ,7 and 9 (six doses,first two doses will be daily from the first day and last 4 doses will be every 2 days)
89547174|NCT03163277|No Intervention|Standard of care|Continue current antiretroviral regimen
89547175|NCT03163277|Experimental|Reduced Neurotoxicity Arm|Emtricitabine plus darunavir/cobicistat plus maraviroc
89547176|NCT05419817|Experimental|Pembrolizumab + Sitravatinib|Standard of care pembrolizumab 200 mg IV combined with oral sitravatinib 100 mg oral QD every 21 days until disease progression, unacceptable toxicities or complete response.
89547177|NCT03160625|Active Comparator|Rate Adaptive Pacing ON|The Rate Adaptive Pacing (RAP) feature in the Medtronic implantable pulse generator (IPG) will be programmed to level 4 (More Active Lifestyle) with ADL rate of 95 bpm or higher, and Upper sensor rate that is subject's age predicted maximum heart rate. The age predicted maximum heart rate (APMHR) will be computed as: APHMR = 220 - age
89547178|NCT03160625|Active Comparator|Rate Adaptive Pacing OFF|The Rate Adaptive Pacing (RAP) feature in the Medtronic implantable pulse generator (IPG) will be turned off for this arm of the study.
89547179|NCT03160391|Experimental|Music Training|Music Training
89547180|NCT03160391|Active Comparator|Dance Training|Dance Training
89547181|NCT03160391|No Intervention|Passive control group|Passive control group
89547182|NCT03163355|Active Comparator|pureed rice with a gelling agent|3 ml of pureed rice containing a gelling agent is attempted to swallow under endoscopic examination of swallowing
89547183|NCT03163355|Placebo Comparator|standard pureed rice|3 ml of standard pureed rice is attempted to swallow under endoscopic examination of swallowing
89547184|NCT03163433|Experimental|Feedback in the consultation|Feedback in the consultation is the intervention. Patients complete PROM before each consultation and take part in a dialogue about the results with their physician.
89547185|NCT03163433|No Intervention|Control|Usual consultations
89547186|NCT05392205|Experimental|68Ga-FAP-2286|Each subject receives a single intravenous injection of 18F-FDG and 68Ga-FAP-2286, and undergo PET/CT imaging within the specified time.
89547187|NCT02679755|Experimental|Experimental arm|Palbociclib plus Letrozole
89547188|NCT05676671|Experimental|Self-etching adhesive Clearfil SE Bond|Group 1 received treatment with Clearfil SE Bond after selective caries removal
89547189|NCT05676671|Experimental|Self-etching adhesiveClearfil SE Protect containing MDPB|Group 2 received treatment with Clearfil SE Protect containing MDPB after selective caries removal
89547190|NCT05231759||Navigable Percutaneous Plasma Disc Decompression (L'DISQ)|The L'DISQ (U&I Co., Uijeongbu, Korea) is one of the minimally invasive disc decompression procedures which was introduced in 2011. The L'DISQ uses a navigable tip and flexible handle allowing resection of the posterolateral or posterior median disc tissue without thermal damage.
89547191|NCT03163121|Experimental|Group 1 - PfSPZ-GA1 Vaccine|"Group 1 will comprise of 3 volunteers who will receive one immunization of 1.35 x 10^5 PfSPZ of PfSPZ-GA1 Vaccine via DVI.~Volunteers will be followed closely for monitoring of adverse events and possible breakthrough blood infections by testing for the presence of parasitemia by qPCR. All volunteers will be treated with a curative regimen of atovaquone/proguanil (A/P) should break-through parasites be detected in the peripheral blood, or at the end of the follow-up period (28 days) if they are not qPCR positive. Six months after the inoculation, a final visit will take place to assess adverse events."
89547192|NCT03163121|Experimental|Group 2 - PfSPZ-GA1 Vaccine|"Group 2 will comprise of 3 volunteers who will receive one immunization of 4.5 x 10^5 PfSPZ of PfSPZ-GA1 Vaccine via DVI.~Volunteers will be followed closely for monitoring of adverse events and possible breakthrough blood infections by testing for the presence of parasitemia by qPCR. All volunteers will be treated with a curative regimen of atovaquone/proguanil (A/P) should break-through parasites be detected in the peripheral blood, or at the end of the follow-up period (28 days) if they are not qPCR positive. Six months after the inoculation, a final visit will take place to assess adverse events."
89547193|NCT03163121|Experimental|Group 3 - PfSPZ-GA1 Vaccine|"Group 3 will comprise of 13 volunteers who will receive one immunization of 9.0 x 10^5 PfSPZ of PfSPZ-GA1 Vaccine via DVI.~Volunteers will be followed closely for monitoring of adverse events and possible breakthrough blood infections by testing for the presence of parasitemia by qPCR. All volunteers will be treated with a curative regimen of atovaquone/proguanil (A/P) should break-through parasites be detected in the peripheral blood, or at the end of the follow-up period (28 days) if they are not qPCR positive. Six months after the inoculation, a final visit will take place to assess adverse events."
89547194|NCT03163121|Experimental|Group 4 - PfSPZ-GA1 Vaccine|"Group 4 will comprise of 13 volunteers who will receive 3 immunizations of 9.0 x 10^5 PfSPZ of PfSPZ-GA1 Vaccine 8 weeks apart via DVI.~3 weeks after the last injection, volunteers will undergo mosquito-bite CHMI with five NF54-infected mosquitoes. After CHMI, volunteers will be followed closely for monitoring of adverse events and blood stage infections, and will be seen once daily from day 6 until day 21 after infection and on day 28. All volunteers will be treated with a curative regimen of antimalarials, which may be A/P or artemether/lumefantrine, at the time of detection of blood stage parasitemia by qPCR or 28 days after CHMI. Adverse events will be assessed up to 6 months after the CHMI."
89547195|NCT03163121|Experimental|Group 5 - PfSPZ-GA1 Vaccine|"Group 5 will comprise of 13 volunteers who will receive 3 immunizations of 4.5 x 10^5 PfSPZ of PfSPZ-GA1 Vaccine 8 weeks apart via DVI.~3 weeks after the last injection, volunteers will undergo mosquito-bite CHMI with five NF54-infected mosquitoes. After CHMI, volunteers will be followed closely for monitoring of adverse events and blood stage infections, and will be seen once daily from day 6 until day 21 after infection and on day 28. All volunteers will be treated with a curative regimen of antimalarials, which may be A/P or artemether/lumefantrine, at the time of detection of blood stage parasitemia by qPCR or 28 days after CHMI. Adverse events will be assessed up to 6 months after the CHMI."
89547196|NCT03163121|Experimental|Group 6 - PfSPZ Vaccine|"Group 6 will comprise of 13 volunteers who will receive 3 immunizations of 4.5 x 10^5 PfSPZ of PfSPZ Vaccine 8 weeks apart via DVI.~3 weeks after the last injection, volunteers will undergo mosquito-bite CHMI with five NF54-infected mosquitoes. After CHMI, volunteers will be followed closely for monitoring of adverse events and blood stage infections, and will be seen once daily from day 6 until day 21 after infection and on day 28. All volunteers will be treated with a curative regimen of antimalarials, which may be A/P or artemether/lumefantrine, at the time of detection of blood stage parasitemia by qPCR or 28 days after CHMI. Adverse events will be assessed up to 6 months after the CHMI."
88961656|NCT05234125|Active Comparator|Intervention arm|Sleep hygiene practices and cognitive-behavioral principles
88961657|NCT05234125|Placebo Comparator|Attention control|Training about pregnancy issues
89547197|NCT03163121|Placebo Comparator|Group 7 - Normal Saline Placebo control|"Group 7 will comprise of 9 volunteers who will receive 3 injections of normal saline placebo 8 weeks apart via DVI.~3 weeks after the last injection, volunteers will undergo mosquito-bite CHMI with five NF54-infected mosquitoes. After CHMI, volunteers will be followed closely for monitoring of adverse events and blood stage infections, and will be seen once daily from day 6 until day 21 after infection and on day 28. All volunteers will be treated with a curative regimen of antimalarials, which may be A/P or artemether/lumefantrine, at the time of detection of blood stage parasitemia by qPCR or 28 days after CHMI. Adverse events will be assessed up to 6 months after the CHMI."
89547198|NCT03114449|Experimental|Auricular acupuncture|Auricular acupuncture (AA) with indwelling fixed needles at specific AA points
89547199|NCT03114449|Sham Comparator|Sham auricular acupuncture|Sham auricular acupuncture with indwelling fixed needles at non- AA points
89547200|NCT03114293|No Intervention|Waiting group|Waiting group
89547201|NCT03114293|Experimental|Smartphone intervention|Smartphone bases behavioural intervention
89547202|NCT03114371|Experimental|Oxytocin|Daily intranasal administrations of oxytocin for 12 weeks, followed by an open-label period of 12 weeks of oxytocin. Oxytocin dose will be 8 International Unit for patients aged from 3 to 6 years and 16 International Unit for patients aged from 7 to 12 years.
89547203|NCT03114371|Placebo Comparator|Placebo|Daily intranasal administrations of placebo for 12 weeks, followed by an open-label period of 12 weeks of oxytocin. Oxytocin dose will be International Unit for patients aged from 3 to 6 years and 16 International Unit for patients aged from 7 to 12 years.
89547204|NCT03162887|Experimental|Screening (education module, counseling)|"Participants receive a research team member-led breast cancer and mammogram educational module and undergo a web-based decision counseling session over 2 hours. Participants then receive a next steps document and may undergo an interview to discuss their decision-making process and relevant experiences during the course of the study."
89547205|NCT03162965|Active Comparator|Choice|Oraquick HIV Self Test or Clinic Based HIV Counseling and Testing (HCT)
89547206|NCT03162965|Active Comparator|HIV Counseling and Testing|Clinic Based HIV Counseling and Testing (HCT)
89547207|NCT03163043|Experimental|Active, Male and Female Children|Participants will receive different levels of amino acid intakes, varying from 0.2-2.67 g/kg/d
89547208|NCT02675075||Veterans With ALS|This Cohort Study will admit all eligible, interested Veterans diagnosed with ALS who meet the inclusion criteria.
89547209|NCT03162419|Active Comparator|Standard Medical Therapy|The patients in group A will be given standard medical therapy only as per requirement. Lactulose, bowel wash, albumin, terlipressin, antibiotics and anti-virals in hepatitis B reactivation will be continued and recorded.
89547210|NCT03162419|Experimental|Standard Medical Therapy + Plasma exchange + GCSF|The patients in group B shall be given GCSF in a dose of 5 ug/kg/day on day 1,2,3,4,5 followed by every 3rd day till day 28 along with alternate day high volume plasma exchange sessions till a maximum of ten sessions.
89547211|NCT03162419|Experimental|Standard Medical Therapy + GCSF|"The patients in this will be given standard medical therapy only as per requirement. Lactulose, bowel wash, albumin, terlipressin, antibiotics and anti-virals in hepatitis B reactivation will be continued and recorded.~The GCSF in a dose of 5 ug/kg/day on day 1,2,3,4,5 followed by every 3rd day till day 28"
89547212|NCT03114137||sickle cell patients|"age: five-year-old or more~major sickle cell syndrome confirmed by hemoglobin phenotype: SS, SC, SBeta+ or Sbeta0~steady state defined as the absence of vaso-occlusive crisis for the previous 15 days, absence of fever or infectious disease for the previous 8 days and absence of transfusion for the previous 2 months"
89547213|NCT03114137||control patients|"volunteer parents or siblings of sickle cell patients~hospital staff or their children matched on country and age +/- 3 ans with the patients"
89547214|NCT04703387||Postextubation Success|
89547215|NCT04703387||Postextubation Distress|
89547216|NCT03114215|Active Comparator|MD1003|The investigational drug will consist in capsules of 100 mg biotin and excipients (lactose, magnesium stearate, croscarmellose sodium, Silica) tid during 12 months
89547217|NCT03114215|Placebo Comparator|PLACEBO|This formulation consists in lactose powder and other excipients (magnesium stearate, croscarmellose sodium, Silica) as placebo, tid during 6 months and then switch to MD1003 tid during 6 additional months.
89547218|NCT04439981|Placebo Comparator|Control Group|treated by ice cream without any Curcuma extract supplementation
89547219|NCT04439981|Experimental|Treatment Group|treated by ice cream supplemented by Curcuma extract
89547220|NCT03374267||aRCC|Patients with advanced renal cell carcinoma
89547221|NCT03374267||aUBC|Patients with advanced urothelial carcinoma
88961658|NCT05233475|Active Comparator|Control group (EUC)|"Enhanced usual care (EUC):~All participants will by a health professional be shortly informed about the typical recovery process, the given reassurance about the prognosis.as well as advice on adaptive illness behaviours post-concussion."
88961659|NCT05233475|Experimental|Intervention Group (EUC + GAIN Lite)|"GAIN Lite:~GAIN Lite in an add-on to EUC, and contains two major components: 1) self-administrated e-learning videos and 2) up to four hours video- or phone sessions with an allocated therapist (either an occupational- or a physiotherapist) during a period of 8 weeks. Health professionals provide feedback and guidance, addressing the specific aims and context of the individual."
88961660|NCT05231512|Experimental|Individuals living with post-Covid-19 respiratory symptoms|Live virtual music therapy interventions for people experiencing difficulties breathing after having had COVID-19 (diagnosed or presumed).
89547222|NCT04665479|Experimental|Intervention group|A total of 30 children with any progressively declining (acute or chronic) life-threatening diagnosis per parent report (aged 8 to 17) and their primary parent caregivers will be recruited as a dyad. Dyads will participate in a nurse-delivered intervention that will guide children to create electronic digital storyboards about themselves during 6 sessions over 6 weeks.
88961661|NCT05199636|Experimental|Dragon fruit product|A dragon fruit beverage
88961662|NCT05199636|No Intervention|General health advice|Based on Eatwell guide and guidelines for type 2 diabetes prevention from the National Institute for Health and Care Excellence (NICE)
88961663|NCT05192486|Experimental|Study treatment|Participants receive GNC-038 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
88961664|NCT05191966|Active Comparator|Group S-QLB3|S-QLB3 block (0.4 ml/kg of 0.25% bupivacaine + 1:400.000 adrenaline) + iv morphine-PCA
88961665|NCT05191966|Active Comparator|Group TPVB|TPVB block (0.4 ml/kg of 0.25% bupivacaine + 1:400.000 adrenaline) + iv morphine-PCA
88961666|NCT05143866|Experimental|Self-help CBT|Evidence based book detailing self-help program to follow plus Telephone support from a non specialist guide
89547223|NCT03186989|Experimental|IONIS-MAPTRx|IONIS MAPTRx (Study Drug)
89547224|NCT03186989|Placebo Comparator|Placebo|Artificial CSF
89547225|NCT03113825|Experimental|AVB-620 & Investigational Imaging Device|Eligible subjects will receive a single dose of AVB-620 as intravenous infusion before the surgical procedure. During the surgical procedure, fluorescent imaging will be undertaken to distinguish between malignant and nonmalignant tissues.
89547226|NCT03113903|Experimental|scheduled surgery|
89547227|NCT03113903|Other|healthy volunteers|
89547228|NCT03113747|Experimental|ALLO-ASCs|The patients receive ALLO-ADSCs. Biological is applied by surface application over perforated (1:3) autologous skin graft following the covering with hypoadhesive bandage. This procedure is carried out twice - once simultaneously with a skin grafting procedure and 2-3 days following autodermoplasty, while bandaging
89547229|NCT03113747|No Intervention|The standard treatment|"All patients will be subjected to standard stepped treatment of burn wounds:~Infusion therapy aimed to eliminate disorders of homeostasis during burn shock and burn toxemia;~Systemic antibiotic therapy for preventing infectious complications;~Adequate analgesia and sedation;~Decompression necrotomy in the first 24 hours following the burn trauma;~Necrectomy simultaneously with imposition of lyophilized xenografts performed in the first 1-5 days after applying burn;~Autologous skin grafting 3-5 days after performed xenografts with the perforation coefficient 1:3"
89547230|NCT02742935|Experimental|camrelizumab|camrelizumab (SHR-1210) injection, 60,200,400mg/dose, intravenous infusion over 30 minutes, every 2 weeks.
89547231|NCT02673515|Active Comparator|Alternate day fasting|"Subjects are requested to alternate fast for 4 weeks (alternate an ad libitum feed day with a 100% restriction fast day)."
89547232|NCT02673515|No Intervention|control group|control group
89547233|NCT02667275|Experimental|A-101 Solution|A-101 Solution 40% administered once
89547234|NCT02667275|Placebo Comparator|Vehicle Solution|Vehicle Solution administered once
89547235|NCT04364789|Active Comparator|Pilot dose Cohort|A pilot dose of 20 mg will be evaluated in 2 subjects (all receiving TT-00920) for safety, tolerability, and PK profile before the initiation of dose escalation.
89547236|NCT04364789|Active Comparator|SAD Dose 1|
89547237|NCT04364789|Active Comparator|SAD Dose 2|
89547238|NCT04364789|Active Comparator|SAD Dose 3|
89547239|NCT04364789|Active Comparator|SAD Dose 4|
89547240|NCT04364789|Active Comparator|Food Effect Cohort|
89547241|NCT04364789|Placebo Comparator|Placebo|
89547242|NCT02125019||Breast cancer patients|This is a single arm study evaluating feasibility of evaluating gait and parameter changes in patients with early stage breast cancer undergoing adjuvant taxane chemotherapy.
89547243|NCT02672423|Experimental|Abemaciclib Part A|Reference formulation (R) = 3 x 50 mg abemaciclib capsules, Test formulation (T150) = 150 mg abemaciclib tablet administered orally on Day 1 in each of 2 periods.
88961667|NCT05121168|Experimental|Active Treatment|Administration of bupivacaine 0.25% through a perineural catheter inserted into the erector spinae plane (programmed intermittent bolus of 21 mL every 4 hours and no patient-controlled bolus)
88961668|NCT05121168|Placebo Comparator|Placebo|Administration of normal saline through a perineural catheter inserted into the erector spinae plane (programmed intermittent bolus of 21 mL every 4 hours and no patient-controlled bolus)
89025137|NCT00439842|No Intervention|Standard HF care|Standard HF care Standard heart failure education includes cardiologists instructions and hospital discharge information.
89025138|NCT00442520||2|colorectal cancer patients
89025139|NCT00442520||3|head and neck cancer patients
89025140|NCT00442520||1|lung cancer patients
89025141|NCT03279666|Active Comparator|tenaculum with intracervical blockage|
89547244|NCT02672423|Experimental|Abemaciclib Part B|R = 3 x 50 mg abemaciclib capsules, T150 = 150 mg abemaciclib tablet, Test Formulation 50 (T50) = 3 x 50 mg abemaciclib tablets administered orally on Day 1 in each of 3 periods.
89547245|NCT02672423|Experimental|Abemaciclib Part C|T150 Fed and T150 Fasted = 150 mg abemaciclib tablet with a high-fat meal (T150 Fed) and then without a high-fat meal (T150 Fasted) on Day 1 in each of 2 periods administered orally.
89547246|NCT04205903|Experimental|Group I (paclitaxel, nilotinib hydrochloride monohydrate)|Patients receive paclitaxel IV on days 1, 8, and 15. Patients also receive nilotinib hydrochloride monohydrate PO on days 7, 8, 14, and 15 of cycle 1 and days -1, 1, 7, 8, 14, and 15 of cycle 2. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
89547247|NCT04205903|Placebo Comparator|Group II (paclitaxel, placebo)|Patients receive paclitaxel IV on days 1, 8, and 15. Patients also receive placebo PO on days 7, 8, 14, and 15 of cycle 1 and days -1, 1, 7, 8, 14, and 15 of cycle 2. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
89547248|NCT05566691|Active Comparator|Positive thinking|Videos will describe negative automatic thoughts and then describe positive thinking, its benefits, and how to use it to cope with negative thoughts. A worksheet will then walk participants through applying the strategy to a recent negative thought of their own. Daily surveys will involve a shortened version of this worksheet.
89547249|NCT05566691|Active Comparator|Positive thinking plus mood induction|The same videos will be used to describe negative automatic thoughts and then describe positive thinking, its benefits, and how to use it to cope with negative thoughts. Participants will then undergo a positive mood induction in which they are asked to recall a pleasant memory and try to re-experience those feelings. A worksheet will then walk participants through applying the strategy to a recent negative thought of their own. Daily surveys will involve the same mood induction and a shortened version of this worksheet.
89547250|NCT05566691|Active Comparator|Thought reevaluation|Videos will describe negative automatic thoughts and then describe reevaluating thoughts, its benefits, and how to use it to cope with negative thoughts. A worksheet will then walk participants through applying the strategy to a recent negative thought of their own. Daily surveys will involve a shortened version of this worksheet.
89547251|NCT05566691|Active Comparator|Thought reevaluation plus mood induction|The same videos will be used to describe negative automatic thoughts and then describe reevaluating thoughts, its benefits, and how to use it to cope with negative thoughts. Participants will then undergo a positive mood induction in which they are asked to recall a pleasant memory and try to re-experience those feelings. A worksheet will then walk participants through applying the strategy to a recent negative thought of their own. Daily surveys will involve the same mood induction and a shortened version of this worksheet.
89547252|NCT02670551|Placebo Comparator|Placebo|Following a 7 to 14 days screening/washout period, placebo-matching cariprazine capsule, one per day, orally for 6 weeks.
89547253|NCT02670551|Experimental|Cariprazine 1.5 mg|Following a 7 to 14 days screening/washout period, cariprazine 1.5 milligram (mg) capsule, one per day, orally for 6 weeks.
89547254|NCT02670551|Experimental|Cariprazine 3.0 mg|Following a 7 to 14 days screening/washout period, cariprazine 1.5 mg capsule, one per day for 2 weeks followed by cariprazine 3.0 milligram (mg) capsule, one per day, orally beginning on Day 15 for 4 weeks.
89547255|NCT01478477|Experimental|Arm I (omega-3 fatty acid supplement)|Omega 3 Polyunsaturated Fatty Acids(n-3 PUFA)
89547256|NCT01478477|Placebo Comparator|Arm II (placebo)|Typical American Diet oils (TAD)
89547257|NCT01478477|Experimental|Clinical Assessments|Brief Pain Inventory (BPI), Stanford's Health Assessment-Disability Index (HAS), FACT-B and endocrine subscale (FACT-ES)
89547258|NCT01478477|Experimental|Assessment of therapy complications|Adverse events will be monitored by self-reporting of signs and symptoms. Patients will maintain a daily diary of time of supplement intake and any possible ill effects, with instructions to contact the PI or Research Nurse to discuss and manage any possible side effects.
89547259|NCT01478477|Experimental|Magnetic Resonance Imaging|Optional bilateral hand and wrist MRI imaging will be obtained
88812007|NCT00885092|Other|RepleniSH / FID 114675A|RepleniSH in Period 1; FID 114675A in Period 2. Each solution was used for 7 days for cleaning, rinsing, conditioning, disinfecting, and storing silicone hydrogel contact lenses, per protocol-specified instructions. A new pair of silicone hydrogel contact lenses was dispensed at the start of each period and worn bilaterally on a daily wear basis.
89547260|NCT01478477|Experimental|Correlative/special studies|Enrolled participants will have peripheral blood samples drawn for plasma and RBC n-3 PUFA levels within 4 weeks of starting AI therapy.
89547261|NCT00893399|Experimental|1|chemotherapy in combination with ATRA with gemtuzumab ozogamicin
89547262|NCT00893399|Active Comparator|2|chemotherapy in combination with ATRA without gemtuzumab ozogamicin
89547263|NCT05675267||patient with chest pain|
89547264|NCT05675111||Nanjing|The First Affiliated Hospital of Nanjing Medical University
89547265|NCT05675111||Zhengzhou|Henan Provincial People's Hospital
89547266|NCT05675111||Qingdao|The Affiliated Hospital of Qingdao University
89547267|NCT05675111||Urumqi|People' s Hospital of Xinjiang Uygur Autonomous Region
89547268|NCT05675111||Jinan|Shandong Provincial Hospital Affiliated to Shandong First Medical University
89547269|NCT04439591|Experimental|Intervention group|Intervention group undergoes computerised brain training programme first.
89547270|NCT04439591|Other|Control group|Waitlist control group: control group undergoes programme after intervention group has completed it in a crossover design.
89547271|NCT05675033|Other|study arm|This is a single arm study.
89547272|NCT02391935|Experimental|RCS-01|Cultured, autologous hair follicle cells suspended in cryomedium
89547273|NCT02391935|Placebo Comparator|Placebo|cryomedium
89547274|NCT02391779|Experimental|BeneFlax® + walking training (Dash)|BeneFlax (0.8 g, twice a day) with exercise training (30-60 minutes walking training, 5 times a week) for 8 weeks; all participants encouraged to follow Dash Eating Plan.
89547275|NCT02391779|Placebo Comparator|Placebo + walking training (Dash)|Placebo (whey powder isocaloric to BeneFlax) with exercise training (30-60 minutes walking training, 5 times a week) for 8 weeks; all participants encouraged to follow Dash Eating Plan.
89547276|NCT02391779|Experimental|BeneFlax® + flexibility training (Dash)|BeneFlax (0.8 g, twice a day) with placebo exercise training (flexibility training, 5 times a week) for 8 weeks; all participants encouraged to follow Dash Eating Plan.
89547277|NCT02391779|Sham Comparator|Placebo + flexibility training (Dash)|Placebo (whey powder isocaloric to BeneFlax) with placebo exercise training (flexibility training, 5 times a week) for 8 weeks; all participants encouraged to follow Dash Eating Plan.
88812008|NCT01512251|Other|No Previous Treatment|150 mg oral dabrafenib twice a day until disease progression, death, or unacceptable adverse events.
88812009|NCT00885638|Placebo Comparator|Placebo|A placebo tablet is given before ingestion of macronutrients
89547278|NCT05545085||Group 1|All included patients meeting the eligibility criteria and scheduled to undergo a lobectomy in the Medical Centre Leeuwarden.
89547279|NCT02391623|Experimental|Cohort 1|Single dose level of PF-06427878 at 5 mg or placebo every 8 hours (Q8H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
89547280|NCT02391623|Experimental|Cohort 2|Single dose level of PF-06427878 at a dose no more than 3.5-fold increase from Cohort 1 or placebo every 8 hours (Q8H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
89547281|NCT02391623|Experimental|Cohort 3|Single dose level of PF-06427878 at a dose no more than 3.5-fold increase from Cohort 2 or placebo every 8 hours (Q8H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
89207934|NCT04041024|Experimental|bulimia nervosa group|Patients with Bulimia Nervosa according to DSM 5 criteria aged between 18 and 35 years and specifically for participants attending MRI scans in the experiments: no counter indication to MRI scans and right handed.
89547282|NCT02391623|Experimental|Cohort 4|Single dose level of PF-06427878 at a dose no more than 3.5-fold increase from Cohort 3 or placebo every 8 hours (Q8H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
89547283|NCT02391623|Experimental|Cohort 5|Single dose level of PF-06427878 at a dose no more than 3.5-fold increase from Cohort 4 or placebo every 8 hours (Q8H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
89547284|NCT02391623|Experimental|Cohort 6|Single dose level of PF-06427878 (with the same total daily dose as Cohort 5) or placebo every 12 hours (Q12H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
89547285|NCT02670473|No Intervention|enfilcon A (habitual)|Participants are habitual wearers of enfilcon A lens and refitted with fanfilcon A lens.
89547286|NCT02670473|Experimental|fanfilcon A (test)|Participants are habitual wearers of enfilcon A lens and refitted with fanfilcon A lens.
89547287|NCT02667119|Experimental|Prolonged Exposure + Contingency Management|Standard services plus Prolonged Exposure and Contingency Management
89547288|NCT02667119|Active Comparator|Standard Care|Standard substance abuse treatment services
89547289|NCT02391389|Experimental|CPAP or PPV during DCC|Infant will receive CPAP or PPV from 30 to 90 seconds after birth while attached to the placenta, and then the umbilical cord will be cut at 90 seconds
89547290|NCT02391233|Experimental|HIV/STI Risk Reduction|This intervention tests the comparative effectiveness of E-WORTH, streamlined HIV Testing and a 5-week multimedia intervention on primary outcomes of decreasing biologically confirmed STIs and the number and proportion of unprotected sexual acts among Black Drug-involved women on probation.
89547291|NCT02391233|Active Comparator|Streamlined HIV Testing Alone|This intervention tests the comparative effectiveness of streamlined HIV Testing alone on primary outcomes of decreasing biologically confirmed STIs and the number and proportion of unprotected sexual acts among Black Drug-involved women on probation.
89547292|NCT04479527|Experimental|the group of HAIC combined with carilizumab and apatinib mesylate treatment|"cTACE or DEBTACE+FOLFOX scheme HAIC, arterial chemotherapy scheme: OXA 65-85mg/m2 arterial H0-4 pump, calcium folinate 200mg/ m2 intravenous pump H2-4, 5-FU 1g-1.5g/ m2 arterial H4-24 pump, once every 6-8 weeks, the interventional treatment times are determined by researchers according to the patient's condition, and two times are adjacent.~Apatinib mesylate tablets, 250mg/ time, once a day. Take it about half an hour after a meal (the daily medication time should be as same as possible), and take it with warm boiled water.~Karelizumab, 200mg, was given intravenously for 30 minutes (including the flushing time, the whole infusion time was not shorter than 20 minutes and not longer than 60 minutes), and the medication period was q3w(±3 days)."
89547293|NCT02391077|No Intervention|Control Arm|Standard PrePex Procedure
89547294|NCT02391077|Experimental|Arm 1 - Maximal intervention|"Foreskin disinfection with Povidone-Iodine~Application of 1gr of Antibiotic topical cream / ointment onto the exposed inner foreskin up to the coronal sulcus~Daily washes with Chlorhexidine 1% (2-3 times a day), for 6 days"
89547295|NCT02391077|Experimental|Arm 2 - Medium intervention|"Foreskin disinfection with Povidone-Iodine~Application of 1gr of Antibiotic topical cream / ointment onto the exposed inner foreskin up to the coronal sulcus"
88812010|NCT00885638|Active Comparator|Sitagliptin|Sitagliptin is given before ingestion of macronutrients
89547296|NCT02391155|Active Comparator|single lumen|Single lumen needle in oocyte retrieval
89547297|NCT02391155|Active Comparator|double lumen|Double lumen needle with follicle flushing during oocyte retrieval
89025142|NCT03279666|No Intervention|No tenaculum with intracercical blockage|
89025143|NCT03279666|Active Comparator|Tenaculum without intracervical blockage|
89025144|NCT03279666|No Intervention|No Tenaculum without intracervical blockage|
89207935|NCT04041024|Other|Control group|healthy participants without any history of eating disorder aged between 18 and 35 years and specifically for participants attending MRI scans in the experiments: no counter indication to MRI scans and right
89207936|NCT00793286|Other|A|Mesh fixation by staples
89547298|NCT02390999|No Intervention|24 hours of therapeutic hypothermia|24 hours of therapeutic hypothermia to a target temperature of 32-34 degrees in comatose cardiac arrest patients is standard treatment in Denmark.
89547299|NCT02390999|Experimental|48 hours of therapeutic hypothermia|48 hours of therapeutic hypothermia to a target temperature of 32-34 degrees
89547300|NCT02390921|Active Comparator|Liosomated iron therapy|Fisiogen Ferro Forte 28mg every day po, during 3 months
89547301|NCT02390921|Experimental|Endovenous Iron Therapy|Venofer 300mg endovenously every 3 months
89517316|NCT04143711|Experimental|Combination Therapy with DF1001 and Nab-paclitaxel Safety/PK/PD Expansion|Expansion cohort of DF1001 in combination with nab-paclitaxel after evaluation for safety in the Combination Therapy with DF1001 and nab-paclitaxel Dose Escalation arm. Additional pharmacokinetic (PK) and pharmacodynamic (PD) samples included in this arm.
89517317|NCT04143711|Experimental|Combination Therapy with DF1001 and Nivolumab Expansion in Urothelial Bladder Cancer|Combination therapy with DF1001 and nivolumab expansion cohort enrolling up to 20 patients with urothelial bladder cancer using the recommended phase 2 dose (RP2D) identified in the Combination Therapy with DF1001 and nivolumab arm.
89025145|NCT00442637|Experimental|1|observation
89207937|NCT00793286|Other|B|Mesh fixation by glue
89207938|NCT00859404|Experimental|1. oglemilast|
89207939|NCT00859404|Experimental|2. oglemilast|
89207940|NCT00859404|Experimental|3. oglemilast|
89207941|NCT00859404|Placebo Comparator|4. placebo|
89207942|NCT02597309|Active Comparator|Intervention Group|Subjects in this group will take canagliflozin in addition to their regular U-500 insulin dose and other antihyperglycemic medications. Canagliflozin dose will be titrated after 2 weeks from 100 mg once daily to 300 mg once daily. This dose will continue for 22 weeks.
89517318|NCT04143711|Experimental|Monotherapy DF1001 Expansion in Metastatic Breast Cancer (HER2 High)|Monotherapy expansion cohort enrolling up to 20 patients with metastatic breast cancer with documented high expression of HER2 using the recommended phase 2 dose (RP2D) identified in the Monotherapy Dose Escalation arm.
88812011|NCT01512797|Active Comparator|Sitagliptin phosphate|100 mg/day sitagliptin phosphate (Januvia) PO once a day for 4-5 weeks
89025146|NCT00442637|Active Comparator|2|capecitabine plus bevacizumab
89547302|NCT02390609|Experimental|Group 1: Sequence 1 (ABC)|Participants will receive Treatment A (Ibrutinib 560 milligram [mg] capsules [reference] under fasted conditions) in Period 1; followed by Treatment B (Ibrutinib 560 mg suspension under fasted conditions) in Period 2; followed by Treatment C (Ibrutinib 560 mg suspension under fed conditions) in Period 3. A washout period of 7 (plus [+] / minus [-] 2) days will be maintained between each treatment period.
89547303|NCT02390609|Experimental|Group 1: Sequence 2 (BCA)|Participants will receive Treatment B (Ibrutinib 560 mg suspension under fasted conditions) in Period 1; followed by Treatment C (Ibrutinib 560 mg suspension under fed conditions) in Period 2; followed by Treatment A (Ibrutinib 560 mg capsules [reference] under fasted conditions) in Period 3. A washout period of 7 (+/- 2) days will be maintained between each treatment period.
89547304|NCT02390609|Experimental|Group 1: Sequence 3 (CAB)|Participants will receive Treatment C (Ibrutinib 560 mg suspension under fed conditions) in Period 1; followed by Treatment A (Ibrutinib 560 mg capsules [reference] under fasted conditions) in Period 2; followed by Treatment B (Ibrutinib 560 mg suspension under fasted conditions) in Period 3. A washout period of 7 (+/- 2) days will be maintained between each treatment period.
89547305|NCT02390609|Experimental|Group 1: Sequence 4 (ACB)|Participants will receive Treatment A (Ibrutinib 560 mg capsules [reference] under fasted conditions) in Period 1; followed by Treatment C (Ibrutinib 560 mg suspension under fed conditions) in Period 2; followed by Treatment B (Ibrutinib 560 mg suspension under fasted conditions) in Period 3. A washout period of 7 (+/- 2) days will be maintained between each treatment period.
89547306|NCT02390609|Experimental|Group 1: Sequence 5 (BAC)|Participants will receive Treatment B (Ibrutinib 560 mg suspension under fasted conditions) in Period 1; followed by Treatment A (Ibrutinib 560 mg capsules [reference] under fasted conditions) in Period 2; followed by Treatment C (Ibrutinib 560 mg suspension under fed conditions) in Period 3. A washout period of 7 (+/- 2) days will be maintained between each treatment period.
89547307|NCT02390609|Experimental|Group 1: Sequence 6 (CBA)|Participants will receive Treatment C (Ibrutinib 560 mg suspension under fed conditions) in Period 1; followed by Treatment B (Ibrutinib 560 mg suspension under fasted conditions) in Period 2; followed by Treatment A (Ibrutinib 560 mg capsules [reference] under fasted conditions) in Period 3. A washout period of 7 (+/- 2) days will be maintained between each treatment period.
89547308|NCT02390609|Experimental|Group 2: Sequence 1 (AFDE)|Participants will receive Treatment A (Ibrutinib 560 mg capsules [reference] under fasted conditions) in Period 1; followed by Treatment F (Ibrutinib 560 mg sprinkle capsule granules suspended in water under fasted conditions) in Period 2; followed by Treatment D (Ibrutinib 560 mg sprinkle capsule granules under fasted conditions) in Period 3; followed by Treatment E (Ibrutinib 560 mg sprinkle capsule granules under fed conditions) in Period 4. A washout period of 7 (+/- 2) days will be maintained between each treatment period.
89547309|NCT02390609|Experimental|Group 2: Sequence 2 (DAEF)|Participants will receive Treatment D (Ibrutinib 560 mg sprinkle capsule granules under fasted conditions) in Period 1; followed by Treatment A (Ibrutinib 560 mg capsules [reference] under fasted conditions) in Period 2; followed by Treatment E (Ibrutinib 560 mg sprinkle capsule granules under fed conditions) in Period 3; followed by Treatment F (Ibrutinib 560 mg sprinkle capsule granules suspended in water under fasted conditions) in Period 4. A washout period of 7 (+/- 2) days will be maintained between each treatment period.
89547310|NCT02390609|Experimental|Group 2: Sequence 3 (EDFA)|Participants will receive Treatment E (Ibrutinib 560 mg sprinkle capsule granules under fed conditions) in Period 1; followed by Treatment D (Ibrutinib 560 mg sprinkle capsule granules under fasted conditions) in Period 2; followed by Treatment F (Ibrutinib 560 mg sprinkle capsule granules suspended in water under fasted conditions) in Period 3; followed by Treatment A (Ibrutinib 560 mg capsules [reference] under fasted conditions) in Period 4. A washout period of 7 (+/- 2) days will be maintained between each treatment period.
89547311|NCT02390609|Experimental|Group 2: Sequence 4 (FEAD)|Participants will receive Treatment F (Ibrutinib 560 mg sprinkle capsule granules suspended in water under fasted conditions) in Period 1; followed by Treatment E (Ibrutinib 560 mg sprinkle capsule granules under fed conditions) in Period 2; followed by Treatment A (Ibrutinib 560 mg capsules [reference] under fasted conditions) in Period 3; followed by Treatment D (Ibrutinib 560 mg sprinkle capsule granules under fasted conditions) in Period 4. A washout period of 7 (+/- 2) days will be maintained between each treatment period.
89547312|NCT02390687|Placebo Comparator|Placebo Arm|Placebo Lozenges (3 Lozenges per day; 1 lozenge in morning and 2 lozenges in the night). Each placebo lozenge contains all excipients except the active constituent (Lactobacillus brevis CD2)
89547313|NCT02390687|Experimental|Probiotic Arm|L. brevis CD2 Lozenges (3 Lozenges per day; 1 lozenge in morning and 2 lozenges in the night). Each probiotic lozenge contains not less than 1 billion CFU of L. brevis CD2
89547314|NCT02390843|Experimental|simvastatin + topotecan/cyclophosphamide|During dose escalation (phase I), standard 3+3 design will be followed.
89547315|NCT02390375|Experimental|A|DW-0929
89547316|NCT02390375|Active Comparator|B|Rosuvastatin
89547317|NCT02670083|Placebo Comparator|Placebo|Participants received intravenous (IV) infusion of Placebo every 4 weeks (Q4W) for 100 weeks.
89547318|NCT02670083|Experimental|Crenezumab|Participants received intravenous (IV) infusion of Crenezumab every 4 weeks (Q4W) for 100 weeks.
89547319|NCT03921203||Type 2 diabetes patients|
89547320|NCT03921203||Healthy controls|
89547321|NCT02669849|Placebo Comparator|Placebo|
89547322|NCT02669849|Experimental|VX-210|
89547323|NCT02390141|Experimental|ZP4207|Five multiple doses of ZP4207 in ascending doses
89547324|NCT02390141|Placebo Comparator|Placebo|Five multiple doses of corresponding placebo in ascending doses
89547325|NCT03836963|Experimental|cognitive and memory strategy training|The cognitive training will include 4 sessions/week for 8 weeks. Each session will take 30min. Total hours of training is 16 hours. For memory strategy training, strategies will be performed daily; this will take only a few minutes a day to accomplish.
89547326|NCT03836963|Active Comparator|cognitive and memory strategy control training|The cognitive training will include 4 sessions/week for 8 weeks. Each session will take 30min. Total hours of training is 16 hours. For the active control of memory strategy training, strategies will be performed daily; this will take only a few minutes a day to accomplish.
89547327|NCT03836963|Active Comparator|active control for cognitive and memory strategy training|The cognitive training will include 4 sessions/week for 8 weeks. Each session will take 30min. Total hours of training is 16 hours. For the active control of memory strategy training, strategies will be performed daily; this will take only a few minutes a day to accomplish.
89025147|NCT00442676|Experimental|1|Celecoxib, 200 mg/day
89547328|NCT03806309|Active Comparator|Arm A : maintenance with FOLFIRI|FOLFIRI (IV; folinic acid 400 mg/m^2, irinotecan 180 mg/m^2, 5-FU bolus 400 mg/m^2 and continuous infusion 2,400 mg/m^2/46h (dose adjustment will be accepted).
89547329|NCT03806309|Experimental|Arm B : maintenance with OSE2101 plus FOLFIRI|"OSE2101 - subcutaneous injection on day 1 and day 15, every 4 weeks for 6 doses then every 8 weeks until month 12 then every 12 weeks up to 24 months.~FOLFIRI - schedules as in Arm A until disease progression on unacceptable toxicity"
89547330|NCT03781583|Experimental|HMD|"We have several versions (listed below) of a headworn smartHMD. Each can provide verbal and/or tactile feedback to the user. Feedback is controlled by either the experimenter or by computer vision algorithms.~1. The ODG Smartglasses is commercially available. This system uses computer vision to guide a user to the destination using audio and/ or vibration feedback.~2) Tactile stimulator array. This device uses an Arduino Micro, HC-05 Bluetooth Module, L293D Motor Driver and coin vibration motors attached to a head-worn headband or glasses frame. The motors can be controlled directly by an experimenter or by computer vision algorithms.~3) Computer Vision Navigation prototyping system consists of two components: Intel RealSense camera and Alienware M15 laptop.~All participants will receive the same 3 interventions: no HMD used, HMD worn but not active, and HMD worn and active. Participants may be tested with any or all of the systems described above."
89547331|NCT03758105|Experimental|Usual care and tDCS (Arm A)|Arm A patient receives a first tDCS treatment in association with usual care (medication, psychotherapy...). If the patient is responding to tDCS, he can have other tDCS treatments in case of relapse.
88811833|NCT00870896|Experimental|Tiotropium|Cough reflex measured by capsaicin Inhalation Challenge will follow Dicpinigaitis performed at 1 and 3 months. Solutions prepared to make a stock solution of 0.01 Mol diluted with physiologic saline to yield 11 doubling concentrations from 0.98 to 1,000 uMol/L. Final diluted capsaicin concentrations are: 0.98, 1.95, 3.9, 7.8, 15.6, 31.2, 62.5, 125, 250, 500, and 1000 uMol/L. Then, place 1 ml of the first concentration into nebulizer. Subjects inhale single breath of capsaicin aerosol. Single breaths are delivered in ascending order, with normal saline randomly interspersed to increase blindness, until two or more coughs (C2) and five or more coughs (C5) are reached. The different concentrations are delivered at 2 minute intervals.
88811834|NCT00825344|Experimental|1|Etanercept 50 mg preoperatively
89025148|NCT00442676|Placebo Comparator|2|Placebo
89547332|NCT03758105|Active Comparator|Usual care without tDCS (Arm B)|Arm B patient receives usual care: medication management and psychotherapy.
89207943|NCT02597309|Placebo Comparator|Control Group|Subjects in this group will take a matched placebo in addition to their regular U-500 insulin dose and other antihyperglycemic medications for 2 weeks then another matched-placebo for 22 weeks.
89547333|NCT03625895||Anagrelide hydrochloride|Participants who received treatment with Anagrelide hydrochloride will be evaluated for this study. Participants will receive interventions as part of routine medical care.
89547334|NCT03489629|Experimental|Treatment|"Subjects are treated with one oral antibiotic, one topical antibiotic, an oral rinse, and instructed to use environmental decontamination techniques.~Trimethoprim Sulfamethoxazole (TMP/SMX) is the primary oral antibiotic to be used. Subjects with allergy or intolerance to TMP_SMX will use minocycline as an alternative antibiotic. Topical antibiotics are nasal Mupirocin, and the oral rinse/gurgle with 0.12% chlorhexidine gluconate."
89547335|NCT02388503|Placebo Comparator|Reference|No added fruit extract
89547336|NCT02388503|Active Comparator|Active 1|lowest dose of fruit extract
89547337|NCT02388503|Active Comparator|Active 2|low dose of fruit extract
89547338|NCT02388503|Active Comparator|Active 3|medium dose of fruit extract
89547339|NCT02388503|Active Comparator|Active 4|high dose of fruit extract
89547340|NCT05345015|Experimental|Acute effects|The experimental group will receive one single session of 20-min electrical energy transfer session (Capacitive mode, 0.5 Mhz radiofrequency, intensity 40%). The control group will receive one 20-minute session of transcutaneous electrical stimulation (TENS, asynchronous rectangular pulse, f< 50Hz). Outcome measures will be measured prior to, immediately after, 24 and 48 hours after.
89547341|NCT05345015|Experimental|Chronic effects|The experimental group will receive 10 sessions of 20-min electrical energy transfer session (Capacitive mode, 0.5 Mhz radiofrequency, intensity 40%). The control group will receive 10 20-minute sessions of transcutaneous electrical stimulation (TENS, asynchronous rectangular pulse, f< 50Hz). Outcome measures will be measured prior to, immediately after, 3 and 6 months after.
89547342|NCT05231291||Young Adults|"Skinfold thickness (SFT) at multiple marked sites on biceps, triceps, subscapular and suprailiac areas using a Harpenden Caliper (Baty, UK) for the non-dominant side.~Hand grip strength measurement Jamar Hydraulic Dynamometers (Hydraulic Hand Dynamometer Fabrication Enterprises Inc, NY) was used as the evaluation tool for measuring grip.~The handgrip measurement was carried out as per the recommendations laid by The National Institute of Health Research (NIHR).~The T score for hand grip strength was also calculated. Also the mean predicted handgrip strength for given height was calculated foe the given height Trunk muscle strength testing was done. An analogue hydraulic push-pull dynamometer (Model: FEI-12-0394) was used to evaluate. The trunk extensor and flexor muscle strength was evaluated using and was recorded in pounds (lbs.)."
89547343|NCT02389751|Experimental|Treatment (ganetespib, paclitaxel, carboplatin, radiation)|Patients receive ganetespib IV over 1 hour, paclitaxel IV over 1 hour, and carboplatin IV over 30 minutes once a week on day 1. Patients also undergo radiation therapy 5 days a week for 5.5 weeks or for a total of 28 treatments. Treatment continues for 28 treatment days (5.5 weeks) in the absence of disease progression or unacceptable toxicity
89547344|NCT02389907||Total Hip Replacement Group|Adults who have undergone a total hip replacement
89547345|NCT02389907||Hysterectomy Group|Adults who have undergone a hysterectomy
89547346|NCT02390063|Experimental|CHAMVA standard regime|ChAdOx1.5T4 prime followed by two boost of MVA.5T4 vaccine at 4 week intervals until radical prostatectomy
89547347|NCT02390063|Experimental|CHAMVA+CTX standard regime|One week of low dose cyclophosphamide pre-conditioning before each vaccination. ChAdOx1.5T4 prime followed by two boost of MVA.5T4 at 4 week intervals until radical prostatectomy.
89547348|NCT02390063|Active Comparator|MVA standard regime|Three MVA.5T4 vaccinations at 4 week intervals until radical prostatectomy
89547349|NCT02390063|Active Comparator|MVA+CTX standard regime|One week of low dose cyclophosphamide pre-conditioning before each vaccination.Three MVA.5T4 vaccinations at 4 week intervals until radical prostatectomy
89547350|NCT02390063|Experimental|CHAMVA accelerated regime|ChAdOx1.5T4 prime followed by one boost of MVA.5T4 one week later until radical prostatectomy.
89547351|NCT02390063|Experimental|CHAMVA+CTX accelerated regime|One week of low dose cyclophosphamide pre-conditioning before each vaccination. ChAdOx1.5T4 prime followed by one boost of MVA.5T4 one week later until radical prostatectomy.
89547352|NCT02390063|Experimental|CHAMVA accelerated regime AS|ChAdOx1.5T4 prime followed by one boost of MVA.5T4 one week later. Patients continue on active surveillance.
89547353|NCT02390063|Experimental|CHAMVA+CTX accelerated regime AS|One week of low dose cyclophosphamide pre-conditioning before each vaccination. ChAdOx1.5T4 prime followed by one boost of MVA.5T4 one week later. Patients continue on active surveillance.
89547354|NCT02388113|Experimental|accumulated exercise|12 exercise sessions of 10 minutes each week, 2 per day, 1 day rest
89547355|NCT02388113|Active Comparator|traditional exercise|4 exercise sessions of 30 minutes each week, 3 in the training laboratory, 1 at home.
89547356|NCT02389673|No Intervention|Without Radiotherapy|Patients just accept breast-conversing surgery without radiotherapy.
89547357|NCT02389673|Experimental|Intraoperative Radiotherapy|Boost with 20 Gy during BCS, EBRT with 46-50 Gy
89207944|NCT04008381|Experimental|Ex-vivo Expanded γδ T Lymphocytes|Patients receive ex-vivo expanded γδ T Lymphocytes (Dose escalation, 2*10^6, 4*10^6, 8*10^6 of cells per kg of body weight).
89025149|NCT00477906|Experimental|1|"MVax + BCG + cyclophosphamide + IL2~2:1 randomization - MVax:Control"
89025150|NCT00477906|Placebo Comparator|2|Placebo Vaccine + BCG + cyclophosphamide + IL2
89207945|NCT00786734|Experimental|Pitavastatin Group|
89207946|NCT00786734|Other|Usual Care Group|
89207947|NCT03974581||Pharmacoinvasive strategy|Patients whom received pharmacoinvasive strategy (fibrinolysis and subsequently PCI) as reperfusion treatment.
89025151|NCT00442793|Experimental|1|
89025152|NCT00442793|Active Comparator|2|
89025153|NCT00439920|Experimental|High-dose anthracycline|
89207948|NCT03974581||Primary PCI|Patients whom primary PCI as reperfusion treatment.
89207949|NCT04089995||Coats + and LCC syndrome|
89207950|NCT00960609||caval confluence HV involvement|Patients carriers of primary or metastatic tumour with direct contact or invasion of one HV at the caval confluence.
89207951|NCT02544204|Active Comparator|8 mg JVS-100|Biological/Vaccine: JVS-100 Injection Intramuscular Injection
89547358|NCT02388035|Experimental|SBP-group 1|Spontanous bacterial peritonitis
89547359|NCT02388035|Experimental|CNNA-group 2|Culture negative neutrocytic ascites
88811835|NCT00825344|Placebo Comparator|2|Subcutaneous saline preoperatively
88811836|NCT00871286|Experimental|CT scan (sinus) pre-tx|Sinus CT scan performed at initial otolaryngology (ear, nose, and throat)visit
89025154|NCT00442832|Experimental|TD-1792|
89025155|NCT00442832|Active Comparator|Vancomycin|
89547360|NCT02388035|Experimental|MNBA-group 3|monomicrobial non-neutrocytic ascites
89547361|NCT02388035|No Intervention|group 4|no evidence of ascitic fluid infection
89547362|NCT02387723|Experimental|Stem cell therapy|Treatment with direct intra-myocardial Injection of 100 million allogeneic adipose derived stem cells (CSCC_ASC) into the heart
89547363|NCT02389439|Experimental|Pyronaridine-artesunate|"Pyronaridine-artesunate (Pyramax®, Shin Poong Pharmaceuticals). One tablet contains 60mg artesunate+ 180mg pyronaridine. Dosing will be according to body weight.~It will be taken orally with water, once daily for 3 days. Each dose will be administered under the supervision. A dose will be repeated in full if vomiting occurs within 30 minutes of administration of the first day of administration only.~20 - < 24 kg = 1 tab 24 - < 45 kg = 2 tabs 45 - < 65 kg = 3 tabs 65 and above = 4 tabs"
89547364|NCT02389283||Rheumatoid arthritis(RA) patients|The patients will be evaluated according to clinical practice (clinical evaluation and inflammation markers) at baseline and 3 and 6 months after the initiation of the treatment with the biologic DMARD.
89547365|NCT02663687|Experimental|Treatment 1- 4|Treatment A: 9 Subjects will receive dose level I of SHP623 intravenously (IV). B: 9 Subjects will receive dose level I of SHP623 subcutaneously(SC).
89547366|NCT02663687|Placebo Comparator|Placebo|3 Subjects will receive placebo for each cohort
89547367|NCT02389205|Placebo Comparator|control group|physical therapy
89547368|NCT02389205|Active Comparator|kinesio group|kinesio taping for ankle joint
89547369|NCT02387879||Group 1|"Subjects should be chosen among relapse/refractory multiple myeloma patients who have received at least one prior antimyeloma chemotherapy regimen (excluding treatment regimens with steroid only) with adequate dose and duration (≥2 cycles) or who have relapse/refractory multiple myeloma after stem cell transplantation.~Patients who are eligible for the study will be consecutively enrolled in the study until the targeted patient number is reached. The responsible investigator will be requested to keep a log of subjects who are invited to enter the study. In the case of any of these subjects will not be enrolled in the study, this information will be documented together with its reason"
89547370|NCT02387645|Experimental|Patients prior to surgery for EC/suspicion|Patient undergoing surgery for strong suspicion of EC
89547371|NCT02388971|Experimental|MLN1202 Dose|MLN1202 Dose, intravenously (IV), once on Days 1, 29 and 57.
89547372|NCT02388971|Experimental|MLN1202 Placebo|MLN1202 placebo, intravenously (IV), once on Days 1, 29 and 57.
89547373|NCT03113591|Experimental|Osteo introducer group|undergo minimal invasive total hip arthroplasty surgery
89547374|NCT03113591|Active Comparator|Control group|undergo common total hip arthroplasty surgery
89547375|NCT03106025|Active Comparator|Patients Receiving Ophthalmology Assessment|Number of subjects with retinal detachment per formal ophthalmology assessment. This assessment is a composite measurement which includes the following chief complain, primary impression, right visual acuity, left visual, acuity, ultrasound diagnosis, diagnosis changed, ophthalmology diagnosis.
89547376|NCT03106025|Experimental|Ocular Ultrasound|Each participant will receive an ocular ultrasound which poses minimal to no harm to the participant and the ultrasound results compared to final diagnosis
89547377|NCT02663453|Experimental|study group|multicomponent lipid emulsion composed of 30% soybean oil, 30% MCTs, 25% olive oil and 15% fish oil (SMOF lipid) was administered at a dose of 1gm/kg/day within 24 hours after birth; lipid dosage was increased by an increment of 0.5 gm/kg/day until the maximal dose of 3.5 gm/kg/day was reached.The macronutrients and micronutrients were provided using the same products in both groups.
88811837|NCT00871286|Other|CT scan (sinus) post-tx|Sinus CT scan performed after 3-4 weeks of antibiotic treatment and any other indicated medical treatment(s), per insurance company guidelines
88811838|NCT01426763|Experimental|SC CINRYZE with rHuPH20 Dose Level 1|Subcutaneous injection of 1000 Units of CINRYZE with 20,000 Units of rHuPH20 twice weekly for two weeks
88811839|NCT01426763|Experimental|SC CINRYZE with rHuPH20 Dose Level 2|Subcutaneous injection of 2000 Units of CINRYZE with 40,000 Units of rHuPH20 twice weekly for two weeks
89025156|NCT00477984|Experimental|A|alcohol and placebo
89025157|NCT00442871|Experimental|Eltrombopag|Eltrombopag 50 mg oral (single dose)
88811840|NCT00825500|Placebo Comparator|Inhaled Placebo|Inhaled Staccato Placebo (0 mg)
88811841|NCT00825500|Active Comparator|Inhaled Loxapine 1.25 mg|Inhaled Staccato Loxapine 1.25 mg, single dose
88811842|NCT00825500|Experimental|Inhaled Loxapine 2.5 mg|Inhaled Staccato Loxapine 2.5 mg, single dose
89025158|NCT00442910|Active Comparator|3% SPL7013|Intravaginal application of 3.5 g SPL7013 gel twice daily for 14 days
89547378|NCT02663453|Active Comparator|control group|pure soybean oil lipid emulsion(intralipid) was administered at a dose of 1gm/kg/day within 24 hours after birth; lipid dosage was increased by an increment of 0.5gm/kg/day until the maximal dose of 3.5gm/kg/day was reached.The macronutrients and micronutrients were provided using the same products in both groups.
89547379|NCT02387489|Active Comparator|NBI|Nurse-delivered Brief Intervention
89547380|NCT02387489|Experimental|CBI|Computerized Brief Intervention
89547381|NCT05225207||All Participants|Participants with uHCC who are prescribed with Lenvima within the scope of the approved label for Korea under the medical judgment of the investigator will be enrolled and observed for up to 12 months.
89547382|NCT02055118|Experimental|idursulfase-IT|10 mg administered via IT using IDDD (intrathecal drug delivery device) once a month for 52 weeks.
89547383|NCT02055118|Other|Nontreatment control|Patients will receive weekly standard of care treatment with IV Elaprase only.
89547384|NCT04439825|Active Comparator|Botox|
89547385|NCT04439825|Placebo Comparator|Placebo|
89207952|NCT02544204|Placebo Comparator|8 mg placebo|Biological/Vaccine: Placebo Injection Intramuscular Injection
89547386|NCT04439747||Control|Ultrasound examination of the thyroid gland and parathyroid glands, osteodensitometry (DXA), biochemical analysis, general blood count, neutrophil- gelatinase assosiated lipocalin-2 (NGAL), adiponectin, urine albumin / creatinine ratio, hormonal tests (TSH, free T4 and T3, total T4 and T3, Tg, antibodies to thyroid peroxidase (Ab-TPO), Ab--R-TSH, Ab-Tg, parathyroid hormone (PTH), vitamin D, osteocalcin, b-cross-laps, prolactin)
89547387|NCT04439747||CKD 1-2|Ultrasound examination of the thyroid gland and parathyroid glands, osteodensitometry (DXA), biochemical analysis, general blood count, NGAL, adiponectin, urine albumin / creatinine ratio, hormonal tests (TSH, free T4 and T3, total T4 and T3, Tg, Ab-TPO, Ab--R-TSH, Ab-Tg, PTH, vitamin D, osteocalcin, b-cross-laps, prolactin)
89547388|NCT04439747||CKD 3-5|Ultrasound examination of the thyroid gland and parathyroid glands, osteodensitometry (DXA), biochemical analysis, general blood count, NGAL, adiponectin, urine albumin / creatinine ratio, hormonal tests (TSH, free T4 and T3, total T4 and T3, Tg, Ab-TPO, Ab--R-TSH, Ab-Tg, PTH, vitamin D, osteocalcin, b-cross-laps,prolactin)
89547389|NCT02388581|Experimental|Anti-H. pylori Therapy|Lansoprazole, Amoxicillin, Clarithromycin, Metronidazole
89547390|NCT02387411|Active Comparator|Interval group|high-intensity interval exercise training
89547391|NCT02387411|Active Comparator|Combined group|combined exercise training
89547392|NCT02387333|Experimental|Study group|in this arm -study group- : patients will receive mesh stoma reinforcement technique with ileal conduit urinary diversion.
89547393|NCT02387333|Sham Comparator|Control group|in this arm -sham comparator- : patients will not receive mesh stoma reinforcement technique with ileal conduit urinary diversion.
89547394|NCT02387567|Experimental|Lidocaine|Paraspinal infusion of 3ml lidocaine at 1%, once a week for three weeks, combined with standard treatment.
89207953|NCT02544204|Active Comparator|16 mg JVS-100|Biological/Vaccine: JVS-100 Injection Intramuscular Injection
89207954|NCT02544204|Placebo Comparator|16 mg placebo|Biological/Vaccine: Placebo Injection Intramuscular Injection
89207955|NCT00263887|Experimental|Group 1|Prolastin
89547395|NCT02387567|Sham Comparator|Sham lidocaine|Sham Injection, without lidocaine, combined with standard treatment.
89547396|NCT02387567|Active Comparator|Standard treatment only|The only intervention is the standard treatment. No lidocaine or shame injection was used.
89547397|NCT02387177|Experimental|Stress Management Group 1|Subjects will attend group stress management sessions via Skype once weekly for 8 weeks and learn stress/NF symptoms managements techniques.
89547398|NCT02387177|Experimental|Stress Management Group 2|Subjects will attend group stress management sessions via Skype once weekly for 8 weeks and learn stress/NF symptoms managements techniques.
89547399|NCT02389127||Group A|"Cirrhosis, either clinically- or biopsy-proven~Child-Pugh-Turcotte (CTP) A, B, and C (only biopsy-proven in the case of CTP-A)~Random glucose <200 mg/dL on at least 3 occasions~No use of insulin or any hypoglycemic agent~(Group A) patients with cirrhosis and varying degrees of liver dysfunction but no prior diagnosis of T2DM will have an OGTT performed after overnight fasting (8-12-hours). HbA1c will be obtained before OGTT along with the following tests: HbA1c, fructosamine, insulin, CBC, HFP, GGT, OP Chem 7, INR, and prealbumin."
88811843|NCT01504997|Experimental|Robot assisted distal gastrectomy|patients who received robot assisted distal gastrectomy
88811844|NCT03489434|Experimental|Intervention Group|Preliminary prevention program component content is based on evidence-based prevention programs and will integrate prevention content for substance use, sexual assault, and sexual risk behaviors.
88811845|NCT03489434|No Intervention|Control|Assessment only control.
88811846|NCT01505933|Active Comparator|dexmedetomidine|
88811847|NCT01505933|Active Comparator|propofol|
88811848|NCT00825734|Experimental|Dose Level 1|Sorafenib PO BID (200mg), Ixabepilone IV every 21 days (40mg/m^2)
88811849|NCT00825734|Experimental|Dose Level -1|Sorafenib PO BID (200mg), Ixabepilone IV every 21 days (32mg/m^2)
88811850|NCT00825734|Experimental|Dose Level 1a|Sorafenib PO BID (400mg), Ixabepilone IV every 21 days (32mg/m^2)
88811851|NCT00826202|Experimental|D serine|60 mg/kg/day
88811852|NCT00826202|Placebo Comparator|Placebo|
88811853|NCT02153528|Active Comparator|Standard TB treatment|Standard regimen for TB treatment according to guidelines of the International Union against Tuberculosis and Lung Disease
88811854|NCT02153528|Experimental|double rimfampicin|2HREZ/4HR Cat. 1, modified by using double dose rifampicin throughout
88811855|NCT00872534|Experimental|PL-2200|PL-2200 is an NSAID product containing 325mg of acetylsalicylic acid and phosphatidylcholine in a neutral lipid matrix.
88811856|NCT00872534|Active Comparator|Aspirin|Immediate release 325mg aspirin
88811857|NCT00873782|Experimental|1|Participants will undergo retrograde high pressure transvenous limb perfusion with normal saline.
88811858|NCT02513160|Experimental|Beclomethasone dipropionate BAI 320|"Beclomethasone Dipropionate Delivered via Breath-Actuated Inhaler (BAI) at 320 mcg/day (40 mcg/inhalation, 4 inhalations twice daily)~Albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) (90 mcg ex-actuator) or equivalent was supplied by the sponsor for use as rescue medication during the run-in and double-blind study periods."
88811859|NCT02513160|Experimental|Beclomethasone dipropionate BAI 640|"Beclomethasone Dipropionate Delivered via Breath-Actuated Inhaler (BAI) at 640 mcg/day (80 mcg/inhalation, 4 inhalations twice daily)~Albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) (90 mcg ex-actuator) or equivalent was supplied by the sponsor for use as rescue medication during the run-in and double-blind study periods."
88811860|NCT02513160|Active Comparator|Beclomethasone dipropionate MDI 320|"Beclomethasone dipropionate Metered Dose Inhaler (MDI) 320 mcg/day (40 mcg/inhalation, 4 inhalations twice daily)~Albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) (90 mcg ex-actuator) or equivalent was supplied by the sponsor for use as rescue medication during the run-in and double-blind study periods."
88811861|NCT02513160|Placebo Comparator|Placebo|"Pooled breath-actuated inhaler (BAI) or metered-dose inhaler (MDI) placebo groups. Participants were instructed to take 4 inhalations twice daily for 6 weeks.~Albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) (90 mcg ex-actuator) or equivalent was supplied by the sponsor for use as rescue medication during the run-in and double-blind study periods."
89547400|NCT02389127||Group B|"Cirrhosis, either clinically- or biopsy-proven~Child-Pugh-Turcotte (CTP) A, B, and C (only biopsy-proven in the case of CTP-A)~Prior diagnosis of T2DM as based on any of ADA criteria~Use of insulin or any hypoglycemic agent~(Group B) patients with known diabetes and cirrhosis with varying degrees of liver dysfunction will wear a continuous glucose monitor (?Dexcom, ?Medtronic) for 2 continuous days during week days and week ends, every 4 weeks for 12 consecutive weeks. On the day the continuous monitor is retrieved by the investigators, patients will have the following blood tests performed after overnight fasting (8-12-hours): HbA1c, fructosamine, CBC, HFP, GGT, BMP, INR, and prealbumin."
89025159|NCT00442910|Placebo Comparator|Placebo for SPL7013 Gel|Intravaginal application of 3.5 g placebo gel twice daily for 14 days
89547401|NCT02389127||Control|"Age 18 to 75~No known chronic liver disease~Prior diagnosis of T2DM as based on any of ADA criteria~Use of insulin or any hypoglycemic agent"
89547402|NCT02383121||No patients|Study has been withdrawn
89547403|NCT02387021|Active Comparator|Continous femoral nerve block|Patients will receive ultrasound-guided (USG) continuous femoral nerve block with 20 ml ropivacaine 0.2% and USG Continuous adductor canal block with 20 ml of saline and USG infragluteal SNB with 20 ml of saline .
89547404|NCT02387021|Experimental|Continuous adductor canal block|Patients will receive ultrasound-guided continuous adductor canal block with 20 ml ropivacaine 0.2% and USG infragluteal SNB with 20 ml ropivacaine 0.2% and USG continuous FNB with 20 ml of saline .
89547405|NCT02386943|Experimental|Sitagliptin|Subjects are assigned to take one pill of sitagliptin(100mg po once) at 7am on experimental day,then the two-step hyperglycaemic clamp is initiated at 9am.
89547406|NCT02386943|Experimental|Saxagliptin|Subjects are assigned to take one pill of saxagliptin(5mg po once) at 7am on experimental day,then the two-step hyperglycaemic clamp is initiated at 9am.
89547407|NCT02386943|Experimental|Blank control|Subjects take no medication for blank control at experimental day,then the two-step hyperglycaemic clamp is initiated at 9am.
89547408|NCT02084056|Experimental|FDC first, fasted|Linagliptin/Metformin FDC followed by single tablets of linagliptin and metformin, fasted
89547409|NCT02084056|Experimental|Single tablets first, fasted|single tablets of linagliptin and metformin followed by Linagliptin/Metformin FDC, fasted
89547410|NCT02084056|Experimental|FDC first, fed|Linagliptin/Metformin FDC followed by single tablets of linagliptin and metformin, fed
89547411|NCT02084056|Experimental|Single tablets first, fed|single tablets of linagliptin and metformin followed by Linagliptin/Metformin FDC, fed
89547412|NCT02386787|Experimental|SEMI EMERGENCY SURGERY PATIENT|patient undergoing a non-elective surgery and having a preoperative fasting period of six hours.
89547413|NCT02386631|Experimental|Orthotic|Custom made orthotic provided for study
89547414|NCT02383277|Experimental|Stretching and Exercise|This group undergo a session of stretching aiming flexibility of the rib cage and later at an exercise test with constant load up to the limit of tolerance for exercise bike
88812012|NCT01512797|Placebo Comparator|Placebo|1 Placebo pill / day PO once a day for 4-5 weeks
89025160|NCT00442910|Placebo Comparator|HEC Placebo Gel|Intravaginal application of 3.5 g HEC placebo gel twice daily for 14 days
89025161|NCT00442949|Active Comparator|2|Catheterization immediate PCI
89025162|NCT00442949|Experimental|1|delayed PCI
89025163|NCT04701099||On ECMO|patients who is receiving vancomycin or meropenem or milrinone or dexmedetomidine or fentanyl during ECMO support.
89547415|NCT02383277|Sham Comparator|Control and Exercise|This group will carry out the exercise test with constant load up to the limit of tolerance for exercise bike after a period of rest under the same environmental conditions and the experimental group time. During this time the therapist will place their hands but not performing the stretch.
89547416|NCT02382887|Active Comparator|Tracheal intubation with Fiberscopy|tracheal intubation with a fiberscope
89025164|NCT04701099||Off ECMO|patients who is receiving vancomycin or meropenem or milrinone or dexmedetomidine or fentanyl after weaning off ECMO.
89025165|NCT00443027|Experimental|Vaginal Heat Wash-Out Device|
89025166|NCT00440154|Experimental|1|oral administration 5 mg breakfast timing
89025167|NCT00440154|Experimental|2|oral administration 25 mg breakfast timing
89025168|NCT00440154|Experimental|3|oral administration 50 mg breakfast timing
89025169|NCT00440154|Experimental|4|oral administration 100 mg breakfast timing
89025170|NCT00440154|Experimental|5|oral administration 25 mg dinner timing
89025171|NCT00440154|Placebo Comparator|6|oral administration
89025172|NCT00440154|Active Comparator|7|oral administration 10mg breakfast timing
89025173|NCT00478374|Experimental|1|
89547417|NCT02382887|Experimental|Tracheal intubation with Airtraq|tracheal intubation with an Airtraq
89547418|NCT02386397|Experimental|Treatment|"Regorafenib: X mg/d, PO, from day 1 to day 14; day 15 to day 20: off-treatment mGEMOX: infusion on days 1 and 8~Gemcitabine 900 mg/m² IV in 30 minutes~Oxaliplatin 80 mg/m² IV in 120 minutes immediately after Gemcitabine"
89547419|NCT02386397|Other|Standard treatment|"mGEMOX: infusion on days 1 and 8~Gemcitabine 900 mg/m² IV in 30 minutes~Oxaliplatin 80 mg/m² IV in 120 minutes immediately after Gemcitabine"
89547420|NCT02386475|Placebo Comparator|Placebo|In all cases, regardless of the assigned treatment group, will follow usual physiotherapy program and vascular risk factors, and treatment of stroke will be controlled according to current recommendations of the American Heart Association / American Stroke Association.
89547421|NCT02386475|Active Comparator|citalopram 20 mg|In all cases, regardless of the assigned treatment group, will follow usual physiotherapy program and vascular risk factors, and treatment of stroke will be controlled according to current recommendations of the American Heart Association / American Stroke Association.
89547422|NCT02386475|Active Comparator|sinemet plus 100 mg|In all cases, regardless of the assigned treatment group, will follow usual physiotherapy program and vascular risk factors, and treatment of stroke will be controlled according to current recommendations of the American Heart Association / American Stroke Association.
89547423|NCT02386475|Active Comparator|Sinemet Plus + citalopram group|In all cases, regardless of the assigned treatment group, will follow usual physiotherapy program and vascular risk factors, and treatment of stroke will be controlled according to current recommendations of the American Heart Association / American Stroke Association.
89547424|NCT02382731|No Intervention|Usual care|Usual care (no intervention)
89547425|NCT02382731|Experimental|Usual care + letters|Usual care plus a series of postal educational reminders (including information for patients to share with clinicians)
89547426|NCT02382731|Experimental|Usual care + letters + automated calls|Usual care plus a series of postal educational reminders (including information for patients to share with clinicians), plus automated reminder interactive voice response phone calls to identify patients at being at risk for non-adherence and a trained lay health worker to provide additional support and navigation for such patients via telephone.
89547427|NCT02382653|Other|oral perixicam|50 patients with Breakthrough pain will receive oral prioxicam for treament of breakthrough pain.
89547428|NCT02382653|No Intervention|oral fentanyl|50 patients with Breakthrough pain will receive sublingual fentanyl for treament of breakthrough pain.
89547429|NCT02386085||Osteopathic manipulative treatment (OMT)|All participants will have received OMT to be eligible and will be followed for 1 week after treatment.
89547430|NCT02382809|Experimental|DC071 (0.2% chlorhexidine digluconate)|
89547431|NCT02382809|Placebo Comparator|Placebo|
89547432|NCT02382263|Experimental|Arm B|Nab-paclitaxel 150 mg/m2 + Gemcitabine 1000 weeks 1,3/4
89547433|NCT02382263|Experimental|Arm C|Nab-paclitaxel 100 mg/m2 + Gemcitabine 1000 weeks 1,2,3/4
89547434|NCT02382263|Experimental|Arm D|Nab-paclitaxel 125 mg/m2 + Gemcitabine 1000 weeks 1,3/4
89547435|NCT02382263|Experimental|Arm E|Nab-paclitaxel 125 mg/m2 + Gemcitabine 1000 weeks 1,2,3/4
89547436|NCT02386007|Experimental|DW-3101_150mg|150mg a day
89547437|NCT02386007|Experimental|DW-3101_300mg|300mg a day
89025174|NCT00478452|Experimental|DC Ova|DC Ova vaccine administered day 2 and week 3,6,9
89547438|NCT02386007|Experimental|DW-3101_600mg|600mg a day
89547439|NCT02386007|Placebo Comparator|a tablet same as experimental agents in formation and shape|Placebo
89547440|NCT02382419|Experimental|Arm I (carrageenan-containing gel)|Participants apply carrageenan-containing gel vaginally within 12 hours prior to each vaginal sex act and as soon as possible within 12 hours after each vaginal sex act and use condoms for 12 months.
89547441|NCT02382419|Placebo Comparator|Arm II (placebo gel)|Participants apply placebo gel vaginally within 12 hours prior to each vaginal sex act and as soon as possible within 12 hours after each vaginal sex act and use condoms for 12 months.
89547442|NCT02382341||Observational|BIOSURE™ HEALICOIL™ PK Interference Screw
89547443|NCT02382185|Experimental|Usual care|No intervention apart from application of clearsight monitor. Prior to induction of anaesthesia the control group will have a Clearsight cardiac monitor probe placed on a suitable finger and baseline haemodynamic measurements will be taken. All fluid management and administration of vasopressor therapy will be at the discretion of the anaesthetist as per the current practice at the host institution. Data on stroke volume, heart rate, blood pressure, cardiac output, oxygen saturations, will be recorded at baseline and then every 5 minutes.
89547444|NCT02382185|Experimental|Fluid optimisation|Application of clearsight monitor, optimisation of blood pressure and fluid optimisation. A Clearsight cardiac probe is attached and after induction of anaesthesia stroke volume is optimised using 250ml boluses of Hartmann's solution. The SV measurement prior to the final fluid bolus will be the optimal SV. Mean arterial blood pressure will be maintained within 30% of baseline values using a phenylephrine infusion.Data on haemodynamics will be recorded at baseline and then every 5 minutes, as well as before and after a fluid bolus. Haemoglobin will be maintained at>10g/dL with blood transfusion as required.
89207956|NCT00263887|Placebo Comparator|Group 2|
89547445|NCT02385851|Experimental|CHS-1701/Neulasta|CHS-1701 followed by Neulasta (crossover)
88811862|NCT00874094|Active Comparator|platelet rich fibrin matrix|Both nasolabial folds treated with 0-2 cc of autologous platelet rich fibrin matrix,sufficient to efface nasolabial fold
88811863|NCT01507103|Experimental|Chemoradiotherapy+tecemotide (L-BLP25)+CPA|
89547446|NCT02385851|Experimental|Neulasta/CHS-1701|Neulasta followed by CHS-1701 (crossover)
89547447|NCT02385773|Experimental|PTM202|PTM202
89547448|NCT02385773|Placebo Comparator|Enfamil Puramino|Formal Placebo
89025175|NCT00478452|Active Comparator|DC Ova with Cyclophosphamide|Cyclophosphomide administered at day 0 prior to administration of DC Ova vaccine administered day 2 and week 3,6,9
89517319|NCT04143711|Experimental|Monotherapy DF1001 Expansion in NSCLC|Monotherapy expansion cohort enrolling up to 20 patients with non-small cell lung cancer with documented erbb2 amplification using the recommended phase 2 dose (RP2D) identified in the Monotherapy Dose Escalation arm.
89517320|NCT04143711|Experimental|Combination Therapy with DF1001 and Nivolumab Expansion in NSCLC|Combination therapy with DF1001 and nivolumab expansion cohort enrolling up to 20 patients with non-small cell lung cancer with documented low expression of HER2 using the recommended phase 2 dose (RP2D) identified in the Combination Therapy with DF1001 and nivolumab arm.
89547449|NCT02385929|Experimental|Swallowing therapy & resistance training|"Mouth opening and swallowing exercise intervention by occupational therapist for half an hour 3 times a week for 5-6 weeks during radiotherapy.~Progressive resistance training by physiotherapist for 1 hour twice weekly for 5-6 weeks during radiotherapy."
89547450|NCT02385929|No Intervention|Standard Care|Patients in this arm are randomized to usual care / control group
89547451|NCT02385695||Posterior Dynamic Stabilization|Surgical treatment with posterior dynamic stabilization
89547452|NCT02385695||Internal Fixation and Fusion|Surgical treatment with internal fixation and fusion
89547453|NCT02382029|Active Comparator|clonazepam|Twenty two patients took clonazepam two times a day (0.5 mg) in the morning and after two weeks one tablet (0.5 mg) in the morning and another tablet (0.5 mg) in the evening during the next two weeks.
89547454|NCT02382029|Experimental|acupuncture|"Traditional Chinese acupuncture was performed on 20 participants 3 times during one week for four weeks. Intervention was performed on acupuncture points as follows: the points ST 8 (stomach- tou wei), GB 2, TE 21, SI 19 (small intestine- ting gong), SI 18 (small intestine- quan liao), LI 4 (large intestine-Yuan) on both sides of the body as well as GV 20 (Governing vessel-bai hui).~Each session lasted half an hour. Sterile acupuncture needles made from surgical stainless steel silicone coated with spring handle were used. The dimensions of the chosen needles were 0.25 in diameter and 30 mm length, inserted at the depth of the 0.5-1 cm. The elicited response was of the type de qi accompanied by redness and a feeling of numbness around the needles."
89547455|NCT02385539|Active Comparator|Levobupivacaine (LB) 6 mg|Patients will be stratified into three groups (80 patients) according to doses of Levobupivacaine (6, 8 or 12 mg, Chirocaine, Abbot Laboratories, amp. 5 mg/ml). Patients who will receive 6 mg of Levobupivacaine will be randomized to one of four treatment groups (each 20 patients), by dose of intrathecal opioids: 25, 35 mcg of Fentanyl (Fentanyl, Janssen Cilag, amp. 50 mcg/ml) or 5, 7 mcg of Sufentanil (Sufenta, Janssen-Pharmaceutica, amp. 5 mcg/ml). The groups will be named according to dose and combination of Levobupivacaine and Fentanyl or Sufentanil that will be given intrathecally as LB6F25 (LB 6 mg, Fentanyl 25 mcg), LB6F35 (LB 6 mg, Fentanyl 35 mcg), LB6S5 (LB 6 mg, Sufentanil 5 mcg), LB6S7 (LB 6 mg, Sufentanil 7 mcg). Hemodynamic and opioid's side effects will be recorded. The level and duration of sensory block, time until two-segment regression, T12 regression andl full skin sensory sensibility at the S1 segment will be registered
89547456|NCT02385539|Active Comparator|Levobupivacaine (LB) 8 mg|Patients will be stratified into three groups (80 patients) according to doses of Levobupivacaine (6, 8 or 12 mg, Chirocaine, Abbot Laboratories, amp. 5 mg/ml). Patients who will receive 8 mg of Levobupivacaine will be randomized to one of four treatment groups (each 20 patients), by dose of intrathecal opioids: 25, 35 mcg of Fentanyl (Fentanyl, Janssen Cilag, amp. 50 mcg/ml) or 5, 7 mcg of Sufentanil (Sufenta, Janssen-Pharmaceutica, amp. 5 mcg/ml). The groups will be named according to dose and combination of Levobupivacaine and Fentanyl or Sufentanil that will be given intrathecally as LB8F25 (LB 8 mg, Fentanyl 25 mcg), LB8F35 (LB 8 mg, Fentanyl 35 mcg), LB8S5 (LB 8 mg, Sufentanil 5 mcg), LB8S7 (LB 8 mg, Sufentanil 7 mcg). Hemodynamic and opioid's side effects will be recorded after intrathecal injection. The level and duration of sensory block, time until two-segment regression, T12 regression andl full skin sensory sensibility at the S1 segment will be registered
89547457|NCT02385539|Placebo Comparator|Levobupivacaine (LB) 12 mg|"Patients will be stratified into three groups by 80 patients: those who will receive 6, 8 or 12 mg of Levobupivacaine intrathecally (Chirocaine, Abbot Laboratories, amp. 5 mg/ml). Patients will receive 12 mg of Levobupivacaine alone intrathecally.~Hemodynamic side effects will be recorded after intrathecal injection. The level and duration of sensory block, time until two-segment regression, T12 regression andl full skin sensory sensibility at the S1 segment will be registered"
89547458|NCT02385461||Inherited Thrombophilia|Women with Common Inherited Thrombophilias and previous foetal loss
88811864|NCT01507103|Experimental|Chemoradiotherapy+tecemotide (L-BLP25)|
88811865|NCT01507103|Active Comparator|Chemoradiotherapy|
88811866|NCT00874250|Experimental|GORE CTAG Device|The primary endpoint of this study is freedom from a Major Device Event (MDE) through 1 month post-treatment in subjects treated with the GORE® Conformable TAG® Thoracic Endoprosthesis.
88811867|NCT02480010|Experimental|Pertuzumab 1050 mg (Cohort B)|Participants in Cohort B will receive 1050 mg pertuzumab via IV infusion on Day 1 of each 3-week cycle. At the end of 3 treatment cycles, response will be evaluated to determine whether additional participants will be enrolled for treatment. If a second stage of enrollment occurs, participants may continue treatment until disease progression or unacceptable toxicity.
89517321|NCT04143711|Experimental|Monotherapy DF1001 Expansion in Gastric Cancer|Monotherapy expansion cohort enrolling up to 20 patients with gastric cancer with documented high expression of HER2 using the recommended phase 2 dose (RP2D) identified in the Monotherapy Dose Escalation arm.
89517322|NCT04143711|Experimental|Combination Therapy with DF1001 and Nivolumab Expansion in Gastric Cancer|Combination therapy with DF1001 and nivolumab expansion cohort enrolling up to 20 patients with gastric cancer with documented low expression of HER2 using the recommended phase 2 dose (RP2D) identified in the Combination Therapy with DF1001 and nivolumab arm.
89517323|NCT04143711|Experimental|Monotherapy DF1001 Expansion in Esophageal Cancer|Monotherapy expansion cohort enrolling up to 20 patients with esophageal cancer with documented high expression of HER2 using the recommended phase 2 dose (RP2D) identified in the Monotherapy Dose Escalation arm.
89517324|NCT04143711|Experimental|Combination Therapy with DF1001 and Nivolumab Expansion in Esophageal Cancer|Combination therapy with DF1001 and nivolumab expansion cohort enrolling up to 20 patients with esophageal cancer with documented low expression of HER2 using the recommended phase 2 dose (RP2D) identified in the Combination Therapy with DF1001 and nivolumab arm.
89517325|NCT04143711|Experimental|Monotherapy DF1001 Exploratory Efficacy Expansion in NSCLC|Monotherapy expansion cohort enrolling up to 20 patients with non-small cell lung cancer with documentation of HER2 activation.
89547459|NCT02385461||Other Thrombophilias with Pregnancy loss|Women with Thrombophilias other than common inherited thrombophilias and previous foetal loss
89547460|NCT02385461||No thrombophilia|Women without thrombophilias and previous foetal loss
89547461|NCT02381717|Experimental|ultra-sound guided femoral nerve block|Patients in this arm will receive a bed-side ultrasound guided femoral nerve block with analgesia 0.5% bupivacaine (2mg/kg)
89547462|NCT02381717|Active Comparator|standard of care- IV morphine|Patients in this arm will have the femoral nerve block block with no ultrasound for guidance with analgesia (IV morphine)
89547463|NCT02381951|Experimental|Spinal cord stimulation|
89547464|NCT02381639|Other|Patients|patients followed in the addiction service of the University Hospital of Nantes (consultations and / or hospitalizations) for restrictive anorexia nervosa
89547465|NCT02381639|Other|Healthy volunteers|control subjects matched for age and sex with the patients
89547466|NCT02385383||Patients with preoperative anemia following treatment protocol|Patients with preoperative anemia according to the WHO definition and treated with a protocol of Iitravenous iron prior to surgery
89547467|NCT02385383||Patients with preoperative anemia - Historical control|Cohort of preoperative anemic patients from the Lundbeckcentre Database. Serving as a historical control
89547468|NCT02385305|Other|Pressure support ventilation|Usual anesthesia management
89547469|NCT02385227|Experimental|Cohort A1|Exclusive blu™ e-cigarette A1
89547470|NCT02385227|Experimental|Cohort A2|Exclusive blu™ e-cigarette A2
89547471|NCT02385227|Experimental|Cohort A3|Exclusive blu™ e-cigarette A3
89547472|NCT02385227|Experimental|Cohort B1|Dual blu™ e-cigarette and usual brand B1
89547473|NCT02385227|Experimental|Cohort B2|Dual blu™ e-cigarette and usual brand B2
89547474|NCT02385227|Experimental|Cohort B3|Dual blu™ e-cigarette and usual brand B3
89547475|NCT02385227|Experimental|Cohort C|Nicotine product cessation C
89547476|NCT02385149|Experimental|whole grain wheat|98g whole grain wheat per day for 12 weeks
89547477|NCT02385149|Experimental|refined wheat|coloured refined wheat control intervention
89547478|NCT02381171|Sham Comparator|Both Sham rTMS and Neuroacupuncture|Subjects will be randomized to receive 10 sessions of both sham treatments. Stimulation will be given on consecutive days (Monday- Friday) for 2 weeks: rTMSat 10hHz (1600pulses) over the primary motor cortex area and neurofunctional electrical acupuncture without current connection over peripheral region.
89547479|NCT02381171|Sham Comparator|Active rTMS and sham Neuroacupuncture|Subjects will be randomized to receive 10 sessions of active rTMS and sham neurofunctional electrical acupuncture treatments. Stimulation will be given on consecutive days (Monday- Friday) for 2 weeks: rTMS at 10Hz (1600 pulses) over the primary motor cortex area and neurofunctional electrical acupuncture without current connection over peripheral region.
89547480|NCT02381171|Sham Comparator|Sham rTMS and Active Neuroacupuncture|Subjects will be randomized to receive 10 sessions of sham rTMS and active Neurofunctional Electrical Acupuncture. Stimulation will be given on consecutive days (Monday- Friday) for 2 weeks: rTMS placebo coil over the primary motor cortex area and neurofunctional electrical acupuncture at 1Hz, continuous, 10mA current for 20 minutes over peripheral region.
89547481|NCT02381171|Active Comparator|Both Active rTMS and Neuroacupuncture|Experimental Subjects will be randomized to receive 10 sessions of both active treatments. Stimulation will be given on consecutive days (Monday- Friday) for 2 weeks: rTMS at 10 Hz (1600 pulses) over the primary motor cortex area and neurofunctional electrical acupuncture at 1Hz, continuous, 10mA current for 20 minutes over peripheral region.
89517326|NCT04143711|Experimental|Combo Therapy with DF1001 and Sacituzumab Govitecan-hziy Exploratory Efficacy Expansion in NSCLC|Combination therapy with DF1001 and sacituzumab govitecan-hziy cohort enrolling up to 20 patients, including safety lead-in, with non-small cell lung cancer with documentation of HER2 activation.
89517327|NCT04143711|Experimental|Monotherapy DF1001 Exploratory Efficacy Expansion in Metastatic Breast Cancer (HR+/HER2-)|Monotherapy expansion cohort enrolling up to 20 patients with metastatic breast cancer with documentation of HR positive and HER2 negative expression.
89547482|NCT05003687|Experimental|Part A: Single Dose of Lu AG06474 or Placebo|Participants will receive single oral dose of Lu AG06474 or placebo.
89547483|NCT05003687|Experimental|Part B: Repeated Dose of Lu AG06474 and Food Interaction|"Participants will receive a single oral dose of Lu AG06474 in each dosing period (Period 1, 2, and 3) in the following sequence:~Sequence B1: Fed - Fasting- Fasting~Sequence B2: Fasting- Fed - Fasting~Sequence B3: Fasting- Fasting - Fed"
89547484|NCT02381327|Experimental|Binge Eating Disorder|Patients with Binge Eating Disorder will use Mandometer as an intervention to reduce food intake and speed of eating.
89547485|NCT02381327|Experimental|Control|Normal weight, healthy control subjects will use Mandometer to obtain data for comparison with the patients with Binge Eating Disorder.
89547486|NCT03113669|Other|Intervention (CBT-GSH)|Participants will receive a clinical intake (1 hour) and 6-sessions (approximately 25 minutes each) over 12 weeks of individual guided self-help CBT for eating disorders based on the treatment approach developed by Dr. Christopher Fairburn to use his self-help book Overcoming Binge Eating with the therapeutic guidance of clinician. Participants will be provided with a copy of Overcoming Binge Eating. The treatment is a largely behavioral treatment that focuses on helping patients engage in more regular eating, reduce dieting behaviors, and eliminate behaviors that contribute to binge eating. All participants in the study will receive the same treatment.
89547487|NCT02381483|Experimental|Lean|Cold exposure
89547488|NCT02381483|Experimental|Obese|Cold exposure
89547489|NCT02385071|Experimental|Panel1: Sequence 1 (ABC)|Participants will receive Treatment A (150 milligram (mg) simeprevir (SMV) capsule with water under fed conditions) in Period 1; followed by Treatment B (3*50 mg capsules of SMV [including 50 mini-tablets of 1 mg each] with water under fed conditions) in Period 2; followed by Treatment C (3*50 mg dispersible SMV tablets dispersed in water under fed conditions) in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
89547490|NCT02385071|Experimental|Panel1: Sequence 2 (BCA)|Participants will receive Treatment B in Period 1; followed by Treatment C in Period 2; followed by Treatment A in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
89025176|NCT03279549|Active Comparator|dressing change group|Routine dressing change group
89547491|NCT02385071|Experimental|Panel1: Sequence 3 (CAB)|Participants will receive Treatment C in Period 1; followed by Treatment A in Period 2; followed by Treatment B in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
89547492|NCT02385071|Experimental|Panel1: Sequence 4 (CBA)|Participants will receive Treatment C in Period 1; followed by Treatment B in Period 2; followed by Treatment A in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
89547493|NCT02385071|Experimental|Panel1: Sequence 5 (BAC)|Participants will receive Treatment B in Period 1; followed by Treatment A in Period 2; followed by Treatment C in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
89547494|NCT02385071|Experimental|Panel1: Sequence 6 (ACB)|Participants will receive Treatment A in Period 1; followed by Treatment C in Period 2; followed by Treatment B in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
89547495|NCT02385071|Experimental|Panel 2: Sequence 1 (DEF)|Participants will receive Treatment D (3*50 mg SMV capsules [including 50 mini-tablets of 1 mg each] with water or 3*50 mg dispersible SMV tablets dispersed in water under fed conditions) in Period 1; followed by Treatment E (3*50 mg SMV capsules [including 50 mini-tablets of 1 mg each] with water or 3*50 mg dispersible SMV tablets dispersed in water under fasted conditions) in Period 2; followed by Treatment F (3*50 mg SMV capsules [including 50 mini-tablets of 1 mg each] with yoghurt or 3*50 mg dispersible SMV tablets dispersed in apple juice under fed conditions) in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
89547496|NCT02385071|Experimental|Panel 2: Sequence 2 (EFD)|Participants will receive Treatment E in Period 1; followed by Treatment F in Period 2; followed by Treatment D in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
89547497|NCT02385071|Experimental|Panel 2: Sequence 3 (FDE)|Participants will receive Treatment F in Period 1; followed by Treatment D in Period 2; followed by Treatment E in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
89547498|NCT02385071|Experimental|Panel 2: Sequence 4 (FED)|Participants will receive Treatment F in Period 1; followed by Treatment E in Period 2; followed by Treatment D in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
89547499|NCT02385071|Experimental|Panel 2: Sequence 5 (EDF)|Participants will receive Treatment E in Period 1; followed by Treatment D in Period 2; followed by Treatment F in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
89547500|NCT02385071|Experimental|Panel 2: Sequence 6 (DFE)|Participants will receive Treatment D in Period 1; followed by Treatment F in Period 2; followed by Treatment E in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
89547501|NCT02381405|Active Comparator|A|Enterade beverage
89547502|NCT02381405|No Intervention|B|Standard of care
89547503|NCT02381093|Active Comparator|Standard BLS Course|Participants will partake in a standard BLS course.
89547504|NCT02381093|Experimental|Contextual Interference|Participants will partake in a BLS course designed using contextual interference scheduling.
89547505|NCT02384681||Exposed|Medical regulation assistants working with headset
89547506|NCT02384681||Non-Exposed|Participants working without headset
89547507|NCT02384915|Experimental|Spinal anesthesia|Intrathecal injection of 2 ml (40 mg) of 2% hyperbaric prilocaine at L3-L4 interspaces through a 100mm Sprotte 25 G spinal needle (Pencan, b-brawn, Germay) in lateral decubitus position, (with limb to operate declive).
89547508|NCT02384915|Active Comparator|peripheral nerve block|Ultrasound-guided sciatic-femoral nerve block injecting 25 ml of a 2% mepivacaine solution,15 ml on femoral nerve and 10 ml on sciatic nerve through a 80 mm 22g eco-reflex needle (Sonoplex, Pajunk, Germany)
89547509|NCT04875377|Experimental|Reformulated pizza|Participants must consume a nutritionally balanced pizza reformulated with seaweed (Ascophyllum nodosum) as an ingredient 3 times a week for 24 weeks
89547510|NCT04875377|Placebo Comparator|Control pizza|Participants must consume a nutritionally balanced pizza without seaweed, 3 times a week for 24 weeks
89547511|NCT04875377|Experimental|Seaweed capsule|Participants must consume a capsule containing powdered Ascophyllum nodosum 3 times a week for 24 weeks
89547512|NCT04875377|Placebo Comparator|Control capsule|Participants must consume an empty capsule 3 times a week for 24 weeks
89025177|NCT03279549|Experimental|Dermal matrix dressing group|Limited debridement & Acellular dermal matrix dressing group.
89025178|NCT03279549|Experimental|Epidermal cell spraying group|Limited debridement & Epidermal cell spraying group
89207957|NCT00972699|Experimental|Mentor Mothers Intervention|In the intervention arm, participants will receive the Department of Health-delivered Prevention of Mother to Child Transmission (PMTCT) program plus the Project Masihambisane mentor mothers support program. HIV positive mentor mothers, who have been through the PMTCT program, will be recruited and trained to deliver the intervention to pregnant mothers living with HIV.
89207958|NCT00972699|No Intervention|Control|Mothers living with HIV in the standard of care control clinics will receive the Department of Health-delivered PMTCT program.
89207959|NCT00960765||Roux-En-Y Gastric Bypass|
88961669|NCT05116332||Obstetrics and Gynaecology (O&G)|"Trainees from ST3/ST4/ST5 grades (n=11) and ST6/ST7 grades (n=12). As O&G training covers both Obstetrics & Gynaecology curriculums, we will recruit trainees in their final two years of training (i.e. ST6 and ST7) with gynaecology special interest; undertaking at least one gynaecology Advanced Training Skills Modules (ATSM). These include advanced laparoscopic training, open and laparoscopic benign abdomen, urogynaecology, gynaecology-oncology and reproductive medicine.~To measure musculoskeletal (Electromyography) and cognitive fatigue (Electroencephalography): A total of 10 trainees had these measured; ST3/4/5 (n=5) and ST6/7 (n=5)."
89547513|NCT04733495|Experimental|Supportive care (resistance exercise, counseling)|Patients undergo personalized resistance exercises over 1 hour daily. Patients receive dietary counseling over 60 minutes at week 1 and then over 15-30 minutes weekly for up to 6 weeks. Patients also receive group-based behavioral counseling BIW in weeks 1-8, QW in weeks 9-12, and then twice a month in weeks 13-24.
88961670|NCT05116332||General Surgery (GS)|"Trainees from ST3/ST4/ST5 (n=11) and senior trainees from ST7/ST8 (n=11).~To measure musculoskeletal (Electromyography) and cognitive fatigue (Electroencephalography): A total of 10 trainees had these measured; ST3/4/5 (n=6) and ST7/8 (n=4)"
88961671|NCT05091905|Active Comparator|Continuous Infusion|Patients will receive a continuous infusion of Ropivacaine 0.2% (6 mL/hr popliteal-sciatic and 8 mL/hr infraclavicular, 4 mL patient controlled bolus with 30-minute lockout).
89547514|NCT04872101|Experimental|Delgocitinib 20 mg/g|Twice-daily topical application for 16 weeks
89547515|NCT04872101|Placebo Comparator|Cream vehicle|Twice-daily topical application for 16 weeks
88961672|NCT05091905|Experimental|Titratable Automated Boluses|Patients will receive patient-titratable intermittent boluses of Ropivacaine 0.2% (8 mL popliteal-sciatic or 11 mL infraclavicular automated bolus every 120 minutes, 4 mL patient controlled bolus with 30-minute lockout).
88961673|NCT05078242|Experimental|Experimental: EaseVRx sessions|This is a study of patients with chronic pain to assess usability of a VR device at home. The main goals are 1) to collect data on feasibility of recruitment, 2) to collect data on daily adherence to therapy, and 3) to collect preliminary effectiveness data on pain and mood outcomes. There will be 7 sessions over one week, with each session lasting about 2-16 minutes. All patients recruited will be in the active arm; this is not a randomized pilot study.
88961674|NCT05057013|Experimental|Part A Arm 1 Dose Escalation (single agent)|Groups of patients will receive increasing doses of HMBD-001 as a single agent to find a safe dose that best targets cancer cells. Approximately 26 patients with tumours known to express HER3 will be entered into this arm.
88961675|NCT05057013|Experimental|Part B Arm 1 Dose Expansion (single agent)|An expansion cohort of up to 25 patients with a confirmed HER3 positive or confirmed NRG1 fusion rearrangement RAS wild type colorectal cancer, castration resistant prostate cancer, triple negative breast cancer or squamous cell head and neck cancer will receive the HMBD-001 single agent RP2D as determined in Part A Arm 1.
89547516|NCT02384837||TCFA|EXCEL biodegradable polymer-coated sirolimus-eluting stent was implanted on lesions which include TCFA (>=1)
89547517|NCT02384837||NO-TCFA|EXCEL biodegradable polymer-coated sirolimus-eluting stent was implanted on lesions which is not include TCFA
88961676|NCT05041114|Other|Single|Implantation of motor neuroprosthesis medical device.
88961677|NCT05028647|Active Comparator|VR treatment|5 subjects per country aged 13-16 treated with VR supported (Oculos) program, one hour a day for 5 days
88961678|NCT05028647|Active Comparator|AR treatment|5 subjects per country aged 10-13 treated with AR supported (tablet) program, one hour a day for 5 days
88961679|NCT05028647|No Intervention|control age 13-16|dyslexic subjects aged 13-16 not randomized to active treatment
88961680|NCT05028647|No Intervention|Control age 10-12|dyslexic subjects aged 10-12 not randomized to active treatment
88961681|NCT05025943|Experimental|Standard lifestyle intervention + omega-3 fatty acid enriched diet|American Heart Association Target Diet/Standard Lifestyle Intervention (SLI) + omega-3 fatty acid enriched foods
88961682|NCT05025943|Active Comparator|Standard lifestyle intervention|American Heart Association Target Diet/Standard Lifestyle Intervention (SLI)
88961683|NCT04997655||Upper Transabdominal Plain Block|All patients in this group are routinely administered general anesthesia. After extubation, the subcostal transverse abdominis area block was directed laterally along the rectus abdominis muscle by finding the linea alba under the xiphoid region under ultrasound guidance with a 22G echogenic block needle, and 20 ml (8 ml 0.5% bupivacaine, 7 ml prilocaine) into the fascia between the rectus abdominis and transverse abdominis muscles. , 5 ml of saline) drug mixture will be performed by the anesthesiologist in charge of that day, who is not aware of the observational measurement to be made, if there is an indication, as a blind practitioner.
88961684|NCT04997655||Opioid analgesia|All patients in this group are routinely administered general anesthesia. Apart from this, in the other group, which does not have peripheral nerve block and only routine opioid analgesia is considered sufficient, only routine peroperative USG diaphragm measurements will be recorded observationally.
88961685|NCT04995549|Experimental|Measures using Cutiscan® CS 100|
89025179|NCT03279549|Experimental|BFGF group|Limited debridement & Basic fibroblast growth factor group
89547518|NCT03113357|Experimental|Myofascial release technique|Subjects lied down in supine with knee flexion. Therapist seated on a stool at the head of the table. Elbows and supinated forearms on the table. Asked the client to lift their head off the table. Position the tips of the first three fingers into the soft tissue immediately inferior to the arc of atlas. The fingers are stabilized in a flexed position - around 45° at the MP and PIP joints. The subject is asked to rest their head back down so the fingertips are in the sub-occipital soft tissues and the finger pads rest firmly against the inferior aspect of the atlas. Once the position is perceived to be comfortable, a series of soft tissue responses will occur, characterized by local softening sensations followed by an increase in the weight of the head.
89547519|NCT03113357|Experimental|conventional exercise therapy|Craniocervical flexion exercises, performed in supine lying, aimed to target the deep neck flexor muscles. Then they trained to be able to hold progressively increasing ranges of craniocervical flexion using feedback from an airfilled pressure sensor placed behind the neck. The muscles of the scapula, particularly the serratus anterior and lower trapezius, were trained using inner range holding exercises of scapular adduction and retraction, practiced initially in the prone lying position. The subjects were trained to sit with a natural lumbar lordosis while gently adducting and retracting their scapulas and gently flexed their cranio-cervical spine to facilitate the deep neck flexors.
89547520|NCT03105791|No Intervention|Normal pre-operative education|• Control group received normal pre-operative education regarding surgery
89547521|NCT03105791|Active Comparator|Opioid usage education|• The study group received formal education detailing recommended post-operative opioid usage, side effects, dependence, and addiction
89547522|NCT02384291|Experimental|Alpha-Bios GRAFT Natural Bovine Bone treatment|Pure Hydroxyapatite ceramic mineral with high similarity to the human bone
89547523|NCT02384291|Active Comparator|natural bone substitute|natural bone substitute material derived from the mineral portion of bovine bone
89547524|NCT04729439|Experimental|Organizational/behavioral intervention + digital health tool|Participants will receive sixteen 30-minute sessions of the organizational/behavioral skills intervention (i.e., Homework Organization and Planning Skills [HOPS]) plus the online digital health application during treatment
89547525|NCT04729439|Active Comparator|Organizational/behavioral intervention only|Participants will receive sixteen 30-minute sessions of the organizational/behavioral skills intervention (i.e., Homework Organization and Planning Skills [HOPS]) only, without the online digital health application during treatment
89547526|NCT03105947|Active Comparator|Coconut oil|50g extra virgin coconut oil to be consumed daily for four weeks
89547527|NCT03105947|Active Comparator|Butter|50g butter to be consumed daily for four weeks
89547528|NCT03105947|Active Comparator|Olive Oil|50g extra virgin olive oil to be consumed daily for four weeks
89547529|NCT03105869|Experimental|fluorocholine PET/CT|all patients will undergo a second PET/CT with fluorocholine
89547530|NCT02380937|Experimental|ablation for typical atrial flutter|This group receives an MR-guide ablation for atrial flutter with the study device (catheter)
89547531|NCT02384369|Experimental|SNC-102 sustained release tablet|SNC-102 sustained release tablet for oral administration, 1600 mg BID for 8 weeks
89547532|NCT02384369|Placebo Comparator|Placebo|Placebo tablet for oral administration, BID for 8 weeks
89547533|NCT02384447||Knee Amputation|Patients that are scheduled to undergo above knee amputation due to complications associated with diabetes will be enrolled
89547534|NCT02384525|Experimental|clinical-based ultrafiltration|
89547535|NCT02384525|Active Comparator|BIA-based ultrafiltration|
89547536|NCT02384603|Experimental|GPR and CBT|Global postural reeducation associated with cognitive behavioral therapy; 01 session per week for 10 weeks
89547537|NCT02384603|Active Comparator|SMSE and CBT|Segmental muscle stretching exercises associated with cognitive behavioral therapy; 01 session per week for 10 weeks
89547538|NCT02384135|Other|interventional|Patients with D-dimer levels between the usual cutoff and the age-adjusted cutoff will be left untreated and followed-up for three months
89547539|NCT02380625|Experimental|Azithromycin|Azithromycin, IV fluids and laboratory testing
88961686|NCT04987983|Experimental|Experimental SLP-R|Infant placed in a SLP-R on the researcher's lap. Infant body positioned on side-lying position on the right side of it's body. Head of the infant symmetrically placed between the shoulders, supported by the researcher's. Shoulder girdle higher than the pelvic girdle, head and back in a straight line - a slight natural bend of the body is allowed. Legs bent at an angle of approx. 90° in the natural flexion of the knee and ankle joint. The infant's arms close to the midline (on the bottle or researcher's hands)
89547540|NCT02380625|Experimental|Sunitinib and Erlotinib|Sunitinib, Erlotinib, IV fluids and laboratory testing
89547541|NCT02380625|Experimental|Atorvastatin and Irbesartan|Atorvastatin, Irbesartan, IV fluids and laboratory testing
88961687|NCT04987983|Experimental|Experimental SLP-L|Infant placed in a SLP-L on the researcher's lap. Infant body positioned on side-lying position on the left side of it's body. Head of the infant symmetrically placed between the shoulders, supported by the researcher's. Shoulder girdle higher than the pelvic girdle, head and back in a straight line - a slight natural bend of the body is allowed. Legs bent at an angle of approx. 90° in the natural flexion of the knee and ankle joint. The infant's arms close to the midline (on the bottle or researcher's hands).
88961688|NCT04983589|Placebo Comparator|Vehicle|Participants received vehicle, one drop bilaterally (in each eye), twice daily (BID), with a gap of 6 hours between both doses, for up to 14 days.
88961689|NCT04983589|Experimental|AGN-190584|AGN-190584 ophthalmic solution, one drop bilaterally (in each eye), BID, with a gap of 6 hours between both doses, for up to 14 days.
89025180|NCT00478491||1|Persons with a parent with Alzheimer's disease
89025181|NCT00478491||2|Persons whose parents survived to old age without memory problems
89025182|NCT00478491||3|Persons with diagnosed mild cognitive impairment
89547542|NCT02380625|Other|IV fluids and laboratory testing|no additional treatment
89547543|NCT02383979|Sham Comparator|Plasma Ball (Control)|"Subjects randomized to standard therapy will participate 14 days of daily mirror therapy sessions preoperatively which will consist of undergoing a sham therapy with a 22 plasma globe involving contralateral limb interaction with the sphere."
89547544|NCT02383979|Experimental|Experimental|Subjects randomized to the mirror therapy limb will undergo 14 days of daily mirror therapy sessions preoperatively which will consist of observing the unaffected limb reflected for 30 minutes in a mirror positioned in the midline to block the view of the affected limb.
89547545|NCT02383979|No Intervention|Non-Surgical|Subjects will undergo 3 questionnaires and one functional fMRI exam. Imaging protocol will be identical to preoperative imaging protocol for amputation subjects. This data will aid in establishing baseline fMR activation values for all fMR paradigms tested. The control group will not be randomized to receive either perioperative plasma ball (sham) or mirror therapy.
89547546|NCT02380313|Experimental|Afuresertib 125 mg + enzalutamide 160 mg|Participants will be receiving enzalutamide at the recommended dose for at least 4 weeks prior to enrolment into this cohort. Afuresertib 125mg and enzalutamide 160 mg will be dosed continuously on a once daily schedule for 28-day intervals.
89025183|NCT00478491||4|Persons without memory problems
89207960|NCT00960765||Gastric Banding|
89207961|NCT00960765||Sucessful Response to RYGB|
89547547|NCT02380313|Experimental|Afuresertib 150 mg + enzalutamide 160 mg|Participants will be receiving enzalutamide at the recommended dose for at least 4 weeks prior to enrolment into this cohort. Afuresertib 150 mg and enzalutamide 160 mg will be dosed continuously on a once daily schedule for 28-day intervals.
89207962|NCT00960765||Failed Response to RYGB|
89547548|NCT02380313|Experimental|Afuresertib 175 mg + enzalutamide 160 mg|Participants will be receiving enzalutamide at the recommended dose for at least 4 weeks prior to enrolment into this cohort. Afuresertib 175 mg and enzalutamide 160 mg will be dosed continuously on a once daily schedule for 28-day intervals.
89547549|NCT02380313|Experimental|Afuresertib 200 mg + enzalutamide 160 mg|Participants will be receiving enzalutamide at the recommended dose for at least 4 weeks prior to enrolment into this cohort. Afuresertib 200 mg and enzalutamide 160 mg will be dosed continuously on a once daily schedule for 28-day intervals.
89547550|NCT02380313|Experimental|Afuresertib 125 mg + abiraterone 1000 mg + prednisone 5 mg|Participants will be receiving abiraterone at the recommended dose for at least 2 weeks prior to enrolment into this cohort. Afuresertib 125mg and abiraterone 1000 mg will be dosed continuously on a once daily schedule for 28-day intervals. Continuous BID prednisone 5mg will be coadministered per the labelled recommendations.
89547551|NCT02380313|Experimental|Afuresertib 150 mg + abiraterone 1000 mg + prednisone 5 mg|Participants will be receiving abiraterone at the recommended dose for at least 2 weeks prior to enrolment into this cohort. Afuresertib 150mg and abiraterone 1000 mg will be dosed continuously on a once daily schedule for 28-day intervals. Continuous BID prednisone 5mg will be coadministered per the labelled recommendations.
89547552|NCT02380313|Experimental|Afuresertib 100 mg + abiraterone 1000 mg + prednisone 5 mg|Participants will be receiving abiraterone at the recommended dose for at least 2 weeks prior to enrolment into this cohort. Afuresertib 100 mg and abiraterone 1000 mg will be dosed continuously on a once daily schedule for 28-day intervals. Continuous BID prednisone 5mg will be coadministered per the labelled recommendations.
89547553|NCT02380313|Experimental|RP2D of Afuresertib + enzalutamide 160 mg|Participants in this arm will receive RP2D of afuresertib established in escalation cohort in addition to plus enzalutamide 160 mg once daily.
89547554|NCT02380313|Experimental|Afuresertib RP2D + abiraterone 1000 mg + prednisone 5 mg|Participants in this arm will receive RP2D of afuresertib established in escalation cohort in addition to abiraterone 1000 mg once daily and continuous BID prednisone 5 mg coadministered per the labelled recommendations.
89547555|NCT02380313|Experimental|Afuresertib RP2D + abiraterone + prednisone in PK cohort|Participants in this arm will receive RP2D of afuresertib established in escalation cohort in addition to abiraterone 1000 mg once daily and continuous BID prednisone 5 mg coadministered per the labelled recommendations
89547556|NCT02380157|Experimental|Kaleorid|4 weeks treatment with Kaleorid, 750mg, 3 tablets 3 times daily.
89547557|NCT02380157|Placebo Comparator|Placebo|4 weeks treatment with Placebo tablets, 3 tablets 3 times daily.
89547558|NCT02380235|Experimental|PEG-somatropin|0.12mg/kg/w
89547559|NCT02380235|Experimental|PEG-Somatropin|0.20mg/kg/w
89547560|NCT02380469|Experimental|Immediate intervention|Immediately after enrollment in the project, caregivers and patients receive the intervention
89547561|NCT02380469|Other|Delayed intervention (3 weeks later)|This group receives the same intervention as in the experimental group, but after the outcome assessment at 2 weeks
89547562|NCT01625182|Experimental|Fingolimod (FTY720)|Participants received Fingolimod 0.5 mg orally once daily.
89547563|NCT01625182|Placebo Comparator|Placebo|Participants received matching placebo to Fingolimod orally once daily.
89547564|NCT02380391||People living with HIV (HIV+)|Adults experiencing first episode of ACS treated with percutaneous coronary intervention.
89547565|NCT02380391||People without HIV (HIV-)|Adults experiencing first episode of ACS treated with percutaneous coronary intervention, matched to HIV+ on age, sex, known diabetes mellitus, and anti-platelet therapy.
89547566|NCT02383823|Active Comparator|Estrogens in menopausal women|Crossover of estrogens or placebo in random order, either 2 mg estradiol or placebo in three months in random sequence, age span 45-55
89547567|NCT02383823|No Intervention|Menopausal men|comparative to menopausal women, age span 45-55
89547568|NCT02383823|No Intervention|Elderly women|comparative to menopausal women, age span 65-80
89547569|NCT02383823|No Intervention|Elderly men|comparative to menopausal women, age span 65-80
89547570|NCT02383823|Placebo Comparator|Placebo in menopausal women|Crossover of estrogen or placebo in random order, either 2 mg estrogen or placebo in three months in random sequence, age span 45-55
89547571|NCT02380001|Experimental|Dexketoprofen trometamol|A White round pill with 25 mg of dexketoprofen will be administered 30 minutes before the impacted third molar surgery start. Immediately after the surgery, a hard-gelatin capsule with placebo will be administered.
89547572|NCT02380001|Placebo Comparator|Preoperative control|A hard-gelatin capsule with placebo will be administered 30 minutes before the impacted third molar surgery start. Immediately after the surgery, a hard-gelatin capsule with 25mg of Dexketoprofen will be administered.
89547573|NCT02384057|Experimental|C8 sciences|cognitive rehabilitation with C8 sciences
89547574|NCT02384057|Active Comparator|Conventional cognitive rehabilitation|cognitive rehabilitation with conventional methods
89547575|NCT02379767||Patients|Subjects aged between 18 and 60 years suffering from unipolar severe depression, who did not respond to conventional pharmacological antidepressant treatment (at least two adequate trials with antidepressants of different pharmacological classes over a minimum period of one month, equivalent to 150mg of tricyclic antidepressants). Concomitant psychotropic medication will be accepted during study participation, however, medication should remain stable throughout the study. Patients will undergo 6 to 14 ECT sessions in accordance with recent consensus statements and based on standard operation procedures (SOPs) of the Department of Psychiatry and Psychotherapy.
89547576|NCT02379767||Healthy subjects|Subjects will be age- and sex-matched to the patients and should present no psychiatric, or major neurological or internistic illness.
89207963|NCT00748553|Experimental|All patients|All participants enrolled.
89207964|NCT03974815|Experimental|ACTIVE|Active stimulation (tDCS) will be used in the dose of 2mA /30 min per day, for 6weeks. (minimum 5 times per week)(total of 30~42 sessions)
89207965|NCT03974815|Sham Comparator|SHAM|Sham stimulation (tDCS) will be used in the dose of 0mA /30 min per day, for 6weeks. (minimum 5 times per week)(total of 30~42 sessions)
89547577|NCT02383511|Other|Sequence 1|Drug: SMT C1100 or placebo 3-treatment (Period 1,2 and 3)
89547578|NCT02383511|Other|Sequence 2|Drug: SMT C1100 or placebo 3-treatment (Period 1,2, and 3)
89547579|NCT02383511|Other|Sequence 3|Drug: SMT C1100 or placebo 3-treatment (Period 1,2 and 3)
89547580|NCT02661815|Experimental|Phase 1 Expansion Cohort A|Paclitaxel 80mg/m2 weekly days 1, 8, and 15 of a 28-day cycle Ricolinostat dosing as identified as the RP2D combination dose
89547581|NCT02661815|Experimental|Phase 1 Expansion Cohort B|Paclitaxel 70mg/m2 weekly days 1, 8, and 15 of a 28-day cycle Ricolinostat dosing as identified as the RP2D combination dose
89547582|NCT02661815|Experimental|Phase 1 Expansion Cohort C|Paclitaxel 80mg/m2 weekly days 1, 8, and 15 of a 28-day cycle Bevacizumab 10mg/kg days 1 and 15 of a 28-day cycle Ricolinostat dosing as identified as the RP2D combination dose
89547583|NCT02661815|Experimental|Phase 1 Escalation Cohort|Ricolinostat with weekly paclitaxel dosed at 80 mg/m2 per week (3 out of 4 weeks).
89547584|NCT02379845|Experimental|Arm A|NBTXR3 + Radiotherapy
89547585|NCT02379845|Active Comparator|Arm B|Radiotherapy alone
89547586|NCT02379689|Active Comparator|injectable placental tissue extract called BioDGenesis|This study will compare injectable placental tissue extract called BioDGenesis (Active Product)
89547587|NCT02379689|Placebo Comparator|Placebo|injectable Tissue Suspension Solution (TSS) (Placebo). The Active Product is supplied by BioD, LLC (BioD).
89547588|NCT02377193|Experimental|Simulect|Simulect IV 40 mg D0 and D4
89547589|NCT02377193|Active Comparator|ATG Fresenius|ATG IV min dose 3 mg/ kg/ day D0, D1, D3, D5
88961690|NCT04945759|Experimental|Isokinetic Exercise (İE) Group:|"Isokinetic Exercise (IE) Group:~(Knee Joint Flexion / Extension, Hip Joint Internal / External Rotation and Abduction / Adduction Strengthening Program)~Patients will be seated on the isokinetic Cybex-Humac Norm device in a 90° upright sitting position. It will be fixed to the seat with torso, pelvis and thigh straps. During this training, patients will be told that the dynamometer arm will bring the knee from extension to flexion. During this exercise, the patient will be advised to resist the dynamometer as much as possible while moving the knee in flexion/extension, internal/external rotation, and abduction/adduction with the dynamometer."
88961691|NCT04945759|Active Comparator|Isokinetic Exercise + Aussie Current (IE+AC)Group:|Aussie Current and Isokinetic Exercise program will be applied to the patients. The distal electrode is placed on the anterior part of the thigh and superior to the patella. The proximal electrode will be placed on the thigh. One electrode will be placed between the anterior superior and posterior superior iliac spine of the PFPS(Patellofemoral Pain Syndrome) side and the other electrode will be placed in a triangle on the greater trochanter of the femur in the gluteus medius muscle. By contacting the Turkish authorities of the BTL 4825SPREMIUM device, the current was adjusted in the Aussie Current 1 kHz frequency, 400 ms phase time, 50 hz burst frequency, 4 ms duration device. This new burst modality medium frequency alternating current will be applied to the patient for 20 minutes.
88961692|NCT04945759|Active Comparator|Isokinetic Exercise + Russian Current (IE+RC) Group:|"Isokinetic Exercise program will be applied to the patients. Similarly, as with the Aussie Current, the Russian current will be applied to the vastus lateralis-medialis and gluteus medius muscles.~Russian current will be set as 2500 Hz sinusoidal current, 200 ms phase time, 50 hz burst frequency, 50% duty cycle, 10 ms duration.~The patient will be treated for 20 minutes."
89547590|NCT02053792|Experimental|rIX-FP|"Subjects will administer rIX-FP by intravenous infusion as routine prophylaxis, prevention, and on-demand treatment during a treatment period of approximately 3 years.~The routine prophylaxis treatment interval for previously treated patients may be changed at each scheduled 6-month follow-up assessment. On-demand treatment with rIX-FP will be used for all bleeding episodes requiring treatment. Subjects (other than those in France) may participate in a surgical 'substudy' in which rIX-FP may be administered before, during and after surgery. An additional substudy will examine the safety and PK of subcutaneous administration of rIX-FP.~For previously untreated patients, subjects will administer rIX-FP intravenously as weekly prophylaxis and/or on-demand treatment during the first 12 months, and as weekly routine prophylaxis thereafter.~The dose of rIX-FP administered will be based on the subject's previous rIX-FP use and/or pharmacokinetic data."
89547591|NCT02379455|Experimental|Comprehensive drug review|
89547592|NCT02379455|No Intervention|Control group|"Follow-up by family physician as usual."
89547593|NCT02379533|No Intervention|sedentary control|
89547594|NCT02379533|Experimental|Home-based aerobic exercise|The training program will be conducted in accordance with the recommendations of the American College of Sports Medicine. All training sessions will be preceded by stretching of large muscle groups and heating (5 minutes) and at the end by cool down and stretching (5 minutes). The program will consist of 24 weeks with three sessions per week on alternate days. The aerobic training will be continuous, with an increment of 10 minutes in duration every 4 weeks. The intensity will be prescribed according to ventilatory threshold, characterized by the highest intensity of physical exertion fully maintained by aerobic energy pathways. The intensity control was done by means of the heart rate value obtained at ventilatory threshold. The home-based exercise group exercise at home with telephone follow-up weekly and once a month will be held at the training center under the supervision of a physical education teacher.
89547595|NCT02379533|Active Comparator|Center-based aerobic exercise|The training program will be conducted in accordance with the recommendations of the American College of Sports Medicine. All training sessions will be preceded by stretching of large muscle groups and heating (5 minutes) and at the end by cool down and stretching (5 minutes). The program will consist of 24 weeks with three sessions per week on alternate days. The aerobic training will be continuous, with an increment of 10 minutes in duration every 4 weeks. The intensity will be prescribed according to ventilatory threshold, characterized by the highest intensity of physical exertion fully maintained by aerobic energy pathways. The intensity control was done by means of the heart rate value obtained at ventilatory threshold. However, a group exercise held in the center on a treadmill with the direct supervision of a physical education teacher.
89547596|NCT02377115|Other|Study cohort|Tablet computer application
89547597|NCT04356287|Experimental|One infusion of UCMSC|Patients receive one intravenous infusion of UCMSC at month 0 and one intravenous infusion of placebo at month 3. Each experimental infusion will consist of 1 million UCMSC/kg suspended in 50 ml of PlasmaLyte A. Each placebo infusion will consist of a similar volume of PlasmaLyte A.
89547598|NCT04356287|Experimental|Two infusions of UCMSC|Patients receive one intravenous infusion of UCMSC at month 0 and one intravenous infusion of UCMSC at month 3. Each experimental infusion will consist of 1 million UCMSC/kg suspended in 50 ml of PlasmaLyte A.
89547599|NCT04356287|Placebo Comparator|Placebo infusions|Patients receive intravenous placebo infusions at months 0 and 3. Each placebo infusion will consist of 50 ml of PlasmaLyte A.
89547600|NCT04688021|Experimental|Tocilizumab cohort|Each patient receives Tocilizumab (8 mg/kg, i.v.) on day -1 added to conventional acute GVHD prophylaxis regimen (CsA+MTX+low-dose MMF+ATG) of haploidentical HSCT.
89547601|NCT02082340|Experimental|Intervention arm|The intervention includes the following components: self-administered drug intake strategy, TB knowledge and socio-psychological counseling session, SMS text messages, phone calls, educational leaflet
89547602|NCT02082340|No Intervention|Control arm|patients included in the control arm will receive traditional - clinical Directly Observed Therapy (DOT) as recommended by WHO
89547603|NCT04349969|Experimental|Treatment|"Parts A and B: AK117 monotherapy intravenous (IV) infusion- weekly doses in a 28-day cycle.~Parts A2: AK117 (QW) + AK104 (Q3W) combination therapy intravenous (IV) infusion in a 21-day cycle."
89547604|NCT04712968|Experimental|Group 1 (intervention group)|Regular exposure to morning daylight
89547605|NCT04712968|No Intervention|Group 2 (control group)|Treatment as usual.
89547606|NCT04327505|Experimental|Hyperbaric oxygen|Hyperbaric oxygen 1,6-2.4 Bar for 30-60 minutes (compression/decompression time, according to local routines) in addition to best practice
89547607|NCT04327505|No Intervention|Control|Best practice
89547608|NCT02053246|Experimental|Nebivolol|Participants will be started at 2.5 mg of nebivolol by mouth daily if on a beta-blocker the dose will start at 5mg, and titrated up to 10 mg daily, as tolerated.
89547609|NCT02053168|Other|Resorbable Mesh|Phasix Mesh
89547610|NCT02052466||Reverse TSA patients|Patients having undergone reverse TSA at the Cleveland Clinic with a high quality preoperative CT of the operative shoulder and who are at least 24 months post surgery.
89547611|NCT02379299|Active Comparator|Single-hormone closed-loop control|Closed-loop glucose control by use of insulin only by use of DiaCon single-hormone closed-loop glucose control algorithm
89547612|NCT02379299|Experimental|Dual-hormone closed-loop control|Closed-loop glucose control by use of insulin and glucagon by use of DiaCon dual-hormone closed-loop glucose control algorithm
89547613|NCT03112967|Experimental|OSS(Suprep)|Oral Sulfate solution (Suprep) in day before and split-dose regimens In the OSS arm: between 17:00 and 18:00 hours on the day before colonoscopy, subjects were instructed to pour one 180-ml bottle of the study medication into a provided 480-ml mixing cup and fill it with water and then drink the entire volume, followed by two additional 480 ml of water. At approximately 6:00 a.m. on the following morning, the subjects took the second dose of OSS by same formulation protocol.
89547614|NCT03112967|Active Comparator|4L PEG solution(Colyte)|4L PEG solution in day before and split-dose regimens In the 4L PEG arm: subjects had the first 2L between 18:00 and 19:00 hours (250mL every 15 minutes) in the evening before the colonoscopy. And the second 2L was given between 07:00 and 08:00 on the day of colonoscopy.
89547615|NCT02379065|Active Comparator|Control nebuliser treatment|"Both groups will receive the same bronchodilator pharmacotherapy, in keeping with National Institute of Clinical Excellence guidelines. For this arm, nebuliser will be standard of care.~Interventions:~Score on the Modified Borg Scale (an interval scale which runs from 0-10, with statements describing level of breathlessness as perceived by the patient) to be completed by both the patient and clinician~Heart rate (as a measure of severity of exacerbation and an indirect measure of salbutamol dosage)~Arterial blood gas changes - pH, pO2, pCO2"
89547616|NCT02379065|Experimental|Treatment nebuliser treatment|"Both groups will receive the same bronchodilator pharmacotherapy, in keeping with National Institute of Clinical Excellence guidelines4. For this arm, nebuliser will be Aerogen.~Interventions:~Score on the Modified Borg Scale (an interval scale which runs from 0-10, with statements describing level of breathlessness as perceived by the patient) to be completed by both the patient and clinician~Heart rate (as a measure of severity of exacerbation and an indirect measure of salbutamol dosage)~Arterial blood gas changes - pH, pO2, pCO2"
89547617|NCT02377037|Experimental|Sitting|Remain seated in a chair, with hands placed on top of the thighs for 10 minutes, remaining motionless in which the calorimeter device is attached to the mask and breath-by-breath VO2 and VCO2 are measured minute by minute.
89547618|NCT02377037|Experimental|Standing|Remain in an upright position (standing) with hands placed on the thighs for 10 minutes, remaining motionless in which the calorimeter device is attached to the mask and breath-by-breath VO2 and VCO2 are measured minute by minute.
89547619|NCT02377037|Experimental|Transitions sit/stand|The participant will perform one sit-to-stand followed by a stand-to-sit transition, every minute in which the calorimeter device is attached to the mask and breath-by-breath VO2 and VCO2 are measured.
89547620|NCT02376881|Experimental|EPO|20,000 IU recombinant human erythropoietin IV infusion in 100 ml normal saline in 2 hr for 3 successive days
89547621|NCT02376881|Placebo Comparator|control group|100 ml normal saline in 2 hr for 3 successive days
89547622|NCT02032888|Experimental|Daclatasvir + Sofosbuvir (Treatment-naive) 12 weeks|Treatment-naïve participants received daclatasvir 30, 60, or 90 mg, and sofosbuvir, 400 mg, once daily for 12 weeks
89547623|NCT02032888|Experimental|Daclatasvir + Sofosbuvir (Treatment-naive) 8 weeks|Treatment-naïve participants received daclatasvir, 30, 60, or 90 mg, and sofosbuvir, 400 mg, once daily for 8 weeks
89547624|NCT02032888|Experimental|Daclatasvir + Sofosbuvir (Treatment-experienced) 12 weeks|Treatment-experienced participants received daclatasvir, 30, 60, or 90 mg, and sofosbuvir, 400 mg, once daily for 12 weeks
89547625|NCT02376959|Placebo Comparator|Control Group|"Application of 8 spiritist passe simulation sessions by people without spiritist training at the same time and in the same environment as the treatment group."
89547626|NCT02376959|Active Comparator|"Treatment Group (Spiritist passe)"|"Application of 8 sessions of spiritist passe by spiritists with more than 2 years of experience in controlled environments for the same period as the control group."
89547627|NCT02376803|Experimental|Morning warfarin ingestion|Patients switch from taking warfarin in the evening to taking warfarin in the morning.
89547628|NCT02376803|Active Comparator|Evening warfarin ingestion|Patients continue taking warfarin in the evening as per their usual routine.
89547629|NCT02082262|Experimental|AGN-229666|One to two drops of AGN-229666 twice daily in each eye for 10 weeks.
89547630|NCT04697069|Experimental|ANB019|Participants received a starting dose of 400 milligrams (mg) of imsidolimab on Day 1 followed by 200 mg imsidolimab every 4 weeks (Days 29, 57 and 85) by subcutaneous injection.
89547631|NCT04697069|Placebo Comparator|Placebo|Participants received imsidolimab matching placebo on Day 1 and thereafter, every 4 weeks (Days 29, 57 and 85) by subcutaneous injection.
89547632|NCT03113279||Obese older individuals|Obese older individuals
89547633|NCT03113279||Lean older individuals|Lean older individuals
89547634|NCT03113279||Young lean individuals|Young lean individuals
89547635|NCT02082184|Experimental|Sensor Based Glucose Monitoring System|Standard system use for 6 months. Followed by open access to the device for 6 months.
89547636|NCT02082184|Active Comparator|Standard Blood Glucose Monitoring|Subjects randomised to the control group will be given blood glucose meters for monitoring for the 6 months study duration.
89547637|NCT02378909|Active Comparator|Group 1|Diabetic Neuropathy with electrical stimulation device and standard of care.
89547638|NCT02378909|No Intervention|Group 2|Diabetic neuropathy with standard of care.
89547639|NCT02378909|Active Comparator|Group 3|Diabetic neuroischemia with electrical stimulation device and standard of care.
89547640|NCT02378909|No Intervention|Group 4|Diabetic neuroischemia with standard of care.
89547641|NCT01624870||CoreValve aortic valve|Implantation of CoreValve aortic valve
89547642|NCT04132427|Experimental|Group A: Treatment|Vancomycin, magnesium citrate, microbiota
89547643|NCT04132427|Placebo Comparator|Group B: Placebo|placebo vancomycin, real magnesium citrate (because it obviously empties the bowels) and placebo microbiota
89547644|NCT02378987||Typical developmental children|Normal children
89547645|NCT02378987||CP children with GMFCS level I and II|Children with CP were classified into Levels I-II based on the Gross Motor Function Classification System (GMFCS).
89547646|NCT02378987||CP children with GMFCS level III and IV|Children with CP were classified into Levels III-IV based on the Gross Motor Function Classification System (GMFCS).
89547647|NCT02378675||Healthy (1)|Adipocytokine levels of patients suffering from GDM are compared to healthy pregnant women
89547648|NCT02378675||GDM (2)|Adipocytokine levels of patients suffering from GDM are compared to healthy pregnant women
89547649|NCT02376491|Active Comparator|High Frequency Left repetitive|High Frequency Left repetitive transcranial magnetic stimulation five days per week for 4 weeks Magventure Cool B65 Coil with Magpro X100
89547650|NCT02376491|Experimental|intermittent Theta Burst Stimulation (iTBS)|intermittent Theta Burst Stimulation (iTBS) five days per week for 4 weeks Magventure Cool B65 Coil with Magpro X100
89547651|NCT02378597|Active Comparator|Delayed Intervention: Control|Delayed intervention: Control was a a behavioral treatment for resiliency delivered in a single 4 hour session delivered in a delayed fashion (waitlist control)
89547652|NCT02378597|Experimental|Experimental: Intervention|Experimental: Intervention was a 4 hour behavioral resiliency intervention.
89547653|NCT02031640|Experimental|BDP 320 mcg BAI|Beclomethasone dipropionate (BDP) via breath-actuated inhaler (BAI) twice daily.
89547654|NCT02031640|Experimental|BDP 640 mcg BAI|Beclomethasone dipropionate (BDP) via breath-actuated inhaler (BAI) twice daily.
89547655|NCT02031640|Active Comparator|BDP 320 mcg MDI|Beclomethasone dipropionate (BDP) via metered dose inhaler (MDI) twice daily.
89547656|NCT02031640|Active Comparator|BDP 640 mcg MDI|Beclomethasone dipropionate (BDP) via metered dose inhaler (MDI) twice daily.
89547657|NCT02031640|Placebo Comparator|Placebo BAI and MDI|Placebo breath-actuated inhaler (BAI), twice daily. Plus placebo metered dose inhaler (MDI), twice daily.
89547658|NCT02378831||PSG and WatchPAT200 in subjects age12-17|Adolescents refered to a sleep lab for sleep lab for full night PSG
89547659|NCT02376725|Active Comparator|Phaco/IOL|Cataract extraction using phacoemulsification technique with intraocular lens implant
89547660|NCT02376725|Active Comparator|Phaco/IOL + goniosynechialysis|Cataract extraction using phacoemulsification technique with intraocular lens implant with goniosynechialysis
89547661|NCT03105635|Other|Patients|"Participating primary care providers will be encouraged to refer their patients who could benefit from community resources to these services. They will complete the study referral form for all patients referred to a resource. They will briefly mention the study to patients who are referred to a community resource, and ask for their verbal consent to be contacted by a member of the research team to learn more about the study, and leave a patient recruitment package with them."
88812013|NCT03838952|Experimental|Chinese herbal medicine group|drug for the subjects
88812014|NCT05620940|Active Comparator|Vivitrol Injection|Vivitrol, Single Dose, IM injection
88812015|NCT05620940|Experimental|IVL3004 (A mg)|IM, Single Dose
88812016|NCT05620940|Experimental|IVL3004 (B mg)|SC, Single Dose
88812017|NCT01395797|Placebo Comparator|Placebo - Heroin|Participants will be maintained on 0 mg of Pioglitazone (PIO) prior to sessions assessing the abuse liability of heroin.
88812018|NCT01395797|Experimental|PIO low dose - Heroin|Participants will be maintained on 15 mg of PIO prior to sessions assessing the abuse liability of heroin.
88812019|NCT01395797|Experimental|PIO high dose - Heroin|Participants will be maintained on 45 mg of PIO prior to sessions assessing the abuse liability of heroin.
88812020|NCT01395797|Placebo Comparator|Placebo - Nicotine|Participants will be maintained on 0 mg of PIO prior to sessions assessing the abuse liability of nicotine.
88961693|NCT04945759|Placebo Comparator|Isokinetic Exercise + placebo Electrical Stimulation (IE+PES) Group:|Isokinetic Exercise program will be applied to the patients. The appropriate modalities will be set on the electrical stimulation device, but the device will not operate. It will be applied for 20 minutes.
88961694|NCT04941560||Algorithm training and test group|Patients undergoing coronary angiography or coronary computer tomography angiography will be enrolled. Patients data will be used to training and validate the algorithm for CAD detection based on facial photos.
88961695|NCT04920799|Active Comparator|Nitrate rich beetroot juice|
89207966|NCT00661388|Experimental|Continuous erythropoietin receptor activator (C.E.R.A.)|Eligible participants will be administered C.E.R.A subcutaneously, every 4 weeks for 44 weeks. The initial dose of C.E.R.A. will be 1.2 micrograms/kilogram. Subsequent doses will be adjusted to maintain the individual participant's hemoglobin within the target range of 10.0 and 12.0 grams/deciliter.
89547662|NCT03105635|Other|Practice and Provider|"Four to six practices will be recruited to participate in this feasibility study. Primary care members working in a participating practice will be invited to participate in the study.~All primary care providers will be encouraged to participate and at least one primary care provider is required to participate to include the practice in the study.~After the obtaining an interest from a practice member to whom the invitation email was sent, we will offer all practice members eligible for the study an information session during which the study is described and participation offered. The practice manager or lead will be provided with the Practice Information and Consent Form"
89547663|NCT02378363||Student 9 to 12 years|Students aged 9 to 12 years and enrolled in classes CM1, CM2 and 6th
89547664|NCT02376413||Traditional BCS|Breast-conserving surgery. Modified radical mastectomy.
89547665|NCT02376413||Oncoplastic-BCS|"Breast-conserving surgery. Modified radical mastectomy. Oncoplastic-BCS based on surgeon preference and/or tumor location.~Superior pedicle mammoplasty / inverted T~Superior pedicle mammoplasty / V scar~Batwing~Inferior pedicle mammoplasty~Racquet mammoplasty/radial scar~vertical-scar mammoplasty"
89547666|NCT02376023|Experimental|mHealth|Women in the mHealth group will receive text and voice messages, in addition to their habitual care from the health clinic they attend. The messages will remind them to schedule a PAP smear, and will be sent for 1 year following enrollment in the study.
89547667|NCT02376023|No Intervention|No mHealth|Women in the No mHealth group will not receive any text messages, and will only receive their habitual care from the health clinic they attend.
89547668|NCT02376101|Active Comparator|Standard ETT size|Their tracheas will be intubated with an appropriately sized ETT using the standard formula. The cuff will be inflated to achieve a seal by the air-leak test when holding CPAP of 20 cmH2O and the intracuff pressure will be measured using a manometer.
89547669|NCT02376101|Experimental|ETT one size smaller|Their tracheas will be intubated with an ETT that is one size smaller (instead of a 5.0 ETT, we would use a 4.0 ETT). The cuff will be inflated to achieve a seal by the air-leak test when holding CPAP of 20 cmH2O and the intracuff pressure will be measured using a manometer.
89547670|NCT02378285|Active Comparator|PRP group|ACP infiltration: 2 mL at 0 and 4 weeks with ultrasound guidance
89547671|NCT02378285|Placebo Comparator|Saline solution group|Saline solution infiltration: 2mL at 0 and 4 weeks with ultrasound guidance
89547672|NCT02378441|Experimental|CJ-30056 20/750mg|fixed-dose combination of Atorvastatin 20mg and Metformin SR 750mg
89547673|NCT02378441|Experimental|Atorvastatin 20mg and Metformin SR 750mg|co-administration of Atorvastatin 20mg and Metformin SR 750mg
89547674|NCT02378519|Experimental|Web-prog, followed by CBT + PT|This arm of the single system experimental design starts with a baseline phase of 8 weeks where the subjects are introduced into to the interactive web-based self-help program. The baseline-period is followed by the intervention period which consists of a continued use of the interactive web-based self-help program, now with with cognitive behavioral therapy coaching in combination with individually tailored physiotherapy according to the person's needs for 16 weeks.
89547675|NCT02378519|Active Comparator|Base, followed by Web + CBT + PT|The intervention consists of a interactive web-based selfadministrated program with cognitive behavioral therapy coaching in combination with tailored physiotherapy according to the person's needs for 16 weeks.
89547676|NCT04600427|Experimental|Epidural anesthesia|The patient will be positioned appropriately and the T11-12 (if not accessible we will accept 1-2 spaces above or below) interspace landmarked using established ultrasound guidance techniques. The patient's back will be prepped and draped in a sterile fashion. An epidural catheter will be inserted into the T11-12 interspace with a midline or paramedian approach using a 17G Tuohy needle. Plain preservative free bupivicaine 0.25% will be the local anesthetic used. After a 2-3 mL test dose to rule out intrathecal catheter positioning, a loading dose of 5-8 mL will be administered over 5-10 minutes to further rule out intravascular positioning of the catheter. Successful epidural placement will be defined by catheter insertion and confirmed by sensory blockade assessed by ice or pin prick testing. When correct positioning is confirmed, a continuous infusion of 3 mL per hour of bupivacaine 0.25% plain solution will begin.
89547677|NCT02378129|Experimental|Clinpro XT (3M ESPE, Minnesota, USA)|Resin-modified glass ionomer cement
89547678|NCT02378129|Active Comparator|Vidrion R (SS White, Gloucester, UK)|Conventional glass ionomer cement
89547679|NCT02377973||Growth and Development|Growth and Development og healthy young children born by Obese mothers
89547680|NCT02375945|Active Comparator|current compression stocking Comprinet®|"Immediately post operatively 24 hours compression therapy starts with Elastomull Haft ®, an elastic bandage, combined with a Comprinet stocking (BSM Medical®) for anti thrombotic purposes. The anti thrombosis stocking is worn 6 weeks post operatively. After 4 hours the patient is ambulated and the physical therapy starts."
89547681|NCT02375945|Experimental|New non-elastic compression kit|"Juxta Reduction Kit ® Immediately post operative compression starts with the Juxta Reduction Kit® for the knee region, combined with an anti thrombosis stocking (Struva 2, for prevention of trombo-embolism). Both the stocking and the Juxtra Pro are used for six weeks. After 4 hours the patient ambulated and the physical therapy starts.~For the first 24 hours and longer if necessary (depending on the skills of the patient) Juxta experienced staff will apply the device and the fit and the use of the device will be checked.~In the second phase between approximately 24 hours and 6 weeks patients may adjust the Juxta-pro according to their needs and comfort by themselves."
88961696|NCT04920799|Placebo Comparator|Nitrate depleted beetroot juice|
88961697|NCT04868851|Active Comparator|Here for Health only|Patients will complete the Here for Health Healthy Lifestyle intervention designed by the Paediatric Diabetes Dietitians at Oxford University Hospitals NHS Foundation Trust.
89207967|NCT00867204||Short-wire device|The Fusion Short-wire ERCP device was used
89547682|NCT02376335|Active Comparator|Rituximab infusion|Participants will be randomised to Rituximab therapy (1000 mg IV on days 1 and 15) or placebo (0.9% Sodium Chloride 250mls) control.
89547683|NCT02376335|Placebo Comparator|Placebo infusion|Participants will be randomised to Rituximab therapy (1000 mg IV on days 1 and 15) or placebo (0.9% Sodium Chloride 250mls) control.
89547684|NCT02375789|Active Comparator|Active RhinoChill|"Following the initial 30 days (and minimum of 2 separate migraine attacks) of data collection the patient will be trained in the use and self administration of the RhinoChill device.~At the onset of an acute migraine, the patient will insert the RhinoChill Migraine Intranasal catheters and commence a 10 minute treatment on the Low Flow setting of the device.~During this time the patient will complete the basic data record sheets to document current symptoms and changes in severity throughout the period of treatment and then at specific time points thereafter.~The patient remains in the trial until two separate migraines have been treated."
89547685|NCT02375789|Placebo Comparator|Placebo RhinoChill|"The same procedure will be followed for the placebo comparator as in the active comparator. The RhinoChill device looks identical and functions in a very similar way to the active device however through some minor design changes the device has been altered to provide a sufficient placebo treatment.~At the onset of an acute migraine headache the patient will insert the RhinoChill Migraine Intranasal catheters and the 10 minute treatment is commenced on Low Flow.~During this time the patient will complete the basic data record sheets to document current symptoms and changes in severity throughout the period of treatment and then at specific time points thereafter.~The patient remains in the trial until two separate migraines have been treated."
89547686|NCT02375867|Active Comparator|prednisolone|This group includes patients with FHF without encephalopathy
89547687|NCT02375867|Active Comparator|methylprednisolone|This group includes patients with FHF with encephalopathy
89207968|NCT00867204||Long-wire device|The traditional Long-wire ERCP device was used
89547688|NCT02375867|No Intervention|Non-intervention|FHF patients without any of the proposed intervention as controls
89547689|NCT02378051|Experimental|Staying Strong with Schools Intervention|The Staying Strong with Schools Intervention includes: (a) a training of all school professionals, and (b) a year-long training and supervision of the school guidance counselor (RSL), by a Liaison-Trainer (LT).
89547690|NCT02378051|Placebo Comparator|Waitlist Control|The waitlist control schools will receive an educational pamphlet outlining resources useful to support military-connected children to be distributed to all educators at the beginning of the Year 1. They will then receive the Staying Strong with Schools Intervention in Year 2.
89547691|NCT02377739|Experimental|non-invasive ventilation|patients will undergo about 14 nights of non-invasive ventilation during pulmonary rehabilitation
89547692|NCT02375633|Experimental|DW-330SR2|DW-330SR(Pelubiprofen) 45mg twice a day
89547693|NCT02375633|Active Comparator|Pelubiprofen|Active Comparator(Pelubiprofen) 30mg three times a day
89547694|NCT02375711|Experimental|Chronic Renal Failure|Patients with renal failure, with creatinine clearance between 60 and 15 ml/min. A blood sample is achieved at 0, 1, 3 and 6 months.
89547695|NCT02375477|Experimental|Health services research (isolation protocol education)|Residents and nurses are given an educational intervention on isolation protocols for diarrhea and enteric pathogens approved by Infection Control and covering their recommendations.
89547696|NCT02375243|Experimental|cases|children who receive midazolam 0.05 mg/kg/h + morphine 10 mcg/kg/h + dexmedetomidne 0.5 mcg/kg/h. Midazolam in administered until extubation, while morphine and dexmedetomidine are administered until removal of surgical drains.
89547697|NCT02375243|No Intervention|controls|standard care: children who receive midazolam 0.1 mg/kg/h + morphine 20 mcg/kg/h. Midazolam in administered until extubation, while morphine is administered until removal of surgical drains.
89547698|NCT02375321|Experimental|Group A|Study Group: patients with OSA and depressive symptoms treated with CPAP and psychological support
89547699|NCT02375321|No Intervention|Group B|Control Group: patients with OSA and depressive symptoms treated with CPAP
89547700|NCT03113045|Experimental|Seated Time|Pts will be seated for the allocated time depending on the previous patients hypotensive response
89547701|NCT03105401||Patients affected by Parkinson's disease|Outpatients affected by Parkinson's Disease consulting in neurology can be included if volunteer
89547702|NCT02375009|Experimental|Treatment Cohort|All subjects will receive bilateral 360 degree Selective Laser Trabeculoplasty therapy in a single session, but will be randomized to one of three treatment sessions at times 0, Month 3 and Month 6. Subjects will be washed out of current IOP-lowering therapy 4-6 weeks pre-SLT. Subjects continuing on meds beyond time 0 will provide a comparator to early SLT to quantify regression to the mean.
89547703|NCT02374775||Group A (Culprit lesion)|The plaque in the culprit vessel of acute myocardial infarction will be defined the Group A.
89207969|NCT00975429|Experimental|WST11 - 4mg (TOOKAD® Soluble)|4mg/kg Treatment with WST11-mediated VTP
89547704|NCT02374775||Group B (Non-culprit lesion)|The plaque in the non-culprit vessel of acute myocardial infarction will be defined as internal control, Group B.
89547705|NCT02374931|Experimental|Diagnostic (18F-FES PET/CT)|Patients undergo 18F-FES PET/CT imaging over 30 minutes.
89547706|NCT02374697||Before tele-expertise|Usual second opinion with pathological slides sent by mailing
89207970|NCT00975429|Experimental|WST11 - 6mg|6mg/kg Treatment with WST11-mediated VTP
89547707|NCT02374697||During Tele-expertise|Second opinion with tele-expertise
89547708|NCT02377583||Diabetic children|"physical examination~Glucocorticoid sensitivity index~DNA sample~Anxiety and depression questionnaires~depression questionnaire~MRI"
89547709|NCT02377583||Controls|"physical examination~Glucocorticoid sensitivity index~DNA sample~Anxiety and depression questionnaires~depression questionnaire~MRI~Laboratory tests"
89547710|NCT02374619|Experimental|Iron supplement|Oral supplementation
89547711|NCT02374619|Placebo Comparator|Control|Oral supplementation
89547712|NCT02377661|No Intervention|Standard Care|Treatment of hypertension according to current guidelines
89547713|NCT02377661|Experimental|Experimental Care|Treatment of hypertension using a standardised and simplified titration regime with single pill combinations, comprising an angiotensin receptor blocker, calcium channel blocker and hydrochlorothiazide.
89547714|NCT02377505|Active Comparator|On-Stimulation|"Disease condition is assessed with stimulation turned on"
89547715|NCT02377505|Placebo Comparator|Off-Stimulation|"Disease condition is assessed with stimulation turned off"
89547716|NCT02372357|Experimental|Posaconazole 120mg/m² tid|"Pediatric patients admitted to receive chemotherapy or hematopoietic stem cell transplantation for the treatment of a hematological malignancy are receiving Posaconazole prophylaxis 120 mg/m² tid.~At steady state, blood sampling will be performed: 9 blood samples will be taken during 1 dosing interval to evaluate the pharmacokinetics of posaconazole."
89547717|NCT02374541|Experimental|Patient Navigation|Assistance from Autism Patient Navigator (APN) to obtain diagnostic evaluation / eligibility determination for possible autism spectrum disorder and, if indicated, early intervention services.
89547718|NCT02374541|No Intervention|Control|Standard referral for diagnostic evaluation / eligibility determination for possible autism spectrum disorder and, if indicated, early intervention services.
89547719|NCT02374385|Experimental|Group 1|1x10(5) pfu VSV G-ZEBOV vaccine (BPSC1001) each dose, total volume 1 mL
89547720|NCT02374385|Experimental|Group 2|5x10(5) pfu VSV G-ZEBOV vaccine (BPSC1001) each dose, total volume 1 mL
89547721|NCT02374385|Experimental|Group 3|3x10(6) pfu VSV G-ZEBOV vaccine (BPSC1001) each dose, total volume 1 mL.
89547722|NCT02374385|Placebo Comparator|Group 4|Group 4 will receive placebo (normal saline).
89547723|NCT02374229|Experimental|The study group|"Procedure: mitral valve surgery, surgical ablation of ganglion plexus pulmonary artery.~Will include 15 patients with mitral stenosis or insufficiency subject to correction, complicated by high pulmonary hypertension. During the operation, a standard surgical procedure for the treatment of heart valve disease will be complemented by the ablation zone of bifurcation of the pulmonary artery, surgical ablation of ganglion plexus pulmonary artery.~For mitral regurgitation or stenosis, the procedures will be a valve repair or mitral valve replacement.~Procedure will be considered effective in the face of declining average pressure in the pulmonary artery for invasive monitoring of 10mm Hg and more."
89547724|NCT02374229|Active Comparator|The control group|"Procedure:mitral valve surgery. Will include 15 patients with mitral stenosis or insufficiency subject to correction, complicated by high pulmonary hypertension. Patients will be made standard procedure correction mitral valve disease without pulmonary artery denervation.~For mitral regurgitation or stenosis, the procedures will be a valve repair or mitral valve replacement only."
89547725|NCT02374151||Women with IUPC|Women at term in second or third phase of labor who are indicated to have an IUPC during active labor
89547726|NCT02374073|Experimental|Intervention group|Treated with protocolized physiotherapy and functional massage
89547727|NCT02374073|Experimental|Control group|Treated with protocolized physiotherapy
89547728|NCT02371967||No Gorlin Syndrome Participants With No Prior HPI Exposure|BCC participants with advanced disease and no Gorlin syndrome, and who have not been exposed previously to an Hedgehog Pathway Inhibitor (HPI) (e.g., Vismodegib, LDE225) prior to diagnosis of advanced disease; will receive vismodegib therapy in compliance with the physician's standard practice as per local label and will be followed-up for approximately 3 years or until death, withdrawal of consent, sponsor's decision, lost to follow-up or end of study.
89547729|NCT02371967||No Gorlin Syndrome Participants With Prior HPI Exposure|BCC participants with advanced disease and no Gorlin syndrome, and who have been exposed previously to an HPI (e.g., during clinical studies with vismodegib [SHH4476g {NCT00833417}, MO25616 {NCT01367665}] or LDE225); will receive vismodegib therapy in compliance with the physician's standard practice as per local label and will be followed-up for approximately 3 years or until death, withdrawal of consent, sponsor's decision, lost to follow-up or end of study.
89547730|NCT02371967||Gorlin Syndrome Participants With/Without Prior HPI Exposure|BCC participants with advanced disease and Gorlin syndrome, and who have or have not been previously exposed to an HPI (e.g., during clinical studies); will receive vismodegib therapy in compliance with the physician's standard practice as per local label and will be followed-up for approximately 3 years or until death, withdrawal of consent, sponsor's decision, lost to follow-up or end of study.
89547731|NCT02373839|Other|PlGF measurement|Determination of PlGF levels. If lower than 100 pg/mL labour will be inducted at the moment of diagnosis. Otherwise standard monitoring will be done with labour induction at 37 weeks.
89547732|NCT02373839|No Intervention|Controls|induction of labour at 37 weeks of gestation.
89547733|NCT02373917||study group|patient who in the biopsy showed lung cancer
89547734|NCT02373917||control group|patient who in the biopsy showed not to have lung cancer
89547735|NCT02371811|Experimental|v care group|In this group we will use (v care) uterine manipulator during abdominal hysterectomy.
89547736|NCT02371811|No Intervention|control group|In this group we will do abdominal hysterectomy without v care.
89547737|NCT02373995|Active Comparator|LAB4|In addition to conventional Anti Thyroid Drug (ATD), LAB4 probiotic preparation will be administered at the 2 cps x 2/die dosing with food for 6 months. It is key to properly store LAB4 at 8°C.
89547738|NCT02373995|Placebo Comparator|Placebo|In addition to conventional Anti Thyroid Drug (ATD) a LAB4 placebo preparation will be administered at the 2 cps x 2/die dosing with food for 6 months. It is key to properly store placebo at 8°C.
88812021|NCT01395797|Experimental|PIO Low Dose - Nicotine|Participants will be maintained on 15 mg of PIO prior to sessions assessing the abuse liability of nicotine
89547739|NCT02371655|Active Comparator|Diet included|Diet is included in bowel preparation
89547740|NCT02371655|Experimental|Diet not included|Diet is not included in bowel preparation
89547741|NCT02371577|Experimental|Lenalidomide|Lenalidomide is administered orally once daily on Days 8-28 of each 28 day cycle. The typical starting dose is 2.5mg PO daily. At the start of each cycle, there is intra-patient dose-escalation to a maximum of 25mg daily, in the absence of grade 2 or higher adverse events.
89547742|NCT02373449|Experimental|RS-fMRI|All subjects will be instructed to keep their eyes closed but to remain awake during the fMRI measurement. Resting State fMRI (RS-fMRI) will be performed within four weeks of planned infusion of ketamine, immediately after the end of infusion of ketamine on the fifth (last) day of infusion, and on the one month follow-up appointment after the infusion.
89547743|NCT02371733|Active Comparator|Training Group|Intervention:Training group will receive upper extremity aerobic exercise training using arm ergometer and breathing exercises.
89547744|NCT02371733|Sham Comparator|Control Group|Sham: Control group will receive alternative upper extremity exercises and breathing exercises.
89547745|NCT02371499|Experimental|1st Arm|Treatment with Lactobacillus casei DG (Enterolactis plus®)
89547746|NCT02371499|Placebo Comparator|2nd Arm|Treatment with equivalent product without bacteria (Enterolactis placebo)
89547747|NCT02371421||Allopurinol|Participants with history of gout indicated by the use of allopurinol or participants who have high serum uric acid without contraindication to use allopurinol.
89547748|NCT02373527|No Intervention|Standard - Strict Fasting|No food after midnight the night before the procedure and will be allowed to drink clear liquids up to 2 hours prior to the procedure.
89547749|NCT02373527|Experimental|Non Fasting|No Fasting prior to catheterization. Usual meal on the day of the procedure and allowed to drink as usual.
89547750|NCT02373605|Experimental|Dry Needling,Thrust Manipulation|
89547751|NCT02373605|Active Comparator|Exercise,Non-thrust Mobilization|
89547752|NCT02371343|Active Comparator|Fish-Oil|"The pregnants with gestational diabetes given fish oil:~(Ocean Plus, 1200 mg, EPA 384 mg DHA 252 mg, total omega-3 782 mg, 50 soft gel, Ocean®, German) During third trimester of pregnancy, Once in a day"
89547753|NCT02371343|Placebo Comparator|Sunflower oil|"The pregnants with gestational diabetes given sunflower oil:~Sunflower oil capsules will be prepared in the pharmacy as the same size and colour with fish oil capsules During third trimester of pregnancy, Once in a day"
89547754|NCT02371109||selftaken vs clinical taken swabs|
89547755|NCT02371031|Experimental|Arm 1: FDOPA-PET/MRI|"Patients with known or suspected brain gliomas that are non-enhancing or have substantial non-enhancing regions will undergo FDOPA-PET/MRI within 2 weeks prior to planned standard of care surgical resection and/or stereotactic biopsy. In the same planning session, the MRI alone will be reviewed and then the FDOPA-PET data will be added to the planning.~In the event that a patient cannot undergo MRI or PET/MRI is not available (e.g. due to maintenance), FDOPA-PET/CT can be performed instead at the discretion of the responsible physician.~When feasible and at the discretion of the neurosurgeon performing the resection, areas of suspected tumor identified on the FDOPA-PET/MRI study but not the MRI alone will undergo tissue sampling."
89547756|NCT03959891|Experimental|Fulvestrant + Ipatasertib|"Ipatasertib will be administered orally on a daily basis~Fulvestrant would be administered as intra-muscular injection twice a month for the first cycle, and then monthly for all other cycles."
89547757|NCT03959891|Experimental|Aromatase Inhibitor + Ipatasertib|"Ipatasertib will be administered orally on a daily basis~Aromatase inhibitors will be administered orally on a daily basis"
89547758|NCT03959891|Experimental|Fulvestrant + Ipatasertib +Palbociclib|"Ipatasertib will be administered orally on a 3 week on and 1 week off schedule~Fulvestrant would be administered as intra-muscular injection twice a month for the first cycle, and then monthly for all other cycles.~Palbociclib will be administered orally on a 3 week on and 1 week off schedule"
89547759|NCT02370953|Experimental|VERION|In this group the VERION-tools (Digital Marker) are used for the alignment of the toric IOL
89547760|NCT02370953|Active Comparator|Conventional, manual ink-marking|In the group the conventional manual marking is used for the alignment of the toric IOL
89547761|NCT02373215|Experimental|Cohort 1 - Groups 1-3|HD patients dosing up to 180mg BID
89547762|NCT02373215|Experimental|Cohort 1 - Group 4|HD patients dosing up to 240mg BID
89547763|NCT02373215|Experimental|Cohort 2|Healthy patients dosing up to 180mg BID
89547764|NCT02370719|Experimental|Intervention Group|Mobile application plus standard of care
89547765|NCT02370719|No Intervention|Control Group|Standard of care
88811868|NCT02480010|Experimental|Pertuzumab 420 mg (Cohort A)|Participants in Cohort A will receive an IV loading dose of 840 milligrams (mg) pertuzumab followed by 420 mg via IV infusion on Day 1 of each 3-week cycle. At the end of 3 treatment cycles, response will be evaluated to determine whether additional participants will be enrolled for treatment. If a second stage of enrollment occurs, participants may continue treatment until disease progression or unacceptable toxicity.
89547766|NCT02370563|Experimental|Arm 1|18F-FSPG will be administered to 30 patients with brain tumors or brain metastases.
89547767|NCT02373059|Experimental|Pharmaceutical care with shared decision making|Use of Diabetes Issue Cards Decision Aids
89547768|NCT02373059|Active Comparator|Usual Pharmaceutical care|Usual Care
89547769|NCT02372981|Experimental|DG-HAL with mucopexy|Mucopexy with DG-HAL is performed using a specific device consisting of a proctoscope equipped with a Doppler probe and a light source. The proctoscope model in our study has a sliding part comprising the operating window and Doppler probe for better proximal and distal movement without repositioning the proctoscope during mucopexy.
89547770|NCT02372981|Active Comparator|mucopexy alone|Mucopexy without DG-HAL is performed using the same specific device consisting of a proctoscope equipped with a Doppler probe and a light source as described above.
89547771|NCT02370485|Experimental|LY2801653 Reference - Fasted|Single oral dose of LY2801653 (Reference Formulation) administered in fasted state in one of three study periods.
88961698|NCT04868851|Experimental|mHealth technology assisted exercise counselling (mHealth)|Patients will complete the Here for Health Healthy Lifestyle intervention before completing a 12 week mHealth technology assisted exercise counselling intervention. Participants will co-develop a 3-month structured exercise and PA programme, with support from an exercise specialist. All participants will have 5 exercise consultations with their exercise specialist. The intervention will be supported by 3 mHealth elements; 1) a wrist worn fitness watch, 2) a smartphone app for patients, and 3) a coaching website for the exercise specialist. The 3 elements will be synced, allowing data to be transferred between platforms.
88961699|NCT04861922|Experimental|Unfractionated Heparin|A bottle solution of Heparin Sodium (2ml:12500IU) is added to 48 ml saline and administered intravenously continuously for 24 hours (10 unit/kgBW/hour), which last 5 days or until the death or discharge.
89517328|NCT04143711|Experimental|DF1001 with Sacituzumab Govitecan-hziy Exploratory Efficacy Expansion in Breast Cancer (HER2+)|Combination therapy with DF1001 and sacituzumab govitecan-hziy cohort enrolling up to 40 patients, including safety lead-in, with metastatic breast cancer with documentation of HER2 positive expression.
89517329|NCT04143711|Experimental|DF1001 with Sacituzumab Govitecan-hziy Exploratory Efficacy Expansion in Breast Cancer (HR+/HER2-)|Combination therapy with DF1001 and sacituzumab govitecan-hziy cohort enrolling up to 40 patients, including safety lead-in, with metastatic breast cancer with documentation of HR positive and HER2 negative expression.
89517330|NCT04141891|Experimental|Driving Decision Aid|Web-based Driving Decision Aid
89517331|NCT04141891|Active Comparator|Older Drivers Website|National Institute on Aging (NIA) Older Drivers website
89517332|NCT04140721|Experimental|Moxonidine then Placebo|After screening/baseline evaluations, patients will be discharged home on moxonidine 0.2-0.4 mg/day PO. After two weeks, the patients will be re-admitted for study testing while on moxonidine. At completion of this testing, patients will start taking matching placebo once daily PO to be continued at home. After two, the patients will be re-admitted for study testing while on placebo.
89517333|NCT04140721|Experimental|Placebo then Moxonidine|After screening/baseline evaluations, patients will be discharged home on placebo identical to moxonidine once daily PO. After two weeks, the patients will be re-admitted for study testing while on placebo. At completion of this testing, patients will start taking moxonidine 0.2-0.4 mg/day PO to be continued at home. After two weeks, the patients will be re-admitted for study testing while on moxonidine.
89517334|NCT04129125|Experimental|Zoom Reperfusion System|"The subject will undergo the endovascular thrombectomy procedure under general anesthesia or conscious sedation. The Imperative Care .088 Catheter will be used to gain access to the vasculature and direct aspiration of the clot will be attempted where feasible. The Zoom Reperfusion System must be the initial and primary device used to remove thrombus."
89517335|NCT04124757|No Intervention|Standard neuromuscular blockade|Subjects will receive regular rocuronium induction dose, followed by bolus foses of 10 mg in case of insufficient conditions
89517336|NCT04124757|Experimental|Deep neuromuscular block|Subjects will receive high dose rocuronium induction dose followed by continuous rocuronium administration, to achieve a depth of neuromuscular block of 1-2 twitches post tetanic count
89517337|NCT04112810|Experimental|Tildrakizumab|Tildrakizumab (IluymaTM) is a humanized monoclonal antibody that specifically binds to the IL-23p19 subunit of IL-23 to neutralize its function.
89517338|NCT04108624|Experimental|MRD2STOP ARM|
89517339|NCT04104451|Experimental|Dose 1|
89517340|NCT04104451|Experimental|Dose 2|
89517341|NCT04104451|Experimental|Dose 3|
89517342|NCT04065477|Experimental|Experimental|The experimental group will receive treatment program designed to train strategic cognitive functions. Sessions will last 50 minutes and take place twice per week for 16 weeks.
89517343|NCT04065477|No Intervention|Control group|"The control group will receive no active treatment and will be treated as a no-contact control group."
89517344|NCT04065048|Experimental|Soy-based diet|Participants will be randomized to follow a soy-based diet for 7 days. The diet will be preceded by a 12-hr overnight fast.
89517345|NCT04065048|Active Comparator|Regular diet|Participants will be randomized to follow a diet without soy for 7 days. The diet will be preceded by a 12-hr overnight fast.
89517346|NCT04050410|Experimental|Moxonidine|Patients will receive a single oral dose of moxonidine 0.4 mg.
89517347|NCT04050410|Placebo Comparator|Placebo|Patients will receive a single oral dose of placebo.
89517348|NCT04047628|Experimental|AHSCT|"AHSCT: Myeloablative and Immunoablative therapy followed by Autologous Hematopoietic Stem Cell Transplantation~Participants will undergo:~Mobilization and graft collection: mobilization of peripheral blood stem cells (PBSC) with cyclophosphamide, filgrastim, and dexamethasone. The autologous graft will be collected by leukapheresis and cryopreserved.~Conditioning: high dose myeloablative and immunoablative conditioning with a six-day BEAM chemotherapy and rabbit anti-thymocyte globulin regimen will be initiated ≥30 days after cyclophosphamide mobilization.~Autologous cryopreserved graft infusion: the cryopreserved peripheral blood stem cells (PBSC) graft will be thawed and infused the day following completion of the conditioning regimen. Each bag will be thawed and infused according to institutional standards consistent with the Foundation for the Accreditation of Cellular Therapy (FACT) guidelines. Participants will receive prednisone following graft infusion."
89517349|NCT04047628|Active Comparator|Best Available Therapy (BAT)|Participants randomized to BAT: Best available therapy will be selected by the Site Investigator from: Cladribine (Mavenclad®), natalizumab (Tysabri®), alemtuzumab (Campath®, Lemtrada®), ocrelizumab (Ocrevus®), ublituximab (BRIUMVI™), rituximab (Rituxan®), or ofatumumab (Arzerra®) (after approval by the FDA for relapsing MS).
89517350|NCT03995147|Experimental|Treatment Arm|
89517351|NCT03936933|Experimental|Goserelin acetate 3.6 mg Injection|3.6 mg, Subcutaneously at every 28 days
89517352|NCT03936933|Active Comparator|ZOLADEX® 3.6mg Injection.|3.6 mg, Subcutaneously at every 28 days
89517353|NCT03890250|Sham Comparator|Sham group|Following the assessments, sham group will participate in a 20-30 minute low-medium intensity aerobic exercise training with cycling ergometer. In Sham training group, NMES will be applied to the same region after aerobic exercise, current frequency is 5 Hz, current transit time is 300 μs, 10 seconds warning, 30 seconds electrical stimulation in 20 seconds rest period. The rehabilitation program will be administered two days a week for 8 weeks under the supervision of a physiotherapist.
89547772|NCT02370485|Experimental|LY2801653 Test - Fasted|Single oral dose of LY2801653 (Test Formulation) administered in fasted state in one of three study periods.
89547773|NCT02370485|Experimental|LY2801653 Test - Fed|Single oral dose of LY2801653 (Test Formulation) administered with a high fat meal in one of three study periods.
89547774|NCT02370173|Experimental|PTSD wavelength-1 bright light|30 minutes of daily light exposure for 6 weeks
89547775|NCT02370173|Placebo Comparator|PTSD wavelength-2 bright light|30 minutes of daily light exposure for 6 weeks
88961700|NCT04861922|Placebo Comparator|Normal saline|The same amount of 0.9% saline as the heparin group (50ml) will be administered in the placebo group.
88961701|NCT04854824||'Recommended algorithm' cohort|COVID-19 patients treated at home by their family doctors according to the proposed recommendations
89547776|NCT02372903|Experimental|Endometriosis|Symptomatic patients with laparoscopic diagnosis of endometriosis
89547777|NCT02372591|Placebo Comparator|Placebo|
89547778|NCT02372591|Active Comparator|Hydromorphone|
89547779|NCT02372591|Experimental|Buprenorphine|
89547780|NCT02372669|Experimental|Chitosan|Enrolled participants presenting with traumatic sensory nerve lesions of the hand without defect zone that were randomized to primary microsurgical repair with the additional use of a chitosan nerve tube.
89547781|NCT02372669|Active Comparator|Gold standard alone|Enrolled participants presenting with traumatic sensory nerve lesions of the hand without defect zone that were randomized to primary microsurgical repair without the additional use of a chitosan nerve tube.
89547782|NCT02370017|Experimental|ANKL combined with chemotherapy|combination of ANKL and doublet chemotherapy as 3rd and 4th course in patients who get stable response after initial x2 courses
89547783|NCT02372747|Experimental|Delta-shaped anastomosis group|The patients in DS group underwent Delta-shaped anastomosis after TLDG.
89547784|NCT02372747|Experimental|Billroth II anastomosis group|The patients in B-II group underwent Billroth-II anastomosis after TLDG.
89547785|NCT02369861|Experimental|ST266|Eye drops
88961702|NCT04854824||'Historic control' cohort|COVID-19 patients enrolled in the ORIGIN study of the Istituto di Ricerche Farmacologiche Mario Negri IRCCS and treated at home by family physicians with drug regimens that are not necessarily guided by those proposed in the recommendations
88961703|NCT04851249||Adult participants operated for Hallux Valgus deformity|All adult participants accepted for hallux valgus corrective surgery at ostfold hospital trust (ØHT) is asked to participate in the study. The goal is to include 200-250 participants.
89547786|NCT02369861|Placebo Comparator|Artificial tears|Refresh lubricant eye drops
89547787|NCT02369783|Experimental|Questionnaire and interview|The patient complete the questionnaire on the tablet to better know their social situation and any difficulties. Then, he will be interview during thirty minutes with a social worker and a nurse navigator. At the end of this intervention we will be offered to the patient monitoring and appropriate resources to its situation.
89547788|NCT02369939|Active Comparator|control arm|Irradiation 1.8Gy/d; T2N0 55.8Gy; T3N0-T4N0 59.4Gy Chemotherapy: Mitomycin C 10mg/m^2/d on d1 and 29; 5-Fluorouracil 1000mg/m^2/d on d1-5, 29-33
89547789|NCT02369939|Experimental|Experimental arm|Irradiation 1.8Gy/d; T2N0 55.8Gy; T3N0-T4N0 59.4Gy Chemotherapy: Mitomycin C 10mg/m^2/d on d1 and 29; 5-Fluorouracil 1000mg/m^2/d on d1-5, 29-33 Hyperthermia: 6
89547790|NCT02372435|Experimental|Short interval|"Re-Implantation of the prosthesis after a short interval of 2-3 weeks after explantation (fast-track-arm)."
89547791|NCT02372435|Active Comparator|Long interval|Re-Implantation of the prosthesis after a Long interval of 6-10 weeks (standard surgical treatment).
89547792|NCT02369627|Experimental|Rapid HIV Self-Test|Participants will perform a rapid HIV self-test using the OraQuick® In-home HIV Test.
89547793|NCT02369627|Active Comparator|Conventional Home-Based HIV Test|Participants will perform a conventional home-based HIV test using the Home Access Express HIV-1 Test System.
89547794|NCT02369627|Active Comparator|Community/Medical-Based HIV Test|Participants will receive a link to a CDC website (https://gettested.cdc.gov) that allows them to search for HIV testing locations of their choice.
89547795|NCT02369549|Active Comparator|Micro-particle curcumin|"Three 30 mg capsules once daily, self-administered for 6 months.~Curcumin is a nutraceutical, which are products isolated or purified from foods. The rhizomes of the plant Curcuma longa produces turmeric, a spice commonly used in Indian cuisine. Turmeric is comprised of three curcuminoids, of which curcumin is the most abundant. Curcumin is a polyphenol molecule that has been investigated for anti-inflammatory and anti-neoplastic properties since the 1970s."
89547796|NCT02369549|Placebo Comparator|Placebo|"Three 30 mg capsules taken once daily, self-administered for 6 months.~Placebo capsules are identical to the curcumin capsules in color, taste, smell, size and shape."
89547797|NCT02372123|Other|control|lifestyle advice
89547798|NCT02372123|Active Comparator|intervention|connective tissue manipulation
89547799|NCT02660489|Experimental|OC459 (CRTH2 antagonist)|OC459 50mg once daily for 5 weeks
89547800|NCT02660489|Placebo Comparator|Placebo|Placebo tablet once daily for 5 weeks
89547801|NCT02372201|Experimental|Hydro Colon Therapy plus probiotic|Hydro Colon therapy including 2-5 washes in 3 weeks, probiotic intervention for 5 weeks after end of hydro Colon therapy
89547802|NCT02369315|Experimental|Treatment (Invited entry 2012)|Children offered entry to music program in September 2012
89547803|NCT02369315|Experimental|Control (Invited entry 2013)|Children offered entry to music program delayed until September 2013
89547804|NCT02365259|Experimental|Phototherapy|This arm involves exposure to a UVB phototherapy device 3 times per week over 8 weeks.
89547805|NCT02365259|Placebo Comparator|Shame phototherapy|This arm is identical with experimental arm, except that participants will be exposed to non-UVB florescent light.
89547806|NCT02365337||vitamin D levels < 20ng/ ml|Vitamin D levels < 20ng/ ml
89547807|NCT02365337||vitamin D levels>20ng/ ml|Vitamin D levels >20ng/ ml
89547808|NCT02365415|Experimental|Sirolimus|Patients randomized to this arm will receive 8 weeks of enteral Rapamycin (sirolimus), with dosage titrated to achieve target blood levels.
89547809|NCT02365415|No Intervention|Control|No treatment.
89547810|NCT02369081|Active Comparator|Spironolactone|Each patient will patients will receive in random order 12 weeks treatment with each of the three active drugs (spironolactone, bisoprolol, doxazosin) or placebo. The dose will be doubled at the six week visit half-way through each phase.
89547811|NCT02369081|Placebo Comparator|Placebo|Each patient will patients will receive in random order 12 weeks treatment with each of the three active drugs (spironolactone, bisoprolol, doxazosin) or placebo. The dose will be doubled at the six week visit half-way through each phase
89547812|NCT02369081|Active Comparator|Doxazosin|Each patient will patients will receive in random order 12 weeks treatment with each of the three active drugs (spironolactone, bisoprolol, doxazosin) or placebo. The dose will be doubled at the six week visit half-way through each phase
89547813|NCT02369081|Active Comparator|Bisoprolol|Each patient will patients will receive in random order 12 weeks treatment with each of the three active drugs (spironolactone, bisoprolol, doxazosin) or placebo. The dose will be doubled at the six week visit half-way through each phase
89547814|NCT02368769||During tele-expertise|Remote site interpretation of frozen section
89547815|NCT02368769||Before tele-expertise|Usual (on site) frozen section
89547816|NCT02365493|No Intervention|Standard therapy|"Intravenous vancomycin dosed as per Australian Therapeutic Guidelines (loading dose of 25 mg/kg followed by maintenance dose of 15-20 mg/kg every 12 hours) with subsequent adjustment to maintain trough levels at 15-20 mg/dL OR Intravenous daptomycin 6-10 mg/kg per day, adjusted for renal function (details of renally adjusted dosing provided in full protocol).~The choice of daptomycin or vancomycin is clinician-determined and may be influenced by such factors as local practice, the vancomycin minimum inhibitory concentration (MIC) of the isolate and evidence emerging during the course of the study"
89547817|NCT02365493|Experimental|Standard therapy + Beta-Lactam|In addition to standard treatment an intravenous Beta-Lactam (β-lactam) will be added for the first 7 calendar days following randomisation (randomisation is day 1 - hence patients will receive 6-7 days of β-lactam). This β-lactam will be intravenous flucloxacillin 2g every 6 hours in Australia and intravenous cloxacillin 2g every 6 hours in Singapore. For those with a history of minor allergy to any penicillin (rash or unclear history, but not anaphylaxis or angiooedema), it will be intravenous cefazolin 2g every 8 hours. For haemodialysis patients, it will usually be cefazolin 2g three times per week post dialysis, however clinicians are also free to choose intermittent (flu)cloxacillin, dosed as for glomerular filtration rate (GFR ) <10, if they desire.
89025184|NCT00443183|Experimental|Brief Negotiation Interview|The Brief Negotiation Interview is a manual guided intervention using techniques based on motivational interviewing, brief advice, and behavioral contracting and is designed to be delivered in less than 10 minutes.
89025185|NCT00443183|Placebo Comparator|Discharge Instructions|Scripted discharge instructions to be read by emergency practitioner and designed to be less than 1 minute in length.
88811869|NCT01388777|Experimental|Cryoablation|Cryoablation therapy followed by re-imaging then complete surgical resection.
88811870|NCT00875342|Experimental|D-cycloserine|100 mg on days of therapy session
88811871|NCT00875342|Placebo Comparator|Placebo|Sugar pill
88811872|NCT00876200|Experimental|Minoxidil|"Normotension: 0.2mg/kg/day for children under 12 and 5mg/day for children aged 12 or more.~Hypertension: 0.2mg/kg/day, increasing up to a maximal dosage of 1 mg/kg) for children under 12. 5mg/day, increasing as needed of 0.1 mg/kg/day (up to a maximal dosage of 40 mg/day) for children aged 12 or more."
88811873|NCT00876200|Placebo Comparator|Placebo|Placebo = lactose
88811874|NCT02512302|Experimental|SUN-101 via eFlow nebulizer|50 mcg glycopyrrolate via Electronic Nebulizer
88811875|NCT02512302|Experimental|SUN-101 via eFlow nebulizer with activated charcoal|50 mcg glycopyrrolate via Electronic Nebulizer with activated charcoal
88811876|NCT02512302|Active Comparator|Seebri® Breezhaler®|63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI
88811877|NCT02512302|Active Comparator|Seebri® Breezhaler® with activated charcoal|: : 63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI with activated charcoal
88811878|NCT02512302|Active Comparator|: Glycopyrrolate Injection|50 mcg glycopyrrolate via IV infusion
88811879|NCT01507181|Experimental|Ketamine|single dose IV ketamine, .5mg/kg
88811880|NCT01507181|Placebo Comparator|Midazolam|single dose IV midazolam, .45mg/kg
88811881|NCT00877058|Experimental|1.Preventive home visit|Preventive home visits: This intervention included a single home visit made by either a nurse, a physiotherapist, a qualified social worker or an occupational therapist. Participants received verbal and written information/advice about what the districts could provide. The preventive home visit was guided by a protocol, which included an opportunity for individuals to further elaborate on certain elements. The visit lasted between one and a half to two hours.
88811882|NCT00877058|Experimental|2. Senior meetings|The senior meetings comprised four weekly meetings with about six participants in each group. The main purpose was to focus on two different topics: 1) information about the ageing process and its consequences and 2) provision of tools and strategies for solving problems that can arise in the home environment. A follow-up home visit took place two to three weeks after the group sessions were completed. The group meetings were led either by an occupational therapist, a registered nurse, a physiotherapist or a qualified social worker, all of whom spoke about their particular dimension of aging.
88811883|NCT00877058|No Intervention|3. Control group|The control group had access to the ordinary range of services if requested from the urban districts for the aged. The aim of the municipal provision of care for the older persons is to ensure the ability to live as independently as possible. This includes remaining in their homes. When an older person in Sweden has difficulties managing independently, she or he can apply for assistance from the district. The extent of such support is subject to an assessment of needs and includes meals on wheels, help with cleaning and shopping, assistance with personal care, safety alarms and transportation service. The older person are also offered healthcare, provided either by municipal home help or home medical care services.
88961704|NCT04850794|Experimental|Case A then Case B|Participant will first review and answer questions about Case A without using the tool. Then, they will use the tool to answer questions about case B.
88961705|NCT04850794|Experimental|Case B then Case A|Participant will first review and answer questions about Case B without using the tool. Then, they will use the tool to answer questions about case A.
88961706|NCT04844437||Digital examination of fetal head decent in pregnant women|Pregnant women at 36 weeks or over gestational age in the active phase of the first stage or second stage of labor were examined by digital examination and fetal head station evaluated by two clinicians.
88961707|NCT04844437||Transperineal assessment of fetal head decent in pregnant women|Pregnant women at 36 weeks or over gestational age in the active phase of the first stage or second stage of labor were examined by transperineal ultrasound and fetal head station evaluated by two experienced clinicians.
88961708|NCT04840472|Experimental|111-In panitumumab|The study drug (111In panitumumab) 5 mCi, allowable range 4.5 to 5.5 will be administered on Day 0, and subjects will undergo one 111In panitumumab SPECT/CT imaging anytime between Day 1 and Day of Surgery. Subjects will undergo surgical resection after infusion of 111In panitumumab.
89547818|NCT02368925|Experimental|Ultherapy™ System|Ultherapy™ System
89547819|NCT02365103|Other|Test meal I (given with water)|Test meal with water
89547820|NCT02365103|Other|Test meal II (simultaneously with tea)|Test meal with tea (simultaneously)
89547821|NCT02365103|Other|Test meal III (1 hour after test meal)|Test Meal with tea given 1 hour after test meal
89547822|NCT02365103|Other|Reference Iron Dose|Reference iron dose administered
89547823|NCT02365181|Experimental|IAL|intra-articular local anesthetic infiltration with catheter
89547824|NCT02365181|Active Comparator|ISB|interscalene block with catheter
89547825|NCT05653895|Active Comparator|Arm 1|Resveratrol (2 gm daily) 50 patients with PCOS will receive Resveratrol 1000mg BD daily
89547826|NCT05653895|Active Comparator|Arm 2|Metformin (1000mg daily),Resveratrol(2 gm daily) 50 patients with PCOS will receive Metformin 500mg,Resveratrol 1000 mg BD daily
89547827|NCT05653895|Active Comparator|Arm 3|L-Arginine(3 gm daily), Acetyl L-Carnitine (3 gm daily),CoQ10(200 mg daily) 50 patients with PCOS will receive L Arginine 1500mg,Acetyl L Carnitine 1500mg ,COQ10 100mg BD daily respectively
88961709|NCT04832477|Other|Stigma Counseling for PrEP Access|Behavioral counseling
88961710|NCT04805450|Active Comparator|ES before SEMS placement|ERCP with ES before biliary fully covered SEMS placement.
88961711|NCT04805450|Active Comparator|no ES before SEMS placement|ERCP without ES before biliary fully covered SEMS placement.
88961712|NCT04783389|Experimental|CBP-201 Dose 1|CBP-201 Dose 1 subcutaneous (SC) injection.
88961713|NCT04783389|Experimental|CBP-201 Dose 2|CBP-201 Dose 2 subcutaneous (SC) injection.
88961714|NCT04783389|Placebo Comparator|Placebo|Placebo subcutaneous (SC) injection.
89207971|NCT04040478||Abdominal|80 patients undergoing surgery for abdominal cancer. Data review for interim analysis will be conducted after the participation of 40 patients to evaluate the requirement for further enrollment.
89547828|NCT05653895|Active Comparator|Arm 4|L-Arginine(3 gm daily), Acetyl L-Carnitine (3 gm daily),CoQ10(200 mg daily),Metformin (1000mg daily) 50 patients with PCOS will receive L Arginine 1500mg,Acetyl L Carnitine 1500mg,COQ10 100mg BD daily respectively
89547829|NCT03589859||Normal Volunteers|Testing motor learning
89547830|NCT03589859||Vestibular hypofunction|Testing feasibility of rehabilitation game
89547831|NCT02368847|Other|Diagnostic tests|For any patient with a suspected urinary tract infection during the course of the study a basic questionnaire will have to be filled out and diagnostic tests (urine sample for culture, dipstick assay for the detection of nitrites and leukocyte- esterase and a POC CRP test) will have to be perform.
89547832|NCT02365025|Experimental|Experimental group|"Step 1: Patients and parents enrolment. Step 2: The parents of the children assigned to the experimental group will fill a questionaire related to familial and social background, electronic media exposure and sleep characteristics of their children.~Step 3: Parents of the children assigned to this group will participate in 6 meetings guides by experts in sleeping disorders. In those meeting the parents will be exposed to sleep disturbances, the importance of sleep habits and the influence of electronic media on sleep and learning.~Step 4: Re evaluation by questioners after the 6 meetings participation. Step 5: 3 months follow up after the intervention (Meetings)."
89547833|NCT02365025|No Intervention|Control group|"Step 1: Patients and parents enrolment. Step 2: The parents of the children assigned to the control group will fill a questionaire related to familial and social background, electronic media exposure and sleep characteristics of their children.~Step 3: Parents of the children assigned to this group will not participate in the meetings as described in the experimental group.~Step 4: Re evaluation by questioners after the time that the experimental group participated in the meetings.~Step 5: 3 months follow up."
89547834|NCT02364869|Experimental|Fructooligosaccharide|12g daily, for 12 weeks
89547835|NCT02364869|Placebo Comparator|Maltodextrin|12g daily, for 12 weeks
89547836|NCT02368613|Placebo Comparator|placebo group|Placebo
89547837|NCT02368613|Active Comparator|test1 group|DW-3102 125mg
89547838|NCT02368613|Active Comparator|test2 group|DW-3102 250mg
89547839|NCT02368613|Active Comparator|test3 group|DW-3102 500mg
89547840|NCT02364479|Experimental|50mg etanercept|Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein Injection, 50mg per week, Subcutaneous injection
89547841|NCT02364479|Experimental|25mg etanercept|Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein Injectio, 25mg per week, Subcutaneous injection
89547842|NCT02364479|Placebo Comparator|Placebo|Placebo, Subcutaneous injection per week
89547843|NCT05653817|Experimental|Advanced or metastatic cholangiocarcinoma|A multicenter clinical study of carralizumab combined with albumin paclitaxel and apatinib mesylate in the second-line treatment of advanced or metastatic cholangiocarcinoma.Albumin-bound paclitaxel 125 mg/m2 d1,8; Carrilizumab 200mg Q3W d1; Apatinib mesylate tablet treatment: 250mg orally, once a day, continuous administration. Treatment continued or was evaluated every 2 cycles until disease progression or toxic side effects of patient intolerance to the treatment regimen.
89547844|NCT02364635|Experimental|Icosabutate dose 1|Dose 1
89207972|NCT04040478||Vascular|20 patients undergoing femoral endarterectomy.
89547845|NCT02364635|Experimental|Icosabutate dose 2|Dose 2
89547846|NCT02364635|Experimental|Icosabutate dose 3|Dose 3
89547847|NCT02364635|Placebo Comparator|Placebo|Placebo (medium chain triglycerides)
89547848|NCT02364635|Experimental|Icosabutate dose 4|Dose 4
89547849|NCT02052310|Experimental|Roxadustat|Participants will receive roxadustat tablets, administered orally 3 times weekly (TIW). Initial roxadustat dose will be based on a tiered, weight-based dosing scheme (low weight [≤70 kilograms (kg)] and high weight [>70 to 160 kg] participants will receive 70 and 100 milligrams [mg] roxadustat, respectively). Dose adjustment to achieve correction and subsequent maintenance of target hemoglobin (Hb) values (10-12 grams [g]/deciliter [dL]) will be based upon regular monitoring of Hb. The maximum roxadustat dose is 3.0 mg/kg per dose or 400 mg per administration (whichever is lower).
89547850|NCT02052310|Active Comparator|Epoetin Alfa|Participants on hemodialysis (HD) will receive epoetin alfa, administered intravenously (IV) TIW, with starting doses and dose adjustment rules as per United States Package Insert (USPI) or summary of product characteristics (SmPC). Participants on home HD or peritoneal dialysis (PD) will receive epoetin alfa, administered subcutaneously (SC) as per the country-specific product label (USPI or SmPC) or local standard of care (SOC).
89547851|NCT02364245|Experimental|Kinect|Receive computer games training for 30 minutes and 30 minutes traditional OT.There are 3 sections for 1 week; the intervention period will be 8 weeks.
89547852|NCT02364245|Placebo Comparator|Traditional|The control group will receive traditional OT for 1 hour. There are 3 sections for 1 week; the intervention period will be 8 weeks.
89547853|NCT02368379|Other|Assessment of Central Adrenal Insufficiency|Patients will undergo low dose ACTH stimulation test followed by overnight metyrapone test to assess for central adrenal insufficiency.
89547854|NCT02368067|Active Comparator|Standard of Care Sentinal Node Dye|Surgery route, as determined by the patient and clinician, will determine which standard clinical dye will be used.
89547855|NCT02368067|Experimental|Installation of Study Sentinal Node Dye|Surgery route, as determined by the patient and clinician, will determine which study dye will be used for delivery by the experimental route.
89547856|NCT02051764|Experimental|Follow-up Flortaucipir PET Scan|
89547857|NCT02364401|Experimental|Impedance Guided Ablation Group|Impedance guided ablation group performs pulmonary vein(PV) isolation guided by annotation criteria with minimum time of 10 seconds, maximum range of 2 mm, and minimum impedance decrease over 5 Ohms instead of CF parameters. In the impedance guided group, operators are blinded to contact force data during PV isolation.
89547858|NCT02364401|Active Comparator|Contact Forced Guided Ablation Group|Contact force(CF) guided ablation group performs pulmonary vein (PV) isolation guided by automated annotation criteria with minimum time of 10 seconds, maximum range of 2mm, CF over time of 50% and minimum CF of 10 g.
89547859|NCT02368223|Experimental|YouGrabber training|Home-based YouGrabber training
89547860|NCT02051296|Experimental|minocycline|perioperative minocycline for 5 days, starting 2 hours prior to surgery then 100mg BID
89547861|NCT02051296|Placebo Comparator|Placebo|PLacebo
89547862|NCT02364167|Experimental|Verum acupuncture|Each patient will receive 16 permanent indwelling acupuncture needles, embedded in adhesive tape, bilaterally in addition to standard postoperative analgesia
89547863|NCT02364167|Placebo Comparator|Placebo acupuncture|Each patient will receive 16 adhesive tapes mimicking the indwelling acupuncture needles bilaterally in addition to standard postoperative analgesia
89547864|NCT02364167|Active Comparator|Standard therapy|Each patient will receive just standard postoperative analgesia
89547865|NCT02367677||Clinical measurements|Measurements are made with a paper ruler
88961717|NCT04771000|Experimental|Ambrisentan|Ambrisentan, 125µg twice a day for up to 28 days
89547866|NCT02367677||Smartphone|Measurements are made with ImageJ from pictures taken with an iPhone 6
89547867|NCT02367677||Digital camera|Measurements are made with ImageJ from pictures taken with a Nikon D700
89547868|NCT04711954||ATHENA|Cohort of people living with HIV in the Netherlands
89547869|NCT04711954||LUKCY|Cohort of people living with HIV in the Lviv area, Ukraine
89547870|NCT02367755|Experimental|Propofol|propofol infusion at a rate of 3 mg/kg/hr during TH.
89547871|NCT02367755|Active Comparator|Lorazepam|lorazepam infusion at a rate of 0.5 mg/kg/hr during TH.
89547872|NCT02050048|Experimental|High Volume Group (Intervention Arm)|"Patients will be randomized to receive intravenous Lactated Ringer's solution. In the high volume group (intervention arm), patients will receive fluids prior to, during, and after the completion of the procedure. Patients in the high volume group will receive fluids via infusion by the following weight based regimen:~initial bolus of LR prior to ERCP of 7.5 cc/kg over 1 hour~LR fluid infusion during the procedure at 5 cc/kg/hr~Post-procedure bolus of 20 cc/kg over 90 minutes"
89547873|NCT02050048|Active Comparator|Low Volume Group (Control Arm)|Patients will be randomized to receive intravenous Lactated Ringer's solution. In the low volume group (control arm), patients will receive fluids at the start of the ERCP. The fluids will be administered via infusion at a rate of 1.5 cc/kg/hr. Fluids may be continued through the 90 minute post-procedure observation period.
89547874|NCT02367287||Sampling strata|Stratified analyses of primary and secondary outcomes based on variables of interest (e.g. sex, age, or BMI) may occur prior to achieving the target for total study enrollment.
89547875|NCT02363777|Active Comparator|Standard of Care|Epidural placed for postoperative pain control
89547876|NCT02363777|Experimental|Experimental Intervention|Bilateral paravertebral catheters placed for postoperative pain control
89547877|NCT02363699|Active Comparator|Lidocaine|Group treated with lidocaine solution
89547878|NCT02363699|Placebo Comparator|Placebo|Group treated with saline solution
89547879|NCT02049814|Experimental|Metformin + Voglibose 0.2 mg|Metformin tablets, at the maximum tolerated dose ≥1000 mg/day, orally, for 12 weeks, in addition to voglibose 0.2 mg, tablets, orally, three times daily, for Weeks 1 and 2, followed by voglibose 0.3 mg, tablets, orally, three times daily, Weeks 3 through 12.
89547880|NCT02049814|Active Comparator|Metformin + Acarbose 50 mg|Metformin tablets, at the maximum tolerated dose ≥1000 mg/day, orally, for 12 weeks, in addition to acarbose 50 mg, tablets, orally, three times daily, Weeks 1 and 2, then acarbose 100 mg, tablets, orally, three times daily, Weeks 3 through 12.
88812022|NCT01395797|Experimental|PIO High Dose - Nicotine|Participants will be maintained on 45 mg of PIO prior to sessions assessing the abuse liability of nicotine
89547881|NCT02363855|Experimental|BAY 1841788(ODM-201)|Cohort 1: Safety, tolerability and PK of 300 mg dose given twice daily. Escalation to cohort 2 in case no safety relevant adverse event has been observed within 28 days after start of multiple dose (MD) Cohort 2: Safety, tolerability and PK of 600 mg dose given twice daily
89547882|NCT04059809|No Intervention|Usual Care|The control group will have usual care according to the orientation of the radiation therapy faculty responsible for the radiotherapy treatment the PBM device will be switched off
89547883|NCT04059809|Experimental|Photobiomodulation (PBM)|Additionally to the usual care, the patients will receive the PBM. Treatment will be done twice a week.
89547884|NCT02363543|Active Comparator|Hyalomatrix|Sterile, single use, flexible, and conformable wound dressing comprised of a derivative of hyaluronic acid which acts as a three dimensional regenerative matrix.
89547885|NCT02363543|Active Comparator|Integra|Sterile, single use, wound care dressing comprised of a porous matrix of cross-linked bovine tendon collagen and glycosaminoglycan
89547886|NCT02363387|Experimental|Incentive Group|Incentive group participants will receive the standard HIV medical care offered in their clinic. In addition, Incentive group participants will receive incentives for viral suppression. These incentives will be presented if the participants maintain suppressed and undetectable viral loads. The incentive program will employ high magnitude incentives, provide incentives for decreases in viral load early in treatment before a patient's viral load has reached undetectable levels, arrange frequent incentives early in treatment and reduce the frequency of incentives as participants achieve progressively longer periods of viral load suppression, arrange a schedule of escalating incentives for sustained suppression of viral load, and the intervention will be maintained for two years.
89547887|NCT02363387|Other|Usual Care Group|Usual Care Control participants will receive the standard HIV medical care offered in their clinic.
89547888|NCT03458975|Active Comparator|Selected liver metastases of the patient|Liver metastases randomized to receive sonoporation (US waves + gaseous microbubbles). The patient continue to receive the usual systemic chemotherapy
89547889|NCT03458975|Placebo Comparator|Not-selected liver metastases of the patient|Liver metatstases not randomized to receive sonoporation (US waves + gaseous microbubbles). The patient continue to receive the usual systemic chemotherapy like the active comparator arm
89547890|NCT03344159|Experimental|Spironolactone|Participants with chronic right-sided heart failure will receive spironolactone 12.5mg daily up to a maximum dose of 50 mg daily for a total duration of 12 weeks.
89547891|NCT03344159|Placebo Comparator|Placebo|Participants with chronic right-sided heart failure will receive placebo daily for a total duration of 12 weeks.
89547892|NCT02363309||Healthy Volunteers|Subjects without liver disease or metabolic syndrome
89547893|NCT02363309||NAFLD subjects|Subjects with Non-Alcoholic Fatty Liver Disease
89547894|NCT02363309||non-NAFLD metabolic syndrome|Subjects who have metabolic syndrome but do not have Non-Alcoholic Fatty Liver Disease
89547895|NCT02363465||Participants aged 18-30 years|"Echographic measurement of skin thickness at the proximal forearm and the deltoid region in participants aged 18-30 years.~aimed number: 12 male & 12 female maximum number: 15 male & 15 female"
89547896|NCT02363465||Participants aged 31-40 years|"Echographic measurement of skin thickness at the proximal forearm and the deltoid region in participants aged 31-40 years.~aimed number: 12 male & 12 female maximum number: 15 male & 15 female"
89547897|NCT02363465||Participants aged 41-50 years|"Echographic measurement of skin thickness at the proximal forearm and the deltoid region in participants aged 41-50 years.~aimed number: 12 male & 12 female maximum number: 15 male & 15 female"
89547898|NCT02363465||Participants aged 51-65 years|"Echographic measurement of skin thickness at the proximal forearm and the deltoid region in participants aged 51-65 years.~aimed number: 12 male & 12 female maximum number: 15 male & 15 female"
89547899|NCT02363231||patients under mechanical ventilation|
89547900|NCT03324113|Experimental|SAR408701 Monotherapy|SAR408701 Dose escalation administered as a single agent intravenously, on Day 1 and once every two weeks, to patients with malignant solid tumors
89547901|NCT02079844|Experimental|Placebo + Roflumilast 100 μg + Roflumilast 250 μg|Roflumilast placebo-matching tablets, orally, once, daily, Days 1 through 8, Period 1, followed by a 14 day washout period, followed by roflumilast 100 μg tablets, orally, once, daily, Days 1 through 8, Period 2, followed by a 14 day washout period, followed by roflumilast 250 μg tablets, orally, once, daily, Days 1 through 8, Period 3. All participants will take a stable dose of second generation antipsychotics throughout the duration of the treatment period.
89547902|NCT02079844|Experimental|Roflumilast 100 μg + Roflumilast 250 μg + Placebo|Roflumilast 100 μg tablets, orally, once, daily, Days 1 through 8, Period 1, followed by a 14 day washout period, followed by roflumilast 250 μg tablets, orally, once, daily, Days 1 through 8, Period 2, followed by a 14 day washout period, followed by roflumilast placebo-matching tablets, orally, once, daily, Days 1 through 8, Period 3. All participants will take a stable dose of second generation antipsychotics throughout the duration of the treatment period.
89547903|NCT02079844|Experimental|Roflumilast 250 μg + Placebo + Roflumilast 100 μg|Roflumilast 250 μg tablets, orally, once, daily, Days 1 through 8, Period 1, followed by a 14 day washout period, followed by roflumilast placebo-matching tablets, orally, once, daily, Days 1 through 8, Period 2, followed by a 14 day washout period, followed by roflumilast 100 μg tablets, orally, once, daily, Days 1 through 8, Period 3. All participants will take a stable dose of second generation antipsychotics throughout the duration of the treatment period.
89547904|NCT02367365||Treatment Naive NVAMD Patients|Patients with treatment naive NVAMD diagnosed in the last three months
89547905|NCT02367365||Newly Reactivated NVAMD Patients|Patients with newly reactivated NVAMD which has been previously quiescent off treatment
89547906|NCT02363153|Experimental|Diet and Exercise|Patients will be given an individualized diet and exercise plan by a physical therapist and registered dietician. The diet and exercise plan will be carried out by the participant for 16 weeks. The exercise plan, an aerobic and strength training regimen, will be performed under the supervision of a personal trainer or certified exercise physiologist that is local to the participant. The participant will complete core-stabilizing exercises which can be performed at home or in an approved group class. The participant will wear an activity tracker at all times during this 16 week period, and will be asked to manually enter data into a phone app, such as daily food intake and weight.
89547907|NCT02363075|Experimental|Dexamfetamine sulphate|Dexamfetamine Sulphate 5 mg Tablets
89547908|NCT02363075|Placebo Comparator|placebo|Aspect tablets identical to the active
89547909|NCT02367443|Experimental|one group|Radiation: Hypofractionated accelerated Radiotherapy with concomitant full dose Chemotherapy
89547910|NCT02362919||A cohort of elderly individuals|A cohort of elderly individuals between 65 and 80 years of age were vaccinated with Fluad, a seasonal inactivated trivalent adjuvanted influenza vaccine. Blood samples before (day 0) and at days 1/3, 7,21 and 70 after vaccination were collected.
89547911|NCT02362763|Experimental|Study group|Subjects received five acupuncture sessions designed to treat pain in the vulvar area
89547912|NCT02362763|Active Comparator|Controls|Controls received five acupuncture sessions designed for sedation
89547913|NCT03097757|Active Comparator|Fracture reduction without ultrasound|Fracture reduction as per standard of care involves closed fracture reduction without real-time imaging, or with c-arm or portable x-ray. Closed reduction of a fractured bone. Closed reduction is a procedure to set (reduce) a broken bone without surgery. This allows the bone to grow back together. It works best when it is done as soon as possible after the bone breaks.
89547914|NCT03097757|Experimental|Fracture reduction with ultrasound|Ultrasound guided Fracture reduction involves closed fracture reduction with the use of real-time ultrasound imaging, prior to, during and after the reduction procedure. C-arm or portable x-ray may also be used as an adjunct.
89547915|NCT02367053|Experimental|ZP4207|single dose of ZP4207 in ascending doses (s.c. and i.m.)
89547916|NCT02367053|Active Comparator|native glucagon|single fixed dose of glucagon
89547917|NCT02048722|Experimental|Treatment (regorafenib)|Patients receive regorafenib PO QD on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89547918|NCT02366897|Other|Tolerability and sensitivity|Stage 1: tolerability as per study design Stage 2: sensitivity as per study design - either quetiapine or risperidone. The intervention is the use of the Manus sensor pen
89547919|NCT04417114|Experimental|Single-Arm Open label|This is a single-arm open label mechanistic clinical trial. Subjects will be treated with rosuvastatin at a dose of 20mg/day and uptitrated as tolerated to a dose of 40mg/day.
89547920|NCT02366975|No Intervention|Eugonadal patients|Patients without hypogonadism has been enrollend but not randomized
89547921|NCT02366975|Active Comparator|Hypogonadal patients A|Patients with hypogonadism has been randomized to testosterone gel solution 2%
89547922|NCT02366975|Placebo Comparator|Hypogonadal patients B|Patients with hypogonadism has been randomized to placebo solution gel
89547923|NCT04417504|Experimental|MobFood breakfast kit|
89547924|NCT04417504|Experimental|Control isocaloric breakfast|
89547925|NCT03009539|Experimental|eHealth Familias Unidas Primary Care|"eHealth Familias Unidas consists of 12 sessions: eight (12 - 15 minute) mock parent sessions in Spanish and four (30 - 45 minute) online family sessions delivered in either Spanish and/or English."
89547926|NCT03009539|No Intervention|Treatment as Usual|Participants in this condition will not receive an intervention.
89547927|NCT04711486|Experimental|Contraloid acetate|"300 mg Contraloid/participant administered orally (for 28 days) as a single daily dose.~Other Name: PRI-002"
89547928|NCT04711486|Placebo Comparator|Placebo|300 mg Placebo (Microcrystalline cellulose)/participant administered orally (for 28 days) as a single daily dose.
89547929|NCT01696721||Pediatric Patients Treated with Protons|Proton Radiation Therapy
89547930|NCT04711330||Patients treated with maintenance immunotherapy after concurrent chemo/RT|"Observation of response and response. The microbiome of the patients throat and stool will be analyzed before the standard treatment with IO is initiated after completion of the chemoradiation therapy.~No intervention is planned."
88961718|NCT04771000|Placebo Comparator|Placebo|Placebo
89547931|NCT04686292||Suspected infection|All patients admitted to the emergency department with suspected infections assessed by the receiving physician
89547932|NCT01288235|Experimental|Proton Radiotherapy|Proton Radiotherapy
89547933|NCT02030002|Experimental|APC Flash-Free Adhesive Coated Appliance System|APC Flash-Free Adhesive Coated Appliance System
89547934|NCT02030002|Active Comparator|APC II Adhesive Coated Appliance System|APC II Adhesive Coated Appliance System
89547935|NCT04479371|Experimental|Liposomal bupivacaine|a penile block administered with novel liposomal bupivacaine during hypospadias repair
89547936|NCT04479371|Active Comparator|Standard Penile Block|Standard weight based bupivacaine penile block during hypospadias repair
89547937|NCT02079610|Experimental|real-time fMRI neurofeedback: Amygdala|Amygdala neurofeedback - attempt to upregulate the left amygdala during positive autobiographical memory recall via real time fMRI neurofeedback from the amygdala. Two sessions will be performed one week apart.
89547938|NCT02079610|Active Comparator|real-time fMRI neurofeedback: HIPS|HIPS neurofeedback - attempt to upregulate the left horizontal segment of the intraparietal sulcus (HIPS), a region not involved in emotional processing, during positive autobiographical memory recall via real time fMRI neurofeedback from the HIPS. Two sessions will be performed one week apart.
89547939|NCT03112733||Patients with ovarian carcinoma|Serum levels of trefoil factor 3 (TFF3), secreted frizzled related protein 4 (sFRP-4), reactive oxygen species modulator 1 (Romo1) and nuclear factor (NF)-κB of patients with a presumed diagnosis of ovarian carcinoma will be determined prior to surgery.
89547940|NCT03112733||Control group|Serum levels of trefoil factor 3 (TFF3), secreted frizzled related protein 4 (sFRP-4), reactive oxygen species modulator 1 (Romo1) and nuclear factor (NF)-κB of women without any adnexal mass nor malignancy will be determined to compare with other groups.
89547941|NCT03112733||Benign adnexal mass|Serum levels of trefoil factor 3 (TFF3), secreted frizzled related protein 4 (sFRP-4), reactive oxygen species modulator 1 (Romo1) and nuclear factor (NF)-κB of women with an adnexal mass will be determined to compare with other groups.
89547942|NCT02366741|Other|Pilot group|Five eligible patients will undergo WBRT with reduced dose to the hippocampi and will be evaluated prospectively by neuro cognitive testing, MRI scans and blood tests.
89207973|NCT02597465|Experimental|SPARC1507|SPARC1507
89207974|NCT02597465|Experimental|Chemotherapy|Chemotherapy
89547943|NCT03112655|Experimental|Human african trypanosomiasis patient|RNA, neopterin and 5-hydroxytryptophan detection
89547944|NCT02366585|Experimental|Treatment with Ciclosporin|Treatment of two periodontal pockets with ciclosporin gel Non-treatment of two periodontal pockets in same patient as comparator
89547945|NCT02362685||metabolic exercise testing|All the subjects referred to performed a metabolic exercise testing.
89547946|NCT02366429|Experimental|ICBT|Internet-based CBT for antenatal depression
89547947|NCT02366429|Active Comparator|TAU|Treatment as usual provided at antenatal clinics and other health care instances
89547948|NCT02079532|Experimental|MabThera (Rituximab)|
89547949|NCT02372279|No Intervention|No embryo observation (NEO)|Study group. No embryonic observation from day one to day five of embryo development.
89547950|NCT02372279|Experimental|Embryo observation (EO)|Control group. Conventional embryonic observations performed in day two, three and five of embryo development.
89547951|NCT02366351|Experimental|SHR3824 Placebo|once daily, 12 weeks
89547952|NCT02366351|Experimental|SHR3824 5 mg|once daily, 12 weeks
89547953|NCT02366351|Experimental|SHR3824 10 mg|once daily, 12 weeks
89547954|NCT02366351|Experimental|SHR3824 20 mg|once daily, 12 weeks
89547955|NCT02366117|Experimental|Training|"Data collected during the first pahse of the study will be presented and discussed in a specialist focus group, which will work with the study team as advisors and trainers, to decide on the type of training to be developed.~This training intervention will be applied to the facilities presenting half the patient sample size."
89547956|NCT02366117|No Intervention|No Training|Facilities representing half the sample size will not be trained as in the Experimental Arm and continue their standard of care for these patients.
89547957|NCT02038673|Experimental|Dose escalation part 0.5 mg QD|Oral
89547958|NCT02038673|Experimental|Dose escalation part 1.0 mg QD|Oral
89547959|NCT02038673|Experimental|Dose escalation part 2.0 mg QD|Oral
89547960|NCT02038673|Experimental|Dose escalation part 2.0 mg BID|Oral
89547961|NCT02038673|Experimental|Dose escalation part 4.0 mg BID|Oral
89547962|NCT02038673|Experimental|Dose escalation part 6.0 mg BID|Oral
89547963|NCT02038673|Experimental|Dose escalation part 10.0 mg BID|Oral
89547964|NCT02038673|Experimental|Dose escalation part 20.0 mg BID|Oral
89547965|NCT02038673|Experimental|Dose escalation part 16.0 mg BID|Oral
89547966|NCT02038673|Experimental|Expansion part Urothelial Carcinoma|Oral
89547967|NCT02038673|Experimental|Expansion part Hepatocellular Carcinoma|Oral
89547968|NCT02038673|Experimental|Expansion part Squamous Cell Lung Carcinoma|Oral
89547969|NCT02958917|Placebo Comparator|pirfenidone 2403 mg/d|Subjects will be randomized in a 2:1 ratio to receive either pirfenidone 2403 mg/d or a placebo equivalent.
89547970|NCT02958917|Active Comparator|Placebo|The placebo will be visually similar to pirfenidone.
89547971|NCT02362529|Experimental|Minocycline|The dose of minocycline would be 50mg per day on week 1, 50mg bid on week 2 and 100mg bid weeks 3-8. For tapering, the dose will be reduced to 50mg bid for a week, and then stopped.
89547972|NCT02362529|Placebo Comparator|Placebo|The number and appearance of the pills would be identical to those in the minocycline arm.
88961719|NCT04766944||Critically ill trauma patients of 50 years old and above|Patients of 50 years old and above admitted to the Montreal General Hospital intensive care unit for trauma
89207975|NCT00972855|Experimental|Bicalutamide|Bicalutamide 50 mg Tablet
89207976|NCT00972855|Active Comparator|Casodex®|Casodex® 50 mg Tablet
89207977|NCT04090931|Experimental|Heat-Activated Nickel-Titanium Archwires|"Heat-activated NiTi (HANT) Group (TruFlex™ Thermal Nickel-Titanium, Ortho Technology, USA):~0.014-inch HANT~0.016-inch HANT"
89207978|NCT04090931|Experimental|Superelastic Nickel-Titanium Archwires|"Superelastic NiTi (SENT) Group (TruFlex™ Nickel-Titanium, Ortho Technology, USA):~0.014-inch SENT~0.016-inch SENT"
89207979|NCT00786812|Other|CAMN107A2109 Extension Patients|
89207980|NCT00786812|Other|AMN107 Naive|
89207981|NCT00859716|Experimental|1|vaccination with ACE393 followed by challenge with campylobacter jejuni
89207982|NCT00859716|Placebo Comparator|2|Placebo vaccination followed by challenge with campylobacter jejuni
89207983|NCT00743483|Experimental|rhBSSL|170 mg rhBSSL three times daily for 5 to 6 consecutive days
89547973|NCT02362529|Other|Celecoxib|This will be an open label trial for those with Hamilton Depression Rating Scale score ≥ 8 following the minocycline v. placebo trial or those not eligible for Phase 2. Dose of celecoxib will be 100 mg bid for the first week and 200mg bid for weeks 2-8. For tapering, the dose of celecoxib will be reduced to 100mg bid for one week, and then stopped.
89547974|NCT02362607|Experimental|Integrated Diabetes Management Protocol|Smartphone apps for food diary, activity monitor, blood glucose will be used for three months.
89547975|NCT02362607|Active Comparator|Standard Diabetes Management Protocol|Subjects will receive standard diabetes management protocol with standard education and standard blood glucose measurement devices.
89547976|NCT02362295||census|qualitative interview
89547977|NCT02769689|Experimental|Methylprednisolone|The primary purpose of this protocol is to investigate the impact of high dose of oral methylprednisolone, given once a month during the washout period between NTZ and Fingolimod (FTY).
89547978|NCT02769689|Placebo Comparator|Placebo|Included patients will receive either methylprednisolone (1 gramme, 1 day every 4 weeks for a total of 3 grammes) or undistinguishable capsules of placebo
89547979|NCT02362061||pregnant|These patients are then assigned to receive fertility treatment (ovulation induction, ICSI, intrauterine insemination and IVF). They undergo a 3D vaginal ultrasound before treatment to measure the junctional zone thickness and followed up after treatment to determine the rate of implantation and they became pregnant
88961720|NCT04763590|Experimental|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) had 3 principal components: (1) psychoeducation, (2) cognitive restructuring, and (3) exposure. In this treatment, derived from an empirically-supported treatment for panic disorder, psychoeducation consisted of teaching about the interrelationship between thoughts, feelings, and physical sensations during weaning. The cognitive component taught patients how to challenge their thoughts, with a particular focus on identifying thoughts that over-estimated the probability of negative medical events. The behavioral component consisted of reducing the need for mechanical ventilation in a step-wise, graduated, manner.
88961721|NCT04696562|Experimental|Intervention group|The intervention group is the group in which the investigors applied deep breathing exercises with triflo.
89547980|NCT02362061||Non pregnant|These patients are then assigned to receive fertility treatment (ovulation induction, ICSI, intrauterine insemination and IVF). They undergo a 3D vaginal ultrasound before treatment to measure the junctional zone thickness and followed up after treatment to determine the rate of implantation and they remained non pregnant
89547981|NCT02454257||Admission to ICU|Patients admitted to an adult critical care unit or cardiothoracic critical care unit
89547982|NCT02454257||In-hospital cardiac arrest|Patients experiencing an in-hospital cardiac arrest
89547983|NCT02362139|Experimental|The study group|200 pregnant women, 18-45 years old, 37-41 weeks of gestation, in spontaneous labor, which were treated with 80 mg of Intra-muscular (IM) Papverine during the latent phase of labor (cervical dilatation<4cm).
89547984|NCT02362139|No Intervention|The control group|200 pregnant women, 18-45 years old, 37-41 weeks of gestation, in spontaneous labor, which were not treated with IM Papverine
89547985|NCT02365571|Experimental|LY3154207 (Part A)|LY3154207 administered in ascending doses once orally in two of three study periods
89547986|NCT02365571|Placebo Comparator|Placebo (Part A)|Placebo matching LY3154207 administered once orally in one of three study periods.
89547987|NCT02365571|Experimental|LY3154207 (Part B)|LY3154207 administered once orally.
89547988|NCT02365571|Placebo Comparator|Placebo (Part B)|Placebo matching LY3154207 administered once orally.
89547989|NCT02365571|Experimental|LY3154207 (Part C)|LY3154207 administered once orally on Day 1
89547990|NCT02365571|Experimental|LY3154207 + Itraconazole (Part C)|Itraconazole administered orally (twice daily on Day 3 and then once daily to Day 12). LY3154207 co-administered once orally, on Day 9. Timing and duration of itraconazole dosing may be adjusted based on data from Part A.
89547991|NCT02362217|Experimental|Group 1|"Interventions: AdCh3NSmut1, MVA-NSmut. Administration schedule: 1 dose AdCh3NSmut1 2.5 x 10^10 vp at week 0 and 1 dose MVA-NSmut 2 x 10^8 pfu at week 8.~Subjects: 8 healthy volunteers."
89547992|NCT02362217|Experimental|Group 2|"Interventions: ChAdV63.HIVconsv, MVA.HIVconsv. Administration schedule: 1 dose ChAdV63.HIVconsv 5 x 10^10 vp at week 0 and 1 dose MVA.HIVconsv 2 x 10^8 pfu at week 8.~Subjects: 8 healthy volunteers."
89547993|NCT02362217|Experimental|Group 3|"Interventions: AdCh3NSmut1, MVA-NSmut, ChAdV63.HIVconsv, MVA.HIVconsv. Administration schedule: 1 dose AdCh3NSmut1 2.5 x 10^10 vp and 1 dose ChAdV63.HIVconsv 5 x 10^10 vp at week 0, and 1 dose MVA-NSmut 1 x 10^8 pfu and 1 dose MVA.HIVconsv 1 x 10^8 pfu at week 8.~Subjects: 16 healthy volunteers."
89547994|NCT02361983||DLT versus bronchial blockers|double lumen tube versus bronchial blockers
89547995|NCT02361827||A1, Vitamin D deficient|Vitamin D level before cycle < 20 ng/mL.
89547996|NCT02361827||B1, Vitamin D insufficient|Vitamin D level before cycle 20-29.9 ng/mL
89547997|NCT02361827||C1, Vitamin D replete|Vitamin D level before cycle > 30 ng/mL
89547998|NCT02361827||A2, Vitamin D deficient|Vitamin D level before ET < 20 ng/mL (FET with Euploid embryos)
89547999|NCT02361827||B2, Vitamin D insufficient|Vitamin D level before ET 20-29.9 ng/mL (FET with Euploid embryos)
89548000|NCT02361827||C2, Vitamin D replete|Vitamin D level before ET > 30 ng/mL (FET with Euploid embryos)
89548001|NCT02365727|Experimental|Exparel plus Adductor Canal Block|Adductor canal block with 20 cc 0.5% Ropivacaine with 1:400,000 epinephrine and 100mcg of clonidine
89548002|NCT02365727|Placebo Comparator|Exparel plus Placebo Block|Adductor canal block with 20 cc saline
89548003|NCT02361593|Experimental|Cap group|Patients will receive endoscopic sclerotherapy(lauromacrogol injection) for esophageal varices with assistance of a transparent cap in front of gastroscopy.
89548004|NCT02361593|Active Comparator|Control group|Patients will receive routine endoscopic sclerotherapy(lauromacrogol injection) for esophageal varices(no transparent cap involved).
89548005|NCT02365805|Active Comparator|Standard FEC Regimen|Epirubicin + Ciclofosfamide + Fluorouracil + Paclitaxel
89548006|NCT02365805|Experimental|No or Low BRCA1 expression|Epirubicin + Cisplatin + Fluorouracil
89548007|NCT02365805|Experimental|Normal or High BRCA1 expression|Docetaxel + Ciclofosfamide
89548008|NCT03112889|Experimental|Sodium Valproate|Subjects will receive sodium valproate modified release 20mg/kg/day (maximum dose 2.0g/day) administered orally once daily for six months.
89548009|NCT04478825|Experimental|BBT-401-1S|BBT-401-1S, rectal administration
89548010|NCT04479059|Experimental|İntracavitary fluid flushing|
89548011|NCT04479059|No Intervention|Control group|
89548012|NCT03112577|Experimental|REGN3500|REGN3500: masked and randomized dosing regimen per protocol (part 1 only)
89548013|NCT03112577|Experimental|Dupilumab|Dupilumab: masked and randomized dosing regimen per protocol (part 1 only)
89548014|NCT03112577|Experimental|REGN3500 plus dupilumab|REGN3500 plus dupilumab: masked and randomized dosing regimen per protocol (part 1 only)
89548015|NCT03112577|Experimental|Placebo|Placebo: masked and randomized dosing regimen per protocol (part 1 only)
89548016|NCT03112577|Active Comparator|Fluticasone propionate|Fluticasone propionate: open label dosing regimen per protocol (part 2 only)
89548017|NCT02361905|Experimental|Ulipristal acetate|women will be treated with an oral dose of ulipristal acetate 5 mg/day for 3 months
89548018|NCT02361905|Active Comparator|Leuprolile acetate|Women will be treated with an intramuscular (IM) injection of leuprolide acetate 11.25 mg in the luteal phase
89548019|NCT02038751||Index proband|moderate to severe OSA (AHI>30 or AHI>15 needing CPAP intervention) age 20-99 y/o
89548020|NCT02038751||Index family|first-degree, second-degree, or spouse of index proband age >20 y/o
89548021|NCT02038751||Control proband|friends of index proband, living in the same environment as index proband age > 20 y/o
89548022|NCT02038751||Control family|first-degree, second-degree, or spouse of control proband age >20 y/o
89548023|NCT02361749|Active Comparator|Myectomy group|Subjects will undergo anal myectomy for their anal sphincter.
89548024|NCT02361749|Active Comparator|Botox Group|Subjects will undergo Botulinum toxin injection into their anal sphincter.
89548025|NCT02361281||Sarcoidosis patients|Clinically relevant sarcoidosis patients with different stages and treatments.
89548026|NCT02361281||Healthy controls|Healthy people without any pulmonary conditions
89548027|NCT02361203|No Intervention|No Exercise|
89548028|NCT02361203|Experimental|Exercise Pre|30 minutes of aerobic exercise before exposure therapy
89548029|NCT02361437|Placebo Comparator|placebo|placebo
89548030|NCT02361437|Experimental|Vasculera|diosmin
89548031|NCT02359409|Active Comparator|water immersion only|Colonoscopy will be performed using the water immersion technique.
89548032|NCT02359409|Experimental|water immersion with goggle balloon|Colonoscopy will be performed using a goggle balloon at the tip of the scope with water immersion technique
89548033|NCT04349735|Experimental|Adults with asthma or COPD|Assessment of inhalation technique by three methods in all patients
89548034|NCT03160469|Experimental|Elipse capsule insertion group|All patient who inserted elipse capsule in single clinic
89548035|NCT02358941|Experimental|Training in a school setting|"A minimum of 30 sessions (45 min.) over at least 12 weeks in the schools of the participants.~Half of the children will be assigned to NF training, the other half to CCT."
89548036|NCT02358941|Experimental|Training in a clinical setting|"A minimum of 30 sessions (45 min.) over approx. 12 weeks at the Department of Child and Adolescent Psychiatry (treatment as usual).~Half of the children will be assigned to NF training, the other half to CCT."
89548037|NCT03160313|Experimental|InFuSE|Experimental group which will receive health education, group discussion, and supervised exercise.
89548038|NCT03160313|Active Comparator|Patient Education/Group Discussion|Active control group which will receive health education and group discussion.
89548039|NCT02358707|Experimental|phonophoresis in knee osteoarthritis|Ibuprofen phonophoresis in patients with knee osteoarthritis
89548040|NCT02358551|Other|Axillary vein|Lead Placement Through the Axillary Vein Technique
89548041|NCT02358551|Other|Subclaivan vein|Lead Placement Through the Subclavian Vein Technique
89548042|NCT02358317|Experimental|Video Game Motor Training|Participants in the treatment group will come to the University of Wisconsin lab for six weeks to train 3-5 days each week under research staff supervision. Each training session will last 30-60 minutes and will include playing our in-house Ninja Training game combined with balance games from the Wii Fit.
89548043|NCT02358317|Active Comparator|Sedentary Video Game Training|Participants randomly assigned to this condition will come to the lab for six weeks to play sedentary video games 3-5 days each week under research staff supervision. Each training session will last 30-60 minutes. Pre-and post assessments will be done identically to the Experimental group.
89548044|NCT02360969||healthy subjects waiting for surgery|patients for whom surgery under general anesthesia with administration of curare is planned will be offered an examination of the eyes before and during surgery
89548045|NCT02361047|Experimental|Phone Coaching Program|Participants will receive a nutrition and physical activity phone coaching program, in addition to standard-of-care physician counseling regarding lifestyle recommendations to achieve/maintain a healthy weight trajectory after cancer treatment.
89548046|NCT02361047|No Intervention|Standard Care Control|Participants will receive standard-of-care physician counseling regarding lifestyle recommendations to achieve/maintain a healthy weight trajectory after cancer treatment.
88961722|NCT04696562|No Intervention|Control group|The control group is the group that receives standard clinical care.
89548047|NCT02358239|Experimental|Efficacy and safety of acupuncture for dizziness and vertigo|To evaluate the efficacy and safety of acupuncture in treating patients with dizziness and vertigo in ED.
89548048|NCT02360813|Experimental|Cognitive Remediation Therapy|Principle driven cognitive remediation therapy, cognitive rehabilitation, cognitive training, cognitive enhancement.
89548049|NCT02360813|Active Comparator|Treatment as Usual|Usual care.
89548050|NCT02360657|Experimental|JNJ-54861911, 10 mg|JNJ-54861911, 10 milligram (mg) (2*5 mg tablet) orally once daily for 4 weeks.
89548051|NCT02360657|Experimental|JNJ-54861911, 50 mg|JNJ-54861911, 50 mg (2*25 mg tablet) orally once daily for 4 weeks.
89548052|NCT02360657|Placebo Comparator|Placebo|Placebo matching to JNJ-54861911 tablet orally once daily for 4 weeks.
89548053|NCT02360735|Active Comparator|Control|Patients randomized to this arm will follow the current standard for post-operative care.
89548054|NCT02360735|Experimental|Experimental|Patients randomized to this arm will follow the current standard for post-operative care as well as 2 daily sessions of manual lymphatic drainage.
89548055|NCT02358005|Experimental|60mJ ESWT|ESWT (0.04 mJ/mm2, 1500 shock + sham stimulation 2500) / total dose per treatment : 60mJ
89548056|NCT02358005|Experimental|120mJ ESWT|ESWT (0.04 mJ/mm2, 4000 shock) / total dose per treatment : 160mJ
89548057|NCT02358005|Placebo Comparator|sham ESWT stimulation|ESWT (0 mJ/mm2, sham stimulation 4000) / total dose per treatment : 0mJ
89548058|NCT02360501|Experimental|treatment arm|docetaxel 75mg/㎡,d1; cisplatin 25mg/㎡,d1-3; capecitabine 2g/㎡, d1-14. repeated every three weeks
89548059|NCT02358629|Experimental|Prospective, non-randomized|use the NovaCross™micro-catheter in respect to providing additional guidewire support that is expected to allow easier crossing of femoropopliteal and infra-popliteal Chronic Total Occlusion (CTO) lesion
89548060|NCT02360423|Experimental|CRE8 group|CRE8 sirolimus-eluting stent system
89548061|NCT02360423|Active Comparator|RESOLUTE group|RESOLUTE zotarolimus-eluting stent system
89548062|NCT02358161|Experimental|LDE225|DLT adn MTD of LED225 co-administered with fixed doses of gemcitabine and nab-paclitaxel in patients with advanced or metastasized pancreatic cancer.
89548063|NCT02357927|Placebo Comparator|control|simple general telephone call
89548064|NCT02357927|Experimental|Mini-AFTERc Intervention|20-30 minute structured conversation with breast cancer patient using Mini-AFTERc Manual
89548065|NCT02360345|Experimental|q1week schedule|ONX-0801 will be administered over a 1-hour IV infusion on Days 1, 8, 15 and 22 of repeated 28-day treatment cycles.
89025186|NCT03275142|Experimental|Icare Applanation|"Evaluation of corneal stability post-applanation with Icare tonometer via pre and post applanation keratometry readings with IOL Master, topography with Pentacam, fluorescein corneal staining. Patient's OD and OS are randomized into study or control, then undergo applanation with Icare. Investigator is masked as to which eye has undergone applanation."
89548066|NCT02360345|Experimental|q2week schedule|ONX-0801 will be administered over a 1-hour IV infusion on Days 1 and 15 of repeated 28-day treatment cycles.
89548067|NCT02357849|Active Comparator|Aripiprazole|To increase homogeneity and assure treatment with a clinically effective dose, patients will undergo a fixed titration phase during the first four weeks (2mg wk1, 5mg wk2, 10mg wk3, 5-30 mg wk4-24), with the option to slow or halt the titration or decrease the target dose if intolerability develops. After 3 weeks, dosing will be flexible and left up to clinical choice and need (5-30mg).
89548068|NCT02357849|Active Comparator|Fluoxetine|To increase homogeneity and assure treatment with a clinically effective dose, patients will undergo a fixed titration phase during the first four weeks (5mg wk1, 10mg wk2, 20mg wk3, 10-60mg wk3-24), with the option to slow or halt the titration or decrease the target dose if intolerability develops. After 3 weeks, dosing will be flexible and left up to clinical choice and need(10-60mg).
89548069|NCT02357693|Experimental|aprepitant|aprepitant 80 mg one hour before surgery
89548070|NCT02357693|Placebo Comparator|placebo|oral placebo one hour before surgery
89548071|NCT02360033|Experimental|Systemic Therapy|Systemic Therapy deals with the experience in private social systems (e.g. couples. Family, friends) and organizational systems (e.g. work teams), their appraisals and the attitude of the members towards each other within the system. It is analyzed how these systems can lead to the development and maintenance of psychological disorders.
89548072|NCT02360033|Experimental|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy deals with individual behavior as well as individual attitude, thoughts, appraisals and beliefs, which can have an influence on the development and maintenance of psychological disorders.
89548073|NCT02357771|Placebo Comparator|Placebo Arm|Placebo Lozenges (4 Lozenges per day; 2 lozenges in morning and 2 lozenges in the night). Each placebo lozenge contains all excipients except the active constituent (Lactobacillus brevis CD2)
89548074|NCT02357771|Experimental|Probiotic Arm|Lactobacillus brevis CD2 Lozenges (4 Lozenges per day; 2 lozenges in morning and 2 lozenges in the night). Each probiotic lozenge contains not less than 1 billion Colony Forming Unit of L. brevis CD2
89548075|NCT02357537|Active Comparator|Traditional|"Subjects in Study Arm 1 will undergo a screening process, and if randomized, will follow a traditional, site-based clinical trial model and undergo a baseline visit and 3 more in-person visits with the Principal Investigator (total of 4 visits).~Subjects in each Study Arm will be randomized (2:1) to follow one of two dietary regimens during the study: the Combined Anti-Inflammatory Diet (CAID) or Control (standard nutritional advice)."
89548076|NCT02357537|Active Comparator|Remote|"Subjects in Study Arm 2 will undergo a screening process, and if randomized, will undergo one Baseline visit at the local Gastroenterologist's office and 4 video visits with the Principal Investigator. A mobile nurse will visit subjects at a distant location (such as their home) to obtain blood samples at visits 1 and 4.~Subjects in each Study Arm will be randomized (2:1) to follow one of two dietary regimens during the study: the Combined Anti-Inflammatory Diet (CAID) or Control (standard nutritional advice)."
89548077|NCT02357615|Experimental|nifedipine CR tablets (Xin Ran)|Subjects will take a nifedipine controlled-release tablet (30 mg, Xin Ran) orally in every morning for a 8-week treatment period.
89548078|NCT02357615|Active Comparator|nifedipine CR tablets (Adalat)|Subjects will take a nifedipine controlled-release tablet (30 mg, Adalat) orally in every morning for a 8-week treatment period.
89548079|NCT03160001|Placebo Comparator|Placebo and etanercept|Placebo lactose 500mg cap twice daily with etanercept 50mg weekly for 8 weeks
89548080|NCT03160001|Experimental|Niclosamide and etanercept|Niclosamide cap 500 mg twice daily with Etanercept 50mg weekly for 8 weeks
89548081|NCT02359643|Placebo Comparator|with high dose aspirin|KD patients treated with high dose IVIG (2gm/kg) and high dose aspirin (>50mg/kg/day) since diagnosed, then taper to low dose aspirin (3-5mg/kg/day) when fever subside.
89548082|NCT02359643|Experimental|Without high dose aspirin|KD patients treated with high dose IVIG (2gm/kg) without high dose aspirin (>50mg/kg/day) since diagnosed, then low dose aspirin (3-5mg/kg/day) when fever subside.
89548083|NCT02038985|Other|+ ICG Dye (Firefly)|Participants will receive ICG Dye
89548084|NCT02359721|Experimental|test group|Base line scaling and root planing was done. Clarithromycin tablet 500 mg( Clarino-500) was given for a period of 7 days orally two times per day
89548085|NCT02359721|No Intervention|control|scaling and root planing
89548086|NCT03160157||laparoscopic surgical group|"Patients suitable for elective cholecystectomy with minimally invasive approach will be consented and randomized into either the robotic or laparoscopic group and both the patient and the operating physician will be notified which technique will be performed. Patients will be randomized to a 1:1 ratio. In order to eliminate bias in randomization, the investigators will be using an online resource available at: https://www.randomizer.org.~After randomization, the investigators will complete a chart review that will follow the patients for a total of 30 days. The patient participation will be limited to the consent discussion and potential sign off. There will be no other clinic visits in regards to this research."
88811884|NCT01428245|Experimental|Progesterone, estrace|"oral progesterone suspension (20 mg/ml, 25-100 mg) three times a day at 0700, 1500, and 2300 hr to achieve mean plasma concentrations over the range of 2-8 ng/ml for seven days~oral estrace, 0.5-1 mg once a day for seven days"
89025187|NCT03275142|Active Comparator|No ICare Applanation|"Evaluation of corneal stability post-applanation with Icare tonometer via pre and post applanation keratometry readings with IOL Master, topography with Pentacam, fluorescein corneal staining. Patient's OD and OS are randomized into study or control, then undergo applanation with Icare. Investigator is masked as to which eye has undergone applanation."
89025188|NCT03271983|Other|metronidazole gel 1|RLD gel
89548087|NCT03160157||robotic surgical group|"Patients suitable for elective cholecystectomy with minimally invasive approach will be consented and randomized into either the robotic or laparoscopic group and both the patient and the operating physician will be notified which technique will be performed. Patients will be randomized to a 1:1 ratio. In order to eliminate bias in randomization, the investigators will be using an online resource available at: https://www.randomizer.org.~After randomization, the investigators will complete a chart review that will follow the patients for a total of 30 days. The patient participation will be limited to the consent discussion and potential sign off. There will be no other clinic visits in regards to this research."
89548088|NCT02359487|Experimental|Intervention|The intervention consists of a 1-hour individual counseling session relating to alcohol consumption and HIV sexual risk behaviors. Intervention counselors will assess alcohol-related sexual risk behaviors through the use of job aids that include a flip chart, guided scripts, activities, role plays, and a take home booklet. Counselors use motivational interviewing and interactive activities to discuss alcohol and HIV myths and facts, participants personal risk behaviors, and a decision-making activity that assists participants in weighing the pros and cons of engaging in risky behavior. Counselors also facilitate role plays to improve communication skills in risky situations, as well as a condom demonstration and skills session, and goal setting. In addition, men in the intervention arm will also receive two cell phone text messages 1-month and 4-months following enrollment to reiterate risk reduction messages.
89548089|NCT02359487|Placebo Comparator|Control|Participants assigned to the control arm will be given a general alcohol information booklet and an alcohol abuse support services brochure. The alcohol information booklet contains information about responsible drinking, signs and symptoms of alcohol abuse, advice and guidance to reduce alcohol intake, and resources for assistance. The alcohol support services brochure contains times, dates, and locations of peer support and counseling services in the Windhoek region.
89548090|NCT02357303|Placebo Comparator|Placebo|Group A - 100mL of water by mouth, 15 to 30 minutes before endoscopy
89548091|NCT02357303|Active Comparator|Simethicone|Group B - 100mL of water plus 100mg Simethicone by mouth, 15 to 30 minutes before endoscopy
89548092|NCT02357303|Active Comparator|Simethicone plus N-acetylcysteine|Group C - 100mL of water plus 100mg Simethicone plus 600mg N-acetylcysteine by mouth, 15 to 30 minutes before endoscopy
89548093|NCT03112811|Experimental|Intubated infant|
89548094|NCT03112811|Experimental|Extubated infant|
89548095|NCT02352857|Placebo Comparator|Sugar|Control group consuming sponge cakes containing in total 24g of dextrose.
89548096|NCT02352857|Experimental|FOS|Group consuming sponge cakes in which 30% of the dextrose was replaced by FOS.
89548097|NCT02352935|Experimental|NanoKnife LEDC System|90 pulses of 70 microseconds each in duration will be administered per electrode pair
89548098|NCT02352935|No Intervention|Control|The patients without any treatment
89548099|NCT02357225|Experimental|Acute Dose of Pyridostigmine|Subjects will receive an acute administration of pyridostigmine bromide, calculated on their body weight at clinical exam (1 mg/kg, 60mg max starting dose), and will be monitored for 2 hours post administration. Subjects will also receive a pre- and post-administration single-fiber EMG, respiratory tests and strength tests in order to evaluate the function of the neuromuscular junction. All study subjects will be enrolled in this arm.
89548100|NCT02357225|Experimental|Prolonged Use of Pyridostigmine|This arm will evaluate the impact of pyridostigmine bromide on respiratory and skeletal muscle function during a 90-day administration period. On Days 1 - 7 subjects will receive 0.5mg/kg of the study drug every 4 hours while awake. On Days 8 - 90 subjects will receive 1.0 mg/kg every 4 hours while awake. Quality of life will also be measured with the SF-36 health survey. Data collection will occur at multiple time points (Days 30 and 90) throughout the study. Subjects will also be contacted at least weekly via telephone. All study subjects will be enrolled in this arm.
89548101|NCT04478903||primary caregiver of patients aged 70 and over|
89548102|NCT02357381||TMS Treatment|TMS( transcranial magnetic stimulation) -treatment for headache
89548103|NCT02356991|Experimental|Famitinib|Famitinib 25 mg qd p.o., 4 weeks per cycle.The treatment continued until disease progression or intolerable toxicity happened or patients withdrawal of consent.
89548104|NCT02356991|Placebo Comparator|Placebo|Placebo 25 mg qd p.o., 4 weeks per cycle.The treatment continued until disease progression or intolerable toxicity happened or patients withdrawal of consent.
89548105|NCT03112265|Experimental|Child STEPS|Child STEPs includes (1) a treatment protocol, Modular Approach to Therapy for Children with Anxiety, Depression, Trauma or Conduct Problems (MATCH-ADTC), and (2) a youth monitoring and feedback system (MFS).
89548106|NCT03112265|Active Comparator|Usual Care|Treatment in the UC condition will use the procedures therapists and their supervisors consider appropriate and believe to be effective, and researchers will not influence their work.
89548107|NCT03112343|Active Comparator|ICT-based intervention|Subjects in the ICT-based intervention group have algorithm-based feedback messages in addition to conventional intervention
89548108|NCT03112343|Placebo Comparator|Conventional intervention group|Subjects in the conventional intervention group will only save and send their health information to the server via the personal health record app
89548109|NCT02357069|Experimental|LBEC0101|Etanercept
89548110|NCT02357069|Active Comparator|Enbrel|Etanercept
89548111|NCT02356913|Experimental|Gum A|4 mg nicotine gum; single dose; chewed 30 minutes
89548112|NCT02356913|Experimental|Gum B|4 mg nicotine gum; single dose; chewed 30 minutes
89548113|NCT02356913|Experimental|Gum C|4 mg nicotine gum; single dose; chewed 30 minutes
89548114|NCT02356913|Active Comparator|Nicorette Freshmint|4 mg nicotine gum; single dose; chewed 30 minutes
89548115|NCT02352545|Experimental|Experimental: Montelukast|Patients in experimental treatment arm were given Montelukast Sodium Tablets (p.o., 10mg, q.d.) .All treatment regimens lasted for 10 days and no other antitussive/decongestant or bronchodilators are given to any patients.
89548116|NCT02352545|Placebo Comparator|Placebo Comparator|Patients in placebo treatment arm were given placebo tablets(main excipient lactose monohydrate,p.o., 10mg, q.d.). All treatment regimens lasted for 10 days and no other antitussive/decongestant or bronchodilators are given to any patients.
88811885|NCT00877370|Experimental|ertapenem|subjects will receive ertapenem while receiving CVVHD
89025189|NCT03271983|Other|metronidazole gel 2|generic gel
89548117|NCT02356835|Experimental|APT001|The APT001 is a medical device that generates a plasma flow containing nitric oxide intended to be applied topically to wound sites. The nitric oxide / plasma flow will be directed at the wound site and surrounding skin at a distance of 11.5 to 15 centimeters from the skin surface. Dose will be 10 seconds / cm2 wound surface area. Administration of the therapy will include a 2 cm border around the defined edges of the wound site.
89548118|NCT02356835|Sham Comparator|SHAM|Treatment with a sham device to deliver non-medicated, heated room air to the wound in the same manner and dose as the active treatment device.
89548119|NCT02352701||Noltec®,ChongkundangAmoxicillin®,Cravit®|Noltec tab 10mg, Chongkundang Amoxicillin Cap 500mg 2caps and Cravit tab 500mg by oral, twice a day for 10 days
89548120|NCT02352623||Cutaneous melanoma AJCC stage IB-III|Patients treated for cutaneous melanoma (AJCC stage IB-III) will fill out a questionnaire, undergo clinical examination and DXA scan
89548121|NCT02352467|Experimental|Aurix + UCC|Subjects will be treated on average twice a week for the first 2 weeks, and then, once a week thereafter while under active treatment, but actual frequency of treatment will be determined by the treating physician. All subjects will receive Aurix treatment and usual and customary care, which can include advanced therapeutics.
89548122|NCT02352467|No Intervention|Usual and Customary Care|Subjects will be treated on average twice a week for the first 2 weeks, and then, once a week thereafter while under active treatment, but actual frequency of treatment will be determined by the treating physician. All subjects will receive usual and customary care, which can include advanced therapeutics.
89548123|NCT02356445||Cytotoxic drug|Patients treated for sarcoidosis
89548124|NCT02356679|Experimental|Eupasidin-s tab.|three times per day, 1 tab for each time, PO, during 2weeks
89548125|NCT02356679|Active Comparator|Stillen tab.|three times per day, 1 tab for each time, PO, during 2weeks
89548126|NCT02352233||colonoscopy group|consecutive patients undergoing for colonoscopy for any formal indication. Patients were submitted to colonoscopy using RETROVIEW colonoscope
89548127|NCT02356289|Experimental|MYK-461|single-dose, tablet formulation
89548128|NCT02356289|Placebo Comparator|Placebo|single-dose, tablet formulation
89548129|NCT02351999|Experimental|TSP Crosser Transseptal Access System|The TSP Crosser Transseptal Access System is a novel integrated system combining an extendable radiopaque loop wire to aid in localizing the fossa ovalis (FO); an innovative flexible needle to enable controlled selection of the FO puncture site; and a steerable sheath for enhanced maneuvering and orientation of catheters during LA navigation.
89548130|NCT02352155|Active Comparator|Second look endoscopy|Second look endoscopy in the following morning with re-treatment to the bleeding vessel using epinephrine injection or heater probe or hemoclips
89548131|NCT02352155|Placebo Comparator|observation only|NO second look endoscopy (Observation)
89548132|NCT02355899|Experimental|PD P 506 A-PDT|One PD P 506 A-patch will be administered to each great toenail for 4 hours. After removal of the study medication the study nail(s) s will be illuminated with red light of defined wavelength (PDT).
89548133|NCT02351921|Experimental|iTBS to primary motor cortex|Intermittent TBS will be delivered using the 30 Hz, 600 pulse protocol targeting the primary motor cortex of the left hemisphere. The iTBS TMS coil will be placed over the motor hotspot for the representation of the flexor carpi radialis muscle.
89548134|NCT02351921|Experimental|iTBS to primary somatosensory cortex|Intermittent TBS will be delivered using the 30 Hz, 600 pulse protocol targeting the primary motor cortex of the left hemisphere. The iTBS TMS coil will be placed over the primary somatosensory cortex located 2cm posterior to the motor hotspot for the representation of the flexor carpi radialis muscle.
89548135|NCT02351921|Sham Comparator|Sham iTBS to primary motor cortex|Sham iTBS will be delivered using the 30 Hz, 600 pulse protocol targeting the primary motor cortex of the left hemisphere. The iTBS sham coil will be placed over the motor hotspot for the representation of the flexor carpi radialis muscle.
89548136|NCT02352311|Experimental|Arm 1 AVODART, CIALIS, DKF-313|In Period 1, AVODART (dutasteride) soft gelatin capsule and CIALIS (tadalafil) tablet 5 mg are administered as single dose. In Period 2, DKF-313 tablet (dutasteride 0.5 mg and tadalafil 5 mg) is administered as single dose.
89548137|NCT02352311|Experimental|Arm 2 DKF-313, AVODART, CIALIS|In Period 1, DKF-313 tablet (dutasteride 0.5 mg and tadalafil 5 mg) is administered as single dose. In Period 2, AVODART (dutasteride) soft gelatin capsule and CIALIS (tadalafil) tablet 5 mg are administered as single dose.
89548138|NCT02352077|Experimental|NeuroRegen Scaffold with BMMCs or MSCs transplantation|
89548139|NCT02356055|Experimental|Intensive Protocol|"Participants in this group will receive the Skill-building through Task-Oriented Motor Practice (STOMP) intervention 3 hours/day, 5 days/week for 2 weeks. Participants will choose functional goals that have an identifiable beginning and concluding step for creation of practice-able steps for task-oriented training. Practice-able steps will embed both task modifications and assistive technology determined by the OT to support performance and will be situated contextually within the participant's habits and environment. Each group will practice the task as many times as possible during their allotted time in training. For the intensive protocol, each hour of training will focus on 1 of 3 identified goals and will include 50 minutes of intervention and a 10 minute break."
88811886|NCT02210039|Experimental|SECM Probe Imaging|SECM probe will be guided to a pre-determined length in the esophagus and spiral imaging will be performed using the SECM Imaging System.
88811887|NCT00877604|Experimental|TUDCA|tauroursodeoxycholic acid di-hydrate
88811888|NCT00877604|Placebo Comparator|placebo|excipient lactose
88811889|NCT01507493||mutant alleles|grouped by SCN9A mutant alleles including 3312T, 1719R, 1150W.
88811890|NCT01507493||wild-type alleles|grouped by SCN9A wild-type alleles including 3312G, 1719C, 1150R.
88811891|NCT01508117|Experimental|Axitinib + Radiation Therapy|Axitinib 5mg twice daily for 28 days followed by concurrent axitinib plus hypofractionated radiation therapy (45 Gy in 15 fractions) followed by maintenance axitinib 5mg twice daily until progression or unacceptable toxicity
88811892|NCT00878228|Experimental|Study Group|The study group will receive intraoperative IV ondansetron and also postoperative oral ondansetron tablets (8 mg each day for two days).
88811893|NCT00878228|Placebo Comparator|Control Group|The control group will receive IV ondansetron intraoperatively and then oral placebo tablets (for 2 days).
89548140|NCT02356055|Active Comparator|Less-Intensive Protocol|"Participants in this group will receive the Skill-building through Task-Oriented Motor Practice (STOMP) intervention 1 hour/day, 2 days/week for 2 weeks. Participants will choose goals that have an identifiable beginning and concluding step for creation of practice-able steps for task-oriented training. Practice-able steps will embed both task modifications and assistive technology determined by the OT to support performance and will be situated contextually within the participant's habits and environment. Each group will practice the task as many times as possible during their allotted time in training. In the less-intensive protocol, each of the 3 ADL goals will be practiced as many times as possible within 20 minutes of the scheduled hour."
89548141|NCT03153215|Active Comparator|Intervention group|women with severe IUGR
89548142|NCT03153215|Active Comparator|Control group|women with severe IUGR
89548143|NCT02355431|Experimental|Itacitinib plus erlotinib|
89548144|NCT02355431|Active Comparator|Placebo plus erlotinib|
89548145|NCT02355353|Experimental|Imaging arm|
89548146|NCT02351687|No Intervention|No Intervention|No specific intervention given after recovery from moderate acute malnutrition.
89548147|NCT02351687|Experimental|Package of interventions|Package of interventions given after recovery from moderate acute malnutrition -- includes lipid-nutrient supplement for 2 months, malaria chemoprophylaxis for 3 months during malaria season, an insecticide-treated bed net, a one-time albendazole treatment, and 14 days of zinc.
89548148|NCT02351843|Experimental|500 mA ECT|Right unilateral, ultra brief pulse ECT, with 500 mA current amplitude
89548149|NCT02351843|Active Comparator|800 mA ECT|Right unilateral, ultra brief pulse ECT, with 800 mA current amplitude
89548150|NCT02355509|Placebo Comparator|Placebo|A placebo drug is given for three months
89548151|NCT02355509|Experimental|Acarbose|Acarbose is given for three months
89548152|NCT02355197|Active Comparator|antioxidant|1 gram L-ascorbic acid (vitamin C capsule) orally once per day from the time of diagnosis until the time of delivery in addition to treatment for gestational diabetes mellitus in the form of diet and insulin
89548153|NCT02355197|No Intervention|control|Only treatment for gestational diabetes mellitus in the form of diet and insulin
89548154|NCT02351609|Experimental|Intervention|Patients in this arm will receive a low literacy smoking cessation educational brochure and a list of resources for smoking cessation. Patients will also receive navigation from a trained navigator Patients will receive up to 4 hours of patient navigation, in person or over the phone, over a 6-month period. Patients will receive financial incentives for biochemically confirmed smoking cessation.
89548155|NCT02351609|Active Comparator|Enhanced Traditional Care control|Patients receive information about smoking cessation resources and an educational brochure developed by the Massachusetts Department of Public Health.
89548156|NCT02351531|Experimental|New Thickened Extensively Hydrolyzed formula|
89548157|NCT02351297|Experimental|Casein supplementation|After the run-in period, volunteers will receive casein supplementation (15 % of energy intake) for 3 weeks.
89548158|NCT02351297|Experimental|Soy protein supplementation|After the run-in period, volunteers will receive soy protein supplementation (15 % of energy intake) for 3 weeks.
89548159|NCT02351297|Placebo Comparator|Maltrodextrin supplementation|After the run-in period, volunteers will receive maltodextrin supplementation (15 % of energy intake) for 3 weeks.
89548160|NCT02355119|Active Comparator|Gemcitabine|Gemcitabine 1000 mg/sqm on days 1,8,15 every 28 days
89548161|NCT02355119|Experimental|FOLFOXIRI|
89548162|NCT02355041|Experimental|Meal Replacement-based Weight Loss Diet|Experimental participants will be instructed to replace 2 meals per day with a PROBAR meal replacement and consume a dinner under 1000 calories or a dinner under 800 calories and a 200 calorie snack for 90 days. No further nutritional advice or education shall be provided.
89548163|NCT02355041|Active Comparator|Educational Video|"Control participants will view The Weight of the World, a 51 min documentary focusing on the topics of obesity and healthy living. Via information presented by medical professionals and lifestyle experts, this film delves into issues related to preventing and combating obesity through healthy lifestyle changes. Major topics include the importance of healthy eating and exercise behaviors and the changes that can be made by communities to reshape our lifestyles. Potential community changes are further addressed with respect to schools by presenting particularly successful programs that have been implemented in some schools. Participants will stream it free on the web."
89025190|NCT03271983|Other|metronidazole cream|generic cream
89025191|NCT04700982||Based on the length of hospital stay|Based on the length of hospital stay, patients were divided into two groups: hospital stays ≤ 3 months (Group 1) and > 3 months (Group 2).
89025192|NCT00443300||Protective environment|Participants in a Protective environment
89025193|NCT00443300||Not a protective environment|Participants not in a protective environment
89548164|NCT03149783|Experimental|Ropivacaine|Participants will have bilateral TAP catheters placed along with continuous infusion of ropivacaine.
89548165|NCT03149783|Placebo Comparator|Placebo|Participants will have bilateral TAP catheters placed along with continuous infusion of placebo.
89548166|NCT02354885|No Intervention|Tranexamic Acid|TXA administered to multiple trauma patients in the helicopter or ambulance
89548167|NCT02354807|Experimental|Experimental group|Subjects that undergo both cold exposure and one-time dose of 100mg of Mirabegron drug
89548168|NCT03159845|Active Comparator|Control|patients undergone autologous stem cell transplantation. They take levofloxacin 500 mg/d, aciclovir 400 mg bid, fluconazole 200 mg bid from day +10 until day +30 after stem cell transplantation
89548169|NCT03159845|Experimental|Zinc|patients undergone autologous stem cell transplantation. They take the same antimicrobial prophylaxis of patients of the Control group, and, in addition, a daily oral supplementation of Zinc Sulfate, 600 mg/die, uncoated tabs, from day +5 until day +100 after transplant
89548170|NCT02351375|Experimental|high protein, low carbohydrate|a high-protein/low-carbohydrate diet (26,7E% protein, 38.2E% carbohydrate)
89548171|NCT02351375|Experimental|low protein, high carbohydrate|a low-protein/high-carbohydrate diet (7E% protein, 59.6E% carbohydrate)
89548172|NCT03159065|Experimental|Bilberry|A bilberry-based beverage with fermented oatmeal
89548173|NCT03159065|Experimental|Blackcurrant|A blackcurrant-based beverage with fermented oatmeal
89548174|NCT03159065|Experimental|Mango|A mango-based based beverage with fermented oatmeal
89548175|NCT03159065|Experimental|Beetroot|A beetroot-based based beverage with fermented oatmeal
89548176|NCT03159065|Experimental|Rose hip|A rose hip-based based beverage with fermented oatmeal
89548177|NCT03159065|Active Comparator|Glucose drink|A reference glucose drink
89548178|NCT02351219|Experimental|FOLFOXIRI|
89548179|NCT02350751|Experimental|MEDI8852|MEDI8852 is a human IgG1 kappa monoclonal antibody (mAb) supplied as 50 mg/mL solution for infusion. MEDI8852 is being evaluated for treatment of patients hospitalized with influenza A.
89548180|NCT02350751|Placebo Comparator|Placebo|Solution containing no active ingredients
89548181|NCT02350829|Active Comparator|Cardiomyopathy|"Clinically established diagnosis of dilated, hypertrophic or arrhythmogenic right ventricular cardiomyopathy~Adding T1 mapping sequence to the clinical cardiac magnetic resonance scan Administering Multihance 0.2ml/kg as part of clinical scan Obtaining bloodwork for assessment of hematocrit and collagen biomarkers"
89548182|NCT02350829|Active Comparator|Congenital Heart Disease|"Diagnosis of Transposition of the great arteries after arterial switch operation, repaired Tetralogy of Fallot, patients after single ventricle palliation at the Fontan stage, native and repaired Aortic Coarctation Adding T1 mapping sequence to the clinical cardiac magnetic resonance scan Administering Multihance 0.2ml/kg as part of clinical scan~Obtaining bloodwork for assessment of hematocrit and collagen biomarkers"
89548183|NCT02350829|Active Comparator|Controls|Patients undergoing a non-cardiac MR investigation (musculoskeletal / abdomen / brain) without a history of cardiac disease Adding limited cardiac sequence to the clinical magnetic resonance scan including T1 mapping Administering Multihance 0.2ml/kg as part of clinical scan Obtaining bloodwork for assessment of hematocrit and collagen biomarkers
89548184|NCT02354729|Experimental|Intervention|Participants received text messages and financial incentives after successfully documenting that they were carrying their epinephrine auto-injectors, based on principles of behavioral economics.
89548185|NCT02354729|No Intervention|Control|Participants received text messages.
89548186|NCT02354573|Active Comparator|Active arm|All subjects will receive Ivabradine 7.5mg twice daily for 2 weeks in a double-blind randomized crossover design.
89548187|NCT02354573|Placebo Comparator|Placebo arm|All subjects will receive matching placebo tablets twice daily for 2 weeks in a double-blind randomized crossover design.
89548188|NCT02350985|Active Comparator|Propranolol|Propranolol up to 160 mg/day
89548189|NCT02350985|Active Comparator|Venlafaxine|Venlafaxine up to 150 mg/day
89548190|NCT02354495|Experimental|Diet intervention arm|Individualized diet prescription following food record, indirect calorimetry (for energy requirement) and body composition assessments. repeat assessments after 12 weeks on interventional diet.
89548191|NCT02354261|Experimental|SUBA-Itraconazole|Subjects will receive an oral dose of 300 mg SUBA-itraconazole daily.
89548192|NCT02350439|Experimental|Adenosine intravenous infusion at 200μg/Kg/min|Fractional flow reserve assessment under Adenosine intravenous infusion at 200μg/Kg/min
89548193|NCT02350673|Experimental|Cergutuzumab+Atezolizumab (Part I)|Participants will receive escalated IV doses of cergutuzumab amunaleukin in combination with atezolizumab. This is a Part I dose escalation phase of the study. Cergutuzumab amunaleukin will be escalated from a starting dose of 6 milligrams (mg) and dosing schedules of every week (qw) and every 2 weeks (q2w) may be explored. Atezolizumab will be administered in fixed flat doses of either 840 mg q2w or 1200 mg every 3 weeks (q3w). Treatment will be continued until loss of clinical benefit, unacceptable toxicities, or withdrawal of consent for a maximum treatment period of 24 months for both cergutuzumab amunaleukin and atezolizumab and may be modified if emerging data suggest longer treatment period is needed.
89548194|NCT02350673|Experimental|Cergutuzumab +Atezolizumab (Part II)|This is a Part II expansion phase of the study. Participants will receive cergutuzumab amunaleukin at maximum tolerated dose (MTD) (or recommended dose) identified during Part I in combination with atezolizumab. Treatment will be continued until loss of clinical benefit, unacceptable toxicities, or withdrawal of consent for a maximum treatment period of 24 months for both cergutuzumab amunaleukin and atezolizumab and may be modified if emerging data suggest longer treatment period is needed.
89548195|NCT02354105||CZP treatment|axSpA patients who have been newly prescribed Certolizumab Pegol (CZP).
89548196|NCT02350361|Experimental|Endostar Arm|Gefitinib re-challenging, oral daily use Docetaxel 60mg/m2 and Cisplatin 70mg/m2, 21 days Recombinant human endostatin 15mg/day, day 1 - 14
89548197|NCT02350361|Active Comparator|Standard Arm|Gefitinib re-challenging, oral daily use Docetaxel 60mg/m2 and Cisplatin 70mg/m2, 21 days Placebo
89548198|NCT02353949|Experimental|Flutmetamol Group|PET-MR-Scan with 80-140 MBq Flutemetamol before observational period for diagnostic purpose
89548199|NCT02354027|Experimental|SHR3824 25mg/metformin 1000mg|Two 500-mg tablets of metformin on Day 1 followed by 25 mg of SHR3824 once daily on Days 4 through 8 followed by two 500-mg tablets of metformin and 25 mg of SHR3824 on Day 8.
89548200|NCT02354183|Experimental|Commitment|A 1-hour orientation session consisting of DBT commitment strategies plus psychoeducation. Therapists will also use commitment strategies to discuss goals related to self-harm. The psychoeducation will consist of information about DBT's biosocial theory and about why people self-harm. All participants will complete a DBT skills training group after their orientation.
89548201|NCT02354183|Active Comparator|Psychoeducation|A 1-hour orientation session consisting of psychoeducation only. The psychoeducation will consist of information about DBT's biosocial theory and about why people self-harm. All participants will complete a DBT skills training group after their orientation.
89548202|NCT03149471||Normal endothelial function|patients diagnosed with PE and have normal endothelial function test- RHI score >=1.67
89548203|NCT03149471||Endothelial dysfunction group|patients diagnosed with PE and have endothelial function- RHI<1.67
89025194|NCT03270930||Survived|Pediatric patients in the age group of 5 to 10 years presenting with acute abdomen and undergoing emergency laparotomy who survived during their index 30-day hospital stay
89025195|NCT03270930||Expired|Pediatric patients in the age group of 5 to 10 years presenting with acute abdomen and undergoing emergency laparotomy who expired during their index 30-day hospital stay
89548204|NCT02353793|Experimental|ReadyHeat® blanket|Patient warming with ReadyHeat® blanket
89548205|NCT02353793|Active Comparator|Cotton wool blanket|Patient warming with cotton wool blanket
89025196|NCT03272763|Experimental|F&P Toffee mask|Participants will be placed on this arm for a total of 14 ± 5 days from Visit two. Participants will be using the trial full-face mask during this treatment arm.
89025197|NCT04700228|Placebo Comparator|Group C|0.25% bupivacaine at a total volume of 0.5ml/kg.
89548206|NCT02350283|Experimental|Solitaire Device|Interventional treatment with Solitaire. After the procedure, the patients will be admitted to intensive care unit. Standard medical management will be provided to these patients.
89548207|NCT02350283|No Intervention|Medical treatment|Standard medical treatment alone.
89548208|NCT03149627||Individuals from selected households|Individuals residing in selected households in Lusaka Province, Zambia.
89548209|NCT03149393|Experimental|Qizhi Weitong Granules Group|Patients in this group will take Qizhi Weitong Granules for 8 weeks.
89548210|NCT03149393|Active Comparator|Mosapride Citrate Tablets Group|Patients in this group will take mosapride citrate tablets for 8 weeks.
89548211|NCT03149315|Experimental|Open Label Administration|Allergic subjects will be given ibrutinib 420mg daily for 2-7 doses to determine the shortest amount of time and fewest ibrutinib doses required to suppress food skin prick testing and basophil activation test reactivity.
89548212|NCT02353559|Experimental|EASE|Patients assigned to the intervention arm will receive 8 - 12 psychotherapy sessions lasting 30 - 60 minutes each, delivered by a trained therapist at our center. Patients will receive specialized symptom control from a nurse/physician team in our Palliative Care Service, when indicated by routine symptom screening.
89548213|NCT02353559|No Intervention|Usual Care|Usual care
89548214|NCT02353637|Active Comparator|Male High Protein, Restricted Carbo, Partial Meal Replacement|A high protein, restricted carbohydrates diet that utilizes partial meal replacements
89548215|NCT02353637|Active Comparator|Female High Protein, Restricted Carbo, Partial Meal Replaceme|A high protein, restricted carbohydrates diet that utilizes partial meal replacements
89548216|NCT02353715||Enzalutamide|Subjects will be administered enzalutamide per standard of care under the care of their treating physician. Cardiopulmonary Exercise Testing (CPET) will be performed at baseline and 21 weeks.
89548217|NCT02353715||Abiraterone|Subjects will be administered abiraterone acetate per standard of care under the care of their treating physician. Cardiopulmonary Exercise Testing (CPET) will be performed at baseline and 21 weeks.
89548218|NCT02353715||Sipuleucel-T|Subjects will be administered sipuleucel-T per standard of care under the care of their treating physician. Cardiopulmonary Exercise Testing (CPET) will be performed at baseline and 21 weeks.
89548219|NCT02353403|Placebo Comparator|Sugar|Control group consuming a dairy dessert containing 35g of dextrose.
89548220|NCT02353403|Experimental|FOS|Group consuming a dairy dessert in which 30% of the dextrose was replaced by FOS.
89548221|NCT02349737||Electromagnetic Interference|
89548222|NCT02353325|Experimental|non-encapsulated FeSO4|Maize porridge with salt fortified with non-encapsulated FeSO4
89548223|NCT02353325|Experimental|encapsulated FeSO4, before cooking|Maize porridge with salt fortified with non-encapsulated FeSO4, added before cooking
89548224|NCT02353325|Experimental|encapsulated FeSO4, after cooking|Maize porridge with salt fortified with non-encapsulated FeSO4, added after cooking
89548225|NCT02353325|Experimental|non-encapsulated FeSO4 + ascorbic acid|Maize porridge with salt fortified with non-encapsulated FeSO4 and ascorbic acid
89548226|NCT02353325|Experimental|encapsulated FeSO4 + ascorbic acid, before cooking|Maize porridge with salt fortified with non-encapsulated FeSO4 and ascorbic acid, added before cooking
89548227|NCT02353325|Experimental|encapsulated FeSO4 + ascorbic acid, after cooking|Maize porridge with salt fortified with non-encapsulated FeSO4 and ascorbic acid, added after cooking
89548228|NCT02353481||Heart Failure|All patients in the audit that meets the eligibility criteria
89548229|NCT02350049||Investigational|Cementless Medial Partial Knee
89548230|NCT02350049||Control|Cemented Medial Partial Knee
89548231|NCT03157895|Experimental|Program group|This group receives the Connecting program with telephone support. It's anticipated the program will take up to 14 weeks to complete.
89548232|NCT03157895|No Intervention|Comparison group|This group receives Children's Administration services as usual.
89548233|NCT02349503|Experimental|NBI-77860 Dose Group1|NBI-77860 administered orally on Night 1 at bedtime (at approximately 2200 hours).
89548234|NCT02349503|Experimental|NBI-77860 Dose Group 2|NBI-77860 administered orally on Night 1 at bedtime (at approximately 2200 hours). Dosing will not commence until all safety and PK results from the dose group 1 have been reviewed to ensure there are no safety concerns and that maximum tolerated dose (MTD) has not been reached.
89548235|NCT02349503|Experimental|NBI-77860 Dose Group 3|NBI-77860 administered orally on Night 1 at bedtime (at approximately 2200 hours). Dosing will not commence until all safety and PK results from the dose group 2 have been reviewed to ensure there are no safety concerns and that maximum tolerated dose (MTD) has not been reached.
89548236|NCT02349659|No Intervention|Conservative Medical Management|Continued medical management restricted to exclude interventional pain treatments
89548237|NCT02349659|Active Comparator|Axium Group|As the CMM group but also treated with Dorsal Root Ganglion stimulation using the Axium neurostimulator
89548238|NCT03157505|Active Comparator|Purethal Birch immunotherapy|Purethat Birch intervention and symptomatic treatment for 24 months
89548239|NCT03157505|Placebo Comparator|placebo and symptomatic treatment|placebo intervention and symtomatic treatment during 24 months
89548240|NCT03157193|Experimental|Test Group|Hyaluronic acid gel 0.2% at baseline and later home applications by the patients during 45 days.
89548241|NCT03157193|Sham Comparator|Control 1 Group|Hydroxypropyl guar based gel, without any biological effect.
89548242|NCT03157193|No Intervention|Control 2 Group|No gel application, only standard perimplantitis treatment.
89548243|NCT03149159|Experimental|Nivolumab + Ipilimumab + SRT|
89548244|NCT03156959|Experimental|EMDR plus CBT-Eb|"20 CBT-Eb sessions will be mandatory for patients with BMI>17.5 and 40 CBT-Eb sessions will be mandatory for patients with BMI≤17.5. In the EMDR plus CBT-Eb arm, 16 EMDR sessions will be mandatory in adjunction to the CBT-Eb sessions, irrespectively of the BMI. EMDR will use an eight-phase approach that will include having the patient recall distressing images while receiving one of several types of bilateral sensory input, such as side to side eye movements.~Patients will follow psychopharmacological treatment for anxiety and depression symptoms if needed, and their parents will be invited to participate to a cycle of eight family meetings on eating disorders and psychological support following ECHO approach (Rhind et al., 2014)."
89548245|NCT03156959|Active Comparator|CBT-Eb alone|"20 CBT-Eb sessions will be mandatory for patients with BMI>17.5 and 40 CBT-Eb sessions will be mandatory for patients with BMI≤17.5.~Patients will follow psychopharmacological treatment for anxiety and depression symptoms if needed, and their parents will be invited to participate to a cycle of eight family meetings on eating disorders and psychological support following ECHO approach (Rhind et al., 2014)."
89548246|NCT03156803|Experimental|Healthy eating blog (HEB)|For a 6-month period, mothers randomised to the HEB group will receive a weekly blog post discussing various positive aspects of healthy eating and presenting recipes and strategies to increase dairy product intakes and vegetable and fruit intakes. The posts will be developed with an emphasis of food skills acquisition.
89548247|NCT03156803|No Intervention|Control|Mothers randomised to the control group will not have access to the healthy eating blog.
89548248|NCT03155477|Experimental|"Cholecalciferol and C. Xanthorrhiza"|Subjects received Cholecalciferol 400 IU 3 times daily and C. Xanthorrhiza 20 mg 3 times daily per oral for 3 months (group II, n=19)
89548249|NCT03155477|Placebo Comparator|"Cholecalciferol and placebo"|Subjects received cholecalciferol 3×400 IU and placebo 3×1 tablet for 3 months (group I, n=20).
89548250|NCT03148925|Experimental|SELA-070|
89548251|NCT03148925|Placebo Comparator|Saline|
89548252|NCT03148847||Baseline care|Patients treated for Cardiogenic Pulmonary Edema into the Northern French Alps Emergency Network between January 1, 2013 and December 31, 2013
89548253|NCT03148847||Referential's dissemination|Patients treated for Cardiogenic Pulmonary Edema into the Northern French Alps Emergency Network between January 1, 2017 and December 31, 2017, after referential's dissemination for management of patients with paroxysmal dyspnea due to left sided heart failure
89548254|NCT02349581|Experimental|Block|Patients with persistent pain after breast cancer surgery receive the ultrasound guided PECS block of 20mls 0.25% bupivacaine
89548255|NCT02349581|No Intervention|Sonoanatomy|16 patients awaiting surgery for breast cancer were scanned using ultrasound to determine the sonoanatomy of the PECS block
89548256|NCT03155633|No Intervention|Rest Group|Rest during the 9 days after the race
89548257|NCT03155633|Experimental|Running Group|Running at 95-105% aerobic Threshold on athletics track 48h, 96h, 144h after the race. Control heart devices
89548258|NCT03155633|Experimental|Elliptical Group|Running at 95-105% aerobic Threshold on elliptical machine 48h, 96h, 144h after the race. Control heart devices
89548259|NCT03155711|Experimental|HFNC|HFNC with a 60 liters per minute flow will be given to the patients before anesthesia induction and before extubation at the end of the surgery
89548260|NCT03155711|Active Comparator|Standard|This patients will be managed as usual care. Pre-oxygenation before induction will be performed with supplemental oxygen but without positive pressure. After extubation patients will be oxygenated through a ventury mask.
89548261|NCT03155165||Group A Retroview™ colonoscope|Patients that have a polyp already seen in a previous colonoscopy and the colonoscopy is indicated for polypectomy will be submitted to a Retroview™ colonoscope
89548262|NCT03155165||Group B Retroview™ colonoscope|The rest of colonoscopies indicated will be submitted to a Retroview™ colonoscope
89548263|NCT02349191|Experimental|Interventional cohort|Omental transposition for mild Alzheimers Disease
89548264|NCT03154385|Experimental|arm 1|"Two intravenous perfusions of 1 g of Rituximab (Mabthera ®) at W0 and W2 coupled with 100 mg intravenous methylprednisone to avoid potential allergic reactions.~Five belimumab (Benlysta ®) injections will be administered (W0 + 2days, W2 + 2 days, W4, W8, W12) at 10mg/kg doses. The first two injections are administered 2 days after Rituximab perfusions. The adopted experimental scheme was once used to show use of belimumab in systemic lupus erythematosus in accordance with AMM regulation"
89548265|NCT03154463|Active Comparator|TAP blocks|TAP group was received TAP block using ultrasound as a guide and injected on three points on trans abdominal plane using 100 mm stimuplex needle and 0.25% bupivacaine with total volume of 20 ml in each point (with total of 60 ml in three points)
89548266|NCT03154463|Active Comparator|continuous epidural infusion|Epidural group received epidural regional anesthesia in sitting position, with epidural regimen of 0.25% bupivacaine without any adjuvant
89548267|NCT03112187|Experimental|Intervention|Ferfer is a food supplement in liposomal form, with essential, vitamins including Vitamin C and Vitamin B12. Ferfer directly dissolves in the mouth without the need for water. The technology of liposomal microencapsulation, allows daily iron supplementation without any of the typical side effects of conventional oral iron supplements, such as heartburn, diarrhea, constipation, nausea and coloring of the mucous membranes and of the stools, which increases patient compliance. It has no metallic taste or smell, does not color mucous membrane and has excellent tolerability
89548268|NCT02353013|Active Comparator|Standard Protein Group|For infants in this group, the target protein-energy ratio (PER) will be ~3 g/100 kcal. This will be achieved by providing standard fortification by adding a commercially available human milk fortifier to human milk or by providing a preterm formula.
89548269|NCT02353013|Experimental|Enhanced Protein Group|For infants in this group, the target protein-energy ratio (PER) will be ~4 g/100 kcal. This will be achieved by providing standard fortification by adding a commercially available human milk fortifier to human milk or by providing a preterm formula. In addition, liquid protein will be added to provide protein supplementation and increase the PER.
89548270|NCT03147677|Experimental|Alfacalcidol and Irbesartan|The subjects in this group orally take Alfacalcidol Soft Capsules at 0.25ug/day and Irbesartan Pills at 150mg/day for 16 consecutive weeks.All subjects will be followed up for 4 weeks after medication is over. A total of 4 visits have been scheduled for this study at week 0, week 8, week 16, week 20.
89025198|NCT04700228|Active Comparator|Group BD1|0.25% bupivacaine + 1mcg/kg dexmedetomidine at a total volume of 0.5ml/kg.
89025199|NCT04700228|Active Comparator|Group BD2|0.25% bupivacaine + 0.5mcg/kg dexmedetomidine at a total volume of 0.5ml/kg.
89025200|NCT00443378|Experimental|1|"Arm 1, CARE+ arm is the study arm that receives the CARE+ computer intervention."
89025201|NCT00443378|No Intervention|2|Arm 2, the control arm, is the study arm that receives computerized risk assessment only.
89025202|NCT00478686||Severe Toxicity|Patients who experienced severe toxicity (at least one grade 4 side effect) with capecitabine chemotherapy
89025203|NCT00478686||Dose-Limiting Toxicity|Patients who experienced dose-limiting toxicity (at least one grade 3, or recurrent grade 2, side effect)with capecitabine chemotherapy
89025204|NCT00478686||Low/No Toxicity|Patients who have experienced low/no toxicity (none or only side effects at grade 1 & 2) with capecitabine chemotherapy.
89025205|NCT03278522|Active Comparator|ramosetron iv at induction (I)|0.6mg of ramosetron is given to the patients intravenously at anesthesia induction
89548271|NCT03147677|Active Comparator|Irbesartan|The subjects in this group orally take Irbesartan Pills at 150mg/day for 16 consecutive weeks.All subjects will be followed up for 4 weeks after medication is over. A total of 4 visits have been scheduled for this study at week 0, week 8, week 16, week 20.
89548272|NCT03147677|Active Comparator|Alfacalcidol|The subjects in this group orally takeAlfacalcidol Soft Capsules at 0.25ug/day for 16 consecutive weeks.All subjects will be followed up for 4 weeks after medication is over. A total of 4 visits have been scheduled for this study at week 0, week 8, week 16, week 20.
89548273|NCT03148535|Experimental|lithium carbonate|recieve lithium carbonate
89548274|NCT03148535|Experimental|lithium carbonate combined with SSRI antidepressant treatment|recieve lithium carbonate combined with SSRI antidepressant treatment
89548275|NCT03148301||Patients with Spina Bifida|Adults with and parents of children with Spina Bifida followed by the team in UZ Leuven will be asked to complete a survey
89548276|NCT03147599|Active Comparator|Mebeverine|Coloverin (Mebeverine hydrochloride 135 mg)
89548277|NCT03147599|Placebo Comparator|Placebo|Placebo
89548278|NCT03147443|Experimental|Individualized Decoction|"It is the highly individualized treatment of traditional Chinese medicine,the modification of Bronchiectasis Stabilization Decoction(Radix Lithospermi 15 g, Rhizoma Fagopyri Cymosi 30 g, Radix Ophiopogonis 15 g, Poria cocos 15 g, Radix Astragali 20 g, Rhizoma Bletillae 10 g, Platycodon grandiflorum 10 g, and Semen Coicis 30 g) based on syndrome differentiation. For example,for patients with qi and yin deficiency syndrome, we added Radix Adenophorae, and Radix Rehmanniae Recens. Besides, the herbs in a prescription could be changed according to different symptoms of individual patients.~The Chinese herbal decoction is taken by one decoction a day and divided into 2 doses, for 3 weeks in each observation period."
89548279|NCT03147443|Placebo Comparator|placebo|"Placebo is made by dextrin, bitter agent, edible pigment etc and added 5% test drug. The placebo and test drug have no differences in dosage form, appearance, color, specification, label, and so forth.~The placebo is taken by one decoction a day and divided into 2 doses, for 3 weeks in each observation period."
89548280|NCT03147443|Active Comparator|Tested drug minus heat-clearing herbs|"It is the decoction of the Individualized Syndrome Differentiation Decoction(tested drug) minus heat-clearing herbs. For example, heat-clearing herbs such as Scutellaria baicalensis or Herba Violae will be removed from the Syndrome Differentiation Decoction.~This control Chinese herbal decoction is taken by one decoction a day and divided into 2 doses, for 3 weeks in each observation period."
89548281|NCT03147521|Experimental|Accidental falls care bundle|Care Bundle Implementation Arm
89548282|NCT03147521|Active Comparator|Accidental falls standard care|Standard Care Implementation Arm (Universal strategy application for the environmental and patient)
89548283|NCT03148223|Experimental|Intervention|Auriculotherapy with application of mustard seeds fixed with adhesive tape at specific points in the auricle during one session per week lasting 20 minutes for 3 consecutive months.
89548284|NCT03148223|Placebo Comparator|Control|Auriculotherapy with tape-only fixation in the auricle, without mustard seeds, following the same stitch protocol used with the intervention group, during a session per week lasting 20 minutes, for three consecutive months.
89548285|NCT03148145|Active Comparator|Constant Steps Goal|Step Goal Delivery by Smartphone
89548286|NCT03148145|Experimental|Averaged Steps Goals and Random Messages|Step Goal Delivery by Smartphone Message Delivery by Smartphone
89548287|NCT03148145|Experimental|Algorithm Steps Goal and Random Messages|Step Goal Delivery by Smartphone Message Delivery by Smartphone
89548288|NCT03148145|Experimental|Algorithm Steps Goal and Messages|Step Goal Delivery by Smartphone Message Delivery by Smartphone
89548289|NCT02348411|Experimental|ExAblate Treatment group|
89548290|NCT03147365|No Intervention|Control group|Twenty five children who will not receive any physical therapy treatment.
89548291|NCT03147365|Experimental|Study group A|Twenty five children who will receive physical therapy treatment which include aerobic exercises.
89548292|NCT03147365|Experimental|Study group B|Twenty five children who will receive physical therapy treatment which include modified strength training program.
89548293|NCT02348879|Experimental|AMG 403|AMG 403 administered as subcutaneous and intravenous doses
89548294|NCT02348879|Placebo Comparator|Placebo|No active drug
89548295|NCT03147209|Experimental|Health Coaching|This group will undergo coaching and activities to improve strength and balance.
89548296|NCT02349035|Experimental|TMR surgery to evaluate pattern recognition control|Perform Targeted Muscle Reinnervation (TMR) surgery and evaluate transradial TMR pattern recognition control of multifunctional prostheses.
89548297|NCT03147053|Experimental|Jiedu Tongluo granules|Patients in this group were administered the Jiedu Tongluo granules .
89548298|NCT03147053|Placebo Comparator|Placebo|Patients in this group were administered the placebo .
89548299|NCT03147131|Active Comparator|Fitmore short stem|"Intervention: Total hip arthroplasty with an uncemented femoral short stem, the Fitmore short stem (Zimmer, Warsaw, USA). Furthermore, an uncemented cup (Allofit, Zimmer, Warzaw, USA).~Device: Fitmore Short Stem"
89548300|NCT03147131|Active Comparator|CLS straight stem|"Intervention: Total hip arthroplasty with an uncemented femoral straight stem, the CLS short stem (Zimmer, Warsaw, USA).Furthermore, an uncemented cup (Allofit, Zimmer, Warzaw, USA).~Device: CLS Straight Stem"
89548301|NCT03146975|No Intervention|Healthy|
88812023|NCT05124704|Experimental|Combined epidural with general anesthesia|Patients in this group received 5-8ml of 0.375% ropivacaine depend on the height and weight of the patient was administrated through the epidural catheter at least 20 min before induction.Followed by a continuous infusion of 4-6 ml 0.375% ropivacaine was applied using micro-infusion pump after induction during surgery.
89548302|NCT03146975|Experimental|Periodontitis without diabetes|
89548303|NCT03146975|Experimental|Periodontitis compensated diabetes|
88812024|NCT05124704|Sham Comparator|General anesthesia|In this group, same dose of normal saline was administered before induction and during surgery.
88812025|NCT00834236|Experimental|gastric cancer|gastric cancer patients
88812026|NCT00834236|Active Comparator|normal subject|healthy subject
88812027|NCT01431131|Active Comparator|Intrasocket graft|Positive control
88812028|NCT01431131|Experimental|Intrasocket plus facial overlay graft|Intrasocket cancellous allograft plus a facial overlay bovine xenograft
88812029|NCT05102318|Experimental|Direct Pulp Capping with Biodentine|Direct Pulp Capping with Biodentine
88812030|NCT05102318|Experimental|Partial Pulpotomy with Biodentine|Partial Pulpotomy with Biodentine
88812031|NCT05102318|Experimental|Pulpotomy with Biodentine|Pulpotomy with Biodentine
88812032|NCT05102318|Experimental|Direct Pulp Capping with MTA|Direct Pulp Capping with MTA
88812033|NCT05102318|Experimental|Partial Pulpotomy with MTA|Partial Pulpotomy with MTA
88812034|NCT05102318|Experimental|Pulpotomy with MTA|Pulpotomy with MTA
88812035|NCT02203019|Active Comparator|Propofol|Propofol will be administered for sedation.
88812036|NCT02203019|Active Comparator|Dexmedetomidine|Dexmedetomidine will be administered for sedation
88812037|NCT00886262|Experimental|Vasopressin|
89548304|NCT03146975|Experimental|Periodontitis decompensated diabetes|
89548305|NCT03146975|No Intervention|Compensated diabetes non periodontitis|
89548306|NCT03146975|No Intervention|Decompensated diabetes non periodontitis|
89548307|NCT02349113|Experimental|Estrogens|Estrogens treatment: Intervention with short course (3 weeks) of treatment with transdermal estrogen (0.1mg/d)
89548308|NCT02348801|Active Comparator|Healthy Lifestyle Group|Group diabetes educations sessions that focus on diet, exercise, and social support.
89548309|NCT02348801|Experimental|Weight Loss plus Exercise Group|Behavioral therapy for weight loss and exercise training
89548310|NCT02348567|Active Comparator|announced hospital surveys|Eleven hospitals will receive announced surveys (control group)
89548311|NCT02348567|Experimental|unannounced hospital surveys|12 hospitals will receive unannounced surveys (intervention group).
89548312|NCT04151849||GLP-1 receptor agonist treatment|Patients starting treatment with any molecule belonging to the class of GLP-1 receptor agonist.
89548313|NCT04151849||SGLT-2 inhibitor treatment|Patients starting treatment with any molecule belonging to the class of SGLT-2 inhibitors.
89548314|NCT03147989||Group 1, 0.10 mmol/kg|For patients having received MULTIHANCE at a standard dose of 0.10 mmol/kg for their clinically indicated MRI examination.
89548315|NCT03147989||Group 2, 0.05 mmol/kg|For patients having received MULTIHANCE at a dose of 0.05 mmol/kg for their clinically indicated MRI examination.
89548316|NCT02348177|Experimental|TB/HIV co-infection|Superboosting lopinavir with ritonavir in 1:1 ratio during TB/HIV co-infection and treatment of HIV with lopinavir/ritonavir 4:1
89548317|NCT02348255|Experimental|Treatment (bevacizumab, carmustine, NovoTTF-100A)|Patients receive bevacizumab IV over 30-90 minutes every 2 weeks beginning on day -7 for up to 13 doses and carmustine IV over 4 hours every 8 weeks beginning on day 1 for up to 3 doses. Patients also undergo NovoTTF-100A according to standard procedures starting one week before the first dose of carmustine.
89548318|NCT02348333|Active Comparator|FYU-981|
89548319|NCT02348333|Placebo Comparator|Placebo|
89548320|NCT02348021|Other|Drug Coated Stent|All patients in the one arm will be treated by PCI with the Drug Coated Stent.
89548321|NCT03147755||Dysphagia|Patients with stroke associated dysphagia
89548322|NCT03147755||No dysphagia|Patients without stroke associated dysphagia
89548323|NCT03147911||Stroke or systemic embolism : Positive|- 583 patients
89548324|NCT03147911||Stroke or systemic embolism : Negative|- 598 patients
89548325|NCT03147833|Experimental|Sport beverages Protein|Intervention group ingesting PROTEIN
89548326|NCT03147833|Active Comparator|Sports beverage Carbohydrate|Placebo group ingesting carbohydrate
89548327|NCT05255627|Experimental|Control Group|"Prevention, Care and Treatment of Pressure Injury was explained by 1 researcher who is responsible for the Nursing Fundamentals course, using written educational material prepared in line with the literature."
89548328|NCT05255627|Experimental|Mobile application group (Experimental Group)|"A mobile application program was installed on their phones for the experimental group students to benefit from. Prevention, Care and Treatment of Pressure Injury was explained by 1 researcher who is responsible for the Nursing Fundamentals course, using a mobile application program prepared in line with the literature."
89548329|NCT05255549|Experimental|Group I|
89548330|NCT05255549|Sham Comparator|Group II|
89548331|NCT02343653|Active Comparator|Nutrition|Participants receive a controlled diet consisting of 1.2-1.5 g of protein/kg/day for 12 weeks according to guidelines for enteral nutrition and patients with cirrhosis. The group receives dietary guidance and protein supplements.
89548332|NCT02343653|Experimental|Nutrition and strength training|"Participants in this group receive same controlled diet consisting of 1.2-1.5 g of protein/kg/day for 12 weeks as the No intervention-group. Participants will also receive supervised strength training 3 x 60 min./week for 12 weeks. The group receives dietary guidance and protein supplements, which on training days should be consumed within 30 minutes after exercise."
89548333|NCT02343497|Experimental|Astaxanthin|Astaxanthin supplement from Phaffia rhodozyma, 6mg in lipid capsules, 2 caps per day, duration 12 weeks
89548334|NCT02343497|Placebo Comparator|Placebo|filling agent, in lipid capsules, 2 caps per day, duration 12 weeks
89548335|NCT02343419|Experimental|Bronchial challenge test|Patients will undergo Methacholine Challenge Test assessed by forced oscillation technique (FOT), plethysmography, interrupter technique and spirometry.
89548336|NCT02343341|Experimental|Preschool Health Promotion Education Program|Children randomized to the intervention arm will receive a 4-month health promotion education program along with their parents/caregivers and teachers.
89548337|NCT02343341|Other|Control:Standard Curriculum|"The Standard curriculum control arm will receive the standard curriculum in their schools.~Children randomized to the control arm will receive the health promotion education program for 4 months after the intervention arm has completed it"
89548338|NCT02343107|Experimental|1|Subgroup of subjects who benefit of the e-coaching
89548339|NCT02343107|No Intervention|2|Subgroup of subjects who are asked to follow the conventional nutritional recommendations of the treatment of abdominal obesity and diabetes
89548340|NCT02343029|Experimental|Intervention|Participants in the Intervention group exercise three times a week for 30 minutes on a bicycle ergometer (optibike med, ergoline GmbH, Bitz, Germany) in the integrated gym hall of one of the participating residencies. Training is individualised as respective performance is adapted to the power at the first ventilator threshold (assessed during cardiopulmonary exercise test).
89548341|NCT02343029|Active Comparator|Waiting Control|Participants of Waiting Control continue their regular physical activity behaviour for 12 weeks. They will start the same exercise intervention after a reassessment at week 12 for the next upcoming 12 weeks. (13-24)
89548342|NCT03146897|Active Comparator|Super Cereal Plus with amylase|
89548343|NCT03146897|Active Comparator|Corn-soy Blend Plus and Vegetable Oil|
89548344|NCT03146897|Active Comparator|Corn-soy Whey Blend and Vegetable Oil|
89548345|NCT03146897|Active Comparator|Ready-to-Use-Supplementary Food|
89548346|NCT02343185|Experimental|diaphragmatic treatment|Subjects in this arm receive different manual techniques for the low back pain and diaphragmatic treatment.
89548347|NCT02343185|Placebo Comparator|Placebo|Subjects in this arm receive different manual techniques for the low back pain and a sham diaphragmatic treatment.
89548348|NCT02342951|Other|LCI|Measure of lung clearance index
89548349|NCT02342717|Experimental|Reference|single dose BI 425809
89548350|NCT02342717|Experimental|Test|multiple doses of Itraconazole + single dose BI 425809
89548351|NCT02342795|Experimental|cigarette substitute|The QuitSmart cigarette substitute is a plastic tube that looks like a real cigarette and is designed to provide the same draw resistance as a smoker's usual cigarette. There is no drug delivery with this product. Two cigarette substitutes and a product manual are provided to participants following randomization and replacement products are provided throughout the intervention period (24 weeks).
89548352|NCT02342795|Experimental|e-cigarette (with 0 mg/ml nicotine)|The e-cigarette used will be the EGO e-cigarette (marketed by www.liquidexpress.com). Each participant randomized to an ECIG condition will receive 2 e-cigarette batteries, 1 wall adapter, 1 USB charger, and a user manual. Cartomizers containing 0 mg/ml nicotine will be provided throughout the intervention period (24 weeks).
89548353|NCT02342795|Experimental|e-cigarette (with 8 mg/ml nicotine)|The e-cigarette used will be the EGO e-cigarette (marketed by www.liquidexpress.com). Each participant randomized to an ECIG condition will receive 2 e-cigarette batteries, 1 wall adapter, 1 USB charger, and a user manual. Cartomizers containing 8 mg/ml nicotine will be provided throughout the intervention period (24 weeks).
89548354|NCT02342795|Experimental|e-cigarette (with 36 mg/ml nicotine)|The e-cigarette used will be the EGO e-cigarette (marketed by www.liquidexpress.com). Each participant randomized to an ECIG condition will receive 2 e-cigarette batteries, 1 wall adapter, 1 USB charger, and a user manual. Cartomizers containing 36 mg/ml nicotine will be provided throughout the intervention period (24 weeks).
89548355|NCT02342873|Active Comparator|NS-guided interscalene block|NS-guided interscalene block is performed using 20 ml of 0.75% ropivacaine.
89548356|NCT02342873|Experimental|US-guided interscalene block|US-guided interscalene block is performed using 20 ml of 0.75% ropivacaine.
89548357|NCT04478435|Active Comparator|1 Hour post intervention|Ultrasound assessment done 1 hour after ingestion of glucose loaded drink
89548358|NCT04478435|Placebo Comparator|2 hours post intervention|Ultrasound assessment done 2 hour after ingestion of glucose loaded drink
89548359|NCT04478357|Other|Treatment A|4 mg fesoterodine ER tablet manufactured at Zwickau.
89548360|NCT04478357|Other|Treatment B|4 mg fesoterodine ER tablet manufactured at Freiburg
89548361|NCT04478357|Other|Treatment C|8 mg fesoterodine ER tablet manufactured at Zwickau
89548362|NCT04478357|Other|Treatment D|8 mg fesoterodine ER tablet manufactured at Freiburg.
89548363|NCT04478513|Experimental|Smokers|Pre-specified group of participants.
89548364|NCT04478513|Experimental|Non-smokers|Pre-specified group of participants.
89548365|NCT02342483|Active Comparator|1g|METHYLSULFONYLMETHANE
89548366|NCT02342483|Active Comparator|3g|METHYLSULFONYLMETHANE
89548367|NCT02342483|Active Comparator|6g|METHYLSULFONYLMETHANE
89548368|NCT02342405|Placebo Comparator|30% oxygen|Inhalation of 30% oxygen
88812038|NCT00886262|Placebo Comparator|Normal saline placebo|
89548369|NCT02342405|Experimental|80% oxygen|Inhalation of 80% oxygen
89548370|NCT04478591||Patients with multiple sclerosis using ocrelizumab.|Patients with multiple sclerosis using ocrelizumab for a minimum of one year.
89548371|NCT02342093|Active Comparator|30EE+DRSP|Combined oral contraceptive containing 30 mcg of ethinylestradiol + 3 mg of drospirenone (30EE+DRSP), 1 pill once a day with a pause of seven days between the blisters for 6 months
89548372|NCT02342093|Active Comparator|20EE+DRSP|Combined oral contraceptive containing 20 mcg of ethinylestradiol + 3 mg of drospirenone (20EE+DRSP), 1 pill once a day with a pause of four days between the blisters for 6 months
89548373|NCT02347319|Experimental|Pennel|This group will treated with DDB 25mg/Garlic oil 50mg for 12 weeks.
89548374|NCT02347319|Active Comparator|Legalon|This group will treated with Silymarin 140mg for 12 weeks.
89548375|NCT02347319|Placebo Comparator|Placebo|This group will treated with Placebo for 12 weeks.
89548376|NCT03146351|Experimental|Early and moderate preterm group|Infants born before 34 weeks included in this group
89548377|NCT03146351|Experimental|Late preterm group|Infants born between 34 and 37 weeks included in this group
89548378|NCT02341781||Relapsed,Progressed,Refractory or Intolerant to ibrutinib|MCL subjects who received lenalidomide after having relapsed or progressed on ibrutinib treatment or were refractory or intolerant to ibrutinib treatment
89548379|NCT02347397|Experimental|SS Bipolar Head + SL-TWIN Stem|Subject will be implanted with the SS Bipolar Head & SL-TWIN Stem
89548380|NCT02347397|Active Comparator|Bipolar Head + SL-PLUS Stem|Subject will be implanted with the Bipolar Head & SL-PLUS Stem
89548381|NCT03146273|Experimental|A|The tablet/capsule will be administered as a single dose after 12 hours of fasting. The participants will be monitored during 6 hours for the level of minerals and Multivitamin minerals in the blood, adverse events and vital signs.
89548382|NCT03146273|Experimental|B|The gel will be administrated to the same group of patients in the single dose after 12 hours of fasting. The participants will be monitored during 6 hours for the level of minerals and Multivitamin minerals in the blood, adverse events and vital signs
89025206|NCT03278522|Active Comparator|ramosetron iv at recovery (R)|0.6mg of ramosetron is given to the patients intravenously at end of surgery
89025207|NCT00440544|Experimental|1|100 ug H1 antigen alone in BCG naive subjects
89025208|NCT00440544|Experimental|2|100 ug H1 antigen + LTK63 adjuvant 30 ug in BCG naive subjects
89025209|NCT00440544|Experimental|3|50 ug H1 antigen in BCG immunized subjects
89548383|NCT02347241|No Intervention|Control period|Assessment of resuscitation quality and clinical outcomes prior to educational intervention
89548384|NCT02347241|Experimental|Educational intervention|Assessment of resuscitation quality and clinical outcomes after educational intervention consisting of debriefing and rolling refreshers.
89548385|NCT02347163|Experimental|Zoledronate|Patients fulfilling the eligibility criteria will receive a pre-operative, single administration of zoledronate (4mg i.v.), 7 days before definitive breast surgery
89548386|NCT02341703|Active Comparator|letrozole-metformin group|"this group will receive letrozole 2.5 mg daily from day 3 of the cycle and for 5 days + metformin 500 mg three times daily from the first day of the cycle and continuous for three months unless pregnancy occurred. treatment will continue for 3 cycles unless pregnancy occurred.~for this group: transvaginal ultrasound will monitor follicular enlargement laboratory investigations in the form of day 3 FSH, LH, TSH and serum testosterone will be done day 12 E2 day 21 serum progesterone"
89548387|NCT02341703|Active Comparator|letrozole-metformin-pioglitazone group|"this group will receive letrozole 2.5 mg daily from day 3 of the cycle and for 5 days + (metformin 850 mg + pioglitazone 15 mg) once daily from the first day of the cycle and for 10 days. treatment will continue for 3 cycles unless pregnancy occurred.~for this group: transvaginal ultrasound will monitor follicular enlargement laboratory investigations in the form of day 3 FSH, LH, TSH and serum testosterone will be done day 12 E2 day 21 serum progesterone"
89548388|NCT02346851|Experimental|triggered FES|
89548389|NCT02346851|Active Comparator|conventional FES|
89548390|NCT02346851|No Intervention|control group|
89548391|NCT02341469|No Intervention|Standard-of-care|
89548392|NCT02341469|Experimental|integrated ediagnostic approach|
89548393|NCT02347007|Experimental|Almond|
89548394|NCT02347007|Active Comparator|Cereal Bar|
89548395|NCT02346929|Experimental|ultrasound-guided hematoma block|Patients in this arm will receive a bed-side ultrasound guided hematoma block with analgesia (0.25% bupivacaine)
89548396|NCT02346929|No Intervention|traditional hematoma block|Patients in this arm will have the hematoma block of the distal radius fracture with no ultrasound for guidance with analgesia (0.25% bupivacaine)
89548397|NCT02341391|Experimental|TissueGene-C(Low dose)|Single intra-articular injection to the damaged knee joint at doses of 3.0 x 10^6 cells
89548398|NCT02341391|Experimental|TissueGene-C(Medium dose)|Single intra-articular injection to the damaged knee joint at doses of 1.0 x 10^7 cells
89548399|NCT02341391|Experimental|TissueGene-C(High dose)|Single intra-articular injection to the damaged knee joint at doses of 3.0 x 10^7 cells
89548400|NCT02341235|Experimental|Game intervention|Participants will receive narrative-based games on a mobile device and telephone counseling (weekly for the first 12 weeks, then once per month until 6 months)
89548401|NCT02341235|Active Comparator|Standard intervention|Participants will receive an electronic activity monitor with a mobile device and telephone counseling (weekly for the first 12 weeks, then once per month until 6 months)
89548402|NCT02341313||Newborns at risk of hypoglycaemia|Measurement of ketones
89548403|NCT02346695||Hypertensives|Untreated consecutive patients with newly diagnosed essential hypertension
89548404|NCT02346695||Controls|Normotensive individuals
89548405|NCT02346773|Active Comparator|ω-3 LC-PUFA group|The intervention product was a full fat (80%) margarine. The active intervention product contained 590 mg docosahexaenoic acid (DHA) and 650 mg eicosapentaenoic acid (EPA) per 10-g daily serving.
89548406|NCT02346773|Placebo Comparator|Placebo group|The placebo product was a similar margarine with the same sensory properties, but with monounsaturated fatty acids (MUFA; refined plant oils) replacing EPA and DHA; total saturated fatty acids (SAFA) and ω-6 long chain polyunsaturated fatty acids (LC-PUFA) content were similar between the active and placebo products.
89025210|NCT00440544|Experimental|4|50 ug H1 antigen + LTK63 adjuvant 30 ug in BCG immunized subjects
89025211|NCT00440544|Experimental|5|100 ug H1 antigen in BCG immunized subjects
89025212|NCT00440544|Experimental|6|100 ug H1 antigen + LTK63 adjuvant 30 ug in BCG immunized subjects
89025215|NCT00440583|Experimental|chemotherapy followed by Zevalin|6 cycles of chemotherapy with CHOP (Cyclophosphamide iv 750 mg/m2 over 15-45 minutes; Doxorubicin iv 50 mg/m2 over 5-20 minutes; and Vincristine iv 1.4 mg/m2 over 5-15 minutes on day 1 and oral prednisone 40 mg/m2 on days 1-5 repeated every 21 days), followed by Zevalin
89025216|NCT04700384|No Intervention|Control Group|"Control Group - Baseline Training~25 Participants allocated. Individuals receive introductory information on using the simulator and the scenario. They perform 5 simple subpial tumour resections for practice and have 5 minutes per trial. After each attempt, the student takes a 5-minute break with no assessment or feedback on their performance. On their 6th attempt they have 13 minutes to perform a different realistic scenario."
89207984|NCT00972933|Experimental|Ipilimumab|Induction ipilimumab 10 mg/kg IV day 0, 21 (baseline, week 3) Maintenance Ipilimumab 10 mg/kg IV days 63 (+28 days) and, 84 (+28 days) - (3 weeks apart, starting 2-4 weeks following definitive lymphadenectomy)
89032988|NCT02926014|Experimental|Lingual Tonsil Hypertrophy participants|"The research group consisted of 50 consecutive adult outpatients suffering from swallowing disorders, examined by otorhinolaryngologist at the Hospital of Lithuanian University of Health Sciences.~Lingual Tonsil Hypertrophy was diagnosed using videolaryngoscopy."
89207985|NCT00867282|Experimental|Treatment A|
89548407|NCT02346617|Experimental|allogeneic HSCT|The present study will investigate in a single-center (Samsung Medical Center), open-label, single arm by direct infusions of donor-derived CMV-spefic IFN-γ positive T-cells for the treatment of refractory CMV infection in allogeneic hematopoietic stem cell transplant (HSCT) recipients.
89548408|NCT02341079|Active Comparator|Femoral Nerve Blockade|Femoral nerve block delivered via indwelling femoral nerve catheter
89548409|NCT02341079|Experimental|Bupivacaine Liposome Injection|Intraoperative intracapsular injection of bupivacaine liposome
89548410|NCT02340923||Healthy Subjects|Healthy subjects aged 0-18 years old. Subjects cannot have a presence or past history of a neurological disorder or other disease that would be expected to substantially impact health.
89548411|NCT02340923||Duchenne Muscular Dystrophy Subjects|Male subjects aged 0-18 years old with genetic or histopathologic diagnosis of duchenne muscular dystrophy, or signs and symptoms of DMD and genetic or histopathologic diagnosis in a family member. Additionally, subjects cannot have the presence of a superimposed neuromuscular or other medical condition that substantially impacts the individual's health or ability to cooperate.
89548412|NCT02346539|Experimental|Nicotine|"2mg of nicotine in the form of a nicotine polacrilex lozenge will be administered orally, one time.~4mg of nicotine in the form of a nicotine polacrilex lozenge will be administered orally, one time."
89548413|NCT02346539|Placebo Comparator|Placebo|Placebo comparator
89548414|NCT02340689||Genetic testing|Genetic Analysis
89548415|NCT02346149|Other|Patient with impaired glucose tolerance|Bold-MRI before and after glucose injection
89548416|NCT05254691|No Intervention|Standard care|All children are put on a time-cycled, pressure limited ventilation mode (AVEA, CareFusion, Yorba Linda, CA, USA). Inspiratory pressures are set to deliver a expiratory tidal volume of 5-7 ml/kg ideal bodyweight. The frequency of the delivered machine-breaths is set in accordance with age and disease condition of the patient. Then the patient set rate of breaths per minute delivered by the ventilator is reduced with 25%, allowing for more spontaneous breaths.
89548417|NCT05254691|Experimental|Sprinting|The ventilator mode is switched to PS ventilation. The level of PS is set to meet the level of PS set when the patient is ventilated in the SIMV-PS mode. The patient will be in the PS mode until he or she clinically shows increased work-of-breathing (tachypnoea and the presence of nasal flaring and intercostal and/or interjugular retractions indicate increased work of breathing).
89548418|NCT02346227|Active Comparator|AV2|Drug: application of topical spray on the cervix one time (2 puffs) topical application of 100µl AV2 antiviral spray( natural essential oil components in equal volumes diluted 50% in olive oil)
89548419|NCT02346227|Placebo Comparator|Placebo|Drug: application of topical spray on the cervix one time (2 puffs) topical spray of 100 µl on the cervix.
89548420|NCT03146039|Other|Radiation Therapy|The patient will receive Whole Pelvis Radiation Therapy 40 - 50.4 Gy in 1.8 - 2.0 Gy daily fractions over 4.5 - 5.5 weeks followed by Stereotactic Body Radiotherapy 5.5 - 8.0 Gy per fraction x 5 fractions using arc therapy.
89548421|NCT03146195||POP|Female patients with pelvic organ prolapse,such as: cystocele, uterine prolapse, the vault prolapse, rectal prolapse ,undergo pelvic floor reconstruction surgery.Before and after sugery,take dynamic magnetic resonance imaging scan.
89548422|NCT03146195||Non-POP|Females with normal pelvic floor support,don't need pelvic floor reconstruction surgery,only take once dynamic magnetic resonance imaging scan.
89548423|NCT05254223|Experimental|Control Diet (NDA)|No dietary advice (NDA)
89548424|NCT05254223|Experimental|Anti-inflammatory Diet (AIDA)|Anti-inflammatory Dietary advice (AIDA)
89548425|NCT05254145||Group A|This group will include participants without an arthritic knee. These participants will be recruited from the Orthopedic Sports Medicine consultation
89548426|NCT05254145||Group B|This group will include participants undergoing primary knee arthroplasty (KA).
89548427|NCT05254145||Group C|This group will include participants undergoing a surgical procedure whose opposite knee has no history of arthritis
89548428|NCT05254145||Group D|This group will include participants undergoing knee revision surgery with no suspicion of infection (aseptic knee revision replacement)
89207986|NCT00867282|Active Comparator|Treatment B|
89548429|NCT05254145||Group E|This group will include participants undergoing knee revision with a known infection (septic knee revision replacements)
89548430|NCT02345915|Other|Young adult acute leukemia-survivor|
89548431|NCT02341001|No Intervention|Standard care|Patients are discharged from the bariatric service at 18 months after surgery.
89548432|NCT02341001|Experimental|Standard care with text message support|Patients are discharged from the bariatric service at 18 months after surgery but receive a daily text message for one year.
89548433|NCT02340845|Active Comparator|Bromalian 10 mg/kg/day|The number of patients suffering from well-documented malignancies to be assigned to this group will be at least 30: with mixed types of carcinoma of breast, lung, colon, gastro-intestinal, ovarian, cervical, uterine, prostatic, bladder, hepatic, lymphoma, melanoma and so forth. These patients will be given Bromelain at 500 mg/day, divided into two doses of 250 mg/dose and taken with meals.
89548434|NCT02340845|Active Comparator|Bromalian 50mg/kg/day|The number of patients suffering from well-documented malignancies with be at least 60: with mixed types of carcinoma of breast, lung, colon, gastro-intestinal, ovarian, cervical, uterine, prostatic, bladder, hepatic, lymphoma, melanoma and so forth. These patients will be given Bromelain at 2400 mg/day, divided into two doses of 1200 mg/dose and taken with meals.
89548435|NCT02340533|Experimental|adenomyosis|females attending the gynecology outpatient clinic complaining of chronic pelvic congestion will get enrolled in the study. Two dimensional ultrasonography will be performed to asses the presence or absence of adenomyosis or any associated lesions. All the patients were then be subjected to office hysteroscopy and endo-myometrial biopsies will be taken. Histopathological examination of the samples will then be done. From these recruited patients, some will be indicated to perform hysterectomy. The final diagnosis will then be based on the histopathological examination of the specimen retrieved from hysterectomy. The accuracy of the ultrasound and the hysteroscopic endo-myometrial biopsy will then be compared and assessed.
89548436|NCT02345759||Keto-diet group|Vegetarian very low protein regimen (0.3 g proteins/kg ideal body weight per day) supplemented with ketoanalogues of essential amino acids (Ketosteril®, Fresenius Kabi, Bad Homburg, Germany), 1 capsule for every 5 kg of ideal dry body weight per day.
89548437|NCT02345759||Conventional LPD group|0.6 g/kg per day, including high biological value proteins
89548438|NCT02340455|Experimental|Pregabalin_male|
89548439|NCT02340455|Experimental|Pregabalin_female|
89548440|NCT02340455|Active Comparator|Placebo_male|
89548441|NCT02340455|Active Comparator|Placebo_female|
89548442|NCT02345837|Active Comparator|clomiphene and endometrial sampling|Couples who will undergo endometrial sampling in the luteal phase of the cycle preceding ovulation induction by clomiphene citrate.
89548443|NCT02345837|Active Comparator|clomiphene citrate|Couples who will undergo ovulation induction with clomiphene citrate.
89548444|NCT02346071|Active Comparator|Enhanced Usual Care (EUC)|Clinical psychiatric and somatic assessment. Standard psychiatric consultation (SPC) given 2 weeks after randomization.
89548445|NCT02346071|Experimental|Acceptance and Commitment Therapy (ACT)|Clinical psychiatric and somatic assessment. Standard psychiatric consultation (SPC) given 2 weeks after randomization. ACT-based group therapy.
89548446|NCT02345993|Active Comparator|Extra fine Formoterol/Beclomethasone|"Group receiving the drug additional to standard treatment standard treatment consisting in: Albuterol 2.5 mg via nebulizer at baseline, 0, 20, 40 minutes + Systemic steroid (methylprednisolone 60 mg) at the moment of evaluation~+ formoterol/beclomethasone, 3 puffs administered via aerochamber at baseline (0), 20, 40 minutes"
89548447|NCT02345993|Placebo Comparator|Placebo|"Group receiving placebo additional to standard treatment consisting in:~Albuterol 2.5 mg via nebulizer at baseline (0), 20, 40 minutes + Systemic steroid (methylprednisolone 60 mg) at the moment of evaluation~+ Placebo, 3 puffs administered via aerochamber at baseline (0), 20, 40 minutes"
89548448|NCT02345447|Active Comparator|Herbal-based Medication|"Trade Name of active comparator: Otovowen® Substances: Aconitum napellus Dil. D6; Capsicum annuum Dil. D4; Chamomilla recutita; Echinacea purpurea; Hydrargyrum bicyanatum Dil. D6; Hydrastis canadensis Dil. D4; Iodum Dil. D4; Natrium tetraboracicum Dil. D4; Sambucus nigra; Sanguinaria canadensis.~Manufacturer: Weber & Weber, Inning/Ammersee Dose: Three times daily 7 drops Mode of Application: orally Duration of Treatment: at first signs of Upper respirtory tract infection until symptoms resolve (maximally 8 weeks of continuous application)."
89548449|NCT02345447|Placebo Comparator|Placebo|Placebo Substance: Aqueous ethanol solution non-distinguishable from verum. Manufacturer: Weber & Weber, Inning/Ammersee Dose: Three times daily 7 drops Mode of Application: orally Duration of Treatment: at first signs of URI until symptoms resolve (maximally 8 weeks of continuous application).
89548450|NCT05253989|No Intervention|Control|Regular assessments as outlined in the outcomes assessment section. No other change from standard of care.
89548451|NCT05253989|Active Comparator|VR Intervention Group|Regular assessments as outlined in the outcomes assessment section. Regular VR training sessions.
89548452|NCT05253989|Active Comparator|VR Intervention + FES Group|Regular assessments as outlined in the outcomes assessment section. Regular VR training sessions, with FES stimulation.
89548453|NCT05253599|Experimental|Isokinetic training|In the IKT group before isokinetic training, the subjects were asked to perform five minutes' warm-up followed by slow stretching of back extensors and flexors. The subject was asked to be in an isokinetic dynamometer (Biodex Corporation, New York, USA) in a vertical standing position.
89548454|NCT05253599|Experimental|Virtual reality training|The VRT group received virtual reality training with (Pro-Kin system PK 252 N Techno body, Pelvic Module balance trunk MF, Italy) focusing on the balance of core stability muscles.
89548455|NCT05253599|Active Comparator|Control group|The Control group focused on conventional balance training for core muscles. The training includes active isotonic and isometric exercise for abdominal muscles (Internal oblique, external oblique, transverse abdominus and Rectus abdominus) deep abdominal muscles (Psoas major, Psoas minor, Illiacus and Quadratus Lumborum) and back muscles (Erector spinae, Transverses spinalis, inter spinalis and Inter transverse).
89548456|NCT02345681|Experimental|Test Furosemide|We will test our furosemide algorithm in one arm
89548457|NCT02345681|No Intervention|Classical Strategy|It's a classical strategy without diuretics
89548458|NCT02345525|Active Comparator|mCIMT|2 hours intensive upper limb practice with shaping techniques supervised by an experienced physiotherapist + 2 hours ADLs at home (supervised by a caregiver) Patients are supposed to wear a mitt on the unaffected hand for 4 hours daily.
89032989|NCT02926014|Other|Control participants|The control group consisted of 50 healthy adult participants, who were examined using videolaryngoscopy and no pharyngeal pathologies were diagnosed, including lingual tonsil hypertrophy.
89548459|NCT02345525|Experimental|hCIMT|"2 hours intensive upper limb practice with shaping techniques + 2 hours ADLs supervised by a caregiver.~Patients are supposed to wear a mitt on the unaffected hand for 4 hours daily."
89548460|NCT02345291|Experimental|NRD135S.E1 A|A = 10 mg NRD135S.E1 once daily PO for 21 days
89548461|NCT02345291|Experimental|NRD135S.E1 B|B = 40 mg NRD135S.E1 once daily PO for 21 days
89548462|NCT02345291|Experimental|NRD135S.E1 C|C = 150 mg NRD135S.E1 once daily PO for 21 days
89548463|NCT02345291|Placebo Comparator|Placebo to match NRD135S.E1 D|D = Placebo once daily PO for 21 days
89548464|NCT02340611|Experimental|Cediranib and Olaparib|Cediranib, 20 mg , orally, once a day, every day. Olaparib, 150 mg or 200 mg (depending on previous treatment dose), orally, once a day, every day.
89548465|NCT02345603|Experimental|Cryo-therapy|Cryo-therapy of renal arteries
89548466|NCT02345603|No Intervention|Control|No intervention in renal arteries
89548467|NCT02340143|Active Comparator|Control|Marketed partially hydrolyzed cow's milk protein infant formula
89548468|NCT02340143|Experimental|Investigational|Partially hydrolyzed cow's milk infant formula with a probiotic
89548469|NCT03145883|No Intervention|Control group|Control group
89548470|NCT03145883|Experimental|Home-based Aerobic Exercise|Participants will be prescribed weekly exercise goals starting with 75 minutes a week (e.g., 15 minutes per day, 5 days a week) and progressed to 200 minutes a week (e.g., 40 minutes per day, 5 days a week) by week 12. Exercise will consist of participant preference of mobility exercises, most likely walking. Aerobic exercise, similar to a brisk walk, will be recommended as the primary mode of exercise.
89548471|NCT02340065|Active Comparator|standard colonoscopy|total polyp/adenoma detection with standard colonoscopy, polyp/adenoma detection in the right colon with standard colonoscopy
89548472|NCT02340065|Active Comparator|Endocuff-assisted colonoscopy|total polyp/adenoma detection with Endocuff-assisted colonoscopy, polyp/adenoma detection in the right colon with Endocuff-assisted colonoscopy
89548473|NCT03145649||Gestational diabetes mellitus|Women with gestational diabetes mellitus and their infants. The blood glucose of women with gestational diabetes mellitus was controlled by dietary therapy or insulin injection.
89548474|NCT03145649||Healthy|Healthy mother-infant dyads
89548475|NCT02345213|Experimental|E2020|"Treatment period: Weeks 1-2 E2020 3 mg, Weeks 3-6 E2020 5 mg, Weeks 7-12 E2020 10 mg.~Extension period: Weeks 1-6 E2020 10 mg, After Week 7 up to week 60 E2020 10 mg."
89548476|NCT02345213|Placebo Comparator|Placebo|"Treatment period: Weeks 1-12 placebo~Extension period: Weeks 1-2 E2020 3 mg, Weeks 3-6 E2020 5 mg, After Week 7 up to week 60 E2020 10 mg."
89548477|NCT02339753|Experimental|Carboplatin-treatment arm|"Arm description : Carboplatin intravenous administration once daily for 3 to 4 days~Topotecan + Thiotepa + Carboplatin : carboplatin 500mg/m2/day, for 3 days~MEC for 2nd PBSCT : carboplatin 350 mg/m2/day, for 4 days~MEC for other solid tumor : carboplatin 400 mg/m2/day, for 4 days~MEC + MIBG Tx for 2nd PBSCT (neuroblastoma) : carboplatin 300 mg/m2/day, for 4 days"
89548478|NCT02345135|Active Comparator|Ataxia Telangiectasia|All A-T patients presented for 3 study visits. In all visits patients had a clinical examination, a blood collection and a lung function measurement. Furthermore symptom diaries were distributed and collected on these visits.
89548479|NCT02345135|Active Comparator|Healthy Control|All healthy controls presented for 3 study visits. In all visits patients had a clinical examination and a lung function measurement. Furthermore symptom diaries were distributed and collected on these visits.
89548480|NCT02345057|Experimental|CS-3150 0.625 mg|One CS-3150 0.625 mg tablet and one placebo tablet to match CS-3150 tablet administered orally, once daily after breakfast.
89548481|NCT02345057|Experimental|CS-3150 1.25 mg|Two CS-3150 0.625 mg tablets administered orally, once daily after breakfast.
89548482|NCT02345057|Experimental|CS-3150 2.5 mg|One CS-3150 2.5 mg tablet and one placebo tablet to match CS-3150 tablet administered orally, once daily after breakfast.
89548483|NCT02345057|Experimental|CS-3150 5.0 mg|Two CS-3150 2.5 mg tablets administered orally, once daily after breakfast
89548484|NCT02345057|Placebo Comparator|Placebo|Two placebo tablets to match CS-3150 tablet, administered orally, once daily after breakfast.
89548485|NCT02339597|Experimental|APAP Lab|standard Initiation of APAP therapy in sleep laboratory.
89548486|NCT02339597|Experimental|APAP Home|initiation of APAP therapy in homely environment with additional continuous telemetric support.
89548487|NCT02339675|Other|convential MS rehabilitation|Investigate the quality (psychometric properties) and clinical utility of several measures of the upper limb function
89548488|NCT02339519|Active Comparator|group LMA supreme|Patients who received Laryngeal Mask Airway; LMA supreme
89548489|NCT02339519|Active Comparator|group LMA classic|Patients who received Laryngeal Mask Airway; LMA classic
89548490|NCT02339519|Active Comparator|group Fastrach|Patients who received Laryngeal Mask Airway; LMA fastrach
89548491|NCT02339441||Methotrexate|Patients treated with Methotrexate at the entry of the study.
89548492|NCT02339441||Mycophenolate Mofetil|Patients treated with Mycophenolate Mofetil at the entry of the study.
89548493|NCT02339441||Cyclophosphamide|Patients treated with Cyclophosphamide at the entry of the study
89548494|NCT02339441||No Immunosuppressant|Patients without immunosuppressant treatment at the entry of the study
89548495|NCT02344901||atrial fibrillation patients|>18 year old. Atrial fibrillation patients without mitral stenosis or any prosthesis.
89548496|NCT02344823|Active Comparator|Vardenafil Phase A|HVPG (Hepatic Venous Pressure Measurement) at baseline and Response to Vardenafil 10mg per oral for 7 days at day 7 IIEF5 at baseline and day 7
89548497|NCT02344823|Placebo Comparator|Placebo Phase A|HVPG (Hepatic Venous Pressure Measurement) Measurement at baseline and Response to Placebo per oral for 7 days at day 7 IIEF 5 at baseline and day 7
89548498|NCT02344823|Active Comparator|Vardenfil Phase B|IIEF 5 (International Index of Erectile Function) at baseline and Response to Vardenafil 10mg per oral ad libidum in 28 days at day 28
89548499|NCT02344823|Placebo Comparator|Placebo Phase B|IIEF 5 (International Index of Erectile Function) at baseline and Response to Placebo per oral ad libidum in 28 days at day 28
89548500|NCT03145961|No Intervention|Observation|Patient will have blood samples collected for ctDNA analysis every 3 months for up to 2 years from starting ctDNA screening.
89548501|NCT03145961|Experimental|Pembrolizumab Treatment|Patients will be given pembrolizumab every 3 weeks for up to a maximum of 12 months, with blood samples collected prior to each cycle for continued ctDNA analysis. Following treatment discontinuation, blood samples will be collected for ctDNA analysis every 3 months for a further 12 months.
89548502|NCT02339207|Placebo Comparator|Placebo|Placebo dosed once in human volunteers in increasing dosages or once daily for seven days in patients with chronic Hepatitis C in increasing dosages.
89548503|NCT02339207|Experimental|AL-335|AL-335 dosed once in human volunteers in increasing dosages or once daily for seven days in patients with chronic Hepatitis C in increasing dosages.
89548504|NCT02339363|Experimental|Sitting Meditation|4 weeks (45-min sessions, 2x per week) of sitting meditation, based on MBSR. The sitting meditation condition consisted of three parts: (a) breathing techniques, (b) meditation, and (c) discussion. Participants in the sitting meditation group learned new types of sitting meditation each week. Participants in the sitting meditation group received a CD that consisted of audio meditations that they could follow along at home. The sitting meditation participants were encouraged to practice formal sitting meditation for 15 to 30 minutes every day and asked to record details of their practice on their daily home practice logs.
89548505|NCT02339363|Experimental|Hatha Yoga|4 weeks(45-min sessions, 2x per week) of Hatha Yoga. The adolescent hatha yoga curriculum was used with permission from Shanti Generation Yoga © (2009) created by Abby Wills. The hatha yoga sessions consisted of three parts: (a) breathing techniques, (b) yoga poses, and (c) discussion. Participants in the hatha yoga group learned a series of new yoga poses each week, as well as reviewed old poses. During the first session, participants in the hatha yoga group received a DVD that contained five yoga lessons corresponding to the yoga poses being taught in the intervention. Participants were encouraged to practice the series of yoga poses at home for 15 to 30 minutes each day and record their home practice in their daily home practice logs.
89548506|NCT02339363|No Intervention|Waitlist Control|4-week waitlist control condition. Completed all study measures at same time points as experimental groups. Were randomly assigned to one of the two active treatment conditions after completing the waitlist period.
89548507|NCT03145727|Placebo Comparator|Placebo Group|Placebo Group: In this group the participants received TENS with frequency of 75Hz, pulse duration of 200 microseconds. The stimulation time will be for only 10s.
89548508|NCT03145727|Experimental|Low Frequency Group|Low Frequency Group: In this group the TENS will be adjusted with frequency of 10Hz, pulse duration of 200 microseconds. The stimulation time will be 30 minutes and the intensity will be constantly adjusted in order to keep as high as possible within the tolerance threshold of the patient.
89548509|NCT03145727|Experimental|High Frequency Group|High Frequency Group: In this group the TENS will be adjusted with frequency of 150Hz, pulse duration of 200 microseconds. The stimulation time will be 30 minutes and the intensity will be constantly adjusted in order to keep as high as possible within the tolerance threshold of the patient.
89548510|NCT02344979||Group rHuTPO|Patients were treated with recombinant human thrombopoietin(rHuTPO)on d2,d4,d6,d9 of chemotherapy cycle.
89548511|NCT02344979||Group rHuIL-11|Patients were treated with recombinant human interleukin-11(rHuIL-11)on d9-d15 after chemotherapy.
89548512|NCT02339051|Experimental|One leg jumping|Study subjects will jump on one leg on repeated occasions (incremental daily repetitions) for a period of three months. The same leg will be used for jumping throughout the study. The other leg will serve as control.
89548513|NCT02338895||acutly oliguric patients with ultrasound|Patients with septic shock and acute oliguria that will undergo bedside ultrasonographic assessment of inferior vena caval diameter, respiratory variation and renal perfusion.
89548514|NCT02344511|Experimental|Dalbavancin|"Patients with Creatine Clearance (CrCl) greater than 30 mL/min and patients receiving regular hemodialysis or peritoneal dialysis will receive 15 mg/kg Intravenous (IV) dalbavancin over 30 (+/- 5) minutes on Day 1 and on Day 8, not to exceed 1500 mg per administration in children at least 12 years and not to exceed 1000 mg per administration in children less than 12 years of age.~• Patients with CrCl < 30 mL/min who are not receiving regular hemodialysis or peritoneal dialysis will receive 10 mg/kg IV dalbavancin over 30 (+/- 5) minutes on Day 1 and on Day 8, not to exceed 1000 mg per administration in children at least 12 years and not to exceed 750 mg per administration in children less than 12 years of age.~Additionally, subjects randomized to the dalbavancin group will receive an IV placebo infusion at times corresponding to comparator group dosage times for the first eight days."
89548515|NCT02344511|Active Comparator|4 Comparators|"cefazolin, oxacillin, nafcillin or vancomycin according to the commercial label~Patients with normal renal function will receive either vancomycin 15 mg/kg/dose, infused over 60 (+/- 10) minutes, every 6 hours (+/- 1 hour) not to exceed a daily total dose of 4000 mg, with dose adjustment based on local standard of care to achieve serum trough concentrations of 10 μg/mL to 20 μg/mL; or cefazolin 25 mg/kg/dose, infused over 60 (+/- 10) minutes, every 6 hours (+/- 1 hour); or nafcillin or oxacillin 50 mg/kg/dose, infused over 60 (+/- 10) minutes, every 6 hours (+/- 1 hour)."
89548516|NCT02344589|Experimental|ACB 10|ACB in right leg with 10ml of lidocaine 10mg/ml. Subject and assessor blinded, randomized. given on day 1, 2 or 3
89548517|NCT02344589|Experimental|ACB 20|ACB in right leg with 20ml of lidocaine 10mg/ml. Subject and assessor blinded, randomized. given on day 1, 2 or 3
89548518|NCT02344589|Experimental|ACB 30|ACB in right leg with 30ml of lidocaine 10mg/ml. Subject and assessor blinded, randomized. given on day 1, 2 or 3
89548519|NCT02344589|Active Comparator|FNB|FNB in left leg with 20ml of lidocaine 10mg/ml on day 1. Unblinded arm, used for model control
89548520|NCT02344589|Placebo Comparator|Placebo|ACB in left leg with 30ml of isotonic saline on day 2. Unblinded arm used for model control
89548521|NCT02344667|Experimental|Cyberknife|Cyberknife based SBRT 36.25 Gy in 5 fractions
89548522|NCT02344667|Experimental|Volume Modulated Arc Therapy|Volume Modulated Arc Therapy based SBRT 36.25 Gy in 5 fractions
89548523|NCT02338739|Active Comparator|REC; Outreach if Failure|
89548524|NCT02338739|Active Comparator|REC; SMS + Voucher if Failure|
89548525|NCT02338739|Active Comparator|REC; Navigator if Failure|
89548526|NCT02338739|Active Comparator|SMS; Outreach if Failure|
89548527|NCT02338739|Active Comparator|SMS; Outreach if Failure; Stop SMS if Success|
89548528|NCT02338739|Active Comparator|SMS; SMS+Voucher if Failure|
89548529|NCT02338739|Active Comparator|SMS; SMS+Voucher if Failure; Stop SMS if Success|
89548530|NCT02338739|Active Comparator|SMS; Navigator if Failure|
89548531|NCT02338739|Active Comparator|SMS; Navigator if Failure; Stop SMS if Success|
89548532|NCT02338739|Active Comparator|Voucher; Outreach if Failure|
89548533|NCT02338739|Active Comparator|Voucher; Outreach if Failure; Stop Voucher if Success|
89548534|NCT02338739|Active Comparator|Voucher; SMS+Voucher if Failure|
89548535|NCT02338739|Active Comparator|Voucher; SMS+Voucher if Failure; Stop Voucher if Success|
89548536|NCT02338739|Active Comparator|Voucher; Navigator if Failure|
89548537|NCT02338739|Active Comparator|Voucher; Navigator if Failure; Stop Voucher if Success|
89548538|NCT02338817||GSD 1|These will be subjects with GSD I. The Diabetes Sentry device will be monitored for alarms for possible hypoglycemic. A blood sample will be taken to confirm blood glucose levels, lactate, and ketone values.
89548539|NCT02338817||GSD 0, III, VI, or IX|These will be subjects with GSD 0, III, VI, or IX. The Diabetes Sentry device will be monitored for alarms for possible hypoglycemic. A blood sample will be taken to confirm blood glucose levels, lactate, and ketone values.
89548540|NCT03145337|Active Comparator|Cohort A|FlexHD ADM
89548541|NCT03145337|Active Comparator|Cohort B|AlloDerm RTU ADM
89548542|NCT02344433|Experimental|VICKY|"Relational agent, virtual counselor for collecting family health history (VICKY: VIrtual Counselor for Knowing Your Family History)."
89548543|NCT02344433|Active Comparator|MFHP|Online family health history collection tool (MFHP: My Family Health Portrait).
89548544|NCT02338505|Experimental|Telelap ALF-X in obese patients with gynecological disease|
89548545|NCT02338427|Experimental|proteomic|
89548546|NCT05002595||Modified quadruple therapy|pantoprazole 40mg bid, amoxicillin 1000mg bid, metronidazole 750mg bid, bismuth subcitrate 600mg bid for 14 days
89548547|NCT05002595||Tailored eradication|pantoprazole 40mg bid, amoxicillin 1000mg bid, clarithromycin 500mg bid or pantoprazole 40mg bid, tetracycline 1000mg bid, metronidazole 750mg bid, bismuth subcitrate 600mg bid for 7 days
89548548|NCT02343965|Experimental|Touch-massage group|Patient receive 3 sessions of touch-massage (the duration of a session of touch massage is 15 minutes) ,once a week, for 3 weeks
89548549|NCT02343965|No Intervention|without touch-massage group|
89548550|NCT03145493|Experimental|Usage of suction drains|Usage of suction drains
89548551|NCT03145493|No Intervention|No usage of suction drains|No usage of suction drains
89548552|NCT02338271|Other|a single, open clinical trial|"a single-group, open, investigator-initiated clinical study~: autologous adipose derived mesenchymal stem cell (2 x 10^7 cells/mL /vial or 4 x 10^7 cells/mL /vial) plus Tissuefill (hyaluronic acid derivatives) 1mL/syringe"
89025217|NCT04700384|Experimental|Experimental Group - Virtual Operative Assistance Training|"Experimental Group - Virtual Operative Assistance Training~25 participants allocated. Individuals receive the same information, have the same amount of time and perform the same scenarios as the control group. In the 5-minutes between attempts, participant receive the Virtual Operative Assistance Training assessment of their performance and audiovisual feedback."
89548553|NCT02344043||Critical illness|This prospective cohort of critically ill patients will have brain tissue oxygen levels recorded for 24 hours after admission with near infrared spectroscopy.
89548554|NCT02343887|Active Comparator|control group|"patients without taking into cognitive or psychological treatment for 6 months (period 1) and~if the situation improves in the neuropsychological assessment of M6 further with simple monitoring neuropsychological evaluation M12~or persistence or worsening of the disorder, the beginning of a cognitive remediation program for 6 months (period 2)."
89548555|NCT02343887|Experimental|group with cognitive rehabilitation,|"patients treated for 6 months Cognitive remediation (period 1), then~Stop if the situation improves in the evaluation and monitoring of M6 to M12 with neuropsychological assessment,~or persistence or worsening of the disorder, further cognitive remediation for 6 months (period 2)."
89548556|NCT02343887|Experimental|group with psychological support.|"patients treated with counseling for six months (period 1) and~Stop if the situation improves with neuropsychological assessment and monitoring to M12,~or if persistent or worsening unrest in the neuropsychological assessment of M6, the beginning of a cognitive remediation program for 6 months (period 2)."
89548557|NCT02338115||Weekly paclitaxel treatment group|Breast cancer patients initiating paclitaxel 80mg/m2 weekly x 12 weeks for curative treatment will be followed prospectively for collection of samples and longitudinal neuropathy data.
89548558|NCT02343809|Experimental|Intervention Group|Actual Diacutaneous Fibrolysis and Protocolized Physiotherapy
89548559|NCT02343809|Sham Comparator|Placebo Group|Sham Diacutaneous Fibrolysis and Protocolized Physiotherapy
89548560|NCT02343809|Other|Control Group|Protocolized Physiotherapy
89548561|NCT03112109||Intervention Group|Patients receiving 'new care'
89548562|NCT03112109||Control group|Patients receiving 'old / usual care'
89548563|NCT02039297|Other|No Intervention: Baseline arm|Pre and post design (same arm)
89548564|NCT02343731|Experimental|Dog Introduction|Participants will receive a dog from the Humane Society of Southern Arizona's (HSSA) foster care program to live with them for three months.
89548565|NCT02337803|Experimental|Strength Training Group|Participants will meet three times a week for one hour strength training sessions for twelve weeks.
89548566|NCT02337803|Active Comparator|Usual Care|Participants will be given access to the strength training program after the twelve week study ends.
89032990|NCT00529607||1|- patients with acute ST elevation myocardial infarction and consecutive percutaneous coronary intervention of the infarct-related artery
89032991|NCT00529607||2|- 30 patients with stable CAD (control group 1)
89548567|NCT02337881|Active Comparator|nifedipen and sildenafil|The protocol for nifedipen in our units consists of 20 mg orally stat, followed by 10 mg orally every 6-8 hours, at the same time sildenafil citrate will be administered vaginally in a dose of 25mg at 8 hourly intervals and both medications will be continued for 48-72 hours as indicated.
89548568|NCT02337881|Active Comparator|nifedipen only|nifedipine alone in the same regimen and duration described before.
89548569|NCT02337257|Active Comparator|cholecalciferol|Subjects will take 4000 IU per day for 30 days
89548570|NCT02337257|Placebo Comparator|Placebo|Subjects will take placebo everyday for 30 days
89025218|NCT04700384|Experimental|Experimental Group - remote-based expert Instructor Training|25 participants allocated. Individuals receive the same information, have the same amount of time and perform the same scenarios as the control group. Meanwhile, a trained instructor observes the participant's on-screen performance, that is live-streamed, remotely. Instructors are senior neurosurgery residents with extensive experience in performing and assessing this scenario. During the 5-minute feedback session, they chat with the student, discussing the performance and help in setting goals for the next trial.
89548571|NCT02337569|Experimental|NPC-02|Oral dose
89548572|NCT02337569|Placebo Comparator|Placebo|Oral dose
89548573|NCT02337179|Experimental|Voluntary medical male circumcision|Eligible men will be circumcised according to protocol
89548574|NCT02337101|Active Comparator|Enhanced Usual Care (EUC)|Clinical psychiatric and neurological assessment. Information and advice.
89548575|NCT02337101|Experimental|EUC + Early intervention programme|Clinical psychiatric and neurological assessment. Information and advice. Individually targeted treatment programme.
89548576|NCT02337413|Active Comparator|Urotherapy + Constipation Treatment|This group will be treated with standard behavioral urotherapy in addition to receiving active stool softening with PEG3350 and standard constipation instruction.
89548577|NCT02337413|Other|Urothearpy alone|This group will receive standard behavioral urotherapy alone
89548578|NCT02332265||Program Participant Study SAFE area, control area|"Participants from two types of areas of rural central Malawi: traditional authorities (TA) selected by CARE to receive the SAFE program (intervention group) and TAs receiving other unrelated CARE programming (controls).~Intervention TAs: 598 program participants (398 women, 200 men) were interviewed at baseline and 18- and 36-month follow-ups;~Control TAs: 301 control households were interviewed at baseline and 18- and 36-month follow-ups"
89548579|NCT02332265||Community Impact Study, non-SAFE participants|We conducted random surveys (n = 1002)--501 living in the intervention areas but not directly receiving the SAFE intervention and 501 living in the control areas not receiving the SAFE intervention with a 36-month assessment interval, prior to and after implementation of SAFE. Thus, we examined intervention outcomes both in direct SAFE program participants and their larger communities. We used multilevel modeling to examine mediators and moderators of the effects of SAFE on HIV outcomes at the individual and community levels and determine the ways in which changes in HIV outcomes feed back into economic outcomes and food security at later interviews.
89548580|NCT02332265||Qualitative SAFE program participant in-depth interview & FGD|We conducted a qualitative end-of-program evaluation consisting of in-depth interviews with 90 SAFE participants.
89548581|NCT02332109||ODM 5-group|
89548582|NCT02337023||healthy subjects|
89548583|NCT02337023||patients with Kleine-Levin Syndrome|
89548584|NCT04477811|Active Comparator|vitamin k1|vitamin k1 will be given 10 mg thrice a week for 3 months
89548585|NCT04477811|Active Comparator|vitamin k2|vitamin k2 (menaquinone) will be given 90 ug per day orally
89548586|NCT04477811|Placebo Comparator|placebo|placebo will be given daily per oral for 3 months
89548587|NCT02332031|Experimental|Sorafenib (Nexavar, BAY43-9006) & Levothyroxine|Sorafenib be administrated without and with levothyroxine orally
89548588|NCT03112031|Experimental|Tamoxifen augmented antifungal therapy|Tamoxifen 300mg/day for 2 weeks, combined with standard antifungal therapy (amphotericin B 1mg/kg/day combined with fluconazole 800mg/day for the first 2 weeks followed by fluconazole 800mg/day for 8 weeks)
89548589|NCT03112031|Active Comparator|Standard antifungal therapy|Amphotericin B 1mg/kg/day combined with fluconazole 800mg/day for the first 2 weeks followed by fluconazole 800mg/day for 8 weeks.
89548590|NCT03111797||video-assisted lobectomy group|patients operated of lung lobectomy for an early stage cancer using a video-assisted surgical procedure
89548591|NCT03111797||robot-assisted lobectomy group|patients operated of lung lobectomy for an early stage cancer using a robot-assisted surgical procedure
89548592|NCT03111953|Active Comparator|RYGB|Subjects received Roux-en-Y Gastric Bypass surgery.
89548593|NCT03111953|Experimental|BPD|Subjects received Biliopancreatic Diversion Surgery
89548594|NCT02336867|Experimental|Experimental group|closure clip (OTSC® Proctology Laboratory: OVESCO and French Distributor: Life Partners)
89548595|NCT02336867|Other|Control group|advancement flap technique
89548596|NCT02938013|Experimental|Group A|Monoinfected: Sofosbuvir/Velpatasvir/Voxilaprevir SOF/VEL/VOX days 0-7 Paired liver biopsy at days 0 and 7 (cohort 1) or days 0 and 4 (cohort 2). SOF/VEL days 8 (week 2) through 84 (week 12). Post-treatment follow up through week 12.
89548597|NCT02938013|Active Comparator|Group B|Monoinfected: Sofosbuvir/Velpatasvir (SOF/VEL) days 0 through 7 and Paired liver biopsy at days 0 and 7 (cohort 1) or days 0 and 4 (cohort 2). SOF/VEL on day 8 (week 2) through 84 (week 12) . Post-Treatment follow up through week 12.
89548598|NCT02938013|Active Comparator|Group C|HIV/HCV Co-infection: Sofosbuvir/Velpatasvir (SOF/VEL) days 0 through 7 and Paired liver biopsy at days 0 and 7 (cohort 1) or days 0 and 4 (cohort 2). SOF/VEL on day 8 (week 2) through 84 (week 12) . Post-Treatment follow up through week 12.
89548599|NCT02331875|Experimental|single arm|IPH2201 followed by standard surgery and standard postsurgical adjuvant therapy
89548600|NCT02331719||MiSPACE Eligible Cohort|This will be a prospective record review of patients where the MiSPACE technique is being/was used for the treatment of their ICH.
89548601|NCT02331719||Historical Cohort|This is a retrospective records review of patients who received either medical intervention or conventional surgical intervention for the treatment of their ICH.
89548602|NCT02331797|Experimental|Endoscopic Technique|All patients are operated under the endoscope. The endoscope passed through external auditory canal (transcanal approach) to visualize tympanic remnant.
89548603|NCT02331797|Active Comparator|Microscopic Technique|All patients are operated under the microscope.A postauricular or transcanal approach is chose depend on ear canal size and size of perforation. When the ear canal is too small, the postauricular is used.
89548604|NCT02336945||Type 2 diabetes|Subjects with type 2 diabetes who meet one of the therapy conditions
89548605|NCT02336711|Experimental|Dose escalation|Dose escalation
89548606|NCT02820311|Experimental|TD-4208 175 mcg|double-blind
89548607|NCT02820311|Experimental|TD-4208 700 mcg|double-blind
89548608|NCT02820311|Placebo Comparator|Placebo for TD-4208|double-blind
89548609|NCT02820311|Active Comparator|Moxifloxacin 400 mg|open-label
89548610|NCT02336633|Experimental|1|Resveratrol (80mg/j = 4 capsules/day)
89548611|NCT02336633|Placebo Comparator|2|Placebo (4 capsules/day)
89548612|NCT02336477|Experimental|1|Mexiletine / Placebo
89548613|NCT02336477|Experimental|2|Placebo / Mexiletine
89548614|NCT02336789|Placebo Comparator|placebo|250 ml of normal saline (sham transplantation).
89548615|NCT02336789|Active Comparator|intervention|250 ml of diluted fecal material prepared from a screened donor
89548616|NCT02331953||delirium group|the patients with delirium after spine surgery
89548617|NCT02331953||no delirium group|the patients without delirium after spine surgery
89548618|NCT04700891|Experimental|Patients scheduled for elective surgery aged 65 and +|
89548619|NCT02331485|Experimental|PICO + Acticoat group|Patients randomized to negative pressure group will received negative pressure dressing (Pico Wound Management System - manufacture by Smith & Nephew) associated with Acticoat Flex dressing which will be applied immediately after skin closure in a conventional way and left in place for 7 days. Negative pressure dressing will be changed once during 7 days period - after day 2 to 4. Wound complications within first 30 days of surgery will be recorded on clinical examination.
89548620|NCT02331485|Active Comparator|Standard Wound management|If a patient is randomized to standard wound treatment group - he/she will receive standard skin closure and standard Mepore dressing, which will be changed on a daily basis.
89548621|NCT03111563|Other|warm saline|case group ,
89548622|NCT03111563|Other|room temperature|control group
89548623|NCT03105167|Experimental|CBT-TLIF group|Patients who are randomised to the CBT-TLIF group will have cortical bone trajectory screws instead of pedicle screws During the opreation. After preventive use of antibliotics,A small skin incision was made at the fused segment, an entry point for insertion of the CBT screws was drilled in the junction of the center of the superior articular process and 1 mm inferior to the inferior border of the transverse process according to Matsukawa et al.A straight probe was used to create a trajectory for the CBT screws from the entry point to the opposite corner of the pedicle and vertebral body under anteroposterior fluoroscopic guidance.nilateral facetectomy is performed to gain access to the intervertebral disc.Afterwards, interbody fusion was performed.Device: CBT screws.
89548624|NCT03105167|Experimental|PS-TLIF group|Patients who are randomised to the PS-TLIF group will have pedicle screws During the opreation. A posterior midline incision, about 6 cm, was performed at the level of interest level under fluoroscopic guidance. Pedicle screws were inserted into the vertebral body by using freehand, and the inferior and superior articular processes and part pf the lamina were removed by using an osteotome. To expose the lateral border of the ipsilateral nerve root, the ligamentum flavum was removed. Afterwards, interbody fusion was performed.Device:traditional pedicle screws.
89548625|NCT02642315|Other|open-label|"open-label single arm study~Horizant, 600 mg oral once daily at 5 pm for 360 days."
89548626|NCT02518139|Experimental|TD-4208-1|88 mcg
89548627|NCT02518139|Experimental|TD-4208-2|175 mcg
89548628|NCT02518139|Active Comparator|Tiotropium|18 mcg
89548629|NCT02336321|Experimental|BNCI hand-exoskeleton|Hand motor function before, during and after application of the device
89548630|NCT04477655|Active Comparator|Standard oxygen therapy|Oxygen therapy through high flow nasal cannula (HFNC). Continuous monitoring of vital signs. Inspired fraction of oxygen will be titrated to maintain a capillary saturation of ≥92%. Prone positioning will be allowed as a rescue therapy.
89548631|NCT04477655|Experimental|Awake prone positioning|Oxygen therapy through high flow nasal cannula (HFNC). Patients will be asked to remain in prone position throughout the day as long as possible, with breaks according to tolerance. Pillows will be offered for maximizing comfort at chest, pelvis and knees. Monitoring of vital signs will not be suspended. Inspired fraction of oxygen will be titrated to maintain a capillary saturation of ≥92%.
89548632|NCT02709889|Experimental|Rovalpituzumab Tesirine|Rovalpituzumab tesirine 0.2-0.4 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
89548633|NCT03884569||Patients treated with CLET|"Previously treated with CLET patients are included retrospectively, as the follow-up procedure is already stablished in our centre, and patients treated following standard care or through drugs-in-special-situation request in Spain prospectively. Patients are not treated to be included in the study, only the follow-up variables are taken into account."
89548634|NCT03189901|No Intervention|Regular Management|Patients with acute myocardial infarction(AMI) combined with elevated BNP/NT-proBNP level who treated by regular strategy in guideline.
89548635|NCT03189901|Experimental|Regular management+Levosimendan|Patients with acute myocardial infarction(AMI) combined with elevated BNP/NT-proBNP level who treated by regular strategy in guideline and levosimendan.
89548636|NCT02711995|Experimental|RenuGel|Injection augmentation is the injection of a filler material (Brand: RenuGel; generic: Carboxymethylcellulose) into the vocal cords through the skin of the neck, guided by the view from a flexible laryngoscope inserted through the nostril. The flexible laryngoscopy is identical to the procedure that the doctor has used to examine your vocal cords in the past. It is the routine diagnostic evaluation technique of voice disorders.
89548637|NCT02711995|Active Comparator|Botulinum toxin|Botulinum toxin treatment is the injection of botulinum toxin into the muscles of the vocal cords through the skin of the neck. This is identical to the injections you may have received in the past for your disorder.
89548638|NCT02438605||Treatment group|Patients eligible for AAA repair using Nellix and willing to participate in this trial.
89548639|NCT02438449||Abdominal-based Autogenous Tissue (AAT)|The AAT-based breast reconstruction surgery will include any of the following techniques: pedicled transverse rectus abdominis myocutaneous (TRAM) flap, Free TRAM, muscle-sparting TRAM flap, deep inferior epigastric perforator (DIEP) flap, superficial inferior epigastric artery (SIEA) flap, and Rubens flap.
88961723|NCT04693780|Experimental|Structured guide with pre-appraisal content|Once logged into the website, participants in the intervention group will navigate health information through an annotated structured guide to health evidence which is designed to inform participants where to find specific health information but it will also provide information to understand why such content is more valuable than other content. This structured annotated guide to evidence will also outline the value of pre-appraisal and will help them navigate to products produced for them. These products have been produced by the research team and include a collection of web resource ratings, evidence summaries and blog posts modelled after those developed and presented on the McMaster Optimal Aging Portal. The topics of this citizen content match the scope of the IMAGINE Network.
88961724|NCT04693780|Placebo Comparator|Listing without pre-appraisal content|Once logged into the website, participants in the control group will navigate health information through a structured one-page guide (see Appendix 1) that does not include pre-appraisal information. Instead it will list the main organizations in the field that produce citizen content with descriptions of the type of content they produce with links to their individual websites. This will be presented to participants when they login to the platform. None of the citizen content produced specifically for the study will be provided to them prior to crossing-over.
89207987|NCT00263575|Experimental|sublingual fentanyl tablet|
89207988|NCT00975663|Experimental|1|Optimized TDM of tacrolimus and MMF dosing
88961727|NCT04607564|Experimental|No comparison pilot group|Attendance at ten Ntombi Vimbela workshops running for a total 35 hours over six weeks.
89548640|NCT02438449||Tissue Expander-Implants (TE/I)|The TE/I approach will include two-stage breast reconstruction surgery. In the initial stage, immediately after mastectomy and with or without sentinel node biopsy, an expander will be placed in the subpectoral plane and the defect closed. Two weeks after the surgery, the expansion of the TE will commence until the desired volume of the respective expander is achieved. The second stage will include removal of the TE and the placement of a permanent implant which may be either saline or gel. The delayed method will be similar to the immediate reconstruction with the exception of the incision, which will be relatively smaller as the mastectomy was performed previously with breast cavity being fully closed.
89548641|NCT02443051|Experimental|Attention Bias Modification|Training in bias modification for 80% of experimental trials
88961728|NCT04603677||Acute phase of SARS-CoV-2 infection|Participants with an acute SARS-CoV-2 infection. Intervention will not be implemented in this study.
89548642|NCT02443051|Active Comparator|Control|Bias modification for 50% of trials
89548643|NCT02443129|Experimental|control group|"18-99 year old male + female~Intervention:~DRI-1 Swept source OCT, Atlantis, Topcon"
89548644|NCT02443129|Experimental|mydramide only|"Patients in the clinics undergoing pupil dilation~Intervention:~Tropicamide instillation to both eyes DRI-1 Swept source OCT, Atlantis, Topcon"
89548645|NCT02443129|Experimental|mydramide and ephrine 10%|"Patients in the clinics undergoing pupil dilation~Intervention:~Tropicamide and ephrine 10% instillation to both eyes DRI-1 Swept source OCT, Atlantis, Topcon"
89548646|NCT02443129|Experimental|All patients presenting with RD|"Patients with retinal detachment~Intervention:~RD surgery DRI-1 Swept source OCT, Atlantis, Topcon"
89548647|NCT02443129|Experimental|Impact of previous grid treatment|"Patients after grid laser~Intervention:~DRI-1 Swept source OCT, Atlantis, Topcon"
89548648|NCT02443129|Experimental|Effect of glaucoma medications|"Patients requiring new intraocular presssur (IOP)-lowering treatment Patients with long-term IOP-lowering treatment~Intervention:~If needed, start of new IOP-lowering treatment DRI-1 Swept source OCT, Atlantis, Topcon"
89548649|NCT02443129|Experimental|Effect of arteritic/non-arteritic AION|"About 180 living patients diagnosed at ShaareZedek with anterior ischemic optic neuropathy (AION).~Longitudinal arm with newly diagnosed patients for 2 years follow-up~Intervention:~DRI-1 Swept source OCT, Atlantis, Topcon"
89548650|NCT02443129|Experimental|NVAMD poorly responsive to Rx|"Patients with neovascular age-related macular degeneration and epiretinal membreane/vitreomacular traction who do not respond to first course of Avastin~Intervention:~DRI-1 Swept source OCT, Atlantis, Topcon"
89548651|NCT02443129|Experimental|Retrospective analysis|"All patients pictured with DRI-OCT~Intervention:~DRI-1 Swept source OCT, Atlantis, Topcon"
89548652|NCT02438215|Experimental|IRX4204|IRX4204 20 mg QD for Days 1-30
89548653|NCT03193723|Active Comparator|Group A|US guided five step field block will be performed
89548654|NCT03193723|Active Comparator|Group B|Spinal anesthesia will be administered in sitting position
89548655|NCT04483609||pre-test Group|10 people with multiple sclerosis. The eligibility criteria were: (1) age 18-65; (2) definitive diagnosis of MS according to McDonald criteria; (3) ability to read and write in Turkish. The exclusion criteria are: (1) acute attacks of MS (within 3 months); (2) cognitive impairment (Mini Mental test result 24 points and below); (3) any chronic disease other than MS; (4) active malignant tumors; (5) symptomatic urinary tract infections; (6) patients who changed treatment within the test-retest period.
89548656|NCT04483609||Validation and Reliability Group|80 people with multiple sclerosis. The eligibility criteria were: (1) age 18-65; (2) definitive diagnosis of MS according to McDonald criteria; (3) ability to read and write in Turkish. The exclusion criteria are: (1) acute attacks of MS (within 3 months); (2) cognitive impairment (Mini Mental test result 24 points and below); (3) any chronic disease other than MS; (4) active malignant tumors; (5) symptomatic urinary tract infections; (6) patients who changed treatment within the test-retest period.
89548657|NCT04483453|Experimental|EXPL feeding regimen|Lower protein / lower estimated glycemic index regimen
88961729|NCT04603677||Convalescent phase of SARS-CoV-2 infection|Participants with a previous diagnosis of SARS-CoV-2 infection, now in the convalescent phase of disease. Intervention will not be implemented in this study.
88961730|NCT04575207|Experimental|caFFR-guided|Participants who are randomly assigned to caFFR-guided group will receive the detection of Coronary Angiography-Derived Fractional Flow Reserve (caFFR) Measurement System. The online caFFR value is used to guide the PCI strategy. If caFFR ≤ 0.80, PCI treatment will be performed in lesions and optimal medicine treatment will be performed when caFFR > 0.80.
89207989|NCT00975663|Active Comparator|2|Current tacrolimus and MMF dosing strategies
89548658|NCT04483453|Active Comparator|CTRL feeding regimen|Standard protein / standard glycemic index regimen
89548659|NCT02438293||children undergoing cardiac surgery|paediatric patients with a congenital heart disease undergoing elective cardiac surgery
88961731|NCT04575207|Active Comparator|FFR-guided|Participants who are randomly assigned to FFR-guided group will receive the detection of pressure wire. The FFR value is used to guide the PCI strategy. If FFR ≤ 0.80, PCI treatment will be performed in lesions and optimal medicine treatment will be performed when FFR > 0.80.
88961732|NCT04567420|Experimental|Arm A|Palbociclib/Fulvestrant Combination
88961733|NCT04567420|Active Comparator|Arm B|Adjuvant Therapy
89548660|NCT03193411|Other|microkeratome group|30 eyes were treated by microkeratome
89548661|NCT03193411|Other|femtosecond group|30 eyes were treated by femtosecond laser
89548662|NCT02437825|Experimental|octreotide treatment|The studied drug Octreotide 100 mcg will be administered I.V in the evening prior to surgery and for two weeks on a thrice daily basis.
89548663|NCT02437825|Placebo Comparator|placebo treatment|plasebo will be administrated I.V in the evening prior to surgery and two weeks on a thrice daily basis
89548664|NCT03192319|Experimental|2years to 5years after HCT|Patients will be vaccinated with Zostavax from 2years to 5years after hematopoietic stem cell transplantation
89548665|NCT03192319|Active Comparator|5years to 10years after HCT|Patients will be vaccinated with Zostavax from 5years to 10years after hematopoietic stem cell transplantation
89548666|NCT03192319|Active Comparator|6 month after chemotherapy for leukemia|Patients will be vaccinated with Zostavax 6 months after the leukemia is cured with chemotherapy
89548667|NCT03192319|Active Comparator|healthy people|Healthy adults over 50 years old will be vaccinated with Zostavax
89548668|NCT02442895||Long luteal protocol|Subcutaneous administration of GnRH agonist (Triptorelina pamoato 0.1 mg/ml) in the medium-luteal phase (21th day) of the cycle before the stimulation. The next menstruation, in the presence of estradiol level (E2)<30pg/ml and in the absence of follicular cysts, the gonadotropin stimulation was begun. In the presence of at least three follicles of diameter ≥18mm was induced final oocyte maturation by administration of human chorionic gonadotropin (hCG).
89548669|NCT02442895||Daily antagonist protocol|GnRH antagonist (cetrorelix acetate 0.25 mg) was administered subcutaneously with a fixed protocol from the day +6 of stimulation or with a flexible protocol from the day in which at least one follicle reached a diameter of 14mm. In both protocols GnRH antagonist was administered until the day of the assumption of hCG. Recombinant Follicle Stimulating Hormone (rFSH) was administered from the 3rd day of menstruation at a dose of 150-300 IU/die according to the characteristics of women. The hCG was administered when at least three follicles had reached 18 mm in diameter and estradiol levels were higher than 150 pg/mL/dominant follicle.
89548670|NCT02442895||Depot antagonist protocol|"GnRH antagonist (Cetrorelix acetate 0.25 mg) was administered subcutaneously with a fixed or flexible protocol until the day of the assumption of hCG. Corifollitropila alfa was used at dose of 100μg (in women with weight ≤60 kg and age ≤36 years) or 150μg (in women with weight> 60 kg of any age or weight ≥50 kg and age greater than 36 years). Corifollitropina alfa was administered subcutaneously in the day +3 and in the day +5 or +6 was supplemented with rFSH at doses 112-300 IU/day.~The hCG was administered when at least three follicles had reached 18 mm in diameter and estradiol levels were higher than 150 pg/mL/dominant follicle."
89548671|NCT02442583|No Intervention|Arm 1: Phase 1, Step 1|In this part, 15 early stage colorectal cancer survivors will fill out surveys and have a recorded phone interview regarding their physical activity and sedentary behaviors, to inform the creation of a brochure about sedentary behaviors.
89548672|NCT02442583|No Intervention|Arm 2: Phase 1, Step 2|5 early stage colorectal cancer survivors will have recorded telephone interviews to provide feedback about the brochure.
89548673|NCT02442583|Experimental|Arm 3: Phase 2|15 early stage colorectal cancer survivors will complete a baseline survey about sedentary behaviors, then wear an Actigraph device and self-report their sedentary activities for one week. They will receive feedback regarding their activity, and one month after receiving the feedback will participate in a phone survey regarding use of the brochure, physical activity and sedentary behaviors.
89548674|NCT02438059|Experimental|Intervention|Access to the SoSu-liv website and app for 38 weeks.
89548675|NCT02438059|No Intervention|Control|No treatment for 38 weeks.
89548676|NCT03193489|Experimental|Exercise therapy|Parkinson's group takes part in a treadmill treatment that takes place 3 times a week for 2 years.
89548677|NCT03192163||ResearchMatch Group|
89548678|NCT03192163||Northwestern Center for Ethnic Skin Group|
89548679|NCT03193255|Active Comparator|No daily lens rubbing|Daily lens disinfection with OPHTECS cleadew GP without lens rubbing
89548680|NCT03193255|Active Comparator|Daily rubbing|Daily lens disinfection with OPHTECS cleadew GP after lens rubbing with cleadew GP
89548681|NCT03193255|Active Comparator|Daily rubbing with separate cleaner|Daily lens disinfection with OPHTECS cleadew GP after lens rubbing with a daily lipid cleaner
89548682|NCT03193255|Active Comparator|Daily rubbing and weekly protein removal|Daily lens disinfection with OPHTECS cleadew GP after daily lipid cleaner followed by weekly protein removal treatment
89548683|NCT02442817|Active Comparator|Linagliptin patients with schizophrenia|This group will be made up of 8 participants with schizophrenia and minimal thought disorder who have been stable and taking their prescribed antipsychotics; they will have 12 weeks of treatment and week for assessment. They will receive linagliptin, 5 mg by mouth once per day, while continuing their antipsychotic treatment.
88961734|NCT04565119||Severe traumatic brain injury (TBI)|This observational study is ancillary to the Brain Oxygen Optimization in Severe TBI Phase 3 (BOOST-3) trial (NCT 03754114). All participants in Bio-BOOST are enrolled in BOOST-3.
89548684|NCT02442817|Active Comparator|Linagliptin control group|This group will be made up of 10 control participants with no diagnosis of mental disorder; they will have 12 weeks of treatment and week for assessment. They will receive linagliptin, 5 mg by mouth once per day.
89548685|NCT02437747|Experimental|SRP+ Aloe Group|Scaling and root planing was done along with application of aloe vera gel as an adjunct in selected sites.
89548686|NCT02437747|Sham Comparator|SRP Group|Only scaling and root planing was done on the opposite side.
89548687|NCT02437357|Experimental|Metacognitive Training|D-MCT is conceptualized as a variant of cognitive behavioral therapy (CBT) that uses a metacognitive perspective to focus on the modification of cognitive biases by using creative and engaging strategies (e.g., multimedial presentation). The training seeks to enable group members to recognize and correct the often automatic and unconscious depressive thought patterns, in part by viewing this depressive thought process at a distance (i.e., depersonalizing). Besides dysfunctional assumptions about one's thought processes, more general cognitive biases, which have been identified by basic research are at the core of the D-MCT. Finally, dysfunctional coping-strategies (i.e., thought suppression, rumination as problem-solving) are discussed and modified.
89548688|NCT02437357|Active Comparator|Positivity Training|"Positivity Training (PT) is a euthymic therapy group based on cognitive behavioral therapy (CBT) with a focus on the education and training of sensual enjoyment and pleasure. Aim of the training is to reduce depressive symptomatology by increasing the ability to enjoy and to (re-)install positive sensory experiences. Therefore, group members are informed about the impact of positive experiences on well-being and the awareness of the five senses is trained in different practical exercises (hearing, sight, smell, taste, and touch)."
89548689|NCT03193177||the 21-day fasting-like diet|Participants will be supplied with fasting-like diet containing only 5% of normal calorie intake. Physical examinations will be performed on day 0, 4,7,14,21 and 51 after the clinical trial.
89548690|NCT03503617|Experimental|RehabTouch Exercise Program|Participants will perform targetted movement exercises by interacting with the RehabTouch pucks, as described and monitored on a computer. Participants will be asked to exercise at least 3 hours per week for 3 consecutive weeks.
89548691|NCT03503617|Active Comparator|Conventional tabletop exercise program|Conventional tabletop exercise program is a traditional exercise program described in a booklet similar to what is typical provided to stroke patients upon their discharge from the hospital. Participants will be asked to perform these exercises at least 3 hours per week for 3 consecutive weeks.
89548692|NCT02437591|Experimental|fidaxomicin|tablet twice daily
89548693|NCT02442739|Experimental|Ketamine|oral ketamine 0.5 mg/kg mixed with syrup
89548694|NCT02442739|Placebo Comparator|Placebo|oral placebo (syrup)
89548695|NCT03189667|Experimental|Drug coated balloon angioplasty|"Vessel preparation with Pre dilatation~Vessel treatment with Drug-coated balloon"
89548696|NCT03189667|Active Comparator|Plain balloon angioplasty|"Vessel preparation with Pre dilatation~Vessel treatment with additional Plain balloon angioplasty:"
89548697|NCT02437201|Experimental|Liberty Group|Weekly intensive support group for women with children who have suffered or are still suffering from domestic abuse (DA).
89548698|NCT02437201|No Intervention|Control group|
89548699|NCT02437123|Experimental|The Cedar Project mHealth Intervention|The Cedar Project mHealth intervention consists of a package of culturally-safe supports, including a mobile phone and long-distance cellular plan, weekly two-way text messaging, and support from community-based Cedar Advocates.
89548700|NCT02437123|No Intervention|Comparison group|The comparison group will be sampled from The Cedar Project, an ongoing cohort study of young Indigenous people who use drugs under its existing informed consent with no change whatsoever to their participation in the overall study.
89548701|NCT03022903|Other|Photodynamic Therapy (PDT)|PDT with ALA (photosensitizer) for 3 hours
89548702|NCT02442037|Experimental|UCMSC group|Human umbilical cord MSCs are administrated to patients by three intravenous infusion
89548703|NCT02442037|Other|Control group(Normal saline)|Patients will receive normal saline at the same time points as that in experimental group.
89548704|NCT02442427|Active Comparator|Palivizumab|A single dose of IV palivizumab
89548705|NCT02442427|Placebo Comparator|Placebo|An equivalent volume of 0.9% normal saline.
89548706|NCT02442193|Experimental|Individual Placement and Support|Individual Placement and Support
89548707|NCT02442193|No Intervention|Treatment as Usual|Treatment as Usual is comprised of routine clinical care.
89548708|NCT03189511|Experimental|Experimental|Volunteers receive calorimetric tests and FDG PET scans pre and post 2 weeks of Fluvastatine.
89548709|NCT04483687|Experimental|Filgotinib 200 mg (Main Study - Blinded)|Participants will receive filgotinib 200 mg + placebo to match (PTM) filgotinib 100 mg for up to 16 weeks.
89548710|NCT04483687|Experimental|Filgotinib 100 mg (Main Study - Blinded)|Participants will receive filgotinib 100 mg + PTM filgotinib 200 mg for up to 16 weeks.
89548711|NCT04483687|Placebo Comparator|Placebo (Main Study - Blinded)|Participants will receive PTM filgotinib 200 mg + PTM filgotinib 100 mg for up to 16 weeks.
89548712|NCT04483687|Experimental|Filgotinib 200 mg (LTE)|"Before study-wide unblinding, participants will receive filgotinib 200 mg + PTM filgotinib 100 mg.~After study-wide unblinding, participants will receive filgotinib 200 mg."
89548713|NCT04483687|Experimental|Filgotinib 100 mg (LTE)|"Before study-wide unblinding, participants will receive filgotinib 100 mg + PTM filgotinib 200 mg.~After study-wide unblinding, participants will receive filgotinib 100 mg."
88961735|NCT04556591|Active Comparator|Control|Participants will wear the Fitbit® and provide daily reports of health related quality of life (HRQOL) over a three-month (90 day) period (without the personalized feedback).
88961736|NCT04556591|Experimental|Just-in-time adaptive intervention (JITAI)|Participants will wear the Fitbit®, provide daily reports of health related quality of life (HRQOL) and receive personalized pushes over a three-month (90 day) period.
89025219|NCT00440622|Experimental|1|GHer
89548714|NCT02065141|Other|Healthy|"screening visit: body weight and composition by DXA, height, and vital signs will be assessed.~study day: stable isotope infusions with blood draws, sip feed"
89548715|NCT02065141|Other|Chronic Obstructive Pulmonary Disorder|"screening visit: body weight and composition by DXA, height, and vital signs will be assessed. Subjects may sign a medical release form to obtain medical information about them that will help determine study eligibility or can be used for later coding.~study day: stable isotope infusions with blood draws, sip feed"
89548716|NCT02065141|Other|Chronic Heart Failure|"screening visit: body weight and composition by DXA, height, and vital signs will be assessed. Subjects may sign a medical release form to obtain medical information about them that will help determine study eligibility or can be used for later coding.~study day: stable isotope infusions with blood draws, sip feed"
89207990|NCT00748241|Experimental|Astra Tech Fixture ST|
89207991|NCT00570128|Active Comparator|Donepezil HCl|
89548717|NCT03189043|Experimental|Test|Use of antimicrobial surface
89548718|NCT03189043|No Intervention|Control|No antimicrobial surface
89548719|NCT01654315|Experimental|Experimental: Myomo Only Group|"Experimental: Myomo Only Group Patients are administered rehabilitative therapy known as repetitive task specific practice (RTP) using only the Myomo robotic device targeting their affected arms on 3 days/week, in 1/2 hour increments, during an 8-week period."
89548720|NCT01654315|Experimental|Experimental: Myomo + RTP Group|Experimental: Myomo + RTP Group Patients are administered rehabilitative therapy using both the Myomo robotic device and RTP targeting their affected arms on 3 days/week in 1/2 hour increments, during an 8 week period. These patients engage in activities that emphasize use of their affected arms repetitively, with the device providing assistance as needed with movement through the arm's range of motion. As patients progress, the amount of assistance provided by the device during the activities is reduced.
89548721|NCT01654315|Active Comparator|Active Comparator: RTP Group|Active Comparator: RTP Group Patients are administered rehabilitative therapy using only RTP that is targeting their affected arms on 3 days/week during a 8 week period. In this condition, patients engage in activities that emphasize use of their affected arms repetitively, with the therapist providing assistance as needed with movement through the arm's range of motion. As patients progress, the amount of assistance provided by the therapist during the activities is reduced.
89548722|NCT03188575|Experimental|iCBT for Depression and Anxiety|SilverCloud Internet-Delivered Cognitive Behavioural Therapy
89548723|NCT03188575|Active Comparator|Waiting List|Waiting list control
89548724|NCT05233735|Other|topical treatment|Topical Betamethasone for the Treatment of Vitiligo Disease
89548725|NCT05233735|Experimental|Enhanced Transcutaneous Delivery|Enhanced Transcutaneous Delivery of Topical Betamethasone after a treatment with Tixel device for the Treatment of Vitiligo Disease
89548726|NCT03188341||vascular surgery patients|"clinically concealed repolarization disturbances during vascular surgery procedure~clinically disclosed cardiac complications during and after vascular surgery procedure"
89548727|NCT02441959|Active Comparator|Endoscopic Discectomy|Randomized to Endoscopic Discectomy Lumbar discectomy Endoscopic Intervention type is lumbar endoscopic surgery- no device or drug
89548728|NCT02441959|Active Comparator|Open Discectomy|Randomized to Open Discectomy Lumbar discectomy Open Intervention type is lumbar open surgery- no device or drug
89548729|NCT02441959|Other|Open Discectomy-Cross Over Arm|Randomized to Endoscopic Discectomy Cross over to lumbar discectomy open based on surgeons assessment pre or post incision Intervention type is lumbar open surgery- no device or drug
89548730|NCT02436499|Experimental|Treatment with Botox and fMRI screening|"Following baseline screening, participants will receive two subsequent treatments with botulinum-A toxin, each separated by 12 weeks. Participants will receive standardized botulinum-A toxin dosing for chronic migraine prophylaxis, comprised of 155 total units given at 31 specified sites across 7 head/neck muscles (protocol to be explicitly described in full protocol). Second dose of botulinum-A toxin will either be maintained at 155 total units as dosed initially, or be increased to 195 total units, depending on response to clinical questionnaires and examination to evaluate response and efficacy (to be described in full protocol, consistent with the Follow-the-Pain Injection Paradigm)."
89548731|NCT02434315|Active Comparator|Group A - Control|FreeStyle Libre Pro 3 sensor wears
89548732|NCT02434315|Experimental|Group B - Intervention|FreeStyle Libre Pro 4 sensor wears, 2 with reviews
89025220|NCT00440622|Experimental|2|CapHer
89025221|NCT00443417|Placebo Comparator|1|
89548733|NCT02434315|Experimental|Group C - Intervention|FreeStyle Libre Pro 6 sensor wears, 4 with reviews
89548734|NCT02514239|Experimental|Intravenous Infusion of BI 836909 (0.2 μg/d)|
89548735|NCT02514239|Experimental|Intravenous Infusion of BI 836909 (0.4 μg/d)|
89548736|NCT02514239|Experimental|Intravenous Infusion of BI 836909 (0.8 μg/d)|
89548737|NCT02514239|Experimental|Intravenous Infusion of BI 836909 (1.6 μg/d)|
89548738|NCT02514239|Experimental|Intravenous Infusion of BI 836909 (3.2 μg/d)|
89548739|NCT02514239|Experimental|Intravenous Infusion of BI 836909 (6.5 μg/d)|
89548740|NCT02514239|Experimental|Intravenous Infusion of BI 836909 (13 μg/d)|
89548741|NCT02514239|Experimental|Intravenous Infusion of BI 836909 (25 μg/d)|
89548742|NCT02514239|Experimental|Intravenous Infusion of BI 836909 (50 μg/d)|
89548743|NCT02514239|Experimental|Intravenous Infusion of BI 836909 (100 μg/d)|
89548744|NCT02514239|Experimental|Intravenous Infusion of BI 836909 (200 μg/d)|
89548745|NCT02514239|Experimental|Intravenous Infusion of BI 836909 (400 μg/d)|
89548746|NCT02514239|Experimental|Intravenous Infusion of BI 836909 (800 μg/d)|
89025222|NCT00443417|Active Comparator|2|200mg qd
89025223|NCT00443417|Active Comparator|3|200mg bid
89025224|NCT00443417|Active Comparator|4|400mg qd
89025225|NCT03278444|Experimental|One-drug Regimes|Basic drugs therapy of HCC
89025226|NCT03278444|Experimental|Two-Drug Regimens|Basic drugs therapy of HCC; Arginine hydrochloride
89025227|NCT03278444|Experimental|Three-Drug Regimens|Basic drugs therapy of HCC; Arginine hydrochloride;Trimetazidine hydrochloride
89207992|NCT00570128|Placebo Comparator|Placebo|
89025228|NCT00440739|Placebo Comparator|1|1=placebo
89548747|NCT02436421|Other|Atrial Fibrillation BPA|The alert will notify providers when patients with atrial fibrillation are not on anticoagulation
89548748|NCT02436421|Other|Hypertension BPA|The alert will notify providers when patients have elevated blood pressure
89025229|NCT00440739|Active Comparator|2|2= etoricoxib
89025230|NCT00440739|Active Comparator|3|3=falvoxate
89025231|NCT00440739|Active Comparator|4|etoricoxib and flavoxate
89548749|NCT02436421|Other|Atrial Fibrillation and Hypertension BPA|Providers in this arm will receive both alerts
89548750|NCT03189355|Experimental|Patients With Septic Shock|Blood sampling on D1 PTP1B + zonulin +PAXGENE tube +aprotinin tube and D4 zonulin Bioelectrical impedance vector analysis on D1 + D4 Muscular echography on D1 + D4
89548751|NCT02441881|Active Comparator|Venefit|Endovenous radiofrequency ablation device for truncal great saphenous vein ablation
89548752|NCT02441881|Active Comparator|Radiofrequency Induced Thermal Therapy|Endovenous radiofrequency ablation device for truncal great saphenous vein ablation
89548753|NCT02441881|Active Comparator|Endovenous Radiofrequency|Endovenous radiofrequency ablation device for truncal great saphenous vein ablation
89548754|NCT02441647|Experimental|Experimental group|
89548755|NCT02441725|Other|Pulmonary Rehabilitation Patients|"Validation of the 1-minute sit-to-stand test; for participants who consent including a extended daily assessment period of physical activity and patient-reported symptoms of exacerbations:~Male and female COPD inpatients (≥40 years of age) from two pulmonary rehabilitation clinics (Klinik Barmelweid and Zürcher Höhenklinik Wald)"
89548756|NCT02441725|Other|Acute Care Hospital Patients|"Validation of the 1-minute sit-to-stand test, including daily assessment of physical activity and patient-reported symptoms of exacerbations:~Male and female COPD inpatients from two acute care hospitals (≥40 years of age; Stadtspital Waid and Spital Uster)"
89548757|NCT04483271|Experimental|n-3FA group|Dietary Supplement: 1,000 mg of wild salmon and fish oil complex once daily, which contains 300 mg of omega3-FA for 2 months.
89548758|NCT04483271|No Intervention|Control group|No intervention was given
89548759|NCT02434237||patients|
89548760|NCT02434237||healthy subjects|
89548761|NCT02336009|Experimental|total wrist arthroplasty, Trimed|This is a pilot study where all patients will be operated with the Trimed total wrist arthroplasty.
89548762|NCT03117283|Experimental|LTG with Bursectomy|laparoscopic D2 radical total gastrectomy with bursectomy using a left outside bursa omentalis approach
89548763|NCT03117283|Sham Comparator|LTG without Bursectomy|laparoscopic D2 radical total gastrectomy without bursectomy
89548764|NCT02331563|Experimental|0.5% bupivacaine|group 1 receiving TAP block with 0.25% bupivacaine 20 ml for each side of abdomen Bupivacaine is a local anaesthetic agent. transvers abdominis plane block with %0.5 Bustesin which is diluated with normal saline
89548765|NCT02331563|Active Comparator|dexmedetomidine added bupivacaine|group II receiving TAP block with 0.25% bupivacaine + 0.5 mcg/kg dexmedetomidine each side of abdomen
89548766|NCT03188107||Risky Infants|Infants that have risk of developing motor impairment, or infants diagnosed as Spina Bifida, Down Syndrome ect.
89548767|NCT03188107||Healthy Infants|Healthy infants that have normal motor development
89548768|NCT02336243|Experimental|Docosahexaenoic acid (DHA)|Docosahexaenoic acid (DHA) 200 mg capsules, 3 capsules by mouth every day, from early gestation until the end of pregnancy
89548769|NCT02336243|Placebo Comparator|Placebo|Placebo 200 mg capsules, 3 capsules by mouth every day, from early gestation until the end of pregnancy
89548770|NCT02331641||Major hepatectomy (MH)|Patients who underwent MH for CLM instead of multiple minor hepatectomy (MMH)
89548771|NCT02331641||Multiple minor hepatectomy (MMH)|Patients who underwent MMH for CLM instead of MH
89548772|NCT02436343||obese pregnant women|"pregnant women wit body mass index more than or equal to 30 kg/m2 will be subjected to four serial echocardiograms in the 3 trimesters of pregnancy and in the postpartum state.~Height, weight, systolic and diastolic blood pressures will be measured at each echocardiographic evaluation."
89548773|NCT02436343||lean pregnant women|"pregnant women wit body mass index less than or equal to 25kg/m2 will be subjected to four serial echocardiograms in the 3 trimesters of pregnancy and in the postpartum state.~Height, weight, systolic and diastolic blood pressures will be measured at each echocardiographic evaluation."
89548774|NCT02330939|Active Comparator|Low fat- Low glycemic index|Participants consumed a meal with low glycemic index and poor in fat
89548775|NCT02330939|Experimental|MUFA- Low glycemic index|Participants consumed a meal with low glycemic index and rich in MUFA
89548776|NCT02330939|Experimental|SAFA- Low glycemic index|Participants consumed a meal with low glycemic index and rich in SAFA
89548777|NCT02330939|Active Comparator|Low fat- High glycemic index|Participants consumed a meal with high glycemic index and low in fat
89025232|NCT00478725|Experimental|Part A|Absorption, Distribution, Metabolism and Elimination of a Single Oral [14C] Labeled Dose of GW786034
89025233|NCT00478725|Experimental|Part B|characterize the pharmacokinetics of a single IV dose of GW786034
89025234|NCT00440778|Experimental|Gr 1 - intracoronary + infusion|abciximab bolus 0.25 mg/kg ic + 12 hrs iv infusion
89548778|NCT02330939|Experimental|MUFA- High glycemic index|Participants consumed a meal with high glycemic index and rich in MUFA
89548779|NCT02330939|Experimental|SAFA- High glycemic index|Participants consumed a meal with high glycemic index and rich in SAFA
89548780|NCT02331017|Experimental|Bimodal users|"Bilateral-bimodal users with moderate-to-severe hearing loss who use hearing aids for at least 75% of their waking hours.~Administration of Speech perception tests and self-rating questionnaire"
89548781|NCT02335931||Charcot foot|Patients with Charcot foot and diabetes mellitus 1 or 2
89548782|NCT02335931||No charcot foot|patients with diabetes mellitus type 1 or 2
89548783|NCT02331173||Main Study Group|All subjects enrolled in this study will be seen every 6 months following the screening visit. During the 3 main study visits, a series of tests will be performed to assess visual function. Some of these tests are part of routine care that patients would receive on an annual basis regardless of study participation. Other tests are being performed to determine if they are effective at monitoring disease progression in this population. For each of the 3 main study visits, testing may be spread over multiple days to ensure completion of all tests.
89548784|NCT02331173||Carbonic anhydrase inhibitor sub-study|Subjects with maculoschisis may be offered topical treatment with CAIs. These subjects will be asked to visit the study site at 1 month and 3 months after starting topical treatment. During these additional visits, subjects will undergo a dilated eye exam, BCVA, and SD-OCT imaging to assess efficacy of treatment (i.e. reduction of maculoschisis).
89548785|NCT02335853||women with metabolic syndrome and overactive bladder|"women with urinary urgency+frequency+nocturia and current ATP III criteria define the metabolic syndrome as the presence of any three of the following five traits:~Abdominal obesity, defined as a waist circumference in men ≥88 cm~Serum triglycerides ≥150 mg/dL (1.7 mmol/L) or drug treatment for elevated triglycerides~Serum HDL cholesterol <40 mg/dL (1 mmol/L) in men and <50 mg/dL (1.3 mmol/L) in women or drug treatment for low HDL-C~Blood pressure ≥130/85 mmHg or drug treatment for elevated blood pressure~Fasting plasma glucose (FPG) ≥100 mg/dL (5.6 mmol/L) or drug treatment for elevated blood glucose"
89548786|NCT02335853||women with overactive bladder|women with urinary urgency+frequency+nocturia
89548787|NCT02335853||healthy control group|women not overactive bladder and metabolic syndrome
89548788|NCT02709109|Experimental|Sequence 1: VX-371 + Hypertonic Saline (HS), then HS|Participants received 85 microgram (mcg) VX-371 diluted in 3 milliliter (mL) 4.2 percent (%) HS through oral nebulized inhalation twice daily for 28 days (Day 1 to Day 28) in treatment period 1 followed by a 28 days washout period (Day 29 to Day 56) and then received 3 mL 4.2% HS through oral nebulized inhalation twice daily for 28 days (Day 57 to Day 84) in treatment period 2. Participants also received a stable dose of 2 tablets of Orkambi (lumacaftor 400 milligram (mg)/ivacaftor 250 mg) orally every 12 hours with fat-containing food throughout the study as part of their cystic fibrosis (CF) standard of care.
89548789|NCT02709109|Experimental|Sequence 2: HS, then VX-371 + HS|Participants received 3 mL 4.2% HS through oral nebulized inhalation twice daily for 28 days (Day 1 to Day 28) in treatment period 1 followed by a 28 days washout period (Day 29 to Day 56) and then received 85 mcg VX-371 diluted in 3 mL 4.2% HS through oral nebulized inhalation twice daily for 28 days (Day 57 to Day 84) in treatment period 2. Participants also received a stable dose of 2 tablets of Orkambi (lumacaftor 400 mg/ivacaftor 250 mg) orally every 12 hours with fat-containing food throughout the study as part of their CF standard of care.
89548790|NCT02709109|Experimental|Sequence 3: VX-371 + Placebo, then Placebo|Participants received 85 mcg VX-371 diluted in 3 mL 0.17% Saline (placebo) through oral nebulized inhalation twice daily for 28 days (Day 1 to Day 28) in treatment period 1 followed by a 28 days washout period (Day 29 to Day 56) and then received 3 mL 0.17% saline (placebo) through oral nebulized inhalation twice daily for 28 days (Day 57 to Day 84) in treatment period 2. Participants also received a stable dose of 2 tablets of Orkambi (lumacaftor 400 mg/ivacaftor 250 mg) orally every 12 hours with fat-containing food throughout the study as part of their CF standard of care.
89548791|NCT02709109|Experimental|Sequence 4: Placebo, then VX-371 + Placebo|Participants received 3 mL 0.17% saline (placebo) through oral nebulized inhalation twice daily for 28 days (Day 1 to Day 28) in treatment period 1 followed by a 28 days washout period (Day 29 to Day 56) and then received 85 mcg VX-371 diluted in 3 mL 0.17% saline (placebo) through oral nebulized inhalation twice daily for 28 days (Day 57 to Day 84) in treatment period 2. Participants also received a stable dose of 2 tablets of Orkambi (lumacaftor 400 mg/ivacaftor 250 mg) orally every 12 hours with fat-containing food throughout the study as part of their CF standard of care.
89548792|NCT01979003|Experimental|Fluorescein Injection|All research participants will receive fluorescein injection through existing intravenous line during the operative procedure. This will consist of one ampule (5 cc) injected intravenously 5- 10 minutes prior to ligation of the uterine arteries.
89548793|NCT02436109||study group|elective cesarean delivery patients
89548794|NCT01827761||Questionnaire|After informed consent for this study is obtained, patients will be given questionnaire #1 that includes rating their knowledge of the side effects of treatment, their understanding of the treatment schedule, what do in the event of complication, how to reach the medical team and an assessment of the level of anxiety. The questionnaire will be repeated at day 1 of the first chemotherapy treatment to assess the effectiveness of the teaching session. In addition, questionnaire #3 will be administered at day 1 of cycle 2 of their first chemotherapy.
89548795|NCT03188029|Experimental|adrenocortical function|repeated general anesthesia with 0.3 mg/kg etomidate, 0.5 mg/kg propofol and 0.5 mg/kg succinylcholine, every 2 days for 3 to 4 weeks for electroconvulsive therapy.
89548796|NCT02441569|Experimental|Common factors intervention|Children and parents in this arm will be cared for by a provider who has received brief training in common factors patient engagement skills (the intervention) for use in addition to standard anxiety-related advice. Thus this arm will receive common factors engagement training for provider.
89548797|NCT02441569|Active Comparator|Control|Children and parents in this arm will be cared for by a provider who is able to offer standard pediatric anxiety-related advice (the control intervention). Families will receive standard pediatric advice for childhood anxiety.
89548798|NCT04289051|Experimental|HYDRAL Oral Rinse|Subjects use the oral rinse four times daily adding to a regular oral hygiene routine with a fluoride toothpaste and a soft tooth brush.
89025235|NCT00440778|Experimental|Gr 2 - intracoronary|100% abciximab bolus dose 0.3 mg/kg ic
89025236|NCT00440778|Active Comparator|Gr 3 - intravenous|abciximab bolus dose 0.25 mg/kg iv + 12 hrs iv infusion
89025237|NCT00440778|Experimental|Gr 4 - intravenous|100% abciximab bolus dose 0.3 mg/kg iv
89025238|NCT03278405|Experimental|Intervention Arm|Treatment with avelumab
89548799|NCT04289051|Active Comparator|BIOTENE® Oral Rinse|Subjects use the oral rinse four times daily adding to a regular oral hygiene routine with a fluoride toothpaste and a soft tooth brush.
89025239|NCT00440817||Patients with lymphoma|Lymphoma Occurring in Patients with Rheumatoid Arthritis or Crohn's Disease
89025240|NCT00443612|Experimental|1|"12 weeks on treatment 1~2 week washout period~12 weeks on treatment 2"
89548800|NCT04289051|Placebo Comparator|Placebo Oral Rinse|Subjects use the oral rinse four times daily adding to a regular oral hygiene routine with a fluoride toothpaste and a soft tooth brush.
89548801|NCT02441413|Experimental|HRCT scans|HRCT scan will be taken
89548802|NCT03188419||1|Retrospective chart review of patients with inherited immunodeficiency diseases requiring allogeneic hematopoietic stem cell transplant (allo HSCT)
89548803|NCT03117595|Active Comparator|BF|Interventions: Intrathecal administration -Bupivacaine 2.5mg (0.5ml) + Fentanyl 25mcg (0.5ml) + 1ml sterile water in one shot Ephedrine 3-5mg in aliquots in the event of hypotension Promethazine 12.5 - 25mg in the event of vomiting or significant pruritus naloxone 2mcg/kg in the event of respiratory distress
89548804|NCT03117595|Active Comparator|BFM|Interventions: Intrathecal administration - Bupivacaine 2.5mg (0.5ml) + fentanyl 25mcg (0.5ml) + 0.25mg morphine (0.25ml) + 0.75ml sterile water in one shot ephedrine 3-5mg in aliquots for hypotension Promethazine 12.5 - 25mg for vomiting or significant pruritus Naloxone 2mcg/kg in the event of respiratory distress
89548805|NCT02434159|Active Comparator|Scan|Heart scan prior to device insertion
89548806|NCT02434159|No Intervention|No scan|No heart scan prior to device insertion
89548807|NCT02039531|Experimental|Plasma rich in growth factors (PRGF)|"Patients in this group will receive one cycle of three intra-articular injections of PRGF every 15 days.~Procedure for the application of the treatment:~1. Study Group or PRGF group~Blood sample :~Taken minimum after 4 hours of fasting and drinking only water in order to maintain low levels of glucose.~20 cc of peripheral blood will be taken by sterile systems with Sodium Citrate buffer to avoid hemolysis.~Spinning of the sample:~8 minutes at 1800 rpm .~getting the blood fraction containing the PRGF~activation of PRGF with 50 ul of 10% CaCl2 per ml of plasma.~the application of PRGF should not exceed 90 minutes after the blood sample extraction in order to avoid risk of contamination."
89548808|NCT02039531|Active Comparator|Hyaluronic acid (Durolane®)|Patients in this group will receive a single intra-articular injection at visit 1.
89548809|NCT02435875||hypertensive|Patients with confirmed hypertension or systolic blood pressure≥140 mmHg or diastolic blood pressure≥90 mmHg without antihypertensive treatment.After anesthesia induction,baroreflex sensitivity will be measured by nitroglycerin.
89548810|NCT02435875||nonhypertensive|systolic blood pressure <140 mmHg and diastolic blood pressure<90 mmHg.After anesthesia induction,baroreflex sensitivity will be measured by nitroglycerin.
89548811|NCT02331251|Experimental|Arm 1|Pembrolizumab 2mg/kg administered intravenously over 30 minutes every 3 weeks Gemcitabine 1000 mg/m2 on day 1 and day 8 every 21 days
89548812|NCT02331251|Experimental|Arm 2|Pembrolizumab 2mg/kg administered intravenously over 30 minutes every 3 weeks Gemcitabine 900 mg/m2 on day 1 and 8 and docetaxel 75 mg/m2 on day 8 every 21 days
89548813|NCT02331251|Experimental|Arm 3|Pembrolizumab 2mg/kg administered intravenously over 30 minutes every 3 weeks Gemcitabine 1000 mg/m2 and nab-paclitaxel 125 mg/m2 on day 1 and day 8 every 21 days
89548814|NCT02331251|Experimental|Arm 4|Pembrolizumab 2mg/kg administered intravenously over 30 minutes every 3 weeks Gemcitabine 1000 mg/m2 and vinorelbine 25 mg/m2 on day 1 and day 8 every 21 days
89548815|NCT02331251|Experimental|Arm 5|Pembrolizumab 2mg/kg administered intravenously over 30 minutes every 3 weeks Irinotecan 300 mg/m2 on day 1 every 21 days
89548816|NCT02331251|Experimental|Arm 6|Pembrolizumab 2mg/kg administered intravenously over 30 minutes every 3 weeks Liposomal doxorubicin 30 mg/m2 on day 1 every 21 days
89548817|NCT02435953|Experimental|TACE-RFA|1-2 times of TACE treatment, then followed by RFA treatment.
89548818|NCT02435953|Active Comparator|TACE alone|TACE treatment several times till tumor progress to advance stage
89548819|NCT02335619|Active Comparator|Early Palliative Care|During their first oncology appointment, the intervention arm patients will self-report any symptoms related to their cancer or treatment to the study team; scores at or above a defined benchmark will be seen by Pain and Symptom Management/Palliative Care team members during or immediately after their oncology appointment. Patients will be asked to self-report symptoms once a month following recruitment, for 4 months.
89548820|NCT02335619|No Intervention|Standard Care|During their first oncology appointment, the control arm patients will self-report any symptoms related to their cancer or treatment to the study team; self-reports will be collected but not shared with the Pain and Symptom Management/Palliative Care team, and patients will continue with their oncology appointment as per standard procedure. Patients will be asked to self-report symptoms once a month following recruitment, for 4 months.
89548821|NCT02435797|Active Comparator|Nicorandil|Nicorandil for injection
89548822|NCT02435797|Placebo Comparator|normal saline|normal saline
89548823|NCT02330861|Other|Normal coronary artery|
89548824|NCT02335697|Other|Intervention|Attitude change towards female circumcision
89548825|NCT02335697|Other|No intervention|No intervention
89548826|NCT02330705|Active Comparator|Group A|IUI at time of HCG
89548827|NCT02330705|Active Comparator|Group B|IUI 12 hours after HCG
89548828|NCT02330705|Active Comparator|Group C|IUI 34-36 hours after HCG
89025241|NCT00443612|Experimental|2|"12 weeks on treatment 2~2 week washout period~12 weeks on treatment 1"
89548829|NCT04174625|Experimental|Omega3-FA group|Omega3-FA group 1000 mg wild salmon and fish oil complex (contains 300 mg of omega3-FA) once daily
89548830|NCT04174625|Experimental|Control group|VD3 group 50,000 IU/week
89025242|NCT00478803|Experimental|1, preservation|aortic valve surgery(Remodeling associated with a subvalvular aortic ring annuloplasty or double sub and supra valvular aortic annuloplasty)
89032992|NCT00529607||3|- 30 healthy volunteers regarding cardiovascular diseases (control group 2)
89548831|NCT02330783|Experimental|Bevacizumab plus Sorafenib|Bevacizumab 5mg/kg Q2w Sorafenib 400mg Bid
89548832|NCT02330783|Active Comparator|Sorafenib|Sorafenib 400mg Bid
89548833|NCT03105323||infertile women|All patients were pretreated with Gonadotropin releasing hormone agonist (decapeptyl®) 0.05 mg/day from 10 days prior to the start of menstruation. The patients'ovaries were stimulated with a recombinant follicle-stimulating hormone (FSH, subcutaneous) from day 2 of the menstrual cycle. human chorionic gonadotropin was administered when at least two follicles vary 18-22mm were observed on ultrasonography.Blood samples were collected on the day of final Human chorionic gonadotropin maturation, and serum P levels were measured.Pregnancy was defined by titers within 11 days following Embryo transfer,Clinical pregnancy was defined by the observation of intrauterine embryo heart motion by 7 weeks gestation.
89548834|NCT03105089|Active Comparator|ischemic preconditioning|ischemic preconditioning will be done after induction and before cardiopulmonary bypass by inflation the cuff of blood pressure above 200mmhg in the lower limb every 5 min for 3cycles
89548835|NCT03105089|No Intervention|control|no intervention will be done
89548836|NCT02330315|Experimental|Active tDCS + Active TUS|Subjects in the experimental group will undergo 20 minutes of active transcranial direct current stimulation (tDCS) and active transcranial ultrasound (TUS).
89548837|NCT02330315|Sham Comparator|Sham tDCS + Sham TUS|Subjects in the sham group will undergo 20 minutes of sham transcranial direct current stimulation (tDCS) and sham transcranial ultrasound (TUS).
89548838|NCT02335307||Control|Patients will continue to receive their current pain management therapy. In addition, a pain assessment questionnaire will be administered at baseline and 3 months.
89548839|NCT02335307||Implementation|Patients will undergo CYP2D6 genotyping, with results entered into the medical record to assist the physician with prescribing pain medication. In addition, a pain assessment questionnaire will be administered at baseline and 3 months.
89548840|NCT02335307||Physician assessment|At the end of the study, a 20-item survey will be administered to physicians who treated patients enrolled in the study. The survey will assess whether having CYP2D6 genotype results is useful to inform prescribing decisions for pain medication from the physician's perspective.
89548841|NCT02335385|Active Comparator|SIL-V|single incision laparoscopic varicocelectomy
89548842|NCT02335385|Active Comparator|CTL-V|conventional transperitoneal laparoscopic varicocelectomy
89548843|NCT02335151|Experimental|Desflurane|General anesthesia with Desflurane
89548844|NCT02335151|No Intervention|Propofol|General anesthesia with Propofol
89548845|NCT02330237|Active Comparator|patients|natural gels
89548846|NCT02330237|Placebo Comparator|subjects|These patients will receive that placebo (vehicle) products.
89548847|NCT03890237|No Intervention|Control|Business as usual, no intervention
89548848|NCT03890237|Experimental|Her Spaces|Starts in year 1; intervention package with 11-13 year old girls for 10 months; standard parental and community engagement. All programming ends after 10 months.
89548849|NCT03890237|Experimental|Act With Her|Starts in year 1; core intervention package with 10-13 year old girls and boys for 10 months; 6 dedicated sessions with parents; and community-level system strengthening up to 24 months.
89548850|NCT03890237|Experimental|Act With Her + Asset Transfer|Starts in year 1; core intervention package with 10-13 year old girls and boys for 10 months; asset transfer for girls over 10 months; 6 dedicated sessions with parents; and community-level system strengthening up to 24 months.
89548851|NCT03890237|Experimental|Act With Her (simple)|Starts in year 1; core intervention package with 10-13 year old girls and boys for 10 months; 6 dedicated sessions with parents; does not include community-level systems strengthening. All programming ends after 10 months.
89548852|NCT02330003|Experimental|IL-YANG PFS|IL-YANG FLU Vaccine Prefilled Syringe INJ.
89548853|NCT02330003|Active Comparator|TIV PFS|Fluarix Prefilled Syringe
89548854|NCT02330159||Novel Wound Healing Protocol|Subjects who have pilonidal disease that are being scheduled for surgical excision with our novel wound healing protocol. The disease can be actively infected or chronic.
89548855|NCT02334839||Preeclampsia|women with diagnosed preeclampsia
89548856|NCT02334839||gestational hypertension|women with diagnosed gestational hypertension without preeclampsia
89548857|NCT02334839||healthy|women without gestational hypertension or preeclampsia
89548858|NCT02329769|Experimental|PRO044 SC 6 mg/kg|Weekly subcutaneous (SC) dosing with 6 mg/kg
89548859|NCT02329769|Experimental|PRO044 IV 6 mg/kg|Weekly intravenous (IV) dosing with 6 mg/kg
89548860|NCT02329769|Experimental|PRO044 SC 9 mg/kg|Weekly intravenous (IV) dosing with 9 mg/kg
89548861|NCT02334917|Experimental|Absorbable suture closure|Patients will have half of their surgical wound closed using one kind of absorbable superficial sutures, and the other half with a different kind of absorbable superficial suture. Which half receives which suture will be randomly determined.
89548862|NCT02329457|Experimental|ID varicella zoster vaccine (VZVv) group|intradermal 0.65 mL Zostavax
89548863|NCT02329457|Active Comparator|SC VZVv group|subcutaneous 0.65 mL Zostavax
89548864|NCT02329457|Placebo Comparator|ID NS Group|intradermal 0.65 mL normal saline
89548865|NCT02329457|Placebo Comparator|SC NS Group|subcutaneous 0.65 mL normal saline
89548866|NCT02709655|Experimental|Vortioxetine 10 mg/day|
89548867|NCT02709655|Experimental|Vortioxetine 20 mg/day|
89548868|NCT02709655|Active Comparator|Fluoxetine 20 mg/day,|A decision has been taken to stop recruitment into this treatment arm.
89548869|NCT02709655|Placebo Comparator|Placebo|
89548870|NCT02334605|Other|cold dry air|"Patients will be asked to acclimatize to room temperature for 20 minutes prior to exposure to cold dry air.~Through a nasal cannula, compressed dry air for medical use will be delivered for 15 minutes (25L/minute). Patients will be instructed to breathe through the nose only. The temperature of the air reaching the nose will be approximately -10°C and the relative humidity less than 10-15%."
89548871|NCT02334605|Other|hyperosmolar discs|A small paper disc (5-6mm of diameter) previously loaded with 50µl NaCl 5,13M will be applied on the right nasal septum for 1 minute and then be discarded.
89548872|NCT02334605|Other|capsaisin nasal spray|one puff of a nasal spray with a solution of capsaicin 0,0001mM will be sprayed in each nostril of the subject and subjects will be asked to score visual analogue scale for irritation of the nasal mucosa immediately after the adminitration.
89548873|NCT02329691||Changes in the WHO checklist|Specific changes in the WHO checklist will be performed after observational studies to enhance the WHO checklist at the specific institution
89207993|NCT05108415||Cohort A|"Blood specimen collection.~Study samples must be collected prior to any treatment."
89548874|NCT02329613|Active Comparator|Standard evening meal|"Patients randomized to this arm will receive standard evening meals.~Intervention: Standard evening meals."
89548875|NCT02329613|Experimental|Improved evening meal|"Patients randomized to this arm will receive improved evening meals. Improved meals will include enriched soup (with starches, butter, cheese or sour cream), a semi-liquid dairy dessert, fruit or a fruit dessert.~Intervention: Improved evening meal"
89548876|NCT02334449|Experimental|Single dose study part|there will be 8 cohorts of healthy volunteers dosed with single doses of LML134 (8 planned dose levels) or with placebo and 2 potential additional cohorts (also dosed with single dose of LML134 or placebo)
89548877|NCT02334449|Experimental|Multiple dose study part|there will be 3 cohorts of healthy volunteers dosed with multiple doses of LML134 (3 planned dose levels) or placebo and one potential additional cohort (also dosed with multiple doses of LML134 or placebo)
89548878|NCT02329535|Experimental|Treatment group|Treatment with 400 mg Micronized progesterone (Utrogestan) daily up to 6 weeks of geastation
89548879|NCT02329535|No Intervention|No treatment|No treatment. Regular follow up
89548880|NCT03187795|Experimental|Oxybutynin chloride IR then Mirabegron|Subjects randomized to this group will receive oxybutynin IR (5 mg three times daily) for 6 weeks. After the initial 6 weeks, subjects in this group will then be switched to an escalating dose of mirabegron for 6 weeks (25 mg once daily for 2 weeks, followed by 50 mg once daily for 4 weeks; Note: two placebo daily will be included with mirabegron once daily to match the frequency of dosing to oxybutynin IR three times daily).
89548881|NCT03187795|Experimental|Mirabegron then Oxybutynin chloride IR|Subjects randomized to this group will receive an escalating dose of mirabegron for 6 weeks (25 mg once daily for 2 weeks, followed by 50 mg once daily for 4 weeks; Note: two placebo daily will be included with mirabegron once daily to match the frequency of dosing to oxybutynin IR three times daily). After the initial 6 weeks, subjects in this group will then be switched to receive oxybutynin IR (5 mg three times daily) for 6 weeks
89548882|NCT02329379|Experimental|Unigoiter, ATA (+), AUS (+) on Tx|The patients who have uninodular goiter demonstrated by thyroid sono and positive autoantibody of thyroglobulin with pathological reports of fine needle aspiration showing atypical undetermined of significance will take eltroxin for TSH suppression therapy to ameliorate of goiter
89548883|NCT02329379|Active Comparator|Unigoiter, ATA (-), AUS (+) on Tx|The patients who have uninodular goiter demonstrated by thyroid sono and negative autoantibody of thyroglobulin with pathological reports of fine needle aspiration showing atypical undetermined of significance will take eltroxin for TSH suppression therapy to ameliorate of goiter
89548884|NCT02329379|No Intervention|Unigoiter, ATA (+), AUS (+) without Tx|The patients who have uninodular goiter demonstrated by thyroid sono and positive autoantibody of thyroglobulin with pathological reports of fine needle aspiration showing atypical undetermined of significance decide not to take eltroxin for TSH suppression therapy; instead, only observation with following will be conducted
89548885|NCT02329379|No Intervention|Unigoiter, ATA (-), AUS (+) without Tx|The patients who have uninodular goiter demonstrated by thyroid sono and negative autoantibody of thyroglobulin with pathological reports of fine needle aspiration showing atypical undetermined of significance decide not to take eltroxin for TSH suppression therapy; instead, only observation with following will be conducted
89548886|NCT02329379|Experimental|Multigoiter, ATA (+), AUS (+) on Tx|The patients who have multinodular goiter demonstrated by thyroid sono and positive autoantibody of thyroglobulin with pathological reports of fine needle aspiration showing atypical undetermined of significance will take eltroxin for TSH suppression therapy to ameliorate of goiter
89548887|NCT02329379|Active Comparator|Multigoiter, ATA (-), AUS (+) on Tx|The patients who have multinodular goiter demonstrated by thyroid sono and negative autoantibody of thyroglobulin with pathological reports of fine needle aspiration showing atypical undetermined of significance will take eltroxin for TSH suppression therapy to ameliorate of goiter
89548888|NCT02329379|No Intervention|Multigoiter, ATA (+), AUS (+) without Tx|The patients who have multinodular goiter demonstrated by thyroid sono and positive autoantibody of thyroglobulin with pathological reports of fine needle aspiration showing atypical undetermined of significance decide not to take eltroxin for TSH suppression therapy; instead, only observation with following will be conducted
89548889|NCT02329379|No Intervention|Multigoiter, ATA (-), AUS (+) without Tx|The patients who have multinodular goiter demonstrated by thyroid sono and negative autoantibody of thyroglobulin with pathological reports of fine needle aspiration showing atypical undetermined of significance decide not to take eltroxin for TSH suppression therapy; instead, only observation with following will be conducted
89548890|NCT03187717||TIVA (Total intravenous anesthesia)|Group TIVA; patients who used intravenous anesthesia procedure
89548891|NCT03187717||IA (Inhalation anesthesia)|Group IA; patients who used inhalation anesthesia procedure
89548892|NCT02334293|Other|Omegaven|
89548893|NCT02441257|Experimental|control ventilation|patients are scheduled to receive control or spontaneous ventilation
89207994|NCT05108415||Cohort B|"Blood specimen collection.~Samples must be collected prior to perform the ultrasonography."
89207995|NCT05108415||Cohort C|"Blood specimen collection.~Study samples must be collected prior to any treatment."
89025243|NCT00478803|Sham Comparator|2, Bentall|Mechanical aortic valve replacement(isolated or composite valve and graft replacement);actual surgical standard for dystrophic aortic roots
89025244|NCT00443690|Placebo Comparator|2|placebo control
89025245|NCT00443690|Experimental|1|KW-3902IV
89548894|NCT02329067|Experimental|walnut-CH|Western type diet including walnuts (43g/day); Walnuts substitute carbohydrates
89548895|NCT02329067|Experimental|Walnut-SFA|Western type diet including walnuts (43g/day); Walnuts substitute saturated fatty acids
89548896|NCT02329067|Experimental|Walnut-LIB|Western type diet including walnuts (43g/day); no specific recommendation
89548897|NCT02329067|No Intervention|Control|Isocaloric western type diet w/o nuts, nut butters or nut oils of any kind
89548898|NCT02334137||iPad app|This group will have unlimited access to educational iPad app while waiting for ophthalmology visits.
89548899|NCT02334137||Educator sessions|This group will have unlimited access to educational iPad app AND at least one appointment with a certified diabetes educator or registered dietitian while waiting for ophthalmology visits.
89548900|NCT02334137||Educator sessions + retinal photos|"This group will have same access as iPad app + education sessions and in addition will be able to briefly review their own retinal photos (compared to normal retina) with a resident ophthalmologist during timeline of pilot program."
89548901|NCT02329145|Experimental|Active treatment|Renal denervation
89548902|NCT02329145|No Intervention|Observational|
89548903|NCT02435563|Experimental|Ticagrelor 180 mg|Single dose of 180mg ticagrelor administered orally
89548904|NCT02435563|Experimental|Ticagrelor adjusted dose+ritonavir 100mg|adpated dose of ticagrelor calculated after PK modelisation with the Simcyp® simulator administered simultaneously with 100 mg ritonavir
89548905|NCT02329301|Experimental|MDA with DHAp (Eurartesim)|All consenting community members eligible to receive DHAp will be provided age-appropriate treatment dose of DHAp regardless of the malaria rapid diagnostic test (RDT) result. Treatment will be administered in a house-to-house campaign.
89548906|NCT02329301|Experimental|Focal MDA with DHAp (Eurartesim)|All consenting household members eligible to receive DHAp and living in a household where anyone in the household tests positive with a malaria rapid diagnostic test (RDT) will receive the age-appropriate treatment dose of DHAp. If no one in the household tests RDT positive then no one in the household will receive DHAp. Treatment will be administered in a house-to-house campaign.
89548907|NCT02329301|No Intervention|Standard of Care (Control)|The standard of care arm will reflect no community-based treatment interventions but will have the standard of care offered by the Ministry of Health and Ministry of Community Development, Mother and Child Health which applies to all arms. This includes available mosquito net coverage, indoor residual spraying and passive case detection of individuals seeking treatment from a health provider at a clinic or health post.
89548908|NCT03187639|Experimental|FFRct default primary investigation|All patients undergo FFRct as the default test assuming they have no pre-specified contraindications to CT angiography. The result of the FFRct will be conveyed to the supervising physician within 24 hours and will be used to determine the subsequent management plan.
89548909|NCT03187639|Active Comparator|Standard care|All patients will be assessed and managed exactly as they are usually treated by the randomising centre and the RACP using the local algorithms interpreted from the NICE Chest Pain of Recent Onset Guidance.
89548910|NCT02441335||Group 1 (Preterm labor, PPROM, cervical insufficiency)|Singleton pregnancy between 20 0/7 36 6/7 weeks gestational age who is admitted with PTL or cervical insufficiency (Equal or greater than 2 cm dilated) or PPROM
89548911|NCT02441335||Group 2 (Term labor)|Admitted to the hospital with spontaneous labor (regular contractions, cervical dilation) or spontaneous rupture of membranes
89548912|NCT02441335||Group 3 (PTB-medically indicated)|Singleton pregnancy between 20 0/7 34 5/6 weeks gestational age who is admitted with a medically indicated preterm birth (IOL for abruption, non reassuring fetal heart tones, intrauterine growth restriction, preeclampsia, trauma, etc.)
89548913|NCT02328989|Experimental|Pessary|The device will be placed in the vagina during the consultation. It is rinsed in sterile water for lubrification and left in place until delivery or remove at 36 weeks in case of no delivery before. There is no need to use any analgesia. The good position of the pessary is checking in the same time than the placement with digital examination.
89548914|NCT02328989|No Intervention|No pessary|No pessary will be placed in the vagina.
89548915|NCT03187873|Experimental|Chama cha MamaToto|Women attending chamas will meet twice per month, receive social and health education from CHVs and participate in a savings/loans program.
89548916|NCT03187873|No Intervention|Control|The CHVs in the control group will be given refresher training on health roles they are supposed to play according to the standard MOH activities
89548917|NCT02435485|Experimental|spondylolisthesis with balance training|Intervention: 1. Biodex balance training including weight shift training and random control training, 2. Regular rehabilitation including core spinal stabilization exercise.
89548918|NCT02435485|Active Comparator|spondylolisthesis, no balance training|Intervention: Regular rehabilitation including core spinal stabilization exercise
89548919|NCT02435485|Active Comparator|lumbar spondylitis|Intervention: Regular rehabilitation including core spinal stabilization exercise
89548920|NCT02334371|Other|MR-PET|Preoperative whole-body MR-PET with 18F-FDG
89548921|NCT02435641||ICU Questionnaires|"After enrollment, all subjects (patients and their primary caregiver) will be given baseline measures assessing: sociodemographics, depression, anxiety, distress, stress, PTSD, coping, mindfulness, quality of life, satisfaction with life, resiliency/self efficacy (patient only), patient caregiver interaction, caregiver preparedness (caregiver only), caregiver self efficacy (caregiver only), quality of adherence measure, and health care satisfaction.~Subjects will complete the same measures again at time 2 (3 months) and time 3 (6 months). The study endpoint is time 3 follow up (6 months)."
89548922|NCT02708485|No Intervention|Control group|No intervention
89548923|NCT02708485|Experimental|Physical exercise|A 3-month walking program (3 times a week for 12 weeks) on treadmill supervised by a physiotherapist. Duration of the exercise is progressively increased from 15 min to 45 min over a 6-week period and the intensity of the exercise is moderate (a 12-13 score on Borg scale).
89548924|NCT02435407|Experimental|SOS arm|The Sequential Oral Sensory (SOS) approach treatment protocol, involving systematic desensitization hierarchy of skills needed to build feeding skills.
89548925|NCT02435407|Active Comparator|Education arm|Parents will participate in educational talks around the cause and management of feeding difficulties in children with autism spectrum disorder.
89548926|NCT02333903|Experimental|Personalized Physical Activity|Patients will undergo a personalized physical activity program after sleeve gastrectomy.
89548927|NCT02333903|No Intervention|Regular Activity|Patients will have regular physical activity after sleeve gastrectomy.
89548928|NCT02441023|Experimental|Nutritional therapy and education|"Nutritional therapy guidance according to sex, age, weight and comorbidity present. The recommendations of calories and macronutrients intake were indicated according to the Official Mexican Standards for Diabetes treatment and the American Diabetes Association standards for medical care in diabetes.~Education with multimedia application: Patients were exposed to the multimedia application previous to the nutritional counseling. Multimedia application comprises the following modules: 1) Introduction, 2) Nutrition, 3) Physical Exercise, 4) Diabetes myths 5) Metabolic control indicators 6) Knowing diabetes, 7) Diabetes complications including testimonials."
89548929|NCT02441023|No Intervention|Nutritional Therapy|Nutritional therapy guidance according to sex, age, weight and comorbidity present. The recommendations of calories and macronutrients intake were indicated according to the Official Mexican Standards for Diabetes treatment and the American Diabetes Association standards for medical care in diabetes.
89548930|NCT02333981|Experimental|Passive oral motor therapy group|All the subjects received passive treatment which included light touch, stroking, vibration, tapping, pressure and stretch. All the techniques have been proved to be effective in treating drooling. Relative sterility and hygiene was maintained throughout the procedure as sterilized gloves and napkins were used. The measurement protocol was designed to check effectiveness on drooling in children. The protocol was given for 4 weeks with treatment sessions given 3 times per week and the treatment duration was 30min.12 sessions of oral motor stimulation therapy given during the 4 weeks..
89548931|NCT02433847|Experimental|mosapride|
89548932|NCT02328833|Experimental|Active Implementation of Guidelines|Primary Care Centers where the experimental strategies of guidelines implementation will be done
89548933|NCT02328833|No Intervention|No Active Implementation of Guidelines|Primary Care Centers where the experimental strategies of guidelines implementation not will be done
89548934|NCT02435329||Healthy volunteers|"10 healthy volunteers~Anthropometric measures: Height, weight, BMI, waist circumference~Vital parameters: supine and standing blood pressure, pulse, respiratory rate and temperature~Laboratory assessment that includes markers of endothelial activation, inflammation and bone metabolism.~Assessment of skin microcirculation with Laser Doppler Iontophoresis~Assessment of calcaneal bone mineral density (BMD) with Bone Sonometer (ultrasound)~Advanced glycation end-products will be assessed by an AGE reader which uses the technique of skin autofluorescence"
89548935|NCT02435329||Type 2 diabetes without neuropathy|"10 patients~Anthropometric measures: Height, weight, BMI, waist circumference~Vital parameters: supine and standing blood pressure, pulse, respiratory rate and temperature~Laboratory assessment that includes markers of endothelial activation, inflammation and bone metabolism.~Assessment of skin microcirculation with Laser Doppler Iontophoresis~Assessment of calcaneal bone mineral density (BMD) with Bone Sonometer (ultrasound)~Advanced glycation end-products will be assessed by an AGE reader which uses the technique of skin autofluorescence"
89548936|NCT02435329||Type 2 diabetes with painful neuropathy|"10 patients~Anthropometric measures: Height, weight, BMI, waist circumference~Vital parameters: supine and standing blood pressure, pulse, respiratory rate and temperature~Laboratory assessment that includes markers of endothelial activation, inflammation and bone metabolism.~Assessment of skin microcirculation with Laser Doppler Iontophoresis~Assessment of calcaneal bone mineral density (BMD) with Bone Sonometer (ultrasound)~Advanced glycation end-products will be assessed by an AGE reader which uses the technique of skin autofluorescence"
89025246|NCT00440856|No Intervention|Control|
89025247|NCT00440856|Experimental|experimental|Participants are given their disc fragments following their operation
89025248|NCT00443768||1|
89025249|NCT00443768||2|
88812039|NCT00887510|Active Comparator|Thiazide First|Participants will receive 25 mg of hydrochlorothiazide (HCTZ) each day for 6 weeks, followed by 25 mg of HCTZ every day plus 4 mg of trandolapril each day for 6 weeks, followed by 4 mg trandolapril each day for 6 weeks.
88812040|NCT00887510|Active Comparator|Trandolapril First|Participants will receive 4 mg of trandolapril each day for 6 weeks, followed by 4 mg of trandolapril for 6 weeks plus 25 mg of HCTZ each day for 6 weeks, followed by 25 mg of HCTZ each day for 6 weeks.
88812041|NCT00834626|Other|Surgery group|Interventional study of the effects of a novel metabolic procedure of Ileal Interposition with Sleeve Gastrectomy
88812042|NCT00836342||Previous history of SCC|Participants had previous history of SCC
88812043|NCT00836342||Previous history of BCC|Participants had previous history of BCC
88812044|NCT00836342||Control|Participants had no previous history of squamous cell carcinoma or basal cell carcinoma
88812045|NCT01431989|Active Comparator|Test formulation|Test product: Amoxicillin powder for oral suspension (Clamoxyl®) 500mg/5mL in Period 1; followed by 14-days washout period during which no medication was administered; followed by reference product: Amoxil® 500mg/5mL in Period 2.
88812046|NCT01431989|Active Comparator|Reference formulation|Reference product: Amoxil® 500mg/5mL powder for oral suspension in Period 1; followed by 14-days washout period during which no medication was administered; followed by test product: Amoxicillin powder for oral suspension (Clamoxyl®) 500mg/5mL in Period 2
88812047|NCT01397591|Experimental|Ofatumumab with Bortezomib|Ofatumumab was given intravenously on cycle 1 day 1 at a dose of 300mg, followed by a cycle 1 day 8 dose of 1000mg. During cycles 2 through cycle 6, Ofatumumab was given at a dose of 1000mg on day 1 of each cycle, with no dosing on any other day of the cycle. Bortezomib was given intravenously at a dose of 1.6mg/m2 on days 1, 8, and 15 of each cycle, following the Ofatumumab infusion, if given.
88812048|NCT01398059|Experimental|Sedentary|In this condition, participants will engage in 8 hours of uninterrupted sedentary behaviour.
88812049|NCT01398059|Experimental|Sedentary With Breaks|In this condition participants will engage in 8 hours of sitting, although the sitting will be interrupted every 20 minutes. During these interruptions participants will spend 2 minutes walking at an intensity equivalent to 30% of VO2peak.
88961741|NCT04461587|Experimental|Pirfenidone [Esbriet]|"Pirfenidone recommended daily dose for patients is 801 mg three times a day with food, for a total of 2403 mg/day. Upon initiating treatment, the dose should be titrated to the recommended daily dose of 2403 mg/day over a 14day period as follows:~Days 1 to 7: a dose of 267 mg administered three times a day (801 mg/day)~Days 8 to 14: a dose of 534 mg administered three times a day (1602 mg/day)~Day 15 onward: a dose of 801 mg administered three times a day (2403 mg/day) It will be provided in 267mg capsules. Treatment will be for a minimum of 12 months. Treatment duration will continue until last patient enrolled received 12 months of treatment."
88961742|NCT04428034|Experimental|Learning Skills Together Intervention|Participants in the Learning Skills Together program will begin their participation with a one-on-one phone call with an interventionist, who will ensure the participant is prepared to to attend the group sessions (e.g., familiar with videoconference technology) and will help the participant to set individual goals. The caregiver participant will then attend 4, group-based sessions lasting approximately 1.5 hours each, to learn about common complex care tasks managed by family caregivers to someone with mid-stage Alzheimer's disease, such as managing behavioral symptoms of dementia, incontinence, nutrition, transferring, medication management, and more. Sessions will integrate interactive activities, such as videos, case studies, and discussions. Approximately four weeks later, caregivers will be asked to attend a group reflection session to discuss application of what was learned and progress in meeting individual goals.
88961743|NCT04424355||Patients with suspected pneumonia COVID-19|"Chest MRI findings: bilateral, diffuse ground-glass opacity (GGO), consolidation, crazy paving pattern, pleuritis."
89548937|NCT02435329||Type 2 diabetes with painless neuropathy|"10 patients~Anthropometric measures: Height, weight, BMI, waist circumference~Vital parameters: supine and standing blood pressure, pulse, respiratory rate and temperature~Laboratory assessment that includes markers of endothelial activation, inflammation and bone metabolism.~Assessment of skin microcirculation with Laser Doppler Iontophoresis~Assessment of calcaneal bone mineral density (BMD) with Bone Sonometer (ultrasound)~Advanced glycation end-products will be assessed by an AGE reader which uses the technique of skin autofluorescence"
89548938|NCT02435329||Type 2 diabetes with Charcot foot|"10 patients~Anthropometric measures: Height, weight, BMI, waist circumference~Vital parameters: supine and standing blood pressure, pulse, respiratory rate and temperature~Laboratory assessment that includes markers of endothelial activation, inflammation and bone metabolism.~Assessment of skin microcirculation with Laser Doppler Iontophoresis~Assessment of calcaneal bone mineral density (BMD) with Bone Sonometer (ultrasound)~Advanced glycation end-products will be assessed by an AGE reader which uses the technique of skin autofluorescence"
89548939|NCT02328677||ColoCare FHCRC|Active patient recruitment, follow-up, and multiple specimen collection Repeated sampling at multiple timepoints Longitudinal assessment of biomarkers and health behaviors Recruitment Status August 31, 2021: n=679
89548940|NCT02328677||ColoCare Moffitt (affiliated cohort)|Active patient recruitment, follow-up, and multiple specimen collection Repeated sampling at multiple timepoints Longitudinal assessment of biomarkers and health behaviors Recruitment Status August 31, 2021: n=895
89548941|NCT02328677||University Hospital Heidelberg|Active patient recruitment, follow-up, and multiple specimen collection Repeated sampling at multiple timepoints Longitudinal assessment of biomarkers and health behaviors Recruitment Status August 31, 2021: n=721
89548942|NCT02328677||ColoCare Huntsman Cancer Institute|Active patient recruitment, follow-up, and multiple specimen collection Repeated sampling at multiple timepoints Longitudinal assessment of biomarkers and health behaviors Recruitment Status August 31, 2021: n=394
89548943|NCT02328677||Cedars-Sinai Medical Center|Active patient recruitment, follow-up, and multiple specimen collection Repeated sampling at multiple timepoints Longitudinal assessment of biomarkers and health behaviors Recruitment Status August 31, 2021: n=234
89548944|NCT02328677||Washington University School of Medicine in St. Louis|Active patient recruitment, follow-up, and multiple specimen collection Repeated sampling at multiple timepoints Longitudinal assessment of biomarkers and health behaviors Recruitment Status August 31, 2021: n=232
89548945|NCT02328677||University of Tennessee|Active patient recruitment, follow-up, and multiple specimen collection Repeated sampling at multiple timepoints Longitudinal assessment of biomarkers and health behaviors Recruitment Status August 31, 2021: n=183
89548946|NCT03187483|Active Comparator|Flash-free bracket group|Orthodontic treatment with flash-free bracket system
89548947|NCT03187483|Active Comparator|Control|Orthodontic treatment with conventional adhesive-coated brackets
89548948|NCT02435017||Adults 20-85 years|Data from adults 20-85 years old will be evaluated for serum phosphorus concentration.
89548949|NCT02328911|Experimental|Laser treatment|Twice-per-week laser treatment for 4 weeks and once-per-week laser treatment for 8 weeks. Inflammatory markers, functional status, and quality of life will be examined.
89548950|NCT02328911|Sham Comparator|Sham treatment|Twice-per-week sham treatment for 4 weeks and once-per-week sham treatment for 8 weeks. Inflammatory markers, functional status, and quality of life will be examined.
89548951|NCT02435095|Active Comparator|Maintenance treatment (Control)|287 female and male patients with schizophrenia according to Diagnostic and Statistical Manual of Mental Disorders-V (DSM-V) will be directed randomly to the maintenance treatment group (control). Patients will be treated according to the current clinical standard of long-term maintenance antipsychotic treatment. Study related procedures include safety assessments (physical examination, questionaires), laboratory assessments (blood sampling, urine analysis), efficacy assessments (questionaires) and volumetric Magnetic Resonance Imaging (structural MRI incl. volumetry). Study procedures are the same for both study groups (control/experimental).
89548952|NCT02435095|Experimental|Intermittent Treatment (Experimental)|"287 female and male patients with schizophrenia according to DSM-V will be directed randomly to the intermittent treatment group (experimental). Patients directed to this group will be tapered off medication.~Study related procedures include safety assessments (physical examination, questionaires), laboratory assessments (blood sampling, urine analysis), efficacy assessments (questionaires) and volumetric Magnetic Resonance Imaging (structural MRI incl. volumetry). Study procedures are the same for both study groups (control/experimental)."
89548953|NCT04477421|Active Comparator|FS-LASIK Group|100 eyes of 50 patients underwent bilateral FS-LASIK (Femtosecond laser Insitu Keratomileusis)
88961744|NCT04424355||Patients with suspected pneumonia with COVID -19|"Chest CT findings: bilateral, diffuse ground-glass opacity (GGO), consolidation, crazy paving pattern, pleuritis."
89548954|NCT04477421|Experimental|FS-SMILE|100 eyes of 50 patients who underwent bilateral FS-SMILE (femtosecond small incision lenticule extraction)
89025250|NCT00440895|Experimental|1 intracoronary + infusion|Bolus abciximab i.c. (0.25 mg/kg) followed by 12 h infusion at 0.125 µg/kg/min (max 10µg/min).
89548955|NCT01307813|Experimental|Endoscopic suturing device|Assess the safety and effectiveness of the Apollo endoscopic suturing device (Overstitch) and cinching device for placement of sutures and surgical knots in a segment of colon under laparoscopic or open visualization of the operative area.
89548956|NCT03111251|Experimental|Provider-only intervention|New provider- and system-level evidence-based strategies for increasing HPV vaccination rates are being implemented throughout the entire clinic network. This includes provider assessment and feedback, provider reminders, provider education, and patient reminders.
89548957|NCT03111251|Experimental|Provider plus parent intervention|Clinics randomized to the provider plus parent intervention will receive both the provider intervention and the parent education intervention.
89548958|NCT02333669||Control group|The control blood samples, which were collected from healthy neonatal umbilical cord blood, were obtained from the maternity ward of 80 hospitals in Chongqing and nearby areas
89548959|NCT02333669||RDS group|Newborns with RDS were consecutively recruited for this study from the neonatal intensive care unit (NICU) at Daping Hospital, Third Military Medical University, Chongqing, China, a tertiary care facility
89548960|NCT02333747|Experimental|the TEAS group|Patients in the TEAS group received pre-operative TEAS for 30 min before the induction of anesthesia using the Hans electronic acupuncture apparatus (HANS-100A, Nanjing Jisheng Medical Technology Company, Nanjing, China) in the holding area. TEAS was applied to two pairs of acupoints: bilateral Hegu (LI4) and Neiguan (PC6).
89548961|NCT02333747|Sham Comparator|the sham group|In the sham group, the patients were connected to the Hans electronic acupuncture apparatus (HANS-100A, Nanjing Jisheng Medical Technology Company, Nanjing, China), but electronic stimulation was not applied.
89548962|NCT02333591|Active Comparator|GlucagonLikePeptide-1 (7-36)|"GLP-1 (7-36) is diluted in saline and human serum albumin. Plasma levels of GLP-1 (7-36) are rapidly raised and then maintained stable with 5,91 pmol/kg/min (0-2 min) reduced to 2,53 pmol/kg/min (2-4 min) reduced to 2,34 pmol/kg/min (4-6 min) reduced to 2,2 pmol/kg/min (6-8 min) reduced to 2,02 pmol/kg/min (8-10 min) and then maintained stable for 2½ hours with 1.5 pmol/kg/min.~A DPP-IV inhibitor - Januvia 100 mg is given the evening before and ½ an hour before the infusion is started."
89548963|NCT02333591|Active Comparator|GlucagonLikePeptide-1 (9-36)|GLP-1 (9-36) is diluted in saline and human serum albumin. Plasma levels of GLP-1 (9-36) are rapidly raised and then maintained stable with 5,91 pmol/kg/min (0-2 min) reduced to 2,53 pmol/kg/min (2-4 min) reduced to 2,34 pmol/kg/min (4-6 min) reduced to 2,2 pmol/kg/min (6-8 min) reduced to 2,02 pmol/kg/min (8-10 min) and then maintained stable for 2½ hours with 1.5 pmol/kg/min
89548964|NCT02333591|Placebo Comparator|NaCl|Saline is infused with a flow rate of 240 ml/h for 10 min and then reduced to 86 ml/h for 2½ hours.
89548965|NCT02709577|Experimental|EndoBarrier Gastrointestinal Liner|Subjects randomized and implanted with the EndoBarrier Gastrointestinal liner; subjects will be implanted for 24 weeks to 52 weeks and evaluated for study endpoints.
89548966|NCT02709577|Experimental|Sham: endoscopy and standard of care|Subjects randomized to sham arm received an upper GI examination and were evaluated for study endpoints.
89548967|NCT02328521|Experimental|Nicorandil group|Drug: Nicorandil (Chugai Pharmaceutical Co, Japan). The first dose is given 8h before selective percutaneous coronary intervention, 10mg, oral. After the percutaneous coronary intervention, nicorandil is given for 30 days, 5mg each time, 3 times daily oral.
89548968|NCT02328521|Placebo Comparator|Control group|Drug: Nicorandil placebo (Sihuan Pharmaceutical Co, China). The first dose is given 8h before selective percutaneous coronary intervention, 2 tablets, oral. After the percutaneous coronary intervention, placebo is given for 30 days, 1 tablet each time, 3 times daily oral.
89548969|NCT03192241|Experimental|Pump|Mothers provided with a manual breast pump
89548970|NCT03192241|Active Comparator|book|Mothers provided with a children's book
89548971|NCT02333279||Organ transplant recipients|Follow-ups in regular intervals following the organ transplant date.
89548972|NCT03187093|Active Comparator|Vortioxetine|
89548973|NCT03187093|Active Comparator|Escitalopram|
89548974|NCT02039999|Experimental|Chronic cough|"Cough challenges to be administered include:~Nebulised citric acid in serial dilutions Nebulised ATP solution in serial dilutions Nebulised TRPA1 agonist solution in serial dilutions"
89548975|NCT02039999|Active Comparator|Normal volunteer|"Cough challenges to be administered include:~Nebulised citric acid in serial dilutions Nebulised ATP solution in serial dilutions Nebulised TRPA1 agonist solution in serial dilutions"
89548976|NCT02078752|Experimental|Part 1|
89548977|NCT03187249|Experimental|Cognitive Behavioral Therapy|receive cognitive-behavioral therapy for 12 weeks
89548978|NCT03187249|Experimental|Pulmonary Rehabilitation Therapy|receive pulmonary rehabilitation therapy for 12 weeks
89548979|NCT03187249|Experimental|Combined Therapy|receive both cognitive-behavioral therapy and pulmonary rehabilitation therapy for 12 weeks
89548980|NCT03187249|No Intervention|Regular Therapy|receive regular therapy for chronic obstructive pulmonary disease
89548981|NCT03145805||liver resection patients|Liver resection patients sited with an epidural catheter for bupivacaine infusion for 3-5 days postoperatively to manage postoperative pain
89548982|NCT03191851|Active Comparator|Standard Device|Standard device
89548983|NCT03191851|Experimental|Melody Device|Melody device without Pump
89548984|NCT03191851|Experimental|Melody Device with pump|Melody Catheter device with Andromeda Pump
89548985|NCT03145571|Other|Continuity of midwifery care|Clinics where the continuity of midwifery care program was implemented during 2013
89025251|NCT00440895|Active Comparator|2 intravenous|Bolus abciximab i.v. (0.25 mg/kg) followed by 12 h infusion at 0.125 µg/kg/min (max 10µg/min).
89025252|NCT00440895|Placebo Comparator|3 Placebo|Bolus of placebo followed by 12 h infusion (placebo).
89025253|NCT04697706|Active Comparator|"Study period Water"|Participants will take in 1L of tap water per day plus ad lib, self-selected fluids.
89025254|NCT04697706|Experimental|"Study period Moonstone"|Participants will take one packet of Moonstone powder reconstituted in 500 ml water, twice a day, to total 1 L per day (66 meq of potential alkali/day) plus ad lib fluids. Moonstone packets will be supplied by Dr. Arnie's, Inc.
89548986|NCT03145571|No Intervention|Control|Clinics where no structured changes had been made to the ante- and post- natal care during the period 2013-2015
89548987|NCT02434627|Experimental|Sodium Nitrate (Beetroot Juice)|Sodium nitrate in the form of beetroot juice will be administered orally. Patients will be assessed with a number of functional muscle assessments.
89548988|NCT03145103|Experimental|409M|CT ASPHINA 409M IOL
89548989|NCT03187171|Active Comparator|Allograft Fusion Group|The anterior approach to the cervical spine for discectomy and fusion by the insertion of an autologous iliac crest tricortical bone graft.
89548990|NCT03187171|Active Comparator|Cohere PEEK Fusion Group|The anterior approach to the cervical spine for discectomy and fusion by the insertion of a Cohere porous PEEK fusion device.
89548991|NCT02434861|Experimental|Part A|Rolapitant IV and Digoxin
89548992|NCT02434861|Experimental|Part B|Rolapitant IV and Sulfasalazine
89548993|NCT02434861|Experimental|Part C|Rolapitant IV and Cooperstown Cocktail
89548994|NCT02328365|No Intervention|Standard|Patients screened positive for cardiopulmonary disease and having a medical (pulmonary and/or cardiology) visit preoperatively, but randomized to standard follow-up
89548995|NCT02328365|Experimental|Intervention|Patients screened positive for cardiopulmonary disease and having a medical (pulmonary and/or cardiology) visit preoperatively, but randomized to structured medical follow-up after operation
89548996|NCT03187015|Other|Midazolam|Treatment A: 2 mg of Midazolam administered - Period 1, Day 1 Treatment B: 2 mg of Midazolam with 5 mg Entinostat (after 14 day minimum washout from Period 1, Day 1) - Period 2, Day 1
89548997|NCT02328053|Experimental|Collagen crosslinking group|patients not resolving to standard antifungal therapy were assigned to receive adjuvant collagen crosslinking with riboflavin and Ultraviolet-A along with topical medical therapy
89548998|NCT02328053|Active Comparator|standard medical therapy|patients were continued on topical antifungal therapy namely Natamycin eye drops and voriconazole eye drops
89548999|NCT03186937|Experimental|Hominex-2|"Participants will receive an individualized dietary prescription that incorporates a methionine-free amino acid-modified medical food (Hominex-2, Abbott Nutrition) supplemented with low-methionine foods. Hominex-2 contains a mixture of L-amino acids but lacks methionine.~Participants will be asked to have an optional non-contrast MRI to assess body composition prior to and at completion of the methionine-restricted (MR) diet. Not completing a scheduled MRI is not considered a protocol deviation.~Participants will be followed for 30 days after surgery or biopsy date. Subjects removed from study for unacceptable adverse events (AEs) will be followed until resolution or stabilization of the AE."
88961745|NCT04394247||Breast Cancer Patients|HR + /HER2- Advanced/Metastatic Breast Cancer patients in U.S.A
88961746|NCT04371107|Experimental|azithromycin|azithromycin treatment 500 mg on day 1 then 250 mg the following 4 days from day 2 to day 5, per os.
89549000|NCT02022748|Experimental|Sequence 1|hemodialysis patients: subjects will receive treatment A (ticagrelor oral 90 mg 1 day following the dialysis session but 2 days before the next dialysis session) in period 1 and treatment B (ticagrelor oral 90 mg just prior to dialysis session) in period 2.
89549001|NCT02022748|Experimental|Sequence 2|hemodialysis patients: subjects will receive treatment B (ticagrelor oral 90 mg just prior to dialysis session) in period 1 and treatment A (ticagrelor oral 90 mg 1 day following the dialysis session but 2 days before the next dialysis session) in period 2.
89549002|NCT02022748|Experimental|Treatment H|Healthy subjects: ticagrelor oral 90 mg on 1 day of treatment
89549003|NCT02333513|Experimental|case group|
89549004|NCT02434549|Active Comparator|Botulinum toxin-A (Dysport®)|Intramuscular injections of Botulinum toxin-A in spastic muscles with regional muscle-related pain
89549005|NCT02434549|Placebo Comparator|Normal saline|Intramuscular injections of normal saline solution in spastic muscles with regional muscle-related pain
89549006|NCT03993665||affected|All patients with a histologically confirmed squamous cell carcinoma in the head and neck region
89549007|NCT03993665||control|Whartin tumour or pleomorphic adenoma of the parotid gland without malignant transformation
89549008|NCT03191773|Experimental|Anti-CD19 CAR transduced T cells|Patients will receive a lymphodepleting preconditioning regimen with Fludarabine and Cyclophosphamide followed by anti-CD19 CAR-transduced T cells.
89549009|NCT02328287|Experimental|ALLOB® Implantation|
88961747|NCT04371107|Active Comparator|symptomatic treatment|continuation of symptomatic treatment
88961748|NCT04368494|No Intervention|Control|Continue with normal activity.
88961749|NCT04368494|Experimental|Exercise|12-weeks of home based exercise involving 30 minutes of brisk walking on 5 days per week.
88961750|NCT04364984||ARB group|Hypertensive patients with COVID-19 who received ARBs
88961751|NCT04364984||ACEi group|Hypertensive patients with COVID-19 who received ACEis
88961752|NCT04364984||DRi group|Hypertensive patients with COVID-19 who received direct renin inhibitor (DRis)
88961753|NCT04294095|Experimental|Intervention|During the first four weeks of the MBMM+ program, participants will receive electronic informational handouts covering topics on weight management as well as the benefits and safety concerns related to prenatal physical activity. Starting week 5 of the 12-week intervention, participants will attend two in-person, group physical activity sessions per week with each session lasting approximately 60 minutes and will be held at a local community center located close to the recruitment clinics. Sessions will be held on weekday evenings and weekend mornings as these times were preferred by pregnant women. Each session will include both didactic and experiential components to increase knowledge and skill building.
89549010|NCT02328209|Experimental|ranibizumab|ranibizumab
89549011|NCT02022670|Placebo Comparator|Placebo|inert oral capsules (0 mg sodium nitrite morning; 0 mg sodium nitrite in evening) for 10 weeks
89549012|NCT02022670|Experimental|Sodium Nitrite 80 mg/d|80 mg/day (40 mg in morning; 40 mg in evening) oral capsules for 10 weeks
89549013|NCT02022670|Experimental|Sodium Nitrite 160 mg/d|160 mg/day (80 mg in morning; 80 mg in evening) oral capsules for 10 weeks
89549014|NCT02434783||1st level of arterial insufficiency|asymptomatic PAD patients
89549015|NCT02434783||2nd level of arterial insufficiency|Intermittent claudication patients
89549016|NCT02434783||3rd level of arterial insufficiency|Critical limb ischemia patients
89549017|NCT02434783||No arterial insufficiency|Healthy individuals (control)
89549018|NCT02433769|Active Comparator|TOf-Watch-SX|Train-of-four (TOF) ratios will be measured with the TOF-Watch-SX and compared to TOF ratios measured simultaneously with the TOFscan
89025255|NCT00440973|Other|treatment arm|PI relocated, currently data is no longer available
89025256|NCT00443924|Placebo Comparator|1|Arm 1
89025257|NCT00443924|Experimental|2|Arm 2
89025258|NCT00443924|Experimental|3|Arm 3
89549019|NCT02433769|Experimental|TOFscan|Train-of-four (TOF) ratios obtained from the TOFscan will be compared to TOF ratios measured simultaneously with the TOF-Watch-SX
89549020|NCT02328443|Experimental|midazolam alone|midazolam administration alone
89549021|NCT02328443|Experimental|midazolam and itraconazole|Itraconazole 200 mg PO twice; midazolam iv single administration
89549022|NCT02328443|Experimental|midazolam and rifampicin|rifampicin 150 mg PO for 9 days administration, midazolam iv single administration
89549023|NCT02076334|Active Comparator|Compression + normal garment|Far Infrared Fabric during exercise + Spandex at night
89549024|NCT02076334|Active Comparator|Normal Garment + Test garment at night|Spandex during exercise + Far Infrared Fabric at night
89549025|NCT02076334|Sham Comparator|Normal Garment + normal garment|Spandex during exercise + Spandex at night
89549026|NCT02076334|Active Comparator|Test garment + Test garment|Far Infrared Fabric during exercise + Far Infrared Fabric at night
89549027|NCT02039765|Experimental|Brimonidine tartrate|One drop of brimonidine tartrate ophthalmic solution 0.025% in each eye once at Visit 2 (Day 1) then four times daily (QID) approximately 4 hours apart at Visit 3 (Day 2) through day 6, and then once at Visit 4 (Day 7).
89549028|NCT03189121||Healthy Volunteers|20 overweight and obese adult men
89549029|NCT03191539|Experimental|Apremilast|30 mg of Apremilast twice a day during 52 weeks. During the first 6 days will be a dose escalation as the following: Day 1: 10 mg daily Day 2: 10 mg day- 10 mg night Day 3: 10 mg day- 20 mg night Day 4: 20mg day- 20mg night Day 5: 20 mg day- 30 mg night Day 6: 30 mg day- 30 mg night
89549030|NCT02327975|Experimental|Training group|Participants in this group received twice-weekly non-consecutive sessions of physical exercise for 10 weeks. Each session lasted approximately 60-70 minutes. Exercise program consisted of strength training and aerobic exercise. Each session began with a warm low intensity (10 min), then the main part of the session (25 min) and aerobic training and recovery period (25-35 min) was performed. The equipment used during the procedure was the Thera-Band elastic band.
89549031|NCT02327975|Experimental|Mobile group|Intervention content was the same in both intervention arms; only the delivery mode differed. Participants in this group received two podcast (digital multimedia file available for download in a media player) per week for 10 weeks of the intervention, each podcast lasted about 5 min. Participants in this group received a weekly message with the aim of fostering motivation toward physical activity. Subjects in this group performed two sessions per week on non-consecutive days, the days could be chosen by the participants themselves.
89549032|NCT02327975|Other|Control group|No received intervention.
89549033|NCT02433925|Active Comparator|Supplement B|Administration of 500mg of trans-resveratrol per day, for 4 weeks
89549034|NCT02433925|Placebo Comparator|Supplement A|Administration of 500mg of placebo per day, for 4 weeks
89025259|NCT00443924|Experimental|4|Arm 4
89025260|NCT00443924|Experimental|5|Arm 5
89025261|NCT00443963|Experimental|PPI|PPI Medication
89025262|NCT00443963|Experimental|H2RA|H2RA Medication
89025263|NCT00444002||Hepatitis C - Steatosis|Patients with chronic Hep C infection undergoing liver biopsy with >=5% steatosis on liver biopsy
89025264|NCT00444002||Hepatitis C - no steatosis|Patients with chronic Hep C infection without steatosis on liver biopsy (<5% of hepatocytes involved)
89025265|NCT04701255|Experimental|aberration-free IOL|20 human eyes with aberration-free intraocular lens Implantation after phacoemulsification cataract surgery
89549035|NCT02332967|Active Comparator|Whey predominant starter formula|Whey predominant starter formula
89549036|NCT02332967|Experimental|Whey predominant starter formula + 40% palmitic acid|Whey predominant starter formula + 40% palmitic acid in sn-2 position
89549037|NCT02332967|Experimental|Whey predominant starter formula + 50% palmitic acid|Whey predominant starter formula + 50% palmitic acid in sn-2 position
89549038|NCT02433691|Active Comparator|Sequential Exercise and Memory Training|Aerobic exercise via stationary bicycling followed by memory training.
89549039|NCT02433691|Experimental|Simultaneous Exercise & Memory Training|Simultaneous aerobic exercise via stationary bicycling while receiving memory training.
89549040|NCT02433691|Placebo Comparator|Stretching and Toning|Anerobic stretching and toning followed by memory training
89549041|NCT02327663|Experimental|HBeAg positive CHB group|1000 patients take generic emtricitabine capsule(200 mg one time per day) for 96 weeks,and for patients who have HBV DNA > 500 copies/ml, adefovir dipivoxil were combined
89549042|NCT02327663|Experimental|HBeAg negativie CHB group|1000 patients take generic emtricitabine capsule(200 mg one time per day) for 96 weeks,and for patients who have HBV DNA > 500 copies/ml, adefovir dipivoxil were combined
89549043|NCT02440867|No Intervention|Healthy subjects|Multimodal imaging data acquisitions Clinical data acquisitions
89549044|NCT02440867|Experimental|TBS-MPC|"Intervention with active TBS aiming Medial Prefrontal Cortex in 6 patients with schizophrenia~Baseline: Multimodal imaging data acquisitions; Clinical data acquisitions; P50 acquisition~Endpoint: Multimodal imaging data acquisitions; Clinical data acquisitions; P50 acquisition~Continuous actimetry acquisition"
89549045|NCT02440867|Active Comparator|TBS-CPDLF|"Intervention with active TBS aiming Dorsolateral Prefrontal Cortex in 6 patients with schizophrenia~Baseline: Multimodal imaging data acquisitions; Clinical data acquisitions; P50 acquisition~Endpoint: Multimodal imaging data acquisitions; Clinical data acquisitions; P50 acquisition~Continuous actimetry acquisition"
89549046|NCT02440867|Sham Comparator|TBS-Sham|"Intervention with Sham TBS in 8 patients with schizophrenia~Baseline: Multimodal imaging data acquisitions; Clinical data acquisitions; P50 acquisition~Endpoint: Multimodal imaging data acquisitions; Clinical data acquisitions; P50 acquisition~Continuous actimetry acquisition"
89549047|NCT02021812|Experimental|Branched TAG® Device|Treatment with the GORE® TAG® Thoracic Branch Endoprosthesis
89549048|NCT03191929|Experimental|HIT Intervention Arm|The Health Information Technology Intervention Study Arm consisted of: 1) web-based tutorial on delivering trauma-informed care, 2) Multi-media mental health risk assessment, 3) Immediate provider notification, which included flagging patients' scores that met criteria for symptoms of depression and/or PTSD, 4) subsequent integration into the patient electronic medical record, and 5) Clinical decision support adapted from the Harvard Program in Refugee Trauma.
89549049|NCT03191929|Active Comparator|Minimal Intervention Control Arm|The Minimal Intervention Control Arm consisted of: 1) web-based tutorial on delivering culturally competent health care in general, 2) Multi-media mental health risk assessment, 3) Provider notification only in the event that patients' scores evidenced symptoms of being at risk to harm either themselves or others.
89549050|NCT02333123|Experimental|Aspirin|Aspirin 300mg capsule by mouth once a day for 24 weeks.
89549051|NCT02333123|Placebo Comparator|Placebo|Placebo capsule (for aspirin 300mg capsule) by mouth once a day for 24 weeks.
89549052|NCT03188887|Active Comparator|CONTROL|Treatment with Renin Angiotensin system (RAS) blockade or SGLT2i.
89549053|NCT03188887|Experimental|EXPERIMENTAL|Corticotherapy + RAS blockade or SGLT2i treatment. Drug injection (intravenous) + tablets
89549054|NCT02332811|Experimental|CKD patients not on dialysis 800 mg|Sevelamer carbonate 800 mg in tabs 3 times per day with meals
89549055|NCT02332811|Experimental|CKD patients not on dialysis 2.4 g|Sevelamer carbonate 2.4 g powder carbonate per day
89549056|NCT02332811|Experimental|CKD patients on dialysis 800 mg|Sevelamer carbonate 800 mg in tabs 3 times per day with meals
89549057|NCT02332811|Experimental|CKD patients on dialysis 2.4 g|Sevelamer carbonate 2.4 g powder carbonate per day
89549058|NCT02433457|Experimental|CC-292 SDD (Spray Dried Dispersion)300mg - Fasted Condition|Single oral dose of 300 mg CC-292 SDD under fasted conditions (100 mg SDD x 3 tablets)
89549059|NCT02433457|Experimental|CC-292 SDD 300mg - Fed Condition|Single oral dose of 300 mg CC-292 SDD under fed conditions (100 mg SDD x 3 tablets)
89549060|NCT02433457|Experimental|375mg P22 - Fasted condition|Single oral dose of 375 mg P22 under fasted conditions (125 mg P22 x 3)
89549061|NCT02433457|Experimental|375mg P22 Fed Condition|Single oral dose of 375 mg P22 under fed conditions (125 mg P22 x 3)
89549062|NCT02433457|Experimental|CC-292 SDD 100 mg Fasted Condition|Single oral dose of 100 mg CC-292 SDD under fasted conditions
89549063|NCT02433457|Experimental|SDD plus OMP (Oral Omeprazole)|Single oral dose of 300 mg CC-292 SDD under fasted conditions (100 mg SDD x 3 tablets) in the presence of 40 mg
89549064|NCT02433457|Experimental|P22 plus OMP|Single oral dose of 375 mg P22 under fasted conditions (125 mg P22 x 3) in the presence of 40 mg oral OMP
89549065|NCT02021656|Experimental|LDV/SOF|Treatment-experienced and treatment-naive participants will receive LDV/SOF for 12 weeks.
89549066|NCT03188653|Active Comparator|CeraVe® Eczema Soothing Body Wash|One of the 7 forearm locations will be selected to receive CeraVe® Eczema Soothing Body Wash one time only.
89549067|NCT03188653|Active Comparator|Cetaphil® RestoraDerm® Eczema Calming Body Wash|One of the 7 forearm locations will be selected to receive Cetaphil® RestoraDerm® Eczema Calming Body Wash one time only.
89549068|NCT03188653|Active Comparator|Dove® Sensitive Skin Body Wash|One of the 7 forearm locations will be selected to receive Dove® Sensitive Skin Body Wash one time only.
89549069|NCT03188653|Active Comparator|Eucerin® Skin Calming Body Wash|One of the 7 forearm locations will be selected to receive Eucerin® Skin Calming Body Wash one time only.
89549070|NCT03188653|Active Comparator|Aveeno® Skin Relief Body Wash|One of the 7 forearm locations will be selected to receive Aveeno® Skin Relief Body Wash one time only.
89549071|NCT03188653|Active Comparator|MooGoo® Milk Wash|One of the 7 forearm locations will be selected to receive MooGoo® Milk Wash one time only.
89549072|NCT03188653|Active Comparator|Free & Clear Liquid Cleanser|One of the 7 forearm locations will be selected to receive Free & Clear Liquid Cleanser
89025266|NCT04701255|Active Comparator|negative spherical aberration IOL|20 human eyes with negative spherical aberration intraocular lens Implantation after phacoemulsification cataract surgery
89025267|NCT00444041|Experimental|Xelox, Bev|
89549073|NCT03144947|Experimental|Group A|"Trastuzumab IV (8 mg/kg loading dose, followed by 6 mg/kg) plus pertuzumab IV (840 mg loading dose, followed by 420 mg) plus docetaxel (75 mg/m2)*, every 3 weeks for 4 cycles.~After surgery, study patients will receive trastuzumab IV x 14 cycles"
89549074|NCT03144947|Experimental|Group B|Trastuzumab SC (fixed dose of 600 mg) plus pertuzumab IV (840 mg loading dose, followed by 420 mg) plus docetaxel (75 mg/m2)*, every 3 weeks for 4 cycles. After surgery, study patients will receive trastuzumab SC x 14 cycles
89549075|NCT02440555||patients included|fulfill the self-administered questionnaire.
89549076|NCT02433535|Experimental|Simvastatin|Simvastatin 40 mg daily will be given for 12 weeks.
89549077|NCT02433535|Placebo Comparator|Placebo|A placebo capsule will be given daily for 12 weeks.
89549078|NCT03144791||elderly , young adults|Participants are in 9 light conditions, 5 minute for each condition.
89549079|NCT03144713|Experimental|Terlipressin|Terlipressin 1mg intravenous bolus at the onset of paracentesis and the remaining as 1 mg doses intravenous at 8 and 16 h after the first dose. ( total -3mg)
89549080|NCT03144713|Active Comparator|Midodrine|Midodrine 7.5 mg thrice daily for 3 days.
88961754|NCT04294095|Active Comparator|Control|Electronic materials related to various prenatal topics including preparation for birth, birthing options, and responsive parenting will be distributed twice a week for the first 4-weeks of the program. Starting week 5 of the 12-week intervention, participants will attend two in-person, group sessions per week with each session lasting approximately 60 minutes and will be held at a local community center located close to the recruitment clinics.
88961755|NCT04281446|Experimental|G-FBM-CEN|Photobiomodulation application in women of endogenous cycle. Antares® equipment (IBRAMED, Amparo-SP, Brazil) will be used, by means of a cluster, with two wavelengths (13 LEDs of 630 nm, 300 mW + 13 LEDs of 850 nm, 500 mW), being its area of 80 cm² contact, acting 180 J of energy being applied at 15 points on each thigh - 9 in the anterior region and 6 in the posterior region, in addition to 2 points in the gastrocnemius.
89549081|NCT03144713|Active Comparator|Standard Medical Therapy|Albumin-8g/L of tap- one half of dose at beginning of tap and rest half after 6 hours of tapping.
89549082|NCT03191617|Experimental|Liquid human milk fortifier|Liquid human milk fortifier which has higher protein content and also LCPUFA
89549083|NCT03191617|Active Comparator|Powder human milk fortifier|Powder human milk fortifier with less protein content and no LCPUFA
89549084|NCT02076022|Active Comparator|Standard fat grafting|Once harvested the aspirated fat tissue will be processed as standard graft material. It will be divided into small aliquots and centrifuged in a sterile rotor (3000 rpm for 3 minutes/1200g), and top fluid oil layer from the fat tissue fractions were removed, and transferred into 1ml syringes and injected into the amputation stump. This graft preparation will be performed in the operating room. Standard fat graft material will serve as a control treatment and will be injected into limb using specialized injection cannulas
89549085|NCT02076022|Experimental|Enhanced Fat Grafting|"Approximately 60 cc of lipoaspirate will be collected from the subject to be processed with the Tissue Genesis Cell Isolation System™ (CIS) to yield approximately 35cc of Stromal Vascular Fraction (SVF).Once harvested the aspirated fat will then be divided into two portions: one portion will be processed as standard graft material (standard/control graft) while the other portion will be used in a processing step that concentrates the adipose stromal cells.~The aspirated fat processed as standard graft material will be divided into small aliquots and centrifuged in a sterile rotor (3000 rpm for 3 minutes/1200g), and allowed to decant before separating the fluid and oil layers from the fat tissue fractions, and transferred into 50 ml syringes. This graft preparation will be performed in the operating room."
89549086|NCT03191383|Experimental|GSK3003891A vaccine formulation 1 mother Group|Subjects in this group will receive a single 30µg dose of the GSK3003891A investigational vaccine, by intramuscular injection into the deltoid region of the non-dominant arm.
89549087|NCT03191383|Experimental|GSK3003891A vaccine formulation 2 mother Group|Subjects in this group will receive a single 60µg dose of the GSK3003891A investigational vaccine, by intramuscular injection into the deltoid region of the non-dominant arm.
89549088|NCT03191383|Experimental|GSK3003891A vaccine formulation 3 mother Group|Subjects in this group will receive a single 120µg dose of the GSK3003891A investigational vaccine, by intramuscular injection into the deltoid region of the non-dominant arm.
89549089|NCT03191383|Placebo Comparator|Control group|Subjects in this group will receive a single placebo injection, intramuscularly into the deltoid region of the non-dominant arm.
89549090|NCT03191383|No Intervention|GSK3003891A vaccine formulation 1 infant Group|Infants born to mothers vaccinated with a single 30µg dose of the investigational GSK3003891A vaccine
89549091|NCT03191383|No Intervention|GSK3003891A vaccine formulation 2 infant Group|Infants born to mothers vaccinated with a single 60µg dose of the investigational GSK3003891A vaccine
89549092|NCT03191383|No Intervention|GSK3003891A vaccine formulation 3 infant Group|Infants born to mothers vaccinated with a single 120µg dose of the investigational GSK3003891A vaccine
89549093|NCT03191383|No Intervention|Control infant Group|Infants born to mothers who received a single placebo injection
89549094|NCT03111641|Experimental|Lung ultrasonography|
89549095|NCT02332733|Experimental|TV003 Vaccine|Participants will receive a single injection of TV003 at Days 0 and 180.
89549096|NCT02332733|Placebo Comparator|Placebo vaccine for TV003|Participants will receive a single injection of placebo for TV003 at Days 0 and 180.
89549097|NCT03191071|Experimental|UltraPro|"General practitioners randomly assigned to the UltraPro arm will be responsible to recruit patients fulfilling the inclusion criteria and manage them using the UltraPro algorithm.~The UltraPro algorithm combines the result of a procalcitonin point-of-care test with lung ultrasound result to decide on antibiotic prescription. Blood sampling will be performed to identify potential novel biomarkers. Naso-pharyngeal swabs as well as sputum culture will allow for microbiologic identification of aetiological agents."
89025268|NCT03278288|Experimental|WellWe-Intervention group|WellWe-intervention includes the use of WellWe-app to assess the current situation of the wellbeing of the family at home and utilizing these results using WellWe-app during the health visit in Child health clinic.
89549098|NCT03191071|Experimental|Procalcitonin|"General practitioners randomly assigned to the procalcitonin arm will be responsible to recruit patients fulfilling the inclusion criteria and manage them using the procalcitonin algorithm.~The procalcitonin point-of-care test will be performed, as described above, to decide on antibiotic prescription. Blood sampling will be performed to identify potential novel biomarkers. Naso-pharyngeal swabs as well as sputum culture will allow for microbiologic identification of aetiological agents."
89549099|NCT03191071|Active Comparator|Usual Care|"General practitioners randomly assigned to the usual care arm will be responsible to recruit patients fulfilling the inclusion criteria and will manage and treat these patients as they usually do. Only general practitioners who do not use procalcitonin and lung ultrasonography routinely will be included in the usual care arm.~Naso-pharyngeal swabs as well as sputum culture will be performed to allow for microbiologic identification of aetiological agents."
89549100|NCT03111329|Experimental|GRASS - Intervention group|"The intervention group (GRASS) will receive 3 hourly feeds, with no gastric residuals being aspirated. Solely opening of the nasogastric tube once every 6 hours to relieve possible backflow of gastric content will be allowed. Amount of enteral feeds given and increase in dose will be specified in an enteral feeding plan prior to start of the study. Amount of enteral feeds given will increase every six hours with a calculated overall increase of 20 ml/kg of birth weight in the total amount given every 24 hours.~Intervention = NO aspiration of gastric residuals"
89549101|NCT03111329|No Intervention|Standard Approach group|Standard Approach group serving as control group will be treated as per standard approach - participants will be fed 3 hourly and gastric residuals checked via nasogastric tube prior to each feed. Amount of enteral feeds given and increase in dose will be specified in an enteral feeding plan prior to start of the study. Amount of enteral feeds given will increase every six hours with a calculated overall increase of 20 ml/kg of birth weight in the total amount given every 24 hours.
89549102|NCT03188497|Experimental|Experience group 1|The dose of lobaplatin is 25mg/m2 on d1,d22,d43.
89549103|NCT03188497|Experimental|Experience group 2|The dose of lobaplatin is on d1,d22,d43.
89549104|NCT03188497|Experimental|Experience group 3|The dose of lobaplatin is on d1,d22,d43.
89549105|NCT03188497|Experimental|Experience group 4|The dose of lobaplatin is 40mg/m2 on d1,d22,d43.
89549106|NCT03188497|Experimental|Experience group 5|The dose of lobaplatin is 45mg/m2 on d1,d22,d43.
89549107|NCT03188497|Experimental|Experience group 6|The dose of lobaplatin is 50mg/m2 on d1,d22,d43.
89549108|NCT03104933||Patients with septic shock|patients in septic shock admitted to the ICU
89549109|NCT02433223||2006 Patients|Comparison of Respiratory Chronic Disease Management provided against recommendations in 2005 Respiratory Nursing Guidelines through documentation
89549110|NCT02433223||2011 Patients|Comparison of Respiratory Chronic Disease Management provided against recommendations in 2005 Respiratory Nursing Guidelines through documentation. With comparison of data against 2006 results.
89549111|NCT02433223||2013 Patients|Comparison of Respiratory Chronic Disease Management provided against recommendations in 2005 Respiratory Nursing Guidelines through documentation. With comparison of data against 2006 & 2011 results.
89549112|NCT02433223||2015 Patients|Group added to reflect recency of practice. Comparison of Respiratory Chronic Disease Management provided against recommendations in 2005 Respiratory Nursing Guidelines through documentation. With comparison of data against 2006 & 2011 results.
89549113|NCT02332421|Experimental|modified dentoalveolar distractor|Canine retraction will be accomplished using a modified dentoalveolar distractor
89549114|NCT02332421|No Intervention|conventional dentoalveolar distractor|Canine retraction will be accomplished using a conventional dentoalveolar distractor
89549115|NCT02075632|Experimental|Alclometasone dipropionate cream|Alclometasone dipropionate cream 0.05% will be applied by the participants topically on the affected areas per label instructions for 14 days.
89549116|NCT02430259|Experimental|Weekly Isoniazid / Rifapentine|Weekly INH / RRT given by DOT
89549117|NCT02430259|No Intervention|No preventive treatment|Follow up without intervention
89549118|NCT02332499|Active Comparator|Anlotinib|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
89549119|NCT02332499|Placebo Comparator|Placebo|Placebo QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
89549120|NCT02075554|Other|CALIBER|1 or 2 levels of DDD between L2 and S1, treated with transforaminal interbody fusion
89549121|NCT02327819|Active Comparator|BCAA supplement|Branched-chain amino acids supplement, 12 g/day
89549122|NCT02327819|Sham Comparator|non-BCAA protein supplement|non-BCAA protein supplement
89549123|NCT02075476|Active Comparator|Hemiarthroplasty Global Fx(DePuy)|in this technique the prosthesis is implanted in similar approach to shoulder anatomy
89549124|NCT02075476|Experimental|reverse arthroplasty Delta Xtent(DePuy)|In this technique the prosthesis is implanted in the inverse mode of shoulder anatomy
89549125|NCT02327585|Experimental|Executive function training|Children diagnosis of ADHD are randomized to the experimental condition(Executive Function training) or waiting group experimental:participants will receive 12 sessions of executive function training weekly no intervention :waiting participants will not be treated with executive function therapy and keep waiting for 12 weeks for comparison
89549126|NCT02326961|Experimental|Celution ADRCs; Low Dose|Adipose Derived Regenerative Cells (ADRCs) processed by the Celution Device 20,000,000 ADRCs per single intraarticular administration
89549127|NCT02326961|Experimental|Celution ADRCs; High Dose|Adipose Derived Regenerative Cells (ADRCs) processed by the Celution Device 40,000,000 ADRCs per single intraarticular administration
89549128|NCT02326961|Placebo Comparator|Placebo|Sterile Lactated Ringers Solution (5mL) mixed with ≤ 0.20 ml of the study subject's own freshly drawn blood.
89549129|NCT02075320|Experimental|Stationary Digital Chest Tomosynthesis|All patients will be included in the experimental group.
89549130|NCT02327273|Experimental|Part A SAD: BMS-963272 or Placebo|BMS-963272 or Placebo oral capsule on specific days
89207996|NCT04042194|Experimental|Thickened with T-PRF|Following local anaesthesia, the measurement of soft tissue thickness at three points [1) occlusal part of the alveolar crest (OAC), 2) midbuccal mucosa level (MBML), 3) over 1 mm of mucogingival junction (MGJ1)] was performed with an endodontic spreader and digital caliber. Following the mid-crestal incision, the buccal flap was raised with double layer technique, while the lingual flap was left to enable direct visibility. The implant bed was drilled according to the manufacturer's protocol. The implants (BEGO Semados® RS/RSX implant system, Bremen, Germany) were placed at the bony crest. Right after the implant placement, the randomisation procedure was performed. In this group, the implants were placed in thin tissues, and T-PRF was inserted in the prepared mucoperiosteal flap at the facial site and secured with horizontal mattresses.
89207997|NCT04042194|Active Comparator|Thickened with CTG|Following local anaesthesia, the measurement of soft tissue thickness at three points [1) occlusal part of the alveolar crest (OAC), 2) midbuccal mucosa level (MBML), 3) over 1 mm of mucogingival junction (MGJ1)] was performed with an endodontic spreader and digital caliber. Following the mid-crestal incision, the buccal flap was raised with double layer technique, while the lingual flap was left to enable direct visibility. The implant bed was drilled according to the manufacturer's protocol. The implants (BEGO Semados® RS/RSX implant system, Bremen, Germany) were placed at the bony crest. Right after the implant placement, the randomisation procedure was performed. In this group, the implants were placed in thin tissues, and CTG was inserted in the prepared mucoperiosteal flap at the facial site and secured with horizontal mattresses.
89207998|NCT00960921|Experimental|Iron group|Patients with high altitude pulmonary hypertension receive six intravenous infusions of iron sucrose, administered on days 0, 4, 8, 12, 16 and 20 of the study. The total study period is 28 days. Pulmonary artery systolic pressure is measured before each infusion, and again on day 28.
89207999|NCT00960921|Placebo Comparator|Saline group|Patients with high altitude pulmonary hypertension receive six intravenous infusions of normal saline, administered on days 0, 4, 8, 12, 16 and 20 of the study. The total study period is 28 days. Pulmonary artery systolic pressure is measured before each infusion, and again on day 28.
89208000|NCT00863382|Active Comparator|1|Standard Event Monitor
89549131|NCT02327273|Experimental|Part B MAD: BMS-963272 or Placebo|BMS-963272 or Placebo oral capsule on specific days
89549132|NCT02327507||Toothpaste & Telephone Support|A tool kit with toothpaste and toothbrushes for the whole family along with oral hygiene instructions in both English and Spanish will be mailed to the homes of all OHP children and adolescents every three months. Half the populations will be assigned to also receive telephone support.
89549133|NCT02327507||Toothpaste only|A tool kit with toothpaste and toothbrushes for the whole family along with oral hygiene instructions will be mailed every three months
89549134|NCT03144869|Experimental|physical activity monitor only|"Children will wear a Runscribe accelerometer for two weeks. Runscribe is a small inertial sensor (weight 15g, size 35x25x7.5 mm). It can be attached to the body in several positions (wrist, waist, sacrum, chest, thigh, foot) and is used for monitoring movement. Runscribe does not beep, flash or have a visual display. It will not provide PA feedback to the individuals in real-time, only via a researcher after the data has been downloaded. In this study, we are not wishing to influence children's behaviour by providing PA feedback in real-time. We are trying to establish whether PA monitoring is feasible and acceptable - and further research could go on to explore the use of real-time PA feedback as an educational technique.~Phase 1 findings will help to determine: i) method of monitor distribution to participants (post, clinic or in-person), ii) preferred wear position."
89549135|NCT03144869|Experimental|physical activity monitor plus constant glucose monitor|Children using a personal constant glucose monitor (CGM) or CGM on loan from clinic as part of clinical care will be approached for Arm 2. These children will wear Runscribe at the same time as a CGM. Runscribe and CGM worn over the same 2 week period.
89549136|NCT02708095|Experimental|2 mg Baricitinib|Participants received 2 (milligrams) mg of Baricitinib tablet orally once a day for 24 weeks.
89549137|NCT02708095|Experimental|4 mg Baricitinib|Participants received 4 mg of Baricitinib tablet orally once a day for 24 weeks.
89549138|NCT02708095|Placebo Comparator|Placebo|Participants received Placebo orally once daily (QD) for 24 weeks.
89549139|NCT02327039|Experimental|Dapagliflozin|Dapagliflozin 10 mg tablet once daily for 12 weeks
89549140|NCT02327039|Placebo Comparator|Placebo|Placebo 10 mg tablet once daily for 12 weeks
89549141|NCT03142607|Active Comparator|Group A|subjects will be instructed to apply a standard 0.2 % Chlorhexidine gel (clinica gel) on the marginal gingiva for the next 14 days, twice a day for 30 minutes, after morning and evening tooth brushing
89549142|NCT03142607|Active Comparator|Group B|Subjects will be instructed to apply 0.8 % Metronidazole gel (anaerobic gel) twice daily for 30 minutes after morning and evening tooth brushing for two weeks
89549143|NCT03142607|Active Comparator|Group C|subjects will be instructed to apply 0.2 % Chlorhexidine gel (clinica gel) on the marginal gingiva after morning tooth brushing for 30 minutes and 0.8 % metronidazole gel (anaerobic gel) after evening tooth brushing for 30 minutes for two weeks. Subjects in these groups will receive the detailed and precise instruction and demonstrations on the diurnal alternate application of the two gels
89549144|NCT03144557|Experimental|Intervention|Education protocol to correct inhalation technique
89549145|NCT03186547|Experimental|Botulinum Toxin A Injection|this group will receive Botulinum Toxin A Injection at doses of 2.5 or 5 IU (depending on the degree of gum exposure) on each side of the nasolabial fold with follow up at at 2,4,8,12 and 24 weeks.
89549146|NCT03186547|Experimental|Modified Lip Repositioning Surgery|this group will receive Modified Lip Repositioning Surgery with follow up at at 2,4,8,12 and 24 weeks.
89025269|NCT03278288|No Intervention|Usual care group|Usual care includes the filling of normal paper-based questionnaires to assess the current situation of the wellbeing of the family at home and utilizing these results during the normal health visit in Child health clinic.
89208001|NCT00863382|Active Comparator|2|Sleuth recorder
89549147|NCT02440477||partial rotator cuff tears|50 subjects with shoulder pain who are diagnosed with partial rotator cuff degenrative tears by ultrasound. All patients will be measured for their body weight and height and their hand dominance will be notified. Following reliability trials on the first 10 subjects, all subjects will be tested for pain provocation and level of pain (VAS) in both shoulders with 3 commonly used clinical shoulder tests for the diagnosis of rotator cuff diseases Empty can ,Neer test and Hawkins-Kennedy test in 3 sitting postures; normal resting posture, slouched posture, and upright posture with scapular retraction. In addition, the rotator cuff muscle strength tests during shoulder abduction, internal rotation and external rotation will be measured for the 2 shoulders using a hand-held dynamometer.
89549148|NCT02440477||control group|50 volunteering subjects without any pain in the upper quadrant.All patients will be measured for their body weight and height and their hand dominance will be notified. Following reliability trials on the first 10 subjects, all subjects will be tested for pain provocation and level of pain (VAS) in both shoulders with 3 commonly used clinical shoulder tests for the diagnosis of rotator cuff diseases Empty can ,Neer test and Hawkins-Kennedy test in 3 sitting postures; normal resting posture, slouched posture, and upright posture with scapular retraction. In addition, the rotator cuff muscle strength tests during shoulder abduction, internal rotation and external rotation will be measured for the 2 shoulders using a hand-held dynamometer.
89549149|NCT05077475|Experimental|Sequence A|Period 1: C52R1H(Valsartan/Amlodipine) and C52R2(Chlorthalidone), single dose Period 2: AJU-C52L(FDC tablet, Valsartan/Amlodipine/Chlorthalidone), single dose
89549150|NCT05077475|Experimental|Sequence B|Period 1: AJU-C52L(FDC tablet, Valsartan/Amlodipine/Chlorthalidone), single dose Period 2: C52R1H(Valsartan/Amlodipine) and C52R2(Chlorthalidone), single dose
89549151|NCT02433067|Experimental|Physical activity intervention|"- Arm A standard oncologic care coupled with physical activity intervention (3 times / week)  during 3 months"
89549152|NCT02433067|Active Comparator|Control group|"- Arm B (control group) standard oncologic care"
89549153|NCT02326727|Active Comparator|General Anesthesia|Patients receiving general anesthesia with Fentanyl,Propofol, Isoflurane and Nitrous Oxide only during colonic cancer surgery
89549154|NCT02326727|Active Comparator|Combined anesthesia|Patients receiving general anesthesia and epidural analgesia with Ropivacaine during colonic cancer surgery
89549155|NCT02430025||control subjects|people had no clinical history of cardiovascular diseases,no family history of premature cardiovascular diseases.
89549156|NCT02430025||coronary atherosclerosis|Subjects with CAD also had at least one <50% stenotic lesion on coronary angiography.
89549157|NCT02430025||stable coronary artery disease|Subjects with stable CAD had clinically established atherosclerotic vascular disease but had been stable for ≥3 months.
89549158|NCT02430025||acute coronary syndrome|Subjects with CAD also had at least one ≥50% stenotic lesion on coronary angiography or a history of myocardial infarction, percutaneous coronary intervention, or coronary artery bypass grafting. All subjects with ACS exhibited acute ECG changes consistent with myocardial ischemia or elevated troponin levels. ACS was confirmed with urgent coronary angiography; all subjects had at least one ≥50% stenotic lesion with ruptured plaque or thrombus.
89549159|NCT02432911|Experimental|CAG regimen|Aclacinomycin 20mg/d for 4 days combined with cytarabine 20mg bid for 10 days with/without G-CSF 6ug/m2 from 1 day before therapy to day 10 of therapy.
89549160|NCT02432911|Active Comparator|Low dose cytarabine|cytarabine 20mg bid for 10 days.
89549161|NCT03588767|Experimental|Vitamin D3 + anabolic substance|Prospectively enrolled patients with polytrauma, administration of vitamin D3 + anabolic substance
89549162|NCT03588767|Active Comparator|Retrospective analysis|Retrospectively analyzed patients, no vitamin D3 + anabolic substance administration.
89549163|NCT02429947||INC Contact Registry Participants|Adult CMT patients who have self-registered at the Inherited Neuropathies Consortium (INC) Contact Registry, a web-based contact registry developed and supported by the Data Management and Coordinating Center (DMCC) for the Rare Diseases Clinical Research Consortium (RDCRN), located at the University of South Florida.
89549164|NCT02440321|Experimental|parent-child interactive program|The parent-child interactive program is designed by three phase: precontemplation/ contemplation stage, preparation stage, and action/maintenance stage. In phase 1, the main focus is to promote motivation through information providing and being aware of children's perception toward ETS and smoking. In phase 2, the main focus is strengthening parents/children's ability to plan and implement smoke-free home. In phase 3, intervention focus is on maintaining behavioral change and smoke-free home by continuously strengthening implementing ability, identifying and eliminating barriers, and reinforcing successful experience. Parent-child interaction is designed through three phases, and parents perceive children's feedback through all phases.
89549165|NCT02440321|Active Comparator|written materials|The mailed materials included information on ETS and its adverse effects, smoking behavior that causes ETS at home, and a workbook for smoking cessation.
89025270|NCT00478842|Experimental|1|Deep brain stimulation
89208002|NCT02554604||Pregnant woman|Pregnant woman with identified risk factors for the development of preeclampsia
89208003|NCT00743249|Experimental|Canalicular stent, 10 mm|MINI MONOKA canalicular stent (tube), 10 mm, inserted in the lower lacrimal canaliculus (tear duct) of one eye for up to 3 months
89025271|NCT00478959|Experimental|Lenalidomide|Lenalidomide given as a daily oral dose of 25 mg on days 1 - 21 followed by 7 days of no therapy of a 28 day cycle in the treatment of a population with relapsed or refractory Hodgkin's lymphoma.
89025272|NCT00444236|Active Comparator|1|
89025273|NCT00444236|Placebo Comparator|2|
89549166|NCT02440399|Experimental|Fix protocol - Oral treatment|"During 48 hours following surgery pain medications will be given as followed (listed in brackets are the generic names of each medication):~At patient arrival to the department: Intravenous Tramadol hydrochloride 100 milligrams + TAB. Paracetamol 500 milligrams + TAB. Diclofenac 100 milligrams~After 6 hours from patient arrival and every 6 hours: TAB. Zaldiar (Paracetamol 650 milligrams + Tramadol 75 milligrams).~After 12, 24 and 48 hours from patient arrival: TAB. Diclofenac 100 milligrams.~Rescue medication: TAB. Percocet (Oxycodone 5MG/Paracetamol 325 MG)as necessary up to 4 times per day.~The total amount of paracetamol is limited to 4 gr per day."
89549167|NCT02440399|Experimental|Spinal morphine|The women will receive 150 mcg morphine with the spinal anesthesia given in the cesarean section
89549168|NCT02432989|No Intervention|Resting Control Group|Patients will receive standard concussion management, but will be asked not to exercise for the first 7 days after their concussion.
89549169|NCT02432989|Experimental|Exercise Group|Patients will receive standard concussion management, but will be asked to exercise on a stationary bike on two different occasions (once for 15 minutes and again for 30 minutes) in their first week of recovery. This group will also be asked to complete a 30 minute leisurely walk at their convenience on the two days they are not tested at UBC or Fortius.
89549170|NCT03186625|Experimental|Compound Panax Notoginseng Granule|On the basis of the standard treatment for ACS,eligible participants are randomized to receive Compound Panax Notoginseng Granule when they enroll.
89549171|NCT03186625|Placebo Comparator|Placebo Granule|On the basis of the standard treatment for ACS,eligible participants are randomized to receive Placebo Granule when they enroll.
89549172|NCT03184909|Experimental|Tulsi active|
89549173|NCT03184909|Placebo Comparator|Tulsi placebo|
89549174|NCT02429635|Experimental|My exercise|"Health Screening I and II Questionnaires on health and lifestyle, physiological test of fitness, physiological health tests and blood profile - compiled in a health profile report. Individual guidance and advice from professional health advisor.~Team-workshop I and II A 2 hours' workshop lead and facilitated by a trained and professional health advisor. It consists of short talks on exercise and health, and on health behavior change and motivation in addition to work with self-reflection and discussion tasks. Competence, support and advice during 2. workshp.~Exercise groups Small groups with similar exercise level and ambitions who support each other in their efforts to establish new exercise habits according to their individual exercise plan."
89549175|NCT02429635|Experimental|Control group - delayed intervention|"Health Screening I and II Questionnaires on health and lifestyle, physiological test of fitness, physiological health tests and blood profile - compiled in a health profile report. Individual guidance and advice from professional health advisor.~Team workshops and training groups The control groups will consist of teams that will receive the team-based health promotion measures about 9 months after the Team-based health promotion measures group."
89549176|NCT03110939|Experimental|hyperthermic perfusion group|hyperthermic perfusion 1800-2000ml, normal saline, 45-48℃, 1 hour, speed 300-600ml/min (after standard surgery of advanced lung cancer/esophageal cancer)
89549177|NCT03110939|No Intervention|control group|standard surgery of advanced lung cancer/esophageal cancer
89549178|NCT02429713|Experimental|Short-duration tourniquet group|The tourniquet was inflated immediately before cement application and deflated after its hardening
89549179|NCT02429713|Active Comparator|Long-duration tourniquet group|The tourniquet was inflated immediately before incision and deflated after the hardening of the cement
89549180|NCT03144479|Experimental|Positioning of right-sided double lumen tube with fluoroscopy|positioning of the right-sided double lumen tube with a wire guide and fluoroscopy
89549181|NCT03144479|Experimental|Positioning of right-sided double lumen tube with fibroscope|positioning of the right sided double lumen tube in the same patient but with a fibroscope
89549182|NCT03186703|Experimental|Tailored knowledge translation|During the 12-week intervention, intervention group participants will have access to the Portal and will receive targeted weekly email alerts including blog posts and evidence summaries relevant to cancer prevention and be invited to follow a Twitter and Facebook feed; a unique hashtag will be created to identify and collate relevant cancer prevention information.
89549183|NCT03186703|No Intervention|Control|Participants in the control group will have access to the Portal in a 'self-serve' fashion. These participants will be able to browse the Portal, subscribe to email alerts, follow social media, etc. but will not receive the tailored intervention.
89549184|NCT03142529|No Intervention|Integrated Therapy|This arm is an control group,in which participants will receive conventional integrated therapy on CRF.
89549185|NCT03142529|Experimental|Integrated Therapy and colonic dialysis|This arm is a treatment group,in which participants will receive integrated therapy on CRF and traditional Chinese medicine Colonic dialysis with traditional Chinese medicine colon lotion once a day.
89549186|NCT03191305|Active Comparator|Coumadin Group|Patients in Coumadin Group would be administered Coumadin with overlap of heparin for first two days followed by Coumadin given orally ,dose being adjusted according to INR .The INR range would be between 2-3.it would be given once a day.The total duration OFf coumadin would be six months.
89549187|NCT03191305|Active Comparator|Rivoroxaban Group|The dose protocol would be similar to the one used in Deep Venous Thrombosis. 15 mg PO q12hr for 21 days with food, THEN 20 mg PO qDay for 6 months.
89549188|NCT03144401|Active Comparator|Preoperative|"• Group no.1 will receive preoperative sublingual 400 microgram of misoprostol (Sigma) 2 tablets and postoperative sublingual placebo2 tablets."
89025274|NCT02957279||Sepsis group|The patients were admitted to the Jinling Hospital, who met the diagnosis of sepsis(Sepsis 3.0).
89025275|NCT02957279||Healthy control group|Healthy volunteers.
89025276|NCT03278210||with EEG-fMRI data|EEG-fMRI was performed during the pre surgical evaluation, and its results were provided to the clinicians before surgery planification. The final surgery strategy was decided with EEG-fMRI results.
89208004|NCT00743249|Experimental|Canalicular stent, 20 mm|MINI MONOKA canalicular stent (tube), 20 mm, inserted in the lower lacrimal canaliculus (tear duct) of one eye for up to 3 months
89549189|NCT03144401|Active Comparator|Postoperative|"• Group no.2 will receive preoperative sublingual placebo 2 tablets and postoperative sublingual 400 microgram of misoprostol (Sigma)  2 tablets ."
89549190|NCT04483765||post-spinal hypotension|Patients with a fall in SBP by 25% of the preoperative baseline or an absolute value <90 mm of Hg; MAP ≤65 mmHg after spinal anesthesia
89549191|NCT04483765||post-spinal normotension|Patients with Fall of SBP<%25 of the preoperative value or absolute value >90 mm Hg, MAP>65 mmHg
89549192|NCT05054231|Experimental|Patient treated with CAR-T cells|
89549193|NCT03186391||Patients with suspected PAD|Use the data collected during a usual consultation to study the relationship between different parameters (rest pressure ...) and imaging
89549194|NCT02326571||spontaneous intracerebral hemorrhage|
89549195|NCT03186469|Active Comparator|Behavioral: Safety Baby shower Teen Only|Only the teen will receive the educational intervention.
89549196|NCT03186469|Active Comparator|Behavioral: Safety Baby shower Dyad|Both the teen and the teens support person will receive the educational intervention.
89549197|NCT03186469|Other|Behavioral: Standard of Care Control|Standard of care.
89549198|NCT03142217|Other|Patient with Huntington's Disease|
89549199|NCT02326415|Active Comparator|"Clinical Pathway With Fast-Track"|All the clinical performances that the health personal have to do about the patient with uncomplicated acute appendicitis is already established in a care maps since the patient comes to hospital until the discharge.
89549200|NCT02326415|Active Comparator|Postoperative Usual Protocol|The postoperative time and the clinical cares in patients with uncomplicated acute appendicitis, are defined by responsability sugery as he thinks he should be according to the literature.
89549201|NCT03117907||Infants with low infectious status|
89549202|NCT03117907||Infants with high infectious status|
89549203|NCT03142295|Experimental|Urine transfusion|Intervention: Two transfusions of 100 ml of urine within 5 days by transurethral catheterization after an antibiotic free interval of 3 days.
89549204|NCT03186313|Experimental|Part A: Arm 1|Single daily dose (2 Tablets) of Dactavira Plus each tablet contains (EPGCG 200 mg , Sofosbuvir 200mg, Daclatasvir 30 mg, Ribavirin 400 mg) for 12 weeks.
89549205|NCT03186313|Active Comparator|Part A: Arm 2|"Daily dose including Sofosbuvir 400 mg , Daclatasvir 60 mg & Ribavirin 800 mg for 12 weeks.~Treatment assignments will be stratified according to the presence or absence of cirrhosis."
89549206|NCT03186313|Experimental|Part B: Arm 3|Single daily dose (1 Tablet) of Dactavira each tablet contains (EPGCG 400 mg , Sofosbuvir 400mg, Daclatasvir 60 mg) for 12 weeks.
88961756|NCT04281446|Sham Comparator|G - Sham - CEN|"Sham Photobiomodulation (disabled) application in women of endogenous cycle.~The procedure and equipment will be the same as for the experimental groups, however no dosage will be applied:~Antares® equipment (IBRAMED, Amparo-SP, Brazil) will be used, by means of a cluster, with two wavelengths (13 LEDs of 630 nm, 300 mW + 13 LEDs of 850 nm, 500 mW), being its area of 80 cm² contact, with 0 J of energy being applied at 15 points on each thigh - 9 in the anterior region and 6 in the posterior region, in addition to 2 points in the gastrocnemius."
89549207|NCT03186313|Active Comparator|Part B: Arm 4|Daily dose including Sofosbuvir 400 mg & Daclatasvir 60 mg for 12 weeks.
89549208|NCT03144245|Experimental|AMV564|Continuous infusion or subcutaneous dosing of AMV564 at increasing dose levels
89549209|NCT03144245|Experimental|Combination AMV564|Continuous infusion or subcutaneous dosing of AMV564 at increasing dose levels in combination with pembrolizumab
89549210|NCT02326493|Experimental|CRT implantation|Patients who have a class I indication for cardiac resynchronization therapy according to current international guidelines
89549211|NCT04996199|Experimental|Oxcarbazepine GROUP|Oxcarabazepine 150mg BD starting dose & will be increased if the patient is not relieved
89549212|NCT04996199|Active Comparator|Carbamzepine GROUP|carbamazepine 100mg BD initial dose & will be increased if the patient is not relieved
89549213|NCT02432833|Experimental|Envarsus® (tacrolimus)|prolonged-release tablets once daily and orally
89549214|NCT02432833|Active Comparator|Prograf or Advagraf|Prograf® hard capsules, twice daily, oral formulation or Advagraf® prolonged-release hard capsules, once daily, oral formulation
89549215|NCT02326337|Active Comparator|Topical Wound Oxygen Device|"Application of the Topical Wound Oxygen (TWO2) device that supplies cyclical oxygen pressure directly to the wound site within a sealed and humidified environment for 90 minutes, 5 times a week with Advanced Moist Wound Therapy (AMWT) dressings.~Other Names:~Topical Wound Oxygen Therapy~TWO2"
89549216|NCT02326337|Placebo Comparator|Placebo Device|Application of placebo device that does not supply cyclical oxygen pressure directly to the wound site within a sealed and humidified environment for 90 minutes, 5 times a week with AMWT dressings.
89549217|NCT02429323|Active Comparator|sevoflurane concentration 8%|sevoflurane concentration 8% from the start
89549218|NCT02429323|Active Comparator|incremental sevoflurane (1-8%)|incremental increase of the concentration each few breaths from 1% to 8%
89549219|NCT02326103|Active Comparator|Ciprofloxacin|Oral administration of Ciprofloxacin 500mg twice daily
88961757|NCT04278833|Other|Particulate Corticosteroid Injection|Intra-articular, peri-tendinous, or intra-bursal corticosteroid injection using 10-80mg of triamcinolone or 3-9mg of betamethasone depending on anatomical structure. Injections may be repeated up to 3 times in the 6 month study period based on physician discretion.
88961758|NCT04278833|Other|Non-particulate Corticosteroid Injection|Intra-articular, peri-tendinous, or intra-bursal corticosteroid injection using 4-10mg of dexamethasone depending on anatomical structure. Injections may be repeated up to 3 times in the 6 month study period based on physician discretion.
89208005|NCT00973089|No Intervention|Complete caries removal|Control group
89208006|NCT00973089|Other|Incomplete caries removal|Test group
89549220|NCT02326103|Placebo Comparator|Placebo|Oral administration of Placebo pill twice daily
89549221|NCT02707861|Experimental|Cohort 1|"IV ibalizumab (combined with optimized background regimen):~800 mg once every two weeks for patients receiving that dosage on prior, successfully completed ibalizumab clinical trial~OR~2000 mg once every four weeks for patients receiving that dosage on prior, successfully completed ibalizumab clinical trial~Administered for 48 weeks, or until ibalizumab becomes commercially available"
88961759|NCT04270838|Experimental|Group AC1 (Adult low dose)|Volunteers aged 18-45 years. Volunteers will receive a standalone dose of 2.5×10^10 vp ChAdOx2 RabG on D0. Volunteers will receive two doses of Rabies IRV as simulated post-exposure prophylaxis (SPEP), 14 days apart during the follow-up period. All participants will receive Verorab as a 4 site ID on SPEP+0, and Verorab as a 2 site ID on SPEP+14. Participants who return a virus neutralising antibody (VNA) result below 0.5IU/mL will be randomised (1:1 ratio) for the SPEP+0 visit to happen at the next available visit or at the final annual visit. Any participants who do not return a VNA result below 0.5IU/mL will have their SPEP+0 visit take place at the final annual visit.
88961760|NCT04270838|Experimental|Group AC2 (Adult high dose)|Volunteers aged 18-45 years. Volunteers will receive a standalone dose of 5×10^10 vp ChAdOx2 RabG. Volunteers will receive two doses of Rabies IRV as simulated post-exposure prophylaxis (SPEP), 14 days apart during the follow-up period. All participants will receive Verorab as a 4 site ID on SPEP+0, and Verorab as a 2 site ID on SPEP+14. Participants who return a virus neutralising antibody (VNA) result below 0.5IU/mL will be randomised (1:1 ratio) for the SPEP+0 visit to happen at the next available visit or at the final annual visit. Any participants who do not return a VNA result below 0.5IU/mL will have their SPEP+0 visit take place at the final annual visit.
89025277|NCT03278210||without EEG-fMRI data|EEG-fMRI was performed during the pre surgical evaluation, but clinicians were blinded to the results. The final surgery strategy was decided without EEG-fMRI results.
89025278|NCT03278171||Patients in intensive care unit|Cohort of patients leaving intensive care unit after a stay of more than 72 hours
89208007|NCT00863460|Active Comparator|A|MTX-based chemotherapy followed by WBRT
89208008|NCT00863460|Experimental|B|MTX-based chemotherapy followed by intensive chemotherapy and hematopoietic stem cell rescue
89549222|NCT02707861|Experimental|Cohort 2|"IV ibalizumab (combined with optimized background regimen):~800 mg once every two weeks for qualifying patients who have never received ibalizumab~Administered for 48 weeks, or until ibalizumab becomes commercially available"
89549223|NCT04908137|Experimental|2-Octyl Cyanoacrylate (Dermabond) Group|2-Octyl Cyanoacrylate (Dermabond) 0.5ml/ sticks topical application around post-circumcision site subcoronal area immediately after the circumcision devise is removed and circumcision procedure was done
89549224|NCT04908137|No Intervention|Control Group|will receive Vaseline cream application around the post-circumcision site immediately after circumcision
89549225|NCT02432599|Experimental|F18-choline PET|F18-choline PET examination will be performed before surgery
89549226|NCT02326181|No Intervention|control group|without inspiratory and expiratory pressure threshold training
89549227|NCT02326181|Experimental|inspiratory pressure training group|The patients will perform daily in 2 sessions of 30 minutes, using a pressure threshold trainer.
89549228|NCT02326181|Experimental|mixed training group|The patients will perform daily in 2 sessions of 30 minutes, using a pressure threshold trainer.
89549229|NCT02432755|Experimental|home-based MTOT|Home-based mirror therapy combined with task-oriented training (MTOT)
89549230|NCT02432755|Active Comparator|hospital-based therapy|hospital-based individualized occupational therapy
89549231|NCT02432755|Experimental|hospital-based MTOT|hospital-based mirror therapy combined with task-oriented training (MTOT)
89549232|NCT04904705|Active Comparator|Cognitive Orientation to Daily Occupational Performance (CO-OP) Approach|"It will be given a home program. Then The Cognitive Orientation to Daily Occupational Performance (CO-OP) Approach will be applied by video conferencing method in a total of 10 sessions, 2 sessions per week, through 5 weeks, and a total of 12 sessions with initial and final evaluations.~The Cognitive Orientation for Daily Activity Performance (CO-OP) approach is a person-oriented, performance-solving. and problem-solving approach that enables strategy acquisition and guided exploration for the acquisition and learning of new skills."
89549233|NCT04904705|Active Comparator|Home Program|It will be given a home program only.
89549234|NCT02429401|Experimental|Culturally adapted brief intervention|
89549235|NCT02429401|Active Comparator|Non-adapted brief intervention|
89549236|NCT05076851|Placebo Comparator|placebo group|placebo+ADT
89549237|NCT05076851|Experimental|Proxalutamide|Proxalutamide +ADT
89549238|NCT04890509|Experimental|Standard of Care + Bemcentinib|Bemcentinib will be administered for up to 15 days, or until discharge from hospital, whichever comes sooner. SoC will be administered based on local guidelines.
89549239|NCT04890509|Active Comparator|Standard of Care|The SoC will be administered based on local guidelines in place at the time of treatment during the study.
89549240|NCT03185143|Experimental|Naltrexone and Acetaminophen Combination|
89549241|NCT03185143|Active Comparator|Sumatriptan 100 mg|
89549242|NCT03185143|Placebo Comparator|Placebo|
89549243|NCT05076773|Placebo Comparator|Control Group (D)|Patient will receive opioid only for management of their perioperative pain
89549244|NCT05076773|Active Comparator|Paravertebral block Group (A)|Will receive thoracic paravertebral block
89549245|NCT05076773|Active Comparator|Pectoral block Group (B)|Will receive pectoral 1 and 2 block
89549246|NCT05076773|Active Comparator|Erector spinae block Group (C)|Will receive erector spinae block
89549247|NCT02432677|Experimental|Remifentanil + Active tDCS|"tDCS session: the procedure will initiate by placing an anode electrode on the primary motor cortex (contralateral to the dominant cortex) and the cathode electrode on the contralateral supra-orbital region. The current employed is 2mA of transcranial direct-current stimulation administered for 20 minutes.~Remifentanil - 0,06mcg.kg.min - Infusion 10min before the tDCS session, during the tDCS session and after the tDCS session, until the end of pain tests."
89549248|NCT02432677|Other|Placebo + Active tDCS|"tDCS session: the procedure will initiate by placing an anode electrode on the primary motor cortex (contralateral to the dominant cortex) and the cathode electrode on the contralateral supra-orbital region. The current employed is 2mA of transcranial direct-current stimulation administered for 20 minutes.~Placebo: Saline infusion - Infusion 10min before the tDCS session, during the tDCS session and after the tDCS session, until the end of pain tests."
89549249|NCT02432677|Other|Remifentanil + Sham tDCS|"Sham tDCS: consists in the same montage of the active tDCS, but the device is turned off 30 seconds after starting stimulation (without letting the patient notice it). The rest of the montage is kept identical to the active one during the 20 minutes session.~Remifentanil - 0,06mcg.kg.min - Infusion 10min before the tDCS session, during the tDCS session and after the tDCS session, until the end of pain tests."
89549250|NCT02432677|Other|Placebo + Sham tDCS|"Sham tDCS: consists in the same montage of the active tDCS, but the device is turned off 30 seconds after starting stimulation (without letting the patient notice it). The rest of the montage is kept identical to the active one during the 20 minutes session.~Placebo: Saline infusion - Infusion 10min before the tDCS session, during the tDCS session and after the tDCS session, until the end of pain tests."
89549251|NCT03144167|Other|Patients, aged 18-88, with glioblastoma|
89549252|NCT02432443|Experimental|Motor and pre-literacy program|First group to receive the motor and pre-literacy program.
89549253|NCT02432443|Active Comparator|Wait-list comparison|Second group to receive the motor and pre-literacy program after the experimental arm has completed the program.
89549254|NCT03442673|Active Comparator|CG (Chemotherapy/G-CSF) - Regime|Vinorelbine 35 mg/m2 at day 1 as an i.v. infusion over 10 minutes or gemcitabine 1250 mg/m2 as a 30 minutes infusion at day 1. G-CSF will be started at day 4 at 10mcg/kg b.w. split in two daily doses, until the end of the stem cell collection procedure, with the first collection attempt on day 8.
89549255|NCT03442673|Experimental|G (G-CSF) - Regime|G-CSF at 10mcg/kg b.w. split in two daily doses starting from day 1 until the end of the stem cell collection procedure, with the first collection attempt on day 5.
89549256|NCT03184831|Active Comparator|sinus lift, implant placement, sole bovine bone|sinus floor elevation with simultaneous implant placement together with grafting the sinus with a deproteinized bovine bone solely.
89549257|NCT03184831|Experimental|sinus lift, implant placement, injectable PRF + bovine bone|sinus floor elevation with simultaneous implant placement together with grafting the sinus with a mixture of injectable platelet rich fibrin with a deproteinized bovine bone.
89549258|NCT03185299|Experimental|Video|Patients randomized to the intervention arm will be contacted 48-72h before their procedure via telephone using a standardized script and will be provided a link to a website allowing posting of videos for public viewing
89549259|NCT03185299|Experimental|Standard preparation instructions|The control arm will receive written instruction on preparing for a colonoscopy per standard of care
89549260|NCT03117673||group 1|Patients with mild to moderate TI and normal RVSP (< 40mmHg) and mean PAP (< 25mmHg)
89025279|NCT00441597|Active Comparator|1|first 3 day treatment placebo and 4 weeks later three day treatment with atorvastatin 80 mg
89549261|NCT03117673||group 2|Patients with mild to moderate TI and elevated RVSP (> 40mmHg) and mean PAP (> 25mmHg)
89549262|NCT03117673||group 3|Patients with severe TI (defined as Vena contracta > or equal 7mm, reversed systolic hepatic vein flow, proximal isovelocity surface area (PISA) radius > 9 mm, and very large central jet or eccentric wall impinging jet)
89549263|NCT04741841|Placebo Comparator|Placebo|The placebo product is identical to active product in taste and appearance but without probiotic
89549264|NCT04741841|Active Comparator|Treatment high dose|High dose GutMagnific™
89549265|NCT04741841|Active Comparator|Treatment low dose|Low dose GutMagnific™
89549266|NCT02432365|Experimental|Weekly paclitaxel and cisplatin|7-day cycle schedule of paclitaxel (60 mg/m2) combining with cisplatin (40 mg/m2) NAC regimen followed by radical hysterectomy and bilateral pelvic lymphadenectomy
89549267|NCT05076695|Experimental|TPPF group|Patients will be treated with Trastuzumab, Pyrotinib, Palbociclib plus Fulvestrant(TPPF).
89549268|NCT03143933|Active Comparator|propofol|this arm will receive propofol in induction of anesthesia and blood sample will be withdrawn before induction and another sample will be withdrawn after induction with 3 mins
89549269|NCT03143933|Active Comparator|propofol and fentanyl|this arm will receive propofol and fentanyl in induction of anesthesia and blood sample will be withdrawn before induction and another sample will be withdrawn after induction with 3 mins
89549270|NCT02440243|Active Comparator|Patients active|Purethal Grass
89549271|NCT02440243|Placebo Comparator|Patients placebo|Placebo
89549272|NCT04723043|Active Comparator|v group|patients will ventilate with volume controlled mode
89549273|NCT04723043|Active Comparator|p group|patients will ventilate with pressure controlled mode
88961761|NCT04270838|Experimental|Group AC3 (Adult preferred dose)|Volunteers aged 18-45 years. Volunteers will receive a preferred dose of ChAdOx2 RabG on D0. The adult preferred dose will be 2.5×10^10 vp OR 5×10^10 vp. Volunteers will receive two doses of Rabies IRV as simulated post-exposure prophylaxis (SPEP), 14 days apart during the follow-up period. All participants will receive Verorab as a 4 site ID on SPEP+0, and Verorab as a 2 site ID on SPEP+14. Participants who return a virus neutralising antibody (VNA) result below 0.5IU/mL will be randomised (1:1 ratio) for the SPEP+0 visit to happen at the next available visit or at the final annual visit. Any participants who do not return a VNA result below 0.5IU/mL will have their SPEP+0 visit take place at the final annual visit.
88961762|NCT04270838|Experimental|Group AV1 (Adult single-visit Verobab)|Volunteers aged 18-45 years. Volunteers will receive Rabies IRV on D0. Volunteers will receive two further doses of Rabies IRV as simulated post-exposure prophylaxis (SPEP), 14 days apart during the follow-up period. All participants will receive Verorab as a 4 site ID on SPEP+0, and Verorab as a 2 site ID on SPEP+14. Participants who return a virus neutralising antibody (VNA) result below 0.5IU/mL will be randomised (1:1 ratio) for the SPEP+0 visit to happen at the next available visit or at the final annual visit. Any participants who do not return a VNA result below 0.5IU/mL will have their SPEP+0 visit take place at the final annual visit.
88961763|NCT04270838|Experimental|PC1a (Paediatric low dose)|Volunteers aged 2-6 years. Volunteers will receive a standalone dose of 1×10^10 vp ChAdOx2 RabG on D0. Volunteers will receive two doses of Rabies IRV as simulated post-exposure prophylaxis (SPEP), 14 days apart during the follow-up period. All participants will receive Verorab as a 4 site ID on SPEP+0, and Verorab as a 2 site ID on SPEP+14. Participants who return a virus neutralising antibody (VNA) result below 0.5IU/mL will be randomised (1:1 ratio) for the SPEP+0 visit to happen at the next available visit or at the final annual visit. Any participants who do not return a VNA result below 0.5IU/mL will have their SPEP+0 visit take place at the final annual visit.
88961764|NCT04270838|Experimental|PC1b (Paediatric low dose)|Volunteers aged 2-6 years. Volunteers will receive a half adult preferred dose of ChAdOx2 RabG on D0. The adult preferred dose will be 2.5×10^10 vp OR 5×10^10 vp. Volunteers will receive two doses of Rabies IRV as simulated post-exposure prophylaxis (SPEP), 14 days apart during the follow-up period. All participants will receive Verorab as a 4 site ID on SPEP+0, and Verorab as a 2 site ID on SPEP+14. Participants who return a virus neutralising antibody (VNA) result below 0.5IU/mL will be randomised (1:1 ratio) for the SPEP+0 visit to happen at the next available visit or at the final annual visit. Any participants who do not return a VNA result below 0.5IU/mL will have their SPEP+0 visit take place at the final annual visit.
89025280|NCT00441597|Active Comparator|2|first 3 day treatment atorvastatin 80 mg and 4 weeks later three day treatment with placebo
89025281|NCT00441597|No Intervention|3|3 days treatment with placebo twice
89549274|NCT02440165|Experimental|Experimental|"The early nursing nutrition intervention will include malnutrition screening (during outpatient clinic visit) with the MUST. If patients are ´at risk for malnutrition´ or ´malnourished´, a standardized nutrition care plan will be discussed with the patient by the nurse. This nutrition care plan will include:~Information and advice;~Examples of energy and protein rich meals;~patients will be asked to register their nutritional intake for two days at home;~after a week, the nurse will call the patients to answer questions and to give advice.~This nutrition care plan will be tailored to the individual patient requirements.~Furthermore, if patients are 'malnourished', a visit to the dietician is always suggested, because this is usual care."
89549275|NCT02440165|No Intervention|Usual care|All participants, both in the intervention group and the control group, receive usual care containing a regular visit to a nurse who will perform a malnutrition screening with the MUST (Malnutrition Universal Screening Tool). If patients are 'malnourished', a visit to the dietician is suggested.
89549276|NCT04705259|Active Comparator|ENGAGEMENT bundle|A multimodal bundle of interventions to optimise antibiotic prescribing in residential aged care facilities. The bundle includes education for nurses and general practitioners caring for residents, telehealth support and implementation of state-wide guidelines.
89549277|NCT04705259|Placebo Comparator|Usual care|Usual facility practices with regards to antibiotic prescribing and review
89549278|NCT05076461|Experimental|ondansetron group|Children in ondansetron group received oral suspension of ondansetron as 0.15mg per body weight
89549279|NCT05076461|Experimental|Domperidone group|Children in domperidone group, oral suspension of domperidone was given as 0.5 mg per kg body weight
89549280|NCT02428933|Other|Before and after bromocriptine|Subjects will be investigated before and after the use of bromocriptine. They will use bromocriptine for two weeks in the evening (1.25mg/day during the first week and 2.5mg/day during the second week).
89549281|NCT02428777|Active Comparator|Tramadol|Women will receive oral tramadol 100 mg 1 hour before the procedure
89549282|NCT02428777|Active Comparator|Diclofenac|Women will receive oral diclofenac 100 mg 1 hour before the procedure
89549283|NCT02428777|Placebo Comparator|Placebo|Women will receive an oral placebo 1 hour before the procedure
89549284|NCT03142373|Experimental|CV4 group|CV4 technique
89549285|NCT03142373|Experimental|RR group|Rib Raising technique
89549286|NCT03142373|Placebo Comparator|Placebo group|Light touch
89549287|NCT02429011||MDD|patients with current MDD
89549288|NCT02429011||Healthy Control (HC)|healthy control volunteers
89549289|NCT05233657|Experimental|JX11502MA 0.25mg、0.5mg、1mg、2mg、3mg、6mg、8mg|Participants received JX11502MA capsule 0.25mg、0.5mg、1mg、2mg、3mg、6mg、8mg orally administration once, once on an empty stomach in the morning, with about 240ml of warm water.
89549290|NCT05233657|Placebo Comparator|Placebo 0.25mg、0.5mg、1mg、2mg、3mg、6mg、8mg|Participants received placebo capsule 0.25mg、0.5mg、1mg、2mg、3mg、6mg、8mg orally administration once, once on an empty stomach in the morning, with about 240ml of warm water..
89549291|NCT03142139||Danish Birth Cohorts 1997-2012|"RQ1a: Delayed vs. timely vaccination with the 1st dose of DTaP-IPV-Hib~RQ1b: Delayed vs. timely vaccination with the 2nd dose of DTaP-IPV-Hib among children who received a timely first dose of DTaP-IPV-Hib~RQ2: Vaccination with DTaP-IPV-Hib compared to being unvaccinated on development of Atopic Dermatitis."
89549292|NCT02432131||Divers with PFO|
89549293|NCT02432131||Divers without PFO|
89549294|NCT02030327||No trauma|n=5 patients
89549295|NCT02030327||trauma without organ dysfunction|n=40 patients
89549296|NCT02030327||trauma with organ dysfunction|n=40 patients
89025282|NCT03278132|Experimental|EV71 vaccine & blood sampling (0, 10,60)|This group receive two doses injection of EV71 vaccine (0, 28 days), and three times of blood sampling on day of 0, 10, and 60 respectively for EV71 neutralizing antibody detection.
89025283|NCT03278132|Experimental|EV71 vaccine & blood sampling (0, 20,60)|This group receive two doses injection of EV71 vaccine (0, 28 days), and three times of blood sampling on day of 0, 20, and 60 respectively for EV71 neutralizing antibody detection.
89549297|NCT02432053|Experimental|Transplantation|Advagraf
89549298|NCT04624919|Active Comparator|Hot/Dry|
89549299|NCT04624919|Experimental|Warm/Humid|
89549300|NCT03186157||Decompressive craniectomy patients|All of the patients that undergo decompressive craniectomy due to intracranial mass lesion and are transferred to neuro-rehabilitation unit in our university hospital.
89549301|NCT02429089|Experimental|Group I|The patients will receive the same molecules (cetuximab and LEE011) but this phase I study will determine the DLTs by dose escalation of LEE011 (400 mg and 600mg).
89549302|NCT03141827|Experimental|Insulin|Nasal spray, insulin 40 IU, single dose
89549303|NCT03141827|Placebo Comparator|Placebo|Nasal spray, placebo, single dose
89549304|NCT03190681|Experimental|methylphenidate|
89549305|NCT03190681|Placebo Comparator|inactive pill|
89549306|NCT03143777|No Intervention|Baseline|Standard physiotherapy and mobilisation
89549307|NCT03143777|Experimental|Sara Combilizer group|Ongoing care with the sara combilizer available for use
89549308|NCT04604405|Experimental|photobiomodulation|Eyes are irradiated with 650nm low energy red light
89549309|NCT04604405|No Intervention|blank|no intervention except for wear glasses
89549310|NCT03186235||Group I : 18 healthy controls|Two milliliter of heparinized whole blood samples will be used for the Flow cytometry analysis to quantify percentages of circulating regulatory T cells in human peripheral blood in chronic hepatitis C patients in comparison with that of controls by four-colour flow cytometry analysis using a set of fluorochrome-labeled monoclonal antibodies against regulatory T cell surface markers and estimation of the level of IL35 by ElISA.
89549311|NCT03186235||group II : 16 Hepatitis C infected patients (naïve)|Two milliliter of heparinized whole blood samples will be used for the Flow cytometry analysis to quantify percentages of circulating regulatory T cells in human peripheral blood in chronic hepatitis C patients in comparison with that of controls by four-colour flow cytometry analysis using a set of fluorochrome-labeled monoclonal antibodies against regulatory T cell surface markers and estimation of the level of IL35 by ElISA.
89549312|NCT03186235||group III:18 HCV-infected patients complicated with cirrhosis|Two milliliter of heparinized whole blood samples will be used for the Flow cytometry analysis to quantify percentages of circulating regulatory T cells in human peripheral blood in chronic hepatitis C patients in comparison with that of controls by four-colour flow cytometry analysis using a set of fluorochrome-labeled monoclonal antibodies against regulatory T cell surface markers and estimation of the level of IL35 by ElISA.
89549313|NCT03186235||group IV: 18 HCV-infected patients with Hepatocellular cancer|Two milliliter of heparinized whole blood samples will be used for the Flow cytometry analysis to quantify percentages of circulating regulatory T cells in human peripheral blood in chronic hepatitis C patients in comparison with that of controls by four-colour flow cytometry analysis using a set of fluorochrome-labeled monoclonal antibodies against regulatory T cell surface markers and estimation of the level of IL35 by ElISA.
89549314|NCT03186235||Group V:18 patients with sustained viral response (SVR).|Two milliliter of heparinized whole blood samples will be used for the Flow cytometry analysis to quantify percentages of circulating regulatory T cells in human peripheral blood in chronic hepatitis C patients in comparison with that of controls by four-colour flow cytometry analysis using a set of fluorochrome-labeled monoclonal antibodies against regulatory T cell surface markers and estimation of the level of IL35 by ElISA.
89549315|NCT05068115||1|Young breast cancer patients in China from 2000 to 2015, of whom the clinical features, diagnosis and treatment models and survival status are described.
89549316|NCT03186001|Experimental|v shape|Technique 1Lateral orbicularis and corrugator injections: 5 equally spaced injections will be placed intramuscularly into the orbicularis under the lateral eyebrow starting lateral to the level of the lateral limbus and extending to the level of the inferior orbital rim. In addition, 2 injections will be placed 1cm apart into the corrugator starting at the medial brow and extending laterally. Then 5 equally spaced injections, in a V pattern will be placed in the frontalis. The first injection between the medial brows, 2 injection 1cm below the hairline at the level of the lateral canthus and one injection equidistant to medial and lateral injection.
89025284|NCT03278132|Experimental|EV71 vaccine& blood sampling (0, 30, 60)|This group receive two doses injection of EV71 vaccine (0, 28 days), and three times of blood sampling on day of 0, 30, and 60 respectively for EV71 neutralizing antibody detection.
89025285|NCT04701372||Obsessive-Compulsive Disorder|adults, adolescents, and children with obsessive-compulsive disorder
89025286|NCT00479193|Other|1|There is one arm to the study. The same subjects are their own control. One of the investigators will identify two sites that appear to be the same depth on each patient [1 site Polymen and 1 site bacitracin/xeroform )]. One site will be identified for bacitracin/xeroform and one site for Polymen. All burns will be initially debrided and cleaned according to burn unit protocol. Laser Doppler will be utilized to determine burn depth at both the trial and control sites. On each subsequent visit, patients will rate the pain of the dressing change on a 1-10 pain intensity scale.The study will end for each patient when the investigator determines that 95% of their burn has re-epithelized.
89025287|NCT03278054|Active Comparator|Manual group|Root Canal Treatment with hand instruments:Root canal treatment was done with instrumentation using manual K files.
89549317|NCT03186001|Experimental|middle frontalis|: Lateral orbicularis and corrugator injections: 5 equally spaced injections will be placed intramuscularly into the orbicularis under the lateral eyebrow starting lateral to the level of the lateral limbus and extending to the level of the inferior orbital rim. In addition, 2 injections will be placed 1cm apart into the corrugator starting at the medial brow and extending laterally. Then 5 equally spaced injections, in a straight pattern will be placed in the frontalis. One injection in the middle of the forehead, one on the same level of the lateral canthus and one between them.
89549318|NCT03186001|Experimental|high frontalis|: Lateral orbicularis and corrugator injections: 5 equally spaced injections will be placed intramuscularly into the orbicularis under the lateral eyebrow starting lateral to the level of the lateral limbus and extending to the level of the inferior orbital rim. In addition, 2 injections will be placed 1cm apart into the corrugator starting at the medial brow and extending laterally.Then 5 equally spaced injections, in a straight pattern 1 cm below the hairline will be placed in the frontalis. One injection in the middle of the forehead, one on the same level of the lateral canthus and one between them.
89549319|NCT04593563|Experimental|Psilocybin 25mg|Psilocybin 25mg Single does with supportive conditions.
89549320|NCT03185923|Experimental|TCM plus conventional drug|The experimental group will receive three type of TCM inaddition conventional drug according to china CAP guidline 2016.
89549321|NCT03185923|Placebo Comparator|TCM placebo plus conventional drug|The control group will receive three type of placebo TCM inaddition conventional drug according to china CAP guidline 2016.
89549322|NCT04551911|Experimental|30 mcg calcifediol Extended-Release (ER) Capsule|Subjects will be instructed to take a loading dose of 10 capsules (300 mcg) of study drug per day on Days 1, 2 and 3 at bedtime after fasting for at least 3 hours following dinner, with any nonalcoholic liquid, by the oral route. On Days 4-27, subjects will take a maintenance dose of 2 capsules per day at bedtime unless otherwise directed.
89549323|NCT04551911|Placebo Comparator|0 mcg calcifediol Extended-Release (ER) Capsule|Subjects will be instructed to take a loading dose of 10 capsules (0 mcg) of study drug per day on Days 1, 2 and 3 at bedtime after fasting for at least 3 hours following dinner, with any nonalcoholic liquid, by the oral route. On Days 4-27, subjects will take a maintenance dose of 2 capsules per day at bedtime unless otherwise directed.
89549324|NCT02428465|Experimental|Purposeful Parenting|Families randomized to the intervention group will receive their pediatric provider's usual anticipatory guidance plus Purposeful Parenting.
89549325|NCT02428465|No Intervention|Control Group|Families randomized to the control group will receive usual anticipatory guidance, delivered at the discretion of their pediatric provider, at each well-child visit in the first 12 months of life.
89549326|NCT03143387|Active Comparator|Atraumatic Restorative Treatment|Partial removal of carious tissue using manual instruments.
89549327|NCT03143387|Experimental|Chemo-mechanical Removal|Partial removal of carious tissue using manual instruments and the material Chemo-mechanical removal group using Papacarie™gel.
89549328|NCT02431975|Experimental|Early ART|All infants enrolled in the trial, regardless of maternal PMTCT regimen, will be initiated on a triple ARV regimen consisting of nevirapine (NVP), zidovudine (ZDV) and lamivudine (3TC) presumptively based on the initial positive result. This regimen will be continued to 42 weeks post menstrual age (PMA). At this time, infants will be switched to LPV/r, ZDV and 3TC to be continued to 104 weeks or longer unless otherwise preferred by the treating clinician or if any clinical or laboratory contraindications are identified.
89549329|NCT03143465|Experimental|CGRP|
89549330|NCT03143465|Experimental|Sildenafil|
89549331|NCT03143465|Placebo Comparator|Placebo|
89025288|NCT03278054|Active Comparator|ProTaper group|Root canal treatment with Protaper instruments:Root canal treatment was done using ProTaper rotary files S1, S2, F1, and F2.
89549332|NCT02431819|Experimental|contention socks|Patients wear evolutive contention socks during 15 days.
89549333|NCT05034809|Experimental|Treatment Group|Other than the guided management of Dengue Fever with warning signs, the treatment group will receive a standard dose of 20mg/day of melatonin20-21 for 5 days. The dosing was based on the study by Leiberman et al and Malhotra et al. If a patient is unable to tolerate the whole or punctured tablet, it will be given with milk or water. There is no known interaction between melatonin and milk known to date. Daily complete blood count will be done and be recording in an electronic record using Microsoft Excel.
89549334|NCT05034809|No Intervention|Control Group|Other than the guided management of Dengue Fever with warning signs, the control group will be manage according the Department of Health Dengue Management Guideline. No placebo will be given.
89549335|NCT02428543|Experimental|Ponatinib arm|dose-escalation Arm _ 15, 30, 45mg Ponatinib per day. Each cohort will consist of 3 evaluable patients
89549336|NCT04428203|Experimental|single arm|A Phase I/Ib on the Safety of Epidiolex in Patients with Prostate Cancer with Rising PSA after Localized Therapy with either Surgery or Radiation
89549337|NCT04381325|Experimental|MSB0254 Injection|This experiment will start from 4mg/kg with a dose increase of 3+3, and is planned to be carried out in 5 dose groups, namely 4mg/kg, 8mg/kg (100% increase), 12mg/kg (50% increase), 16mg/kg (33% increase) and 20mg/kg (25% increase).MSB0254 injection was administered intravenously on day 1 and day 15 every 28 days.To collect pharmacokinetic blood samples after repeated administration, MSB0254 injection was not administered on day 1 of the third cycle (C3D1).The observation period of DLT was 28 days after the first administration. An intravenous infusion with concentration 20 mg/kg every 3 weeks (Q3W).
89549338|NCT02431663|Experimental|ketamine up to 100 mcg/kg/min|Two intravenous boluses of 2-3 mg/kg each of ketamine will be administered 5 minutes apart and immediately followed by a continuous infusion of 5-10 mcg/kg/min. Based on both clinical or electrographic responses, dosage will be increased every 10 minutes or longer, using 2 to 10 mcg/kg/ min increments, up to 60 mcg/kg/min. Maximum duration of infusion will be of 7 days.
89549339|NCT02431663|Active Comparator|midazolam & thiopental & propofol|"Midazolam intravenous will be increased every 5 minutes, using 2 mcg/kg/min increments, up to 12 mcg/kg/min and Thiopental intravenous will be increased every 30 minutes or longer, using 1 mg/kg/h increments, up to 6 mg/kg/h and Propofol intravenous will be increased every 5 minutes or longer, using 1 mg/kg/h increments, up to 5 mg/kg/h.~Maximum duration of infusion for each drug will be 48 hours."
89549340|NCT05014217||Mentalization-based Treatment|Participants who have been oriented to the mentalization-based treatment among the clinical adult population with a cluster B personality disorder.
89549341|NCT05014217||Dialectical Behavior Therapy-inspired Treatment|Participants who have been oriented to the dialectical behavior therapy-inspired treatment among the clinical adult population with a cluster B personality disorder.
89549342|NCT02428621|Experimental|Twicare® appliance|Group treated with the Twicare® appliance. This appliance is a removable mandibular propulsive adjustable preformed medical device. It is made out of soft and stiff thermoplastics. Its two gutters are linked to each other according to different antero-posterior positions. It is EC marked since 2011.
89549343|NCT02428621|Active Comparator|Removable Herbst appliance|Group treated with the removable Herbst appliance. This appliance is a medical device measured made composed of telescopic metallic hinges and resin gutters made-to-measure based on dental impression.
89549344|NCT02428621|No Intervention|Untreated|Children will not wear any interceptive activator. They will have a routine follow-up with their orthodontist waiting for the placing of a fixed appliance.
89549345|NCT02428387|Experimental|Intervention|"The intervention group (Group 1) will receive instructions on how to access My Tools 4 Care for 3 months."
89549346|NCT02428387|No Intervention|Educational Control|An educational control group (Group 2) will receive a copy of the Alzheimer's Society' The Progression of Alzheimer's Disease - Overview Booklet.
89549347|NCT02431585|Other|rechallenge|Double blind placebo controlled cross over
89549348|NCT03143231|Experimental|Normal saline|Sodium Chloride 0.9% will be provided
89549349|NCT03143231|Experimental|Hypertonic saline|500 ml Sodium Chloride 0.9% with 60 ml Sodium Chloride 20% will be provided
89549350|NCT03185845|Experimental|Prolonged anticoagulation|3 months longer anticoagulation after regular treatment
89549351|NCT03185845|No Intervention|Regular anticoagulation|stop anticoagulation after regular treatment
89549352|NCT03184597|Experimental|Group with two strong risk factors|When HLA screening before commencing aromatic AEDs shows positive for both HLA-A*24:02 and HLA-B*15:02 in a patient, aromatic AEDs were not administrated for this patient.
89549353|NCT03184597|Experimental|Group with one strong risk factors|"When HLA screening before commencing aromatic AEDs shows positive for HLA-B*15:02, carbamazepine (CBZ) was not administrated, and other aromatic AEDs were prescribed with caution or avoided if alternative non-aromatic AEDs can be prescribed instead.~When HLA screening before commencing aromatic AEDs shows positive for HLA-B*15:01 or HLA-A*24:02, aromatic AEDs were prescribed with caution or avoided if alternative non-aromatic AEDs can be prescribed instead."
89549354|NCT03184597|Experimental|Group with one potential risk factors|When HLA screening before commencing aromatic AEDs shows positive for any potential risk allele such as HLA-B*15:11, HLA-A*02:01and HLA-DRB1*01:01, aromatic AEDs were prescribed with caution or avoided if alternative non-aromatic AEDs can be prescribed instead.
89549355|NCT03184597|Experimental|Group without known risk factors|When HLA screening before commencing aromatic AEDs shows negative for any known HLA risk allele , aromatic AEDs was administrated to these patients.
89549356|NCT04327193|Experimental|Driving pressure|The selected PEEP which makes the driving pressure lowest is applied during the operation.
88961765|NCT04270838|Experimental|PC2 (Paediatric high dose)|Volunteers aged 2-6 years. Volunteers will receive a full adult preferred dose of ChAdOx2 RabG on D0. The adult preferred dose will be 2.5×10^10 vp OR 5×10^10 vp. Volunteers will receive two doses of Rabies IRV as simulated post-exposure prophylaxis (SPEP), 14 days apart during the follow-up period. All participants will receive Verorab as a 4 site ID on SPEP+0, and Verorab as a 2 site ID on SPEP+14. Participants who return a virus neutralising antibody (VNA) result below 0.5IU/mL will be randomised (1:1 ratio) for the SPEP+0 visit to happen at the next available visit or at the final annual visit. Any participants who do not return a VNA result below 0.5IU/mL will have their SPEP+0 visit take place at the final annual visit.
89025289|NCT03278054|Active Comparator|Hybrid group|Root canal treatment with hybrid instrumentation:Root canal treatment was carried out using ProTaper and Hyflex CM files.
89025290|NCT00441636|Experimental|CPAP treatment|Continuous Positive Airway Pressure (CPAP)for 4 weeks
89025291|NCT00441636|No Intervention|No CPAP|routine psychiatric care for 4 weeks followed by CPAP titration and initiation after followup measures.
89025292|NCT00441636|No Intervention|Control group|No obstructive sleep apnea detected.
89549357|NCT04327193|Active Comparator|Conventional|Conventional PEEP (5cmH2O) is applied.
89549358|NCT04293029|Experimental|Normal liver function|Patients will receive single dose of SHR0302
89549359|NCT04293029|Experimental|Mild Hepatic Impairment|Patients will receive single dose of SHR0302
89549360|NCT04293029|Experimental|Moderate Hepatic Impairment|Patients will receive single dose of SHR0302
89025293|NCT03278015|Experimental|Nab-paclitaxel plus Gemcitabine|Nanoparticle albumin-bound paclitaxel is given at 100mg/m2 intravenously over 30 minutes in combination with Gemcitabine 1000mg/m2 intravenously on day 1 and 8 of each 21-days cycle. Number of cycle: 6 cycles.
89025294|NCT03278015|Experimental|Gemcitabine monotherapy|Gemcitabine is given at 1000mg/m2 intravenously on day 1 and 8 of each 21-days cycle. Number of cycle: 6 cycles.
89025295|NCT03278015|Experimental|S-1 monotherapy|S-1 is orally administered (40-60 mg according to the body surface, Bid) on day 1-14 of each 21-days cycle. Number of cycle: 6 cycles.
89025296|NCT00441675||Salmeterol/Fluticasone|Previous Salmeterol/Fluticasone treatment
89025297|NCT00441675||Fluticasone|Previous Fluticasone propionate treatment
89025298|NCT00444314|Experimental|A|
89549361|NCT03184753|Experimental|Single arm|OC-IgT cells to treat ovarian cancer.
89549362|NCT03185767|Other|SLE group|
89549363|NCT03185767|Other|control group|
89549364|NCT03184675|Experimental|Functional action observation training|
89549365|NCT03184675|Other|General action observation training group|
89549366|NCT04747457|Experimental|Adults and pediatric patients, all etiologies combined|
89549367|NCT03182803|Experimental|Anti-CTLA-4/PD-1 expressing meso-CAR-T|This study have only one arm that is the CTLA-4/PD-1 antibodies expressing mesoCAR-T cells group. All patients with advanced solid tumors will take part in the screening, who matching all the conditions will be chosen for the treatment.New CAR-T cells are cultured from PBMC and returned to the patients by venous transfusion.
89549368|NCT04596917|Experimental|Preferred music listening|Patients will be randomized to listen to music with iPod that has preferred music selections that patients can choose.
89549369|NCT04596917|Experimental|Hypnotic music with relaxation breathing|Patients will be randomized to listen to hypnotic music with relaxation breathing narrative.
89549370|NCT03185689|Experimental|Intervention group|Effectiveness of an intensified DSME in T2D adult patients
89549371|NCT03185689|No Intervention|Comparison group|The comparison group have got the usual traditional way of education, which is given occasionally for all of diabetes patients at waiting area. Other than this, the comparison group didn't get an organized and intensified DSME.
89549372|NCT04199897|Experimental|Intervention group (sucrose + probiotics)|Sucrose rinsing 8 times a day for 14 days Probiotic lozenges 2 times a day for 25 days
89549373|NCT04199897|Active Comparator|Intervention group (sucrose + placebo|Sucrose rinsing 8 times a day for 14 days Placebo lozenges 2 times a day for 25 days
89549374|NCT04199897|Placebo Comparator|Control group (xylitol + probiotics)|Xylitol rinsing 8 times a day for 14 days Probiotic lozenges 2 times a day for 25 days
89549375|NCT04199897|Placebo Comparator|Control group (xylitol + placebo|Xylitol rinsing 8 times a day for 14 days Placebo lozenges 2 times a day for 25 days
89549376|NCT03185611|Experimental|Rifaximin and Thiopurine|Prescribed Rifaximin (600mg, twice daily) combined with Azathioprine (2.0-2.5mg/kg/day) for 3 months after surgery, and then Azathioprine monotherapy (2.0-2.5mg/kg/day) for the next 3months.
89549377|NCT03185611|Active Comparator|Thiopurine|Prescribed Azathioprine (2.0-2.5mg/kg/day) for 6 months after surgery.
89549378|NCT03185533||to reduce ED length of stay|to reduce ED length of stay to lessen ED crowding by using Lean-sigma management and quality improvement interventions including reducing boarding time and medical decision time.
89025299|NCT00444314|Experimental|B|
89549379|NCT03182959|Experimental|Lower dose, higher dose|"During the first cycle, the patient will self-administer Avmacol® (70 μmol/day SF equivalent) starting on the evening of Day 1 of the cycle. Participants will self-administer four tablets of Avmacol® every evening, ideally between 4 pm and 8 pm, through the evening of Day 28. Participants will record the date and time of each Avmacol® administration on the provided diary.~During the second cycle, the patient will self-administer Avmacol® (140 μmol/day SF equivalent) starting on the evening of Day 1 of the cycle. Participants will self-administer eight tablets of Avmacol® every evening, ideally between 4 pm and 8 pm, through the evening of Day 28. Participants will record the date and time of each Avmacol® administration on the provided diary."
89549380|NCT03182959|Experimental|Higher dose, lower dose|"During the first cycle, the patient will self-administer Avmacol® (140 μmol/day SF equivalent) starting on the evening of Day 1 of the cycle. Participants will self-administer eight tablets of Avmacol® every evening, ideally between 4 pm and 8 pm, through the evening of Day 28. Participants will record the date and time of each Avmacol® administration on the provided diary.~During the second cycle, the patient will self-administer Avmacol® (70 μmol/day SF equivalent) starting on the evening of Day 1 of the cycle. Participants will self-administer four tablets of Avmacol® every evening, ideally between 4 pm and 8 pm, through the evening of Day 28. Participants will record the date and time of each Avmacol® administration on the provided diary."
89549381|NCT02431429||miltefosine|miltefosine: target of 2.5 mg/kg/day for 28 days
89549382|NCT04158245|Experimental|18F-fluciclovine PET Scan|Single intravenous administration of 18F-fluciclovine for PET Scan.
89549383|NCT03182881|Experimental|Miofascial-reléase|Myofascial Release (MR), with the purpose of releasing fascial restriction zones and major fibrosis (thoraco-brachial) caused by restriction after CM tto. IM therapy was applied to the affected area. The position of the patient was identical during both treatment sessions.
89032993|NCT02922972|Experimental|Platelet Rich Plasma|Interventions: Four injections of PRP: The first injection of A-PRP after complete resection of the keloid scar,Three additional injections were administered with a one-month interval.
89549384|NCT03182881|Active Comparator|Manual Lymphatic Drainage (MLD)|It was applied following the Leduc method with the patient in a supine position with 30º elevation of the arm and very superficial and smooth maneuvers were performed in the axillary lymph nodes, in the chest region and in the arm with the same sequence as Guerero et al. The objective of the application in our study is to obtain a beneficial treatment for the patient since it produces an increase of blood and lymphatic circulation, with positive effects on the peripheral vegetative nervous system.
89549385|NCT03143543|Experimental|Group A Lorcaserin (10mg)|10 mg lorcaserin orally for 7 days
89549386|NCT03143543|Placebo Comparator|Group B Parallel Placebo|Placebo orally for 7 days vs Group A
89549387|NCT03143543|Experimental|Group A2 Lorcaserin (20 mg)|20 mg lorcaserin orally for 7 days
89549388|NCT03143543|Placebo Comparator|Group B2Parallel Placebo|Placebo orally for 7 days vs Group A2
89549389|NCT02428075|Experimental|FCHV visit-normotensive|
89549390|NCT02428075|No Intervention|FCHV no visit-normotensive|
89549391|NCT02428075|Experimental|FCHV visit-prehypertensive|
89549392|NCT02428075|No Intervention|FCHV no visit-prehypertensive|
89549393|NCT02428075|Experimental|FCHV visit-hypertensive|
89549394|NCT02428075|No Intervention|FCHV no visit-hypertensive|
89549395|NCT02428153|Experimental|cases|static and dynamic stretching exercises
89549396|NCT03142061|Experimental|ECT|
89549397|NCT04402307|No Intervention|Usual care|Usual care to patients with dysphagia
89549398|NCT04402307|Experimental|Training|Chin Tuck Against Resistance to patients with dysphagia
89549399|NCT02427919|Experimental|Early G-CSF use|"Refractory AML undergoing salvage chemotherapy (MEC regimen in AML). After finishing application of chemotherapy, G-CSF will be started post chemotherapy D+7~D+10 when blasts disappear from peripheral blood smear.~When blasts reappear on peripheral blood smear, G-CSF will be discontinued.~Intervention type : Drug Intervention name : G-CSF (Filgrastim)~-> Comparison of the effect of G-CSF (Filgrastim) use"
89549400|NCT02427919|Active Comparator|No or delayed G-CSF use|"Refractory AML undergoing salvage chemotherapy (MEC regimen in AML). After finishing application of chemotherapy, G-CSF will not be applied at least post chemotherapy D+25~D+28. If patient suffers from severe infectious complication and when no blasts are detected on peripheral blood smear, G-CSF can be started then.~Intervention type : Drug Intervention name : G-CSF (Filgrastim)~-> Comparison of the effect of G-CSF (Filgrastim) use"
89549401|NCT03110783|No Intervention|suture (control)|Subjects randomized to control will receive additional dural sutures as deemed necessary by the surgeon. CSF leakage will be re-evaluated with the Valsalva maneuver to 10-20 cm H2O for 5 to 10 seconds. Closure of the remaining layers of the surgical site will be performed according to the surgeon's standard of practice.
89549402|NCT03110783|Experimental|Bioseal|Subjects randomized to receive Bioseal, a thin layer will be applied to the entire length of the suture line and the adjacent area to approximately 5mm away, including all suture holes. Up to two layers of Bioseal may be used for each application. While Bioseal achieves complete coagulation, CSF leakage will be re-evaluated with the Valsalva maneuver to 10-20 cm H2O for 5 to 10 seconds. Up to two applications (one application includes applying up to two layers of Bioseal product followed by the CSF leakage re-evaluation with Valsalva maneuver) per subject are allowed. Closure of the remaining layers of the surgical site will be performed according to the surgeon's standard of practice.
89549403|NCT02425189||LQT Positive (Group 1)|"Gene-positive LQTS patients~Gene negative LQTS patients with confirmed phenotypic diagnosis of LQTS (Schwartz score ≥4)"
89549404|NCT02425189||Asyptomatic Patients (Group 2)|Asymptomatic patients, those free of syncope on beta blocker, or gene negative unaffected family members
89549405|NCT02027428|Experimental|Abraxane + Best Supportive Care (BSC)|Dosing will occur in two phases - induction and maintenance. During induction, the subject will receive Abraxane plus carboplatin as standard of care. At the end of 4 cycles, if the subject has a complete response, partial response, or stable disease, he/she will continue on to the maintenance phase. Maintenance dosing on this arm includes Abraxane plus best supportive care.
89549406|NCT02027428|Other|Best Supportive Care (BSC)|Dosing will occur in two phases - induction and maintenance. During induction, the subject will receive Abraxane plus carboplatin as standard of care. At the end of 4 cycles, if the subject has a complete response, partial response, or stable disease, he/she will continue on to the maintenance phase. Maintenance dosing on this arm includes best supportive care only.
89549407|NCT03182647||Non surgery|Patients were not treated with surgery initially
89549408|NCT03182647||Surgery|Patients had an initial surgical treatment
89549409|NCT03143699|Experimental|Immediate feedback|Submitted to a training on blood pressure measurement skills and an immediate feedback after their encounter with an standardized patient - SP
89549410|NCT03143699|No Intervention|Students with no immediate feedback|Submitted to a training on blood pressure measurement skills, but without an immediate feedback after their encounter with an standardized patient - SP
89549411|NCT04016363|Experimental|ProbeFix arm|The echocardiography probe is fixated on the patient's thorax using the ProbeFix
89549412|NCT04016363|Active Comparator|Controll arm|The sonographer manually holds the probe on the patient's thorax
89549413|NCT03399071|Experimental|FLOT plus Avelumab (FLOT-A)|"Avelumab 10mg/kg (or Maximum Administered Dose established in safety run-in) iv infusion over 1 hour.~Followed by FLOT: Oxaliplatin 85mg/m2 iv infusion day 1 over 2 hours, Folinic acid 200mg/m2 iv infusion day 1 over 2 hours, Docetaxel 50mg/m2 iv day 1 over 1 hour, Fluorouracil 2600mg/m2 over 24 hours iv"
89549414|NCT02425033|Experimental|Intervention|Patients undergoing POEM for spastic esophageal disorders such as achalasia at the University Health Network, Toronto, Canada
89032994|NCT02922855|No Intervention|Contemporaneous Control|This group is our 'usual care' control group. They were not contacted for an interview and were not offered an incentive to visit their primary care physician.
89032995|NCT02922855|Active Comparator|$0 group|This group completed a baseline interview but was not offered any incentive if they visited their primary care physician.
89032996|NCT02922855|Experimental|$25 group|This group completed a baseline interview and was offered $25 they visited their primary care physician within 6 months.
89549415|NCT03857165|Experimental|Low dose SAP-001|SAP-001 (Experimental drug) low dose versus placebo
89549416|NCT03857165|Experimental|Mid dose SAP-001|SAP-001 (Experimental drug) mid dose versus placebo
89549417|NCT03857165|Experimental|High dose SAP-001|SAP-001 (Experimental drug) high dose versus placebo
89549418|NCT03184363|Experimental|Clostridium Botulinum A Toxin|Clostridium Botulinum A Toxin
89549419|NCT02431039|Experimental|NEOSORB PLUS|Subjects who are treated by NEOSORB PLUS
89549420|NCT02431039|Active Comparator|NEOSORB|Subjects who are treated by NEOSORB
89549421|NCT04346693|Active Comparator|group 1|80 patients with moderate and critical severity of the COVID19 with respiratory symptoms without Acute Respiratory Distress Syndrome (ADRS). Standard therapy is prescribed recommended by the Ministry of Health of the Russian Federation.
89549422|NCT04346693|Experimental|group 2|80 patients with moderate to critical severity of the COVID19 with respiratory symptoms without Acute Respiratory Distress Syndrome (ADRS). A standard concomitant therapy will be given recommended by the Ministry of Health of the Russian Federation, with the additional intramuscular injection of the drug Dalargin (solution for intravenous and intramuscular doses of 1 mg once a day for 10 days).
89549423|NCT04346693|Experimental|group 3|80 patients with moderate to critical severity of the COVID19 with respiratory symptoms without Acute Respiratory Distress Syndrome. A standard concomitant therapy will be given recommended by the Ministry of Health of the Russian Federation, with the additional inhalation of the drug Leitragin, at a dose of 10 mg daily once a day until the symptoms of pulmonary complications will be ceased.
89549424|NCT04346693|Experimental|group 4|80 patients with moderate to critical severity of the disease with respiratory symptoms without Acute Respiratory Distress Syndrome. A standard concomitant therapy will be given recommended by the Ministry of Health of the Russian Federation, with the additional intramuscular administration of the drug Dalargin (solution for intravenous and intramuscular doses of 1 mg once a day for 10 days) in conjunction with inhalation of the drug Leitragin, at a dose of 10 mg daily once a day until the symptoms of pulmonary complications will be ceased.
89549425|NCT02430805|Other|NOE|multicentric family-based cohort. prospective and transversal study
89549426|NCT01995136|Experimental|TRAVATAN Z|Travoprost Ophthalmic Solution 0.004%, 1 drop instilled in each eye once daily at 9PM for 3 months.
89549427|NCT04483141||non-communicant stroke patients|Patients suffering from stroke, and unable to efficient communication. They will be assessed for pain through several tools (hetero-assessment of pain).
89549428|NCT04483141||communicant stroke patients|Patients suffering from stroke, and unable to efficient communication. They will be assessed for pain through several tools (including hetero-assessment and auto-assessment of pain)
89549429|NCT02430883|Active Comparator|first group|patients who have upper pole kidney stones treated with flexible renoscopy
89549430|NCT02430883|Active Comparator|second group|patients u who have mid pole kidney stones treated with flexible renoscopy
89549431|NCT02430883|Active Comparator|third group|patients who have lower pole kidney stones treated with flexible renoscopy
89549432|NCT02430883|Active Comparator|forth group|patients who have kidney stones in pelvis treated with flexible renoscopy
89549433|NCT02430883|Active Comparator|fifth group|patients who have multiple calixes kidney stones treated with flexible renoscopy
89549434|NCT03141593|Active Comparator|Vitamin D: liquid form, start weekly|5'600 IU weekly (1.4 ml oily drops) start for 3 months, will cross-over to 24'000 IU monthly (5 ml alcoholic drops) for the following 3 months.
89549435|NCT03141593|Active Comparator|Vitamin D: solid form, start weekly|5'600 IU weekly (1 soft capsule) start for 3 months, will cross-over to 20'000 IU monthly (1 tablet) for the following 3 months.
89549436|NCT03141593|Active Comparator|Vitamin D: liquid form, start monthly|24'000 IU monthly (5 ml alcoholic drops) start for 3 months, will cross-over to 5'600 IU weekly (1.4 ml oily drops) for the following 3 months.
89549437|NCT03141593|Active Comparator|Vitamin D: solid form, start monthly|20'000 IU monthly (1 tablet) start for 3 months, will cross-over to 5'600 IU weekly (1 soft capsule) for the following 3 months.
89549438|NCT03183973|Experimental|PRF group|patients who will receive Platelet Rich Fibrin (PFR) suspension
89549439|NCT03183973|Experimental|placebo group|
89549440|NCT03143309|Experimental|Walking + WhatsApp|The participants assigned to the intervention group will be given a brief (15-minute) orientation where they learn about the importance of exercise, diet, and the benefits of weight reduction. They will be given further instruction on the regular use of the pedometer. They will be enrolled into a WhatsApp group. They will receive 2-3 health-promotional (walking and diet) messages per week via WhatsApp.
89549441|NCT03143309|Active Comparator|WhatsApp Only|The control participants will be enrolled into a WhatsApp group. They will receive 2-3 non-health related messages per week via WhatsApp.
89549442|NCT04102241|Placebo Comparator|Placebo|Patients with chronic plaque psoriasis will be treated BID for 16 weeks with placebo in first phase. Then will be treated BID for 36-week extension followed with 30mg of Hemay005.
89549443|NCT04102241|Experimental|15mg Hemay005|Patients with chronic plaque psoriasis will be treated BID for 16 weeks with 15mg Hemay005 in first phase. Then will be treated BID for 36-week extension followed with 15mg of Hemay005.
89549444|NCT04102241|Experimental|30mg Hemay005|Patients with chronic plaque psoriasis will be treated BID for 16 weeks with 30mg Hemay005 in first phase. Then will be treated BID for 36-week extension followed with 30mg of Hemay005.
89549445|NCT04102241|Experimental|60mg Hemay005|Patients with chronic plaque psoriasis will be treated BID for 16 weeks with 60mg Hemay005 in first phase. Then will be treated BID for 36-week extension followed with 60mg of Hemay005.
89549446|NCT01994902|Experimental|First Coloplast test product|"The subjects test:~test period 1: Coloplast test product test period 2: SenSura Convex Light"
89549447|NCT01994902|Experimental|First SenSura Convex Light|"The subjects test:~test period 1: SenSura Convex Light test period 2: Coloplast test product"
89549448|NCT03111095|Experimental|Mobile Health Participants|Subjects will use the mobile health device to record their blood pressure and weight measurements everyday for 6 weeks postpartum.
89549449|NCT03111095|No Intervention|Standard of Care|This arm is a chart review done on hypertensive women who do not participate in using the mobile health device.
89549450|NCT02425267|Experimental|Telerehabilitation|Telerehabilitation at home from a clinic
89549451|NCT02425267|Active Comparator|Face-to-face intervention in a clinic|Conventional physiotherapy
89549452|NCT03777137||TMS during heat pain stimuli|This is a single institution, single-blinded, long-term exploratory study using participant as his/her own control to evaluate and compare the analgesic effect of experimental heat pain of TMS during early versus late times on a vigilance behaviors toward pain (CPT, Continuous Performance Task). Vigilance behaviors include errors, reaction times and activation.
89549453|NCT02026258|Active Comparator|Orthodontics no piezocision|Subjects will have orthodontic treatment without corticision with piezotome. Subjects will be followed every 4-5 weeks after the first wire placement until full alignment of the lower arch (irregularity index 0-2mm). The archwire sequence will be 0.014-in Cu-NiTi wire for the first two visits followed by a 0.014 X 0.025-in Cu-NiTi wire until completion of alignment. The time taken to reach complete alignment for each patient and the rate of tooth alignment will be calculated.
89549454|NCT02026258|Experimental|Orthodontics with piezotome corticision|Subjects receiving orthodontic treatment in conjunction with piezotome-corticision. Subjects will be followed every 4-5 weeks after the first wire placement until full alignment of the lower arch (irregularity index 0-2mm). The archwire sequence will be 0.014-in Cu-NiTi wire for the first two visits followed by a 0.014 X 0.025-in Cu-NiTi wire until completion of alignment. The time taken to reach complete alignment for each patient and the rate of tooth alignment will be calculated.
89549455|NCT03576443|Experimental|Treatment arm|Idelalisib 150 mg x 2 p o, until progression
89549456|NCT03141515|Active Comparator|Control group|After anesthesia induction patients received lung recruitment maneuver using pressure-control ventilation with a patient in supine position with 10 cmH2O level of positive end-expiratory pressure PEEP during 180 seconds. Lung ultrasound examination will be performed at two different times-point immediately after induction and after recruitment maneuver to monitor lung aeration.
89549457|NCT03141515|Experimental|Recruitment maneuver group|Patients received lung recruitment maneuver with postural changes of lateral decubitus using pressure-control ventilation, 10 cmH2O level of PEEP in left and in right lateral decubitus during 90 seconds in each one. Lung ultrasound examination will be performed at two different times-point immediately after induction and after recruitment maneuver to monitor lung aeration.
89549458|NCT02427529|Experimental|HCG Group|This group received daily subcutaneous injections of Human Chorionic Gonadotropin while eating a very low calorie diet of 500 calories per day.
89549459|NCT02427529|Placebo Comparator|Saline/Placebo|This group received daily subcutaneous injections of saline while eating a very low calorie diet of 500 calories per day.
89549460|NCT03336671|Active Comparator|Adenoidectomy|Current standard of care for pediatric chronic rhino sinusitis.
89549461|NCT03336671|Experimental|Adenoidectomy plus Endoscopic Sinus Surgery|endoscopic sinus surgery in addition to adenoidectomy
89549462|NCT02427763|Active Comparator|Retainer use|"The volunteer use a thermoplastic appliance (Essix) for 8hours~Interventions:~hours of use~collect biofilm~collect saliva~collect epithelium"
89549463|NCT02427763|Active Comparator|Aligner use|"The volunteer use thermoplastic appliance (Essix) for 22 hours~Interventions:~hours of use~collect biofilm~collect saliva~collect epithelium"
89549464|NCT04438733|Experimental|test-anastrozole tablet|1 mg anastrozole was produced and provided by Salutas Pharma GmbH
89549465|NCT04438733|Experimental|reference-anastrozole tablet|1 mg anastrozole was produced by AstraZeneca Pharmaceuticals LP.
89549466|NCT04438811|Other|Consultant Anesthetist|Patients who are randomized to this arm will receive their spinal anesthesia froma consultant anesthetist
89549467|NCT04438811|Other|Medical Officer|Patients randomized to this arm will receive their spinal anesthetic from a medical officer. There will be a consultant anesthetist immediately available if needed but they will not be a direct participant in this arm. Any involvement by the consultant will result in the label of failure for this patient.
89549468|NCT02427295|Experimental|Group 2: Surgery + Medical treatment|"MRI : residual tumor 6 months post-op : IGF-1 >600 ng/ml~medical treatment : Sandostatin (Octreotide Acetate)"
89549469|NCT02427295|No Intervention|Group 3 : Rescue group|If IGF-1 levels fails to normalize till post-op 18 months post-op, medical treatment will be added.)
89549470|NCT02427295|No Intervention|Gruop1 : Surgery only group|"MRI : without residual tumor 6months post-operation~and IGF-1 <600ng/ml"
88961766|NCT04270838|Experimental|PC3 (Paediatric preferred dose)|Volunteers aged 2-6 years. Volunteers will receive a paediatric preferred dose of ChAdOx2 RabG on D0. The paediatric preferred dose will be 50-100% of the adult preferred dose. Volunteers will receive two doses of Rabies IRV as simulated post-exposure prophylaxis (SPEP), 14 days apart during the follow-up period. All participants will receive Verorab as a 4 site ID on SPEP+0, and Verorab as a 2 site ID on SPEP+14. Participants who return a virus neutralising antibody (VNA) result below 0.5IU/mL will be randomised (1:1 ratio) for the SPEP+0 visit to happen at the next available visit or at the final annual visit. Any participants who do not return a VNA result below 0.5IU/mL will have their SPEP+0 visit take place at the final annual visit.
89549471|NCT01994590|Experimental|Dovitinib + Abiraterone Acetate + Prednisone|"Participants receive a single daily oral dose of Dovitinib for 5 consecutive days, on Days 1-5, 8-12, 15-19, and 22-26 of each 28 day cycle. Starting dose will be 400 mg daily.~Participant to take 4 tablets (250 mg each) orally (PO) daily of Abiraterone acetate.~Participant to take 5 mg oral prednisone, twice daily."
89549472|NCT02427373|Active Comparator|fish oil ethyl ester|1.3g/d dose of DHA+EPA in fish oil EE (6 capsules) administered for 4 weeks
89549473|NCT02427373|Active Comparator|fish oil triglyceride|1.3g/d dose of DHA+EPA in fish oil TG (6 capsules) administered for 4 weeks
89549474|NCT02427373|Active Comparator|krill oil|1.3g/d dose of DHA+EPA in krill oil (6 capsules) administered for 4 weeks
88961767|NCT04270838|Experimental|PV1 (Paediatric single-visit Verobab)|Volunteers aged 2-6 years. Volunteers will receive Rabies IRV (Verorab) as a 2 site ID on D0. Volunteers will receive two further doses of Rabies IRV as simulated post-exposure prophylaxis (SPEP), 14 days apart during the follow-up period. All participants will receive Verorab as a 4 site ID on SPEP+0, and Verorab as a 2 site ID on SPEP+14. Participants who return a virus neutralising antibody (VNA) result below 0.5IU/mL will be randomised (1:1 ratio) for the SPEP+0 visit to happen at the next available visit or at the final annual visit. Any participants who do not return a VNA result below 0.5IU/mL will have their SPEP+0 visit take place at the final annual visit.
89032997|NCT02922855|Experimental|$50 group|This group completed a baseline interview and was offered $50 they visited their primary care physician within 6 months.
89549475|NCT02427061|Experimental|Intervention Program (Manhood 2.0)|"Curricular Content: The 18 hour content will be spread over 3 to 6 sessions (3 weeks duration up to a 2 month period). Youth are guided to explore social constructions of masculinity, describe healthy relationships, discuss healthy sexual behaviors, identify coercive and disrespectful behaviors, and practice skills to intervene when witnessing peers' disrespectful and harmful behaviors, with repeated reflection on gender norms throughout these sessions.~Module One focuses on themes of gender and masculinity. Module Two focuses on themes of violence and sexual consent. Module Three focuses on themes of sexual health and decision making."
88961768|NCT04270838|Experimental|PV2 (Paediatric two-visit Verobab)|Volunteers aged 2-6 years. Volunteers will receive Rabies IRV (Verorab) as a 2 site ID on D0. Volunteers will receive two further doses of Rabies IRV as simulated post-exposure prophylaxis (SPEP), 14 days apart during the follow-up period. All participants will receive Verorab as a 4 site ID on SPEP+0, and Verorab as a 2 site ID on SPEP+14. Participants who return a virus neutralising antibody (VNA) result below 0.5IU/mL will be randomised (1:1 ratio) for the SPEP+0 visit to happen at the next available visit or at the final annual visit. Any participants who do not return a VNA result below 0.5IU/mL will have their SPEP+0 visit take place at the final annual visit.
88961769|NCT04266028|Experimental|DM-101 Single Dose|Participants received a single subcutaneous (SC) dose of DM-101 30 ng on Day 1
88961770|NCT04266028|Placebo Comparator|Placebo Single Dose|Participants received a single SC injection of placebo on Day 1
88961771|NCT04266028|Experimental|DM-101 Low Multiple Ascending Doses (MAD)|Participants received 5 biweekly administered SC doses of DM-101 as follows: 30 ng on Day 1,50 ng on Day 14, 100 ng on Day 28, 42, and 56.
88961772|NCT04266028|Placebo Comparator|Placebo Low MAD|Participants received 5 biweekly administered SC injections of placebo on Day 1,14, 28, 42, and 56.
88961773|NCT04266028|Experimental|DM-101 High MAD|Participants received 5 biweekly administered SC doses of DM-101 as follows: 30 ng on Day 1,50 ng on Day 14, 100 ng on Day 28, 200 ng (dose divided into two SC injections) on Day 42, and 300 ng (dose divided into three SC injections) on Day 56.
89208009|NCT00262951|Experimental|Pancreatic Adenocarcinoma Patients|Pancreatic Adenocarcinoma Patients treated with chemotherapy regimen and radiation (and or surgery).
89549476|NCT02427061|Active Comparator|Control Program (Job Skills Training)|"Youth in the control arm receive the same amount of time with an intervention -- 18 hours of curriculum divided into 3 to 6 sessions, over 3 weeks up to 2 months duration.~The control intervention focuses on job skills development."
89549477|NCT03184051||Ultrasound assessment|All subject of the study have a knee osteoarthritis (OA) and are going to have a total arthroplasty. Diagnostic performance of ultrasonography is evaluated on ex vivo cartilage samples (2 samples per patient are selected with different stage of OA : 1 with early stage and 1 with advanced stage).
89549478|NCT03430115||Weight loss plus exercise (WL+EX)|This group was randomized and previously assigned to weight loss plus exercise.
89549479|NCT03430115||Exercise alone (EX)|This group was randomized and previously assigned to exercise alone.
89549480|NCT03430115||Weight loss alone (WL)|This group was randomized and previously assigned to weight loss alone.
89549481|NCT03430115||Control|This group was randomized and previously assigned to control.
89549482|NCT03182569|Experimental|flexible catheter|The flexible Subcutaneous catheter for insulin administration
89549483|NCT03182569|Active Comparator|hourly rigid needle puncture|Hourly rigid needle puncture for Subcutaneous insulin administration
89549484|NCT03306173|Experimental|Ventilated cigarettes|Participants in this ARM will be assigned to ~25% filter ventilation commercially available cigarettes.
89549485|NCT03306173|Experimental|Unventilated cigarettes|Participants in this ARM will be assigned to ~0% filter ventilation commercially available cigarettes.
89549486|NCT02019550|Experimental|First Rebif Rebidose, Then Rebiject II|Subjects will self-inject Rebif at a dose of 44 microgram (mcg) subcutaneously three times a week by using Rebif Rebidose self-injector device in Treatment Period 1 for 4 weeks followed by self-injecting Rebif at a dose of 44 mcg subcutaneously three times a week by using Rebiject II self-injector device in Treatment Period 2 (4 weeks) for the next 4 weeks.
89549487|NCT02019550|Experimental|First Rebiject II, Then Rebif Rebidose|Subjects will self-inject Rebif at a dose of 44 mcg subcutaneously three times a week by using Rebiject II self-injector device in Treatment Period 1 for 4 weeks followed by self-injecting Rebif at a dose of 44 mcg subcutaneously three times a week by using Rebif Rebidose self-injector device in Treatment Period 2 for the next 4 weeks.
89549488|NCT03182413|Placebo Comparator|PBO|Placebo
89549489|NCT03182413|Active Comparator|MOD|Modafinil 100mg
89549490|NCT03182413|Experimental|THN102 100/1|modafinil 100 mg + 1 mg flecainide
89549491|NCT03182413|Experimental|THN102 100/3|modafinil 100 mg + 3 mg flecainide
89549492|NCT03182413|Experimental|THN102 100/9|modafinil 100 mg + 9 mg flecainide
89549493|NCT02430649|Experimental|IRE Group|irreversible electroporation for Unresectable Prostatic Neoplasms
89549494|NCT02430649|No Intervention|Control|The patients without treatment
89549495|NCT03182257|Experimental|ONO-7579 Part A|Single Ascending doses of ONO-7579
89549496|NCT03182257|Experimental|ONO-7579 Part B|Expansion phase of ONO-7579
89549497|NCT03166631|Experimental|Part A|BI 891065 alone (Solid Tumours)
89549498|NCT03166631|Experimental|Part B|BI 891065 in combination with BI 754091 (Solid Tumours)
89549499|NCT03166631|Experimental|Part C|BI 891065 in combination with BI 754091 (Non Small Cell Lung Cancer)
89549500|NCT05117827|Experimental|Power Wheelchair Standing Device User|
89549501|NCT03159377||Patients scheduled for a chest CT|Inpatients or outpatients scheduled for a chest CT in our medical center
89549502|NCT02980367|Experimental|ACL Rehabilitation Group|Non-surgical management [Rehabilitation] with option for later Anterior Cruciate Ligament (ACL) reconstruction, only if required.
89549503|NCT02980367|Active Comparator|ACL Reconstruction Group|Surgical Management - Anterior Cruciate Ligament (ACL) reconstruction surgery
89549504|NCT03185221|Experimental|Cordimax|Rapamycin Eluting Coronary Stent
89549505|NCT03185221|Active Comparator|XIENCE V|Everolimus Eluting Coronary Stent
89549506|NCT03184129|Experimental|trial group|Patients with knee disease who will undergo knee arthroplasty will be randomized into trial group. The patients from the trial group will receive knee arthroplasty with knee prostheses purchased from Wuhan Yijiabao Biomaterial Co., Ltd., Wuhan, China (newly developed).
89549507|NCT03184129|Experimental|control group|Patients with knee disease who will undergo knee arthroplasty will be randomized into control group. The patients from the control group will receive knee arthroplasty with knee prostheses purchased from Beijing AKEC Medical Co., Ltd., Beijing, China (approved by China Food and Drug Administration).
89549508|NCT02507765|Experimental|Treatment (SBRT, TACE)|Patients undergo SBRT on day 1 and TACE on day 2.
89549509|NCT03184285|Experimental|bariatric surgery|baseline alert 1; Anti-Trendelenburg-position (ATB); Anti-Trendelenburg-position (ATB) in narcosis; baseline in narcosis 1; passive leg raising; volume bolus substitution (15 ml/kgKG Sterofundin balanced solution); baseline in narcosis 2; start capnoperitoneum; Anti-Trendelenburg-position (ATB) plus capnoperitoneum; ATB plus capnoperitoneum plus volume bolus substitution (15 ml/kgKG Sterofundin balanced solution); ATB loss of capnoperitoneum; baseline in narcosis; baseline alert 2; torso position rising 30° at the beginning; torso position rising 30° at the end
89549510|NCT02916017||Participants receiving adalimumab|Participants receiving adalimumab for the treatment of Non-infectious Intermediate-, Posterior-, or Pan-uveitis
89549511|NCT03183817|Experimental|Person-centred care at distance|Person-centred care at distance through an eHealth platform, used both by professionals, patients and relatives
89549512|NCT03183817|No Intervention|Usual Care|Evidence-based care
89549513|NCT03183739|Experimental|ASP8062 lower dose|Subjects will receive a single dose of ASP8062 on Day 1, followed by 5 days of washout (Days 2-6) and once daily dosing for 14 consecutive days (Days 7-20) at the same dose level.
89549514|NCT03183739|Experimental|ASP8062 middle dose|Subjects will receive a single dose of ASP8062 on Day 1, followed by 5 days of washout (Days 2-6) and once daily dosing for 14 consecutive days (Days 7-20) at the same dose level.
89549515|NCT03183739|Experimental|ASP8062 higher dose|Subjects will receive a single dose of ASP8062 on Day 1, followed by 5 days of washout (Days 2-6) and once daily dosing for 14 consecutive days (Days 7-20) at the same dose level.
89549516|NCT03183739|Placebo Comparator|Placebo|Subjects will receive a single dose of Placebo on Day 1, followed by 5 days of washout (Days 2-6) and once daily dosing for 14 consecutive days (Days 7-20) at the same dose level.
89549517|NCT03182023||ECMO mode|ECMO mode includes Venovenous- ECMO and Venoarterial- ECMO
89549518|NCT05080361||Reports of adverse events associated with the use of BRAF +/- MEK inhibitors|"Reports of adverse event (individual case safety reports) from Vigibase, the World Health Organization pharmacovigilance database related to the use of BRAF +/- MEK inhibitors from inception (1986) until March, 1, 2021 will be extracted.~Cases concurrently reporting on immune checkpoint inhibitor therapies will be excluded."
89549519|NCT02430415|Experimental|Group A|laryngoscope-assisted lightwand intubation - traditional lightwand intubation
89549520|NCT02430415|Experimental|Group B|traditional lightwand intubation - laryngoscope-assisted lightwand intubation
89549521|NCT05080205|Experimental|Morbidly obese subjects|Bariatric surgery (Roux-en-Y gastric bypass or sleeve gastrectomy)
89549522|NCT05080205|No Intervention|Control subjects|Non-obese controls are only studied at baseline
89549523|NCT03117439|No Intervention|Control Group|Patients undergoing empirical anti fungal therapy. Interruption of anti fungal treatment will be decided on the basis of standard clinically and microbiologically criteria.
89549524|NCT03117439|Experimental|1-3 Beta-D-Glucan Group|Patients undergoing anti fungal de-escalation according to 1-3 Beta-D-Glucan results
89549525|NCT02741141|Active Comparator|Classical partograph|Labour dystocia is diagnosed when cervical dilation is less than 1 cm per hour or after 3 hours at complete cervical dilation without engagement of the presentation. In this case, active management of labour is started with introduction of oxytocin, artificial rupture of membranes and supportive therapy.
89549526|NCT02741141|Experimental|New partograph|The second strategy is based on the partograph developped by Neal and Lowe. An active management of labour is started when crossing the dystocia line or when there are no cervical modifications after 4 hours beyond 5 cm of cervical dilation. In this case, active management of labour is started with introduction of oxytocin, artificial rupture of membranes and supportive therapy.
89549527|NCT02430493||ticagrelor|Chinese subjects aged over 18, diagnosed as ACS and treated with ticagrelor at least one tablet
89549528|NCT02616263|Experimental|Foot Intervention|The intervention is a progressive, home based exercise program aimed to increase ankle and foot plantarflexion muscle strength, increase ankle dorsiflexion and toe flexion range of motion, and to retrain individuals to dorsiflex the ankle while keeping the toes in a neutral position. A trained physical therapist with experience working with older adults with diabetes and foot specific complications will monitor and progress the exercise program assuring participant safety and maximizing exercise benefit.
89549529|NCT02616263|Active Comparator|Shoulder Intervention|Participants will be trained in a progressive home exercise program that includes passive stretching of end range shoulder flexion and external rotation and a tailored dose of active shoulder motion.
88961774|NCT04266028|Placebo Comparator|Placebo High MAD|Participants received 5 biweekly administered SC injections of placebo as follows: single injection on Day 1, 14 and 28; two injections on Day 42; three injections on Day 56.
88961775|NCT04266028|Experimental|DM-101 2-Day Ultra-Rush Dose Escalation|Participants received 9 SC doses of DM-101 as follows: 100, 250, 500, 1000, 2500, 5000, 10000 and 25000 ng during Day 1 and Day 2.
88961776|NCT04266028|Placebo Comparator|Placebo 2-Day Ultra-Rush Dose Escalation|Participants received 9 SC injections of placebo during Day 1 and Day 2.
88961777|NCT04227132|Experimental|Labyrinth training, then Standard training|Patients will receive at first the Labyrinth training for 10 sessions of 45 minutes, delivered 4 days per week. The, they will undergo the Standard training for 10 sessions of 45 minutes, for around 4 days per week. Before and after each training patients are tested for primary and secondary outcomes with standardized tests.
89025300|NCT00479271|Active Comparator|Home Care|"A flexible home-care program tailored to the needs of the individual and the family. The components of the intervention will include:~Basic education about dementia (what is the disease, its course, its features etc)~Education about common behaviour problems and how they can be managed~Support to the carer, for example for an elderly carer living alone with the patient, in activities of daily living~Referral to specialists when behaviour problems are severe and warrant medication intervention (sedatives)."
89208010|NCT00793364|Active Comparator|Stanol ester|Stanol-ester administration group
89549530|NCT02427139|Experimental|ANSiStim|"The ANSiStim device is designed to administer auricular point stimulation treatment over several days. The advantage of using the ear for this treatment is that it provides numerous points for stimulation within a small area. Stimulation is performed by electrical pulses emitted through strategically positioned needles.~Three zinc air batteries with 1.4 V provide the required stimulation energy for 96 hours. This constant current source guarantees equivalent stimulation energy regardless of the individual impedance of the skin. The treatment period varies based on the severity of the pain. To minimize the risk of adaption or tolerance to the electrical stimulation, it is applied for 3 hours, followed by a pause of 3 hours."
89549531|NCT02426905|No Intervention|Retrospective|
89549532|NCT02426905|Other|Prospective|
89549533|NCT05079893||Cases|The cases will be the patients suffering from low back pain for at least three months and referred by an orthopedic doctor or general physician.
89549534|NCT05079893||Controls|The controls will be the patients matched for age, sex, handedness who had no complaints of lower back pain
89549535|NCT05079737||Subjects with Fitzpatrick Skin Type I-III|Subjects 21 years of age or older with Fitzpatrick Skin Type I-III will be enrolled and analyzed by age.
89549536|NCT05079737||Subjects with Fitzpatrick Skin Type IV-VII|Subjects 21 years of age or older with Fitzpatrick Skin Type IV-VII will be enrolled and analyzed by age.
89549537|NCT03181945|Active Comparator|Group 4 weeks|Anti-epileptic drug (as used by treating physician for management of acute symptomatic seizure) for 4 weeks followed by taper in 10-14days
89549538|NCT03181945|Active Comparator|Group 12 weeks|Anti-epileptic drug (as used by treating physician for management of acute symptomatic seizure) for 12 weeks followed by taper in 10-14days
89549539|NCT02031107|Active Comparator|cTBS|A transcranial magnetic stimulator (MagPro X100, Medtronic Functional Diagnostics, Skovlunde, Denmark) will deliver continuous bursts of bipolar magnetic pulses exerting an inhibition on the underlying brain tissue (cTBS). The stimulation coil will be placed over the unaffected primary motor cortex. The stimulation protocol implies 200 bursts, each consisting of three pulses applied at 30 Hz, repeated at inter-burst intervals of 167 ms. Two stimulation trains of 30 s, separated by 15 min, will be applied 3 times per week for 3 weeks and will be immediately followed by physical therapy.
89549540|NCT02031107|Active Comparator|cathodal tDCS|A stimulator (NeuroConn GmbH, Illmenau, Germany) will deliver cathodal transcranial direct current stimulation (tDCS) of the unaffected motor cortex. The anode will be placed over the contralateral supraorbital region. Stimulation will be performed for 25 min, 3 times per week for 3 weeks during upper extremity treatment sessions.
89549541|NCT02031107|Sham Comparator|sham stimulation|This group will receive the same stimulation protocol as used for the active groups except that sham stimuli will be applied. Half of the patients receive sham cTBS, the other half sham tDCS.
89549542|NCT02421523|Experimental|Aim 2 Exercise group|The 10 subjects randomized to the experimental group will participate in an isometric exercise strengthening intervention of the knee extensor and knee flexor muscles in both legs with a frequency of ~three times/week for 12 weeks.
89549543|NCT02421523|Active Comparator|Aim 2 Control group|The 10 subjects randomized to the control group will not participate in any exercise program during the 12 weeks and will be instructed to continue with their normal activities.
89549544|NCT02421523|Experimental|Aim 1 Exercise Dosing|In order to implement a pilot home exercise intervention, the dose response and safety of this intervention must first be determined. We will enroll 12 boys with DMD for this aim and testing will be performed on the right leg.
89549545|NCT02421289|Experimental|CYP2B6 guided group|Patients were assigned to perform CYP2B6 study before ART initiation. If CYP2B6 *6/*6 was found in CYP2B6 *6/*6, the patients will be initiated a low dose of 400 mg of efavirenz (2 tablets of 200 mg) with tenofovir 300 mg and lamivudine 300 mg.
89549546|NCT02421289|No Intervention|control group|Patients were promptly ART initiation regardless CYP2B6 results. Treatments were efvirenz 600 mg, tenofovir 300 mg and lamivudine 300 mg.
89549547|NCT03142997||group S|anesthetized children on spontaneous ventilation.
89549548|NCT03142997||group C|anesthetized children on controlled ventilation.
89549549|NCT02424643|No Intervention|No Incentive|Participants in this arm will receive no compensation for taking the online survey.
89549550|NCT02424643|Experimental|Monetary Incentive|Participants in this arm will receive a $20 Amazon.com incentive for participating in the online survey.
89025301|NCT00479271|Other|Wait-list|This group will be put on a waiting list to receive the intervention after 6 months. Families will be free to choose any health care they desire during the waiting period.
89032998|NCT04689321||Phase 1|Patients recruited for phase 1 will undergo a semi-structured interview to identify issues that may be relevant to include in the revised EORTC QLQ-BN20 questionnaire.
89032999|NCT04689321||Phase 3|Patients recruited for phase 3 will complete the draft questionnaire, and rate each item for relevance, and indicate the 10 most important items. Also, a semi-structured interview will be conducted including debriefing questions to determine if the questionnaire is complete and the questions are acceptable.
89033000|NCT00529841|Experimental|1 (Hydrocortisone sodium acetate)|Subcutaneous administration of Hydrocortisone sodium acetate via insulin pump
89549551|NCT02424643|Experimental|Altruistic Incentive|Participants in this arm will receive altruistic messages throughout the length of the survey in hopes of improving survey completion.
89549552|NCT02424643|Experimental|Dashboard Incentive|Participants in this arm will receive a dashboard at the end of the survey that will compare their data entered into the survey to other participants who have taken the survey. A preview of this dashboard will be shown at the beginning of the survey as a teaser in the hopes to improve survey completion.
89549553|NCT03142685|Experimental|Arm B: Kub + Bowel US|Subjects clinical suspected of NEC whom are randomized into Arm B at time of consent will receive a bowel ultrasound q24 for 48 hours and a KUB q12 for 48 hours.
89025302|NCT03277898|Experimental|Aerobic Exercise|Participants will complete three supervised aerobic exercise sessions each week using the treadmill, stationary bicycle or elliptical training for the duration of their chemotherapy (12-18 weeks). Aerobic exercise will be performed for 20-40 minutes at 50-75% of heart rate reserve. Participants will wear heart rate monitors during all supervised sessions (Polar Electro Inc., Lake Success, NY) and will be provided with target heart rates that will be individualized using their baseline (i.e., week 0) assessment data. Home-based exercise will be introduced in week 3. For the home-based sessions, participants will be asked to complete at least 1 session per week of 30 minutes of aerobic exercise (an activity of their choosing; e.g., walking).
89025303|NCT03277898|Other|Usual Care (Wait-list Control)|Participants randomly assigned to UC group will be advised to continue with their regular activities of daily living. Following their chemotherapy, the UC group will receive the exercise intervention (lasting 12 weeks).
89025304|NCT02274051|Experimental|Kinetin|"Kinetin titration phase to 30mg/kg dose or individual max dose taken once daily.~Patients will then proceed to steady state long-term phase at maximum individual dose of kinetin over a 3 year period."
89025305|NCT03277859|Experimental|YOGA-NOW|Participant will start the SAA-TBI (yoga) about 2 weeks (+/- 2 weeks) after Study Visit 3.
89549554|NCT03142685|No Intervention|Arm A: KUB Only|Subjects clinical suspected of NEC whom are randomized into Arm A at time of consent will receive a KUB q12 for 48 hours. This is the current standard-of-care procedures.
89549555|NCT02424877|Experimental|SandRA|cell phone monitoring
89549556|NCT02424877|No Intervention|Control|conventional monitoring
89549557|NCT05079503|Experimental|TNT plus GEN-001|Total neoadjuvant therapy (TNT) includes short-course radiotherapy (25 Gy/5fx), followed by systemic chemotherapy with FOLFOX regimen for 3-6 months. GEN-001 is orally administered once daily during total TNT periods and surgery will be performed 1 month after systemic chemotherapy.
89549558|NCT02424487||Intracuff pressure during one-lung ventilation|Measurement of changes in intracuff pressure with one-lung ventilation during thoracic surgery.
89549559|NCT03141125|Experimental|Physalis angulata ethanol extract|"Physalis angulata ethanol extract was given with dosage 3 x 250 mg/day, orally, for 3 months.~In addition, patients also received standard therapy for scleroderma."
89549560|NCT03141125|Placebo Comparator|Placebo|Patients received standard therapy and placebo (amylum powder) for comparator at dosage 3 x 250 mg/day, orally, for 3 months.
89549561|NCT02427217||Fibrinogen Concentrate, Human (FCH)|A cohort of subjects who have retrospectively received FCH for the treatment of bleeding, routine prophylaxis and/or use in surgery, and who may continue to prospectively receive FCH at the discretion of the treating physician.
89549562|NCT02426983|Active Comparator|Direct Current Stimulation active|Electrodes will be placed on the scalp overlying the left auditory cortex (anodal electrode) and on the contralateral forehead above the orbit (reference/cathode). Stimulation will be applied using a battery-driven constant-current regulator (Oasis Pro, Edmonton). In active tDCS sessions, the DC current will be initially increased in a ramp-like fashion over 10 s until reaching 2 mA and will be similarly decreased at the end of stimulation. In active tDCS, stimulation will be maintained for a total of 20 minutes. This will occur in two separate sessions, occurring within weeks.
89549563|NCT02426983|Sham Comparator|Direct Current Stimulation sham|In sham sessions, the device will have the same placement and intensity, but will only be turned on for 30 seconds. The DC current will be initially increased in a ramp-like fashion over 10 s until reaching 2 mA and will be similarly decreased at the end of stimulation. This will occur in two separate sessions, occurring within weeks.
89549564|NCT02426983|Active Comparator|NMDA antagonist active|Dextromethorphan (DMO), a non-competitive NMDA antagonist, will be delivered in the form of generic Life Brand Clear Cough Syrup DM (Trillium Healthcare Products Inc, Brockville, ON). Each subject will receive a dose of 50 ml DM with no-sugar cranberry juice (100 ml) to drink. This same dose will be delivered in two separate sessions, occurring within weeks.
89549565|NCT02426983|Placebo Comparator|NMDA antagonist placebo|Each subject will receive a dose of a placebo (150 ml of no-sugar cranberry juice) to drink. This same dose will be delivered in two separate sessions, occurring within weeks.
89549566|NCT02426827|Experimental|SCS in CV|
89549567|NCT05078801||Endoscopic drainage|All patients with perihilar malignant biliary obstruction treated with endoscopic drainage. This drainage can be multimodal using endoscopic retrograde cholangiopancreatography (ERCP) or endoscopic ultrasound (EUS)-guided biliary drainage.
89549568|NCT05078801||Radiologic percutaneous drainage|All patients with perihilar malignant biliary obstruction treated with percutaneous drainage
89549569|NCT03141047|Experimental|Lifespan Integration|This arm is given one session of Lifespan Integration. Differences on Impact of Event Scale from the first measurement at inclusion and the second measurement 20 +/- 3 days after the first measurement, and after treatment, is analyzed and compared with the results from the Group on waiting list. A third measurement and comparison is being made 6 months +/- 6 weeks after the first measurement at inclusion.
89549570|NCT03141047|No Intervention|Waiting list|This arm gets no treatment, and differences on Impact of Event Scale from the first measurement at inclusion at the second measurement 20 +/- 3 days after, without treatment, is analyzed and compared with the results from the treatment Group. A third measurement and comparison is being made 6 months +/- 6 week after the first measurement at inclusion.
89549571|NCT03183349|Experimental|platelet rich fibrin|immediate implant grafting
89549572|NCT03183349|Active Comparator|deprotienized bovine bone (tutogen)|immediate implant grafting
89549573|NCT03142763|Experimental|Egg intake|Consumption of 3 eggs per day for breakfast, 4 weeks
89549574|NCT03142763|Experimental|Choline Supplement intake|Consumption of choline supplement, 1 1/2 tablet (395mg choline), with breakfast for 4 weeks
89549575|NCT03183271|Experimental|Experimental: External beam radiotherapy|A total of 20 patients will be irradiated with protons after photon IMRT
89549576|NCT03183193|Placebo Comparator|Control diet|A conventional and balanced diet based on American Heart Association (AHA) guidelines and lifestyle advice to achieve the objective of American Association for the Study of Liver Diseases (AASLD): loss of at least 3-5% of the initial body weight and up to 10% needed to improve necroinflammation.
89549577|NCT03183193|Experimental|FLiO diet|A mediterranean dietary strategy based on macronutrient distribution (quantity and quality), antioxidant capacity, meal frequency, dietary behaviour and lifestyle advice to achieve the objective of AASLD: loss of at least 3-5% of the initial body weight and up to 10% needed to improve necroinflammation.
89025306|NCT03277859|Active Comparator|YOGA-WAIT|Participant will start SAA-TBI (yoga) about 10 weeks (+/- 2 weeks) after Study Visit 3.
89549578|NCT05653505||Endovascular therapy|According to current guideline recommendations, patients enrolled in this cohort will receive standardized perioperative management, endovascular therapy, and postoperative medical therapy.
89549579|NCT05653505||Endovascular therapy+Remote ischemic conditioning|"Patients enrolled in this cohort will receive the same treatment as those in the endovascular therapy alone cohort as well as additional remote ischemic conditioning treatment.~Remote ischemic conditioning treatment protocol: RIC will be applied immediately after admission to the integrated neurovascular ward and the treatment continues until the patient is discharged, Once the patient is discharged, the choice of whether to continue RIC treatment depends on the patient's preference. RIC was induced through a standard blood pressure cuff placed around the non-paretic arm. The protocol includes 5 cycles of intermittent manually induced upper limb ischemia, alternating 5 minutes of inflation (20mmHg above systolic blood pressure), and 5 minutes of deflation twice a day."
89549580|NCT03179059|Experimental|Pregnancy tests at baseline & follow-up|We offer free pregnancy test service at baseline and at follow-up survey.
89025307|NCT00444470|Active Comparator|A|Active drug being tested in this study is Tranexamic Acid
89549581|NCT03179059|Experimental|Pregnancy tests only at baseline|We offer free pregnancy test service at baseline
89549582|NCT03179059|No Intervention|Do Not Offer Pregnancy Test|Control group. No intervention is implemented.
89549583|NCT05078645|Other|Group 1: Maya use on 1st, 3th and 5th day|Group 1 uses the Maya on the 1st, 3th and 5th day and not on the 2nd, 4th and 6th day of their admission to either the ICU, MC or CCU.
89549584|NCT05078645|Other|Group 2: Maya use on the 2nd, 4th, and 6th day|Group 2 uses the Maya on the 2nd, 4th and 6th day and not on the 1st, 3th, and 5th day of their admission to either the ICU, MC or CCU.
89549585|NCT02426593||Subjects without heart failure|
89549586|NCT05078567|Experimental|Single arm open label study|Topical used natural lactic acid-enriched cream twice daily.
89549587|NCT02426515|Experimental|Hilotherm® Device|Patients undergo removal of lower third molar with Hilotherm® cooling device applied.
89549588|NCT02426515|No Intervention|Control|Patients undergo removal of lower third molar without the Hilotherm® cooling device applied.
89549589|NCT05081765||Patients with diabetes mellitus|olaparib 2 x 300mg /24h tablets = olaparib 2 x 400mg/24 olaparib 2 x 250mg/24h tablets = olaparib 2 x 200mg/24h olaparib 2 x 200mg/24h tablets = olaparib 2 x 100mg/24h
89549590|NCT05081765||Patients with hyperglycemia,|olaparib 2 x 300mg /24h tablets = olaparib 2 x 400mg/24 olaparib 2 x 250mg/24h tablets = olaparib 2 x 200mg/24h olaparib 2 x 200mg/24h tablets = olaparib 2 x 100mg/24h
89549591|NCT05081765||Patient with normal glucose level|olaparib 2 x 300mg /24h tablets = olaparib 2 x 400mg/24 olaparib 2 x 250mg/24h tablets = olaparib 2 x 200mg/24h olaparib 2 x 200mg/24h tablets = olaparib 2 x 100mg/24h
89549592|NCT04482829|Experimental|Experimental Group|On the basis of PC chemotherapy and symptomatic treatment, the patients in the experimental group will receive jing-yuan-kang granule with one dose daily.
89549593|NCT04482829|Other|Control Group|All the patients in control group will receive PC chemotherapy and symptomatic treatment without other treatment.
89549594|NCT02426359|Experimental|Q301 Cream|Q301 Cream
89549595|NCT02426359|Placebo Comparator|Vehicle|Vehicle
89549596|NCT05078177|Experimental|AHSCT + intrathecal Rituximab|AHSCT with reduced intensity condition regimen (RIC). Lumbar puncture with intrathecal injection of 25 mg Rituximab will be performed once from about D+12 to D+14 AHSCT, depending on the duration of cytopenia.
89549597|NCT03183427||Group of patients with pineal cyst|Group of patients with pineal cyst
89549598|NCT03183427||Control group|Group of subjects without pineal cyst
89549599|NCT05387369||Paxlovid|Patients with COVID-19 who visit Huashan Hospital,Fudan University from 2022 to 2027 and receive Paxlovid therapy
89549600|NCT05387369||Routine therapy|Patients with COVID-19 who visit Huashan Hospital,Fudan University from 2022 to 2027 and receive routine therapy without paxlovid
89549601|NCT05387213|Experimental|Huddle attendees|Participants in this arm participated in huddles
89549602|NCT05387213|No Intervention|Huddle non-attendees|Participants in this arm did not participate in huddles
89549603|NCT05387135|Sham Comparator|sham Transcutaneous Vagus Nerve Stimulation|For sham-t-VNS device was turned 180°, stimulating the outer earlobe which does not contain fibers of the ABVN. A similar protocol as for active stimulation was used.
89025308|NCT00444470|Placebo Comparator|B|Normal saline was used as the Placebo
89208011|NCT00793364|Placebo Comparator|Placebo spread|Placebo spread group
89549604|NCT05387135|Active Comparator|Transcutaneous Vagus Nerve Stimulation|Afferents of the Auricular branch of vagus nerve (ABVN) were stimulated using a t-VNS device (TENS 7000TM) made by Roscoe Medical Inc., will be used. TENS 7000TM device was labeled as nerve stimulator and low-risk medical device (Instruction manual for TENS 7000). The electrode was placed in the left cymba concha with direct contact on the skin after cleaning with an alcohol swab. The stimulation for both groups will last for 30 minutes once a day for 3 days per week for 12 weeks. The amplitude of the output current was between 0.25-2.0 mA as tolerated and 250 µs width at 10 Hz.
89549605|NCT05080985|Experimental|Group P : TPVB|Thoracic paravertebral block
89549606|NCT05080985|Experimental|Group E : ESPB|Erector spinae plane block
89549607|NCT05080829|Experimental|Mutation Register|Measure of myeloid mutations after detection of relapse or refractoriness to ITK treatment
89549608|NCT05258591|Experimental|Axem Home|Patients receive at-home access to Axem Home system for duration of the study period.
89033001|NCT02922504|Experimental|Music intervention group|For the patients in the Music intervention group, a adjuvant treament by a music intervention will be use before the procedure
89549609|NCT03139643|Experimental|Cognitive Dissonance|After reading the materials about their chosen behavior, participants will be asked write an essay about their behavior of choice (studying/exercising). For this essay they will be asked to imagine that they have reached their ideal level of academic achievement/fitness, describe what this would look and feel like, and reflect on how this would impact how they view themselves, their relationships, and their day to day life.
89549610|NCT03139643|Experimental|Action Planning|After reading the materials about their chosen behavior, participants will be asked to make a detailed plan for the following two weeks based on the following items taken from a study by Sniehotta and colleagues (2004): 1) when to complete studying/exercise, 2) where to complete studying/exercise, 3) how to complete studying/exercise (e.g., what types of exercise- cardio, class, etc. or what types of studying activities- reading, taking notes, creating outlines, etc.), and 4) how often to complete studying/exercise. Participants will be given a calendar as an aid to planning their behavior.
89549611|NCT03139643|Placebo Comparator|Reflection (Control Condition)|After reading the materials about their chosen behavior, participants will be asked to summarize and reflect on what they read.
89549612|NCT05072171||Biopsies from 3D hernia scaffold ProFlor in the short term|3 patients biopsied 3-5 weeks post implantation of ProFlor
89549613|NCT05072171||Biopsies from 3D hernia scaffold ProFlor in the midterm|5 patients biopsied 3-4 months post implantation of ProFlor
89549614|NCT05072171||Biopsies from 3D hernia scaffold ProFlor in the long term|4 patients biopsied between 3-4 months post implantation of ProFlor
89549615|NCT05072171||Biopsies from 3D hernia scaffold ProFlor in the extra long term|3 patients biopsied more than 3 years after implantation of ProFlor
89549616|NCT03139487|Active Comparator|Low molecular weight heparin|Dalteparin, 200 IU/kg subcutaneously once daily for 4 weeks followed by 150 IU/kg once daily for 20 weeks
89549617|NCT03139487|Experimental|Direct oral anticoagulant|"Rivaroxaban, 15 mg orally twice daily for 3 weeks followed by 20mg once daily for 21 weeks~Apixaban, 10 mg orally twice daily for 7days followed by 5mg twice daily for 21 weeks"
89549618|NCT03139253|Experimental|clarithromycin susceptible|"Patients will receive a 14-day triple therapy to eradicate H. pylori. The regimen is consist of Ilaprazole, amoxicillin and clarithromycin.~Ilaprazole 5 mg b.i.d is used as the proton pump inhibitor (PPI)."
89549619|NCT03139253|Experimental|metronidazole susceptible|Patients will receive a 14-day triple therapy to eradicate H. pylori. The regimen is consist of Ilaprazole, amoxicillin and tinidazole.
89549620|NCT03139253|Experimental|levofloxacin susceptible|Patients will receive a 14-day triple therapy to eradicate H. pylori. The regimen is consist of Ilaprazole, amoxicillin and levofloxacin.
89549621|NCT03139253|Experimental|furazolidone susceptible|Patients will receive a 14-day triple therapy to eradicate H. pylori. The regimen is consist of Ilaprazole, amoxicillin and furazolidone.
89549622|NCT03139253|Experimental|tetracycline susceptible|Patients will receive a 14-day triple therapy to eradicate H. pylori. The regimen is consist of Ilaprazole, amoxicillin and tetracycline.
89549623|NCT03139409|Active Comparator|conventonal adhesive|peak lc bond
89549624|NCT03139409|Other|Time variable|Diagnosis and follow up will be immediate ,6 months later and 1 year
88812050|NCT01398059|Experimental|Sedentary With Breaks and Physical Activity|In this condition participants will engage in 8 hours of sitting, although the sitting will be interrupted every 20 minutes. During these interruptions participants will spend 2 minutes walking at an intensity equivalent to 30% of VO2peak. Participants will also engage in 20 minutes of structured physical activity at an intensity of 60% of VO2peak in both the morning and afternoon.
88812051|NCT03855332|Placebo Comparator|Placebo|"All participants will undergo three phases in random order:~The placebo phase will include overencapsulated placebo, matched to overencapsulated active agents, 2 tablets 3 times daily"
88812052|NCT03855332|Experimental|Sildenafil|25mg three times daily, overencapsulated tablet, increased after 1 week to 50mg three times daily
88812053|NCT03855332|Active Comparator|Cilostazol|50mg bd, overencapsulated tablet (with midday placebo), increased after 1 week to 100mg bd (with midday placebo)
88812054|NCT01514279|Experimental|HealthyCHANGE|Cognitive behavioral strategies to address diet, physical activity, sedentary behavior and sleep for children.
88812055|NCT01514279|Experimental|SystemCHANGE|Intervention (based on systems improvement and choice architecture theories) System improvement and choice architecture theories seek to teach a set of skills using family self-designed experiments to redesign daily routines
88812056|NCT01514279|No Intervention|Tools4CHANGE|In contrast to the behavioral arms, youths with their parent(s)/guardian randomized to this group will have one 60-minute face-to-face meeting at initiation of the study with a dietitian who is also trained in recommendations for exercise and sedentary behavior.
88812057|NCT03226730|Experimental|Arm 1: Household Visits|Arm 1 will receive gender synchronized household visits (i.e., visits by a female community health worker to the participating married adolescent female and visits by a male community health worker to the participating husband of the married adolescent female). Approximately 10-12 visits with wives and 4-6 visits with husbands are expected to take place over the course of the project. Study Arms 1-3 will additionally receive community enabling environment activities and adolescent-specific service delivery activities to support adolescent contraception use. Community enabling environment activities will include engaging religious leaders, community leaders, and familial gatekeepers of the married adolescent wives, such as in-laws, in community dialogues on a monthly basis.
88812058|NCT03226730|Experimental|Arm 2: Small Groups|This arm will receive, in addition to the community-level components, gender synchronized group-based interventions (i.e., separate group-based interventions for husbands of adolescent wives and adolescent wives, themselves). Male-only and female-only small groups for participating husbands and wives will be held separately on bimonthly and monthly intervals, respectively. In this project, each small group will consist of 10-15 participants and will be held in places participants have deemed safe spaces (e.g., a place that has auditory and visual privacy, is safe for girls to walk to, has been designated by community leaders as a protected place for girls to meet). Approximately 8-10 female small groups and 4-6 male groups are expected to take place over the course of the project.
89549625|NCT02019472|Experimental|Group 1 (adalimumab 40 mg)|Adalimumab 40 mg SC at Weeks 0, 2, and every 2 weeks through Week 52. At Week 16, subjects who have < 20% improvement from baseline in both swollen and tender joint counts will early escape in a blinded fashion and receive adalimumab 40 mg every week through Week 52.
89549626|NCT02019472|Experimental|Group 2 (sirukumab 100 mg)|Sirukumab 100 mg SC at Weeks 0, 2, and every 2 weeks through Week 52. Subjects may meet the early escape criteria at Week 16 (< 20% improvement from baseline in both swollen and tender joint counts) but no sirukumab dose adjustments will made for these subjects. However, these subjects will receive placebo injections every 2 weeks between the sirukumab injections (ie, subjects that early escape will receive a weekly injection of alternating sirukumab and placebo, to preserve the blind).
89549627|NCT02019472|Experimental|Group 3 (sirukumab 50 mg)|Sirukumab 50 mg SC at Weeks 0, 4, and every 4 weeks through Week 52. Between sirukumab injections, placebo SC injections will be administered at Weeks 2, 6, and every 4 weeks through Week 50. At Week 16, subjects who have < 20% improvement from baseline in both swollen and tender joint counts will early escape in a blinded fashion and receive sirukumab 100 mg every 2 weeks through Week 52 and placebo injections every 2 weeks between the sirukumab injections (ie, subjects that early escape will receive a weekly injection of alternating sirukumab and placebo, to preserve the blind).
89549628|NCT03140891|Experimental|NHFOV|NHFOV is used as the supporting mode after extubation
89549629|NCT03140891|Active Comparator|NCPAP|NCPAP is used as the supporting mode after extubation
89549630|NCT04587245||Physicians|Physician or healthcare Provider based anywhere in the United States who is eligible to submit claims to an insurance company on behalf of patients
89549631|NCT05092061|Experimental|Moderate-repetition resistance training|The participants will undergo a full-body resistance training protocol with moderate repetitions (6-12), moderate load (70-85% of 1RM), and moderate rest between sets (60-90s). Training will be undertaken three times per week.
89549632|NCT05092061|Experimental|High-repetition resistance training|The participants will undergo a full-body resistance training protocol with high repetitions (15+), low load (<60% of 1RM), and short rest between sets (30s). Training will be undertaken three times per week.
89549633|NCT03139565|Experimental|Fluzone High-dose Influenza Vaccine|This treatment consists of 60 microgram of each influenza antigen provided as a single injection, which will be injected in the deltoid muscle of the non-dominant arm.
89549634|NCT03139565|Active Comparator|Standard 2016-2017 Flu vaccine|This will be the Standard 2016-2017 influenza vaccine made available by public health. It will contain 15 microgram of each strain and will be delivered in the deltoid muscle of non-dominant arm.
89549635|NCT04566185||Patients with recurrent glioblastoma|
89549636|NCT03139175|Experimental|temporomandibular disorder group|subjects with TMD and CLBP symptoms undergo balance assessment with Biodex balance system
89549637|NCT03139175|Active Comparator|chronic low back pain group|subjects only with LBP symptoms undergo balance assessment with Biodex balance system
89549638|NCT03139175|Other|Normal|subjects without temporomandibular disorder and low back pain symptoms undergo balance assessment with Biodex balance system
89549639|NCT03139331|Experimental|Pazopanib, irinotecan, temozolomide (PAZIT)|Patients will receive daily oral pazopanib on days 1-21 in a 21-day cycle. This will be combined with intravenous or oral irinotecan and oral temozolomide on days 1-5. Dosing of irinotecan will be from 25 to 37.5 mg/m2/day for IV dosing or from 45 to 67.5 mg/m2/dose for oral dosing and oral temozolomide will be 100 mg/m2/day for dose levels at each assigned dose level. In the absence of disease progression or unacceptable toxicity, patients will receive cycles of therapy repeating every 21 days for a maximum of 12 months on study.
89549640|NCT04423601|Experimental|Treatment|subjects receiving a single oral dose of SHR6390 tablets, then itraconazole capsules 200 mg/day orally with a single oral dose of SHR6390 tablets co-administered.
89549641|NCT04418141|Experimental|Single Arm|"Five planned CN1 dose levels of 0.03 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg, and 10 mg/kg.~Subjects will receive CN1 by intravenous infusion (IV) on Day 1 (D1) of each cycle (once every 3 weeks per cycle)."
89549642|NCT04345991|Experimental|COVID-19 convalescent plasma|A plasma unit provided by a COVID-19 convalescent pathogen-reduced plasma will be used for the treatment of the patients.
89549643|NCT04345991|No Intervention|Control patients|Control patients will receive the best standard of care
89549644|NCT03139019|Experimental|Process incentives|Process incentives participants will receive incentives based on visit attendance in the YMCA DPP session. This incentive will be $ 15 for attending each session.
89549645|NCT03139019|Experimental|Outcome incentives|Outcome incentives participants will be weighed at 8 and 16 weeks after the program starts and if they have lost 2.5% of their body weight at each time point then they will receive $100 and $140 respectively.
89549646|NCT03139019|Experimental|Process and Outcome incentives|If assigned to the Process and Outcome arm participants will be informed that they can earn additional incentives for attending DPP classes and losing weight. Participants in this arm can earn $7.50 per DPP class (max 16) and $50 and $70 for achieving 2.5% weight loss at 8 and 16 weeks respectively.
89549647|NCT03139019|No Intervention|Control arm|If assigned to the Control arm participants will not be eligible for any additional incentives and will just learn the goals of the DPP program itself.
89549648|NCT04085705||Patients with diabetic foot ulcers|All patients with diabetic foot ulcers will undergo a PATCH test to determine the prevalence of contact allergies against wound dressings.
89549649|NCT04902287|Experimental|TIES Engagement Strategies|Participants in this arm will receive a 30-minute TIES engagement intervention during their referral phone call.
89549650|NCT04902287|No Intervention|Referral as Usual|Participants in this arm will receive a standard call to schedule an intake appointment by an administrative assistant with no clinical training.
89549651|NCT04880759|Experimental|Bike desks in classroom|All participants receive the same intervention: the use of bike desks during school.
89549652|NCT04877405||Intracerebral hemorraghe|Patients that suffered an intracerebral hemorraghe and that have been subjected to CT and MRI scans
89549653|NCT03495479||OMN54 -Treated|Six-month, daily oral dosing in softgel capsules throughout the first 6 months of treat.
89549654|NCT03140813|Experimental|Placebo - Low-Dose - High-Dose|Placebo AZD7325 5mg BID in gelatin capsules AZD7325 15mg BID in gelatin capsules
89549655|NCT03140813|Experimental|Placebo - High-Dose - Low-Dose|Placebo AZD7325 15mg BID in gelatin capsules AZD7325 5mg BID in gelatin capsules
89549656|NCT03140813|Experimental|Low-Dose - Placebo - High-Dose|AZD7325 5mg BID in gelatin capsules Placebo AZD7325 15mg BID in gelatin capsules
89549657|NCT03140813|Experimental|Low-Dose - High-Dose - Placebo|AZD7325 5mg BID in gelatin capsules AZD7325 15mg BID in gelatin capsules Placebo
89549658|NCT03140813|Experimental|High-Dose - Low-Dose - Placebo|AZD7325 15mg BID in gelatin capsules AZD7325 5mg BID in gelatin capsules Placebo
89549659|NCT03140813|Experimental|High-Dose - Placebo - Low-Dose|AZD7325 15mg BID in gelatin capsules Placebo AZD7325 5mg BID in gelatin capsules
89549660|NCT04792931|Other|Adult Autoimmune Myopathies|It is a description Autoimmune Myopathie cohort
89549661|NCT02936687|Experimental|Metabolic Syndrome NOS Inhibition|Will occur over two separate study visits after screening. Eligible subjects with MetSyn will undergo NOS Inhibition during one visit and placebo infusion in the other visit. Subjects will also undergo 3 Tesla MRI scanning and an intravenous catheter, and will complete an Oral Glucose Tolerance Test during the study visits. More details under Study Description.
89549662|NCT02936687|Experimental|Metabolic Syndrome ET-1 Inhibition|Will occur over two separate study visits after screening. Eligible male subjects with MetSyn will complete an oral ET-1 Inhibition during one visit and an oral placebo in the other visit. Subjects will also undergo 3 Tesla MRI scanning and an intravenous catheter, and will complete an Oral Glucose Tolerance Test during the study visits. More details under Study Description.
89549663|NCT02936687|Experimental|Control NOS Inhibition|Will occur over two separate study visits after screening. Eligible control subjects will undergo NOS Inhibition during one visit and placebo infusion in the other visit. Subjects will also undergo 3 Tesla MRI scanning and an intravenous catheter, and will complete an Oral Glucose Tolerance Test during the study visits. More details under Study Description.
89549664|NCT02936687|Experimental|Control ET-1 Inhibition|Will occur over two separate study visits after screening. Eligible male control subjects will complete an oral ET-1 Inhibition during one visit and an oral placebo in the other visit. Subjects will also undergo 3 Tesla MRI scanning and an intravenous catheter, and will complete an Oral Glucose Tolerance Test during the study visits. More details under Study Description.
89549665|NCT04728737|Experimental|combined swallowing and IOPI group|the patients will receive swallowing therapy and IOPI biofeedback exercise program
89549666|NCT04728737|Active Comparator|combined swallowing and NMES group|the patients will receive swallowing therapy and neuromuscular electrical stimulation
89549667|NCT04728737|No Intervention|Normal group|20 normal people will receive sonography evaluations to verify the inter-rater and intra-rater reliability of sonography, and use IOPI to assess maximal muscle strength and endurance of oropharyngeal muscles.
89549668|NCT04722809|Experimental|Symptomatic patients in the context of bruxism|
89549669|NCT05083793|Experimental|Study group|patients have spine surgery receive oral pregabalin 150 mg 1 hour before surgery
89549670|NCT05083793|Placebo Comparator|Placebo group|patients will receive placebo 1 hour before surgery with a sip of water.
89549671|NCT03139097||Healthy Volunteers|Blood samples from healthy volunteers analyzed on the Quantra System.
89549672|NCT04561193||Retrospective Cohort|Patients admitted to Methodist Richardson, Methodist Mansfield, Methodist Charlton, or Methodist Dallas Medical Centers between February 1, 2020 and April 30, 2020 with positive COVID-19 PCR test.
89549673|NCT03140657|Experimental|Nanocurcumin Arm|Nanocurcumin capsules (the formulation of curcumin nanoparticles, Exirnanosina). Subjects randomized to Nanocurcumin Arm will receive 80 mg/day for 4 months.
89549674|NCT03140657|Placebo Comparator|Placebo|Subjects randomized to Placebo Arm will receive placebo in the form of capsules for 4 months.
89549675|NCT04427345||Covid19 infection related patients|Patients admitted to COVID wards of the S. Gerardo Hospital of Monza, including Intensive Care wards.
89549676|NCT03140501|Experimental|Immediate Intervention|"Participants randomized to this group will receive the intervention, the mobile application (app), immediately after baseline data are collected."
89549677|NCT03140501|Other|Delayed intervention|"Participants randomized to this group will receive the intervention, the mobile application (app), after a three month delay."
89549678|NCT04415021|Experimental|Diaphragmatic and İliopsoas Myofascial Release Techniques|Subjects in this arm will receive different myofascial release techniques aimed to relaxation the myofascial tension of the diaphragmatic and iliopsoas muscles.
89549679|NCT04415021|Sham Comparator|Sham Myofascial Release Techniques|Subjects in this arm will receive the same manual techniques of the diaphragmatic and iliopsoas myofascial release group, but without the myofascial stimulus.
89549680|NCT05083013||COVID-19 with DM|"All patients will be screened for diabetes according to history and blood glucose measurements as well as HbA1C.~Accordingly, the patients will be divided into two groups, diabetic and non-diabetic group."
89549681|NCT05083013||COVID-19 without DM|"All patients will be screened for diabetes according to history and blood glucose measurements as well as HbA1C.~Accordingly, the patients will be divided into two groups, diabetic and non-diabetic group."
89549682|NCT05082623|Experimental|Music group|"MusiCure® compositions specially composed for the music group will be performed twice a day, between 10.00-11.00 a.m. and 14.00-15.00 p.m., for five days with headphones and a music player. Before the application, the sound level of the ICU environment will be measured with a decibel meter. At the 0th minute of the music application, at the 30th minute after starting the music, and at the 60th minute after the end of the music, the characteristics of delirium, pain, sedation level, anxiety and vital parameters will be recorded with data collection tools."
89549683|NCT05082623|Active Comparator|Earplug group|In this group, patients will be given only earplugs. Before the application, the sound level of the ICU environment will be measured with a decibel meter. At the 0th minute of the intervention, at the 30th minute after starting intervention, and at the 60th minute after the end of the intervention, the characteristics of delirium, pain, sedation level, anxiety and vital parameters will be recorded with data collection tools.
89549684|NCT05082623|No Intervention|Control group|The control group involves neither music intervention nor using earplug.
89025309|NCT00444509|Experimental|Treatment 1|Subjects will receive GW685698X 800 microgram (mcg) single inhaled dose via a DISKUS inhaler. There will be a wash-out period of at least 5 days between doses.
89549685|NCT03111017|Experimental|Exercise Training|Subjects will perform continuous endurance exercise (arm and leg cycle on Schwinn AD6 Airdyne ergometer, treadmill walking) 3 days per week. During the first 4-weeks, the exercise intensity will be set at 60%-70% of heart rate reserve and will increase by 5% per month. The initial exercise duration be 30 minutes and will gradually increase by 10 minutes every month. A 5-minute warm up and cool-down will precede and follow the aerobic conditioning phase. After the aerobic training phase is completed, patients will also perform unilateral handgrip exercise at an initial intensity of 50% maximal voluntary contraction for 1 set of 10 repetitions, and the intensity and sets will increase by 5% and 1 set, respectively each month.
89549686|NCT03111017|No Intervention|Attention Control|These subjects will be asked to continue with normal activity and will not be given any exercise training. The subjects will be contacted by the study coordinator at pre-arranged times and dates once a month and involve inquiry regarding overall well-being of the subject.
89549687|NCT02705755|Experimental|TD-9855 Part A|Subjects will receive placebo and escalating single doses of TD-9855
89549688|NCT02705755|Experimental|TD-9855 Part B|Subjects will receive a single dose of TD-9855 or placebo.
89549689|NCT02705755|Experimental|TD-9855 Part C|Subjects will receive once daily doses of TD-9855 for up to 5 months as part of an optional outpatient open-label extension arm.
89549690|NCT05073653|Other|68Ga-PSMA PET/CT Imaging|Injection of the radioligand 68Ga-PSMA; Device: PET/CT; Following injection of 68Ga-PSMA, the participants will be subjected to whole body PET/CT.
89549691|NCT05073653|Other|68Ga-GRP PET/CT Imaging|Injection of the radioligand 68Ga-GRP; Device: PET/CT; Following injection of 68Ga-GRP, the participants will be subjected to whole body PET/CT.
89549692|NCT02024932|Experimental|BVS857 Part A Open label (Cohort 1)|Participants received single doses of 0.01 mg/kg BVS857 intravenously (i.v.) on day 1, 0.01 mg/kg BVS857 subcutaneously (s.c.) on day 15, 0.03 mg/kg BVS857 s.c. on day 29, 0.06 mg/kg BVS857 s.c. on day 43 and 0.10 mg/kg BVS857 s.c. on day 57.
89549693|NCT02024932|Experimental|BVS857 Part A double blind (Cohort 2)|Participants received single doses of 0.03 mg/kg BVS857 i.v on day 1, 0.03 mg/kg BVS857 s.c. on day 15, 0.06 mg/kg BVS857 s.c. on day 29, 0.10 mg/kg BVS857 s.c. on day 43 and 0.10 mg/kg BVS857 s.c. on day 57. (BVS857 concentrations differed on days 43 and 57.)
89549694|NCT02024932|Placebo Comparator|Placebo Part A double blind (Cohort 2)|Participants received single doses of matching placebo i.v. on day 1 and matching placebo s.c. on days 15, 29, 43 and 57.
88961778|NCT04227132|Experimental|Standard training, then Labyrinth training|Patients will receive at first the Standard training for 10 sessions of 45 minutes, delivered 4 days per week. Then they will undergo the Labyrinth training for 10 sessions of 45 minutes, for around 4 days per week. Before and after each training patients are tested for primary and secondary outcomes with standardized tests.
88961779|NCT04225065|Active Comparator|Chlorhexidine prep|Chlorhexidine prep prior to their operation
88961780|NCT04225065|Active Comparator|Betadine prep|Betadine prep prior to their operation
89208012|NCT00793364|Other|Mediterranean diet group|Mediterranean diet group
89208013|NCT01563315||Adults with CAP admitted to hospital|All adult patients with CAP admitted to Vestre Viken HF-Buskerud Hospital (VVHF-BH), a 400-bed community general hospital, between January 2008 og January 2011 were evaluated for inclusion in the study.
89208014|NCT02597153|Experimental|Mitoxantrone HCL Liposome Injection|Each treatment cycle lasts for 28 days with 20mg/m2
89208015|NCT00867438|Placebo Comparator|1|
89208016|NCT00867438|Experimental|2|
89208017|NCT00975741|Experimental|Monodose device|Mometasone furoate 400 µg DPI capsules administered through a monodose device.
89208018|NCT00975741|Active Comparator|Multidose device|Mometasone furoate 400 µg DPI capsules administered through a multidose device
89208019|NCT00786890||no treatment|observational, no treatment needed
89208020|NCT00262873|Experimental|Bortezomib|
89208021|NCT00867516|Experimental|1|ALD518 80 mg
89208022|NCT00867516|Experimental|2|ALD518 160 mg
89208023|NCT00867516|Experimental|3|ALD518 320 mg
89208024|NCT00867516|Placebo Comparator|4|No ALD518
89208025|NCT00786968|Experimental|intrathecal laronidase|drug laronidase, dose 1.74 mg, route intrathecal, frequency every 30-90 days, duration 1 year
89208026|NCT00975819|Experimental|Sirolimus|
89208027|NCT02598323|Experimental|patients with active singleton pregnancy between 16 and 26 SA|
89208028|NCT00793442||Novel Endothelial Markers Derivation|"Our study participants will come from the Protocolized Care for Early Severe Sepsis (ProCESS) trial will be eligible participants.~From the ProCESS subjects, the researchers will include those who were: 1) recruited by participating centers who participated in other components of this ancillary study or 2) who were sequentially enrolled from periods derived from the beginning, middle, and end of the ProCESS study."
89208029|NCT00793442||Novel Endothelial Marker Validation|Our study participants will come from the Protocolized Care for Early Severe Sepsis (ProCESS) trial will be eligible participants; the researchers will recruit a sequential 300 patient validation set.
89549695|NCT02024932|Experimental|BVS857 Part B open-label (Cohort 4)|Participants received 0.1 mg/kg BVS857 i.v. weekly for 12 weeks.
89549696|NCT02024932|Experimental|BVS857 Part B double blind (Cohort 5)|Participants received 0.06 mg/kg (maximum 6 mg) BVS857 i.v. weekly for 12 weeks.
89549697|NCT02024932|Placebo Comparator|Placebo Part B double blind (Cohort 5)|Participants received matching placebo i.v. to BVS857 weekly for 12 weeks.
89517354|NCT03890250|Experimental|NMES group|"Following the assessments, both groups will participate in a 20-30 minute low-medium intensity aerobic exercise training with cycling ergometer.~After the aerobic exercise in NMES group, bilateral NMES application on Quadriceps femoris muscle will be applied as symmetrical biphasic square wave current with a wave frequency of 35-60 Hz, phase transition time of 8 seconds and active resting time of 15 seconds."
89517355|NCT03879629|Experimental|Pre-Emptive Strategy|Carvedilol titrated to maximally tolerated doses (3.125 mg to 25 mg twice a day) initiated one week before start of therapy and continued until end of therapy
89517356|NCT03879629|Experimental|Reactive Strategy|Carvedilol titrated to maximally tolerated doses (3.125 mg to 25 mg twice a day) initiated after documentation of subclinical cardiotoxicity, defined by an abnormal global longitudinal strain (GLS) or high-sensitive cardiac troponin (hsTnI) elevation and continued until end of therapy
89517357|NCT03879629|Active Comparator|Standard of Care|Carvedilol titrated to maximally tolerated doses (3.125 mg to 25 mg twice a day) initiated after documentation of a drop in LVEF by >10% to a value less than 53% and continued until end of therapy
89517358|NCT03872947|Experimental|Arm A: TRK-950 + FOLFIRI|"Colorectal Cancer~TRK-950 will be administered intravenously (IV) on days 1, 8, 15, and 22 of a 28-day cycle. On days 1 and 15 Irinotecan will be administered IV. Leucovorin will be infused to match the duration of the irinotecan infusion. 5-FU will be administered as IV bolus, followed by TRK-950 administration. After the TRK-950, 5-FU will be administered by a continuous infusion."
89517359|NCT03872947|Experimental|Arm B: TRK-950 + Gemcitabine/Cisplatin|"Cholangiocarcinoma or Bladder Cancer~TRK-950 will be administered IV on days 1, 8 and 15 of a 21-day cycle. After the administration of TRK-950 on days 1 and 8, Cisplatin will be administered by infusion. Then, Gemcitabine will be administered as an IV infusion."
89517360|NCT03872947|Experimental|Arm C: TRK-950 + Gemcitabine/Carboplatin|"Ovarian Cancer~TRK-950 will be administered IV on days 1, 8 and 15 of a 21-day cycle. After the administration of TRK-950 on days 1 and 8, Gemcitabine will be administered as an intravenous infusion. On day 1, following the administration of TRK-950 and Gemcitabine, Carboplatin will be administered IV."
89517361|NCT03872947|Experimental|Arm D: TRK-950 + Ramucirumab/Paclitaxel|"Gastric Cancer~TRK-950 will be administered IV on days 1, 8, 15, and 22 of a 28-day cycle. After the administration of TRK-950 on days 1 and 15, Ramucirumab will be administered as an IV infusion. Paclitaxel will be dosed on days 1, 8 and 15, after the Ramucirumab on days 1 and 15 and after the TRK-950 on day 8."
89517362|NCT03872947|Experimental|Arm E: TRK-950 + PD1 inhibitors|"•Solid Tumors~E-1: TRK-950 + Nivolumab~•TRK-950 will be administered IV on days 1, 8, 15, and 22 of a 28-day cycle. After the administration of TRK-950 on days 1 and 15, Nivolumab will be administered as an IV infusion.~E-2: TRK-950 + Pembrolizumab~•TRK-950 will be administered IV on days 1, 8 and 15 of a 21-day cycle. After the administration of TRK-950 on day 1, Pembrolizumab will be administered as an IV infusion."
89517363|NCT03872947|Experimental|Arm F: TRK-950 + Imiquimod Cream|"Palpable subcutaneous malignant lesions~TRK-950 will be administered IV on days 1, 8 and 15 of a 21-day cycle. Imiquimod cream is to be applied 5 of 7 days in a row with 2 days rest for a maximum of 2 cycles (total 6 weeks)."
89517364|NCT03872947|Experimental|Arm G: TRK-950 + Bevacizumab|"Renal Cell Carcinoma~TRK-950 will be administered IV on days 1, 8, 15, and 22 of a 28-day cycle. After the administration of TRK-950 on days 1 and 15, Bevacizumab will be administered as an IV infusion."
89517365|NCT03872947|Experimental|Arm H: TRK-950 + PD1 inhibitors|"•Melanoma~H-1: TRK-950 + Nivolumab~•TRK-950 will be administered IV on days 1, 8, 15, and 22 of a 28-day cycle. After the administration of TRK-950 on days 1 and 15, Nivolumab will be administered as an IV infusion.~H-2: TRK-950 + Pembrolizumab~•TRK-950 will be administered IV on days 1, 8 and 15 of a 21-day cycle. After the administration of TRK-950 on day 1, Pembrolizumab will be administered as an IV infusion."
89517366|NCT03872947|Experimental|Arm J: TRK-950 + FOLFIRI|"Colorectal Cancer~TRK-950 will be administered IV on days 1, 8, 15, and 22 of a 28-day cycle. On days 1 and 15 Irinotecan will be administered IV. Leucovorin will be infused to match the duration of the irinotecan infusion. 5-FU will be administered as IV bolus, followed by TRK-950 administration. After the TRK-950, 5-FU will be administered by a continuous infusion."
89517367|NCT03872947|Experimental|Arm K: TRK-950 + Gemcitabine / Carboplatin / Bevacizumab|"Platinum Sensitive epithelial ovarian, primary peritoneal or fallopian tube cancer~TRK-950 will be administered IV on days 1, 8 and 15 of a 21-day cycle. On all dosing days, TRK-950 will be administered IV after the relevant combination regimen is dosed. Gemcitabine will be administered as an intravenous infusion on days 1 and 8. On day 1, following the administration of Gemcitabine, Carboplatin will be administered as an intravenous infusion. Also on Day 1 of each cycle, Bevacizumab will be administered IV next. After 6 cycles of chemotherapy the patient will be transitioned to maintenance treatment. On Day 1 of each maintenance cycle, Bevacizumab will be administered IV. Maintenance treatment will be continued as long as there is no evidence of progressive disease."
89517368|NCT03872947|Experimental|Arm O: TRK-950 + PLD|"Platinum Resistant epithelial ovarian, primary peritoneal or fallopian tube cancer~TRK-950 will be administered IV on days 1, 8, 15, and 22 of a 28-day cycle. PLD will be dosed as IV on Day 1 of each cycle. On days that TRK-950 and PLD are both dosed, PLD will be dosed first."
89517369|NCT03872947|Experimental|Arm Q: TRK-950 + Ramucirumab/Paclitaxel|"Gastric cancer~TRK-950 will be administered IV on days 1, 8, 15, and 22 of a 28-day cycle. On all dosing days, TRK-950 will be administered IV after the relevant combination regimen is dosed. On days 1 and 15, ramucirumab will be administered IV. Paclitaxel will be dosed on days 1, 8 and 15, after ramucirumab on days 1 and 15, before TRK-950 on day 8."
89517370|NCT03872947|Experimental|Arm R: TRK-950 + Bevacizumab|"Renal cell carcinoma cancer~TRK-950 will be administered IV on days 1, 8, 15, and 22 of a 28-day cycle. Bevacizumab will be dosed as IV on Day 1 and 15 of each cycle. On days that TRK-950 and Bevacizumab are both dosed, Bevacizumab will be dosed first."
89549698|NCT02034149|Other|general management|All participants received a general education with the knowledge on care for early chronic kidney disease recently establishes by the National Health Insurance system. We then used the cross-theoretical model to assess the intervention among the three groups.We collected information on baseline and follow-up data on biochemical and physiological check-ups, health promotion behavior, dietary intake status, self-efficacy and cost etc. The effectiveness assessments have been set for the baseline, 3rd, 6th, 12th and 18th months.
89549699|NCT02034149|Experimental|self-management|Participants in the self-management group are expected to emphasize on self-managed interventions, including self-monitoring and records keeping, self-education with digital video disc (DVD) courses. We negotiated their behavior change set goals for them etc.With one year of intervention period, the 3 groups will be assessed at the 18th months of follow-up next year.
89549700|NCT02034149|Experimental|peer-assisted management|The peer-assisted management group received the peer oriented group activities followed, including group discussions to share experience and sports map etc. With one year of intervention period, the 3 groups will be assessed at the 18th months of follow-up next year.
89549701|NCT02420899|Experimental|Statins,lipid-lowering drugs|rosuvastatin 10mg or 20mg per day，pro
89549702|NCT05042141|Experimental|KOVIR|Standard dose, 3 capsules/time x 3 times/day x 14 days
89549703|NCT05042141|Placebo Comparator|Placebo|Placebo, 3 capsules/time x 3 times/day x 14 days
89549704|NCT02426203||Pulmonary Endarterectomy patients|Patients undergoing pulmonary endarterectomy surgery at Papworth Hospital
89549705|NCT03194165||antiretroviral dosage|titration of Dolutegravir, Raltegravir, Rilpivirine, Nevirapine, Atazanavir, Darunavir, Ritonavir
89549706|NCT02426437|Other|Early Pulmonary Rehabilitation (EPR)|Patients randomized to EPR will be enrolled into the Breath Easy pulmonary rehabilitation (PR) program at the Centre for Lung Health within 1 month of discharge. They will proceed through the program in a typical fashion.
89549707|NCT02426437|Other|Late Pulmonary Rehabilitation (LPR)|Patients randomized to LPR will be enrolled into the Breath Easy pulmonary rehabilitation (PR) program at the Centre for Lung Health within 3 months of discharge. They will proceed through the program in a typical fashion.
89549708|NCT02426437|Other|Usual Care|Usual care patients will be followed-up by their most responsible physician as determined by the admitting team.
89549709|NCT03117205|Experimental|Kinesio Taping® group|
89549710|NCT03117205|Placebo Comparator|placebo group|
89549711|NCT04065113|Experimental|Embolization Only|Medically managed patient receives middle meningeal artery embolization
89549712|NCT04065113|Experimental|Embolization + Evacuation|Participant receives standard of care evacuation and then undergoes MMA embolization
89549713|NCT04065113|No Intervention|Medical Management|Historical control of medically managed patients
89549714|NCT04065113|Active Comparator|Surgical Patients|Historical control of patients receiving standard surgery alone
89549715|NCT03178903|Active Comparator|tDCS and Aerobic Exercise|Each participant will undergo a 20-minute session of transcranial direct current stimulation (tDCS) delivered to the dorsolateral prefrontal cortex (DLPFC). Each session of tDCS will be immediately followed by a supervised 30-minute, moderate-intensity bout of exercise. These procedures will occur 3x/week for 8 weeks.
89549716|NCT03178903|Sham Comparator|Sham tDCS and Aerobic Exercise|Each participant will undergo a 20-minute session of sham transcranial direct current stimulation (tDCS) delivered to the dorsolateral prefrontal cortex (DLPFC). Each session of tDCS will be immediately followed by a supervised 30-minute, moderate-intensity bout of exercise. These procedures will occur 3x/week for 8 weeks.
89549717|NCT05005871|Active Comparator|Quadratus lumborum intramuscular block|The quadratus lumborum intramuscular block will be performed immediately at the end of the surgery. Administration of 0.4 mL of 0.25% bupivacaine will be carried out under ultrasound guidance and performed by experienced anesthesiologists.
89549718|NCT05005871|Active Comparator|Quadratus lumborum transmucular block|The quadratus lumborum transmuscular block will be performed immediately at the end of the surgery. Administration of 0.4 mL of 0.25% bupivacaine will be carried out under ultrasound guidance and performed by experienced anesthesiologists.
89549719|NCT02425969|Experimental|Optimal Medical Therapy|Patients will receive secondary prevention and optimal medical therapy to control their anginal symptoms according to international guidelines without PCI of their grey-zone FFR lesion
89549720|NCT02425969|Active Comparator|PCI with Optimal Medical Therapy|Patients will undergo PCI of their grey-zone FFR lesion as well as appropriate secondary prevention. Anti-anginal therapy will be administered as per clinical requirements according to international guidelines.
89549721|NCT04029155|Active Comparator|TBNA with Conventional bronchoscope|patients in this arm will undergo bronchoscopy by a conventional probe
89549722|NCT04029155|Experimental|TBNA with a Ultrathin bronchoscope|Patients in this arm will undergo bronchoscopy by a ultra thin probe
89549723|NCT03116737|Experimental|Benzocaine Otic Solution|
89549724|NCT03116737|Placebo Comparator|Placebo|
89549725|NCT02426047|Experimental|Modified Atkins diet plus betaquik®|Participants will continue on the modified Atkins diet (with a 20 net grams carbohydrate per day limit) and add betaquik® (a liquid emulsion of medium chain triglycerides) for 10 days per month for 5 months. The days chosen are based on their particular catamenial pattern (there are 3 types that have been identified in the literature).
89549726|NCT04910243||Physicians|Physicians managing patients with COVID-19 admitted at ICU during period of COVID-19 pandemic.
89549727|NCT04910243||Nurses|Nurses providing care to patients with COVID-19 admitted at ICU during period of COVID-19 pandemic.
89549728|NCT03116659|Experimental|Single Arm|Doxycycline 100 mg PO BID x 14 days, then Imiquimod up to 2 packs 3/ week x 28 days
89033002|NCT02922504|Active Comparator|Controlled group|"For the patients in the  controlled  group, the use of analgesic will be use if needed during the procedure"
89033003|NCT02944643|Experimental|Active group|Will get the mindfulness and support groups
89033004|NCT02925702||Radium-223|Radium-223 55 mBq/Kg every 4 weeks IV
89033005|NCT00531089|Experimental|Study group|"All patients in the study will be in the study group and will receive rituximab. There is no control arm."
89549729|NCT04889573|Experimental|Blood sample|
89208030|NCT03974737||Adolescents with POTS|"Adolescents with Postural Orthostatic Tachycardia Syndrome (POTS) who meet diagnostic criteria for an orthostatic heart rate increase of >30, between ages 12-21 are eligible for this group. They will have a urine specific gravity conducted at the beginning of the clinic visit to assess hydration status. If urine specific gravity shows adequate hydration, subjects will proceed with orthostatic measurements with concomitant CRI measurements (via a non-invasive pulse oximetry monitor). (Subjects who are dehydrated will be given electrolyte drinks for rehydration and urine specific gravity will be rechecked after survey completion and before CRI and orthostatic measurements.) Following the CRI and orthostatic measurements, subjects and their parents will be asked to complete a series of surveys via REDcap.~Interventions performed:~Urine specific gravity measurement~CRI measurements, orthostatic vitals measurements~Survey administration"
89208031|NCT03974737||Adolescents without POTS, Control Group|"Adolescents without Postural Orthostatic Tachycardia Syndrome (POTS) between ages 12-21 are eligible for this group. This group of subjects will have a urine specific gravity conducted at the beginning of the clinic visit to assess hydration status. If the urine specific gravity shows adequate hydration, subjects will proceed with orthostatic measurements with concomitant CRI measurements (via a non-invasive pulse oximetry monitor). (Subjects who are dehydrated will be given electrolyte drinks for rehydration and their urine specific gravity will be rechecked after survey completion and before CRI and orthostatic measurements.) Following the CRI and orthostatic measurements, subjects and their parents will be asked to complete a series of surveys via REDcap.~Interventions performed:~Urine specific gravity measurement~CRI measurements, orthostatic vitals measurements~Survey administration"
89208032|NCT03974737||Adolescents diagnosed with POTS who do not meet HR|"Adolescents diagnosed with Postural Orthostatic Tachycardia Syndrome (POTS) between ages 12-21, who do not meet diagnostic heart rate criteria, are eligible for this group. This group of subjects will have a urine specific gravity conducted at beginning of the clinic visit to assess hydration status. If the urine specific gravity shows adequate hydration, subjects will proceed with orthostatic measurements with concomitant CRI measurements (via a non-invasive pulse oximetry monitor). (Subjects who are dehydrated will be given electrolyte drinks for rehydration and urine specific gravity will be rechecked after survey completion and before CRI and orthostatic measurements.) Following the CRI and orthostatic measurements, subjects and their parents will be asked to complete a series of surveys via REDcap.~Interventions performed:~Urine specific gravity measurement~CRI measurements, orthostatic vitals measurements~Survey administration"
89208033|NCT00973167|No Intervention|Control|Remains sedentary with normal lifestyle
89208034|NCT00973167|Experimental|Treatment|Receive LMHFV treatment for 18 months.
89208035|NCT00859872|Experimental|oral group|risperidone oral solution combination clonazepam oral
89208036|NCT00859872|Active Comparator|IM group|haloperidol IM injection
89208037|NCT02555696||nab-paclitaxel|nab-paclitaxel 260mg/m^2 in intravenous (IV) infusion every 3 weeks until progression or toxicity
89208038|NCT03974659|Active Comparator|Theta Burst Stimulation|"Intervention group: ten consecutive days bilateral cerebellar VIIa lobules Theta Burst Stimulation.~Intermittent Theta Burst Stimulation(Positive stimulation) is used in right cerebellar VIIa lobule.Each stimulus had three 50 Hz monopulses, which were repeated every 200 ms. Each stimulation continued for 2 seconds and rested for 8 seconds. The total intervention time was 200s (600 pulses) Continuous Theta Burst Stimulation(Negative stimulation) is used in left cerebellar VIIa lobule,three 50 Hz monopulses in each stimulus, each with an interval of 200 ms, and each intervention lasted 40s (600 pulses).~The stimulation intensity was 80% Rest Motor Threshold.According to the patients' condition, age and tolerance,the intensity should be adjusted."
89208039|NCT03974659|Sham Comparator|sham Theta Burst Stimulation|sham group: we flip coil to make fake stimulation, the stimulation will also make sounds, but no magnetic field effect, the stimulation mode is the same as the intervention group.
89208040|NCT02598245|Active Comparator|TOT 8/4|"Transobturator sling (TOT) is placed according to the original description. Instead of a Metzenbaum Scissor which should guarantee the distance between the urethra and the sling a Hegar dilator sound of 4 mm diameter is used (Hegar 4). An additional Hegar dilator sound of 8 mm is placed in the urethra before tightening the sling and suturing the vaginal skin."
89549730|NCT01993888|Experimental|EVARREST® Fibrin Sealant Patch|EVARREST® Fibrin Sealant Patch is a sterile bio-absorbable combination product consisting of two constituent parts - a flexible matrix and a coating of two biological components (Human Fibrinogen and Human Thrombin).
89549731|NCT01993888|Other|Standard of Care (SoC)|SoC is a composite of techniques/methods typically used by the surgeon to control bleeding after conventional methods (i.e. suture, ligation, cautery) are ineffective or impractical. For this study, SoC will be initiated with continuous firm manual compression with or without gauze or sponge and with or without a topical absorbable hemostat (example SURGICEL).
89549732|NCT02425813|Experimental|Treatment (methylprednisolone sodium succinate, budesonide)|"STUDY AGENT: Patients receive methylprednisolone sodium succinate IA QD on days 1-3.~CONVENTIONAL THERAPY: Patients also receive conventional therapy comprising methylprednisolone sodium succinate IV every 12 hours on for 7-14 days beginning on day 1 and budesonide PO on days 1-56. Patients with response by day 7-14 may begin taper and receive methylprednisolone PO on days 28-56. Treatment continues in the absence of disease progression or unacceptable toxicity.~IST: Patients receive conventional IST or continue their previous prophylactic regimen beginning on day 1 to 56 (or beyond) at the discretion of the treating physician."
89549733|NCT04862429|Experimental|Contrast enhanced mammography guided biopsy|"Patients will be subjected to CESM; the two orthogonal mammographic projections, after intravenous administration of iodized contrast-enhancement (Omnipaque), will be performed.~Surgical and medical treatments will be defined accordingly to the imaging and histological findings obtained with the experimental procedure."
88812059|NCT03226730|Experimental|Arm 3: Household Visits + Small Groups|In addition to the community enabling environment components, this arm will receive a combination of household visit and small groups intervention components, as described above for Arms 1 and 2, in order to understand the combined effect of these two interventions on the outcomes of interest.
89208041|NCT02598245|Experimental|TOT 6/3|"Transobturator sling (TOT) is placed according to the original description. Instead of a Metzenbaum Scissor which should guarantee the distance between the urethra and the sling a Hegar dilator sound of 3 mm diameter is used (Hegar 3). An additional Hegar dilator Sound of 6 mm is placed in the urethra before tightening the sling and suturing the vaginal skin."
89549734|NCT04862429|Active Comparator|mammography guided biopsy|"Patients will be subjected to stereotactic biopsy Mammotome as normal clinical practice.~Surgical and medical treatments will be defined accordingly to the imaging and histological findings obtained with the standard procedure."
89549735|NCT03181555|Other|Pregnant Obese African American Women|Exploratory
89549736|NCT04852133||Burn subjects|exposure to burn injury
89549737|NCT04852133||Non-burned control|no exposure to burn injury
89549738|NCT04683562|Other|Normal pregnancy group|
89549739|NCT04683562|Other|Placenta accreta group|
89549740|NCT04804787|Experimental|Experimental group : patients with multiple sclerosis|The experimental group will be constituted of patients with multiple sclerosis.
89549741|NCT04804787|Active Comparator|Control group : volunteers|The control group will be constituted of healthy volunteers with the same characteristics concerning age, sex, education's level as experimental group's patients
89549742|NCT03116581|Other|Vicarious reward|"If a decision influences the well-being of another (through monetary payoff), the decision making processes should differ from a decision that would influences only oneself. The difference will be reflected in the reaction-times and in the accuracy of the response to the task. The drift diffusion models care then used to estimate le decision parameter in each condition and understand which parameter is influenced by the beneficiary of the payoff associated with a decision.~Once the decision parameter characterized with behavioral experiment, the study aims to better understand the neural network sustaining the influence of others on the decision making process, by assessing the neural activity related to the decision making processes. Also, the research compares how the brain responses for payoff for others and payoffs for oneself, specially to confirm that these responses are located in different areas of the Anterior cingulate Cortex."
89549743|NCT03116581|Other|Audience effect|In order to clarify the complex changes in the decision-making processes induced by simple observation by others (audience) , the experiment have two levels of difficulty . These levels of difficulty will be determined in such a way as to achieve better 'public' performance than 'private' when the task is easy (high level of consistency) and poor performance when the task is difficult (low level of coherence) As described in the literature in psychology. Drift diffusion models will be used to better understand the variations in performance, to decipher between a modulation of the diffusion velocity and or of the decision threshold. This study will help characterize how observation by others modulates performance. Once the decision parameter characterized with behavioral experiment, the study aims to better understand the neural network sustaining the impact of observation by others on the decision making process.
89549744|NCT02024698|Active Comparator|omafilcon A|Study participants are randomized to wear omafilcon A lenses.
89549745|NCT02024698|Active Comparator|etafilcon A|Study participants are randomized to wear etafilcon A lenses.
89549746|NCT03106831|Experimental|Pituitrin arm|To begin with 0.02 U/min to maintain mean arterial pressure(MAP) higher than 65 mmHg.
88961781|NCT04221087|Placebo Comparator|Placebo Arm|Participants will be given a placebo of sugar water (0.6ml/kg/dose) in a single oral dose and standard of care for bronchiolitis (supplemental oxygen, antipyretics, suctioning etc.)
88961782|NCT04221087|Experimental|Dexamethasone Arm|Participants will be given dexamethasone (0.6mg/kg/dose) in a single oral dose in addition to the standard of care for bronchiolitis (supplemental oxygen, antipyretics, suctioning etc.)
88961783|NCT04219605||Symptomatic vaginitis patients|Symptomatic patients evaluated in the clinic for vulvovaginal symptoms.
88961784|NCT04174092|Experimental|rheumatoid arthritis|Filling in several self-questionnaires: on function (HAQ), pain EVA, quality of life (SF12, EQ5D), anxiety score (GAD-7), insomnia score (ISI), catastrophic score (PCS), coping score (coping ability, CSQ), compliance scores (CQR, Health Insurance Compliance Assessment Questionnaire) and fibromyalgia diagnostic score (FiRST), activity of rheumatic disease (RAID, RAPID-3) Patients will be seen at 3, 6 and 12 months
88961785|NCT04174092|Experimental|spondyloarthritis|"Filling in several self-questionnaires: on function (HAQ), pain EVA, quality of life (SF12, EQ5D), anxiety score (GAD-7), insomnia score (ISI), catastrophic score (PCS), coping score (coping ability, CSQ), compliance scores (CQR, Health Insurance Compliance Assessment Questionnaire) and fibromyalgia diagnostic score (FiRST), activity of rheumatic disease (BASDAI, BASFI).~Patients will be seen at 3, 6 and 12 months"
88961786|NCT04174092|Experimental|Psoriatic arthritis|"Filling in several self-questionnaires: on function (HAQ), pain EVA, quality of life (SF12, EQ5D), anxiety score (GAD-7), insomnia score (ISI), catastrophic score (PCS), coping score (coping ability, CSQ), compliance scores (CQR, Health Insurance Compliance Assessment Questionnaire) and fibromyalgia diagnostic score (FiRST), activity of rheumatic disease (BASDAI, BASFI).~Patients will be seen at 3, 6 and 12 months"
88961787|NCT04153357|Active Comparator|intubation time airtraq|intubation time of Airtraq
89549747|NCT03106831|Experimental|Norepinephrine arm|To begin with 0.04 μg/kg.min to maintain mean arterial pressure(MAP) higher than 65 mmHg.
89549748|NCT02425735|Experimental|Group A|DC-CIK cells will be used against tumor cells.
89549749|NCT02425735|Experimental|Group B|γδ T cells will be used against tumor cells.
89549750|NCT02425735|Experimental|Group C|Combination of γδ T cells/ DC-CIK be used against tumor cells.
89549751|NCT03106675|Experimental|HIFU-treatment|"Pre-treatment imaging~Pre-treatment questionnaires and laboratory blood samples~Intervention (Thermal ablation of bone metastasis with MR-HIFU device Philips Sonalleve coupled with Philips Ingenia 3.0T)~Follow-up (imaging, questionnaires, laboratory)~Follow-up pain medication usage"
88961788|NCT04153357|Active Comparator|intubation time of c-mac|intubation time of c-mac
88961789|NCT04153344||Infrared hyperreflective area|Patients with neurofibromatosis type 1 and with infrared hyperreflective areas
88961790|NCT04153344||No infrared hyperreflective areas|Patients with neurofibromatosis type 1 and with no infrared hyperreflective areas
88961791|NCT04153344||Controls|Patients with no neurofibromatosis type 1
88961792|NCT04099862||ERCP|Endoscopic retrograde cholangiopancreatography (ERCP)
88961793|NCT04099862||EUS-BD|Endoscopic UltraSound Biliary Drainage
88961794|NCT04062591|Active Comparator|piroxicam|piroxicam group who received induction with piroxicam(0.4mg/kg) IM
88961795|NCT04062591|Sham Comparator|placebo|saline IM in the same dose of piroxicam
88961796|NCT04059770|Experimental|single dose of L-AmB|single IV dose of 10 mg/kg of L-AmB on day 1;
88961797|NCT04059770|Experimental|2 doses of L-AmB|IV dose of 10 mg/kg of L-AmB on day 1, followed by 5 mg/kg of L-AmB on day 3;
89025310|NCT00444509|Experimental|Treatment 2|Subjects will receive GW685698X 800 mcg containing magnesium stearate inhaled dose via a DISKUS inhaler. There will be a wash-out period of at least 5 days between doses.
89025311|NCT02957175||Patients that develop SIRS|Immunophenotyping of patients that develop SIRS after heart surgery
89549752|NCT03106675|Active Comparator|Radiation therapy|"Pre-treatment imaging~Pre-treatment questionnaires and laboratory blood samples~Intervention (Varian Truebeam Radiotherapy System)~Follow-up (imaging, questionnaires, laboratory)~Follow-up pain medication usage"
89025312|NCT02957175||Patients that develop no SIRS|Immunophenotyping of patients that develop no SIRS after heart surgery
89549753|NCT03138785|Experimental|conventional treatment|In this arm, patients with documented fungal keratitis undergo conventional medical treatment.
89549754|NCT03138785|Active Comparator|conventional treatment +CXL|In this arm, patients with documented fungal keratitis undergo conventional medical treatment plus CXL, beginning on the first day
89549755|NCT02424331|Experimental|Quiet Breathing or Pursed Lips Breathing|Free or natural breathing for six minutes.
89549756|NCT05393843|Active Comparator|intervention|"patients receiving~diet~Omega-3 fatty acids (EnerZona Omega3Rx®, Enervit, Italia), at a daily dosage of 2.4 gr at breakfast.~Anthocyanins (EnerZona Maqui Response Buste®, Enervit, Italia) at a total daily dosage of 108 mg divided into three equal intakes at breakfast, lunch and dinner.~Alpha-cyclodextrins (EnerZona Maqui Response Buste®, Enervit, Italia) at a total daily dosage of 15 gr divided into three equal intakes at breakfast, lunch and din-ner"
89549757|NCT05393843|Placebo Comparator|placebo|"patients receiving~diet~placebo (sunflower oil as placebo for Omega3 fatty acids; isomaltulosio as placebo for Anthocyanins and Alpha-cyclodextrins)"
89549758|NCT03106597|Experimental|Manidipine 20mg|50 patients will be administered orally manidipine 20mg/day after 1~2 week run-in period
89549759|NCT03106597|Active Comparator|Amlodipine 10mg|50 patients will be administered orally amlodipine 10mg/day after 1~2 week run-in period
89549760|NCT03140267|Experimental|Difficult to wean patients|Maximal Inspiratory Pressure and Peak Pressure from the inclusion day to the extubation day will be measure.
89549761|NCT03178825|Experimental|Hybrid Fractional Laser|Hybrid fractional 2940 nm and 1470 nm laser treatment
89549762|NCT02018458|Experimental|LA TNBC: DC vaccine+Preop chemo|LA TNBC patients will receive standard preop AC followed by TCb chemo for 24 weeks. Chemo and DC vaccinations will be given intratumoral and subcutaneous for 4 times prior surgery. During the AC cycles, vaccines will be given on any day between Days 9-12 of Cycles 1 and 3 of AC. Vaccines will be given on any day between Days 11-15 of Cycles 1 and 3 of TCb. Patients will undergo biopsies of their cancer prior to treatment and 1-2 days prior to or on Day 1 of Cycle 4 of AC. After this, patients will have surgery, locoregional radiation therapy to the breast or chest wall and regional lymphatics per standard of care, and will receive 3 boost DC vaccinations subcutaneously, rotating injection sites in the upper arm. The 1st vaccination will occur after the surgery and prior to radiation; 2nd will occur 30 days ± 3 days after radiation; the 3rd will occur 90 days ± 3 days after the 2nd boost.
89549763|NCT02018458|Experimental|ER+/HER2-BC:DC vaccine+Preop chemo|ER+/HER2- BC patients will receive standard preop AC followed by weekly T given for 22 weeks. Chemo and DC vaccinations will be given intratumoral and subcutaneous, for 4 times prior surgery. During the AC cycles, vaccines will be given any day between Days 9-12 of Cycles 1 and 3 of AC. Vaccines will be given on Day 1 during Cycle 2 or Cycle 3 and on Day 1 during either Cycle 8 or Cycle 9 of T. Vaccine will be given after T infusion is completed. Patients will undergo biopsies of their cancer prior to treatment and 1-2 days prior to or on Day 1 of Cycle 4 of AC. Patients will have surgery, locoregional radiation therapy to the breast or chest wall and regional lymphatics per standard of care, and will receive 3 boost DC vaccinations subcutaneously, rotating injection sites in the upper arm. The 1st vaccination will occur after surgery and prior to radiation; the 2nd will occur 30 days ± 3 days after radiation; and the 3rd will occur 90 days ± 3 days after the 2nd boost.
89549764|NCT02017522|Experimental|11C-PBR PET|"Subjects will have a blood sample drawn to evaluate the presence of a specific genetic variation which would prevent the new type of imaging test we are evaluating from working and we will test the inflammatory cells in the blood for the same purpose.~All participants who proceed will have to return on at least one additional day to undergo a positron emission tomography (PET) scan similar to the scan your doctor ordered. we will use 11C-PBR28 as the radiotracer. This study will evaluate whether 11C-PBR28 can show areas of inflammation due to cardiac sarcoidosis. On either the same day or a different day, you will also undergo a cardiac MRI."
89549765|NCT05393687|Experimental|eccentric exercise group|8 weeks of progressive eccentric ankle muscle strengthening program with elastic bands. Regular swimming training program five times a week.
89549766|NCT05393687|No Intervention|Control group|Regular swimming training program five times a week.
89549767|NCT03183505|Experimental|Anyu Peibo|Anyu Peibo Capsule, oral, 0.8g twice per day
89549768|NCT03183505|Placebo Comparator|Placebo|Placebo,oral, twice per day
89549769|NCT02423083|Experimental|Treatment arm|
89549770|NCT05393531|Other|Mandibular advancement device|Active therapy
89549771|NCT05393531|Other|Continuous positive airway pressure|Active therapy
89549772|NCT02017444|Placebo Comparator|Placebo|Matched placebo tablet B.D for 12 weeks
89549773|NCT02017444|Active Comparator|AZD4017 (11b-HSD1 inhibitor)|AZD4017 400mg tablet B.D. for 12 weeks
89025313|NCT00479349|Active Comparator|1|SAM 531 + placebo
89025314|NCT03279354|Experimental|Intervention group|Family Move app intervention
89025315|NCT03279354|Placebo Comparator|Control group|"HK FitNuts app intervention"
88961798|NCT04059770|Active Comparator|2 weeks of L-AmB|IV dose of 3 mg/kg of L-AmB for 2 weeks.
88961799|NCT04051892|Experimental|Implantation of FixNip™ NRI|Female Patients Seeking Reconstructive Surgery of the Nipple
88961800|NCT04050280|Experimental|CLAG-GO|Cladribine, Cytarabine, and Granulocyte-Colony Stimulating Factor with Fractionated Gemtuzumab Ozogamicin (CLAG-GO)
88961801|NCT04026308|No Intervention|Written Safety Plan|Participants will complete a traditional written suicide safety plan.
88961802|NCT04026308|Experimental|Electronic Safety Plan|Participants will complete a suicide safety plan in the Safety Net app using a tablet.
89549774|NCT02423941|Experimental|Retrograde reperfusion|During the transplant procedure the liver is initially reperfused retrogradely via hepatic veins. Venting of 300 ml blood is allowed via donor portal vein. After completion the portal vein anastomosis and retrograde venting of another 100 ml blood the antegrade portal reperfusion is performed.
89549775|NCT02423941|Active Comparator|Antegrade reperfusion|During the transplant procedure the liver is reperfused conventionally, antegradely via portal vein after completion of caval and portal anastomoses. Venting of 300 ml blood is allowed via tube placed in infrahepatiс caval anastomosis before unclamping the vena cava.
89549776|NCT03138395||Experimental: Specimen Collection|Collection of peripheral blood and bone marrow samples will occur during routine care procedures. Collection of finger stick and saliva specimens will occur on the same day as the peripheral blood and bone marrow procedure, or during routine clinical procedures.
89549777|NCT02421367|Experimental|TDENV-PIV (0-1)|"The intervention is a tetravalent dengue virus purified inactivated vaccine (1µg/DENV type) with adjuvant, AS03B.~The placebo is sodium chloride.~TDENV-PIV vaccine and placebo will be administered in a single 0.5 mL dose intramuscularly in the non-dominant (whenever possible) deltoid region of the upper arm.~The intervention will be administered on Day 0 and Day 28. The placebo will be administered on Day 84 and Day 168."
89549778|NCT02421367|Experimental|TDENV-PIV (0-1-6)|"The intervention is a tetravalent dengue virus purified inactivated vaccine (1µg/DENV type) with adjuvant, AS03B.~The placebo is sodium chloride.~TDENV-PIV vaccine and placebo will be administered in a single 0.5 mL dose intramuscularly in the non-dominant (whenever possible) deltoid region of the upper arm.~The intervention will be administered on Day 0, Day 28, and Day 168. The placebo will be administered on Day 84."
89025316|NCT02957045|Experimental|Cough|
89549779|NCT02421367|Experimental|TDENV-PIV (0-3)|"The intervention is a tetravalent dengue virus purified inactivated vaccine (1µg/DENV type) with adjuvant, AS03B.~The placebo is sodium chloride.~TDENV-PIV vaccine and placebo will be administered in a single 0.5 mL dose intramuscularly in the non-dominant (whenever possible) deltoid region of the upper arm.~The intervention will be administered on Day 84 and Day 168. The placebo will be administered on Day 0 and Day 28."
89549780|NCT05393063|Experimental|AK127|Subjects will receive AK127 by intravenous administration
89549781|NCT02420587|Experimental|AMG 208|Dose of AMG 208 is 400 mg by mouth daily given in 6 weeks cycles. Participants receive AMG 208 until radiographic progression of disease and/or unequivocal clinical progression. Questionnaire completion about pain at baseline, Day 22 of Cycle 1, Day 1 of Cycle 2, Day 22 of Cycle 2, every 6 weeks, and at end of study visit.
89549782|NCT02425657||Junior Doctors|Surgical trainees (PGY1, 2 and 3 - Danish equivalents: introduktionsstilling, hoveduddannelse 1, 2).
89549783|NCT03138551|Experimental|Mealtime PREP|"Every participant enrolled in this single-case experimental design trial with multiple replications progressed through three phases.~A: Baseline - typical mealtimes in the home.~B: Parent-Training - parents trained in Mealtime PREP (Promoting Routines of Exploration and Play) intervention.~B-prime: Family Autonomy - parents continue to deliver treatment strategies. Therapist support withdrawn."
89549784|NCT03140111|Other|Treatment A, followed by Treatment B|Treatment group that will receive Treatment A for 28 days, followed by Treatment B for 28 days. There will be a minimum 7 day washout between Treatments. LAMELLEYE Dry Eye Drops and OPTIVE FUSION will be administered to all subjects in this arm. Treatments will be self-administered at least 3 times a day.
89549785|NCT03140111|Other|Treatment B, followed by Treatment A|Treatment group that will receive Treatment B for 28 days, followed by Treatment A for 28 days. There will be a minimum 7 day washout between Treatments. LAMELLEYE Dry Eye Drops and OPTIVE FUSION will be administered to all subjects in this arm. Treatments will be self-administered at least 3 times a day.
89549786|NCT02423863|Experimental|Hiltonol Poly-ICLC|"Open labeled, non randomized adaptive 2-stage design protocol. 21 study subjects were enrolled in stage I of the protocol. Up to an additional 60 patients. . Enrolled study subjects will receive Poly-ICLC (Hiltonol®) treatment alone or in combination with anti-PD-1 (Nivolumab, Pembrolizumab or Cemiplimab) or anti-PD-L1 (Atezolizumab or Durvalumab) over 6 months as defined in study treatment described below. MRI or CT imaging will be done per SOC at screening, 3 and 6-month time points.~For purposes of analysis patients enrolled in Stage II of this study will be prospectively identified at initial screening as belonging to statistical Cohorts A, B, or C, which are based on patient status with regard to aPD1/aPDL1 therapy at study entry, (PD, SD, or treatment naïve). For purposes of this study, patient status is considered to be the primary eligibility variable, although sub analyses will also consider histology and particular checkpoint blocker used when possible."
89549787|NCT03178747|Active Comparator|Case|Patients who clinically diagnosed as herpes simplex, herpes zoster or varicella zoster skin infection.
89549788|NCT03178747|Sham Comparator|Negative control|Patients who develops vesicular lesion but not typically considered as herpesviral skin infection, such as acute eczema, Paederus dermatitis
89549789|NCT03181321|Experimental|The First Twenty|The TF20 incorporates individual goal setting and health coaching, leveraging cultural aspects of the fire service and group cohesion to motivate behavior change. The TF20 focuses on the unique needs of FF with culturally relevant nutrition and fitness strategies. TF20 was primarily designed as a cost-effective, stand-alone program for departments which have no health promotion initiative. Program components include practical approaches to nutrition, fitness and mental health.
89549790|NCT03181321|No Intervention|Control|Participants in this arm will not be asked to change anything in their lifestyle during the 6 month period.
89549791|NCT02425423|Experimental|New thickened infant formula|
89549792|NCT05392673|Experimental|comprehensive medical treatment|All the 62 patients enrolled received comprehensive medical treatment after admission to the hospital, including anti-viral treatment, general supportive treatment, supplementation of blood products, such as albumin and plasma, and symptomatic treatment.
89025317|NCT00479583|Active Comparator|A|
89025318|NCT00479583|Active Comparator|B|
89025319|NCT04699643|Experimental|EVER4010001 combination with Pembrolizumab|EVER4010001 combination with Pembrolizumab, EVER4010001 started dose escalation from 40mg bid, and then to 60mg bid, 80mg bid, 100mg bid and 120 mg bid if applicable, dose escalation decision will be made by safety monitoring committee which is composed of the study team members. After phase II dose was recommended by safety monitoring committee, this dose will be applied to phase II patients. Pembrolizumab will be administered at 200mg every 3 weeks through the study.
89025320|NCT04699916|No Intervention|Control (Usual care)|Sedation will be guided with a standard protocol based on Sedation Agitation Scale already implemented in the Intensive Care Unit
89549793|NCT05392673|Experimental|PE(plasma exchange)|In addition to comprehensive medical treatment, the PE groups were treated with PE or PE plus half-dose sequential PE. In the current study, PE was carried out using the KM-8800 plasma exchange device (Kuraray, Tokyo, Japan). The device was pre-flushed with 2000 mL of normal saline and 20 U/mL heparin dilution. And the blood pump speed was 100 to 120 mL/min and the plasma exchange speed was 25 to 30 mL/min. Before PE, calcium gluconate and diphenhydramine were routinely administrated to prevent an allergic reaction. For each time of plasma exchange,2800 mL fresh frozen plasma was administrated.
89549794|NCT05392673|Experimental|DPMAS+half-dose sequential PE|DPMAS with half-dose sequential PE was applied using the EC-40W plasma separator (Asahi Kasei Medical, Tokyo, Japan), BS330 bilirubin adsorption column (Jianfan Biotechnology, Zhuhai, China), and the neutral microporous adsorption resin HA330-Ⅱ (Jianfan Biotechnology). After the bilirubin adsorption and hemoperfusion treatment, sequential half-dose PE treatment begins. 1400 mL plasma replacement was conducted each time.
89549795|NCT02425579|Experimental|Cohort 1|Inhaled Carbon Monoxide at 100 ppm for up to 90 minutes daily for 5 days
89549796|NCT02425579|Placebo Comparator|Cohort 1 (placebo)|Inhaled Medical Air for up to 90 minutes daily for 5 days
89549797|NCT02425579|Experimental|Cohort 2|Inhaled Carbon Monoxide at 200 ppm for up to 90 minutes daily for 5 days
89549798|NCT02425579|Placebo Comparator|Cohort 2 (Placebo)|Inhaled Medical Air for up to 90 minutes daily for 5 days
89549799|NCT05392595|Experimental|Group A|Caw-throne and Cooksey exercise, Epley's repositioning maneuver will be performed also cervical stretches with basic balance exercises.
89549800|NCT05392595|Other|Group B|Epley's repositioning maneuver will be performed also cervical stretches with basic balance exercises.
89549801|NCT03178591|Active Comparator|vildagliptin|Vildagliptin is a dipeptidyl peptidase-4 inhibitor (DPP-4 inhibitor) Dose of Vildagliptin is 50 mg once or twice daily.
89549802|NCT03178591|Active Comparator|Dapagliflozin|Dapagliflozin is a sodium glucose cotransporter-2 (SGLT-2 inhibitor) Dose of Dapagliflozin is 10 mg once daily.
89549803|NCT01993186|Experimental|UX007|"Participants randomized to receive UX007 enter a 2-week dose titration period to achieve study drug treatment comprising up to 35% of total daily calories or to the maximum tolerated dose level and maintained at the 35% total daily calorie dose level for a 6-week treatment period.~Following completion of the Week 8 study visit, participants continue treatment with open-label UX007 at the 35% dose level for an additional 44 weeks (Weeks 8-52)."
89549804|NCT01993186|Placebo Comparator|Placebo|"Participants randomized to receive placebo enter a 2-week dose titration period to achieve study drug treatment comprising up to 35% of total daily calories or to the maximum tolerated dose level and maintained at the 35% total daily calorie dose level for a 6-week treatment period.~Following completion of the Week 8 study visit, placebo participants continue treatment with open-label UX007 at the 35% dose level for an additional 44 weeks (Weeks 8-52)."
89549805|NCT03181243|Experimental|MadaJet|Jet injector (Madajet medical Urology) preloaded as manufacturer's instruction
89549806|NCT03181243|Experimental|Needle injection|01 sterile 10-mL syringe with small gauge needle (25 ga), solution for sterile preparation, 10 - 15 mL Lidocaine 2%
89549807|NCT03139955||Bodytrak|This is a single group study. 8 participants will be recruited and will receive the same intervention of physiological data collection using Bodytrak.
89549808|NCT03178435|No Intervention|Observational|patients will be recruited to this arm to observe prospectively the incidence of AKI among critically ill patients.patients will receive the standard care.No other intervention will be delivered
89549809|NCT03178435|Active Comparator|Interventional|Patients in this arm will be subject to AKI risk score. This risk score was recently developed and validated in Mayo clinic the intervention will be Measures to prevent AKI among critically ill patients
89549810|NCT03110705||recreational diving group|middle-class populations registered at a leisure sports club
89549811|NCT03110705||recrational multisport course|middle-class populations registered at a leisure sports club
89549812|NCT02416375||Observation|Adult Cystic Fibrosis patients
89549813|NCT02420665|Experimental|High-Resolution Microendoscopy (HRME) + Colposcopy|Visual inspection of cervix performed using 3 - 5% acetic acid to the cervix. Participants undergo standard colposcopy and abnormal lesions noted by quadrant. Then 0.01% proflavine applied topically to the cervix. High-resolution microendoscopy (HRME) then performed. HRME images obtained from one visually normal site and from up to 3 visually abnormal lesions based on visual exam and/or colposcopic findings. Study staff follow up with participant by phone one month after procedure.
89549814|NCT02016898|Experimental|Sponge placement of Mitomycin-C|Randomization will be stratified by age (age ≥65 or age < 65), baseline IOP (IOP ≥ 28 mmHg or IOP < 28 mmHg), and concurrent cataract surgery.
89549815|NCT02016898|Experimental|Irrigation placement of Mitomycin-C|Randomization will be stratified by age (age ≥65 or age < 65), baseline IOP (IOP ≥ 28 mmHg or IOP < 28 mmHg), and concurrent cataract surgery.
89549816|NCT04482907|Active Comparator|Group receiving dill|They took 3 meals a day, 3x300 mg dry dill powder by mouth. They bought dry dill powder for 90 days.
89549817|NCT04482907|Placebo Comparator|Group receiving placebo|They took 3 meals a day and 3 cellulose placebo capsules by mouth. They took placebo capsules for 90 days.
89549818|NCT03110627|Experimental|VDD ICD|VDD ICD - A single-lead ICD system with the ability to sense atrial rhythm from the floating electrode (a VDD-ICD known as the DX) - Experimental group
89549819|NCT03110627|Active Comparator|VVI ICD|VVI ICD - Single chamber ICD system - Control group
89549820|NCT04682938||adrenal incidentalomas in Chinese community adults|On weekdays, the first 100 individuals, aged 18 to 78 years, taking health checkup in the Community Health Examination Center were invited to take part in the study.
89025321|NCT04699916|Experimental|EEG-based sedation protocol|Sedation will be guided using a protocol based on 2 parameters from the EEG: Suppression Rate and Spectral Edge Frequency
89025322|NCT02274090|Placebo Comparator|Placebo Group|Placebo gel without the active ingredient. Delivered in biodegradable gel. Frequency- One dose each at baseline, 3 month and 6 month.
89025323|NCT02274090|Active Comparator|1% Metformin|1% Metformin gel. Delivered in biodegradable gel. Frequency- One dose each at baseline, 3 month and 6 month.
89549821|NCT02416297|Experimental|Micro-osteoperforation|Minimally invasive micro-osteoperforation procedure used to achieve accelerated orthodontic tooth movement. Topical and local anesthetic will be delivered in the area to be treated in accordance with standard practice.
89549822|NCT02416297|No Intervention|Control|Anterior retraction after premolars extraction will be done conventionally (slide mechanics)
89549823|NCT03110549|Experimental|Cohort 1 Arm A|Subcutaneous 200 mg of TMB-607 on Day 0 or Placebo
89549824|NCT03110549|Experimental|Cohort 1 Arm B|Subcutaneous 500 mg of TMB-607 on Day 0 or Placebo
89549825|NCT03110549|Experimental|Cohort 1 Arm C|Subcutaneous 1000 mg of TMB-607 on Day 0 or Placebo
89549826|NCT03110549|Experimental|Cohort 2 Arm A|Subcutaneous 100 mg of TMB-607 on Day 0 or Placebo
89549827|NCT03110549|Experimental|Cohort 2 Arm B|Subcutaneous 400 mg of TMB-607 on Day 0 or Placebo
89549828|NCT03110549|Experimental|Cohort 2 Arm C|Subcutaneous 800 mg of TMB-607 on Day 0 or Placebo
89549829|NCT03110549|Experimental|Cohort 2 Arm D|Subcutaneous 1500 mg of TMB-607 on Day 0 or Placebo
89549830|NCT02420509||systemic chemotherapy after CRS/HIPEC|Single-arm, prospective study of systemic chemotherapy after CRS/HIPEC. Subjects will be given twelve months of 5-FU or capecitabine with bevacizumab starting 4-8 weeks after surgery. CTRI Biostatistics Core personnel will assist in conducting analyses using the latest version of R (R Foundation for Statistical Computing, Vienna, Austria. http://www.R-project.org/).
89549831|NCT01993030|Experimental|HQ® Matrix Medical Wound Dressing|After harvesting the graft, the donor site wounds were treated with the dressing material. Dressing changes if needed. An operative removal of the HQ® Matrix Medical Wound Dressing is not required as it becomes spontaneously detached from the regenerated skin areas.
89549832|NCT01993030|Active Comparator|Sidaiyi® wound dressing|After harvesting the graft, the donor site wounds were treated with the dressing material. Dressing changes if needed.
89549833|NCT02416531|Active Comparator|Corticosteroid|Clobetasol propionate 0.05% ointment applied once daily at a dose of 1 g/application (1 g sachets) for 4 weeks.
89549834|NCT02416531|Experimental|Photodynamic therapy|Methylene blue 0.01% intralesional, λ = 660 ± 10 nm, P = 100 mW, PD = 510 mW/cm2, E = 4 J, ED = 20 J/cm2, t = 40 s, once a week for 4 weeks.
89549835|NCT02416531|Experimental|Low level laser therapy|λ = 660 ± 10 nm, P = 100 mW, PD = 510 mW/cm2, E = 4 J, ED = 20 J/cm2, t = 40 s, once a week for 4 weeks.
89549836|NCT03138317|Experimental|PRP|Goup 1: knee injection of Platelet Rich Plasma (PRP)
89549837|NCT03138317|Experimental|Plasma|Group 2: knee injection of Plasma
89549838|NCT03138317|Placebo Comparator|Placebo|Group 3: knee injection of placebo (saline solution)
89549839|NCT04483063|Experimental|Extended shoulder group|2% chlorhexidine gluconate skin cleanser over the not only the operative shoulder and axilla but also the chest, back, neck, and face
89549840|NCT04483063|Experimental|Shoulder group|2% chlorhexidine gluconate skin cleanser over the operative shoulder and axilla
89549841|NCT04483063|No Intervention|Control group|Skin prepare with soap as usual
89549842|NCT03110393|Experimental|Ambu® AuraGain™|Intervention with Ambu® AuraGain™Laryngeal Mask
89549843|NCT03110393|Active Comparator|Intersurgical i-gel®|Intervention with Intersurgical i-gel® Laryngeal Mask
89549844|NCT03181165|Experimental|Low-carbohydrate Therapeutic Nutrition|A 12-week low-carbohydrate, energy-restricted diet will be administered using a combination of pre-packaged foods and whole foods from pre-specified lists.
89549845|NCT03181165|No Intervention|Treatment-as-usual waitlist control|Participants will receive standard lifestyle advice to follow a low-fat, low-sugar, high fibre diet and aim to accumulate 150 minutes of moderate activity per week.
89549846|NCT03180853||Relapsed Multiple Myeloma Participants|The participants in the United States with a confirmed diagnosis of relapsed multiple myeloma following 1 to 3 prior lines of therapy who initiate treatment with a proteasome inhibitor (PI) and/or immunomodulatory drug (IMiD) used either as monotherapy or combination therapy with other treatments as per routine clinical practice within 90 days prior to study enrollment. These participants will be observed for the sequence of systemic myeloma treatments used during routine clinical practice, considering the life expectancy of patients with myeloma in the registry.
89549847|NCT05392049|Experimental|Bowen's therapy|Bowens therapy will be given to 12 patients of temporomandibular joint disorder .
89549848|NCT05392049|Experimental|Post isometric relaxation|post isometric relaxation technique will be given to12 patients of temporomandibular joint disorder.
89549849|NCT02416141|Active Comparator|Fast release oro-dispersible tramadol|"This group receives a fast release oro-dispersible tramadol 30 minutes before the vacuum aspiration procedure. A paracervical block with a 27-gauge spinal needle with lidocaine will be injected at the the start of the procedure.~Intervention: use of fast release oro dispersible tramadol 50 mg"
89025324|NCT03278327|Other|Endoscopic resection|
89033006|NCT02922699|Experimental|Omeprazole 40mg|Omez 40mg OD
89549850|NCT02416141|Placebo Comparator|Placebo-controlled arm|"This group receives a placebo 30 minutes before the vacuum aspiration procedure. A paracervical block with a 27-gauge spinal needle with lidocaine will be injected at the the start of the procedure.~Intervention: use of placebo"
89549851|NCT03138239|Experimental|16 patients diagnosed with HCC|"12 patients will be tested at the stage of diagnosis (staging)~4 patients who have tested at staging, will be tested again after treatment.~4 patients with treatment failure or recurrence."
89549852|NCT02001233||EV71 Vaccine|Inactivated vaccine (vero cell) against EV71 of 400U /0.5ml in 5000 infants aged 6-35 months old on day0,28
89549853|NCT02001233||Placebo|placebo in 5000 infants aged 6-35 months old on day0,28
89549854|NCT02420197|Experimental|High-intensity resistance training|Full body, progressive strength training with Theraband® Elastic bands. Three times per week for 12 weeks - 3 weeks with supervised sessions at the clinic, and 9 weeks of home training.Three guided sessions will be offered during the home training period.
89549855|NCT02420197|Active Comparator|General physical activity|12 weeks of general physical activity - 3 weeks with supervised sessions at the clinic, and 9 weeks of individually adjusted home training. This include circle-training, low-intensity resistance exercises, endurance exercises, ball playing, body awareness, stretching, and relaxation techniques, and similar activities. Neither moderate nor high-intensity resistance exercise is included for participants in this group.Three guided sessions will be offered during the home training period.
89549856|NCT05391659|Active Comparator|current workflow in Flanders|patient visits ophthalmologist
89549857|NCT05391659|Active Comparator|AI-only workflow|patient is imaged, images are interpreted by DR AI tool, only referrable cases identified by DR AI tool will visit ophthalmologist
89549858|NCT05391659|Active Comparator|AI-human workflow|patient is imaged, images are interpreted by DR AI tool, referrable cases identified by DR AI tool will be remotely graded by a human, only the high risk patients will visit ophthalmologist
89549859|NCT02416219||Cricoid Cartilage localization|The caregiver will be asked to palpate the cricoid cartilage and draw aline where he will apply cricoid pressure during rapid sequence induction
89549860|NCT02416063|Active Comparator|caudal Dexmedetomidine|"Drug:Caudal Bupivacaine 0.25% 1ml/kg .~Drug:caudal Dexmedetomidine 1μg /kg.~Intravenous :10 ml normal saline~Anesthesia was induced and maintained with sevoflurane"
89549861|NCT02416063|Active Comparator|Intravenous Dexmedetomidine|"Drug:Caudal bupivacaine 0.25% 1ml/kg~Drug: Intravenous dexmedetomidine 1µg/kg in a 10 ml volume normal saline~Anesthesia was induced and maintained with sevoflurane"
89549862|NCT02416063|Placebo Comparator|Placebo|"Caudal: bupivacaine 0.25% 1ml/kg .~Intravenous: 10 ml Normal saline~Anesthesia was induced and maintained with sevoflurane"
89549863|NCT01828697|Active Comparator|Low dose LMWH|"Fixed low dose low-molecular-weight heparin:~Fixed low dose nadroparin, or;~Fixed low dose enoxaparin, or;~Fixed low dose dalteparin, or;~Fixed low dose tinzaparin."
89549864|NCT01828697|Active Comparator|Intermediate dose LMWH|"Intermediate dose low-molecular-weight heparin. Dosing is weight-adjusted according to the protocol.~Intermediate dose nadroparin, or;~Intermediate dose enoxaparin, or;~Intermediate dose dalteparin, or;~Intermediate dose tinzaparin."
89549865|NCT02420275|Placebo Comparator|Severe brain injury patient|Severe brain injury patients with placebo
89549866|NCT02420275|Experimental|Severe brain injury patient with device|"Severe brain injury patients withe with Luminette,Lucimed Belgium"
89549867|NCT02419963|Other|IBS-D patients|Subjects on this arm will have an endoscopy for tissue biopsy, and provide blood samples and stool samples.
89549868|NCT02419963|Other|Healthy Controls|Subjects on this arm will have an endoscopy for tissue biopsy, and provide blood samples and stool samples.
89549869|NCT02415985|Other|rifabutin 150|rifabutin 150 mg (1 capsule) once daily
89549870|NCT02415985|Other|rifabutin 300|rifabutin 150 mg (2 capsules) 300 mg 3 times a week
89549871|NCT02415907|Experimental|Idalopirdine|"Period I: Initial administration of Lu AF67709 single dose at baseline.~Period II: Administration of Lu AF67708 single dose (week 4)"
89549872|NCT03138083|Experimental|Module 1 Monotherapy Multiple Ascending Dose|Multiple ascending dose cohorts dosing OMO-1 (bid) monotherapy in all comer patients up to a maximally tolerated or maximally feasible dose
89549873|NCT03138083|Experimental|Module 1 Monotherapy Paired Biopsy|Paired biopsy cohort(s) dosing OMO-1 (bid) monotherapy in patients selected for MET dependent tumours at minimally biologically active doses and above
89549874|NCT03138083|Experimental|Module 1 Monotherapy Expansion Cohort(s)|Expansion cohort(s) dosing OMO-1 (bid) monotherapy in patients selected for MET dependent tumours at recommended phase 2 dose (RP2D)
89549875|NCT03138083|Experimental|Module 2 Combination with EGFR-TKI Multiple Ascending Dose|Multiple ascending dose cohorts dosing OMO-1 (bid) in combination with EGFR-TKI in MET amplified patients up to a maximally tolerated or maximally feasible dose
89549876|NCT03138083|Experimental|Module 2 Combination with EGFR-TKI Paired Biopsy|Paired biopsy cohort(s) dosing OMO-1 (bid) in combination with EGFR-TKI in MET amplified patients at minimally biologically active doses and above
89549877|NCT03138083|Experimental|Module 2 Combination with EGFR-TKI Expansion Cohort|Expansion cohort dosing OMO-1 (bid) monotherapy in combination with EGFR-TKI in MET amplified patients at recommended phase 2 (combination) dose (RP2D)
89549878|NCT02415829|Experimental|Neoadjuvant chemotherapy|A total of 55 cases of locally advanced colon cancer will be enrolled in this arm. After radiological staging, patients were treated first with 3 cycles of neoadjuvant chemotherapy consisting of oxaliplatin, 130 mg/m² on day 1, with capecitabine, 1000 mg/m² twice daily for 14 days every 3 weeks (the XELOX regimen), followed by tumor resection, and then with another 5 cycles of adjuvant chemotherapy with the XELOX regimen. Radiological response was evaluated after 2 cycles of neoadjuvant chemotherapy . A total of 3 cycles neoadjuvant chemotherapy was completed unless there was unacceptable toxicity, emergency operation condition or tumor progression during the period. Tumor responses, toxicities, and surgical complications were recorded. The pathological tumor response in the primary tumor was evaluated according to tumor regression grade (TRG) score.
89549879|NCT03180931||Scaffold thrombosis|Any patients who suffered from scaffold thrombosis occurring beyond 1 year after implantation of a Absorb BVS 1.1 and investigated by OCT with sufficient image quality allowing for CoreLab analysis at the timepoint of thrombosis.
89549880|NCT04482725|Experimental|S1|"Day 1: Trial products 1-2-12-3-11-4 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen.~Day 2: Trial products 10-5-9-6-8-7 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen."
89549881|NCT04482725|Experimental|S2|"Day 1: Trial products 2-3-1-4-12-5 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen.~Day 2: Trial products 11-6-10-7-9-8 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen."
89549882|NCT04482725|Experimental|S3|"Day 1: Trial products 3-4-2-5-1-6 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen.~Day 2: Trial products 12-7-11-8-10-9 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen."
89549883|NCT04482725|Experimental|S4|"Day 1: Trial products 4-5-3-6-2-7 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen.~Day 2: Trial products 1-8-12-9-11-10 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen."
89549884|NCT04482725|Experimental|S5|"Day 1: Trial products 5-6-4-7-3-8 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen.~Day 2: Trial products 2-9-1-10-12-11 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen."
89549885|NCT04482725|Experimental|S6|"Day 1: Trial products 6-7-5-8-4-9 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen.~Day 2: Trial products 3-10-2-11-1-12 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen."
89549886|NCT04482725|Experimental|S7|"Day 1: Trial products 7-8-6-9-5-10 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen.~Day 2: Trial products 4-11-3-12-2-1-given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen."
89549887|NCT04482725|Experimental|S8|"Day 1: Trial products 8-9-7-10-6-11 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen.~Day 2: Trial products 5-12-4-1-3-2 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen."
89549888|NCT04482725|Experimental|S9|"Day 1: Trial products 9-10-8-11-7-12 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen.~Day 2: Trial products 6-1-5-2-4-3 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen."
89549889|NCT04482725|Experimental|S10|"Day 1: Trial products 10-11-9-12-8-1 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen.~Day 2: Trial products 7-2-6-3-5-4 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen."
89549890|NCT04482725|Experimental|S11|"Day 1: Trial products 11-12-10-1-9-2 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen.~Day 2: Trial products 8-3-7-4-6-5 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen."
89549891|NCT04482725|Experimental|S12|"Day 1: Trial products 12-1-11-2-10-3 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen.~Day 2: Trial products 9-4-8-5-7-6 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen."
89549892|NCT03180775|Sham Comparator|Control|Other: Cellulose (control): cellulose, water soluble powder, 2 g in one daily dose, during 30 days
89549893|NCT03180775|Experimental|Glycine (Trade name: Glycine)|Dietary Supplement: Glycine, water soluble powder, 7.8 g daily in one dose, during 30 days.
89549894|NCT03180775|Experimental|Alanine (Trade name: L-Alanine)|Dietary Supplement: Alanine, water soluble powder, 8.5 g daily in one dose, during 30 days.
89549895|NCT03180775|Experimental|Leucine (Trade name: L-Leucine)|Dietary Supplement: Leucine, water soluble powder, 14 g daily in one dose, during 30 days.
89549896|NCT03180775|Experimental|Isoleucine (Trade name: L-Isoleucine)|Dietary Supplement: Isoleucine, water soluble powder, 8.2 g daily in one dose, during 30 days.
89549897|NCT03180775|Experimental|Valine (Trade name: L-Valine)|Dietary Supplement: Valine, water soluble powder, 9 g daily in one dose, during 30 days.
89549898|NCT03180775|Experimental|Cysteine (Trade name: L-Cysteine)|Dietary Supplement: Cysteine, water soluble powder, 2.2 g daily in one dose, during 30 days.
89549899|NCT03180775|Experimental|Arginine (Trade name: L-Arginine)|Dietary Supplement: Arginine, water soluble powder, 10 g daily in one dose, during 30 days.
89549900|NCT03180775|Experimental|Methionine (Trade name: DL-Methionine)|Dietary Supplement: Methionine, water soluble powder, 4 g daily in one dose, during 30 days.
89549901|NCT03180775|Experimental|Glutamate (Trade name: L-Glutamic acid)|Dietary Supplement: Glutamate, water soluble powder, 33 g daily in one dose, during 30 days.
89549902|NCT03180775|Experimental|Glutamine (Trade name: L-Glutamine)|Dietary Supplement: Glutamine, water soluble powder, 30 g daily in one dose, during 30 days.
89549903|NCT03180697||APT MR imaging|Patients who will receive target therapy( Bevacizumab) for recurrent malignant gliomas will be asked to participate in this study. The routine sequences, Gd- enhanced MR imaging and APT MR imaging will be performed before and after target therapy.
89549904|NCT03178357|Other|HCM patients with CR|30 HCM patients treated as standard subjected to 4-week hospital cardiac rehabilitation (CR) including psychological care (counseling and / or psychoeducation) and physical training followed by 8 weeks of telerehabilitation in the patient's home (cardiac rehabilitation + standard therapy)
89549905|NCT03178357|Other|HCM patients without CR (control group)|30 HCM patients in control group - standard treatment according to current guidelines and outpatient visits with psychological and / or psychoeducational counseling (standard therapy)
89549906|NCT03180541|Experimental|Dialectical Behaviour Therapy|"Participants receive the standard 12 month DBT programme where all four modes of treatment are delivered including: individual therapy, group skills training, telephone coaching and DBT team consultation"
89549907|NCT03180541|No Intervention|Treatment-As-Usual|"The Treatment-As-Usual arm will include individuals who:~live in areas where no DBT intervention is currently available OR~were offered a place on the DBT programme but decided not to partake at that time"
89549908|NCT05391425||premenopausal|Premenopausal patients, presented in Arnavutkoy State Hospital Gynecology Clinic with lower urinary tract symptoms that will be treated with Solifenacin (Vesicare 5mg).
89549909|NCT05391425||postmenopausal|Postmenopausal patients, presented in Arnavutkoy State Hospital Gynecology Clinic with lower urinary tract symptoms that will be treated with Solifenacin (Vesicare 5mg).
89549910|NCT02415673|Experimental|NiTi Af 37ºC|Patients were treatment with fixed orthodontics appliance and arch wire. Two nickel-titanium alignment and leveling sequences were employed - NiTi archwire: 0.012 in and 0.019 X 0.025 in; and thermal activated NiTi archwires: 0.018 in and 0.016 X 0.022 in with different austenite finish temperatures (37ºC).
89549911|NCT02415673|Experimental|NiTi Af 35ºC|Patients were treatment fixed orthodontics appliance and arch wire. Two nickel-titanium alignment and leveling sequences were employed - NiTi archwire: 0.012 in and 0.019 X 0.025 in; and thermal activated NiTi archwires: 0.018 in and 0.016 X 0.022 in with different austenite finish temperatures (35ºC)
89549912|NCT05390099|Experimental|moringa plant toothpaste|
89549913|NCT05390099|Active Comparator|Fluoride toothpaste|
89549914|NCT02415751||self-care education|All patients in the study will receive self-care education
89549915|NCT03137927|Experimental|Group 1 Vaccine GamLPV|9 individuals will be vaccinated intranasally with 2,5*10*8 bacteria cells (CFU)
89549916|NCT03137927|Placebo Comparator|Group 1 placebo|3 individuals will get placebo
89549917|NCT03137927|Experimental|Group 2 Vaccine GamLPV|9 individuals will be vaccinated intranasally with 10*9 bacteria cells(CFU)
89549918|NCT03137927|Placebo Comparator|Group 2 placebo|3 individuals will get placebo
89549919|NCT03137927|Experimental|Group 3 Vaccine GamLPV|9 individuals will be vaccinated intranasally with 4*10*9 bacteria cells(CFU)
89549920|NCT03137927|Placebo Comparator|Group 3 placebo|3 individuals will get placebo
89549921|NCT04482985|Active Comparator|Meclizine responders|
89549922|NCT04482985|Active Comparator|Meclizine non responders|
89549923|NCT05388305|Experimental|CAR--γδT|
89549924|NCT03178513|Experimental|Home visit|A participant in this arm will receive a home visit after discharge from the hospital.
89549925|NCT03178513|No Intervention|Usual Care|A participant in this arm will not receive a home visit after discharge from the hospital.
89549926|NCT03178279|Experimental|Use of the Physical Health Plan|Use of the Physical Health Plan
89549927|NCT04286789|Experimental|ORTD-1-Low Dose|5.6 mg/0.45 mL of active study drug
89549928|NCT04286789|Placebo Comparator|Vehicle Control -Low Dose|Vehicle (Identical formulation without the active DP)
89549929|NCT04286789|Experimental|ORTD 1-High Dose|22.5 mg/1.8 mL of active study drug
89549930|NCT04286789|Placebo Comparator|Vehicle Control -High Dose|Vehicle (Identical formulation without the active DP)
89549931|NCT02415517|Experimental|Experimental group|Intervention: Cognitive Training
89549932|NCT02415517|Active Comparator|Active control group|Intervention: Test of general knowledge
89549933|NCT02415517|No Intervention|Passive control group|No intervention
89549934|NCT05385263|Experimental|NIVOLUMAB|All patients enrolled will be given nivolumab ( 3mg/kg IV) on day +5 Patients with CAR-T expansion<100 cells/microL on day +7 will be given 1 additional dose of nivolumab (3mg/kg IV) on day +19 (two weeks after first dose of nivolumab).
89549935|NCT00706147|Placebo Comparator|1|
89549936|NCT00706147|Active Comparator|2|
89549937|NCT05384561|Experimental|Chemosensory training group 1|For 12 weeks, morning and evening, smell four odors namely eucalyptol, phenyl ethanol, Orange, and eugenol, for a total of five minutes per session.
89549938|NCT05384561|Experimental|Chemosensory training group 2|For 12 weeks, morning and evening, smell four odors namely coffee aroma, cheese aroma, strawberries, and limon, for a total of five minutes per session.
89549939|NCT05384561|Placebo Comparator|Chemosensory training group 3|For 12 weeks, morning and evening, smell four same odorless substance.
89549940|NCT03180229|Active Comparator|Granisetron|Five minutes before the induction 1 ml (1 mg / ml) iv granisetron will use. .Then blood pressure (systolic, diastolic, mean) and heart rate will record per 5 minute during surgery.
89549941|NCT03180229|No Intervention|Control|Five minutes before the induction 1 ml saline iv use.Then blood pressure (systolic, diastolic, mean) and heart rate will record per 5 minute during surgery.
89549942|NCT03137849|Active Comparator|Yoga Poses + Breath control|Twice a week 75 minutes video class of yoga poses routine ( including yoga bandhas with specific muscles contractions) combined with ujjayi pranayama technique as breath control
89549943|NCT03137849|Active Comparator|Yoga Poses|Twice a week 75 minutes video class of yoga poses routine ( including yoga bandhas/ specific muscles contractions)
89549944|NCT03137849|Active Comparator|Stretching Exercises + Breath control|Twice a week 75 minutes video class of stretching exercises routine combined with ujjayi pranayama technique as breath control
89549945|NCT03137849|Active Comparator|Stretching Exercises|Twice a week 75 minutes video class of stretching exercises routine
89549946|NCT05375435|Experimental|experimental group|
89549947|NCT05375435|Experimental|control group|
89549948|NCT03139877||HLP|"Intervention Cohorts:The intended target population is the adolescent with a BMI ≥ 95th percentile.~Healthy Lifestyles Program(HLP) will serve as the primary recruitment site for the intervention cohort. A prospective, longitudinal observational case control study will be performed. All participants will receive HLP standard of care (intensive lifestyle modification and access to Bull City Fit.) Groups: (1) HL-only, (2) HL + Low carbohydrate diet, (3) HL + weight loss medication(s) and (4) HL + Bariatric surgery.~Participants will be assigned to groups as per usual HLP clinical care, based on established standards and guidelines, expert medical provider recommendations, and family preference."
89549949|NCT03139877||Healthy Weight Siblings|Healthy weight siblings of HLP participants who meet age and BMI criteria will be offered enrollment at the time their overweight sibling is consented to provide comparative data. This group will be asked to provide a fecal and blood sample at one time point.
89549950|NCT03139877||Healthy Weight age/sex matched controls|"Healthy weight, age and gender matched patients will be recruited from the Duke Children's primary care practice Participants will be recruited at the time of their annual physical to provide comparative data.~This group will be asked to provide a fecal and blood sample at one time point."
89549951|NCT03178123|Experimental|humanized anti-PD-1monoclonal antibody|humanized anti-PD-1 monoclonal antibody is to be injected intravenously 3mg/kg Q2w until disease progresses or unacceptable tolerability occurs for 1 year (27 treatments)
89549952|NCT03178123|Active Comparator|high-dose recombinant interferon a-2B|Patients receive 15*10^9 U/m2/d recombinant interferon a-2B intravenously on days 1-5. Treatment repeats weekly for 4 weeks in the absence of disease progression or unacceptable toxicity.Then patients receive 15*10^9 U/m2/d recombinant interferon a-2B intravenously three times weekly for 48 weeks.
89549953|NCT02423551|No Intervention|Control|Usual diet
89549954|NCT02423551|Experimental|MRE|MRE consumption
89549955|NCT05111197|Experimental|A. (Immunotherapy + SRT)|Continuation of anti-PD-1 or anti-PD-L1 immunotherapy, started at least 6 months ago, associated with Stereotactic Radiation Therapy (SRT)
89549956|NCT05111197|Active Comparator|B (Immunotherapy alone)|Continuation of anti-PD-1 or anti-PD-L1 immunotherapy alone (started at least 6 months ago)
89549957|NCT03138005|Active Comparator|target SpO2 98-100%|Post ROSC oxygen titrated to maintain SpO2 between 98-100%
89549958|NCT03138005|Experimental|target SpO2 90-94%|Post ROSC oxygen titrated to maintain SpO2 between 90-94%
89549959|NCT05106517|Experimental|denosumab|Denosumab 60mg/6 months subcutaneously + placebo intravenous
89549960|NCT05106517|Experimental|zoledronic acid|intravenous zoledronic acid and placebo /6 months subcutaneously
89549961|NCT02415361|No Intervention|Arm A|"Standard care consists of:~a phone call from a CLP-nurse after the referral from the local birth hospital has been received~telephone service at parents request and at the staffs availability~invitation to a one-day-information course before surgery"
89549962|NCT02415361|Active Comparator|Arm B|"Systematic follow up by a special trained nurse consists of:~telephone contact with the parents shortly after birth~visit at the maternity ward within 36 hours after the referral has been received~telephone follow ups at specific times and at parents request~guidance and support in feeding and treatment~written information~cooperation with the staff at the maternity unit and the health centre~follow up in accordance with a check-list and log~invitation to a one-day-information course before surgery"
89549963|NCT03140033|Active Comparator|Misoprostol oral tablets|79 women will recieve 400 micrograms of misoprostol ( misotac) sublingually and 20 IU of oxytocin at cord clamping
89025325|NCT04700748|Other|Diffusion-weighted MRI to predict treatment response in stereotactic radiotherapy of CNS metastases.|Patients with brain metastases who will receive radiotherapy to the brain will undergo diffusion-weighted magnetic resonance imaging (MRI) at the same time as dose planning MRI is performed, after end of radiotherapy, and after 3 and 6 months after end of radiotherapy.
89025326|NCT04699955|No Intervention|Assessment only Control|Participants received no intervention content. They provided assessments of past week protective strategy use, alcohol use, and alcohol problems. All assessments were delivered via an online survey.
89549964|NCT03140033|Placebo Comparator|Ranitidine oral tablets|79 women will recieve ranitidine oral tablets sublingually and 20 IU of oxytocin at cord clamping
89549965|NCT02415283||HCC positive|¹³C-Octanoate Breath Test in 50 MRI proven HCC positive patients
89549966|NCT02415283||HCC negative|¹³C-Octanoate Breath Test in 50 MRI proven HCC negative patients
89549967|NCT03622697|Experimental|Mindfulness Meditation Arm|Mindfulness meditation intervention: patients will be asked to complete a guided mindfulness meditation phone application intervention.
89549968|NCT03622697|No Intervention|Non-Intervention Arm|Patients assigned to the non-intervention arm will not be instructed to use a mindfulness meditation phone application and instead will listen to educational materials.
89549969|NCT01992094|Experimental|QIVc|Influenza vaccine
89549970|NCT01992094|Active Comparator|TIV1c|Influenza vaccine
89549971|NCT01992094|Active Comparator|TIV2c|Influenza vaccine
89549972|NCT05347043|Experimental|Intervention|All patients will undergo both the MoCA test and the standardized neuropsychological evaluation Montreal cognitive assessment and standardized neuropsychological evaluation (Test of Attentional Performance of Zimmermann and Fimm ; Wechsler Adult Intelligence Scale 4th version digit span ; Wechsler memory scale III, spatial span ; Wisconsin Card Scoring Test, GREFEX version ; Wechsler Adult Intelligence Scale 4th version block design ; Six elements test GREFEX version; free and cued selective reminding test, 16 items, B version ; Behavioral Rating Inventory of Executive Function ; Modified Fatigue Impact Scale)
89549973|NCT03177967|Experimental|Treatment groups spring (1,2)|"Seven sessions CBT-I treatment for two different groups of eight participants (n=16)~Interventions: Sleep restriction/Stimulus Control Discussion of adverse cognitions about sleep"
89549974|NCT03177967|Experimental|Waiting list - Treatment groups fall|"This group (n=22) receives no treatment during the spring and summer, and is measured three times as a waiting list control in this period of time. The same group will receive treatment i three different groups during sept/oct.~Interventions: Sleep restriction/Stimulus Control Discussion of adverse cognitions about sleep"
89549975|NCT03177967|Active Comparator|Psychoeducative course in Nesodden|"This group (expected to be n=16) will receive a four session psychoeducative learning based course on how to manage insomnia~Interventions: Psychoeducative advice to improve sleep"
89549976|NCT05338931|Experimental|AT101(Anti-CD19 Chimeric Antigen Receptor T cell)|Anti-CD19 Chimeric Antigen Receptor T cell
89549977|NCT02414893||Non obese|
89549978|NCT02414893||Morbidly obese|
89549979|NCT02414893||Sleeve gastrectomy|
89549980|NCT03507101||Invasive GAS infection study patients|
89549981|NCT02706691|Experimental|BGJ398 (infigratinib) Dosing|Patients receive BGJ398 (125 mg) by mouth once daily on a three weeks on, one week off schedule. Courses repeat every 28 days until disease progression or unacceptable toxicity.
89549982|NCT03504137|Experimental|mHealth Intervention|Participants will receive the mHealth application either while they are an inpatient post-transplant, or at one of their post-transplant clinic visits. Study personnel will assist participants with downloading the mHealth application and explain its functioning. Participants will then use the application to aid in immunosuppressive medication adherence post-transplant.
89549983|NCT03504137|No Intervention|Standard of Care|Participants will not download the mHealth application. They will continue with their standard of care. Study personnel will send out surveys about general adherence. Participants will take their medications according to the instructions given by their transplant team and without any aid of the mHealth application.
89549984|NCT03177889|Sham Comparator|Usual treatment|oral mucolytics [ambroxol 30mg tid, or N-acetylcysteine 0.2g tid, serrapeptase 10mg tid, or carbocisteine 500mg tid]
89549985|NCT03177889|Active Comparator|TCM treatment|"Traditional Chinese Medicine plus oral mucolytics (described above);~Agastache rugosus 5g, Scutellaria baicalensis 10g, Radix Puerariae 10g, Acorus tatarinowii schott 10g, Fructus Liquidambaris 5g, gypsum 15 g, Rheum officinale 5 g, Folium sennae 5 g, Codonopsis pilosula 10g, Radix Salviae Miltiorrhizae 10g, Lignum millettiae 10 g, Liquiritia glycyrrhiza 10 g"
89549986|NCT02910791||atopic dermatitis|up to 40 subjects with atopic dermatitis will be enrolled into study.
89549987|NCT02910791||psoriasis|up to 20 subjects with psoriasis will be enrolled into study.
89549988|NCT02910791||people without skin conditions|Up to 40 subjects without skin conditions will be enrolled into study.
89549989|NCT02419729|Experimental|CO2 laser & Estrogen|Effective fractional CO2 laser therapy and effective estrogen vaginal cream
89549990|NCT02419729|Active Comparator|CO2 laser & Placebo of Estrogen|Effective fractional CO2 laser therapy and placebo of estrogen vaginal cream.
89549991|NCT02419729|Sham Comparator|Placebo of CO2 laser & Estrogen|Placebo fractional CO2 laser therapy and effective estrogen vaginal cream.
89549992|NCT03176719||Children of 1 years old|200 healthy volunteers aged between 12 and 23 months
89549993|NCT03176719||Children aged 2-4|200 healthy volunteers aged between 24 and 59 months
89033007|NCT02922699|Active Comparator|Omeprazole 80 mg|Omez 80mg OD
89033008|NCT02944604|Experimental|PEG-rhG-CSF|Patients with breast cancer who were treated with intensive chemotherapy received PEG-rhG-CSF.
89549994|NCT03176719||Children aged 5 - 9|200 healthy volunteers aged between 60 and 119 months
89549995|NCT03176719||Children aged 10 - 14|200 healthy volunteers aged between 120 and 179 months
89549996|NCT03176719||Adults of 15 years and older|200 healthy volunteers of 180 months or older
89549997|NCT02414971||Men with prostate cancer|men over 18 years of age diagnosed with prostate cancer receiving external beam radiation
89549998|NCT02729207|Active Comparator|Esflurbiprofen 1.5% Hydrogel Patch|One patch per 24hr for 7 days
89549999|NCT02729207|Placebo Comparator|Placebo comparator|Placebo One patch per 24hr for 7 days
89550000|NCT02415049|Active Comparator|Incremental|This arm of patients will be fed in the traditional standard of care manner following pyloromyotomy. They start with 15ml of pedialyte and advance by 15ml increments of formula or breastmilk to a goal of 100ml/kg/day
89550001|NCT02415049|Experimental|Ad-lib|This arm of patients is fed ad lib following surgery and can feed with formula or breast milk at any time and with any frequency up to 12.5ml/kg/feed
89550002|NCT02709239|Active Comparator|DHA 200mg|Participants will receive 200mg DHA to take per day. Participants will be asked to take four capsules containing 50mg DHA each.
88961803|NCT03994731|Experimental|Pegloticase + MTX|"Following the MTX Tolerability Assessment Period (Week -6 until the Week -4 visit, in which participants take oral MTX 15 mg weekly), participants tolerating MTX are randomized to receive blinded oral MTX 15 mg weekly during the Run-in Period (from Week -4 to Day 1).~During the Pegloticase + Immunomodulator (IMM) Period, in addition to oral 15 mg MTX, participants receive intravenous (IV) pegloticase 8 mg administered every 2 weeks (Q2W) for a total of 26 infusions from Day 1 through the Week 50 Visit.~Per protocol, participants are also required to take folic acid, at least one protocol standard gout flare prophylaxis regimen (i.e. colchicine and/or nonsteroidal anti-inflammatory drugs and/or low-dose prednisone ≤10 mg/day), and a regimen of fexofenadine, acetaminophen, and methylprednisolone for infusion reaction (IR) prophylaxis."
89550003|NCT02709239|Experimental|DHA 800mg|Participants will receive 800mg DHA to take per day. Participants will be asked to take four capsules containing 200mg DHA each.
89550004|NCT01991470|Experimental|Enlite sensors|Each subject will first wear enlite sensors and will come for clinic visit for YSI (Yellow Spring Instruments). Then each subject will wear enlite 3 sensors and will come for clinic visit for YSI (Yellow Spring Instruments) or SMBG (Self-Monitoring of Blood Glucose) testing. SMBG testings are for subjects 2-6 years of age and cannot tolerate YSI. In addition. In addition, subjects aged 2-6 years old will not participate in Enlite phase. They only participate in Enlite 3 phase.
89550005|NCT02419651|Active Comparator|Tramadol|Women will receive oral Tramadol 100 mg before the procedure
89550006|NCT02419651|Active Comparator|Diclofenac|Women will receive oral diclofenac 100 mg before the procedure
89550007|NCT02419651|Placebo Comparator|Placebo|Women will receive oral placebo 1 hour before the procedure.
89550008|NCT02488655|Experimental|Echopulse|Echopulse HIFU
89550009|NCT02414815|Experimental|AF group|Atrial fibrillation
89550010|NCT05088239||PAD|In prophylactic antibiotics for drain group (PAD) (n = 15), prophylactic cefazolin 1000 mg was given 30 minutes before surgery, every 4 hours in the peri-operative period, and every 6 hours in the post-operative for 10-14 days when the drains were removed from the breast and abdomen.
89550011|NCT05088239||PA3|In the 3-day prophylactic antibiotics group (PA3) (n = 11), prophylactic cefazolin 1000 mg was given 30 minutes before surgery, every 4 hours in peri-operative period, and 6-hourly thereafter for 3 days.
89550012|NCT05088239||PA1|In the 1-day prophylactic antibiotics group (PA1) (n = 82), patients received prophylactic cefazolin 1000 mg 30 minutes before surgery, every 4 hours in the peri-operative period, and every 6 hours in the post-operative period and antibiotics were discontinued within 24 hours of surgery.
89550013|NCT02419261|Active Comparator|Adductor Canal Blockade|In this group, patient will benefit of an ultrasound guided adductor canal blockade (20 ml of Ropivacaine 0.75%) as analgesic nerve blockade for their surgery of anterior cruciate ligament repair
89550014|NCT02419261|Active Comparator|Femoral Nerve Blockade|In this group, patient will benefit of an ultrasound guided femoral nerve blockade (20 ml of Ropivacaine 0.75%) as analgesic nerve blockade for their surgery of anterior cruciate ligament repair
89550015|NCT01991314|Experimental|Ferrous sulphate|Ferrous sulphate 200mg twice daily for 6 weeks
89550016|NCT03176641|Active Comparator|PRP group|30 patients will receive autologous platelet-rich plasma gel during meniscus repair surgery.
89550017|NCT03176641|Placebo Comparator|Control group|30 patients will receive meniscus repair surgery only.
89550018|NCT03500471||Experimental: Robotic surgery|Robotic-assisted Total Gastrectomy with D2 Lymphadenectomy
89025327|NCT04699955|Experimental|Positive Message Condition|Participants received information on the positive aspects of individuals that used protective strategies and were encouraged to report why these individuals were viewed so much more positively. They provided assessments of past week protective strategy use, alcohol use, and alcohol problems. All assessments and messaging was delivered via an online survey.
89025328|NCT04699955|Experimental|Negative Message Condition|Participants received information on the negative aspects of individuals that did not used protective strategies and were encouraged to report why these individuals were viewed so much more negatively. They provided assessments of past week protective strategy use, alcohol use, and alcohol problems. All assessments and messaging was delivered via an online survey.
89550019|NCT03500471||Compared: Laparoscopic surgery|Laparoscopic-assisted Total Gastrectomy with D2 Lymphadenectomy
89550020|NCT02414503|Active Comparator|8IU intranasal oxytocin|8IU intranasal oxytocin delivered with the OptiNose Breath Powered Bi directional liquid device
89550021|NCT02414503|Active Comparator|24IU intranasal oxytocin|24IU intranasal oxytocin delivered with the OptiNose Breath Powered Bi directional liquid device
89550022|NCT02414503|Placebo Comparator|Placebo|Placebo delivered with the OptiNose Breath Powered Bi directional liquid device
89550023|NCT03137615||Pituitary Surgery|"Patients having pituitary gland surgery~Inclusion criteria - Any adult patient undergoing trans-sphenoidal pituitary surgery.~Exclusion criteria - Under 16 years of age, pregnancy, uncontrolled hypertension, allergy to any local anaesthetic, patient refusal or revision pituitary surgery"
89550024|NCT03137147|Other|Cognitive-Behavioral Therapy|Intervention for Sleep and Pain in Youth, a 7-session cognitive-behavioral therapy intervention for co-morbid insomnia and headache
89550025|NCT03415061|Experimental|Intranasal Insulin 40 IU|40 IU of Humulin-R via nose Before surgery and everyday after surgery up to postoperative day 7
89550026|NCT03415061|Placebo Comparator|Intranasal Normal Saline|Normal Saline via nose Before surgery and everyday after surgery up to postoperative day 7
89550027|NCT03136211|Experimental|EIRA intervention|"EIRA intervention It is based on the Transtheoretical Model (TTM) and States of Change and it is made by physicians and nurses in routine care of primary care practices according to the conceptual framework of the 5A: Ask, Advise, Assess, Assist, and Arrange. It consists of a first visit of screening (Ask). Subsequently, the professional develops a personalized plan that is negotiated with the participant (Advise and Assess). This plan is reviewed during successive visits and positive changes are reinforced and new objectives are negotiated (Assist and Arrange). The motivational interview is the essential tool of the intervention. The intervention is carried out to different levels: individual, group and community."
89550028|NCT03136211|No Intervention|Usual care|"Health providers of this group integrate in their practice the recommendations of the Program of Preventive Activities and Health Promotion (PAPPS). These guidelines are based on systematic screening and brief advice for the prevention of cardiovascular and mental diseases and cancer as well as vaccine recommendations."
89550029|NCT03275831|Active Comparator|Intrasite Gel|Intrasite Gel is an effective method for hydrating dry necrotic and sloughy wounds. It is an amorphous gel that contains 85% water, and gently increases the moisture level within the wound, encouraging moist wound healing through autolytic debridement.
89550030|NCT03275831|Experimental|PluroGel Burn and Wound Dressing|PluroGel contains a surfactant-based cleanser to assist wound debridement and cleansing
88961804|NCT03994731|Placebo Comparator|Pegloticase + Placebo|"Following the MTX Tolerability Assessment Period (Week -6 until the Week -4 visit, in which participants take oral MTX 15 mg weekly), participants tolerating MTX are randomized to receive blinded oral placebo for MTX weekly during the Run-in Period (from Week -4 to Day 1).~During the Pegloticase + IMM Period, in addition to oral placebo for MTX, all participants receive IV pegloticase 8 mg administered Q2W for a total of 26 infusions from Day 1 through the Week 50 Visit.~Per protocol, participants are also required to take folic acid, at least one protocol standard gout flare prophylaxis regimen (i.e. colchicine and/or nonsteroidal anti-inflammatory drugs and/or low-dose prednisone ≤10 mg/day), and a regimen of fexofenadine, acetaminophen, and methylprednisolone for IR prophylaxis."
88961805|NCT03921489||Subchondroplasty in treating bone marrow edema|These patients will have calcium phosphate mineral compound injected into the bone marrow lesions.
88961806|NCT03868943|Experimental|Solriamfetol|Given orally daily
88961807|NCT03812991|No Intervention|Non-Treatment Group|This is the Non-Treatment Arm of the study. No intervention is to be administered.
88961808|NCT03812991|Experimental|Miacalcin Calcitonin Salmon Nasal Spray|1 spray (200 IU) qDay, alternate nostrils daily
88961809|NCT03801915|Experimental|Cohort 1 - Pre-operative Escalation Doses of MVT-5873 (HuMab-5B1)|Pre-operative escalation doses of MVT-5873, pancreatectomy or hepatectomy and post-operative MVT-5873 treatment
88961810|NCT03801915|Experimental|Cohort 2 - Pre-operative Recommended Dose (RD) of MVT-5873 (HuMab-5B1)|Pre-operative RD of MVT-5873, pancreatectomy or hepatectomy and post-operative MVT-5873 treatment
88961811|NCT03800277|Experimental|Cranberry and Agaves|Cranberry extract (2 capsules) + Agaves powder (1 single-dose packet)
88961812|NCT03800277|Experimental|Cranberry and placebo|Cranberry extract (2 capsules) + Placebo powder (1 single-dose packet)
88961813|NCT03800277|Experimental|Placebo and Agaves|Placebo (2 capsules) + Agaves powder (1 single-dose packet)
88961814|NCT03800277|Placebo Comparator|Placebo and placebo|Placebo (2 capsules) + Placebo powder (1 single-dose packet)
89025329|NCT03279315|Experimental|experimental period|the first period was with non-iodized salt, the second period was with iodized salt.
89025330|NCT00444743|Active Comparator|1|
89550031|NCT03160235|Experimental|Development of MRI protocols|MRI exam to grade differents interventions for future research
89550032|NCT03160235|Experimental|Development of EEG protocols|EEF exam to grade differents interventions for future research
89550033|NCT03160235|Experimental|Development of NIRS protocols|NIRS exam to grade differents interventions for future research
89550034|NCT05088083|Experimental|DCB Treatment Group|Subjects treated with DCB
89550035|NCT05088005||Acute CO poisoning|A diagnosis of CO poisoning was made according to medical history and carboxyhemoglobin >5% (>10% in smokers).
89550036|NCT01990768|Experimental|1 gram Tranexamic Acid (TXA)|Loading dose of 1 gram TXA given prior to hospital arrival followed by a 1 gram TXA infusion over 8 hours after hospital arrival
89550037|NCT01990768|Experimental|2 grams TXA|Loading dose of 2 gram TXA given prior to hospital arrival followed by a placebo of 0.9% Sodium Chloride solution infusion over 8 hours after hospital arrival
89550038|NCT01990768|Placebo Comparator|0.9% Sodium Chloride injectable|Loading dose of 0.9% Sodium Chloride solution given prior to hospital arrival followed by a placebo of 0.9% Sodium Chloride solution infusion over 8 hours after hospital arrival
89550039|NCT03002207|Experimental|The defect is repaired and sutured|Participants with lumbar disc herniation diseases are treated by Microendoscopic discectomy, and they are divided into four groups depend on whether the defect is repaired with Autologous Bone Marrow Stem Cell (BMSC)/gelatin sponge or not and whether the defect is sutured or not. In the first group,the defect of intervertebral disc is repaired with Autologous Bone Marrow Stem Cell (BMSC)/gelatin sponge and sutured.
89025331|NCT00444743|Placebo Comparator|2|
89025332|NCT00479622|Experimental|1|
89025333|NCT00479622|Experimental|2|
89550040|NCT03002207|Experimental|The defect is repaired but not sutured|Participants with lumbar disc herniation diseases are treated by Microendoscopic discectomy, and they are divided into four groups depend on whether the defect is repaired with Autologous Bone Marrow Stem Cell (BMSC)/gelatin sponge or not and whether the defect is sutured or not. In the second group, the defect of intervertebral disc is repaired with autologous Bone Marrow Stem Cell (BMSC)/gelatin sponge but not sutured after discectomy.
89550041|NCT03002207|Experimental|The defect is sutured but not repaired|Participants with lumbar disc herniation diseases are treated by Microendoscopic discectomy, and they are divided into four groups depend on whether the defect is repaired with Autologous Bone Marrow Stem Cell (BMSC)/gelatin sponge or not and whether the defect is sutured or not. In the third group, the defect of intervertebral disc is sutured but not repaired with autologous Bone Marrow Stem Cell (BMSC)/gelatin sponge after discectomy.
89550042|NCT03002207|No Intervention|The defect is neither sutured nor repaired|Participants with lumbar disc herniation diseases are treated by Microendoscopic discectomy, and they are divided into four groups depend on whether the defect is repaired with Autologous Bone Marrow Stem Cell (BMSC)/gelatin sponge or not and whether the defect is sutured or not. In the four group, the defect of intervertebral disc is neither sutured nor repaired with autologous Bone Marrow Stem Cell (BMSC)/gelatin sponge after discectomy.
89550043|NCT05087459||patients with primary hepatocellular carcinoma undergoing elective hepatectomy|The baseline platelet count before enrollment was < 75×10^9/L and > 30×10^9/L.The primary clinical diagnosis of hepatocellular carcinoma was confirmed, and the CNLC stages were Ia and Ib.An elective hepatectomy, including laparotomy or laparoscopic hepatectomy, except hepatectomy combined with splenectomy or radiofrequency ablation.
89550044|NCT01990612|No Intervention|Expectant Management|Expectant management (unless a medical indication arises) until at least 40 weeks 5 days.
89550045|NCT01990612|Other|Elective Induction of Labor|Elective induction of labor between 39 weeks 0 days and 39 weeks 4 days
89550046|NCT05086991||Group Study|Follow up of the patients for 12 months by the community pharmacist in the role of case manager and execution of the activities foreseen by the PAI (individual assistance plan) through telemedicine (ecg, cardiac holter) and self analysis (hemoglobin, hematocrit, creatinine).
89550047|NCT05228327|Active Comparator|Occlusal Splint Group|Only occlusal splint was made for this patients.
89550048|NCT05228327|Active Comparator|Masticatory muscle injection group|Only intramuscular injection was applied to this patients. Intramuscular injectable form of Lidocaine Hydrochloride (20mg/ml, Jetokain Simplex, ADEKA, Samsun, Turkey) was injected. 0,3 ml was injected to all trigger points.
89550049|NCT05228327|Active Comparator|Occlusal splint and masticatory muscle injection combination group|Intramuscular injectable form of Lidocaine Hydrochloride (20mg/ml, Jetokain Simplex, ADEKA, Samsun, Turkey) was injected. 0,3 ml was injected to all trigger points. Patients were started to use their occlusal splints in the evening of the injection day.
89550050|NCT05228327|No Intervention|Control group|16 healthy volunteers was involved. Not given any treatment to these volunteers.
89550051|NCT05086367|Active Comparator|Routine Physical Therapy|This group received only routine physical therapy. This includes thermotherapy, trans-cutaneous electrical nerve stimulation, neck isometrics and stretching that includes 12 sessions (3 sessions per week)
89550052|NCT05086367|Experimental|Breathing Exercises along with routine physical therapy|This group received routine physical therapy along with breathing exercises. This includes thermotherapy, trans-cutaneous electrical nerve stimulation, neck isometrics and stretching that includes 12 sessions (3 sessions per week).
89550053|NCT05090189|Experimental|Exercise training|The experimental arm will enroll in a 6-month, twice-weekly, home-based, remotely monitored exercise training program, the emphasis of which will be to improve musculoskeletal health and function.
89550054|NCT05090189|No Intervention|Control|The control group will receive standard medical care.
89550055|NCT05086211|Experimental|proprioceptive neuromuscular facilitation|"Each session including three PNF techniques:~Balance training exercises,participants will be treated for 20 minutes with PNF techniques that included;Rhythmic initiation, slow reversal techniques practiced with D1 and D2 pattern in lower limb,repeated contraction and Resisted PNF.The Technique will be performed for 3 days per week in same order on all subjects."
89550056|NCT05086211|Experimental|pertubation based balance training|Each session will include a 5-10min warm-up,voluntary tasks intended to induce internal perturbations,voluntary tasks combined with external perturbations and a 5-10mins cool down.The technique will be performed for 2 sets of 10 repetitions on all subjects.
89550057|NCT05089721||Anesthesiologist|
89550058|NCT05089721||Obstetricians|
89550059|NCT05085587|Experimental|Test Product|Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals
89550060|NCT05085587|Active Comparator|Reference Product|ADVAIR DISKUS 250/50
89550061|NCT01990534|Experimental|Brentuximab Vedotin 1.8 mg/kg|Brentuximab vedotin 1.8 mg/kg, 30-minute intravenous (IV) infusion, Day 1 in every 3-week cycle, until there is evidence of disease progression or unacceptable toxicity occurs (Up to 16 cycles). The dose could be decreased or delayed or discontinued in participants who develop treatment-associated non-hematologic, hematologic toxicity or peripheral neuropathy to brentuximab vedotin.
89550062|NCT05085509|Experimental|Ultrasound|Ultrasound guidance and methylene blue staining
89550063|NCT05085509|Active Comparator|Open surgery|Open surgery without ultrasound guidance and methylene blue staining
89550064|NCT05085431|Experimental|Treatment of Sjogren's Syndrome|Experimental：Administration of CD19/BCMA CAR T-cells A dose levels of 1-4*10E6/kg are administrated for each subject.
89550065|NCT05084807|Other|Healthy group|A group of healthy, strictly asymptomatic individuals of both sexes and different age groups.
89550066|NCT05089097||Inhibitors of serotoninergic reuptake on|"patients with a diagnosis of depressive syndrome requiring treatment with Inhibitors of serotoninergic reuptake drugs excluding neurodegenerative diseases and on treatment with antidepressants for more than three months.~Intervention: evaluation of the presence of postoperative delirium with the CAM-ICU score upon awakening and for the following 48 hours."
89550067|NCT05089097||Inhibitors of serotoninergic reuptake off|"patients without a diagnosis of depressive syndrome requiring treatment with Inhibitors of serotoninergic reuptake drugs excluding neurodegenerative diseases and not in treatment with antidepressants.~Intervention: evaluation of the presence of postoperative delirium with the CAM-ICU score upon awakening and for the following 48 hours."
89550068|NCT02414659||Cesarean delivery, cord blood collected|Cesarean delivery patient who opted for cord blood collection during procedure. Cord blood was collected in-utero after delivery and after clamping of the umbilical cord. After cord blood collection operation was continued.
89550069|NCT02414659||Cesarean delivery, control|Routine cesarean delivery patients.
89550070|NCT05085743||Training|Images and related clinical data along with the measured lip to carina length of the training group are fed into and used to fit out deep convolutional neural networks model.
89550071|NCT05085743||Validation|We evaluate the model accuracy and efficacy of predicting the lip to carina length with images and clinical data of those unforeseen cases in the validation group.
89550072|NCT05084573|Experimental|Liposomal bupivacaine|Patients will receive a single bolus interscalene injection of 10mL 1.33% LB followed by placement of indwelling (sham) catheter in the interscalene region. Upon arrival in the recovery room, a nurse will connect the catheter to a fixed-rate portable elastometric pump (Easypump®, B Braun, Germany) filled with 300mL normal saline (NS) at a default fixed rate of infusion of 5mL/hr. The syringe, catheter, pump and clamp will be covered by opaque black bags to conceal the milky appearance of LB. The catheter will be removed on postoperative day 2.
89550073|NCT05084573|Active Comparator|Standard bupivacaine CISB|Patients will receive a single bolus interscalene injection of 10mL 0.25% SB followed by placement of indwelling (sham) catheter in the interscalene region. Upon arrival in the recovery room, a nurse will connect the catheter to a fixed-rate portable elastometric pump (Easypump®, B Braun, Germany) filled with 300mL 0.2% SB at a default fixed rate of infusion of 5mL/hr. The syringe, catheter, pump and clamp will be covered by opaque black bags to conceal the drug appearance. The catheter will be removed on postoperative day 2.
89550074|NCT05069753|Active Comparator|Immediate sequential bilateral cataract surgery (ISBCS)|
89550075|NCT05069753|Active Comparator|Delayed sequential bilateral cataract surgery (DSBCS)|
89550076|NCT05088707|Experimental|sublingual misoprostol|"All patients will receive three doses of sublingual misoprostol every four hours. The first dose of misoprostol 800 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of the second dose will be given upon sending home.~Two doses of misoprostol 800 mcg each (four tablets of 200 mcg per dose). Paracetamol, eight hourly, will be provided as an analgesic or antipyretic. A specimen bottle to collect the POC if passed out. Two pairs of disposable gloves. Pre-filled histopathological examination form to be sent to the laboratory together with the products of conception"
89550077|NCT05088707|Active Comparator|vaginal misoprostol|"All patients will receive three doses of vaginal misoprostol every four hours The first dose of misoprostol 800 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of the second dose will be given upon sending home.~Paracetamol, eight hourly, will be provided as analgesic or antipyretic"
89550078|NCT01967134|Experimental|H56:IC31 (50 ug H56) LTBI Neg|LTBI Negative 3 Doses
89550079|NCT01967134|Experimental|H56:IC31 (15 ug H56) LTBI Pos|LTBI Positive 3 Doses
89550080|NCT01967134|Experimental|H56:IC31 (50 ug H56) LTBI Pos|LTBI Positive 3 Doses
89550081|NCT05028257|Experimental|COVID-19 Vaccinated Patients|
89550082|NCT05075057|Experimental|Experimental Group|A total 400 subjects aged ≥60 years with chronic bronchitis and COPD receive three doses inactivated COVID-19 vaccine on Day 0, Day 21, Day 111, respectively.
89550083|NCT05072639|Experimental|Meditation|Participants randomized to the meditation arm will receive an mp3 audio recording of the visual guided meditation will be sent an additional mp3 file specifically for the recovery phase of surgery. Participants will be asked to complete a series of pre-study questionnaires to determine their baseline anxiety, depression, stress, and quality of life scores. Subjects will then complete the same questionnaires at four additional time points: after 10 days of daily meditations, 1 day before their surgery, and day after discharge, and 4 weeks post-operation.
89550084|NCT05072639|No Intervention|Control group|"Participants received standard of care, including the option to attend a free Prepare for Surgery workshop. Participants will be asked to complete a series of pre-study questionnaires to determine their baseline anxiety, depression, stress, and quality of life scores. Subjects will then complete the same questionnaires at four additional time points: after 10 days of daily meditations, 1 day before their surgery, and day after discharge, and 4 weeks post-operation."
89550085|NCT03135977|Experimental|Apatinib, Etoposide|Patients receive etoposide 50mg from day 1 to day 14 and apatinib 250mg/d from day 1 to day 21, repeated every 21 days until progressive Disease(PD) .
89550086|NCT01966432|Other|SBIRT|"This is a single arm, non-randomized study. However, based on participants' substance use status, participants will be categorized into three groups:~Screening group. Patients who screen for no use of cigarettes, alcohol, or other drugs. Patients are re-screened at followup visits.~Screening, Brief Intervention group. Patients who screen positive for cigarette, alcohol, or other drug use.~Screening, Brief Intervention, and Referral to Treatment group. Patients who screen positive for use and have a positive AUDIT-C and/or positive DAST-10 assessment for problematic alcohol or drug use."
89550087|NCT04937231|Experimental|Aerobic exercises|Treadmill and Cycle ergometer
89550088|NCT04937231|Experimental|Resistance exercises|unilateral leg press, Bilateral leg press, unilateral arm curls
89550089|NCT04937231|Experimental|Combined training|Treadmill and Cycle ergometer along with resistive Training
89025334|NCT03279159|Experimental|Jaluronius CS cream (Difa Cooper S.p.a, Italy)|
89025335|NCT00444860|Experimental|1|Zostavax
89025336|NCT00479661|Experimental|1|Dexmedetomidine
89025337|NCT00479661|Active Comparator|2|Propofol
89025338|NCT00444899|Experimental|Intensive treatment|Submitted to an intensive follow-up by the dietician.
89025339|NCT00444899|Active Comparator|Usual treatment|Subjects will remain under the care of their endocrinologist and/or general practitioner.
89550090|NCT03136133|Active Comparator|Active protein drink|Active protein drink
89550091|NCT03136133|Placebo Comparator|Placebo drink|Placebo drink
89517371|NCT03872947|Experimental|Arm S: TRK-950 + Carboplatin / PLD/ Bevacizumab|"Platinum Sensitive epithelial ovarian, primary peritoneal or fallopian tube cancer~Treatment Phase: TRK-950 will be administered IV on days 1 and 15 of a 28-day cycle. Carboplatin will be administered as an intravenous infusion on day 1. On day 1, following the administration of Carboplatin, PLD will be administered as an intravenous infusion. Also on Day 1 of each cycle, Bevacizumab will be administered IV next.~On days 1 and 15, TRK-950 will be administered IV after the Bevacizumab infusion.~• Maintenance Phase: After 6 cycles of chemotherapy, the patient will be transitioned to maintenance treatment. On Day 1 of each maintenance cycle, Bevacizumab will be administered IV. Following the Bevacizumab administration, TRK-950 will be administered IV. Maintenance treatment will be continued as long as there is no evidence of progressive disease."
89550092|NCT05002439|Experimental|Group multicomponent physical exercise program and a nutritional intervention|Group multicomponent physical exercise program and a nutritional intervention. The exercise program will be delivered by trained experts in groups of 6 participants, and will be based on the recommendations presented in the Spanish Healthcare Ministry document. This program includes balance, flexibility, and strength and power exercises. The program will be realized twice a week, during 45 minutes time, for 16 weeks, twice a year. Nutritional intervention will be based on the results of MNA-SF. If the results of this instrument show normal nutrition status, general nutritional recommendations will de presented by a nutritionist twice a year before the physical exercise program. If MNA-SF shows nutritional risk or malnutrition, oral nutritional supplementation will be offered. Primary Care Physicians will have the opportunity of referring high risk participants to their Geriatrics Department Participants when appropriate, following Healthcare Ministry algorithm
89550093|NCT05002439|No Intervention|Control group|Control group will receive usual care by their Primary Care Physicians. Healthy lifestyle recommendations including exercise and nutritional recommendations will be offered
89550094|NCT04928729|Experimental|Pursed Lip Breathing|
89550095|NCT04928729|Experimental|Pursed Lip Breathing +DB|
89550096|NCT04928729|Experimental|Conservative care|
89550097|NCT04850651|Experimental|Pyrotinib/Fluconazole|Durg: Pyrotinib Durg: Pyrotinib/Fluconazole Participants received a single oral dose of pyrotinib 80 milligram (mg) on day1 and day9. Participants received a loading dose of fluconazole 400 mg on day6 followed by single dose of fluconazole 200 mg for oral administration from D7 to D18.
89550098|NCT04837235|Experimental|75mg group|15mg/tablet. Five tablets (75mg) each time. Participants will receive a single dose of Hemay005 tablet in Day 1 followed by twice a day of Hemay005 tablet in Day 3~Day8 and single dose in Day9.
89550099|NCT04837235|Experimental|90mg group|15mg/tablet. Six tablets (90mg) each time. Participants will receive a single dose of Hemay005 tablet in Day 1 followed by twice a day of Hemay005 tablet in Day 3~Day8 and single dose in Day9.
89550100|NCT04837235|Experimental|105mg group|15mg/tablet. Seven tablets (105mg) each time. Participants will receive a single dose of Hemay005 tablet in Day 1 followed by twice a day of Hemay005 tablet in Day 3~Day8 and single dose in Day9.
89550101|NCT04767971||Standard Colonoscopy|Colonoscopy with a standard colonoscope
89550102|NCT04767971||G-EYE® Colonoscopy|Colonoscopy with a G-EYE Colonoscopy
89208042|NCT00787280|Experimental|Low Carbohydrate Ketogenic Diet (LCKD)|participants will follow a low carbohydrate ketogenic diet for six weeks
89208043|NCT00787280|Experimental|Low Fat Diet (LFD)|particpants will follow a low fat diet for six weeks
89550103|NCT04829981|Experimental|Intervention community|Two communities in rural Colombia
89550104|NCT04829981|No Intervention|Control community|One community in rural Colombia
89550105|NCT02702401|Experimental|Pembrolizumab+Best Supportive Care|Participants receive a pembrolizumab 200 mg intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 cycles of treatment PLUS BSC. Participants who complete 35 administrations or achieve a complete response (CR) but progress after discontinuation can initiate a second course of pembrolizumab for up to 17 cycles (approximately 1 additional year).
89550106|NCT02702401|Placebo Comparator|Placebo+Best Supportive Care|Participants receive a placebo IV infusion on Day 1 of each 3-week cycle for up to 35 cycles of treatment PLUS BSC.
89550107|NCT04736615|Experimental|Intervention community|Households will be randomly allocated to the intervention every 1-2 months over the12 month intervention
89550108|NCT02423707|Active Comparator|ALK Alutard Birch and/or 5-grasses|3 intralymphatic injections with dose 1000 SQ-U and dose interval 4 weeks.
89550109|NCT02423707|Placebo Comparator|ALK diluent|3 intralymphatic injections with dose interval 4 weeks.
89210569|NCT00542919|Experimental|Indolent B-Cell|Indolent B-Cell (IBCL): Small lymphocytic lymphoma, follicular lymphoma (Grade 1 or 2) and marginal zone lymphoma. Participants received enzastaurin 1125 mg loading dose then 500 mg, oral, daily until progressive disease or predefined criteria for discontinuation is met. Participants who progress within the first 28 days may remain on study treatment, provided that the participant is not in need of immediate treatment with another anticancer therapy. Study treatment occurs in cycles. 1 cycle = 28 days
89550110|NCT02423629|Other|Agili C™|Candidates will be screened for possible inclusion in the trial. Candidates that are approved by the adjudication committee will be considered for study enrollment and then operated. Note: in case intra-operatively a medical condition is observed which is not aligned with the inclusion/exclusion criteria, the Subject will not be implanted with the Agili-C™ device and will not be considered enrolled in the study.
89550111|NCT04729829|Active Comparator|FAD + SBC|Community will be exposed to increased availability of fish from a fish aggregating device and will receive information and messaging as part of a social and behaviour change communication about consuming fish.
89550112|NCT04729829|Active Comparator|FAD only|Community will be exposed to increased availability of fish from a fish aggregating device only
89550113|NCT04729829|Active Comparator|SBC only|Community will receive information and messaging as part of a social and behaviour change communication about consuming fish.
89550114|NCT04729829|No Intervention|Control|Control (No FAD or SBC)
89550115|NCT04719533|Experimental|Pre-marked episiotomy location|Women in this group will undergo pre-marking of episiotomy location
89550116|NCT04719533|No Intervention|No pre-marked episiotomy location|Women in this group will not undergo pre-marking of episiotomy location
89550117|NCT02419183||Sequence A|Participants will receive a computer administered Word List Recall (WLR) [SAMSTAR] on Test Day 1 and an examiner addminstered WLR [RAVLT] on Test Day 2 of the study.
89550118|NCT02419183||Sequence B|Participants will receive an examiner-administered WLR [RAVLT] on Test Day 1 and a computer adminstered WLR [SAMSTAR] on Test Day 2 of the study.
89550119|NCT02419027|Experimental|GI Flora|Lactobacillus acidophilus LA1 1.312% Lactobacillus rhamnosus LR5 0.656% Lactobacillus paracasei LPC5 0.656% Bifidobacterium lactis BL3 1.312% Bifidobacterium breve BR3 1.312% Pediococcus pentosaceus SL4 1.312% Prolac-T(heat-killed L. acidophilus LA1) 24.286% Dextrose 60.000% Maltodextrin 7.154% Lemon flavor 1.000% Mg-stearate 1.000% TOTAL 100% (1.4g)%
89550120|NCT02419027|Placebo Comparator|placebo|Dextrose 89.846% Maltodextrin 7.154% Lemon flavor 1.000% Mg-stearate 1.000% TOTAL 100% (1.4g)%
89550121|NCT03116971|Experimental|M3814 PiC with Etoposide and Cisplatin|Participants received M3814 100 milligram (mg) powder in capsule (PiC) orally once daily in combination with Etoposide 100 mg/m^2 over a 60 minute intravenous infusion on Days 1-3 and Cisplatin 75 milligram per square meter (mg/m^2) over a 60-minute intravenous infusion on Day 1 for 6 cycles with each cycle lasting 3 weeks (21 days) until progressive disease (PD).
89550122|NCT03116971|Experimental|M3814 (HME Tablet + PiC) with Etoposide and Cisplatin|Participants received M3814 100 mg hot melt extrusion (HME) tablet orally 5 days prior to Day 1 and M3814 100 mg PiC, orally once daily from Day 1 in combination with Etoposide 100 mg/m^2 over a 60 minute intravenous infusion on Days 1-3 and Cisplatin 75 mg/m^2 over a 60-minute intravenous infusion on Day 1 for 6 cycles with each cycle lasting 3 weeks (21 days) until PD.
89550123|NCT02414581|Experimental|Chlorhexidine 0.12% & Ethyl Alcohol 7%|Chlorhexidine 0.12% and Ethyl Alcohol 7% mouthwashes 15ml by 30 seconds, twice day for 9 days.
89550124|NCT02414581|Active Comparator|Ethyl Alcohol 7%|Ethyl Alcohol 7% without chlorhexidine mouthwashes 15ml by 30 seconds, twice day for 9 days.
89550125|NCT02414581|Experimental|Chlorhexidine 2% & Ethyl Alcohol 7%|Chlorhexidine 2% and Ethyl Alcohol 7% mouthwashes 15ml by 30 seconds, once day for 3 days.
89550126|NCT03136679||Group 1 Normal|Spouse or Subject's caregiver. Blood and urine samples will be collected.
89550127|NCT03136679||Mild Cognitive Impairment|Subjects with MCI: Blood and urine samples will be collected.
89550128|NCT03136679||Alzheimer's disease|Subjects with Alzheimer's disease A. Mild B. Moderate C. Severe Blood and urine samples will be collected from these three sub-groups.
89550129|NCT04700267|Experimental|GLPG3970|One dose level of GLPG3970
89550130|NCT04700267|Placebo Comparator|Placebo|One dose level of Placebo
89550131|NCT02419105|Active Comparator|Testosterone + Vitamin D|Testosterone, transdermal gel, 75 mg, once per day, for 12 months AND Colecalciferol, oral drink solution, 24000 IU, once per month, for 12 months
89550132|NCT02419105|Active Comparator|Testosterone + Placebo|Testosterone, transdermal gel, 75 mg, once per day, for 12 months AND Placebo: Colecalciferol, oral drink solution, 0 IU, once per month, for 12 months
89550133|NCT02419105|Active Comparator|Placebo + Vitamin D|Placebo: Testosterone, transdermal gel, 0 mg, once per day, for 12 months AND Colecalciferol, oral drink solution, 24000 IU, once per month, for 12 months
89550134|NCT02419105|Placebo Comparator|Control|Placebo: Testosterone, transdermal gel, 0 mg, once per day, for 12 months AND Placebo: Colecalciferol, oral drink solution, 0 IU, once per month, for 12 months
89550135|NCT03136991|Active Comparator|Cohort 1|Participants will receive AZD4831 5 mg/placebo oral suspension.
89550136|NCT03136991|Active Comparator|Cohort 2|Participants will receive AZD4831 (Additional dose 1)/placebo oral suspension.
89550137|NCT03136991|Active Comparator|Cohort 3|Participants will receive AZD4831 (Additional dose 2)/placebo oral suspension.
89550138|NCT03136991|Active Comparator|Cohort 4|Participants will receive AZD4831 (Additional dose 3)/placebo oral suspension.
89550139|NCT02414737|Experimental|corifollitrophin alfa|corifollitrophin alfa used as COH stimulant in IVF
89550140|NCT04643249|Experimental|Active|Daily treatment
89550141|NCT04482517|Other|Density Gradient Centrifugation (DGC)|Using the routine DGC sperm processing only
89550142|NCT04482517|Active Comparator|Physiological ICSI (PICSI)|Using PICSI dish for selecting sperm with lower sperm DNA fragmentation
89550143|NCT04482517|Active Comparator|Magnetic Activated Cell Sorting (MACS)|Using MACS for selecting sperm with lower sperm DNA fragmentation
89550144|NCT04482517|Active Comparator|Testicular sperm (Testi)|Using testicular sperm not ejaculated sperm
89550145|NCT02418871|Experimental|FluidVision|FluidVision AIOL implanted in the capsular bag of the eye during cataract surgery
89550146|NCT02414425|Experimental|Rectal Injection of Botulinum toxin A|"Botulinum toxin A will be injected during rectoscopy for patient with rectal incontinence.~Anorectal manometry will be performed for evaluation of efficacy of experimental drug"
89550147|NCT02414425|Placebo Comparator|Rectal Injection of physiologic serum|"physiologic serum will be injected during rectoscopy for patient with rectal incontinence.~Anorectal manometry will be performed for evaluation of efficacy of placebo"
89550148|NCT04524143|Other|control group|There was no intervention in the control group during the study (At the end of study all patients were received home-based exercise)
89550149|NCT04524143|Experimental|mobilization group|Cervical mobilization was applied to the mobilization group. Cervical mobilization techniques were applied for 10 minutes in the supine position. (At the end of study all patients were received home- based exercise)
89550150|NCT02414191|No Intervention|Control|Participants in this study arm will receive no form of feedback.
89550151|NCT02414191|Other|Benchmarked Feedback|Participants in this study arm will receive benchmarked feedback regarding their perioperative temperature management.
89550152|NCT02414191|Other|Ranked Feedback|Participants in this study arm will receive ranked feedback regarding their perioperative temperature management.
89550153|NCT05737589||Observation group|This is an observational study, no interventions will be applied to patients in the observation group, and only blood and cerebrospinal fluid ctDNA and TCR data of patients with brain metastases from non-small cell lung cancer treated with radiotherapy will be recorded to predict patient prognosis. Peripheral blood and CSF samples were collected at baseline, 24 h (T0), and 28 days (T28) after completion of radiotherapy and underwent deep sequencing of ctDNA and TCR. The 6-month response rates of brain metastases and systemic lesions were evaluated based on Response Evaluation Criteria in Solid Tumors version 1.1 for further study.
89550154|NCT03116893|Experimental|Reference Treatment|BI 685509 given alone, fasted
89550155|NCT03116893|Experimental|Treatment 1|BI 685509, given alone, after a high fat, high calorie breakfast
89025340|NCT04700670||Group 1|patients with cardiac surgery with CBP. Blood samples in the operating room, 5 to 10 minutes after neutralization of heparin by protamine
89025341|NCT04700670||Group 2|patients who had cardiac surgery with CBP, between day 1 and day 5 after surgery.
89550156|NCT03116893|Experimental|Treatment 2|BI 685509, given together with itraconazole, fasted
89550157|NCT03116893|Experimental|Treatment 3|BI 685509, given together with rifampicin, fasted
89550158|NCT05737511|Experimental|Hydroxyzine|Hydroxyzine (25 mg/day) for eight weeks, the dose of hydroxyzine may be adjusted based on tolerability and clinical judgment, max 100mg/day
89550159|NCT05737511|Active Comparator|Treatment as Usual|Treatment as usual includes the currently approved treatment according to CANMAT and Muadesly guidelines
89550160|NCT03117127|Active Comparator|Whole eggs|After resistance exercise, participants will ingest whole eggs (18 g protein, 17 g fat) cooked in scrambled form.
89025342|NCT04700670||Group 3|hospitalized patients in intensive care unit, including patients on extracorporeal life support (ECLS).
89025343|NCT04700670||Group 4|patients hospitalized in a medical non-intensive care ward.
89025344|NCT00444977|Experimental|Case-management linkage intervention|"The intervention represents a brief, real world intervention that could easily be adopted by HIV care clinics to facilitate linkage and increase use of oral services by their HIV+ patients (if shown to be effective). We are seeking to compare this intervention to usual practice in these clinics."
89025345|NCT00444977|No Intervention|Standard of Care|Subjects will receive standard of care services.
89025346|NCT04700592|Experimental|Gabapentin group|group which receives 600 mg of Gabapentin (two tablets) one hour prior to surgery
89025347|NCT04700592|Experimental|ketamine group|group which receives an injection of ketamine at a dosage of 0.15 mg/Kg before surgery incision
89550161|NCT03117127|Experimental|Egg Whites|After resistance exercise, participants will ingest egg whites (18 g protein, 0 g fat) cooked in scrambled form.
89550162|NCT05737277|Experimental|GABAPRAL|Children with irritative bowel sindrome who received 20 Mld UFC of Bifidobacterium adolescentis PRL 2019 once a day for 12 weeks
89550163|NCT05737277|Placebo Comparator|Placebo|Children with irritative bowel sindrome who received placebo once a day for 12 weeks
89550164|NCT02418637|Experimental|Farm workers|This is a one arm intervention including farm workers and owners
89550165|NCT04187027|No Intervention|the medical care and standard care only group|Group (A) received medical care and standard urotherapy only.
89550166|NCT04187027|Experimental|the medical care and standard care + P.E.M.F group|Group (B) which received the same medical care and standard urotherapy in addition to pulsed electromagnetic field therapy that applied for 20 min, ,three times / weak for three successful months.
89025348|NCT04699526|Experimental|Intervention|Received UPC training, school policy and climate interventions, and Unplugged prevention program
89025349|NCT04699526|No Intervention|Control|Only implemented Unplugged prevention program
89025350|NCT00441909|Experimental|1A|Participants will receive a single application of UC-781 vaginal microbicide, which will be inserted for 8 hours
89025351|NCT00441909|Placebo Comparator|1B|Participants will receive a single application of UC-781 vaginal microbicide placebo, which will be inserted for 8 hours
89550167|NCT03179839|Experimental|Mindfulness-based Cognitive Therapy|MBCT group is a treatment group used mindfulness-based cognitive therapy, and guided by two therapists for 10 sessions. Every collection of about 6-8 patients is a closed structural group. Each session lasts 2.5 hours once a week, and has daily homework assignments.
89550168|NCT03179839|Placebo Comparator|Psycho-education Program|The program is consists of the information and principle of treatment for OCD, group sharing, supporting and discussion.
89550169|NCT03179839|Active Comparator|SSRIs Therapy|This is a control group that can choose to use SSRI drugs which the SFDA approved for the treatment of OCD (Sertraline, Fluvoxamine, initial dose of 50 mg).
89550170|NCT05737043|Placebo Comparator|myocardial performance and epicard thickness in case with polyhidramnios|we will do a fetal echo, and fetal screening with ultrasonography
89550171|NCT05737043|Active Comparator|pregnant women with polyhidramios|
89550172|NCT03135821|Placebo Comparator|10% active Placebo|"Placebo will constitute granules with 10% active core ingredients as below:~White Peony Root 10g Processed Liquorice 3g Immature Bitter Orange 8g White Atractylodes Rhizome 15g~- 2 packets of sachets once before breakfast and once before dinner."
89025352|NCT00441909|Experimental|2A|Participants will receive a single application of UC-781 vaginal microbicide, which will be inserted for 4 hours
89025353|NCT00441909|Placebo Comparator|2B|Participants will receive a single application of UC-781 vaginal microbicide placebo, which will be inserted for 4 hours
89025354|NCT00441909|Experimental|3A|Participants will receive a single application of UC-781 vaginal microbicide, which will be inserted for 2 hours
89025355|NCT00441909|Placebo Comparator|3B|Participants will receive a single application of UC-781 vaginal microbicide placebo, which will be inserted for 2 hours
89025356|NCT00441909|Experimental|4A|Participants will receive a single application of UC-781 vaginal microbicide, which will be inserted for 0 hours
89025357|NCT00441909|Placebo Comparator|4B|Participants will receive a single application of UC-781 vaginal microbicide placebo, which will be inserted for 0 hours
89025358|NCT00445055|Experimental|1|Intravenous injection of 0,625 mg Droperidol, 30 min before the end of anesthesia
89025359|NCT00445055|Experimental|2|Intravenous injection of 2,5 mg Droperidol, 30 min before the end of anesthesia
89025360|NCT00445055|Placebo Comparator|3|Intravenous injection of NaCl 9% (Placebo), 30 min before the end of anesthesia
89550173|NCT03135821|Active Comparator|Traditional Chinese Medication (TCM) Drug A,B,C,D|"Traditional Chinese Medication (TCM) Drug A,B,C,D.~TCM Drug A:~White Peony Root 10g Processed Liquorice 3g Immature Bitter Orange 8g White Atractylodes Rhizome15g~TCM Drug B:~White Peony Root 10g Processed Liquorice 3g Immature Bitter Orange 8g White Atractylodes Rhizome 15g Liver stagnation with heaty transformation: add Scutellaria Root 5g、Prunella Spike 5g~TCM Drug C:~White Peony Root 10g Processed Liquorice 3g Immature Bitter Orange 8g White Atractylodes Rhizome 15g Prominent abdominal pain: White Peony Root to increase to 15g add Bupleurum Root 5g~TCM Drug D:~White Peony Root 10g Processed Liquorice 3g Immature Bitter Orange 8g White Atractylodes Rhizome 15g Hard stools: add Peach Kernel 5g、Areca Seed 5g"
89550174|NCT02418793|Experimental|Dose Cohort 1|Lowest MOD-5014 dose tested in the study
89208044|NCT05147493|Experimental|Single-arm|"Eligible patients will initially receive an induction phase of six 28-day cycles of Isatuximab in combination with Bortezomib, Cyclophosphamide, and Dexamethasone, followed by a maintenance phase with isatuximab and lenalidomide until disease progression, death, unacceptable adverse events (AEs), lost to follow up, or consent withdrawal, whichever occurs first.~Isatuximab will be given at a dose of 10 mg/kg once weekly (QW) on Days 1, 8, 15, and 22 in Cycle 1, on Days 1 and 15 during Cycles 2-6 and on Day 1 from Cycle 7 onwards.~Bortezomib will be given at 1.3 mg/m2 on Days 1, 4, 8, 11 of Cycle 1 and days 1, 8, 15, 22 of Cycles 2-6.~Cyclophosphamide will be given at 300 mg/m2 on Days 1, 8, 15 of Cycle 1 and days 1, 8, 15, 22 of Cycles 2-6.~Dexamethasone will be given at 40 mg (20 mg for ≥75 years old) on Days 1-4 and 9-12 of Cycle 1 and Days 1, 8, 15 and 22 of Cycles 2-6.~Lenalidomide will be given at 10 mg (or according to renal function) daily from Cycle 7 onwards."
89550175|NCT02418793|Experimental|Dose Cohort 2|MOD-5014 Dose cohort 2
89550176|NCT02418793|Experimental|Dose Cohort 3|MOD-5014 Dose cohort 3
89550177|NCT02418793|Experimental|Dose Cohort 4|MOD-5014 Dose cohort 4
89550178|NCT02418793|Experimental|Dose Cohort 5|MOD-5014 Dose cohort 5
89550179|NCT02418793|Experimental|Dose Cohort 6|Highest MOD-5014 dose tested in the study
89550180|NCT03136601|Active Comparator|PTNS monthly|Patients return for PTNS maintenance monthly.
89550181|NCT03136601|Experimental|PTNS as needed|Patients return for PTNS as needed (2-12 weeks).
89550182|NCT05736887|Experimental|N-Acetylcysteine arm|Subjects with recent history of COVID-19 infection randomized to receive N-Acetylcysteine.
89550183|NCT05736887|Placebo Comparator|Placebo arm|Subjects with recent history of COVID-19 infection randomized to receive placebo.
89550184|NCT04074083|Experimental|Intervention electronic IMCI group|15 primary health care clinics will be randomly allocated to intervention group. One IMCI trained HW will be selected in each intervention facility to be trained in electronic IMCI.
89550185|NCT04074083|Active Comparator|Control paper IMCI group|15 primary health care clinics will be randomly allocated to the control group. One IMCI trained HW will be selected in each control facility to receive an IMCI update (designed to mirror eIMCI training).
89550186|NCT02703337|Experimental|LY900014 (Part A)|Individualized doses of LY900014 administered by injection under the skin once in each of 3 periods
89550187|NCT02703337|Active Comparator|Insulin Lispro - Reference (Part A)|Individualized doses of insulin lispro reference formulation administered by injection under the skin once in each of 3 periods
89550188|NCT02703337|Experimental|LY900014 (Part B)|Individualized doses of LY900014 administered by injection under the skin with each meal for 14 days
89550189|NCT02703337|Active Comparator|Insulin Lispro - Reference (Part B)|Individualized doses of insulin lispro reference formulation administered by injection under the skin with each meal for 14 days
89550190|NCT03110081|Experimental|Quadratus lumborum block|Quadratus lumborum (QL) block group will receive a single shot injection of 25 ml 0.25% bupivacaine pre-operatively, followed post-operatively by infusion of ropivacaine 0.2% continuously administered via the QL catheter for at least 48 hours.
89550191|NCT03110081|Active Comparator|Epidural analgesia|Midthoracic catheters will be inserted preoperatively. A bupivacaine 0.1% infusion will be started before the surgical incision, and continuously administered for at least 48 hr at an infusion rate of 5 ml/hr.
89550192|NCT05736809|Experimental|Low-Dye taping|out of 21 participants 7 will be included in the study design as an experimental group using low-dye taping in acute stage
89550193|NCT05736809|Active Comparator|Plantar fascia stretching|out of 21 participants 7 will be included in the study design as an active participants group using plantar fscia stretching in acute stage
89550194|NCT05736809|Placebo Comparator|Sham taping|out of 21 participants 7 will be included in the study design as an active participants group using plantar fscia stretching in acute stage
89550195|NCT02418715|Experimental|Water Aerobics Training|The training period was composed by a 12-week macrocycle with two sessions per week. The macrocycle was divided into three four-week mesocycles that were, in turn, divided into four one-week microcycles composed by two training sessions. Each training session took 45 min. Nine different water-aerobics exercises were used during the training period. These exercises were performed alternating the right and left limbs. Exercise intensities were controlled using the Borg Scale. Interval training was used alternating intensities ranged between 9 (easy) and 15 (hard). During the first mesocycle, participants performed sets of 3min at intensity 13 interspersed by 2min at intensity 9; during the second mesocycle, sets of 3min at intensity 15 followed by 2min at intensity 9 were performed; finally, sessions of the third mesocycle were composed by sets of 3min at intensity 15 followed by 2min at intensity 11.
89550196|NCT02418715|No Intervention|Control|No training, no intervention.
89550197|NCT02414113||Low GNOS donors|
89550198|NCT02414113||High GNOS donors|
89550199|NCT03976895|Other|Supine position (SP)|Supine position (SP) combined with HFNC
89550200|NCT03976895|Experimental|Prone position (PP)|Prone position (SP) combined with HFNC
89550201|NCT02413723|Active Comparator|Videolaryngoscope McGrath Mac|McGrath Mac videolaryngoscope will be used for laryngoscopy for patient's intubation
89550202|NCT02413723|Placebo Comparator|Standard laryngoscope|Macintosh laryngoscope will be used for laryngoscopy for patient's intubation
89550203|NCT03179683|Active Comparator|Diode laser application|An 630-660 nm aluminum gallium indium phosphide (AlGalnP) laser device (Scorpion Dental Optima Model 405-7A; Optica Laser, Sofia, Bulgaria) was used immediately after surgery, third day, fifth day and seventh day only for one operation side (treatment group)
89550204|NCT03179683|No Intervention|No application|no treatment were aplied
89550205|NCT02418559|Experimental|JNJ-63623872 (300 mg) or Placebo|Participants will receive JNJ-63623872 300 milligram (mg) or placebo tablet orally once on Day 1 under fasted conditions.
89550206|NCT02418559|Experimental|JNJ-63623872 (600 mg) or Placebo|Participants will receive JNJ-63623872 600 mg (2*300 mg) or placebo tablet orally once on Day 1 under fasted conditions.
89550207|NCT02418559|Experimental|JNJ-63623872 (1200 mg) or Placebo|Participants will receive JNJ-63623872 1200 mg (4*300 mg) or placebo tablet orally once on Day 1 under fasted conditions.
89550208|NCT03135665|Other|ScoE|This is a cross-sectional study on screened school children recommended for radiographic assessment in the scoliosis screening program of SHS in Hong Kong. Both x-ray, ultrasound and ATR measurement of the spine will be performed on the same day at Prince of Wales Hospital.
89550209|NCT02413645|Other|100 μg TriMix mRNA (TriMix_100)|"Cohort 1 (control group) 3 patients will receive 100 μg of mRNA (i.e. 100 μg TriMix mRNA).If two or more of the three patients have a dose limiting toxicity (DLT), DSMB should be consulted and study will be terminated. If one or no patients have a dose limiting toxicity, three patients will be enrolled at the next dose level.~Each patient will receive 3 immunizations (at weeks 0, 2 and 4)."
89550210|NCT02413645|Other|300 μg TriMix mRNA (TriMix_300)|"Cohort 2 (control group) 3 patients will receive 300 μg of mRNA (i.e. 100 μg TriMix mRNA).If two or more of the three patients have a DLT, DSMB should be consulted and study will be terminated. If one or no patients have a dose limiting toxicity, three patients will be enrolled at the next dose level.~Each patient will receive 3 immunizations (at weeks 0, 2 and 4)."
89550211|NCT02413645|Experimental|600μg mRNA (300 μg HIV mRNA+300 μg TriMix mRNA)|"Cohort 3 (experimental group) 3 patients will receive 600 μg of mRNA (300 μg HIV mRNA + 300 μg TriMix mRNA). If two or more of the three patients have a DLT, DSMB should be consulted and study will be terminated. If one or no patients have a dose limiting toxicity, three patients will be enrolled at the next dose level.~Each patient will receive 3 immunizations (at weeks 0, 2 and 4)."
89550212|NCT02413645|Experimental|900μg mRNA (600 μg HIV mRNA+300 μg TriMix mRNA)|"Cohort 4 (experimental group) 3 patients will receive 900 μg of mRNA (i.e. 600 μg HIV mRNA and 300 μg TriMix mRNA). If two or more of the three first patients have a DLT, then additional three patients will be enrolled at the previous level dose (dose will be reduced to 600 μg of mRNA per vaccination). If one or no patients have a DLT, additional three patients will be enrolled at 900 μg dose level. If two or more of the six patients receiving 900 μg of mRNA have a DLT, then additional 3 patients will be enrolled at the previous level dose (dose will be reduced to 600 μg of mRNA per vaccination). If one or no patients of the six patients have a DLT, six patients will be enrolled at the next dose level.~Each patient will receive 3 immunizations (at weeks 0, 2 and 4)."
89550213|NCT02413645|Experimental|1200μg mRNA(900 μg HIV mRNA+300 μg TriMix mRNA)|"Cohort 5 (experimental group) 6 patients will receive 1200 μg of mRNA (i.e. 900 μg HIV mRNA + 300 μg TriMix mRNA) in case one or no patients of the six patients at the previous dose level have a DLT.~Each patient will receive 3 immunizations (at weeks 0, 2 and 4)."
89550214|NCT03116815|Other|Intervention|Intervention is the use of the MyChart web-application whereby participants record their home blood pressure readings directly into their electronic medical record. Their physicians are then alerted of these blood pressure readings.
89550215|NCT03200483|Experimental|Control Protocol|The volunteer will perform the exercise and recovery exposed to silence
89550216|NCT03200483|Experimental|Classical Music Protocol|The volunteer will perform the exercise and recovery exposed to classical music
89550217|NCT03200483|Experimental|Rock Music Protocol|The volunteer will perform the exercise and recovery exposed to rock musical style
89550218|NCT02418403|Active Comparator|PREPARE|"Access to Prepare for Your Care website and written encouragement to discuss ACP with one's PCP."
89550219|NCT02418403|Experimental|PREPARE+financial incentive|"Access to Prepare for Your Care website and written encouragement to discuss ACP with one's PCP; offer of $50 to complete the website and entry into $1000 lottery for discussing ACP with one's PCP."
89550220|NCT02418247|Active Comparator|low dose RAI|Low dose RAI (radioactive iodine I-131, 30mCi) will be given to ablate remnant thyroid tissue.
89550221|NCT02418247|Sham Comparator|diagnostic RAI|Diagnostic RAI (radioactive iodine I-123, 2-6mCi) will be given to achieve postRAI scan.
89550222|NCT04483219|Experimental|TKI ± anti-PD-1 antibody|According to response to TKI, the combination of anti-PD-1 treatment would be determined.
89550223|NCT03975179|Experimental|Frozen section omission|Intraoperative frozen section biopsy of resection margin will not be performed
89550224|NCT03975179|Active Comparator|Frozen section|Intraoperative frozen section biopsy of resection margin will be performed. Margin evaluation of superior, medial, lateral, inferior margin is recommended but will follow surgeon's discretion.
89550225|NCT02413957|No Intervention|Controll-Group|Patient randomized to the Control-Group will receive the traditional care by physician and nurse on the ward.
89550226|NCT02413957|Experimental|MedRec-Group|Patient randomized to the MedRec-Group will receive the traditional care by physician and nurse on the ward and additional pharmacist led medication reconciliation.
89550227|NCT02413957|Experimental|AMTS-Group|Patient randomized to the AMTS-Group will receive the traditional care by physician and nurse on the ward and additional pharmaceutical care by a pharmacist.
89550228|NCT03176563||Women treated with the herbal drug Uva Ursi|Patients of the clinical trial REGATTA (NCT03151603) who have been randomized in the Uva Ursi arm.
89550229|NCT03176563||Women treated with antibiotics|Patients of the clinical trial REGATTA (NCT03151603) who have been randomized in the fosfomycin arm.
89550230|NCT03955835|Other|ACUTE|Patients with acute ischemic stroke and proven large vessel occlusion (e.g. intracranial internal carotid artery or middle cerebral artery) with unsuccessful recanalization after endovascular treatment with mechanical thrombectomy and suspected underlying stenosis of the occluded intracranial artery amenable to stenting based on judgment by the treating neurointerventionalist.
89550231|NCT03925961|No Intervention|control arm|All subjects in the control arm will receive the current preoperative and post operative instructions.
89550232|NCT03925961|Experimental|'education booklet' arm|All subjects in the 'education booklet' arm will receive the current standard Johns Hopkins Community Physicians Surgery packet and the Patient Information Booklet, specific to participants' surgery
89550233|NCT03925961|Experimental|'education booklet and preoperative' arm|All subjects in the 'education booklet and preoperative' arm will receive the current standard Johns Hopkins Community Physicians Surgery packet and the Patient Information Booklet, specific to participants' surgery. Those subjects randomized to the 'education booklet and preoperative' arm will receive a pre-operative phone call by the research study's lead nurse, Catherine Davidson, approximately 1 week after participants enroll in the study. She will review pre-operative and post-operative guidelines pertinent to participants' operative as outlined in the patient information booklet. The amount of time (in minutes) that this phone call takes will be recorded in an excel file sheet.
89550234|NCT03176485|Experimental|ArmA: With Solar Simulated Light Exposure|
89550235|NCT03176485|Experimental|ArmB: With Solar Simulated Light Exposure (Vemurafenib/Dabraf)|Subjects in this study arm undergo the same procedures as Arm A, with the addition of a blood test for the presence of porphyrins
89550236|NCT03176485|No Intervention|ArmC: Without Solar Simulated Light Exposure|
89550237|NCT03176251|Active Comparator|Control Group: Conventional Training Group|This group will receive 4 hours of didactic and hands-on sessions on colonoscopy theory and non-technical skills. Participants will also watch a video that demonstrates an ideal endoscopic procedure. After each didactic session, a short multiple-choice questionnaire based on the topics covered in that session will be administered. In addition to didactic training, the control group will be given six hours of expert-assisted instruction on low-fidelity (1 hour) and high-fidelity (5 hours) colonoscopy simulators. Six modules of increasing difficulty in colonoscopy will be taught using one-on-one feedback from an expert academic endoscopist. The endoscopy instructor will demonstrate techniques and provide feedback. During training on the high-fidelity simulator, the last two hours will take the form of the integrated scenario, which will feature a standardized patient (SP) and standardized nurse (SN). Feedback will be given after each integrated scenario by the instructor.
89550238|NCT03176251|Experimental|Intervention Group: Gamified-Integrated Curriculum (GIC)|The intervention group will receive the same core training as the control group with additional elements of gamification: leaderboards and badges. First, leaderboards will be used to track and rank participants' performances. This will be done through an anonymized ID tag that allows a participant to identify only their position on the leaderboard. This leaderboard will include 4 components: non-technical skills, technical skills, cognitive skills, and overall ranking. Scores will be aggregated only from participants training on the same days. The leaderboard will be displayed on a central laptop and/or TV screen and will be accessible at any time throughout the day. Second, participants in the GIC group will have the opportunity to be rewarded for their performances using achievement badges which are visual cues to the player that he or she has achieved something. Awards will be given to participants at the top of the leaderboard and with the most badges.
89550239|NCT03909503|Experimental|Porcine-derived collagen wound dressing|The dressing is a sheet of collagen composed of type I collagen derived from porcine peritoneal membrane. The dressing also contains additional components from the procine extracellular matrix. The dressing is a currently marketed, cleared device in the United States indicated for the management of full- and partial-thickness wounds, including: pressure ulcers, diabetic ulcers, venous ulcers, and several other wound types.
89550240|NCT05088551|No Intervention|Control group|When the patients were admitted to the clinic,and the face-to-face interview method and the Patient Information Form,Turkey Health Literacy Scale-32,Patient Learning Needs Scale,Functional Assessment Form and Quality of Life Scale Form were filled.The second interview was conducted on the second or third day after the surgery, just before the patients were discharged.The Functional Assessment Form,Discharge Data Collection Form, and Quality of Life Questionnaire were applied.The third interview was performed 15 days after the surgery when the patients came for control or by phone.The 15th Day Recovery Process Data Collection Form were applied.The last interview was carried out six weeks after the surgery,either face-to-face or by phone,and the Functional Assessment Form,6th Week Post-Discharge Recovery Process Data Collection Form,and Quality of Life Questionnaire were applied again.Except for the routine practices of the service,no intervention was made to the control group patients.
89550241|NCT05088551|Experimental|Intervention group|Unlike the control group, the intervention group was given the education plan prepared by the researcher after filling out the forms when the patients were first encountered, and the education was carried out using various training methods such as lecture, question-answer, demonstration, and practice.Patients whose check-up time after discharge was nearing (15 days after the operation) were called a few days before and their visit time was learned. The forms were filled in by interviewing the patients face-to-face by the researcher on the 15th day and the 6th week after the operation or making a phone call on the same day with the patients who could not be reached.
89025361|NCT02957201|Other|Blood samples|Blood samples taken at baseline, day 1-2, day 3-4 and day 7-8 for Endothelial Progenitor Analysis with flow cytometer
89025362|NCT00479739|Experimental|Arm 1|
89025363|NCT03277820|Experimental|Probiotic group|Intake of 1 portion (=6 droplets) Probactiol Mini during 4 weeks.
89025364|NCT03277820|No Intervention|Control group|No intake of Probactiol Mini
89025365|NCT00442026|Experimental|1|DG
89025366|NCT00442026|Experimental|2|G
89025367|NCT00479895|Other|1|Occlusion with pre-oxygenated HBOC-201 followed by dry occlusion
89025368|NCT00479895|Other|2|Dry occlusion followed by occlusion with pre-oxygenated HBOC-201
89025369|NCT00442065|Active Comparator|Open label, single arm|A prospective, open label, single-arm (non-randomized) multi-center, international clinical device investigation to collect safety and performance data concerning the Aorfix™ Stent Graft System in the treatment of abdominal aortic aneurysm and aorto-iliac aneurysm where a significant degree of vessel angulation exists
89025370|NCT03279120|Experimental|TFV/LNG IVR (8-10mg/20μg) (Continuous)|TFV/LNG IVR is an intravaginal ring 55.0 mm in diameter, consisting of two segments of polyurethane tubing with an outer cross-sectional diameter of 5.5 mm: a longer segment (135 mm) containing white to off-white TFV paste and a shorter one (34 mm) with a translucent LNG core. Used for 90 days (continuous).
89550242|NCT02418325|Experimental|AllogeneicHumanUmbilicalCordTissue-DerivedMesenchymalStemCells|Super selective intravenous administration of 50 million Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (UC-MSC) and intrathecal administration of UC-MSCs in dose of 100 million along with liberation therapy (when associated with CCSVI)
89550243|NCT03877133|Other|Regional oxygen saturation group|Near-infrared spectroscopy application to the skin near the kidney
89550244|NCT02418481|Experimental|Group A|DC-CIK cells will be used against tumor cells.
89550245|NCT02418481|Experimental|Group B|γδ T cells will be used against tumor cells.
89550246|NCT02418481|Experimental|Group C|Combination of γδ T cells/ DC-CIK be used against tumor cells.
89550247|NCT03827447|Active Comparator|Drug: Vancomycin Group|Subjects will receive oral vancomycin capsules by mouth, 125 mg every 6 hours for 14 days.
89550248|NCT03827447|Placebo Comparator|Drug: Placebo Group|Subjects will receive a placebo oral capsule by mouth every 6 hours for 14 days. The placebo oral capsule is manufactured by Study Site's pharmacy to be identical in size, shape, color, appearance and taste as the drug comparator
89550249|NCT02418169||retrospective, severe traumatic brain injury|All patients in 2010-2014 with severe traumatic brain injury admitted to Turku University Central Hospital (TUCH)
89550250|NCT02418169||retrospective, craniofacial fracture|All patients in 2010-2014 with craniofacial fracture admitted to TUCH.
89550251|NCT02418169||prospective, severe traumatic brain injury|All patients in 2015-2017 with severe traumatic brain injury admitted to Turku University Central Hospital (TUCH)
89550252|NCT02418169||prospective, craniofacial fracture|All patients in 2015-2017 with craniofacial fracture admitted to TUCH.
89550253|NCT01680497|Experimental|JUVÉDERM VOLIFT™|All subjects receiving treatment with JUVÉDERM VOLIFT™.
89550254|NCT02423473|Active Comparator|Connective tissue graft (CTG)|After local anesthesia, the surgical procedure performed was the trapezoidal-type of CAF (de Sanctis & Zucchelli, 2007). After the flap was raised, the exposed root surface was gently scaled and planed until it became smooth. Afterward, a thin and small connective tissue graft that was sutured over the root surface. Then, the flap was coronally positioned and sutured to completely cover the graft.
89550255|NCT02423473|Experimental|Connective tissue graft plus composite resin restoration.|After local anesthesia, the surgical procedure performed was the trapezoidal-type of CAF (de Sanctis & Zucchelli, 2007). After the flap was raised, a sterile rubber dam was placed to isolate the operative field and the non-carious cervical lesion restoration was performed with a nanocomposite resin (Filtek Supreme - 3M ESPE - St. Paul, MN, USA), following the manufacturer's instructions. Afterward, a thin and small connective tissue graft that was sutured over the restoration surface. Then, the flap was coronally positioned and sutured to completely cover the graft.
89550256|NCT02417857|Experimental|Laparoscopic Cholecystectomy (SILC)|Group 1: Single Incision Laparoscopic Cholecystectomy (Intervention)
89550257|NCT02417857|Experimental|Laparoscopic Cholecystectomy (CLC)|Group 2: Conventional Laparoscopic Cholecystectomy (Intervention)
89550258|NCT02423395|Experimental|Orphenadrine(Norflex)|50 patients will be treated with orphenadrine 100 mg twice daily for 1 month
89550259|NCT02423395|Placebo Comparator|Placebo|50 patients will be given placebo
89550260|NCT05712083|Experimental|Treatment Group|This is a single arm clinical trial.
89550261|NCT02418091|Experimental|Intervention Telehealth|Using Telehealth to slow progression of diabetic kidney disease automated population program identifies patients and engages them to optimize DKD medication adherence and health behaviors using 2-way communication via patient-selected technology (mobile/web-based applications, text messaging, interactive voice response, or e-mail) backed by case management via the phone for suboptimal control or health status. The STOP-DKDAutomated Population Program will deliver a tailored, multi-factorial intervention to address medication self-management and modify multiple risk factors simultaneously through a combination of patient self-monitoring, behavioral therapies and education that optimize adherence and self-efficacy.
89550262|NCT02418091|No Intervention|Control/No Intervention|Group of subjects that will serve as a comparison group. These subjects will not be approached/enrolled for this study.
89550263|NCT05711147|Experimental|Definitive abutment|Definitive prosthetic abutment placed at the moment of implant placement
89550264|NCT05711147|Active Comparator|Healing abutment|Conventional healing abutment placed at the moment of implant placement and removed 4 times during prosthesis making
89550265|NCT05694689|Active Comparator|Usual care plus placebo|Infants will receive placebo (normal saline) in the first 28 days after birth. Co-interventions will be unaffected and provided based on the judgment of the attending neonatal faculty and NICU policies and routine practices.
89025371|NCT03279120|Experimental|TFV/LNG IVR (8-10mg/20μg) (Interrupted)|TFV/LNG IVR is an intravaginal ring 55.0 mm in diameter, consisting of two segments of polyurethane tubing with an outer cross-sectional diameter of 5.5 mm: a longer segment (135 mm) containing white to off-white TFV paste and a shorter one (34 mm) with a translucent LNG core. Used for 90 days (3x28 days interrupted).
89550266|NCT05694689|Experimental|Usual care plus vitamin D supplementation|Infants will receive cholecalciferol 800 IU/day in the first 28 days after birth, given enterally four times per day (0.5mL per dose = 200 IU) until the infant is provided 400 IU/day. At that point the study cholecalciferol will be reduced to 400 IU/day for a total supplementation of 800 IU/day.
89550267|NCT02423239|Experimental|Relapsed or refractory advanced tumours|Patients with selected relapsed or refractory tumour types to receive single agent dexanabinol.
89550268|NCT02423239|Experimental|Newly diagnosed hepatocellular carcinoma|Patients with hepatocellular carcinoma to receive dexanabinol in combination with standard chemotherapy.
89550269|NCT02423239|Experimental|Newly diagnosed pancreatic cancer|Patients with pancreatic cancer to receive dexanabinol in combination with standard chemotherapy
89550270|NCT02449733|Experimental|HIV+ subjects|Men who test positive for HIV will receive a comprehensive package of HIV prevention services, including condom choices, condom-compatible lubricant choices, risk-reduction counseling, couples HIV counseling and testing, and linkage to care
89025372|NCT03279120|Placebo Comparator|Placebo (Continuous)|Intravaginal ring 55.0 mm in diameter, consisting of two segments of polyurethane tubing with an outer diameter of 5.5 mm containing no active experimental ingredients. Used for one month. Used for 90 days (continuous).
89025373|NCT03279120|Placebo Comparator|Placebo (Interrupted)|Intravaginal ring 55.0 mm in diameter, consisting of two segments of polyurethane tubing with an outer diameter of 5.5 mm containing no active experimental ingredients. Used for one month. Used for 90 days (3x28 days interrupted).
89550271|NCT02449733|Experimental|HIV- subjects|"Men who test negative for HIV will receive a comprehensive package of HIV prevention services, including condom choices, condom-compatible lubricant choices, enhanced HIV testing options, risk-reduction counseling, couples HIV counseling and testing, linkage to care, and screening for and offering of pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP).~If men test positive for HIV during the study, they will be transitioned into the HIV+ subjects arm."
89550272|NCT03176329|Other|INTELLIVENT-ASV / Conventional mode|Full closed-loop ventilation control (INTELLIVENT-ASV) is set 30 minutes before Nursing 1 after randomization. Ventilator is switch to conventional ventilation 30 minutes before Nursing 2
89550273|NCT03176329|Other|Conventional mode / INTELLIVENT-ASV|Conventional ventilation control is set 30 minutes before Nursing 1 after randomization. Ventilator is switch to full closed-loop ventilation (INTELLIVENT-ASV) 30 minutes before Nursing 2.
89550274|NCT05082493|Experimental|Berubicin HCL - MTD phase|Berubicin will be administered as 1-hour infusions each day for 3 consecutive days followed by 18 days off drug (ie, 21-day cycles). The starting dose is based on population PK modeling of data from adult studies and will be 1.20 mg/m2 (Dose Level 1). During the study, PK data will be incorporated into a PK model on an ongoing basis and may be used to inform dose escalation decisions
89550275|NCT02418013|Experimental|Fresh cord blood(experimental group A)|16 males and 16 females are assigned to the experimental group A. Dropout is 20 percent in each gender.
89550276|NCT02418013|Experimental|Frozen cord blood(experimental group B)|16 males and 16 females are assigned to the experimental group B. Dropout is 20 percent in each gender.
89550277|NCT02418013|Experimental|Frozen plasma(experimental group C)|16 males and 16 females are assigned to the experimental group C. Dropout is 20 percent in each gender.
89550278|NCT02418013|Placebo Comparator|Placebo group|16 males and 16 females are assigned to the Placebo group. Dropout is 20 percent in each gender. Total participants are 64 in males and 64 in females.
89550279|NCT05377775|Experimental|Conventional Implantation of mesh stent|Conventional Implantation of mesh stent in iliac stenosis with high-risk plaques
89550280|NCT02413411|Experimental|DA/MI Intervention|Patients randomized to the DA/MI intervention arm will be shown a decision aid video entitled, Treatment Choices for Knee Osteoarthritis. Following the viewing of the decision aid video, the participant will be engaged in a motivational interview by the research study interventionist.
89550281|NCT02413411|Active Comparator|Attention Control|Patients randomized to the attention control arm will receive an educational program (an NIH-developed booklet) that summarizes how to live with knee OA but does not specifically mention joint replacement. This booklet provides examples of exercises one could do to improve pain and reduce stiffness from knee OA.
89550282|NCT01826591|Experimental|Experimental: Low-Carbohydrate Diet|Healthy, Low-Carbohydrate Diet
89550283|NCT01826591|Experimental|Experimental: Low-Fat Diet|Healthy, Low-Fat Diet
89550284|NCT05377931||Normal subjects users of battle ground games (Group 1)|Subjects with no history of any medical diseases that are using mobile battle ground games for average 2 hours per day.
89550285|NCT05377931||Post COVID-19 users of battle ground games (Group 2)|Adults with a recent history of COVID-19 (average of 6 months after onset of the disease) that returned to their normal life style and are using mobile battle ground games.
89550286|NCT05377931||Normal subjects not playing mobile games (Groups 3)|Normal subjects that are not using any action mobile games.
89550287|NCT02417623|Experimental|Smartphone intervention group|The experimental group will receive the standard diet intervention for weight loss plus free Smartphone app plus a wearable device.
89550288|NCT02417623|No Intervention|Control group|Control group will receive a 12-month weight loss programmed that implements recommendations of a Clinical Practice Guideline
89550289|NCT02422849|Other|own GP|The patient is cared for by own General Practitioner in the acute stage
89025374|NCT04699760|Placebo Comparator|Placebo|Nutritional supplement without fish oil
89025375|NCT04699760|Active Comparator|Fish oil|Nutritional supplement with fish oil
89025376|NCT00479934|Experimental|1|6 month treatment with Imtinib 400mg/day
89550290|NCT02422849|Other|Hospital specialist|The patient is cared for by a hospital specialist in the acute stage
89550291|NCT02417467|Experimental|Nicotine E-Cigarette and Counseling|"As with standard nicotine replacement therapies, participants are expected to self-regulate administration of nicotine e-cigarettes according to their withdrawal symptoms. The manufacturer recommends each vaping session to last approximately 10 puffs, with one puff every 30 seconds over a span of approximately 4.5 minutes.~Smoking cessation/relapse prevention counselling will be provided for a minimum of 30 minutes at baseline, 10 minutes during telephone follow-ups, and 15 minutes at clinic visits (20 minutes at week 4). Counselling will consist of a number of approaches, including reviewing smoking history, development/revision of a quit plan, encouragement of self-monitoring, review of triggers and challenges, and skill development."
89550292|NCT02417467|Other|Non-Nicotine E-Cigarette and Counseling|"Participants are expected to self-regulate administration of e-cigarettes. The manufacturer recommends each vaping session to last approximately 10 puffs, with one puff every 30 seconds over a span of approximately 4.5 minutes.~Smoking cessation/relapse prevention counselling will be provided for a minimum of 30 minutes at baseline, 10 minutes during telephone follow-ups, and 15 minutes at clinic visits (20 minutes at week 4). Counselling will consist of a number of approaches, including reviewing smoking history, development/revision of a quit plan, encouragement of self-monitoring, review of triggers and challenges, and skill development."
89550293|NCT02417467|Other|Counseling|Smoking cessation/relapse prevention counselling will be provided for a minimum of 30 minutes at baseline, 10 minutes during telephone follow-ups, and 15 minutes at clinic visits (20 minutes at week 4). Counselling will consist of a number of approaches, including reviewing smoking history, development/revision of a quit plan, encouragement of self-monitoring, review of triggers and challenges, and skill development.
89025377|NCT00479934|Placebo Comparator|2|6 month treatment with Placebo 400mg/day
89208045|NCT00573534|Experimental|Open Label Vyvanse|Open Label Vyvanse (lisdexamphetamine) in doses of 30-70 mgs over 8 weeks in younger siblings of substance abusing older siblings with a history of treatment for ADHD
89550294|NCT02422771|No Intervention|Control group|Athletes in this group will continue with their usual warm-up for the duration of the indoor soccer season.
89550295|NCT02422771|Experimental|Intervention group|FIFA 11+ warm-up
89550296|NCT03199937|Experimental|Flexible Futures|Flexible Futures uses cognitive behavioral therapy (CBT) techniques to target flexibility and planning by teaching core skills through personal goals chosen by students during treatment. Flexible Futures focuses on key functions needed for college success, such as: intrinsic motivation, how to implement skills socially, how thoughts and feelings affect planning and flexibility, self-advocacy skills necessary to promote independence, application of flexibility and organization scripts and strategies in the service of a long-term goal, and management of time and priorities. Guided practice begins with concrete interventionist support, and moves to interventionist cueing, self-cueing, and finally automatic use of the skills without support. Generalization is maximized with school staff as interventionists, parent training, home and classroom extension activities, and role-playing use of strategies in novel situations. Motivation is developed using student choice and natural motivators.
89550297|NCT03199937|Active Comparator|Waitlist control group|Current standard of care
89550298|NCT02422927|Placebo Comparator|Standard of Care + Placebo|low-cholesterol/low-saturated fat diet and a regular aerobic physical activity schedule + once daily placebo
89550299|NCT02422927|Active Comparator|Nutraceutical combination|low-cholesterol/low-saturated fat diet and a regular aerobic physical activity schedule + Nutraceutical combination
89550300|NCT02423005|Experimental|Neurotech Vital Compact|The Neurotech Vital Compact will be used by subjects with Stress Urinary Incontinence 5 days per week for 30 minutes per session for 12 weeks followed by 14 weeks of Kegel exercises.
89550301|NCT02423005|Active Comparator|itouch Sure Pelvic Floor Exerciser|The itouch Sure Pelvic Floor Exerciser will be used by subjects with Stress Urinary Incontinence 7 days per week for 20 minutes per session for 12 weeks followed by 14 weeks of Kegel exercises.
89550302|NCT03199703|Active Comparator|Baylis transseptal system group|Patients randomized to the Baylis transseptal system group (Bayliss Group) will undergo transseptal puncture with a large, preformed curve 71-cm-C1 or 98-cm-C1 18-gauge NRG needle (Baylis Medical) through a TorFlex sheath (Baylis Medical), with the sheath curve selected at the discretion of the operating physician.
89025378|NCT03274778|Experimental|Ruxolitinib|Oral administration of Ruxolitinib 20mg BID for 28 consecutive days
89025379|NCT03274700|Active Comparator|Group 1: Patients receive tamsulosin|"Patients who will receive tamsulosin as a treatment for lower ureteric stones from (10-15)mm up to 8 weeks duration.e foll The cases will be followed up as thowing:~In the first month: abdominal ultrasonography every week, KUB abdomen and pelvis for radiopaque stones.~At the end of the second month: abdominal ultrasonography, KUB abdomen and pelvis for radiopaque stones.~At the end of the third month: abdominal ultrasonography, KUB abdomen and pelvis for radiopaque stones, MSCT abdomen and pelvis for radiolucent stones."
89550303|NCT03199703|Active Comparator|Conventional transseptal group|Patients randomized to the conventional transseptal group (Standard Group) will undergo transseptal puncture with either a large, preformed curve 71- or 98-cm 18-gauge BRK needle (BRK, BRK-1, BRK-2 needle, St. Jude Medical) through any non-Baylis sheath (for example Schwartz SL, Biosense-Webster Preface) selected at the discretion of the operating physician.
89550304|NCT05233501|Sham Comparator|non-surgical perıodontal treatment|
89550305|NCT05233501|Experimental|non-surgical treatment+ low level laser therapy|
89550306|NCT03199781|Experimental|Intervention of mechanical massage with cosmetics|Patients will be treated with motorized mechanical massage and associated with cosmetics with lipolytic active principle, being performed twice a week totaling 10 sessions by a dermato-functional physiotherapist.
89550307|NCT02413177|Active Comparator|EEG-RTNF|Group 1 will receive EEG-RTNF training from the PCC. They will attend an 8 week MBSR class. This feedback will occur at weeks 3, 4, 6 and 7.
89550308|NCT02413177|Active Comparator|EEG-no RTNF|Group 2 will receive EEG (no RTNF feedback). They will attend an 8 week MBSR class. This feedback will occur at weeks 3, 4, 6 and 7.
89550309|NCT02413099|Experimental|KBMSI-2 6gm|Patients were instructed to take investigational products (KBMSI-2 6g) twice a day for 8weeks at least 1 hour after food intake
89550310|NCT02413099|Placebo Comparator|Placebo|Patients were instructed to take placebo twice a day for 8weeks at least 1 hour after food intake
89550311|NCT02607449|Experimental|A|Standard TB treatment+ treatment regiment with FS-1 drug. Study drug was given to the patients orally once per day in dose of 2.5 mg/kg along with other prescribed TB drugs.
89550312|NCT02607449|Placebo Comparator|B|Standard TB treatment + treatment regiment with a placebo. Instead of study drug the placebo was given to the patients orally once per day along with other prescribed TB drugs (in quntity equal to study drug).
89550313|NCT02417389|Experimental|cinacalcet|Phase 1 (12 months): all patients treated with cinacalcet alone; Phase 2 (12 months): all patients treated with cinacalcet plus alendronate
89550314|NCT04928963|Experimental|Fasting mimicking diet|Fasting mimicking diet will be provided with all food to be consumed during each of the 2 cycles. The components of the diet will be approximately 30% calorie restricted and 50% protein restricted but supplemented with 50% of the RDA in vitamins and minerals and also supplemented with both nonessential and essential amino acids identified in animal studies to be effective.
89550315|NCT04928963|Placebo Comparator|Placebo diet|One meal which substitute or lunch or dinner for 5 days, without calories restriction.
89025380|NCT03274700|Placebo Comparator|Patients receive placebo.|"Patients who will receive placebo up to 8 weeks duration.The cases will be followed up as following:~In the first month: abdominal ultrasonography every week, KUB abdomen and pelvis for radiopaque stones.~At the end of the second month: abdominal ultrasonography, KUB abdomen and pelvis for radiopaque stones.~At the end of the third month: abdominal ultrasonography, KUB abdomen and pelvis for radiopaque stones, MSCT abdomen and pelvis for radiolucent stones."
89025381|NCT00479973|Active Comparator|Cinnamonforce|Cinnamonforce™ is a proprietary blend of Cinnamomum aromaticum and Cinnamomum verum bark containing 47 mg of hydroethanolic extract (min. 8% total phenolics) and 23 mg supercritical extract (min. 35% cinnamaldehyde) per capsule.
89025382|NCT00479973|Placebo Comparator|Placebo|
89025383|NCT00454259|Experimental|1|0,5 µg/kg
89025384|NCT00454259|Experimental|2|0,05 µg/kg
89550316|NCT02412943|Experimental|PAPP-A2 Enzyme Replacement|A 20 cc/kg transfusion of Fresh Frozen Plasma will be given over 3 hours on day 0.
89550317|NCT03177655|Experimental|Guided Imagery|Guided Imagery meditation
89550318|NCT03177655|Active Comparator|Journaling|Keeping a journal
89550319|NCT02413021|Experimental|deferasirox + cytarabine|deferasirox + cytarabine group will receive oral deferasirox at 20 mg/kg per day and cytarabine at20 mg/m^2 , SC , two times a day for 10 days every 30 days for 1 cycle.
89550320|NCT02413021|Active Comparator|cytarabine|cytarabine group will receive just cytarabine at 20 mg/m^2 , SC , two times a day for 10 days every 30 days for 1 cycle.
89550321|NCT01680341|Experimental|IDegAsp Simple|
89550322|NCT01680341|Experimental|IDegAsp Step wise|
89550323|NCT03177811|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m
89550324|NCT03177811|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m.
89550325|NCT03175939|Experimental|CCRT alone|External beam radiotherapy > 66 Gy Cisplatin 60 mg/m2 IV D1, 5-FU 600 mg/m2 IV D1-5 at week 1 and 5 of radiotherapy Modified for IMRT: Cisplatin 60 mg/m2 IV D1, 5-FU 600 mg/m2 IV D1-3 at week 1, 4 and 7 of radiotherapy
89550326|NCT03176017|Active Comparator|Ejaculatory sparing TUIP|Ejaculatory sparing TUIP
89550327|NCT03176017|Placebo Comparator|Conventional TUIP|regular non ejaculatory sparing TUIP
89550328|NCT03199625|Experimental|Cognitive Therapy group|treatment with Cognitive Therapy
89550329|NCT03199625|Experimental|Behavior Therapy group|treatment with Behavior Therapy
89550330|NCT03199625|Active Comparator|SSRI antidepressants|treatment by SSRI antidepressant
89550331|NCT02417077||Photographic Review|Photographic review of subjects who received treatment with onabotulinumtoxinA for crow's feet lines.
89025385|NCT00454259|Experimental|3|0,005 µg/kg
89550332|NCT02412865|Experimental|Intervention|quit4baby + text4baby
89550333|NCT02412865|Other|Control|text4baby
89550334|NCT03199313|Active Comparator|Cohort 1 Sentinel Group 1 - Active|N = 2, Initial dosing of Cohort 1 with 300 mg sutezolid or matching placebo, dosed 24 hours before the rest of Cohort 1 Group 2
89550335|NCT03199313|Placebo Comparator|Cohort 1 Sentinel Group 1 - Placebo|N = 1, Initial dosing of Cohort 1 with 300 mg sutezolid or matching placebo, dosed 24 hours before the rest of Cohort 1 Group 2
89550336|NCT03199313|Active Comparator|Cohort 1 Sentinel Group 2 - Active|N = 4, Secondary dosing of Cohort 1 with 300 mg sutezolid or matching placebo, dosed 24 hours after the rest of Cohort 1 Group 1
89550337|NCT03199313|Placebo Comparator|Cohort 1 Sentinel Group 2 - Placebo|N = 1, Secondary dosing of Cohort 1 with 300 mg sutezolid or matching placebo, dosed 24 hours after the rest of Cohort 1 Group 1
89550338|NCT03199313|Active Comparator|Cohort 2 - Active|N = 6, 600mg sutezolid or matching placebo
89025386|NCT00454259|Placebo Comparator|4|NaCl 0,9 %
89025387|NCT00454298|Active Comparator|A|AGG-523 1800 mg QD PO (12 capsules) for 28 days
89025388|NCT00454298|Active Comparator|B|AGG-523 900 mg BID PO (12 capsules) for 28 days
89025389|NCT00454298|Placebo Comparator|C|Placebo QD PO (12 capsules) for 28 days
89025390|NCT00454298|Placebo Comparator|D|Placebo BID PO (12 capsules) for 28 days
89025391|NCT03279042|Experimental|Flapless corticotomy|Flapless corticotomy will be conducted in this group of patients.
89025392|NCT03279042|Active Comparator|Traditional corticotomy|Traditional corticotomy will be performed in this group.
89025393|NCT00454337|Experimental|Intensification arm|emtricitabine/TDF + efavirenz or lopinavir/ritonavir + enfuvirtide
89550339|NCT03199313|Placebo Comparator|Cohort 2 - Placebo|N = 2, 600mg sutezolid or matching placebo
89550340|NCT03199313|Active Comparator|Cohort 3 - Active|N = 6, 1200 mg sutezolid or matching placebo
89550341|NCT03199313|Placebo Comparator|Cohort 3 - Placebo|N = 2, 1200 mg sutezolid or matching placebo
89550342|NCT03199313|Active Comparator|Cohort 4 - Active|N = 6, 1800 mg sutezolid or matching placebo
89550343|NCT03199313|Placebo Comparator|Cohort 4 - Placebo|N = 2, 1800 mg sutezolid or matching placebo
89550344|NCT02412709|Experimental|Parent Performing ECG (PPE)|Parent Performing ECG (PPE) Group--When the baby is 2 weeks old, research staff will contact interested parents to schedule a home visit. During the visit, a research assistant will provide the parents with a kit that includes the QTScreen system and instructions. The parents will perform an ECG on their child using the QTScreen and instructions. If after attempting the ECG on their own parents encounter problems, parents can ask the research assistant for assistance.
89550345|NCT02412709|Active Comparator|Staff Performing ECG (SPE)|Staff Performing ECG (SPE) Group--When the baby is 2-4 weeks of age, research staff will contact the family to schedule a home visit. The QTScreen test will be done by a research assistant.
89550346|NCT03199235|Experimental|LIF + Citrus|Parents of subjects > 1 year and < 5 years with anemia (Hemoglobin < 11.0 g/dL) are provided the lucky iron fish and citrus along with instructions for use. Followed at regular intervals.
89550347|NCT03199235|Active Comparator|enhanced standard of care|Parents of subjects > 1 year and < 5 years with anemia (Hemoglobin < 11.0 g/dL) are provided the oral iron supplementation consistent with standard of care, and then followed at regular intervals in addition to any care determined to be necessary by regular provider.
89550348|NCT03179371||1|Mothers whose fetus has CDH
89550349|NCT03179527|Experimental|Qi deficiency and blood stasis|Patients in this group will be treated by Shuanghe Decoction at the base of conventional western medicine.
89550350|NCT03179527|Other|Conventional western medicine|Patients in this group will be treated by conventional western medicine, including anti-platelet drugss，lipid regulating drugs, coronary vasodilator, etc.
89550351|NCT02412475|Experimental|Treatment Plan - 2 treatment courses|Drug Method Used to Give Drug Days Cytarabine IT 0 or -1 Decitabine IV over 1 hour 1-5 Vorinostat PO 1-5 Fludarabine IV over 30 minutes 6-10 Cytarabine IV over 3 hours 6-10 Filgrastim (G-CSF) IV or SQ 5-12 Sorafenib PO 11-28
89550352|NCT04798625||Rheumatoid arthritis|Patients with a clinical diagnosis of rheumatoid arthritis and treated with immunosuppressive medication
89550353|NCT04798625||Psoriatic arthritis|Patients with a clinical diagnosis of psoriatic arthritis and treated with immunosuppressive medication
89550354|NCT04798625||Spondyloarthritis|Patients with a clinical diagnosis of spondyloarthritis and treated with immunosuppressive medication
89025394|NCT00454337|Active Comparator|Standard arm|emtricitabine/TDF + efavirenz or lopinavir/ritonavir
89025395|NCT00454454||No treatment|
89025396|NCT00454493|Active Comparator|fish oil|
89025397|NCT00454493|Placebo Comparator|placebo|
89025398|NCT00454688|Placebo Comparator|Placebo|
89025399|NCT00454688|Experimental|Asimadoline 0.15 mg|
89025400|NCT00454688|Experimental|Asimadoline 0.5 mg|
89025401|NCT00454688|Experimental|Asimadoline 1.0 mg|
89550355|NCT04798625||Crohn disease|Patients with a clinical diagnosis of Crohn disease and treated with immunosuppressive medication
89550356|NCT04798625||Ulcerative colitis|Patients with a clinical diagnosis of ulcerative colitis and treated with immunosuppressive medication
89550357|NCT04798625||Autoimmune hepatitis|Patients with a diagnosis of autoimmune hepatitis and treated with immunosuppressive medication
89550358|NCT04798625||Liver transplant|Patients who have undergone liver transplantation and are treated with immunosuppressive drugs
89550359|NCT02417311||Control group|40 healthy volunteers will serve as control group. Skin biopsy, genotyping and disease phenotyping
89550360|NCT02417311||DCM patients|20 patients with dilated cardiomyopathy
89550361|NCT02417311||HCM patients|20 patients with hypertrophic cardiomyopathy
89550362|NCT04543643|Experimental|Carvedilol+ berberine|Carvedilol is started at a dose of 6.25 mg once per day. After 1 week, this will increased to a dose of 6.25 mg twice daily per day if systolic blood pressure does not fall below 85mm Hg and HR 55/min. Berberine is started at a dose of 0.3g twice per day.
89550363|NCT04543643|Active Comparator|Carvedilol|Carvedilol is started at a dose of 6.25 mg once per day. After 1 week, this will increased to a dose of 6.25 mg twice daily per day if systolic blood pressure does not fall below 85 mm Hg and HR 55/min.
89550364|NCT02417155|Experimental|HTR|The 'Hoftraining' group (HTR): a group of subjects (n=10) that will be trained extensively by mr. Hof and his team in both hyper/hypoventilation and strength ventilation breathing techniques. Total time training is 8 days.
89550365|NCT02417155|Active Comparator|EIN|The 'extensive instruction' group (EIN): a group of subjects (n=10) that will receive an extensive instruction course supervised by the research team (in absence of Mr. Hof) in both hyper/hypoventilation and strength ventilation breathing techniques.
89550366|NCT02417155|Active Comparator|STR|The 'short training' group (STR): a group of subjects (n=10) that will receive only a short training of 1 hour (immediately prior to the study) by Mr. Hof and his team in both hyper/hypoventilation and strength ventilation breathing techniques.
89550367|NCT02417155|Active Comparator|SIN|The 'short instruction' group (SIN): a group of subjects (n=10) that will receive no training, but only an short instruction course of 1 hour (immediately prior to the study) supervised by the research team (in absence of Mr. Hof) in both hyper/hypoventilation and strength ventilation breathing techniques.
89550368|NCT03177499|Experimental|Single arm study|"Patients will receive CT angiography, Doppler ultrasound, invasive PPG, and vePPG per protocol.~Intervention: Procedure: Invasive PPG"
89550369|NCT05377619|Experimental|prucalopride|prucalopride 2 mg 1 capsule orally 1 hour before the wine challenging (during a dinner), in five dinners (2 dinners per week)
89550370|NCT05377619|Experimental|buspirone|buspirone 10 mg 1 capsule orally 1 hour before the wine challenging (during a dinner), in five dinners (2 dinners per week)
89550371|NCT05377619|Placebo Comparator|placebo|placebo 1 capsule orally 1 hour before the wine challenging (during a dinner), in five dinners (2 dinners per week)
89550372|NCT02412319|Experimental|Experimental Group|Anti-HBV Placenta Transfer Factor Injection: 2mg/4ml, intramuscular injection, the 0-24 week, once every other day; week 24-48, 2 times / week; entecavir tablets: 0.5mg/ tablet / time, daily bedtime fasting oral once, treatment course 96 weeks
89550373|NCT02412319|Placebo Comparator|Comparator Group|Physiological saline injection: 2mg/4ml, intramuscular injection,the 0-24 week, once every other day, week 24-48, 2 times / week; entecavir tablets: 0.5mg/ tablet / time, daily bedtime fasting oral once, treatment course 96 weeks
89550374|NCT04393337|Experimental|Gestational Age Chart Method|In this method, the endotracheal tube insertion depth is obtained from the gestational age chart provided in the 7th edition textbook of neonatal resuscitation program (adapted from Kempley et al. PubMed identifier number: 18372092)
89550375|NCT04393337|Active Comparator|Nasal-Tragus Length Method|In this method, the endotracheal tube insertion depth is calculated based on the formula-the distance from nasal septum tip to ear tragus+1 cm
89550376|NCT04322513||Covid-19 positive patients|all drugs used for standard treatment
89550377|NCT04322513||Covid-19 negative patients|
89550378|NCT00703573|Experimental|Group A|S-777469 400 mg BID (two 200 mg tablets of S-777469 and two tablets of placebo BID)
89550379|NCT00703573|Experimental|Group B|S-777469 800 mg BID (four 200 mg tablets of S-777469 BID)
89550380|NCT00703573|Placebo Comparator|Group C|Placebo BID (four tablets of placebo BID)
89550381|NCT02412241|Other|LEF Measures|"PATIENT-REPORTED OUTCOME MEASURE: Validity of LSIDS-H&N will be assessed using 6 forms (e.g., Vanderbilt Head and Neck Symptom Survey (v2.0); Neck Disability Index; and Hospital Anxiety and Depression Scale).~CLINICIAN-REPORTED OUTCOME MEASURES: External LEF will be assessed using HN-LEF Grading Criteria, CTCAE (v4.03), and digital photos of the head and neck. Internal LEF will be scored using Modified Patterson Scale through an endoscopic exam. Both external/internal measures are re-assessed for intrarater and interrater reliability.~OBJECTIVE/TECHNICAL MEASURES: Patients undergo CT scans and ultrasound exams with results re-scored for intrarater and interrater reliability."
89550382|NCT03199157|Active Comparator|Fentanyl Group|Patients received the fentanyl 12 mcg transdermal patch (FG, n=38) 8 hours preoperatively and until 24 hours after the surgery
89550383|NCT03199157|No Intervention|Control group|
89550384|NCT02412163||IM HTO Nail|Implant with the Ellipse IM HTO Nail
89550385|NCT02422537|Active Comparator|Unmodified wheat bran|One single dose om 20 g
89550386|NCT02422537|Active Comparator|Wheat bran with reduced particle size|One single dose of 20 g
89550387|NCT02422537|Active Comparator|Destarched pericarp-enriched wheat bran|One single dose of 20 g
89550388|NCT02422537|Other|No bran-based dietary platform|No wheat bran fractions is administered
88961815|NCT03737968|Experimental|Durvalumab monotherapy Arm|Patients in the durvalumab (MEDI4736) monotherapy treatment group will receive durvalumab (MEDI4736) (1500mg Q4W) once prior to surgery in this study. After surgical resection, these patients will receive the post op adjuvant treatment including RTx with/without cisplatin based on the pathologic findings and physician's discretion. After completion of adjuvant treatment, durvalumab (MEDI4736) 1500mg Q4W as maintenance treatment for up to a maximum of 12 months until confirmed disease progression unless there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met. The first durvalumab (MEDI4736) monotherapy dose at 1500mg Q4W will be within 8 weeks after the completion of adjuvant therapy. If a patient's weight falls to 30kg or below the patient should receive weight-based dosing equivalent to 20 mg/kg of durvalumab Q4W until the weight improves to >30 kg, at which point the patient should start receiving the fixed dosing of durvalumab 1500mg.
89550389|NCT02416999|Experimental|patient group|
89550390|NCT04194671|Experimental|Mesenchymal stem cells cohort|
89550391|NCT04194671|Placebo Comparator|Saline cohort|
89025402|NCT03278808|Experimental|Chloroquine-Azithromycin (CQ/AZ ) Group|Subjects will receive experimental intervention of 300mg of CQ orally (PO) and 2g of AZ PO weekly for 6 weeks
89550392|NCT02422693|Experimental|Aquatic exercises|Warm-up, lumbar mobilization, stretching and relaxation. 3x-week (9 weeks), indoor pool, 32o.C/89.6o.F.
89550393|NCT02422693|Active Comparator|Aquatic exercises + Deep-water running|Same as AEG with addition of 20 minutes of running without touch the ground, 3x-week (9 weeks), indoor pool, 30o.C/86o.F.
89550394|NCT02412007|Experimental|Group A|"Individualized comprehensive home centred activity based programme. Simple activities would be advised on the basis of child's individual characteristics and parental expectations. These would include but would not be limited to (a) Standing up from squatting position to catch an object of interest.~(b) Squatting from standing position to pick an object of interest. (c) Walking to reach an object of interest. (d) Climbing up steps to get an object of interest. (e) Climbing down steps to keep the above object of interest. (f) Cycling (g) Kicking a football (h) Dancing"
89550395|NCT02412007|Active Comparator|Group B|"Conventional Physiotherapy Conventional physiotherapy would include and would not be limited to~Passive stretching exercises for spasticity reduction~Gait exercises~Walking on treadmill~Lower limb strengthening exercises~Exercises for balance improvenet"
89550396|NCT02412085|Experimental|Golimumab|Subcutaneous golimumab
89550397|NCT01679405|Experimental|Dose level 1 (Part A)|30 mg BIBW 2992, Gemcitabin (1.000 mg/m² BSA i.v.)/Cisplatin (25 mg/m² BSA i.v.)
89550398|NCT01679405|Experimental|Dose level -1 (Part A)|30 mg BIBW 2992, Gemcitabin (800 mg/m² BSA i.v.)/Cisplatin (20 mg/m² BSA i.v.)
89550399|NCT03175705|Experimental|Autologous T cell therapy+Tegafur+Interleukin-2 (IL-2)|Autologous in vitro expanded HCC antigens-specific CD8+ T lymphocytes in conjunction with IL-2 and along with lymphodepleting chemotherapy (Tegafur) will be administered to patients with relapsed/advanced HCC.
89550400|NCT00301457|Experimental|1|6 years adjuvant anastrozole therapy
89550401|NCT00301457|Experimental|2|3 years adjuvant anastrozole therapy
89550402|NCT03175783|Experimental|Treatment Group|Treatment group will receive intervention by putting on Fitbit Zip activity tracker with automatic step counts feedback throughout the study.
89550403|NCT03175783|Sham Comparator|Control Group|Control group will be put on intervention with same Fitbit Zip activity tracker but without automatic feedback for same duration of intervention.
89550404|NCT03175393||postprandial dyslipidemia|
89550405|NCT02422459|Experimental|COMMENCE|ChrOnic pain self-ManageMent support with pain science EducatioN and exerCisE (COMMENCE)
89550406|NCT02422459|No Intervention|Wait-list control|No treatment assigned
89550407|NCT03270527|Experimental|High SFA diet to low SFA diet|Participants will undergo, sequentially, a high SFA diet (Diet 1) followed by a low SFA diet (Diet 2) for 4 weeks each. Study visits will occur before and after each dietary intervention period. To comply with current UK dietary recommendations, Diets 1 and 2 will both contain ~35% energy from total fat. These diets will be consumed within the homes of free-living participants, by the substitution of ~40g of habitual fat, with either SFA-rich or mono/poly-unsaturated fatty acid-rich (MUFA/PUFA) cooking oils, spreads and snack foods, while maintaining their habitual diet (consistent intake of protein and carbohydrates, including dietary fibre). This will be achieved using a dietary exchange model developed and peer-reviewed for a previous dietary intervention study ('DIVAS') at the University of Reading, U.K.
89550408|NCT02422069||Study Population|Gynecology outpatients who meet eligibility criteria will be enrolled and evaluated for the presence of PMO at screening. Women diagnosed with PMO will complete an additional visit to document the prescribed management plan.
89550409|NCT03198845|Active Comparator|video game|"Participants received a total of twelve 40-min sessions of hot pack therapy combined transcutaneous electrical nerve simulation over the knees followed by 20-min supervised video game play therapy 20-min per session for 3 times per week for a 4-week duration.~Therapeutic effects of video game intervention for patients with knee osteoarthritis were assessed."
89550410|NCT03198845|Sham Comparator|exercise group|"Participants received a total of twelve 40-min sessions of hot pack therapy combined transcutaneous electrical nerve simulation over the knees followed by 20-min supervised therapeutic exercise 20-min per session for 3 times per week for a 4-week duration.~Therapeutic effects of therapeutic exercise for patients with knee osteoarthritis were assessed."
89550411|NCT02422225|Experimental|Eldith DC-STIMULATOR group|"Intervention:~20-minutes of transcranial Direct Current Stimulation (tDCS) application 5 days a week for 2 weeks (30 applications for each 3 groups: total 90 applications)"
89550412|NCT02422225|Sham Comparator|sham-Eldith DC-STIMULATOR group|Intervention: 20-minutes of sham-tDCS application 5 days a week for 2 weeks (total 30 applications)
89550413|NCT03177109|Active Comparator|Fluoride Varnish Group|5% fluoride varnish (Acclean) applied topically
89550414|NCT03177109|Active Comparator|Arginine paste Group|8% arginine containing paste (Colgate® Sensitive Pro-Relief™) applied topically
89550415|NCT03177109|Active Comparator|Adhesive Resin Group|Self-adhesive resin (Seal and Protect, Dentsply) applied topically
89550416|NCT03198923|Experimental|natural killer and natural killer T cell|The eligible patients are infused with ten doses of (2-2.5)x10^9 NK and NKT cells in one course of treatment.
89550417|NCT03198455|Experimental|Andosan|The Agaricus blazei Murill-based mushroom extract, Andosan™, is given as one dosage 60 ml/day orally for 2 months. The intervention solution is given for 1 month's consumption at a time in a neutral plastic container
89550418|NCT03198455|Placebo Comparator|Placebo|The placebo is drinking water with brownish food coloring, given as one dosage 60 ml/day orally for 2 months. The placebo solution is given for 1 month's consumption at a time in a neutral plastic container (same as for intervention/experimental solution).
89550419|NCT03198611||Normal function|No systolic dysfunction No diastolic dysfunction No right ventricular dysfunction
89025403|NCT03278808|Active Comparator|Chloroquine (CQ) Group|Subjects will only receive 300mg of CQ orally (PO) weekly for 6 weeks
89550420|NCT03198611||Left ventricular systolic dysfunction|Left ventricular ejection fraction < 50%
89550421|NCT03198611||Left ventricular diastolic dysfunction|"Classification according to:~Mitral lateral annulus e' in tissue Doppler < 10 cm/s~American society of echocardiography (ASE) criteria 2009~ASE criteria 2016"
89550422|NCT03198611||Right ventricular dysfunction|Tricuspid annulus plane systolic excursion < 17 cm
89550423|NCT03176875|Experimental|PEN group|Partial enteral nutrition (PEN) group will receive 75% of their daily dietary needs from a polymeric formula (Alicalm, Nutricia) and a limited (25% of dietary needs = 1 meal per day) from an antiinflammatory diet for CD (AID-CD) for 6 weeks.
89550424|NCT03176875|Active Comparator|EEN group|Exclusive enteral nutrition (EEN) group will receive 100 % of their daily caloric requirements from a poymeric formula (Alicalm, Nutricia) for 6 weeks.
89025404|NCT03278808|Other|CHMI Group - atovaquone-proguanil (Malarone®)|All subjects will participate in the Controlled Human Malaria Infection (CHMI) and will be required to stay at a hotel for evaluation for a maximum of 14 nights starting 7 days after the challenge. A standard dose of atovaquone-proguanil (Malarone®) will be administered to all symptomatic parasitemic subjects under directly observed treatment.
89208046|NCT03974191||131 participants with chronic low back pain|All the participants (n=131) with chronic low back pain (CLBP) from the cross-sectional study in 2006 are invited to participate in the present 13-year follow-up. The same examination battery used in the cross-sectional study plus a supplementary Chair Stand Test will be used.
89550425|NCT03185897||Hemophilia A|Participants with hemophilia A
89550426|NCT03185897||Hemophilia B|Participants with hemophilia B
89550427|NCT02421991|Experimental|TALK study group|This is the experimental arm of the study. This includes 5 weekly sessions of experimental therapy via telephone. Therapy description withheld to protect the integrity of the study.
89550428|NCT02421991|Active Comparator|TALK control group|This is the control arm of the study. This includes 5 weekly sessions of control therapy via telephone.Therapy description withheld to protect the integrity of the study.
89550429|NCT03175627|Active Comparator|Filtek One|Bulk fill composite material used for posterior tooth fillings.
89550430|NCT03175627|Active Comparator|Filtek Z250|Composite material used for incremental filling of posterior teeth.
89550431|NCT01603355|Experimental|Tocilizumab|
89550432|NCT03177031|Active Comparator|Stay Safe (STS)|CAPD system produced by Fresenius Medical Care in Germany
89550433|NCT03177031|Experimental|Stay Safe Link (SSL)|CAPD system produced by Fresenius Medical Care in Malaysia
89550434|NCT02416843|Experimental|Lean|Consumption of a mixed meal relative to individual resting metabolic rate.
89550435|NCT02416843|Experimental|Overweight|Consumption of a mixed meal relative to individual resting metabolic rate.
89550436|NCT02416843|Experimental|Obese|Consumption of a mixed meal relative to individual resting metabolic rate.
89550437|NCT02411851|Active Comparator|Ingenol mebutate alone|At Visit 1, ingenol mebutate 0.015% alone on the second 25 cm2 treatment area. The treatment area receiving ingenol mebutate 0.015% alone will apply the medication as directed per approved drug labeling. Patients will apply ingenol mebutate gel on Day 2 and Day 3.
89550438|NCT02411851|Experimental|Ingenol mebutate and dermasil lotion|At Visit 1, ingenol mebutate 0.015% and dermasil lotion on one 25 cm2 treatment area. The treatment area receiving both ingenol mebutate 0.015% and dermasil lotion, will first apply ingenol mebutate 0.015% allow the gel to dry completely as per drug labeling on Day 1. The patient will allow at least 6 hours between the application of ingenol mebutate and dermasil lotion on Day 2 and 3. Patients will apply dermasil lotion daily on Day 2 until at least Day 8. At Day 8, the physician will reassess whether dermasil application should be continued to Day 15 or ceased. At Day 15, the physician will reassess whether dermasil application should be continued to Day 29 or ceased.
89550439|NCT05094947|Experimental|intermittent catheterization (group B)|Procedure/Surgery: The acute urinary retention in group B is managed by clean intermittent catheterization along with alpha-blockers during 3 period. After 3 days the ability of spontaneous voiding is assessed and registered as an outcome.
89550440|NCT05094947|Active Comparator|Catheter Foley (group A)|The acute urinary retention in group A is managed by trial without catheter along with alpha-blockers during 3 period. After 3 days the indwelling Foley catheter is removed and ability of spontaneous voiding is assessed and registered as an outcome.
89550441|NCT02421913|Active Comparator|S(+)-ketamine group (SG)|Five minutes before surgery, patients in the SG group received an intravenous continuous infusion containing 0.3 mg.kg-1.h-1 of S(+)-ketamine
89550442|NCT02421913|Placebo Comparator|placebo group (PG)|PG received the same dose of saline.
89550443|NCT05094869||APP self-management group|Patients would register on the APP and visit the clinics according to the routine practice and guidelines. During the study, the APP would regularly send messages including the follow-up reminder (manually set up by the patients on the APP), medication reminder, health education knowledge, etc.
89550444|NCT05094869||APP intelligent-management group|Patients would register on the APP and visit the clinics according to the routine practice and guidelines. During the study, the APP would regularly send messages including the follow-up reminder (automatically set up by the APP), medication reminder, health education knowledge, etc. The doctors will evaluate their disease progression every six months through the APP and guide patients' clinical practice accordingly.
89550445|NCT05094869||Control group|History data of another 4000 Patients who have been on the platform of China Registry of Hepatitis B (CR-Hep B) and been diagnosed as compensatory hepatitis B cirrhosis would be extracted and serve as the control group (No APP, no follow-up reminders, no online interaction).
89550446|NCT03179293|Active Comparator|Propofol|propofol 1 mg/kg IV bolus will be given to the patient with a further 2 mg/kg administered manually over the next 3 min prior to the patient leaving the OR
89550447|NCT03179293|Placebo Comparator|Control|Normal saline will be administered IV over the next 3 min prior to the patient leaving the OR
89025405|NCT00480090|Experimental|Cytarabine|eligible patients will receive cytarabine, starting at 075g/m2 and escalating to a maximum of 1.25g/m2, BID IV for 2 days every three weeks for 6 or more cycles if tolerated.
89025406|NCT00454766||Questionnaire|Questionnaire Regarding Tailored Educational Materials
89025407|NCT03274622|Experimental|Impact Parent Training|Parents receive 22 1.5-hour sessions with a Speech Language pathologist coaching them in the implementation of the Impact intervention
89208047|NCT04090385|Experimental|tDCS over M1 and DLPFC|Anodic transcranial direct current stimulation (tDCS) over left primary motor cortex (M1) and left dorsolateral prefrontal cortex (DLPFC). Duration: 20 minutes; Intensity: 2mA.
89550448|NCT02416765|Active Comparator|Sensor-augmented pump therapy|Patients will use conventional pump therapy and freely implement their usual basal rate and CHO-matching full prandial bolus to regulate glucose levels.
89550449|NCT02416765|Active Comparator|Single-hormone CLS with full boluses|Variable subcutaneous insulin infusion rates will be used to regulate postprandial glucose levels. Carbohydrate-matching full prandial bolus will be given 10 minutes before the meal. Each subject insulin-to-carbohydrate ratio will be used to calculate the insulin bolus to be given.
89025408|NCT03274622|Placebo Comparator|No Impact|No parent coaching is provided
89025409|NCT00454883||1 cohort of patients treated with ziprasidone|
89550450|NCT02416765|Active Comparator|Single-hormone CLS with partial boluses|Variable subcutaneous insulin infusion rates will be used to regulate postprandial glucose levels. A pre-meal partial prandial bolus will be given 10 minutes before the meal. The partial bolus will be based on the estimated meal size (snack-regular-large-very large). Meal size will be defined as: snack as any meal less than 30g, regular meal as any meal between 30g and 60g CHO, large meal as any meal between 60g and 90g CHO, very large meal for anything above 90g CHO.
89550451|NCT02416765|Active Comparator|Dual-hormone CLS with full boluses|Variable subcutaneous insulin and glucagon infusion rates will be used to regulate postprandial glucose levels. Carbohydrate-matching full prandial bolus will be given 10 minutes before the meal. Each subject insulin-to-carbohydrate ratio will be used to calculate the insulin bolus to be given.
89025410|NCT00454922|Active Comparator|1|education
89025411|NCT00454922|Placebo Comparator|2|standard of care
89550452|NCT02416765|Active Comparator|Dual-hormone CLS with partial boluses|Variable subcutaneous insulin and glucagon infusion rates will be used to regulate postprandial glucose levels. A pre-meal partial prandial bolus will be given 10 minutes before the meal. The partial bolus will be based on the estimated meal size (snack-regular-large-very large). Meal size will be defined as: snack as any meal less than 30g, regular meal as any meal between 30g and 60g CHO, large meal as any meal between 60g and 90g CHO, very large meal for anything above 90g CHO.
89550453|NCT05094479|Experimental|Health information delivered via health app|Use of a health app with health information
89550454|NCT05094479|No Intervention|Control|Use of a health app without health information
89550455|NCT02703259|Active Comparator|Gabapentin|"As per the enhanced recovery after surgery protocol at our health institution, subject will receive oral medications prior to surgery including acetaminophen, celecoxib, and gabapentin x 1 dose given preoperatively. The number of tablets and capsules will remain identical in both study arms. Medications given include:~Gabapentin 600 mg (two capsules of gabapetin 300 mg); Acetaminophen 975 mg (three tablets of acetaminophen 325 mg); Celecoxib 400 mg (two capsules of celecoxib 200 mg) = Total 3 tablets, 4 capsules"
89550456|NCT02703259|Placebo Comparator|Control|"As per the enhanced recovery after surgery protocol at our health institution, subject will receive oral medications prior to surgery including acetaminophen and celecoxib x 1 dose given preoperatively. The number of tablets and capsules will remain identical in both study arms. Medications given include:~Acetaminophen 975 mg (three tablets of acetaminophen 325 mg); Celecoxib 400 mg (four capsules of celecoxib 100 mg) = Total total 3 tablets, 4 capsules"
89025412|NCT03278652||Patient with renal colic|
89550457|NCT05094167|Experimental|probiotics group|"The oral probiotic (Lactobacillus Bifidobacterium V9,one times a day during the whole treatment) was isolated from healthy women's breast milk samples in 2017 and was identified as Lactobacillus rhamnosus by physiological and biochemical and 16S rRNA. It is listed as the List of Probiotics for Health Food in my country's List of Bacteria Available for Food, which can be directly applied to food production."
89550458|NCT05094167|Placebo Comparator|placebo group|Immunotherapy with placebo alone
89550459|NCT05094167|No Intervention|healthy control group|healthy control group
89025413|NCT03278574|Experimental|Flexible band|Mitral valve repair with flexible posterior annuloplasty band
89025414|NCT03278574|Active Comparator|Complete ring|Mitral valve repair with complete rigid ring
89025415|NCT00455000|Experimental|Active treatment|5 possible active doses
89550460|NCT02416687|Active Comparator|Implanon®|Postpartum women into whom the etonogestrel-releasing contraceptive implant (Implanon®, N.V. Organon, Oss, Netherlands) was inserted in the first 48 h postpartum
89550461|NCT02416687|No Intervention|Control group|Postpartum women who used no contraceptive method in the first six weeks after delivery
89550462|NCT05093465|Active Comparator|Active Control|Participants were provided with sleep hygiene and stimulus control procedures.
89550463|NCT05093465|Experimental|Technology Intervention|Participants were given the same intervention materials as the active control condition plus procedures to change technology use.
89550464|NCT02411695|Experimental|Cohort 1|0.5 mg, Brexpipraxzole (OPC-34712)
89025416|NCT00455000|Placebo Comparator|Placebo|
89550465|NCT02411695|Experimental|Cohort 2|1mg, Brexpipraxzole (OPC-34712)
89550466|NCT02411695|Experimental|Cohort 3|2mg, Brexpipraxzole (OPC-34712)
89550467|NCT02411695|Experimental|Cohort 4|3 mg, Brexpipraxzole (OPC-34712)
89550468|NCT02411695|Experimental|Cohort 5|4mg, Brexpipraxzole (OPC-34712)
89550469|NCT05093309|Experimental|Intervention|The intervention group received naloxone resources + monthly reminders + educational webinar.
89550470|NCT05093309|No Intervention|Control|The control group received naloxone resources + monthly reminders + delayed educational webinar (after the 3-month study period).
88961816|NCT03737968|Active Comparator|Durvalumab + tremelimumab combination therapy Arm|Patients in the durvalumab (MEDI4736) + tremelimumab combination therapy treatment group will receive durvalumab (MEDI4736) (1500mg Q4W) in combination with tremelimumab (75 mg IV Q4W) once prior to surgery in this study. After surgical resection, these patients will receive the post op adjuvant treatment including RTx with/without cisplatin based on the pathologic findings and physician's discretion. After completion of adjuvant treatment, durvalumab (MEDI4736) 1500mg Q4W as maintenance treatment for up to a maximum of 12 months until confirmed disease progression unless there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met. The first durvalumab (MEDI4736) monotherapy dose at 1500mg Q4W will be within 8 weeks after the completion of adjuvant therapy.
89025417|NCT00480207|Experimental|omega-3, folic acid, vitB12|folic acid (1600 mcg per day), and omega-3 (2000 mg per day: active docosahexaenoic acid (DHA) and eicosapentanoic acid (EPA), proportion 1:1), vitamin B12 (1000 mcg per day)
89550471|NCT02416921|Experimental|Weight-gain Prevention|Subjects in this group will engage in a 4-week weight-gain prevention curriculum delivered via Facebook
89550472|NCT02416921|Active Comparator|Women's Health|Subjects in this group will engage in a 4-week women's health curriculum delivered via Facebook
89550473|NCT05093231|Experimental|Pembrolizumab and olaparib|"Pembrolizumab will be given as a fixed dose of 200mg standard dose on Day 1 (+/-3 days) of every 3 weeks cycle , administered intravenously as a ~30 minute infusion, as per standard clinical practice. Patients continuing beyond 27 weeks can switch to pembrolizumab 400mg every 6 weeks (as per standard clinical practice).~Olaparib dose is 300mg given orally, twice daily, from Day 1 to Day 21 continuously of each 3-week cycle. Dosing will start on day 1 of each cycle."
89550474|NCT02411617|Active Comparator|Single drain in modified radical mastectomy|Post modified radical mastectomy with either one or two drains Intervention is use of single or double drain
89550475|NCT02411617|Active Comparator|Double drain in modified radical mastectomy|Post modified radical mastectomy with either one or two drains Intervention is use of single or double drain
89550476|NCT02410525|Experimental|[11C]PF-06427878|Single intravenous infusion of [11C]PF-06427878 in Periods 1, 2 and 3 to investigate the liver and plasma radioactivity, radioactivity in organs relative to plasma, pharmacokinetics, and safety and tolerability
89550477|NCT02410525|Experimental|PF-06427878 10 mg|Single oral dose of 10 mg PF-06427878 in Period 2 or 3 to investigate the liver and plasma radioactivity, radioactivity in organs relative to plasma, pharmacokinetics, and safety and tolerability
89550478|NCT02410525|Experimental|PF-06427878 600 mg|Single oral dose of 600 mg PF-06427878 in Period 2 or 3 to investigate the liver and plasma radioactivity, radioactivity in organs relative to plasma, pharmacokinetics, and safety and tolerability
89550479|NCT03198377|Experimental|TENS: Randomized frequency modulation|TENS transcutaneous electrical stimulation over superficial radial nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
89550480|NCT03198377|Experimental|TENS: Scan 6/6 of frequency modulation|TENS transcutaneous electrical stimulation over superficial radial nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
89550481|NCT03198377|Experimental|TENS: Fixed frequency|TENS transcutaneous electrical stimulation over superficial radial nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
89550482|NCT03198377|Sham Comparator|TENS: Sham stimulation|Sham transcutaneous electrical stimulation over superficial radial nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
89550483|NCT02411383|Experimental|NeuRx Diaphragm Pacing System (DPS)®|The NeuRx Diaphragm Pacing System (DPS)® is placed in the diaphragm during lung transplant.
89550484|NCT03198299|Active Comparator|study group: MEI BIN insoles|Study group: participants in the study group were prescribed with customized insoles (MEI BIN insoles) to keep the subtalar joint in neutral position, for 12 weeks.
89550485|NCT03198299|No Intervention|control group: without MEI BIN insoles|Control group: participants in the control group were not prescribed with customized insoles (MEI BIN insoles) to keep the subtalar joint in neutral position, for 12 weeks.
89550486|NCT02421835|Placebo Comparator|Placebo control|2 capsules of 350 mg maltodextrin to be consumed daily for 12 weeks
89550487|NCT02421835|Active Comparator|Olive leaf extract|2 capsules of 350 mg olive leaf extract equivalent 132 mg of oleuropein in olive leaf extract to be consumed daily for 12 weeks
89550488|NCT02421835|Placebo Comparator|Physical activity|2 capsules of 350 mg maltodextrin to be consumed daily combined with gradually increase physical activity levels over 12 weeks
89550489|NCT02421835|Active Comparator|Physical activity and olive leaf extract|2 capsules of 350 mg olive leaf extract equivalent 132 mg of oleuropein in olive leaf extract to be consumed daily combined with gradually increase physical activity levels over 12 weeks
89550490|NCT04542395|Experimental|Increasing Uptake of COVID-19 Testing and Vaccination|"This is a pre-experimental one group pretest-posttest design to improve COVID-19 associated health outcomes and willingness and uptake toward testing and vaccination among 310 Hispanic and African American public housing residents in South Los Angeles. The proposed intervention will employ (1) culturally sensitive, (2) theoretically based intervention that will be jointly delivered by our COVID-19 health ambassadors and our researchers. We will use the Information, Motivation, and Behavioral Skills (IMB) model and the Transtheoretical Model to implement the intervention."
89550491|NCT02410447|Experimental|Treatment Group|"Defocused shock waves were provided by an electromagnetic generator (DUOLITH® SD1 - Storz Medical AG, Tägerwilen, Switzerland).~The protocol consisted of a series of 3 sessions in 2 weeks, 2 treatments a week. For each patient, a different number of impulses per session was delivered, depending on wound size (300 impulses + 100 impulses per cm2 wound-surface), at an energy flux density of 0.15 mJ/mm2 and a frequency of 5 pulses/s."
89550492|NCT03197831||Private Option Expansion|This group incorporates data from the state of Arkansas and is applicable only to aims 1 and 2 where we are determining the impact of difference methods of Medicaid expansion on inpatient and ED utilization.
89550493|NCT03197831||Managed Medicaid Expansion|This group incorporates data from the state of Kentucky and is applicable only to aims 1 and 2 where we are determining the impact of difference methods of Medicaid expansion on inpatient and ED utilization.
89550494|NCT03197831||No Medicaid Expansion|This group incorporates data from the state of Florida in aims 1 and 2 and all the states which did not expand Medicaid enrollment in 2014 for aim 3.
89550495|NCT03197831||Medicaid Expansion|This group incorporates data from the state of Arkansas and Kentucky in aims 1 and 2 and all the states which expanded Medicaid enrollment in 2014 (except New Hampshire and Michigan) for aim 3.
89550496|NCT03197909||Healthy subjects|Determination of pro-inflammatory plasma factors at Healthy subjects aged from 35 to 85 years old
89550497|NCT03197909||COPD patients|Determination of pro-inflammatory plasma factors at COPD patients aged from 35 to 85 years old
89550498|NCT02411227|Experimental|1|Immediate Intervention
89550499|NCT02411227|No Intervention|2|Wait list
89550500|NCT05093075|Experimental|Treatment Arm|Participants randomized to treatment will received 1.0 plasma volume exchanges daily until discontinuation of vasopressors, death or to a maximum of 5 treatments. The management of septic shock, including but not limited to, antibiotic therapy, infection source control, fluid therapy, mechanical ventilation, and nutrition, will be at the discretion of the treating medical team, and will be recorded and reported.
89550501|NCT05093075|No Intervention|Standard of Care Arm|Participants randomized to Standard-of-Care will be treated at the discretion of the treating medical team. The management of septic shock, including but not limited to, antibiotic therapy, infection source control, fluid therapy, mechanical ventilation, and nutrition, will be at the discretion of the treating medical team, and will be recorded and reported.
89550502|NCT02411149|Placebo Comparator|Local Inflitration Only|"This group will receive LIA and saline solution (placebo) in the adductor canal block with NO morphine in the spinal anesthesia:~30 ml normal saline~3ml 0.5% preservative-free bupivacaine"
89550503|NCT02411149|Active Comparator|Adductor Canal Block|"This group will receive LIA and the standard local anesthetic in the ACB with NO morphine in the spinal anesthetic:~ropivacaine 0.5% with 1:400,000 epinephrine~3ml 0.5% preservative-free bupivacaine"
89550504|NCT02411149|Active Comparator|Adductor Canal Block with Morphine|"This group will receive LIA with local anesthetic in the ACB and morphine in the spinal anesthetic:~ropivacaine 0.5% with 1:400,000 epinephrine~3ml 0.5% preservative-free bupivacaine with 100mcg of intrathecal morphine (0.1ml of intrathecal morphine 1mg/ml)"
89550505|NCT04413227|Experimental|PEG-ENDO+Docetaxel|PEG-ENDO( 1 mg/kg or 2mg/kg or 4mg/kg or 6mg/kg or 8mg/kg）+Docetaxel 75 mg/m2，once every 3 weeks at day 1
89550506|NCT03175315|Experimental|FLASH|"Intervention: Conduct of the newly developed treatment and education program for patients with diabetes who use flash glucose monitoring (FLASH).~FLASH consists of 4 lessons focusing on empowering patients to autonomously use flash glucose monitoring (FGM) in their daily routine. Patients learn to effectively interpret the different information provided by FGM in order to improve not only glycemic control but also to improve the implementation of insulin therapy in daily life. Psychological and motivational aspects of living with diabetes and handling of the FGM are addressed as well."
89550507|NCT03175315|No Intervention|Waiting List|Diabetic patients using FGM receive treatment as usual until the last measurement point. After completion of the study, they are offered participation in the FLASH program.
89550508|NCT02410369|Active Comparator|S-588410|Subjects with HLA-A*2402 in the investigational arm will receive the subcutaneous administration of S-588410.
89550509|NCT02410369|Placebo Comparator|Placebo|Subjects with HLA-A*2402 in the placebo arm will receive the subcutaneous administration of placebo.
89550510|NCT03198143|Experimental|Healthy Subjects - Ghrelin|Healthy subjects will arrive after consuming a standard meal 60 minutes prior to study onset. They will receive a single subcutaneous injection of human synthetic Acyl Ghrelin at the start of the study. 5 minutes post-injection, the subjects will receive written instructions and begin their first decision-making task on a computer.
89550511|NCT03198143|Placebo Comparator|Healthy Subjects - Saline|Healthy subjects will arrive after consuming a standard meal 60 minutes prior to study onset. They will receive a single subcutaneous injection of 0.9% saline at the start of the study. 5 minutes post-injection, the subjects will receive written instructions and begin their first decision-making task on a computer.
89550512|NCT03198143|Experimental|Obese Subjects - Ghrelin|Obese subjects will arrive after consuming a standard meal 60 minutes prior to study onset. They will receive a single subcutaneous injection of human synthetic Acyl Ghrelin at the start of the study. 5 minutes post-injection, the subjects will receive written instructions and begin their first decision-making task on a computer.
89550513|NCT03198143|Placebo Comparator|Obese Subjects - Saline|Obese subjects will arrive after consuming a standard meal 60 minutes prior to study onset. They will receive a single subcutaneous injection of 0.9% saline at the start of the study. 5 minutes post-injection, the subjects will receive written instructions and begin their first decision-making task on a computer.
89550514|NCT03198065|Experimental|Hand-made glove setting|The patients receive Hand-made glove setting
89550515|NCT03198065|Experimental|commercialized multiport setting|The patients receive commercialized single-incision multiport setting
89550516|NCT05233423|Experimental|Intervention Group|The patients in the intervention group were applied 9 cold applications with 30 mmHg pressure for 20 minutes and 40 minutes of rest.
89550517|NCT05233423|No Intervention|Control Group|The patients in the control group were applied 9 times of cold gel in the form of 20 minutes of application and 40 minutes of rest after surgery.
89550518|NCT03197987|Experimental|Endocuff colonoscopy|Endocuff-assisted colonoscopy
89550519|NCT03197987|Active Comparator|Cap colonoscopy|Cap-assisted colonoscopy
89550520|NCT02411071||Patients starting cART|Patients starting cART. Grouping according to the time needed to reach viral loads below 1000, 500, 400, 200, 50 copies/ml, respectively.
89550521|NCT02411071||Patients with cART|Patients with cART. Grouping in patients without and with low-level-viremia (LLV) defined as two consecutive viral loads between 40 copies/ml and 200 copies/ml, 400 copies/ml, 500 copies/ml and 1000 copies/ml, respectively.
89550522|NCT02411305||PCRC Palliative Care Clinicians|
89550523|NCT03175237|Experimental|Group of Motor Patterns|For the mirror therapy protocol applied to the Motor Standard, each patient was treated with 15 mirror therapy sessions, 3 times a week for a total duration of 50 minutes. There were 4 exercises of voluntary range of motion involving the extension and mass flexion of the fingers, adduction and abduction of the fingers, pronation and supination of the forearm and elbow extension with associated shoulder elevation.
89550524|NCT03175237|Experimental|Group of Functional Activities|For the mirror therapy protocol applied to functional activities, four functional exercises were performed: fitting of pieces stimulating fine and thick gripping, stacking of cubes / cups and transfer of objects of different shapes and sizes. Each patient was treated with 15 mirror therapy sessions, 3 times a week with a total duration of 50 minutes
89550525|NCT02410993||CABG surgery|Candidates for CABG surgery for left main disease, three-vessel disease or two-vessel disease with proximal LAD stenosis indicated by current practice guideline
89550526|NCT02410135||Patients with symptomatic LUTS and disordered sleep|Patients exhibiting symptoms of LUTS and disordered sleep and who meet all inclusion/exclusion criteria will be prescribed Mirabegron for 12 weeks.
89550527|NCT05080127|Experimental|study subjects|"Children with proven IgE-mediated food allergy to one of the allergenic foods described.~Parallel to the skin tests that are done as part of the accepted follow-up:~The parents will fill a questionnaire regarding the quality of life (QOL) and another questionnaire regards family and personal relevant medical history.~Patch test sticker with the allergenic food will be placed on the forearm for 15 minutes.~A week later and 2 months later, the same QOL questionnaire will be sent by e-mail."
89550528|NCT05080127|Active Comparator|Control - atopic children|"Children with atopic comorbidities except for food allergy (ie. atopic dermatitis, asthma, allergic rhinitis).~The parents will fill a questionnaire regarding family and personal relevant medical history and foods that the child is exposed to regularly.~Patch test stickers with two of the food allergen list will be placed on the forearm for 15 minutes."
89550529|NCT05080127|Active Comparator|Control - healthy children|"Children without any atopic comorbidity (ie. atopic dermatitis, asthma, allergic rhinitis, and food allergy).~The parents will fill a questionnaire regarding family and personal relevant medical history and foods that the child is exposed to regularly.~Patch test stickers with two of the food allergen list will be placed on the forearm for 15 minutes."
89550530|NCT02410915|Experimental|Study Group|Intervention: Hybrid Assistive Limb (HAL); gait training in combination with conventional training. Training with the exosceleton Hybrid Assistive Limb (HAL) is performed in 1 session per day, 4 days per week during 4 weeks. Time for each session is individualised but does not exceed 60 minutes/session (effective time). Training with HAL is performed in combination with body-weight support system and on a treadmill. The training program is performed by 2 physiotherapists, who have been trained in the HAL method.
89550531|NCT02410915|Active Comparator|Control Group|Intervention: Conventional gait training is individualized and performed according to current practice (approximately 30-60 minutes/session, 5 days a week) and may include standing, weight shifting, stepping, over ground walking with assistance and/or assistant devices as well as the use of a treadmill and body weight support. Conventional gait training is offered to both study groups.
89550532|NCT05054621|Experimental|Heterologous group|1st dose AZD1222, 2nd dose MVC-COV1901
89550533|NCT05054621|Active Comparator|Homologous group (control)|1st dose AZD1222, 2nd dose AZD1222
89550534|NCT02410759|Active Comparator|Carbetocin|100 women with atonic PPH will receive Carbetocin 100 µgm slowly IM
89550535|NCT02410759|Active Comparator|Ergometrine|100 women with atonic PPH will receive Ergometrine 0.5mg IM
89550536|NCT04459091|Experimental|Amino essential acids|oral supplementation with a mixture of amino essential acids 8 gr die in two administrations for six weeks
89550537|NCT04459091|Placebo Comparator|Placebo|placebo consisting in isocaloric product containing maltodextrins in two administrations for six weeks
89550538|NCT03175081|Experimental|Test group|Patients will undergo elective laparoscopic sleeve gastrectomy with ropivacaine diluted in normal saline injected along the stomach region at the end of the surgical procedure.
89550539|NCT03175081|Experimental|Control group|Patients will undergo elective laparoscopic sleeve gastrectomy with only normal saline injected along the stomach region at the end of the surgical procedure.
89550540|NCT05016479|Experimental|Active arTMS (15 Hz)|The treatment involves 15 Repetitive Transcranial Magnetic Stimlation sessions (3/daily for 5 consecutive days, each session lasts 13 min with an interval of 50 min). Coil is placed on the left dorsolateral prefrontal cortex (LDLPFC).The stimulation has a frequency of 15 Hz and a intensity of 120% of the individual resting motor threshold.
89550541|NCT05016479|Sham Comparator|Sham arTMS|Sham group receives the same Repetitive Transcranial Magnetic Stimlation sessions of active compactors. However the interventions in the place group are with a superficial stimulation of scalp muscles only, in order to induce a sensation close to the one experienced with the real rTMS stimulation.
89550542|NCT03175003|Active Comparator|Food Product 1|Macronutrient similar to experimental, micronutrient lower than experimental
89550543|NCT03175003|Active Comparator|Food Product 2|Macronutrient lower than experimental, micronutrient similar to experimental
89550544|NCT03175003|Experimental|Food Product 3|Experimental 1
89550545|NCT03175003|Experimental|Food Product 4|Experimental 2
89550546|NCT02406625|Experimental|Diaclectical Behavioral Therapy|15 adolescents with history of suicidal behaviors receiving Dialectical Behavioral Therapy.
89025418|NCT00480207|Experimental|omega-3, folic acid placebo, vit B12|omega-3,folic acid placebo (starch), vitamin B12 (1000 mcg per day)
89550547|NCT02406625|Experimental|Support Therapy|15 adolescents with history of suicidal behaviors receiving Support Therapy.
89550548|NCT02406625|No Intervention|Controls|A group of 15 healthy controls that are not receiving any kind of therapy.
89550549|NCT02409979|Active Comparator|Carbon dioxide method|Colonoscopy performed as usual, with the minimal CO2 insufflation required to aid insertion and adequate distension during withdrawal for exploration. Washing allowed as needed. Considered to be standard procedure.
89550550|NCT02409979|Experimental|Water Exchange-CO2|Insufflation not used until the cecum is reached. Infusion of a sufficient amount of water to render the lumen a slit to progress with the colonoscope. Part of the infused water will be constantly suctioned back exchanging clean for opaque water. Air pockets and residual feces will be always aspirated. Withdrawal phase done using carbon dioxide insufflation.
89550551|NCT02409979|Experimental|Water Exchange-AI|Insufflation not used until the cecum is reached. Infusion of a sufficient amount of water to render the lumen a slit to progress with the colonoscope. Part of the infused water will be constantly suctioned back exchanging clean for opaque water. Air pockets and residual feces will be always aspirated. Withdrawal phase done using air insufflation.
89550552|NCT02409901|Experimental|Exercise Rehabiliation|12 month personalized exercise rehabilitation in addition to standard clinical care
89550553|NCT02409901|No Intervention|Control|Standard clinical care only
89550554|NCT03171961|Experimental|online visit group|in online visit group , subjects has online visit with dietitian every 2 weeks
89550555|NCT03171961|Experimental|clinic visit group|clinic visit group ,subject has every 2 weeks in person visit at clinic
89550556|NCT03171961|Experimental|self-directed group|self-directed group ,subjects receive nutritional information via web and their energy needs for weight loss
89550557|NCT02409823||patients on atypical antipsychotics|
89550558|NCT02409511||Type 1 diabetic, retinopathy, non cardiovascular disease|Type 1 diabetic patients with microalbuminuria, diabetic retinopathy and without cardiovascular disease
89550559|NCT02409511||Non-diabetic, hipertension|Non-diabetic patients with hypertension and microalbuminuria
89550560|NCT02409511||Type 2 diabetic, non diabetic retinopathy|Type 2 diabetic patients without diabetic retinopathy and microalbuminuria
89550561|NCT02409511||Type 2 diabetic with diabetic retinopathy|Type 2 diabetic patients with diabetic retinopathy and microalbuminuria
89550562|NCT02409511||Type 2 diabetic, with proven nephropathy|Type 2 diabetic patients with biopsy proven diabetic nephropathy.
89550563|NCT02406469|Experimental|Sequence A1-A2|Oral consumption of milk containing both A1 and A2 type beta casein in intervention phase 1 and milk containing only A2 type beta casein in intervention phase 2.
89550564|NCT02406469|Placebo Comparator|Sequence A2-A1|Oral consumption of milk containing only A2 type beta casein in intervention phase 1 and milk containing both A1 and A2 type beta casein in intervention phase 2.
89550565|NCT02406313|Experimental|CTS + ETP|Patients following a standardized thermal cure (CTS) follow an additional program called Fibr'eaux (ETP) that consists in discussion groups and physical activities allowing patients to learn how to manage their illness.
89550566|NCT02406313|Active Comparator|CTS alone|Patients follow a standardized thermal cure that is a sedative, relaxing, antalgic and mobilizing treatment based on muds application, hydrotherapy and physiotherapy. The cure is made of 72 treatments selected among a list including muds application, massages, reeducation in thermal pool, baths and showers.
89550567|NCT04481269|Experimental|Research Group|Research group uses surface-modified composite coated orthopedic implants
89550568|NCT04481269|Active Comparator|Controls Group|Controls group uses conventional orthopedic implants
89550569|NCT02401477|Experimental|Ilaprazole + Amoxicillin|Noltec(Ilaprazole) 10mg 4 tablets BID + Ildong-Amoxicillin 500mg 1capsule and 250mg 1capsule QID by oral for 14 days
89550570|NCT03174769|Active Comparator|Normal Protein with weight loss|"weight loss subjects will consume a 750 reduced calorie daily diet based on current ht. wt and age~Meal Pattern USDA Healthy U.S.-Style Eating Pattern with ~5 oz eq of protein foods for 12 wk"
89550571|NCT03174769|Experimental|High protein and weight loss|"weight loss subjects will consume a 750 reduced calorie daily diet based on current ht. wt and age~Meal Pattern USDA Healthy U.S.-Style Eating Pattern with ~12.5 oz eq of protein foods for 12 wk"
89550572|NCT02401399|Placebo Comparator|regular diet|The patients receive regular diet of 900 Kcal/day during 15 days before surgery
89550573|NCT02401399|Active Comparator|high protein formula|The patients receive high protein formula during 15 days before surgery
89550574|NCT02401399|Experimental|Immunonutrition|The patients receive Immunonutrition during 15 days before surgery
89550575|NCT03174691|Experimental|Hormonal levels|Collect blood samples Blood samples are collected on the following days after human chorionic gonadotropin (hCG) injection: Day 0, Day 1, Day 2, Day 3, Day 4, Day 5, Day 6
89550576|NCT02406157|Experimental|577-MPL|577nm micropulse laser photocoagulation(577MPL) treatment to the macular area of retinal thickening with a focal or grid pattern
89550577|NCT02406157|Active Comparator|532-SLP|532nm subthreshold laser photocoagulation(532-SLP) treatment to the macular area of retinal thickening with a focal or grid pattern
89550578|NCT03174457||Treatment: micafungin|Participants receive once daily by intravenous infusion.
89550579|NCT00701701|Experimental|Regimen A: Alglucosidase alfa and Cyclophosphamide|Participants exhibiting clinical decline since starting alglucosidase alfa (Myozyme®) therapy and having inhibitory antibodies and/or a sustained high recombinant human acid alpha-glucosidase (rhGAA) antibody titer (defined as at least 2 titers greater than or equal to [>=] 25,600 obtained at least 1 month apart), regardless of their CRIM status, were assigned to Regimen A. In Regimen A, participants received alglucosidase alfa (Myozyme®) Intravenous (IV) infusion of 20 milligram per kilogram (mg/kg) every other week (qow) for a minimum of 18 months or, until the participant reached the age of 2 years (if the participant was less than [<6] months of age at the time of enrollment). In addition, cyclophosphamide 250 milligram per square meter (mg/m^2) IV infusion was administered every 4 weeks (q4w) after Myozyme® infusion for 6 months.
89550580|NCT00701701|Experimental|Regimen B: Alglucosidase alfa, Rituximab and Methotrexate|CRIM-negative participants were assigned to Regimen B if they either(1)exhibited clinical decline since starting alglucosidase alfa (Myozyme®)therapy and did not have inhibitory antibodies and/or a sustained rhGAA antibody titer(defined as at least 2 titers >=25,600 obtained at least 1 month apart),or(2) did not exhibit clinical decline since starting alglucosidase alfa(Myozyme®) therapy, regardless of their anti-rhGAA or inhibitory antibody status. Regimen B participants with CRIM-negative status received alglucosidase alfa(Myozyme®) IV infusion of 20 mg/kg qow for a minimum of 18 months or,until participant reached the age of 2 years (if participant was <6 months of age at time of enrollment). In addition,rituximab 375 mg/m^2 IV was administered weekly beginning the day after Myozyme® infusion for 4 weeks(an optional 2nd cycle could be administered at the discretion of the investigator) and biweekly methotrexate 15 mg/m^2 subcutaneous on the day after Myozyme® infusion for 6 months.
89550581|NCT02401711|Active Comparator|Online training|Residents randomized to the control group will only participate in the Breakthroughs in Patient Safety (BIPS) online training (Education - BIPS course). All residents in the comparison arm will receive evaluations on their non-technical skills, but the results will not be fed back to them until after the study has been completed.
89550582|NCT02401711|Experimental|Online training & Safety curriculum & Evaluation and feedback|Those in the intervention group will participate in a formal safety education curriculum in addition to the currently required Breakthroughs in Patient Safety (BIPS) online training. The intervention will have three components: (1) the mandatory online BIPS course (Education - BIPS course), (2) the formal safety curriculum, and (3) ongoing evaluation and feedback of operating room performance.
89550583|NCT03174613|Experimental|LC51-0255|tablets, PO
89550584|NCT03174613|Placebo Comparator|Placebo|tablets, PO
89550585|NCT02409745|Experimental|Young age group-Luteal phase|Endometrial injury in luteal phase (previous menstrual cycle) for patients undergoing Frozen thawed embryo transfer.
89550586|NCT02409745|Active Comparator|Young age group-Early follicular phase|Endometrial injury in early follicular phase for patients undergoing Frozen thawed embryo transfer.
89550587|NCT02409745|Experimental|Advanced age group-Luteal phase|Endometrial injury in luteal phase (previous menstrual cycle) for patients undergoing Frozen thawed embryo transfer.
89550588|NCT02409745|Active Comparator|Advanced age group-Early follicular phase|Endometrial injury in early follicular phase for patients undergoing Frozen thawed embryo transfer.
89550589|NCT02401321|Experimental|Supportive care (Taking Care of Her program)|Patients and spouse caregivers complete the Taking Care of Her Program comprising 5 telephone-delivered intervention sessions over 45-60 minutes every 2 weeks. The intervention sessions are designed to provide training for spouse caregivers and patients to better manage the impact and emotional toll of recently diagnosed ovarian cancer, including its impact on their interpersonal communication and support about the cancer.
89550590|NCT03174145|Active Comparator|Active group|
88812060|NCT03226730|No Intervention|Arm 4: Control|The fourth arm will serve as the control condition. Individuals in these villages will not receive the household, small group, or community-enabling environment intervention components.
88812061|NCT02476968|Other|Olaparib|Open Label Drug
88812062|NCT03201068|Experimental|Probiotic supplement|Renew Life Formulas, Inc
89550591|NCT03174145|Sham Comparator|Control group|
89550592|NCT04480957|Experimental|Escalation Cohort dose 1 of ARCT-021, 21 - 55 years|Escalation Cohort dose 1 of ARCT-021 administered through 0.5 mL intramuscular injection in the deltoid muscle.
89550593|NCT04480957|Experimental|Escalation Cohort dose 2 of ARCT-021, 21 -55 years|Escalation Cohort dose 2 of ARCT-021 administered through 0.5 mL intramuscular injection in the deltoid muscle.
89550594|NCT04480957|Experimental|Escalation Cohort dose 3 of ARCT-021, 21 - 55 years|Escalation Cohort dose 3 of ARCT-021 administered through 0.5 mL intramuscular injection in the deltoid muscle.
89550595|NCT04480957|Experimental|Escalation Cohort dose 4 of ARCT-021, 21 - 55 years|Escalation Cohort dose 4 of ARCT-021 administered through 0.5 mL intramuscular injection in the deltoid muscle.
89550596|NCT04480957|Experimental|Expansion cohort dose regimen 1, 21 - 55 years.|Expansion cohort dose regimen 1, administered through 0.5 mL intramuscular injection in the deltoid muscle.
89550597|NCT04480957|Experimental|Expansion cohort dose regimen 2, 21 - 55 years.|Expansion cohort dose regimen 2, administered through 0.5 mL intramuscular injection in the deltoid muscle.
89550598|NCT04480957|Experimental|Expansion cohort dose regimen 1, 56 - 80 years|Expansion cohort dose regimen 1, administered through 0.5 mL intramuscular injection in the deltoid muscle.
89550599|NCT04480957|Experimental|Expansion cohort dose regimen 2, 56 - 80 years|Expansion cohort dose regimen 2, administered through 0.5 mL intramuscular injection in the deltoid muscle.
89550600|NCT02401243|Experimental|Cohort 1 (INSIGHT titration algorithm)|INSULIN GLARGINE (U300): self-titration of insulin glargine 300 units/mL (U300) will be increased daily by 1 unit until fasting SMPG reaches the target range of 4.4 to 5.6 mmol/L
89550601|NCT02401243|Experimental|Cohort 2 (EDITION titration algorithm)|INSULIN GLARGINE (U300): titration of insulin glargine 300 units/mL (U300) will be adjusted weekly or not more than every 3 days to achieve the target range of fasting SMPG of 4.4 to 5.6 mmol/L
89550602|NCT02406079|Experimental|tracheotomy|
89550603|NCT02406001|Experimental|Tigran PTG|Surgical intervention: open flap debridement and implantation of bone grafting material
89550604|NCT02406001|Other|Control|Surgical intervention: open flap debridement
89550605|NCT02409433|Experimental|lacosamide|The lacosamide group will receive a loading dose of 400 mg IV, and on maintenance dose of up to 400 mg every 12 hours.
89550606|NCT02409433|Active Comparator|phenytoin|the phenytoin group will receive a loading dose of 20 mg/K IV, maximum of 2000 mg, given over 60 min. and will be started on a maintenance dose of 5 mg/K/day. Levels will be checked accordingly.
88961817|NCT03730701|Experimental|Prevention treatment group|Prevention program with 10 week blended intervention utilizing both a digital health app, group-sessions with peers and a interprofessional team of health-care workers chairing 5+1 themed group-sessions as support to change lifestyle habits in to a pattern of activities (behaviors and actions) in everyday life that can promote health and wellbeing and decrease risk for stroke. Lifestyle analysis and stroke risk screening before, at follow up and 12 months after the prevention program.
88961818|NCT03730701|No Intervention|Standard treatment group|Usal care in Swedish primary health care. In addition a Lifestyle analysis and stroke risk screening before, at follow up and 12 months after the prevention program.
88961819|NCT03657849|Experimental|Sampling with 19-gauge and 21-gauge|All patients will be allocated to the same arm. All patients will have EBUS TBNA done with both 19-gauge and 21-gauge needles during the procedure.
89517372|NCT03872947|Experimental|Arm T: TRK-950 + Paclitaxel|"Platinum Resistant epithelial ovarian, primary peritoneal or fallopian tube cancer~TRK-950 will be administered IV on days 1, 8, 15, and 22 of a 28-day cycle. On days 1, 8 and 15 of each cycle, Paclitaxel will be dosed on IV"
89517373|NCT03805594|Experimental|Schedule 1 (lutetium Lu 177-PSMA-617, pembrolizumab)|Patients receive lutetium Lu 177-PSMA-617 IV over 20-30 minutes on day 1. Beginning in cycle 2, patients receive pembrolizumab IV over 30 minutes on day 1. Treatment with pembrolizumab repeats every 21 days for up to 35 cycles (2 years) in the absence of disease progression or unacceptable toxicity. Patients who achieve SD or better may receive 17 additional cycles (approximately 1 year) of pembrolizumab.
88961822|NCT03642249|Experimental|experimental group|"face-to-face delirium care session (30 minutes in duration);~online learning delirium care activities (20 minutes in duration); and~delirium care OSCE and reflective activity (30 minutes in duration)."
89550607|NCT01989754|Experimental|Canagliflozin (JNJ-28431754)|Each patient will receive canagliflozin (JNJ-28431754) 100 mg once daily during the first 13 weeks, then the dose may be increased to 300 mg once daily.
89550608|NCT01989754|Placebo Comparator|Placebo|Each patient will receive placebo (inactive medication) once daily.
89550609|NCT01619878|Experimental|Cohort 1|"One Artemether-lumefantrine (COA566) dispersible tablet taken orally twice a day during 3 days.~Infants age >28 days."
89550610|NCT02015104|Experimental|Bacillus Calmette-Guerin (BCG) + PANVAC|Intravesical TICE BCG (50mg) once weekly starting in week 3 for a total of 6 weeks. PANVAC-V 2 x 10^8 pfu subcutaneous (SQ) at week 0 only; PANVAC-F 1 x 10^9 pfu SQ at weeks 3, 7, 11, and 15
89550611|NCT02015104|Experimental|Bacillus Calmette-Guerin (BCG) Alone|Intravesical TICE BCG (50mg) once weekly starting in week 3 for a total of 6 weeks
89550612|NCT04178746||IVH subjects in the Hyper-Acute Phase|The purpose of this prospective, single center, single arm registry is to assess technical feasibility, peri-procedural complications, post-procedure imaging outcomes, and 30-day safety outcomes in approximately 20 subjects with intracerebral hemorrhages utilizing the Artemis Neuro Evacuation Device in the hyper-acute phase. For the purposes of this registry, the hyper-acute phase as defined by initiation of the MIS procedure no longer than 12 hours from initial NCCT scans and no longer than 18 hours since time patients last known well.
89550613|NCT01619800|Experimental|Blended Sensor Optimization (BSO)|Patients in this arm will undergo pacemaker placement and will have blended sensor optimization. Minute Ventilation will be optimized/activated
89550614|NCT01619800|Sham Comparator|Accelerometer Alone (AA)|Patients in this arm will undergo pacemaker implantation but will not have Minute Ventilation Sensor activated. Only accelerometer will remain active
89550615|NCT01989208|Placebo Comparator|Sugar capsule|One normal healthy subject and two heart failure subjects will be randomized and given placebo throughout the trial period.
89550616|NCT01989208|Experimental|SG1002|200 mg capsule of SG1002 (alpha sulfur/sodium sulfate)
89517374|NCT03805594|Experimental|Schedule 2 (lutetium Lu 177-PSMA-617, pembrolizumab)|Patients receive lutetium Lu 177-PSMA-617 IV over 20-30 minutes and pembrolizumab IV over 30 minutes on day 1. Treatment with pembrolizumab repeats every 21 days for up to 35 cycles (2 years) in the absence of disease progression or unacceptable toxicity. Patients who achieve SD or better may receive 17 additional cycles (approximately 1 year) of pembrolizumab.
89550617|NCT01619410|Active Comparator|linezolid|
89550618|NCT01619410|Active Comparator|Clindamycin|
89550619|NCT01966042|Experimental|Stem Cell Therapy|"All subjects enrolled in the study underwent:~Local Sedation; Bone Marrow Aspiration; Minithoracotomy; Autologous bone marrow mononuclear cells infusion."
89550620|NCT04416724|Experimental|Phacoemulsification|Main study intervention will be Phacoemulsification
89550621|NCT04416724|Experimental|SLT|Main study intervention will be Selective Laser Trabeculoplasty
89550622|NCT02014480|Experimental|Umeclidinium|All subjects will receive UMEC in the dose of 62.5 mcg as inhalation powder in the NDPI once daily in the morning over 14 days in a cross over design.
89550623|NCT02014480|Experimental|Vilanterol|All subjects will receive VI in the dose of 25 mcg as inhalation powder in the NDPI once daily in the morning over 14 days in a cross over design.
89550624|NCT02014480|Experimental|Umeclidinium/Vilanterol|All subjects will receive UMEC/VI in the dose of 62.5/25 mcg as inhalation powder in the NDPI once daily in the morning over 14 days in a cross over design.
89550625|NCT05016167|Other|Control group (replacement every 24 hours)|The monitoring electrodes were not replaced for 24 hours, the electrodes were removed at the end of 24 hours (the protocol currently used in the institution) in control group.
89550626|NCT05016167|Experimental|Experimental Group (replacement every 12 hours)|In the experimental group, the monitoring electrodes were replacement every 12 hours within 24 hours.
89550627|NCT01261247|Experimental|Arm I|Patients receive oral panobinostat 3 times weekly. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
89550628|NCT02449577|Experimental|Beverage sequence ABCD|Each participant randomized to this arm is exposed to 4 test meals in the order ABCD with a washout period of at least a week between each meal. Each meal consisted of a standardized lunch of Parisian toast (sandwichbread, ham, cheese) together with a beverage. Each beverage is assigned a letter, A, B, C, or D. The letter assignment is blinded. The following four drinks were used Placebo: 330 ml of a soft drink (Sports drink), Beer 1 - 330 ml of an alcohol-free beer (<0.1% alcohol), Beer 2 - 330 ml of a regular lager beer (4.6% alcohol), and Beer 3 - 330 ml of a strong beer (7.2% alcohol)
89550629|NCT02449577|Experimental|Beverage sequence CADB|Each participant randomized to this arm is exposed to 4 test meals in the order CADB with a washout period of at least a week between each meal. Each meal consisted of a standardized lunch of Parisian toast (sandwichbread, ham, cheese) together with a beverage. Each beverage is assigned a letter, A, B, C, or D. The letter assignment is blinded. The following four drinks were used Placebo: 330 ml of a soft drink (Sports drink), Beer 1 - 330 ml of an alcohol-free beer (<0.1% alcohol), Beer 2 - 330 ml of a regular lager beer (4.6% alcohol), and Beer 3 - 330 ml of a strong beer (7.2% alcohol)
89550630|NCT02449577|Experimental|Beverage sequence DACB|Each participant randomized to this arm is exposed to 4 test meals in the order DACB with a washout period of at least a week between each meal. Each meal consisted of a standardized lunch of Parisian toast (sandwichbread, ham, cheese) together with a beverage. Each beverage is assigned a letter, A, B, C, or D. The letter assignment is blinded. The following four drinks were used Placebo: 330 ml of a soft drink (Sports drink), Beer 1 - 330 ml of an alcohol-free beer (<0.1% alcohol), Beer 2 - 330 ml of a regular lager beer (4.6% alcohol), and Beer 3 - 330 ml of a strong beer (7.2% alcohol)
89550631|NCT02449577|Experimental|Beverage sequence CBAD|Each participant randomized to this arm is exposed to 4 test meals in the order CBAD with a washout period of at least a week between each meal. Each meal consisted of a standardized lunch of Parisian toast (sandwichbread, ham, cheese) together with a beverage. Each beverage is assigned a letter, A, B, C, or D. The letter assignment is blinded. The following four drinks were used Placebo: 330 ml of a soft drink (Sports drink), Beer 1 - 330 ml of an alcohol-free beer (<0.1% alcohol), Beer 2 - 330 ml of a regular lager beer (4.6% alcohol), and Beer 3 - 330 ml of a strong beer (7.2% alcohol)
89550632|NCT02449577|Experimental|Beverage sequence ABDC|Each participant randomized to this arm is exposed to 4 test meals in the order ABDC with a washout period of at least a week between each meal. Each meal consisted of a standardized lunch of Parisian toast (sandwichbread, ham, cheese) together with a beverage. Each beverage is assigned a letter, A, B, C, or D. The letter assignment is blinded. The following four drinks were used Placebo: 330 ml of a soft drink (Sports drink), Beer 1 - 330 ml of an alcohol-free beer (<0.1% alcohol), Beer 2 - 330 ml of a regular lager beer (4.6% alcohol), and Beer 3 - 330 ml of a strong beer (7.2% alcohol)
89550633|NCT02449577|Experimental|Beverage sequence DABC|Each participant randomized to this arm is exposed to 4 test meals in the order DABC with a washout period of at least a week between each meal. Each meal consisted of a standardized lunch of Parisian toast (sandwichbread, ham, cheese) together with a beverage. Each beverage is assigned a letter, A, B, C, or D. The letter assignment is blinded. The following four drinks were used Placebo: 330 ml of a soft drink (Sports drink), Beer 1 - 330 ml of an alcohol-free beer (<0.1% alcohol), Beer 2 - 330 ml of a regular lager beer (4.6% alcohol), and Beer 3 - 330 ml of a strong beer (7.2% alcohol)
89550634|NCT02449577|Experimental|Beverage sequence DCAB|Each participant randomized to this arm is exposed to 4 test meals in the order DCAB with a washout period of at least a week between each meal. Each meal consisted of a standardized lunch of Parisian toast (sandwichbread, ham, cheese) together with a beverage. Each beverage is assigned a letter, A, B, C, or D. The letter assignment is blinded. The following four drinks were used Placebo: 330 ml of a soft drink (Sports drink), Beer 1 - 330 ml of an alcohol-free beer (<0.1% alcohol), Beer 2 - 330 ml of a regular lager beer (4.6% alcohol), and Beer 3 - 330 ml of a strong beer (7.2% alcohol)
89550635|NCT02449577|Experimental|Beverage sequence DBCA|Each participant randomized to this arm is exposed to 4 test meals in the order DBCA with a washout period of at least a week between each meal. Each meal consisted of a standardized lunch of Parisian toast (sandwichbread, ham, cheese) together with a beverage. Each beverage is assigned a letter, A, B, C, or D. The letter assignment is blinded. The following four drinks were used Placebo: 330 ml of a soft drink (Sports drink), Beer 1 - 330 ml of an alcohol-free beer (<0.1% alcohol), Beer 2 - 330 ml of a regular lager beer (4.6% alcohol), and Beer 3 - 330 ml of a strong beer (7.2% alcohol)
89550636|NCT02449577|Experimental|Beverage sequence ADCB|Each participant randomized to this arm is exposed to 4 test meals in the order ADCB with a washout period of at least a week between each meal. Each meal consisted of a standardized lunch of Parisian toast (sandwichbread, ham, cheese) together with a beverage. Each beverage is assigned a letter, A, B, C, or D. The letter assignment is blinded. The following four drinks were used Placebo: 330 ml of a soft drink (Sports drink), Beer 1 - 330 ml of an alcohol-free beer (<0.1% alcohol), Beer 2 - 330 ml of a regular lager beer (4.6% alcohol), and Beer 3 - 330 ml of a strong beer (7.2% alcohol)
89550637|NCT02449577|Experimental|Beverage sequence BADC|Each participant randomized to this arm is exposed to 4 test meals in the order BADC with a washout period of at least a week between each meal. Each meal consisted of a standardized lunch of Parisian toast (sandwichbread, ham, cheese) together with a beverage. Each beverage is assigned a letter, A, B, C, or D. The letter assignment is blinded. The following four drinks were used Placebo: 330 ml of a soft drink (Sports drink), Beer 1 - 330 ml of an alcohol-free beer (<0.1% alcohol), Beer 2 - 330 ml of a regular lager beer (4.6% alcohol), and Beer 3 - 330 ml of a strong beer (7.2% alcohol)
89550638|NCT02449577|Experimental|Beverage sequence ACDB|Each participant randomized to this arm is exposed to 4 test meals in the order ACDB with a washout period of at least a week between each meal. Each meal consisted of a standardized lunch of Parisian toast (sandwichbread, ham, cheese) together with a beverage. Each beverage is assigned a letter, A, B, C, or D. The letter assignment is blinded. The following four drinks were used Placebo: 330 ml of a soft drink (Sports drink), Beer 1 - 330 ml of an alcohol-free beer (<0.1% alcohol), Beer 2 - 330 ml of a regular lager beer (4.6% alcohol), and Beer 3 - 330 ml of a strong beer (7.2% alcohol)
89550639|NCT03233243|Experimental|Patients with positive 18F-NaF plaques|Patients with 18F-NaF-positive plaques (coronary, aortic or carotid) with TBR > 1.5
89550640|NCT03233243|No Intervention|Patients without 18F-NaF-positive plaques|Subjects without 18F-NaF- positive plaques will be excluded from the pharmacological intervention study
89550641|NCT02449655|Experimental|AZD5363 plus paclitaxel|AZD5363 4800mg bid 4 days on/ 3 days off of a 7 day cycle for each week that paclitaxel is given + paclitaxel 80mg/m2 given days 1, 8 and 15 of a 28 day cycle. AZD5363 and paclitaxel will be received for 3 consecutive weeks, followed by one week off-therapy in 4-week cycles.
89550642|NCT02449655|Active Comparator|AZD2014 plus paclitaxel|AZD2014 50mg BD 3 days on 4 days off of a 7 day cycle + paclitaxel 80mg/m2 given days 1, 8 and 15 of a 28 day cycle
88812063|NCT03201068|Placebo Comparator|Placebo|Placebo capsule
88812064|NCT01514513|Experimental|Licefreee Spray|
89550643|NCT04400123|Experimental|Treatment group TR|Intervention: Drug: famitinib malate, new formulation; Intervention: Drug: famitinib malate, old formulation.
89550644|NCT04400123|Experimental|Treatment group RT|Intervention: Drug: famitinib malate, old formulation; Intervention: Drug: famitinib malate, new formulation.
89550645|NCT03197753|Experimental|Laryngeal mask airway|Laryngeal mask airway insertion
89550646|NCT03197753|Active Comparator|Nasotracheal intubation|Nasotracheal tube insertion
89550647|NCT01677767||Cohort|
89550648|NCT03197519|Experimental|Experimental group|The experimental group will receive treatment as usual, that is to say, the standard treatment based on CBT principles that is offered by the different ED units in Spain, plus an online intervention using TCApp for a period of 12 weeks.
89550649|NCT03197519|Other|TAU control group|The TAU control group will receive treatment as usual, offered by the different ED units in Spain. Patients from the control group will be offered access to TCApp after a 6-month period.
89550650|NCT04897295|Active Comparator|Active tDCS|The intervention will be the stimulation with transcranial Direct Current Stimulation (tDCS). Each patient will undergo a 20 minutes session with anode placed on the right Dorso-Lateral Prefrontal Cortex (RDLPFC) and the cathode on the left DLPFC (LDLPFC); the tDCS will administrate a 1 mA stimulation. During the intensive treatment phase participant will undergo one stimulation/day for 5 consecutive days. After this, participants will receive one stimulation per week for 3 months with the same parameters. Device: tDCS device (E.M.S. Electromedical Systems, Bologna, Italy) with a maximum output of 5 mA and administered by two 25-cm2 sponge electrodes of rectangular shape.
89550651|NCT04897295|Sham Comparator|Sham tDCS|The intervention will be the stimulation with sham transcranial Direct Current Stimulation (sham tDCS). The device will be set by staff member not involved with data collection analysis to ensure the blinding of assessors. The device will be set to give a weak amperage for the first and the last 20 second of stimulation to ensure the blinding of participant giving them a similar sensation experienced by the active tDCS participants without stimulate brain tissues. Device: tDCS device (E.M.S. Electromedical Systems, Bologna, Italy) with a maximum output of 5 mA and administered by two 25-cm2 sponge electrodes of rectangular shape.
89550652|NCT03189563|Placebo Comparator|Placebo|placebo, tid
89550653|NCT03189563|Experimental|DA-9805 low|DA-9805 45mg
89550654|NCT03189563|Experimental|DA-9805 high|DA-9805 90mg
89550655|NCT04254731|Other|Cross over study before and after drug switch|Stabilized on racemic methadone dose, switched to R-methadone of half racemic methadone dose. Cross over study, own control
89550656|NCT01603277|Experimental|Anti-GM-CSF Monoclonal Antibody 400mg|
89550657|NCT01603277|Placebo Comparator|Normal Saline|
89550658|NCT04192487|Experimental|Healthy Volunteers (HIV-negative)|Drug: crofelemer delayed-release tablets, 125 mg BID x 30 days
89550659|NCT04192487|Experimental|HIV+ Patients (Fully Suppressed, Viral Load < 50c/mL)|Drug: crofelemer delayed-release tablets, 125mg BID x 30 Days
89550660|NCT04192487|Experimental|HIV+ Patients (Not fully suppressed viral load > 1000c/mL|Drug: crofelemer delayed-release tablets, 125mg BID x 30 Days
89550661|NCT04107623|Active Comparator|Grupp 1|Patients will be allocated to preserving the right gastric artery during the resection of GEJ cancer.
89550662|NCT04107623|Active Comparator|Grupp 2|Patients will be allocated to an extensive lymphatic resection (ligating the right gastric artery) during the resection of GEJ cancer.
89550663|NCT03197597||Strain isolation from the nasopharynx|A group of culture positive whooping cough patients.
88812065|NCT01514513|Active Comparator|Nix Creme Rinse, 1% Permethrin|
89208048|NCT04090385|Experimental|tDCS over M1 and FPA|Anodic transcranial direct current stimulation (tDCS) over left primary motor cortex (M1) and left frontal polar area (FPA). Duration: 20 minutes; Intensity: 2mA.
89208049|NCT04090385|Active Comparator|tDCS over M1|Anodic transcranial direct current stimulation (tDCS) over left primary motor cortex (M1). Duration: 20 minutes; Intensity: 2mA.
89208050|NCT00783770||30-33 weeks|mother infant pairs with gestation of 30-33 weeks
89550664|NCT04655027|Experimental|Roxadustat|Patients will receive oral dose of roxadustat three times a week (TIW) for 2- weeks during treatment period.
88812066|NCT02476578|Experimental|Intervention Email|An email is sent, alerting the primary care providers about low values of BMI, HbA1c% or cholesterol and advising to consider appropriate dietary and medical revision.
89208051|NCT00783770||34-37 weeks|mother infant pairs with gestation of 34-37 weeks
89550665|NCT04655027|Active Comparator|rHuEPO|Patients will receive uniform brand of short acting intravenous or subcutaneous dose of rHuEPO two times a week (BIW) or TIW based upon their previous dose of rHuEPO for 2- weeks during treatment period.
89550666|NCT04631705|Experimental|Group 1A (uninfected) - low dose|SARS-CoV-2-uninfected volunteers will receive a single dose of DZIF-10c by inhalation
89550667|NCT04631705|Experimental|Group 1B (uninfected) - mid dose|SARS-CoV-2-uninfected volunteers will receive a single dose of DZIF-10c by inhalation
89550668|NCT04631705|Experimental|Group 1C (uninfected) - high dose|SARS-CoV-2-uninfected volunteers will receive a single dose of DZIF-10c by inhalation
89550669|NCT04631705|Experimental|Group 2A (infected) - low dose|SARS-CoV-2-infected volunteers will receive a single dose of DZIF-10c by inhalation
89550670|NCT04631705|Experimental|Group 2B (infected) - mid dose|SARS-CoV-2-infected volunteers will receive a single dose of DZIF-10c by inhalation
89550671|NCT04631705|Experimental|Group 2C (infected) - high dose|SARS-CoV-2-infected volunteers will receive a single dose of DZIF-10c by inhalation
89550672|NCT04631705|Experimental|Group 2D (infected)|SARS-CoV-2-infected volunteers will be randomized 1:1:1 to receive DZIF-10c by inhalation and infusion, DZIF-10c by inhalation and placebo by infusion, or placebo by inhalation and infusion
88812067|NCT02476578|No Intervention|Control|No email is sent.
88812068|NCT01432145|Experimental|6MP/MTX|6-Mercaptopurine 55mg/m2 per day, and methotrexate 15mg/m2 per week
88812069|NCT04979520|Experimental|Brodalumab treated moderate-to-severe HS patients|Weekly Brodalumab treatment 210mg/1.5ml, given subcutaneously for 12 weeks.
89208052|NCT00783770||38-42 weeks|mother infant pairs with gestation of 38-42 weeks
89550673|NCT03197285|Active Comparator|Control Group|All patients are given a Combined Physiotherapy Protocol (CPP) consisting of: Thermotherapy (70 w continuous microwave for 10 minutes), therapeutic massage (surface rubbing for 5 minutes, 10 minutes of compression and kneading massage and 2 minutes of final surface friction), application of analgesic currents (TENS, by self-adhesive silicone electrodes 4x4 cm, symmetrical biphasic rectangular current, 200 µs width pulse, a frequency of 1 Hz for 10 minutes. The patient should notice a slight vibration, without it being painful).
89550674|NCT03197285|Experimental|Experimental Group|"All patients are given a Combined Physiotherapy Protocol (CPP) consisting of: Thermotherapy (70 w continuous microwave for 10 minutes), therapeutic massage (surface rubbing for 5 minutes, 10 minutes of compression and kneading massage and 2 minutes of final surface friction), application of analgesic currents (TENS, by self-adhesive silicone electrodes 4x4 cm, symmetrical biphasic rectangular current, 200 µs width pulse, a frequency of 1 Hz for 10 minutes. The patient should notice a slight vibration, without it being painful). The ECRP developed by Revel et al.(Revel et al., 1994) was also applied to patients in the experimental group.~EYE-CERVICAL RE-EDUCATION PROGRAM (ECRP) This includes a total of 10 exercises that has proprioceptive reprogramming in the cervical area"
89550675|NCT03876977|No Intervention|Non-invasive|Neuropathic drugs Pudendal infiltration
89550676|NCT03876977|Experimental|Robotic laparoscopic decompression|Robotic laparoscopic decompression of pudendal nerve entrapment.
89550677|NCT04508933||Typical ARDS|ARDS due to non Covid19 causes
89550678|NCT04508933||C-ARDS|ARDS due to Covid19
89550679|NCT03197441|Experimental|PRP group|Arthroscopic knee surgery plus intraoperative platelet-rich plasma
89550680|NCT01678313|Experimental|Study group|Doxazosin 4 mg daily plus celecoxib 200 mg every day (QD)
89025419|NCT00480207|Experimental|omega-3 placebo, folic acid, vit B12|folic acid, omega-3 placebo(canola oil),vitamin B12 (1000 mcg per day)
89208053|NCT03974425|Other|Diabetic macular edema resistant to Bevacizumab|Patients resistant to 6 monthly Bevacizumab injection were switched to Aflibercept.
89550681|NCT01678313|Experimental|Control group|Doxazosin 4 mg every day (QD)
89550682|NCT03197207|Experimental|lifting and thrusting|"Dragon and Tiger warring in lifting and thrusting"
89208054|NCT00867672|Experimental|Decitabine|i.v. Decitabine 20 mg/m² over 1h, 5 days (total dose 100 mg/m²), repeated every 4 weeks
89550683|NCT03197207|Experimental|twisting and rotating|"Dragon and Tiger warring in twisting-rotating"
89550684|NCT02449499||therapy|patients who meet inclusion criteria, continue to work with individual therapist, and participate in adjunct weekly group therapy
89550685|NCT02449499||control|patients who meet inclusion criteria, continue to work with individual therapist, and are eligible for group therapy participation but cannot participate in group due to schedule constraints
89550686|NCT03409991|Experimental|Experimental|Receives the 12-week Opening Doors group sessions, and up to 8 individual career counseling sessions.
89550687|NCT03409991|No Intervention|Waitlist Control|Offered non-vocational classes at the Boston University Center for Psychiatric Rehabilitation, and offered the chance to attend the Opening Doors program at the end of their enrolled 12-month study period.
89550688|NCT04435379|Experimental|VPM1002|"The active ingredient of the recombinant BCG vaccine, VPM1002, is Mycobacterium bovis rBCGΔureC::hly, freeze-dried and standardized to the number of viable mycobacteria (colony forming units; CFU) per application.~Dose: 2-8 x 10e5 CFU VPM1002 administered in 0.1 ml reconstituted suspension."
89550689|NCT04435379|Placebo Comparator|Placebo|Physiological saline 0.1ml
88812070|NCT00889928|Experimental|cholecystectomy|transvaginal cholecystectomy
88812071|NCT01432379||botulinum toxin Type A|155-195 U of botulinum toxin Type A administered intramuscularly in the face, head, and neck areas as directed by physician (approximately every 12 weeks) for 1 year.
88812072|NCT02504892|Experimental|Birt-Hogg-Dube Syndrome|Birt-Hogg-Dube Syndrome (BHD)-associated renal tumors
88812073|NCT02504892|Experimental|Sporadic chromophobe renal tumors|Sporadic chromophobe renal tumors
88812074|NCT02504502|Experimental|Enhanced genomic report|routine clinical care for return of results per whole genome sequencing study with enhanced genetic test results report developed through phase 1 and 2 of this study
88812075|NCT02504502|Other|Control with delayed access|routine clinical care for return of results per whole genome sequencing study and no intervention through three months. This arm will crossover to receipt of enhanced report upon completion of baseline and 3 month post-baseline followup surveys. Participants in this arm will complete a third survey at 3 months post receipt of enhanced report
88812076|NCT01432535|Active Comparator|Healthy Participants|Participants with normal renal function defined as having a creatinine clearance test value of ≥80 mL/min/1.73 m^2. Participants receive a single subcutaneous dose of PegIFN-2b, 4.5 μg/kg.
88812077|NCT01432535|Experimental|Participants with Moderate Renal Impairment|Participants with moderate renal impairment defined as having a creatinine clearance test value of 30-50 mL/min/1.73 m^2. Participants receive a single subcutaneous dose of PegIFN-2b, 4.5 μg/kg.
88812078|NCT01432535|Experimental|Participants with Severe Renal Impairment|Participants with severe renal impairment defined as having a creatinine clearance test value of <30 mL/min/1.73 m^2 or end stage renal disease on hemodialysis. Participants receive a single subcutaneous dose of PegIFN-2b, 4.5 μg/kg.
88812079|NCT05947045|Active Comparator|IPad Cogmed Training|The investigator will be randomizing participants to complete Cogmed training on an iPad.
88812080|NCT05947045|Experimental|Virtual Reality Cogmed Training|The investigator will be randomizing participants to complete Cogmed training in Virtual Reality.
89550690|NCT03407495|Experimental|single arm: IOP injection (MPB-1523)|single group treatment
89550691|NCT01603121|Experimental|Lisofylline subcutaneous|Lisofylline 12mg/kg as a continuous subcutaneous infusion over a 10 hours period
89550692|NCT01603121|Experimental|Lisofylline intravenous|Lisofylline 9 mg/kg as a continuous intravenous infusion over a 10 hours period
89550693|NCT04365803||patient with radiological complete response|patient with radiological complete response after neoadjuvant chemotherapy
89550694|NCT04413383|Active Comparator|Traditional Curved Iris Scissors|The traditional curved Iris scissors are used to during the dermatologic surgery. Patients complete a survey after the surgery on sights, sounds and smells experienced during the procedure.
89550695|NCT04413383|Experimental|Modified Curved Iris Scissors|"The Wuennenberg modified curved Iris scissors are used during the dermatologic surgery.~Patients complete a survey after the surgery on sights, sounds and smells experienced during the procedure."
89550696|NCT04413383|Other|Comparative Experience|Both the traditional and modified curved Iris scissors are used and patients are asked which they prefer. Patients complete a survey after the surgery on sights, sounds and smells experienced during the procedure.
89550697|NCT03246425|Active Comparator|1. Volume control- Pressure control- APRV- VPA group|
89550698|NCT03246425|Active Comparator|2. Pressure control- APRV- Volume control- PAV group|
89550699|NCT03246425|Active Comparator|3. APRV- Volume control- pressure control- AVP group|
89550700|NCT03139721||Primary cohort|Subjects requiring aortic or mitral valve replacement
89550701|NCT02356757|Experimental|Personalized Behavioral Intervention (PBI)|The PBI is a 12-month long integrated, multicomponent counseling and dermal thermometry intervention targeting foot self-care, foot self-monitoring, diet, medication and physical activity. The intervention is based on self-regulation theory, the Transtheoretical Model and
89550702|NCT02356757|Placebo Comparator|Current Best Practice (CBP)|This group will receive all the enhancements that the VA has targeted to improve foot risk in diabetes and foot care, and will also receive counseling regarding preventing general health conditions.
89550703|NCT03196895|Active Comparator|WR|Weight reduction training
89550704|NCT03196895|Active Comparator|GE|PPG training
89550705|NCT03196895|Experimental|GEM|PPG training + discrete BG feedback
89550706|NCT03196895|Experimental|GEM+CGM|PPG training + continuous BG feedback
89550707|NCT02449265|Experimental|ISRT group|"Six cycles chemotherapy (cyclophosphamide 750mg/square meter on day 1 + doxorubicin 50mg/square meter on day 1 + vincristine 1.4mg/square meter on day 1 (up to a maximal dose of 2 mg) +prednisone 60mg/square meter on day 1 through 5, repeated at 21-day intervals).~Consolidation involved-site radiotherapy (ISRT) following in patients with complete or paratial response beginning 1 month after the last cycle of chemotherapy."
89550708|NCT02449265|Active Comparator|IFRT group|"Six cycles chemotherapy (cyclophosphamide 750mg/square meter on day 1 + doxorubicin 50mg/square meter on day 1 + vincristine 1.4mg/square meter on day 1 (up to a maximal dose of 2 mg) +prednisone 60mg/square meter on day 1 through 5,repeated at 21-day intervals ).~Consolidation involved-field radiotherapy (IFRT) following in patients with complete or paratial response beginning 1 month after the last cycle of chemotherapy."
89550709|NCT05092685|Experimental|AAVLK03hOTC (also known as ssAAV-LK03.hAAT.hcoOTC)|Dose escalation in three groups from 6x10^11vg/kg (low dose), 2x10^12vg/kg (intermediate dose) to 6x10^12vg/kg (high dose). Dose expansion in a fourth group with the best acceptable safety:efficacy ratio
89550710|NCT05092217|Experimental|Tirelizumab plus salvage surgery|Tirelizumab: Tirelizumab treatment after salvage surgery. Salvage surgery: endoscopic nasopharyngectomy for recurrent nasopharyngeal carcinoma
89550711|NCT05092217|Active Comparator|salvage surgery alone|Salvage surgery: endoscopic nasopharyngectomy for recurrent nasopharyngeal carcinoma
89208055|NCT00867672|Experimental|Decitabine+VPA|i.v. Decitabine 20 mg/m² over 1h, 5 days (total dose 100 mg/m²), repeated every 4 weeks, and VPA (p.o.) from day 6 of first cycle continuously throughout all treatment cycles
89208056|NCT00867672|Experimental|Decitabine+ATRA|i.v. Decitabine 20 mg/m² over 1h, 5 days (total dose 100 mg/m²), repeated every 4 weeks and ATRA (45 mg/m² p.o.) from day 6 to day 28 of each treatment cycle
89550712|NCT04413305|Experimental|WGS-based screen and control group|For intervention group, we screen admitted patients for carbapenem-resistant Klebsiella pneumoniae and carry out 'Bundle' infection and control measures. When outbreak or tranmission of CRKP was observed, we take whole-genome sequencing to track origin and transmission route to decease CRKP rate.
89550713|NCT04413305|No Intervention|Non-intervention|Non-intervention
89550714|NCT03854747|No Intervention|control group|
89550715|NCT03854747|Experimental|working group|
89550716|NCT03196817|Active Comparator|Carpal tunnel injection|Carpal tunnel injection (infiltration) group of patients will be referred to the Hospital Alvorada to carry out steroid injection. The injection in carpal tunnel will be an association of 6.43 mg of betamethasone dipropionate, 2.63 mg of betamethasone disodium phosphate and 0.5 ml plus lidocaine 2%, totaling 1.5 ml.
89550717|NCT03196817|Active Comparator|Wrist splinting|Wrist splinting will be use in the nigth time, remain the wrist in the 15th degree in extension, until its removal in the morning.
89550718|NCT05091827||Pregnant women with pre-eclampsia|Pre-eclamptic pregnant women with singleton uncomplicated ≥ 20 week old pregnancies will be recruited in this group of the study.
89550719|NCT05091827||Normotensive pregnant women|Normotensive pregnant women with singleton uncomplicated ≥ 20 week old pregnancies will be recruited in this group of the study
89550720|NCT05091827||Offspring of pre-eclamptic women|Both male and female offspring of pre-eclamptic women recruited in this study will be recruited into this study group.
89550721|NCT05091827||Offspring of normotensive pregnant women|Both male and female offspring of from normotensive pregnant women recruited in this study will be recruited into this study group.
89550722|NCT03118661|Experimental|Maraviroc after allo-HCT|"Step 1: participants who have received at least 30 days of maraviroc immediately post allo-HCT can be enrolled. Blood will be drawn at 2 time points at least 2 weeks apart, but within 4 weeks, and assessed for HIV-1 reservoir using both DNA assays and cell-associated reactivation by infectivity after stimulation. If any biopsies post allo-HCT are performed as part of standard of care and available, these will also be assessed for HIV-1~Step 2: If HIV-1 reservoir is undetecable, antiretrovirals (ART) will be stopped in a structured treatment interruption (STI). HIV-1 VLs and CD4+ T-cells check weekly. Week 16, participants will have a large volume blood draw if remain suppressed. If confirmed return of viremia, ART will be reinitiated and he/she will be followed until HIV VL is <50 copies/ml. If he/she remains suppressed at Week 16 and repeat assays confirm no detectable HIV-1, HIV-1 VLs and CD4+ T-cell counts will be checked monthly until Week 52, and then quarterly until Year 5"
89550723|NCT01603043|Experimental|AL-78898A|1 intravitreal injection per month for up to 12 months
89550724|NCT01603043|Sham Comparator|Sham Injection|1 mock injection per month for 12 months
89550725|NCT05091515||Health workers|Medical personnel: doctors, nurses.
89550726|NCT05091359|Experimental|Study group|Participants in which absorbable graft of tricalcium ß phosphate / calcium sulfate hemihydrate paste at the time of the placement of the hip implant to prevent loosening of it's unstable trans-trochanteric fractures of the proximal femur, were applied.
89550727|NCT05091359|No Intervention|Control Group|Participants without application of graft during hip implant.
89550728|NCT03670745|Experimental|Pre-visit Planning Tool|To determine the effectiveness an electronic self-administered pre-visit planning tool allowing adolescents to list areas of concern to support shared decision-making during an office visit. Interviews will also explore approaches to implement and evaluate such a tool.
89550729|NCT03670745|Active Comparator|control group|Will not be receiving an electronic self-administered pre-visit planning tool.
89550730|NCT03197051||Q1|Measure the Concentration of Syndecan-1, Heparan sulfate before anesthetic induction and immediately after weaning from cardiopulmonary bypass. Categorize the patients by serum syndecan-1 concentration(off-CPB) quartile. Q1 means a group of lowest 25% of serum syndecan-1 concentration.
89550731|NCT03197051||Q2|Q2 means a group of lower 25~50% of serum syndecan-1 concentration.
89550732|NCT03197051||Q3|Q3 means a group of higher 50~75% of serum syndecan-1 concentration.
89550733|NCT03197051||Q4|Q4 means a group of highest 75~100% of serum syndecan-1 concentration.
89550734|NCT03196739|Experimental|Virtual rehabilitation|Upper limb rehabilitation using virtual reality with a head-mounted display (HTC Vive; HTC Co., New Taipei City, Taiwan)
89550735|NCT05091125||Patients over 65 years old who have undergone a mild head trauma.|
89550736|NCT03196583|Experimental|Single-arm study|Velo-Lingual Bite (BVL)
89550737|NCT03328013||Women aged 25 to 33 years in 2017|"Women aged 25 to 33 years in 2017 and having performed an analyzed smear at the Brest University Hospital.~They are invited to fill out an online questionnaire asking them about :~vaccine status against HPV~if vaccinated, the name of the vaccine and the number of injection~age of first sexual intercourse~do they have a gynecological pathology"
89550738|NCT02014402|Experimental|IG1202-A (Vascular)|
89550739|NCT02014402|Experimental|IG1202-B (Hepatic)|
89550740|NCT02014402|Experimental|IG1202-C (Soft Tissue)|
89550741|NCT02014402|Experimental|IG1202-D (Spinal)|
89550742|NCT01988662|Experimental|Ranibizumab|104 patients with an eligible study eye were randomized to be treated with Ranibizumab IVT. 0.5 mg of commercially available Ranibizumab were used for intravitreal injection adminstered by an unblinded injecting physician. 3 injections were performed (Baseline, Month 1, Month 2).
89550743|NCT01988662|Active Comparator|Aflibercept|101 patients with an eligible study eye were randomized to be treated with Aflibercept IVT. 2.0 mg of commercially available Aflibercept were used for intravitreal injection admistered by an unblinded injecting physician. 3 injections were performed (Baseline, Month 1, Month 2).
89550744|NCT02839343|Experimental|mFOLFIRINOX + surgery + FOLFOX|Patients receive 8 cycles of mFOLFIRINOX. One cycle is 14 days. mFOLFIRINOX consists of oxaliplatin, irinotecan, leucovorin and 5-FU. Patients undergo surgery and receive 4 cycles of FOLFOX 4-12 weeks after surgery. FOLFOX consists of oxaliplatin, leucovorin and 5-FU.
89025420|NCT00480207|Experimental|omega-3 placebo, folic acid placebo, vit B12|omega-3 placebo (canola oil),folic acid placebo (starch), vitamin B12 (1000 mcg per day)
89550745|NCT02839343|Experimental|mFOLFIRINOX + radiation + surgery + FOLFOX|Patients receive 7 cycles of mFOLFIRINOX. One cycle is 14 days. mFOLFIRINOX consists of oxaliplatin, irinotecan, leucovorin and 5-FU. Patients receive radiation therapy then undergo surgery and receive 4 cycles of FOLFOX 4-12 weeks after surgery. FOLFOX consists of oxaliplatin, leucovorin and 5-FU.
89550746|NCT00127673|Active Comparator|CBT no choice|Participants will receive no choice cognitive behavioral therapy (CBT no choice)
89550747|NCT00127673|Active Comparator|CBT choice|Participants will receive choice cognitive behavioral therapy (CBT choice)
89550748|NCT00127673|Active Comparator|sertraline no choice|Participants will receive no choice sertraline (sertraline no choice)
89550749|NCT00127673|Active Comparator|sertraline choice|Participants will receive choice sertraline (sertraline choice)
89550750|NCT05377073|Experimental|Hatha Yoga|Participants performed 1 hour supervised Yoga sessions once a week for a total of eight weeks.
89550751|NCT05377073|Experimental|Stretching|Participants performed 1 hour supervised Stretching sessions once a week for a total of eight weeks.
89550752|NCT03196661|Placebo Comparator|H7N9 split influenza vaccine (15μg/dose)|"This group was divided into three subgroups according ages of subjects, the ages of those subjects are: 3 to 11(36 subjects got inoculated test vaccines, 18 subjects got inoculated reference vaccines)，12 to 17(36 subjects got inoculated test vaccines, 12 subjects got inoculated reference vaccines)，≥18 (36 subjects got inoculated test vaccines, 12 subjects got inoculated reference vaccines).~Immune procedure: 0,21st day; Physical examination: 0,4th, 21st,25th day; Antibody detection: 0,21st,42nd day."
89550753|NCT03196661|Placebo Comparator|H7N9 split influenza vaccine (30μg/dose)|"This group was divided into three subgroups according ages of subjects, the ages of those subjects are: 3 to 11(36 subjects got inoculated test vaccines, 18 subjects got inoculated reference vaccines)，12 to 17(36 subjects got inoculated test vaccines, 12 subjects got inoculated reference vaccines)，≥18 (36 subjects got inoculated test vaccines, 12 subjects got inoculated reference vaccines).~Immune procedure: 0,21st day; Physical examination: 0,4th, 21st,25th day; Antibody detection: 0,21st,42nd day."
89550754|NCT03196661|Placebo Comparator|H7N9 whole virus influenza vaccine (7.5μg/dose)|"This group was divided into two subgroups according ages of subjects, the ages of those subjects are: 12 to 17(54 subjects got inoculated test vaccines,18 subjects got inoculated reference vaccines)，≥18 (54 subjects got inoculated test vaccines, 18 subjects got inoculated reference vaccines).~Immune procedure: 0,21st day; Physical examination: 0,4th, 21st,25th day; Antibody detection: 0,21st,42nd day."
89550755|NCT03196661|Placebo Comparator|H7N9 whole virus influenza vaccine (15μg/dose)|"This group was divided into two subgroups according ages of subjects, the ages of those subjects are: 12 to 17(54 subjects got inoculated test vaccines,18 subjects got inoculated reference vaccines)，≥18 (54 subjects got inoculated test vaccines, 18 subjects got inoculated reference vaccines).~Immune procedure: 0,21st day; Physical examination: 0,4th, 21st,25th day; Antibody detection: 0,21st,42nd day."
89550756|NCT05376995|Experimental|Graston technique.|The Graston Technique is a form of manual therapy known as soft-tissue instrument-assisted mobilization
89550757|NCT05376995|Experimental|muscle energy technique|Muscle Energy Technique (MET), uses a muscle's own energy in the form of gentle isometric contractions to relax the muscles via autogenic or reciprocal inhibition and lengthen the muscle
89550758|NCT05090735|Active Comparator|SPIP Block|50 Patients-Post-operatively patients will receive bilateral SPIP blocks by injecting 20 mL of 0.25% bupivacaine (on each side) between the pectoralis major and external intercostal muscle aponeurosis at 2 cm lateral to the right and left of the sternal edge, corresponding to the fifth rib.
89550759|NCT05090735|Active Comparator|SPIP Block with TAP Block|50 Patients-Post-operatively patients will receive bilateral SPIP blocks by injecting 20 mL of 0.25% bupivacaine (on each side) between the pectoralis major and external intercostal muscle aponeurosis at 2 cm lateral to the right and left of the sternal edge, corresponding to the fifth rib. This group of patients will also receive unilateral TAP block by injecting 20 mL of 0.25% bupivacaine in the plane between the internal oblique and transversus abdominis muscles.
89550760|NCT02379611|Active Comparator|normally hearing children|
89550761|NCT02379611|Experimental|Congenital profound deaf children|
89550762|NCT05376605||lung transplant|Patients who have passed at least 3 months after lung transplantation
89550763|NCT02449187|Experimental|JLP-1310, Fasted followed by fed|"JLP-1310 dosing in the fasted state followed by fed dosing~Interventions:~Drug: JLP-1310"
89550764|NCT02449187|Experimental|JLP-1310, Fed followed by fasted|"JLP-1310 dosing in the fasted state followed by fed dosing~Interventions:~Drug: JLP-1310"
89550765|NCT02449343|Experimental|Anlotinib|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
89550766|NCT02449343|Placebo Comparator|Placebo|Placebo QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
88961823|NCT03642249|Active Comparator|control group|"face-to-face delirium care session (30 minutes in duration);~online learning delirium care activities (20 minutes in duration)"
88961824|NCT03636230|Active Comparator|Remote Patient Management|Remote monitoring only
88961825|NCT03636230|Placebo Comparator|Standard of Care|In-clinic visits
89550767|NCT05376527|Experimental|VV-GMCSF-Lact|Double Recombinant Vaccinia Virus VV-GMCSF-Lact
89550768|NCT05090579|Active Comparator|Group I (BN10)|patients will receive an ultrasound-guided TAP block with 20 mL of 0.25% bupivacaine , 1 mL of 10 mg of nulbuphine plus 4 mL of normal saline to reach 25 mL as total volume on each side of the abdominal wall.
88961826|NCT03621774|Experimental|Mobile-assisted CBT-informed Skills Training|Psychosocial intervention combining in-person and smartphone-based CBT-informed skills training for experiential negative symptoms in schizophrenia, called Mobile-assisted Cognitive-Behavioral Therapy for Negative symptoms (mCBTn).
88961827|NCT03621774|Placebo Comparator|Supportive Contact|An active group leader- and device-contact control group.
88961828|NCT03615053|Other|Tailored Regimen|Implementation of WAPPS-Hemo personalized dosing regimen.
89550769|NCT05090579|Active Comparator|Group II (BN20)|patients will receive an ultrasound-guided TAP block with 20 mL of 0.25% bupivacaine ,2 mL of 20 mg of nulbuphine plus 3 mL of normal saline to reach 25 mL as total volume on each side of the abdominal wall.
89550770|NCT05090579|Active Comparator|Group lll(B)|patients will receive 20 mL of 0.25%bupivacaine plus 5 mL of normal saline to reach 25 mL as total volume on each side of the abdominal wall.
88961829|NCT03607942|Experimental|Experimental Formula|The experimental group will receive a liquid supplement containing 2 specific HMOs
88961830|NCT03607942|Placebo Comparator|Control Formula|The control group will receive a liquid placebo
89550771|NCT02449109|No Intervention|Control|Liver cancer patients never received any interventional therapy.
89550772|NCT02449109|Experimental|Nano drug|Liver cancer patients received nano drug interventional therapy using digital subtraction angiography（DSA）. The nano drug is made by mixing Gemzar® with Compound Glycyrrhizin Injection.
89550773|NCT02449109|Active Comparator|Drug microspheres|Liver cancer patients received drug microspheres (HepaSphere Microspheres) interventional therapy using digital subtraction angiography（DSA）.
89550774|NCT05087537|Active Comparator|Valve ablation|Valve ablation
89550775|NCT05087537|Active Comparator|Valve ablation and bladder neck incision|Valve ablation and bladder neck incision
89550776|NCT05095493|Experimental|zinc, then placebo|Participants first received oral zinc acetate 50 mg tab each day for 7 days before scheduled BoNT injection. 3 months later participants received oral placebo (matching oral zinc) tablet each day for 7 days before scheduled BoNT injection.
89550777|NCT05095493|Experimental|placebo, then zinc|Participants first received placebo tablet (matching oral zinc) each day for 7 days before scheduled BoNT injection. 3 months later participants received oral zinc acetate 50 mg tablet each day for 7 days before scheduled BoNT injection.
89550778|NCT05095415|Active Comparator|Typical Pre-operative Experience|Participants will be be placed in appropriate subgroups based upon their diagnosis and surgical intervention. Subgroups include: CMC Arthroplasty, ORIF of the Distal Radius, and Flexor/Extensor Tendon Repairs.
89550779|NCT05095415|Experimental|Occupational Therapy Consult Experience|Participants will be be placed in appropriate subgroups based upon their diagnosis and surgical intervention. Subgroups include: CMC Arthroplasty, ORIF of the Distal Radius, and Flexor/Extensor Tendon Repairs.
89550780|NCT01965652|Experimental|Naldemedine|Participants received 0.2 mg naldemedine tablets orally once daily for 52 weeks.
89550781|NCT01965652|Placebo Comparator|Placebo|Participants received matching placebo tablets orally once daily for 52 weeks.
89550782|NCT02677181|Experimental|ATG combined regimen|"ATG combined regimen for prophylaxis of GVHD, includes ATG, MMF(Mycophenolate mofetil ),CsA (cyclosporin A) and MTX (methotrexate).~All recipients in this arm received ATG, CsA, mycophenolate mofetil, and short-term methotrexate for GVHD prophylaxis. ATG (Thymoglobuline, rabbit) was used as 1.5 mg/kg/d on day -5 and 3.5 mg/kg/d on day -4. CsA (3 mg/kg, q12h, i.v.) was used from day -9, and the concentration was adjusted to 180-200 ng/mL. CsA was switched to oral administration when the patient's bowel function recovered. From day -9, 0.5 g of mycophenolate mofetil was administered orally from every 12 h, which was withdrawn on day +30. After graft infusion, MTX was given for all patients at 15 mg/m2 on day +1 and 10 mg/m2 on days +3, +6 and +11."
89550783|NCT02677181|Active Comparator|no-ATG|regimen for prophylaxis of GVHD without ATG. The regimen includes MMF,CsA and MTX.CsA (3 mg/kg, q12h, i.v.) was used from day -9, and the concentration was adjusted to 180-200 ng/mL. CsA was switched to oral administration when the patient's bowel function recovered. From day -9, 0.5 g of mycophenolate mofetil was administered orally from every 12 h, which was withdrawn on day +30. After graft infusion, MTX was given for all patients at 15 mg/m2 on day +1 and 10 mg/m2 on days +3, +6 and +11.
89550784|NCT01602965|Experimental|counseling monthly phone calls|the dietician will call the patient at home, and invite them to answer 11 open questions.The questionnaire collects information about weight loss, behaviours that need to be changed, problem-solving as to how to make the changes and physical activity levels.
89550785|NCT01602965|Active Comparator|self help informative Booklet|Self help informative booklet includes information on how to manage healthy weight, how to lose weight, physical activity and a simplified and abbreviated version of the main behavioural strategies.
89550786|NCT05095103||Stable Immunosuppressed|Acetylcholine repector antibody positvie myasthenia gravis, stable for two years on prednsiolone <5mg/day and azathioprine or mycophenolate.
89550787|NCT05095103||Stable Non-immunosuppressed|Acetylcholine repector antibody positvie myasthenia gravis, stable for two years on ≤120mg pyridostigmine/day and no immunosuppression.
89550788|NCT05095103||Refractory|Acetylcholine repector antibody positvie myasthenia gravis, meeting the NHS England criteria for Rituximab
89550789|NCT05095103||Healthy Controls|No autoimmune disease or current solid organ or haematological malignancy.
89550790|NCT05095025|Experimental|Bupivacaine dose finding|Sequential up and down dose modification based on the outcome of the intervention in the preceding participant
89550791|NCT03196271|Other|Study arm|One single arm, consisting of a 3 day baseline period, a 28 day control period and a 28 day intervention period (Ketocal 2.5:1), in that order.
89550792|NCT05065073|Active Comparator|Iso-Osmolar Contrast Media|Will receive iso-osmolar media first, low-osmolar media second
89550793|NCT05065073|Active Comparator|Low-Osmolar Contrast Media|Will receive low-osmolar media first, iso-osmolar media second
89550794|NCT05059379|Active Comparator|Breast/chest wall+undisseted axillary+IMN+medial SCL ( medial SCL radiation)|Radiation is delivered to the breast/chest wall, undissected axilla, internal mammary nodes and medial supraclavicular node. Treatment will be given by normfractionated or hypofractionated radiotherapy (50Gy/25Fx/5w or 42.5Gy/16Fx/3.5w). IMRT and VMAT technique are recommended.
88961831|NCT03581305|Active Comparator|Dopaminergic arm|"25 eligible HIV-infected individuals and 50 eligible HIV-negative (HIV-) individuals for the dopaminergic arm.~Dopaminergic arm:~Group A: HIV-positive subjects with or without co- morbidities; Group B: HIV-negative subjects with co-morbidities; Group C: HIV-negative subjects without co-morbidities"
88961832|NCT03581305|Active Comparator|Serotonergic arm|"20 HIV-infected individuals and 20 HIV-negative individuals for the serotonergic arm~Serotonergic arm:~Group D: HIV-positive subjects with or without co-morbidities; Group E: HIV-negative subjects with or without co-morbidities"
88961833|NCT03556202|Experimental|125 Milligram (mg) Mirikizumab Q8W|Participants received 125 mg mirikizumab administered subcutaneously (SC) every eight weeks (Q8W).
88961834|NCT03556202|Experimental|250 mg Mirikizumab Q8W Excluding Secukinumab|Participants received 250 mg mirikizumab administered SC Q8W excluding participants who received secukinumab of their originating study (AMAJ)
88961835|NCT03556202|Experimental|Secukinumab/250 mg Mirikizumab Q8W|Participants from previous originating study [who received secukinumab (AMAJ)] received 250 mg mirikizumab administered SC Q8W.
88961836|NCT03554616|Experimental|Pyriproxyfen LLIN|Royal Guard® (Disease Control Technologies, LLC) is a Long Lasting Insecticidal Net made of polyethylene incorporating a mixture of 225 mg/m2 pyriproxyfen and 261mg/m2 alpha-cypermethrin. This LLIN will be distributed to all the households in 21 clusters on a 1 LLIN per two household residents basis.
89208057|NCT00867672|Experimental|Decitabine+VPA+ATRA|i.v. Decitabine 20 mg/m² over 1h, 5 days (total dose 100 mg/m²), repeated every 4 weeks and VPA (p.o.) from day 6 continuously throughout all treatment cycles and ATRA (45 mg/m² p.o.), from day 6 to day 28 of each treatment cycle
89208058|NCT01071421||Control Group (B): Other Infections|Other infections admitted to the hospital
89208059|NCT01071421||Community Acquired Pneumonia (Group A)|Patients admitted to hospital with Community Acquired Pneumonia defined by respiratory symptoms, fever and lung infiltrates
89550795|NCT05059379|Experimental|Breast/chest wall+undisseted axillary+IMN+entie SCL (entire SCL radiation)|Radiation is delivered to the breast/chest wall, undissected axilla, internal mammary nodes and entire supraclavicular node. Treatment will be given by normfractionated or hypofractionated radiotherapy (50Gy/25Fx/5w or 42.5Gy/16Fx/3.5w). IMRT and VMAT technique are recommended.
89550796|NCT05056259||newly diagnosed endometrial cancer|
89550797|NCT05056259||Recurrent cases of endometrial cancer|
89550798|NCT01987960|Placebo Comparator|Placebo|Placebo adjunct to open-label treatment with a commercially available approved treatment for PTSD (PAR/SER)
89550799|NCT01987960|Experimental|Brexpiprazole|Brexpiprazole adjunct to open-label treatment with a commercially available approved treatment for PTSD (PAR/SER). Brexpiprazole dosing was 1mg/day for one week, followed by 2mg/day for 3 weeks. Thereafter the dose was flexible and could be adjusted from 1 to 3 mg/day.
89550800|NCT05084027|Experimental|treatment group|older patients accepting venetoclax combining with fludarabine and melphalan as conditioning regimen prior to allogeneic hematopoietic stem cell transplantation treatment
89550801|NCT02013778|Experimental|TACE + HCQ|Subjects will receive HCQ plus standard of care TACE.
89550802|NCT05374889|Experimental|Exercise Group|Athletes were asked to throw the ball at predetermined targets in different positions with their eyes closed. In the first exercise, the athlete was positioned 2 m from the target in a sitting position, facing the marked lines on the wall. It was asked to make 3 trial shots with a basketball ball while the eyes were open, from the bottom up to the 3 lines on the wall. Then the shots were made while the eyes were closed. In the next exercise, it was requested to make 3 trial shots from the bottom up by looking at the same 3 lines marked in the supine position at the distance of 1 m from the target. Then the shots were made with the eyes facing the ceiling. The last exercise was in a standing position, from the line marked 5 m from the target to the basket, it was requested to make 3 trial free throw with eyes open to the basket. Then, after each throw, the athlete was asked to turn around his own axis and continue to next throw, with eyes closed.
89550803|NCT05374889|No Intervention|Control Group|Control group did not participate in any exercise program.
89550804|NCT04676308||AI arm|Standard colonoscopy with Artificial Intelligence-GI GeniusTM
89550805|NCT04676308||Cuff arm|Endo-cuff Vision aided colonoscopy with Artificial Intelligence -GI GeniusTM
89550806|NCT05074745|Experimental|Buccal and nasopharyngeal swabs|One patient will have 3 swabs taken, 2 buccal for PCR and ELISA POCT, 1 nasopharyngeal for PCR
89550807|NCT02013622|Experimental|Brexpiprazole|Up to 4 mg/day, once daily dose, tablets, orally
89550808|NCT02448797|Experimental|icotinib|125 mg three times daily (375 mg per day) orally for two years.
89550809|NCT02448797|Active Comparator|standard chemotherapy|"Vinorelbine 25 mg/m^2, intravenously guttae, day 1 and day 8, 21 days/cycle, 4 cycles.~cisplatin 75 mg/m^2, intravenously guttae, day 1, 21 days/cycle, 4 cycles.~For adenocarcinoma: pemetrexed (500 mg/m^2, day 1)/cisplatin (75 mg/m^2, day 1) for 4 cycles."
89550810|NCT05374733|Other|Single arm|Coronary physiology measurements both pre- and post- transcatheter left-sided valvular intervention.
89550811|NCT04438421|Experimental|BMG0703|Subjects will then be given the test product, BMG0703, to be used twice a day after meals and after normal oral hygiene procedures. Next, the subjects will be re-evaluated after 3 days and after one month.
89550812|NCT04438421|Active Comparator|Chlorhexidine 0.2%|Subjects will then be given a 0.2% Chlorhexidine product, to be used twice a day after meals and after normal oral hygiene procedures. Next, the subjects will be reevaluated after 3 days and after one month.
89550813|NCT04438421|Placebo Comparator|Placebo Product|Subjects will then be given a placebo product, to be used twice a day after meals and after normal oral hygiene procedures. Next, the subjects will be reevaluated after 3 days and after one month.
89550814|NCT05099081|Experimental|diode laser|diode laser application
89550815|NCT05099081|Active Comparator|sclerotherapy|intra-lesional injection of ethanolamine oleate
89550816|NCT04438577|Experimental|Efficacy of Lidocaine mucilage-ICG|Efficacy of Lidocaine mucilage-ICG for intraoperative tumor delineation
89550817|NCT04846439|Experimental|CAR-T infusion|CD19 and BCMA CAR-T cells were infused into complete remission acute leukemia patients with PTR sequentially, with（1.0-2.0）×10e7/kg respectively. Each patient was followed up for 1 years.
89550818|NCT03196037|Experimental|Tai Chi|The Tai Chi intervention will be lead by an expert Tai Chi instructor with 15 years of teaching experience, and will take place at a local Yoga studio. The 8-week intervention entails two 75-minute sessions per week for a total of 16 sessions. Each session will begin with a 15- minute warm-up followed by 25 minutes of performing basic stances, footwork, upper-body/arm/hand movement, proper body alignment, mental/visual focus, and balance; 30 minutes of instruction in a choreographed form (first section of the Yang style long-form); and ending with a 5-minute cool-down.
89550819|NCT05087615|No Intervention|Control|Patients who did not receive any antiemetic during hospitalization (NA).
89550820|NCT05087615|Experimental|MA|Patients receiving metoclopramide alone (MA).
89550821|NCT05087615|Experimental|OA|Patients who received ondansetron only (OA).
89550822|NCT05087615|Experimental|MO|Patients receiving a combination of metoclopramide and ondansetron (MO).
89550823|NCT05087615|Experimental|GA|Patients who received granisetron alone (GA).
89550824|NCT01987102|Experimental|Cohort 1|"1 MAP cycle (incl. 2 HDMTX Courses using Calcium Folinate rescue 15mg/m2)~1 MAP cycle (incl. 2 HDMTX Courses using [6R] 5,10-methylenetetrahydrofolate rescue 15mg/m2)"
89550825|NCT01987102|Experimental|Cohort 2|"1 MAP cycle (incl. 2 HDMTX Courses using Calcium Folinate rescue 15mg/m2)~1 MAP cycle (incl. 2 HDMTX Courses using [6R] 5,10-methylenetetrahydrofolate rescue 7,5mg/m2 or 30mg/m2*)~*Dose will depend on outcome from Cohort 1"
89550826|NCT02448953|Active Comparator|negative lymph node|lymph node along the right recurrent laryngeal nerve should be confirmed negative by intraoperative frozen pathology examination
89550827|NCT02448953|Active Comparator|positive lymph node|lymph node along the right recurrent laryngeal nerve should be confirmed negative by intraoperative frozen pathology examination
89550828|NCT02013544|Placebo Comparator|Placebo|Placebo vaginal ovule daily for 12 weeks
89550829|NCT02013544|Experimental|Prasterone|Prasterone (DHEA) vaginal ovule daily for 12 weeks
89550830|NCT04284605|Experimental|Group1|
89550831|NCT04284605|Experimental|Group2|
89550832|NCT03968939|No Intervention|Control group (Usual Care)|Usual care
89208060|NCT05145231||grup 1|GMFCS PEDİ ABİLOCO-KİDS FMS
89550833|NCT03968939|Active Comparator|Sleep Hygiene Education|Sleep Hygiene Education
89550834|NCT03968939|Active Comparator|Over-the-counter sleep aids (25 mg Benadryl + 3mg melatonin)|Over-the-counter sleep aids (25 mg Benadryl + 3mg melatonin) and Sleep Hygiene Education
89550835|NCT03856619|Experimental|Aubagio®/Teriflunomide|Single dose of Aubagio® to be taken orally, once daily in the morning
89550836|NCT02448407|Experimental|Platelet rich plasma|Three intraarticular injection, one each fifteen days
89208061|NCT00783926|Experimental|Cohort 1|60 subjects randomized in an equal number to six different vaccine doses
89550837|NCT02448407|Active Comparator|Hyaluronic acid|Infiltrations of Hyaluronic acid as Hyaluronate 2,5 ml, 1 % solution, administered by intraarticular injection (3 doses, one each fifteen days)
89550838|NCT03195647|Experimental|Relaxed control|Those randomised to the 'Relaxed' Group will receive potassium supplementation only if their serum potassium drops below or equals 3.6 mEq/L.
89550839|NCT03195647|Active Comparator|Tight Control|Patients randomised to the 'Tight' group will receive potassium supplementation if their serum potassium falls below 4.5 mEq/L (current practice).
89550840|NCT05374343|Active Comparator|Group A and C (normal kidney function)|Each subject will receive a single dose of rongliflozin on Day 1
89550841|NCT05374343|Experimental|Group B (mild renal impairment)|Each subject will receive a single dose of rongliflozin on Day 1
89550842|NCT05374343|Experimental|Group D (moderate renal impairment)|Each subject will receive a single dose of rongliflozin on Day 1
89550843|NCT05374265|No Intervention|Registry|Patients with non-viable myocardium will be treated with standard clinical care.
89550844|NCT05374265|Other|OMT with revascularization|Patients with viable myocadium will be randomised to OMT with revascularization. PCI will be performed according to standard techniques using newer generation drug eluting stents. All patients will receive dual anti-platelet treatment for 12 months, or as per local practice guidelines.
89550845|NCT05374265|Other|OMT alone|Patients with viable myocardium will be radomised to OMT alone. PCI will be performed according to standard techniques using newer generation drug eluting stents. All patients will receive dual anti-platelet treatment for 12 months, or as per local practice guidelines.
89550846|NCT02013388|Experimental|10 mg|single oral daily dose of 10 mg N91115 for 14 days
89550847|NCT02013388|Placebo Comparator|Placebo|single oral daily dose of placebo for 14 days
89550848|NCT02013388|Experimental|50 mg|single oral daily dose of 50 mg N91115 for 14 days
89550849|NCT02013388|Experimental|50 mg (single dose)|single oral dose of 50 mg N91115
89550850|NCT02013388|Experimental|250 mg|single oral daily dose of 250 mg N91115 for 14 days (fasted)
89550851|NCT02013388|Experimental|250 mg (Fed)|single oral daily dose of 250 mg N91115 for 1 day (fed fat meal)
89550852|NCT02013388|Experimental|500 mg|single oral daily dose of 500 mg N91115 for 14 days
89550853|NCT02013388|Placebo Comparator|Placebo-Day 1 only|Single oral dose of placebo (Day 1 only)
89550854|NCT05200715||Patients affected by autoinflammatory diseases|
89550855|NCT02012686|Placebo Comparator|Control group|numerical rating scale of TENS non-applied group
89550856|NCT02012686|Active Comparator|TENS group|numerical rating scale of TENS applied group
89550857|NCT02012452|Experimental|tobacco treatment|participants will be provided contingency management and cognitive behavioral therapy to help them quit tobacco prior to PTSD treatment
89550858|NCT02012452|Sham Comparator|health education treatment|Participants will be provided education on a variety of health topics and will set health goals around each topic
88812081|NCT05947019|Experimental|Low-Level Red-Light threapy plus glasses threapy|Myopic amblyopia comprehensive treatment equipment + conventional optometry with glasses for treatment
89208062|NCT00783926|Experimental|Cohort 2|Following review of safety data of Cohort 1, approximately 360 additional subjects randomized in an equal number to the six different vaccine doses
89550859|NCT05098847|Experimental|Cryoablation in combination with Sintilimab plus lenvatinib|
89550860|NCT03195179||Suprapubic tube placement|Standard of care management for men with complete urethral injuries where a Foley catheter fails to be placed will have a suprapubic tube placed to manage the acute urethral injury. This is a standard of care approach and a retrospective review will be done on the patient record to determine outcomes.
89550861|NCT03195179||Urethral realignment|Standard of care management for men with complete urethral injuries where a Foley catheter fails to be placed will undergo urethral realignment with a combined antegrade / retrograde approach within 7 days of injury. This is a standard of care approach and a retrospective review will be done on the patient record to determine outcomes.
89550862|NCT01676909|Experimental|Living Well|This study will involve a clinical trial of Living Well (LW), a 12-session, peer co-led, group intervention designed to help veterans with co-occurring Serious Mental Illnesses and Chronic Medical Conditions learn techniques for better health management and ways to live a healthier lifestyle. Key topics that will be discussed are medication side effects, how symptoms of mental illness may affect veterans' ability to manage their medical conditions, effects of substance use on medical and mental health functioning, learning ways to eat healthier and exercise, and how to communicate more effectively with care providers. After completing the 12 weekly groups, participants will return to complete once monthly booster group sessions for the next three months.
89550863|NCT01676909|Active Comparator|Medical Illness Education & Support Group|We selected a comparison condition that would provide parallel focus (i.e. medical illness) but not include use of the core ingredients undergirding the Living Well intervention including behavioral action planning, problem solving, in-session and between session practice using specific disease self-management techniques and involvement of peer co-facilitators to enhance modeling and improve self-efficacy and activation. As with Living Well, the content of the intervention will have broad applicability across diverse chronic disease conditions. The comparison condition will be a once-weekly support and education group focusing on living with a chronic medical condition.
89550864|NCT04437953|Experimental|Avatrombopag|Patients will receive an initial dose of Avatrombopag 60 mg on Day 1.Starting on Day 2, the dose will be Avatrombopag 20 mg daily.
89550865|NCT03051971|Active Comparator|Jet nebulizer|short-acting bronchodilator (albuterol and/or ipratropium bromide) according to standard of care practices and physician discretion will be administered with a jet nebulizer
89025421|NCT03274583||Study Group|Patients being treated in the wards of Heart Center and Acute Internal Medicine of Turku University Hospital, Turku Finland between April and September 2017 with atrial fibrillation as the prevalent rhythm.
89550866|NCT03051971|Active Comparator|Vibrating Mesh Nebulizer|short-acting bronchodilator (albuterol and/or ipratropium bromide) according to standard of care practices and physician discretion will be administered with a vibrating mesh nebulizer
89550867|NCT04517357|Experimental|Safety Lead-in or Parallel， Fluzoparib+Apatinib|Participants will receive Fluzoparib-Apatinib combination until progression
89550868|NCT04517357|Active Comparator|Fluzoparib monotherapy|Participants will receive Fluzoparib monotherapy until progression
89550869|NCT04517357|Other|Exploratory cohort: Fluzoparib+Apatinib|Participants who has previously received PARP inhibitor, will receive Fluzoparib-Apatinib combination until progression
89025422|NCT03274583||Control group|Patients being treated in the wards of Heart Center and Acute Internal Medicine of Turku University Hospital, Turku Finland between April and September 2017 with sinus rhythm as the prevalent rhythm.
89025423|NCT00442455|Experimental|Erlotinib, radiotherapy.|There are three cohorts of patients in whom the dose of Erlotinib chlorhydrate(100 and 150 mg) and Cisplatin (30 and 40 mg / m2) will be increase, and the doses of Radiation therapy being fixed (63 Gy during 5 days a week during 7 weeks)
89550870|NCT02012296|Active Comparator|Treatment (enzalutamide)|Patients receive enzalutamide PO per standard of care.
89550871|NCT02012296|Experimental|Treatment (enzalutamide, mifepristone)|Patients receive enzalutamide PO and mifepristone PO.
89550872|NCT02012218|Experimental|ADT and Brexpiprazole|ADT and Brexpiprazole
89550873|NCT04658836|Experimental|Triamcinolone application|Patients will recieve intratympanic triamcinolone acetonide 24h before vestibular schwannoma surgery
89550874|NCT01965262|Active Comparator|Hema-copolymer Lens|Participants were randomized to wear the Hema-copolymer lens pair for one week during the cross over study.
89550875|NCT01965262|Active Comparator|etafilcon A Lens|Participants were randomized to wear the etafilcon A lens pair for one week during the cross over study.
89550876|NCT01677377|Experimental|Cohort 1, RBP-7000 60 mg|Participants who were stable on 2 mg oral daily risperidone during the run-in period received 3 single,unblinded, subcutaneous (SC) injection doses of 60 mg risperidone in RBP-7000 on study days 1, 29 and 57. Participants returned to 2 mg oral daily risperidone on days 85-87.
89550877|NCT01677377|Experimental|Cohort 2, RBP-7000 90 mg|Participants who were stable on 3 mg oral daily risperidone during the run-in period received 3 single,unblinded, subcutaneous (SC) injection doses of 90 mg risperidone in RBP-7000 on study days 1, 29 and 57. Participants returned to 3 mg oral daily risperidone on days 85-87.
89550878|NCT01677377|Experimental|Cohort 3, RBP-7000 120 mg|Participants who were stable on 4 mg oral daily risperidone during the run-in period received 3 single,unblinded, subcutaneous (SC) injection doses of 120 mg risperidone in RBP-7000 on study days 1, 29 and 57. Participants returned to 4 mg oral daily risperidone on days 85-87.
89550879|NCT01964950||Alogliptin|All participants who received alogliptin 25 milligram (mg), tablets, orally, once daily for up to 12 months along with Sulfonylurea (SU) or without SU within 3 months from the start of administration of alogliptin and during the treatment period of alogliptin as per routine clinical practice were observed in this study.
89550880|NCT02893865|Experimental|Experimental|Continuous positive airway pressure Patients will receive continuous positive airway pressure during three months
89550881|NCT02893865|Sham Comparator|Sham Comparator|Sham-continuous positive airway pressure Patients will receive sham-continuous positive airway pressure during 3 months
89550882|NCT05104151|Experimental|Group with nutritional bar|Participants will recieve two nutritional bars per day during eight weeks, and will receive a healthy habits intervention wich includes: nutritional intervention providing a caloric deficit of 500 calories, and a prescription of moderate physical activity from 60 to 90 minutes daily.
89550883|NCT05104151|Active Comparator|Group without nutritional bar|Participants will receive a healthy habits intervention wich includes nutritional intervention providing a caloric deficit of 500 calories, and a prescription of moderate physical activity from 60 to 90 minutes daily during eight weeks.
89550884|NCT02492009|Placebo Comparator|Standard Resource Sheet|Women allocated to the control intervention will login to the study website and receive a printable PDF containing references to standard published information on antidepressant use in pregnancy. This ensures women have access to accurate information on the benefits and risks of antidepressant medication in pregnancy (even though they will not receive the PDA).
89550885|NCT02492009|Active Comparator|Electronic Patient Decision Aid|"The electronic Patient Decision Aid (PDA) is an interactive website with 3 main sections:~Evidence-based information on (a) depression in pregnancy, (b) each treatment option and procedure;~(a) Evidence-based information on the risks and benefits of both untreated depression and antidepressant treatment, (b) exercises to help women determine which risks and benefits are most important to them; and~A summary section that outlines the information reviewed and which benefits and risks they deemed most important.~At the end of the PDA, women allocated to this intervention will ALSO receive the standard resource sheet which is being used as the placebo comparator."
89025424|NCT02956655|Experimental|Fasting therapy|Fasting therapy, lasting for 14 days, all subjects are isolated from ordinary food. However, drinking water is not limited and they are encouraged to drink more, at least 3 liters. Besides, they need to take some middle intensity exercise for at least 2 hours. They will take some prescribed medications except for hypoglycemic drugs.
89025425|NCT02956655|Active Comparator|Insulin intensive therapy|Insulin intensive therapy, receive continuous subcutaneous insulin infusion. (Human Insulin (Novolin-R, Novo Nordisk) Device: H-Tron Plus V100; Disetronic Medical System, Burgdorf, Switzerland). The insulin dose used will be adjusted everyday according to their glucose by a physician until a target blood glucose level been reached.
89025426|NCT00455117|Placebo Comparator|1|placebo (2 ml normal saline) administered intravenously at dural closure during craniotomy
89025427|NCT00455117|Active Comparator|2|parecoxib 40 mg in 2 ml normal saline administered intravenously at dural closure during craniotomy
89025428|NCT00442494|Other|Study couldn´t start due to investigator|Study couldn´t start due to investigator
89550886|NCT04458623|Active Comparator|positive air test|postoperative in the recovery room.patients received supplemental oxygen through a venture mask with a jet and flow adjusted to a theoretical fio2 of 100% for 10 min. The Air-Test was then performed by removing the oxygen mask and leaving the patients breathing room air for 10 min while continuously monitoring SpO2 with a pulse oximeter finger probe. The Air-Test result was considered positive when the recorded SpO2 was ≤96%.
89550887|NCT04458623|Active Comparator|negative air test|negative when SpO2 was >96 %.
89550888|NCT05098691||Group 1 (Early onset Preeclampsia )|43 cases The groups were matched for gestational age and gravidity.
89550889|NCT05098691||Group 2 ( Healthy pregnant woman) control group|41 cases The groups were matched for gestational age and gravidity
89550890|NCT04430387|Active Comparator|Group 1- The saliva ejector|
89550891|NCT04430387|Active Comparator|Group 2- The high-volume evacuator|
89550892|NCT04430387|Active Comparator|Group 3- The DryShield|
89550893|NCT04066205|Experimental|SLEEPSMART PROGRAM|"Arm: Placebo Comparator (Usual care)-This treatment arm will receive usual JIA care, including annual Rheumatology clinic visits, medications, routine clinical and laboratory tests, physical therapy, follow-up appointments, and no sleep intervention.~Arm: Experimental -Each child and parent will create a login, choose treatment goals, and interact with fields in the Web site. The modules will focus on improving sleep hygiene, relaxation, or increasing sleep duration. The intervention will last 6 to 8 weeks."
89550894|NCT05098535|Experimental|Visual Aid + Scripted Risk Discussion|This will involve the group of patients randomized to receive their perioperative risk discussion supplemented with the use of a visual aid in addition to a scripted discussion of their personalized perioperative risk of myocardial injury (MINS) during their consultation with an anesthesiologist in the PSS clinic.
89550895|NCT05098535|Active Comparator|Scripted Risk Discussion|This will involve a group of patients randomized to receive a scripted discussion of their personalized perioperative risk of myocardial injury (MINS) during their consultation with an anesthesiologist in the PSS clinic.
89550896|NCT05103995||ABO matched|Donor-recipient ABO matched
89550897|NCT05103995||Minor incompatibility|Donor-recipient minor incompatibility
89550898|NCT05103995||Major incompatibility|Donor-recipient major incompatibility
89550899|NCT05103995||Bidirectional incompatibility|Donor-recipient bidirectional incompatibility
89550900|NCT05103917|Experimental|X4P-001-201|trial to Study the Safety, Tolerability and Antitumor Activity of X4P-001 in Combination with Toripalimab in Patients with Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)
89550901|NCT03861221|Experimental|Conebeam Breast Computed Tomography|
89550902|NCT05098223|No Intervention|Promotions|Participants in this group will see a version of the website which will reproduce the types and frequency of promotions that can be found in any online supermarket, for example multi-buy offers and temporary price reductions will be applied to a pre-determined percentage of food products within the target categories [confectionery; biscuits and crackers; crisps, nuts and snacking fruit; cakes and tarts]. Promotions will be applied to match the current levels and types of promotions on the website of the largest UK retailer present in a specific week, shortly before the study launch.
89550903|NCT05098223|Experimental|No promotions|All price promotions will be removed so no promotions will be present on any of the products within the target food categories [confectionery; biscuits and crackers; crisps, nuts and snacking fruit; cakes and tarts] offered to participants when searching for products.
89550904|NCT05097911|Experimental|Advanced HCC patients|Patients will receive treatment as outlined until unacceptable toxicity or loss of clinical benefit as determined by the investigator after an integrated assessment of radiographic and biochemical data, and clinical status. If scheduled dosing and study assessments are precluded because of a holiday, weekend, or other event, then dosing may be postponed to the soonest following date, with subsequent dosing continuing on a 21-day schedule. If treatment was postponed for fewer than 3 days, the patient can resume the original schedule.
89550905|NCT03732209|Experimental|Episodic future thinking|Participants will generate positive future events and related text cues that will be accessed via an electronic app to engage in episodic future thinking.
89550906|NCT03732209|Sham Comparator|Control thinking|Participants will generate non-future-oriented information and related text cues that will be accessed via an electronic app to engage in control thinking..
89550907|NCT05097365|Experimental|Supplemented Lean Group|
89550908|NCT05097365|Experimental|Supplemented Obese Group|
89550909|NCT05097365|Placebo Comparator|Control Lean Group|
89550910|NCT05097365|Placebo Comparator|Control Obese Group|
89550911|NCT01964716|Experimental|Multidose Vial Group|Subjects will receive three doses of 13-valent pneumococcal conjugate vaccine in the multidose vial formulation. Each dose is 0.5 mL
89550912|NCT01964716|Active Comparator|Single-Dose Syringe Group|Subjects will receive three doses of 13-valent pneumococcal conjugate vaccine in the single-dose syringe formulation. Each dose is 0.5 mL
89550913|NCT01964560|Experimental|Lacosamide|"In the first week after enrollment into EP0034 subjects will be dosed according to their weight:~Lacosamide (LCM) 10 mg/kg/day (oral solution) for subjects weighing <30 kg~LCM 6 mg/kg/day (oral solution) for subjects weighing ≥30 kg to <50 kg~LCM 300 mg/day (tablets) for subjects weighing ≥50 kg~After 1 week the investigator may adjust the LCM dose during the Treatment Period based on clinical judgment within a range of 2 mg/kg/day to 12 mg/kg/day for the oral solution and 100 mg/day to 600 mg/day for the tablets."
88812082|NCT05947019|Experimental|glasses threapy|conventional optometry with glasses for treatment
89550914|NCT02659943|Experimental|LEVEL 1 - Participants Who Received 0.66x10^6 CAR T Cells Only|LEVEL 1 - participants who received - 0.66x10^6 Chimeric Antigen Receptor (CAR) T cells only
89550915|NCT02659943|Experimental|LEVEL 1 Foll/by LEVEL 2-Participants Who Received - 0.66x10^6 CAR T Cells Foll/by 2x10^6 CAR T Cells|LEVEL 1 followed by LEVEL 2 - participants who received - 0.66x10^6 Chimeric Antigen Receptor (CAR) T cells followed by 2x10^6 CAR T cells
89025429|NCT03274427|Experimental|One-drug Regimes|Basic drugs therapy of HCC by TACE.
89025430|NCT03274427|Experimental|Two-Drug Regimens|Basic drugs therapy of HCC by TACE; Arginine hydrochloride
89025431|NCT03274427|Experimental|Three-Drug Regimens|Basic drugs therapy of HCC by TACE; Arginine hydrochloride;Trimetazidine hydrochloride
89550916|NCT02659943|Experimental|LEVEL 1 Foll/by LEVEL 3 - Participants Who Received 0.66x10^6 CAR T Cells Foll/by 6x10^6 CAR T Cells|LEVEL 1 followed by LEVEL 3 - participant who received - 0.66x10^6 Chimeric Antigen Receptor (CAR) T cells followed by 6x10^6 CAR T cells
89550917|NCT02659943|Experimental|LEVEL 2 - Participants Who Received 2x10^6 CAR T Cells Only|LEVEL 2 - participants who received - 2x10^6 Chimeric Antigen Receptor (CAR) T cells only
89025432|NCT03274388|Experimental|Control|Intervention of protein-rich nutritional therapy and counseling
89025433|NCT03274388|Experimental|Intervention|Intervention of protein-rich nutritional therapy and counseling combined with whole body electromyostimulation exercise training
89025434|NCT03274349|Active Comparator|Control|Group of patients receiving individualized protein-rich nutritional therapy without exercise, 12 weeks intervention per patient
89025435|NCT03274349|Experimental|EMS-group|Group of patients receiving individualized protein-rich nutritional therapy with personalized whole body electromyostimulation exercise, 12 weeks intervention per patient
89550918|NCT02659943|Experimental|LEVEL 2 Followed by LEVEL 3-Participants Who Received 2x10^6 CAR T Cells Foll/by 6x10^6 CAR T Cells|LEVEL 2 followed by LEVEL 3 - participants who received - 2x10^6 Chimeric Antigen Receptor (CAR) T cells followed by 6x10^6 CAR T cells
89550919|NCT02659943|Experimental|LEVEL 3 - Participants Who Received 6x10^6 CAR T Cells Only|LEVEL 3 - participants who received - 6x10^6 Chimeric Antigen Receptor (CAR) T cells only
88812083|NCT05947006|Active Comparator|Standard care|Patients in this arm will receive the standard care stablished in the emergency room after a febrile seizure
89025436|NCT02273687|Experimental|Prognostic study population|"The study population consists of patients treated for acute respiratory distress in the emergency department at the Nîmes University Hospital. See inclusion and exclusion criteria.~Intervention: Diaphragmatic ultrasound"
89025437|NCT00480363|Experimental|1|Lenalidomide + Dexamethasone for 9 cycles and maintenance
89025438|NCT00480363|No Intervention|2|Observation
89025439|NCT00442806|Placebo Comparator|Placebo|Placebo is injected
89550920|NCT03257969|Experimental|The DROP program|
89550921|NCT03257969|Other|Standard of care|
89550922|NCT05103371|Experimental|"Mili prevention program, adolescents and active parents"|"The program Mili will be delivered to adolescence aged 10-12, over 3 months. The program contains nine weekly, 90-min sessions that focus on Media literacy, self-esteem, self-image and body image. The parents will also participate by a phone app that will pass the parents activities to do with their children, in parallel to the program. All participants will complete a self-report questionnaire at baseline, after the program ends, and three months after the completion of the program."
89550923|NCT05103371|Active Comparator|"Mili prevention program, adolescents only"|"The program Mili will be delivered to adolescence aged 10-12, over 3 months. The program contains nine weekly, 90-min sessions that focus on Media literacy, self-esteem, self-image and body image, no parental involvement in the program. Adolescents will complete a self-report questionnaire at baseline, after the program ends, and three months after the completion of the program."
89550924|NCT05103371|No Intervention|control group|The control group will not receive the intervention program. The control group will complete the same self-report questionnaire as the intervention group at baseline, after the program ends, and three months after the completion of the program
89550925|NCT05369663||no mask|no mask use
89550926|NCT05369663||surgical mask|surgical mask use
89550927|NCT05369663||N99 mask|N99 mask use
89550928|NCT05369663||face shield|face shield use
89550929|NCT05369663||surgical mask+ faceshield|surgical mask+ faceshield use
89550930|NCT05369663||N99 mask+ faceshield|N99 mask+ faceshield use
89550931|NCT05083325|Experimental|Oseltamivir Phosphate Test Product|Participants will receive one capsule of the test formulation containing Oseltamivir 75 mg. The capsules will be taken with water and in a fasting condition.
89550932|NCT05083325|Active Comparator|Oseltamivir Phosphate Referent Product|Participants will receive one capsule of the marketed reference containing Oseltamivir 75 mg. The capsules will be taken with water and in a fasting condition.
89025440|NCT00442806|Experimental|Treatment|ADRC's are injected
89025441|NCT00455507|Experimental|1|20 mg KW-6002 per day (two 10 mg tablets orally once daily for 12 weeks)
89025442|NCT00455507|Experimental|2|40mg KW-6002 per day (two 20 mg KW-6002 tablets orally once daily for 12 weeks)
89025443|NCT00455507|Placebo Comparator|3|Two placebo tablets once daily for 12 weeks
89025444|NCT00442923|Placebo Comparator|CTRL|
89208063|NCT01071499|Active Comparator|1|Subjects recruited will be block assigned to one of the three doses of morphine. Sampling will be done for 4 hrs to determine the key pharmacokinetic parameters.
89550933|NCT01677299|Active Comparator|1000 mg EFB0026 (metformin immediate-release)|BID
89550934|NCT01677299|Experimental|1000 mg EFB0027 (metformin delayed-release)|BID
89550935|NCT01677299|Experimental|500 mg EFB0027 (metformin delayed-release)|BID
89550936|NCT01677299|Experimental|500 mg EFB0026 + 1000 mg EFB0027|BID
89025445|NCT00442923|Experimental|TREAT|
89025446|NCT00480402|Experimental|400 mg Progesterone|Approximately one third of the bichorionic biamniotic twin pregnant women randomized to the 400 mg Progesterone Group vaginal pessaries arm.
89025447|NCT00480402|Experimental|200 mg Progesterone Group|Approximately one third of the bichorionic biamniotic twin pregnant women randomized to the 200 mg Progesterone Group vaginal pessaries arm.
89025448|NCT00480402|Active Comparator|Placebo|Approximately one third of the bichoronic biamniotic twin pregnant women were randomized to the placebo vaginal pessaries arm.
89025449|NCT01240005|Experimental|DCIK|
89550937|NCT04436783|Experimental|Virtual Reality Epley Maneuver System - VREMS|Patients in the VREMS cohort will be provided with the VREMS device, which will help guide them through the Epley maneuver in a virtual reality environment. All participants will be asked to rate the severity of their symptoms before undergoing the Epley maneuver. Subsequently, patients will be supervised as they perform the Epley maneuver - VREMS assisted. In both groups, once the patient has performed the Epley maneuver (whether with VREMS assistance or with the IH), they will be asked to rate their symptom severity after undergoing the Epley maneuver
89550938|NCT04436783|Active Comparator|Instructional Handout (IH)|Those in the control cohort will be provided an instructional handout (IH) to help them perform the Epley maneuver. They will be given a chance to review the IH, and then they will have a chance to perform the Epley maneuver.
89550939|NCT03185117||All patients|Adult patients scheduled to undergo a total knee arthroplasty or total hip arthroplasty, who give written informed consent to participate in the study.
89550940|NCT05102825||Respiratory Disease|Any physician-diagnosed lung disease
89550941|NCT05102825||Healthy|Healthy control with no physician-diagnosed lung disease
89550942|NCT05012267|No Intervention|Control group|48 hours of PP
89550943|NCT05012267|Experimental|Experimental group|Anytime from 16 hours when PaO2/FiO2 ≥ 150 mmHg with a FiO2 < 60%
89550944|NCT04999631|Experimental|Squaric Acid Dibutyl Ester (SADBE)|Following sensitization, subjects will apply 0.2% SADBE in ethanol to a predetermined area of their nevus 3 times per week for 12 weeks, with adjustment of frequency depending on response.
89550945|NCT04999631|Placebo Comparator|Control|Subject will apply an ethanol solution to a specified area of the nevus.
89550946|NCT05337761|Experimental|Intervention|The peers will be trained to train their colleagues (fellow boaters) on proper lifejacket use. A training manual has been developed for this.
89550947|NCT05337761|Placebo Comparator|Control|The Marine Police will be encouraged to continue conducting their community policing on water safety and emphasize lifejacket wear.
89550948|NCT04437875|Experimental|Component 1|rAd26 Component, 1 vaccination Component 1 consists of a recombinant adenovirus vector based on the human adenovirus type 26, containing the SARS-CoV-2 S protein gene.
89550949|NCT04437875|Experimental|Component 2|rAd5 Component, 1 vaccination Component 2 consists of a vector based on the human adenovirus type 5, containing the SARS-CoV-2 S protein gene.
89550950|NCT04437875|Experimental|Prime-Boost Immunization|Day 1 rAd26 Component Day 21 rAd5 Component
89550951|NCT02718833|Experimental|Elotuzumab, pomalidomide, bortezomib, dex|"Each cycle is 28 days.~Elotuzumab will be administered by intravenous infusion. For cycles 1-2, elotuzumab will ge given weekly. For cycles 3-8, elotuzumab will be given every other week. For cycles 9+, elotuzumab will be given on day 1.~Pomalidomide will be given orally on days 1-21.~Bortezomib will be given weekly subcutaneously on days 1, 8, 15.~Dexamethasone will be given as a combination orally and intravenously."
89550952|NCT04908293|Experimental|Trial Group|Use of New Biorepair Advanced Sensitive toothpaste for home oral care.
89550953|NCT04908293|Active Comparator|Control Group|Use of Colgate toothpaste for home oral care.
89550954|NCT04437797|Experimental|Surgical Extrusion|The next step will be atraumatic extraction which will be initiated by using straight periotome until it is sufficiently luxated and gently pulled out to the amount of sufficient ferrule effect without encroaching the biological width. 90- or 180-degrees rotation of the tooth will be done if needed. The tooth will be supported from palatal side, etching will be done using 37% phosphoric acid, rinsing, drying, bonding agent and then application of 3M Filtek flowable composite on rounded 16mm stainless steel wire for splinting in the middle of the tooth without extension of flowable composite neither to the mesial nor to the distal. This procedure should be followed by occlusal adjustment if needed. Splint will be removed after 2 weeks.
89550955|NCT04437797|Active Comparator|Immediate Implant Placement|The patient is anaesthetized. Atraumatic extraction of the badly broken-down teeth will be performed using peroiotome. Luxation should be done mesiodistally and not buccolingually, 11 to avoid damaging the buccal plate. After tooth removal, a curette is used to confirm that the location of the buccal plate is intact. Standard drilling procedures are performed according to the manufacturer's instructions. Then the implant is placed in the prepared site. Temporization should be done using composite 3M Filtek Z250 XT material. Finally, a porcelain fused to zirconia crown will be performed. Jumping gap occurring subsequent to atraumatic extraction and immediate implant placement more than 2 mm will be grafted using Xenograft.
88812084|NCT05947006|Experimental|CONSULFE Consultation|Patients in this arm will receive a consultation managed by the pediatric nurse (CONSULFE)
88812085|NCT05946980|Experimental|Intervention arm for primary health care facilities in Mali and Burkina Faso|This arm receives the multi-component intervention for primary health care facilities described under interventions
89025450|NCT00455897|Experimental|GMCSF-RCHOP|
89025451|NCT00455936|Experimental|study arm|Gefitinib 250mg table/QD, daily every 3 weeks
89025452|NCT00455936|Active Comparator|control arm|gemcitabine 1250mg/m2 iv on D1 & D8 every 3 weeks Cisplatin 80mg/m2 iv on D1 every 3 weeks
89025453|NCT00443196|Experimental|Experimental|
89025454|NCT03274310|Experimental|Surveillance + Education arm|Receipt of educational text message about ways to decrease household transmission of influenza and other respiratory infections in addition to surveillance messages
89550956|NCT01964326|Experimental|Atorvastatin calcium 10 mg|
89550957|NCT04786457|Experimental|Dengue 1 Live Virus Human Challenge (DENV-1-LVHC)|open-label injection of DENV-1-LVHC to 15-20 adults who were previously vaccinated and 5 adults who have never received a dengue vaccination
89550958|NCT04436705|Experimental|Progressive Muscle Relaxation (PMR) technique|Participants in intervention group continued Progressive Muscle Relaxation (PMR) technique daily for 20 minutes for a total of four weeks addition to usual care. The usual care consists of pharmacological interventions to manage Cancer-related pain.
89550959|NCT04436705|No Intervention|control|control group received only usual care for their pain during the study period. The usual care consists of pharmacological interventions to manage Cancer-related pain.
89550960|NCT05102045|Experimental|TMS group|In the TMS group (n=10) rTMS was applied to the bilateral dorsolateral prefrontal cortex (DLPFC) at 20 Hz, for 5 consecutive days per week for over 2 weeks (totally 10 sessions) in addition to the pharmacological treatment.
89550961|NCT05102045|Experimental|AE group|AE group (n=9) received a moderate- intensity aerobic exercise program lasting 50 minutes per session, 5 consecutive days per week for over 2 weeks (totally 10 sessions) in addition to the pharmacological treatment.
89550962|NCT05102045|Active Comparator|Control group|No additional intervention was given to the patients in the control group (n=8) and participants were only treated pharmacologically.
89550963|NCT04934267|Experimental|Eccentric exercise of elbow in order to induce Delayed Onset of Muscle Soreness|There will be two groups, an experimental group with hypermobile individuals, and a control group with individuals that are not hypermobile with normal ranges of motion. All participants will take part in an exercise session with eccentric bicep curls based on their 1 repetition maximum (1RM).Both groups will perform 1 set of standing eccentric bicep curls based on their 1RM to failure in order to induce DOMS.The exercise will stop when the participant cannot volitionally keep up with the 5 second count lowering the weight. Prior to exercise, baseline measurements will be taken for all dependent variables. These measures will be taken every day at the same time of day,for the next 4 days.
89550964|NCT04867655|Experimental|Orange juice only|Experimental test for 24 hours after consumption of orange juice only (Tropicana 'with bits').
89550965|NCT04867655|Experimental|Orange Juice mixed with either 6g or 3 g of β-Glucan|Experimental test for 24 hours after consumption of orange juice (Tropicana 'with bits') with either 6g or 3 g of β-Glucan.
89025455|NCT03274310|No Intervention|Surveillance-only arm|No intervention solely surveillance messages
89550966|NCT04855019|Active Comparator|periarticular injection group (PI)|the group to be given a periarticular injection by an orthopedist
89550967|NCT04855019|Active Comparator|Combined suprascapular-axillary nerve block group (CSAB)|the group in which an anesthesiologist will perform combined suprascapular axillar border block under ultrasound guidance
89550968|NCT04414241|Experimental|Hydroxychloroquine|Hydroxychloroquine prophylaxis plus standard measures of personal protection.
89550969|NCT04414241|No Intervention|Control|Standard measures of personal protection.
89550970|NCT05101967|Experimental|Dynamic Cervical Implant|
89550971|NCT05101967|Active Comparator|Anterior Cervical Discectomt and Fusion|
89550972|NCT04779905||Non-alcoholic Fatty Liver Diseases|patients diagnosed to has NAFLD by ultrasonography presented to the outpatient clinic of Sohag University Hospital
89550973|NCT04779905||control|healthy volunteers who looks normal on ultrasonography
89550974|NCT04764773||Case|Patient who had COVID19 infection
89550975|NCT04764773||control|healthy volunteer who were age and sex matched with our patients
89550976|NCT04758377|Experimental|Arm 1|Serial MRI scans of patients with acute cervical SCI to quantify hemorrhage.
89550977|NCT05101889|Experimental|Immunonutrition|"Oral immunomodulating formula (Oral Impact®, Nestle) One sachet of Oral Impact® consisted of 74 g of powder providing 303 kilocalories.~Three ready-to-drink bottles contained 303 kilocalories/bottle per day, starting 5 days before each chemotherapy session."
89550978|NCT05101889|Active Comparator|Control|An isocaloric isonitrogenous standard enteral nutrition formula. Three ready-to-drink bottles contained 303 kilocalories/bottle per day, starting 5 days before each chemotherapy session.
89550979|NCT04531553|Active Comparator|Thoracic epidural analgesia|Patients will preoperatively receive thoracic epidural at the level T5 & T6 with bolus 20 ml of levobupivacaine 0.25% then levobupivacaine 0.1% infused at a rate of 0.1 mL/Kg/h until chest tube removal ( 5-6 days).
89550980|NCT04531553|Active Comparator|ESPB with levobupivacaine|patients will preoperatively receive US guided ESP block on the side to be operates upon, the puncture point of the skin is infiltrated with 2% lidocaine, and once the structures are identified with ultrasound at the level of T5 transverse process, we will inject bolus 20ml of levobupivacaine 0.25% on the deep aspect of erector spinae muscle then catheter inserted.A 20 ml bolus of levobupivacaine 0.1% is injected every 6 hours until chest tube removal.
89550981|NCT04531553|Active Comparator|ESPB with levobupivacaine and dexmedetomidine|patients will preoperatively receive US guided ESP block on the side to be operates upon, the puncture point of the skin is infiltrated with 2% lidocaine, and once the structures are identified with ultrasound at the level of T5 transverse process, we will inject bolus 20ml of levobupivacaine 0.25% plus 0.5mic/Kg dexmedetomidine on the deep aspect of erector spinae muscle then catheter inserted. 20 ml bolus of levobupivacaine 0.1% with dexmedetomidine 0.5 μg/Kg was injected every 6 hours until chest tube removal.
89550982|NCT05101811|Experimental|Control women without polycystic ovary syndrome|Normal fertile women without polycystic ovary syndrome
89550983|NCT05101811|Experimental|Case women with polycystic ovary syndrome|Women with polycystic ovary syndrome
89550984|NCT04088123||Healthy Patients|The study design will involve analysis of platelet splicing/activity before and after exposure to a single, 180 mg loading dose of ticagrelor. All subjects will be cardiovascular healthy.
89550985|NCT05307419|Active Comparator|Rectal suction biopsy first|Children randomised for pahtological evaluation of rectal suction biopsy tissue first.
89550986|NCT05307419|Active Comparator|Full thickness biopsy first|Children randomised for pathological evaluation of full thickness biopsy tissue first.
89550987|NCT05199779|Experimental|Self-Compassion Intervention (SCI)|First, participants will be taught to implement a 20-second self-compassion induction via video recording. Second, participants will be taught to choose a cue that will precede their daily use of the self-compassion induction. Participants will document the cue they chose, and will be emailed a record of their selected cue, along with the recording and transcript of the self-compassion induction that they can refer back to for reference. Third, participants will be asked to use the self-compassion induction as much as they can and at least once during their daily routine following exposure to their chosen cue.
89550988|NCT05199779|Active Comparator|Finger-Tapping Active Control (AC)|The active control will receive the same procedures as described above, except for receiving a different video containing different instructions describing a finger-tapping exercise. The videos will be virtually identical in length, quality, instructor/their outfit, and lighting.
89550989|NCT03847181||NVAF-patients_1|Adult patients with non-valvular atrial fibrillation (NVAF) and one year health records in the British THIN-database, who have not yet used rivaroxaban, apixaban and warfarin.
89550990|NCT03847181||NVAF-patients_2|Adult patients with non-valvular atrial fibrillation (NVAF) and one year health records in the British THIN-database, who have not yet used rivaroxaban, apixaban and warfarin.
89550991|NCT03847181||NVAF-patients_3|Adult patients with non-valvular atrial fibrillation (NVAF) and one year health records in the British THIN-database, who have not yet used rivaroxaban, apixaban and warfarin.
89550992|NCT03825107|Active Comparator|Patching|2 hours per day 7 days per week patching of the fellow eye
89550993|NCT03825107|Experimental|Dichoptic Videos|watching 6 dichoptic videos during each 2 week period
89550994|NCT05101499|Experimental|AKIN osteotomy with screw fixation|
89550995|NCT05101499|Active Comparator|AKIN osteotomy without screw fixation|
89550996|NCT03477851|Placebo Comparator|Placebo|Patients randomized to receive 0,9% sodium hydrochloride solution 5ml i.m. (gluteus muscle) after spinal anesthesia, simultaneously with the sciatic nerve block.
89550997|NCT03477851|Experimental|Tramadol|Patients randomized to receive 100mg of Tramadol hydrochloride in 5ml 0,9% sodium hydrochloride i.m. (gluteus muscle) after spinal anesthesia, simultaneously with the sciatic nerve block.
89550998|NCT05101343|No Intervention|Control|Uses Fitbit, does not participate in breathing meditation.
89550999|NCT05101343|Experimental|Meditation|Uses Fitbit and participates in brief, daily breathing meditation.
89551000|NCT04437407|Other|Control|The first night will be a control night with infrared video recording where only the Ajuvia sleep monitor is worn in passive mode so that each participant can act as her own control for comparison of treatment effect on outcomes.
89551001|NCT04437407|Experimental|PB2-1|During this night, the PB2-1 prototype will be worn with the Ajuvia in passive mode.
89551002|NCT04437407|Experimental|PB2-2|During this night, the PB2-2 prototype will be worn with the Ajuvia in passive mode.
89551003|NCT04437407|Experimental|PB2-3|During this night, the PB2-3 prototype will be worn with the Ajuvia in passive mode.
89551004|NCT04437407|Experimental|PB2-4|During this night, the PB2-4 prototype will be worn with the Ajuvia in passive mode.
89551005|NCT04437407|Experimental|PB2-5|During this night, the PB2-5 prototype will be worn with the Ajuvia in active mode.
89551006|NCT05375045||prospective|A prospective cohort will be recruited into the study to meet the secondary objective of improving quality of life. In fact, to measure the improvement in quality of life, a questionnaire must be completed by the patient before the implant is placed. Answers to this questionnaire preoperatively cannot be collected for patients recruited retrospectively.
89551007|NCT05375045||retrospective|Patients who received one or more EUROTEKNIKA implants before 2017 may be included in the study for the retrospective cohort
89551008|NCT04437251|Experimental|Brain stimulation-induced improvements in leg skill learning|"To examine the degree of stimulation-induced improvements in learning capacity between three groups: stroke group, healthy young group, and healthy older group. Up to date, most studies have investigated the effects of brain stimulation on hand skill improvements in healthy young adults; little is known about stimulation-induced improvement in the leg skill improvement in stroke survivors as well as in older healthy adults. The investigators will answer the question: Do stroke survivors improve leg skill learning at a comparable rate as healthy young and older adults after brain stimulation transcranial direct current stimulation (tDCS)?"
89551009|NCT04437251|Experimental|Effects of brain stimulation on functional improvements|"To determine the effect of brain stimulation (tDCS) on functional improvements in stroke survivors. Specifically, the investigators will compare stepping reaction time, cortical neuronal activity, peripheral nerve activity, and walking function in the stroke survivors before and after tDCS, and also compared these findings with results from healthy adults. The investigators will answer the question: Do stroke survivors shorten stepping reaction time and improve leg muscle activation and gait performance after tDCS, and these improvements are at a similar rate as compared to data collected from healthy young and older adults?"
89551010|NCT04437251|Sham Comparator|Effects of brain stimulation combined with stepping training|After enrolling to the study, participants with chronic stroke will be randomly assigned to one of two groups: anodal tDCS or sham tDCS groups. All subjects will then undergo a total of twelve training sessions over four weeks in which subjects will learn a novel visuomotor stepping task immediately after visuomotor learning training while 20-minute tDCS (anodal or sham stimulation) is delivered over the leg area of primary motor cortex.The investigators will measure changes in brain neuronal activity, peripheral nerve activity, and walking performance before and after a 12-session training program, and will follow up one week later.
89551011|NCT03310697|Experimental|Children with afebrile seizure|"For each child, a toxicological screening will be carried out on the blood and urine for the research of proconvulsive molecules by conventional technique on the one hand and by gas chromatography coupled with a mass spectrograph on the other hand.~Intervention : Collection of blood and urine samples, and Clinical examination"
89551012|NCT02699749|Experimental|TAK-931|"TAK-931 30 mg, capsules, orally, QD or BID on Days 1-14 of each 21-day treatment cycle in dosing schedule A followed by dosing schedule B, C, D, E and F. In dosing schedules B through F, starting doses and dosing escalations will vary depending on the dosing data obtained from dosing in the previous schedule.~Dose escalation of TAK-931 will be based on evaluation of clinical safety and tolerability and guided by accumulating PK data. 3-4 dose cohorts are expected for each dosing schedule.~If the PK from the early cohorts support BID dosing, then study drug administration in subsequent cohorts may transition to a BID dosing schedule."
89551013|NCT02409199|Experimental|apatinib|Apatinib 850 mg qd po, and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
89551014|NCT02409199|Active Comparator|Docetaxel|Docetaxel 60mg/m2 ivgtt every 3 weeks, and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
89551015|NCT02405923|Experimental|HRF (Rice formula)|Hydrolyzed Rice Protein Formula (HRF)
89551016|NCT02405923|Placebo Comparator|eHF (Extensive Hydrolysed Formula)|Extensive Hydrolysed Cow's Milk Protein Formula (eHF)
89551017|NCT02409121|Experimental|Open label|All participants will receive a tablet educational intervention (health IT platform) during the patient inpatient hospitalization for autologous or allogeneic transplant
89551018|NCT02405611|Active Comparator|active control|mothers and children are in active control group and only receive the questionnaires
89551019|NCT02405611|Experimental|mother and student|an intervention group in which mothers and children receive the intervention and questionnaires
89551020|NCT02405611|Experimental|children|only the children receive the intervention and mothers and children receive the questionnaires
89551021|NCT03169465|Experimental|open group|patients with posterior calcaneal deformity
89551022|NCT03169465|Active Comparator|endoscopic group|patients with posterior calcaneal deformity
89551023|NCT03169543|Experimental|Sleep deprivation|36-hours of total sleep deprivation
89551024|NCT03115489|Placebo Comparator|Traditional Treatment (Group T)|Group T patients will be placed into burst suppression with the traditional drug infusions which include any single or combination of drugs; usually benzodiazepines, barbiturates and or propofol.
89551025|NCT03115489|Active Comparator|Ketamine Infusion (Group K)|Patients in the group K arm will receive a loading dose of 2.5 mg/kg of ketamine followed by a continuous infusion with a starting dose of 3mg/kg/hr with titration in 1mg/kg/hr increments until burst suppression is achieved or a maximum dose of 10mg/kg/hr is reached. After 48 hours of burst suppression the ketamine dosage will be reduced by 2mg/kg/hr in a stepwise fashion to evaluated for EEG or clinical evidence of seizure recurrence.
89551026|NCT02405533|Experimental|Group 1|AHCC 3 grams once a day on an empty stomach x 6 months then placebo once a day x 56 months.
89551027|NCT02405533|Placebo Comparator|Group 2|Placebo once a day on an empty stomach x 12 months
89551028|NCT02409043||Control|Non-stroke participants. Blood drawn for analysis of biomarkers.
89551029|NCT02409043||Ischemic Stroke|Participants presenting at the University of Florida Shands Emergency Department with an ischemic stroke. Blood drawn at day 1, day 3, and at 2-8 weeks after stroke, NIH stroke scale scores, modified Rankin scale scores, and MRI infarct size assessed in hospital. 3 month modified Rankin scale score collected by phone interview.
89551030|NCT02409043||Hemorrhagic Stroke|Participants presenting at the University of Florida Shands Emergency Department with an ischemic stroke. Blood drawn at day 1, day 3, and at 2-8 weeks after stroke, NIH stroke scale scores, modified Rankin scale scores, and MRI infarct size assessed in hospital. 3 month modified Rankin scale score collected by phone interview.
89208064|NCT01071499|Active Comparator|2|Subjects recruited will be block assigned to one of the three doses of morphine. Sampling will be done for 4 hrs to determine the key pharmacokinetic parameters.
89551031|NCT02409043||Stroke Mimic|Participants presenting at the University of Florida Shands Emergency Department with signs and symptoms resembling a stroke, but which are determined to be from another cause. Blood drawn during initial emergency room evaluation.
89551032|NCT02699593|Experimental|Test / Control Sequence|Subjects will be dispensed the Test Contact Lens to wear for two weeks, to be worn in a daily wear modality, attending a follow-up visit in 12-17 days. At the follow-up visit, subjects will be dispensed the Control Contact Lens to wear for two weeks, to be worn in a daily wear modality.
89551033|NCT02699593|Active Comparator|Control / Test Sequence|Subjects will be dispensed the Control Contact Lens to wear for two weeks, to be worn in a daily wear modality, attending a follow-up visit in 12-17 days. At the follow-up visit, subjects will be dispensed the Test Contact Lens to wear for two weeks, to be worn in a daily wear modality.
89551034|NCT02408731|Experimental|Single dose of 0.005 mg/kg of PMZ-2010|A single dose of 0.005 mg/kg of PMZ-2010 (n=3) or placebo (n=1)
89551035|NCT02408731|Experimental|Single dose of 0.01 mg/kg of PMZ-2010|A single dose of 0.01 mg/kg of PMZ-2010 (n=3) or placebo (n=1)
89551036|NCT02408731|Experimental|Single dose of 0.05 mg/kg of PMZ-2010|A single dose of 0.05 mg/kg of PMZ-2010 (n=3) or placebo (n=1)
89551037|NCT02408731|Experimental|Single dose of 0.10 mg/kg of PMZ-2010|A single dose of 0.10 mg/kg of PMZ-2010 (n=3) or placebo (n=1)
89551038|NCT02408731|Experimental|3 doses equivalent to MTD of PMZ-2010|Three equally divided doses (total dose/day equivalent to MTD) of PMZ-2010 (n=3) or placebo (n=1) for 2 days
89551039|NCT02408731|Experimental|3 doses equivalent to 2*MTD of PMZ-2010|Three equally divided doses (total dose/day equivalent to 2*MTD) of PMZ-2010 (n=3) or placebo (n=1) for 2 days
89551040|NCT03169309|Experimental|Pre and Post Intervention|One Study Arm - Quantitative and qualitative sleep quality measure will be captured at baseline (Phase I/Week 1-2), while using Brain Entrainment Technology (Phase II/Week3-4), and after using the technology.
89551041|NCT03168997|Other|Mild AD|Memantine Hydrochloride 20mg tablet per day by mouth on mild AD
89551042|NCT03168997|Other|Moderate AD|Memantine Hydrochloride 20mg tablet per day by mouth on moderate AD
89551043|NCT03168997|Other|Severe AD|Memantine Hydrochloride 20mg tablet per day by mouth on severe AD
89551044|NCT02405767|Experimental|Foot ulcer impedance|Diabetic patients with a diabetic foot ulcer
89551045|NCT02408809|Active Comparator|Control|
89551046|NCT02408809|Active Comparator|Intervention|
89551047|NCT02408575|Experimental|Notched filtering (verum)|"The Hearing aid with notched amplification filters frequencies in a specific manner, depending on the individual tinnitus frequency. Through this special filtering the neuronal functional changes of the auditory cortex are supposed to be affected therapeutically.~Intervention: Device: Conventional hearing aid type Carat 7bx with M-Receiver; Adjustment by Connexx 7.3"
89551048|NCT02408575|Experimental|No filtering (placebo)|"Conventional hearing aid type Carat 7bx with M-Receiver Adjustment by Connexx 7.3~No notched filtering~Intervention: Device: Conventional hearing aid type Carat 7bx with M-Receiver; Adjustment by Connexx 7.3"
89551049|NCT03171727|Experimental|study group|After TIPS procedure was performed, low molecular weight heparin was given for three days.
89551050|NCT03171727|No Intervention|control group|After TIPS procedure was performed, no low molecular weight heparin was given.
89551051|NCT02401165|Other|patient|patient
89551052|NCT02400931|Active Comparator|mask ventilation|Mask ventilation will be performed before the tracheal intubation.
89551053|NCT02400931|Experimental|no mask ventilation|Mask ventilation will not be performed before the tracheal intubation.
89551054|NCT02408653|Active Comparator|conventional EEG-registration type 1|conventional EEG-registration with wet bridge electrodes and conductive gel
89551055|NCT02408653|Active Comparator|conventional EEG-registration type 2|conventional EEG-registration with wet cup electrodes and collodion
89551056|NCT02408653|Experimental|EEG-registration with dry electrodes|EEG-registration with dry electrodes
89551057|NCT03169387|Experimental|Virtual Reality|Microsoft's Xbox 360® will be used with Kinect™,
89033009|NCT02922660|Experimental|Group TIVA|method of anesthesia is total intravenous anesthesia(TIVA) and maintenance with propofol Cp 2-4 μg/ml and remifentanil 2-4 ng/ml in target controlled infusion(TCI) during the procedure
89551058|NCT03169387|Active Comparator|Conventional Training|treadmills (embreex) will be used to perform the aerobic training for a period of 30 minutes and free weights and weight training equipment for the resistance training
89551059|NCT03116191|Experimental|SK-1404 high dose|
89551060|NCT03116191|Experimental|SK-1404 middle dose|
89551061|NCT03116191|Experimental|SK-1404 low dose|
89551062|NCT03116191|Placebo Comparator|Placebo|
89551063|NCT03116503|Experimental|bipolar disorder and comorbid depression|number of diagnosis of bipolar disorder and comorbid depression of suicidal behaviors in the pediatric population.
89551064|NCT03171649|Experimental|RETRAINER-S1 & Conventional Therapy|27 sessions, 3 sessions per week for a total of 9 weeks. Each session consists of 30-minute training with the RETRAINER-S1 system plus 60 minutes of conventional therapy. The training session is customized on the patients' need and can be adapted to their improvement during the intervention.
89551065|NCT03171649|Active Comparator|Conventional Therapy|27 sessions, 3 sessions per week for a total of 9 weeks. Each session lasts about 90 minutes and consists of different training modalities typically used in the rehabilitation of the arm after stroke. The training session is customized on the patients' need and can be adapted to their improvement during the intervention.
89551066|NCT03116269|Experimental|cilostazol group|aspirin placebo daily and 100 mg cilostazol twice daily
89551067|NCT03116269|Active Comparator|aspirin group|100 mg aspirin daily and cilostazol placebo twice daily
89551068|NCT03168763|Experimental|Video 1A|"Questionnaires completed at baseline, after each video viewing, and at completion.~Participants shown Video 1A or 1B, then shown Video 2A or 2B."
89551069|NCT03168763|Experimental|Video 1B|"Questionnaires completed at baseline, after each video viewing, and at completion.~Participants shown Video 1A or 1B, then shown Video 2A or 2B."
89551070|NCT03168763|Experimental|Video 2A|"Questionnaires completed at baseline, after each video viewing, and at completion.~Participants shown Video 1A or 1B, then shown Video 2A or 2B."
89551071|NCT03168763|Experimental|Video 2B|"Questionnaires completed at baseline, after each video viewing, and at completion.~Participants shown Video 1A or 1B, then shown Video 2A or 2B."
89551072|NCT03174223||Deep neuromuscular block|patients received a continuous rocuronium dose to maintain a depth of neuromuscular block of 1-2 twitches post tetanic count
89551073|NCT03174223||moderate neuromuscular block|patients received neuromuscular block aimed at > 0 twitches train of four
89551074|NCT03174067|Experimental|Buprenorphine|Patient receives buprenorphine in the emergency room based on a clinical trial protocol as well as a take home prescription for buprenorphine
89551075|NCT03174067|Active Comparator|Clonidine|Patient receives clonidine in the emergency room based on a clinical trial protocol and also receives a take home prescription for clonidine
89551076|NCT03171571|Experimental|Coaching procedure|Volunteers will received Updated National Dietary Guidelines about food and physical activity with a one year follow-up, plus connected coaching.
89551077|NCT02408341||Routine clinical practice of induction anesthesia|There was no intervention, just monitoring of clinical routine practice using non-invasive Doppler tissue imaging.
89551078|NCT03168685|Experimental|Experimental|"Multiple device intervention~SureSource Engage mobile application~ActiGraph Link~weight scale"
89551079|NCT03168607|Experimental|FOLFIRI|Irinotecan：180mg/m2 ，iv drip for 90min d1, 5-FU 2400mg/m2, iv drip for 46h, 5-FU 400mg/m2 iv d1, CF 200mg/m2 iv drip for 2h d1, q2W
89551080|NCT02408185|Experimental|Colistin 6 million units + 240mg/8h|Loading dose of 6 million units of colistin+ 240mg/8h maintenance
89551081|NCT02408185|Experimental|Colistin 6 million units + 360mg/12h|Loading dose of 6 million units of colistin+ 360mg/12h maintenance
89551082|NCT02400541|Experimental|Cognitive remediation therapy|10 sessions of the cognitive remediation therapy program conducted during five weeks
89551083|NCT02400541|Placebo Comparator|relaxation therapy|10 relaxation sessions during 5 weeks
89551084|NCT02408419|Experimental|Local anesthetic|15 ml. of local anesthetic
89551085|NCT02408419|Placebo Comparator|Saline|15 ml. of saline
89551086|NCT00708097|Experimental|NaF toothpaste(1450 ppmF)|Study toothpaste containing 1450 ppm F as NaF and 0.4% carbopol as excipient.
89551087|NCT00708097|Active Comparator|NaF toothpaste (1400 ppmF)|Study toothpaste containing 1400 ppm F as NaF
89551088|NCT00708097|Active Comparator|NaMFP/NaF toothpaste (1450 ppmF)|Reference toothpaste containing 1000 ppm F as NaMFP and 450 ppm F as NaF
89551089|NCT00708097|Active Comparator|NaF toothpaste (675 ppmF)|Study toothpaste containing 675 ppm F as NaF
89551090|NCT00708097|Placebo Comparator|Placebo toothpaste (0 ppmF)|Fluoride free placebo toothpaste (0 ppm F)
89551091|NCT02400697||<30 wks gestation or 1500 grams|Preterm infants born at participating hospitals
89551092|NCT02400697||30 wks to <34 wks gestation|Preterm infants born at participating hospitals
89551093|NCT02400775|Experimental|Azilsartan|Azilsartan orally once daily in the morning, either before or after breakfast
89551094|NCT02405689|Active Comparator|remifentanil|In the remifentanil group, anesthesia was maintained with 0.5-1.5% sevoflurane and 0.125-0.25 μg/kg/min remifentanil infusion during surgery
89551095|NCT02405689|Active Comparator|dexmedetomidine|In the dexmedetomidine group anesthesia was maintained with 0.5-1.5% sevoflurane and 0.5 μg/kg dexmedetomidine loading dose during 10 minute and then 0.3-0.9 μg/kg/min infusion.
89551096|NCT03173989|Experimental|Orthosis Exercises Orientation|Patients used orthosis, made exercises and received orientation for home.
89551097|NCT03173989|Active Comparator|Orientation|Patients received orientation for home.
89551098|NCT02405455|Experimental|Cerclage|Cervical cerclage.
89551099|NCT02405455|Experimental|Cervical pessary|Cervical pessary
89551100|NCT02400619|Active Comparator|shock waves|A comparative study with patients with spasticity in gastrocnemius and soleus where a group start having shockwave treatment and receive three sessions at weekly intervals, gastrocnemius and soleus applied in 2000 impacts at a frequency of 8hz and energy intensity is proposed between 2.2-2.4 Bars (0,10-0,12mj ). Swiss dolor clast EMS. The other group will receive botulinum toxin Type A in the same muscles. The dose of toxin is in accordance with the weight of each patient, the dose normally used with each user and always with the same brand is always respected, Botox (4-8-12 U/Kg) Patients will be assessed before treatment, after three weeks, two months and three months after three months when the groups exchange the therapy.
89551101|NCT02400619|Active Comparator|botulinum toxin|A comparative study with patients with spasticity in gastrocnemius and soleus where a group start having shockwave treatment and receive three sessions at weekly intervals, gastrocnemius and soleus applied in 2000 impacts at a frequency of 8hz and energy intensity is proposed between 2.2-2.4 Bars (0,10-0,12mj ). Swiss dolor clast EMS.The other group will receive botulinum toxin type A in the same muscles. The dose of toxin is in accordance with the weight of each patient, the dose normally used with each user and always with the same brand is always respected. Botox (4-8-12 U/Kg)Patients will be assessed before treatment, after three weeks, two months and three months after three months when the groups exchange the therapy.
89551102|NCT02400853|Experimental|preterm infants with intracranial hemorrhage|Cord blood analysis of preterm infants with radiological finding of intracranial hemorrhage, detected by ultrasound between day 5 and day 7 post-birth (Standard cranial echography) will be collected and analysed
89551103|NCT02400853|Active Comparator|preterm infants without intracranial hemorrhage|Cord blood analysis of preterm infants without radiological finding of intracranial hemorrhage, detected by ultrasound between day 5 and day 7 post-birth (Standard cranial echography) will be collected and analysed
89551104|NCT03173755||People with normal weight|
89551105|NCT03173755||people with overweight and obesity|
89551106|NCT02659631|Experimental|PF-06671008|
89551107|NCT03173833|No Intervention|Control group|Participants will not receive the outcome of their questionnaire in the form of computerized assessment with graphic outcome (CAGO) after the first time they fill in the questionnaire. And they will be able to discuss their care needs with their health care practitioners.
89551108|NCT03173833|Experimental|Experimental group|"Participants will receive the outcome of their questionnaire in the form of computerized assessment with graphic outcome (CAGO) every time after the first time they fill in the questionnaire.~And they will be able to discuss their care needs with their health care practitioners."
89551109|NCT02405143|Experimental|Active tACS using DC-Stimulator MC|15 to 30 patients will be randomized to the arm receiving the active transcranial alternating current stimulation (tACS) treatment using DC-Stimulator MC.
89551110|NCT02405143|Sham Comparator|Sham stimulation using DC-Stimulator MC|The same number of patients as in the active arm, 15 to 30, will be randomized to receive sham stimulation using DC-Stimulator MC.
89551111|NCT03173911|Active Comparator|Ankle|composed by 12 participants who will receive the application of the bandage for the ankle strategy in both lower limbs, being determined the application of the technique in I without fixed point, from medial malleolus to lateral malleolus passing under the hindfoot, finally a cleavage technique passing over the malleoli and ending in the anterior region of the ankle joint. The balance of each individual will be evaluated in the force platform at four different times, before, immediately after, after 24 and 48 hours after the application of the bandage, in three different tasks of postural control in the force platform, being: unipedal right, unipedal left and task Of bipedal support in the semi-tandem position. Will be performed three evaluations of 30s each, with 30s of interval between each evaluation.
89551112|NCT03173911|Active Comparator|Hamstrings|composed by 12 participants who will receive the application of the bandage for the posterior thigh (hamstrings) strategy in both lower limbs. The technique will be determined in I with fixed point of the skin of the ischial tuberosity and moving point until the Lateral tibia (near the head of the fibula) and medial tibia (goose-foot insertion). The balance of each individual will be evaluated in the force platform at four different times, before, immediately after, after 24 and 48 hours after the application of the bandage, in three different tasks of postural control in the force platform, being: unipedal right, unipedal left and task Of bipedal support in the semi-tandem position. Will be performed three evaluations of 30s each, with 30s of interval between each evaluation.
89551113|NCT03173911|Active Comparator|Lumbar|composed by 12 participants who will receive the application of the bandage for the hip (lumbar) strategy, being determined the application of the technique in I with fixed point in the ischial tuberosity and moving point until the height of the last ribs, making a cleavage in the Height of the superior iliac spine. The balance of each individual will be evaluated in the force platform at four different times, before, immediately after, after 24 and 48 hours after the application of the bandage, in three different tasks of postural control in the force platform, being: unipedal right, unipedal left and task Of bipedal support in the semi-tandem position. Will be performed three evaluations of 30s each, with 30s of interval between each evaluation.
89551114|NCT03173911|Active Comparator|Total|composed by 12 participants who will receive the application of the bandage for all strategies in both lower limbs, being determined the application of the technique in I with fixed point in the II and III toes and moving point until the height of the last ribs , Passing through the entire posterior region. The balance of each individual will be evaluated in the force platform at four different times, before, immediately after, after 24 and 48 hours after the application of the bandage, in three different tasks of postural control in the force platform, being: unipedal right, unipedal left and task Of bipedal support in the semi-tandem position. Will be performed three evaluations of 30s each, with 30s of interval between each evaluation.
89551115|NCT02408107|Experimental|Physical activity intervention|Received a 30 min physical activity counselling session which employed motivational interviewing to encourage the adoption of current recommended physical activity guidelines. This arm also received 3 support phone calls (1 at the end of months 1, 2 and 3) and a physical activity reminder postcard on months 4 and 5.
89551116|NCT02408107|No Intervention|Usual care|This arm received usual care (i.e. no physical activity counselling, support phone calls or post-cards).
89551117|NCT04459247|Experimental|Intervention|Vitamin D high dose
89551118|NCT04459247|No Intervention|Control arm|No Vitamin D supplementation
89551119|NCT02405377|Experimental|CVP guided hydration|The fluid rate was adjusted according to the CVP dynamically
89551120|NCT02405377|Active Comparator|Control|The control group was hydrated at 1 mL/kg per h.
89551121|NCT04402463|Experimental|GPR Group|"Global Postural Reeducation with 2 parts in each session:~st: 2 postures in lying position - without gravity load (15 minutes each posture): The aim of these postures is to achieve and maintain postural balance and to stretch the posterior muscle chain. In order to achieve this, specific exercises in the lying position are used. That exercises involve a precise use of contractions, stretch reflexes, light and controlled manual tractions and sustained elongations.~The maintenance of alignment during posture will be achieved by verbal commands and manual contact of the therapist, guaranteeing the active engagement of patient to reach the correct posture.~st: Standing posture - integration under gravity load (10 minutes): With the participant standing the physiotherapist makes final corrections for postural integration."
89551122|NCT04402463|Experimental|Exercise Group|"Therapeutic exercises. That they will be divided into 3 phases:~The exercises in these phases will consist in active exercises of the cervical spine and shoulder girdle, motor control exercises, and finally strength and endurance of the cervical flexors and extensors and of the musculature of the shoulder girdle."
89551123|NCT02405299|Experimental|Experimental Group|neuropsychological reeducation disorder specific of inhibition (bottom-up and top-down protocol): 24 bi-weekly sessions (30 subjects)
89551124|NCT02405299|Placebo Comparator|Control Group|non-specific and general cognitive neuropsychological reeducation (comprehension, syntactic, visuospatial) : 24 bi-weekly sessions (30 subjects)
89551125|NCT04342871|Experimental|Fam-CT|Patients will receive access to intervention materials.
89551126|NCT04480879|Experimental|AZD8154 nebuliser suspension|The study subjects will receive 1 mg delivered dose of AZD8154 nebuliser suspension
89551127|NCT04480879|Experimental|AZD8154 Monodose|The study subjects will receive 1 mg capsule delivered dose of AZD8154 Monodose DPI formulation
89551128|NCT04480879|Placebo Comparator|AZD8154 Placebo Monodose DPI|The study subjects will receive AZD8154 placebo Monodose DPI formulation dosed to correspond to 1 mg delivered dose AZD8154 Monodose DPI formulation
89551129|NCT02400229|Experimental|Computed Tomography Angiography (CTA)|Computed Tomography Angiography including coronary calcium scoring and coronary computed tomography angiography
89551130|NCT02400229|Active Comparator|Invasive coronary angiography (ICA)|Invasive coronary angiography
89551131|NCT02717663|Experimental|Static goals with delayed incentives|Participants will receive static physical activity goals with delayed, non-contingent incentives
89551132|NCT02717663|Experimental|Adaptive goals with delayed incentives|Participants will receive adaptive physical activity goals with delayed, non-contingent incentives
89551133|NCT02717663|Experimental|Static goals with immediate rewards|Participants will receive static physical activity goals with immediate rewards
89551134|NCT02717663|Experimental|Adaptive goals with immediate rewards|Participants will receive adaptive physical activity goals with immediate rewards
89551135|NCT02699125|Experimental|Placebo, Guanfacine, Hydrochlorothyazide|Sequence: Placebo, Then Guanfacine1 mg for 2 weeks followed by guanfacine 2 mg for 4 weeks, Then Hydrochlorothiazide 12.5 mg for 2 weeks followed by hydrochlorothiazide 25 mg for 4 weeks.
89551136|NCT02699125|Experimental|Placebo, Hydrochlorothyazide, Guanfacine|Sequence: Placebo, Then Hydrochlorothiazide 12.5 mg for 2 weeks followed by hydrochlorothiazide 25 mg for 4 weeks, Then Guanfacine1 mg for 2 weeks followed by guanfacine 2 mg for 4 weeks.
89551137|NCT04279535|Experimental|ascorbic acid|Participants applied topical solution of ascorbic acid twice daily for 8 weeks
89551138|NCT04279535|Active Comparator|Imiquimod|Participants applied 5% imiquimod cream topically 5x/week
89551139|NCT05049317|Experimental|FTME group|Participants will undergo laparoscopic FTME surgery.
89551140|NCT02400151|Other|Non-Obese group|"Non-obese patients will be recruited and frequency matched to obese groups according to sex and level of sexual maturation.~Intervention: Normal control"
89551141|NCT02400151|Experimental|Obese group, Vitamin D|"Subjects randomized to this group will receive vitamin D supplementation. They are recruited from the St Pierre Institute at Palavas-les-Flots, France.~Intervention: 3 months lifestyle and dietary management Intervention: Vitamin D supplementation"
89551142|NCT02400151|Placebo Comparator|Obese group, placebo|"Subjects randomized to this group will receive a placebo supplement. They are recruited from the St Pierre Institute at Palavas-les-Flots, France.~Intervention: 3 months lifestyle and dietary management Intervention: Placebo"
89551143|NCT02407951|Experimental|CBIT group|
89551144|NCT02407951|Placebo Comparator|Psycho-Educational group|
89551145|NCT02400385|Experimental|Treatment|Sunitinib 50mg/day, 4 weeks on and 2 weeks off, and concurrent nivolumab 3mg/kg iv every 2 weeks, both for three years if tolerated.
89551146|NCT03173677|Active Comparator|Lipid intake|12 subjects had 300 Calories of lipids or 300 mL of water. Blood samples were drawn at 0, 1, 2, and 3 hrs post intake. There was a one week period between the 2 intakes.
89551147|NCT03173677|Active Comparator|Glucose intake|12 subjects had 300 Calories of glucose or 300 mL of water. Blood samples were drawn at 0, 1, 2, and 3 hrs post intake. There was a one week period between the 2 intakes.
89551148|NCT03173677|Active Comparator|Protein intake|12 subjects had 300 Calories Whey protein intake or 300 mL of water. Blood samples were drawn at 0, 1, 2, and 3 hrs post intake. There was a one week period between the 2 intakes.
89551149|NCT02405065|Experimental|HM95573|single arm
89551150|NCT03173599|Experimental|PNA 40mg|"Metacavir Enteric-coated Capsules,oral before meal~The beginning dose is 40mg,If no adverse effects were observed in 40 mg, the next dose group was started of 80mg."
89551151|NCT03173599|Experimental|PNA 80mg|"Metacavir Enteric-coated Capsules,oral before meal~The single dose is 80mg,If no adverse effects were observed in 80 mg, the next dose group was started of 160mg."
89551152|NCT03173599|Experimental|PNA 160mg|"Metacavir Enteric-coated Capsules,oral before meal~The single dose is 160mg,If no adverse effects were observed in 160 mg, the next dose group was started of 240mg."
89551153|NCT03173599|Experimental|PNA 240mg|"Metacavir Enteric-coated Capsules,oral before meal~The single dose is 240mg,If no adverse effects were observed in 240 mg, the next dose group was started of 360mg."
89551154|NCT03173599|Experimental|PNA 360mg|"Metacavir Enteric-coated Capsules,oral before meal~The single dose is 360mg,If no adverse effects were observed in 360 mg, the next dose group was started of 480mg."
89551155|NCT03173599|Experimental|PNA 480mg|"Metacavir Enteric-coated Capsules,oral before meal~The single dose is 480mg."
89551156|NCT03173599|Placebo Comparator|PNA Placebo|"Metacavir Enteric-coated Capsules Placebo,oral before meal~The beginning dose is 40mg/d, the dose escalation method is 40mg/80mg/160mg/240mg/360mg/480mg"
89551157|NCT03173287|Experimental|Patients with hepatic biopsy|The patients having benefited from a hepatic biopsy for evaluation of the hepatic fibrosis, will benefit in 10 days of a MRI in the service of radiology of the hospital Gabriel Montpied.
89551158|NCT02425787||Parents of deceased children (no BMT)|"Participants will be parents who have lost a child at St. Jude Children's Research Hospital (SJCRH). They will participate in a 60-90 minute interview.~(Not recruiting)"
89551159|NCT02425787||Parents of deceased children (haploidentical BMT)|Participants will be parents whose child died after receiving a haploidentical bone marrow transplant at St. Jude Children's Research Hospital (SJCRH), and who have not previously participated in an interview through this study. They will participate in a 30-90 minute interview.
89551160|NCT02425787||Parents of deceased children (non-haploidentical BMT)|Participants will be parents whose child died after receiving a non-haploidentical bone marrow transplant at St. Jude Children's Research Hospital (SJCRH), and who have not previously participated in an interview through this study. They will participate in a 30-90 minute interview.
89551161|NCT02425787||Parents of deceased children (not interviewed)|Participants will be parents who have lost a child at SJCRH, who have not previously participated in an interview through this study.They will participate in a 30-90 minute focus group.
89551162|NCT02425787||Hematology/Oncology Fellows|Participants will be Hematology/Oncology Fellows at SJCRH. They will participate in a 30-90 minute focus group.
89551163|NCT02425787||Legacy-Building|Participants will be parents who have lost a child at SJCRH and received legacy items. They will participate in a 30-90 minute interview.
89551164|NCT03173365|Experimental|Brimonidine Tartrate|The respective palm to be treated with Brimonidine will be randomly assessed and will be matched for handedness to include equal numbers of dominant and non-dominant treated palms.
89551165|NCT05100953|Experimental|Experimental Group|After informing about the benefits of physical activity at the beginning of the study, physical activity counseling will be applied once a week for two months via videoconference.
89551166|NCT05100953|No Intervention|Control Group|At the beginning of the study, a one-session briefing will be given on the benefits of physical activity.
89551167|NCT03171337|Experimental|Acupuncture|Acupuncture at acupoints for CTTH according to TCM theory, twice 1 week for 4 weeks，fMRI will be used to detect the cerebral function changes
89551168|NCT03171337|Active Comparator|Fu's subcutaneous needling (FSN)|FSN at the points related with CTTH, twice 1 week for 4 weeks, fMRI will be used to detect the cerebral function changes.
89551169|NCT03171337|Sham Comparator|Sham acupuncture|Streitberger placebo needles at nonacupoint for CTTH, twice 1 week for 4 weeks,fMRI will be used to detect the cerebral function changes.
89208065|NCT01071499|Active Comparator|3|Subjects recruited will be block assigned to one of the three doses of morphine. Sampling will be done for 4 hrs to determine the key pharmacokinetic parameters.
89551170|NCT05100719|Active Comparator|alverine-citrate + simethicone and lactase|Patients diagnosed with irritable bowel syndrome based on the ROME IV criteria will go through a lactase intolerance test (LTT) and (lactose H2 breath test) LHBT. Those who have positive LTT and LHBT will receive alverine-citrate + simethicone and lactase.
89551171|NCT05100719|Placebo Comparator|alverin-citrate + simethicone with placebo|Patients diagnosed with irritable bowel syndrome based on the ROME IV criteria will go through a lactase intolerance test (LTT) and (lactose H2 breath test) LHBT. Those who have positive LTT and LHBT will receive alverine-citrate + simethicone with placebo.
89551172|NCT05100329|Experimental|Mitoxantrone Hydrochloride Liposome Injection|Patients will receive mitoxantrone hydrochloride liposome injection every 3 weeks (q3w, a cycle).
89551173|NCT04530539|Experimental|Experimental- Melatonin|Patients will receive melatonin
88812086|NCT05946980|No Intervention|Control arm for primary health care facilities in Mali and Burkina Faso|No intervention until the end of the cRCT. After completion of data collection, this arm will receive the same intervention as the intervention arm has received previously.
89208066|NCT04040868|Other|robot-assisted technique|
89208067|NCT04040868|Other|conventional fluoroscopy-assisted technique|
89208068|NCT02554526||Combination therapy|Effects of aPCC reaction in the presence of FVIII
89551174|NCT04530539|Experimental|Experimental- Vit C|Patients will receive vitamin C
89551175|NCT04530539|Placebo Comparator|Control|Patients will receive placebo
89551176|NCT02698891|Experimental|Paclitaxel|"After the screening procedures confirm participation in the research study:~175 mg/m^2 Paclitaxel via IV, once every 2 weeks x 4 cycles. (1 cycle = 2 weeks)~-- Neulasta™ (Pegfilgrastim) 6 mg SQ x1 is administered on day 2 of each treatment cycle, approximately 24 hours after the chemotherapy treatment, if:~The patient experiences a prior episode of fever and neutropenia.~If the patient has an active infection this decision will be at provider discretion.~If Neulasta™(Pegfilgrastim) is administered in any Paclitaxel cycle for a given patient, it will be then administered for all future cycles."
89551177|NCT04719065|Experimental|Group A, Mitoxantrone Hydrochloride Liposome Injection, q4w|Subjects with advanced or metastatic solid tumor will receive Mitoxantrone Hydrochloride Liposome every 28 days (a cycle) for a maximum of 8 cycles. The starting dose of Mitoxantrone Hydrochloride Liposome is 20mg/m2.
89551178|NCT04719065|Experimental|Group B, Mitoxantrone Hydrochloride Liposome Injection, q3w|Subjects with advanced or metastatic solid tumor will receive Mitoxantrone Hydrochloride Liposome every 21 days (a cycle) for a maximum of 8 cycles. The starting dose of Mitoxantrone Hydrochloride Liposome is 20mg/m2.
89551179|NCT03171181|Experimental|UPVD non compensated|Intervention group: 30 participants with unilateral peripheral vestibular disorders. Exposed to vestibular reeducation.
89551180|NCT03171181|No Intervention|control group|Control group, to obtain reference values.
89551181|NCT03171181|No Intervention|UPVD compensated|Registered spatial orientation in a group of 30 participants with compensated lesion.
89551182|NCT04567745|Other|Cognitive diagnosis|
89551183|NCT03173443|Experimental|single lumen tube|fiberoptic intubation with single lumen tube with bronchial blocker.
89551184|NCT03173443|Experimental|double lumen tube|fiberoptic intubation with double lumen tube.
89551185|NCT05087147|Experimental|Bonded space maintainer|Wire bonded with composite to abutment teeth
89551186|NCT05087147|Active Comparator|Banded space maintainer|Band and loop space maintainer
89551187|NCT03173209|Other|school professional development|Professional development in Calm Moments Cards program. Occupational therapists used lecture and coaching to educate school personnel on signs of stress and how to embed evidence based strategies (cognitive behavioral, mindfulness, and sensory) throughout the school day to reduce stress and enhance emotional well-being in students using the Calm Moments Cards program.
89551188|NCT05099627||Prospective cohort study arm|"The questionnaire Cervical myelopathy treatment outcome questionnaire attached records information relating to co-morbidities and symptomology. The examination will be a thorough neurological examination in addition to a focused cardiovascular examination. Biochemical blood markers from existing blood markers or from GP records, which have been or would have been performed regardless of this trial. Radiological findings will be taken from routine MRI and cervical spine X-rays performed as part of the CSM diagnostic work-up.~The mJOA score and JOACMEQ score are the outcome measures for the prospective arm of the study. Good response to surgery is a 1-point improvement in mJOA score at 3 and 6 months."
89551189|NCT05099627||Retrospective cohort study arm|"The retrospective questionnaire CSM early diagnosis questionnaire contains all the questions which will be collected retrospectively via telephone. Furthermore patients from the community MSK team, those diagnosed with CM eventually and those examined for CM query, their clinical, biochemical and radiological data from the local SystemOne Databases will be collected for analysis and comparison.~Radiological confirmation of cervical myelopathy is the outcome measure for the retrospective arm."
89551190|NCT02399683||Trichuris trichiura eggs|One healthy volunteer
89551191|NCT02407873||Cardiac surgery|
89551192|NCT02399605|No Intervention|Control|No intervention, group control.
89551193|NCT02399605|Experimental|Stimulation|Subcutaneous Electrical Intervention
89551194|NCT05076383|Experimental|Motor relearning program (MRP)|
89551195|NCT05076383|Active Comparator|Conventional physical therapy program (CPT)|
89551196|NCT02408029||Trauma Patients Group|Patients undergoing treatment for injuries and trauma.
89551197|NCT05108207|Placebo Comparator|Control Group|will receive the standard delirium prevention measures outlined above, plus the use of a mobile device without delirium prevention software for 5 days (Control Group: nPPD package, without PREVEDEL).
89551198|NCT05108207|Experimental|Experimental Group|will receive the standard delirium prevention measures, plus the use of a mobile device with PREVEDEL software for 5 days (Experimental Group: nPPD package, with PREVEDEL).
89551199|NCT02399059|Experimental|Antibiotic lavage|Peritoneal irrigation with Gentamycin - clndamycin solution
89551200|NCT02399059|Active Comparator|Normal saline lavage|Peritoneal irrigation with normal saline
89551201|NCT05108051|Experimental|sequence 1|Period 1: study of ZSP1273's pharmacokinetics at steady state； Period 2: study of Oseltamivir's pharmacokineticsat at steady state； Period 3: study of ZSP1273's pharmacokinetics under Oseltamivir at steady state.
89551202|NCT05108051|Experimental|sequence 2|Period 1: study of Oseltamivir's pharmacokineticsat at steady state; Period 2: study of ZSP1273's pharmacokinetics under Oseltamivir at steady state; Period 3: study of ZSP1273's pharmacokinetics at steady state.
89551203|NCT05108051|Experimental|sequence 3|Period 1: study of ZSP1273's pharmacokinetics under Oseltamivir at steady state; Period 2: study of ZSP1273's pharmacokinetics at steady state; Period 3: study of Oseltamivir's pharmacokineticsat at steady state.
89551204|NCT02404909||Patients with liver tumors candidate to hepatectomy|
89551205|NCT03765359|Active Comparator|metforminhydrochloride|Metformin medication starts on 12-14 weeks of gestation. The starting dosage is 1 tablet (500 mg) x1 and it is increased gradually 1 tablet a week up to 2+2 tablets (2000mg) daily. Duration of the treatment is approximately until one week before delivery. Otherwise metformin treatment combined with regular insulin and follow-up during pregnancy follows the national guidelines.
89551206|NCT03765359|Placebo Comparator|Placebo Oral Tablet|Placebo tablets starts on 12-14 weeks of gestation. The starting dosage is 1 tablet x1 and it is increased gradually 1 tablet a week up to 2+2 tablets daily. Duration of the treatment is approximately until one week before delivery. Otherwise placebo treatment combined with regular insulin and follow-up during pregnancy follows the national guidelines.
89551207|NCT02407483|Experimental|Laser Visual Guidance group|Will be tested using simulated laparoscopic tasks with the use of laser visual guidance
89551208|NCT02407483|Active Comparator|Normal 2D vision group|Will be tested using simulated laparoscopic tasks without the use of laser visual guidance
89551209|NCT02404987||Nutritional Supplement|Free living and residing and nursing home malnourished patients
89551210|NCT04351295|Experimental|Faviprevir|Faviprevir
89551211|NCT04351295|Active Comparator|chloroquine|chloroquine
89551212|NCT05107895|Experimental|Experimental: Intervention group|A 10-week coping skills training was given to the training group from the randomly separated groups. The Coping Skills Training program will take place in a total of 10 online sessions, and the entire program was implemented in 10 weeks. The duration of each session is between 40 and 50 minutes, and it is determined as 5 minutes of introduction to the session, recognizing the general topics, 5 minutes of briefly summarizing the previous session, and the subject of the session for 30-40 minutes. In all sessions, reflections previously prepared with the power point program were used. In the sessions, question-answer method, audio-visual (audio-visual) method, role-playing and performance feedback phases were used when necessary. In addition to knowledge, experiences were also emphasized in education and it was possible to make comparisons with the subject learned in education.
89551213|NCT05107895|Active Comparator|Comparator: Control group|The control group will be informed about their coping skills for a week. Both groups will receive a final evaluation 10 weeks later and a follow-up evaluation 1 month after the last evaluation.
89551214|NCT02407639|Active Comparator|co2 arm|insufflation with CO2
89551215|NCT02407639|Placebo Comparator|air arm|insufflation with air
89551216|NCT04344587|Experimental|Intervention group|Participants in the intervention arm will receive a text message on their smartphones linking to the Qualtrics intervention website
89551217|NCT04344587|Active Comparator|Usual care group|Participants in the usual care arm will receive a text message on their smartphone linking to the Qualtrics usual care website
89551218|NCT02399137|Experimental|Arm A (Experimental Arm)|MM-141 in combination with nab-paclitaxel and gemcitabine
89551219|NCT02399137|Active Comparator|Arm B (Comparator Arm)|Placebo in combination with nab-paclitaxel and gemcitabine
89551220|NCT02399137|No Intervention|Observational Group|
89551221|NCT05236205|Experimental|Control Group|This group will receive the treatment of caries removal with a lowspeed drill (conventional treatment).
89551222|NCT05236205|Experimental|Papacarie|In this group, partial caries removal with Papacarie will be performed.
89551223|NCT05236205|Experimental|Papacarie and Bixa orellana extract|In this group, partial caries removal with Papacarie and the application of Bixa orellana extract (20%) will be performed.
89551224|NCT05236205|Experimental|Partial removal with aPDT|In this group, partial removal of the carious tissue will be performed, with Papacarie and the application of Bixa orellana extract (20%) with blue LED (aPDT).
89551225|NCT05093387|Experimental|Interventional (SGT-53, pembrolizumab, carboplatin)|Patients receive SGT-53 IV over 90-120 minutes on days 1, 8, and 15, pembrolizumab IV over 30 minutes on day 3, and carboplatin IV over 30-60 minutes on day 3. Treatment repeats every 21 days for up to 35 cycles in the absence of disease progression or unacceptable toxicity.
89551226|NCT02399293|Experimental|Patient N-back|Patients training the N-back task
89551227|NCT02399293|Active Comparator|Patient Visual Search|Patients training the Visual-Search task
89551228|NCT02399293|Experimental|Non-impaired N-back|Non-impaired training the N-back task
89551229|NCT02399293|Active Comparator|Non-impaired Visual Search|Non-impaired training the Visual-Search task
89551230|NCT03952793|Experimental|Experimental|Extended biopsy
89551231|NCT02698423|Experimental|Cobas HPV DNA test|Women will be invited to perform HPV self-testing with the Cobas HPV DNA test at home.
89551232|NCT02698423|Active Comparator|Papanicolau test|Women will be invited to come to the hospital to undergo a Papanicolau test (Pap test), which will be performed by the clinician.
89551233|NCT02967965||Cohort|Clinical Evaluation, Coronarography, Imagery by MRI, Echocardiography and Biological samples will be collected for each patient.
89551234|NCT02850263||Cohort 1 / Anti-VEGF treatment naïve patients|Anti-VEGF treatment of naïve patients (who have not received any previous anti-VEGF treatment) with visual impairment due to diabetic macular oedema (DMO) in routine clinical practice in the United Kingdom.
89551235|NCT02850263||Cohort 2 / Anti-VEGF treatment non-naïve patients|Anti-VEGF treatment of non-naïve patients (who have received previous anti-VEGF treatment) with visual impairment due to diabetic macular oedema (DMO) in routine clinical practice in the UK.
89551236|NCT02850263||Cohort 3 / Total study population|Anti-VEGF treatment naïve patients and anti-VEGF treatment non-naïve patients with visual impairment due to diabetic macular oedema (DMO) in routine clinical practice in the UK.
89551237|NCT04481815|Experimental|R2-MTX|Experimental arm will be treated with R2-MTX regimen(Lenalidomide plus Rituximab and Methotrexate) for 6 cycles as initiate induction.If the patients achieved complete remission（CR）or partial remission（PR）with additional whole-brain radiotherapy（WBRT）, they processed to R2 maintenance(Lenalidomide plus Rituximab) for 4 cycles.
88812087|NCT05946967|Active Comparator|Biofeedback with TENS|Patients with constipation will undergo biofeedback treatment along with transcutaneous electrical stimulation (TENS)
88812088|NCT05946967|Sham Comparator|Biofeedback only|Patients with constipation will undergo biofeedback treatment only
88812089|NCT05946772|Placebo Comparator|Placebo|A concealed 0.9% sodium chloride (NaCl) preparation will be applied intravenously at baseline, 12h, and 24h.
88812090|NCT05946772|Experimental|CsA|Cyclosporine A will be applied intravenously at baseline, 12h, and 24h.
88812091|NCT05946720|Experimental|Taining group|Nurses in the training group were given training on aggression and the use of BVC.
88812092|NCT05946720|No Intervention|Control group|Nurses in the control group were not trained, till the study ends.
88812093|NCT05946694||students|30 students of the third year of Emergency Medicine, full-time first-degree program at the Medical University of Lodz, Poland, were enrolled in the study.
88812094|NCT05946668||Observational (vaginal sample, questionnaires, records)|Participants undergo vaginal specimen self-collection via vaginal swab collection kit, complete questionnaires, and have medical records reviewed on study.
88812095|NCT05946616|Experimental|Active non-invasive brain stimulation during behavioral memory interference|Non-invasive brain stimulation with transcranial alternating current stimulation will be applied during a memory interference intervention.
88812096|NCT05946616|Sham Comparator|Sham stimulation during behavioral memory interference|Inactive (sham) stimulation will be applied during a memory interference intervention.
88812097|NCT05946577||Patients treated by chemoradiotherapy with high dose of cisplatin|radiotherapy 60-70 Gy in 30-35 fractions with concomitant chemotherapy by cisplatin 100 mg/m2 every 3 weeks (week 1, 3 and 7)
89033010|NCT02922660|Experimental|Group Des|method of anesthesia is inhalation anesthesia and maintenance with desflurane ranged from 0.5~1.5 MAC during the procedure
89033011|NCT02276924|Experimental|Laser confocal microscopy|Patients undergoing a reno-ureteroscopy for diagnosis or treatment indication will follow a laser confocal microscopy procedure.
89033012|NCT02922465|Experimental|K-877 & Clopidogrel|K-877 & Clopidogrel orally
89033013|NCT02944292|Experimental|All enrolled patients|"Study population:~Adult, mechanically ventilated patients with IAP between 12 and 20 mmHg in at least two consecutive measurements, spontaneous breathing activity of at least 6 breaths/minute, RASS score between 0 and -4, if no contraindications to propofol administration are present and no other immediate interventions to reduce IAP are planned~Intervention: Deepening of sedation Deepening of sedation will be achieved with a bolus of propofol followed by continuous infusion for one hour."
89033014|NCT02922426|Experimental|ALKS 3831|Oral, bilayer tablet
89033015|NCT02922426|Active Comparator|Olanzapine|Oral, bilayer tablet
89033016|NCT02922426|Placebo Comparator|Placebo|Oral, bilayer tablet
89033017|NCT00529919|Active Comparator|1|MCT oil consumption
89033018|NCT00529919|Placebo Comparator|2|Olive oil consumption
89033019|NCT02922114|Experimental|Ultrasonography|B-mode and power Doppler Ultrasonography examination
89033020|NCT02925663|Experimental|EFI-E|10-session web-based modules to teach about executive functioning with videoconferencing with a therapist
89033021|NCT02943629|Experimental|Non-Obese: Apneic Oxygenation: eight minute|Non-obese healthy female patients requiring endotracheal anesthesia for gynecologic (open or laparoscopic) abdominal surgery will have the Pentax AWSTM video laryngoscope with attached P blade placed and then receive 10 l/minute flow of oxygen through the P blade (apneic oxygenation) for eight minutes, or earlier if SpO2 falls to ≤ 95%. The trachea will then be intubated and the ventilation of the lungs will commence using 100% oxygen until SpO2 ≥ 98%.
89033022|NCT02943629|Other|Non-Obese: Without Apneic Oxygenation|Non-obese healthy female patients requiring endotracheal anesthesia for gynecologic (open or laparoscopic) abdominal surgery will have the Pentax AWSTM video laryngoscope with attached P blade placed for eight minutes, or earlier if SpO2 falls to ≤ 95%. The trachea will then be intubated and the ventilation of the lungs will commence using 100% oxygen until SpO2 ≥ 98%.
89033023|NCT02943629|Experimental|Obese: Apneic Oxygenation: five minute|Morbidly obese patients (BM I ≥ 40 kg/m2) requiring endotracheal anesthesia for gynecologic (open or laparoscopic) abdominal surgery will have the Pentax AWSTM video laryngoscope with attached P blade placed and then receive 10 l/minute flow of oxygen through the P blade (apneic oxygenation) for five minutes, or earlier if SpO2 falls to ≤ 95%. The trachea will then be intubated and the ventilation of the lungs will commence using 100% oxygen until SpO2 ≥ 98%.
89033024|NCT02943629|Other|Obese: Without Apneic Oxygenation|Morbidly obese patients (BM I ≥ 40 kg/m2) requiring endotracheal anesthesia for gynecologic (open or laparoscopic) abdominal surgery will have the Pentax AWSTM video laryngoscope with attached P blade placed for five minutes, or earlier if SpO2 falls to ≤ 95%. The trachea will then be intubated and the ventilation of the lungs will commence using 100% oxygen until SpO2 ≥ 98%.
89033025|NCT02925624|Experimental|CLOSE guided PVI and insertable cardiac monitor|
89033026|NCT02925351|Experimental|Imaging (fluorine F 18 clofarabine, PET/CT)|Patients receive fluorine F 18 clofarabine IV and undergo a single PET/CT scan for up to 120 minutes.
89033027|NCT00531167|Experimental|A|combination therapy
89033028|NCT00531167|Active Comparator|B|entecavir
89033029|NCT02944214|Experimental|Febuxostat|take orally,10-80mg per day, for 1 year,start with a low dose, and adjust the dose according to the level of uric acid
89033030|NCT02944214|Experimental|Benzbromarone|take orally,12.5-100mg per day, for 1 year,start with a low dose, and adjust the dose according to the level of uric acid
89033031|NCT02925546|Experimental|GSK2798745 ABCD treatment sequence|Subjects will be given 2.4 mg single oral doses of GSK2798745 (micronized API without SLS and hypromellose) in fasted state (treatment A), 2.4 mg of GSK2798745 (micronized API with SLS and hypromellose) in fasted state (treatment B), GSK2798745 (milled API with SLS and hypromellose) in fasted state (treatment C), and GSK2798745 tablet in fed state (treatment D) in either treatment periods 1, 2, or 3; the three treatment periods will each be separated by a minimum washout period of 7 days
89033032|NCT02925546|Experimental|GSK2798745 CABD treatment sequence|Subjects will be given 2.4 mg GSK2798745 (milled API with SLS and hypromellose) in fasted state (treatment C), 2.4 mg single oral doses of GSK2798745 (micronized API without SLS and hypromellose) in fasted state (treatment A), 2.4 mg of GSK2798745 (micronized API with SLS and hypromellose) in fasted state (treatment B), and GSK2798745 tablet in fed state (treatment D) in either treatment periods 1, 2, or 3; the three treatment periods will each be separated by a minimum washout period of 7 days
89033033|NCT02925546|Experimental|GSK2798745 ACBD treatment sequence|Subjects will be given 2.4 mg single oral doses of GSK2798745 (micronized API without SLS and hypromellose) in fasted state (treatment A), 2.4 mg GSK2798745 (milled API with SLS and hypromellose) in fasted state (treatment C), 2.4 mg of GSK2798745 (micronized API with SLS and hypromellose) in fasted state (treatment B), and GSK2798745 tablet in fed state (treatment D) in either treatment periods 1, 2, or 3; the three treatment periods will each be separated by a minimum washout period of 7 days
89033034|NCT02925546|Experimental|GSK2798745 BACD treatment sequence|Subjects will be given 2.4 mg of GSK2798745 (micronized API with SLS and hypromellose) in fasted state (treatment B), 2.4 mg of GSK2798745 (micronized API without SLS and hypromellose) in fasted state (treatment A), 2.4 mg GSK2798745 (milled API with SLS and hypromellose) in fasted state (treatment C), and GSK2798745 tablet in fed state (treatment D) in either treatment periods 1, 2, or 3; the three treatment periods will each be separated by a minimum washout period of 7 days
89033035|NCT02925546|Experimental|GSK2798745 BCAD treatment sequence|Subjects will be given 2.4 mg of GSK2798745 (micronized API with SLS and hypromellose) in fasted state (treatment B), 2.4 mg GSK2798745 (milled API with SLS and hypromellose) in fasted state (treatment C), 2.4 mg single oral doses of GSK2798745 (micronized API without SLS and hypromellose) in fasted state (treatment A), and GSK2798745 tablet in fed state (treatment D) in either treatment periods 1, 2, or 3; the three treatment periods will each be separated by a minimum washout period of 7 days
89551238|NCT04481815|Sham Comparator|R-MTX|Control arm will be treated with R-MTX regimen(Rituximab and Methotrexate) for 6 cycles as initiate induction.If the patients achieved CR or PR with additional WBRT, they processed to Lenalidomide maintenance for 4 cycles.
89551239|NCT05107037|Experimental|TQ-B3234 capsule|"In the dose escalation phase, enrolled subjects first received a single dose on an empty stomach for a 3-day observation period. If Dose limiting toxicity (DLT) did not occur, continuous multiple doses were continued, once a day on an empty stomach for a treatment cycle of 28 days.~After the dose escalation phase was completed, cohort extension studies were conducted according to the identified phase ii clinical recommended doses.type I neurofibromatosis （NF1） patients and malignant peripheral nerve sheath tumors （MPNST） patients were selected."
89551240|NCT02407093|Experimental|High-Intensity Functional Training|CrossFit will be the HIFT intervention framework with training elements, exercise programming, and scheduling set by CrossFit staff. Workouts will be comprised of one or more of three exercise modalities: aerobic/monostructural (e.g., running), gymnastics (e.g., pullups), and weightlifting/resistance training with workouts designed to maximize use of equipment available in deployed environments (e.g.,vehicle tires). All workouts will be individually scaled to each soldier's current level of fitness by a certified trainer. Sessions will be standardized across the 6 months of intervention so that each cluster will receive exactly the same training.
89551241|NCT02407093|Active Comparator|Army Physical Readiness Training|"The APRT program has combat readiness as the primary focus and is mandated for active duty personnel. For this study, APRT sessions have been standardized across the 6 months of the intervention according to FM 7-22 Army Physical Readiness Training manual so each cluster will receive the same training program using the Reset Phase. Sessions will consist of preparation, activities and recovery and will include strength, endurance, and mobility exercises that involve on-ground (e.g., running), off-ground (e.g., climbing), and combatives (e.g., striking and grappling) training, with supervision by a certified trainer."
89551242|NCT05106959|Experimental|Pilot Training|In this arm participants will complete a variety of baseline assessments then participate in 15-20 minute conversation based on motivational interviewing principles in which they are trained in shame resilience. Follow-ups will be conducted a month later. Assessments will be repeated and then participants will engage in a qualitative interview regarding the training.
89551243|NCT02404831|Active Comparator|Traditional hospital-based PR|Class based pulmonary rehabilitation
89551244|NCT02404831|Experimental|Web-based PR|web-based pulmonary rehab
89551245|NCT05106803||Wound infection|Patients with surgical site infection as diagnosed by the attending physician
89551246|NCT02404753|Experimental|Laparoscopic gastrectomy|Laparoscopic distal gastrectomy and D2 lymph node dissection are performed for locally advanced gastric cancer after neoadjuvant chemotherapy.
89551247|NCT02404753|Active Comparator|Open gastrectomy|Open distal gastrectomy and D2 lymph node dissection are performed for locally advanced gastric cancer after neoadjuvant chemotherapy.
89551248|NCT03780803|Experimental|Patients with PAH|home cardiac rehabilitation and respiratory rehabilitation
89551249|NCT03780803|Experimental|Patients with HFREF|home cardiac rehabilitation and respiratory rehabilitation
89551250|NCT03780803|Experimental|Patients with IHD|home cardiac rehabilitation and respiratory rehabilitation
89551251|NCT03780803|No Intervention|Control group|No rehabilitation
88961837|NCT03554616|Experimental|Chlorfenapyr LLIN|Interceptor® G2 (BASF corporation) is a LLIN made of polyester coated with a wash-resistant formulation of 200 mg/m2 chlorfenapyr and 100 mg/m2 alpha-cypermethrin. This LLIN will be distributed to all the households in 21 clusters on a 1 LLIN per two household residents basis.
88961838|NCT03554616|Experimental|Piperonyl butoxide LLIN|Olyset® Plus (Sumitomo Chemicals) is a LLIN combining Piperonyl butoxide (400mg/m2) and the repellent pyrethroid permethrin (800 mg/m2) incorporated into the polyethylene fibres. This LLIN will be distributed to all the households in 21 clusters on a 1 LLIN per two household residents basis.
89551252|NCT02404675|Experimental|21 icotinib (250mg)|Patients with EGFR 21 exon positive are randomly assigned to higher dose icotinib group to receive icotinib with a dose of 250 mg three times per day, till progressive disease or unaccepted toxicity.
88961839|NCT03554616|Active Comparator|Standard LLIN|Interceptor® (BASF Corporation) is a single pyrethroid-treated LLIN with alpha-cypermethrin (coated onto filaments) at a target dose of 200 mg/m2 of polyester fabric. This LLIN will be distributed to all the households in 21 clusters on a 1 LLIN per two household residents basis.
88961840|NCT03541174|Experimental|Aprocitentan 25 mg in Part 1 (double-blind)|Participants will receive aprocitentan 25 mg, orally, once daily in the morning for 4 weeks.
88961841|NCT03541174|Experimental|Aprocitentan 12.5 mg in Part 1 (double-blind)|Participants will receive aprocitentan 12.5 mg, orally, once daily in the morning for 4 weeks.
88961842|NCT03541174|Placebo Comparator|Placebo in Part 1 (double-blind)|Participants will receive placebo (matching aprocitentan), orally, once daily in the morning for 4 weeks.
88961843|NCT03541174|Experimental|Aprocitentan 25 mg in Part 2 (single-blind, single arm)|After 4-weeks in the double-blind randomized part (Part 1), participants will received 25 mg aprocitentan, orally, once daily in the morning for 32 weeks.
88961844|NCT03541174|Experimental|Aprocitentan 25 mg in Part 3 (double-blind withdrawal)|After 32-weeks in the single-blind, single-arm part (Part 2), participants will be re-randomized and receive aprocitentan 25 mg, orally, once daily in the morning for 12 weeks.
88961845|NCT03541174|Placebo Comparator|Placebo in Part 3 (double-blind withdrawal)|After 32-weeks in the single-blind, single-arm part (Part 2), participants will be re-randomized and receive placebo (matching aprocitentan), orally, once daily in the morning for 12 weeks.
88961846|NCT03493633||EzyGain at Home|Setting up a walking device at home for people aged 60 years with partial walking disability regardless of etiology and pathology leading to walking disability.
89551253|NCT02404675|Active Comparator|21 icotinib (125mg)|Patients with EGFR 21 exon positive are randomly assigned to routine dose icotinib group to receive icotinib with a dose of 125 mg three times per day, till progressive disease or unaccepted toxicity
88961847|NCT03486730|Experimental|Dose escalation phase|Groups of patients will receive increasing doses of BT1718 to find a safe dose that best targets the cancer cells. In this phase it is expected that approximately 50-60 patients with advanced solid tumours will be entered in the study.
89025456|NCT00443235|Active Comparator|A|"One cycle:~Melfalan, 9 mg/m2 v.o days 1 to 4 Prednisone, 60 mg/m2 v.o days 1 to 4 Velcade, 1,3 mg/m2 iv (days 1, 4, 8, 11, 22, 25, 29 and 32) Five cycles: Melfalán, 9 mg/m2 vo, days 1 to 4 Prednisone, 60 mg/m2 v.o days 1 to 4, Velcade,1,3 mg/ m2 iv (days 1, 8, 15 and 22)"
89551254|NCT02404675|Experimental|19 icotinib (125mg)|Patients with EGFR del 19 exon positive are assigned to routine dose icotinib group to receive icotinib with a dose of 125 mg three times per day, till progressive disease or unaccepted toxicity
89551255|NCT05025761|Experimental|Personal protection package|A personal protection package that includes Long-lasting insecticidal hammock net (LLIHN),insect repellent (DEET), Insecticide-treated clothes (ITC), and mobile and migrant population-tailored behavioural change communication (BCC) package
89551256|NCT05025761|No Intervention|Control|No personal protection package
89551257|NCT03106441|Experimental|High flow oxygen therapy by nasal cannula|Experimental Device : High flow oxygen therapy by nasal cannula.
89551258|NCT03106441|Active Comparator|Facial mask oxygenation in BIPAP ventilation|Active Comparator: Facial mask oxygenation in BIPAP ventilation
89551259|NCT05017883|Experimental|TAA05 cell injection|TAA6 cell injection#Targeting FLT3 autologous chimeric antigen receptor T cells#
89551260|NCT05008991||Study group|The study group will consist of (20) obese menopausal women whom are recently recovered from mild-moderate COVID-19 after one month.
89551261|NCT05008991||Control group|The control group will consist of (20) obese menopausal women; whom are not be affected by COVID-19.
89551262|NCT02700997|Experimental|Vascular clip|Application of a clip to dissolvable sutures.
89551263|NCT02407015|Active Comparator|3D gameplay|Participants will play a game for 30 minutes on the Nintendo 3DS in 3D.
89551264|NCT02407015|Active Comparator|2D gameplay|Participants will play a game for 30 minutes on the nintendo 3DS in 2D.
89551265|NCT02404597|Experimental|NICOM|"Subjects with burns greater than 20% total body surface area (TBSA) will have a NICOM placed on them after the first 24 hours of admission if subject has an episode of hypotension (mean arterial pressure < 65 or a systolic blood pressure < 90mmHg). The NICOM will generate a number that reflects stroke volume of the heart. If the number is greater than 10 percent, subject will be given a bolus of crystalloid fluids. If the number is less than 10 percent, subject will start a medication to raise the blood pressure.~Physicians may also use traditional endpoints of resuscitation include base deficit values and urine output goals of 0.5cc/kg/hr as indications of adequate intravenous fluid resuscitation."
89551266|NCT02404597|No Intervention|Control|This is a retrospective comparison control group of patients with burns greater than 20% total body surface area (TBSA) admitted to the hospital from 7/1/2014-12/31/2014.
89551267|NCT04481659|Experimental|A group|Patients who are initially staged as T1-2, according to MRI and intraluminal ultrasound, are assigned to the direct surgery group (determined by the multidisciplnary team [MDT] group)
89551268|NCT04481659|Experimental|B group|Patients who are initially staged as T3M0, according to MRI and intraluminal ultrasound, should undertake preoperative chemoradiotherapy (determined by the MDT group). The operation was performed 8-12 weeks after the end of the chemoradiotherapy.
89551269|NCT03115645|Experimental|Intervention group|Participants in the intervention group will receive the Dynamic Working Intervention program, as described in the next section.
89551270|NCT03115645|No Intervention|Control group|Participants in the control group will not receive any intervention and will perform their work in the same manner as before.
89551271|NCT02398981|No Intervention|Baseline|Baseline data collection ( 20 patients per ICU)
89551272|NCT02398981|Experimental|Checklist|This study is about training and implementation of best critical care practices in the international ICUs with variable resources facilitated by access to a specifically designed electronic checklist 40 patients per ICU
89551273|NCT04826081||Case|women who contracted symptomatic dengue fever during pregnancy
89551274|NCT04826081||Control|women who did not contract symptomatic dengue fever during pregnancy
89551275|NCT02398903||Obese women SG|Obese women operated by sleeve gastrectomy
89551276|NCT02398903||Normal weight women|Normal weight women
89551277|NCT02398903||Obese women GBP|Obese women operated by Rougastric bypass
89551278|NCT04923971|Active Comparator|0C Trial|Participants will be sitting in a chair performing hand dexterity tasks in 0C (32F) conditions. Total rest period is 2 hours. After 2 hours, participants will perform athletic performance related tasks consisting of agility, power, muscular strength, and aerobic fitness.
89551279|NCT04923971|Active Comparator|-10C Trial|Participants will be sitting in a chair performing hand dexterity tasks in -10C (14F) conditions.Total rest period is 2 hours. After 2 hours, participants will perform athletic performance related tasks consisting of agility, power, muscular strength, and aerobic fitness.
89551280|NCT04923971|Active Comparator|-20C Surrogate Trial|Participants will be sitting in a chair performing hand dexterity tasks in -10C + 3m/s wind (14F+6 mph wind) conditions. Total rest period is 2 hours. After 2 hours, participants will perform athletic performance related tasks consisting of agility, power, muscular strength, and aerobic fitness.
89551281|NCT02398669|Experimental|lorcaserin 10 mg|Cohort 1 - obese pediatric participants between age group of 6 and 8 years (inclusive) Cohort 2 - obese pediatric participants between age group of 9 and 11 years (inclusive)
89551282|NCT05041751|Active Comparator|Arm I (trigger point injections)|Patients receive standard of care trigger point injections at baseline
89551283|NCT05041751|Experimental|Arm II (myofascial release)|Patients perform myofascial release for 10 minutes each day.
89551284|NCT02398591|Experimental|JNJ 53718678 250 milligram (mg)|Participants will receive either single oral dose of 250 mg of JNJ 53718678 or matching placebo on Day 1.
89551285|NCT02398591|Experimental|JNJ 53718678 500 mg|Participants will receive either single oral dose of 500 mg of JNJ 53718678 or matching placebo on Day 1.
89551286|NCT02398591|Experimental|JNJ 53718678 1000 mg|Participants will receive either single oral dose of 1000 mg of JNJ 53718678 or matching placebo on Day 1.
89551287|NCT05031845||COVID-19 positive, Hospitalized with ARDS|"Patients with chest imaging at the time of the first COVID-positive PCR test will have their first LDCT within 3 to 4 months after COVID 19 diagnosis. A second LDCT between 3 to 6 months after the initial LDCT.~Patients without chest imaging at the time of the first COVID-positive PCR test or with a negative COVID PCR test will have their first LDCT within 2 weeks to 1 month after their recovery from COVID 19, or testing. A second LDCT may be performed between 3 to 6 months after the initial LDCT."
89551288|NCT05031845||COVID-19 positive, not hospitalized with ARDS|"Patients with chest imaging at the time of the first COVID-positive PCR test will have their first LDCT within 3 to 4 months after COVID 19 diagnosis. A second LDCT between 3 to 6 months after the initial LDCT.~Patients without chest imaging at the time of the first COVID-positive PCR test or with a negative COVID PCR test will have their first LDCT within 2 weeks to 1 month after their recovery from COVID 19, or testing. A second LDCT may be performed between 3 to 6 months after the initial LDCT."
89551289|NCT05031845||COVID-19 negative, not hospitalized with ARDS|"Patients with chest imaging at the time of the first COVID-positive PCR test will have their first LDCT within 3 to 4 months after COVID 19 diagnosis. A second LDCT between 3 to 6 months after the initial LDCT.~Patients without chest imaging at the time of the first COVID-positive PCR test or with a negative COVID PCR test will have their first LDCT within 2 weeks to 1 month after their recovery from COVID 19, or testing. A second LDCT may be performed between 3 to 6 months after the initial LDCT."
89551290|NCT02398357|No Intervention|Control|No anticoagulation，just routine follow-up
89551291|NCT02398357|Experimental|Anticoagulation|Nadroparin Calcium and Warfarin
89551292|NCT04437641||Experimental|A questionnaire on smoking habits was given to all parents of children being followed in consultation for cystic fibrosis or type 1 diabetes, or whose child was hospitalized for the first time for bronchiolitis.
89551293|NCT02398435|Experimental|Cohort 80 mg|Cohort 1 included 10 patients. Patients received Tadekinig alfa s.c with a dosage of 80mg. Safety assessments were conducted by data safety monitoring board. Non-responder patients were upscaled to next dose (160mg) after 3 weeks of treatment.
89551294|NCT02398435|Experimental|Cohort 160 mg|Cohort 2 included 13 patients. all patients were treated with Tadekinig alfa s.c with a dosage of 160mg. Safety was evaluated by data safety monitoring board.
89551295|NCT02398513|Experimental|Regorafenib (Stivarga, BAY73-4506)|Patients enrolled in the study will start treatment with Regorafenib160 mg (given by four 40 mg tablets of Regorafenib) on Day 1 of the first week followed by 6 days off treatment (Cycle 0, single dosing period). After Cycle 0, Regorafenib 160 mg QD will be administered for 21 days, followed by 7 days off treatment. Treatment with Regorafenib will continue until the patient either progresses or meets one of the criteria for withdrawal prespecified in the study protocol.
89551296|NCT04436939|Experimental|PEEK healing abutment|Healing abutment made of polyetheretherketone (PEEK)
88961848|NCT03486730|Experimental|Dose expansion phase|Larger groups of patients will receive the selected dose of BT1718 to allow us to find out more about how the drug is working. In this phase it is proposed that up to 70 patients with tumour types known to commonly overexpress MT1-MMP and where MT1-MMP overexpression is confirmed during prospective and retrospective (in appropriate patients) selection at enrolment (i.e. squamous non-small cell lung cancer) will be entered in the study.
88961849|NCT03480633||Control|Defined as patients without a history of heart failure
88961850|NCT03480633||Heart Failure w/NormalEjectionFraction|Heart Failure with Normal Ejection Fraction is defined as having a Left Ventricle Ejection Fraction of greater than or equal to 50%.
89551297|NCT04436939|Active Comparator|Ti healing abutment|Healing abutment made of titanium (Ti)
89551298|NCT02398279|Experimental|L-Arginine-First|For the first three weeks, L-Arginine 3 g bid (500mg capsules 6 x 2), one week wash-out, then for the next three weeks placebo capsules (6 x 2)
88961851|NCT03480633||HeartFailure w/ReducedEjectionFraction|Heart Failure with Reduced Ejection Fraction is defined as having a Left Ventricle Ejection Fraction of less than 50%.
89551299|NCT02398279|Experimental|Placebo-First|For the first three weeks, placebo capsules (6 x 2), one week wash-out, then for the next three weeks L-Arginine 3 g bid (500 mg capsules 6 x 2)
89551300|NCT04611425|Experimental|Remimazolam|"Patients will receive an infusion of Remimazolam for a maximum duration of 48 hours.~The dose of Remimazolam will be adapted according to our ICU protocol of analgesia-sedation management, based on validated scale (Richmond Assessment Sedation Scale)"
89551301|NCT04436471|Experimental|Component 1|"rAd26 Component, 1 vaccination~Component 1 consists of a recombinant adenovirus vector based on the human adenovirus type 26, containing the SARS-CoV-2 S protein gene"
89551302|NCT04436471|Experimental|Component 2|"rAd5 Component, 1 vaccination~Component 2 consists of a vector based on the human adenovirus type 5, containing the SARS-CoV-2 S protein gene."
89551303|NCT04436471|Experimental|Prime-Boost Immunization|Day 1 rAd26 Component Day 21 rAd5 Component
89551304|NCT02398201|Experimental|Interventional|Bezafibrate tablets (200-600mg) three times daily for 12 weeks.
89551305|NCT05106179|Active Comparator|Previously treated + Atenolol|The investigators suppose the outcome might be compromised if patient has been previously treated, that's why it is going to be compared to the main cohort. The results are going to be analysed separately
89551306|NCT05106179|Active Comparator|Previously treated + Propranolol|The investigators suppose the outcome might be compromised if patient has been previously treated, that's why it is going to be compared to the main cohort. The results are going to be analysed separately
89551307|NCT04480567|Experimental|Dose 1 of BMN 307|
89551308|NCT04480567|Experimental|Dose 2 of BMN 307|
89551309|NCT04480567|Experimental|Dose 3 of BMN 307|
89551310|NCT02406781|Experimental|Treatment strategy A|Combination of MK3475 with Metronomic CP. MK3475 will be administered intraveinously. Metronomic CP (Cyclophosphamide) will be adminstered orally.
89551311|NCT02406781|Experimental|Treatment strategy B|Combination of MK3475 with Metronomic CP and G100. MK3475 will be administered intravenously. Metronomic CP (Cyclophosphamide) will be administered orally. G100 will be administered by intra-tumoral injection.
89551312|NCT05106023|Experimental|SHR-1701 combined with temozolomide|SHR-1701 combined with temozolomide
89551313|NCT02398123|Active Comparator|Transversus abdominis plane block|Transversus Abdominis Plane block
89551314|NCT02398123|Placebo Comparator|Caudal block|Caudal block
89551315|NCT05105945|Experimental|Single port inflatable mediastinoscope and synchronized laparoscopic radical resection|"Detailed surgical procedures and related instructions have been published in Single-Port Inflatable Mediastinoscopy Combined With Laparoscopic-Assisted Small Incision Surgery for Radical Esophagectomy Is an Effective and Safe Treatment for Esophageal Cancer J Gastrointest Surg. 2019 Aug;23(8):1533-1540. doi: 10.1007/s11605-018-04069-w. Epub 2019 Jan 11."
89551316|NCT05105945|Active Comparator|Thoracoscopy combined with laparoscopic radical resection|Patients will receive a standardized thoracoscopy and laparoscopy combined radical esophageal cancer surgery
89551317|NCT04480801|Experimental|thermal evaluation and foot care|Participants in the experimental group will be given foot care in the clinic and will be taught to the patient and / or their relatives. The foot care video will be uploaded to the patient and / or relative's phone. Thermal evaluation will be done. The application of the thermal evaluation, the foot areas to be applied and how to record the results of the application will be taught to the patient and / or their relatives. In addition, the thermal evaluation video will be uploaded to the phone of the patient and / or their relative. While the participants in the experimental group were discharged; Blood glucose monitoring chart, Checklist to record foot care interventions, Thermal evaluation registration form, Daily step number registration form will be provided and participants will be invited to check every 2 months.
89551318|NCT04480801|Other|foot care|Participants in the control group will be given foot care in the clinic and will be taught to the patient and / or their relatives. The foot care video will be uploaded to the patient and / or relative's phone.While the participants in the control group were discharged; Blood glucose monitoring chart, Checklist to record foot care interventions will be provided and participants will be invited to check every 2 months.
89551319|NCT02397967|Experimental|Children NF1|Children diagnosed with NF1 according the NIH criteria Neuropsychological assessments
89551320|NCT02397967|Placebo Comparator|Control group|Control group children without NF1 with the same reading level Neuropsychological assessments
89551321|NCT04458077|Experimental|Mobile-phone-based SEIL Intervention|This group will receive the Discover Learning 10-session intervention through a mobile-phone based platform over the course of 10 weeks (1 session per week).
89551322|NCT02404363|Experimental|Clopidogrel|Clopidogrel tablets 75 mg for six months:
89551323|NCT02404363|Placebo Comparator|Comparator|Placebo tablet 75 mg for six months:
89551324|NCT02404519|Active Comparator|Menaquinone-7|Menaquinone-7 180 microgram tablet, by mouth, daily for 1 year
89551325|NCT02404519|Placebo Comparator|Placebo|Placebo tablet, by mouth, daily for 1 year
89551326|NCT03173131|Experimental|Opioid counseling group|Counseling provided to patients prior to surgery regarding opioid usage, side effect, long term effect and risks of opioids.
89551327|NCT03173131|No Intervention|No Counseling|No preoperative counseling will be provided to this group. Standard medication information will be provided only.
89551328|NCT02398045|Experimental|Computerised CBT|Computerised CBT for OCD
89551329|NCT02658149|Experimental|Psoas Compartment Block|After exposure anesthetic (Ropivacaine with NaCl) is introduced directly into the iliopsoas muscle, where it then spreads to the lumbar plexus (the nerves responsible for sensation around the surgical site).
89551330|NCT02658149|Active Comparator|Periarticular Local Anesthetic|"An anesthetic cocktail of four drugs (ropivacaine, epinephrine, ketorolac tromethamine, morphine) is injected at five locations at the surgical site to the surrounding tissues."
89551331|NCT03511079|Experimental|Music|This group will be given a subscription to Pandora Plus for the duration of the study. Beginning two nights before surgery, they will listen to a music playlist they created for 30 minutes prior to going to sleep. This will continue each night with the final time being 6 nights after surgery.
89551332|NCT03511079|No Intervention|Control|This group will not listen to music each night for the duration of the study.
89517375|NCT03805594|Experimental|Schedule 3 (lutetium Lu 177-PSMA-617, pembrolizumab)|Starting day -21, patients receive pembrolizumab IV over 30 minutes. Patients also receive lutetium Lu 177-PSMA-617 IV over 20-30 minutes on day 1. Treatment with pembrolizumab repeats every 21 days for up to 35 cycles (2 years) in the absence of disease progression or unacceptable toxicity. Patients who achieve SD or better may receive 17 additional cycles (approximately 1 year) of pembrolizumab.
89517376|NCT03789760|Experimental|active group|take two pills (120 mg) of SaiLuoTong capsule each time, twice a day, 0.5 hours before breakfast and dinner, taking with lukewarm water.
89517377|NCT03789760|Placebo Comparator|control group|take two pills (120 mg) of placebo each time, twice a day, 0.5 hours before breakfast and dinner, taking with lukewarm water.
89551333|NCT03458195|Experimental|Crohn's disease patients|Patients aged 18 or more, for whom Crohn's disease diagnosis is confirmed and ileum or ileocecal Crohn's disease require surgical resection. in addition to usual practice, a bio-banking (blood samples, biopsies and surgical specimens) is collected.
89517378|NCT03729180|Other|Pain Cohort|Patients with a post-operative pain consult will be included in a pain sub-analysis to assess pain scores, pain therapy administration, and rate of opioid-induced adverse events.
89517379|NCT03729180|Experimental|Pharmacogenomic (PGx) Arm [Randomization Arm 1]|All patients will undergo preemptive genotyping prior to their surgical procedure, and all patients will have pharmacogenomic results made available to providers.
89517380|NCT03729180|Other|Control Arm [Randomization Arm 2]|All patients will undergo preemptive genotyping prior to their surgical procedure. Pharmacogenomic test results will not be made available to providers (standard of care). Genotyping results will be released to study providers (and patients) at the 6-month unblinding timepoint for patients in the control group.
89517381|NCT03718884|Experimental|Drug Cocktail|"Period 1:~Participants received a single dose of the following drug cocktail on Day 1: 1 mg midazolam, 10 mg warfarin, 10 mg vitamin K, 30 mg dextromethorphan, 20 mg omeprazole, 100 mg Caffeine administered orally"
89517382|NCT03718884|Experimental|Mirikizumab + Drug Cocktail|"Period 2:~Participants received 250 mg mirikizumab subcutaneously (SC) once every 4 weeks (Q4W) for 16 weeks (Days 1 to Day 113)~Period 2:~Participants received the second dose of the drug cocktail: 1 mg midazolam, 10 mg warfarin, 10 mg vitamin K, 30 mg dextromethorphan, 20 mg omeprazole, 100 mg caffeine administered orally on Day 116."
89517383|NCT03633643|Placebo Comparator|Group A|Single-dose Trimethoprim (TMP)/sulfamethoxazole (SMX, i.e. Cotrimoxazole) perioperative as two ampoules of TMP/SMX 400/80 mg (Bactrim Inf Konz®) solved in 250 ml sodium chloride short infusion followed by five oral applications of placebo (lactose tablet; Fagron Gesellschaft mit beschränkter Haftung (GmbH) & Co.KG) at the evening of the surgery and thereafter twice daily on day 1 and 2 after surgery while the patient is in hospital.
89517384|NCT03633643|Active Comparator|Group B|3-day application with TMP/SMX (i.e. Cotrimoxazole): Preoperatively as two ampoules of TMP/SMX 400/80mg (Bactrim Inf Konz®) solved in 250 ml sodium chloride short infusion, followed by five oral applications of TMP/SMX 800/160 mg (Nopil forte® tablets) at the evening of the surgery and thereafter twice daily on day 1 and 2 after surgery while the patient is in hospital.
89517385|NCT03595683|Experimental|Cohort 1: Anti-PD1 naive|Participants that have not received prior anti-PD1 therapy for their cancer will be enrolled to this arm.
89517386|NCT03595683|Experimental|Cohort 2: Anti-PD1 refractory|Participants that have received prior anti-PD1 therapy for their cancer will be enrolled to this arm.
89517387|NCT03515564|Experimental|Alternative therapy|"Dance/Movement Therapy, Art Therapy, Mindful Yoga~60 minutes once weekly for 8 weeks"
89517388|NCT03515564|No Intervention|No Intervention|No Intervention
89517389|NCT03509467|Experimental|Intervention Group A|"Intervention Group A: Non-Hispanic White Population~Post determination of MC1R Genotypes, participants randomized to the intervention group, will receive personalized information about ways that they can protect themselves and their child from developing melanoma.~By the end of the study, all participants will have had the opportunity to receive information about their inherited risk."
89517390|NCT03509467|Experimental|Intervention Group B|"Intervention Group B: Hispanic Population~Post determination of MC1R Genotypes, participants randomized to the intervention group, will receive personalized information about ways that they can protect themselves and their child from developing melanoma.~By the end of the study, all participants will have had the opportunity to receive information about their inherited risk."
89517391|NCT03509467|Placebo Comparator|Control Group A|"Control Group A: Non-Hispanic White Population~Post determination of MC1R Genotypes, participants randomized to the control group, you will receive standard information about ways that they can protect themselves and their child from developing melanoma.~By the end of the study, all participants will have had the opportunity to receive information about their inherited risk. Participants randomized into the control group, by the end of the study will also have had the opportunity to receive personalized information about ways they can protect themselves and their child from developing melanoma."
89208069|NCT03974269|Active Comparator|Hypnosis arm|TAVI procedures will be either Medtronic Corevalve, or Edwards Sapien implantations, at operator's discretion. All procedures will be supervised by one of the two senior interventional cardiologists. Hypnosis sessions will be performed by two trained anesthesiologists, and Remifentanil sedations will be administered by the rest of the anesthesiologists staff. Postoperative care will be provided in the CICU for the 3 first postoperative days at least.
89551334|NCT05111873||waiting-list control|Participants enquired prior to the treatment appointment in the neurological day clinic service, no intervention
89551335|NCT05111873||post-treatment group|Participants enquired after the treatment in the Neurological day clinic service
89551336|NCT05105321|Placebo Comparator|Placebo Group|Placebo plus healthy lifestyle intervention. Placebo with same appearance of berberine tablet will be orally taken twice daily and maintained until the last subject completes 3-year intervention.
89551337|NCT05105321|Experimental|Berberine Group|Berberine plus healthy lifestyle intervention. Berberine dose is 500mg twice daily and maintained until the last subject completes 3-year intervention.
89551338|NCT02698189|Experimental|Birabresib 20 mg AML Cohort|Participants in the AML cohort received 20 mg of birabresib as an oral capsule twice a day for 21 consecutive days per cycle (21-day cycle).
89551339|NCT02698189|Experimental|Birabresib 20 mg DLBCL Cohort|Participants in the DLBCL cohort received 20 mg of birabresib as an oral capsule twice a day for 21 consecutive days per cycle (21-day cycle).
89551340|NCT03172663|Experimental|group 1|
89551341|NCT03172663|Active Comparator|group 2|
89551342|NCT02397733|Active Comparator|Prophylactic cranial irradiation (PCI)|Radiation. Prophylactic cranial irradiation : 25 Gy in 10 daily fractions, five times a week
89551343|NCT02397733|Experimental|Hippocampal avoidance PCI|Hippocampal avoidance prophylactic cranial irradiation. 25 Gy in 10 daily fractions, five times a week
89551344|NCT04482127|Experimental|SubEpithelial connective graft|"SCTG harvested from palatal tissue by single line incision technique, blade will be oriented perpendicular to the palatal tissue surface. A single incision will be made down to the bone in a horizontal direction approximately 2 to 3 mm apical to the gingival margin of the maxillary teeth. A partial thickness dissection will then be made within the single incision, leaving an adequate thickness of the palatal flap intact to minimize the chance of sloughing of the overlying tissue. Careful manipulation of the graft with tissue forceps will be required and care must be taken to prevent compression or tearing of the graft.~The fatty tissue (yellow in color) will be eliminated and some contouring of the graft will be done to fit the prepared envelope. The harvested SCTG will be placed at the extraction sites in a supra-periosteal partial dissection (pouch II technique) prepared at the buccal aspect without using vertical incisions and without flap elevation."
89551345|NCT04482127|No Intervention|Atraumatic extraction|Extraction with Periotomes and Luxators keeping the buccal plate of bone intact
89551346|NCT02397811|Experimental|Enteric Coated Softgels|Enteric coated softgel capsule containing 4 mg astaxanthin, 3 softgels per dose
89551347|NCT02397811|Experimental|Liposomal Astaxanthin|Liposomal astaxanthin containing 4.5 mg astaxanthin per gram. 2.66 grams per dose
89551348|NCT02397811|Experimental|Standard Softgel|Standard softgel containing 4 mg per softgel. 3 softgels per dose
89551349|NCT02397811|Experimental|Astaxanthin Water Soluble Emulsion|Astaxanthin water soluble emulsion containing 1% astaxanthin. 1.2 grams per dose
89551350|NCT02397811|Experimental|Astaxanthin Water Dispersible Powder|Astaxanthin water dispersible powder containing 3% astaxanthin. 0.4 grams per dose
89551351|NCT02397811|Experimental|Standard Softgel with Astaxanthin Gel|Statndard softgel with astaxanthin gel containing 4 mg astaxanthin. 3 softgels per dose
89551352|NCT04481971|Experimental|40 mg|
89551353|NCT04481971|Experimental|20 mg|
89551354|NCT04481971|Placebo Comparator|Placebo|
89551355|NCT03170791|Experimental|vagal nerve stimulation intervention|All participants consented to the study will undergo an exercise session using equipment such as pedals and cylinders to facilitate activity. During the exercise session the therapist will press a switch to trigger a run of vagal nerve stimulation in time with the patient's activity. Patients will be videoed during the therapy sessions to allow researchers to retrospectively count the number and type of repetitive movements successfully performed. At the end of the exercises, the stimulator clip will be removed from the patient's ear and cleaned with an alcohol disinfectant wipe ready for next use.
89551356|NCT03172741|Placebo Comparator|Placebo group: THC (0%) / CBD (0%)|The matching dose for high THC, high CBD or mixed CBD/THC is a 1 gram placebo cigarette (THC (0%) / CBD (0%)) smoked once per day of for 3 months.
89551357|NCT03172741|Experimental|CBD group:THC (<1%) / CBD (>10%)|The dose for the CBD group (THC (<1%) / CBD (>10%)) is 1 gram medical marijuana cigarette smoked once per day for 3 months.
89551358|NCT03172741|Experimental|THC group: THC (>10%) / CBD (<1%) THC group|The dose for the THC group (THC (>10%) / CBD (<1%)) is 1 gram medical marijuana cigarette smoked once per day for 3 months.
89551359|NCT03172741|Experimental|Mixed group:THC (5-10%) / CBD (5-10%)|The dose for the mixed group THC (5-10%) / CBD (5-10%) ) is 1 gram medical marijuana cigarette smoked once per day for 3 months.
89551360|NCT02702011|Experimental|empagliflozin low dose|
89551361|NCT02702011|Experimental|empagliflozin medium dose|
89551362|NCT02702011|Experimental|empagliflozin high dose|
89551363|NCT02702011|Placebo Comparator|placebo|
89551364|NCT03170713|Active Comparator|arveles|800 mg ibuprofen and 50 mg arveles in 150 cc normal saline before operation will be given in 30 minutes.
89551365|NCT03170713|Active Comparator|intrafen|intrafen 800 mg in 150 cc normal saline before operation will be given in 30 minutes.
89551366|NCT03170713|Placebo Comparator|placebos|Pre-operative 150 cc normal saline will be delivered in 30 minutes
89551367|NCT02404207|Active Comparator|Soybean oil|
89551368|NCT02404207|Experimental|High-oleic soybean oil|
89551369|NCT02404207|Experimental|High-oleic soybean oil + fully hydrogenated soybean oil|
89551370|NCT02404207|Active Comparator|Palm olein + palm stearin|
89551371|NCT02657369|Experimental|Lenvatinib|Participants will receive lenvatinib 24 milligrams (mg) (2 10-mg capsules and one 4-mg capsule) once daily by oral administration at approximately the same time each morning for up to approximately 24 months.
89551372|NCT02397421|Active Comparator|Treatment|Dapagliflozin 10mg once daily
89551373|NCT02397421|Placebo Comparator|Control|Capsules containing microcrystalline cellulose Ph Eur overencapsulated in a hard gelatine capsule shell to match the active comparator
89551374|NCT04862507||Stroke Patients with an ASPECTS of 0-5 on baseline neuroimaging undergoing thrombectomy|acute stroke patients treated with endovascular treatment combined with thrombolysis or without previous thrombolysis Intervention.
89551375|NCT04862507||Stroke Patients with an ASPECTS of 0-5 on baseline neuroimaging not undergoing thrombectomy|acute stroke patients treated with or without thrombolysis
89551376|NCT03172429||High altitude pulmonary hypertension|Highlanders with high altitude pulmonary hypertension living above 2500 m.
89551377|NCT03172429||High altitude control|Healthy highlanders living above 2500 m.
89551378|NCT03172429||Low altitude control|Healthy lowlanders living below 1000 m.
89551379|NCT03168451|Experimental|Intervention|Members of the intervention group will receive culturally tailored text messages encouraging them to quit smoking. They will receive data collection text messages at 6, 12, 18, and 26 weeks post target quit date, assessing their current tobacco smoking behavior.
89551380|NCT03168451|No Intervention|Control|Members of the control group will receive data collection text messages at 6, 12, 18, and 26 weeks post target quit date, assessing their current tobacco smoking behavior.
89551381|NCT05110859||first work experience nurses|
89551382|NCT02397343|Other|Session 1|HBO given the first day of study period and sensory test battery performed. 4 weeks later no intervention is given but the sensory test battery performed.
89551383|NCT02397343|Other|Session 2|No intervention first day of study period and sensory test battery performed. 4 weeks later HBO intervention is given and the sensory test battery performed.
89551384|NCT04850339|Active Comparator|ANXV single dose|ANXV in a single ascending dose pattern in four dose levels.
89551385|NCT04850339|Placebo Comparator|Placebo single dose|Placebo in a single ascending dose pattern in four dose levels.
89551386|NCT04850339|Active Comparator|ANXV multiple dose|ANXV in a multiple ascending dose pattern in three dose levels.
89551387|NCT04850339|Placebo Comparator|Placebo multiple dose|Placebo in a multiple ascending dose pattern in four dose levels.
89551388|NCT02403973|Other|Patient hotel group|
89551389|NCT02403973|Other|Ward group|
89551390|NCT04832009|Experimental|Glucose Infusion|Hyperglycemia (glucose infusion) will receive an I.V. Glucose infusion with a co-infusion of ascorbic acid or placebo at your visit 2 and the alternative treatment of ascorbic acid or placebo will be given on the subsequent study visit 3.
89551391|NCT04832009|Experimental|Lipid Infusion|Hyperlipidemia (lipid infusion) will receive an I.V. Lipid infusion with a co-infusion of ascorbic acid or placebo at your visit 2 and the alternative treatment of ascorbic acid or placebo will be given on the subsequent study visit 3.
89551392|NCT03115957|Experimental|Early PN|Patients who can not tolerate 30% of target energy EN will receive supplemental parenteral nutrition at day 3 after abdominal surgery.
89551393|NCT03115957|Experimental|Delayed PN|Patients who can not tolerate 30% of target energy EN will receive supplemental parenteral nutrition at day 8 after abdominal surgery.
89025457|NCT00443235|Experimental|B|"One cycle:~Thalidomide,day 1 cycle 1 v.o (50 mg). If toxicity < grade 2, dose will be increased to 100 mg on day 15 cycle 1 Prednisona, 60 mg/m2 vo, days 1 to 4, Velcade, 1,3 mg/ m2 iv (days 1, 4, 8, 11, 22, 25, 29 and 32)~Five cycles:~Thalidomide, 100 mg vo all days, Prednisone, 60 mg/m2 vo days 1 to 4, Velcade, 1,3 mg/ m2 iv (days 1, 8, 15 and 22)"
89551394|NCT03129113|Experimental|maraviroc (Arm A)|maraviroc dosed BID p/o (dose adjusted depending on background combination antiretroviral therapy).
89551395|NCT03129113|Experimental|metformin (Arm B)|metformin 500mg BID p/o.
89551396|NCT03129113|Experimental|maraviroc + metformin (Arm C)|maraviroc dosed BID p/o (dose adjusted depending on background combination antiretroviral therapy) PLUS metformin 500mg BID p/o.
89551397|NCT03129113|No Intervention|no adjunctive therapy (Arm D)|no adjunctive therapy
89551398|NCT03116035|Active Comparator|Web-based decision aid|A commercially available web-based breast cancer surgery decision aid
89025458|NCT03274232|Experimental|SUNEKOS ® 200|The 1st intradermal treatment (T1i) was performed during the basal visit (T0), after basal evaluations planned by the study procedure and repeated after 10 (T2i), 20 (T3i) and 30 (T4i) days.
89025459|NCT00456131|Experimental|Intervention|The intervention group (other group is a control without any intervention) involves 6 one-hour group sessions teaching healthy eating habits and weight gain prevention tools.
89025460|NCT03278535||age group 18-29 years|CAREN-based gait analysis: 20 men and 20 women aged between 18-29 years
89025461|NCT03278535||age group 30-39years|CAREN-based gait analysis: 20 men and 20 women aged between 30-39years
89025462|NCT03278535||age group 40-49years|CAREN-based gait analysis: 20 men and 20 women aged between 40-49years
89551399|NCT03116035|Active Comparator|Standard websites|selected, high-quality standard web-sites
89551400|NCT05105165||Antibody positive group|
89551401|NCT05105165||Antibody negative group|
89551402|NCT05105165||Health Group|
89551403|NCT03170635|Other|6 week Refreshing Recess program|Education and coaching for recess supervisors to learn about how to promote positive social interaction and active play with all students during recess. Provision of play activities for students during recess that foster active play, teamwork, and inclusion of students with disabilities and/or social challenges.
89551404|NCT05110547||Idiopathic Parkinson's disease|patients meeting the current clinical criteria whose disorders have progressed for strictly more than 2 years and strictly less than 7 years.
89551405|NCT05110547||atypical Parkinsonian syndromes|including the subgroups: multiple system atrophy, progressive supranuclear palsy, corticobasal degeneration with a duration of disease progression strictly greater than 2 years and strictly less than 7 years, and meeting the current clinical criteria for each
89551406|NCT02397577|Other|gastric emptying measurements|
89551407|NCT05105009|Active Comparator|Healthy Kidney Donors|12 Healthy Kidney Organ Donors
89551408|NCT05105009|Experimental|CKD Patients|12 patients for each CKD Stage
89551409|NCT03168529|Active Comparator|Ivabradine (Corlanor)|All subjects will complete the same number of follow-ups, dose titrations (if necessary) and study procedures however, subjects in this arm will be receiving active drug for study duration.
89551410|NCT03168529|Placebo Comparator|Placebo|All subjects will complete the same number of follow-ups, dose titrations (if necessary) and study procedures however, subjects in this arm will be receiving placebo for study duration.
89551411|NCT03115879|Placebo Comparator|Placebo Group|Hip manipulation simulation
89551412|NCT03115879|Experimental|Manipulation Group|Hip manipulation
89551413|NCT05104931|Experimental|Nanoformed Piroxicam IR Tablet|orally delivered nanoformed piroxicam immediate release tablets (20mg)
89551414|NCT05104931|Active Comparator|Felden (piroxicam) Tablets|orally delivered Felden (piroxicam) tablets (20mg)
89551415|NCT05104931|Active Comparator|Brexidol (piroxicam) Tablets|orally delivered Brexidol (piroxicam) tablets (20mg)
89551416|NCT02397499|Experimental|LIPO-202|Experimental arm
89551417|NCT02397499|Placebo Comparator|Placebo|Placebo comparator
89551418|NCT02847689|Experimental|Language Treatment Arm|An infant participant randomized to the language treatment arm will be played recordings of his/her mother's voice 2-3 hours daily in the intermediate care nursery until discharge.
89551419|NCT02847689|Sham Comparator|Control Treatment Arm|An infant participant randomized to the control treatment arm will receive standard of care. Standard of care does not include being played recordings of his/her mother's voice while admitted to the intermediate care nursery. However, an infant randomized to the control treatment will have the same auditory equipment placed in his/her isolette or crib as an infant randomized to the Language Treatment Arm.
89551420|NCT02406703||Chloroprocaine|Patient undergoing popliteal block with chloroprocaine
89551421|NCT02406703||Mepivacaine|Patient undergoing popliteal block with mepivacaine
89551422|NCT02397031|Experimental|Mindfulness|As proposed in dialectical behavioral therapy, mindfulness training consist of a set of behavioral skills that aim at improving patient's attentional control and emotional regulation.
89551423|NCT02397031|Active Comparator|Interpersonal effectiveness|Interpersonal effectiveness skills are focused on improving interpersonal relationships and enhancing patient's ability to display social effective behavior.
89551424|NCT05110469|Experimental|Group M|IV Magnesium sulphate 30 mg/kg in 100 ml NaCl 0.9%
89551425|NCT05110469|Experimental|Group P|IV Meperidine 0.5 mg/kg in 100 ml NaCl 0.9%
89551426|NCT02404129|Other|Non-fallers|"The subjects had to report having no difficulties with mobility, activities of daily living, or turning while walking and had no falls for a year period. The test that will be performed: Turn 180 test, Timed Up and Go test, Tinetti Balanced Test, Berg Balance Scale."
89551427|NCT02404129|Other|In a risk to fall|"Subjects who report about 1-2 falls in a year period. The test that will be performed: Turn 180 test, Timed Up and Go test, Tinetti Balanced Test, Berg Balance Scale."
89551428|NCT02404129|Other|Multiple fallers|"Subjects who reported to have more than two falls per year. The test that will be performed: Turn 180 test, Timed Up and Go test, Tinetti Balanced Test, Berg Balance Scale."
89551429|NCT04831775|Experimental|Memory, Attention, and Problem Solving Skills for Diabetes|The intervention is composed of 4 small-group webinar classes and home-based individual online cognitive skills practice over 8 weeks. Classes 1 & 2 will focus on common cognitive problems in T2DM and strategies to improve cognitive skills. Classes 3 & 4 focus on lifestyle changes to support cognitive functioning and DM-SM skills. The computer-training component uses a model for cognitive training that adapts to the user through an integrated hierarchical structure. The BrainHQ website houses the interactive program that runs on standard web browsers. Each participant will be registered by the project staff using anonymous ID numbers that will allow unlimited access during the study. The website stores each session completed, and participants can start subsequent sessions wherever they stopped the last time logged on. The intervention group will be asked to practice 20 minutes, 7 days a week.
89551430|NCT04831775|Active Comparator|Brain Games Only|An active control group will be used. The differing variable between the two groups is the class sessions. Those randomized to the control group will only receive a link to the BrainHQ games site. A specific amount of practice will not be prescribed, but the frequency and duration of participant's practice will be obtained from BrainHQ. Participants will receive a weekly phone call to maintain connection to the study. Data collection will be on the same schedule as the intervention group.
89551431|NCT02404051|Experimental|ARM 1|Everolimus plus Exemestane -> progression disease (PD) -> fulvestrant (ARM 1)
89551432|NCT02404051|Experimental|ARM 2|Fulvestrant -> progression disease (PD) -> everolimus plus exemestane (ARM 2)
89551433|NCT02406547|Experimental|WLE-NBI|Participants will be evaluated by same endoscopist, back-to-back tandem colonoscopy. It consists of two withdrawal from the cecum to sigmoid colon using firstly High Definition White Light Endoscopy (WLE) and secondly Narrow Band Imaging (NBI). All detected polyps will be classified macroscopically and resected in each withdrawal.
89551434|NCT02406547|Experimental|NBI-WLE|Participants will be evaluated by same endoscopist, back-to-back tandem colonoscopy. It consists of two withdrawal from the cecum to sigmoid colon using firstly Narrow Band Imaging (NBI) and secondly High Definition White Light Endoscopy (WLE). All detected polyps will be classified macroscopically and resected in each withdrawal.
89551435|NCT04436549||Patients with varicose veins|Patients with varicose veins and eligible to receive open surgery (stab avulsion of varicose veins) as routinely care.
89551436|NCT03172585|Other|High Resolution computed tomography|Patients will be included in the study when High resolution chest computed tomography without contrast enhancement is ordered by the primary physician. Before the High resolution chest computed tomography scan, a Trans thoracic ultrasonography will be performed.
89551437|NCT05094323|Active Comparator|Group I|Patients will receive ultrasound-guided deep serratus anterior plane block.
89551438|NCT05094323|Active Comparator|Group II|Patients will receive local wound infiltration (LWI).
89551439|NCT05094323|Placebo Comparator|Group III|Patients will receive ultrasound-guided thoracic paravertebral block.
89551440|NCT03170323|Experimental|Mycophenolate mofetil|Drug: Mycophenolate mofetil, high dose steroid Duration: 1 year
89551441|NCT03170323|Active Comparator|Cyclosporin|Drug: Cyclosporin, low dose steroid Duration: 1 year
89551442|NCT04480489|Experimental|Group A|In Group A, students will first perform Task 1 (walk from anesthesia lounge to the day surgery unit) using intervention 1 (using the virtual reality video) first, then Task 2 (walk from anesthesia lounge to the pre-operative clinic) using intervention 2 (using the traditional 2D video).
89025463|NCT03278535||age group 50-59years|CAREN-based gait analysis: 20 men and 20 women aged between 50-59years
89551443|NCT04480489|Active Comparator|group B|In Group B, students will first perform Task 1 (follow route 1: walk from anesthesia lounge to the day surgery unit) using intervention 2 (using the traditional 2D video) first, then Task 2 (follow route 2: walk from anesthesia lounge to the pre-operative clinic) using intervention 1 (using the virtual reality video).
89551444|NCT02396797|Experimental|The new atWork intervention|The intervention group will receive the new atWork intervention, which include a management course and workplace courses for all employees targeting mental health complaints and musculoskeletal complaints.
89551445|NCT02396797|Active Comparator|The original atWork intervention|The control group will receive the original atWork intervention, targeting musculoskeletal complaint, and peer support.
89551446|NCT04788875|Active Comparator|Small Bite Technique Group|closure of laparotomy by small bites technique using PDS 2.0
89551447|NCT04788875|Other|Standardised Large Bites Technique Group|usual practice closure of laparotomy by standardised large bites technique using PDS 2.0
89551448|NCT02396875|Experimental|Group 1|40 patients undergoing CRT will have venous samples taken from two CS tributaries, peripheral venous and peripheral arterial sites at the time of CRT insertion at the time of device implant. Blood samples will be analysed for metabolites and novel biomarkers They will then undergo repeat sampling at 6 months to assess for changes in the biomarker profile including CS sampling.
89551449|NCT02396875|Active Comparator|Group 2|A control arm of 15 patients with heart failure and no dyssynchrony will undergo peripheral venous sampling for novel biomarkers and this will be repeated at 6 months. These samples will allow for control against the dyssynchronous heart failure group and also for temporal changes in biomarker expression.
89551450|NCT02396875|Active Comparator|Group 3|A control arm of 15 patients with normal hearts will undergo peripheral venous sampling for novel biomarkers and this will be repeated at 6 months. These samples will allow for control against the dyssynchronous heart failure group and also for temporal changes in biomarker expression.
89551451|NCT02396875|Experimental|Group A|"10 patients from Group 1~On the day preceding the CRT implant will attend hospital for a temporary invasive catheter study. The patient will have a radial sheath positioned in the arterial system. A pacing protocol will be performed using a pacing wire inserted into the right atrium. Coronary sinus venous blood sampling will be performed using a catheter placed via the femoral or internal jugular vein. At the chief investigator's discretion a specially designed exercise bicycle that allow supine exercise in the catheter lab will be used rather than the atrial pacing wire.~6 months post implant the patients will return to the catheter laboratory for a further study. This will repeat the protocol but with the device having been on for 6 months. This will require further study as described above."
89551452|NCT02396875|Active Comparator|Group B|"5 patients form Group 2.~Patients will undergo a pacing or exercise protocol and have venous, coronary sinus and arterial blood sampled. They will revert to Group 2 for 6 month follow up"
89551453|NCT02396875|Active Comparator|Group C|"5 patients form Group 3~Patients will undergo a pacing or exercise protocol and have venous, coronary sinus and arterial blood sampled. They will revert to Group 3 for 6 month follow up"
88961852|NCT03480438|Experimental|Blinatumomab|"Patients will receive blinatumomab at a dose of 28 μg/day as continuous intravenous infusion at constant flow rate for four weeks defined as one treatment cycle. Up to four cycles will be performed.~In case of defined toxicities, the dose of blinatumomab may be reduced to 9 μg/day."
88961853|NCT03463876|Experimental|SHR-1210+Apatinib|Patients will received apatinib orally every day and SHR-1210 200mg (3mg/kg for underweight patients) iv every 2 weeks.
88961854|NCT03461120|Experimental|Treatment|Bupivacaine 0.3% [or ropivacaine 0.5%] infusion for 7 days via femoral and sciatic perineural catheters
88961855|NCT03461120|Other|Control|Bupivacaine 0.1% [or ropivacaine 0.2%] infusion for 1 day followed by normal saline for a total of 7 days via femoral and sciatic perineural catheters
89551454|NCT02396641|Experimental|Single Study Arm|This study arm consists of providers who will identify their baseline in Best Supportive Care, then have the intervention of using a Best Supportive Care checklist.
89551455|NCT03172507||Atherosclerosis group|Patients with significant coronary artery disease.
89551456|NCT03172507||Control group|Healthy controls without confirmed coronary artery disease.
89551457|NCT05109923|Experimental|New Mood Supplementation|The New Mood herbal supplement includes lemon balm, 5-HPT, L-Tryptophan and valerian root.
89551458|NCT05109923|Placebo Comparator|Placebo Supplementation|The placebo includes rice bran and maltodextrin.
89551459|NCT02396563||epidural analgesia|women in labor with epidural analgesia
89551460|NCT02396563||no epidural analgesia|
89551461|NCT05109767|Experimental|Virtual reality glass game application|
89551462|NCT05109767|Active Comparator|Smartphone game application|
89551463|NCT05109767|No Intervention|Control group|
89551464|NCT03170245||B thalassemia group|"Laboratory investigations :~complete blood count~renal and liver function tests~serum ferritin~lipid profile~Interleukin -6~HsC-RP~Adiponectin level~Imaging :~Abdominal ultrasound~Echocardiography~Carotid intima media thickness"
88961856|NCT03405740|Active Comparator|Remote Patient Management|Patients will be followed by remote monitoring only.
88961857|NCT03405740|Placebo Comparator|Standard of Care|Remote monitoring at 6 month intervals, alternating with yearly in-clinic visits at their usual site.
88961858|NCT03396588|Active Comparator|Clonidine|Babies randomized to clonidine will receive 1mcg/kg/dose (with a dosing interval of 3 or 4 hours).
88961859|NCT03396588|Active Comparator|Morphine|Babies randomized to morphine will receive 0.06 mg/kg/dose (with a dosing interval of 3 or 4 hours).
88961860|NCT03350451|Experimental|Lumasiran (ALN-GO1)|
88961861|NCT03335878||Type 1 Diabetes Mellitus Group|T1DM Group - 150 otherwise healthy children, ages 4-16 years old, diagnosed with T1DM within 3 months prior to their initial study visit. This is not a treatment study therefore there is no intervention in this study.
88961862|NCT03335878||Healthy Control Sibling Group|Sibling Control Group - 50 age and gender matched healthy siblings without a diagnosis of T1DM. This is not a treatment study therefore there is no intervention in this study.
88961863|NCT03329508|Experimental|P2B001 0.6/0.75 mg|Fixed dose combination once daily capsule of pramipexole 0.6mg and rasagiline 0.75mg, + matching placebo tablet
88961864|NCT03329508|Experimental|rasagiline 0.75mg|Rasagiline 0.75mg Once daily capsule, component of P2B001, + matching placebo tablet
89551465|NCT03170245||Control group|"Laboratory investigations :~complete blood count~renal and liver function tests~serum ferritin~lipid profile~Interleukin -6~HsC-RP~Adiponectin level~Imaging :~Abdominal ultrasound~Echocardiography~Carotid intima media thickness"
89551466|NCT05109689|Experimental|ACT-P|ACT-P is a cognitive behavioral program based on acceptance and commitment therapy, and it has been modified for use in the prison setting.
89551467|NCT05109689|Active Comparator|T4C|Thinking for Change (T4C) is an evidence-based cognitive behavioral program focused on changing criminal thinking.
89551468|NCT02701777|Active Comparator|STDP|Paired stimulation will be given to the brain and to a peripheral nerve so that the messages are received at the spinal cord at predetermined time.
89551469|NCT02701777|Active Comparator|STDP + Training|Paired stimulation will be given to the brain and to a peripheral nerve so that the messages are received at the spinal cord at predetermined time. Motor training will follow paired stimulation.
89551470|NCT02701777|Active Comparator|Sham STDP + Training|Sham or fake paired stimulation will be given to the brain and to a peripheral nerve so that the messages are received at the spinal cord at predetermined times. Motor training will follow stimulation.
89551471|NCT02701777|Other|Multisite-STDP + Training|Prospective Single Cohort Multisite-Paired stimulation will be given to the brain and to a peripheral nerve so that the messages are received at the spinal cord at predetermined time. Motor training will follow paired stimulation.
89551472|NCT05109533|No Intervention|Group 1 - ARM WITH STANDARD TREATMENT|Standard specific treatment for vaginal infections following latest version of CDC guidelines
89551473|NCT05109533|Experimental|Group 2 - ARM WITH STANDARD TREATMENT PLUS PROBIOTICS IMPLEMENTATION|Standard specific treatment for vaginal infections plus long-lasting (9 months) vaginal and oral probiotics implementation (Lactobacillus rhamnosus BMX 54 vaginally and Lactobacillus reuteri RC-14/Lactobaciullus rhamnosus GR-1 combination orally)
89551474|NCT05109377|Other|5mg tadalafil|5mg tadalafil
89551475|NCT05109377|Other|20mg tadalafil|20 mg tadalafil
89551476|NCT03170167||Patients|This is a pre-post survey study of Communitas, a pre-existing integrative medicine and mind-body skills group visit for adolescents living with chronic illness and their parents. Approximately 50-100 patient enrollees of the Communitas group visits will be recruited to participate in this survey study optionally.
89551477|NCT03170167||Parents|This is a pre-post survey study of Communitas, a pre-existing integrative medicine and mind-body skills group visit for adolescents living with chronic illness and their parents. Approximately 50-100 parent enrollees of the Communitas group visits will be recruited to participate in this survey study optionally.
89551478|NCT05109299|Experimental|Miswak toothpaste|Dabur meswak herpal toothpaste
89551479|NCT05109299|Active Comparator|Fluoride toothpaste|Signal fluoride toothpaste, containing 1450 ppm of fluoride
89551480|NCT03172351|Experimental|EDoF1|
89551481|NCT03172351|Active Comparator|Monofocal|
89551482|NCT03172351|Active Comparator|EDoF2|
89551483|NCT05108753||Group 1|5 patients underwent TaTME under proctoring
89551484|NCT05108753||Group 2|the first 10 patients underwent TaTME without proctoring
89551485|NCT05108753||Group 3|the second 10 patients underwent TaTME without proctoring
89551486|NCT03170089|Active Comparator|Intervention|Professional tooth cleaning (scaling) Oral Health educational program
89551487|NCT03170089|No Intervention|Control|NO program or scaling done
89551488|NCT02396719||LenSx|Phacoemulsification cataract surgery in at least 1 eye using LenSx® Laser technology
89551489|NCT04673591|Experimental|Tregalizumab|
89551490|NCT04673591|Placebo Comparator|Matched placebo|
89551491|NCT05108597|Experimental|Misoprostol (Study Group)|In study group, 400ug misoprostol will be administered through rectal route, 1 hour before surgery.
89551492|NCT05108597|No Intervention|No drug|In control group no dose will be administered
89551493|NCT02397187|Experimental|LOOP intervention|"Patients enrolled in this arm will be treated by the LOOP interventional technique.~The LOOP conceptualizes the psyche by a three-dimension structure: the space (the potential of experiencing, the place where our experiences occur), the content (the experiences themselves; action, thoughts, feelings, experiences and being) and the order (the relationship between the various contents). The LOOP intervene with these three dimensions by a structures scheme, aimed at allowing the patient to quickly reclaim the responsibility on his psyche, stabilize and initiate long-term rehabilitation processes."
89551494|NCT02397187|Active Comparator|TAU|Patients enrolled in this arm will be TAU, which is based upon short-term supportive PT.
89551495|NCT02396485|Experimental|Early Feeding Arm|Patients will be started on regular diet within 6 hrs postoperative.
89551496|NCT02396485|No Intervention|Late Feeding Group|Patients will be remaining nothing per os (NPO, i.e nothing per mouth) for 12hrs, and the diet then advanced as tolerated after 12hrs as standard postoperative protocol in the investigators' institution.
89551497|NCT03167593|Placebo Comparator|Control|Capsules containing 300 mg of maltodextrin.
89551498|NCT03167593|Experimental|Probiotic|Capsules containing 3x10(9) colon-forming units of the strain L. coryniformis K8 CECT5711 in a matrix of maltodextrin.
89551499|NCT02396173|Experimental|Risk Score for non-return to work|The WORRK model is a predictive tool (19 items) of the non-return to work risk useful for all kinds of orthopaedic trauma and for patients needing vocational rehabilitation. It is constructed with variables independent of the patient's education and language fluency. It is a short patient's bedside tool and takes less than 20 minutes.
89551500|NCT02396173|No Intervention|Control group|In this group the medical staff will not be informed about the risk score (WORRK).
89551501|NCT04524767|Experimental|SBIRT|SBIRT will involve screening with the Patient Health Questionnaire-9 (PHQ-9); brief intervention with Motivational Interviewing (MI); and referral to specialty treatment, as needed for subjects with persistent depressive symptoms.
89551502|NCT04524767|Active Comparator|Referral As Usual|Referral as Usual will involve distributing depression educational materials (e.g., from the National Institute of Mental Health) and contact information for treatment providers in our target community
89551503|NCT02396407|Active Comparator|Combined water, sanitation, and hygiene|Water quality, Sanitation, Handwashing
89551504|NCT02396407|No Intervention|Non-intervention arm|None. Households will continue their usual practices.
88961865|NCT03329508|Experimental|Pramipexole 0.6mg|Pramipexole 0.6mg once daily capsule, component of P2B001 + matching placebo tablet
89551505|NCT03170011|Experimental|Intervention|The training protocol will be include 12 sessions completed over six weeks following a periodization training format. Each session will last approximately 40 minutes. At first, training will focus on high volume, low intensity, self-selected velocity with a progression to high intensity, low volume, self-selected velocity ending with a focus on power training (moderate intensity, moderate volume, high velocity movement) over the six weeks of training.
89551506|NCT05086913|Experimental|Lifestyle medicine smartphone app|The app group will receive an app to facilitate lifestyle modification such as video demonstrations of physical activity, diet recommendations, stress and sleep management.
89551507|NCT05086913|Experimental|lifestyle medicine booklets|The booklet group will receive 8 lifestyle medicine and psychoeducation booklets with identical content with the lifestyle medicine app.
89551508|NCT05086913|Sham Comparator|waitlist control|The waitlist control group will receive access to the lifestyle medicine app and booklets at the end of the study.
89551509|NCT05745805||Mild COVID-19 group|Confirmed diagnosis of mild Covid-19 (WHO criteria)
89551510|NCT05745805||Moderate COVID-19 group|Confirmed diagnosis of moderate Covid-19 (WHO criteria)
89551511|NCT05745805||Uninfected Healthy controls|Healthy people who have not had COVID-19
89551512|NCT03169855||Refractive media opacities: present|Refractive media opacities: present
89551513|NCT03169855||Refractive media opacities: absent|Refractive media opacities: absent
89551514|NCT04436627|Experimental|Mild severity:|Brunnstrom stage of distal part: 5-6
89551515|NCT04436627|Experimental|Moderate severity:|Brunnstrom stage of distal part: 4
89551516|NCT04436627|Experimental|severe severity:|Brunnstrom stage of distal part: 2-3
89551517|NCT02396329|Experimental|chlorhexidine _based antisepsis|"Including cases undergoing elective&non elective caesarean section.Patients will be were prepared similarly by three applications of 2%chlorhexidine solution time given between each application about 30 seconds followed by drying with a sterile towel and three applications of 70% alcohol after one minute The area scrubbed was from the xiphoid to the knee, reaching the midaxillary line laterally. In both groups, patients received preoperative prophylactic i.v antibiotics (cefotrixone 1 gm) one hour before skin incision.~."
89551518|NCT02396329|Active Comparator|povidone_iodine based antisepsis|Including cases undergoing elective&nonelective caesarean section.Patients will be scrubbed preoperative with an applicator that contain 10%povidone-iodine scrub aqueous solution(3 consecutive applications)followed by drying with sterile towel and 3 application of 70% alcohol after one minute The area scrubbed was from the xiphoid to the knee, reaching the midaxillary line laterally. In both groups, patients received preoperative prophylactic i.v antibiotics (cefotrixone 1 gm) one hour before skin incision
89551519|NCT04967651||Patients with pulmonary complications following cardiac surgery|
89551520|NCT04967651||Patients without pulmonary complications following cardiac surgery|
89551521|NCT04964921||Impaired Fasting Glucose Individuals|The group contains subjects with various stages of impaired fasting glucose tolerance levels and diabetes (with or without complications). All subjects will be considered in one group since the heart rate variability and vital signs are monitored in a single visit.
89551522|NCT04053049|Active Comparator|High fat/ Semi-solid|Subject will receive a high fat/semi-solid meal.
89551523|NCT04053049|Active Comparator|High carbohydrate/ Semi-solid|Subject will receive a high carbohydrate/semi-solid meal.
89551524|NCT04053049|Active Comparator|High fat/ solid|Subject will receive a high fat/solid meal.
88961866|NCT03329508|Active Comparator|Pramipexole Extended Release|Marketed pramipexole ER tablet titrated to optimal dose of 1.5, 3.0 or 4.5mg + matching placebo capsule
89551525|NCT04053049|Active Comparator|High carbohydrate/ solid|Subject will receive a high carbohydrate/solid meal.
89551526|NCT04648553|Experimental|Task-Based Grounding|Participating parents will be provided with three 50-minute Task Based Grounding sessions using a standardized manual over 6 weeks.
89551527|NCT04648553|Sham Comparator|Connected Care (Enhanced treatment as usual)|"Participating parents will be provided with two sessions and one phone check-in call over 6 weeks. They will work with a care navigator to assess their child's needs, find them an appropriate referral for care, and help problem solve barriers to finding a therapist."
89551528|NCT03167515|Experimental|074-6751 Lotion|
89551529|NCT03168139|Experimental|Olaptesed pegol + Pembrolizumab|
89551530|NCT02396017|Active Comparator|Single-dose Polyethylene Glycol regimen|Drug: Polyethylene Glycol Intervention: 2 liters of Polyethylene Glycol will be given in the day before Capsule Endoscopy ingestion.
89551531|NCT02396017|Experimental|Split-dose Polyethylene Glycol regimen|Drug: Polyethylene Glycol Intervention: 1 liter of Polyethylene Glycol will be given in the day before Capsule Endoscopy ingestion and another 1 liter Polyethylene Glycol will be given in the same day of Capsule Endoscopy ingestion.
89551532|NCT02395939|Active Comparator|CT guided core biopsy|In patients allocated to this arm a CT guided core biopsy will be performed
89551533|NCT02395939|Active Comparator|Cryo-biopsy via Radial EBUS navigation|"If the patient is randomised to this arm, the lesion will be located via R-EBUS.~Each patient will have 3 cryo biopsies and 3 forceps biopsies. The order of the cryo biopsy and forcep biopsy will be randomly allocated at the time of initial randomisation."
89551534|NCT02395783|Active Comparator|Melatonin dose1|Melatonin 10 µg
89551535|NCT02395783|Active Comparator|Melatonin dose2|Melatonin 20 µg
89551536|NCT02395783|Placebo Comparator|Placebo|Placebo
89551537|NCT04470713||Group A - Retrospective data collection|Participants with a confirmed diagnosis, either deceased patients or patients whose survival status is not known at enrollment.
89551538|NCT04470713||Group B - Prospective data collection|Participants who are alive at enrollment. Data collection is retrospective for the time between birth and enrollment visit, and data collection is prospective from the enrollment visit onwards. Visits are performed as per local standard of care.
89551539|NCT04604015|Experimental|NeuralBot Investigational System/TTE Std of Care|Investigational Robotic Transcranial Doppler (TCD)/TTE Std of Care
89551540|NCT04569383|Experimental|1x10E7 IU (low dose)|1x10E7 IU MVA-SARS-2-S. Subgroup will receive additionally Comirnaty
89551541|NCT04569383|Experimental|1x10E8 IU (high dose)|1x10E8 MVA-SARS-2-S. Subgroup will receive additionally Comirnaty
89551542|NCT04555343|Experimental|Intervention- TXA|"Drug: one-time intravesical administration of 1gm of TXA instilled via urinary catheter, instilled for 15min before continuous bladder irrigation treatment beings.~1gm of TXA will be mixed with 100cc NS"
89551543|NCT04450667|No Intervention|Fasting|"Patient will be nil per os from midnight before their cesarean section"
89551544|NCT04450667|Active Comparator|Rehydration|Patient will receive 400 mL of Nutricia Preop ® 2 hours before their cesarean section
89551545|NCT04436237|Experimental|Non-visual exproprioception training|The training requires the participant to place the foot at a target without visual cues of the foot in virtual environment.
89551546|NCT04436237|Active Comparator|Visual exproprioception group|The training requires the participant to place the foot at a target with visual cues of the foot in virtual environment.
89551547|NCT04466657|Active Comparator|Standard of Care (SOC)|Participants in this arm will receive SOC alone, which will be as determined by the clinical team at the treatment centres in line with the current National Interim Guidelines for Clinical Management of COVID-19
89551548|NCT04466657|Experimental|SOC plus Intervention|Participants in this arm will receive SOC plus daily antioxidant supplement composed of two proprietary formulations that include reduced glutathione, N-acetylcysteine, superoxide dismutase, and bovine lactoferrin and immunoglobulins.
89551549|NCT04392323|Experimental|Study Group|Patients will be recruited as an outpatient prior to their surgical procedure or during their hospital admission. If they consent, they will provide signed informed consent and will receive testing with serology and PCR for COVID-19 infection at pre-surgical testing 24-48 hours prior to their scheduled procedure. If they consent while inpatient postoperatively, signed informed consent will be procured after they have completed their pre-operative COVID-19 testing. PCR for COVID entails obtaining a nasopharyngeal swab to determine whether there is active viral replication and viral shedding. They will then have a second test with serology and PCR for COVID-19 infection 12-16 days after discharge from the hospital.
89551550|NCT04528667|Experimental|STI-5656|STI-5656 (abivertinib maleate) capsules administered orally 100 mg QD for 7 days, in addition to standard of care
89551551|NCT04528667|Placebo Comparator|Placebo|Placebo capsules administered orally daily for 7 days, in addition to standard of care
89551552|NCT04309877|Experimental|PO theophylline & IV LPS|Oral (PO) theophylline 400 mg/day for 2 weeks followed by a single intravenous (IV) bolus of lipopolysaccharide (LPS) 0.8 ng/kg of body weight
89551553|NCT04309877|Experimental|PO placebo & IV LPS|PO methylcellulose (placebo) daily for 2 weeks followed by a single intravenous (IV) bolus of lipopolysaccharide (LPS) 0.8 ng/kg of body weight
89551554|NCT04309877|Experimental|PO theophylline & IV placebo|PO theophylline 400 mg/day for 2 weeks followed by a single IV bolus of 0.9% saline
89551555|NCT04309877|Placebo Comparator|PO placebo & IV placebo|PO methylcellulose (placebo) daily for 2 weeks followed by a single IV bolus of 0.9% saline
89551556|NCT04367909|Experimental|Nimotuzumab plus TC Regimen chemotherapy|Nimotuzumab (200 mg) plus TC Regimen chemotherapy every 3 weeks
89551557|NCT04367909|Active Comparator|TC Regimen chemotherapy|TC Regimen chemotherapy every 3 weeks
89551558|NCT04221425|Experimental|VRRS GROUP|Home rehabilitation program is provided through a virtual reality based telerehabilitation system
89551559|NCT04221425|Active Comparator|CONTROL GROUP|Home rehabilitation program is provided through illustrative booklet containing characteristics of exercises and indications for recovery
89551560|NCT04196075|Experimental|Andrographis Paniculata treatment|Single lot of Andrographis paniculata (AP) concentrated granules (Andrographis Herba) will be manufactured by Nong's Company Limited under GMP standard
89551561|NCT04142255|Experimental|FMT|20 subjects will be enrolled in this arm to receive FMT treatment.
89551562|NCT03863483|Experimental|Sintilimab plus chemotherapy|Sintilimab (200 mg) plus chemotherapy (physicians' choice between docetaxel and pemetrexed) every 3 weeks.
89551563|NCT03863483|Active Comparator|Placebo plus chemotherapy|Placebo plus chemotherapy (physicians' choice between docetaxel and pemetrexed) every 3 weeks.
89551564|NCT03871595|Experimental|BI 894416 30 mg fed (T)|3 tablets with 10 milligram (mg) of BI 894416 (total: 30 mg) were administered as one single oral dose with 240 milliliter (mL) of water after a high-fat, high-calorie meal (fed conditions) as test treatment (T).
89551565|NCT03871595|Experimental|BI 894416 30 mg fast (R)|3 tablets with 10 milligram (mg) of BI 894416 (total: 30 mg) were administered as one single oral dose with 240 milliliter (mL) of water after an overnight fast of at least 10 hours (fasted conditions) as reference treatment (R).
89551566|NCT03840005|Placebo Comparator|Placebo|2:1 in favour of UDCA
89551567|NCT03840005|Experimental|Ursonorm (Ursodeoxycholic acid)|UDCA 30 mg/kg daily, tablet form taking orally , administered 3 monthly for 12 months, dose titration during the 1st month will occur.
89551568|NCT03780725|Experimental|Part 1: Ezabenlimab 240mg + BI 754111 600mg|
89551569|NCT03780725|Experimental|Part 2: Ezabenlimab 240mg + BI 754111 40mg|
89551570|NCT03830411|Experimental|Arm A: Sintilimab|Participants will receive Sintilimab as long as they continue to experience clinical benefit in the opinion of the investigator until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator.
89551571|NCT03830411|Active Comparator|Arm B: Chemotherapy (Docetaxel or Pemetrexed)|Participants randomized to the chemotherapy arm will receive docetaxel or pemetrexed until disease progression per standard RECIST v1.1 or unacceptable toxicity.
89551572|NCT03300479|Experimental|Clevidipine|The treatment starts at admission to the ICU for 24 hours with 2 mg to a maximum of 16 mg Clevidipine per hour infused intravenously and continuously to reach the systolic target pressure < 160 mmHg (>120 mmHg).
89551573|NCT03300479|Active Comparator|Urapidil|The treatment starts at admission to the ICU for 24 hours with 5 mg to a maximum of 40 mg Urapidil per hour infused intravenously and continuously to reach the systolic target pressure < 160 mmHg (>120 mmHg).
89551574|NCT04718987|Experimental|Prostate Cancer Patients|Low- or favourable intermediate-risk prostate cancer patients
89551575|NCT04708379|Experimental|Intervention group|Nutrition education and physical activity education.
89551576|NCT04708379|No Intervention|Control group|No specific intervention.
89551577|NCT03702569||Patients needing a volume expansion|
89551578|NCT04685447|Experimental|Expanded Hemodialysis|Hemodialysis modality performed by using a medium cut-off membrane
89551579|NCT04685447|Experimental|Protein-leaking hemodialysis|Hemodialysis modality performed by using a membrane with accentuated absorption capacities.
89551580|NCT03012425|Experimental|Cognitive Behavioral Therapy for Insomnia (CBT-I)|Session 1- Review of initial sleep diary, formulation of impression of type/subtype of insomnia, determine modifiable factors, address immediate concerns about participation, discuss motivation & compliance. Session 2- Review of sleep diary, present 4-P model of insomnia, prescribe Sleep Restriction & Stimulus Control Therapy. Session 3- Review of sleep diary, continue with stimulus control & sleep restriction procedures, review of sleep hygiene. Session 4- Review of sleep diary, continue with stimulus control & sleep restriction procedures, introduce & practice relaxation strategies. Session 5- Review of sleep diary, continue with stimulus control & sleep restriction procedures, conduct cognitive therapy to address dysfunctional thoughts underlying insomnia. Session 6- Review of sleep diary, continue with stimulus control & sleep restriction procedures Session 7- Review of sleep diary & overall progress, discuss relapse prevention, further sleep restriction guidelines & prophylaxis.
89551581|NCT03012425|Experimental|Acupuncture|Session 1 - Detailed history and examination, introduction to acupuncture. Sessions 2 - 10 - Each session will begin with insertion and manipulation of needles, which will remain in place for 30 minutes.
89551582|NCT03587675|Other|EVH in high-school elite athletes|EVH-test, skin prick test, sputum induction in all subjects Interventional but no drug or device tested
89551583|NCT03540875|Experimental|Full automation group|Full automation control of propofol and remifentanil
89551584|NCT03540875|Other|Control group|Manual control of of propofol and remifentanil using TCI system
89551585|NCT03536507|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
89551586|NCT03536507|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
89551587|NCT03220685||1.normal persons|normal persons include 25 person
89551588|NCT03220685||2.CKD pt with anemia|includes 25 previously diagnosed CKD patients with or without treatment of anemia.
89551589|NCT04765787||Painful musculoskeletal disorders in random order|Nuberol Forte® (Paracetamol 650 mg + Orphenadrine 50 mg) for the symptomatic management of the painful musculoskeletal disorders one tablet three times a day or as per physician discretion or as per severity of pain and treatment duration is 7-10 days
89551590|NCT04672967||Autism Spectrum Disorder|Children diagnosed with ASD between the ages of 18-60 months
89551591|NCT04672967||Non-ASD (developmental delay or typically developing)|Children diagnosed with non-ASD between the ages of 18-60 months
89551592|NCT04663217||Pulmonary arterial hypertension|Patients with mean pulmonary arterial pressure above 25 mmHg, and a pulmonary capillary wedge pressure below 15 mmHg classified into group 1 of the clinical classification of pulmonary hypertension.
89551593|NCT04663217||Pulmonary hypertension due to left heart disease|Patients with mean pulmonary arterial pressure above 25 mmHg, and a pulmonary capillary wedge pressure above 15 mmHg with left heart disease, classified into group 2 of the clinical classification of pulmonary hypertension.
89551594|NCT04663217||Chronic thromboembolic pulmonary hypertension|Patients with mean pulmonary arterial pressure above 25 mmHg, and a pulmonary capillary wedge pressure below 15 mmHg with a history of pulmonary embolism, classified into group 4 of the clinical classification of pulmonary hypertension.
89551595|NCT04663217||Control|Patients with mean pulmonary arterial pressure below 25 mmHg, and a pulmonary capillary wedge pressure below 15 mmHg with exclusion of pulmonary hypertension.
89551596|NCT02749331|Experimental|AdVince|"Dose escalation, minimum 3 patients per dose in Phase I. Dose levels:~10 000 000 000 virus particles~100 000 000 000 virus particles~300 000 000 000 virus particles~1000 000 000 000 virus particles~Maximum tolerated dose will be confirmed by 12 additional patients treated at this dose level in Phase IIa."
89551597|NCT05115149|Experimental|Volga: tSCS during the exercise|Stimulation during the excercise
89551598|NCT05115149|Experimental|Neva: tSCS prior to the exercise|Stimulation prior to the action
89551599|NCT05112341||group 1 standared hypofractonation|
89551600|NCT05112341||group 2 fast forward group|
89551601|NCT04638803|Experimental|Crossover (fasted)|On Day 1 subjects are dosed with 100 µg of PRX-P4-003 and PK samples are drawn according to protocol, on Day 15 subjects are dosed with 40 µg of (-)-FCF. Both treatment will be administered under the fasted conditions.
88961869|NCT03281304|Experimental|CP-690,550 5 mg|CP-690,550 5 mg tablet by mouth twice a day (BID)
88961870|NCT03281304|Experimental|CP-690,550 10 mg|CP-690,550 10 mg BID
88961871|NCT03204305|Active Comparator|Cannabis users|Smoked Cannabis plant material (0 and 25 mg THC) will be administered to volunteers who are regular cannabis users. Cannabis users will also complete a PET scan where 20 millicurie of 11C-OMAR
88961872|NCT03204305|Active Comparator|Nonuser controls|No cannabis administration. Non-user controls will complete a PET scan where 20 millicuries of 11C-OMAR
88961873|NCT03200717|Experimental|Pazopanib- 2nd line treatment|Participants received pazopanib as 2nd line treatment
88961874|NCT03200717|Experimental|Pazopanib- 3rd line treatment|Participants received pazopanib as 3rd line treatment
88961875|NCT03153319|Experimental|Adalimumab|20 mg subQ every other week (weight 15to <30 kg) 40 mg subQ every other week (weight ≥30 kg). Non-responders will be escalated to weekly dosing.
88961876|NCT03153319|Placebo Comparator|Placebo|Saline placebo comparator
88961877|NCT03153319|Experimental|Open-label adalimumab|Open-label extension of adalimumab dose
89551602|NCT04638803|Experimental|Single Group (fed)|On Day 1 subjects are dosed with 100 µg of PRX-P4-003 and PK samples are drawn according to protocol. The treatment will be administered under the fed condition.
89551603|NCT04592783|Experimental|Tight Blood Pressure Control|Antihypertensive medications will be initialed once BP is at or above 140/90 mmHg
89551604|NCT04592783|Experimental|Liberal Blood Pressure Control|Antihypertensive medications will be initialed once BP is at or above 150/95 mmHg
89551605|NCT05114525|Experimental|Patients Who are Anticipated to Receive Definitive Treatment|
89551606|NCT05112107|No Intervention|Control|
89551607|NCT05112107|Experimental|Intervention|
89551608|NCT04521881|Active Comparator|Active|A single dose of Tranexamic acid 500mg given by intramuscular injection
89551609|NCT04521881|Placebo Comparator|Placebo|One Injection of the placebo which is 10 mL Sodium Chloride (0.9%)
89551610|NCT04570787|Active Comparator|No Catheterization|After mini-PCNL standardized follow-up protocol supposes drainage the upper urinary tract with nephrostomy, tubeless (using ureteral stent without nephrostomy) or totally tubeless (no drainage) tactics. Bladder catheterization is not performed.
89551611|NCT04570787|Active Comparator|Catheterization|After mini-PCNL standardized follow-up protocol supposes drainage the upper urinary tract with nephrostomy, tubeless (using ureteral stent without nephrostomy) or totally tubeless (no drainage) tactics. The bladder is to be drained with the urethral catheter in all cases.
89551612|NCT05114369||Early (<4weeks), Intermediate (4-12 weeks) and Late (>12 weeks)|Interval between index cholecystectomy and radical re-resection with curative intent
89551613|NCT04305899|Experimental|Treatment Group 1|
89551614|NCT04305899|Experimental|Treatment Group 2|
89551615|NCT04305899|Experimental|Treatment Group 3|
89551616|NCT04305899|Experimental|Treatment Group 4|
89551617|NCT04305899|Experimental|Treatment Group 5|
89551618|NCT04305899|Experimental|Treatment Group 6|
89551619|NCT04305899|Experimental|Treatment Group 7|
88961878|NCT03145272|Experimental|Age group|"An orogastric tube will be placed in the stomach (placement verified by routine accepted clinical guidelines) under anesthesia as is part of standard routine clinical care to remove gastric contents. The same orogastric tube will be used for intragastric liquid oxycodone administration in a dose of 0.1 mg/kg before the surgical incision. This weight-adjusted dose of 0.1 mg/kg is administered as per standard clinical dosing guidelines.~This arm can be divided into 2 subgroups; (1)12 months - 1.9 years age group. (2) 2 - 5.9 years age group."
89025464|NCT03278535||age group 60-69years|CAREN-based gait analysis: 20 men and 20 women aged between 60-69years
89025465|NCT03278535||age group 70+|CAREN-based gait analysis: 20 men and 20 women aged between 70 years and older
89208070|NCT03974269|Placebo Comparator|Sedation arm|TAVI procedures will be either Medtronic Corevalve, or Edwards Sapien implantations, at operator's discretion. All procedures will be supervised by one of the two senior interventional cardiologists. Hypnosis sessions will be performed by two trained anesthesiologists, and Remifentanil sedations will be administered by the rest of the anesthesiologists staff. Postoperative care will be provided in the CICU for the 3 first postoperative days at least.
89208071|NCT00917189|Experimental|Computerized Cognitive Skills Training|Participants will receive the Challenging Our Minds intervention, delivered in-person in Phase 1 and remotely in Phases 2 and 3.
89551620|NCT04305899|Experimental|Treatment Group 8|
89551621|NCT04305899|Experimental|Treatment Group 9|
89551622|NCT04305899|Experimental|Treatment Group 10|
89551623|NCT01675661|Active Comparator|NAC plus CM|N-acetylcysteine (NAC) plus Contingency Management (CM)
89551624|NCT01675661|Placebo Comparator|Placebo plus CM|Placebo plus Contingency Management (CM)
89551625|NCT05113823|Active Comparator|High Fidelity Simulator|Subjects will receive training using high fidelity simulator
89551626|NCT05113823|Active Comparator|Low Fidelity Simulator|Subjects will receive training using low fidelity simulator
89551627|NCT04003493|Experimental|Intervention group of nutrition|On the basis of a blood test, Mini Nutritional Assessment, food diary and nutritional anamnesis, the nutritionist developed a plan for individualised nutritional care and discussed with the caregivers. If the caregivers seemed unable to increase the energy and/or protein of their diet, daily complementary dietary drinks were recommended to them. The participants were re-examined six months after the baseline interviews to evaluate the effectiveness of the interventions.
89551628|NCT04003493|No Intervention|Control group of nutrition|The control group has the same examinations as the intervention group, they do not get dietary counseling.
89551629|NCT04003493|Experimental|Intervention group of oral health|After the dental hygienist interview and oral health examination, the caregivers in need were targeted for oral health intervention. The intervention included individualised instructions on either dental hygiene, denture hygiene, cleaning of the oral mucosa or for dry mouth. The participants were re-examined six months after the baseline interviews to evaluate the effectiveness of the interventions.
89551630|NCT04003493|No Intervention|Control group of oral health|The control group has the same examinations as the intervention group, they do not get oral health counseling.
89551631|NCT03956849||Professionals working with children|The studypopulation for this mixed-methods study is consisting of healthcareprofessionals working with children (with overweight or obesity), such as pediatric residents, paediatricians and youth health care professionals. Also other professionals working with children, not working in the field of healthcare, such as teachers, can be included in the study population.
89551632|NCT05113511|Experimental|SCT510|SCT510
89551633|NCT05113511|Active Comparator|bevacizumab|bevacizumab
89551634|NCT05113433|Experimental|group a|15 minute on standing frame .
89551635|NCT05113433|Experimental|group b|30 minute on standing frame .
89551636|NCT05113433|Experimental|group c|45 minute on standing frame.
89551637|NCT05113433|Experimental|group d|60 minute on standing frame.
89551638|NCT05112887|Experimental|OMT Group|"The OMT protocol treatment sequence was performed in the following order:~1. Rib raising from a seated position 2. Suboccipital Release from a supine position 3. Thoracic Inlet Release 4. Miller Lymphatic Pump 5. Pedal Pump 6. Suboccipital Release 7. Cranial Sinus Effleurage~Engaging the sagittal midline of occiput with pressure until release of the tissue is palpated~Direct pressure along the external region of the transverse sinus until release of the tissue is palpated.~Pressure on sagittal suture with transverse traction until release of the tissue is palpated~Pressure on metopic suture with transverse traction in a pulsatile manner~Vault hold~1. Appreciate cranial respiratory motion 2. Diagnose cranial strain pattern 3. Place cranial strain pattern into position of ease"
89551639|NCT05112887|Placebo Comparator|Placebo/Light Touch/Sham Group|Participants in the sham/placebo group were lightly touched in equivalent positions to the OMT treatments. First, sham participants were lightly touched on the thoracic cage while seated, followed by light touch of the neck, chest, feet, and cranium while supine. The length of light touch was modeled after the approximate time needed for the OMT matching each treatment region. Each treatment sequence lasted about 20 minutes in total.
89033036|NCT02925546|Experimental|GSK2798745 CBAD treatment sequence|Subjects will be given 2.4 mg GSK2798745 (milled API with SLS and hypromellose) in fasted state (treatment C), 2.4 mg of GSK2798745 (micronized API with SLS and hypromellose) in fasted state (treatment B), 2.4 mg single oral doses of GSK2798745 (micronized API without SLS and hypromellose) in fasted state (treatment A), and GSK2798745 tablet in fed state (treatment D) in either treatment periods 1, 2, or 3; the three treatment periods will each be separated by a minimum washout period of 7 days
89208072|NCT00961155|Active Comparator|cyklezonid|children will receive 160 mcg once daily cyklezonid for 3 months
89208073|NCT00961155|Active Comparator|montelukast sodium|children will receive 5 or 10 mg montelukast sodium for 3 months
89551640|NCT01602341|Experimental|AN2728 Topical Ointment, 2% QD vs 0.5% QD|"AN2728 Topical Ointment, 2% applied once daily for 29 days to a target lesion, and AN2728 Topical Ointment, 0.5% applied once daily for 29 days to a target lesion~Treatments will be randomly assigned to target lesions A and B."
89551641|NCT01602341|Experimental|AN2728 Topical Ointment, 2% BID vs 0.5% BID|"AN2728 Topical Ointment, 2% applied twice daily for 29 days to a target lesion, and AN2728 Topical Ointment, 0.5% applied twice daily for 29 days to a target lesion.~Treatments will be randomly assigned to target lesions A and B."
89551642|NCT05112653||2|"Group of Philadelphia positive leukemic patients will included in the study who divide into:~patient newly diagnosed CML treated with first line of tyrosine kinase inhibitors therapy.~Philadelphia positive acute leukemic patients(ALL, mixed-phenotype acute leukemia) on TKI therapy who achieved complete hematological remission(CHR) and who failed to achieve CHR."
89551643|NCT05111171||6F sheath CAG group|No PCI is required, only diagnostic CAG is required.
89551644|NCT05111171||6F sheath PCI group|PCI is required, simple lesions are group.
89551645|NCT05111171||7F sheath PCI group|PCI is required for the complicated disease.
89551646|NCT03330197|Experimental|Arm 1 - Closed|Intratumoral Ad-RTS-hIL-12 freehand injection after tumor resection and oral veledimex (activator ligand) in pediatric patients with brain tumors.
89551647|NCT03330197|Experimental|Arm 2 - Open|Intratumoral Ad-RTS-hIL-12 stereotactic injection and oral veledimex (activator ligand) in pediatric patients with DIPG.
89551648|NCT03155399|Experimental|Proprioceptive based training (PBT)|The treatment will last one hour and will be divided as follows: 2 proprioceptive based stimulation sessions per 3 minutes for each movement, with a rest of 2 minutes between each session. Every patient will receive 15 treatments, 5 days a week, for 3 weeks.
89551649|NCT03155399|Other|Conventional neuromotor treatment (CNT)|The CNT group will be treated for one hour daily by means of a CNT programme. The treatment will last 3 weeks.
89551650|NCT05065307|Experimental|Video game in Virtual reality|The study subject will be playing a video game during the venipuncture, in virtual reality
89033037|NCT02922075|Placebo Comparator|CTL|No soft tissue graft was used. It was performed tooth extraction, immediate implant, immediate restoration, bone regeneration, post operative medication and definitive prosthesis.
89551651|NCT05065307|Active Comparator|Video game on a tablet|The study subject will be playing a video game during the venipuncture, on a tablet
89551652|NCT01013129||Probands|
89551653|NCT05103761|Active Comparator|Ketogenic diet|Diet administered to induce ketosis.
89551654|NCT05103761|Placebo Comparator|Low glycemic index treatment diet|Diet matched with a ketogenic diet with added carbohydrates to avoid ketosis.
89551655|NCT02700919|Experimental|Regimen 1|Drug: BCT197 Dose 1, Day 1 to Day 5
89551656|NCT02700919|Experimental|Regimen 2|Drug: BCT197 Dose 2, Day 1 to Day 5
89551657|NCT02700919|Placebo Comparator|Regimen 3|Placebo Day 1 to Day 5
89551658|NCT05088473||Mutliple sclerosis|
89551659|NCT05088473||CIS/RIS|
89551660|NCT05088473||Other CNS inflammatory diseases|
89551661|NCT05088473||Non inflammatory CNS diseases|
89551662|NCT05119127|Experimental|vivity toric IOL implantation arm|vivity toric intraocular lens will be implanted in one eye and undergo digital imaging intra op and post op to evaluate for toric intraocular lens rotational stability.
89551663|NCT04161989|Other|Group I (omega-3 fatty acids group)|received omega 3 (Omega 3 plus, SEDICO, Egypt); once daily from 28-30 weeks till delivery. The omega 3 plus capsule contains 1000 mg Fish Oil plus 100 mg Wheat Germ Oil is a natural source of Vitamin E.
89551664|NCT04161989|Other|Group II (vaginal progesterone plus omega-3 group)|received vaginal progesterone (Prontogest 400 mg vaginal suppository, Marcyrl Pharmaceutical Industries, Egypt) and omega 3 once daily from 28-30 weeks till delivery.
89551665|NCT01986010|Experimental|HCMV seropositive (+) V160 Low Dose Intramuscular (IM)|Participants seropositive for HCMV at Baseline will receive V160 vaccination by IM injection on Day 1, Month 1, and Month 6
89551666|NCT01986010|Experimental|HCMV seronegative (-) V160 Low Dose IM|Participants seronegative for HCMV at Baseline will receive V160 vaccination by IM injection on Day 1, Month 1, and Month 6
89551667|NCT01986010|Experimental|HCMV+ V160 Medium Dose IM|Participants seropositive for HCMV at Baseline will receive V160 vaccination by IM injection on Day 1, Month 1, and Month 6
89551668|NCT01986010|Experimental|HCMV- V160 Medium Dose IM|Participants seronegative for HCMV at Baseline will receive V160 vaccination by IM injection on Day 1, Month 1, and Month 6
89551669|NCT01986010|Experimental|HCMV+ V160 High Dose IM|Participants seropositive for HCMV at Baseline will receive V160 vaccination by IM injection on Day 1, Month 1, and Month 6
89551670|NCT01986010|Experimental|HCMV- V160 Medium Dose plus MAPA 225 µg IM|Participants seronegative for HCMV at Baseline will receive vaccination with V160 plus MAPA adjuvant by IM injection on Day 1, Month 1, and Month 6
89551671|NCT01986010|Experimental|HCMV- V160 High Dose IM|Participants seronegative for HCMV at Baseline will receive V160 vaccination by IM injection on Day 1, Month 1, and Month 6
89551672|NCT01986010|Experimental|HCMV+ V160 High Dose plus MAPA 225 µg IM|Participants seropositive for HCMV at Baseline will receive vaccination with V160 plus MAPA adjuvant by IM injection on Day 1, Month 1, and Month 6
89551673|NCT01986010|Experimental|HCMV+ V160 Maximum Dose IM|Participants seropositive for HCMV at Baseline will receive V160 vaccination by IM injection on Day 1, Month 1, and Month 6
89551674|NCT01986010|Experimental|HCMV- V160 High Dose plus MAPA 225 µg IM|Participants seronegative for HCMV at Baseline will receive vaccination with V160 plus MAPA adjuvant by IM injection on Day 1, Month 1, and Month 6
89551675|NCT01986010|Experimental|HCMV- V160 Maximum Dose IM|Participants seronegative for HCMV at Baseline will receive V160 vaccination by IM injection on Day 1, Month 1, and Month 6
89551676|NCT01986010|Placebo Comparator|HCMV+ Placebo IM|Participants seropositive for HCMV at Baseline will receive placebo by IM injection on Day 1, Month 1, and Month 6
89551677|NCT01986010|Placebo Comparator|HCMV- Placebo IM|Participants seronegative for HCMV at Baseline will receive placebo by IM injection on Day 1, Month 1, and Month 6
89551678|NCT01986010|Experimental|HCMV+ V160 Medium Dose Intradermal (ID)|Participants seropositive for HCMV at Baseline will receive V160 vaccination by ID injection on Day 1, Month 1, and Month 6
89551679|NCT01986010|Experimental|HCMV- V160 Medium Dose ID|Participants seronegative for HCMV at Baseline will receive V160 vaccination by ID injection on Day 1, Month 1, and Month 6
89551680|NCT01986010|Placebo Comparator|HCMV+ Placebo ID|Participants seropositive for HCMV at Baseline will receive placebo by ID injection on Day 1, Month 1, and Month 6
89551681|NCT01986010|Placebo Comparator|HCMV- Placebo ID|Participants seronegative for HCMV at Baseline will receive placebo by ID injection on Day 1, Month 1, and Month 6
89551682|NCT04160117|Experimental|Intervention|Colchicine 0.6 mg p.o. twice daily for 10 days after catheter ablation for atrial fibrillation
89551683|NCT04160117|Placebo Comparator|Control|Matching placebo p.o. twice daily for 10 days after catheter ablation for atrial fibrillation
89551684|NCT04414631|Active Comparator|active treatment arm|treatment with conestat alfa in addition to standarf of care
89025466|NCT04700943||Regional awake anesthesia|"In non-intubated patients, an epidural catheter was placed at T5-T6. An anesthetic load of 0,5 mg/kg of ropivacaine was administered to reach anesthesia of the thoracic wall. Adjunctive local anesthetic infiltration of the incision site was performed by the surgeon with 2% lidocaine and 7,5% Ropivacaine. The cumulative dose of anesthetics drugs was computed as not to exceed the recommended dosage.~To improve patient comfort through the procedure, sedation with Target Controlled Infusion of propofol (using Schnider algorithm) and low dose remifentanil (0,05 mcg/kg/min) was also administered."
89033038|NCT02922075|Experimental|CM|Patient received a collagen matrix graft. It was performed tooth extraction, immediate implant, immediate restoration, bone regeneration, post operative medication and definitive prosthesis.
89551685|NCT04414631|No Intervention|Standard of care treatment arm|Standard of care treatment established at the centers
89551686|NCT03115255|Experimental|serum VEGF level|Serum samples are collected 1 day before and 1 day, 3 days, 1 week after intravitreal ranibizumab
89551687|NCT02403583|Other|Intervention- Home visits|Participants randomized to intervention arm receive 3 home visits conducted by one female and one male lay health worker.
89551688|NCT02403583|No Intervention|Standard Care|Participants will receive current standard clinic-based services including the option for women and partners to return to the clinic for male partner HIV testing or CHCT.
89551689|NCT05042063||Participants with cough as a symptom|This group will be composed of patients at the Clínica Universidad de Navarra that complain of having cough as a remarkable symptom.
88812098|NCT05946577||Patients treated with exclusive radiotherapy or radiotherapy with non-ototoxic chemotherapy|"patient ineligible for chemotherapy with cisplatin:~exclusive radiotherapy: 60-70 Gy in 30-35 fractions~radiotherapy with a non-ototoxic chemotherapy (due to contraindication to cisplatin): 60-70 Gy in 30-35 fractions"
89208074|NCT00961155|Placebo Comparator|placebo|children will receive placebo for 8 weeks out of allergy season to house dust mite
89208075|NCT00961155|Active Comparator|formoterol|children will receive formoterol aerolzol 12mcg twice daily for 3 months
89208076|NCT00793676|Other|A= Asthma|
89551690|NCT05042063||Validation subgroup 1|This subgroup will be composed by both, patients belonging to the main study group, as well as voluntaries, who will be asked to provide a series of elicited cough and non-cough sounds for validation purposes.
89551691|NCT05042063||Validation subgroup 2|This subgroup will be composed by inpatients admitted to the Clínica Universidad de Navarra with a diagnosis of respiratory disease, or presenting cough as a symptom, as well as healthy individuals. This group will be monitored with Hyfe Cough Tracker and Hyfe Air for a variable period of 6-24 hours, while they are recorded with a MP3 recorder connected to a lapel microphone.
89551692|NCT03168061|Experimental|NC-6300|"In Part 1, patients will receive an intravenous infusion of NC-6300 at escalating doses starting at a fixed dose on Day 1 of a 21-day cycle. After enrollment of the initial patient, the first patient in each cohort will not be enrolled until all patients at the immediately lower cohort have completed at least 1 full 21-day cycle. In Part 1, patients will continue to receive treatment until they experience disease progression, experience unacceptable toxicity, or withdraw voluntarily.~Part 2 will begin after the RPII dose of NC-6300 is identified. All patients in Part 2 will receive NC-6300 at the RPII dose."
89551693|NCT01963780|Experimental|OCS Lung Tx.|A prospective, pivotal single arm trial.
89551694|NCT03167983||dementia|patients with dementia
89551695|NCT03167983||control|healthy control
89551696|NCT02009878|Other|tolvaptan 3.75 mg|tolvaptan 3.75 mg
89551697|NCT02009878|Other|tolvaptan 7.5 mg|tolvaptan 7.5 mg
89551698|NCT02009878|Other|tolvaptan 15 mg|tolvaptan 15 mg
89551699|NCT04439968|Active Comparator|Targeted Csats|Subjects randomized to the targeted Csat arm will have NIRS monitoring of cerebral saturations (Csat) and will have algorithm-driven clinical interventions to maintain Csat within target range in the first week of life.
89551700|NCT04439968|No Intervention|Non-targeted Csats|Subjects randomized to the non-targeted Csat arm will have NIRS (near-infrared spectroscopy) monitoring of Csats, but Csat values will be obscured and not available to providers. These subjects will not have any algorithm-driven clinical interventions for Csat.
89551701|NCT02009722|Active Comparator|Intrathecal hydromorphone|Patients will be randomized to receive a one-time dose of intrathecal hydromorphone or intrathecal morphine as part of their spinal anesthesia. The starting dose of intrathecal hydromorphone will be 40 micrograms. This will be adjusted in subsequent patients based on the previous patient's success or failure according to an up-and-down methodology utilizing a biased coin design.
89551702|NCT02009722|Active Comparator|Intrathecal morphine|Patients will be randomized to receive a one-time dose of intrathecal hydromorphone or intrathecal morphine as part of their spinal anesthesia. The starting dose of intrathecal morphine will be 100 micrograms. This will be adjusted in subsequent patients based on the previous patient's success or failure according to an up-and-down methodology utilizing a biased coin design.
89551703|NCT04416880|Experimental|Press Tack Needle Acupuncture|Patients in this group were given seirin pyonex press tack needle treatment in the acupuncture points CV17 Danzhong and SI1 Shaoze bilateral for 7 days.
89551704|NCT04416880|Sham Comparator|Sham Control Press Tack Needle Acupuncture|Patients in this group were given sham treatment in the acupuncture points CV17 Danzhong and SI1 Shaoze bilateral for 7 days.
89551705|NCT02655419|Experimental|ATM-AVI + Metronidazole|Aztreonam-avibactam + metronidazole
89551706|NCT01962922|Active Comparator|LCP-Tacro|Envarsus XR
89551707|NCT01962922|Active Comparator|Tacrolimus - IR|Tacrolimus
89551708|NCT04198961|Experimental|Electronic Intervention|Individualized opioid taper and safety recommendations will be communicated to prescribers via an electronic medical record encrypted message.
89551709|NCT05118971||elliptical (GE)|The patient is suspended supported by the hip positioner, secured by nylon straps to a galvanic iron grid fixed to the ceiling with parabolts. The height of the seat belts will be measured according to the patient's proper position in the device. The weight support belt will be adjusted to maximize load bilaterally without knee deformation during correct posture, manual assistance will be provided by physical therapists on each leg. A physical therapist's hand will be placed on the anterior surface of the leg below the patella to aid in knee extension during the elliptical gait simulation. The other hand will be placed on the ankle to aid in the movement of the feet during the alternating movement of the legs and the return of the heel placement to the starting position. The patient performs the movements at the maximum speed he can, recording the electromyographic signal of the selected muscles for 20 seconds.
89208077|NCT00793676|Other|B= COPD|
89208078|NCT00793676|Other|C= Control|
89208079|NCT00863538|Experimental|1|
89208080|NCT00260533|Experimental|1|Atomoxetine
89208081|NCT00260533|Placebo Comparator|2|Placebo
89208082|NCT02596919|Other|No arms|No randomisation therefore no arms. All patients will receive the same research treatment.
89551710|NCT05118971||elliptical with biofeedback (GEB)|The same described in the elliptical group adding biofeedback.
89551711|NCT05118971||bicycle (GB)|The patient will have the help of two physiotherapists to position themselves, who will also assist in pedaling as needed. The patient will also be asked to perform the movements at the maximum speed he can, recording the electromyographic signal of the same selected muscles for 20 seconds.
89551712|NCT05118971||bike with biofeedback (GBB)|The patient will have the help of two physiotherapists to position themselves, who will also assist in pedaling as needed. The patient will also be asked to perform the movements at the maximum speed he can, recording the electromyographic signal from the same selected muscles for 20 seconds, adding biofeedback.
89551713|NCT04436315|Experimental|Intervention|Exergame intervention
89551714|NCT04436315|Sham Comparator|Control|Active control condition
89551715|NCT01984684|Experimental|Delafloxacin|Delafloxacin 300 mg IV Q12H for 6 doses, then Delafloxacin 450 mg oral tablet Q12H for a minimum of 10 up to a maximum of 28 doses total
89551716|NCT01984684|Active Comparator|Vancomycin plus Aztreonam|Vancomycin 15 mg/kg IV plus two grams Aztreonam every 12 hours for a minimum of 10 up to a maximum of 28 doses total (Aztreonam was discontinued as soon as possible if a gram-negative organism was not identified in baseline cultures)
89208083|NCT00863616|Experimental|HFCWO|HFCWO twice a day delivered by SmartVest device at 13Hz FOR 20min x2. Duration 4 weeks in each phase with a 2week washout.
89551717|NCT05118659|Experimental|SNAG GROUP|The SNAG group received a treatment based on sustained apophyseal glides in a postero-anterior direction on C2 with a dose of three series of ten repetitions each, combined with active cervical extension.
89551718|NCT05118659|Sham Comparator|SHAM SNAG GROUP|The placebo SNAG group received a simulation of the contact used for the SNAGs, without any vertebral glide, and with an active cervical extension.
89551719|NCT05118659|No Intervention|CONTROL GROUP|The control group did not receive any type of intervention, they only waited for four minutes, sat down on a chair
89551720|NCT04999553|Active Comparator|Intermittent Theta Burst Stimulation (iTBS)|iTBS to the L-DLPFC
89551721|NCT04999553|Active Comparator|Low Frequency Right (LFR)|1Hz stimulation to the R-DLPFC
89551722|NCT04657588|Experimental|Anal insert|This group will be asked to use anal inserts to help manage their faecal incontinence during the treatment period
89551723|NCT04657588|Sham Comparator|Care as usual|This group will be asked to continue with their care as usual (e.g. incontinence pads)
89551724|NCT05118347|Experimental|Buteyko Breathing Technique|Buteyko Breathing Method teaches you how to bring your breathing volume back toward normal or, in other words, reverse what's called chronic hyperventilation or chronic over-breathing. When your breathing is normal (ideally it is shown you should breathe lightly, in a calm fashion, and only through the nose, not mouth), you have better oxygenation of tissues and organs, including your brain.
89551725|NCT05118347|Experimental|Incentive Spirometer|An incentive spirometer is a device that measures how deeply you can inhale (breathe in). It helps you take slow, deep breaths to expand and fill your lungs with air. This helps prevent lung problems, such as pneumonia. The incentive spirometer is made up of a breathing tube, an air chamber, and an indicator.
89551726|NCT05109845||Control group|Healthy volunteers
89551727|NCT05109845||Suicidal patients|Patients with a history of suicidal thoughts or behaviors
89551728|NCT05109845||Non-suicidal patients|Patients without a history of suicidal thoughts or behaviors
89551729|NCT02694523|Active Comparator|Adalimumab (Part A)|Participants randomized to receive double-blind (DB) adalimumab 80 mg by subcutaneous (SC) injection at Week 0, then 40 mg at Week 1 and every 2 weeks for 15 weeks (Part A).
89551730|NCT02694523|Experimental|Risankizumab (Part A)|Participants randomized to receive risankizumab at Weeks 0 and 4 (Part A).
89551731|NCT05038475||Mild group|"As per the WHO guidelines, the patients were divided into two groups based on disease severity: Mild and Moderately severe.~This was based on the self-reported symptoms experienced by the patients during the infection period (March 2020).~Intervention:~COVID-19 Antibody testing at different time points"
89551732|NCT05038475||Moderately-severe group|"As per the WHO guidelines, the patients were divided into two groups based on disease severity: Mild and Moderately severe.~This was based on the self-reported symptoms experienced by the patients during the infection period (March 2020).~Intervention:~COVID-19 Antibody testing at different time points"
89551733|NCT02395861|Experimental|Electrophysiologic analyses|
89551734|NCT04848935|Experimental|CURATE.AI|A cognitive evaluation and a Digital Diagnostic (DD) session performed anytime before radiotherapy will serve as the baseline. After the radiotherapy treatment, which can last between 1 to 6.5 weeks, patients will have a variable recovery time (0 to 4 weeks). Subsequently, patients will be subject to a cognitive evaluation and a DD session, right before starting the Digital Intervention (DI) training. This training will comprise ten weeks of DI (three 10-15 minute sessions per week). Patients will complete cognitive evaluations and DD sessions at the end of DI, and 16 and 32 weeks after the end of DI.
89551735|NCT04827095|Experimental|Web-Based Support and Education Program 1|The support and education program involves 6 weeks of web-based classes (75-90 minutes per class) given once per week with weekly homework assignments of approximately one hour per week.
89551736|NCT04827095|Experimental|Web-Based Education and Support Program 2|The support and education program involves 6 weeks of web-based classes (75-90 minutes per class) given once per week with weekly homework assignments of approximately one hour per week.
89551737|NCT01353703|Experimental|INFANRIX HEXA 6-10-14 GROUP|Healthy male or female subjects, aged between and including 6 and 10 weeks of age at the time of first vaccination, who received 3 doses of Infanrix hexa™ vaccine at 6, 10 and 14 weeks of age, administered intramuscularly in the right side of the thigh.
88812099|NCT05946564|Experimental|Pioglitazone (ACTOS®)|Pioglitazone given once a day, orally, at 30 mg dose, for 26 weeks
89208084|NCT00863616|No Intervention|Placebo/Control|Self-administered breathing exercises
89208085|NCT00973245|Experimental|Arm 1|
89208086|NCT00973245|Experimental|Arm 2|
89208087|NCT00973245|Active Comparator|Arm 4|
89551738|NCT01353703|Active Comparator|INFANRIX HEXA 2-4-6 GROUP|Healthy male or female subjects, aged between and including 6 and 10 weeks of age at the time of first vaccination, who received 3 doses of Infanrix hexa™ vaccine at 2, 4 and 6 months of age, administered intramuscularly in the right side of the thigh.
89551739|NCT04096703|No Intervention|Expectant management of EGJOO Group|The participants randomized to this group will receive expectant management of EGJOO. Expectant management is evaluating whether symptoms improve over time without an intervention
89551740|NCT04096703|Experimental|Pneumatic dilation of EGJOO Group|The participants randomized to the pneumatic dilation cohort will undergo an initial pneumatic dilation with a 30mm Rigiflex (Boston Scientific).
89551741|NCT02009332|Experimental|Phase 1: ABI-009 100 mg/week|Phase 1, Cohort 1: ABI-009 injectable suspension, 100 mg in 80 mL 0.9% saline, administered intravesically and retained for 2 hours, once per week for 6 weeks
89551742|NCT02009332|Experimental|Phase 1: ABI-009 200 mg/week|Phase 1, Cohort 2: ABI-009 injectable suspension, 200 mg in 80 mL 0.9% saline, administered intravesically and retained for 2 hours, once per week for 6 weeks
89551743|NCT02009332|Experimental|Phase 1: ABI-009 100 mg 2×/week|Phase 1, Cohort 2b: ABI-009 injectable suspension, 100 mg in 80 mL 0.9% saline, administered intravesically and retained for 2 hours, twice per week (total dose 200 mg per week) for 6 weeks
89551744|NCT02009332|Experimental|Phase 1: ABI-009 300 mg/week|Phase 1, Cohort 3: ABI-009 injectable suspension, 300 mg in 80 mL 0.9% saline, administered intravesically and retained for 2 hours, once per week for 6 weeks
89551745|NCT02009332|Experimental|Phase 1: ABI-009 400 mg/week|Phase 1, Cohort 4: ABI-009 injectable suspension, 400 mg in 80 mL 0.9% saline, administered intravesically and retained for 2 hours, once per week for 6 weeks
89551746|NCT02009332|Experimental|Phase 2: ABI-009 400 mg/week + Gemcitabine 2000 mg/week|ABI-009 injectable suspension, 200 mg in 80 mL 0.9% saline, administered intravesically and retained for 1 hour, once per week for 6 weeks; Gemcitabine, 2000 mg in 100 mL saline, administered intravesically after voiding of ABI-009 and retained for 1 hour, once per week for 6 weeks
89551747|NCT03169699||Cough Arm|Children age 16 years old and below with cough at presentation - Patients presenting with active or chronic or residual cough
89551748|NCT03169699||Well Arm|Children age 16 years old and below and Well with no presentation of cough
89551749|NCT04480021|Experimental|Multiuser Interactive Health Response Application (MITHRA)|Randomization is at the level of the Community Based Organization (CBO). CBOs randomized to MITHRA will have access to the MITHRA app on tablets. MITHRA app will include depression screening and behavioral activation modules.
89551750|NCT04480021|Placebo Comparator|Enhanced Usual Care (EUC)|CBOs randomized to EUC will receive standardized monthly group education (45 min) regarding the symptoms of depression
89551751|NCT04480177|Other|insole group|the control group receives insole only.
89551752|NCT04480177|Experimental|exercise group|the experimental group receives exercise and insole.
89551753|NCT03166969|Experimental|Patients taken care in neurovascular unit|
89551754|NCT01984294|Experimental|LDV/SOF+RBV|Participants will receive LDV/SOF plus RBV for 8 weeks.
89551755|NCT01984294|Experimental|LDV/SOF + GS-9669 250 mg|Participants will receive LDV/SOF plus GS-9669 250 mg for 8 weeks.
89551756|NCT01984294|Experimental|LDV/SOF + GS-9669 500 mg|Participants will receive LDV/SOF plus GS-9669 500 mg (2 x 250 mg) for 8 weeks.
89551757|NCT04932707|Experimental|Study group 1|sub-occipital muscle inhibition applied plus passive stretch of hamstring muscle
89551758|NCT04932707|Experimental|Study group 2|Received neural slump sliding stretch plus passive stretch of hamstring muscle
89551759|NCT04932707|Active Comparator|control group|Received passive stretch of hamstring muscle
89551760|NCT03170479|Experimental|RUTF with Vitamin D|Two groups (arms) of malnourished children will be made, one study and one control group; Experimental arm will use RUTF and two mega doses of 200,000 IU vitamin D randomly first after 15 days of enrollment and second after 15 days of first dose.
89551761|NCT03170479|Placebo Comparator|RUTF with Placebo|Placebo arm will receive Ready to Use Therapeutic Food (RUTF) and extra virgin olive oil as Placebo.
89551762|NCT03953027||Health Services Research (surveys about drug shortages)|At baseline, practice sites complete a Baseline Drug Shortage Survey and Pharmacy Baseline Survey; Drug Shortage Incident Reports are completed in real time as cancer care delivery problems occur; and the Quarterly Follow-Up Survey Number Treated Report every 3 months for one year (4 total).
89551763|NCT05745493|Experimental|Social Engage Coaching (S-ENG)|Social Engage Coaching is 10 individual sessions of coaching to increase social connection.
89208088|NCT00973245|Experimental|Arm 3|
88812100|NCT05946564|Placebo Comparator|Placebo of pioglitazone|Placebo of pioglitazone, given once a day, orally, for 26 weeks
89208089|NCT00793754|No Intervention|1|
89551764|NCT01962298|Placebo Comparator|Single rocuronium dose - placebo|The patients will receive a single rocuronium dose, and no reversal agent.
89551765|NCT01962298|Active Comparator|Single rocuronium dose - sugammadex|The patients will receive a single rocuronium dose and sugammadex 2mg/kg as a reversal agent
89551766|NCT01962298|Active Comparator|Repeated rocuronium dose - neostigmine|The patients will receive multiple rocuronium doses and neostigmine 70 mcg/kg as a reversal agent
89551767|NCT01962298|Active Comparator|Repeated rocuronium dose - sugammadex|The patients will receive multiple rocuronium doses and neostigmine 2mg/kg as a reversal agent
89551768|NCT01962298|Active Comparator|Continuous rocuronium dose|The participants will receive a continuous rocuronium infusion and sugammadex 4 mg/kg as a reversal agent
89551769|NCT04418921|Experimental|Experimental Group|"Intervention on self-regulation will be carried out through a non-immersive virtual reality platform, SR-Mrehab: Un colegio emocionante in which students must conduct a series of activities designed specifically for this purpose. These activities will be performed by the children using mainly their hands to manage the virtual objects showed in the screen. To do this, our system make use of a Kinect motion sensor connected to the computer to control the body movements of the children. Moreover, our system records some relevant data of the execution of these activities for further analysis of the children's performance.The exercises will be divided into two blocks, emotional regulation (ER) and cognitive regulation (CR), in a total of 10 sessions, once a week, performing an exercise of each block per session. Each session will consists of 60 minutes. ."
89208090|NCT00793754|Experimental|2|Aspirin 100 mg / day
89551770|NCT04418921|Active Comparator|Control group|The children from control group will follow a program of emotional education of Primary Schools, though group activities in the classroom (5, 49). Each session will last 50 minutes, just like in the experimental group. The content of the sessions will include 5 sessions of emotional awareness and 5 sessions of emotional and cognitive regulation. The activities are similar for the experimental group, but the virtual reality system will not be used. It will be held in parallel in another room of the school, on the same day and time, carried out by occupational therapists and students from the students in the last year of occupational therapy degree.
89551771|NCT03169933|Other|intensified and modulated adjuvant RT|All patients underwent combined, intensified and modulated adjuvant radiotherapy for 5 days a week with the following doses: 1) pelvic node irradiation (45 Gy; 1.8 Gy/fraction) followed by boost on the prostate bed (19.8-25.2 Gy; 1.8 Gy/fraction; total dose: 64.8-70.2 Gy) or 2) exclusive prostate bed irradiation (64.8 -70.2 Gy; 1.8 Gy/fraction).
89551772|NCT03169621||Patients with RIF|Patients with repeated implantation failure (RIF) with indication of hysteroscopy within normal clinical practice, who will undergo FIV or ICSI and embryo transfer within their assisted reproduction treatment (ART).
89551773|NCT05745415||pancreatic cancer patients|
89551774|NCT04416256||France|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
89551775|NCT04416256||Spain|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
89551776|NCT04416256||Portugal|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
89551777|NCT04416256||Croatia|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
89551778|NCT04416256||Germany|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
89551779|NCT04416256||Italy|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
89551780|NCT04416256||Netherlands|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
89551781|NCT04416256||Austria|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
89551782|NCT04416256||US|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
89551783|NCT04416256||Canada|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
89551784|NCT04416256||Mexico|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
89551785|NCT04416256||Brazil|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
89551786|NCT04416256||Uruguay|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
89551787|NCT04416256||Argentina|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
89551788|NCT04416256||Chile|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
89551789|NCT04416256||Australia|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
89551790|NCT04416256||Belgium|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
89551791|NCT04416256||Finland|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
89551792|NCT02403349|Experimental|Fimasartan|fimasartan potassium 60mg, 1 tablet by mouth, every day Angiotensin ll receptor blocker
89551793|NCT02403349|Active Comparator|Valsartan|valsartan 80mg, 1 tablet by mouth, every day angiotensin II receptor antagonists
89551794|NCT02403349|Active Comparator|Atenolol|atenolol 50mg, 1 tablet by mouth, every day beta-blocker
89551795|NCT04735822|Experimental|Part 1: Belumosudil Sequence ABFCED|Subjects receive 1 dose of belumosudil 40 mg/mL in oral suspension in the following sequence: Regimen A (delivered by Vehicle 1); Regimen B (delivered by Vehicle 2); Regimen F (delivered by Vehicle 6); Regimen C (delivered by Vehicle 3); Regimen E (delivered by Vehicle 5); Regimen D (delivered by Vehicle 4);
89551796|NCT04735822|Experimental|Part 1: Belumosudil Sequence BCADFE|Subjects receive 1 dose of belumosudil 40 mg/mL in oral suspension in the following sequence: Regimen B (delivered by Vehicle 2); Regimen C (delivered by Vehicle 3); Regimen A (delivered by Vehicle 1); Regimen D (delivered by Vehicle 4); Regimen F (delivered by Vehicle 6); Regimen E (delivered by Vehicle 5)
89208091|NCT00793754|Experimental|3|Atorvastatin 40 mg / day
89208092|NCT00793754|Experimental|4|Aspirin 100 mg / day + Atorvastatin 40 mg / day
89208093|NCT02596763|Other|Baclofen|Patient with current alcohol use disorder included by any baclofen prescriber located in the French region of Nord - Pas-de-Calais - Picardie.
89208094|NCT03976141||a|
89208095|NCT00793832|Active Comparator|1|Supervised exercise.
89208096|NCT00793832|Active Comparator|2|Diet Advice
89551797|NCT04735822|Experimental|Part 1: Belumosudil Sequence CDBEAF|Subjects receive 1 dose of belumosudil 40 mg/mL in oral suspension in the following sequence: Regimen C (delivered by Vehicle 3); Regimen D (delivered by Vehicle 4); Regimen B (delivered by Vehicle 2); Regimen E (delivered by Vehicle 6); Regimen A (delivered by Vehicle 1); Regimen F (delivered by Vehicle 6)
89025467|NCT04700943||General anesthesia|"Either epidural block or an interfascial plane block of the thoracic wall, such as serratus anterior plane block or erector spinae plane block, were performed.~Patients were then anesthetized with Propofol plus opiates (usually remifentanil) and muscle paralysis was achieved with Rocuronium."
89025468|NCT00456248|Experimental|1|Infergen 15 ug QD plus RBV for 36 weeks
89025469|NCT00456248|Experimental|2|Infergen 15 ug QD plus RBV for 48 weeks
89025470|NCT00456248|Active Comparator|3|
89025471|NCT00480558|Active Comparator|1|Group 1: M. tb
89025472|NCT00480558|Active Comparator|2|Group 2: HIV (not on antiretrovirals [ARV])
89025473|NCT00480558|Active Comparator|3|Group 3: M. tb and HIV (not on ARV)
89551798|NCT04735822|Experimental|Part 1: Belumosudil Sequence DECFBA|Subjects receive 1 dose of belumosudil 40 mg/mL in oral suspension in the following sequence: Regimen D (delivered by Vehicle 4); Regimen E (delivered by Vehicle 5); Regimen C (delivered by Vehicle 3); Regimen F (delivered by Vehicle 6); Regimen B (delivered by Vehicle 2); Regimen A (delivered by Vehicle 1)
89551799|NCT04735822|Experimental|Part 1: Belumosudil Sequence EFDACB|Subjects receive 1 dose of belumosudil 40 mg/mL in oral suspension in the following sequence: Regimen E (delivered by Vehicle 5); Regimen F (delivered by Vehicle 6); Regimen D (delivered by Vehicle 4); Regimen A (delivered by Vehicle 1); Regimen C (delivered by Vehicle 3); Regimen B (delivered by Vehicle 2)
89551800|NCT04735822|Experimental|Part 1: Belumosudil Sequence FAEBDC|Subjects receive 1 dose of belumosudil 40 mg/mL in oral suspension in the following sequence: Regimen F (delivered by Vehicle 6); Regimen A (delivered by Vehicle 1); Regimen E (delivered by Vehicle 5); Regimen B (delivered by Vehicle 2); Regimen D (delivered by Vehicle 4); Regimen C (delivered by Vehicle 3).
89551801|NCT04735822|Experimental|Part 2: Belumosudil Sequence GHI|Subjects receive 1 dose in the following sequence; Regimen G (belumosudil 200 mg tablet fed); Regimen H (powder for oral suspension or oral suspension belumosudil 200 mg fasted); Regimen I (powder for oral suspension or oral suspension belumosudil 200 mg fed)
89551802|NCT04735822|Experimental|Part 2: Belumosudil Sequence HIG|Subjects receive 1 dose in the following sequence: Regimen H (powder for oral suspension or oral suspension belumosudil 200 mg fasted); Regimen H (powder for oral suspension or oral suspension belumosudil 200 mg fed); Regimen G (belumosudil 200 mg tablet fed)
89551803|NCT04735822|Experimental|Part 2: Belumosudil Sequence IGH|Subjects receive 1 dose in the following sequence: Regimen I (powder for oral suspension or oral suspension belumosudil 200 mg fed); Regimen G (belumosudil 200 mg tablet fed); Regimen H (powder for oral suspension or oral suspension belumosudil 200 mg fasted)
89551804|NCT04735822|Experimental|Part 2: Belumosudil Sequence IHG|Subjects receive 1 dose in the following sequence: Regimen I (powder for oral suspension or oral suspension belumosudil 200 mg fed); Regimen H (powder for oral suspension or oral suspension belumosudil 200 mg fasted); Regimen G (belumosudil 200 mg tablet fed)
89551805|NCT04735822|Experimental|Part 2: Belumosudil Sequence GIH|Subjects receive 1 dose in the following sequence: Regimen G (belumosudil 200 mg tablet fed); Regimen I (powder for oral suspension or oral suspension belumosudil 200 mg fed); Regimen H (powder for oral suspension or oral suspension belumosudil 200 mg fasted)
89551806|NCT04735822|Experimental|Part 2: Belumosudil Sequence HGI|Subjects receive 1 dose in the following sequence: Regimen H (powder for oral suspension or oral suspension belumosudil 200 mg fasted); Regimen G (belumosudil 200 mg tablet); Regimen I (powder for oral suspension or oral suspension belumosudil 200 mg fed);
89551807|NCT02395393|Other|Lung transplant recipients|In patients scheduled for bronchoscopy as part of regular clinical care/diagnostic workup, the investigators will offer the patient concurrent confocal microscopy imaging to be performed during the bronchoscopic procedure. A 1.4mm or 1.9mm diameter Alveoflex Confocal MiniprobeTM (MaunaKea Technologies, France) will be deployed down the working channel of the standard bronchoscope and advanced distally into the alveoli.
89551808|NCT02693743|Active Comparator|Active rTMS|Repetitive Transcranial Magnetic Stimulation (rTMS) will be delivered to the left PFC, deﬁned as a location 6 cm (cm) anterior to the right hand motor thumb area. A research nurse will deliver the treatments. rTMS will be delivered with a ﬁgure-eight coil at 120% motor threshold, 10 Hertz (Hz), 5 s (s) train duration, 20 s intertrain interval for 50 min (6000 pulses) 3 times daily for 3 days (total 9 sessions, 54,000 stimuli).
89551809|NCT02693743|Sham Comparator|Sham rTMS|Parameters for sham Repetitive Transcranial Magnetic Stimulation (rTMS) are identical to those for active stimulation except that aluminum plate blocks the propagation of a magnetic field. The sound and physical sensation is the same as with the active coil while been biologically inactive.
89551810|NCT02655887|Experimental|VENOVO™ Venous Stent.|Implant of the VENOVO™ Venous Stent
89025474|NCT00480558|Active Comparator|4|Group 4: M. tb and HIV (on ARV)
89025475|NCT00456326||HIT Patients|Patients at Brigham and Women's Hospital diagnosed with Heparin Induced Thrombocytopenia.
89025476|NCT04700709|Experimental|RaparoBell® Tablet|ABO-i De novo Living Kidney transplant recipients will be randomized after Kidney transplant.
89025477|NCT04700709|Active Comparator|Mycophenolate Mofetil Tablet/Capsule|ABO-i De novo Living Kidney transplant recipients will be randomized after Kidney transplant.
89025478|NCT04698317|Experimental|beta-tricalcium phosphate plus concentrated growth factors|surgery plus biodegradable gelatin sponge loaded with Beta-tricalcium phosphate socked in concentrated growth factors (test group).
89025479|NCT04698317|Placebo Comparator|beta tricalcium phosphate alone(control group)|surgery plus biodegradable gelatin/beta-tricalcium phosphate sponges alone. (control group),
89025480|NCT04700475|Experimental|Laser group|Laser group composes of thirty patients who will receive low level laser three times a week, on alternate day (48h interval) Laser therapy will be initiated before the first radiotherapy session and ended after the last session, totaling 21 sessions
89025481|NCT04700475|Other|Control group|control group composes of thirty patients will be treated with 15mL of a 2% citric acid solution applied as a mouth rinse for 30 sec
89025482|NCT04700436|Experimental|Test group|Subject administered with Rosuzet tablet 10/5 mg (Ezetimibe 10 mg/Rosuvastatin 5 mg)
89025483|NCT04700436|Active Comparator|Control group|Subject administered with Suvast tablet 10 mg (Rosuvastatin 10 mg)
89025484|NCT00456482|Experimental|Fluocinolone Acetonide 0.59mg|Fluocinolone acetonide intravitreal implant 0.59mg
89025485|NCT00456482|Experimental|Fluocinolone Acetonide 2.1mg|Fluocinolone acetonide intravitreal implant 2.1mg
89551811|NCT02008318|Experimental|Phase (ph) 2: Galunisertib + BSC|Ph 2. 150 milligrams Galunisertib given orally twice daily (BID) for 14 days followed by 14 days with no study drug (28 day cycles). Participants will receive best supportive care (BSC) according to institutional guidelines. Treatment is expected to last for 6 cycles. Participants may receive additional cycles if they are deriving clinical benefit.
89551812|NCT02008318|Placebo Comparator|Ph 3: Placebo + BSC|Placebo administered orally BID for 14 days followed by 14 days with no study drug (28 day cycles). Participants will receive BSC according to institutional guidelines. Treatment is expected to last for 6 cycles. Participants may receive additional cycles if they are deriving clinical benefit. This arm is contingent on the data from the phase 2 arm.
89551813|NCT02008318|Experimental|Ph 3: Galunisertib + BSC|150 milligrams Galunisertib given orally twice daily (BID) for 14 days followed by 14 days with no study drug (28 day cycles). Participants will receive best supportive care (BSC) according to institutional guidelines. Treatment is expected to last for 6 cycles. Participants may receive additional cycles if they are deriving clinical benefit. This arm is contingent on the data from the phase 2 arm.
89551814|NCT04009265|Experimental|Chemotherapy|Docetaxel 75mg/m2, 3w, 2cycles. DDP 75mg/m2, 3wl, 2cycles.
89551815|NCT04009265|Experimental|Chemoradiotherapy|5040cGy, 180cGy/d, 28F Concurrent Docetaxel 60mg/m2, 3w, 2cycles DDP 60mg/m2, 3w, 2cycles
89551816|NCT04009265|No Intervention|Surgery alone|Surgery alone, no adjuvant treatment.
89551817|NCT01982812|Experimental|Oral Levetiracetam|Oral Levetiracetam administered by NG tube.
89551818|NCT01982812|Active Comparator|Standard AED|Standard AED regimen
89551819|NCT03996785|Active Comparator|Urban|"Patients will go for a silent 60-minute walk in an urban setting. The walk will take place in the months of June, July, August and September between 10:00 to 11:00 am.~Participants will walk in groups of two to three participants accompanied by two research assistants trained in mental health (doctoral students in psychology). The urban walk will be located on Boulevard de la Vérendrye with large arteries with three to four lanes."
89551820|NCT03996785|Experimental|Nature|"Patients will go for a silent 60-minute walk in a nature park setting. The walk will take place in the months of June, July, August and September between 10:00 to 11:00 am.~Participants will walk in groups of two to three participants accompanied by two research assistants trained in mental health (doctoral students in psychology).~The nature walk will take place at Parc Angrignon, an area of 96 hectares, one of Montreal's largest green and biodiverse spaces with a forest of 20 000 trees and a pond surrounded by willow trees."
89551821|NCT04541693|Other|Hip revision|Revision to cup and stem, cup only or stem only.
89551822|NCT04910087|Active Comparator|Group K: Ketofol|"A ketofol mixture of 15 cc propofol 2%, 2 cc ketamine 50 mg/ml, and 13 cc serum saline will be prepared in a 50 cc non-transparent syringe and delivered to the patient intravenously through perfuser device. (at a ratio of 100 mg ketamine/300 mg propofol) After the loading dose is administered at 1 mg/kg IV in 5 minutes based on propofol, 0.5 cc/kg/hour ketofol infusion will be initiated.~If patients cannot tolerate the ERCP procedure or have a BIS value >85 or FPS (Faces Pain Scale)> 3, 0.25 mg/kg propofol will be administered as a separate IV push."
89551823|NCT04910087|Active Comparator|Group P: Propofol|"A propofol mixture of 15 cc propofol 2% and 15 cc serum saline will be prepared in a 50 cc non-transparent syringe and delivered to the patient intravenously through the perfuser device.~After the loading dose is administered at 1 mg/kg IV propofol in 5 minutes ,0.5 cc/kg/hour propofol infusion will be initiated.~If patients cannot tolerate the ERCP procedure or have a BIS value >85 or FPS (Faces Pain Scale)> 3, 0.25 mg/kg propofol will be administered as a separate IV push"
89551824|NCT02007070|Experimental|Pembrolizumab 10 mg/kg|Participants receive pembrolizumab 10 mg/kg intravenously over 30 minutes on Day 1 of each 21-day cycle for up to 2 years.
89551825|NCT03906617|Experimental|Bupivacaine/epinephrine + dexamethasone|
89551826|NCT03906617|Active Comparator|Liposomal bupivacaine|
89551827|NCT03897725|Experimental|Telehealth Intervention|Study participants will be randomized into either the control or experimental group. Participants in the intervention group will receive routine care which will follow the schedule from previous adolescent PrEP studies where participants are recommended to follow up at 4, 8, and 12 weeks and then every 3 months following initiation of PrEP. This group will also receive SMS texting every 4 weeks between in-person visits (weeks 16, 20, 28,32, 40, 44) reminding them to pick up their medication. The experimental group will also be seen in follow up every month for the first 3 months and then spaced out to visits every 3 months. The SMS texting will occur every 4 weeks between in-person visits, the experimental group will also have 2 tele-health visits (which will be conducted within a participant's home using an app) that will occur every 4 weeks between each of the traditional in-person visits to provide more frequent monitoring and counseling regarding adherence.
89551828|NCT03897725|No Intervention|Routine Care|The control group will follow the schedule from previous adolescent PrEP studies where participants are recommended to follow up at 4, 8, and 12 weeks and then every 3 months following initiation of PrEP.
89551829|NCT03844919|Experimental|rTMS + CBIT|Repetitive transcranial magnetic stimulation (rTMS) and Comprehensive Behavioural Intervention for Tics (CBIT)
89551830|NCT03844919|Active Comparator|Sham rTMS + CBIT|Sham repetitive transcranial magnetic stimulation (rTMS) and Comprehensive Behavioural Intervention for Tics (CBIT)
89551831|NCT02006758||Uncontrolled hypertension patients|The study will enroll 500 patients planned to undergo a renal denervation procedure (with the 'EnligHTN™ Renal Denervation System') for the treatment of their uncontrolled hypertension.
89551832|NCT01960816|Experimental|InFlux System|Intervention: Procedure: thermal coagulation of tissue in the nasal airway
89551833|NCT01602419||Patients using Wilate as standard of care treatment|This patient population is being treated with Wilate as standard of care treatment
89208097|NCT00860106|Other|Follow up|"ED score and DDimer level of patients who have stopped their VKA treatment (after the first or the second previous proximal VTE).~Phone follow up for 2 years."
89025486|NCT00456482|No Intervention|No Intervention|Fellow eye
89025487|NCT00480675|Experimental|1|Trochanteric bursa injections done into the bursa under fluoroscopic guidance
89208098|NCT00973323|Experimental|Arm 1|
89208099|NCT00973323|Experimental|Arm 2|
89208100|NCT00973323|Experimental|Arm 3|
89208101|NCT00973323|Active Comparator|Arm 4|
89551834|NCT04655482|Experimental|Treatment arm|"Patients treated with aflibercept (2.0ml/0.05cc) using treat-and-extend regimen.~Three monthly loading injections followed by proactive treatment using treat-and-extend regimen. Extension of injection interval by 2 weeks. The maximum injection interval was set as 16 weeks."
89551835|NCT04866173|Experimental|Dog|Being subjected to two standardised stress situations with a dog and its handler present
89551836|NCT04866173|Experimental|No Dog|Being subjected to two standardised stress situations without a dog present, but in the presence of a person (dog handler)
89551837|NCT03571841|Experimental|Educational Intervention|"For breast cancer survivors currently on chemical ovarian suppression who are experiencing sexual dysfunction.~Group Session~Telephone Booster Session"
89551838|NCT04866095|Experimental|Surgery|All patients, who have given their consent, aged over 18 years, with a sinus rhythm, requiring a surgical procedure that allows obtaining high quality transthoracic echocardiogram imaging without pain and discomfort.
89551839|NCT01959815||Scleroderma and diagnosed PAH|
89551840|NCT01959815||"Low risk scleroderma"|
89551841|NCT01959815||Healthy volunteers|
89551842|NCT01959815||"High risk scleroderma"|
89551843|NCT02184767|Experimental|ADASUVE®|oral inhalation using a single-use, hand-held, inhaler; dosage determined by the investigator according the participants weight
89551844|NCT01981954|Experimental|Solifenacin succinate|Children aged 6 months to less than 5 years were treated with sequential titrated doses of solifenacin up to 12 weeks in the Titration period after which a fixed dose of solifenacin was given for at least 40 weeks in the Fixed-dose assessment period. Children received solifenacin once daily during these 2 periods.
89551845|NCT04248413|Other|Standard rehabilitation protocol|Patients with non-operative rotator cuff and biceps tendinopathy assigned to this study arm will undergo the standardized physical rehabilitation protocol at our institution.
89551846|NCT04248413|Experimental|Standard rehabilitation plus Blood Flow Restriction Therapy|Patients with non-operative rotator cuff and biceps tendinopathy assigned to this study arm will undergo the standardized physical rehabilitation protocol at our institution in addition to the BFR therapy. Per recommendations of Owens Recovery Science, the organization responsible for certifying physical therapists in BFR therapy, the therapy will take place concurrently throughout the duration of the rehabilitation.
89551847|NCT03514043||Ambulatory care surgical patients|Patients who have attended the surgical assessment unit with an emergency general surgical condition and have their care completed without an inpatient stay.
89551848|NCT03514043||Surgical assessment unit staff|Staff who are involved in the care of patients on the surgical assessment unit. This includes senior and junior doctors, nurses, healthcare assistants and ward receptionists.
89551849|NCT05122403||FUS Thalamotomy|The cohort includes patients with neuropathic pain who underwent MRgFUS central lateral thalamotomy.
89551850|NCT05122403||Sham Procedure|The cohort includes patients with neuropathic pain who underwent sham MRgFUS central lateral thalamotomy.
89551851|NCT05120687||Corticosteroid group|Patients in corticosteroid group will receive systemic corticosteroid. In case of severe, the patients may receive methylprednisolone (no more than 1 gram/day) followed by gradual taper of oral prednisone.
89551852|NCT05120687||Corticosteroid + NCSIT group|Patients in corticosteroid + NCSIT group will receive systemic corticosteroids combined with Methotrexate or Adalimumab or other noncorticosteroid systemic immunomodulatory such as cyclophosphamide.
89551853|NCT05120609|Experimental|Parkinson's Application|Subjects will complete at-home allied health therapy exercises delivered through a smartphone application. Subjects will use the application daily for 4 weeks, each daily session takes up to 30 minutes to complete.
89551854|NCT05120609|Placebo Comparator|Digital Placebo|Subjects will have access to a digital placebo application and continue usual care.
89551855|NCT05121935||MAL-ED cohort|Children initially followed from birth through 2 years old in the MAL-ED study (with some additional assessments in follow-up studies since then).
89551856|NCT03416855||Overall population|Participants will be decided to be treated with Ryzodeg® FlexTouch® by physicians before the enrolment in the study based on clinical judgement in the diabetes management.
89551857|NCT05121779|Experimental|68Ga-FAPI-04 PET/CT and 18F-FDG PET/CT|All patients diagnosed with Lung fibrosis underwent 68Ga-FAPI PET/CT and 18F-FDG PET/CT.
89551858|NCT02693119|Experimental|Group 1|One drop elamipretide (MTP-131) 1% topical ophthalmic solution BID applied to the left eye (OS) and one drop of vehicle topical ophthalmic solution BID in the fellow eye
89551859|NCT02693119|Experimental|Group 2|One drop elamipretide (MTP-131) 1% topical ophthalmic solution BID applied to the right eye (OD) and one drop of vehicle topical ophthalmic solution BID in the fellow eye
89551860|NCT02693119|Experimental|Group 3|One drop elamipretide (MTP-131) 1% topical ophthalmic solution BID applied to both eyes (OU).
89551861|NCT02693119|Experimental|OLE|One drop elamipretide (MTP-131) 1% topical ophthalmic solution BID applied to both eyes (OU).
89551862|NCT04224311|Active Comparator|Low number plateletpheresis donations|Participants that have had 1-2 plateletpheresis donations in the last 365 days. Menactra will be administered as a 0.5 mL dose.
89551863|NCT04224311|Active Comparator|Medium number plateletpheresis donations|Participants that have had 3-19 plateletpheresis donations in the last 365 days. Menactra will be administered as a 0.5 mL dose.
89551864|NCT04224311|Active Comparator|High number plateletpheresis donations|Participants that have had 20-24 plateletpheresis donations in the last 365 days. Menactra will be administered as a 0.5 mL dose.
89551865|NCT05121389|Experimental|study group|Patients of study group will receive intravenous normal saline 30cc per kilogram of body weight, one fifth of which will be given as a bolus followed by delivery of the remaining four fifth as a constant infusion over a period of 12 hours.
89551866|NCT05121389|Sham Comparator|control group|Patients of control group will receive intravenous normal saline 10cc per kilogram of body weight as a constant infusion in the first 12 hours.
89551867|NCT02395549|Experimental|0.375% (w/w) MTC896 Gel|0.375% (w/w) MTC896 Gel will be applied bid to the whole face for 12 weeks.
89551868|NCT02395549|Experimental|0.75% (w/w) MTC896 Gel|0.75% (w/w) MTC896 Gel will be applied bid to the whole face for 12 weeks.
89551869|NCT02395549|Experimental|1.5% (w/w) MTC896 Gel|1.5% (w/w) MTC896 Gel will be applied bid to the whole face for 12 weeks.
89551870|NCT02395549|Placebo Comparator|Vehicle Control Gel|Vehicle Control Gel will be applied bid to the whole face for 12 weeks.
89551871|NCT05121233|Active Comparator|Diclofenac|Group A will receive a single dose 75 mg IV diclofenac by infusion prior to the procedure
89551872|NCT05121233|Placebo Comparator|Placebo|Group B who will receive placebo
89551873|NCT02403427|Experimental|VoiceDiab expert system|the VoiceDiab system using before every main meal; three times per day.
89551874|NCT02403427|No Intervention|manual calculation|manula insulin calculation before every main meal; three times per day
89551875|NCT06121401|Other|Olaparib - Bevacizumab|Olaparib 300 mg 2*daily + Bevacizumab 15mg/kg (q3w)
89551876|NCT06121375|Active Comparator|Participants receiving OCA|Participants will be randomized to receive OCA (starting at 1.5 milligrams [mg] adult equivalent dose [AED]) orally, with water, once daily. Dose will be titrated every 2 weeks in a stepwise manner for the first 6 weeks, starting at 1.5 mg AED and titrating through 3 mg AED to a maximum of 5 mg AED, as tolerated; a discussion with the Medical Monitor is encouraged when determining uptitration if considerable signs or symptoms have arisen. Following the 6-week dose titration phase, participants will continue at the tolerated dose for approximately 24 months in Age Expansion Treatment Phase.
89551877|NCT06121375|Placebo Comparator|Participants receiving Matching placebo|Participants will be randomized to receive matching placebo orally, with water, once daily. Dose will be titrated every 2 weeks in a stepwise manner for the first 6 weeks, starting at 1.5 mg AED and titrating through 3 mg AED to a maximum of 5 mg AED, as tolerated; a discussion with the Medical Monitor is encouraged when determining uptitration if considerable signs or symptoms have arisen. Following the 6-week dose titration phase, participants will continue at the tolerated dose for approximately 24 months in Age Expansion Treatment Phase.
89551878|NCT06121310||Survey grup|No intervention is to be administered. Just a survey study
89551879|NCT06121284|Experimental|D-Cycloserine|Participants will orally ingest a weight-based dose of D-Cycloserine (25mg/17.5kg) daily (Monday-Friday) during 2 weeks of accelerated rTMS treatments (20 sessions; 2 sessions/day separated by 1 hour). D-Cycloserine will be ingested 60-120 minutes prior to the first rTMS treatment of the day.
89551880|NCT06121284|Placebo Comparator|Placebo|Participants will orally ingest a weight-based dose of a microcrystalline placebo capsule (25mg/17.5kg) daily (Monday-Friday) during 2 weeks of accelerated rTMS treatments (20 sessions; 2 sessions/day separated by 1 hour). The Placebo will be ingested 60-120 minutes prior to the first rTMS treatment of the day.
89551881|NCT06121245|Experimental|Esomeprazol|On the day before the study visits participants will ingest a capsule in the morning on a capsule in the evening containing Esomperazol
89551882|NCT06121245|Placebo Comparator|Placebo|On the day before the study visits participants will ingest a capsule in the morning on a capsule in the evening containing a placebo
89551883|NCT06121232|Experimental|Treatment Group|Group 1 will receive neuromodulation.
89551884|NCT06121232|Experimental|Control Group|Group 2 will not receive neuromodulation.
89551885|NCT06121180|Experimental|Cemiplimab + Ziv-Aflibercept|"One cycle consists of 3 weeks during which:~Cemiplimab 350 mg administered IV every 3 weeks given with Ziv-Aflibercept 4 mg/kg administered IV every 2 weeks."
89551886|NCT06121141|Active Comparator|Control|Full-strength lidocaine with epinephrine
89551887|NCT06121141|Experimental|Experimental|Dilute lidocaine with epinephrine
89551888|NCT06121128|Sham Comparator|Female Control Group (FCON)|female endurance trained athletes between 18 and 44 years old
89551889|NCT06121128|Experimental|Female Training Group (FTRAIN)|female endurance trained athletes between 18 and 44 years old
89551890|NCT06121128|Sham Comparator|Male Control Group (MCON)|male endurance trained athletes between 18 and 44 years old
89551891|NCT06121128|Experimental|Male Training Group (MTRAIN)|male endurance trained athletes between 18 and 44 years old
89551892|NCT06121076|Experimental|SDM-EBP training|the group received SDM combined with EBP training
89551893|NCT06121076|Other|control|the group received received SDM without EBP training
89551894|NCT06120959|Active Comparator|Control group A|They received exercise program in the form of Bridging, Seated Marching Twist, Quadruped pelvic tilts, Modified Side Plank, and Bird dog for 6 successive weeks.
89551895|NCT06120959|Experimental|Study group B|They received the same stabilization exercise program plus Pelvic floor exercise for 6 successive weeks.
89551896|NCT06120946||Control arm|Patients randomised in the BHF PROTECT study to TAVI without Sentinel cerebral embolic protection
89551897|NCT06120946||Intervention arm|Patients randomised in the BHF PROTECT study to TAVI with Sentinel cerebral embolic protection
89551898|NCT06120933|Experimental|Test population|"For the first 8 weeks, each participant will take both the Hair Nutra Growth and Hair Nutra Boost supplements daily.~For the remaining 4 weeks, participants will only take the Hair Nutra Growth supplement."
89551899|NCT06120920|Active Comparator|Conventional Physical Therapy and Routine Knee Exercises with Core Stability Exercises.|Patient will receive Conventional physical therapy include hot pack, Tens and routine knee strengthening exercises with core stability exercises.
89551900|NCT06120920|Experimental|Conventional Physical Therapy and Routine Knee Exercises with Hip Strengthening Exercises.|In this group, patient will receive conventional physical therapy include hot pack, Tens and routine knee exercises with hip strengthening exercises
89551901|NCT06120868|Experimental|Surefil one Self-adhesive bulk fill restorative (SABF)|
89551902|NCT06120868|Active Comparator|Filtek One Bulk Fill (FOBF)|
89551903|NCT06120829|Active Comparator|Control Arm|FNA followed by Core Needle biopsy
89551904|NCT06120829|Experimental|Experimental Arm|FNA followed by cryobiopsy through a introducer sheath
89551905|NCT06120777|Experimental|Test Subject|All subjects who are enrolled into the test group and participate in data collection have the Masimo INVSENSOR00069.
89551906|NCT06120764|Experimental|Guided imagery group|Participants will receive guided imagery intervention.
89551907|NCT06120764|No Intervention|Control|Participants will receive routine care.
89551908|NCT06120738||smartphone addiction group|smartphone addiction will be assessed using smartphone addiction scale short version(SAS-SV) evaluation of trunk muscles performance using isokinetic dynamometer
89551909|NCT06120686|Experimental|biofeedback-based therapy (BBT)|study group - implementing the conventional therapy program supplemented additionally by training with visual and auditory biofeedback on a dynamic balance platform
89551910|NCT06120686|Other|conventional therapy program (CT)|control group - implementing only the conventional therapy program
89025488|NCT00480675|Active Comparator|2|Trochanteric bursa injection done with sham fluoroscopy using only landmarks as guidance.
89025489|NCT04700358||Patients with Cystic Fibrosis|Patients with pulmonary Cystic Fibrosis with or without bacterial colonization
89025490|NCT04700358||Control group|Healthy age- and sex-matched controls including healthy individuals and patients with acute or chronic bacterial infections
89025491|NCT00456638|Experimental|Depodur|Depodur arm
89551911|NCT06120673|Experimental|Obinutuzumab|
89551912|NCT06120673|Active Comparator|Oral prednisolone and cyclophosphamide|
89551913|NCT06120660|Experimental|Case Group|Music
89551914|NCT06120660|No Intervention|Control Group|
89551915|NCT06120634|Active Comparator|Open surgical method|In this group, the participants were circumcised using the open method. A total of 304 patients were enrolled in this group.
89551916|NCT06120634|Active Comparator|Plastibell method|A total of 304 patients were enrolled in this group and underwent the process of circumcision by the Plastibell method.
89551917|NCT06120621|Active Comparator|Arm 1|Visco-Circumferential-Suture-Trabeculotomy followed by Phacoemulsification
89551918|NCT06120621|Active Comparator|Arm 2|phacoemulsification alone
89551919|NCT06120595|Other|Control group|Patients will receive standard follow-up according to national guidelines developed by the Norwegian Breast cancer group (NBCG).
89551920|NCT06120595|Experimental|Experimental arm|Patients will, in addition to receiving standard follow-up every 6 months, also receive REBECCA-assisted follow-up at frequencies when the REBECCA-system indicate this. The patients will receive a REBECCA smartwatch that they will wear for 12 months. They will also have to install a REBECCA patient app on their mobile and a REBECCA plug-in on their computer for objective RWD collection related to their QoL and lifestyle over the next 12 months. The REBECCA system detects signs of deterioration in patients' QoL during the study period, the intervention will include changes in medication given, dietary advice, referral to a psychologist/psychiatrist and/or personal training with a physiotherapist at 'Pusterommet' (SUH) who will create a personalized traning programme, e.g. 2-4 sessions per week.
89551921|NCT06120582|Experimental|Cohort 1|Subjects in Cohort 1 will receive ANB-002 at a dose 1. Follow-up for the assessment of dose-limiting toxicity (DLT) will be carried out for 28 days. If no DLT events are observed in the subject of Cohort 1, the following subjects will be included in Cohort 1.
89551922|NCT06120582|Experimental|Cohort 2|Subjects in Cohort 2 will receive ANB-002 at a dose 2. The decision to continue enrolling in Cohort 1 or dosing in Cohort 2 subjects will be made at the IDMC meeting. After the IDMC makes a decision regarding the dosing in Cohort 2 subjects, the next subject will be included in Cohort 2. If no DLT events are observed in the subject of Cohort 2, the following subjects will be included in Cohort 2.
89551923|NCT06120569|Experimental|Soleus muscle exercise in diabetes|Soleus muscle decrease blood glucose
89551924|NCT06120569|Experimental|Decrease glucose level by soleus exercise|Soleus ms exercise in decrease blood glucose
89551925|NCT06120530|Active Comparator|Intraperitoneal bupivacaine|30 mL of bupivacaine without epinephrine 0.25%
89025492|NCT00456638|Active Comparator|Traditional|traditional management
89025493|NCT04700085|Experimental|ReMotion Knee|The ReMotion Knee (mechanical prosthetic knee type) was used during measurements
89025494|NCT04700085|No Intervention|Current prosthetic knee|The participant's current prosthetic knee was used during measurements
89025495|NCT00456677|Experimental|Minocycline|Addition of minocycline 150 mg po twice daily to current asthma treatment regimen.
89025496|NCT00456677|Placebo Comparator|Placebos|Addition of placebo capsules po twice daily to current asthma treatment regimen
89025497|NCT03278496|Experimental|Recovery housing plus counseling|Intensive counseling in a 5-day per week program plus abstinence-contingent rent payment in a community recovery house. Intervention lasts 12 weeks with follow-up at 12 and 24 weeks post treatment entry.
89551926|NCT06120530|Placebo Comparator|placebo|Saline
89551927|NCT06120478||xi'an|
89551928|NCT06120478||shanxi|
89551929|NCT06120465|Active Comparator|Yoga intervention group|12 week programme of yoga - encouraged to complete 1 live class and one pre-recorded class a week. Participants will continue with usual cystic fibrosis care.
89551930|NCT06120465|No Intervention|Control group|Usual cystic fibrosis care.
89551931|NCT06120452|Experimental|Test arm: Acne Serum|Participants will use the serum after cleansing and toning every morning for 8 weeks (56 days).
89551932|NCT06120439|Experimental|T Group|The T Group received PECS II(PMID: 22939099) combined with intercostal nerve block
89551933|NCT06120439|Active Comparator|C Group|C Group underwent laryngeal mask insertion after general anesthesia induction.
89551934|NCT06120400|Experimental|Healthy Diet + Eggs (HD+E)|2020-2025 Dietary Guidelines for Americans adherent dietary pattern containing 2 eggs/day/2000 kcal
89551935|NCT06120400|Active Comparator|Healthy Diet (HD)|2020-2025 Dietary Guidelines for Americans adherent dietary pattern containing 3 eggs/week/2000 kcal (HD)
89551936|NCT06120387||Kidney sparing surgery+Postoperative radiotheray cohort|Kidney sparing surgery+Postoperative radiotheray cohort
89551937|NCT06120387||Radical surgery cohort|Preoperative CT/MRI, chest CT and other examinations are performed to determine the stage of the patient's disease. The surgical plan is the same as the current conventional treatment. After surgery, there is no restriction on the use of postoperative adjuvant chemotherapy or postoperative adjuvant radiotherapy according to the patient's pathological stage and the patient's wish.
89551938|NCT06120374||Surveillance alone|Participants underwent radical total nephroureterectomy alone (with or without lymph node dissection) without postoperative adjuvant therapy
89025498|NCT03278496|Experimental|Recovery Housing only|Abstinence-contingent payment for recovery housing rent in absence of any formal counseling. Intervention lasts 12 weeks with follow-up at 12 and 24 weeks post treatment entry.
89025499|NCT03278496|Active Comparator|Usual Care Referral|Participants receive referral resources for community substance abuse counseling and recovery housing but no formal treatment or help with rent payments. All participate in follow-up data collection.
89025500|NCT04700397||Repeatability group 1|The patient with systolic blood pressure above 120 mmHg, who will receive a repeatability test with 200mcg, then another 100 mcg nitroglycerine injection, with a time interval of 3 minutes apart.
89551939|NCT06120374||Adjuvant chemotherapy/immunotherapy|Participants underwent radical total nephroureterectomy and adjuvant chemotherapy/immunotherapy postoperatively.
89551940|NCT06120374||Adjuvant radiotherapy|Participants underwent radical total nephroureterectomy and adjuvant radiotherapy postoperatively.
89551941|NCT06120374||Adjuvant combined therapy|Participants underwent radical total nephroureterectomy (with or without lymph node dissection) with a combination of adjuvant chemotherapy/immunotherapy and radiation therapy postoperatively
89551942|NCT06120322||Ulcerative Colitis (UC)|Patients will be enrolled in all the centers participating in this study: Ospedale San Raffaele - Milano, Ospedale Casa Sollievo della Sofferenza - Foggia and Azienda Ospedaliera San Camillo Forlanini - Roma as follows: 100 UC patients at OSR, 75 at San Camillo Hospital and 75 at CSS
89551943|NCT06120322||Diabetes Type 1 (T1D)|50 new onset T1D patients recruited and enrolled at OSR
89551944|NCT06120309||NACT Group|
89551945|NCT06120296|No Intervention|control group|In the blinded HPI group (the control group) the arterial waveform and pressure will be presented on a Philips patient monitor (the standard monitor), while the display of the hemosphere monitor shall be covered and the alarms will be silenced.
89551946|NCT06120296|Experimental|intervention group|In the unblinded HPI group (the intervention group), the arterial waveform and pressure will be displayed on the anesthesia monitor and the HPI on the Hemosphere monitor of Edwards Lifesciences (the study monitor).
89551947|NCT06120192|Experimental|Research group|Receives the full piano training
89551948|NCT06120179|Experimental|Patients who present with PE|The Bashir™ Endovascular Catheter (BEC) is a device intended for the localized infusion of therapeutic agents into the pulmonary artery and peripheral vasculature. Two sizes of BECs will be used in this study
89551949|NCT06120166|Experimental|Administration of Metabolically Armed CD19 CAR-T cells|Patients undergo leukapheresis. Patients will receive a lymphodepletion chemotherapy with cyclophosphamide and fludarabine before CAR-T cells infusion. A dose of metabolically armed CD19 CAR-T cells will be infused on day 0.
89551950|NCT06120153|Active Comparator|POC PCR-test device|In the seven-week intervention, the Point-of-Care PCR-testing device will be made available for approximate 50 clinics. Besides the general instructions on how to include patients, clinics in the intervention arm will be instructed that it is entirely up to the GP whether or not to use the PCR-testing device on each individual patient. In addition, no specific instructions on medical treatments or follow up procedures are made.
89551951|NCT06120153|No Intervention|Standard testing|In the seven-week control period, the Point-of-Care PCR-testing device will not be available in approximately 50 clinics. Patients attended by the GP during control periods will receive treatment as usual. Like GPs in the intervention arm, GPs in the control arm are not actively encouraged to change their prescription patterns, but they must record data from patients with respiratory tract infections parallel to the intervention group.
89551952|NCT06120127|Experimental|chemotherapy with radiotherapy and immunotherapy|radiotherapy: SBRT of liver lesions; postoperative chemotherapy and immunotherapy: chemotherapy by investigators' choice with sintilimab for 18 weeks
89551953|NCT06120127|Active Comparator|chemotherapy|postoperative chemotherapy: chemotherapy by investigators' choice for 18 weeks
89551954|NCT06120114|Experimental|Modified percutaneous internal ring suturing|Patients with indirect inguinal hernia operated with modified percutaneous internal ring suturing
89551955|NCT06120088||The Bupivacaine|Patients in this group received bilateral ultrasound-guided erector spinae plane block at the level of T7 transverse process using 20 mL of bupivacaine 0.25% on each side + 1ml saline placebo.
89551956|NCT06120088||The Bubpivacaine and dexamethasone|Patients in this group received bilateral ultrasound-guided erector spinae plane block at the level of T7 transverse process using 20 mL of bupivacaine 0.25% plus 1ml dexamethasone on each side
89551957|NCT06120088||The Bubpivacaine and fentanyl|Patients in this group received bilateral ultrasound-guided erector spinae plane block at the level of T7 transverse process using 20 mL of bupivacaine 0.25% in addition to calculated dose of fentanyl on each side
89551958|NCT06120062||1st experimental group|swaddled
89551959|NCT06120062||2nd experimental group|inhale the mother's breast milk odour
89025501|NCT04700397||Repeatability group 2|The patient with systolic blood pressure above 120 mmHg, who will receive a repeatability test with 200mcg, then another 200 mcg nitroglycerine injection, with a time interval of 3 minutes apart.
89025502|NCT04700397||Repeatability group 3|The patient with systolic blood pressure above 120 mmHg, who will receive a repeatability test with 200mcg, then another 300 mcg nitroglycerine injection, with a time interval of 3 minutes apart.
89025503|NCT04700397||pressure-recommended doses of NTG|The patient with systolic blood pressure above 100 mmHg, who will receive the nitroglycerine injection with the dose of recommendation, adjusted according to the blood pressure.
89025504|NCT00456833|Experimental|RAD 5mg/day + erlotinib|
89025505|NCT00456833|Active Comparator|erlotinib 150mg/day|
89025506|NCT04700319|Experimental|CD19/CD20 CAR-T cell infusion|CD19/CD20 CAR-T cell infusion on relapsed or refractory hematological malignancies of CD19 / CD20+ B cell line
89025507|NCT00456872|Experimental|buffered lidocaine|Sodium bicarbonate is a buffering additive that decreases the pH of the solution allowing for decrease in pain upon filtration.
89551960|NCT06120062||3rd experimental group|both swaddled and made to inhale the mother's breast milk odour
89551961|NCT06120062||the control group|no procedure
89551962|NCT06120049|Experimental|Healthy controls (part 2)|"25 healthy subjects (5 young 20-40y and 20 between 50-85y) will be enrolled for the head-to-head comparison with [18F]-MFBG, [123I]-MIBG and [18F]-FE-PE2I (Part 2).~In 5 healthy controls, arterial sampling will be carried out for kinetic modelling."
89551963|NCT06120049|Experimental|PD vs MSA cohort (part 3a)|"In total, 40 PD patients will be included. In order to determine relationships with disease progression, two subgroups will be included with disease duration up to 5 years and 5 years or more respectively. In total, 15 MSA-P patients will be enrolled. For both groups, abnormal previous [18F]-FE-PE2I or [123I]-FP-CIT SPECT scan is required.~Head-to-head comparison with [18F]-MFBG, [123I]-MIBG and [18F]-FE-PE2I (Part 3)."
89551964|NCT06120049|Experimental|AD vs DLB cohort (part 3b)|"In total 15 patients with probable DLB (including biomarker selection through abnormal previous [18F]-FE-PE2I or [123I]-FP-CIT SPECT scan) and 15 patients with probable AD (including biomarker proven amyloid-beta positivity either by cerebrospinal fluid biomarker analysis or by [18F]-NAV4694 imaging as standard of care).~Head-to-head comparison with [18F]-MFBG, [123I]-MIBG and [18F]-FE-PE2I (Part 3)."
89551965|NCT06120049|Experimental|Dosimetry in healthy controls (Part 1)|For dosimetry of [18F]-MFBG only, 3 subjects (18-80 y) will be enrolled (Part 1).
89551966|NCT06120036|Active Comparator|Kybella Injection|
89551967|NCT06120036|Active Comparator|Asclera Injection|
89551968|NCT06119984|Experimental|Community mobilization|a six-month community mobilization intervention that consisted of advocacy to stakeholders, community workshops and small group discussions in intervention communities
89551969|NCT06119984|No Intervention|No intervention|
89551970|NCT06119971|Experimental|ACUPLUS|ACU+ : patients receives stimulation on the true experimental points (Yin-Tang + Shen-Men)
89551971|NCT06119971|Placebo Comparator|ACUMOINS|"ACU- : patients receives stimulation on placebo points (sham point)"
89551972|NCT06119958|Experimental|DWC202313|DWC202313
89551973|NCT06119958|Experimental|DWC202314|DWC202314
89551974|NCT06119945|Experimental|DWJ1568|DWJ1568
89551975|NCT06119945|Active Comparator|DWC202215|DWC202215
89551976|NCT06119906|Experimental|Standard + Experimental Endoscopy|The endoscopist will intubate the patient with a high resolution white light endoscope (Olympus GIFH290Z or GIF-EZ1500) and thoroughly inspect the mucosal surface of the oesophagus. A careful note will be made of any visible lesion with their location, and the surrounding mucosa will be marked with cautery to localize the lesion for further hyperspectral imaging and biopsy. We will aim to identify at least two areas of interest per patient with the possibility to select more if the length of the Barrett's oesophagus allows. The endoscopist will remove the standard of care endoscope and then reintubate the patient with the experimental device and perform unbiased imaging first followed by targeted imaging of the endoscopic areas previously marked
89551977|NCT06119880|Experimental|PERT Group|After surgery, resume diet and begin receiving standard PERT treatment (2 capsules per meal, 1 capsule per snack, taken with meals, starting at a dose of 40000 to 50000 units of lipase) for 8 weeks.
89551978|NCT06119880|Placebo Comparator|Placebo Group|Follow the routine treatment plan for pancreatic tumors during the perioperative period.
89551979|NCT06119828|Experimental|Parallel Asignment|Power analysis was performed using the G*Power(v3.1.9) program to determine the sample size. The power of the study is expressed as 1-β (β = probability of type II error) and in general, studies must have 80% power. According to the effect size coefficients determined by Cohen, assuming that the evaluations to be made between two independent groups will have a medium effect size (d = 0.5), α = 0.05 and β = 0.20, it was determined that there should be at least 64 people in each group, according to the calculation.
89025508|NCT00456872|Experimental|unbuffered lidocaine|lidocaine is injected without sodium bicarbonate added
89025509|NCT03274154|Experimental|Pre-Hyaluron 465 Innēov|43 caucasian female subjects have taken during a meal, for the first 4 months of trial,1 capsule and 1 tablet/die of the food supplement composed with a precursor of HA (glucosamine) and an enzymatic co-factor of HA synthesis (manganese) .
89025510|NCT03274154|No Intervention|Untreated group|23 caucasian female subjects untreated
89025511|NCT03274115|No Intervention|White Light (WL)|White light will be used for histology prediction of colonic polyps (hyperplastic versus adenomatous).
89025512|NCT03274115|Active Comparator|Blue Light Imaging (BLI)|Switch from white light to BLI (Blue Laser Imaging) to predict the histology of colonic polyps.
89208102|NCT00793988|Active Comparator|1|Group receiving vibration-assisted anaesthesia
89551980|NCT06119802||Atrial Fibrillation cohort|The diagnosis of AF was based on 12-lead electrocardiography (ECG) or 24-hour Holter monitoring, and classification was based on the published 2020 ESC guidelines for the diagnosis and management of AF. The exclusion criteria were as follows: (1) acute heart failure and acute myocardial infarction; (2) severe liver or kidney dysfunction (with aspartate aminotransferase or alanine aminotransferase levels three times higher than normal and estimated glomerular filtration rate <30 ml/ (min*1.73 m2)); (3) malignant tumors; and (4) missing data of laboratory indicators at baseline.
89551981|NCT06119802||Non-atrial Fibrillation cohort|Patients attending the Department of Cardiology to rule out atrial fibrillation.The exclusion criteria were as follows: (1) acute heart failure and acute myocardial infarction; (2) severe liver or kidney dysfunction (with aspartate aminotransferase or alanine aminotransferase levels three times higher than normal and estimated glomerular filtration rate <30 ml/ (min*1.73 m2)); (3) malignant tumors; and (4) missing data of laboratory indicators at baseline.
89551982|NCT06119789|Experimental|treatment according to genetic alterations|treatment according to genetic alterations
89551983|NCT06119776||Study|Patients who underwent Whipple over the splenic artery (WOTSA) as a treatment for PDAC
89551984|NCT06119776||Control|Patients who underwent total pancreatectomy (TP) as a treatment for PDAC
89025513|NCT04700241|Active Comparator|Potassium nitrate|During this experimental day, men will receive 10 mmol of potassium nitrate
89025514|NCT04700241|Placebo Comparator|Placebo|During this experimental day, men will receive an isomolar dose of potassium chloride
89025515|NCT00480792|Active Comparator|A|GenHevac-B 20 microgramme Intramuscular use at M0, M1, M6
89208103|NCT00793988|Placebo Comparator|2|Group receiving switched-off vibrating device
89208104|NCT00973401||Diabetic individuals|
89551985|NCT06119763||group A|systemic lupus erythematosus cases, diagnosed by SLICC criteria with negative levels of AntiDFS antibodies
89551986|NCT06119763||group B|systemic lupus erythematosus cases, diagnosed by SLICC criteria with positive levels of AntiDFS antibodies
89551987|NCT06119750|Experimental|MIS Solution|device under investigation
89551988|NCT06119750|Placebo Comparator|Saline|0.9%
89551989|NCT06119750|Active Comparator|Sodium Lauryl Sulfate|20%
89551990|NCT06119737|Experimental|Moderate Intensity Continuous Training|
89551991|NCT06119737|Active Comparator|Resistance Training|
89551992|NCT06119737|Active Comparator|High-Intensity Interval Training|
89551993|NCT06119737|Active Comparator|1/2- High-Intensity Interval Training|
89551994|NCT06119724|Active Comparator|Bipolar enbloc resection of bladder tumors|Patients who have odd number will be in the first group which will be enrolled in bipolar enbloc group
89551995|NCT06119724|Active Comparator|Thulium enbloc resection of bladder tumors|patients who have even number will be in the second group which will be Thulium-Yag laser enbloc group
89551996|NCT06119698|Experimental|GetActive+|A mind-body program focused on increasing physical and emotional function in older adults with chronic musculoskeletal pain
89551997|NCT06119698|No Intervention|Treatment as usual|Treatment as Usual (TAU) includes traditional primary care management of chronic pain.
89551998|NCT06119672|Active Comparator|systemic probiotic (A)|Systemic probiotic capsules will be given twice daily in addition to topical application of topical clobetasol in orabase twice daily
89551999|NCT06119672|Active Comparator|topical corticosteroid (B)|topical clobetasol in orabse application will be given 4 times daily ( 3 times after meals and once before bed time) prophylactic topical antifungal will be given in the fourth week to prevent candidal infection
89552000|NCT06119659|Experimental|KL001 injection solution|Subjects will be dosed with three different dose of KL001 injection solution at 2.5x10^12 vg/kg to 1.0x10^13 vg/kg.
89552001|NCT06119646|Experimental|Warm Pads Applied to the Breast|When repairing the episiotomy of a pregnant woman who has given birth, a pad heated in a microwave oven at 180 W for 1 minute is applied to each breast for 20 minutes. The application is made when the temperature of the pad, measured with a thermometer, reaches a maximum of 40.5 C.
89552002|NCT06119646|No Intervention|Control|A routine care was performed.
89552003|NCT06119620|Other|ABAB|all participants will go through sham (control) and active (experimental) stimulation. So either sham - active - sham - active or active - sham - active - sham
89552004|NCT06119516|Experimental|Esophageal pressure-guided strategy,|The second generation esogastric multifunction Nutrivent catheter (SIDAM, Mirandola, Italy) will be used to monitor esophageal and gastric pressures during several days. Ventilator settings will be adjusted to the evaluated esophageal pressure-guided strategy, aiming to obtain a slightly positive transpulmonary pressure at the end of expiration.
89552005|NCT06119477|Experimental|Bioceramic Putty Apical Plugs|The Bioceramic Putty will be inserted in the apical 4 mm of the canal using the modified cannula and adapted to the canal walls with a hand plugger.
89552006|NCT06119477|Experimental|Single Cone Gutta-percha with Bioceramic Sealer|A large sized (#80 - #120, and a taper of 2%) gutta-percha cone (GC) will be inserted, measuring according to the width of the canal, to the working length, then the immature canal will be gently filled with Bioceramic sealer and the GC.
89552007|NCT06119477|Experimental|Combination of Bioceramic Putty and Sealer|The immature canal will be gently filled with Bioceramic sealer and then 3 to 5 small balls of BP will be inserted into the canal orifice and gently plugged with hand pluggers.
89552008|NCT06119126|Experimental|Group A|Diode laser application only
89552009|NCT06119126|Experimental|Group B|SDF application only
89552010|NCT06119126|Experimental|Group C|Diode laser application followed by pits and fissure sealant.
89552011|NCT06119126|Experimental|Group D|SDF application followed by pits and fissure sealant.
89552012|NCT06117748|Experimental|Group (PCV-VG): Pressure controlled ventilation-volume guaranteed|Patients will receive pressure controlled ventilation-volume guaranteed
89552013|NCT06117748|Other|Group (VCV): Volume controlled ventilation|Patients will receive Volume controlled ventilation
89552014|NCT06117228||women with Down syndrome aged 18 to 30|women aged 18 to 30 with Down syndrome, whether or not they were receiving medical care, who agreed to take part in the study.
89552015|NCT06117124|Active Comparator|Quantitative ultrasound|Participants will undergo bone density measurement using two different modalities - quantitative ultrasound and digital x-ray radiogrammetry. Each method will be performed twice over a 12 month period, to assess changes in bone density over time.
89552016|NCT06117124|Active Comparator|Digital x-ray radiogrammetry.|Participants will undergo bone density measurement using two different modalities - quantitative ultrasound and digital x-ray radiogrammetry. Each method will be performed twice over a 12 month period, to assess changes in bone density over time.
89552017|NCT06116812|Experimental|the laughter therapy group|Women diagnosed with breast cancer who meet the inclusion criteria and are receiving chemotherapy will receive laughter therapy twice a week for an average of 40-60 minutes for 8 weeks.
89552018|NCT06116812|Experimental|the mindfulness therapy group|Women diagnosed with breast cancer who meet the inclusion criteria and are receiving chemotherapy will receive an average of 40-60 minutes of mindfulnes therapy twice a week for 8 weeks.
89552019|NCT06116812|No Intervention|the control group|Women diagnosed with breast cancer who meet the inclusion criteria and are receiving chemotherapy will receive standard hospital care only.
88961879|NCT03136471||EMR data extraction|"EMR Data extraction from the Louisiana Clinical Data Research Network (LaCDRN). The Louisiana Clinical Data Research Network (LaCDRN) data will be requested, including patients' records of pharmacy, inpatient, outpatient and lab results from January 01, 2016 to December 31, 2021. It is a retrospective data analysis without interaction with any participants. All data is de-identified and the study participants will not be contacted in any way.~Inclusion criteria: Patients with type 2 diabetes, whose age>=18 years old will be extracted from database of LaCDRN.~Exclusion criteria: Patients without type 2 diabetes or age<18 years old."
88961880|NCT03136471||Healthcare Professionals|"Healthcare professionals (physician, nurse) will be randomly selected from LaCDRN partner health system. An email will be distributed to the registered clinicians at partner health systems.~Inclusion criteria: physicians and nurses who treat diabetes patients and work at clinic settings within LaCDRN network and consent to participate the study.~Exclusion criteria: physicians and nurses who do not treat diabetes patients or not work at clinic settings within LaCDRN network; refuse to participate the study."
88961881|NCT03136471||Patients for Qualitative Study|"Patients with diabetes who are a members of Diabetes Advisory Group or partner LaCDRN health system will be contacted via email, letter or phone call.~Inclusion criteria:~Diabetes patients who consent to participate the study.~Age 65+;~Diagnosis code for diabetes in the last 2 years;~Diagnosis code for at least one additional chronic condition in the last 2 years.~Exclusion criteria: age<65; patient with diabetes without other chronic conditions."
88961882|NCT03136471||LaCDRN partner health system's medical directors|Face-to-face semi-structured interviews will be used to explore organizational cultures, their social architecture, resources, capacity, communication networks, assess barriers, and refine the data collection for the assessing the RE-AIM framework. The one time interview will take 1 hour. A 10 minutes questionnaire of Diabetes care coordination readiness assessment (DCCRA) will be emailed to them annually during entire 5 years of study period.
88961883|NCT03136471||PROMIS® survey|"Patients for PROMIS® survey (National Institutes of Health's Patient-Reported Outcome Measurement Information System Global Health Measures). Patients will be administered the surveys at the point-of-care visit (in exam rooms) using REACHnet's tablet-based application.~Inclusion criteria:~All patients age 18+ who registered at REACHnet.~Able to provide informed consent~Exclusion criteria: patients who do not provide inform consent or age<18 years old."
88961884|NCT03136471||PACIC+ survey|"Patients for PACIC+ survey (Group Health Research Institute's Patient Assessment of Care for Chronic Conditions+). Patients will be administered the surveys at the point-of-care visit (in exam rooms) using REACHnet's tablet-based application.~Inclusion criteria:~All patients age 18+ with a Diabetes diagnosis and who registered at REACHnet.~Able to provide informed consent~Exclusion criteria: patients who do not provide inform consent or without diabetes diagnosis or age<18 years old"
88961885|NCT03136471||Telehealth Services using HCPCS/CPT for COVID-19 Patients|Study population with versus without telehealth services. Telehealth services using the HCPCS/CPT codes will be defined in the following categories: Medicare telehealth visits (CPT codes: 99201-99215; HCPCS codes: G0425-G0427, G0406-G0408), virtual check-in (HCPCS codes: G2010, G2012), and e-visits (CPT codes: 99421-99423, HCPCS codes: G2061-G2063). Propensity score-matching will be used to ensure comparison groups are comparable at baseline.
88961886|NCT03119233|Experimental|Single-Arm|The PQ Bypass system is used during a minimally invasive procedure to place stent grafts in the peripheral vasculature to improve blood flow.
88961887|NCT03109093|Experimental|Blinatumomab|"Patients will receive four cycles of treatment, unless criteria for treatment discontinuation apply. The duration of one cycle is 6 weeks, including a four week continuous intravenous infusion and a two week infusion free interval, which may be extended by a maximum of 7 days.~Patients entered with MRD level <10-4 (non quantifiable/MolNE1, quantifiable/MolNE2) or positive MRD, non quantifiable (MolNE3) will receive up to two cycles of Blinatumomab.~Transfer of patients to alloHSCT after one cycle or after subsequent cycles is considered as per protocol discontinuation and as premature treatment discontinuation In case of hematological or extramedullary relapse, the study treatment will be permanently discontinued."
88961888|NCT03105700|Experimental|Low Frequency TMS Intervention|Patients will receive low-frequency TMS on an accelerated schedule over three consecutive days.
89552020|NCT06116500|Experimental|Modified twin block appliance with expander group|For 24 patients with class II division malocclusion in their growing stages, using a 2 mm biocompatible and rigid PET-G thermoforming material to create two clear appliances for each patient. The material will be adapted separately on maxillary and mandibular casts using a pressure molding vacuum machine. Then, the appliances will be trimmed and finished and transferred to the articulator with the aid of a pre-existing working wax bite. The ramps will be made of cold cure acrylic on the thermoplastic sheets. Next, the expansion screw will be placed in the midline of the maxillary cast, and the maxillary appliance will be split midpalatally to fit the patient's individual needs.
89552021|NCT06116500|Experimental|Conventional twin block appliance with expander group|For 24 patients in a growing stage with class II division 1 malocclusion, these appliances will consist of removable maxillary and mandibular appliances. These will have a labial bow, Adam's clasps on the first molars, ball end clasps with incisal capping and expansion screw. The inclined bite blocks (ramps) will act as a guide to move the mandible forward.
89552022|NCT06116396||1|Urothelial neoplasia
89552023|NCT06116396||2|Age-matched individuals free of neoplasia
89552024|NCT06116383||Patients undergoing laparoscopic cholecystectomy.|Basal rSO2 values will be recorded by placing NIRS probes under the 10-11th intercostal space in the bilateral posterior lateral flank region. Age, gender, BMI, ASA scores, Hb/Htc values, intraoperative hemodynamic parameters, NIRS values, N-GAL (preoperative, 2nd hour and 24th hour), urea/creatinine (preoperative, postoperative 24th hour) values of the patients will be recorded. .
89552025|NCT06116370|Active Comparator|BPH patients treated with Rezum procedure|Patients aged 50-80 years with prostate volumes of 50-120 ml, sexually active, and have severe LUTS treated with Rezum procedure
89552026|NCT06116370|Active Comparator|BPH patients treated with B-TURP procedure|Patients aged 50-80 years with prostate volumes of 50-120 ml, sexually active, and have severe LUTS treated with Rezum procedure
89552027|NCT06115668|Active Comparator|Positive end-expiratory pressure 5 (PEEP 5)|Patients will receive fixed positive end-expiratory pressure(= 5 cmH2O) as a control group
89552028|NCT06115668|Experimental|Individualized positive end-expiratory pressure (PEEPIND)|Patients who will receive the individualized positive end-expiratory pressure.
89552029|NCT06115395|Active Comparator|(Group 1) 25 (H. NIV): Hypoxemic patients{hypoxemic NIV group}|who will undergo fiber-optic bronchoscopy under non- invasive ventilation and conventional oxygen therapy
89552030|NCT06115395|Active Comparator|(Group 2) 25 (H. conv.): Hypoxemic patients{hypoxemic conventional group }|who will undergo conventional fiber-optic bronchoscopy under conventional oxygen therapy without non- invasive ventilation
89552031|NCT06115395|Active Comparator|(Group 3) 25 (N.H.NIV): Non- hypoxemic patients{non-hypoxemic NIV group}|who will undergo fiber-optic bronchoscopy under non- invasive ventilation and conventional oxygen therapy
89552032|NCT06115395|Active Comparator|(Group 4) 25(N.H. conv.): Non- hypoxemic patients{non-hypoxemic conventional group}|who will undergo conventional fiber-optic bronchoscopy under conventional oxygen therapy without non- invasive ventilation
89552033|NCT06114927||Participants|To answer a 15-question survey.
89552034|NCT06114719|Experimental|Experimental group|Silymarin 400 mg daily, orally, divided into two doses, for three days preoperatively
89552035|NCT06114719|No Intervention|Control group|Optimal standard therapy
89552036|NCT06114654||Participants|Physiotherapy students of the Rovira i Virgili University aged between 18 and 35 years enrolled during the academic year 2022-2023. All participants were allowed three practice trials for each test. Consistent feedback was provided throughout to ensure proper technique. Electrodes were placed to assess muscle activity according to SENIAM recommendations in gluteus medius, gluteus maximus, tibialis anterior and peroneus longus. After electrode placement, a maximal isometric strength test (MVIC) was performed for each muscle to normalize the electromyographic data. During this MVIC test, the maximum isometric force was measured using the Chronojump Boscosystem force gauge. Following this, ankle stability evaluation tests were performed. The Single Leg Stance Test, the Hurdle Step test and finally the Single leg vertical jump will be performed.
89552037|NCT06114160||pregnant women|Pregnant women between 20 and 41 weeks of amenorrhoea, primiparous.
89552038|NCT06113575|Experimental|Scheduled Treatment Arm|5 day treatment course, 36 total treatments and clinical assessments.
89552039|NCT06113549|Experimental|Knee Joint Distraction (KD)|Knee joint distraction (KJD) is a joint-preserving treatment for knee OA for younger patients, where the knee joint is temporarily fully unloaded by distraction of tibia and femur, using an external fixation frame. KJD treatment is performed according to the current approved concept NOV recommendations for clinical practice.
89552040|NCT06113549|Active Comparator|Knee Prosthesis|KP is indicated and surgically implanted according to regular clinical practice (can be a total- or unicompartmental KP, in line with local practice in consultation with the patient and conform the national guideline by Dutch orthopaedic society (NOV)).
89552041|NCT06113484|Experimental|DIET + EXERCISE|This group engages in physical exercise plus a nutritional intervention. Monthly individual nutrition consultations are conducted. Additionally, this group also benefits from a group culinary workshop.
89552042|NCT06113484|Other|WITHOUT DIET + EXERCISE|This group engages in physical exercise; however, it is not the target of the nutritional intervention. Only a group educational session is conducted.
89552043|NCT06113484|No Intervention|WITHOUT DIET + WHITOUT EXERCISE (CONTROL)|This group does not engage in physical exercise, nor is it the target of the nutritional intervention. Only a group educational session is conducted.
89552044|NCT06112964||Participants with cancer and cancer associated weight loss/ loss of appetite|Participants with a non-haematological malignancy, reporting weight loss of >5% body weight in 6 months, or loss of appetite.
89552045|NCT06112964||Healthy volunteers|No malignancy or weight loss in the past 6 months
89552046|NCT06110858|Experimental|Tinkering Activities|
89552047|NCT06105034||Conservative management|150 patients
89552048|NCT06105034||CS hysterectomy|150 patients
89552049|NCT06103201|Experimental|Metabolic MRI in traumatic brain injury patients|Perform metabolic magnetic resonance imaging on patients who have traumatic brain injury to understand early brain metabolism changes in this population
89552050|NCT06103201|Experimental|Metabolic MRI in subarachnoid hemorrhage patients|Perform metabolic magnetic resonance imaging on patients who have subarachnoid hemorrhage to understand early brain metabolism changes in this population
89552051|NCT06103201|Experimental|Metabolic MRI in healthy volunteers|Perform metabolic magnetic resonance imaging on healthy volunteers to understand early brain metabolism changes in this population
89552052|NCT06101225|Experimental|RegularMente Intervention|"Relaxation exercises, breathing and closing the eyes, focusing on body parts;~The proposal of a guided imagery through narrated scripts, leading children through the visualization of beautiful scenarios and exposure to Social and Emotional Learning content - based on the Collaborative for Academic, Social, and Emotional Learning framework (CASEL), in three major themes: Me with myself (self-awareness and self-management); Me with the others (social-awareness and relationships skills); Me with the world (responsible decision making and social awareness);~Instructions for self-regulation of body posture and the use of touch (shoulders) to support children in posture regulation."
89025516|NCT00480792|Experimental|B|GenHevac-B 40 microgramme Intramuscular use at M0, M1, M2, M6
89552053|NCT06101225|Active Comparator|Relaxation|Relaxation exercises, breathing and closing the eyes, focusing on body parts.
89552054|NCT06101225|Other|Control|No intervention - regular school activities.
89208105|NCT04040322|Placebo Comparator|Placebo|Subjects will receive study drug for 5 consecutive days as an IV infusion over 6 hours each day via a peripheral line. Study drug will be initiated at a starting dose 0.5 ng/kg/min up to 2.0 ng/kg/min.
89552055|NCT06090058||A|Patients with acute ischemic stroke having focal neurological deficits lasting for more than 24 hour with relevant lesion in brain computerized tomography (CT) or magnetic resonance (MR) image
89552056|NCT06090058||B|Patients with chronic ischemic stroke , having these symptoms for 6-12 month
89552057|NCT06090058||C|Healthy controls
89552058|NCT06085131||Argos Biometer|Preoperative biometry with the Argos device
89552059|NCT06082752|Experimental|Massage group|In the intervention group measures will be taken twice: before and after the 5-minute massage session.
89552060|NCT06082752|No Intervention|Non-massage group|In the control group measures will be taken twice: at the beginning of the meeting and again after 5 minutes.
89552061|NCT06077916|Placebo Comparator|Control|iv perfusion of 250 mL of 0.9% saline solution
88812101|NCT05946538|Other|Device accuracy observational arm|Two nasopharyngeal swabs will be collected from each enrolled participant and analysed on the AusDiagnostics in vitro diagnostic device panel and the comparator BioFire in vitro diagnostic device panel.
88812102|NCT05946512|Experimental|yoga intervention|
88812103|NCT05946512|Active Comparator|social contact|
88812104|NCT05946486|No Intervention|control group|continuation of ongoing psychiatric care (with or without standard treatment as usual (i.e. antipsychotics, mood stabilisers, antidepressants and/or anxiolytics)).
89025517|NCT00480792|Experimental|C|GenHevac-B 4 microgramme Intradermal use at M0, M1, M2, M6
89025518|NCT00480870|Experimental|A|Donepezil treated Alzheimer patients
89025519|NCT00480870|Placebo Comparator|B|Placebo treated Alzheimer patients
89025520|NCT00480948|Active Comparator|1|Infant formula with InFat™ oil(containing ~49% of C16:0 at sn-2 position).
89552062|NCT06077916|Experimental|Azithromycin|iv perfusion of 500 mg azithromycin in 250 mL of 0.9% saline solution
89552063|NCT06077838|Active Comparator|RELAX Group 1|Participants will receive access to the RELAXaHEAD app version 1 which contains certain features for migraine self-management with written materials.
89552064|NCT06077838|Active Comparator|RELAX Group 2|Participants will receive access to the RELAXaHEAD app version 2 which contains certain features for migraine self-management with written and audio materials.
89552065|NCT06076785||OdySight users|OdySight users between 07/21/2021 and 11/14/2022 who performed Visual Acuity testing through OdySight and according to standard practice.
89552066|NCT06076707|Experimental|Tramadol (T) group|Participants will be infiltrated with only 200mg tramadol around the wound.
89552067|NCT06076707|Placebo Comparator|Bupivacain (B) group|participants will be infiltrated with only bupivacaine around the wound
89552068|NCT06076707|Experimental|Tramadol + bupivacain ( T+B) group|The participants will be infiltrated with tramadol and bupivacaine which are mixed together in the same syringe.
89552069|NCT06076525|Experimental|Older Adult Fallers (participate in Aim 1 only)|This group is exposed to the perturbations during treadmill walking in Aim 1 to collect data on their balance control mechanisms.
89552070|NCT06076525|Active Comparator|Older Adult Non-Fallers - Control Group (participate in Aims 1 and 2)|This group acts as a comparison for the Older Adult Non-Fallers - Experimental Group within the same demographic.
89552071|NCT06076525|Experimental|Older Adult Non-Fallers - Experimental Group (participate in Aims 1 and 2)|This group is exposed to the interventions in both Aims 1 and 2, the latter of which involves targeted training designed to improve their balance control flexibility.
89552072|NCT06076525|Active Comparator|Younger Adult Non-Fallers - Control Group (participate in Aims 1 and 2)|This group serves as the control for the Younger Adult Non-Fallers - Experimental Group.
89552073|NCT06076525|Experimental|Younger Adult Non-Fallers - Experimental Group (participate in Aims 1 and 2)|This group is exposed to the interventions in both Aims 1 and 2, the latter of which involves targeted training designed to improve their balance control flexibility.
89208106|NCT04040322|Active Comparator|Iloprost Injection, for intravenous use|Subjects will receive study drug for 5 consecutive days as an IV infusion over 6 hours each day via a peripheral line. Study drug will be initiated at a starting dose 0.5 ng/kg/min up to 2.0 ng/kg/min.
89208107|NCT00787358|Active Comparator|ZT-031|
89552074|NCT06072313|Experimental|Monopolar electrical diathermy plus therapeutic yoga|The Experimental Group formed by 30 subjects will receive two sessions per week of monopolar electrical diathermy by radiofrequency emission (MDR) by means of the Physicalm® device (device developed by Biotronic Advance Develops SL), and one session of therapeutic neck yoga per week. Diathermy is applied by means of rotational and translational movements, adapting to the muscular fibers of the cervical area, with a pulsed emission of 840 KHz AND 30v dynamically during a treatment time of 20 minutes.
89552075|NCT06072313|Active Comparator|Therapeutic Exercise|"The Control Group formed by 30 subjects will be administered a supervised therapeutic exercise with the same protocol of postures and sequences as in the Experimental Group, but for three days a week. The duration of the sessions will be 60 minutes.~The yoga program will be designed specifically for people who have chronic neck pain and no previous experience with therapeutic exercise. Classes will be led by a certified Iyengar yoga instructor and physical therapist. The exercise program will consist of standing, seated and supine postures, starting with simple postures and moving on to more complex ones. Props such as belts, blocks, and blankets will be used to enhance safety and alignment. Participants will be asked to focus on their posture, joint positions, and muscle tension in each exercise posture. No formal breathing techniques will be used, but participants will be instructed to align their breath with their movements."
89552076|NCT06070584|Active Comparator|group A|received aerobic exercises only
89552077|NCT06070584|Experimental|Group B|aerobic exercises with moderate intensity in the form of walking on electrical treadmill
89552078|NCT06067087||Patients with advanced cancer|Patients with advanced cancer that are referred to the Enhanced Supportive Care Team at University College London Hospital
89552079|NCT06063629|Experimental|Subcutaneous drain|The drain will be inserted into subcutaneous layer of the surgical wound. Redivac drain will be used in this study.
89552080|NCT06063629|Other|No drain|No drain will be inserted into the surgical wound in this arm.
89552081|NCT06062849|Active Comparator|totally tubeless|there is no nephrostomy tube or double J (JJ) stent
89552082|NCT06062849|Active Comparator|tubeless|only JJ stent
89552083|NCT06062849|Experimental|nephrostomy tube|nephrostomy tube
89552084|NCT06062641|Experimental|SR-GDP|
89552085|NCT06054529||Participants in surgery|Surgical removal of the GBM tumor.
89552086|NCT06050512|Experimental|Phase l: Mezigdomide + Ixazomib + Dexamethasone|Dose level -2: Mezigdomide: 0.3 mg daily on days 1-21 of a 28-day schedule; Ixazomib: 2.3 mg PO weekly on days 1, 8 and 15 of a 28-day schedule; Dexamethasone: 40 or 20 mg on days 1, 8, 15 and 22 Dose level -1: Mezigdomide: 0.6 mg daily on days 1-21 of a 28-day schedule; Ixazomib: 2.3 mg PO weekly on days 1, 8 and 15 of a 28-day schedule; Dexamethasone: 40 or 20 mg on days 1, 8, 15 and 22 Dose level 0 (Starting dose): Mezigdomide: 0.6 mg daily on days 1-21 of a 28-day schedule; Ixazomib: 3.0 mg PO weekly on days 1, 8 and 15 of a 28-day schedule; Dexamethasone: 40 or 20 mg on days 1, 8, 15 and 22 Dose level +1: Mezigdomide: 1.0 mg daily on days 1-21 of a 28-day schedule; Ixazomib: 3.0 mg PO weekly on days 1, 8 and 15 of a 28-day schedule; Dexamethasone: 40 or 20 mg on days 1, 8, 15 and 22 Dose level +2: Mezigdomide: 1.0 mg daily on days 1-21 of a 28-day schedule; Ixazomib: 4.0 mg PO weekly on days 1, 8 and 15 of a 28-day schedule; Dexamethasone: 40 or 20 mg on days 1, 8, 15 and 22
89552087|NCT06050512|Experimental|Phase ll (RP2D): Mezigdomide + Ixazomib + Dexamethasone|Mezigdomide: RP2D daily on days 1-21 of a 28-day schedule Ixazomib: RP2D PO weekly on days 1, 8 and 15 of a 28-day schedule Dexamethasone: RP2D on days 1, 8, 15 and 22
89552088|NCT06029920|Experimental|Subjects|
89552089|NCT06025448|Active Comparator|BIO-RSA|
89552090|NCT06025448|Experimental|MIO-RSA|
89552091|NCT06025331|Experimental|BIO-RSA|
89552092|NCT06025331|Active Comparator|RSA|
89552093|NCT06008977|No Intervention|Standard Group- No Exercise (Adjuvant)|Patients randomized to the standard arm will receive clinical care following AH standards for the patient's disease type and therapeutic setting. This includes history and physical and laboratory studies to be conducted on each infusion day before clearing the patient for infusion.
89552094|NCT06008977|Active Comparator|Intervention Group- Moderate Exercise (adjuvant)|Patients randomized to the exercise arm will complete up to 30 minutes of same-day exercise prior to each administration of checkpoint blockade immunotherapy across all cycles. The preferred exercise is 30 minutes of moderate exertion on a cycle ergometer.
89552095|NCT06008977|No Intervention|Standard Group- No Exercise (Neoadjuvant)|Patients randomized to the standard arm will receive clinical care following AH (AdventHealth) standards for the patient's disease type and therapeutic setting. This includes history and physical and laboratory studies to be conducted on each infusion day before clearing the patient for infusion.
89552096|NCT06008977|Active Comparator|Intervention Group- Moderate Exercise (Neoadjuvant)|Patients randomized to the exercise arm will complete up to 30 minutes of same-day exercise prior to each administration of checkpoint blockade immunotherapy across all cycles. The preferred exercise is 30 minutes of moderate exertion on a cycle ergometer.
89552097|NCT05998954|Experimental|Transmuscular quadratus lumborum and modified erector spinae plane (QLESP) block (QLESP group)|The patient was turned to the lateral decubitus position with the side to be blocked upward and a low-frequency curved array transducer was placed on the ﬂank cranially to the iliac crest to identify the transverse process of L4, quadratus lumborum muscle, erector spinae muscle, and psoas muscle. The needle was advanced to gently contact the transverse process using an in-plane technique and 15 ml of 0.375% ropivacaine was administered between the erector spinae muscle and the transverse process. The needle was subsequently withdrawn and redirected toward the interfascial plane between the quadratus lumborum and the psoas major muscles, where 15 ml of 0.375% ropivacaine was injected with repeated negative aspiration.
89025521|NCT00480948|Placebo Comparator|2|Standard vegetable oil based infant formula
89025522|NCT00443469|Experimental|Magnetic Stimulation|
89208108|NCT00787358|Placebo Comparator|Placebo|
89208109|NCT00794066||1|TIA
89208110|NCT00794066||2|Ischemic stroke
89208111|NCT00794066||3|Hemorrhagic stroke
89208112|NCT00784004|Other|Volunteers|Ten healthy volunteers
88961889|NCT03063398||Patients after acute pancreatitis|Such patients will be followed and assessed for the development of Exocrine Pancreatic Insufficiency. 'No intervention, this is an observational study.
88961890|NCT03048201|Other|Physica KR|Subjects that receive the Physica Kinematic Retaining Knee System
88961891|NCT03048201|Other|Physica CR|Subjects that receive the Physica Cruciate Retaining Knee System
88961892|NCT03048201|Other|Physica PS|Subjects that receive the Physica Posterior Stabilized Knee System
89552098|NCT05998954|Active Comparator|Suprainguinal fascia iliaca block (SFI group)|With the patient in the supine position, the ultrasound transducer was placed in a parasagittal orientation over the inguinal ligament, inferior medially to the anterior superior iliac spine. Using real-time ultrasound imaging internal oblique, sartorius and iliacus muscles, covered by the fascia iliacus, were identified. With the needle tip placed beneath the fascia and above the iliacus muscle from caudad-to-cephalad direction (in-plane technique), 30 ml of 0.375% ropivacaine was injected slowly to separate the fascia iliaca from the iliacus muscle.
89552099|NCT05968105||Group 1|Inferior vena cava diameter <1.5 cm and VCI-CI > 50% according to Vena Cava Inferior Collapsibility Index (VCI-CI)
89552100|NCT05968105||Group 2|Inferior vena cava diameter >1.5 cm and VCI-CI < 50% according to Vena Cava Inferior Collapsibility Index (VCI-CI)
89552101|NCT05961293|Other|Control Cohort (Healthy Cohort)|Healthy participants who participate in 1 study visit. The healthy participant will undergo one functional MRI which using the NeuroGlove.
89552102|NCT05961293|Experimental|Treatment Arm|The treatment cohort will undergo two functional MRIs once at baseline and the final fMRI will occur six weeks after initial study visit after daily use of the NeuroGlove.
89552103|NCT05955495|Active Comparator|Delayed feeding|
89552104|NCT05955495|Experimental|Early feeding|
89552105|NCT05950867|Other|1 arm including patients with CAP and/or SFN|"1 arm including patients with chronic axonal length-dependent polyneuropathy and/or small-fiber neuropathy.~All participants will be screened with ECG and echocardiography. All participants will be asked to complete questionnaires about there polyneuropathy and cardiological symptoms."
89552106|NCT05938465|Experimental|Phase 1b Open Label|EXE-346 live biotherapeutic product, 1500x10^9 colony forming units (CFU) twice daily (BID), 4 weeks
89552107|NCT05938465|Experimental|Phase 2: Active Arm|EXE-346 live biotherapeutic product, 1500x10^9 CFU BID, 8 weeks
89552108|NCT05938465|Placebo Comparator|Phase 2: Placebo Arm|Powder containing same inactive ingredients as EXE-346 but none of the active ingredients, BID, 8 weeks
89552109|NCT05938465|Experimental|Phase 2 Open Label Extension (optional)|EXE-346 live biotherapeutic product, 1500x10^9 CFU BID, 8 weeks
89552110|NCT05937685|No Intervention|Usual Care|Participants receive the usual care received by patients of the medical center
89552111|NCT05937685|Experimental|Intervention|Participants follow the intervention protocol, including receiving educational materials, a home blood pressure monitor, coaching calls from BP REACH coaches and medication management from a pharmacist.
89552112|NCT05901753|Experimental|Laryseal pro supra glottic device (SGD)|Laryseal pro SGD, the jaw will be lifted during insertion and the head will be extended, proper lubrication of both the front and back of the laryseal pro as if the patient's mouth is dry the laryseal pro ridges can get hung up on the back of the tongue during placement.
89552113|NCT05901753|Experimental|Laryngeal Mask Airway- Proseal™|The LMA-Proseal™ will be inserted using the digit method. The size will be determined according to the patient's weight and inserted according to the manufacture's recommendation with the use of an introducer.
89552114|NCT05891587|Experimental|Semaglutide|Participants will receive subcutaneous injections of semaglutide in escalating doses (.25mg to 1.0mg) over the course of 12 weeks.
89552115|NCT05891587|Placebo Comparator|Placebo|Participants will receive subcutaneous injections of a placebo saline solution over the course of 12 weeks.
89552116|NCT05888090|Experimental|Intervention Group 1|
89552117|NCT05888090|Experimental|Intervention Group 2|
88961893|NCT03048201|Other|Physica CR with LMC Liner|Subjects that receive the Physica Cruciate Retaining Knee System with LMC Liner
89208113|NCT00784004|Other|Patients|Sixteen patients with respiratory insufficiency
89208114|NCT00867750|Experimental|RE|Device: Radioembolisation with yttrium-90 labelled SIR-Spheres microspheres
88961896|NCT02953431|Placebo Comparator|Sham CPAP|Participants will be randomized to Sham CPAP
88961897|NCT02953431|Active Comparator|CPAP 10|Participants will be randomized to CPAP 10
88961898|NCT02885337|Active Comparator|Usual Care|"Patients in the control arm will receive usual care which may include the recommendation to attend fitness classes before surgery, however these patients will not receive the more intensive assessment/intervention of the physiotherapist and other intervention components. Control participants will be asked pre-operatively and post-operatively to indicate whether or not they exercise, take protein or vitamin supplements.~For participants in intervention and control groups will, 1) we will monitor the YMCA attendance and 2) participants will be instructed on the completion a dietary intake log (including days of the week and weekend days) that indicate the type of food and amount over a four-day period in order to calculate energy and micronutrient consumption."
89025523|NCT00443469|Placebo Comparator|Magnetic Stimulation with tilted coil|Magnetic Stimulation with tilted coil
89025524|NCT01240044|No Intervention|Control Group|In this group the newborns remained at rest 20 minutes and receive no intervention of respiratory therapy.
89025525|NCT01240044|Experimental|Physical Therapy|In this group the newborns are submitted to the mechanical vibrator.
89552118|NCT05888090|Experimental|Intervention Group 3|
89552119|NCT05885997|Experimental|Intervention Clinics, Pre-Implementation Period|Usual care
89552120|NCT05885997|Experimental|Intervention Clinics, Post-Implementation Period|Access to Supported HBPM program plus a multifaceted implementation strategy designed to increase uptake of the program by primary care patients with uncontrolled hypertension
89552121|NCT05885997|Other|Control Clinics, Pre-Implementation Period|Usual care
89552122|NCT05885997|Other|Control Clinics, Post-Implementation Period|Usual care
89552123|NCT05881031|No Intervention|Standard of care|Standard of care is NiPPV initiation during a one-night, in-hospital PSG, during which NiPPV settings are titrated during the night by a PSG technologist to determine optimal settings according to current international guidelines. Once NiPPV equipment is obtained and NiPPV is used at home (time 0), NiPPV setting changes may occur at 1, 4, and 12 weeks when participants are contacted by the respiratory therapist. Additional titration of NiPPV settings may be guided by reported participant symptoms and comfort, as per standard of care.
89552124|NCT05881031|Experimental|Home Initiation of NiPPV|NiPPV settings will be titrated during an awake NiPPV trial by the respiratory therapist. Once NiPPV equipment is obtained and NiPPV is used at home (time 0), further titration of the NiPPV settings will occur on an outpatient basis guided by remote telemonitoring and home overnight oximetries at 1, 4, and 12 weeks. Additional titration of NiPPV settings may be guided by reported participant symptoms and comfort, as per standard of care. Participants will complete an in-hospital PSG after 12 weeks, during which NiPPV settings are titrated during the night by a PSG technologist to determine optimal settings according to current international guidelines.
89552125|NCT05869071||Healthy volunteers|Participants with no chronic disease and no acute symptoms
89552126|NCT05869071||Patients with Allergic rhinitis or Nasal Polyps|Participants with allergic rhinitis or nasal polyps
89552127|NCT05869071||Patients with asthma|Participants with asthma
89552128|NCT05869071||Patients with COPD|Participants with Chronic Obstructive Pulmonary Disease
89552129|NCT05859178|Experimental|Exercise group|Each participant in the exercise group will undergo hand grip exercise for 30 minutes a day, 5 days a week for a total of 12 weeks. To activate the ulnar nerve innervated muscles, the exercise will be done using an electronic hand grip device with adjustable resistance individualized to the strength of each participant.
89552130|NCT05859178|Experimental|Control group|Participants will carry out a stretch exercise routine that is not known to have any effect on nerve regeneration.
89552131|NCT05848778|Active Comparator|Acute Intermittent Hypoxia|Patients with hand weakness and numbness secondary to median nerve entrapment and scheduled for carpal tunnel release surgery will be randomly assigned to receive acute intermittent hypoxia
89552132|NCT05848778|Placebo Comparator|Normoxia control|Patients with hand weakness and numbness secondary to median nerve entrapment and scheduled for carpal tunnel release surgery will be randomly assigned to receive normoxia
89552133|NCT05847543||Non-weaned Children|Children who have not started weaning food
89552134|NCT05847543||Weaned Children (Non-Caucasian)|Non-Caucasian children who have started weaning food
89552135|NCT05847543||Weaned Children (Caucasian)|Caucasian children who have started weaning food
89552136|NCT05842044|Experimental|Group 1: NSAID|Participants in this group will be prescribed NSAIDs instead of the standard of care treatment. Participants will be in this group for approximately 21 days.
89552137|NCT05842044|Active Comparator|Group 2: No-NSAID|Participants in this group will follow standard of care treatment. Participants will be in this group for approximately 21 days.
89552138|NCT05833373|Experimental|Verum group|Verum group - active vagal stimulation with the stimulation device tVNS from tVNS Technologies GmbH. The stimulation is performed with an ear-electrode at the Tragus. Minimal stimulation duration is 1 hour per day for 3 months.
89552139|NCT05833373|Sham Comparator|Sham group|Sham group with ineffective vagal stimulation. Same stimulation procedure like in the verum group with the stimulation device tVNS from tVNS Technologies GmbH. The stimulation is performed with an ear-electrode at the Tragus, too. Minimal stimulation duration is 1 hour per day for 3 months, but with a non conducting ear electrode.
89552140|NCT05793320|Experimental|Carpal Tunnel Release|
89552141|NCT05786274|Other|Cardiac surgery with cardiopulmonary bypass patients|Patients will be enrolled before cardiac surgery with cardiopulmonary bypass (CPB) and monitored until after the surgery. Patients enrolled will undergo diffusion weighted magnetic resonance imaging and will be administered with cognitive tests one day before surgery and within one week after surgery. Cerebral blood flow velocity as derived from transcranial Doppler recordings will be acquired from the middle cerebral artery synchronously with arterial pressure, invasively derived from the radial artery, and with the electrocardiogram as derived from patient's monitor. Signals will be acquired before anesthesia induction (BASAL), after anesthesia induction and intubation of the chest (ANESTH) and during CPB (CPB). Each acquisition will last at least 5 minutes and will be prolonged to the maximum possible length in keeping with clinical scheduling. Partial pressure of carbon dioxide and other clinical parameters will be acquired too during the intervention.
89552142|NCT05785585|Experimental|Methylcobalamin group|One capsule daily with 500 µg of methylcobalamin for 12 weeks
89025526|NCT01240044|Experimental|Thoracoabdominal rebalancing|In this group the newborns receive the thoracoabdominal rebalancing.
89552143|NCT05785585|Active Comparator|Cyanocobalamin group|One capsule daily with 500 µg of Cyanocobalamin for 12 weeks
89552144|NCT05785585|Placebo Comparator|Control group|One capsule daily with microcrystalline cellulose for 12 weeks
89552145|NCT05780892|Experimental|Emotional Wellbeing|This arm consists of 6 30-minute group sessions taking place every 2 weeks for a total of 12 weeks. The sessions will be led by licensed therapists based on cognitive behavioral therapy and acceptance and commitment therapy. Session topics are sequential in nature such that each session builds on the previous session. Between sessions, participants will complete worksheets based on the material covered in the previous session. If a participant misses a session, they will be provided with a pre-recording with the content they missed.
89025527|NCT00457223|Experimental|1Fibrin glue|After pterygium excision, amniotic membrane was shaped and attached to bare scleral area using fibrin glue (Quixil®)
89025528|NCT00457223|Active Comparator|2 Suture|After pterygium excision, amniotic membrane was shaped and attached to bare scleral area using continuous suture with nylon 10-0
89025529|NCT03278418|Experimental|Tricuspid Valve Repair|Concomitant tricuspid valve repair in patients undergoing left-sided valve surgery
89025530|NCT03278418|Active Comparator|left-sided valve surgery|No concomitant tricuspid valve repair in patients in pts undergoing left-sided valve surgery
89552146|NCT05780892|Experimental|EHR Skills Optimization|This arm consists of 6 individual educational sessions taking place every 2 weeks for a total of 12 weeks which will be scheduled to accommodate clinicians schedule and preferences. These sessions will be led by a member of the clinical informatics team and target optimization of the EHR. The sessions will be conducted on site, virtually, or a combination of both onsite and virtual. Between sessions participants are to note any challenges, questions, or recommendations related to the EHR. If participant misses 2 sessions, they will be asked to reschedule, but if they miss 3 sessions they may be asked to withdraw from the intervention.
89552147|NCT05780892|Experimental|Performance Improvement|This arm consists of 6 virtual group sessions taking place over every 2 weeks for a total of 12 weeks. The sessions target improving perceptions of the work environment through foundational performance improvement knowledge and skills, and they will be led by a member of the systems-reengineering team. Between sessions, participants will be asked to follow through on tasks outlined in the learning sessions and share in the next session. If a session is missed, they will be provided with a prerecording of the didactic material presented in the learning sessions.
89552148|NCT05780892|Active Comparator|Control|Participants randomly assigned to the control condition will continue as usual care and will not complete any intervention during the duration of the study.
89552149|NCT05778760|Active Comparator|Retinol|Product will be used once daily in the evening for 12 weeks. 1-2 pumps (size of quarter) of product will be applied on the face.
89552150|NCT05778760|Experimental|Adapinoid|Product will be used once daily in the evening for 12 weeks. 1-2 pumps (size of quarter) of product will be applied on the face.
89552151|NCT05777941|Experimental|Eccentric Training|This Group will train on the KREHA for 20 Trainings
89552152|NCT05762263|No Intervention|Control group|Habitual diet - healthy eating guidelines provided for ethical reasons, no restrictions on the time of eating
89552153|NCT05762263|Experimental|Flexitarian diet group|Flexitarian diet (FD) will be based on planetary diet recommendations (predominantly plants; pulses and legumes as protein sources, meat and poultry consumed occasionally). Ways to facilitate this diet will be presented in the booklet prepared for them by the PI and a dietitian.
89552154|NCT05762263|Experimental|Time-restricted eating group|Time restricted eating (TRE) with 6 hour eating window - start and end hour to be an individual choice (some may prefer to consume their meals within an early window, e.g. 10am-4pm, some may prefer to consume their meals later in the day, e.g. 12:00-6pm). However, participants will be asked to be fairly consistent with their choice of their timing of eating hours. During fasting only water will be permitted;
89552155|NCT05762263|Experimental|Flexitarian diet & time-restricted eating group|Treatment TRE and FD combined.
89552156|NCT05757908|Other|Long-Acting Beta Agonist|Standard of care LABA
89552157|NCT05753891|Experimental|Carpometacarpal (CMC) Suture Tape Ligament Reconstruction|Patients in this arm will undergo trapeziectomy with suture tape suspension of the 1st metacarpal to the 2nd metacarpal via Arthrex InternalBrace device. This is the experimental group.
89552158|NCT05753891|No Intervention|Carpometacarpal (CMC) Standard Ligament Reconstruction|Patients in this arm are considered the control group and will undergo trapeziectomy with ligament reconstruction and tendon interposition.
89552159|NCT05729256|Experimental|Self-Regulation Intervention|Single session motivational intervention on reducing heavy drinking and sexual risk behavior, encouraging consideration of pre-exposure prophylaxis (PrEP), followed by 4 weeks of text messages on content relevant to drinking goals and support for healthy sexual choices
89552160|NCT05729256|Active Comparator|Brief Advice and Information|Single session to provide psychoeducation about heavy drinking risks, discussion of barriers to safe sex, information about pre-exposure prophylaxis (PrEP)
89552161|NCT05727878|Experimental|Cohort 1, Arm 1|KPI-012 High Dose KPI-012 Ophthalmic Solution 3 U/mL 1 drop 4 times/day for 56 days
89552162|NCT05727878|Experimental|Cohort 2, Arm 1|KPI-012 Low Dose KPI-012 Ophthalmic Solution 1 U/mL 1 drop 4 times/day for 56 days
89552163|NCT05727878|Experimental|Cohort 2, Arm 2|KPI-012 High Dose KPI-012 Ophthalmic Solution 3 U/mL 1 drop 4 times/day for 56 days
89552164|NCT05727878|Placebo Comparator|Cohort 2, Arm 3|KPI-012 Vehicle KPI-012 Ophthalmic Solution 0 U/mL 1 drop 4 times/day for 56 days
89552165|NCT05704257|Experimental|fetoscopic surgical repair|Single arm study. All patients will receive the fetoscopic repair.
89552166|NCT05697094|Experimental|Meditation to Remove Stress and Create A Proper System in Mind|The study intervention will be administered to participants randomized to the intervention arm. The meditation intervention will be delivered virtually via the hospital-approved Microsoft Teams platform. Participants will be taught an evidence-based meditation technique which includes two online sessions (60 minutes/day) with a trained, experienced, and certified teacher of Prasanna Wellness, a non-profit service organization. Participants will learn how to respond to experiences that arise in meditation, will discuss what enhances or detracts from effective meditation, and review methods for meditating at home. The participants in the intervention arm will complete 60-minute follow-up sessions with the Prasanna Wellness staff which will include 33 minutes of guided meditation practice, and then a discussion of participants' experiences with meditation during the week, additional observations, and a review of relevant knowledge to support their home practice.
89552167|NCT05697094|No Intervention|Usual Care|Participants will continue with their usual care.
89025531|NCT03278379|Experimental|Intervention Arm|Treatment with Avelumab
89208115|NCT00867750|Active Comparator|TACE|Transarterial Chemoembolisation with embolising agent Embospheres and chemotherapeutic agent epirubicin
89208116|NCT00787436|No Intervention|1|Standard of care with normal treatment
89208117|NCT00787436|Active Comparator|Thalidomide|Standard of care and treatment using Thalidomide
89025532|NCT01240083|Experimental|Thetaburst Stimulation|1: Thetaburst stimulation: right DLPFC continuous TBS followed by left DLPFC intermitted TBS each with 50 Hz, together 1200 stimuli, 80% motorthreshold
89025533|NCT01240083|Experimental|High frequency rTMS|2: Experimental high frequency rTMS ( Alpine Biomed Mag Pro Option) : 1000 stimuli of 1 Hz over the right DLPFC, 110% motor threshold, followed by 1000 stimuli of 10 Hz over the left DLPFC , 110% motorthreshold
89552168|NCT05685368|Experimental|Acceptance Commitment Therapy|This study will use a 10-session ACT protocol to support Black adolescents and young adults in coping with race related stress.
89025534|NCT01240083|Experimental|Placebo Stimulation|3: Sham Stimulation (Sham coil): right DLPFC continuous TBS, followed by left DLPFC intermitted TBS each with 50 Hz, together 1200 Stimuli, 80% motorthreshold
89552169|NCT05680597|Experimental|Supervised Tele-Rehabilitation Home Exercise|40 participants will have tele-rehabilitation virtually with a physical therapist for 60 minutes approximately three times per week for four weeks of intervention (12 visits). Participants will also be assessed for daily life mobility for seven days pre and post intervention with wearable sensors.
89552170|NCT05680597|Active Comparator|Unsupervised Rehabilitation Home Exercise|40 participants will complete their home exercise Agility Boot Camp (ABC) program for 60 minutes approximately three times per week for four weeks of intervention (12 sessions). Participants will also be assessed for daily life mobility for seven days pre and post intervention with wearable sensors.
89552171|NCT05676593|Active Comparator|People living with diabete standard TPE|HBA1c at 3 and 6 months Therapeutic education Auto questionnary on Aviitam plateform at 3 and 6 months
89552172|NCT05676593|Experimental|People living with diabete standard TPE + FSL 28 days|"Continuous mesure of glucose (FSL2) during 28 days at enrollment Therapeutic education HBA1c at 3 and 6 months Auto questionnary on Aviitam plateform at 3 and 6 months~Auto questionnary on Aviitam plateform at 3 and 6 months"
89552173|NCT05667116||EVUSHELD arm|3,000 Individuals given EVUSHELD for pre-exposure prophylaxis
89552174|NCT05667116||Concurrent Control arm|3,000 individuals eligible for EVUSHELD pre-exposure prophylaxis but did not receive Evusheld
89552175|NCT05660265|Experimental|Cohort 1|Participants in this arm will receive either single dose of GSK4172239D (Dose 1) or matching placebo.
89552176|NCT05660265|Experimental|Cohort 2|Participants in this arm will receive either single dose of GSK4172239D (Dose 2) or matching placebo.
89552177|NCT05660265|Experimental|Cohort 3|Participants in this arm will receive either single dose of GSK4172239D (Dose 3) or matching placebo.
89552178|NCT05660265|Experimental|Cohort 4|Participants in this arm will receive either single dose of GSK4172239D (Dose 4) or matching placebo.
89552179|NCT05660265|Experimental|Cohort 5|Participants in this arm will receive either single dose of GSK4172239D (Dose 5) or matching placebo.
89552180|NCT05660265|Experimental|Food effect cohort|One selected cohort will also receive an additional single dose of GSK4172239D (or matching placebo) under fed (high calorie and high fat) conditions.
89552181|NCT05655312|Experimental|Dose Escalation|"Dose Escalation to determine MTD/MFD among 4 different dose levels in up to 32 patients receiving up to 3 administrations of [212Pb]VMT01 approximately 8 weeks apart.~The second part of the study is a dose expansion based on the identified MTD/MFD for the selection of [212Pb]VMT01 dose(s) in up to 20 additional subjects for further clinical development.~A dosimetry sub-study utilizing [203Pb]VMT01 has been incorporated into the study."
89552182|NCT05655312|Experimental|Dose Expansion with RPh2D|Up to 20 patients with advanced or metastatic melanoma
89552183|NCT05647850||Baseline characteristics of all patients|
89552184|NCT05647850||General characteristics of the patients.|
89552185|NCT05641311|Experimental|Cohort 1: Japanese Participants|All Japanese participants will receive a single dose of ALXN1840 15 milligrams (mg) in Dosing Period 1 and will receive a single dose of ALXN1840 60 mg in Dosing Period 2.
89552186|NCT05641311|Experimental|Cohort 2: Non-Japanese Participants|All non-Japanese participants will receive a single dose of ALXN1840 15 mg in Dosing Period 1 and will receive a single dose of ALXN1840 60 mg in Dosing Period 2.
89552187|NCT05638373|Experimental|One shade universal composite|shade matching composite
89552188|NCT05638373|Active Comparator|Nanohybrid resin composite|Conventional Nanohybrid resin composite
89552189|NCT05638204|Experimental|Intervention Group|Participants in the intervention group received the Suicidal Crisis Intervention( SCI) in addition to their treatment as usual.
89552190|NCT05638204|No Intervention|Control Group|Participants in the control group received their treatment as usual.
89552191|NCT05635214||Patients with RUQ or Flank Pain|These are patients who present to the emergency department with abdominal pain or flank pain.
89552192|NCT05634525|Experimental|MRTX849 (Adagrasib)|Helps to control pancreatic cancer that has a KRAS G12 mutation.
89552193|NCT05633225||Patient-group|Ninety adolescents, 13-17 years of age Diagnosed with Hypermobility Spectrum Disorder or hypermobile Ehlers Danlos Syndrome.
89552194|NCT05633225||Control-group|Ninety adolescents, 13-17 years of age. Participants have to be pain free at time of investigation (NRS score <3/10)
89552195|NCT05633082|Experimental|Lens 1|All participants wore Lens 1 for 15 minutes (Period 1)
89552196|NCT05633082|Experimental|Lens 2|All participants wore Lens 2 for 15 minutes (Period 2)
89552197|NCT05619237|No Intervention|Control Period|"Patients receive the current standard of care for their chronic wound in the first four weeks of enrollment~Standard of care (SOC) involves:~Offloading of pressure as needed~High compression bandaging, as needed~Debridement, as needed~Nutrition management, as needed~SOC dressings, such as silver/iodine dressings, antibiotic ointment~Management of infection~Management of pain during debridement, as needed"
89552198|NCT05619237|Experimental|Intervention Period|Patients receive the intervention, NanoSALV wound dressing, in the consecutive four weeks following the control period
89552199|NCT05613972|Experimental|Brief Suicide and Trauma Therapy (BSTT)|This novel suicide intervention integrates Brief Skills for Safer Learning (B-SfSL) with trauma therapy. BSTT incorporates the guiding principles of taking a non-pathologizing approach to treatment, emphasizing safety, attending to the therapeutic relationship, empowering clients, and incorporating solution-focused concepts.
89025535|NCT02956538|Experimental|thalidomide|thalidomide 100mg tablet by mouth, every night for 8 weeks
89025536|NCT02956538|Active Comparator|placebo|placebo (for thalidomide) 100mg tablet by mouth, every night for 8 weeks
89025537|NCT01240161||Patients with high grade gliomas|All subjects will have radiographically suspected or surgically proven de novo high grade gliomas. There are no control patients.
89025538|NCT00457496|Active Comparator|A|
89552200|NCT05594147||TKIs treated group|Adult cancer patients with newly diagnosed COVID-19 who used Tyrosine kinase inhibitors (TKIs) within 30 days before COVID-19 diagnosis.
89552201|NCT05594147||Non-TKIs treated group|Adult cancer patients with newly diagnosed COVID-19 who used other anti-cancer therapies 30 days before COVID-19 diagnosis
89552202|NCT05592613|Experimental|PrEP Participants|Participants will ingest one Truvada digital pill as PrEP per day, for 30 days total, while using the next-generation Reader and ID-Cap System.
89552203|NCT05592613|Experimental|ART Participants|Participants will ingest one Biktarvy digital pill as ART per day, for 30 days total, while using the next-generation Reader and ID-Cap System.
89552204|NCT05592600|Experimental|Neurofeedback|Subjects will undergo one session where they will visualize real-time feedback of signals recorded from their brains.
89552205|NCT05591105||Group A:|At the end of surgery, on the recovery room, this group will receive lidocaine (1 mg/kg/h) and Ketamine (0,15 mg/kg/h) for 90 minutes
89552206|NCT05591105||Group B:|At the end of surgery, on the recovery room, this group will receive placebo (normal salin solution) for 90 minutes
89552207|NCT05590832|Experimental|İnitiative group|"All pregnant women participating in the study were divided into intervention and control groups by applying randomization. Pre-test data of both groups will be collected before 18th gestational week, and post-test data will be collected after 37th gestational week.~Pregnant women assigned to the initiative group were added to a group established via Whatsapp. Information messages will be sent via Whatsapp on Mondays, Wednesdays and Fridays for the first 10 weeks / three times a week (up to the 28th week), and reminder messages will be sent once a week on Wednesdays between the 29th-36th weeks. When necessary, individual messages will be sent to the pregnant women and special directions will be given according to their weight gain rates."
89552208|NCT05590832|No Intervention|Control group|In the same way, a Whatsapp group will be set up to the control group and messages will be sent once a month about the subjects included in antenatal care up to 37 weeks. Topics included in routine maintenance will be included.
89552209|NCT05583435|Experimental|One-on-one professional coaching|"One-on-one professional coaching (N=30). Six one-on-one coaching sessions via Zoom with one of two private professional coaches every other week for 3 months.~The professional coaching method includes (but will not be limited to) the following themes: optimizing meaning and engagement in work, building social support and community, improving work efficiency, addressing workload and boundary setting, enhancing communication, and building leadership skills, pursuing hobbies and creation/innovation, and promoting self-compassion and self-care (with a focus on physical and mental health)."
89552210|NCT05583435|Experimental|Small-group professional coaching with coach-guided activities/behavioral internventions|"Coach-facilitated small group professional coaching sessions and coach-guided activities/behavioral interventions (N=30). Six small-group coaching sessions via Zoom with one of two private professional coaches and three physician participants in each group, every other week for 3 months. Group 2 includes coach-guided activities/behavioral interventions in addition to small group coaching sessions. These activities will be sent by coaches to participates throughout the 3 month period and include, but are not limited to: Wheel of Life, visioning exercise, one page miracle: core values, purpose, and goals, buckets and mental models.~The professional coaching method is similar to those receiving 1:1 professional coaching. The primary difference in this intervention group is that coaching sessions will be group-based with 3 physician participants and they will also be receiving behavioral interventions/activities in between group sessions, sent by coaches directly to participants."
89552211|NCT05583435|Experimental|Delayed-entry group (placebo then one-on-one professional coaching)|"Delayed-Entry Group 3 (N=30). No intervention during the 90 day study period. Note: once participation in the pilot study has been completed for Groups 1 and 2, physicians participating in Group 3 will be offered to participate in six one-on-one sessions with a private professional coach over a 3 month period.~The professional coaching method includes (but will not be limited to) the following themes: optimizing meaning and engagement in work, building social support and community, improving work efficiency, addressing workload and boundary setting, enhancing communication, and building leadership skills, pursuing hobbies and creation/innovation, and promoting self-compassion and self-care (with a focus on physical and mental health)."
89552212|NCT05580107|Experimental|Dose|"Five patients will be included into the 24 mg dose level. In case of dose limiting toxicity (DLT) in at least one patient, 5 additional patients will be enrolled in the 24 mg dose level.~If the treatment is well tolerated, i.e. no DLT is encountered, the dose of MDPK67b is escalated to 48 mg on a second cohort of 5 patients. In case of DLT in at least one patient at the 48 mg dose level, the 24 mg dose level of MDPK67b is expanded from 5 to 10 patients, or declared the maximum tolerated dose (MTD) if already expanded to 10 patients."
89552213|NCT05567601|Active Comparator|Current Manufacturing Site|On Day 1 of Cycle 1 of the open-label treatment phase, patients will be randomized to receive drug from either current or new manufacturing site, and then after 28 days cross-over to the drug produced from the other manufacturing site in Cycle 2.
89552214|NCT05567601|Experimental|New Manufacturing Site|On Day 1 of Cycle 1 of the open-label treatment phase, patients will be randomized to receive drug from either current or new manufacturing site, and then after 28 days cross-over to the drug produced from the other manufacturing site in Cycle 2.
89552215|NCT05567055|Experimental|Capmatinib|400 mg orally, twice daily
89552216|NCT05566002||Patients with pulmonary hypertension|A series of routine examinations, including chest X-ray, electrocardiography, echocardiography, etc, would be performed on consecutive patients at Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. An RHC with an mPAP of >20 mmHg would confirm the diagnosis of PH. All these data will be collected as a source for machine learning or other artificial intelligence-assisted programs.
89025539|NCT01240239||telephone group|The telephone group must be healthy adults scheduled for an ENT surgery.
89025540|NCT01240239||telemedicine group|This group if qualified will randomly be chosen to be in the telemedicine group.
89025541|NCT01240239||pre-anesthesia consultation|This will be the group that will be randomized to the pre-anesthesia clinic.
89025542|NCT00443586|Active Comparator|Developmental Screening|Participants received sensory and developmental screening and referral for further evaluation and treatment of suspected problems at 12 and 24 months of age.
89025543|NCT00443586|Active Comparator|Screening plus Transportation|Participants received sensory and developmental screening and referral for further evaluation and treatment of suspected problems at 12 and 24 months of age; their mothers received free transportation for regular prenatal and well-child care (through child age two).
89025544|NCT00443586|Active Comparator|Screening, Transport, Prenatal Visits|Participants received sensory and developmental screening and referral for further evaluation and treatment of suspected problems at 12 and 24 months of age; their mothers received free transportation for regular prenatal and well-child care (through child age two), plus nurse home visiting during pregnancy.
89552217|NCT05566002||Patients without pulmonary hypertension|A series of routine examinations, including chest X-ray, electrocardiography, echocardiography, etc, would be performed on consecutive patients at Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. An RHC with an mPAP of ≤20 mmHg would confirm the absence of PH. All these data will be collected as a source for machine learning or other artificial intelligence-assisted programs.
89552218|NCT05565586|Experimental|High-Fiber Diet (HFD) Intervention|Participants are expected to eat only the study meals and snacks provided
89552219|NCT05565586|Experimental|Prebiotic Food-Enriched Diet (PreFED) Intervention|Participants are expected to incorporate study snacks and meal components provided into your usual diet.
89552220|NCT05558007|Active Comparator|Daily oral Tadalafil 5mg + Topical Placebo|Patient that underwent Radical Prostatectomy will receive daily oral Tadalafil 5mg and topical placebo
89552221|NCT05558007|Experimental|Daily oral placebo + topical BZ371A|Patient that underwent Radical Prostatectomy will receive daily oral placebo and topical BZ371A
89552222|NCT05558007|Active Comparator|Daily oral Tadalafil 5mg + topical BZ371A|Patient that underwent Radical Prostatectomy will receive daily oral Tadalafil 5mg and topical BZ371A
89552223|NCT05555550|Experimental|18F-Fluciclovine|18F-Fluciclovine PET-MRI
89552224|NCT05543187|Experimental|TAK-625, Primary cohort|TAK-625 orally, twice daily (BID) for 4 weeks as Dose Escalation Period. The dose in Dose Escalation Period will be increased weekly, 150 mcg/kilograms (kg), 300 mcg/kg, 450 mcg/kg, and 600 mcg/kg. After Dose Escalation Period, TAK-625 600 mcg/kg (or maximum tolerated dose [MTD]), orally, BID up to study completion.
89552225|NCT05543187|Experimental|TAK-625, Supplemental cohort|TAK-625 orally, twice daily (BID) for 4 weeks as Dose Escalation Period. The dose in Dose Escalation Period will be increased weekly, 150 mcg/kilograms (kg), 300 mcg/kg, 450 mcg/kg, and 600 mcg/kg. After Dose Escalation Period, TAK-625 600 mcg/kg (or maximum tolerated dose [MTD]), orally, BID up to study completion.
89552226|NCT05543174|Experimental|TAK-625|TAK-625 200 mcg per kilogram, orally, once daily for 1 week. After that, TAK-625 400 mcg per kilogram, orally, once daily after Week 1.
89552227|NCT05532007|Active Comparator|Peanut Group|Peanuts: 2-3 ounces per day to replace 20% of daily energy intake
89552228|NCT05532007|Active Comparator|Control Group|Habitual diet abstain from eating peanuts
89552229|NCT05528263|Experimental|Acupuncture|"Breast cancer patients will be recruited who are scheduled to receive taxane-based chemotherapy (with or without anti-HER2 therapy) and who have no neuropathic symptoms at baseline.~40 participants will be randomized into the acupuncture Arm:~The acupuncture arm will receive a standardized acupuncture protocol 1-2 times a week for 12 weeks (a total of 14 sessions)."
89552230|NCT05528263|Active Comparator|Nature scenery videos with relaxation exercise|"Breast cancer patients will be recruited who are scheduled to receive taxane-based chemotherapy (with or without anti-HER2 therapy) and who have no neuropathic symptoms at baseline.~40 Participants will be randomized into the Control Arm:~The control arm will receive and watch videos with nature scenery with a relaxation exercise guide 1-2 times a week for 12 weeks (a total of 14 sessions)"
89552231|NCT05514587||Suicidal act|Patients who has committed a suicidal act
89552232|NCT05514587||Suicidal thoughts without acting on them|Patients with suicidal thoughts without acting on them
89552233|NCT05514587||No suicidal ideation or acting out|Patients without suicidal ideation or acting out of patients in crisis admitted to the Crisis Center
89552234|NCT05502289|Experimental|TEST/CONTROL|Eligible subjects will be randomized to the wear sequence (TEST/CONTROL) to wear the study lenses during each dispensing period (1 week) with a wash-out period (1 week) between wear periods.
89552235|NCT05502289|Experimental|CONTROL/TEST|Eligible subjects will be randomized to the wear sequence (CONTROL/TEST) to wear the study lenses during each dispensing period (1 week) with a wash-out period (1 week) between wear periods.
89552236|NCT05497726|Experimental|Sentinel lymph node detection using intravenous bevacizumab-800CW|Sentinel lymph node detection using intravenous bevacizumab-800CW
89552237|NCT05494060|Experimental|Penpulimab + Anlotinib + XELOX|Penpulimab in combination with Anlotinib and XELOX (Capecitabine and Oxaliplatin)
89552238|NCT05494060|Active Comparator|XELOX|XELOX (Capecitabine and Oxaliplatin)
89552239|NCT05490121|Active Comparator|Facilitator-Led VEGA|"Facilitator-led VEGA uses a group-based approach where participants complete the Violence, Evidence, Guidance, Action Project (VEGA) content as a virtual or face-to-face workshop. In this study, all workshops will be virtual to prevent social gathering during COVID-19.~If a participant is randomized to this arm, the active control (AC) arm, they will be informed that they need to attend a facilitator-led VEGA session via virtual workshop format. The AC intervention will be facilitated via Zoom technology, by two trained facilitators with between 10 to 20 participants in each workshop (keeping the recommended 10:1 participant-to-facilitator ratio) and will last approximately 3 hours. The workshop approach is delivered by trained facilitators and is standardized via the use of a flexibly structured facilitator's guide. Facilitator-led VEGA will deliver material didactically with synchronous lecturing, use case-based role play, and include group-based polling."
89033039|NCT02922075|Experimental|CTG|Patient received a connective tissue graft. It was performed tooth extraction, immediate implant, immediate restoration, bone regeneration, post operative medication and definitive prosthesis.
89025545|NCT00443586|Experimental|Screen, Transport, Prenatal/Inf Visits|Participants received regular sensory and developmental screening and referral for further evaluation and treatment of suspected problems at 12 and 24 months of age; their mothers received free transportation for regular prenatal and well-child care (through child age two), plus nurse home visiting during pregnancy and through child age two.
89025546|NCT00481026|Sham Comparator|Placebo|Placebo tDCS
89552240|NCT05490121|Experimental|Self-Directed VEGA|"Self-directed VEGA uses an approach where participants complete the Violence, Evidence, Guidance, Action Project (VEGA) content online as a self-directed educational activity, at their own pace in a series of modules. Individuals will register to access the VEGA Educational Resources site. Participants have the option of completing the self-directed VEGA arm in either English or French as the VEGA Educational Resources site offers the content in French and English.~If a participant is randomized to the experimental arm, they will be asked to complete the self-directed VEGA at their convenience, within one week of when they are informed they have been asked to complete the self-directed VEGA program. It will take approximately 3 hours for participants to complete all modules.~Participants will read didactic material, complete case-based animated simulations, and complete individual multiple-choice questions with response feedback."
89552241|NCT05478707|Placebo Comparator|Placebo|Saline subcutaneous injection, volume matched to dulaglutide, i.e. 0.5 mL weekly for 14 weeks
89552242|NCT05478707|Active Comparator|Dulaglutide|Dulaglutide (0.75 mg/0.5 mL weekly for 2 weeks, then 1.5 mg/0.5 mL weekly for 12 weeks) subcutaneous injection
89552243|NCT05478707|Active Comparator|Exercise training|Supervised high intensity interval training on a stationary bicycle will be conducted 3 days per week for 14 weeks. Participants will warm up at low intensity for 3 min then repeat 1-min bouts of 100% peak power output followed by 1-min recovery at 50 W. Training will start with 6 intervals per session, increasing by 2 intervals every 2 weeks. Sessions will end with a 10-min cool-down.
89552244|NCT05476718|Active Comparator|kinesio group|"The tape will be applied in the first 24 hours postoperatively and on the 5th, 10th, 15th days of the surgery. The posterior superior iliac spine (PSI) and 12th thoracic vertebra (T12) will be marked while the participant is sitting in a comfortable position. Tape application will be made bilaterally between PSI and T12 with tapes cut in an I shape along the erector spine muscles. The anchor and end parts of the tape will be rounded. The anchor part will be glued without tension. Afterward, individuals are asked to flex and rotate their trunks as much as possible, and the middle part of the band is slightly stretched 10-15%; After the spine is brought to its normal anatomical position, the tip will be glued without tension. After sticking, the tape will be manually activated. This transaction will be carried out by both parties. After the tape adheres, individuals will be asked to keep the tape for five days until the next taping."
89552245|NCT05476718|Placebo Comparator|placebo group|The tape will be applied in the first 24 hours postoperatively and on the 5th, 10th, 15th days of the surgery. The placebo-tape application will be applied the lumbar region in a tension-free and horizontal form, while the spine is in a neutral position without positioning the patients. After sticking, the tape will be manually activated. After the tape adheres, individuals will be asked to hold the tape for five days until the next taping.
89552246|NCT05469347|Experimental|Alirocumab|Critically ill participants with sepsis leading to cardiovascular and/or respiratory failure who are randomized to receive alirocumab.
89552247|NCT05469347|Placebo Comparator|Placebo|Critically ill participants with sepsis leading to cardiovascular and/or respiratory failure who are randomized to receive a placebo to match alirocumab.
89552248|NCT05462938|Active Comparator|Propofol group|Continuous infusion of propofol
89552249|NCT05462938|Active Comparator|Dexmedetomidine group|Continuous infusion of dexmedetomidine
89552250|NCT05459935|Experimental|PBM Tonsil Arm|Photobiomodulation exposure of hypertrophic tonsils
89552251|NCT05459935|Sham Comparator|Tonsil Control Arm|Sham (non-powered) exposure of hypertrophic tonsils
89025547|NCT00481026|Active Comparator|active tDCS|active tDCS
89025548|NCT00457652|Active Comparator|1|7 day treatment rosuvastatin
89025549|NCT00457652|Placebo Comparator|2|7 day treatment placebo
89025550|NCT00457769|Experimental|Aricept- A|Half of subjects are randomized to immediate treatment with donepezil 5mg orally daily following baseline testing, with retesting at 12 and 24 weeks.
89208118|NCT03945981|Experimental|Participants receiving Dolutegravir + Lamivudine FDC|Participants will receive DTG 50mg and 3TC 300 mg FDC tablet orally once daily (OD) with or without food
89552252|NCT05456542|Experimental|Intervention - Cuff Leak Test|A respiratory therapist will perform a Cuff Leak Test on all patients prior to extubation. If no air leak is auscultated (a failed CLT), extubation will be delayed. During this time, the patient will receive dexamethasone 4mg intravenous every 6 hours for 12-24 hours and the clinical team will be advised to consider optimizing a patient's fluid status through either diuresis or ultrafiltration if the patient has renal failure. After 12-24 hours, and once the clinical team decides the patient is ready for another extubation attempt, the CLT will be repeated. If the patient fails the CLT again, it will be at the discretion of the clinical team how to proceed (i.e. continue steroid administration, and further delay extubation vs immediately extubating despite a failed CLT) (Figure 3). A passed CLT at any time point will result in immediate extubation.
89552253|NCT05456542|No Intervention|Control - No Cuff Leak Test|In the control group, once the patient is deemed ready for extubation by the clinical team, the patient will be extubated without performing a CLT, without administration of corticosteroids, and without delay.
89552254|NCT05455086|Experimental|Arm I (pronated e-liquid, unprotonated e-liquid|"VISIT 2: Patients receive 1 puff of tobacco flavored or unflavored protonated e-liquid and undergo 0-15 min head and 5 min chest PET?CT and then 0-15 min chest and 5 min head PET/CT. About 2 hours post initial PET/CT, patients receive a second puff of tobacco flavored or unflavored protonated e-liquid and undergo 0-15 min chest and 5 min head PET/CT and then 0-15 min head and 5 min chest PET/CT.~VISIT 3: Patients receive 1 puff of tobacco flavored or unflavored unprotonated e-liquid and undergo 0-15 min head and 5 min chest PET/CT and then 0-15 min chest and 5 min head PET/CT. About 2 hours post initial PET/CT, patients receive a second puff of tobacco flavored or unflavored protonated e-liquid and undergo 0-15 min chest and 5 min head PET/CT and then 0-15 min head and 5 min chest"
89552255|NCT05455086|Active Comparator|Arm II (unprotonated e-liquid, protonated e-liquid|"VISIT 2: Patients receive 1 puff of tobacco flavored or unflavored unprotonated e-liquid and undergo 0-15 min head and 5 min chest PET/CT and then 0-15 min chest and 5 min head PET/CT. About 2 hours post initial PET/CT, patients receive a second puff of tobacco flavored or unflavored unprotonated e-liquid and undergo 0-15 min chest and 5 min head PET/CT and then 0-15 min head and 5 min chest.~VISIT 3: Patients receive 1 puff of tobacco flavored or unflavored protonated e-liquid and undergo 0-15 min head and 5 min chest PET/CT and then 0-15 min chest and 5 min head PET/CT. About 2 hours post initial PET/CT, patients receive a second puff of tobacco flavored or unflavored protonated e-liquid and undergo 0-15 min chest and 5 min head PET/CT and then 0-15 min head and 5 min chest PET/CT."
89552256|NCT05445921|Experimental|Stellate Ganglion Block|The ultrasound guided stellate ganglion blocks will be performed by a pain management specialist with extensive experience performing these blocks. The first SGB at the initial visit will be performed on the right side, and the second SGB will be on the left side 5-10 days after the first SGB, given that the patient tolerated the first SGB.
89552257|NCT05444478|Experimental|Microwave ablation|Patients only accepted microwave ablation
89552258|NCT05444478|Experimental|Microwave ablation plus lenvatinib|Patients accepted microwave ablation plus lenvatinib
89552259|NCT05434637|Experimental|Individualized Physiotherapy|Individuals randomized to this group will receive physical therapy, personalized for the participant's specific needs, and include exercises to be performed at home.
88961899|NCT02885337|Experimental|Multi-Modal Frailty Intervention|"Exercise: A physiotherapist will develop an individualized exercise program and schedule appointments with patients at a physiotherapist clinic. Participants will be offered free YMCA membership.~Cognitive-behavioural Change Strategy(CBCS) and education: Throughout the intervention, CBCS and education about exercise, hip or knee arthroplasty and osteoarthritis will be administered.~Protein Supplement: Participants will be provided with 1-2 daily supplements (containing 20-40 gram protein, 1.5 g β-Hydroxy β-Methylbutyrate /serving) to be taken with a meal or on activity days within 3-hours of exercise.~Vitamin D: All participants in the intervention arm will be provided with a supply of Vitamin D3 (1000 IU/day tablets) for the duration of the intervention period.~Medication Review: A geriatrician will review the medications for patients in the intervention arm."
88961900|NCT02807506|Experimental|Aim 1 (Survey): Elders|Observe Elders, Clinicians and Caregiver's survey, interview and observational responses to stage-wise experimental deployments of a mobile service robot - 1st concept (elders, clinicians, caregivers), 2nd mobile base (elders only), and 3rd mobile base with arm in daily supportive tasks (elders only)
88961901|NCT02807506|Experimental|Aim 1 (Survey): Clinicians|Observe Elders, Clinicians and Caregiver's survey, interview and observational responses to stage-wise experimental deployments of a mobile service robot - 1st concept (elders, clinicians, caregivers), 2nd mobile base (elders only), and 3rd mobile base with arm in daily supportive tasks (elders only)
88961902|NCT02807506|Experimental|Aim 1 (Survey): Caregivers|Observe Elders, Clinicians and Caregiver's survey, interview and observational responses to stage-wise experimental deployments of a mobile service robot - 1st concept (elders, clinicians, caregivers), 2nd mobile base (elders only), and 3rd mobile base with arm in daily supportive tasks (elders only)
88961903|NCT02807506|Experimental|Aim 2: Deployment 1 (Elders)|Observe Elders, Clinicians and Caregiver's survey, interview and observational responses to stage-wise experimental deployments of a mobile service robot - 1st concept (elders, clinicians, caregivers), 2nd mobile base (elders only), and 3rd mobile base with arm in daily supportive tasks (elders only)
88961904|NCT02807506|Experimental|Aim 2: Deployment 2 (Elders)|Observe Elders, Clinicians and Caregiver's survey, interview and observational responses to stage-wise experimental deployments of a mobile service robot - 1st concept (elders, clinicians, caregivers), 2nd mobile base (elders only), and 3rd mobile base with arm in daily supportive tasks (elders only)
88961905|NCT02787499|No Intervention|Standard of Care|Follows the 2013 World Health Organization (WHO) HIV treatment guidelines. Study participants will receive adherence support and return for a repeat viral load test in 3 months (or in 1 month for pregnant participants). Treatment failure will be defined by two consecutive viral load measurements greater than 1,000 copies/mL. Participants who meet this criteria will be switched to second-line therapy. Those with a viral load <1,000 copies/mL at repeat testing will be retained on first-line therapy.
89552260|NCT05434637|Active Comparator|Sound-based Therapy|Individuals randomized to this group will receive sound-based therapy, consistent with an audiology-based standard of care treatment.
89552261|NCT05434637|Experimental|Combination Therapy|Individuals randomized to this group will receive both individualized physical therapy and sound-based therapy.
89552262|NCT05424120|Active Comparator|Manual aspiration|pleural fluid is drained using a standard thoracentesis kit and via a syringe and three-way stopcock
89552263|NCT05424120|Active Comparator|Wall suction|pleural fluid is drained using a standard thoracentesis kit and by attaching tubing to wall suctioning set at -50 mmHg continuously
89552264|NCT05424120|Active Comparator|Vacuum bottle drainage|pleural fluid is drained using a standard thoracentesis kit and tubing that attaches to a glass vacuum container
89552265|NCT05419232|Active Comparator|Short Message Service (SMS) with an associated link to a multi-media website|The participant will receive a SMS with a brief message containing the following: (1) statement encouraging them to get vaccinated and (2) a link to a multi-media page with videos and additional resources encouraging individuals to be vaccinated. The multi-media website will be housed in the Safe Return To School website and updated by a designated study team members. This page will include the following COVID-19-related resources: publicly available vaccine promotion videos, videos consisting of community members discussing vaccine topics, resources regarding local vaccine sites, and links to additional literature resources.
89552266|NCT05419232|Active Comparator|Phone Call with Peer|The participant's peer will be a study team member who has the same or similar racial demographic as the participant. All team members conducting the peer phone calls will be trained in motivational interviewing. The participant will be called by their peer via zoom or phone. Motivational interviewing techniques will be utilized with the participant to promote vaccine uptake. The team member will use a facilitator guide throughout the peer intervention.
89552267|NCT05384665|Experimental|Group A (placebo + remifentanil)|
89552268|NCT05384665|Experimental|Group B (sufentanil + placebo)|
89552269|NCT05384665|Placebo Comparator|Group C (placebo + placebo)|
89552270|NCT05361382|Experimental|Individuals across the aging and Alzheimer's disease (AD) spectrum|Approximately 620 individuals (40 young healthy, 280 cognitively unimpaired older, 200 mild cognitive impairment, and 100 Alzheimer's disease dementia) will be enrolled in the HEAD study.
89552271|NCT05350696|Active Comparator|Erector Spinae Plane block group|(30 patients) will receive bilateral ultrasound guided erector spinae plane block using plain bupivacaine 100 mg diluted to volume using normal saline to achieve 50% concentration ( 50 mg plain pubivicaine in each side ).
89552272|NCT05350696|Active Comparator|Intravenous Morphine group|(30 patients) will receive 0.1 mg /kg of intravenous morphine diluted to 10 ml volume using saline at the end of the operation.
89552273|NCT05343182|Active Comparator|Modified Vestibulectomy|
89552274|NCT05343182|Active Comparator|Traditional Vestibulectomy|
89552275|NCT05339360||ZNN Bactiguard Antegrade Femoral Nail|Subjects that have received or will receive the ZNN Bacitugard Antegrade Femoral Nail to treat femoral fractures or osteotomies according to the cleared/approved indications.
89552276|NCT05337553|Experimental|taldefgrobep alfa|"taldefgrobep alfa - Double-blind (DB) Phase: Participants receive weight based 35 mg/50 mg weekly subcutaneous injection for 48-week DB phase.~taldefgrobep alfa/taldefgrobep alfa - Extension Phase: Participants receive weight based 35 mg/50 mg weekly subcutaneous injection for 48-week Open label Extension (OLE) phase."
89552277|NCT05337553|Placebo Comparator|Placebo|"Placebo - Double-blind (DB) Phase: Participants receive weight based 35 mg/50 mg weekly subcutaneous injection for 48-week DB phase.~Placebo/taldefgrobep alfa - Extension Phase: Participants who receive placebo during DB phase, receive weight based 35 mg/50 mg weekly subcutaneous taldefgrobep alfa injection for 48-week OLE phase."
89552278|NCT05336383|Experimental|Radiation Therapy|Radiation treatment will be to bony or soft tissue plasmacytomas in up to five radiation treatment fields to 10-20Gy (or equivalent dose in 2Gy fractions of 10-21Gy
89552279|NCT05336266|Experimental|Ketorolac (open label)|Pancreatic patients receiving Ketorolac four times a day for up to five days
89552280|NCT05333939|Experimental|Moringa|4 g moringa leaf powder in green capsules divided into 4 capsules twice daily x 7 days
89552281|NCT05333939|Placebo Comparator|Control|comparable weight green capsules with cornstarch divided into 4 capsules twice daily x 7 days
89552282|NCT05329038|Experimental|Adult group|90 subjects aged 18-59 years received two dose inactivated COVID-19 vaccine in primary immunization will receive the booster immunization (the third dose )of inactivated COVID-19 vaccine.
89552283|NCT05329038|Experimental|Elderly group|90 elderly aged 60 year and older received two dose inactivated COVID-19 vaccine in primary immunization will receive the booster immunization (the third dose )of inactivated COVID-19 vaccine.
89552284|NCT05321394|Active Comparator|Sotrovimab|Sotrovimab 500 mg administered in 100 mL prefilled 0.9% sodium chloride injection infusion solution over 1/2 hour
89552285|NCT05321394|Experimental|Tixagevimab Cilgavimab|300 mg of tixagevimab and 300 mg of cilgavimab administered as two separate consecutive intramuscular injections
89552286|NCT05321394|Experimental|Nirmatrelvir Ritonavir|300 mg nirmatrelvir (two 150 mg tablets) with 100 mg ritonavir (one 100 mg tablet) with all three tablets taken together twice daily for 5 days
89552287|NCT05304065|Active Comparator|SAFETY-Acute within Usual ED Care|The SAFETY-Acute (A) approach to safety planning and stabilization will be integrated within usual ED Care. SAFETY-A was formerly called the Family Intervention for Suicide Prevention, FISP.
89552288|NCT05304065|Active Comparator|Combined|The combined treatment arm includes both 1) SAFETY-A integrated within usual ED Care, and 2) therapeutic follow-up contacts using the Coping Long Term with Active Suicidality Program (CLASP) model.
89033040|NCT02944487|Experimental|Single ascending doses of lucerastat|Subjects were enrolled sequentially in 4 groups and received a single oral dose of lucerastat from 100 mg to 1000 mg in the morning of Day 1
88961906|NCT02787499|Experimental|HIV-1 RNA Resistance Testing|Participants will receive HIV-1 RNA drug resistance testing at study enrollment. ART treatment regimen decisions will be determined based on the results of resistance testing.
88961907|NCT02747836||Healthy Volunteers|Ultrasound of the wrist
88961908|NCT02747836||Participants with Carpal Tunnel Syndrome|Ultrasound of the wrist
88961909|NCT02738853|Experimental|Medtronic Transcatheter Aortic Valve 2.0 Replacement System|Treatment of Aortic Stenosis by replacing native valve with the Medtronic Transcatheter Aortic Valve 2.0 System
88961910|NCT02730858|Experimental|Palliative and oncology care model|"After the screening procedure confirm eligibility to participate in the research study. Participants will be randomized into one of two study groups;~-- Standard oncology care with palliative care."
88961911|NCT02730858|Active Comparator|Standard oncology care|"After the screening procedure confirm eligibility to participate in the research study. Participants will be randomized into one of two study groups;~-- Standard oncology care"
88961912|NCT02691065|Experimental|Integrase Inhibitor|Switch from protease inhibitor-based regimen to raltegravir-based regimen
88961913|NCT02691065|No Intervention|Protease inhibitor|Continuation of protease-inhibitor based regimen
88961914|NCT02649998|Active Comparator|Group 1|Each patient will initially receive a 40 mg bolus of IV furosemide (10 mg/mL) and a 2 mL bolus of IV saline placebo, followed by IV saline placebo 6 mL/h
88961915|NCT02649998|Active Comparator|Group 2|Each patient will initially receive a bolus of IV saline placebo and a 2 mL bolus of IV isosorbide dinitrate (1 mg/mL), followed by IV isosorbide dinitrate 6 mL/h
88961916|NCT02649998|Active Comparator|Group 3|Each patient will initially receive a 40 mg bolus of IV furosemide (10 mg/mL) and a 2 mL bolus of IV isosorbide dinitrate (1 mg/mL), followed by IV isosorbide dinitrate 6 mL/h
89552289|NCT05301595|Active Comparator|TAP block|"All patients will have paravertebral (PV) blocks of the chest performed prior to induction of general anesthesia.~Patients in this group will have bilateral sham blocks performed after PV block is complete. 2ml of normal saline will be injected under the skin bilaterally near the insertion site of a typical QL block.~TAP block will be performed intraoperatively by the surgeon. The anesthesiologist will provide the surgeon with 40ml of LA mixture (ropivacaine 0.25%, epinephrine 100mcg and dexamethasone 4mg) for patients in this group. The surgeon will be blinded to the injectate content. The TAP block is performed once the abdominal flap has been harvested. The triangle of Petit is landmarked by the iliac crest inferiorly, the latissimus dorsi muscle posteriorly and the external oblique muscle anteriorly. A blunt tip needle is advanced through the external oblique fascia and internal oblique fascia. A total volume 20mL of the LA mixture will be injected per side."
89552290|NCT05301595|Active Comparator|QL block|"All patients will have paravertebral (PV) blocks of the chest performed prior to induction of general anesthesia.~Patients in this group will have QL block performed after PV block is complete. This will be performed with patients in the prone position using the transverse in-plane technique. With realtime U/S guidance, the quadratus lumborum muscle is identified before a short-bevel needle is advanced into the plane between the quadratus lumborum and psoas major muscles. Needle tip position is confirmed by separation of quadratus lumborum and psoas major upon injection. 20ml of ropivacaine 0.25%, epinephrine 50mcg and dexamethasone 2mg will be injected per side.~TAP block is performed intraoperatively similar to above but with 40mL of normal saline to perform a sham block. The anesthesiologist will provide the surgeon with 40ml of normal saline in this group. The surgeon will be blinded to the injectate content."
89552291|NCT05274750|Experimental|Participants receiving depemokimab (GSK3511294)|
88961917|NCT02503358|Experimental|Arm I (continuous selumetinib and paclitaxel)|Patients receive selumetinib PO BID on days 1-21 and paclitaxel IV over a fixed rate on days 1 and 8.
88961918|NCT02503358|Experimental|Arm II (intermittent selumetinib and paclitaxel)|Patients receive selumetinib PO BID on days 1-5, 8-12, and 15-19 and paclitaxel as in Arm I.
88961919|NCT02503358|Experimental|Arm III (pulsatile selumetinib and paclitaxel)|Patients receive selumetinib PO BID on days 1-3, 8-10, and 15-17 and paclitaxel as in Arm I.
88961920|NCT02482493|Active Comparator|All-polyethylene Tibial component|Sigma PFC All polyethylene Tibial component will be implanted
88961921|NCT02482493|Active Comparator|Metal Backed Tibial component|Sigma PFC metal-backed tibial component will be implanted
88961922|NCT02432963|Experimental|Treatment (p53MVA, pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes followed by modified vaccinia virus Ankara vaccine expressing p53 SC at least 30 minutes later once in weeks 1, 4, and 7. Patients may receive additional doses of pembrolizumab in weeks 10, 13, 16, and 19, for a maximum of 7 doses if there are no signs of progressive disease. Treatment continues in the absence of disease progression or unacceptable toxicity.
88961923|NCT02432950|Experimental|Supportive care (PNP)|Patients participate in the PNP intervention, which begins with a baseline meeting with a diet and lifestyle instructor to discuss baseline testing results, begin an educational plan, determine an individualized eating plan, and print out food choices. Patients also undergo automated glucometry every 15 minutes, review their individual food choices and blood glucose levels 90 minutes after eating, keep a daily nutrition and lifestyle journal log, fill out a daily meal discovery card log, and attend weekly meetings with a diet and lifestyle instructor for 12 weeks.
89552292|NCT05274750|Placebo Comparator|Participants receiving placebo|
88961924|NCT02380079|Experimental|SCD-101|SCD-101 dosed TID for 28-days
88961925|NCT02380079|Placebo Comparator|Placebo|Placebo dosed TID for 28-days
89025551|NCT00457769|Experimental|A2-12-week waiting period|The remaining nine subjects are randomized to testing followed by a 12-week waiting period. After the 12 week wait, this group of subjects is retested and begins taking donepezil, 5 mg orally daily, with retesting at 24 weeks
89025552|NCT00481143|Experimental|deferasirox|
89025553|NCT00457964|Experimental|Administration of RAD001|
89025554|NCT01240395|Experimental|MBCT intervention|
89025555|NCT01240395|No Intervention|Control group|
89025556|NCT00458081|Experimental|Rimonabant|
89025557|NCT00458081|Placebo Comparator|Placebo|
89552293|NCT05268991||AGE Participants|Participants aged 65 and older with diagnosis of solid tumor malignancy or lymphoma and planned to start a new chemotherapy regimen in the outpatient setting
89552294|NCT05263934|Experimental|Participants receiving depemokimab+placebo matching mepolizumab|
89552295|NCT05263934|Active Comparator|Participants receiving mepolizumab+placebo matching depemokimab|
89552296|NCT05254158|Experimental|NNC0174 0833 1.8 mg|Each participant will receive one single dose of NNC0174 0833
89552297|NCT05254158|Experimental|NNC0174 0833 0.9 mg|Each participant will receive one single dose of NNC0174 0833
89552298|NCT05254158|Experimental|NNC0174 0833 0.3 mg|Each participant will receive one single dose of NNC0174 0833
89552299|NCT05208346|Experimental|Canola oil high-fat|Participants randomized to receive a mixed meal with 50 g canola oil
89552300|NCT05208346|Experimental|Coconut oil high-fat|Participants randomized to receive a mixed meal with 50 g coconut oil
89552301|NCT05208346|Experimental|Canola oil low-fat|Participants randomized to receive a mixed meal with 25 g canola oil
89552302|NCT05208346|Experimental|Coconut oil low-fat|Participants randomized to receive a mixed meal with 25 g coconut oil
89552303|NCT05197647||Patients with mild COVID-19|Patients with symptomatic COVID-19 disease not requiring hospitalization.
89552304|NCT05192980|Other|Peripheral neuroblastic tumors (ganglioneuroma, ganglioneuroblastoma and neuroblastoma)|
89552305|NCT05186428|Other|"The before period"|
89552306|NCT05186428|Experimental|"the after period"|
89552307|NCT05184634|Active Comparator|Working group|The data of the control group will be compared with the data of the study group.
89552308|NCT05184634|Active Comparator|Control Group|The data of the study group will be compared with the data of the control group.
89552309|NCT05180552|Experimental|Experimental|Participants will wear HEALiX Device while intubated and sedated in the critical care setting
88961926|NCT02358538|Experimental|Ganaxolone|Maximum of 1800 mg/day or 63 mg/kg/day
88961927|NCT02349906|Experimental|Treosulfan|"One Treosulfan dose per day administered i.v. on three consecutive days (-6, -5 and -4); given over 2 hours as part of background conditioning prior to allogeneic stem cell transplantation.~The dose has to be calculated as follows:~If the BSA (m2) is equal or less than 0.3, the Treosulfan dose should be 10g/m2/day.~If the BSA (m2) is greater than 0.3 and equal or less than 0.8, the Treosulfan dose should be 12g/m2/day.~If the BSA (m2) is greater than 0.8, the Treosulfan dose should be 14g/m2/day."
89025558|NCT00443859||PPHN|Infants with persistent pulmonary hypertension (PPHN)
89025559|NCT00458120|Experimental|1|Participants previously vaccinated with rDEN4delta30 will receive one subcutaneous vaccination (10^3 dose of vaccine) of rDEN1delta30 vaccine into the deltoid region of either arm.
89025560|NCT00458120|Experimental|2|Participants previously vaccinated with rDEN4delta30 will receive one subcutaneous vaccination (10^3 dose of vaccine) of rDEN2/4delta30(ME) into the deltoid region of either arm.
89552310|NCT05180552|Active Comparator|Control|Participants will wear wrist restraints while intubated and sedated in the critical care setting
89552311|NCT05165979||Hospitalized COVID-19 patients|Hospitalized COVID-19 patients
89552312|NCT05165511|Experimental|Executive Function-Enhanced Parent-Based Behavioral Treatment (PBT-EF)|PBT-EF will integrate executive function training with family-based behavioral treatment (FBT) for obesity, the gold-standard behavioral treatment for childhood obesity. PBT-EF will include self-monitoring, calorie reduction, and dietary and physical activity recommendations in addition to planning, organization, and problem-solving skills.
89552313|NCT05157698|Experimental|BWL + NB medication|Participants randomly assigned to this arm will receive 6 months of Behavioral Weight Loss (BWL) counseling and NB medication. The naltrexone and bupropion will be taken daily in pill form.
89552314|NCT05157698|Experimental|BWL + Placebo|Participants randomly assigned to this arm will receive 6 months of Behavioral Weight Loss (BWL) counseling and placebo. Placebo will be inactive and taken daily in pill form.
89552315|NCT05157698|Experimental|NB medication|Participants randomly assigned to this arm will receive 6 months of NB medication taken daily in pill form.
89552316|NCT05157698|Placebo Comparator|Placebo|Participants randomly assigned to this arm will receive 6 months of placebo. Placebo will be inactive and taken daily in pill form.
89552317|NCT05151835|Experimental|Robotic Surgery|Prospective single arm study to investigate effect of a novel robotic surgical system on safety, efficacy and outcomes for performance of minimally invasive surgery across urology, upper and lower GI surgery.
89552318|NCT05151653|Experimental|BI 765250 arm|
89025561|NCT00458120|Experimental|3|Participants previously vaccinated with rDEN2/4delta30(ME) will receive one subcutaneous vaccination (10^3 dose of vaccine) of rDEN1delta30 vaccine into the deltoid region of either arm.
89552319|NCT05151653|Placebo Comparator|Placebo arm|
89552320|NCT05149911|Experimental|Coaching|Participants randomized to the coaching group will receive a 1-hour initial professional coaching session followed by five 30-minute professional coaching sessions occurring at a goal frequency of every 2 to 3 weeks within 5 months (total of 3.5 coaching hours). All coaching sessions will be conducted individually (i.e. between one coach and one participant). Participants will be able to request coaching on any topic to individualize the intervention, but the general structure of the sessions will be standardized across participants. All coaching sessions will be performed over the phone or virtual web meeting as standard in coaching practices.
89552321|NCT05149911|No Intervention|Control|"Participants randomized to the control group will receive no intervention but will be asked to complete the distress and wellness survey at the same time points as participants in the intervention group. Participants in the control group will receive the life coaching intervention after the statistical analysis is completed."
89552322|NCT05130008|Experimental|Intervention|Patients identified by the MGH readmission database and the EHR as eligible for the study will be enrolled. Participants will be paired with a community health worker and oriented to the digital platform ( mobile app, digital weight scale, digital blood pressure monitor, biosensor with armband). Participants will have access to the community health worker and the digital platform throughout the 30-day study interval.
89552323|NCT05130008|Active Comparator|Usual CHW Care|Patients identified by the MGH readmission database and the EHR as eligible for the study will be enrolled. Participants will be paired with a community health worker. Participants will have access to the community health worker throughout the 30-day study interval.
89552324|NCT05111314|Experimental|Diagnostic (embolization, 68Ga-PSMA, PET/CT)|Patients undergoing clinically indicated hepatic artery embolization will receive 68Ga-PSMA intraarterially (IA) over 5 minutes. After 60-90 minutes, patients undergo PET/CT scan over 1 hour.
89552325|NCT05110183|Experimental|electrical and optical hybrid stimulation stimulation|Patients with large tumors of the skull base, requiring a translabyrinthine craniotomy with sacrifice of their cochlea and vestibular system during the tumor resection may participate. A recording electrode will be placed on the round window, a cochleostomy will be created, and different Light delivery systems (LDSs) will be inserted into the cochlea. LDSs include angle polished optical fibers to determine the accuracy of the orientation of the radiation beam, and hybrid arrays of small optical sources and electrical contacts to evaluate electric-alone stimulation as a reference, and compare it to optic-alone and combined electrical and optical stimulation. Compound action potentials (CAPs) of the auditory nerve will be recorded.
89552326|NCT05100823|Experimental|Nasal cells sampling and/or rectal biospy|"Depending of the patient' genotype, specific ONB-CFTR (50 nM) will be incubated at the apical face of in vitro epithelium, alone and in combination with CFTR modulators. Efficacy of ONB will be compared to a condition with oligonucleotide control incubation.~Rectal biopsies from volunteer patients were stored as a bio-bank of organoids."
89552327|NCT05096221|Experimental|Delandistrogene Moxeparvovec followed by Placebo|Participants will receive single intravenous (IV) infusion of delandistrogene moxeparvovec on Day 1. Then, participants will receive a single IV infusion of matching placebo at Year 2.
89552328|NCT05096221|Placebo Comparator|Placebo followed by Delandistrogene Moxeparvovec|Participants will receive matching placebo IV infusion on Day 1. Then, participants will have the opportunity to receive a single IV infusion of delandistrogene moxeparvovec at Year 2.
89552329|NCT05093439||Patients presenting at Emergency Department with severe disease|Participants will be patients with (possible) sepsis, myocardial infarction, cerebrovascular accident, polytrauma or Covid 19 pneumonia who were triaged red or orange following the Manchester triage system.
89552330|NCT05073835|Experimental|Intervention|Semaglutide 2.4mg/week subcutaneous injection for 68 weeks. The treatment includes an initial 16-week escalation phase followed by 52 weeks of treatment at study dose, i.e., 2.4mg/week.
89552331|NCT05073835|Placebo Comparator|Control|Placebo administration, once weekly, subcutaneous injection.
89552332|NCT05069467|Experimental|Acupuncture|Licensed acupuncturists with more than 5 years of experience will be responsible for administering interventions three times per week for 6 weeks. The needles (30 or 40 mm and 0.25 mm gauge; Soochow, Hwato) will be inserted and manipulated until De Qi, a sensation of soreness and tingling. Acupuncture was defined as targeting the 10 bilateral acupuncture points: Xinshu (BL15), Shenshu (BL23), Zhongliao (BL33), Sanyinjiao (SP6), Yinlingquan (SP9). The needle will be left in place for 30 minutes with brief manipulation at the beginning, middle, and end of therapy.
88961928|NCT02349906|Active Comparator|Busulfan|Total daily Busilvex dose (3.2 to 4.8 mg/kg/day, based on body weight) according to authorised dosage for children and adolescents administered i.v. as part of the background conditioning regimen on four consecutive days (days -7, -6, -5 and -4); given in 1, 2, or 4 portions per day according to the respective hospital's standard.
88961929|NCT02338037|Experimental|Treatment (eribulin mesylate)|Patients undergo tumor resection or biopsy and have microdialysis catheter placed on day 0. Beginning at least 24 hours later, patients receive eribulin mesylate IV over 2-5 minutes on day 1. Serial brain fluid samples are collected for approximately 72 hours and the microdialysis catheter is then removed. Beginning at least 2 weeks after tumor resection or biopsy, patients may continue to receive eribulin mesylate IV over 2-5 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
88961930|NCT02336087|Experimental|Treatment (gemcitabine, Abraxane, metformin, DS)|Patients receive gemcitabine hydrochloride and paclitaxel albumin-stabilized nanoparticle formulation IV on days 1, 8, and 15. Patients also receive metformin hydrochloride PO BID starting day -6 and dietary supplement PO BID starting day -3. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89025562|NCT00458120|Experimental|4|Participants previously vaccinated with rDEN1delta30 will receive one subcutaneous vaccination (10^3 dose of vaccine) of rDEN2/4delta30(ME) vaccine into the deltoid region of either arm.
89025563|NCT00458120|Placebo Comparator|5|One subcutaneous vaccination with placebo into the deltoid region of either arm.
89025564|NCT00458159|Experimental|1|
89025565|NCT00455780|Experimental|MR-/REDE-|Weight Loss through cognitive behavioral therapy and meal replacement use, and continued therapy for weight loss maintenance.
89033041|NCT02944487|Experimental|B.i.d. Dose Group|Subjects received two doses of lucerastat (2 x 1 g) 12 hours apart on Day 1
89552333|NCT05069467|Sham Comparator|Sham Acupuncture|Treatment will be the same for the sham acupuncture, except for the following: the acupuncturist selected the same number of nonacupuncture, nontrigger points. Instead of eliciting De Qi, the needles will be minimally manipulated to avoid eliciting sensations other than initial contact with skin.
89552334|NCT05069467|No Intervention|Usual Care|Patients receiving usual care received neither acupuncture nor sham acupuncture. After the 6-week assessment, patients will be offered the option to receive acupuncture treatment as the acupuncture group.
89552335|NCT05067933|Experimental|Part 1 Cohort 1a (Naïve, low dose, young adult)|1E10 repeat-dose vaccinations with VXA-CoV2-1.1-S at Days 1 and 29 in young adults (18-55 yrs) who are vaccine naïve
89025566|NCT00455780|Experimental|MR+/REDE-|Weight Loss through cognitive behavioral therapy and meal replacement use, and continued therapy and use of meal replacements for weight loss maintenance.
88812105|NCT05946486|Experimental|experimental group|immunomodulatory treatment by rituximab, 1g for adults or 375 mg/m2 for children, renewed at 14 days (+/- 3 days), added to stable ongoing psychiatric care (with or without standard treatment as usual ( i.e. antipsychotic, mood stabiliser, antidepressant and/or anxiolytic)). The rituximab is the best immunomodulatory treatment recommended for neurologic encephalitis.
88812106|NCT05946473|Experimental|Experimental gum formulation|Participants will be asked to chew 2 pieces of chewing gum containing additives 2 times a day for a four-week period
89552336|NCT05067933|Experimental|Part 1 Cohort 1b (Naïve, high dose, young adult)|1E11 repeat-dose vaccinations with VXA-CoV2-1.1-S at Days 1 and 29 in young adults (18-55 yrs) who are vaccine naïve
89552337|NCT05067933|Experimental|Part 1 Cohort 1c (Naïve, low dose, older adult)|1E10 repeat-dose vaccinations with VXA-CoV2-1.1-S at Days 1 and 29 in older adults (56-75 yrs) who are vaccine naïve
89552338|NCT05067933|Experimental|Part 1 Cohort 1d (Naïve, high dose, older adult)|1E11 repeat-dose vaccinations with VXA-CoV2-1.1-S at Days 1 and 29 in older adults (56-75 yrs) who are vaccine naïve
89552339|NCT05067933|Experimental|Part 1 Cohort 2a (Prior vaccinated, low dose, young adult)|1E10 repeat-dose vaccinations with VXA-CoV2-1.1-S at Days 1 and 29 in young adults (18-55 yrs) who have received prior vaccinations with an mRNA vaccine
89552340|NCT05067933|Experimental|Part 1 Cohort 2b (Prior vaccinated, high dose, young adult)|1E11 repeat-dose vaccinations with VXA-CoV2-1.1-S at Days 1 and 29 in young adults (18-55 yrs) who have received prior vaccinations with an mRNA vaccine
89552341|NCT05067933|Experimental|Part 1 Cohort 2c (Prior vaccinated, low dose, older adult)|1E10 repeat-dose vaccinations with VXA-CoV2-1.1-S at Days 1 and 29 in older adults (56-75 yrs) who have received prior vaccinations with an mRNA vaccine
89552342|NCT05067933|Experimental|Part 1 Cohort 2d (Prior vaccinated, high dose, older adult)|1E11 repeat-dose vaccinations with VXA-CoV2-1.1-S at Days 1 and 29 in older adults (56-75 yrs) who have received prior vaccinations with an mRNA vaccine
89552343|NCT05067933|Experimental|Part 2 Healthy Adults: Active vaccine|Repeat dose vaccinations with VXA-CoV2-1.1-S at dose selected from Part 1 in healthy male and female adult volunteers 18 to 75 years old
89552344|NCT05067933|Placebo Comparator|Part 2 Healthy Adults: Placebo control|Repeat dose administration with matching placebo tablets in healthy male and female adult volunteers 18 to 75 years old
89552345|NCT05058677|Experimental|aerosolized lidocaine then Instilled lidocaine solution then instilled saline solution|Treatment will be performed before the endotracheal suctioning
89552346|NCT05058677|Experimental|aerosolized lidocaine then instilled saline solution then Instilled lidocaine solution|Treatment will be performed before the endotracheal suctioning
89552347|NCT05058677|Experimental|Instilled lidocaine solution then aerosolized lidocaine then instilled saline solution|Treatment will be performed before the endotracheal suctioning
89552348|NCT05058677|Experimental|Instilled lidocaine solution then instilled saline solution then aerosolized lidocaine|Treatment will be performed before the endotracheal suctioning
89552349|NCT05058677|Experimental|Instilled saline solution then aerosolized lidocaine then Instilled lidocaine solution|Treatment will be performed before the endotracheal suctioning
89552350|NCT05058677|Experimental|Instilled saline solution then Instilled lidocaine solution then aerosolized lidocaine|Treatment will be performed before the endotracheal suctioning
89552351|NCT05058300||Patients with Chest Pain|An unselected patient-population with chest pain in emergency department
88812107|NCT05946473|Placebo Comparator|Placebo|Participants will be asked to chew 2 pieces of pure gum base with no additives chewing gum 2 times a day for the same four-week period.
88812108|NCT05946460|Experimental|Neoadjuvant Aumolertinib|Single Arm
88812109|NCT05946434|Experimental|Kinesio Tape Group|Kinesio tape applied along with conventional treatment
88812110|NCT05946434|Experimental|Rigid tape Group|Rigid tape applied along with conventional treatment
88812111|NCT05946421||Severe Asthma patients on biologics|
89025567|NCT00455780|Experimental|MR-/REDE+|Weight Loss through cognitive behavioral therapy and meal replacement use, and continued therapy as well as Reduced Energy Density Education for weight loss maintenance.
89552352|NCT05052307||Fully vaccinated with BNT162b2 COVID-19 vaccine|Defined as 2 doses of Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine received with ≥7 days between receipt of the 2nd dose and acute respiratory illness (ARI) symptom onset. This group will serve as the 'exposed' group evaluated in the primary objective.
88812112|NCT05946421||Healthy controls|
88812113|NCT05946356||Fibromyalgia patients|Participants will complete self-reported questionnaires to assess psychological wellbeing, physical activity, and disability.
88812114|NCT05946343||Small Rotator Cuff Tear Group|The Cofield classification system is a commonly cited classification system for full-thickness rotator cuff tears. It is based on the size of the tear. Small tear: Less than 1 cm.
88812115|NCT05946343||Medium Rotator Cuff Tear Group|The Cofield classification system is a commonly cited classification system for full-thickness rotator cuff tears. It is based on the size of the tear. Medium tear: 1-3 cm
88812116|NCT05946343||Large Rotator Cuff Tear Group|The Cofield classification system is a commonly cited classification system for full-thickness rotator cuff tears. It is based on the size of the tear. Large tear: 3-5 cm
88812117|NCT05946343||Massive Rotator Cuff Tear Group|The Cofield classification system is a commonly cited classification system for full-thickness rotator cuff tears. It is based on the size of the tear. Massive tear: Greater than 5 cm
89552353|NCT05052307||Ever vaccinated with BNT162b2 COVID-19 vaccine|defined as ≥1 dose of Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine received with ≥14 days between receipt of the 1st dose and ARI symptom onset.
89552354|NCT05052307||Partially vaccinated with BNT162b2 COVID-19 vaccine|Defined as 1 dose (only) of Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine received with ≥14 days between receipt of the 1st dose and ARI symptom onset.
89552355|NCT05052307||Fully vaccinated with other available COVID-19 vaccines|Defined as fully vaccinated with available COVID-19 vaccines other than the BNT162b2 according to the manufacturer recommendations.
89552356|NCT05052307||Never vaccinated|Defined as never received any COVID-19 vaccine. This group will serve as the reference exposure group (i.e., 'unexposed' group) in all vaccine effectiveness analyses.
89552357|NCT05052307||Fully vaccinated plus booster dose of BNT162b2 COVID-19 vaccine|Defined as fully vaccinated with available COVID-19 vaccines according to the manufacturer recommendations plus booster dose of BNT162b2 COVID-19 vaccine received with ≥14 days between receipt of the 1st dose and ARI symptom onset.
89552358|NCT05049538||Observational (biospecimen collection, Pap smear)|Patients undergo collection of blood samples for liquid biopsy during pre-treatment consultation before hysterectomy, after hysterectomy but before starting any chemotherapy, and at the end of last chemotherapy cycle. Patients also undergo collection of tissue samples during hysterectomy. Patients may also undergo Pap smears before and after hysterectomy.
89552359|NCT05048147|Experimental|CM Intervention Group|Cluster. RCT of 16 urban and rural communities. Community mobilizers and health education officers will facilitate use of CF-CS (bioethanol and LPG fuels/stoves) and educate households on HAP exposure throughout the intervention period
89552360|NCT05048147|No Intervention|Self-Directed Group|Receive information on CFCS use and education on HAP in 16 urban and rural communities; will not receive the CM intervention
89552361|NCT05040971|Experimental|Semaglutide|Participants will receive subcutaneus (s.c.) semaglutide 2.4 mg once weekly for 52 weeks
89552362|NCT05040971|Placebo Comparator|Placebo (semaglutide)|Participants will receive subcutaneus (s.c.) placebo (semaglutide) once weekly for 52 weeks
89552363|NCT05037513|Active Comparator|CDC-PrEP|1 session PrEP education following CDC guidelines delivered one on one by an Advanced Practice Registered Nurse to individual clients in the syringe service program setting
89552364|NCT05037513|Experimental|SBCM-PrEP|Multi-session Strengths-Based Case Management intervention adapted for PrEP related educational content delivered one on one by an Advanced Practice Registered Nurse to individual clients in the syringe service program setting
89552365|NCT05004662|Active Comparator|Standard Treatment|Participants randomized to Standard Treatment (ST) will be provided with a 10-week supply of nicotine patches and lozenges. ST participants will be connected with Florida Quitline services and will complete weekly 4-item smartphone assessments electronically for 26 weeks. The weekly assessments consist of questions on smoking status, motivation, self-efficacy, and perceived stress.
89552366|NCT05004662|Experimental|Automated Treatment|Participants randomized to Automated Treatment (AT) will be given a 10-week supply of nicotine patches and lozenges. AT will also comprise of: 1) 12 proactive treatment videos, delivered weekly, that are tailored on smoking status, motivation, agency, and/or negative affect/stress; 2) 26 weeks of on-demand access to treatment content; 3) 26 weeks of text content
89552367|NCT05002075|No Intervention|Usual care arm|Participants in the usual control group will receive standard of care per their providers' discretion.
89552368|NCT05002075|Experimental|m-health cardiac rehabilitation intervention arm|Participants randomized to m-Health cardiac rehabilitation will receive a 24-week home-based exercise program
89025568|NCT00455780|Experimental|MR+/REDE+|Weight Loss through cognitive behavioral therapy and meal replacement use, and continued therapy, as well as Reduced Energy Density Education and continued meal replacement use, for weight loss maintenance.
89025569|NCT00458198|Experimental|1|Participants will receive integrated behavioral therapy
89552369|NCT04984629|Experimental|HYDRAFIL Implant|Polymer Implant of HYDRAFIL into a one or two lumbar intervertebral discs
89552370|NCT04979780||Cancer patients with acute venous thromboembolism (VTE)|Cancer-associated thrombosis (CAT) patients treated with Rivaroxaban or any DOAC (Direct Oral Anticoagulants) or LMWH (Low molecular weight heparin).
88812118|NCT05946187|Experimental|Apolo_Bari Stepped-care intervention group|The Apolo_Bari stepped-care intervention offers two different steps from low- to high-intensity strategies. The intervention will run for 18 months. All participants receive first step intervention. Patients will move through the second step according to the degree of disordered eating behaviors or weight regain which is assessed through a short Monthly Monitoring Questionnaire.
88812119|NCT05946187|Active Comparator|Treatment as usual group|Treatment As Usual control group receives the standard intervention for bariatric surgery offered by multidisciplinary teams in Portuguese public hospitals. It consists of endocrinology, nutrition and surgery consultations, usually lasting 30 minutes every 6 months. These consultations usually include a physical exam (weight, height) and personalized diet/lifestyle recommendations. The Treatment as usual intervention is common to the Apolo_Bari Steppped-care intervention group and the treatment as usual control groups.
88812120|NCT05946148||Empagliflozin group|Oral Empagliflozin 10mg daily, as add-on to their previous treatment regimen.
88812121|NCT05946148||Dulaglutide group|Subcutaneous Dulaglutide 1.5mg weekly, as add-on to their previous treatment regimen.
88812122|NCT05946148||Control group|Optimal anti-diabetic treatment (apart from agents of the GLP1-ras or SGLT2-is families), targeting glycemic control.
88812123|NCT05946135|Active Comparator|Control|lansoprazole + placebo for Fexuprazan Hydrochloride
88812124|NCT05946135|Experimental|Intervention|placebo for lansoprazole + Fexuprazan Hydrochloride
88812125|NCT05946122|Placebo Comparator|control group|
88812126|NCT05946122|Active Comparator|Active ( Ator) group|
88812127|NCT05946109|Active Comparator|ACTIVE-AGE@home by professionals|"Training program of 24 weeks supervised by professionals with a relevant background in the treatment and/or training of the older adults.~The older adults are trained by either a physiotherapist, an occupational therapist or an exercise professional. The professionals will receive a 3x4h training course to gain more knowledge and practice regarding following aspects:~Frailty and ageing.~Physical training principles + ACTIVE-AGE@home exercise program~Motivational coaching.~All participants in the three arms will receive the same monthly newsletter with tips and tricks to obtain good health in older age."
89552371|NCT04972513||Prevention (survey, breathe tests, biospecimen collection)|Participants undergo computer-based spirometry testing, nitric oxide breath testing, airwave oscillometry, and an assessment of endothelial function. Participants will undergo collection of blood. Current e-cigarette users also vape their own e-cigarette device for 30 minutes.
89552372|NCT04972110|Experimental|Phase Ib Dose Escalation|Multiple dose levels of RP-3500 (camonsertib) for oral administration in combination with niraparib and/or Multiple dose levels of RP-3500 (camonsertib) for oral administration in combination with olaparib
89552373|NCT04972110|Experimental|Phase 2 Expansion Cohorts|Expansion cohort with RP-3500 (camonsertib) + niraparib and/or Expansion cohort RP-3500 (camonsertib) + olaparib
89552374|NCT04951466|Experimental|Mindfulness-based therapy for insomnia (MBTI)|Participants randomly assigned to the MBTI will receive 2 hours weekly session of mindfulness meditation and behavioral sleep strategies for 8 weeks.
89552375|NCT04951466|Active Comparator|Healthy Lifestyle Education|Participants in the control group will receive sessions on the following topics: Introduction to health promotion, disease prevention and screening, healthy eating, physical activity, communication, and endings.
89552376|NCT04941950|Experimental|PlaySmart|Video game intervention.
89552377|NCT04941950|Other|Control Game|Control video game intervention.
89552378|NCT04939051|Experimental|Arm I (OCA)|Patients receive OCA PO QD for 6 months in the absence of disease progression or unacceptable toxicity. Patients undergo liver ultrasound during screening, EGD with biopsies, brushings and gastric aspirate at end of treatment visit and blood sample collection throughout the study.
89552379|NCT04939051|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD for 6 months in the absence of disease progression or unacceptable toxicity. Patients undergo liver ultrasound during screening, EGD with biopsies, brushings and gastric aspirate at end of treatment visit and blood sample collection throughout the study.
89552380|NCT04921384|Experimental|Eptinezumab 300 mg|300 mg eptinezumab by intravenous (IV) infusion.
89552381|NCT04921384|Experimental|Eptinezumab 100 mg|100 mg eptinezumab by IV infusion.
89552382|NCT04921384|Placebo Comparator|Placebo|Placebo by IV infusion.
89552383|NCT04910074|Experimental|Low-level therapy intervention|Patients will receive low-level laser therapy on the skin overlying the mandible for 40 seconds per side. All other post-operative care will be as per clinic routine.
89552384|NCT04910074|Placebo Comparator|dummy intervention|Patients will receive no dose of laser, but the handpiece will be used against their skin top mimic the LLLT. All other post-operative care will be as per clinic routine.
89552385|NCT04890938|Experimental|Sputum-guided management and comprehensive care management|The intervention consists of 6-months of CCM and sputum biomarker-directed treatment of airway inflammation, including hospital and clinic visits. Clinic visits at 2, 6, and 16 weeks. The key elements of CCM will be provided, including case management, self-management education, and coordination of community/hospital resources (1). Clinic nurse will review inhaler technique with the patient. Sputum (spontaneous) biomarkers will be measured with results used to direct therapy at the time of AECOPD and during clinic visits after hospital discharge, at both sites.
89552386|NCT04890938|Active Comparator|Usual Care|This group will also receive clinic visits at 2, 6, and 16 weeks with a study physician, and also education material, inhaler technique assessment and education, and case management from the clinic personnel. The study physician will pursue further investigation and/or further intervention if they see fit.
89552387|NCT04830137|Experimental|Phase 1a Dose Escalation|Multiple dose levels of NX-2127 to be evaluated; determination of MTD/Phase 1b recommended dose
89552388|NCT04830137|Experimental|Phase 1b Dose Expansion in CLL or SLL with no BTK C481 mutation|CLL/SLL patients with no BTK C481 mutation whose disease has failed treatment with a BTK inhibitor
89552389|NCT04830137|Experimental|Phase 1b Dose Expansion in BTK C481 mutation-positive CLL/SLL|BTK C481 mutation-positive CLL/SLL patients whose disease has failed treatment with a BTK inhibitor
89552390|NCT04830137|Experimental|Phase 1b Dose Expansion in MCL|MCL patients whose disease has failed treatment with a BTK inhibitor and an anti-CD20 monoclonal antibody (mAb) based regimen
88961931|NCT02332980|Experimental|Treatment (pembrolizumab, idelalisib, or ibrutinib)|"Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity. Patients receiving benefit may continue to receive treatment for an additional 12 months at the discretion of the investigator. Patients with CLL or CLL with Richter's transformation experiencing stable disease without partial remission or progressive disease at 3 months of treatment with pembrolizumab proceed to the treatment continuation phase.~CONTINUATION PHASE: Patients receive pembrolizumab IV over 30 minutes on day 1. Patients also receive idelalisib PO BID on days 1-21 OR ibrutinib PO QD on days 1-21. Treatment repeats every 21 days for up to 12 or 24 months in the absence of disease progression or unacceptable toxicity. Patients receiving benefit may continue to receive treatment for an additional 12 months at the discretion of the investigator."
88961932|NCT02268253|Experimental|Tagraxofusp (SL-401)|
89025570|NCT00458198|Active Comparator|2|Participants will receive integrated behavioral therapy after a 12-week waitlist period
89025571|NCT00487929|Experimental|CPAP|Continuous positive airway pressure
89025572|NCT00487929|Sham Comparator|Sham CPAP|Sham nasal continuous positive airway pressure
89025573|NCT00458354|Experimental|Spinal Sealant|Dural repair with the Spinal Sealant System.
89552391|NCT04830137|Experimental|Phase 1b Dose Expansion in FL, MZL or PCNSL|FL or MZL patients whose disease has failed treatment with an anti-CD20 mAb-based regimen; or PCNSL whose disease has failed at least 1 prior line of treatment
89552392|NCT04830137|Experimental|Phase 1b Dose Expansion in DLBCL or WM|DLBCL patients whose disease has failed treatment with an anti-CD20 mAb-based regimen and either an anthracycline, an anti-CD19-based regimen, or another/palliative regimen; or WM patients whose disease has failed treatment with a BTK inhibitor
89552393|NCT04824144|Experimental|Dexmedetomidine subcutaneous continuous infusion|Participants will be given a starting low dose of 0.4 mcg/kg/hr, to be titrated up to a medium dose of 0.7 mcg/kg/hr and potentially up to a maximum dose of 1.0 mcg/kg/hr by subcutaneous infusion until the target RASS-PAL level has been achieved.
89552394|NCT04824079|Experimental|Keynatinib treatment group|All subjects shall be treated with Keynatinib twice a day (once every 12±3 hours), 20 mg each time, fasting within 2 hours before and 1 hour after taking the drug, and taking warm water when taking the drug. Every 21 days is a treatment cycle .
89552395|NCT04817410|Experimental|Oral Naloxone|Oral Naltrexone initiation
89552396|NCT04816877||Patient controlled analgesia (PCA) group|Patients in this group will be allocated to the PCA arm, i.e., they will be receiving a PCA pump for administration of opioids.
89552397|NCT04816877||Physician directed analgesia (PDA) group|Patients in this group will be allocated to the PDA arm, i.e., they will be receiving opioids administered by the nurse, as and when directed by the physician.
89552398|NCT04812067|Experimental|TTHX1114 weekly x 5|TTHX1114 via IC injection weekly x 5
89552399|NCT04807881|Experimental|Keynatinib treatment group|Keynatinib, 20 mg，BID
89552400|NCT04795531|Experimental|Once weekly insulin icodec + once daily placebo|Participants will get once daily and once weekly injections
89552401|NCT04795531|Experimental|Once weekly placebo and once daily insulin degludec|Participants will get once daily and once weekly injections
89552402|NCT04787575|Experimental|Arm A|Oxygen-ozone therapy plus antibiotic therapy
89552403|NCT04787575|Other|Arm B|Antibiotic therapy
89552404|NCT04781933|Active Comparator|Treatment with Combo|3 dietary supplements will be given
89552405|NCT04781933|Placebo Comparator|Treatment with Placebo|3 placebos will be given
89552406|NCT04778592|Experimental|ETX-018810|Drug: ETX-018810 BID for 4 weeks
89552407|NCT04778592|Placebo Comparator|Placebo|Matching Placebo BID for 4 weeks
89552408|NCT04765267|Active Comparator|Topical Corticosteroid with Systemic Zinc.|Octozinc: Zinc sulphate heptahydrate 25 mg tablets - October Pharma
89025574|NCT00458354|Active Comparator|Standard Methods|Dural repair with standard methods such as the closing of the dura with stitches.
89025575|NCT00444015|Experimental|Dose Escalation|
89552409|NCT04765267|Active Comparator|Topical Corticosteroid with Systemic Vitamin D|Cholecalciferol: vitamin D3 15 ml oral solution - Medical Union Pharmaceuticals
89552410|NCT04765267|Other|Topical Corticosteroid|Kenacort A Orabase: triamcinolone acetonide 0.1% adhesive paste - Dermapharm
89552411|NCT04737265|Experimental|Biomarker Guided Arm|"NTproBNP will be monitored serially prior to start of anthracycline based chemotherapy, at each cycle of anthracycline based chemotherapy, and at 3 month intervals for a total of 12 months.~Clinical, echocardiographic, and biomarker data will be collected on all patients at baseline and at standardized intervals at 3, 6, 9, and 12 months following initiation of Anthracycline chemotherapy."
89552412|NCT04737265|No Intervention|Usual Care|NTproBNP will not be monitored while patients are on study unless clinically indicated. Clinical, echocardiographic, and biomarker data will be collected on all patients at baseline and at standardized intervals at 3, 6, 9, and 12 months following initiation of Anthracycline chemotherapy. Biomarker data will also be collected at each cycle of Anthracycline chemotherapy.
89552413|NCT04737252|Experimental|Sage|Immediately receives 12 sessions of couple intervention aimed to improve self-injury thoughts and behaviours, emotion dysregulation, borderline personality disorder symptoms, and intimate relationship dysfunction.
89552414|NCT04737239||Patient with CTS/Mild EMG|
89552415|NCT04737239||Patient with CTS/Negative EMG|
89552416|NCT04730921|Experimental|LBBAP group|AV block patients randomized to left bundle branch area pacing
89552417|NCT04730921|Active Comparator|RVP group|AV block patients randomized to right ventricular pacing group
89552418|NCT04725383|Active Comparator|amitriptyline|Subjects will receive active amitriptyline compounded into look-alike capsules to resemble placebo capsules. Dosing will be as tolerated, up to tid and maximum of 100mg/day or 1.5mg/kg/day, for 10 weeks.
89552419|NCT04725383|Placebo Comparator|placebo|Subjects in this arm will receive placebo compounded into capsules that resemble the compounded amitriptyline capsules, up to 4 capsules a day (1 qam, 1 q4pm and 2 capsules qhs), for 10 weeks.
88812128|NCT05946109|Experimental|ACTIVE-AGE@home by volunteers|"Training program of 24 weeks supervised by volunteers who are presented by the older adults themselves or who are recruited by the research group.~The older adults are trained by an informal caregiver or a newly recruited volunteer. The informal caregivers and volunteers will receive a 3x4h training course to gain more knowledge and practice regarding following aspects:~Frailty and ageing.~Physical training principles + ACTIVE-AGE@home exercise program~Motivational coaching.~All participants in the three arms will receive the same monthly newsletter with tips and tricks to obtain good health in older age."
88812129|NCT05946109|No Intervention|Standard care for frail older adults|"The two intervention conditions will be compared with the current standard care for frail community-dwelling elderly that does not include physical activity interventions.~All participants in the three arms will receive the same monthly newsletter with tips and tricks to obtain good health in older age."
88812130|NCT05946096|Experimental|dynamic surface exercise training group|This group includes 19 subjects all of which are children with spastic diplegic cerebral palsy of GMFCS levels 3 and 4. This group received a set of exercises on various dynamic surfaces along with routine physical therapy. This group underwent a 60-minutes vigorous exercise program four days a week for two months
88812131|NCT05946096|Active Comparator|conventional physical therapy group|This group includes 19 subjects all of which are children with spastic diplegic cerebral palsy of GMFCS levels 3 and 4. This group received only conventional physical therapy which is based upon principles of NDT. This group underwent a 60-minutes vigorous exercise program four days a week for two months.
88812132|NCT05946083|Active Comparator|Binge Drinkers with Inulin Intervention|23 binge drinkers (~50 % male and ~50 % female) will be given a daily dose of inulin.
88812133|NCT05946083|Placebo Comparator|Binge Drinkers with Maltodextrin Intervention|23 binge drinkers (~50 % male and ~50 % female) will be given a daily dose of maltodextrin.
88812134|NCT05946083|No Intervention|Non/Low-Drinkers|36 non/low-drinkers will not be given any dietary fiber.
88812135|NCT05946005|Experimental|Honey|Honey is referred to in the Qur'an as a wound healing agent (QS: 16:68 - 69) and has antimicrobial, antioxidant and anti-inflammatory effects. Honey, as an anti-inflammatory, has components of hydrogen peroxide, flavonoids, and phenolic acids that play a role in stimulating angiogenesis (8). Honey also has a high osmolality which provides moisture to the wound, thereby reducing edema and hyperemia and functioning as an antibacterial, so it is expected to reduce the use of antibiotics. Research reported in 2012 stated that honey had the same effect on wound healing and perineal wound pain in postpartum mothers with routine use two times a day for five days (P < 0.05) (9).
89552420|NCT04718389|Experimental|Participants receiving GSK3511294 (Depemokimab) plus placebo matching prior anti-IL-5/5R treatment|Participants will receive GSK3511294 (Depemokimab) plus placebo treatment matching the active comparator (participant's anti-Interleukin-5/ 5 receptor [anti-IL-5/5R] treatment prior to randomization): either placebo matching mepolizumab or placebo matching benralizumab. All participants will continue their non-biologic Baseline SoC asthma treatment throughout the study.
89552421|NCT04718389|Active Comparator|Participants receiving prior anti-IL-5/5R treatment plus placebo matching GSK3511294 (Depemokimab)|Participants will receive active comparator (participant's anti-IL-5/5R treatment prior to randomization): either mepolizumab or benralizumab, plus placebo matching GSK3511294 (Depemokimab). All participants will continue their non-biologic Baseline SoC asthma treatment throughout the study.
89552422|NCT04696237||orthodontists|orthodontists with more than 2 years of working experience
89552423|NCT04696237||general dentists|with more than 2 years of working experience
89025576|NCT00444054|Experimental|Dietary modification|Patients are placed on a low carbohydrate diet (<30 grams/day) for 28 days.
89552424|NCT04696237||oral and maxillofacial surgeons|with more than 2 years of working experience
89552425|NCT04696237||plastic surgeons|with more than 2 years of working experience
89552426|NCT04696237||cleft nurses|with more than 2 years of working experience
89552427|NCT04696237||speech therapists|with more than 2 years of working experience
89552428|NCT04696237||ENT specialists|with more than 2 years of working experience
89552429|NCT04696237||psychiatrists|with more than 2 years of working experience
89552430|NCT04696237||Social workers|with more than 2 years of working experience
89552431|NCT04688775|Experimental|Sequence 1: Eptinezumab Then Placebo|Eptinezumab in the Placebo-controlled Period, followed by administration of placebo in the Active Treatment Period
89552432|NCT04688775|Experimental|Sequence 2: Placebo Then Eptinezumab|Placebo in the Placebo-controlled Period, followed by administration of eptinezumab in the Active Treatment Period
89552433|NCT04688671|Experimental|ETX-018810|1000 mg BID for 4 weeks
89552434|NCT04688671|Placebo Comparator|Placebo|matching placebo BID for 4 weeks
89552435|NCT04677816|Experimental|Vitamin D Supplementation Group - Deficient Levels|Along with standard of care neoadjuvant chemotherapy treatments and procedures, participants will receive oral 50,000 international units of Vitamin D3 supplementation at the initiation of chemotherapy once a week.
89552436|NCT04677816|Active Comparator|Observational Arm - Vitamin D at Normal Levels|Standard of care neoadjuvant chemotherapy
89552437|NCT04676737|No Intervention|Group 1 DWEK/DSO|Study subjects in Group 1 will undergo DWEK/ DSO and will not receive any TTHX1114
89552438|NCT04676737|Experimental|Group 2 TTHX1114 in combination with DWEK/DSO|Study subjects in Group 2 will receive TTHX1114 (5 injections) and undergo DWEK/ DSO
89552439|NCT04676737|Experimental|Group 3 TTHX1114 in combination with DWEK/DSO|Study subjects in Group 3 will receive TTHX1114 (1 injection) and undergo DWEK/ DSO
89552440|NCT04676737|Experimental|Group 1a|Study subjects in Group 1a will consist of subjects in Group 1 if not recovered from DWEK/ DSO by Day 84 and will receive TTHX1114 (5 injections)
89552441|NCT04676737|Experimental|Group 3a|Study subjects in Group 3a will consist of subjects who had participated in in Group 3 if not recovered from DWEK/ DSO by the median time observed in Group 2 and will receive TTHX1114 (4 injections)
89552442|NCT04669574||Group 1|Participants who are newly diagnosed and have initiated front-line treatment.
89552443|NCT04669574||Group 2|Participants who have previously had one progression.
89552444|NCT04669574||Group 3|Participants who have previously had a second recurrence.
89552445|NCT04669574||Group 4|Participants who are on imaging surveillance and not receiving anti-neoplastic treatment
89552446|NCT04668209|Active Comparator|Silmitasertib|Standard of care / supportive care in combination with Silmitasertib (CX-4945)
89552447|NCT04668209|No Intervention|Standard of Care|Standard of care / supportive care
89552448|NCT04661878|Experimental|MASI|Participants randomized to the intervention condition will receive access to MASI, the smartphone app customized for this study. MASI is an adapted version of HealthMpowerment, a theory-based smartphone app with features including an anonymous interactive discussion forum, a medication and adherence tracker, a platform to ask questions to an expert, a section with engaging activities (including quizzes, self-assessments, and goal-setting activities), and a multi-media resource center.
89552449|NCT04661878|Active Comparator|Information-only version of MASI|Participants randomized to the control condition will an information-only version of MASI which will include the Resources feature and the home page.
89552450|NCT04655196|Experimental|Internet-based self-help + weekly feedback by a coach|Internet-based self-help on the basis of CBT-interventions, mindfulness and self-compassion to address cognitions, emotions and behavior related to loneliness. The self-help program consists of nine text, audio and video-based sessions, various exercises (e.g., breathing meditation, diaries) and tasks. Participants receive weekly feedback by a coach.
89552451|NCT04655196|Experimental|Internet-based self-help + weekly automated messages|Internet-based self-help on the basis of CBT-interventions, mindfulness and self-compassion to address cognitions, emotions and behavior related to loneliness. The self-help program consists of nine text-, audio- and video-based sessions, various exercises (e.g., breathing meditation, diaries) and tasks. Participants receive weekly automated messages in order to increase motivation.
89552452|NCT04655196|No Intervention|Waiting control group|
89552453|NCT04637581|Experimental|Wraparound|Wraparound is a 12-month intervention including a family-centered discovery process to identify values, needs, and strengths to help the family be successful in reaching family functioning and parental recovery goals; weekly or twice weekly family meetings with the Wraparound coordinator; intensive care coordination among systems and providers (substance use disorder, mental health, schools, pediatrics, homeless shelters, etc.); and bi-monthly family-centered team meetings (including the family's natural and professional supports) to discuss strategies, progress and continued needs. Wraparound coordinators (2) work with up to 10 families at a time and receive extensive training (including observation) and supervision by expert trainers at University of New Hampshire.
88961933|NCT02235051|Experimental|Arm I (exercise intervention)|Patients participate in a supervised Curves exercise program three days a week for 16 weeks. The circuit-style workout consists of 14 exercises constructed with pneumatic or hydraulic resistance that target opposing muscle groups in a concentric-only fashion. Each session at Curves will include two complete circuits which correspond to exercising for approximately 30 minutes followed by a standardized stretching routine.
89552454|NCT04637581|No Intervention|treatment-as-usual|"The treatment-as-usual group will receive a packet of local services and referral contacts and treatment as usual as directed by any healthcare providers working with the family. The project team will contact treatment-as-usual families on a monthly basis to confirm any services the family may be receiving, provide reminders of scheduled assessment dates, and give small incentives ($10 gift card) when families report changes in contact information to reduce risk for loss to follow-up."
89552455|NCT04597697|Experimental|Subjects with normal hepatic function|The participants will be allocated into four groups. Receiving one insulin icodec dose, administered subcutaneously.
89552456|NCT04597697|Experimental|Subjects with mild hepatic impairment, child-pugh grade A|The participants will be allocated into four groups. Receiving one insulin icodec dose, administered subcutaneously.
89552457|NCT04597697|Experimental|Subjects with moderate hepatic impairment, child-pugh grade B|The participants will be allocated into four groups. Receiving one insulin icodec dose, administered subcutaneously.
89552458|NCT04597697|Experimental|Subjects with severe hepatic impairment, child-pugh grade C|The participants will be allocated into four groups. Receiving one insulin icodec dose, administered subcutaneously.
89552459|NCT04578951||Patients receiving a prosthesis from the FHK® range|
89552460|NCT04566653||dialysis-dependent|chronic kidney disease patients with hyperkalaemia and dialysis-dependent
89552461|NCT04566653||non-dialysis-dependent|chronic kidney disease patients with hyperkalaemia and non-dialysis-dependent
89552462|NCT04565158||Women with bilateral salpingo-oophorectomy (BSO)|
89552463|NCT04565158||Women without bilateral salpingo-oophorectomy (BSO)|
89552464|NCT04555187||Covid19-positive|Covid19 test positive. age >= 18 y.
89552465|NCT04555187||Covid19-negative|Covid19 test negative. age >=18y
89552466|NCT04554277|No Intervention|Control|Usual management of heart failure. The sST-2 level will be blunted.
89552467|NCT04554277|Experimental|Biomarker guided therapy|Guided therapy using sST-2 monitoring at the discharge from initial hospitalisation, 6, 12, 18 and 24 months of following.
89552468|NCT04540575|Active Comparator|Mother Provides MOM|Receive Rush NICU standard of care lactation support
89552469|NCT04540575|Experimental|NICU Acquires MOM|Receive economic interventions in addition to Rush NICU standard of care lactation support
89552470|NCT04537377|Experimental|VTX-801|
89552471|NCT04515745||ILI/Treatment group|This group includes Look AHEAD participants who were initially assigned to the intensive lifestyle intervention (ILI), consented to administrative data linkages, and were successfully linked to Social Security Administration (SSA) databases.
89552472|NCT04515745||DSE/Control group|This group includes Look AHEAD participants who were initially assigned to the diabetes support and education (DSE) control arm, consented to administrative data linkages, and were successfully linked to SSA databases.
89552473|NCT04491344||Children with overweight and obesity|Overweight and obese children and adolescents visiting the adiposity outpatient clinic.
89552474|NCT04491344||adults|follow up of patients into adulthood
89552475|NCT04491344||control group|matched control group with children, adolescents and aduts without obesity
89552476|NCT04484350|Experimental|Intensive Blood Pressure management|Participants assigned to the intensive blood pressure management arm will be treated using approved antihypertensive medications to have systolic blood pressure readings under 140 mmHg for the first 48 hours after enrollment into the study.
89552477|NCT04484350|Active Comparator|Standard Blood Pressure management|Participants assigned to the standard blood pressure management arm will be treated using approved antihypertensive medications to have systolic blood pressure readings under 180 mmHg for the first 48 hours after enrollment into the study.
89552478|NCT04481113|Experimental|Treatment (abemaciclib, niraparib)|Patients receive abemaciclib PO BID and niraparib PO QD. Treatment repeats every 28 days for up to 2-4 cycles in the absence of disease progression or unacceptable toxicity. Patients who complete 4 cycles undergo standard of care mastectomy or lumpectomy. Patients demonstrating progressive disease after only 2 cycles are switched to receive standard of care chemotherapy prior to undergoing mastectomy or lumpectomy.
89552479|NCT04456998|Experimental|GB002 (seralutinib)|GB002 (seralutinib) inhaled orally twice per day (BID) for 24 weeks
89552480|NCT04456998|Placebo Comparator|Placebo|Placebo inhaled orally BID for 24 weeks
89552481|NCT04433897||Oral estrogen + IUD|Women who opt to be treated for their postmenopausal symptoms using Oral estrogen + IUD
89552482|NCT04433897||Oral estrogen + hysterectomy|Women who opt to be treated for their postmenopausal symptoms using Oral estrogen + hysterectomy.
89552483|NCT04433897||Oral estrogen + oral progesterone|Women who opt to be treated for their postmenopausal symptoms using Oral estrogen + oral progesterone.
89552484|NCT04433897||Transdermal estrogen + IUD|Women who opt to be treated for their postmenopausal symptoms using transdermal estrogen + IUD.
89552485|NCT04433897||Transdermal estrogen + hysterectomy|Women who opt to be treated for their postmenopausal symptoms using transdermal estrogen + hysterectomy.
89552486|NCT04433897||Transdermal estrogen + oral progesteron|Women who opt to be treated for their postmenopausal symptoms using transdermal estrogen + oral progesteron
89552487|NCT04433897||SERM|Women who opt to be treated for their postmenopausal symptoms using SERM's
89552488|NCT04433897||Aromatase inhibitor|Women who opt to be treated for their postmenopausal symptoms using aromatase inhibitor.
89552489|NCT04433897||Duavive|Women who opt to be treated for their postmenopausal symptoms using duavive.
89552490|NCT04433897||No treatment|Women who opt not to be treated for their postmenopausal symptoms.
89552491|NCT04414696|Experimental|Intervention|Participants will be asked to use a web-based (eHealth) exercise intervention for 3 months. This eHealth exercise intervention includes over 90, 10-minute exercise videos with options for exercise type, time, and intensity, customized to the weight of the infant. Users can either select up to three 10-minute videos to create a 10 to 30-minute workout or choose a 'Ready Made' workout that is either 10, 20, or 30-minutes long.
89552492|NCT04414696|No Intervention|Usual Care|Participants in the usual care condition will follow their usual standard care as suggested by their provider. Participants will complete the same assessments and incentives as the active intervention but will not receive the eHealth exercise intervention.
89552493|NCT04408950||Patients with uncharacterized immune defects|Patients with uncharacterized immune defects
89552494|NCT04408950||Unaffected biological relatives|Unaffected biological relatives
89552495|NCT04405089|Experimental|Active tDCS with cognitive training|Participants will receive 5 sessions of cognitive training concurrent with transcranial direct current stimulation (anode over right frontal cortex, cathode over left frontal cortex; 2 mAmps for 26 minutes).
89552496|NCT04405089|Sham Comparator|Sham tDCS with cognitive training|Participants will receive 5 sessions of cognitive training concurrent with sham tDCS. For sham tDCS, electrodes are placed at the same locations as for active tDCS, but current is ramped up for the initial 30 secs, then immediately ramped back down. This method mimics the initial physical sensation of stimulation, but there is no active current for the remainder of the session.
89552497|NCT04404530||Palynziq Therapy for PKU|Participants with PKU who are starting Palynziq therapy, or have recently started Palynziq therapy but have not achieved response.
89552498|NCT04403802|Experimental|Arm A: Voxx socks followed by placebo socks|Continuous wear of Voxx Human Performance Technology Socks for 2 weeks, followed by continuous wear of placebo socks for 2 weeks (separated by a 2-week washout period)
89552499|NCT04403802|Experimental|Arm B: Placebo socks followed by Voxx socks|Continuous wear of placebo socks for 2 weeks, followed by continuous wear of Voxx Human Performance Technology Socks for 2 weeks (separated by a 2-week washout period)
89552500|NCT04400760|Other|DAPA Tx|This arm will comprise the participants who are administered Dapagliflozin 10mg per oral once daily for 2 weeks.
89552501|NCT04378634|Experimental|ME/CFS Exercise|Patients undergoing the physical stress test (aerobic power index)
89552502|NCT04378634|Experimental|Patients Stress|Patients undergoing the mental stress task (MIST)
89552503|NCT04378634|Active Comparator|Healthy Exercise|Healthy controls undergoing the physical stress test (aerobic power index)
89552504|NCT04378634|Active Comparator|Healthy Stress|Healthy controls undergoing the mental stress task (MIST)
89552505|NCT04366440|Other|Order set review and modification|The antimicrobial stewardship program will review and change order sets of clean or clean-contaminated procedures to eliminate unnecessary post-operative antibiotics.
89552506|NCT04366440|Other|Order Set review and Modification plus facilitation|The antimicrobial stewardship program will receive facilitation training to aid in reviewing and changing order sets of clean or clean-contaminated procedures to eliminate unnecessary post-operative antibiotics.
89552507|NCT04362657|Experimental|Computer aided diagnosis|Using CAD to assist in completeness of the examination during OGD
89552508|NCT04338776|Experimental|UroLift|Patient randomized to the UroLift arm will receive the FDA-approved UroLift procedure.
89552509|NCT04338776|Experimental|Rezūm|Patient randomized to the Rezūm arm will receive the FDA-approved Rezūm procedure.
89552510|NCT04302961|Experimental|Auditory Feedback|Participants will complete 8 sessions over a 2-week period of walking gait retraining on a treadmill while receiving auditory feedback.
89552511|NCT04302961|Active Comparator|No Feedback|Participants will complete 8 sessions over a 2-week period of walking on a treadmill without receiving feedback.
89552512|NCT04286308|Experimental|Brain signal data collection|Brain signal data collection at the time of deep brain stimulation (DBS) surgery.
89552513|NCT04286243|Active Comparator|Model 1 - Clinic Based Screening|Model 1 involves: 1) cervico-vaginal self-sampling for high-risk HPV (hr-HPV) while waiting for appointments at the VFP clinic or other clinics, 2) same-day VIA for those women found to be hr-HPV-positive by rapid GeneXpert HPV testing, and 3) same-day thermocoagulation treatment for HPV-positive women who are eligible for ablative therapy by VIA
88961934|NCT02235051|No Intervention|Arm II (no formal exercise intervention)|Patients do not participate in a formal exercise program for 16 weeks. Patients are then offered the Curves exercise intervention.
89552514|NCT04286243|Experimental|Model 2 - Community Based Screening|Model 2 will offer women the same services as in Model 1, but they will also be given the option to perform cervico-vaginal self-sampling in the community, via Heath Surveillance Assistants (HSAs) who will bring their HPV sample to the clinic and notify them to return to the clinic for VIA and possible same-day thermocoagulation if their hr-HPV test is positive
89552515|NCT04283994|Experimental|Survey-based Patient/Clinician Jumpstart|The Survey-based Patient/Clinician Jumpstart Guide will be developed with two types of data: 1) EHR data; and 2) Survey data. Using automated methods and NLP/ML algorithms, the presence/absence of POLST, advance directives and DPOA documentation will be identified from both inpatient and outpatient notes (e.g., progress notes, specialty consult notes, alerts and care plans) preceding the current hospitalization. The survey data will be completed by patients or their surrogate/family at enrollment and will provide assessments of the following: a) preferences for discussions about goals of care; b) most important barrier and facilitator for having such discussions; and c) current goals of care. These elements are contained within the Jumpstart guides and the information is tailored to each recipient (i.e., patient, surrogate/family, or clinician).
89552516|NCT04283994|Active Comparator|EHR-based Clinician Jumpstart|The EHR-based Clinician Jumpstart Guide will be developed by using automated methods and NLP/ML algorithms to both inpatient and outpatient EHR notes (e.g., progress notes, specialty consult notes, alerts and care plans) preceding the current hospitalization. It will summarize the presence/absence of POLST, advance directives and DPOA documentation. It will not include survey-based information.
89552517|NCT04283994|No Intervention|Usual care|Patients in this arm receive usual care; neither subjects nor providers will receive either version of the Jumpstart Guide.
89552518|NCT04271202|Other|Treatment|Effects of galacenezumab (emgality) treatment (injectable 240 mg initial dose followed by 120 mg treatments 1 and 2 month later) on brain functioning.
89208119|NCT00784082||Homozygous SS sickle cell children|"Hydroxycarbamide, Hydroxyurea (drug):~Homozygous SS sickle cell children, aged > 3 years, of sub-Saharian Africa extraction, in a steady-state of disease , taken no drug except penicillin-V, folate or iron supplementation, hydroxyurea, divided into three groups :~children treated with hydroxyurea 20-25 mg/kg/day since at least 3 months with clinical efficacy on vaso-occlusive events~untreated children with major vaso-occlusive events~children > 5 year-old without a history of vaso-occlusive events~Controls : heterozygous AS parents or siblings of the patients, and AA siblings or healthy African unrelated subjects, aged > 3 years, taken no drug on the day of blood sampling."
89552519|NCT04253964|Experimental|Performance Status 0-1 Participants|"ALL study participants will receive pembrolizumab 200 mg intravenously (IV) on day 1 of each 3-week cycle.~Participants with predictive biomarker PD-L1 greater than or equal to 50%: Participants will not receive any other drugs besides pembrolizumab.~Participants with Non-squamous subtype, predictive biomarker (PD-L1 less than 50%): Participants will ALSO receive:~- Carboplatin area under the curve (AUC) 5 IV on day 1 of each 3-week cycle for 4 cycles.~PLUS~- Pemetrexed 500 mg/m2 IV on day 1 of each 3-week cycle for 4 cycles.~Participants with Squamous subtype, predictive biomarker (PD-L1 less than 50%): Participants will also receive:~Carboplatin AUC 5 IV on day 1 of each 3-week cycle for 4 cycles. PLUS~Paclitaxel 200 mg/m2 IV on day 1 of each 3-week cycle for 4 cycles. OR~Nab-paclitaxel 100 mg/m2 on day 1, 8, 15 of 3-week cycle for 4 cycles"
89025577|NCT00458510|Experimental|Fentanyl, Open-Label treatment|All patients take NasalFent at effective dose to treat up to four episodes of breakthrough cancer pain per day
89208120|NCT00784082||Homozygous SS children|"Hydroxycarbamide, Hydroxyurea (drug):~Homozygous SS children, aged > 3 years, of sub-Saharian Africa extraction, in a steady-state of disease, taken no drug except penicillin-V, folate or iron supplementation, hydroxyurea, divided into three groups :~children treated with hydroxyurea 20-25 mg/kg/day since at least 3 months with clinical efficacy on vaso-occlusive events~untreated children with major vaso-occlusive events~children > 5 year-old without a history of vaso-occlusive events~Controls : heterozygous AS parents or siblings of the patients, and AA siblings or healthy African unrelated subjects, aged > 3 years, taken no drug on the day of blood sampling."
89208121|NCT03926598||Patients/Caretakers Group|Patients with Type II Diabetes and caretakers of patients with Type II Diabetes.
89208122|NCT03926598||Certified Diabetes Educators Group|Diabetes educators who help patients manage their Type II Diabetes.
89552520|NCT04253964|Experimental|Performance Status 2 Participants|"ALL study participants will receive pembrolizumab 200 mg intravenously (IV) on day 1 of each 3-week cycle.~Participants with predictive biomarker PD-L1 greater than or equal to 50%: Participants will not receive any other drugs besides pembrolizumab.~Participants with Non-squamous subtype, predictive biomarker (PD-L1 less than 50%): Participants will ALSO receive:~- Carboplatin area under the curve (AUC) 5 IV on day 1 of each 3-week cycle for 4 cycles.~PLUS~- Pemetrexed 500 mg/m2 IV on day 1 of each 3-week cycle for 4 cycles.~Participants with Squamous subtype, predictive biomarker (PD-L1 less than 50%): Participants will also receive:~Carboplatin AUC 5 IV on day 1 of each 3-week cycle for 4 cycles. PLUS~Paclitaxel 200 mg/m2 IV on day 1 of each 3-week cycle for 4 cycles. OR~Nab-paclitaxel 100 mg/m2 on day 1, 8, 15 of 3-week cycle for 4 cycles"
89552521|NCT04251221|Experimental|Moderate Drinkers|"Aim 1:~A baseline PET scan with [11C]PBR28, a TSPO-specific radioligand, will be conducted with moderate drinkers. Next, subjects will drink a fixed alcohol dose, followed a post-alcohol [11C]PBR28 PET scan timed to capture acute neuroimmune response. [11C]PBR28 distribution volumes (VT), which are proportional to TSPO number, will be measured throughout the brain. We will test the hypothesis that acute alcohol robustly increases [11C]PBR28 VT, consistent with microglial activation. The percent change in [11C]PBR28 VT (ΔVT) from baseline will quantify the magnitude of neuroimmune response."
89208123|NCT03926598||Physician Group|Physicians who help patients manage their Type II Diabetes.
89552522|NCT04251221|Experimental|Alcohol Use Disorder (AUD)|"Aim 2:~AUD subjects will participate in the study design described in Aim 1 (a baseline [11C]PBR28 PET scan, drink a fixed alcohol dose, followed by a post-alcohol [11C]PBR28 PET scans). The magnitude of neuroimmune response, quantified by ΔVT, will be compared between moderate drinkers and individuals with AUD to test the hypothesis that the neuroimmune response to alcohol is greater in those with AUD compared to moderate drinkers, consistent with the concept of alcohol 'priming microglia'."
89552523|NCT04248257|Experimental|PeACE peer coaching arm|Behavioral, PeACE, PeACE consists of 3 streamlined 30-minute psychosocial telephone counseling sessions delivered by a well-trained peer coach. Coaches are lay YARs from HBOC families demonstrating good knowledge, communication skills, and protocol mastery.
89552524|NCT04248257|Active Comparator|Community peer coaching arm|Behavioral, usual care, Participants in the usual care arm will receive navigation to peer support with a range of community groups who provide these services.
89552525|NCT04221451|Experimental|GZ402671|"Primary population: participant will receive venglustat dose once daily during the primary analysis period (104 weeks) and the open-label extension period (104 weeks).~Secondary population: participant will receive venglustat at various doses once daily during the primary analysis period open-label (104 weeks) and the open-label extension period (104 weeks)."
89552526|NCT04221451|Placebo Comparator|Placebo|Primary population: participants will receive placebo once daily during the primary analysis period (104 weeks) and will receive venglustat dose once daily during the open-label extension period (104 weeks).
89552527|NCT04203238|Experimental|Potatoes Lean Meat (PLM)|The main entrée in the PLM arm will consist of a menu item in which 40% of the meat in the original recipe will be replaced with potatoes. The diet is designed to provide six or less ounces of meat/day which is consistent with the DASH diet.
89552528|NCT04203238|Experimental|Lean Meat Pulses (LMP)|The main entrée in the LMP arm will consist of a menu item in which 40% of the meat in the original recipe will be replaced with pulses. The diet is designed to provide six or less ounces of meat/day which is consistent with the DASH diet.
89552529|NCT04200313|Experimental|Bionic Pancreas (BP)|Some adults and 1/2 peds will be randomized to use the Bionic Pancreas (BP) with lispro or aspart for 13 weeks
89552530|NCT04200313|Experimental|Bionic Pancreas with Fiasp (BPFiasp)|Some adults will be randomized to use the Bionic Pancreas (BP) with Fiasp for 13 weeks during RCT
89025578|NCT00488007|Experimental|Active Hearing aids|Active
89025579|NCT00488007|Placebo Comparator|Inactive Hearing aids|Hearing aids turned off
89025580|NCT00458549|Experimental|omega-3 fatty acids|omega-3 fatty acids Oral 8g once a day for 21 days prior to (biopsy) surgery
89552531|NCT04200313|Other|Usual Care (UC)|Adults and peds will use their own diabetes insulin regimen plus continuous glucose monitoring (CGM) during the RCT
88961935|NCT02087826|Active Comparator|Carriers of the SLC16A11 risk allele|"Day 1: Mixed Meal Tolerance Test~Day 3-7: 500mg metformin, twice daily~Day 8: Mixed Meal Tolerance Test in presence of Metformin"
88961936|NCT02087826|Placebo Comparator|Non-carriers of the SLC16A11 risk allele|"Day 1: Mixed Meal Tolerance Test~Day 3-7: 500mg metformin, twice daily~Day 8: Mixed Meal Tolerance Test in presence of Metformin"
88961937|NCT02056119|Active Comparator|Jet Nebulizer Arm|"The Jet Nebulizer Protocol:~Physician order received for subject, randomization to jet nebulizer occurred.~Jet nebulizer, Misty Max 10™ (Carefusion, CA), placed into spring loaded t-piece between the humidifier and the ventilator (approximately 15 cm from the gas outlet).~Aerosol treatment delivered per physician order at flow rates of 8-10 L/min.~Jet nebulizer to be replaced every 3 days per hospital protocol. a. Prior to every nebulizer change or every 3 days, study staff to be notified in order to obtain cultures."
88961938|NCT02056119|Experimental|Vibrating Mesh Nebulizer Arm|"Physician order received for subject, randomization to vibrating mesh nebulizer occurred.~Aeroneb® Solo (Aerogen, Galway, Ireland) vibrating mesh nebulizer to be placed before the heater on the dry side of the heater water chamber on the inspiratory ventilator circuit.~Aerosol treatment delivered per physician order.~Mesh nebulizer to be replaced every 30 days per hospital protocol. a. Prior to every nebulizer change or every 3 days, study staff to be notified in order to obtain cultures."
88961939|NCT02048150|Experimental|Diagnostic (MDX1201-A488, IOOI, RALP)|Patients receive anti-PSMA monoclonal antibody MDX1201-A488 IV over 30 minutes on day 1 and undergo IOOI during RALP on day 3.
88961940|NCT02038452|Active Comparator|Steroid Injection|Single steroid injection into Carpal Tunnel (as Depo-medrone 20mg)
88961941|NCT02038452|Active Comparator|Wrist Splint|Wrist splint to be worn at night
88961942|NCT02019693|Experimental|Capmatinib (INC280)|INC280 400 mg twice every day by mouth, continuously
88961943|NCT01748448|Active Comparator|Vitamin D|Every month 100 000 units of Vitamin D in syringe oral dispenser is taken . Study duration is maximum 3,5 years or until relapse occurs
88961944|NCT01748448|Placebo Comparator|arachides oleum raffinatum|Every month 100 000 units of vitamin D in syringe Oral dispenser is taken. Study duration is maximum of 3.5 years or until relapse occurs
88961945|NCT01476839|Experimental|Treatment (radiolabeled monoclonal antibody, chemotherapy)|"DOSIMETRY STUDY: Patients receive basiliximab IV and indium In 111 basiliximab IV on day -21. Patients undergo indium In 111 imaging scans daily. Patients with appropriate biodistribution continue on to treatment.~TREATMENT: Patients receive basiliximab IV and yttrium Y 90 basiliximab IV on day -14. Patients also receive BEAM chemotherapy comprising carmustine IV over 2 hours on days -7 and -6, etoposide IV BID over 4 hours and cytarabine IV over 2 hours BID on days -5 to -2, and melphalan IV on day -1. Patients undergo autologous hematopoietic progenitor cell infusion on day 0."
88961946|NCT01441687|Experimental|Arm I (PMU)|Patients receive digital rectal palpation and then void a spontaneous urine sample for PMU analysis. Patients then undergo a prostate biopsy.
88961947|NCT01441687|Experimental|Arm II (EPS)|Patients receive DRE with prostatic massage for 30-60 seconds and are then milked at the urethra to provide a collection of EPS. Patients then undergo a prostate biopsy.
89552532|NCT04200313|Experimental|Bionic Pancreas Extension|Used by all participants in the EXT study
89552533|NCT04200313|Experimental|Transition Phase - BP Guidance|Adults and peds will use their own diabetes insulin regimen plus SMBG and blinded continuous glucose monitoring (CGM) in the Transition phase and use dosing based on guidance from the BP system
89552534|NCT04200313|Other|Transition- Pre-study dosing|Adults and peds will use their own diabetes insulin regimen plus SMBG and blinded continuous glucose monitoring (CGM) in the Transition phase and use dosing based on their pre-study regimen
89552535|NCT04198337|Experimental|Endoscopic Full Thickness Resection|Resection of the gastric GIST by ESD techniques followed by endoscopic closure of defect with suturing or clips and loop
89552536|NCT04197180|Experimental|Hybrid Argon Plasma Coagulation|The Hybrid-Argon Plasma Coagulation probe combines waterjet technology with Argon Plasma Coagulation. The probe comprises a central water channel for the submucosa injection function and a peripheral gas channel for the Argon Plasma Coagulation function
89552537|NCT04196062|Experimental|Robotic ESD|Treatment of early colorectal neoplasia / lateral spreading tumors by ESD using EndoMASTER EASE robotic system
89552538|NCT04194723|Experimental|Antireflux Mucosectomy|Antireflux mucosectomy targeted at resection of gastric cardia muocsa to induce fibrosis and improve on the flap value over the gastroesophageal junction
89552539|NCT04187326|Experimental|6 Month Micro Expression Training Task|The Micro Expression Training Task (METT) presents videos of subtle emotional face expressions; participants receive real-time feedback following forced choice emotional identification. The METT includes a brief pre-test, training, and then a post-test.
89552540|NCT04187326|Experimental|12 Month Micro Expression Training Task|The Micro Expression Training Task (METT) presents videos of subtle emotional face expressions; participants receive real-time feedback following forced choice emotional identification. The METT includes a brief pre-test, training, and then a post-test. Participants in this group will complete this task twelve month after their first visit.
89552541|NCT04184609|Experimental|Exercise test|"All participants will undergo a moderate-intensity exercise test under three conditions in a repeated measures study design:~Control~Albuterol"
89552542|NCT04182477||Patients with at least one general anesthesia in anamnesis|Patients who underwent during their life at least one anesthesia in anamnesis
89552543|NCT04182477||Patient without general anesthesia in anamnesis|Patients who never underwent general anesthesia during their life
89552544|NCT04174859||NVAF patients|Start treatment with rivaroxaban at the discretion of physician.
89552545|NCT04149600||Bicuspid aortic valve|We wish to investigate the etiology of calcific aortic valve disease, and aortic dilation or aneurysm in patients with a bicuspid aortic valve undergoing aortic valve replacement or aortic surgery.
89552546|NCT04149600||Tricuspid aortic valve|Data and samples will be compared using a control group comprised of patients with a tricuspid aortic valve undergoing aortic surgery.
89552547|NCT04119804||septic loosening|Septic loosening of primary hip implants according to the 2014 CDC criteria (as routinely performed in the clinical setting), adding another major and necessary criterion: at least 3 positive intraoperative tissue samples (same micro-organism).
89025581|NCT00458549|Placebo Comparator|Corn Oil|Oral 8g once a day for 21 days prior to (biopsy) surgery
89025582|NCT00488046|Experimental|1|Two, 0.5 ml doses of vaccine in nasal spray form administered at study entry and sometime between 4 and 8 weeks after initial vaccination
89208124|NCT03926598||Front Desk Staff|Front desk staff who work with physicians that treat Type II Diabetes.
89552548|NCT04119804||aseptic loosening|aseptic loosening of primary hip implants not meeting the CDC 2014 criteria
89552549|NCT04101851|Experimental|No axillary SLNB|After radiologic complete remission at the end of NAST all patients will be treated with breast-conserving surgery alone without any axillary surgery. Approximately 80% of these patients will be assigned to the single study arm (no axillary SLNB) due to breast pCR (ypT0/ypTis) at the final pathology of lumpectomy.
89552550|NCT04099524|Experimental|active tDCS|We will apply the stimulation for 20 minutes using current at 1.5mA with a ramp up and ramp down period of 30 seconds at the start and end of the session.
89552551|NCT04099524|Sham Comparator|sham tDCS|tDCS will ramp up for 30 seconds with 1 mA current and then ramp off within 10 seconds. As 30 seconds is too short for tDCS to have any effects, this will be the control condition. tDCS is on for 30 seconds because that is usually the only time individuals would experience tingling and itching - a factor we aim to equate between experimental and control conditions.
89552552|NCT04055844|Experimental|Decitabine + Ruxolitinib + DLI|Eligible subjects will receive up to 4 cycles of combined modality treatment. The number of cycles depends on response, toxicity, and the remaining cell dose.
89552553|NCT04053322|Experimental|Study Arm|
89552554|NCT04050176|Experimental|Blinded Hypnotic Medication Taper (BT)|Participants assigned to the Blinded Taper group will not know the medication dose they receive during the Structured Medication Taper (SMT) phase.
89552555|NCT04050176|Active Comparator|Open-Label Hypnotic Medication Taper (OLT)|Participants assigned to the Open-Label Hypnotic Medication Taper group will know the medication dose they receive during the SMT phase.
89552556|NCT04049279|Active Comparator|BiMobile standard cement|25 patients will receive a cemented THA with a BiMobile dual mobility cup, in a standard size after optimal reaming, resulting in a cement mantle of approximately 2mm.
89552557|NCT04049279|Active Comparator|BiMobile larger cement|25 patients will receive a cemented THA with a BiMobile dual mobility cup, in one size smaller than standard after optimal reaming, resulting in a cement mantle of approximately 4mm.
89552558|NCT04049279|Active Comparator|Avantage standard cement|25 patients will receive a cemented THA with an Avantage dual mobility cup, in a standard size after optimal reaming, resulting in a cement mantle of approximately 2mm.
89552559|NCT04031820|Active Comparator|unipolar cup|550 patients will receive a total hip arthroplasty with a unipolar cup.
89552560|NCT04031820|Active Comparator|Dual Mobility cup|550 patients will receive a total hip arthroplasty with a dual mobility cup.
89552561|NCT04029025|Active Comparator|Workflow A|Dentalwings DWOS Intraoral Scan (IOS A) + Dentalwings DWOS Implant Prosthetics Lab-Software (CAD A)
89552562|NCT04029025|Active Comparator|Workflow B|3Shape TRIOS Pod Intraoral Scan (IOS B) + Straumann CARES Lab-Software (CAD B)
89552563|NCT04029025|Active Comparator|Workflow C|Conventional Impression + conventional porcelain-fused-to metal iFDP (LabS C/CAD C).
89552564|NCT04028037|Experimental|FTPGT treated patients|"The recipient site will be prepared according to Langer&Langer modified technique, raising a split-thickness flap without vertical incisions. The harvest of palatal graft will be done using FTPG technique ant it will be made up of an apico-lateral portion of connective tissue and periosteum, and of a full-thickness central U shaped part.The palatal graft will be adapted to the recipient site and sutured."
89552565|NCT04028037|Active Comparator|CAF+SCTG treated patients|A tension-free trapezoidal flap will be elevated by the split-full-split technique. A 1-mm thick SCTG will be harvested from the palate as epithelialized graft. After epithelium removal, the graft was positioned and sutured 1mm apical to the cement-enamel junction with 5-0 resorbable sutures . The SCTG will then be covered by the tension-free coronally positioned flap by 5-0 silk sutures.
89552566|NCT04020744|Active Comparator|healthy elderly participants receiving feedback from the hippocampus|This group will consist of healthy elderly volunteers, who will receive feedback from their hippocampal activity.
89552567|NCT04020744|Sham Comparator|healthy elderly participants receiving feedback from another area|This group will consist of healthy elderly volunteers, who will receive feedback from another brain area.
89025583|NCT03274037|Experimental|Examination of cerebral MRI elastography|The mechanical waves will be induced by pressure waves guided to the mouth of the elongated subject in the MRI
89025584|NCT02956733|Active Comparator|dermotaxis|In dermotaxis (Singhs skin traction) method two parallel kirschner wires (1.5mm) will be passed through the dermis on either side of the wound margins and interconnected by compression device consisting of threaded rod having two blocks and compression knob. Gradual compression will be applied daily at the rate of 1 turn/12hours on both sides of the wound.
89033042|NCT02944487|Placebo Comparator|Placebo for singe ascending doses|These subjects received matching placebo administered orally in the morning of Day 1
89033043|NCT02944487|Placebo Comparator|Placebo for b.i.d.Group|These subjects received matching placebo administered orally in the morning and in the evening of Day 1
89033044|NCT00529997|Experimental|1|Posterior Dynamic Stabilization with the Stabilimax NZ
89033045|NCT00529997|Active Comparator|2|Posteriolateral instrumented fusion
89033046|NCT03458585||Group 1: patients attending for a 99mTc-MDP bone scan.|Group 1: Patients will be approached after they had their injection for the bone scan procedure. Completion of questionnaire will take place during the three hour uptake period, before they have the scan.
89208125|NCT03926598||Nurses|Nurses who help patients manage their Type II Diabetes.
89552568|NCT04020744|Experimental|patients with MCI receiving feedback from the hippocampus|This group will consist of patients with mild cognitive impairment, who will receive feedback from their hippocampal activity.
89552569|NCT04020744|Sham Comparator|patients with MCI receiving feedback from another brain area|This group will consist of patients with mild cognitive impairment, who will receive feedback from another brain area.
89552570|NCT04015973|No Intervention|Group A: Control|Standard Care
89552571|NCT04015973|Experimental|Group B: High energy diet|High energy diet for 8-12 weeks pre-surgery
89552572|NCT04006210|Experimental|ND0612 Group|ND0612 continuous SC infusion + Active IR-LD/CD (grey capsules) + Placebo IR-LD/CD (white capsules). Randomized DBDD Maintenance Treatment for 12 weeks.
89552573|NCT04006210|Active Comparator|IR-LD/CD Group|Placebo for ND0612 continuous SC infusion + Placebo IR-LD/CD (grey capsules) + Active IR-LD/CD (white capsules). Randomized DBDD Maintenance Treatment for 12 weeks.
89552574|NCT04006210|Other|Oral IR-LD/CD Adjustment|Active IR-LD/CD (white capsules). Open-label Treatment in Run-in 1 for 4-6 weeks.
89552575|NCT04006210|Other|ND0612 Conversion|ND0612 continuous SC infusion + Active IR-LD/CD (grey capsules). Open-label Treatment in Run-in 2 for 4-6 weeks.
89552576|NCT04006210|Other|Open-Label Extension|ND0612 continuous SC infusion + Standard of care LD/dopa-decarboxylase inhibitor. Open-label Treatment in Extension for up to 54 months.
89552577|NCT03963817||Normals|Imaging normal subjects for equipment refinement
89552578|NCT03963817||Subjects with AMD|Imaging subjects with AMD
89552579|NCT03960177|Experimental|Treatment (glucarpidase)|Patients receive standard of care HDMTX IV over 4 hours on day 1 of weeks 4, 5, 9, and 10. After 24 hours after the start of each HDMTX infusion, patients also receive glucarpidase IV over 5 minutes in the absence of disease progression or unacceptable toxicity.
89552580|NCT03939533|Experimental|Increased Volume Cohort - Cohort 1|Increased volume at each infusion site - patients will receive CUTAQUIG weekly and increase infusion volumes every 4 weeks
89552581|NCT03939533|Experimental|Increased Infusion Rate Cohort - Cohort 2|Increased infusion rate - patients will receive CUTAQUIG weekly and increase infusion rates every 4 weeks
89552582|NCT03939533|Experimental|Every Other Week Dosing Cohort - Cohort 3|Every other week dosing - patients will receive CUTAQUIG every other week at the equivalent of twice their body-weight dependent [mg/kg] weekly dose
89552583|NCT03932461|Active Comparator|Vacuum assisted closure|The VAC® Abdominal Dressing System (KCI Vacuum Assisted Closure, San Antonio, TX, USA) will be used. Intestines, including lateral aspects, are covered by the visceral protective layer. The first layer of foam is placed in the laparostoma on the visceral protective layer and must extend below the fascia at a distance of 5 cm from the facial opening. Above this, a minimum of one piece of foam is folded and placed in the laparostoma. Finally, the laparostoma will be covered by the occlusive drape. A circular opening of approximately 5 cm in diameter will be created in the drape where the connection tubes to the vacuum pump will be placed. Simultaneously while applying the negative pressure of 125 mmHg, the wound edges are approximated manually towards the midline. Each dressing change must be performed in the operation theatre with the patient in general anesthesia and muscle relaxation.
88961948|NCT01332097|Experimental|Treatment A|Single 75mg oral dose of BCT197 capsules + single oral dose of prednisone placebo capsules
88961949|NCT01332097|Placebo Comparator|Treatment B/G/E/I|Matching placebo comparator arm
88961950|NCT01332097|Active Comparator|Treatment C|Single oral dose of BCT 197 placebo capsules + single oral dose of 40mg prednisone capsules
89552584|NCT03932461|Active Comparator|"Relaparotomy on-demand"|"The Isreaelsson principle includes a running suture of the fascia with a distance of 5 mm between the stitches of 5 mm and the distance to the facial edge of 5-10 mm. Monofilament PDS 2-0 or equivalent is used. The suturing is started cranially and caudally, and the sutures are tied with self-locking knots. Four times as much suture material as the length of the wound must be used. The peritoneal fluid must be cultured at closure.~The treating surgeon decides to perform a ROD and should be guided by the patient's general condition, gastrointestinal function, renal function, and inflammatory parameters at daily rounds."
89552585|NCT03931655||Spectroscopic photoacoustic imaging|Any suspicious lymph nodes identified through ultrasound will be imaged with spectroscopic photoacoustic imaging, which is a diagnostic test to measure saturated oxygen in the nodes.
89552586|NCT03915002||Patients|"Steatohepatitis:~Alcoholic Steatohepatitis and Alcoholic liver disease~Nonalcoholic fatty liver disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH)"
89552587|NCT03915002||Disease control|Patients 18 years or older with a diagnosis of cholestatic liver diseases (primary biliary cholangitis or primary sclerosing cholangitis) or hepatotropic virus (hepatitis C or B virus), according to the current international guidelines.
89552588|NCT03915002||Control subjects|"Patients over 18 years old without a diagnosis of liver disease that for any other reason (i.e candidate to liver donor, patients with liver metastasis that require surgery, patients with any type of benign liver tumor or HCC in a healthy liver).~Patient over 18 years old with a documented alcoholic used disorder in their clinical records and without any evidence of liver disease."
89552589|NCT03905655|Placebo Comparator|Group 1|Three placebo tablets administered orally twice daily with food in addition to continuing TDF, TAF or ETV therapy
89552590|NCT03905655|Active Comparator|Group 2|Two 300 mg NTZ tablets and one placebo tablet administered orally in the morning and three placebo tablets in the evening in addition to continuing TDF, TAF or ETV therapy
88961951|NCT01332097|Experimental|Treatment D|Single oral dose of 20mg dose of BCT197 capsules
88961952|NCT01332097|Experimental|Treatment F|Single oral dose of 20 mg dose of BCT197 capsules on Day 1 and Day 6
88961953|NCT01332097|Experimental|Treatment H|Single oral dose of 75mg dose of BCT197 capsules on Day 1 and Day 6
88961954|NCT01238172|Experimental|Arm A - MEAL Program Intervention|Patients will receive dietary education and telephone counseling sessions over 24 months.
88961955|NCT01238172|Experimental|Arm B - Prostate Cancer Foundation Booklet|Patients receive information about diet, nutrition, exercise and cancer. Patients also receive regularly scheduled newsletters.
88961956|NCT01163357|Experimental|Group I (bortezomib, fludarabine phosphate, TMI, melphalan)|Patients receive fludarabine phosphate IV on days -9 to -5 and melphalan IV on day -4. Patients also undergo TMI BID on days -9 to -7. If no DLT is observed in the first cohort, bortezomib IV will be added on days -6 and -3 for subsequent cohorts.
89552591|NCT03905655|Active Comparator|Group 3|Two 300 mg NTZ tablets and one placebo tablet administered orally twice daily with food in addition to continuing TDF, TAF or ETV therapy
89552592|NCT03905655|Active Comparator|Group 4|Three 300 mg NTZ tablets administered orally twice daily with food in addition to continuing TDF, TAF or ETV therapy
89552593|NCT03863730|Experimental|Profermin Plus®|Intervention group will be drinking the liver-specialized product Profermin Plus®, based on fermented oats, Lactobacillus Plantarum 299v, barley malt and lecithin. The product also contains Thiamin, which is beneficial in patients with liver diseases.
89552594|NCT03863730|Active Comparator|Fresubin®|Fresubin® is a standard FSMP and will be used as control product. Since Profermin Plus® is a disease-specific FSMP, the documentation must prove an effect that cannot be achieved by modification of the normal diet alone or by standard FSMP's. Therefor the comparator must be a standard FSMP, i.e. a nutritionally complete FSMP with standard nutrient formulation, which may constitute the sole source of nourishment of a person, hence the reason for using Fresubin® as comparator.
89552595|NCT03862365||Polyneuropathy with pain|Clinical and diagnostic test evaluation for the establishment of polyneuropathy with pain.
89552596|NCT03862365||Polyneuropathy without pain|Clinical and diagnostic test evaluation for the establishment of polyneuropathy without pain.
89552597|NCT03862365||Diabetic polyneuropathy with pain|Clinical and diagnostic test evaluation for the establishment of diabetic polyneuropathy with pain.
89552598|NCT03862365||Diabetic polyneuropathy without pain|Clinical and diagnostic test evaluation for the establishment of diabetic polyneuropathy without pain.
89552599|NCT03862365||Carpal tunnel syndrome with pain|Clinical and diagnostic test evaluation for the establishment of carpal tunnel syndrome with pain.
89552600|NCT03862365||Carpal tunnel syndrome without pain|Clinical and diagnostic test evaluation for the establishment of carpal tunnel syndrome without pain.
89552601|NCT03851406|Active Comparator|5% Hypertonic Saline, then No Inhaled Treatment|Participants will receive 5% Hypertonic Saline following WSP exposure. After a 2-week washout period, participants will receive no treatment following WSP exposure.
89552602|NCT03851406|Active Comparator|No Inhaled Treatment, then 5% Hypertonic Saline|Participants will receive no inhaled treatment following WSP exposure. After a 2-week washout period, participants will receive 5% Hypertonic Saline following WSP exposure.
89552603|NCT03836950|Experimental|active rTMS|For active rTMS, a butterfly coil and MagVenture MagProX100 stimulator (MagVenture, Falun, Denmark) will be used. One rTMS session will consist of 40 trains of 5sec each at 110% of resting motor threshold and 15Hz will be provided at the left DLPFC.
89552604|NCT03836950|Sham Comparator|sham rTMS|For sham rTMS, the procedure will be carried out at the left DLPFC but a sham coil will be used. The MagVenture coil has an active side and a placebo side allowing a double-blind study to be conducted. The sham system looks, sounds and feels like active rTMS.
89552605|NCT03821129|Other|GORE® CARDIOFORM Septal Occluder|Single Arm Commercially available GORE® CARDIOFORM Septal Occluder
89552606|NCT03814928|Experimental|Caregivers eCourse|Education post-hip fracture delivered via eCourse.
89552607|NCT03794726|Active Comparator|Orthodontic Molar Protraction|Molar protraction using orthodontic tooth movement alone
89552608|NCT03794726|Experimental|Orthodontic Molar Protraction and PAOO|Molar protraction using orthodontic tooth movement and adjunctive Periodontally Accelerated Osteogenic Orthodontics (PAOO)
89552609|NCT03751800||Women with HMB|Women with a diagnostic of HMB according to medical criteria and based on clinical judgment that have freely chosen a chronic hormonal treatment under therapeutic indication of HMB in Spain
89552610|NCT03737786|Active Comparator|GA with mild hypercarbia (GAH)|Controlled ventilation with target end-tidal CO2 levels 50 (±5%)
89552611|NCT03737786|Active Comparator|GA with normocarbia (GAN)|Controlled ventilation with target end-tidal CO2 levels 40 (±5%)
89552612|NCT03654508|Active Comparator|ADRB2-genotype guided treatment arm|In the genotype-stratified arm, children will be treated based on their ADRB2 genotype. Children homozygous for the risk variant Arg16 and heterozygotes (Arg16Gly) will be treated with doubling dosages of their ICS. Children homozygous for the wild type allele (Gly16Gly) will receive LABA.
89552613|NCT03654508|Active Comparator|Control arm|In the control arm, genotyping will be performed for retrospective analysis, but the genotype information will not be used to guide treatment. Children in this study arm will proceed randomisation between doubling ICS dosage (n=75) or LABA treatment (n=75), the two most commonly preferred add-on options among paediatric pulmonologists in the Netherlands. The investigators choose to randomize between both treatments options, since international guidelines do not agree on the preferred treatment option.
89552614|NCT03613727|Experimental|IV Vitamin C followed by oral Vitamin C|All study participants will receive the same treatment. Each participant will be given intravenous, which means by vein (IV), vitamin C three times a day for 14 days. Then participants will take vitamin C orally (by mouth in pill form) twice a day each day until 6 months after transplant. The treatment is IV vitamin C 50 mg/kg/day. After completion of the IV vitamin C doses, oral vitamin C 500 mg twice each day.
89552615|NCT03604432|No Intervention|Control group|Electric cardiac surgery only
89552616|NCT03604432|Experimental|Treatment group|Elective cardiac surgery plus prophylactic maze procedure
89552617|NCT03593525|Experimental|SPARK Intervention|"Participants will complete symptom screening using SPARK once daily on a study-supplied iPad. For inpatients, daily reminders to complete SSPedi will appear on the iPad. Reports will be available to the child at any time. For outpatients, clinical research associates will provide the iPad in person daily and reports may be viewed at those encounters. The intervention is daily symptom screening with provision of reports to the healthcare team. Severe symptoms will result in email alerts. More specifically, SSPedi reports will be printed daily and provided in the patient chart. On days 1 and 3, an alert will be emailed to the physician providing direct medical care if any symptom is a lot or extremely bothersome (score 3 or 4 on 0-4 scale). Reports and alerts will have links to SPARK-housed CPGs."
89552618|NCT03593525|No Intervention|Standard of Care Arm|Participants randomized to the control arm will not complete daily symptom screening. They will complete SSPedi on days 1 and 5 to obtain the primary outcome. Health care providers will not be notified of their SSPedi scores and no symptom reports or symptom alerts will be generated.
89552619|NCT03572335||HIV positive with normal PFT's|HIV positive with normal baseline DLco. Subjects with DLco>80% predicted after adjustments for Hgb and Co
89552620|NCT03572335||HIV positive with mild DLco impairment|HIV positive with mild DLco impairment DLco <80% predicted after adjustments for Hgb and Co.
89552621|NCT03561441|Active Comparator|Tailored standard hydration|Patients will be randomly allocated to tailored standard hydration arm. Patients will receive hydration with lactated Ringer's solution with rate of 1.5 milliliter(mL)/kg/hr during and after ERCP. Hydration and feeding will be tailored by each patient's symptoms and serum amylase levels.
89208126|NCT00784160|Experimental|1|Lactic Acid
89208127|NCT00976053|Active Comparator|SPECT myocardial perfusion imaging|
88961957|NCT01163357|Experimental|Group II (bortezomib, fludarabine phosphate, melphalan|Patients receive fludarabine phosphate IV and melphalan IV as in Stratum I. Patients also receive bortezomib IV on days -6, -3, 1, and 4.
89208128|NCT00976053|Active Comparator|PET myocardial perfusion imaging|
89208129|NCT03906747||Patients|Patients at their end-of-life (EOL) phase attending the emergency department
89552622|NCT03561441|Experimental|Tailored aggressive hydration|Patients will be randomly allocated to tailored aggressive hydration arm. Patients will receive hydration with lactated Ringer's solution with rate of 3.0 milliliter(mL)/kg/hr during and after ERCP and bolus injection of 20mL/kg over 1 hour after ERCP. Hydration and feeding will be tailored by each patient's symptoms and serum amylase levels.
89552623|NCT03555149|Active Comparator|Regorafenib (Control)|Participants will receive treatment until unacceptable toxicity or disease progression per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.
89552624|NCT03555149|Experimental|Atezolizumab + Imprime PGG + Bevacizumab|Participants will receive treatment until unacceptable toxicity or loss of clinical benefit as confirmed by disease progression per RECIST V1.1 or lack of continued benefit as determined by the investigator.
89552625|NCT03555149|Experimental|Atezolizumab + Isatuximab|Participants will receive treatment until unacceptable toxicity or loss of clinical benefit as confirmed by disease progression per RECIST V1.1 or lack of continued benefit as determined by the investigator.
89552626|NCT03555149|Experimental|Atezolizumab + Selicrelumab + Bevacizumab|Participants will receive treatment until unacceptable toxicity or loss of clinical benefit as confirmed by disease progression per RECIST V1.1 or lack of continued benefit as determined by the investigator.
89552627|NCT03555149|Experimental|Atezolizumab + Idasanutlin|Participants will receive treatment until unacceptable toxicity or loss of clinical benefit as confirmed by disease progression per RECIST V1.1 or lack of continued benefit as determined by the investigator.
89552628|NCT03555149|Experimental|Atezolizumab + Regorafenib|Participants will receive treatment until unacceptable toxicity or loss of clinical benefit as confirmed by disease progression per RECIST V1.1 or lack of continued benefit as determined by the investigator.
89552629|NCT03555149|Experimental|Atezolizumab + Regorafenib + AB928|Participants will receive treatment until unacceptable toxicity or loss of clinical benefit as confirmed by disease progression per RECIST V1.1 or lack of continued benefit as determined by the investigator.
89552630|NCT03555149|Experimental|Atezolizumab + LOAd703|Participants will receive treatment until unacceptable toxicity or loss of clinical benefit as confirmed by disease progression per RECIST V1.1 or lack of continued benefit as determined by the investigator.
89552631|NCT03541512|Active Comparator|Mindfulness & Education|Mindfulness practice using guided HeadSpace medications plus educational materials
89552632|NCT03541512|Active Comparator|Education only|Educational materials only
89552633|NCT03530267|Active Comparator|Arm A (mFOLFOX7)|"Patients in the 5-FU / oxaliplatin arm receive modified (m) FOLFOX 7: Folinic acid 350 mg/m² and oxaliplatin 68 mg/m² by concurrent 2-h intravenous infusion, 5-fluorouracil 1920 mg/m² 46-h intravenous infusion every 2 weeks (qd15).~This regimen represents the 80% dosage reduced mFOLFOX 7. The 80% dose reduction was shown to be a tolerable regimen in frail elderly patients in the FOCUS 2 study."
89552634|NCT03530267|Experimental|Arm B (Aflibercept + mLV5FU2)|"Patients in the 5-FU / aflibercept arm receive aflibercept 4mg/kg as 1-h infusion followed by folinic acid 350 mg/m² by 2-h intravenous infusion, 5-fluorouracil 1920 mg/m² 46-h intravenous infusion (mLV5FU2) every 2 weeks (qd15).~The decision to use reduced doses of 5-FU and folinic acid was made to have comparable doses to the reduced FOLFOX 7."
89552635|NCT03515811||Abdominal|"Signia™ Stapling System using Signia™ Intelligent Loading Units with Tri-Staple™ 2.0 Intelligent Reloads.~Abdominal (approximately 53 subjects)."
89552636|NCT03515811||Thoracic|"Signia™ Stapling System using Signia™ Intelligent Loading Units with Tri-Staple™ 2.0 Intelligent Reloads.~Thoracic (approximately 74 subjects)."
89552637|NCT03463265|Experimental|Arm A, Cohort 1: nab-sirolimus in patients with recurrent high grade glioma|nab-Sirolimus (ABI-009, nab-rapamycin, albumin-bound rapamycin) was administered at 100 mg/m2 as a 30-minute IV infusion on Days 1 and 8 of every 21-day cycle.
89552638|NCT03463265|Experimental|Arm A, Cohort 2: nab-sirolimus + temozolomide (TMZ) in patients with recurrent high grade glioma|"nab-Sirolimus (60 mg/m 2 as a 30-minute IV infusion on Days 1, 8, and 15 of every 28-day cycle).~Temozolomide (PO at 50 mg/m2 daily)"
89552639|NCT03463265|Experimental|Arm A, Cohort 3: nab-sirolimus + bevacizumab in patients with recurrent high grade glioma|"nab-Sirolimus (IV 60 mg/m 2 as a 30-minute infusion on Days 1, 8, and 15 of every 28-day cycle).~Bevacizumab (IV at a fixed dose of 5 mg/kg on Days 1 and 15 of every 28-day cycle)."
89552640|NCT03463265|Experimental|Arm A, Cohort 4: nab-sirolimus + lomustine (CCNU) in patients with recurrent high grade glioma|"nab-Sirolimus was administered at 60 mg/m 2 as a 30-minute IV infusion on Days 1 and 8 of every 21-day cycle.~CCNU was administered PO at 90 mg/m2 on Day 1 of each odd 21-day cycle (ie, every 6 weeks)."
89552641|NCT03463265|Experimental|Arm A, Cohort 5: nab-sirolimus + marizomib (MRZ) in patients with recurrent high grade glioma|"nab-Sirolimus was administered at 60 mg/m 2 as a 30-minute IV infusion on Days 1, 8, and 15 of every 28-day cycle.~MRZ was administered at 0.8 mg/m 2 as a 10-minute IV infusion on Days 1, 8, and 15 of every 28-day cycle. MRZ was administered approximately 10 minutes after the end of the nab-sirolimus infusion."
89208130|NCT03906747||Family members and next-of-kin of (EOL) patients|Family members and next-of-kin of EOL patients in the emergency department
89208131|NCT03906747||Healthcare workers|Comprised of doctors in the emergency department, nurses and general practitioners
89208132|NCT00860184||50-79% stenosis|Subjects with 50-79% stenosis of the carotid artery Absence of prior ischemic neurological symptoms Age 18 or older
89208133|NCT00794300||Acute myocardial infarction patients|
89208134|NCT00787592||Silver Sulfadiazide (SSD)|Patients that receive SSD as the topical debriding agent
89208135|NCT00787592||Collagenase|Patients that receive collagenase as the debriding agent
89552642|NCT03463265|Experimental|Arm B: nab-sirolimus + temozolomide + radiotherapy in patients with newly diagnosed glioblastoma|"Induction Treatment (4 weeks) with nab-sirolimus (60 mg/m2 IV weekly); followed by~Concomitant Treatment (standard of care; 2 cycles): nab-sirolimus (60 mg/m2 IV on Days 8 and 15 of every 21-day cycle) in combination with TMZ (75 mg/m2 PO daily for 6 weeks) + radiotherapy (30 × 200 cGy, 5 days/week); followed by~Adjuvant Treatment (6 cycles) starting 4 weeks after Concomitant Treatment, with nab-sirolimus(60 mg/m2 IV on Days 1, 8, and 15 of every 28-day cycle) in combination with TMZ (150 mg/m2 PO daily on Days 1-5 of every 28-day cycle)"
89552643|NCT03459092|Experimental|Botox-based treatment regimen|First intervention is a Botulinum toxin type A injection. If further treatment is necessary, strabismus surgery can be performed.
89552644|NCT03459092|Active Comparator|Surgery-based treatment regimen|First intervention is strabismus surgery. If further treatment is necessary, strabismus surgery can be repeated.
89552645|NCT03438552|Experimental|SBRT at a total dose of 30 Gy|Placement of fiducials marker seeds in the prostate followed by the administration of stereotactic body radiotherapy at 30 Gy (5 sessions at a level of 6 Gy each- 1 session per day) 30 Gy is the first dose-level. During the treatment phase of the study, no study specific visits are scheduled and the patients will be followed as per standard of care.
89552646|NCT03438552|Experimental|SBRT at a total dose of 25 Gy|Placement of fiducials marker seeds in the prostate followed by the administration of stereotactic body radiotherapy at 25 Gy (5 sessions at a level of 5 Gy each- 1 session per day) During the treatment phase of the study, no study specific visits are scheduled and the patients will be followed as per standard of care.
89552647|NCT03438552|Experimental|SBRT at a total dose of 36 Gy|Placement of fiducials marker seeds in the prostate followed by the administration of stereotactic body radiotherapy at 36 Gy (6 sessions at a level of 6 Gy each- 1 session per day) During the treatment phase of the study, no study specific visits are scheduled and the patients will be followed as per standard of care.
89552648|NCT03373968|Experimental|givinostat|Givinostat oral suspension (10 mg/mL) twice daily in a fed state
89552649|NCT03329300|Other|All participants|Family-based Behavioral Treatment (FBT)
89552650|NCT03304210|Experimental|Abraxane 35 mg/m²|PIPAC with Abraxane (35 mg/m²) will be administered every 4 weeks for 3 cycles.
89552651|NCT03304210|Experimental|Abraxane 70 mg/m²|PIPAC with Abraxane (70 mg/m²) will be administered every 4 weeks for 3 cycles.
89552652|NCT03304210|Experimental|Abraxane 90 mg/m²|PIPAC with Abraxane (90 mg/m²) will be administered every 4 weeks for 3 cycles.
89552653|NCT03304210|Experimental|Abraxane 112.5 mg/m²|PIPAC with Abraxane (112.5 mg/m²) will be administered every 4 weeks for 3 cycles.
89552654|NCT03304210|Experimental|Abraxane 140 mg/m²|PIPAC with Abraxane (140 mg/m²) will be administered every 4 weeks for 3 cycles.
89552655|NCT03297346|Other|Breast cancer patients treated with RT|"Cardiac imaging and circulating biomarkers measurements to evaluate:~myocardial dysfunction and deformation (ECHO-ST)~coronary artery lesions and coronary artery calcium score (CT)~myocardium including tissue abnormalities, cardiac morphology and function (MRI)~blood-based biomarkers of cardiovascular changes (BLOOD)"
89552656|NCT03289741|Experimental|Octreotide then Lanreotide|Each patient on study will receive three injections of intramuscular (IM) octreotide Long Acting Release (LAR). Octreotide LAR for 3 injections followed by lanreotide for 3 injections
89552657|NCT03289741|Experimental|Lanreotide then Octreotide|Each patient on study will receive three injections of deep subcutaneous (subq) lanreotide. Lanreotide for 3 injections followed by octreotide LAR for 3 injections
89552658|NCT03125343|Experimental|No surgery|Patients with indication of complete response on follow-up MRI will undergo endoscopy, and digital rectal examination to ascertain complete response. MRI together with documentation from endoscopy will be reviewed at the Regional University Hospital to establish agreement regarding interpretation.
89552659|NCT03125343|Active Comparator|Surgery|Patients with indication of complete response on follow-up MRI will undergo endoscopy, and digital rectal examination to ascertain complete response. MRI together with documentation from endoscopy will be reviewed at the Regional University Hospital to establish agreement regarding interpretation. Patients with complete response will be offered watch and wait strategy, but the patients that want surgery will be operated according to the multi disciplinary conference decision.
89552660|NCT03109210|No Intervention|Standard Care|Participants randomized to standard care will receive normal follow-up care with their health care provider. This will include routine assessment and adjustment of PAP therapy, and instruction in proper sleep hygiene.
89552661|NCT03109210|Experimental|Intervention|In addition to standard care procedures, participants randomized to the intervention arm will receive up to two sequential treatments. First, participants will receive Online Cognitive Behavioral Therapy (OCBT). Those who meet criteria for remission after this first treatment will continue through follow-up without further treatment. Those who do not will be randomized again to either extended OCBT, or Therapist-directed Cognitive Behavioral Therapy (TCBT).
89552662|NCT03086798|Experimental|Magill forceps|experimental Magill forceps group: Magill forceps technique to facilitate nasotracheal tube advancement into trachea
89552663|NCT03086798|Experimental|cuff inflation|experimental cuff inflation group: cuff inflation technique to facilitate nasotracheal tube advancement into trachea
89552664|NCT03083652|Sham Comparator|Control|Conventional physiotherapy with NMEs device not activated
89552665|NCT03083652|Experimental|Intervention|Conventional physiotherapy with daily 30-minutes NMEs (5 days/week)
89552666|NCT03035877|Experimental|Multisystemic Therapy-Emerging Adults|This group will receive Multisystemic Therapy-Emerging Adults.
89552667|NCT03035877|Active Comparator|Enhanced Treatment as Usual|This group will have access to an enhanced version of services typically delivered to young adults who have a substance use disorder and have been in trouble with the law.
88812136|NCT05946005|Experimental|Lidocaine|Lidocaine is used to reduce sensation in the tissues in certain areas. Lidocaine can be injected or applied topically, depending on the need. These topical anesthetics are popular due to their low cost and minimal side effects. The effect of lidocaine on wound healing is still controversial. A study showed the role of lidocaine in wound healing by significantly reducing wound tensile strength on day eight and increasing collagen maturation (7)
89552668|NCT03017560|Experimental|Computerized cognitive treatment|Chosen exercises from the rehabilitation package of a commercially available, computerized, cognitive training program called Happy Neuron Pro will be used. This program was designed by a team of neurologists, neuropsychologists and cognitive psychologists, and has been successfully adapted for varying conditions of cognitive dysfunction.
89552669|NCT03017560|No Intervention|Wait list control|Participants assigned to the wait list control arm will receive no treatment while the experimental arm is participating in the computerized treatment. However, the computerized treatment program will be made available for these participants to utilize at the end of the study period.
89552670|NCT03015805|Experimental|Contingency Management|This group will receive regular probation services but will also receive the Contingency Management program for substance abuse from their juvenile probation officer during regular meetings.
89552671|NCT03015805|Active Comparator|Probation as Usual|This group will receive regular services that are usually provided by juvenile probation officers.
89552672|NCT02975453||Rivaroxaban|Non-valvular atrial fibrillation (NVAF) patients treated with rivaroxaban for at least 6 months prior to the study inclusion
89552673|NCT02911142|Experimental|1|Lenalidomide, Rituximab, Prednisone, Etopiside, Doxorubicin, Vincristine and Cyclophosphamide
89552674|NCT02864758||Group 1|Adult patients with nonvalvular atrial fibrillation (NVAF) treated with rivaroxaban
89552675|NCT02864758||Group 2|Adult patients with nonvalvular atrial fibrillation (NVAF) treated with vitamin k anatognists
89552676|NCT02864758||Group 3|Adult patients with nonvalvular atrial fibrillation (NVAF) treated with dabigatran
89552677|NCT02847598|Experimental|Part A: BIIB059 450 mg|BIIB059 450 mg administered SC, Q4W with an additional dose at Week 2 for a total of 7 doses (Weeks 0, 2, 4, 8, 12, 16, and 20) in participants with SLE with active skin manifestations and joint involvement.
89552678|NCT02847598|Placebo Comparator|Part A: Placebo|BIIB059 matching placebo administered SC, Q4W with an additional dose at Week 2 for total of 7 doses (Weeks 0, 2, 4, 8, 12, 16, and 20) in participants with SLE with active skin manifestations and joint involvement.
89552679|NCT02847598|Experimental|Part B: BIIB059 50 mg|BIIB059 50 mg administered SC, Q4W with an additional loading dose at Week 2 for a total of 5 doses (Weeks 0, 2, 4, 8, and 12) in participants with active CLE with or without systemic manifestations.
89552680|NCT02847598|Experimental|Part B: BIIB059 150 mg|BIIB059 150 mg administered SC, Q4W with an additional loading dose at Week 2 for a total of 5 doses (Weeks 0, 2, 4, 8, and 12) in participants with active CLE with or without systemic manifestations.
89552681|NCT02847598|Experimental|Part B: BIIB059 450 mg|BIIB059 450 mg administered, Q4W with an additional loading dose at Week 2 for a total of 5 doses (Weeks 0, 2, 4, 8, and 12) in participants with active CLE with or without systemic manifestations.
89552682|NCT02847598|Placebo Comparator|Part B: Placebo|BIIB059 matching placebo administered SC, Q4W with an additional loading dose at Week 2 for a total of 5 doses (Weeks 0, 2, 4, 8, and 12) in participants with active CLE with or without systemic manifestations.
89552683|NCT02834975|Experimental|Pembrolizumab, Paclitaxel + Carboplatin|"The following therapy will be administered during each 21-day cycle for a maximum of eight (8) cycles:~Pembrolizumab 200mg intravenously (IV);~Paclitaxel 175 mg/m2 IV in a neoadjuvant setting (NACT);~Paclitaxel same as NACT, OR 80 mg/m2 IV dose dense option in an adjuvant setting (ACT);~Carboplatin IV area under the curve (AUC) of 6."
89552684|NCT02822508|Experimental|BLI801 Laxative (high dose)|BLI801 Laxative (high dose)
89552685|NCT02822508|Experimental|BLI801 Laxative (mid dose)|BLI801 Laxative (mid dose)
89552686|NCT02822508|Experimental|BLI801 Laxative (low dose)|BLI801 Laxative (low dose)
89552687|NCT02822508|Placebo Comparator|BLI801 Placebo|BLI801 Placebo
89552688|NCT02811198||MDD with SI and No Attempt|Subjects will have MDD with current MDE, current suicidal ideation and no lifetime suicide attempts
89552689|NCT02811198||MDD with SI and Recent Attempt|Subjects with have MDD with current MDE, current suicidal ideation and a suicide attempt within the past 6 months
89552690|NCT02811198||MDD with no SI and Lifetime Attempt|Subjects with MDD and current MDE but no current suicidal ideation and a lifetime suicide attempt.
89552691|NCT02811198||Healthy Controls|Subjects will have no personal or family psychiatric history and no suicide attempts.
89552692|NCT02755272|Experimental|Pembrolizumab with Standard Chemotherapy|Pembrolizumab plus standard chemotherapy using carboplatin and gemcitabine.
89552693|NCT02755272|Active Comparator|Standard Chemotherapy Alone|Standard chemotherapy alone using carboplatin and gemcitabine.
89552694|NCT02741440||Affected Participants|Twenty-five (25) participants with molecularly-confirmed SCA7
89552695|NCT02708940|Active Comparator|Usual care|Control arm - these patients will get usual care as part of the PHP and IOP programs at UCLA. They will not receive mobile support messages.
89552696|NCT02708940|Active Comparator|Participatory technology development|Intervention - Patients will have access to a website that allows them to co-create mobile support messages with their therapist to support their care as part of the PHP and IOP programs at UCLA.
89552697|NCT02684123|Active Comparator|Apremilast|Apremilast 30mg twice daily
89552698|NCT02684123|Placebo Comparator|Placebo|Placebo pills twice daily
89552699|NCT02606448|Active Comparator|Femoral Nerve Block|Patients in this group received preoperative ultrasound guided femoral nerve blocks by senior anesthesiologist using ropivicaine.
89552700|NCT02606448|Experimental|Liposomal Bupivacaine|Patients in this group received local infiltration of Liposomal bupivacaine before the end of surgery.
89552701|NCT02584309|Experimental|Arm 1: Doxorubicin and Upfront Dexrazoxane|"Dexrazoxane will be given intravenously on an outpatient basis over 15 minutes on each day that doxorubicin is given.~Dexrazoxane should be given no more than 30 minutes prior to administration of doxorubicin, which is typically given on Day 1 of a 21-day cycle.~Dosing is a 10:1 ratio of dexrazoxane to doxorubicin; doxorubicin is typically given at 75 mg/m2, so dexrazoxane dosing would be 750 mg/m2.~In the event of a national shortage of dexrazoxane, 72-hour infusional doxorubicin can be used instead of dexrazoxane and bolus doxorubicin.."
89552702|NCT02584309|Active Comparator|Arm 2: control (Doxorubicin and Standard of Care Dexrazoxane)|"Doxorubicin is given as standard of care. Doxorubicin is typically given at 75 mg/m2 on Day 1 of a 21-day cycle.~Starting with cycle 5, standard of care dexrazoxane (75 mg/m2) will be given for 4 cycles.~The last 10 patients enrolled after completion of enrollment to Arm 1 will be enrolled to Arm 2."
89552703|NCT02540967||BAY86-4875|Gadovist administration goup
89552704|NCT02439775|Experimental|Renal Denervation|Renal angiography and Renal Denervation (Symplicity Spyral™ multi-electrode renal denervation system)
89552705|NCT02439775|Sham Comparator|Sham Procedure|Renal angiography
89552706|NCT02403661|Active Comparator|Post surgical electrical stimulation|Balanced AC pulse at 20 Hz with less than 30V and 0.01 ms duration will be delivered for 1 hour.
89552707|NCT02403661|Placebo Comparator|Sham stimulation|Stimulation with the same parameters delivered only for 5 s.
89552708|NCT02389244|Experimental|Regorafenib|"For adult patients (≥18 years old) : 160 mg/d once daily for the 3 weeks on / 1 week off plus Best Supportive Care (BSC) until progression (according to RECIST 1.1), intolerance or withdrawal of consent .~For children Age ≥10 years to <18 years old and BSA ≥1.30 m², regorafenib (82 mg/m²) once daily for the 3 weeks on/1 week off (without exceeding 160 mg/day) plus Best Supportive care (BSC) until progression (according to RECIST 1.1), intolerance or withdrawal of consent."
89552709|NCT02389244|Placebo Comparator|placebo|Placebo plus BCS until progression (according to RECIST V1.1) intolerance or withdrawal of consent. Patients who have received placebo will receive open-label regorafenib after objective tumor progression.
89552710|NCT02257177|Active Comparator|0.15 mg TD139 (Part 1)|4 Healthy Subjects are administered a single dose of 0.15mg TD139 inhaled as a dry powder in a fasted state. Each cohort will include a dose leader volunteer to be dosed a day before the rest of the cohort, followed by the remaining 3 subjects who will be dosed approximately 24 hours later.
89552711|NCT02257177|Active Comparator|1.5 mg TD139 (Part 1)|4 Healthy Subjects are administered a single dose of 1.5mg TD139 inhaled as a dry powder in a fasted state. Each cohort will include a dose leader volunteer to be dosed a day before the rest of the cohort, followed by the remaining 3 subjects who will be dosed approximately 24 hours later.
89552712|NCT02257177|Active Comparator|3 mg TD139 (Part 1)|4 Healthy Subjects are administered a single dose of 3mg TD139 inhaled as a dry powder in a fasted state. Each cohort will include a dose leader volunteer to be dosed a day before the rest of the cohort, followed by the remaining 3 subjects who will be dosed approximately 24 hours later.
89552713|NCT02257177|Active Comparator|10 mg TD139 Part 1|4 Healthy Subjects are administered a single dose of 10mg TD139 inhaled as a dry powder in a fasted state. Each cohort will include a dose leader volunteer to be dosed a day before the rest of the cohort, followed by the remaining 3 subjects who will be dosed approximately 24 hours later.
89552714|NCT02257177|Active Comparator|20 mg TD139 Part 1|4 Healthy Subjects are administered a single dose of 20mg TD139 inhaled as a dry powder in a fasted state. Each cohort will include a dose leader volunteer to be dosed a day before the rest of the cohort, followed by the remaining 3 subjects who will be dosed approximately 24 hours later.
89552715|NCT02257177|Active Comparator|50 mg TD139 Part 1|4 Healthy Subjects are administered a single dose of 50mg TD139 inhaled as a dry powder in a fasted state. Each cohort will include a dose leader volunteer to be dosed a day before the rest of the cohort, followed by the remaining 3 subjects who will be dosed approximately 24 hours later.
89552716|NCT02257177|Placebo Comparator|Placebo Part 1|12 Healthy Subjects are administered placebo inhaled as a dry powder in a fasted state. Each cohort will include a dose leader volunteer to be dosed a day before the rest of the cohort, followed by the remaining 3 subjects who will be dosed approximately 24 hours later.
89552717|NCT02257177|Active Comparator|0.3 mg TD139 Part 2|5 Patients with IPF are administered a single dose of 0.3mg TD139 once daily for 14 days inhaled as a dry powder.
89552718|NCT02257177|Active Comparator|3 mg TD139 Part 2|5 Patients with IPF are administered a single dose of 3mg TD139 once daily for 14 days inhaled as a dry powder.
89552719|NCT02257177|Active Comparator|10 mg TD139 Part 2|5 Patients with IPF are administered a single dose of 10mg TD139 once daily for 14 days inhaled as a dry powder.
89552720|NCT02257177|Placebo Comparator|Placebo Part 2|9 Patients with IPF are administered placebo inhaled as a dry powder.
89552721|NCT02229656|Experimental|radiotherapy and olaparib|Radiotherapy will be given with accelerated fractionation following the DAHANCA schedule Olaparib: dose escalation
89552722|NCT02207465|Experimental|Subtrial 1-Arm A (Dose Level 1 of Abraxane)|Determine if it is safe or not (via occurrence of dose limiting toxicities) for patients to receive both Abraxane and radiation therapy.
89552723|NCT02207465|Experimental|Subtrial 1-Arm B (Dose Level 2 of Abraxane: 3+4 enrollment)|Determine the maximum dose of Abraxane that is allowable and safe for patients receiving both Abraxane and radiation therapy.
89552724|NCT02207465|Experimental|Subtrial 2- Abraxane 125mg; Borderline get 55cGY, unresectable get 57.5cGY until next escalation|
89552725|NCT02203331|Placebo Comparator|Placebo|Placebo intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection
89552726|NCT02203331|Experimental|Levonorgestrel|Levonorgestrel 40 µg/d intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection
89552727|NCT02203331|Experimental|Anastrozole 300 µg/d + Levonorgestrel|Anastrozole 300 µg/d + Levonorgestrel 40 µg/d intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection
89552728|NCT02203331|Experimental|Anastrozole 600 µg/d + Levonorgestrel|Anastrozole 600 µg/d + Levonorgestrel 40 µg/d intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection
89552729|NCT02203331|Experimental|Anastrozole 1050 µg/d + Levonorgestrel|Anastrozole 1050 µg/d + Levonorgestrel 40 µg/d intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection
89552730|NCT02203331|Active Comparator|Lupron / Leuprolide acetate|Placebo intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Lupron / Leuprolide acetate 11.25 mg 3-months depot intramuscular injection
89552731|NCT02178436|Experimental|Group I: Phase Ib (gemcitabine, nab-paclitaxel, selinexor)|Patients receive gemcitabine hydrochloride IV, nab-paclitaxel IV, and selinexor PO on days 1, 8, and 15. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
89552732|NCT02178436|Experimental|Group II: Phase II Group I (gemcitabine, selinexor)|Patients receive gemcitabine hydrochloride IV on days 1, 8, and 15. Patients also receive selinexor PO on days 3, 8, and 15 of cycle 1 and on days 1, 8, and 15 for the subsequent cycles. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity
89552733|NCT02178436|Experimental|GroupIII: Phase II Group II (gemcitabine, selinexor)|Patients receive gemcitabine hydrochloride IV and selinexor PO on days 1, 8, and 15. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
89552734|NCT02170025|Experimental|Riociguat (Adempas, BAY63-2521)|Participants received 0.5 mg BAY63-2521 three times daily (tid) for 14 days. The dose would be increased to 1 mg BAY63-2521 for an additional 14 days, if this was considered safe and tolerable on the basis of the available data for a given patient.
89552735|NCT02170025|Experimental|Placebo|Participants received matching placebo tid.
89552736|NCT02164578|Experimental|Rivaroxaban|5mg b.i.d. for 20 weeks (primary phase) + additional 32 weeks (extension phase)
89552737|NCT02164578|Active Comparator|Aspirin|100mg once daily for 20 weeks (primary phase) + additional 32 weeks (extension phase)
89552738|NCT02054247|Experimental|ultrasound|ultrasound : a frequency of 1 megahertz and with an intensity of 1 W/cm2
89552739|NCT02054247|Experimental|pulsed ultrasound|pulsed ultrasound : a frequency of 1 megahertz and with an intensity of 1 W/cm2 and a pulsed mode duty cycle of 1:4
89552740|NCT02054247|Placebo Comparator|placebo ultrasound|placebo ultrasound : same ultrasound device as described above seemed to be working but without delivering any output
88961958|NCT01030250||Under 65 years|Breast cancer patients receiving adjuvant chemotherapy. Those under 65 years of age will be prospectively evaluated for outcome.
88961959|NCT01030250||Over 65 years|Breast cancer patients receiving adjuvant chemotherapy. Those over 65 years of age will be prospectively evaluated for outcome.
88961960|NCT00977457|Experimental|Diagnostic (specimen collection)|Patients receive prostatic massage and undergo a digital rectal examination. Laboratory assessments are performed and blood samples are collected for molecular biology testing. On the day of the scheduled prostatectomy, a second blood collection is performed prior to surgery.
88961961|NCT00967005|Experimental|N Acetyl Cysteine|The objective of this application is to examine whether, given its mechanism of action, the dietary supplement, N-acetyl cysteine (NAC) will reduce both tobacco use and PG symptoms in nicotine dependent pathological gamblers.
88961962|NCT00967005|Placebo Comparator|Sugar Pill|
88961963|NCT00873288|Active Comparator|Usual Care mailing intervention|routine colposcopy reminder letter mailed
88961964|NCT00873288|Experimental|CIS support mailing intervention|Mailed reminder plus provider recommendation to call CIS and sample questions to ask
88961965|NCT00660946||37 dialysis patients|37 chronic hemodialysis patients on warfarin requiring Laboratory INR monitoring for anticoagulation management.
88961966|NCT00538031|Active Comparator|Arm I|Patients receive oral cyclophosphamide once daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
88961967|NCT00538031|Experimental|Arm II|Patients receive oral cyclophosphamide once daily and oral celecoxib twice daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
88961968|NCT00477958|Experimental|Geriatric Assessment Tool|
88961969|NCT00203996|No Intervention|Aim 1: Placebo|One of the 3 treatment arms in Aim 1: Placebo. No subjects were randomized to this arm.
88961970|NCT00203996|Experimental|Aim 1: Pioglitazone|One of the 3 treatment arms in Aim 1: Pioglitazone. No subjects were randomized to this arm.
88961971|NCT00203996|Experimental|Aim 1: Leuprolide + Estrogen/Progestin|One of the 3 treatment arms in Aim 1: depot leuprolide plus estrogen/progestin replacement. No subjects were randomized to this arm.
88961972|NCT00203996|Experimental|Aim 2: PCOS + SDB|One of the 2 study groups in Aim 2: Women with polycystic ovary syndrome (PCOS) and sleep disordered breathing (SDB) were treated with 8 weeks of continuous positive airway pressure (CPAP).
88961973|NCT00203996|Experimental|Aim 2: Matched Controls|One of the 2 study groups in Aim 2: Women who were of similar age to those in the PCOS+SDB group were treated with 8 weeks of continuous positive airway pressure (CPAP). The recruitment of control subjects for this protocol was hindered by the difficulty in finding subjects who met both inclusion and exclusion criteria. As a consequence, the sample size of control subjects was insufficient to allow for any meaningful conclusions to be drawn. Statistical analyses were not possible due to insufficient sample size.
88961974|NCT00203996|Experimental|Aim 3: REM frag - SWS supp - Baseline|"Each subject was assessed under three experimental conditions in the following order.~REM fragmentation: Rapid eye movement (REM) sleep will be fragmented by experimentally induced microarousals for 3 consecutive nights and non-REM sleep will be left undisturbed.~Slow wave sleep (SWS) suppression: Slow wave activity will be suppressed without awakening the subject and REM sleep will be left undisturbed.~Baseline: Baseline sleep (i.e., with no experimental intervention) assessment is recorded. This assessment may have been recorded as the first, second, or third intervention."
89552741|NCT01946100|Other|Multifocal Lung Adenocarcinoma|
89552742|NCT01823198|Experimental|Treatment (NK cells, PBSC transplant)|Patients receive fludarabine phosphate IV over 1 hour and busulfan IV over 3 hours on days -13 to -10. Patients then receive allogeneic CD56-positive CD3-negative natural killer cells IV over 1 hour on day -8. Patients also receive aldesleukin SC QD on days -8 to -4. Patients then undergo allogeneic PBSC transplant on day 0.
89552743|NCT01761292|Experimental|Givinostat|Givinostat will be administered as 2 oral doses daily while the child is in fed state.
89552744|NCT01742819||Advanced glaucoma|Patients with MD < -6 or visual field loss within the central 10 degrees of the visual field.
89552745|NCT01725113|Experimental|Calcitriol, then Paricalcitol|Patients randomized to an active vitamin D treatment protocol based on IV calcitriol. After 14 weeks, patients cross-over to an active vitamin D protocol based on IV paricalcitol for 14 weeks.
89552746|NCT01725113|Active Comparator|Paricalcitol, then Calcitriol|Patients randomized to an active vitamin D treatment protocol based on IV paricalcitol. After 14 weeks, patients cross-over to an active vitamin D protocol based on IV calcitriol for 14 weeks.
89552747|NCT01580293|Experimental|Arm 1|On-demand treatment of BAY94-9027 at individual dose and number of infusions based upon location and severity of bleeds
89552748|NCT01580293|Experimental|Arm 2|Prophylaxis treatment of BAY94-9027; 2 infusions per week over 10 weeks followed by 2 infusions per week over 26 weeks in the main trial; and at least 1 day per week in the extension for at least 100 ED
89552749|NCT01580293|Experimental|Arm 3|Prophylaxis treatment of BAY94-9027; 2 infusions per week over 10 weeks followed by infusion every 5 days over 26 weeks in the main trial; and at least 1 day per week in the extension for at least 100 ED
89552750|NCT01580293|Experimental|Arm 4|Prophylaxis treatment of BAY94-9027; 2 infusions per week over 10 weeks followed by infusion every 7 days over 26 weeks in the main trial; and at least 1 day per week in the extension for at least 100 ED
89552751|NCT01546766||Subjects with diabetes|(Subjects that have been diagnosed with diabetes).
89552752|NCT01546766||Control volunteers|(Subjects with no history of ocular problems).
89552753|NCT01546766||Subjects with retinal conditions|(Subjects with a history of retinal disorders except diabetes).
89552754|NCT01089933|Experimental|Thoracic PVB + multimodal anesthesia|Thoracic PVB + multimodal anesthesia
89552755|NCT01089933|Active Comparator|Local anesthetic + multi-modal analgesia|Local anesthetic + multi-modal analgesia
89552756|NCT00668772|Experimental|Tiotropium/Salmeterol QD|Tiotropium/Salmeterol Inhalation Powder, Hard Polyethylene Capsule
89552757|NCT00668772|Active Comparator|Tiotropium QD|Tiotropium Inhalation Powder, hard gelatine capsule (Spiriva®)
89552758|NCT00668772|Active Comparator|Salmeterol BID|Salmeterol Inhalation Powder, hard PE capsule
89552759|NCT00668772|Active Comparator|Tiotropium/Salmeterol QD + Salmeterol|Tiotropium/Salmeterol Inhalation Powder, Hard Polyethylene Capsule, plus Salmeterol Inhalation Powder, hard PE capsule
89552760|NCT00668772|Placebo Comparator|Placebo|Placebo Inhalation Powder, hard PE capsule / hard gelatine capsule
89552761|NCT00595491|Experimental|allergic asthmatic, allergic nonasthmatic, healthy|Adults who are allergic asthmatics, allergic nonasthmatics, or healthy controls will receive segmental allergen challenge to the lung
89552762|NCT00487305|Experimental|Biological/Vaccine|"Biological/Vaccine: Lethally Irradiated Lymphoma cells with GM-CSF K562 Cells Dose will vary depending upon number of cells collected and when the participant is enrolled on the study: the vaccine is given as an injection under the skin once weekly for 3 weeks then every other week for 3 vaccines.~--------------------------------------------------------------------------------"
89552763|NCT00294827|Experimental|Liver transplantation|
89552764|NCT00208507|Active Comparator|Delta Ceramax Ceramic-on-Ceramic Acetabular Cup System|Total hip replacement with a 28 mm ceramic head and liner.
89552765|NCT00208507|Active Comparator|Pinnacle™ Acetabular Cup with Marathon® Polyethylene|Total hip replacement with 28 mm ceramic head with a polyethylene liner.
89552766|NCT00167219|Experimental|Intent-to-Treat|Patients receiving study regimen.
89552767|NCT05120921|Active Comparator|standard osteopathic manual treatment|Pragmatic individualised osteopathic manual treatment which is a system of diagnosis and treatment for a wide range of musculoskeletal conditions. Osteopaths take a detailed case history and perform a thorough clinical examination to help understand the nature of patients' pain and symptoms so that they can arrive at a diagnosis. Practitioners use touch, physical manipulation, stretching and massage to help increase the mobility of joints, to relieve muscle/joint tension and pain. Osteopaths often combine a range of other treatment techniques in their approach, such as rehabilitative exercises, advice about how patients can self-manage their condition and educational approaches to help them understand their pain. Osteopathy is a regulated profession (regulated by the General Osteopathic Council) in the UK
89552768|NCT05120921|Active Comparator|biopsychosocially informed osteopathic manual treatment|As for the active comparator + biopsychosocial management: after having a completed a 8-10 hour e-learning on the biopsychosocial model for the management of low back pain, osteopaths will use the same approaches as in the active comparator group, plus techniques to help patients making sense of their symptoms, to develop patients' self-efficacy, and psychosocial management skills.
89552769|NCT05745259|Active Comparator|Alteplase|Patients will receive intravenous Alteplase at the standard licensed dose of 0.9 mg/kg up to a maximum of 90mg, 10% as bolus and the remainder over 1 hour.
89552770|NCT05745259|Experimental|Tenecteplase|Patients will receive intravenous Tenecteplase, 0.25mg/kg, maximum 25mg, administered as a bolus over 5~10 seconds
89552771|NCT05118581|Experimental|patients need vascular access|Arterial or venous cathetrization guided by ultrasound
89552772|NCT02928107|Experimental|At-Home Telephone Screening (Tele-HS)|Subjects receive printed educational materials about hearing loss and access to at-home Tele-HS
89552773|NCT02928107|Experimental|PCP Encouragement, At-Home Tele-HS|Subjects receives encouragement from primary care provider (PCP) or hearing screening, printed materials and access to at-home Tele-HS.
89552774|NCT02928107|Experimental|PCP Encouragement, In-Office Tele-HS|Subjects receives PCP encouragement for hearing screening, printed materials and access to Tele-HS while in clinic.
89552775|NCT02928107|No Intervention|CHEER Cohort (non-randomized)|Participants will complete a one page questionnaire related to Red Flag conditions during a routine Otolaryngology appointment for suspected hearing loss. The audiologist will be complete a questionnaire about the participants audiological assessment including Red Flag conditions. The Otolaryngology provider will complete a questionnaire about the participants otoscopic exam findings, Red Flag conditions, and indicate if any other conditions exist that me be considered a medical contraindication to hearing aid fitting.
89552776|NCT02893241||Cohort A|Patients ≥ 50 years old, with pre-existing comorbidities, who receive general anaesthesia
89552777|NCT02893241||Cohort B|Patients, who undergo caesarean section under spinal anaesthesia
89033047|NCT03458585||Group 2: patients attending for a 18F- FDG PET/CT scan.|Group 2: Patients will be approached and consented after they had their injection and scan for 18F- FDG PET/CT. Completion of questionnaire will take place immediately after patients have changed and wait to leave the department, while they wait for their scan to be checked .
89033048|NCT02943395|Experimental|dual cure amine free adhesive resin cement|resin cement that get activated by both light and chemicals
89552778|NCT02395237|Experimental|Amaryl® M IR 2/1000 (manufactured in India)|Investigational products :Reference formulation Trade Name: Amaryl® M IR 2/1000 (manufactured in India) Dosage Form: Film coated tablet 1x1 Active Substance: Glimepiride/metformine HCl 2 mg/1000 mg Manufacturer: Goa, India
89552779|NCT02395237|Experimental|Amaryl® M IR 2/1000 (manufactured in Turkey)|Dosage form: Film coated tablet 1x1 Active substance : Glimepiride/metformine HCl 2 mg/1000 mg Manufacturer: Zentiva TR, Lüleburgaz
89552780|NCT02394847|Other|propofol|dose of propofol according to the number of therapies
89552781|NCT03167125|Active Comparator|Automated Prompts|Patients randomized to this arm will receive automated prompts to complete and return the FIT kit.
89552782|NCT03167125|Active Comparator|Automated Plus Live Prompts|Patients randomized to this arm will receive automated prompts plus linguistically and culturally tailored live prompts to complete and return the FIT kit.
89552783|NCT03167125|No Intervention|Usual Care|Patients randomized to this arm will receive usual care screening opportunities per recommended colorectal cancer screening guidelines.
89552784|NCT05745181|Experimental|CAR-T Cell Infusion|Peripheral blood mononuclear cells were isolated, amplified and cultured in vitro, pretreated with FC regimen, and Anti-CD1a CAR-T cells were transfused.
89552785|NCT01960348|Active Comparator|patisiran (ALN-TTR02)|
89552786|NCT01960348|Placebo Comparator|Sterile Normal Saline (0.9% NaCl)|
89552787|NCT04508699|Experimental|Developmental language disorder|Children with language impairment but in the absence of cognitive deficits
89552788|NCT04508699|Active Comparator|Typical language|Children with typical language development and typical cognitive development
89552789|NCT02395159|Experimental|Prevena™ IMS|The patients in the experimental arm will be treated with the Prevena™ IMS seven days after the surgery
89552790|NCT02395159|Other|sterile plaster dressings|The wound will be treated with the conventional wound management method of sterile plaster dressing.
89552791|NCT05021861||Test group 1|FEMALE PATIENTS WITH PCOS ON CPA/EE DRUG REGIMEN FOR ATLEAST 6 MONTHS.
89552792|NCT05021861||Test group 2|FEMALE PATIENTS WITH PCOS( NEWLY DIAGNOSED) ,NOT ON ANY MEDICATION,
89552793|NCT05021861||Control group|SYSTEMICALLY HEALTHY FEMALES
89552794|NCT02403115||Lupus Nephritis|Collection of serum at onset and during subsequent follow-up at 6, 12, 24 and 36 months for the dosage of circulating autoantibodies.
89552795|NCT02403115||Incident SLE without nephritis|Collection of serum at onset and during subsequent follow-up at 6, 12, 24 and 36 months for the dosage of circulating autoantibodies, in order to evaluate the presence of nephritic manifestations.
89552796|NCT02403115||Prevalent SLE without nephritis|Collection of serum at onset and during subsequent follow-up at 6, 12, 24 and 36 months for the dosage of circulating autoantibodies in order to evaluate the presence of nephritic manifestations.
89552797|NCT02403115||Rheumatoid arthritis|Collection of serum at onset and during subsequent follow-up at 6, 12, 24 and 36 months for the dosage of circulating autoantibodies in order to evaluate the presence of nephritic manifestations.
89552798|NCT02403115||Membranous glomerulonephritis|Collection of serum at onset and during subsequent follow-up at 6, 12, 24 and 36 months for the dosage of circulating autoantibodies in order to exclude secondary forms of the disease.
89552799|NCT05230355|Active Comparator|group A the standard technique|cyclophotocoagulation is applied along the upper and lower hemispheres over pars plana -3 mm behind the limbus
89552800|NCT05230355|Active Comparator|Group B a modified technique|cyclophotocoagulation is applied over one hemisphere only (180 degrees) along pars plana-3 mm behind the limbus- followed by a second application over pars plicata-1.2 mm behind the limbus- along the same hemisphere (ie, in a double arc fashion).
89552801|NCT04664062|Active Comparator|Home|This induction arm is asynchronous and unobserved. The home induction is done primarily by the participant in their home or current residence. The participant receives instruction on induction process from clinic team at an in-person or telehealth visit. Home induction is initiated by the participant at a time and place (other than the practice) determined by the participant. The participant determines when to stop taking opioids, begins withdrawal, monitors symptoms, administers the SOWS, and determines when to take first dose of medication, per the instructions and protocol provided. The clinic team does not observe or have contact with the participant while the participant undergoes these steps or takes the first dose. The participant continues this process for additional doses. Follow-up contact with clinic team may occur after the first or second day, typically within a week.
89552802|NCT04664062|Active Comparator|Office|This induction arm is synchronous and observed by the clinical team. The participant receives instruction from clinic team at an in-person or telehealth visit. On a pre-determined day, the participant stops taking opioids and comes to office with mild to moderate withdrawal. The clinic team monitors the participant, assesses symptoms, administers COWS to determine time of first dose of medication, and administers first dose with the participant. The clinic team observes and has in-person contact with the participant. Office induction includes the observed administration of the first dose, followed by observation and evaluation 30-60 minutes after the first dose. After 30-60 minutes of observation, the clinic team and participant decide whether to administer the second dose in the office or for the participant to leave the clinic to administer subsequent doses. On rare occasions, a second dose may not be needed (if the participant has a low COWS score after just one dose).
89608659|NCT05582655|Experimental|ONLINE + COACH|"Families randomized to add coaching will receive access to the ONLINE intervention program as described above. However, every second check in call will be shifted to a 45-minute live coaching session with their community interventionist. The coaching session will begin with a brief check-in and review of the target content for the session. This will be followed by support to set up the environment. The child will then join the interaction and the interventionist will provide real time coaching supports for the caregiver to practice the intervention strategies with their child. The session will end with a short discussion to debrief on the practice session.~Slower responders to phase 1 ONLINE + COACH intervention will intensify in phase 2 where check in calls are modified to include video feedback and review."
89208136|NCT00787670|Experimental|Gastric Bypass Surgery|Gastric Bypass Surgery consists of a laparoscopic approach and includes the creation of an isolated 10-15-ml proximal gastric pouch, a retro-colic, retro-gastric Roux-en-Y gastrojejunostomy with linear stapler technique, a 100-cm Roux-limb, a 30-cm biliopancreatic limb, and a stapled end-side enteroenterostomy.
89033049|NCT02943395|Active Comparator|light cured adhesive resin cement|resin cement that only get activated by light
89208137|NCT00787670|Active Comparator|Diabetes Support and Education|Diabetes Support and Eduction. Subjects attend three educational/social support sessions for 1 year after enrollment. The educational sessions offered for diabetes support and education including informational sessions on diet/nutrition and exercise. These sessions are informational only and do not teach behavioral self-regulation skills. Different nutrition and exercise topics are covered each session. Education
89208138|NCT00787670|Active Comparator|Tissue Control Group|Tissue control group includes subjects who are undergoing other non-gastric bypass abdominal surgery. A pea size piece of omentum and subcutaneous fat will be collected.
89208139|NCT00863850|Experimental|1|
89552803|NCT04664062|Active Comparator|Telehealth|This induction arm is synchronous via phone or video contact and observed. The participant receives instruction on induction process from clinic team at an in-person or telehealth visit. The participant undergoes the same process as an office induction but from a location other than the clinic. Like an office induction, the participant has regular contact with someone from the practice team on Day 1 of induction. Prior to initiating the first dose, the participant has contact by phone or video with the clinic team to assess symptoms and determine level of withdrawal (using COWS or SOWS). The administration of the first dose of medication is determine by the clinic team during phone or video contact, and the clinic team is in contact with the participant by phone or video when the first dose is taken. This process continues through the second and possible third dose. The participant is re-assessed via video or phone regularly by clinic staff and prescriber throughout this process.
89208140|NCT00794456|Experimental|1|Association of Passiflora incarnata L; Crataegus Oxyacantha L and Salix alba L.
88961975|NCT00203996|Experimental|Aim 3: REM frag - Baseline - SWS supp|"Each subject was assessed under three experimental conditions in the following order.~REM fragmentation: Rapid eye movement (REM) sleep will be fragmented by experimentally induced microarousals for 3 consecutive nights and non-REM sleep will be left undisturbed.~Baseline: Baseline sleep (i.e., with no experimental intervention) assessment is recorded. This assessment may have been recorded as the first, second, or third intervention.~SWS suppression: Slow wave activity will be suppressed without awakening the subject and REM sleep will be left undisturbed."
89208141|NCT00794456|Active Comparator|2|Valeriana officinalis 50 mg
89552804|NCT02403037|Experimental|True Auricular Acupressure Group|Participants in this group will receive standard antiemetics before and during chemotherapy, and a 5-day auricular acupressure treatment protocol for controlling nausea and vomiting during the first cycle of chemotherapy.
89552805|NCT02403037|Sham Comparator|Sham Auricular Acupressure Group|Participants in this group will receive standard antiemetic medications before and during chemotherapy, and a 5-day sham auricular acupressure intervention protocol during the first cycle of chemotherapy.
89552806|NCT02403037|Other|Standard Care Group|Participants in this group will only receive standard anti-emetic treatment before and during chemotherapy.
89552807|NCT02653625|Experimental|Cenicriviroc 150 mg|One tablet of Cenicriviroc 150 mg once daily with food in the morning for 24 weeks.
89552808|NCT05745025|Experimental|rTMS and Rehabilitation|Subjects in this arm will get rTMS to the contralateral motor cortex and best practice rehabilitation.
89552809|NCT05745025|Sham Comparator|Sham rTMS and Rehabilitation|Subjects in this arm will get sham rTMS to the contralateral motor cortex and best practice rehabilitation.
89552810|NCT01981096|Experimental|Fibromyalgia Integrative Training|8 week (16 sessions) combined intervention with cognitive-behavioral therapy and neuromuscular training
89552811|NCT01981096|Active Comparator|Cognitive Behavioral Therapy|8 week (16 session) cognitive-behavioral therapy treatment.
89552812|NCT02394613|Experimental|ANX776|Using and increasing dose storer design, GLAUCOMA and NORMAL patients will be randomly grouped to received the intervention (0.1 mg, 0.2 mg, 0.4 mg, 0.5 mg). 1 NAION patient will receive each dose once it has been proven safe in GLAUCOMA and NORMAL patients, as part of the secondary objective of this trial.
89552813|NCT02394691|Active Comparator|anodal stimulation|Patients receive an anodal tDCS (on the left dorsolateral prefrontal cortex) every day for 4 weeks, 5 days per week (tDCS of 2mA during 20minutes). A CRS-R is performed at baseline (before the first stimulation) and after the tDCS session. A final CRS-R is performed 8 week after the end of the session to assess the potential long term effects of tDCS.
89552814|NCT02394691|Placebo Comparator|sham stimulation|Patients receive a sham tDCS (on the left dorsolateral prefrontal cortex) every day for 4 weeks, 5 days per week (tDCS of 2mA during 5 secondes at the begining and the end of the stimulation to mimic the effects of tDCS). A CRS-R is performed at baseline (before the first stimulation) and after the tDCS session. A final CRS-R is performed 8 week after the end of the session to assess the potential long term effects of tDCS.
89552815|NCT02652767|Experimental|GS010-treated Eyes|Each participant will have one eye randomly selected to receive a single injection of GS010 and the other eye will receive a sham injection. GS010-treated Eyes: GS010 is a recombinant adeno-associated viral vector serotype 2 (rAAV2/2) containing the wild-type ND4 gene (rAAV2/2-ND4). Participants will receive a single dose of GS010 in one of their randomly selected eyes, via intravitreal injection containing 9E10 viral genomes in 90μL balanced salt solution (BSS) plus 0.001% Pluronic F68®.
89208142|NCT00860340|Experimental|1|Study patient will take 100mg tablet of Spironolactone
89208143|NCT00867828|Experimental|1|Neptune Krill Oil(TM)softgels (1g QD). Each softgel of Neptune Krill Oil will provide approximately 150 mg EPA and 100 mg DHA.
89208144|NCT00867828|Active Comparator|2|Fish oil softgels (1g QD). Each softgel of Fish Oil will provide approximately 150 mg EPA and 100 mg DHA.
89208145|NCT00867828|Placebo Comparator|3|Placebo (soy oil) softgels (1g QD. The soy oil placebo will provide neither EPA nor DHA.
89208146|NCT00784316|Active Comparator|metoprolol|
89208147|NCT00784316|Active Comparator|amiodarone|
89208148|NCT04040556||anesthesia residence|anesthesia residences who currently study in the department of Anesthesia and voluntarily enrolled into the study
89208149|NCT00286429|Placebo Comparator|Insulin|
89208150|NCT00286429|Experimental|Alogliptin 12.5 mg QD|
89208151|NCT00286429|Experimental|Alogliptin 25 mg QD|
89208152|NCT00665444|Experimental|A|Aripiprazole
89208153|NCT00860418|Active Comparator|1|Standard asthma education delivered during 2 home visits by a nurse.
89208154|NCT00860418|Experimental|2 PAAL|PAAL
89208155|NCT00867906|Other|Cohort 1|Asthmatics using salbutamol only, subjects to receive either Cat-PAD or placebo comparator
89552816|NCT02652767|Sham Comparator|Sham-treated Eyes|Each participant will have one eye randomly selected to receive GS010 and the other eye will receive a sham injection. Eyes receiving sham injection will undergo the same preparatory procedures as eyes receiving GS010 injection, including pupillary dilation, topical anti-infection and topical anesthetic procedures. Sham intravitreal injection will be performed by applying pressure to the eye at the location of a typical intravitreal injection procedure using the blunt end of a syringe without a needle.
89552817|NCT04480333|Experimental|Drug: NA-831 - 0.10 mg/kg|3 Subjects will take inhaled formulation of NA-831 once a day for 5 days
89552818|NCT04480333|Placebo Comparator|Comparable Placebo- 0.10 mg/kg|3 subjects will take inhaled formulation of placebo once a day for 5 days
89552819|NCT04480333|Experimental|Drug: NA-831 - 0.20 mg/kg|6 Subjects will take inhaled formulation of NA-831 once a day for 5 days
89552820|NCT04480333|Placebo Comparator|Comparable Placebo- 0.20 mg/kg|3 subjects will take inhaled formulation of placebo once a day for 5 days
89552821|NCT04480333|Experimental|Drug: GS-5734 - 1.00 mg/kg|3 Subjects will take inhaled formulation of GS-5734 once a day for 5 days
89552822|NCT04480333|Placebo Comparator|Comparable Placebo- 1.00 mg.kg|3 Subjects will take inhaled formulation of GS-5734 once a day for 5 days
89552823|NCT04480333|Experimental|Drug: GS-5734 - 2.00 mg/kg|6 Subjects will take inhaled formulation of GS-5734 once a day for 5 days
89552824|NCT04480333|Placebo Comparator|Comparable Placebo - 2.00 mg/kg|3 Subjects will take inhaled formulation of GS-5734 once a day for 5 days
89552825|NCT04480333|Experimental|Drugs: NA-831 (0.10 mg/kg) plus GS-5734 (1.00 mg/kg)|3 Subjects- will take inhaled formulation NA-831 (0.10 mg/kg) plus GS-5734 (1.00 mg/kg) once/day for 5 days
89552826|NCT04480333|Placebo Comparator|Placebo- 0.10- mg/kg placebo+1.00 mg mg/kg|3 Subjects - inhaled formulation of placebo once/day for 5 days
89552827|NCT04480333|Experimental|Drugs: NA-831( 0.20 mg/kg) + GS-5734 (2.00 mg/kg)|6 Subjects- inhaled formulation of NA-831 (0.20 mg/kg) + GS-5734 (2.00 mg/kg) once/day for 5 days
89552828|NCT04480333|Placebo Comparator|Placebo- 0.20 mg/kg + 2.00mg/kg|3 Subjects- inhaled formulation of placebo once/day for 5 days
89552829|NCT03166891|Experimental|chiauranib|Patients take Chiauranib capsules 50mg, orally once daily, 28 days as a cycle.
89552830|NCT04969601|Experimental|Anti Covid with COMIRNATY® (BNT162b2) vaccine|Two injections of COMIRNATY® (BNT162b2) vaccine 21-28 days apart
89552831|NCT01980940|Experimental|Pt 1: ETOR 75 DMSO/ETOR 150 PG/ETOR 75 PG/ETOR 150 DMSO|Single-dose etoricoxib 75 mg (1.97 mL) 4% DMSO gel, followed by single-dose etoricoxib 150 mg (4.30 mL) 4% PG gel, followed by single-dose etoricoxib 75 mg (2.15 mL) 4% PG gel, followed by single-dose etoricoxib 150 mg (3.94 mL) 4% DMSO gel. All treatments were applied topically.
89552832|NCT01980940|Experimental|Pt 1: ETOR 75 PG/ETOR 75 DMSO/ETOR 150 DMSO/ETOR 150 PG|Single-dose etoricoxib 75 mg (2.15 mL) 4% PG gel, followed by single-dose etoricoxib 75 mg (1.97 mL) 4% DMSO gel, followed by single-dose etoricoxib 150 mg (3.94 mL) 4% DMSO gel, followed by single-dose etoricoxib 150 mg (4.30 mL) 4% PG gel. All treatments were applied topically.
89552833|NCT01980940|Experimental|Pt 1: ETOR 150 DMSO/ETOR 75 PG/ETOR 150 PG/ETOR 75 DMSO|Single-dose etoricoxib 150 mg (3.94 mL) 4% DMSO gel, followed by single-dose etoricoxib 75 mg (2.15 mL) 4% PG gel, followed by single-dose etoricoxib 150 mg (4.30 mL) 4% PG gel, followed by single-dose etoricoxib 75 mg (1.97 mL) 4% DMSO gel. All treatments were applied topically.
89552834|NCT01980940|Experimental|Pt 1: ETOR 150 PG/ETOR 150 DMSO/ETOR 75 PG/ETOR 75 DMSO|Single-dose etoricoxib 150 mg (4.30 mL) 4% PG gel, followed by single-dose etoricoxib 150 mg (3.94 mL) 4% DMSO gel, followed by single-dose etoricoxib 75 mg (1.97 mL) 4% DMSO gel, followed by single-dose etoricoxib 75 mg (2.15 mL) 4% PG gel. All treatments were applied topically.
89552835|NCT01980940|Experimental|Pt 1: ETOR OD/ ETOR 150 DMSO/ ETOR 75 DMSO/ ETOR 75 PG|Single-dose etoricoxib 163 mg (4.30 mL) 4% DMSO gel (DMSO formulation administered in error/overdose [OD]), followed by single-dose etoricoxib 150 mg (3.94 mL) 4% DMSO gel, followed by single-dose etoricoxib 75 mg (1.97 mL) 4% DMSO gel, followed by single-dose etoricoxib 75 mg (2.15 mL) 4% PG gel. All treatments were applied topically.
89552836|NCT01980940|Other|Pt 1: Placebo (Deviation)|Participants randomized to a treatment sequence in Part 1 who received single dose placebo gel (1.97 or 3.94 mL) applied topically in error instead of active study drug and dropped out after the first treatment period in the sequence. Included in the safety assessments only.
89552837|NCT01980940|Experimental|Pt 2: ETOR 50 DMSO|Etoricoxib 50 mg (1.31 mL, 4% DMSO gel) applied topically twice daily to the affected knee for a period of 2 weeks.
89552838|NCT01980940|Placebo Comparator|Pt 2: Placebo|Matching placebo to etoricoxib 50 mg 1.31 mL 4% DMSO gel applied topically twice daily to the affected knee for a period of 2 weeks.
89552839|NCT02394223||Full Field Optical Coherence Tomography (FFOCT) procedure|
89552840|NCT04857437|Experimental|Part 1|Single, Escalating Doses of PF-07202954 or Placebo (Cohorts 1 and 2)
89552841|NCT04857437|Experimental|Part 2|Repeated, Escalating Doses of PF-07202954 or placebo from Day 1 to Day 14, inclusive (Cohorts 3, 4, 5, 6 7, and optional Cohort 8)
89552842|NCT04857437|Experimental|Part 3|Single dose of PF-07202954 with a high-fat/high-caloric meal and a single dose following an overnight fast of ≥10 hours
89552843|NCT02394379||Trulign™ Toric IOL|Trulign™ Toric Posterior Chamber IOL is a modified plate haptic lens
89552844|NCT05229575|Experimental|Stereotactic Body Radiation Therapy (SBRT)|Patients undergo 5 fractions of image-guided stereotactic body radiation therapy to primary breast tumor over 2 weeks
89552845|NCT04842929|Active Comparator|Active Stimulation|Active Comparator: Active stimulation with pulses emitted according to intervention description
89552846|NCT04842929|Sham Comparator|Sham Stimulation|Sham Comparator: The blinding will be done with a sham coil, which consists of a coil that reproduces the sound that the true coil does, but without generating the magnetic field.
89552847|NCT02699983|Experimental|Group I (SparkPeople program)|"Participants receive one 30-minute session with the research assistant for training on how to use the SparkPeople website, and they may request additional training if needed.~Participants are instructed to self-monitor their diet at least weekly using the SparkPeople tool, and to self-monitor their activity daily using the Fitbit monitoring device.~Participants receive weekly motivational reminders to log into the website for 3 months via email, text, or phone, based on patient preference (active phase). Participants then enter the maintenance phase for 3 months without reminders.~All participants answer survey questions on quality of life and social cognitive theory variables and undergo anthropometric measurements at baseline, 3, and 6 months."
89552848|NCT02699983|Active Comparator|Group II (wait list)|Participants receive the weight loss handout and a Fitbit activity monitoring device and proceed with their usual life. After 6 months, patients receive the SparkPeople treatment as in Group I. All participants answer survey questions on quality of life and social cognitive theory variables and undergo anthropometric measurements at baseline, 3 and 6 months.
89552849|NCT01960114|Experimental|Acetaminophen ER|
89552850|NCT01960114|Placebo Comparator|Placebo|Single dose (2 tablets) Acetaminophen ER 750 mg matching placebo
89552851|NCT04752527|Experimental|Treatment regime|combination of venetoclax plus azacitidine, and Sorafenib for patients with high FLT3-ITD allelic ratio
89552852|NCT05229497|Experimental|Phase Ib#Dosage regimen 1#|Subjects receive AK112 (20 mg/kg Q3W) + AK117 (30 mg/kg QW)
89552853|NCT05229497|Experimental|Phase Ib#Dosage regimen 2#|Subjects receive AK112 (20 mg/kg Q3W) + AK117 (45 mg/kg QW)
89552854|NCT05229497|Experimental|Phase II#Cohort 1#|Head and neck squamous cell carcinoma (HNSCC): AK112 (20 mg/kg Q3W)
89552855|NCT05229497|Experimental|Phase II#Cohort 2#|HNSCC: AK112 (20 mg/kg Q3W) + AK117 (recommended Phase 2 dose)
89552856|NCT05229497|Experimental|Phase II#Cohort 3#|HNSCC: AK112 (20 mg/kg Q3W) + AK117 (recommended Phase 2 dose)+Carboplatin/cisplatin+5-fluorouracil
89552857|NCT02005276|No Intervention|Control|Participants receive either an email or text message daily (based on the participant's preference) stating whether the participant achieved the 7000 step goal during the previous day.
89552858|NCT02005276|Experimental|Basic Lottery|"Participants receive either an email or text message daily (based on the participant's preference) stating whether the participant achieved the 7000 step goal during the previous day. Each day a lottery will be held, and participants will be eligible to collect monetary rewards only if the participant met the step goal the day before. The names of the winners will be announced during each lottery. The daily lotteries are as follows:~About a 1 in 4 chance of winning $5. Expected value is about $1.40 per person per day."
89552859|NCT02005276|Experimental|Combined Lottery|"Participants receive either an email or text message daily (based on the participant's preference) stating whether the participant achieved the 7000 step goal during the previous day. Each day a lottery will be held, and participants will be eligible to collect monetary rewards only if the participant met the step goal the day before. The names of the winners will be announced during each lottery. The daily lotteries are as follows:~About a 1 in 5 chance of winning $5 and a 1 in 100 chance of winning $50. Expected value is about $1.40 per person per day."
89552860|NCT02005276|Experimental|Jackpot Lottery|"Participants receive either an email or text message daily (based on the participant's preference) stating whether the participant achieved the 7000 step goal during the previous day. Each day a lottery will be held, and participants will be eligible to collect monetary rewards only if the participant met the step goal the day before. The names of the winners will be announced during each lottery. The daily lotteries are as follows:~About a 1 in 400 chance of winning $500. Expected value is about $1.40 per person per day."
89552861|NCT03169777|Experimental|Nant CRC Vaccine|avelumab, bevacizumab, capecitabine, cetuximab, cyclophosphamide, 5-fluorouracil, fulvestrant, leucovorin, nab paclitaxel, nivolumab, lovaza, oxaliplatin, stereotactic body radiation therapy, ALT-803, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, and haNK.
89552862|NCT02306915|Experimental|lipegfilgrastim 30|
89552863|NCT02306915|Experimental|lipegfilgrastim 60|
89552864|NCT02306915|Experimental|lipegfilgrastim 100|
89552865|NCT04105907|Experimental|Partial root canal treatment with the Sonendo GentleWave|
89552866|NCT03167047|Active Comparator|Caudal block|"Caudal epidural given for post-operative pain relief. Dose used is 1.5ml/kg of weak Levo-Bupivacaine solution (0.125%).~Patients will also receive standardised pain relief of paracetamol and fentanyl"
89552867|NCT03167047|Active Comparator|Nerve block|"Peripheral nerve block given for post operative pain relief. Levo-Bupivacaine 0.25% 2mg/Kg given under ultrasound guidance.~Patients will also receive standardised pain relief of paracetamol and fentanyl"
89552868|NCT01980706|Placebo Comparator|Placebo|Participants will take placebo for 16 weeks, 3 times per day. Placebo will be given in blister packs.
89552869|NCT01980706|Active Comparator|30 Mg Baclofen|Participants will take baclofen/placebo for 16 weeks, 3 times per day. Baclofen will be given in blister packs. The 30 mg/d arm will reach 30 mg/d at day 3 and titrate down starting at day 101.
89552870|NCT01980706|Active Comparator|90 mg Baclofen|Participants will take baclofen/placebo for 16 weeks, 3 times per day. Baclofen will be given in blister packs. The 90 mg/d arm will reach 90 mg/d at day 12 and titrate down starting at day 95.
89552871|NCT02092571|Experimental|Treatment A|1 ring intravaginal for 7 days, produced from the new process
89552872|NCT02092571|Experimental|Treatment B|1 ring intravaginal for 7 days, produced from the legacy process
89552873|NCT02402959||Cohort 1|Based on the first TCM expert's experience and his knowledge, the insomnia patients will be treated with the best individualized treatment options, which should be at least in accordance to the current China Traditional Chinese herbal medicine pharmacopoeia and the China adult insomnia diagnosis and treatment guidelines. In addition, the expert could determine the treatment in consideration of individual patient's preferences and best existed evidence. Therefore, the choices of medicine, dosage form, dosage, frequency and duration are not restricted.
89552874|NCT02402959||Cohort 2|Based on the second TCM expert's experience and his knowledge, the insomnia patients will be treated with the best individualized treatment options, which should be at least in accordance to the current China Traditional Chinese herbal medicine pharmacopoeia and the China adult insomnia diagnosis and treatment guidelines. In addition, the expert could determine the treatment in consideration of individual patient's preferences and best existed evidence. Therefore, the choices of medicine, dosage form, dosage, frequency and duration are not restricted.
89552875|NCT02402959||Cohort 3|Based on the third TCM expert's experience and his knowledge, the insomnia patients will be treated with the best individualized treatment options, which should be at least in accordance to the current China Traditional Chinese herbal medicine pharmacopoeia and the China adult insomnia diagnosis and treatment guidelines. In addition, the expert could determine the treatment in consideration of individual patient's preferences and best existed evidence. Therefore, the choices of medicine, dosage form, dosage, frequency and duration are not restricted.
89025585|NCT02956733|Active Comparator|loop suture technique|The loop suture technique involves using corrugated drains and Ethilon no.1. It is an extension of the purse string suture technique where a surgical suture is passed as a running stitch in and out along the edge of a wound in such a way that when the ends of the suture are drawn tight the wound is closed. Two corrugated drains (1 & 2) will be anchored to the skin adjacent to the fasciotomy incision using Ethilon no.1. Then the sutures will be passed from one edge of the wound through the skin and corrugated drain to the other in an alternating fashion.
89552876|NCT02402959||Cohort 4|Based on the fourth TCM expert's experience and his knowledge, the insomnia patients will be treated with the best individualized treatment options, which should be at least in accordance to the current China Traditional Chinese herbal medicine pharmacopoeia and the China adult insomnia diagnosis and treatment guidelines. In addition, the expert could determine the treatment in consideration of individual patient's preferences and best existed evidence. Therefore, the choices of medicine, dosage form, dosage, frequency and duration are not restricted.
89552877|NCT02402959||Cohort 5|Based on the fifth TCM expert's experience and his knowledge, the insomnia patients will be treated with the best individualized treatment options, which should be at least in accordance to the current China Traditional Chinese herbal medicine pharmacopoeia and the China adult insomnia diagnosis and treatment guidelines. In addition, the expert could determine the treatment in consideration of individual patient's preferences and best existed evidence. Therefore, the choices of medicine, dosage form, dosage, frequency and duration are not restricted.
89552878|NCT02402959||Cohort 6|Based on the sixth TCM expert's experience and his knowledge, the insomnia patients will be treated with the best individualized treatment options, which should be at least in accordance to the current China Traditional Chinese herbal medicine pharmacopoeia and the China adult insomnia diagnosis and treatment guidelines. In addition, the expert could determine the treatment in consideration of individual patient's preferences and best existed evidence. Therefore, the choices of medicine, dosage form, dosage, frequency and duration are not restricted.
89552879|NCT02402959||Cohort 7|Based on the seven TCM expert's experience and his knowledge, the insomnia patients will be treated with the best individualized treatment options, which should be at least in accordance to the current China Traditional Chinese herbal medicine pharmacopoeia and the China adult insomnia diagnosis and treatment guidelines. In addition, the expert could determine the treatment in consideration of individual patient's preferences and best existed evidence. Therefore, the choices of medicine, dosage form, dosage, frequency and duration are not restricted.
89552880|NCT02402959||Cohort 8|Based on the eighth TCM expert's experience and his knowledge, the insomnia patients will be treated with the best individualized treatment options, which should be at least in accordance to the current China Traditional Chinese herbal medicine pharmacopoeia and the China adult insomnia diagnosis and treatment guidelines. In addition, the expert could determine the treatment in consideration of individual patient's preferences and best existed evidence. Therefore, the choices of medicine, dosage form, dosage, frequency and duration are not restricted.
89552881|NCT02402959||Cohort 9|Based on the nineth TCM expert's experience and his knowledge, the insomnia patients will be treated with the best individualized treatment options, which should be at least in accordance to the current China Traditional Chinese herbal medicine pharmacopoeia and the China adult insomnia diagnosis and treatment guidelines. In addition, the expert could determine the treatment in consideration of individual patient's preferences and best existed evidence. Therefore, the choices of medicine, dosage form, dosage, frequency and duration are not restricted.
89025586|NCT00458900|Experimental|IV and enteral administration of moxifloxacin|IV and enteral administration of moxifloxacin
89552882|NCT02402959||Cohort 10|Based on the tenth TCM expert's experience and his knowledge, the insomnia patients will be treated with the best individualized treatment options, which should be at least in accordance to the current China Traditional Chinese herbal medicine pharmacopoeia and the China adult insomnia diagnosis and treatment guidelines. In addition, the expert could determine the treatment in consideration of individual patient's preferences and best existed evidence. Therefore, the choices of medicine, dosage form, dosage, frequency and duration are not restricted.
89552883|NCT02085863|Experimental|Laquinimod|once daily oral doses of laquinimod (with combination oral contraceptives)
89552884|NCT02085863|Placebo Comparator|Placebo|Matching placebo (with combination oral contraceptives)
89552885|NCT02402725|Experimental|Ultra-high dose dexamethasone|Ultra-high dose dexamethasone administered intravenously and orally
89552886|NCT02054351|Experimental|IMAB027 administration|Monotherapy - different dose Levels.
89552887|NCT02394145|Experimental|Ticagrelor 180mg in ESRD patients|After randomization, ESRD patients on HD will be treated by an initial loading dose of ticagrelor (180 mg) and maintenance doses (ticagrelor 90 mg twice daily) for 14 days. Platelet reactivity and genetic polymorphism will be assessed.
89552888|NCT02394145|Active Comparator|Clopidogrel 75mg in ESRD patients|After randomization, ESRD patients on HD will be treated by an initial loading dose of clopidogrel 300 mg) and maintenance doses (clopidogrel 75 mg once a day) for 14 days. Platelet reactivity and genetic polymorphism will be assessed.
89552889|NCT02394145|Active Comparator|Clopidogrel 150mg in ESRD patients|After randomization, ESRD patients on HD will be treated by an initial loading dose of clopidogrel 300 mg) and maintenance doses (clopidogrel 150 mg once a day) for 14 days. Platelet reactivity and genetic polymorphism will be assessed.
89552890|NCT02394145|Active Comparator|Ticagrelor 180mg in normal kidney|After randomization, patients with normal kidney function will be treated by an initial loading dose of ticagrelor (180 mg) and maintenance doses (ticagrelor 90 mg twice daily) for 14 days. Platelet reactivity and genetic polymorphism will be assessed
89025587|NCT03273959|No Intervention|Group control|Patients randomized to the control group will receive routine physiotherapeutic follow-up, performed by the physiotherapist of the hospital during the hospitalization period. Supervision includes inhalation therapy and respiratory physiotherapy. Respiratory exercises and thoracic maneuvers for bronchial hygiene will be performed, according to what the patient is accustomed to perform. Other techniques besides these can be added at the discretion of the physiotherapist according to the needs of the patient. In pediatric hospitalization patients also receive care from physical educators who associate recreational and recreational activities with the treatment.
88812137|NCT05946005|Experimental|povidone - iodine|Povidone iodine is an antibacterial and anti-inflammatory agent that accelerates wound healing neovascularization. Several studies have used betadine in postpartum mothers with perineal rupture to provide faster wound healing. A study shows that povidone-iodine cream has a better absorption effect on the skin than betadine solution (10).
89025588|NCT03273959|Experimental|Intervention group|Patients randomized to the intervention group, in addition to routine physical therapy follow-up, will receive a program of physical exercises, illustrated in the form of a booklet and guided by a health professional. The patient is instructed to perform physical exercises five times a week until a hospital discharge. The participant will receive with a booklet a diary to write down the days in which to carry out the proposed exercises, in case of fault he will write down the reason for not performing. The exercise protocol includes: Punching, climbing and descending steps, sit and stand, push-ups on the wall, stationary gait, abdominal, physiotherapy bridge, jumping on the floor ladder, cycling on the cycle ergometer and stretching.
89025589|NCT00488163|Active Comparator|Atomoxetine|Atomoxetine 40 mg compounded into capsules.
89025590|NCT00488163|Placebo Comparator|Placebo|Inactive matching compounding of placebo capsules
89552891|NCT02394145|Active Comparator|Clopidogrel 75mg in normal kidney|After randomization, patients with normal kidney function will be treated by an initial loading dose of clopidogrel 300 mg) and maintenance doses (clopidogrel 75 mg once a day) for 14 days. Platelet reactivity and genetic polymorphism will be assessed.
89552892|NCT03167827|Experimental|Group isoflavone and exercise|The isoflavone group received daily 100mg of isoflavones.
88812138|NCT05946005|Other|control groups|the control group were not given any intervention
89025591|NCT00444249|Active Comparator|1|White Alcon IOL
89025592|NCT00444249|Active Comparator|2|Yellow Alcon IOL
89025593|NCT00444249|Active Comparator|3|White Hoya IOL
89025594|NCT00444249|Active Comparator|4|Yellow Hoya IOL
89025595|NCT00459212|Experimental|Arm I|Patients receive GTI-2040 IV continuously on days 1-4 and 15-18.
89552893|NCT03167827|Placebo Comparator|Group placebo and exercise|The placebo group received 100mg containing starch of corn.
89552894|NCT04103099|Other|HLNatural Immune Cohort|Observational one arm virtual study of HLNatural Immune supplement
89552895|NCT02692417|Experimental|Posterior Tibial Nerve Stimulation Group|Subjects in this group will have transcutaneous electrical nerve stimulation electrodes placed on the skin surface over their posterior tibial nerve, that is in the area of the ankle, and receive stimulation for 30 minutes in weekly sessions for 12 weeks.
89552896|NCT02692417|Experimental|Dorsal Genital Nerve Stimulation Group|Subjects in this group will have transcutaneous electrical nerve stimulation electrodes placed on the skin surface over the dorsal genital nerve, that is above and/or on the lateral side of the clitoris, and receive stimulation for 30 minutes in weekly sessions for 12 weeks.
89552897|NCT04091555|Other|Adult patients who suffer from symptoms of tension headaches|Patients will begin taking the capsules at the onset of headache symptoms.
89552898|NCT02393911|Active Comparator|Study A - with diet|Patients with LPV, treated by Low Oxalate Diet for three months.
89552899|NCT02393911|Active Comparator|Study B- no diet|Patients with LPV, not treated by Low Oxalate Diet for three months.
89552900|NCT02393911|Active Comparator|Control|Healthy women without LPV, not treated by Low Oxalate Diet
89552901|NCT02004886|Experimental|MK-0893 (40 mg)|MK-0893 40-mg q.d. (quaque die, once daily) group will receive MK-0893 40-mg tablets (after loading dose with 160 mg) and matching placebo to metformin and matching placebo to MK-0893.
89552902|NCT02004886|Experimental|MK-0893 (120 mg)|MK-0893 at 120 mg q.d. group will receive MK-0893 120 mg q.d. tablets (after loading dose of 500 mg on Day 1) and matching placebo tablets to metformin and matching placebo to MK-0893
89552903|NCT02004886|Active Comparator|Metformin (2000 mg)|Metformin taken orally, 500 mg tablets, Day 1 to Day 6: 500 mg b.i.d. (bis in die, twice daily), Day 7 to Day 13: 1000 mg in the morning and 500 mg in the evening, and Day 14 to Day 28: 1000 mg. b.i.d. and matching placebo to MK-0893.
89552904|NCT02004886|Placebo Comparator|Placebo|Placebo tablets matching the MK-0893 and placebo tablets matching metformin.
89552905|NCT02393989|Experimental|Active comparator|posterior restorations
89552906|NCT04065893||Catheter ablation group|Patients with reduced biventricular pacing due to PVC or VT receiving catheter ablation of PVC/VT according to guidelines and clinical practices
89552907|NCT04065893||Medical treatment group|Patients with reduced biventricular pacing due to PVC or VT receiving intensified medical therapy (antiarrhythmics/betablocker) according to guidelines and clinical practices
89552908|NCT05744713||Disease Cohort|
89552909|NCT05744713||Engaged Cohort|
89552910|NCT05228561|No Intervention|Control Group|After the physician involved in the study asks the participants for their biochemical tests (FBC, HbA1C, LDL-C, HDL-C, Total K, Triglyceride), the outpatient dietitian will give routine nutrition education to the participants. In addition, a data collection form including socio-demographic information, health history, nutrition history and height, weight, waist circumference measurements will be made and filled by the thesis student.
89025596|NCT00459407|Experimental|Arm I (green tea catechin extract)|"Patients receive oral defined green tea catechin extract daily for 4-7 weeks.~All patients undergo surgery one day after the last dose of study agent."
89552911|NCT05228561|Experimental|Study Group|The software developed for this research will be downloaded to the phones of the participants in the intervention group. With this software prepared, written and visual information (pictures, mini-videos) will be given to participants every day for 3 months on diabetes, self-management of diabetes and nutrition. Whether the participants read the messages or not will also be monitored through this software. At the end of 3 months, the participants in the intervention and control groups will be invited again, and their biochemical parameters and self-management status will be measured according to the diabetes self-management scale. Data will be collected through face-to-face interviews in the outpatient clinic, and weight will be measured with the bioelectrical impedance analyzer in the outpatient clinic, height will be measured with a height meter fixed to the wall, and waist circumference will be measured with a non-stretchable measuring tape.
89552912|NCT05228483|Experimental|Photodynamic treatment monotherapy or combined with CO2 fractional laser|For patients who receive photodynamic therapy, lesions will be symmetrically randomized into two sides. One side will receive 5-aminolevulinic acid (5-ALA) with a red light illumination(80mW/cm2, and 120J/ cm2); while the other side will receive CO2 fractional laser(parameter: 20mm *20mm, spot coverage rate 10%, and 18-25mJ/cm2) before photodynamic therapy. Treating area should cover 0.5cm beyond the visible boundary of the lesion. In total 6 therapies will be given for each patient, with 14±3d intervals.
89552913|NCT05228483|Active Comparator|Mometasone furoate cream|Mometasone furoate cream (0.1%) for topical application, frequency: once daily, 5 days/week, for the first month; once every other day, for the second month; twice a week for the third month; the area of application should cover 0.5cm beyond the visible boundary of the lesion.
89552914|NCT01959880|Other|Primary Augmentation|The Augmentation cohort will include patients who have post-lactational mammary involution or wish general breast enlargement.
89552915|NCT01959880|Other|Primary Reconstruction|"The Reconstruction cohort will include patients with loss of breast due to mastectomy or with deformities secondary to disease, malignancy, trauma, and congenital deformity.~Congenital deformities will include deformities of the breast itself as well as skeletal abnormalities reflected in breast deformity or asymmetry."
89552916|NCT01959880|Other|Revison Augmentation|Patients in this cohort will have had previous breast augmentation with silicone or saline filled implants and are having a revision surgery to correct or improve the result of any previous breast augmentation surgery.
89552917|NCT01959880|Other|Revision Reconstruction|Patients in this cohort will have had previous breast reconstruction with silicone or saline filled implants and are having a revision surgery to correct or improve the result of any previous breast reconstruction surgery.
89552918|NCT05228405||1/caregivers of disabled children|1/Caregivers of disabled children will be assessed by the questionnaire of the Disease, Physiotherapy and Sports Awareness
89552919|NCT04255277|Other|Period 1: First administration of combined oral contraceptives|Participants randomized to placebo or cenerimod will receive a single oral dose of levonorgestrel (100 μg) and ethinylestradiol (20 μg) in the morning on Day 1.
89552920|NCT04255277|Other|Period 2: Second administration of Combined Oral Contraceptive|Participants randomized to placebo or cenerimod will receive a single oral dose of levonorgestrel (100 μg) and ethinylestradiol (20 μg) in the morning on Day 42.
89552921|NCT04255277|Experimental|Period 2: Cenerimod 0.5 mg|Participants randomized to cenerimod 0.5 mg will receive a single oral dose in the morning from Day 7 to Day 56.
89552922|NCT04255277|Experimental|Period 2: Cenerimod 4 mg|Participants randomized to cenerimod 4 mg will receive a single oral dose in the morning from Day 7 to Day 56.
89552923|NCT04255277|Other|Period 2: Moxifloxacin|Participants randomized to moxifloxacin will receive a single oral 400 mg dose in the morning of Day 42.
89552924|NCT04255277|Placebo Comparator|Period 2: Placebo|Participants randomized to placebo will receive a single oral dose of placebo in the morning from Day 7 to Day 56.
89552925|NCT04255277|Experimental|Period 3: Cenerimod 0.5 mg and charcoal|Participants randomized to cenerimod 0.5 mg in Period 2 will receive 50 g of activated charcoal every 12 hours from Day 57 to Day 67.
88812139|NCT05945992|Experimental|Condition 1: emotions, self, mindfulness, resources|(1) emotion regulation, (2) self-acceptance, (3) mindfulness, (4) resource activation
88812140|NCT05945992|Experimental|Condition 2: emotions, self, mindfulness, conflict resolution|(1) emotion regulation, (2) self-acceptance, (3) mindfulness, (4) constructive conflict resolution
88812141|NCT05945992|Experimental|Condition 3: emotions, self, stress, resources|(1) emotion regulation, (2) self-acceptance, (3) stress management, (4) resource activation
88812142|NCT05945992|Experimental|Condition 4: emotions, self, stress, conflict resolution|(1) emotion regulation, (2) self-acceptance, (3) stress management, (4) constructive conflict resolution
88961976|NCT00203996|Experimental|Aim 3: Baseline - REM frag - SWS supp|"Each subject was assessed under three experimental conditions in the following order.~Baseline: Baseline sleep (i.e., with no experimental intervention) assessment is recorded. This assessment may have been recorded as the first, second, or third intervention.~REM fragmentation: Rapid eye movement (REM) sleep will be fragmented by experimentally induced microarousals for 3 consecutive nights and non-REM sleep will be left undisturbed.~SWS suppression: Slow wave activity will be suppressed without awakening the subject and REM sleep will be left undisturbed."
88961977|NCT00203996|Experimental|Aim 3: SWS supp - REM frag - Baseline|"Each subject was assessed under three experimental conditions in the following order.~SWS suppression: Slow wave activity will be suppressed without awakening the subject and REM sleep will be left undisturbed.~REM fragmentation: Rapid eye movement (REM) sleep will be fragmented by experimentally induced microarousals for 3 consecutive nights and non-REM sleep will be left undisturbed.~Baseline: Baseline sleep (i.e., with no experimental intervention) assessment is recorded. This assessment may have been recorded as the first, second, or third intervention."
89025597|NCT00459407|Placebo Comparator|Arm II (placebo)|"Patients receive oral placebo daily for 4-7 weeks.~All patients undergo surgery one day after the last dose of study agent."
89025598|NCT03278262||>= 70 letters|Baseline VA >= 70 letters
89025599|NCT03278262||36-69 letters|Baseline VA 36-69 letters
89025600|NCT03278262||<=35 letters|Baseline VA <=35 letters
89025601|NCT00488280|Experimental|Kids Step Study: Locomotor Training|All children who participate will be in the experimental cohort, KSS-#, and receive 60 sessions of daily locomotor training. This experimental cohort will also undergo clinical and neurophysiological testing pre, during, and post 60 sessions of locomotor training.
89025602|NCT03273764||Preterm neonates with RDS|Singleton Preterm neonates with gestational age between 26 completed weeks to 34 completed weeks with clinical diagnosis of RDS without any major congenital anomalies.
89025603|NCT04698044||Healthy|Have not chronic disease
89025604|NCT04698044||Cancer|Have cancer
89025605|NCT04698044||Non-Cancer Crhronic Disease|Have non-cancer chronic disease
89552926|NCT04255277|Experimental|Period 3: Cenerimod 4 mg and charcoal|Participants randomized to cenerimod 4 mg in Period 2 will receive 50 g of activated charcoal every 12 hours from Day 57 to Day 67.
89552927|NCT04255277|No Intervention|Period 3: Cenerimod elimination period|Participants randomized to cenerimod 0.5 mg or 4 mg in Period 2 will receive no treatment (i.e., activated charcoal from Day 57 to Day 67) but will have blood samples taken.
89552928|NCT05228093|Experimental|Surgery group|Prior to surgery, a bacterial cultivation for purulent nasopharyngeal secretions and drug sensitivity assays were performed to identify sensitive antibiotics to be used postoperatively. Radical endoscopic necrectomy was performed under general anesthesia using the endoscopic endonasal approach. One side flap, typically the ipsilateral side, was harvested after complete radical endoscopic necrectomy.
89025606|NCT00459485|Experimental|Zinc supplement (20 mg)|Daily intake of 20 mg supplementary zinc
89025607|NCT00459485|Experimental|Zinc supplement (10 mg)|Daily intake of 10 mg supplementary zinc
89025608|NCT00459485|Placebo Comparator|Placebo supplement|Daily intake of placebo supplement
89025609|NCT00459524||Questionnaire|AML and MDS Patients
89552929|NCT05228093|Active Comparator|Conservative group|"Patients receive debridement treatment of the necrotic tissues guided by endoscope and systematic antibiotic therapy partly under the guidance of nasopharyngeal secretion drug sensitivity test.~Patients could use a common nasopharyngeal irrigation pot to wash the nasopharynx three times a day with warm boiled water or light saltwater (500 ml). If possible, patients could also received direct irrigation with an electronic nasopharyngoscopy operated by a physician.~In addition, patients can receive hyperbaric oxygen therapy when conditions permit."
89552930|NCT01980628|Experimental|ibrutinib|ibrutinib capsules: 560 mg once daily
89208156|NCT00867906|Other|Cohort 2|Asthmatics using inhaled corticosteroid, subjects to receive either Cat-PAD or placebo comparator
89552931|NCT01255943||prevalent hemodialysis patients|These patients are observed in two outpatient dialysis units with a combined census of approximately 175 patients
89025610|NCT03278145||Pediatric acute leukemia|Patients of the Institute of Hematology and Pediatric Oncology (IHOPe) with acute leukemia (LA) who came for initial diagnosis, relapse, or at the time of their remission .
89025611|NCT00459563|Placebo Comparator|Placebo|
89025612|NCT00459563|Active Comparator|Cholecalciferol|Cholecalciferol
89025613|NCT00459563|Active Comparator|Calcitriol|Calcitriol
89025614|NCT01242384|No Intervention|Expectant Management|
89025615|NCT01242384|Experimental|Placement of cervical pessary since 23 weeks until 37 weeks|
89025616|NCT00459602||Laparoscopic incisional hernia repair|Subjects with an incisional, ventral, umbilical, or spigelian hernia no larger tham 15 cm at the largest measurement, who are candidates for laparoscopic repair of the hernia, and who are able to commit to long-term followup. Laparoscopic repair will proceed as per the standard technique, using polyester mesh.
89025617|NCT00488397||1|
89025618|NCT00459641|Experimental|1|I-040302 doses of up to 1 mg, 2 mg or 4 mg of TGplPTH1-34
89025619|NCT00459641|Active Comparator|2|Standard of care (bone marrow aspirate or steroids)
89025620|NCT00459680|Experimental|Acupuncture|
89025621|NCT00459680|Experimental|Laser Acupoint|
89025622|NCT03277950|Experimental|virtual reality with feedback|Participants received training via virtual reality game with feedback, 60 minutes/day, 3 days/week for 4 weeks, then follow up after 4 weeks.
89025623|NCT03277950|Active Comparator|virtual reality without feedback|Participants received training via virtual reality game without feedback, 60 minutes/day, 3 days/week for 4 weeks, then follow up after 4 weeks.
89025624|NCT03277950|Other|Healthy|Participants do not play virtual reality game.
89025625|NCT00488553||Cases|Participants of study with newly diagnosed lymphoma.
89025626|NCT00488553||Control|Participants of study from matched control group.
89025627|NCT00459719|Experimental|1|In combination with steroids
89025628|NCT00459719|Active Comparator|2|In combination with steroids
89025629|NCT00495183|Experimental|1|caffeine + placebo
89025630|NCT00495183|Experimental|2|caffeine + biperiden
89025631|NCT00495183|Placebo Comparator|3|Placebo+placebo
89025632|NCT00459797|Active Comparator|Conventional Glidescope|
89025633|NCT00459797|Experimental|Single-use Glidescope|
89025634|NCT00495261|Experimental|1|
89025635|NCT00495261|Active Comparator|2|
89025636|NCT00459914|Active Comparator|1 CPAP|Nasal continuous positive airway pressure
89552932|NCT04007705|Experimental|Anti-inflammatory and low FODMAPs diet|The anti-inflammatory diet is characterized by the exclusion of potential inflammatory foods, such as gluten, dairy and processed food, for three months. During the first month, a low FODMAPs diet will be implemented, followed by the reintroduction of all fruits and vegetables over a consecutive period of 2 months. Additionally, some potentially anti-inflammatory foods will be promoted: Omega-3 through specific fish (tuna fish, salmon, sardine, horse mackerel) and nuts, antioxidant rich foods, such as fruit and vegetables, and the maintenance of glycemic index.
88812143|NCT05945992|Experimental|Condition 5: emotions, communication, mindfulness, resources|(1) emotion regulation, (2) communication skills, (3) mindfulness, (4) resource activation
89025637|NCT00459914|No Intervention|2|Pharmacological treatment alone
89552933|NCT04007705|Active Comparator|Control|Dietary counselling based on general recommendations for healthy eating according to the World Health Organization
89552934|NCT03978533|Experimental|Family Support Group|Family Support Groups will be piloted with families in community and clinical sites. Each pair of facilitators will pilot two groups of 6 families each. Each group is 4 sessions lasting 2 hours each. Each of the sessions incorporates didactic talks, family discussion, and separate breakout groups for adolescents and adults. Family Support intervention incorporates cognitive-behavioral theory of PM+ which underlies evidence-based techniques focused on stress management and behavioral activation. Family support intervention also incorporates resilience theory, which explains family protective processes that can ameliorate the negative consequences of hardships and challenges and enable healing and growth in families.
89552935|NCT03840707|Experimental|Experimental group|"LIFEwithIBD Programme is a manualized acceptance, mindfulness and compassionate-based group intervention for inflammatory bowel disease patients. It included 9 weekly group sessions, 1.30h hours each, run in small groups (ranging from 10 to 15 participants).~Participants in this group also receive inflammatory bowel disease treatment as usually performed at the Coimbra University Hospital."
89552936|NCT03840707|No Intervention|Control group|Treatment as Usual (TAU) Standard personalized treatment of inflammatory bowel disease
89552937|NCT03670121|Experimental|BTVA Treatment|All patients that will receive Bronchoscopic Thermal Vapor Ablation (BTVA) Treatment
89552938|NCT04435925|Active Comparator|Remifentanil|Patients assigned to this group will receive IV Remifentanil as an opioid for general anesthesia.
89552939|NCT04435925|Placebo Comparator|Fentanyl|Patients assigned to this group will receive IV Fentanyl as an opioid for general anesthesia.
89552940|NCT03648281||Semaglutide|Participants will receive semaglutide at the treating physician's discretion as part of the usual clinical practice. The prescription and use of semaglutide is completely independent of this study. Total study duration for the individual patient will be approximately 30 weeks.
89552941|NCT01979614|Experimental|Serelaxin|Serelaxin was administered at a dose of 30 μg/kg/24h by intravenous infusion for 48 hours
89552942|NCT01979614|Placebo Comparator|Placebo|Placebo was administered by intravenous infusion for 48 hours
89552943|NCT00001349||1|Donors first admitted to another approved clinical research protocol of the NIAID before having the apheresis procedures described in this protocol.
89552944|NCT05205707||Covid-19 Patients|Blood sample from admitted patients will be drawn
89552945|NCT05205707||Control Patients|Blood sample from control group will be drawn
89552946|NCT04649476|Experimental|Neoadjuvant PD-1 blockade alone|The participants will receive 3 doses of neoadjuvant PD-1 blockade. Then the participants will take a radical surgery followed by radiotherapy or chemoradiotherapy if necessary.
89552947|NCT04649476|Experimental|Neoadjuvant PD-1 blockade plus TPF induction chemotherapy|The participants will receive 3 doses of PD-1 blockade and 2 courses of TPF induction chemotherapy. Then the participants will take a radical surgery followed by radiotherapy or chemoradiotherapy if necessary.
89552948|NCT04671784||Enlarged mediastinal or abdominal|Consecutive patients with enlarged mediastinal or abdominal detected by cross-sectional imaging and confirmed at EUS will be enrolled.
89552949|NCT05117957|Experimental|Sorafenib|Sorafenib will be administered orally at a dose of 600mg (3 tablets; 400mg orally in the morning and 200mg orally in the evening about 12 hours apart or 200mg orally in the morning and 400mg orally in the evening about 12 hours apart) daily without food (at least 1 hour before or 2 hours after a meal).
89552950|NCT04671628|Experimental|Relaxing music|
89552951|NCT04671628|No Intervention|Control|
89552952|NCT04671238||Patient for SPECT/CT scan|Patients referred for SPECT/CT scan of the spine as part of a vertebroplasty workup and selected retrospectively.
89552953|NCT02654717|Experimental|DFD-07 cream|DFD-07 cream applied twice daily
89552954|NCT02654717|Placebo Comparator|Placebo cream|Placebo cream applied twice daily
89552955|NCT05117879|Other|Cold snaring polypectomy|The sessile serrated adenoma size between 10-20mm would be resected by cold snaring polypectomy
89552956|NCT05117879|Other|Non-electrocautery Endoscopic Mucosal Resection (Cold EMR)|The sessile serrated adenoma size between 10-20mm would be resected by cold EMR
89552957|NCT05117879|Other|Electrocautery Endoscopic Mucosal Resection( Hot EMR)|The sessile serrated adenoma size between 10-20mm would be resected by Hot EMR
89552958|NCT05117801|Experimental|children at the general practitioner or pediatrician|Children between 9 months and 3 years-old coming to their doctor for any consultation
89552959|NCT03094871|Experimental|Intervention group|FACE-PC comprises 3 weekly and 2 bi-weekly sessions (total 5 sessions), delivered by a bachelors' prepared nurse care manager (CM) over 8 weeks. Over the five sessions, the nurse care manager will (1) review the patient medical history and set health goals for depression and chronic condition with the dyad, (2) review all medication, the level of adherence, challenges and facilitating factors of adherence, (3) deliver brief behavioral activation therapy.
89552960|NCT03094871|No Intervention|Enhanced usual care group|Participants in this group will receive a typical primary care enhanced with reporting of their depression status and their goal for medical condition to their PCP for 8 weeks. Upon enrolment, a research nurse will review the patient medical history and identify goals for depression and a chronic condition with the dyad.
89552961|NCT05191043|Experimental|Group A/ kinesio taping group|Routine physical therapy along with Kinesio Taping
89552962|NCT05191043|Active Comparator|Group B/ routine physical therapy|routine physical therapy
89552963|NCT05190029|Experimental|Complete sample|Group of 120 children evaluated by craniosacral therapy for cranial blocks and primitive reflexes.
89552964|NCT05117645||Cases|patients come to surgical emergency unit and complaining of intestinal obstruction and CT Abdomen and pelvis will be done to detect the cause then will be compared with operative findings .
89552965|NCT03297827||Patients with stroke|Adult stroke patients with the stroke diagnosis will be recruited on admission to the University of New Mexico Hospital. Serum and Urine measurement of cytokines from two sets of serum and urine samples will be done on the admission and at the 24-hour mark respectively, form the specimens collected for the clinical purposes and are meant to be discarded. Consent will be taken from the patients to use these samples for our study.
89552966|NCT03297827||Patients without stroke|Age/Sex matched adult control patients without the diagnosis of stroke, myocardial infarction, inflammatory flare, acute trauma, neurodegenerative or neuroinflammatory disease (AD, PD, TM, PSP, etc.) except MS will be recruited on admission to the University of New Mexico Hospital. Serum and Urine measurement of cytokines from two sets of serum and urine samples will be done on the admission and at the 24-hour mark respectively, form the specimens collected for the clinical purposes and are meant to be discarded. Consent will be taken from the patients to use these samples for our study.
89552967|NCT05136365|Experimental|Xiongdan Wan group|Xiongdan Wan is used in patients diagnosed with Major Depressive Disorder. The daily dose (1350mg per day) should be strictly controlled according to the experimental design.
89552968|NCT03251729|Experimental|Cerclage|Cervical cerclage placement along with vaginal progesterone 200mg suppository or 90mg gel nightly from randomization until 36 weeks.
89552969|NCT03251729|Other|Control|Vaginal progesterone 200mg suppository or 90mg gel nightly from randomization until 36 weeks.
89552970|NCT03248843|Experimental|KN035|Cohorts of 3-6 subjects will be enrolled sequentially at escalating doses of 1.0, 2.5, 5.0 and 10 mg/kg weekly. Dose escalation will continue until identification of MTD up to a maximum dose of 10 mg/kg.
89552971|NCT02696785|Experimental|Q2W Ixekizumab|"Double Blind Period: Starting dose of 80 or 160 milligrams (mg) ixekizumab given subcutaneously (SC) at baseline followed by 80 mg ixekizumab given SC every two weeks (Q2W) to week 14.~Extended Treatment Period: 80 mg ixekizumab given SC Q2W from week 16 to week 52."
89552972|NCT02696785|Experimental|Q4W Ixekizumab|"Double Blind Period: Starting dose of 80 or 160 mg ixekizumab given SC at baseline followed by 80 mg ixekizumab given SC every four weeks (Q4W) to week 14.~Extended Treatment Period: 80 mg ixekizumab given SC Q4W from week 16 to week 52."
89552973|NCT02696785|Placebo Comparator|Placebo|"Double Blind Period: Placebo given SC Q2W to week 14.~Extended Treatment Period: 80 mg ixekizumab given SC Q2W or Q4W from week 16 to week 52."
89552974|NCT02696785|Active Comparator|Adalimumab|"Double Blind Period: 40 mg Adalimumab given SC Q2W to week 14.~Extended Treatment Period: 80 mg ixekizumab given SC Q2W or Q4W from week 20 to week 52."
89552975|NCT05117567|Experimental|Personal protection package|A personal protection package that includes Long-lasting insecticidal hammock net (LLIHN), insect repellent (Icaridin), and mobile and migrant population-tailored behavioural change communication (BCC) package
89552976|NCT05117567|No Intervention|Control|No personal protection package
89552977|NCT02004262|Experimental|Primary Cohort: Cy/GVAX + CRS-207|"200 mg per square meter (mg/m^2) cyclophosphamide (Cy) administered by intravenous (IV) infusion on Day 1 of Weeks 1 and 4; GVAX pancreas vaccine (GVAX, 5 × 10e8 cells) administered by intradermal injection on Day 2 of Weeks 1 and 4; CRS-207 (1 × 10e9 colony forming units [CFU]) administered by IV infusion on Day 1 of Weeks 7, 10, 13, 16.~The Primary Cohort comprised those subjects who failed at least 1 gemcitabine-based regimen administered for pancreatic cancer in any setting and failed at least 2 prior chemotherapy regimens administered for pancreatic cancer in the metastatic setting."
89552978|NCT02004262|Experimental|Primary Cohort: CRS-207|"CRS-207 (1 × 10e9 CFU) administered by IV infusion on Day 1 of Weeks 1, 4, 7, 10, 13, 16.~The Primary Cohort comprised those subjects who failed at least 1 gemcitabine-based regimen administered for pancreatic cancer in any setting and failed at least 2 prior chemotherapy regimens administered for pancreatic cancer in the metastatic setting."
89025638|NCT00495339|Experimental|1|Levofloxacin
89552979|NCT02004262|Active Comparator|Primary Cohort: Chemotherapy|"Investigator's choice of one of the following: gemcitabine (1000 mg/m^2) administered by IV infusion on Days 1, 8, and 15 of a 28-day cycle; capecitabine (1000 mg/m^2) administered orally twice a day on Days 1 through 14 of a 21-day cycle; fluorouracil with or without leucovorin (2400 mg^m2) administered by IV infusion over 46 hours on Days 1 and 15 of a 28-day cycle; irinotecan (150 mg/m^2) administered by IV infusion on Days 1 and 15 of a 28-day cycle; or erlotinib (100 mg) administered orally once a day for a 21-day cycle.~The Primary Cohort comprised those subjects who failed at least 1 gemcitabine-based regimen administered for pancreatic cancer in any setting and failed at least 2 prior chemotherapy regimens administered for pancreatic cancer in the metastatic setting."
89552980|NCT02004262|Experimental|2nd-line Cohort: Cy/GVAX + CRS-207|"200 mg/m^2 Cy administered by IV infusion on Day 1 of Weeks 1 and 4; GVAX pancreas vaccine (5 × 10e8 cells) administered by intradermal injection on Day 2 of Weeks 1 and 4; CRS-207 (1 × 10e9 CFU) administered by IV infusion on Day 1 of Weeks 7, 10, 13, 16.~The 2nd-line Cohort comprised those subjects who received and failed 1 prior chemotherapy regimen administered for pancreatic cancer in the metastatic setting."
89552981|NCT02004262|Experimental|2nd-line Cohort: CRS-207|"CRS-207 (1 × 10e9 CFU) administered by IV infusion on Day 1 of Weeks 1, 4, 7, 10, 13, 16.~The 2nd-line Cohort comprised those subjects who received and failed 1 prior chemotherapy regimen administered for pancreatic cancer in the metastatic setting."
89025639|NCT01242423|Experimental|superficial 2nd degree burn|Group A (n=50): Consent-capable male and female patients between ≥18 and ≤80 years of age who have sustained a superficial 2nd degree burn on ≥1% and ≤30% of the surface of the body.
89025640|NCT01242423|Experimental|deep 2nd degree burn|Group B (n=50): Consent-capable male and female patients between ≥18 and ≤80 years of age who have sustained a deep 2nd degree burn on ≥1% and ≤30% of the surface of the body.
89552982|NCT02004262|Active Comparator|2nd-line Cohort: Chemotherapy|"Investigator's choice of one of the following: gemcitabine (1000 mg/m^2) administered by IV infusion on Days 1, 8, and 15 of a 28-day cycle; capecitabine (1000 mg/m^2) administered orally twice a day on Days 1 through 14 of a 21-day cycle; fluorouracil with or without leucovorin (2400 mg^m2) administered by IV infusion over 46 hours on Days 1 and 15 of a 28-day cycle; irinotecan (150 mg/m^2) administered by IV infusion on Days 1 and 15 of a 28-day cycle; or erlotinib (100 mg) administered orally once a day for a 21-day cycle.~The 2nd-line Cohort comprised those subjects who received and failed 1 prior chemotherapy regimen administered for pancreatic cancer in the metastatic setting."
88961978|NCT00203996|Experimental|Aim 3: Baseline - SWS supp - REM frag|"Each subject was assessed under three experimental conditions in the following order.~Baseline: Baseline sleep (i.e., with no experimental intervention) assessment is recorded. This assessment may have been recorded as the first, second, or third intervention.~SWS suppression: Slow wave activity will be suppressed without awakening the subject and REM sleep will be left undisturbed.~REM fragmentation: Rapid eye movement (REM) sleep will be fragmented by experimentally induced microarousals for 3 consecutive nights and non-REM sleep will be left undisturbed."
89552983|NCT05117411||Patients group|Subjects over 18 years that after cataract surgery, showed pseudophakic cystoid macula edema.
89552984|NCT05117411||Control Group|Normal subjects over 18 years that did not show pseudophakic cystoid macula edema.
89552985|NCT01675427|Experimental|Chronic hepatitis C patients|
89552986|NCT02394067||Idiopathic Intracranial Hypertension|All participants of our study will be in this arm. These will be patients with a diagnosis of IIH. These patients will be followed throughout their standard of care treatment, with neuro-radiological imaging.
89552987|NCT02393833|Active Comparator|Induction chemotherapy|Approved induction CT regimen after randomization
89552988|NCT02393833|Experimental|Induction chemotherapy followed by CM maintenance|Approved induction chemotherapy followed by 12 months of CM maintenance
89552989|NCT02393599|Experimental|Lorcaserin|Lorcaserin (10mg) will be administered 2 times per day from Days 3 to 9 and only one time on Day 10
88961979|NCT00001582||1|Suspected or known disorder of the immune system or cancer; or, known or potential carrier of autoimmune disorder or immunodeficiency disease.
88961980|NCT02009280|Experimental|Propofol group|Propofol group
88961981|NCT02009280|Active Comparator|Sevoflurane group|Sevoflurane group
88961982|NCT02009293||Cough IPF|Male and female with idiopathic pulmonary fibrosis and cough and about to start on Pirfenidone according to regular practice will be asked to wear a cough monitor 24 hours before starting Pirfenidone and twice 24 hours while using Pirfenidone. Patients will also be asked to fill in questionnaires about quality of life and cough.
89552990|NCT02393599|Placebo Comparator|Placebo|Placebo will be administered 2 times per day from Days 3 to 9 and only one time on Day 10
89552991|NCT02393365|Other|HCV screening|All patients admitted to the one day clinic for surgery and gastroenterology.
89552992|NCT02402491|Active Comparator|24 months of P2Y12 receptor antagonist|Receive 24 months of dual antiplatelet therapy (with a P2Y12 receptor antagonist in addition to aspirin) after index procedure. All subjects receive aspirin for the duration of study.
89552993|NCT02402491|Placebo Comparator|12 months of P2Y12 receptor antagonist|Receive 12 months of dual antiplatelet therapy (with a P2Y12 receptor antagonist in addition to aspirin) after index procedure. All subjects receive aspirin for the duration of study.
89552994|NCT03166423|Experimental|MU001 patches (Investigational)|"Patches MU001 (snail slime, calendula extract and propolis extract) more standard of care. Two or three application for week. Treatment until 60 days.~Patches MU001 (snail slime, calendula extract and propolis extract) on health zone. Three days of treatment."
89552995|NCT03166423|Experimental|Conventional patches (Control)|Conventional patches approved for diabetic foot ulcers more standard of care. Two or three application for week. Treatment until 60 days.
89552996|NCT02402335||1 Fracture of vertebra|Osteoporotic fracture of the vertebra
89552997|NCT02402335||2 Nerve Compression|Osteochondria, Spinal disc herniation, Nerve compression
89552998|NCT02402569|Experimental|Multi-electrodes / single electrode|Multi stimulation / single stimulation
89552999|NCT02402569|Experimental|Single-electrode / Multi electrodes|Single stimulation / Multi stimulation
89553000|NCT02402413|Experimental|PCOS women|
89553001|NCT04440241|Experimental|Test group|submerged healing treatment of peri-implantitis using guided bone regeneration with a bone substitute and a resorbable membrane.
89553002|NCT04440241|Experimental|Control group|non submerged healing treatment of peri-implantitis using guided bone regeneration with a bone substitute and a resorbable membrane.
89553003|NCT03166501|Experimental|Treatment|Lanicemine 100mg Intravenous
89553004|NCT03166501|Placebo Comparator|Placebo|Normal saline Intravenous
89553005|NCT02402257||Traditionally-trained|Patients who undergo CVC procedures by traditionally-trained providers who have not undergone simulation-based mastery learning. This could be retrospective (before the study started) or at a site where the training was not implemented.
89553006|NCT02402257||CVC Train the Trainer|Patients who undergo CVC procedures by providers who have participated in simulation-based mastery learning.
89553007|NCT03166579|Experimental|Dialectical Behaviour Therapy|"Participants receive the standard 12 month DBT programme where all four modes of treatment are delivered including: individual therapy, group skills training, telephone coaching and DBT team consultation."
89553008|NCT01978912|Experimental|Cohort 1|one time 5 μg/disc dose of KTP-001 by intradiscal injection
89553009|NCT01978912|Experimental|Cohort 2|one time 15 μg/disc dose of KTP-001 by intradiscal injection
89553010|NCT01978912|Experimental|Cohort 3|one time 50 μg/disc dose of KTP-001 by intradiscal injection
89553011|NCT01978912|Experimental|Cohort 4|one time 150 μg/disc dose of KTP-001 by intradiscal injection
88961983|NCT02009306|Experimental|PecFent and Epistatus|Medication administered by family / carer for symptoms
88961984|NCT02009306|Active Comparator|Standard subcutaneous medication|Standard subcutaneous medication - diamophine and / or midazolam administered by nursing staff
88961985|NCT02009306|Experimental|Epistatus Alone|"From 28/11/17 following approval from sponsor, ethics committee and MHRA a 3rd observational arm was introduced:~Epistatus administered PRN by family / carer for symptoms"
89553012|NCT02393443|Experimental|Intranasal oxytocin|Participants will self-administer 24 IU oxytocin (Syntocinon, Novartis Pharmaceuticals). 5 puffs per nostril (1 puff = 2.4 IU oxytocin).
89553013|NCT02393443|Placebo Comparator|Intranasal placebo|2 mls Glycerine and 3 mls purified water (methylparaben and propylparaben mixed according to purified water formula) for a total of 5 ml, which will be filtered with a 5mu filter. Participants will self-administer 5 puffs per nostril.
89553014|NCT01977898|Experimental|Morphine|Patients randomized to the treatment group (morphine) will receive preservative-free morphine 0.3 mL (150 mcg) intrathecally.
89553015|NCT01977898|Placebo Comparator|Saline|Patients randomized to the control group will receive normal saline 0.3 mL intrathecally.
89553016|NCT02393287||Reproline|this is an observational trial ; there is no intervention
89553017|NCT02392975|Experimental|Fast magnetic resonance imaging (Fast MR)|All subjects will undergo fast MR in addition to Computerized Tomography (CT) (the current criterion standard). Fast MR will be interpreted independently for research purposes by 2 blinded radiologists. Consensus interpretation will be compared to the clinical reading of the CT.
89553018|NCT02003638|Experimental|Niacin|Niacin titrated up to 6 grams taken orally every day for 12 weeks
89553019|NCT02003638|Placebo Comparator|Placebo|Placebo taken orally every day for 12 weeks
89553020|NCT02393131|Experimental|Hippocampal avoidance WBRT|Conformal whole brain radiotherapy with hippocampal avoidance
89553021|NCT02393131|Active Comparator|Conformal WBRT|Conformal whole brain radiotherapy without hippocampal avoidance
89553022|NCT02696317|Other|AO1D, then AO|Senofilcon A contact lenses with HydraLuxe™, followed by senofilcon A contact lenses. Each product worn bilaterally (in both eyes) for 10 days in a daily wear, daily disposable modality.
89553023|NCT02696317|Other|AO, then AO1D|Senofilcon A contact lenses, followed by senofilcon A contact lenses with HydraLuxe™. Each product worn bilaterally for 10 days in a daily wear, daily disposable modality.
89553024|NCT02393053|Sham Comparator|subepithelial connective tissue graft|Surgery: Treatment with subepithelial connective tissue graft for gingival recession
89553025|NCT02393053|Experimental|non-pedicled buccal fat pad graft|Surgery: Treatment with non-pedicled buccal fat pad graft for gingival recession
89553026|NCT01959412|Experimental|Treatment Period Sequence 1|Indacaterol 37.5 mcg in the morning + matching placebo in the evening, 14 days later indacaterol 55 mcg in the morning + matching placebo in the evening, 14 days later placebo in the morning + matching placebo in the evening, 14 days later indacaterol 75 mcg in the morning + matching placebo in the evening, 14 days later indacaterol 27.5 mcg in the morning + 27.5 mcgin the evening, 14 days later indacaterol 150 mcg in the morning + matching placebo in the evening
89553027|NCT01959412|Experimental|Treatment Period Sequence 2|Indacaterol 55 mcg in the morning + matching placebo in the evening, 14 days later indacaterol 75 mcg in the morning + matching placebo in the evening, 14 days later 37.5 in the morning + matching placebo in the evening, 14 days later indacaterol 150 mcg in the morning + matching placebo in the evening, 14 days later placebo in the morning + placebo in the evening, 14 days later indacaterol 27.5 mcg in the morning + 27.5 mcg in the evening
89553028|NCT01959412|Experimental|Treatment Period Sequence 3|Indacaterol 75 mcg in the morning + matching placebo in the evening, 14 days later indacaterol 150 mcg in the morning + matching placebo in the evening, 14 days later 55mcg in the morning + matching placebo in the evening, 14 days later indacaterol 27.5 mcg in the morning + 27.5 mcg in the evening, 14 days later indacaterol 37.5 mcg in the morning + matching placebo n the evening, 14 days later placebo in the morning + matching placebo in the evening
89553029|NCT01959412|Experimental|Treatment Sequence Period 4|Indacaterol 150 mcg in the morning + matching placebo in the evening, 14 days later indacaterol 27.5 mcg in the morning + 27.5 mcg in the evening, 14 days later 75 mcg in the morning + matching placebo in the evening, 14 days later placebo in the morning + matching placebo in the evening, 14 days later indacaterol 55 mcg in the morning + matching placebo in the evening, 14 days later indacaterol 37.5 mcg in the morning + matching placebo in the evening
89553030|NCT01959412|Experimental|Treatment Period Sequence 5|Indacaterol 27.5 mcg in the morning + 27.5mcg in the evening, 14 days later placebo in the morning + matching placebo in the evening, 14 days later 150mcg in the morning + matching placebo in the evening, 14 days later indacaterol 37.5 mcg in the morning + matching placebo in the evening, 14 days later indacaterol 75 mcg in the morning + matching placebo in the evening, 14 days later indacaterol 55 mcg in the morning + matching placebo in the evening
88961986|NCT03581877|Experimental|Peripheral low dose thrombolysis|Peripheral low dose thrombolysis will use a peripheral vein into an arm as in routine intravenous therapy. This is the experimental arm. Alteplate (R-tpa) belong to thrombolytic or fibrnolytic drug class. Routine hospital policies for peripheral venous therapy will be used. A fixed dose of 24 mg of Activase (Atleplase) over 12 hours or 2.0 mg/hr will be administered peripherally. Simultaneously, intravenous unfractionated heparin will be given with a target partial thromboplastin time of 40 to 60 secs.
88961987|NCT03581877|Active Comparator|Catheter directed acoustic thrombolysis|For ACDT, routine hospital protocols and EKOS(generic) will be used. EKOS is made up of 3 parts which include the drug delivery pulmonary artery catheter, a removable microsonic device, and a reusable Eko-Sonic control unit. Venous access will be obtained by ultrasound guidance in the internal jugular vein or femoral vein. After catheter placement, the right heart pressures will be measured. R-tpa will be directly given into the pulmonary catheter. A fixed dose of 24 mg of tpa over 12 hours or 2.0mg/hr will be given. For unilateral PE, a single catheter will be used with infusion rate of 2 mg//hr and two catheters will be used for bilateral PEs each with 1 mg /hr infusion rate. Intravenous unfractionated heparin will be given with a target partial thromboplastin time of 40 to 60 secs.
88961988|NCT02009358|Experimental|Mental health promotion group|
88961989|NCT02009371|Experimental|Light therapy|In this group, participants will be exposed to the LED treatment device (light box) which delivers bright light and meanwhile medicated with just one particular antipsychotics drug(a mood stabilizer or an atypical antipsychotic drug)except of antidepressants.
89025641|NCT01242423|Experimental|skin excision for the purpose of a skin graft|Group C (n=50): Consent-capable male and female patients between ≥18 and ≤80 years of age who require a skin excision for the purpose of a skin graft. The minimal size of the skin-graft donor site must not be less than 1% of BBS.
89553031|NCT01959412|Experimental|Treatment Period Sequence 6|Placebo in the morning + matching placebo in the evening, 14 days later indacaterol 37.5 mcg in the morning + matching placebo in the evening, 14 days later 27.5 mcg in the morning + 27.5mcg in the evening, 14 days later indacaterol 55 mcg in the morning + matching placebo in the evening, 14 days later indacaterol 150 mcg in the morning + matching placebo in the evening, 14 days later 75 mcg in the morning + matching placebo in the evening
89553032|NCT02402101|Active Comparator|active tDCS|Intensity : 2mA Duration : 20 minutes ramp up/ramp down 30sec anodal tDCS applied over the left DLPFC cathodal tDCS applied over the right DLPFC
89553033|NCT02402101|Placebo Comparator|sham tDCS|Placebo built-in mode (30 sec ramp periods at the beginning and the end of the sham stimulation to mimic the somatosensory artifact of real tDCS) Same electrode montage than in the active group.
89553034|NCT02402179|Experimental|Tryptophan Amino Acid|13.2, 26.4, 39.7, 52.9% of the mean tryptophan requirement of 3.78 mg/kg/d will be given to subjects.
89553035|NCT02401945|Experimental|DE-120 Monotherapy|DE-120 intravitreal injection given as monotherapy on a PRN basis
89553036|NCT02401945|Experimental|Eylea® and DE-120 Concomitant Therapy|DE-120 intravitreal injection given on a PRN basis after Aflibercept (Eylea®) injection as an induction therapy.
89553037|NCT01977820|Experimental|Sapropterin|
89553038|NCT01977820|Placebo Comparator|Placebo|
89553039|NCT02402023|Active Comparator|Standard Care (SC)|Patients in the SC arm will receive 4 counseling sessions and nicotine patches as part of typical cessation measures delivered to patients.
88961990|NCT02009371|Placebo Comparator|Control group|In this group, participants will be exposed to the same LED treatment device (light box) which delivers dim red light,which is considered to be biologically inactive, and meanwhile medicated with just one particular antipsychotics drug(a mood stabilizer or an atypical antipsychotic drug)except of antidepressants.
88961991|NCT02009410|Experimental|Creon|
88961992|NCT02009410|Placebo Comparator|Placebo|
88961993|NCT02009436|Experimental|Treatment (azacitidine)|Patients receive azacitidine via nebulizer over 20 minutes QD on days 1-5 and 15-19. Treatment repeats every 28 days for up to 24 weeks in the absence of disease progression or unacceptable toxicity. Patients may continue treatment on a case-by-case basis at the discretion of principal investigator and Institutional Review Board.
88961994|NCT02009462|Experimental|Artefill|Four treatment visits using Artefill dermal filler
88961995|NCT02009475|Active Comparator|Continues aerobic training|Treadmill or exercise bike training with target heart rate of 50-70% of the heart rate reserve (or 50-60% of the peak VO2 reserve). Overall 45 minutes of exercise (including the 5-10 minute warm-up period).
88961996|NCT02009475|Experimental|Interval Exercse Training|Bouts of high intensity interval treadmill or exercise bike training, comprising of 85-95% of the heart rate reserve (or 80-90% of the peak VO2 reserve), for the duration of 4 minutes, separated by periods of low intensity activity until the heart rate reaches 50% of the peak heart rate. This set will be repeated 3 times.
88961997|NCT02009488|Experimental|Canagliflozin (JNJ-28431754)|Each patient will receive canagliflozin 100 mg once daily during the first 4 weeks of the 25 weeks double-blind period, then the dose may be increased to 300 mg once daily, till the end of the period.
88961998|NCT02009488|Placebo Comparator|Placebo|One placebo capsule taken orally (by mouth) once daily for approximately 28 days during the Pre-Treatment Run-In and the Baseline Periods, then during double-blind study for 178 days (approximately 24-25 weeks).
88961999|NCT02009527|Experimental|N-hydroxy-nor-arginine|N-hydroxy-nor-arginine 0.1 mg/ min i.a. for 20 min
88962000|NCT02009527|Placebo Comparator|NaCl|NaCl 0.9%, 6 ml/min i.a. for 20 min
88962001|NCT02009540|Placebo Comparator|Botulinum toxin injected to bladder body|arm will receive 100u of onaBoNT-A in 20x1ml aliquots (5u/ml). 20 injections will be given into the bladder wall, sparing the trigone. Injections will be given through all layers of the bladder eg suburothelially and intradetrusor.
88962002|NCT02009540|Active Comparator|Botulinum toxin injected into trigone|Arm B will receive 100u onaBoNT-A injected into 10x1ml suburothelial peri-trigonal sites (aliquot dose 10u/ml).
88962003|NCT02009553||Information sheet, Applied|In this group, all patients will receive the information sheet one month before the procedure
88962004|NCT02009553||Information sheet, not applied|In this group, patients will not receive a pre-procedural information sheet
88962005|NCT02009566|Experimental|Abdominal radiographs with microfabricated tags|
88962006|NCT02009592|Active Comparator|Hepatosteatosis|Rifaximin was given to patients with hepatosteatosis in the doses of 3x2 daily, 200 mg tablets for 4 weeks.
88962007|NCT02009592|Active Comparator|Steatohepatitis|Rifaximin was given to patients with steatohepatitis patients in the doses of 3x2 daily, 200 mg tablets for 4 weeks.
88962008|NCT02009605|Experimental|one arm|Icotinib of routine dose Icotinib: 125mg, oral administration, three times per day.
88962009|NCT02009618|Placebo Comparator|Irritable bowel syndrome patients|placebo tablet was given to another group in same doses for 10 days
88962010|NCT02009618|Experimental|Rifaximin|"Irritable bowel syndrome patients~Rifaximin is given to patients 200 mg tablets, 3x2/daily, for 10 days"
88962011|NCT02009631|Experimental|Sequence Group A|200 mg Veliparib
88962012|NCT02009631|Experimental|Sequence Group B|400 mg Veliparib
88962013|NCT02009631|Placebo Comparator|Sequence Group C|Placebo
88962014|NCT02009670|Experimental|13C inulin|13C inulin combined with an inulin load are administered orally
88962015|NCT02009670|Placebo Comparator|Placebo|A placebo is administered orally
88962016|NCT02009709|Active Comparator|9 mW/cm2|CCL-VARIO UV lamp Riboflavin 0.1% ophthalmic solution
89553040|NCT02402023|Experimental|Contingency Management (CM)|Patients in the CM arm will receive monetary payment contingent on smoking abstinence (in addition to SC: 4 counseling sessions and nicotine patches).
89553041|NCT02392897|Experimental|High Eating Frequency|6 Eating Occasions
89553042|NCT02392897|Experimental|Low Eating Frequency|3 Eating Occasions
89553043|NCT02003014||Pioglitazone 15 mg to 30 mg|administered orally once daily
89553044|NCT03166345|Experimental|PRP injection into Uterine Cavity|PRP injection into Uterine Cavity For Treatment of Thin Endometrium
89553045|NCT03166345|Experimental|CSF (colony stimulating factor)|CSF for Treatment of Thin Endometrium
89553046|NCT03166345|No Intervention|No intervention|The control arm.
89553047|NCT04411498||Group of Systemic Sclerosis|Patients who were followed-up with the diagnosis of diffuse systemic sclerosis in the Hospital of Rheumatology Clinic were evaluated in terms of inclusion criteria. 44 female patients who met the inclusion criteria were included in the study. All patients were evaluated by a rheumatologist with detailed history and physical examination. Scleroderma patient group was evaluated for the presence of other rheumatic diseases that may accompany.
89553048|NCT04411498||Group of control|The healthy control group (96 female ) was evaluated for rheumatic diseases [undiagnosed connective tissue diseases and additional rheumatological diseases] that may accompany secondary FMS exclusion.
89553049|NCT02392819|Experimental|test product|Arm: Panax ginseng
89553050|NCT02392819|Placebo Comparator|placebo product|Arm: a placebo with similar appearance but without Panax ginseng. The tablet include all the other non-active bulk ingredients.
89553051|NCT01977352|Active Comparator|Bupivacaine 0.25%|20 cc of bupivacaine 0.25%
89553052|NCT01977352|Experimental|Liposomal bupivacaine|liposomal bupivacaine (EXPAREL®; 88 mg in 20 cc)
89553053|NCT03166033||Case Group|"age between 41 and 70years. People in the case group with the symptom numbness and then were clinical and neural-electrophysiological diagnosed CTS. People in the control group would be exclude the symptom numbness. The case group included clinical diagnosed carpal tunnel syndrome which was divided into 4 parts every 10 years old age. The gender of the patients of the control group was matched to the case group and divided into 4 parts by age."
89553054|NCT03166033||Control Group|The present case-control study was based on the single medical center in Shanghai, China, in which more than 5000 CTS patients per year are treated. The hospital involved in the study is a university teaching hospital. Cases were recruited from the surgical wards and appropriate outpatient clinics, while the controls were recruited from the outpatient clinics. Both groups filled out a standardized questionnaire, and a standardized patient record was filled out by a hand surgeon. In addition, participants with jobs involving lifting and carrying of loads were interviewed.
89553055|NCT03166189|Experimental|bone marrow-derived MSC and HRT|endometrial injection of autologous cell product of MSC with hormonal replacement therapy before frozen/thawed ET
89553056|NCT03166189|Active Comparator|hormonal replacement therapy|standard endometrial preparation for frozen/thawed ET
89553057|NCT03166111|Experimental|lidocaine group|lidocaine in-situ gel inserted vaginally
89553058|NCT03166111|Placebo Comparator|placebo group|placebo gel inserted vaginally
89553059|NCT02001688|Experimental|Kamada-AAT for Inhalation, 80mg|Daily inhalation of Kamada-AAT for Inhalation, 80mg
89553060|NCT02001688|Placebo Comparator|Placebo|Placebo administered by inhalation daily
89553061|NCT02001688|Experimental|Kamada-AAT for Inhalation, 160mg|Daily inhalation of Kamada-AAT for Inhalation, 160mg
89553062|NCT05668507|Experimental|REACHOUT|The REACHOUT intervention arm will receive access to the REACHOUT mobile app through which they will be able to review profiles of Peer Supporters and connect with one of their choosing. They will also have access to the other app features including a 24/7 chat room and face-to-face support via virtual happy hours. Participants will complete questionnaires (baseline, 1 month, 3 months, 6 months) and a blood draw (baseline and 6 months). Monetary compensation will be provided for their time and effort.
89553063|NCT05668507|No Intervention|Wait-list|The wait-list control group will receive access to the mobile app/support program after six (6) months. They will complete questionnaires and a blood draw at baseline and 6 months. Monetary compensation will be provided for their time and effort.
89553064|NCT02392741|No Intervention|Control|The control group will follow the IMIP prenatal routine.
89553065|NCT02392741|Experimental|Physical exercise program|The intervention group witch will be submitted to an exercise program consisting of daily post prandial, 10' after breakfast, lunch and dinner.
89553066|NCT03114943|Experimental|NBP608|Single dose 0.5mL of NBP608 by subcutaneous injection into the outer aspect of the upper arm or the anterolateral thigh
89553067|NCT03114943|Active Comparator|Varivax|Single dose 0.5mL of Varivax by subcutaneous injection into the outer aspect of the upper arm or the anterolateral thigh
89553068|NCT05117021|Experimental|Group of Bupivacaine injection in Caudal block group|The children will receive of 0.25% plain bupivacaine infiltration as caudal block for post operative analgesia in infraumblical surgeries
89553069|NCT05117021|Experimental|Group 2 : Group of Bupivacaine injection in TAP block group|The children will receive of 0.25% plain bupivacaine infiltration as Transversus Abdominis Plane Block for post operative analgesia in infraumblical surgeries
89553070|NCT02001064|Experimental|Care4Today v2.0 mobile application + electronic monitoring of adherence|"Care4Today v2.0 mobile application~Participants in the experimental application arm will use the Care4Today v2.0 mobile application for antiretroviral medication adherence support. Alert messages generated via the app will be targeted to the specific schedule and needs of the individual.~Electronic monitoring of adherence:~Participants' adherence to antiretroviral therapy medication is measured via Medication Event Monitoring System (MEMS) cap."
89553071|NCT02001064|No Intervention|Electronic monitoring of adherence|Participants' adherence to antiretroviral therapy medication is measured via Medication Event Monitoring System (MEMS) cap.
88962017|NCT02009709|Active Comparator|18 mW/cm2|CCL-VARIO at 18 mW/cm2 Riboflavin 0.1% ophthalmic solution
88962018|NCT02009735|Experimental|virosensor|virus detection
88962019|NCT02009748|Active Comparator|Vitamin D supplementation|Colecalciferol 2.800 IU/day
88962020|NCT02009748|Placebo Comparator|Placebo|Vehicle (coconut oil)
89553072|NCT02392585|Active Comparator|Single tourniquet|
89553073|NCT02392585|Active Comparator|Triple tourniquet|
88962021|NCT02009774||Controll group|Patients from the control group will be examined using a CF-HQ 190 EVIS Exera III Advanced Diagnostic Video Colonoscope. If colon polyps are detected optical diagnosis will be determined WITHOUT using the NBI function of the scope.
88962022|NCT02009774||Intervention|Patients from the control group will be examined using a CF-HQ 190 EVIS Exera III Advanced Diagnostic Video Colonoscope. If colon polyps are detected optical diagnosis will be determined WITH THE HELP OF the NBI function of the scope.
89553074|NCT03068273|Experimental|Intervention|For type 2 patients in the intervention group, CGM data will be viewed real-time.
89553075|NCT03068273|Experimental|Control|For type 2 patients in the control group, CGM data is blinded to all and only gathered for comparison purposes to intervention group.
88962023|NCT02009787|Experimental|Vitamin D supplementation group|drug: vitamin D3 tablets (Vigantoletten; Merck Pharma, Germany); the frequency: 2000 IU vitamin D3 tablets were taken daily; duration: 6 months.
89553076|NCT02392663|Active Comparator|Hypertonic saline solution|"Hypertonic saline (7%) solution (5 ml) will be nebulized by all patients in a randomized order. Immediately after, patients will perform a bronchial drainage session. The airway clearance technique selected will be autogenic drainage (AD).~Both patients and physiotherapist will be blind to the intervention."
89553077|NCT02392663|Active Comparator|Hyaneb solution|"Hyaneb (acid hyaluronic + hypertonic saline [7%]) solution (5 ml) will be nebulized by all patients in a randomized order. Immediately after, patients will perform a bronchial drainage session. The airway clearance technique selected will be autogenic drainage (AD).~Both patients and physiotherapist will be blind to the intervention."
89553078|NCT02392663|Placebo Comparator|Isotonic saline solution|"Isotonic saline (0,9%) solution (5 ml) will be nebulized by all patients in a randomized order. Immediately after, patients will perform a bronchial drainage session. The airway clearance technique selected will be autogenic drainage (AD).~Both patients and physiotherapist will be blind to the intervention."
89553079|NCT02000752|Experimental|Acupuncture|In the intervention group with real acupuncture, after the umbilical cord is clamped, the acupuncturist disinfects the abdominal area with antiseptic and pricks the needle in the point Ren Mai 6. This point is located on the anterior midline, between the umbilicus and the upper part of the pubic symphysis, at a distance of 0.3d from the umbilicus, being d the distance from the umbilicus to the upper part of the pubic symphysis. A sterilized steel needle of 0.25x40 mm is inserted in this point at 15-30 mm, depending on the adipose tissue of the woman.
89553080|NCT02000752|Sham Comparator|Sham acupuncture|Regarding to the control group with sham acupuncture, after the umbilical cord is clamped, the acupuncturist disinfects the abdominal area with antiseptic and pricks the needle in the placebo point with a sterilized 0.25x40 mm steel needle. The control point is located at the same horizontal level than the Ren Mai 6 point, but at 0.6d to the left of the anterior midline of the mother. In this case, the sterilized steel needle of 0.25x25 mm is inserted 15 mm into the tissue.
89553081|NCT02982941|Experimental|Dose Escalation & Cohort Expansion|enoblituzumab administered IV weekly
89553082|NCT02392117||Insulin degludec|
89553083|NCT02812433|Active Comparator|Sildenafil|Sildenafil 2 mg/kg/dose per os twice a day for seven consecutive days (from day 2 of life to day 9 of life) if brain injury on day 2 of life
89553084|NCT02812433|Placebo Comparator|Ora-Blend|Ora-Blend 2 mg/kg/dose per os twice a day for seven consecutive days (from day 2 of life to day 9 of life) if brain injury on day 2 of life
89553085|NCT02392039|Experimental|Group 1 - Loratadine|"Pegfilgrastim 6 mg subcutaneously between 24 and 72 hours after completion of chemotherapy once per 21 day cycle.~Cycle 1 and 3:~Loratadine 10 mg by mouth daily, starting on the day of Pegfilgrastim administration and continuing for a total of 7 days.~Cycle 2 and 4:~Placebo by mouth daily, starting on the day of Pegfilgrastim administration and continuing for a total of 7 days.~Three questionnaires completed about bone pain and quality of life. These are completed before Pegfilgrastim received during Cycles 1 - 4 (and if participant has pain, during Cycles 6 - 7), on Day 7, and 8 weeks after last dose of study drugs."
89553086|NCT02392039|Experimental|Group 2 - Placebo|"Pegfilgrastim 6 mg subcutaneously between 24 and 72 hours after completion of chemotherapy once per 21 day cycle.~Cycle 1 and 3:~Placebo by mouth daily, starting on the day of Pegfilgrastim administration and continuing for a total of 7 days.~Cycle 2 and 4:~Loratadine 10 mg by mouth daily, starting on the day of Pegfilgrastim administration and continuing for a total of 7 days.~Three questionnaires completed about bone pain and quality of life. These are completed before Pegfilgrastim received during Cycles 1 - 4 (and if participant has pain, during Cycles 6 - 7), on Day 7, and 8 weeks after last dose of study drugs."
89553087|NCT03995693|Experimental|Concentric cycling with placebo ingestion|Participants will complete 45 minutes of arm cranking at an intensity corresponding to 30% of the concentric cycling VO2max, followed by 35 minutes of CONCENTRIC cycling on a recumbent ergometer at the same VO2. A PLACEBO solution (water with a non-caloric sweetener) will be ingested 30 min prior to starting exercise and every 15 min thereafter, until the exercise is completed. Indirect respiratory calorimetry, expired gas sampling, blood sampling will occur will be performed 4 minutes before each ingestion.
89553088|NCT03995693|Experimental|Concentric cycling with glucose ingestion|Participants will complete 45 minutes of arm cranking at an intensity corresponding to 30% of the concentric cycling VO2max, followed by 35 minutes of concentric cycling on a recumbent ergometer at the same VO2. A GLUCOSE solution (glucose with a trace amount of 13C) will be ingested 30 min prior to starting exercise and every 15 min thereafter, until the exercise is completed. Indirect respiratory calorimetry, expired gas sampling, blood sampling will occur will be performed 4 minutes before each ingestion.
89553089|NCT03995693|Experimental|Eccentric cycling with placebo ingestion|Participants will complete 45 minutes of arm cranking at an intensity corresponding to 30% of the concentric cycling VO2max, followed by 35 minutes of ECCENTRIC cycling on a recumbent ergometer at the same VO2. A PLACEBO solution (water with a non-caloric sweetener) will be ingested 30 min prior to starting exercise and every 15 min thereafter, until the exercise is completed. Indirect respiratory calorimetry, expired gas sampling, blood sampling will occur will be performed 4 minutes before each ingestion.
88962024|NCT02009787|Placebo Comparator|Control group|drug: placebo tablets; the frequency: 2000 IU placebo tablets were taken daily; duration: 6 months.
88962025|NCT02009826||Healthy controls|Healthy age- and sex-matched controls
89553090|NCT03995693|Experimental|Eccentric cycling with glucose ingestion|Participants will complete 45 minutes of arm cranking at an intensity corresponding to 30% of the concentric cycling VO2max, followed by 35 minutes of ECCENTRIC cycling on a recumbent ergometer at the same VO2. A GLUCOSE solution (glucose with a trace amount of 13C) will be ingested 30 min prior to starting exercise and every 15 min thereafter, until the exercise is completed. Indirect respiratory calorimetry, expired gas sampling, blood sampling will occur will be performed 4 minutes before each ingestion.
89553091|NCT02000440|Experimental|Losmapimod (GW856553X)|The subjects will be administered with 7.5 mg (1 tablet) of losmapimod following the completion of the Baseline (time zero) assessments. Subjects will continue to take one tablet in the morning and one tablet in the evening for approximately 2 weeks. After all the pre-dose assessments are completed at the Week 2 visit, subjects will be administered the first 15 mg (2 tablets) dose. Subjects will continue to take two tablets in the morning and two tablets in the evening every day for approximately 22 weeks. Doses of study treatment will be separated by at least 6 hours
88962026|NCT02009826||Schizophrenia patients|Young schizophrenia patients 18-40y
88962027|NCT02009839|Experimental|Meeky Mouse program|"14-week Meeky Mouse program consists of 8 training sessions (psychoeducation and anxiety management) followed by 6 practice sessions (exposure using social skills training)"
88962028|NCT02009839|Placebo Comparator|Computer Games|14 weeks of interactive session with the therapist while playing computer games
88962029|NCT02009852||Oral cancer|"Subjects who suffer from oral cancer.~Subjects must:~Should have a blood exam (20ml/each time) before the surgery and 3 months after the surgery.~In the case the disease recurs after the surgery, subjects need to receive the surgery again and take another blood exam before the surgery and 3 months after the surgery.~Before the surgery site staff must:~Collect subjects' saliva once a day (in the morning before breakfast) for 3 consecutive days.~Collect a 0.5x0.5Cm2 tissue sample of the tumor during the surgery."
88962030|NCT02009891||Control|Control couples who will not use predictive model
88962031|NCT02009891||Predictive model|Couples who will use predictive model
88962032|NCT02009904||Phenylketonuria (PKU); Healthy Controls|Children with PKU (5-18y); Age and Gender matched healthy subjects for comparison
88962033|NCT02009943|Experimental|Ferric carboxymaltose (FDA IND pending)|15 mg/kg, up to 750 mg IV x 1 on the day of study enrollment.
88962034|NCT02009943|Active Comparator|Iron sucrose (FDA IND 109,877)|"Iron sucrose 100 mg IV will be dosed daily using goal-direction up to a total of 700 mg over a 7-day period. Specifically, iron sucrose will be dosed daily if:~TSAT < 25%~Serum iron concentration < 150 ug/mL~Serum ferritin concentration < 1,500 ng/mL"
88962035|NCT02009943|No Intervention|Control|No iron supplementation
88962036|NCT02009956|Other|DESyne Novolimus Eluting CSS|Enrollment of up to 50 patients with up to two de novo native coronary artery lesions measuring between 2.5 and 4.0 mm in diameter and </= 34 mm in length receiving the DESyne Novolimus Eluting CSS.
88962037|NCT02009995|Active Comparator|Aerobic Training (AT) only|All subjects will participate in a 10-week ramp-in period with the goal of achieving 150 minutes of moderate-to-vigorous physical activity per week. Walking and jogging will be the primary modes of achieving the prescribed aerobic activity as these are the modes of aerobic exercise that are most accurately recorded by an accelerometer. Subjects will use the Rate of Perceived Exertion (RPE) to guide aerobic exercise intensity. Aerobic activity will be objectively monitored by the Technogym MyWellness Key (MWK) accelerometer, which is a lightweight device worn on the waistband.
88962038|NCT02009995|Experimental|AT plus Primarily Home-Based Resistance Band Training|"Both of the bands + AT groups will engage in RBT 3 times per week, progressing to 3 sets of 8-12 repetitions of 12 exercises. The exercises will be: chair squat, sitting chest press, seated rear fly, seated row, overhead press, lateral raise, biceps curl, triceps extension, leg extension, hamstring curl, gluteal extension, and abdominals. The resistance band exercise sessions will be between 25-60 minutes.~Participants in this group will attend supervised group sessions weekly in weeks 1-4, every 2 weeks in weeks 5-8, and every 4 weeks thereafter to ensure proper form and appropriate progression. Participants in this group will be responsible to complete all remaining sessions (a total of 3 per week, including supervised sessions) at home on their own time."
89025642|NCT00460226||lamotrigine|there is only one group.
89553092|NCT02781701|Experimental|Tongue Trainer|"The strength of participants tongue will be measured and participants will be shown how to perform tongue training exercises using a special device. Participants will be given instructions on how to perform a workout for the tongue. Each day once in the morning (am) and once in the afternoon/evening (pm), participants will train with the device and have a tongue workout that lasts about 10 minutes.~Therefore, participants will work out about 20 minutes a day for 6 weeks."
89553093|NCT03106363|Active Comparator|Alcohol/Placebo Cannabis|Participant will drink an alcoholic beverage to obtain a target blood alcohol content of 0.08mg% and will smoke a placebo delta 9 tetrahydrocannabinol (< 0.03%) cigarette.
89553094|NCT03106363|Active Comparator|Placebo Alcohol/Cannabis|Participant will drink tonic water (capped with a minimal amount of alcohol to enhance alcohol cues) and will smoke a delta 9 tetrahydrocannabinol (potency 12.5%) cigarette.
89553095|NCT03106363|Active Comparator|Alcohol/Cannabis|Participant will drink an alcoholic beverage to obtain a target blood alcohol content of 0.08mg% and will smoke a delta 9 tetrahydrocannabinol (potency 12.5%) cigarette.
89553096|NCT03106363|Placebo Comparator|Placebo Alcohol/Placebo Cannabis|Participant will drink tonic water (capped with a minimal amount of alcohol to enhance alcohol cues) and will smoke a placebo delta 9 tetrahydrocannabinol (< 0.03%) cigarette.
89553097|NCT04413071||Health care workers|Health care workers from the University Hospital of Salamanca who have passed SARS-CoV-2 infection.
89553098|NCT03106519|Experimental|Single mixture LB & bupivacaine|A single mixture of liposome bupivacaine 1.3% (5 mL) + bupivacaine 0.5% (2.5 mL) injected into the median and ulnar nerves
89553099|NCT03106519|Active Comparator|Bupivacaine alone|Bupivacaine 0.5% (7.5 mL) injected into the median and ulnar nerves
89553100|NCT05657587||PNS Group|All subjects will receive the PNS device. The Sprint system delivers mild electrical stimulation to the shoulder. The Sprint system includes up to two leads (small wires) that are placed through your skin in your shoulder. The leads attach to devices worn on your body that delivers stimulation (stimulators).
88962039|NCT02010008|Experimental|Motivational Interviewing Intervention|Motivational Interviewing (MI) Intervention includes in -person home visit that elicits behavior change by helping participants explore and resolve ambivalence. A telephone follow-up call also uses MI technique.
88962040|NCT02010008|No Intervention|Comparison|Usual care
88962041|NCT02010034|Other|Compassionate use|This lipid preparation is only being used for compassionate use.
88962042|NCT02010047|Experimental|IHC, FISH and qPCR ALK assays|ALK testing by IHC and FISH will be compared to ALK qPCR testing on NSCLC FFPE tissue.
88962043|NCT02010060|No Intervention|Control|The goal of this group is to maintain their current lifestyle habits during the intervention. participants are asked to make no conscious changes to their physical activity or dietary habits.
88962044|NCT02010060|Experimental|Aerobic Exercise Training|The Aerobic training group will participate in 6 months of aerobic training and asked to make no conscious alterations in their physical activity outside of exercise session, or dietary habits
88962045|NCT02010060|Experimental|Aerobic Exercise+ Physical Activity|The goal of this group is to perform 6 months of aerobic exercise and increase the amount of physical activity outside of their training sessions. They will be asked to make no conscious changes to their dietary habits
89553101|NCT02626793||Patients with ≤ 1 conventional, systemic pre-treatment|After failure (inadequate response/intolerance) to or contraindication for ≤ 1 conventional, systemic pre-treatment
88812144|NCT05945992|Experimental|Condition 6: emotions, communication, mindfulness, conflict resolution|(1) emotion regulation, (2) communication skills, (3) mindfulness, (4) constructive conflict resolution
88812145|NCT05945992|Experimental|Condition 7: emotions, communication, stress, resources|(1) emotion regulation, (2) communication skills, (3) stress management, (4) resource activation
88812146|NCT05945992|Experimental|Condition 8: emotions, communication, stress, conflict resolution|(1) emotion regulation, (2) communication skills, (3) stress management, (4) constructive conflict resolution
88962046|NCT02010073||One Group|This is a prospective observational study, aimed at collecting an adequate dataset on a large cohort of patients admitted to a large number of ICUs.
88962047|NCT02010086|Experimental|Individual Cognitive Behavioral Therapy|
88962048|NCT02010086|Active Comparator|Standard Community Treatment|
88962049|NCT02010099|Experimental|PP110 Gel|PP110 Gel
88962050|NCT02010099|Experimental|PP110 medicated wipes|PP110 Medicated wipes
88962051|NCT02010099|Active Comparator|Preparation-H cream|Preparation-H cream
89025643|NCT01242462|Active Comparator|AB|2 hours of treatment with conventional ventilation strategy, then crossover to 2 hours of treatment with mid-frequency ventilation strategy
89553102|NCT02626793||Patients with > 1 conventional, systemic pre-treatment|After failure (inadequate response/intolerance) to or contraindication for > 1 conventional, systemic pre-treatment
89553103|NCT02687815|Experimental|vitamin D3|Cholecalciferol (Vitamin D3) 4000 IU oral gel cap daily
89553104|NCT02687815|Placebo Comparator|placebo|placebo formulations will be in gel cap form and identical to the active drug
89553105|NCT05742451|Active Comparator|intervention group|The kids yoga was applied to the intervention group for 8 weeks, once a week (8 sessions), 40 minutes per session, by a yoga instructor occupational therapist.
89553106|NCT05742451|No Intervention|Control group|The control group was evaluated at 8-week intervals.
89553107|NCT03916133|Other|Intervention group|Included patients will undergo angiographic FDCT perfusion imaging.The study will be embedded in the standard procedure of pre-operative diagnostics and angiographic control after EC-IC bypass treatment of steno-occlusive disease and during pre-embolization mapping and embolization procedure. An informed consent will be acquired during consultations in the preparatory process of the different examinations and treatments
89553108|NCT03915665|Active Comparator|Standard treatment|Manual treatment One application of Chlorhexidine 1% gel
89553109|NCT03915665|Experimental|Comprehensive treatment|Supragingival biofilm removal with Erythritol air-powder Submucosal biofilm removal with Erythritol air-powder (30%-60% power)
89553110|NCT01959334|Active Comparator|Glucagon IM|Glucagon dose of 1 milligram (mg) administered intramuscularly (IM).
89553111|NCT01959334|Experimental|Nasal Glucagon (NG|Nasal Glucagon (NG) doses of 3 mg administered intra-nasally.
89553112|NCT04722419|Experimental|Functional dyspepsia|
89553113|NCT04722419|Active Comparator|Healthy subjects|
89553114|NCT02687581|Experimental|12-hour IO-therapy Glasses|wear IO-therapy glasses for 12-hour
89553115|NCT02687581|Active Comparator|6-hour patching|wear the eye patch for 6-hour
89553116|NCT04173754||MSAT Group|"The MSAT group who are treated with korean medical treatment including MSAT will be evaluated on first, second, third visit and 2weeks after baseline. And the patients will receive telephone inquires after 3months from the baseline.~The Korean medical treatment includes acupuncture, chuna, pharmaco-acupuncture and Korean herbal medicine."
89553117|NCT04173754||Control Group|"The control group who are treated with Korean medical treatment not including MSAT will be evaluated on first, second, third visit and 2weeks after baseline. And the patients will receive telephone inquires after 3months from the baseline.~The Korean medical treatment includes acupuncture, chuna, pharmaco-acupuncture and Korean herbal medicine."
89553118|NCT02248805|Experimental|Does Escalation Arm A|MGD007 treatment once weekly
89553119|NCT02248805|Experimental|Dose Escalation Arm B|MGD007 treatment once every 3 weeks
89553120|NCT02248805|Experimental|Dose Expansion Arm C|MGD007 once every 3 weeks for K-ras wild-type and mutant metastatic CRC
89553121|NCT02248805|Experimental|Dose Expansion Arms|MGD007 2, 3, 6, or 12 doses/cycle
89553122|NCT01977040||Vasa Previa|Women with the diagnosis of Vasa Previa made during the pregnancy or at time of delivery who delivered between January 1, 2000 and December 31, 2012.
89553123|NCT02021279|Experimental|MatriStem Pelvic Floor Matrix|surgical mesh device
89553124|NCT02021279|Active Comparator|Native Tissue Repair|suture repair
89553125|NCT05652439||Fixed triple therapy BDP/FF/GB via DPI|COPD patients new users of fixed triple therapy BDP/FF/GB administered via DPI formulation according to local clinical practice
89553126|NCT05652439||Fixed triple therapy BDP/FF/GB via pMDI|COPD patients new users of fixed triple therapy BDP/FF/GB administered via pMDI formulation according to local clinical practice
89553127|NCT04813705|Experimental|Reduced dose group|The patients achieving CMR and more than 70% PMR at 25th fraction will receive reduced-dose radiotherapy for 30 fractions.
89553128|NCT04813705|Active Comparator|Conventional dose group|The patients who do not achieve CMR or 70% PMR at 25th fraction will receive conventional dose radiotherapy for 33 fractions.
89553129|NCT01958476|Active Comparator|Neonatal Morphine Solution|"Infants randomized to this arm will receive neonatal morphine solution (0.2mg/mL) for first line therapy. Infants will be scored using the standardized Finnegan scoring system and will be initiated on treatment if they have 2 consecutive scores greater than or equal to 8 or 1 score greater than or equal to 12. Dosing will be weight and symptom based. A double dummy design will be used - each infant will be ordered for both a methadone/placebo study drug at 0.4 mg/mL and a morphine/placebo study drug at 0.2 mg/mL. Starting doses will range from 0.3mg/kg/day to 0.9mg/kg/day divided every 4 hours depending on the severity of the Finnegan scores. Doses will be increased to a maximum of 0.9mg/kg/day for continued scores generally >8 caused primarily by worsening NAS. Infants will be weaned by 10% of the maximum dose once every 24 - 48 hours and the medication will be discontinued once at 25% of the maximum dose."
89553130|NCT01958476|Active Comparator|Methadone|"Infants randomized to this group will receive methadone oral solution (0.4mg/mL) for first line therapy. Infants will be scored using the standardized Finnegan scoring system and will be initiated on treatment if they have 2 consecutive scores greater than or equal to 8 or 1 score greater than or equal to 12. Dosing will be weight and symptom based. Starting doses will range from 0.3mg/kg/day to 0.9mg/kg/day divided every 8 hours depending on the severity of the Finnegan scores. To maintain blinding of the two study arms, a double dummy design will be used - each infant will receive both methadone/placebo study drug at 0.4 mg/mL and a morphine/placebo study drug at 0.2 mg/mL. Doses will be increased to a maximum of 0.9mg/kg/day for continued scores generally >8 caused primarily by worsening NAS as needed. Infants will be weaned by 10% of the maximum dose once every 24-48 hours and the medication will be discontinued once at 25% of the maximum dose."
89553131|NCT04809181|Experimental|MRD positive AML/MDS patients after allogeneic hematopoietic stem cell transplantation|MRD positive AML/MDS patients after allogeneic hematopoietic stem cell transplantation
89553132|NCT05737381|No Intervention|Control group|"The oocytes from a patient, retrieving more than 8 oocytes will be divided into 2 sibling groups. The control group and the study group.~The first part of the collected oocytes, will be included as controls. If an unequal numbers of oocytes are collected, the extra oocyte will be included into the control group.~Control oocytes are, after fertilization, placed in conventional 5% O2 incubators and cultured herein for 5 days."
89553133|NCT05737381|Experimental|Study group|"The second part of the collected oocytes, from a patient retrieving more than 8 oocytes, will be included as study group.~Study oocytes, are after fertilization, placed and cultured in conventional 5% O2 incubators for the first 3 days. At day 3, the embryos are moved to an incubator with 2% O2 tension and cultured until day 5."
89553134|NCT01057121|Experimental|Lenalidomide|Patients receive lenalidomide PO once daily on days 1-21. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
89553135|NCT02695537|Experimental|Epidiolex 100 milligram/milliliter (mg/mL) oral solution|"Participants will receive a CBD starting dose of 5 mg/kg/day in twice daily dosing and titrate by 5 mg/kg/2 weeks up to 25 mg/kg/day. Additional increases in dosing, by 5 mg/kg/day up to a maximum of 50 mg/kg/day, may be instituted at the discretion of the treating Principle Investigator (PI).~If a subject experiences a clinically significant or dose limiting adverse event (AE) or severe adverse event (SAE) attributable to CBD, the investigator will determine if a dose reduction or taper is necessary (decreases will occur in 5 mg/kg/2 week increments or at a rate felt appropriate by the treating PI)."
89553136|NCT04692389|Experimental|Jalosome® Soothing gel|"The medical device will be applied by the patient himself, after appropriate training carried out by the nurse, twice a day, in the quantity necessary to cover the lesion (0.2g of gel /16 cm2 of skin (one spray), repeated as many times as necessary to cover the entire lesion). The treatment will last 8 weeks.~The medical device will be delivered in the quantity strictly necessary to carry out the therapies between visits, in order to monitor its use. Patients will be seen weekly by the nurse, in order to ensure the best continuity of care and promote adherence to the study. Patients will be asked to keep a weekly diary, in which they will report their level of pain, analgesic therapy and medication. Nurses will be available for telephone counselling, if necessary."
89553137|NCT04620941||ventilator-associated pneumonia|Ret-He values will be studied on the day (1st day), 4th and 7th days of VID diagnosis in patients receiving mechanical ventilation support in the intensive care unit. The hemogram, CRP, and NLR values that are routinely studied in the intensive care unit will be recorded. In addition, in case of infection, the routinely studied procalcitonin value will also be recorded. The patient's age, gender, APACHE II, SOFA scores will be recorded; respiratory system examination, fever, the mental status evaluation will be done daily.
89553138|NCT04615871|Experimental|semaglutide|Eligible subjects randomized to this arm will receive semaglutide 0.25 mg s.c. after randomization (Day 0), then semaglutide 0.5 mg s.c. on Day 7, Day 14 and Day 21 in addition to standard of care.
89553139|NCT04615871|No Intervention|control|Eligible subjects randomized to the control arm will receive no active treatment, only standard of care.
89553140|NCT04991129|Experimental|WJ01024 5mg repeat dose every 28 days|
89553141|NCT04991129|Experimental|WJ01024 10mg repeat dose every 28 days|
89553142|NCT04991129|Experimental|WJ01024 20mg repeat dose every 28 days|
89553143|NCT04991129|Experimental|WJ01024 40mg repeat dose every 28 days|
89553144|NCT04991129|Experimental|WJ01024 60mg repeat dose every 28 days|
89553145|NCT04991129|Experimental|WJ01024 80mg repeat dose every 28 days|
89553146|NCT04991129|Experimental|WJ01024 100mg repeat dose every 28 days|
89553147|NCT04991129|Experimental|WJ01024 120mg repeat dose every 28 days|
88812147|NCT05945992|Experimental|Condition 9: group dynamics, self, mindfulness, resources|(1) social behavior in groups, (2), self-acceptance, (3) mindfulness, (4) resource activation
89553148|NCT04991129|Experimental|WJ01024 140mg repeat dose every 28 days|
89025644|NCT01242462|Active Comparator|BA|2 hours of treatment with mid-frequency ventilation strategy, then crossover to 2 hours of treatment with conventional ventilation strategy
89025645|NCT00460343|Experimental|max|
89553149|NCT04991129|Experimental|WJ01024 160mg repeat dose every 28 days|
89553150|NCT04888793||Cancer Patients on active treatment|
89553151|NCT04888793||Bone marrow transplant patients|
89553152|NCT04888793||Solid organ transplant recipients|
89553153|NCT04888793||HIV patients|
89553154|NCT04888793||Rheumatic disease patients|
89553155|NCT04888793||Healthy controls|
89553156|NCT04746989||Probenecid|Exposure group
89553157|NCT04746989||Allopurinol|Reference group
89553158|NCT02691247|Experimental|CLBS03 Low Dose|A single infusion of CLBS03 Low Dose, a cell product comprised of autologous, ex vivo expanded regulatory T-cells resuspended in sterile USP (United States Pharmacopoeia) infusion solution.
89553159|NCT02691247|Experimental|CLBS03 High Dose|A single infusion of CLBS03 High Dose, a cell product comprised of autologous, ex vivo expanded regulatory T-cells resuspended in sterile USP infusion solution.
89553160|NCT02691247|Placebo Comparator|Placebo|A single infusion of placebo, consisting of the infusion solution only
89553161|NCT04383821|Experimental|Double-Trunk Mask|The oxygen delivery system is the DTM
89553162|NCT04383821|Active Comparator|Non-Rebreather Mask|The oxygen delivery system is the NRM
89553163|NCT04349423|Experimental|No Social Media Use|Participants will be asked to refrain from using all social media
89553164|NCT04349423|Experimental|Maximum 30 minutes of use|Participants will be asked to only use social media at most 30 minutes a day.
89553165|NCT04349423|Experimental|Maximum 1 hour of use|Participants will be asked to only use social media at most 60 minutes a day.
89553166|NCT04349423|Experimental|Control|Control Group
89553167|NCT04163393|Experimental|R-One|Patients treated with robotic assistance
89553168|NCT04428749||Study group|"Participants are screened using the Yale Swallow Protocol (YSP) 2-4 hours after extubation:~Ability to swallow is assessed by an ICU nurse using the YSP. If the YSP is negative, the patient may start oral feeding and drinking. In case of a positive YSP, the screening may be repeated within the next 24 hours provided the patient improves clinically. If YSP continues to be positive the patient is referred to assessment by a speech language pathologist (SLP).~Participants are screened within 24 hours:~To evaluate YSP against the FEES, the patient undergoes 1) YSP performed by an ICU nurse followed by 2) FEES performed by a SLP (until PAS>6 (aspiration on any food consistency on the Penetration Aspiration Scale (20)). The SLP will be blinded to the assessment made by the ICU nurses. Patients will follow recommendations for oral feeding and drinking as given by the SLP."
89553169|NCT04238585|Active Comparator|Negative message frames|Participants will receive messages framed in a negative manner to avoid sugar-sweetened beverages
89553170|NCT04238585|Active Comparator|Sugar content information messages|Participants will receive messages framed in a positive manner to promote healthy beverage consumption
89553171|NCT04238585|Placebo Comparator|Attention Control-Infant Safety|Participants will receive messages with infant safety education materials-attention control group
89553172|NCT04677803|Experimental|Treatment|"Subcutaneous (SC) injection:~BT200 dose 3 mg on Day 0, Day 4, and again on Day 7 BT200 dose titrated thereafter between 3 and 9 mg on Days 14, 21, and 28. It is anticipated that dose adjustments will be performed in 2 mg steps. The 9 mg dose will only be applied on day 28 in exceptional circumstances, if no relevant changes in pharmacodynamic and safety parameters will be observed on day 21."
89553173|NCT04671953|Experimental|Arm 1: BMS-986165 Dose 1 + Metformin|
89553174|NCT04671953|Experimental|Arm 2: BMS-986165 Dose 2 + Metformin|
89553175|NCT04616105|Experimental|Cohort 1|Single ascending subcutaneous (SC) dose 1 of REGN6490 or matching placebo
89553176|NCT04616105|Experimental|Cohort 2|Single ascending subcutaneous (SC) dose 2 of REGN6490 or matching placebo
89025646|NCT00460343|Active Comparator|min|
89025647|NCT00495417|Active Comparator|1|
89025648|NCT00495417|Active Comparator|2|
89025649|NCT01242501|Experimental|60 Min. Risk Reduction Counseling|Single 60 min Social Cognitive Theory-based counseling session delivered in STI clinic setting in Cape Town South Africa. Includes educational, motivational, and sexual risk reduction skills components delivered in a single face-to-face counseling session.
89553177|NCT04616105|Experimental|Cohort 3|Single ascending subcutaneous (SC) dose 3 of REGN6490 or matching placebo
89553178|NCT04616105|Experimental|Cohort 4|Single ascending intravenous (IV) dose 4 of REGN6490 or matching placebo
89553179|NCT04585061|Active Comparator|sweet test group|Local anesthesia with conventional syringe Procedure: Local anesthesia with conventional syringe + xylitol sublingual tablet Buccal infiltration in posterior maxillary region with traditional technique. A 27 gauge short needle is inserted in the mucobuccal fold above the tooth to be anesthetized.
89553180|NCT04585061|Active Comparator|Virtual reality group|"Local anesthesia with conventional syringe + VR device Device: Local anesthesia with conventional syringe + VR device Virtual reality device (Harga Miniso Vr Glass 3d terbaru) is placed on the face of the patient, playing a video of Tom and Jerry cartoon.~Buccal infiltration in posterior maxillary region with traditional technique. A 27 gauge short needle is inserted in the mucobuccal fold above the tooth to be anesthetized."
89553181|NCT04531007|Experimental|Intermediate LMS stenosis|Patients with intermediate left main stem stenosis with additional severe downstream lesion will be subject to physiology (FFR and iFR) at multiple sites along the target vessels before and after PCI of the severe lesion located in the downstream vessel. Intravascular imaging (IVUS and OCT) will be performed for additional evaluation of the left main stem stenosis.
89553182|NCT03902717||minimally invasive cardiac surgery|Group of patients that will undergo minimally invasive cardiac surgery
89553183|NCT03874091|Active Comparator|GA group|Patients will receive general anaesthesia for laparoscopic nephrectomy/NSS/ Hynes Anderson procedures. Analgesia will be provided by titration of fentanyl during surgery. An intravenous patient controlled morphine pump will be used postoperatively.
89553184|NCT03874091|Experimental|ESP group|Patients will receive general anaesthesia with bilateral ESP block for laparoscopic nephrectomy/NSS/ Hynes Anderson procedures. Catheter will be inserted in the erector spinae plane on the side of surgery. Postoperatively patients will get continuous infusion of 0,125% Bupivacaine+Adrenaline to the catheter for 24h and PCA morphine pump intravenously.
89553185|NCT03786965|Other|On-pump CABG.|On-pump CABG.
89553186|NCT03786965|Other|Off-pump CABG.|Off-pump CABG.
89553187|NCT03786965|Other|Pump-assisted CABG.|Pump-assisted CABG.
89553188|NCT03786965|Other|Heart Valve Procedure without CABG.|Heart Valve Procedure without CABG.
89553189|NCT03786965|Other|Heart Valve Procedure with CABG.|Heart Valve Procedure with CABG.
89553190|NCT03735017|Active Comparator|Non-Interactive|Participants will receive non-interactive virtual reality walking sessions.
89553191|NCT03735017|Experimental|Interactive|Participants will receive interactive virtual reality walking sessions.
89553192|NCT01362491|Experimental|Treatment A|
89553193|NCT01362491|Active Comparator|Treatment B|
89553194|NCT01362491|Placebo Comparator|Treatment C|
89553195|NCT02687191|Experimental|PF-05230907 (Cohort 1)|PF-05230907 IV bolus injection
89553196|NCT02687191|Experimental|PF-05230907 (Cohort 2)|PF-05230907 IV bolus injection
89553197|NCT02687191|Experimental|PF-05230907 (Cohort 3)|PF-05230907 IV bolus injection
89553198|NCT02687191|Experimental|PF-05230907 (Cohort 4)|PF-05230907 IV bolus injection
89553199|NCT02687191|Experimental|PF-05230907 (Cohort 5)|PF-05230907 IV bolus injection
89553200|NCT02687191|Experimental|PF-05230907 (Cohort 6)|PF-05230907 IV bolus injection
89553201|NCT02687191|Experimental|PF-05230907 (Cohort 7)|PF-05230907 IV bolus injection
89553202|NCT02687191|Experimental|PF-05230907 (Cohort 8)|PF-05230907 IV bolus injection
89553203|NCT02687191|Experimental|PF-05230907 (Cohort 9)|PF-05230907 IV bolus injection
89553204|NCT02687191|Experimental|PF-05230907 (Cohort 10)|PF-05230907 IV bolus injection
89553205|NCT02687191|Experimental|PF-05230907 (Cohort 11)|PF-05230907 IV bolus injection
89553206|NCT02687191|Experimental|PF-05230907 (Cohort 12)|PF-05230907 IV bolus injection
89553207|NCT02687191|Experimental|PF-05230907 (Cohort 13)|PF-05230907 IV bolus injection
89553208|NCT02687191|Experimental|PF-05230907 (Cohort 14)|PF-05230907 IV bolus injection
89553209|NCT02687191|Experimental|PF-05230907 (Cohort 15)|PF-05230907 IV bolus injection
89553210|NCT02687035|Experimental|TAVR|Intermediate risk patients receiving transcatheter aortic valve replacement (TAVR)
89553211|NCT04515563|Placebo Comparator|Control Group|Subjects in the care control group will perform once-a-week stretching exercise intervention. Each session lasts for 75 minutes and covers the major muscle groups.
89553212|NCT04515563|Experimental|Low-frequency, moderate-intensity walking group|A personalized walking exercise program will be arranged and conducted individually. Exercise training will be prescribed as a 12-week program, with one 150-minute instructor-led session per week. In each session, there will be 5-min warm-up and cool-down, and 150 minutes of exercise time. If needed, there will be two 10-20 min breaks for the subject to get hydrated and rest. The intensity level will be set to 3.5 metabolic equivalents (METs), in which 1 MET refers to the metabolic rate during quiet sitting [23]. During the training session, the heart rate will be continuously monitored by Polar E68 HR Sensor to make sure the subject meet the exercise intensity. 10 bpm fluctuation of the heart rate is acceptable [24].
89553213|NCT04515563|Experimental|High-frequency, moderate-intensity walking group|Intervention of high-frequency, moderate-intensity walking exercise will be given to subjects in this group. A personalized walking exercise program will be arranged and conducted individually. Exercise training will be prescribed as a 12-week program, with three 50-minute instructor-led sessions per week. In each session, there will be 5-min warm-up and cool-down, and 50 minutes of exercise time. If needed, there will be one 10-20 min break for the subject to get hydrated and rest. The intensity level will be set to 3.5 metabolic equivalents (METs), in which 1 MET refers to the metabolic rate during quiet sitting [23]. During the training session, the heart rate will be continuously monitored by Polar E68 HR Sensor to make sure the subject meet the exercise intensity. 10 bpm fluctuation of the heart rate is acceptable [24].
89553214|NCT04515563|Experimental|Low-frequency, vigorous-intensity walking group|Intervention of low-frequency, vigorous-intensity walking exercise will be given to subjects in this group. A personalized walking exercise program will be arranged and conducted individually. Exercise training will be prescribed as a 12-week program, with one 75-minute instructor-led session per week. In each session, there will be 5-min warm-up and cool-down, and 75 minutes of exercise time. If needed, there will be two 10-20 min breaks for the subject to get hydrated and rest. The intensity level will be set to 7.0 metabolic equivalents (METs), in which 1 MET refers to the metabolic rate during quiet sitting [23]. During the training session, the heart rate will be continuously monitored by Polar E68 HR Sensor to make sure the subject meet the exercise intensity. 10 bpm fluctuation of the heart rate is acceptable [24].
89553215|NCT04515563|Experimental|High-frequency, vigorous-intensity walking group|Intervention of high-frequency, vigorous-intensity walking exercise will be given to subjects in this group. A personalized walking exercise program will be arranged and conducted individually. Exercise training will be prescribed as a 12-week program, with three 25-minute instructor-led sessions per week. In each session, there will be 5-min warm-up and cool-down, and 25 minutes of exercise time. If needed, there will be a 10-20 min break for the subject to get hydrated and rest. The intensity level will be set to 7.0 metabolic equivalents (METs), in which 1 MET refers to the metabolic rate during quiet sitting [23]. During the training session, the heart rate will be continuously monitored by Polar E68 HR Sensor to make sure the subject meet the exercise intensity. 10 bpm fluctuation of the heart rate is acceptable [24].
89553216|NCT03167749||Patients group|Male patients with liver cirrhosis of any etiology and severity. Laboratory tests will be done
89553217|NCT03167749||Control group|Healthy males without history or features of liver disease. Laboratory tests will be done
89553218|NCT03684473|Experimental|Yoga Intervention|Participants in the intervention condition will be assigned to an 8-week online delivered trauma-informed yoga protocol focused on home-based daily practice of yoga and mindfulness meditation.
89553219|NCT03560297|Experimental|SeRenade Program|Parent-Child Music Class Program (parent training, peer inclusion, musical play)
88962052|NCT02010125||Acute ACL injury|"Subjects with acute ACL injury will be recruited and enrolled within 28 days of injury Serum, urine, and synovial fluid will be collected at baseline, 6wks post-injury or post-surgery, 6 months, and 1 year Patients will have a quantitative MRI on both knees 7 days after initial visit, then at 6 months and 1 year.~Patients may or may not opt for ACL reconstruction Patients will have functional testing (One-legged hop tests and Star excursion balance test) at 6 months and 1 year Patients will fill out questionnaires (Knee Osteoarthritis Outcome Survey, Veteran Rand-12, Lysholm, International Knee Documentation Committee, Marx Questionnaire) at baseline, 6 weeks, 6 months, and 1 year"
88962053|NCT02010138|Active Comparator|Small Extent Group (SG)|Patients who were scheduled for surgery for idiopathic macular hole were randomly assigned to the SG. The small-extent peeling was performed in SG.
88962054|NCT02010138|Active Comparator|Large Extent Group (LG)|Patients who were scheduled for surgery for idiopathic macular hole were randomly assigned to the LG. The large-extent peeling was performed in LG.
88962055|NCT02010164|Experimental|Old-CoQ10|
89553220|NCT03560297|Experimental|Delayed/Waitlist Program|Participants do not participate in the program for a time period
89553221|NCT02691013|Placebo Comparator|Placebo|Patients will receive a Placebo tablet every evening.
89553222|NCT02691013|Active Comparator|Ramelteon|Patients will receive Ramelteon 8mg every evening.
89553223|NCT03423407||PET/MR|"Participants will be scanned on a PET-MRI scanner which is FDA-approved and will operate within FDA-approved guidelines.~Participants will be asked to lie still within the scanner for up to 90 minutes"
89553224|NCT03342989|Experimental|Speed of Processing Training|Training involves detection, localization, and discrimination of briefly displayed stimuli (17-500 milliseconds) using tasks with varying demands on visual attention. Cognitive processing speed is defined as response accuracy at a given display duration, regardless of motor speed. Training involves detection, localization, and discrimination of briefly displayed stimuli (17-500 milliseconds) using tasks with varying demands on visual attention. Speed of processing is defined as response accuracy at a given display duration, regardless of motor speed. Training consists of 10 lab-based sessions over 5 weeks, followed by home-based practice on a tablet computer for 24 months with supportive home visits.
89553225|NCT03342989|Active Comparator|Internet-Based Contact Control|Training involves mentally stimulating activity and consists of three levels: (1) using a computer (e.g., mouse training, pull-down menus, selecting options), (2) internet search engine training, and (3) search engine proficiency tasks. Training consists of 10 lab-based sessions over 5 weeks, followed by home-based practice on a tablet computer for 24 months with supportive home visits.
89553226|NCT03274505||Stroke patients|Patients seen by a rehabilitation physician at a routine 3 months' post-stroke examination
89553227|NCT03274505||TIA patients|"Patients seen by a stroke specialist at the SOS TIA examination"
89553228|NCT02690701|Experimental|Secukinumab|Eligible patients received secukinumab 300 mg once weekly at Baseline, Weeks 1, 2, 3 and 4 followed by monthly dosing starting at Week 8 through Week 48 inclusive
89553229|NCT02690701|Placebo Comparator|Placebo then Secukinumab|"Eligible patients received placebo doses once weekly at Baseline, Weeks 1, 2, 3 and 4 followed by a dose after four weeks at Week 8.~Beginning with the Week 12 dose, participants were switched to treatment with secukinumab 300 mg and were dosed once weekly at Weeks 12, 13, 14, 15 and 16 followed by monthly dosing through Week 48 inclusive."
89553230|NCT04122287|Experimental|levofloxacin-tetracycline-containing quadruple group|patients in levofloxacin-tetracycline-containing quadruple group will receive lansoprazole 30mg po bid, tetracycline 500mg po qid , bismuth subcitrate (Colloidal Bismuth Pectin) 200mg po bid, and levofloxacin 500mg po qd for 14d
89553231|NCT04122287|Active Comparator|tinidazole-tetracycline-containing quadruple group|patients in tinidazole-tetracycline-containing quadruple group will receive lansoprazole 30mg po bid, tetracycline 500mg po qid , bismuth subcitrate (Colloidal Bismuth Pectin) 200mg po bid, and tinidazole 500mg po tid for 14d.
89553232|NCT05746351|Active Comparator|epidural Bupivacaine with Dexmedetomidine in normal labor|Epidural analgesia will be initiated and maintained using a solution of 0.125% bupivacaine with Dexmedetomidine 0.5 μg/ml
89553233|NCT05746351|Active Comparator|epidural Bupivacaine with fentanyl in normal labor|Epidural analgesia will be initiated and maintained using a solution of 0.125% bupivacaine with fentanyl 2 μg/ml.
89553234|NCT05746351|Active Comparator|epidural Bupivacaine with Nalbuphine in normal labor|Epidural analgesia will be initiated and maintained using a solution of 0.125% bupivacaine with 0.2 mg/ml Nalbuphine.
89553235|NCT05403437||Group 1: Pregnant women with PGP and newly diagnosed with GDM|Pregnant women with PGP who were newly diagnosed with Gestational Diabetes Mellitus (GDM) according to routine control examinations and whose treatment for diabetes was not started
89553236|NCT05403437||Group 2: Pregnant women with PGP and diagnosed with GDM|Pregnant women with PGP who were diagnosed with Gestational Diabetes Mellitus (GDM) according to routine control examinations and whose treatment has been already started for diabetes
88962056|NCT02010164|No Intervention|Old|
88962057|NCT02010164|No Intervention|Young|Young less than 33 years old participants
88962058|NCT02010190||Cancer Survivors|Participants will be survivors of a childhood cancer.
88962059|NCT02010190||Control Group|Control participants will consist of age- and gender-matched individuals who are non-first-degree relatives of the survivor group.
88962060|NCT02010229||women at high risk of placenta accreta|Parturient women with placenta praevia and at least one previous caesarean delivery
88962061|NCT02010242|Experimental|GKT137831|GKT137831 100 mg capsules twice a day
88962062|NCT02010242|Placebo Comparator|Placebo|Placebo capsule twice a day
88962063|NCT02010268|Experimental|preterm neonates|Preterm neonates (birth before 33 weeks of gestation)
88962064|NCT02010281|Experimental|rTMS of the motor cortex (Magventure)|experimental : rTMS of the motor cortex : repetitive magnetic stimulation targeting the motor cortex assisted by neuronavigation
88962065|NCT02010281|Placebo Comparator|rTMS placebo (magventure)|sham stimulation of the motor or prefrontal cortex with the placebo face of the device
88962066|NCT02010281|Experimental|rTMS prefrontal cortex (magventure)|Experimental : repetitive transcranial stimulation targeting the prefrontal cortex as indicated by neuronavigation
88962067|NCT02010294||Children hospitalized for invasive GAS infection|Children hospitalized for invasive GAS infection
88962068|NCT02010294||Children with non-invasive infection|Children with non-invasive infection such as pharyngitis, tonsillitis, proctitis or skin infection diagnosed by a positive test for rapid diagnosis of GAS performed at the site of infection with a positive GAS culture
88962069|NCT02010307|Experimental|aggressive periodontitis|25 patients with aggressive periodontitis blood extraction
89553237|NCT05403437||Group 3: Pregnant women with PGP|Pregnant women with PGP who were not diagnosed with GDM according to routine control examinations
88962070|NCT02010307|Experimental|chronic periodontitis|25 patients with chronic periodontitis blood extraction
88962071|NCT02010307|Experimental|healthy|25 healthy periodontal patients blood extraction
88962072|NCT02010320|Experimental|Computer dosed|Patients for which the computer model will calculate the individual doses
88962073|NCT02010320|Active Comparator|Control|Patients which will get their tacrolimus doses determined by experience transplant physicians
88962074|NCT02010346|Experimental|Early headgear treatment|Headgear treatment is initiated at the age of 7-8 years and continued as long as Class I occlusion is achieved
89553238|NCT02694757|Experimental|Ostom-i device|Subjects will receive an Ostom-i device which will be worn over the ostomy bag underneath the subject's clothing. Output will be monitored daily by the Ostom-i application.
89553239|NCT05403281|Experimental|Sequence A|Period 1: Dapagliflozin and Sitagliptin / Period 2: DW6012
89553240|NCT05403281|Experimental|Sequence B|Period 1: DW6012/ Period 2: Dapagliflozin and Sitagliptin
89553241|NCT03158831|Other|Placebo-Controlled Graded Drug Challenge|This is a single arm study. All patients will receive a placebo prior to a graded drug challenge. Each patient serves as his/her own control.
89553242|NCT03165877|Experimental|Low-glycemic index|Low-glycemic index lunches and dinners (<55%)
89553243|NCT03165877|Active Comparator|Control|Medium/high glycemic index lunches and dinners (>60%)
89553244|NCT03115099|Placebo Comparator|Placebo (Part A)|Single oral dose of placebo (sugar pill) administered to healthy participants in up to 1 study period in Part A
89553245|NCT03115099|Experimental|LY3325656 (Part A)|Single ascending dose of LY3325656 administered orally to healthy participants in up to 3 study periods in Part A
88962075|NCT02010346|No Intervention|Later headgear treatment|Headgear treatment is initiated in the beginning of the growth spurt.
88962076|NCT02010372|Experimental|Reminder Recall Reports|Training in how to use reminder-recall reports in the Immunization registry will be given to administrators who will then be asked to regularly run these reports for a period of one year.
89553246|NCT03115099|Placebo Comparator|Placebo (Part B)|Single oral dose of placebo (sugar pill) administered to participants with T2DM in 1 study period in Part B
89553247|NCT03115099|Experimental|LY3325656 (Part B)|Single oral dose of LY3325656 administered to participants with T2DM in 1 study period in Part B
89553248|NCT03115099|Active Comparator|Liraglutide (Part B)|Single subcutaneous dose of liraglutide administered to participants with T2DM in 1 study period in Part B
89553249|NCT03115099|Experimental|LY3325656 + Sitagliptin (Part B)|Single oral dose of LY3325656 and sitagliptin administered to participants with T2DM in 1 study period in Part B
88962077|NCT02010372|Experimental|Audit-Feedback/Immunization Forecasting Reports|Training in how to use audit-feedback/immunization forecasting reports in the Immunization registry will be given to administrators who will then be asked to regularly run these reports for a period of one year.
88962078|NCT02010372|No Intervention|Control|No intervention will be administered to this group.
89553250|NCT03165097|Experimental|ACT-709478|"40 subjects will receive multiple doses of ACT-709478 at the planned dose levels of 30, 60, 100, and 200 mg.~Each dose level will be investigated in a new cohort of 10 healthy male and female subjects (4 male subjects on active drug and 1 on placebo, 4 female subjects on active drug and 1 on placebo) undergoing one treatment period with a once daily dosing scheme."
89553251|NCT03165097|Placebo Comparator|Placebo|Matched placebo administered accordingly
89553252|NCT03165097|Other|Midazolam|4 mg taken by mouth on Day 1 of the corresponding cohort
89553253|NCT03165097|Experimental|ACT-709478 combined with Midazolam|On Day 22 and Day 30, midazolam (4 mg) and ACT-709478 (60 mg or 100 mg) to be co-administered.
88962079|NCT02010398|Active Comparator|Cross-Training healthy subjects|A cohort of healthy subjects (N=15) will undergo a phase of intervention consisting of cross-training of the stronger limb employing an isokinetic contraction regimen at maximal intensity.
88962080|NCT02010398|Active Comparator|Standard-Training multiple sclerosis|A cohort of patients with multiple sclerosis (N=15), presenting with a marked asymmetry in limb strength, will undergo a standard-training of the more-impaired limb employing an isokinetic contraction regimen at maximal intensity.
89553254|NCT03165019||High altitude pulmonary hypertension|Highlanders with high altitude pulmonary hypertension living above 2500 m.
89553255|NCT03165019||High altitude control|Healthy highlanders living above 2500 m.
89553256|NCT03165019||Low altitude control|Healthy lowlanders living below 1000 m.
88962081|NCT02010398|Experimental|Cross-Training multiple sclerosis|A cohort of patients with multiple sclerosis (N=15), presenting with a marked asymmetry in limb strength, will undergo a cross-training of the less-impaired limb employing an isokinetic contraction regimen at maximal intensity.
88962082|NCT02010398|No Intervention|Healthy Control|A cohort of healthy subjects (N=15) will undergo baseline assessment and a second evaluation after one month of no-intervention
88962083|NCT02010411|Active Comparator|Prolastin|Prolastin 250 mg nebulized BID, 10 days
89208157|NCT00867906|Other|Cohort 3|Asthmatics using inhaled corticosteroid and LABA, subjects to receive either Cat-PAD or placebo comparator
89553257|NCT03165799|Experimental|Mindfulness Education|"Participants viewed an informational video titled, All it Takes is 10 Mindful Minutes by mindfulness expert, Andy Puddicombe. Following the video, a guided discussion was provided that focused on how the principles of mindfulness can be used to influence a physician's state of mental presence, allowing for moments of clarity, insight, and reflection, and potentially enhance provider and patient safety."
89553258|NCT03165799|No Intervention|No Intervention|Participants did not receive mindfulness education.
89553259|NCT03165643||NGT-normal birth weight|
89553260|NCT03165643||NGT-macrosomia|
89553261|NCT03165643||GDM-normal birth weight|
89553262|NCT03165643||GDM-macrosomia|
89553263|NCT04436003|Experimental|Muscle and Articulation chains GDS method treatment|"Participants in the intervention Group are examined and treated according to the principles of Muscle and Articulation Chains GDS Method. They receive GDS treatment individually, up to 8 sessions of 1 hour."
89553264|NCT04436003|No Intervention|Control (treatment as usual)|The Control Group receives standard treatment from their RGP/ doctor. Some are prescribed physiotherapy or chiropractor treatment, or they choose their own alternatives.
89553265|NCT04436159|Active Comparator|Nissen fundoplication|Addition of 360 fundoplication after crural closure
89553266|NCT04436159|Active Comparator|Toupet fundoplication|Addition of 180 posterior fundoplication after crural closure
89553267|NCT05403125|Experimental|Package|Topical application of 38% silver diamine fluoride plus 5000 PPM fluoride gel 1 mo before and 1 and 3 months after radiation treatment
89553268|NCT05403125|Active Comparator|Gel Alone|Placebo application of silver diamine fluoride plus 5000 PPM fluoride gel 1 mo before and 1 and 3 months after radiation treatment
89553269|NCT05701423||Natalizumab (NTZ)|Participants who receive NTZ intravenously (IV) or subcutaneously (SC) as standard interval dosing (SID), or as SC extended interval dosing (EID) will be followed prospectively for up to 30 weeks.
89553270|NCT02795351|Experimental|Active|Sildenafil 100 mg single dose
89553271|NCT02795351|Placebo Comparator|Placebo|Placebo capsule
89553272|NCT05403047|Other|pregnant woman - tenofovir|Participants will be started on tenofovir disoproxil fumarate (TDF) 245 mg one tablet per day from week 28 of pregnancy until 6 weeks postpartum.
89553273|NCT04626713|Experimental|Intervention|Participants will undergo a brief interactive psychoeducation session four times a week for two weeks. For each session, participants will wear a commercially available Electroencephalography (EEG) headset and play a downloaded online game for a total of 30 minutes. Participants can feel free to play the game for more than the instructed frequency during their 2-week intervention participation.
89553274|NCT04626713|No Intervention|Waitlist control|Participants in Waitlist Control will receive no intervention in the first four weeks of the study. After the Intervention group has completed treatment, participants in the Waitlist Control will then undergo the same intervention as the Intervention group.
89553275|NCT05399303|Experimental|bioceramic sealer obturation|
89553276|NCT05399303|Experimental|resin sealer|
89553277|NCT01979315||patients with LBP|
89553278|NCT01979315||healthy individulas|
89553279|NCT03927443|Experimental|Test|
89553280|NCT03927443|Active Comparator|Reference|
89553281|NCT02872493||RYGB|Roux-en-Y Gastric Bypass - these are patients that undergo a Roux-en-Y gastric bypass operation for their bariatric operation.
89553282|NCT02872493||VSG|Vertical Sleeve Gastrectomy - these are patients that undergo a vertical sleeve gastrectomy operation for their bariatric operation.
89553283|NCT05124353|Active Comparator|G1 : Treatment Group (TG)r|Patients in TG receive neuroprotective drug: standard dose of Cerebrolysin 30ml i.v. in the first 6 hours after first symptoms. After EVT the administration is continued for 10 days.
89553284|NCT05124353|No Intervention|G2 : Control Group (CG)|Patients in CG receive no additional i.v. treatment.
89553285|NCT02222831|Experimental|Day 0 - Study arm|"Day 0 denudation and time lapse culture on IVF-oocytes.:~After insemination the oocytes will subsequently be denuded and cultured in the EmbryoScope (day 0).~The embryo culture media will be collected at day 2-5."
89553286|NCT02222831|No Intervention|Day 1 - control arm|"After insemination oocytes in the control group will be incubated in a standard incubator overnight. On day 1 the oocytes in the will be denuded and further cultured in the EmbryoScope.~The embryo culture media will be collected at day 2-5."
89553287|NCT05124197||Cohort of ICU patients with COVID-19 related ARDS requiring at least one extended PP session|patients with COVID-19 related ARDS requiring prone position because of profound hypoxemia were applied the investigators' strategy to extend duration of prone position: after being turned prone, they spent at least two complete nights in prone position before being turned to supine position
89553288|NCT03805841|Experimental|Active|tarloxotinib bromide
89553289|NCT02815943|Other|Before DBP-DS surgery|
89553290|NCT02815943|Experimental|After DBP-DS surgery|It is a bariatric surgery. BPD consists in the exclusion of the duodenum from the alimentary tract with re-anastomosis of the blind loop 100 to 150 cm proximal to the ileo-coecal valve. This leads to bypass of the biliopancreatic secretions towards the distal small intestine, resulting in fat malabsorption. BPD also entails a distal gastrectomy to avoid the occurrence of peptic ulceration of the gastrointestinal anastomosis.
89208158|NCT00864006|Experimental|1|Divalproex Sodium 125 MG Delayed Release Tablets Sandoz
89553291|NCT02815943|Other|Before SG surgery|
89553292|NCT02815943|Experimental|After SG surgery|It is a bariatric surgery where the stomach is reduced to about 15% of its original size, by surgical removal of a large portion of the stomach along the greater curvature.
89553293|NCT04440995|Experimental|PECS block(P) group|PECS group (P) received general anesthesia and pectoral nerve block(PECS block) with 025% ropivacaine after surgical resection of breast by operator.
89553294|NCT04440995|No Intervention|Control(c) group|only received general anesthesia
89553295|NCT03563651||Ancillary-Correlative (biospecimen collection, biopsy)|Participants undergo collection of blood and urine at baseline, on day 1 of courses 1, 2, and 3, at restaging, and at disease progression. Participants may undergo collection of stool at baseline, on day 1 of course 2, and at disease progression. Participants also undergo biopsy within 4 weeks of disease progression.
89553296|NCT03560765|Experimental|Using MED assigned buddy|Participant has been randomly assigned a student volunteer buddy, and has chosen to purchase an MED following training
89553297|NCT03560765|Active Comparator|Using MED training only|Participant has been randomly assigned to not have a student volunteer buddy, and has chosen to purchase an MED following training
89553298|NCT03560765|Active Comparator|No MED, assigned buddy|Participant has been randomly assigned a student volunteer buddy, and has chosen not to purchase an MED following training
89553299|NCT03560765|No Intervention|No MED, no buddy|Participant has been randomly assigned to not have a student volunteer buddy, and has chosen not to purchase an MED following training
89208159|NCT00864006|Active Comparator|2|Depakote 125 MG DR Tablets Abbott Laboratories USA
89553300|NCT04207073|No Intervention|Control group|No intervention.
89553301|NCT04207073|Experimental|Exercise group|Participants in the exercise group will perform 2 sets of 5 repetitive Median nerve mobilization exercises (total of 20 sessions) per day for 10 days.
89553302|NCT04435847|Experimental|HST 001|HST 001 (also known as hair stimulating complex [HSC]) is a mixture of growth factors secreted by human dermal fibroblasts when cultured in proprietary bioreactors which are then harvested and concentrated to specific ranges.
89553303|NCT04435847|Placebo Comparator|Placebo - Phosphate Buffered Saline|Phosphate Buffered Saline
89553304|NCT05123651|Placebo Comparator|Control group|who met inclusion criteria, will receive an identical X253 Probiotic lozenge Supplement looking and tasting placebo.
89553305|NCT05123651|Experimental|Viable group|who met inclusion criteria, will receive an identical X253 Probiotic lozenge(containing active L.r X253).
89553306|NCT05123651|Experimental|Inactivated group|who met inclusion criteria, will receive an identical X253 Probiotic lozenge(containing inactive L.r X253).
89553307|NCT02811887|Active Comparator|Usual care|12 weeks of supervised physical exercise followed by usual care in the outpatient liver cirrhosis rehabilitation clinic
89553308|NCT02811887|Experimental|SMS-messages|12 weeks of supervised physical exercise followed by usual care in the outpatient liver cirrhosis rehabilitation clinic + regular text messages via SMS over a 12-week period
89553309|NCT03995303|Active Comparator|NCP and home-delivered meals|Preventing malnutrition with NCP by a registered dietician and home-delivered meals
89553310|NCT03995303|No Intervention|Current practice|Current practice after discharge from the University Hospital of Iceland.
89553311|NCT03957707|Experimental|stereotactic surgery with drugs treatment|
89553312|NCT03957707|Sham Comparator|drugs treatment alone|
89553313|NCT02739659|Experimental|carbon-ion radiotherapy|Five dose levels [59.2 GyE(Gray equivalent)/16Fx, 60.8 GyE/16Fx, 62.4 GyE/16Fx, 64.0 GyE/16Fx and 65.6 GyE/16Fx] are planned within the Phase I part. After the recommended dose (RD), i.e., MTD, is determined or if the treatments to 65.6 GyE/16Fx are safely delivered, the recommended dose (or 65.6 GyE/16Fx) will be the prescribed dose in the Phase II part of the study.
89553314|NCT05123261|Experimental|the mindfulness-based elder care (MBEC) therapy|The experimental group was offered eight 50-minute courses once a week.
89553315|NCT05123261|No Intervention|the routine activities|The control group maintained routine activities.
89553316|NCT05123105|Experimental|Experimental|Each person participated in three tests with an interval of approximately one week between them.
89553317|NCT05122949|Experimental|Adults with neurological disorders|
89553318|NCT02684617|Experimental|rrCLL Cohort|Participants with refractory chronic lymphocytic leukemia (rrCLL) received an infusion of pembrolizumab 200 mg followed by infusion of dinaciclib 7 mg/m^2 on Cycle 1 Day 1, and infusion of dinaciclib 10 mg/m^2 alone on Cycle 1 Day 8. Participants then received an infusion of pembrolizumab 200 mg followed by infusion of dinaciclib 14 mg/m^2 on Cycles 2-35 Day 1 and infusion of dinaciclib 14 mg/m^2 alone on Cycles 2-35 Day 8. Each cycle is 21 days.
89553319|NCT02684617|Experimental|rrMM Cohort|Participants with relapsed or refractory multiple myeloma (rrMM) received an infusion of pembrolizumab 200 mg followed by infusion of dinaciclib 7 mg/m^2 on Cycle 1 Day 1, and infusion of dinaciclib 10 mg/m^2 alone on Cycle 1 Day 8. Participants then received an infusion of pembrolizumab 200 mg followed by infusion of dinaciclib 14 mg/m^2 on Cycles 2-35 Day 1 and infusion of dinaciclib 14 mg/m^2 alone on Cycles 2-35 Day 8. Each cycle is 21 days.
89553320|NCT02684617|Experimental|rrDLBCL Cohort|Participants with relapsed or refractory diffuse large B-cell lymphoma (rrDLBCL) received an infusion of pembrolizumab 200 mg followed by infusion of dinaciclib 7 mg/m^2 on Cycle 1 Day 1, and infusion of dinaciclib 10 mg/m^2 alone on Cycle 1 Day 8. Participants then received an infusion of pembrolizumab 200 mg followed by infusion of dinaciclib 14 mg/m^2 on Cycles 2-35 Day 1 and infusion of dinaciclib 14 mg/m^2 alone on Cycles 2-35 Day 8. Each cycle is 21 days.
89553321|NCT01999972|Experimental|Axitinib in combination with crizotinib, escalation phase|Dose Escalation Advanced solid tumor that is resistant to standard therapy or for which no standard therapy is available
88962084|NCT02010437|Active Comparator|Foam Sclerotherapy Group|"The axial vein will be cannulated under local anaesthesia and ultrasound guidance with the patient reclined in a supine position for GSV or ASV treatment, prone position if SSV or GV treatment.~The foam is then prepared by the Tessari technique by the surgeon. Two 2-ml syringes will be connected via a three way stop-cock tap and a 5 micron filter in series (Braun Medical, Sheffield, UK). The syringes will contain 1 part Sodium Tetradecyl Sulphate 3% and 3 parts air. In practice 0.5ml of 3% STS will be drawn up against 2 ml of air. The foam will be produced by at least 20 passages from syringe to syringe through the filter.~Up to 2ml of foam will be injected into each cannula under ultrasound control to observe venous spasm, followed by gentle massaging of the skin to propagate the foam through the segment of vein treated."
89025650|NCT01242501|Active Comparator|20-min single session education|Single brief HIV/STI education only session for men and women receiving sexually transmitted infection clinic services in South Africa. Includes only brief educational information on sexual risks for HIV infection in a single face-to-face counseling session.
89025651|NCT01242579|Active Comparator|Maraviroc Vaginal Gel|Drug: Maraviroc dosage form: vaginal gel dosage: 2.5g frequency: once daily duration: 11 days
89553322|NCT01999972|Experimental|Expansion Phase Cohort 1|Dose Expansion, Cohort 1: axitinib in combination with crizotinib Advanced renal cell cancer [RCC] with no prior systemic therapy
89553323|NCT01999972|Experimental|Expansion Phase Cohort 2|Dose Expansion, Cohort 2: axitinib in combination with crizotinib Advanced renal cell cancer with at least one but no more than two prior systemic treatment regimens directed at advanced RCC
89553324|NCT04055389|Experimental|AT-III treatment|
89553325|NCT04055389|Placebo Comparator|Placebo|
88812148|NCT05945992|Experimental|Condition 10: group dynamics, self, mindfulness, conflict resolution|(1) social behavior in groups, (2) self-acceptance, (3) mindfulness, (4) constructive conflict resolution
88812149|NCT05945992|Experimental|Condition 11: group dynamics, self, stress, resources|(1) social behavior in groups, (2) self-acceptance, (3) stress management, (4) resource activation
88812150|NCT05945992|Experimental|Condition 12: group dynamics, self, stress, conflict resolution|(1) social behavior in groups, (2) self-acceptance, (3) stress management, (4) constructive conflict resolution
88812151|NCT05945992|Experimental|Condition 13: group dynamics, communication, mindfulness, resources|(1) social behavior in groups, (2) communication skills, (3) mindfulness, (4) resource activation
89553326|NCT03106207|Other|Upper gastric endoscopy (UGE)|Patients will be submitted to a UGE before the gastric bypass surgery without a ring and at two, six and 12 months after the surgical procedure .
89553327|NCT05697055|Experimental|Azvudine|
89553328|NCT05697055|Active Comparator|Nirmatrelvir-Ritonavir|
89553329|NCT03162445||Typically developing controls|Boys between ages 7 and 14 years old at study onset without medications or diseases impairing bone development
89553330|NCT03162445||Autism spectrum disorder|Boys between ages 7 and 14 years old at study onset without medications or diseases impairing bone development
89553331|NCT03162367|Experimental|Autologous epidermal cell suspension group|
89553332|NCT03162367|Active Comparator|Silver sulfadiazine ointment group|
89553333|NCT01999894|Experimental|Memantine|Once daily oral administration of memantine for 48 weeks: 6-week double-blind dose-titration period followed by a 42-week maintenance period.
89553334|NCT03165565|Experimental|MI and ACT|Participants will receive behavioral therapy including Motivational Interviewing (MI) and Acceptance and Commitment Therapy (ACT).
89553335|NCT03165565|Active Comparator|Conventional Care|Conventional care from the hospital for NICU mothers who test positive for drug use, which includes visits and resources from hospital social workers.
89553336|NCT02679235|Experimental|Triheptanoin|Participant will undergo POST Triheptanoin suppementation 1g/kg body weight for 28 days (dose gradually increased each week, starting at, 0.25, 0.5, 0.75 and then 1 g) separated in 4 doses (with eah meal and before night) after a control PRE supplementation imaging protocol.
89553337|NCT01976806|Experimental|Aspirin & Docosahexaenoic acid|Aspirin 81 mg 1 tablet by mouth daily and Docosahexanoic acid (DHA) 500 mg 4 capsules by mouth daily (total daily dose of 2 grams DHA) for 3 months
89553338|NCT01976806|Active Comparator|Aspirin & Placebo|Aspirin 81 mg by mouth daily and placebo (50% corn oil/50% soybean oil) 4 capsules by mouth daily for 3 months
89553339|NCT02679079|Placebo Comparator|Placebo|Administered once daily for 6 weeks
89553340|NCT02679079|Experimental|Dose Group 1|Administered once daily for 6 weeks
89553341|NCT02679079|Experimental|Dose Group 2|Administered once daily for 6 weeks
89553342|NCT02678923|Experimental|MDCO-216|20 mg/kg of MDCO-216 administered intravenously (IV) as a 360 milliliter (mL) infusion over 2 hours on Days 1, 8, 15, 22, and 29
89553343|NCT02678923|Placebo Comparator|Placebo|360 mL of placebo (0.9% sodium chloride [NaCl] solution) infusion, IV, over 2 hours on Days 1, 8, 15, 22, and 29
88962085|NCT02010437|Active Comparator|Catheter Directed Foam Sclerotherapy (CDS) Group|The straight segment of axial vein will be cannulated under local anaesthesia at the lowest point of demonstrable reflux and a guide-wire inserted to facilitate the placement of the catheter system.The appropriate Unifuse® catheter will be selected and deployed through the introducer sheath and advanced to within 2cm of the junction or perforator at the upper limit of incompetence or the top of the incompetent segment in the case of segmental reflux. A 1:3 foam of 3% STD will be produced as described for FS. At this point the patient will be repositioned into a Trendelenburg position (head up)
88962086|NCT02010437|Active Comparator|ClariVein Group (CV) Treatment|The straight segment of axial vein will be cannulated under local anaesthesia at the lowest point of demonstrable reflux and the ClariVein device 4-F micro sheath will be introduced up the vein via a guide wire as per manufacturer's instructions. Concentration of STD will depend on axial vein to be treated; if treating GSV or ASV 1.5% STD liquid will be used, if SSV or GV 1.0% STD liquid will be used. Volume of STD to be prepared for the CV treatment will be calculated using a dosage chart provided by the manufacturer
89553344|NCT01976728|Experimental|LutrePulse 10 µg/pulse|Gonadorelin acetate 10 µg/pulse
89553345|NCT01976728|Experimental|LutrePulse 15 µg/pulse|Gonadorelin acetate 15 µg/pulse
89553346|NCT01976728|Experimental|LutrePulse 20 µg/pulse|Gonadorelin acetate 20 µg/pulse
89553347|NCT01976728|Placebo Comparator|Placebo|Placebo
89553348|NCT02689219|Experimental|CD30 positive|Brentuximab vedotin, 1.8 mg/kg (1.2 mg/kg in patients with grade 2 peripheral neuropathy at enrollment) will be administered by IV infusion given over approximately 30 minutes on Day 1 of each 21-day cycle.
89553349|NCT02689219|Experimental|CD30 negative/unknown|Brentuximab vedotin, 1.8 mg/kg (1.2 mg/kg in patients with grade 2 peripheral neuropathy at enrollment) will be administered by IV infusion given over approximately 30 minutes on Day 1 of each 21-day cycle.
89553350|NCT03162133|Experimental|Exercise group|After completing the baseline tests, participants in exercise group were instructed to attend 90-minute, supervised Baduanjin exercise 2 times per week. The Baduanjin intervention used the standardized Baduanjin training program, designed by the General Administration of Sports of China. Two senior Baduanjin teachers from Guangzhou Sports University conducted the training.
89553351|NCT03162133|Experimental|Waiting list Control group|"Participants assigned to the wait-list control were told to continue performing their usual care and daily activities, and to refrain from doing any Baduanjin exercise.~After their post-assessment they were able to attend the Baduanjin classes."
89553352|NCT05673733|Experimental|Group A|Exergaming training combined with Scapular stabilization exercises will be performed for 6 weeks for 3 times per week.
89553353|NCT05673733|Active Comparator|Group B|Exergaming training will be performed for 6 weeks for 3 times per week.
89553354|NCT05673421|Experimental|Exergaming Training Group|VR game-assisted intervention will perform for 30-45 min, 5 sessions per week for a duration of 8 weeks.
88962087|NCT02010450|Experimental|Wearable Blanket|subjects randomized to this group will receive a wearable blanket (sleep sack) that contains a safe sleep message.
89025652|NCT01242579|Active Comparator|Dapivirine Vaginal Gel|Drug: Dapivirine dosage form: vaginal gel dosage: 2.5g dapivirine frequency: once daily duration: 11 days
89553355|NCT05673421|Active Comparator|Visual Feedback Training|During the visual feedback practices, patients will be seated or in a standing phase close to a table on which a mirror would be placed vertically. The practice would be consisted of nonparetic-side shoulder, elbow, wrist and finger flexion, extension, abduction, adduction movements, task oriented activities like, unscrewing lid of jar ,card stacking, moving coins or marbles from one box to another, Folding towels and stacking them, picking glass, while patient will look into the mirror, -watching the image of their noninvolved hand, thus seeing the reflection of the hand movement projected over the involved hand. After watching the practices on the uninvolved side, patient will be asked to try to do the same movements with the paretic limb while they will be moving the nonparetic limb. Each activity will be performed for 4 min, with a 1 min preparation time between tasks.
89553356|NCT03165253|Active Comparator|Synbiotic Group|The patients will be treated with the standard triple therapy that consists of amoxicillin oral tablet 50 mg/kg/d and clarithromycin oral tablet 15 mg/kg/d twice daily for 14 days, and omeprazole 1 mg/kg/d once daily for a month, and the synbiotic Bifidobacterium animalis oral product (5000000000 colony forming units/dose) plus inulin (900 mg) given a single dose for 14 days, concurrently.
89553357|NCT03165253|Other|Standard Therapy Group|The patients in this group will be treated with standard triple therapy only. The standard triple therapy consists of amoxicillin oral tablet 50 mg/kg/d and clarithromycin oral tablet 15 mg/kg/d twice daily for 14 days, and omeprazole 1 mg/kg/d once daily for a month.
89553358|NCT05543317|Experimental|68Ga-FAPI-RGD|Each subject receives a single intravenous injection of 18F-FDG and 68Ga-FAPI-RGD, and undergo PET/CT imaging within the specified time.
89553359|NCT03114241|Active Comparator|Intervention|An increase in step count of 15% compared to baseline will be set as the minimal goal for each patient during 3 months.
89553360|NCT03114241|No Intervention|Control|Usual care.
89553361|NCT03161977||Mannitol|Mannitol was intravenous infused within 15-20 mins when drilling skull
89553362|NCT02683525|Experimental|Sitagliptin|Sitagliptin 600 mg q 12 hours PO starting on Day -1 before transplant to be administered between 8:00 am and 10:00 am then given every 12 hours (total 32 doses) through day +14.
89553363|NCT01976338|Experimental|Ranibizumab 0.5 mg|PRN Intravitreal injection
89553364|NCT01976338|Sham Comparator|Sham injection|As of Month 6 ranibizumab 0.5 mg PRN intravitreal injection
89553365|NCT02674633|Active Comparator|AKL-T01 (EVO Multi)|AKL-T01, or EVO Multi, is a digital intervention that requires the subject to navigate a character through a game-like space, while collecting objects, in a fixed period of time.
89553366|NCT02674633|Active Comparator|AKL-T09 (EVO Words)|AKL-T09, or EVO Words, is a digital intervention that requires the subject to spell as many words as possible, by connecting letters in a game-like grid, in a fixed period of time.
89553367|NCT02651987|Experimental|Lanreotide Autogel®|One subcutaneous (SC) injection of lanreotide Autogel® 120mg every 14 days until disease progression or death or unacceptable toxicity or tolerability.
89553368|NCT05676307|Experimental|Bilateral Vestibular Hypofunction|Vestibular Rehabilitation in Bilateral Vestibular Hypofunction
89553369|NCT05115773|Experimental|Intraligamentary Anaesthesia|Before the restorative treatment of mandibular first molar, SOPIRA® 30 gauge extra-short cartridge needle attached to the tip of the SOPIRA® Citoject (SOPIRA® Heraeus Kulzer, Hanau, Almanya) pressure injector will be inserted into the periodontal sulcus 1-2 mm until resistance. The needle will be at an angle of 30 degrees to the long axis of the tooth. As recommended by the manufacturer, a total of 0.36 ml (mesiobuccal and distobuccal) 4% articaine solution containing 1:100,000 epinephrine (Ultracaine DS forte cartridge, Sanofi-Aventis GmbH, Almanya) will be injected slowly over 42 seconds by pressing the dosing lever 3 times for each root. If the anaesthesia will be failed, we would use the 4-point IL injection by injecting the mesiolingual sulcus and distolingual sulcus with the same technique.
89553370|NCT05115773|Active Comparator|Mandibular Anaesthesia|Before the restorative treatment of mandibular first molar, inferior alveolar nerve block will be provided using the direct standard method. The 27 gauge needle of a 2ml disposable plastic syringe (Ayset, Adana, Turkey) enters from the intersection of the internal oblique edge and the midline of the pterygomandibular raphe, and 1 ml of 4% articaine solution containing1:100,000 epinephrine (Ultracaine DS Forte ampul, Sanofi-Aventis GmbH, Almanya) will be injected slowly in 60 seconds. 15 minutes after the injection the anaesthesia of the lip/tongue will be checked by probing the labial mucosa of the ipsilateral canine tooth.
89553371|NCT05108285||MNV group|Eyes affected by MNV. The dark halo of MNV was evaluated by OCTA and ICGA
89553372|NCT02677987|Experimental|Intervention light|30 minutes of intervention systematic light exposure daily for 4 weeks.
89553373|NCT02677987|Active Comparator|Comparison light|30 minutes of comparison systematic light exposure daily for 4 weeks.
89553374|NCT02463773|Experimental|Ultrasound|Adults older than 18 years old who develop ARDS, as defined by the Berlin criteria, within 72 hours of ICU admission.
89553375|NCT05676151|Experimental|Music Therapy in Pain Rehabilitation|Subjects undergoing care at the Mayo Clinic Florida Pain Rehabilitation Center (PRC) to address pain will receive a 20-minute music therapy intervention
89553376|NCT04701853|Experimental|Specific abdominal muscle training|Specific abdominal muscle training which is introduced preoperatively and performed the first year after surgery
89553377|NCT04701853|Active Comparator|Usual care treatment|No specific abdominal muscle training
89553378|NCT03049397|Experimental|Supportive Care (Enhancing Connections program)|Patients and co-parents participate in the Enhancing Connections program consisting of 5 sessions over 1 hour each in the clinic or over the telephone. Session topics include managing cancer-related emotions when talking to children, developing deep listening skills, initiating difficult cancer-related conversations with children, interpreting a child's behavior, recognizing newly acquired gains from the program, and identifying available resources that can be used after program completion.
89553379|NCT04657939|Active Comparator|Liraglutide-Pioglitazone|Participants randomised to receive liraglutide treatment for 16 weeks, followed by an 8 week washout then commencing 16 weeks of treatment with pioglitazone.
89553380|NCT04657939|Active Comparator|Pioglitazone-Liraglutide|Participants randomised to receive pioglitazone treatment for 16 weeks, followed by an 8 week washout then commencing 16 weeks of treatment with liraglutide.
89553381|NCT01999114|Experimental|BTDS|Buprenorphine transdermal patches 10, 40 (2 x 20), and 80 (4 x 20) mcg/hr
89553382|NCT01999114|Experimental|BTDS with naltrexone|Buprenorphine transdermal patches 10, 40 (2 x 20), and 80 (4 x 20) mcg/hr and naltrexone 50 mg tablets
89553383|NCT01999114|Active Comparator|Naltrexone|Naltrexone 50 mg tablets
89553384|NCT01999114|Placebo Comparator|Placebo|Matching placebo for transdermal patches and/or naltrexone tablets and/or moxifloxacin tablets
89553385|NCT01999114|Active Comparator|Moxifloxacin|Moxifloxacin 400-mg tablets
89553386|NCT02968355||Subjects/Specimens|Subjects/Specimens that meet the eligibility criteria
89553387|NCT02783105|Experimental|Musical intervention|"Music is provided through headphones: Two 30-min musical sessions per day (one in the morning and one in the evening) beginning at the onset of desedation (Day 0) until day 21.~Both have inverted U shape."
89553388|NCT02783105|Sham Comparator|Control|Patients wear headphones twice a day during 30 minutes, starting at the onset of desedation (Day 0) until day 21, but no music is provided (blank playlist): Sham
89553389|NCT03161665|Experimental|BMT Roadmap|The BMT Roadmap information system will be tested in 20 caregivers of patients undergoing autologous or allogeneic BMT and in 20 patients undergoing autologous or allogeneic BMT.
89553390|NCT02666339|Experimental|Hortitherapy group|Hortitherapy + Usual care
89553391|NCT02666339|Active Comparator|Control group|Usual care
89553392|NCT05062421||Cases 1|Patients treated with JAK-type kinase inhibitors.
89553393|NCT05062421||Cases 2|Patients treated with monoclonal antibodies against TNF.
89553394|NCT05062421||Cases 3|Patients treated with soluble receptor against TNF.
89553395|NCT05062421||Cases 4|Patients treated with FAME group biosimilars.
89553396|NCT05062421||Cases 5|Patients treated with rituximab.
89553397|NCT05062421||Cases 6|Patients treated with abatacept.
89553398|NCT05062421||Cases 7|Patients treated with drugs that block the IL6.
89553399|NCT02382497|Experimental|AN Active tDCS|"Treatment as usual plus experimental treatment"
89553400|NCT02382497|Sham Comparator|AN Sham tDCS|"Treatment as usual plus placebo treatment"
89553401|NCT02382497|Experimental|BED Active tDCS|"Treatment as usual plus experimental treatment"
89553402|NCT02382497|Sham Comparator|BED Sham tDCS|"Treatment as usual plus placebo treatment"
89553403|NCT05061875||Cases|Patients treated with ceftriaxone doses equal to or higher 4 grams / day.
89553404|NCT04503161|Experimental|Hydrogel recipient|
89553405|NCT02214407|Experimental|ARM A: DECITABINE (DACOGEN)|"Decitabine (DAC) will be administered at 20 mg/m2 intravenously daily for 5 days every 28 days.~Allopurinol, 300mg/d, will be started at the time of inclusion; hydration during treatment will be administered to all patients. In (the rare) case of necessity, prophylactic anti-emetics could be given.~Hydroxyurea may be added during the first 3 cycles if WBC counts > 30 G/L, and mandatory if WBC > 50 G/L. The daily dose will be adapted to maintain WBC below 15 to 20 G/L."
89553406|NCT02214407|Experimental|ARM B: HYDROXYUREA|"Hydroxyurea (HY) 1g/d once daily, with dose adjustments (up to 4g/d) to maintain a WBC count between 5 and 10 G/L. Allopurinol, 300mg/d started at the time of inclusion will be administered to all patients.~Dose escalation will be performed by steps of 0.5 g/d, up to 4 g/d, if the WBC has been reduced by less than 20% and remains > 15 G/L. HY will then be adapted to maintain a WBC count between 5 and 10 G/L. HY will be lowered if platelets decrease by > 30 X 109/L (if initially below 100 X 109L). HY will be discontinued in cases of grade 4 thrombocytopenia or neutropenia, and reintroduced at a lower dose after recovery to grade ≤ 3. Persistent grade 4 thrombocytopenia or neutropenia after a 4 week discontinuation will mandate bone marrow evaluation."
88812152|NCT05945992|Experimental|Condition 14: group dynamics, communication, mindfulness, conflict resolution|(1) social behavior in groups, (2) communication skills, (3) mindfulness, (4) constructive conflict resolution
88812153|NCT05945992|Experimental|Condition 15: group dynamics, communication, stress, resources|(1) social behavior in groups, (2) communication skills, (3) stress management, (4) resource activation
88812154|NCT05945992|Active Comparator|Condition 16: group dynamics, communication, stress, conflict resolution|(1) social behavior in groups, (2) communication skills, (3) stress management, (4) constructive conflict resolution
88812155|NCT05945979|Experimental|A power supplement with biotin|40 participants using the product for 90 days. Aims to evaluate the clinical, subjective and instrumental usage
88812156|NCT05945914||Study group|Patients with unilateral breast cancer received robotic-assisted mastectomy and robotic assisted free DIEP flap harvest for breast reconstruction.
88812157|NCT05945862|Experimental|Nutrition-Physical activity Program|Participants within the nutrition education and physical activity program
88812158|NCT05945771|Active Comparator|Randomized double blind grape seed extract design|Grape seed extract
88812159|NCT05945771|Placebo Comparator|Control|Placebo (starch)
89553407|NCT02682823|Experimental|Caregivers|CGs will perform injection of SC tocilizumab to a subset of participants with RA using the AI-1000 G2 device. Visit 1 (Day 0) will be conducted for administration training, while Visits 2 and 3 (Days 14 and 28) will be conducted for use/performance evaluation.
89553408|NCT02682823|Experimental|Healthcare Professionals|HCPs will perform injection of SC tocilizumab to a subset of participants with RA using the AI-1000 G2 device. Because enrolled HCPs are to be professionally qualified to deliver SC injections, no administration training will be provided. Visits 2 and 3 (Days 14 and 28) will be conducted for use/performance evaluation.
89553409|NCT02682823|Experimental|RA Group 1 (Self-Administration)|Participants with RA will perform self-injection of SC tocilizumab with the AI-1000 G2 device. Visit 1 (Day 0) will be conducted for administration training, while Visits 2 and 3 (Days 14 and 28) will be conducted for use/performance evaluation.
89553410|NCT02682823|Other|RA Group 2 (Administration by CG)|CGs will perform injection of SC tocilizumab to participants with RA using the AI-1000 G2 device. Visit 1 (Day 0) will be conducted for administration training, while Visits 2 and 3 (Days 14 and 28) will be conducted for use/performance evaluation.
89553411|NCT02682823|Other|RA Group 3 (Administration by HCP)|HCPs will perform injection of SC tocilizumab to participants with RA using the AI-1000 G2 device. Because enrolled HCPs are to be professionally qualified to deliver SC injections, no administration training will be provided. Visit 1 (Day 0) will be performed by the study nurse. Visits 2 and 3 (Days 14 and 28) will be conducted by the HCP for use/performance evaluation.
88962088|NCT02010450|Active Comparator|Control Group|subjects randomized to this group will receive an incentive item (such as a University of Kansas Pediatrics water Bottle) that does not contain the safe sleep message.
88962089|NCT02010463|Other|Exercise Intervention|9-month exercise program involving four exercise education sessions
88962090|NCT02010476||Normal insulin sensitivity|cognitively normal men without insulin resistance
88962091|NCT02010476||Insulin resistance|cognitively normal men with insulin resistance
88962092|NCT02010489|No Intervention|Control|Following randomization, the control group will receive usual preoperative care consisting of two to four multidisciplinary visits over six months. During this time, patients will be provided with exercise counseling through the team kinesiologist. They will complete a behavior modification program called Craving ChangeTM and must achieve usual goals of lifestyle and dietary modification, along with modest weight loss of approximately 5%, in order to be scheduled for surgery. Patients will also complete a liquid diet consisting of 900 calories per day for two weeks prior to their procedure in order to reduce intra-abdominal obesity and facilitate the procedure.
88962093|NCT02010489|Other|12 Week Exercise Program|The intervention group will undergo standard pre-operative care and will also be enrolled in a 12-week exercise program at the Reh-Fit Centre in Winnipeg. The Reh-Fit Centre is a non-profit organization with the mission to enhance the health and wellbeing of its members and the community by providing innovative health and fitness services. The intervention will be offered at no cost to the patient. It will involve regular supervised exercise sessions at the Reh-fit centre three times per week. Most patients will complete the intervention prior to commencing the liquid diet but will otherwise discontinue the program while on the diet two weeks prior to surgery.
88962094|NCT02010502|Active Comparator|Concentrated Beet Root Juice|500ml per day for 6 days
88962095|NCT02010502|Active Comparator|Beet root powder|500ml per day for 6 days
88962096|NCT02010502|Placebo Comparator|Placebo juice|Negligible nitrate
89553412|NCT01634711|Experimental|The L-C Ligament|Soft Tissue Regeneration's L-C Ligament is an interventional device intended for ACL reconstruction surgery within 13 weeks of acute rupture of the ACL and no previous treatment. The L-C Ligament temporarily replaces the human anterior cruciate ligament (ACL) and provides a bioresorbable scaffold within and around which the native ACL will regenerate over time.
89553413|NCT01478555|Experimental|Dose 1 of Bromfenac in DuraSite|
88962097|NCT02010515||Sinus rhythm, first ICD implantation|
88962098|NCT02010528||Type 1 diabetes|Parents or caregivers of children and adolescents with type 1 diabetes
89553414|NCT01478555|Experimental|Dose 2 of Bromfenac in DuraSite|
89553415|NCT01478555|Experimental|Dose 3 of Bromfenac in DuraSite|
89553416|NCT01478555|Active Comparator|DuraSite|
89553417|NCT01478555|Active Comparator|Vehicle|
89553418|NCT02261285|Experimental|ONO-4538 1mg/kg|ONO-4538 water-soluble injection, 100 mg/vial, 1mg/kg, single dose
89553419|NCT02261285|Experimental|ONO-4538 3mg/kg|ONO-4538 water-soluble injection, 100 mg/vial, 3mg/kg, single dose
89553420|NCT02261285|Experimental|ONO-4538 10mg/kg|ONO-4538 water-soluble injection, 100 mg/vial, 10mg/kg, single dose
89553421|NCT01422083|No Intervention|Control group|This group of athletes do not perform a 6-week stretching program.
89553422|NCT01422083|Experimental|Home stretching program|These athletes take on a home stretching program (sleeper's stretch).
89553423|NCT01288625|Experimental|Cytofos group A|Amifostine 500 mg sc, qod, 3 times per week Radiation treatment 30 min after amifostine treatment, 1.8-2.0 Gy/day × 30-35 times
89553424|NCT01288625|Experimental|Cytofos group B|Amifostine 500mg rinsing wash, qod, 3 times per week Radiation treatment 5 min after amifostine treatment, 1.8-2.0 Gy/day × 30-35 times
89553425|NCT01288625|Active Comparator|Control group|Radiation treatment 1.8-2.0 Gy/day × 30-35 times
89553426|NCT05041829|Experimental|lowsodium|Participants in this arm will be guided to have low dietary sodium intake of <2.3 g/day (<100 mmol/day) for 4 weeks.
89553427|NCT05041829|Active Comparator|highsodium|Participants in this arm will be guided to have low dietary sodium intake of ≥4 - <6 g/day (≥174 - <261 mmo/day) for 4 weeks.
89553428|NCT05129813||Buprenorphine MOUD in FQHC|Participants receiving buprenorphine treatment and Recovery Guide counseling in a Federally Qualified Health Center. Recovery Guide counseling is provided weekly.
89553429|NCT05129813||Telemedicine Provision of Buprenorphine MOUD in a community site|Participants receiving buprenorphine treatment provided by telemedicine from a hub clinic and Recovery Guide counseling in a church or faith-based community organization. Recovery Guide counseling is provided weekly.
89553430|NCT05129579|Experimental|MBRSEG|The group in which the mindfulness-based stress reduction intervention will be implemented.
89553431|NCT05129579|Other|control group|The group to which mindfulness-based stress reduction intervention will not be applied
89553432|NCT05129267|Active Comparator|Group B|Scaling and Root Debridement + iPRF
89553433|NCT05129267|Active Comparator|Group C|Scaling and Root Debridement + iPRF +Vitamin C
89553434|NCT05129267|No Intervention|Group A|Scaling and Root Debridement
89553435|NCT01374451|Experimental|Paseriotide LAR + Everolimus|everolimus 10 mg once daily po in combination with pasireotide LAR 60 mg every 28 days (q28d) im
88962099|NCT02010528||Controls|Parents or caregivers of children and adolescents without diabetes
89553436|NCT01374451|Experimental|Everolimus|everolimus 10 mg once daily po alone
89553437|NCT02674477|Experimental|Therapeutic Education System (TES)|Participants will have the opportunity to use the TES program while hospitalized, at specific, monitored times, and can also use it when discharged by using participant's specific login information. Participants can use it as much or as little as participants like. Participants will continue with treatment as usual during and after hospitalization, as well.
89553438|NCT02674477|Other|Treatment as Usual (TAU)|Standard treatment comprises a psychiatrist-led interdisciplinary team as well as face-to-face group counseling for substance use and skills for improving general mental health. There will be no change to the routine care (treatment at usual [TAU]) provided to patients on the service.
89553439|NCT03161587||Subjects with COPD|Subjects with diagnosis of COPD at least one year, visiting outpatient clinics in tertiary hospitals in China and in stable state at enrolment.
89553440|NCT03164941||Nasal SLT|This cohort will have 180 degree SLT completed on the nasal quadrants of the trabecular meshwork.
89553441|NCT03164941||Temporal SLT|This cohort will have 180 degree SLT completed on the temporal quadrants of the trabecular meshwork.
88962100|NCT02010541||insulin pump group|20 children below the age of 7 years who use an insulin pump for at least 6 months, more than 6 months of duration of type 1 diabetes, complete remission, no associated disease (normal blood pressure for age, only therapy insulin).
88962101|NCT02010541||RT (real time) -CGMS group|20 children below the age of 7 years who use an insulin pump and RT-CGMS on regular basis for at least 6 months, more than 6 months of duration of type 1 diabetes, complete remission, no associated disease (normal blood pressure for age, only therapy insulin). pump for at least 6 months, and children below the age of 7 years who use RT-CGMS on regular
88962102|NCT02010554|Active Comparator|Brief Education|Patients receive a brief educational packet along with treatment as usual
88962103|NCT02010554|Experimental|MI-CBT Treatment|Patients receive five 20 minute phone sessions of motivational interviewing/cognitive behavioral therapy weekly along with a brief educational packet.
88962104|NCT02010580||Osphena|Subjects will be randomized in a ratio of 1:1 to receive either 60 mg of ospemifene (Osphena, Shionogi, Florham, NJ) or placebo tablet.
88962105|NCT02010619|Experimental|Cognitive behavior therapy|
88962106|NCT02010619|Active Comparator|Supportive therapy|
88962107|NCT02010671||Women with a prior cesarean section|Survey of women who had a cesarean section with their last pregnancy and no other prior cesarean section deliveries
88962108|NCT02010710|Experimental|Decison support|"Decision-support - CTGs with the decision support software running that will alert clinicians to the presence of abnormalities in the CTG in real time."
89553442|NCT01352845|Experimental|rLP2086|
89553443|NCT01352845|Placebo Comparator|Control|Steril normal saline solution
89553444|NCT02674399|Experimental|JointStem|autologous adipose tissue derived mesenchymal stem cells (AdMSC)
89553445|NCT02674399|Active Comparator|Synvisc-One|hyaluronic acid
89553446|NCT05675839|Experimental|Experimental|"Before the intervention, students filled the Nursing Professional Pride Scale. Nursing students watched a documentary and a movie about nursing profession. After the intervention, students filled the Nursing Professional Pride Scale."
89553447|NCT05675839|No Intervention|Control|"First of all, Control group filled the Nursing Professional Pride Scale. The control group have no intervention. They filled the scale again, after 2 week."
89553448|NCT03161509|Experimental|paracetamol|10 participants will undergo measurement of paracetamol levels before and after sleeve gastrectomy
89553449|NCT03161509|Experimental|antiepileptic drug|Up to 10 participants in each drug (up to 4 medications, total of up to 40 participants) will undergo measurement of levels of their chronic medication after a dose before and after sleeve gastrectomy
89553450|NCT02676895|Experimental|1790GAHB 25 μg Group|Subjects who received 2 injections of 1790GAHB vaccine containing 25 μg of S. sonnei.
89553451|NCT02676895|Experimental|1790GAHB 100 μg Group|Subjects who received 2 injections of 1790GAHB vaccine containing 100 μg of S. sonnei.
89553452|NCT02676895|Active Comparator|Control Group|Subjects who received one dose of Menveo vaccine and a second dose of Boostrix vaccine.
89553453|NCT05235451|Experimental|Intervention group|The 2 HAI intervention reading groups will receive visits from a registered canine team during children's small group reading sessions twice a week over 12 weeks.
89553454|NCT05235451|No Intervention|Control group|The 2 control reading groups will receive care as usual and offered a 1-time visit from the dog at the end of the study (after T3 completed).
88962109|NCT02010710|No Intervention|No Decision Support|"No decision-support - CTGs with no additional interpretation (UK standard care),"
88962110|NCT02010723|Active Comparator|surgery|crossectomy and avulsion of the varicose anterior accessory great saphenous vein (AAGSV) under local anesthesia
88962111|NCT02010723|Experimental|sclerotherapy|foam sclerotherapy with aethoxysclerol foam
88962112|NCT02010736|Experimental|Spastic Hemiparetic Cerebral Palsy|Single treadmill gait training with additional loading
88962113|NCT02010749||Control|Control: Children who had received Standard formula (SF) as infants
89553455|NCT05675683||Asymptomatic Brain Metastases|Patients with Asymptomatic Brain Metastases
89553456|NCT05675683||Symptomatic Brain Metastases|Patient with Symptomatic Brain Metastases
89553457|NCT04691999|Experimental|Intermittent Fasting|All participants will either delay their first meal of the day or advance their last meal to achieve an approximate 16-18 hour fasting period four times per week.
89553458|NCT03161275||nirs|The cerebral oxymetry saturation was monitored continuously, using a non-invasive method. The cerebral saturation was monitored intraoperatively with near infrared spectroscopy (INVOS 4100; Somanetics Inc, Troy, MI). Data acquired from the device were automatically and continuously recorded in 10-second intervals throughout the anaesthesia. A lead for the cerebral saturation monitoring was placed on degreased skin on the patient's forehead, on the right side, some 1 cm over the eyebrow. The baseline value was determined before induction of anaesthesia. The following criteria were accepted as significant reduction of the cerebral oxygenation (saturation) value: reduction of the cerebral oxymetry by over 25% in relation to the baseline; the absolute value of cerebral oxymetry below 50%.
89553459|NCT03161275||cognitive function|Upon the day preceding the actual surgery, and again at 5 days after the surgery, the Mini Mental State Examination test was completed, with a view to assessing the chang-es in the patients' cognitive function. The difference between score in Mini Mental State Examination higher than 2 points defined a diagnosis of cognitive dysfunction.
89553460|NCT01680809|Experimental|Compression stocking 15-20mmHg|Compression stocking 15-20mmHg
89553461|NCT01680809|Experimental|Compression stocking 20-30mmHg|Compression stocking 20-30mmHg
88962114|NCT02010749||Experimental|Experimental: Children who had received lower protein formula as infants
88962115|NCT02010762|Active Comparator|Vitamin D|Weekly Vitamin D3 drops 25.000 IU for 6 months following ileocoecal resection
88962116|NCT02010762|Placebo Comparator|Placebo|Weekly placebo drops for 6 months following ileocoecal resection
88962117|NCT02010788||BOTOX®|Patients who receive botulinum toxin Type A (BOTOX®) treatment for Neurogenic Detrusor Overactivity or Overactive Bladder as per local standard of care in clinical practice.
88962118|NCT02010801|Experimental|IRE for tumor before tumor resection|
88962119|NCT02010827||Patients|Patients
88962120|NCT02010827||healthy controls|healthy controls
89553462|NCT04440085|Active Comparator|Intervention group|Midodrine will be administered every 8 hours, increasing the dose gradually until a maximum of 30 mg a day is reached. It will be given orally in the following sequence: 2.5 mg - 5 mg - 7.5 mg - 10 mg. The target standard perfusion pressure for all the patients will be a mean arterial pressure (MAP) > 65 mmHg, with unchanged dose of midodrine after target pressure is reached. If the pressure continues to increase, the same sequence will be followed for dose de-escalation.
89553463|NCT04440085|Placebo Comparator|Control group|By placebo group will be followed the same strategy.The target standard perfusion pressure for all the patients will be a mean arterial pressure (MAP) > 65 mmHg, with unchanged dose of placebo after target pressure is reached. If the pressure continues to increase, the same sequence will be followed for dose de-escalation.
89553464|NCT05129033|Active Comparator|anti-fungal agent plus OCS|Prednisone tablets is given orally 0.5mg/kg/d for 4 weeks and gradually reduced to stop for a total usage of 6 months Itraconazole is given orally 200mg bid for 8 months and 100mg bid for another 8 months
89553465|NCT05129033|Active Comparator|anti-IgE mAb plus OCS|Prednisone tablets is given orally 0.5mg/kg/d for 4 weeks and gradually reduced to stop for a total usage of 6 months Omalizumab is given by subcutaneous injection of 600mg q4w for at least 6 months
89553466|NCT04780399|Experimental|Yangxue Qingnao pills high dose group|Yangxue Qingnao pills 7.5 g per time,2 times per day.
89553467|NCT04780399|Experimental|Yangxue Qingnao pills lower dose group|Yangxue Qingnao pills 5 g per time,2 times per day, and placebo identified to Yangxue Qingnao pills 2.5 g per time, 2 times per day.
89553468|NCT04780399|Placebo Comparator|Placebo group|Placebo identified to Yangxue Qingnao pills 7.5 g per time,2 times per day
89553469|NCT05404997|Experimental|Shockwave Therapy|Common Treatment : Conventional physical therapy (lumbar stretching exercises and core strengthening exercises) Group A: Shockwave Therapy
89553470|NCT05404997|Experimental|Maitland's Lumbar Mobilizations|Common Treatment: Conventional Physical Therapy (lumbar stretching exercises and core strengthening exercises) Group B: Maitland's Lumbar mobilizations
89553471|NCT03114163||Cohort 1: Nivolumab|≥2nd line treatment for recurrent/ metastatic (R/M) Squamous cell carcinoma of the head and neck (SCCHN), prior platinum-based therapy was administered for locally advanced, metastatic or recurrent disease
89553472|NCT03114163||Cohort 2: Nivolumab|1st line treatment for R/M SCCHN, prior platinum-based therapy was administered for locally advanced disease in the adjuvant or primary setting
89553473|NCT03114007|Experimental|Preventure, Equipe and Inter-Action|Preventure program, Equipe program and Inter-Action services: Early personality-targeted interventions for students most at risk of mental health problems and substance misuse (Preventure program), parent program mainly for parents of high risk youth, especially those reporting discord at home (Equipe program) and integrated services for youth with significant internalizing and externalizing problems (Inter-Action services).
89208160|NCT02554448|Experimental|Circulating Tumor Cells|Use ISET system to test the number of CTCs from patients before and during treatment.
89208161|NCT02544126|Experimental|eSMART-MH|HIV+ young adults will be randomized to receive Electronic Self-Management Resource Training for Mental Health (eSMART-MH)
89553474|NCT03114007|Experimental|Preventure program and Equipe program|Early personality-targeted interventions for students most at risk of mental health problems and substance misuse (Preventure program) and parent program mainly for parents of high risk youth, especially those reporting discord at home (Equipe program)
89553475|NCT03114007|No Intervention|Control|Treatment as usual
89553476|NCT04557709||Observational (chart review)|Patients' medical charts are reviewed.
89553477|NCT05128721|Active Comparator|NRC-VACC-101 vaccine 3 microgram|Volunteers will receive two IM doses of the vaccine, concentrations of 3 mcg, 28 days apart.
89553478|NCT05128721|Active Comparator|NRC-VACC-101 vaccine 6 microgram|Volunteers will receive two IM doses of the vaccine, concentrations of 6 mcg, 28 days apart.
89553479|NCT05128721|Placebo Comparator|Control arm|Volunteers will receive two IM doses of the placebo (excipients only), 28 days apart.
89553480|NCT03161119|Experimental|Catheter Cook K-Jets-551910-S|Catheter Cook K-Jets-551910-S consists of an outer firm and an inner ultrasoft catheter. The outer guiding catheter (17 cm long) is slightly stiff, with a preshaped curve and a rounded bulb tip to help negotiate the cervical canal. It has a depth marker at 4 cm from the tip, which can be pulled back to a second marker at 5 cm. The inner catheter (23 cm long) is made of a soft material with a rounded bullet tip. In general, the inner catheter does not negotiate the cervical canal directly but rather is introduced into the uterine cavity through the outer catheter.
89553481|NCT03161119|Active Comparator|Catheter Cook k-soft-5000 (or K-J-SP-681710, K-J-SPPE-68171)|This catheter system consists of an outer firm and inner soft catheter. The outer guiding catheter (15,4 cm long) is straight and made of flexible material. The inner catheter (23 cm long) is made of a very soft and flexible polyurethan. The inner catheter is introduced directly through the cervix.
89553482|NCT05128565||Females under 40|females from 18 years old to 40 years old
89553483|NCT05128565||Males under 40|males from 18 years old to 40 years old
89553484|NCT05128565||Females above 40|females older than 40 years old
89553485|NCT05128565||Males above 40|males older than 40 years old
89553486|NCT04496609|Experimental|Stimulation-automated rehabilitation/automated rehabilitation|"Stimulation and automated rehabilitation (2 sessions of 45 minutes per day) for 40 working days~Washout 30 days~Automated rehabilitation (2 sessions of 45 minutes per day) for 40 working days"
89553487|NCT04496609|Experimental|Automated rehabilitation/Stimulation-automated rehabilitation|"Automated rehabilitation (2 sessions of 45 minutes per day) for 40 working days~Washout 30 days~Stimulation and automated rehabilitation (2 sessions of 45 minutes per day) for 40 working days"
89553488|NCT05128175|Experimental|25 mg /100 mg treatment A group|Treatment A: carbidopa/levodopa (25 mg /100 mg)
89553489|NCT05128175|Experimental|25 mg /150 mg treatment B group|Treatment B: carbidopa/levodopa (25 mg/150mg)
89208162|NCT02544126|Active Comparator|Attention Control|HIV+ young adults will be randomized to receive screen-based health education
89208163|NCT00794612|Experimental|1|Dermacyd Femina Pocket BR (Lactic Acid)
89208164|NCT00794690|Experimental|black cohosh extract, liver|100 postmenopausal women
89553490|NCT05128175|Experimental|25 mg /150 mg treatment C group|Treatment C: carbidopa/levodopa (25 mg /150 mg)
89553491|NCT05128175|Experimental|25 mg /150 mg treatment D group|Treatment D: carbidopa/levodopa (25 mg /150 mg)
89553492|NCT05128175|Placebo Comparator|25 mg /100 mg placebo group|Treatment E(Reference): Carbidopa and Levodopa tablets (a generic version of Sinemet® IR) 25 mg/100 mg
89553493|NCT05341427|Experimental|burn wound receiving electromagnetic therapy|There will be only one intervention group. The duration of the study will be 6 weeks divided to 18 sessions (three sessions per week). Sixty patients (male and female) will be recruited from the burn units of Cairo university hospitals
89553494|NCT04184453|Experimental|Deferiprone treated|Deferiprone (25 mg/kg/day) was given to the enrolled patient.
89553495|NCT05127707|No Intervention|No exposure control group|This group was not exposed to any message frame.
89553496|NCT05127707|Experimental|Words Matter - Visual Campaign|Participants randomized to this arm were exposed to a visual campaign communicating the importance of use of non-stigmatizing language regarding substance use disorder and opioid use disorder in clinical settings.
89553497|NCT05127707|Experimental|Words Matter - Visual Campaign & Narrative Vignette (Messenger: Person with Opioid Use Disorder)|Participants randomized to this arm were exposed to a visual campaign communicating the importance of use of non-stigmatizing language regarding substance use disorder and opioid use disorder in clinical settings and a narrative vignette told from the perspective of a person with opioid use disorder.
89553498|NCT05127707|Experimental|Words Matter - Visual Campaign & Narrative Vignette (Messenger: Clinician)|Participants randomized to this arm were exposed to a visual campaign communicating the importance of use of non-stigmatizing language regarding substance use disorder and opioid use disorder in clinical settings and a narrative vignette told from the perspective of a clinician.
88962121|NCT02010840|Experimental|Psychodeucation program|Both couples receive the father inclusive psychoeducation program which consists of a single 3-hour session during pregnancy and two telephone follow up at postpartum.
88962122|NCT02010840|Active Comparator|Mother only|Only the women receives the psychoeducation program.
88962123|NCT02010840|No Intervention|Control group|Receives usual perinatal care services only
88962124|NCT02010853|Experimental|patient|"each patient TGA will receive an evaluation in resting state IRMf during three successive visits:~During the acute phase within 24 hours~In 72 hours~In 3 months"
88962125|NCT02010853|Other|control|"each control will receive an evaluation in resting state IRMf during three successive visits:~During the acute phase within 24 hours~In 72 hours~In 3 months"
88962126|NCT02010866|Other|Counseling|in-person counseling through RFWP to distressed respondents on the ISP and patients who seek counseling without completing the ISP
88962127|NCT02010892||Watchful Waiting|Patients with aneurysms considered to be at low risk of rupture will remain under surveillance with annual CT / MRI scans and multi-disciplinary team review (as per local practice). These patients' data will contribute to the natural history component of the study.
88962128|NCT02010892||Best Medical Therapy|This refers to lifestyle modification (smoking cessation and dietary management) as well as medical management of hypercholesterolaemia and hypertension for patients who are considered unsuitable for, or who refuse, OSR / ESG.
88962129|NCT02010892||Open Surgery (OSR)|Replacement of the aneurysmal aorta with prosthetic conduit via a sternotomy or thoracotomy with circulatory support.
88962130|NCT02010892||Stenting (ESR)|Endovascular repair of the aneurysm via transluminal introduction of a stent-graft under X-ray guidance. Hybrid procedures that comprise a combination of a conventional surgical component and a transluminal repair are to be included in this group.
88962131|NCT02010905|Active Comparator|Losartan 150mg daily|Losartan: white film-coated biconvex tablet (50mg) with a diameter of 8mm. One time daily three tablets.
88962132|NCT02010905|Placebo Comparator|Placebo 150mg daily|Placebo: white film-coated biconvex tablet (50mg) with a diameter of 8mm. One time daily three tablets.
89553499|NCT05127707|Experimental|Words Matter - Visual Campaign & Narrative Vignette (Messenger: Health System Administrator)|Participants randomized to this arm were exposed to a visual campaign communicating the importance of use of non-stigmatizing language regarding substance use disorder and opioid use disorder in clinical settings and a narrative vignette told from the perspective of a health system administrator/leader.
89553500|NCT05127707|Experimental|Medication Treatment Works - Visual Campaign|Participants randomized to this arm were exposed to a visual campaign communicating the effectiveness of medications for treating opioid use disorder in saving lives.
88962133|NCT02010918|Experimental|glucosamine sulfate /chondroitin sulfate capsule|500 mg glucosamine sulfate + 400 mg chondroitin sulfate - capsules; One capsule, three times daily.
88962134|NCT02010918|Experimental|glucosamine sulfate /chondroitin sulfate - sachet|1500 mg glucosamine sulfate / 1200 mg chondroitin sulfate - sachet; One sachet preparation, once daily.
89553501|NCT05127707|Experimental|Medication Treatment Works - Visual Campaign & Narrative Vignette (Person with OUD)|Participants randomized to this arm were exposed to a visual campaign communicating the effectiveness of medications for treating opioid use disorder in saving lives and a narrative vignette told from the perspective of a person with opioid use disorder.
89553502|NCT05127707|Experimental|Medication Treatment Works - Visual Campaign & Narrative Vignette (Clinician)|Participants randomized to this arm were exposed to a visual campaign communicating the effectiveness of medications for treating opioid use disorder in saving lives and a narrative vignette told from the perspective of a clinician.
88962135|NCT02010918|Active Comparator|Cosamin DS®|500 mg glucosamine hydrochloride + 400 mg chondroitin sulfate - Capsules; One capsule, three times daily.
88962136|NCT02010944|Experimental|1: FDC-SET-SET|Fixed Dose Combination followed by two periods of the Single Entity Tablets
88962137|NCT02010944|Experimental|2: SET-FDC-FDC|Single Entity Tablets followed by two periods of Fixed Dose Combination
88962138|NCT02010957|Experimental|FDG positron emission tomography and Iodometomidate imaging|Combined FDG PET and Iodometomidate imaging prior adrenal surgery of uncertain adrenal neoplasms
88962139|NCT02010970|Experimental|Group 1 AZD3293-itraconazole|Subjects from Group 1 will receive a single dose of AZD3293 as an oral solution on Day 1 . In Group 1, itraconazole will be administered orally twice daily starting on Day 5 for 9 consecutive days (Days 5 to 13). On Day 8, a single dose of AZD3293 will be coadministered as an oral solution after the morning dose of itraconazole. Group 1 subjects will be discharged on Day 14.
89208165|NCT00860496|Other|1|Treatment Arm 1 will receive one single dose of CP-690,550 on Day 1, Tacrolimus on Days 1-8, and one single dose of CP-690,550 on Day 8.
89553503|NCT05127707|Experimental|Medication Treatment Works - Visual Campaign & Narrative Vignette (Health System Administrator)|Participants randomized to this arm were exposed to a visual campaign communicating the effectiveness of medications for treating opioid use disorder in saving lives and a narrative vignette told from the perspective of a health system administrator/leader.
89553504|NCT05018975|Experimental|Tazemetostat|Subjects will receive tazemetostat 800mg BID for 15 days in addition to standard of care treatment. The duration of the interventional part of the study will last 15 days.
89553505|NCT05018975|No Intervention|Control|Subjects receiving standard of care treatment
89553506|NCT03741881||Patients with haemophilia|Patients with haemophilia A or B and with or without inhibitors
89553507|NCT02673697|Experimental|Perceval|The Perceval sutureless aortic heart valve (Perceval valve) is a bioprosthesis manufactured with bovine pericardium and assembled on a Nitinol stent. The Perceval valve is designed to offer an alternative to surgically implanted flexible prostheses (stented and stentless biological valves). A special feature of the device is that it is self-anchoring and does not require sutures to be fixed to the implant site.
89553508|NCT02673697|Active Comparator|other Stented biological valves|The comparator will be other commercially approved standard biological sutured stented valves, both bovine and porcine. The choice of the comparator tissue valve will be at the discretion of the participating investigators.
89553509|NCT02891993|Experimental|IMPROVED Intervention|"Patients randomized to IMPROVED will self-report their symptoms each day using a tablet computer.~The clinical team will view reports detailing their patients' symptom burden~Clinicians will be provided with a graphic depiction of their patients' daily symptom trajectory for that admission"
89553510|NCT02891993|Active Comparator|Usual Care|"Patients randomized to Usual Care will self-report their symptoms each day using a tablet computer~Patients will report their symptoms to their clinicians as they usually would~Clinicians will not be provided with a graphic depiction of their patients' daily symptom trajectory for that admission"
89553511|NCT02433509|Experimental|HUCB monocyte cells w/ Mannitol in acute ischemic stroke|"The cord blood need to be infusion within less than 10 days after the onset of stroke, with the cord blood mononuclear cells 200 million ~ 500 million will used.~20% mannitol 200 ml iv for 30±10 min/q8h±2h will be administered twice after cord blood infusion ."
89553512|NCT05168579|Experimental|Deliberate practice|Trainees will be paired with a coach, and will meet, once per week for thirty minutes, over a three week period. During the training session, coach-trainee dyads will play a puzzle video game, and will discuss contextual cues that should inform triage decisions. At the completion of the three weeks, trainees will complete a semi-structured, debriefing interview and a virtual simulation to assess triage performance.
89553513|NCT05168579|No Intervention|Control|Participants in the control group will complete a virtual simulation.
89553514|NCT05404607|Experimental|Fascial distortion method with neuromuscular inhibition technique|27 participants will receive the fascial distortion method followed by the neuromuscular inhibition technique for trigger points. After this, neural mobilization will be given as stander treatment.
89553515|NCT05404607|Active Comparator|Fascial distortion method|Fascial distortion will be applied to 27 participants where the tip of the thumb worms its way through the peripheral tissue until it rests on the distortion. Force is focused directly on the most painful spot until the provider feels like a button-slipping-into-a-buttonhole. After this, neural mobilization will be given as a stander treatment.
89553516|NCT05404451|Experimental|Mulligan Mobilization|Using the Technique of Mulligan Mobilization
89553517|NCT05404451|Experimental|Mckenzie Exercises|Using Mckenzie Exercises
89553518|NCT05127239|Experimental|smartphone application with education|participants were provides 3 times lifestyle modification education and using smartphone app program
89553519|NCT05127239|Experimental|smartphone application|participants were only provided smartphone app program
89553520|NCT05127239|No Intervention|waiting list|No intervention was provided, but researchers explained the results of OSA screening for participants after every examination
89553521|NCT05127083|Experimental|toluidine blue-mediated photodynamic therapy|The number of points will be variable according to the lesion size. Patients will be treated with localized PBM with a diode laser with continuous wave +toluidine blue
89553522|NCT05127083|Active Comparator|photodynamic therapy + gel|The number of points will be variable according to the lesion size.atients will be treated with localized PBM with a diode laser with continuous wave
89553523|NCT05127083|Sham Comparator|acetonide triamcinolone 0.2%+sham|Patients will be treated with acetonide triamcinolone 0.2% for 30 consecutive days. Laser device will be positioned over the lesion but will be switched off to mask the treatment. Patients will be instructed to apply the gel in the entire lesion three times/days.The number of points will be variable according to the lesion size.
89553524|NCT04566497|Experimental|Experimental|no systematic stress testing during follow-up
89553525|NCT04566497|Active Comparator|Active Comparator|systematic annual stress testing during follow-up
89553526|NCT05134337|Experimental|Part 1 Period 1 (LOXO-305 Alone)|LOXO-305 administered orally
89553527|NCT05134337|Experimental|Part 1 Period 2 (Itraconazole + LOXO-305)|Itraconazole + LOXO-305 co-administered orally
89553528|NCT05134337|Experimental|Part 2 Period 1 (LOXO-305 Alone)|LOXO-305 administered orally
89553529|NCT05134337|Experimental|Part 2 Period 2 (Rifampin + LOXO-305)|Rifampin + LOXO-305 co-administered orally
89553530|NCT05134181|Active Comparator|Group MTP|will receive ultrasound-guided intra-articular SIJ injection with 40 mg of methylprednisolone with a uniform dose of 2 mL of 2% lidocaine hydrochloride.
89553531|NCT05134181|Active Comparator|- Group TMC|will receive ultrasound-guided intra-articular SIJ injection with 40 mg of Triamcinolone acetonide with a uniform dose of 2 mL of 2% lidocaine hydrochloride .
89553532|NCT05323175|Active Comparator|ESP Nerve Block for Renal colic|On top of receiving standard of care, At T8 nerve level, with ultrasound guidance to bathe the nerve
89553533|NCT05323175|Active Comparator|Standard of care|Whatever medications the clinician normally treats renal colic with
88962140|NCT02010970|Experimental|Group 2 AZD3293-diltiazem|Subjects from Group 2 will receive a single dose of AZD3293 as an oral solution on Day 1 . In Group 2, diltiazem will be administered orally once daily starting on Day 5, for 9 consecutive days (Days 5 to 13). On Day 8, a single dose of AZD3293 will be coadministered as an oral solution after the diltiazem dose. Group 2 subjects will be discharged on Day 14.
88962141|NCT02010970|Experimental|Group 3 AZD3293-midazolam|Subjects from Group 3 will receive a single dose of midazolam on Day 1 . AZD3293 will be administered as an oral solution once daily starting on Day 2 for 9 consecutive days (Days 2 to 10) followed by a 7 day wash-out period. On Day 8 and Day 17 a single dose of midazolam will be administered. Group 3 subjects will be discharged on Day 18
89553534|NCT02673619|Experimental|Umeclidinium once daily (QD) 1.85%|Subjects will apply UMEC topically once daily (2microliter [µL]/centimeter [cm]^2) to both the hands (palm and fingers) using graduated syringe at night before bedtime for 28 days. Randomization will be 4:1 (UMEC 1.85%: vehicle)
88962142|NCT02011009|Experimental|BLSE|The main objective of this study is to measure the carriage of antibiotic-resistant bacteria (enterobacteria ESBLs) in HIV seropositive patients looking for potential factors associated with sexual transmission. As a matter of fact, there is currently a worldwide community epidemic outbreak of enteric bacteria resistant to antibiotics for which the modes of transmission are still not fully known. There are many open questions about the possibility of sexual transmission and this study aims to find an answer.
89553535|NCT02673619|Placebo Comparator|Vehicle QD|subjects will apply vehicle topical once daily (2µL/cm^2) to both the hands (palm and fingers) using graduated syringe at night before bedtime for 28 days.
89553536|NCT05279963|Active Comparator|medication group|Participants in the medication group will be merely treated with oral administration of amitriptyline capsule. The dosage of amitriptyline is 25mg bid, for 4 weeks. Any changes in the medications of participants will be recorded on diary cards.
89553537|NCT05279963|Experimental|EA group|Patients allocated to this group will receive treatment with electroacupuncture. The location of acupoints will be determined based on the National Standard Nomenclature and Location of Acupoints. Patients will receive a total number of 12 EA sessions, with the frequency of 3 sessions per week for 4 weeks.
89553538|NCT05279963|Sham Comparator|SA group|Patients allocated to this group will receive acupuncture in non-meridian and non-acupoints regions. The needles are shallowly inserted to the subcutaneous area, and acupoints are connected to the EA apparatus without electricity. The frequency, intensity and duration of treatment will be the same as the EA group.
89553539|NCT03161197|Experimental|Intervention|The intervention consists of 8-10 sessions consisting of mindfulness-based stress reduction. Key components of what the intervention consists relate to stress management, breathing, and meditation exercises, as well as, techniques aimed at improving relations with others, sense of mastery and purpose in life. Additionally, during every point of contact subjects will be asked how often they utilized the strategies they were taught. This information will be helpful in understanding each subject's individual level of mastery and proficiency in Mindfulness-Based Stress Reduction (MBSR).
89553540|NCT03160963||Ages 18-29|Power testing 18-29 year old men and women
89553541|NCT03160963||Ages 30-39|Power testing 30-39 year old men and women
89553542|NCT03160963||Ages 40-49|Power testing 40-49 year old men and women
89553543|NCT03160963||Ages 50-59|Power testing 50-59 year old men and women
89553544|NCT03160963||Ages 60-69|Power testing 60-69 year old men and women
89553545|NCT03160963||Ages 70-79|Power testing 70-79 year old men and women
89553546|NCT03160963||Ages 80+|Power testing men and women 80 years of age and above
89553547|NCT05158543|Active Comparator|Control Group|the control group will receive conventional intervention for upper and lower limb motor function & balance.
89553548|NCT05158543|Experimental|moderate intensity group|this group will get task-oriented training with moderate intensity using Functional activities specific training-table (FAST-Table) with 100 functional tasks.
89553549|NCT05158543|Experimental|high intensity group|this group will get task-oriented training with high intensity using Functional activities specific training-table (FAST-Table) with 100 functional tasks.
89553550|NCT05133869|Experimental|Baseline + intervention + follow up|All participants receive the same treatment in the same order. First there is a phase without treatment, the baseline phase. The length of this phase is randomly assigned to each participant. Then all participants follow a 42 day intervention, in which direct training and metacognitive training is combined. Afterwards they have a follow-up period, this length of this period is counterbalanced with the length of the baseline period so that the full study adds up to 150 days.
89553551|NCT05231863||Observational Group|Patients receive TKIs after T-DM1 progression.
89553552|NCT03164317|Active Comparator|Intervention|Trained NCC together with electronic decision support system
89553553|NCT03164317|Other|Control|No trained NCC and electronic decision support system
88962143|NCT02011022|Experimental|3g group|The dose of MTX is 3 g/m2
88962144|NCT02011022|Experimental|5g group|The dose of MTX is 5g/m2
88962145|NCT02011048||Giant ventral incisional hernia|Patient with a giant ventral incisional hernia (> 10 cm fascial defect) scheduled to undergo endoscopic components separation.
88962146|NCT02011048||Control group|Patients scheduled to undergo surgery on other indications.
88962147|NCT02011087|Experimental|Diagnostic (bioelectric impedance analysis)|Patients undergo bioelectrical impedance phase angle measurement on day 1 of treatment.
88962148|NCT02011100|Experimental|CARNOSINE|3 months oral carnosine administration in a dose of 2 gram per day, twice a day 1 gram dose (1-0-1)
88962149|NCT02011100|Placebo Comparator|placebo|3 months placebo intake - taken twice a day (1-0-1)
88962150|NCT02011126|Experimental|Treatment (imetelstat sodium)|Patients receive imetelstat sodium IV over 2 hours on days 1 and 8. Treatment repeats every 21 days for up to 36 courses in the absence of disease progression or unacceptable toxicity.
88962151|NCT02011139|Active Comparator|Group A|12 sessions of Cognitive-behavioral group therapy in the first 12 weeks
89553554|NCT03164239|Experimental|Intervention group - telephone and print exercise intervention|The intervention group (IG) received a total of three intervention packages, one every second month, during the intervention period. The first intervention package was distributed at intervention start. The intervention package consisted of a tailored exercise program, national recommendations for physical activity, prompts and reminders. Additionally the IG received fortnightly supportive motivational contact every two weeks, alternately by telephone og email
89553555|NCT03164239|No Intervention|Control group|The control group (CG) were encouraged to continue previous lifestyle.
89553556|NCT05133635|Active Comparator|Pulse methylprednisolone|250 mg methylprednisolone for 3 days
89553557|NCT05133635|Active Comparator|Tocilizumab|Tocilizumab 400-800 mg for one time
89553558|NCT05133557|Placebo Comparator|Placebo|Half the participants receiving placebo gum (2 gram; 1 gram xylitol) first,
89553559|NCT05133557|Experimental|BBE gum|Half receiving first the BBE gum (2 gram; 1 gram xylitol and 100 mg BBE) that were identical in size, shape, color and flavor. After 1 week the groups cross-over and chewed the other gum.
89553560|NCT04253587|Experimental|LabyrinthVR Trackers|Multi-session cognitive intervention with head-mounted display virtual reality computer game that presents an adaptive spatial wayfinding challenge. Game movement via participant ambulation wearing leg-position trackers.
89553561|NCT04253587|Experimental|LabyrinthVR Scoot|Multi-session cognitive intervention with head-mounted display virtual reality computer game that presents an adaptive spatial wayfinding challenge. Game movement via teleporting technique.
89553562|NCT04253587|Placebo Comparator|Placebo Controls|Multi-session cognitive intervention with handheld tablet or wireless virtual reality headset presentation of commercially available, narrative computer games.
89553563|NCT04253587|Active Comparator|Coherence|Multi-session cognitive intervention with head-mounted display virtual reality computer game that presents an adaptive rhythm training game.
89553564|NCT04253587|Experimental|Labyrinth Tablet|Multi-session cognitive intervention with tablet computer, displaying 2.5D version of Labyrinth game in an adaptive spatial wayfinding challenge. Game movement via on-screen control buttons.
89553565|NCT04253587|Experimental|Labyrinth VR wireless|Multi-session cognitive intervention with head-mounted display virtual reality computer game using wireless, narrower filed technology to presents an adaptive spatial wayfinding challenge. Game movement via teleporting technique.
89553566|NCT05133167|Experimental|GROUP A|In group A, balloon tamponade (using Foley catheter 28 Fr) was used intra-operatively to prevent post-partum hemorrhage.
89553567|NCT05133167|Experimental|GROUP B|In group B, B lynch suture was used intra-operatively to prevent post-partum hemorrhage.
89553568|NCT05132777|Experimental|JMT101 in combination with Osimertinib|
89553569|NCT02680639|Active Comparator|optimal EPAP determination|On the BiPAP Synchrony ventilator the EPAP (and IPAP) will be automatically adjusted by the ventilator to find optimal EPAP that abolishes EFL. Peak-to-Peak pressure oscillations will be set at 2.5 cmH2O (centimeters of water)
89553570|NCT02680639|Experimental|Optimized EPAP w/ no peak-to-peak|On the BiPAP Synchrony ventilator the EPAP (and IPAP) will be set at optimal pressure as determined by the Auto EPAP. Peak-to-Peak pressure oscillations will be set at 0 cmH2O (centimeters of water)
89553571|NCT02680639|Experimental|Optimized EPAP w/ max peak-to-peak|On the BiPAP Synchrony ventilator EPAP (and IPAP) will be set at optimal pressure as determined by the Auto EPAP. Peak-to-Peak pressure oscillations will be set at 5 cmH2O (centimeters of water)
89553572|NCT02680639|Experimental|non-optimized EPAP w/ no peak-to-peak|On the BiPAP Synchrony ventilator EPAP will be set at 4 cmH2O and IPAP will be set at 10 cmH2O (centimeters of water). Peak-to-Peak pressure oscillations will be set at 0 cmH2O (centimeters of water).
89553573|NCT05126615|Experimental|Patients with auriculotherapy|Mastectomy operated patient then, auriculotherapy
89553574|NCT05126615|Placebo Comparator|Patient with placebo|Mastectomy operated patient then, they received placebo
89553575|NCT05126069||Standalone Xen45|consecutive patients from June 2012 - July 2017 who received standalone Xen45®
89553576|NCT05126069||Standalone Trabeculectomy|consecutive patients from June 2012 - July 2017 who received standalone trabeculectomy
89553577|NCT05422027|Experimental|Selinexor-VRd（XVRd）|bortezomib SC 1.3mg/sqm on day 1,4,8,11, lenalidomide oral 25 mg on day 1-14, and dexamethasone 40mg on day 1,8,15 in a 21-day cycle; Selinexor dose escalation: 40，60mg respectively on day 1,8,15 for 21-days cycles. Then Selinexor will be given at the recommended dose level on phase II.
89553578|NCT05132621||Participants diagnosed with SLE|
89553579|NCT05132621||Participants diagnosed with IgA nephropathy|
89553580|NCT05132621||Healthy Participants|
89553581|NCT05080777|Experimental|Tele-Savvy Group|The participants will be enrolled into the Tele-Savvy group. Software analytics monitor caregivers' use of asynchronous material each week.
89553582|NCT05080777|Active Comparator|Attention Control Group|The participants will be enrolled in the Caregiving During Crisis program. Software analytics monitor caregivers' use of asynchronous material each week.
89553583|NCT05132309||Chronic pancreatitis without pancreatic external insufficiency|
89553584|NCT05132309||Chronic pancreatitis with mild pancreatic external insufficiency|
89553585|NCT05132309||Chronic pancreatitis with severe pancreatic external insufficiency|
89553586|NCT05132309||Chronic pancreatitis with severe pancreatic external insufficiency who underwent pancreatic surger|
88962152|NCT02011139|Active Comparator|Group B|12 sessions of Cognitive-behavioral group therapy in the second 12 weeks
89553587|NCT03164005||Group 1|subjects without metabolic diseases
89553588|NCT03164005||Group 2|subjects with metabolic diseases
88962153|NCT02011165||Tennis ball|Night with tennis ball fastened in the back of the night shirt. A positioning measuring device mounted.
88962154|NCT02011165||No tennis ball|Night without tennis ball fastened in the back of the night shirt. A positioning measure device mounted.
88962155|NCT02011178|Active Comparator|Optimal medical treatment and surgery|In the study 50 obese patients with CKD 3 andT2DM will be treated using the European Association for Study of Diabetes protocol in combination with RYGB surgery.
89553589|NCT01674725|Experimental|ABT-450/r/ABT-267 and ABT-333, Plus RBV|ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
89553590|NCT01674725|Experimental|ABT-450/r/ABT-267 and ABT-333|ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily) for 12 weeks
89553591|NCT03164083|Experimental|mesenchymal stem cell|Patients with knee joint osteoarthritis who underwent intra articular mesenchymal stem cell injection
89553592|NCT03164083|Experimental|placebo|The patients who are in control group and underwent placebo injection
89553593|NCT03164395|Experimental|Internal Cardioversion|Patients randomized to external cardioversion will undergo external synchronized cardioversion per institutional protocol.
89553594|NCT03164395|Active Comparator|External Cardioversion|Patients randomized to internal cardioversion will have a maximum energy shock delivered from the device between the RV coil and can. If cardioversion is not successful they will then undergo external cardioversion per institutional protocol.
89553595|NCT05404061|No Intervention|Gut hormone secretion study|"This will be a retrospective study of participants who have undergone bariatric surgery. On the day of the visit participants will undergo comprehensive physiological profiling which will include the following tests:~Body weight and bioelectrical impedance analysis~Mixed Meal Tolerance Test. This will be analysed for metabolites including gut hormones, insulin, glucose, bile acids and their sub-fractions, fibroblast-growth factors, lipids and immune profiles.~Resting Energy Expenditure and Diet Induced Thermogenesis assessed via Indirect Calorimetry~Metabolomic and Metagenomic Assessment"
89553596|NCT05404061|Placebo Comparator|Gut hormone sensitivity study|This will be a single blinded study with participants attending three visits. Their first visit will act as an acclimatisation visit and participants will be infused subcutaneously with a triple gut hormone infusion (GLP-1, PYY and OXM). This will not only allow us to acclimatise the study volunteer to the study visits, but also allow us to test for subject tolerability of the gut hormones. Occasionally some volunteers are more sensitive to the gut hormone infusion and the doses needs to be titrated down. The doses used will be established doses of the gut hormones infused previously and which have been shown to be safe and tolerated, and to reduce appetite (In house data).
89553597|NCT05404061|No Intervention|Prospective assessment of gut hormone response pre and post-surgery|"This will be a prospective study assessing the gut hormone response pre and post bariatric surgery.~On the day of the visit participants will undergo comprehensive physiological profiling which will include the following tests:~Body weight and bioelectrical impedance analysis~Mixed Meal Tolerance Test. This will be analysed for metabolites including gut hormones, insulin, glucose, bile acids and their sub-fractions, fibroblast-growth factors, lipids and immune profiles.~Resting Energy Expenditure and Diet Induced Thermogenesis assessed via Indirect Calorimetry~Metabolomic and Metagenomic Assessment"
89553598|NCT03161041|Experimental|Bevacizumab and CRS with oxaliplatin|Perioperative chemotherapy plus bevacizumab and CRS with oxaliplatin
89553599|NCT05123495||Device Briefing Tool Implementation|Surgical departments which receive training on use of the Device Briefing Tool
89553600|NCT05123495||Comparator|Surgical departments that do not receive training on use of the Device Briefing Tool
89553601|NCT05120219|Experimental|food effect cohort A|
89553602|NCT05120219|Experimental|food effect cohort B|
89553603|NCT05120219|Experimental|multiple dose pharmacokinetics|
88962156|NCT02011178|Other|Optimal medical treatment|In the study 50 obese patients with CKD 3 andT2DM will be treated using the European Association for Study of Diabetes protocol
88962157|NCT02011191|Active Comparator|Biotin|10,000 micrograms biotin daily for 8 weeks
88962158|NCT02011191|Placebo Comparator|Sugar pill|
88962159|NCT02011204||People with ALS|"People diagnosed with early ALS (possible, probable, probable-laboratory supported or definite ALS according to El Escorial criteria)~Intervention: Electrical Impedance Myography (EIM)."
88962160|NCT02011204||Other Neurological Diseases|People with a diagnosis of a disease that mimics ALS
88962161|NCT02011204||Healthy Controls|Healthy Volunteers that do not have ALS or another neurological disease that mimics ALS.
88962162|NCT02011217|Experimental|Rye crisp bread A|
88962163|NCT02011217|Experimental|Rye crisp bread B|
88962164|NCT02011217|Experimental|Wheat crisp bread C|
88962165|NCT02011230|No Intervention|Control|Patients in the control group will not be given any special fluids to take after surgery Patients will use their discretion to drink as needed following surgery
88962166|NCT02011230|Experimental|Hoist|Patients in the Hoist group will be given a 10 day supply of Hoist that they will self administer
88962167|NCT02011243||Professional players, men|This group includes professional, male, handball players meeting study inclusion criteria.
88962168|NCT02011243||Professional players, women|This group includes professional, female, handball players meeting study inclusion criteria.
88962169|NCT02011243||Junior players, men|This group includes junior, male, handball players meeting study inclusion criteria.
88962170|NCT02011243||Junior players, women|This group includes junior, female, handball players meeting study inclusion criteria.
88962171|NCT02011256|Experimental|Implantable loop-recorder|
88962172|NCT02011269|Active Comparator|7500 TSO|7500 active Trichuris suis ova will be provided in a15 mL of aqueous suspension (supplied in 30 mL glass containers) administered orally, once every 2 weeks for 10 weeks
88962173|NCT02011269|Active Comparator|15000 TSO|15000 active Trichuris suis ova will be provided in two 15 mL of aqueous suspension (supplied in 30 mL glass containers) administered orally, once every 2 weeks for 10 weeks
88962174|NCT02011269|Placebo Comparator|Non-active treatment|The TSO placebo drug product is a non-sterile, 15 mL aqueous solution containing phosphate buffer, pH 5 and 0.05% potassium sorbate as antimicrobial preservative. The TSO placebo is supplied in two 30 mL glass containers that is identical to the container/closure described above for the active drug product.
88962175|NCT02011282|Experimental|Electro-Neuro-Muscular Stimulation|Patients will receive daily sessions of electrostimulation with a commercially available device (En-Stimulation 4, Netherlands) in the quadriceps muscle for 10 days
88962176|NCT02011282|No Intervention|Control|Patients in this arm will receive the usual standard treatment
88962177|NCT02011295|Other|Microfracture|Procedure/Surgery: ankle arthroscopy with debridement and microfracture of the OLT
88962178|NCT02011295|Other|microfracture + injection of autologous BMAC|Procedure/Surgery: ankle arthroscopy with debridement and microfracture of the OLT plus injection of autologous Bone Marrow Aspirate Concentration
88962179|NCT02011308|Active Comparator|Green Light Laser|
88962180|NCT02011308|Active Comparator|TURP|Transurethral Resection of the Prostate
89025653|NCT01242579|Placebo Comparator|Matching Placebo Gel|Drug: placebo dosage form: vaginal gel dosage: 2.5g placebo frequency: once daily duration: 11 days
89553604|NCT05119517|Experimental|Osteopathic manipulative medicine pedal pump|
89553605|NCT05119049|Experimental|Aquatic exercise plan in the pool.|The experimental group underwent 20 sessions with an aquatic exercise plan in the pool at the rehabilitation department.
89553606|NCT05119049|Active Comparator|Exercises in a rehabilitation room.|The control group did the same exercises and sessions in one of the rooms in the rehabilitation department.
89553607|NCT05113355|Experimental|Chidamide + Sintilimab|Experimental arm will be treated by chidamide combined with sintilimab for up to 24 months.
89553608|NCT03163693|Experimental|Group dexmedetomidine|20 eligible patients are received 0.5ug/kg dexmedetomidine intravenously 15 minutes before surgery
89553609|NCT03163693|Placebo Comparator|Group control|20 eligible patients are received equal volumes normal saline intravenously 15 minutes before surgery
89553610|NCT05054543|Experimental|Uproleselan|Uproleselan in combination with mitoxantrone, etoposide and cytarabine (MEC) during induction; Uproleselan in combination with HiDAC/IDAC during consolidation
89553611|NCT05054543|Placebo Comparator|Placebo (Saline, 0.9% Sodium Chloride)|Placebo in combination with mitoxantrone, etoposide and cytarabine (MEC) during induction; Placebo in combination with HiDAC/IDAC during consolidation
89553612|NCT05125757|Experimental|intervention group|The patients of this group will receive their usual immuno-modulating therapy plus life style modification (energy or diet restriction in addition to daily walking, 15000 steps)
89553613|NCT05125757|Active Comparator|control group|The participants of this group will receive their usual immuno-modulating therapy and continuing their usual diet and activities
89553614|NCT04439617||sepsis patient|
89553615|NCT04439617||Sepsis-free patient|
89553616|NCT05030545|Experimental|Eplerenone Treatment|Eplerenone (50-100mg daily, as tolerated by blood pressure and potassium) for 6 months
89553617|NCT03163927|Experimental|Intervention|Participants receive a 1.5-hour standardized simulation-based training course, with mastery learning.
89553618|NCT03163927|No Intervention|Control|Participants observe a procedure performed by a senior.
89553619|NCT03106805|Experimental|insertion by the end of the 4th week postpartum|
89553620|NCT03106805|Active Comparator|insertion by the end of the 6th week postpartum|
89553621|NCT03164161|Active Comparator|Cold Pressor Test Results|Participants, enrolling the healthy participants high and low pain perception groups, will undergo cold pressor test. According to the results patients will be assigned according to time (min:s) until first pain felt (pain threshold) and time (min:s) until unbearable pain and test withdraw (pain tolerance). Also, pain ratings (1-10) at same points will be used as participants alignment tool.
89553622|NCT03164161|Active Comparator|β-endorphins level in saliva|Participants will be sorted according to β-endorphin levels in saliva., therefore the β-endorphins evaluation in saliva intervention will be performed.
89553623|NCT03164161|Active Comparator|β-endorphin level in blood plasma|Participants will be sorted according to β-endorphin levels in blood plasma, therefore β-endorphins evaluation in blood plasma will be performed.
89553624|NCT03164161|No Intervention|Pain perception rating|Healthy participants will be sorted in to groups: high and low pain perception groups, according to the results of questionnaires, containing various oral surgery procedures pain ranking.
89553625|NCT02627183||Paroxysmal AF + catheter ablation|Subjects with paroxysmal Atrial Fibrillation (AF) undergoing catheter ablation.
89553626|NCT02627183||Permanent/persistent AF + exercise|Subjects with permanent or persistent Atrial Fibrillation (AF) undergoing exercise training two times weekly for 12 weeks as part of their involvement in the OPPORTUNITY Study (NCT02602457).
89553627|NCT04960475||A/D group|Chronic ankle sprain patient with anxity or depression
89553628|NCT04960475||Control group|Chronic ankle sprain patient with no emotional issues
89553629|NCT03163615|Experimental|Tibet Rhodiola Capsule|
89553630|NCT03163615|Placebo Comparator|Placebo oral capsule|
89553631|NCT01712633||Volunteers|Healthy Volunteers
89553632|NCT04439695|Experimental|Low Dose KBP-V001|Subjects in this group will receive the low dose of KBP-V001.
89553633|NCT04439695|Experimental|Intermediate KBP-V001|Subjects in this group will receive the intermediate dose of KBP-V001.
88962181|NCT02011334|Experimental|RoActemra/Actemra|
88962182|NCT02011347|Experimental|Ketamine|Patients will receive a closed-loop administration of propofol and remifentanil according to bispectral level and Ketamine (bolus dose of Ketamine (0.15 mg.kg-1) followed by an infusion of Ketamine (0.15 mg.kg-1 h-1) until the end of anesthesia)
88962183|NCT02011347|Experimental|Placebo|patients will receive a closed-loop administration of propofol and remifentanil according to bispectral level and a placebo (NaCl 9/00 (same volume as in the Ketamine group)
88962184|NCT02011360|Other|Low carbohydrate diet|Low carbohydrate diet: 15%carb; 65%fat; 20% protein. This will be administered over 72 hour hospital stay.
88962185|NCT02011360|Other|Low Fat diet|Low fat diet: 65%carb; 15%fat; 20% protein. This will be administered over a 72 hour hospital stay.
88962186|NCT02011373|Experimental|IFABOND|
88962187|NCT02011412||Intermountain Risk Score known|
88962188|NCT02011412||Intermountain Risk Score Unknown|
88962189|NCT02011425|Experimental|mandibular advancement appliance|mandibular advancement appliance (SomnoDent by SomnoMed)
88962190|NCT02011425|No Intervention|without mandibular advancement appliance|no therapy
88962191|NCT02011438|Experimental|UTalk Intervention|Active preventative intervention condition.
88962192|NCT02011438|No Intervention|Control|Education/Support Condition
88962193|NCT02011451|Experimental|95% Pure ECGC capsules 200mg|95% Pure ECGC capsules 200mg three times a day with food for 6 months
88962194|NCT02011451|Placebo Comparator|Sugar pill|Matched placebo capsules
89553634|NCT04439695|Experimental|High Dose KBP-V001|Subjects in this group will receive the high dose of KBP-V001.
89553635|NCT04439695|Placebo Comparator|Placebo|Subjects in this group will receive placebo
89553636|NCT05675215||Normal subjects with suspicion of psychopathological disorder|Adults over 18 years old who are fluent in French (oral and written). Participant with neurological or organic mental disorder (not induced by substances) including dementia, organic amnesic syndrome, delirium, other mental, personality or behavioural disorders due to brain damage, dysfunction or to physical disease.
88962195|NCT02011477|Experimental|Neural glide|This technique involves two movements, initial and final. It consists of going from one to the other constantly. The therapist took the subject's head by putting his hands on the suboccipital and front region. In the initial movement, the therapist perform craniocervical flexion in the subject, while he helped with his right elbow to rectify the dorsal spine of the subject; at the same time, the subject perform dorsiflexion of the right ankle. In the final movement, the subject must increase thoracic kyphosis at the same time as perform plantarflexion in the right ankle; also, the therapist performed craniocervical extension in the subject. The session lasted 7 minutes.
88962196|NCT02011477|Placebo Comparator|Placebo|The model of the ultrasound (ENRAF-NONIUS, P.O. Box 12080, 3004 GB Rotterdam, The Netherlands). The subject was placed in a prone position, with arms along the body and the head in the hole of the examining couch. The therapist applied a non-therapeutic dose of ultrasound for 7 minutes with no break all over the cervical area and trapezius, in circles.
89553637|NCT03114787|Other|Patient receiving respiratory physiotherapy|
89553638|NCT03114787|Other|Patient not receiving respiratory physiotherapy|
89553639|NCT05125445|Experimental|Crestally positioned implants|
89553640|NCT05125445|Active Comparator|Subcrestally positioned implants|
89553641|NCT03114475|Experimental|CO2 Laser Irradiation|This group of patients will be treated by splitting the dental arches into four quadrants: upper right, upper left, lower right and lower left. Two quadrants will receive the CO2 laser irradiation whereas the remaining two quadrants will receive no treatment (i.e. the placebo light).
89553642|NCT03114475|Placebo Comparator|Placebo|A placebo light will be used as if the patient is irradiated with the laser beam.
89553643|NCT00754949|Experimental|1|
89553644|NCT00754949|Active Comparator|2|
89553645|NCT00754949|Active Comparator|3|
89553646|NCT03114709|Experimental|Mindful Movement|8, 90-minute, in-person, group sessions over 8 weeks
89553647|NCT03114709|Active Comparator|10 Keys to Health & Wellbeing|8, 90-minute, in-person, group sessions over 8 weeks
89553648|NCT00406445||carrier LFS family members|96 carrier LFS family members
89553649|NCT00406445||non-carrier LFS family members or normal|60 non-carrier LFS family members or normal
89553650|NCT00406445||non-carrier mitochondrial disorder family members or normal controls|20 non-carrier mitochondrial disorder family members or normal controls
89553651|NCT00406445||normal controls for MR spectroscopy study|30 normal controls for MR spectroscopy study
89553652|NCT00406445||subjects with mitochondrial disorders|20 subjects with mitochondrial disorders
89553653|NCT05675137|Experimental|Mobile-based multidomain intervention|
89025654|NCT01242579|Experimental|Maraviroc/Dapivirine Gel|Drug: Maraviroc/Dapivirine dosage form: combination vaginal gel dosage: 2.5g - Maraviroc 0.1%, Dapivirine 0.05% frequency: once daily duration: 11 days
89025655|NCT00460499|Active Comparator|B Low dose GIK|This group will have low doses of glucose and insulin
89553654|NCT05675137|Active Comparator|paper-based intervention group|
89553655|NCT04620707|Experimental|RGS based therapy|
89553656|NCT04620707|Active Comparator|Treatment as usual|
89553657|NCT03160807|Experimental|Levofloxacin 5 days|Levolet 500 mg given for 5 days
89553658|NCT03160807|Active Comparator|Levofloxacin 10 days|Levolet 500 mg given for 10 days
89553659|NCT01674569|Experimental|50 mg X-82 oral alternate days|50 mg X-82 oral on alternate days with intravitreous ranibizumab (Lucentis) using predefined retreatment criteria for 24 weeks or until unacceptable toxicity develops
89553660|NCT01674569|Experimental|50 mg X-82 oral QD|50 mg X-82 oral QD with intravitreous ranibizumab (Lucentis) therapy using predefined retreatment criteria.for 24 weeks or until unacceptable toxicity develops
89553661|NCT01674569|Experimental|100 mg X-82 oral alternate days|100 mg X-82 oral on alternate days with intravitreous ranibizumab (Lucentis) using predefined retreatment criteria.for 24 weeks or until unacceptable toxicty develops
89553662|NCT01674569|Experimental|100 mg X-82 oral QD|100 mg X-82 oral QD with intravitreous ranibizumab (Lucentis) using predefined retreatment criteria for 24 weeks or until unacceptable toxicity occurs
89553663|NCT01674569|Experimental|200 mg X-82 oral QD|200 mg X-82 oral QD with intravitreous ranibizumab (Lucentis) therapy using predefined retreatment criteria for 24 weeks or until unacceptable toxicity occurs
89553664|NCT01674569|Experimental|300 mg X-82 oral QD|300 mg X-82 oral QD with intravitreous ranibizumab (Lucentis) therapy using predefined retreatment criteria for 24 weeks or until unacceptable toxicity occurs.
89553665|NCT03160729|Active Comparator|High dose|Dexamethasone 24 mg
89553666|NCT03160729|Active Comparator|Low dose|Dexamethasone 8 mg
89553667|NCT04589117|Experimental|Expressive writing|"The 4-week study intervention will invite participants through a progression of expressive writing exercises designed to support emotional expression and enhance personal resilience. Weekly instruction writing sessions will be conducted via Zoom. The sessions will not be recorded, but participants who cannot attend the sessions live (or prefer not to, for any reason) will receive each week's instructions and prompts via email.~The progression of writing exercises flows as follows:~Week 1: Writing to expressive difficult emotions~Week 2: Writing to cultivate compassion & forgiveness~Week 3: Writing to nurture positive emotions~Week 4: Writing to invite insight, perspective, & growth"
89553668|NCT04439929|Experimental|Adalimumab-TUR01|
89553669|NCT04439929|Active Comparator|Adalimumab-EU|
89553670|NCT05131841|Active Comparator|One-week group|Cipterbin combined with Vinorelbine Injection every week in the treatment of patients with HER2-positive metastatic breast cancer
89553671|NCT05131841|Experimental|Three-week group|Cipterbin combined with Vinorelbine Injection every three weeks in the treatment of patients with HER2-positive metastatic breast cancer
89553672|NCT03163849|Placebo Comparator|control group|oral tablets
89553673|NCT03163849|Experimental|Study group|sofosbuvir , daclatasvir oral tablets
89553674|NCT04520867||Qualifying Subjects|Patients seen in the EGMDC for treatment planning who are recommended to receive neoadjuvant treatment followed by surgery at UCCC Metro
88962197|NCT02011477|Active Comparator|Neural Stretching|In the start position, the subject was supine on a couch, with knees bent with the right leg above the left, and supported with the popliteal zone. Both hands were crossed over the chest. One hand was placed on the occipital, and the other hand was placed over the crossed hands of the subject . In the final position, the therapist made the subject execute a craniocervical flexion while he pushed the subject's hands against the chest, in order to increase thoracic kyphosis. At the same time, the subject had to raise the elevated leg without separating the popliteal zone in the other knee, while maintaining dorsiflexion of the ankle and a maximum knee extension. The session lasted 7 minutes.
89553675|NCT04509947|Experimental|Ad26.COV2.S: High Dose|Participants (healthy adults aged greater than or equal to (>=) 20 to less than or equal to (<=) 55 years [cohort 1] and >= 65 years [cohort 2]) will receive intramuscular (IM) injection of Ad26.COV2.S at high dose, as 2-dose schedule on Day 1 and Day 57.
89553676|NCT04509947|Experimental|Ad26.COV2.S: Low Dose|Participants (healthy adults aged >= 20 to <= 55 years [cohort 1] and >= 65 years [cohort 2]) will receive IM injection of Ad26.COV2.S at low dose, as 2-dose schedule on Day 1 and Day 57.
89553677|NCT04509947|Placebo Comparator|Placebo|Participants (healthy adults aged >= 20 to <= 55 years [cohort 1] and >= 65 years [cohort 2]) will receive IM injection of placebo on Day 1 and Day 57.
89553678|NCT05131763|Experimental|KD-025|NKG2D-based CAR T-cells Injection; Dosage:1-10x10^6/kg, 70ml/time, The CAR-T cells will be administered by i.v. or hepatic portal artery injection over 20-30 minutes Frequency: total one time
89553679|NCT05178641|Experimental|Ninjamas Pyjama Pant, Then Participant's Overnight Current Standard of Care|For the first 3 weeks participants use Ninjamas Pyjama Pants, then for the next 3 weeks they switch to the Overnight Current Standard of Care.
89553680|NCT05178641|Experimental|Participant's Overnight Current Standard of Care, Then Ninjamas Pyjama Pant|For the first 3 weeks participants use their Overnight Current Standard of Care, then for the next 3 weeks they switch to Ninjamas Pyjama Pants.
89553681|NCT04501913||Observational (remote telemonitoring)|Patients undergo remote perioperative telemonitoring with home monitoring devices activity monitor beginning 7 days before surgery and up to 30 days after hospital discharge.
89553682|NCT03163537||Kidney transplantation, postmortal, day|
89553683|NCT03163537||Kidney transplantation, postmortal, night|
89553684|NCT03163537||Kidney transplantation, living donor|
89553685|NCT03163381|Experimental|Apatinib|Apatinib 500mg/d from day 1 to day 28, repeated every 28 days until progressive Disease(PD) .
89553686|NCT05131295|Experimental|Dapsone|Besides the standard of care, those assigned to the dapsone group received orally 100mg (2.5 ml) of dapsone suspension daily, from the admission day until the 15th-day post-ictus.
89553687|NCT05131295|Placebo Comparator|Placebo|Besides the standard of care, those assigned to the placebo group received orally 2.5 ml of aluminum hydroxide gel daily, from the admission day until the 15th-day post-ictus.
89553688|NCT05130905|Experimental|Supplementation with RiteStart|Once enrolled into the study, participants were instructed to take RiteStart Supplement daily for 12 weeks.
89553689|NCT03163459|Active Comparator|mechanical thrombectomy group|Conventional mechanical thrombectomy
89553690|NCT03163459|Experimental|mechanical thrombectomy plus selective brain cooling group|A microcatheter which was used to deploy the stent retriever was threaded into the femoral artery in the groin through a guiding catheter and up through the neck, until it reached beyond the clot causing the stroke under the assistance of micro-guide wire, 50 mL cold 0.9% saline (4°C) was infused into the ischemic territory at 10 mL/min through the microcatheter, thus allowing the cold solution to infuse into the ischemic territory prior to reperfusion. After that, mechanical thrombectomy with a stent retriever was performed to recanalize the occluded vessel as soon as possible. After the recanalization, cold 0.9% saline (4°C) was infused into the ischemic brain tissue through the guide catheter at 30 mL/min for 10 minutes.
89553691|NCT05130749||Primary Healthcare Nurses|Nurses allocated in primary Healthcare settings
89553692|NCT05130749||Non Nurses Primary Healthcare|Other Healthcare providers allocated in primary health care settings
89553693|NCT05130203|Experimental|MouvMat Exergaming|Older adults in the intervention group will participate in a 6-week, 3 times per week, 45 minutes per session exercise program involving use of the MouvMat. Each resident from the intervention group will engage with the exergame supervised by a qualified and trained RA. Each intervention session will involve groups of 4-5 participants, with participants taking turns. An RA blinded to participants' condition will collect the outcome data.
89553694|NCT05130203|Other|Standard Recreational Programming|A control group will meet on a similar schedule as the MouvMat group for standard recreational programming conducted by onsite recreational therapists. The same RA from the experimental group will collect outcome measurements from control group participants.
89553695|NCT05124587||Patients with confirmed COVID-19 in the hospital setting|
89553696|NCT01374217|Experimental|Tadalafil|Subject will take tadalafil in combination with with Lenalidomide and dexamethasone (Rd) or Clarithromycin/Lenalidomide/ dexamethasone (BiRd)
89553697|NCT04494815|Experimental|Treatment A|Treatment A: Single 20 mg oral suspension dose of SR419 + single active control placebo capsule.
89553698|NCT04494815|Active Comparator|Treatment B|Treatment B: Single SR419 placebo oral suspension + single 300 mg oral capsule of active control.
89553699|NCT04494815|Placebo Comparator|Treatment C|Treatment C: Single SR419 placebo oral suspension + single active control placebo capsule.
88962198|NCT02011503|Experimental|dHACM|Application of multi-layer compression therapy with application of dHACM.
88962199|NCT02011503|Other|Control|Application of multi-layer compression therapy without application of dHACM.
88962200|NCT02011529|Active Comparator|TEAMcare treatment of diabetes|
89553700|NCT04494737|Active Comparator|Active Comparator: Program 1|Mindfulness Training program is based on mindfulness based stress reduction developed by Kabat-Zinn, but the didactic content is focused on attention training and meta-awareness. Participants will be taught formal open awareness meditation, gentle yoga, and a 'body scan' meditation during weekly classes. Importantly, there is no retreat day included in the program.
89553701|NCT04494737|Active Comparator|Active Comparator: Program 2|Stress Management Education (SME) is designed to control for non-specific factors such as contact hours, stress education, and gentle exercise. Stress education classes will consist of teaching about the effects of stress on health and optimizing one's personal health care, understanding positive coping behavior, optimizing nutrition to decrease stress, and exercise and strength training.
89553702|NCT05676541|Experimental|Intervention|
89553703|NCT05676541|No Intervention|Control|
89553704|NCT03688763|Other|Digital CBTi administered|Participants will receive 6 sessions of digitally administered CBTi using the Sleepio platform over the course of 12 weeks. Each session lasts on average 30-60 minutes, and is tailored to participant's progress and problems. During the treatment phase, between sessions, participants complete the Consensus Sleep Diary to track their progress.
89553705|NCT03278249|Experimental|Modified Atkins Ketogenic Diet|Modified Atkins Ketogenic Diet in combination with Temodar and Radiation
89553706|NCT04941937|Experimental|Arm I: Selinexor+Thalidomide+Dexamethasone|Arm I is given XTd regimen Selinexor 60mg/d QW, Thalidomide 100mg/d, d1-28 and Dexamethasone 40mg/d QW) in approximately 30 subjects. 4 weeks per cycle and include a total of 12 cycles.
89553707|NCT04941937|Experimental|Arm II: Selinexor+Lenalidomide+Dexamethasone|Arm II is given XRd regimen Selinexor 60mg/d QW, Lenalidomide 25mg/d, d1-21 and Dexamethasone 40mg/d QW) in approximately 30 subjects. 4 weeks per cycle and include a total of 12 cycles.
89553708|NCT04941937|Experimental|Arm III: Selinexor+Pomalidomide+Dexamethasone|Arm III is given XPd regimen Selinexor 60mg/d QW, Pomalidomide 4mg/d, d1-21 and Dexamethasone 40mg/d QW) in approximately 30 subjects. 4 weeks per cycle and include a total of 12 cycles.
89553709|NCT05124431|Experimental|Anlotinib hydrochloride+Everolimus|"Anlotinib hydrochloride: ,12 mg given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).~Everolimus:5mg po. qd in 21-day cycle"
89553710|NCT04435613|Other|protective mechanical ventilation|Ten patients with moderate to severe ARDS were subjected to a nearly ultra-protective ventilation strategy generating a reduction in minute ventilation (Tidal volume of 5 ml/kg of predicted body weight together with a 20% reduction in respiratory rate). In addition to end-inspiratory pause, prolongation was set to avoid hypercapnia. Protocol phases: Baseline conditions: Tidal volume of 7 ml/kg. I: Tidal volume of 6 ml/kg. II: Tidal volume of 5 ml/kg. III: Increase end-inspiratory pause until achieving an I:E ratio equal to 1. IV: Respiratory rate reduction until 20% of the basal condition keeping constant I:E ratio equal to 1
89553711|NCT04955249|Experimental|Dexmedetomidine group|Patients in this group receive dexmedetomidine-supplemented patient-controlled analgesia for up to 3 days after surgery. The formula is a mixture of dexmedetomidine (1 microgram/ml) and sufentanil (1 microgram/ml), diluted with normal saline to 200 ml. The analgesic pump is programmed to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml at each time and a lockout interval of 8 minutes.
89553712|NCT04955249|Placebo Comparator|Control group|Patients in this group receive routine patient-controlled analgesia for up to 3 days after surgery. The formula is a mixture of placebo and sufentanil (1 microgram/ml), diluted with normal saline to 200 ml. The analgesic pump is programmed to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml at each time and a lockout interval of 8 minutes.
89553713|NCT04876417|Active Comparator|tDCS and fatigue|This group will receive the active form of tDCS.
89553714|NCT04876417|Sham Comparator|Sham and fatigue|This group will receive the sham form of tDCS.
89553715|NCT05097443|Experimental|Orelabrutinib+R+chemotherapy|Orelabrutinib+R-CHOP;Orelabrutinib+R-DA-EPOCH;Orelabrutinib+R-HD MTX；Orelabrutinib+R+other regimens
89553716|NCT02285621|Experimental|Optimized brace|Test group: Patient will receive optimized brace (3D computer assisted design of the brace)
89553717|NCT02285621|Active Comparator|Standard brace|Control goup: Patient will receive the Boston Thoracolumbosacral orthosis (TLSO) (conventional design method)
89553718|NCT00197873|Active Comparator|Lactophilus|Lactophilus supplementation
89553719|NCT00197873|Placebo Comparator|Placebo|Placebo is administered during chemotherapy.
89553720|NCT03114085|Experimental|Apatinib Combined with Capecitabine|Apatinib,500mg,once a day, orally (after breakfast),from day 1 to day 21 (including day 21) for continuous administration, every 21 days for one cycle. If after two dose adjustments, the subject still can not tolerate toxicity, he or she should be out of group; Capecitabine,1000mg/m2,twice a day (at intervals of 12 hours,equivalent to a total daily dose of 2000 mg / m2),orally,sustained 14 days, off for 7 days, every 21 days for a cycle. If after two dose adjustments, the subject still can not tolerate toxicity, he or she should be out of group.
89553721|NCT03114085|Active Comparator|Apatinib|Apatinib,500mg,once a day, orally (after breakfast),from day 1 to day 21 (including day 21) for continuous administration, every 21 days for one cycle. If after two dose adjustments, the subject still can not tolerate toxicity, he or she should be out of group;
89553722|NCT04854317||Patients undergoing adjustable or nonadjustable fluid-filled intragastric balloon placement|Obese patients with obesity (BMI >30 kg/m2) and previous multiple failed attempts of diet.
89553723|NCT04854317||Patients undergoing Endoscopic Sleeve Gastroplasty|Obese patients with obesity (BMI >30 kg/m2) and previous multiple failed attempts of diet.
89553724|NCT04854317||Patients undergoing Endoluminal Vertical Gastroplasty|Obese patients with obesity (BMI >30 kg/m2) and previous multiple failed attempts of diet.
89553725|NCT04854317||Patients undergoing Primary Obesity Surgical Endolumenal 2|Obese patients with obesity (BMI >30 kg/m2) and previous multiple failed attempts of diet.
89553726|NCT04440553|Active Comparator|Uniform random|In this arm the types of messages were sent out randomly, i.e. with a uniform random distribution.
89553727|NCT04440553|Experimental|Reinforcement learning|In this arm the types of messages were chosen by a reinforcement learning algorithm. The decision about which message to send was based on several contextual variables, including data for the pedometer app, and consecutive days since messages from different categories were sent.
89553728|NCT03114631|Experimental|Dendritic cells lysate-pulsed group|Patients treated according to clinical protocols plus autologous dendritic cells, pulsed with tumor lysate
89553729|NCT03114631|No Intervention|Control group|Patients treated according to clinical protocols
89553730|NCT03114631|Experimental|Dendritic cells peptide-pulsed group|Patients treated according to clinical protocols plus autologous dendritic cells, pulsed with MUC-1/WT-1 peptides
89553731|NCT03162835||Educated group|Children within this group will receive Pain Neuroscience Education.
89553732|NCT03162835||Non-educated group|Children within this group will not receive Pain Neuroscience Education
89553733|NCT04918511|Experimental|Dose cohort 1|In dose cohort 1, treatment with OPD5 solution will be given as one single i.v. infusion over 30 minutes at a dose level of 30 mg/m2 (dose based on body surface area)
89553734|NCT04918511|Experimental|Dose cohort 2|In dose cohort 2, treatment with OPD5 solution will be given as one single i.v. infusion over 30 minutes at a dose level decided based on the results from Dose Cohort 1
89553735|NCT04918511|Experimental|Dose cohort 3|In dose cohort 3, treatment with OPD5 solution will be given as one single i.v. infusion over 30 minutes at a dose level decided based on the results from Dose Cohort 2
89553736|NCT04918511|Experimental|Dose cohort 4|In dose cohort 4, treatment with OPD5 solution will be given as one single i.v. infusion over 30 minutes at a dose level decided based on the results from Dose Cohort 3
89553737|NCT04918511|Experimental|Dose cohort 5|In dose cohort 5, treatment with OPD5 solution will be given as one single i.v. infusion over 30 minutes at a dose level decided based on the results from Dose Cohort 4
89553738|NCT04918511|Experimental|Dose cohort 6|In dose cohort 6, treatment with OPD5 solution will be given as one single i.v. infusion over 30 minutes at a dose level decided based on the results from Dose Cohort 5
89553739|NCT04918511|Experimental|Dose cohort 7|In dose cohort 7, treatment with OPD5 solution will be given as one single i.v. infusion over 30 minutes at a dose level decided based on the results from Dose Cohort 6
89553740|NCT03162757|Experimental|Subclavian vein access|
89553741|NCT03162757|Experimental|Internal jugular vein access|
89553742|NCT03162991|Experimental|12-Week Aerobic Exercise Intervention|
89553743|NCT03162991|No Intervention|12-Week Control Period|
89553744|NCT03163069|Experimental|Conventional Whitening dentifrice|in-office bleaching with the conventional whitening dentifrice
89553745|NCT03163069|Experimental|Whitening dentifrice containing blue covarine|in-office bleaching with the whitening dentifrice containing blue covarine
89553746|NCT03163069|Experimental|Regular dentifrice|in-office bleaching with the regular dentifrice
89553747|NCT05136599|Experimental|Study 1 (Dose-identification study), Dose 1|Challenge dose of 10^3 cfu B. pertussis in 0.2 mL (0.1 mL per naris)
89553748|NCT05136599|Experimental|Study 1 (Dose-identification study), Dose 2|Challenge dose of 5 x 10^3 CFU B. pertussis in 0.2 mL (0.1 mL per naris)
89553749|NCT05136599|Experimental|Study 1 (Dose-identification study), Dose 3|Challenge dose of 10^4 CFU B. pertussis in 0.2 mL (0.1 mL per naris)
89553750|NCT05136599|Experimental|Study 1 (Dose-identification study), Dose 4|Challenge dose of 5 x 10^4 CFU B. pertussis in 0.2 mL (0.1 mL per naris)
89553751|NCT05136599|Experimental|Study 1 (Dose-identification study), Dose 5|Challenge dose of 10^5 CFU B. pertussis in 0.2 mL (0.1 mL per naris)
89553752|NCT05136599|Experimental|Study 1 (Dose-identification study), Dose 6|Challenge dose of 5 x 10^5 CFU B. pertussis in 0.2 mL (0.1 mL per naris)
89025656|NCT00460499|Active Comparator|C High Dose GIK|This group will have high doses of insulin and glucose
89025657|NCT00460499|Active Comparator|A Insulin|This group will receive only an intravenous insulin infusion
89025658|NCT00495573||1|HSV-2 seropositive subjects who will receive a 5-day course of acyclovir for treatment of a genital herpes recurrence.
89025659|NCT00495573||2|HSV-2 seropositive subjects who will be observed during a genital herpes recurrence but not receive acyclovir.
89553753|NCT05136599|Experimental|Study 1 (Dose-identification study), Dose 7|Challenge dose of 10^6 CFU B. pertussis in 0.2 mL (0.1 mL per naris)
89025660|NCT00460538|Placebo Comparator|2|
89025661|NCT00460538|Active Comparator|1|
89025662|NCT00488787|Experimental|A|Intranasal ketamine low dose
89553754|NCT05136599|Experimental|Study 1 (Dose-identification study), Dose 8|Challenge dose of 5 x 10^6 CFU B. pertussis in 0.2 mL (0.1 mL per naris)
89553755|NCT05136599|Experimental|Study 1 (Dose-identification study), Dose 9|Challenge dose of 10^7 CFU B. pertussis in 0.2 mL (0.1 mL per naris)
89553756|NCT05136599|Experimental|Study 1 (Dose-identification study), Dose 10|Challenge dose of 5 x 10^7 CFU B. pertussis in 0.2 mL (0.1 mL per naris)
89553757|NCT03162679|Experimental|Emotion Regulation Group Therapy|Participants assigned to this condition will receive treatment immediately after assignment.
89553758|NCT03162679|No Intervention|Wait List Control|This condition is a wait-list control and receives no intervention during the study period, but is offered treatment after the final assessment directly after the treatment phase of the intervention group.
89553759|NCT03162601||Neurovascular|Patients to receive percutaneous neurovascular intervention
89553760|NCT05136521|Experimental|300 mg trazodone hydrochloride (HCl) prolonged-release tablets (new polymer)|Subjects treated with 300 mg trazodone HCl prolonged-release tablets containing a new polymer,
89553761|NCT05136521|Active Comparator|Trittico®, 300 mg trazodone HCl prolonged-release tablets (Contramid®)|Subjects treated with Trittico®, 300 mg trazodone HCl prolonged-release tablets containing Contramid®
89553762|NCT03162523||Scandinavian Prostate Cancer Group (SPCG), study number 7|Patients included in hallmark study of SPCG-7 receiving EBRT to 70 Gy in combination with lifelong anti-androgen treatment
89553763|NCT03162523||Norwegian Urologic Cancer Group (NUCG) study number 7|Patients receiving EBRT to 74 Gy in combination with hormonal therapy. Approved by ethical comittee. Questionnaires already been completed during a different study (NUCG-7). These patients will therefore not be contacted again.
89553764|NCT03330067|Sham Comparator|Cold and dry CO2 pneumoperitoneum|Pneumoperitoneum is created by insufflation of standard cold (19-21°C) and nonhumidified (0%) CO2 directly from a standard CO2 tank or wall source.
89553765|NCT03330067|Experimental|Warm and humidified CO2 pneumoperitoneum|The humidification and warming device to be used is the Insuflow Synergy Port (Lexion Company, FDA approved) which is a specialized 5 mm port that delivers warmed (95° F) and humidified (95% relative humidity) CO2, the source of which is a standard CO2 tank or wall source.
89553766|NCT05136209|Experimental|PCCC procedure without A-vit|Procedure/Surgery: PCCC procedure without A-vit ACCC + I / A + PCCC or ACCC + I / A +PCCC + IOL
89553767|NCT05136209|Active Comparator|PCCC+A-Vit procedure|Procedure/Surgery: PCCC+A-Vit procedure ACCC + I / A + PCCC + A-vit or ACCC + I / A +PCCC + IOL + A-vit
89553768|NCT05135897||Patients, depression, ECT|Patients in major depressive episode undergoing ECT
89553769|NCT05135897||Patients, depression, TMS|Patients in major depressive episode undergoing TMS
89553770|NCT05135897||Healthy|Healthy controls who do not receive ECT nor TMS but otherwise the same assessments.
89553771|NCT03850171|Experimental|ExEarly|Patients completing the exercise training concurrent to anthracycline chemotherapy treatment during months 1 to 3
89553772|NCT03850171|No Intervention|ExStandard|Patients will be encouraged to continue with their regular physical activity routine and will be medically managed as per standard of care by their Cardiologist and Oncologists.
89553773|NCT04937465||Elderly|Elderly (> 70 yrs) eligible for a short term rehabilitation
89553774|NCT04725877|Experimental|VIR-1111|
89553775|NCT04725877|Placebo Comparator|Placebo|
89553776|NCT02388529|Experimental|Low dose|
89553777|NCT02388529|Experimental|Intermediate dose|
89553778|NCT02388529|Experimental|High dose|
89553779|NCT02388529|Placebo Comparator|Placebo|
89553780|NCT02388373|Active Comparator|Seretide 250|Seretide® Evohaler® 25 microgram /50 microgram per metered dose pressurised inhalation, suspension. 25 micrograms of salmeterol (as salmeterol xinafoate) and 250 micrograms of fluticasone propionate. This is equivalent to a delivered dose (ex actuator) of 21 micrograms of salmeterol and 220 micrograms of fluticasone propionate. 2 puffs twice daily for 12 weeks Phase 1.
89553781|NCT02388373|Active Comparator|Flutiform 250|flutiform® 250 microgram/10 microgram per actuation pressurised inhalation, suspensions. 250 micrograms of fluticasone propionate and 10 micrograms of formoterol fumarate dihydrate. This is equivalent to a delivered dose (ex-actuator) of approximately 230 microgram of fluticasone propionate/9.0 microgram of formoterol fumarate dihydrate. 2 puffs twice daily for 12 weeks in Phase 1 and 12 weeks in Phase 2.
89553782|NCT02388373|Active Comparator|Flutiform 125|flutiform 125 microgram/5 microgram per actuation pressurised inhalation, suspensions. 125 micrograms of fluticasone propionate and 5 micrograms of formoterol fumarate dihydrate. This is equivalent to a delivered dose (ex-actuator) of approximately 115 microgram of fluticasone propionate/4.5 microgram of formoterol fumarate dihydrate. 2 puffs twice daily for 12 weeks in Phase 2.
89553783|NCT05231239|Active Comparator|Active tDCS|tDCS will be applied for 20 min with 2 mA
89553784|NCT05231239|Placebo Comparator|Placebo tDCS|tDCS will be applied for only 20 sec, monatge will be left on the head for 20 min
89553785|NCT02388451|Experimental|Feuerstein Program|15 subjects conforming to inclusion and exclusion criteria with a known clinical diagnosis of MCI and who provide informed consent will undergo cognitive and functional assessment to confirm the diagnosis of MCI. Baseline assessment using the Mindstreams Mild Cognitive Impairment Computerized Assessment Battery will be performed. Subjects will then participate 30 twice weekly meetings of 90 minutes duration each (for a total of 15 weeks). Mindstreams testing will be repeated after 15 sessions and at completion of the study.
89553786|NCT03239587||No Musical Intervention - Control Group|"Participants wait for 30 minutes in a standard pre-surgery waiting area without music.~Blood drawn before, and about 30 minutes after participant stands in the waiting room without music.~Participants complete 2 questionnaires about anxiety and stress levels."
89553787|NCT03239587||Musical Intervention Group|"Participants wait for 30 minutes in waiting area with a Steinway Spirio grand piano that plays 30 minutes of simulated piano music.~Blood drawn before, and about 30 minutes after participant in the waiting room with a Steinway Spirio grand piano that plays 30 minutes of simulated piano music.~Participants complete 2 questionnaires about anxiety and stress levels."
89553788|NCT01674647|Experimental|Rivaroxaban (Xarelto, BAY59-7939)|A Direct Cardioversion Strategy can be performed only if sufficient anticoagulation is proven during the last 21 days prior to randomization and/or a transesophageal echocardiogram (TEE) is planned before cardioversion. Rivaroxaban will be given for 1-5 days before planned direct cardioversion. The run-in of 1-5 days is needed due to potential pretreatment with VKA. Treatment with rivaroxaban will be continued for 42 days after the cardioversion. A Delayed Cardioversion Strategy will be chosen if sufficient anticoagulation is not proven during the last 21 days prior to randomization and no TEE is planned. Rivaroxaban will be given for at least 21 (+4) days before the planned cardioversion, to a maximum of 56 (+4) days prior to planned cardioversion.
89553789|NCT01674647|Active Comparator|Vitamin K antagonist (VKA)|A Direct Cardioversion Strategy can be performed only if sufficient anticoagulation is proven during the last 21 days prior to randomization and/or a transesophageal echocardiogram (TEE) is planned before cardioversion. VKA will be given for 1-5 days before planned direct cardioversion. The run-in of 1-5 days is needed due to potential pretreatment with VKA. Treatment with VKA will be continued for 42 days after the cardioversion. A Delayed Cardioversion Strategy will be chosen if sufficient anticoagulation is not proven during the last 21 days prior to randomization and no TEE is planned. VKA will be given for at least 21 (+4) days before the planned cardioversion, to a maximum of 56 (+4) days prior to planned cardioversion.
89553790|NCT02669407|Experimental|Regional nerve anesthesia|Regional nerve anesthesia of splanchnic nerve
89553791|NCT05135741|Experimental|pressure bio feedback|Experimental
89553792|NCT05135741|Experimental|deep cervical exercises|comparative
89553793|NCT02667457|Experimental|CAD Participants|Participants with asymptomatic or previously symptomatic with TIA only carotid atherosclerotic plaque with evidence of 50% or more carotid stenosis in one or more carotid arteries on carotid ultrasound within 2 years, received a single intravenous bolus of 350 MBq ± 10 % of 99mTc-rhAnnexin V-128 via an intraveneous (IV) catheter in an antecubital vein, followed by a saline flush on screening (Day 0).
88962201|NCT02011529|No Intervention|Treatment as usual|Participants randomized to treatment as usual will receive their usual mental health treatment and primary care treatment
88962202|NCT02011568|Other|Moderate hypothermia|Therapeutic hypothermia at 31 degrees celsius
88962203|NCT02011568|Active Comparator|Mild Hypothermia|Therapeutic Hypothermia at 34 degrees Celsius
89553794|NCT02667457|Experimental|Healthy Participants|Healthy participants with no significant carotid artery disease on carotid ultrasound, received a single intravenous bolus of 350 MBq ± 10 % of 99mTc-rhAnnexin V-128 via an IV catheter in an antecubital vein, followed by a saline flush on screening (Day 0).
89553795|NCT05135507|Experimental|An interactive stress reduction and behavioral parent training program|This feasibility evaluation will track and analyze individual program usage and examine changes in parents' psychological flexibility, parents' stress, parenting self-efficacy, parents' mindfulness and child behavior in a within subject pretest and posttest design with 50 parents of children who have DD
89553796|NCT05135429|Experimental|Bathing group|Newborn bathing will be done by the same nurse for each newborn in the study group. Since the evening hours are thought to be calmer for the baby bath, the hours between 22:00-24:00 will be chosen. Each newborn will be disinfected with only water beforehand and showered in the sinks used to wash the baby in the clinic. Bath time will be limited to two minutes. Newborns will be dried and dressed immediately after bathing. Monitor probes for monitor follow-ups and blood pressure cuffs will be connected to prevent extra touching during measurements.
89553797|NCT05135429|No Intervention|control group|Newborns in the control group will not receive any intervention. However, body temperature, pulse, respiration, systolic and diastolic blood pressure, saturation, oxygen demand and N-PASS scores will be evaluated and recorded in accordance with the measurement intervals of the newborns in the study group.
89553798|NCT05403905|Experimental|non-surgical treatment|The patient who was diagnosed with complete rupture of the ACL in the Institute of Sports Medicine of the Third Hospital of Peking University was informed by the doctor that there is a chance that the ACL may grow back after 6 weeks of strict bracing.
89553799|NCT05403905|Active Comparator|surgical treatment|"The patient who was diagnosed with complete rupture of the ACL in the Institute of Sports Medicine of the Third Hospital of Peking University was informed by the doctor that there is a chance that after 6 weeks of strict brace immobilization, the ACL may grow back without surgery. However, the choice was still made for immediate ACL reconstruction.~This group of patients underwent anterior cruciate ligament reconstruction surgery in the Third Hospital of Peking University."
89553800|NCT04893707|Experimental|CM310|"adults and teenagers (12 ~ 18 years) with weight ≥60 kg : 600mg for 1st dose, and then 300 mg, every 2 weeks and up to 1 year, SC.~teenagers (12 ~ 18 years) with weight ≥30 kg and <60kg : 400mg for 1st dose, and then 200 mg, every 2 weeks and up to 1 year, SC."
89553801|NCT02669095|Experimental|Arm 1 (Test Lens)|Subjects will be dispensed the Investigational Contact Lenses (Test) to be worn as daily wear.
89553802|NCT02669095|Active Comparator|Arm 2 (Control Lens)|Subjects will be dispensed the Marketed Contact Lenses (Control) to be worn as daily wear.
89553803|NCT04637555|Experimental|LCZ696 (sacubitril/valsartan)|Following start of treatment, patients will receive LCZ696. Possible doses are level 1, 2, and 3 (50, 100 and 200 mg twice daily respectively)
89553804|NCT02388061|Experimental|Intravenous tenecteplase (TNK)|Patients will receive intravenous tenecteplase (0.25mg/kg, maximum 25mg, administered as a bolus over ~10 seconds).
89553805|NCT02388061|Active Comparator|Intravenous tissue plasminogen activator (tPA)|Patients will receive intravenous t-PA at the standard licensed dose of 0.9 mg/kg up to a maximum of 90mg, 10% as bolus and the remainder over 1 hour.
88962204|NCT02011594|Experimental|Arm A|Nimotuzumab
88962205|NCT02011594|Placebo Comparator|Arm B|Placebo (normal saline)
88962206|NCT02011620|Active Comparator|Isosorbide-5-mononitrate|Tablet Isosorbide mononitrate 20 mg; 1 tablet to be taken daily at night for a total duration of 6 months.
88962207|NCT02011620|No Intervention|Standard care|Standard care - no intervention with nitrates
88962208|NCT02011633|Experimental|HCP1201, Part 1|Participants received a single oral dose of the HCP1201 500/10 mg under fasting condition, on Period 1(for participants randomized to Sequence 1) or on Period 2(for participants randomized to Sequence 2).
88962209|NCT02011633|Active Comparator|Metformin and Rosuvastatin, Part1|Participants received a single oral dose of coadministration of Metformin SR 500 mg and Rosuvastatin 10 mg under fasting condition, on Period 1(for participants randomized to Sequence 1) or on Period 2(for participants randomized to Sequence 2).
88962210|NCT02011633|Experimental|HCP1201, Part 2|Participants received a single oral dose of the HCP1201 500/10mg under fed condition, on Period 1(for participants randomized to Sequence 1) or on Period 2(for participants randomized to Sequence 2).
89025663|NCT00488787|Experimental|B|intranasal ketamine medium dose
89025664|NCT00488787|Experimental|C|intranasal ketamine high dose
89025665|NCT00488787|Placebo Comparator|D|placebo
89025666|NCT00460616||1|Patients already receiving treatment with cabergoline.
89025667|NCT00460616||2|healthy controls sex and age-matched with the patients
89025668|NCT00495651|Active Comparator|I|Standard of care
89025669|NCT00495651|Experimental|II|Standard of care+Isoniazid Prophylaxis:
89025670|NCT00495651|Experimental|III|Early Antiretroviral therapy
89025671|NCT00495651|Experimental|IV|Early Antiretroviral therapy + Isoniazid prophylaxis
89025672|NCT01244841|No Intervention|Standard care|Randomised to standard post MI care and length of hospital stay decided by treating physician.
89208166|NCT00860496|Other|2|Treatment Arm 2 will receive one single dose of CP-690,550 on Day 1, Cyclosporine on Days 1-6, and one single dose of CP-690,550 on Day 6.
89553806|NCT05134961||Patients undergoing resection of primary duodenal cancer|Tumors comprised histologically confirmed adenocarcinomas in the duodenum excluding adenocarcinoma of the ampulla of Vater and adenocarcinomas with gastric and pancreato-biliary morphology and immunohistochemistry.
89553807|NCT04587635|Active Comparator|PHGG fiber|PHGG Fiber
89553808|NCT04587635|Placebo Comparator|Placebo Maltodextrin|Maltodextrin
89553809|NCT02387827|Experimental|Diet+ short -term physical activity (DST)|
89553810|NCT02387827|Experimental|Diet+ long -term physical activity (DLT)|
89553811|NCT04556357|Active Comparator|Control group|Phenylephrine infusion simultaneous with subarachnoid block
89553812|NCT04556357|Experimental|Norepinephrine group|Norepinephrine infusion simultaneous with subarachnoid block
89553813|NCT02933281|Experimental|Cohort 1: MTBVAC 5 x 10^3 CFU|Quantiferon (QFT) negative, 1 dose on Day 0
89553814|NCT02933281|Experimental|Cohort 2: MTBVAC 5 x 10^4 CFU|QFT Negative, 1 dose on Day 0
89553815|NCT02933281|Experimental|Cohort 3: MTBVAC 5 x 10^5 CFU|QFT Negative, 1 dose on Day 0
89553816|NCT02933281|Experimental|Cohort 4: MTBVAC 5 x 10^6 CFU|QFT Negative, 1 dose on Day 0
89553817|NCT02933281|Experimental|Cohort 5: MTBVAC 5 x 10^3 CFU|QFT Positive, 1 dose on Day 0
89553818|NCT02933281|Experimental|Cohort 6: MTBVAC 5 x 10^4 CFU|QFT Positive, 1 dose on Day 0
89553819|NCT02933281|Experimental|Cohort 7: MTBVAC 5 x 10^5 CFU|QFT Positive, 1 dose on Day 0
89553820|NCT02933281|Experimental|Cohort 8: MTBVAC 5 x 10^6 CFU|QFT Positive, 1 dose on Day 0
89553821|NCT02933281|Active Comparator|BCG 5 x 10^5 CFU|Both QFT positive and negative, 1 dose on Day 0
89553822|NCT05134883|Experimental|Propioceptive neuromuscular facilitation (PNF)|This group will undergo a PNF stretching on the hamstring muscles.
89553823|NCT05134883|Active Comparator|self myo-fascial release (SMR)|This group will undergo a SMR stretching on the hamstring muscles.
89553824|NCT05134805|Other|BHA group|Patients will undergo Bipolar hemiarthroplasty operation
89553825|NCT05134805|Other|PFN group|Patients will undergo cehphalo-medullary fixation (Proximal femoral nail)
89553826|NCT02667301|Experimental|EMG, TAS and tympanometry|"All treatments were performed by the same group of professionals. EMG needle administration by an ENT specialist with 30+ year experience, EMG recording by a neurologist with 20+ year experience. Tympanic cavity Air exchange Sensor (TAS) recording is done by an experienced technician. The following are done to all patients:~The patient is subjected to tympanometry test on the specific ear,~The patient is subjected to TAS test on the specific ear while sipping water and signals from ear and nasal cavity recorded,~The patient is hooked up to EMG instrument and TAS test equipment simultaneously and signals are recorded by both instruments for a duration of 150-300 seconds while the patient is at rest without sipping water. The patient is allowed to swallow during the test."
89553827|NCT02803333||Data Capture Participants|This is a prospective observational cohort study of advanced non-small cell lung cancer patients (stage 3b/4) receiving treatment at the Moffitt Cancer Center (MCC) or The Ohio State Comprehensive Cancer Center (OSUCCC) to assess treatment impact at monthly intervals from baseline to 6 months post-enrollment.
88962211|NCT02011633|Active Comparator|Metformin and Rosuvastatin, Part 2|Participants received a single oral dose of coadministration of Metformin SR 500mg and Rosuvastatin 10mg under fed condition, on Period 1(for participants randomized to Sequence 1) or on Period 2(for participants randomized to Sequence 2).
88962212|NCT02011646|Experimental|Healthy Weight|intervention four times per week and consist of approximately 10 participants.
89553828|NCT04553939|Experimental|Toripalimab in Combination With Gemcitabine Therapy|
89553829|NCT03113773|Experimental|Part A|Proleukin/Placebo in patients with stable ischaemic heart disease
89553830|NCT03113773|Experimental|Part B|Proleukin/Placebo in patients with cute coronary syndromes
89553831|NCT04874831|Experimental|domatinostat and avelumab|Single arm study of Domatinostat tablets in combination with avelumab infusion
89553832|NCT04454879|Experimental|standard roxadustat dosage group|Peritoneal dialysis patients diagnosed with renal anemia will receive standard dosage of roxadustat according to weight.
89553833|NCT04454879|Experimental|lower roxadustat dosage group|Peritoneal dialysis patients diagnosed with renal anemia will receive lower dosage of roxadustat according to weight.
89553834|NCT05122169|Experimental|chlorhexidine|Pre-vaginal delivery skip prep using chlorhexidine-alcohol
89553835|NCT05122169|Active Comparator|Povidone-iodine|Pre-vaginal delivery skip prep using Povidone-iodine
89553836|NCT04387955|Other|Acrovid|Cohort
89553837|NCT04359329|Experimental|Active|Estradiol Patch
89553838|NCT04359329|No Intervention|Control|No intervention
89553839|NCT04494035|Experimental|AVATR-Toronto|Thrombectomy of arteriovenous graft using CAPERE Thrombectomy System
89553840|NCT03041285|Experimental|Group 1 NOX66 400mg and SBRT|Group 1 patients will receive 400mg of Idronoxil (NOX66) suppository (1 suppository) daily from Day 0 (1 day before radiotherapy) until 7 days after completion of radiotherapy. Stereotactic Body Radiation Therapy will be given on Days1-5 (5 fractions). Total treatment course is 13-15 days, depends on whether radiotherapy is given on consecutive days or over the weekend.
89553841|NCT03041285|Experimental|Group 2 NOX66 800mg and SBRT|Group 2 patients will receive 800mg of Idronoxil (NOX66) suppository (2 suppositories) daily from Day 0 (1 day before radiotherapy) until 7 days after completion of radiotherapy. Stereotactic Body Radiation Therapy will be given on Days1-5 (5 fractions). Total treatment course is 13-15 days, depends on whether radiotherapy is given on consecutive days or over the weekend.
89553842|NCT04794023|Experimental|Intervention_Corneal Ablation|
89553843|NCT04256681|Experimental|patients affected by hereditary spastic paraplegia|40 subjects affected by genetically determined hereditary spastic paraparesis or subjects without defined genetics but who unequivocally show a dominant or recessive familiarity with exclusive involvement of the pyramidal system.
89553844|NCT04256681|Active Comparator|healthy subjects|40 healthy subjects will also be recruited to whom the questionnaire will be submitted to assess the variability of the score within a healthy population.
89553845|NCT04766645||Covid patients|Inpatients and outpatients admitted to the investigators' rehabilitation facility with covid symptoms
89553846|NCT05301725||PPI group|PPI regimen
89553847|NCT05301725||P-CAB group|P-CAB regimen
89553848|NCT05301647||Active Group|
89553849|NCT05301647||Control Group|
88962213|NCT02011646|Active Comparator|Controlled Intervention|Participants will be given a copy of the DVD. They will also be given the choice to stream it free on the web.
88962214|NCT02011659|Active Comparator|Ramosetron|
88962215|NCT02011672|Experimental|nutrient-enriched milk|consumption of 250 ml three times per day
88962216|NCT02011672|Placebo Comparator|regular milk|consumption of 250 ml three times per day
88962217|NCT02011698|Experimental|absorbable sutures|mesh fixation with absorbable sutures in lichtenstein anterior inguinal herniorrhaphy
88962218|NCT02011698|Active Comparator|non absorbable sutures|mesh fixation with non absorbable sutures in lichtenstein anterior inguinal herniorrhaphy. This is the method to be considered the standard of care thus far.
88962219|NCT02011698|Experimental|fibrin biological glue|mesh fixation with fibrin biological glue in lichtenstein anterior inguinal herniorrhaphy
88962220|NCT02011711||Mirena|Women interested in beginning use of Mirena
88962221|NCT02011711||Depot-medroxyprogesterone acetate|Women interested in beginning use of depot-medroxyprogesterone acetate
88962222|NCT02011711||Oral Contraception|Women interested in beginning use of oral contraception
88962223|NCT02011724|Experimental|Apligraf|
88962224|NCT02011737|Active Comparator|Naftopidil|Naftopidil 75mg once daily
88962225|NCT02011737|Placebo Comparator|Placebo|Placebo once daily
88962226|NCT02011750|Experimental|Sodium Valproate treatment|Sodium Valproate treatment:During the entry period, all patients will have a placebo run-in for two weeks after which they will be evaluated for the outcome variables and then randomized to either Sodium Valproate (Depakote, DEP) or placebo (PLA) group in a 1:1 proportion. For the Sodium Valproate treatment grou, this will be followed by a two week period to adjust the dose of DEP and attain therapeutic levels (50-100 µg/mL). Then DEP treatment will continue for 16 more weeks, after which DEP will be discontinued. Subject will be followed up for four weeks post-DEP discontinuation to monitor delayed adverse side effects.
88962227|NCT02011750|Placebo Comparator|Placebo|Placebo Comparator: During the entry period, all patients will have a placebo run-in for two weeks after which they will be evaluated for the outcome variables and then randomized to either the experimental Sodium Valproate (Depakote, or DEP) or placebo (PLA) group in a 1:1 proportion. For the PLA group, this will be followed by a two week period of placebo during which members of the experimental Sodium Valproate (Depakote/DEP) will have DEP dose adjusted to attain therapeutic levels (50-100 µg/mL). Then PLA treatment will continue for 16 more weeks. Subjects will be followed up for four weeks post PLA-discontinuation to monitor for delayed adverse side effects.
88962228|NCT02011763|Experimental|Study Group|Toddlers, children and adolescents aged 12 months to 15 years
88962229|NCT02011776||Group 1|using the 0.1% fluorometholone eye drops combined with the 0.1% sodium hyaluronate eye drops
88962230|NCT02011776||Group 2|using the 0.5% cyclosporin A eye drops combined with 0.1% sodium hyaluronate eye drops
88962231|NCT02011789|Experimental|Group1|Group 1 consumes Placebo beverage for 56 days followed by Citrus Limonoid Beverage for 56 days.
88962232|NCT02011789|Active Comparator|Group 2|Group 2 consumes Citrus Limonoid Beverage for 56 days followed by Placebo beverages for 56 days
88962233|NCT02011802|Active Comparator|Algosteril TM|Calcium alginate dressings are made from seaweed. Calcium alginate dressings form a natural gel of the exudates against the healing tissue that keeps it moist and supple, aiding in healing and tissue growth. In addition, this gel material forms a natural barrier to bacteria that may complicate healing with secondary infections of the wound. Alginates are the reference of dressing after sinus pilonidal excision.
88962234|NCT02011802|Experimental|Sorbact TM|DACC (dialkylcarbamoyle chloride) is a main component of the bacterial binding wound dressing: Sorbact. DACC is a hydrophobic fatty acid derivative that can be used to coat dressing materials, resulting in a dressing with highly hydrophobic pathogen binding properties. This is a primary wound interface dressing and is effective when in close contact with the wound bed in a moist environment.
88962235|NCT02011815||Breast cancer|Diagnosed breast cancer patients who are getting chemotherapy for the first time.
88962236|NCT02011828|Experimental|Ergocalciferol, then Placebo|Participants first receive Ergocalciferol 50,000 international units (IU)/week for the first 12 weeks. After a 4 week wash-out period, they then receive matching placebo treatment for 12 weeks.
88962237|NCT02011828|Experimental|Placebo, then Ergocalciferol|Participants first receive placebo treatment (matching ergocalciferol 50,000 IU/week) for the first 12 weeks. After a 4 week wash-out period, they then receive ergocalciferol 50,000 IU/week treatment for 12 weeks.
88962238|NCT02011841|Experimental|Rifaximin group|Rifaximin 1200 mg/day orally for 6 months
88962239|NCT02011841|Active Comparator|Control group|Ciprofloxacin 500 mg/day orally for 6 months
88962240|NCT02011854|Experimental|Acupuncture with rehabilitation|Electric acupuncture,Chinese medicine,Chinese medicine cupping,rehabilitation,To treat five times a week,Total course is eight weeks
88962241|NCT02011854|Other|rehabilitation|rehabilitation,To treat five times a week,Total course is eight weeks
88962242|NCT02011867|Experimental|Cork Electrode|Using Cork Electrode for CSF leak prevention for inner ear malformations.
88962243|NCT02011906|Active Comparator|CAD, OMEGA 3|patients with CAD who receive 4 gr/day omega 3 in the form of 4 softgels each of them contains 1000 mg omega 3 and a softgel contains placebo of vitamin E
88962244|NCT02011906|Active Comparator|CAD, omega 3 and vitamin E|patients with CAD who receive 4 gr/day omega 3 in the form of 4 softgels each of them contains 1000 mg omega 3 and a softgel contains 400 IU vitamin E
88962245|NCT02011906|Placebo Comparator|CAD, placebo|patients with CAD who receive 4 softgels/day each of them contains placebo of omega 3 and a softgel/day contains placebo of vitamin E
88962246|NCT02011919|Other|Echopulse|Echopulse HIFU
88962247|NCT02011932||Healthy volunteers|
88962248|NCT02011932||Chronic hepatitis C|
88962249|NCT02011958|Experimental|Liposomal Amphotericin B / Miltefosine|"Liposomal Amphotericin B : 30mg/kg total dose: IV infusion 5mg/kg per day on day 1, 3, 5, 7, 9, 11~Miltefosine: orally taken every day during 28 days~1 x 50 mg capsule per day if patient weights less or equal to 25 kg~2 x 50 mg capsules per day if the patient weights more than 25 kg"
88962250|NCT02011958|Experimental|Liposomal Amphotericin B|Liposomal Amphotericin B: 40 mg/kg total dose : IV infusion of 5mg/kg per day on day 1 to 5, 10, 17, 24
88962251|NCT02011984||peripheral artery disease|de novo stenotic lesions in superficial femoral artery
89553850|NCT04412759|No Intervention|Porcine xenograft|porcine xenograft derived from dermal porcine skin. Standard of care treatement for partila thickness burn at the specfic centre
89553851|NCT04412759|Experimental|Microbial cellulose|Novel dressing consisting of a biopolymer spun by the bacteria Acetobacter xylinum (later removed).
89553852|NCT04203875|Experimental|Orencia® (Abatacept)|Abatacept 125 mg, subcutaneous once a week for 6 months or up to one year if subject has a favorable response
89553853|NCT05283785||( group 1)|End to End sutures
89553854|NCT05283785||( group 2 )|End to Side sutures
89553855|NCT04491461|Active Comparator|Herbal tea blend|1 cup of herbal tea blend containing Rosehip and other berry extracts.
89553856|NCT04491461|Sham Comparator|Warm water|1 cup of warm water.
89553857|NCT04151927|Experimental|Normobaric Hypoxia (NH)|Overnight exposure (8 hours) to NH conditions (~15% oxygen; achieved with nitrogen dilution, equivalent to ~8500 feet elevation) using a commercially available tent and generator system (Hypoxico, Inc., New York, NY).
89553858|NCT04151927|Sham Comparator|Normobaric Normoxia (NN)|Overnight exposure (8 hours) to NN conditions (~20% oxygen; achieved with nitrogen dilution, equivalent to ~1000 feet elevation) using a commercially available tent and generator system (Hypoxico, Inc., New York, NY).
89553859|NCT04142645|Experimental|Intervention|The intervention group (i.e. all eligible and consented residents of 2 NHs) will receive the OptiMEDs intervention: the combination of an electronic decision support tool (for the appraisal of potentially inappropriate medication use, anticholinergic use, or medications that can be de-prescribed in view of limited life expectancy) with focused nurse observations (using a list of potential medication-related symptoms based on the individual medication chart of the nursing home residents), that will serve as the basis during a multidisciplinary medication review with the input of GPs, trained community pharmacists and nurses.
89553860|NCT04142645|No Intervention|Control|The control group (i.e. all eligible and consented residents of one control NH) will receive usual care .
89553861|NCT05900687|No Intervention|Focus Group (Aim 1)|Participants give feedback about day-to-day challenges with GERD.
89553862|NCT05900687|No Intervention|Focus Group (Aim 2)|Participants give feedback about mobile health app prototype
89553863|NCT05900687|Experimental|mHealth app (Aim 3)|Participants will be exposed to an app-based question prompt list with gamification features to promote medication adherence as part of their communication with their health provider.
89553864|NCT05900687|No Intervention|Standard of care (Aim 3)|Participants will be exposed to standard of care communication with their health provider (no mHealth app).
89553865|NCT05900674|Active Comparator|IV thrombolysis|Local institutional IV thrombolysis: IV alteplase (0.9 mg/kg) or IV Tenecteplase (TNK) (0.25 mg/kg) according to local institutional practice.
89553866|NCT05900674|Experimental|IV reteplase (9 U bolus)|
89553867|NCT05900674|Experimental|IV reteplase (9 U bolus+9 U bolus)|
89553868|NCT05900661|Experimental|myo-inositol|will recive Inofolic (myo-inositol 600µgm + folic acid 0.2 mg) 2 capsules at the morning and 2 capsules at the evening on empty stomach for 12 weeks
89553869|NCT05900661|Experimental|Somatropin|Somatropin (4 IU for 1month), SEDICO ,6th of october .Egypt. 1 s.c injection every 3 days for at least 1 month.
89553870|NCT05900661|Experimental|Dehydroepiandrosterone|DHEA 50 mg twice per day for 12 weeks in the last group , NATROL UK.Ltd.
88962252|NCT02011997|Experimental|segmentectomy|Patients undergo cVATS (complete Video-assisted Thoracoscopic Surgery) segmentectomy
89553871|NCT05900635|Experimental|Control|Patients in this group will initiate treatment with oral ferrous glycine sulfate (100mg) every other day for 3 months
89553872|NCT05900635|Active Comparator|Intervention|Patients in this group will initiate treatment with oral lactoferrin (one sachet that contains 100mg) with oral ferrous glycine sulfate (100mg) every other day for 3 months
89553873|NCT05900622|No Intervention|Control group|Lower extremity on the puncture side with a 4-hour brake+Get out of bed after 8 hours
89553874|NCT05900622|Experimental|Test group A|Lower extremity on the puncture side with a 2-hour brake+Get out of bed after 4 hours
89553875|NCT05900622|Experimental|Test group B|No braking of the lower limb on the side of the puncture+Get out of bed after 2 hours
89553876|NCT05900583||MRD positive group|
89553877|NCT05900583||MRD negative group|
89553878|NCT05900557|Experimental|ECoG monitoring|Patients undergoing standard of care surgical evacuation of cSDH. will have subdural ECoG monitoring electrode placed crossing frontal and temporal lobes for 1-5 days of post operative monitoring. All subjects will undergo long term followup testing.
89553879|NCT05900544|Experimental|Implementation|New lung cancer screening participants with clinically significant incidental findings received new patient-centered report
89553880|NCT05900531|Experimental|K-757 (Panel A)|
89553881|NCT05900531|Experimental|K-757 (Panel B)|
89553882|NCT05900531|Experimental|K-757 + sitaglipitin (Panel C)|
89553883|NCT05900531|Experimental|K-757 and K-833 (Panel D)|
89553884|NCT05900531|Experimental|K-757 and K-833 (Panel E)|
89553885|NCT05900531|Placebo Comparator|Panel A|
89553886|NCT05900531|Placebo Comparator|Panel B|
89553887|NCT05900531|Placebo Comparator|Panel C (+ sitagliptin)|
89553888|NCT05900531|Placebo Comparator|Panel D|
88962253|NCT02011997|Active Comparator|Lobectomy|Patients undergo cVATS lobectomy
88962254|NCT02012010|Experimental|Manual syringe infusion method|Infuse the distension medium of hysteroscopy by manual syringe infusion method
89208167|NCT00864162|Experimental|A|Ramipril10 mg Capsules, single dose
89553889|NCT05900531|Placebo Comparator|Panel E|
89553890|NCT05900440|Experimental|Artificial Intelligence Group|
89553891|NCT05900440|Active Comparator|Non Artificial Intelligence Group|
89553892|NCT05900414|Experimental|Intervention|Receives web-based information and access to patient decision aid before clinic visit
89553893|NCT05900414|Active Comparator|Control|Receives web-based information only before clinic visit
89553894|NCT05900349|Experimental|Carbohydrate mouth rinsing|Rinsing mineral water for 20 seconds
89553895|NCT05900349|Experimental|caffeine gum|placebo gum chewing for 10 min
89553896|NCT05900323|Experimental|Enteral Nutrition Guidelines Group|It will include 34 patients who will receive enteral nutrition guidelines.
89553897|NCT05900323|No Intervention|Routine Enteral Nutrition Unit Care Group|It will include 34 patients who will receive routine enteral nutrition unit care.
89553898|NCT05900219|Experimental|Assigned Interventions|The treatment regimen was HL-085 9mg BID+ Vemurafenib 720mg BID oral administration
89553899|NCT05900193|Experimental|Participants receiving oral glucose tolerane tests with TAS1R agonists|Participants received a standard oral glucose tolerance test alone and with the addition of the TAS1R2/3 agonist sucralose in admixture
89553900|NCT05900193|Experimental|Participants receiving oral glucose tolerane tests with TAS1R antagonists|Participants received a standard oral glucose tolerance test alone and with the addition of the the TAS1R2/3 antagonist lactisole in admixture
89553901|NCT05900167||enteral nutrition group|
89553902|NCT05900102||Melanoma of the head and neck|
89553903|NCT05900102||Melanoma of the trunk, arms, or legs|
89553904|NCT05900089|Experimental|SHR0302 Group A|
89553905|NCT05900089|Experimental|SHR0302 Group B|
89553906|NCT05900089|Experimental|SHR0302 Group C|
89553907|NCT05900024|Experimental|Cycle Bites|Participants will consume 1 Cycle Bite per day.
89553908|NCT05900011||Patients in the pediatric population with eosinophilic eosphagitis|Patients in the pediatric population with eosinophilic eosiphagitis responding to the PedsQL eosinophilic eosophagitis module
89553909|NCT05899959||Patients receiving an EKG holter|
89553910|NCT05899959||Patients receiving an automatic blood pressure cuff|
89553911|NCT05899946|Other|pre- and post-educational group|This project will deliver an integrated program by nursing students with robots to clarify the misunderstanding about cannabis among parents and their children in Hong Kong
89553912|NCT05899920|Active Comparator|Controlled arterial hypertension|"Controlled arterial hypertension according the results of 24-hour blood pressure monitoring.~Blood samples will be taken for pharmacokinetics and pharmacogenetics"
89553913|NCT05899920|Experimental|Uncontrolled arterial hypertension|"Uncontrolled arterial hypertension according the results of 24-hour blood pressure monitoring.~Blood samples will be taken for pharmacokinetics and pharmacogenetics"
89553914|NCT05899907|Experimental|Treatment group|Standard of care plus Telitacicept 160 mg sc per week; after week 12, the dose can be reduced to 80 mg per week due to safety considerations.
89553915|NCT05899907|Other|Control group|Standard of care
89553916|NCT05899894|Active Comparator|A - Low dose morphine|Low dose morphine 5mcg/kg/hr
89553917|NCT05899894|Active Comparator|B- standard dose morphine|Standard dose morphine 20mcg/kg/hr
89553918|NCT05899855||Group 1|30 subjects with rigid flatfoot and chronic ankle instability
89553919|NCT05899855||Group II|30 subjects with flexible flatfoot and chronic ankle instability
89553920|NCT05899842|Experimental|Systematic protein pump inhibitor therapy|
89553921|NCT05899842|No Intervention|Protein pump inhibitor therapy as necessary|
89553922|NCT05899803|Experimental|Using Walker Group|Children who used baby walkers during childhood were included in this group. All assessment procedures were then performed.
89553923|NCT05899803|Active Comparator|Walker-Free Group|Children who did not use a baby walker during childhood were included in this group. All assessment procedures were then performed.
89553924|NCT05899790|No Intervention|Control Group|Forty patients who received standard care in the pre-abdominal surgery clinic and preoperative waiting area will form the control group.
89553925|NCT05899790|Experimental|intervention group|In addition to standard care, 40 patients who were informed about the SG application and the operating room environment will form the intervention group.
89553926|NCT05899777|Experimental|Treatment group|After proficiently mastering the complete set of Yizhi Baduanjin, the practice group is required to practice sitting posture of YizhiBaduanjin twice a day and standing posture of YizhiBaduanjin once every two days.
89553927|NCT05899777|No Intervention|control group|The control group is a waiting control group, and after 24 weeks, they will continue to learn the Yizhi Baduanjin.
89553928|NCT05899764|Experimental|BRIV Experimental|25 subjects with MCI or AD who meet inclusion criteria will receive the drug: brivaracetam. A scalp EEG will record their brain activity for 6 days at the hospital. On nights 4 and 5, we will intravenously administer brivaracetam. Doses will vary depending on their effects on epileptic activity. We will determine whether brivaracetam 25 mg IV suppresses the number of epileptic events and pHFOs by >50%, which is analogous to our preclinical investigations with this drug in AD models. If the 50% suppression is reached, the same dosage will be repeated the following night to ensure reproducibility. If the 50% suppression is not reached, then the dosage of brivaracetam will be increased to 50 mg the following night. Once the depth electrode is surgically removed, subjects will go home with a supply of brivaracetam. They will take the drug for 12 months.
89553929|NCT05899751||Patients Treated With High-dose Methotrexate|Patients with a diagnosis of any cancer receiving high-dose methotrexate chemotherapy.
89553930|NCT05899712|Active Comparator|Group A|Digitally obtained altered cast for construction of mandibular free end saddle removable partial denture
88812160|NCT05945758|Experimental|Spacing in the maxillary anterior teeth area treated with injectable resin composite technique.|"The injectable composite resin technique is an indirect/direct method that uses a transparent silicone index for accurate and predictable translation of diagnostic wax-up into composite restorations without the need for tooth preparation.~The Spaces will be restored with injectable resin composite."
88962255|NCT02012010|Active Comparator|Pump infusion method|Infuse the distension medium of hysteroscopy by pump infusion method
89553931|NCT05899712|Active Comparator|Group B|Conventionally obtained altered cast for construction of mandibular free end saddle removable partial denture
89553932|NCT05899686|Experimental|Tetanic Stimulus|all participants receive the same intervention
89553933|NCT05899660|Placebo Comparator|Olive oil|Dosage form : capsule Dosage : 1000 mg oleic acid (olive oil) + 3.6 mg D-α-tocopherol (vitamin E) Frequency : 4 capsules per day Duration : 3 months
89553934|NCT05899660|Active Comparator|Omega-3|Dosage form : capsule Dosage : 330 mg EPA, 220 mg DHA, 100 mg other n-3 PUFA + 3.6 mg D-α-tocopherol (vitamin E) Frequency : 4 capsules per day Duration : 3 months
89553935|NCT05899621||GR|Induction(six 21-day cycles): obinutuzumab (G), 1000mg, IV, D1/8/15 (C1), D1 (C2-6); lenalidomide (R), 25mg, PO, D2-11; Maintenance: obinutuzumab (G), 1000mg, every 3 months for 2 years; lenalidomide (R), 25mg, PO, D1-10, every 28 days for 6 cycles
89553936|NCT05899621||GB|Induction(six 21-day cycles): obinutuzumab (G) 1000mg, IV, D1/8/15 (C1), D1 (C2-6); bendamustine (B), 90 mg/m2, IV, D1-2; Maintenance: obinutuzumab (G), 1000mg, IV, every 3 months for 2 years
89553937|NCT05899621||GCHOP|Induction(six 21-day cycles): obinutuzumab (G), 1000mg, IV, D1/8/15 (C1), D1 (C2-6); prednisone (P), 100 mg, PO, D1-5；cyclophosphamide (C), 750 mg/m2, IV, D1; vincristine (O), 1.4 mg/m2 (maximum 2 mg), IV, D1; doxorubicin (H), 50 mg/m2, IV, D1; Maintenance: obinutuzumab (G), 1000mg, IV, every 3 months for 2 years
89553938|NCT05899517|Experimental|Oral oxytocin then placebo|Subjects will first receive oral lollipop with oxytocin (24IU). After a washout period of 2 weeks, they will then receive oral lollipop with placebo (identical ingredients, except the active agent).
89553939|NCT05899517|Experimental|Oral placebo then oxytocin|Subjects will first receive oral lollipop with placebo (identical ingredients, except the active agent). After a washout period of 2 weeks, they will then receive oral lollipop with oxytocin (24 IU).
89553940|NCT05899504|Experimental|(Interventional) Patients undergoing Esophageal stenting with over the scope clip (OTSC) stent fix|Marking clips will be placed with endoscopy at the upper end of the stricture. In mild stricture cases that allowed the passage of the endoscope, marking clips will also placed in the lower end. A stent that of at least 4 cm longer than the stricture will be used to allow at least a 2-cm extension above and below the proximal and distal tumor margins. The stent positioned over a guidewire and deployed under fluoroscopy guidance and, in some cases, also under endoscopy guidance. Subsequently, the OTSC system will be loaded onto the scope and part of the upper rim of the stent will be suctioned into the transparent cap before releasing the OTSC, grasping both the SEMS and esophageal wall. Investigator will avoid deploying the OTSC in areas of pulsations to prevent potential grasping of the vasculature structure. Only a single OTSC will be placed per participants.
89553941|NCT05899504|No Intervention|(Non- Interventional) Participants undergoing Esophageal stenting without OTSC stent fix|This will be the standard procedure of esophageal stent placement under fluro imaging/screening
89553942|NCT05899491|Active Comparator|ARMA Group|All patients in this group will undergo Anti-reflux mucosal ablation using upper gastrointestinal endoscopy. The stomach will be insufflated with CO2 to visualize the cardia in retroflex view.
89553943|NCT05899491|Sham Comparator|Sham Group|UGI Endoscopy will be performed under Propofol based sedation with scope kept inside for at least 5 minutes.
89553944|NCT05899478|Experimental|Tyknot® Suture-Mediated Closure System|Arterial closure device used is Tyknot® Suture-Mediated Closure System
89553945|NCT05899478|Active Comparator|Perclose® ProGlide Suture-Mediated Closure System|Arterial closure device used is Perclose® ProGlide Suture-Mediated Closure System
89553946|NCT05899400||Study Group|400 Male and Female Ugandan Africans
89553947|NCT05899374|Experimental|Experimental KindMap Group|Participants in the experimental group will register, complete the baseline assessment and have immediate access to the KindMap web app.
89553948|NCT05899374|No Intervention|Wait-list Control Group|Participants in the WL-CG will complete the baseline assessment and will be able to register and have access to the KindMap web app 10 weeks later.
89553949|NCT05899348|Experimental|iTEST|
89553950|NCT05899322|Experimental|Primary Care Intervention for PTSD (PCIP) Spanish Speaking Adolescents and Families|This arm will receive the culturally adapted and translated PCIP intervention lasting from 1-3 weeks, and will complete baseline, post treatment, and 1-month follow up assessments.
89553951|NCT05899322|Active Comparator|Waitlist Treatment as Usual|Receive standard care treatment and will complete baseline, post treatment, and 1-month follow up assessments, and are offered translated and adapted PCIP treatment after conclusion of the study.
89553952|NCT05899309||Liver cirrhosis with metabolic syndrome|Liver cirrhosis patients with metabolic syndrome on standard treatment
89553953|NCT05899309||Liver cirrhosis without metabolic syndrome|Liver cirrhosis patients without metabolic syndrome on standard treatment
89553954|NCT05899296|Active Comparator|Traditional syringe|Dental anesthesia delivered by a traditional syringe
89553955|NCT05899296|Experimental|NumBee|Dental anesthesia delivered by a novel needle-less syringe
89553956|NCT05899283|Experimental|Group A(OCI-HF160+FX800HDF)|Group A first used the hemodialysis filter OCI-HF160, then used FX800HDF.
89553957|NCT05899283|Experimental|Group B(FX800HDF+OCI-HF160)|Group B first used the hemodialysis filter FX800HDF, and then used OCI-HF160.
89553958|NCT05899270|Experimental|3D group|In 3D group, the investigator will intubate using DLT chosen by an automatic comparison software for 3D reconstruction based on CT data (3DRACS).
89553959|NCT05899270|Placebo Comparator|control group|In control group, the size of DLT is based on patient's sex and weight and the height is used to guide the depth of DLT insertion.
89553960|NCT05899088|No Intervention|Control Arm|Patients follow-up as normal with physician. Recommended by physician to engage in physical activity 4x/w. No other intervention or follow-up.
89553961|NCT05899088|Experimental|Study Arm|Patients engage in weekly exercise program as recommended by the study. Researchers follow up weekly with patient to assess progress. Complete surveys at beginning and end.
89553962|NCT05899075|Experimental|group A|
89553963|NCT05899075|Placebo Comparator|group B|
89553964|NCT05899062|Other|Control group|"The patients in the control group will be given education about constipation, which lasts about 45-60 minutes, with the telerehabilitation method. In addition, a Constipation Training Booklet will be sent via e-mail or WhatsApp, related to the training content given to all patients and to reinforce the training. Definition of constipation in education, its causes, medications that cause constipation, risk factors, suggestions for prevention of constipation (such as regular defecation, not delaying defecation, best position for defecation, not straining for a long time), constipation treatment and the importance of individual management, healthy and balanced diet, nutrition Types, adequate fluid intake, benefits of exercise and appropriate exercise selection, abdominal massage, toilet training and individual methods of preventing constipation will be included."
89553965|NCT05899062|Other|Intervention group|The patients in intervention group will be given an exercise program in addition to all the practices in the control group. Training and exercise practices will be carried out with the telerehabilitation method. Exercise training, which will last 40-60 minutes, 3 days a week for 6 weeks, will consist of warm-up and breathing exercises, exercises for constipation and cooling movements. Patients will be asked to walk for at least 30 minutes, 2 days a week, on days without exercise training.
89553966|NCT05898997|Experimental|Normal (Visual Field Defects: >-2.00 dB)|Do the formal acupressure
89553967|NCT05898997|Experimental|Mild (Visual Field Defects: -2.00~-6.00 dB)|Do the formal acupressure
89553968|NCT05898997|Experimental|Moderate (Visual Field Defects: -6.01~-12.00 dB)|Do the formal acupressure
89553969|NCT05898997|Experimental|Severe (Visual Field Defects: -12.01~-20.00dB)|Do the formal acupressure
89553970|NCT05898997|Experimental|Profound (Visual Field Defects: <-20 dB)|Do the formal acupressure
89553971|NCT05898984|Experimental|single dose of CHF 5993 BDP/FF/GB 200/6/12.5 µg pMDI (T)|CHF 5993 BDP/FF/GB 200/6/12.5 µg via pressurized metered dose inhaler: 4 inhalations alternated with 4 inhalations of CHF 5993 placebo, corresponding to 8 inhalations in total and giving a total daily dose (TDD) of BDP/FF/GB: 800/24/50 µg.
89553972|NCT05898984|Active Comparator|single dose of CHF 5993 BDP/FF/GB 100/6/12.5 µg pMDI (R1)|CHF 5993 BDP/FF/GB 100/6/12.5 µg via pressurized metered dose inhaler: 4 inhalations alternated with 4 inhalations of CHF 5993 placebo, corresponding to 8 inhalations in total and giving a TDD of BDP/FF/GB: 400/24/50 µg.
89553973|NCT05898984|Active Comparator|Single dose of BDP HFA (QVAR REDIHALER®, BDP 80 μg) (R2)|BDP HFA (QVAR REDIHALER®, BDP 80 μg): pressurised, breath-actuated, metered dose aerosol with a dose counter): 8 inhalations (TDD of BDP: 640 µg ex-actuator, 800 µg ex valve).
89553974|NCT05898958|No Intervention|I.v morphine infusion|A loading i.v. dose of 0.15 mg/kg morphine sulphate diluted in 10 ml of normal saline was given slowly over4-5 min. Then, the morphine infusion will be started bysyringe pump in a dose of 0.05 mg/kg/h that wastitrated to keep the VAS less than 3 at rest andRamsay Sedation Scale (RSS) up to 4
89553975|NCT05898958|Experimental|Thoracic paravertebral block(TPVB)|Procedure/Surgery: thoracic paravertebral block The block will be performed in the lateral position.After skin sterilization,the ultrasound transducerprobe (6-13-MHz high-frequency linear transducer) is positioned in the vertical plane ∼2.5 cm lateral tomarked spinous process with its orientation directedcranially. T.After local anesthetic infiltration, an 18-gauge Tuohy needle will be inserted into the paravertebral spacein an 'in plane' technique. After a negativeaspiration through the needle, 20 ml of 0.25%bupivacaine with 1: 200 000 epinephrine will be injected slowly over 3 min.A20-G epidural catheter will be threaded through Tuohyneedle and advanced 2-3 cm into the paravertebral space.Anyprocedure-related adverse effects will be noted, and thedermatomal loss of pin prick sensation will be testedover both sides.
89553976|NCT05898958|Experimental|Rhomboid Intercostal , subserratus block (RISSB)|The ultrasound probe will be placed in the obliquesagittal plane orientation, 1-2 cm medial to the medial scapula at theT5-T6 level. The trapezius muscle, rhomboid major muscle, ribs, intercostal muscle and pleura will be visualized respectively using ultrasound.After local anesthetic infiltration, needle will be inserted from the cranial to the caudal direction using the in-plane technique. The needle will be advanced between the rhomboid major and intercostal muscle fascia. The location of the needle will be confirmed with 2 mL saline solution, 10 ml of 0.25% bupivacaine with 1 : 200 000 epinephrine will beinjected slowly over 3min.for the subserratus block 10 ml of 0.25%bupivacaine with 1 : 200 000 epinephrine will be injected betweenthe serratus and intercostal muscle fascia at level of t9.
89553977|NCT05898893|Experimental|Intervention group|
89553978|NCT05898880|Experimental|Self acupressure group|The first acupressure application will be administered and taught individually by the researcher to the oncology patients in the self-administered group. Afterwards, each patient who learns the application will be asked to apply acupressure on his own for three days. In the self-acupressure group, a questionnaire form consisting of a personal information form, visual analog scale, nausea, vomiting and retching index and mental well-being scale will be applied first (pre-test) before the acupressure application is taught to the group by the researchers. Afterwards, patients will apply acupressure on their own for three days, and at the end of this period (post-test), a questionnaire consisting of personal information form, visual analog scale, nausea, vomiting and retching index and mental well-being scale will be applied. Acupressure will be applied the large intestine meridian 4th Point (LI4), the pericardium meridian Neiguan (P6) and Yintang (EX-HN3).
89553979|NCT05898880|Other|Acupressure by therapist|In this group, acupressure will be administered to stage I, stage II, and stage III cancer patients receiving at least one course of chemotherapy for a total of three days by researchers with acupressure certification. Before the application (pre-test) by the therapist, a questionnaire consisting of a personal information form, visual analog scale, nausea, vomiting and retching index and mental well-being scale will be applied to the patients in the group in question. At the end of the three-day acupressure application (post-test) applied to the patients included in the study by the therapist, a questionnaire consisting of a personal information form, visual analog scale, nausea, vomiting and retching index and mental well-being scale will be applied. In the acupressure group applied by the therapist, a total of three points will be applied to the upper extremity: the 4th point of the large intestine meridian (LI4), the Pericardium Meridian/Neiguan (P6), Yintang (EX-HN3) point.
89553980|NCT05898880|Other|Control group|The control group will receive the routine treatment applied in the hospital, and acupressure will not be applied to this group.
89553981|NCT05898815||Healthy subjects and stroke patients|Healthy subjects and stroke patients
89553982|NCT05898802|Experimental|Kimchi inoculated Leuconostoc mesenteroides|3,600mg/day containing 80% Kimchi inoculated Leuconostoc mesenteroides powder (3 tablets 3 times per day after meals over the 16-week regimen)
89553983|NCT05898802|Experimental|Kimchi|3,600mg/day containing 80% Kimchi powder (3 tablets 3 times per day after meals over the 16-week regimen)
89553984|NCT05898802|Placebo Comparator|Lactose|3,600mg/day containing lactose placebo capsules to look identical. (3 tablets 3 times per day after meals over the 16-week regimen)
89553985|NCT05898685|Experimental|Intermittent hypoxia|The intermittent hypoxia protocol will consist of eight 4-minute hypoxic cycles (arterial oxygen saturation of 80%) interspersed with normoxic cycles to resaturation.
89553986|NCT05898685|Sham Comparator|Intermittent normoxia|The intermittent normoxia protocol will consist of eight 4-minute normoxic cycles (compressed air) interspersed with 1-minute normoxic cycles (room air).
89553987|NCT05898542|Experimental|Nature-based therapy intervention group|Patients getting additional therapies outdoors
89553988|NCT05898542|No Intervention|Control group|Patients getting additional rehabitation tasks indoors
89553989|NCT05898503|Experimental|Combined training group|
88962256|NCT02012023|Experimental|Controllable tube ileostomy|After LAR, the experimental group accepted controllable tube ileostomy.
89553990|NCT05898503|Experimental|Resistance training group|
88962257|NCT02012023|Active Comparator|Loop ileostomy|After LAR, the experimental group accepted loop ileostomy.
88962258|NCT02012036||TUR-B|TUR-B in patients suspected to have non-muscle-invasive bladder cancer (NMIBC).
89208168|NCT00864162|Active Comparator|B|Atlace® 10 mg capsules, single dose
89553991|NCT05898503|Experimental|Walking exercise group|
89553992|NCT05898503|Active Comparator|Positive control group|
89553993|NCT05898503|Sham Comparator|Negative control group|
89553994|NCT05898490|Experimental|Animation Therapy Group|10 sessions of Animation Therapy (2 session/week)
89553995|NCT05898490|No Intervention|Control Froup|No intervention
89553996|NCT05898477||Hemophagocytic lymphohistiocytosis (HLH) Patients|
89553997|NCT05898451|Experimental|Independent use of Refnot|Refnot is administered at a dose of 400,000 IU subcutaneously 3 times a week for 4 weeks. 4 weeks constitute 1 course of treatment with Refnot. In the absence of progression of the disease - an additional 4 weeks.
89553998|NCT05898451|Experimental|The use of Refnot in combination with chemotherapy|Refnot is administered at a dose of 400,000 IU subcutaneously 3 times a week for 4 weeks. 4 weeks constitute 1 course of treatment with Refnot. In the absence of progression of the disease - an additional 4 weeks. Chemotherapy may be used after 4-8 weeks of Refnot use.
89553999|NCT05898373|Experimental|vedicitumomab|RC48 (2.5 mg/kg every two weeks) intravenously for 6-8 cycles
89554000|NCT05898373|Experimental|vedicitumomab in combination with pyrrolizidine|RC48 （2 mg/kg every two weeks) intravenously for 6-8 cycles in combination with oral HER2 TKI (pyrrolizidine 400 mg qd po)
89554001|NCT05898373|Experimental|RC48 in combination with a platinum-based chemotherapeutic agent|RC48 (2 mg/kg every two weeks) in combination with a platinum-based chemotherapeutic agent of the physician's choice (carboplatin 200-250 mg/m2 every two weeks or cisplatin 50 mg/m2 every two weeks) administered intravenously for 6-8 cycles
89554002|NCT05898373|Experimental|RC48 in combination with teraplizumab|RC48(2 mg/kg every two weeks) in combination with an immune checkpoint inhibitor (teraplizumab, 3 mg/kg every two weeks)
89554003|NCT05898360|Experimental|daily time-restricted eating (TRE) for 2 weeks|Subjects will be instructed to consume all calories needed for a stable weight (based on their resting energy expenditure) in either one meal per day (TRE; between 10:00-11:00; a protein snack at 13 h) or in three meals per day (control; breakfast, lunch and dinner). Prior to the intervention, a dietician will instruct subjects on nutritional intake based on their caloric need measured by indirect calorimetry (see indirect calorimetry). During the intervention, subjects will fill in online or written dietary diary (e.g. eetmeter) and a physical activity diary. Halfway the intervention, a telephone consult with a dietician will take place
89554004|NCT05898360|Placebo Comparator|control protocol for each two weeks|Subjects will be instructed to consume normal diet/calories. Prior to the intervention, a dietician will instruct subjects on nutritional intake based on their caloric need measured by indirect calorimetry (see indirect calorimetry). During the intervention, subjects will fill in online or written dietary diary (e.g. eetmeter) and a physical activity diary. Halfway the intervention, a telephone consult with a dietician will take place
89554005|NCT05898347||Gorlin syndrome|Children aged six to seventeen years old with Gorlin syndrome and nevoid basal cell carcinomas.
89554006|NCT05898334|Experimental|Treatment|Active biophoton generators will be placed under the hotel bed to be used by the participant who is randomized to the Treatment Group and activities of daily living will be observed for 4 weeks.
89554007|NCT05898334|Placebo Comparator|Control|Placebo biophoton generators will be placed under the hotel bed to be used by the participant who is randomized to the Control Group and activities of daily living will be observed for 4 weeks.
89554008|NCT05898321|Experimental|GnRHa group|Patients with fibroid remained will be enrolled and one third of them will be administrated with Zoladex (3.60mg/28 days) for three to six months,.
89554009|NCT05898321|Experimental|mifepristone group|Patients with fibroid remained will be enrolled and one third of them will be administrated with mifepristone(10.0mg/d) for three to six months.
89554010|NCT05898321|No Intervention|control group|Patients with fibroid remained will be enrolled and the third group was serviced as controls and no drugs will be used.
89554011|NCT05898308|No Intervention|"standard-of-care arm"|"Patients will be initially treated according to the French guidelines (PNDS) based on the Ritux-3 regimen: 1000 mg of rituximab on Day1-Day14, and 500 mg at Month 12 and Month 18, plus oral prednisone 1 mg/kg/day initially, with the aim to stop prednisone after 6 months.~The prednisone dose could be increased up to 1.5 mg/kg/day in patients who do not achieve disease control with the initial 1 mg/kg/day dose."
89554012|NCT05898308|Experimental|"personalized maintenance treatment arm"|Patients will be treated with the same regimen (1000 mg of rituximab on Day1-Day14, and 500 mg at Month 12 and Month 18, plus oral prednisone 1 mg/kg/day initially, with the aim to stop prednisone after 6 months), which will then be adapted according to the evolution of anti-Dsg Abs: During the initial phase of treatment: patients i) whose serum anti-Dsg Abs have not sufficiently decreased ii) and/or those who initially had a severe pemphigus (at the inclusion visit) defined by a PDAI score > 45) will receive 1 g of rituximab at Month 6 ; Beyond the second year from Month 22 (4 months after the Month 18 infusion of 500 mg of rituximab) until the end of the study: patients whose anti-Dsg3 Abs re-increase >50 UI/ml and/or anti-Dsg1Abs re-increase>20 UI/ml) will receive 1 g of rituximab. A maximum of 2 additional maintenance infusions of rituximab per year will be allowed during the study.
89554013|NCT05898282||anesthesia professionals|anesthetists working at teaching and referral hospitals of north west Ethiopia
89554014|NCT05898256|Experimental|Bispecific Antibody + GP Group|"Cadonilimab will be administered once every 3 weeks (Q3W), for up to 2 years；~Gemcitabine on Day 1, Day 8 of each 3 weeks cycle, for 4 to 6 cycles；~Cisplatin on Day 1 of each 3 weeks cycle, for 4 to 6 cycles."
89554015|NCT05898204|Experimental|Ketogenic diet arm|Ketogenic diet for a month, or a longer period if clinically necessary
88962259|NCT02012049|Experimental|Risperdal OD / Risperdal Quicklet|Risperdal OD (investigational drug) + Risperdal Quicklet (control drug)
88962260|NCT02012049|Experimental|Risperdal Quicklet / Risperdal OD|Risperdal Quicklet (control drug) + Risperdal OD (investigational drug)
88962261|NCT02012062|Active Comparator|Arm Cisplatin|Neoadjuvant TPF chemotherapy (docetaxel 75 mg/m2, cisplatin 75 mg/m2, 5-FU 2500 mg/m2 every 3 weeks for 3 cycles), followed by cisplatin 40 mg/m2/week in concurrent with IMRT
89554016|NCT05898204|Active Comparator|Balanced diet arm|Balanced diet for a month, or a longer period if clinically necessary
88962262|NCT02012062|Experimental|Arm Nimotuzumab|Neoadjuvant TPF chemotherapy (docetaxel 75 mg/m2, cisplatin 75 mg/m2, 5-FU 2500 mg/m2 every 3 weeks for 3 cycles), followed by weekly nimotuzumab 200mg in concurrent with IMRT
88962263|NCT02012075|Experimental|Extended-Release Carvedilol Sulfate|18-72mg/d,po
88962264|NCT02012075|Active Comparator|Sustained-release Metoprolol Succinate|11.875-190mg/d,po
88962265|NCT02012101|Experimental|niv plus oxygen therapy|oxygen therapy is given during the whole experimental process, niv is given at peak exercise until the borg scale reaches it's baseline point
88962266|NCT02012101|Active Comparator|oxygen therapy|oxygen therapy is given during the whole experimental process
88962267|NCT02012127||Acromegalic patients|
89208169|NCT00787826|Experimental|Vaccination|Live Francisella Tularensis Vaccine
89554017|NCT05898178|Experimental|8-5-2% oxygen gradient concentration in the incubator|A physiological oxygen gradient concentration in the incubator (8-5-2% O2).
89554018|NCT05898178|No Intervention|Control (no intervention)|Arbitrary cultivation conditions (static 5% 02).
89554019|NCT05898152||Adult patients with catamenial epilepsy|A questionnaire regarding the menstrual cycle and the catamenial epilepsy will be administrated to the participants.
89554020|NCT05898087|Experimental|Study Group 1 - Intervention|Participants in this group will receive 20cc of subpectoral bupivacaine injected into the fascia
89554021|NCT05898087|Placebo Comparator|Study Group 2 - Control|Participants in this group will receive 20cc of subpectoral saline injected into the fascia
89554022|NCT05898074|Active Comparator|PuraGel (RADA16) Hydrogel|Participant will have PuraGel (RADA16) Hydrogel applied to the nasoseptal flap harvest site following endoscopic skull base surgery
89554023|NCT05898074|Active Comparator|Non-absorbable Packing (Silastic Splint)|Participant will have a silastic splint (Non-Absorbable Packing) applied to the nasoseptal flap harvest site following endoscopic skull base surgery with no additional packing or agent
89554024|NCT05898035|Experimental|Piezo endodontic surgery|The osteotomy will be applied under magnification with a surgical operating microscope (at the apical third of the root .Osteotomy will be done with the Piezosurgery touch
89554025|NCT05898035|Active Comparator|Conventional endodontic surgery|The osteotomy will be applied under magnification with a surgical operating microscope at the apical third of the root .Osteotomy will be done with air motor high speed hand-piece and round bur with copious irrigation
89554026|NCT05898009|Experimental|BRCA2 mutation detection|
89554027|NCT05897970||ACLR patients with Return-to-sport (RTS) follow-up|All sports patients who had a muscle evaluation at 3-4 months after ACLR since January 2017
89554028|NCT05897944||COPD|Participants with clinically diagnosed Chronic obstructive pulmonary disease. Total 34 recruitment, 18 Female, 16 Male
89554029|NCT05897944||HC|Participants without Chronic obstructive pulmonary disease diagnosis. Total 38 recruitment, 20 Female, 18 Male
89554030|NCT05897918|Other|single group|
89554031|NCT05897697||Pregnant / postpartum women|Adult women during pregnancy or the early postpartum period (within 7 days of delivery)
89554032|NCT05897450||Patients with TAP block|After induction of anesthesia, TAP block was applied to the patients under ultrasound guidance.
89554033|NCT05897450||Patients without TAP block|
89554034|NCT05897034|Active Comparator|control group|This group will take doxycycline 100 mg twice daily
89554035|NCT05897034|Active Comparator|Comparative group|This group will take doxycycline 100 mg twice daily, pentoxifylline 400 mg twice daily, and nitazoxanide 500 mg twice daily.
89554036|NCT05897008|Experimental|CMAB007|150 mg Subcutaneous injection
88962268|NCT02012140|Experimental|Ticagrelor|As per ACC/AHA and ESC guidelines 180 mg is the recommended LD. The ticagrelor 90 mg BID dose, following the loading dose, has been selected for the clopidogrel naïve patients with stable angina, NSTEMI and STEMI patients undergoing PCI as the maintenance dose for this study since it is the FDA recommended dose.
88962269|NCT02012166|Experimental|MK-0893 40 mg→MK-0893 200 mg→placebo|In Part 1 of the study, participants receive MK-0893 (10 mg, 40 mg or 200 mg) or placebo on Day 1 of each period, and Sandostatine® (30 ng/kg/min), insulin (0.10 mIU/kg/min), and glucagon (3 ng/kg/min) at 24 and 72 hours post dose. In Part 2 of the study, participants receive MK-0893 (200 mg or 1000 mg) or placebo on Day 1 of each period and Sandostatine®, insulin, and glucagon at 120 hours post dose. There will be at least 21 days between administrations of study drugs.
89025673|NCT01244841|Active Comparator|Early discharge|Randomised patient where all post MI investigations, treatment, follow-up plans and information will be performed within 3 days, and the patients are thereafter discharged.
89025674|NCT00460733|Experimental|1|
89025675|NCT00460733|Active Comparator|2|
89025676|NCT00488904|Experimental|a|
89025677|NCT00488904|Placebo Comparator|b|
89208170|NCT00795314|Active Comparator|1|Propofol-fentanyl combined anesthesia
89208171|NCT00795314|Experimental|2|Propofol-butorphanol combined anesthesia
89208172|NCT03926169|Experimental|Risankizumab 180 mg|In Period A, participants receive blinded risankizumab 180 mg via a subcutaneous (SC) injection at Weeks 0 (Baseline), 1, 2, 4, and 12.
89554037|NCT05897008|Active Comparator|Xolair|150 mg Subcutaneous injection
89554038|NCT05896865|Experimental|Postoperative radiation therapy to breast / chest wall and regional lymph node area|"Patient achieved complete response after neoadjuvant chemotherapy will receive postoperative radiation therapy with dose of 42.4 Gy in 16 fractions to whole breast / chest wall and regional lymph node area. Internal mammary or supraclavicular lymph node area boost will be simultaneously delivered with total dose of 53.6 Gy in 16 fractions.~Patient with partial response, stable disease, or progressive disease after neoadjuvant chemotherapy will receive postoperative radiation therapy with dose of 42.4 Gy in 16 fractions to whole breast / chest wall and regional lymph node area. Internal mammary or supraclavicular lymph node area boost will be simultaneously delivered with total dose of 56.0 Gy in 16 fractions."
89554039|NCT05896410|Active Comparator|Thermoplastic Splint(orthosis)|A static hand-based splint (orthosis) made with a thermoplastic material that immobilizes the CMC and MCP joint will be used.
89554040|NCT05896410|Experimental|3D printed splint (orthosis)|A static hand-based 3D-printed splint (orthosis) made with 3D printing that immobilizes both the CMC and MCP joint will be used.
89554041|NCT05894304|Active Comparator|Excercise therapy group|The group that recived scapular muscle training exercises
89554042|NCT05894304|Experimental|Suspension group|The group that recived scapular muscle training using suspension system
89554043|NCT05893667||High levels of inflammatory scores|
89554044|NCT05893667||Low levels of inflammatory scores|
89554045|NCT05893251|Active Comparator|Protocol group|The treatment plan includes active postural exercises for the cervical spine.
89554046|NCT05893251|Experimental|Manual therapy group|The treatment plan includes active postural exercises and manual therapy for the cervical spine.
89554047|NCT05892939|Experimental|Oxytoxin group|Drug: intranasal Oxytocin(24IU)
89554048|NCT05892939|Placebo Comparator|Placebo group|Drug: intranasal Placebo
89554049|NCT05892861|Experimental|multi domain dietary education as cognitive stimulation|video lifestyle education, board game, and 24-hour dietary recall record from 1st week to 10th week as cognitive stimulation.
89554050|NCT05892861|Experimental|usual clinical treatment|usual treatment in clinic
89554051|NCT05890534|Experimental|Pycnogenol®|People with post COVID-19 condition randomly allocated to the Pycnogenol® arm will take 4 capsules of Pycnogenol® per day (4x50mg capsules, 200mg total) over a period of 12 weeks.
89554052|NCT05890534|Placebo Comparator|Placebo|People with post COVID-19 condition randomly allocated to the Placebo arm will take 4 capsules of Placebo per day (4x50mg capsules, 200mg total) over a period of 12 weeks.
89554053|NCT05888545|Experimental|anti-adhesion diaphragm|Participants will be asked to place an anti-adhesion diaphragm in the uterus for 3-7 days after the abortion procedure.
89554054|NCT05888545|No Intervention|control group|Participants will be treated routinely with no other interventions.
89554055|NCT05885061|Active Comparator|Spinal cord stimulation turned on|
89554056|NCT05885061|Placebo Comparator|Spinal cord stimulation turned off|
89554057|NCT05885061|Active Comparator|Spinal cord stimulation turned on and suggestions|
89554058|NCT05885061|No Intervention|Control|
89554059|NCT05880966|Experimental|COBRE Single Group|All participants will complete the 6-mos functional fitness interventions
89554060|NCT05867836|Active Comparator|IFA-90|Iron and folic acid (IFA) for 90 days
89554061|NCT05867836|Experimental|MMS-90|Multiple micronutrient supplementation (MMS) for 90 days with 2 distributions of MMS supplements (2 x 90 pill bottles; distributed at different ANC visits)
89554062|NCT05867836|Experimental|MMS-180|Multiple micronutrient supplementation (MMS) for 180 days but with 1 distribution of MMS supplements (1 x 180 pill bottle)
89554063|NCT05861765|Experimental|Papaverine|Slowly inject 10ml of papaverine hydrochloride solution (30mg/10ml) through the successfully implanted radial artery sheath, and continuously drip papaverine hydrochloride solution (60mg/500ml, 4ml/min) through the artery sheath during the operation. The compatible solutions are normal saline(0.9%);
89554064|NCT05861765|Placebo Comparator|Placebo|After inserting the radial artery sheath, slowly inject 10ml normal saline(0.9%) through the artery sheath, and continuously drip normal saline(0.9%, 500ml, 4ml/min) through the artery sheath during the operation.
89554065|NCT05860595|Experimental|KL003 cell injection Drug Product|Each recruited subject will accept KL003 Transplantation.
89554066|NCT05842304|Active Comparator|active cTBS group|active cTBS combined with conventional rehabilitation therapy
89025678|NCT00460850|Experimental|1|
89554067|NCT05842304|Sham Comparator|sham cTBS group|Sham cTBS combined with conventional rehabilitation therapy
89554068|NCT05836454|Experimental|Progressive Muscle Relaxation Group:|Progressive Muscle Relaxation technique will be applied to this group. Technique will be applied 3 days a week for 2 menstrual cycles.
89554069|NCT05836454|Experimental|Myofascial Release Technique Group|Myofascial Release Technique will be applied to this group. Technique will be applied 3 days a week for 2 menstrual cycles.
89554070|NCT05836454|No Intervention|Control Group|The control group will be asked to continue their normal lives.
89554071|NCT05823259|Experimental|Hybrid Telehealth Inspiratory and Expiratory Muscle Training Program with Patient Education|Participants will be instructed in performing a home respiratory muscle training program using a device called the Breather that trains both inspiratory and expiratory muscle strength for 8 weeks. They will also be provided patient education on proper breathing techniques to pass a bowel movement and optimal toilet posture.
89554072|NCT05823259|Active Comparator|Standard of Care Physical Therapy With No Study Intervention|Participants will receive 8 weeks of standard physical therapy care that includes interventions such as biofeedback treatment, manual therapy, therapeutic exercise, and education on improving bowel health.
89554073|NCT05818618|Active Comparator|Clobetasol propionate 0,05% gel|Patients were treated with a topic gel of clobetasol propionate 0,05%
89554074|NCT05818618|Placebo Comparator|Placebo|Patients were treated with a topic placebo gel control
89554075|NCT05814016|Experimental|High Dose Danavorexton|Participants will receive danavorexton intravenous (IV) infusion as high dose on Day 1 of the treatment period.
89554076|NCT05814016|Experimental|Low Dose Danavorexton|Participants will receive danavorexton IV infusion as low dose on Day 1 of the treatment period.
89554077|NCT05814016|Placebo Comparator|Placebo|Participants will receive a placebo-matching danavorexton IV infusion on Day 1 of the treatment period.
89025679|NCT00495729|Experimental|Cohort 1|Subjects in Cohort 1 will be randomized to receive 5 milligram (mg) of SB-649868 or Placebo along with 10 mg of simvastatin.
89025680|NCT00495729|Experimental|Cohort 2|Subjects in Cohort 2 will be randomized to receive two or three times higher than the starting dose of SB-649868 or Placebo along with 10 mg of simvastatin.
89554078|NCT05811702|Experimental|High fat Ketogenic Diet (HFKD)|A randomized acute controlled trial of twenty-eight healthy overweight or obese women in Saudi Arabia, aged between 18 and 40 with a body mass index between 25 and 34.5 kg m2 and fat parentage above 30% . The participants have followed ether HFKD for 12 weeks. The weight will be measured weekly, body fat % and blood samples before and after 12 weeks of following HFKD.
89554079|NCT05811702|Experimental|low-fat diet (LFD|A randomised acute controlled trial of twenty-eight healthy overweight or obese women in Saudi Arabia, aged between 18 and 40 with a body mass index between 25 and 34.5 kg m2 and fat parentage above 30% . The participants have followed ether LFD for 12 weeks. The weight will be measured weekly, body fat % and blood samples before and after 12 weeks of following LFD.
89208173|NCT03926169|Experimental|Risankizumab 360 mg|In Period A, participants receive blinded risankizumab 360 mg via a SC injection at Weeks 0 (Baseline), 1, 2, 4, and 12.
89208174|NCT03926169|Placebo Comparator|Placebo|In Period A, participants receive blinded placebo via a SC injection at Weeks 0 (Baseline), 1, 2, 4, and 12.
89554080|NCT05804513|Placebo Comparator|Placebo, healthy volunteers|Sodium chloride 0.9% solution. Subcutaneous injection administered once.
89554081|NCT05804513|Active Comparator|Lixisenatide 10 micrograms, healthy volunteers|Lixisenatide 10 micrograms. Subcutaneous injection administered once.
89554082|NCT05804513|Placebo Comparator|Placebo, type 1 diabetic patients|Sodium chloride 0.9% solution. Subcutaneous injection administered once.
89554083|NCT05804513|Active Comparator|Lixisenatide 10 micrograms, type 1 diabetic patients|Lixisenatide 10 micrograms. Subcutaneous injection administered once.
89554084|NCT05799989||Surgical fixation|Pediatric patients with intravenous and/or intraarterial catheter in situ secured with surgical fixation
89554085|NCT05799989||Atraumatic fixation|Pediatric patients with intravenous and/or intraarterial catheter in situ secured with surgical fixation
89554086|NCT05794087|Experimental|Clean Air, Then Ozone|Subjects will be exposed to clean air for 3 hours at the first exposure visit and 0.2ppm ozone for 3 hours at the second exposure visit. The visits will be at least 2 weeks apart.
89554087|NCT05794087|Experimental|Ozone, Then Clean Air|Subjects will be exposed to 0.2 ppm ozone for 3 hours at the first exposure visit and clean air for 3 hours at the second exposure visit. The visits will be at least 2 weeks apart.
89554088|NCT05783219|Experimental|topical lidocaine patch|4% lidocaine patch placed over the sacrum 30 minutes prior to PNE procedure
89554089|NCT05783219|Placebo Comparator|Placebo|Adhesive patch placed over the sacrum 30 minutes prior to PNE procedure
88962270|NCT02012166|Experimental|MK-0893 200 mg→placebo→MK-0893 10 mg|In Part 1 of the study, participants receive MK-0893 (10 mg, 40 mg or 200 mg) or placebo on Day 1 of each period, and Sandostatine® (30 ng/kg/min), insulin (0.10 mIU/kg/min), and glucagon (3 ng/kg/min) at 24 and 72 hours post dose. In Part 2 of the study, participants receive MK-0893 (200 mg or 1000 mg) or placebo on Day 1 of each period and Sandostatine®, insulin, and glucagon at 120 hours post dose. There will be at least 21 days between administrations of study drugs.
88962271|NCT02012166|Experimental|Placebo→MK-0893 10 mg→MK-0893 40 mg|In Part 1 of the study, participants receive MK-0893 (10 mg, 40 mg or 200 mg) or placebo on Day 1 of each period, and Sandostatine® (30 ng/kg/min), insulin (0.10 mIU/kg/min), and glucagon (3 ng/kg/min) at 24 and 72 hours post dose. In Part 2 of the study, participants receive MK-0893 (200 mg or 1000 mg) or placebo on Day 1 of each period and Sandostatine®, insulin, and glucagon at 120 hours post dose. There will be at least 21 days between administrations of study drugs.
89554090|NCT05771246||Case group|Patients with third molar agenesis.
89554091|NCT05771246||Control group|Patients with the presence of all third molars.
89554092|NCT05766878|Active Comparator|machined collar|"The arm will be constituted by healthy people, that need to be rehabilitated by dental implant placement.~A short implant (length 6mm; diameter 4.3) will be inserted in an edentulous site. The implant will present a surface treated with double acid etching and traditional machined collar. A definitive transgingival standard machined abutment will be immediately screwed. Four months later, prosthetic procedures will start."
89554093|NCT05766878|Experimental|anodized collar|"The arm will be constituted by healthy people, that need to be rehabilitated by dental implant placement.~A short implant (length 6mm; diameter 4.3) will be inserted in an edentulous site. The implant will present a surface treated with double acid etching and anodized collar. A definitive transgingival anodized abutment will be immediately screwed. Four months later, prosthetic procedures will start."
89554094|NCT05759013|Experimental|VentFree Respiratory Muscle Stimulator|In the VentFree treatment group, abdominal functional electrical stimulation (FES) will be applied with a frequency of 30 hertz (Hz) and a pulse width of 350µs to cause a strong visible or palpable muscle contraction. The stimulation amplitude will be set to 90% of the participant's maximum tolerable level that does not cause discomfort to the participant. Participant discomfort will be measured using a visual analog pain scale (VAS) with pain ratings from zero (no pain) to ten (worst pain). For participants who are unable to communicate their level of pain, the Behavioral Pain Scale (BPS) will be used. The stimulation will be titrated for each participant and each stimulation session. After the stimulation has been titrated, a visible or palpable contraction of the abdominal wall will be confirmed. The stimulation will be evaluated every 10(± 2) minutes after the start of each stimulation session and adjusted as necessary so that no discomfort is caused to the participant.
89554095|NCT05759013|Sham Comparator|Sham Respiratory Muscle Stimulator|In the sham group, abdominal functional electrical stimulation (FES) will be set to cause sensory stimulation but no muscle contraction. Abdominal FES will be applied with a frequency of 30 hertz (Hz), a pulse width of 350 µs and a stimulation amplitude that does not cause abdominal wall muscle contraction. The stimulation amplitude will initially be set at 10 mA and reduced in steps of 2 milliamp (mA) until no muscle contraction is seen.
89554096|NCT05756114|Active Comparator|Psychoeducation Condition|Participants receive a weekly email with a Qualtrics survey link containing psychoeducational content.
89554097|NCT05756114|Experimental|Support Group Condition|Participants will attend six weekly online SMART Recovery meetings in groups of five to eight.
89208175|NCT03926169|Experimental|Risankizumab 180 mg / Risankizumab 360 mg|"In Period A, participants receive blinded risankizumab 180 mg via a subcutaneous (SC) injection at Weeks 0 (Baseline), 1, 2, 4, and 12.~In Period B, participants receive blinded placebo at Weeks 16, 17, and 18. Starting at Week 20, participants receive open-label risankizumab 360 mg every 8 weeks (q8w) at Weeks 20, 28, 36, 44, 52, and 60."
89554098|NCT05740124|Experimental|Slip recovery training|Once weekly sessions of slip recovery training for 3 or 6 weeks. Each session will be 20 minutes of training. Training will involve volitional and reactive stepping movements that mimic the movements necessary to recover balance after slipping while walking.
89554099|NCT05740124|Active Comparator|Alternative balance training|Once weekly sessions of balance training for 3 or 6 weeks. Each session will be 20 minutes of training. Training will involve standing balance under varied sensory conditions, and tandem walking forward and backward under varied sensory conditions.
89554100|NCT05709444|Experimental|Subcutaneous Bremelanotide|BMT sterile aqueous solution for injection provided as a prefilled syringe, administered by subcutaneous (SQ) injection into the abdomen.
89554101|NCT05682482|Active Comparator|LT4/LT3 combination therapy|The intervention group is treated with once daily a LT4 tablet and twice daily a LT3 tablet with a LT4:LT3 ratio 16:1.
89554102|NCT05682482|Placebo Comparator|LT4/placebo therapy|The control group is treated with once daily a LT4 tablet and twice daily a placebo tablet.
89554103|NCT05672329|Experimental|Group 1: Low-flow apnoeic oxygenation|Group 1) 0.2 L/kg/min using OptiFlow system by Fisher&Paykel and an oxygen inspiration concentration FiO2 of 1.0;
89554104|NCT05672329|Experimental|Group 2: High-flow apnoeic oxygenation|Group 2) 2 L/kg/min using OptiFlow system by Fisher&Paykel and an oxygen inspiration concentration FiO2 of 1.0;
89554105|NCT05672329|Active Comparator|Group 3: Control group apnoeic oxygenation|Group 3) 4 L/kg/min using OptiFlow system by Fisher&Paykel and an oxygen inspiration concentration FiO2 of 1.0;
89554106|NCT05672329|Experimental|Group 4: High-flow apnoeic oxygenation|Group 4): 2 l/kg/min with OptiFlow FiO2 1.0 using OptiFlow-Switch system by Fisher&Paykel
89554107|NCT05642611|Experimental|Arm 1 (Cryocompression)|Patients undergo cryocompression (cooling plus moderate and low pressure to the arms and legs) for 30-minutes pre-taxane chemotherapy infusion, during taxane chemotherapy infusion, and for 30 minutes after completion of each taxane infusion. Patients may also undergo collection of blood, serum and plasma samples during screening and on study.
89554108|NCT05642611|Experimental|Arm 2 (Continuous Compression)|Patients undergo continuous compression (moderate, steady pressure to the arms and legs) for 30-minutes pre-taxane chemotherapy infusion, during taxane chemotherapy infusion, and for 30 minutes after completion of each taxane infusion. Patients may also undergo collection of blood, serum and plasma samples during screening and on study.
89554109|NCT05642611|Active Comparator|Arm 3 (Low Cyclic Compression)|Patients undergo low cyclic compression (low pressure that comes and goes to the arms and legs) for 30-minutes pre-taxane chemotherapy infusion, during taxane chemotherapy infusion, and for 30 minutes after completion of each taxane infusion. Patients may also undergo collection of blood, serum and plasma samples during screening and on study.
89554110|NCT05641948||Low Back Pain|
89554111|NCT05627102|Experimental|Percutaneous Electrolysis and neuromodulation.|The intervention for this group consisted of Therapeutic Percutaneous Electrolysis and neuromodulation. Patient received once week for four weeks associated with eccentric exercises device at home.
89554112|NCT05627102|Active Comparator|Conventional group|"The multimodal physical therapy program includes 10 sessions of:~ultrasound pulsatil therapy (US) for 10 minutes , transcutaneous electric nerve stimulation (TENS) for 20 minutes ans associated with eccentric exercises device at home."
89554113|NCT05612971|Experimental|iAmHealthy Parents First|"iAmHealthy Parents First families will take part in a group program with other adults. These sessions will be delivered over Zoom. Children will not be involved during this time. Adults will participate in these group sessions weekly for 3 months. Each meeting will last approximately an hour and cover topics such as nutrition, physical activity, and meal planning. Fifteen dyads from each town will be randomized to the iAmHealthy Parents First group.~After 3 months, both iAmHealthy Parents First and iAmHealthy families will take part in an educational group program with parents and their children. These meetings will also take place over Zoom and will occur weekly for 4 months then bi-monthly for 2 months."
89554114|NCT05612971|Active Comparator|Self-Guided|"Self-Guided families will receive an informational newsletter once a month for three months. This group will be given the flexibility to start their weight loss journey using self-guided methods. No formal group sessions will be provided for 3 months. Fifteen dyads from each town will be randomized to the Self-Guided group.~After 3 months, both iAmHealthy Parents First and Self-Guided families will take part in an educational group program with parents and their children. These meetings will also take place over Zoom and will occur weekly for 4 months then bi-monthly for 2 months."
89208176|NCT03926169|Experimental|Risankizumab 360 mg / Risankizumab 360 mg|"In Period A, participants receive blinded risankizumab 360 mg via a SC injection at Weeks 0 (Baseline), 1, 2, 4, and 12.~In Period B, participants receive blinded placebo at Weeks 16, 17, and 18. Starting at Week 20, participants receive open-label risankizumab 360 mg q8w at Weeks 20, 28, 36, 44, 52, and 60."
89554115|NCT05610176|Experimental|Amvia Sky pacemaker or CRT-P implantation|Patients implanted with an Amvia Sky pacemaker or CRT-P device
89554116|NCT05606042||IM Implant|Male and female patients who present with a pelvic ring and/or acetabular fracture that has recently undergone surgery to be fixed with a CurvaFix IM Implant.
89554117|NCT05589922||Patients with abnormal modified Schober index|This group will include the patients with Ankylosing Spondylitis who have modified Schober index smaller than 5 cm
89554118|NCT05589922||Patients with normal modified Schober index|This group will include the patients with Ankylosing Spondylitis who have modified Schober index bigger than 5 cm
89554119|NCT05583110|Experimental|Trastuzumab-Vinorelbine-Tucatinib|Trastuzumab-Vinorelbine-Tucatinib
89554120|NCT05570604|Experimental|Cognitive Training|As tested in the investigator's pilot, the Brain HQ program is designed to enhance specific areas of cognitive functioning that will be tested in this study. The goals of the Brain HQ program are to improve visual processing speed, learning and memory and attention. The exercises include time-order judgment, discrimination, spatial-match, forward-span, instruction-following, and narrative-memory tasks. This program systematically reduces the stimulus duration during a series of increasingly difficult information-processing tasks presented via computer. The exercises automatically adjust to user performance to maintain an 85% correct rate. The program will include 4 hours per week over a 10-week period for a total of up to 40 hours. The study team has support from the original developer and Posit Science. For the purposes of this trial, any participants who do not complete the total of up to 40 hours will not be counted as deviations.
89554121|NCT05570604|Placebo Comparator|Attention Control|Control participants will be asked to complete activities on the computer. The program offers a choice of activities that will consist of crossword puzzles and word jumbles. The program offers a pre-determined set of computerized crossword puzzles. The site has over 100,000 puzzles and can be accessed easily via the web and are free to users. The computerized crossword puzzles do not provide for progressive challenges of increasing speed, visual field size, number of distractors or degree of difficulty of targeted stimulus differentiation. Training: Participants will be instructed to perform this active attention control intervention 4 hours per week over 10 weeks for a total of up to 40 hours, the same as BrainHQ.
89025681|NCT00495729|Experimental|Cohort 3|Subjects in Cohort 3 will be randomized to dose higher than that administered in Cohort 2 of SB-649868 or Placebo along with 10 mg of simvastatin.
89554122|NCT05537935|No Intervention|Control|"Once a potential subject has been identified they may be contacted with information about the study in advance of their appointment in order to allow time for them to consider the study. A qualifying pain score will be confirmed with the subject prior to initiating consent. This may occur up to 30 days before the baseline, treatment visit, but inclusion/exclusion criteria will be re-confirmed prior to initiating study treatment. Patients may also be approached during a clinic visit.~Should a patient decline participation in the treatment plan, they will be invited to participate in a control group. They will be invited to complete the PROMIS questionnaire every 4 weeks, and the NPRS pain assessment every week from Baseline through week 12. These participants will receive follow up phone calls to confirm completion of these assessments weekly and will not have any in-person visits."
89554123|NCT05537935|Experimental|Low Dose Naloxone (LDN)|"Once a potential subject has been identified they may be contacted with information about the study in advance of their appointment in order to allow time for them to consider the study. A qualifying pain score will be confirmed with the subject prior to initiating consent. This may occur up to 30 days before the baseline, treatment visit, but inclusion/exclusion criteria will be re-confirmed prior to initiating study treatment. Patients may also be approached during a clinic visit.~Subjects will be started with 3mg LDN orally administered daily for one week with a planned increase to 4 mg/day beginning week two, if tolerated. They will be provided a 4 week supply of study medication. LDN will be given as a daytime dose."
89554124|NCT05535660||LGA neonates|Researchers will compare lipid levels in large for gestational age (LGA) and non-LGA neonates.
89554125|NCT05535660||non-LGA neonates|Researchers will compare lipid levels in large for gestational age (LGA) and non-LGA neonates.
89554126|NCT05461014|Experimental|Digital Cognitive Behavioral Intervention (DCBI)|The dCBI, RxWell, is a trans cognitive behavioral therapy (CBT) mobile app product addressing depression and anxiety that was developed based on standard CBT techniques.
89554127|NCT05457803||In-persom kratom users|10 subjects that use kratom an additional cross-sectional evaluation: one session day at the NIDA IRP preceded by a consent session day; 2 visits at our BRC building total.
89554128|NCT05457803||Online kratom users|240 subjects that use kratom, prospective observational cohort study in which each participant provides intensive longitudinal data on kratom use for 15 consecutive days via smartphone app
89554129|NCT05456893||UC patients|All patients with an established ulcerative colitis
89554130|NCT05440851|Other|Ultra-protective ventilation facilitated by extracorporeal carbon dioxide removal (ULTIMATE) domain|Patients with acute hypoxemic respiratory failure in the high elastance state will be randomized to ultra-protective ventilation facilitated by extracorporeal carbon dioxide removal or to conventional lung-protective ventilation.
89554131|NCT05440851|Other|Invasive Mechanical Ventilation (IMV) Strategies domain|Patients on invasive mechanical ventilation in the low elastance, high elastance, and ECLS states will be randomized to one of two or three mechanical ventilation interventions (including conventional lung-protective ventilation as a control group). Most sites will randomize patients to two arms (one of which is the control group, LPV). A subset of sites will randomize patients to all three arms.
89554132|NCT05440851|Other|The Corticosteroid Early and Extended (CORT-E2) Randomized Controlled Trial domain|Patients with acute hypoxemic respiratory failure (AHRF) requiring invasive or non-invasive respiratory support will be randomized in the Early Cohort to receive corticosteroid or usual care without corticosteroids. Patients treated with corticosteroids who still require invasive or non-invasive respiratory support after 10 days will be randomized in the Extended Cohort to extending corticosteroid use or stopping corticosteroids after 10 days.
89554133|NCT05419076|Experimental|Participants with small cell lung cancer with brain metastases|Participants may be newly diagnosed small cell lung cancer with brain metastases at initial staging, or can alternatively be patients who develop brain metastases on therapy or during surveillance of systemic disease.
89554134|NCT05411679|Experimental|Arm 1|patients with ataxia-telangiectasia mutated protein (ATM)-negative relapsed, advanced GC.
89554135|NCT05411679|Experimental|Arm 2|patients with relapsed extensive stage SCLC.
89554136|NCT05409105|Experimental|Mangoes|Frozen mangoes, 2 cups per day (with 2 cups water), 2 weeks.
89554137|NCT05409105|Active Comparator|Water|Bottled water, 2 cups per day
89554138|NCT05406479|Experimental|BE-PEP (Bedaquiline Post-Exposure Prophylaxis)|Eligible participants will receive one dose of Bedaquiline plus Rifampicin
89554139|NCT05406479|Active Comparator|SDR-PEP (Single-Dose Rifampicin Post-Exposure Prophylaxis)|Eligible participants will receive one dose of Rifampicin (WHO recommendation)
89554140|NCT05400837|Experimental|Corrie Virtual Atrial Fibrillation Management Program|Multicomponent virtual atrial fibrillation management program
88962272|NCT02012166|Experimental|MK-0893 10 mg→MK-0893 40 mg→MK-0893 200 mg|In Part 1 of the study, participants receive MK-0893 (10 mg, 40 mg or 200 mg) or placebo on Day 1 of each period, and Sandostatine® (30 ng/kg/min), insulin (0.10 mIU/kg/min), and glucagon (3 ng/kg/min) at 24 and 72 hours post dose. In Part 2 of the study, participants receive MK-0893 (200 mg or 1000 mg) or placebo on Day 1 of each period and Sandostatine®, insulin, and glucagon at 120 hours post dose. There will be at least 21 days between administrations of study drugs.
89208177|NCT03926169|Placebo Comparator|Placebo / Risankizumab 360 mg|"In Period A, participants receive blinded placebo via a SC injection at Weeks 0 (Baseline), 1, 2, 4, and 12.~In Period B, participants receive blinded risankizumab 360 mg at Weeks 16, 17, and 18. Starting at Week 20, participants receive open-label risankizumab 360 mg q8w at Weeks 20, 28, 36, 44, 52, and 60."
88962273|NCT02012166|Experimental|Placebo→MK-0893 1000 mg→MK-0893 200 mg|In Part 1 of the study, participants receive MK-0893 (10 mg, 40 mg or 200 mg) or placebo on Day 1 of each period, and Sandostatine® (30 ng/kg/min), insulin (0.10 mIU/kg/min), and glucagon (3 ng/kg/min) at 24 and 72 hours post dose. In Part 2 of the study, participants receive MK-0893 (200 mg or 1000 mg) or placebo on Day 1 of each period and Sandostatine®, insulin, and glucagon at 120 hours post dose. There will be at least 21 days between administrations of study drugs.
88962274|NCT02012166|Experimental|MK-0893 200 mg→placebo→MK-0893 1000 mg|In Part 1 of the study, participants receive MK-0893 (10 mg, 40 mg or 200 mg) or placebo on Day 1 of each period, and Sandostatine® (30 ng/kg/min), insulin (0.10 mIU/kg/min), and glucagon (3 ng/kg/min) at 24 and 72 hours post dose. In Part 2 of the study, participants receive MK-0893 (200 mg or 1000 mg) or placebo on Day 1 of each period and Sandostatine®, insulin, and glucagon at 120 hours post dose. There will be at least 21 days between administrations of study drugs.
89554141|NCT05400837|No Intervention|Usual Care|Receives usual care. Usual care is defined as care according to the patients care team's standard practice
89554142|NCT05380505|Experimental|Condition 1: Race Congruent Ads|Participants will complete a 15-minute survey in which they will be randomized to view and rate Facebook food ads associated with their condition. Then they will complete a food purchasing task in which they will shop in an online store that will display six food items and six beverages. Finally, they will answer demographic questions (e.g., self-reported height and weight) and view a debriefing summary that describes the full purpose of the study.
89554143|NCT05380505|Experimental|Condition 2: Race Incongruent Ads|Participants will complete a 15-minute survey in which they will be randomized to view and rate Facebook food ads associated with their condition. Then they will complete a food purchasing task in which they will shop in an online store that will display six food items and six beverages. Finally, they will answer demographic questions (e.g., self-reported height and weight) and view a debriefing summary that describes the full purpose of the study.
89554144|NCT05325281|Experimental|CPI-613® (Dose level -1.0 250 mg/m^2)|Dose escalation/de-escalation for CPI-613® (devimistat) will be conducted using a Bayesian optimal interval (BOIN) design. Gemcitabine will be infused over 30 minutes at a fixed dose of 400 mg/m^2 weekly. Intensity-modulated radiation therapy will be administered at 54 Gy in 30 fractions of 1.8 Gy per fraction, with five fractions given per week. CPI-613® will be given once per week by IV infusion.
89554145|NCT05325281|Experimental|CPI-613® (Dose level 1.0 500 mg/m^2)|Dose escalation/de-escalation for CPI-613® (devimistat) will be conducted using a Bayesian optimal interval (BOIN) design. Gemcitabine will be infused over 30 minutes at a fixed dose of 400 mg/m^2 weekly. Intensity-modulated radiation therapy will be administered at 54 Gy in 30 fractions of 1.8 Gy per fraction, with five fractions given per week. CPI-613® will be given once per week by IV infusion.
89554146|NCT05325281|Experimental|CPI-613® (Dose level 2.0 1,000 mg/m^2)|Dose escalation/de-escalation for CPI-613® (devimistat) will be conducted using a Bayesian optimal interval (BOIN) design. Gemcitabine will be infused over 30 minutes at a fixed dose of 400 mg/m^2 weekly. Intensity-modulated radiation therapy will be administered at 54 Gy in 30 fractions of 1.8 Gy per fraction, with five fractions given per week. CPI-613® will be given once per week by IV infusion.
89554147|NCT05325281|Experimental|CPI-613® (Dose level 3.0 1,500 mg/m^2)|Dose escalation/de-escalation for CPI-613® (devimistat) will be conducted using a Bayesian optimal interval (BOIN) design. Gemcitabine will be infused over 30 minutes at a fixed dose of 400 mg/m^2 weekly. Intensity-modulated radiation therapy will be administered at 54 Gy in 30 fractions of 1.8 Gy per fraction, with five fractions given per week. CPI-613® will be given once per week by IV infusion.
89554148|NCT05325281|Experimental|CPI-613® Maximum Tolerated Dose (MTD)|MTD of CPI-613® from initiation of treatment to 30 days after treatment. MTD will be determined by testing increasing doses of CPI-613®, starting from 500 mg/m^2 and up to 1,500 mg/m^2, on dose escalation cohorts of three patients (maximum 24 patients) in combination with Gem-RT therapy. MTD reflects the highest drug dose that does not cause unacceptable adverse effects, with a target dose-limiting toxicity (DLT) rate of 30%. Final dose will be revised as appropriate.
89554149|NCT05289505||Prospective phase|This prospective phase involves all patients with an initial HADS score > 7 and initiating treatment in the radiotherapy department. The treatment sessions will be performed with music, using the MUSIC-CARE device. In the event of technical problems, unavailability of equipment, or the patient's wishes, some radiotherapy sessions may be conducted without music. Nevertheless, a minimum of one weekly session with music is required for the analysis of the study.
89554150|NCT05274165|Active Comparator|Group A|Participants will be fit with commercially available Lyric devices, which range from size XXS to XXL.
89554151|NCT05274165|Experimental|Group B|Participants will be fit either with the commercially available Lyric devices OR devices which are designed with a new fitting characteristic. This increases the pool of sizes from which the hearing care professional can choose to fit participant.
89554152|NCT05254275|Experimental|Peri-implant mucositis sites|Peri-implant mucositis sites will be randomly assigned to ozone treatment.
89554153|NCT05254275|Experimental|Contralateral peri-implant mucositis sites|Contralateral peri-implant mucositis sites with respect to those treated with ozone will be assigned to chlorhexidine treatment.
89554154|NCT05248438||Multiple sclerosis patients|patients affected by multiple sclerosis based on McDonald Criteria 2017
89554155|NCT05244629|Active Comparator|Bare Metal Stent|
89554156|NCT05244629|Active Comparator|Covered Stent|
89554157|NCT05242809|No Intervention|Control group|The control group receives standard care, which means the participants will receive verbal instruction on PFMT from midwives without any further supervision. For reasons of equipoise, women in the comparator group will be offered the group-based PFMT intervention at the end of the study if they wish.
89554158|NCT05242809|Experimental|Group-based PFMT group|The participants in the intervention group will receive PFMT supervision in groups. The number of women per group and the detail of the intervention will be decided through stakeholder development group meetings.The intervention will be teaching the participants to do PFMT in groups. The intervention will help women to identify their pelvic floor muscles and then guide them how to contract the pelvic floor muscle correctly (the detail of the intervention will be discussed and determined in phase 1 of this project).
89554159|NCT05193994|Experimental|Dolutegravir/Abacavir/Lamivudine|"Combination of Dolutegravir, Abacavir and Lamivudine in a single product/capsule.~4 capsules to be taken orally once daily (all 4 at the same time, each capsule is Dolutegravir 12.5mg, Abacavir 150mg and Lamivudine 75mg). Maximum duration is 24months"
89554160|NCT05193994|Placebo Comparator|Placebo|4 capsules to be taken orally once daily (all 4 at the same time). Maximum duration is 24months
89554161|NCT05191784|Experimental|GX-I7 and bevacizumab|Bevacizumab at a dose of 10 mg/kg intravenously, and GX-I7 intramuscularly.
89554162|NCT05161715|Experimental|10mg obicetrapib tablets|10mg obicetrapib (5mg tablets) administered orally daily for 24 weeks
89025682|NCT00460928|Experimental|intravenous immune globulin (IVIG)|
89025683|NCT00460967|Experimental|1|Rheopheresis treatment
89025684|NCT00460967|Sham Comparator|2|Sham treatment
89025685|NCT00461084||1|lymphoma follicular
89025686|NCT00461084||2|lymphoma non-follicular
89025687|NCT00495807|No Intervention|1|No Words was delivered during the PCA management
89554163|NCT05147974|Experimental|Intervention arm|A cohort of YAC patients to be studied, pre & post-intervention, prospectively. All participants will be assigned to the intervention (complete DOZE app: Sleep diary and DOZE modules).
89554164|NCT05146024||Formative Research|Alcohol-serving establishment owners, managers, and servers in New Mexico and Washington State.
89554165|NCT05145595|Experimental|Psychophysical assessments of experimental pain|"At baseline, participants will complete a 2.5-hours study session. In the study session, psychophysical assessments of thermal and pressure stimuli will be performed and sex hormone levels will be analyzed. In addition, demographic, social, pubertal maturation, behavioral and psychological factors will be collected via questionnaires.~In the optional follow-up portion, participants can complete short surveys every 3 months and/or return for study visits every year depending on the participant's availability. The study visits will include the same procedures as the baseline study visit. Additional surveys regarding new symptoms of pain will be completed. In some cases, participants will meet a pediatric physician who will determine if they meet the criteria for any pain syndrome (for research purposes only)."
89554166|NCT05137717|Experimental|Maribavir|Maribavir 400 milligrams (mg), tablets, orally twice a day (BID) for up to 8 weeks.
89554167|NCT05119179|Experimental|Semaglutide|Semaglutide 0.25 mg subcutaneously weekly for 4 weeks, followed by semaglutide 0.5 mg subcutaneously weekly for 8 weeks.
89554168|NCT05091112||Active group|Patients who are scheduled to undergo lumbar spinal surgery and fulfill the inclusion and exclusion criteria
89554169|NCT05089084|Experimental|ARO-APOC3|"4 doses of ARO-APOC3 by subcutaneous (sc) injection (randomized period)~8 doses of ARO-APOC3 by sc injection (open-label period)"
89554170|NCT05089084|Placebo Comparator|Placebo|calculated volume to match active treatment by sc injection (randomized period)
89208178|NCT00860808|Experimental|1 AM-101|low dose
89554171|NCT05077709|Experimental|Arm A (NSCLC)|NSCLC patients (metastatic stage IV) treated with IO102-IO103 SC Q3W in combination with pembrolizumab IV 200mg Q3W
89554172|NCT05077709|Experimental|Arm B (SCCHN)|SCCHN patients (metastatic stage IV) treated with IO102-IO103 SC Q3W in combination with pembrolizumab IV 200mg Q3W
89554173|NCT05077709|Experimental|Arm C (mUBC)|mUBC patients (metastatic stage IV) treated with IO102-IO103 SC Q3W in combination with pembrolizumab IV 200mg Q3W
89554174|NCT05073471|Experimental|PSE Only|Participants will exercise their hands, arms, shoulders, and torso with musical cues provided by neurologic music therapist. A simple gross/fine movements and emotional level will be assessed before and after each session. During the session, participants will be measured their brainwaves using electroencephalography (EEG) to understand their neurophysiological responses. Participant's motion will be also captured to acquire kinematic quantities.
89554175|NCT05073471|Experimental|PSE+tDCS|Participants in this group will proceed with the same procedure as PSE only group, but tDCS modulation will be additionally provided.
89554176|NCT05071287|Placebo Comparator|Control Group (mHealth+low-fat diet group)|The low-fat group will be asked to restrict total calorie and total fat consumption according to the Look AHEAD intervention and MyPlate guidelines, with 26-44% carbs, 10-30% protein, and less than 30% fat.
88962275|NCT02012166|Experimental|MK-0893 1000 mg→MK-0893 200 mg→placebo|In Part 1 of the study, participants receive MK-0893 (10 mg, 40 mg or 200 mg) or placebo on Day 1 of each period, and Sandostatine® (30 ng/kg/min), insulin (0.10 mIU/kg/min), and glucagon (3 ng/kg/min) at 24 and 72 hours post dose. In Part 2 of the study, participants receive MK-0893 (200 mg or 1000 mg) or placebo on Day 1 of each period and Sandostatine®, insulin, and glucagon at 120 hours post dose. There will be at least 21 days between administrations of study drugs.
88962276|NCT02012205|Experimental|wet cupping|patient will receive wet cupping
88962277|NCT02012205|No Intervention|control|not cupping
88962278|NCT02012231|Experimental|Dose Escalation|Cohort 1/Day -7 = 300 mg/day PLX8394; Cohort 1/Day 1 = 900 mg/day PLX8394
88962279|NCT02012244|Experimental|fentanyl-based analgesia|fentanyl intravenous patient-controlled analgesia + additional pethidine
88962280|NCT02012244|Experimental|local anesthetic wound infiltration-based anlagesia|continuous wound inflitration with ropivacaine + tramadol intravenous patient-controlled analgesia + additional ketorolac or propacetamol
89554177|NCT05071287|Experimental|Intervention Group (mHealth + low-carbohydrate/ketogenic diet group)|Total calories will be set according to Look AHEAD intervention, and carbohydrate consumption restriction will be set based on recommendations from American Diabetic Association, National Kidney Foundation, and other evidence-based resources. Participants in this group will be asked to consume a low-carb/ketogenic diet. Specially, participants will receive a carbohydrate, protein, and fat intake goal based on 1.5 : 1 ratio (1.5 grams of fat to 1 gram of carbohydrate and protein combined). Daily macronutrient and calorie consumption will be individualized for each participant using ideal body weight as inferred from wrist circumference and activity level. Carbohydrate consumption will be less than 10% (20~50 g), protein 10-20% (1.0~1.2g/kg ideal body weight), and fat 70-80% of total daily energy, respectively. Nutritional ketosis will be reached by consuming such diet (0.5 mmol/L).
89554178|NCT05047705|Experimental|Distress Tolerance Skills Training|Distress tolerance skills training is a multicomponent intervention drawn from third-wave cognitive-behavioral therapy (CBT) protocols.
89554179|NCT05020470|Experimental|Self-guided mAPA (S-mAPA)|S-mAPA group will be provided with instructions so that participants can learn to self-administer APA weekly for four weeks and then followed by weekly telecommunication for Q & As.
89554180|NCT05020470|Experimental|In-Person Training + mAPA (IP-mAPA)|Participants will receive one in-person training after baseline data is collected and then will self-administer APA on the same schedule with weekly telecommunication as those in the mAPA group.
89554181|NCT05020470|Active Comparator|Usual Care Control (UC)|"Participants will receive usual care only for their pain; after enrolled, patients will receive weekly telecommunication to control for attention and time. The content of the phone/video call will focus on the pain problem they have and the investigators will provide additional information published by the National Center for Complementary and Integrative Health Chronic Pain: In-Depth (https://www.nccih.nih.gov/health/chronic-pain-in-depth) which the investigators used in the R01 study for participants enrolled in the control group"
89208179|NCT00860808|Experimental|2 AM-101|high dose
89554182|NCT04996264|Experimental|Varespladib-methyl|"Varespladib-methyl is an immediate-release (IR), oval, white, film-coated tablet at a dosage strength of 250 mg for oral administration.~Scaled pediatric doses of varespladib-methyl are supplied as 50 mg IR capsules for oral administration.~Adult subjects will receive an initial loading dose of 500 mg (2 × 250 mg oral tablet) varespladib-methyl upon randomization, followed by dosing with 250 mg varespladib-methyl (1 × 250 mg oral tablet) approximately 12 hours later, and subsequent twice daily (BID) dosing with 1 × 250 mg varespladib-methyl oral tablets for the remainder of the 7-day treatment period. Tablets may be administered via naso- or orogastric tubes in patients requiring mechanical ventilation.~Pediatric subjects (5 to < 18 years) will be administered doses of varespladib-methyl determined by allometric scaling, provided as 50 mg capsules. Age-appropriate capsules may be administered via naso- or orogastric tubes in patients requiring mechanical ventilation."
89554183|NCT04996264|Placebo Comparator|Placebo|"The oral placebo is supplied as a white film-coated oval tablet to match the appearance of the varespladib-methyl 250 mg tablet and contains a subset of the excipients present in the active tablet formulation: lactose monohydrate, microcrystalline cellulose, and magnesium stearate.~Placebo for scaled pediatric dosing is supplied as an immediate-release capsule to match the varespladib-methyl 50 mg capsule, and contains the excipients lactose monohydrate, microcrystalline cellulose, and magnesium stearate.~The dosing of placebo will match that of varespladib-methyl."
89554184|NCT04969822|No Intervention|Embryo selection by standard morphologic criteria|The embryo for transfer will be selected by the embryologist on the basis of the morphologic appearances on day 5, according to the Gardner criteria using the ranking guideline.
89554185|NCT04969822|Experimental|Embryo selection by iDA|Time-lapse videos will be analyzed by iDA and the embryo for fresh transfer on day 5 will be prioritized on the strict basis of the embryo with the highest iDA score. For a frozen cycle; the first embryo to be warmed will be the one with the highest iDA score.
89554186|NCT04957134|Experimental|Electro-acupuncture|Participants will receive electro-acupuncture combined with lifestyle intervention. Participants will receive the treatment of electroacupuncture 3 times a week to fulfill a 8-session treatment course.
89554187|NCT04957134|Placebo Comparator|Sham electro-acupuncture|Participants will receive the treatment of sham electro-acupuncture 3 times a week to fulfill a 8-session treatment course, A superficial skin penetration (2-3 mm in depth) at nonacupoints will be performed in the sham acupuncture group, without needle manipulation for De qi. The internal output power cord of the electrical acupuncture stimulation instrument is interrupted.
89554188|NCT04931953|Active Comparator|Group 1|iTBS intervention lasting 30 minutes, given 4 days a week, for 1 week
89554189|NCT04931953|Active Comparator|Group 2|iTBS intervention lasting 30 minutes, given 4 days a week, for 2 weeks
89554190|NCT04931953|Active Comparator|Group 3|iTBS intervention lasting 30 minutes, given 4 days a week, for 4 weeks
89554191|NCT04931953|Sham Comparator|Group 4|Sham iTBS intervention lasting 30 minutes, given 4 days a week, for 2 weeks.
89554192|NCT04924712||Initial disease : nephrotic INS vs INS in remission|"25 nephrotic INS patients in primary visit: harvesting of 25 ml supplementary blood, urine and feces. No intervention, no treatment administration other than usual/routine INS treatment.~vs. the same 25 patient in INS remission : harvesting of 25 ml supplementary blood, urine and feces at the remission visit. No intervention."
89554193|NCT04924712||Post-transplantation recurrence : recurring vs non-recurring INS|"25 INS patients recurring the initial disease after renal transplantation in post-recurrence visit: harvesting of 25 ml supplementary blood, urine and feces. No intervention, no treatment administration other than usual/routine INS treatment.~vs. the 25 others INS patient non recurring after renal transplanatation: harvesting of 25 ml supplementary blood, urine and feces. No intervention."
89554194|NCT04911062|Experimental|Cohort 1: Bupivacaine HCl|Bupivacaine HCl without epinephrine, via injection into the surgical site.
89554195|NCT04911062|Experimental|Cohort 2: HTX-011|HTX-011 (bupivacaine/meloxicam) via application into the surgical site.
89554196|NCT04911062|Experimental|Cohort 3: HTX-011|HTX-011 (bupivacaine/meloxicam) via application into the surgical site.
89554197|NCT04818749|Placebo Comparator|Placebo|Participants allocated to this arm will have placebo administered intravenously before block performance and placebo administered intravenously after induction of general anaesthesia.
89554198|NCT04818749|Active Comparator|Dexamethasone 12 mg|Participants allocated to this arm will have dexamethasone 12 administered intravenously before block performance and placebo administered intravenously after induction of general anaesthesia.
89554199|NCT04818749|Experimental|Dexamethasone 12 mg + dexmedetomidine 1 mcg/kg|Participants allocated to this arm will have dexamethasone 12 administered intravenously before block performance and dexmedetomidine 1 mcg/kg administered intravenously after induction of general anaesthesia.
89554200|NCT04817137|Other|All Enrolled Patients|Patients will wear the Caretaker Pulse Decomposition Analysis (PDA) Device, which will record the patient's blood pressure.
89554201|NCT04815551|Experimental|AV-380 IV 4 mg/kg|IV infusion of AV-380 at dose level 4 mg/kg
89554202|NCT04815551|Experimental|AV-380 IV 8 mg/kg|IV infusion of AV-380 at dose level 8 mg/kg
89554203|NCT04815551|Experimental|AV-380 IV 13 mg/kg|IV infusion of AV-380 at dose level 13 mg/kg
89554204|NCT04815551|Experimental|AV-380 IV 20 mg/kg|IV infusion of AV-380 at dose level 20 mg/kg
89554205|NCT04815551|Experimental|AV-380 SC 4 mg/kg|Subcutaneous injection of AV-380 at dose level 4 mg/kg
89554206|NCT04815551|Experimental|AV-380 SC 2 mg/kg|Subcutaneous injection of AV-380 at dose level 2 mg/kg
89554207|NCT04815551|Experimental|AV-380 SC 1 mg/kg|Subcutaneous injection of AV-380 at dose level 1 mg/kg
89554208|NCT04815551|Placebo Comparator|Placebo|
89554209|NCT04795960|Experimental|Low serine diet|
89554210|NCT04795960|Experimental|High serine diet|
89025688|NCT00495807|Active Comparator|2|Positive words was delivered as a positive control group during the therapy of the pain with PCA
89554211|NCT04790071|Active Comparator|Conventional therapy|It covers the classical physical therapy modalities that patients will take for shoulder pain.
88962281|NCT02012257|Experimental|Anterior Site|AMSA nerve block injection
88962282|NCT02012257|Experimental|Common Site|AMSA nerve block injection
88962283|NCT02012257|Experimental|Posterior Site|AMSA nerve block injection
89554212|NCT04790071|Active Comparator|Conventional therapy plus dry needling|It covers the classical physical therapy modalities that patients will take for shoulder pain. It also refers to the dry needling treatment to be applied.
89554213|NCT04789980||Patients|Patients with locally advanced or metastatic pancreatic cancer who plan to receive palliative chemotherapy
89554214|NCT04776395|Experimental|Arm A (iberdomide hydrochloride, dexamethasone)|Patients receive iberdomide hydrochloride PO QD on days 1-21 and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive iberdomide hydrochloride PO QD on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89554215|NCT04776395|Active Comparator|Arm B (iberdomide hydrochloride)|Patients receive iberdomide hydrochloride PO QD on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89554216|NCT04726748||Urolift cohort|80 patients with prostatic urethral lift surgery will be included
89554217|NCT04726748||Transurethral Resection of the Prostate/laser cohort|80 patients with a transurethral resection of the prostate or laser surgery (enucleation or vaporisation) will be included.
89554218|NCT04726748||National healthcare insurance system database (SNDS) cohort|1200 patients with any transurethral surgery (TURP/laser) will be included and randomly matched to patients of the Urolift cohort with ratio 5:1.
89554219|NCT04716036|Active Comparator|Alcohol|Participants will be dosed to a 0.08g% blood alcohol concentration.
89554220|NCT04716036|Placebo Comparator|Placebo|Participants will receive a low dose of alcohol (placebo condition).
89554221|NCT04712552||Stereotactic robot-guided deep brain stimulation procedure|Patients requiring a stereotactic robot-guided deep brain stimulation procedure (Parkinson's disease, disabling tremor, dystonia)
89554222|NCT04671771|Experimental|Experimental: InnAVasc AVG treatment|"Patients will be surgically implanted with an InnAVasc AVG in the forearm or upper arm using standard vascular surgical techniques. The graft will be placed in a straight (soft C) configuration in the upper arm, or looped configuration in the forearm (forearm loop) or upper arm (axillary loop)."
89554223|NCT04657549|Active Comparator|Tonsillectomy|Patients will undergo tonsillectomy under general anesthesia within three weeks after enrollment.
89554224|NCT04657549|Active Comparator|Tonsillotomy|Patients will undergo tonsillotomy under general anesthesia within three weeks after enrollment.
89554225|NCT04657549|No Intervention|Watchful waiting|Patients will be closely monitored for the 5-6 months monitoring period.
89554226|NCT04630613||Patients with a previous diagnosis of ADPKD|Patients that have been diagnosed with ADPKD and are classified as Class 1A, 1B, 1C, 1D and 1E.
89554227|NCT04612049|Experimental|Children with hemiplegia|40 children with hemiplegia, 7-16 years-old at Gross Motor Function Classification System (GMFCS) Levels I-III and Manual Ability Classification System (MACS) Levels I-II will be recruited as participants. This age range was chosen based on our preliminary research in which children under the age of 7 had difficulty attending to repetitive task practice. Individuals will be recruited without regard to race or ethnicity. Our goal is to have a study sample that is 50% male and 50% female, and approximates the population of the Greater Boston, MA region.
89554228|NCT04612049|Experimental|Typically developing children|40 typically developing children, 7-16 years-old.
89554229|NCT04588688|Experimental|Mifepristone|Patients will be provided a single dose of 600 milligram (mg) mifepristone to be administered orally, and subjects will be instructed to take the drug between 10PM and 11PM on Day 1.
89554230|NCT04588662||Uveal Melanoma|Diagnosis of uveal melanoma Ability to provide written informed consent for participation in the prospective registry OR an institutional waiver by the IRB/ethics committee for retrospective data collection without written informed consent
88962284|NCT02012270||Conventional Group|Group of patients in whom after open AAA repair abdominal wall will be closed by conventional technique by the operating surgeons. There will be a great variation in sutures and techniques used
89208180|NCT00860808|Placebo Comparator|3 Placebo|
89554231|NCT04587830|Experimental|ADI-PEG 20 plus Radiotherapy and Temozolomide|"ADI-PEG 20 Dose: 18 and 36 mg/m2 given weekly Route of Administration: Intramuscular (IM)~Radiotherapy Dose: 60 Gy in 30 daily (Monday-Friday) fractions of 2 Gy each; to start within 5 weeks of surgery (diagnostic and/or resection)~Temozolomide Dose: 75 mg/m2 daily during radiotherapy; 150-200 mg/m2 for 5 days every 4 weeks (1 cycle) x 6 cycles during maintenance period Route of Administration: oral or intravenous"
89554232|NCT04558281|Experimental|Active Treatment|This group will receive a single injection nerve block of ropivacaine 0.5% (20 mL) followed by an infusion/boluses of ropivacaine 0.3% (continuous block)
89554233|NCT04558281|Placebo Comparator|Placebo|This group will receive a single injection nerve block of ropivacaine 0.5% (20 mL) followed by an infusion/boluses of normal saline
89554234|NCT04510090|Experimental|EP547 Single Dose|Single doses of EP547
89554235|NCT04510090|Experimental|EP547 Multiple Doses|Multiple doses of EP547
89554236|NCT04510090|Placebo Comparator|Placebo Single Dose|Single doses of placebo
89554237|NCT04510090|Placebo Comparator|Placebo Multiple Doses|Multiple doses of placebo
89554238|NCT04491006|Experimental|Low Dose|Daily subcutaneous (SC) injection of Low Dose ATH-1017
88962285|NCT02012270||PRINCIPLES Group|Group of patients in whom after open AAA repair abdominal wall will be closed by PRINCIPLES technique by the operating surgeons.
88962286|NCT02012309|Experimental|HIV-seronegative|HIV-seronegative subjects will receive Prevnar (PCV-13) at week 0.
89025689|NCT00495807|Active Comparator|3|Partially negative words was delivered during the PCA pain management
89208181|NCT00285649|Experimental|HVLA-SM|HVLA-SM, Experimental, high-velocity low amplitude spinal manipulation
89208182|NCT00285649|Experimental|LVVA-SM|LVVA-SM, Experimental, low velocity variable amplitude spinal manipulation
89554239|NCT04491006|Experimental|High Dose|Daily subcutaneous (SC) injection of High Dose ATH-1017
89554240|NCT04491006|Placebo Comparator|Placebo|Daily subcutaneous (SC) injection of Placebo
89554241|NCT04436510|Experimental|Verdiperstat|Verdiperstat is administered twice daily p.o. for 24 weeks.
89554242|NCT04436510|Placebo Comparator|Matching Placebo|Matching placebo is administered twice daily p.o. for 24 weeks.
89025690|NCT00495807|Active Comparator|4|Totally negative words was delivered during the PCA pain management
89554243|NCT04433052|Experimental|Personalised prevention program (PPP)|Participants will be invited to return to the study site six times over a three year period to receive lifestyle coaching and exercise prescriptions. Eupropean Society of Cardiology/European Association of Preventive Cardiology (ESC/EAPC) -designed lifestyle counselling will be partially delivered by novel smartphone applications. Participants will also receive pharmaceutical treatment according to the ESC guideline for chronic coronary syndromes.
89554244|NCT04433052|No Intervention|Usual care (UC)|"Participants will be referred back to usual care provided by their treating physicians. It is anticipated that physicians will treat these participants according to local usual medical practices. Patients randomized to UC group will not receive any treatment recommendations nor restrictions by the study investigators or nurses.~Randomized UC patients are invited to site visits twice over a three year period."
89554245|NCT04365400|Experimental|DS102 2000mg|Participants in this group received 1000mg DS102 capsules twice daily.
89554246|NCT04365400|Experimental|DS102 4000mg|Participants in this group received 2000mg DS102 capsules twice daily.
89554247|NCT04365400|Placebo Comparator|Placebo|Participants in this group received placebo capsules twice daily.
89554248|NCT04343222|Experimental|Group A: Bromfenac then Artificial Tears|Participant receives 1 drop of topical Bromfenac 0.09% 30 minutes prior to the injection and then 1 drop of an artificial tear eye drop immediately after the injection and wash.
89554249|NCT04343222|Experimental|Group B: Artificial Tears then Bromfenac|Participant receives 1 drop of an artificial tear eye drop 30 minutes prior to the injection and then 1 drop of topical Bromfenac 0.09% immediately after the injection and wash.
89554250|NCT04343222|Placebo Comparator|Group C: Artificial Tears then Artificial Tears|Participants receives 1 drop of an artificial tear eye drop 30 minutes prior to the injection and then 1 drop of an artificial tear eye drop immediately after the injection and wash.
89554251|NCT04342039|Placebo Comparator|Placebo|Participants will use a placebo nasal spray before being exposed to a series of allergen and pollution challenges.
89554252|NCT04342039|Active Comparator|Budesonide nasal|Participants will use budesonide nasal spray before being exposed to a series of allergen and pollution challenges.
89554253|NCT04281108|Experimental|APT-1011|APT-1011 3 mg HS
89554254|NCT04281108|Placebo Comparator|Placebo|HS
89554255|NCT04268849|Active Comparator|Oral Iron|The subject will receive one IV infusion of ferumoxytol administered as 1020 mg over 30 minutes or an equivalent volume of normal saline. At the time of the infusion, the patient will also be given an opaque bottle, containing either vitamin C tablets or ferrous sulfate 325 mg.
89554256|NCT04268849|Active Comparator|IV Iron|The subject will receive one IV infusion of ferumoxytol administered as 1020 mg over 30 minutes or an equivalent volume of normal saline. At the time of the infusion, the patient will also be given an opaque bottle, containing either vitamin C tablets or ferrous sulfate 325 mg.
89554257|NCT04258046|Experimental|Oral Trametinib|Patients will receive oral trametinib once daily
89554258|NCT04227587|Experimental|Zero Time Exercise training|Subjects in this group will attend two 2-hour ZTEx training lessons. Each subject will receive a handout and an exercise log. The handout includes a picture-illustrating ZTEx step-by-step protocol. The exercise log is for them to record their time spending on performing the ZTEx.
89554259|NCT04227587|Active Comparator|Sleep hygiene education|Subjects in this group will receive two 2-hour lessons of sleep hygiene education delivered by a registered nurse. Each subject will receive a handout and a sleep hygiene log.Subjects will be told to record their daily compliance with sleep hygiene instructions using yes/no questions in the sleep hygiene log.
89554260|NCT04217161|Experimental|Dexcom G6 Continuous Glucose Monitor|
89554261|NCT04192227|Experimental|Wellness Group 1|Administered by wellness facilitator and co-facilitator.
89554262|NCT04192227|Active Comparator|Wellness Group 2|Administered by wellness facilitator and co-facilitator.
89554263|NCT04189055|Experimental|Cohort #1|Cetuximab monotherapy (500mg/m² IV, day 1)
89554264|NCT04189055|Experimental|Cohort #2|Cetuximab and irinotecan (cetuximab 500mg/m² IV, day 1; irinotecan 180mg/m² IV, day 1).
89554265|NCT04162470|Experimental|REGN3918|Participants who have completed 1 of the 2 parent studies (R3918-PNH-1852 [NCT03946748] or R3918-PNH-1853)
89554266|NCT04147806|Active Comparator|IGRT 45 Gy in 5 fractions of 9 Gy|Hypofractionated IGRT at a prescription dose of 45 Gy in 5 fractions of 9 Gy delivered in five consecutive days
89554267|NCT04147806|Experimental|IGRT 24 Gy single dose|single fraction IGRT at a prescription dose of 24 Gy
89554268|NCT04131361|Active Comparator|Crystalloid -control group:|
89554269|NCT04131361|Experimental|Colloid- study group:|
89554270|NCT04122625|Experimental|Part A - Debio 1143 150 mg + Nivolumab|Participants received Debio 1143, 150 milligrams (mg) capsules, orally once on Days 1 to 10 and Days 15 to 24 of each 28-day treatment cycle along with nivolumab 240 mg, intravenous (IV) infusion on Days 1 and 15 of each 28-day treatment cycle allowed for a maximum of 26 cycles.
89554271|NCT04122625|Experimental|Part A - Debio 1143 200 mg + Nivolumab|Participants received Debio 1143, 200 mg capsules, orally once on Days 1 to 10 and Days 15 to 24 of each 28-day treatment cycle along with nivolumab 240 mg, IV infusion on Days 1 and 15 of each 28-day treatment cycle allowed for a maximum of 26 cycles.
89554272|NCT04122625|Experimental|Part B - Cohort 1 (SCLC): Debio 1143 200 mg + Nivolumab|Participants with small-cell lung cancer (SCLC) received Debio 1143, 200 mg capsules, orally once on Days 1 to 28 in each 28-day treatment cycle along with nivolumab 240 mg, IV infusion on Days 1 and 15 of each 28-day treatment cycle allowed for a maximum of 26 cycles.
89554273|NCT04122625|Experimental|Part B - Cohort 2 (SCCHN): Debio 1143 200 mg + Nivolumab|Participants with squamous cell carcinoma of the head and neck (SCCHN) received Debio 1143, 200 mg capsules, orally once on Days 1 to 28 in each 28-day treatment cycle along with nivolumab 240 mg, IV infusion on Days 1 and 15 of each 28-day treatment cycle allowed for a maximum of 26 cycles.
89025691|NCT00461162|Experimental|1: i-DSMP|Internet Dyspnea Self-management Program (i-DSMP)
89025692|NCT00461162|Experimental|2: f-DSMP|Face-to-Face Dyspnea Self-management Program (f-DSMP)
89025693|NCT00461162|Active Comparator|3: AC|Attention Control (AC)
89208183|NCT00285649|Active Comparator|Usual Medical Care|Usual Medical Care, Active Comparator, advice, exercises and medications
89208184|NCT00864240|Experimental|A|Clobex TM 0.05% Lotion, single exposure
89554274|NCT04122625|Experimental|Part B - Cohort 3 (GI Cancers): Debio 1143 200 mg + Nivolumab|Participants with gastrointestinal (GI) cancers received Debio 1143, 200 mg capsules, orally once on Days 1 to 28 in each 28-day treatment cycle along with nivolumab 240 mg, IV infusion on Days 1 and 15 of each 28-day treatment cycle allowed for a maximum of 26 cycles.
89554275|NCT04122625|Experimental|Part B - Cohort 4 (Gynecologic Cancers): Debio 1143 200 mg + Nivolumab|Participants with gynecologic cancers received Debio 1143, 200 mg capsules, orally once on Days 1 to 28 in each 28-day treatment cycle along with nivolumab 240 mg, IV infusion on Days 1 and 15 of each 28-day treatment cycle allowed for a maximum of 26 cycles.
89554276|NCT04091984||Prospera Arm|There is no intervention in this study. Adult patients who have received a kidney allograft from a genetically different donor in the past 2 years including within 60 days and who have been selected by their healthcare provider to receive Prospera dd-cfDNA testing according to their regular interval testing schedule as part of their clinical care will have medical records pertaining to their kidney rejection status collected at each study visit.
89554277|NCT04091984||Control Arm|The control arm will consist of retrospective data review of cases where a renal allograft from a genetically different donor was performed. Data pertaining to to their kidney rejection status from a minimum of 3 time points per year post allograft (up to 5 years) or until renal allograft failure will be collected.
89554278|NCT04077346|Experimental|Transcutaneous Spinal Stimulation- Acute and with Training.|"For Aim 1: Participants will receive transcutaneous stimulation (TcStim) in supine or side lying position at a single or multi site spinal levels to produce stepping/locomotor activity in lower limbs.~For Aim 2: TcStim will be delivered while participants are stepping on a computerized treadmill with an overhead partial body weight support (BWS) system and while stepping overground.~For Aim 3: Participants will first receive a combination of Activity-based locomotor training (AB-LT)+TcStim for 60 sessions."
89554279|NCT04058288||Stroke|People suffering from upper-limb motor dysfunction due to stroke
89554280|NCT04057105|Active Comparator|MusicGlove and Active HD-tDCS|During Active HD-tDCS, current up to 2mA will be delivered transiently for only 30 seconds and it will be turned ON for the remainder of 20 minutes.
89554281|NCT04057105|Sham Comparator|MusicGlove and Sham HD-tDCS|During Sham HD-tDCS, current up to 2mA will be delivered transiently for only 30 seconds to simulate the real-tDCS based skin sensation.
89554282|NCT04044313|Experimental|HAIC plus Lenvatinib and Toripalimab|Hepatic arterial infusion of oxaliplatin , fluorouracil, and leucovorin every 3 weeks. Lenvatinib 12 mg (or 8 mg) once daily (QD) oral dosing. Toripalimab 240mg intravenously every 3 weeks.
89554283|NCT04042337|Experimental|PRT Telehealth|Participating parents will receive 12 weekly 60-minute parent training sessions via secure videoconference to learn Pivotal Response Treatment
89554284|NCT04042337|No Intervention|Waitlist|Participants will continue stable community-based treatments
89554285|NCT04032990|Experimental|Transcutaneous spinal stimulation - Acute and Training|Safety and feasibility outcome measures are collected during application of transcutaneous spinal stimulation while upper extremity function is assessed at 3 time points (acute) and/or in combination with activity-based upper extremity training (40 sessions, 1.5 hours/day, 5 days/week); stimulation will be applied intermittently for no more than 10 minutes at a time. Upper extremity training is based on usual care activities to challenge use of the hands and arms, e.g. reaching, grasping, manipulating objects.
89554286|NCT03975634|Experimental|Transcutaneous spinal stimulation|Safety and feasibility outcome measures are collected during application of transcutaneous spinal stimulation while trunk control is assessed at 3 time points (acute) and/or while transcutaneous stimulation is applied in combination with activity-based locomotor training (40 sessions, 1.5 hours/day, 5 days/week; stimulation will be applied intermittently for no more than 10 minutes at a time during training)
89554287|NCT03968757||Obese patients eligible for laparoscopic RYGB surgery.|
89554288|NCT03941756|Experimental|Group I (LVB)|Patients receive indocyanine green IV and undergo lymphangiography, then undergo LVB at the time of ALND.
89554289|NCT03941756|No Intervention|Group II (no intervention)|Patients do not receive indocyanine green, undergo lymphangiography, nor undergo LVB at the time of ALND.
89554290|NCT03887455|Experimental|Core Study: Lecanemab 10 mg/kg biweekly|
89554291|NCT03887455|Placebo Comparator|Core Study: Placebo|
89554292|NCT03887455|Experimental|Extension Phase: Lecanemab 10 mg/kg biweekly|
89554293|NCT03887455|Experimental|Extension Phase: Lecanemab 720 mg Subcutaneous Injection Weekly|This will include approximately 40 de novo participants (those that did not participate in the core study) with early Alzheimer disease (AD).
89554294|NCT03836976|Experimental|All participants|All participants receive auditory gamma sensory stimulation.
89554295|NCT03824704|Experimental|Cohort A: Ovarian Cancer Cohort|"Oral rucaparib and Intravenous (IV) nivolumab (combination therapy)~Cohort A1~Cohort A2"
89554296|NCT03800537|Experimental|All Participants|All participants will receive the investigational MR Fingerprinting sequence.
89554297|NCT03798106|Experimental|durvalumab+pazopanib|Durvalumab 1500mg IV 1hr q3weeks Pazopanib 800mg QD PO q3wwks
89554298|NCT03767075|Experimental|Module 1 - Atezolizumab|"Genomically selected populations will all receive the same drug~Arm 1A: BRCA1 or BRCA2 mutations~Arm 1B: MLH1, MSH2, MSH6, or PMS2 mutations~Arm 1C: tumors with POLE mutation, POLD1 mutation~Arm 1D: hypermutated tumors~Arm 1E: tumors with other mutations in DNA-repair genes~Arm 1F: tumors with amplified PDL1~Arm 1G: tumours with CDK12 mutations~Subjects will be recruited and allocated to arms according to their biomarker profile. It is assumed that 1000 subjects will need to be screened in part A in order to enroll 120 patients in part B of module 1."
89554299|NCT03767075|Experimental|Module 2 - Futibatinib|"Genomically selected populations will all receive the same drug~Arm 2A: Known pathogenic FGFR1-3 mutations~Arm 2B: Variants of unknown significance in FGFR1-3 with functional relevance or pathogenic FGFR4 mutations.~Arm 2C: Highly amplified FGFR1-3 with high FGFR1-3 mRNA (with the exception of gastric and breast cancer)~Arm 2D: Highly amplifiedFGFR1-3 without high FGFR1-3 mRNA (with the exception of gastric and breast cancer)~Subjects will be recruited and allocated to arms according to their biomarker profile. It is assumed that 2000 subjects will need to be screened in part A in order to enroll 80 patients in part B of module 2."
89208185|NCT00795392||1|Patients assessed with ASA physical status scale
89208186|NCT00795392||2|Patients assessed with full-scale psychological factors
89554300|NCT03767075|Experimental|Module 3 - Amivantamab|"Genomically selected populations will all receive the same drug~Arm 3A: kinase domain mutations/ MET fusion-genes (including intragene exon skipping MET-MET fusions)~Arm 3B: MET copy number gain (equivalent CNG ≥6) (exception: colorectal cancer)~Arm 3C: EGFR mutations (exception: primary lung malignancies)~Subjects will be recruited and allocated to arms according to their biomarker profile. It is assumed that 1725 subjects will need to be screened in part A in order to enroll 69 patients in part B of module 3."
89554301|NCT03766581|Placebo Comparator|BMS-986177 Placebo|Specified Dose on Specified Days
89554302|NCT03766581|Experimental|Dose 1: BMS-986177 + Aspirin + Clopidogrel|Specified Dose on Specified Days
89554303|NCT03766581|Experimental|Dose 2: BMS-986177 + Aspirin + Clopidogrel|Specified Dose on Specified Days
89554304|NCT03766581|Experimental|Dose 3: BMS-986177 + Aspirin + Clopidogrel|Specified Dose on Specified Days
89554305|NCT03766581|Experimental|Dose 4: BMS-986177 + Aspirin + Clopidogrel|Specified Dose on Specified Days
89554306|NCT03766581|Experimental|Dose 5: BMS-986177 + Aspirin + Clopidogrel|Specified Dose on Specified Days
89554307|NCT03766581|Experimental|Dose 6: BMS-986177 + Aspirin + Clopidogrel|Specified Dose on Specified Days
89554308|NCT03766581|Experimental|Dose 7: BMS-986177 + Aspirin + Clopidogrel|Specified Dose on Specified Days
89554309|NCT03743129|Experimental|Anlotinib|Anlotinib p.o, qd. Treatment from Day 1 of randomization(after concurrent chemoradiation 4-6 weeks) to disease progress or untolerated toxicity or consent withdrawal. The 2:1 ratio (Anlotinib to blank).
89554310|NCT03743129|No Intervention|Blank|No intervention from Day 1 of randomization(after concurrent chemoradiation 4-6 weeks) .The 2:1 ratio (Anlotinib to blank).
89554311|NCT03723850|Experimental|Older, active tDCS, dlPFC|"Older adults (ages 60-75) randomized to this arm will receive 2 sessions of active tDCS stimulation (Soterix Medical) delivered to the left dorsolateral prefrontal cortex. One session will occur in the morning (8 or 9am) and one will occur on a separate day in the afternoon (3 or 4pm).~2."
89554312|NCT03723850|Sham Comparator|Older, sham tDCS, dlPFC|Older adults (ages 60-75) randomized to this arm will receive 2 sessions of sham tDCS stimulation (Soterix Medical) delivered to the left dorsolateral prefrontal cortex. One session will occur in the morning (8 or 9am) and one will occur on a separate day in the afternoon (3 or 4pm).
89554313|NCT03723850|Experimental|Younger, active tDCS, dlPFC|Younger adults (ages 18-30) randomized to this arm will receive 2 sessions of active tDCS stimulation (Soterix Medical) delivered to the left dorsolateral prefrontal cortex. One session will occur in the morning (8 or 9am) and one will occur on a separate day in the afternoon (3 or 4pm).
89554314|NCT03723850|Sham Comparator|Younger, sham tDCS, dlPFC/parietal|Younger adults (ages 18-30) randomized to this arm will receive 2 sessions of sham tDCS stimulation (Soterix Medical) delivered to either the left dorsolateral prefrontal cortex (area F3 using the 10-20 EEG system, n = 25), or the left parietal cortex (area P5 using the 10-20 EEG system, n = 25). One session will occur in the morning (8 or 9am) and one will occur on a separate day in the afternoon (3 or 4pm).
89554315|NCT03723850|Active Comparator|Younger, active tDCS, parietal cortex|Younger adults (ages 18-30) randomized to this arm will receive 2 sessions of active tDCS stimulation (Soterix Medical) delivered to the left parietal cortex (area P5 using the 10-20 EEG system). One session will occur in the morning (8 or 9am) and one will occur on a separate day in the afternoon (3 or 4pm).
89554316|NCT03716778|Other|Classical exercise training modality in concentric mode (CON)|Description: Control group, usual medical care according to the rehabilitation recommendations
88962287|NCT02012309|Experimental|HIV-infected|HIV-infected subjects will receive Prevnar (PCV-13) at week 0, and Pneumovax (PPSV-23) at week 8 per Advisory Committee on Immunization Practices (ACIP) guidelines.
88962288|NCT02012322|Other|Placebo vs. Q10 100mg vs. Q10 300mg|
88962289|NCT02012322|Other|Placebo vs. Q10 300mg vs. Q10 100mg|
89554317|NCT03716778|Experimental|experimental, active group (ECC)|Patients perform a mixed program combining eccentric pedalling session with the usual sessions
89554318|NCT03705520||Cross-Sectional|This cohort is composed of only medicated PD subjects and their spouse or 1st degree relative.
89554319|NCT03705520||Logitundinal|This cohort is composed of only non-medicated PD subjects and their spouse or first degree relative.
89554320|NCT03675321|Experimental|Auricular Neurostimulation|Intervention: Active Percutaneous Electrical Nerve Field Stimulation (PENFS) 5 days/week x 4 weeks
89554321|NCT03675321|Sham Comparator|Sham Auricular Neurostimulation|Intervention: Sham (Inactive) Percutaneous Electrical Nerve Field Stimulation (PENFS) 5 days/week x 4 weeks.
89554322|NCT03638596|Experimental|Contingency Management|Incentive delivery contingent upon maintaining transdermal alcohol concentration below cut-off
89554323|NCT03638596|Placebo Comparator|Control|Incentive delivery not contingent on transdermal alcohol concentration
88962290|NCT02012322|Other|Q10 100mg vs. Placebo vs. Q10 300mg|
88962291|NCT02012322|Other|Q10 100mg vs. Q10 300mg vs. Placebo|
88962292|NCT02012322|Other|Q10 300mg vs. Placebo vs. Q10 100mg|
88962293|NCT02012322|Other|Q10 300mg vs. Q10 100mg vs. Placebo|
88962294|NCT02012335|Placebo Comparator|ECT + saline|Brief pulse ECT with saline as placebo in each session
88962295|NCT02012335|Experimental|ECT + Ketamine|Brief pulse ECT with 0.05 mg/kg ketamine infusion in each session
88962296|NCT02012361|Active Comparator|Control Group|This group will be treated as any other patient would. Their anesthesia will be conducted as per routine with a target Fraction of inspired oxygen concentration (FiO2) of 0.25. During the course of the operation a small muscle biopsy will be collected.
89208187|NCT02554370|Experimental|Psychoeducational programme|Psychoeducational programme
89554324|NCT03613363|Experimental|Helix Ventilator|The Helix ventilator is a non-FDA cleared ventilator device. The Helix ventilator has similar modalities to the Trilogy ventilator, which has FDA clearance. The Helix device has improved algorithms, controls, and features to enhance the therapy delivery. Additionally, Helix has an updated hardware platform which has been adequately tested to ensure that the device specifications are met. No pre-clinical or developmental clinical work was required because of Trilogy being the established predicate.
88962297|NCT02012361|Active Comparator|Single-Dose Heliox Group|This group will be treated with a single dose of inspired 75/25 heliox (75% helium 25% oxygen) breathed continuously for 15 minutes prior to the inflation of the surgical tourniquet. During the course of the operation a small muscle biopsy will be collected.
88962298|NCT02012387|Active Comparator|Active|Omalizumab 300 mg Subcutaneous route 300 mg dose (independent from total IgE, weight or high)
88962299|NCT02012387|Placebo Comparator|Placebo|Placebo Saline serum Subcutaneous route 0.6 ml saline serum with same volume as an active treatment
88962300|NCT02012387|Active Comparator|Open labeled|After the double blinded period, all patients from both arms will receive the active drug for 8 more months.
88962301|NCT02012400|Experimental|Intervention group|
88962302|NCT02012400|No Intervention|Control group|
88962303|NCT02012413|Active Comparator|PST group|roughly 20 patients will be treated with PST protocol, outcomes will be Kujala score improvement at 3, 6 and 12 months.
89554325|NCT03538262||former phase 3 PD trial participants|The AT-HOME PD cohort enrolled upon completion of STEADY-PD3 or during completion of SURE-PD3; enrolling 2 to 6 years after diagnosis, and on standard dopaminergic therapy for 0 to 3 years. Former STEADY-PD3 participants had been randomized (1:1) to 3 years of isradipine or placebo treatment; SURE-PD3 participants had been randomized (1:1) to 2 years of inosine or placebo treatment.
89554326|NCT03527745|Experimental|200 mg albendazole|against T. trichiura in preschool-aged children or against hookworm infections in preschool-aged children, school-aged children and adults
89554327|NCT03527745|Experimental|400 mg albendazole|against T. trichiura in preschool-aged children, school-aged children and adults or against hookworm infections in preschool-aged children, school-aged children and adults
89554328|NCT03527745|Experimental|600 mg albendazole|against T. trichiura in preschool-aged children, school-aged children and adults or hookworm infections in preschool-aged children, school-aged children and adults
89554329|NCT03527745|Experimental|800 mg albendazole|against T. trichiura in school-aged children and adults or against hookworm infections in school-aged children and adults
89554330|NCT03527745|Placebo Comparator|Placebo|against T. trichiura in preschool-aged children, school-aged children and adults or hookworm infections in preschool-aged children, school-aged children and adults
89554331|NCT03524534|Active Comparator|Telephone Follow-Up Intervention|
89554332|NCT03524534|Active Comparator|In-person follow-up intervention|
89554333|NCT03522584|Experimental|Treatment (tremelimumab, durvalumab, HIGRT, SBRT)|Patients receive tremelimumab IV over 1 hour and durvalumab IV over 1 hour on day 1, week 1. Treatment repeats every 4 weeks for up to 4 cycles or every 6 weeks for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive durvalumab IV over 60 minutes on day 1, week 16. Treatment repeats every 4 weeks for up to 9 cycles or every 6 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo hypofractionated radiation therapy using either HIGRT or SBRT over 3 fractions QOD during week 3.
89554334|NCT03515083|Experimental|Experimental|"In the experimental group, each patient will be issued an AliveCor Kardia electrocardiogram monitor that is compatible with their smartphone. Patients will be instructed on the use of the monitor at the initial visit with the study nurse. The patient will submit daily electrocardiogram transmission via on online portal. The study nurse may contact them via text message to remind them to submit their recordings, if they forget.~The remainder of the treatment of the experimental group will be identical to the control group. At the conclusion of the study, the patient will complete their final atrial fibrillation symptom assessment scale. Their smartphone electrocardiogram monitor will be reviewed to ensure that all of the recordings were retrieved successfully."
89554335|NCT03515083|No Intervention|Control|"Patients in the control group would receive the standard of care treatment for atrial fibrillation, including cardioversion and ablation as indicated. At monthly visits with the study nurse, a smartphone electrocardiogram monitor will be used to record patient's heart rhythm. No other intervention would be performed during the monthly visit. It is necessary to meet the subject at least once per month to receive the previous month's supply of pills and provide them with the next month's supply of pills. If these subjects were met less frequently, it is possible that the previous month's supply of pills might be lost by the end of the study.~During the study, if the patient is taken off anticoagulation due to medical contraindication or after an ablation, they will continue to be followed monthly but will not receive apixaban medication."
89554336|NCT03495115|Active Comparator|SCREENING MRI|Standard MRI procedure will be used.
89554337|NCT03495115|Experimental|SCREENING MG BI-RADS 4/5|"RSI is a DWI sequence with a built in distortion-correction technique that can be applied to any diffusion technique using echo planar imaging acquisition.~RSI will be performed using pulsed-field gradient, spin-echo, echo planar imaging with multi-shell diffusion data .~The b0 images will be collected in both the forward and reverse phase encoding directions to allow for post-processing correction of spatial distortion from magnetic field."
89554338|NCT03482557|Experimental|CESM VS MRI|"Each enrolled participant will receive both a CESM and MRI exam prior to the breast biopsy, if they had not been performed already as part of clinical care.~MRI: Breast MRI will be performed, if not already performed as part of clinical care.~CESM: After the MRI is complete, patients will be brought to the mammography department for the contrast enhanced mammogram. The CESM will only occur if not already performed as part of the patient's clinical care.~Biopsy: Patients will then have their biopsy. Any additional findings seen on the CESM or MRI will be worked up also.~Reader Study: The CESM and the MRI images will be included in a case set that is ready by 10 study radiologists at a later date, after the biopsy is performed. These radiologists will look at the images to see if CESM and MRI find the same number of breast cancers."
88962304|NCT02012413|Placebo Comparator|Control group|roughly 20 patients will be submitted to a placebo PST protocol, outcomes will be Kujala score improvement at 3, 6 and 12 months.
88962305|NCT02012426|Experimental|Intervention Group|Participants enrolled in commercial weight management program
88962306|NCT02012426|Active Comparator|Control group|Participants enrolled in standard care weight management provision
88962307|NCT02012439|Active Comparator|Mindfulness Based Cognitive Therapy|Mindfulness Based Cognitive Therapy
88962308|NCT02012439|Active Comparator|Cognitive therapy|Cognitive Therapy
89208188|NCT02554370|No Intervention|Usual care|No psychoeducational programme
89554339|NCT03305562||Retrospective cohort|The cohort of patients seen prior to the implementation of a standardized clinical management protocol on 10/01/2017 whose data is collected retrospectively.
89554340|NCT03305562||Prospective cohort|The cohort of patients seen initially seen after implementation of a standardized clinical management protocol on 10/01/2017 whose data is collected prospectively.
89554341|NCT03284463|Active Comparator|Glibenclamide|Glibenclamide Tablets
89554342|NCT03284463|Placebo Comparator|Placebo|Placebo for Glibenclamide
89554343|NCT03223103|Experimental|Mutation-derived tumor vaccine|MTA-based Personalized Vaccine (peptides + Poly-ICLC with Tumor Treating Fields
89554344|NCT03208907|Active Comparator|CQ coadministered with PQ|Chloroquine was administered for 3 days according to the brazilian protocol and Primaquine was administered for 14 days (0.50mg/kg/day)
89554345|NCT03208907|Experimental|DHA-PQP coadministered with PQ|Dihydroartemisinin/Piperaquine was administered according to the weight and Primaquine (0.50mg/kg/day)
89554346|NCT03208907|Experimental|CQ and PQ starting on Day 42|Chloroquine was administered for 3 days according to the brazilian protocol and Primaquine started on Day 42 for 14 days (0.50mg/kg/day) [arm halted after preliminary analysis]
89554347|NCT03208907|Experimental|DHA-PQP and PQ starting on Day 42|Dihydroartemisinin/Piperaquine was administered for 3 days according to the weight and Primaquine started on Day 42 for 14 days (0.50mg/kg/day) [arm halted after preliminary analysis]
89554348|NCT03191058|Experimental|Magnetic Seizure Therapy (MST)|MST treatments will be administered using the MagPro MST with Cool TwinCoil.
89554349|NCT03191058|Active Comparator|Electroconvulsive Therapy (ECT)|ECT treatments will be administered using the MECTA spECTrum 5000Q or the MECTA Sigma devices.
89554350|NCT03187860|Experimental|Non-smoking controls|"Subjects in this group have never smoked and have no known lung disorders.~Intervention: Bronchial Biopsy + ALI culture (Air Liquid Interface)"
89554351|NCT03187860|Experimental|Smokers without COPD|"Subjects in this group are smokers or former smokers who do not have signs of obstructive disease (no chronic obstructive pulmonary disease (COPD))~Intervention: Bronchial Biopsy + ALI culture"
89554352|NCT03187860|Experimental|Smokers with COPD|"Subjects in this group are smokers or former smokers who have COPD~Intervention: Bronchial Biopsy + ALI culture"
89554353|NCT03187860|Experimental|Severe asthma|"Subjects in this group are non-smokers or former (light) smokers who have severe asthma.~Intervention: Bronchial Biopsy + ALI culture"
89554354|NCT03174782|Active Comparator|Treatment|Patients randomized to the treatment group will receive regional nerve blocks (sciatic and femoral) with bupivacaine at the dose of 1 mg/kg.
89554355|NCT03174782|Placebo Comparator|Control|Patients randomized to the control group will receive two needle sticks (in the sciatic and femoral distributions) with normal saline to maintain the double-blinded investigation.
89554356|NCT03145298|Experimental|Biological: Allogeneic Human Cardiosphere-Derived Cells (CDCs)|The Phase 1a portion (N=6 subjects) consists of an open-label, single-arm, study design - dose escalation. The potentially conducted Phase 1b portion of the study (N=20 subjects) consists of a double-blind, randomized, placebo-controlled study design.
89554357|NCT03145298|Placebo Comparator|Placebo|The placebo study arm only applies to the Phase Ib portion of the study design. The Phase Ia portion (N=6 subjects) consists of an open-label, single-arm, study design. The potentially conducted Phase Ib portion of the study (N=20 subjects) consists of a double-blind, randomized, placebo-controlled study design with a 1:1 ratio.
89554358|NCT03115333|Experimental|Diagnostic (DSC-MRI)|Patients undergo DSC-MRI within 3 days before bevacizumab initiation and at day 15.
89554359|NCT03110523|Experimental|Group A|High Dose: X0002 or placebo, BID (in the morning and before going to bed), n=376
89554360|NCT03110523|Experimental|Group B|Low Dose: X0002 or placebo, BID (in the morning and before going to bed), n=376
89554361|NCT03090659|Experimental|LCAR-B38M treatment group|r/r multiple myeloma patients be treated with a split doses of LCAR-B38M cells. Total dose of 0.5-5 millions /kg cells will be administered at day 0, day 2 and day 6 by split dose (20%, 30% and 50% respectively).
89554362|NCT03081364||Outpatients|MRI; Critical Care Monitoring, Device Programming
89554363|NCT02973685|Experimental|Hepatic arterial infusion chemotherapy|Procedure/Surgery: Hepatic arterial infusion chemotherapy Drug: Folfox Protocol. Hepatic intra-arterial infusion via the tumor feeding arteries of Oxaliplatin , fluorouracil, and leucovorin
89554364|NCT02973685|Active Comparator|Transarterial chemoembolization|Procedure/Surgery: Transarterial chemoembolization Drug: TACE Drug Protocol. Hepatic intra-arterial infusion with lipiodol mixed with chemotherapy drugs (EADM, lobaplatin, with or without MMC), and embolization with polyvinyl alcohol particles (PVA).
89554365|NCT02919969|Experimental|Pembrolizumab|"Pembrolizumab is administered every 3 week intravenously~Dosage to be determine by physician"
89554366|NCT02905812|Active Comparator|RGI & Massage|"relaxation and guided imagery with background music (RGI) (40 min, headphones)~a brief moderate pressure massage session (massage: 15 min)"
89554367|NCT02905812|No Intervention|Control|Sham intervention: Silent headphones to mask the audio component, and presence of an intervention nurse at the bedside with drawn curtains.
89554368|NCT02840656||healthy adult subject|oropharyngeal and rectal swabbing to collect Gram-negative bacilli
89554369|NCT02837263|Experimental|SBRT + Pembrolizumab|Subjects will receive stereotactic body radiotherapy (SBRT) within 4 weeks of enrollment. Following SBRT, subjects will receive one cycle of pre-operative pembrolizumab given as an IV over approximately 30 minutes. Surgical management to remove all known sites of metastatic disease should occur 2 weeks post pembrolizumab treatment. Approximately 4-8 weeks after surgery subjects will being the second phase of pembrolizumab treatment. They will receive this treatment every 3 weeks (cycle) for 8 more cycles after surgery. Prior to the 5th cycle of pembrolizumab subjects will also have tumor imaging (CT or MRI).
89554370|NCT02729350|Experimental|Guided Relaxation video clip|This intervention is a 12-minute guided audio-visual relaxation intervention delivered at the baseline (Day 1) visit to determine the immediate effects of guided relaxation intervention on stress and pain in inpatients with sickle cell disease. The GR intervention also includes six video clips, ranging from 2 to 20 minutes in length to determine the short-term (Day 5) effects of guided relaxation intervention on stress and pain.
89554371|NCT02729350|Other|Sickle cell experience discussion|Attention Control Group: This intervention is a 12-minute sickle cell disease experience discussion. In this computer-based discussion, patients will discuss their experience of having sickle cell disease. The audio-taped questions and onscreen directions were programmed to be self-administered. Subjects' responses will be captured via the microphone so that Data Collectors are not involved in this discussion process, and it is equivalent to the guided relaxation activity.
89554372|NCT02694055|Experimental|Proactive Community Case Management (ProCCM)|Villages assigned to the experimental arm will receive the following health system strengthening interventions: training of primary health centre staff, infrastructure improvements at primary health centre, removal of point-of-care user fees, and the presence of Community Health Workers providing proactive case detection in addition to integrated Community Case Management (ProCCM).
89554373|NCT02694055|Active Comparator|integrated Community Case Management (iCCM)|Villages assigned to the active comparator arm will receive the following health system strengthening interventions: training of primary health centre staff, infrastructure improvements at primary health centre, removal of point-of-care user fees, and the presence of Community Health Workers providing passive integrated Community Case Management (iCCM) exclusively at a fixed health post to patients who initiate their own care-seeking.
89554374|NCT02416622|Experimental|Groups 1A and 1B|Subjects at least 18 y/o treated with a lower dose of rAAV2tYF-CB-hRS1 study drug.
89554375|NCT02416622|Experimental|Groups 2 and 2A|Subjects at least 6 y/o treated with a middle dose of rAAV2tYF-CB-hRS1 study drug.
89554376|NCT02416622|Experimental|Group 3|Subjects at least 18 y/o treated with a higher dose of rAAV2tYF-CB-hRS1 study drug.
89554377|NCT02416622|Experimental|Group 4|Subjects at least 6 y/o treated with a maximum tolerated dose of rAAV2tYF-CB-hRS1 study drug determined for Groups 1A, 1B, 2 and 3.
89554378|NCT02352883|Experimental|Arm A (MRI)|Patients undergo MRI prior to surgery. Patients undergo additional imaging and/or biopsies if indicated based on MRI.
89554379|NCT02352883|Experimental|Arm B (mastectomy)|Patients undergo a mastectomy. Patients do not register for Step 3.
89554380|NCT02352883|Experimental|Arm C (wide local excision)|Patients undergo wide local excision +/- re-excision. Patients may cross-over to Arm B if mastectomy is indicated. Tissue samples collected during surgery are used to calculate the DCIS score using genetic analysis testing. Patients may then proceed to Step 3.
89554381|NCT02352883|Experimental|Arm D (endocrine therapy)|Patients undergo endocrine therapy as directed.
89554382|NCT02352883|Experimental|Arm E (radiation therapy, endocrine therapy)|Patients undergo radiation therapy and endocrine therapy as directed.
89554383|NCT02270632|Placebo Comparator|Arm 1|Placebo
89554384|NCT02270632|Experimental|Arm 2|F8IL10, 30 μg/kg
89554385|NCT02270632|Experimental|Arm 3|F8IL10, 160 μg/kg
89025694|NCT00495846|Experimental|A|"Patients with cirrhosis without HCC in all liver function classes already receiving specific therapy for cirrhosis who accept be subjected to liver biopsy and to sign the written informed consent to participate to the study~Patients with cirrhosis with multifocal HCC and clinical and/or radiological signs of persistence or recurrence of HCC in presence or absence of trombosis of the portal vein, with a single nodule of >6 cm in size or multiple nodules of >3 cm in size who accept be subjected to liver biopsy and to sign the written informed consent to participate to the study"
89025695|NCT00495846|Other|B|Historical controls
89025696|NCT00461240||acromegaly|
89554386|NCT01891344|Experimental|Ovarian cancer|rucaparib
89554387|NCT01399138|Experimental|Blueberry Powder|A blueberry smoothie will be consumed at the breakfast and dinner meals.
89554388|NCT01399138|Placebo Comparator|Placebo|A placebo smoothie will be consumed at the breakfast and dinner meals.
89554389|NCT01188096|Experimental|Poly ICLC|Children will receive poly-ICLC 20 mcg/kg twice weekly intramuscular injection (IM). The first 2 doses will be administered in the clinic under supervision.
89554390|NCT01094691|Experimental|Renal Allograft Biopsy|Urine left over from clinic visits is analyzed for 'Haufen' by negative staining electron microscopy as a marker of intra-renal polyomavirus nephropathy. Correlate Haufen, urine, and plasma data with the clinical presentation and with renal biopsy findings. Patients with PVN will be approached for study participation in which their routine samples will be monitored until urine is negative for 'Haufen', and a study protocol biopsy will be obtained for confirmation.
89554391|NCT01005420|Experimental|Blueberry Powder|"A blueberry smoothie will be consumed at the breakfast and dinner meals.~Nutritional Value:(based on one 16oz smoothie and subjects had to consume two a day)~206.4 Kcals~40.3 g Carbohydrate~11.5 g Protein~0.08 g Fat~0.05 g Sat fat~4.2 g Fiber~Ingredients:~245.0 g Dannon Light & Fit yogurt~105 .0 g Skim milk~22.5 g Freeze-dried blueberry powder~5.0 g Imitation vanilla flavor~1.0 g Splenda~16 oz plastic cup with lid~Smoothie total weight - 378.5 g"
89554392|NCT01005420|Placebo Comparator|Placebo|"A placebo smoothie will be consumed at the breakfast and dinner meals.~Nutritional Value:(based on one 16oz smoothie and subjects had to consume two a day)~201.3 Kcals~40.3 g Carbohydrate~10.7 g Protein~0.08 g Fat~0.05 g Sat fat~4.3 g Fiber~Ingredients:~245.0 g Dannon Light & Fit yogurt~105 .0 g Skim milk~5.0 g Benefiber~12.0 g Sugar~4.0 g Artificial blueberry flavor(liquid & powder)~1.5 g Red food color~0.7 g Blue food color~16 oz plastic cup with lid~Smoothie total weight - 373.2 g"
89554393|NCT00632853|Active Comparator|Arm A - Standard Radiotherapy + Chemotherapy|"Radiotherapy (every day, Monday-Friday, for a total of 3 weeks) XRT: 45 Gy BID (1.5 Gy/fx) starting on day 1 of Cycle 1 or 2, every day, for 3 weeks~Chemotherapy (every 21 days for 4 cycles, for a total of 12 weeks):~Cisplatin 80 mg/m2 IV on day 1 OR Carboplatin AUC 5 IV day 1, every 21 days~Etoposide 100 mg/m2 IV Register/ on days 1, 2, and 3, every 21 days"
89554394|NCT00632853|Experimental|Arm B - High Dose Radiotherapy + Chemotherapy|"Radiotherapy (every day, Monday-Friday, for a total of 7 weeks) XRT: 70 Gy QD (2.0 Gy/fx), starting on day 1 of Cycle 1 or 2, every day, for 7 weeks~Chemotherapy (every 21 days for 4 cycles, for a total of 12 weeks):~Cisplatin 80 mg/m2 IV on day 1 OR Carboplatin AUC 5 IV day 1, every 21 days~Etoposide 100 mg/m2 IV on days 1, 2, and 3, every 21 days"
89554395|NCT00579826|Experimental|Letrozole|Letrozole, 2.5 mg daily for 6 months
89554396|NCT00579826|Placebo Comparator|Placebo|Placebo, daily for 6 months
89025697|NCT00461240||growth hormone deficiency|
89025698|NCT00495924||PD|Patients undergoing pancreaticoduodenectomy for pancreatic or peri-ampullary tumours.
88962309|NCT02012465|Experimental|Insulin protocol|"For diabetic patients, as part of the initial chemotherapy orders on admission, the following will be calculated by the primary oncologist to determine the amount of neutral protamine Hagedorn (NPH) insulin needed to cover steroid use in prednisone equivalents (all insulin in this study is to be administered subcutaneously):~Use 0.1 (mg of prednisone equivalent - 20)/20 x weight (kg) to estimate total insulin in 24 hours (Total daily dose (TDD))~Total daily NPH dose will be divided equally based on the frequency of steroid administration, and given with each steroid dose.~For nondiabetic participants with hyperglycemia recruited during admission, the inpatient oncology team will consult the endocrine team within 24 hours of eligibility for NPH dosing as above."
88962310|NCT02012478|No Intervention|No intervention|baseline session - with surveys and HbA1C only
88962311|NCT02012478|Experimental|MI-informed SMS intervention|Baseline session with surveys & HbA1C MI baseline session Technology tutorial Intervention x 3 months
89554397|NCT00106691|Experimental|20 mg Toremifene Citrate|The subject takes one dose by mouth of the 20mg Toremifine Citrate tablet once a day for the length of the trial (360 days).
89554398|NCT00106691|Experimental|Placebo|The subject takes a placebo tablet identical in appearance to the toremifene 20mg tablet, administered by mouth daily for 360 days
89554399|NCT04089137|No Intervention|Control|This is an assessment only control condition.
89554400|NCT04089137|Experimental|Positive Change (+Change)|This is an integrated social norms-based personalized feedback intervention for college students targeting alcohol misuse and sexual assault. This intervention targets alcohol use, sexual assault victimization risk, sexual assault perpetration, and bystander intervention and is tailored by gender and sexual orientation.
89554401|NCT04004429|Experimental|50 mg AP1189|50 mg AP1189. The treatment is a 4 week treatment. Each daily dose will be administered as a suspension, i e. the powder will be added 50 ml water.
89554402|NCT04004429|Experimental|100 mg AP1189|100 mg AP1189. The treatment is a 4 week treatment. Each daily dose will be administered as a suspension, i e. the powder will be added 50 ml water.
89554403|NCT04004429|Placebo Comparator|Placebo|Placebo. The treatment is a 4 week treatment. Each daily dose will be administered as a suspension i e. the powder will be added 50 ml water.
89554404|NCT03826901|Experimental|Part 1: adults and adolescents (12 years and above)|Delgocitinib cream (dosage: A mg/g).
89554405|NCT03826901|Experimental|Part 2: children (2-11 years)|Delgocitinib cream (dosage: B mg/g).
89554406|NCT04590443|Experimental|NMP in Infrapiriformis level|Participants in this group received NMP of the sciatic nerve in the gluteus region
89554407|NCT04590443|Experimental|NMP in middle thigh level|Participants in this group received NMP of the sciatic nerve in the middle of the thigh
89554408|NCT04590443|Experimental|NMP in middle distal level|Participants in this group received NMP of the sciatic nerve before popliteus region
89554409|NCT03476759|Active Comparator|Tubal adhesiolysis|laparoscopic tubal adhesiolysis and\or tuboplasty
89554410|NCT03476759|Active Comparator|IVF/ICSI|These patients will undergo IVF/ICSI
89554411|NCT04582643|Experimental|6P intervention|6P assessment along with education provided based on the 6P components.
89554412|NCT04576325|Experimental|Voriconazole Inhalation Powder|Investigational drug will be supplied as capsules, each capsule contains 10 mg of Voriconazole Inhalation Powder. The capsules will be administered with the provided breath actuated Plastiape RS00 Model 8 Dry Powder Inhaler device.
89554413|NCT04576325|Placebo Comparator|Placebo|Placebo will be supplied as capsules, each capsule will contain no active ingredient. The capsules will be administered with the provided breath actuated Plastiape RS00 Model 8 Dry Powder Inhaler device.
89554414|NCT05231993|Active Comparator|Active comparator|"All women ages <41, women ages ≥41 with TZ1 and TZ2, and women ages ≥41 with a desire for further childbearing Clinical management and follow-up according to the national screening guidelines published in 2017 (same as for the comparator group, see below).~Women with TZ3 and women ages ≥41 with no desire for further childbearing a. Referral to (diagnostic) excision. The depth of the diagnostic excision will be clinically determined in the trial. It should be with the intent to treat but no so extensive that the risk for side effects increases.~The excision should include a cervical abrasion and endometrial sampling."
89554415|NCT05231993|Placebo Comparator|Placebo comparator|"Clinical management and follow-up according to the national screening guidelines published in 2017:~Colposcopy with biopsy within 3 months, endocervical sample, ultrasound and endometrial biopsy if the woman is ≥40~Colposcopy after 12 months if the first colposcopy and biopsies are normal~Cytology and HPV testing at 12 and 24 months if the second colposcopy is normal"
89554416|NCT05223257|Experimental|Experimental group|AOT is based on the observation of meaningful actions followed by their execution
89554417|NCT05223257|No Intervention|Control group|"Children will continue standard care for 8 weeks~Subject allocated to standard care group will have to continue what they normally do; they (if > 13 years) or their parents will have to fill a diary in which they will write the rehabilitative activities they do, specifying their intensity and whether these activities are more focused on the lower limbs or upper limbs."
89554418|NCT03390491|Experimental|OnTrack>TheGame (OTG)|Participants randomized to the OTG group (n=100) will have the option to play the online role-playing game for a period of 2 months. They will receive weekly email reminders that the game remains available to them.
88962312|NCT02012504||Western medicine|venlafaxine or escitalopram
88962313|NCT02012504||Chinese medcine|Shuganjieyu capsule
88962314|NCT02012517|Active Comparator|short antibiotic course|Intravenous 2 gram cefazolin every 8 hours for 24 hours beginning at surgery
88962315|NCT02012517|Experimental|Prolonged antobiotic treatment|Intravenous 2 gram cefazolin every 8 hours for 48 hours starting at surgery followed by oral cefalexin 500 mg every 6 hours until removal of drains
89025699|NCT00461279|Other|1|
89025700|NCT00461279|Other|2|
89554419|NCT03390491|Other|Recovery Videos (RV)|Participants randomized to the RV group (n=100) will have the option to visit a website that will contain the recovery videos and the static information that is contained in the game. The RV group will also have 2 months to view the materials on the website and will receive weekly email reminders that the website/videos remain available to them. At the end of the study (after the follow-up assessment), the RV participants will be provided access to the game.
89554420|NCT04422743|Experimental|standard of care + citicoline plus homotaurine (CIT/HOMO)|CIT/HOMO was supplemented for 4 months to the standard of care (SOC, i.e. topical intraocular pressure, IOP, lowering medication)
89025701|NCT04697082|Placebo Comparator|Group A|The open surgical method and a moist gauze (with saline) were applied to patients in group A
89025702|NCT04697082|Experimental|Group B|Open surgery and then PRP application were performed on patients in group B. After the cavity was filled with PRP, the wound was covered with a dry gauze.
89554421|NCT04422743|No Intervention|standard of care|only standard of care (SOC, i.e. topical IOP lowering medication) for 4 months
89554422|NCT04421417|Active Comparator|Standard Arthroscopic Rotator Cuff Repair|
89554423|NCT04421417|Experimental|Microfracture and Arthroscopic Rotator Cuff Repair|
89554424|NCT04401371||Hybrid learning group|students enrolled in hybrid learning pediatric dentistry course
89554425|NCT04401371||distance learning group|students enrolled in distance learning pediatric dentistry course
89554426|NCT05403515|No Intervention|Control group|Routine nursing interventions were performed on the patients.
89554427|NCT05403515|Experimental|Foot massage group:|For the patients in this group, sociodemographic form, happiness questionnaire, and PSQI was applied as pretest in preliminary examination. The final examination was performed 1 month later (posttest) by using the same scale. For the patients in foot massage group, 30-min foot massage sessions (15 min for each foot, 3 sessions per week for 1 month) were performed in a special room of rehabilitation center, in a quiet atmosphere at suitable temperature and without environmental stimulants.
89554428|NCT05403515|Experimental|Foot massage +Aromatherapy group:|For the patients in this group, sociodemographic form, happiness questionnaire, and PSQI was applied as pretest in preliminary examination. The final examination was performed 1 month later (posttest) by using the same scale. During the foot massage + aromatherapy lavender inhalation intervention, the patients were given lavender oil for 30 minutes by using a censer. The intervention protocol was developed reviewing the literature about lavender oil inhalation
89554429|NCT05140421|Experimental|Early Implementation|This arm will receive D2S intervention components during Period 1 (Early Implementation) as well as throughout Period 2 of the stepped-wedge trial.
89554430|NCT05140421|Active Comparator|Delayed Implementation|This arm will receive no D2S intervention components during Period 1 (Early Implementation), but will then receive all D2S intervention components in Period 2, starting 12 months later.
89554431|NCT05127629|Placebo Comparator|Control|
89554432|NCT05127629|Experimental|Collagen matrix|
89554433|NCT02535221|Experimental|Endocrine therapy;|Interventions：Goserelin+TAM+AI：Goserelin 3.6mg subcutaneous injection per 4 weeks, for 16-20weeks. TAM 10mg oral twice a day for the first four weeks(to wait the Goserelin start to work in body) than change to AI 1mg oral once a day with Goserelin for the next 12-16 weeks.
89554434|NCT02535221|Active Comparator|Chemotherapy|Interventions：Epirubicin+CTX+5-Fu：Epirubicin(80-100 mg/m2 Q21 days) + CTX(600 mg/m2 Q 21days) + 5-Fu (600 mg/m2 Q21 days or 200 mg/m2 •day from Day1 to day 21) for four to six cycles.
89554435|NCT05138237|Active Comparator|benign stricture|"no of cases suspected to be benign by using the diagnostic tools imaging , laboratory investigations , ERCP ,brushing ,cytology or histopathology"
89554436|NCT05138237|Active Comparator|malignant stricture|"no of cases suspected to be malignant by using the diagnostic tools imaging , laboratory investigations , ERCP ,brushing ,cytology or histopathology"
89554437|NCT05089253|Active Comparator|Dry needling|The standard 9- point dry needling technique will be applied for 20 minutes per session 3 times a week for 4 weeks.
89554438|NCT05089253|Active Comparator|kinesio taping|The Kinesio tape will be applied to the participants in supine with the knee in 90 flexions. Two Y-shaped tapes are applied above and below the patella. The tape will be removed after 48 hours after application. The Kinesio tape will be applied 3 times a week for 4 weeks
89554439|NCT04567121|Other|Intensive intervention group|intensive life-style and care intervention
89554440|NCT04567121|Other|Standard intervention group|standard life-style and care intervention
89554441|NCT04492007|Experimental|PRISMS|In addition to usual care, participants assigned to this arm will have access to our Patient-Reported Outcomes-Informed Symptom Management System (PRISMS) program.
89554442|NCT04492007|No Intervention|Usual Care|Participants assigned to this arm will receive the standard of care that is provided to all patients.
89554443|NCT05138159|Experimental|Experimental: Donafenib + S-1|Donafenib: 200mg po bid； S-1 capsule: According to the body surface area <1.25m2 40mg/d, 1.25 ~ 1.5 m2 50 mg/d, > 1.5m2 60mg/d po bid, taking 14 days, stopping for 7 days, 21 days for 1 cycle.
89554444|NCT04592159|Experimental|Nabiximols|Nabiximols is a complex botanical medicine formulated from extracts of the cannabis plant that contains the principal cannabinoids delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) and also contains minor constituents, including other cannabinoid and non-cannabinoid plant components, such as terpenes, sterols, and triglycerides.Each spray delivers 100 microliters (μL) of nabiximols.
89025703|NCT04697082|Experimental|Group C|PRP was applied to the patients in group C after curettage of the sinus cavity. And again the wound was covered with a dry gauze.
89025704|NCT00105482|Experimental|Naltrexone, Transdermal Nicotine|Arm 1 (Experimental) = Transdermal nicotine replacement (21 mg for first 6 weeks post-quit then 14 mg for 2 weeks) once per day + Naltrexone 25 mg oral capsule once per day
89025705|NCT00105482|Placebo Comparator|Placebo Naltrexone, Transdermal Nicotine|Arm 2 (Placebo Comparator) = Transdermal nicotine replacement (21 mg for first 6 weeks post-quit then 14 mg for 2 weeks) once per day + Placebo Naltrexone 25 mg oral capsule once per day
89025706|NCT03273686|Experimental|group without NG tube after surgery|In this goup, patients will undergo preoperative gastrointestinal decompression and investigators will discharge the NG tube during the surgery.
89025707|NCT03273686|No Intervention|group with NG tube after surgery|In this goup, patients will undergo preoperative gastrointestinal decompression and investigators will discharge the NG tube 6-7 days after the surgery.
89025708|NCT03273647|Experimental|surgery plus radiation|adjuvant radiotherapy is developed in this arm
89025709|NCT03273647|No Intervention|surgery alone|No adjuvant radiotherapy,that is surgery alone is developed in this arm
89025710|NCT00489099|Experimental|V232 Modified Process Hepatitis B Vaccine: Lot A|Recombivax HB™ (Hepatitis B Vaccine [Recombinant]) modified process Lot A administered as a 1 mL intramuscular injection on Day 1, Month 1, and Month 6.
89554445|NCT04592159|Placebo Comparator|Placebo|Placebo to match nabiximols will be presented as an oromucosal spray containing the excipients ethanol and propylene glycol (50% v/v) with colorings and flavored with peppermint oil (0.05% v/v). Each spray will deliver 100 μL containing no active ingredients. Placebo will be self-administered by participants as an oromucosal spray in the morning and evening, up to a maximum of 12 sprays per day for 8 weeks.
88962316|NCT02012530|Active Comparator|HA|Patients in this arm will have hyaluronic acid (HA) injected into their knee along with 3 ml local anaesthetic. The HA injection is in the form of 2 ml aqueous sodium hyaluronate. The exact constituents of the HA change in a proprietary manner. All HA injections used will have the CE marking on them.
89554446|NCT05061485|Experimental|Sucrose|The participants will be served a test drink with 75g sucrose dissolved in water
89554447|NCT05061485|Experimental|Sucrose + protein|The participants will be served a test drink with 75g sucrose dissolved in water and ~ 100 kcal protein (whey protein)
89554448|NCT05061485|Experimental|Sucrose + fat|The participants will be served a test drink with 75g sucrose dissolved in water and ~ 100 kcal fat (cream)
89554449|NCT05138081|Experimental|PNF Stretching: Group A|Routine physical therapy treatment
89554450|NCT05138081|Experimental|Stabilization Exercises: Group B|Routine physical therapy treatment
89554451|NCT05137613|Active Comparator|One visit root canal retreatment|The teeth were treated in one-visit (OV) root canal retreatment. Final root canal irrigation was performed with 5% EDTA, followed by 2.5% NaOCl and received an additional final rinse with 2% CHX before obturation.
89554452|NCT05137613|Active Comparator|Two visit root canal retreatment|The teeth were treated in two visit (TV) root canal retreatment. After completion of root canal instrumentation, calcium hydroxide (CH) paste was placed into the root canal. In second visit, all root canals were irrigated with 5% EDTA followed by 2.5% NaOCl before obturation.
89554453|NCT05137535||Children diagnosed with Covid-19|Pediatric patients enrolled by the family pediatricians participating in this study, affected by Covid-19 disease whose diagnosis was confirmed by SARS-Cov-2 molecular test
89554454|NCT05137457|Experimental|"Delivering Online ZZZ's with Empirical support (DOZE) app"|"The mobile Cognitive Behavioral Therapy for insomnia (CBTi) will be offered using the Delivering Online ZZZ's with Empirical support (DOZE) app. Patients assigned to the intervention group will be given the DOZE app which is an integrated smart phone app and web based self-management program for adolescents and young adults with sleep problems. The intervention will be delivered on restricted password-protected application. Participants will be encouraged to log onto the sleep dairy once a day over 10-weeks to complete sleep diary, develop and track their goals, and receive sleep health education tailored sleep health interventions. After 10-weeks, participants will complete questionnaires on sleep health, pain, and Health Related Quality of Life (HQRL). The use of actigraphy will be optional in view of the COVID19 pandemic."
89554455|NCT05137457|Active Comparator|Sleep Diary Only Attention Control|"The control group will receive the control version of the DOZE app where the patients will be able to access the sleep diary only, without the CBTi intervention. Participants will simply use the app to input entries into their sleep diary as an attention control over a 10-week period.~After the 10-week intervention period, participants will again complete a battery of questionnaires on sleep health, pain, and HRQL. The use of actigraphy will be optional in view of the COVID19 pandemic."
89554456|NCT05137145|Experimental|The control group|The control group was given 4L of Compound Polyethylene Glycol Electrolyte Powder to clear the intestines
89554457|NCT05137145|Experimental|the observation group 1|the observation group 1 was given Linaclotide(290 ug) in 1 day combined with 4L of Compound Polyethylene Glycol Electrolyte Powder to clear the intestine
89554458|NCT05137145|Experimental|the observation group 2|the observation group 2 was given Linaclotide(290 ug) in 1 day combined with 4L of Compound Polyethylene Glycol Electrolyte Powder to clear the intestine
89554459|NCT05137145|Experimental|the observation group 3|the observation group 3 was given Linaclotide(290 ug) in 3 day combined with 3L of Compound Polyethylene Glycol Electrolyte Powder to clear the intestine.
89554460|NCT05136911|Experimental|Intervention Group|The intervention group will receive the standard care in the form of HTN Canada Booklet, advice to see their health care provider, urgent care or walk-in clinic and the Salt Intervention (Salt Intervention Manual, five weekly online modules and five weekly telephone calls.
89554461|NCT05136911|No Intervention|Usual Care Group|All participants in the usual care group will receive the standard care in the form of HTN Canada Booklet, advice to see their health care provider, urgent care of walk-in clinic.
89554462|NCT05121467||Patients with Cervical Disc Herniation|Endurance tests were performed for 9 muscles/muscle groups in the cervical and scapular regions, upper limb, and trunk Visual Analogue Scale (VAS) and Neck Disability Index (NDI) Fremantle Neck Awareness Questionnaire (FreNAQ) Tampa Scale of Kinesiophobia (TSK)
89554463|NCT05306171|Experimental|Intervention group (I)|Online training for healthcare professionals which will follow a protocol made especially for this research. The online training is composed by 4 modules and each module has 3 meetings. Each meeting has 35 minutes long.
89554464|NCT05306171|No Intervention|Control group (C)|No intervention. The control group will receive the intervention after study is completed.
89554465|NCT05305937|Experimental|One arm - all patients|
89554466|NCT05305703|Experimental|Cervical muscles Stretching|Stretching is applied to the effected muscles in order to increase the muscle length and flexibility by breaking adhesions. Stretching exercises considerably decrease neck pain and improve range of motion
88962317|NCT02012530|Active Comparator|PRP|Patients in this arm will have platelet rich plasma (PRP) injected into their knee. The PRP sample will be produced at the time of the injection. 30 ml of blood is drawn fro the patient a few minutes before the injection. Using a CE marked differential centrifugation device, the platelets are isolated. This concentrated sample of platelets is injected into the knee after the skin around the injection site is anaesthetised with local anaesthetic.
88962318|NCT02012543|Experimental|Agar jelly, constipation|Subjects eat a cap of agar jelly (180g) shortly before eating dinner every day for 4 weeks.
88962319|NCT02012556|Experimental|Tesamorelin|
88962320|NCT02012569|Experimental|TT.173|It is applied directly to the bleeding of the donor site
88962321|NCT02012569|Placebo Comparator|placebo|It is applied directly to the bleeding of the donor site
89554467|NCT05305703|Experimental|Soft tissue mobilization with trigger point release.|Soft tissue mobilization increases skin temperature, a rise in skin temperature indicates increase blood flow of involved area, provide relaxation and reduce muscle tension.Trigger point therapy is consisting of rubbing and pressing on trigger points.Heavy pressure must be applied to release trigger, light pressure is not effective. Pressure should be applied slowly and released slowly for best results and the pressure should be maintained until there is a change in pain
89554468|NCT05305625|Experimental|standard therapy|Patients will be treated with Guideline standard
89554469|NCT05305625|Experimental|remote ischemic postcondioning and standard therapy|Patients will be treated with remote ischemic postcondioning and Guideline standard , remote ischemic postcondioning twice a day for a total of 3 days.
89554470|NCT05305469||GN|Gram-negative bacteria infection group
89554471|NCT05305469||GP|Gram-positive bacteria infection group
88962322|NCT02012595||Parkinson's patients|Participants with Parkinson's Disease
88962323|NCT02012595||Healthy Controls|Healthy participants
88962324|NCT02012660||Hyponatremia, seasonality|Summer months = June, July, August Winter months = December, January, February
88962325|NCT02012673|Experimental|Bronchoscopic lung volume reduction|Bronchoscopic lung volume reduction with the RePneu Lung Volume Reduction Coil system
88962326|NCT02012712|Experimental|Personal Health Record (PHR)|Subjects were sent an invitation to use an online Personal Health Record (PHR)
88962327|NCT02012712|No Intervention|Usual care|Subjects received usual care (no invitation or access to the study PHR)
88962328|NCT02012725||Arm 1 Mycardial Fibrosis|MRI with Intravenous administration of gadolinium
88962329|NCT02012725||Arm 2 Chronic Kidney Disease|MRI with no gadolinium administration
88962330|NCT02012738|Active Comparator|Assignment to FORNET|17 participants were randomly assigned to FORNET
88962331|NCT02012738|Active Comparator|Assignment to CBT|14 participants were randomly assigned to CBT
88962332|NCT02012738|Other|Waiting List Control Group (camp)|7 participants were randomly assigned to the Waiting List Control Group (camp)
88962333|NCT02012738|Other|Waiting List Control Group (no camp)|36 participants were assigned to the Waiting List Control Group (no camp)
88962334|NCT02012751|Experimental|Nevus doctor program|Use of Nevus doctor program to assess the diagnostic category of pigmented skin lesions
88962335|NCT02012764||Musculoskeletal symptoms - Pre diagnosis|Patients presenting with non-specific musculoskeletal complaints at risk of development of RA.
88962336|NCT02012777|Active Comparator|cohort 1 10mg propranolol|"first study arm will consist of 5 subjects who will be administered a dose of 10mg propanolol and followed 1-4 weeks.~Data safety and monitoring committee has reviewed the data for safety and instructed the study to continue based on the findings."
88962337|NCT02012777|Active Comparator|cohort 2 20mg propranolol|This cohort will involve the administration of 5 subjects with 20mg propanolol. The data safety and monitoring committee will review the data for safety when the 5 subjects are recruited and instruct the study to continue depending on the findings.
88962338|NCT02012777|Active Comparator|cohort 3 40mg propranolol|This cohort will involve the administration of 10 subjects with 40mg propanolol. The data safety and monitoring committee will review the data for safety when the 10 subjects are recruited and instruct the study to continue depending on the findings.
88962339|NCT02012790|Experimental|Diet A|Whole food diet modifies dietary fatty acids. Foods provided for 16 weeks; study oils provided for 22 weeks.
88962340|NCT02012790|Experimental|Diet B|Whole food diet modifies dietary fatty acids. Foods provided for 16 weeks; study oils provided for 22 weeks.
88962341|NCT02012790|Active Comparator|Diet C|Whole food diet modifies dietary fatty acids. Foods provided for 16 weeks; study oils provided for 22 weeks.
88962342|NCT02012803|Experimental|Operative treatment|
88962343|NCT02012803|Active Comparator|conservative treatment|
88962344|NCT02012816|Other|Uncircumcised men|The program allows each man coming for circumcision to refer up to 5 uncircumcised men in their social network for VMMC services and receive a monetary reward for each successful referral.
88962345|NCT02012829|No Intervention|control group|GPs from practices in the control group are asked to continue their usual care, as if they were not participating in this trial. They had to send their patients list to the research team to calculate their eligible population. They were also asked to list all the gaiac Fecal occult blood test ( gFOBT) delivered during the six months period of the study.
88962346|NCT02012829|Active Comparator|intervention|GPs communication skills and CRC screening :the intervention was a four hours educational training for GPs of the intervention group focused on communication skills with a patients' centered care approach to improve patients participation at CRC screening
88962347|NCT02012842|Active Comparator|Immediate periodontal treatment|Strict supragingival plaque control and non surgical periodontal treatment immediately after the baseline examination(test group).
88962348|NCT02012842|Other|Delayed periodontal treatment|Strict plaque control and non surgical periodontal treatment 6 months after the baseline examination (control group).
88962349|NCT02012855|Experimental|Exercise only|90 minutes of exercise
88962350|NCT02012855|Experimental|Exercise and high glycemic index meal|90 minutes of exercise followed by a high glycemic index meal matched for calories expended during the exercise
88962351|NCT02012855|Experimental|Exercise and low glycemic index meal|90 minutes of exercise followed by a low glycemic index meal matched for calories expended during the exercise
88962352|NCT02012855|No Intervention|No exercise and no meal|No exercise and no meal
89554472|NCT05305469||Fungal|Fungal infection group
88962353|NCT02012868||bariatric surgery, obstructive sleep apnoea|bariatric surgery
88962354|NCT02012881|Experimental|Physical activity intervention|60 minutes of physical activity on every school day
88962355|NCT02012881|Active Comparator|Control|Usual practice
88962356|NCT02012894||Obese patients with preoperative GER|Obese patients selected for laparoscopic sleeve gastrectomy with preoperative GER at 24 H pH-monitoring (Group A)
89554473|NCT05305469||Viral|Viral infection group
89554474|NCT05305469||Control|Non-sepsis group
89554475|NCT05305157||Experts on forensic odontology|Experts on forensic odontology, members of AFIO (French Association of odontological identification) and UIO (Odontological identification Unit)
89554476|NCT04938791|Experimental|Isometric activity|All participants will be included in this arm
89554477|NCT04457141|Other|first:shod ,second:minimalist shoes|"The first group will race with conventional shoes and then minimalist shoes. The group run 5 minutes for warming and then 30 seconds at 6km/h, 30 seconds at 9 km/h and 30 seconds at 11km/h.~They have a washout period of 10 minutes between both interventions."
89554478|NCT04457141|Other|first:minimalist shoes ,second:shod|"The second group will race with minimalist shoes and then conventional shoes. The group run 5 minutes for warming and then 30 seconds at 6km/h, 30 seconds at 9km/h and 30 seconds at 11km/h.~They have a washout period of 10 minutes between both interventions."
89554479|NCT05305079||ODD-AION|NA-AION patients with ODD aka. Optic disc drusen associated non-arteritic anterior ischemic optic neuropathy.
89554480|NCT05305079||nODD-AION|NA-AION patients without ODD aka Non-optic disc drusen associated non-arteritic anterior ischemic optic neuropathy.
88962357|NCT02012894||Obese patients without preoperative GER|Obese patients selected for laparoscopic sleeve gastrectomy without preoperative GER at 24 H pH-monitoring (Group B)
88962358|NCT02012920|Experimental|Single Failure of Abiraterone or Enzalutamide|Seviteronel: given orally once daily in 28 day cycles
88962359|NCT02012920|Experimental|Double Failure of Abiraterone and Enzalutimide|Seviteronel: given orally once daily in 28 day cycles
88962360|NCT02012946|Active Comparator|dobutamine|patient receiving dobutamine
89554481|NCT05304845|Experimental|Cohort 1|Aspirin (substrate), DWP14012 (Perpetrator)
89554482|NCT05304845|Experimental|Cohort 2|DWP14012 (substrate), Aspirin (Perpetrator)
89554483|NCT04407143||lung cancer+COVID-19|Lung cancer patients infected by COVID-19
89554484|NCT04385927|Experimental|Immediate e-NET Group|Parents of neurodiverse children with PTSI will receive e-NET immediately after the baseline survey
88962361|NCT02012946|Active Comparator|Levosimendan|patient receiving levosimendan
89554485|NCT04385927|Experimental|Wait List Control Group|Parents of neurodiverse children with PTSI will receive e-NET 3 months after the baseline survey
89554486|NCT05304299|Experimental|Cordyceps Cicadae Mycelia only|Only Cordyceps Cicadae Mycelia will be given.
89554487|NCT05304299|Experimental|Cordyceps Cicadae Mycelia with Taflotan (saflutan)|Cordyceps Cicadae Mycelia with Taflotan (saflutan) will be given.
89554488|NCT04924517|Experimental|Extended Evening Fasting|Participants will eat between 8am-4pm
88962362|NCT02012972||NCD Risks|Study subjects with NCD risks or disease at enrollment. Each of these subjects will have a Referral for NCD care
88962363|NCT02012972||No NCD Risks|Study subjects without NCD risks or disease at enrollment.
89554489|NCT04924517|Active Comparator|Control|Participants will eat between 8am-8pm
89554490|NCT04892459|Experimental|heterologous boost arm with Ad5 vectored vaccine|Subjects who have been primed with two doses of inactive SARS-CoV-2 vaccine will receive a booster of recombinant SARS-CoV-2 Ad5 vectored vaccine after 3~6 months.
89554491|NCT04892459|Active Comparator|homogeneous boost arm with inactive vaccine|Subjects who have been primed with two doses of inactive SARS-CoV-2 vaccine will receive a booster dose of inactive SARS-CoV-2 vaccine after 3~6 months.
88962364|NCT02012985|Experimental|Oxabact OC5 capsules|The active study drug consists of Oxalobacter formigenes OC5 in enteric-coated size-4 capsules. The dose (not less than (NLT) 1E+09 colony forming units (CFU)) will be administrated orally with breakfast and dinner as one capsule two times per day for 8 to 10 weeks.
88962365|NCT02012985|Placebo Comparator|Placebo capsules|The placebo study drug consists of microcrystalline cellulose in enteric-coated size-4 capsules. It has been manufactured to mimic the OC5 capsule. The dose will be administrated orally with breakfast and dinner as one capsule two times per day for 8 to 10 weeks.
88962366|NCT02012998|Experimental|HBVAXPRO Challenge dose|HBVAXPRO 5µg
88962367|NCT02013011|Active Comparator|recruitment maneuver and PEEP|apply recruitment maneuver and positive end expiratory pressure (PEEP) 5 centimeter of water (cmH2O) after induction of anesthesia
88962368|NCT02013011|Active Comparator|PEEP|apply positive end expiratory pressure (PEEP) 5 cmH2O after induction of anesthesia
88962369|NCT02013024|Active Comparator|cryopreservation technique|slow freezing cryopreservation technique
89554492|NCT04892459|Experimental|heterologous regimen with Ad5 vectored vaccine|Subjects who have been primed with one dose of inactive SARS-CoV-2 vaccine will receive one dose of recombinant SARS-CoV-2 Ad5 vectored vaccine after 1~3 months.
88962370|NCT02013024|Active Comparator|vitrification cryopreservation technique|vitrification cryopreservation technique
88962371|NCT02013076||Oral corticosteroids (OCS)|"All patients receive:~Prednisone or Prednisolone at 1 mg/kg (in 1 site) or 2 mg/kg (in all other sites) (max. 50 mg); if vomiting prednisone/prednisolone: they receive dexamethasone (0.3 mg/kg, max. 10 mg)~2 to 3 doses of salbutamol within the first hour of therapy according to severity Those with severe exacerbations receive 3 treatments with salbutamol and ipratropium bromide within the initial hour of therapy."
89554493|NCT04892459|Active Comparator|homogeneous regimen arm with inactive vaccine|Subjects who have been primed with one dose of inactive SARS-CoV-2 vaccine will receive one dose of inactive SARS-CoV-2 vaccine after 1~3 months.
89554494|NCT04890431|Experimental|Oxygen|
89554495|NCT04890431|Placebo Comparator|Placebo|
89554496|NCT04881539|Experimental|Cannabidiol (CBD)|Each group member will receive one dose of CBD daily for 8 weeks.
89554497|NCT04881539|Placebo Comparator|Placebo|Each group member will receive a calorie matched placebo daily for 8 weeks.
89554498|NCT04854083|Experimental|Semaglutide|The intervention study for the patients with T2DM begins with a low-calorie diet (LCD) phase run-in for 13 weeks. During re-introduction of food, the participants will be assigned to semaglutide 1.34mg/ml treatment for 44 weeks (dose escalation in total 8 weeks, maintenance period for 36 weeks).
89554499|NCT04854083|Placebo Comparator|Placebo|The intervention study for the patients with T2DM begins with a low-calorie diet (LCD) phase run-in for 13 weeks. During re-introduction of food, the participants will be assigned to placebo treatment for 44 weeks (dose escalation in total 8 weeks, maintenance period for 36 weeks).
89554500|NCT05303441||patients with acute coronary syndrome|patients with chronic kidney disease having chest pain with ecg, symptom or cardiac troponin levels compatible with ACS
89554501|NCT05303441||patients without acute coronary syndrome|patients with chronic kidney disease having chest pain with ecg, symptom or cardiac troponin levels NONcompatible with ACS
89025711|NCT00489099|Experimental|V232 Modified Process Hepatitis B Vaccine: Lot B|Recombivax HB™ (Hepatitis B Vaccine [Recombinant]) modified process Lot B administered as a 1 mL intramuscular injection on Day 1, Month 1, and Month 6.
89025712|NCT00489099|Experimental|V232 Modified Process Hepatitis B Vaccine: Lot C|Recombivax HB™ (Hepatitis B Vaccine [Recombinant]) modified process Lot C administered as a 1 mL intramuscular injection on Day 1, Month 1, and Month 6.
89025713|NCT00489099|Active Comparator|V232 Current Process Hepatitis B Vaccine|Recombivax HB™ (Hepatitis B Vaccine [Recombinant]) current process administered as a 1 mL intramuscular injection on Day 1, Month 1, and Month 6.
89025714|NCT03273569|Experimental|Women with placenta accreta|PDI-UC protocol
89554502|NCT03050879|Experimental|Indocyanine Green Tracer|Indocyanine Green Tracer will be used in laparoscopic gastrectomy with lymph node dissection for gastric adenocarcinoma in this group.
89554503|NCT03050879|Active Comparator|No Indocyanine Green Tracer|Indocyanine Green Tracer will not be used in laparoscopic gastrectomy with lymph node dissection for gastric adenocarcinoma in this group.
89025715|NCT03273530|Experimental|Integrated Supported Employment|Individual placement support intervention plus work-related social skills training
89025716|NCT03273530|No Intervention|Individualised Placement Support|Individual placement support intervention with pre-vocational training followed by placing individual participants to the job according to their preference and abilities
89554504|NCT05303285|Experimental|Secukinumab 300mg|Induction with secukinumab 150 mg s.c. once per week (Week 0, 1, 2, 3 and 4) followed by maintenance with secukinumab 300 mg s.c. every 4 weeks for an additional 48 weeks.
89554505|NCT05303285|Active Comparator|Secukinumab 150 mg|Induction with secukinumab 150 mg s.c. once per week (Week 0, 1, 2, 3 and 4) followed by maintenance with secukinumab 150 mg s.c. every 4 weeks for an additional 48 weeks.
89554506|NCT04288661|No Intervention|Drain|The patients of this arm undergo perianastomotic drain placement, as per standard of care institutional practice
89554507|NCT04288661|Experimental|No drain|The patients of this arm do not undergo perianastomotic drain placement.
89554508|NCT04280939|Active Comparator|spinal anesthetic without intrathecal narcotic|spinal anesthetic with standard painkillers without intrathecal narcotics
89554509|NCT04280939|Experimental|spinal anesthetic with morphine|spinal anesthetic with 100 micrograms of intrathecal morphine
89554510|NCT04280939|Experimental|spinal anesthetic with hydromorphone|spinal anesthetic with 20 micrograms of intrathecal hydromorphone
89554511|NCT04276571|Experimental|GRAIL|
89554512|NCT04276571|No Intervention|No treatment|
89554513|NCT04831385|Experimental|CBT-i|
89554514|NCT04831385|No Intervention|Control (Usual Care)|Control
89554515|NCT04328441|Experimental|BCG vaccine|Intracutaneously 0.1ml BCG vaccine, which accounts for 0.075mg of attenuated Mycobacterium bovis.
89554516|NCT04328441|Placebo Comparator|Placebo|Intracutaneously 0.1ml of 0.9% NaCl solution
89554517|NCT05302739|Experimental|Facial cooling|Between each simulated fencing match participants will spend the first 30 s of rest having a facial water mist sprayed onto the face with accompanying fanning from 50 cm away from the face.
89554518|NCT05302739|No Intervention|Placebo|
89554519|NCT05302661|Experimental|case group will receive re-education after leave hospital|The participants were randomly divided into re-education group and non re-education group according to the random number table. The re-education group will receive regular re-education not noly when they leave hospital but also after leave hospital in our preset time by telephone or wechat. The content of re-education includes diet form and diet structure,medication compliance and regularity, and recheck compliance, moderate exercise and so on
89554520|NCT05302661|No Intervention|control case group will receive no re-education after leave hospital|The participants were randomly divided into re-education group and non re-education group according to the random number table. without re-education group will receive regular re-education when they leave hospital.The content of re-education includes diet form and diet structure,medication compliance and regularity, and recheck compliance, moderate exercise and so on
89554521|NCT04314713|Placebo Comparator|Scopolamine HBT 0.005 mg/kg|Dose of Scopolamine 0.005mg/kg verses Placebo
89554522|NCT04314713|Placebo Comparator|Scopolamine HBT 0.007 mg/kg|Dose of Scopolamine 0.007mg/kg verses Placebo
89554523|NCT04314713|Placebo Comparator|Scopolamine HBT 0.011 mg/kg|Dose of Scopolamine 0.011mg/kg verses Placebo
89554524|NCT04314713|Placebo Comparator|Scopolamine HBT 0.014 mg/kg|Dose of Scopolamine 0.014mg/kg verses Placebo
89554525|NCT04314713|Placebo Comparator|Scopolamine HBT 0.021 mg/kg|Dose of Scopolamine 0.021mg/kg verses Placebo
89554526|NCT04314713|No Intervention|Placebo|Placebo controlled
89554527|NCT05302193|Experimental|Blood pressure and heart rate measurement|Calm measurement of blood pressure and heart rate simultaneously by smartwatch and vital signs monitor. Each participant will undergo this measurement a total of 6 times.
89554528|NCT04777253|Experimental|Biofeedback method and Health-resort based rehabilitation|Health-resort based treatments supplemented with biofeedback training
89025717|NCT03273530|No Intervention|Traditional Vocational Rehabilitation|general pre-vocational training and placement
89554529|NCT04777253|Other|Health-resort based rehabilitation|Control group - health-resort based treatments, without biofeedback training.
89554530|NCT04775771|Experimental|Animal Assisted Practice (Experimental) Group|
89025718|NCT00489138|Experimental|1|Noradrenalin infusion
89025719|NCT00489138|No Intervention|2|No adrenalin infusion
89025720|NCT00461396||Group 1|
89025721|NCT00489177|Active Comparator|A|QuickOpt
89025722|NCT00489177|Placebo Comparator|B|Usual care
89025723|NCT01327651|Active Comparator|Daily dosing|Participants will receive oral FTC/TDF daily.
89554531|NCT04775771|No Intervention|Control Group|
89554532|NCT05302037|Experimental|Dose-Escalation Arm|Four infusions of CTM-N2D at escalating doses: 1x10^7, 1x10^8, 3x10^8 or 1x10^9 per infusion at an interval of one infusion every 7 days.
89554533|NCT05302037|Experimental|Optimal Dose Arm|Four infusions of CTM-N2D at the optimal dose (expected to be 1x10^9) at an interval of one infusion every 7 days.
89554534|NCT04121507|Experimental|alloSCT|defined high-dose chemotherapy (HDT) followed by allogeneic stem cell transplantation (alloSCT)
89554535|NCT04762043|Experimental|MyoVoice Device|MyoVoice Device for individuals with total laryngectomy
89554536|NCT04261595|Active Comparator|Dates group 1|For the group of the date 1, Diagnosed autistic patients will be given three pieces of Dates will be given on daily basis for 12 weeks as follow: Three pieces (each about 10 -15 gm), of Dates, will be taken with breakfast or between breakfast and lunch as a test dose daily (without drinking any tea after it by at least one hour).
89554537|NCT04261595|Active Comparator|Dates group 2|For the group of the date 2, Diagnosed autistic patients matched for age and sex will be given five pieces of Dates will be given on daily basis for 12 weeks as follow: five pieces (each about 10 -15 gm), of Dates, will be taken with breakfast or between breakfast and lunch as a test dose daily (without drinking any tea after it by at least one hour).
89554538|NCT04261595|Active Comparator|Group 3|Group 3 (no- Dates fruit group): Diagnosed autistic patients matched for age and sex will not receive any dates
89554539|NCT04743167|Active Comparator|Surgery|Patients undergoing surgery for endometriosis, after surgery, will receive indications for seeking for a natural pregnancy up to 12 months from the time of randomization
89554540|NCT04743167|Active Comparator|In Vitro Fertilization|Patients included in the IVF arm will undergo three complete cycles of IVF (i.e. three oocytes retrievals regardless of the number of embryo transfers)
89554541|NCT01449149|Experimental|Proton group|Proton radiation total dose 72.00 to 79.2 Gy(RBE) in 40-44 fractions
89554542|NCT00905957|Active Comparator|Transversus abdominis plane (TAP) Group|Patients will receive a TAP block using a local anaesthetic agent after induction of anaesthesia
89554543|NCT00905957|Placebo Comparator|Control Group|Patients will receive a TAP block using a placebo after induction of anaesthesia
89554544|NCT04704479|Experimental|combined Russian and EMT|Russian current will be applied over the participant expiratory muscles in addition to application of EMT for more enhancement and strengthening of the expiratory muscles.
89554545|NCT04704479|Active Comparator|EMT only|the participant receives EMT only over the whole study period
89554546|NCT04039763|Experimental|Real Time Continuous Glucose Monitoring|"Participants wear Real time continous glucose monitoring (Dexcom G6), with alarms for when their glucose is too low or too high. They will be able to view their data on the Dexcom app on their smartphones or a Dexcom receiver and share this with a nominated caregiver. Participants can chose to share data between study visits via Dexcom clarity with the research/clinical team, who will support them making changes to their insulin regime in light of the data."
89554547|NCT04039763|Placebo Comparator|Standard care|Standard care - finger prick self monitoring of blood glucose.
89554548|NCT03982043|Experimental|Text2Connect|Participants receiving Text2Connect (T2C) personalized messages aimed at increasing motivations in at-risk adolescents and their parents. The most salient of the following behavior change techniques will be selected and targeted messaging will be deployed on the participants' phone: psychoeducation, cued mood monitoring, adolescent-parent communication prompts, cognitive bias modification, and cues to action. Intervention material will be tailored to baseline characteristics and T2C will generate reports to providers.
89554549|NCT03948503|Experimental|Mobilization with movement (MWM) group|Application of the Mulligan concept
89554550|NCT03948503|Placebo Comparator|Sham group|Sham treatment
89554551|NCT03867773|Experimental|4-hour Time restricted feeding|4-h TRF subjects will consume food ad libitum between 3pm and 7pm (4-h feeding window), and refrain from eating and drinking caloric beverages from 7pm to 3pm (20-h fasting window) each day. These subjects will not be instructed to limit/monitor energy intake during the feeding window. Subjects will be encouraged to drink plenty of water during the fasting period.
89554552|NCT03867773|No Intervention|Control|Controls will be instructed to maintain their weight throughout the trial, and not to change eating or physical activity habits. Controls will visit the research center at the same frequency as the TRF groups (for outcome measurements).
89554553|NCT03867773|Experimental|6-hour Time restricted feeding|6-h TRF subjects will consume food ad libitum between 1pm and 7pm (6-h feeding window), and refrain from eating and drinking caloric beverages from 7pm to 1pm (18-h fasting window) each day. These subjects will not be instructed to limit/monitor energy intake during the feeding window. Subjects will be encouraged to drink plenty of water during the fasting period.
89554554|NCT03800771|Experimental|Practice dual-task tests|"The study consists to practice these dual-task tests with a new device which name is Cycléo BRAU that allows to the patients to achieve carefully an attentional task: cycle. Results will be compared tothe results obsvered during the routine GAITRITE analysis ( a validated tool for elderly patients and gait analysis)."
89554555|NCT03428165|Other|human chorionic gonadotropin (HCG)|Ovulation triggered using HCG: choriogonadotropin alpha (Ovitrelle, Merck Serono), 250 μg/0.5ml
89554556|NCT03428165|No Intervention|spontaneous|
89554557|NCT01171937|Active Comparator|Open-Label Risperidone|Risperidone oral solution (1mg/mL) qd for 8 weeks.
89554558|NCT01171937|Placebo Comparator|Placebo|Placebo
89554559|NCT03102983|Experimental|Healthy Volonteers|
89554560|NCT05302349|Experimental|Core Exercise Group|Core Exercise Group will performe core stabilization exercises and routine physiotherapy exercises.
89554561|NCT05302349|Active Comparator|Routine Therapy Group|Routine Therapy Group will performe routine physiotherapy exercises.
88962372|NCT02013102|Experimental|Arm Ⅰ|Decitabine Injection 20mg/m2/d*5d, IV> 1h, one cycles per 4 weeks.
88962373|NCT02013102|Experimental|Arm Ⅱ|Decitabine Injection 12mg/m2/d*8d, IV> 1h, one cycles per 4 weeks.
88962374|NCT02013115|No Intervention|Cursurf|The baby with respiratory distress syndrome was given Cursurf through intubation.
88962375|NCT02013115|Experimental|Cursurf and Budesonide|The baby with respiratory distress syndrome was given Cursurf and Budesonide through intubation.
88962376|NCT02013193|Experimental|Ranger(TM) Paclitaxel-coated balloon|Index lesion treated with Ranger(TM) Paclitaxel-coated PTA balloon catheter (Ranger DCB)
88962377|NCT02013193|Active Comparator|uncoated PTA balloon|Index lesion treated with an uncoated standard PTA dilatation balloon catheter selected upon investigator´s discretion
88962378|NCT02013219|Experimental|Stage 1: Alectinib and Atezolizumab|In Stage 1, starting dose of atezolizumab will be 1200 mg IV q3w administered on Day 8 of Cycle 1 and on Day 1 (21-day cycle) of each cycle thereafter along with alectinib at a starting dose of 600 mg PO BID for 28 consecutive days during Cycle 1 and on Days 1-21 of each cycle thereafter; unless maximum tolerable dose (MTD) is exceeded. The combination will be given to treatment-naive participants with ALK-positive, locally advanced or metastatic NSCLC.
89554562|NCT04483349||Observational (survey administration)|Patients and healthcare providers complete a survey over 10-15 minutes.
89554563|NCT03350711||Microbiota Enrichment Program (MEP)|Patients who are seeking a fecal microbiota transplant (FMT), for any reason, who will be part of a registry of patients to potentially screen for a FMT study.
89554564|NCT00887783|Experimental|B: 66Gy/33F+Navelbine oral 150 mg q3w|"Navelbine oral 150 mg of Vinorelbine administered in 3 weekly doses a week for 6-6½ weeks concomitant with curatively intended irradiation to 66 Gy (2 Gy x 30, 5 F á weeks).~Radiation technique: 3D, 4D og VMAT techniques. The patients all had 2 cycles of carboplatin and vinorelbine before randomization"
89554565|NCT00887783|Active Comparator|A: 60Gy/30F+Navelbine oral 150 mg q3w|Navelbine oral 150 mg of Vinorelbine administered in 3 weekly doses a week for 6-6½ weeks concomitant with curatively intended irradiation to 60 Gy (2 Gy x 30, 5 F á weeks) Radiation technique: 3D, 4D og VMAT techniques. The patients all had 2 cycles of carboplatin and vinorelbine before randomization
89554566|NCT03287843|Experimental|Early surgery group|İn this arm patients will go under surgery before eight weeks, after neoadjuvant chemoradiation therapy.
89554567|NCT03287843|Experimental|Late surgery group|İn this arm patients will go under surgery after eight weeks, after neoadjuvant chemoradiation therapy.
89554568|NCT02156609|Experimental|Percutaneous coronary intervention|Percutaneous ventricular support with the HeartMate PHP during high risk percutaneous coronary intervention
89554569|NCT02047097||dimethyl fumarate (DMF)|Patients with multiple sclerosis receiving dimethyl fumarate (DMF) under routine clinical care
89025724|NCT01327651|Experimental|Time-driven dosing|Participants will receive oral FTC/TDF twice weekly with a post-exposure dose.
89025725|NCT01327651|Experimental|Event-driven dosing|Participants will receive oral FTC/TDF before and after a potential exposure to HIV infection.
89025726|NCT03273491|Experimental|Daily Self-Weighing Group|"Participants will be provided with a scale and instructions necessary to engage in daily self-weighing, first thing in the morning for the next three months.~Height and weight will be measured using standard procedures~Questionnaires will be administered at baseline and EOT: Sociodemographic questions (i.e. age, race/ethnicity, self-weighing frequency, weight goals will be collected at baseline. To assess factors that may modify reaction to intervention condition,a questionnaire will assess participant's eating attitudes, behaviors, and perception of their body.~Questionnaires (baseline, end of Week 1, 2, 3, 4 and EOT): In order to compare results with published studies assessing constructs over varying time frames, self-esteem, anxiety, and depression will be measured at baseline, weekly for the first month, and again at EOT."
89208189|NCT04018404|No Intervention|Control|Subjects will be approached for enrollment prior to or following clinic visit with physician. Only children present with a biological mother will be considered for enrollment. Charts of controls will be flagged so that they will not be able to be enrolled in the FRI clinical program if they present to a morning clinic where the program is offered.
89554570|NCT01125371|Experimental|Computerized Brief Alcohol Intervention + IVR|Computer-delivered brief alcohol intervention (CBI) with booster phone calls delivered by IVR+ text messages (TM)
89554571|NCT01125371|Active Comparator|Computerized Brief Alcohol Intervention|Computerized Brief Alcohol Intervention only (CBI)
89554572|NCT01125371|Placebo Comparator|Attention Control|Attention control
89554573|NCT03199547|Experimental|AZITHROMYCIN|A single dose of 2G Azithromycin or Placebo will be administered orally to women in labour
89554574|NCT03199547|Placebo Comparator|Placebo oral tablet|A single dose of 2G Azithromycin or Placebo will be administered orally to women in labour
89554575|NCT03180905|Experimental|Validity|ImPACT Online a computerized test will be administered to subjects. They will also receive a battery of paper and pencil neuropsychological tests.
89554576|NCT03180905|Active Comparator|Test/Re-Test|ImPACT Online will be administered at 2 time points
89554577|NCT04042571|Experimental|Cerebral oxymetry monitoring (NIRS)|Cerebral oxymetry (NIRS) -by rSO2 measurement - in order to detect vasospasm in patient with severe subarachnoid hemorrhage compare to standard monitoring tools
89554578|NCT04038593|No Intervention|Non interventional arm|Standard conditions of complex dressing cares, without experimental intervention. It will be a control intervention
89554579|NCT04038593|Active Comparator|Comparative arm with relaxation music from Youtube©|Standard conditions of complex dressing cares + use of non standardized music relaxation during complex dressing cares
89554580|NCT04038593|Experimental|Interventional arm with MUSIC CARE©|Standard conditions of complex dressing cares + administration of a specific music therapy program (U method) delivered through headphones from a tablet, under the direction of trained nurses.
89554581|NCT00416351|Experimental|Clofarabine|Patients will receive intravenous clofarabine once daily for three consecutive days. Doses of clofarabine will start at 4 mg/m2/day and will be escalated to higher dose levels.
89554582|NCT03104777|No Intervention|Control Group|No intervention materials will be distributed in the control schools during the intervention period.
89554583|NCT03104777|Experimental|Intervention Group|Intervention materials will be distributed to parents of children in years 3 - 6.
89554584|NCT03105011|Experimental|EpxDiabetes software|Subjects will interact daily with a commercially available telemedicine product, Epharmix Diabetes (EpxDiabetes).
89554585|NCT03965273|Experimental|Full TP|Full TP intervention including emphasized social norms change
89554586|NCT03965273|Experimental|Light TP|Light TP intervention without emphasized social norms change
89554587|NCT03965273|No Intervention|Pure control|Pure control
89554588|NCT03102827|Active Comparator|Oxygen - ambient air|high-flow oxygen therapy administered during first night, ambient air without high-flow therapy (placebo) administered during second night
89554589|NCT03102827|Placebo Comparator|Ambient air - oxygen|Ambient air without high-flow therapy (placebo) administered during first night , high-flow oxygen therapy administered during second night
89554590|NCT03102515|Other|Spinal-anesthesia|Caesarean section performed under spinal anaesthesia and receiving either USG-TAP block or CIC
89554591|NCT03102515|Other|Epidural-anesthesia|Caesarean section performed under epidural anaesthesia and receiving either USG-TAP block or CIC
89554592|NCT03102749||Normal weight|Included patients with a BMI < 25 will be part of this group.
89554593|NCT03102749||Overweight|Included patients with a BMI >= 25 and <30 will be part of this group.
89554594|NCT03102749||Obese|Included patients with a BMI >= 30 will be part of this group.
88962379|NCT02013219|Experimental|Stage 1: Erlotinib and Atezolizumab|In Stage 1, starting dose of atezolizumab will be 1200 mg IV q3w administered on Day 8 of Cycle 1 and on Day 1 (21-day cycles) of each cycle thereafter along with erlotinib at a starting dose of 150 mg PO QD, for 28 consecutive days during Cycle 1 and on Days 1-21 of each cycle thereafter; unless MTD is exceeded. The combination will be given to participants with EGFR TKI treatment-naive, locally advanced or metastatic NSCLC.
88962380|NCT02013219|Experimental|Stage 2: Alectinib and Atezolizumab|In Stage 2, participants received the RP2D on the basis of the MTD or maximum allowed dose (MAD) of the combination treatment established in Stage 1. Treatment-naive participants with ALK-positive, locally advanced or metastatic NSCLC will be included.
88962381|NCT02013219|Experimental|Stage 2: Erlotinib and Atezolizumab|In Stage 2, participants received the RP2D on the basis of the MTD or MAD of the combination treatment established in Stage 1. Previously untreated (or with one prior treatment that was not an EGFR TKI), EGFR mutation positive, locally advanced or metastatic NSCLC participants will be included.
88962382|NCT02013232|Placebo Comparator|placebo|risperidone plus placebo
88962383|NCT02013232|Experimental|aripiprazole 5mg|risperidone treatment plus aripiprazole 5mg/day
88962384|NCT02013232|Experimental|aripiprazole 10mg|risperidone plus aripiprazole 10mg/day
88962385|NCT02013232|Experimental|aripiprazole 20mg|risperidone plus aripiprazole 20mg/day
89554595|NCT03947333|Experimental|Intervention|Patients have access to an existing patient web portal (My Health at Vanderbilt) embedded with the My Diabetes Care.
89554596|NCT03947333|No Intervention|Control|Patients will have access to an existing patient web portal (My Health at Vanderbilt) NOT embedded with the My Diabetes Care (i.e., usual care).
89554597|NCT03938831|Experimental|dexmedetomidine group|dexmedetomidine mixture with fentanyl-based PCA infusion for 2 days
89554598|NCT03938831|Placebo Comparator|control group|Fentanyl-based PCA infusion for 2 days
89554599|NCT03875183|Experimental|INL1 50mg BID|INL1 50mg dose to be given twice daily using one 50mg capsule and two matching placebo capsules at each dose
89554600|NCT03875183|Experimental|INL1 150 mg BID|INL1 150mg dose to be given twice daily using three 50mg capsules at each dose
89554601|NCT03875183|Experimental|INL1 300 mg BID|INL1 300mg dose to be given twice daily using three 100mg capsules at each dose
89554602|NCT03875183|Placebo Comparator|Placebo|Placebo dose to be given twice daily using 3 placebo capsules at each dose
89554603|NCT03872375|Experimental|Intermittent Calorie Restriction + Dietary Counseling|"Participants will be asked to consume a single 530 kilocalorie shake (i.e., High Calorie Boost shake) on a given day for two consecutive days each week. Participants will eat ad libitum during the remaining 5 days. Participants will also receive Registered Dietitian of Nutrition (RDN) consultations about dietary modifications to induce moderate weight loss. Participants will utilize these recommendations in addition to shake consumption.~Subjects are also asked to follow RDN dietary recommendations."
89554604|NCT03872375|Active Comparator|Dietary Counseling|A Registered Dietitian of Nutrition (RDN) will consult with subjects about dietary modifications to induce moderate weight loss. Participants will utilize these recommendations.
89554605|NCT03102671|Experimental|AB sequence|Usual care followed by use of HeartHab application: Treatment A comprises the usual care (i.e. one information session on the importance of medication adherence, risk factor control and healthy lifestyle), followed by telemonitoring during treatment B. The tele-intervention will consist of two months telerehabilitation and telecoaching concerning physical activity, healthy lifestyle and medication adherence.
89554606|NCT03102671|Experimental|BA sequence|Use of HeartHab application followed by usual care: patients will be followed by telemonitoring during treatment B. The tele-intervention will consist of two months telerehabilitation and telecoaching concerning physical activity, healthy lifestyle and medication adherence, followed by treatment A comprises the usual care (i.e. one information session on the importance of medication adherence, risk factor control and healthy lifestyle)
89554607|NCT02431091|Experimental|Definite Case|"Patients with abnormal response on both the screening questions and at least one of the cognitive screening tests.~Optical Coherence Tomography is performed in all definite cases"
89554608|NCT02431091|Active Comparator|Control|"Patients with normal response on both the screening questions and all the cognitive screening tests.~Optical Coherence Tomography is performed in matched control A patients"
89554609|NCT03104621|Experimental|Group 1|Group 1, for the first 6 months, the subjects of group 1 used non-preservative disposable 0.0015% tafluprost product(Taflotan-S®) and then changed to 0.001% Benzalkonium chloride (BAK), 0.0015% tafluprost product (Taflotan®)for 6 months.
89554610|NCT03104621|Experimental|Group 2|Group 2, for the first 6 months, the subjects of group 2 used 0.001% Benzalkonium chloride (BAK), 0.0015% tafluprost product(Taflotan®) and then changed to non-preservative disposable 0.0015% tafluprost product(Taflotan-S®) for 6 months.
89554611|NCT03104387|Experimental|Diesel train - exposure scenario|"The same study person will be exposed to two different scenarios, at different times and for three consecutive days. It will be a lag time of 2 weeks between each exposure scenario. The exposure scenario is defined as a workday (6 hours) on the diesel ME-driven model regional train. The Diesel Train Scenario is performed twice. After the scenario completion (on the third day in defined train routes) the vascular function, lung function, blood and urine samplings are performed."
88962386|NCT02013258|Active Comparator|Intranasal oxytocin|Intranasal oxytocin. 16 IU intranasal oxytocin x 5 days. One month interval between arms of treatment.
88962387|NCT02013258|Placebo Comparator|Placebo|Placebo will be administered via nasal spray - 1 spray in each nostril x5 days.
88962388|NCT02013271||Lutonix DCB|Lutonix Paclitaxel Drug Coated Balloon
88962389|NCT02013323|Active Comparator|Septilin Group|Subjects in septilin group received Septilin tablets (Septilin tablets, Himalaya Drug Company, India), 500 mg of 2 tablets to be taken thrice daily for 7 days after scaling and root planing
88962390|NCT02013323|Placebo Comparator|Placebo Group|Subjects in placebo group received Placebo tablets thrice daily for 7 days after Scaling and root planing
88962391|NCT02013349|Other|DESyne Novolimus Eluting CSS|approved device continued access
89025727|NCT03273491|Active Comparator|Daily Temperature-Taking Group|"Participants will be provided with a thermometer and instructions necessary to engage in daily temperature-taking, first thing in the morning for the next three months.~Height and weight will be measured using standard procedures~Questionnaires will be administered at baseline and EOT: Sociodemographic questions (i.e. age, race/ethnicity, self-weighing frequency, weight goals will be collected at baseline. To assess factors that may modify reaction to intervention condition,a questionnaire will assess participant's eating attitudes, behaviors, and perception of their body.~Questionnaires (baseline, end of Week 1, 2, 3, 4 and EOT): In order to compare results with published studies assessing constructs over varying time frames, self-esteem, anxiety, and depression will be measured at baseline, weekly for the first month, and again at EOT."
89025728|NCT04329169|Experimental|Virtual Implant Planning|
89025729|NCT00591604|Experimental|1|Vitamin D administration
89025730|NCT00591643|Experimental|Imaging, Adrenal acans & Radiation|
89025731|NCT00461747|Active Comparator|A|"Four alternating cycles of VBMCP/VBAD + Velcade VBMCP: Vincristine, 0,03 mg/Kg (iv) day 1, BCNU, 0,5 mg/Kg iv day 1, Cyclophosphamide, 10 mg/Kg iv day 1, Melfalán, 0,25 mg/Kg oral days 1 to 4 Prednisone, 1 mg/Kg oral days 1 to 4; 0,5 mg/Kg oral days 5 to 8 and 0,25 mg/Kg oral days 9 to 12.~VBAD : Vincristine, 1mg via iv day 1, BCNU, 30 mg/m2 iv day 1, Adriamycine, 40mg/m2 iv day 1 Dexamethasone, 40 mg oral days 1 to 4, 9 to 12 and 17 to 20. The interval between VBMCP and VBAD is 5 weeks and between VBAD and VBMCP is 4 weeks. The patients will received two cycles of VBMCP and two cycles of VBAD. After 4 weeks of last cycle of VBAD, patients will received two cycles of Velcade, 1,3 mg/ m2 iv twice a week (days 1, 4, 8 and 11), followed by 10 days without treatment"
89025732|NCT00461747|Experimental|B|"Six cycles of 4 weeks of Thalidomide/Dexamethasone. Thalidomide day 1, cycle 1 (50 mg/day v.o). If toxicity < grade 2, dose will be 100 mg/day on day 15, cycle 1 and 200 mg/day on day 1, cycle 2.~Dexamethasone:40 mg/day v.o.days 1 to 4 and 9 to 12, with a period without treatment of 16 days"
89025733|NCT00461747|Experimental|C|"Thalidomide: day 1 cycle 1 (50 mg/day).If toxicity is < grade 2, the dose will be increased (100 mg/day) at day 15 cycle 1 and (200 mg de Thalidomide) at day 1 cycle 2.~Dexamethasone: 40 mg/day v.o days 1 to 4 and 8 to 11, with a period without treatment of 17 days.~Velcade: 1,3 mg/m2 iv twice a week (days 1, 4, 8 and 11) with a period without treatment of 17 days."
89554612|NCT03104387|Sham Comparator|Electric train - low exposure scenario|"The same study person will be exposed to two different scenarios, at different times and for three consecutive days. It will be a lag time of 2 weeks between each exposure scenario. The low exposure scenario is defined as a workday (6 hours) on the electric train. The Diesel Train Scenario is performed twice. After the scenario completion (on the third day in defined train routes) the vascular function, lung function, blood and urine samplings are performed."
89554613|NCT03104465|Experimental|Mindfulness training|6 90-minute sessions interactive, web-based mindfulness training complemented with mobile application
89025734|NCT04437589||Exposure group|In this group the treatment applied for postoperative pain involves Free-opioid anesthesia (LKDi).
89025735|NCT04437589||Control group|In this group the treatment applied for postoperative pain involves an opioid-based anesthesia.
89025736|NCT04434976||delayed diagnosis|The length from the first clinical visit date to the diagnosis confirmed date is more than 14 days. Diagnosis is confirmed by any positive result of anti fast bacteria smear, culture, histological test, and molecular detection such as GeneXpert.
89025737|NCT04434976||undelayed diagnosis|The length from the first clinical visit date to the diagnosis confirmed date is equal or less than 14 days. Diagnosis is confirmed by any positive result of anti fast bacteria smear, culture, histological test, and molecular detection such as GeneXpert.
89025738|NCT04328935|Experimental|written exposure therapy|The treatment consists of written exposure therapy (WET), which is manualized trauma-focused CBT in five sessions over 5 weeks.
89025739|NCT04434898||Ｍild cognitive impairment patients|"The patients with mild cognitive impairment have a Clinical Dementia Rating score of 0.5. First, we will evaluate the correlation between diffusion MRI and the clinical severity and cognitive decline of patients. Second, we will evaluate if diffusion MRI can predict if these patients will develop Alzheimer's Disease and hence be involved in the third year of the study. Patients with mild cognitive impairment should meet the following criteria:~Between 50-80 years old~Right-handed~Clinical Dementia Rating score equal to 0.5~For patients who have a CDR score of 0.5, should be diagnosed by clinician's judgement of clinical information, daily living activities, and extent of neuropsychological disorders~Able to understand study requirements and give informed consent"
89025740|NCT04434898||Parkinson's Disease patients|This group consists of patients starting from 2012 to 2013 and includes 87 patients with typical Parkinson's Disease (PD), 15 patients with Progressive Supranuclear Paralysis (PSP), 15 patients with Multiple System Atrophy (MSA), and 15 patients with Cortico-Basal Degeneration (CBD). In differential diagnosis in the first year of the study, diffusion MRI will be used for a retrospective study.
89554614|NCT03102359|Experimental|Selective Head Cooling|Participants received a cooling helmet filled with ice water mixture after an-esthesia induction until the end of the surgery.
89554615|NCT03102359|Experimental|Dexmedetomidine|Giving dexmedetomidine1μg/kg i.v for 10 minutes, then use computerized infusion pump at 0.5μg/kg.h until the end of the surgery.
89554616|NCT03102359|Experimental|Selective Head Cooling and Dexmedetomidine|Using selective head cooling combined with dexmedetomidine as described before
89554617|NCT03102359|No Intervention|Control|No intervention in this group
89554618|NCT03104231|Experimental|study group|All the patients will be shown three-dimensional (3D) movie.
89554619|NCT03104309|Other|Levonorgestrel intrauterine system|
88962392|NCT02013362|Experimental|Pralatrexate injection|Dietary Supplement: Vitamin B12, Folic Acid
88962393|NCT02013453|Active Comparator|Observational|Patients on the Observational arm are currently being treated with a proton pump inhibitor (PPIs) such as Omeprazole. They will receive standard of care chemotherapy. Standard treatment is the choice of the treating physician and may include Carboplatin in combination with either 5FU, Paclitaxel, or Pemetrexed.
88962394|NCT02013453|Active Comparator|Standard Chemo + Placebo|Patients on the Standard Chemo and Placebo arm are not currently being treated with a proton pump inhibitor (PPI). They will be randomized to receive placebo along with standard of care chemotherapy. Standard treatment is the choice of the treating physician and may include Carboplatin in combination with either 5FU, Paclitaxel, or Pemetrexed.
88962395|NCT02013453|Experimental|Standard Chemo + Omeprazole|Patients on the Standard Chemo and Placebo arm are not currently being treated with a proton pump inhibitor (PPI). They will be randomized to receive Omeprazole along with standard of care chemotherapy. Standard treatment is the choice of the treating physician and may include Carboplatin in combination with either 5FU, Paclitaxel, or Pemetrexed.
88962396|NCT02013466|Other|Bolus ONS intake|Bolus ONS A Bolus ONS B Bolus ONS C Bolus ONS D ONS = oral nutritional supplement 4-way cross-over design: Determination of the product order is based on a Latin square design. 3 Latin squares (4x4) are used, resulting in 12 unique product orders. Subjects receive a randomisation number corresponding with 1 of the 12 product orders. Study product labels will contain randomisation number and appropriate visit number.
88962397|NCT02013518|Experimental|Cognitive behavioural therapy|11 standardised weekly one-hour sessions/6 modules: Module one - introduction to the programme. Module two - pleasant activities to improve mood and depressive symptoms. Module three - the use of external memory aids to help the patients to maintain independence in their daily life. Module four - establishing behavioural routines to reduce demands on memory. Module five - stimulates patients to actively engage in reminiscence and memories to improve mood and well-being. Module six - review of the programme and individual treatment goals.
88962398|NCT02013518|Other|Control group|Treatment as usual at the participating memory clinics
88962399|NCT02013557|Experimental|Intervention Group|Women in the intervention group will receive a test text-message reminder at the time of enrollment. They will then receive a text-reminder to schedule their oral glucose tolerance test at 6 weeks postpartum, with further reminders at 3 months and 6 months if they have not completed their testing.
88962400|NCT02013557|No Intervention|Control group|This arm will only receive the test text-message reminder at the time of enrollment. Otherwise they will receive usual postpartum care.
88962401|NCT02013570|Active Comparator|Dexmedetomidine|Group S peritonsillar 2ml normal saline (1 ml per tonsil) via peritonsillar infiltration.
88962402|NCT02013570|Placebo Comparator|Normal saline, postoperative pain|Group S peritonsillar 2ml normal saline (1 ml per tonsil) via peritonsillar infiltration.
88962403|NCT02013596|No Intervention|Control|Patients were given no TEAS
88962404|NCT02013596|Experimental|TEAS Pretreatment|Patients were given 30min of TEAS before pneumoperitoneum
88962405|NCT02013596|Experimental|TEAS Treatment|Patients were given 30min of TEAS during pneumoperitoneum
88962406|NCT02013635||Cerebral Venous Thrombosis|patients over 16 years old with acute cerebral venous thrombosis
89554620|NCT03832049|Active Comparator|15 to 26 years - 3 dose|9-valent human papillomavirus vaccine (Gardasil 9) - 3 doses
89554621|NCT03832049|Experimental|9 to 14 years - 2 dose|9-valent human papillomavirus vaccine (Gardasil 9) - 2 doses
89554622|NCT03832049|Experimental|4 to 8 years - 2 dose|9-valent human papillomavirus vaccine (Gardasil 9) - 2 doses
88962407|NCT02013661||Suture in Periodontal resective surgery|Four types of suture including silk, polypropylene, PGA, and PTFE
88962408|NCT02013700|Experimental|20 million hMSCs|Patients will receive a single administration of Allogeneic Adult Human Mesenchymal Stem Cells (hMSCs): 2 x10^6 (20 million) cells delivered via peripheral intravenous infusion
88962409|NCT02013700|Placebo Comparator|Placebo|Patients will receive a matched placebo delivered via peripheral intravenous infusion
88962410|NCT02013700|Experimental|100 million hMSCs|Patients will receive a single administration of Allogeneic Adult Human Mesenchymal Stem Cells (hMSCs): 100 x10^6 (20 million) cells delivered via peripheral intravenous infusion
88962411|NCT02013700|Experimental|200 million hMSCs|Patients will receive a single administration of Allogeneic Adult Human Mesenchymal Stem Cells (hMSCs): 200 x10^6 (200 million) cells delivered via peripheral intravenous infusion
88962412|NCT02013713||Family Hypercholesterolemia in cardiology|
88962413|NCT02013726|Experimental|MBI Scan & Tomosynthesis Scan|Patients will receive both scans.
88962414|NCT02013739||Patients with chronic heart failure|other
88962415|NCT02013739||Healthy volontiers|other
88962416|NCT02013752|Active Comparator|Perineal device during delivery|"Delivery should be managed by using the perineal protection device when the head was crowning and 5-6 cm of it was visible. One part the tongue was inserted between the head and the posterior vaginal wall and the two wings were held against the perineum and kept in place by the delivery attendant's hand."
88962417|NCT02013752|Other|Standard care|Standard care at delivery: Manual support of the perineum
88962418|NCT02013804|Experimental|Dose arms|Dose Escalation
88962419|NCT02013843|Other|Community-based treatment|"Overweight and obese children are seen on a regular basis by health care professionals in the 8 communities included in the project. The care providers are all trained thoroughly in using the Holbaek-method for treatment of pediatric obesity."
88962420|NCT02013856|Experimental|Low Epicatechin and procyanidin|Low epicatechin and procyanidin doses
88962421|NCT02013856|Experimental|High Epicatechin and procyanidin|High epicatechin and procyanidin doses
88962422|NCT02013856|Experimental|High Procyanidin|High procyanidin only
88962423|NCT02013856|Placebo Comparator|Placebo|No epicatechin and procyanidin
88962424|NCT02013869|Experimental|Flow-I|"Wash in of desflurane (SupraneR) in an anaesthesia machine without below, a new technique that do not have abag/reservoir that is compressed but pushes the gas into the patient. This technique uses far less of fresh gas volume. Thus lower anaesthetic gas will be consumed per hour.~The primary outcome is the amount of anaesthetic consumed, the decrease in liquid desflurane (SupraneR) in the vaporiser of the ananesthetic machine. The vaporizer will be weighed before and after the anaesthetic to define the amount used."
89554623|NCT03832049|Experimental|9 to 14 years - 1 dose|9-valent human papillomavirus vaccine (Gardasil 9) - 1 dose
89554624|NCT03832049|Experimental|4 to 8 years - 1 dose|9-valent human papillomavirus vaccine (Gardasil 9) - 1 dose
89554625|NCT02281175|No Intervention|No contact intervention|Informative document that proposes a 12-week self-withdrawal grid
89554626|NCT02281175|Active Comparator|a weekly physician intervention|Informative document + 12 meetings (once a week; 30 minutes) with a physician who will supervise the gradual withdrawal
89554627|NCT02281175|Experimental|psychosocial intervention|Informative document + 12 meetings (once a week; 30 minutes) with a physician who will supervise the gradual withdrawal + psychosocial intervention (PASSE-65+ program: 12 sessions over 16 weeks)
88962425|NCT02013869|Active Comparator|Asys|"Wash in of desflurane (Suprane) in conventional anaesthesia machine Asys, with the anaesthesia machine Asys that has a bag/reservoir that is compressed for insufflation of gas into the patient, thus it is expected that more gas will be consumed per hour.~The primary outcome is the amount of anaesthetic consumed, the decrease in liquid desflurane (SupraneR) in the vaporiser of the ananesthetic machine. The vaporizer will be weighed before and after the anaesthetic to define the amount used."
88962426|NCT02013882||1-1-12 wash-in|wash-in using O2:N2O 1:1 L/min with desflurane 12%
88962427|NCT02013908|Active Comparator|Standard ED management alone|Radiographic and physical examinations to exclude fractures or other serious conditions will be performed for all patients before considering eligibility in the study. After completion of the examination, patients who have pain of at least a level 4, as measured by the Wong-Baker scale (ranges 0 to 10), will receive intravenous or intramuscular injections of non-steroidal anti-inflammatory drugs (NSAIDs) for immediate pain control. All patients will be observed 30 minutes after the administration of the NSAIDs. In patients with primary headaches who respond poorly to the initial NSAID injection, an intravenous injection of opioid analgesics will be provided. After these initial standard ED management interventions, patients who are still suffering from acute pain will be asked to participate in the trial. During the study, rescue medication for immediate pain control will be allowed for patients allocated to both groups.
88962428|NCT02013908|Experimental|Acupuncture plus standard ED management|The patients in this group will receive a single session of individualized acupuncture treatment delivered by a certified Korean Medicine Doctor (KMD) specialized (or in-training) in acupuncture and moxibustion medicine and with at least 3 years of clinical experience. The acupuncture formulas will be composed based on the individual patient's symptoms and at the KMD's discretion. Acupuncture treatments will be provided in line with standard ED management, the same as in the control group.
88962429|NCT02013921||Physical Activity|Patients with a breast cancer and are completing treatment
88962430|NCT02013934|Active Comparator|Probiotics|Dietary supplement
88962431|NCT02013934|Placebo Comparator|Placebo|Dietary supplement
88962432|NCT02013947|Other|Moderate altitude group|2 weeks of exercise at 1900 meters sea level
88962433|NCT02013947|Other|low altitude group|2 weeks of exercise at 400 meters sea level
88962434|NCT02013960|Experimental|Laminaria|cytotec and laminaria
88962435|NCT02013960|Active Comparator|Cytotec|Cytotec only
88962436|NCT02013973|Experimental|AMH-group|The patients randomized to the AMH-group calculation of gonadotropin starting dose will be made from an algorithm including age, BMI, AFC and AMH-analysis.
88962437|NCT02013973|No Intervention|Non-AMH-group|The patients randomized to the non-AMH-group, calculation of gonadotropin starting dose will be made from an algorithm including only age, BMI and AFC
88962438|NCT02013986|Experimental|etomidate & midazolam|a bolus of midazolam(Jiangsu Enhua Pharmaceutical Ltd.) 0.1mg/kg then a bolus of etomidate(Etomidate Fat Emulsion Injection, Jiangsu Enhua Pharmaceutical Ltd.)0.3 mg/kg and intravenously, during induction period, the other steps as usual.
88962439|NCT02013986|Active Comparator|midazolam & propofol|During induction period,use a bolus of midazolam injection 0.1mg/kg(Jiangsu Enhua Pharmaceutical Ltd.) and then a bolus of propofol injection 2mg/kg(Astrazeneca PLC.)intravenously, the other steps are as usual.
88962440|NCT02013999|Experimental|Virtual reality program|mobile device for virtual reality program
88962441|NCT02013999|Active Comparator|Control|standard occupuational therapy
88962442|NCT02014025|Experimental|laparoscope hepatectomy|We let the 45 patients who are meet the inclusion criteria .Hospital in hepatobiliary surgery E district is Group B ,they will accept laparoscopic hepatectomy: tumors are totally resected through laparoscopic.
88962443|NCT02014025|Experimental|open hepatectomy|We let the 45 patients who are meet the inclusion criteria .Hospital in hepatobiliary surgery A and D district is Group A ,they will accept Open Hepatectomy: tumors are totally resected by conventional laparotomy.
88962444|NCT02014064|Experimental|Atomoxetine|Double-blind, Placebo controlled, 2-phase study the safety & efficacy of Atomoxetine
89554628|NCT02102477|Experimental|Prostatectomy/Surgery|Patients with locally advanced prostate adenocarcinoma recieves Prostatectomy/Surgery with or without adjuvant or salvage radiotherapy
89554629|NCT02102477|Active Comparator|Radiotherapy with adjuvant androgen deprivation therapy|Patients with locally advanced prostate adenocarcinoma treated with adjuvant androgen deprivation therapy
89554630|NCT04482413|Experimental|Treatment|Treatment group will be administered via intravenously AstroStem which consists of two syringes and each syringe contains 2.0 x 10^8 cells / 20 mL of saline with 30% auto-serum.
89554631|NCT04482413|Placebo Comparator|Placebo Control|Placebo control group will receive AstroStem Placebo.
89554632|NCT03103997|Active Comparator|New Needle|EUS-guided liver biopsy with needle and suction, no preparation
88962445|NCT02014064|Placebo Comparator|Placebo|"Control Group Schedule:~Day 1: 40mg @ 8:00am Day 2: 40mg @ 8:00am Day 3: 40mg @ 8:00am, 40mg @ 8:00pm Day 4: 40mg @ 8:00am, 40mg @ 8:00pm Day 5: 40mg @ 8:00am, 40mg @ 8:00pm Day 6: 40mg @ 8:00am = Testing day (fMRI scan & cognitive testing session)"
88962446|NCT02014077|Active Comparator|Thoracostomy Tube|patients selected for thoracostomy tube reinsertion after failure of drainage with first thoracostomy tube for traumatic haemothorax
88962447|NCT02014077|Active Comparator|VATS|patients selected for VATS after failure of first thoracostomy tube drainage of traumatic haemothorax will undergo a Video-Assisted Thoracoscopic clearance of the persistent/retained haemothorax
88962448|NCT02014090|Active Comparator|half supine bicycle Exercise|60 minutes of half supine bicycle exercise with submaximal workload
88962449|NCT02014090|Active Comparator|ECP|90 minutes of ECP
89554633|NCT03103997|Experimental|Dry Heparin|EUS-guided liver biopsy with needle flushed with heparin, then flushed with air, suction then attached
89554634|NCT03103997|Experimental|Wet Heparin|EUS-guided liver biopsy with needle flushed with heparin, 2 cc of liquid added to suction then attached.
89554635|NCT04435223||COVID-19 severe pneumonia|
89554636|NCT04435223||Severe pneumonia due to other pathogene|
89554637|NCT04412603|Experimental|Conventional Mirror Therapy group|"Therapy:~-With the affected upper limb into the mirror box, perform the exercise with the non-affected extremity which is reflected in the mirror box. -The affected side must perform the corresponding movement within its possibilities, according to the exercise that is being performed with the healthy arm. - It is very important to look at the mirror at all times, which reflects the non-affected side while doing the exercises."
89554638|NCT04412603|Experimental|Mirror Therapy Virtual Reality group|"Therapy:~-Perform the exercises with the non-affected limb, which must be watched constantly with virtual reality glasses, to interpret that this limb corresponds to the affected side. - The affected side accompanies the movement within its possibilities (out of sight of the patient, it can be covered with a handkerchief). - It is very important to look at the non-affected side. The affected side should be out of the visual field to avoid confusion."
89554639|NCT03103685|Placebo Comparator|ASA alone|The patient in this arm will be ask to stop P2Y12 inhibitor before dental procedure, 5 days for clopidogrel and ticagrelol and 7 days for prasugrel.
89025741|NCT04434898||Healthy volunteers|"The healthy volunteers should meet the following criteria:~Between 50-80 years old~Right-handed~MMSE score greater than or equal to 26~Able to understand study requirements and give informed consent"
89025742|NCT00489372|Placebo Comparator|Arm I (placebo)|Participants receive oral placebo on day 1.
89554640|NCT03103685|Experimental|Uninterrupted DAPT|The patient in this arm will continue dual anti platelet until the date of dental procedure.
89554641|NCT03102281||recurrent group|Patients who had recurrent common bile duct stones.
89554642|NCT03102281||control group|Patients who had not recurrent common bile duct stones.
89025743|NCT00489372|Experimental|Arm II (Se-methyl-seleno-L-cysteine)|Participants receive oral Se-methyl-seleno-l-cysteine (MSC) on day 1. Cohorts of 5 participants receive escalating doses of MSC until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 5 or 2 of 10 patients experience dose-limiting toxicity.
89025744|NCT04432870||MGH Patients|Patients aged 45-75 who had their screening or surveillance colonoscopy postponed or delayed due to the COVID pandemic at Massachusetts General Hospital
89025745|NCT04427800||CKD G4|Chronic kidney disease stage (G4). (eGFR < 30 mL/min/1.73m2)
89554643|NCT00999011|Active Comparator|One 20 minute period of activity daily|passive and/or active range of motion, chair sitting, sitting at edge of bed, standing and walking
89554644|NCT00999011|Active Comparator|Two periods of 20 minute activity daily|passive and/or active range of motion, chair sitting, sitting at edge of bed, standing and walking
89554645|NCT03103529|Experimental|Early Rehab|Children will begin active rehabilitation 2 weeks post-injury
89025746|NCT04427800||CKD G5|Chronic kidney disease stage (G5). (eGFR < 15 mL/min/1.73m2) with imminent initiation of RRT
89025747|NCT04427800||ESRD on ICHD|End stage renal disease on in centre haemodialysis
89025748|NCT04427800||ESRD on HHD|End stage renal disease on home haemodialysis
89025749|NCT04427800||ESRD on PD|End stage renal disease on peritoneal dialysis
89554646|NCT03103529|Active Comparator|late rehab|Children will begin active rehabilitation 4 weeks post-injury
89554647|NCT00418301|Experimental|Precision Spinal Cord Stimulation and PET Scan|Positron emission tomography (PET) scan imaging procedures to assess Spinal Cord Stimulation.
89554648|NCT03103451|Experimental|Cohort 1|"This cohort includes 3 subjects in BCD-121 group and 1 subject in placebo group.~Intervention: BCD-121/ placebo"
89554649|NCT03103451|Experimental|Cohort 2|"This cohort includes up to 6 subjects in BCD-121 group and 1 subject in placebo group.~Intervention: BCD-121/ placebo"
89554650|NCT03103451|Experimental|Cohort 3|"This cohort includes up to 6 subjects in BCD-121 group and 1 subject in placebo group.~Intervention: BCD-121/ placebo"
89554651|NCT03103451|Experimental|Cohort 4|"This cohort includes up to 6 subjects in BCD-121 group and 1 subject in placebo group.~Intervention: BCD-121/ placebo"
89554652|NCT03103451|Experimental|Cohort 5|"This cohort includes up to 6 subjects in BCD-121 group and 1 subject in placebo group.~Intervention: BCD-121/ placebo"
89554653|NCT03103451|Experimental|Cohort 6|"This cohort includes up to 6 subjects in BCD-121 group and 1 subject in placebo group.~Intervention: BCD-121/ placebo"
89554654|NCT03103451|Experimental|Cohort 7|"This cohort includes up to 6 subjects in BCD-121 group and 1 subject in placebo group.~Intervention: BCD-121/ placebo"
89554655|NCT03103295|Experimental|3D-Tissue Engineered Bone Equivalent|"Patients with bone defects of critical size of long bones~3D Tissue Engineered Bone Equivalent: allogeneic or xenogeneic partially demineralized bone matrix (DBM) and plasma-derived fibrin gel seeded with autologous cultured bone marrow-derived multipotent mesenchymal stromal cells (BM-MSCs), periosteal progenitor cells (PPCs), peripheral blood-derived endothelial progenitor cells (PB-EPCs)."
89554656|NCT03656159|Active Comparator|Non-directive support group|This intervention will provide time and space to discuss the impact of AD. The objective will be to help participants feel less alone and better understood and to address the implications of AD in their daily life.
89025750|NCT04427800||Post-transplant|Participants post-transplant
89025751|NCT00461903|Placebo Comparator|Placebo (for perindopril)|Sugar pill manufactued to mimic perindopril
89025752|NCT00461903|Active Comparator|Perindopril|Perindopril (coversyl) 4 mg tablets
89025753|NCT00591682|Experimental|1|MSX-122
89025754|NCT04329013|Active Comparator|Left lateral position|The patient will be in left lateral position during EGD
89025755|NCT04329013|Experimental|Prone position|The patient will be in prone position during EGD
89025756|NCT02893696|Active Comparator|Immediately Supine Position|Women placed in supine position within 30 seconds after spinal injection of local anesthetic drug.
89025757|NCT02893696|Active Comparator|Delayed Supine Position|Women placed in supine position after three minutes of seating after spinal injection of local anesthetic drug.
89025758|NCT04424446||NIH staff|NIH staff undergoing standard NIH COVID-19 screening willing to donate additional research samples.
89025759|NCT00496509|Experimental|ZD6474 (vandetanib) 100mg|
89025760|NCT00496509|Experimental|ZD6474 (vandetanib) 300mg|
89025761|NCT04135729||Personal trainer (PT)|Cross-sectional study on mental health symptoms in personal trainers
89025762|NCT04135729||Group instructors (GI)|Cross-sectional study on mental health symptoms in group instructors
89025763|NCT04135729||Combined instructors (PT + GI)|Cross-sectional study on mental health symptoms in personal trainers
89554657|NCT03656159|Experimental|Cognitive-Behavioral group therapy|The intervention will include behavioral activation, cognitive restructuring, and stress/anger management strategies (e.g. abdominal breathing, progressive muscle relaxation). In addition, knowledge about memory management and sleep disorders will be provided.
89554658|NCT05001815|Experimental|Continuous subcutaneous insulin infusion (CSII)|Patients with indications will receive continuous subcutaneous insulin infusion (CSII) treatment achieved by patch insulin pump devices.
89554659|NCT05001815|Active Comparator|Multiple daily insulin injection (MDI)|Patients with indications will receive traditional multiple daily insulin injection (MDI) treatment.
89554660|NCT02644967|Experimental|Phase 2, 8 mg Tilso/Ipi|IMO-2125 intratumoral injection plus ipilimumab
89554661|NCT04435535|Other|Positive expiratory pressure (PEP)|PEP 10 cmH2O 15 min
89554662|NCT04945109|Experimental|Mankai beverage first|Two weeks of Mankai supplementation followed by two weeks of water supplement
89554663|NCT04945109|Experimental|Mankai beverage last|Two weeks of water supplementation followed by two weeks of Mankai supplement
89554664|NCT04896749|Experimental|Group A/ Nerve mobilization group|In this group, patients will receive nerve mobilization exercises along with routine physical therapy. Patients will also be given home plan for cervical isometric exercises.
89554665|NCT04896749|Active Comparator|Group B/ Conventional physical therapy group|In this group, patients will receive routine physical therapy and also given home plan for cervical isometric exercises
88962450|NCT02012647|Active Comparator|People with Parkinsons Disease|Participants have been diagnosed with Parkinson's Disease, and as recommended by their physicians, have undergone DBS surgery for both sides of the brain. These participants will undergo TMS and motor physiology testing, and results will be compared to participants without Parkinson's Disease.
88962451|NCT02012647|Placebo Comparator|Healthy Controls|These participants do not have Parkinson's Disease, nor have they had DBS surgery, and are a healthy controls. These participants will undergo TMS and motor physiology testing, and results will be compared to participants with Parkinson's Disease.
88962452|NCT02013089|Experimental|Erlotinib or Gefitinib|Erlotinib 150 mg tablet or Gefitinib 250 mg tablet by mouth every day
89554666|NCT04890821|Experimental|CI Percutaneous Ring Annuloplasty System|Patients treated with the CI Percutaneous Ring Annuloplasty System
89554667|NCT04771637|Placebo Comparator|control with normal saline|
89554668|NCT04771637|Experimental|dexmedetomidine loading dose 1 µg/kg + maintenance dose 0.25 µg/kg/h|
89554669|NCT04771637|Experimental|dexmedetomidine loading dose 0.5 µg/kg + maintenance dose 0.5 µg/kg/h|
89554670|NCT04771637|Experimental|dexmedetomidine loading dose 1 µg/kg + maintenance dose 0.5 µg/kg/h|
89554671|NCT04751591|Experimental|Endoscopic resection|The endoscopist will perform endoscopic resection for patients enrolled in this group.
89554672|NCT04751591|Other|Laparoscopic partial gastrectomy|The endoscopist will perform laparoscopic partial gastrectomy for patients enrolled in this group.
89554673|NCT04731389|Experimental|internet CBT|Intervention with remote and self-applicable cognitive behavioral therapy, during 4 weeks.
89554674|NCT04731389|Active Comparator|Quality of life promotion|Control intervention, during 4 weeks.
89554675|NCT03588377|Active Comparator|Intervention Cluster|Signs and symptoms of severe pneumonia Pulse Oximetry
89554676|NCT03588377|No Intervention|Non-Intervention Cluster|Signs and symptoms of severe pneumonia
89554677|NCT03103217|Experimental|Brief CBT intervention|
89554678|NCT03103373|Active Comparator|Conventional monitor group|Patients will be monitoring with invasive blood pressure, central venus catheter, plasma lactate, urinary output, oximeter, capnography and electrocardiography Echocardiography group: Patients will be monitoring with echocardiography, invasive blood pressure, central venus catheter, plasma lactate, urinary output, oximeter, capnogrphy and electrocardiography
89554679|NCT03103373|Active Comparator|Echocardiography group|Patients will be monitoring with echocardiography, invasive blood pressure, central venus catheter, plasma lactate, urinary output, oximeter, capnography and electrocardiography
89554680|NCT04695041|Experimental|Cohort A: 1200 mg PBI-4050|
89554681|NCT04695041|Experimental|Cohort B: 1600 mg PBI-4050|
88962453|NCT02013089|Experimental|Everolimus|Everolimus 10 mg orally once daily every day
88962454|NCT02013089|Experimental|Imatinib|Imatinib 400 mg tablet orally per day
88962455|NCT02013089|Experimental|Sorafenib or Sunitinib|Sorafenib 400 mg twice a day at least one hour before or two hours after eating or Sunitinib 50 mg orally once a day
88962456|NCT02013089|Experimental|Vandetanib|Vandetanib 300 mg orally once daily
89554682|NCT04695041|Experimental|Cohort C: 2000 mg PBI-4050|
89554683|NCT04695041|Experimental|Cohort D: 2400 mg PBI-4050|
89554684|NCT04695041|Experimental|Cohort E: 2400 mg PBI-4050|
89554685|NCT04695041|Experimental|Cohort F (Supplemental): 1600 mg PBI-4050|
89554686|NCT04626869|Active Comparator|Interscalene block|"patients will be placed in a semi-sitting position with their heads facing the opposite side. Linear ultrasound probe (GE Loqic P9 7-15 MHz) to detect the brachial plexus. At the cervical level 5-6, the posterior brachial plexus will be approached as in-plane from the posterior with the needle (Contiplex C, Braun) through the catheter. The nerve structure will be confirmed with stimulation in the upper extremity muscles with a nerve stimulator and 5 ml 0.5% Bupivacaine will be injected."
89554687|NCT04626869|Active Comparator|Anterior suprascapular nerve block|"patients will be placed in a semi-sitting position with their heads facing the opposite side. Linear ultrasound probe (GE Loqic P9 7-15 MHz) will be placed in the suprascapular region in a coronal oblique manner. The omohyoid muscle, under it the suprascapular nerve, the brachial plexus and the subclavian artery will be identified. The suprascapular nerve will be approached from the posterior as in-plane with a needle (Contiplex C, Braun) through the catheter. The nerve structure will be confirmed by stimulation in the supraspinous muscle with a nerve stimulator and 5 ml 0.5% Bupivacaine will be injected."
88962457|NCT02013089|No Intervention|Control|No intervention was performed for patients without any gene alternation or without any available target agents
88962458|NCT02014103|Other|Sequence 1|Patients will be randomized to a sequence of administration of the various 6 tacrolimus formulations. Sequence 1: Formulation 3, 5, 6, 4, 2, 1.
88962459|NCT02014103|Other|Sequence 2|Patients will be randomized to a sequence of administration of the various 6 tacrolimus formulations. Sequence 2: Formulation 3, 4, 6, 5, 1, 2.
89554688|NCT04435145|Experimental|Intervention|Sugar-sweetened beverage warning label
89554689|NCT04435145|No Intervention|Control|No label
89554690|NCT04435301|Experimental|Gamma modulation effect|40Hz current is applied by a battery-driven current stimulator(NeuroConn, Germany). Two pairs of electrodes are attached to the middle and lower part of the face to stimulate the maxillary nerve (V2) and the mandibular nerve (V3), respectively. 40Hz acoustic stimuli and 40Hz electric stimuli are synchronously applied for 40min/day, for a total of 5 days.
89554691|NCT04435301|Experimental|Beta modulation effect|28Hz current is applied by a battery-driven current stimulator. Two pairs of electrodes are attached to the middle and lower part of the face to stimulate the maxillary nerve (V2) and the mandibular nerve (V3). 28Hz acoustic stimuli and 28Hz electric stimuli are synchronously applied for 40min/day, for a total of 5 days.
89554692|NCT04435301|Sham Comparator|Sham modulation group|Sham stimulation was identical to the 40Hz stimulation, except that the acoustic and electric stimulation were ramped down after 0.5 min to remain turned off for the remaining 39.5 min. Sham stimuli are applied for 40min/day, for a total of 5 days.
89554693|NCT03471221|Experimental|Therapy Dog Visits|"Participants randomized to Therapy Dog Visits will receive a visit from a therapy dog and handler team up to one time per week for up to four weeks, depending on length of hospitalization and therapy dog team capacity.~Therapy dog visits will last up to about 20 minutes and activities may include: petting the dog, watching the dog perform a trick, and talking with the dog handler.~All activities will follow the current procedures and regulations in place at Seattle Children's Hospital."
89554694|NCT03471221|No Intervention|Control Group|Participants randomized to the Control Group will receive usual medical care.
88962460|NCT02014103|Other|Sequence 3|Patients will be randomized to a sequence of administration of the various 6 tacrolimus formulations. Sequence 3: Formulation 4, 3, 5, 1, 6, 2.
88962461|NCT02014155|Experimental|Group Pulmonary Rehabilitation|Pulmonary Rehabilitation consists of isotonic exercises of upper and lower limbs, 20-minute workout on cycle ergometer in standard desinsuflativo (expiration at the time of muscle contraction), is performed three times a week for eight weeks.
88962462|NCT02014155|Experimental|Group TMI + Pulmonary Rehabilitation|Will be held inspiratory muscle training associated with a pulmonary rehabilitation program. The inspiratory muscle training is performed with a load of 40 to 50% of the muscle strength of the subjects. Pulmonary Rehabilitation consists of isotonic exercises of upper and lower limbs, 20-minute workout on cycle ergometer in standard deflation (expiration at the time of muscle contraction), is performed three times a week for eight weeks.
88962463|NCT02014155|Experimental|Control Group|Inspiratory muscle training will be held three times a week for eight weeks
88962464|NCT02014155|Experimental|COPD group not rehabilitation|
88962465|NCT02014168|Experimental|Viroflu® and MVA-NP+M1|1 dose (0.5ml) of Viroflu® and 1 dose of 1.5 x10^8 pfu MVA-NP+M1 intramuscularly into the vastus lateralis muscle on day 0. The vaccines will be given side by side, with MVA NP+M1 being given immediately after the seasonal influenza vaccine.
88962466|NCT02014168|Placebo Comparator|Viroflu® and saline placebo|1 dose (0.5ml) of Viroflu® and 1 dose of a 0.9% saline placebo injected intramuscularly into the vastus lateralis muscle on day 0. The placebo will be administered immediately after the seasonal influenza vaccine.
88962467|NCT02014181|Experimental|Flaxseed|40 grams finely ground flaxseed powder daily for one month in patient with cystic fibrosis
88962468|NCT02014194|Placebo Comparator|attentional bias modification, placebo|Measure of attentional bias modification treatment after 10 sessions of attentional bias modification (two arms). There are two arms with 15 OCD patients each one.
88962469|NCT02014194|Active Comparator|attentional bias modification, active group|Measure of attentional bias modification treatment after 10 sessions of attentional bias modification (two arms).
88962470|NCT02014207|Experimental|golden crinkle|
88962471|NCT02014207|Experimental|high blanch|
88962472|NCT02014207|Experimental|low blanche|
88962473|NCT02014207|Experimental|high chill|
88962474|NCT02014207|Experimental|low chill|
88962475|NCT02014220|Experimental|Atlantic Western chips|deep fried potato chips
88962476|NCT02014220|Experimental|Dakota Pearl chips|deep fried potato chips
89554695|NCT05244941||Cross site-case study|Qualitative methods: semi-structured interviews for patients, front line clinical practitioners, and health system stakeholders, case study building across sites
89554696|NCT03464669||Group prenatal education|Prenatal education delivered in-person by health and social services centers
89554697|NCT03464669||Online prenatal education|Online prenatal education provided or recommended by health and social services centers
89554698|NCT03464669||Control group|Absence of prenatal education
88962477|NCT02014220|Experimental|Andover Ontario chips|deep fried potato chips
88962478|NCT02014220|Experimental|white bread with margarine|energy control
88962479|NCT02014220|Experimental|white bread|control
88962480|NCT02014233|Experimental|Omega-3|Participants will consume 5 mL of omega-3 (2333 mg essential fatty acids) with 1000 IU vitamin D3 for 21 days.
88962481|NCT02014233|Placebo Comparator|Olive oil|Participants will consume 5 mL of olive oil with 1000 IU vitamin D3 for 21 days.
88962482|NCT02014259|Experimental|Subjects with renal impairment|
88962483|NCT02014259|Active Comparator|Subjects with normal renal function|
88962484|NCT02014285||Muscle Ultrasound/Sample|30 subjects enrolled from Wake Forest Baptist Health Intensive Care Units. Each study subject will undergo an ultrasound to examine the size and echogenicity of their muscles and a muscle biopsy from the rectus femoris. The muscles studied will include the biceps brachii, wrist extensors, quadriceps, and tibialis anterior.
88962485|NCT02014298|Other|Control|One area assessed as a control area, compared to the laser-treated area
88962486|NCT02014298|Active Comparator|Non-ablative Laser treatment|3 Non-ablative fractional laser treatments of one area
88962487|NCT02014324||(suspected) NSCLC, mediastinal staging, endosonography|Patients with potentially medically operable and resectable NSCLC are eligible if there is an indication for pathological evaluation of mediastinal lymph nodes.
88962488|NCT02014337|Experimental|Mifepristone and Eribulin in combination|Single Arm
88962489|NCT02014350||DePuy Delta Xtend RTSA|
88962490|NCT02014428|Experimental|Hyaluronic acid|220 mg hyaluronic acid per tablet (two tablets/day for 10 days, and subsequently one tablet/day for three months)
89554699|NCT05244863||One group|Geriatric individuals
88962491|NCT02014428|Placebo Comparator|Placebo|two tablets/day for 10 days, and subsequently one tablet/day for three months
88962492|NCT02014454|Experimental|Propranolol eye drops|"All the enrolled preterm newborns will receive propranolol as ophthalmic solution (0,1%): 3 microdrops of 6 microliters (μL) propranolol solution (= 6 μg propranolol/microdrop) will be topically applied with a calibrated pipette, in each eye, three times daily (every 8 hours).The treatment will continue until the complete development of retinal vascularization, but no more than 60 days.~The propranolol treatment will be always associated to the conventional approach adopted by the Early Treatment for Retinopathy of Prematurity Study (ETROP Cooperative Group."
88962493|NCT02014493|Active Comparator|HFNC first|4 hours with High Flow Nasal Cannulae (HFNC) 6 l/pr.min, then 4 hours with Continuous Positive Airway Pressure (CPAP) 6l/pr.min.
88962494|NCT02014493|Active Comparator|CPAP first|4 hours Continuous Positive Airway Pressure (CPAP) 6 l/pr.min, then 4 hours High Flow Nasal Cannulae (HFNC) 6 l/pr.min.
88962495|NCT02014506|Experimental|HAPLO|
88962496|NCT02014532|Active Comparator|Montelukast|Patients in Test Group were given Leukotriene receptor antagonist, Montelukast 1 tablet twice daily for 3 weeks then medications were stopped and changes in all parameters were again checked after 6 weeks.
88962497|NCT02014532|Placebo Comparator|Placebo|Patients in Control Group were given placebo drug 1 tablet twice daily for 3 weeks then medications were stopped and changes in all parameters were again checked after 6 weeks.
88962498|NCT02014545|Active Comparator|WBRT + Lucanthone|Treatment will consist of WBRT given in a dose of 30 Gy in ten fractions with lucanthone given as an adjunct. Lucanthone will be administered as 25 mg and 100 mg tablets to be swallowed. Dosage will be one of the following: 250 mg bid, 250 tid, or 375 mg tid.
88962499|NCT02014545|Placebo Comparator|WBRT + Placebo|Patients will receive prophylactic cranial irradiation at 3 Gy per fraction, 5 days per week, for 2 weeks to a total dose of 30 Gy.
88962500|NCT02014558|Experimental|Gilteritinib 20 mg in Escalation Phase|Participants received a single dose of 20 mg gilteritinib orally on day -2 to evaluate pharmacokinetics of gilteritinib. Then starting on day 1 of cycle 1, participants received 20 mg gilteritinib orally once daily in 28-day cycles until disease progression or participant discontinuation in the escalation phase of the study.
88962501|NCT02014558|Experimental|Gilteritinib 40 mg in Escalation Phase|Participants received a single dose of 40 mg gilteritinib orally on day -2 to evaluate pharmacokinetics of gilteritinib. Then starting on day 1 of cycle 1, participants received 40 mg gilteritinib orally once daily in 28-day cycles until disease progression or participant discontinuation in the escalation phase of the study.
88962502|NCT02014558|Experimental|Gilteritinib 80 mg in Escalation Phase|Participants received a single dose of 80 mg gilteritinib orally on day -2 to evaluate pharmacokinetics of gilteritinib. Then starting on day 1 of cycle 1, participants received 80 mg gilteritinib orally once daily in 28-day cycles until disease progression or participant discontinuation in the escalation phase of the study.
88962503|NCT02014558|Experimental|Gilteritinib 120 mg in Escalation Phase|Participants received a single dose of 120 mg gilteritinib orally on day -2 to evaluate pharmacokinetics of gilteritinib. Then starting on day 1 of cycle 1, participants received 120 mg gilteritinib orally once daily in 28-day cycles until disease progression or participant discontinuation in the escalation phase of the study.
88962504|NCT02014558|Experimental|Gilteritinib 200 mg in Escalation Phase|Participants received a single dose of 200 mg gilteritinib orally on day -2 to evaluate pharmacokinetics of gilteritinib. Then starting on day 1 of cycle 1, participants received 200 mg gilteritinib orally once daily in 28-day cycles until disease progression or participant discontinuation in the escalation phase of the study.
88962505|NCT02014558|Experimental|Gilteritinib 300 mg in Escalation Phase|Participants received a single dose of 300 mg gilteritinib orally on day -2 to evaluate pharmacokinetics of gilteritinib. Then starting on day 1 of cycle 1, participants received 300 mg gilteritinib orally once daily in 28-day cycles until disease progression or participant discontinuation in the escalation phase of the study.
88962506|NCT02014558|Experimental|Gilteritinib 450 mg in Escalation Phase|Participants received a single dose of 450 mg gilteritinib orally on day -2 to evaluate pharmacokinetics of gilteritinib. Then starting on day 1 of cycle 1, participants received 450 mg gilteritinib orally once daily in 28-day cycles until disease progression or participant discontinuation in the escalation phase of the study.
88962507|NCT02014558|Experimental|Gilteritinib 20 mg in Expansion Phase|Participants received 20 mg gilteritinib orally once daily stating on day 1 of cycle 1 and continued in 28-day cycles until disease progression or participant discontinuation in the expansion phase of the study. Starting on day 16 of cycle 1, participants also received 200 mg voriconazole orally every 12 hours through day 1 of cycle 2.
88962508|NCT02014558|Experimental|Gilteritinib 40 mg in Expansion Phase|Participants received 40 mg gilteritinib orally once daily starting on day 1 of cycle 1 and continued in 28-day cycles until disease progression or participant discontinuation in the expansion phase of the study.
88962509|NCT02014558|Experimental|Gilteritinib 80 mg in Expansion Phase|Participants received 80 mg gilteritinib orally once daily starting on day 1 of cycle 1 and continued in 28-day cycles until disease progression or participant discontinuation in the expansion phase of the study.
88962510|NCT02014558|Experimental|Gilteritinib 120 mg in Expansion Phase|Participants received 120 mg gilteritinib orally once daily starting on day 1 of cycle 1 and continued in 28-day cycles until disease progression or participant discontinuation in the expansion phase of the study.
88962511|NCT02014558|Experimental|Gilteritinib 200 mg in Expansion Phase|Participants received 200 mg gilteritinib orally once daily starting on day 1 of cycle 1 and continued in 28-day cycles until disease progression or participant discontinuation in the expansion phase of the study. On day -1 and day 15 of cycle 1, certain participants also received 500 mg cephalexin as a single oral dose.
89554700|NCT03446027|No Intervention|Control|There will be no change to the local site standard of care for patients with IC attributed to participation in this trial. Those sites with Supervised Exercise Therapy (SET) will continue to provide this intervention as per their normal standard of care and locally agreed protocol.
89554701|NCT03446027|Experimental|Device|Local therapy + Neuromuscular Electrical Stimulation (NMES)
89554702|NCT05244707|Experimental|Mediterranean style diet|Mediterranean style diet.
89554703|NCT05244707|Active Comparator|Standard of care|Standard of care.
89025764|NCT02956577||T2|Patients with type 2 diabetes without myocardial infarction, heart failure and symptoms of cardiac disease at inclusion, were invited from the Outpatient Clinic of Endocrinology or The Eye Photo Clinic at Odense University Hospital (OUH) Svendborg. Diagnosis of diabetes was classified by trained endocrinologists according to international standards with relevant biochemistry. Historical data on urine- and blood samples as well as micro- and macrovascular diabetic complications have been registered consecutively in patients followed at the outpatient clinic in the regional Funen Diabetes Database (FDDB). Data on historical invasive procedures due to cardiac disease were registered in Western Denmark Heart Registry (WDHR).
89025765|NCT02956577||T1|Patients with type 1 diabetes without myocardial infarction, heart failure and symptoms of cardiac disease at inclusion, were invited from the Outpatient Clinic of Endocrinology or The Eye Photo Clinic at OUH Svendborg. Diagnosis of diabetes was classified by trained endocrinologists according to international standards with relevant biochemistry. Historical data on urine- and blood samples as well as micro- and macrovascular diabetic complications have been registered consecutively in patients followed at the outpatient clinic in the regional FDDB. Data on historical invasive procedures due to cardiac disease were registered in WDHR.
89025766|NCT02956577||Non-diabetic subjects|Non-diabetic subjects without myocardial infarction, heart failure and symptoms of cardiac disease at inclusion, were included from The Danish Cardiovascular Screening trial (DANCAVAS). A randomized controlled trial with the primary aim to evaluate the health benefits and costeffectiveness of using non-contrast full truncus computer tomography (CT) scans (to measure coronary artery calcification (CAC) and identify aortic/iliac aneurysms) and measurements of the ankle brachial blood pressure index (ABI) as part of a multifocal screening and intervention program for cardiovascular disease in men aged 65-74.
89025767|NCT00496548|Experimental|1|Fecal calprotectin and urinary PGE-M levels will be tested on all participants.
89554704|NCT05244317|Placebo Comparator|cast group|treatment of the participant of this group will be by the standard method which is by casting
89554705|NCT05244317|Experimental|splint group|treatment of the participant of this group will be by the removable splint
89554706|NCT05244161|No Intervention|Radio messaging (RM)|Radio messaging only (RM)
89554707|NCT05244161|Active Comparator|RM, Video job aids, Early Childhood Development program (RMV-ECD)|Radio messaging, short video job aids primarily for CHW use, and the UNICEF Care for Childhood Development program (RMV-ECD)
89554708|NCT05243927|Experimental|Aerobic exercise group|Aerobic exercise will be performed under the supervision of a physiotherapist with a treadmill during 40-60 minutes, 3 days a week for 8 weeks.
89554709|NCT05243927|Active Comparator|Stabilization exercise group|Spinal stabilization exercises will be performed with a physiotherapist during 40-60 minutes, 3 days a week for 8 weeks.
89554710|NCT04961879|Active Comparator|Reversed Cross Finger Flap group 1|
89554711|NCT04961879|Active Comparator|Reversed island Homo-digital Flap group 2|
89554712|NCT05243849||Ischemic Stroke|The diagnosis of ischemic stroke was obtained from previous diagnostic reports or electronic medical records, according to the diagnostic criteria from the Trial of Org 10172 in Acute Stroke Treatment (TOAST).
89554713|NCT05243849||Control|Inclusion criteria for healthy controls were no history of ischemic stroke or other neurological and ocular diseases.
89554714|NCT04937075||Before period without multiplex PCR identification|
89554715|NCT04937075||After period with multiplex PCR identification|
89554716|NCT05243771||Rectal resection with diverting stoma|Patients operated for rectal cancer with rectal resection and diverting stoma.
89554717|NCT05243771||Rectal resection without diverting stoma|Patients operated for rectal cancer with rectal resection without diverting stoma.
89554718|NCT05243771||Rectal resection with primary colostomy|Patients operated for rectal cancer with rectal resection with primary colostomy.
89554719|NCT05243693|Experimental|Brentuximab vedotin and DHAP|A clinical study of safety and efficacy of treatment with Brentuximab vedotin and DHAP in patients with relapsed/refractory Hodgkin lymphoma
89554720|NCT05243225||laparoscopic management of post cholecystectomy bile duct injury.|Under general intubation anaesthesia, trocars are inserted in the abdomen, insufflation by CO2 adhesiolysis is performed to reach the bile duct. Evaluation by intraoperative cholangiogram then according to the site and the size of the injury repair will done. If the injury is small simple repair or repair on T-tube will be done. If the injury is large repair on T-tube or hepaticojejunostomy will be done .If it is a distal injury repair on T-tube or biloenteric shunt will be done .If the injury is proximal biloenteric shunt will be done. Intra-abdominal drains insertion
89554721|NCT05243225||open surgical management of post cholecystectomy bile duct injury.|Under general intubation anaesthesia, a generous right subcostal incision is performed and could be extended on demand upward to the xiphoid process and/or to the left subcostal area. Thorough dissection and adhesiolysis is performed to reach the bile duct. Evaluation by intraoperative cholangiogram according to the site and the size of the injury repair will be done. If the injury is small simple repair or repair on T-tube will be done . If the injury is large repair on T-tube or hepaticojejunostomy will be done .If it is a distal injury repair on T-tube or biloenteric shunt will be done .If the injury is proximal biloenteric shunt will be done .Intra-abdominal drains insertion.
89554722|NCT04640987|Experimental|Experimental: Stem Cell Transplant|The participant will undergo a stem cell transplant using donor cells that have been manipulated through an investigational device. The participant's cells will then be manipulated via a T-allo10 cell addback. Participants will be followed for outcomes for two years.
89554723|NCT02644343|Experimental|Remote Programming Group|"Subjects will undergo remote programming of Nucleus cochlear implants via Custom Sound software using an online interactive meeting platform.~The intervention is the programming of the cochlear implant, the experimental aspect is the remote delivery method."
89554724|NCT04552847|Experimental|Patients|"In the main part of the trial (part A) 75 patients with cytologically and/or histologically confirmed neuroendocrine tumors of all grades of gastroenteropancreatic, pulmonary, neural crest or unknown primary origin will receive a single intravenous injection of Al18F-NOTA-octreotide. At two hours after tracer injection they will undergo a whole-body PET/CT scan.~In part B of the trial 10 up to 20 patients with with cytologically and/or histologically confirmed neuroendocrine tumors of all grades of gastroenteropancreatic, pulmonary, neural crest or unknown primary origin will receive a single intravenous injection of Al18F-NOTA-octreotide. At two hours after tracer injection they will undergo a whole-body PET/MR scan."
88962512|NCT02014558|Experimental|Gilteritinib 300 mg in Expansion Phase|Participants received 300 mg gilteritinib orally once daily starting on day 1 of cycle 1 and continued in 28-day cycles until disease progression or participant discontinuation in the expansion phase of the study. On day -1 and day 15 of cycle 1, participants also received 2 mg midazolam as a single oral dose.
89554725|NCT05167331|Active Comparator|Virtual Reality|"(T1) after fitting the headset to the child's face, the assistant starts the VR program chosen by the child.~(T2) Five minutes after induction, local anesthesia with the QUICKSLEEPER device is performed. The injection of a cartridge of anesthetic Articaïne SEPTANEST 1/200 000 is administered intraosseously.~(T3) After placing the rubber dam, the investigator performs restorative +/- endodontic care of the selected temporary molar.~(T4) Once the treatment is finished, the sedation is stopped and the patient rests in the chair for 5 minutes.~(T5) As soon as the investigator considers that the child is back to normal state, he can leave the office with his parents."
89554726|NCT05167331|Active Comparator|Nitrous oxide sedation|"(T1) With the nitrous oxide/oxygen inhalation system titrated to 50%/50% whose flow rate is adapted to the child's respiratory flow. The assistant is responsible for controlling the sedation. Verbal encouragement is always present to reassure the child.~(T2) Five minutes after induction, local anesthesia with the QUICKSLEEPER device is performed. The injection of a cartridge of anesthetic Articaïne SEPTANEST 1/200 000 is administered intraosseously.~(T3) After placing the rubber dam, the investigator performs restorative +/- endodontic care of the selected temporary molar.~(T4) Once the treatment is finished, the sedation is stopped and the patient rests in the chair for 5 minutes.~(T5) As soon as the investigator considers that the child is back to normal state, he can leave the office with his parents."
89554727|NCT04509401|Active Comparator|Interventional|High dose of Vitamin B6 with Magnesium. Vitamin B6 will be given orally 150 mg for ages 2-3 years, 200 mg for ages 4-6 years,300 mg for ages 7-8 years and Magnesium will be given orally 50 mg for 2-3 years, 100 mg for ages 7-8 years for three months.
89554728|NCT04509401|Placebo Comparator|Control|Control group will receive oral placebo in the same manner, schedule and time frame.
89554729|NCT05155007|Experimental|Treatment Sequence ABC|Participants will receive a single oral dose of rilematovir (Treatment A) in Treatment Period 1, followed by a single oral dose of ciclosporin (Treatment B) in Treatment Period 2 and then single oral dose of ciclosporin plus single oral dose of rilematovir (Treatment C) in Treatment Period 3 on Day 1 of each Treatment Period under fasted conditions. Each treatment period will be separated by a washout period of at least 5 days and maximum 21 days between subsequent intakes of study intervention.
89554730|NCT05155007|Experimental|Treatment Sequence BCA|Participants will receive Treatment B in Treatment Period 1, followed by Treatment C in Treatment Period 2 and then Treatment A in Treatment Period 3 on Day 1 of each Treatment Period under fasted conditions. Each treatment period will be separated by a washout period of at least 5 days and maximum 21 days between subsequent intakes of study intervention.
89554731|NCT05155007|Experimental|Treatment Sequence CAB|Participants will receive Treatment C in Treatment Period 1, followed by Treatment A in Treatment Period 2 and then Treatment B in Treatment Period 3 on Day 1 of each Treatment Period under fasted conditions. Each treatment period will be separated by a washout period of at least 5 days and maximum 21 days between subsequent intakes of study intervention.
89554732|NCT05155007|Experimental|Treatment Sequence ACB|Participants will receive Treatment A in Treatment Period 1, followed by Treatment C in Treatment Period 2 and then Treatment B in Treatment Period 3 on Day 1 of each Treatment Period under fasted conditions. Each treatment period will be separated by a washout period of at least 5 days and maximum 21 days between subsequent intakes of study intervention.
89554733|NCT05155007|Experimental|Treatment Sequence BAC|Participants will receive Treatment B in Treatment Period 1, followed by Treatment A in Treatment Period 2 and then Treatment C in Treatment Period 3 on Day 1 of each Treatment Period under fasted conditions. Each treatment period will be separated by a washout period of at least 5 days and maximum 21 days between subsequent intakes of study intervention.
89554734|NCT05155007|Experimental|Treatment Sequence CBA|Participants will receive Treatment C in Treatment Period 1, followed by Treatment B in Treatment Period 2 and then Treatment A in Treatment Period 3 on Day 1 of each Treatment Period under fasted conditions. Each treatment period will be separated by a washout period of at least 5 days and maximum 21 days between subsequent intakes of study intervention.
89554735|NCT01641107|Experimental|Ponatinib|
89554736|NCT04425317|Other|Diagnostic arm|Blood sample and endometrial biopsy Collection of follicular fluid, immature oocytes and cumulus cells
89554737|NCT04411511||Lean children|Children between 4-18 years, living in the Netherlands.
89554738|NCT04411511||Children with overweight or obesity|Children between 4-18 years, living in the Netherlands. Besides inclusion from the general population, childhood expertise centres will contact their patients to pay attention to this study.
89554739|NCT03101423|Active Comparator|interleukin-2|interleukin-2 treatment per month
89554740|NCT03101423|Active Comparator|DLI|donor lymphocyte infusion (DLI) treatment per month
89554741|NCT04409405||Cured population|• Age ≥ 5 year old
89554742|NCT04409405||Contact population|"Age ≥ 5 year old~Contact of a participant included in cured-population cohort~Not diagnosed with EVD"
89554743|NCT04309799|Other|Single 10 minute session|Study assessments will be performed before single 10 minute session of wearing the Tear Restore Mask and then study assessments will be repeated after the 10 minute single session has been completed.
89554744|NCT04309799|Other|Optional Extension|Subjects can choose to extend use of the Tear Restore Mask at home for a period of 28 to 60 days. They will use the mask for a 10 minute time period one time per day and record the use in a diary.
89554745|NCT05073029|Active Comparator|standard care group|3-month course of individually selected nutrition program developed by a gastroenterologist-nutritionist and modification of physical activity (8000-10000 steps daily)
89554746|NCT05073029|Experimental|intervention group|additionally to previous group recieved treatment with synbiotic (Fructooligosaccharides+Lactobacillus rhamnosus GG ATCC 53103) and vitamin D3 - 2000 IU. The students were instructed to take vitamin D3 and synbiotic sachets twice a day for 3 months.
89554747|NCT02644109|Experimental|Phytosterols|"Milk powder: subjects will be instructed to consume 22 g/day of the product, with 0.65 g of esterified phytosterols (0.39 g of free equivalent sterols). The product will be reconstituted with 200 ml of water at time of consumption, preferably at breakfast or tea time. The total amount of product will be provided at the beginning of the study (day 1), together with instructions, material for preparation, and storage.~Drinking yoghurt: the daily volume consumed will be 90 ml/day with 1.3 grs of esterified phytosterols (0.78 g of free equivalent phytosterols). Subjects will be instructed to consume this beverage with main meal (not later than 15 min after it. The product should be kept refrigerated. Products will be distributed to subjects on a weekly basis."
89554748|NCT02644109|Placebo Comparator|Placebo|"Milk powder: subjects will be instructed to consume 22 g/day of the product, without phytosterols. The product will be reconstituted with 200 ml of water at time of consumption, preferably at breakfast or tea time. The total amount of product will be provided at the beginning of the study (day 1), together with instructions, material for preparation, and storage.~Drinking yoghurt: the daily volume consumed will be 90 ml/day without phytosterols. Subjects will be instructed to consume this beverage with main meal (not later than 15 min after it. The product should be kept refrigerated. Products will be distributed to subjects on a weekly basis."
89554749|NCT02642159|Experimental|Alirocumab 75 mg Q2W/Up to 150 mg Q2W|Alirocumab 75 mg subcutaneous (SC) injection every 2 weeks (Q2W) added to insulin or other antihyperglycemic drugs, stable maximally tolerated dose of statin therapy without other lipid modifying therapy (LMT) for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when non-high-density lipoprotein cholesterol (non-HDL-C) levels >=100 mg/dL (2.59 mmol/L) at Week 8.
89554750|NCT02642159|Active Comparator|Usual Care|Participants on usual care continued on insulin or other antihyperglycemic drugs, stable maximally tolerated dose of statin therapy without additional LMT or with either ezetimibe, fenofibrate, omega-3 fatty acids or nicotinic acid as per Investigator's judgment for 24 weeks.
89554751|NCT05072873|Experimental|Topical tranexamic acid|temporary uterine packing with gauze of the dimensions soaked with 2 gm tranexamic diluted in 60ml saline acid
89554752|NCT05072873|Placebo Comparator|normal saline|temporary uterine packing with gauze of the dimensions soaked with 2 gm placebo to tranexamic diluted in 60ml saline acid
89554753|NCT05072405|Other|simvastatin 20 mg (Zocor®, MSD)|simvastatin 20 mg are given on 3 occasions: 1. without herbs; 2. with green tea extract containing EGCG 800 mg once daily for 14 days before statin dosing; 3. with soy isoflavones extract containing isoflavones 120 mg once daily for 14 days before statin dosing, with at least 4-week washout period between phases.
89554754|NCT05072405|Other|rosuvastatin 10 mg (Crestor®, Astra Zeneca)|rosuvastatin 10 mg are given on 3 occasions: 1. without herbs; 2. with green tea extract containing EGCG 800 mg once daily for 14 days before statin dosing; 3. with soy isoflavones extract containing isoflavones 120 mg once daily for 14 days before statin dosing, with at least 4-week washout period between phases
89554755|NCT05072327|Experimental|Mohs surgery conbind with cryotherapy|patients in this group received both Mohs surgery and cryotherapy.
89554756|NCT05072327|Active Comparator|Mohs surgery|patients in this group received only Mohs surgery.
89554757|NCT03101579|Experimental|Intra-pemetrexed|Patients were treated with intrathecal pemetrexed at dose escalation. The regimen of intrathecal pemetrexed is 10/15/20 mg, plus dexamethasone 5 mg, twice per week for 2 weeks, followed by once per week for 2-4 weeks. Pemetrexed is administrated by intrathecal injection via lumbar puncture. Folic acid 200-400 μg is administered orally once daily, prior to the first intrathecal pemetrexed, until 21 days after the last intrathecal pemetrexed. A single dose of vitamin B12 1000 μg is administered by intramuscular injection before the first intrathecal pemetrexed，once per 3 weeks. To detect the pharmacokinetics of intrathecal pemetrexed, the serum and cerebrospinal fluid samples are collected. These samples would be analyzed by spectrometer for drug concentration.
89554758|NCT05071547|Experimental|Internet-delivered acceptance and commitment therapy addition|The IACT addition supplies participants with weekly educational material and additional exercises in line with live IRPR, although enriched with multimedia. Participants will have access to their rehabilitation content via the web-site and can practice in their homes in-between live sessions of IRPR.
89554759|NCT05071547|Active Comparator|Interdisciplinary pain rehabilitation program|A 6-week long multimodal treatment including approximately 108 hours on site, focusing on return to work. Psychologists, physicians, physiotherapists (PT) and occupational therapists (OT) give synchronized treatments with a CBT/ACT approach.
89554760|NCT03101345|Other|nutrition product|Peptamen® 1.5 Vanilla, orally administration
89554761|NCT05071391||Obese|Obese patients undergoing Roux-en-Y gastric bypass
89554762|NCT05071781|Active Comparator|Cortisol releasing hormone group|HVs will start with CRH infusion.
89554763|NCT05071781|Placebo Comparator|Placebo (sodium choride) group|HVs will start with NaCl 0.9% (placebo) infusion
89554764|NCT05071001|Experimental|A|
89554765|NCT05071001|Experimental|B|
89554766|NCT03882905|Experimental|Ezetimibe: Base Study|10-mg tablet, oral taken once daily concomitantly with the participant' s current statin therapy for 8 weeks.
89554767|NCT03882905|Placebo Comparator|Placebo: Base Study|Placebo for ezetimibe 10-mg tablet, oral taken once daily concomitantly with the participant' s current statin therapy for 8 weeks.
89554768|NCT03882905|Experimental|Ezetimibe: Extension|10-mg tablet, oral taken once daily concomitantly with simvastatin for 48 weeks.
89554769|NCT03882905|Placebo Comparator|Placebo: Extension|Placebo for ezetimibe tablet, oral taken once daily concomitantly with simvastatin for 48 weeks.
89554770|NCT03572543|Active Comparator|Active tDCS|Current will be ramped in/out for 30 seconds at the begging and end of a 20-minute period and a constant current will be delivered for the 20-minutes between ramping.
89554771|NCT03572543|Sham Comparator|Sham tDCS|Current will be ramped in/out for 30 seconds at the begging and end of a 20-minute period during which no stimulation will be delivered.
89554772|NCT02669017|Experimental|Part 1: ADCT-402 dose escalation|In Part 1 (dose escalation) participants will receive intravenous (IV) infusions of ADCT-402 at escalating doses, according to a 3+3 study design. Doses will be escalated from 15 µg/kg to 200 µg/kg on Day 1 of each cycle, with cycle lengths of 3 or 6 weeks.
89554773|NCT02669017|Experimental|Part 2: ADCT-402 dose expansion|"In Part 2 (expansion), participants will be assigned to the recommended dose level(s) and schedule(s) of ADCT-402 identified in Part 1 by the Dose Escalation Steering Committee.~Participants will receive intravenous (IV) infusions of ADCT-402 at either 120 μg/kg or 150 μg/kg on Day 1 of each 3 week cycle (Q3W)."
89554774|NCT02387671|Experimental|mHealth Platform|The primary interventions employed in the study are wifi enabled tracking devices, text message communications and behavioral counseling.
89554775|NCT04479865|Experimental|Sequence 1|Period 1, Aricept 5mg → DA-5207 150mg; Period 2, Aricept 5mg → Aricept 10mg
89554776|NCT04479865|Experimental|Sequence 2|Period 1, Aricept 5mg → Aricept 10mg; Period 2, Aricept 5mg →DA-5207 150mg
89554777|NCT04479865|Experimental|Sequence 3|Period 1, Aricept 5mg → DA-5207 170mg; Period 2, Aricept 5mg → Aricept 10mg
89554778|NCT04479865|Experimental|Sequence 4|Period 1, Aricept 5mg → Aricept 10mg; Period 2, Aricept 5mg →DA-5207 170mg
89554779|NCT02153047|Experimental|Spirometry|Will be given a brief but structured smoking cessation advice (according to the standards of the Tobacco Study Group of the Catalan Society of Family Medicine) together with a detailed and structured 20-minutes visit with details of the spirometry data (values of respiratory capacity and volumes referring on the theoretical)
89554780|NCT02153047|No Intervention|Brief smoking cessation advice|Will be given a brief but structured smoking cessation advice (according to the standards of the Tobacco Study Group of the Catalan Society of Family Medicine).
88962513|NCT02014571|Experimental|Cohort A|Eight subjects will be randomized to receive either 10 mg of GSK2878175 active treatment (4 HCV genotype 1a [GT1a] and 2 HCV genotype 1b [GT1b]) or matching placebo (1 GT1a and 1 GT1b) daily for 2 days fasted.
89554781|NCT02387515|Experimental|intensive rehabilitation program|Patients will follow an intensive rehabilitation program (2x/week for 18 weeks), with emphasis on motor control training that is supported by technology.
89554782|NCT03113539|Experimental|Subjects awaiting for an aortic evaluation|"Subjects already waiting for an aortic evaluation, either a first diagnostic scan or follow-up of a known aneurysm.~Each subjects will have the two CT-scans on the same day."
89554783|NCT03106051||Patients with active psoriatic arthritis|Patients who suffer from active psoriatic arthritis with at least moderate disease corresponding to a PGA of ≥2
89554784|NCT02668393|Other|Level 0|Nintedanib low dose with docetaxel
89554785|NCT02668393|Other|Level 1|Nintedanib medium dose with docetaxel
89554786|NCT02668393|Other|Level 2|Nintedanib high dose with docetaxel
88962514|NCT02014571|Experimental|Cohort B|Eight subjects will be randomized to receive either 30 mg of GSK2878175 active treatment (4 GT1a and 2 GT1b) or matching placebo (1 GT1a and 1 GT1b) daily for 2 days fasted.
88962515|NCT02014571|Experimental|Cohort C|Eight subjects will be randomized to receive either GSK2878175 active treatment (4 GT1a and 2 GT1b) or matching placebo (1 GT1a and 1 GT1b) daily for 2 days fasted.
88962516|NCT02014571|Experimental|Cohort D|Twenty subjects will be randomized to receive either 60 mg of GSK2878175 active treatment (6 GT2, 6 GT3, 3 GT4) or matching placebo (2 GT2, 2 GT3, 1 GT4).
88962517|NCT02014623|Active Comparator|Grass pollen sublingual immunotherapy tablet|A sublingual allergen immunotherapy tablet (Oralair) containing: 300 index of reactivity (IR) of 5 grass pollen allergen extracts:perennial ryegrass (Lolium perenne), meadow grass (Poa pratensis), timothy grass (Phleum pratense), cocksfoot (Dactylis glomerata) and sweet vernal grass (Anthoxanthum odoratum) in an open label fashion administered for 4 months prior to the pollen season.
89554787|NCT02668393|Other|Level 3|Nintedanib continuous high dose with docetaxel
88962518|NCT02014623|Other|Control|Standard medical therapy: oral antihistamines AND/OR nasal steroids AND/OR nasal antihistamines
88962519|NCT02014636|Experimental|Part 1|Part 1 is a dose escalation phase in which subjects will receive pazopanib orally and the MK 3475 intravenously. Subjects will be evaluated for a minimum of 8 weeks before the next dose level cohort is enrolled.
88962520|NCT02014636|Experimental|Part 2|"Part 2 is a randomized phase in which subjects will be enrolled in each treatment arm:~Pazopanib monotherapy Pazopanib+MK-3475 MK-3475 monotherapy"
88962521|NCT02014662|Other|Arm 1|Healthy subjects aged 18 to 35 years
88962522|NCT02014688||American Indian or Alaskan Native Descent|
88962523|NCT02014688||Black or African American Descent|
88962524|NCT02014688||Asian Descent|
88962525|NCT02014688||Hispanic Descent|
88962526|NCT02014701|Other|Echocardiogram|Patients presenting with NSTEMI who are scheduled to undergo elective cardiac catheterization and coronary angiography with primary PCI will be selected for participation in the study. The patients will undergo a clinically indicated resting non-contrast echocardiogram to assess LV function and regional wall motion. They will then undergo contrast echocardiography with bolus injection of Optison™ contrast to reassess LV ejection fraction, improve LV opacification and assess regional wall motion abnormalities. Finally, they will be given a continuous infusion of Optison™ and will have assessment of myocardial perfusion of each of the 17 myocardial segments using low mechanical index continuous imaging of the myocardium and blood pool.
88962527|NCT02014714|Active Comparator|Morphine|Intrathecal Morphine 0.1mg
88962528|NCT02014714|Active Comparator|Fentanyl|Intrathecal Fentanyl 40mcg
88962529|NCT02014727|Experimental|AMA1-DiCo + Alhydrogel|AMA1-DiCo: 50µg Alhydrogel® : 0.85 mg Al3+ per dose Route : Intramuscular Vaccination schedule : Do, W4, W26
89554788|NCT03105739|Experimental|Anesthetised|LMA removal once the halogenated anesthetic turned off
89554789|NCT03105739|Active Comparator|Awake|LMA removal once the patient fully regained consciousness
89554790|NCT03473821|No Intervention|Neuromuscular Training|Participants in this group will undergo rehabilitation for ACL injury consisting of neuromuscular training according to care-as-usual treatment common to physical therapy professionals.
89554791|NCT03473821|Experimental|MOTIFS|Participants in this group will receive an intervention that has been developed according to our new training model, known as MOTor Imagery to Facilitate Sensorimotor re-learning (MOTIFS). In this intervention, patients will receive a neuromuscular training rehabilitation program with integrated dynamic motor imagery.
89554792|NCT05263843||Patients|Patients with a complex congenital heart disease
89554793|NCT05263843||controls|healthy subjects
89554794|NCT02383147|Experimental|Tomographic Neurofeedback (TONF)|15x Neurofeedback Trainings, 1-2 times per week
89554795|NCT02383147|Active Comparator|Non Tomographic Neurofeedback (NTE)|15x Neurofeedback Trainings, 1-2 times per week
89554796|NCT05206591|Experimental|Secukinumab|Secukinumab 300 mg s.c
88962530|NCT02014727|Experimental|AMA1-DiCo+ GLA-SE|"Group A2 (15) : European volunteer : AMA1-DiCo + GLA-SE~AMA1-DiCo: 50µg~GLA-SE 2.5 µg GLA per dose~Route : Intramuscular Vaccination schedule : Do, W4, W26"
88962531|NCT02014727|Experimental|AMA1-DiCo + GLA-SE|"Group B1 (18) : African volunteer : AMA1-DiCo + GLA-SE~AMA1-DiCo: 50µg~GLA-SE 2.5 µg GLA per dose~Route : Intramuscular Vaccination schedule : Do, W4, W26"
88962532|NCT02014727|Placebo Comparator|Placebo|"Group B2 (18) : African volunteer : Placebo~Placebo : isotonic saline solution~Route : Intramuscular Vaccination schedule : Do, W4, W26"
88962533|NCT02014753||CoCr-EES, 2-week OCT follow-up|Undergo primary PCI with cobalt-chromium everolimus-eluting stent (CoCr-EES) for AMI culprit lesion and perform OCT observation at 2-week after PCI.
88962534|NCT02014753||CoCr-EES, 3-month OCT follow-up|Undergo primary PCI with cobalt-chromium everolimus-eluting stent (CoCr-EES) for AMI culprit lesion and perform OCT observation at 3-month after PCI.
88962535|NCT02014766|Active Comparator|Interscalene block|Interscalene block is performed under ultrasound guidance. Linear probe is placed on the ipsilateral interscalene groove visualizing the brachial plexus located between anterior and middle scalene muscles. Using in-plane technique, an insulated needle is advanced into the brachial plexus sheath, into which 20 ml of 0.375% ropivacaine is injected.
88962536|NCT02014766|Experimental|Supraclavicular block|Supraclavicular block is performed under ultrasound guidance. Linear probe is placed on the ipsilateral supraclavicular fossa visualizing the brachial plexus located lateral to the subclavian artery. Using in-plane technique, an insulated needle is advanced into the brachial plexus sheath, into which 20 ml of 0.375% ropivacaine is injected.
88962537|NCT02014779|Experimental|eChange web-based relapse prevention|A relapse intervention program consisting of 14 modules. Patients will have access to therapist support through an internal secure messaging system.
88962538|NCT02014779|Active Comparator|Face-to-face therapy|Face-to-face psychotherapy, consisting of 20 sessions. The content will be vary for different therapists, but all have an evidence-based approach to therapy
88962539|NCT02014792||Chronic kidney disease, stage 5|Patients with stage 5 chronic kidney disease who have recently commenced haemodialysis treatment (within 6-10 weeks of starting treatment)
88962540|NCT02014805|Experimental|radiotherapy|postoperative conformal radiotherapy for Masaoka stage II-III B type thymoma
88962541|NCT02014805|No Intervention|observation|no treatment after radical resection for thymoma
88962542|NCT02014818|Experimental|3 month OCT follow-up, CoCr-EES|Elective PCI can be performed with the use of an EES. PCI in another vessel or follow-up angiography is expected to be performed 3 months after the index procedure.
88962543|NCT02014818|Experimental|1 month OCT follow-up, CoCr-EES|Elective PCI can be performed with the use of an EES. PCI in another vessel or follow-up angiography is expected to be performed 1 months after the index procedure.
88962544|NCT02014831|Active Comparator|TIP|"Reference arm; Patients will be treated with 6 cycles of Paclitaxel + Ifosfamide + Cisplatin (TIP treatment)"
88962545|NCT02014831|Experimental|Cetuximab + TIP|"Experimental arm: Patients will be treated with 6 cycles of Paclitaxel + Ifosfamide + Cisplatin (TIP treatment) and weekly infusion of Cetuximab."
88962546|NCT02014857||Periodonatlly healthy smokers|Gingival crevicular fluid sampling
88962547|NCT02014857||Periodontally healhty non-smokers|Gingival crevicular fluid sampling
88962548|NCT02014870|Experimental|Cohort 1|1:1000 dilution of neat virus
88962549|NCT02014870|Experimental|Cohort 2|1:100 dilution of neat virus
88962550|NCT02014870|Experimental|Cohort 3|1:10 dilution of neat virus
88962551|NCT02014883|Experimental|GLUT1 DS|
88962552|NCT02014896||Ischemic Stroke|"Ischemic stroke subjects presenting within 24 hours from symptom onset will have serial PAX Gene Blood RNA tubes drawn within 18 hours of onset of symptoms upon arrival to the Emergency Department (if available) or hospital; 24 hours +/- 6 hours from symptom onset (if available) and 48 hours+/- 6 hours from symptom onset (if available).~Biomarker blood draw"
88962553|NCT02014896||TIA (Transient Ischemic Attack)|"TIA subjects presenting within 24 hours from symptom onset will have serial PAX Gene Blood RNA tubes drawn within 18 hours of onset of symptoms upon arrival to the Emergency Department (if available) or hospital; 24 hours +/- 6 hours from symptom onset (if available) and 48 hours+/- 6 hours from symptom onset (if available).~Biomarker blood draw"
88962554|NCT02014896||Non-Ischemic TNE|"Non-Ischemic Transient Neurological Event (TNE) subjects will have serial PAX Gene Blood RNA tubes drawn within 18 hours of onset of symptoms upon arrival to the Emergency Department or hospital.~Biomarker blood draw"
88962555|NCT02014896||Control|"Control group subjects will have PAX Gene Blood RNA tubes drawn within 8 hours of arrival to the Emergency Department or hospital. Control group matched with ischemic stroke and TIA subjects for age, race, gender, smoking history with at least one of the following vascular risk factors: diabetes, hypertension, atrial fibrillation, hyperlipidemia.~Biomarker blood draw"
88962556|NCT02014909|Experimental|KTN3379|KTN3379
88962557|NCT02014909|Experimental|Part II, Arm A|Combination of KTN3379 and cetuximab
88962558|NCT02014909|Experimental|Part II, Arm B|Combination of KTN3379 and erlotinib
88962559|NCT02014909|Experimental|Part II, Arm C|Combination of KTN3379 and vemurafenib
88962560|NCT02014909|Experimental|Part II, Arm D|Combination of KTN3379 and trastuzumab
89554797|NCT05206591|Placebo Comparator|Placebo|Placebo s.c.
89554798|NCT02383069|Experimental|Intervention Group|The intervention group will have supervised rehabilitation program held twice a week, each session will have 60 minutes duration, with minimum interval of 24 hours, for a period of 8 weeks. Each session will consist of three parts: aerobic training, strength training and respiratory physiotherapy. The aerobic training will be held for 35 minutes (10 min of warm up, 20 min on target load and 5 min of slowdown) with initial intensity of 60% of the maximum load obtained in the maximal cardiopulmonary exercise testing or in incremental shuttle walk test (ISWT). The intensity will be gradually increased up to 80%, so that fatigue or dyspnea values are kept between 4 and 6, according to the modified Borg scale.
89208190|NCT04018404|Experimental|Subject|Mothers and children will be approached by study personnel (separate from Outreach Coordinators who will obtain consent for use of information to evaluate the FRI Clinical Program) for enrollment in the FRI Research Program following completion of all FRI Clinical Program activities for that day. Both mother and child will be enrolled and contribute data and samples to the FRI Research Program.
89554799|NCT02383069|Active Comparator|Control Group|The control group will be subjected to supervised respiratory physiotherapy and stretching exercises twice a week, each session with duration of 60 minutes, with minimum interval of 24 hours, for a period of 8 weeks. The oral high-frequency oscillation device (Flutter®) will be used for 10 minutes, 5 minutes in each lateral decubitus, followed by the stretching of upper and lower limbs for 40 minutes. All exercises will be active, performed in sitting and lying positions without increasing the heart rate. The remaining 10 minutes will be used to discuss doubts about the disease and the use of the booklet.
89554800|NCT02387593|Experimental|colonoscopy with endocuff|To the usual colonoscopy will place a endocuff at the tip of the colonoscope
89554801|NCT02387593|No Intervention|standard colonoscopy without endocuff|Routine colonoscopy without endocuff
89554802|NCT02383303|Experimental|Program|The program group is eligible to participate in the Individual Development Account savings program.
89554803|NCT02383303|No Intervention|Comparison|The comparison group cannot enter the Individual Development Account program.
89554804|NCT02383225|Experimental|Condition A|Substance use resistance skills; no Lakota language enhancement, no FaceBook supplement
89554805|NCT02383225|Experimental|Condition B|FaceBook supplement; no Lakota language enhancement; no Substance Use resistance skills
89554806|NCT02383225|Experimental|Condition C|Lakota language enhancement; no FaceBook supplement; no Substance Use resistance skills
89554807|NCT02383225|Experimental|Condition D|Lakota language enhancement; FaceBook supplement; Substance Use resistance skills
89554808|NCT02387437|Experimental|SI recruitment|Compare the effect of three recruitment maneuvers before and after recruitment maneuvers is implemented,SI continuous positive airway pressure (CPAP) held at 40 cm H2O for 40 secs.
89554809|NCT02387437|Experimental|IP recruitment|Compare the effect of three recruitment maneuvers before and after recruitment maneuvers is implemented,Incremental positive end-expiratory pressure (PEEP) with a fixed peak pressure (IP), PEEP increased in 5 cm H2O increments (allowing 30 secs/step) from a baseline PEEP of post-trial to 40 cm H2O while decreasing tidal volume to limit peak inspiratory pressure to 40 cm H2O. After CPAP of 40 cm H2O was held for 30 secs, PEEP was decremented in 5-cm H2O steps to the post-RM PEEP setting, while increasing tidal volume toward the baseline value of 10 mL/kg (as the 40 cm H2O peak pressure limit allowed).
89554810|NCT02387437|Experimental|PCV recruitment|Compare the effect of three recruitment maneuvers before and after recruitment maneuvers is implemented,PCV peak pressure = 40 cm H2O, inspiratory to expiratory ratio = 1:2, and PEEP level = 15cm H2O for 2 min
89554811|NCT02387281||"PD with FOG on"|"Subjects diagnosed with Parkinson disease (PD) and sub-categorized as on freezing of gait (FOG) based on evaluation using motion capture"
89554812|NCT02387281||"PD with FOG off"|"Subjects diagnosed with Parkinson disease (PD) and sub-categorized as off freezing of gait (FOG) based on evaluation using motion capture"
89554813|NCT02387281||PD without FOG|Subjects with Parkinson disease (PD) and an absence of freezing of gait (FOG)
89554814|NCT02387281||Non-PD with FOG|Subjects with freezing of gait (FOG) and an absence of Parkinson disease (PD) (exception granted for those with FOG and atypical parkinsonism: PSP or MSA)
89554815|NCT02383615|Active Comparator|DTSNB|Distal transsartorial saphenous nerve block
89554816|NCT02383615|Active Comparator|ACSNB|Adductor canal saphenous nerve block
89554817|NCT01226563|Experimental|IK-5001|IK-5001 Sodium Alginate Calcium Gluconate intracoronary injection
89554818|NCT01226563|Placebo Comparator|Saline Solution|Saline Solution intracoronary injection
89554819|NCT02382757||Children|
89554820|NCT02382679|Placebo Comparator|Placebo|Non-nutritional non-immunogenic non-allergic oil-based capsule with same appearance, weight and density of active experimental vitamin.
89554821|NCT02382679|Experimental|Experimental: Vitamin Mixture|Vitamin coenzyme Q10, magnesium, riboflavin and omega-3-fatty acid combination.
89208191|NCT04936880|Experimental|Experimental : Virtual reality + analgesia-sedation|Use of a virtual reality device + analgesia-sedation drugs according to SFMU/SFAR 2010 guidelines during reduction procedure
89554822|NCT02387125|Experimental|Part 1 Dose Escalation of CMB305|Patients with melanoma, NSCLC, ovarian cancer, or sarcoma will be enrolled. Patients will receive CMB305, a sequential regimen of LV305 and G305. Two cohorts are planned based on LV305 dose.
89554823|NCT02387125|Experimental|Part 2 Expansion of CMB305|Arm A will enroll up to 9 patients each with NSCLC or ovarian cancer, or up to 18 patients with the sarcoma subtypes, synovial sarcoma or MRCL. Arm B will enroll up to 9 additional patients with selected sarcoma subtypes to explore subcutaneous (SC) dosing of LV305 and G305 on the same schedule. Arm C will enroll up to 9 patients with synovial sarcoma or MRCL for treatment with CMB305 and with oral metronomic CPA. Arm D will enroll up to 9 patients with synovial sarcoma or MRCL at selected sites for treatment with CMB305 and IT G100. Arm E will enroll up to 6 patients with soft tissue sarcoma any subtype for treatment with a higher dose of CMB305 than previous arms.
89554824|NCT02386891|Experimental|Cold|The cold treatment was 18-20°C (64.5-68°F), which is at the lower end of the thermalneutral zone in healthy adults.
89554825|NCT02386891|Experimental|Warm|The warm treatment was 25-27°C (77-80.6°F), which is above the range of the thermalneutral zone.
89554826|NCT02386969|Experimental|Active rTMS then sham rTMS|Active rTMS in 1st period and sham rTMS in 2nd period
89554827|NCT02386969|Experimental|Sham rTMS then active rTMS|Sham rTMS in 1st period and active rTMS in 2nd period
89554828|NCT02386813||Training cohort|"Patients diagnosed with ENKTL, nasal type between January 1, 1995 and December 31, 2013;~Patients treated with non-anthracycline based therapy as an initial treatment."
89554829|NCT02386813||Validation cohort|"Patients diagnosed with ENKTL, nasal type between January 1, 1998 and December 31, 2014;~Patients treated with non-anthracycline based therapy as an initial treatment."
89554830|NCT02386657||Emergency admitted sickle cell disease patients|Sickle Cell Disease Patients admitted inside the Emergency Department of the Brugmann Hospital for a vaso-occlusive crisis.
89554831|NCT00916747|Experimental|Treatment arm|All patients will receive zoledronic acid, pravastatin and lonafarnib
89554832|NCT02382835||Metal-on-Metal Hip Replacement|
89554833|NCT02382835||Other Hip Replacement|Other types of hip replacement, such as metal-on-polyethylene or ceramic-on-ceramic
89554834|NCT05231317|Experimental|Experimental: Plant-based diet|Diet rich in fruit and vegetables (42% carbohydrates, 17.2% fibres; 15% proteins and 43% fats).
89554835|NCT05231317|Active Comparator|Active Comparator: Western diet|Diet Rich in Processed Foods (48% carbohydrates, 10.4% fibres; 14% proteins and 39% fats).
89554836|NCT02391883||Clopidogrel|Patients in Clopidogrel or Dual Antiplatelet Therapy (Clopidogrel+Acetylsalicylic acid) at the time of admission AND who are operated <24 hours after admission.
89554837|NCT02391883||Control|Patients NOT in anticoagulation treatment (Except acetylsalicylic acid) AND who are operated <24 hours after admission.
89554838|NCT02386423|Experimental|RESTIFFIC|RESTIFFIC™ Brand Pressure Application System
89554839|NCT02386267|Experimental|L-leucine pills|L-leucine , dose- 700mg/m2 , per os, three time a day, course duration 6 months
89554840|NCT02382523|Experimental|Acthar injection 2 times per week|Acthar 80 unit injection 2 times a week
89554841|NCT02382523|Experimental|Acthar injection 3 times per week|Acthar 80 unit injection 3 times a week
89554842|NCT02386501|Experimental|ADXS31-164|Dose/Potency 5 x 108 CFU; 1 x 109 CFU; 5 x 109 CFU; 1 x 1010 CFU
89554843|NCT05547841||Trial group|A total of 680 singleton pregnant women in the first trimester (gestational age of 6-13 weeks + 6 days), who had normal results in various examinations and experienced regular obstetric examinations throughout the pregnancy, were selected from the obstetric outpatients in 34 centers, with 20 cases in each center.
89554844|NCT02391727|Other|SYN004|open label study
89554845|NCT02391805|Placebo Comparator|Placebo, Every Other Day (QOD)|Placebo orally (PO) QOD for 12 weeks + noninvestigational entecavir or tenofovir as prescribed by participant's physician
89554846|NCT02391805|Placebo Comparator|Placebo, Once a Week (QWk)|Placebo PO QWk for 12 weeks + noninvestigational entecavir or tenofovir as prescribed by participant's physician
89554847|NCT02391805|Experimental|RO6864018, 1200 milligrams (mg) QOD|RO6864018 1200 mg PO QOD for 12 weeks + noninvestigational entecavir or tenofovir as prescribed by participant's physician
89554848|NCT02391805|Experimental|RO6864018, 1200 mg QWk|RO6864018 1200 mg PO QWk for 12 weeks + noninvestigational entecavir or tenofovir as prescribed by participant's physician
89554849|NCT02391805|Experimental|RO6864018, 800 mg QOD|RO6864018 800 mg PO QOD for 12 weeks + noninvestigational entecavir or tenofovir as prescribed by participant's physician
89554850|NCT02391805|Experimental|RO6864018, 800 mg QWk|RO6864018 800 mg PO QWk for 12 weeks + noninvestigational entecavir or tenofovir as prescribed by participant's physician
89554851|NCT02391649|Experimental|Self-learning program|The participants in the Problem-solving Based Self-learning Program will complete the self-help and problem-solving manual developed by the research team for caregivers of people with psychotic disorders over 20 weeks. In addition to the orientation, understanding about psychosis and its care and final review sessions (4 sessions in 3 weeks) facilitated by the research nurse, the caregivers will work independently through the modules over 15-17 weeks.
89554852|NCT02391649|Active Comparator|Psycho-education (in Phase 2)|Two trained advanced practice psychiatric nurses who are experienced in psychiatric rehabilitation and group programs will lead the psychoeducation group, which is guided by a validated treatment protocol based on the research team's and McFarlane and his colleagues' psychoeducation programs for psychosis. The program consists of 12 two-hour sessions held weekly/biweekly (similar to the self-learning program, completed in 5 months), with 4 main components, including 'introduction and goal setting'; 'an education workshop on mental illness, treatment and community services'; 'group exercises/rehearsals and discussion on symptom management, coping and self-care'; and ''review and future plan'.
89554853|NCT02391649|No Intervention|Routine community care|Participants in the control group (and treatment groups) will receive routine psychiatric outpatient and family services.
89554854|NCT02382289|Active Comparator|bipolar RF 6 points|Six RF needles will be put between the SIJ and the lateral aspects of the ipsilateral dorsal sacral foramina. After sensory and motor stimulation, bipolar lesion RF at 80oc for 90 sec will be applied between each successive pairs of needles.
89554855|NCT02382289|Active Comparator|monopolar RF 6 points|RF needle is inserted at six levels in the area between the SIJ and the lateral aspects of the ipsilateral dorsal sacral foramina. after sensory and motor stimulation, monopolar lesion RF at 80oc for 90 sec will be applied.
89554856|NCT02382289|Active Comparator|monopolar RF 3 points|RF needle is inserted at three levels in the upper , middle and lower part of the area between the SIJ and the lateral aspects of the ipsilateral dorsal sacral foramina. after sensory and motor stimulation, monopolar lesion RF at 80oc for 90 sec will be applied.
89554857|NCT02386579||Diabetics with Charcot foot|
89554858|NCT02382367|Experimental|Pulmonary emphysema|Blood tests (Alpha-1 antitrypsin protein measurement, elastase-inhibitory capacity of plasma measurement, phenotypic and genotypic studies)
89554859|NCT02391493|Experimental|healthy early bilinguals|healthy early bilinguals functional magnetic resonance imaging
89554860|NCT02391493|Experimental|healthy late bilinguals|healthy late bilinguals functional magnetic resonance imaging
89554861|NCT02391493|Experimental|bilingual patients|bilingual patients suffering from low-grade glioma in the language areas functional magnetic resonance imaging
89554862|NCT02391415|Experimental|HIV-unexposed infants VPM1002|HIV-unexposed infants vaccinated with VPM1002
89554863|NCT02391415|Active Comparator|HIV-unexposed infants BCG|HIV-unexposed infants vaccinated with BCG
89554864|NCT02391415|Experimental|HIV-unexposed infants VPM1002(Hyg+)|HIV-unexposed infants vaccinated with VPM1002(Hyg+)
89554865|NCT02391415|Active Comparator|HIV-exposed infants BCG|HIV-exposed infants vaccinated with BCG
89554866|NCT02391415|Experimental|HIV-exposed infants VPM1002|HIV-exposed infants vaccinated with VPM1002
89554867|NCT02382055|Experimental|REACH|Psychotherapy
89554868|NCT02382055|Active Comparator|Supportive Psychotherapy|Psychotherapy
89554869|NCT02391181|Experimental|test product|Iron sucrose injection solution 100mg (5 mL single dose ampoule 20mg/mL elemental iron as iron sucrose in water for injection)
89554870|NCT02391181|Active Comparator|reference product|Iron sucrose injection solution 100mg (5 mL single dose vial 20mg/mL elemental iron as iron sucrose in water for injection)
89554871|NCT02381821||pregnant|women undergoing ICSI who became pregnant
89554872|NCT02381821||Not pregnant|women undergoing ICSI who fail to achieve pregnancy
89554873|NCT02381899||BR in CLL|Patients receive bendamustine hydrochloride 90mg/m2 IV on days 1 and 2 each cycle. Patients also receive rituximab 375 mg/m2 IV on day 1 at first cycle and 500 mg/m2 on day 1 all subsequent cycles.
89554874|NCT01998958|Experimental|Esketamine 14 mg|Participants in Panel B will self-administer intranasal esketamine 14 milligram or placebo on Days 1, 4, 8, and 11 during the double-blind phase and intranasal esketamine on Days 15, 18, 22, and 25 during the optional open-label phase. During the optional open-label phase, participants will start with treatment with a 56-mg dose of intranasal esketamine on Day 15 (the dose of esketamine can be adjusted if desired based on the Investigator's clinical judgment of efficacy and tolerability).
89554875|NCT01998958|Experimental|Esketamine 28 mg|Participants in Panel A will self-administer intranasal esketamine 28 mg or placebo on Days 1, 4, 8, and 11 during the double-blind phase and intranasal esketamine on Days 15, 18, 22, 25, 32, 39, 46, 60, and 74 during the optional open-label phase. During the optional open-label phase, all participants will start treatment with a 56-mg dose of intranasal esketamine on Day 15 (the dose of esketamine can be adjusted if desired based on the Investigator's clinical judgment of efficacy and tolerability).
89554876|NCT01998958|Experimental|Esketamine 56 mg|Participants in Panel A and Panel B will self-administer intranasal esketamine 56 mg or placebo on Days 1, 4, 8, and 11 during the double-blind phase. During the optional open-label phase, participants in Panel A will self-administer intranasal esketamine on Days 15, 18, 22, 25, 32, 39, 46, 60, and 74 and participants in Panel B will self-administer intranasal esketamine on Days 15, 18, 22, and 25. During the optional open-label phase, all participants will start treatment with a 56-mg dose of intranasal esketamine on Day 15 (the dose of esketamine can be adjusted if desired based on the Investigator's clinical judgment of efficacy and tolerability).
89554877|NCT01998958|Experimental|Esketamine 84 mg|Participants in Panel A will self-administer intranasal esketamine 84 mg or placebo on Days 1, 4, 8, and 11 during the double-blind phase and intranasal esketamine on Days 15, 18, 22, 25, 32, 39, 46, 60, and 74 during the optional open-label phase. During the optional open-label phase, all participants will start treatment with a 56-mg dose of intranasal esketamine on Day 15 (the dose of esketamine can be adjusted if desired based on the Investigator's clinical judgment of efficacy and tolerability).
89554878|NCT01998958|Placebo Comparator|Placebo|Participants in Panel A and B will self-administer intranasal placebo on Days 1 and 4 during the double-blind phase. Depending on response on Day 8, participants will receive intranasal placebo on Days 8 and 11 or be re-randomized to receive intranasal placebo or esketamine at a dose of 28 mg, 56 mg, or 84 mg (Panel A) or 14 mg or 56 mg (Panel B) on Day 8 and Day 11.
89554879|NCT02386111|Experimental|Varlilumab and Sunitinib|
89554880|NCT02381743|No Intervention|Group 1|Weekly non-medical SMS messages
89554881|NCT02381743|Experimental|Group 2|Receipt of a daily SMS text message describing various aspects of clinical practice
89554882|NCT02381743|Experimental|Group 3|Receipt of a daily SMS text message describing various aspects of clinical practice, but phrased as multiple choice question
89554883|NCT02386033|Placebo Comparator|SRP plus placebo|SRP was done for all the subjects. Placebo gel was delivered subgingivally into the pocket
89554884|NCT02386033|Active Comparator|SRP plus Atorvastatin|SRP was done for all the subjects. Atorvastatin was delivered in the pocket subgingivally
89554885|NCT05233345|Experimental|Experimental group: web based occupational therapy program|"Web-based occupational therapy classes were carried out as 5 sessions per week, each session lasting 1 hour, for 3 weeks. In total, 15 sessions were performed during the study period.~Group activities were performed through the Zoom application by means of a video camera. Included painting and cake making together, sports activities to be performed simultaneously with the movements shown by the researcher, memory games, and games that can be played with the group, such as the categories game. Sports activities were performed in the last 15 minutes of group activities, 5 days a week, in order to increase the physical activity level of children whose physical activities decreased during the lockdown period at home.~Also, all study participants continued taking classes from the EBA program as part of their routine education plan while taking occupational therapy program. EBA program is online classes given by government on local television."
88962561|NCT02014922|No Intervention|Control|Participants randomized to the control group will be allowed to continue using their habitual artificial tears, and / or additional habitual concurrent dry eye treatments.
88962562|NCT02014922|Experimental|Treatment|"Participants in the study treatment group will receive all four products:~TheraTears® Lubricant Eye Drop (15mL) - Dosage: Ophthalmic, 1 or 2 drops, prn~TheraTears® preservative-free single-use containers (32-pack, 0.6mL each) - Dosage: Ophthalmic, 1 or 2 drops, prn~TheraTears® Nutrition (90 pack) - Dosage: Oral, 3 capsules QD~TheraTears® TheraLid® Eyelid Cleanser (48mL) - Dosage: Ophthalmic, 1 or 2 application OU, QD"
89025768|NCT04135573||New untreated GD patients|Before treatment and application of anti-thyroid drugs (methimazole) or radioactive iodine treatment
88962563|NCT02014935|Experimental|Low intensity laser|"So that this research recrutarou 30 subjects with spastic hemiparesis sequel, post stroke who have gone through three phases, with three evaluations. If this conformation is necessary, therefore, it is a search for intergroup analysis, and the values found in Phase I were faced with the values found in Phases II and III.~The phases comprise:~Phase I (1st Cycle): Individuals treated with LLLT not only performed the evaluation of muscle activity, torque and lactic acid level.~Phase II (2nd Cycle): Individuals undergoing the application of LLLT, with the same off, and assessment of muscle activity, torque and lactic acid level.~Phase III (3rd Cycle): Individuals undergoing the application of LILT and evaluation of muscle activity, torque and lactic acid level."
88962564|NCT02014948|Experimental|Exercises|This group will consist of 20 individuals, 10 with lumbar disc herniation and 10 with chronic low back pain who underwent treatment with exerxises.
89554886|NCT05233345|No Intervention|Control Group|There are no interventions except EBA which all study participants are already taking classes from as part of their routine education plan. EBA program is online classes given by government on local television. This program is out of our study.
88962565|NCT02014961|Active Comparator|Mutation Carriers|Whole-exome sequencing (WES) Dermal biopsy Gastro-intestinal questionnaire
88962566|NCT02014961|Placebo Comparator|Non-Mutation Carriers|Whole-exome sequencing (WES) Gastro-intestinal questionnaire
88962567|NCT02014961|Other|Spouse|Whole-exome sequencing (WES) 12-Lead ECG
88962568|NCT02014974||Public Hospitals|Patients presenting and treated in public trauma centers in India.
89554887|NCT02385955|Experimental|Myeloablative dUCBT|Myeloablative conditioning with (1) TBI, cyclophosphamide, and cytarabine, or (2) thiotepa, busulfan, and fludarabine, followed by double unit umbilical cord blood transplant
89554888|NCT02381665|Experimental|Group A|Patient enrolled in this group will receive a device for effective interferential current stimulation.
88962569|NCT02014974||Private Hospitals|Patients presenting and treated in private trauma centers in India.
88962570|NCT02014987|Experimental|Running training programmes|"Runners with a high body mass index are going to follow a training programme of 3 kilometres per week compared to a training programme of 6 kilometres per week.~The amount of running will be increased with 10 % per week."
88962571|NCT02015000|Experimental|pterygium recurrence|Surgical Result of Primary and Recurrent Pterygium by Using Pterygium Extended Removal followed by Fibrin Glue Assisted Amniotic Membrane Transplantation (P.E.R.F.A.M.T)
89554889|NCT02381665|Placebo Comparator|Group B|Patient enrolled in this group will receive a device that does not deliver current stimulation
89554890|NCT01958164|Experimental|Actilyse 2 mg/2 ml|First dose of Actilyse 2mg/2ml will be given at time 0. Second dose will be given at 120 if CVAD function has not been restored.
89554891|NCT01958164|Sham Comparator|Saline solution (NaCl 0.9%)|Saline solution will be given at time 0. First dose of Actilyse 2mg/2ml will be given to patients if CVAD function has not been restored.
89554892|NCT02381431|Experimental|Thermal Imaging|imaging using a thermal camera
88962572|NCT02015091|Experimental|1, 4, 5, 6, 7|Vaccination schedules with 3 to 4 IV vaccinations per subject. Evaluation of protection against controlled human malaria infection (CHMI) is included.
88962573|NCT02015091|Experimental|2|Vaccination schedules 4 IM vaccinations per subject. Evaluation of protection against controlled human malaria infection (CHMI) is included.
88962574|NCT02015091|Experimental|3|Vaccination schedules 5 IV vaccinations per subject. Evaluation of protection against controlled human malaria infection (CHMI) is included.
88962575|NCT02015091|No Intervention|8|Participation in controlled human malari infection (CHMI) without prior vaccinations to serve as controls.
88962576|NCT02015130|Experimental|individual treatment|Individualized treatment
88962577|NCT02015130|No Intervention|control group|treatment according to current national guidelines
89554893|NCT02385877|Experimental|Protocol 1: [18F]4F-MHPG|Subjects (n = 4) will be injected one time with 6.5 mCi of 4-[18F]fluoro-meta-hydroxyphenethylguanidine ([18F]4F-MHPG) and receive a 90 minute PET scan.
89554894|NCT02385877|Experimental|Protocol 1: [18F]3F-PHPG|Subjects (n = 4) will be injected one time with 6.5 mCi of 3-[18F]fluoro-para-hydroxyphenethylguanidine ([18F]3F-PHPG) and receive a 90 minute PET scan.
89554895|NCT02385877|Experimental|Protocol 2: Biodistribution Studies|Subjects (n = 4) will be injected one time with 6.5 mCi of either [18F]4F-MHPG or [18F]3F-PHPG (whichever is selected based on Protocol 1 studies) and receive four whole-body PET scans, starting at 5 min, 60 min, 150 min and 360 min after tracer injection.
89208192|NCT04936880|Active Comparator|Control: Analgesia-sedation|Use of analgesia-sedation drugs according to SFMU/SFAR 2010 guidelines during reduction procedure
89208193|NCT00979641|Experimental|chemoterapy|docetaxel/paclitaxel + bevacizumab
88962578|NCT02015143||Bipolar Disorder|
88962579|NCT02015143||Unipolar Disorder|
88962580|NCT02015156|Experimental|PF-05280014|
88962581|NCT02015156|Active Comparator|Trastuzumab-US|
88962582|NCT02015169|Experimental|XELOX+lapatinib|"D1 Oxaliplatin130mg/m2 + D5W 500ml MIV over 2hrs~D1-D14 Capecitabine 850mg/m2 p.o bid~D1 ~ Lapatinib 1250 mg qd dailiy"
88962583|NCT02015182||Blood sample for bupivicaine pharmacokinetics|Children undergoing TAP block will have blood sampled for bupivacaine pharmacokinetics
88962584|NCT02015208|Experimental|Ruxolitinib|Ruxolitinib will be administered over a 28-day cycle, which will be repeated 6 more times in the absence of intolerable toxicity, disease progression, patient withdrawal of consent, or investigator decision to end therapy. The dose and schedule have been adapted from the product monograph for myelofibrosis. The starting dose will be 20 mg orally twice a day with normal .platelet and absolute neutrophil counts and no hepatic and renal impairment.
88962585|NCT02015247|Other|computer-assisted surgery|use of computer-assisted navigation during periacetabular osteotomy
88962586|NCT02015260|Placebo Comparator|placebo|placebo 0% nitrite cream and placebo 0% citric acid cream
88962587|NCT02015260|Active Comparator|Topical NO Dose A|3% sodium nitrite + 4.5% citric acid twice daily
88962588|NCT02015260|Active Comparator|Topical NO Dose B|6% sodium nitrite + 9% citric acid once daily
89208194|NCT00788060|Experimental|RAD001|
89208195|NCT00961389||delirious patients|minimal any positive CAM-ICU score during ICU admission
89208196|NCT00961389||non-delirious patients|without any positive CAM-ICU score during ICU admission
89208197|NCT00788138|Experimental|1|Vitamin D3 250,000 PO Once
88962589|NCT02015260|Active Comparator|Topical NO Dose C|6% sodium nitrite + 9% citric acid twice daily
89554896|NCT01976104|Experimental|Group A (avatrombopag, lower baseline platelet count)|60 mg avatrombopag (3 x 20 mg tablets) once daily on Days 1 through 5
89554897|NCT01976104|Placebo Comparator|Group B (placebo, lower baseline platelet count)|placebo (3 x 20 mg matching placebo tablets) once daily on Days 1 through 5
89554898|NCT01976104|Experimental|Group C (avatrombopag, higher baseline platelet count)|40 mg avatrombopag (2 x 20 mg tablets) once daily on Days 1 through 5
89554899|NCT01976104|Placebo Comparator|Group D (placebo, higher baseline platelet count)|placebo (2 x 20 mg matching placebo tablets) once daily on Days 1 through 5
89554900|NCT01372501|Experimental|Experimental: Device|All patients will be implanted with the Endobarrier Liner device
89554901|NCT02391259|Experimental|AMG 557|AMG 557 administered as subcutaneous and intravenous doses.
88962590|NCT02015273||Growth Disorders|
88962591|NCT02015286||Growth Disorders|
88962592|NCT02015299|Experimental|Linagliptin|Linagliptin 5 mg/day + lifestyle advise
88962593|NCT02015299|Placebo Comparator|Placebo|Matching placebo + lifestyle advise
88962594|NCT02015312|Experimental|Epigallocatechin-3-gallate (EGCG)|EGCG 400 mg/d p.o. for 3 months; 800 mg/d p.o. for 3 months, 1200 mg/d p.o. for 6 months
88962595|NCT02015312|Placebo Comparator|Placebo|"capsules~Dose:~400 mg/d for 3 months; 800 mg/d for 3 months, 1200 mg/d for 6 months Route of administration: p.o. Treatment duration: 12 months"
88962596|NCT02015338||Typically Developing Children|Children with typical development (e.g. no presence of neurological disorders or diagnoses)
88962597|NCT02015338||Children with Hemiparesis|Children diagnosed with Hemiparesis
88962598|NCT02015364|Experimental|Controlled early mobilization|The intervention group: Must perform controlled mobilization-exercises from the beginning of week 3 to 8
89554902|NCT02391259|Placebo Comparator|Placebo|No active drug
89554903|NCT02385643|Experimental|Intervention group|This group of subjects receives mobile support system and conventional treatment
89554904|NCT02385643|No Intervention|Control group|This group of patients receive conventional treatment only
89554905|NCT02385565|Experimental|high fat diet|10 % proteins, 30 % lipids, 60 % carbohydrates
88962599|NCT02015364|No Intervention|Immobilization|The control group: In line with the current treatment regimen the patients must keep the boot on at all times and they are not allowed to move the ankle.
88962600|NCT02015377|Experimental|High Sugar/Low Fiber (HSLF) meals|Comparing the impact of High sugar/Low fiber (HSLF) meal versus Low Sugar/High Fiber meals (LSHF) on insulin and glucose profiles, gut hormones (ghrelin, amylin, leptin) free fatty acids, cortisol, mood (MOOD), meaning of physical activity (MEANPA), and physical activity engagement (PA) in overweight African American and Hispanic youth
88962601|NCT02015377|Experimental|Low Sugar/High Fiber (LSHF) meals|Comparing the impact of High sugar/Low fiber (HSLF) meal versus Low Sugar/High Fiber meals (LSHF) on insulin and glucose profiles, gut hormones (ghrelin, amylin, leptin) free fatty acids, cortisol, mood (MOOD), meaning of physical activity (MEANPA), and physical activity engagement (PA) in overweight African American and Hispanic youth
88962602|NCT02015403|Experimental|Standard Care + NAC (N-ACETYLCYSTEINE) infusion|
88962603|NCT02015403|Active Comparator|Standard Care|
88962604|NCT02015416|Experimental|IDC-G305|NY-ESO-1 recombinant protein together with GLA-SE
88962605|NCT02015429|Active Comparator|Control|Pasta meal with added fractions or control with no fractions Pasta meal with no pea fractions
88962606|NCT02015429|Experimental|10 g protein|Pasta meal with added fractions or control with no fractions 10 g net yellow pea protein added to pasta meal
88962607|NCT02015429|Experimental|7 g yellow pea fibre|Pasta meal with added fractions or control with no fractions 7 g net yellow pea fibre added to pasta meal
88962608|NCT02015429|Experimental|Yellow pea fibre & protein|Pasta meal with added fractions or control with no fractions 10 g net yellow pea protein plus 7 g net yellow pea fibre added to pasta meal
88962609|NCT02015455|Experimental|Intervention Arm|Epidemiologic benchmarks included in lumbar imaging reports
89025769|NCT04135573||Healthy control|No thyroid related diseases and other immune diseases
89554906|NCT02385565|Placebo Comparator|Normal fat diet|10 % proteins, 45 % lipids, 45 % carbohydrates
89554907|NCT02391103|Experimental|NMES group|Anterior muscles of both thighs were electrically stimulated twice a day (2×30 minutes of NMES with a break of at least 30 minutes between both sessions) 7 days a week during the entire ICU stay but no longer than 14 days, starting on postoperative day 1. Highest tolerable intensity was applied.
89554908|NCT02391103|Sham Comparator|Control group|In the control group, the electrodes were applied, connected to the stimulator, but no electricity was delivered.
89554909|NCT01958008|Experimental|BI 113608 low dose b.i.d.|Film-coated tablet, oral administration with 240 mL water
89554910|NCT01958008|Experimental|BI 113608 medium dose b.i.d.|Film-coated tablet, oral administration with 240 mL water
89554911|NCT01958008|Experimental|BI 113608 high dose b.i.d.|Film-coated tablet, oral administration with 240 mL water
89554912|NCT04479163|Experimental|Plasma|Convalescent plasma with an IgG titer against SARS-CoV2
89554913|NCT04479163|Placebo Comparator|Placebo|Normal Saline 0.9%
89554914|NCT04645264|Experimental|Indwelling Foley|Indwelling Foley placed during surgery
89554915|NCT04645264|Active Comparator|Straight Catheter|straight catheterization (in-and-out straight catheterization) will take place at the end of the surgery
89554916|NCT04645264|No Intervention|No Catheter|Patient is not catheterized
89554917|NCT02380963|Experimental|Colorado Diet with soy protein|
89554918|NCT02380963|Active Comparator|Colorado Diet|
89554919|NCT02381509||IVC Filter|IVC filter for the prevention of PE
89554920|NCT02381197||pregnant women|Women presenting for prenatal care will provide urine samples at each antenatal care visit. The sample will be used to perform a Congo Red Dot test.
89554921|NCT02385409||Elective Total Hip- or Knee arthroplasty patients|Patients scheduled for elective Hip- or knee replacement at Hvidovre Hospital, Denmark.
89554922|NCT04694287||Volume flow group|The study will include consecutive patients undergoing standard fluoroscopically-guided percutaneous balloon angioplasty due to dysfunctional AVF. Intraprocedural volume flow measurements will be obtained just prior to the procedure and after final balloon dilation.
89554923|NCT02385253|Active Comparator|Educational training program|PCPs randomized to the intervention group will receive the educational training program at the beginning of the study, extending over a maximum of five months.
89554924|NCT02385253|No Intervention|Control|PCPs randomized to the control group will have the option of receiving the educational training program at the end of the study.
88962610|NCT02015455|No Intervention|Usual Care Arm|Clinics with typical lumbar imaging reports (no epidemiologic benchmarks included)
88962611|NCT02015468|Experimental|Early mobilization|
88962612|NCT02015468|Experimental|Late mobilization|
89554925|NCT02385487||Critical illness and type 2 MI|Critically ill adults with abnormal serum troponin I during hospitalization for critical illness.
89554926|NCT02385487||Critical illness without type 2 MI|Critically ill adults without an elevation in troponin I complicating critical illness.
89554927|NCT02390947|Experimental|Famitinib arms|Famitinib 25 mg p.o. qd and the medication continued until disease progression or intolerable toxicity or patients withdrawal of consent
88962613|NCT02015494|Experimental|4 mcg VAX2012Q|4 mcg VAX2012Q
88962614|NCT02015494|Experimental|8 mcg VAX2012Q|8 mcg VAX2012Q
88962615|NCT02015494|Experimental|14 mcg VAX2012Q|14 mcg VAX2012Q
88962616|NCT02015494|Experimental|18 mcg VAX2012Q|18 mcg VAX2012Q
88962617|NCT02015494|Experimental|12 mcg VAX2012Q|12 mcg VAX2012Q
88962618|NCT02015494|Experimental|8 mcg VAX2012Q repeated|8 mcg VAX2012Q
88962619|NCT02015494|Experimental|12 mcg VAX2012Q repeated|12 mcg VAX2012Q
88962620|NCT02015507|Active Comparator|Cohort 1|participants in Cohort 1 will be administered ivacaftor alone followed by ivacaftor with concomitant ciprofloxacin.
88962621|NCT02015507|Experimental|Cohort 2|Participants in Cohort 2 will be administered VX-661 in combination with ivacaftor followed by VX-661 in combination with ivacaftor and concomitant ciprofloxacin
88962622|NCT02015533|Experimental|CR8020|
88962623|NCT02015533|Placebo Comparator|Placebo|
88962624|NCT02015559|Experimental|Arm I (mucoadhesive oral wound rinse)|Patients receive mucoadhesive oral wound rinse PO as a gentle swish for 30-60 seconds 3-6 times daily beginning on day 1 of everolimus therapy and continuing for up to 6 months in the absence of unacceptable toxicity.
88962625|NCT02015559|No Intervention|Arm II (no intervention)|Patients receive no intervention.
88962626|NCT02015572|Experimental|Occupational intervention|Early coordinated occupational intervention. Supervision in physically activities by a physiotherapist.
88962627|NCT02015572|Active Comparator|Usual care|Intervention from the patient's general physician.
88962628|NCT02015585|Experimental|Interocclusal appliance|Patients will be submitted to the treatment with interocclusal appliances 30 days before the replacement of their complete dentures.
88962629|NCT02015585|Experimental|Relining complete denture base|Patients will be submitted to a procedure of relining their old dentures 30 days before the replacement of the complete dentures.
88962630|NCT02015585|Active Comparator|Only Rehabilitation|Patients will be treated with a complete denture without any kind of previous intervention
89554928|NCT02390947|Placebo Comparator|Control arms|Placebo 25 mg p.o. qd and the medication continued until disease progression or intolerable toxicity or patients withdrawal of consent
89554929|NCT04693507|Experimental|Teverelix TFA 120 mg 6-weekly|Participants receive teverelix TFA loading dose on Day 0 (120 mg SC + 120 mg IM) and teverelix TFA maintenance doses of 120 mg SC at week 6 and 6-weekly thereafter up to week 24
89554930|NCT04693507|Experimental|Teverelix TFA 180 mg 6-weekly|Participants receive teverelix TFA loading dose on Day 0 (180 mg SC + 180 mg IM) and teverelix TFA maintenance doses of 180 mg SC at week 6 and 6-weekly thereafter up to week 24
89554931|NCT03105661|Active Comparator|Treatment Arm|"Patients will be randomized to treatment with antihypertensive medications used with pregnancy for thirty years.~Labetalol Hydrochloride 200 mg orally every 12 hours Nifedipine 60 mg orally daily Atenolol 25 mg daily"
89554932|NCT03105661|No Intervention|Non-treatment Arm|Patients who are randomized to the non-treatment arm will not receive antihypertensive medications.
89554933|NCT02381119|Experimental|Personalized advice|Dietitian provides Personalized dietary advice (based on genetic, blood and food intake profiles) (the type of advice is the intervention)
89554934|NCT02381119|Active Comparator|Regular care|Dietitian provides regular care for diabetes type 2 (regular advice is the control condition)
89554935|NCT02385175||Adults with suspected Eustachian tube dysfunction|Age 18+ with possible Eustachian tube dysfunction on the basis of symptoms and examination findings.
89554936|NCT02384785||Spinal Cord Stimulation|"Patients who underwent implantation of electrodes spine for treatment in chronic pain.~'Transcutaneous Electric Nerve Stimulation' and Transcranial Direct Current Stimulation (one after another)"
89554937|NCT02390713|Experimental|MID-AVR|Tolerance and functionality of MID-AVR during surgery (Phase A) and after surgery (Phase B)
89554938|NCT02380885|Experimental|SCIT|Social Cognition and Interaction Training: psychosocial group intervention
89554939|NCT02380885|Experimental|TAFT|Therapeutic Alliance Focused Therapy
89554940|NCT02380885|No Intervention|TAU|Treatment as Usual
89554941|NCT02380729||Index patients|"Children between birth and 18 years of age manifesting with a suspected genetic disorder.~Investigation: First Gene Panel Sequencing and if no mutation ist found > Whole Genome Sequencing (WGS)"
89554942|NCT02380729||Parents of the index patient|"Both parents of the index patient.~Investigation: Whole Genome Sequencing (WGS) if no mutation is found by Gene Panel Sequencing of the index patient."
89554943|NCT02390401|Experimental|Vacuum-assisted closure (VAC)|Prevena (VAC) device
89554944|NCT02390401|Active Comparator|Standard sterile dressing|Standard sterile dressing
89554945|NCT04903327|Experimental|COVI-MSC|Subjects will receive intravenous infusions of COVI-MSC (two vials or a total of ≈ 30 million cells) on Day 0, Day 2, and Day 4
89554946|NCT04903327|Placebo Comparator|Placebo|Subjects will receive intravenous infusions of placebo (two vials) on Day 0, Day 2, and Day 4
89554947|NCT02380807|Experimental|Dry Needling Therapy|Dry Needly Therapy will be assesses in trigger points on latissimus dorsi, iliocostalis muscle, multifidus muscles, and quadratus lumbourum muscle.
89554948|NCT02380807|Active Comparator|Cross Tape Therapy|Cross Tape is a grid-shaped bandage easy aplicacionen different parts of the body that regulates the tension.
89554949|NCT02390479|Active Comparator|Chronic periodontitis|"GCF samples were taken before and after treatment chronic periodontitis patients.~Intervention: Non- surgical periodontal treatment (SRP and oral hygiene instructions)"
89554950|NCT02390479|Placebo Comparator|clinically healthy periodontium|GCF samples were taken at baseline Intervention: oral hygiene instructions
89554951|NCT02380495||Allergic rhinitis with/without asthma, from 14 to 17 years age|600 adolescents with allergic rhinitis with/without asthma, from 14 to 17 years age, recruited from Pediatricians of the Italian territory.
88962631|NCT02015598|Experimental|Carbocysteine|Carbocysteine , tablet ,250mg per one tablet , patients oral intake with 500mg .tid.(1500mg/day)
88962632|NCT02015598|Active Comparator|Continuous Positive Airway Pressure|Continuous Positive Airway Pressure(CPAP),auto-CPAP(USA,Philips), patients use Nasal CPAP overnight.
89554952|NCT02380495||Without respiratory pathology|600 subject (5 for each participant Pediatrician) of the same age range, without respiratory pathology (patient family)
89554953|NCT01998880|Experimental|obinutuzumab + chlorambucil (GClb)|Participants received 1000 mg obinutuzumab intravenous (IV) infusion, on Days 1 [first infusion split 100 mg on Day 1 and 900 mg on Day 2 as per protocol amendment], 8 and 15 in Cycle 1 and Day 1 in Cycles 2-6 (28-day cycles) plus chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 Cycles).
88962633|NCT02015650|Active Comparator|Cetuximab|Patients in treatment group A will receive Cetuximab at a loading dose of 400 mg/m2 (administered over 120 minutes) and weekly maintenance doses of 250 mg/m2 (administered over 60 minutes) in combination with radiation therapy.
88962634|NCT02015650|Active Comparator|Mitomycin-C / 5-Fluorouracil|Patients in treatment group B will receive 7 weeks of radiation therapy concomitant with Mitomycin-C 10mg/m² (max. 15mg/m²) d 8 and d 43 and 5-Fluorouracil 1000mg/m²/24h (max. 1500mg/m²/24h) d 8 - 12 and d 43 - 47. Radiation therapy will begin on day 8.
88962635|NCT02015689|Experimental|Benefits to Child|CDC VIS + message emphasizing benefits of MMR vaccine to child
88962636|NCT02015689|Active Comparator|CDC VIS|CDC Vaccine Information Statement (VIS)
88962637|NCT02015689|Experimental|Benefits to Society|CDC VIS + message emphasizing benefits of MMR vaccine to society
88962638|NCT02015689|Experimental|Benefits to Child and Society|CDC VIS + message emphasizing benefits of MMR vaccine to both child and to society
88962639|NCT02015702|Experimental|One-on-one physician training|One-on-one physician training Physicians in the experimental arm were visited by a instructing physician at a computer while performing clinical duties who had observed others to identify best practices. Instructors watched subjects' work, looking for a specific tip that could be applied to the current work, then demonstrated the tip, and answered any questions the subject had about using or applying this new technique .
89025770|NCT02893618|Experimental|DCCR 75 mg fasted|Administered a single 75 mg dose of DCCR after an overnight fast followed by 4 hours of fasting
89554954|NCT01998880|Active Comparator|rituximab + chlorambucil (RClb)|Participants received 375 mg/m^2 rituximab IV infusion on Day 1 of Cycle 1 then 500 mg/m^2 IV infusions on Day 1 of Cycles 2-6 (28-day cycles) plus chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 cycles).
89554955|NCT01998880|Active Comparator|Chlorambucil (Clb)|Participants received chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 Cycles). Participants with Progressive Disease or within 6 months of follow-up were allowed to cross over to receive obinutuzumab + chlorambucil.
89554956|NCT04747561|Experimental|18F-PEG3-FPN PET|A positron probe for the targeted melanin
88962640|NCT02015702|Active Comparator|Usual training|Usual training. This group will get the usual specified training for learning to use our electronic health record. Both groups received 12 hours of EPIC classroom training, exposure to the EPIC e-learning modules, user acceptability testing classes, and unlimited time on the EPIC 'playground', a site to practice on virtual patients. All had 90 days of elbow support with an EPIC-training non-physician technician, who were visible and available on all inpatient wards, as well as access to a physician-only support line available at all hours.
88962641|NCT02015715|Experimental|RO6864018|Asian participants will receive a single oral dose of RO6864018 capsule on Day 1. The first dose escalation cohort will receive a single 400 mg oral dose. Dose will be escalated in subsequent cohorts (up to Cohort 4) up to a maximum of 1600 mg, based on safety, pharmacokinetic, and pharmacodynamic data available from lower dose cohorts. The Cohort 5 will include Caucasian participants who will receive a single 1200 mg (or the highest dose well-tolerated by Asian participants, if lower than 1200 mg) oral dose of RO6864018 capsules on Day 1.
88962642|NCT02015715|Placebo Comparator|Placebo|Participants will receive a single oral dose of placebo matching to RO6864018.
88962643|NCT02015728|Experimental|Regimen B|"Depending on tumor biology testing, subjects assigned to Regimen B will receive:~Temozolomide 150 mg/m2/dose daily PO on days 1-5, Etoposide 50 mg/m2/dose daily PO on days 1-12, and Everolimus 3 mg/m2/dose daily PO on days 1-28. Cycles will be repeated every 28 days for up to 12 cycles."
89554957|NCT04745221|Experimental|with auto-FMT|The patients in the experimental group took autologous fecal bacteria capsule about 3 weeks after bone marrow transplantation.
89554958|NCT04745221|No Intervention|empty capsule|The patients in this group took empty capsule about 3 weeks after bone marrow transplantation
89554959|NCT02385019|Experimental|Administration of 0.5 x 10ˆ6 donor Treg/kg|First group of 5 patients will receive a total of 0.5 x 10ˆ6 donor Treg/kg. Part of Phase 1 study.
89554960|NCT02385019|Experimental|Administration of 1.0 x 10ˆ6 donor Treg/kg|Second group of 5 patients will receive a total of 1.0 x 10ˆ6 donor Treg/kg. Part of Phase 1 study.
89554961|NCT02385019|Experimental|Administration of 2.0-3.0 x 10ˆ6 donor Treg/kg|Third group of 5 patients will receive a total of 2.0-3.0 x 10ˆ6 donor Treg/kg. Part of Phase 1 study.
89554962|NCT02385019|Experimental|Administration of MTD of donor T reg|Preliminary Phase 2 study will include another 5 to 10 patients at the MTD identified in the Phase 1 study
89554963|NCT02384629|Experimental|AXXESS stent1|AXXESS stent (OCT-guided)
89554964|NCT02384629|Experimental|Conventional DES1|Conventional DES (Biomatrix flex stent, OCT-guided)
89554965|NCT02384629|Active Comparator|AXXESS stent2|AXXESS stent (Angio-guided)
89554966|NCT02384629|Active Comparator|Conventional DES2|Conventional DES (Biomatrix flex stent, Angio-guided)
89554967|NCT02384707|Experimental|allergic food|"Reintroduction procedure for small doses :~Administration of the first dose the first dose must be allergic food or placebo~Clinical monitoring for 45 minutes~Administration of the second dose"
89554968|NCT02380417||Single lung transplant paravertebral catheter placement|Those patients who underwent single lung transplant either right or left.
89554969|NCT02380417||bilateral lung transplant paravertebral catheter placement|those patients who underwent bilateral lung transplantation
89554970|NCT02380339|Active Comparator|Psych-Educational and Bio Feedback (BF_|Participants in the control group will undergo Psych-Educational and BF sessions in which they will receive information about FOH and about ways of coping with FOH and BF training. More specifically, they will learn about factors associated with FOH, behavioral manifestations of FOH, negative consequences of these behavioral manifestations and about ways of coping with FOH. They will be instructed to practice BF for 15 minutes, at home for 5 initial training sessions during a week. After which they will receive another session of BF training and will be instructed to practice it at home for 10 sessions course, (5 weekly sessions for 2 weeks). Each session will be for 15 minutes.
89554971|NCT02380339|Experimental|Psych-Educational session and virtual reality (VR)|Participants in the intervention group will receive Psych-Educational session as the control group and in addition they will participate in training for VR system and will be asked to use it at home for 5 initial training sessions during a week. During this week, they will practice reducing their GSR levels as indicated by the BF device. Following this they will receive a combined biofeedback-virtual reality system and use it at home for a 10 sessions course, (5 weekly sessions for 2 weeks). Each session will be for 15 minutes.
89554972|NCT01975948|Experimental|Mental Health PSP: Physicians|Physicians training in Adult Mental Health Practice Support Program
89554973|NCT01975948|Active Comparator|Treatment as Usual: Physicians|Those administering treatment as usual for depression
89554974|NCT01975948|Experimental|Mental Health PSP: Patients|Those belonging to a physician who has completed the Adult Mental Health Practice Support Program training.
89554975|NCT01975948|Active Comparator|Treatment as Usual: Patients|Those receiving treatment as usual for depression
89554976|NCT02380105|Experimental|Counseling Group|Patients allocated to the counseling group (Group I) were informed about possible etiological factors and educated to not overload the temporomandibular joint and masticatory muscles. Techniques to relieve pain and tension were taught to correct postural habits, food and sleep irregularities. The patients received written instructions, as a way of reinforcing the information provided during the initial consultation. In subsequent returns at 7, 15, 30 and 60 days of follow-up, the instructions were given again and patients were asked whether they had detected any habits related to the initiation and maintenance of painful symptoms of TMD, as a way to further highlight the association between the presence of these harmful behaviors and the worsening signs and symptoms of TMD.
89554977|NCT02380105|Active Comparator|Splint Group|Patients allocated to the splint group (Group II) were treated using interocclusal appliances, according to the following protocol: At baseline, an anterior bite plate (front-plateau) was made from acrylic resin that was placed in the maxillary arch to include the the canine to canine region and promote the disocclusion of the posterior teeth. Patients were instructed to use the device for 24 hours, interspersed with rests of equal length during the first week. After 7 days, the device was removed. A hard splint was then made. At 30 days of follow-up, the splint was fitted and the patients were also asked to use it when they were sleeping.
89554978|NCT04645030||Patients suspected of pneumonia|Patients suspected for pneumonia after initial evaluation by the treating physician.
89554979|NCT02390089|Active Comparator|Healthy control|Healthy age-matched adult participants with no history of Parkinson's disease Participants in this group will receive capsaicin vapor cough provocation test. The vapor will be delivered using a small hand-held nebulizer.
89554980|NCT02390089|Experimental|Parkinson's disease - no PA|People with Parkinson's disease without penetration or aspiration during swallowing; based on results of videofluoroscopic swallow evaluation. Participants in this group will receive capsaicin vapor and fog cough provocation test using a small, hand-held nebulizer.Participants in the group will also receive a fluoroscopic swallow evaluation.
89554981|NCT02390089|Experimental|Parkinson's disease - PA|People with Parkinson's disease with penetration or aspiration during swallowing;based on results of videofluoroscopic swallow evaluation.Participants in this group will receive capsaicin vapor and fog cough provocation test using a small, hand-held nebulizer. Participants in the group will also receive a fluoroscopic swallow evaluation.
89554982|NCT04644874||Older cancer patients|All outpatients, age 70 years or more, with solid malignancies, referred to the Department of Oncology at Odense University Hospital for 1st line antineoplastic treatment or information,
89554983|NCT02379871|Experimental|Experimental Group|While lying in supine, subjects will receive a single posterior to anterior directed spinal manipulation to the mid-thoracic region (T4-5).
89554984|NCT02379871|Sham Comparator|Sham Group|Sham group will procedures will be identical with the exception of the spinal manipulation intervention. Sham shall not receive the spinal manipulation intervention.
89554985|NCT03521986|Experimental|Subxiphoid uniportal VATS|Standard Subxiphoid single-port video assisted mediastinal thymectomy, no use of rib-spreader.
89554986|NCT03521986|Active Comparator|Intercostal uniportal VATS|Standard Intercostal single-port video assisted mediastinal thymectomy, no use of rib-spreader.
89554987|NCT02379793|Experimental|LEO 80185 gel, vehicle, liquid paraffin|Each subject has all 3 treatments applied topically at the same time. However, the location on which the treatments are applied is randomised in an investigator blinded manner.
89554988|NCT01975246|Experimental|Telmisartan+amlodipine+HCTZ|telmisartan 80 mg + amlodipine 5 mg fixed dose combination (FDC) and hydrochlorothiazide (HCTZ) 12.5 mg tablet
89208198|NCT00788138|Placebo Comparator|2|Matching Placebo
89208199|NCT00864396|Experimental|Prevacid|
89025771|NCT02893618|Experimental|DCCR 150 mg fasted|Administered a single 150 mg dose of DCCR after an overnight fast followed by 4 hours of fasting
89025772|NCT02893618|Experimental|DCCR 300 mg fasted|Administered a single 300 mg dose of DCCR after an overnight fast followed by 4 hours of fasting
89025773|NCT02893618|Experimental|DCCR 450 mg fasted|Administered a single 450 mg dose of DCCR after an overnight fast followed by 4 hours of fasting
89025774|NCT02893618|Experimental|DCCR 300 mg fed|Administered a single 300 mg dose of DCCR after a standardized meal
89025775|NCT04423315||patients with covid-19 pneumonia|patients with covid-19 pneumonia above 18 years old who were diagnosed by pcr testing and computed tomography of thorax
89554989|NCT01975246|Active Comparator|Telmisartan+amlodipine|telmisartan 80 mg + amlodipine 5 mg fixed dose combination (FDC) and placebo matching hydrochlorothiazide 12.5 mg tablet
89554990|NCT04669834|Other|group A|Patients in this group will receive a traditional therapeutic knee rehabilitation program based on a recent systematic review in the form of mini-squatting exercise (up to 45 degree knee flexion measured by a universal goniometer) , strengthening of hip abductors and external rotators using clamshell exercise . No emphasis will be placed on stabilizing the core musculature before initiating any of those exercises.
89554991|NCT04669834|Experimental|group B|Patients in this group will receive the same program as group (A) plus core stability exercise , but the principles of core stability will be explained to patients before initiation of treatment and patients will be asked to comply with these principles during exercise. These principles include learning how to activate transversus abdominus by abdominal bracing without allowing pelvis tilting and ensure neutral spine and diaphragmatic breathing during exercise.
89554992|NCT01621126|Experimental|Intra-op neuromonitoring|
89554993|NCT02389699|Experimental|Intraoperative Radiotherapy|Boost with 20 Gy during BCS, EBRT with 46-50 Gy
89554994|NCT02389699|Active Comparator|whole breast radiation|WRT:whole breast radiation after BCS with 46-50 Gy
89554995|NCT01973998|Experimental|Roflumilast|500 ug tablet daily for 180 days
89025776|NCT03273452|Experimental|treatment group|In this group, patients will be given prednisone 100mg,qd,d1-5; etoposide 100mg,qd,d1-5; thalidomide 100mg,qn,d1-14; Chidamide 30mg,biw;
89025777|NCT00496665|Experimental|Vandetenib|Cyclophosphamide 50 mg daily, methotrexate 2.5 mg days 1-2 weekly, and daily vandetanib (zactima) in 3 dose-escalation cohorts (100mg=Cohort 1) (200mg=Cohort 2) (300mg=Cohort3)
89025778|NCT04420312||Group 1|Enrolled the Covid-19 patients with a negative CT Pulmonary Angiogram.
89025779|NCT04420312||Group 2|Enrolled the Covid-19 patients in whom only a CT was performed.
89208200|NCT00745823|Active Comparator|Raltegravir 400 mg b.i.d.|
89208201|NCT00745823|Experimental|Raltegravir 800 mg q.d.|
89554996|NCT01973998|Placebo Comparator|Placebo|Placebo 1 tablet daily x 180 days
89554997|NCT02380027|Experimental|MRI-arm|Men in this arm will undergo multi-parametric MRI. In the presence of a suspicious area, a man will undergo MRI-targeted biopsy with cores targeted to the suspicious lesion. In the absence of a suspicious area, no biopsy will be taken.
89554998|NCT02380027|Active Comparator|TRUS-biopsy arm|Men in this arm undergo standard 12-core trans-rectal ultrasound guided prostate biopsy
89554999|NCT02383849||Arm 1|Breastfeeding infants 7 to 14 days of age with birth weight less than 2500 grams born to HIV-infected mothers not receiving maintenance ARV therapy including NVP; Mother HIV-infected and TB negative; infant receiving NVP prophylaxis but not TB prophylaxis or treatment
89555000|NCT02383849||Arm 2|Breastfeeding infants 7 to 84 days of age with birth weight less than or equal to 4000 grams born to HIV-infected mothers not receiving maintenance ARV therapy including NVP; Mother HIV-infected with active TB disease; infant receiving NVP prophylaxis plus isoniazid (INH) but not rifampicin (RIF) for TB prophylaxis
89555001|NCT02383849||Arm 3|Breastfeeding infants 7 to 14 days of age with birth weight less than 2500 grams born to HIV-infected mothers not receiving maintenance ARV therapy including NVP; Mother HIV-infected with active TB disease; infant receiving NVP prophylaxis plus INH plus RIF for TB prophylaxis or treatment
89555002|NCT02383849||Arm 4|Breast or formula feeding infants 7 to 84 days of age with birth weight less than or equal to 4000 grams born to HIV-uninfected mothers with active TB disease; infant receiving INH alone or INH plus RIF for TB prophylaxis
89555003|NCT02383849||Arm 5|Breast or formula feeding infants newly diagnosed with HIV infection weighing less than or equal to 4000 grams at birth and are less than or equal to 12 weeks of age. Infants who were enrolled in Arms 1, 2 or 3 and later determined to be HIV infected are then are eligible to enroll in Arm 5 if started on an LPV/r regimen. Infants initiating treatment with LPV/r plus 2 NRTIs, and not receiving RIF (but may be receiving INH)
89555004|NCT02383849||Arm 6|Breast or formula feeding infants newly diagnosed with HIV infection weighing less than 2500 grams at birth and are less than or equal to 12 weeks of age. Infants who were enrolled in Arms 1, 2 or 3 and later determined to be HIV infected are then are eligible to enroll in Arm 6 if started on an LPV/r regimen. Infants initiating treatment with LPV/r plus 2 NRTIs, and receiving RIF (and may be receiving INH)
89025780|NCT04420507||GDM group|pregnant women who are diagnosed after 75g OGTT test between 24~27+6 gestational weeks
89025781|NCT04420507||health group|pregnant women who pass the 75g OGTT test and aren't diagnosed as GDM, and also don't have any other conditions, like hypertensive disorders, IBD, gastrointestinal ulcer, and so on.
89025782|NCT04698005|Experimental|Supplementation of exogenous ketones|Exogeneous ketones will be administered orally using monoester 3-OHB concentrate without added salts (25g 3-OHB in 65ml H.V.M.N Ketone Ester, H.V.M.N, USA or equivalent). The drink will be administered over 10 mins every 3 hours, 3 times in a row.
89025783|NCT04698005|Placebo Comparator|Control group|The patients will receive a placebo drink (drinking water) of equivalent volume (3x 65ml)
89025784|NCT02893852|Active Comparator|standard CO-OP Approach|Task oriented and client-centred intervention with 12 sessions (10 interventional and 2 assessment sessions) with children and parents.
89208202|NCT00961467|Experimental|RMPT (Arm A -thalidomide 50 mg/day)|
89208203|NCT00961467|Experimental|RMPT (Arm B - thalidomide 100 mg/day)|
89208204|NCT00979797|Experimental|Maternal & Child Health|Community-based interventions to promoto Maternal and Child Survival in collaboration with GoB, Donors and NGOs.
89555005|NCT02384161|Experimental|Total RBF + Exercise Isometric|"Volunteers will undergo a year of intermittent isometric handgrip (intervention) in the dominant member associated with a total obstruction of blood flow, which will be conducted through a cuff pressure applied to the proximal region of the dominant limb."
89555006|NCT02384161|Experimental|Partial RBF + Exercise Isometric|"Volunteers will undergo a year of intermittent isometric handgrip (intervention) in the dominant member associated with a partial obstruction of blood flow, which will be conducted through a cuff pressure applied to the proximal region of the dominant limb."
89555007|NCT02384161|Placebo Comparator|Free BR + Exercise Isometric|Volunteers will undergo a year of intermittent isometric handgrip (intervention) in the dominant limb with the free blood flow. A 'cuff' pressure on the member of the proximal region, but with a pressure that will not interfere with blood flow will be applied.
89555008|NCT02384005|Other|Self-anal exam arm|Study only has one arm.
89555009|NCT02379949|Experimental|Virtual Reality Exposure Therapy|During virtual reality exposure therapy, a person encounters a feared stimulus (public speaking) in a computer-generated environment.
89555010|NCT02379949|Active Comparator|Exposure Group Therapy|Exposure Group Therapy a behavioral treatment for social phobia. Participants face their fears by giving speeches to other group members.
88962644|NCT02015728|Experimental|Regimen C|"Depending on tumor biology testing, subjects assigned to Regimen C will receive:~Temozolomide 150 mg/m2/dose daily PO on days 1-5, Etoposide 50 mg/m2/dose daily PO on days 1-12, and Erlotinib 85 mg/m2/dose daily PO on days 1-28. Cycles will be repeated every 28 days for up to 12 cycles."
88962645|NCT02015728|Experimental|Regimen D|"Depending on tumor biology testing, subjects assigned to Regimen D will receive:~Temozolomide 150 mg/m2/dose daily PO on days 1-5, Etoposide 50 mg/m2/dose daily PO on days 1-12, and Dasatinib 60 mg/m2/dose BID PO on days 1-28. Cycles will be repeated every 28 days for up to 12 cycles."
88962646|NCT02015728|Experimental|Regimen A|"Depending on tumor biology testing, subjects assigned to Regimen A will receive:~Temozolomide 150 mg/m2/dose daily PO on days 1-5, Etoposide 50 mg/m2/dose daily PO on days 1-12, and Sorafenib 150 mg/m2/dose BID PO on days 1-28. Cycles will be repeated every 28 days for up to 12 cycles."
88962647|NCT02015741||Aged patients|EEG monitoring with Bispectral Index and NeuroSENSE
88962648|NCT02015767||Roflumilast|Participants prescribed roflumilast (Daxas®) according to local guidelines and marketing authorization.
88962649|NCT02015780|Placebo Comparator|Placebo|Fasiglifam placebo-matching tablets, once daily, and stable antihyperglycemic therapy for up to 16 weeks. Then Fasiglifam placebo-matching tablets, once daily and antihyperglycemic therapy, adjusted as necessary per the Investigator's discretion, for up to 36 weeks.
88962650|NCT02015780|Experimental|Fasiglifam|Fasiglifam 50 mg tablets, once daily and stable antihyperglycemic therapy for up to 16 weeks. Then Fasiglifam 50 mg tablets, once daily and antihyperglycemic therapy, adjusted as necessary per the Investigator's discretion, for up to 36 weeks.
88962651|NCT02015845|Experimental|Accuvein|Use of Accuvein to facilitate placement of peripheral intravenous catheters in obese patients
88962652|NCT02015845|Active Comparator|Routine technique|Routine technique used to insert a peripheral intravenous catheters in obese patients.
88962653|NCT02015858||Epidural analgesia|Postoperative patients with epidural analgesia
88962654|NCT02015858||Oral analgesics|Postoperative patients with oral analgesics
89555011|NCT02379949|No Intervention|Waitlist|Participants assigned to wait list were re-randomized to virtual reality exposure therapy or exposure group therapy following the waiting period.
89555012|NCT02379715|Experimental|Remifentanil|When the particapants arrived into the operating room, the investigators applied standard monitoring and after preoxygenation, 2 mg remifentanil was diluted into 50 ml of normal saline (40 μg/ml solution) and was infused by Target concentration infusion (TCI) via syringe pump (Pilot Anesthesia 2. Fresenius vial, France) using the pharmacokinetic model. Investigator started to infuse remifentanil at 4 ng/ml and after the Ce of remifentanil reached the target concentration level, opened the dial of desflurane vaporizer at 4 vol%. After 30 seconds, increase the concentration of desflurane 8% and 12% at last. If there is no spontaneous respiration or loss of consciousness, the muscle relaxant esmerone 0.6mg/kg is injected and after 90 seconds the tracheal intubation is performed.
88962655|NCT02015884||All patients admitted to the ophthalmologic emergency unit.|
88962656|NCT02015923|Experimental|colonic resection|Arm A (experimental): surgery (complete tumoral resection; R0) followed by chemotherapy, regimen according to each center.
88962657|NCT02015923|Active Comparator|Chemotherapy|Arm B (control): chemotherapy alone, regimen according to each center
88962658|NCT02015949|Active Comparator|Methylphenidate|2 weeks of 0.3mg/kg twice daily of methylphenidate to the nearest 5mg
88962659|NCT02015949|Placebo Comparator|Sugar pill|2 weeks of twice daily placebo
88962660|NCT02015962|Experimental|Intravenous potassium|Patients in this arm will be administered intravenous potassium if they develop hypokalemia. As per CICU protocol 1-ml blood sample from already placed art-line or central venous line is sent for analysis of serum potassium concentration in all the immediate post operative patients. In the IVPR group, potassium will be given according to the hospital protocol through a central line. As per a previously established protocol and bioavailability data, repeat serum potassium will be sent 1 hour after replacement in the IVPR group.
88962661|NCT02015962|Experimental|Enteral potassium (ERP)|Once included in the study, patients in this arm will be given oral potassium if they develop an episode of hypokalemia. As per CICU protocol 1-ml blood sample from already placed art-line or central venous line is sent for analysis of serum potassium concentration in all the immediate post operative patients. As per a previously established protocol and bioavailability data, repeat serum potassium will be sent 2 hours after replacement in the EPR group. Replacement and serum level monitoring will be done till the episode of hypokalemia is resolved
88962662|NCT02015988|Experimental|Simvastatin and Fenofibrate|Simvastatin 40 mg once daily and fenofibrate 145 mg once daily orally for 52 weeks (1 year)
88962663|NCT02015988|Active Comparator|Simvastatin|Simvastatin 40 mg once daily orally for 52 weeks (1 year)
88962664|NCT02016001|Experimental|toothpaste 1|tooth paste 1 will be the tested intervention with maximum fluoride concentration (1500ppm), which will be provided to the case group. They will brush the teeth twice daily for 2 minutes
88962665|NCT02016001|Experimental|toothpaste 2|toothpaste 2 will be the intervention with 1000 ppm of fluoride, which will be used by control group. They will brush the teeth twice daily for 2 minutes
89025785|NCT02893852|Experimental|standard CO-OP Approach plus coaching parents|"Task oriented and client-centred intervention with 12 sessions (10 interventional and 2 assessment sessions) with children and parents with a boost of 4 group sessions of coaching for parents in groups."
89555013|NCT02379559|Experimental|Exercise Group|Eligible participants randomized into the intervention group will receive a mix of supervised moderate-intensity aerobic and light weight-resistance exercises.
89555014|NCT02379559|Active Comparator|Attention Control Group|Eligible participants randomized in the attention control group will be asked to maintain their current daily activities and exercise habits for 6-months.
89025786|NCT00496899||1|Women in active labor
89025787|NCT04415710||Group|Women with diagnosed Sjogren syndrome
89025788|NCT04415437||healthy|Healthy participants
89025789|NCT04415437||mentally ill|Participants with mental disorders
89025790|NCT04415437||physically ill|Participants with organic disease
89025791|NCT04415437||mentally and physically ill|Participants with mental disorders and organic disease
89025792|NCT00591877|Active Comparator|AC|"Acupuncture:~The patients will receive acupuncture by a trained doctor with acupuncture expertise, at 3 points relevant to reflux symptoms. Each patient will undergo a 30 minute session, twice a week, for a total of 12 sessions. The technique will involve electro-stimulation at predefined points followed by needle manipulation."
89025793|NCT00591877|Sham Comparator|SAC|The patients randomized to this arm will receive acupuncture for a similar duration and number of sessions. The sham acupoints are at least 2 cm away from the actual acupoints to prevent acupressure effects
89025794|NCT00591877|Active Comparator|Yoga|The participants in this arm will undergo a 60 min session of yoga exercises. These exercises are specifically designed for reflux symptoms by a yoga instructor. This includes a set of specific physical postures (asana) and breathing techniques within the four-element setup. The set of asana are divided into (a) standing, (b) sitting, and (c) lying down positions. The session will begin with asana in standing position, followed by a position called Shavasan (relaxation), then asana in sitting down position followed by Shavasan, finally asana in lying down position followed by Shavasan. At the end of all asana, Pranayam (special breathing exercises) will be practiced.
89208205|NCT04090073|Experimental|Electroacupuncture Plus Fast-track Perioperative Program|Patients who are randomized to the intervention arm will receive Electroacupuncture combined with Fast-track program. Each session of Electroacupuncture will last for 20 minutes. The patients will undergo one session of Electroacupuncture daily from day 1 till day 4, or until the time when the primary outcome has occurred, whichever is earlier.
89208206|NCT04090073|Active Comparator|Fast-track Perioperative Program|Patients who are randomized to the control arm will receive Fast-track program alone.
89555015|NCT04835779||SFN Patients|Patients with diagnosed Small Fibre Neuropathy
89555016|NCT04835779||Patients undergoing chemotherapy|Patients undergoing chemotherapy and are expected to develop SFN as a result
89555017|NCT04835779||Healthy Volunteer|Healthy test person
89555018|NCT04835779||Healthy Volunteer PREPs|For the pain-evoked potentials (PREPs), 20 additional healthy control subjects are to be included. Four subjects (2 male, 2 female) from each of the age decades 20-29, 30-39, 40-49, 50-59, 60-69.
89555019|NCT02379481|Experimental|NS 550mg|NS 550mg/day
89555020|NCT02379481|Experimental|NS 1100mg|NS 1100mg/day
89555021|NCT02379481|Placebo Comparator|placebo|placebo
89555022|NCT02389153|Experimental|collaborative care, CHD|Participants start with the collaborative care intervention at baseline directly after inclusion.
89555023|NCT02389153|Active Comparator|collaborative care CHD - waitlist|Participants start with the intervention 6 months after baseline, in the meantime they receive tau.
89555024|NCT04439773|Placebo Comparator|control group|the control group will be given the same volume of saline as the experimental group
89555025|NCT04439773|Experimental|lidocaine group|the experimental group will be given l-1.5mg lidocaine and then 2mg/kg/h
89555026|NCT02664415|Experimental|VRC01|Participants will receive an intravenous (IV) infusion of 40 mg/kg of VRC01 at Week 0 and every 3 weeks until Week 24 or until criteria for resumption of ART are met.
88962666|NCT02015806|Experimental|All meds but depression, 1x daily use, RxTimerCap|Individuals who are taking 1-3 cardiovascular or other non-depression chronic disease medications and who are suboptimally adherent to these therapies, whose medications are all intended for once daily use, and who are randomized to receive a RxTimerCap.
88962667|NCT02015806|Experimental|All meds but depression, 1x daily use, Take-N-Slide|Individuals who are taking 1-3 cardiovascular or other non-depression chronic disease medications and who are suboptimally adherent to these therapies, whose medications are all intended for once daily use, and who are randomized to receive a Take-N-Slide.
88962668|NCT02015806|Experimental|All meds but depression, 1x daily use, pillbox|Individuals who are taking 1-3 cardiovascular or other non-depression chronic disease medications and who are suboptimally adherent to these therapies, whose medications are all intended for once daily use, and who are randomized to receive a standard pillbox.
88962669|NCT02015806|No Intervention|All meds but depression, 1x daily use, control|Individuals who are taking 1-3 cardiovascular or other non-depression chronic disease medications and who are suboptimally adherent to these therapies, whose medications are all intended for once daily use, and who are randomized to continue with usual care.
88962670|NCT02015806|Experimental|All meds but depression, ≥1 med >1 daily use, RxTimerCap|Individuals who are taking 1-3 cardiovascular or other non-depression chronic disease medications and who are suboptimally adherent to these therapies, who have at least one medication that is intended for use more than once daily, and who are randomized to receive a RxTimerCap.
89208207|NCT00980031|Placebo Comparator|Lactose Tablet|Compounded capsule using Lactose Monohydrate Powder
89208208|NCT00980031|Active Comparator|Eplerenone|25 mg tablet placed in a capsule filled with Lactose Monohydrate Powder.
89555027|NCT02664415|Placebo Comparator|Placebo for VRC01|Participants will receive an IV infusion of placebo at Week 0 and every 3 weeks until Week 24 or until criteria for resumption of ART are met.
89555028|NCT02389231|Experimental|Low doses of Interleukine-2|Low doses of Interleukine-2 over a 9 week treatment period
89555029|NCT02383927|Experimental|Cohort 1|Thyroid Cancer
89555030|NCT02383927|Experimental|Cohort 2|Squamous Head and Neck Cancer
89555031|NCT02383693|Active Comparator|repetitive transcranial magnetic stimulation|Repetitive Transcranial Magnetic Stimulation (rTMS) Treatment 5 days/week for up to 4 weeks
89555032|NCT02383693|Sham Comparator|Sham comparator|Placebo Comparator: Placebo Treatment 5 days/week for up to 4 weeks
89555033|NCT02379325|Experimental|Lets Quit|Given text message
89555034|NCT02379325|Active Comparator|Pamplets education|Given pamplets on smoking and complication
89555035|NCT02383771|Experimental|Single Anti-platelet Treatment|Ticagrelor
89555036|NCT02383771|Experimental|Dual Anti-platelet Treatment|Aspirin + Ticagrelor
89555037|NCT02383771|Sham Comparator|Control|No Drug
88962671|NCT02015806|Experimental|All meds but depression, ≥1 med >1 daily use, pillbox|Individuals who are taking 1-3 cardiovascular or other non-depression chronic disease medications and who are suboptimally adherent to these therapies, who have at least one medication that is intended for use more than once daily, and who are randomized to receive a standard pillbox.
89555038|NCT02383771|Other|CAD undergoing PCI|Patients with coronary artery disease undergoing percutaneous coronary intervention and receiving dual anti-platelet therapy (ticagrelor 90mg bid + aspirin 100mg daily)
89555039|NCT02388919|Experimental|Anlotinib|Anlotinib p.o, qd and it should be continued until disease progress or toxicity cannot be tolerated or patients withdraw consent
89555040|NCT02388919|Placebo Comparator|Placebo|Placebo p.o, qd and it should be continued until disease progress or patients withdraw consent
89555041|NCT02383537||Pregnant women with diabetes|Pregnant women with diabetes type 1, type 2 or gestational diabetes
89555042|NCT02383537||Healthy pregnant women|Healthy pregnant women with no underlying illness
89555043|NCT04685317|Experimental|Sentinel® Cerebral Protection System Group|Sentinel® Cerebral Protection System in patients undergoing AF catheter ablation
89555044|NCT04685317|Active Comparator|Standard of Care Group|Standard of care (no cerebral protection device) in patients undergoing AF catheter ablation
89555045|NCT02388841||Pulmonary embolism|Distribution of the characteristics of Pulmonary Embolism patients according to thrombus localization
89555046|NCT02388841||tomographic pulmonary angiography|Distribution of the characteristics of Pulmonary Embolism patients according to the localization of thrombi in the most proximal level of Main pulmonary artery and other arterial branches as confirmed by Computed tomographic pulmonary angiography
89555047|NCT02379013|Experimental|Volunteer with MRI|All volunteer will be included in the arm MRI
89555048|NCT02377297|Active Comparator|Restoration with Fuji IX|The cavities will be restored with Fuji IX (GC Europe, Leuven, BE).
89555049|NCT02377297|Experimental|Restoration with Vitro Molar|The cavities will be restored with Vitro Molar (DHL, Rio de Janeiro, BR).
89555050|NCT02377297|Experimental|Restoration with Maxxion R|The cavities will be restored with Maxxion R (FGM, Rio de Janeiro, BR).
89555051|NCT02377375|Experimental|Micro-assisted|In each patient, one electrode will be implanted using the standard technique and one electrode will be implanted using the micro-electrode assisted technique. The side is randomized.
89555052|NCT02377375|Active Comparator|Standard|In each patient, one electrode will be implanted using the standard technique and one electrode will be implanted using the micro-electrode assisted technique. The side is randomized.
89555053|NCT02379169|Experimental|Sea buckthorn & lutein|Sea buckthorn oil complemented with lutein. Dose: 2 g/day as capsules taken twice/day for 6 months
89555054|NCT02379169|Placebo Comparator|Placebo|Triglycerides of medium-chain fatty acids. Dose: 2 g/day as capsules taken twice/day for 6 months
89555055|NCT02377219|Experimental|couples|couples attending an IVF or intra cytoplasmic sperm injection (ICSI) attempt have hormonal and blood analysis
89555056|NCT02388607||assessing attention span|"Electrophysiological measurements (evocated potentials and spectral densities)~Clinical scales and subjective assessments of difficulty of the tasks performed, and commitment to the task"
89555057|NCT02377141|Active Comparator|Endoscopic Variceal Band Ligation (EVBL)|Participants in this group will receive standard medical care consisting of vasoactive drugs (Terlipressin 2mg QDS (where there are no contraindications e.g. severe ischaemic heart disease), antibiotics, and entry into a variceal banding programme (in-patient or out-patient).
88962672|NCT02015806|No Intervention|All meds but depression, ≥1 med >1 daily use, control|Individuals who are taking 1-3 cardiovascular or other non-depression chronic disease medications and who are suboptimally adherent to these therapies, who have at least one medication that is intended for use more than once daily, and who are randomized to continue with usual care.
88962673|NCT02015806|Experimental|Only depression meds, 1x daily use, RxTimerCap|Individuals who are taking only antidepressants and who are suboptimally adherent to these therapies, whose medications are all intended for once daily use, and who are randomized to receive a RxTimerCap.
88962674|NCT02015806|Experimental|Only depression meds, 1x daily use, Take-N-Slide|Individuals who are taking only antidepressants and who are suboptimally adherent to these therapies, whose medications are all intended for once daily use, and who are randomized to receive a Take-N-Slide.
88962675|NCT02015806|Experimental|Only depression meds, 1x daily use, pillbox|Individuals who are taking only antidepressants and who are suboptimally adherent to these therapies, whose medications are all intended for once daily use, and who are randomized to receive a standard pillbox.
88962676|NCT02015806|No Intervention|Only depression meds, 1x daily use, control|Individuals who are taking only antidepressants and who are suboptimally adherent to these therapies, whose medications are all intended for once daily use, and who are randomized to continue with usual care.
89555058|NCT02377141|Active Comparator|Early TIPSS|For those randomized to early TIPSS the Transjugular Intrahepatic Porto-Systemic Stent Shunt (TIPSS) procedure will be performed within 72 hours (and preferably within the first 24 hours) after initial endoscopy. Vasoactive drugs will be continued until the TIPSS is performed and antibiotics continued for 5-7 days.
89555059|NCT02378623|Active Comparator|Apixaban|Intervention group: Apixaban 5 mg by mouth two times daily in addition to usual medical therapy (or 2.5 mg two times daily for subjects who fulfilled any 2 of the following criteria: age≥80 years, body weight≤60kg, and/or serum creatinine≥1.5 mg/dL). Planned treatment duration is 2 years
89555060|NCT02378623|Placebo Comparator|Placebo|Control group: Matched placebo by mouth two times daily in addition to usual medical therapy. Planned treatment duration is 2 years.
89555061|NCT02372149|Experimental|IVIg--Washout--0.9% NaCl (CROSSOVER)|"10% caprylate-chromatography purified intravenous immunoglobulin (IVIg) Initial dose: 1.0gm/kg/day for 2 days (maximum 80gm/day). Maintenance dose (monthly x3): 1.0mg/kg/day for 1 day (maximum 80gm/day)~Washout period~0.9% sodium chloride in water - equal volume to IVIg - Monthly x4"
89555062|NCT02372149|Experimental|0.9% NaCl--Washout--IVIg (CROSSOVER)|"0.9% sodium chloride in water - equal volume to IVIg - Monthly x4~Washout period~10% caprylate-chromatography purified intravenous immunoglobulin (IVIg) Initial dose: 1.0gm/kg/day for 2 days (maximum 80gm/day). Maintenance dose (monthly x3): 1.0mg/kg/day for 1 day (maximum 80gm/day)"
89555063|NCT02372305|Active Comparator|FlexHD|Patients randomly assigned to receive FlexHD for breast reconstruction.
89555064|NCT02372305|Active Comparator|Alloderm|Patients randomly assigned to receive Alloderm for breast reconstruction.
89555065|NCT02661061|Experimental|Ketamine|Trial Interventions: participants will receive four two-weekly infusions of ketamine at 0.05mg/kg. All infusions will be administered by a consultant anaesthetist.
89555066|NCT02661061|Active Comparator|Midazolam|Trial Interventions: participants will receive four two-weekly infusions of midazolam at 0.045mg/kg. All infusions will be administered by a consultant anaesthetist.
89555067|NCT02371915|Experimental|Videoconference follow-up|These subjects will remain in or near their home communities for rheumatology follow-up visits. Follow-up visits will occur via telehealth/videoconferencing, with a physiotherapist present, performing the in-person assessment, supported by the rheumatologist via videoconference.
89555068|NCT02371915|No Intervention|Control|These subjects will continue to travel into Saskatoon for the rheumatology visits, as they normally would for routine follow-up visits with their rheumatologist.
89555069|NCT02371837|Experimental|pilates group|Pilates based protocol for 6 weeks
89555070|NCT02371837|No Intervention|control group|No treatment group
89555071|NCT02376985|Placebo Comparator|Brushing instruction group|"Drug: Everolimus and Exemestane Everolimus, 10 mg/day Exemestane, 25 mg/day Administration on consecutive days once daily after breakfast until tumor progression or for a minimum 8 weeks.~Oral treatment:~Brushing and gargling with saline after every meal (initially instructed by a dental/oral surgeon)."
89555072|NCT02376985|Experimental|Dental oral management group|"Drug: Everolimus and Exemestane Everolimus, 10 mg/day Exemestane, 25 mg/day Administration on consecutive days once daily after breakfast until tumor progression or for a minimum 8 weeks.~Oral treatment:~Scaling and enamel polishing will be performed by a dental and oral surgeon or dental hygienist before everolimus treatment, and once weekly after everolimus treatment.~Brushing and gargling with Neostelin Green 0.2% mouthwash solution after every meal (initially instructed by a dental/oral surgeon)."
89555073|NCT02378857||Patient group|Adolescents (15-18 years of age) With univentricular heart defects and Fontan type palliation.
89555074|NCT02378857||Control group|Age- and gender-matched healthy individuals
89555075|NCT02376907||EUS-BD or ERCP with duodenal SEMS|Patients who underwent endoscopic placement of a duodenal self-expandable metal stent (SEMS) for nonresectable malignant GOO and endoscopic biliary drainage for nonresectable distal MBO.
89555076|NCT02371993|Experimental|Choline 650 mg twice daily|See above
89555077|NCT02371993|Placebo Comparator|Placebo|See above
89555078|NCT02378779|Other|Interventional GP : GP trainned in communication skills|"The subjects have to answer to the questionary SF12 on pre and post consultation to evaluate the quality of life.~He must so answer to the questionary PEDT. Then the interventional GP group must use one of the six strategies to approach the subject of premature ejaculation.~There three strategies of attitude (Total attention, Humour, Take the drama out) and three investigative strategies (Question about premature ejaculation, Symptoms of premature ejaculation, Help to verbalize)."
89555079|NCT02378779|Other|Usual care : GP did not trainnd in communication skills|"The subjects have to answer to the questionary SF12 on pre and post consultation to evaluate the quality of life.~He must so answer to the questionary PEDT. This classical GP group make a classical consultation like each day without use any strategies to speak about"
89555080|NCT02371603|Experimental|Part A: GSK1278863, pioglitazone and rosuvastatin|Subjects will receive single, oral 15 milligram (mg) pioglitazone, 10 mg rosuvastatin and 25 mg dose of GSK1278863 (Treatment A) or 15 mg pioglitazone and 10 mg rosuvastatin (Treatment B) on Day 1 and a 25 mg dose of GSK1278863 alone on Day 2 in two treatment periods as per treatment sequence AB or BA. The 2 treatment periods will be separated by a wash out period of approximately 7 days
89555081|NCT02371603|Experimental|Part B: GSK1278863 and trimethoprim|Subjects will receive a single, oral 25 mg dose of GSK1278863 on Day 1 and Day 6 morning. The subjects will also receive 200 mg dose of trimethoprim twice daily from Day 3 to 6, with Day 6 dosing being concomitant with morning dosing of GSK1278863
89555082|NCT02371525|No Intervention|Standard of Care|
89555083|NCT02371525|Experimental|Prepmate|
89555084|NCT02378545|Active Comparator|Hyperoxia|Oxygen will be administered using a non-re-breathe oxygen mask applied over the face and nose. The oxygen delivery device will be set to deliver oxygen at 15 litres per minute. The oxygen will be continuously delivered throughout the patients stay in the Emergency Department.
88962677|NCT02015806|Experimental|Only depression meds, ≥1 med >1 daily use, RxTimerCap|Individuals who are taking only antidepressants and who are suboptimally adherent to these therapies, who have at least one medication that is intended for use more than once daily, and who are randomized to receive a RxTimerCap.
88962678|NCT02015806|Experimental|Only depression meds, ≥1 med >1 daily use, pillbox|Individuals who are taking only antidepressants and who are suboptimally adherent to these therapies, who have at least one medication that is intended for use more than once daily, and who are randomized to receive a standard pillbox.
88962679|NCT02015806|No Intervention|Only depression meds, ≥1 med >1 daily use, control|Individuals who are taking only antidepressants and who are suboptimally adherent to these therapies, who have at least one medication that is intended for use more than once daily, and who are randomized to continue with usual care.
88962680|NCT02016014|Experimental|Intervention group|Lifestyle counseling in physical activity and alimentation and add for three months a smartphopne with a app (EVIDENT) to improve alimentation and physical activity
88962681|NCT02016014|Active Comparator|Lifestyle counseling|Lifestyle counseling in physical activity and alimentation
88962682|NCT02016027|Experimental|Carica folia Arm|
88962683|NCT02016040|Active Comparator|HIFU hemi-ablation|Focal Therapy Using High Intensity Focused Ultrasound (Ablatherm)
89025795|NCT00591916|Experimental|1|Microbial Nanocellulose (NC), an inert material produced by Acetobacter xylinum is one of three drug interventions the patient will be randomized to receive. One of the three drugs will be placed on a patient donor site immediately after harvesting skin while the patient is in surgery.
89025796|NCT00591916|Experimental|2|fine mesh gauze impregnated with hyaluronan and thrombin (HT) is one of three drug interventions the patient will be randomized to receive. One of the three drugs will be placed on a patient donor site immediately after harvesting skin while the patient is in surgery.
89025797|NCT00591916|Active Comparator|3|Scarlet Red is one of three drug interventions the patient will be randomized to receive. One of the three drugs will be placed on a patient donor site immediately after harvesting skin while the patient is in surgery.
89025798|NCT00496938|Other|1|Observational cohort using an all-comers design
89025799|NCT00462098|Experimental|HBO|Subject receives 40 HBO sessions at 2 atmospheres of pressure over 4 weeks
89025800|NCT00462098|Active Comparator|Control|non-HBO comparison group
89025801|NCT00462137||1|control group
89025802|NCT00462137||2|hypnotic group
89025803|NCT04413058||Female healthcare workers|Healthy female healthcare workers at Covid 19 clinic in Istanbul, Turkey
89555085|NCT02378545|Active Comparator|normoxia|Oxygen will not be administered if a patient's oxygen saturations (as measured using a pulse oximeter) are less than 94%. If a patient's oxygen saturations are less than 94%, oxygen will be 'titrated' using a 'venturi' type oxygen delivery device to achieve target saturations of 94%. Following initial dynamic titration (to identify correct oxygen delivery level) the oxygen delivery device will be re-evaluated hourly during the patient's stay in the emergency department.
89555086|NCT02378311||Cases|Those satisfying the inclusion & exclusion criteria whose injury involved impact with the handlebar end who have sustained an injury more severe than a skin or subcutaneous tissue contusion from an end-on handlebar impact
89555087|NCT02378311||Controls|Those satisfying the inclusion & exclusion criteria in whom the handlebars were not implicated in the mechanism of injury
89555088|NCT04149145|Experimental|M4344+Niraparib|all PARP resistant, recurrent ovarian cancer
89555089|NCT02378389|Experimental|Pyrotinib/Pyrotinib with Docetaxel|Subjects would be treated with Pyrotinib (Part 1) or Pyrotinib with Docetaxel (Part 2). A subject is only allowed to participant in one part of this trial.
89555090|NCT02376595||Rocuronium Bromide|Rocuronium 0,3 mg/kg administered in less than five seconds, followed by a saline bolus.
89555091|NCT02371213|Experimental|social networking on mobile phone|Audio-video media via social networking on mobile phone to antenatal women from the first ANC visit four times every month and four times biweekly plus usual antenatal care group-health education
89555092|NCT02371213|No Intervention|no social networking on mobile phone|usual antenatal care group-health education
89555093|NCT02378155|Other|electrical cardioversion|Hemodynamic unstable patients with atrial fibrillation who are scheduled to undergo electrical reconversion to convert their irregular heart rhythm into a normal sinus rhythm. Cerebral tissue oxygen saturation is measured by means of SenSmart Model X-100, Nonin Medical.
89555094|NCT02378155|Other|pharmacological cardioversion|Patients who develop atrial fibrillation after cardiac surgery. Pharmacological treatment with amiodarone is started in order to convert their irregular heart rhythm into a normal sinus rhythm. Cerebral tissue oxygen saturation is measured by means of SenSmart Model X-100, Nonin Medical.
89555095|NCT02378467|Experimental|Active Treatment Group|7% Hypertonic Saline administered via inhalation twice daily for 48 weeks
89555096|NCT02378467|Active Comparator|Control Group|0.9% Isotonic Saline administered via inhalation twice daily for 48 weeks
89555097|NCT02371291|Experimental|Memory Flexibility Training|The MemFlex programme draws on cognitive bias modification and memory specificity training techniques (Raes et al., 2009; Dalgleish et al., 2014), and was developed by clinical psychologists. MemFlex is primarily self-guided and aims to reduce autobiographical memory biases associated with depression. The training material is presented over one face-to-face session and eight self-guided sessions. In the initial session, the researcher introduces cued-recall tasks which are used throughout the workbook, and guides the participant in completion of these tasks. When understanding of the basic principles is satisfactory, the researcher assists the participant to set a schedule for completion of the workbook over the following four weeks. The participant will receive weekly emails during this period, encouraging them to complete the workbook. They will also receive a phone call from a team member at the beginning of week three to check progress.
89555098|NCT02371291|Placebo Comparator|Psychoeducation|The psychoeducation condition will also complete an initial face-to-face session. This session will cover the symptoms and causes of depression, and the workbook will be introduced. As in the MemFlex condition, the workbook will consist of eight self-guided sessions that the individual will be required to complete over four weeks. The participant will receive weekly emails during this period, encouraging them to complete the workbook. They will also receive a phone call from a team member at the beginning of week three to check progress, and clarify any difficulties with the workbook material. The workbook content will cover the presentation of depression and basic information on factors associated with depression, such as worry, procrastination, and sleep difficulties. Each session consists of information on psychological theories of the topic, followed by a series of questions about the material to ensure participant engagement. The workbook was developed by clinical psychologists.
89555099|NCT02370979|Experimental|Dolutegravir|
89555100|NCT02371057||patients under follow-up known to have sleep apnoea|
89025804|NCT00462176||1|All women (n=45) who had undergone CO2 laser laparoscopic radical excision of deep infiltrating endometriosis with active involvement of the colorectal surgeon performing a bowel resection were selected retrospectively from the list of all patients (n=more than 400) operated at the Leuven University Fertility Centre (LUFc) between September 2004 and July 2006.
89025805|NCT02893969|Experimental|Experimental group|Gradual reintroduction of non-contact physical activity at 72 hours post-concussion.
89025806|NCT02893969|Sham Comparator|Control Group|Physical and cognitive rest post-injury until fully asymptomatic. Once asymptomatic participants can gradually reintroduce physical activity.
89208209|NCT02595671|Active Comparator|Waiting Group|Patients will not receive a treatment during the actual intervention. This group will receive the digital super coach as an incentive at the end of the trial.
89555101|NCT02371057||patients attending the sleep apnoea clinic for assessment|Patients who are attending clinic who have not yet been diagnosed.
88962684|NCT02016053||cirrhosis with baseline renal function|500 patients of cirrhosis with normal baseline renal function will be enrolled.
89555102|NCT02376517|Active Comparator|Educational program|Participants randomized to the intervention group will receive the educational program at the baseline visit.
89555103|NCT02376517|No Intervention|Control|Participants randomized to the control group will receive the educational program at the follow-up visit.
89555104|NCT02378077|Experimental|Lean or Obese, Non-Diabetic|To determine whether eosinophil content of adipose tissue is related to insulin sensitivity. We will use euglycemic clamps, fat biopsy (obtained during a scheduled abdominal surgery) and fat aspiration for analysis of subcutaneous (Sc) and omental (OM) adipose tissue from obese, insulin resistant and lean, insulin sensitive volunteers to test the hypothesis that, as in mice, eosinophil content in human subcutaneous and omental white adipose tissue, inversely correlates with body weight, with skeletal muscle and hepatic insulin sensitivity.
89555105|NCT02378077|Experimental|Fish oil supplementation|Determine whether, in adipose tissue, levels of, anti-inflammatory molecules correlate with insulin sensitivity and whether these levels are altered by a treatment designed to promote resolution of inflammation. Volunteers will take a fish oil supplement for three months.
89555106|NCT02376439||Siblings|Siblings will consume four test meals after 4 different exposures, including two types of koolaid, a control and a smell condition.
89555107|NCT02377843|Experimental|Participatory|This arm includes 10 pediatric or family medicine clinics located within a 2-hour driving distance of Chapel Hill, NC, and have 100 or more 11-12 year old patients with active records in the NCIR. Clinics randomized to the participatory study arm will receive a 1-hour in-person communication training.
89555108|NCT02377843|Experimental|Efficient|This arm includes 10 pediatric or family medicine clinics located within a 2-hour driving distance of Chapel Hill, NC, and have 100 or more 11-12 year old patients with active records in the NCIR. Clinics randomized to the efficient study arm will receive a 1-hour in-person communication training.
89555109|NCT02377843|No Intervention|Control|This arm includes 10 pediatric or family medicine clinics located within a 2-hour driving distance of Chapel Hill, NC, and have 100 or more 11-12 year old patients with active records in the NCIR. Clinics randomized to the control study arm will not receive a 1-hour in-person communication training.
89555110|NCT02376673|Active Comparator|Brochures|Mothers in this arm will receive safe sleep education from home visitors using standard brochures (including 1-page handouts and pamphlets) that are customarily used in this home visiting program.
89555111|NCT02376673|Experimental|Children's Book|Mothers in this arm will receive safe sleep education from home visitors using a specially-designed children's book incorporating American Academy of Pediatrics safe sleep guidelines.
89555112|NCT02370745|Experimental|Post absorptive insulin without GLP-1|"Subjects with receive post absorptive insulin concentrations while measures of muscle metabolism and microvascular blood flow are taken through the acute study hours.~The intervention in this group is Insulin Actrapid to achieve post absorptive insulin levels and glucose infusion to achieve postprandial glucose levels of 7.0-7.5 mmol/L . This will form base line measurement for the next arm which will receive GLP-1 in addition."
89555113|NCT02370745|Experimental|Postabsorptive insulin with GLP-1|"Subjects will receive post absorptive insulin concentrations with GLP-1 while measures of muscle metabolism and microvascular blood flow are taken through the acute study hours. This arm will cross over with the previous arm.~The intervention in this group is in the form of GLP-1, Insulin Actrapid to achieve post absorptive insulin levels and glucose infusion to achieve postprandial glucose levels of 7.0-7.5 mmol/L ."
88962685|NCT02016053||Cirrhosis with Acute Kidney Injury (AKI).|Cirrhotics patients who present with AKI (Acute Kidney Injury) will be enrolled.
88962686|NCT02016066|Experimental|CR6261|
88962687|NCT02016066|Placebo Comparator|Placebo|
88962688|NCT02016079|Experimental|Omega-3|a fruit drink containing omega-3
88962689|NCT02016079|Placebo Comparator|Fruit drink|the same fruit drink given in the experimental arm, but not containing omega-3
88962690|NCT02016092||Patients with Parkinson's disease|
88962691|NCT02016092||Healthy Controls|
88962692|NCT02016118||Ialuril|Intravesical administration of combined hyaluronic acid (HA) 1.6% and chondroitin sulphate (CS) 2.0% once per week for the first month, followed by one instillation every two weeks for the second month and one instillation per month until stable remission of the symptoms.
89208210|NCT02595671|Active Comparator|Conventional face to face PA & dietitian|Participants will receive both dietary and physical activity advice. The advice is provided my medical trained staff (eg. dieticia, physiotherapist) according to a standardised protocol. The number of consultations are respectively three and four for diet and physcial activity.
88962693|NCT02016118||Standard of care|Antimicrobial prophylaxis (continuous or postcoital), as described in the Guidelines on Urological Infections of the European Association of Urology or Immunoactive prophylaxis or Prophylaxis with probiotics or Prophylaxis with cranberry, or combination of these.
88962694|NCT02016131||none endoleak events|Patients who have no further endoleaks related adverse events including aneurysm enlargement and rupture or persistent endoleaks.
88962695|NCT02016131||Endoleak events|Patients who undergo endoleaks related adverse events or persistent endoleaks during follow up.
88962696|NCT02016157|Experimental|Moxifloxacin, Chronic periodontitis|50 micrograms Moxifloxacin
88962697|NCT02016196|Experimental|rifaximin|6 rifaximin caps of 200 mg per day morning and night, during 15 days before TIPS, and after TIPS during 6 months.
88962698|NCT02016196|Placebo Comparator|placebo|6 caps placebo morning and night, 15 days before and 6 months after TIPS
88962699|NCT02016209|Experimental|nanoparticle albumin-bound paclitaxel|Neoadjuvant chemotherapy of platinum-based nanoparticle albumin-bound paclitaxel in stage Ⅱ B and IIIA non-small cell lung cancer
88962700|NCT02016222|Experimental|Tears sampling|
88962701|NCT02016261|Experimental|Remitted Depression Outpatients|Adults 18-65 years old, males and females with the diagnosis of recurrent depressive disorder and who had at least two severe depressive episodes (with or without psychotic symptoms) of the disorder and who currently in remission
89208211|NCT02595671|Active Comparator|Digital Super Coach|Only receive coaching via digital super coach.
89555114|NCT02370745|Experimental|Postprandial insulin without GLP-1|"Subjects will receive postprandial insulin concentrations without GLP-1 while measures of muscle metabolism and microvascular blood flow are taken through the acute study hours.~The intervention in this group is Insulin Actrapid to achieve postprandial insulin levels and glucose infusion to achieve postprandial glucose levels of 7.0-7.5 mmol/L . This will form base line measurement for the next arm which will receive GLP-1 in addition"
89555115|NCT02370745|Experimental|Postprandial insulin with GLP-1|"Subjects with receive postprandial insulin concentrations with GLP-1 while measures of muscle metabolism and microvascular blood flow are taken through the acute study hours. This arm will cross over with the previous arm.~The intervention in this group is in the form of GLP-1, Insulin Actrapid to achieve postprandial insulin levels and glucose infusion to achieve postprandial glucose levels of 7.0-7.5 mmol/L ."
89555116|NCT02370745|Experimental|Oral amino acids-Young|"Gut hormones will be measured post oral drink containing 15 g of amino acids in young persons. This will cross over with the following 2 arms.~The intervention here is: 15g of mixed essential amino acid drink."
89555117|NCT02370745|Experimental|Intravenous (IV) amino acids- Young|"Gut hormones will be measured after intravenous amino acid infusion delivering iso equivalent amount of amino acids in young persons.~The intervention in this group: Intravenous amino acids delivering iso-equivalent amount of 15g mixed essential amino acids"
89555118|NCT02370745|Experimental|IV amino acids, GLP-1, GIP -Young|"Gut hormones will be measured after intravenous amino acid infusion delivering iso equivalent amount of amino acids, GLP-1, GIP in young persons.~The intervention in this group: Intravenous amino acids iso-equivalent to oral 15 g mixed essential amino acids, GLP-1 infusion and GIP infusion"
89555119|NCT02370745|Experimental|Oral amino acids- Older|"Gut hormones will be measured post oral drink containing 15 g of mixed essential amino acids in older persons.~The intervention in this arm: 15 gram of oral mixed essential amino acid drink"
89555120|NCT02377999|Experimental|Treatment of genetial warts with Picato|
89555121|NCT01995838|Experimental|E2006|E2006 1 mg, 2.5 mg, 5 mg, 10 mg, 15 mg, or 25 mg, in tablet form, taken orally, 30 minutes prior to bedtime, each night for 15 consecutive nights
89555122|NCT01995838|Placebo Comparator|Placebo|E2006-matched placebo in tablet form, taken orally, 30 minutes prior to bedtime, each night for 15 consecutive nights
89555123|NCT02377765|Active Comparator|Percutaneus Stimulation|PTNS performed bilaterally every 4 weeks within the Physiotherapy Department.
89555124|NCT02377765|Experimental|Transcutaneous Stimulation|TPTNS applied bilaterally, using two surface, self-adhesive, round electrodes (3 cm in diameter) in each leg at least 3 times per week.
89555125|NCT02370823||Knee OA Treated with Regenexx SD|20 subjects with unilateral knee osteoarthritis. Collection of synovial fluid from both knees will serve as the experimental condition, i.e. the osteoarthritic knee, and the matched control, i.e. the knee not demonstrating signs of osteoarthritis. Alterations in the concentration of the synovial fluid proteins and cellular components will be evaluated up to 6 weeks post-Regenexx® SD - Same Day Bone Marrow Concentrate Injection treatment.
89555126|NCT04589377|Experimental|Mindfulness Training|Participants receive 20 minutes of mindfulness training per day for five continuous days (Monday through Friday). Training is delivered remotely to participants' computers and smartphones.
89555127|NCT04589377|No Intervention|No-Training|Participants do not receive training. On Monday and Friday, they listen to a 20 minute audiobook to match for time.
89555128|NCT02376049|Active Comparator|Pimecrolimus cream|Pimecrolimus 1% cream once daily for 14 days
89555129|NCT02376049|Active Comparator|Betamethasone dipropionate cream|Betamethasone dipropionate 0.05% cream once daily for 14 days
89555130|NCT02376049|Active Comparator|Clobetasol propionate cream|Clobetasol propionate 0.05% cream once daily for 14 days
89555131|NCT02376049|Placebo Comparator|Glaxal Base cream vehicle|Glaxal Base cream vehicle once daily for 14 days
89555132|NCT02376205|Experimental|bupivacaine hydrochloride 0.5% solution|Bupivacaine hydrochloride 0.5% 10 mL solution poured into the retropharyngeal space intraoperatively before wound closure during anterior cervical discectomy and fusion procedure
89555133|NCT02376205|Placebo Comparator|0.9% NaCl solution|0.9% NaCl 10 mL solution poured into the retropharyngeal space intraoperatively before wound closureduring anterior cervical discectomy and fusion procedure
88962702|NCT02016274|Experimental|sequential treatment|paclitaxel/cisplatin treatment and radiotherapy
88962703|NCT02016287|Experimental|sequential treatment|paclitaxel treatment and radiotherapy
88962704|NCT02016313|Experimental|Immediate therapy|Physiotherapy protocol
88962705|NCT02016313|Placebo Comparator|waiting list|Physiotherapy protocol
88962706|NCT02016326|Experimental|HD Colon|High Definition White Light modality will be used by the endoscopist for the entire procedure.
88962707|NCT02016326|Experimental|I-Scan 1|I-scan 1 modality will be used by the endoscopist for the entire procedure.
88962708|NCT02016326|Experimental|I-Scan 2|I-Scan 2 modality will be used by the endoscopist through out the procedure.
88962709|NCT02016339|Active Comparator|Standard Care|24 hour consultation telephone line to the sleep nurses will be open for the patients. Patients were reviewed at 1 month and at 3 month intervals during the first year and every 6 months thereafter in the CPAP clinic. Additional visits or phone calls by sleep specialist if doubts about a patient's compliance or willingness to continue with the therapy
88962710|NCT02016339|Active Comparator|Intensive care|"Standard group care plus:~Involvement of the patient's partner or family. Extra education on sleep apnea syndrome and CPAP by sleep specialists via a 15-min videotape. 10- to 15-min lecture from the sleep clinic's nurses. Phone calls by nurses at 2 and 7 days. Early review of patients by sleep specialists at 15 and 30 days. Home visits by sleep nurses, if there doubts about a patients adherence."
88962711|NCT02016352|Experimental|patient|patient CSF extraction with hydrocephalus
88962712|NCT02016352|Other|witness|patient without hydrocephalus but with peridural catheter for anesthetic. Witness CSF extraction has realized on catheter.
88962713|NCT02016365|Experimental|Doxycycline and UDCA|Doxycycline (200 mg/day intermittently) and UDCA (750 mg/day continuously)
88962714|NCT02016391|Experimental|Dexmedetomidine|
88962715|NCT02016404|Active Comparator|Low-sodium, high-potassium salt|Iodized low-sodium, high-potassium botcanh (a traditional mixture of salt, mono sodium glutamate (MSG), sugar and herbs) plus and iodized low-sodium, high-potassium salt for home food preparation
88962716|NCT02016404|Placebo Comparator|Regular salt|Regular iodized high-sodium botcanh (a traditional mixture of salt, MSG, sugar and herbs) and high-sodium salt
88962717|NCT02016417|Experimental|A combination of Gemcitabine and cisplatin|The GP regimen consists of gemcitabine at a dose of 1,000 mg/m2 by intravenous (i.v.) infusion over 30 min on day 1 and day 8, and cisplatin 80 mg/m2 by i.v. infusion for 4 h on day 1-3, The regime will be repeated every 3 weeks up to a total of 2-3 courses. Concurrent chemoradiotherapy is administrated with 3 cycles of weekly Cisplatin 100 mg/m2 starting on the first day of IMRT.
88962718|NCT02016417|Active Comparator|A combination of Docetaxel, cisplatin and 5-Fluorouracil|The TPF regimen consists of docetaxel at a dose of 60 mg/m2/day on day 1, cisplatin 60 mg/m2 by i.v. infusion for 4 h on day 1-3, plus 5-Fluorouracil 600 mg/m2 CIV over 120 hours. The regime will be repeated every 3 weeks up to a total of 2-3 courses. Concurrent chemoradiotherapy is administrated with 3 cycles of weekly Cisplatin 100 mg/m2 starting on the first day of IMRT.
88962719|NCT02016443|Experimental|Tizanidine|Group Tizanidine (Group T) will receive 4 mg tizanidine per oral twice a day during the postoperative first week and the first dose will be administered 1 hour before surgery
88962720|NCT02016443|Placebo Comparator|Placebo|Group Placebo (Group P) will receive placebo per oral twice a day during the postoperative first week and the first dose will be administered 1 hour before surgery
88962721|NCT02016456|Experimental|Theta-Burst Stimulation|Theta-Burst protocol for transcranial magnetic stimulation on dorsolateral prefrontal cortex (exact location to be determined using neuronavigation guided by Magnetic Resonance Imaging)
88962722|NCT02016456|Active Comparator|High Frequency stimulation|High frequency Transcranial Magnetic Stimulation using the standard protocol for depression, on left dorsolateral prefrontal cortex.
88962723|NCT02016469|Experimental|co-transplantation of FMT and pectin|300ml Bacterial suspension (from 60g fresh stool )given for the first day and 20g pectin given from the second to the sixth day for total five days
88962724|NCT02016469|Active Comparator|single fecal microbiota transplantation|300ml Bacterial suspension (from 60g fresh stool )given for the first day
88962725|NCT02016469|Active Comparator|give pectin 20g/d|pure give pectin 20g/d for five days
88962726|NCT02016495|Active Comparator|Magnesium + Lipoic Acid|
88962727|NCT02016495|Placebo Comparator|Placebo|
88962728|NCT02016508|Experimental|autologous bone marrow stem cells|use of autologous bone marrow derived stem cells as intravitreal injection in AMD patients
88962729|NCT02016521|Experimental|Cooling Fabric|Garment made of 100% nylon fabric consisting of long sleeved shirt and full trouser.
88962730|NCT02016521|Placebo Comparator|Placebo Garment|Garment made of 100% polyester consisting of long sleeved shirt and full trouser.
88962731|NCT02016547|Experimental|abciximab IV and thrombectomy|abciximab IV (0.25mg/kg by IV bolus, following by 0.125μg/kg by 12 hours IV drip) and thrombectomy
88962732|NCT02016547|Active Comparator|alteplase|alteplase 0.9mg/kg (10% by IV bolus following by 90% by 1 hour IV drip)
89555134|NCT01957462|Experimental|FirstColplast Test V, Then Coloplast Test X|The subject tests two experimental coloplast products in a randomised order. Coloplast Test product V and after cross over ColoplastTest product X
89555135|NCT01957462|Experimental|First Coloplast Test X, Then Coloplast Test V|The subjects test the two experimental Coloplast products in a randomised order: Coloplast Test product X and after cross over Coloplast Test product V
88962733|NCT02016573|No Intervention|Usual care|participants randomised to the usual care group will receive additional antihypertensive medication in an attempt to achieve blood pressure targets
88962734|NCT02016573|Experimental|Renal Denervation Group|participants randomised to undergo the renal denervation procedure
88962735|NCT02016586|No Intervention|Control Group|Subjects in the control group will continue to take the prenatal supplement primarily consisting of folic acid (400 mcg), elemental iron (60 mg) and will receive breastfeeding advice during prenatal visits.
88962736|NCT02016586|Experimental|Intervention|Lactation support in conjunction with a maternal nutritional supplement S348S0
88962737|NCT02016638|Experimental|polysomnography and AMBP on pregnant females|"Consecutive patients undergoing antenatal check up at the Antenatal Clinic at AIIMS hospital and obstetrics wards will be recruited and followed.Using Somnomedic systems, GmbH polysomnography machine by trained staff nurses and technicians at:~Obstetrics ward, AIIMS hospital"
88962738|NCT02016651|Experimental|Right side position|Premature infants on mechanical ventilation are kept on their right side
88962739|NCT02016651|No Intervention|Supine position|Premature infants on mechanical ventilation are kept on their back
89555136|NCT02370433|Experimental|Bowel Evacuation via IV|The study design will consist of an intravenous (IV) screening visit to determine each individual's response to neostigmine and glycopyrrolate (NG).
89555137|NCT02370433|Experimental|Bowel Evacuation Titration|This design will consist of a dose titration for those subjects who respond positively to IV. These subjects will receive either a low dose and/or a high dose of NG via iontophoresis to determine their responsiveness.
89555138|NCT02370433|Experimental|Bowel Evacuation Iontophoresis|This design will consist of the incorporation of iontophoresis administration into clinical bowel care. The subject will receive the exact dose they responded to during the titration 3x per week for 2weeks.
89555139|NCT01957150|Experimental|Fluticasone Furoate/Vilanterol 100/25 micrograms (mcg) QD|Subjects will self administer FF/VI 100/25 mcg inhalation powder once daily for 156 weeks via the NDPI.
88962740|NCT02016664|Experimental|Chronic pain patients on oral ketamine|"Days 1-7:~Subjects will be given a 7 day supply of 10 mg ketamine tablets three times per day for seven days and to return to clinic on Day 7. They will be instructed not to take their morning dose of ketamine and to eat a light breakfast on Day 7. Upon arrival, the patient will have a 20 gauge (saline locked) IV started in the antecubital fossa to allow for five blood samples: Time Zero,30, 60,90 and 120 minutes. The first blood sample at Time 0 will be obtained just before the patient takes his/her oral dose of ketamine.~Days 8-14:~The subjects will be given a supply of 20 mg ketamine capsules and instructed to take them three times per day, at specified times, and to return to clinic on Day 14. The instructions and procedures at the second clinic visit will be the same as on Day 7."
88962741|NCT02016677||observation|no specific treatment. Long term observation the results of any breast lifting or reduction surgeries
88962742|NCT02016703|Experimental|5 g group|5g erythritol dissolved in 250 ml (2% w/v) consumed within 15 min between meals (tested vs. 250 ml isosweet saccharose placebo under same conditions)
88962743|NCT02016703|Experimental|15 g group|15g erythritol dissolved in 250 ml (6% w/v) consumed within 15 min between meals (tested vs. 250 ml isosweet saccharose placebo under same conditions)
88962744|NCT02016703|Experimental|25 g group|25g erythritol dissolved in 250 ml (10% w/v) consumed within 15 min between meals (tested vs. 250 ml isosweet saccharose placebo under same conditions)
88962745|NCT02016703|Experimental|20 g group|20g erythritol dissolved in 250 ml (8% w/v) consumed within 15 min between meals (tested vs. 250 ml isosweet saccharose placebo under same conditions)
88962746|NCT02016729|Experimental|AMG 232|AMG 232 is an anti-cancer agent
88962747|NCT02016729|Experimental|AMG 232 & Trametinib|AMG 232 and Trametinib are anti cancer agents
88962748|NCT02016742|Experimental|RDC5 dose level 1|Single dose of RDC5
88962749|NCT02016742|Experimental|RDC5 dose level 2|Single dose of RDC5
88962750|NCT02016742|Experimental|RDC5 dose level 3|Single dose of RDC5
88962751|NCT02016742|Experimental|RDC5 dose level 4|Single dose of RDC5
88962752|NCT02016768||operation|To make decompressive cervical surgery, either anterior cervical discectomy and fusion or posterior laminoplasty on the patients suffering from cervical spondylotic myelopathy and hypertension.
88962753|NCT02016794||Patients|Patients suffering from degenerative cervical condition that requires anterior decompression and fusion in a single or multiple levels
89555140|NCT01957150|Experimental|Vilanterol 25 mcg QD|Subjects will self administer VI 25 mcg inhalation powder once daily for 156 weeks via the NDPI.
89555141|NCT04661332||Endoscopic retrograde cholangio-pancreatography|Endoscopic retrograde cholangio-pancreatography procedure
89555142|NCT01955122|Other|Group A|"Tandem Colonoscopy- Each patient will undergo 2 colonoscopy procedures:~a Standard view colonoscopy followed immediately by an EndoRings™ colonoscopy."
89555143|NCT01955122|Other|Group B|"Tandem Colonoscopy- Each patient will undergo 2 colonoscopy procedures:~an EndoRings™ colonoscopy followed immediately by a Standard view colonoscopy."
89555144|NCT01995526|Experimental|Insulin Peglispro|Single subcutaneous dose of 1.3 Units per kilogram (U/kg) insulin peglispro on Day 1.
89555145|NCT01955044|Experimental|"high dose LCPUFA"|"the high dose LCPUFA supplement is a drop that will be administered to ELBW infants."
89555146|NCT01955044|Experimental|"low dose LCPUFA"|"the low dose LCPUFA supplement is a drop that will be administered to ELBW infants."
89555147|NCT01955044|Placebo Comparator|placebo|"the placebo is a drop that will be administered to ELBW infants."
89555148|NCT01973218|Experimental|rMenB|Subjects received two doses of rMenB+OMV NZ vaccine (at Day 1 and Day 31) in the study.
88962754|NCT02016807||1-Treat OroEsophageal Mucositis|Prothelial: Arm 1 Patients with oroesophageal mucositis (with pain, erythema, ulceration and difficult pain swallowing as prominent symptom/signs) [n=30] Intervention: ProThelial 1.5 gram Taken tid x 2 days then bid swish and swallow. (Phase I)
88962755|NCT02016807||2-Treat Upper Alimentary Mucositis|Prothelial: Arm 2 Patients with gastric/small intestinal mucositis (delayed nausea, vomiting as prominent symptom/sign) [n=30] Intervention: ProThelial 1.5 gram Taken tid x 2 days then bid swish and swallow. (Phase I)
88962756|NCT02016807||3-Treat Lower Alimentary Mucositis|ProThelial: Arm 3 Patients with lower GI mucositis develop chemoradiation diarrhea as their \ prominent symptom/sign[n=30]. Intervention: ProThelial 1.5 gram Taken tid x 2 days then bid swish and swallow. (Phase I)
88962757|NCT02016807||4-Prevent Oral Mucositis|ProThelial: Arm 4 Patients anticipated to develop oroesophageal mucositis (with pain, erythema, ulceration and difficult pain swallowing as prominent symptom/signs) [n=30] Intervention: ProThelial 1.5 gram Taken tid x 2 days then bid swish and spit. (Phase IV)
88962758|NCT02016807||5- Prevent Upper Alimentary Mucositis|ProThelial: Arm 5 Patients anticipated to develop gastric/small intestinal mucositis (delayed nausea vomiting as prominent symptom/sign) [n=30]. Intervention: ProThelial 1.5 gram Taken tid x 2 days then bid swish and swallow. (Phase I)
88962759|NCT02016807||6- Prevent Lower Alimentary Mucositis|ProThelial: Arm 6 Patients anticipated to develop chemoradiation diarrhea as their prominent symptom/sign [n=30]. Intervention: ProThelial 1.5 gram taken tid x 2 days then bid swish and swallow. (Phase I)
89555149|NCT01973218|Active Comparator|Placebo/MenACWY|Subjects received one dose of saline placebo (Day 1) and one dose of MenACWY-CRM vaccine (Day 31) in the study.
89555150|NCT01954342||Pregnant|Obese pregnant women
89555151|NCT01972438|Experimental|ASEDs - Saline|Participants administer autologous serum eye drops (ASEDs) daily for the first three months, then crossover to administer control (normal saline) eye drops daily beginning at Month 3 through Month 6.
89555152|NCT01972438|Placebo Comparator|Saline - ASEDs|Participants administer control (normal saline) eye drops daily for the first three months, then crossover to administer autologous serum eye drops (ASEDs) daily beginning at Month 3 through Month 6.
89555153|NCT01946152|Experimental|Treatment (pomalidomide, dexamethasone, filgrastim-sndz)|"INDUCTION: Patients receive pomalidomide PO daily on days 1-21, dexamethasone PO on days 1, 8, 15, and 22, and filgrastim-sndz SC on days 22-28. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive lower-dose pomalidomide PO daily on days 1-21 and dexamethasone PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
89555154|NCT01945996|Active Comparator|TExT-MED only|Patients will receive TExT-MED intervention, but supporters will not receive additional messages
89555155|NCT01945996|Experimental|TExT-MED FANS|Patients get TExT-MED intervention, supporter gets FANS curriculum
89555156|NCT01971346|Other|Etanercept|100 mg Etanercept injections per week for 3 months.
89555157|NCT01945216||Alogliptin 25mg, tablets, orally, once daily, up to 36 months|
89555158|NCT02641379|Experimental|PEG-IFN 24 weeks|Participants will receive PEG-IFN (180 microgram [mcg]), subcutaneously (sc), once weekly for 24 weeks and Ribavirin 1000-1200 milligram per day (mg/day) (<75 kilogram (kg); >75 kg) for 24 weeks.
89555159|NCT02641379|Experimental|PEG-IFN 24/72 weeks|Participants will receive PEG-IFN (180 mcg), sc, once weekly and Ribavirin 1000-1200 mg/day (<75kg; >75 kg) till week 24; if patient is still HCV RNA positive. Treatment will be stopped if participant is HCV RNA negative at week 24 -treatment with PEG-IFN (180 mcg), sc, once weekly and Ribavirin 1000-1200 mg/day (<75kg; >75 kg) till week 72
89555160|NCT02641379|Experimental|PEG-IFN 48 weeks|Participants will receive PEG-IFN (180 mcg), sc, once weekly for 48 weeks and Ribavirin 1000-1200 mg/day (<75kg; >75 kg) for 48 weeks.
88962760|NCT02016833||Cancer patients|Patient with histologically confirmed diagnosis of cervical cancer or cervical intraepithelial neoplasia (grade 3) or of high-grade serous (or undifferentiated) ovarian cancer or patients with AML or CML confirmed by bone marrow biopsy or peripheral blood Not treated - prior standard of care therapy acceptable one blood sampling performed on the visit day
88962761|NCT02016846|Placebo Comparator|Placebo|
88962762|NCT02016846|Active Comparator|Intervention|Liraglutide, tapered from 0.6 mg/day to 1.8 mg/day.
88962763|NCT02016859||Critically ill patients admitted to ICU|those patients who are admitted to ICU with multiorgan failure/injury
88962764|NCT02016859||Neutropinc Fever patients|admitted to ER, haemato-oncology or oncology
88962765|NCT02016859||Patients of Hip's Fracture|admitted to orthopedic departement
88962766|NCT02016911|Experimental|Subjects with hepatic impairment|
88962767|NCT02016911|Active Comparator|Subjects with normal hepatic function|
88962768|NCT02016937||group g|general anesthesia, n: 21
88962769|NCT02016937||group S|spinal anesthesia, n: 21
89555161|NCT02641379|Experimental|PEG-IFN 72 weeks|Participants will receive PEG-IFN (180 mcg), sc, once weekly for 72 weeks and Ribavirin 1000-1200 mg/day (<75 kg; > 75 kg) for 72 weeks.
89555162|NCT02660983|Placebo Comparator|Double Blind Phase: Placebo|Participants will receive donepezil matching placebo, once daily in the evening during the double blind period.
89555163|NCT02660983|Experimental|Double Blind Phase: Donepezil|Participants will receive donepezil 5 milligram (mg), once daily in the evening during the titration phase and then the dose will be increased to 10 mg at Week 4 during the double blind period. During the maintenance period, dose reduction to 5 mg/day will be permitted only when 10 mg/day is intolerable due to adverse events.
89555164|NCT02660983|Experimental|Open-Label Extension Phase: Donepezil|All participants who will complete the double-blind phase and want to continue the study participation, can be enrolled in the 24-week open-label extension phase. In this phase, treatment will be initiated at 5 mg/day, and the dose will be maintained until Week 6 (Day 28-42). After assessing clinical response during the period by examination, the dose can be increased to 10 mg/day. Dose reduction (from 10 mg/day to 5 mg/day) will be permitted when the investigator judges it difficult to continue the 10 mg/day administration. It will be possible to increase the dose to 10 mg/day again.
89555165|NCT05070611|Experimental|Recurrent chalazia with IPL-MGX|The patients whose lesions had failed to respond to warm compresses and antibiotic and steroid treatment underwent incision and curettage. One week after lesion incision, the E-Eye machine (E-SWIN company, France) IPL treatment was administered to the skin area below the lower eyelid. After removal of the ultrasound gel, meibomian gland expression (MGX) was performed with forceps-shaped meibomian gland compressor.
89555166|NCT05070221|Experimental|Arm A|Patients histologically confirmed mucosal melanoma will get OH2 （once every two weeks）and HX-008 (once every three weeks)and Axitinib (once every day).
89555167|NCT05070221|Experimental|Arm B|Patients histologically confirmed non-mucosal melanoma will get OH2 （once every two weeks）and HX-008 (once every three weeks)and Axitinib (once every day).
89555168|NCT05069909|Active Comparator|Conventional technique|The group of patients who received dentures fabricated with conventional technique first
89555169|NCT05069909|Active Comparator|Simplified technique|The group of patients who received dentures fabricated with simplified technique first
89555170|NCT02962115|Experimental|Decision Aid Invitation|Electronic invitation to complete a web-based lung cancer screening decision aid
89555171|NCT02370355||Group I (retrospective analysis)|Previously collected plasma samples are analyzed for ctDNA via PCR and NSG.
89555172|NCT02370355||Group II (prospective analysis)|Patients undergo collection of blood samples before and following systemic therapy for analysis of CTC enumeration, RNA expression, and ctDNA via PCR and NSG.
89555173|NCT03099941|Experimental|Biofeedback group|The biofeedback application which helps patient to understand neutral position and how to maintain it in exercises that are prescribed by the physical therapist
89555174|NCT03099941|Active Comparator|Physical therapist feedback group|In physical therapist feedback group feedback applied by oral and tactile stimulation of physical therapist to helps patient to understand neutral position and how to maintain it in exercises that are prescribed
89555175|NCT03099629|Experimental|IMT|inspiratory muscle training
89555176|NCT02370277||Group A (stool collection after adjuvant chemotherapy)|Patients undergo collection of stool samples at baseline (before surgery), at 1 week before initiation of adjuvant chemotherapy (after surgery), and at 1 and 4 months after completion of adjuvant chemotherapy.
89555177|NCT02370277||Group B (stool collection after adjuvant chemotherapy)|Patients undergo collection of stool samples at baseline (after surgery), at 1 week before initiation of adjuvant chemotherapy, and at 1 and 4 months after completion of adjuvant chemotherapy.
89555178|NCT02370277||Group C (stool collection after neoadjuvant chemotherapy)|Patients undergo collection of stool samples at baseline, 1 month after completion of neoadjuvant chemotherapy (before surgery), and at 1 and 4 months after surgery
88962770|NCT02016937||group E|epidural anesthesia, n: 21
88962771|NCT02016937||group V|vaginal birth, without anesthesia, n: 21
88962772|NCT02016950||Permanent pacemaker|Pre-existing permanent pacemakers
88962773|NCT02016976|Active Comparator|EMLA analgesic cream|Patients who have had EMLA analgesic cream applied to area before pacemaker implantation
88962774|NCT02016976|Active Comparator|Routine treatment|Patients who have received routine treatment (Dormicum 2.5 mg and Pethidine 25 mg) before and during pacemaker implantation
88962775|NCT02016989|Other|Physiological salt solution|The purpose of this study is to evaluate efficiency of CACICOL20 for bacterial keratitis. It is a double blinded comparison of epithelial defect in two groups of patients randomized between CACICOL20 and physiological salt solution.
88962776|NCT02016989|Experimental|CACICOL20|The purpose of this study is to evaluate efficiency of CACICOL20 for bacterial keratitis. It is a double blinded comparison of epithelial defect in two groups of patients randomized between CACICOL20 and physiological salt solution.
88962777|NCT02017002|Active Comparator|Tri-incision|a cervical incision was required for esophagogastrostomy after esophagectomy and gastric mobilization
88962778|NCT02017002|Placebo Comparator|Ivor Lewis|for the patients with lower-to mid third esophageal cancer, some surgeon performed Ivor lewis esophagectomy, which performing the esophago-gastrostomy in the chest after gastric mobilization without cervical incision wound
89555179|NCT05068895||Group1|Volunteers with normal glucose tolerance.
89555180|NCT05068895||Group2|type 2 diabetic patients without microvascular (retinopathy, nephropathy or neuropathy) or macrovascular (coronary, cerebrovascular or lower extremity arterial disease) complications.
88962779|NCT02017041||buprenorphine/naloxone|Opioid substitution therapy patient taking buprenorphine/naloxone, MedSignals and smartphone app.
89555181|NCT05068895||Group3|type 2 diabetic patients with lower extremity artery disease diagnosed through the measurement of ABI (the ratio of ankle-to-brachial systolic blood pressure).
89555182|NCT02375815|Experimental|Statin Choice Implementation|
89555183|NCT02375737|Experimental|m-health|Patients will receive text message, emails, and monthly phone calls
89555184|NCT05067881||Pneumohematocele|Patients with SARS CoV-2 diagnosis and PHC on imaging studies
89555185|NCT04404439|Experimental|Nortriptyline + topiramate|Nortriptyline (7.5 mg) plus topiramate (10 mg) in a single pill initially taken once daily. Dose may be increased as directed by care provider by 7.5mg weekly (to a maximum of 60mg) for nortriptyline, and by 10mg weekly (maximum 80mg) for topiramate.
89555186|NCT04404439|Experimental|Verapamil + paroxetine|Verapamil (30 mg) plus paroxetine (4 mg) in a single pill initially taken once daily. Dose may be increased as directed by care provider by 30mg weekly (to a maximum of 240mg) for verapamil, and by 4mg weekly (maximum 32mg) for paroxetine.
89555187|NCT04404439|Placebo Comparator|Placebo|Placebo pill.
89555188|NCT01953328|Placebo Comparator|A5 Placebo Q2W|Participants received atorvastatin 5 mg (A5) once daily during the 4 week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.
89555189|NCT01953328|Placebo Comparator|A5 Placebo QM|Participants received atorvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every month (QM) for 12 weeks.
89555190|NCT01953328|Experimental|A5 Evolocumab Q2W|Participants received atorvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
89555191|NCT01953328|Experimental|A5 Evolocumab QM|Participants received atorvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for 12 weeks.
89555192|NCT01953328|Placebo Comparator|A20 Placebo Q2W|Participants received atorvastatin 20 mg (A20) once daily during the 4 week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for 12 weeks.
89555193|NCT01953328|Other|A20 Placebo QM|Participants received atorvastatin 20 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every month for 12 weeks.
89555194|NCT01953328|Experimental|A20 Evolocumab Q2W|Participants received atorvastatin 20 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
89555195|NCT01953328|Experimental|A20 Evolocumab QM|Participants received atorvastatin 20 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for 12 weeks.
89555196|NCT05067959||IBD patients|patients with IBD (Chron's disease, Ulcerative colitis, IBD-Unspecify). patients will be divided into two sub-groups: IBD patients on anti-TNF therapy IBD patients on any other therapy
89555197|NCT05067959||Controls|healthy volunteers
89555198|NCT02375893||Coronary patients|Feces, blood sample, clinical and biological data. Presence (1) of coronary disease defined as the presence of atheroma during the coronary angiogram
89555199|NCT02375893||Healthy subjects (2)|Feces, blood sample, clinical and biological data. Absence (2) of atheroma during the coronary angiogram
89555200|NCT03100955|Active Comparator|EP chemotherapy|Standard treatment or active comparator group contains a platinum drug and a topoisomerase inhibitor. Platinum drug=cisplatin 75 mg/m2 iv on day 1; topoisomerase inhibitor=etoposide 120 mg/m2 iv day 1-3, 3 weeks a cycle, total numbers of cycles 6.Used drugs=cisplatinum and etoposide.
89555201|NCT03100955|Experimental|EP chemotherapy plus apatinib|Apatinib treatment or experimental group contains standard chemotherapy and apatinib, a VEGF tyrosine kinase inhibitor. It contains a platinum drug, a topoisomerase inhibitor and a VEGF-TKI. Platinum drug=cisplatin 75 mg/m2 iv on day 1; topoisomerase inhibitor=etoposide 120 mg/m2 iv day 1-3, 3 weeks a cycle, total numbers of cycles 6.Used drugs=cisplatinum and etoposide. Numbers of cycles 6. In addition to this, subjects will receive VEGF-TKI=apatinib, 500 mg, oral daily after chemotherapy, until disease progression or death or un-tolerated toxicites. Used drugs=cisplatinum and etoposide and apatinib.
89555202|NCT02377609||Kidney or Liver Transplant Patients|adult kidney or liver Advagraf® (tacrolimus) recipients
89555203|NCT05067413|Sham Comparator|Total mesorectal excision approach|Patients of the control group who are to receive the traditional approach-- total mesorectal excision approach to transect the distal rectum are assigned into this arm.
89555204|NCT05067413|Experimental|Transanterior obturator nerve gateway approach|Patients of the experimental group who are to receive the novel approach-- transanterior obturator nerve gateway approach to transect the distal rectum are assigned into this arm.
89555205|NCT02375581|Experimental|Icotinib & Radiotherapy|Icotinib, 125mg, Po, Tid, during the course of radiotherapy; Thoracic radiotherapy, 50-60Gy, conventional fraction, 3D-CRT/IMRT.
89555206|NCT02375581|Active Comparator|Radiotherapy alone|Thoracic radiotherapy alone, 50-60Gy, conventional fraction, 3D-CRT/IMRT.
89555207|NCT04435067||Cohort A|patients in whom lung metastasis were resected for therapeutic purposes
89555208|NCT04435067||Cohort B|patients in whom lung metastasis were removed for diagnostic purposes only
89208212|NCT02595671|Active Comparator|Digital Super Coach + minimal coaching|Receive digital super coach and only have a few appointments with a physical activity coach and a dietitian.
88962780|NCT02017054||Cath patients|Patients with previous cardiac cath via the radial access who are planned for additional radial access cardiac cath
88962781|NCT02017067|No Intervention|control|Maintain regular physical activity as usual, and received health education material about their disease, importance of nutrition and risks factors.
89555209|NCT02377531|Other|Early glucose screen group|Participants with high risk factors for gestational diabetes, will be randomly assigned to an early glucose screen group: it consists of an oral load of 50 grams of glucose followed by a measurement of serum glucose 1 hour later, and if abnormal (higher than 130mg/dl), will undergo a 100 gram oral load of glucose followed by serum glucose levels drawn 1,2 and 3 hours after the load. If abnormal according to Carpenter-Cousant criteria, the participant will undergo standard of care for Gestational Diabetes.
89555210|NCT02377531|Other|Standard glucose screen group|The participants in this group will be randomized to undergo the testing process previously described at 24 to 28 weeks.
89555211|NCT03101189|Experimental|ACT-541468 (25 mg)|8 Japanese and 8 Caucasian subjects will receive 25 mg (1 capsule) of ACT-541468 once daily for 5 days
88962782|NCT02017067|Experimental|hydraulic resistance circuit training|12 weeks resistance training
88962783|NCT02017080||Hyperthyroid pregnant women|Autoimmune hyperthyroidism diagnosed and treated by an endocrinologist, based on clinical and laboratory tests and ultrasound clinical examination
88962784|NCT02017080||Hypothyroid pregnant women|Autoimmune hypothyroidism diagnosed and treated by an endocrinologist, based on clinical and laboratory tests and ultrasound thyroid examination
88962785|NCT02017080||Healthy pregnant women|Euthyroid women with uncomplicated pregnancies, with antithyroid antibodies within reference ranges
88962786|NCT02017106|Experimental|Concomitant phlebectomies|Removal of varicose tributaries during Endovenous laser ablation
88962787|NCT02017106|Active Comparator|Sequential Phlebectomies|Endovenous laser ablation only
88962788|NCT02017119|Experimental|Lactulose|Lactulose 15ml oral intake 8hrs daily for 6 months. The dose may be modified depending on the number of total bowel movements, (the expected range is 2 - 4 per day).
88962789|NCT02017119|Experimental|Lactulose-paraffin|Paraffin 15g daily for 6 months. The dose may be modified depending on the number of total bowel movements, (the expected range is 2 - 4 per day).
88962790|NCT02017132|Active Comparator|Pomegranate extract|1.1g pomegranate extract capsule administered daily to each participant for 8 weeks
88962791|NCT02017132|Placebo Comparator|Placebo capsule|1.1g placebo capsule taken daily by each participant for 8 weeks
88962792|NCT02017145|No Intervention|no reapplication|This group will not have chloraprep reapplied after their surgery and prior to dressing application.
88962793|NCT02017145|Experimental|reapplication|This group will have chloraprep reapplied following their lower extremity surgical procedure and prior to dressing application.
88962794|NCT02017158|Experimental|Virtual Sprouts|The Virtual Sprouts intervention arm will play Virtual Sprouts in a school-based implementation of the game.
88962795|NCT02017158|No Intervention|Control group|The control group will consist of students who will not play the Virtual Sprouts game at school.
88962796|NCT02017184|Experimental|Research arm|This trial contains one group which will undergo the described protocol while connected to both sensors: a rectal thermistor and a non invasive thermistor.
88962797|NCT02017197|Other|Sequence A|"Phase 1 (run-in): Marevan®~Phase 2: Marevan®~Phase 3: generic warfarin #1~Phase 4: generic warfarin #2"
88962798|NCT02017197|Other|Sequence B|"Phase 1 (run-in): generic warfarin #1~Phase 2: generic warfarin #1~Phase 3: Marevan®~Phase 4: generic warfarin #2"
89208213|NCT00976287|Active Comparator|Conserved Therapy|Conserved Therapy
89555212|NCT03101189|Experimental|ACT-541468 (50 mg)|8 Japanese and 8 Caucasian subjects will receive 50 mg (2 capsules) of ACT-541468 once daily for 5 days
88962799|NCT02017197|Other|Sequence C|"Phase 1 (run-in): generic warfarin #1~Phase 2: generic warfarin #1~Phase 3: generic warfarin #2~Phase 4: Marevan®"
88962800|NCT02017197|Other|Sequence D|"Phase 1 (run-in): Marevan®~Phase 2: Marevan®~Phase 3: generic warfarin #2~Phase 4: generic warfarin #1"
89555213|NCT03101189|Placebo Comparator|Placebo|2 Japanese / 2 Caucasian subjects will receive 1 placebo capsule to match subjects in the ACT-541468 (25 mg) group and 2 other Japanese / 2 Caucasian subjects will receive 2 placebo capsules to match subjects in the ACT-541468 (50 mg) group
89555214|NCT02377687||elderly >75 years|all patients aged ≥ 75 having an emergency GI laparotomy or laparoscopy
89555215|NCT02369965|Experimental|albuvirtide, lopinavir-ritonavir|albuvirtide once a week and lopinavir-ritonavir twice daily for 48 weeks
89555216|NCT02369965|Active Comparator|lopinavir-ritonavir,tenofovir,lamivudine|lopinavir-ritonavir twice daily, tenofovir once daily and lamivudine once daily for 48 weeks
88962801|NCT02017197|Other|Sequence E|"Phase 1 (run-in): generic warfarin #2~Phase 2: generic warfarin #2~Phase 3: Marevan®~Phase 4: generic warfarin #1"
88962802|NCT02017197|Other|Sequence F|"Phase 1 (run-in): generic warfarin #2~Phase 2: generic warfarin #2~Phase 3: generic warfarin #1~Phase 4: Marevan®"
88962803|NCT02017236|Experimental|Volitinib ,after high fat meal intake|A:single oral Volitinib after high fat meal intake
88962804|NCT02017236|Experimental|Volitinib,after general diet|B:single oral Volitinib, after general diet
88962805|NCT02017249|Experimental|Arginine|24.15g of arginine supplement in powder form will be administered orally 3 times per day for 7 days before surgery and 7 days after surgery.
88962806|NCT02017249|Placebo Comparator|Silica and cellulose placebo powder|3.5 teaspoons of placebo powder will be mixed with a sweet beverage and given orally 3 times per day for 7 days prior to surgery and 7 days after surgery.
88962807|NCT02017262|Experimental|Self-management group|8 weekly sessions of group self-management
88962808|NCT02017262|Active Comparator|Enhanced usual care|Usual care by primary care provider, plus educational pamphlet about depression, list of local mental health resources, and letter for provider advising him/her of depression diagnosis
88962809|NCT02017275|Experimental|BuMA group|Implant BuMA stent only
88962810|NCT02017275|Active Comparator|EXCEL group|Implant EXCEL stent
88962811|NCT02017288||Cancer|Participants diagnosed with incident oral cancer
88962812|NCT02017288||Control|Participants without oral lesions or cancers matched to oral cancer/precursor participants on age, gender, smoking/betel nut habits
88962813|NCT02017288||Precursor|Participants clinically diagnosed with oral lesions
88962814|NCT02017314|Active Comparator|Group 5|Patients with BMI > 50
88962815|NCT02017314|Active Comparator|Group IV|Patients with BMI between 40 and 49.9
88962816|NCT02017314|Active Comparator|Group III|Patients with BMI between 35 and 39.9
88962817|NCT02017314|Active Comparator|Group II|patients with BMI between 30 and 34.9
88962818|NCT02017314|Active Comparator|Group I|Patients with BMI <30
88962819|NCT02017340|Placebo Comparator|Placebo|250 patients will receive the placebo
88962820|NCT02017340|Active Comparator|Nilvadipine|250 patient will receive the active drug Nilvadipine 8mg
88962821|NCT02017353|Experimental|Curcuphyt|Intake of Curcuphyt capsules, 2 g per day during 2 weeks
88962822|NCT02017392|Experimental|Compound Lidocaine Cream|The cuff of endotracheal tube is covered by 1-2g compound lidocaine cream before the general anesthesia.
88962823|NCT02017392|No Intervention|blank control|No intervention.
88962824|NCT02017405|Other|5g Serum-derived bovine immunoglobulin protein isolate (SBI)|"Phase 1: Twelve subjects will receive either a 5.0 g total daily dose of SBI on Day 1 followed by 5.0 g Placebo on Day 2 or a 5.0 g total daily dose of Placebo on Day 1 followed by 5.0 g SBI on Day 2 during the double-blind, crossover phase.~Phase 2: 2.5g SBI will be taken two times a day for 14 days during the open-label phase."
88962825|NCT02017405|Other|10g Serum-derived bovine immunoglobulin protein isolate (SBI)|"Phase 1: Twelve subjects will receive either a 10.0 g total daily dose of SBI on Day 1 followed by 10.0 g Placebo on Day 2 or a 10.0 g total daily dose of Placebo on Day 1 followed by 10.0 g SBI on Day 2 during the double-blind, crossover phase.~Phase 2: 5.0 g SBI will taken two times a day for 14 days during the open-label phase."
89555217|NCT02377453||Control|Control: Healthy adult
89555218|NCT02377453||Experimental|Experimental: patients with stroke
89555219|NCT02369809|Experimental|Neovasculgen®|Single group prospective treatment
88962826|NCT02017405|Other|20g Serum-derived bovine immunoglobulin protein isolate (SBI)|"Phase 1: Twelve subjects will receive either a 20.0 g total daily dose of SBI on Day 1 followed by 20.0 g Placebo on Day 2 or a 20.0 g total daily dose of Placebo on Day 1 followed by 20.0 g SBI on Day 2 during the double-blind, crossover phase.~Phase 2: 20.0 g SBI will be taken two times a day for 14 days during the open-label phase."
89555220|NCT02369809|Active Comparator|standard care|
89555221|NCT02375659||Focus group|Each focus group (4 total) will be approximately 90 minutes in duration. A trained facilitator will pose 8 scripted questions to the focus group participants and manage the conversation, ensuring all participants have an opportunity to respond and steering the conversation to remain on task. A note-taker will also be present at the focus group to document via handwritten notes the flow and content of the focus group conversation. All focus groups will be audio taped and transcribed.
89555222|NCT02640755|Experimental|[14C]AZD2014 followed by AZD2014 Monotherapy|Arm will be comprised of [14C]AZD2014 followed by AZD2014 Monotherapy
89555223|NCT02640755|Experimental|[14C]AZD2014 followed by AZD2014 + Fulvestrant|Arm will be comprised of [14C]AZD2014 followed by AZD2014 + Fulvestrant
89555224|NCT02640755|Experimental|[14C]AZD2014 followed by AZD2014 + Paclitaxel|Arm will be comprised of [14C]AZD2014 followed by AZD2014 + Paclitaxel
89555225|NCT02375425||No contraceptive use|BV-/HSV- BV-/HSV+ BV+/HSV- BV+/HSV+
89555226|NCT02375425||levonorgestrel IUD|BV-/HSV- BV-/HSV+ BV+/HSV- BV+/HSV+
89555227|NCT02375425||paraguard IUD|BV-/HSV- BV-/HSV+ BV+/HSV- BV+/HSV+
89555228|NCT02375425||DMPA|BV-/HSV- BV-/HSV+ BV+/HSV- BV+/HSV+
89555229|NCT04400539|Experimental|Malignant Pleural Mesothelioma patients|
88962827|NCT02017405|Other|Matching Placebo|Placebo will be taken either on Day 1 or on Day 2 based on the randomization during the double-blind, crossover phase.
88962828|NCT02017418|Experimental|zeaxanthin|placebo zeaxanthin
88962829|NCT02017418|Active Comparator|combinatory supplement|placebo combinatory supplement
88962830|NCT02017431|Active Comparator|Filtered air|Exposure for 2 hours to filtered air followed by subject specific inhaled allergen challenge
88962831|NCT02017431|Experimental|Diesel exhaust|Exposure for 2 hours to diesel exhaust followed by subject specific inhaled allergen challenge
88962832|NCT02017431|Active Comparator|Filtered air control|Exposure for 2 hours to filtered air followed by inhaled saline challenge
88962833|NCT02017431|Experimental|Particle depleted diesel exhaust|Exposure for 2 hours to particle depletion diesel exhaust followed by inhaled allergen challenge
88962834|NCT02017457|Experimental|Azacytidine + Donor lymphocyte infusion|"Azacytidine will be administered subcutaneously for 5 days. During the first cycle, a dose of 100mg/m2/day will be used and for the following cycles a dose of 35mg/m2/day will be administered. Each cycle will consist in 28 days. All patients will receive at least 6 cycles of Azacytidine and the total number of cycles will depend on the response to treatment.~Donor lymphocyte infusion will be performed on day 1 of cycle 2, 4 and 6 of Azacytidine. The amount of cells infused will depend on donor origin."
88962835|NCT02017470|Experimental|Gender-tailored women's heart health outpatient programme|The programme consists of general cardiologist, advanced practice nurse, dietician, physiotherapist and occupational therapist. The participant will be asked to participate in one-on-one interviewing, focus group discussions, and the forthcoming health promotion strategies that are developed based on the data collected
88962836|NCT02017470|No Intervention|Conventional general cardiology outpatient programme|
89555230|NCT02369497||Primary cohort|Primary cohort of subjects who receive the HRA device.
89555231|NCT03099785|Active Comparator|Treatment group 1: dose regimen 1|Rifamycin SV-MMX® 600 mg modified release tablets, three times daily (t.i.d.)
89555232|NCT03099785|Active Comparator|Treatment group 2: dose regimen 2|Rifamycin SV-MMX® 600 mg modified release tablets, two times daily (b.i.d.) + matching placebo daily (q.d.)
89555233|NCT03099785|Placebo Comparator|Treatment group 3: matching placebo|Rifamycin SV-MMX® matching placebo tablets, t.i.d.
89555234|NCT02389075||Ankylosing Spondylitis|Subjects with a diagnosis of ankylosing spondylitis undergoing routine colonoscopy or willing to undergo a flexible sigmoidoscopy for research purposes only. They will be asked to fill out questionnaires, give blood, perform a rectal swab, and have pinch biopsies taken during endoscopy.
89555235|NCT02389075||Inflammatory Bowel Disease|Subjects with a diagnosis of inflammatory bowel disease undergoing routine colonoscopy. They will be asked to fill out questionnaires, give blood, perform a rectal swab, and have pinch biopsies taken during endoscopy.
89555236|NCT02389075||Healthy Controls|Subjects without any major autoimmune diseases or pathologies undergoing routine colonoscopy. They will be asked to fill out questionnaires, give blood, perform a rectal swab, and have pinch biopsies taken during endoscopy.
89555237|NCT02375503|Experimental|Calcium/Vitamin D|Dietary supplement distributed and consumed as one calcium and vitamin D fortified snack bar per day
89555238|NCT02375503|Placebo Comparator|Placebo|Placebo distributed and consumed as one isocaloric, unfortified snack bar per day
89555239|NCT02375269|Experimental|RIPC (Remote Ischemic Preconditioning)|Preoperatively in the operation theater a tourniquet will be applied to the left arm and RIPC will performed. Therefore the tourniquet will be insufflated to suprasystolic pressure levels for 5 minutes, followed by 5 minutes reperfusion (deflated). Three cycles are planned. Duration of the procedure is 30 minutes.
89555240|NCT02375269|No Intervention|Control|Preoperatively in the operation theater a tourniquet will be applied to the left arm. The tourniquet will not be insufflated. The tourniquet will be removed after 30 minutes.
89208214|NCT00976287|Experimental|Interventional Therapy|Patients with liver cirrhosis were randomly separated into two groups. Autologous MSCs were infused to patients using interventional method via hepatic artery for One group. The catheter was inserted to proper hepatic artery. After the catheter placed at proper hepatic artery was confirmed by angiography, autologous bone marrow MSCs were infused slowly for 20-30 minutes. The control group accepted conserved therapy.
89555241|NCT00867191|Placebo Comparator|1|Placebo, 1 tablet daily, per os
89555242|NCT00867191|Active Comparator|2|Desloratadine, one 5 mg tablet daily, per os
89555243|NCT02640677||Pregnant women exposed to 4CMenB|Pregnant women within the United States (U.S) who received at least 1 dose of 4CMenB vaccine within 30 days prior to Last Menstrual Period (LMP) or at any time during pregnancy
89555244|NCT05067023|Experimental|MRI scan|All participants will undergo 1 DCE-MRI scan before surgery or puncture.
89555245|NCT00834119|Experimental|Mometasone furoate|
89555246|NCT00834119|Experimental|Mometasone furoate plus an oral antihistamine|
89555247|NCT02643251|Experimental|Clonidine Hydrochloride Topical Gel,0.1%|Clonidine Hydrochloride Topical Gel,0.1%
89555248|NCT02643251|Placebo Comparator|Clonidine Hydrochloride Gel Comparator|Clonidine Hydrochloride Gel Comparator
89555249|NCT02375191|Active Comparator|fentanyl|0.2% ropivacaine+ 1 mcg/kg fentanyl
89208215|NCT00976365|Experimental|THL-P|Solution for study only.
89555250|NCT02375191|Experimental|dexmedetomidine|0.2% ropivacaine+1 mcg/kg dexmedetomidine
89555251|NCT03100877|Experimental|Treatment (mel/TMI, ASCT)|"MOBILIZATION AND APHERESIS: Patients receive cyclophosphamide IV over 2 hours. Beginning 24 hours after cyclophosphamide administration, patients receive filgrastim SC or IV. Patients also undergo apheresis over 4 hours on day 10.~CONDITIONING REGIMEN: Patients receive palifermin IV on days -8, to -6, undergo TMI on days -5 to -2, and receive melphalan IV over 30 minutes on day -1. Patients then undergo ASCT IV on day 0, receive palifermin IV on days 1-3, and receive filgrastim SC or IV on day 5.~MAINTENANCE THERAPY: Beginning 30 days after ASCT, patients receive lenalidomide PO daily."
89555252|NCT02374879|Experimental|Blood Glucose monitoring System (BGMS)|Intervention: Blood Glucose monitoring System (BGMS) Results obtained from the BGMS for UP and SA are compared to a reference instrument (YSI)
89555253|NCT02369419||CRT|Patients over 70 years age, selected for CRT according to the ESC 2013 guidelines.
89555254|NCT03099551|Active Comparator|Manual Toothbrush users|Group using manual toothbrush Curaprox 5460 Ultra Soft
89555255|NCT03099551|Active Comparator|Sonic Toothbrush users|Group using sonic toothbrush Edel White
88962837|NCT02017509||Rectal Cancer Patients|Patients with a diagnosis adenocarcinoma of the rectum will provide a tumor sample from their diagnostic biopsy and surgical procedure for research purposes, including RNA gene expression analysis. In addition to a standard MRI, patients will have an Intravoxel Incoherent Motion MRI (IVIM) and a Dynamic Contrast Enhanced MRI (DCE-MRI) for research purposes.
88962838|NCT02017548|Experimental|Life-extension default|Subjects in this group will receive an advance directive form that defaults to an overall goal of care directed towards life extension (vs. comfort oriented care) unless the subject specifies otherwise. The form also states 4 specific life extending interventions (cardiopulmonary resuscitation, mechanical ventilation, hemodialysis, and feeding tube insertion) will be provided unless patients specifically opt-out from such selections. It also will state that upon discharge from the hospital, long-term care (vs. hospice care) will be provided unless the patient chooses otherwise.
89025807|NCT04328896|Experimental|Intervention|Tele-CGM-monitoring: Subjects are remotely monitored daily through a continuous glucose monitoring (CGM) system (Dexcom G5/6) that communicates via smart phone to a Tidepool designed dashboard. Alerts set for: ≥4 hours without CGM signal, ≥2 hours 54-70 mg/dl, and 15 minutes <54 mg/dl. Tidepool dashboard automatically emails daily alerts to the Certified Diabetes Educator (CDE). If alerts occurred, the CDE performed telemedicine outreach based on type of alert.
89555256|NCT03099473|Experimental|ocular electroacupuncture|Patients will receive electroacupuncture for 40 mins with certain parameter at ocular area, once daily, 5 times a week and 6 weeks in all. The acupoints are selected based on the anatomy of extraocular muscles innervated by trochlear nerve.
89555257|NCT03099473|Experimental|ocular acupuncture|Patients will receive acupuncture for 40 mins at ocular area, once daily, 5 times a week and 6 weeks in all. The acupoints are selected based on the anatomy of extraocular muscles innervated by trochlear nerve.
89555258|NCT03099473|Sham Comparator|sham acupuncture|Patients will receive sham acupuncture for 40 mins at ocular area, once daily, 5 times a week and 6 weeks in all. The acupoints are selected based on the anatomy of extraocular muscles innervated by trochlear nerve. When the care provider performed operating acupuncture, the needles of sham acupuncture set will not be inserted into the skin of patient.
89555259|NCT02369107|Experimental|Verum acupuncture and medicine|Participants will receive acupuncture therapy 1 hour prior to chemotherapy administration ，6 hours after chemotherapy administration，and once acupuncture therapy on the following day2,3,4,5. The stimulation points are RN12,LR13(bilaterally), RN6, ST25(bilaterally), PC6(bilaterally), ST36(bilaterally). The acupuncture needle in ST36 and auxiliary point will be connected to form a circuit containing a SDZ-V stimulator for 30 min with a frequency of 2/100 Hz.They will receive 8mg Ondansetron Intravenously twice a day during the chemotherapy administration period (5 days in total).
89555260|NCT02369107|Sham Comparator|Sham acupuncture and medicine|Participants will receive minimal acupuncture therapy at the same time as the intervention group .The stimulation points are not belong to traditional Chinese medicine.They will receive 8mg Ondansetron Intravenously twice a day during the chemotherapy administration period (5 days in total).
89555261|NCT00794495|Experimental|Clarinex followed by Zyrtec|Clarinex 5 mg by mouth daily for 7 days followed by Zyrtec 10 mg by mouth daily for 7 days, with 5-28 days washout between treatments.
89555262|NCT00794495|Experimental|Zyrtec followed by Clarinex|Zyrtec 10 mg by mouth daily for 7 days followed by Clarinex 5 mg by mouth daily for 7 days, with 5-28 days washout between treatments.
89555263|NCT02369029|Experimental|Arm 1|To determine maximum tolerated dose (MTD) of BAY 1238097
89555264|NCT03099317|Experimental|Sinew acupuncture|Subject in the arm will receive real acupuncture intervention.
89555265|NCT03099317|Sham Comparator|Sham acupuncture|Subject in the arm will receive sham acupuncture intervention.
89555266|NCT03105973|Experimental|Open-Label Trial Arm|Will receive 4 weeks of technology-enabled CBT treatment.
89555267|NCT04157075|Placebo Comparator|No injection|No injection will be performed
89555268|NCT04157075|Sham Comparator|Normal Saline Injection|Normal saline will be injected into the uterosacral ligaments prior to colpotomy
89555269|NCT04157075|Active Comparator|Bupivacaine Injection|Bupivacaine will be injected into the uterosacral ligaments prior to colpotomy
89555270|NCT00763529|Experimental|Arm 1|
89555271|NCT00763529|Active Comparator|Arm 2|
89555272|NCT03105505|Active Comparator|Permethrin 5%|Contains permethrin 5% w/w (equivalent to 50 mg/g), formaldehyde solution 0.278% w/w and butylated hydroxytoluene (E321) 0.02% w/w.
88962839|NCT02017548|Experimental|Comfort default|Subjects in this group will receive an advance directive form that defaults to an overall goal of care directed towards comfort and relief of pain and suffering (vs. life extension) unless the subject specifies otherwise. The form also states 4 specific life extending interventions (cardiopulmonary resuscitation, mechanical ventilation, hemodialysis, and feeding tube insertion) will be not provided unless patients specifically opts into such selections. It also will state that upon discharge from the hospital, hospice care (vs. long-term care) will be provided unless the patient chooses otherwise.
88962840|NCT02017548|No Intervention|Standard advance directive|Subjects in the standard advance directive (AD) group will receive an AD that will have no options pre-selected.
88962841|NCT02017561|Active Comparator|Lifestyle Counseling|Written and individualized information during the interview in all clinic visits, emphasizing the importance of regular moderate-intensity physical activity and healthy diet.
88962842|NCT02017561|Experimental|Metformin + Lifestyle Counseling|Metformin: maximum dose of 1000mg twice daily. Lifestyle counseling: Written and individualized information during the interview in all clinic visits, emphasizing the importance of regular moderate-intensity physical activity and healthy diet.
89208216|NCT00976365|Placebo Comparator|Sugar pill|THL-p
89555273|NCT03105505|Active Comparator|Synthomycine 5%,|Contains chloramphenicol 5%.
89555274|NCT03105505|Active Comparator|Fusidic Acid 1%|Contains 1% w/w fusidic acid anhydrous (as the hemihydrates) and 0.011% w/w.
89555275|NCT03105193|Experimental|Intraperitoneal Lignocaine|IP Lignocaine
89555276|NCT03105193|Experimental|Intravenous lignocaine|IV lignocaine
89555277|NCT05066633|Placebo Comparator|Control Group|Matching placebo will be supplied by the sponsor in child-proof bottles containing dividable tablets with the following dosage of 25mg of IMP and 100mg of IMP. The drug will be administered orally at singular daily doses ranging from 0.75 to 4.5 mg/kg over a Double-Blind Treatment Period (DBTP) of up to 60 months or less dependently on the time of enrolment. The Treatment Period will begin with up to 12-weeks long Up-titration Phase, during which the dose will be gradually escalated. If patient presents with signs and symptoms of intolerance the dose may be temporarily or permanently downgraded at the discretion of the clinician. The up titration ends with reaching maximal tolerated dose level or at a dose corresponding to 4.5 mg/kg.
89555278|NCT05066633|Experimental|Treatment Group|Metoprolol succinate will be supplied by the sponsor in child-proof bottles containing dividable tablets with the following dosage of 25mg of IMP and 100mg of IMP. The drug will be administered orally at singular daily doses ranging from 0.75 to 4.5 mg/kg over a Double-Blind Treatment Period (DBTP) of up to 60 months or less dependently on the time of enrolment. The Treatment Period will begin with up to 12-weeks long Up-titration Phase, during which the dose will be gradually escalated. If patient presents with signs and symptoms of intolerance the dose may be temporarily or permanently downgraded at the discretion of the clinician. The up titration ends with reaching maximal tolerated dose level or at a dose corresponding to 4.5 mg/kg.
89555279|NCT02365129|No Intervention|Usual care group (control)|Participants randomly assigned to the usual care (control) group will receive general advices from the exercise-training specialist about the positive effects of physical activity at the start of the study. The investigators will prepare informative pamphlets describing the benefits of physical activity that the investigators group has prepared for the Region of Andalucía (Southern Spain),http://www.juntadeandalucia.es/salud/servicios/contenidos/andaluciaessalud/docs/130/Guia_Recomendaciones_AF.pdf.
89555280|NCT02365129|Experimental|Moderate-intensity group|Exercise training based on recommendations for adults (WHO)
89555281|NCT02365129|Experimental|Vigorous-intensity group|Exercise training based on recommendations for adults (WHO)
88962843|NCT02017587||Chronic HBV|chronic HBV strata: HBV tolerant, Chronic active HBe+ or HBe-, suppressed with antiviral therapy
88962844|NCT02017600|Experimental|Induction Chemotherapy DCF followed by Surgery|All eligible patients will receive ND-420, Cisplatin and fluorouracil every 3 weeks for 2 cycles. After induction chemotherapy, patients will be planned to receive Surgery.
88962845|NCT02017613|Experimental|Single arm|RP6530 administered orally
88962846|NCT02017626|Experimental|group 1|5 patients will receive 10 single rising doses of mCyp c 1 (modified allergen)from 0.6 ng to 6 ug and two maintenance doses, and 2 patients will receive placebo
88962847|NCT02017626|Experimental|Group 2|6 patients will receive 10 single rising doses of mCyp c 1 from 6 ng to 60 ug and two maintenance doses, and two patients will receive placebo.
88962848|NCT02017639|Experimental|Sarilumab SAR153191 (REGN88)|Single dose of simvastatin before and after sarilumab administration
88962849|NCT02017652||Preterm Infants|Preterm infants 32 to 36 weeks will be eligible for this study
88962850|NCT02017678|Experimental|JX-594 IV Infusion|Patients with peritoneal carcinomatosis of ovarian origin that are not eligible for curative treatments will receive 5 weekly IV infusions of JX-594
89555282|NCT03100799|Other|Patients with osteoarthritis of the knee|This is an exploratory non-drug, interventional biomarker study, however, there are study related procedures which are interventional such as arthroscopy, arthrocentesis and MRI assessment with infusion of a gadolinium-contrast agent.
88962851|NCT02017691|Experimental|Near Infrared Spectroscopy|crSO2 measurements in addition SpO2 measurements will be visible to guide supplemental oxygen support and respiratory support according predefined interventions depending on the infants breathing efforts and the heart rate during the first 15 minutes after birth
89555283|NCT04439305|Experimental|Treatment (dasatinib)|Patients receive dasatinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89555284|NCT02368951|Experimental|BAY1187982|"Dose-escalation phase:~Approximately 30 subjects will participate in the dose-escalation phase The total number of subjects will depend on the number of cohorts necessary to identify the MTD.~MTD expansion phase:~Once the MTD has been determined, two expansion cohorts in FGFR2 expressing indications are planned:~Cohort 1: Triple negative breast cancer (TNBC). This cohort will enroll 80 subjects (N=40 with low to moderate FGFR2 expression and N=40 with high FGFR2 expression) Cohort 2: Other indications expressing FGFR2. This cohort 40 subjects will be enrolled."
89555285|NCT02364973||PET-MRI|Patients with chronic inflammatory bowel disease who are treated at Turku University hospital outpatient clinic or ward
89555286|NCT03100721|Experimental|PNE+Physiotherapy|Pain neuroscience education (PNE) can be defined as an educational session or sessions describing the neurobiology and neurophysiology of pain, and pain processing by the nervous system. It will be applied one time (at baseline). Physiotherapy includes kinesitherapy and exercises.
89555287|NCT03100721|Active Comparator|Physiotherapy|Physiotherapy includes kinesitherapy and exercises.
89555288|NCT02368873|Active Comparator|Intervention group|Patients with IPOM Dynamesh mesh around the straight permanent colostomy.
89555289|NCT02368873|No Intervention|Control group|Patients with the straight permanent colostomy without a mesh.
89555290|NCT02368795|Placebo Comparator|Pharmacological Prevention|Combination of rectal indomethacin, sublingual isosorbide dinitrate and intravenous hydration with Ringer's lactate serum without pancreatic stenting
89555291|NCT02368795|Active Comparator|Pancreatic Stent|Pancreatic Stent PLUS Pharmacological Prevention
89555292|NCT05066243||focus group|15 service users for focus group
89555293|NCT05066243||questionnaire|150 patients to test questionnaire
89555294|NCT00650663|Experimental|Ezetimibe + Simvastatin|
89555295|NCT00650663|Active Comparator|Simvastatin|
89555296|NCT02374723|Experimental|NuCornea (Biosynthetic corneas)|6 patients will receive biosynthetic corneas when undergoing corneal transplantation
89555297|NCT02374723|Active Comparator|Donated human corneas|6 patients will receive a donated human cornea when undergoing corneal transplantation
89555298|NCT02368717|Experimental|Mesalazine|Mesalazine Enema
89555299|NCT02368717|Placebo Comparator|Placebo|Placebo Enema
89555300|NCT02364817||Post-Detox Cohort|"All the patients included should meet Diagnostic and Statistical Manual 4th edition revised (DSM-IV-Tr) criteria for Alcohol Dependance. They are all recruited at the end of an inpatient alcohol detoxification process (see inclusion criteria).~The initial screening is performed just before the end of hospitalization. The subsequent follow-up is 12 weeks-long. There is no drug for abstinence maintenance during the study. The psychosocial intervention is based on the BRENDA model."
89555301|NCT05065931||Before|before CDSS on-line
88962852|NCT02017691|Other|Pulse-oximetry|Only SpO2 measurements will be visible to guide supplemental oxygen support and respiratory support according predefined interventions depending on the infants breathing efforts and the heart rate during the first 15 minutes after birth
89555302|NCT05065931||After|after CDSS on-line
89555303|NCT02374801|Experimental|Treatment|"This is a single-arm trial. All patients will be implanted with the PARADYM RF SONR CRT-D device and the SonRtip bipolar atrial lead. After successful implant, all patients will be programmed with the SonR automatic optimization feature turned ON (AV+VV)."
89555304|NCT02375113|Experimental|Intervention|Soy supplementation: Isoflavones 160 mg/day + 25 gram soy protein / day
89555305|NCT02375113|Placebo Comparator|Control|Placebo capsules + 25 gram whey protein / day
89555306|NCT02364895|Experimental|Male arm|Males control group: Deferred letter Males Group 1: Current CCC invitation letter Males Group 2: New letter with neutral gender content Males Group 3: New letter with male-specific content
89555307|NCT02364895|Experimental|Female arm|Females control group: Deferred letter Females Group 1: Current CCC invitation letter Females Group 2: New letter with neutral gender content
89555308|NCT03100565|Placebo Comparator|colposcopic biopsy under local anesthetic sp|
89555309|NCT03100565|Placebo Comparator|Patients underwent colposcopic biopsy under forced coughing|
89555310|NCT05064995||Patients|Patients with the Diagnosis of a Bipolar Disorder
89555311|NCT05064995||Healthy Controls|Individuals with no diagnosis of Bipolar Disorder
88962853|NCT02017730|Experimental|Part 1: [11C]BMT-136088 (Safety Study)|Single PET SCAN with single bolus injection of [11C]BMT-136088
89555312|NCT03099395||No re-MI, one re-MI, > one re-MI|From a population with MI surviving one year (78 468 pts) the number of pts with no re-MI, one re-MI or > re-MI will be described.
89555313|NCT03113149||knee osteoarthritis|Patients with knee osteoarthritis after having started physical therapy
89555314|NCT03113227|Active Comparator|Successful Induction of labor group|Both transvaginal ultrasound and vaginal examination will be done for that group
89555315|NCT03113227|Active Comparator|Failed induction of labor group|Both transvaginal ultrasound and vaginal examination will be done for that group
89555316|NCT05035277|Active Comparator|Acetylsalicylic acid|Patients in the active control arm will receive 75 mg acetylsalicylic acid once daily indefinitely.
89555317|NCT05035277|Experimental|Direct oral anticoagulation (DOAC)|Patients in the experimental arm will receive an anti Xa-type DOAC (apixaban, rivaroxaban or edoxaban) in approved therapeutic dose for 12 months. The choice of DOAC agent will be made by the treating clinician after discussion with the patient. After 12 months, these patients will abort DOAC therapy. Acetylsalicylic acid, 75 mg once daily will be started after DOAC discontinuation and continued indefinitely.
89555318|NCT02374645|Experimental|Volitinib (AZD6094) 600mg + gefitinib 250 mg|Cohort 1: Volitinib（AZD6094） 600 mg od + gefitinib 250 mg od
89555319|NCT02374645|Experimental|Volitinib (AZD6094) 800mg + gefitinib 250 mg|Cohort 2: Volitinib（AZD6094） 800 mg od + gefitinib 250 mg od
89555320|NCT02368483|Experimental|Neuromuscular training|
89555321|NCT02368327|Active Comparator|Fluad|Participants receive one dose of Fluad vaccine
89555322|NCT02368327|Active Comparator|Fendrix|Participants receive one dose of Fendrix vaccine
89555323|NCT02368327|Placebo Comparator|Placebo|Participants receive one dose of saline placebo
89555324|NCT02368561|Experimental|Hyaluronic Acid Injection|Hyaluronic Acid Injection in 20 adult patients with IAT
89555325|NCT04095845|Active Comparator|CO THA|Computerised tomography based planning of conventional total hip arthroplasty
89555326|NCT04095845|Experimental|Mako THA|Mako robotic-arm assisted total hip arthroplasty
89555327|NCT02368639|Experimental|Positive airway pressure (PAP) device|Fisher & Paykel Healthcare PAP Device. Participants will sleep overnight using themodified positive airway pressure device. Their pressures will be titrated by a qualified sleep technician, they will then be optimised during the night.
89555328|NCT02374489|Experimental|single-arm studies|"LDK378 in suitable patients:~Collect tumor tissue for immunohistochemistry staining to confirm the status of ROS1 or ALK expression. If the patient fits all criteria, LDK378 750 mg ( p.o.) daily, with 3 week as a treatment cycle"
89555329|NCT02374567|Experimental|Psychiatric drugs|
88962854|NCT02017730|Experimental|Part 2: [11C]BMT-136088 (Test/Retest study)|Single PET SCAN with Intravenous (IV) bolus plus infusion of [11C]BMT-136088 followed by a re-test PET scan (approximately 6 hours apart) with IV bolus plus infusion of [11C]BMT-136088
88962855|NCT02017730|Experimental|Part 3: BMS-986020+[11C]BMT-136088 (Receptor Occupancy study)|BMS-986020 Tablets or Oral Solution of 4 dose levels from from the 6 dose levels of (50 mg, 150 mg, 300 mg, 600 mg, 1200 mg and 1500 mg) and 3 PET SCANS (Pre-Dose, Post-Dose1, Post-Dose2) with bolus plus infusion of [11C]BMT-136088
89555330|NCT04981535|Experimental|Patients undergoing upper gastrointestinal endoscopy with head box|experimental group
89555331|NCT04981535|No Intervention|Patients undergoing upper gastrointestinal endoscopy without head box|standard of care group
89555332|NCT04434989|Experimental|Stereotactic Body Radiation Therapy|SBRT is defined as a special radiotherapy technique. The high dose of radiotherapy is accurately injected into the tumor lesion in one to several times using external irradiation technique. Then the tumor is exposed to high dose and the surrounding normal tissue to low dose.
89555333|NCT04434989|Active Comparator|Radiofrequency Ablation|Percutaneous radiofrequency ablation to the tumor
89555334|NCT05064215||injection behind NAC|in 7 breasts dye was injected behind the nipple areola complex before breast reduction
89555335|NCT05064215||Injection into lateral upper quadrant|in 5 breasts dye was injected into upper lateral glandular tissue before breast reduction
89555336|NCT05064215||injection into medial upper quadrant|in 2 breasts dye was injected into upper medial glandular tissue before breast reduction
89555337|NCT03965741||Men with Prostate Cancer (PCa)|
89555338|NCT03965741||Men without PCa|
89555339|NCT02364505|Experimental|Telemedicine mindfulness intervention|Participants are assigned to a telemedicine mindfulness intervention group. The protocol lasts 8 weeks and it is composed by one online course session each week and home exercises. The course sessions, with a synchronous communication, will be conducted by a trainer, through teleconferences, that will explain how to practice the exercises to develop mindfulness attitude, following the mindfulness-based intervention-multiple sclerosis protocol. Subjects will be able to take part of these sessions everywhere, through a computer, tablet o mobile. During these sessions, individuals will interact with the trainer with teleconference or textual communications.
89555340|NCT02364505|Active Comparator|Psycho-education control group|Psycho-education control group, provided with a telemedicine approach. Subject in this group will use a similar software than the experimental intervention, with identical time efforts required. Software contents will be psycho-educative.
89555341|NCT02368171||Obstructive sleep apnea with pulmonary hypertension|Patients with AHI> 5/h and pulmonary hypertension with RVSP>35 mmHg on Echo
89555342|NCT02368171||control|patients with AHI<5/h and RVSP<35 mmHg on Echo
89555343|NCT02368171||OSA with no Pulmonary hypertension|patients with AHI>5/h, but RVSP<35 mmHg on Echo
88962856|NCT02017730|Experimental|Part 4: [11C]BMT-136088 (Tissue Distribution study)|Single PET SCAN with [11C]BMT-136088 to evaluate additional tracer uptake sites in humans other than the lung, such as heart, kidney, liver, gallbladder, etc.
88962857|NCT02017769||CIDP - treated|Patients diagnosed with CIDP and fulfilling the criteria by EFNS and PNS and in maintenance treatment with subcutaneous immunoglobulin
88962858|NCT02017769||Healthy controls|Healthy, gender and age matched controls
88962859|NCT02017769||CIDP - untreated|Patients newly diagnosed with CIDP and untreated are treated with immunoglobulin and re-examined after 4 months of treatment
88962860|NCT02017782|Experimental|Dust, Ozone, Interaction Dust & Ozone|Dust (250-300µg/m3), Ozone (0,1ppm ozone),Dust+Ozone (250-300µg/m3 + 0,1 ppm ozone), Filtered air (<20µg/m3). with at least 2 weeks between each exposure session
88962861|NCT02017782|Active Comparator|Interaction Dust & Ozone and placebo Filtered air|Dust+Ozone (250-300µg/m3 + 0,1 ppm ozone), Filtered air (<20µg/m3) with at least 2 weeks between each exposure session.
88962862|NCT02017795|Experimental|SMS-Web eAAP group|electronic asthma action plan (eAAP) group
88962863|NCT02017795|Active Comparator|regular-care group|written asthma action plan (WAAP) group
88962864|NCT02017808||Copaxone|Patients with multiple sclerosis who are currently prescribed glatiramer acitate (Copaxone)
88962865|NCT02017808||OCT|Healthy controls
88962866|NCT02017821|Experimental|training group|high intensity aerobic training 3 weekly sessions for 8 weeks
88962867|NCT02017821|No Intervention|care as usual|
88962868|NCT02017834|Experimental|harmonic scalpel|
88962869|NCT02017834|Active Comparator|standard technique|
88962870|NCT02017847||Gen100|150 participants in the Generation 100 study with anticipated 3000 participants aged 70-75
89555344|NCT04412447|Experimental|Subjects|"Phase V1: 1 month of home-based FES-training using isometric contractions of quadriceps and hamstring muscles (3 times a week).~Phase V2: 2 months of home-based FES-training on an ergo-cycle with arm support (3 times a week)~Phase V3: 1 month of home-based FES-training on an ergo-cycle with arm support (1-2 times a week) and FES-cycling training overground on a tricycle (1-2 times a week) in the clinical setting.~Optional (only for selected pilot):~Phase V4: 2-4 months of home-based FES-training on an ergo-cycle with arm support (1-2 times a week) and FES-cycling training overground on a tricycle (1-2 times a week) in the clinical setting. This phase is focussing on optimizing the performance of the pilot and improving the mechanical efficiency of the tricycle.~Phase V5: Participation on Cybathlon 2020"
89555345|NCT02364739|Experimental|Written information|Written information
89555346|NCT02364739|Experimental|Written and oral information|Written and oral information
89555347|NCT02364739|No Intervention|No intervention|Control
89555348|NCT02374411||HIPEC surgeons|
89555349|NCT02374333|Experimental|huCART19|CART19 cells transduced with a lentiviral vector to express humanized anti-CD19 administered by IV injection
89555350|NCT05063669|Experimental|Cognitive Occupational Therapy|Occupational therapy applications were carried out 40 minutes, twice a week (one individual session and one group intervention session) and total of 8 weeks. In the sessions, activities aimed at reasoning and empathy skills, problem solving, evaluating emotional cues, evaluating events from different perspectives, providing personal control, delaying reactions, motor planning, visual perception and prolonging attention span were applied. The interventions were varied according to the personal characteristics of the individuals. In group interventions with three or four participants, group games in the form of cooperation or competition were planned to develop motor planning and cognitive strategy and it was aimed to improve children's rapid decision making and adaptation skills.
89208217|NCT02596529|Experimental|Fixation|Patients with a medium-sized posterior fragment which will be treated by open reduction and internal fixation of all fractured malleoli.
89208218|NCT02596529|Active Comparator|No fixation|Patients with a medium-sized posterior fragment which will be treated bij open reduction and internal fixation of lateral and medial malleolus alone. No fixation of the posterior malleolus take place.
89555351|NCT05063669|No Intervention|Control|No intervention was performed in this group.
88962871|NCT02017873|Active Comparator|healthy patients bleaching|Healthy patients Peroxide Carbamide 10% - Dental bleaching treatment
88962872|NCT02017873|Experimental|Smokers bleaching|smokers patients Peroxide Carbamide 10% - Dental bleaching treatment
88962873|NCT02017886|Active Comparator|L. reuteri DSM 17938/ATCC PTA|L. reuteri DSM 17938/ATCC PTA twice daily for three weeks.
89555352|NCT02364583|Active Comparator|14 day dose regimen|0.5 mg/kg oral Primaquine administered daily for 14 days
89555353|NCT02364583|Active Comparator|7 day dose regimen|1.0 mg/kg oral Primaquine administered daily for 7 days
89555354|NCT02364583|Active Comparator|3.5 day dose regimen|1.0 mg/kg oral Primaquine administered twice daily (bd) for 3.5 days
89555355|NCT05062967||HAOD Cohort|"This cohort includes patients with acute hepatitis of unknown origin, meaning its origin could not be determined after screening of (at least) HAV, HAB, HAC, HAE, Epstein-Barr virus and cytomegalovirus. Patients will be recruited in 17 centres nationwide.~The research group will receive a 1mL plasma / serum sample from each patient to study the presence of Ortho-C infection"
89555356|NCT05062967||OrthoC-Tx Cohort|This cohort includes liver or kidney transplant patients under follow-up. The research group will receive a 1mL plasma / serum sample every year from each patient to study the presence of Ortho-C infection
88962874|NCT02017886|Placebo Comparator|Placebo|Placebo tablet twice daily for three weeks
88962875|NCT02017925|Experimental|Arm I (early intervention)|Beginning within 2 weeks of starting chemoradiation, patients undergo an individualized rehabilitation program comprising aerobic exercise and strength training, including treadmill walking, stationary bicycle, NU-Step, upper body resistance training and breathing retraining, 3 times per week for 8 weeks (36 sessions).
88962876|NCT02017925|Experimental|Arm II (late intervention)|Beginning 1 month after completion of chemoradiation, patients undergo an individualized exercise rehabilitation program as in Arm I.
88962877|NCT02017938|No Intervention|Stage 1: Health group|To establish non-invasive fatigue monitoring method via testing healthy individuals.
89208219|NCT00663260|Active Comparator|Dapagliflozin (10 mg)|
89208220|NCT00663260|Active Comparator|Dapagliflozin (5 mg)|
89208221|NCT00663260|Placebo Comparator|Placebo|
89555357|NCT05062967||Ortho-CoRIS Cohort|"This cohort includes VIH positive patients who are in follow-up by the Spanish Network of AIDS Research.~The research group will receive a plasma / serum sample every year from each patient to study the presence of Ortho-C infection."
89555358|NCT05062967||TrazHE Cohort|"This cohort includes patients whose clinical picture is compatible with HAE infection.~The presence of Ortho-C infection will be studied in patients with positive IgM for HAE and absence of RNA-HAE."
89555359|NCT05062967||Ortho-C-Rodent Cohort|This cohort includes wild rats. Feces and liver samples will be taken in order to determine the prevalence of Ortho-C in wild rats (Ortho-C's main reservoir).
89555360|NCT05062967||Ortho-C-Domestic Rodent Cohort|This cohort includes domestic rats and mustelids. Feces and liver samples will be taken in order to determine the prevalence of Ortho-C in domestic rats and mustelids.
89555361|NCT05062967||Ortho-C-Carnivore Cohort|"This cohort includes 236 wild carnivores that feed off rodents. Carnivores' cause of death is they were run over.~Feces, liver and serum samples will be taken to study the transmission of Ortho-C."
89555362|NCT02374177||Propofol group|Patient anesthetized using propofol
89555363|NCT02374177||Sevoflurane group|Patients anesthetized using sevoflurane
89555364|NCT03100409|Experimental|Dietary modification|Personalized dietary intervention, low residue diet
89555365|NCT03100409|No Intervention|Control|Dietary recommendations currently used in the INCan
89555366|NCT02368015|Other|Patients with a large hepatic cyst|"During this study all subjects undergo aspiration sclerotherapy and receive antibiotic prophylaxis with a single dose of cefazolin (intravenous infusion 1000mg) following standard care.~In order to secure patient safety and allow accurate measurement of cefazolin concentrations, an additional peripheral intravenous cannula (IVC) will be placed to allow blood withdrawal at three timepoints."
89555367|NCT02364661|Experimental|Hepatitis B virus infected patients|HBV patients with detectable viremia will be analyzed for their level of viremia following an over-night starvation (fasting) versus fed state
89555368|NCT02364427||Arterial stiffness|Arterial stiffness - Vicorder to measure pulse wave velocity
89555369|NCT02373943|Experimental|β-carotene biofortified maize|Participants will ingest porridge bF: this will be the β-carotene fortified maize porridge where each 250 g will be made with 50 g of dry maize flour obtained from fortified corn seeds. The contents of β-carotene and other provitamin A carotenoids in this flour will be determined before preparing the porridges.
89555370|NCT02373943|Active Comparator|white maize supplemented with β-carotene|Participants will ingest porridge F: this will be also a β-carotene fortified maize porridge but in this case it will be made with 50 g of dry maize flour obtained from non fortified corn seeds and supplemented with a 500-1500 µg β-carotene reference dose. The exact dose of β-carotene that will be added to these porridges will be established according to the amount of β-carotene found in the flour used with porridges BF.
89555371|NCT02373943|Sham Comparator|white maize|Participants will ingest porridge N which will be the control porridge and will be made with 50 g of dry maize flour obtained from non fortified corn seeds.
89555372|NCT05062499|Active Comparator|Active TENS|electrical stimulation
89555373|NCT05062499|Sham Comparator|Sham TENS|no stimulation
89555374|NCT02364193|Experimental|Thoracic fluid status assessment|"Cardiac MRI by a 1.5 Tesla scanner:~Left ventricular ejection fraction (LVEF), tracing short axis endocardial borders.~CO, phase contrast angiography.~Fluid challenge by auto-transfusion by distal leg compression using inflatable cuffs (Lympamat Digital Gradient system).~DCE-MRI, bolus injection of Gd-CA intravenously by an injector. Each subject will receive repeated injections (10% of maximum dose).~BIS, impedance will be measured continuously using ImpediMed-SFB7 and surface electrodes on the thorax. ."
89555375|NCT03100175|Experimental|intervention|"the patient will be scheduled for another appointment and taught a set of exercises including strength training for upper and lower limbs (with elastic bands and weights, rising up from chair and climbing stairs), fitness work out (brisk walking) and balance exercises, as recommended by senior sport programs.~Patients will be provided with printed instructions explaining the recommended exercises, and with a diary to fill in, with days and number of repetitions of specific training elements to be checked in according to their compliance. Patients will also be equipped with a pedometer and will be asked to record the counts regularly~Patients will be met again by a physiotherapist for follow up at the start of every chemotherapy course (once in 3-4 weeks) and will be contacted by phone twice weekly to assure they stick to the training recommendations"
89555376|NCT03100175|No Intervention|control|The control group will receive standard treatment and follow-up with no special emphasis on physical activity
89555377|NCT03100097|Experimental|Intervention (Aspen Horizon 627 LSO)|Patients receive a lumbar brace, Aspen Horizon 627 LSO, in addition to normal medical management
89555378|NCT03100097|No Intervention|Medical Management|Normal medical management
89555379|NCT02368249|Placebo Comparator|Control Group|Patients receiving post-operative placebo (Ringer lactate solution) treatment to preserve the renal function
89555380|NCT02368249|Experimental|Terlipressin Group|Patients receiving a post-operative intravenous terlipressin treatment in association with human albumin to preserve the renal function
89555381|NCT04473443||Cohort A|Patients with a challenging anatomy, including bicuspid aortic valve, severely calcified aortic valves or small aortic roots
89555382|NCT04473443||Cohort B|Consecutive patients eligible for TAVI with ACURATE-NEO2 valve
89555383|NCT02367937|Experimental|PRC-4016 (Icosabutate)|
89555384|NCT02364349|Active Comparator|Bee Venom (BV) group|All subjects are injected with Bee Venom (BV, intervention), randomly assigned to the right or left forearm. Raw BV used dried BV prepared through collection from bee venom sacs and removal of impurities. The BV administration site on each subject was on the palmar side of the designated arm 5 cm below the middle of the elbow crease as it is convenient for observation and has high responsiveness. Pharmacopuncture sessions were also conducted in the morning for higher responsiveness.
89555385|NCT02364349|Experimental|essential Bee Venom (eBV) group|All subjects are injected with essential Bee Venom (eBV, intervention), randomly assigned to the right or left forearm. eBV was prepared through the following methods: BV was collected from bee venom sacs and dried. LC/MS was used to analyze subdivisions of dried BV dissolved in purified water and passed through a sephadex G-25 column to collect histamine-free units. Collected units were filtered to eliminate allergenic substances including PLA2 of molecular weight 10 kDa or higher. The eBV administration site on each subject was on the palmar side of the designated arm 5 cm below the middle of the elbow crease as it is convenient for observation and has high responsiveness. Pharmacopuncture sessions were also conducted in the morning for higher responsiveness.
89555386|NCT02373787|Experimental|creos xenoprotect|resorbable collagen membrane
89555387|NCT02373787|Active Comparator|Bio-Gide|Bio-Gide, resorbable collagen membrane
89555388|NCT05062187||Proprioseption in hemiparetics|Proprioception on balance and gait functions in hemiparetic individuals
89555389|NCT05062187||Healthy Individual|Proprioception on balance and gait functions in healthy individuals
89555390|NCT02373709||Cases: Perinatal depression|Cases will be defined as those with a depressive episode with onset during the antenatal or postnatal period.
89555391|NCT02373709||Controls: No perinatal depression|Controls will be defined as those who score < 7 on Edinburgh Postnatal Depression Scale and/or no episode of clinical depression from pregnancy until 6 months postnatal.
89555392|NCT02367547|Experimental|Hexylaminolevulinate cream|2% Hexylaminolevulinate (Hexvix, Photocure) mixed with Unguentum M (Allmiral) cream
89555393|NCT02367547|Experimental|Aminolevulinic Acid Nano Emulsion|78 mg/g Aminolevulinic Acid Nano Emulsion
88962878|NCT02017938|Experimental|Stage 2: PD group|To find the optimal feedback variables for anti-fatigue training on individuals with PD.
88962879|NCT02017938|Experimental|Stage 2: Health group|Stage 2 controlled group
89555394|NCT02367547|Active Comparator|Methylaminolevulinate cream|160 mg/g Methylaminolevulinate cream
89555395|NCT05061641|Active Comparator|progesterone 200mg|Each group was given prophylactic vaginal progesterone up to 34 weeks of gestation，Vaginal progesterone 200mg
89555396|NCT05061641|Experimental|progesterone 400mg|Each group was given prophylactic vaginal progesterone up to 34 weeks of gestation，Vaginal progesterone 400mg
89555397|NCT05061641|Experimental|progesterone 600mg|Each group was given prophylactic vaginal progesterone up to 34 weeks of gestation，Vaginal progesterone 600mg
89555398|NCT02367625|Experimental|Arm 1|20 women with normal cervical cytology will be randomized to receive MedGYn MGC 200 therapy
89555399|NCT02367625|Active Comparator|Arm 2|20 women with normal cervical cytology will be randomized to receive MedGYn MGC 200 therapy
89555400|NCT03055403|Experimental|M201-A Injection|Active Substance: M201-A Route of administration: continuous intravenous injection
89555401|NCT03055403|Placebo Comparator|Placebo|Saline Placebo for M201-A Route of administration: continuous intravenous injection
89555402|NCT02367703|Experimental|standard instrument|That is why we propose a randomized comparative study between standard instrument and less than 3 millimeter diameter's instruments to achieve in daily practice laparoscopic hysterectomy
89555403|NCT02367703|Other|less than 3 millimeter diameter's instruments|That is why we propose a randomized comparative study between standard instrument and less than 3 millimeter diameter's instruments to achieve in daily practice laparoscopic hysterectomy
89555404|NCT03100019|Experimental|Resveratrol Hypoxia|500mg of trans-resveratrol, tested at a 16% atmospheric oxygen level; the equivalent to 2134m above sea level.
89555405|NCT03100019|Placebo Comparator|Placebo Hypoxia|Pharmaceutical grade fumed silica, tested at a 16% atmospheric oxygen level; the equivalent to 2134m above sea level.
89555406|NCT03100019|Experimental|Resveratrol Normoxia|500mg of trans-resveratrol, tested at a 20.9% atmospheric oxygen level; the equivalent to sea level.
89555407|NCT03100019|Placebo Comparator|Placebo Normoixa|Pharmaceutical grade fumed silica, tested at a 20.9% atmospheric oxygen level; the equivalent to sea level.
89555408|NCT02363725|Other|Conventionnal treatment|"Optimal conventional treatment used for patients admitted for STEMI (ESC guidelines 2012):~Double anti-aggregation~IEC (or sartan) at best tolerated dose~Beta-blocker at best tolerated dose~High dose statin (usually atorvastatin 80 mg daily)~If ventricular dysfunction; inhibitor minérolcorticoïdes (the eplerenone more often)~Any other treatment will be logged."
89555409|NCT02363725|Experimental|Conventionnal + Colchimax®|Optimal conventional treatment + Colchimax®
89555410|NCT05060393|Experimental|Intervention group|Daily use of mindfulness-based mobile application for 30 days.
88962880|NCT02017938|Experimental|Stage 3: PD group|To evaluate the effect of four weeks of VR anti-fatigue ergo cycling training on various fatigue components and functional abilities in individuals with PD.
88962881|NCT02017938|No Intervention|Stage 3: PD controlled group|Stage 3 controlled group
89208222|NCT00980109|Placebo Comparator|placebo oseltamivir|Placebo capsules, one capsule daily for 112 days. The capsule should be administered at approximately the same time each day.
88962882|NCT02017951||Urban-Rural Classification 1: Large Urban Areas|Settlements of over 125,000 people.
89208223|NCT00980109|Active Comparator|zanamivir for inhalation|Zanamivir for inhalation, (5 mg per inhalation), two inhalations, once daily using a ROTADISK/DISKHALER for 112 days. The dose should be administered at approximately the same time each day.
89555411|NCT05060393|No Intervention|Control group|Treatment as usual
89555412|NCT02367235|Experimental|Traditional vaginal positioning device|Patients will undergo their robotic-assisted sacrocolpopexy using a vaginally placed endo anal sizer.
89555413|NCT02367235|Experimental|Colpassist vaginal positioning device|Patients will undergo their robotic-assisted sacrocolpopexy using a vaginally placed Colpassist vaginal manipulator.
89555414|NCT02373631|Experimental|Dry Needling, Conventional PT|
89555415|NCT02373631|Active Comparator|Conventional PT|
89555416|NCT02363413|Active Comparator|IniVAH|Initiation of the NIV in hospital : current care. 3 days hospitalization to start-up the NIV as usual.
89555417|NCT02363413|Experimental|IniVAD|Initiation of the NIV at home : experimental care.
89555418|NCT03099239|Experimental|Single hCT-MSC infusion|Subjects 1-3 will receive a single infusion of hCT-MSCs.
89555419|NCT03099239|Experimental|Two hCT-MSC infusions|Subjects 4-6 will receive two infusions of hCT-MSCs.
89555420|NCT03099239|Experimental|Three hCT-MSC infusions|Subjects 6-12 will receive three infusions of hCT-MSCs.
89555421|NCT02373475|Experimental|Conventional ventilation|Conventional ventilation with TV of 10 mL/kg predicted body weight (PBW) without positive end-expiratory pressure (PEEP) during the surgery under general anesthesia
89555422|NCT02373475|Active Comparator|Protective lung ventilation|Protective lung ventilation with TV of 6 mL/kg PBW, PEEP of 6 cmH2O and recruitment maneuver during the surgery under general anesthesia
89555423|NCT05059613|Experimental|probiotics group|Use thalidomide in combination with probiotics during radiotherapy and chemotherapy
89555424|NCT05059613|No Intervention|thalidomide group|Thalidomide is used only during radiotherapy and chemotherapy
89555425|NCT05059613|No Intervention|healthy control group|healthy control group
89555426|NCT02373553|No Intervention|Group 1( G1): CONTROL GROUP|not be submitted to intervention, only receive informations about health education.
89555427|NCT02373553|Experimental|Group 2(G2) : HEALTH EDUCATION|The family will receive a booklet of guidance of exercises to be performed at home.
89555428|NCT02373553|Experimental|Group 3(G3): EXERCISES IN OUTPATIENTS UNIT|The postural reeducation through lengthening of the anterior muscles and strengthening of the posterior muscles of the trunk.
89555429|NCT03098849|Experimental|Buteyko Training|Breathing exercises according to the Buteyko Breathing Technique
89555430|NCT03098849|No Intervention|Control Group|Standard care as usual
89555431|NCT02373397|Experimental|Cacicol20|Instillation of Cacicol20 eye drops after laser corneal surgery. 3 eye drops total, to be given once immediately after surgery, once 2 days after surgery, and a final time 4 days after surgery.
89555432|NCT02373397|Placebo Comparator|Placebo|Instillation of placebo eye drops (vehicle missing the active ingredient) after laser corneal surgery. 3 eye drops total, to be given once immediately after surgery, once 2 days after surgery, and a final time 4 days after surgery.
89208224|NCT00980109|Placebo Comparator|placebo inhalation|Placebo (lactose powder), two inhalations, once daily using a ROTADISK/ DISKHALER for 112 days. The dose should be administered at approximately the same time each day.
88962883|NCT02017951||Urban-Rural Classification 2: Other Urban Areas|Settlements of 10,000 to 125,000 people.
88962884|NCT02017951||Urban-Rural Classification 3: Accessible Small Towns|Settlements of between 3,000 and 10,000 people and within 30 minutes drive of a settlement of 10,000 or more.
88962885|NCT02017951||Urban-Rural Classification 4: Remote Small Towns|Settlements of between 3,000 and 10,000 people and with a drive time of over 30 minutes to a settlement of 10,000 or more.
89208225|NCT00980109|Active Comparator|active oseltamivir|Oseltamivir capsules (75 mg per capsule), one capsule daily by mouth (PO) for 112 days. The dose should be administered at approximately the same time each day.
89208226|NCT00740597|Experimental|Arm 1|pre-operative radiation + surgery PTV will receive a total dose of 50 Gy in 25 fractions, 2 Gy per fraction, 5 fractions per week, over approximately 5 weeks. Concurrently, the GTV2, if present, will receive 54 Gy in 25 fraction. Dose will be prescribed to the isodose volume that encompasses the PTV. All patients will be treated by 6 MV photon beam.
89208227|NCT00976443|Placebo Comparator|Placebo (normal saline)|Gastric injections of normal saline
89208228|NCT00976443|Active Comparator|BTA 100 U|Gastric injections of botulinum toxin A, 100 Units
89555433|NCT05059847|No Intervention|Standard Care Group|Each patient will receive the standard pharmacological treatment for patients with Acute Lymphoblastic Leukemia based on 3 cycles of chemotherapy (21 days duration per cycle); plus the World Health Organization recommendation that indicates at least 150 min a week of moderate physical activity, equivalent to walking 30 minutes a day for 5 days at an intensity between 60 and 70% of your maximum heart rate.
89555434|NCT05059847|Active Comparator|Resistance Training Group|Each patient will receive the standard pharmacological treatment for patients with Acute Lymphoblastic Leukemia based on 3 cycles of chemotherapy (21 days duration per cycle); plus a resistance exercise routine using weights. An individualized program with exercises supervised by a trainer and basic medical team will be developed for each patient during their hospital stay. Each training routine will have a monthly exercise progression based on intensity, frequency and / or duration.
89555435|NCT05059847|Experimental|Cross-training Group|Each patient will receive the standard pharmacological treatment for patients with Acute Lymphoblastic Leukemia based on 3 cycles of chemotherapy (21 days duration per cycle); plus a cross-training routine using implements without any extra weight to improve stability, joint mobility and general strength of the body. An individualized program with exercises supervised by a trainer and basic medical team will be developed for each patient during their hospital stay. Each training routine will have a monthly exercise progression based on intensity, frequency and / or duration.
89555436|NCT03098927|Active Comparator|Early intervention|Early intervention patients will undergo 3 weeks of motor imagery training immediately upon enrolling in the study between 3 and 6 months post spinal cord injury.
89555437|NCT03098927|Active Comparator|Late intervention|Late intervention patients will undergo 3 weeks of motor imagery training after 6 weeks of standard of care physical rehabilitation following enrollment.
89208229|NCT00976443|Active Comparator|BTA 300 U|BTA 300 U, gastric injections under EUS guidance
89555438|NCT05060159|No Intervention|Hemodialysis|Conventional hemodialysis
89555439|NCT05060159|Experimental|Hemofiltration|Postdilutional hemofiltration
89555440|NCT03099083||Participants receiving adalimumab|Participants with Psoriasis receiving adalimumab
89555441|NCT03098771|Experimental|the cell transplantation group|Patients with atherosclerotic lower limb ischemia will be randomly assigned to the cell transplantation group, which peripheral blood CD34+ cells transfected with ActiveMax® recombinant human vascular endothelial growth factor 165 (VEGF165) gene will be transplanted into the muscles of ischemic limbs in elderly patients with atherosclerotic lower limb ischemia.
89555442|NCT03098771|Experimental|the control group|Patients with atherosclerotic lower limb ischemia will be randomly assigned to the control group, which 9% physiological saline will be injected into the muscles of ischemic limbs.
89555443|NCT03098537|Active Comparator|Enteral nutrion only|
89555444|NCT03098537|Other|Enteral nutrion + proton pump inhibitor|
89555445|NCT05046665|Other|Staging cohort|Eligible participants recruited to the staging cohort
89555446|NCT05046665|Other|Metastatic cohort|Eligible participants recruited from the metastatic cohort
88962886|NCT02017951||Urban-Rural Classification 5: Very Remote Small Towns|Settlements of between 3,000 and 10,000 people and with a drive time of over 60 minutes to a settlement of 10,000 or more.
88962887|NCT02017951||Urban-Rural Classification 6: Accessible Rural|Areas with a population of less than 3,000 people, and within a 30 minute drive time of a settlement of 10,000 or more.
88962888|NCT02017951||Urban-Rural Classification 7: Remote Rural|Areas with a population of less than 3,000 people, and with a drive time of over 30 minutes to a settlement of 10,000 or more.
88962889|NCT02017951||Urban-Rural Classification 8: Very Remote Rural|Areas with a population of less than 3,000 people, and with a drive time of over 60 minutes to a settlement of 10,000 or more.
88962890|NCT02017951||Travel Time - see below|Travel time will be analysed as both a continuous and discrete variable.
88962891|NCT02017977||Urban-Rural Classification 1: Large Urban Areas|Settlements of over 125,000 people
88962892|NCT02017977||Urban-Rural Classification 2: Other Urban Areas|Settlements of 10,000 to 125,000 people
88962893|NCT02017977||Urban-Rural Classification 3: Accessible Small Towns|Settlements of between 3,000 and 10,000 people and within 30 minutes drive of a settlement of 10,000 or more.
88962894|NCT02017977||Urban-Rural Classification 4: Remote Small Towns|Settlements of between 3,000 and 10,000 people and with a drive time of over 30 minutes to a settlement of 10,000 or more.
88962895|NCT02017977||Urban-Rural Classification 5: Very Remote Small Towns|Settlements of between 3,000 and 10,000 people and with a drive time of over 60 minutes to a settlement of 10,000 or more
88962896|NCT02017977||Urban-Rural Classification 6: Accessible Rural|Areas with a population of less than 3,000 people, and within a 30 minute drive time of a settlement of 10,000 or more
88962897|NCT02017977||Urban-Rural Classification 7: Remote Rural|Areas with a population of less than 3,000 people, and with a drive time of over 30 minutes to a settlement of 10,000 or more
88962898|NCT02017977||Urban-Rural Classification 8: Very Remote Rural|Areas with a population of less than 3,000 people, and with a drive time of over 60 minutes to a settlement of 10,000 or more
88962899|NCT02017977||Travel Time - see below|Travel time will be analysed as a continuous and discrete variable.
88962900|NCT02017990||Renal transplant recipients|No intervention. Measurements of plasma marine n-3 polyunsaturated fatty acids levels, indicating intake of fish and seafood.
88962901|NCT02018016||High volume hospitals|The hospitals in the upper tertile for procedural volume
88962902|NCT02018016||Medium volume hospitals|The hospitals in the middle tertile for procedural volume
88962903|NCT02018016||Low volume hospitals|The hospitals in the lowest tertile for procedural volume.
88962904|NCT02018029||cardiac resynchronisation therapy|
89555447|NCT05046041|Experimental|Mifepristone + Misoprostol|200mg mifepristone followed 24-48 h later with 400mcg misoprostol (repeat Q3)
89555448|NCT04434833||Extra nodal diseases|Patients with both lymph node and extra nodal involvement.
89555449|NCT04434833||Target drugs|Patients enrolled in clinical trials of novel target drugs.
89555450|NCT04434833||Relapse|Patients with high risk of relapse.
89555451|NCT05045729||OHCA SPORTS|All OHCA, where the patient was engaged in sports at the time of the event
88962905|NCT02018055|Active Comparator|Aspirin+Ticagrelor|A Group treated with Aspirin+Ticagrelor
88962906|NCT02018055|Experimental|Aspirin+Clopidogrel|A Group treated with Aspirin+Clopidogrel
88962907|NCT02018068|Experimental|Remote control|"For patient randomized in arm Remote Control, the communication with anesthesiologist will be done by teletransmission. The intervention Remote control is assigned to this arm. When evaluated pain values, sensory or motricity blockades are over the selected threshold then, the patient enters the data in the PCA (Patient Control Analgesia) pump, the physician in charge of the patient for the protocol is alerted by SMS on a specific smart phone and makes the necessary settings changes by Remote Control on the Micrel CareTM site."
88962908|NCT02018068|Active Comparator|At bedside care|"For patient randomized in arm At bedside care, the communication with the anesthesiologist in charge of the patient will be done via the nurses and referent physician of the medical unit, as a routine procedures. The necessary changes of pump settings are doing by the anesthesiologist. The intervention at beside care is assigned to arm at bedside care."
89208230|NCT00800618|Experimental|PF-02413873|PF-2413873 active treatment
89555452|NCT01970878|Experimental|GFF MDI (PT003)|
89555453|NCT01970878|Experimental|GP MDI (PT001)|
89555454|NCT01970878|Experimental|FF MDI (PT005)|
89555455|NCT01970878|Active Comparator|Open-label tiotropium bromide inhalation powder|Open-label tiotropium bromide inhalation powder (Spiriva® Handihaler®)
89555456|NCT05045651|Experimental|patient specific knee prosthesis|TKA with Gender Solution® posterior stabilized NexGen® LPS Hi-Flex; Zimmer Biomet, Inc, Warsaw, IN, USA
89555457|NCT05045651|Experimental|Unisex knee prosthesis|TKA with posterior stabilized NexGen® LPS Hi-Flex; Zimmer Biomet, Inc, Warsaw, IN, USA
89555458|NCT05045417||Cases with SLE|"110 patients with SLE will be divided to :~40 patients with lupus nephritis~40 patients interstitial lung disease~30 SLE patients without internal organ affection)"
89555459|NCT05045417||control group|30 sex and age matched healthy individuals as a control group
89555460|NCT05045339|Experimental|Exercise Group|Five different ball exercises were implemented for 35 minutes, 3 sessions per week for 2 months.
89555461|NCT05045339|No Intervention|Control Group|No exercises were performed in control group
89555462|NCT05059145|Experimental|Chlorhexidine gluconate, 1% vaginal cream|8 ml vaginal cream every night for a week and then prophylactic treatment with 8 ml/week for another 11 weeks
88962909|NCT02018081|Experimental|Levofloxacin|Population having a community-acquired pneumonia of which the indication of the treatment is administration of Levofloxacin
88962910|NCT02018094|Active Comparator|24 hour antibiotic course|24 hours of the stated antibiotics administered intravenously (Augmentin and metronidazole. Teicoplanin and or gentamicin will be used if penicillin allergic and state of renal function)
88962911|NCT02018094|Active Comparator|5 day antibiotic Course|24 hours of IV antibiotics followed by 4 days of oral antibiotics (Augmentin and metronidazole. Teicoplanin and or gentamicin will be used if penicillin allergic and state of renal function. Clindamycin will be used as a an oral replacement for penicillin allergic patients)
88962912|NCT02018094|Active Comparator|Iodine|Skin Preparation used pre-operatively: Alcoholic Povidone
88962913|NCT02018094|Active Comparator|Chlorhexidine|Skin preparation to be used preoperatively: Alcoholic chlorhexidine
88962914|NCT02018120|Active Comparator|connective tissue graft|connective tissue graft harvested from palatum of subjects and placed under modified coronally advanced flap
88962915|NCT02018120|Experimental|Platelet rich fibrin|Autogenous platelet rich fibrin was obtained from subjects own blood samples after centrifugation. Platelet rich fibrin membranes were placed under modified coronally advanced flaps.
88962916|NCT02018133||Vitamin D or Placebo|Take vitamin D for 2 weeks. 2mg daily before meal
88962917|NCT02018146|Other|Nasopharyngeal then mask|Patients will be randomized to nasopharyngeal airway placement and ventilation followed by mask ventilation
88962918|NCT02018146|Other|Mask then nasopharyngeal|Patients will be randomized to mask ventilation followed by nasopharyngeal airway placement and ventilation
88962919|NCT02018159||Women treated with Menopur|Women treated with Menopur can participate with more than one cycle. 700 cycles will be enrolled.
88962920|NCT02018172||Zomacton® treatment with Zomajet® Vision X device|
88962921|NCT02018185|Active Comparator|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation
88962922|NCT02018185|Sham Comparator|Sham rTMS|Sham Transcranial Magnetic Stimulation
88962923|NCT02018211|Experimental|experimental group|All participants performed a modified version of the Loughborough Intermittent Shuttle Test (LIST; Nicholas et al, 2000), an exercise protocol designed to simulate the activity pattern characteristics of intermittent sports such as soccer. The LIST was performed on three occasions, at the same time of day, each separated by approximately four weeks. Following each exercise trial, one of three recovery interventions were applied, the order of which were randomly allocated.
88962924|NCT02018224|Experimental|End-to-end suturation without augmentation|
88962925|NCT02018224|Experimental|End-to-end suturation with augmentation|
88962926|NCT02018237|Active Comparator|NAFLD|Subjects with nonalcoholic fatty liver disease (NAFLD) will complete baseline testing and then be assigned to either the high fructose corn syrup diet or the standard diet (low in high fructose corn syrup) for 4 weeks. Post intervention testing will be completed after the subjects have completed the 4 week diet intervention.
88962927|NCT02018237|Active Comparator|Non-NAFLD|Subjects without nonalcoholic fatty liver disease (Non-NAFLD) will complete baseline testing and then be fed a high fructose corn syrup diet for 4 weeks. Post intervention testing will be completed after the subjects have completed the 4 week diet intervention.
88962928|NCT02018250|Experimental|0.6 mg/kg MMB4 DMS|0.6 mg/kg 1,1'-Methylenebis[4-[(hydroxyimino) methyl]-pyridinium] dimethanesulfonate (MMB4 DMS), intramuscular (i.m.) to the anterior thigh.
88962929|NCT02018250|Placebo Comparator|Placebo|5 mg benzyl alcohol USP/NF and 5 mg methanesulfonic acid adjusted to a pH 2.3 administered intramuscular (i.m.) to the anterior thigh.
89208231|NCT00800618|Placebo Comparator|Placebo|Placebo
89555463|NCT05059145|Active Comparator|Fluconazole, 150 mg oral capsule|Fluconazole150 mg (oral capsule) every 3 days for the first 3 doses, then prophylactic treatment with 150 mg/week for another 11 weeks
89555464|NCT05045105||ICU physicians|Intensive Care physicians who will apply the method of invasive insertion of the intracerebral catheter for ICP monitoring
89555465|NCT05045105||Neurosurgeons|Neurosurgeons who will apply the method of invasive insertion of the intracerebral catheter for ICP monitoring
89555466|NCT05059067||Macintosh blade size 3|Patients intubated using Macintosh blade size 3
89555467|NCT05059067||Macintosh blade size 4|Patients intubated using Macintosh blade size 4
89555468|NCT05058599||facial videos dataset|facial videos collected from Zhongshan Ophthalmic Center of Sun Yat-sen University.
89555469|NCT01970488|Experimental|ABP 501|"Participants received 80 mg ABP 501 subcutaneously on week 1/day 1 (initial loading dose) and 40 mg at week 2 and every 2 weeks thereafter until week 16.~Participants with a PASI 50 response at week 16 continued to receive 40 mg APB 501 until week 48."
88962930|NCT02018250|Experimental|0.9 mg/kg MMB4 DMS|0.9 mg/kg 1,1'-Methylenebis[4-[(hydroxyimino) methyl]-pyridinium] dimethanesulfonate (MMB4 DMS), intramuscular (i.m.) to the anterior thigh.
88962931|NCT02018250|Experimental|1.2 mg/kg MMB4 DMS|1.2 mg/kg 1,1'-Methylenebis[4-[(hydroxyimino) methyl]-pyridinium] dimethanesulfonate (MMB4 DMS), intramuscular (i.m.) to the anterior thigh.
88962932|NCT02018250|Experimental|1.5 mg/kg MMB4 DMS|1.5 mg/kg 1,1'-Methylenebis[4-[(hydroxyimino) methyl]-pyridinium] dimethanesulfonate (MMB4 DMS), intramuscular (i.m.) to the anterior thigh.
88962933|NCT02018250|Experimental|2.0 mg/kg MMB4 DMS|2.0 mg/kg 1,1'-Methylenebis[4-[(hydroxyimino) methyl]-pyridinium] dimethanesulfonate (MMB4 DMS), intramuscular (i.m.) to the anterior thigh.
88962934|NCT02018250|Experimental|3.0 mg/kg MMB4 DMS|3.0 mg/kg 1,1'-Methylenebis[4-[(hydroxyimino) methyl]-pyridinium] dimethanesulfonate (MMB4 DMS), intramuscular (i.m.) to the anterior thigh.
88962935|NCT02018276|Experimental|The effect of perioperative lidocaine infusion|
88962936|NCT02018276|Active Comparator|The effect of perioperative magnesium infusion|
88962937|NCT02018289|Experimental|Triclosan|Suture of the abdominal wall with triclosan coated suture
89555470|NCT01970488|Active Comparator|Adalimumab|"Participants received 80 mg adalimumab subcutaneously on week 1/day 1 (initial loading dose) and 40 mg at week 2 and every 2 weeks thereafter until week 16.~At week 16 participants with a PASI 50 response were re-randomized to treatment with adalimumab or were transitioned to ABP 501 until week 48."
89555471|NCT03097835|Other|Group A|Group A will be treated with Hyper-Diluted Botox on day 1 and on day 30 they will be treated with 0.9% saline solution.
89555472|NCT03097835|Other|Group B|Group B will be treated with 0.9% saline solution on day 1 and on day 30 they will be treated with Hyper-Diluted Botox.
89555473|NCT05058521||In-hospital VTE group|In-hospital VTE group includes patients who were with a hospital stay over 3 days and new-onset of VTE during their stay. Patients who presented for VTE were excluded.
89555474|NCT05058521||Negative group|Negative group includes patients who were with a hospital stay over 3 days and did not have a VTE during their hospital stay.
89555475|NCT03097601||sunitinib cohort|independent cohorts of patients who received sunitinib for metastic kidney cancer, on who we intend to demonstrate that ELR+CXCL cytokines levels are of sunitinib response
89555476|NCT05044247|Experimental|ESP block|ESP block under mixed local anesthetics, betamethasone agent
89555477|NCT05044169|Experimental|Broncho-Vaxom|Intervention
89555478|NCT05058365|Experimental|Intervention group|
89555479|NCT05058365|No Intervention|Wait-list control|Participants in wait-list control group will receive the same intervention, two months after their counterparts in experimental group completed the intervention.
89555480|NCT05044559|Experimental|Continuous Positive Air Way Group|"Day 1: Use of CPAP between 10 and 12 cmH2O according to tolerance for 20 minutes two time a day at first day of post surgery bed mobility chest physiotherapy ,active assistive ROM 5 repetitions of upper and lower limb, ACBT cycle. ABGS was analyses at first minute of exercise. and vital was record after exercise.~Day 2: Active ROM exercise progress of 5 repetitions bed to chair mobility. same exercise progress with 5 repetition and 5 minute walk( day 3rd ).walking time was increase with 10 min at 4 day and at 5th day stair climbing the ABGS was record in ICU 3 days."
89555481|NCT05044559|Active Comparator|Control Group|"Day 1: Bed mobility chest physiotherapy, active assistive ROM 5 repetitions of upper and lower limb, ACBT cycle. ABGS was analyses at first minute of exercise and vital was record after exercise.~Day 2: Active range of motion exercise progress with 5 repetitions bed to chair mobility. same exercise progress with 5 repetition and 5 minute walk( day 3rd ).walking time will increase with 10 min at 4 day and at 5th day stair climbing the ABGS was record in ICU 3 days."
89555482|NCT05058053|Experimental|Cold application group|"After starting amiodarone treatment, cold application was applied a total of 12 times on the infused PVC with cold gel packs for 15 minutes at 2-hour intervals. At all stages of the study, the researcher closely monitored the patients. During the treatment, the development of phlebitis after cold application during the 24-hour infusion was evaluated every 2 hours by the researcher using the Visual Infusion Phlebitis Scale and recorded. After starting the amiodarone infusion, the patients were observed for the development of phlebitis for 24 hours until the end of the procedure and for 2 hours after the end of the treatment."
89555483|NCT05058053|No Intervention|Control group|"the patients who were started on amiodarone infusion were observed for the development of phlebitis, receiving no intervention. During the treatment, phlebitis development was evaluated and recorded by the researcher using the Visual Infusion Phlebitis Scale every 2 hours during the 24-hour infusion. After starting the amiodarone infusion, the patients were observed for the development of phlebitis for 24 hours until the end of the procedure and for 2 hours after the end of the treatment."
89555484|NCT03097679|Active Comparator|low COF-group|The low COF-group receives a thin-strut stent (Pulsar, Biotronik AG, Bülach, Switzerland) with minimal oversizing (according to manufacturer's Instructions For Use)
89555485|NCT03097679|Active Comparator|high COF-group|The high COF-group receives a stiffer-stent (Lifestent Flexstar, Bard Peripheral Vascular Inc., Tempe, AZ, USA) with maximal oversizing (according to manufacturer's Instructions For Use).
89555486|NCT05058209|Active Comparator|Arm 1|Triamcinolone acetonide extended-release injectable suspension. Single intra-articular extended-release injection of triamcinolone acetonide, to deliver 32 mg (5 mL). For intra-articular use only and should not be administered by the following routes: epidural, intrathecal, intravenous, intraocular, intramuscular, intradermal, subcutaneous.
89555487|NCT05058209|Active Comparator|Arm 2|Betamethasone sodium phosphate and betamethasone acetate Injectable Suspension, USP 6 mg per mL, 3 mg per milliliter betamethasone, as betamethasone sodium phosphate, and 3 mg per milliliter betamethasone acetate. When oral therapy is not feasible, the Injectable Suspension is indicated for intramuscular use only.
89555488|NCT05057663|Active Comparator|Bleomycin group|
89555489|NCT05057663|Active Comparator|5-Fluorouracil group|
89555490|NCT03097445|Experimental|Nicotine Replacement Therapy|mailed 5 week course of transdermal nicotine patches
88962938|NCT02018289|Sham Comparator|No triclosan|Suture of the abdominal wall with the same suture, but without triclosan
89555491|NCT03097445|No Intervention|Control|No intervention control group
89555492|NCT05057351|Experimental|Active ingredient|Isopentenyltheophylline 0.44% + Glycerin 4.56%
89555493|NCT05057351|Placebo Comparator|Placebo|Glycerin 4.56%
88962939|NCT02018328|No Intervention|Triple therapy, helicobacter pylori|
88962940|NCT02018328|Experimental|triple therapy+curcumin helicobacter pylori|Curcumin will be added to the regular triple therapy
88962941|NCT02018341|Experimental|homeopathic remedy in 30C potency|5 lactose globules containing a commonly used homeopathic remedy in the potency of 30C will be administered twice daily for 3 days
88962942|NCT02018341|Placebo Comparator|placebo|5 lactose globules without any homeopathic remedy will be administered twice daily for 3 days
89555494|NCT03097523|Experimental|Study Arm|"Patients with intraventricular catheter meeting eligibility criteria will undergo the following procedures:~Blood pressure, heart rate, electrocardiogram and Intracranial Pressure (ICP) monitoring after standard of care procedures are completed~Continuous ICP monitoring using a disposable pressure transducer (i.e., TruWaveTM)~Sequential placement in an upright, seated, supine 0°, and supine 15° head down tilt (HDT) positions for approximately 15 minutes for stabilization, followed by: Non-invasive ICP, intra-ocular pressure (IOP) assessment, femoral vascular ultrasound, jugular vascular ultrasound, and assessment of adverse events"
89555495|NCT03097211|Experimental|Group 1: BIA 6-512 25 mg or placebo|Subjects were administered with those investigational products at approximately 8-h intervals, starting in the morning (approximately at 8h00) of Day 1 and finishing in the morning of Day 5 (last dose). On Day 4, concomitantly with the BIA 6-512/Placebo morning dose, one tablet of Madopar® 250 was administered. On Day 5, concomitantly with the BIA 6-512/Placebo morning dose, one tablet of Madopar® 250 and one tablet of nebicapone 150 mg were administered
89555496|NCT03097211|Experimental|Group 2: BIA 6-512 50 mg or placebo|Subjects were administered with those investigational products at approximately 8-h intervals, starting in the morning (approximately at 8h00) of Day 1 and finishing in the morning of Day 5 (last dose). On Day 4, concomitantly with the BIA 6-512/Placebo morning dose, one tablet of Madopar® 250 was administered. On Day 5, concomitantly with the BIA 6-512/Placebo morning dose, one tablet of Madopar® 250 and one tablet of nebicapone 150 mg were administered
89555497|NCT03097211|Experimental|Group 3: BIA 6-512 75 mg or placebo|Subjects were administered with those investigational products at approximately 8-h intervals, starting in the morning (approximately at 8h00) of Day 1 and finishing in the morning of Day 5 (last dose). On Day 4, concomitantly with the BIA 6-512/Placebo morning dose, one tablet of Madopar® 250 was administered. On Day 5, concomitantly with the BIA 6-512/Placebo morning dose, one tablet of Madopar® 250 and one tablet of nebicapone 150 mg were administered
89555498|NCT03097211|Experimental|Group 4: BIA 6-512 100 mg or placebo|Subjects were administered with those investigational products at approximately 8-h intervals, starting in the morning (approximately at 8h00) of Day 1 and finishing in the morning of Day 5 (last dose). On Day 4, concomitantly with the BIA 6-512/Placebo morning dose, one tablet of Madopar® 250 was administered. On Day 5, concomitantly with the BIA 6-512/Placebo morning dose, one tablet of Madopar® 250 and one tablet of nebicapone 150 mg were administered
89555499|NCT05056961|Other|Large tidal volumes without respiratory distress symptoms|Large tidal volumes (> 10 mL.kg-1 of predicted body weight) despite low pressure support, without respiratory distress symptoms
89555500|NCT05056961|Other|Large tidal volumes with respiratory distress symptoms|Large tidal volumes (> 10 mL.kg-1 of predicted body weight) despite low pressure support, with respiratory distress symptoms (for example, supra-clavicular and thoracic-abdominal asynchronies...)
89555501|NCT05044403|Active Comparator|Conventional treatment|Patients receiving conventional treatment for multiorganic dysfunction syndrome from septic origin.
89555502|NCT05044403|Experimental|Extracorporeal support with haemoperfusion treatment|Patients receiving extracorporeal support with haemoperfusion for multiorganic dysfunction syndrome from septic origin.
89555503|NCT05056649||Heart Failure Patients with impaired ejection fraction|
89555504|NCT04434443|Experimental|trunk exercise on unstable surface|trunk exercise training in supine and sitting positions, with unstable surfaces
89555505|NCT04434443|Sham Comparator|upper limb range of motion exercise|upper limb range of motion exercise in sitting with back fully supported
89555506|NCT05043935|Experimental|L-PRF with antimicrobial photodynamic therapy|Application of L-PRF with antimicrobial photodynamic therapy in the defect
89555507|NCT05043935|Active Comparator|antimicrobial photodynamic therapy|Application antimicrobial photodynamic therapy in the defect
89555508|NCT05056571|Experimental|Relaxation exercise|Intensive care nurses will apply 20 minutes of online (zoom meeting) progressive muscle relaxation exercise twice a week, for 8 weeks, for a total of 16 group sessions. In order to support nurses' adaptation to the research, the group counselor will remind the nurses by phone twice a week during the implementation process, and their regular participation in online sessions will be supported.
89555509|NCT05056571|No Intervention|Control|No attempt will be made during the research.
89555510|NCT03096977|Experimental|CHUB-TST02 patients|All patients who participated in the NCT02805634 (CHUB-TST02) study.
88962943|NCT02018367|Experimental|Proflavine, high resolution imaging|Proflavine hemisulfate will be used as a topical contrast agent in conjunction with the high resolution imaging device to visualize and image areas suspicious for neoplasia. Biopsies will be taken per Seattle biopsy protocol for Barrett's Esophagus surveillance.
88962944|NCT02018367|No Intervention|Standard of care|Standard of care examination of the upper GI tract using the standard high resolution endoscope with bipsies taken per Seattle biopsy protocol for Barrett's Esophagus surveillance.
88962945|NCT02018380|Experimental|Shock Absorbing Insoles vs. Athletic shoes|
88962946|NCT02018393||Prophylaxis group|Prophylaxis with FEIBA is defined in this study as the regular infusion of FEIBA for the prevention of bleeding at a dose of ≥50 UF/kg on at least three non-consecutive days a week. Patients must have been on this modality for at least 6 months prior to the study visit
88962947|NCT02018393||On demand group|On-demand Treatment is defined as the administration of FEIBA only to control bleeding. Patients must have been on this modality for at least 6 months prior to the study visit.
88962948|NCT02018406|Experimental|Intervention|Intervention Group
89555511|NCT05056181|Experimental|PAI|Participants assigned to the PAI arm will receive brief information on the benefits of being more active and will be given information about the best way to training. They will receive conventional medical treatment. They will also participate in 2 weeks of training (12 sessions), plus telematic assistance of a specialized practitioner who will follow them during the post-discharge training sessions for a period of 12 weeks, with 3 workouts per week.
89555512|NCT05056181|No Intervention|TAU|Participants assigned to the TAU arm will receive brief information on the benefits of being more active and will be given information about the best way to training. They will also receive conventional medical treatment.
89555513|NCT05056337|Experimental|Treatment group|Patients with potentially resectable HCC who meet the study inclusion criteria will be treated with lenvatinib(8mg/d for BW<60kg and 12mg for BW≥60kg) in combination with toripalimab(240mg iv Q3W) and TACE (on demand). Tumor response will be regularly evaluated, data will be collected, and complete surgical resection will be evaluated by an independent review committee, the conversion resection rate will be calculated, and patient survival will be assessed.
89555514|NCT05056337|Active Comparator|Control group|Patients with potentially resectable HCC who meet the study inclusion criteria will be treated with TACE alone. Tumor response will be regularly evaluated, data will be collected, and complete surgical resection will be evaluated by an independent review committee, the translational resection rate will be calculated, and patient survival will be assessed.
89555515|NCT05056025|Experimental|postbiotics with vitamins|postbiotics (IGENH35.3A) with vitamins (AREDS formulation and recommended daily dose)
89555516|NCT05056025|Placebo Comparator|vitamins|vitamins (AREDS formulation and recommended daily dose)
89555517|NCT03097055|Experimental|Traditional Acupuncture|"Traditional acupoints and traditional deqi manipulation"
89555518|NCT03097055|Sham Comparator|Minimal Acupuncture|To avoid traditional acupoints and minimal manipulation
89555519|NCT02661217|Other|Pre-discharge treatment initiation|Patients received first dose at any point after Randomization but no later than 12 h before discharge.
89555520|NCT02661217|Other|Post-discharge treatment initiation|Patients received first dose after discharge and up to 14 days thereafter.
89555521|NCT05044091||ovarian/fallopian tube/primary peritoneal cancer patients|ovarian/fallopian tube/primary peritoneal cancer patients treated with PAPRi for more than four weeks
88962949|NCT02018406|Placebo Comparator|Control|Control Group
88962950|NCT02018419|Experimental|Dosing Schedule A|"the priming step with ID injection of AlloStim on Days 0, 7, and 14;~the ablation step with cryoablation and intra-tumor injection of AlloStim on Day 21;~the activation step with an IV infusion of AlloStim on Day 28;~the booster step with intravenous booster infusion of AlloStim on Days 56 and 84;~Protocol follow-up procedures continue until day 168 and at investigator discretion thereafter."
88962951|NCT02018419|Experimental|Dosing Schedule B|"the priming step with ID injection of AlloStim on Days 0 and 3 and an additional ID injection of AlloStim on Days 7 and 10;~the ablation step with cryoablation and intra-tumor injection of AlloStim on Day 14;~the activation step with an IV infusion of AlloStim on Day 21;~the booster step with intravenous booster infusion of AlloStim on Days 49 and 77.~Protocol follow-up procedures continue until day 168 and at investigator discretion thereafter."
88962952|NCT02018419|Experimental|Dosing Schedule C|"the priming step with ID injection of AlloStim on Days 0 and 3 and an additional ID injection of AlloStim on Days 7 and 10;~the ablation step with cryoablation and intra-tumor injection of AlloStim on Day 14, and intra-tumor injection of AlloStim again into the same cryoablated lesion on Day 17;~the activation step with an IV infusion of AlloStim on Day 21;~the booster step with intravenous infusion of AlloStim on days 49 and 77.~Protocol follow-up procedures continue until day 168 and at investigator discretion thereafter."
88962953|NCT02018432|Experimental|Roflumilast escalation dosage|Roflumilast 250 μg qd (4 weeks) →500 μg qd
88962954|NCT02018432|Experimental|Roflumilast conventional dosage|Roflumilast 500 μg qd
88962955|NCT02018471|Experimental|Pilot group|Forty-three patients who had to undergo one or more diagnostic tests (PET, TAC, fMRI, Mammography, Endoscopy, Colonoscopy) took part in the study. Most of the 43 patients had to undergo only one diagnostic test, and only 6 patients had more than one. They have attended a psychoeducative training.
88962956|NCT02018484|Experimental|Patient specific cutting guides|Unicompartmental knee replacement with patient specific cutting guides
88962957|NCT02018510|Experimental|Group 1A|"HIV-uninfected individuals~1 mg/kg, single dose IV administration of 3BNC117"
88962958|NCT02018510|Experimental|Groups 1B|HIV-uninfected individuals 3 mg/kg, single dose IV administration of 3BNC117
88962959|NCT02018510|Experimental|Group 1C|HIV-uninfected individuals 10 mg/kg, single dose IV administration of 3BNC117
88962960|NCT02018510|Experimental|Group 1D|HIV-uninfected individuals 10 mg/kg, two doses IV of 3BNC117
88962961|NCT02018510|Experimental|Group 1E|HIV-uninfected individuals 30 mg/kg, single dose IV administration of 3BNC117
88962962|NCT02018510|Experimental|Group 1F|HIV-uninfected individuals 30 mg/kg, two doses IV of 3BNC117
88962963|NCT02018510|Experimental|Group 2A|"HIV-infected individuals on or off ART~1 mg/kg, single dose IV administration of 3BNC117"
88962964|NCT02018510|Experimental|Group 2B|HIV-infected individuals on or off ART 3 mg/kg, single dose IV administration of 3BNC117
88962965|NCT02018510|Experimental|Group 2C|HIV-infected individuals on or off ART 10 mg/kg, single dose IV administration of 3BNC117
88962966|NCT02018510|Experimental|Group 2D|HIV-infected individuals on or off ART 30 mg/kg, single dose IV administration of 3BNC117
88962967|NCT02018510|Experimental|Group 2E|HIV-infected individuals off ART, VL 2,000-100,000 copies/ml 30 mg/kg, single dose IV administration of 3BNC117
88962968|NCT02018510|Experimental|Group 3|HIV-infected individuals off ART, VL < 2,000 copies/ml 30 mg/kg, single dose IV administration of 3BNC117
89555522|NCT01952080|Experimental|teduglutide|Open label teduglutide, subcutaneously injected.
89555523|NCT01952080|No Intervention|Standard of Care|
89555524|NCT05043779|Other|Preoperative Awake Airway Nasoendoscopy|only one arm
89555525|NCT05055791|Experimental|Arm 1|Cohort 1-3 dose level 1-3 in subjects with relapsed or refractory haematological malignancies including AML/ALL/CMML/CLL.
89555526|NCT05055791|Experimental|Arm 2|Cohort 1-3 dose level 1-3 in subjects with relapsed or refractory haematological malignancies including AML/ALL/CMML/CLL.
88962969|NCT02018510|Experimental|Group 4|HIV-infected individuals on ART, VL < 100,000 copies/ml 30 mg/kg, single dose IV administration of 3BNC117
88962970|NCT02018510|Experimental|Group 5A|HIV-infected individuals on ART, VL < 20 copies/ml 10 mg/kg, single dose IV administration of 3BNC117
88962971|NCT02018510|Experimental|Group 5B|HIV-infected individuals on ART, VL < 20 copies/ml 30 mg/kg, single dose IV administration of 3BNC117
89555527|NCT01951378|Active Comparator|Hudson RCI® nebulizer|"Patients randomized to the standard arm will receive treatments as dictated by our standard ED asthma pathway (Fig. 1). All treatments will be administered with our standard ED nebulizer, the Hudson RCI® Up-Draft® Neb-U-Mist® nebulizer (Teleflex Medical®, Research Triangle Park, NJ), and a simple mask (Hudson RCI®, Teleflex Medical®, Research Triangle Park, NJ)."
89555528|NCT01951378|Active Comparator|NebuTech® HDN® nebulizer|"Patients randomized to the NebuTech® arm will receive treatments as dictated by our trial pathway, referred to as the rapid Albuterol/Proventil delivery pathway (Fig. 2). All nebulizations in this arm will be administered via the Breath-Enhanced High Density Jet Nebulizer, NebuTech® HighDensityNebulizer®,(Salter Labs®, Arvin, CA). Respiratory Therapists (RT) will attempt to deliver all treatments with a mouthpiece, as that has been shown to be the most efficient and reliable mode of aerosol delivery for most children 31, 32. If the Respiratory Therapist feels that the child will not or cannot effectively use a mouthpiece, a mask will be used."
89555529|NCT05055635|Experimental|Doseescalated pencil beam proton therapy|Neo-adjuvant or definitive pencil beam proton therapy: 55 Gy(RBE)/44fx - 65 Gy(RBE)/52 fx (1.25 Gy per fraction), two fractions a day.
89555530|NCT05055557||ARDS group|"1.85 years≥Age≥18 years. 2.Moderate-to-severe ARDS, defined by the ARDS Definition Task Force in the Berlin definition (partial pressure of arterial oxygen [PaO2]:FiO2 ratio ≤200 mmHg with a PEEP ≥5 cmH2O).~3.Diagnosis of ARDS less than 72 hours. 4.Just observation"
89555531|NCT05055557||Critically ill patients without ARDS group|Unstable vital signs, rapid changes in the condition, unstable function of more than two organ systems (excluding the respiratory system), decline or failure, the development of the disease may endanger the life of the patient.
89555532|NCT05055557||healthy adult group|Healthy adults, voluntarily join the study.
89555533|NCT01944670|Experimental|Internal Joint Stabilizer Group|Patients implanted with the Internal Joint Stabilizer - Elbow (IJS-E)
89555534|NCT05043467||Duvie(Lobeglitazone)|patients with type 2 diabetes who received lobeglitazone 0.5mg for more than one year between February 1, 2014 and December 20, 2018
89555535|NCT03096821||ngFDS selected treatment|Treatment with commercially available treatments (per package insert instructions) chosen via next-generation functional drug screening (ngFDS).
89555536|NCT02363179|No Intervention|Non Music Group|500 non-intervention patients will be consented to serve as the control group
89555537|NCT02363179|Experimental|Music Intervention Group|500 intervention patients will be consented to participate in the live preferential music intervention
89555538|NCT05055245||Patients undergoing assisted reproductive technology|Patients undergoing in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI)
89555539|NCT03096587|Experimental|XP Endo Finisher file|XP Endo Finisher file is used to activate irrigation as a final step in irrigation protocol
89555540|NCT03096587|Active Comparator|ultrasonic activated irrigation|ultrasonic activated irrigation as a final step in irrigation protocol
89555541|NCT02363569||case-|"Pregnant women (age 18-40) at 4-23 weeks of pregnancy that have appealed to the Women ER 24 hours after bleeding or bleeding secretions due to intercourse."
89555542|NCT02363569||control|"Pregnant women (age 18-40) at 4-23 weeks of pregnancy that have appealed the women ER due to spontaneous bleeding or bleeding secretions"
89555543|NCT03096665||Blood test group|All patients receive the three types of blood test (venous blood test, skin puncture blood (capillary blood) test and arterial blood gas analysis
89555544|NCT02373319|Experimental|CV-screening-1 plus personalized|Cardiovascular risk screening supervised by health professional - 15 minutes wash-out - Self-screening of cardiovascular risk; Communication of personalized recommendations according to the health exam results for the control of cardiovascular risk factors
89555545|NCT02373319|Experimental|CV-screening-2 plus personalized|Self-screening of cardiovascular risk - 15 minutes wash-out - Cardiovascular risk screening supervised by health professional; Communication of personalized recommendations according to the health exam results for the control of cardiovascular risk factors
89555546|NCT02373319|Active Comparator|CV-screening-1 plus standard|Cardiovascular risk screening supervised by health professional - 15 minutes wash-out - Self-screening of cardiovascular risk; Standard communication of the health exam results
89555547|NCT02373319|Active Comparator|CV-screening-2 plus standard|Self-screening of cardiovascular risk - 15 minutes wash-out - Cardiovascular risk screening supervised by health professional; Standard communication of the health exam results
89555548|NCT05055167|Experimental|Envafolimab|Elderly NSCLC Patients with high PD-L1 expression
88962972|NCT02018523|Experimental|Lenalidomide|Oral lenalidomide 10 mg daily until disease progression
88962973|NCT02018536|Experimental|Part 1, Cohort A|8 participants to receive a single oral dose of 30 mg of GSK2336805 (6 participants) or placebo (2 participants) on Day 1.
88962974|NCT02018536|Experimental|Part 1, Cohort B|8 participants to receive a single oral dose of 60 mg of GSK2336805 (6 participants) or placebo (2 participants) on Day 1.
88962975|NCT02018536|Experimental|Part 1, Cohort C|8 participants to receive a single oral dose of 120 mg of GSK2336805 (6 participants) or placebo (2 participants) on Day 1.
88962976|NCT02018536|Experimental|Part 2, Sequence 1|6 participants to receive Treatment A (TMC435 150 mg), D (TMC435 150 mg+GSK2336805 60 mg), B (GSK2336805 60 mg), and C (TMC435 100 mg+GSK2336805 60 mg) in a sequence with a 7 days washout period between each treatment sessions.
88962977|NCT02018536|Experimental|Part 2, Sequence 2|6 participants to receive Treatment B (GSK2336805 60 mg), A (TMC435 150 mg), C (TMC435 100 mg+GSK2336805 60 mg), and D (TMC435 150 mg+GSK2336805 60 mg) in a sequence with a 7 days washout period between each treatment sessions.
88962978|NCT02018536|Experimental|Part 2, Sequence 3|6 participants to receive Treatment C (TMC435 100 mg+GSK2336805 60 mg), B (GSK2336805 60 mg), D (TMC435 150 mg+GSK2336805 60 mg), and A (TMC435 150 mg) in a sequence with a 7 days washout period between each treatment sessions.
89555549|NCT05043233||Patients with Graves' disease|Graves' disease was diagnosed based on clinical symptoms and laboratory findings. The clinical symptoms included heat intolerance, fatigue, increased appetite, increased sweating, weight loss, muscle weakness, tremors, and diffusely enlarged thyroid glands. The laboratory results included increased serum concentrations of free thyroxine (FT4) and/ or free triiodothyronine (FT3), decreased basal thyroid-stimulating hormone (TSH) level, and TRAb positivity. All participants in this study would be treated with anti-thyroid drugs(MMI: methimazole) according to the 2016 ATA guildline.
89555550|NCT02372929||Endoscopic Ultrasound Staging|Prospective study of esophageal cancer patients referred for endoscopic ultrasound
89555551|NCT05054855|Experimental|Full Treatment|Steps of the Intervention Condition. Following an in-person session in which a pretest assessment is completed, each member of the intervention group will participate in three face-to-face sessions with the interventionist at the student's campus or at the interventionist's office to complete the CST component of the intervention.
89208232|NCT00984555||A1 (Inoculation with 7 timepoints)|Semen exposure via inoculation, Vaginal swabs at 7 time points
89555552|NCT05054855|Active Comparator|Abbreviated Treatment|Steps of the Control Condition. Following an inperson session in which the pretest assessment is completed, each member of the control group will participate in two telephone or Skype sessions with the interventionist to discuss her or his needs for electronic cognitive supports. An abbreviated version of Scherer's (2012) MPT assessment will be administered via telephone or Skype in the first of these virtually-administered sessions. In the second telephone or Skype session, the interventionist will summarize the results of the abbreviated MPT assessment, suggest a variety of cognitive enhancement apps for tablet computers or smart phones that the control group participant can consider.
89555553|NCT05054933|Other|ultrasound capsule endoscopy examination|Healthy volunteers or patients with suspected esophageal disease will be enrolled to take ultrasound capsule endoscopy examination followed by conventional endoscopic ultrasound examination within 2 weeks.
89555554|NCT05054777||oncoplastic breast-conserving surgery|The oncoplastic breast-conserving surgery were mainly those surgeries using volume displacement or volume replacement techniques
89555555|NCT05054777||conventional breast-conserving surgery|The conventional breast-conserving surgery were performed without any oncoplastic operations
89555556|NCT03112915|Active Comparator|QLB: Quadratus lumborum block|"QLB: Quadratus lumborum block :Quadratus Lumborum block group (QL)~patients will receive a bilateral Quadratus Lumborum block using Bupivicaine 0.25 %"
89555557|NCT03112915|Active Comparator|TAP: transversus abdominis plan block|"TAP: Transversus abdominis plane block (TAP)~patients will receive a bilateral TAP block using Bupivicaine 0.25%"
89555558|NCT02367079|Active Comparator|Switched on diathermy|Switched on diathermy was used on DOMS compared to sham diathermy
89555559|NCT02367079|Sham Comparator|Switched OFF diathermy|Switched OFF diathermy was used on DOMS compared to REAL diathermy
89555560|NCT05054465|Experimental|Pre-transplant consolidation and post-transplant maintnance with navitoclax and venetoclax.|Patients will be treated with VEN 400 mg QD and NAV 50mg QD according to the RP2D presented by Pullarkat et al. (doi: 10.1158/2159-8290.CD-20-1465) for two 28 day cycles. Following 2 cycles re-staging marrow including MRD assessment and imaging will be followed by alloSCT according to local protocol.Within 90 days from alloSCT patients will be started on VEN and NAV maintenance. For post-alloSCT maintenance a dose escalation scheme based on the BOIN design will be applied with a maximal dose of VEN 400 mg QD and NAV 50mg QD according to the RP2D presented by Pullarkat et al.
89555561|NCT02367001|Other|1: standard invitation|"Group 1: sending a standard invitation signed by the coordinating doctor (send by the structure responsible for organized screenings)~Intervention : Normal invitation"
89555562|NCT02367001|Experimental|2: Revised invitation|"Group 2: Sending a revised invitation ( text, layout) signed by the coordinating doctor (send by the structure responsible for organized screenings)~Intervention : revised invitation signed by the coordinating doctor"
89555563|NCT02367001|Experimental|3 : revised invitation signed by the attending physician|"Group 3: Sending a revised invitation signed by the attending physician (send by the structure responsible for organized screenings)~Intervention : Revised invitation signed by the attending physician"
89555564|NCT05054699|Experimental|MST|Subjects will receive 12-18 sessions of frontal Magnetic Seizure Therapy under general anaesthesia, twice a week. Clinical and cognitive measures will be assessed before, during and after the treatment
89555565|NCT05054699|Active Comparator|ECT|Subjects will receive 12-18 sessions of bilateral Electroconvulsive Therapy under general anaesthesia, twice a week. Clinical and cognitive measures will be assessed before, during and after the treatment
89555566|NCT02367157|Experimental|Experimental: Kinesio taping|Epicondilar and epitroclear muscle Kinesio Taping with a Space Correction on the wrist according Kenzo Kase Method
89555567|NCT02367157|No Intervention|No intervention: Control|
89555568|NCT04059835|Active Comparator|standard|Standard bra, soft
89555569|NCT04059835|Experimental|compression bra|experimental bra, compression and stabile
89555570|NCT02366533||Sites Implementing the LTC Program|This study will be conducted at the 15 ATN-funded clinical sites, known as the Adolescent Medicine Trial Units (AMTU). Each enrolling site must have the capability to input field data that can be used to evaluate the effectiveness of the Strategic Multisite Initiative for the Identification, Linkage, and Engagement in Care of Youth with Undiagnosed HIV Infection (SMILE in CARING for YOUTH) Project.
89555571|NCT02366455||Thoracic CT-Scan|Measurement of the length of the right main stem bronchus and of the right upper lobe bronchus antero-posterior angulation on consecutive thoracic CT-Scan reconstruction
89555572|NCT03860233|Experimental|Visit 1 Randomization|At visit 1subjects will receive one of two interventions: either Oxytocin Intranasal spray (40 IU) or Placebo Intranasal spray. Subjects will be blinded as to which drug they are receiving.
89555573|NCT03860233|Experimental|Visit 2 Crossover Randomization|At visit 2 subjects will receive the opposite intervention from the one they received at visit 1: either Oxytocin Intranasal spray (40 IU) or Placebo Intranasal spray. Subjects will be blinded as to which drug they are receiving.
89555574|NCT02373007|Other|Classic Scopinaro Surgery|Patients will get the Bariatric surgery using the Classic Scopinaro Techniques
89555575|NCT02373007|Other|Modified Scopinaro Surgery|Patients will get Bariatric surgery using the Modified Scopinaro Techniques
89555576|NCT02373085|Experimental|A: Antibiotic adjusted to antibiogram|A course of 3-14 days of antimicrobial treatment, according to the antibiogram results, will be prescribed for every episode of asymptomatic bacteriuria beyond 2 months after transplantation and during the first 2 years after transplantation
89555577|NCT02373085|No Intervention|B: no treatment|No treatment of any episode of asymptomatic bacteriuria beyond 2 months after transplantation in kidney transplant recipients.
89555578|NCT02372851|Active Comparator|Pureit As+ Filter|Each household will receive one water filter and a replacement battery for free during distribution. The intervention will be distributed door-to-door by the implementation team. Households will be trained on use and maintenance of the device according to the manufacturer's instructions. Households will be advised to drink exclusively from the water filter and to carry water with them if attending school or work. Households will also be advised to clean and cook their rice with filtered water only.
89555579|NCT02372851|No Intervention|Control arm|The control arm will be advised to continue with their traditional drinking water and cooking practices. The control arm will receive the intervention at the end of the study period.
89555580|NCT01361009||pramipexole group|It's a open-label, non-intervention,observation post marketing surveillance to observe the safety and efficacy of pramipexole in real world.
89555581|NCT02373163|Active Comparator|Diuretic|Therapy with hydrochlorothiazide (25 mg daily) taken once daily between 6 and 8 AM
89555582|NCT02373163|Active Comparator|Calcium-channel blocker|Therapy with amlodipine (10 mg daily) taken once daily between 6 and 8 AM
89555583|NCT02373163|Active Comparator|Angiotensin Receptor Blocker|Therapy with Telmisartan (80 mg daily) taken once daily between 6 and 8 AM
89555584|NCT02372539||Non-diabetes|Patients without diabetes will serve as the control group
89555585|NCT02372539||Diabetes|Patients with diabetes will be further stratified based upon antihyperglycemic medications (insulin versus oral medications)
89555586|NCT02366377|Experimental|SHR3824 Placebo|SHR3824 Placebo , once daily, 12 weeks, Metformin, Three times daily, 500mg, background drug.
89555587|NCT02366377|Experimental|SHR3824 5 mg|SHR3824 5 mg , once daily, 12 weeks, Metformin, Three times daily, 500mg, background drug.
89555588|NCT02366377|Experimental|SHR3824 10 mg|SHR3824 10 mg , once daily, 12 weeks, Metformin, Three times daily, 500mg, background drug.
89555589|NCT02366377|Experimental|SHR3824 20 mg|SHR3824 20mg , once daily, 12 weeks, Metformin, Three times daily, 500mg, background drug.
88962979|NCT02018536|Experimental|Part 2, Sequence 4|6 participants to receive Treatment D (TMC435 150 mg+GSK2336805 60 mg), C (TMC435 100 mg+GSK2336805 60 mg), A (TMC435 150 mg) and B (GSK2336805 60 mg) in a sequence with a 7 days washout period between each treatment sessions.
89555590|NCT02362867|No Intervention|Total Knee Replacement|Total knee replacement is indicated for patients suffering from severe knee pain and disability. Specific indications include femoral, tibial and patellar replacement due to degenerative bone disease such as osteoarthritis, rheumatoid arthritis, primary and secondary traumatic arthritis, polyarthritis, collagen disorders, avascular necrosis of the femoral condyles, or complications from a previous prosthesis. The Balanced Knee System (BKS) will be used to treat patients undergoing a total knee replacement.
89555591|NCT05053685||Obstructive Sleep Apnoea (OSA)|Subjects with OSA
88962980|NCT02018549|Experimental|Placebo|Inhalation through Chiesi NEXThaler DPI containing Placebo Dry Powder. Each patient will perform at least two inhalations using the Chiesi NEXThaler DPI device containing placebo dry powder. There is no comparator and all patients will receive the same study treatment.
88962981|NCT02018575|Experimental|levels of lysine intake.|Randomly selected levels of lysine intake which are lower than the lysine requirement (previously derived).
88962982|NCT02018588|Experimental|tryptophan intake|Graded levels of tryptophan will be given to each subject on different study days around the anticipated breakpoint.
88962983|NCT02018601|Experimental|BRILMA&dexketoprofen&paracetamol|dexketoprofen: 50 mg/8h paracetamol: 1gr/6h
88962984|NCT02018601|Active Comparator|paravertebral block&dexketoprofen&paracetamol|dexketoprofen: 50 mg/8h paracetamol: 1g/6h
88962985|NCT02018614||testretest relaibility|Data from a sample of 50 patients will be used to explore the test-retest reliability of the scale administered by the same trained clinician, on two occasions four hours apart, without any treatment in between. The ALGOPLUS® scores obtained from the patients at a time t will be compared with their (t + 4 hours) scores to assess test-retest reliability
88962986|NCT02018614||statistical test|For a sample of at least 50 patients, two physicians trained for the use of ALGOPLUS, will assess pain independently. A statistical test will be used to compare the results for the inter-rater reliability
88962987|NCT02018666|Experimental|spontaneous NAVA mode|
88962988|NCT02018666|Active Comparator|Inspiratory pressure support (IPS)|
89025808|NCT04410757||Point of Care Ultrasound (POCUS) group|When the provider in charge of covering the post-anesthesia care unit, they would apply POCUS examinations in their PACU assessment as per the study protocol of hypotensive and hypoxic events.
89025809|NCT04410757||No Point of Care Ultrasound (POCUS) group|When the provider in charge of covering the post-anesthesia care unit, they would apply routine bedside examination techniques in their PACU assessment as per the study protocol of hypotensive and hypoxic events.
88962989|NCT02018679|Experimental|Er:YAG AFL-PDT|AFL was performed using a 2940-nm Er:YAG ablative fractional laser (Joule, Sciton Inc., CA, UA) at 550-600 µm ablation in depth, level 1 coagulation, 22% treatment density, and a single pulse. Immediately afterwards, a 1-mm thick layer of MAL (16% Metvix® cream, PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, Saint Paul, MN, US) for 3 hours, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light. Each treatment area was then separately illuminated with red light-emitting diode (LED) lamps (Aktilite CL128; Galderma, Bruchsal, Germany) with peak emission at 632 nm and total light dose of 37 J cm2.
89025810|NCT00462215|Experimental|1|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 6-month booster vaccination with the H5N1 vaccine containing 3.75 mg HA antigen strain A/Vietnam/1203/2004
89208233|NCT00984555||A2 (Inoculation with 4 timepoints)|Semen exposure via inoculation, Vaginal swabs at 4 time points
89555592|NCT05053685||Elevated Urine Metanephrines|Subjects with elevated metanephrines
89555593|NCT02366299|Active Comparator|dexmedetomidine|Treatment of delirium by dexmedetomidine i.v. infusion
89555594|NCT02366299|Active Comparator|propofol|Treatment of delirium by propofol i.v. infusion
89555595|NCT05042297|Active Comparator|Combined Posterior and anterior ring fixation|Posterior ring fixation via a single posterior Sacroiliac screw or two Iliac wing plates. While anterior ring fixation was via a single para-symphyseal plate in Tile B2 injuries. Meanwhile, we used double superior and anterior symphyseal plates in Tile C1 injuries.
89555596|NCT05042297|Experimental|Isolated Posterior ring fixation|We used either two Sacroiliac screws in S1 and S2, or two Iliac wing plates.
89555597|NCT05053919|Experimental|SR device group|
89555598|NCT05053919|Placebo Comparator|placebo device group|
89555599|NCT02997553|Experimental|sentinel lymph node detection|"Each patient receive both injections of Technetium99 (standard care) and indocyanine green.~The detection of sentinel lymph node will be conducted by an optonuclear probe able to detect the radioactive and the fluorescence signal during surgery."
89555600|NCT05041985|Experimental|group A (the Test group)|arm which received Diazepam 5 mg therapy for 7 days after whiplash
89555601|NCT05041985|No Intervention|group B (the control group)|a group which did not receive Diazepam 5 mg therapy
89555602|NCT02372695|Experimental|Treatment|Patient will take one pill of paricalcitol a day.
89555603|NCT02372695|No Intervention|Usual treatment.|Patient allocated to this arm will only take his/her habitual treatment
89555604|NCT05053841|No Intervention|Control group|fifteen obese females who received letrozole only
89555605|NCT05053841|Active Comparator|metformin group|fifteen obese females who received the same dose of letrozole plus metformin (2000 ± 500) mg daily
89555606|NCT05053841|No Intervention|lean group|fifteen non- obese breast cancer females who received letozole for six months, treatment period
89555607|NCT02372461|Placebo Comparator|Experimental|Placebo
89555608|NCT02372461|Active Comparator|Control|Amoxicillin Liquid
89555609|NCT05053529|Experimental|Mirror therapy|Session consist of total 1hour,20 min of passive mobilization, 30 minutes for Movement mirror therapy,10 minutes standard ADL activities 5 times a week and for consecutive 3 weeks in a month.
89555610|NCT05053529|Experimental|Constrained induced movement therapy (CIMT)|Session consist of total 1hour ,20 min of passive mobilization, 30 min session to CIMT and 10 minutes standard ADL activities 5 times a week and for consecutive 3 weeks in a month.
89555611|NCT03096431|Active Comparator|Arm 1: Physical activity intervention|Undergo baseline testing of physical (lower body strength, endurance) and cognitive (executive functioning) abilities. 14 days (± 2 days) following WBRT/SRS: all arms undergo testing of physical (lower body strength, endurance) and cognitive (executive functioning) abilities. Arm 1: intervention of physical activity begins. 60 days (± 5 days) post testing after WBRT/SRS: all arms undergo final testing of physical (lower body strength, endurance) and cognitive (executive functioning) abilities.
89555612|NCT03096431|Active Comparator|Arm 2:Physical activity and cognitive intervention|Undergo baseline testing of physical (lower body strength, endurance) and cognitive (executive functioning) abilities. 14 days (± 2 days) following WBRT/SRS: all arms undergo testing of physical (lower body strength, endurance) and cognitive (executive functioning) abilities. Arm 2: intervention of both cognitive rehabilitation and physical activity begins. 60 days (± 5 days) post testing after WBRT/SRS: all arms undergo final testing of physical (lower body strength, endurance) and cognitive (executive functioning) abilities.
89555613|NCT03096431|Active Comparator|Arm 3: Cognitive and begin physical activity intervention|Undergo baseline testing of physical (lower body strength, endurance) and cognitive (executive functioning) abilities. Arm 3: Intervention of cognitive rehabilitation begins prior to and is concurrent with WBRT/SRS treatment. 14 days (± 2 days) following WBRT/SRS: all arms undergo testing of physical (lower body strength, endurance) and cognitive (executive functioning) abilities. Arm 3: continue intervention of cognitive rehabilitation; add intervention of physical activity. 60 days (± 5 days) post testing after WBRT/SRS: all arms undergo final testing of physical (lower body strength, endurance) and cognitive (executive functioning) abilities.
89555614|NCT02372773||Frontotemporal Dementia - MAPT|Frontotemporal Dementia with microtubule associated protein tau (MAPT) mutation
89555615|NCT02372773||Frontotemporal Dementia - PGRN|Frontotemporal Dementia with progranulin (PGRN; also known as granulin or GRN) mutation
89555616|NCT02372773||Frontotemporal Dementia - C9OR72|Frontotemporal Dementia with chromosome 9 open reading frame 72 (C9ORF72) mutation.
89555617|NCT02372773||Control|Member of family with a known mutation in one of the three major FTD related genes: MAPT, PGRN, and C9ORF72.
89555618|NCT02372617||Group A|bone graft - autologous
89555619|NCT02372617||Group B|bone graft - ceramic
89555620|NCT05053373|Experimental|Electroacupuncture Added to Pelvic Floor Muscle Training|Patients will be in a prone position. Bilateral Zhongliao (BL33) and Huiyangacupoint (BL35) will be identified and punctured by an acupuncturist. The electrodes will be placed on the needle handles, and stimulate for 30 minutes at 50 Hz with a current intensity between 1 to 5 mA. PFMT will be performed 3 sets a day (morning, around noon, and night).
89555621|NCT05053373|Experimental|Sham Electroacupuncture Added to Pelvic Floor Muscle Training|The preparation for the patients will be the same as that for the patients who will receive EA. Whereas, instead of using real acupuncture needles, special designed placebo needles (size 0.30 × 25 mm) with the blunt-head will be used in the PFMT+sham EA group to penetrate the fixed pad to the skin surface but without skin penetration. The same procedure for deqi will be performed as in the PFMT+EA group. A special-designed cable (the intermediate wire of the cable is cut off but the appearance is normal) will be used to connect the electrodes to the electroacupuncture machine. Therefore, the electroacupuncture machine appears to work, but does not actually stimulated acupoints. The sham EA treatment will also be maintained for 30 minutes. PFMT will be performed 3 sets a day (morning, around noon, and night),
89555622|NCT05053061|Experimental|Telerehabilitation Arm|
89555623|NCT04499131|Experimental|I: Artificial endometrial preparation cycle|Artificial endometrial preparation cycle with estrogens and vaginal natural micronized progesterone 400mg/12h
89555624|NCT04499131|Experimental|II: Artificial endometrial preparation cycle|Artificial endometrial preparation cycle with estrogens and subcutaneous natural progesterone 25mg/24h
89555625|NCT04499131|Experimental|III: Artificial endometrial preparation cycle|Artificial endometrial preparation cycle with estrogens and subcutaneous natural progesterone 25mg/12h
89555626|NCT04499131|Experimental|IV: Artificial endometrial preparation cycle|Artificial endometrial preparation cycle with estrogens and a combination of subcutaneous natural progesterone 25mg/24h + vaginal natural micronized progesterone 400mg/24h
89555627|NCT04499131|Experimental|V: Artificial endometrial preparation cycle|Artificial endometrial preparation cycle with estrogens and intramuscular natural progesterone 50mg/24h
88962990|NCT02018679|Active Comparator|MAL-PDT|Immediately afterwards, a 1-mm thick layer of MAL (16% Metvix® cream, PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, Saint Paul, MN, US) for 3 hours, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light. Each treatment area was then separately illuminated with red light-emitting diode (LED) lamps (Aktilite CL128; Galderma, Bruchsal, Germany) with peak emission at 632 nm and total light dose of 37 J cm2. Areas which were scheduled to receive MAL-PDT received the second treatment 7 days later.
88962991|NCT02018705||POEM|group of Achalasia patients treated with POEM (peroral endoscopic myotomy)
88962992|NCT02018705||LHM|group of Achalasia patients treated with LHM (laparoscopic Heller myotomy)(+ fundoplication)
88962993|NCT02018718|Other|Marathoners|
88962994|NCT02018731|Experimental|Metformin and Metformin & L-Citrulline|1500 mg/d metformin for 6 weeks, followed by 1500 mg/d metformin and 15 g/d L-citrulline for 6 further weeks
88962995|NCT02018731|Experimental|L-Citrulline and Metformin & L-Citrulline|15 g/d L-citrulline for 6 weeks, followed by 1500 mg/d metformin and 15 g/d L-citrulline for 6 further weeks
88962996|NCT02018757|Experimental|As2O3|Subjects will be treated with TACE containing As2O3
88962997|NCT02018757|Placebo Comparator|placebo|Subjects will be treated with TACE containing placebo which mimics the arsenic trioxide
88962998|NCT02018770|Experimental|Phototherapy|Three groups will receive different fototerapia of light sources, and group 1 will not receive dose: Group A (0, 65Joules), Group B (1.30 Joules) and Group C (1.95 Joules) .
88962999|NCT02018770|Placebo Comparator|Placebo phototherapy|The volunteers will be subjected to the same Groups intervention Phototherapy . The but researcher will receive placebo pen. It is the caveat that, after completed the voluntary participation, will be held with the active pen treatment.
88963000|NCT02018783|Experimental|Sensodyne|Digital application for 60 seconds.
88963001|NCT02018783|Experimental|Colgate|Slow-speed handpiece with a Robson brush for 3 seconds by repeating the procedure
88963002|NCT02018783|Experimental|Nano P|Slow-speed handpiece with a Robson brush for 10 seconds
88963003|NCT02018783|Placebo Comparator|Cocorico|Digital application for 60 seconds
88963004|NCT02018848|Placebo Comparator|Attention Training Placebo|"Same procedure, stimulus material, frequency and duration as in experimental group.~The only difference: In the placebo group the probe randomly appears at one of the two locations on the screen so as not to train attention in any direction.~Thus, the placebo training sessions are identical to the bias assessment sessions."
88963005|NCT02018848|Experimental|Attention Training Program|"The Attention Training consists of a modified dot-probe task. In this task pairs of pictures (OCD-relevant/neutral) are presented for 500 ms on a computer screen. Next, a probe appears on one of the two former picture locations. Participants have to react to that probe by pressing the corresponding button on the keyboard. One training session takes approximately 10 minutes in which 160 stimulus pairs are shown.~In the experimental group the probe always appears at the location of the neutral picture so as to train attention away from OCD-relevant stimuli.~Participants are asked to complete at least 2 training sessions per week over a period of 5 weeks. The first and last session are bias assessment sessions (see outcome measures), but participants stay blind to this."
88963006|NCT02018874|Experimental|LY2780301|
88963007|NCT02018900|Placebo Comparator|Placebo|Placebo
88963008|NCT02018900|Experimental|Ecologic 825/scFOS|Ecologic 825/scFOS
89208234|NCT00984555||B1 (intercourse with 7 timepoints)|Semen exposure via unprotected intercourse, Vaginal swabs at 7 time points
89555628|NCT04499131|Active Comparator|Natural menstrual cycle|Natural menstrual cycle (without any exogenous steroid hormone Treatment)
89555629|NCT02805595|Experimental|Hypertonic Saline|23.4% Hypertonic Saline injection(s) with a maximum of 0.4cc per treatment. If necessary every two weeks, with a maximum of three treatments.
89555630|NCT05053295|Experimental|Immuncell-LC/Nivolumab group|Patients will receive nivolumab once a day at 4-week intervals and Immuncell-LC 12 times (3 treatments once a week, followed by 5 treatments every other week, and finally 4 treatments every 4 weeks).
89555631|NCT02372227|Experimental|VS-5584 and VS-6063|
89555632|NCT03095963|Active Comparator|Probiotics|The study group took a mixture of highly charged Lactobacilli and Bifidobacteria (VSL#3®) in addition to levothyroxine
89555633|NCT03095963|Active Comparator|Levothyroxine|The control group took levothyroxine only
89555634|NCT05653687|Experimental|Fluoroscopy|
89555635|NCT05653687|No Intervention|Freehand|
89555636|NCT05053217|Active Comparator|Patients diagnosed with fibromyalgia|
89555637|NCT05053217|Active Comparator|Patients without a diagnosis of fibromyalgia|
89555638|NCT02366065|Experimental|Acetaminophen|study subjects will have their intraocular pressure measured at 8 am, 10 am, 12 pm and 4 pm. They will then take acetaminophen 650 mg qid for 7 days and the intraocular pressures again measured at 8 am, 10 am, 12 pm, and 4 pm. Subjects will then stop the acetaminophen and return one week later for one more set of intraocular pressure measurements at 8 am, 10 am, 12 pm, and 4 pm.
89555639|NCT05052593|Experimental|Compressive myofascial release|". patients in this group will receive treatment through CMR that includes shaking the muscle belly of vastus lateralis for 30 seconds. Then the hip is fully extended on treatment table and CMR is applied on Vastus lateralis muscle for 1 minute. Treatment consists of broad strokes applied with clinicians knuckles to release superficial restrictions, followed by more specific strokes applied with clinicians' thumb on tight muscle. Strokes are applied at a contact point of 45 degree. with pressure directed from distal to proximal.~Conventional treatment of Hot pack and Tens for 20 minutes, Range of motion exercises (knee flexion and extension ROM's), Stretching exercises (3sets, 10 reps for 5 second hold)"
89555640|NCT05052593|Active Comparator|Conventional treatment|Patients in this group will receive treatment of Hot pack and Tens for 20 minutes, Range of motion exercises (knee flexion and extension ROM's), Stretching exercises (3sets, 10 reps for 5 second hold)
89555641|NCT02362945|Experimental|Intervention group:|Treatment with 1 gr hexakapron Intra-Venous (IV) after delivery of the fetus in addition to accepted treatment with oxytocin (10 units in 100ml NaCl (sodium chloride)0.9% solution IV). ( the oxytocin is the routine practice in our department).
89555642|NCT02362945|No Intervention|Control:|Treatment with oxytocin after fetal extraction (10 units in 100ml NaCl 0.9% solution IV). as commonly given for Post-Partum Hemorrhage (PPH) at our obstetrical ward.Active Comparator: (this is the routine practice in our department).
89555643|NCT02365909|Active Comparator|Acitve|This group will receive 0.3 ml of 0.5% bupivacaine per nare, applied with the Tx360®
89555644|NCT02365909|Placebo Comparator|Placebo|This group will receive 0.3 ml of normal saline per nare, applied with the Tx360®
89555645|NCT05052515|Placebo Comparator|Placebo|Oral treatment Two tablets twice a day for one year
89555646|NCT05052515|Experimental|Nutritional Supplementation|Oral treatment Two tablets twice a day for one year
89555647|NCT02365675|Active Comparator|Cotton gauze with petrolatum|The dressing to be used is regular cotton gauze impregnated in petrolatum (a mixture of solid hydrocarbons) creating a film that reduces the adherence of the gauze to the wound.
89555648|NCT02365675|Active Comparator|Cellulose acetate with petrolatum|The dressing to be used is a mesh or tulle base of cellulose acetate polymers that do not easily adhere to the wound impregnated in petrolatum (a mixture of solid hydrocarbons).
89555649|NCT02365675|Active Comparator|Nanocrystalline silver|The dressing to be used consists of two layers of a silver-coated, high-density polyethylene mesh, enclosing a single layer of an apertured non-woven fabric of rayon and polyester. The three components are ultrasonically welded together to maintain the integrity of the dressing in use. Silver is applied to the polyethylene mesh by a vapour deposition process, which results in the formation of microscopic 'nanocrystals' of metallic silver.
89555650|NCT02365675|Active Comparator|Carboxymethylcellulose with ionic silver|The dressing to be used is a soft, sterile, non- woven pad dressing made from sodium carboxymethylcellulose containing 1.2% silver in an ionic form.
89555651|NCT05052437|Experimental|Utidelone|
89555652|NCT05052437|Experimental|Utidelone plus capecitabine|
89555653|NCT02365753|Placebo Comparator|SofPulse nonfunctional device.|The Sofpulse non-functional device is placed over the incision after cesarean delivery and then turned on. The device only appears to be function correctly because the lights turn on, but does not emit a pulsed electromagnetic frequency..
89555654|NCT02365753|Active Comparator|Active|The Sofpulse Pulsed electromagnetic frequency device is placed over the incision after cesarean delivery and then turned on. Device appears to be operational and functions correctly.
89555655|NCT02365831||Prospective|Observation of treatment management of patients with metastatic breast cancer that have been treated or not with hormonal therapy and candidate for a first line chemotherapeutic treatment in the years 2014-2015 will be observed until the end of the study.
89555656|NCT02365831||Retrospective|Observation of treatment management of patients with metastatic breast cancer that have been treated with a first, second or following line of chemotherapeutic treatment for metastatic disease in the years 2012-2013.
89555657|NCT05041517|No Intervention|Control|No intervention
89555658|NCT05041517|Experimental|BOLT + 1 PTC|BOLT Training + 1 PTC Call
89555659|NCT05041517|Experimental|BOLT + 2 PTC|BOLT Training + 2 PTC Calls
89555660|NCT05041517|Experimental|BOLT + 4 PTC|BOLT Training + 4 PTC Calls
89555661|NCT02365987|Experimental|Interesterified|Interesterified blend of palm kernal and plam stearin. 50g fat.
89555662|NCT02365987|Active Comparator|Un-interesterified|Un-interesterified blend of palm kernal and plam stearin. 50g fat.
89555663|NCT03095573|Experimental|Lateral-viewing capsule|Examination of the small bowel by means of the lateral-viewing CapsoCam device
89555664|NCT03095573|Active Comparator|Axial-viewing capsule|Examination of the small bowel by means of the axial-viewing capsule
89555665|NCT05051423||Patients diagnosed with primary gastric tumors referred to our department for EUS local staging.|"Patients will be included or excluded according to the following criteria used throughout the study:~Inclusion criteria: Patients diagnosed with primary gastric tumors referred for local staging by EUS (n=40); Age 18 to 90 years old, men or women; Signed informed consent for EUS with contrast-enhancement and tissue sampling~Exclusion criteria: Prior treatment with chemo-radiotherapy; Failure to provide informed consent; severe coagulopathy.~Data collected for each participant will include: Personal data (name, surname, age, sex); results from previous investigations (blood count, liver and renal function tests, tumoral markers, gastroscopy, computed tomography), EUS variables (including CEH-EUS), histological and immunohistochemical findings, TNM and pTNM status (if possible), molecular analysis findings."
89555666|NCT02359201|Experimental|Sequence 1|Treatment group sequence: Test Product (V0018) on Day 1 and Placebo on Day 2
89555667|NCT02359201|Experimental|Sequence 2|Treatment group sequence: Placebo on Day 1 and Test Product (V0018) on Day 2
89555668|NCT05041283|No Intervention|Standard Preparation|Control arm; patients receive a standard support for bowel preparation consisting of a explanatory dialogue with a gastroenterologist and a brochure with a structurated description of bowel preparation and colonoscopy conduct
89555669|NCT05041283|Active Comparator|Phone-call Supported Preparation|In addition to standard preparation, patients receive a phone call every day starting at 3 days before colonoscopy in which a investigator explains key points of bowel preparation and patients can ask questions concerning bowel preparation and colonoscopy conduct.
89555670|NCT05041283|Experimental|Chatbot Supported Preparation|In addition to standard preparation, patients receive an access to a chatbot which can be contacted via Whats App starting at 3 days before colonoscopy. The chatbot is programed to answer questions concerning bowel preparation and colonoscopy conduct.
89555671|NCT02363023||VAP suspects|Collect tracheal and pulmonary secretions. All patients (n: 72) will be submitted to endotracheal aspirate, bronchoscopic and non-bronchoscopic bronchoalveolar lavage.
89555672|NCT05041205|Placebo Comparator|Placebo control group|placebo drink powder without active ingredients, 1 sachet per day with 50 ml water for 12 weeks
89555673|NCT05041205|Experimental|Beauty drink powder group|Beauty drink powder is the test article provide to participants, 1 sachet per day with 50 ml water for 12 weeks
89555674|NCT05041205|Placebo Comparator|cosmetic apparatus group|This group is designed for a cosmetic apparatus control group without consumption of placebo or test article. Together with the specified cleanser, the apparatus is used for daily facial cleaning, two times in the morning and evening for 12 weeks.
89555675|NCT05041205|Experimental|Beauty drink powder + cosmetic apparatus group|In this group, Beauty drink powder is consumed 1 sachet daily with 50 ml water and the cosmetic apparatus is used together with the specified cleanser for daily facial cleaning, two times in the morning and evening for 12 weeks.
89555676|NCT02362711|Experimental|NPC-16 Standard Dosing Regimen Group|Levonorgestrel 0.09mg, Ethinylestradiol 0.02mg
89555677|NCT02362711|Experimental|NPC-16 Continuous Dosing Regimen Group|Levonorgestrel 0.09mg, Ethinylestradiol 0.02mg
89555678|NCT02362711|Placebo Comparator|Placebo Group|Placebo for NPC-16
88963009|NCT02018939|Experimental|Pharmacokinetic profiling in Hemodialysis|Patients with chronic intermittent hemodialysis receiving doripenem therapy are included in this arm. Pharmacokinetic samples are drawn.
88963010|NCT02018939|Experimental|Pharmacokinetic profiling in CVVH|Patients receiving continuous venovenous renal replacement therapy in an ICU setting receiving doripenem therapy are included in this arm. Pharmacokinetic samples are drawn.
88963011|NCT02018939|Experimental|Pharmacokinetic profiling in MARS|Patients receiving liver replacement therapy (MARS) in an ICU setting receiving doripenem therapy are included in this arm. Pharmacokinetic samples are drawn.
88963012|NCT02018952|Other|Ultrasonography assessment|
88963013|NCT02018965|Other|ER niacin followed by ART alone|For Arm 1, ER niacin administration begins Week 0 and ends Week 24 (defined as 'immediate use' arm).
88963014|NCT02018965|Other|ART alone followed by ER niacin|For Arm 2, ER niacin administration begins after the Week 24 Visit and ends Week 48 (defined as 'deferred use' arm).
88963015|NCT02018978|Experimental|CTHP|"HIV Voluntary Counseling and Testing at Community Prevention Center-The center will be open to all community members.~Community Mobilization-HIV/AIDS and VCT information will be disseminated with pamphlets, community discussions, and meetings.~Risk Assessment and Triaged Counseling and Recruitment-Clients identified at high-risk for HIV infection and HIV-infected clients we be offered an additional counseling session. Participation will be incentivized. These clients will also be provided with up to 3 referral cards to give to sexual partners. If partners come for VCT, they will receive a small incentive.~Incentives & Support Activities - Modest and ethically appropriate incentives, including those providing nutritional support (food), health and hygiene benefits (bed nets), transport to access interventions, or income generation potential, will be provided for participation in some project interventions, and these will be graduated based on HIV risk potential."
88963016|NCT02018978|No Intervention|Standard of Care|This arm will receive standard of care HIV-related services, including clinic-based voluntary counseling and testing and referrals to HIV care and treatment government-run facilities.
88963017|NCT02018991|Active Comparator|Everolimus-Eluting-Stent (EES)|Patients treated with EES
89555679|NCT04434677|Active Comparator|Hypofractionation|Control arm:patients who will receive standard 40.05 Gray (2.67 Gy/ fx) over 15 fractions with or without boost over 3 weeks
89555680|NCT04434677|Experimental|Ultrahypofractionation|Experimental arm: Patients who will receive 26 Gray (5.2 Gy/fx) over 5 fractions over 1.5 weeks
89555681|NCT01944046|Placebo Comparator|DB Placebo Nasal Spray|Placebo treatment during weeks 0-24 double blind phase
89555682|NCT01944046|Active Comparator|DB Oxytocin Nasal Spray|DB Oxytocin- quadruply masked treatment with intranasal oxytocin during weeks 0-24 of study during double blind phase of study
89555683|NCT01944046|Active Comparator|open label intranasal oxytocin|non masked treatment with intranasal oxytocin from weeks 24-48 in those participants who completed first 24 weeks of double blind treatment
89555684|NCT05040737|Experimental|Study Arm|Patients will be dialysed according to the usual dialysis schedule of three weekly sessions. The study has a duration of 8 days in order to include 4 haemodialysis sessions. The first and third haemodialysis sessions will be dialysed with PS membrane and the second and fourth sessions with PMMA membrane, both dialysers with a surface area of 1.8 m2.
89208235|NCT00984555||B2 (Intercourse with 4 timepoints)|Semen exposure via unprotected intercourse, Vaginal swabs at 4 time points
89555685|NCT02087891|No Intervention|CTL|Wait-list control, no intervention. Intervention offered after week 16 and outcomes are collected.
89555686|NCT02087891|Experimental|Web-based stress management (WSM)|Subjects randomized to this group will receive access to the WSM program to complete on their own time.
89555687|NCT02087891|Experimental|WSMg1|Subjects randomized to this group will receive access to WSM with group support. They will meet once per week for 1 hour. Meeting will be led by one of their peers who is a non-expert facilitator.
89555688|NCT02087891|Experimental|WSMg2|Subjects randomized to this group will receive access to WSM and group support and clinical expert support. They will attend 4 weekly support groups led by a peer non-expert facilitator and 4 weekly support groups led by a clinical psychologist.
89555689|NCT00773695|Active Comparator|Chemotherapy|Participants will receive epirubicine, 5-fluorouracil, and cyclophosphamide (FEC 100) for 12 weeks followed by taxane therapy (paclitaxel or docetaxel) for next 12 weeks.
89555690|NCT00773695|Experimental|Chemotherapy and Bevacizumab|Participants will receive epirubicine, 5-fluorouracil, and cyclophosphamide (FEC 100) for 12 weeks followed by taxane therapy (paclitaxel or docetaxel) for next 12 weeks. Participants will also receive concurrent treatment with bevacizumab every 3 weeks for 24 weeks.
89555691|NCT00773695|Active Comparator|Endocrine Therapy|Participants will receive aromatase inhibitor therapy at discretion of the investigator for a period of 24 weeks.
89555692|NCT00773695|Experimental|Endocrine Therapy and Bevacizumab|Participants will receive aromatase inhibitor therapy at discretion of the investigator and concurrent treatment with bevacizumab for a period of 24 weeks.
89555693|NCT04643704||FPIES|100 patients
89555694|NCT04643704||IgE mediated food allergy|100 patients
89555695|NCT04643704||Celiac disease|100 patients
89555696|NCT04643704||Control group|100 patients
89555697|NCT02362633|Experimental|Real tDCS|Subjects will receive real tDCS treatment for ten times for two weeks (five times per week).
89555698|NCT02362633|Sham Comparator|Sham tDCS|Subjects will receive sham tDCS treatment for ten times for two weeks (five times per week).
89555699|NCT03112525||Patient under Rivaroxaban|
89555700|NCT03112525||Patient under Apixaban|
89555701|NCT05040425|Experimental|Chinese herbal medicine treatment|
89555702|NCT05040425|No Intervention|Non-Chinese herbal medicine treatment|
89555703|NCT03112837|Experimental|drug group|live Lactobacillus, Bifidobacterium and Enterococcus ( two pills two times a day)with radiotherapy and Chemotherapy
88963018|NCT02018991|Active Comparator|Zotarolimus-Eluting-Stent (ZES)|Patients treated with ZES
88963019|NCT02018991|Active Comparator|Biolimus-Eluting-Stent (BES)|Patients treated with BES
88963020|NCT02019017|Experimental|Botulinum Toxin Type A 25 IU|The first five patients will be injected 25 IU of Botulinum Toxin Type A
88963021|NCT02019017|Experimental|Botulinum Toxin Type A 50 IU|the next five patients will receive 50 IU of Botulinum Toxin Type A
88963022|NCT02019030||BPH on anticoagulation|Patients with Benign Prostatic Hyperplasia (BPH) undergoing Transurethral Vaporization of Prostate and are on anticoagulant medication
88963023|NCT02019043|Experimental|Syphilis testing with routine HIV bloodwork|The intervention condition will be implemented as standing orders for syphilis serology whenever patients undergo their standard battery of follow-up bloodwork, i.e., when there is an order for HIV viral load or CD4 cell count.
88963024|NCT02019043|No Intervention|Current care practice|The control condition will remain the current care practice, which is generally opportunistic screening or diagnostic testing for those presenting with signs/symptoms or who report sexual risk behaviour.
88963025|NCT02019056|Placebo Comparator|Placebo|enteric coated capsule
88963026|NCT02019056|Experimental|MG 500mg|Metadoxine + garlic oil
88963027|NCT02019056|Experimental|MG 1000mg|Metadoxine + garlic oil
88963028|NCT02019056|Sham Comparator|Metadoxine 500mg|enteric coated capsule
89208236|NCT00800696|Experimental|oral care|intervention: The study group will have their teeth brushed three times a day by the nursing staff by using a suction connected toothbrush, daily examination of the oropharynx by the nursing staff, and use of chlorhexidine varnish or another suitable antibacterial agent in the oropharynx.
89555704|NCT03112837|No Intervention|non-drug group|only receiving radiotherapy and chemotherapy
89555705|NCT03112837|No Intervention|healthy control group|
89555706|NCT01969084|Experimental|Linagliptin|Subjects given Linagliptin
89555707|NCT01969084|Placebo Comparator|Sugar pill|Subjects given sugar pill/placebo
89555708|NCT05040347||PVTT group|The diagnosis of portal vein tumor thrombosis was confirmed by clinical correlation using histologic features taken from liver biopsy as determined by a pathologist,and findings from image studies including ultrasound, computed tomography, and MRI, verified by a radiologist.
89555709|NCT05040347||HCC group|The diagnosis of HCC was confirmed by clinical correlation using histologic features taken from liver biopsy as determined by a pathologist,and findings from image studies including ultrasound, computed tomography, and MRI, verified by a radiologist.
89555710|NCT05040347||control group|The presence of PVTT or HCC was confirmed by medical record review and all the recorded events were confirmed by a radiologist using imaging studies, ultrasound, contrast-enhanced, or MR.
89555711|NCT02359123|Experimental|Cannabics 5mg|Patients will be treated initially for 3-4 days with 1x5mg Cannabics capsules per day for gradual adaptation. From the 5th day, patients will be treated 2x5mg capsules per 24 hours for a period of 3 months. However, since some patients may suffer from side effects mainly, dizziness and or anxiety, dosage for these patients will be reduced to 5mg per day.
89555712|NCT02362477|Active Comparator|Control CPT|'Cognitive Processing Therapy in-person. Cognitive Processing Therapy is delivered to female veterans and civilians, who have been diagnosed with PTSD, in-person.
89555713|NCT02362477|Experimental|Experimental CPT via VTC|'Cognitive Processing Therapy through videoteleconference. Cognitive Processing Therapy is delivered to female veterans and civilians, who have been diagnosed with PTSD, through videoteleconference.
89555714|NCT05040191|Experimental|Control Group|"Application in the Control Group: After the theoretical lesson, the control group was taken to the Nursing Fundamentals Skills Laboratory. The laboratory consists of 3 practice rooms, 1 control room and 1 analysis room. A video prepared by the researcher on the Simple Nasogastric Tube Application Model in line with the steps of Checklist for Teaching Nasogastric Tube Application Skills was watched and preliminary information was given. The questions were answered by allowing the students to ask questions."
89555715|NCT05040191|Experimental|Haptic Interactive Virtual Reality Simulation(Experiment 1 group)|Application in the Experiment-1 Group: After the theoretical lesson, the students in the Experiment-1 group were taken to the computer laboratory room where the haptic interactive virtual reality application was installed. The Nasogastric Tube Application with Haptic Interactive Virtual Reality Simulation was applied and explained by the researcher and preliminary information was given. The questions were answered by allowing the students to ask questions.
89555716|NCT05040191|Experimental|Haptic Interactive Computer Based Simulation(Experiment 2 group)|Application in the Experiment-2 Group: After the theoretical lesson, the students in the Experiment-2 group were taken to the laboratory room where the haptic interactive computer-based simulation was located. This computer-assisted simulation allows us to see the application on the computer screen while performing an application with a haptic arm. It gives feedback on hand manipulations similar to reality. It was explained by the researcher by applying the nasogastric tube application skill with haptic interactive computer-based simulation and preliminary information was given. The questions were answered by allowing the students to ask questions.
89555717|NCT02358577|Experimental|Cycle ergometry|Participants will receive In-bed cycling for 30 minutes per day in addition to Usual Care, until the physiotherapist deems that the patient is mobilizing well, or a maximum of 7 days (whichever comes first).
89555718|NCT02358577|Active Comparator|Usual care|Usual care physiotherapy will be applied to patients in the control arm, according to the unit specific guidelines for early mobilization
89555719|NCT04636840|No Intervention|Control Group|Access to a self-help version of Space From Body and Eating Concerns Program on SilverCloud Health App
89555720|NCT04636840|Experimental|Experimental Group A- Mobile App with Social Networking Feature|Access to a coached Space From Body and Eating Concerns program on SilverCloud Health App with private social media group for social networking support.
89555721|NCT04636840|Experimental|Experimental Group B- Mobile App Only|Access to a coached Space From Body and Eating Concerns program on SilverCloud Health App.
89555722|NCT02353039|Experimental|GC6101A 37.5mg|Administer 12.5mg of GC6101A t.i.d for 2 weeks.
89025811|NCT00462215|Experimental|2|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 6-month booster vaccination with the H5N1 vaccine containing 7.5 mg HA antigen strain A/Vietnam/1203/2004
89025812|NCT00462215|Experimental|3|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 6-month booster vaccination with the H5N1 vaccine containing 3.75 mg HA antigen strain A/Indonesia/05/2005
89025813|NCT00462215|Experimental|4|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 6-month booster vaccination with the H5N1 vaccine containing 7.5 mg HA antigen strain A/Indonesia/05/2005
89025814|NCT00462215|Experimental|5|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 12-month booster vaccination with the H5N1 vaccine containing 3.75 mg HA antigen of the A/Indonesia/05/2005 strain
89025815|NCT00462215|Experimental|6|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 24-month booster vaccination with the H5N1 vaccine containing 3.75 mg HA antigen of the A/Indonesia/05/2005 strain
89025816|NCT04410952||no EES|Patients with a Type-C pelvic ring fracture who underwent no external emergency stabilization (EES) for the posterior pelvic ring
89025817|NCT04410952||Pelvic binder|Patients with a Type-C pelvic ring fracture who received a pelvic binder for emergency stabilization of the posterior pelvic ring
89025818|NCT04410952||Pelvic C-clamp|Patients with a Type-C pelvic ring fracture who received a pelvic C-clamp for emergency stabilization of the posterior pelvic ring
89025819|NCT04134481||low intervention group|from 0-7 clustered nursing intervention
89555723|NCT02353039|Experimental|GC6101A 75mg|Administer 25mg of GC6101A t.i.d for 2 weeks.
89555724|NCT02353039|Experimental|GC6101A 150mg|Administer 50mg of GC6101A t.i.d for 2 weeks.
89555725|NCT02353039|Placebo Comparator|Placebo|Administer placebo t.i.d for 2 weeks.
89555726|NCT05039957|Active Comparator|A|
89555727|NCT05039957|Experimental|B|
89555728|NCT01942486|Experimental|Investigational Coating|
89025820|NCT04134481||high intervention group|from 8-15 clustered nursing intervention
89208237|NCT00800696|No Intervention|control|continue to receive oral care as performed today.
89555729|NCT03095729||Healthy|40 healthy subjects, during quiet breathing and under an inspiratory load (inspiratory threshold loading)
89555730|NCT03095729||Ondine syndrome|12 patients presenting with central hypoventilation syndrome or Ondine's curse syndrome, during spontaneous breathing and with Non Invasive Ventilation
89555731|NCT03095729||Amyotrophic Lateral Sclerosis|30 patients presenting with Amyotrophic Lateral Sclerosis during spontaneous breathing and with Non Invasive Ventilation
89555732|NCT04660084|Other|Ultra-rapid molecular point-of-care testing|Extended and more rapid diagnostics on microbiological specimens and an active feedback to treating staff with results.
89555733|NCT04660084|No Intervention|Standard of care|Standard collection of microbiological specimens and standard reply to treating staff.
88963029|NCT02019082|Active Comparator|electrical stimulation|electrical stimulation group, group who received direct current ES at sensory threshold intensity for 1 h/day, 3 days/week, for 4 weeks (12 sessions)
88963030|NCT02019082|Placebo Comparator|placebo|In the placebo group, the treatment procedure was the same as that the ES group, but the current intensity was zero.
88963031|NCT02019095||Acute Respiratory Failure - Bronchoalveolar lavage|Intensive care unit patients with acute respiratory failure due to ventilator-associated pneumonia or the acute respiratory distress syndrome. Bronchoalveolar lavage (BAL) fluid will be obtained on days 1 and 5 post-enrollment for the determination of biochemical markers, and microbiological studies.
88963032|NCT02019134|Active Comparator|usual care waiting list|Patients allocated to the usual care waiting list group will continue with their usual care without receiving any additional therapy
88963033|NCT02019134|Experimental|relaxation exercise|Participants allocated to the relaxation group will apply daily but at least five days a week a 15-minutes relaxation exercise, guided by a smartphone application (App). On a daily basis, participants can select one out of the three exercises (guided imagery, mindfulness based training, autogenic training) which they want to apply
89555734|NCT02352805||(1) veno-venous ECMO|ECMO - Patients being connected to veno-venous extracorporeal membrane oxygenation (ECMO)
89555735|NCT02352805||(2) veno-arterial ECLS|ECLS - Patients being connected to veno-arterial extracorporeal life support (ECLS)
89555736|NCT02352805||(3) LVAD (Heart Mate II)|LVAD - Patients being connected to a left ventricular assist device (LVAD) (Heart Mate II)
89555737|NCT02352805||(4) LVAD (Heart Ware)|LVAD - Patients being connected to a left ventricular assist device (LVAD) (Heart Ware)
89555738|NCT02352805||(5) LVAD (Impella)|LVAD - Patients being connected to a left ventricular assist device (LVAD) (Impella)
89555739|NCT02352805||(6) Dialysis system|Patients being connected to a dialysis system
89555740|NCT02352805||(7) LVAD (Heart Mate III)|LVAD - Patients being connected to a left ventricular assist device (LVAD) (Heart Mate III)
89555741|NCT02352805||(8) HLM|HLM = Heart Lung Machine - patients undergoing coronary artery bypass grafting surgery and / or aortic valve replacement with cardiopulmonary bypass
89555742|NCT05050877||coronary angiography|The investigators recruit all consecutive patients who were undergoing coronary angiography or percutaneous coronary intervention.
89555743|NCT02362399|Active Comparator|sildenafil citrate|50 mg single oral dose
89555744|NCT02362399|Active Comparator|placebo|single tablet of placebo
89555745|NCT04410887|Experimental|PISOXO|"st cycle of PIPAC during 1st laparoscopic exploration Three cycles of SOX~nd cycle of PIPAC during 2nd laparoscopic exploration Surgery Three cycles of SOX +/-OLAPARIB~PIPAC Intraperitoneal chemotherapy for PIPAC is Docetaxel Neoadjuvant Chemotherapy Patients will receive three cycles of a standard dose of Tegafur gimeracil oteracil potassium capsule (TGO) plus oxaliplatin (SOX) +Olaparib prior to curative gastrectomy.~Adjuvant chemotherapy Three cycles of SOX +/- OLAPARIB will be given as postoperative chemotherapy.~Chemotherapy regimen A cycle consists of Day 1: Oxaliplatin 130mg/M2 intravenous Day 1-14 Tegafur gimeracil oteracil potassium capsule (TGO) 80mg/M2 oral (twice daily) Repeated every 21st day OLAPARIB Day 1-14: Olaparib 300mg oral twice a day"
89555746|NCT02362555||ossification of nuchal ligament|check neck function, radiography characteristics and complete functional disability questionnaire
89555747|NCT02362555||Non ossification of nuchal ligament|check neck function, radiography characteristics and complete functional disability questionnaire
89555748|NCT05050331|Experimental|Muscle Energy Technique (MET) Group|Post-isometric relaxation was given as the form of MET. It was applied to gastrocnemius and soleus with patient supine and foot extended, knee was flexed for soleus and extended for gastrocnemius muscle. The patient ankle was dorsiflexed by the therapist until the point of discomfort or resistance, and the patient was instructed to exert pressure using 20% force for 5-7 seconds toward plantar flexion. Relaxation was given for 5 seconds and the therapist passively dorsiflex the ankle to a new barrier. Gastrocnemius and soleus both received a single set of 5 repetitions separately. Treatment was given for 4 weeks, 3 sessions per week.
89555749|NCT05050331|Experimental|Trigger Point Release Group|Trigger points of gastrocnemius muscle was released. The patient in prone lying with legs extended and the therapist in walk standing position, applied vertical downward pressure toward the trigger points for 90 seconds with the therapist's thumb. Three repetitions was given with 30 seconds relaxation time. After that, 3 longitudinal strokes in caudal to cranial direction was given by the therapist's thumb over the taut band. Treatment was provided for 4 weeks, 3 sessions per week.
89555750|NCT05039333||RUS (Surgical navigation, anatomy 3D-reconstruction)|single-arm study : prospective observational 1-arm (RUS group)
89555751|NCT01941940|Experimental|Tocilizumab|Tocilizumab at a fixed dose of 162 milligrams (mg) will be administered as subcutaneous (SC) injection alone or along with methotrexate and/or other non-biological DMARDs irrespective of body weight, once every week for a total of 52 weeks. After 52-weeks of treatment, at the discretion of the treating physician, participants can continue the study treatment with SC tocilizumab until it becomes commercially available in Italy.
89555752|NCT02358733|Experimental|Treatment|Intra-cytoplasmic Morphologically-selected Sperm Injection (IMSI)
89555753|NCT02358733|Active Comparator|Control|Intracytoplasmic sperm injection (ICSI)
89555754|NCT02358499|Experimental|Posaconazole Injection|We will give a single dose of intravenous posaconazole and collect blood samples for pharmacokinetics (PK). The study pool will be enriched by selecting participants with known sequence variations. Every effort will be made to balance age and disease state (HSCT vs. non-HSCT).
88963034|NCT02019147||Term Hypoxic Ischaemic Encephalopathy|Term Hypoxic Ischaemic Encephalopathy (HIE)
88963035|NCT02019147||Healthy Term Neonates|Controls
88963036|NCT02019160|Experimental|Silver nitrate|Biannual application of 25% AgNO3 solution followed by 5% NaF varnish.
89208238|NCT00980187|Active Comparator|Hydrochlorothiazide|
89555755|NCT03098069||KMC Scale up in a district|This is an implementation research project on scaling up KMC in selected government and private health facilities in an entire district, aiming to cover newborns weighing less than 2000gms at birth.
89555756|NCT02358421||Initial cohort|Patients at risk of developing OHSS according to the inclusion criteria
89555757|NCT03095807|Experimental|NNC9204-1706 A|
89025821|NCT00462254|Other|A|Day 1-3: placebo run-in - 8 mg of placebo orally 30 minutes before bedtime. Days 4-11: true drug - 8 mg of Ramelteon orally 30 minutes before bedtime. Days 12-14: crossover - 8 mg of placebo orally 30 minutes before bedtime. Days 15-22: continue placebo.
89025822|NCT00462254|Other|B|Day 1-3: Placebo run-in - 8 mg of placebo orally 30 minutes before bedtime. Days 4-11: continue placebo. Days 12-14: crossover - 8 mg of placebo orally 30 minutes before bedtime. Days 15-22: true drug - 8 mg of Ramelteon orally 30 minutes before bedtime.
89025823|NCT04407637||neck pain patients|Patients with acute non-specific neck pain were consecutively recruited from a private manual physiotherapy center as sample of convenience. Inclusion criteria were acute (<3months) non-specific neck pain with a neck disability index (NDI) > 8% and a Numerical Pain Rating Scale (NPRS) >3 . Patients were excluded if they reported any of the following: a history of neck surgery, dizziness caused by neck or head movements and cervical radiculopathy diagnosed by a physician.
89025824|NCT04407637||healthy|Healthy control participants were included if they reported a NDI < 8% and a NPRS =0. They were excluded if they reported neck pain during the last year, radiating symptoms in the shoulder or arm regions, or headache. Participants with a history of neck trauma or in treatment for spinal disorders or reporting pain during the manual assessment were excluded as well.
89025825|NCT04328545|Experimental|Anodal tDCS on DLPFC|Participants will receive anodal tDCS on the left DLPFC for 30 mins duration, cathode will be placed over the right supra orbital area. The electrodes are 25cm², The stimulation current is 2 milliamperes (2mA).
89025826|NCT04328545|Active Comparator|Anodal tDCS on M1|Participants will receive anodal tDCS on the left M1 for 30 min duration, cathode will be placed over the right supra orbital area. The electrodes are 25cm², The stimulation current is 2 milliamperes (2mA).
89555758|NCT03095807|Placebo Comparator|Placebo|
89555759|NCT02358655|Other|Phase 1: Retrospective Chart Review|Retrospective chart review of all patients who presented to the emergency department (ED) with ECG-documented AF during 1 year prior to study commencement. The main purpose of Phase 1 is to determine if oral anticoagulants were prescribed for eligible AF patients at ED discharge.
89555760|NCT02358655|Other|Phase 2: Low-Intensity Intervention|Low-intensity intervention will be applied in the ED during 6 months, involving physician education, distribution of an AF patient education package, short-term oral anticoagulant prescription, and a follow-up letter to the patient's family physician.
89555761|NCT02358655|Other|Phase 3: High-Intensity Intervention|Phase 3 incorporates the Phase 2 intervention, and adds immediate follow-up (within 48-72 hours) in a community AF clinic run by a nurse/pharmacist who is supervised by a specialist in AF.
89025827|NCT04328545|Sham Comparator|Sham tDCS|Participants will receive sham tDCS. The anode will be placed on the left DLPFC and the cathode on the over the right supra orbital area. The electrodes are 25cm², There will be a ram up and down of 30 seconds each, after the ramp up the current will be turned off.
89208239|NCT00980187|Experimental|Indapamide SR|
89208240|NCT00795470|No Intervention|No catheter change no antimicrobial|Urinary catheter will not be changed and no antimicrobials will be prescribed
89208241|NCT00795470|Active Comparator|Antimicrobial and catheter change|
89555762|NCT02358265|Active Comparator|10 mg Rupatadine on demand|Rupatadine 10 mg, on demand
89555763|NCT02358265|Active Comparator|10 mg Rupatadin|Rupatadine 10 mg, continuously
89555764|NCT02358265|Active Comparator|20 mg Rupatadine|Rupatadine 20 mg, continuously
89555765|NCT02358265|Active Comparator|10 mg rupatadine on demand (sham upd.)|Rupatadine 10 mg, on demand (sham updosing to 20 mg)
89555766|NCT05038397|Experimental|Therasphere|
89555767|NCT03112213||Participants With RA|Participants with RA who are being treated with tocilizumab and NSAIDs will be observed for approximately 6 months to evaluate the quantitative pattern of NSAID use and the impact of treatment with tocilizumab on NSAID use.
89555768|NCT01968694|Experimental|IV Lidocaine|IV lidocaine dosed at 8mg/kg IV (maximum 500 mg) and infused over 30 minutes
89555769|NCT01968694|Placebo Comparator|IV diphenhydramine|IV diphenhydramine 50mg total dosed as a 10mg IV bolus and then 40mg IV infusion over 30 minutes
89555770|NCT03097913||video-stylet tube assembly|patients who undergo oxo-maxillofacial surgery with nasotracheal intubation general anesthesia are recruited
89208242|NCT00795470|Active Comparator|Catheter change and NO antimicrobial|
89208243|NCT00795470|Active Comparator|Antimicrobial and NO catheter change|
89555771|NCT05049941||group1|Group (1): veno-arterial carbon dioxide tension / arteriovenous oxygen content P(v-a)CO2/C(a-v)O2 ratio group.
89555772|NCT05049941||group 2|Group (2): Lactate clearance (LC) group; Lactate level was measured then LC rate was calculated by the equation [(lactate(T0)- lactate(T8))/lactate(T0)] × 100%.
89555773|NCT05049941||group 3|"Group (3):~veno-arterial carbon dioxide tension group; P(v-a)co2 difference"
89555774|NCT02362243|Placebo Comparator|Control Group|Participants in the control arm will complete the placebo comparator intervention.
89555775|NCT02362243|Experimental|Supervised Exercise Group|Participants in the supervised exercise intervention arm will perform the experimental intervention under direct 1-on-1 supervision of an exercise specialist.
89555776|NCT02362243|Experimental|Web-based Exercise Group|Participants in the web-based exercise intervention arm will perform the experimental intervention with use of a web-based exercise system for exercise instruction and guidance, and without direct 1-on-1 on-site supervision.
89555777|NCT05038007|Active Comparator|Control|Bupivacaine Hydrochloride in perioperative intercostal blockades
89555778|NCT05038007|Experimental|Intervention|Liposomal bupivacaine in perioperative intercostal blockades
89555779|NCT04639102|Experimental|PATH Intervention|Patients in the treatment arm will receive a personalized plan of care upon discharge from the emergency department.
89555780|NCT04639102|No Intervention|Routine Care|Patients in the control arm will receive standard-of-care services (the care plan that the emergency physician would normally offer if PATH were not available) without PATH enrollment.
89555781|NCT04479007||Mechanically ventilated patients|Critically ill patients of 18 years or older who receive invasive mechanical ventilation for acute respiratory failure and have an indication for an intervention in the airways.
89555782|NCT01968226|Experimental|PET imaging with [F-18] RDG-K5|This is an observational study of a group of individuals who all have carotid artery stenosis. The observation will be the measurement of [F-18]RGD-K5 uptake by the carotid artery plaque after intravenous administration of this radiolabeled tracer using PET imaging.
89555783|NCT02358109|Experimental|Intervention arm|Intervention group receive directed classes of physical conditioning, 3 hours/week during a period of 16 weeks
89555784|NCT02358109|No Intervention|Control arm|Control group do not receive physical conditioning intervention but usual care advice and are measured at the beginning and at the end of the study
89555785|NCT05038319|Active Comparator|Cyanoacrylate injection and EUS guided coil and glue injection|The procedure would be performed under conscious sedation.The endoscope would be used to reach the site of Varices. In Conventional technique treatment with cyanoacrylate the injection was performed using a 23-G sclerotherapy needle catheter . One vial of N-butyl-2-cyanoacrylate (0.5 mL) was mixed with Lipiodol) in a 1:1 ratio, and injected intravesically as a 1 mL bolus. The injection was repeated until total hardening of the varix. In treatment with coil and cyanoacrylate once the gastric varix was identified, the total diameter of the vascular pseudotumor was measured and the puncture was made at the site of the widest varix. The puncture was performed using a 19 G needle . the size of the coil after release should not be greater than the caliber of the vessel. Following coil deployment, 2 mL of distilled water was injected, followed by one vial (0.5 mL) of N-butyl-2-cyanoacrylate mixed with Lipiodol in 1:1 ratio.
89555786|NCT05038319|Placebo Comparator|COIL and GLUE|"Cyanoacrylate injection, first published by Soehendra in 1986, remains the conventional treatment method.~Since coils were first used to treat ectopic varices by Levy in 2008(6), this technique has been increasingly implemented into clinical practice. However, its higher cost has been a limiting factor in more widespread use.~Depending on the ectasia of the varix the following coil was deployed: 8 mm x 20 cm, 10 mm x 20 cm, or 10 mm x 30 cm (Interlock-18 Fibered IDC Occlusion System,Cook)."
89555787|NCT05049629|Experimental|Eye 1|The contralateral eye serves as the control eye. After the baseline examination and the follow-up examination one hour later, patients will be released with a prescription of one drop of Lacrimera® into the study eye per day in the evening and with one drop of single-use preservative-free hyaluronic acid containing eye drops (Hylo-Vision® sine) into the control eye three times a day for 14 consecutive days.
89555788|NCT05049629|Active Comparator|Eye 2|The contralateral eye serves as the control eye. After the baseline examination and the follow-up examination one hour later, patients will be released with a prescription of one drop of Lacrimera® into the study eye per day in the evening and with one drop of single-use preservative-free hyaluronic acid containing eye drops (Hylo-Vision® sine) into the control eye three times a day for 14 consecutive days.
89555789|NCT02362165|Experimental|CyBorD regimen|this arm will receive cyclophosphamide (500mg/d,once-weekly),bortezomib(1.3mg/㎡，once-weekly,subcutaneous injection), and dexamethasone (40mg/d,once-weekly)(CyBorD) as induction therapy.
89555790|NCT02362165|Active Comparator|PAD regimen|this arm will receive bortezomib(1.3mg/㎡，once-weekly,subcutaneous injection), dexamethasone (40mg/d,once-weekly), and doxorubicin (9mg/㎡，d1-4)(PAD) as induction therapy.
89555791|NCT02352571|Experimental|Single group assignment|GC1118 recombinant human anti-EGFR antibody
89555792|NCT03095495|Experimental|Early use of HHHFNC|Heated Humidified High Flow Nasal Cannula
89555793|NCT03095495|Active Comparator|Standard Therapy and Rescue HHHFNC|Low Flow Nasal Cannula only if the patient needs oxygenation and Rescue HHHFNC if the patient needs PICU
89208244|NCT00980421|Experimental|IT|Iron Tablet group (12.5 mg/d) + Placebo Biscuit
89555794|NCT02352649|Experimental|Neovasculgen 1|Gene therapy drug Neovasculgen will be administered by several intraneural injections after surgical nerve reconstruction before wound closing. A dose is 0,6 mg will be dissolved in 1 ml of aqueous vehicle (water for injection) prior to injection.
89555795|NCT02352649|Experimental|Neovasculgen 2|Gene therapy drug Neovasculgen will be administered by several intraneural injections after surgical nerve reconstruction before wound closing. A dose is 1,2 mg will be dissolved in 1 ml of aqueous vehicle (water for injection) prior to injection.
89555796|NCT02352649|Placebo Comparator|water for injections|Instead of the gene therapy drug, 1 ml of aqueous vehicle (water for injections) will be administered by several intraneural injections.
89208245|NCT00980421|Experimental|IZ|Iron (12.5mg/d)+Zinc (10 mg/d) Tablet Group + Placebo Biscuit
89555797|NCT05037773|Experimental|Group 1|In this condition, the intervention is administered immediately after the baseline.
88963037|NCT02019160|Active Comparator|Silver diamine fluoride|Biannual application of 38% SDF solution followed by placebo varnish.
89555798|NCT05037773|Experimental|Group 2 (waiting-list group)|This group is both a control and an experimental group. Indeed, the intervention (i.e., the same as for group 1) is administered but after a second baseline which is held after the completion of the Group 1. This condition will allow to check the specific efficiency of the intervention.
89555799|NCT05049239|Experimental|Physical training|Medium-high-intensity physical training 3 times a week, 60 min / time for 12 weeks.
89555800|NCT05049239|Active Comparator|Physical training combined with cognitive support|"Medium-high-intensity physical training 3 times a week, 60 min / time for 12 weeks.~The cognitive support consists of person centred individual occupational therapy."
89555801|NCT05049239|No Intervention|Control group|The control group receive no intervention.
89555802|NCT05049473|Experimental|Chemotherapy|"Pts with biological age up to 55 y with advanced stage will receive 6 cycles of intensive treatment: blocks (A1-B1-C1-A2-B2-C2). If after A1 and B1 cycles CR is observed, the rest of the cycles will be administered with reduced doses.~In pts with biological age >55 y with advanced stage block will receive A and B with attenuated doses (A1*-B1*-A2*-B2*-A3*-B3*).~Pts with biological age up to 55 y with localized stage (non-bulky I or II) with CR after 2 cycles will finish treatment after 4 blocks. If CR is not reached, patients will complete the 6 treatment cycles.~Pts with a biological age >55 y with localized stage (non-bulky I or II) with CR after 2 cycles will finish treatment after 4 attenuated blocks (A1*-B1*-A2*-B2*). If CR is not reached, patients will complete the 6 cycles of treatment."
89555803|NCT02361931|Experimental|Treatment group (erythropoietin)|10 patients receive RMD-G1 (gel with 2000 IU/ml of erythropoietin) as an adjunct therapy to standard of care (SOC). Topical application on wound bed, daily for 12 weeks.
89555804|NCT02361931|Placebo Comparator|Control group (standard of care)|10 patients receive SOC alone daily for 12 weeks. A moisturizing gel is applied on wound bed as a part of SOC.
89555805|NCT02361853||Active labor at term|Women in active labor normal pregnancy at term
89555806|NCT02361853||Non-active labor at term|"Women, normal pregnancy at term who come for usual follow up without signs for labor ( contraction / show discharge/ rupture of membranes)."
89555807|NCT02361853||Active labor, pre-term|Women in active pre term labor (34- 37w) normal pregnancy.
89555808|NCT05037695|Experimental|empagliflozin + OMT|empagliflozin 25mg - Daily - at least 15 days before the PCI procedure OMT - Optimized Medical Therapy - conventional drug therapy with oral antidiabetics and/or insulin plus use of anti-platelet, anti-hypertensive and lipid-lowering agents necessary to obtain adequate values for pressure, lipid control and glycemia, in accordance with international guidelines and protocols. Strategies to reduce Contrast-induced acute kidney injury will be used in both study arms
89555809|NCT05037695|No Intervention|OMT|OMT - Optimized Medical Therapy - conventional drug therapy with oral antidiabetics and/or insulin plus use of anti-platelet, anti-hypertensive and lipid-lowering agents necessary to obtain adequate values for pressure, lipid control and glycemia, in accordance with international guidelines and protocols. Strategies to reduce Contrast-induced acute kidney injury will be used in both study arms
89555810|NCT02361697|Other|DTI-MRI|MRI of the brain with specific DTI-sequences according to a specific investigation protocol
89555811|NCT05049395|Active Comparator|Control group|The patients are administered oxygen of 3L-6L/min until the end of the hysteroscopy operation.
89555812|NCT05049395|Experimental|HFNO group|The patients are administered oxygen of 30L-60L/min until the end of the hysteroscopy operation.
89555813|NCT02357641||Patients with thoracal disorder|"300 patients with thoracal disorder, cardiac or non- cardiac, are enrolled prospectively to undergo routinely examinations such as clinical and hemodynamic chemistry as well as echocardiography for strain analysis refering to myocardial deformation.~Especially analysis of strain data (circumferential and radial), regional and global left and right ventricular wall movement data and diastolic parameters will be analysed retrospectively to investigate a probable cut off value corresponding to acute coronary disease or non cardiac disorder (Intervention: retrospective echographic myocardial strain analysis refering to acute coronary syndrome)."
88963038|NCT02019173|Experimental|Boot camp balance training|Intense physical rehabilitation directed at improving balance and mobility will be provided to individuals in a group setting (6 participants in a group) for 4 weeks, 3 days a week for 6 hours per day.
88963039|NCT02019186|Experimental|Vitamin C and E|6 weeks of daily treatment with Vitamin C and E
88963040|NCT02019212||MPI Perfusion Imaging|Clinical patients who have undergone myocardial perfusion imaging with 99mTc
89555814|NCT05048771||FERTITOP|300 patients (15-25 years) from 5 different hospitals (University Hospitals of Nancy, Strasbourg, Reims, Besançon, Dijon (France)) who have finished all cancer treatments for at least 2 years.
89025828|NCT04407598||Glenfield Complex COPD Clinic Cohort|Patients previously seen in the complex COPD clinic at the Glenfield Hospital.
89555815|NCT02352181|Placebo Comparator|S group|S Group: will be transfused patients according to standard management based on conventional coagulation profile of the laboratory
89555816|NCT02352181|Experimental|R group|The R group will consist of patients transfused according to an algorithm based on the data of the coagulation ROTEM analysis.
89555817|NCT02357563|Experimental|Ulipristal acetate|Women will be treated with an oral dose of ulipristal acetate 5 mg/day for 2 courses of 3 months each
89555818|NCT02357563|Active Comparator|Leuprolile acetate|Women will be treated with an injection IM on leuprolide acetate 11,25 in the luteal phase repeated 3 months later
89555819|NCT04478929||gastroscopy clinic patients|NBT gastroscopy clinic invited participants. Patients are already due to attend the clinic, and we are inviting them to share their gastroscopy data with our research study.
89555820|NCT02361541||HCV screening|All adult patients of an existing HIV cohort
89555821|NCT03160105|No Intervention|Continuing cART + Standard monitoring|Patients randomized to this arm will continue their current standard ART regimen (cART) and will continue a standard 3-monthly routine safety biological monitoring (including CD4 cell count, fasting lipids and glucose, renal and hepatic function tests) at their SHCS site.
89555822|NCT03160105|Experimental|Continuing cART + Patient-centered monitoring|Patients randomized to this arm will continue their current cART and will have immunological and safety blood examinations performed once per year and at least one options (decentralised venipuncture and blood tests, delivery of ARV drugs by mail and interview by phone or skype call) for weeks 6, 12 and 36
89025829|NCT02893891|Active Comparator|Laparoscopic sleeve gastrectomy|Patients undergoing bariatric surgery procedure of laparoscopic sleeve gastrectomy.
89208246|NCT00980421|Experimental|IB|Iron Fortified Biscuit Group(12.5 mg/d)+ Placebo Tablet
89208247|NCT00980421|Placebo Comparator|CO|Placebo Tablet + Placebo Biscuit
89555823|NCT03160105|Experimental|Switch to DTG+FTC + Standard monitoring|Patients randomized to this arm will be switched to DTG + FTC dual maintenance therapy and will have immunological and safety blood examinations performed once per year and at least one options (decentralised venipuncture and blood tests, delivery of ARV drugs by mail and interview by phone or skype call) for weeks 6, 12 and 36
89555824|NCT03160105|Experimental|Switch to DTG+FTC + Patient-centered monitoring|Patients randomized to this arm will be switched to DTG + FTC dual maintenance therapy and will have immunological and safety blood examinations performed at screening and at week 48. In addition, patients will be ask to choose at least one of the following alternative options for weeks 6, 12 and 36: decentralised venipuncture and blood tests, delivery of ARV drugs by mail and Assessment and clinical interview by phone or skype call
89555825|NCT02640053|Experimental|Arm I (topical cryotherapy, paclitaxel)|Patients apply bags filled with crushed ice to hands and feet for 15 minutes before, for 60 minutes during administration, and for 15 minutes after finishing administration of paclitaxel. Courses repeat once a week for 12 weeks in the absence of disease progression or unacceptable toxicity.
89555826|NCT02640053|Active Comparator|Arm II (paclitaxel)|Patients receive paclitaxel IV over 60 minutes on weeks 1-12. Courses repeat once a week for 12 weeks in the absence of disease progression or unacceptable toxicity.
89555827|NCT03160261|Experimental|Exenatide|Single injection of 10 μg Exenatide subcutaneously.
88963041|NCT02019225|Experimental|Dialysis session of at least 4.25 hours|Dialysis facilities randomized to the Intervention arm will adopt an approach of recommending that all patients who are initiating treatment with maintenance hemodialysis have a treatment session duration of at least 4.25 hours.
88963042|NCT02019225|No Intervention|Usual care|There will be no trial-driven approach to dialysis session duration in the Usual Care arm.
88963043|NCT02019238|Placebo Comparator|Group 1-Standard PVI ablation|Pulmonary Vein Isolation procedure combined with ablation of documented non-PV triggers of AF
88963044|NCT02019238|Active Comparator|Group 2-PVI with empiric ablation|Pulmonary Vein Isolation procedure combined with empiric ablation of common sites of non-PV triggers of AF and locations that may sustain AF sources on long term arrhythmia control
88963045|NCT02019251|Experimental|Post single or double lung transplant|The subjects will receive the gas by breathing perfluorinated gas/oxygen mixture using Disposable Face mask and a standard Douglas Bag system.
88963046|NCT02019290|Experimental|bitopertin-Midazolam|
88963047|NCT02019316|Experimental|BioSteel Sports Drink|Participants will ingest 500ml of BioSteel Sports Drink 3 times during an exercise session.
88963048|NCT02019316|Placebo Comparator|Isoenergetic Control|Participants will orally ingest 500ml of Isoenergetic Control (0.18 calories/kg body weight) 2 times separated by 60 minutes.
88963049|NCT02019329|Placebo Comparator|Placebo + risperidone|
88963050|NCT02019329|Experimental|RO5545965 + risperidone|
88963051|NCT02019342||Post-quality improvement cohort|Patient cohort after FACE quality improvement initiative is implemented
88963052|NCT02019342||Pre-quality improvement cohort|Patient cohort prior to implementation of FACE quality improvement initiative
88963053|NCT02019355|Experimental|calcipotriol plus 5-fluorouracil|calcipotriol 0.005% ointment and 5-fluorouracil 5% cream are mixed at 1:1 weight ratio. The compounded medication is applied topically twice a day for 4 days.
88963054|NCT02019355|Active Comparator|5-fluorouracil plus vaseline|5-fluorouracil 5% cream and vaseline are mixed at 1:1 weight ratio. The compounded medication is applied topically twice a day for 4 days.
88963055|NCT02019368|Placebo Comparator|Placebo|Smoker subjects take 6 capsules once a day for 4 weeks.
88963056|NCT02019368|Experimental|Aged garlic extract|Smoker subjects take 1.5 g of aged garlic extract in 6 capsules once a day for 4 weeks.
88963057|NCT02019368|No Intervention|Non-smoker|Oxidative status in non-smoker
88963058|NCT02019381|Other|Endocrine Society UL Dosage Vitamin D|Participants will be randomly assigned vitamin D + calcium dose based on Endocrine Society Upper limit guidelines. And given 10,000IU Vitamin D + 1200mg Calcium (600IU Placebo Vitamin D, in addition to two calcium tablets of 600mg) each to be taken per day.
88963059|NCT02019381|Other|Institute of Medicine Dosage Vitamin D|Participants will be randomly assigned Vitamin D dose based on IOM guidelines; calcium dose will be as per IOM upper limits. And will receive 600 IU Vitamin D + 1,200 mg of calcium tablets to be taken per day.
88963060|NCT02019394|Experimental|Lu AE58054|
88963061|NCT02019407|Experimental|CTI group|CTI(Cavo-Tricuspid Isthmus)
88963062|NCT02019407|Placebo Comparator|Non CTI group|Non CTI (Cavo-Tricuspid Isthmus)
88963063|NCT02019433||Structan®|
88963064|NCT02019446|Experimental|Laser Treatment|Participants randomized to laser group will undergo laser treatment at baseline and be asked to return for 2 subsequent visits six weeks apart (at weeks 6 and 12) to undergo further laser treatment of the hallux. Each visit will last approximately 45 minutes. Laser energy (1064 nm Nd:YAG) will be delivered via an optical fibre (300 μm core/320 μm clad) secured in a hand piece. Laser energy will be delivered by maintaining the tip of the optical fibre 3 mm from the treatment area to achieve around 1-1.5 mm diameter spot size (25.5 J/cm2 fluence per pulse; 10-pulse pulse-train to each spot in 0.5 seconds). Multiple treatment spots will be delivered to cover the entire area of involvement.
88963065|NCT02019446|Active Comparator|Standard Treatment (control group)|Control group volunteers will be asked to dedicate the same amount of time to the project with the same number of visits. However, they will receive conventional terbinafine therapy instead of laser treatments. Therefore, each of the 3 treatment visits would last only about 20 minutes.
88963066|NCT02019459|Active Comparator|0.8 mg nicotine with 10.5 mg tar|SPECTRUM Cigarette: 0.8 (±0.15) mg nicotine yield with 9 (±1.5) mg tar (standard nicotine and tar yields of commercially-available cigarettes; control condition)
88963067|NCT02019459|Experimental|0.03 mg nicotine with 9 mg tar|SPECTRUM Cigarette: 0.03 mg (± 0.02) nicotine yield with 9 mg (± 1.5) tar
88963068|NCT02019485|Experimental|Treatment Sequence AB|Participants will receive single dose of new tapentadol Extended Release (ER) Tamper-Resistant Formulation (TRF) tablet and later, participants will receive single dose of current tapentadol prolonged-release formulation 2 (PR2) tablet without food. Administration of the study medications will be separated by a washout period (no treatment) of 7 to 14 days.
89025830|NCT02893891|Active Comparator|Laparoscopic gastric plication|Patients undergoing bariatric surgery procedure of laparoscopic gastric plication.
89025831|NCT02893891|Active Comparator|Intragastric balloon|Patients undergoing bariatric surgery procedure with intragastric balloon implantation.
89555828|NCT05036837|Experimental|OZOPROMAF_SEQ1|"OZOPROMAF consists of: local superficial anesthesia by application of EMLA® cream, intra-tissue injection of a 15 ml OxigenOzone (O2O3) mixture by 26Gx 1⁄2 - 0.45x13mm needle into mucosal margin surrounding bone exposure or around situs evidenced by CT scans.~Pain intensity and/or other symptoms are assessed at each visit and the day after by a questionnaire (numerical rating scale).~OZOPROMAF is applied on 7-15 days, depending on patient compliance, until the resolution (i.e. formation of sequestrum and clinical healing -T1).~Follow-up visits are scheduled to confirm healing at 1 (T2), 3, 6 (T3), 12 (T4), 18- 24 months (T5). Radiographic evaluations of bone healing are scheduled at T3/ T4/T5.~Positive outcomes~at T1/T2 clinical healing (no signs of acute phlogosis and no symptoms compatible with MRONJ);~at T3/ T4/T5 clinical healing and no radiological signs of MRONJ."
89555829|NCT05048225||Low-salt (LS) group|intake of < 5 g of salt per day
89555830|NCT05048225||Normal-salt (NS) group|intake of 5 - 7.5 g of salt per day
89555831|NCT05048225||High-salt (HS) group|intake of 7.5 - 10 g of salt per day
89555832|NCT05048225||Very high-salt (VHS) group|intake of > 10 g of salt per day
89555833|NCT02361775|Experimental|Paravertebral catheter|a paravertebral catheter is placed and an elastomeric pump is connected to infuse 0.2% ropivacaine postoperatively
89555834|NCT02361775|Active Comparator|IV PCA|opioid PCA consisting of hydromorphone is connected to patient in the post anesthesia care unit
89555835|NCT05036759|Experimental|68Ga-FAPI, PET/MR|inject 68Ga-FAPI，and then perform PET/MR
89025832|NCT00497094|Active Comparator|1|Patients receive medical treatment including medical therapy with statins (at least 40mg simvastatin irrespective of the baseline cholesterol level) and clopidogrel (75mg daily). Further conservative medical treatment includes modification of cardiovascular risk factors according to current recommendations. Additionally patients will undergo carotid artery stenting using a filter wire protection device.
89555836|NCT02361619|Experimental|1|
89555837|NCT02361463|Experimental|3D group|Will practice under 3D vision conditions on a laparoscopic virtual reality simulator
89555838|NCT02361463|Active Comparator|2D group|Will practice under 2D vision conditions on a laparoscopic virtual reality simulator
89555839|NCT05048303|Experimental|Individualized Lutajet operative group|Arthroscopic modified individualized flexible Latarjet procedure with preservation of the coracoacromial arch. During the procedure, we perform coracoid osteotomy with preservation of coracoacromial arch, then split subscapular tendon, transfer the bone graft and fix it with double button under arthroscopy.
89555840|NCT02352025|Experimental|S-equol|After having a core needle biopsy of the breast confirming triple negative breast cancer, eligible women enrolled on the study will be treated with S-equol at a dose of 50 mg PO twice daily for 14 days.
89555841|NCT01950364|Experimental|Arm A: Brentuximab vedotin|Brentuximab vedotin will be administered every 3 weeks at a dose of 1.8 mg/kg.
89555842|NCT01950364|Experimental|Arm B: Brentuximab vedotin and rifampicin|Brentuximab vedotin will be administered every 3 weeks at a dose of 1.8 mg/kg beginning on Cycle 1, Day 1; daily rifampicin (600 mg PO) will be administered during Cycles 0 through 3 only, beginning on Cycle 0, Day 1 (7 days before the Cycle 1, Day 1 dose of brentuximab vedotin) and continuing through Cycle 3, Day 21.
89555843|NCT05047991|Experimental|Cohort 1: Irinotecan Liposome Injection + 5-FU/LV + Oxaliplatin|The patients in cohort 1 will receive irinotecan liposome injection combined with 5-fluorouracil (5-FU), leucovorin(LV) and oxaliplatin intravenously on day 1 and day 15 of every 28-day cycle until disease progression or unacceptable toxicity, or termination of the study due to other reasons.
89555844|NCT05047991|Active Comparator|Cohort 2: Nab-paclitaxel + Gemcitabine|The patients in cohort 2 will receive nab-paclitaxel and gemcitabine intravenously on day 1、day 8 and day 15 of every 28-day cycle until disease progression or unacceptable toxicity, or termination of the study due to other reasons.
89555845|NCT05035979|Experimental|TCM comprehensive treatment group|Participants in the TCM treatment group will receive BaiDi Quzhi granule two times daily after meals, Ju Yin cream therapy three times per week for 8 weeks.
89555846|NCT05035979|Active Comparator|TCM internal treatment group|Participants in the TCM internal treatment group will receive Baidi Quzhi granule two times daily after meals and Ju Yin placebo therapy three times per week for 8 weeks.
89555847|NCT05035979|Active Comparator|TCM external treatment group|Participants in the TCM external treatment group will receive Baidi Quzhi placebo granule two times daily after meals and Ju Yin cream therapy three times per week for 8 weeks.
89555848|NCT05035979|Placebo Comparator|Placebo group|Participants in the placebo group will receive Baidi Quzhi placebo granule two times daily after meals, Ju Yin placebo therapy three times per week for 8 weeks.
88963069|NCT02019485|Experimental|Treatment Sequence BA|Participants will receive single dose of current tapentadol PR2 tablet and later, participants will receive single dose of new tapentadol ER TRF tablet without food. Administration of the study medication will be separated by a washout period of 7 to 14 days.
88963070|NCT02019498|Experimental|relaxation|Participants allocated to the relaxation group will apply daily but at least five days a week a 15-minutes relaxation exercise, guided by a smartphone application (App). On a daily basis, participants can select one out of the three exercises (guided imagery, mindfulness based training, autogenic training) which they want to apply
88963071|NCT02019498|Active Comparator|Usual care waiting list|Patients allocated to the usual care waiting list group will continue with their usual care without receiving any additional therapy
88963072|NCT02019524|Experimental|E39 peptide vaccine|Patients receive 6 monthly injections of E39 peptide + GM-CSF. Immunologic data is assessed at 1 month and 6 months (+/- 2 weeks) after the primary vaccine series (PVS), specifically ex vivo immunologic recognition of E39 and J65 is assessed by clonal expansion using a dextramer assay and the in vivo response is assessed by delayed type hypersensitivity. The 6-month post-PVS immunologic data is then used to assess each patient for significant residual immunity. Patients are then sorted into two groups: those with SRI and those without. Patients within each group will be randomized to receive 1 booster inoculation of the J65 vaccine or the E39 vaccine. Patients return to the clinic within 1-2 weeks of their 6-month post-PVS visit to receive their booster inoculation.
88963073|NCT02019524|Experimental|E39 vaccine then J65 vaccine|Patients receive 3 inoculations with the E39 vaccine followed by 3 inoculations with the J65 vaccine. Immunologic data is assessed at 1 month and 6 months (+/- 2 weeks) after the primary vaccine series (PVS), specifically ex vivo immunologic recognition of E39 and J65 is assessed by clonal expansion using a dextramer assay and the in vivo response is assessed by delayed type hypersensitivity. The 6-month post-PVS immunologic data is then used to assess each patient for significant residual immunity. Patients are then sorted into two groups: those with SRI and those without. Patients within each group will be randomized to receive 1 booster inoculation of the J65 vaccine or the E39 vaccine. Patients return to the clinic within 1-2 weeks of their 6-month post-PVS visit to receive their booster inoculation.
88963074|NCT02019524|Experimental|J65 vaccine then E39 vaccine|Patients receive 3 inoculations with the J65 vaccine followed by 3 inoculations with the E39 vaccine. Immunologic data is assessed at 1 month and 6 months (+/- 2 weeks) after the primary vaccine series (PVS), specifically ex vivo immunologic recognition of E39 and J65 is assessed by clonal expansion using a dextramer assay and the in vivo response is assessed by delayed type hypersensitivity. The 6-month post-PVS immunologic data is then used to assess each patient for significant residual immunity. Patients are then sorted into two groups: those with SRI and those without. Patients within each group will be randomized to receive 1 booster inoculation of the J65 vaccine or the E39 vaccine. Patients return to the clinic within 1-2 weeks of their 6-month post-PVS visit to receive their booster inoculation.
88963075|NCT02019537|Active Comparator|Steroid group|Triamcinolone injection group
88963076|NCT02019537|Experimental|PRP group|Allogeneic PRP injection group
88963077|NCT02019576|Other|Stereotactic radiotherapy (SRT)|Stereotactic radiotherapy will be administered for up to five areas of metastatic sites showing oligo-progression within the same time period. During the Sunitinib break period, stereotactic radiotherapy will be delivered in a single fraction or up to a maximum of eight fractions. The number of fractions will depend on how many sites are being irradiated.
88963078|NCT02019615|Active Comparator|anodal stimulation|Patients received anodal tDCS (on the left dorsolateral prefrontal cortex) every day for 5 days (tDCS of 2mA during 20minutes). A CRS-R is performed at baseline (before the first stimulation) and after each tDCS. A final CRS-R is performed one week after the end of the session to assess the potential long term effects of the tDCS.
89555849|NCT05047367||single-group studies|A total of 149 patients diagnosed with CTS, 126 female and 23 male, were included in the study
89555850|NCT05036057||COPD patients and their proxies|"Patients will do the Individual Knowledge Statement Questionnaire of Chronic Obstructive Pulmonary Disease (COPD), the COPD Assesment Test (CAT), the Saint George Respiratory Disease Questionnaire (SGRQ), the Charlson Comorbidity Index, and will rate the disease and general knowledge level on a numerical scale.~Proxies of patients will do the Individual Knowledge Statement Questionnaire of Chronic Obstructive Pulmonary Disease (COPD) and will rate the disease and general knowledge level on a numerical scale."
89555851|NCT02351635||IBD|Adult subjects with inflammatory bowel disease, confirmed by endoscopy and histologic support. Fecal calprotectin Level.
89555852|NCT02351635||IBS|Adult subjects with Irritable Bowel Syndrome meeting the Rome III criteria. Fecal calprotectin Level.
89555853|NCT02351635||other GI disorders|Adult subjects with gastrointestinal disorders other than IBD or IBS. Fecal calprotectin Level.
89555854|NCT02351635||pediatric|Pediatric patients (2-21 y) diagnosed with IBD, IBS, or other gastrointestinal disorders. Fecal calprotectin Level.
89555855|NCT02351635||healthy controls|Normal adult subjects with no abdominal complaints. Fecal calprotectin Level.
89555856|NCT05047133|Experimental|Early Adminstration of TXA + Intraoperative TXA|This group receives 1 G of TXA as soon as possible after a diagnosis of an acute hip fracture if the patient meets inclusion and exclusion criteria. The group will also receive 2 grams of TXA total intraoperatively.
89555857|NCT05047133|Other|Intraoperative only TXA|This group will only receive the intraoperative TXA.
89555858|NCT02357251|Active Comparator|Enhanced recovery protocol|Aspects of perioperative care will be standardized. Specific protocol for pre-operative, intra-operative, and post-operative care will be followed in this group.
89555859|NCT02357251|No Intervention|Standard of care|Treating physicians will determine all aspects of patients' perioperative care. Specifically, the individual surgeon, nurse, resident, fellow, and anesthesiologist caring for the patient will determine the patients' pre-operative counseling, bowel preparation, postoperative nausea and vomiting prophylaxis, IV fluid replacement, use of drains, timing of urinary catheter removal, mobilization, post-operative nutrition, pain medication, and bowel stimulation.
89555860|NCT05035355|Experimental|weaning protocol group|spontaneous breathing trial (SBT)-based protocol-directed weaning combined with the high-flow nasal cannula group
89555861|NCT05035355|No Intervention|routine SBT weaning group|
89517392|NCT03509467|Placebo Comparator|Control Group B|"Control Group B: Hispanic Population~Post determination of MC1R Genotypes, participants randomized to the control group, you will receive standard information about ways that they can protect themselves and their child from developing melanoma.~By the end of the study, all participants will have had the opportunity to receive information about their inherited risk. Participants randomized into the control group, by the end of the study will also have had the opportunity to receive personalized information about ways they can protect themselves and their child from developing melanoma."
89517393|NCT03490201|Active Comparator|Randomized - Control|Subjects with ICM and randomized to the Control group will undergo mapping and substrate-based ablation for the treatment of ventricular tachycardia with any of the protocol-specified commercially available ablation catheters indicated for patients with ICM. A protocol-specified commercially available mapping system will be used in conjunction with the control catheter in the ablation procedure. Subjects will be followed for 12 months post-procedure.
89517394|NCT03490201|Active Comparator|Randomized - Treatment|Subjects with ICM and randomized to the Treatment group will undergo mapping and substrate-based ablation for the treatment of ventricular tachycardia with the investigational FlexAbility SE Catheter. The Ampere Generator, Cool Point Irrigation Pump and the EnSite Precision Cardiac Mapping System or EnSite X EP System will be used in conjunction with the FlexAbility SE catheter in the ablation procedure. Subjects will be followed for 12 months post-procedure.
89025833|NCT00497094|No Intervention|2|Patients receive medical treatment including medical therapy with statins (at least 40mg simvastatin daily irrespective of the baseline cholesterol level) and clopidogrel (75mg daily). Further conservative medical treatment includes modification of cardiovascular risk factors according to current recommendations
89517395|NCT03490201|Experimental|Non-randomized - Treatment|Subjects with NICM will undergo mapping and substrate-based ablation for the treatment of ventricular tachycardia with the investigational FlexAbility SE Catheter. The Ampere Generator, Cool Point Irrigation Pump and the EnSite Precision Cardiac Mapping System or EnSite X EP System will be used in conjunction with the FlexAbility SE catheter in the ablation procedure. Subjects will be followed for 12 months post-procedure.
89517396|NCT03478670||ADA-SCID subjects treated with Strimvelis|Subjects with ADA-SCID who have received Strimvelis (previously GSK2696273) gene therapy, comprising patients treated prior to marketing authorisation (i.e. clinical studies and compassionate use programs) and those treated after marketing authorisation (including within compassionate use and early access programs).
89517397|NCT03436485|Experimental|ODM-208 Part 1 Dose escalation|
89025834|NCT00222872|Active Comparator|1 - PTHrP Group|Group receiving study drug: PTHrP(1-36)
89025835|NCT00222872|Placebo Comparator|2 - Single Blind Placebo Group|Receives placebo injections daily via subcutaneous injection
89025836|NCT00497172|Experimental|1|drug-eluting stent
89025837|NCT00497172|Active Comparator|2|bare-metal stent
89025838|NCT03273296|Active Comparator|Amoxicillin|
89025839|NCT03273296|Active Comparator|Azithromycin|
89025840|NCT03273296|Active Comparator|Vancomycin|
89025841|NCT00497250|Other|1|Thoracic RT for patients will start from 54Gy, and then escalate dose at 2Gy increment to 60Gy. At each dose level, 8 patients are required to complete RT without dose limiting toxicity(DLT). Evaluation will be done after 8 patients have completed the treatment.If there are >=2 DLT in the first 8 patients, the maximum tolerated dose (MTD) is achieved. If there is a single DLT revealed, an additional 8 patients will be recruited to that dose level. Should there be severe complication occurred again be at least 1 more DLT, then MTD is thought to be achieved.Hence,MTD will be achieved if at least 2 out of the first 8 patients have a DLT,or if a further 8 patents are recruited, >=2 out of 16 patients have a DLT. Concurrent with RT, patients will be given gefitinib 250 mg/day PO as well as same dose PO for 60 days after the completion of RT.
89517398|NCT03436485|Experimental|ODM-208 Part 2 Dose expansion|
89517399|NCT03436485|Experimental|ODM-208 Part 2 Drug drug interaction|
89517400|NCT03423264|Experimental|Gabapentin|Participants randomized to this arm will receive gabapentin beginning on evening of the first day of radiation treatment at a dose of 600 mg. Gabapentin will continue to be taken twice a day (morning and evening) for the next 4 days of radiation treatment at increasing doses (up to 900 mg). Participants will continue to receive standard best supportive care medications as per their treating physician's recommendation.
89517401|NCT03423264|No Intervention|Supportive Care Only|Participants will receive standard best supportive care medications as per their treating physician's recommendation.
89517402|NCT03406156|Experimental|Obinutuzumab|"Obinutuzumab (100 mg on Day 1 of Cycle 1, 900 mg on Day 2 of Cycle 1, and 1000 mg on Days 8 and 15 of Cycle 1 and Day 1 of Cycle 2; for Cycles 3 - 6 (1000 mg on Day 1) only as needed for participants to achieve low tumor burden) was administered via intravenous infusion during the debulking regimen.~After debulking, obinutuzumab (1000 mg) was administered via intravenous infusion on Day 1 of one 5-week and four 4-week cycles during the obinutuzumab/venetoclax combination part of the regimen. Venetoclax was administered according to a weekly ramp-up schedule over 5 weeks to the recommended daily dose of 400 mg."
89517403|NCT03406156|Experimental|Obinutuzumab/bendamustine|"Obinutuzumab (100 mg on Day 1 of Cycle 1, 900 mg on Day 2 of Cycle 1, and 1000 mg on Days 8 and 15 of Cycle 1 and Day 1 of Cycle 2; for Cycles 3 - 6 (1000 mg on Day 1) only as needed for participants to achieve low tumor burden) was administered via intravenous infusion during the debulking regimen.~Bendamustine (90 mg/m^2 ) was to be administered to those with nodes or nodal mass > 10 cm, or with del(11q) and > 5 cm nodes, or at the discretion of the investigator as above, via intravenous infusion over 10 minutes on Days 1 and 2 (or Days 2 and 3 at the discretion of the investigator during Cycle 1) of each 28-day cycle for up to 6 cycles during the debulking regimen. After debulking, obinutuzumab (1000 mg) was administered via intravenous infusion on Day 1 of one 5-week and four 4-week cycles during the obinutuzumab/venetoclax combination part of the regimen. Venetoclax was administered according to a weekly ramp-up schedule over 5 weeks to the recommended daily dose of 400 mg."
89517404|NCT03366649|Other|UMA (Group 1)|Participants in the UMA group will receive an undersizing mitral annuloplasty (UMA).
89517405|NCT03366649|Other|UMA + PMA (Group 2)|Participants in the UMA + PMA group will receive an undersizing mitral annuloplasty (UMA) with papillary muscle approximation (PMA).
89555862|NCT04334863|Experimental|WP1066|There will be 5 groups based on the enrollment timing. The first group of participants will receive the lowest dose level of WP1066. Each subject within a group will receive an assigned dose of the investigational drug. The dose levels are 4, 6, 8 and 16 mg/kg of the investigational drug given twice a day. The first group will receive the lowest dose level, 4mg/kg twice a day, and subsequent groups will escalate to the next higher dose level. All groups will be treated identically, except for the dose of drug administered, with the liquid formulation of the drug.
89555863|NCT02357329||Taste and hedonic ratings of NEFA|Linoleic acid solutions from 0.005% to 1.58%. Participants swish and spit 10 - 7.5mL solutions.
89555864|NCT02357407|Experimental|Patients in intensive care|30 patients in intensive care treated with ciprofloxacin IV
88963079|NCT02019615|Sham Comparator|sham stimulation|Patients received sham tDCS (5 secondes of stimulation) every day for 5 days. A CRS-R is performed at baseline (before the first stimulation) and after each tDCS. A final CRS-R is performed one week after the end of the session.
89555865|NCT02357407|Experimental|Osteoarticular infected patients|30 patients in orthopedics treated with oral ofloxacin
89555866|NCT05035433|Experimental|First lithotripsy and then EPBD|After successful selective bile duct intubation, contrast agent was injected to measure the thickness of the bile duct and the size of bile duct stones under fluoroscopy. For those meeting the inclusion criteria, sphincterotomy was performed first.Papillary sphincter incision after indwelling godet in bile duct, anti-popular character silk will be crushed stone on top into rubble after biliary tract, broken line to suitable size after the switch to expanding balloon EPBD and further kidney stones, papillary sphincter incision after indwelling godet in bile duct, anti-popular character silk will be crushed stone on top into rubble after biliary tract, broken balloon to suitable size after the switch to expansion, expansion size 10-12 mm, according to the lower bile duct diameter, expansion time of 30 seconds.Then, the stones were removed with a net basket or balloon, and the nasobiliary duct was placed to end the operation.
89555867|NCT05035433|Experimental|First EPBD and then lithotripsy|After puncture of the papillary sphincter, the guide wire was indwelled in the bile duct, and the columnar dilating balloon was inserted in exchange. The dilation size was 10-12mm, and the dilation time was 30 seconds according to the diameter of the lower end of the bile duct.At the end of the expansion, the stones were broken to a suitable size using a one-piece gravel net basket.The calculi were removed by using a stone net basket or balloon, and the nasobiliary duct was placed to end the operation.
89555868|NCT02038699|Experimental|ONC201|Oral ONC201 will be administered once every three weeks at various doses.
89555869|NCT05046743|Experimental|Colonic gas load|
89555870|NCT05046743|Sham Comparator|Sham|
89555871|NCT03160651|Active Comparator|methylprednisolone|Patients will receive 28 days of methylprednisolone 32 mg/day
89555872|NCT03160651|Placebo Comparator|placebo|Patients will receive 28 days of matching placebo
89555873|NCT05046977|Active Comparator|Single tibial osteotomy|Single tibial osteotomy done to achieve correction
88963080|NCT02019732||Study Group|Applicable subjects less than 65 years of age identified in the Marketscan Commercial database during the period from July 2000 through April 2009, and October 2010 to May 2011 and subjects 65 years of age and older identified in MarketScan Medicare Supplemental database during the period from July 2006 through April 2009, and October 2010 to May 2011.
88963081|NCT02019745||LAIV (FluMist)|All subjects will receive a 0.2 mL dose of LAIV (FluMist) once during the study.
88963082|NCT02019784|Active Comparator|Rifaximin-α|Rifaximin-α (TARGAXAN TM, manufactured by Alfa-Wasserman, Bologna, Italy) tablets - 550mg twice daily for 90 days
88963083|NCT02019784|Placebo Comparator|Placebo|Placebo tablets - 550mg twice daily for 90 days
88963084|NCT02019797|Experimental|Desflurane|Desflurane inhalation at 1-2 MAC during surgery.
88963085|NCT02019797|Active Comparator|Propofol|5-8 mg/kg/hr infusion during surgery.
88963086|NCT02019810|Active Comparator|Noradrenaline alone|Treatment for 30 minutes with noradrenaline alone
88963087|NCT02019810|Experimental|Noradrenaline + dobutamine|Treatment with noradrenaline and dobutamine for 30 minutes
88963088|NCT02019823|Active Comparator|Enhanced usual care|"In addition to usual care participants will receive the pre-randomisation Welcome to the *StAR Study SMS-text, post-randomisation they will received a Happy Birthday SMS-text on their date of birth and up to six additional SMS-text messages containing study specific information and thanking the participant for taking part in the study. Participants in the Enhanced Usual Care group will receive no more than one study specific SMS-text every two months."
88963089|NCT02019823|Experimental|Informational SMS-text|"In addition to enhanced usual care, participants allocated to the informational SMS-text support group will receive a series of text-messages covering the following areas:~I. Medication pick-up reminders send 48 hours before scheduled medication pick-up date a) Participants who fail to pick-up medication within 3 days of scheduled pick-up date will be sent one further reminder SMS-text~II. III. Clinic appointment reminder 48 hours before scheduled follow-up appointment~a) Participants who fail to attend clinic appointment will be sent an additional SMS-text checking they are alright and inviting them to rebook their appointment via the clinic IV. Messages which support medication adherence (focused on organisation, memory, and habit) or provide hypertension related health information"
88963090|NCT02019823|Experimental|Interactive SMS-text|"In addition to enhanced usual care and informational SMS-text messages, SMS-text messages sent to participants in the interactive SMS-text group will contain a prompt to respond which will guide participants to additional SMS-text based resources."
88963091|NCT02019836||sepsis group, control group|Sepsis group; infants with the diagnosis of high probable sepsis Control group; infants without sepsis
88963092|NCT02019862||TRJ®|
88963093|NCT02019901|No Intervention|Regular care|"The control-group is treated according to care as usual with visits to physician every 6th month."
88963094|NCT02019901|Experimental|Nurse-led clinic|Nurse-led visits every 6th week, with structured person-centered care and evaluation of disease activity. If disease remission is not reached, pharmacological treatment including both short-term (intra-articular and oral steroids) and long-term alterations (DMARDs and biologics) is modified according to a predefined algorithm.
88963095|NCT02019914||PTSD and OSA|Veterans diagnosed with Post Traumatic Stress Disorder (PTSD) and Obstructive Sleep Apnea (OSA), interested in a trial of CPAP therapy.
88963096|NCT02019953|Other|Yoga 3 times per week|Yoga participation 3 x per week for 24 weeks; 48 week follow-up.
89555874|NCT05046977|Active Comparator|Double tibial osteotomy|Double tibial osteotomy done to achieve correction
89555875|NCT02357095|Experimental|hysteroscopic monitoring|Method used for the treatment of CSP：Uterine artery chemo-embolization followed by suction curettage under hysteroscopic monitoring.The brand of hysteroscope machine is STORZ.
89555876|NCT02357095|Experimental|ultrasonography monitoring|Method used for the treatment of CSP：Uterine artery chemo-embolization followed by suction curettage under ultrasonography monitoring.The brand of ultrasonograph is mindray(Z6).
89555877|NCT02357095|Experimental|no monitoring|Method used for the treatment of CSP：Uterine artery chemo-embolization followed by suction curettage under no monitoring
89555878|NCT05026307|Experimental|Pterygium|Simple surgical excision of pterygium withe bare sclera
89555879|NCT02351713|Experimental|Threshold based method|Exercise Week 1 Heart rate (HR) < first ventilatory threshold (VT1) 3 days 20 min/day Week 2 HR < VT1 4 days 25 min/day Week 3 HR < VT1 4 days 30 min/day Week 4 HR < VT1 5 days 30 min/day Week 5-6 HR ≥ VT1 to < second ventilatory threshold (VT2) 5 days 30 min/day Weeks 7-8 HR ≥ VT1 to < VT2 5 days 30 min/day Weeks 9-12 HR ≥ VT2 5 days 30 min/day
89555880|NCT02351713|Experimental|Relative percent method|Exercise Week 1 40-45% heart rate reserve 3 days 20 min/day Week 2 40-45% heart rate reserve 4 days 25 min/day Week 3 40-45% heart rate reserve 4 days 30 min/day Week 4 40-45% heart rate reserve 5 days 30 min/day Week 5-6 50-55% heart rate reserve 5 days 30 min/day Weeks 7-8 50-55% heart rate reserve 5 days 30min/day Weeks 9-12 60-65% heart rate reserve 5 days 30 min/day
89555881|NCT02351713|No Intervention|Control|Non-exercise control group
89555882|NCT05034965|Active Comparator|deep injection of hyaluronic acid fillers|Each female will receive filler injection deep to the muscle (supraperiosteal) on one side of the face.
89555883|NCT05034965|Active Comparator|superficial injection of hyaluronic acid fillers|Each female will receive filler injection at superficial level to the muscle (subcutaneous) on the contralateral side(same dose and same site).
89555884|NCT03094091|Active Comparator|News with Spin|News items reporting results of phase I/II (non-randomized) trials with spin
89555885|NCT03094091|Experimental|News without spin|News items reporting results of phase I/II (non-randomized) trials without spin
89555886|NCT05025839||C healthy|Healthy control group
89555887|NCT05025839||C pneum|Control group of patients who were hospitalised and diagnosed with pneumonia ( COVID-19 pneumonia excluded)
89555888|NCT05025839||Mild|Outpatients presenting to the hospital with COVID-19
89555889|NCT05025839||Moderate|In-patients with COVID-19 not requiring ICU admission
89555890|NCT05025839||Severe|Patients with COVID-19 admitted to the ICU
89555891|NCT05034887|Experimental|Trastuzumab Deruxtecan (T-DXd)|One cycle is 21 days, with T-DXd repeated 3 cycles before surgery as the neo adjuvant treatment.
89555892|NCT05035121|Experimental|milk supplement|The milk group provided 200 mL milk two times per day. The participants joined the resistance exercise training program, three times per week (30 min/time) during 12 weeks.
88963097|NCT02019953|Other|Yoga 2 times per week|Yoga participation 2 x per week for 24 weeks; 48 week follow-up
88963098|NCT02019953|Other|Yoga 1 time per week|Yoga participation 1 x per week for 24 weeks; 48 week follow-up
88963099|NCT02019953|Other|Walking 3 times per week|Walking 3x per week for 24 weeks; 48 week follow-up
88963100|NCT02019953|Other|Healthy Lifestyles Education|Healthy Lifestyles Education Participation 1 x per week for 24 weeks; 48 week follow-up
88963101|NCT02019966||TDF monotherapy|"TDF monotherapy - treated by tenofovir alone~patients with CHB receiving rescue TDF (300mg once daily) monotherapy"
88963102|NCT02019966||TDF-based combination therapy|"TDF-based combination therapy - treated by tenofovir based combination therapy.~patients with CHB receiving rescue TDF-based combination therapy (TDF 300mg once daily with any other nucleoside analogue such as lamivudine 100mg, telbivudine 600mg, or entecavir 1.0 mg once daily)."
89555893|NCT05035121|Experimental|soy milk supplement|The soy milk group provided 200 mL soy milk two times per day. The participants joined the resistance exercise training program, three times per week (30 min/time) during 12 weeks.
89555894|NCT05035121|Placebo Comparator|control|The participants joined the resistance exercise training program, three times per week (30 min/time) during 12 weeks.
89555895|NCT02351557||Reference|Baseline cardiac index more than or equal to 2.1 liters per minute per square meter
89555896|NCT02351557||Low cardiac output|Baseline cardiac index less than 2.1 liters per minute per square meter
89555897|NCT05034653|Experimental|Intermittent Fasting Healthy Plate (IFHP)|Dry fasting from dawn to dusk for two days a week (Monday and Thursday) and Healthy Plate for the rest of the week. Female participants were discouraged from fasting during their menstruation period.
89555898|NCT05034653|Active Comparator|Healthy Plate|Practice the Healthy Plate concept in at least one meal every day
89555899|NCT02357017|Active Comparator|Low salt diet|The low-salt meals will be formulated to provide 50 mmol of sodium per day. Two diets with different caloric amounts (2000 or 2500) will be available.
89555900|NCT02357017|Active Comparator|High salt diet|High dietary salt intake, NaCl tablets (6 grams/day) will added to the subject's study diet in order to increase dietary sodium intake to >250 mmol/day.
89555901|NCT05025917|Experimental|Shatavari|1000 mg per day shatavari root powder (2 x 500 mg opaque capsules; equivalent to 26,500 mg fresh weight shatavari). Ingested in the morning, daily for 6 weeks.
89555902|NCT05025917|Placebo Comparator|Placebo|1000 mg per day magnesium stearate powder (2 x 500 mg opaque capsules). Ingested in the morning, daily for 6 weeks.
88963103|NCT02019992||sepsis|sepsis defined as suspected infection and systemic inflammatory response
88963104|NCT02019992||severe sepsis|sepsis with organ dysfunction or septic shock defined as sepsis plus hypotension
88963105|NCT02019992||control group|control defined as non-infected patients without systemic inflammatory response.
89025842|NCT01242618|Experimental|engineered nasal cartilage graft|Biological intervention: autologous nasal chondrocytes expanded in vitro and cultured in a collagen Type I/III scaffold
89025843|NCT01242696||Coronary artery stenting|All subjects who are candidates for coronary artery stenting, signed the Informed Consent Form and are eligible to receive a TAXUS Element stent will be evaluated for enrollment in this study.
89025844|NCT00462956|Experimental|lapatinib 1500mg daily|Subjects will self-administer lapatinib 1500 mg orally once daily.
89555903|NCT02039011|Active Comparator|Indacaterol|
89555904|NCT02039011|Experimental|Indacaterol & tiotropium|
89555905|NCT04449055|Experimental|DPFC first|Participants in this arm will undergo all study procedures including consent; pre-, during, and post-psychological assessments; pre- and post- MRI and fMRI; 16 treatments of dual target TMS over a 4-week period; and substance use-related assessments to include substance use, withdrawal symptoms, and cravings to use. This arm will receive the dorsolateral prefrontal cortex stimulation first.
89555906|NCT04449055|Experimental|MPFC first|Participants in this arm will undergo all study procedures including consent; pre-, during, and post-psychological assessments; pre- and post- MRI and fMRI; 16 treatments of dual target TMS over a 4-week period; and substance use-related assessments to include substance use, withdrawal symptoms, and cravings to use. This arm will receive the medial prefrontal cortex stimulation first.
89555907|NCT05025215|Experimental|Group A： Precise|The experimental group accepts improved precise aerosol inhalation nursing program，which was based on the traditional oxygen aerosol inhalation treatment, including precise body position care, time control, observation and treatment, evaluation, etc. This group is planned to enroll 100 patients.
89555908|NCT05025215|Experimental|Group B：Traditional|The control group accepts traditional aerosol inhalation nursing method. This group is planned to enroll 100 patients.
89555909|NCT02361385||this is a pilot study|All patients will undergo PET-CT with PBR28, with the CT being localised to one group of joints only
89555910|NCT02356627|Experimental|The Cancer Home Life Intervention|"One or more of the following:~prioritisation of resources and everyday activities~adaptation of activities~adaptation of posture and seating positioning~provision of assistive devices~modification of the physical home environment And usual care from hospital and municipality"
89555911|NCT02356627|No Intervention|Control|Usual care from hospital and municipality
89555912|NCT05025137|Experimental|Flexi-Bar group|Participants in the Flexi-Bar group performed a 60-minute Flexi-Bar exercise every week for 12 consecutive weeks.
89208248|NCT00284089|Experimental|Group A: Ranibizumab 0.3 mg|In the single dose phase, all patients randomized in Group A received a single intravitreal injection of 0.3 mg of ranibizumab into the study eye. Those patients who successfully completed this phase entered the multiple dose phase, where they received an intravitreal injection of 0.3 mg of ranibizumab once a month for an additional 11 months. Subsequently patients enrolling in the extension phase received an intravitreal injection of 0.3 mg of ranibizumab according to an individualized flexible interval regimen guided by monthly best corrected visual acuity scores and other ophthalmic examinations. In the extension phase patients received the same dose level as they received in the multiple dose phase of the study, for an average of 1.70 years.
89517406|NCT03366649|No Intervention|Retrospectively identified patients|Retrospectively identified patients, who already underwent the standard of care surgery for the lesion of interest at Emory, within 6 months (± 1 month) after the date of their surgery, and are suitable for recruitment to the study for their post-operative research.
89517407|NCT03339466|Experimental|Experimental arm - Inspiratory Muscle Training|Single arm study. All subjects will perform 6-8 weeks of inspiratory muscle therapy with cardiopulmonary stress test (both standard and constant work rate) before and after intervention.
88963106|NCT02020005|Experimental|non-flavored 2mg nicotine gum|All subjects will test six different nicotine replacement products over the course of the 2-week product sampling phase. The six nicotine replacement products being tested are non-flavored 2mg nicotine gum, non-flavored 4mg nicotine gum, mint-flavored 2mg nicotine gum, mint-flavored 4mg nicotine gum, non-flavored nicotine inhaler and mint-flavored inhaler. The order in which the subjects test these products will be randomized and subjects will be blinded to the nicotine content of the product but will be instructed about the flavor of the product.
88963107|NCT02020005|Experimental|non-flavored 4mg nicotine gum|All subjects will test six different nicotine replacement products over the course of the 2-week product sampling phase. The six nicotine replacement products being tested are non-flavored 2mg nicotine gum, non-flavored 4mg nicotine gum, mint-flavored 2mg nicotine gum, mint-flavored 4mg nicotine gum, non-flavored nicotine inhaler and mint-flavored inhaler. The order in which the subjects test these products will be randomized and subjects will be blinded to the nicotine content of the product but will be instructed about the flavor of the product.
88963108|NCT02020005|Experimental|mint-flavored 2mg nicotine gum|All subjects will test six different nicotine replacement products over the course of the 2-week product sampling phase. The six nicotine replacement products being tested are non-flavored 2mg nicotine gum, non-flavored 4mg nicotine gum, mint-flavored 2mg nicotine gum, mint-flavored 4mg nicotine gum, non-flavored nicotine inhaler and mint-flavored inhaler. The order in which the subjects test these products will be randomized and subjects will be blinded to the nicotine content of the product but will be instructed about the flavor of the product.
89025845|NCT01242735|Experimental|Exercise|12-week moderate-intensity behavioral exercise intervention (AE)
89025846|NCT01242735|Active Comparator|Health and Wellness|12-week health and wellness education control (HEC)
89025847|NCT00462995|Active Comparator|Erlotinib|Erlotinib 150mg once a day p.o
89517408|NCT03283137|Experimental|TGR-1202 and pembrolizumab|All patients will receive TGR-1202 and pembrolizumab. Patients will start receiving TGR-1202 daily for 6 weeks (2 cycles). Pembrolizumab will be given every 3 weeks for 8 cycles. If the daily dose of TGR-1202 (dose level 1) is tolerated in the first cohort the dose will be increased which is the only and final dose escalation. If TGR-1202 is not tolerated the dose will be decreased.
89517409|NCT03276923||Maternal Autoimmune Disease ReseArch (MADRA) Registry|Women with autoimmune diseases who are pregnant
89517410|NCT03223155|Experimental|Sequential Arm|Patients will be randomized to either the Sequential Arm or the Concurrent Arm. Patients in the Sequential Arm will complete SBRT to 2-4 sites and then begin treatment with nivolumab/ipilimumab between 1-7 days after completion of SBRT.
89517411|NCT03223155|Experimental|Concurrent Arm|Patients will be randomized to either the Sequential Arm or the Concurrent Arm. Patients in the Concurrent Arm will begin treatment with nivolumab/ipilimumab first and must complete planned SBRT to 2-4 sites within 2 weeks (prior to second dose of nivolumab).
89517412|NCT03194815|Active Comparator|Intravenous immunoglobulin and Rituximab|One cycle of intravenous immunoglobulin (IVIG) 2g/kg over 2-5 days (days 1-5) followed by (b) two infusions of 1g rituximab (the first infusion starting between days 28-35, and the second infusion 14 days later), each with 100mg methylprednisolone.
89517413|NCT03194815|Placebo Comparator|Placebo|One cycle of 0.9% saline solution over 2-5 days (days 1-5) followed by (b) two infusions of placebo solution alongside placebo pill - in equal volumes to steroid pre-medication and rituximab.
89517414|NCT03170648|Experimental|Acupuncture|Patients will receive a 30-minute session of a standardized ear acupuncture treatment Acupuncture needles will be gently manipulated to increase stimulation For each ear acupuncture session, the patient will have ear acupuncture therapy administered to each ear
89517415|NCT03153410|Experimental|Cyclophosphamide, GVAX, Pembrolizumab and IMC-CS4|
89517416|NCT03025256|Experimental|Treatment (nivolumab)|Patients receive nivolumab IT over 5 minutes on day 1 of every cycle. Beginning in cycle 2, patients also receive nivolumab IV over 30 minutes on day 1 (4 hours after the IT dose). Cycles repeat every 14 days for 18 cycles and then every 28 days (cycles 19 and beyond) in the absence of disease progression or unacceptable toxicity. Patients will have CSF and blood specimen collection on days 1, 2, 8 of each cycle and end of treatment. Patients undergo CT or PET at baseline, cycle 5 and then every 8 weeks. Patients undergo MRI at baseline, cycles 3, 5, and then every 8 weeks.
89517417|NCT03021954|Experimental|Intervention Group|Platelet rich plasma injected intramuscularly in pelvic floor muscle immediately following labor and before perineoraphy, simultaneously with the injection of local anesthesia
89517418|NCT03021954|No Intervention|Control Group|No intervention given, patient will only get local anesthesia injection before perineoraphy
89517419|NCT03017573|Experimental|Tumor and blood sampling|Patients will have a biopsy or a surgery and blood sampling at different time points.
89519575|NCT03855995||Enhanced Hospitalisation Surveillance Group|Children at least 6 weeks and <5 years of age, within the study areas in both exposed and unexposed clusters, not already enrolled in the active surveillance (because parents/ Legally Acceptable Representative (LARs) declined enrolment in active surveillance or because recruitment had been completed) or not eligible for active surveillance at the time of hospitalisation, living in the HDSS area are eligible for enrolment in the Enhanced Hospital Surveillance (EHS) group.
88963109|NCT02020005|Experimental|mint-flavored 4mg nicotine gum|All subjects will test six different nicotine replacement products over the course of the 2-week product sampling phase. The six nicotine replacement products being tested are non-flavored 2mg nicotine gum, non-flavored 4mg nicotine gum, mint-flavored 2mg nicotine gum, mint-flavored 4mg nicotine gum, non-flavored nicotine inhaler and mint-flavored inhaler. The order in which the subjects test these products will be randomized and subjects will be blinded to the nicotine content of the product but will be instructed about the flavor of the product.
88963110|NCT02020005|Experimental|non-flavored nicotine inhaler|All subjects will test six different nicotine replacement products over the course of the 2-week product sampling phase. The six nicotine replacement products being tested are non-flavored 2mg nicotine gum, non-flavored 4mg nicotine gum, mint-flavored 2mg nicotine gum, mint-flavored 4mg nicotine gum, non-flavored nicotine inhaler and mint-flavored inhaler. The order in which the subjects test these products will be randomized and subjects will be blinded to the nicotine content of the product but will be instructed about the flavor of the product.
88963111|NCT02020005|Experimental|mint-flavored inhaler|All subjects will test six different nicotine replacement products over the course of the 2-week product sampling phase. The six nicotine replacement products being tested are non-flavored 2mg nicotine gum, non-flavored 4mg nicotine gum, mint-flavored 2mg nicotine gum, mint-flavored 4mg nicotine gum, non-flavored nicotine inhaler and mint-flavored inhaler. The order in which the subjects test these products will be randomized and subjects will be blinded to the nicotine content of the product but will be instructed about the flavor of the product.
88963112|NCT02020044|Other|Endothelial Keratoplasty|Descemet membrane endothelial keratoplasty DMEK Ultra-thin Descemet stripping automated endothelial keratoplasty Ultra-thin DSAEK
88963113|NCT02020057|Active Comparator|Conventional|knee receiving Total knee arthroplasty with conventional polyethylene inserts
88963114|NCT02020057|Experimental|Prolong|knee receiving total knee arthroplasty with highly cross linked polyethylene insert
88963115|NCT02020096|Experimental|U+N group|Ultrasound and nerve stimulator guided lumbar plexus block combined with nerve stimulator guided sciatic block
88963116|NCT02020096|Active Comparator|N group|Nerve stimulator guided lumbar plexus block combined with nerve stimulator guided sciatic nerve block
88963117|NCT02020109||Patients with Chronic Lymphatic Leukemia|Patients with Chronic Lymphatic Leukemia treated with splenic irradiation
88963118|NCT02020122|Active Comparator|Duloxetine|DUL 60mg x once a day x 2 days. This arm will also take 2 non-active placebo x once a day x 2 days
88963119|NCT02020122|Active Comparator|Pregabalin|PGB 150mg x twice a day x 2 days
88963120|NCT02020122|Placebo Comparator|Placebo|Non active placebo x twice a day x 2 days
89555913|NCT05025137|Experimental|Multi-Component exercise group|Participants in the Multi-Component exercise group performed a 60-minute Multi-Component exercise every week for 12 consecutive weeks.
89555914|NCT02351479|Other|Hula|Hula is an ancient, Native Hawaiian dance form of cultural expression and physical activity. Participants will attend one-hour hula classes twice a week for six months.
89555915|NCT05024669|No Intervention|Control Group|where no desensitizer application was done,
89555916|NCT05024669|Experimental|Group GL|applied with Gluma dentin desensitizer
89555917|NCT05024669|Experimental|Group SF|applied with Shieldforce desensitizer
89555918|NCT05024669|Experimental|Group TC|applied with Telio CS desensitizer
89555919|NCT02039167|Active Comparator|Left atrial appendage occlusion|Percutaneous left atrial appendage closure using the WATCHMAN device.
89555920|NCT02039167|No Intervention|OAC with a vitamin K antagonist|Oral anticoagulants (OAC) as Standard of Care (SOC) provided by primary care physician
89555921|NCT05024825|Experimental|Gabapentin|Patients in the gabapentin group will receive gabapentin preoperatively, one time dose of 10 mg/kg PO (maximum dose 600 mg) and will resume scheduled doses postoperatively of PO gabapentin, 300 mg PO every 8 hours, in addition to acetaminophen and ibuprofen for 7 days postoperative. Acetaminophen 15mg/kg PO (max 1 gm) every 4-6 hours as needed for pain, max dose 4 gm per day; Ibuprofen 4-10 mg/kg PO divided over 8 hours as needed for pain, max dose 40 mg/kg/day; gabapentin, 10 mg/kg standing every 8 hours (22).
89555922|NCT05024825|Active Comparator|Hydrocodone|Patients in the hydrocodone group will receive scheduled doses of hydrocodone, acetaminophen and ibuprofen at scheduled doses. Acetaminophen 15mg/kg (max 1 gm) every 4-6 hours as needed for pain, max dose 4 gm per day; Ibuprofen 4-10 mg/kg PO divided over 8 hours as needed for pain, max dose 40 mg/kg/day; hydrocodone acetaminophen solution 7.5mg-325mg/15mL 5mL for ages 12-14yrs and 10 mL for ages 15-18yrs, q 4-6 hours as needed for pain.
89555923|NCT02361151|Active Comparator|TECH (standard program)|"Receive 3-month healthy eating and physical activity intervention delivered via email newsletters and mobile apps plus self-monitoring with paper records; based on standard behavior change recommendations and materials (e.g., Diabetes Prevention Program)~Intervention: remotely-delivered evidence-based intervention to support healthy eating and physical activity; use of supporting app-based games and activities and self-monitoring."
89555924|NCT02361151|Experimental|TECH+ (enhanced program)|"Receive 3-month family-based healthy eating and physical activity intervention delivered via email newsletters and mobile apps plus self-monitoring with special study website~Intervention: remotely-delivered evidence-based intervention to support healthy eating and physical activity; use of supporting app-based games and activities; enhanced self-monitoring and family activities via special study website"
89555925|NCT05033795|Experimental|Water A|2 L of water A per day
89555926|NCT05033795|Other|Water B|2 L of water B per day
89555927|NCT03149965|Active Comparator|Body mass index 18.5-24.9|The anovaginal distance was measured with transperineal ultrasound. The standardized method consisted of placing the vaginal probe at a right angle to the posterior vaginal distal wall, and in a transversal scanning plane. The internal anal sphincter was detected as a low-echogenic ring when the probe was moved cranially from the distal anal canal to the mid anal canal. The anovaginal distance was defined as the distance between the anal mucosa and the vaginal wall at the middle level of the anal.
88963121|NCT02020161|Experimental|ATRA-Idarubicin|
89555928|NCT03149965|Experimental|body mass index ≥30|The anovaginal distance was measured with transperineal ultrasound. The standardized method consisted of placing the vaginal probe at a right angle to the posterior vaginal distal wall, and in a transversal scanning plane. The internal anal sphincter was detected as a low-echogenic ring when the probe was moved cranially from the distal anal canal to the mid anal canal. The anovaginal distance was defined as the distance between the anal mucosa and the vaginal wall at the middle level of the anal.
89555929|NCT02361073||Takotsubo|
88963122|NCT02020187|Experimental|Exercise|10 weeks of home training on a cycle-ergometer. Exercise 30 minutes every other day or at least three times a week.
88963123|NCT02020187|No Intervention|Controls|Controls with diagnosed congenital myopathy. Subjects are tested two times on a cycle ergometer. There will be ten weeks between the tests. In between tests the subjects are living life as usual without any interventions.
88963124|NCT02020200|Experimental|MPH or Placebo|MPH dosage will be determined according to participants' body weight: dosage: 10 mg in case weight<40 kg; 30 mg in case weight>90 kg; otherwise 20 mg. Both participants and investigators will be blinded to when participant receives MPH or Placebo.
88963125|NCT02020213|Other|Posaconazole, salvage|Posaconazole, per oral , 400 mg, bid , 8 weeks.
88963126|NCT02020226|Experimental|TH-302|480 mg/m2 by IV infusion over 30 minutes on Days 1, 8, and 15 of each 28-day cycle
88963127|NCT02020239|Experimental|Prescribed exercise|Participants will be asked to choose one activity and stick to it for the duration of the intervention. Participants will be able to choose between brisk walking/slow jogging or cycling. The intervention will require the completion of 30 minutes of chosen activity on 5 days of the week, which will be recorded in a physical activity diary.
88963128|NCT02020239|Experimental|Points-based physical activity|Participants will be asked to achieve a pre-set, individualised points target for physical activity each week. Points are acquired through the completion of a minimum 10 minutes of activity, choosing from the extensive list of activities provided; for example, 10 minutes of jogging achieves 4.5 points, whereas 10 minutes of washing a car achieves 1.5 points. The target will be 35-40 points per week, which equates to approximately 6 points per day. Any combination of activity, duration and frequency can be selected.
88963129|NCT02020239|No Intervention|Waiting list control|Participants will be asked to maintain their normal activities and diet. They will be added to a waiting list to receive either exercise intervention after completing the 24-week trial period, so that they do not miss out on the opportunity to receive the exercise intervention.
88963130|NCT02020265|Experimental|NF group|This group will train modulation of the amygdala EEG fingerprint by EEG neurofeedback.
88963131|NCT02020265|Sham Comparator|Sham NF|This group preform the same procedure as the NF group only reviving sham feedback
88963132|NCT02020265|Active Comparator|A\T NF|This group will train modulation of A\T ratio by EEG neurofeedback
88963133|NCT02020291|Experimental|Foxy-5|Slow infusion of lyophilised and reconstituted Foxy-5 three times weekly on Monday, Wednesday and Friday for three weeks.
88963134|NCT02020317|Active Comparator|computer-based reminders and alerts|Behavioral: display of computer-based reminders for serum potassium monitoring and hyperkalemia alerts (decision support in potassium-inc. drug-drug-interactions)
88963135|NCT02020317|No Intervention|no computer-based reminders or alerts|Behavioral: no display of computer-based reminders for serum potassium monitoring and hyperkalemia alerts
88963136|NCT02020330|Active Comparator|AL3days|Artemether-lumefantrine 3 days
88963137|NCT02020330|Experimental|AL5days|Artemether-lumefantrine 5 days
88963138|NCT02020343||Healthy|Not insulin resistant
88963139|NCT02020343||Insulin resistant|Insulin resistant by IVGTT
88963140|NCT02020343||Type 2 diabetics|Type 2 diabetics
88963141|NCT02020356|Experimental|Music therapy|"U sequence: the musical sequence lasts 20 minutes and is made up of several phases that progressively induce a relaxed state in the patient. The phase of maximum relaxation is followed by a stimulating phase."
89555930|NCT02361073||Healthy|
89555931|NCT02361073||ACS|
88963142|NCT02020356|Placebo Comparator|Placebo|Interview with an occupational activity (such as discussion of personal pictures or news) with the caregiver in charge of music therapy sessions with the same period.
88963143|NCT02020382|Other|Crohn adult colic|testing qPCR diagnostic KIT of microRNAS from colonic biopsies
88963144|NCT02020382|Other|RCH adults|testing qPCR diagnostic KIT of microRNAS from colonic biopsies
88963145|NCT02020382|Other|Witnesses healthy adults|testing qPCR diagnostic KIT of microRNAS from colonic biopsies
88963146|NCT02020382|Other|Witnesses adults with non-IBD inflammation|testing qPCR diagnostic KIT of microRNAS from colonic biopsies
88963147|NCT02020382|Other|Children with colitis|testing qPCR diagnostic KIT of microRNAS from colonic biopsies
88963148|NCT02020382|Other|Witnesses healthy children|testing qPCR diagnostic KIT of microRNAS from colonic biopsies
88963149|NCT02020395|Placebo Comparator|Test meal (500 kcal)_normal weight|ham sandwich chocolate cream orange juice
88963150|NCT02020395|Active Comparator|Test meal (500 kcal)_obese weight|ham sandwich chocolate cream orange juice
88963151|NCT02020421|Experimental|rTMS|Participants will receive real rTMS and sham tDCS
88963152|NCT02020421|Experimental|tDCS|Participants will receive real tDCS and sham rTMS
88963153|NCT02020421|Sham Comparator|Sham|Participants will receive both sham rTMS and sham tDCS
89555932|NCT02356549|Active Comparator|GROUP 1: (EMR) Tailoring Alone|Patients will be randomized to receive tailored messages based on demographic and disease information extracted from Massey Cancer Center (MCC) electronic medical records (EMR) that will include a) demographic information: age, income, education and health insurance status, b) disease variables: cancer type and severity and c) trial variables: phase of trial being offered and prior trial participation.
89555933|NCT02356549|Active Comparator|GROUP 2:EMR Tailoring+Feedback|Patients will be randomized to receive tailored messages based on information extracted from the EMR as in Group 1. Physicians also receive a summary of tailored messages provided to patients.
89555934|NCT02356549|Active Comparator|GROUP 3:EMR+Survey Tailoring alone|Patients will be randomized to receive tailored messages based on EMR data as in Group 1. Patients will complete a survey that will be used to provide a deeper level of tailored messages
88963154|NCT02020434|Experimental|Single dose of RPX7009 and RPX2014|Single dose of combination RPX7009 and RPX2014
88963155|NCT02020460|Active Comparator|Subdural trial lead|SCS trial lead in the subdural space.
88963156|NCT02020460|Active Comparator|Epidural trial lead|SCS trial lead in the epidural space.
88963157|NCT02020473||WLS group|patients with informed consents for withholding/withdrawing life support
88963158|NCT02020473||non-WLS group|patients without informed consents for withholding/withdrawing life support
88963159|NCT02020486|Experimental|Group A|Experimental
88963160|NCT02020486|Experimental|Group B|Days 1-14: Multiple oral dose of 2 mg perampanel (one 2 mg tablet) Days 15-28: Multiple oral dose of 4 mg perampanel (two 2 mg tablets) Days 29-42: Multiple oral dose of 6 mg perampanel (three 2 mg tablets)
88963161|NCT02020499||Acromegalic patients|Acromegalic subjects treated with Somatuline Autogel® (Lanreotide)
88963162|NCT02020525|Experimental|restrictive transfusion strategy|Patients allocated to the restrictive transfusion strategy were transfused only when their hemoglobin concentration decreased below 7.7 g d dL-1 and were then maintained at hemoglobin concentrations between 7.7 and 9.9 g d dL-1.
88963163|NCT02020525|Active Comparator|liberal transfusion strategy|Patients assigned to the liberal strategy were transfused when their hemoglobin concentration fell below 9.9 g dL-1, aiming at maintaining hemoglobin at or above 10 g dL-1.
88963164|NCT02020538|Placebo Comparator|Chloride-rich IV fluid|The chloride-rich strategy will include 0.9% saline as the perioperative crystalloid of choice with 4% albumin as the perioperative colloid of choice.
88963165|NCT02020538|Active Comparator|Chloride-poor IV fluid|A low-chloride strategy of perioperative IV fluid will include PlasmaLyte 148 or Hartmann's solution as the crystalloid of choice with 20% albumin as the colloid of choice.
88963166|NCT02020551|Placebo Comparator|saline spray application|Placebo group
88963167|NCT02020551|Experimental|lidocaine spray application|2 puff lidocaine spray applicated before IUD insertion
88963168|NCT02020603|Active Comparator|APC group|epinephrine injection plus argon plasma coagulation
88963169|NCT02020603|Active Comparator|Forceps group|epinephrine injection plus soft coagulation using hemostatic forceps
88963170|NCT02020629|Experimental|Lixisenatide|Lixisenatide 20µg daily
88963171|NCT02020642|Experimental|Intervention Group|A baseline polysomnography (PSG) is performed at inclusion (before renal transplantation, Tx), followed by a post-Tx PSG 6 months after transplantation
88963172|NCT02020642|No Intervention|Control Group|A baseline polysomnography (PSG) is performed at inclusion, followed by a follow-up PSG at 6 months if the patient is not already transplanted
88963173|NCT02020655||10 healthy volunteers|Shear- force model
88963174|NCT02020668|Experimental|Physiotherapy|Physiotherapy included joint protection strategies, performance of therapeutic exercises and patient education.
88963175|NCT02020668|Other|Wait list control|Wait list control received standard care and were invited to join the physiotherapy once intervention period is finished.
89555935|NCT02356549|Active Comparator|GROUP 4:EMR+Survey Tailoring+Feedback|Patients will be randomized to receive tailored messages based on information extracted from their EMR as in Group I. Patients will complete a survey that will be used to provide a deeper level of tailored messages as in Group 3. Physicians also receive a summary of tailored messages provided to patients as in Group 2.
89555936|NCT05024435|Experimental|Nasogastric Tube|
89555937|NCT05024435|Experimental|Lisacath|
89555938|NCT02360917|Experimental|Intervention|Participants in the intervention group will undergo 6 weeks of psycho-educational classes provided in a live setting at Cedars Sinai and a web based setting at The University of Kansas. Each class will focus on a different realm of coping with chemo-brain.
88963176|NCT02020681|Experimental|Curodont Repair|Single application of Curodont Repair on treatment day D0 followed by a single application of fluoride (Duraphat) on D90.
88963177|NCT02020681|Placebo Comparator|Placebo|Single application of Placebo on treatment day D0 followed by a single application of fluoride (Duraphat) on D90.
88963178|NCT02018796||Women seeking medical abortion|Women with pregnancies less than 71 days gestation seeking medical abortion. Women who choose to participate in the study will be administered 200 mifepristone, followed 24 to 48 hours later by 600 mcg misoprostol.
88963179|NCT02020733|Other|balloon catheter|
88963180|NCT02020733|Other|metal cannula|
88963181|NCT02020746|Active Comparator|EscharEx|Enzymatic debridement
88963182|NCT02020746|Placebo Comparator|Gel Vehicle|Control arm
88963183|NCT02020759||Patient on ECMO|Neurological monitoring with transcranial Doppler ultrasound
88963184|NCT02020759||Healthy subjects|Neurological monitoring with transcranial Doppler ultrasound
88963185|NCT02020759||ICU patients|Neurological monitoring with transcranial Doppler ultrasound
88963186|NCT02020772|Experimental|coordinating primary health care 1|musculoskeletal pain care by a coordinating team of one general practitioner and two physical therapists
88963187|NCT02020772|Active Comparator|usual primary health care 1|usual care of musculoskeletal pain in general practice
88963188|NCT02020772|Experimental|coordinating primary health care 2|musculoskeletal pain care by a coordinating team of one general practitioner and two physical therapists
88963189|NCT02020772|Active Comparator|usual primary health care 2|usual care of musculoskeletal pain in general practice
88963190|NCT02020798|Placebo Comparator|Nutrient formulations without active ingredient|4 nutrient formulations without active ingredient and variable level of available placebo ingredient
88963191|NCT02020798|Experimental|Nutrient formulation with active ingredien|4 nutrient formulations with increasing amount of active ingredient
88963192|NCT02020811|Experimental|sentinel arm|all patients will be recieving Iv therapy by using the sentinel controller, a device that is mounted on the IV administration set.
89555939|NCT02360917|Other|Waitlist|Participants assigned to the control group will be placed on a wait list for the Haze program. While they are waiting for admittance to the program, they will receive the same surveys as the participants who are taking the Haze class. Additionally, participants assigned to the control group will receive the surveys again when taking the class in order to allow comparison of the effects of the program on the control group. Participants assigned to the wait list will be enrolled in the following Haze series.
89555940|NCT03093467|Experimental|Experimental|Participants receive psychiatric treatment and psychotherapy as usual. In addition, participants have access to the internet-based program ASCENSO: an adjunct support and monitoring system for the treatment of depression.
89555941|NCT03093467|Active Comparator|Control|Patients receive psychiatric treatment and psychotherapy as usual.
89555942|NCT02356237|Experimental|No episiotomy|Episiotomy will not be performed in this group. Deviation from protocol (i.e. episiotomy performance) will be allowed only according to the discretion of obstetrician in charge of the delivery, in cases of unequivocal benefit to the fetus.
88963193|NCT02020824|Active Comparator|Exposure without control|"Exposure to anxiogenous environments: 20 acrophobic patients will be exposed during 8 sessions to anxiogenous environments without control.~Imagery with functional MRI initial. Imagery with functional MRI final. Imagery with PET-scanner initial. Imagery with PET-scanner final."
88963194|NCT02020824|Experimental|Exposure with control|"Exposure to anxiogenous environments: 20 acrophobic patients will be exposed during 8 sessions to anxiogenous environments with the ability to control and secure these.~Imagery with functional MRI initial. Imagery with functional MRI final. Imagery with PET-scanner initial. Imagery with PET-scanner final."
88963195|NCT02020824|Other|Healthy volunteers|"20 healthy volunteers will be submitted to the same initial measurements in order to explore potential differences between them and the patients.~Imagery with functional MRI initial. Imagery with PET-scanner initial."
88963196|NCT02020850||Toe-Brachial and Ankle-Brachial Index|toe systolic blood pressure, ankle systolic blood pressure, brachial systolic blood pressure test
88963197|NCT02020876||Practicing urologic surgeons|Performing at least 60 radical prostate surgeries annually
88963198|NCT02020915||Patients with chronic anal fissure|Patients are included who had previous treatment with diltiazem or glycerol-nitrate and botox injections
88963199|NCT02020928|Experimental|Low level laser therapy|The Low level laser therapy application is performed from the first day of conditioning of the patient until the second day after bone marrow transplantation (D + 2). The patients are divided into two groups. The first will contain the patients who will receive the red laser light, whereas the second will cover patients who receive sham or placebo controlled - the device is triggered, but not deliver the laser light.
88963200|NCT02020928|Sham Comparator|sham|patients will receive sham Low level laser therapy - the device is triggered, but not deliver the laser light
88963201|NCT02020954||Dystrophinopathy|Patients with mutations in the DMD gene and Becker muscular dystrophy and/or dilated cardiomyopathy
88963202|NCT02020993||Respiratory distress group|Newborns with respiratory distress will constitute the study group. All patients will be evaluated by Urine NT-proBNP and echocardiography on postnatal days 1-2 and 5-7.
88963203|NCT02020993||Control Group|Newborns without any respiratory and cardiac diseases will constitute the control group, and will be evaluated by urine Nt-proBNP and echocardiography on postnatal days 1-2 and 5-7.
88963204|NCT02021032|Experimental|Prolieve|Prolieve® is a transurethral microwave therapy device equipped with automated controls designed to deliver microwave energy to the prostate and balloon-administered compression for the treatment of symptomatic BPH. This device utilizes a transurethral catheter with microwave antenna to heat the prostate, with simultaneous 46 Fr. prostatic urethral catheter balloon-administered compression.
88963205|NCT02021045||Patient on Hemodialysis|Renal hemodialysis
89555943|NCT02356237|No Intervention|Selective episiotomy|The decision to perform episiotomy in this group will be based on routine delivery care, i.e. indistinguishable from any other delivery not participating in the trial.
89555944|NCT03095261|Experimental|Self-monitoring (financial incentives then virtual rewards)|Participants will be asked to track their exercise daily, using an online tool called ExTracker.ca, for 52 weeks. Date, type of exercise, time spent exercising, and distance covered will be self-reported, as will steps per day and 10-minute bouts of MVPA per day (measured by an accelerometer). In the first six months, participants will earn financial incentive (ex. grocery vouchers) each day exercise is tracked. In the second six months, participants will earn virtual rewards (i.e. heart badges) each day exercise is tracked.
89555945|NCT03095261|Active Comparator|Self-monitoring (virtual rewards then financial incentives)|Participants will be asked to track their exercise daily, using an online tool called ExTrack.ca, for 52 weeks. Date, type of exercise, time spent exercising, and distance covered will be self-reported, as will steps per day and 10-minute bouts of MVPA per day (measured by an accelerometer). In the first six months, participants will earn virtual rewards (i.e. heart badges) each day exercise is tracked. In the second six months, participants will earn financial incentive (ex. grocery vouchers) each day exercise is tracked.
89555946|NCT03149653|Experimental|1 Home Parenteral Nutrition, Cross-over|Random Cycle Sequence - Cycle 1: Clinoleic (baseline), 50g/per day, 42 days Clinoleic + Omegaven, 40g + 10g/per day, 28 days. Cycle 2: Lipoplus (baseline), 50g/per day, 42 days Lipoplus + Omegaven, 40g + 10g/per day, 28 days. Cycle 3: SMOFlipid (baseline), 50g/per day, 42 days SMOFlipid + Omegaven, 40g + 10g/per day, 28 days.
89555947|NCT03149653|Active Comparator|2 Home Parenteral Nutrition, Cross-over|Random Cycle Sequence - Cycle 1: Clinoleic (baseline), 50g/per day, 42 days Clinoleic + Omegaven, 40g + 10g/per day, 28 days. Cycle 2: Lipoplus (baseline), 50g/per day, 42 days Lipoplus + Omegaven, 40g + 10g/per day, 28 days. Cycle 3: SMOFlipid (baseline), 50g/per day, 42 days SMOFlipid + Omegaven, 40g + 10g/per day, 28 days.
89555948|NCT03149653|No Intervention|Comparator3|Healthy Control
89555949|NCT03093545|Other|Normal BMI or underweight (< 24 Kg/m2)|
89555950|NCT03093545|Experimental|Obese (BMI > 30 Kg/m2)|
88963206|NCT02021045||Patient in a hemodialysis-free interval|No Renal hemodialysis
88963207|NCT02021058|Experimental|Experimental Formula|Experimental Formula
88963208|NCT02021058|Other|Standard Formula|Standard Control formula
88963209|NCT02021084|Placebo Comparator|placebo, response, adverse effect|children (5-17 years old) with FMF that are currently followed in the pediatric rheumatology clinic at Mayer children hospital Israel Haifa that are being treated with colchicine and suffering from either gastrointestinal adverse effect or partial response to colchicine.in the first 3 month patients will be followed with no interventions and will be required to record all there FMF episodes and their GIT adverse effect, in the second period the patients will be randomly divided into two groups patients that will received placebo arm one and patients that will receive probiotics arm two.
88963210|NCT02021084|Active Comparator|probiotic, response, adverse effect|children (5-17 years old) with FMF that are currently followed in the pediatric rheumatology clinic at Mayer children hospital Israel Haifa that are being treated with colchicine and suffering from either gastrointestinal adverse effect or partial response to colchicine.in the first 3 month patients will be followed with no interventions and will be required to record all there FMF episodes and their GIT adverse effect, in the second period the patients will be randomly divided into two groups patients that will received placebo arm one and patients that will receive probiotics arm two.
88963211|NCT02021097|Experimental|LNG100 mcg/EE20 mcg|
88963212|NCT02021097|Active Comparator|LNG 150mcg/ EE 30mcg|
88963213|NCT02021110|No Intervention|Control group|This group will receive standard care (no treatment)
88963214|NCT02021110|Experimental|Ursodeoxycholic Acid|The intervention group will receive 15-20mg/kg/day UDCA for 24 weeks
89555951|NCT02351401|Experimental|Education with ultrasonography|Intervention includes education of self-assessment of synovitis using ultrasonography as a feedback training tool
89555952|NCT02351401|No Intervention|Standard Care|Normal standard care where patients are not taught how to self-assess for synovitis, without ultrasonography a training tool
89555953|NCT03093623|Experimental|Physical activity|In physical activity experimental group, trained study nurses will interview with patients,give health education,teach how to use and record the Activity meter.Professionals will calculate Metabolic Equivalent of Task(MET) with formula weekly.MET = (intensity level 9 points * time of each exercise (hours) * Number of times per week + moderate level 5 points * time per activity (hours) * number of times per week + low level 3 points * time per activity (hours) * number of times per week),investigators hope patients in the first month MET can reach (3.75-7.49 MET-h/ week), and reach moderate or more than moderate activity (>= 7.5-16.49 MET-h/ week) at the starting of second month for at least one year.
89555954|NCT03093623|No Intervention|Non-Physical activity|the non-physical activity group,investigators do not give them any physical interventions
89555955|NCT02360761|Active Comparator|Lobectomy|Patients undergo lobectomy by thoracotomy or thoracoscopy/Video assisted thoracoscopic surgery(VATS).
89555956|NCT02360761|Experimental|Sublobar resection|Patients undergo sublobar resection(wedge resection or anatomic segmentectomy) by thoracotomy or thoracoscopy/VATS.
89555957|NCT05024357|Experimental|Dasatinib for 1 year|After the allo-HSCT treatment, the patients in this group will continue to take dasatinib orally for 1 year.
89555958|NCT05024357|Experimental|Dasatinib for 6 months|After the allo-HSCT treatment, the patients in this group will receive dasatinib for 6 months.
89555959|NCT03095183|Placebo Comparator|Traditional Tongue Depressor|The posterior oropharynx exam was performed with a traditional, unflavored Puritan Regular tongue depressor.
89555960|NCT03095183|Active Comparator|Flavored Tongue Depressor|The posterior oropharynx exam was performed with a grape flavored, commercially available, Puritan Junior tongue depressor.
89555961|NCT02356315||Healthy subjects|Functional magnetic resonance imaging of healthy subjects
89555962|NCT02356315||Chronic neck pain patients|Functional magnetic resonance imaging of chronic neck pain patients
89555963|NCT03095339|Active Comparator|Educational package|The educational package included the offering of the Self-Esteem , Associative strengths, Resourcefulness, Action-planning and Responsibility (SARAR) Participatory Hygiene and Sanitation Transformation (PHAST) approach, a 52 minutes educational movie and accompanying cartoon booklet. The package was developed using the PRECEDE approach.
89555964|NCT03095339|No Intervention|Control|The control group did not receive any intervention
89555965|NCT03095105|Experimental|Young group|"The study was performed in two consecutive phases: single-dose and multiple-dose.~Subjects were institutionalised on Day 0, the day prior to the single-dose administration (Day 1). Single dose (dose 1) of BIA 6-512 200 mg was administered on Day 1 and subjects remained confined in the Unit until the 24 h post-dose procedures (Day 2). Then, subjects started being administered BIA 6-512 200 mg thrice-daily until the morning of Day 4 (Dose 8). Blood samples were taken at pre-determined time-points for the assay of BIA 6-512"
89555966|NCT03095105|Experimental|Elderly group|"The study was performed in two consecutive phases: single-dose and multiple-dose.~Subjects were institutionalised on Day 0, the day prior to the single-dose administration (Day 1). Single dose (dose 1) of BIA 6-512 200 mg was administered on Day 1 and subjects remained confined in the Unit until the 24 h post-dose procedures (Day 2). Then, subjects started being administered BIA 6-512 200 mg thrice-daily until the morning of Day 4 (Dose 8). Blood samples were taken at pre-determined time-points for the assay of BIA 6-512"
89555967|NCT02351323|Experimental|Glutamine + Lifestyle change|Glutamine 30 grams/day X 12-14 weeks, Lifestyle change
89555968|NCT02351323|Placebo Comparator|No glutamine + Lifestyle change|Lifestyle change
89555969|NCT05024123|Placebo Comparator|Placebo|
89555970|NCT05024123|Experimental|Experimental|
89555971|NCT02360449|No Intervention|Wait List|
89555972|NCT02360449|Experimental|Social Initiation Motivation Intervention|
89555973|NCT05033951||Cohort 1|Patients who start NIV in the first two months after the first visit to the HMV
89555974|NCT05033951||Cohort 2|Patients who do not start NIV in the first two months after the first visit to the HMV.
89555975|NCT01968070|Experimental|LY3127760 (Single)|Single oral dose of up to 900 milligram (mg) LY3127760 administered in up to 3 of 3 study periods.
89555976|NCT01968070|Placebo Comparator|Placebo (Single)|Single oral dose of placebo administered in up to 2 of 3 study periods. Placebo matches LY3127760 in appearance.
89555977|NCT01968070|Experimental|LY3127760 (Multiple)|Multiple ascending oral doses of up to 900 mg LY3127760 administered once or twice daily (QD or BID) for 28 days.
89555978|NCT01968070|Placebo Comparator|Placebo (Multiple)|Multiple oral doses of placebo administered QD or BID for 28 days. Placebo matches LY3127760 in appearance.
89555979|NCT01968070|Active Comparator|Celecoxib (Multiple)|Multiple oral doses of 400 mg celecoxib administered QD for 28 days.
89555980|NCT02351089|Placebo Comparator|Placebo|capsules containing corn starch
89555981|NCT02351089|Active Comparator|Probiotic low dose|capsules containing probiotic powder and corn starch
89555982|NCT02351089|Active Comparator|Probiotic high dose|capsules containing probiotic powder and corn starch
89555983|NCT03093311|Experimental|Arm A|Brain tissue oxygenation is measured by NIRS. In time of desaturation the interventions according to NIRS based protocol start.
89555984|NCT03093311|No Intervention|Arm B|Brain tissue oxygenation is not measured.
89555985|NCT02351245||lip hemangiomas|
89555986|NCT05033405|Experimental|Experimental:Neuro Linguistic Programming|One session (20-minute long) of NLP application was performed. The NLP techniques that were employed were representational systems and submodality. In this technique, the sensory, auditory, and kinesthetic feelings of the individual are learned. These emotions are modified by imagining. The NLP application was carried out by a researcher who has a certificate in this field.
89555987|NCT05033405|No Intervention|control group|No NLP was applied on the control group patients.
89555988|NCT02351011|Experimental|Cohort 1|1 x 10^6 MSCs
89555989|NCT02351011|Experimental|Cohort 2|10 x 10^6 MSCs
89555990|NCT02351011|Experimental|Cohort 3|50 x 10^6 MSCs
89555991|NCT03093233||VKA- and NOAC-related ICH|"Analysis of hematoma enlargement: prevalence, risk factor, associations with therapeutic interventions (in patients with cranial follow-up imaging)~Association of hematoma evacuation surgery with clinical outcomes~Associations of antithrombotic management with ischemic and hemorrhagic complications~Safety of intraventricular fibrinolysis (in patients with severe intraventricular hemorrhage)"
89555992|NCT02350855|Experimental|Intervention group|Patients in the intervention group were given dietary supplement (Improved Atta: 100 g) daily along with nutritional counseling and physical activity counseling for six months.
89555993|NCT02350855|Other|Control group|Patients in the control group were given nutritional and physical activity counseling for six months every fortnight.
89555994|NCT03093389|Experimental|BIA 6-512 25 mg or Placebo|1 capsule of BIA 6-512 25 mg or 1 capsule of placebo.
89555995|NCT03093389|Experimental|BIA 6-512 50 mg or Placebo|1 capsule of BIA 6-512 50 mg or 1 capsule of placebo.
89555996|NCT03093389|Experimental|BIA 6-512 100 mg or Placebo|1 capsule of BIA 6-512 100 mg or 1 capsule of placebo.
89555997|NCT03093389|Experimental|BIA 6-512 150 mg or Placebo|1 capsule of BIA 6-512 150 mg or 1 capsule of placebo.
89555998|NCT05033249||Normal|Alvarado Score 4 - 7 Normal according to the initial computed tomographic evaluation
89555999|NCT05033249||Patient|Alvarado Score 4 - 7 Acute appendicitis according to the initial computed tomographic evaluation
89556000|NCT02356081|Experimental|ASyMS intervention Group|Patients in the intervention group will be instructed to use the ASyMS intervention once daily (and whenever they feel unwell) for up to 6 cycles of chemotherapy treatment.
89556001|NCT02356081|No Intervention|Control Group|Patients in the control group will receive standard care as is currently available at their clinical site.
89556002|NCT01918774|Other|Cognitive behavior therapy for work success|Fifty participants will take part in the 12 week CBTw program. All participants will receive standard SE services during the study. The longitudinal design will consist of assessments of competitive employment outcomes, important psychosocial outcomes, and background and demographic variables at baseline and at two follow-up periods' immediately following the conclusion of the CBTw program and six months after the conclusion of the program.
89556003|NCT02355925|Experimental|uhCG|The patients who receive Intrauterine injection of 500 IU of uhCG (0.5ml) before embryo transfer
89556004|NCT02355925|Placebo Comparator|Placebo|The patients who underwent Intrauterine injection of placebo (normal saline 0.5 ml) before embryo transfer
89556005|NCT02355925|Other|control|the embryonic transfer is done without the intrauterine hCG injection. The ET procedure is performed just like in the other two groups.
89556006|NCT03092999|Experimental|Healthy subjects|healthy subjects
89556007|NCT03092999|Experimental|Subjects with mild hepatic impairment|hepatically impaired patients (classified as Child Pugh A)
89556008|NCT03092999|Experimental|Subjects with moderate hepatic impairment|hepatically impaired patients (classified as Child Pugh B)
89556009|NCT02355847|Other|Healthcare Worker Education|Educational Lectures
89556010|NCT03093077|Experimental|Anatomic alignment|The aim of anatomic alignment is to recreate an individual's pre-operative alignment using the DePuy ATTUNE total knee arthroplasty system.
89556011|NCT03093077|Active Comparator|Mechanical alignment|The aim of mechanical alignment is to achieve a neutral mechanical alignment regardless of pre-operative status, using the DePuy ATTUNE total knee arthroplasty system.
89556012|NCT02350933|Other|0° rigid endoscope|Endoscopy of the trachea is performed using a 0° rigid endoscope
89556013|NCT03092921|Experimental|F&P Mask Seal|Participants to use trial seal in-home for 1 week
89556014|NCT03092921|Experimental|F&P Mask|Participants to use trial mask in-home for 2 weeks
89556015|NCT02360527||Type 2 diabetic patients with AD|35 patients
89556016|NCT02360527||Type 2 diabetic patients with MCI|35 patients
89556017|NCT02360527||Type 2 diabetic patients controls|35 patients
89556018|NCT02360527||Non-diabetic patients with AD|35 patients
89556019|NCT05024201|Experimental|experimental group for effect of therapeutic touch|Therapeutic touch was applied to the experimental group for three days every other day.
89556020|NCT05024201|No Intervention|control group for effect of therapeutic touch|No application was applied to the control group. Only pretest and posttest were done.
89556021|NCT04408183|Experimental|GLS-1200|1 mL of GLS-1200 per nostril, TID
89556022|NCT04408183|Placebo Comparator|0.9 %Saline|1 mL of 0.9% Saline per nostril, TID
89556023|NCT01949116|Experimental|Low-dose methotrexate (LDMTX)|From study entry through Week 1, participants received 5 mg of LDMTX once a week. For participants who were clinically stable at the Week 1 study visit, the dose of LDMTX was increased to 10 mg once a week through Week 12. For participants who were clinically stable at the Week 12 study visit, the dose of LDMTX was increased to 15 mg once a week through Week 24. Participants who did not meet the criteria for dose escalation were re-evaluated at the following study visit. In addition to LDMTX, all participants also received 1 mg of folic acid once a day from study entry throughout Week 24. After taking the final dose of LDMTX, all participants continued taking folic acid for an additional 4 weeks.
89210570|NCT00542919|Experimental|Aggressive B-Cell|Aggressive B-Cell (ABCL): Primary central nervous system (CNS) lymphoma, follicular lymphoma (Grade 3a and 3b) and aggressive lymphoma with prior clinical history of indolent lymphoma. Participants received enzastaurin 1125 mg loading dose then 500 mg, oral, daily until progressive disease or predefined criteria for discontinuation is met. Participants who progress within the first 28 days may remain on study treatment, provided that the participant is not in need of immediate treatment with another anticancer therapy. Study treatment occurs in cycles. 1 cycle = 28 days
88963215|NCT02021123|Experimental|Anidulafungin 100 mg single dose|100 mg single dose anidulafungin pre-surgery (gastric bypass)
88963216|NCT02021136|Experimental|Rebel reliever|Rebel Reliever(R) knee brace + usual antalgic treatment + physical exercises recommendations.
88963217|NCT02021136|Active Comparator|Control|usual antalgic treatment + physical exercises recommendations.
88963218|NCT02021149|Other|Psychotherapy and Questionnaire Group|Participants in this arm will have their regular psychotherapy sessions with their psychotherapist and will, prior to each session, fill out study related questionnaires.
88963219|NCT02021149|Experimental|High intensity whole-body infrared heating and Psychotherapy.|Subjects will have weekly psychotherapy sessions and fill out study questionnaires. The participant's 4th psychotherapy session will be conducted while the patient undergoes the WBH intervention where subjects will be induced to levels of heat that increases core body temperature to approximately 37.5-38.5 °C.temperature.
88963220|NCT02021149|Sham Comparator|Low intensity whole-body infrared heating and Psychotherapy|Subjects will have weekly psychotherapy sessions and fill out study questionnaires. The participant's 4th psychotherapy session will be conducted while the patient undergoes WBH-control where subjects will be induced to levels of heat that causes only a minor increase in body temperature.
88963221|NCT02021162||Gilenya|MS patients taking Gilenya
88963222|NCT02021162||Healthy Controls|Healthy controls age and gender matched to MS patients taking Gilenya
88963223|NCT02021175|Experimental|Tailored CBME Therapy via Technology|6 weeks of tailored interactive Cognitive-Behavioral Motivational Enhancement Therapy delivered through internet and cell phones
88963224|NCT02021175|Other|Standard of Care|Referral to currently available resources for 6 weeks of a standard smoking cessation approach
88963225|NCT02021188||Carotid artery disease|Participants with symptomatic or asymptomatic carotid artery plaques
88963226|NCT02021188||Coronary artery disease|Participants with stable coronary artery disease or recent acute coronary syndrome
88963227|NCT02021201|Experimental|1|Patients with schizophrenia will be treated with risperidone or sertindole for a period of 10 weeks, after which they will cross-over for an additional treatment of 10 weeks with the other compound
89556024|NCT01949116|Placebo Comparator|Placebo|From study entry through Week 1, participants received 5 mg of placebo once a week. For participants who were clinically stable at the Week 1 study visit, the dose of placebo was increased to 10 mg once a week through Week 12. For participants who were clinically stable at the Week 12 study visit, the dose of placebo was increased to 15 mg once a week through Week 24. Participants who did not meet the criteria for dose escalation were re-evaluated at the following study visit. In addition to placebo, all participants also received 1 mg of folic acid once a day from study entry throughout Week 24. After taking the final dose of placebo, all participants continued taking folic acid for an additional 4 weeks.
89556025|NCT01673009|Experimental|Administration of Gleevec|Gleevec® will be dosed orally 440 mg/m^2/day (max 800 mg/day) for pediatric subjects and 800 mg/day for adult patients.
89556026|NCT02355535|Experimental|Open label|Using a dose-escalation design, PAC-1 is administered orally on days 1-21, at the assigned dose, of a 28-day cycle.
89556027|NCT05033015|Experimental|Test|Mouth rinse containing enzymes
89556028|NCT05033015|Active Comparator|Placebo|Control, same content as test, without enzymes
89556029|NCT02350387|Experimental|High Intensity Short Duration Exercise|Participants randomized to this group will perform 4 sets of 8-15 repetitions of eccentric exercise using the Eccentron set at 50-80% of the participant's one repetition maximum.
89556030|NCT02350387|Experimental|Low Intensity Long Duration Exercise|Participants randomized to this group will perform 5-20 minutes of continuous eccentric exercise using the Eccentron set at 50% of the participant's one repetition maximum.
88963228|NCT02021201|Experimental|2|Patients with schizophrenia will be treated with risperidone or sertindole for a period of 10 weeks, after which they will cross-over for an additional treatment of 10 weeks with the other compound
88963229|NCT02021214|Experimental|Methylphenidate/Placebo|40 mg Methylphenidate, per os, single dose Placebo, single dose
88963230|NCT02021227|No Intervention|Standard group|
88963231|NCT02021227|Other|Chair sitting group|
88963232|NCT02021240|Active Comparator|Ketamine|Single dose of intravenous ketamine 0.5mg/kg before incision
88963233|NCT02021240|Active Comparator|Dexamethasone|Single dose of intravenous dexamethasone 8mg before incision
88963234|NCT02021240|Placebo Comparator|Normal saline|Single dose of intravenous normal saline before incision
88963235|NCT02021253|Placebo Comparator|Placebo of Probiotics|"Placebo: Composition: Each capsule contains 560 mg:~459 mg of corn starch~6 mg of magnesium stearate~Dosage: 2 capsules / day, in the morning at sunrise, one at bedtime.~Methods of administration: Oral.~Duration of treatment: 14 days"
89556031|NCT05023499||With glutamine supplementation|perioperative glutamine supplementation (PGS) was defined as the subjects with five-day parenteral plus one-month oral use.
89556032|NCT05023499||Without glutamine supplementation|no glutamine use
89025848|NCT01242852|Experimental|Additional diagnostic tests|Participants in the experimental arm will undergo standard hysteroscopy with treatment-on-the spot of predefined intrauterine abnormalities. In two of the participating clinics, also a 'Saline Infusion Sonography' (SIS) will be performed, 1 week before the hysteroscopy. After the additional diagnostic test(s), standard IVF/ICSI treatment will be initiated.
89025849|NCT01242852|No Intervention|Routine fertility workup|Patients allocated to the conventional strategy will be scheduled for IVF and undergo standard treatment, without SIS or hysteroscopy.
89210571|NCT00927420||1|Patients diagnosed with bipolar disorder I or II (DSM-IV) in ambulatory settings
89210572|NCT00820118|Experimental|Intermittent treatment|6 months on antiretroviral treatment and 6 months off treatment
89556033|NCT02350621|Active Comparator|ACDF|Anterior Cervical Discectomy and Fusion
89556034|NCT02350621|Active Comparator|miPCF|minimal invasive Posterior Cervical Foraminotomy
89556035|NCT05023421||Problematic media use of children with CP|The participants in the current study were parents of children with CP aged 4-18 years. They were recruited at the Hacettepe University Physical Therapy and Rehabilitation Faculty Cerebral Palsy and Pediatric Rehabilitation Unit and Special Education and Rehabilitation Centers. The inclusion criteria were having a child with CP aged 2-18 years without severe cognitive problems, being a primary caregiver.
89556036|NCT02350543|Active Comparator|Aspirin continuation|Continued use of Acetylsalicylic acid at prior dosage (75mg or 100mg tablet one-per-day).
89556037|NCT02350543|No Intervention|Aspirin discontinuation|Discontinuation of Acetylsalicylic acid ten days prior to surgery, and re-initiation two weeks after hospital discharge.
89556038|NCT05033093|Active Comparator|Ah Plus|All samples will be filled with Ah Plus root canal sealer and gutta percha
89556039|NCT05033093|Active Comparator|I Root SP|All samples will be filled with I Root SP root canal sealer and gutta percha
89556040|NCT05033093|Active Comparator|GuttaFlow Bioseal|All samples will be filled with GuttaFlow Bioseal canal sealer and gutta percha
89556041|NCT02359747||In Vitro Fertilization treatment|culture medium discarded after IVF treatment
89556042|NCT05023577|Experimental|CL group|Rabeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid, clarithromycin 0.5 g bid and levoflaxacin 0.5 g qd for 14 days
89556043|NCT05023577|Experimental|LM group|Rabeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid, metronidazole 0.4 g qid and levoflaxacin 0.5 g bid for 14 days
89556044|NCT05023577|Active Comparator|CM group|Rabeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid, metronidazole 0.4 g qid and clarithromycin 0.5 g bid for 14 days
89556045|NCT03149497|Active Comparator|improved anterior approach only in traumatic cervical spine|
89556046|NCT03149497|Active Comparator|failed anterior approach only in traumatic cervical spine|
89556047|NCT03149419|Active Comparator|Paroxetine|Paroxetine 7,5 mg - 1 pill/day for 12 weeks
89556048|NCT03149419|Placebo Comparator|Placebo|Placebo oral capsule (corn starch) - 1 pill/day for 12 weeks
89556049|NCT03092765|Experimental|low-dose, high-frequency E6011; high-dose, low-frequency E6011|Participants will receive low-dose E6011 at a relatively higher frequency up to approximately Week 12. Participants will then receive high-dose E6011 at a relatively lower frequency from Week 12 to Week 64.
89556050|NCT03092765|Experimental|low-dose, high-frequency E6011; low-dose, low-frequency E6011|Participants will receive low-dose E6011 at a relatively higher frequency up to approximately Week 12. Participants will then receive low-dose E6011 at a relatively lower frequency from Week 12 to Week 64.
89556051|NCT03092765|Experimental|high-dose, low-frequency E6011; high-dose, low-frequency E6011|Participants will receive high-dose E6011 at a relatively lower frequency up to approximately Week 12. Participants will then receive high-dose E6011 at a relatively lower frequency from Week 12 to Week 64.
89556052|NCT03092765|Experimental|high-dose, low-frequency E6011; low-dose, low-frequency E6011|Participants will receive high-dose E6011 at a relatively lower frequency up to approximately Week 12. Participants will then receive low-dose E6011 at a relatively lower frequency from Week 12 to Week 64.
89556053|NCT03092765|Experimental|low-dose, low-frequency E6011; high-dose, low-frequency E6011|Participants will receive low-dose E6011 at a relatively lower frequency up to approximately Week 12. Participants will then receive high-dose E6011 at a relatively lower frequency from Week 12 to Week 64.
89556054|NCT03092765|Experimental|low-dose, low-frequency E6011; low-dose, low-frequency E6011|Participants will receive low-dose E6011 at a relatively lower frequency up to approximately Week 12. Participants will then receive low-dose E6011 at a relatively lower frequency from Week 12 to Week 64.
89556055|NCT03092765|Experimental|Placebo; high-dose, low-frequency E6011|Participants will receive placebo up to approximately Week 12. Participants will then receive high-dose E6011 at a relatively lower frequency from Week 12 to Week 64.
89556056|NCT03092765|Experimental|Placebo; low-dose, low-frequency E6011|Participants will receive placebo up to approximately Week 12. Participants will then receive low-dose E6011 at a relatively lower frequency from Week 12 to Week 64.
89556057|NCT02355223|Other|FAST Implementation|This single center study will consist of introducing a TB screening program called FAST (Find cases Actively, Separate safely, and Treat Effectively) within the hospital among patients presenting for care who have cough or TB risk factors, and testing them for tuberculosis using a combination of rapid screening and diagnostics tools. The study will evaluate the process of implementation as well as the impact on reducing tuberculosis transmission to health care workers over successive years.
89556058|NCT05032391|Experimental|The pentavalent rotavirus vaccine (live attenuated oral, freeze-dried)|Live attenuated bovine-human [UK] reassortant rotavirus vaccine manufactured by the Serum Institute of India, Limited (SIIL). The pentavalent vaccine contains rotavirus serotypes G1, G2, G3, G4, and G9 (≥5.6 log10 FFU/serotype/dose). The vaccine is lyophilized and supplied with 2.5 ml of citrate bicarbonate buffer added for reconstitution before oral administration.
89210573|NCT00927498|Active Comparator|Arm A Daunorubicin and Cytarabine|"Daunorubicin(DNR) induction : 60 mg/m2/day IV (30 min), Days 1,2,3 Daunorubicin (DNR)first consolidation : 60 mg/m2 day 1. Daunorubicin (DNR)second consolidation : 60 mg/m2 day 1 and day 2.~Cytarabine induction :200 mg/m2/day by continuous infusion, Days 1 to 7. Cytarabine (AraC)first and second consolidation: 1g/m2/12h days 1 to 4."
89519576|NCT05396651|Experimental|LOW FODMAP Diet group|"42 Children aged 5-15 years old fulfilling ROME IV criteria of IBS diagnosis, and didn't have any of the following :o Abdominal pain or diarrhea that wakes the child from sleep~Delay in onset or progression of puberty.~Faltering growth.~Family history of inflammatory bowel disease, celiac disease.~History of significant weight loss .~Bleeding per rectum.~Persistence of severe vomiting or diarrhea~. Persistent joint pain.~Recurrent unexplained fever.~Unexplained pallor they followed the low fodmapdiet for 6 weeks"
89556059|NCT05032391|Placebo Comparator|Diluent is a sterile solution (Citrate Bicarbonate Buffer)|Same constituents as the active vaccine but without the viral antigens; manufactured by SIIL.
89025850|NCT03273140|Experimental|Gamification Diabetes Education Program (GDEP)|"The GDEP consists of two components, which are 1) gamification app on diabetes education, and 2) usual care group (face-to-face discussion with a DNE).~1) Gamification: The development of this gamification app, a mobile-based app of serious gaming, addresses the limitation and few recommendations from the current literature review. It aimed to enhance the user experience, and to facilitate diabetes education in an effective and efficient way, aligning with ADA (2014) guidelines, work instructions, and protocols in one tertiary organization. The learning modules are framed by socio-cognitive framework and self-efficacy. The gaming concept has been implemented into a mobile app, which can be accessed via iOS and Android platforms. It takes an average of 15 minutes to complete per stage. Hence, allowing flexibility for participants to access the games anywhere and anytime using i-pad or mobile devices."
89025851|NCT03273140|No Intervention|Standard group|The control group comprises of the standard care or usual care group, which is the face-to-face session with the DNE. The content during each session is dependent upon the individual's needs and concerns, including the reason for referral to DNE by the endocrinologist. For example, teaching the individual patient on self-management of blood glucose (SMBG) and emphasizing on diet modification and exercise if necessary. Educational pamphlets on diabetes management will be given to him/her if deemed necessary. Each session will usually requires an average of 45 minutes, which is considered as long consultation that costs 16 dollars. On the other hand, short consultation is categorised as less than 30 minutes that costs around eight dollars. The difference is that there is no GDEP in the control group. However, after the completion of data collection at six months time, the control group will also receive the intervention (GDEP). This is in order to give them equal opportunity.
89025852|NCT00222989|Other|no label study|1
89025853|NCT00489567||Group A|Children hospitalised with community-acquired severe RV GE and children acquiring nosocomial severe RV GE.
89025854|NCT00489645|Placebo Comparator|1|Placebo, euglycemia
89025855|NCT00489645|Experimental|2|Pramlintide, euglycemia
89025856|NCT00489645|Placebo Comparator|3|placebo, hyperglycemia
89025857|NCT00489645|Experimental|4|pramlintide, hyperglycemia
89025858|NCT00465686|Experimental|A|
89025859|NCT04697199|Placebo Comparator|Placebo group|patients received scaling and root planing using hand and ultrasonic instruments.
89025860|NCT04697199|Active Comparator|Probiotic group|"patients received SRP and by using blunt syringe, subgingival delivery of 1ml of probiotic suspension was applied to these sites at baseline (immediately after SRP), one, two and four weeks. Periodontal dressing was applied after placement of the drug.~After placement of the drug, patients were instructed to keep away from chewing hard or sticky food, brushing near the treated areas, or using any interdental aids for 24 hours."
89025861|NCT00463268|Active Comparator|1|Alendronate 70 mg every 2 weeks
89556060|NCT02359981|Active Comparator|Generic suggestions|Control group participants received suggestions generated by the a nutritionist and exercise trainer. These suggestions didn't relate to user's life or their past behavior.
89556061|NCT02359981|Experimental|MyBehavior|Experiment group participants received personalized suggestions from MyBehavior that relates their life and past behavior.
89556062|NCT03092687||psychiatric disorders|decedents with and without psychiatric use disorders
89556063|NCT03092687||substance disorders|decedents with and without substance use disorders
89556064|NCT02355145||Patient group in moment 1 of evaluation|Study group enrolled in moment 1 of evaluation (Feb - Mar 2015)
89556065|NCT02355145||Patient group in moment 2 of evaluation|Study group enrolled in moment 2 of evaluation (Feb - Mar 2016) - 1 year distance from moment 1
89556066|NCT01939366|Experimental|Cebranopadol 300 µg|
89556067|NCT01939366|Experimental|Cebranopadol 600 µg|
89556068|NCT01939366|Active Comparator|Pregabalin|
89556069|NCT01939366|Placebo Comparator|Matching Placebo|
89556070|NCT01939366|Experimental|Cebranopadol 100 µg|
89556071|NCT04434365|Experimental|Berberine+standard therapy Arm|In the Berberine Arm, patients will receive berberine 100 mg twice daily for 4±1 weeks (Stage 1); then, 200 mg twice daily for 4±1 weeks (Stage 2); then, 300 mg twice daily for 4±1 weeks (Stage 3) in addition to standard treatment, including aspirin (100mg/day), clopidogrel (75mg/day), statins, the use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, calcium channel blockers, beta-blockers, and/or antidiabetic therapy (including insulin or oral medication) was decided on an individual basis by the attending physician for 12±1 weeks.
89556072|NCT04434365|Active Comparator|Standard therapy Arm|In the Control Arm, patients will receive standard treatment, including aspirin (100mg/day), clopidogrel (75mg/day), statins, the use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, calcium channel blockers, beta-blockers, and/or antidiabetic therapy (including insulin or oral medication) was decided on an individual basis by the attending physician for 12±1 weeks.
89556073|NCT02359669|Active Comparator|Growing up milk (GUM)|GUM associated with StimuLearn intervention.
89556074|NCT02359669|Placebo Comparator|Skimmed Milk|Control group given skimmed milk without StimuLearn intervention.
89556075|NCT02359591||text-based or multimedia|Subject fills in a questionnaire regarding whether the child meets developmental milestones for his/her developmental age, both the text-based and the multimedia version. A total score will be calculated and compared.
89025862|NCT00463268|Placebo Comparator|2|Alendronate 70 mg placebo tablet every 2 weeks
89556076|NCT05032469|Experimental|Refloxology Intervention|The first foot reflexology was applied to the intervention group for 30 min (20 min on the right foot, 10 min on the left foot) on the first postoperative day (24 h after the surgery). On the second postoperative day, 30 min of foot reflexology was applied to the patients who decided to chest tube removal (CTR). After the foot reflexology applied by the researcher, CTR was performed by the doctor within 10 min. Immediately after CTR, the patient's pain and anxiety level during CTR was measured. At the 15th minute after CTR, the pain and anxiety level of the patients was measured, their satisfaction with the reflexology application was measured. Then, the patients were asked to describe the pain and feelings and thoughts during CTR, 1 hr after CTR, pain level was measured, and they were asked to express their feelings and thoughts about the reflexology application.
89556077|NCT05032469|No Intervention|Standart Care|Participants in the control group will receive standart postoperative care.
89556078|NCT02350075|Experimental|Short implants group|Patients receive short dental implants installation (6mm) without additional augmentation procedures.
89556079|NCT02350075|Other|Standard implants with OSFE group|Patients receive standard dental implants installation (10mm) combined with osteotome sinus floor elevation.
89556080|NCT02359279|Experimental|Contrast|All subjects will be in one group who will have a control radiograph before applying sodium iodide to interproximal surfaces of teeth when another radiograph will be taken to test for the presence of caries cavitation.
89556081|NCT02359357|Placebo Comparator|Placebo single dose|Placebo administered as a single dose
89556082|NCT02359357|Experimental|Single dose (Dose level 1)|FDL169 (Dose level 1) administered as a single dose
89556083|NCT02359357|Experimental|Single dose (Dose level 2)|FDL169 (Dose level 2) administered as a single dose
89556084|NCT02359357|Experimental|Single dose (Dose level 3)|FDL169 (Dose level 3) administered as a single dose
89556085|NCT02359357|Experimental|Single dose (Dose level 4)|FDL169 (Dose level 4) administered as a single dose
89556086|NCT02359357|Experimental|Single dose (Dose level 5)|FDL169 (Dose level 5) administered as a single dose
89556087|NCT02359357|Experimental|Single dose (Dose level 6)|FDL169 (Dose level 6) administered as a single dose
89556088|NCT02359357|Experimental|Single dose (Dose level 7)|FDL169 (Dose level 7) administered as a single dose
89556089|NCT02359357|Experimental|Single dose (Dose level 8)|FDL169 (Dose level 8) administered as a single dose
89556090|NCT02359357|Experimental|Additional single dose 1|Single dose of FDL169 to be administered at a dose level to be determined (up to Dose level 8)
89556091|NCT02359357|Experimental|Additional single dose 2|Single dose of FDL169 to be administered at a dose level to be determined (up to Dose level 8)
89556092|NCT02359357|Experimental|Additional single dose 3|Single dose of FDL169 to be administered at a dose level to be determined (up to Dose level 8)
89556093|NCT02359357|Experimental|Additional single dose 4|Single dose of FDL169 to be administered at a dose level to be determined (up to Dose level 8)
89556094|NCT02359357|Experimental|Food effect - fasted|Single dose of FDL169 in fasted conditions
89556095|NCT02359357|Experimental|Food effect - fed|Single dose of FDL169 in fed conditions
89556096|NCT02359357|Placebo Comparator|Placebo - multiple dose|Repeat doses of placebo
89556097|NCT02359357|Experimental|Multiple dose - Dose level 1|Repeat doses of FDL169 to be administered at a dose level to be determined (up to Dose level 8)
89556098|NCT02359357|Experimental|Multiple dose - Dose level 2|Repeat doses of FDL169 to be administered at a dose level to be determined (up to Dose level 8)
89556099|NCT02359357|Experimental|Multiple dose - Dose level 3|Repeat doses of FDL169 to be administered at a dose level to be determined (up to Dose level 8)
89556100|NCT02359357|Experimental|Multiple dose - Dose level 4|Repeat doses of FDL169 to be administered at a dose level to be determined (up to Dose level 8)
89556101|NCT02359357|Experimental|Multiple dose - additional dose level 1|Repeat doses of FDL169 to be administered at a dose level to be determined (up to Dose level 8)
88963236|NCT02021253|Active Comparator|Probiotics- Lactibiane Tolerance|"Active substance mixture of lactic 10% Bifidobacterium lactis LA 303, 10% Lactobacillus acidophilus LA 201, LA 40% Lactobacillus plantarum 301, 20% Lactobacillus salivarius LA 302, LA 20% Bifidobacterium lactis 304 Dosage: 10 X 10^9 probiotic / capsule~Composition: One capsule of 560 mg contains Lactibiane tolerance:~345 mg of corn starch~114 mg premix lactic~6 mg of magnesium stearate Excipients: magnesium stearate~Method of administration: Oral~Dosage: 2 capsules per day for 14 days in two doses: one capsule at sunrise, one capsule at bedtime;"
88963237|NCT02021305||Patients|60 children with a recorded episode of acute Urinary Track infection who attended 4th Department of Pediatrics of Medical School of Aristotle University of Thessaloniki.
88963238|NCT02021305||Controls|100 children with no history of Urinary Track Infection who attended 4th Department of Pediatrics of Medical School of Aristotle University of Thessaloniki.
88963239|NCT02021344|No Intervention|Pure control|Practice as usual (no MHFA) in all residences on these campuses.
88963240|NCT02021344|Experimental|Intervention residence on mixed campus|Mental Health First Aid delivered to these residences, but not all other residences at the same campus.
88963241|NCT02021344|Experimental|Pure intervention residence|Mental Health First Aid delivered to this residence and all other residences at the same campus
88963242|NCT02021344|No Intervention|Control at mixed campus|Practice as usual (no MHFA) at this residence, but some other residences at same campus are in experimental condition (MHFA).
89556102|NCT02359357|Experimental|Multiple dose - additional dose level 2|Repeat doses of FDL169 to be administered at a dose level to be determined (up to Dose level 8)
89556103|NCT05023265|Experimental|SBRT for Medically Inoperable RCC|35-40 Gy in five fractions (7-8 Gy/day)
89556104|NCT05031923|Experimental|SMV and antimicrobial photodynamic therapy|Application SMV and antimicrobial photodynamic therapy in intrabony defect
89556105|NCT05031923|Active Comparator|SMV application|Application SMV in intrabony defect
89556106|NCT02354755||Cold room|Anesthesia providers intraoperatively placed in ambient room temperature of 65 degreees (cold room), completing a 10-minute psychomotor vigilance test (PVT), followed up by a questionnaire on SurveyMonkey
89556107|NCT02354755||Hot room|Anesthesia providers intraoperatively placed in ambient room temperature of 80 degreees (hot room), completing a 10-minute psychomotor vigilance test (PVT), followed up by a questionnaire on SurveyMonkey
89556108|NCT02354755||Control Room|as a control placed Anesthesia providers in ambient room temperature of 75 degreees (neutral room), completing a 10-minute psychomotor vigilance test (PVT), followed up by a questionnaire on SurveyMonkey
89556109|NCT02354989|Active Comparator|RR on first|Rate Response on first
89556110|NCT02354989|Active Comparator|RR off first|Rate Response off first
89556111|NCT05023187|Experimental|Social and Cognitive Online Training Group (SCOT)|A group of participants randomly assigned to a social-cognitive online training through individual cognitive training sessions and group sessions to improve social functioning.
89556112|NCT05023187|Active Comparator|Control Group (CON)|A group of participants randomly assigned to receive an active control intervention to compare performances with the experimental group.
89556113|NCT05032001|Experimental|Metformin|Metformin 1.7-2.5mg per day during twelve weeks
89556114|NCT05032001|Experimental|Metformina + IDDP-4|Metformin 1.7-2.5mg per day plus Linagliptin 5mg per day or Sitagliptin 50-100mg per day
89556115|NCT05032001|Experimental|Metformina + ISGLT-2|Metformin 1.7-2.5mg per day plus Empaglifozin 10-25mg per day or Dapaglifozin 10mg per day
89556116|NCT05022875|Experimental|Experimental app intervention|The complete Healthcare CEO app will be used for intervention in the experimental group.
89556117|NCT05022875|Sham Comparator|Control app intervention|"Participants in the control group will only install the CEO's Profile and Health Tracking interfaces of the Healthcare CEO app."
89556118|NCT03149263||Toxin-clown|"Botulinum toxin injections are carried out according to the usual injection protocol.~40 children will be included into the arm toxin with clown distraction. During injections, clowns take information with the doctor before the procedure on the child's pathology, the cognitive level, the number of injections. During injections, clowns fit and distraction can change depending on the reaction of the child to their intervention."
89556119|NCT03149263||Toxin-usual distraction|"40 children will be included into the arm toxin with usual distraction The usual distraction involves discussion with the child, and its accompanying its interests, to define the use of music, songs, television, video games or other distraction during the session. If the first distraction doesn't work, it's possible to switch to another distraction during injections"
89556120|NCT03149341||Study|Congenital heart disease or acquired cardiopulmonary disease who will get (or have gotten) and MRI
89556121|NCT03149341||Normal Volunteers|No congenital heart disease or acquired cardiopulmonary disease who will get (or have gotten) and MRI
89556122|NCT04963517|Experimental|Exercise therapy|"8 weeks personalized, multi-modal exercise with focus on lower extremity~Initial consultation with recommendations for general physical activity~Brochure with exercise recommendations~2x per week multi-modal group-based and supervised exercise (endurance, strength, mobility, coordination)~week 1 and 2 supervised, week 3 and 4 partially supervised, week 5 and 6 only one supervised session, week 7 and 8 last two sessions supervised"
89556123|NCT04963517|Active Comparator|Information group|"Initial consultation with recommendations for general physical activity~Brochure with exercise recommendations."
89556124|NCT03159715|Experimental|Internet-based Global Protocol|Intervention group that carries out the Internet-based Global Protocol and receives therapist support.
89556125|NCT03159715|Experimental|Internet-based Behavioral Activation Protocol|Intervention group that carries out the Internet-based Behavioral Activation Protocol and receives therapist support.
89556126|NCT03159715|Experimental|IInternet-based Positive Psychology Protocol|Intervention group that carries out the Internet-based Positive Psychology Protocol and receives therapist support.
89556127|NCT05031689|Placebo Comparator|SPF 30 and Placebo|Control Group will use SPF 30 sunscreen plus pharmaceutical formulation without green banana peel extract
89556128|NCT05031689|Active Comparator|SPF 30 and pharmaceutical formulation with green banana peel|In Study Group, in addition to the SPF 30 sunscreen, a pharmaceutical formulation containing the extract of the green banana peel will be used.
89556129|NCT03147469|No Intervention|Neutral|After insertion of Ambu AuraGain™, the variables will be assessed at each positions including neutral, flexion, extension, right rotation under random order.
88963243|NCT02021383|Experimental|Contest Plus|The Contest Plus group were eligible to receive the financial incentives for weight loss maintenance at three monthly follow ups; weeks 16, 20 and 24. Eligible participants completed online surveys and in person weigh ins verifying weight maintenance. In addition to the financial incentives, participants in this group had bi-weekly in person meetings with a Registered Dietician during phase 2 (week 16-24) of the trial. They also received an in home scale to monitor weight daily.
88963244|NCT02021383|No Intervention|Control|The Control condition did not receive any intervention and were not eligible to win the lottery based incentive. Participants completed follow surveys (weeks 16, 20 and 24) and received remuneration for completing surveys and in person weigh in.
88963245|NCT02021383|Experimental|Contest Only|The Contest only group were eligible to receive the financial incentives for weight loss maintenance for maintaining weight lost at three monthly follow ups; weeks 16, 20 and 24. Eligible participants completed online surveys and in person weigh ins verifying weight maintenance.
88963246|NCT02021396|Experimental|Embolization|this arm of the study was interventional (embolization) with CT scans at inclusion (D0, to validate the inclusion criteria), at one month (D30-validating the primary endpoint) and at 6 months (D180) read by 2 expert radiologists blinded to the study arm
88963247|NCT02021396|No Intervention|Surveillance|this arm of the study was non-interventional (surveillance), with CT scans at inclusion (D0, to validate the inclusion criteria), at one month (D30-validating the primary endpoint) and at 6 months (D180 ) read by 2 expert radiologists blinded to the study arm
89556130|NCT03147469|Experimental|Flexion|After positioning the subjects' neck to flexion, the variables will be assessed.
89556131|NCT03147469|Experimental|Extension|After positioning the subjects' neck to extension, the variables will be assessed.
89556132|NCT03147469|Experimental|Right rotation|After positioning the subjects' head to right rotation, the variables will be assessed.
89025863|NCT04697433||Myotonometry|The evaluation of myotonometry will be carried out by two independent evaluators. The first evaluator will perform the test bilaterally on the middle deltoid, upper trapezius, pectoralis major, biceps brachii, rectus femoris, anterior tibialis, triceps brachii, lumbar multifidus, biceps femoris and soleus previously marked. Immediately after, the second appraiser will perform the same measurements in the same order (Inter-rater reliability). After a 15-minute interval, the retest (intra-rater reliability) will be performed following the same procedure and order as the test step.
89025864|NCT00105443|Experimental|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400 mg was administered orally at a dose of 400 mg (2 x 200 mg tablets) twice daily; 2 dose reductions to predefined levels of 400 mg once daily (OD) and 400 mg every other day were permitted for adverse events related to study treatment. Follow-up / Open Label phase: Subjects on sorafenib who continued the study, continued on the same dose of sorafenib as during the double-blind study.
89025865|NCT00105443|Placebo Comparator|Placebo|Sorafenib-matching placebo tablets were orally administered twice daily (bid). Follow-up / Open Label phase: Subjects on placebo who chose to switch to sorafenib, received an oral dose of 400 mg (2 x 200 mg tablets) bid; similar to the double-blind study.
89025866|NCT00489801|Other|Exercise intervention|Exercise intervention and lifestyle counseling at centre or exercise intervention at home
89025867|NCT01243047|Active Comparator|Arm A|Continuous erlotinib administration (21-day cycle). Erlotinib dose given at 100mg daily
89025868|NCT01243047|Active Comparator|Arm B|Intermittent erlotinib administration (21-day cycle). Erlotinib dose given at 150mg.
89025869|NCT00489840|Experimental|anecortave acetate|
89025870|NCT00465725|Experimental|1|two-period crossover, open label study in which a single dose (Cycle 1) of picoplatin will be given either IV or PO, followed 4 weeks later by a single dose (Cycle 2) of picoplatin given by the route not used for Cycle 1. Subjects subsequently may continue to receive IV picoplatin commencing with Cycle 3 in a Continuation Study.
89025871|NCT00489957||Normals|
89556133|NCT05022953|Experimental|Digital Story Group|"Digital Story Group: One of the researchers gave the experimental group participants a 15-minute briefing on how to perform digital storytelling. She also told them not to talk to the control group participants about the content of the briefing. She created a Pixton account (https://edu.pixton.com/educators/) and a class named Isolation. She sent the link (https://join.pixton.com/x5xb6) to the experimental group participants. She asked them to click on the link and make stories out of their knowledge of isolation in four weeks."
89556134|NCT05022953|No Intervention|Control Group|Control group participants did not go through any training in isolation.
89556135|NCT03159013|Other|Pesticide toxicokinetics- oral|Exposure type: ORAL Toxicokinetics
89556136|NCT03159013|Other|Pesticide toxicokinetics- dermal|Exposure type: DERMAL Toxicokinetics
89556137|NCT05031377|Experimental|Experimental Arm: Integrated Intervention|Receive an integrated exercise and cardiovascular health education programme (HE programme)
89556138|NCT05031377|Sham Comparator|Control|Receive usual care
89556139|NCT02350231|Active Comparator|The progesterone vaginal pessary group|Where they will have progesterone vaginal pessary (Prontogest 400 mg) daily at bed time from 28 weeks of pregnancy till delivery in addition to tonic and calcium
89556140|NCT02350231|Placebo Comparator|Tonics group|Where they will receive only tonics and calcium from 28 weeks of pregnancy till delivery
89556141|NCT03092141|Active Comparator|Patients|Patients will be submitted to physical training (12-weeks, twice/week)
89556142|NCT03092141|Active Comparator|Control group|Healthy individuals will be submitted to physical training (12-weeks, twice/week)
89025872|NCT00489957||Cardiomyopathy|
89025873|NCT00465764|Experimental|Protein formula|Feed as per HCP direction
89025874|NCT00465764|Active Comparator|Standard infant formula|Feed as per HCP instructions
89025875|NCT00490074|Experimental|3 DNA-C + 1 NYVAC-C|
89025876|NCT00490074|Active Comparator|2 DNA-C + 2 NYVAC-C|
89556143|NCT02350153||Patients with verified Cushing's Disease|Patients with verified Cushing's Disease
89556144|NCT05031299|Active Comparator|Control group (Standard care)|Participants in the control group will receive only the standard care as provided by the local and national healthcare system as well as one face-to-face counselling session for lifestyle modification to improve their risk factors for 3 months.
89025877|NCT00465842||A - Normal Volunteers|"Normal volunteers without any history of liver disease and with normal liver functions test (LFT), including total protein/Albumin, LDH, ALT, AST, GGT, total bilirubin, direct and indirect bilirubin and do not belong to group B.~Volunteers will be screened using questionnaires. Those deemed suitable will then be asked to have the blood test done. All blood tests are done free of charge to subjects."
89025878|NCT00465842||B - Hepatitis B or C carriers with normal liver functions|
89025879|NCT00465842||C - Hepatitis B or C carriers with abnormal liver functions|
89025880|NCT00465842||D - Liver Cirrhosis|Liver cirrhosis, proven by liver biopsy or on clinical evidences, such as varices on CT scan indicative of portal hypertension.
89025881|NCT00465842||E - Hepatocellular Carcinoma (HCC) with Resection|HCC patients with resection.
89025882|NCT00465842||F - Unresectable HCC|Unresectable HCC patients with treatment
89025883|NCT00465842||G - Malignant HCC|HCC patients with active malignant disease and only palliative care are offered.
89025884|NCT04696926||patients who underwent an aortic valve replacement|
89025885|NCT00463541|Experimental|1|
89025886|NCT00490113|Experimental|1|
89556145|NCT05031299|Experimental|Intervention group 1 (Application)|Participants will will be additionally provided with a health-promotion application for self-management for 3 months.
89556146|NCT05031299|Experimental|Intervention group 2 (Devices)|"Participants will be additionally provided with wearables and devices for 3 months including:~A weighing scale (assessing also body composition) device~A smartwatch/wristband to assess physical activity but also sleep pattern."
89556147|NCT03147391||LAA closure with LAmbre|The patients with atrial fibrillation who received left atrial appendage (LAA) closure using the LAmbre device in our center from April 2014 to November 2015.
89556148|NCT03147547|Active Comparator|Promotional Brochure|Participants in this condition received one of the strategies in the Parent Engagement Package: a promotional brochure with information about the parenting intervention being offered at their child's school, the Triple P Positive Parenting Program. This information included the location of meetings, free childcare, topics covered, choice of English or Spanish groups, meeting day and time, and an enrollment form. Parents who returned the enrollment form received a confirmation letter prior to the first parenting program session.
89556149|NCT03147547|Experimental|Parent Engagement Package|Participants in this condition received all engagement strategies in the Parent Engagement Package, which included: 1) the promotional brochure; 2) family testimonial flyer that included photos and quotes from prior participants; 3) teacher endorsement of the Triple P program; 4) provider engagement call to motivate parents to attend; and 5) phone reminders prior to each Triple P session.
89556150|NCT01918306|Experimental|1PHIbA Arm A - cisplatin + GDC - 0941|"Determine the safety and tolerability of GDC-0941 given in combination with cisplatin in patients with AR- TN MBC. Determination of the maximally tolerated dose (MTD) of GDC-0941.~Cohort 1, 3 of 3 patients received:~Cisplatin 25 mg/m2 IV D1, 8, 15 GDC-0941 260 mg PO, days 2-6, 9-13, 16-20, 23-27, 28 day cycle GDC-0941 dose to start at Max dose of 260mg.~If no patient in the first cohort of 3 experiences a DLT, an additional cohort of 3 patients will be treated at the same dose level.~If 1 patient experiences a DLT in the first cohort, an additional cohort of 3 patients will be treated at the same dose level.~If ≤1 patient has a DLT in 6 treated at this same dose, this will be considered a tolerable dose to move to phase II~If patients experience a DLT considered related to GDC-0941, the patient may remain on GDC-0941 and/or Cisplatin after resolution of the DLT. All such cases will be considered a DLT for the purposes of defining the MTD."
89556151|NCT01918306|Experimental|1PHIbB - Arm B - Cisplatin + GDC 0941 dose level -1|"If 2 or more patients in 3 or 6 patients treated at a given dose experience DLT, the dose will be de-escalated to the next lower dose level. Once the lowest dose level is reached, if a DLT occurs, the regimen will be considered too toxic and the corresponding cohort within the study will be discontinued.~Determination of the maximally tolerated dose (MTD) of GDC-0941."
89556152|NCT01918306|Active Comparator|2PHII1 Arm 1 - Cisplatin|"Evaluate the efficacy, as measured by the overall response rate (ORR), of Cisplatin +GDC-0941 versus Cisplatin alone in patients with AR- TN MBC.~Patients will be randomized in a 1:1 fashion to arm 1: cisplatin, or arm 2: cisplatin + GDC-0941.~Arm 1 Cisplatin Only Patient received:~Cisplatin given intravenously (IV) over 1 hour for three consecutive weeks, then off one week (days 1, 8, and 15 of a 28 day cycle)."
89556153|NCT01918306|Experimental|2PHII2 - Arm 2 - Cisplatin + GDC - 0941|"Evaluate the efficacy, as measured by the overall response rate (ORR), of Cisplatin +GDC-0941 versus Cisplatin alone in patients with AR- TN MBC. Patients are randomized in a 1:1 fashion to arm 1: cisplatin, or arm 2: cisplatin + GDC-0941.~Arm 2 Cisplatin + GDC-0941 Patients received:~Cisplatin given intravenously (IV) over 1 hour for three consecutive weeks, then off one week (days 1, 8, and 15 of a 28 day cycle).~GDC-0941 260 mg PO, administered orally on days 2-6, 9-13, 16-20, 23-27 of a 28 day cycle."
89556154|NCT01918306|Experimental|2PHIICO|"Arm 2: Crossover post-progression~Patients who are randomized to Cisplatin alone (Arm 1) can crossover to receive Cisplatin + GDC-0941 upon disease progression.~Patient received:~Cisplatin given intravenously (IV) over 1 hour for three consecutive weeks, then off one week (days 1, 8, and 15 of a 28 day cycle).~GDC-0941 260 mg PO, administered orally on days 2-6, 9-13, 16-20, 23-27 of a 28 day cycle."
89556155|NCT05031611|Experimental|Intuitive Eating Treatment|"The intervention was a novel 10-week program aimed at promoting IE through pre-recorded videos, reading material, and bi-weekly discussion sessions. The intervention introduced the following modules sequentially: Unconditional Permission to Eat, Reliance to Hunger and Fullness Cues, Body-Food Choice Congruence, Gentle Nutrition, and Joyful Movement.~Every other week, a new module was introduced. Participants were taught the concept of this module through video and reading, then prompted to practice it over the week. On opposite weeks, the module last introduced was discussed in greater detail through video, and participants were given the opportunity to discuss amongst one another and have all questions answered by the researchers."
89556156|NCT05031611|No Intervention|Waitlist Control|Waitlist control group participants completed a series of questionnaires at the beginning and end of a 10-week interval, to compare changes in those who completed the intervention versus those who did not. This group was subsequently invited to participate in the intervention after their time on the wait-list.
88963248|NCT02021409|Experimental|BAY85-3934 (25mg)|Fixed starting dose of 25 mg of BAY85-3934 oral tablet (once daily dose) titrated at the scheduled dose control visits. Titration occuring every 4-weeks will be based on the subject's hemoglobin (Hb) response and tolerability of the prior dose. Total treatment time is 16 weeks. Planned doses include 15, 25, 50, 75, 100, and 150 mg once daily.
88963249|NCT02021409|Experimental|BAY85-3934 (50mg)|Fixed starting dose of 50 mg of BAY85-3934 oral tablet (once daily dose) titrated at the scheduled dose control visits. Titration occuring every 4-weeks will be based on the subject's Hb response and tolerability of the prior dose. Total treatment time is 16 weeks. Planned doses include 15, 25, 50, 75, 100, and 150 mg once daily.
88963250|NCT02021409|Experimental|BAY85-3934 (75mg)|Fixed starting doses of 75 mg of BAY85-3934 oral tablet (once daily dose) titrated at the scheduled dose control visits. Titration occuring every 4-weeks will be based on the subject's Hb response and tolerability of the prior dose. Total treatment time is 16 weeks. Planned doses include 15, 25, 50, 75, 100, and 150 mg once daily.
88963251|NCT02021409|Active Comparator|Darbepoetin alfa|Darbepoetin (intravenous or subcutaneous) will be administered according to the local label and titrated at the scheduled dose control visits. Titration will be based on the subject's Hb response and tolerability of the prior dose.
88963252|NCT02020980||Post-stroke lower limb spasticity patients|
88963253|NCT02021422|Other|Anakinra with Modified Folfirinox|"8-weeks of anakinra and modified FOLFIRINOX regimen (refer to Appendix 9 for regimen) as follows~Kineret (anakinra) Dosage Route Administration 100 mg SC Every Other Day~Modified FOLFIRINOX Drug Dose Administration Oxaliplatin 85 mg/m2 2-4 hours Irinotecan 180 mg/m2 90 minutes fluorouracil 2400 mg/m2 48 hours"
88963254|NCT02021435|Experimental|Salt Substitute|salt substitute
89556157|NCT05031533|Experimental|Assigned Interventions|"Radiation therapy: Dose-painting radiation~Systemic treatment: Choose a systemic treatment plan according to the patient's genetic testing status~(1) Chemotherapy~Squamous cell carcinoma: Paclitaxel 135mg/m2 D1 + Cisplatin 25mg/m2 D1-3, every 21 days, a total of 2-4 cycles.~Non-squamous cell carcinoma (adenocarcinoma, large cell carcinoma): Pemetrexed 500mg/m2 d1 + Cisplatin 75 mg/m2 d1-3, a total of 2-4 cycles.~(2) Targeted therapy: According to the patient's genetic testing status, molecular targeted therapy such as EGFR-TKI and ALK inhibitors can be selected; (3) Immunotherapy: According to the patient's genetic testing status, immunotherapy such as PD1/PD-L1 inhibitors can be selected;"
89556158|NCT02348515||Heart failure or coronary disease|This group will have small samples collected from the apex core (that would be routinely discarded at the time of the implantation procedure) by undergoing a left ventricular assist device implantation. In addition, a blood sample will be collected.
89556159|NCT02348515||Heart transplant patients|This group will have multiple samples collected including, excess myocardial biopsy samples that will not be utilized by pathology. In addition, a blood sample will be collected.
89556160|NCT02348515||Orthotopic Heart Transplant Patients|This group will have myocardial tissue samples collected from the diseased heart. In addition, a blood sample will be taken.
88963255|NCT02021435|No Intervention|Control|Participants continue to buy salt at their own expense
89556161|NCT02348515||Heart Surgery Patients|This groups will have samples collected from the left atrial appendages that are routinely removed to prevent thrombosis during atrial fibrillation surgery and a piece of the right atria will be cut in order to implant the cannula. In addition, a blood sample will be taken.
89556162|NCT05022797|Experimental|Glucarpidase, methotrexate, R-CHOP|Glucarpidase 2000Units per dose. IV. Bolus injection over 5 minutes. Administered 12 hours following after each HDMTX cycle, for a maximum of 3 cycles.
89556163|NCT01917526|Active Comparator|oxygen mask|Oxygen mask with oxygen flow 5 L/min will be given to allocated post general anesthesia patients. The incidence and causes of hypoxemia will be recorded.
88963256|NCT02021500||Patients previously enrolled in study CA046|No intervention is being given in this extension study which is gathering survival information on participants of study NCT 00844649 (Celgene study CA046) who were known to be alive as of March 2013)
88963257|NCT02021513|Experimental|Fish Oil|Fish Oil (2.25gm EPA and 2.25gm DHA total)
88963258|NCT02021513|Placebo Comparator|Placebo|Olive Oil
89517420|NCT03011528|Other|VDC - IE x2 & Surgery|"Patients in Arm A receive~VDC-IE x2: Intensified induction phase:~4 cycles of VDC (Vincristine Doxorubicine Cyclophosphamide) association alternative with 4 cycles of IE (Ifosfamide-Etoposide) association if good response after the 4th treatment, followed by:~4 cycles of VDC (Vincristine-Doxorubicine-Cyclophosphamide) association alternative with 4 cycles of IE (Ifosfamide-Etoposide) association~Consolidation BuMel High dose chemotherapy (Busulfan Melphalan) followed by Peripheral Blood Stem Cell Infusion~Local treatment by surgery of primary tumour/metastatic sites (outside pulmonary sites): indicated before of after consolidation phase (BuMel) among multidisciplinary decision. Radiotherapy can be added~Maintenance phase~1st year : VC (Vincristine Cyclophosphamide) association~2nd year : Cyclophosphamide po 25 mg/m²"
89556164|NCT01917526|Active Comparator|Oxygen cannula|Oxygen cannula with oxygen flow 4 L/min will be given to allocated post general anesthesia patients. The incidence and causes of hypoxemia will be recorded.
89556165|NCT05031143|Active Comparator|SCTA injection (n=6 eyes)|Suprachoroidal Trimacinolone Acetonide injection 4mg/0.1ml, single dose, follow up for 6 months.
88963259|NCT02021526|Experimental|No Dietary Therapy|Patients currently on no dietary therapy will receive triheptanoin (C7 oil), dosed at 1 g/kg body weight and divided into 4 doses daily, administered for 6 months
88963260|NCT02021526|Experimental|Ketogenic Diet|Patients on ketogenic diet will receive triheptanoin (C7 oil) in place of their usual fat intake, at a dose sufficient to maintain their ketogenic diet ratio (based on patient weight and current ratio). Patients will receive triheptanoin for 6 months.
88963261|NCT02021539||The study population|"The study population consists of pregnant women presenting between the 24th and 34th week of pregnancy, with uterine contractions associated with cervical changes objectified by ultrasound examination of the cervix (5-25mm) who consult for obstetric emergencies (both single or multiple pregnancies can be included).~Intervention : Cervical ultrasound +elastography 1 Intervention : Vaginal fibronectin measurement Intervention : Tocolytic treatment for 2 hours Intervention : Cervical ultrasound +elastography 2"
88963262|NCT02021552||trauma patients|trauma patients 18 years or older requiring treatment in the ICU >24 hours. All subjects will undergo blood sampling.
88963263|NCT02021591|No Intervention|Control|Control Arm: Study participants attending one of the 4 control arm centers will receive usual diabetes education provided by staff at the site; be provided with free test strips for their blood glucose meters during the 4-week intervention period; given access to the MODD application at the end of the study. Instructions on how to use the MODD will be provided by site staff.
89556166|NCT05031143|No Intervention|Non-injected eyes (Standard Treatment) (n=6 eyes)|Non-injected eyes on systemic steroids (standard treatment) and follow up for 6 months
89556167|NCT01948258|Other|Clearblue Advanced Fertility Monitor|Use of Clearblue Fertility Monitor
89556168|NCT02354677|Experimental|Heathy volunteers, smokers and COPD|
89556169|NCT02348437|Experimental|Repair|Repair of the pronator quadratus muscle
89556170|NCT02348437|Active Comparator|Non-repair|Non-repair of the pronator quadratus muscle
89556171|NCT01916980|Experimental|Desloratadine: Eczema/Dermatitis|Participants with eczema/dermatitis receive desloratadine 5 mg, taken as one 5-mg tablet, orally once daily in the evening for up to 12 weeks. After Week 4, the dose of desloratadine can be increased from 5 mg/day to 10 mg/day (two 5-mg tablets, orally once daily in the evening for up to 8 weeks), if criteria for dose up-titration are met, there is insufficient antipruritic efficacy and there is no safety concern.
89556172|NCT01916980|Experimental|Desloratadine: Dermal Puritus|Participants with dermal pruritus receive desloratadine 5 mg, taken as one 5-mg tablet, orally once daily in the evening for up to 12 weeks. After Week 4, the dose of desloratadine can be increased from 5 mg/day to 10 mg/day (two 5-mg tablets, orally once daily in the evening for up to 8 weeks), if criteria for dose up-titration are met, there is insufficient anti-pruritic efficacy and there is no safety concern.
89556173|NCT05021627|Experimental|Cardiac autonomic nerve modification|
88963264|NCT02021591|Experimental|Intervention|Intervention: Mobile Diabetes Detective (MoDD) Study participants attending one of the 4 Intervention sites will receive usual diabetes education provided by staff at the site and be given access to the MODD application and instructions for use for 4 weeks at the beginning of the study. After the initial 4 weeks of access to the MODD application, participants will be offered an option to continue using MODD for the duration of the study.
88963265|NCT02021617|No Intervention|Intraosseous Access|This study will evaluate the proximal humerus and proximal tibia IO infusion sites for infusion flow rates attainable at specified infusion pressures. We will evaluate the IO infusion pathway to determine the mean time from IO contrast injection at the proximal humerus and proximal tibia sites to delivery to central circulation. This study will provide additional data regarding the relationship between IO and IV blood when used for routine laboratory analysis, adding to the current sample size. Lastly, this study will provide data to determine the average time from IO needle insertion to access of the IO space for immediate drug administration, and the average time from IO needle insertion to the ability to infuse fluids in the conscious subject. Intraosseous access.
88963266|NCT02021630||Patient|No intervention will occur during this study. Evaluation of changes in patients' family after having patient has bariatric surgery.
88963267|NCT02021630||Spouse/Partner|No intervention will occur during this study. Evaluation of changes in patients' family after having patient has bariatric surgery.
88963268|NCT02021630||Child(ren)|No intervention will occur during this study. Evaluation of changes in patients' family after having patient has bariatric surgery.
88963269|NCT02021682||Amyloid positive (Amyloidosis)|Amyloidosis defined by positive Positive emission tomography (PET)/Pittsburg Compound B (PIB) score, or low CSF Aβ42 concentration.
89556174|NCT05021627|Active Comparator|Pacemaker|
89556175|NCT02348281|Experimental|bicalutamide|150mg, po, qd, d1-28
89556176|NCT05021783||Patients|Patients with Axial SpondyloArthritis
89556177|NCT03147313|Sham Comparator|Sham|
89556178|NCT03147313|Active Comparator|Shockwave 300 pulses|300 pulses of extracorporeal shock wave will be applied
89556179|NCT03147313|Active Comparator|Shockwave 500 pulses|500 pulses of extracorporeal shock wave will be applied
89556180|NCT02354287||Patients having outpatient Colonoscopy.|Patients with Polyps ≤7mm that are deemed appropriate to be removed by cold forceps polypectomy with pre lift
88963270|NCT02021682||Amyloid negative (Control)|Amyloid negative defined by negative Positive emission tomography (PET)/Pittsburg Compound B (PIB) score or high/normal CSF Aβ42 concentration .
88963271|NCT02021708||Non-smoker|This group will include individuals without any history of lung disease, including asthma, and without recurrent or acute pulmonary disease. Individuals must also have smoked less than 100 cigarettes and/or less than 10 shisha pipes in their lifetime.
89556181|NCT03094949|Active Comparator|Partial Nephrectomy|a kind of operation for renal tumor
89556182|NCT03094949|Experimental|microwave ablation|a kind of minimally invasive therapy by using microwave device for renal tumors
89556183|NCT02349919|Experimental|Procaterol|Procaterol 25 micrograms/tablet, 1 tablet twice daily for 4 weeks
89556184|NCT02349919|Placebo Comparator|Placebo|Placebo twice daily for 4 weeks
89556185|NCT03091985|Experimental|Group A|"Drainage of the lactating breast using:~PersonalFit - Breast shield & Brownie - Breast shield~Breast shields are each to be used for 15 min pumping with the symphony breastpump"
89556186|NCT03091985|Experimental|Group B|"Drainage of the lactating breast using:~Brownie - Breast shield & PersonalFit - Breast shield~Breast shields are each to be used for 15 min pumping with the symphony breastpump"
89556187|NCT03147235|Experimental|vitrectomy with music listening|Patients undergoing vitrectomy surgery will listen to a designed playlist of music during the entire duration of surgery
89556188|NCT03147235|No Intervention|vitrectomy without music listening|Patients undergoing vitrectomy surgery will not be exposed to music listening.
89556189|NCT02349763|Active Comparator|Oral Dexamethasone|Dexamethasone 20 mg (4 mg/tablet) or 5 tablets given orally at 12 and 6 hours before paclitaxel infusion and 0.9% NaCL (Placebo) 4 ml given intravenously at 30 minutes before paclitaxel infusion
89556190|NCT02349763|Experimental|Intravenous Dexamethasone|Lactose (Placebo) 5 tablets given orally at 12 and 6 hours before paclitaxel infusion and dexamethasone 20 mg (5mg/ml) given intravenously at 30 minutes before paclitaxel infusion
89556191|NCT02349841|Experimental|Meropenem;amoxycillin/clavulanic acid|Meropenem 2g will be administered intravenously 8-hourly; plus amoxycillin/CA 500mg/125mg will be administered orally 8-hourly for 14 days
89556192|NCT02349841|Experimental|Faropenem; amoxycillin/CA|Faropenem 600mg will be administered orally 8-hourly; plus amoxycillin/CA 500mg/125mg will be administered orally 8-hourly for 14 days
89556193|NCT02349841|Active Comparator|Rifafour e-275|Rifafour e-275 will be administered orally once daily for 14 days as per South African National TB Treatment Guidelines
89556194|NCT04971629||Cohort 1|Patients with knee osteoarthritis who use medical cannabis to manage MSK symptoms.
89556195|NCT04971629||Cohort 2|Patients with knee osteoarthritis who do not use medical cannabis.
89025887|NCT01243164|Experimental|Wheelchair Skills Training Program|A standardized wheelchair skills training program to teach 32 specific wheelchair skills.
89025888|NCT01243203|Placebo Comparator|Placebo|patient will receive placebo pills
89556196|NCT02349997||OSA group|"Of the 180 heart failure patients,20 OSA were enrolled. Clinical evaluations including NYHA class, electrocardiographic, echocardiographic, arterial blood gas analysis findings, baseline medication, and 6-minute walk test (6MWT) were recorded.~The fluid index, head and neck CT and pharyngeal resistance were tested at 20:00. Then a full night PSG and percutaneous PaCO2 were performed. The fluid index, head and neck CT and pharyngeal resistance were repeated at 6:00 after PSG.~The volume of fluid shift from legs to head and neck,inside diameter of the upper airway, and water content of neck soft tissue were calculated. The lung-to-finger circulation time and loop gain were measured."
89556197|NCT02349997||CSA group|"Of the 180 heart failure patients,20 CSA were enrolled. Clinical evaluations including NYHA class, electrocardiographic, echocardiographic, arterial blood gas analysis findings, baseline medication, and 6-minute walk test (6MWT) were recorded.~The fluid index, head and neck CT and pharyngeal resistance were tested at 20:00. Then a full night PSG and percutaneous PaCO2 were performed. The fluid index, head and neck CT and pharyngeal resistance were repeated at 6:00 after PSG.~The volume of fluid shift from legs to head and neck,inside diameter of the upper airway, and water content of neck soft tissue were calculated. The lung-to-finger circulation time and loop gain were measured."
89556198|NCT05020925|Experimental|SHR-1701 plus Famitinib|SHR-1701+Famitinib for R/M NPC failure after platinum-based chemotherapy and anti PD-1/PD-L1 antibody therapy
89556199|NCT02349373|Active Comparator|Preconditioning running|An 8 week preconditioning period. The variables of interest are running distance and running intensity: running speed >80% VO2max (maximal oxygen uptake).
89556200|NCT02349373|Active Comparator|Follow-up period|"The Volume group progress 23% in total weekly running distance in the last adaptation week in the prior 4 week block.~The Intensity group progress 23% in weekly distance of running above 80% VO2 max (maximal oxygen uptake), based on the distance of running above 80% VO2max in the last adaptation week in the prior 4 week block."
89556201|NCT02349529|Experimental|Psychosocial group intervention|
89556202|NCT02349529|Other|Waiting List control|Participants in the waiting list control will continue in TAU but will then start the intervention once the first group of participants have completed the 3 month follow up in the psychosocial group intervention arm.
89556203|NCT02354209||HIV-1 patients receiving bPI ARV|"Non interventional study. Interventions will be clinically directed rather than by protocol.~The following procedures will be carried out:~Questionnaire on compliance and adherence~Clinic Visit~20ml blood sample to be taken for Virological Resistance Testing and Next Generation Sequencing (only if plasma viral load is detectable)"
89556204|NCT05021159||Methotrexate Group|20 acute lymphocytic leukemia patients receiving MTX treatment (3- 5 mg/ cm2)
89556205|NCT05021159||Healthy control group|20 healthy pediatric subjects not receiving any treatment
89556206|NCT02353975|Experimental|SHR3824 10mg fasted to fed|SHR3824 tablet, fasting conditions day 1, visit 2, 7 days wash-out, SHR3824 tablet, high fat, high calorie breakfast day 1, visit 3.
89556207|NCT02353975|Experimental|SHR3824 10mg fed to fasted|SHR3824, high fat, high calorie breakfast day 1, visit 2, 7 days wash-out, SHR3824, fasting conditions day 1, visit 3.
89556208|NCT05020613|Other|Early group|Patients whose catheters are removed within the first 48 hours after surgery will form the early group.
89556209|NCT05020613|Other|Late group|Patients whose catheters are removed after the first 48 hours of surgery will form the early group.
89556210|NCT03094559|Experimental|FlowMet device|This is a feasibility study
89025889|NCT03273101|Experimental|Intervention group|The sit-to-stand training is assisted by mechanical device
89025890|NCT03273101|Active Comparator|Control group|The sit-to-stand training is assisted by manual device
88963272|NCT02021708||Shisha smoker|This group will include individuals who have a shisha smoking history of more than 5 pipe-years and must currently smoke more than 5 pipes per week. Individuals must not show any signs of acute lung infection or have medical history of significant illness or other significant medical issues.
88963273|NCT02021708||Cigarette smoker|This group will include individuals who have a cigarette smoking history that will be confirmed by urine testing. Individuals must not show any signs of acute lung infection or have medical history of significant illness or other significant medical issues.
88963274|NCT02021721||Cohort|Subjects who fulfill the inclusion criteria will be pre-identified by consultation with their attending physicians and by thorough review of the literature to establish that the disease is indeed genetic and unsolved.
88963275|NCT02021747||Individuals with TB|"Diagnosis of pulmonary tuberculosis without extra-pulmonary TB, confirmed by at least one of the following:~Symptoms consistent with TB~Chest X-rays and or chest CT consistent with TB~Positive PPD test~Positive sputum test"
88963276|NCT02021747||Smokers|"Active smoker as evidenced by self report and urine nicotine >30 ng/mL and urine cotinine >50 ng/mL~Diagnosis of pulmonary tuberculosis without extra-pulmonary TB, confirmed by at least one of the following:~Symptoms consistent with TB~Chest X-rays and or chest CT consistent with TB~Positive PPD test~Positive sputum test"
89025891|NCT00490152||1|Participants use Vivagel™, applied vaginally twice daily for 14 days, and report their experiences via phone diary and teleconference.
89025892|NCT00490152||2|Participants use VivaGel™ Placebo, applied vaginally twice daily for 14 days, and report their experiences via phone diary and teleconference.
89025893|NCT00490152||3|Participants use HEC Placebo Gel (HEC Gel), applied vaginally twice daily for 14 days, and report their experiences via phone diary and teleconference.
89025894|NCT01245036|Active Comparator|Glucocorticoid arm|Prednisolone 0.75 mg/kg/day for 6 weeks (maximum 60 mg) Prednisolone 0.5 mg/kg/day for 6 weeks (maximum 40 mg) Prednisolone 0.25 mg/kg/day for 6 months (maximum 20 mg) Taper over the next three months Prednisolone 0.25 mg/kg EOD for 15 days Prednisolone 0.125 mg/kg EOD for 15 days Then taper by 5 mg every 15 days to complete one year
89556211|NCT02354053|Active Comparator|Current ART|Current ART + adherence support
89556212|NCT02354053|Experimental|Triumeq|Triumeq + adherence support
89556213|NCT05029037|Experimental|Group A|80 patients randomized to group A will receive two doses (High) of vitamin C intravenously, twice a day for seven days.
89556214|NCT05029037|Placebo Comparator|Group B|80 patients assigned to group B will receive two doses of Dextrose 500 mL, twice a day for seven days.
89556215|NCT03091907||Case|Children with a history of necrotizing enterocolitis
89556216|NCT03091907||control|Children with no history of necrotizing enterocolitis
89556217|NCT05028959|Experimental|Female athletes|highly trained subjects
89556218|NCT05028959|Experimental|Leisure sport women|recreational sportswomen practicing regular physical activity
89556219|NCT02353741|Experimental|EGFR-TKIs combined with radiotherapy|EGFR-TKIs combined with concurrent thoracic radiotherapy. Receive oral erlotinib 150mg per day with concurrent thoracic radiotherapy, within 2 weeks, pGTV54～60Gy/27～30f/5.5～6w.
89556220|NCT03092063|Experimental|Tomando Control-Nurse|Tomando Control de su Diabetes-Nurse is a culturally tailored, community-based, Diabetes Self-Management program delivered in a group format by licensed nurses working with individual patients and families.
89556221|NCT03092063|Experimental|Tomando Control-Promotora|Tomando Control de su Diabetes-Promotora is a culturally tailored, community-based, Diabetes Self-Management program delivered in a group format by community health workers (promotoras) working with individual patients and families.
89556222|NCT03092063|Experimental|Enhanced Engagement-Nurse|Tomando Control de su Diabetes-Nurse is a culturally tailored, community-based, Diabetes Self-Management program delivered in a group format by licensed nurses working with individual patients and families. If subjects do not benefit sufficiently, the subject may be randomized to receive three home visits to facilitate engagement with treatment.
89556223|NCT03092063|Experimental|Enhanced Engagement-Promotora|Tomando Control de su Diabetes-Promotora is a culturally tailored, community-based, Diabetes Self-Management program delivered in a group format by licensed nurses working with individual patients and families. If subjects do not benefit sufficiently, the subject may be randomized to receive three home visits to facilitate engagement with treatment.
89556224|NCT03092063|Experimental|Multifamily Group-Promotora|"If subjects do not benefit sufficiently from the initial Tomando Control intervention offered by the promotoras, they may be randomized to receive a multifamily group intervention consisting of three components: three initial joining sessions conducted with each of the families separately; a one-day (six hour) educational workshop; and ongoing multifamily group sessions."
89556225|NCT03092063|Experimental|Multifamily Group-Nurses|"If subjects do not benefit sufficiently from the initial Tomando Control intervention offered by the nurses, they may be randomized to receive a multifamily group intervention consisting of three components: three initial joining sessions conducted with each of the families separately; a one-day (six hour) educational workshop; and ongoing multifamily group sessions."
89556226|NCT02353663||All study participants|Schoolgoing children 5 to 16 years of age
88963277|NCT02021747||Non-smokers|"Never smokers is defined as someone who has smoked < 100 cigarettes per lifetime and whose urine nicotine <2 ng/mL and urine cotinine <5 ng/mL, at entry into the study~Diagnosis of pulmonary tuberculosis without extra-pulmonary TB, confirmed by at least one of the following:~Symptoms consistent with TB~Chest X-rays and or chest CT consistent with TB~Positive PPD test~Positive sputum test"
89556227|NCT02347969|Experimental|X34|Arm supplemented with X34
89556228|NCT05028803|Experimental|Phenylbutyrate|Volunteers will recieve 5 grams of Sodium Phenylbutyrate daily for 3 weeks (21 days). Sodium Pheburane will come in granuale form and 5 grams will be dosed every day.
89556229|NCT03146923|Active Comparator|Standard Care Arm|Patients randomised to the standard care arm will be re educated using the current low phosphorus diet prescription.
89556230|NCT03146923|Experimental|Modified Intervention Arm|Patients randomised to the intervention arm will be educated using a modified low phosphorus diet prescription.
89556231|NCT05020223|Experimental|MTA pulpotomy|Usuing MTA as capping material for cervical pulpotomy as a treatment option for deep carious primary teeth with signs and symptoms of reversible pulpitis in presence of pulp exposure
89556232|NCT05020223|Experimental|MTA direct pulp capping|Using MTA as capping material in case of trearment of deep carious primary teeth with signs and symptoms of reversible pulpitis with presence of pulp exposure
89556233|NCT05020223|Experimental|MTA indirect pulp capping|Using MTA as indirect capping material for treatment of deep carious primary teeth with signs and symptoms of reversible pulpitis
89556234|NCT03147001|Experimental|Protein ingestion|Subjects ingested protein drinks
89556235|NCT03147001|Placebo Comparator|Placebo|Subjects ingested a non-caloric placebo drink
89556236|NCT03094481|Active Comparator|US guided SCPB medial fracture|Bupivacaine hydrogen chloride Inj 0.5% (1:200,000) epinephrine. 10ml injected for ultrasound guided Superficial Cervical Plexus Block at C4 or C5.
89556237|NCT03094481|Active Comparator|US guided ISB medial fracture|Bupivacaine hydrogen chloride Inj 0.5%(1:200,000) epinephrine. 10ml injected for ultrasound guided Interscalene Brachial Plexus Block at C5 or C6.
89556238|NCT03094481|Active Comparator|US guided SCPB + ISB medial fracture|Bupivacaine hydrogen chloride Inj 0.5% (1:200,000) epinephrine. 10ml injected for ultrasound guided Superficial Cervical Plexus Block at C4 or C5. 10ml injected for ultrasound guided Interscalene Brachial Plexus Block at C5 or C6.
89556239|NCT03094481|Active Comparator|US guided SCPB lateral fracture|Bupivacaine hydrogen chloride Inj 0.5% (1:200,000) epinephrine. 10ml injected for ultrasound guided Superficial Cervical Plexus Block at C4 or C5.
89556240|NCT03094481|Active Comparator|US guided ISB lateral fracture|Bupivacaine hydrogen chloride Inj 0.5%(1:200,000) epinephrine. 10ml injected for ultrasound guided Interscalene Brachial Plexus Block at C5 or C6.
89556241|NCT03094481|Active Comparator|US guided SCPB + ISB lateral fracture|Bupivacaine hydrogen chloride Inj 0.5% (1:200,000) epinephrine. 10ml injected for ultrasound guided Superficial Cervical Plexus Block at C4 or C5. 10ml injected for ultrasound guided Interscalene Brachial Plexus Block at C5 or C6.
89556242|NCT04438837|No Intervention|control group|no intervention
89556243|NCT04438837|Active Comparator|intervention group|participants will recieve hydroxychloroquine in a dosage regimen of 400mg BID in the first day followed by 200mg BID for overall 10 days.
89556244|NCT05020067|Experimental|SPLS-IMRT|The superficial parotid lobe was contoured as an OAR, and V26 (the percentage volume receiving 26 Gy or more) in the superficial parotid lobe was constrained to be less than 30%
89556245|NCT05020067|No Intervention|C-IMRT|The entire parotid gland was delineated as an OAR, and V36 (the percentage volume receiving 36 Gy or more) in the entire parotid gland was constrained to be less than 40%
89556246|NCT02348125|Experimental|Mitochondrial Cocktail|"The precise content of the Mitochondrial Cocktail will be:~ubiquinol (liquid form, 150 mg/kg subject weight/day~carnitine, 50 mg/kg subject weight/day~alpha-lipoic acid, 100 mg/ day"
89556247|NCT05019911||Patients with COPD alone|In the cross-sectional part, the group of patients with COPD alone will be monitored by traditional sleep monitoring equipment (polysomnography) and millimeter wave radar equipment. In the cohort part, this group of patients will be continuously monitored by millimeter wave radar equipment for vital signs combined with pulse oxygen saturation, end expiratory CO2 and other indicators continuously monitored.
89556248|NCT05019911||Patients with COPD combined with sleep apnea hypopnea syndrome|In the cross-sectional part, the group of patients with COPD combined with sleep apnea hypopnea syndrome will be monitored by traditional sleep monitoring equipment (polysomnography) and millimeter wave radar equipment. In the cohort part, this group of patients will be continuously monitored by millimeter wave radar equipment for vital signs combined with pulse oxygen saturation, end expiratory CO2 and other indicators continuously monitored.
89556249|NCT02353273|Experimental|WH-1 ointment|WH-1 ointment(1.25%),15g ointment per tube.
89556250|NCT05028335|Other|Group G1|Home bleaching treatment (Carbamide Peroxide (PC) 22%) + placebo gel
89556251|NCT05028335|Experimental|Group G2|Home bleaching treatment (Carbamide Peroxide (PC) 22%) + 1.5% Potassium Oxalate gel
89556252|NCT04434053|Experimental|MIETHKE M.blue®|
89556253|NCT04434053|Active Comparator|MIETHKE proGAV 2.0® (with SA 2.0®)|
89556254|NCT02348047|Active Comparator|Conventional ventilation|Conventional ventilation - manual mode
89556255|NCT02348047|Experimental|ASV|Intellivent ASV ( Adaptative Support Ventilation )Ventilation- automatic mode
89556256|NCT03094403|Experimental|Azelaic Acid 15% topical gel|Topical, twice daily, for 84 days A thin layer of study treatment was gently massaged into the affected areas on the face
89556257|NCT03094403|Active Comparator|Finacea® (azelaic acid) Gel, 15%|Topical, twice daily, for 84 days A thin layer of study treatment was gently massaged into the affected areas on the face
89556258|NCT03094403|Placebo Comparator|Placebo|Topically to the face, twice a day A thin layer of study treatment was gently massaged into the affected areas on the face
89556259|NCT03158155||Patients with vitamin D deficiency|1. children with vitamin D deficiency with age group from 2-5 years old
89556260|NCT02347735||Anastomotic leakage|Of the entire cohort, data collected from patients suffering from anastomotic leakage will be evaluated and compared to patients that did not develop anastomotic leakage. No interventions, only data collection.
89556261|NCT02347735||No anastomotic leakage|Of the entire cohort, data collected from patients suffering from anastomotic leakage will be evaluated and compared to patients that did not develop anastomotic leakage. No interventions, only data collection.
89556262|NCT03091517|Other|GlycoLeap|Since this is a single arm study, all participants will receive the GlycoLeap intervention.
89556263|NCT03147157|Experimental|research group,low MR group|tacrolimus regimen guided by HLA matching rate
89556264|NCT03147157|No Intervention|observation group,low MR group|tacrolimus regimen is applied according to clinical experience
89556265|NCT03147157|Experimental|research group,middle MR group|tacrolimus regimen guided by HLA matching rate
89556266|NCT03147157|No Intervention|observation group,middle MR group|tacrolimus regimen is applied according to clinical experience
89556267|NCT03147157|Experimental|research group,high MR group|tacrolimus regimen guided by HLA matching rate
89556268|NCT03147157|No Intervention|observation group,high MR group|tacrolimus regimen is applied according to clinical experience
89556269|NCT05028023|Experimental|Pediatric patients with tracheal stenosis undergoing tracheal balloon dilatation|Pediatric patients with severe to median acquired tracheal stenosis undergoing tracheal balloon dilatation, and the effects of apneic oxygenation on regional cerebral oxygen saturation rSO2, pulse oximetry SpO2, and arterial oxygen partial pressure PaO2
89556270|NCT03146767|Experimental|Tetanic Group|A Tetanic stimulation (Tetanus stabilization of baseline) is administered to the monitorized arm before calibrating the neuromuscular block monitor. Then Train-of-four (TOF) stimuli are administered every 20 seconds for 20 minutes.
89556271|NCT03146767|No Intervention|Control Group|Conventional monitor baseline stabilization: Train-of-four stimuli are administered every 20 seconds for 20 minutes
89556272|NCT02347579||Patients with CRPS|Patients with Complex Regional Pain Syndrome, Type I
89556273|NCT02347579||Patients with CLBP|Patients with chronic low back pain
89556274|NCT02347579||Healthy controls|
89556275|NCT02347501|Experimental|A|"Sitagliptin 100mg once daily orally or 50mg once daily for participants with moderate kidney disease for 24 weeks and narrowband ultraviolet-B (NBUVB) phototherapy.~NBUVB light therapy is continued until the participants' psoriasis clears (<1% body surface area involved)."
89556276|NCT02347501|No Intervention|B|"No additional treatment other than narrowband ultraviolet-B (NBUVB) phototherapy.~NBUVB light therapy is continued until the participants' psoriasis clears (<1% body surface area involved)."
89556277|NCT05020301|Experimental|Control group|Participants who have never practiced mindfulness
89556278|NCT05020301|Experimental|Beginner Practitioner|Participants with less than two years of mindfulness practice
89556279|NCT05020301|Experimental|Advanced Practitioner|Participants with more than two years of mindfulness practice
89556280|NCT03155581|Other|User intervention|Bilingual key women from Somalia and Pakistan trained as peer educators for their respective communities will meet the women to increase awareness regarding the importance of cervical cancer prevention and to help peers overcome detected barriers and increase attendance to screening during meetings with the women organised according to their practical needs, using videos and interactive material
89556281|NCT03155581|Other|Health professional intervention|"General practitioners working in the intervention areas are contacted by letter and an appointment is made for a short meeting to increase awareness of the health professionals involved in screening working in the chosen areas. Material is given(posters and reminding objects) to remind practitioners of the intervention and invite women attending to the center to make an appointment with their GP. No change in screening as usual will be implemented for health professionals working in the control areas."
89556282|NCT04130165|Experimental|Matched donor human milk|Infants randomized to the matched donor human milk arm, will receive donor human milk which is matched to their mother's secretor status.
89556283|NCT04130165|No Intervention|Standard issue donor human milk|Infants randomized to the standard issue donor human milk arm, will receive donor human milk which is prepared without consideration of secretor status as per standard practice.
88963278|NCT02021747||Individuals with COPD|"All study subjects should meet the Lung Disease protocol criteria for having COPD may be of any stage (GOLD I - IV), be ambulatory and have no evidence of respiratory failure~Diagnosis of pulmonary tuberculosis without extra-pulmonary TB, confirmed by at least one of the following:~Symptoms consistent with TB~Chest X-rays and or chest CT consistent with TB~Positive PPD test~Positive sputum test"
89556284|NCT03148717|Active Comparator|Preoperative|"Group no.1 will receive preoperative rectal 400 microgram of misoprostol (Sigma) 2 tablets and postoperative rectal placebo2 tablets."
89556285|NCT03148717|Active Comparator|Postoperative|"Group no.2 will receive preoperative rectal placebo 2 tablets and postoperative rectal 400 microgram of misoprostol (Sigma)  2 tablets ."
89556286|NCT02349607|Experimental|PF-05089771 300 mg|
89556287|NCT02349607|Experimental|PF-05089771 300 mg + pregabalin 300 mg|
89556288|NCT02349607|Placebo Comparator|Placebo|
89556289|NCT02349607|Active Comparator|pregabalin 300 mg|
89556290|NCT02349607|Active Comparator|ibuprofen 600 mg|
89556291|NCT05019755|Experimental|A(First period) to B(Second period) order|"A: Oral Administration of IN-A002(IN-115314) in fasting status~B: Oral Administration of IN-A002(IN-115314), 30 minutes after high-fat diet~There will be a wash out period of 7days between period"
89556292|NCT05019755|Experimental|B(First period) to A(Second period) order|"B: Oral Administration of IN-A002(IN-115314), 30 minutes after high-fat diet~A: Oral Administration of IN-A002(IN-115314) in fasting status~There will be a wash out period of 7days between period"
89556293|NCT04478461|Experimental|MW11 injection|1, 3, 10 mg/kg and maybe an additional fixed dose (e.g., to evaluate 200 mg or other fixed dose as RP2D). The drug is scheduled to be administrated Q3W.
89556294|NCT02039089|Experimental|1|Part A: dose escalation of E2006 in Japanese subjects from 2.5 mg (1 x 2.5-mg tablet) up to 10 mg (1 x 10-mg tablet) then to 25 mg (2 x 10-mg tablet, 1 x 5-mg tablet).
89556295|NCT02039089|Experimental|2|Part B: E2006 10 mg for White subjects that will be group matched to the Japanese subjects in the 10 mg period in Part A.
89556296|NCT02039089|Placebo Comparator|3|E2006-matched placebo tablets
89556297|NCT02353507|Active Comparator|Opticell Ag+|Absorbent, antibacterial, barrier dressing
89556298|NCT02353507|Active Comparator|Aquacel Ag+|Absorbent, antibacterial, barrier dressing
89556299|NCT03148561|Other|Misoprostol group|The women received misoprostol 800 µg (Misotac 200 µg tablets, SIGMA pharmaceutical, Egypt) once dose placed in the posterior vaginal fornix
89556300|NCT03148561|No Intervention|Expectant group|Women did not receive any medication.
89556301|NCT05027555|Experimental|Multisensory training group|The intervention is a 50-minute session and 2-sessions/week, totaling 6 weeks
89556302|NCT05027555|Active Comparator|Conventional training group.|The intervention is a 50-minute session and 2-sessions/week, totaling 6 weeks
89556303|NCT05027321|No Intervention|Control|control
89556304|NCT05027321|Experimental|Preparation in Self-Hypnosis by anchoring|1-hour consultation with a hypnopractor just before the examination
89556305|NCT05027321|Experimental|Conversational Hypnosis|conversational hypnosis support during the examination by a radiology technician and a radiologist specifically trained
89556306|NCT05027321|Experimental|Preparation in Self-Hypnosis by anchoring + Conversational Hypnosis|1-hour consultation with a hypnopractor just before the examination and conversational hypnosis support during the examination by a radiology technician and a radiologist specifically trained
89556307|NCT02348983|Experimental|Interventional Arm|Health coaching arm to assess feasibility of intervention among truck driving population. Coaching will be weekly with emphasis on both diet and physical activity. No medication or treatment devices are administered.
89556308|NCT02353429|Experimental|Toremifene treatment|Patients will receive 60 mg daily of Toremifene and the dose will be escalated to 180 mg daily in case of progression
89556309|NCT05019989|Experimental|Intervention group: on diet and physical activity|"Individual advice on diet and on physical activity Kitchen courses to teach basic Mediterranean and macrobiotic recipes (two 1-day course plus ten 3-h courses associated with common dinner) (15-20 participants at a time) Fortnightly common lunch or dinner (50-60 participant at a time) Basic gymnastic course (twelve - monthly- 2-hour courses)~Study newsletter, with scientific information, kitchen recipes, study facilities~Periodic conferences on diet and health~Periodic reinforcement meetings with common meals, gymnastic sessions, and dancing, after the first year~Periodic body weight assessment (weekly self-measurement and monthly measurement at the study center)~Discounted rate for advanced kitchen courses~Psychological support groups"
89556310|NCT05019989|Experimental|Control group: only public recommendations on lifestyle|"Invitation leaflet, explaining the rationale of the study and including basic life-style recommendations, based on the 1997 World Cancer Research Fund recommendations (to be updated in 2007) and the Italian National Institute of Nutrition food pyramid.~Dissemination of the information on the study by media~Yearly follow-up questionnaire on breast events and dietary and physical activity chang"
89556311|NCT04478305|Other|Intervention group|Patient will be provided with study medication. To be taken once a day for 16 weeks (112 days). Active drug brand name - Duavive/Duavee. Dose consisting of 1 pill of 0.45mg conjugated estrogens and 20mg bazedoxifene as bazedoxifene acetate.
89556312|NCT05027243|Experimental|bilateral temporomandibular joint arthroscopy|
89556313|NCT03147079|Experimental|Intervention|Lifestyle intervention
89556314|NCT03147079|Experimental|Internal controls|
89556315|NCT03147079|Experimental|External controls|
89556316|NCT03148639|Experimental|Avatar therapy|Immediate Avatar therapy.
89556317|NCT03148639|Other|Treatment-as-usual|Treatment-as-usual then delayed Avatar therapy.
89556318|NCT05019599|No Intervention|normal controls|subjects with normal renal function
89556319|NCT05019599|Experimental|CKD_Low protein diet|CKD patient with low protein diet (<0.8g/kg/BW)
89556320|NCT05019599|Active Comparator|CKD_normal protein diet|CKD patient with normal protein diet
89556321|NCT03112135|Active Comparator|Systemic TXA|TXA 10-15 mg i.v over 30 min. followed by infusion in a dose of 1 mg / kg /hr
89556322|NCT03112135|Active Comparator|Topical TXA|Topical TXA 1 gm diluted in 200 ml saline
89556323|NCT03112135|Active Comparator|Topical adrenaline|Topical adrenaline 1 mg diluted in 200 ml saline
89556324|NCT03090893|Experimental|Infusion group|Subjects will receive ATryn continuous infusion for maintaining serum antithrombin III levels between 80 - 100
89556325|NCT03112759|Experimental|Cognitive Behavioral Therapy|Patients randomly selected for CBT will attend 8 weekly one-on-one therapy sessions. Patients will be prescribed conventional narcotic therapy as needed.
89556326|NCT03112759|No Intervention|No Cognitive Behavioral Therapy|Patients randomly selected for no CBT will be treated with conventional narcotic therapy alone.
89556327|NCT05019287|Experimental|Menstrual blood stem cell secretome group|Intravenous Allogeneic Menstrual Blood Stem Cells Secretome injection+Routine treatment
89556328|NCT05019287|Placebo Comparator|Control group|Intravenous saline injection (Placebo)+Routine treatment
89556329|NCT03094169|Experimental|Dose escalation|Minimum of 1 to 3 patients per dose cohort; approximately 4 dose cohorts to be evaluated to establish the Maximum tolerated dose.
89556330|NCT03094169|Experimental|Phase 2a Triple Negative Breast Cancer|Addition of up to 15 patients in each of 2 subpopulations of patients with triple negative breast cancer (30 total). One group of 15 patients will have 3+ EGFR over-expression. The second group will have 2+ EGFR over-expression.
89556331|NCT03094169|Experimental|Phase 2a Head and Neck Carcinoma|Addition of 15 patients with squamous head and neck carcinoma. Patients will have 3+ EGFR over-expression.
89556332|NCT03094169|Experimental|Phase 2a Non-Small Cell Lung Carcinoma|Addition of 15 patients with squamous histology non-small cell lung carcinoma. Patients will have 3+ EGFR over-expression
89556333|NCT04477993|Experimental|Experimental Group - ruxolitinib|Ruxolitinib 5 mg PO b.i.d. for 14 days
89556334|NCT04477993|Placebo Comparator|Placebo Group|
89556335|NCT03112447|Experimental|absorbable cartilage nail Group|10 males and 7 females, ages 7-15 years (average, 11.8), and 3 patients with elbow dislocation, the fractures were fixed by absorbable cartilage nail
89556336|NCT03112447|Active Comparator|traditional Kirschner wire Group|10 males and 5 females, ages 8-14 years (average, 12.6), and 4 patients with elbow dislocation, the fractures were fixed by traditional Kirschner wires
89556337|NCT05019443|Active Comparator|Conventional balloon predilation|the target lesion can be prepared according to standard clinical practice using SC balloons sized 0.8-1:1. Stenting using a drug-eluting stent (DES) is performed and the inflation pressure for delivery is noted, as well as the expected balloon diameter at that pressure. 2 enhanced stent imaging acquisitions (StentBoost or equivalent depending on the X-ray system used), are acquired in 2 orthogonal views. Post dilatation can be performed at operator discretion followed by a final acquisition of 2 similar orthogonal views with enhanced stent imaging. Intravascular imaging is left to the operator's discretion and is encouraged
89556338|NCT05019443|Experimental|Scoring balloon predilation|the target lesion must be prepared with a scoring balloon (SC) inflated 3 times at nominal pressure. To allow the scoring balloon to cross the lesion, it might be necessary to predilate with a small compliant balloon. The size of the scoring balloon to be used for is based on the size of the vessel. Stenting using a DES is performed and the inflation pressure for delivery is noted, as well as the expected balloon diameter at that pressure. 2 enhanced stent imaging acquisitions (StentBoost or equivalent depending on the X-ray system used), are acquired in 2 orthogonal views. Post dilatation can be performed at operator discretion followed by a final acquisition of 2 similar orthogonal views with enhanced stent imaging. Intravascular imaging is left to the operator's discretion and is encouraged
89556339|NCT03146533|Experimental|CD19 CART|patients will receive a pre-conditioning with cyclophosphamide and fludarabine before infusion of CD19 CART cells. The CD19 CART cells are to be administered on day0,day1,day2.
89556340|NCT03093935|Experimental|StimRouter Neuromodulation System|"All eligible patients who are enrolled in this study will be treated with StimRouter stimulation therapy as part of standard of care for the entire duration of the study (6 months) and observed for post-market population-specific data.~Standard recommended stimulation parameters for post-stroke shoulder pain include settings to elicit sensory response (paresthesia) as well as motor response (muscle contraction)."
89556341|NCT03148483|Experimental|Early PT plus Fortified Milk|early periodontal therapy (during pregnancy) plus fortified milk
89556342|NCT03148483|Experimental|Early PT plus Plain Milk|early periodontal therapy (during pregnancy) plus plain milk
89556343|NCT03148483|Experimental|Delayed PT plus Fortified Milk|delayed periodontal therapy (after delivery) plus fortified milk
89556344|NCT03148483|Placebo Comparator|Delayed PT plus Plain Milk|delayed periodontal therapy (after delivery) plus plain milk
89556345|NCT03091049||EMLA anesthetic ointment (AO)|In AO group a layer of 2.5 gr EMLA cream (standard adult dose) is applied to both wrists, 1 cm above the styloid process of the radius 30 minutes before the puncture, by an experienced cathlab nurse
89556346|NCT03091049||Local Skin Anesthetic Injection (LA)|In LA group the radial artery is infiltrated with 1-2 mL of 2% lidocaine, using a 26 G needle, 0.5-1 cm proximal to the styloid process one minute before the puncture
89556347|NCT02353117|Active Comparator|Intervention|Behavioral intervention. The intervention will be multifaceted, tailored by formative research, and include: 1) opinion leaders, reminders, monitoring, and feedback; 2) point-of-care rapid tests and immediate treatment if the rapid test is positive; and 3) locally packaged treatment kits (benzathine penicillin 2.4 MIU, syringe and needle, instructions, and information on side-effects).
89556348|NCT02353117|No Intervention|Control|Prenatal care providers at control clinics will be invited to participate in a training workshop. They will be given refresher concepts on the prenatal care package and maternal and congenital syphilis and will be trained in syphilis case detection and management, using their standard and available screening methods. They will also be trained on how to document the screening and treatment process, using the same system as the intervention clinics. No other activities are planned in the control group; providers will be encouraged to disseminate and implement any strategy they consider useful to improve screening and treatment. Study personnel will ensure the availability of screening tests already in-use, as well as ensure the availability of benzathine penicillin at all control prenatal clinics.
89556349|NCT03093779||Deaf|Individuals who are deaf and use sign language to communicate.
89556350|NCT03093779||Hearing|Individuals with no hearing loss and who communicate in spoken English.
89556351|NCT02353195|Experimental|Radio-frequency group|The equipment used, (INDIBA® activ 902, (448kHz)). The electricity was administered in the following manner: cream was applied to the site with the severe rest pain and its adjacent area, and the electrical output was increased by moving the movable electrode within the patient´s tolerance level, while monitoring the skin temperature tolerable to the patient. Therapy was conducted for 12 minutes, two times per week over four weeks (eight sessions in total)
89556352|NCT02353195|Placebo Comparator|Placebo group|All patients were treated with the same device in a nonfunctional application (no energy source) and the therapy was conducted for 12 minutes, two times per week over four weeks (eight sessions in total).
89556353|NCT03090971|Experimental|Cutaneous neurofibromas|Each subject will have two treatment neurofibromas and two control neurofibromas. Following microporation, the two treatment neurofibromas will be treated with topical diclofenac while the two control neurofibromas will be treated with topical saline.
89556354|NCT03154177|No Intervention|Standard ANC and PNC care only|Standard care offered following national guidelines of ANC and PNC.
89556355|NCT03154177|Other|Standard Care + Ultrasound+Pregnancy Testing|Standard care in combination with early pregnancy testing and ultrasound.
89556356|NCT03154177|Experimental|Group ANC and PNC only|Health facilities randomized to provide group ANC/PNC.
89556357|NCT03154177|Experimental|Group Care + Ultrasound+Pregnancy Testing|Group ANC and PNC care, in combination with early pregnancy testing and ultrasound.
89556358|NCT05019365||Participants with previous HER2 breast cancer|
89556359|NCT05019365||Healthy Volunteers|
89556360|NCT05018741||Liver transplant|
89556361|NCT03146689|Experimental|Topical NSAID and topical capsaicin|"Within each participant:~Topical NSAID (A) or capsaicin (B) are taken for a treatment period of four weeks. This is followed by another four week treatment period with the other treatment. These two treatment periods comprise one treatment cycle. The order of treatments within a treatment cycle is determined randomly (AB or BA).~This treatment cycle is repeated so that all participants undergo a maximum of three topical NSAID treatment periods and three topical capsaicin treatment periods (i.e., three treatment cycles). This is reduced to two cycles if they are found to meet the criteria for response at the interim analysis (after cycle two)."
89556362|NCT02347267|Experimental|Caloric and non-caloric SSBS reduction|Sweetened beverages (SSBS) caloric and non-caloric were not permitted and allowed only plain water
89556363|NCT02347267|Active Comparator|Caloric SSBS reduction|Only plain water and non-caloric sweetened beverages (SSBS) were allowed
89556364|NCT02347267|No Intervention|All beverages|Beverages were not restricted
89556365|NCT05025995|Experimental|Serious health game|Children played a serious health game with Garfield promoting health behavior, such as less intake of energy dense snacks, drink more water, and exercise more often.
89556366|NCT05025995|Experimental|control|Children in this condition did not play a serious health game and were in control condition.
89556367|NCT05255575||ertapenem treatment|
89556368|NCT05026229|Experimental|Dasatinib, Vincristine and Prednisone|After induction therapy, the patients in the 'Dasatinib, Vincristine and Prednisone' group will receive dasatinib and consolidation chemotherapy with vincristine and prednisone.
89556369|NCT05026229|Experimental|Dasatinib, Methotrexate and Cytarabine|After induction therapy, the patients in the 'Dasatinib, Methotrexate and Cytarabine' group will receive dasatinib and consolidation chemotherapy with high-dose methotrexate and cytarabine.
89556370|NCT02343679|Experimental|Ceritinib for ALK + patients|all ALK + hematologic malignancies patients will receive ceritinib
89556371|NCT03148249|Experimental|interview with an ophthalmologist|Patients get an interview with an ophthalmologist
89556372|NCT03148249|Experimental|interview/treatment by a psychiatrist|patients get an interview and a possible treatment by a psychiatrist
89556373|NCT05026073||Group 1 Endometrial Cancer:|Women with histological diagnosis of cancer of the endometrium (any type) undergoing hysterectomy
89556374|NCT05026073||Group 2 Endometrial Hyperplasia:|Women with histological diagnosis of endometrial hyperplasia (with or without atypia) undergoing hysterectomy
89556375|NCT05026073||Group 3 Controls:|Healthy women undergoing hysterectomy for a benign reason
89556376|NCT03148171|No Intervention|Routine PrEP Care|Routine PrEP Care at each clinical site.
89556377|NCT03148171|Active Comparator|WERK Supportive Contact|Support contact will provide emotional support and practical support in order to help their friend/family member to stay engaged in PrEP Care.
89556378|NCT04478149|Experimental|Active Cameras|active cameras in the room
89556379|NCT04478149|Sham Comparator|Inactive Cameras|camera in the room, not activated
89556380|NCT02347423|Experimental|1/3 IPV-Al SSI|3 vaccinations of 1/3 IPV-Al SSI given at 6, 10 and 14 weeks of age
89556381|NCT02347423|Experimental|1/5 IPV-Al SSI|3 vaccinations of 1/5 IPV-Al SSI given at 6, 10 and 14 weeks of age
89556382|NCT02347423|Experimental|1/10 IPV-Al SSI|3 vaccinations of 1/10 IPV-Al SSI given at 6, 10 and 14 weeks of age
89556383|NCT02347423|Active Comparator|IPV Vaccine SSI|3 vaccinations of IPV Vaccine SSI given at 6, 10 and 14 weeks of age, The comparator IPV Vaccine SSI contains: Type 1: 40DU, Type 2: 8 DU and Type 3: 32 DU.
89556384|NCT05018429||nerve sparing group|Patients will be preverved the neurovascular bundles during the resection of bladder and prostate of the operation.
89556385|NCT05018429||non nerve sparing group|Patients will receive standard radical cystectomy (not preserve the neurovascular bundles) during the operation.
89208249|NCT00284089|Experimental|Group A: Ranibizumab 0.5 mg|In the single dose phase, all patients randomized in Group A received a single intravitreal injection of 0.5 mg of ranibizumab into the study eye. Those patients who successfully completed this phase entered the multiple dose phase, where they received an intravitreal injection of 0.5 mg of ranibizumab once a month for an additional 11 months. Subsequently Group A patients enrolling in the extension phase received an intravitreal injection of 0.5 mg of ranibizumab according to an individualized flexible interval regimen guided by monthly best corrected visual acuity scores and other ophthalmic examinations. In the extension phase patients received the same dose level as they received in the multiple dose phase of the study, for an average of 1.93 years.
89556386|NCT03146611||COPD patients|A diagnosis of COPD was made by a clinical history, examination and spirometer (forced expiratory volume in 1st second/forced vital capacity (FEV1/FVC)ratio of <0.7). The severity of COPD was graded according to the Global Initiative for Chronic Obstructive Lung Disease guidelines. [9] (Stage I, mild COPD: FEV1≥80.0% predicted; Stage II, moderate COPD: FEV1 80-50.0%; Stage III, severe COPD: FEV1 50- 30.0%; Stage IV, very severe COPD: FEV1< 30.0%). The exacerbation of COPD was defined as the patient being diagnosed with COPD with two or more of the following three symptoms of exacerbations: new or worsening cough, worsened dyspnea, and worsened sputum volume and/or change in its color.
89556387|NCT03146611||control|healthy sex and age matched group
89556388|NCT03146299|Active Comparator|Group A: TLH|
89556389|NCT03146299|Active Comparator|Group B: LAVH|
89556390|NCT05009693|Experimental|white light intervention group|Between the second and the eighth days of the application phase, the patients in the intervention group were administered a standard white light at 10,000 Lux intensity by an independent nurse (RA1) in their home environment using a Litebook Elite light source (The Litebook Company Ltd., Medicine Hat, AB). The distance between the light source and the patient's face was set at 50 cm, and the intensity of the light for each patient was checked using a Lux Meter. The intervention was applied between 07:00 and 10:00 in the morning for 30 minutes without interruption, and it was continued for seven successive days. The light application procedure was followed based on the previous studies on oncology patients. The second and third evaluations of the fatigue status of patients were completed on the 9th and 21st days.
89556391|NCT05009693|No Intervention|Control group|
89556392|NCT02343601|No Intervention|Control group|Control group using a hemodynamic standard protocol
89556393|NCT02343601|Other|Photoplethysmography group|Hemodynamic optimization using Photoplethysmography device (ClearSight, Edwards Lifesciences, Irvine, CA)
89556394|NCT03090815||Patient receiving TKI|Patients are diagnosed with primary adenocarcinoma and have no concurrent cancers and are going to receive TKI
89556395|NCT03090815||Patient receiving ALK-TKI|Patients are diagnosed with primary adenocarcinoma and have no concurrent cancers and are going to receive ALK-TKI
89556396|NCT03090815||Patient receiving chemotherapy|Patients are diagnosed with primary adenocarcinoma and have no concurrent cancers and are going to receive chemotherapy
89556397|NCT02348905|Experimental|ACTHAR Gel 40 units twice weekly|ACTHAR Gel at a dose of 40 units twice weekly sub cutaneous injections between Baseline and week 12.
89556398|NCT02348905|Experimental|ACTHAR Gel 80 units twice weekly|ACTHAR gel at a dose of 80 units twice weekly sub cutaneous injections between Baseline and week 12.
89556399|NCT04954157|Placebo Comparator|Healthy Subjects|This arm will consist of health subjects, not infected with COVID-19
89556400|NCT04954157|Active Comparator|COVID 19 Subjects|This arm will consist of subjects who are currently diagnosed with COVID-19 and fit all other criteria to be enrolled in this study.
89556401|NCT02347033|Active Comparator|Sertraline|The pharmacological arm of the trial is the Selective Serotonin Reuptake Inhibitor (SSRI) Sertraline, prescribed at a daily dose of between 25 and 150mg by the patient's general practitioner (GP). If the medication is well tolerated and associated with reported clinical improvement we are asking the patients in this arm to continue taking it for 12 months.
89556402|NCT02347033|Active Comparator|Cognitive Behavioural Therapy (CBT)|The psychological therapy arm of the trial is Cognitive Behavioural Therapy (CBT) delivered by high intensity psychological therapists from local IAPT services. They will provide 14 to 16 sessions of a manualised treatment developed specifically for use in GAD and will be trained in its delivery.
89556403|NCT04949633|Experimental|Induction of labor|women randomized in the experimental group will be admitted to the labor ward to undergo induction of labor with intra-veinous oxytocin and early amniotomy. Oxytocin will be administered according to the French guidelines for induction of labor. Maximum oxytocin used should not exceed 10 UI.
89025895|NCT00463658|Experimental|1|Subjects in the interdisciplinary group received home care services from a team of professional service providers (CCAC Case Manager, Registered Nurse, Occupational Therapist, Physiotherapist, Registered Dietician) with experience and training in falls prevention. The team provided a comprehensive, coordinated and evidence based approach to falls prevention through regular home visits, weekly case conferencing, a single accessible fall prevention plan,and joint client visits.
89556404|NCT04949633|Active Comparator|Second cervical ripening|"women randomized in the control group will undergo a second cervical ripening lasting a maximum of 24 hours with either:~Vaginal slow releasing system of dinoprostone PROPESS® which is inserted in the vagina, against the cervix and left in place during 24 hours.~Oral misoprostol (ANGUSTA®) 25 µg every 2 hours, 8 times (maximum dosage should not exceed 200µg). Tablets will be given one at the time by midwives.~Vaginal gel of dinoprostone (2 mg PROSTINE®) every 6 hours, maximum dose of 6 mg.~The choice of the cervical ripening agent will depend of the local protocol of the participating maternity unit. The choice between ANGUSTA®, PROPESS® and PROSTINE® will be made by investigators of each participating unit at the beginning of the trial.~At the end of the second cervical ripening procedure women not in labor will be transferred to the labor ward for induction of labor with oxytocin."
89556405|NCT02343367|Active Comparator|Standard Care|Brief patient-centered behavioral counseling using the Healthy Lifestyle Prescription, health education materials and a community resource guide. Follow-up visits scheduled at 1, 6, and 12 months. Parent receives weekly general health education cell phone text messages for 12 months
89556406|NCT02343367|Experimental|Pediatric Obesity Management|All elements of standard care plus a family-based face to face counseling session with a health educator, telephone counseling, mailed newsletters and regularly scheduled cell phone text messages with tips and motivational messages for healthy eating and PA, as well as information on community events and resources.
89556407|NCT03146377|Experimental|Xeloxiri|
89556408|NCT05018195|Active Comparator|Benign|Women who receive surgery for benign lesions including leiomyoma, adenomyosis, or ovarian cysts. We will obtain one 5*5 cm omental fat and one 3*3 cm subcutaneous adipose tissue during surgery.
89556409|NCT05018195|Experimental|Endometrial cancer|Women who receive surgery(staging or cytoreductive surgery) for endometrial cancer. We will obtain one 5*5 cm omental fat and one 3*3 cm subcutaneous adipose tissue during surgery.
89556410|NCT02343055|Experimental|Case Management and Self-Management Education|A Certified Respiratory Educator (CRE) will obtain a detailed COPD history, provide general and self-management education, and confirm a management plan with the primary care physician. Specific elements of evidence-based management are targetted for intervention. Subjects will return for a follow-up visit in-person with the interdisciplinary care team including a CRE to review their health status including COPD symptoms, exacerbation diary, symptoms, MRC scale, etc as a minimum at 3 and 12 months. Telephone follow up will occur at a minimum at 6 and 9 months.
89556411|NCT02343055|Placebo Comparator|Usual Care|A Certified Respiratory Educator (CRE) will meet with subjects to obtain a detailed COPD history and do a breathing test. Subjects will receive COPD care as usually provided by their physician.
89556412|NCT05009615|Experimental|Green coffee extract|Nutraceutical containing a decaffeinated green coffee extract rich in phenolic compounds (hydroxycinnamates). Participants received powdered sachets containing 300 mg of GC extract twice daily for 8 weeks
89556413|NCT05009615|Experimental|Beta-glucan|Nutraceutical containing a oat beta-glucan. Participants received powdered sachets containing 2.5 g of BG twice daily for 8 weeks
89556414|NCT05009615|Experimental|Green coffee + Beta-glucan|Nutraceutical containing both green coffee extract and beta-glucan. Participants received powdered sachets containing 2.5 g of BG plus 300 mg of GC extract twice daily for 8 weeks
89556415|NCT02343133|Experimental|HemaMax|Single subcutaneous 12 microgram dose of HemaMax
89556416|NCT02343133|Placebo Comparator|Placebo|Single subcutaneous dose
89556417|NCT02349139|Experimental|ASN001: Escalating dose Part A|The dose of ASN001 will be based on the assigned study group. The initial dose level of ASN001 will be 50 mg daily. After a safety review, the dose may be escalated for the next group of subjects. Additional dose levels are 100 mg, 200 mg, 300 mg, and 400 mg.
89025896|NCT00463658|No Intervention|2|Participants allocated to the control group received standard home care services arranged by the CCAC. These include routine follow-up by the CCAC case manager whose focus is on assessing client's eligibility for in-home health services, arrangement and coordination of professional (i.e. nursing, occupational therapy, physiotherapy, social work, speech-language pathology, nutrition) and non-professional HSS, information and referral to community agencies, and ongoing monitoring and evaluating the plan of care through in-home assessments with clients.
89025897|NCT00497328|Other|N-acetylcysteine Group (NAC)|"N-acetylcysteine Group (NAC)~Intravenous infusion 154mEq/L of sodium chloride (0.9% normal saline) at a rate of 1mL/kg/hour from 12 hours before till 6 hours after cardiac catheterization Oral NAC 1200mg dissolve in 250ml of water twice a day the day before to the day after the procedure (total 6 doses)"
89556418|NCT02348827|Experimental|Family psychoeducation|The intervention consists of group-based family psychoeducation-program aimed at the patients' relatives. Each group will consist of 5 participants and the patients will not be present at group sessions. The program consists of four weekly sessions each consisting of both short lectures on relevant topics as well as interactive séances designed to give participants problem-solving skills.
89556419|NCT02348827|Active Comparator|Social support group|Relatives in the social support group will attend the same number of sessions of the same duration, as the relatives in the intervention group (family psychoeducation). The psychiatric nurse who will be in charge of the social support group will not give any psychoeducational intervention.
89025898|NCT00497328|Other|Sodium Bicarbonate Group (SOB)|"Sodium Bicarbonate Group (SOB)~Intravenous infusion154meq/L sodium bicarbonate in 5% dextrose in water at a rate of 3 mL/kg/hour for 1 hour immediately before radiocontrast injection. For patients weighing more than 110 kg, the initial fluid bolus and drip will be limited to those doses administered to a patient weighing 110 kg.~Intravenous infusion154meq/L sodium bicarbonate in 5% dextrose in water at a rate of 1 mL/kg/hour during the contrast exposure and for 6 hours after the procedure"
89556420|NCT03090581|Active Comparator|Biopsies CP 1|Obtain transbronchial lung biopsies with cryoprobe (CP) 1
89025899|NCT00497328|Other|Combination Group (COM: NAC and SOB)|"Combination Group (COM: NAC and SOB)~Intravenous infusion of 154 meq/l sodium bicarbonate at a rate of 3ml/kg/hour for 1 hour before cardiac catheterization and 1 ml/kg/hour till 6 hours after procedure Oral NAC 1200mg dissolve in 250ml of water twice a day the day before to the day after the procedure (total 6 doses). All patients will be monitored regularly for pulmonary congestion and hemodynamics compromise hourly after PCI for 6 hours and every 4 hour thereafter for 24 hours."
89025900|NCT01245075|Active Comparator|Deep Brain Stimulation|Stimulator setting is ON
89025901|NCT01245075|Sham Comparator|Placebo|Stimulator setting is OFF
89556421|NCT03090581|Active Comparator|Biopsies CP 2|Obtain transbronchial lung biopsies with cryoprobe (CP) 2
89556422|NCT03090581|Active Comparator|Biopsies FC|Obtain transbronchial lung biopsies with forceps (FC).
89556423|NCT03079583|Placebo Comparator|Control-group|Control Rice used for meal, normal zinc level
89025902|NCT00463697|Experimental|GW642444M 25mcg|Subject will inhale single dose of GW642444M 25 mcg via a DISKUS device in morning.
89025903|NCT00463697|Experimental|GW642444M 100mcg|Subject will inhale single dose of GW642444M 100 mcg via a DISKUS device in morning.
89556424|NCT03079583|Active Comparator|Intervention-group|Biofortified Rice used for meal, around 30% higher zinc level
89556425|NCT02346955|Experimental|Cohort A Monotherapy Dose Escalation|Participants will be enrolled in a staggered manner starting at a dose of 0.01 mg/kg of CM-24 (MK-6018) and continuing to 0.03, 0.1, 0.3, 1.0, 3.0, and 10 mg/kg to determine the recommended Phase 2 dose (RP2D). The dose will be escalated after a 6- to 8-week DLT window. Participants will be treated for 12 weeks during Cycle 1. Afterwards participants with clinical benefit and no dose-limiting toxicites (DLTs) are treated for up to 6 cycles.
89556426|NCT02346955|Experimental|Cohort B Combination Dose Escalation|Participants will be enrolled at the recommended phase 2 dose (RP2D) of CM-24 (MK-6018), determined by escalation studies, minus 1 dose level of MK-6018 in combination with a fixed dose of 200 mg pembrolizumab. Participants will be escalated to the RP2D of MK-6018 + 200 mg pembrolizumab. If the RP2D of MK-6018 + 200 mg pembrolizumab is not tolerated, the dose of MK-6018 will be de-escalated but will not fall below 1 mg/kg. Participants will be treated for 6 weeks during Cycle 1 and 2. Afterwards participants with clinical benefit and no DLTs are treated for up to 35 cycles.
89556427|NCT02346955|Experimental|Cohort C Monotherapy Expansion|Participants with advanced or recurrent cutaneous melanoma will be enrolled and treated at the recommended phase 2 dose of CM-24 (MK-6018) for up to 17 cycles.
89025904|NCT00463697|Experimental|GW642444M 400mcg|Subject will inhale single dose of GW642444M 400 mcg via a DISKUS device in morning.
89556428|NCT02346955|Experimental|Cohort D Monotherapy Expansion|Participants with advanced or recurrent colorectal cancer will be enrolled and treated at the recommended phase 2 dose of CM-24 (MK-6018) for up to 17 cycles.
89556429|NCT02346955|Experimental|Cohort E Monotherapy Expansion|Participants with advanced or recurrent gastric cancer will be enrolled and treated at the recommended phase 2 dose of CM-24 (MK-6018) for up to 17 cycles.
89556430|NCT02346955|Experimental|Cohort C1 Combination Expansion|Participants with advanced or recurrent cutaneous melanoma will be enrolled and treated at the recommended phase 2 dose of CM-24+ 200 mg of Pembrolizumab for up to 17 cycles and may continue to receive 200 mg of Pembrolizumab as monotherapy for up to an additional 18 cycles (up to 35 total cycles).
89556431|NCT02346955|Experimental|Cohort D1 Combination Expansion|Participants with advanced or recurrent colorectal cancer will be enrolled and treated at the recommended phase 2 dose of CM-24+ 200 mg of Pembrolizumab for up to 17 cycles and may continue to receive 200 mg of Pembrolizumab as monotherapy for up to an additional 18 cycles (up to 35 total cycles).
89556432|NCT02346955|Experimental|Cohort E1 Combination Expansion|Participants with advanced or recurrent gastric cancer will be enrolled and treated at the recommended phase 2 dose of CM-24+ 200 mg of Pembrolizumab for up to 17 cycles and may continue to receive 200 mg of Pembrolizumab as monotherapy for up to an additional 18 cycles (up to 35 total cycles).
89025905|NCT00463697|Experimental|GW642444H 100mcg|Subject will inhale single dose of GW642444H 100 mcg via a DISKUS device in morning.
89025906|NCT00463697|Placebo Comparator|placebo|Subject will inhale single dose of Placebo via a DISKUS device in morning.
89025907|NCT00490230|Experimental|WR 279,396|CL lesions treated with WR 279396
89025908|NCT00490230|No Intervention|Natural Healing|CL lesions healed naturally
89025909|NCT00490230|Placebo Comparator|vehicle control|CL lesions were treated with the vehicle alone
89025910|NCT00463736|Active Comparator|Magnesium sulfate|x 48 hours IV
89556433|NCT02346955|Experimental|Cohort F Combination Expansion|Participants with advanced or recurrent non-small cell lung adenocarcinoma will be enrolled and treated at the recommended phase 2 dose of CM-24+ 200 mg of Pembrolizumab for up to 17 cycles and may continue to receive 200 mg of Pembrolizumab as monotherapy for up to an additional 18 cycles (up to 35 total cycles).
89556434|NCT03079505|Active Comparator|Dasatinib|Dasatinib 100mg, once daily (QD), will be given to 25 patients, orally
89025911|NCT00463736|Placebo Comparator|Normal saline|x 48 hours IV
89556435|NCT03079505|Experimental|Nilotinib|Nilotinib 300mg, twice daily (BID), will be given to 25 patients, orally
89556436|NCT02343211|Experimental|immunoglobulin|
89556437|NCT03090503|Active Comparator|Aripiprazole|Oral, dose range 10-30 mg/day, once or twice a day during study duration.
89556438|NCT03090503|Active Comparator|Risperidone|Oral, dose range 1-6 mg/day, once or twice a day during study duration.
89556439|NCT02343289|Experimental|Esketamine Regimen|All participants will first receive 28 milligram (mg) of esketamine as a single, 40-minute, intravenous infusion on Day 1 of Period 1, followed by 84 mg of esketamine solution as a single, oral dose on Day 1 of Period 2, followed by 84 mg of intranasal esketamine on Day 1 of Period 3 and then 500 mg of clarithromycin twice daily on Days -3, -2, -1, 1, and 2 of Period 4 and 84 mg of intranasal esketamine on Day 1 of Period 4. Each period will be separated by a washout period of up to 21 days in between.
89556440|NCT03090113|Experimental|Shuxuetong Injection|Shuxuetong Injection,12ml,ivgtt,day1; Shuxuetong Injection,6ml,ivgtt,day2 to day10;
89025912|NCT00497367|Experimental|TAXUS® Petal™ Paclitaxel-Eluting Coronary Stent|This arm received the TAXUS® Petal™ Paclitaxel-Eluting Coronary Stent.
89025913|NCT00497445|Experimental|Angioplasty / surgery and exercise therapy|Angioplasty / surgery followed by supervised exercise therapy
89025914|NCT00497445|No Intervention|Angioplasty / surgery|Angioplasty / surgery alone
89025915|NCT00497523|Experimental|Beclomethasone dipropionate|
89556441|NCT03090113|Placebo Comparator|Placebo Injection|Placebo Injection,12ml,ivgtt,day1; Placebo Injection,6ml,ivgtt,day2 to day10;
89556442|NCT02346799|Experimental|Control|Participants in the control group will not receive any additional treatment, apart from receiving daily emails 15 minutes before the start of their self-reported workout window. This is to control for reminder effects that may be present in the other treatment conditions. Participants in this condition will also receive a lump payment upon completion of an exit survey at the end of the intervention to equalize overall compensation.
89556443|NCT02346799|Experimental|Flexible Incentive|Participants in the flexible incentive condition will be paid $3 or $7 for each workout they complete during the treatment period (with a limit of one incentivized workout per day, and twelve incentivized workouts during the four-week treatment period). These participants will receive daily emails 15 minutes before the start of their self-reported workout window, but they can work out anytime of the day and still receive their incentive payment.
89556444|NCT02346799|Experimental|Routine Incentive|Participants assigned to the routine incentive condition will receive the same treatment as those in the flexible incentive condition except that, in order to receive their incentive payment, they must begin their workout within their two-hour workout window. For instance, if an employee chooses a 2pm to 4pm workout window, she will receive a reminder to exercise at 1:45 pm and must swipe into the gym between 2pm and 4pm in order to receive the $3 or $7 incentive payment.
89556445|NCT02346799|Experimental|Social Routine Incentive|Participants assigned to this condition will have an identical experience to those in the routine incentive except that both partners who sign up for the study will be required to coordinate and select a common workout window. Thus, both partners will receive their daily reminders at the same time (and will be incentivized for working out at the same time). The incentive payment, however, will not be linked to whether or not a participant's partner completes a workout - only to the participant's own exercise decision.
89556446|NCT02346799|No Intervention|Holdout Control|If experimental enrollment exceeds target, exercise data will be collected for these additional participants, but they will receive no intervention of any kind.
89556447|NCT03146221|Other|Person to be surgically treated for arteritis|
89556448|NCT03090269|Experimental|Methylphenidate pill|"18 mg tablets with a 3-week titration phase to a maximum dose of 108 mg per day, orally~Associated with phone interviews every month, urine drug toxicologies and blood sampling (PK/PD)"
89556449|NCT02342899|Active Comparator|Control Goup|Inpatient initiation of noninvasive ventilation.
89556450|NCT02342899|Active Comparator|Intervention Group|Initiated on NIV during an elective outpatient clinic review during which an arterial blood gas measurement will be obtained to confirm the presence of chronic respiratory failure.
89556451|NCT05008679|No Intervention|Control|patients with heart failure to receive standard HF therapy
89556452|NCT05008679|Experimental|Oseltamivir|patients with heart failure to receive oseltamivir (at a dose of 75 mg twice daily) for 1 month in addition to standard HF therapy
89556453|NCT03090035|Experimental|chronic hepatitis C genotype 2 or 3|In all patients Pegylated Interferon α2 (pegIFN) plus Ribavirin were given in standard doses. Peg-INF was given in a dose of 180 μg/week and ribavirin 1200 mg/day to every patient for the period of 24 weeks for HCV genotype 2 & 3
89556454|NCT03147781|No Intervention|Standard care|Participants in this group only receive standard post-cesarean care of the study hospital. It includes mobility restraint, foley retention, IV fluid infusion, oral intake instructions, oral pain medications routine, and breastfeeding practice.
89556455|NCT03147781|Sham Comparator|Sham AT with Medulla Junci|Participants in this group receive auricular tape with Medulla Junci in addition to standard post-cesarean care during the early 96 postpartum hours.
89025916|NCT00497523|Experimental|Beclomethasone dipropionate/Salbutamol combination|
89025917|NCT00497523|Active Comparator|Salbutamol|
89025918|NCT00463853|Experimental|Arm 1|direct intramyocardial injection of cells as adjunct to CABG
89025919|NCT00490620|Placebo Comparator|1|blinded placebo control
89025920|NCT00490620|Active Comparator|2|Antiretroviral therapy
89025921|NCT00466232|Experimental|1|Weekly Topetecan in combination with Sorafenib
89025922|NCT00490737|Experimental|Hemodialysis (HD) Participants|Participants will receive daptomycin 6 mg/kg by intravenous infusion (i.v.) at 48-hours intervals (with dialysis) for a total of 3 doses.
89556456|NCT03147781|Experimental|True AT with magnetic pellets|Participants in this group receive auricular tape with magnetic pellets in addition to standard post-cesarean care during the early 96 postpartum hours.
88963279|NCT02021760|Active Comparator|Remote Ischemic per-postconditioning|Remote conditioning is induced by inflation of a blood pressure cuff around the left thigh to 200 mmHg or 20 mmHg above systolic blood pressure (if >180 mmHg) for 5 min followed by deflation for 5 min. At least one of these conditioning cycles is performed before PCI is initiated. If time allows, cycles of remote conditioning (5 min leg ischemia and 5 min reperfusion) are repeated until PCI is performed. Following reperfusion, defined as first balloon inflation, four additional cycles of remote conditioning will be performed.
89556457|NCT03147703|Experimental|Early Eating (EE)|The intervention is Food Timing, Early Eating is defined at 13:00 hours for lunch
89556458|NCT03147703|Experimental|Late Eating (LE)|The intervention is Food Timing, Late Eating is defined for 17:30 hours for lunch
89556459|NCT03079349|Active Comparator|Traditional Classroom|Medical Education
89556460|NCT03079349|Experimental|Online Synchronous Classroom|Medical Education
89556461|NCT03147625|Experimental|SHAPE Intervention|Participants in this group will receive a 12-week SHAPE intervention, comprising of 2 home visits, 10 weekly group-based activity sessions and a SHAPE health-promotion booklet.
89556462|NCT03147625|No Intervention|Control group|Participants in the control group will continue to participate in activities offered in the senior activity centre, community centres and voluntary welfare organisations.
89556463|NCT05008367|Active Comparator|Treatment A|24 mg dexamethasone i.v. perioperatively and 24 mg dexamethasone i.v. on the first postoperative day
89556464|NCT05008367|Active Comparator|Treatment B|24 mg dexamethasone i.v. perioperatively and placebo (isotonic saline) i.v. on the first postoperative day
89556465|NCT05008367|Placebo Comparator|Placebo|Placebo (isotonic saline) i.v. perioperatively and placebo (isotonic saline) i.v. on the first postoperative day
89556466|NCT02346175|Experimental|Cohort1|5-mg/day SHR3824 or placebo once daily on Day 1 and on Days 4 through 10.
89556467|NCT02346175|Experimental|Cohort2|10-mg/day SHR3824 or placebo once daily on Day 1 and on Days 4 through 10.
89556468|NCT02346175|Experimental|Cohort3|20-mg/day SHR3824 or placebo once daily on Day 1 and on Days 4 through 10.
89556469|NCT02342587|Experimental|single arm|Patients will be treated with oral lapatinib 1250mg once daily for 21 days.
89556470|NCT02346331|Experimental|WHO intervention|This arm will be treated with the 2011 WHO sepsis recommendations for the first 6 hours of their hospitalization. The WHO recommendations involve fluid boluses guided by vital signs and physical exam, frequent patient monitoring, rapid and early administration of empiric antibiotics, oxygen delivery, correction of hypoglycemia, and correction of severe anemia.
89556471|NCT02346331|No Intervention|Standard care|This arm will be managed per standard care by the hospital clinicians.
89556472|NCT05017259|Experimental|low carbohydrate trial|The energy distribution was carbohydrate 10%, protein 40-50%, fat 40-50% in the LC trial.
89556473|NCT05017259|Active Comparator|high carbohydrate trial|The energy distribution was carbohydrate 60-65%, protein 30-40%, fat 5-10% in the HC trial.
89556474|NCT02342509|Experimental|Desflurane|Desflurane 5.0-6.0 Vol% (1.0 MAC) in Oxygen (FiO2 0.8-0.95)
89556475|NCT02342509|Experimental|Sevoflurane|Sevoflurane 1.4-2.1 Vol% (1.0 MAC) in Oxygen (FiO2 0.8-0.95)
89556476|NCT02342509|Active Comparator|Isoflurane|Isoflurane 0.9-1.2 Vol% (1.0 MAC) in Oxygen (FiO2 0.8-0.95)
89556477|NCT03079193||videoscopic laryngeal examination|50 patients post thyroidectomy will do mandatory post thyroidectomy videoscopic examination of the larynx
89556478|NCT03079193||No vedioscopic larygeoscopic examination|50 patients post thyroidectomy will be followed up and will not do vedeoscopic videoscopic laryngeal examination routinely they will do it if indicated
89556479|NCT02342431|Active Comparator|Forced air compressible warming|Warming with a compressible forced air mattress
89556480|NCT02342431|Experimental|Forced air non-compressible|Warming with a non-compressible forced air mattress
89556481|NCT03079271|Other|open label|
89556482|NCT02342353|Experimental|Phase I (pacritinib and erlotinib)|"Pacritinib will be administered orally twice a day; dosing will depend on the dose level the patient is enrolled.~Erlotinib will be taken by mouth on an outpatient basis daily at a dose of 150 mg.~A 28-day interval is defined as a cycle"
89556483|NCT02342353|Experimental|Phase II (pacritinib and erlotinib)|"Pacritinib will be administered orally twice a day; the dose used will be the dose determined to be the MTD in phase I.~Erlotinib will be taken by mouth on an outpatient basis daily at a dose of 150 mg.~A 28-day interval is defined as a cycle"
89556484|NCT02337127|Active Comparator|Arm A|250 treatment-naïve CHB patients who received at least 3-year of oral antiviral agents will receive Lamivudine extending therapy for 5 years.
89556485|NCT02337127|No Intervention|Arm B|250 treatment-naïve CHB patients who received at least 3-year of oral antiviral agents will receive follow-up.
88963280|NCT02021760|Sham Comparator|Sham|"The sham procedures include application of the cuff around the thigh but it is not inflated.~Otheriwize normal primary PCI."
88963281|NCT02021786|Experimental|Mobile phone based intervention|The intervention in the present study is a web- and mobile phone based intervention aiming to develop healthy lifestyle behaviors regarding physical activity and dietary habits in 4-year-olds. The intervention will be delivered to the parents and it is available to the parents during six months.
88963282|NCT02021786|No Intervention|Control|The control group receive a pamphlet on healthy eating and physical activity in pre-school children based on the existing guidelines. The information is similar to what parents receive from the Swedish child healthcare system
88963283|NCT02021799|No Intervention|Undernourished Pregnant Women|Pregnant women who are classified as undernourished
88963284|NCT02021799|No Intervention|Nourished Pregnant Women|Pregnant women who are classified as healthy
88963285|NCT02021799|No Intervention|Overweight/obese Pregnant women|Pregnant women who are classified as obese or overweight
88963286|NCT02021799|Experimental|Undernourished + Yogurt Pregnant Women|Pregnant women who are undernourished and selected to receive Moringa and Lactobacillus rhamnosus GR-1 probiotic yogurt. Yogurt contained 4.3 grams of Moringa and 10^8 CFU/mL of Lactobacillus rhamnosus GR-1 as well as Streptococcus thermophilus and Lactobacillus bulgaricus starter cultures.
88963287|NCT02021799|Experimental|Nourished + Yogurt Pregnant Women|Pregnant women who are healthy and selected to receive Moringa and Lactobacillus rhamnosus GR-1 probiotic yogurt. Yogurt contained 4.3 grams of Moringa and 10^8 CFU/mL of Lactobacillus rhamnosus GR-1 as well as Streptococcus thermophilus and Lactobacillus bulgaricus starter cultures.
88963288|NCT02021825|Other|MITO, annual relapse rate, safety|For refractory NMO patients aged 18-55, the initial dose 12 mg/m2 mitoxantrone was administered over a five day course every 3 months for 2 years (a total of eight courses). The initial dose was reduced to 9 mg/m2 if the preinfusion white-blood-cell count was 3.0-3.99 ×109/L,and to 6 mg/m2 if the white-blood-cell count was 2.0-2.99 ×109/L. No infusion if the white-blood-cell count was less than 2.0×109/L. The initial dose was reduced to 10 mg/m2 for nonhaematological toxic effects of WHO grade 2-3. Subsequent dose after 3 month was reduced to 10 mg/m2 for infections that occurred within 3 weeks of a previous infusion accompanied by a white-blood-cell count below 2×109/L, or to 8 mg/m2 for infections accompanied by white-blood-cell count of less than 1×109/L.
89556486|NCT02336971|Experimental|CBCT for PTSD|"CBCT for PTSD is a time-limited, problem-focused treatment that aims to improve PTSD and relationship functioning. The study investigators have developed a 15-session treatment plan each session lasting 75-minutes.~The treatment is sequenced such that the rationale and psychoeducation provide the basis for the behavioral skills training designed to improve communication and relationship functioning, and to overcome behavioral and experiential avoidance. These skills are used in the final phase of the treatment that is focused on cognitive mechanisms contributing to PTSD and relationship dysfunction."
89556487|NCT02336971|Experimental|Prolonged Exposure|"PE for combat-related stress disorders [13-14] serves as the comparison treatment.~The therapy is usually conducted in 10-12 sessions, each lasting 90-minutes, with the majority of the sessions devoted to imaginal exposure to traumatic memories and homework assignments that include in vivo exposure assignments. In the present study, participants will complete 12 sessions of PE to equate the number of sessions with those of CBCT. Partners of individuals with PTSD are not typically incorporated into the treatment program and so for this study a revised version of PE [1-3] will be administered in which the partner is seen during the second session to discuss PTSD, other reactions to trauma and the treatment procedures."
89556488|NCT05016635||Sub-arachnoid Hemorrhage Patients|
89556489|NCT02337205|Experimental|KX2-391 Ointment|
89556490|NCT05007587|Experimental|Lenvatinib，Then HAIC of mFOLFOX regimen|Cohort1：Participants were treated with 8mg lenvatinib (weight<60kg) or 12mg lenvatinib (weight>60kg) orally once daily on days 1 through 21, and HAIC regimen was performed every 3 weeks. The mFOLFOX regimen was administered via hepatic artery: oxaliplatin , 85mg/m2 , from hour 0 to 2 on day1 ; leucovorin , 400mg/m2 , from hour 2 to 3 on day 1 ; fluorouracil , 400mg/m2 , bolus at hour 3 ; and 2400mg/m2 over 46 hours on days 1 and 2.
89556491|NCT05007587|Experimental|Lenvatinib，Then HAIC of ROX regimen|Cohort2：Participants were treated with 8mg lenvatinib (weight<60kg) or 12mg lenvatinib (weight>60kg) orally once daily on days 1 through 21, and HAIC regimen was performed every 3 weeks. The ROX regimen was administered via hepatic artery: oxaliplatin , 100mg/m2 , from hour 0 to 4 on day1 ;raltitrexed , 3mg/m2 , from hour 4 to 5 on day 1.
89556492|NCT05015933|Experimental|Refill at home|Patients will have one pump refill at home instead of at the hospital.
88963289|NCT02021838||California|Lethality Assessment Program
88963290|NCT02021838||North Carolina|Lethality Assessment Program
88963291|NCT02021838||Ohio|Domestic Violence High Risk Team
88963292|NCT02021838||Illinois|Lethality Assessment Program
89556493|NCT03146143|Experimental|ultrafiltration group|ultrafiltration after cardiopulmonary bypass in congenital cardiac surgery
89556494|NCT03146143|No Intervention|non ultrafiltration control group|no ultrafiltration will be applied in this group
89556495|NCT05015465||70 patients with juvenile SLE.|Anterior segment OCT for juvenile SLE patients.
89556496|NCT05015465||70 normal subjects as control group of similar age and gender|Anterior segment OCT for normal subjects
89556497|NCT05015777|Experimental|Intervention Group|Participated in the exercise programme
89556498|NCT05015777|No Intervention|Control Group|Were advised not to change anything about their current lifestyle, and in particular not to undertake any new structured physical activity.
89556499|NCT02039323|Experimental|All Participants|Maraviroc 600 mg + Tenofovir 600 mg
89556500|NCT05015699|Experimental|HT Supreme|Device: HT Supreme ( R&D by Sinomed, Tianjin, China) Drug: 11-month ticagrelor monotherapy following one-month dual antiplatelet therapy (DAPT) after HT Supreme drug-eluting stent system interventions
89556501|NCT04958161|Experimental|Exercise Therapy|Exercise therapy will be performed three times per week for 12 weeks.
89556502|NCT04958161|No Intervention|Wait List Control|Wait-list-control participants will be asked to continue their normal activities over the 12 week period.
89556503|NCT02342119|Experimental|KTFT+TALK|Patients who are being evaluated for a kidney transplantation via Kidney Transplant Fast Track and who are receiving the Talking About Living Kidney Donation intervention
89556504|NCT02342119|Active Comparator|KTFT+No TALK|Patients who are being evaluated for a kidney transplantation via Kidney Transplant Fast Track and who are not receiving the Talking About Living Kidney Donation intervention
88963293|NCT02021838||Michigan|Lethality Assessment Program
88963294|NCT02021838||Tennessee|Lethality Assessment Program
88963295|NCT02021851|Active Comparator|Group DA: Dexamethasone and aprepitant|Group DA: Dexamethasone: 8 mg (intravenous), Aprepitant: 40 mg (oral)
88963296|NCT02021851|Placebo Comparator|Group DO: Dexamethasone and ondansetron|Group DO: Dexamethasone: 8 mg (intravenous), Ondansetron: 4 mg (intravenous)
88963297|NCT02021864|Experimental|vitamin D3, prenatal multivitamin|vitamin D3 50,000 unit/week for 8 weeks, daily prenatal multivitamin containing elemental calcium 250 mg/day and vitamin D3 400 unit
88963298|NCT02021864|Active Comparator|prenatal multivitamin|daily prenatal multivitamin containing elemental calcium 250 mg/day and vitamin D3 400 unit
88963299|NCT02021877||TBI subjects|Unselected adult patients with acute TBI from the Emergency Departments of the recruiting hospitals
89556505|NCT03079115|Active Comparator|High-dose Atorvastatin Arm|High dose Atorvastatin (80 mg QD from 3 days before to 3 days after carotid artery stenting, thereafter conventional dose of Atorvastatin with 20mg QD until 30 days after CAS)
89556506|NCT03079115|Other|Conventional-dose Atorvastatin Arm|Conventional dose Atorvastatin (20mg QD from 3 days before to 30 days after CAS)
89025923|NCT00490737|Experimental|Continuous Ambulatory Peritoneal Dialysis (CAPD) Participants|Participants will receive daptomycin 6 mg/kg, i.v., at 48-hours intervals for a total of 3 doses.
89025924|NCT00497601|Experimental|A|Amphotericin B in fat emulsion (Amphomul) 7.5 mg/kg on day 1 and 3
89556507|NCT02342041|Placebo Comparator|Single ascending dose|Single dose of SUVN-G3031or placebo in healthy male subjects
89556508|NCT02342041|Placebo Comparator|Multiple ascending dose|Multiple doses of SUVN-G3031 or placebo in healthy male subjects
89556509|NCT05014997||Patient|30 male patients with Klinefelter syndrome who were not previously given testosterone replacement.
89556510|NCT05014997||Control|30 healthy control subject without diagnosis of any chronic disease
89556511|NCT05255185|Experimental|All the patients|domino therapy treat the infection around the prosthesis after the limb salvage surgery of bone tumor
89556512|NCT05015075|Experimental|CR group|participants who have exercise-based cardiac rehabilitation program after PM.
88963300|NCT02021877||Control subjects|Acute orthopaedic non-trivial trauma that needs either surgery or conservative measures and clinical follow-up (including mere superficial soft tissue injuries)
88963301|NCT02021890|Experimental|ballroom and Latin dance program|two-hour dancing session twice a week
88963302|NCT02021890|Active Comparator|Self-selected physical activity|self-selected program of physical activity
88963303|NCT02021903|Experimental|HGPO + Placebo|V1: HGPO 75 mg + meal and V2: Placebo 75 mg + meal
88963304|NCT02021903|Placebo Comparator|Placebo + HGPO|V1: Placebo 75 mg + meal and V2: HGPO 75 mg + meal
88963305|NCT02021968|Experimental|TetraVax-DV-TV003 vaccine|Participants in this arm will receive a single injection of the TetraVax-DV-TV003 vaccine on Day 0 (study entry). On Day 180, participants will receive a single injection of the attenuated rDEN2∆30-7169 virus.
88963306|NCT02021968|Placebo Comparator|Placebo|Participants in this arm will receive a single injection of placebo on Day 0 (study entry). On Day 180, participants will receive a single injection of the attenuated rDEN2∆30-7169 virus.
89556513|NCT05015075|Placebo Comparator|non-CR group|participants who have only routine regular follow-up after PM instead of CR program
89556514|NCT04919863|Experimental|NTP42:KVA4|
89556515|NCT04919863|Placebo Comparator|Placebo|
89556516|NCT04909177|Experimental|Smartphone application (app) in combination with headset|The intervention oVRcome is self-help VRET for specific phobia, that is delivered through a smartphone application (app) in combination with headset that holds the smartphone and uses 360º video. oVRcome includes 6 modules of psychoeducation, relaxation, mindfulness, cognitive techniques, exposure through VR, and a relapse prevention module which are aimed to be completed weekly.
89556517|NCT04909177|No Intervention|Waitlist|Participants in the waitlist condition will be offered the intervention directly after post-test.
89556518|NCT05917431|Experimental|SBRT plus Tislelizumab and Regorafenib|Participants will receive SBRT (8 Gy × 3-5 fractions) to all visible lesions. Systemic treatment (tislelizumab and regorafenib) will start concurrently and last for 2 years, or until disease progression, intolerable side-effects or death. Tislelizumab will be delivered every 21 days at a dose of 200mg, and regorafenib will be given at a dose of 120mg for the first 21 days of a 28-day cycle. Appropriate dose adjustments of regorafenib will be made if side-effects are intolerable, while the dose of tislelizumab should not be adjusted, but could be paused.
88963307|NCT02021981||Observational Group 1|Coach care teams in the practice site on how to implement evidence-based enhancements in hypertension care delivery processes, using established quality improvement principles and methods. In one year, figure out the best way to help different types of ambulatory clinical practices achieve improved blood pressure control.
88963308|NCT02021981||Observation Group 2|Coach care teams in the practice site on how to implement evidence-based enhancements in hypertension care delivery processes, using established quality improvement principles and methods. In one year, figure out the best way to help different types of ambulatory clinical practices achieve improved blood pressure control.
89025925|NCT00497601|Experimental|B|Amphotericin B in fat emulsion (Amphomul) 10 mg/kg on day 1 and 5 mg/kg on day 3
89025926|NCT00497601|Experimental|C|Amphotericin B in fat emulsion (Amphomul) 12.5 mg/kg on day 1 and 2.5 mg/kg on day 3
89025927|NCT00497601|Experimental|D|Amphotericin B in fat emulsion (Amphomul) 15 mg/kg in a single dose administration on day 1
89025928|NCT00466388|Experimental|Cevimeline|Evoxac tid for xerostomia
89556519|NCT05917418|Experimental|Nutritional support therapy group|All participants in this group will receive proper nutritional support.
89025929|NCT00466388|Placebo Comparator|Placebo|sugar pill
89025930|NCT00466466|Experimental|Daily dosing RAD001|
89025931|NCT00466466|Experimental|Weekly dosing RAD001|
89025932|NCT00490854|Experimental|1|
89025933|NCT00490854|Experimental|2|
89025934|NCT00463970|Active Comparator|1|Brief Intervention
89025935|NCT00463970|Experimental|2|Cognitive Behavioural Therapy
89556520|NCT05917418|No Intervention|Routine hospital management group|All participants in this group will receive routine hospital management, without additional nutritional interventions.
89556521|NCT05917405|Experimental|Experimental: CloB2 arm|"30 mg/m2/day IV clofarabine for 5 days (day-6 to day-2)~130 mg/m2/day IV busulfan once daily for 2 days (day -4 and -3)~ATG (Thymoglobuline®) 2.5 mg/Kg/day IV for 2 consecutive days (day -2 and -1) Corticosteroids may be used in profilaxis"
89556522|NCT05917405|Active Comparator|Comparator: FB2A2 arm|"30 mg/m2/day IV fludarabine for 5 days (day-6 to day-2)~130 mg/m2/day IV busulfan once daily for 2 days (day -4 and -3)~ATG (Thymoglobuline®) 2.5 mg/Kg/day IV for 2 consecutive days (day -2 and -1)"
89556523|NCT05917392|Active Comparator|Supplementation-standard|Supplementation with Kimchi 50 gram daily for two months
89556524|NCT05917392|Experimental|Supplementation with probiotic|Supplementation with Kimchi plus LGG 50 gram daily for two months
89556525|NCT05917392|Experimental|Supplementation with polyphenol|Supplementation with Kimchi plus polyphenol 50 gram daily for two months
89556526|NCT05917366|Experimental|Coccyx Manipulation|Manual therapy sessions, in addition to the exercise group, were performed once a week for four weeks.
89556527|NCT05917366|Active Comparator|Exercises|A total of 4 sessions were applied, 3 times a week.
89556528|NCT05917314|Experimental|Intervention Group (SlimBiotic Probiotic)|Participants will take 1 serving (1 capsule) per day.
89556529|NCT05917314|Placebo Comparator|Placebo Group|Participants will take 1 serving (1 capsule) per day.
89556530|NCT05917288|Experimental|Participants receiving belimumab + Standard of care (SOC)|Participants will receive belimumab 200 milligrams SC injection according the Baseline body weight plus SOC.
89556531|NCT05917197||Medical students|
89556532|NCT05917184||Neurological Outpatients|Participants in this group will be recruited from the outpatient clinical population at participating MGNet sites. Treating physicians will make the initial determination of patients' potential eligibility to participate in the study.
89025936|NCT00463970|Experimental|3|Seal oil
89025937|NCT00463970|Placebo Comparator|4|Soy oil
89556533|NCT05917158|Experimental|RC48-ADC and JS001|
89556534|NCT05991674||Allergic Contact Dermatitis Patients|
89556535|NCT05991648|Experimental|Kangaroo Care (skin-to-skin contact)|Skin-to-skin contact between the mother and the child. The naked newborn, wearing only a diaper and a hat, is placed in a vertical position in direct contact between the mother's breasts. An elastic fabric support (made of cotton or synthetic elastic fiber) will be used to facilitate the position.
89556536|NCT05991648|No Intervention|Routine care in an incubator|The newborn, dressed only in a clean diaper, is placed in a nest in the double-walled servo-controlled incubator.
89556537|NCT05991622|Experimental|Preliminary Test of Combined LAI Treatment|"The combined injectable treatment includes a dual-administration of rilpivirine (CAB/RPV) cabenuva for HIV and extended-release buprenorphine (XR-B) sublocade for OUD."
89556538|NCT05991609||Individuals with extreme body size|Any individual with a form of skeletal dysplasia, or extremely small or large body size.
89556539|NCT05991583|Experimental|Phase Ia - Dose escalation|The goal of the Dose Escalation Phase (Part A) is to initially characterize the safety and tolerability of IBB0979, and more specifically to describe the DLTs for each dose level studied and to define the MTD based on the frequency of the occurrence of DLTs in each cohort during the DLT evaluation period.
89556540|NCT05991583|Experimental|Phase Ib - Dose extension|During the Dose Expansion Phase , patients will be enrolled to receive IBB0979 at the MTD established from the Dose Escalation Phase of the study.
89556541|NCT05991583|Experimental|Phase IIa - Clinical Exploratory Stage|After finishing Phase 1, invesigators will discuss with the sponsor about how to carry out the Phase IIa due to the results acheived from Phase I.
89025938|NCT00464009|Active Comparator|A|Group A practices (n=39) received didactic training and course materials in oral health screening, referral, counseling and application of fluoride varnish.
89556542|NCT05991505|No Intervention|1- Control|Volunteers with no physical activity during 10 weeks
89556543|NCT05991505|Active Comparator|2 - Training|Volunteers with supervised home physical activity, twice a week, during 10 weeks
89025939|NCT00464009|Active Comparator|B|Group B practices (n=41) received the same as Group A and were offered weekly conference calls providing advice and support.
89025940|NCT00464009|Active Comparator|C|Group C practices (n=41) received the same as Group B and were also offered in-office follow-up visits providing hands-on advice and support.
89025941|NCT00464126|Active Comparator|Colloid|5% albumin for volume resuscitation
89025942|NCT00464126|Placebo Comparator|Crystalloid|Saline for volume resuscitation
89025943|NCT03272399|Experimental|H3-L6|High Omega-3, low Omega-6 diet
89556544|NCT05991466|Active Comparator|Group(A)|Spinal anaesthesia will be performed with 0.5% hyperbaric bupivacaine 10-12 mg and TAP block will be performed with 30 ml 0.25% bupivacaine in each side.
89556545|NCT05991466|Active Comparator|Group (B)|Spinal anaesthesia will be performed with 0.5% hyperbaric bupivacaine10-12 mg and TAP block will be performed with 50 mcg Dexmedetomidine added to 30ml 0.25% bupivacaine in each side.
89556546|NCT05991466|Active Comparator|Group (C)|Spinal anaesthesia will be performed with 0.5% hyperbaric bupivacaine 10-12 mg added to 5 mcg dexmedetomidine. TAP block will be performed with 30ml 0.25% bupivacaine in each side.
89556547|NCT05991388|Experimental|Treatment Arm I - BsAb - Odronextamab|Patients will receive odronextamab given as an intravenous infusion weekly for 12 weeks, then every two weeks until nine months, and every four weeks thereafter until progression or for a maximum of two years
89556548|NCT05991388|Experimental|Treatment Arm II - ADC with Standard Chemotherapy - Loncastuximab tesirine with modified R-ICE|Patients will receive loncastuximab tesirine given as a 30-minute intravenous infusion with each cycle of modified R-ICE (maximum three cycles)
89556549|NCT05991388|Experimental|Treatment Arm III - CAR T-cells - TBC|Patients will receive CAR-T cell therapy - agent TBC
89556550|NCT05991375|Active Comparator|BUPIvacaine 0.25%|(Injection bupivacaine (0.25%) 28 ml plus 2 ml. normal saline) making a total volume of local anaesthetic solution equal to 30 mL
89556551|NCT05991375|Experimental|Bupivacaine0.25%+DEX|Injection bupivacaine (0.25%) 28 mL plus dexmedetomidine I ug/kg diluted to 2 ml) making a total volume of local anaesthetic solution equal to 30 mL
89556552|NCT05991336||Gene therapy group|TDT Children who have received gene therapy between 3~14 years old.
88963309|NCT02021981||Observation Group 3|Coach care teams in the practice site on how to implement evidence-based enhancements in hypertension care delivery processes, using established quality improvement principles and methods. In one year, figure out the best way to help different types of ambulatory clinical practices achieve improved blood pressure control.
89556553|NCT05991336||Supportive therapy group|TDT Children who received lifelong treatment with blood transfusions and iron chelation. They were selected based on the age and sex of the gene therapy group.
89025944|NCT03272399|Active Comparator|L3-H6|Control diet containing average US polyunsaturated fatty acid (PUFA) content with low omega-3 and high omega-6 content
89025945|NCT03272126|Experimental|vitamin D bolus|vitamin D 160 000 IU given as bolus
89556554|NCT05991336||Healthy children group|Healthy children were selected based on the age and sex of the gene therapy group.
89556555|NCT05991297|Active Comparator|Classical physical therapy and rehabilitation program|Classical rehabilitation program (stretching, strenght, balance and coordination exercise) for fifty minutes.
88963310|NCT02021981||Observation Group 4|Coach care teams in the practice site on how to implement evidence-based enhancements in hypertension care delivery processes, using established quality improvement principles and methods. In one year, figure out the best way to help different types of ambulatory clinical practices achieve improved blood pressure control.
89025946|NCT03272126|Experimental|vitamin D daily|vitamin D 4000 IU daily for 28 days
89556556|NCT05991297|Experimental|Deep sensory asisted therapy and rehabilitation program|Deep sensory asisted rehabilitation program (stretching, strenght, balance and coordination and deep sensory exercises) for fifty minutes.
89556557|NCT05991245||MATRIX|Thrombotic microangiopathy with kidney biopsy
89556558|NCT05991141|Experimental|Experimental Group|Experimental Group
89556559|NCT05991141|Sham Comparator|Control Group|Control Group
89556560|NCT05991115|No Intervention|Standard of Care|Control arm will receive the standard of care (SOC) after hospital discharge.
89556561|NCT05991115|Experimental|Hospital to Home Transition (H2H)|The intervention for this study is a multi-component navigation-supported intervention for children hospitalized with asthma. Navigators will work with families for 12-months post-discharge. Trained asthma educator/navigators will work to address challenges with asthma care after discharge; will include maximum 15 contacts/12 months. The asthma navigators within this study will attempt to maintain direct contact with participants primary care doctors through email, fax, and/or postal mail as means for delivering asthma action plans, prescription updates, and patient appointment scheduling. The asthma navigators for intervention participants will attempt to maintain contact with the school nurse in efforts to have a line of communication with the school. Asthma navigators will assist families in all home-based needs pertaining to their child's asthma.
89556562|NCT05991037|Experimental|"overdosed group"|The experimental group will be made up of falling patients recruited for whom at least one psychoactive drug has been measured in a concentration higher than the usual therapeutic ranges.
89556563|NCT05991037|Other|"non-overdosed group"|The control group will be made up of falling patients recruited for whom none of the psychoactive drugs have been measured in supra-therapeutic concentrations (therefore concentrations measured therapeutic or infra-therapeutic)
89556564|NCT05991011|Experimental|I2WE (Immersive and interactive wall exergames)|
89556565|NCT05991011|Experimental|2CMA (Complex Cognitive and Motor Activities)|
89556566|NCT05991011|Experimental|EXER|
89556567|NCT05991011|Active Comparator|VG (video games)|
89556568|NCT05991011|Active Comparator|BIKE (bike)|
89556569|NCT05991011|Active Comparator|VG-bike (Video games + bike)|
89556570|NCT05991011|No Intervention|CON (control group)|
89556571|NCT05990972|Experimental|FMT group|
89556572|NCT05990959||HCC_surg|HCC surgical patients who would receive surgical interventions based on clinical judgment and would donate biospecimen for research after signing informed consent permission.
89556573|NCT05990933|Experimental|People with type 1 diabetes|The participants with type 1 diabetes will receive an intravenous infusion of adrenaline at a rate of 0.04ug/kg/min for 1 hour.
89556574|NCT05990933|Active Comparator|Healthy individuals|The participants without type 1 diabetes will receive an intravenous infusion of adrenaline at a rate of 0.04ug/kg/min for 1 hour.
89556575|NCT05990907|Other|Tilting table without and with RIC|The experimental setup consists of two separate measurements. In the first measurement, the subject is ortho-statically stressed by changing the position (lying to upright) on a tilting table (similar to the established tilting table test). 24 hours after the first measurement, the ischemic preconditioning will be carried out in three cycles with a directly subsequent tilting table test.
89025947|NCT03272126|Placebo Comparator|placebo|identical looking as vitamin d
89025948|NCT00497913|Active Comparator|A|
89556576|NCT05990881|Active Comparator|Control|Patients in this group will receive standard-of-care corticosteroid injections.
89556577|NCT05990881|Experimental|Botulinum Toxin|Patients in this group will receive a Botulinum Toxin injection.
89556578|NCT05990868|Active Comparator|Rectal tylenol group: Group 1|Randomization to the study group (Group 1): will receive standard anesthesia and 650 mg rectal Tylenol at the time of egg retrieval.
89556579|NCT05990868|Placebo Comparator|Placebo group: Group 2|Randomization to the standard of care group (Group 2): will receive standard anesthesia and rectal placebo at the time of oocyte retrieval. Placebo is a substance that has no therapeutic effect and used as a control in testing new drugs.
89556580|NCT05990842|Experimental|antibiotic prophylaxis|
89556581|NCT05990842|Placebo Comparator|placebo|
89556582|NCT05990829|Experimental|Ozurdex group|Standard 25-gauge pars plana vitrectomy (PPV) will be performed under retrobulbar anaesthesia using high-speed vitrectomy system. Clear all the vitreous hemorrhage and proliferative membrane during PPV operation, panretinal photocoagulation should be completed. The vitreous cavity will be filled with balanced salt solution. An injection of Ozurdex will be performed at the end of the surgery.
89556583|NCT05990829|Active Comparator|Aflibercept group|Standard 25-gauge pars plana vitrectomy (PPV) will be performed under retrobulbar anaesthesia using high-speed vitrectomy system. Clear all the vitreous hemorrhage and proliferative membrane during PPV operation, panretinal photocoagulation should be completed. The vitreous cavity will be filled with balanced salt solution. An injection of aflibercept will be performed at the end of the surgery.
89556584|NCT05990725|Experimental|Lebrikizumab|Participants will receive lebrikizumab 250 milligrams (mg) subcutaneous (SC) injection, once every two weeks (Q2W) on Day 1 for up to Week 16. A loading dose of lebrikizumab 500 mg (2 injections) SC will be administered on Day 1 and at Week 2, further followed by lebrikizumab 250 mg (1 injection), SC, once every four weeks (Q4W) after Week 16 for up to Week 24.
89556585|NCT05990712|Experimental|Omega-3|Participants in this arm will take oral omega-3 supplement for 4 weeks pre-operatively and 4 weeks post-operatively. They will also receive the Zocular intervention in clinic and the lid wipe and Thealoz eyedrops at home.
89556586|NCT05990712|Active Comparator|No Omega-3|Participants in this arm will not take oral omega-3 supplement. They will only receive the Zocular intervention in clinic and the lid wipe and Thealoz eyedrops at home.
89556587|NCT05990673|Experimental|remimazolam|remimazolam is given for anesthesia induction
89556588|NCT05990647|Active Comparator|Group I|32 patients who underwent classic abdominal wall anterior components separation and bridged hernia repair.
89556589|NCT05990647|Active Comparator|Group II|34 patients who underwent posterior components separation with the internal oblique myofascial release by Rives-Stoppa
89556590|NCT05990647|Active Comparator|Group III|29 patients who underwent posterior components separation with transversus abdominis release (TAR).
89556591|NCT05990634|Experimental|LifeChamps Platform|Participants will be asked to use the LifeChamps platform and will be provided with the study equipment (sensors/home kit).
89556592|NCT05990621|Experimental|Anti-CD70 CAR-T cells|Anti-CD70 CAR-T cells are autologous genetically modified T cells.
89556593|NCT05990608||Group I|Healthy Children
89556594|NCT05990608||Group II|Children with DMD
89556595|NCT05990582|Experimental|MLPTI Cohort|Group of 9 year old children born between 32 and 36 weeks of gestational age
89556596|NCT05990582|Active Comparator|Control cohort|Group of 9 year old children born at term
89556597|NCT05990556|Experimental|interventional procedure to block bilateral meningeal blood supply|
89556598|NCT05990543|Experimental|Group 1|Nelmastobart + Capecitabine
89025949|NCT00497913|Placebo Comparator|B|
89025950|NCT03272360||Chronic Pelvic Pain|
89025951|NCT03272360||Elective Tubal Ligation|
89556599|NCT05990530|Experimental|YD02-2022|
89556600|NCT05990517|Experimental|YD01-2022|
89556601|NCT05990374|Active Comparator|Dulaglutide|Once a week, subcutaneous injection
89556602|NCT05990374|Active Comparator|semaglutide|Once a week, subcutaneous injection
89556603|NCT05990374|Active Comparator|Loseenatide|Once a week, subcutaneous injection
89556604|NCT05990374|Active Comparator|tirzepatide|Once a week, subcutaneous injection
89556605|NCT05990374|Active Comparator|elbenatide|Once a week, subcutaneous injection
89556606|NCT05990374|Active Comparator|original treatment|Once a week, subcutaneous injection
89556607|NCT05990374|Placebo Comparator|placebo|The patients will be treated according to the original protocol
89556608|NCT05990322|Experimental|Project EMPOWER|"Project EMPOWER is a web-based, self-administered SSI for parents that takes about 30 minutes to complete. The program includes 5 elements, based on current best-practices in SSI design (Schleider, Dobias, Sung, & Mullarkey, 2020) and existing interventions targeting accommodation (Lebowitz & Omer, 2014): (1) an introduction to the program's rationale; (2) psychoeducation around child anxiety and avoidance, along with how parental accommodation can inadvertently maintain child anxiety; (3) information on how parents can better identify children's patterns of avoidance and encourage brave behavior instead; (4) facilitating parents' creation of an action plan for promoting brave behavior and reduce avoidance in their own child; (5) a vignette exercise in which parents read about another family's difficulty managing their child's anxiety; parents identify the elements of the anxiety cycle and provide possible solutions to these parents based on what they learned."
88963311|NCT02021981||Observation Group 5|Coach care teams in the practice site on how to implement evidence-based enhancements in hypertension care delivery processes, using established quality improvement principles and methods. In one year, figure out the best way to help different types of ambulatory clinical practices achieve improved blood pressure control.
88963312|NCT02021981||Observation Group 6|Coach care teams in the practice site on how to implement evidence-based enhancements in hypertension care delivery processes, using established quality improvement principles and methods. In one year, figure out the best way to help different types of ambulatory clinical practices achieve improved blood pressure control.
88963313|NCT02021981||Observation Group 7|Coach care teams in the practice site on how to implement evidence-based enhancements in hypertension care delivery processes, using established quality improvement principles and methods. In one year, figure out the best way to help different types of ambulatory clinical practices achieve improved blood pressure control.
89556609|NCT05990322|Placebo Comparator|Online Resources and Referrals|Online Resources and Referrals (ORR) is an information sheet containing materials about the nature of child anxiety and a list of national resources related anxiety treatment. ORR does not include any psychoeducational components regarding parental accommodation.
89556610|NCT05990309|Active Comparator|non-segmental vitiligo|patients with non-segmental vitiligo
89556611|NCT05990309|Active Comparator|control group|
89556612|NCT05990296|No Intervention|Control|Clinicians in this arm will not receive CDS or focused education and will experience usual care.
89556613|NCT05990296|Experimental|Multiprong CDS with GDMT order set|Clinicians and patients with HFrEF in this arm will receive electronic notification of GDMT care gaps encouraging treatment options. The CDS will inform, encourage, and facilitate prescribing of GDMT via a focused order set.
89556614|NCT05990296|Experimental|Multiprong CDS with referral to pharmacist co-management|Clinicians and patients with HFrEF in this arm will receive electronic notification of GDMT care gaps encouraging treatment options. The clinician-facing BPA will include an option to refer patients to embedded pharmacist co-management. Pharmacists are expected to meet with patients and optimize GDMT through a collaborative practice agreement with clinicians.
89556615|NCT05990296|Experimental|Focused education|Clinicians in this arm will receive focused education and no CDS.
89556616|NCT05990296|Experimental|Multiprong CDS with GDMT order set + focused education|Clinicians in this arm will receive focused education in addition to clinician BPA heads-up and BPA with GDMT order set for their eligible patients with HFrEF.
89556617|NCT05990296|Experimental|Multiprong CDS with referral to pharmacist co-management + focused education|Clinicians in this arm will receive focused education along with clinicians/patient CDS. The clinician-facing BPA will include an option to refer patients to embedded pharmacist co-management. Pharmacists are expected to meet with patients and optimize GDMT through a collaborative practice agreement with clinicians.
89556618|NCT05990270|Experimental|EXPERIMENTAL GROUP|Cervical cancer education will be provided. (The training will be in three sessions, each session will last 20-30 minutes. In the training; ppt presentation for cervical cancer, HPV virus, question and answer method will be used. In addition, female pelvic anatomy, gynecological examination, how the Pap Test is done, and cervical exam on the gynecological examination model. will be explained by showing cancer pathologies ) After the training, the final test data will be obtained by applying the questionnaire again.
89556619|NCT05990270|No Intervention|control group|
89556620|NCT05990218|Active Comparator|control, experienced|Patients received colonoscopy with double insertion of right sided colon under white light by experienced endoscopist
89556621|NCT05990218|Active Comparator|control, beginner|Patients received colonoscopy with double insertion of right sided colon under white light by beginner endoscopist
89556622|NCT05990218|Experimental|AI, experience|Patients received colonoscopy with double insertion of right sided colon under AI by experienced endoscopist
89556623|NCT05990218|Experimental|AI, beginner|Patients received colonoscopy with double insertion of right sided colon under AI by beginner endoscopist
89556624|NCT05990205|Active Comparator|Life Style Intervention|Hypocaloric diet, 25 kcal/kg of ideal weight, 45% of the total intake of carbohydrates, 30% lipids, and 25% protein sources + physical activity (>150 min medium intensity per week)
89556625|NCT05990205|Active Comparator|Life Style Intervention + Metformin|Hypocaloric diet, 25 kcal/kg of ideal weight, 45% of the total intake of carbohydrates, 30% lipids, and 25% protein sources + physical activity (>150 min medium intensity per week) + (750 mg metformin twice a day).
88963314|NCT02021981||Observation Group 8|Coach care teams in the practice site on how to implement evidence-based enhancements in hypertension care delivery processes, using established quality improvement principles and methods. In one year, figure out the best way to help different types of ambulatory clinical practices achieve improved blood pressure control.
88963315|NCT02021981||Observation Group 9|Coach care teams in the practice site on how to implement evidence-based enhancements in hypertension care delivery processes, using established quality improvement principles and methods. In one year, figure out the best way to help different types of ambulatory clinical practices achieve improved blood pressure control.
88963316|NCT02021981||Observation Group 10|Coach care teams in the practice site on how to implement evidence-based enhancements in hypertension care delivery processes, using established quality improvement principles and methods. In one year, figure out the best way to help different types of ambulatory clinical practices achieve improved blood pressure control.
88963317|NCT02021994||Arm Automatic Electronic BPM|
89556626|NCT05990179|Experimental|Enrolled in the study|All newborns enrolled in the study will be evaluated.
89556627|NCT05990153|Experimental|Myofascial Release (MR) + Therapeutic exercise (TE)|Patients in the MR+TE group will undergo 12 sessions (3 d/week) of sub-occipital inhibition treatment as a combined muscle and soft tissue inhibition technique. The physiotherapist will apply deep pressure which will be maintained for a total of 10 minutes until the sub-occipital tissues are released. In addition to this technique, the method of pumping and manual treatment (acupressure) of the trigger points on the sub-occipital muscles, on the upper bundles of the trapezius bilaterally, on the sternocleidomastoid bilaterally and on the scalene muscles bilaterally will be applied for a further 10 minutes for a total treatment with myofascial release equal to 20 minutes. At the end of the MR session, the 20-minute TE session will be performed in the same way as described in the TE intervention group.
88963318|NCT02021994||mercury sphygmomanometer|
88963319|NCT02022046||2/study, control|Study group: children aged<18 years with chronic kidney disease Control group: children aged<18 years without chronic kidney disease Methylation biosignature, CKD staging, assessment of cardiovascular function, and traditional/uremia-related risk factors will be performed.
88963320|NCT02022072|Other|measure of assisted vital capacity by mechanical insufflation|measure of assisted vital capacity by a mechanical insufflation/exsufflation
88963321|NCT02022124|Experimental|microcrystalline cellulose (open-label inert substance)|3-week course of non-deceptive placebo using placebo pills plus the usual regime that the patients had been prescribed at the time of intake.
88963322|NCT02022124|No Intervention|Usual care treatment|This arm will entail a 3-week course of the stable treatment the patient is following at time of intake.
88963323|NCT02022137|Experimental|Red cereal bar|It includes the intervention of the red cereal bar for the designation of the group.
88963324|NCT02022137|Placebo Comparator|Green cereal bar|It includes the intervention of the green cereal bar for the designation of the group.
88963325|NCT02022137|Active Comparator|White cereal bar|It includes the intervention of the white cereal bar for the designation of the group.
88963326|NCT02022150||Body composition in paracentesis|Taking blood samples and bioelectrical impedance, Psychometric Hepatic Encephalopathy Score (PHES) and Critical Flicker Frequency (CFF) before and after paracentesis.
88963327|NCT02022163|Experimental|Low dose of H7 VLP vaccine + Alhydrogel|Biological: Low dose of H7 VLP vaccine mixed with Alhydrogel, 2 doses given 21 days apart
88963328|NCT02022163|Experimental|Med dose of H7 VLP vaccine + Alhydrogel|Biological: Med dose of H7 VLP vaccine mixed with Alhydrogel, 2 doses given 21 days apart
88963329|NCT02022163|Experimental|High dose of H7 VLP vaccine + Alhydrogel|Biological: High dose of H7 VLP vaccine mixed with Alhydrogel, 2 doses given 21 days apart
88963330|NCT02022163|Experimental|High dose of H7 VLP vaccine|Biological: High dose of H7 VLP vaccine, 2 doses given 21 days apart
88963331|NCT02022163|Placebo Comparator|Placebo|Placebo, 2 doses given 21 days apart
88963332|NCT02022176|Active Comparator|Sodium nitrate|0.1 mmol NaNO3 / kg bodyweight / day for three days.
88963333|NCT02022176|Placebo Comparator|Sodium Chloride|0.1 mmol NaCl / kg bodyweight / day for three days.
88963334|NCT02022176|Active Comparator|Sodium nitrite infusion|Sodium nitrite (NaNO2) at a rate of 1, 10 and 100 nmol kg-1 min-1 (10 minutes per dose) was infused intravenously.
88963335|NCT02022176|Placebo Comparator|Saline infusion|Saline at a rate corresponding to 1, 10 and 100 nmol NaCl kg-1 min-1 (10 minutes per dose) was infused intravenously.
88963336|NCT02022189||Dent Disease patients|Patients with diagnosed Dent Disease
88963337|NCT02022228|Experimental|0.2mg triptorelin and 500 IU hCG|Patients were triggered with 0.2mg triptorelin and 500 IU hCG
88963338|NCT02022228|Experimental|0.2mg triptorelin and 1000 IU hCG|Patients were triggered with 0.2mg triptorelin and 1000 IU hCG
88963339|NCT02022241|Experimental|Repeated GnRHa|Patients were triggered with repeated GnRHa
88963340|NCT02022254|Experimental|Semaglutide administrations|
88963341|NCT02022267||study group|Patients with a minimum age of three years from our prospective, consecutive database of patients with clubfoot treated with the Ponseti method beginning in 2002 are considered for this study. Patients with unilateral or bilateral idiopathic clubfoot are included. Patients with clubfoot associated with syndromes or neurological diseases, with mild clubfoot that required fewer than three casts for initial correction, who first presented at an age older than three months, who were living outside of the country, and who were initially treated elsewhere with more than three casts are excluded.
88963342|NCT02022267||control group|healthy children of employees of our hospital
88963343|NCT02022293|Active Comparator|Atorvastatin|Patients will take atorvastatin 20mg per night, totally 2 years.
88963344|NCT02022293|Placebo Comparator|Placebo|Patients will take placebo once per night for 2 years. The appearance and dosage of placebo will be the same as atorvastatin.
88963345|NCT02022306|Placebo Comparator|SAD TD-6450|Single ascending dose (Part A)
88963346|NCT02022306|Placebo Comparator|MAD TD-6450|Multiple ascending dose (Part B)
88963347|NCT02022306|Active Comparator|Food effect of TD-6450|Food effect will be assessed in Part A (SAD) of this study.
88963348|NCT02022319|Other|Shear Wave Elastography|All included patients undergo a supplementary Shear Wave Elastographic scan
88963349|NCT02022345|Active Comparator|PCI at pilot hospitals|Percutaneous Coronary Interventions performed at pilot hospitals which do not have onsite cardiac surgery.
88963350|NCT02022345|Active Comparator|PCI at non-pilot hospitals|Percutaneous Coronary Intervention performed at non-pilot hospitals which have onsite cardiac surgery or perform only primary PCIs for STEMI patients.
89025952|NCT03272321|Experimental|Oxytocin|Syntocinon nasal spray (40 IU/ml; oxytocin, product code RVG 03716); single intranasal dose of 24 international units (IU; 3 puffs of 4 IU per nostril)
89025953|NCT03272321|Placebo Comparator|Placebo|saline natriumchloride solution nasal spray; single intranasal dose (3 puffs per nostril)
89556628|NCT05990153|Experimental|Manual therapy (MT) + Therapeutic exercise (TE)|The MT+TE intervention group will carry out rehabilitation treatment with a structured protocol based on mobilizations according to the Mulligan method. Treatment according to Mulligan will be carried out at the discretion of the therapist on the basis of daily evaluations of cervical dysfunction and the eventual manifestation of headache. 5 different techniques will be performed on the patient in 12 sessions (3 v/week, for 4 weeks) as described in Satpute, K., Bedekar, N. & Hall, T. Effectiveness of Mulligan manual therapy over exercise on headache frequency, intensity and disability for patients with migraine, tension-type headache and cervicogenic headache - a protocol of a pragmatic randomized controlled trial. BMC Musculoskelet Disord 22, (2021)..
89556629|NCT05990153|Experimental|Therapeutic exercise (TE)|Patients in the TE intervention group will be asked to perform 12 sessions (3 day/week) of TE supervised by a physiotherapist. Each session will have a total duration of 40 min divided into 20 min of aerobic exercise and 20 min of TE. Aerobic exercise consists of a total of 20 min of activity on a stationary bike using parameters to increase performance (intensity over 20 min) progressively based on fatigue (Borg scale).The TE consists of warm-up and cool-down exercises for the cervical ROM, associated with stretching exercises of the cervical and scapulothoracic muscles. After the warm-up, muscle strengthening exercises will be performed (isometric, concentric and eccentric contractions of the cervical muscles).
89556630|NCT05990153|Active Comparator|Control|Patients assigned to the control group will follow the pharmacological treatment according to medical doctor indications (clinical practice).
89556631|NCT05990140|Experimental|Experimental|"Consent of all patients will be obtained the night before surgery. Biochemical parameter levels and state trait anxiety scale and apfel risk scale will be recorded.~As it will be difficult for the experimental group to be oriented while giving mouthwash training after the surgery, mouthwash training will be given at a time when it is available the night before the operation. State anxiety scale, visual comparison scale and nausea and vomiting effect scale will be administered before discharge (approximately 48 hours). After discharge, he will continue to gargle in the same way 3 times a day. At the end of the first week, all patients will be called by the researcher and the state anxiety scale, visual comparison scale and nausea and vomiting effect scale shared on the digital environment will be filled and recorded. This process will continue for 4 weeks. In the last measurement, visual comparison scale, nausea vomiting and state trait anxiety scale will also be filled."
89556632|NCT05990140|No Intervention|Control|"Consent of all patients will be obtained the night before surgery. Biochemical parameter levels and state trait anxiety scale and apfel risk scale will be recorded.~The state anxiety scale, visual comparison scale and nausea and vomiting effect scale will be administered to the control group before they are discharged (approximately at the 48th hour). At the end of the first week, all patients will be called by the researcher, and the state anxiety scale, visual comparison scale and nausea and vomiting effect scale will be filled and recorded. This process will continue for 4 weeks. In the last measurement, visual comparison scale, nausea vomiting and state trait anxiety scale will also be filled. At the end of the first month, the biochemical parameters taken during the routine hospital control will be recorded."
89556633|NCT05990127|Experimental|AK104 arm|
89556634|NCT05990127|Active Comparator|Tislelizumab arm|
89556635|NCT05990114|Experimental|intervention group|The structured caregiver support program is a psychosocial training program developed to improve caregivers' burden of care, psychological well-being and resilience.This training program will be applied to the intervention group.
89556636|NCT05990114|No Intervention|control group|No intervention will be applied to the control group.
89556637|NCT05990101|Experimental|APP group|Awake prone position (APP) for 4 or more hours per day in addition to standard care for the first 72 hours from randomisation. After the initial period, use of APP is at discretion of the treating clinician. Awake prone can be discontinued earlier if patients meets pre-specified criteria of sustained improvement.
89556638|NCT05990101|No Intervention|Control group|Standard care excluding APP
89556639|NCT05990062|Experimental|Verify performance gains for the innovative KSH system that can be delivered to Veterans. The new de|The investigators will perform several functional tests of the both the KSH system and the standard of care prosthesis: tensile static load bearing capacity before failure, test rowing ergometer 10-minute test before failure measured using strokes per minute, power in Watts, distance in meters, maximal force, and time before failure, range of motion in flexion/extension, and donning/doffing time.
88963351|NCT02022358|Active Comparator|M|"Methotrexate (12 g/m2 x 1, intravenously) with standard folinic acid rescue~In arm A patients will receive cycle M first followed by cycle GluM. Cycle M starts with course M1 on day 1 followed by course M2 planned for day 8. Cycle GluM starts with course GluM1 on day 1 followed by GluM2 planned for day 8. Cycle GluM will not start for a minimum of 14 days from the beginning of course M2, or until bone marrow, renal and hepatic functions have completely recovered and the patient is clinically ready to receive further chemotherapy ."
88963352|NCT02022358|Experimental|GluM|"Methotrexate (12 g/m2 x 1, intravenously) with folinic acid and glucarpidase rescue (50 units/kg x 1, intravenously).~In arm B, patients will receive cycle GluM first followed by cycle M. Cycle GluM starts with course GluM1 on day 1 followed by GluM2 planned for day 8.Cycle M starts with course M1 on day 1 followed by course M2 planned for day 8. Cycle M will not start for a minimum of 14 days from the beginning of course GluM2, or until bone marrow, renal and hepatic function have completely recovered and the patient is clinically ready to receive further chemotherapy"
88963353|NCT02022371|Experimental|Targeted biopsy|Snap frozen targeted biopsies of the prostate for genomic analysis
88963354|NCT02022397||difficult intubation|general population necessitating tracheal intubation for general anesthesia
88963355|NCT02022410||CAS after primary and revision TKA|CAS and RAPT
88963356|NCT02022449|No Intervention|Control|participants only complete assessments
88963357|NCT02022449|Experimental|Stress management|Cognitive Behavioral Stress management Coping enhancement strategies Progressive muscle relaxation Guided imagery relaxation skills Deep breathing relaxation skills Social support
88963358|NCT02022475|Active Comparator|Cholecalciferol|100 000 units vitamin D3 single dose
88963359|NCT02022475|Placebo Comparator|Placebo|similar appearance
88963360|NCT02022488|Active Comparator|midazolam and alfentanil|Midazolam 0.5mg/kg (oral) Alfentanil 10 microgram/kg (oral)
88963361|NCT02022488|Active Comparator|midazolam and ketamine|Midazolam 0.5mg/kg (oral) Ketamine 2mg/kg (intranasal)
88963362|NCT02022488|Placebo Comparator|midazolam|Midazolam 0.5mg/kg
88963363|NCT02022501|Experimental|Low Dose DE-120|Single 20 µL intravitreal injection of Low Dose DE-120 injectable solution
88963364|NCT02022501|Experimental|Medium Dose DE-120|Single 20 µL intravitreal injection of Medium Dose DE-120 injectable solution
88963365|NCT02022501|Experimental|High Dose DE-120|Single 20 µL intravitreal injection of High Dose DE-120 injectable solution
88963366|NCT02022527|Experimental|Combination|Warfarin tablets adjusted according to international normalized ratio (INR) (2 for Aortic Valve Replacement & 2.5-3 for Mitral Valve Replacement, 2.5-3.5 for Double Valve Replacement) and oral 75 mg Acetyl Salicylic Acid tablets daily long life.
88963367|NCT02022527|Active Comparator|Warfarin|Warfarin tablets adjusted according to INR (2 for Aortic Valve Replacement & 2.5-3 for Mitral Valve Replacement, 2.5-3.5 for Double Valve Replacement) and placebo long life.
88963368|NCT02022540|Experimental|Stage 1 - Group 1|Patients randomized to Group 1 will receive PAN-90806 Ophthalmic Solution daily for 8 weeks.
88963369|NCT02022540|Experimental|Stage 1 - Group 2|Patients randomized to Group 2 will receive PAN-90806 Ophthalmic Solution daily for 8 weeks.
88963370|NCT02022540|Experimental|Stage 1- Group 3|Patients randomized to Group 3 will receive PAN-90806 Ophthalmic Solution daily for 8 weeks.
88963371|NCT02022540|Experimental|Stage 1- Group 4|Patients randomized to Group 4 will receive PAN-90806 Ophthalmic Solution daily for 8 weeks.
88963372|NCT02022540|Experimental|Stage 1 - Group 5|Patients randomized to Group 5 will receive PAN-90806 Ophthalmic Solution daily for 8 weeks.
88963373|NCT02022540|Experimental|Stage 2|Patients enrolled in Stage 2 will receive an intravitreal injection of ranibizumab and then 7-9 days later begin daily dosing with PAN-90806 Ophthalmic Solution for 12 weeks
88963374|NCT02022553|Experimental|rectal cancer, surgery|
88963375|NCT02022553|Active Comparator|rectal cancer, RACHEL, surgery|
88963376|NCT02022579|Experimental|DCE-MRI and DWI|Single arm study, diagnosis defined as BIRADS 3, 4, or 5 lesion(s) based on DCE-MRI only with DWI collected in tandem as standard practice.
88963377|NCT02022605|Experimental|Hands-on EMS training group|
88963378|NCT02022605|Active Comparator|Standard training group|
88963379|NCT02022683|Experimental|Endoscopic Lung Volume Reduction|Patients are implanted with Zephyr Valves
88963380|NCT02022683|No Intervention|Standard of Care|Patients are given Standard Medical Care
88963381|NCT02022722|Active Comparator|Pelvic Rehabilitation|Pelvic Rehabilitation will be conduction on weekly basis for a total of 6 weeks
88963382|NCT02022722|Active Comparator|Trigger Point Injections|Trigger point injections will be administered on weekly basis for a total of 6 weeks
88963383|NCT02022761|Experimental|40 mg Laninamivir octanoate|Dry Powder Inhaler
88963384|NCT02022761|Experimental|80 mg Laninamivir octanoate|Dry Powder Inhaler
88963385|NCT02022761|Placebo Comparator|Matching placebo|Dry Powder Inhaler
88963386|NCT02022787||Renal cell carcinoma|Patients with renal cell carcinoma scheduled for partial or radical nephrectomy
88963387|NCT02022800|Other|PET 18FDOPA|PET 18FDOPA
88963388|NCT02022813|No Intervention|Enteral nutrition only|Enteral nutrition to be progressed as soon as possible to energy target measured on day 3, and verified on day 4, using the usual facilitators (prokinetics)
88963389|NCT02022813|Experimental|Supplemental parenteral nutrition|"Addition of supplemental parenteral nutrition to complete the gap between energy delivered by enteral feeding and energy target measured on day 4.~Aim: 100% of this target, and not exceeding it, no catch up for energy deficit accumulated before day 4."
88963390|NCT02022852|Active Comparator|Concurrent chemoradiotherapy|Capecitabine neoadjuvant concurrent radiochemotherapy and XELOX adjuvant therapy
88963391|NCT02022852|Experimental|Sequential therapy|XELOX/capecitabine/XELOX neoadjuvant chemo-chemoradio-chemo sequential therapy and XELOX adjuvant therapy
88963392|NCT02022865||periodontitis patients|according to american academy of periodontology classification of periodontal diagnosis.
88963393|NCT02022865||healthy periodontium|according to american academy of periodontology classification of periodontal diagnosis.
88963394|NCT02022878||Attempted PCI of CTO|Attempted PCI of CTO with preprocedural coronary CTA scan
88963395|NCT02022891||systematic psychological care|Systematic psychological treatment plan added to medical care for children with SCD. Bio-psychosocial paradigm applied at pediatric consultations.
88963396|NCT02022891||Control|medical care only at routine pediatric consultations for SCD. Psychological support provided only when the pediatrician consider it appropriate.
88963397|NCT02022904|Experimental|Metastatic prostate cancer|Near infrared (NIR) emissive nanotechnology
88963398|NCT02022917|Experimental|Epithelial Ovarian Cancer|Neoadjuvant Carboplatin, Paclitaxel, and Bevacizumab 21 day cycles of carboplatin, paclitaxel, and bevacizumab
88963399|NCT02022930|Experimental|Hydros|Hydros Joint Therapy
88963400|NCT02022930|Experimental|Hydros-TA|Hydros-TA Joint Therapy
88963401|NCT02022930|Active Comparator|Triamcinolone acetonide|Triamcinolone acetonide
88963402|NCT02022956|Experimental|Open-Label Lorcaserin (BELVIQ)|
88963403|NCT02022995||Patients with cetuximab treatment|Patients with cetuximab treatment
88963404|NCT02022995||Patients without cetuximab treatment|Patients without cetuximab treatment
89025954|NCT00498069|Active Comparator|1|Injection of autologous bone marrow concentrate into ischemic tissues of the lower extremity
89025955|NCT00498069|Placebo Comparator|2|Injection of placebo into ischemic tissues of the lower extremity
89025956|NCT03273062|Active Comparator|Study Period 1|"15 days of Tolcapone 200mg TID~OR~Placebo Comparator 15 days of Placebo pill TID"
89556640|NCT05990062|Experimental|Verify functionality of the KSH system through testing with end-users.|The investigators will use System Usability Scale (SUS) to assess high usability with setup and operation of the device. The investigators will assess Comfort Scores (SCS), evaluate weight and correlate it with user satisfaction. The investigators will report selection outcome between new design and current design. The investigators will asses 1) functional status, (2) health- related quality of life, and (3) satisfaction with services and (4) device scores through the Orthotics and Prosthetics User Survey (OPUS).
88963405|NCT02023008|Experimental|Supportive care (internet-based integral yoga intervention)|Participants undergo 12 sessions of cancer-adapted integral yoga classes using an internet-based videoconferencing platform. Integral yoga includes postures, deep relaxation, breathing practices and meditation to create a profound experience of peace and well-being. Participants take part in study classes from home (or other location that is convenient for the participant and that allows them to access the internet-based classes) with two-way interaction with group instructors and members alike over 75 minutes twice weekly for 6 weeks during radiation therapy. Participants are encouraged to complete additional yoga practice sessions outside of the twice weekly study sessions.
88963406|NCT02023021|Experimental|nab-paclitaxel + gemcitabine|nab-paclitaxel at 100 mg/m^2 on days 1, 8, and 15; gemcitabine at 1000 mg/m^2 on days 1, 8, and 15
88963407|NCT02023034|Experimental|Virtual exercises|"All patients underwent 12 sessions, twice a week for a period of 06 weeks. The exercises were performed in the on dopaminergic medication, supervised by the researchers, the period instrument used was the video game with the Nintendo ® Wii Balance Board ® platform."
88963408|NCT02023034|Sham Comparator|Control|"Traditional exercises. All patients underwent 12 sessions, twice a week for a period of 06 weeks. The exercises were performed in the on dopaminergic medication, supervised by the researchers."
88963409|NCT02023047|Experimental|Once daily|Nifedipine 12 mg Once daily
88963410|NCT02023047|Experimental|Twice Daily|Nifedipine 12 mg twice daily
88963411|NCT02023086||FABRY group|"contrast sensitivity measurement~slit lamp assessment and intra-ocular pressure measurement~ocular coherence tomography at the optic nerve head~visual field testing~OSOME (oxygen flow at the optic nerve head measurement)~Tropicamide"
88963412|NCT02023086||CONTROL group|"contrast sensitivity measurement~slit lamp assessment and intra-ocular pressure measurement~ocular coherence tomography at the optic nerve head~visual field testing~oxygen flow at the optic nerve head measurement (OSOME)~Under tropicamide"
88963413|NCT02023138|Active Comparator|Focus group|
88963414|NCT02023138|Experimental|Wiki|
88963415|NCT02023177||Phase angle|Phase angle obtained from bioelectrical impedance
88963416|NCT02023190||Nutritional assessment|Nutritional assessment will be performed by bioelectrical impedance vector analysis
88963417|NCT02023203|Experimental|LP PTFE|Placement of Large Pore PTFE mesh for inguinal hernia treatment
88963418|NCT02023203|Active Comparator|SP-PPL|Placement of Small Pore polypropylene mesh for inguinal hernia treatment
88963419|NCT02023229|Experimental|Diet plus branched chain aminoacids|High-fiber high-protein diet Oral supplement : branched chain aminoacids
88963420|NCT02023229|Active Comparator|Diet|High-fiber high-protein diet
88963421|NCT02023255|Experimental|Part A: Cohort 1|8 participants will be included in this cohort. 6 participants will receive a single dose of 50 mg JNJ-39393406 and 2 participants will receive placebo for 7 consecutive days.
88963422|NCT02023255|Experimental|Part A: Cohort 2|8 participants will be included in this cohort. 6 participants will receive a single dose of 150 mg JNJ-39393406 and 2 participants will receive placebo for 7 consecutive days.
88963423|NCT02023255|Experimental|Part A: Cohort 3|8 participants will be included in this cohort. 6 participants will receive a single dose of 450 mg JNJ-39393406 and 2 participants will receive placebo for 7 consecutive days.
88963424|NCT02023255|Experimental|Part A: Cohort 4|8 participants will be included in this cohort. 6 participants will receive a single dose of 1,350 mg JNJ-39393406 and 2 participants will receive placebo for 7 consecutive days.
88963425|NCT02023255|Experimental|Part A: Cohort 5|8 participants will be included in this cohort. 6 participants will receive a single dose of 2,700 mg JNJ-39393406 and 2 participants will receive placebo for 7 consecutive days.
88963426|NCT02023255|Experimental|Part B: Cohort A|16 participants will be included in this cohort. 12 participants will receive a single dose of JNJ-39393406 selected based on the pharmacokinetic (PK) data from Part A of the study and 4 participants will receive placebo for 13 consecutive days.
88963427|NCT02023255|Experimental|Part B: Cohort B|16 participants will be included in this cohort. 12 participants will receive a single dose of JNJ-39393406 selected based on the PK data from Part A of the study and 4 participants will receive placebo for 13 consecutive days.
88963428|NCT02023255|Experimental|Part B: Cohort C|16 participants will be included in this cohort. 12 participants will receive a single dose of JNJ-39393406 selected based on the PK data from Part A of the study and 4 participants will receive placebo for 13 consecutive days.
88963429|NCT02023281|No Intervention|Control Group|Control group will serve as a wait list and not be exposed to the intervention.
88963430|NCT02023281|Experimental|Experimental Group|The experimental group will engage in a mild-moderate level of structured and clinically supervised exercise program for approx. 30-45 mins 2-3 days per week for 12 weeks
88963431|NCT02023294|Active Comparator|Lap|Patients candidate to bariatric surgery undergoing Conventional laparoscopic Sleeve Gastrectomy
88963432|NCT02023294|Experimental|SILS|Patients candidate to bariatric surgery undergoing Single Incision Laparoscopic Sleeve Gastrectomy supported by Endograb
88963433|NCT02023307|Experimental|Rhytidectomy with Covidien|25 patients receiving a mid-face lift in short-flap rhytidectomy
89556641|NCT05990023|Active Comparator|Traditional vestibule rehabilitation training|The intervention for the control group primarily follows conventional rehabilitation methods but incorporates the computerized training system developed in this project.
88963434|NCT02023320|Experimental|Low dose of blueberry dry powder|0.5 g blueberry dry powder, twice a day for 12 weeks
89556642|NCT05990023|Experimental|Dual-task vestibule rehabilitation training|The intervention for the experimental group is based on the intervention for the control group, with additional components based on the findings from the second year of the study. These dual-task exercises are integrated into the training using the computerized training system and provided to the experimental group.
89556643|NCT05989984|Experimental|ODF Iron Supplement|ODF iron supplement contains 30 mg of elemental iron (corresponding to 120 mg of ferric pyrophosphate) and 400 μg of folic acid.
89556644|NCT05989984|Active Comparator|Iron Supplement in Capsule|Iron supplement in capsule contains 30 mg of elemental iron (corresponding to 120 mg of ferric pyrophosphate) and 70 mg of vitamin C.
89556645|NCT05989971||Extracorporeal carbon dioxide removal combined with continuous renal replacement therapy|extracorporeal carbon dioxide removal combined with continuous veno-venous hemofiltration or continuous veno-venous hemodialysis.CVVH and CVVHD set-up: predilution 30 ml/kg/h, dialysate dose 30 ml/kg/h, ultrafiltration rate was equal to the total rate of substitution fluid infusion.
89556646|NCT05989893|Experimental|Neural recordings and stimulation during language tasks|
89556647|NCT05989880|Experimental|SafeLM as a supraglottic airway device with video capability|
89556648|NCT05989880|Experimental|SafeLM as a supraglottic airway device without video capability|
88963435|NCT02023320|Experimental|High dose of blueberry dry powder|5.0 g blueberry dry powder, twice a day for 12 weeks
88963436|NCT02023346||Malignant Glioma patients|This is a cross-sectional study of patients with MG who are admitted to the inpatient Neurology service at MSKCC. We anticipate that participants will be accrued over approximately 18-24 months. All patients with MG admitted to Neurology, will be screened for eligibility and willingness to participate in the study.
88963437|NCT02023359||Treatment|Everolimus and exemestane
88963438|NCT02023372|Other|NuCel with Autograft|NuCel will be used with local autograft during surgical treatment of one, two or three level degenerative disease of the lumbar spine
88963439|NCT02023385|Experimental|LLLT group|Subjects in the Low Level Laser Therapy (LLLT) group will be treated with the BTL-9000 LLLT
88963440|NCT02023385|Placebo Comparator|Placebo group|Subjects in the Placebo group with be treated with the sham BTL-9000 LLLT
88963441|NCT02023398|Experimental|HFT group|Subjects in the High Frequency Therapy (HFT) group will be treated with the BTL-9000 HFT
88963442|NCT02023398|Placebo Comparator|Placebo group|Subjects in the Placebo group with be treated with the sham BTL-9000 HFT
88963443|NCT02023424|Experimental|Copaxone|Glatiramer Acetate (Copaxone® , Teva Pharmaceutical Industries Ltd.) 20 mg daily or in an interval determined in the Dose Setting period. Administration will be subcutaneous to various areas on the body: back of the upper arms (2 areas), front and outside of thighs (2 areas), upper buttocks/rear hips (2 areas), and stomach (the abdomen).
88963444|NCT02023437|Experimental|Experimental: Femtosecond laser cataract surgery|"Laser group: a pre-fragmentation of the ocular lens will be performed by VICTUS femtosecond laser lens fragmentation procedure."
88963445|NCT02023437|Active Comparator|Manual cataract surgery|"Manual: manual group acts as a control group where the lens fragmentation are performed manually without femtosecond laser assisted lens fragmentation"
88963446|NCT02023450|Experimental|micro/low dose saquinavir and ritonavir|To determine if micro dose and low dose SQV+RIT mediates parameters of chronic inflammation in patients with IPAH.
88963447|NCT02023450|Experimental|standard dose saquinavir and ritonavir|To determine if short-term use of SQV+RIT reduces parameters of chronic inflammation and PA pressure of IPAH based on echocardiographic parameters. Safety issue also evaluated at the same time.
88963448|NCT02023476|Experimental|wide tourniquet|(Zimmer A.T.S.®3000 ) wide tourniquet MRI intervention
88963449|NCT02023476|Active Comparator|narrow tourniquet|HemaClear ™ tourniquet MRI intervention
88963450|NCT02023489|Other|Type 2 Diabetes Mellitus|
88963451|NCT02023489|Other|Insulin sensitive volunteers|
88963452|NCT02023489|Other|prediabetic subjects|
88963453|NCT02023489|Other|familiar hypocalciuric hypercalcemic patients|
88963454|NCT02023489|Other|Type 1 diabetes mellitus|
88963455|NCT02023541|Other|Resectable disease|Patients with resectable disease will undergo treatment with proton beam therapy.
88963456|NCT02023541|Other|Unresectable disease|Patients with unresectable disease will undergo treatment with proton beam therapy.
88963457|NCT02023554|Experimental|Theophylline with azithromycin|steady-state plasma concentration of theophylline in the presence of azithromycin
88963458|NCT02023554|Active Comparator|Theophylline alone|steady-state plasma concentration of theophylline alone
89025957|NCT03273062|Placebo Comparator|Study Period 2|"15 days of Placebo pill TID~OR~Active Comparator 15 days of Tolcapone 200mg TID"
89556649|NCT05989880|Experimental|SafeLM as a conduit for intubation using an endotracheal tube with video capability|
89556650|NCT05989880|Experimental|SafeLM as a conduit for intubation using a bougie with video capability|
89556651|NCT05989867||CP|patients with chronic pancreatitis but not combined with diabetes
89556652|NCT05989867||PPDM-C|patients with post-chronic pancreatitis diabetes mellitus
89556653|NCT05989867||CP+IGT|patients with chronic pancreatitis combined with impaired glucose tolerance
89556654|NCT05989867||CP+T2DM|patients with chronic pancreatitis combined with type 2 diabetes mellitus
89556655|NCT05989854|Experimental|Exercise|Exercise arm
89556656|NCT05989789|Other|Radioactive seed-guided resection of cholangiocellular carcinoma in cirrhotic patients|"Detection of cholangiocellular and hepatocellular carcinomas can be challenging in both radiologic imaging and during surgical resection. Therefore, radioactive seed-guided resection of these tumors, analogously to breast cancer, could be an interesting approach.~This report emphasizes the difficulties, which surgeons and radiologists may face in tumor entities that are difficult to identify both macroscopically, by palpation and intraoperative imaging techniques. It also highlights the successful adaption of a procedure commonly used for breast cancer surgery for liver surgery"
89556657|NCT05989659||Patient - Home Dialysis|Patients transitioning to home dialysis
89556658|NCT05989659||Patient - Facility Hemodialysis|Patients transitioning to facility hemodialysis
89556659|NCT05989659||Caregivers - Home dialysis|Caregivers of patients transitioning to home dialysis
89556660|NCT05989659||Caregivers - Facility Hemodialysis|Caregivers of patients transitioning to facility hemodialysis
89556661|NCT05989646|Experimental|Transcutaneous Electric Nerve Stimulation (TENS)|Sacral TENS
89556662|NCT05989607|Experimental|Low Sugar Flavored Water|A commercially available low sugar flavored water (2.88kcal/100ml; 0.57(sugar) +0.03 (stevia)=0.60g/100ml; sodium 7.9mg/100ml).
89556663|NCT05989607|Active Comparator|Plain Water|Plain water (bottled, spring).
89556664|NCT05989594|Active Comparator|The REHAB-TAVR group|For the REHAB-TAVR group, discharge preparation will involve an exercise endurance test, exercise prescription guidance, motivational interviews, instruction on telerehabilitation, and the provision of family and peer support. Following discharge, patients will be required to adhere to their personalized exercise prescription and attend scheduled onsite follow-ups after discharge. The management model employed for this group is called home-based mobile guided exercise-based cardiac rehabilitation.
89556665|NCT05989594|Other|The Routine-TAVR group|Preparation for discharge will only involve an exercise endurance test and the guidance of an exercise prescription for the Routine-TAVR group. Following discharge, nurses will conduct monthly telephone follow-ups to check on the patient's progress. Additionally, patients will be scheduled for onsite follow-ups at the Outpatient Department.
89556666|NCT05988879||ART combined with interferon group|The treatment protocol is ART combined with pegylated interferon α-2b injection. The pegylated interferon α-2b injection is administered subcutaneously at a dose of 180ug once a week. Follow-up times are at baseline, and during treatment at weeks 4, 8, 12, 24, 36, 48, 60, and 72.
89556667|NCT05988879||ART group|Continuously using ART treatment, without the use of interferon. Follow-up times are at baseline, and during treatment at weeks 12, 24, 36, 48, 60, and 72.
89556668|NCT05988593|Placebo Comparator|placebo drink|
89556669|NCT05988593|Experimental|MelaGene+|
89556670|NCT05987826|Experimental|Furmonertinib (AST2818) 80mg QD group|All patients enrolled into this study will receive furmonertinib 80mg for 8 weeks neoadjuvant therapy before surgery.
89556671|NCT05985993|Active Comparator|single-target group (left DLPFC)|34 eligible patients will be treated with active TUS for 4 weeks on the left DLPFC
89556672|NCT05985993|Active Comparator|both-target group (both left DLPFC and right STG)|34 eligible patients will be treated with active TUS for 4 weeks on the both left DLPFC and right STG
89556673|NCT05985993|Sham Comparator|sham group|34 eligible patients will be treated with sham TUS for 4 weeks on the left DLPFC
89556674|NCT05985824|Experimental|Applications to the Intervention Group|Patients with lung cancer admitted to the outpatient chemotherapy unit will be given pranayama breathing exercises every day for 4 weeks, covering 15-20 minutes. In patient education, the pranayama breathing exercise will be applied face-to-face by the researcher on the first day of chemotherapy treatment, before drug treatment. The application steps will be repeated until the patient learns, both by explaining and showing the patient, and if there are points that the patient cannot do, they will be corrected. When the patients are observed to perform the application fully and the chemotherapy treatments are finished, they will be asked to do the pranayama breathing exercise every day for 4 weeks, and with the same researcher 3 days a week (Monday, Wednesday, Saturday) with a smart phone whatsapp video call, the effectiveness and continuity of the application will be ensured and the patients will be monitored.
89556675|NCT05985824|No Intervention|Applications to the Control Group|A pre-test will be applied to lung cancer patients in the control group who applied to the day chemotherapy unit. After the application of the personal information form and the quality of life scale, no breathing exercises will be performed. Individuals will continue their daily lives. After 4 weeks, the quality of life scale will be administered again. After the implementation of the quality of life scale, pranayama breathing exercise training will be given to all control group patients and they will be applied for 2 sessions.(The study will begin before the patients in both the experimental and control groups receive chemotherapy, which is their routine treatment).
89556676|NCT05985421||Patients|
89556677|NCT05985421||Control|
89556678|NCT05985356|Experimental|iTBS|intermittent Theta Burst Stimulation (a form of transcranial magnetic stimulation) targeting the left dorsolateral prefrontal cortex
89556679|NCT05980286|Experimental|Piano Improvisation|This intervention will involve group piano improvisation training sessions once a week for 12 weeks, in addition to daily in-home practice for 4-5 days.
89556680|NCT05980286|Active Comparator|Music Listening|The music listening condition will involve group music listening sessions (led by a trained instructor) once a week for 12 weeks and daily in-home music listening practice.
89556681|NCT05979701|No Intervention|Theoretical education|
89556682|NCT05979701|Experimental|Theoretical education PLUS simulation training|
88963459|NCT02023567|Experimental|MDD group|Drugs: SSRIs fluoxertine hydrochloride (20- 60m/day),paroxetine hydrochloride (20- 60m/day),sertraline hydrochloride (50- 200m/day),citalopram (20-60m/day), escitalopram (10-20mg/day),fluvoxamine (50-300mg/day)
89556683|NCT05973838|Experimental|"Peer-Delivered Behavioral Activation (Peer Activate)"|Participants in the Peer Activate intervention will receive a PRS-delivered behavioral activation intervention to address barriers to retention in methadone treatment and increase substance-free, positive reinforcement to support retention and reduce polysubstance use.
89556684|NCT05973838|No Intervention|Treatment As Usual|Participants in the TAU group will receive enhanced treatment as usual, defined as MTU services as usual enhanced with additional community referrals and follow-ups on those referrals, in addition to regular meetings with an addiction medicine physician and PRS on the MTU. Standard PRS contact typically includes connection to local resources and general peer support as needed.
89556685|NCT05968131|Active Comparator|Conventional Physical Therapy|Conventional Physical Therapy will consist of application heat pack, ROM exercises, stretching, and strengthening exercises
89556686|NCT05968131|Experimental|Conventional Physical Therapy with Proprioceptive Training Exercises|Conventional Physical Therapy with Proprioceptive Training Exercises
89556687|NCT05967858||gastroenterological|Consecutive admissions - n= 43 - 34 operated (79%) - 10 patients acutely admitted Diseases in Esophagus (8), gastric cavity (8), pancreas (7), colon/rectum (8), bile (4), small intestine (3), IBD (5) No interventions in the treatments, just observation
89556688|NCT05967858||head and neck cancer|Consecutive admissions - n=8 - 7 radiation therapy - 1 operated Locations: 2 Larynx, 1 oro-pharynx, 4 tonsillar, 1 tung No interventions in the treatments, just observation
89556689|NCT05965505|Experimental|AXT-1003|"Dose Escalation: Level 1 (Starting Dose) Oral AXT-1003 100 mg BID; Level 2 Oral AXT-1003 200mg BID; Level 3 Oral AXT-1003 300mg BID ; Level 4 Oral AXT-1003 450mg BID; Level 5 Oral AXT-1003 600mg BID; Level 6 Oral AXT-1003 750mg BID~Dose Expansion: 1 or 2 cohorts at the dose levels selected from dose escalation part"
89556690|NCT05945017|Experimental|Bifidobacterium bifidum NCDO 2203 and Lactobacillus acidophilus NCDO 1748|Daily dose of 6x109 UFC Infloran® -Berne, Switzerland- (Bifidobacterium bifidum NCDO 2203 and Lactobacillus acidophilus NCDO 1748) from 7 days of life until reaching a postmenstrual age of 34 weeks or discharge
89556691|NCT05945017|No Intervention|Control|Untreated control group
89556692|NCT05940077|Experimental|Community-based exercise|
89556693|NCT05918601|Experimental|Intervention group|Each participant will receive the telephone that will be delivered by a trained peer supporter using the Ask, Warn, Advise, Refer and Do-it-Again (AWARD) model. For the advice steps, participants will be asked about the priority they place on engagement in health-related lifestyles. A brief intervention on the selected health-related lifestyle will be given. In addition, they will be informed that they will receive instant messaging via WeChat or WhatsApp to assist them to adhere to their schedule of the desirable health-related lifestyle throughout the study period. For the first 6 months of the study period, peer supporters will send WhatsApp or WeChat messages approximately once per week to the participants to remind them to adhere to their schedule of the desirable health-related lifestyle. In addition, the participants will receive four independent 1-minute videos which focus on the health risks associated with abusing drugs and the benefits of quitting drugs.
89556694|NCT05918601|Placebo Comparator|Control Group|Trained peer supporters will answer calls from potential participants and explain the nature and purpose of the project to them. Each participant will then receive a brief intervention over the telephone that will be delivered by a trained peer supporter using the Ask, Warn, Advise, Refer and Do-it-Again (AWARD) model. Participants will be asked to quit drugs immediately or progressively. In addition, they will be informed that they will receive instant messaging via WeChat or WhatsApp from peer supporters to assist them to adhere to their schedule of quitting drugs throughout the study period. For the first six months, participants will receive four independent 1-minute videos which focus on the health risks associated with abusing drugs and the benefits of quitting drugs without any schedule of the desirable health-related lifestyle throughout the study period.
89556695|NCT05918159||Elderly|Group of 274 elderly
89556696|NCT05915949|Experimental|Dapagliflozin|Dapagliflozin 10 mg once daily will be given to participants.
89556697|NCT05915949|Active Comparator|Lobeglitazone|Lobeglitazone 0.5 mg once daily will be given to participants.
89556698|NCT05915949|Active Comparator|Dapagliflozin and Lobeglitazone combined|Dapagliflozin 10 mg and lobeglitazone 0.5 mg once daily together will be given to participants.
89556699|NCT05902455||Patients diagnosed with oral squamous cell carcinoma|
89556700|NCT05888441|Experimental|Low Vision Group|At a single study visit, the group of low vision participants will be asked to perform a series of short walking trials. During each trial they will walk at a self-selected speed along a walkway (6 meters in length) that may or may not contain an obstacle to step over. The trials will be randomly varied with regard to an obstacle's presence, height, and contrast from the walkway surface. Repeated trials of each condition variation will be performed during the visit.
89556701|NCT05888441|Active Comparator|Control Group|At a single study visit, the group of age-matched participants without low vision will be asked to perform a series of short walking trials. During each trial they will walk at a self-selected speed along a walkway (6 meters in length) that may or may not contain an obstacle to step over. The trials will be randomly varied with regard to an obstacle's presence, height, and contrast from the walkway surface. Repeated trials of each condition variation will be performed during the visit.
89556702|NCT05874037|Experimental|Fluvoxamine|
89556703|NCT05874037|Placebo Comparator|Placebo|
89556704|NCT05864573|Experimental|ZGGS15|
88963460|NCT02023567|No Intervention|Healthy controls|This group just receive baseline evaluation and did not receive any intervention.
89025958|NCT00464321|Experimental|Cohort A|Dose Group
89025959|NCT00464321|Experimental|Cohort B|Dose Group
89556705|NCT05855941||Cervix cancer|Newly diagnosed cervix cancer.
89556706|NCT05855941||Endometrial cancer|Newly diagnosed endometrial cancer.
89556707|NCT05855941||Ovarian cancer|Strong suspicion of newly diagnosed epithelial ovarian cancer; histopathological confirmation required within 6 months after inclusion.
89556708|NCT05840198|Experimental|Active intervention|Half of youth will be assigned to the active Recovery & Care Canine-Assisted Therapy intervention arm.
89556709|NCT05840198|Other|Waitlist control|Half of youth will receive treatment as usual.
89556710|NCT05825365|Active Comparator|Selumetinib|Participants will orally receive selumetinib twice daily (BID) (approximately every 12 hours) at a dose of 25 mg per square meter of body surface area (BSA) on a continuous dosing schedule (28-day per cycle with no rest periods between cycles) for a maximum of 36 cycles.
89556711|NCT05825365|Placebo Comparator|Placebo|Participants will orally receive placebo twice daily (BID) (approximately every12 hours) at a dose of 25 mg per square meter of body surface area (BSA) on a continuous dosing schedule (28-day per cycle with no rest periods between cycles) for a maximum of 36 cycles. Transfer to selumetinib on REiNS-defined PD.
88963461|NCT02023580|Experimental|Intervention|The Video Treatment arm will complete baseline, 3-, 6-, 9-, and 12-month online survey assessments. Between baseline and 3-month follow-up, men will view 6 video vignettes (participants will receive a link to view a video vignette once a week for 6 weeks). Based on our team's experience of attenuated intervention effects at 6 months, men will receive 4 video boosters, spaced 1 week apart, after the 6-month assessment survey. Spacing the dose over time can improve critical thinking. The additional videos will be a continuation of the dramatic series plus additional video scenes on disclosure and serodiscordant partnerships.
88963462|NCT02023580|Active Comparator|Control|The video control arm will complete baseline, 3-, 6-, 9-, and 12-month online survey assessments. The control arm will receive the same number (and timing of) video clips as the intervention arm, but from a non-theoretically driven gay-oriented show with videos that are similar in length in order to preserve dosing equality across both arms. As the video treatment arm will be provided efficacious theory-driven videos, investigators expect to find a significant decrease in sexual risk behaviors in the intervention arm, compared to the control arm. Should this occur by month 6, with agreement from the data safety monitoring board (DSMB), investigators will provide the control arm with the video treatments.
88963463|NCT02023606|Experimental|SPN-810M|Single dose of 20 mL solution containing 50 mg of SPN-810M and no less than 8.5 MBq (225 µCi) carbon-14 (14C)-SPN-810M, and no more than 11.3 MBq (305 µCi) [14C] SPN-810M.
88963464|NCT02023619||Keratoconus|Eyes with confirmed keratoconus diagnosis
88963465|NCT02023619||Astigmatism >2.0 D|Healthy eyes with astigmatism >2.0 D
88963466|NCT02023632|Experimental|Similar-Age-Same-Gender (SASG)|Participants in this trial arm will be of similar age (65+) and of the same gender (i.e., separate groups for male older adults and female older adults).
88963467|NCT02023632|Active Comparator|Similar-Age-Mixed-Gender (SAMG)|This group will include participants of both genders who are similar aged (65+).
88963468|NCT02023632|Sham Comparator|Mixed-Age-Mixed-Gender (MASG)|This group is used as the 'standard' group based exercise course; including those of mixed age and mixed gender.
88963469|NCT02023645|Experimental|Active supplement|10 mg lutein + 2 mg zeaxanthin
88963470|NCT02023645|Placebo Comparator|inert placebo|placebo for comparison
88963471|NCT02023658|Experimental|Systems analysis and improvement|pMTCT systems analysis and improvement
88963472|NCT02023658|No Intervention|Control|No systems analysis and improvement intervention for prevention of mother to child HIV transmission services in place.
88963473|NCT02023684|Placebo Comparator|control|Irrigation will be carried out with saline
88963474|NCT02023684|Active Comparator|Lidocaine|Irrigation will be carried out with Lidocaine
88963475|NCT02023684|Active Comparator|Ropivacaine|Irrigation will be carried out with Ropivacaine
88963476|NCT02023710|Experimental|BEV plus Chemotherapy|Paclitaxel 175mg/m2, d1; Carboplatin AUC=5, d1; Bevacizumab 5mg/kg, d1、15; 28 days a cycle
88963477|NCT02023710|Active Comparator|Chemotherapy alone|Paclitaxel 175mg/m2, d1; Carboplatin AUC=5, d1; 28 days a cycle
88963478|NCT02023723|Experimental|Energy Drink|16oz original flavor energy drink consume 2 -16oz energy drinks within 60 minutes
88963479|NCT02023723|Active Comparator|Active Control|16oz control drink: Caffeine 160mg, Sucrose 115g consume 2 - 16oz drinks within 60 minutes
88963480|NCT02023736|Active Comparator|Treatment as Usual|Patients in the Treatment as Usual condition receive the same psychotherapy treatment as they would were they not enrolled in the study.
88963481|NCT02023736|Experimental|Treatment as Usual with the STIC (TAU + STIC)|Patients in the TAU + STIC condition receive the treatment that they normally would from their therapist, but with the addition of the STIC measurement and feedback system.
88963482|NCT02023749|Active Comparator|Nut group|Subjects were supplemented with 30 g of mixed nuts including walnuts, peanuts, and pine nuts for 6 weeks
89556712|NCT05814939|Experimental|VC005 Tablets Low Dose groups|
89556713|NCT05814939|Experimental|VC005 Tablets Medium Dose groups|
89556714|NCT05814939|Experimental|VC005 Tablets High Dose groups|
89556715|NCT05814939|Active Comparator|Tofacitinib Citrate Tablets groups|
89556716|NCT05814939|Placebo Comparator|VC005 Tablets Placebo groups|
89556717|NCT05811234||CAL/BDP PAD Cream:|Participants who have been prescribed CAL/BDP PAD cream treatment to manage plaque psoriasis of the scalp according to summary of product characteristic (SmPC) in routine clinical practice settings will be observed prospectively for up to 8-12 weeks.
89556718|NCT05795049||IBS Patient|IBS patient with diarrhoea or alternating bowel habit
89556719|NCT05795049||Healthy subject|Participants without IBS
89556720|NCT05786014|Experimental|Moderate Intensity Walking|Subjects allocated to moderate intensity walking will be given a gift card to purchase a paid of running shoes. A chest-based heart rate monitor and an activity tracker watch will be provided. Subjects will aim to achieve 150 minutes a week of moderate intensity walking. Subjects will also be receiving text messages, phone calls, and emails from study staff to gauge and encourage subject participation and physical activity.
89208250|NCT00284089|Experimental|Group B: Ranibizumab 0.3 mg|Group B patients received a total of 12 monthly intravitreal injections of 0.3 mg of ranibizumab into the study eye in the multiple dose phase of the study. Group B patients who enrolled in the extension phase received an intravitreal injection of 0.3 mg of ranibizumab according to an individualized flexible interval regimen guided by monthly best corrected visual acuity scores and other ophthalmic examinations. In the extension phase patients received the same dose level as they received in the multiple dose phase of the study, for an average of 1.45 years.
89556721|NCT05786014|Experimental|High Intensity Interval Exercise|Subjects will receive a recumbent bike to be delivered and assembled to their home as well as a heart rate monitor and activity tracker. Subjects will undergo high intensity interval exercise 3 days a week, with the goal of achieving 85-90% of their heart rate max. Subjects will also be receiving text messages, phone calls, and emails from study staff to gauge and encourage subject participation and physical activity.
89556722|NCT05783505|Experimental|Treatment group|Multicomponent intervention program
89556723|NCT05783505|No Intervention|Control group|Standard care
89556724|NCT05782686|Experimental|Shaving|Subsequent to lumpectomy, a circumferential enlargement of all lumpectomy margins, including lateral, medial, superior, inferior, anterior, and posterior, approximately 5-10mm thick, will be resected.
89556725|NCT05782686|Active Comparator|No Shaving|Standard lumpectomy
89556726|NCT05732389|Experimental|nivolumab + ipilimumab|"Patients will be treated with 1 or 2 cycles of combination immunotherapy:~Cycle 1: Nivolumab 3 mg/kg days 1 and 15 & ipilimumab 1 mg/kg day 1 Cycle 2: Nivolumab 3 mg/kg days 50 and 65 & ipilimumab 1 mg/kg day 50"
89556727|NCT05716841|No Intervention|Control Group|It was treated with stretching and simple baseline strengthening of the upper limb through any regular mean (like TheraBand) in a moderate manner with 10 to 20 repetitions for 3 days per week for six weeks.
89556728|NCT05716841|Experimental|Experimental group|This experimental group was treated with stretching and then strengthening of the upper limb through ballistic six exercises from a moderate to intense manner with 3 sets of 10 repetitions with a 30 sec gap between sets, 3 sets of 15 repetitions with a 30sec gap between sets, and 3 sets of 20 repetitions with a 30sec gap between sets for 3 to 4 days per week for six weeks.
89556729|NCT05712408|Experimental|Diet Intervention|8 week non-restrictive diet program
89556730|NCT05699538|Experimental|Minimal-Dose Home-Based Resistance Exercise|8-week home-based resistance exercise performed one day per week.
88963483|NCT02023749|No Intervention|Control group|Control group maintained their usual diet without nut supplement
88963484|NCT02023775||Patients implanted with Medtronic Melody valve|All patients that received a valve implantation were included in the registry.
89556731|NCT05699538|No Intervention|Standard of Care|Subjects will be asked to follow standard of care recommendations as prescribed by the physician.
89556732|NCT05698511|Experimental|Psilocybin|Healthy volunteers will receive up to four doses of psilocybin separated from each other by at least one week. The first dosing session will involve 10 mg psilocybin, the remaining three dosing sessions will receive up to 25mg psilocybin.
89556733|NCT05690672|Active Comparator|3D-CAM screening|
89556734|NCT05690672|Active Comparator|4AT screening|
89556735|NCT05675488||Trigger Finger Patients|
89556736|NCT05675488||Healthy individuals|
89556737|NCT05671029|Experimental|Group 1|"Subjects (32 male and female subjects) receive 400 mg pritelivir on Day 1, 100 mg pritelivir from Day 2 to 6 and 400 mg pritelivir from Day 7 to 16.~Furthermore, these subjects receive 400mg moxifloxacin matching placebo on the Days 2 and 17."
89556738|NCT05671029|Experimental|Group 2a|"Subjects (16 male and female subjects) receive 400 mg pritelivir matching placebo on Day 1, 100mg pritelivir matching placebo from Day 2 to Day 16.~Furthermore, these subjects receive 400 mg moxifloxacin on Day 2 and 400 mg moxifloxacin matching placebo on Day 17."
89556739|NCT05671029|Experimental|Group 2b|"Subjects (16 male and female subjects) receive 400 mg pritelivir placebo on Day 1, 100mg pritelivir placebo from Day 2 to Day 16.~Furthermore, these subjects receive 400 mg moxifloxacin matching placebo on Day 2 and 400 mg moxifloxacin on Day 17."
89556740|NCT05669443|Experimental|conventional PEEP|Apply of PEEP 5
89556741|NCT05669443|Active Comparator|optimized PEEP|Apply of optimized PEEP derived using EIT (airtom®)
89556742|NCT05653921|Other|Dry Eye Disease Group|Symptoms of ocular surface discomfort or dry eye disease for at least 3 months, supported by clinical exam findings. Reported quality of life is not effected by ocular pain.
89556743|NCT05653921|Other|Neuropathic Corneal Pain Group|Symptoms of ocular surface discomfort or pain for at least 3 months, that are reported to have a significant impact on quality of life and ability to perform daily activities.
89556744|NCT05653921|Other|Control Group|No symptoms of ocular surface discomfort or dry eye disease.
88963485|NCT02023788||Pneumostem®|"Low Dose Group (3 subjects): 1.0 x 10^7 cells/kg, High Dose Group (6 subjects): 2.0 x 10^7 cells/kg~Intervention: Biological: Pneumostem®"
88963486|NCT02023814||Study group|All patients who underwent stem cell mobilization after chemotherapy and G-CSF at our institution between 2002 and 2013
88963487|NCT02023827|Experimental|RAYS intervention|In addition to standard care, participants receive three monthly online RAYS sessions, each followed by a one-on-one discussion with the probation officer
88963488|NCT02023827|No Intervention|Standard care|Participants receive standard care from the probation officer
88963489|NCT02023840|Active Comparator|ultrasonics and erythritol, metronidazole gel|Scaling and root planing with ultrasonics and erythritol air powder will be followed by application of metronidazole gel
88963490|NCT02023840|Placebo Comparator|ultrasonics and erythritol, placebo|Scaling and root planing with ultrasonics and erythritol air powder will be followed by application of placebo
88963491|NCT02023853|Experimental|ultrasonic, erythritol, metronidazole gel|
88963492|NCT02023892|Experimental|atorvastatin|atorvastatin 20mg tablet, single dose of 80mg by mouth
88963493|NCT02023892|Placebo Comparator|placebo|placebo 20mg tablet, single dose of 80mg by mouth
88963494|NCT02023931|Experimental|Broccoli Sprout Extract Drink|Three different regimens of BSE delivery will be evaluated in each participant, with participants serving as their own controls. Each regimen will involve a 3 day exposure, with daily collection of buccal cell scrapings. Between regimens, a minimum 3 day (72 hour) washout period will occur.
89556745|NCT05643469|Experimental|Intervention group|Each subject will receive a specially designed leaflet for smokers with cancer. subjects will receive brief interventions using the AWARD model and they will be allowed to select their own quit schedules (quit immediately, or quit progressively) with the ultimate goal of complete cessation. Subjects who opt to quit progressively will receive a smoking reduction leaflet. Over the next 6 months, the research nurse will help them to adhere to their schedules by sending WhatsApp/WeChat messages. subjects will receive four independent 1-minute videos (one video will be sent in weeks 1, 5, 9, and 13) via WhatsApp/WeChat.
89556746|NCT05643469|Placebo Comparator|Control group|Subjects will receive a brief intervention using the AWARD model. However, all subjects will be advised to quit immediately. Control group subjects will receive the same leaflet for smokers with cancer as intervention group subjects. Subjects will receive a placebo intervention that follows the same WhatsApp/WeChat schedule as the intervention group, but the messages will contain only general health advice, such as to perform more physical activity and eat more fruit and vegetables. The control group will not receive any videos.
88963495|NCT02023957|Experimental|Interactive computer-assisted screening|Eligible patients completed the interactive computer-assisted screening (iCAS) tool in English or Spanish before seeing the consenting clinician. Participating patients then received the iCAS generated tailored recommendation sheet. Participating clinicians received the iCAS generated risk report.
89556747|NCT05633615|Experimental|Step I (lymphodepleting chemotherapy)|Patients receive lymphodepleting chemotherapy consisting of fludarabine IV and cyclophosphamide IV on study. Patients then receive tisagenlecleucel IV, axicabtagene ciloleucel IV, or lisocabtagene maraleucel IV on study.
89556748|NCT05633615|Experimental|Step II Arm I (mosunetuzumab)|Patients receive mosunetuzumab IV on study. Patients also undergo PET-CT and/or CT and undergo collection of blood and tissue samples throughout the study.
88963496|NCT02023957|No Intervention|Usual Care|Eligible patients randomized to the control group completed their standard visit to the participating clinician. There was no pre-visit health risk screening. There were no tailored reports for the patients or clinicians.
88963497|NCT02023970|Other|Phase A: Diagnostic Study|Objective: to assess the differential immune response in patients with or without SVD (given the low rate of SVD) a matched cases-controls study allows a powerful statistical analysis avoiding main confounding factors for a first discovery of a SVD-specific immune response. Results will be validated in prospective Phase B.
88963498|NCT02023970|Other|Phase B1 (Prospective Study): Cohort of prevalent patients|This cohort is specifically designed to study the kinetics of the immune response before and after implantation of an aortic BHV. Eight of the most frequently implanted BHV worldwide will be assessed:
88963499|NCT02023970|Other|Phase B2 (Prospective Study): Cohort of incident patients|Due to the low incidence of SVD during the first 4 post-operative years, a second cohort will be constituted by patients undergone biological aortic valve replacement at least 5 years before. The objective of this second cohort is to cover a period of time where risk of SVD occurrence is potentially high.
88963500|NCT02024009|Experimental|Arm A|"12 weeks (3 cycles) of induction Gemcitabine and Nab-paclitaxel (GEMABX) chemotherapy then 1 cycle of GEMABX* whilst radiotherapy (RT) planned then capecitabine (830mg/m2 oral bd) + Nelfinavir** + 50.4 Grays (Gy) in 28#~*1 cycle GEMABX = 28 day cycle of intravenous Abraxane 125mg/m2 followed by gemcitabine 1000mg/m2 on day 1, 8 and 15."
88963501|NCT02024009|Experimental|Arm B|"12 weeks (3 cycles) of induction GEMABX chemotherapy then 1 cycle of GEMABX* whilst RT planned then capecitabine (830mg/m2 oral bd) + 50.4Gy in 28#~*1 cycle GEMABX = 28 day cycle of intravenous Abraxane 125mg/m2 followed by gemcitabine 1000mg/m2 on day 1, 8 and 15."
88963502|NCT02024009|Experimental|Arm C|"12 weeks (3 cycles) of induction GEMABX chemotherapy then~1 cycle of GEMABX* whilst RT planned then capecitabine (830mg/m2 oral bd) + Nelfinavir** + 60Gy in 30#~*1 cycle GEMABX = 28 day cycle of intravenous Abraxane 125mg/m2 followed by gemcitabine 1000mg/m2 on day 1, 8 and 15"
88963503|NCT02024009|Experimental|Arm D|"12 weeks (3 cycles) of induction GEMABX chemotherapy then~1 cycle of GEMABX* whilst RT planned then capecitabine (830mg/m2 oral bd) + 60Gy in 30#~*1 cycle GEMABX = 28 day cycle of intravenous Abraxane 125mg/m2 followed by gemcitabine 1000mg/m2 on day 1, 8 and 15."
89025960|NCT00464321|Experimental|Cohort C|Dose Group
89025961|NCT00464321|Experimental|Cohort D|Dose Group
89025962|NCT03272984|Experimental|ERAS group|Patients will undergo the ERAS programs.
89025963|NCT03272984|Other|SC group|Patients will undergo the SC group.
89025964|NCT00498147||ADEC <6months|Patients new to the ADEC program who will be provided the ADEC interventions (prospective study)
89556749|NCT05633615|Experimental|Step II Arm II (polatuzumab vedotin)|Patients receive polatuzumab vedotin IV on study. Patients also undergo PET-CT and/or CT and undergo collection of blood and tissue samples throughout the study.
89556750|NCT05633615|Experimental|Step II Arm III (polatuzumab vedotin, mosunetuzumab)|Patients receive polatuzumab vedotin IV and mosunetuzumab IV on study. Patients also undergo PET-CT and/or CT and undergo collection of blood and tissue samples throughout the study.
89556751|NCT05633615|Active Comparator|Step II Arm IV (observation)|Patients undergo observation on study. Patients also undergo PET-CT and/or CT and undergo collection of blood and tissue samples throughout the study. Patients with subsequent progression within 12 months of CAR T-cell therapy may crossover to Arm III.
89556752|NCT05619510|Other|Wait List Control Group|This group will be randomized to wait list control. They will serve as a control for the intervention at time points 1 and 2. However after a 2-3 month period they will receive the intervention.
89556753|NCT05619510|Experimental|Intervention Group|Individuals randomized to this group will start the intervention immediately and have outcomes measured at three time points.
89556754|NCT05608070|Experimental|IV Oxytocin|
89556755|NCT05608070|Placebo Comparator|Placebo- NaCl 0.9%|
89556756|NCT05587543|Experimental|CAR-T|Target A positivity was assigned to CAR-T cell therapy.
89556757|NCT05587543|Experimental|TCR-T|Target A negative, Target B positive and Target C positive were assigned to TCR-T cell treatment group.
89556758|NCT05587504|Experimental|Cigarette and/or e-Cigarette users|Each participant will participate in 4 sessions. During each session, participants will first complete a 10-puff product use period with the ECIG assigned for that session, then a 30-minute ad lib product use period, and then a cigarette/e-cigarette challenge paradigm.
89556759|NCT05579470|Other|NIATx Model|Receiving NIATx Coaching
89556760|NCT05564130|Experimental|Sodium bicarbonate|50 ml of 1 mmol/ml sodium bicarbonate given as soon as possible after the first dose of adrenaline. If the patient remains in cardiac arrest, one additional dose of 50 ml of 1 mmol/ml sodium bicarbonate will be administered after the second dose of adrenaline dose for a maximum of two doses.
89556761|NCT05564130|Placebo Comparator|Placebo|"50 mL of 9 mg/mL NaCl (normal saline) given as soon as possible after the first dose of adrenaline. If the patient remains in cardiac arrest, one additional dose of 50 mL of 9 mg/mL NaCl will be administered after the second dose of adrenaline dose for a maximum of two doses."
89556762|NCT05553691|Experimental|Test Cohort|Patients who are currently taking an SSRI that is not effective in fully relieving their depression (prescribed outside of study). Patients will be administered a single dose of SPL026 by intravenous infusion.
89556763|NCT05553691|Experimental|Control Cohort|Patients who are not currently taking any pharmacological treatment for their depression. Patients will be administered a single dose of SPL026 by intravenous infusion.
89556764|NCT05528926|Other|Non-Violent Resistance (NVR) program|The Non-Violent Resistance (NVR) parent group-format program has been designed to develop a positive form of authority based on parental presence, a parental support network, strategies of nonviolent responses which avoid escalation and reconciliation gestures.
89556765|NCT05528926|Other|Parent Management Training (PMT) program based on Barkley's program for defiant children|The Parent Management Treatment (PMT) program is an evidence-based treatment for disruptive behaviour disorder in which the child's social environment is modified according to principles of operant conditioning and contingency management. The parental response to the child's behaviour increases or decreases the likelihood of targeted behaviour.
89556766|NCT05528926|Other|Treatment as usual (TAU)|The TAU group receives non-pharmacological and pharmacological therapies as usually provided in the participating centres but without having had a structured parent program.
88963504|NCT02024009|Experimental|Arm E|"6 cycles of GEMABX*~*1 cycle GEMABX = 28 day cycle of intravenous Abraxane 125mg/m2 followed by gemcitabine 1000mg/m2 on day 1, 8 and 15."
88963505|NCT02024022|Active Comparator|Standard approach|"patients will be randomized to one of the 2 currently used bowel preparation regimens in our clinic:~4L split polyethylene glycol solution~split magnesium citrate/sodium picosulphate preparation regimen"
88963506|NCT02024022|Experimental|Individualized approach|patients will receive either the 4L split polyethylene glycol bowel prep regimen or the sodium picosulphate/magnesium citrate split prep regimen according to personal characteristics assessed using a self-administered questionnaire (including bowel habits, the preference for large-volume preparation and education level)
88963507|NCT02024035||Tomotherapy|
88963508|NCT02024035||Arc'therapy Vmat|
88963509|NCT02024035||Arctherapy Rapid'Arc|
88963510|NCT02024048||Pregnant|OCT
88963511|NCT02024048||Control|OCT
88963512|NCT02024061|Experimental|Peer support|"The intervention will be similar with the exception that in the experimental group during the interventions (Interactive Sessions, Physical activity sessions and holiday camps), the presence of peers is predominant, indispensable and motivational in the context and the dynamics of development of activities.~A team composed by a paediatrician and five exercise physiologists will conduct the delivery of the intervention. They all have previous training in adolescent obesity, resulting from their involvement in the adolescent obesity consult at the Hospital of Santa Maria."
88963513|NCT02024061|Active Comparator|Regular treatment|"The intervention will be similar with the exception that in the experimental group during the interventions (IS, PA sessions and holiday camps), the presence of peers is predominant, indispensible and motivational in the context and the dynamics of development of activities.~A team composed by a paediatrician and five exercise physiologists will conduct the delivery of the intervention. They all have previous training in adolescent obesity, resulting from their involvement in the adolescent obesity consult at the Hospital of Santa Maria."
88963514|NCT02024074|Other|Sestamibi(Tc- MBI) scan of the breast|
88963515|NCT02024113||Lung cancer|"Subjects with lung cancer detected by a computed tomography (CT)-scan and referred to a positron emission tomography (PET)/CT-scan are included. The diagnosis of lung cancer is confirmed by means of an pathological biopsy or by a medical doctor specialized in oncology with respect to radiological or clinical data.~Intervention: a fasted venous blood sample is taken before PET-scan"
88963516|NCT02024113||Control subjects|"The control group consists of subjects who were referred to the department Nuclear Medicine for an examination of the heart. This control group represents the average population, consists of healthy subjects and patients with non-cancer diseases and who did not undergo a PET/CT-scan.~Intervention: fasted venous blood sample"
88963517|NCT02024126|Experimental|High dosage exercise therapy|The high-dosage exercise treatment will be conducted under supervision of experienced physiotherapists, and it follows an exercise protocol previously described as Medical Exercise Therapy, MET. The regimen contains different semi-global and local exercises for the knee. To be able to reach a high number of repetitions despite ongoing pain, the principle of de-loading (reducing weight) will be applied. The use of de-loading allows high number of repetitions nearly or entirely pain free. Later, as the patient improves and tolerates increased loading, the exercises are adapted to be more functional, using closed chain exercises without de-loading the body. Each of the exercises will be performed in 3 sets of 30 repetitions with 30-60s rest in between. Global exercises using a stationary bike will be performed three times during one treatment-session; first 20 minutes as global pain modulation, ten minutes in the middle of the treatment, and then ten minutes at the end of the treatment.
88963518|NCT02024126|Active Comparator|Lower dosage exercise therapy|Patients in the comparison-/control group will perform six exercises, of which, five will be in 2 sets of 10 repetitions combining local and semi-global exercises, again using the principle of de-loading. The five semi-global and local exercises are the same as performed in the MET-group, and the regimen will be supervised in the same manner as for the MET-group. The therapy starts with 10 minutes using a stationary bike, and the same principles will be applied as for the MET-group regarding grading and follow-up with exercises and adjusting the exercises so that they are performed close to pain-free.
88963519|NCT02024139|Experimental|Chewing Sugarless Gum and Mouthwash|Patients are asked to chew sugarless gum 3 times per day in addition to using a fluoridated mouthwash 3 times per day
88963520|NCT02024139|Placebo Comparator|Using fluoridated mouthwash|Using Mouthwash: Patients are asked to use a fluoridated mouthwash 3 times per day as a placebo
88963521|NCT02024178|Experimental|Ultrasound Imaging|Men already electing to undergo radical prostatectomy will undergo transrectal ultrasound procedure at induction of anesthesia prior to their surgery procedure.
88963522|NCT02024191|Experimental|Glutamine|The patient group had 3x10 gr daily glutamine during first 4 cycles of mFOLFOX6 regimen.
88963523|NCT02024191|No Intervention|Observation|The group who had only mFOLFOX6 regimen, no additional intervention for neuropathy prophylaxis..
88963524|NCT02024217|Experimental|chemoradiotherapy, S1, oxaliplatin|chemoradiotherapy is given before surgical therapy,S1(Tegafur，Gimeracil and Oteracil Potassium Capsules) is given during radiation therapy and neoadjuvant chemotherapy, oxaliplatin is given during neoadjuvant chemotherapy.
89208251|NCT00284089|Experimental|Group B: Ranibizumab 0.5 mg|Group B patients received a total of 12 monthly intravitreal injections of 0.5 mg of ranibizumab into the study eye in the multiple dose phase of the study. Group B patients who enrolled in the extension phase received an intravitreal injection of 0.5 mg of ranibizumab according to an individualized flexible interval regimen guided by monthly best corrected visual acuity scores and other ophthalmic examinations. In the extension phase patients received the same dose level as they received in the multiple dose phase of the study, for an average of 1.36 years.
89208252|NCT00984633|Experimental|0.6 mg/kg intubation dose + sevoflurane|
89208253|NCT00984633|Experimental|0.9 mg/kg intubation dose + sevoflurane|
89556767|NCT05526534|Experimental|HFNC group|HFNC group was given heated humidified high flow nasal cannula oxygen therapy on the day of surgery and the first day after surgery to maintain oxygen saturation at 92% ~ 95%.Chest CT was reviewed 36-48 hours after surgery.
89556768|NCT05526534|Other|Control group|The control group was given conventional nasal catheter oxygen inhalation on the day of surgery and the first day after surgery, and oxygen flow was adjusted to maintain oxygen saturation at 92% ~ 95%.Chest CT was reviewed 36-48 hours after surgery.
89556769|NCT05515848||AORTLANTIC registry|Patients undergoing aortic root surgery with aortic valve conservation, using the inclusion technique described by Tirone David, between January 1, 2004 and December 31, 2021, at five centers (Nantes - Rennes - Brest - Angers - Tours University Hospital (UH))
89556770|NCT05509972||Columbus® DD Primary CoCr|Columbus® Deep Dish (DD) Primary Cobalt Chromium (CoCr)
89556771|NCT05509972||Columbus® DD Primary CoCr AS coated|Columbus® Deep Dish (DD) Primary Cobalt Chromium (CoCr) Advanced Surface
89556772|NCT05453188|Experimental|LongCOVID|Patients who have had COVID-19 and have been diagnosed with longCOVID or persistent COVID
89556773|NCT05453188|Active Comparator|Control|Patients who have had COVID-19, but have not been diagnosed with longCOVID or persistent COVID
89556774|NCT05439668|Experimental|Classic abdominal exercises Group|This group will carry out an abdominal strengthening exercise program based on the classic abdominal exercises.
89556775|NCT05439668|Experimental|Abdominal hypopresives exercise Group|This group will carry out an abdominal strengthening exercise program based on the abdominal hypopressives exercises.
89556776|NCT05421949||Exercise|Patients who have been randomised to the exercise group will be asked to undertake a incremental shuttle walking test following their initial blood tests.
89556777|NCT05421949||No Exercise|Patients who have been randomised to the exercise group will be asked to rest for 60 minutes following their initial blood tests.
89556778|NCT05384171|Experimental|MBTA intervention|assessment, feedback, and resource referrals
89556779|NCT05384171|Active Comparator|Assessment Only|assessment only
89556780|NCT05374564|Experimental|18F-flutemetamol|All clinical trial subjects will receive 18F-flutemetamol
89556781|NCT05370599|Active Comparator|Amlodipine 2.5 mg + Home BP monitoring with cuffed device|Use of at least the minimum dose of amlodipine and use of a home BP monitoring device for BP monitoring
89556782|NCT05370599|Experimental|Chlorthalidone 12.5 mg + Home BP monitoring with cuffed device|Use of at least the minimum dose of chlorthalidone and use of a home BP monitoring device for BP monitoring
89556783|NCT05370599|Experimental|Losartan 12.5 mg daily + home BP monitoring with cuffed device|Use of at least the minimum dose of losartan and use of a home BP monitoring cuffed device only for BP monitoring
89556784|NCT05370599|Experimental|amlodipine 2.5 mg daily + home BP monitoring with patch|Use of at least the minimum dose of this agent and use of a home BP monitoring device only + a patch for BP monitoring
89556785|NCT05370599|Experimental|Chlorthalidone 12.5 mg daily + home BP monitoring with patch|Use of at least the minimum dose of this agent and use of a home BP monitoring device only + a patch for BP monitoring
89556786|NCT05370599|Experimental|Losartan 12.5 mg daily + home BP monitoring with patch|Use of at least the minimum dose of this agent and use of a home BP monitoring device only + a patch for BP monitoring
89556787|NCT05370599|Experimental|amlodipine 2.5 mg daily + home BP monitoring with watch|Use of at least the minimum dose of this agent and use of a home BP monitoring device only + a watch for BP monitoring
89556788|NCT05370599|Experimental|chlorthalidone 12.5 mg daily + home BP monitoring with watch|Use of at least the minimum dose of this agent and use of a home BP monitoring device only + a watch for BP monitoring
89556789|NCT05370599|Experimental|losartan 12.5 mg daily + home BP monitoring with watch|Use of at least the minimum dose of this agent and use of a home BP monitoring device only + a watch for BP monitoring
89556790|NCT05365529|Placebo Comparator|Standard of Care|The participants in this arm will receive the standard health and nutritional wellness guidelines and will be required to log food entries through the use of a smartphone app.
89556791|NCT05365529|Experimental|Time-Restricted Eating|The participants in this arm will limit the number of hours they eat in day to a 8-10-hour window and will also receive the standard health and nutritional wellness guidelines. They will also be required to log food entries through the use of a smartphone app.
88963525|NCT02024256|Active Comparator|Magnesium sulfate|Pads soaked in cold magnesium sulfate solution
88963526|NCT02024256|Sham Comparator|Water|Pads soaked with cold water
89556792|NCT05331482|Experimental|Training protocol with the cervical device for treatment (CDAT).|Endurance training program of deep cervical flexors and deep cervical extensors with the cervical device for treatment.
89556793|NCT05331482|Active Comparator|Conventional training protocol-|Endurance training program of deep cervical flexors and deep cervical extensors with the conventional protocol.
89556794|NCT05331482|No Intervention|Control Group|Subject continues with activities of daily living. Does not receive deep cervical muscle training.
89208254|NCT00984633|Experimental|0.6 mg/kg intubation dose + propofol|
89208255|NCT00984633|Experimental|0.9 mg/kg intubation dose + propofol|
89208256|NCT00659984|Experimental|Ultratrace™ Iobenguane I 131|"Eligible patients received a diagnostic imaging dose of Ultratrace™ Iobenguane I 131 (1-5 mCi) within 7 days of study enrollment, followed by three dosimetry scans over 3-6 days. If the imaging dose demonstrated normal biodistribution and tumor uptake, then the patient received a therapeutic dose within 7-28 days of the diagnostic imaging dose, followed by a single imaging scan on Day 7 post therapy. As per protocol, therapeutic dosing was to begin at 12.0 mCi/kg and escalate to 15.0, 18.0, and 21.0 mCi/kg until the MTD was established or the 21.0 mCi/kg dose level was reached. Actual doses administered ranged from 8.8 to 18.6 mCi/kg. Based on actual doses administered, patients were grouped into 3 mean dose groups: 11.2, 15.5, and 18.2 mCi/kg.~The dosimetry dose was administered over a period of 1-3 minutes by injection; the therapeutic dose was diluted in up to 25 mL normal saline and infused intravenously over 30 to 60 minutes."
89208257|NCT00976755|Experimental|Arm A: Everolimus|"Everolimus:~10mg daily"
89556795|NCT05301712|Experimental|Naloxone hydrochloride 5.0mg/5ml|Naloxone hydrochloride 60mg (However, the dose may be appropriately increased or decreased according to the judgement of the investigator)
89556796|NCT05301712|Placebo Comparator|Placebo|Placebo 60ml (However, the dose may be appropriately increased or decreased according to the judgement of the investigator)
89556797|NCT05288712|Experimental|Experimental: Training protocol with the cervical device for treatment (CDAT).|"Endurance and stabilization training program of deep cervical flexors with the cervical device for treatment.~Endurance and stabilization training program of deep cervical extensors with the cervical device for treatment."
89556798|NCT05288712|Active Comparator|Conventional training protocol:|"Endurance and stabilization training program of deep cervical flexors with conventional protocol.~Endurance and stabilization training program of deep cervical extensors with conventional protocol."
89556799|NCT05288712|No Intervention|Control Group|Subject continues with activities of daily living. Does not receive deep cervical muscle training.
89556800|NCT05279053||Male|
89556801|NCT05279053||Female|
89556802|NCT05277181||Runners|"Recreational runners will be recruited and assessed over one season (June 2021 to January 2024).~Participants will be asked to complete a battery of sub-maximal walking and running trials.~Participants will be stratified according to gender (males n≈20, and females n≈20). Participants may also be further stratified based on injury status (i.e. injury history and location) and performance level (i.e. 5km personal best time)."
89556803|NCT05268939|Experimental|Nasal Swab|Nasal swab from subjects with signs and symptoms of COVID-19 and/or Influenza and/or RSV-like illness
89556804|NCT05268939|Experimental|Nasopharyngeal Swab|Nasopharyngeal swab from subjects with signs and symptoms of COVID-19 and/or Influenza and/or RSV-like illness
89556805|NCT05266612|Experimental|Monotherapy Arm|This is an open label trial using standard 3+3 design, in up to 24 HSV seropositive subjects. This rule-based design proceeds with cohorts of three patients.
88963527|NCT02024269|Experimental|Adipose Stem Cells|
88963528|NCT02024282|Other|usual care|
89208258|NCT00864474||Maraviroc Tablets|Patients administered.
88963529|NCT02024282|Active Comparator|Use of C-reactive protein point of care (CRP POC) test|"CRP analysis will be performed during the consultation in accordance with the manufacturer's instructions.~The CRP point of care test will be performed in case of a positive decision tree (irrespective of the intervention group) and also in case of a negative decision tree by clinicians of intervention group 1 and 2. Because no reliable cut-off points for CRP are known currently (as this is the aim of this study) for acute infections in children in primary care (nor for referral, nor for prescription of antibiotics), clinicians will not be given guidance on the interpretation of the CRP results.~We will not impose restrictions on the clinicians about treatment, other technical investigations nor referrals.~The device distributor will provide technical assistance. All clinicians will be trained in the use of the CRP device prior to the start of the study."
88963530|NCT02024282|Active Comparator|Brief intervention and parent leaflet|
88963531|NCT02024282|Active Comparator|CRP POC test and brief intervention & parent leaflet|Combination of CRP POC test and the brief intervention & parent information leaflet intervention groups (factorial design)
88963532|NCT02024295|Experimental|Ademethionine|ademethionine 1000mg ivgtt qd for 2 weeks, then orally 1000mg bid for 4 weeks.
88963533|NCT02024295|Active Comparator|Polyene Phosphatidyl choline|Polyene Phosphatidyl choline 10ml ivgtt qd for 2 weeks, then Polyene Phosphatidyl choline 456 mg tid orally for 4 weeks.
88963534|NCT02024308|Experimental|Fludarabine|The patients in experimental arm should receive the consolidation chemotherapy regimen with fludarabine and cytarabine. The dosage of fludarabine is 30mg/m2/d for 5 days intravenously and cytarabine is 1.4g/m2/d for 5 days intravenously.
88963535|NCT02024308|Active Comparator|HD-Arac|The patients in control arm should receive the consolidation chemotherapy regimen with high-dose cytarabine. The dosage of cytarabine is 2000mg/m2/12h for 3 days (1,3,5) intravenously.
88963536|NCT02024321||Tumor patients, TPN, surgery|This work involved prospective study of surgical patients receiving TPN during the calendar year of 2013 at Cancer Hospital.
88963537|NCT02024334|Active Comparator|leflunomide|leflunomide tablet: for patients less than 20 kg: 10 mg every 2 day, for patients 20 - 40 kg: 10 mg daily, for patients more than 40 kg: 20 mg daily.
89208259|NCT00283387|Experimental|Betaine|Subjects were randomly assigned oral betaine 12 grams/day in subjects younger than 10 years of age, and 20 grams/day in subjects 10 years of age and older, in two divided doses. This was followed by a 2 month washout period. Subjects then received the alternative study medication, oral lactose placebo, in two doses daily, for 2 months.
89208260|NCT00283387|Placebo Comparator|Placebo|Subjects were randomly assigned to receive oral lactose placebo, in two doses daily, for 2 months. This was followed by a 2 month washout period. Subjects then received the alternative study medication, oral betaine 12 grams/day in subjects younger than 10 years of age, and 20 grams/day in subjects 10 years of age and older, in two divided doses, for 2 months.
89208261|NCT00788216||Healthy Volunteers|Women over the age of 18 without the diagnosis of cervical cancer.
89208262|NCT00788216||Cervical Cancer Patients|Women over the age of 18 with a history of cervical cancer treated with surgery or chemoradiation.
89556806|NCT05266612|Experimental|Combination Arm|The starting dose of VG2025 in the combination cohorts will be a dose level lower than RP2D of monotherapy arm and Nivolumab will be administered intravenously as a flat dose of 240 mg every two weeks.
89556807|NCT05222191|Active Comparator|Spironolactone + Placebo|Subjects with stage 3B/4 chronic kidney disease and poorly controlled hypertension will be randomized into two groups: one receiving spironolactone and placebo and one receiving spironolactone and chlorthalidone. At randomization, subjects will begin at 25 mg spironolactone and 6.25 mg placebo/chlorthalidone daily.
89556808|NCT05222191|Experimental|Spironolactone + Chlorthalidone|Subjects with stage 3B/4 chronic kidney disease and poorly controlled hypertension will be randomized into two groups: one receiving spironolactone and placebo and one receiving spironolactone and chlorthalidone. At randomization, subjects will begin at 25 mg spironolactone and 6.25 mg placebo/chlorthalidone daily.
89556809|NCT05189015|Experimental|Olmesartan|- Olmesartan group: Olmesartan, 20 (40) mg once a day, oral administration
89556810|NCT05189015|Active Comparator|Amlodipine|- Comparator group: Amlodipine, 5 (10) mg once a day, oral administration
89556811|NCT05161845|Experimental|Experimental group|Participants randomized to receive one injections of 0.5 mL Measles, Mumps and Rubella Combined Vaccine, Live at Day 0.
89556812|NCT05161169|Experimental|Sequencing cohort|Infants receive genome sequencing with analysis of approximately 1000 genes associated with childhood-onset and highly actionable adult-onset disease risks. Pathogenic and likely pathogenic variants are reported to the child's parents and pediatrician. Participants also receive a detailed family history report and standard well-child care.
89556813|NCT05161169|No Intervention|Control cohort|Infants receive a detailed family history report plus standard well-child care.
89556814|NCT05153070|Experimental|Ciclosporin/ILT-101|Ciclosporin during 2 months (for all patients) followed by ILT-101 during 10 months
89556815|NCT05153070|Placebo Comparator|Ciclosporin/placebo|Ciclosporin during 2 months (for all patients) followed by placebo during 10 months
89556816|NCT05138705|Experimental|Outcome|Quadrivalent influenza vaccine Participants randomized to receive two injections of 0.5 mL quadrivalent influenza vaccine at Day 0 and 28.
89556817|NCT05129631|Experimental|HEARTPrep|HEARTPrep is a virtually-delivered psychosocial intervention for mothers expecting a baby with CHD. HEARTPrep consists of three distinct modules: Adjusting, Connecting, and Preparing. Each module targets one distinct primary outcome (emotional distress, social isolation, parenting self-efficacy) and a common secondary outcome (hope) through a suite of evidence-based intervention elements (e.g., psychoeducation, cognitive restructuring, mindfulness) for addressing emotional problems in other populations, including pregnant women. HEARTPrep elements include: a) telehealth with a psychosocial provider, b) recorded videos, c) educational tools, and d) links to resources.
89556818|NCT05107661||Telephone Prompt|Following consent, the Research Team will call participants three times in the first month (within the first week of signing consent at week 2 and repeated at week 3) and then one time per month for the following two months with scripted messaging reminding the participant to complete the screening activity (colonoscopy or fecal test). Interpreter services via phone will be utilized for non-English speaking participants.
88963538|NCT02024334|Placebo Comparator|placebo|placebo tablet for patients less than 20 kg: 10 mg every 2 day, for patients 20 - 40 kg: 10 mg daily, for patients more than 40 kg: 20 mg daily.
89556819|NCT05107661||Digital Prompt|Following consent, scripted messaging will be sent three times in the first month (within the first week of signing consent at week 2 and repeated at week 3) and then once time per month for the following two months with scripted messaging reminding the participant to complete the screening activity (colonoscopy or fecal test). Digital prompts will be available in Spanish and English.
89556820|NCT05061407||Paediatric surgical patients|All patients < 18 years old, admitted to participating hospitals during the study period who undergo elective and non-elective surgery
89556821|NCT05057741|Experimental|Multimodal Prehabilitation|Multimodal prehabilitation: exercise, nutrition and relaxation
88963539|NCT02024347||LSSM arm|Intervention: upper endoscopy only performed to patients with high LSM (≥12.0kPa) or SSM (≥41.3kPa) values
88963540|NCT02024347||Control arm|Intervention: upper endoscopy performed to all patients in this group.
88963541|NCT02024373|Experimental|Atorvastatin|atorvastatin：20 mg (every evening orally) for 8 weeks
89556822|NCT05057741|No Intervention|Standard of Care|Usual care group: advice of surgeons about self care
89556823|NCT05045638|Experimental|Rosuvastatin alone|
89556824|NCT05045638|Experimental|Rosuvastatin + sotorasib|
89556825|NCT05040360|Experimental|Arm I (capecitabine, temozolomide)|Patients receive capecitabine PO BID on days 1-14 and temozolomide PO once QD on days 10-14. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
89556826|NCT05040360|No Intervention|Arm II (surveillance)|Patients undergo surveillance with no active treatment.
89556827|NCT05017948|Experimental|Intervention|Discharge medication regimen instructions will be provided upon discharge after being assessed using the MWRS, optimized, and assessed by the prescriber.
89556828|NCT05017948|No Intervention|Standard of Care|Discharge medication regimen instructions will be provided upon discharge after being assessed by the prescriber.
89556829|NCT05011513|Experimental|PF-07321332/ritonavir|Orally administered PF-07321332+ritonavir
89556830|NCT05011513|Placebo Comparator|Placebo|Orally administered Placebo
89556831|NCT05010317|Experimental|Group receiving the mindfulness and acceptance intervention|This group will under go four sessions of the mindfulness and acceptance based therapy. These sessions will be delivered in four weeks, utilizing 2 hours every week. This will be in addition to the standard of care (clinic based counselling).
89556832|NCT05010317|Active Comparator|Control group|This group will continue receiving the usual clinic based care (counselling) only.
89556833|NCT04983771||Expert in ultrasound-guided regional anaesthesia|"At least 15 UGRA experts, member of a relevant professional society (e.g., RA-UK, ESRA, ASRA) and meeting at least 3 of the following criteria) will be recruited from centres in the UK.~Completed advanced training in UGRA or have >10 years of independent practice in UGRA~Hold a qualification related to UGRA (e.g., EDRA, higher degree or equivalent)~Regularly delivers direct clinical care using UGRA, including for 'awake' surgery where indicated~Regularly teaches UGRA in the course of their clinical work, including advanced techniques (Plan B/C/D blocks) where indicated"
89556834|NCT04969185||Group 1: Children eligible to receive SMC diagnosed with uncomplicated Plasmodium falciparum malaria|Children eligible to receive SMC (6-59 months of age) who were diagnosed with uncomplicated P. falciparum malaria at the health facility.
89556835|NCT04969185||Group 2: Children eligible to receive SMC presenting at health facility without malaria parasitemia|Group 2 will be defined as children eligible to receive SMC (6-59 months of age) who presented at the health facility and tested negative for malaria parasitemia.This group will serve as the control group to Group 1 Cases to compare the SP-AQ drug levels between children who did and did not get malaria.
89556836|NCT04969185||Group 3: Children 5-10 years of age diagnosed with uncomplicated Plasmodium falciparum malaria|Group 3 will be defined as children ineligible to receive SMC (5-10 years of age) who were diagnosed with uncomplicated P. falciparum malaria at the health facility. This group will serve as the control group to Group 1 Cases to compare the prevalence of SP and AQ resistance markers.
89556837|NCT04958759|Experimental|Functional Inspiratory Muscle Training Group|Functional inspiratory muscle training in patients with chronic kidney disease
89556838|NCT04958759|Experimental|Inspiratory Muscle Training Group|Inspiratory muscle training in patients with chronic kidney disease
88963542|NCT02024373|Placebo Comparator|placebo|placebo:20 mg (every evening orally) for 8 weeks
88963543|NCT02024399|Other|Exercise|Strength training x 20 sessions (10 weeks) Aerobic exercise core strengthening Running
89208263|NCT00976833|Active Comparator|Usual Care|Usual Care
89556839|NCT04958759|Experimental|Control Group|Breathing exercises in patients with chronic kidney disease
89556840|NCT04956978|Experimental|Patient Decision Support Tool|Patient decision support tool to be used in conjunction with physician counseling to discuss the risk and benefits of systemic oral anticoagulation.
89556841|NCT04956978|No Intervention|Usual Healthcare Counseling|Traditional physician counseling regarding the risk and benefits of systemic oral anticoagulation
89556842|NCT04944862|Experimental|CDX-0159 1.5mg/kg|CDX-0159 1.5mg/kg administered once
89556843|NCT04944862|Experimental|CDX-0159 3mg/kg|CDX-0159 3.0 mg/kg administered once
89556844|NCT04944862|Placebo Comparator|Placebo|Normal saline administered once
89556845|NCT04920552|Placebo Comparator|Placebo binder first|"Participants in this arm will wear the placebo comparator (Clima Care body warmer, Bort Medical GmbH) for 2 hours on treatment day-1 (i.e. Visit 1), followed by the active comparator (ABDO-SYNCRO 3-BAHNIG elastic abdominal binder, SYNCRO-MED GmbH) for 2 hours on treatment day-2 (i.e. Visit 2)."
89556846|NCT04920552|Active Comparator|Elastic abdominal binder first|"Participants in this arm will wear the active comparator (ABDO-SYNCRO 3-BAHNIG elastic abdominal binder, SYNCRO-MED GmbH) for 2 hours on treatment day-1 (i.e. Visit 1), followed by the placebo comparator (Clima Care body warmer, Bort Medical GmbH) for 2 hours on treatment day-2 (i.e. Visit 2)."
88963544|NCT02024412|Experimental|monosialotetrahexosylganglioside Sodium|arm A: monosialotetrahexosylganglioside Sodium Injection, 40mg,one hour before chemotherapy(mFOLFOX6), every two weeks until tumor progress or patients become intolerant
88963545|NCT02024412|Placebo Comparator|placebo|arm B: equal saline as placebo ,one hour before chemotherapy(mFOLFOX6) every two weeks until tumor progress or intolerant
89208264|NCT00976833|Other|Standardized Rehabilitation|Intervention arm to receive Standardized Rehabilitation Therapy
89556847|NCT04872309||Asthma Patients|Adults with physician diagnosis of stable asthma (BTS guideline Step 3 or above).
89556848|NCT04872309||COPD Patients|Adults with Stage 3 or 4 COPD (as defined by GOLD guideline 2018)
89556849|NCT04872309||ICU COVID-19|Adults who have been hospitalised on ICU with COVID-19 (requiring CPAP or mechanical ventilation)
89556850|NCT04872309||Moderate/Severe COVID-19|Adults hospitalised with COVID-19
89556851|NCT04872309||Mild- Non-hospitalised COVID-19|Adult with proven COVID-19 infection, not hospitalised for COVID-19
89556852|NCT04872309||Non-hospitalised symptomatic (long-COVID group)|Patients presenting at secondary care clinics post COVID-19 with ongoing symptoms.
89556853|NCT04832022||Vaccinated|Seronegative Chronic Inflammatory Rheumatism (CIR) who accepted vaccination against SARS-CoV2
89556854|NCT04832022||Non vaccinated|Seronegative Chronic Inflammatory Rheumatism (CIR) who refused vaccination against SARS-CoV2
89556855|NCT04818034|Experimental|Study Drug|The study drug Dapagliflozin
89556856|NCT04812028|Experimental|Prospective Experimental Group|Participants in this group will prospectively receive the intervention.
89556857|NCT04812028|No Intervention|Retrospective Review Group|Participants in this group will have their medical records retrospectively reviewed.
89556858|NCT04807972|Experimental|Phase 1b Dose Escalation|Participants will receive escalating doses of ABBV-927 in combination with modified FOLFIRINOX (mFFX) and Budigalimab.
89556859|NCT04807972|Experimental|Phase 2 Cohort A|Participants will receive modified FOLFIRINOX on Day 1 and Day 15 of each 28 day cycle.
89556860|NCT04807972|Experimental|Phase 2 Cohort B|Participants will receive modified FOLFIRINOX (Day 1 and Day 15) + ABBV-927 in each 28 day cycle.
88963546|NCT02024425|Active Comparator|Functional bioactive supplement|The functional bioactive supplement is composed of antioxidant extracted from rosemary, oligosaccharides derived from lactulose and bioactive peptides. It will be used for obese and overweight treatment
88963547|NCT02024425|Placebo Comparator|Maltodextrin and saccharose|The control supplement is composed of maltodextrin and saccharose . It has no effect for obese and overweight treatment
88963548|NCT02024438|Other|placebo|arm B: equal saline as placebo ,one hour before chemotherapy(mFOLFOX6) every two weeks until tumor progress or intolerant
88963549|NCT02024438|Experimental|monosialotetrahexosylganglioside Sodium|arm A: monosialotetrahexosylganglioside Sodium Injection, 40mg,one hour before chemotherapy(mFOLFOX6), every two weeks until tumor progress or patients become intolerant
88963550|NCT02024451|Active Comparator|Radial shock wave, Acupuncture|"Radial shock wave: 2 Hz with 2000 shock waves, and the energy level of 0.056mJ/mm2 in the trapezius muscle. It will be done once per week for 3 weeks.~Acupuncture: performed at Fenfchi (GB20) point over upper back. It will be performed once per week for 3 weeks ."
88963551|NCT02024451|No Intervention|radial shock wave& no treatment|No treatment: patients recieved no intervention.
88963552|NCT02024464|Experimental|Hydrus Microstent|Patients randomized to the Hydrus Microstent
88963553|NCT02024464|Active Comparator|iStent Trabecular Micro Bypass|Patients randomized to the iStent Trabecular Micro Bypass
88963554|NCT02024490||RDS group, non-RDS group|RDS group; infants with clinical, radiological and laboratory findings of RDS non-RDS group; infants without clinical, radiological and laboratory findings of RDS
88963555|NCT02024503||Experimental group|Hospitalized patients with acute stroke.
88963556|NCT02024503||Control group|Healthy Volunteers.
88963557|NCT02024516|Experimental|50 gr concentrated pomegranate juice|
88963558|NCT02024555|Active Comparator|Concomitant Levaquin, Ethambutol, Azithromycin and Rifampin|Levofloxacin 500mg po QD; Ethambutol 1200mg po QD; Azithromycin 250 mg po QD; Rifampin 600mg po QD or Rifabutin 300mg po QD
88963559|NCT02024555|Placebo Comparator|Placebo|"Riboflavin will be used for rifampin; encapsulated microcrystalline cellulose will be used to replace the levofloxacin, ethambutol and azithromycin.~The pill count will be the same as the comparator regimen."
88963560|NCT02024568|Active Comparator|Pregabalin|"Includes 19 out of 38 subjects reporting athralgia-myalgia in the wake of paclitaxel infusion in the course of breast cancer treatment.~Pregabalin started on the evening before receiving infusion of paclitaxel and 5 day thereafter. Initial dosing of 75mg twice daily (morning + evening). Option for dose increase with additional 75mg in case of inadequate pain control. A minimal interval of 2 hours is required between doses.~In case of poorly tolerated side effects a reduction to 50mg doses is available.~Access to additional analgesic interventions is open as required for patient wellbeing."
88963561|NCT02024568|Placebo Comparator|Placebo|"Includes 19 out of 38 subjects reporting athralgia-myalgia in the wake of paclitaxel infusion in the course of breast cancer treatment.~Placebo externally identical to the pregabalin 75mg capsules will be started on the evening before receiving infusion of paclitaxel and 5 day thereafter. Initial dosing of 1 capsule twice daily (morning + evening). Option for dose increase with additional capsule in case of inadequate pain control. A minimal interval of 2 hours is required between doses.~In case of poorly tolerated side effects a reduction to capsules with the appearance of 50mg pregabalin capsules is available.~Access to additional analgesic interventions is open as required for patient wellbeing."
88963562|NCT02024581|Active Comparator|10% East Indian sandalwood oil cream|East Indian sandalwood oil in a cream formulation administered twice a day for ninety (90) days
88963563|NCT02024581|Placebo Comparator|Placebo cream|A scented cream formulation administered twice a day for ninety (90) days
88963564|NCT02024594|Experimental|Nitrous Oxide-Oxygen|Children in this group were sedated by rapid induction method by means of Nitrous Oxide-Oxygen gas.
89556861|NCT04807972|Experimental|Phase 2 Cohort C Expansion|Participants will receive modified FOLFIRINOX (Day 1 and Day 15) + ABBV 927 and Budigalimab as Intravenous (IV) Infusion in each 28 day cycle.
89556862|NCT04792190|Active Comparator|Intervention Management Arm (Dapagliflozin)|A block randomization method will be use to randomize subjects to treatment with dapagliflozin 10 mg once daily. Subjects will take 1 blinded tablet of study drug (dapagliflozin) dosed once daily, per the randomization scheme, for 12 months. Each subject will be dispensed 35 blinded doses per month, during each month of participation in the trial. Quarterly pill counts will be performed to track compliance.
89556863|NCT04792190|Placebo Comparator|Control Arm (Placebo)|Subjects will take 1 blinded tablet of placebo drug dosed once daily, per the randomization scheme, for 12 months. Each subject will be dispensed 35 blinded doses per month, during each month of participation in the trial. Quarterly pill counts will be performed to track compliance.
89556864|NCT04789044|Experimental|PEG mediated reconstruction|NTX-001 will be administered topically via isolation chamber medical device. Dose Unit: 2.5 mL NTX-001 is a single use surgical product intended for use as adjunct treatment in the repair of severed peripheral nerves in patients requiring standard suture neurorrhaphy.
89556865|NCT04789044|No Intervention|Conventional nerve reconstruction|Conventional nerve reconstruction
89556866|NCT04775199|No Intervention|Control|Control: In all conditions, the examiners will teach science using the Full Option Science System Next Generation Edition (FOSS, 2015, https://www.fossweb.com/) curriculum that involves 1) Prediction, 2) Experiment, 3) a visual Journal/Reflection, and 4) a pre-recorded reading centered around a given theme such as sound. A research speech-language pathologist will provide two 30-minute interactive science lessons per week for six weeks to children with language learning challenges recruited nationwide. Children will participate in groups of three. Families will log on five additional times during each week to view the science book reading. In the control condition, children will receive these science lessons but no language intervention. Therefore, this intervention constitutes a nonintervention.
89556867|NCT04775199|Experimental|Science + Grammar Intervention|"Grammar: In the science + grammar condition, focused stimulation plus explicit instruction will be employed. Focused stimulation an intervention commonly used to target expressive language, will be used to treat complement clauses during the FOSS activities.. The active ingredients are models (30) and recasts (5 per child) of the target structure (e.g., You measured how long the ramp is). Recasts occur when an examiner responds to a child's naturally occurring utterance by expanding or extending the child's utterance to include a target grammatical structure. Focused stimulation will be supplemented with explicit instruction using choral production and visual supports (3x per lesson) and a definition of the meaning of the structure (1 per lesson)."
89556868|NCT04775199|Experimental|Science + Vocabulary Intervention|Vocabulary: This arm will provide Robust Vocabulary Instruction, an explicit approach that emphasizes multiple and rich encounters in authentic contexts to promote depth of semantic knowledge of 12 words that pertain to scientific practices applicable to the FOSS lessons. The words are: compare, diagram, evidence, explanation, hypothesis, materials, model, multiple, pattern, problem, scientist, search. Two words will be targets in each session. The examiners will ensure that for each target word per session there will be at least one definition model and 3 other models directed to the triad of participants and at least 2 elicitations per child. The recorded books also include 6 additional exposures to the words, for a cumulative exposure of 12.
89556869|NCT04770012|Placebo Comparator|placebo|
89556870|NCT04770012|Active Comparator|clopidogrel|
89556871|NCT04770012|Active Comparator|aspirin|
89556872|NCT04755244|Experimental|evorpacept (ALX148) + venetoclax + azacitidine|"Phase 1a: Participants will receive escalating doses of evorpacept (ALX148) in combination with venetoclax and azacitidine~Phase 1b/2: Participants will receive evorpacept (ALX148) at the recommended Phase 2 dose in combination with venetoclax and azacitidine"
89556873|NCT04750239|Experimental|Nivatrotamab|Subcutaneous administration of nivatrotamab up to 13 cycles
89556874|NCT04721717||People with SCI|People with paraplegia and quadriplegia People with multiple sclerosis People with transverse myelitis Caregivers of people with amyotrophic lateral sclerosis (ALS)
88963565|NCT02024594|Experimental|cognitive-behavioral therapy|Children in this group were asked to come to playroom before entering operation room. Modeling , Benson relaxation and positive self-talking were instructed to them.
88963566|NCT02024594|No Intervention|control|No intervention
88963567|NCT02024620|Experimental|Behavioral activation plus mobile app|Standard behavioral activation protocol with the addition of the Mood Coach mobile app to replace the paper and pencil forms used in the standard protocol.
89556875|NCT04718740|Experimental|fluzoparib|"Experimental: group A Intervention: Drug: fluzoparib, caffeine, vitamin K, warfarin, omeprazole, and midazolam~Experimental: group B Intervention: Drug: fluzoparib, repaglinide and bupropion"
89556876|NCT04717544|Active Comparator|Intervention Arm|"Healthcare providers from clinics participating in the intervention refer existing clients to study coordinators for smoking cessation services, wherein the coordinators link clients to the smoking cessation services, which include: 1) a weekly cognitive-behavioral therapy smoking cessation (CBT) counseling group; and 2) smoking cessation medication, which include varenicline (Chantix), bupropion (Zyban) and nicotine patches, gum, and lozenges. Clients interested in these medications will meet with the prescribing clinician to help choose the best prescription option.~In addition to linking clients to the smoking cessation services, coordinators will invite clients to participate in the outcome study.~Existing clients can sign-up for these services and/or the outcome study directly with the study coordinators and do not require a healthcare provider referral."
89556877|NCT04717544|No Intervention|Treatment As Usual Arm|Existing clients can be referred to the outcome study by their healthcare providers from clinics designated as TAU or they can sign-up directly with the study coordinators.
88963568|NCT02024620|Active Comparator|Standard behavioral activation|Standard behavioral activation protocol using paper and pencil forms for treatment delivery and homework completion.
88963569|NCT02024633|Experimental|icotinib plus gemcitabine|"Three dose of icotinib are designed to be evaluated, 125 mg three times per day, 250 mg three times per day, and 375 mg three times per day. Dose escalations are based on predefined dose escalation decision rules. The Maximum Administered Dose (MAD) was reached at the dose level when at least 30% patients developed a dose limited toxicity.~Gemcitabine: 1000 mg/m2 on Days 1, 8, and 15 of a 28 day cycle by IV administration every 4 weeks."
88963570|NCT02024659|Experimental|budesonide|
88963571|NCT02024659|Placebo Comparator|placebo|
89556878|NCT04699305||ActiGraft|Whole blood clot (WBC) gel
89556879|NCT04663828|Other|Structured counseling|Patients will receive a structured counseling therapy
89556880|NCT04663828|Other|Hearing Aids|Patients will receive hearing aids support
88963572|NCT02024672||Immediate postpartum placement of IUD|Women who plan to have an IUD placed at the time of cesarean section or vaginal delivery, or women who have had an IUD placed at the time of cesarean section or vaginal delivery.
88963573|NCT02024685|Active Comparator|Standard patient-physician counseling interaction|The control arm will receive counseling regarding treatment options using standard patient-physician interactions and nomogram-predicted probabilities of treatment outcome for the various treatment options and they will be unaware of the decision analysis recommendation.
88963574|NCT02024685|Experimental|Personalized treatment recommendations|The treatment arm would be provided with a personalized treatment recommendations based on the decision analysis model prior to treatment selection.
88963575|NCT02024737||Moderate-Severe COPD|"Patients with moderate to severe COPD, as defined by GOLD 2-3 (The GOLD classifications are the main method doctors use to describe the severity of COPD.~GOLD is short for the Global Initiative for Chronic Obstructive Lung Disease, a collaboration between the National Institutes of Health and the World Health Organization)"
88963576|NCT02024763|Experimental|Educational Intervention|Intervention was applied to classroom teachers by the RRIDA Project team. Training lasted six weeks, 12 hours devoted to physical activity and 18 hours to nutritional content. Modules of educational activities were taught in order to be replicated at PE classes to 1st and 2nd grades' children of three exposed schools. Physical activity module was based on a theoretical approach of physical activity benefits and risks for health, children's physical fitness and activity patterns, physical education and change behavior models. In each meeting the PE professionals, performed PE classes with the classroom teachers as students, focusing in strategies to keep them in movement for the most of PE class time to stimulate students' joint participation instead of individual participation or games.
88963577|NCT02024763|No Intervention|No Intervention|No educational intervention was taken place in the control schools while the project was running. Afterwards, control schools received training.
88963578|NCT02024776|Active Comparator|Prehabilitation|Prehabilitation program is defined as a tailored physical exercise program to be carried out to a patient on the basis of his/her health condition, social circumstances and adherence profile. The intervention consisted of a standard 4-6 week supervised outpatient program including global endurance exercise training, or educational sessions followed by a self-management program supported by ICT during the follow-up period, or a combination of both.
88963579|NCT02024776|No Intervention|No-intervention|Standard counseling and conventional pre-surgical measures
88963580|NCT02024789|Placebo Comparator|Placebo|
89208265|NCT00788294|Active Comparator|10 mg IV|
89208266|NCT00788294|Active Comparator|5 mg SC|
89208267|NCT00788294|Active Comparator|10 mg SC|
89208268|NCT00788294|Active Comparator|19 mg SC|
89208269|NCT00795548|Experimental|5-Azacitidine|5-Azacitidine in addition to standard donor lymphocyte infusions.
89556881|NCT04663828|Other|Cognitive behavioral therapy|Patients will receive cognitive behavioral therapy
89556882|NCT04663828|Other|Sound therapy|Patients will follow a sound therapy program
89556883|NCT04663828|Other|Combination of sound therapy and cognitive behavioral therapy|Patients will receive a combination of sound therapy and cognitive behavioral therapy
89556884|NCT04663828|Other|Combination of hearing aids and cognitive behavioral therapy|Patients will receive a combination of hearing aids and cognitive behavioral therapy
89556885|NCT04663828|Other|Combination of hearing aids and structured counseling|Patients will receive a combination of hearing aids and structured counseling
89556886|NCT04663828|Other|Combination of structured counseling and sound therapy|Patients will receive a combination of structured counseling and sound therapy
88963581|NCT02024789|Experimental|RG1662 120 mg bid|
88963582|NCT02024789|Experimental|RG1662 240 mg bid|
88963583|NCT02024815|Experimental|External Beam radiotherapy|Single 8 Gy fraction
88963584|NCT02024815|Active Comparator|3 Gy x 10 fractions|External Beam radiotherapy - total dose 30 Gy, 3 Gy per fraction.
89025965|NCT00498147||ADEC >6months|Patients who have been with the ADEC program as early as 2002 (coincides with ADEC's EMR initiation date) who continue to be provided the ADEC interventions (combined retrospective/prospective study)
89025966|NCT00498225|Experimental|1|Gemcitabine plus TS-1
89025967|NCT00498225|Experimental|2|TS-1
89208270|NCT00980577|Active Comparator|NS|stimulating catheter will be inserted using stimulator
89208271|NCT00282919|Experimental|Azithromycin plus chloroquine|Single Arm, Open label study
89208272|NCT00800774|Experimental|1|Nine eyes of nine patients (3 male and 6 female) with high anisometropia (>3.50 D), were included in this study. Minimum follow-up was 10 years. All patients were treated with the Chiron Technolas 217 excimer laser.
89208273|NCT00984789|Experimental|Arm 1|
89208274|NCT00984789|Active Comparator|Arm 2|
89208275|NCT00864552||Group 1|
89208276|NCT03975673|Active Comparator|Conventional Total Hip Replacement (cTHR )|"Osteoarthritic patient undergoing the conventional technique~medializing the hip center of rotation~obtain a standing acetabular cup position fitting the Lewinneck recommendations (inclination 40°±10°, version 15°±10°)"
89556887|NCT04663828|Other|Combination of hearing aids and sound therapy|Patients will receive a combination of hearing and sound therapy
89556888|NCT04663828|Other|Combination of cognitive behavioral therapy and sound therapy|Patients will receive a combination of cognitive behavioral therapy and sound therapy
89556889|NCT04659122|Experimental|AT-100 75 mg|Once daily AT-100 via intratracheal administration for up to 7 doses.
89556890|NCT04659122|Experimental|AT-100 150 mg|Once daily AT-100 via intratracheal administration for up to 7 doses, if the prior dose level was safe & tolerated.
89556891|NCT04659122|Experimental|AT-100 75 mg or 150 mg (Optional Cohort)|Once daily AT-100 via intratracheal administration for up to 7 doses, at the highest safe & tolerated dose as determined by the prior 2 dosing levels.
89556892|NCT04652063|Experimental|OMM|Neonates randomized to receive osteopathic manipulation
89556893|NCT04652063|No Intervention|Control|Neonates randomized to receive standard care only
88963585|NCT02024828|Experimental|Early/Slow|Infants were offered oral feedings beginning at 32 weeks PMA. They were offered 2 oral feedings per day for 3 days (Days 1-3). The number of oral feedings offered per day increased by 1 feeding every other day until day 14 when they were offered 8 oral feedings each day (Days 4-5, 3 oral feeds offered; Days 6-7, 4 oral feeds offered; Days 8-9, 5 oral feeds offered; Days 10-11, 6 oral feeds offered; Days 12-13, 7 oral feeds offered; Day14, 8 oral feeds offered). Any feedings not offered orally were provided by gavage.
88963586|NCT02024828|Experimental|Early/Fast|Infants were first offered oral feedings beginning at 32 weeks PMA. They were offered 8 oral feedings every day, at each of 8 scheduled daily feedings.
88963587|NCT02024828|Experimental|Late/Slow|Infants were offered oral feedings beginning at 34 weeks PMA. They were offered 2 oral feedings per day for 3 days (Days 1-3). The number of oral feedings offered per day increased by 1 feeding every other day until day 14 when they were offered 8 oral feedings each day (Days 4-5, 3 oral feeds offered; Days 6-7, 4 oral feeds offered; Days 8-9, 5 oral feeds offered; Days 10-11, 6 oral feeds offered; Days 12-13, 7 oral feeds offered; Day14, 8 oral feeds offered). Any feedings not offered orally were provided by gavage.
88963588|NCT02024828|Experimental|Late/Fast|Infants were offered oral feedings beginning at 34 weeks PMA. They were offered 8 oral feedings every day, at each of 8 scheduled daily feedings.
88963589|NCT02024841|Experimental|Intraperitoneal docetaxel|"Intraperitoneal docetaxel in 1litre normal saline infused over 1 hour on day 1 every 3 weeks:~- Level I: 40mg/m2; Level II: 50mg/m2; Level III: 60mg/m2~Intravenous cisplatin: 60mg/m2 on day 1 every 3 weeks~Oral TS-ONE: 40-60mg twice daily on day 1 -14 every 3 weeks"
88963590|NCT02024880|Experimental|Protective catheter group|Protective catheter group uses Guardia™ Pro Protective ET catheter from Cook.
88963591|NCT02024880|Active Comparator|Conventional catheter group|Conventional catheter group uses Sydney IVF catheter from Cook.
88963592|NCT02024893||National womens water- polo team|Observational study-members of the national womens waterpolo team participating in formal team training and tournaments for the 2014-2015 season.
89556894|NCT04647916|Experimental|Treatment (sacituzumab govitecan)|Patients receive sacituzumab govitecan IV over 1-3 hours on days 1 and 8. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
89556895|NCT04615546|Experimental|Remote Phase: Post-Bariatric Hypoglycemia Patients|Participants will wear continuous glucose monitor (CGM) in a blinded manner (cannot see data output) for 20 days followed by in an unblinded manner (can see data output) for 20 days.
89556896|NCT04615546|No Intervention|In-Clinic Phase: Post-Bariatric Hypoglycemia Patients|Participants will attend 1-3 study visits over the period of approximately 2 months, with metabolic parameters assessed under a variety of conditions. This group will also wear CGM during a portion of the metabolic tests. This may include participants from the Remote Phase or newly enrolled participants.
89556897|NCT04615546|No Intervention|In-Clinic Phase: Surgical Controls|Participants will attend 1-3 study visits over the period of approximately 2 months, with metabolic parameters assessed under a variety of conditions.
89556898|NCT04615546|No Intervention|In-Clinic Phase: Nonsurgical Controls|Participants will attend 1-3 study visits over the period of approximately 2 months, with metabolic parameters assessed under a variety of conditions.
89556899|NCT04615546|No Intervention|In-Clinic Phase: Post-Bariatric Hypoglycemia Patients with indwelling gastrostomy tube|Participants will undergo standardized mixed meal tolerance tests via oral, gastrostomy tube, and concomitant oral + gastrostomy tube routes of delivery with metabolic parameters assessed.
89556900|NCT04590248|Experimental|Adavosertib|Subjects will receive adavosertib 300 mg administered orally, once daily on Days 1 to 5 and Days 8 to 12 of a 21-day treatment cycle.
89556901|NCT04586231|Experimental|Belzutifan + Lenvatinib|Belzutifan 120 mg and lenvatinib 20 mg orally once a day
89556902|NCT04586231|Active Comparator|Cabozantinib|Cabozantinib 60 mg orally once a day
89556903|NCT04572139||Young participants|18-45 years old
88963593|NCT02024893||National mens handball team|Observational study-Twenty men , members of the national , over 18 years old handball team preparing for the european championships for summer 2014
89556904|NCT04572139||Old participants|55-80 years old
89556905|NCT04572139||Oldest old participants|over 80 years old
88963594|NCT02024893||National womens volleyball team|20 players who are part of the women's national olympic volleyball team
89025968|NCT00498225|Active Comparator|3|Gemcitabine
89556906|NCT04560816|Experimental|Treatment Sequence 1|"On Day 1 of each period, participants will receive a single dose of the following study interventions:~Period 1: ALXN1840.~Period 2: Placebo-matching ALXN1840.~Period 3: Moxifloxacin."
89556907|NCT04560816|Experimental|Treatment Sequence 2|"On Day 1 of each period, participants will receive a single dose of the following study interventions:~Period 1: ALXN1840.~Period 2: Moxifloxacin.~Period 3: Placebo-matching ALXN1840."
89556908|NCT04560816|Experimental|Treatment Sequence 3|"On Day 1 of each period, participants will receive a single dose of the following study interventions:~Period 1: Placebo-matching ALXN1840.~Period 2: ALXN1840.~Period 3: Moxifloxacin."
89556909|NCT04560816|Experimental|Treatment Sequence 4|"On Day 1 of each period, participants will receive a single dose of the following study interventions:~Period 1: Placebo-matching ALXN1840.~Period 2: Moxifloxacin.~Period 3: ALXN1840."
89556910|NCT04560816|Experimental|Treatment Sequence 5|"On Day 1 of each period, participants will receive a single dose of the following study interventions:~Period 1: Moxifloxacin.~Period 2: ALXN1840.~Period 3: Placebo-matching ALXN1840."
89556911|NCT04560816|Experimental|Treatment Sequence 6|"On Day 1 of each period, participants will receive a single dose of the following study interventions:~Period 1: Moxifloxacin.~Period 2: Placebo-matching ALXN1840.~Period 3: ALXN1840."
89556912|NCT04530682||SARS-CoV-2 seropositive patients with chronic inflammatory rheumatisms (CIRs)|200 SARS-CoV-2 seropositive patients with chronic inflammatory rheumatisms (CIRs) from the COVID-RIC-1 cohort.
89556913|NCT04530682||Control group|100 health professionals participating in the COVID-BIOTOUL cohort will be selected to be matched on age, gender, and the time between the date of infection with Covid-19 and the first serology of CIR patients.
89556914|NCT04520425|Experimental|Intervention|Participants will receive 5 standardized osteopathic manipulative treatments, two weeks apart. (To be considered a study completer, a participant must complete at least 3 of these treatments.) In addition to assessments at intake and during treatments, 1 and 3 months after their last treatment patients will be asked to provide follow-up data. Assessments include the HIT-6, MIDAS, and MSQ surveys, treatment satisfaction assessments, and a headache diary. Participants will also consent to an electronic medical record extraction of medication and healthcare services utilization.
89025969|NCT00466622|Experimental|1|Metformin 1000mg x 2 daily. Orally. From Weifa
89025970|NCT00466622|Placebo Comparator|2|Placebo 2 tablets x 2 daily. Orally From Weifa
89025971|NCT01327612|Experimental|Conatumumab Monotherapy|Participants will continue to receive conatumumab every 2 weeks (Q2W) or every 3 weeks (Q3W) at the same dose and regimen as at the conclusion of the parent study.
89556915|NCT04511013|Experimental|Arm I (encorafenib, binimetinib, nivolumab)|Patients receive encorafenib PO QD on days 1-28, binimetinib PO BID on days 1-28, and nivolumab IV on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89556916|NCT04511013|Experimental|Arm II (nivolumab, ipilimumab)|Patients receive nivolumab IV on day 1 of all cycles and ipilimumab IV over 30 minutes on day 1 of cycles 1-4. Cycles repeat every 21 days for 4 cycles and then every 28 days in the absence of disease progression or unacceptable toxicity.
89556917|NCT04510597|Active Comparator|Arm 1: Continued Systemic Therapy Only|"Nivolumab 240 mg IV 1 q 2 weeks~OR~Nivolumab 480 mg IV 1 q 4 weeks~OR~Pembrolizumab 200 mg IV 1 q 3 weeks Axitinib 5 mg oral Daily BID~OR~Avelumab 10 mg/kg IV 1 q 2 weeks Axitinib 5 mg oral Daily BID"
89556918|NCT04510597|Experimental|Arm 2: Nephrectomy and Continued Systemic Therapy|"Continued systemic therapy as above, plus:~Radical or partial nephrectomy may be performed using laparoscopic, open, or robotic approaches. Surgery should be performed within 8 weeks of randomization."
89556919|NCT04468061|Experimental|Sacituzumab Govitecan + Pembrolizumab|"Participants will receive Sacituzumab Govitecan + Pembrolizumab at a pre-determined dose during a 21 day cycle.~Sacituzumab Govitecan will be given on days 1 and 8 of the 21 day cycle Pembrolizumab will be given on day 1 of the 21 day cycle."
89556920|NCT04468061|Experimental|Sacituzumab Govitecan|"Participants will receive Sacituzumab Govitecan at a pre-determined dose during a 21 day cycle.~Sacituzumab Govitecan will be given on days 1 and 8 of a 21-day cycle"
89556921|NCT04468061|Experimental|Retreatment|"Participants randomized to the combination arm (Sacituzumab Govitecan + Pembrolizumab) who stop with CR after at least 24 weeks of treatment may be eligible for additional pembrolizumab and/or sacituzumab govitecan therapy if they progress after stopping study treatment. This is termed the Second Course Phase and is only available if the study remains open and the subject meets conditions.~."
89556922|NCT04465591||Myocardial infarction|Recruited patients with STEMI or NSTEMI and elevated Troponin T
89556923|NCT04465591||Myocardial injury|Recruited patients with myocardial injury based on elevated Troponin T and associated with renal failure, severe infection, strenouos exercise, atrial fibrillation, myocarditis, takotsubo cardiomyopathy or other similar conditions
89556924|NCT04417517|Experimental|evorpacept (ALX148) + azacitidine|"Phase 1: Participants will receive escalating doses of evorpacept (ALX148) in combination with azacitidine 75 mg/m2 IV or subcutaneous daily for 7 days of a 28 day cycle~Phase 2: Participants will receive evorpacept (ALX148) at the recommended Phase 2 dose in combination with azacitidine 75 mg/m2 IV or subcutaneous daily for 7 days of a 28-day cycle"
89556925|NCT04417517|Active Comparator|azacitidine|Phase 2 only: Participants will receive azacitidine 75 mg/m2 IV or subcutaneous daily for 7 days of a 28-day cycle
89556926|NCT04381806|Experimental|5-ALA|orally-administered 5-aminolevulinic acid (ALA) given as a radiosensitizer prior to low-dose radiation therapy (RT)
89556927|NCT04374760|No Intervention|in-person control|Usual care, initial screening measures conducted in-person in the Emergency Department.
89556928|NCT04374760|No Intervention|Self-Administered Control|Usual care, initial screening measures conducted on their own via an iPad.
89556929|NCT04374760|Experimental|In-person Treatment|Treatment group (receives text messages), initial screening measures conducted in-person in the Emergency Department.
89208277|NCT03975673|Experimental|Kinematically Aligned Total Hip Replacement (KATHR )|"Osteoarthritic patient undergoing the kinematically aligned technique~restoring the acetabular center of rotation~restoring the constitutional acetabular anteversion by using the transverse acetabular ligament (TAL) as a reference landmark.~making personalized choice for the hip component design~considering additional spine surgery based on the assessment of the individual spine-hip relation."
89556930|NCT04374760|Experimental|Self-Administered Treatment|Treatment group (receives text messages), initial screening measures conducted on their own via an iPad.
89556931|NCT04337177|Experimental|90 mg/m2/day VAL-413 (Orotecan®)|Orotecan® at 90 mg/m2/day administered with Temozolomide at 100 mg/m2/day orally for 5 consecutive days at the beginning of every 21-day cycle. A single dose of the intravenous preparation of irinotecan taken orally (IRN-IVPO) will be substituted at the same dosage as Orotecan® for during Cycle 1.
89025972|NCT01327612|Experimental|Conatumumab + Ganitumab|Participants will receive conatumumab and ganitumab by intravenous infusion at the same dose and regimen as at the conclusion of the parent study.
89025973|NCT01327612|Experimental|Ganitumab Monotherapy|Participants will continue to receive ganitumab Q3W or every 4 weeks (Q4W) at the same dose and regimen as at the conclusion of the parent study.
89025974|NCT01327612|Experimental|Conatumumab + mFOLFOX6 ± Bevacizumab|Participants will continue to receive conatumumab by intravenous infusion in addition to modified FOLFOX6 chemotherapy with or without bevacizumab.
89025975|NCT01243281|Active Comparator|drug combination|
89025976|NCT04133545||DOAC|Direct oral anticoagulant
89025977|NCT04133545||OAC|Vitamin K anticoagulant
89025978|NCT01243359|Experimental|Treatment (sunitinib malate, bevacizumab)|Patients receive sunitinib malate PO on days 1-28 and bevacizumab IV over 30-90 minutes on day 29. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
89025979|NCT02893579|Experimental|Early Intervention|Stress reduction intervention 1 time a month
89025980|NCT02893579|Experimental|Delayed Intervention|Wait list Control
89556932|NCT04337177|Experimental|110 mg/m2/day VAL-413 (Orotecan®)|Orotecan® at 110 mg/m2/day administered with Temozolomide at 100 mg/m2/day orally for 5 consecutive days at the beginning of every 21-day cycle. A single dose of the intravenous preparation of irinotecan taken orally (IRN-IVPO) will be substituted at the same dosage as Orotecan® for during Cycle 1.
89556933|NCT04337177|Experimental|75 mg/m2/day VAL-413 (Orotecan®)|In the event the 90 mg/m2/day starting dose is not tolerable due to toxicity, a lower starting dose of 75 mg/m2/day may be implemented. Orotecan® at 75 mg/m2/day administered with Temozolomide at 100 mg/m2/day orally for 5 consecutive days at the beginning of every 21-day cycle. A single dose of the intravenous preparation of irinotecan taken orally (IRN-IVPO) will be substituted at the same dosage as Orotecan® for during Cycle 1.
89556934|NCT04327609|Experimental|SELUTION SLR™ DEB|Med Alliance SELUTION SLR™ 018 DEB Sirolimus Eluting Balloon Catheter.
89556935|NCT04327609|Active Comparator|Control Treatment|POBA
89556936|NCT04310202||Single-arm|In this single-arm study, the only interventions compared to routine clinical practice are the completion of two patient questionnaires (APHAB and GBI) and additional follow-up visits after surgery.
89556937|NCT04205968|Experimental|Arm I (ramucirumab, paclitaxel)|Patients receive ramucirumab IV over 30-60 minutes on days 1 and 15, and paclitaxel IV over 30 minutes on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89556938|NCT04205968|Experimental|Arm II (irinotecan, leucovorin, fluorouracil)|Patients receive irinotecan IV over 90 minutes on days 1 and 15, leucovorin IV over 2 hours on days 1 and 15, and fluorouracil IV bolus on days 1 and 15. Patients also receive fluorouracil IV over 46-48 hours on days 1-3 and 15-17. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89556939|NCT04146922|Active Comparator|IV Group|Eligible patients randomized to complete their antimicrobial therapy course through intravenous (IV) administration.
89556940|NCT04146922|Experimental|Oral Group|Eligible patients randomized to step down to oral antimicrobial therapy for the remainder of their treatment course.
89556941|NCT04141020|Experimental|Microsurgical Clipping Treated with Sirolimus|Participants undergoing standard of care microsurgical clipping of unruptured cerebral aneurysm will be treated with 2 mg Sirolimus daily for 14-18 consecutive days prior to surgery.
89556942|NCT04141020|Experimental|Endovascular Treatment Treated with Sirolimus|Participants undergoing standard of care endovascular treatment of unruptured cerebral aneurysm procedure will be treated with 2 mg Sirolimus daily for 14-18 consecutive days prior to procedure.
89556943|NCT04097743|Experimental|Coping statement|Daily practice of pain coping statements for 7 days
89556944|NCT04097743|No Intervention|Control|No instruction about pain coping statement.
89556945|NCT04092582|Experimental|MTPS9579A|
89556946|NCT04092582|Placebo Comparator|Placebo|
89556947|NCT04071457|No Intervention|Study Entry / Screening|Study entry/screening to follow patient until Maintenance.
89556948|NCT04071457|Active Comparator|Arm 1: Lenalidomide|Lenalidomide 10 mg/day, D1-28, q28 days for 3 cycles, then 15 mg/day, D1-28 for up to 2 years from starting treatment.
89208278|NCT04046822|Active Comparator|Active drug|Liraglutide is administered once daily by subcutaneous injections with the pen-injector, either in the abdomen, thigh or upper arm. Injections can be done at any time of day irrespective of meals. Subjects will be instructed to escalate the liraglutide dose to 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day.
88963595|NCT02024906|Experimental|soy protein isolate (SPI)|25 grams soy protein isolate (SPI) containing approximately 30 mg/d isoflavones
88963596|NCT02024906|Active Comparator|milk protein isolate (MPI)|milk protein isolate (MPI) containing 0 mg/d isoflavones
88963597|NCT02024919|Active Comparator|Diltiazem|intracoronary diltiazem 5 milligrams which is diluted with 5 mL of saline
88963598|NCT02024919|Placebo Comparator|Saline|intracoronary saline 5 mL
89556949|NCT04071457|Experimental|Arm 2: Lenalidomide + Daratumumab/rHuPH20|Lenalidomide 10 mg/day, D1-28, q28 days for 3 cycles, then 15 mg/day, D1-28 for up to 2 years from starting treatment. Plus Daratumumab/rHuPH20 1800 mg/30,000 units D1, 8, 15, 22 q 28 days for 2 cycles, then D 1 and 15 q 28 days for cycles 3-6 then D1 q 28 days for subsequent cycles for up to 2 years from starting treatment.
89556950|NCT04071457|Active Comparator|Arm 1a: Continue Lenalidomide|MRD+ or MRD- and randomized to Arm 1a: Lenalidomide 10 mg/day, D1-28, q28 days for 3 cycles, then 15 mg/day, D1-28 for up to 7 years from starting treatment.
89556951|NCT04071457|No Intervention|Arm 1b: Stop Lenalidomide|MRD- and randomized to Arm 1b: Discontinue protocol therapy.
89556952|NCT04071457|Active Comparator|Arm 2a: Continue Lenalidomide + Daratumumab/rHuPH20|MRD+ or MRD- and randomized to Arm 2a: Lenalidomide 10 mg/day, D1-28, q28 days for 3 cycles, then 15 mg/day, D1-28 for up to 7 years from starting treatment. Plus Daratumumab/rHuPH20 1800 mg/30,000 units D1, 8, 15, 22 q 28 days for 2 cycles, then D 1 and 15 q 28 days for cycles 3-6 then D1 q 28 days for subsequent cycles for up to 7 years from starting treatment.
89556953|NCT04071457|No Intervention|Arm 2b: Stop Lenalidomide + Daratumumab/rHuPH20|MRD- and randomized to Arm 2b: Discontinue protocol therapy.
89556954|NCT04060719|Experimental|Reference (Period 1) - BI 894416 alone|Reference (Period 1) followed by Test (Period 2)
89556955|NCT04060719|Experimental|Test (Period 2) - BI 894416 + Rifampicin|
88963599|NCT02024945||Propiverine|Participants with symptoms of OAB, prescribed propiverine in accordance with the summary of product characteristics (SPC).
89025981|NCT04401592||disease and control|
89025982|NCT01243398|Experimental|Gefitinib 500mg once daily|Gefitinib 500mg once daily
89025983|NCT01243398|Placebo Comparator|Placebo|Gefitinib 500mg once daily
89025984|NCT04399291||Residential care facility residents|Older adults recruited from care homes in Northern Ireland
89025985|NCT00466856|Experimental|Sir-Spheres|
89025986|NCT02893189|Experimental|4G7-CARD T-cells|All patient will receive modified CAR19 T-cells.
89556956|NCT04011384|No Intervention|Control Group|Participants in this arm will view the typical web-based ordering system platform (usual care group).
89556957|NCT04011384|Experimental|Behavioral Economic Intervention Group|Participants in this arm will be exposed to the web-based ordering system with multiple behavioral economic interventions applied, including healthy food shopping cart defaults, healthy placement choice architecture, traffic light nutrition labels, social norms messaging, and healthy swaps.
89556958|NCT03910413|Other|Dual Energy CT|
89556959|NCT03877406|Active Comparator|Control group|up-titration of standard medication including monotherapy or combination of Metformin, Sulfonylurea, DPP4 inhibitor
89556960|NCT03877406|Experimental|Study group|addition of empagliflozin 10mg qd on standard oral antihyperglycemic agents
89556961|NCT03808675|Experimental|Aerobic|Participants randomized to aerobic exercise
89556962|NCT03808675|Other|Control|Participants randomized to usual care with PD specific health education
89556963|NCT03746106|Active Comparator|Thiamine only|5mg thiamine tablet by mouth. This arm will be included in both Parts 1 and 2 of the study.
89556964|NCT03746106|Experimental|Trimethporim + thiamine combination|5mg thiamine tablet and 300mg trimethoprim tablet by mouth. This arm will be included in both Parts 1 and 2 of the study.
89556965|NCT03746106|Experimental|Metformin + thiamine combination|5mg thiamine tablet and 1000mg metformin tablet by mouth. This arm will be included in only Part 1 of the study.
89556966|NCT03737461|Experimental|Allogenic BM-MSCs Injection|Injection of a dose of 20.106 allogenic BM-MSCs via imaging control into the disk affected by DDD where they are expected to exert their therapeutic effects.
89556967|NCT03737461|Sham Comparator|Sham Procedure|anesthetic infiltration with 2 ml of 1% xylocaine in the paravertebral muscles close to the affected segment
89556968|NCT03722173|Experimental|BI 894416 alone (R) / BI 894416+Itraconazole (T)|"Participants were administered 3 milligram (mg) BI 894416 tablet (1 mg X 3 tablets) orally on Day 1 alone in treatment period 1 (R), and along with 20 milliliter (mL) of 10 mg/ mL Itraconazole oral solution in treatment period 2 (T).~In period 2 (T), participants received 200 mg ((20 milliliter (mL)) of Itraconazole oral solution once daily for 5 days, from Day -3 to Day 2. On Day 1 participants received additionally after the Itraconazole dosing, 3 mg BI 894416 tablet (1 mg X 3 tablets) orally in treatment period 2 (T). Both treatment periods were separated by a washout period of at least 6 days between BI 894416 administrations. In both treatments, BI 894416 was administered to subjects in the fasting state."
88963600|NCT02024958||indirect calorimetry measurement|Measurement of energy expenditure in made by indirect calorimetry in patients laying down in a supine position on a bed during ongoing measure by connecting the calorimeter to the endotracheal tube (invasive mechanical ventilation) or to the facemask (non-invasive mechanical ventilation), or by using a transparent canopy in plexiglas to cover the head while room-air flows through and is mixed with the expirate (spontaneous breathing). This mixture of patient breath and room air is finally collected and analyzed by the IC device for O2 and CO2 concentrations, and used to calculate EE. EE is calculated using the modified Weir equation.
88963601|NCT02024984|Experimental|Group A|Luteal Phase Administration of Clomiphene (50mg twice per day for 5 days)
88963602|NCT02024984|Active Comparator|Group B|Follicular Phase Administration of Clomiphene Citrate in PCOS(50mg twice per day for 5 days)
88963603|NCT02024997|Experimental|Abdominal MRI|Subjects will undergo magnetic resonance imaging (MRI) with contrast. Magnetic resonance (MR)_freebreathing scan will be acquired. MR_inspiration scan will be acquired. MR_expiration scan will be acquired.
88963604|NCT02025023|Active Comparator|Incision and Curettage|A vertical incision over the area of chalazion will be done. Inflammatory material will be removed and the chalazion capsule will be excised.
89556969|NCT03717194|Experimental|Ertugliflozin|Ertugliflozin 5 mg in addition to their preexisting metformin and/or DPP4 inhibitor
88963605|NCT02025023|Active Comparator|Injection of Triamcinolone Acetonide|0.1 ml of triamcinolone is injected directly in the chalazion.
89556970|NCT03717194|Placebo Comparator|Control group|Placebo in addition to their preexisting metformin and/or DPP4 inhibitor
89556971|NCT03695380|Experimental|Arm A: Cobimetinib - Niraparib|Stage 2 - Patients will receive cobimetinib PO QD on Days 1-21 (21/7 schedule) in combination with niraparib PO QD on Days 1-28 of each 28-day cycle at the established dose for the doublet regimen in Stage 1, Cohort 1.
89556972|NCT03695380|Experimental|Arm B: Cobimetinib - Niraparib - Atezolizumab|Stage 2 - Patients will receive cobimetinib PO QD on Days 1-21 (21/7 schedule) in combination with niraparib QD on Days 1-28 at the established doses for the triplet regimen in Stage 1,Cohort 2 plus atezolizumab by IV infusion at the fixed dose of 840 mg on Days 1 and 15 (+/-3 days) of each 28-day cycle.
89556973|NCT03695380|Experimental|Cohort 1 - Cobimetinib - Niraparib|"Stage 1 - Patients in Cohort 1 will be treated with cobimetinib plus niraparib.~Cobimetinib: Patients will receive a starting dose of 60 mg by mouth (PO) daily (QD) on Days 1-21 of each 28-day cycle.~Niraparib: Patients will receive a starting dose of 200 mg of niraparib PO QD on Days 1-28 of each 28-day cycle."
89556974|NCT03695380|Experimental|Cohort 2 - Cobimetinib - Niraparib - Atezolizumab|"Stage 1 - Patients in Cohort 2 will be treated with cobimetinib plus niraparib and atezolizumab.~Cobimetinib: Patients will receive a starting dose of 60 mg by mouth (PO) daily (QD) on Days 1-21 of each 28-day cycle.~Niraparib: Patients will receive a starting dose of 200 mg of niraparib PO QD on Days 1-28 of each 28-day cycle.~Atezolizumab: Patients will also receive atezolizumab administered as an IV infusion at a fixed dose of 840 mg on Days 1 and 15 (+/-3 days) of each 28-day cycle."
88963606|NCT02025023|Active Comparator|Injection of 5-fluorouracil|0.1 ml of 5-fluorouracil is injected directly in the lesion transconjunctivally.
88963607|NCT02025023|Active Comparator|Injection of triamcinolone/5FU mixture|0.1 ml of a 4:1 mixture of 4 parts 5-FU and 1 part triamcinolone is injected in the lesion.
88963608|NCT02025049|Experimental|DP-b99|Intravenous DP-b99, 1.0 mg/kg twice daily for 2 consecutive days
88963609|NCT02025049|Placebo Comparator|Placebo|Intravenous placebo (mannitol based, DP-b99 look-alike) twice daily for 2 consecutive days
89556975|NCT03678025|Active Comparator|Arm I (SST)|Participants receive 1 acceptable form of SST as in Induction except for treatment with docetaxel and prednisone.
89556976|NCT03678025|Experimental|Arm II (SST, prostatectomy or radiation therapy)|Participants receive 1 acceptable form of SST as in Induction except for treatment with docetaxel and prednisone. Participants undergo prostatectomy within 8 weeks after randomization or radiation therapy within 4 weeks of randomization.
89556977|NCT03678025|Active Comparator|Step 1 (pre-randomization)|Standard treatment data collection prior to randomization
88963610|NCT02025062|No Intervention|Control|In the control arm, patients are followed-up by the head-and-neck physician, oncologist and radiotherapists and did not benefit of Comprehensive Geriatric Assessment.
89025987|NCT00464516|Experimental|estetrol|
89025988|NCT00464516|Placebo Comparator|placebo|
89556978|NCT03636256|Experimental|Non-Muscle Invasive Bladder Cancer|Subjects will be enrolled in sequential, dose escalating cohorts of NanoDoce direct injection (0.75, 1.5, 2.5, or 3.75 mg/mL). Subjects will also receive an initial NanoDoce intravesical instillation at 2.0 or 3.0 mg/mL and additional Induction (6 weekly NanoDoce intravesical instillations, followed by 6 weeks of rest) and Maintenance (3 weekly NanoDoce intravesical instillations, followed by 9 weeks of rest) instillations at 2.0 or 3.0 mg/mL.
89556979|NCT03636256|Experimental|Muscle Invasive Bladder Cancer|Subjects will be enrolled in sequential, dose escalating cohorts of NanoDoce direct injection (0.75, 1.5, 2.5, or 3.75 mg/mL). Subjects will also receive an initial NanoDoce intravesical instillation at 2.0 or 3.0 mg/mL. Subjects will then go on to receive institutional standard of care.
89556980|NCT03633201|Active Comparator|Cruciate Retaining|
89556981|NCT03633201|Active Comparator|Medial Congruent|
89556982|NCT03633201|No Intervention|Healthy Controls|
89556983|NCT03614676|Other|Pregnant Women/Mothers Group|Subjects, 18 to 45 years of age enrolled in the study in view of determining pregnancy outcomes and related events of interest, as well as the occurrence of lower respiratory tract illness (LRTI) associated with respiratory syncytial virus (RSV).
89556984|NCT03614676|Other|Neonates/Infants Group|Infants born to mothers aged 18-45 years old, enrolled for the collection of infant events of interest, nasal swabs and the incidence of RSV LRTI and RSV hospitalization.
89556985|NCT03559946|Sham Comparator|Standard Protocol (SP) group|The patients in the SP group will receive one PTNS treatment and one sham treatment per week for 12 weeks
89556986|NCT03559946|Experimental|Condensed Protocol (CP) group|The patients in the CP group will receive 2 PTNS treatments per week for 12 weeks.
89556987|NCT03480581|Experimental|Reverse First ICARE Training|Participants will engage in 12-sessions in the reverse direction followed by 12-sessions in the forward direction.
88963611|NCT02025062|Experimental|Comprehensive Geriatric Assessment|The CGA (Comprehensive Geriatric Assessment) is a multidimensional assessment of general health status, using validated scales. It produces an inventory of problems which can then serve to develop an individualized geriatric intervention plan of care and follow-up.
88963612|NCT02025088|Active Comparator|Laser|In each laser session, the non-ablative fractional erbium laser 1340 nm ProDeep (Etheria ® platform/Industra) with tip 100mtz/cm ² will be applied across the face, with a power of 120mJ/mtz time and pulse time of 5ms.
88963613|NCT02025088|Active Comparator|Microneedling|"In the microneedling sessions, the instrument contains 192 microneedles with 2 mm depth, which will be applied to the face in four different directions, making up about 20 movements of coming and going in each direction."
88963614|NCT02025101||Slow Coronary Flow|Patients who were hospitalized with anginal pain and with laboratory markers or pathological ECG for ischemia.
88963615|NCT02025114|Experimental|Capsule|The starting dose of selumetinib in combination with the standard dose of gefitinib (250mg QD) on a continuous dosing schedule will be 50mg QD. Total 3 doses of selumetinib will be tested (50mg QD, 50mg BID and 75mg BID).
88963616|NCT02025127|Experimental|Trophic feeding|Mechanically ventilated patients with septic shock > 18 years old randomized to this group will receive more than 50 but less than 600 kilocalories of enteral nutrition per day while on vasopressors. This will be started within 24 hours of intensive care unit admission.
88963617|NCT02025127|No Intervention|No Enteral Nutrition|Mechanically ventilated patients with septic shock randomized to this group will receive no enteral nutrition while on vasopressor support.
88963618|NCT02025140|Active Comparator|: This group consisted of 30 patients.|The traditional IANB injection was given according to the standard technique (Evers and Haegerstam 1981). From everyday practice, it is known that the present operator takes approximately 60 to 90 seconds to give a mandibular block
88963619|NCT02025140|Experimental|30 IANB with Computer controlled|The IANB injection was given by a computer- regulated device performed with the STA system. The IANB injection was given according to the manufacturer's instruction (the model was used is the STA Single Tooth Anesthesia System produced by Milestone Scientific, Livingston, NJ).
88963620|NCT02025140|Experimental|consisted of 30 periodontal anesthesia|The interligamental injection was given by computer- regulated device performed with the STA system.
89208279|NCT04046822|Placebo Comparator|Placebo|Placebo is administered once daily by subcutaneous injections with the pen-injector, either in the abdomen, thigh or upper arm. Injections can be done at any time of day irrespective of meals. Subjects will be instructed to escalate the placebo dose to 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day.
89556988|NCT03480581|Experimental|Forward First ICARE Training|Participants will engage in 12-sessions in the forward direction followed by 12-sessions in the reverse direction.
89556989|NCT03451331|Experimental|Arm A|Gemcitabine plus carboplatin plus nivolumab
89556990|NCT03451331|Experimental|Arm B|Gemcitabine plus oxaliplatin plus nivolumab
89556991|NCT03418961|Experimental|Arm I (carvedilol)|Patients not taking beta blocker, ARB, or ACE inhibitor at registration receive carvedilol PO BID. Courses repeat every 12 weeks for 108 weeks in the absence of disease progression or unacceptable toxicity.
89556992|NCT03418961|Active Comparator|Arm II (no intervention)|Patients not taking beta blocker, ARB, or ACE inhibitor at registration receive no study intervention for up to 108 weeks.
89556993|NCT03418961|Active Comparator|Arm III (observation)|Patients undergo observation for up to 108 weeks.
89556994|NCT03406884|Experimental|Open label C-kit+ cells Group A|Group A is an open-label treatment group determining safety and feasibility. Participants enrolled in this group will be receiving previously harvested c-kit+ cells during their Stage II BDCPA operation. Harvested c-kit+ cells will be injected into the right ventricle directly intramyocardially.
89556995|NCT03406884|Active Comparator|C-kit+ cells Group B|Participants randomized to Group B Treatment Group will receive previously harvested c-kit+ cells during their Stage II BDCPA operation. Harvested c-kit+ cells will be injected into the right ventricle directly intramyocardially.
89556996|NCT03406884|No Intervention|No Intervention Group|Participants randomized to Group B Control Group will receive only their standard of care (SOC) Stage II BDCPA operation without the injection of harvested c-kit+ cells.
89556997|NCT03386357|Experimental|A (pembrolizumab+RT)|Pembrolizumab (200mg absolute, q3w) combined with radiotherapy (12x3Gy) of one, two or three metastases.
89556998|NCT03386357|Active Comparator|B (pembrolizumab)|Pembrolizumab (200mg absolute, q3w) without radiotherapy
89556999|NCT03293784|Other|COHORT 1|Nivolumab+Ipilimumab in combination with Anti TNF-α Certolizumab
89557000|NCT03293784|Other|COHORT 2|Nivolumab+Ipilimumab in combination with Anti TNF-α Infliximab
89557001|NCT03279029|Experimental|patients with aortic valve disease (AVD).|
89557002|NCT03279029|Experimental|patients with left ventricular assist device (LVAD|
89557003|NCT03230890|Experimental|HIRREM|This is the intervention, treatment arm that all participants receive in this open label, single arm trial. The intervention is High-resolution, relational, resonance-based, electroencephalic mirroring (HIRREM).
89557004|NCT03041220||cesarean section|Obese pregnant patients who have had a cesarean section.
89557005|NCT02996487|Placebo Comparator|Placebo|Placebo every 6 hours. A placebo will look like the drug being studied, but have no active ingredients, in this case it will be fruit punch with vitamins added to mimic the taste of vancomycin.
89557006|NCT02996487|Active Comparator|vancomycin|Vancomycin 125 mg by mouth every 6 hours
89557007|NCT02980276|Active Comparator|Treatment|Participants randomised to the treatment arm will receive active metformin in addition to standard care. Metformin tablets will be titrated according to a dosing schedule to achieve the pre-specified glucose targets. Tablets will be in 500mg doses and will commence at 1 tablet per day (500mg) increasing to a maximum of 5 tablets per day (2500mg).
89557008|NCT02980276|Placebo Comparator|Control|Participants randomised to the placebo arm will receive placebo in addition to standard care. Placebo will be titrated according to the dosing schedule to achieve the pre-specified glucose targets. Placebo tablets will commence at 1 tablet per day and will be increased to a maximum of 5 tablets per day over 10 days as with the treatment group.
89557009|NCT02920671||Mitochondrial Disease|Clinical history consistent with the diagnosis of mitochondrial disease, and molecular genetic diagnosis.
89557010|NCT02920671||Obese|BMI > 30 kg/m2. These will be matched with subjects with mitochondrial disease by age, sex, estrogen status (women), and usual self-reported physical activity.
89557011|NCT02920671||Normal Weight & Overweight|BMI 18.5 - < 30 kg/m2. These will be matched with subjects with mitochondrial disease by age, sex, estrogen status (women), and usual self-reported physical activity.
89557012|NCT02914600|Experimental|Filgotinib 200 mg (blinded dosing)|Filgotinib 200 mg + placebo to match filgotinib 100 mg for up to 390 weeks
89557013|NCT02914600|Experimental|Filgotinib 100 mg (blinded dosing)|Filgotinib 100 mg + placebo to match filgotinib 200 mg for up to 390 weeks
89557014|NCT02914600|Placebo Comparator|Placebo (blinded dosing)|Placebo to match filgotinib 200 mg for up to 390 weeks
89557015|NCT02914600|Experimental|Filgotinib 200 mg (open-label)|Filgotinib 200 mg for up to 390 weeks
88963621|NCT02025153|Other|Cohort|pain testing. All 444 subjects enrolled in the study. Subjects will receive preoperative physical (tonic heat stimulation, mechanical temporal summation and wound hyperalgesia), psychological (State Trait Anxiety Inventory, Pain Catastrophizing Scale), and genetics test; postoperative pain score assessment at 24, 48 hours; postoperative wound hyperalgesia in open abdominal hysterectomy at 72 hours; and phone survey for CPSP at 4 months.
89557016|NCT02914600|Experimental|Filgotinib 100 mg (open-label)|Filgotinib 100 mg for up to 390 weeks
89557017|NCT02727478|Experimental|Balance training group|1 hour group balance training twice weekly for 10 weeks, as well as perform a home exercise program.
89557018|NCT02727478|No Intervention|Control group|Subjects in this group will receive no intervention and will be advised to continue their normal level of exercise throughout the intervention period.
89557019|NCT02614794|Experimental|Tucatinib in combination with capecitabine & trastuzumab|Tucatinib + capecitabine + trastuzumab
89557020|NCT02614794|Active Comparator|Placebo in combination with capecitabine & trastuzumab|Placebo + capecitabine + trastuzumab
89557021|NCT02495896|Experimental|Arm A (sEphB4-HSA, nab-paclitaxel, gemcitabine hydrochloride)|Patients receive recombinant EphB4-HSA fusion protein IV over 1 hour on days 1, 8, 15, and 22 (beginning course 2), paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89557022|NCT02495896|Experimental|Arm B (sEphB4-HSA, docetaxel)|Patients receive recombinant EphB4-HSA fusion protein IV over 1 hour on days 1, 8, and 15 (beginning course 2) and docetaxel IV over 1 hour on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
88963622|NCT02025153|Other|Chronic Post-surgical Pain|pain testing. physical testing, psychological testing, genetics testing and functional brain imaging
88963623|NCT02025153|Other|No Chronic Post-surgical Pain|pain testing. physical testing, psychological testing, genetics testing and functional brain imaging
88963624|NCT02025166|Active Comparator|Paracetamol|Pain treatment, aniline analgesics
88963625|NCT02025166|Active Comparator|lornoxicam|Pain treatment, nonsteroidal anti-inflammatory (NSAID)
88963626|NCT02025192|Experimental|Tucatinib (ONT-380) in combination with capecitabine|
88963627|NCT02025192|Experimental|Tucatinib (ONT-380) in combination with trastuzumab|
88963628|NCT02025192|Experimental|Tucatinib (ONT-380) combined with capecitabine and trastuzumab|
88963629|NCT02025218|Experimental|Re-administration gefitinib|
89557023|NCT02495896|Experimental|Arm C (sEphB4-HSA, cisplatin, gemcitabine hydrochloride)|Patients receive recombinant EphB4-HSA fusion protein IV over 1 hour on days 1, 8, and 15 (beginning course 2), cisplatin IV over 120 minutes and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89557024|NCT02442297|Experimental|HER2-specific T cells - High Risk|Subjects with HER2 staining of Grade 3 (51-100% of cells staining for HER2) and intensity scores of 3+ will be assigned to the High Risk arm. Three cell dosing schedules (1, 2, 3) consisting of combinations of three cell doses (A, B, C) will be evaluated.
89557025|NCT02442297|Experimental|HER2-specific T cells - Standard Risk|All other patients not meeting the high risk description will be assigned to the Standard Risk arm. Three cell dosing schedules (1, 2, 3) consisting of combinations of three cell doses (A, B, C) will be evaluated.
89557026|NCT02411253|Experimental|rhIL-2|"0.5 MIU/m²/day of IL2 with a maximum of 1MIU/day in a volume of 1 ml for children and adolescents,~1MIU/day for adults.~Subcutaneous injection every day (5 days) then:~Regimen A injection every two weeks between D15 and D351,~Regimen B injections every week between D15 and D351"
89557027|NCT02411253|Placebo Comparator|Placebo|"Placebo with a identical formulation and regimen of injections i.e. Subcutaneous injection every day (5 days) then:~Regimen A injection every two weeks between D15 and D351~Regimen B injections every week between D15 and D351"
89557028|NCT02266745|Experimental|Arm 1: PT-112 injection|Arm 1: PT-112 Injection, administered by intravenous infusion, biweekly 360 mg/m2
89557029|NCT02266745|Experimental|Arm 2: PT-112 injection|Arm 2: PT-112 Injection, administered by intravenous infusion, biweekly 250 mg/m2
89557030|NCT02266745|Experimental|Arm 3: PT-112 injection|Arm 3: PT-112 Injection, administered by intravenous infusion, 360 mg/m2 for two doses, 250 mg/m2 for subsequent doses
89557031|NCT02125968|Active Comparator|interactive video game|"Participants in interactive video game group receive six 20-min sessions of hot pack therapy combined 20-min of diathermy therapy over the low back followed by 15-min interactive video game intervention, for 3 times per week for a 2-week duration.~Short- and medium-term therapeutic effects of interactive video game intervention for patients with chronic low back pain will be assessed."
89557032|NCT02125968|Sham Comparator|therapeutic exercise|"Participants received six 20-min sessions of hot pack therapy combined 20-min of diathermy therapy over the low back followed by 15-min supervised therapeutic exercise,for 3 times per week for a 2-week duration.~short- and medium-term therapeutic effects of video game play therapy for patients with chronic low back pain will be evaluated."
89557033|NCT02100904||Women undergoing radiofrequency ablation.|Most women (75%) in the trial will be in the group who receive treatment with radiofrequency ablation (Acessa).
89557034|NCT02100904||Women undergoing myomectomy|About 25% of women in the trial will be in the group who receive treatment with myomectomy.
89557035|NCT02015325|No Intervention|Control|Control schools were included if they did not have any ongoing water and sanitation hygiene initiative.
89557036|NCT02015325|Experimental|Planet Water Program Intervention|School were included that were receiving the Planet Water Foundation's Program (PWP) providing a school-based program focusing on three components: (a) access to safe water, (b) access to hand washing facilities, and (c) access to water-health and hygiene education. Children will have access to safe water in the schools provided through the use of an AquaTower, and a 4 week educational program.
89557037|NCT01886391|Experimental|Diaphragmatic Breathing Retraining|Diaphragmatic breathing retraining (DBR) with a slow breathing pattern such that breathe in slowly through the nose for 4 seconds and breathe out slowly through the mouth for 6 seconds and mediated by Self-efficacy for DBR. Patients in this group will receive detailed instructions, in-person, as to how to carry out the DBR intervention at home. They will provide a return demonstration to the research staff about how to do the deep breathing. They will also receive a written script of the DBR intervention. In addition to the script, patients in this group will receive 3 audio CDs (1 for week 1 [5-min DBR], 1 for week 2 [10-min DBR], 1 for weeks 3-8 [15-min DBR]), developed by the PI, to use to practice their deep breathing.
89557038|NCT01803165||Single shot femoral and sciatic nerve block|Prospective patient study group who present for infrainguinal bypass grafting and will receive single shot femoral and sub gluteal sciatic nerve blocks.
89557039|NCT01803165||Retrospective study group|Retrospective chart review will be performed and data collected on patients who have undergone infrainguinal bypass grafting under general anesthesia and without the use of regional or neuraxial anesthesia.
89557040|NCT01782443|Experimental|Experimental Treatment Arm|Ziv-aflibercept IV every 2 weeks, 4 mg/kg
89557041|NCT01736072|Active Comparator|Laparoscopic Resection of Rectal Cancer|Research Subjects will be randomized to Surgical Resection of Rectal Cancer by Standard Laparoscopic Surgery.
89557042|NCT01736072|Active Comparator|Robotic Resection of Rectal Cancer|Research Subjects will be randomized to Surgical Resection of Rectal Cancer by Robotic Assisted Laparoscopic Surgery.
89557043|NCT01712815|Experimental|Diagnostic (fluorine F 18-clevudine PET/CT)|Patients receive fluorine F18-clevudine IV over 1 minute and then undergo PET/CT scan at baseline. Patients with HER2+ breast cancer also undergo fluorine F 18-clevudine PET/CT scan 2-3 weeks after the first course of treatment and after completion of treatment.
88963630|NCT02025231|Experimental|External beam radiotherapy|Hypofractionated external beam radiation delivered in 4 different sequential dose/fractionation groups.
88963631|NCT02025244|Active Comparator|Key Hole Biopsy|Patients with endoscopically detected Upper Gastrointestinal Submucosal Tumors with diameter ≥ 2cm are, according to randomization, allocated to undergo esophagogastroduodenoscopy with Key Hole Biopsy consisting of forceps biopsy through mucosal incision by a needle knife, with subsequent cytological /histological and immunohistochemical evaluation of specimen. In the case of Gastrointestinal Stromal Tumors (GIST), the possibility to determine the mitotic activity is evaluated.
88963632|NCT02025244|Active Comparator|EUS-FNA|Patients with endoscopically detected Upper Gastrointestinal Submucosal Tumors with diameter ≥ 2cm are after randomization allocated to undergo endosonography-guided fine-needle-aspiration biopsy (EUS-FNA) by 22G needle, with subsequent cytological /histological and immunohistochemical examination of the specimen. In the case of Gastrointestinal Stromal Tumors (GIST), the possibility to determine the mitotic activity is evaluated.
88963633|NCT02025283||Group Decompression|Group Decompression: Patients assigned to Group Decompression. After determination of the appropriate space for the approach under fluoroscopy guidance, a 17 gauge trochar needle was advanced posterolaterally up to the center of the disc. Then site verification was done again with water soluble contrast material under floroscopy guidance. Then flexible intradiscal decompression catheter (SpineCATH®, Smith & Nephew, Memphis, TN) were advanced inside the trochar needle towards the disc and decompression was performed. After being sure of achieving sufficient decompression inside the disc, the decompression device were removed under fluoroscopy guidance and the incision site was closed and the patients were recommended to have bedrest for 2 hours.
89557044|NCT01649232||active tDCS|The patients with ADHD received electro-stimulation at 20 sessions with 2 mAmp 1 session per day alternative days. The investigators used an ERP analysis derived of 20 channel EEG recordings during resting state and visual CPT to define the tDCS site and polarity at refractory ADHD patients to conventional treatments. Time courses, topography and amplitude of ERPs, correlated with clinical scores, were compared with the controls average (data base)to guide the selection of personal tDCS parameters. The following relation shown how many patients were submitted to intervention in each electrode, according to their polarity: Anodal tDCS: T5, T6, etc. Cathodal tDCS: T5, T6, etc.
88963634|NCT02025283||Group Nucleoplasty|Group Nucleoplasty : Patients assigned to Group Nucleoplasty. After determination of the appropriate space for the approach under fluoroscopy guidance, a 17 gauge trochar needle was advanced posterolaterally up to the center of the disc. Then site verification was done again with water soluble contrast material under floroscopy guidance. Then radiofrequency-compatible needle (Coblation: Perc DLE SpineWandTM [ArthroCare Spine, Sunnyvale, CA] were advanced inside the trochar needle towards the disc and nucleoplasty was performed. After being sure of achieving sufficient decompression inside the disc, the nucleoplasty probe was removed under fluoroscopy guidance and the incision site was closed and the patients were recommended to have bedrest for 2 hours.
88963635|NCT02025296|No Intervention|Self-Monitoring of Blood Glucose|measurement of their blood glucose level using a glucometer at least eight times a week
88963636|NCT02025296|Experimental|U-healthcare|individualized multidisciplinary u-healthcare service combined with exercise monitoring and dietary feedback on glucose control
88963637|NCT02025309|Active Comparator|Group Methylprednisolone|Patient in this group received general anaesthesia for surgical procedures. During the anesthesia management methylprednisolone was administered intravenously (1mg/kg) to the patients in this group. Also neuromuscular monitorisation was performed to assess the train of four ratio at the end of the procedure, after the reversal of neuromuscular block. All patients were followed during the recovery period from general anaesthesia and the time needed to regain a full neuromuscular recovery was noted. For that, the train of four ratio was followed up and the ratio of 0.9 was recorded.
88963638|NCT02025309|Placebo Comparator|Group Control|Patients who received general anaesthesia and endothracheal entubation but who did not recieved methyprednisone during general anaesthesia were enrolled in the study as control group. Neuromuscular monitorisation was performed to assess the train of four ratio at the end of the procedure, after the reversal of neuromuscular block. All patients were followed during the recovery period from general anaesthesia and the time needed to regain a full neuromuscular recovery was noted. For that, the train of four ratio was followed up and the ratio of 0.9 was recorded.
88963639|NCT02025322|No Intervention|Standard of Care|Between baseline and 4-month follow-up, control group patients will receive current standard of care which includes: (a) two or more HIV basics education and medication adherence counseling sessions with their HIV specialty care provider and Patient Navigator; (b) resource referrals from a Patient Navigator based on the participant's needs (e.g., mental health, substance abuse, social support groups, etc.); and (c) automated medical appointment reminders via phone.
89025989|NCT04397809||Acute Pulmonary Exacerbation (APE)|Those subjects presenting with APE will be treated with at least two pathogen specific I.V. antibiotics, as dictated by their treating physician and compliant with standard guidelines for care of an APE.
89557045|NCT01649232||controls|Healthy people that not receive tDCS
89557046|NCT01555632|Placebo Comparator|Arm I (placebo)|Patients receive placebo PO QD for 6 months in the absence of disease progression or unacceptable toxicity.
89557047|NCT01555632|Experimental|Arm II (atorvastatin calcium)|Patients receive atorvastatin calcium PO QD for 6 months in the absence of disease progression or unacceptable toxicity.
89557048|NCT01337921|Experimental|Multi-strain Synbiotic|Multi-strain probiotic with prebiotics
89557049|NCT01337921|Active Comparator|Multi-strain Probiotic|Multi-strain Probiotic without prebiotics.
89557050|NCT01274026||evaluation of benefit of sapropterin|Intervention 'sapropterin dihydrochloride': 20 individuals, either known to be non-responsive, or naive to sapropterin, are given a 4 week administration of sapropterin. Pre-, and Post- evaluation of behavior, executive function, neurotransmitter function, and genomic expression are assessed and evaluated for change.
89557051|NCT01225757|Experimental|Echocardiography|These patients will have echocardiography guided fluid management
89557052|NCT01225757|Active Comparator|Traditional fluid management|Fluid management will be guided by monitoring of central venous pressure and urine output.
89557053|NCT01186029|Active Comparator|EMEND Added to the Treatment Regimen for Post-Discharge and Post-Operative Nausea and Vomiting|The addition of Aprepitant (Emend), an antiemetic, to 2 drugs that are already used as a standard of care for post-operative nausea and vomiting and post-discharge nausea and vomiting.
89557054|NCT01186029|No Intervention|Standard Treatment Regimen for Post-Discharge and Post-Operative Nausea and Vomiting|No addition of Aprepitant (Emend), an antiemetic, to 2 drugs that are already used as a standard of care for post-operative nausea and vomiting and post-discharge nausea and vomiting.
89557055|NCT00983463||Obese, bariatric surgery, liver biopsy|Obese subjects approved and scheduled for bariatric surgery at Vanderbilt University Medical Center
89557056|NCT00983463||Normal BMI, abdominal surgery, liver biopsy|Normal weight subjects having elective abdominal surgery at Vanderbilt University Medical Center.
89557057|NCT00983463||Liver transplantation donors and recipients|All livers made available for implantation or explantation will be eligible.
89557058|NCT00955968|Experimental|Continue HAART|Continue receiving HAART within 0-42 days after delivery or other pregnancy outcome.
89557059|NCT00955968|Active Comparator|Stop HAART|Stop receiving HAART within 0-42 days after delivery or other pregnancy outcome and resume HAART when protocol specified criteria were met.
89557060|NCT00955136|Experimental|High MI impulses, myocardial infarction, echocardiography|Using the transthoracic three dimensional imaging probe, low mechanical index (MI) will examine wall motion. Intermittent high MI impulses will be administered over the microvasculature where there are wall motion abnormalities using an imaging plan that best aligns itself with the risk area. One vial of MRX 801 to be infused intravenously during echocardiography with high mechanical index impulses.
89557061|NCT00896012|Experimental|1. Low-dose tacrolimus arm|Patients in this group will continue to receive tacrolimus at reduced doses. Doses will be titrated to achieve tacrolimus trough blood levels between 4 and 6. Myfortic at doses of 720 mg BID and steroids will be continued for the duration of the study (12 months). All patients will undergo a second protocol biopsy at 12 months.
89557062|NCT00896012|Experimental|2. Rapamune conversion arm:|Patients in this group will undergo a gradual conversion from tacrolimus to Rapamune therapy. Tacrolimus will be withdrawn progressively over a period of 7-10 days. Dosage adjustments will be made with the aim of reducing the blood levels of tacrolimus by 25% every other day until tacrolimus is discontinued. Rapamune will be given at a dose of 5mg/day for two days beginning at the initiation of tacrolimus reduction. Thereafter, Rapamune will be given at a dose of 3 mg/day. The dose of Rapamune will be titrated to achieve a blood level (by HPLC) between 5 and 10 for the duration of the study.
89557063|NCT00876226|Experimental|Pharmacokinetics of Citalopram in Patients With Short Bowel Syndrome|"Citalopram pharmacokinetics will be studies in subjects with short bowel syndrome.~Citalopram 20mg orally will be given to the subjects and on the seventh day blood will be drawn at hours 0,1,2,3,4,6,8,12,16 and 24 hours post-dose."
89557064|NCT00816413|Experimental|Donor Stem Cell Transplant, Pentostatin & Total-Body Irradiation for Hematological Cancer|This phase I/II trial is studying the side effects of giving a donor stem cell transplant after pentostatin and total-body irradiation and to see how well it works in treating patients with hematological cancer.
89557065|NCT00734838|Experimental|Core needle biopsy|Patients needing a needle biopsy of a breast mass
89557066|NCT00734838|Placebo Comparator|Reduction mammoplasty|Any patients scheduled for a reduction mammoplasty who would like to participate in a study to better understand breast cancer
89557067|NCT00579241|Experimental|1 Transcranial imaging using Doppler Ultrasound|Transcranial imaging using Doppler ultrasound
89557068|NCT00187668||African American|Must self identify as African American with parents and grandparents of the same ethnicity. Must be healthy taking no over the counter medications or prescription medications.
89557069|NCT00187668||Cuacasian|Must self identify as Caucasian with parents and grandparents of the same ethnicity. Must be healthy taking no over the counter medications or prescription medications.
89557070|NCT00187668||Hispanic|Must self identify as Hispanic with parents and grandparents of the same ethnicity. Must be healthy taking no over the counter medications or prescription medications.
89557071|NCT00187668||Asian|Must self identify as Asian with parents and grandparents of the same ethnicity. Must be healthy taking no over the counter medications or prescription medications.
89557072|NCT05917080|Experimental|Group A (Experimental Group)|Manual Therapy Technique Anti-Pronation Low- Dye Taping Technique Intrinsic Foot Muscles Exercises Calf Muscle & Plantar Fascia Stretching VMO Strengthening
89557073|NCT05917080|Experimental|Group B (Experimental Group)|Neuromuscular Training Anti-Pronation Low- Dye Taping Technique Intrinsic Foot Muscles Exercises Calf Muscle & Plantar Fascia Stretching VMO Strengthening
89557074|NCT05917080|Other|Group C (Control Group)|Intrinsic Foot Muscles Exercises Calf Muscle & Plantar Fascia Stretching VMO Strengthening
89557075|NCT05917054||Group 1-bipolar sealing|During the back-table preparation stage of these kidney transplant recipients, bipolar sealing method will be used for sealing the small vessels and lymphatics of the renal allograft.
89557076|NCT05917054||Group 2-conventional silk tie|During the back-table preparation stage of these kidney transplant recipients, conventional silk-tie method will be used for sealing the small vessels and lymphatics of the renal allograft.
89557077|NCT05917041|Experimental|SAT-001|
89557078|NCT05917041|No Intervention|Control Group|Wearing glasses or not
89557079|NCT05917015|Placebo Comparator|Placebo Treatment|a placebo tablet (microcrystalline cellulose) identical in size, shape and color to the treatment
89557080|NCT05917015|Experimental|Dietary supplement intervention|Participants were treated with 2 beta-glucan containing tablets per day for a total duration of 6 weeks.
89557081|NCT05917002|Experimental|Real TBS to the mPFC|The type of stimulation to be used will be intermittent theta burst (iTBS) stimulation to the mPFC with a figure 8 coil (Coil Cool-B65 A/P). Participants will receive three 3-minute sessions of iTBS (600 pulses; 190s; 120% resting motor threshold) with 10-15-minute breaks in between each session or more per participant preference.
88963640|NCT02025322|Experimental|Peer Mentoring|Between baseline and 4-month follow-up, experiment group patients will be receiving (a) Weekly contacts with their Peer Mentor, with the option of receiving more frequent contact, if needed; and (b) 4 monthly, 1-hour workshops on HIV/AIDS, medication adherence, health literacy, and health and wellness. In addition, experiment group participants will also be provided with all standard practice services given to control group participants, including: (c) Two more or HIV basics education and medication adherence counseling sessions with their HIV specialty care provider and Patient Navigator; (d) resource referrals from a Patient Navigator based on the participant's needs; and (e) automated medical appointment reminders via phone.
88963641|NCT02025335||high CMV ELISPOT results|high spot counts in ELISPOT
88963642|NCT02025335||low CMV ELISPOT results|low spot counts in ELISPOT
88963643|NCT02025348|Experimental|Treatment A metoprolol 50mg|IntelliCap® capsule Release profile 1 filled with metoprolol gastroenteral solution 233 mg/mL (dose 50 mg).
89557082|NCT05917002|Sham Comparator|Sham TBS to the mPFC|The MagVenture MagPro system has an integrated, active sham which passes current through two surface electrodes placed on the scalp. The electrodes will be placed on the left frontalis muscle for all sessions. A patient identification card will randomize participants to receive either sham or active stimulation in the first session.This system maintains blinding by a gyroscope in the coil which indicates to the clinical staff whether the coil should be rotated up or down for this participant once the card is entered into the machine. One side of the coil is active, the other is sham. The integrity of the double blind procedure will be assessed by asking the patients and study personnel rate their confidence regarding whether they thought they received real or sham. (Scale 1-10)
88963644|NCT02025348|Experimental|Treatment B metoprolol 50mg|IntelliCap® capsule Release profile 2 filled with metoprolol gastroenteral solution 233 mg/mL (dose 50 mg).
88963645|NCT02025348|Experimental|Treatment C metoprolol 50mg|IntelliCap® capsule Release profile 3 filled with metoprolol gastroenteral solution 233 mg/mL (dose 50 mg).
88963646|NCT02025348|Experimental|Treatment D metorpolol 50mg|metoprolol oral solution 1 mg/mL (dose 50 mg).
88963647|NCT02025361|Experimental|intrarectal lidocaine gel|transrectal ultrasound guided prostate biopsy was performed with intrarectal lidocaine gel anesthesia: 10 minutes before the procedure % 2 lidocaine hydrochloride gel instilated into the rectum for local anesthesia
88963648|NCT02025361|Experimental|periprostatic nerve blockade|transrectal ultrasound guided prostate biopsy was performed with intrarectal lidocaine gel anesthesia: 10 minutes before the procedure transrectal ultrasound guided 10 ml prilocaine and serum physiologic blend (5ml %2 prilocaine and 5 ml serum physiologic) injected separetly 5ml right and 5ml left junction between the prostate base and seminal vesicle.
88963649|NCT02025374|Experimental|Hyperbaric levobupivacaine|Group 2 Hyperbaric levobupivacaine % 0.5 plus fentanyl; 2 ml total intrathecally
88963650|NCT02025374|Active Comparator|Hyperbaric bupivacaine|Group 1 Hyperbaric bupivacaine % 0.5 plus fentanyl 2 ml intrathecally
88963651|NCT02025387|Experimental|Experimental|Patients will receive physical activity feedback and be encouraged to achieve the daily goals of physical activity
88963652|NCT02025387|Sham Comparator|Control|Physical activity will be measured but not be informed to patients. She will receive usual care.
88963653|NCT02025400|Active Comparator|Physical Therapy|This arm will receive the standard of care for orthopedic patients receiving a diagnosis and then a recommendation for outpatient physical therapy referral. They will follow through on the referral and attend physical therapy.
88963654|NCT02025400|Experimental|eRehab|This group will not go to formal therapy but receive Internet delivered patient education and exercise instruction. This group will then perform those exercises at home.
89557083|NCT05916976|Other|rTOF-patients|rTOF-patients with age 16 and above enrolled in Adult Congenital Heart Disease (ACHD)-outpatient clinics program with regularly scheduled MRI-exam
89557084|NCT05916898||S-IVL Intervention|"Patients with the presence of a highly calcified, resistant lesion or a significantly under-expanded, previously implanted stent (regardless of the time of implantation) were part of the study cohort. The lesion was defined as resistant after an unsuccessful high-pressure NC balloon inflation (at least 20% under-expansion; whit at least 16 atm.). The decision regarding initial lesion preparation was left to the operators' dissertation and did not imply a recruitment process.~There were no angiographic exclusion criteria regarding lesion anatomy regarding the length, tortuosity, severity, or prior stent placement. Operators supported by angiography assessment with optional intravascular imagining (IVUS/OCT) determined the size of the S-IVL catheter and an appropriate number of pulses for optimal vessel preparation or management of an under-expanded coronary stent."
89557085|NCT02342977|Placebo Comparator|Placebo|Patient will randomly receive a placebo
89557086|NCT02342977|Experimental|Experimental|Patients will randomly receive experimental drug (lacosamide).
89557087|NCT05916859|Placebo Comparator|Group 1. Placebo|routine endodontic treatment will be applied and the application of laser will be simulated with the equipment, but no radiation will be emitted
89557088|NCT05916859|Experimental|Group 2. PDT 10 s|Conventional ET + PDT. PDT will be carried out with diode laser with optical fibre coupled to the equipment (660 nm, 100 mW, 10 s). The photosensitizer used will be methylene blue.
89557089|NCT05916859|Experimental|Group 3: PDT 20 s|Conventional ET + PDAT. PDAT will be carried out with diode laser with optical fibre coupled to the equipment (660 nm, 100 mW, 20 s). The photosensitizer used will be methylene blue.
89557090|NCT05916846|Other|EUS-guided radiofrequency ablation of pancreatic cystic lesion(s)|Single arm study. EUS-guided intervention with radiofrequency ablation of pancreatic cystic lesions. Primary population of interest: Branch duct IPMN (intraductal papillary mucinous neoplasm) with high-risk for surgical intervention. The intervention is performed using an FDA-cleared device (EUS-RFA probe).
89557091|NCT05916781|Experimental|steroid tapering group|0~6th month: mycophenolate mofetil (1g/d) + tacrolimus (2.0mg/d) + steroid (1 pill/d) 6th~18th month: mycophenolate mofetil (1g/d) + tacrolimus (2.0mg/d) 18th~30th month: Participants who stop steroid treatment and do not flare will be randomly assigned to monotherapy with mycophenolate mofetil or tacrolimus
89557092|NCT05916781|Active Comparator|steroid maintenance group|0~18th month: mycophenolate mofetil (1g/d) + tacrolimus (2.0mg/d) + steroid (1 pill/d) 18th~30th month: Participants who do not flare will be randomly assigned to therapy with mycophenolate mofetil + steroid (1 pill/d) or tacrolimus + steroid (1 pill/d)
89557093|NCT05916768|Experimental|Intervention group|"The solution of Pelargonium sidoides extract EPs® 7630:~3x30 drops/day for 7 days and will be advised to pursue the treatment until the end of symptoms if bothered by the cough up to a maximum of 21 days."
89557094|NCT05916768|Active Comparator|Control group|Usual care. Reference therapies, which are classified as symptomatic treatments, are chosen freely by the PCP except for phytotherapy
89557095|NCT05916755||Cohort A|Pembrolizumab + neoadjuvant chemotherapy
88963655|NCT02025413|Other|Metastatic progressive castration-resistant prostate cancer|Mesenchymal-marker based ferrofluid (N-cadherin or O-cadherin based)
88963656|NCT02025413|Other|Metastatic progressive breast cancer|Mesenchymal-marker based ferrofluid (N-cadherin or O-cadherin based)
88963657|NCT02025452|Active Comparator|Rapid diagnostics and probiotic|
88963658|NCT02025452|Placebo Comparator|Rapid diagnostics and placebo|
88963659|NCT02025452|Experimental|Delayed diagnostics and probiotic|
88963660|NCT02025452|Placebo Comparator|Delayed diagnostics and placebo|
89557096|NCT05916755||Cohort B|Neoadjuvant chemotherapy
89557097|NCT05916742|Experimental|CAF+VCMX+i-PRF|The surgical procedure for root coverage will be the trapezoidal-type of coronally advanced flap previously described (de Sanctis & Zucchelli 2007). Thus, it will start with two divergent releasing incisions lateral to the gingival recession defect. These releasing incisions will then be united by a sulcular incision, and the flap will be raised beyond the mucogingival junction. Subsequently, a VCMX functionalized with injectable platelet rich-fibrin (I-PRF) will be placed at the cemento-enamel junction (CEJ) level and stabilized in the adjacent interdental connective beds by interrupted sutures. Then, sling sutures will be placed to stabilize the flap margin 2 mm coronal to CEJ, followed by interrupted sutures to close the releasing incisions.
89557098|NCT05916742|Experimental|CAF+VCMX|The surgical procedure for root coverage will be the trapezoidal-type of coronally advanced flap previously described (de Sanctis & Zucchelli 2007). Thus, it will start with two divergent releasing incisions lateral to the gingival recession defect. These releasing incisions will then be united by a sulcular incision, and the flap will be raised beyond the mucogingival junction. Subsequently, a VCMX will be placed at the cemento-enamel junction (CEJ) level and stabilized in the adjacent interdental connective beds by interrupted sutures. Then, sling sutures will be placed to stabilize the flap margin 2 mm coronal to CEJ, followed by interrupted sutures to close the releasing incisions.
89557099|NCT05916742|Active Comparator|CAF|The surgical procedure for root coverage will be the trapezoidal-type of coronally advanced flap previously described (de Sanctis & Zucchelli 2007). Thus, it will start with two divergent releasing incisions lateral to the gingival recession defect. These releasing incisions will then be united by a sulcular incision, and the flap will be raised beyond the mucogingival junction. Then, sling sutures will be placed to stabilize the flap margin 2 mm coronal to CEJ, followed by interrupted sutures to close the releasing incisions.
89557100|NCT05916729|Active Comparator|Healthy subjects with acrylate dentures and oral Candida spp infection-Miconazole group|"These group includes systematically healthy patients wearing acrylate dentures and with microbiologically confirmed oral infection caused with Candida spp.~These patients were treated with Miconazole gel."
89557101|NCT05916729|Experimental|Healthy subjects with acrylate dentures and oral Candida spp infection-Candberrol-Miconazole group|"These group includes systematically healthy patients wearing acrylate dentures and with microbiologically confirmed oral infection caused with Candida spp.~These patients were treated with Miconazole gel and Candberrol lozenges."
88963661|NCT02025465|Experimental|Metoprolol|"Metoprolol 2.5 to 5.0 mg IV bolus over two minutes~Repeat every five minutes up to a total dose of 15 mg as long as tolerated (Blood pressure is over 100 mm /Hg systolic (or BP is 90 to 100 mm\Hg systolic and the patient is not dizzy))~If rate inadequate the physician has option of:~Further doses of metoprolol IV or PO~Intravenous amiodarone~IV diltiazem~Observation"
88963662|NCT02025465|Active Comparator|Diltiazem|"Bolus 0.25 Mg/Kg over two minutes (average adult dose 20 mg).~If after 15 minutes~The first dose is tolerated, and~Ventricular rate is over 100 beats a minute AND~Blood pressure is over 100 mm /Hg systolic (or BP is 90 to 100 mm\Hg systolic and the patient is not dizzy)~Give diltiazem 0.35 Mg/Kg over two minutes (average adult dose 25 mg).~After initial bolus', start infusion 5 to 15 Mg/hour to maintain rate control as long as:~1. BP over 100 mm/Hg or between 90 and 100 mm/Hg and the patient is not dizzy.~If rate inadequate the physician has an option of:~Metoprolol PO (by mouth) or IV (intravenous)~Digoxin PO or IV~Intravenous amiodarone~Observation"
88963663|NCT02025478|Experimental|Enteral Donor Breastmilk|"Donor breast milk will be pasteurized prior to use.~Given orally or by nasogastric (NG) or nasojejunal (NJ) tube.~Feeding will be supervised and will be advanced as quickly as tolerated with a goal of providing 40-50% of nutritional needs from the donor milk.~It is recognized that the volume of enteral feeds will need to be adjusted per patient tolerance."
88963664|NCT02025491|Experimental|Liposomal Amphotericin|Liposomal Amphotericin by intravenous route, 3 to 5 mg/kg/day, during 7 to 14 days of treatment.
88963665|NCT02025504|Experimental|ColoWrap Intervention Group|Patients randomized to ColoWrap Intervention Group will have the ColoWrap abdominal binder secured firmly around their lower abdomen just prior to colonoscopy.
88963666|NCT02025504|Sham Comparator|Sham Group|Sham Group will also have a ColoWrap binder placed around their lower abdomen, but it will be placed loosely so no appreciable lower abdominal pressure is generated by the device.
88963667|NCT02025517|No Intervention|Without Cognitive Tasks|Gait training on treadmill during 20 minutes.
88963668|NCT02025517|Experimental|Cognitive Tasks|Treadmill training plus cognitive verbal fluency, memory and spatial planning tasks, during 20 minutes.
88963669|NCT02025569|Experimental|Experimental group|Strain counterstrain intervention
88963670|NCT02025569|Sham Comparator|Control Group|Sham Strain Counterstrain intervention
88963671|NCT02025582|Experimental|Kinesio tape|
88963672|NCT02025595||Monozygotic twin pairs|15 monozygotic twin pairs discordant for obesity
88963673|NCT02025595||Genetic predisposition for obesity|15 obese and 15 non-obese individuals with a high genotype obesity risk score and 15 obese and 15 non-obese individuals with a low genotype obesity risk score. Genotype obesity risk score will be based on genome wide association single-nucleotide polymorphisms (SNP's) associated with obesity.
88963674|NCT02025608|Experimental|Pramipexole|Pramipexole, 0.25 mg, daily for 4 weeks
88963675|NCT02025608|Placebo Comparator|Placebo|Placebo, daily for 4 weeks
88963676|NCT02025660|Experimental|Mw|
88963677|NCT02025660|Placebo Comparator|Saline; 0.3 ml x three days sc|
88963678|NCT02025673||Healthy Controls|Healthy subjects as control group.
88963679|NCT02025673||Type 2 diabetes|Patients with type 2 diabetes.
88963680|NCT02025673||Gestational diabetes mellitus|Patients with gestational diabetes mellitus.
88963681|NCT02025686|Experimental|Hyperbaric Oxygen|Subjects will breathe oxygen (FIO2 = 1.0) at 2.4 ATA in a hyperbaric chamber after the tonic heat stimulations. The duration of oxygen exposure is 90 min
88963682|NCT02025699||LRTI|
88963683|NCT02025699||Sepsis|
88963684|NCT02025699||Non-Infectious disease group|
88963685|NCT02025712|Experimental|Exemestane plus Everolimus|Exemestane 25 mg daily in combination with Everolimus 10 mg daily until disease progression or intolerable toxicity
89557102|NCT05916729|Active Comparator|Diabetic subjects without dentures and with oral Candida spp infection - Miconazole group|"These group includes diabetes mellitus patients without acrylate dentures and with microbiologically confirmed oral infection caused with Candida spp.~These patients were treated with Miconazole gel."
88963686|NCT02025738|Active Comparator|MAGNET|magnet application over cardiac device
89557103|NCT05916729|Experimental|Diabetic subjects without dentures and with oral Candida spp infection - Miconazole-Candberrol group|"These group includes diabetes mellitus patients without acrylate dentures and with microbiologically confirmed oral infection caused with Candida spp.~These patients were treated with Miconazole gel and Candberrol lozenges."
89557104|NCT05916729|Active Comparator|Diabetic subjects with acrylate dentures and oral Candida spp - Miconazole group|"These group includes diabetes mellitus patients with acrylate dentures and microbiologically confirmed oral infection caused with Candida spp.~These patients were treated with Miconazole gel."
89557105|NCT05916729|Experimental|Diabetic subjects with acrylate dentures and oral Candida spp - Miconazole and Candberrol group|"These group includes diabetes mellitus patients with acrylate dentures and microbiologically confirmed oral infection caused with Candida spp.~These patients were treated with Miconazole gel and Candberrol lozenges."
88963687|NCT02025738|Active Comparator|REPROGRAMING|reprograming of cardiac device by trained technician/electrophysiologist
88963688|NCT02025738|Active Comparator|NO ACTION|no action is performed if patient meets inclusion criteria
88963689|NCT02025777|Experimental|capsule endoscopy and colonoscopy|
88963690|NCT02025790|Experimental|Group A - POEM|Per Oral Endoscopic Myotomy for treatment of achalasia
88963691|NCT02025790|Active Comparator|Group B - Dilatation|- Pneumatic dilatation using a balloon for treatment of achalasia.
88963692|NCT02025803|Experimental|TAS-114/capecitabine|See intervention description
88963693|NCT02025842||Chronic hepatitis B patients|Chronic hepatitis B patients treated with nucleoside/nucleotide
88963694|NCT02025842||Compensated cirrhosis patients|Compensated cirrhosis patients treated with nucleoside/nucleotide
88963695|NCT02025855|Experimental|Methadone|Methadone will be administered at a dose calculated from the subjects total daily opioid requirements, with a maximum methadone dose of 60 mg per day. The methadone will be administered every 8 hours as 5 mg capsules that will be given via an enteral feeding tube.
89557106|NCT05916716|Active Comparator|PR+CAF|Partial restoration will be performed, and its apical margin will be placed 1 mm beyond the estimated position of the cementoenamel junction. Patients enrolled in this group will receive a coronally advanced flap (CAF). Two horizontal incisions will be performed at the papilla base united by an intrasulcular incision around the tooth. In sequence, releasing incisions will be designed and a split-full-split flap will be raised beyond the mucogingival junction. Sling sutures will be placed to stabilize the flap margin 2 mm coronal to CEJ, followed by interrupted sutures to close the releasing incisions.
89557107|NCT05916716|Experimental|PR + CAF + VCMX|Partial restoration will be performed, and its apical margin will be placed 1 mm beyond the estimated position of the cementoenamel junction. Patients enrolled in this group will receive a coronally advanced flap (CAF) associated with a volume-stable collagen matrix (VCMX). Two horizontal incisions will be performed at the papilla base united by an intrasulcular incision around the tooth. In sequence, releasing incisions will be designed and a split-full-split flap will be raised beyond the mucogingival junction. In sequence, VCMX will be cut according to the recession defect and moistened with saline solution. The biomaterial will be placed at the cementoenamel junction level and stabilized in the adjacent surgery papillae by interrupted sutures. Then, sling sutures will be placed to stabilize the flap margin 2 mm coronal to CEJ, followed by interrupted sutures to close the releasing incisions.
89557108|NCT05916703|Experimental|SOLUS examination arm|At least 40 adult women, 20 with malignant and 20 with benign breast lesions visible at US examination, aged over 18 years, will be included.
89557109|NCT05916599||Goal directed|The inferior vena cava collapse index IVC CI and lung ultrasound score (LUS) measurements and goal directed fluid therapy will be done.Patients in the group will be started with fluid replasment at an hourly rate of 2ml/kg/h and with ultrasound measurement the infused fluid will be evaluated and regulated.
89557110|NCT05916599||conventional|. Group applying zero balance liquid therapy to patients with conventional methods is planned. Crystalloid liquid infusion at a rate of 2ml/kg/hour will be administered to the patients in the group additional fluid replacement will be decided by monitoring bleeding and urinary output, zero balance is aimed at patients.
89557111|NCT05916573|Experimental|Mild Renal Impairment|
89557112|NCT05916573|Experimental|Moderate Renal Impairment|
89557113|NCT05916573|Experimental|Severe Renal Impairment|
89557114|NCT05916573|Experimental|Normal Renal function|
89557115|NCT05916521|Active Comparator|Positive Control|2 brushings per day (AM and PM)
89557116|NCT05916521|Sham Comparator|Negative Control|2 brushings per day (AM and PM)
89557117|NCT05916521|Experimental|Experimental Control|Brush with Positive control in the morning and negative control in the evening
89557118|NCT05916508|Active Comparator|Positive Control|2 brushings per day (AM and PM)
89557119|NCT05916508|Sham Comparator|Negative Control|2 brushings per day (AM and PM)
89557120|NCT05916508|Experimental|Experimental Control|Brush with Positive control in the morning and negative control in the evening
89557121|NCT05916469||Bleeding disorder using LNG-IUD|Adolescents and young adults ages 10-24 with diagnosed bleeding disorder planning use of LNG-IUD.
89557122|NCT05916469||Non-bleeding disorder using LNG-IUD|Adolescents and young adults ages 10-24 without diagnosed bleeding disorder planning use of LNG-IUD.
89557123|NCT05916469||Bleeding disorder using NETA|Adolescents and young adults ages 10-24 with diagnosed bleeding disorder planning use of NETA.
89557124|NCT05916430||General Population Screening Cohort|A general population cohort of 9-month-old infants presenting for well-child visits will be screened initially at 9 months of age, and then screened again sequentially at 12, 15, 18, 21, and 24 months, to test screening performance relative to outcome status with autism or developmental disabilities.
89557125|NCT05916391|Experimental|FT003 Dose 1|Low dose of FT-003
89557126|NCT05916391|Experimental|FT003 Dose 2|Mid dose of FT-003
89557127|NCT05916391|Experimental|FT003 Dose 3|High dose of FT-003
89557128|NCT05916365|Experimental|Lebrikizumab|Adult and adolescent participants (12 to less than [<] 18 years and weighing greater than or equal to [>=] 40 kilogram [kg]) with moderate-to-severe AD will receive lebrikizumab 250 milligrams (mg) subcutaneous (SC) injection via pre-filled syringe (PFS) for every fourth week (Q4W) for up to Week 104. If participants response is below EASI50 at any visit, lebrikizumab dosing frequency may be increased to every two weeks (Q2W) at any time during the course of the study; thereafter, lebrikizumab Q4W dosing may be resumed at the Investigator's discretion. Lebrikizumab will be administered up to Week 106 for participants who continue Q2W dosing, and these participants will undergo a safety follow-up assessment at Week 110.
89557129|NCT05916326|Experimental|Experimental vaccine group|
89557130|NCT05916326|Placebo Comparator|placebo group|
89557131|NCT05916326|Experimental|Experimental vaccine group（Immunogenic subgroup ）|
89557132|NCT05916326|Placebo Comparator|placebo group（Immunogenic subgroup）|
89557133|NCT05916274|Other|Patients with samples|"Blood and fecal samples, and colonic biopsies will be analysed and compared between 3 groups of participants :1/ Active IBD; 2/Inactive IBD; 3/Controls non-IBD."
89557134|NCT05916248|Experimental|Personalized neoantigen vaccine or neoantigen tumor vaccine + Pembrolizumab|In dose escalation phase, subject will only receive personalized neoantigen tumor vaccine. In dose expansion phase, subject will receive personalized neoantigen tumor vaccine combination with Pembrolizumab
89557135|NCT05916209||PENG + LFCN Block|group in which PENG + LFCN Block was performed
89557136|NCT05916209||FIC Block|group in which FIC Block was performed
89557137|NCT05916105||Ciprofloxacin|151 record of Ciprofloxacin
89557138|NCT05916066|Other|Healthy controls|Healthy controls
89557139|NCT05916066|Other|Pseudoexfoliative glaucoma|PEXG
89557140|NCT05916066|Other|POAG|POAG
89557141|NCT05916066|Other|NTG|NTG
89557142|NCT05916027|No Intervention|Control|Each participating clinic serves as its own control and as control for active clinics, in the stepped-wedge design. All clinics are inactive (no intervention) during the baseline period of three months.
89557143|NCT05916027|Active Comparator|Active|Active clinics are trained in the intervention object (the 15-method) prior to switching to the active group. Clinics are enrolled as active clinics (intervention) in four steps (4-5 clinics in each step). The intervention is implemented into the clinic, and the staff are free to use the intervention in everyday work.
89557144|NCT05916014||Chronic atrophic gastritis observed by white light endoscope|Get pictures from gastric antrum,gastric angle,lesser curvature of gastric body, cardia, gastric fundus, greater curvature of gastric body by white light endoscope
89557145|NCT05916001|Active Comparator|A, Impact oral + Colorectal Surgery|"the supplement Oral Impact will be administered 3 times a day for 10 days before the operation.~Colon surgery will be performed according to standard clinical practice."
89557146|NCT05916001|Placebo Comparator|B, Placebo group + Colorectal Surgery|A Placebo will be administered 3 times a day for 10 days before the operation. Colon surgery will be performed according to standard clinical practice.
89557147|NCT05915962|Experimental|volunteer for an autograft|Collecting and preparing a Nanofat-type autograft using a special kit.
89557148|NCT05915936||laparoscopic ventral mesh rectopexy|correction of rectal prolapse through laparoscopic ventral mesh rectopexy
89557149|NCT05915936||perineal stapler resection|correction of rectal prolapse through perineal stapler resection
89557150|NCT05915923|Experimental|Low-frequency rTMS Group|Healthy adults treated with 1Hz repetitive transcranial magnetic stimulation (rTMS)
89557151|NCT05915923|Experimental|High-frequency rTMS Group|Healthy adults treated with 10Hz repetitive transcranial magnetic stimulation (rTMS)
89557152|NCT05915923|Sham Comparator|Control group|The Control group received rTMS with sham transcranial magnetic stimulation (sham-rTMS)
89557153|NCT05915871|Experimental|Tegoprazan, Bismuth, Amoxicillin and Clarithromycin|"Oral administration of Tegoprazan 50 mg twice daily on Days 1 to 7. Oral administration of Bismuth 600 mg twice daily, Amoxicilli 1000 mg twice daily and Clarithromycin 500 mg twice daily on Days 14 to 20.~Oral administration of Tegoprazan 50 mg twice daily, Bismuth 600 mg twice daily, Amoxicilli 1000 mg twice daily and Clarithromycin 500mg twice daily on Days 21 to 27."
89557154|NCT05915858|Experimental|muscle energy technique|muscle energy technique
89557155|NCT05915858|Active Comparator|stretching exercise|stretching exercises along with piriformis stretch
89557156|NCT05915845|Experimental|Laura Mitchell's Relaxation technique|
89557157|NCT05915845|Active Comparator|Papworth exercise|
89557158|NCT05915819|Experimental|Plyometric Training|"This group will trained with Plyometric training This training of this group will be Plyometric in which many exercises of both region upper extremity and lower extremity guided to weightlifter for assessment of functional performance. Before starting the plyometric training the trainer will perform a traditional exercise like push-ups or cycling for warmup, 5-10minutes. In plyometric training the exercise we will focus all over the body fitness, The exercise prescription according to weeks, sets and repetition.~sessions will be 6 days a week 6 weeks training sessions"
89557159|NCT05915819|Experimental|Eccentric Training|"This group will Trained with Eccentric muscle training Before starting the eccentric heavy load exercise trainers will perform warm up exercise then we will continue training.~Sessions will be 6 days a week 6 weeks training sessions"
89557160|NCT05915793|Experimental|Diaphragm strengthening and accessory muscles stretchings|
89557161|NCT05915793|Active Comparator|Diaphragm strengthening|
89557162|NCT05915780|Experimental|Experimental|The experimental group will be administered with the cycling exercises in addition to the complete plan of care that is being administered to the control group. The cycling intervention will be performed 3 times per week, for 30 minutes, within a 8-week period
89557163|NCT05915780|Other|Controlled|Control group will be given with the standard physical therapy intervention that includes progressive resistance training that will be performed using weights, two sets of 10 repetitions will be given for each muscle group, resistance will be increased by ½ Kg as children are able to complete without undue stresses); balance exercises (stand on a balance board, one-leg stance, heal-to-toes stance, walking on balance board, walking on a balance beam, walking on a line, and walking on the inclined surface); flexibility exercises (if required);
89557164|NCT05915754|Experimental|Hip abductors stretching and strengthening exercises|Patients will get the hip abductor stretching and strengthening exercise treatment for four weeks four times per week and will consist of four sets of 15 repetitions.
89557165|NCT05915754|Experimental|Posterior oblique sling strengthening exercises|Patients will get treatment plan of Hip abductors stretching and strengthening exercises plus a posterior oblique sling strengthening program for four weeks, four times per week and will consist of four sets of 15 repetitions.
89557166|NCT05915663|Experimental|Arm A|nasogatric tube in period 1 and orogastric tube in period 2
89557167|NCT05915663|Experimental|Arm B|orogastric tube in period 1 and nasogatric tube in period 2
89557168|NCT05915650|Experimental|Pain Neuroscience Education Group|
89557169|NCT05915650|Experimental|Routine Education Group|
89557170|NCT05915624|Experimental|telephone counseling group|After signing the voluntary informed consent form, the patients in the experimental group were given a Preoperative Patient Information Brochure, prepared by the researcher when they came to the hospital for the surgery date. Data will be collected using the Introductory Information Form and the Surgery-Specific Anxiety Scale, and counseling was provided by tele-nursing information about the surgery process one day before the surgery.
89557171|NCT05915624|No Intervention|Control group|The patients in the control group were given a Preoperative Patient Information Brochure, which was prepared by the researcher on the day of the surgery, when they came to the hospital for the surgery date after signing the voluntary informed consent form.
89557172|NCT05915611|Experimental|Intervention group|Participants will receive a twelve-week combined physical and psychological intervention.
89557173|NCT05915611|Active Comparator|Control group|Participants will receive a twelve-week of standard care of splinting, tendon and nerve gliding exercises.
89557174|NCT05915598|Experimental|Intervention group|"Right/left discrimination training: The training program will consist of tasks such as identifying the laterality of images (e.g., hands, feet, faces) and sounds (e.g., spatially localized sounds). The tasks will be designed with increasing levels of difficulty to challenge participants and promote skill development.~Training schedule: Participants will be instructed to engage in the right/left discrimination training for 20 minutes per day, 5 days per week, over a six-week period. They will be encouraged to complete the training sessions at consistent times to support habit formation.~Monitoring and feedback: The research team will remotely monitor participants' progress and provide personalized feedback on a weekly basis. This will include reviewing performance metrics within the app, discussing any challenges or barriers to adherence, and offering guidance to support continued engagement in the training program."
89557175|NCT05915598|Active Comparator|Control group|Usual care: Participants will continue their usual care management for fibromyalgia, including any prescribed medications and physician consultations. No specific right/left discrimination training will be provided to the control group.
89557176|NCT05915585|Experimental|High-Intensity Laser Therapy (HILT)|
89557177|NCT05915520|Experimental|group A|the 20-geriatric group will receive 5-session per-week 40-minute baduinjuin for 8 weeks plus the daily dose of pantoprazole (40 mg orally administered tablet drug)
89557178|NCT05915520|Other|group B|this 20-geriatric group will receive the daily dose of pantoprazole (40 mg orally administered tablet drug for 8 weeks .
89557179|NCT05915507|Experimental|pranayama and acupoint stimulation by laser|the 30-geriatric group will receive 3-session per-week laser stimulation for 8 weeks to some selected acupoints and daily pranyama exercises (nearly every session will be one hour, for 8 weeks), the stimulated points will be (LI 19, LI 20, ST2, and ST4. ST6, ST7, ST17, ST36, SI18, BL2, GB14, GV24 and EXHN5). Every acupoint will be stimulated with laser power of 100 mw that will be used on a spot area of 1 cm2 for 1 minute.
89557180|NCT05915507|Active Comparator|acupoint stimulation by laser|the 30-geriatric group will receive 3-session per-week laser stimulation for 8 weeks to some selected acupoints (LI 19, LI 20, ST2, and ST4. ST6, ST7, ST17, ST36, SI18, BL2, GB14, GV24 and EXHN5). Every acupoint will be stimulated with laser power of 100 mw that will be used on a spot area of 1 cm2 for 1 minute.
89557181|NCT05915481|Experimental|SBRT plus Cadonilimab|Participants will receive SBRT combined with Cadonilimab. Cadonilimab will be administered, 6mg/kg, twice a week, intravenous until disease progression or intolerable toxicities or death. The first cycle of Cadonilimab was started within 3 days before and after the first fraction of SBRT treatment.
89557182|NCT05915416|Experimental|Experiment Group|The participants in the experiment group were first administered the pre-test and then CANPP. A Child abuse and neglect Training Booklet was sent to the participants after the pre-test and before the program. Trainings within the scope of CANPP were provided over the Google Meet application in four sessions. A link was sent to the pregnant women via WhatsApp just before the specified training hours so that they could participate in the online training which is carried out individually.
89557183|NCT05915416|No Intervention|Control group|Participants in control group does not receive intervention. They were then applied CANPP and were given the training booklet after the finalization the program.
89557184|NCT05915403||Patient|female patient with fibromyalgia
89557185|NCT05915403||healthy controls|women
89557186|NCT05915377||Readi Set Go Patient Oriented Sample|Hospitalized older adults at risk of developing delirium providing informed consent
89557187|NCT05915377||Readi Set Go Administrative Sample|All patient admitted to the study wards for the duration of the study
89557188|NCT05915364||HF patients|Adult subjects with all forms of HF will be recruited
89557189|NCT05915312||BD group|patients with bipolar disorder for the first stage
89557190|NCT05915312||MDD group|patients with major depressive disorder for the first stage
89557191|NCT05915312||healthy control|participants without psychosis for the first stage
89025990|NCT04397809||Baseline Health|Those subjects presenting at baseline health will be identified by their treating physician as such and will not be starting on any treatments for APE.
89025991|NCT01243437|Experimental|ciprofloxacin|
89557192|NCT05915312||BD group II|patients with bipolar disorder for the second stage
89557193|NCT05915312||MDD group II|patients with bipolar disorder for the second stage
89557194|NCT05915273|Experimental|CAD/CAM group|
89557195|NCT05915273|Active Comparator|Lab group|
89557196|NCT05915273|Active Comparator|Chairside group|
89557197|NCT05915260||Patients with type 2 diabetes|This group will be split up into different groups. DM2 with vs. without complications to diabetes DM2 with vs. without albuminuria/nephropathy or autonomic neuropathy or retinopathy or peripheral neuropathy or macrovascular angiopathy
89557198|NCT05915260||sex and age matched control subjects|
89557199|NCT05915221|No Intervention|Control group|The control group was chosen to be the group that did not receive SMS.
89557200|NCT05915221|Experimental|SMS group|The intervention group was chosen to be the group that received SMS messages.
89557201|NCT05915156|Other|Post-acute home physiotherapy program (PAHP)|This health services research aimed to assess the effects of a post-acute home physiotherapy program that was designed to provide home physiotherapy services to patients recently discharged from acute or post-acute care.
89557202|NCT05915130|Experimental|Virtual reality training program|In the VR group, participants will practice the training sessions in an experimental room. In one training session, participants will negotiate 60 trials. Participants will practice gait training sessions in a fully immersive virtual reality. They will negotiate virtual obstacles such as avoiding a rock or crossing over a tree root, thus improving their gait adaptability capacities.
89557203|NCT05915130|Experimental|Nordic walking training program|Participants will be instructed to walk with poles continuously around the park. Each training session will consist of a warm-up (10 min), main exercise (40 min), and cool-down (5 min) periods. Participants will adapt their locomotion to uneven terrain. They will negotiate natural obstacles such as avoiding a rock or crossing over a tree root, thus improving their gait adaptability capacities.
89557204|NCT05915117|Experimental|Polyphenols of pomegranate fruit peel extract (PoPex)|All subjects will treated only with PoPex in total daily dosis of 500 mg/orally over 8 weeks.
89557205|NCT05915117|Placebo Comparator|Placebo|All subjects will treated only with PoPex placebo capsules/orally over 8 weeks
89557206|NCT05915091|Experimental|Dry Needling|
89557207|NCT05915091|Other|Cross Friction Massage|
89557208|NCT05915065|Other|Phantom Limb Pain Management System during at-home use.|"Participants attend either in person at Shirley Ryan AbilityLab or virtually via Zoom~Educational documents provided on pain and phantom limb pain.~Participants are measured for an electrode cuff either in person or virtually~Complete several questionnaires.~Provided training on the Phantom Limb Pain Program with use of the electrode cuff and muscular contractions of their limb~Participate in a 8 week home trial (1.5 hours per week of use, 20-40 minutes, 4-5x each week)~Once home trial is complete - participants will be asked to participate in a phone or Zoom call at weeks 16,24 and 32 to repeat questionnaires."
89557209|NCT05915052|Active Comparator|the B-type suture ileostomy group|the B-type suture ileostomy group underwent laparoscopic low anterior resection and a B-type suture ileostomy
89557210|NCT05915052|Active Comparator|the traditional ileostomy group|the traditional ileostomy group underwent laparoscopic low anterior resection and a traditional ileostomy
89025992|NCT01243437|Active Comparator|doxycycline|
89025993|NCT00592033|No Intervention|2|Rehabilitation, no supplemental oxygen
89025994|NCT00592033|Experimental|1|Rehabilitation plus supplemental oxygen
89208280|NCT04007835|Experimental|Anlotinib Hydrochloride combined with EGFR-TKI|Patients receive anlotinib (12 mg orally daily for 14 days every 21 days cycle) combined with one of following EGFR-TKIs: Gefitinib is administered 250 mg once per day. Erlotinib is administered 150 mg once per day , or Icotinib is administered 125 mg three times per day, until disease progression or untolerated toxicity.
89557211|NCT05915013|Experimental|ketamine plus perampanel|A screening session is conducted to ensure that the subject can safely receive perampanel and ketamine (physical exam, blood and urine analyses, electrocardiogram, drug and alcohol testing). The participant will then receive 6 milligrams (mg) oral perampanel and intravenous ketamine. Participants will then undergo a 2-hour magnetic resonance imagining (MRI) scan. The following day, participants will return for an additional scan and symptom assessment.
89557212|NCT05915013|Placebo Comparator|ketamine plus placebo|A screening session is conducted to ensure that the subject can safely receive perampanel and ketamine (physical exam, blood and urine analyses, electrocardiogram, drug and alcohol testing). The participant will then receive an oral placebo (in lieu of 6 mg oral perampanel) and intravenous ketamine. Participants will then undergo a 2-hour MRI scan. The following day, participants will return for an additional scan and symptom assessment.
89557213|NCT05914935|Experimental|Recombinant L-IFN adenovirus injection and Ommaya reservoir|Recombinant L-IFN adenovirus injection was locally injected through the Ommaya reservoir.A single injection dose of 5.0×10^10 VP (total dose per injection) was administered during the treatment period.
89557214|NCT05914922|No Intervention|FMRL CTL-PGY1 (Post Graduate Year 1) and FMRL CTL - PGY2 (Post Graduate Year 2)|This arm of participants reflects family medicine resident learners (FMRLs) who will not be exposed to the 1-20 MSK case simulations.
89557215|NCT05914922|Experimental|FMRL EXP - PGY1 and FMRL EXP - PGY2|This arm of participants reflects family medicine resident learners (FMRLs) who will be exposed to the 1-20 MSK case simulations.
89557216|NCT05914896|No Intervention|NormOsmo|This group received a priming solution with normal osmolality.
89557217|NCT05914896|Active Comparator|HighOsmo|This group received a priming solution with high osmolality
89557218|NCT05914844||Group 1:|Proliferative phase endometrium (PPE)
89557219|NCT05914844||Group 2:|Secretory phase endometrium
89557220|NCT05914844||Group 3:|Benign endometrial hyperplasia
89557221|NCT05914844||Group 4:|Endometrial intraepithelial neoplasia
89557222|NCT05914844||Group 5:|Early stage of endometrial carcinoma
89557223|NCT05914844||Group6:|Advanced stage of endometrial carcinoma
89557224|NCT05914753|Experimental|Experimental group|Experimental group: Epirubicin :90 mg/m2, D1, q3W; Cyclophosphamide :600 mg/m2, D1, q3W; Xihuang Pill：3g po bid，4 cycles, Follow Docetaxel :100 mg/m2, D1, q3W；Xihuang Pill：3g po bid，4 cycles
89557225|NCT05914753|Placebo Comparator|Control group|Control group: Epirubicin :90 mg/m2, D1, q3W; Cyclophosphamide :600 mg/m2, D1, q3W，4 cycles, Follow Docetaxel :100 mg/m2, D1, q3W，4 cycles
89557226|NCT05914740|Experimental|Venous valve remodeling|Venous valve function was remodeled under ultrasound guidance
89557227|NCT05914727|Other|ASMD patients|ASMD patients
89557228|NCT05914727|Other|Healthy controls|Healthy controls
89557229|NCT05914714|Experimental|treatment arm|
89557230|NCT05914701|Experimental|treatment arm|
89557231|NCT05914675|Experimental|treatment arm|
89557232|NCT05914662|Experimental|Zanubrutinib, bendamustine, rituximab combination therapy Group|Patients were treated with ZBR regimen for 6 cycles, followed by zanubrutinib monotherapy for an additional 6 months.
88963696|NCT02025855|Placebo Comparator|Placebo|This will be a capsule containing only lactose and will be given every 8 hours via an enteral feeding tube. The number of placebo capsules will be calculated based on the subjects opioid requirements. This will ensure the same number of capsules will be given despite which arm the patient is enrolled in.
88963697|NCT02025868|Experimental|Adherence reinforcement before switch to 3rd-line ART|
88963698|NCT02025881|Experimental|Treatment|carboplatin + etoposide then thiotepa then Cyclophosphamide + Busilvex
88963699|NCT02025894||PCVCs|Cohort of cancer patients with indication PCVC under the usual practice
89557233|NCT05914623|Active Comparator|rTMS|Patients are treated with repetitive transcranial magnetic stimulation (rTMS).
89557234|NCT05914623|Placebo Comparator|sham-rTMS|Patients are treated with sham repetitive transcranial magnetic stimulation (sham-rTMS).
89557235|NCT05914610|Experimental|Envolimab + fruquinitinib +SOX regimen|
89557236|NCT05914610|Active Comparator|SOX regimen|
89557237|NCT05914597|Other|Participant|Patients with lower gastrointestinal symptoms who have been selected by overseeing clinician meeting NHS England criteria to undergo colon capsule endoscopy as part of their standard of care and are 18 or over .
89557238|NCT05914584|Experimental|Baricitinib + Standard of care|"Baricitinib injected per os for 10 days (4mg/day). the first administration of this treatment is performed within the 6 hours following the randomization, followed by daily administration for a total of 10 days.~The standard of care : for treating HAP will comply with international guidelines. For all patients, empiri antimicrobial therapy is initiated imedialty after collecting the respiratory sample and can thus be started before the randomization to avoid delayed antimicrobial therapy. Its recommanded to broaden the spectrum in case of resistant bacteria resistant to the empirical antimicrobial therapy but il is not recommanded to prolong the antibiotic tratment for more than 7-8 days"
89557239|NCT05914584|Sham Comparator|Standard of care alone|Same as described in arm 1
89557240|NCT05914558||TN cohort|The patient was diagnosed with trigeminal neuralgia which has active symptoms in the past 30 days.
89557241|NCT05914545|Experimental|Experimental: FZ-AD004|Participants enrolled in the dose escalation part or dose expansion part
89557242|NCT05914519|Active Comparator|Group 1|
89557243|NCT05914519|Active Comparator|Group 2|
89557244|NCT05914454|Experimental|anakinra|anakinra 100 mg/day for 14 consecutive days
89557245|NCT05914454|No Intervention|standard of care|
89557246|NCT05914428||sepsis|We selected blood samples from sepsis patients from the biological bank of Qilu hospital.The ALDH2 genotype (rs671) was detected in these septic patients and divided into ALDH2 wild-type ,ALDH2 rs671 mutation.
89557247|NCT05914415|Placebo Comparator|Control|standard preoperative training
88963700|NCT02025920|Experimental|Salmon Group|Participants will eat 150g salmon for dinner, 3 times per week for 12 weeks
88963701|NCT02025920|Experimental|Cod Group|Participants will eat 150g cod for dinner, 3 times per week for 12 weeks
88963702|NCT02025920|Active Comparator|Meat Group|Participants will eat 150g mixed meat for dinner, 3 times per week for 12 weeks
88963703|NCT02025933||Salmon Group|Participants will eat 75 - 150 grams of salmon for dinner, three times a week for 12 weeks.
88963704|NCT02025933||Cod Group|Participants will eat 75-150 grams of cod for dinner, three times a week for 12 weeks.
88963705|NCT02025933||Meat Group|Participants will eat 75-150 grams of mixed meat for dinner, three times a week for 12 weeks.
88963706|NCT02025946||Total Ankle Arthroplasty|
88963707|NCT02025946||Tibiotalar Arthrodesis|
88963708|NCT02025959|Experimental|Educational Intervention|Educating hospital staff on good sleep hygiene for patients and screening for sleep disorders
89557248|NCT05914415|Experimental|Experimental|structured training app
89557249|NCT05914402|Experimental|Observation group( Axillary surgical evaluation is spared)|Breast cancer patients with initial axillary metastasis（T1-3N1-3M0） who are preparing for neoadjuvant therapy(NAT)，including neoadjuvant chemotherapy, targeted therapy, immunotherapy, etc. will received imaging examination（MRI、mammography、ultrasonography）at baseline and after every two cycles of NAT before surgery, dedicated breast/lymph positron emission tomography(DB/L-PET) at baseline and after first 1-2 cycle of NAT. We have developed a prediction model, which includes clinical parameters, pathological parameters, imaging examination parameters and DB/L-PET to predict the probability of complete pathological remission of axillary lymph nodes after receiving NAT. If the probability is more than 90%, the process of axillary surgical evaluation will be spared. If the probability is 50% -90%, Sentinel lymph node biopsy will be performed. If the probability is less than 50%, standard axillary lymph node dissection will be performed.
89557250|NCT05914363|Experimental|Intervention (improved floor)|"Replacement of rudimentary floors with an improved floor,~Support for behaviour change through 'floor clubs'.~Annual mass treatment for STH infections (400 mg albendazole)~Treatment of tungiasis in those affected by heavy infections (at 0 and 12 months) according to county DoH recommendations"
88963709|NCT02025972|Experimental|Allogeneic umbilical cord blood therapy|Allogeneic umbilical cord blood therapy
88963710|NCT02025998|Experimental|Ibudilast|Ibudilast will be administered for 7 days at the target dose of 50 mg/bid
88963711|NCT02025998|Placebo Comparator|Sugar pill|Placebo pills will be administered for 7 days and taken twice daily
88963712|NCT02026037|Experimental|Experimental|Brief Treatment for Acutely Burned Patients (BTBP)
89557251|NCT05914363|No Intervention|Control (rudimental floor)|"Annual mass treatment for STH infections (400 mg albendazole)~Treatment of tungiasis in those affected by heavy infections (at 0 and 12 months) according to county DoH recommendations"
89557252|NCT05914350|Experimental|Group 1|40 mg methylprednisolone acetate and 1 mL lidocaine will be injected in sacroiliac joint in first week by ultrasound. While the second and third injections in the second and third weeks will be done by sham injection
89557253|NCT05914350|Experimental|Group 2|3 mL PRP and 1 mL lidocaine will be injected in sacroiliac joint by ultrasound once/week for 3 weeks
89557254|NCT05914350|Experimental|Group 3|10 ml of medical ozone of 20 μg/ml will be injected in sacroiliac joint by ultrasound once/week for 3 weeks
88963713|NCT02026050|Active Comparator|intraarticular dexamethasone|interscalene brachial plexus block was preoperative performed 30 ml 0.5 % bupivacaine+ 2 ml serum phsyologic and after surgery 2 ml 8 mg dexamethasone+ 8 ml serum phsyologic administration for intraarticular
89557255|NCT05914337|Experimental|Rheumatoid Arthritis Group|30 patients aged 18-60 years who met the 2010 American College of Rheumatology / European League Against Rheumatism Rheumatoid arthritis criteria were included in the study. A program consisting of strengthening and stretching exercises 2 days a week was applied to the study group for 8 weeks. One day a week, 30 minutes of mild moderate walking was requested. 30 healthy controls aged 18-60 years who included in the study. Of the cases at the beginning and at the end of the treatment; 5-10 cc peripheral blood samples were taken into one Ethylenediaminetetraacetic acid tube. Then Numeric Rating Scale (NRS) was used for pain, 28-joint Disease Activity Score (DAS28) was used to calculate disease activity, Health Assessment Questionnaire (HAQ) was used to assess general health and Short Form-36 (SF-36) was used to evaluate quality of life. In the samples taken, gene expressions of miRNA-146a, miRNA-155, miRNA-16, miRNA-145 were determined by real-time polymerase chain reaction method.
89557256|NCT05914298||HME group|"204 children and adult patients with HME, admitted to our Hospital for diagnosis and treatment.~the patients will be stratified by age in four subgroups:~subgroup I (0-7 Years)~subgroup II (8-12 Years)~subgroup III (13-18 Years)~subgroup IV (>18 Years)"
89557257|NCT05914298||healty control group|204 children and adult voluntary healty controls will be stratified in the same manner and matched with the population in study in order to assess normal and pathologic growth.
89557258|NCT05914285|Placebo Comparator|Control group|Normal saline
89557259|NCT05914285|Experimental|Salbutamol group|Salbutamol + normal saline
89557260|NCT05914272||trement group|Patient has used osmotic drugs within 72 hours of admission.
88963714|NCT02026050|Active Comparator|interscalene dexamethasone|interscalene brachial plexus was preoperative performed 30 ml 0.5 % bupivacaine added 2 ml 8mg dexamethasone and after surgery 10 ml serum phsyologic administration for intraarticular
88963715|NCT02026050|Placebo Comparator|serum phsyologic|interscalene brachial plexus block was preoperative performed 30 ml 0.5 % bupivacaine+ 2ml serum phsyologic and after surgery 10 ml serum phsyologic administration for intraarticular
88963716|NCT02026076|Experimental|manual unloading|All subjects will first undergo a manual unloading test, followed by a single application of mechanical lumbar traction to determine predictive effect
89557261|NCT05914272||control group|Patient has not used osmotic drugs within 72 hours of admission.
89557262|NCT05914207|Experimental|Vestibular Migraine group|Written, verbal and pictorial descriptions will be provided for each participant regarding lifestyle modifications and vestibular rehabilitation exercise
88963717|NCT02026089|No Intervention|Sero-positive for varicella at least 5 years prior|No treatment
88963718|NCT02026089|Active Comparator|Varicella vaccine|One dose varicella vaccine (Varivax).
88963719|NCT02026102|No Intervention|Usual Care|Patients will receive no additional ICD specific information other than what is offered by the clinic consistent with usual care. The control group will be asked where they went for information in the follow-up interviews.
88963720|NCT02026102|Experimental|ICD Decision Aid Toolkit|In the intervention arm, research assistants will provide the patients with the toolkit of decision aids. At that time, participants will have the option of using all of the decision aids or just some of the decision aids. Participants who do not have access to the internet, will be offered a DVD (digital video disc) version of the video and they will be asked if they would like to arrange a visit where they can review the website with the research assistant.
89208281|NCT00795626|Experimental|Lifestyle counseling|"Two groups:~control - conventional care~intervention - systematic education in the reduction of the risk estimate to cardiovascular events"
89208282|NCT00867984|Experimental|1|Torsion-guided VV optimization plus AV optimization.
89208283|NCT00867984|Active Comparator|2|AV optimization only.
88963721|NCT02026115|Active Comparator|usual hospice care|The usual care group will receive the typical hospice care and interact with PAINReportIt to provide data necessary for the analysis of study aims. They will use the tablet computer at baseline and at the study end and daily between. They also will have access to what looks like PAINUCope, but is really computer games so that they have similar attention with the computer as the experimental group. For ethical purposes, we will provide a PAINReportIt Summary to their hospice nurses to have access to their pain assessment information, something we did not do in previous studies focused on efficacy of the interventions.
88963722|NCT02026115|Experimental|PAINRelieveIt (experimental group)|We will use Nursing Consult LLC's PAINRelieveIt software that includes: (1) PAINReportIt that has screens to collect pain, medications, and misconception data; (2) the intervention for the nurse clinicians, PAINConsultN; and (3) the intervention for the patients and lay caregiver, PAINUCope. This innovative, new program is the first computerized, multi-dimensional, self-report measure of pain with clinician decision support for analgesic prescriptions and multimedia patient education tailored to the patient's misconceptions and pain. Prototype versions of PAINConsultN and PAINUCope were tested in recently completed studies among outpatients with cancer and patients with sickle cell disease in outpatient, emergency and hospital settings.
89208284|NCT00800930|Active Comparator|1|Patients will be instructed to lie on a bed (cholera cot) in left lateral position. A soft rectal catheter will be introduced by a nurse/physician, through which 80 ml of butyrate solution will be instilled slowly with a 50 ml plastic syringe. Patients will be asked to retain the enema for at least ½ hour by remaining supine for 30 minutes after the administration. However, if a patient cannot retain the enema for 30 minutes, he will be given a second round of enema immediately after defecation.
89208285|NCT00800930|Placebo Comparator|2|Patients will be instructed to lie on a bed (cholera cot) in left lateral position. A soft rectal catheter will be introduced by a nurse/physician, through which 80 ml of saline solution will be instilled slowly with a 50 ml plastic syringe. Patients will be asked to retain the enema for at least ½ hour by remaining supine for 30 minutes after the administration. However, if a patient cannot retain the enema for 30 minutes, he will be given a second round of enema immediately after defecation.
89208286|NCT00868062|Experimental|1|
88963723|NCT02026154||A, B, C|Group A- 15 patients without symptoms of heart failure - control group Group B- 30 patients with exertional dyspnoea Group C - 40 patients with overt heart failure
88963724|NCT02026167|No Intervention|Usual Care|No intervention, usual care
88963725|NCT02026167|Experimental|Intervention|Collaborative care with Health Care Assistant
88963726|NCT02026180|Active Comparator|Micropuncture Access|Vascular access using micropuncture needle kit
88963727|NCT02026180|Active Comparator|Standard 18G vascular access needle|Vascular access using standard 18G needle
89208287|NCT00860886||1|Mongolian Women
89208288|NCT00860886||2|Women in other parts of the world other than Mongolia.
89208289|NCT00282295|Experimental|Boostrix + Menactra Group|Subjects, 11 through 18 years of age, received a booster dose of Boostrix® co-administered with Menactra™ at Day 0. The Boostrix® vaccine was administered intramuscularly into the left deltoid region and Menactra™ vaccine was administered intramuscularly into the right deltoid region.
89557263|NCT05914168|Experimental|Study arm|Subjects with investigational acquisition
89557264|NCT05914129|Sham Comparator|Control Group (GC)|To each volunteer, after 2 questionnaires, sham techniques will be performed to this group. The investigator will mimic the technique contacts without actually performing any type of tissue traction or compression, maintaining contact for the same amount of time described in the refered techniques. Following the technique, volunteers will answer the same 2 questionnaires shown previously.
88963728|NCT02026219|Experimental|Clopidogrel|Clopidogrel 600mg loading
88963729|NCT02026219|Experimental|Ticagrelor|Ticagrelor 180mg loading
88963730|NCT02026245|Experimental|5DT electronic data glove|"Using the electronic data gloves to perform a set routine of movements.~Intervention: Data gloves to perform movements"
88963731|NCT02026245|Experimental|Tyndall/UU electronic data glove|"Using the electronic data gloves to perform a set routine of movements~Intervention: Data gloves to perform movements"
89208290|NCT00282295|Experimental|Boostrix-Menactra Group|Subjects, 11 through 18 years of age, received one dose of Boostrix® vaccine at Day 0, followed by one dose of Menactra™ vaccine at Month 1. Both vaccines were administered intramuscularly into the left deltoid region.
89557265|NCT05914129|Experimental|Experimental Group A (GEA)|To each volunteer, after 2 questionnaires, Diaphragm Stretching, Lower stomach mobilization and Liver pump techniques will be performed to this group. The diaphragm technique is performed 2 times with 1 minute interval, with the duration of 10 respiratory cycles. The lower stomach mobilization and liver pump techniques are performed one time, for 5 minutes each. Following the technique, volunteers will answer the same 2 questionnaires shown previously.
88963732|NCT02026271|Experimental|Ad-RTS-hIL-12+veledimex|varying doses of intratumoral Ad-RTS-hIL-12 (INXN-2001) and oral veledimex (activator ligand).
89557266|NCT05914129|Experimental|Experimental Group B (GEB)|To each volunteer, after 2 questionnaires, Lower stomach mobilization and Liver pump techniques will be performed to this group. These 2 techniques are the same ones as described for the experimental group A. Following the technique, volunteers will answer the same 2 questionnaires shown previously.
89557267|NCT05915494|Experimental|group A|intermittent pneumatic compression group (n = 20 inhalation injury children). in this children group, intermittent pneumatic compression will be used to resist diaphragm muscle during 10-set-training session which will be done five session per the week, for 12 weeks. besides this training, traditional physical therapy program will be handled). In other inhalation group, n =20, traditional physical therapy program will be handled only). Also, free walking for 30 minutes daily will be performed by children.
89557268|NCT05915494|Active Comparator|group B|traditional physiotherapy group (n = 20 inhalation injury children). In this inhalation group, traditional physical therapy program will be handled only for 12 weeks. Also, free walking for 30 minutes daily will be performed by children.
89557269|NCT05914103|Experimental|Intervention|
89557270|NCT05914103|No Intervention|Control|
89557271|NCT05914051|Experimental|Volume preload optimization.|Volume overload with 250 cc saline solution will be performed in the intervention arm, verifying the response of the cardiac output and stroke volume with non invasive continue monitoring.
89557272|NCT05914051|No Intervention|Control group|Standard care without volume preload.
89557273|NCT05914025|Experimental|Behavioral Activation Intervention|All individuals enrolled in the study will be assigned to this arm and will receive a brief behavioral activation psychoeducation module among other self-report assessments.
89557274|NCT05914012|Experimental|Intervention Group|125 older adults aged 65 and over, who do not have any neurological, cognitive and communication problems that may affect the evaluations, and who volunteer to participate in the study and who are sedentary.
89557275|NCT05914012|No Intervention|Control Group|125 older adults not participating in any exercise program during the study, not having any neurological, cognitive and communication problems that may prevent completing the assessments.
89557276|NCT05913999||Anthracycline|Patients undergoing chemotherapy with an anthracycline-containing regimen.
89557277|NCT05913999||VEGF Inhibitor|Patients undergoing chemotherapy with a vascular endothelial growth factor (VEGF) inhibitor-containing regimen.
89557278|NCT05913999||Immune Checkpoint Inhibitor|Patients undergoing chemotherapy with an immune check point inhibitor-containing regimen.
88963733|NCT02026284||Gravid women|A questionnaire was performed to gravid women
88963734|NCT02026310|Experimental|glimepiride|on the basis of metformin and glargine, the initial dose of glimepiride is 2 mg,qd (before breakfast), and adjust the dosage for fasting plasma glucose, dosage-adding indicator is the FPG≥7.2, maximum dose of glimepiride is 4 mg/d per day.
88963735|NCT02026310|Active Comparator|Metformin and glargine|on the basis of Metformin and glargine,no glempiride addition. dose of glargine was adjust according to the FPG, with the target less than 7.2mmol/l
89208291|NCT00282295|Experimental|Menactra-Boostrix Group|Subjects, 11 through 18 years of age, received one dose of Menactra™ vaccine at Day 0 followed by one dose of Boostrix® vaccine at Month 1. Both vaccines were administered intramuscularly into the left deltoid region.
89557279|NCT05913986|Experimental|Alpha-lipoic acid and y silybum marianum|LUDLEV®300 mg/46.2 mg once day
89557280|NCT05913986|Placebo Comparator|Placebo|Placebo treatment (maltodextrin), once daily (u.i.d)
89557281|NCT05913960|Sham Comparator|Placebo stimulation|The sham group of MDD will receive sham rTMS stimulation.
89557282|NCT05913960|Active Comparator|accelerated intermittent theta burst stimulation|Stimulation site: According to the localization of neural orientation navigation system, magnetic resonance data was read in Brainsight software, and three-dimensional brain reconstruction was carried out. The stimulation target was located in the coordinates of Montreal Neurological Institute (MNI), which was located in the left dorsolateral prefrontal cortex BA46(-44, 40, 29).The treatment intensity was 100% exercise threshold, and a TBS stimulus series was stimulated for 2 seconds, including 10 times of 3 intra plexus stimuli of 50Hz and 5Hz intraplexus stimuli, 10s of interval, repeated 60 times, that is, a total of 1800 pulses per treatment, 10 times a day, 50 minutes interval, a total of 18000 pulses per day, continuous for 5 days.
88963736|NCT02026323|Experimental|acupuncture|"Normal weight group,the PCOS women with insulin resistance who are normal weight( BMI=18.5-23Kg/m2).The acupuncture treatment will last for six months, 3 times per week, 30 minutes per treatment."
88963737|NCT02026323|Experimental|acupuncture 2|"Over weight or obese group ,the PCOS women with insulin resistance who are overweight or obese: BMI >23 Kg/m2.The acupuncture treatment will last for six months, 3 times per week, 30 minutes per treatment."
88963738|NCT02026336|No Intervention|enose|Electronic nose can discriminate the inflammatory asthma phenotypes, supporting their potential as a non-invasive alternative tool to induced sputum.
88963739|NCT02026362|Other|The foundation treatment after radical operation or RFA|The foundation treatment including against hepatitis b virus treatment using nucleoside analogue drug and protect liver treatment
88963740|NCT02026362|Experimental|MASCT:Multiple Antigens Specific Cellular Therapy|autologous immune cytotoxic of T-lymphocytes (CTL) induced by dendritic cells, (DC) loaded with multiple antigens DC loaded with survivin p53 her2 ect total 17 antigens
88963741|NCT02026427||Drotaverine|40 mg of drotaverine hydrochloride administered intramuscularly just after the proper level of spinal anesthesia was achieved.
88963742|NCT02026427||Control|Without intramuscular administration of drotaverine hydrochloride.
89557283|NCT05913960|Active Comparator|high frequency stimulation|Stimulation site: According to the localization of neural orientation navigation system, magnetic resonance data was read in Brainsight software, and three-dimensional brain reconstruction was carried out. The stimulation target was located in the coordinates of Montreal Neurological Institute (MNI), which was located in the left dorsolateral prefrontal cortex BA46(-44, 40, 29).Treatment intensity was 100% exercise threshold, continuous 10Hz stimulation, repeated 75 times, that is, 3000 pulses per treatment, 6 times a day, 50 minutes interval, a total of 18000 pulses per day, continuous stimulation for 5 days.
89557284|NCT05913947|Experimental|Lithium|Lithium citrate from 12 mmol increased to result in af 12-hour se-lithium between 0.6 and 0.8 mmol/l
88963743|NCT02026440||Smokers|Those who smoke at least one cigarette a day.
88963744|NCT02026440||Non smokers|Those who have not smoked for at least one week when the sample is collected.
88963745|NCT02026466||CAD with CTO|Subjects will have Coronary Artery Disease with a diagnosed Chronic Total Occlusion: a coronary artery with TIMI flow of zero(no flow) for at least three months.
88963746|NCT02026479|Experimental|regular treatment comparator|Ginaton
89557285|NCT05913947|Experimental|Cariprazine|Cariprazine from 1.5 mg to 3 mg daily in a single dose.
89557286|NCT05913934||Gait analysis parameters|Twins: Gait analysis
89557287|NCT05913856|Experimental|Chlorhexidine group|Applying 0.12% chlorhexidine mouthwash for oral care thrice daily.
89557288|NCT05913856|Active Comparator|Normal saline group|Applying normal saline for oral care thrice daily.
89557289|NCT05913830|Experimental|Experimental group:|Experimental Group A total of 36 methadone patients will receive auricular pressure
89557290|NCT05913830|No Intervention|Control group:|Control group 36 bits No interventions implemented
89557291|NCT05913804|Experimental|YTS104 cells injection|Subjects will receive cell infusion, with the initial cell dose of 1E6/kg. 1-6 subjects will be enrolled. The second dose group was 3E6 cells /kg with 1-6 subjects; The third and fourth dose groups were 6E6 cells /kg and 1E7 cells /kg, respectively, with 3-6 subjects.
89557292|NCT05913778|Experimental|Enhanced external counterpulsation 35 hours per year|Subjects with Heart failure with Enhanced external counterpulsation therapy (inflation pressure 220-280 mm Hg; 35 procedures) was given as a 1-hour session, once daily, for a total of 35 sessions, 1 course per 12 months
89557293|NCT05913778|Experimental|Enhanced external counterpulsation 70 hours per year|Subjects with Heart failure with Enhanced external counterpulsation therapy (inflation pressure 220-280 mm Hg; 35 procedures) was given as a 1-hour session, once daily, for a total of 35 sessions, 1 course per 6 months
89557294|NCT05913778|Sham Comparator|SHAM external counterpulsation|Subjects with Heart failure with SHAM external counterpulsation (inflation pressure 80 mm Hg; 35 procedures) was given as a 1-hour session, once daily, for a total of 35 sessions, 1 course per 12 months
89557295|NCT05913661|Experimental|pemigatinib combined with PD-1 inhibitor|pemigatinib combined with PD-1 inhibitor as first-line treatment within advanced unresectable or metastatic intrahepatic cholangiocarcinoma
88963747|NCT02026479|Experimental|Dexamethasone Phosphate low dose|5mg
88963748|NCT02026479|Experimental|Dexamethasone Phosphate high dose|10mg
88963749|NCT02026492|Other|40 patients aged 6-18 years|All 40 patients with a diagnosis of asthma are recruited from the outpatients clinic of the department of Pediatric Pneumology and Allergology of the University Hospital Frankfurt. Patients undergo a methacholine challenge and two exercise challenges in a cold chamber and one exercise challenge in room temperature.
88963750|NCT02026492|Other|40 subjects aged 18-45 years|All subjects show bronchial hyperresponsiveness e.g. dyspnea when exercising in cold environment, in their medical history. Subjects undergo a methacholine challenge and exercise challenge in a cold chamber and one exercise challenge in room temperature.
88963751|NCT02026505||Multiple Myeloma, Bortezomib|
88963752|NCT02026518|Experimental|Soy|Group Soy receiving placebo similar to 50000 IU cholecalciferol (includes MCT oil) biweekly for 6 weeks in addition to 40 milligram (2 capsules per day) soy isoflavones capsules for 6 weeks
88963753|NCT02026518|Experimental|Soy- Cholecalciferol|Group Soy- Cholecalciferol receiving Supplement in form of 40 milligrams soy isoflavones (diadzein, genistein, glycitin) per day (2 capsules of 20 milligrams) for 6 weeks in addition to supplement of cholecalciferol (vitamin D3) biweekly for 6 weeks
88963754|NCT02026518|Placebo Comparator|Placebo|Group Placebo receiving Placebo in similar form of cholecalciferol supplement biweekly for 6 weeks in addition to 40 milligrams placebo in similar form of soy isoflavones including starch for 6 weeks
88963755|NCT02026518|Experimental|Cholecalciferol|Group Cholecalciferol receiving oral Placebo in similar form to soy isoflavones (diadzein, genistein, glycitin) supplement including starch (2 capsules per day) for 6 weeks in addition to 50000 IU cholecalciferol supplement biweekly for 6 weeks
88963756|NCT02026531|Experimental|3-Helium inhalation gas|This is a pilot study. The aim is to recruit 20 patients who will all receive the product under investigation.
88963757|NCT02026544|Experimental|Low Frequency Therapeutic Ultrasound|Low Frequency Therapeutic Ultrasound (LOTUS) applied transcutaneously
88963758|NCT02026570|No Intervention|Control|Persons with unilateral transtibial amputation receiving standard physical therapy.
89557296|NCT05913635|Experimental|No-breakfast|One-day meal plan with no breakfast. The dietary plan has been developed according to the Dietary Guidelines for Chinese Residents (2022), and the energy distribution of the two meals (lunch and dinner) is 1:1, with the energy percentage of carbohydrates, proteins, and fats being 55%, 15%, and 30%, respectively. The total daily calorie intake has been calculated based on the gender difference of the participants. Since the recommended daily calorie intake for males is 2000 kcal while for females it is 1600 kcal, each meal for males is designed to provide 667 kcal calories, comprising 92g carbohydrates, 22g fat, and 25g protein; each meal for females is designed to provide 533 kcal calories, comprising 73g carbohydrates, 18g fat, and 20g protein. The carbohydrates are sourced from buckwheat flour and mixed grain rice, which create similar glycemic indexes for each meal. Additionally, the one-day meal for both males and females includes 450g of vegetables and 320g of fruits.
89557297|NCT05913635|Experimental|No-dinner|One-day meal plan with no dinner. The dietary plan has been developed according to the Dietary Guidelines for Chinese Residents (2022), and the energy distribution of the two meals (breakfast and lunch) is 1:1, with the energy percentage of carbohydrates, proteins, and fats being 55%, 15%, and 30%, respectively. The total daily calorie intake has been calculated based on the gender difference of the participants. Since the recommended daily calorie intake for males is 2000 kcal while for females it is 1600 kcal, each meal for males is designed to provide 667 kcal calories, comprising 92g carbohydrates, 22g fat, and 25g protein; each meal for females is designed to provide 533 kcal calories, comprising 73g carbohydrates, 18g fat, and 20g protein. The carbohydrates are sourced from buckwheat flour and mixed grain rice, which create similar glycemic indexes for each meal. Additionally, the one-day meal for both males and females includes 450g of vegetables and 320g of fruits.
89557298|NCT05913622|Experimental|IABP unloading arm|This group of patients will receive an intra-aortic balloon pump (IABP) as an adjunct to VA ECMO support. When allocated to the IABP unloading arm, patients must receive an IABP within 8 hours after VA ECMO initiation.
89557299|NCT05913622|No Intervention|ECMO alone arm|This group of patients will receive VA ECMO support without left ventricular unloading device after randomization.
89557300|NCT05913596|Experimental|Patient with CaAMR|This is a multicenter, prospective, single arm clinical study. The study will enroll 15 renal transplant recipients with positive DSA and CaAMR confirmed by biopsy after renal transplantation. According to inclusion and exclusion criteria patients will be screened to participate in the trial.
89557301|NCT05913583||ICI group|Recipients with exposure to immune checkpoint inhibitors before liver transplantation
89557302|NCT05913583||non-ICI group|Recipients without exposure to immune checkpoint inhibitors before liver transplantation
89557303|NCT05913570|Experimental|Experimental: Cadonilimab (®), a PD-1/CTLA-4 bi-specific antibody|Neoadjuvant therapy with Cadonilimab
89557304|NCT05913557|Experimental|Treatment Group|Participants completed a baseline assessment, received 4 months of RO DBT therapy, then completed a follow-up assessment.
89557305|NCT05913557|No Intervention|No Treatment Group|Participants completed baseline assessment but did not receive treatment. A small subset also completed a follow-up assessment.
89557306|NCT05913557|No Intervention|Healthy Controls|Participants completed baseline assessment but did not receive treatment.
89557307|NCT05913505|Experimental|OSC+|Twenty-five participants will complete five weeks of heart rate variability biofeedback using emWave software (HeartMath®Institute, 2020). Participants will receive a weekly 30-minute heart rate variability biofeedback session for five weeks at the University Parkway Center, Brigham Young University. The heart rate variability biofeedback protocol will be based on Lehrer et al., 2013 and Yoo et al., 2022. This format will aid participants in implementing and learning breathing and heart rate variability biofeedback skills (Lehrer et al., 2020). All participants will wear an ear sensor to measure their pulse. The heart rate variability biofeedback will focus on autonomic balance through slow breathing at a resonance frequency of approximately 6 breathes per minute. The best approximate breathing pace for resonance frequency will be estimated and participant's resonance frequency will be provided and used for their homework and subsequent training sessions.
89557308|NCT05913505|Sham Comparator|OSC-|"Twenty-five participants will complete five weeks of Osc-. Similarly, for the Osc- procedures, the client will be required to complete a five-week intervention. During the weekly session, participants will also be wearing an earlobe monitor with HeartMath. Participants will be administered the Scale of Positive and Negative Experience at the beginning of each session to assess for mood. Participants will also be administered the 3-item Rivermead Post Concussion Symptoms Questionnaire at the beginning of each session. Participants will be instructed that the purpose of this portion of the study is to decrease their breathing oscillations. A program was designed by Yoo and colleagues (2022) that gives feedback regarding a calmness score which reflects a better score (i.e., higher) when participants breath in a pattern that elicits less variability (i.e., less oscillations)."
89557309|NCT05913492||Group 1|Each volunteer went through two simulation scenarios of difficult airway management on the first time
89557310|NCT05913492||Group 2|Each volunteer went through two simulation scenarios of difficult airway management after training in difficult airway management according to DAS guidelines, using the same equipment as during the simulation
88963759|NCT02026570|Experimental|Motor Control Internal Focus|Persons with unilateral transtibial amputation receiving standard physical therapy and additional training with motor control internal focus of attention instructions.
88963760|NCT02026570|Experimental|Motor Control External Focus|Persons with unilateral transtibial amputation receiving standard physical therapy and additional training with external focus of attention instructions.
88963761|NCT02026583|Experimental|Simvastatin|
88963762|NCT02026596||aSAH patients|Patients suffering from aneurysmal subarachnoid haemorrhage
88963763|NCT02026609||TIPS|Patients 18-75 year old with refractory ascites or hepatic hydrothorax and cirrhosis, eligible for TIPS placement. All patients will have a baseline oral glutamine challenge and psychometric tests.
88963764|NCT02026622|Other|3 groups of subjects|"3 groups: depressive subjects, subjects remitted from depression and control subjects, with the same interventions.~psychometric tests, MRI, transcranial doppler and TPI, explicitative interview"
88963765|NCT02026635||Optivol® Device in CareLink|A single cohort group of heart failure patients with already implanted Optivol® capable devices who are discharged home from the hospital
88963766|NCT02026648||cases with cervical cancer|
88963767|NCT02026661||those that did not receive ICSI or LAH|
88963768|NCT02026661||those that received ICSI only|
88963769|NCT02026661||those that received LAH only|
88963770|NCT02026661||those that received both ICSI and LAH|
89208292|NCT00742781|Experimental|Dietary supplement|Dietary supplement of vitamin D
89557311|NCT05913492||Group 3|Each volunteer went through two simulation scenarios of difficult airway management after 6 month
89557312|NCT05913466|Experimental|Tranexamic Acid group|Patients in this group will receive 1 gm of Tranexamic Acid (Cyklokapron) that will be dissolved in 50 ml of injectable 0.9% saline
89557313|NCT05913466|Placebo Comparator|Distilled water group|This group will receive 10 mL of distilled water (placebo) in 1 L of irrigation solution sterile wash (glycine).
89557314|NCT05913453||Procedures corresponding to technical failure|
89557315|NCT05913427|Experimental|EDP-M plus MEGESTROL ACETATE 160 mg|EDP will be administered at the following doses: doxorubicin 40 mg/m2 on day 1, etoposide 100 mg/m2 days 2-4, cisplatin 40 mg/m2 days 3-4, every 28 days. Concomitant mitotane therapy will be administered continuously. Megestrole 160 mg 2 tablets will be administered once daily (in the morning) and will be stopped 21 days after the last administration of the EDP.
89557316|NCT05913427|Placebo Comparator|EDP-M plus PLACEBO|EDP will be administered at the following doses: doxorubicin 40 mg/m2 on day 1, etoposide 100 mg/m2 days 2-4, cisplatin 40 mg/m2 days 3-4, every 28 days. Concomitant mitotane therapy will be administered continuously. Placebo 2 tablets will be administered once daily (in the morning) and will be stopped 21 days after the last administration of the EDP.
89557317|NCT05913414|Experimental|Iron Isomaltide|Patients receive iron Isomaltide after anti-tumor therapy.
89557318|NCT05913414|Active Comparator|Oral iron supplement|Patients receive polysaccharide iron complex after anti-tumor therapy.
89557319|NCT05913362|Experimental|IVUS based ultra-low contrast PCI|IVUS based ultra-low contrast PCI
89557320|NCT05913362|No Intervention|Standard of care PCI|Guideline directed contrast induced nephropathy provention strategy with standard of care PCI procedure.
89557321|NCT05913349|Experimental|The clinical response of the group cognitive behavioural therapy|A randomized controlled study of GCBT with one-month and six-month post-treatment follow-up was conducted to explore the short- and long-term efficacy of GCBT on mental sub-health
89557322|NCT05913349|Experimental|The alterations of behavior and physiological features in the group cognitive behavioral therapy.|To understand the possible biological mechanism underlying the efficacy of group cognitive behavioral therapy by analyzing alterations of the alterations of behaviors and Physiological features in the group cognitive behavioral therapy features.
89557323|NCT05913336|Experimental|Remimazolam Tosilate|IV of Remimazolam Tosilate
89557324|NCT05913310|Active Comparator|Kui-Yuan Chewable Tablets|
89557325|NCT05913310|Placebo Comparator|Placebo of Kui-Yuan Chewable Tablets|
88963771|NCT02026674|Experimental|FloRite|LUTS patients that used FloRite for home urine flow diagnostics.
88963772|NCT02026700|Experimental|bariederm, barrier cream|one arm study: use of bariederm cream on hands twice daily for 21 days
88963773|NCT02026713|Experimental|smokers on dual antiplatelet therapy with ASA and Prasugrel or|All patients quit smoking for a 2 weeks period
88963774|NCT02026713|Experimental|smokers on dual antiplatelet therapy with ASA and ticagrelor|All patients on chronic dual antiplatelet therapy (>1 month) quit smoking for a 2 weeks period
88963775|NCT02026713|Active Comparator|smokers on dual antiplatelet therapy with ASA and Clopidogrel|All patients on chronic dual antiplatelet therapy (>1 month) quit smoking for a 2 weeks period
88963776|NCT02026739|Experimental|low supplemental oxygen concentration|The group in which low supplemental oxygen concentration of 40% will be performed during minimally invasive esophagectomy.
88963777|NCT02026739|Active Comparator|high supplemental oxygen concentration (conventional)|The group in which high supplemental oxygen concentration (onventional) of 80% will be performed during minimally invasive esophagectomy.
88963778|NCT02026752||Study Population|
88963779|NCT02026765|Other|Heparin Surface Modified Aspheric Lens|Heparin Surface Modified Aspheric Lens
88963780|NCT02026765|Other|traditional lens|traditional Aspheric lens
89208293|NCT00663026|Experimental|A|5 mg/week
89208294|NCT00663026|Experimental|B|10 mg/week
89208295|NCT00663026|Experimental|C|Placebo
89557326|NCT05913297||Malformation Chiari 1|Magnetic Resonance
89557327|NCT05913297||Malformation Chiari 2|Magnetic Resonance
89557328|NCT05913258|Experimental|Er:YAG Laser Caries Removal group|Complete isolation was performed using a rubber dam and saliva ejector. Patients received topical anesthesia before the clamp was placed. Dental caries was excavated using the Er:YAG laser with a wavelength of 2940nm according to the manufacturer's instructions until visual inspection showed that the carious lesions have been thoroughly removed. If the patient experienced pain and requested local anaesthesia, the procedure was stopped, local anaesthesia has been applied, and then the procedure has resumed. Cavities were restored using the Clearfil Universal Bond Quick system in total each mode; 37% phosphoric acid was used, then the Clearfil Universal Bond system was applied, light cured for 90 seconds, after which composite resin was applied (3M Filtek TM Z350 XT Universal Restorative Composite (3M ESPE) according to the manufacturer's instructions.
89557329|NCT05913258|Active Comparator|Conventional Caries Removal Group|Complete isolation was performed using a rubber dam and saliva ejector. Patients received topical anesthesia before the clamp was placed. Dental caries was excavated using the Mastertorque high/low-speed air rotor handpiece until visual inspection showed that the carious lesions have been thoroughly removed. If the patient experienced pain and requested LA, the procedure was stopped, LA was applied, and then the procedure resumed. According to the manufacturer's instructions, cavities were restored using the Clearfil Universal Bond Quick system and composite resin (3M Filtek TM Z350 XT Universal Restorative Composite (3M ESPE).
89557330|NCT05913245|No Intervention|Fasting arm|Patients included in the fasting arm will not drink or eat anything after the dinner of the night before the surgery.
88963781|NCT02026778|Experimental|ondansetron-betahistine|ondansetron-betahistine group
88963782|NCT02026778|Placebo Comparator|ondansetron|ondansetron group
88963783|NCT02026791|Experimental|The clinical efficacy of the I-gel|The clinical efficacy of the I-gel
88963784|NCT02026791|Active Comparator|The clinical efficacy Supreme-LMA|The clinical efficacy Supreme-LMA
88963785|NCT02026804||Prenatal mental disorders|
88963786|NCT02026817|Experimental|HCP1201|Participants received a single oral dose of the HCP1201 750/10 mg under fed condition, on Period 1(for participants randomized to Sequence 1) or on Period 2(for participants randomized to Sequence 2).
88963787|NCT02026817|Active Comparator|Metformin and Rosuvastatin|Participants received a single oral dose of coadministration of Metformin SR 750 mg and Rosuvastatin 10 mg under fed condition, on Period 1(for participants randomized to Sequence 1) or on Period 2(for participants randomized to Sequence 2).
88963788|NCT02026830||Diabetic foot infection|Patients with DM (Diabetes Mellitus) presenting with a diabetic foot infection will be enrolled in the current trial to determine the causative microorganisms and their antibiotic sensitivity patterns in diabetic patients with a foot infection in Turkey.
88963789|NCT02026843||Diabetic retinopathy,humor,angiogenic|Samples of aqueous humor was taken before injection and before surgery. The injection include bevacizumab or triamcinolone.
88963790|NCT02026843||Nondiabetic,angiogenic,humor|Aqueous humor was taken before surgery. Surgery include pars plana vitrectomy of macular hole, epiretinal membrane, cataract surgery.
88963791|NCT02026856||Se-OI> 200|patients who received form of sodium selenite pentahydrate at 750 mg/day for 6 days immediately after admission to our department (1000 mg of sodium selenite pentahydrate = 333 micrograms of selenium) and oxygenation index (OI) by PaO2/FiO2 (partial pressure of oxygen in arterial blood/ fraction of inspired oxygen) was higher than 200
88963792|NCT02026856||Se-OI <200|patients who received form of sodium selenite pentahydrate at 750 mg/day for 6 days immediately after admission to our department (1000 mg of sodium selenite pentahydrate = 333 micrograms of selenium) and oxygenation index (OI) by PaO2/FiO2 (partial pressure of oxygen in arterial blood/ fraction of inspired oxygen) was lower than 200
88963793|NCT02026856||Placebo-OI> 200|patients who received continuous saline NaCl 50 ml/day for 6 days as a continuous infusion (excluding additional infusion therapy) and oxygenation index (OI) by PaO2/FiO2 (partial pressure of oxygen in arterial blood/ fraction of inspired oxygen) was higher than 200
88963794|NCT02026856||Placebo-OI <200|patients who who received continuous saline NaCl 50 ml/day for 6 days as a continuous infusion (excluding additional infusion therapy) and oxygenation index (OI) by PaO2/FiO2 (partial pressure of oxygen in arterial blood/ fraction of inspired oxygen) was lower than 200
88963795|NCT02026869|Active Comparator|Oral metformin|Metformin 850 mg tablets taken by mouth every 12 hours for 6 months
89557331|NCT05913245|Active Comparator|Water arm|Patients included in the water intake arm will drink the same amount of mililiters than the carbohydrate loading drink.
89557332|NCT05913245|Experimental|Carbohydrate loading arm|"Patients included in the intake arm of carbohydrate loading treatment should take 400ml the night before the intervention and 200ml the two hours before the intervention.~The hydrocarbonate drink provided will be Sugarmix (Maltodextrin 12.5%)."
89557333|NCT05913206|No Intervention|Control|No new communication approaches received.
89557334|NCT05913206|Experimental|Ambiguity only|Receive information about ambiguity related to the clinical decision.
89557335|NCT05913206|Experimental|Ambiguity and complexity only|Receive information about ambiguity and complexity related to the clinical decision.
89557336|NCT05913206|Experimental|Ambiguity and normalizing only|Receive information about ambiguity and normalizing language related to the clinical decision.
89557337|NCT05913206|Experimental|Ambiguity, complexity, and normalizing only|Receive information about ambiguity, complexity, and normalizing language related to the clinical decision.
89557338|NCT05913206|Experimental|Complexity only|Receive information about complexity related to the clinical decision.
88963796|NCT02026869|Active Comparator|Vaginal metformin|Metformin 850 mg tablets taken vaginally every 12 hours for 6 months
88963797|NCT02026882|Other|Supreme Laryngeal Mask Airway|Supreme Laryngeal Mask Airway with gastric tube. Preoxygenation, rapid sequence induction and cricoid pressure. Induction of general anaesthesia.
88963798|NCT02026895|Experimental|Patient with infection by Staphylococcus lugdunensis|
88963799|NCT02026921|Experimental|Carboplatin and docetaxel|Intravenous infusion every 3 weeks Carboplatin plus docetaxel
88963800|NCT02026947|Placebo Comparator|Placebo|In both arms, one capsule at the morning for the first week. One capsule at the morning and one at the evening for the weeks 2-12.
88963801|NCT02026947|Experimental|Sodium benzoate|0.5 g/day during the first week, 1.0 g/day for the next 11 weeks. One capsule at the morning for the first week. One capsule at the morning and one at the evening for 2-12 weeks.
89557339|NCT05913206|Experimental|Complexity and normalizing only|Receive information about complexity and normalizing language related to the clinical decision.
89557340|NCT05913206|Experimental|Normalizing only|Receive information about normalizing language related to the clinical decision.
89557341|NCT05913206|Experimental|Narratives only|Receive narratives in addition to the control condition.
89557342|NCT05913206|Experimental|Ambiguity and narratives only|Receive information about ambiguity and narratives related to the clinical decision.
89557343|NCT05913206|Experimental|Ambiguity, complexity, and narratives only|Receive information about ambiguity, complexity, and narratives related to the clinical decision.
89557344|NCT05913206|Experimental|Ambiguity, normalizing, and narratives only|Receive information about ambiguity, normalizing language, and narratives related to the clinical decision.
89557345|NCT05913206|Experimental|All|Receive all new communication approaches
89557346|NCT05913206|Experimental|Complexity and narratives only|Receive information about complexity and narratives related to the clinical decision.
89557347|NCT05913206|Experimental|Complexity, normalizing, and narratives only|Receive information about complexity, normalizing language, and narratives related to the clinical decision.
89557348|NCT05913206|Experimental|Normalizing and narratives only|Receive information about normalizing language and narratives related to the clinical decision.
89557349|NCT05913180|Active Comparator|Vitamin C|1000mg Ascorbic acid daily starting the day of elective gynecological surgery for 10 days
89557350|NCT05913180|Placebo Comparator|Placebo|Placebo daily starting the day of elective gynecological surgery for 10 days
89557351|NCT05913167|Active Comparator|Erector spina plan block|Erector spina plan block will be administered to the patients in this group.
89557352|NCT05913167|Active Comparator|Transversus abdominis plan block|Transversus abdominis plan block will be administered to the patients in this group.
89557353|NCT05913154||Cognitive/executive apathy|
89557354|NCT05913154||Behavioural/inhibition apathy|
89557355|NCT05913154||Emotional apathy|
89557356|NCT05913154||Social apathy|
89557357|NCT05913141||Patients with PDO/PDO-TIL/PDOTS|Patients whose tumors were established into patient-derived organoids, patient-derived organoids-tumor-infiltrating lymphocyte coculture systems, or patient-derived organotypic tissue spheroids, and screened for drug-sensitive.
88963802|NCT02026960|Experimental|Renal Cell Carcinoma Tumor Tissue|
89557358|NCT05913128|Active Comparator|First arm|Glandular Urethral Disassembly technique
89557359|NCT05913128|Active Comparator|Second arm|Tubularized Incised Plate technique
89557360|NCT05913115|Experimental|FPA144|Participants will receive escalating doses of FPA144. On completion of Cycle 1 (Cycles = 28 days in length) participants may participate in an optional Extended Treatment Period based on the Investigator's discretion, which begins on Day 1 of Cycle 2. FPA144 will be administered once every 2 weeks (Q2W) in 4-week cycles until disease progression, or until the patient meets any of the other withdrawal criteria.
89557361|NCT05913102|Experimental|experimental|administer PDLLA
89557362|NCT05913102|Active Comparator|active comparator|administer saline
89557363|NCT05913076|Experimental|Investigation of the Effects of Alt-RAMEC and Facemask 1 week Use in Class III Malocclusion|A sample of 40 patients, consisting of 18 males and 22 females with a mean age of 10.64 ± 0.98, who were in the growth and developmental stage, were divided into three treatment groups. The formation of groups was carried out with the aim of achieving a near-equal distribution of male and female participants within each group, as indicated in Table 1. The first group comprised 14 patients, while the second and third groups consisted of 13 patients each. The skeletal age of the individual was determined through the acquisition of hand-wrist X-rays and the application of the Greulich and Pyle atlas at T1.
88963803|NCT02026960|Experimental|Genitourinary tumor tissue (Expansion cohort)|Bladder, prostate or testicular cancer
88963804|NCT02026973|Experimental|IM Placebo/Oral Placebo|IM placebo given once on Day 1; Oral placebo pills daily x14-18 days. Somatostatin 1mcg/kg/hr will be administered for 2 hours from 8-10AM on the overnight visit.
88812284|NCT05812183|Experimental|Medical weight loss|The medical weight loss intervention will follow the University of California at Los Angeles's (UCLA) Research For Obesity (RFO) standard protocol. Over a period of 12 months, patients in the medical weight loss group will follow a very loc caloric diet (VLCD) at the UCLA RFO program. All study patients will be prescribed a VLCD, an exercise regimen and will participate in group classes on behavioral modification. The caloric intake consists of a commercially prepared meal replacement powder supplying 700-800 cal/day. Each formula packet provides 100kcal and 15g of high biological value protein, and the daily allowance of required minerals and vitamins.
89557364|NCT05913076|Experimental|Investigation of the Effects of Alt-RAMEC and Facemask 3 week Use in Class III Malocclusion|The second group comprised 13 patients who were in the growth and developmental stage. The skeletal age of the individual was determined through the acquisition of hand-wrist X-rays and the application of the Greulich and Pyle atlas at T1.
89557365|NCT05913076|Experimental|Investigation of the Effects of Alt-RAMEC and Facemask 5 week Use in Class III Malocclusion|The third group comprised 13 patients who were in the growth and developmental stage. The skeletal age of the individual was determined through the acquisition of hand-wrist X-rays and the application of the Greulich and Pyle atlas at T1.
89557366|NCT05913063|Experimental|Participants with Age-Related Macular Degeneration|Conducting the psychophysical task on the perception of OAM-coupled polarized light
89557367|NCT05912998|Active Comparator|cartilage regeneration|35 patient will have knee arthroscopy and cartilage regeneration technique and high tibial osteotomy
89557368|NCT05912998|Active Comparator|microfracture|35 patient will have knee arthroscopy and microfracture with high tibial osteotomy
89557369|NCT05912998|Placebo Comparator|high tibial osteotomy|35 patient will have knee arthroscopy and high tibial osteotomy
89557370|NCT05912985||nasal cannula group|Nasal cannula will be used in bronchoscopy procedures in which sedation is applied in this group.
89557371|NCT05912985||modified nasopharyngeal cannula group|In this group, modified nasopharyngeal cannula will be used in bronchoscopy procedures with sedation.
89557372|NCT05912985||HFNO group|HFNO will be used in bronchoscopy procedures in which sedation is applied in this group.
89557373|NCT05912972||Cervical cancer|No interventions
89557374|NCT05912972||Endometrial cancer|No interventions
89557375|NCT05912972||Ovarian cancer, Fallopian tube cancer, Peritoneal cancer|No interventions
89557376|NCT05912933||Cohort|New users of palbociclib for inoperable or recurrent breast cancer divided into 4 groups based on severity levels of hepatic impairment
89557377|NCT05912907|Experimental|potassium nitrate in polycarboxilate cement|
89557378|NCT05912907|Active Comparator|Mineral Trioxide Aggregate|
89557379|NCT05912881|Placebo Comparator|Placebo|Participants receive placebo olfactory training kits that only contain medium chain triglycerides that lack any discernible odor
88812285|NCT05811286|Experimental|Hysteroscopic morcellation 19 Fr. intrauterine BIGATTI Shaver for uterine intracavitary lesions|Single experimental arm of patients with a intracavitary lesion and elligible for hysteroscopic morcellation.
88812286|NCT05806567|Experimental|Part 1|Belumosudil + UGT1A1 victim drug administered in the fed state
88812287|NCT05806567|Experimental|Part 2|Belumosudil + P-gp victim drug administered in the fed state
88812288|NCT05806567|Experimental|Part 3|Belumosudil + OATP1B1/BCRP victim drug administered in the fed state
88812289|NCT05806359|Experimental|Japanese Cohort - Dose 1|
88812290|NCT05806359|Experimental|Japanese Cohort - Dose 2|
88812291|NCT05806359|Experimental|Japanese Cohort - Dose 3|
88812292|NCT05806359|Experimental|Caucasian Cohort - Dose 3|
88812293|NCT05789927||Patient who received antibiotic prophylaxis|"Severe T2-High asthmatics treated with biotherapy"
88812294|NCT05789329|Experimental|Trauma Informed Guilt Reduction Therapy (TrIGR)|behavioral intervention aimed to reduce trauma-related guilt and shame
88812295|NCT05789329|Active Comparator|Cognitive Processing Therapy (CPT)|behavioral intervention aimed at reducing PTSD symptoms
88812296|NCT05739812|Experimental|Urological disease group|Patients with urological diseases (renal cell carcinoma, nonfunctioning kidney and adrenal tumor, renal pelvis carcinoma, ureteral tumor, bladder cancer, prostate cancer, pelvic tumor) will be treated by telesurgery.
88812297|NCT05731518|Experimental|SC0245 and irinotecan combination|SC0245 and irinotecan combination are administered one cycle that is consisted of 28 days until disease progression or death or loss of follow-up or withdrawal.
88812298|NCT05729048||Hemodynamic Monitoring|Over the course of a patient's hospitalization, data will be collected on patients from the initiation to completion of hemodynamic monitoring with the Starling monitor during CRRT treatment.
88812299|NCT05728385|Experimental|Modified SPD as adjunct to asthma medications in children|Explore if the modified specific carbohydrate diet has an effect on asthma control in children and if it will affect the frequency, severity, and duration of asthma and thus provide it as a potential complementary treatment option for them.
88812300|NCT05728385|No Intervention|Usual asthma medications only in children with moderate asthma|Assess control based on the usual asthma medications only
88812301|NCT05721976|Experimental|"With Love, Grandma (Con Cariño, Abuelita) Group"|"Cancer survivor-Daughter dyads randomized to the With Love, Grandma (Con Cariño, Abuelita) group will access a digital lifestyle program that includes 8 modules of didactic, behavioral, and family communication/parenting/grandparenting content from smartphones over the course of 10-12 weeks."
88812302|NCT05721976|No Intervention|Control Group|This group is intended to reflect typical services cancer survivors and family members receive from healthcare providers.
88812303|NCT05721391||Non Frail Group|The patients in no frail group did not have any component of Frailty criteria
88812304|NCT05721391||Pre Frail Group|The patients in prefrail Group had 1-2 component of Frailty criteria.
88812305|NCT05721391||Frail Group|The patients in Frail Group had 3-5 component of Frailty criteria.
88812306|NCT05715632|Experimental|Carrelizumab combined with XELOX|Before surgery, the patient received standard dose of Carrelizumab combined with XELOX regimen for 4 courses of treatment, and within 3-4 weeks after the completion of the fourth administration, preoperative imaging examination was conducted to evaluate the efficacy of new adjuvant treatment and the possibility of radical D2 resection, and to receive radical surgery for gastric cancer
89557380|NCT05912881|Experimental|Treatment|Participants receive treatment olfactory training kits that contain essential oils that have scents (lavender, lemon, clove, eucalyptus)
89557381|NCT05912868||Ventral hernia repair|Endoscopic Mini/Less Open Repair
89557382|NCT05912855||BPS（Behavioral Pain Scale）and physiological index monitoring guided analgesia group|
89557383|NCT05912855||Analgesia group guided by qNOX|
89557384|NCT05912842|Experimental|Medical Legal Partnerships|Component 1 is a comprehensive training for all MLP care providers delivered to clinical, social and behavioral, and legal staff together to establish a collaborative environment. Component 2 consists of the screening tool and screening protocol that is designed to identify health-harming legal needs of PLWH patients. Component 3 includes the provision of legal support through partnership with the Legal Clinic for the Disabled. Upon a positive legal needs screening, the case manager connects the patient to this attorney, at which point the patient, after signing a letter of engagement, becomes a client and can now address the identified legal issue(s) with legal representation.
89557385|NCT05912842|Active Comparator|Standard of Care|Comparison arm health organization will only receive the HIV standard of care (U.S. CDC HIV standard of care) and referral to legal aid.
89557386|NCT05912816|Experimental|RC48 Combined With Tislelizumab|"In this trial, RC48 was scheduled to be administered at a dose of 2.0 mg/kg every 3 weeks, with the first dose on day 1 of the first cycle.~Tislelizumab was administered at a dose of 200 mg every 3 weeks, with the first dose on day 1 of the first 21-day cycle. The drug is diluted with normal saline and administered by intravenous drip for one hour."
89557387|NCT05912751|Other|Exercise Then Foam Roll|This arm (sequence) will first complete the exercise intervention promoting muscular engagement resisting gravitational collapsing tendencies, then the control intervention involving self-myofascial release of muscle groups not thought to resist gravitational collapse.
89557388|NCT05912751|Other|Foam Roll Then Exercise|This arm (sequence) will first complete the control intervention involving self-myofascial release of muscle groups not thought to resist gravitational collapse, then the exercise intervention promoting muscular engagement resisting gravitational collapsing tendencies.
89557389|NCT05912725|Experimental|Accuracy of Implant impression techniques|"Active comparative : digital implant impression Participants underwent intra-oral scanning digital impression~Experimental : conventional implant impression Participants underwent conventional impressions And right side of pt mouth received screw retained prosthesis constructed from conventional impression left side received screws retained prosthesis constructed from digital impression"
89557390|NCT05912712|Experimental|Platelet-rich Plasma (PRP) Gel Treatment Group|Rectal 10ml platelet rich plasma gel enema + infliximab standard treatment at fixed time every day for seven consecutive days
89557391|NCT05912712|Sham Comparator|Platelet Poor Plasma (PPP) Gel Treatment Group|Rectal 10ml PPP gel enema + infliximab standard treatment for 7 consecutive days
89557392|NCT05912712|Active Comparator|Mesalazine Suppository Treatment Group|Patients were given 1g mesalazine suppository and infliximab daily for 7 consecutive days
89557393|NCT05912699|Experimental|Intervention Group (SlimBiotic Postbiotic)|Participants will take 1 serving (1 capsule) per day.
89557394|NCT05912699|Placebo Comparator|Placebo Group|Participants will take 1 serving (1 capsule) per day.
89557395|NCT05912686|Active Comparator|high-dose arm|The test group will undergo high-dose atorvastatin treatment (80mg/day) for the first 3 days after the mechanical embolectomy, transitioning to a standard dose (20mg/day) of atorvastatin thereafter.
89557396|NCT05912686|Other|standard-dose arm|a standard dose (20mg/day) of atorvastatin after the mechanical embolectomy
89557397|NCT05912660||Aortic valve replacement with surgically implanted bioprostheses|
89557398|NCT05912660||Aortic valve replacement with TAVI|
89557399|NCT05912621|Experimental|2.5 mg (up to 15 mg) Tirzepatide|Patients assigned to tirzepatide will undergo dose titration starting with 2.5 mg per day with an increase every four weeks if tolerated by nausea. During the first 6 weeks, weight loss must be matched with the dietary weight loss arm at 0.6 kg/week. Participants will be seen every two weeks to review diet and physical activity, evaluate tolerability/side effects, and obtain morning weight. If weight loss is greater than 0.6 kg/week, recommendations to increase caloric intake will be made through the week 6 visits that repeat baseline testings (biopsy, metabolic tests, and regional fat scans). After the 6th week, weight loss can occur naturally without any restrictions (no further matching to the dietary weight loss group is required). Starting at week 8 the visits are decreased to every 4 weeks. Biopsies, metabolic tests, and regional fat scans are completed at baseline, week 6, and end of study (week 22).
88963805|NCT02026973|Experimental|IM Placebo/PO Anastrozole|IM placebo given once on Day 1; Oral Anastrozole 2.0mg pills daily x14-18 days. Somatostatin 1mcg/kg/hr will be administered for 2 hours from 8-10AM on the overnight visit.
88963806|NCT02026973|Experimental|IM Fulvestrant/PO Placebo|IM Fulvestrant 250mg given once on Day 1; Oral Placebo pills daily x14-18 days. Somatostatin 1mcg/kg/hr will be administered for 2 hours from 8-10AM on the overnight visit.
88963807|NCT02026973|Experimental|IM Fulvestrant/IM Anastrozole|IM Fulvestrant 250mg given once on Day 1; Oral Anastrozole pills daily x14-18 days. Somatostatin 1mcg/kg/hr will be administered for 2 hours from 8-10AM on the overnight visit.
88963808|NCT02026986|Experimental|sleep deprivation|Ten subjects in the SD group were examined after a SD experiment in which they did not sleep for 24 h.
88963809|NCT02026986|No Intervention|control|The 10 subjects in the control group were not sleep deprived (had 8 h of sleep).
88963810|NCT02027012|Experimental|Renal denervation with Vessix system|
88963811|NCT02027038|Experimental|Patients with sacroiliac joint pain|Patients suffering from sacroiliac joint pain
88963812|NCT02027038|Active Comparator|Controls|healthy controls
88963813|NCT02027064|Experimental|interferon|
88963814|NCT02027077|Active Comparator|Control group|Control group
88963815|NCT02027077|Active Comparator|Lifestyle counseling|Behavioral intervention group
88963816|NCT02027090|Experimental|Higher dose icotinib|Patients with stable disease after 8-week routine dose icotinib treatment, are randomly assigned to higher dose icotinib group to receive icotinib with a dose of 375 mg three times per day, till progressive disease or unaccepted toxicity.
88963817|NCT02027090|Active Comparator|Routine dose icotinib|Patients with stable disease after 8-week routine dose icotinib treatment, are administered with icotinib with a dose of 125 mg three times per day, till progressive disease or unaccepted toxicity.
88963818|NCT02027103|Active Comparator|Metformin|patients receiving fixed dose metformin 1000 mg daily
88963819|NCT02027103|Active Comparator|Pioglitazone|patients receiving fixed dose pioglitazone 30 mg daily
88963820|NCT02027116|Experimental|Experimental: 1mg of DNA/dose|Subjects will receive a 3 dose series of VGX-6150 containing 1mg DNA/dose administered via IM injection + electroporation at Day 0, Week 4, Week 8, Week 12
88963821|NCT02027116|Experimental|Experimental: 3mg of DNA/dose|Subjects will receive a 3 dose series of VGX-6150 containing 3mg DNA/dose administered via IM injection + electroporation at Day 0, Week 4, Week 8, Week 12
88963822|NCT02027116|Experimental|Experimental: 6mg of DNA/dose|Subjects will receive a 3 dose series of VGX-6150 containing 6mg DNA/dose administered via IM injection + electroporation at Day 0, Week 4, Week 8, Week 12
88963823|NCT02027129|Other|Low frequency HFO/HFO-TGI vs high frequency HFO|Total study population for the testing of the ventilatory strategies
88963824|NCT02027142||Cases|Women referred to two academic centres for the diagnosis and treatment of endometriosis.
88963825|NCT02027142||Controls|Women referred to our Institutions because of routine gynaecologic consultations.
88963826|NCT02027168||CPA treatment|CPA treatment group receives 20 hours of patient centered manual physical therapy
88963827|NCT02027181|Experimental|device FreeO2|Automatic adjustment of oxygen
88963828|NCT02027181|Active Comparator|Manual oxygenation|Manual adjustment of oxygen
88963829|NCT02027194|Experimental|Cure-Allergic Rhinitis Syrup|In syrup form, 20 ml once daily for 4 weeks
88963830|NCT02027194|Active Comparator|Yu-ping-fung San|In syrup form, 20ml once daily for 4 weeks
88963831|NCT02027194|Placebo Comparator|Placebo group|In syrup form (wheat powder with ginger and flavors), 20 ml once daily for 4 weeks
88963832|NCT02027207|Experimental|Shanchol|
88963833|NCT02027207|Placebo Comparator|Placebo|
88963834|NCT02027220|Experimental|G-CSF/Bortez/Cyc/Dex|G-CSF IC on days 0, 1, 7, 8, 14, 15, 21 and 22. Bortezomib IV on days 1, 8, 15 and 22. Cyclophosphamide CIV on days 1, 8, 15 and 22. Dexamethasone IV on days 1, 2, 8, 9, 15, 16, 22 and 23.
88963835|NCT02027246|Experimental|Stem cell|Autologous bone marrow mononuclear cell transplantation
88963836|NCT02027259|Experimental|Group visits with behavioral activation|Group visits with behavioral activation (BA) will consist of 4 weekly group visits of 2-hour duration followed by monthly booster group visits for 6 months to prevent relapse.
88963837|NCT02027259|No Intervention|Standard group visits|Standard group visits will consist of 4 weekly group visits of 2-hour duration followed by monthly booster group visits for 6 months to prevent relapse.
88963838|NCT02027285|Experimental|fortified milk|The subjects assumed daily 250 ml of fortified milk for 12 weeks. Then, after a period of wash-out of 12-14 weeks they start to assume placebo milk for 12 weeks.
88963839|NCT02027285|Placebo Comparator|placebo milk|The subjects assumed daily 250 ml of placebo milk. Then, after a period of wash-out of 12-14 weeks they start to assume fortified milk for 12 weeks.
88963840|NCT02027298|Experimental|Abatacept|Abatacept by SC injection of 125 mg weekly for 6 months
88963841|NCT02027324|Experimental|Chlorhexidine-alcohol group|2% chlorhexidine in 70% isopropyl alcohol in accordance with manufacturer's instructions for safe usage.
88963842|NCT02027324|Experimental|Povidone-Iodine group|10% Povidone-iodine applied topically according to manufacturer's instructions
88963843|NCT02027337|No Intervention|Control group|Healthy women that no use combined oral contraceptives
88963844|NCT02027337|Experimental|20 mcg EE/3 mg drospirenone|Women that use combined oral contraceptives containing 20 mcg ethinylestradiol/3 mg drospirenone (Yaz)
88963845|NCT02027337|Experimental|20 mcg EE/3 mg drospirenone and Selmevit|Women that use combined oral contraceptives containing 20 mcg ethinylestradiol/3 mg drospirenone (Yaz) and antioxidant complex Selmevit
88963846|NCT02027337|Experimental|30 mcg EE/3 mg drospirenone|Women that use combined oral contraceptives containing 30 mcg ethinylestradiol/3 mg drospirenone (Yasmin)
88963847|NCT02027337|Experimental|30 mcg EE/3 mg drospirenone and Selmevit|Women that use combined oral contraceptives containing 30 mcg ethinylestradiol/3 mg drospirenone (Yasmin) and antioxidant complex Selmevit
88963848|NCT02027337|Experimental|35 mcg EE/2mg cyproterone|Women that use combined oral contraceptives containing 35 mcg ethinylestradiol/2 mg cyproterone
88963849|NCT02027337|Experimental|35 mcg EE/2 mg cyproterone and Selmevit|Women that use combined oral contraceptives containing 20 mcg ethinylestradiol/2 mg cyproterone and Selmevit
88963850|NCT02027350|Experimental|Pressure-volume relationship|Changes in pressure-volume relationships will be compared to changes in LV and RV systolic pressure during respiration.
88963851|NCT02027363|Experimental|Observation group|Patients with metastatic colorectal cancer who achieved objective response or stable disease after 4-6 months first-line chemotherapy would stop the chemotherapy and observation.
88963852|NCT02027363|Experimental|Capecitabine group|"Patients with metastatic colorectal cancer who achieved objective response or stable disease after 4-6 months first-line chemotherapy could continue to receive oral capecitabine as maintenance therapy, capecitabine, 1000mg/m2 bid d1-14, every 3 week.~The maintenance treatment was continued until progression, unacceptable toxicity, or patient withdrawal."
88963853|NCT02027389||control|Patients with growth of S. aureus from sterile site cultures between Sept 15, 2012 - Dec 31, 2012. No rapid testing was performed, and standard bacterial culture and susceptibility testing was done.
88963854|NCT02027389||intervention|Patients with growth of S. aureus from sterile site cultures between Sept 15, 2013 - Dec 31, 2013. Rapid PBP2a testing was performed along with pharmacist notification of service if modification to therapy needed based on rapid test results.
88963855|NCT02027415|Experimental|Beet Orange|Beet juice will be given prior to the first car ride and orange juice will be given prior to the second car ride.
88963856|NCT02027415|Experimental|Orange Beet|Orange juice will be given before the first car ride and beet juice will be given before the second car ride.
88963857|NCT02027441||Home-based Testing|"At enrollment, consenting index participants will provide the study staff with locator information and a complete list of individuals currently living in his/her home who may be eligible for home-based HIV testing intervention (Household Composition form).~The study staff and index participant will schedule a date/time for the study staffto visit the index participant's home. Study staff will also provide the index participant with an information sheet to give to household members.~A study testing team comprised of trained counselors and interviewers will visit the index participant's home on the pre-determined date/time and offer home-based HIV testing to those household members who are present."
88963858|NCT02027454|Experimental|Sequence 1|Participants in this arm will receive treatment A in period 1, treatment B in period 2 and treatment C in period 3. Where treatment A= Three doses of GSK1265744 150 mg (5 x 30mg tablets) every 12 hours. B= Three doses of GSK1265744 placebo (5 tablets) every 12 hours. C= A single dose of Moxifloxacin 400mg (one 400mg tablet).
89557400|NCT05912621|No Intervention|Diet-controlled|The group assigned to dietary weight loss will undergo intensive dietary counseling with initial 3 day food diary evaluation followed by specific dietary recommendations that include macronutrient balanced, healthful and calorie-restricted diet, weekly dietitian visits, alternating between video and in person, use of a mobile app for food logging, weekly weights at home and biweekly weights, and review of these data by the study dietitian who will give individualized feedback at the weekly visits in order to attain targeted weight loss of 0.6 kg per week. The goal is to match weight loss in the tirzepatide and diet groups for the first six weeks. Any residual differences in weight loss at 6 weeks will be adjusted statistically. At six weeks all baseline tests (biopsy, metabolic tests, and regional fat scans) will be repeated, after which no further attempts for matching for weight loss will occur. At the end of the study (week 22), all baseline testing will occur again.
89557401|NCT05912582||Observation Group|
88963859|NCT02027454|Experimental|Sequence 2|Participants in this arm will receive treatment A in period 1, treatment C in period 2 and treatment B in period 3. Where treatment A= Three doses of GSK1265744 150 mg (5 x 30mg tablets) every 12 hours. B= Three doses of GSK1265744 placebo (5 tablets) every 12 hours. C= A single dose of Moxifloxacin 400mg (one 400mg tablet).
88963860|NCT02027454|Experimental|Sequence 3|Participants in this arm will receive treatment B in period 1, treatment A in period 2 and treatment C in period 3. Where treatment A= Three doses of GSK1265744 150 mg (5 x 30mg tablets) every 12 hours. B= Three doses of GSK1265744 placebo (5 tablets) every 12 hours. C= A single dose of Moxifloxacin 400mg (one 400mg tablet).
88963861|NCT02027454|Experimental|Sequence 4|Participants in this arm will receive treatment B in period 1, treatment C in period 2 and treatment A in period 3. Where treatment A= Three doses of GSK1265744 150 mg (5 x 30mg tablets) every 12 hours. B= Three doses of GSK1265744 placebo (5 tablets) every 12 hours. C= A single dose of Moxifloxacin 400mg (one 400mg tablet).
88963862|NCT02027454|Experimental|Sequence 5|Participants in this arm will receive treatment C in period 1, treatment A in period 2 and treatment B in period 3. Where treatment A= Three doses of GSK1265744 150 mg (5 x 30mg tablets) every 12 hours. B= Three doses of GSK1265744 placebo (5 tablets) every 12 hours. C= A single dose of Moxifloxacin 400mg (one 400mg tablet).
88963863|NCT02027454|Experimental|Sequence 6|Participants in this arm will receive treatment C in period 1, treatment B in period 2 and treatment A in period 3. Where treatment A= Three doses of GSK1265744 150 mg (5 x 30mg tablets) every 12 hours. B= Three doses of GSK1265744 placebo (5 tablets) every 12 hours. C= A single dose of Moxifloxacin 400mg (one 400mg tablet).
88963864|NCT02027467|Experimental|StemAlive®|Stem Alive® includes ingredients like green tea, ashwagandha. Dose: 3 capsules twice daily to be taken orally for 14 days.
88963865|NCT02027467|Placebo Comparator|Placebo|Matching placebo capsules (for StemAlive®) containing polyethylene glycol, rice powder and magnesium stearate. Dose: 3 capsules twice daily to be taken orally for 14 days.
88963866|NCT02027480||Prospective Cohort|"The study will be a prospective cohort study of HIV-infected adults initiating ART at 4-8 health facilities in Nyanza Province, Kenya. Participants will be asked to take part in four visits over a 12 month period.~At each study visit, participants will be asked questions related to demographic characteristics, medical history, including history of/recent medical conditions, family medical history, TB history and smoking status. Participants will also have their height (at baseline visit only) and weight measured for calculation of BMI and blood pressure reading. Blood and urine specimens will be collected and stored at each study visit for future testing."
88963867|NCT02027493|Active Comparator|Reiferon R weekly plus ribavirin|patients who continued treatment on weekly basis (7-day schedule). This group included patients who were HCV-RNA negative at week 12 and those who had < 1 log decrease in HCV-RNA viremia
88963868|NCT02027493|Active Comparator|Reiferon R (every 5-day) plus ribavirin|patients who continued treatment on a 5-day schedule. This group included patients who had ≥ 1 log decrease in viremia (compared to pre-treatment level) at week 12
88963869|NCT02027519||Home-based Self-testing|"Index participants who have tested positive for HIV will be provided with information regarding the importance of HIV testing for their partners and other household members and the role of home-based self-testing in potentially increasing the number of partners and household members tested for HIV. In addition, index participants will be counseled about ways in which to talk to partners and household members about HIV testing and provided with information sheets that can be distributed within the household. Lastly, index participants will be introduced to a member of the testing team that will present at their home and offer the study intervention."
88963870|NCT02027532|Active Comparator|Cefazolin|intravenous, weight-based dose (1gm<80kg, 2gm>80kg), perioperatively
88963871|NCT02027532|Active Comparator|Vancomycin|intravenous, weight-based dose (1gm<80kg, 2gm>80kg), perioperatively
88963872|NCT02027571|Experimental|Intensive Lifestyle Intervention (ILI)|ILI consists of weight loss ( > 10%); caloric reduction; physical activity (180 min/week); monthly visits for group counseling for 6 months, followed by quarterly visits; and meal replacements.
88963873|NCT02027584||parturient|mother who had given birth within 48 hours of clinically indicated blood sampling
89557402|NCT05912569|Experimental|Delay sentinel node biopsy|sinlge arm
89557403|NCT05912543|No Intervention|Conventional arm|"Moderate hyperoxia as determined by T1 arterial blood gas. For moderate hyperoxemia (PaO2 > 300 mmHg), reduce the inspired oxygen concentration to 80% and for severe hyperoxemia to 70%.~In the situation of hypoxia, where the peripheral oxygen saturation decreases to less than 95% even in 100% of FiO2, the following treatment is indicated: Fluid administration, inotropes administration (dopamine), alveolar recruitment, return to two-lung ventilation, and application of continuous positive airway pressure."
89557404|NCT05912543|Experimental|ORI arm|Target ORi™ of 0.15, check the ORi™ every 5 minutes and adjust the inspired oxygen concentration in 5% increments. If the ORi™ decreases to less than 0.15, treat it in the same way as if hypoxia occurred in the conventional group.
89557405|NCT05912530||male|All of the participants were Al jouf University students between the ages of 20 and 35. A BMI between 18 and 30 as well as a normal ROM at the time of the test were inclusion criteria. Additionally, participants had been excluded if they were taking any medications, showed a musculoskeletal injury to the leg, had a cognitive impairment, had a history of surgery, had a cardiovascular condition, or had any other health issue that would have an impact on their physical ability. There was no incentive for the individuals to participate. Prior to data collection, every single participant were informed that being involved in the investigation was voluntary and private, and they provided signed informed consent.
89557406|NCT05912530||female|All of the participants were Al jouf University students between the ages of 20 and 35. A BMI between 18 and 30 as well as a normal ROM at the time of the test were inclusion criteria. Additionally, participants had been excluded if they were taking any medications, showed a musculoskeletal injury to the leg, had a cognitive impairment, had a history of surgery, had a cardiovascular condition, or had any other health issue that would have an impact on their physical ability. There was no incentive for the individuals to participate. Prior to data collection, every single participant were informed that being involved in the investigation was voluntary and private, and they provided signed informed consent.
89208296|NCT00280735|Other|Single Arm Trial|adjuvant carboplatin plus docetaxel carboplatin area under curve (AUC) = 6 IV on day 1 every 3 weeks for 4 cycles docetaxel 75 mg/m² IV on day 1 every 3 weeks for 4 cycles
89557407|NCT05912491||Urinary stress incontinence (UI)|Women with clinical symptoms of stress urinary incontinence
89557408|NCT05912491||No Urinary stress incontinence (no-UI)|Women without clinical symptoms of stress urinary incontinence
89557409|NCT05912478|Experimental|Study group|Videogame-Based Therapy Games for the Nintendo Switch (Version 2) will be used for eight weeks, three days per week, for a total of 24 sessions.
89557410|NCT05912478|Other|Control Group|The participants on the waiting list will be evaluated as the control group. For eight weeks, the control group will be instructed to maintain their daily routine.
89557411|NCT05912465|Experimental|Treatment-Naive Lung Cancer Patients|This arm includes 150 treatment-naive lung cancer patients. Assessments include medical history, physical exams, lab tests, and imaging. Objective: investigate cancer cachexia, stress, and metabolic changes. Cachexia criteria: weight loss, reduced food intake, inflammation markers. Stress assessment: questionnaires, biomarkers. Metabolic changes measured by PET-CT scans analyzing FDG uptake in organs/lesions. Data will uncover the relationship between cancer cachexia, stress, and metabolic changes in treatment-naive lung cancer patients, leading to improved interventions/outcomes.
89557412|NCT05912439|No Intervention|Control|Measures for participants in control group are obtained at baseline and 42 days later. The control group receives no further contact, access to the mHealth application or information until study-end questionnaire measures are provided.
89557413|NCT05912439|Active Comparator|Treatment-As-Usual|For participants in Treatment-As-Usual (TAU) group measures are obtained at baseline and 42 days later. Participants receive an approximately 10 minutes long introduction regarding study specifications and the mHealth application. Active participation in TAU group is defined as downloading the Sidekick app and completing at least 3 health exercises within it. Time of exercise is defined as the timestamp on completion of exercise within any of the three types of exercise categories (physical activity, nutrition and mental health) of the app. Exercise frequency refers to how often a given exercise was completed by a participant in TAU group. Time of attrition is defined as the time stamp of last completing health exercise within the Sidekick throughout intervention period. Participants in TAU group use the application individually throughout trial period without any motivational support.
88963874|NCT02027584||healthy, non-pregnant, female volunteers|healthy, non-pregnant, female volunteers
88963875|NCT02027584||preterm infant|gestational age at birth < 37 weeks
88963876|NCT02027584||term infant|gestational age at birth >36 weeks
88963877|NCT02027597|Experimental|Video Game Treatment|This group received the AOTSM game experience followed by additional oral health information. They did not receive any follow-up treatment after the exhibit.
88963878|NCT02027597|Active Comparator|Control|Instead of playing Attack of the S. Mutans!, children in the control group attended a 90 minute classroom session about virtual reality applications for relieving pain and for therapy. This content was unrelated to oral health.
88963879|NCT02027597|Experimental|Video Game Treatment Plus Follow-Up|Children assigned to the Treatment-Plus conditions not only had the Attack of the S. Mutans video game experience, but also gained access to an educational website that reinforced the exhibit's teachings two months later. These students received a special login and password in the mail and were instructed to visit the site before completing their next questionnaire.
88963880|NCT02027636|Active Comparator|Engagement and Counseling for Latinos (ECLA-F)|Patients in this arm (ECLA-F) receive the 6-8 session CBT plus care-management intervention, administered in person.
88963881|NCT02027636|Active Comparator|Engagement and Counseling for Latinos (ECLA-T)|Patients in this arm received the 6-8 session CBT intervention via telephone.
88963882|NCT02027636|No Intervention|Usual Care|Patients in this arm receive usual care for depression from their primary care providers, which could include antidepressant prescription or referral to specialty mental health care.
88963883|NCT02027649||Bladder cancer|Patients who suffered a bladder cancer
89208297|NCT02555462|Experimental|Real-Ear Measurement|The study arm goes through a comparative test run followed by a comparative hearing aid fitting.
89208298|NCT00979719|Experimental|Intervention Group (IG)|Patients in the IG will receive an interactive, computerized expert system which tailors treatment components to the individual needs of the patients
88963884|NCT02027649||Control group|Patients with urologic diseases of non tumoral origin
88963885|NCT02027662|Experimental|Osvaren Granules|Osvaren Granules
88963886|NCT02027662|Active Comparator|Osvaren film-coated tablets|Osvaren film-coated tablets
89208299|NCT00979719|Placebo Comparator|Active Control Group (ACG)|Patients in the ACG will get an interactive computerized standard program which has been proven to be effective (Göhner, & Fuchs, 2007) Göhner, W. & Fuchs, R. (2007). Änderung des Gesundheitsverhaltens. MoVo-Gruppenprogramme für körperliche Aktivität und gesunde Ernährung. Göttingen: Hogrefe.
89557414|NCT05912439|Experimental|Intervention|For participants in intervention group measures are obtained at baseline and 42 days later. Participants receive an approximately 10 minutes long introduction regarding study specifications and the mHealth application. Active participation in intervention group is defined as downloading the Sidekick app and completing at least 3 health exercises within it. Time of exercise is defined as the timestamp on completion of exercise within any of the three types of exercise categories (physical activity, nutrition and mental health) of the app. Exercise frequency refers to how often a given exercise was completed by a participant in TAU group. Time of attrition is defined as the time stamp of last completing health exercise within the Sidekick throughout intervention period. Participants in intervention group receive weekly motivational support in form of individual and group feedback on usage, participation in friendly health task competitions and weekly altruistic rewards for usage.
89557415|NCT05912374|Active Comparator|Control arm with standard intervention|Participants will complete a 4-week CHRP-BB standard intervention
89557416|NCT05912374|Experimental|Experimental arm with enhanced intervention|Participants will complete a 4-week CHRP-BB intervention enhanced with included cognitive dysfunction accommodation strategies.
89557417|NCT05912348|Experimental|Obesogenic Lifestyle Model Group|10-days of sedentary activity (~5,000 steps/day) while consuming added sugar-sweetened beverages (250g/day).
89557418|NCT05912348|Placebo Comparator|Sedentary Control|10-days of sedentary activity (~5,000 steps/day).
89557419|NCT05912348|No Intervention|Normal Activity Control|Maintains normal physical activity levels and exercise training
88963887|NCT02027675|Experimental|Meal Exercise Challenge- Order 2|Two different meals,an high fat micronutrient poor meal and Mediterranean Meal will be followed by an exercise challenge and performed at different orders accordingly to the cross over design.
88963888|NCT02027675|Experimental|Meal Exercise Challenge- Order 1|"Two different meals,an high fat micronutrient poor meal and Mediterranean Meal will be followed by an exercise challenge and performed at different orders accordingly to the cross over design.~Each arm corresponds to a different intervention order."
88963889|NCT02027688|Active Comparator|Every 6 hour Feeding Schedule|Infants in this arm will be offered oral feedings every 6 hours if they are safe and ready to feed by mouth.
88963890|NCT02027688|Active Comparator|Every 3 Hour Oral Feeding|Infants in this arm will be offered oral feedings every 3 hours if they are safe and ready to feed by mouth.
88963891|NCT02027714||Women's Quantitative Survey|"Quantitative surveys will be administered to 200 pregnant and recently postpartum women. Surveys will be conducted in either English or Sesotho depending on the participant's preference. Surveys will be administered by a study-staff member. Survey activities will be conducted in a private space either within or around the clinic building. All study activities will take approximately 1 hour to complete.~The survey is comprised of 62 close-ended questions. Included in this survey are questions related to demographics, sexual behaviors, HIV and various HIV testing services."
88963892|NCT02027714||Women's Focus Group Discussions|"6-8 focus groups of approximately 6-12 pregnant or recently postpartum women will be conducted. Focus group discussions will be organized according to HIV serostatus to allow for open dialogue and participant comfort. All group discussions will be conducted in Sesotho. Each group discussion will be facilitated, preferably, by a female study-staff member. All group discussions will be held in a private space either within a study site or another speciﬁed location within the community. All study activities will take approximately two hours to complete.~Topics that will be discussed during these interviews include relationship dynamics between Basotho men and women, knowledge of HIV and various related issues, including HIV testing, HIV treatment and discordancy in HIV status. Additionally, questions about knowledge and attitudes regarding male circumcision will be asked."
88963893|NCT02027714||Male Interviews|"30 in-depth individual interviews with men. In-depth semi structured interviews consisting of open-ended questions will be conducted in either English or Sesotho depending on the participant's preference will be conducted. Interview activities will be conducted in a private space either within or around the clinic building.~Topics that will be discussed during these interviews include relationship dynamics between Basotho men and women, knowledge of HIV and various related issues, including HIV testing, HIV treatment and discordancy in HIV status. Additionally, questions about knowledge and attitudes regarding traditional and medical male circumcision will be asked.~Following the completion of the interview, the same facilitator will administer a brief survey to the study participant."
88963894|NCT02027727||No intervention|No intervention- this is an observational study of patients receiving Infliximab.
88963895|NCT02027740|Experimental|almond|almonds are substituted for visible fat and carbohydrates
88963896|NCT02027753|Experimental|Insulin glargine and Oral anti diabetic treatment(s)|"Insulin glargine: Lantus~Add basal insulin: starting with 0.2 U/kg/day or 10 U/day~Adjust insulin glargine dose according to Fasting blood glucose~Oral Anti Diabetic treatment(s): DPP-4 inhibitors and Metformin plus or minus Sulphonylurea - Only Sulphonylurea can either be omitted or reduced at the physician's discretion."
88963897|NCT02027766|Experimental|Stretching|Daily stretching of the calf (dominant side; defined as leg used to kick a ball). 2 stretching exercises are performed daily: 1) stretching of the soleus muscle; 2) stretching of the gastrocnemius muscle.
88963898|NCT02027766|No Intervention|Control|
89208300|NCT00979719|No Intervention|Passive Control Group (PCG)|patients are asked to answer the questionnaires only
89208301|NCT01070251|Active Comparator|Existing state-sponsored PA program|standard children-focused gym lessons approach
89208302|NCT01070251|Active Comparator|Participatory intervention plus state-sponsored PA program|Participatory parent-focused intervention over nine months in addition to state-sponsored PA program
89208303|NCT00801008|Experimental|Exercise and Relaxation Intervention|Participants in this arm will receive a 12 week exercise and relaxation intervention
89208304|NCT00801008|No Intervention|Wait List Control Condition|Participants in this arm will be offered the exercise and relaxation intervention after a 12 week delay.
89208305|NCT03975283|Experimental|Exparel (Liposomal Bupivicaine)|20 ml vial of liposomal bupivacaine containing 266 mg (maximum dose), will be diluted with 20 ml of 0.25% bupivacaine (containing 50 mg of bupivacaine) and 20 ml saline (60 ml total). That total volume will be divided into two 30 ml syringes, and each will be used (per side) for the TAP blocks.
89557420|NCT05912335|Active Comparator|Topical anesthetic available on the market - Lidocaine (2.5%), Prilocaine (2.5%)|"Applied at palatal mucosa (first premolar region), for 2 minutes. After that, this formulation will be removed.~100 mg."
89557421|NCT05912335|Placebo Comparator|Xanthan hydrogel 2%|"Applied at palatal mucosa (first premolar region), for 2 minutes. After that, this formulation will be removed.~100 mg."
88963899|NCT02027779|Experimental|Prophylaxis safety and efficacy substudy|Hemostatic efficacy of GreenGene™ F will be assessed by its effectiveness in controlling spontaneous or traumatic bleeding episodes and by the rate of breakthrough bleeding during prophylaxis over ≥ 50 additional exposure days.
88963900|NCT02027779|Experimental|On-demand safety and efficacy substudy|Hemostatic efficacy of GreenGene™ F will be assessed by its effectiveness in controlling spontaneous or traumatic bleeding episodes and by the rate of breakthrough bleeding in a minimum of 10 on demand treated subjects during additional 50 exposure days.
88963901|NCT02027792|Experimental|Cabbage leaf wraps|Daily application of cabbage leaf wraps over night, 4 weeks application
88963902|NCT02027792|Active Comparator|Diclofenac gel|daily application of diclofenac gel 4 weeks application
88963903|NCT02027792|No Intervention|Usual care|no specific intervention
88963904|NCT02027805|Experimental|T-Guard|Four doses of T-Guard (4 mg/m2), administered at 48-hour intervals as 4 hour infusions.
89557422|NCT05912335|Experimental|Xanthan hydrogel (2%), Lidocaine (2.5%), Prilocaine (2.5%) in NLC|"Applied at palatal mucosa (first premolar region), for 2 minutes. After that, this formulation will be removed.~100 mg. Local Anesthetic encapsulated in nanostructured lipid carriers (NLC)"
89557423|NCT05912335|Experimental|Xanthan hydrogel (2%), Lidocaine (2.5%), Prilocaine (2.5%)|"Applied at palatal mucosa (first premolar region), for 2 minutes. After that, this formulation will be removed.~100 mg."
89557424|NCT05912322|Experimental|Black chokeberry juice|100ml black chokeberry juice/day
89557425|NCT05912322|No Intervention|Control|Lifestyle changes. No juice
89557426|NCT05912309|Experimental|Time Restricted Eating (TRE)|
89557427|NCT05912309|Experimental|Time Restricted Eating (TRE) + Exercise|
89557428|NCT05912309|Active Comparator|Caloric restriction (CR) + Exercise|
89557429|NCT05912296|Experimental|RBD7022 SAD experimental group|Subjects in SAD experimental groups will receive a single subcutaneous injection of RBD7022 on Day 0.
89557430|NCT05912296|Experimental|RBD7022 MAD experimental group|Subjects in MAD experimental groups will receive one subcutaneous injection of RBD7022 on Day 0 and another subcutaneous injection of RBD7022 on Day 28.
88963905|NCT02027831|Experimental|Indocyanine Green|Intravenous injection of 0,25 mg/kg Indocyanine Green
88963906|NCT02027857|No Intervention|mannitol empirical therapy|There would be 20 patients in this group, who would be given mannitol to relieve the brain edema depending on the empirical therapy by doctors.
88963907|NCT02027857|Experimental|EIT monitoring|There would be 20 patients in this group, who would be given mannitol to relieve the brain edema depending on the results of Electrical impedance tomography monitoring.
88963908|NCT02027857|Other|non-invasive ICP monitoring|There would be 20 patients in this group, who would be given mannitol to relieve the brain edema depending on the results of non-invasive intracranial pressure monitoring.
88963909|NCT02027870||EXCEL-II DES|Using EXCEL-II biodegradable polymer sirolimus-eluting stent treating CAD
88963910|NCT02027909||Therapy group one|Lower rate of 60 bpm and out of the box rate response settings of an ADL Rate of 95 bpm and rate profile optimization on with the only change being adjusting the activity threshold from med/low to low.
88963911|NCT02027909||Therapy group two|Rate response programming will be determined by an exercise test consisting of a 2 minute hall walk will be performed at the 2 week follow up and set points will be manually adjusted to achieve an ADL rate of 95 bpm. Rate Profile Optimization will be turned off. Activity threshold is programmed to low.
88963912|NCT02027909||Therapy group three|Lower rate of 60 bpm and the ADL rate based upon 220- age x 55%. Activity threshold is programmed to low. Rate Profile Optimization will be turned ON.
88963913|NCT02027922|Experimental|Fluoride varnish Fluor Protector S|Fluoride varnish Fluor Protector S (Ivoclar Vivadent) with 1.5% ammonium fluoride was not scored. The emergence of a new varnish implies the necessity to compare the effectiveness of both agents in preventing caries in deciduous teeth. All of the elements of a clinical trial and the varnish applications will be performed four times at three-month intervals: examination - 0 (initial score), follow-ups to the initial examination and intervention: 1 - after 3 months, 2 - after 6 months, 3 - after 9 months. Changes in OHI-S, spot carious lesion discovered at the initial assessment as invisible, visible and inactive, active, cavities), dmft and dmfs, and their components will be scored at follow-up examinations.
88963914|NCT02027922|Active Comparator|Duraphat|5% Sodium fluoride varnish Duraphat Colgate implies the necessity to compare the effectiveness with Fluor Protector S in preventing caries in deciduous teeth. All of the elements of a clinical trial and the varnish applications will be performed four times at three-month intervals: examination - 0 (initial score), follow-ups to the initial examination and intervention: 1 - after 3 months, 2 - after 6 months, 3 - after 9 months. Changes in OHI-S, spot carious lesion discovered at the initial assessment as invisible, visible and inactive, active, cavities), dmft and dmfs, and their components will be scored at follow-up examinations.
88963915|NCT02027922|No Intervention|an oral hygiene tutorial|an oral hygiene tutorial
89033050|NCT02922348|Experimental|Hormone Replacement Therapy|Patient will be given hormones in the form of: transdermal estradiol patch (Climara) 100 mcg/24 hours weekly, progesterone (Prometrium) 200 mg per day for first 12 calendar days of each month (If patients insurance plan does not cover transdermal estradiol, they will be prescribed oral estradiol 2 mg daily. If patients insurance plan does not cover Prometrium, they will be prescribed medroxyprogesterone (Provera) 10 mg per day for first 12 calendar days of each month).
89557431|NCT05912296|Placebo Comparator|Placebo SAD group|Subjects in SAD placebo groups will receive a single subcutaneous injection of placebo on Day 0.
89557432|NCT05912296|Placebo Comparator|Placebo MAD group|Subjects in MAD placebo groups will receive one subcutaneous injection of placebo on Day 0 and another subcutaneous injection of placebo on Day 28 .
89557433|NCT05912218|Experimental|MEDI6570|Biological MEDI6570,subcutaneous injection
88963916|NCT02027961|Experimental|Cohort A1: Durvalumab (3 mg/kg) + Dabrafenib +Trametinib|Participants will receive intravenous (IV) dose of 3 milligrams per kilogram (mg/kg) durvalumab every 2 weeks (Q2W) from Day 1 up to 12 months along with oral 150 mg dabrafenib capsule twice daily (BID) and oral 2 mg trametinib tablet once daily (QD) until confirmed disease progression (PD), initiation of alternate cancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue treatment. Post-durvalumab treatment period, participants who developed PD and meet the criteria for re-administration, will receive durvalumab 3 mg/kg up to an additional 12 months and continued the treatment of dabrafenib and trametinib.
88963917|NCT02027961|Experimental|Cohort A2: Durvalumab (10 mg/kg) + Dabrafenib +Trametinib|Participants will receive IV dose of 10 mg/kg durvalumab Q2W from Day 1 up to 12 months along with oral doses of dabrafenib 150 mg capsule BID and trametinib 2 mg tablet QD until confirmed PD, initiation of alternate cancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue treatment. Post-durvalumab treatment period, participants who developed PD and meet the criteria for re-administration, will receive durvalumab 10 mg/kg up to an additional 12 months and continued the treatment of dabrafenib and trametinib.
88963918|NCT02027961|Experimental|Cohort B: Durvalumab (10 mg/kg) +Trametinib (Concurrent)|Participants will receive concurrent doses of IV 10 mg/kg durvalumab Q2W from Day 1 up to 12 months along with oral dose of trametinib 2 mg tablet QD until confirmed PD, initiation of alternate cancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue treatment. Post-durvalumab treatment period, participants who developed PD and meet the criteria for re-administration, will receive durvalumab 10 mg/kg up to an additional 12 months and continued the treatment of trametinib.
88963919|NCT02027961|Experimental|Cohort C: Durvalumab (10 mg/kg) +Trametinib (Sequential)|Participants will receive sequential doses of oral trametinib tablet 2 mg QD from Day 1 to Day 42 and IV durvalumab 10 mg/kg Q2W starting from Day 29 (Week 5) up to 12 months. Post-durvalumab treatment period, participants who developed PD and meet the criteria for re-administration, will receive durvalumab 10 mg/kg up to an additional 12 months.
88963920|NCT02027974|Active Comparator|Iconacy Hip System|Iconacy hip system prosthesis components
88963921|NCT02027974|Active Comparator|Stryker Accolade Hip System|Stryker Accolade hip system prosthesis components
88963922|NCT02027987|Experimental|valproate acid|The patients began receiving treatment at a dose of 400 mg VPA twice daily on the day after randomization by intravenous drip, with this dose continued for 14 days.The dose was increased to 500 mg twice daily at week 3 and to 400 mg three times daily at week 4 if the DRS score had not improved by at least 2 points from baseline. After the week 4 assessment, the study drug was tapered over a period of 2 to 3 days, with assessment of the patients continued through week 6. Additional procedural details are provided in the study protocol.
88963923|NCT02027987|Placebo Comparator|placebo|
88963924|NCT02028000|Active Comparator|INSORB staples skin closure|Women undergoing cesarean section delivery will have skin closure with INSORB staples.
88963925|NCT02028000|Active Comparator|Monocryl skin closure|Women undergoing cesarean section delivery will have skin closure with Monocryl.
88963926|NCT02028000|Active Comparator|Vicryl skin closure|Women undergoing cesarean section delivery will have Vicryl skin closure
88963927|NCT02028026|Experimental|Vilazodone|10mg/day for 1 week, 20 mg/day for 1 week, and then 40 mg/day for 6 weeks.
88963928|NCT02028026|Active Comparator|Citalopram|20 mg/day for 2 weeks and then 40 mg/day for 6 weeks.
88963929|NCT02028039|Experimental|IPI-145|IPI-145 given at dose of 75 mg orally twice daily for 4 weeks. Courses repeated about every 4 weeks (range 4-6 weeks).
88963930|NCT02028052|Other|ROSE|In the case of ROSE, sampling frequency will occur similarly, but no additional samples will be taken in the case of provision of a preliminary diagnosis.
88963931|NCT02028052|Other|NO ROSE|In the case of no ROSE, sampling frequency will be predetermined at 4 needle aspirations per site
88963932|NCT02028078|Experimental|Insulin human (Actrapid)|At 22:00 subject will receive insulin human (Actrapid) intravenously in order to obtain a steady state of a PG level of 5.5 mmol/L overnight until approximately 08:00 in the morning of day 2. At 8:00 am, in the morning at day 2, human insulin infusion will be increased to 1.5 mU/kg/min for each subject until approx. 12 pm for hypoglycaemia induction.
88963933|NCT02028091||Diabetes mellitus|All patients over 18 years with diagnosed diabetes mellitus type II.
88963934|NCT02028091||Non Diabetic|Patients over 18 years with no known diabetes mellitus or other known/diagnosed vascular diseases.
88963935|NCT02028104|Experimental|stem cells|autologous bone marrow mononuclear cell transplantation
88963936|NCT02028117|Experimental|Enadenotucirev|
89557434|NCT05912218|Placebo Comparator|Placebo|Saline Control,subcutaneous injection
88812307|NCT05696795|Experimental|Abrocitinib 200 mg daily|6 months of treatment with abrocitinib 200 mg daily
88812308|NCT05687110|Experimental|Treatment (novobiocin sodium)|Patients receive novobiocin sodium PO BID on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo a tumor biopsy at baseline, on day 15 of cycle 1, and at time of progression. Patients undergo medical imaging scans at baseline and every 8 weeks. Patients also undergo blood sample collection on study.
88812309|NCT05683392|Experimental|Control-IQ 2.0 Alternate Target|Participants will use t:slim X2 pump with Control-IQ technology 2.0 at an alternate target for two weeks.
88812310|NCT05683392|Experimental|Control-IQ 2.0 Standard Target|Participants will use t:slim X2 pump with Control-IQ technology 2.0 at a standard target for two weeks.
88812311|NCT05674565|Experimental|Loading dose only|Those receiving only the loading dose of magnesium sulphate 4 gm infusion over 20 minutes therapy within one hour before delivery without the maintenance dose
88812312|NCT05674565|Experimental|Loading plus maintenance dose|Receiving magnesium sulphate loading 4 gm infusion over 20 minutes, followed by maintenance therapy 1gm per hour infusion until delivery or completion of 24 hours, the sooner.
88812313|NCT05674565|No Intervention|Control|comparable number of women who did not receive magnesium sulphate neuroprotection for any reason
89208306|NCT03975283|Active Comparator|0.25% Bupivicaine HCL|Two 30 ml of 0.25% bupivacaine is drawn up and given on each side after identification of planes and levels via laparoscopy. Medication will be given just below the last rib and extend to below the lowest incision.
89208307|NCT00795782|Experimental|UniCND|Limited/ipsilateral central lymph node dissection
89208308|NCT00795782|Active Comparator|BiCND|Comprehensive/bilateral central lymph node dissection
89208309|NCT00795782|No Intervention|NoCND|No central lymph node dissection
89208310|NCT01070407|Experimental|Arm A, group 1|4 volunteers
89208311|NCT01070407|Experimental|Arm A, group 2|4 volunteers
89208312|NCT01070407|Experimental|Arm A, group 3|5 volunteers
89208313|NCT01070407|Experimental|Arm B, group 5|4 volunteers
89208314|NCT01070407|Experimental|Arm B, group 6|4 volunteers
89208315|NCT01070407|Experimental|Arm B, group 7|5 volunteers
89208316|NCT01070407|Experimental|Arm C, group 9|5 volunteers
89208317|NCT01070407|Experimental|Arm C, group 10|5 volunteers
88812314|NCT05673772|Experimental|Study group|Short-course radiotherapy and 4 cycles of mFOLFOX6 followed by TME. Adjuvant chemotherapy will be given according to the pathological stage (CR~pStageI: 6 cycles of capecitabine or 4 cycles of 5-FU with leucovorin, pStageII-III: 8 cycles of mFOLFOX6)
88812315|NCT05673772|Active Comparator|Control group|Conventional chemoradiotherapy followed by TME. Adjuvant chemotherapy will be given according to the pathological stage (CR~pStageI: 6 cycles of capecitabine or 4 cycles of 5-FU with leucovorin, pStageII-III: 8 cycles of mFOLFOX6)
88812316|NCT05630495|Experimental|Enable high qualitative estimation of bilirubin levels in the blood of new-borns|In this study we aim to collect data of newborns with wider range of bilirubin levels and additionally measurements of skin color reflectance with a spectrophotometer, to adjust the Picterus JP algorithm and optimize the app performance. This will enable a high qualitative estimation of bilirubin levels in the blood of new-borns of South-East Asian ethnicity and skin type.
88812317|NCT05626712|Experimental|CELZ-201 Treatment Group|Participants in this group will receive a single dose of CELZ-201, in addition to standard of care of care for Type 1 Diabetes treatment.
88812318|NCT05626712|Placebo Comparator|Control Group|Participants in this group will receive standard of care for Type 1 Diabetes only.
88812319|NCT05609045|Experimental|test product group|
88812320|NCT05609045|Placebo Comparator|placebo group|
88812321|NCT05554276|Experimental|neoadjuvant chemotherapy+ PD-1 antibody + radical radiotherapy|All patients received three cycles of 21 days each, with chemotherapy on day 1 (nab-paclitaxel 150 mg/m2 plus cisplatin 75 mg/m2) and camrelizumab 200 mg, followed by radical radiotherapy.
88812322|NCT05540678|Placebo Comparator|Placebo|Chewing gum containing maltitol powder
88812323|NCT05540678|Experimental|Investigational|chewing gums containing fibers
88812324|NCT05540678|No Intervention|No-treatment control|No study chewing gum
88812325|NCT05537311|Experimental|Social engagement using VR|Patients will receive social engagement with emphasize on meaningful conversation, cognitive engagement, and emotional support provided by trained research assistant using virtual reality as a vehicle for delivery. Subjects will receive 15-45 minutes of treatment per day for 5 days initiated after respiratory support (Intubation via mask or tube, high-flow nasal cannula) have been weaned to nasal cannula. Experimental group will also receive standard of care
89557435|NCT05912205|Experimental|Disitamab Vedotin combined with radiotherapy|Disitamab Vedotin (RC48) 2.0mg/kg, once every two weeks, intravenous drip (60-90 min); Radiotherapy (SBRT, bladder irradiation field with a total dose greater than 50 Gy)
89025995|NCT02893345|Experimental|Safe@Home Intervention Group|Participants receive: (1) computer-generated, personalized assessment of abilities, risk, and recommended next steps; (2) 2 person-family education visits to develop a shared understanding of client strengths and risks, set goals, develop better ways to work as a team, and problem-solve; (3) 8 in-home visits in which personal transition trainer/life skills coach provides training, compensatory strategies, and social/technological supports on self-selected activities. The ten visits last 90-120 minutes and ideally take place over a three month period.
89557436|NCT05912192|Experimental|Elonide Nasal Spray|Elonide is generic nasal spray Dose: 50 mcg/dose mometasone furoate 140 sprays per nasal spray One pump for both nostrils twice daily
89025996|NCT02893345|Active Comparator|Usual Care Group|Participants receive the computer-generated, personalized assessment of abilities, risk, and recommended next steps. Participants may seek services as usual over the 3-month period.
89025997|NCT00491439||Corneal wounds after Epi-LASIK|Corneal wounds after Epi-LASIK
89025998|NCT00491439||penetrating keratoplasty|Corneal wound after penetrating keratoplasty
89208318|NCT01070407|Experimental|Arm C, group 11|4 volunteers
89557437|NCT05912192|Active Comparator|Nasonex Nasal Spray|Nasonex Aqueous Nasal Spray Dose: 50 mcg/dose mometasone furoate 140 sprays per nasal spray The usual recommended dose for prophylaxis and treatment is two sprays (50 micrograms/spray) in each nostril once daily (total dose 200 micrograms) One pump for both nostrils twice daily
89557438|NCT05912192|Placebo Comparator|Normal Saline|Placebo used is 0.9% sodium chloride Dose: 50 mcg/dose of 0.9% sodium chloride One pump for both nostrils twice daily
89557439|NCT05912179||EUS guided liver biopsy|Patients having liver biopsy through endoscopic ultrasound technique
89557440|NCT05912179||Percutaneous liver biposy|Patients having liver biopsy percutaneously
89557441|NCT05912179||Transjugular liver biopsy|Patients having liver biopsy via a transjugular route
89557442|NCT05912140||Trunk Aesthetic Clinical Evaluation|
89557443|NCT05912127|Active Comparator|• Group 1 (control group)|patients who received All on 4 implant-supported fixed restoration. The patients received 2 inclined implants anterior to the mental foramina and 2 vertical implants in the lateral incisor/canine areas.
89557444|NCT05912127|Active Comparator|• Group 2 (test group);|patients who received All on 3 implant-supported fixed restoration. The patients received 2 inclined implants anterior to the mental foramina and 1 vertical implant in the midline of the mandible.
89557445|NCT05912114|Experimental|Mannitol|Use of oral 1L Mannitol for remediation of intestinal uncleanliness
89557446|NCT05912114|Active Comparator|Polyethylene glycol electrolyte|Use of oral 1L PEG for remediation of intestinal uncleanliness
89557447|NCT05912036|Experimental|CA-CRT|Computer-Assisted Cognitive Remediation Therapy
89557448|NCT05912036|No Intervention|TAU|Treatment as Usual
89557449|NCT05912010||case group|patients from fever clinics and pediatric wards
89557450|NCT05912010||control group|healthy community children
89557451|NCT05911984|Experimental|9MW3811 Injection|
89557452|NCT05911971|Experimental|Specific reeducation|Specific reeducation
89557453|NCT05911971|Sham Comparator|Sham comparator|Sham reeducation
89557454|NCT05911945|Active Comparator|Flexible Ureterorenoscopy|Underwent a JJ stent insertion and underwent f-URS 4-6 weeks later (Group 1).
88812326|NCT05537311|No Intervention|Control|Control will receive standard of care
89025999|NCT00491439||corneal epithelial debridement|Corneal wound after pars plana vitrectioy with corneal epithelial debridement for diabetic retinopathy
89026000|NCT03272945|Experimental|LCI|Once the randomization assignment was announced, the whole colonoscopy from insertion to cecum to withdrawal of endoscope was carried out entirely by using Linked-color imaging (LCI).
89026001|NCT03272945|Placebo Comparator|WL|Once the randomization assignment was announced, the whole colonoscopy from insertion to cecum to withdrawal of endoscope was carried out entirely by using white light (WL).
89026002|NCT04396171||Probable bruxism(+)|
89026003|NCT04396171||Probable bruxism(-)|
89026004|NCT00466895|Experimental|Stratum 1 Acute Leukemias|Patients must have a diagnosis of Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia(ALL)according to the WHO (World Health Organization) classification.
89026005|NCT00466895|Experimental|Stratum 2 Chronic lymphocytic leukemia|Patients must have diagnosis of B-Cell, Chronic Lymphocytic Leukemia(CLL) or Small Lymphocytic Leukemia (SLL) (including Waldenstrom's Macroglobulinemia) requiring therapy (see eligibility criteria for definition of this) and have previously received treatment with one or more prior chemotherapy regimens.
89026006|NCT00498459|Experimental|ICAPS|Promotion Physical Activity
89026007|NCT00498459|No Intervention|Control|No specific physical activity promotion Ususal school program
89026008|NCT03272087|Active Comparator|Pleuroscopy|According to BTS guideline thoracoscopy is the next procedure for patients who remain undiagnosed despite PET-CT and attempts to obtain biopsies. Eligible patients will be randomised to pleuroscopy or VATS. Patients with inconclusive pleuroscopy will proceed to VATS.
89208319|NCT00801086|Experimental|1|MTS-01 (7% Tempol gel)
89208320|NCT00801086|Placebo Comparator|2|Vehicle
89557455|NCT05911945|Active Comparator|Mini Percutaneous Nephrolithotomy|Underwent mPNL operation in the same session after prone positioning (Group 2).
89557456|NCT05911919||Patients|Patients with ABCD1 pathogenic variant
89557457|NCT05911919||Healthy volunteers|Healthy volunteers inclusion in order to calibrate the MRI machine used and its settings.
89557458|NCT05911893|Experimental|high caloric oral nutritional supplements group|Participants aged 1 to 3 years who are malnourished (underweight and wasting). They will receive nutritional education,dietary instruction and daily high caloric oral nutritional supplements for 12 months.
89557459|NCT05911893|Active Comparator|nutritional education and dietary guidance group|Participants aged 1 to 3 years who are malnourished (underweight and wasting). They will receive nutrition education and dietary instruction.
89557460|NCT05911867|Experimental|combination of mobilization with movement and muscle energy techniques|"Mulligan technique (MWM) involves the therapist using a belt around the humeral head to guide appropriate gliding while the patient moves their shoulder actively through the range. The therapist applies pressure to the scapula in a counter direction.~Regarding the cervical spine, the second technique, Cervical Self-Natural Apophyseal Glides (SNAG), involves the therapist standing behind the patient and applying force to the spinous process of each vertebra using a thumb-over-thumb technique.~The examiner passively abducts the arm in the horizontal plane until the first barrier to motion by applying pressure to the distal humerus. This passive stretch will be held for three seconds."
89557461|NCT05911867|Active Comparator|mobilization with movement|"Regarding the shoulder joint, the Mulligan technique (MWM) involves the therapist using a belt around the humeral head to guide appropriate gliding while the patient moves their shoulder actively through the range. The therapist applies pressure to the scapula in a counter direction. This technique is usually performed for five sets of five repetitions with one minute of rest between sets in a sitting position.~Regarding the cervical spine, the second technique, Cervical Self-Natural Apophyseal Glides (SNAG), involves the therapist standing behind the patient and applying force to the spinous process of each vertebra using a thumb-over-thumb technique. The patient actively performs repeated flexion or extension of their neck, returning back to the neutral position."
89557462|NCT05911867|Active Comparator|muscle energy techniques|The examiner passively abduct the arm in the horizontal plane until the first barrier to motion by applying pressure to the distal humerus. This passive stretch will be held for three seconds. The examiner then instruct the participant to attempt to horizontally adduct the test arm at 25% of their maximal effort while the examiner applies manual resistance at the distal humerus to create an isometric contraction lasting five seconds. The participant then actively abduct the arm in the horizontal plane for a three-second active-assisted stretch.
89557463|NCT05911854|Experimental|Study group (A) Multi-waved Locked System Laser group|
89557464|NCT05911854|Experimental|Study group (B) Cold Compression Therapy group|
88963937|NCT02028130|Experimental|LAA electrical isolation + occlusion|Standard persistent AF ablation protocol + LAA electrical isolation + Watchman device implantation to occlude LAA
88963938|NCT02028143|Experimental|Study arm|The study arm group will have the ICE catheter placed through one of two existing 8F sheaths already in the left atrium. The ICE catheter will be exchanged in the sheath utilizing the lasso multipolar mapping catheter during left pulmonary vein ablation lines. During exchange, suction and irrigation techniques will be utilized to avoid any air or thrombus embolization. All patients will have standard anticoagulation during the procedure with heparin infusion adjusted to an activated clotting time (ACT) of 350-400. The left sided ICE catheter will be adjusted to visualize left sided structures, ablation tip and tissue interface, and adjacent noncardiac structures such as the esophagus during radiofrequency ablation of the left pulmonary vein system.
89557465|NCT05911854|Active Comparator|Group (C) Control group|
88963939|NCT02028143|Active Comparator|Control arm|The control arm group will receive standard pulmonary vein isolation (PVI) procedure utilizing intracardiac guided ultrasound (ICE) placed within the right atrium via the femoral vein.
88963940|NCT02028156|Experimental|Partially Hydrolyzed Infant Formula|Fed ad lib.
88963941|NCT02028195|Experimental|Health check|The intervention consists of invitation for a behavioural and clinical examination followed by either (I) referral to a health promoting consultation in general practice (II) targeted behavioural programmes at the local Health Centre or (III ) no need for follow-up.
88963942|NCT02028195|No Intervention|No invitation|The persons randomised to the control arm does not get invitation to a health care examination before time for follow up in the intervention group.
88963943|NCT02028234|Active Comparator|pantoprazole|Patients were randomly assigned to omeprazole (20 mg day) or pantoprazole (20 mg day) for 30 days. After 1-week wash-out period to avoid any carryover effect, cross-over was performed, and patients were switched to the other drug which was continued for 30 days.
88963944|NCT02028234|Active Comparator|Omeprazole|Patients were randomly assigned to omeprazole (20 mg day) or pantoprazole (20 mg day) for 30 days. After 1-week wash-out period to avoid any carryover effect, cross-over was performed, and patients were switched to the other drug which was continued for 30 days.
88963945|NCT02028260|Active Comparator|Modafinil|Modafinil 200 mg qAM enterally for the duration the patient is confirmed to be in a hypoactive delirium to a maximum of 14 days.
88963946|NCT02028260|Placebo Comparator|Placebo|normal saline
88963947|NCT02028273||Control|Healthy control group. No history of substance abuse or dependence.
88963948|NCT02028273||Actively using patients|Participants actively using cocaine.
88963949|NCT02028273||Abstinent Patients|Participants who have been abstinent from cocaine use for 3-6 months.
88963950|NCT02028286|Experimental|CLS001|CLS001
88963951|NCT02028299|Experimental|2D doppler echo with Definity solution|Study subjects will already be scheduled for right heart catheterization to diagnose pulmonary hypertension. Prior to the catheterization, each subject will have a 2D doppler echocardiogram with Definity solution as well.
89557466|NCT05911737||Patients diagnosed with Obstructive Sleep Apnea|Patients diagnosed with Obstructive Sleep Apnea
89557467|NCT05911737||Patients not diagnosed with Obstructive Sleep Apnea|Patients not diagnosed with Obstructive Sleep Apnea
88963952|NCT02028312|Active Comparator|Loteprednol etabonate + Restasis|Loteprednol Etabonate Ophthalmic Gel 0.5%, BID 30 days Restasis, BID 45 days
88963953|NCT02028312|Placebo Comparator|Artificial Tears + Restasis|Artificial Tears, BID 30 days Restasis, BID 45 days
88963954|NCT02028351||Normal|No Intervention
88963955|NCT02028351||Cataract|No intervention
88963956|NCT02028351||Maculopathy|No Intervention
88963957|NCT02028377|Experimental|Imaging|PET/MRI
89208321|NCT00788606|Experimental|bevacizumab and Rituximab|This study evaluates the feasibility using the anti-VEGF drug, bevacizumab, in combination with the standard treatment Rituximab in patients with stage II, III and IV diffuse large B cell lymphoma (DLBCL)
89208322|NCT00801164|Experimental|Frio Oral Rinse|Prescription Mouth Rinse. Rinse with 15ml twice daily then expectorate.
89208323|NCT00801164|Experimental|Placebo|Prescription Mouth Rinse. Rinse with 15ml twice daily then expectorate.
89208324|NCT00801320|Experimental|Cohort 1|Patients with either primary ovarian carcinoma or ovarian carcinoma in first relapse treated with DC/Ovarian tumor cells + GM-CSF
89026009|NCT03272087|Active Comparator|VATS (thoracoscopy)|According to BTS guideline thoracoscopy is the next procedure for patients who remain undiagnosed despite PET-CT and attempts to obtain biopsies. Eligible patients will be randomised to pleuroscopy or VATS. Patients with inconclusive pleuroscopy will proceed to VATS.
89026010|NCT02893306|Experimental|DMT1+MSCs|type 1 diabetic patients receiving a single dose of allogeneic ex vivo expanded mesenchymal stem cells
89026011|NCT02893540|Experimental|Metronomic|accept capecitabine metronomic chemotherapy (500mg, twice per day, everyday)
89026012|NCT02893540|Active Comparator|Conventional|accept capecitabine conventional chemotherapy (1000mg/m2, twice per day for 14 days, every 21 days)
89557468|NCT05911711||Sepsis patient in Medical ICU|"Eligibility Criteria:~adults over the age of 19 a sepsis patient in Medical ICU~Patients are excluded from the study :~If the patient or care giver does not agree to participate in the study a bone marrow transplant or an organ transplant patient a Do not resuscitation (DNR) patient"
89557469|NCT05911685|Experimental|Left atrial appendage occlusion|
89557470|NCT05911672|Experimental|Full Intervention|This group will receive the app (PRICE) which will collect their PROMs (pain, fatigue and stress) three times a day for 2 weeks. They will be prompted each time they have elevated levels of pain, fatigue and stress to use the VR glasses (EMI). This is the EMI provided: https://dl.acm.org/doi/abs/10.1145/3491101.3503562?casa_token=tC5fSN8-k5EAAAAA:56_TMf6HitVQXZypY2j9FCCcroIFZW9kxxzCEt0yJNFJmNrv79m9W7htznSzMWqGLwE4eimBU0vkLA
89557471|NCT05911672|Active Comparator|Partial Intervention|This group will receive the EMA app and the EMI but they will not be prompted to use the EMI according to their EMA data.
89557472|NCT05911672|No Intervention|Control|This group will receive the EMA but no the EMI.
89557473|NCT05911659||Non smokers- non diabetic patients|
89557474|NCT05911659||smokers non diabetic patients|
89026013|NCT01327573|Experimental|Eculizumab|"eculizumab will be given in addition to standard immunosuppression regimen (oral tacrolimus or equivalent, MMF [mycophenolate mofetil~], prednisone)"
89026014|NCT01327573|No Intervention|no additional therapy|patients in this arm will receive standard immunosuppression regimen (oral tacrolimus or equivalent, MMF, prednisone only, no additional therapy
89026015|NCT04328428|Experimental|(A)modified BL40 acupuncture|modified BL40 acupuncture Participants receive BL40 acupuncture once on the same site of low back pain.
89026016|NCT04328428|Active Comparator|(B)EM32 acupuncture|EM32 acupuncture Participants receive EM32 acupuncture once on the opposite site.
89026017|NCT04328428|Active Comparator|(C)BL40 acupuncture|BL40 acupuncture Participants receive BL40 acupuncture once on the same site of low back pain
89026018|NCT04390555||CV involvement|Patients with COVID-19 and preexisting cardiovascular diseases and/or cardiovascular risk factors (diabetes mellitus, arterial hypertension and/or dyslipidaemia).
89026019|NCT04390555||Control|Patients with COVID-19 without preexisting cardiac involvement.
89026020|NCT04389658||Asymptomatic population|Subjects who underwent PCR and ELISA tests for the diagnosis of COVID-19: mainly asymptomatic individuals from three main areas of Spain (Madrid, Barcelona and Valencia) with high impact of COVID-19 that have performed the PCR and ELISA test for the diagnosis of COVID-19 before initiating the work immediately after Spanish lockdown.
89026021|NCT02893384|Experimental|Local Anesthetic Injection|"The intervention involves injection of local anesthetic (0.25% bupivacaine with 1:200,000 epinephrine) under direct vision in the serratus anterior muscle plane at the end of surgery.~Local Anesthetic Injection above the serratus anterior"
89026022|NCT02893384|No Intervention|Control Arm|Retrospective control group who have not had the new injection technique.
89026023|NCT02893228|Experimental|Group S (saline group)|In plane posterior approach will be used with a 50mm short bevel block needle (Braun), advanced through the middle scalene muscle. At the location chosen for interscalene block the needle tip will be positioned anterior to the anterior scalene muscle. At this point 10ml of 0.9% saline will be injected. This will be followed by repositioning of the needle between roots C5 and C6 where 20 ml of 0.25% levobupivicaine will be injected in 5ml increments with intermittent aspiration.
89026024|NCT02893228|Active Comparator|Group C (control group)|In plane posterior approach will be used with a 50mm short bevel block needle (Braun), advanced through the middle scalene muscle. The needle tip will be positioned between roots C5 and C6 where 20 ml of 0.25% levobupivicaine will be injected in 5ml increments with intermittent aspiration.
89557475|NCT05911659||non smokers diabetic patients|
89557476|NCT05911659||smokers diabetic patients|
89608660|NCT05582577|Experimental|Simultaneous intravitreal bevacizumab injection with subthreshold micropulse laser|"After the eye examination, the eyes will be randomly divided into 2 groups {group A: intravitreal interjection of Bevacizumab and subthreshold micropulse laser, and group B: intravitreal injection of Bevacizumab alone}. For both groups, 3 intravitreal injections of bevacizumab with a dose of 1.25 mg will be performed, in sterile conditions at 1-month intervals as a loading dose.~A subthreshold micropulse laser will be performed after the third injection in group A. Then, the intravitreal injection of Bevacizumab will be continued if the central thickness of the macula is equal to or greater than 300 microns.~The follow-up will be performed 2, 3, 4, 6, 8, 10, and 12 months after the first injection. In each follow-up (except for the first month), ophthalmological examinations and Optical Coherence Tomography will be performed."
89026025|NCT00466973|Active Comparator|Dry bipolar radiofrequency (RF) clamp|used for ablation during surgical procedure
89026026|NCT00466973|Active Comparator|Unipolar microwave antenna|used for ablation during surgical procedure
89026027|NCT00466973|Active Comparator|Unipolar cryothermic probe|used for ablation during surgical procedure
89026028|NCT00466973|Active Comparator|Irrigated unipolar RF antenna|used for ablation during surgical procedure
89026029|NCT00466973|Active Comparator|Irrigated bipolar RF clamp|used for ablation during surgical procedure
89026030|NCT00466973|Active Comparator|Hi-intensity focused ultrasound wand|used for ablation during surgical procedure
89026031|NCT00498537|Other|1|
89026032|NCT00498537|Other|2|
89026033|NCT04386928||Elderly patients with hematological disease|older than 60 years who received hematopoietic stem cell transplantation (HSCT)
89026034|NCT03272204|Other|Natural Pubic Hair|Participant with natural hair crosses over to removed pubic hair
89026035|NCT03272204|Other|Removed Pubic Hair|Participant with no pubic hair crosses over to natural pubic hair
89026036|NCT00491517|Experimental|Sirolimus|
89557477|NCT05911646|Experimental|OSA-18 Case Group|"Case group participants will be given the OSA-18 survey at the start of their consultation. OSA-18 is an 18-item questionnaire that collects information about 5 subscales that are considered to be elements in quality of life: sleep disturbance, physical symptoms, emotional symptoms, daytime function, and caregiver concerns. The score is calculated that ranges from 18 (no impact on quality of life) to 126 (major negative impact).~Upon completion of OSA-18, scores are tabulated and relayed to families through a decisional aid. The score and the aid, which explains treatment options, risks and benefits will be used to guide discussion throughout the consultation.~After the consultation is complete and the provider leaves the room, families will be given a decisional conflict scale survey. All surveys will remain anonymous by using a unique study identifier. Forms will be placed in a locked box by parents prior to departure from the exam room."
88963958|NCT02028390|Experimental|subjects with external wounds|Subjects with external wounds or body surface areas of interest are imaged visually and thermally with the Scout to trace the wound's perimeter visually and measure thermal variation data as described in the primary outcomes, using the ImageReview software.
88963959|NCT02028403|Experimental|Cohort 1A: single dose 0.3 mg/kg BMS-936559|Participants will receive 0.3 mg/kg of BMS-936559, administered as a single infusion once at study entry.
88963960|NCT02028403|Placebo Comparator|Cohort 1B: single dose placebo for BMS-936559|Participants will receive placebo for BMS-936559, administered as a single infusion once at study entry.
88963961|NCT02028403|Experimental|Cohort 2A: single dose 1 mg/kg BMS-936559|Participants will receive 1 mg/kg of BMS-936559, administered as a single infusion once at study entry.
88963962|NCT02028403|Placebo Comparator|Cohort 2B: single dose placebo for BMS-936559|Participants will receive placebo for BMS-936559, administered as a single infusion once at study entry.
88963963|NCT02028403|Experimental|Cohort 3A: single dose 3 mg/kg BMS-936559|Participants will receive 3 mg/kg of BMS-936559, administered as a single infusion once at study entry.
88963964|NCT02028403|Placebo Comparator|Cohort 3B: single dose placebo for BMS-936559|Participants will receive placebo for BMS-936559, administered as a single infusion once at study entry.
88963965|NCT02028403|Experimental|Cohort 4A: single dose 10 mg/kg BMS-936559|Participants will receive 10 mg/kg of BMS-936559, administered as a single infusion once at study entry.
88963966|NCT02028403|Placebo Comparator|Cohort 4B: single dose placebo for BMS-936559|Participants will receive placebo for BMS-936559, administered as a single infusion once at study entry.
88963967|NCT02028416|Active Comparator|ATG-Fresenius 3 Days|In one group Injection ATG-Fresenius will be given @ 10mg/kg will be given for 3 days along with Capsule Cyclosporin 5mg/kg for 6 months followed by very slow tapering of dose
88963968|NCT02028416|Experimental|ATG-Fresenius 5 Days|In other arm injection ATG will be given @10mg/Kg for 5 days (different dose regimen, according to the randomization) with capsule Cyclosporin@5mg/Kg (same dose) for 6 months followed by very slow tapering. There is a difference of days of treatment received i-e 5 days.
88963969|NCT02028429|Experimental|Intervention 'Sildenafil'.|MHE patient receiving Sildenafil. Intervention: Sildenafil Drug Dosage: 25 mg once a day for one week followed by 25 mg twice daily for two weeks then 25 mg thrice daily for one week.
88963970|NCT02028429|No Intervention|'No sildenafil'|Control Arm: MHE patients not receiving SIldenafil Intervention.Followed up for 4 weeks.
88963971|NCT02028442|Experimental|Enadenotucirev|
88963972|NCT02028481|Experimental|Postoperative air tamponade|Pars plana vitrectomy, ILM peeling and air tamponade. No postoperative face down positioning. All patients need to be pseudophakic prior to intervention.
88963973|NCT02028494|Experimental|Arm A: Capecitabine 2,000 mg (flat dose)|Arm A: Capecitabine 2,000 mg (flat dose), orally, twice daily for 7 days followed by a 7 day rest (7-7) (4-week cycle length ).
88963974|NCT02028494|Active Comparator|Arm B: Capecitabine 1,000 mg/m2 twice daily for 14 day|Arm B: Capecitabine 1,000 mg/m2, orally, twice daily for 14 days followed by a 7 day rest (14-7) (3-week cycle length ). The control arm dose of capecitabine has been reduced from the US Food and Drug Administration approved dose of 1,250 mg/m2, orally, twice daily due to common clinical practice.
88963975|NCT02028507|Experimental|Palbociclib plus Exemestane or Fulvestrant|"Palbociclib 125 mg orally once daily on Day 1 to Day 21 followed by 7 days off treatment on every 28 days cycles in combination with~Cohort 1: Exemestane 25 mg orally once daily.~Cohort 2: Fulvestrant 500 mg on Days 1 and 15 of Cycle 1, and Day 1 of each subsequent 28 days Cycle."
88963976|NCT02028507|Active Comparator|Capecitabine|Capecitabine, 1,250 mg/m2 twice daily for 2 weeks followed by a 1 week rest period, given as 3 weeks cycles. Capecitabine must be administered at a dose of 1,000 mg/m2 twice daily for 2 weeks followed by a 1 week of rest period, given as 3 weeks cycles, in patients over 70 years of age.
88963977|NCT02028533|Active Comparator|Patients 1|Participants will receive intranasal oxytocin 40 International Units (IU).
88963978|NCT02028533|Placebo Comparator|Patients 2|Participants will receive 40 International Units of intranasal placebo.
89208325|NCT00801320|Experimental|Cohort 2|Patients with either primary ovarian carcinoma or ovarian carcinoma in first relapse treated with DC/Ovarian tumor cells + GM-CSF and topical Imiquimod at site of vaccination
88963979|NCT02028546|Experimental|Water|The patients in water group were soaking an arm for 10 minutes with tap water before application of moisturizer. (Excepted the 4th regimen included no bathing, waited for 10 minutes and followed by moisturizer application.)
89026037|NCT00491517|Active Comparator|conventional therapy|
89026038|NCT00467012|Experimental|step 1|6 enrollment for 1 cycle(4 weeks)
89026039|NCT00467012|Experimental|step 2|114 enrollment through to meet the stopping criteria
89026040|NCT00498576||1|kidney transplant with hypertension
89208326|NCT00795860|Active Comparator|Weight loss - diet only|
89208327|NCT00795860|Experimental|Weight loss plus exercise|
89208328|NCT00795938|Active Comparator|Conventional Oral Tablet With Water|
89208329|NCT00795938|Experimental|Experimental Tablet With Water|
89557478|NCT05911646|Active Comparator|Control Group|"During the consultation, families will be given a printed form, decisional aid, which is given to families to explain treatment options as well as their risks and benefits. The consultation will proceed as normal according to standard of care with the aid being used to guide conversation.~After the consultation is complete and the provider leaves the room, families will be given a decisional conflict scale survey to complete. All surveys will remain anonymous and only a unique study identification number will be placed on the surveys to correctly match each survey. Forms will be placed in a locked box by parents prior to departure from the exam room."
88812327|NCT05531942|Active Comparator|Ginkgo and aspirin|Ginkgo Diterpene Lactone Meglumine Injection 25mg/5ml,once/day from Day 1 to Day 14. The injection was diluted with 250ml physiological saline,intravenous drip for about 3 hours;combined with Acetylsalicylic acid (Aspirin) given at a dose of 100 mg per day for 90 days.
88812328|NCT05531942|Placebo Comparator|aspirin|Patients in the aspirin group received the same volume saline injection as placebo for 14 days plus aspirin at a dose of 100 mg per day for 90 days.
89026041|NCT00498576||2|hypertensive patients with native kidneys
89026042|NCT00498576||3|healthy controls
89026043|NCT03272867|Experimental|Intervention group|One group of volunteers will ingest a powder with dose of 6.1 g ProManna twice a day for a period of 2 weeks
89026044|NCT03272867|Placebo Comparator|Control group|Another group of volunteers will ingest a powder with the same amount of a placebo twice a day for a periode of 2 weeks
89557479|NCT05911633|Other|Single arm|Transarterial Chemo Embolization (TACE) with BioPearl™ microspheres loaded with Doxorubicin
89557480|NCT05911607|Active Comparator|Red Laser|Photobiomodulation using nm Diode.
89557481|NCT05911607|Active Comparator|Infrared Laser|Photobiomodulation using nm Diode.
89557482|NCT05911581|Active Comparator|room temperature washing solution|İntra-arterial flushing with heparinized fluid kept in room air
89557483|NCT05911581|Active Comparator|washing solution at patient temperature|Intra-arterial flushing with heparinized fluid at patient body temperature
89557484|NCT05911555||Non-Dry Eye Subjects|Subjects with no reported history of dry eye disease will be enrolled
89557485|NCT05911555||Dry Eye Disease|Subjects who have been diagnosed with dry eye disease in a previous trial will be enrolled.
89557486|NCT05911542||General Dental Practitioners|Participants are asked to complete a survey about pain management strategies.
89557487|NCT05911542||Specialist Paediatric Dentists|Participants are asked to complete a survey about pain management strategies.
89557488|NCT05911529|Experimental|Motivational Interviewing Group|Patients will receive four sessions of Motivational Interviewing within two weeks.
89557489|NCT05911529|Active Comparator|Control Group|Patients in the control group receive four sessions of supportive conversations within two weeks.
89557490|NCT05911503|Experimental|2% Ganciclovir Eye Drops therapy Group|Administration method and dosage adjustment: 2% ganciclovir eye drops, 10 times/day for two weeks, 8 times/day for two weeks, 6 times/day for two weeks, 4 times/day for more than 6 weeks
89557491|NCT05911490|Active Comparator|Prolonged sitting|Participants sat on a chair during the trial in the laboratory.
89557492|NCT05911490|Experimental|Breaking prolonged sitting|Participants walked regularly during the trial in the laboratory.
89026045|NCT01327495|Placebo Comparator|Arm 1: Placebo|Placebo acyline every 2 weeks for two weeks + daily placebo gel x 12 weeks
89026046|NCT01327495|Active Comparator|Arm 2:1.25g Testosterone|Acyline (300µg/kg every two weeks) + testosterone 1% gel 1.25 g daily x 12 weeks
89026047|NCT01327495|Active Comparator|Arm 3: 2.5g Testosterone|Acyline (300µg/kg every two weeks) + testosterone 1% gel 2.5 g daily x 12 weeks
89026048|NCT01327495|Active Comparator|Arm 4: 5g Testosterone|Acyline (300µg/kg every two weeks) + testosterone 1% gel 5.0 g daily x 12 weeks
89026049|NCT01327495|Active Comparator|Arm 5: 10g Testosterone|Acyline (300µg/kg every two weeks) + testosterone 1% gel 10 g daily x 12 weeks
89026050|NCT01327495|Active Comparator|Arm 6: 15g Testosterone|Acyline (300µg/kg every two weeks) + testosterone 1% gel 15 g daily x 12 weeks
89026051|NCT00491634|Experimental|1|treosulfan
89026052|NCT04328155|Experimental|Hotpack Group|Group I (15 subjects) received 18 sessions hotpack to hamstring muscles and self stretching exercise3 times per week.
89026053|NCT04328155|Experimental|Infrared Group|Group II (15 subjects) received 18 sessions infrared to hamstring muscles and self stretching exercise3 times per week.
89026054|NCT04328155|Experimental|Ultrasound Group|Group III (15 subjects) received 18 sessions ultrasound to hamstring muscles and self stretching exercise 3 times per week.
89026055|NCT04328155|Active Comparator|Control|Group IV (15 subjects) received 18 sessions self stretching exercise 3 times per week.
89026056|NCT01327339||Subjects eligible for REQUIP prescription|Male and female subjects who were considered appropriate to be prescribed REQUIP according to the prescribing information will be included in this study.
89026057|NCT01243515||Chronic Kidney Disease|minimum 7 subjects (male and female)
89026058|NCT01243515||Healthy subjects|minimum 3 subjects (male and female)
89557493|NCT05911477|Experimental|rhBMP-2 group|
89557494|NCT05911477|No Intervention|No rhBMP-2 group|
89557495|NCT05911464|Experimental|HS-10386|Participants will receive HS-10386 once daily. The duration of each treatment cycle is 21 days.
89557496|NCT05911438|Experimental|Experimental group|
89557497|NCT05911438|Placebo Comparator|Control group|
89557498|NCT05911425|Other|Prospective Research|Envolizumab 300mg, Q2W, day 1, subcutaneous injection Soventinib 200mg, Q2W, once daily, orally Every 2 weeks as a cycle.
89557499|NCT05911412|Experimental|NMBCT intervention|Participants in this arm enter the 8-week NMBCT course immediately after the baseline visit.
89557500|NCT05911412|Experimental|Waitlist|Participants in the waitlist control arm will wait for 8 weeks after the baseline visit, and then will be offered an identical 8-week NMBCT course.
89557501|NCT05911386||MYOCARDITIS|No intervention Study of available clinical, biological, and echocardiographic data
89557502|NCT05911386||KAWASAKI|No intervention Study of available clinical, biological, and echocardiographic data
89557503|NCT05911386||PIMS|No intervention Study of available clinical, biological, and echocardiographic data
89557504|NCT05911373|Placebo Comparator|group serratus|preoperative superficial serratus block with local anaesthetics and parasternal block with saline
89208330|NCT00795938|Experimental|Experimental Tablet Without Water|
89557505|NCT05911373|Active Comparator|group serratus and parasternal|preoperative superficial serratus block and parasternal block with local anaesthetics
89557506|NCT05911347|Active Comparator|Psyllium|Psyllium 15 g+ inulin 15 gm in 375ml water
89557507|NCT05911347|Placebo Comparator|maltodextrin|Maltodextrin 15 g + inulin 15 gm in 375 ml water
89557508|NCT05911347|Experimental|Methylcellulose|Methylcellulose 15g + Inulin 15 g in 375 ml water
89557509|NCT05911282|Experimental|NAC|NAC group was given 1.2 g of N-acetylcysteine before and 1.2 g after drinking alcohol
89557510|NCT05911282|Placebo Comparator|PLACEBO|Placebo group was given lemon juice before and after drinking alcohol
88963980|NCT02028546|Experimental|mild cleanser|The patients in mild cleanser group were soaking an arm for 10 minutes with mild cleanser before application of moisturizer. (Excepted the 4th regimen included no bathing, waited for 10 minutes and followed by moisturizer application.) Non soap base cleanser contained Sodium Cocoyl Isethionate was used in this mild cleanser arm.
88963981|NCT02028572||Primary open angle glaucoma|Subjects diagnosed to have primary open angle glaucoma with intraocular pressure > 21 mm Hg and characteristic glaucomatous damage to the optic nerve.
88963982|NCT02028585|Active Comparator|Low-fat milk group|The low-fat milk group was instructed to consume 2 packs of low-fat milk per day (200 mL twice daily) for 6 weeks.
88963983|NCT02028585|No Intervention|Control group|Control group maintained their usual diet without low-fat milk supplement.
88963984|NCT02028598|Experimental|Sequence A|Treatment 1 - Treatment 2 - Treatment 3
88963985|NCT02028598|Experimental|Sequence B|Treatment 1 - Treatment 3 - Treatment 2
88963986|NCT02028598|Experimental|Sequence C|Treatment 2 - Treatment 1 - Treatment 3
88963987|NCT02028598|Experimental|Sequence D|Treatment 2 - Treatment 3 - Treatment 1
88963988|NCT02028598|Experimental|Sequence E|Treatment 3 - Treatment 1 - Treatment 2
89208331|NCT00260065|Experimental|1|
89557511|NCT05911230|Other|ADW-MRI imaging|Patients with a histopathologically proven glioblastoma or brain metastasis who have suspected tumor progression on standard MRI after standard first line therapy and who are candidates for surgical resection and undergoing the ADW-MRI preoperatively.
89557512|NCT05911139||pediatric patients|Patients indicated for surgical treatment of single-layer craniosynostosis will be selected for the study, anticipated 15 patients per calendar year
89557513|NCT05911100||Main|Patients 18 years of age and older who have undergone COVID-19 and who are scheduled for the second stage of rehabilitation at the Federal Research Center for Fundamental and Translational Medicine
88963989|NCT02028598|Experimental|Sequence F|Treatment 3 - Treatment 2 - Treatment 1
88963990|NCT02028624|Experimental|Face-to-face|Patients received face-to-face nutrition counseling.
88963991|NCT02028624|Experimental|Telephone|Patients received telephone nutrition counseling.
88963992|NCT02028624|No Intervention|Minimum Intervention|Patients in this group received no further lifestyle-related counseling and contact until the 6-month evaluation.
88963993|NCT02028637|Experimental|toll like receptor (TLRs)|TLRs are a family of proteins responsible for the recognition of Pathogen-Associated Molecular Patters
88963994|NCT02028650||the first donor|the original donor applicable patients were assigned to receive the first donor's stem cell treatment after G-CSF mobilization or combination chemotherapy
88963995|NCT02028650||the second donor|HLA-mismatched, the second donor's stem cell infusion
88963996|NCT02028663|Experimental|CJ-12420 Amg|50 volunteers will be administered CJ-12420 Amg
88963997|NCT02028663|Experimental|CJ-12420 Bmg|50 volunteers will be administered CJ-12420 Bmg
88963998|NCT02028663|Experimental|CJ-12420 Cmg|50 volunteers will be administered CJ-12420 Cmg
88963999|NCT02028663|Active Comparator|Esomeprazole 40mg|50 volunteers will be administered Esomeprazole 40mg
88964000|NCT02028689|Experimental|Lesinurad and Metformin|"Sequence A- Day 1: Metformin 850 mg; Day 5: Lesinurad 400 mg with metformin 850 mg~Sequence B- Day 1: Lesinurad 400 mg with metformin 850 mg; Day 5: Metformin 850 mg"
88964001|NCT02028689|Experimental|Lesinurad and Furosemide|"Sequence C - Day 1: Furosemide 40 mg; Day 5: Lesinurad 400 mg with furosemide 40 mg~Sequence D - Day 1: Lesinurad 400 mg with furosemide 40 mg; Day 5: Furosemide 40 mg"
89208332|NCT00796094||Evaluation of tissue elasticity|Evaluate the potential importance of tissue elasticity in the assessment soft tissue structures.
89557514|NCT05911022|Active Comparator|Group A (Colchicine group)|consisted of COVID-19 participants with mild to moderate disease who received the recommended course of care in accordance with the protocol established by the Egyptian Supreme Council of University Hospitals, as well as Colchicine tablets (0.5 mg) three times per day for three days and subsequently twice per day for four days
88964002|NCT02028702|Active Comparator|Red Clover extract|150 ml/d Red Clover extract
88964003|NCT02028702|Placebo Comparator|Placebo|150 ml/d sweetened and coloured water
89557515|NCT05911022|Active Comparator|Group B (Probiotic group)|consisted of COVID-19 participants with mild and moderate COVID-19 severity got probiotics in the form of oral sachets once daily for two weeks in addition to protocol prescribed by the Egyptian Supreme Council of University Hospitals.
89557516|NCT05911022|Placebo Comparator|Group C (Control group)|consisted of COVID-19 participants with mild and moderate severity who received the recommended course of care in accordance with the protocol established by the Egyptian Supreme Council of University Hospitals (Vitamin C 500 mg twice daily, Vitamin D3 2000-4000 IU/day, Zinc 75 mg once daily for two weeks, and necessary protocol of management based on case assessment and severity).
88964004|NCT02028728||Orsiro|
88964005|NCT02028741|Experimental|symptomatic intervention group|Paitients with mechanical neck pain were treated with transverse vertebral pressures
88964006|NCT02028741|Sham Comparator|aymptomatic non-intervention group|Sham treatment to aymptomatic subjects
88964007|NCT02028793||Pharmacists provide pharmaceutical care|The group is the community pharmacists who attend the protocol to provide home visit to the patients with heavy health expenditure, through pharmaceutical care approach.
88964008|NCT02028832|Active Comparator|Usual care|Usual care provided to pediatric inpatients
88964009|NCT02028832|Experimental|PIM consult and service provision|Pediatric integrative medicine service (PIM) through which pediatric inpatients will have the option of supplementing their usual care with acupuncture/acupressure, massage, and/or reiki
88964010|NCT02028845|Active Comparator|Loop guidewire|This study has two arms. We will compare the performance of a loop-tipped guidewire with a straight-tipped guidewire in achieving successful deep biliary cannulation with loop guidewire.
88964011|NCT02028845|Active Comparator|Straight guidewire|This study has two arms. We will compare the performance of a loop-tipped guidewire with a straight-tipped guidewire in achieving successful deep biliary cannulation with straight guidewire.
88964012|NCT02028897|Active Comparator|Conventional embryo culture|Conventional embryo culture in dishes, in droplets under oil.
88964013|NCT02028897|Experimental|Alternative embryo culture|Embryo culture in system using small enclosed containers
88964014|NCT02028910|Experimental|Ondansetron|"The treatments in the form of cases numbered 1 vial of 50 ml of ondansetron 0.8 mg / ml oral solution + 5 ml syringe for oral administration.~No special storage conditions ondansetron syrup.The treatment is administered orally as a single dose of 2.5 ml = 2 mg per 5 kg weight of the child, not to exceed a maximum dose of 10mg. A second outlet, at the same dose, is restored if the child vomits within 15 minutes after the first administration."
88964015|NCT02028910|Placebo Comparator|placebo|"The treatments in the form of cases numbered 1 vial of 50 ml of placebo 0.8 mg / ml oral solution + 5 ml syringe for oral administration.~No special storage conditions placebo syrup.The treatment is administered orally as a single dose of 2.5 ml = 2 mg per 5 kg weight of the child, not to exceed a maximum dose of 10mg. A second outlet, at the same dose, is restored if the child vomits within 15 minutes after the first administration."
88964016|NCT02028923|Experimental|Morphine gel|morphine 30 mg, quantity of gel per application: 15mg (15ml)
88964017|NCT02028923|Placebo Comparator|Neutral gel|water for injection, quantity of gel per application: 15mg (15ml)
89557517|NCT05910931||Patients undergoing ICG angiography|All women operated on in the breast unit who require a reduction mammoplasty, a skin-sparing mastectomy (or skin and nipple) with immediate reconstruction and local flaps for remodeling or implant coverage.
89557518|NCT05910918|Experimental|Intensive Care Nurses' Training Package|For the study group, the researcher will explain the method of the training package program application to critical care nurses as follows; firstly, the researchers will assess the nurses' roster, then the researchers will classify the subjects into groups in order to conduct the training package for a group of them while the other subjects taking care of the patients in the intensive care units and repeat the same session to the others in the same manner.
89557519|NCT05910918|Active Comparator|comparison group|for the comparison group receive the general intensive care rules manual for routine care.
89557520|NCT05910905|Experimental|Prefabricated pediatric zirconia crown group|Zirconia crowns (ZK; EZ Crowns, Spring Oral Health Technologies, Inc:, Loomis, Calif., USA).
89557521|NCT05910905|Active Comparator|Prefabricated stainless steel crown group|Stainless Steel Crown (SSC, Kids Crown, Shinghung, Seoul, Korea)
89557522|NCT05910892|Active Comparator|Aromatherapy before treatment|Subject receives aromatherapy before IMS treatment or trigger point injection
89557523|NCT05910892|Placebo Comparator|Placebo before treatment|Subject receives placebo before IMS treatment or trigger point injection
89557524|NCT05910710||Subjects administered Neoadjuvant Pembrolizumab|Neoadjuvant Weekly paclitaxel, Carboplatin followed by Doxorubicin, Cyclophosphamide add Pembrolizumab
88964018|NCT02028936|Experimental|Grape juice rich in polyphenols|
88964019|NCT02028936|Active Comparator|grape juice not enriched with polyphenols|
88964020|NCT02028949|Experimental|Chemo-lipiodol|
88964021|NCT02028962|Experimental|Lifestyle counseling|The experimental group will receive three letters with advices for smoking cessation-the first letter after the enrolment in the study, the second one one month after the first letter, the third one three months after the first letter
89208333|NCT01072435|Active Comparator|patient-controlled sedation|PCS
89208334|NCT01072435|Active Comparator|target-controlled infusion|TCI
89208335|NCT01072513|Other|Semen analysis|Analysis of semen before and after proton radiation therapy.
89208336|NCT00796172|Experimental|1|Medication adherence system (MAS) plus counseling from doctors
89208337|NCT00796172|Active Comparator|2|Usual care
89557525|NCT05910710||Subjects not administered Neoadjuvant Pembrolizumab|Neoadjuvant Weekly paclitaxel, Carboplatin followed by Doxorubicin, Cyclophosphamide
89557526|NCT05910684|No Intervention|Control Group|These participants will complete their online simulations and treat their real-life patients without access to the Aegis test.
89557527|NCT05910684|Experimental|Educational Materials and Test Access|These participants will complete their online simulations and treat their real-life patients with access to educational materials and the Aegis test results. Investigators will compare intervention participants' clinical recommendations to those in the control arm.
89557528|NCT05910138|Active Comparator|case|
88964022|NCT02028962|No Intervention|Control|
89208338|NCT01071655|Experimental|2|"Patients with zero favorable genotype: BVZ + XELIRI.~Patients with one favorable genotype: TS 3'UTR +6bp/+6bp and ERCC1-118 T/T: BVZ + XELOX or TS 3'UTR +6bp/-6bp and ERCC1-118 C/T ó C/C: BVZ + FUIRI.~Patients with two favorable genotypes : BVZ + FUOX."
89208339|NCT01071655|Active Comparator|1|BVZ + XELOX
89557529|NCT05910138|Active Comparator|control|
89557530|NCT05910021||Women with ODS and POP|This pilot study established and standardized an interdisciplinary surgical approach of laparoscopic resection rectopexy (L-RRP) combined with a laparoscopic mesh sacrocolpopexy (L-SCP) used synonymously for sacrohysteropey and sacrocervicopexy, as well. Additionally, an absorbable biological mesh (
89557531|NCT05909306|Experimental|Education Group|The education group was applied partograph education in addition to formal education by using the partograph e-learning tool that was developed.
89557532|NCT05909306|No Intervention|Control Group|The control group continued their formal education.
89557533|NCT05909241|Experimental|BA1202|BA1202 is a bispecific antibody targeting CEA and CD3.
89557534|NCT05909098|Experimental|NK cell|autologous NK cell adjuvant therapy
89557535|NCT05908825|Other|20 day application of study product A and B|Subjects will be given study drug and instructed to topically apply to the treatment area, Study Product A or Study Product B, placebo serum or novel exfoliative serum, to the respectively randomized half of the face, once daily for 20 consecutive days.
89557536|NCT05908825|Other|42 day application of study product A and B|Subjects who the investigator decides to continue treatment at Day 21, will be given study drug and instructed to topically apply to the treatment area, Study Product A or Study Product B, placebo serum or novel exfoliative serum, to the respectively randomized half of the face, once daily for an additional 21 consecutive days.
89557537|NCT05908578|Active Comparator|High-Frequency Training|Exercise performed on a stationary bike four times per week. Total weekly exercise volume (the product of intensity, duration, and frequency) will be matched between groups. Intensity will be the same, so the high-frequency group will perform half the duration of exercise in each session compared to the low-frequency group.
89557538|NCT05908578|Experimental|Low-Frequency Training|Exercise performed on a stationary bike two times per week. Total weekly exercise volume (the product of intensity, duration, and frequency) will be matched between groups. Intensity will be the same, so the low-frequency group will perform double the duration of exercise in each session compared to the high-frequency group.
89557539|NCT05908136|Active Comparator|GROUP A|• Group A: 12 primary molars received stainless steel crowns (SSCs).
89557540|NCT05908136|Active Comparator|group b|• Group B: 12 primary molars received resin composite strip crowns (RCSCs).
89557541|NCT05908136|Active Comparator|group c|• Group C: 12 primary molars received zirconium-filled composite strip crowns (ZFSCs).
89557542|NCT05908123|Experimental|Blank Center CARE Model (Communication, Advocacy, Resilience, Education)|
89557543|NCT05908071|Experimental|SHEN26|Participants will receive SHEN26 400mg twice daily for 5 days.
89557544|NCT05908071|Placebo Comparator|SHEN26 placebo|Participants will receive SHEN26 placebo twice daily for 5 days.
89557545|NCT05907785|Experimental|Prepubertal group: Educational intervention|An educational intervention to improve physical activity and promote healthy dietary habits will be carried out in prepubertal (8-10 years) volunteers with normal weight (NW), overweight (OW), and obesity (OB).
89557546|NCT05907785|Experimental|Postpubertal group: Educational intervention|An educational intervention to improve physical activity and promote healthy dietary habits will be carried out in postpubertal (13-15 years) volunteers with normal weight (NW), overweight (OW), and obesity (OB).
89557547|NCT05907655||Adult patients with migraine|Diagnosis of migraine, by the ICHD-3 criteria. Age between 18 and 60 years. Female and males. Right-handed
89557548|NCT05907655||Healthy controls|Age between 18 and 60 years. Female and males. Right-handed
89557549|NCT05907512|Experimental|Drug group|
89557550|NCT05907460|No Intervention|Control group|Perform standard advanced life support. No examination of transesophageal echocardiography during cardiopulmonary resuscitation.
89557551|NCT05907460|Experimental|Intervention group|Perform examination of transesophageal echocardiography during cardiopulmonary resuscitation and adjust the chest compression site to avoid left ventricular outflow tract according to the result of transesophageal echocardiography
89557552|NCT05907421||NSSI|
89557553|NCT05907421||HC|
89557554|NCT05907356|Experimental|Study Group One|sciatic nerve slider technique in a supine lying position in combination with Conventional physiotherapy
89557555|NCT05907356|Experimental|Study Group Two|sciatic nerve slider technique in a slump position in combination with Conventional physiotherapy
89557556|NCT05907356|Experimental|Control Group|Conventional physiotherapy alone
89557557|NCT05907200|Experimental|Treatment Group|It received rehabilitation treatment consisting of a combination of manual therapy (McMennel joint manipulation, pumping and connective tissue massage) and US water immersion.
88964023|NCT02028975|Other|Patients with type 2 diabetes|
88964024|NCT02028975|Other|Obese patients without diabetes|
88964025|NCT02028975|Other|Healthy volunteers|
88964026|NCT02029014|Experimental|LAmbre closure system|
88964027|NCT02029027|Experimental|GYNEFFIK(R)|30 min-session of vaginal electro-stimulation by GYNEFFIK thrice a week for 6 months (except during menstrual periods)
88964028|NCT02029027|Other|Usual Care|Any treatment / physiotherapy sessions / muscular training ... usually recommended and/or prescribed by the patient's general practitioner or gynaecologist with the exception of vaginal electro-stimulation
89208340|NCT02531581|Experimental|Furosémide|"Furosemide: a dose of 40 mg IV bolus initially and live according to the diuretic response: possibility of 2nd Live IV bolus 40 mg if urine output <500 cc / 24 at the 4th hour.~Establishment of an infusion G5 500cc% in vein custody."
89208341|NCT02531581|Active Comparator|NaCl 9% isotonic|"Infusion of 500 cc of isotonic NaCl 9% in 4 hours and 1000 cc 24-hour peripheral vein. The filling is being used in an empirical in severe EP and this group is therefore the control group."
89208342|NCT00801554||ASD|Children and adults with Autism Spectrum Disorders.
89208343|NCT00801554||Non-ASD|Healthy volunteers who have never been diagnosed with an Autism Spectrum Disorder in their lifetime.
89557558|NCT05907200|Placebo Comparator|Control Group|It received rehabilitation treatment consisting of manual therapy alone
89557559|NCT05906446|Experimental|Intervention|Regular exercise sessions incorporating balance, resistance training, and walking to accommodate diminished endurance, with synergistic protein and nutritional supplementation
89557560|NCT05906056|Experimental|Continuous passive motion (CPM)|"10 ICU patients receiving CPM at HO joints that continuously stretches slowly the joint passively at a constant velocity in a painless range and for a substantial amount of time until there is evidence both laboratory (bone alkaline phosphatase) and radiographically (CT), that osteogenesis has entered a quiescent state. Conventional PT will also be performed.~Plus a single dose of zoledronic acid (Aclasta) once the diagnosis of HO is made."
89557561|NCT05906056|Active Comparator|Physiotherapy (PT)|10 ICU patients receiving the conventional PT, plus a single dose of zoledronic acid (Aclasta) once the diagnosis of HO is made.
89557562|NCT05906043|No Intervention|Cross Sectional Study to define the extent and severity of fatigue|All patients attending the IBD service that meet inclusion criteria will be given the opportunity to participate in this study. Information will be collected at baseline including demographic data, IBD history and symptoms, co-morbidities and disease activity. Patients will have baseline blood tests taken to assess for causes of fatigue as well as faecal calprotectin to assess for evidence of inflammation. Patients without fatigue will at this point exit the study and will not require any further follow up.
89557563|NCT05906043|No Intervention|Treatment for active disease and its effect on fatigue.|A longitudinal study of contemporary treatment for active disease and its effect on fatigue. Patients with active disease and fatigue will be followed prospectively while undergoing treatment for active IBD with the IBD team. If their fatigue resolves, they will exit the study at this point. If their fatigue persists, they will be further assessed as detailed below.
88812329|NCT05525533|Experimental|No feedback|AGYW customer feedback will be collected but not shared with shopkeepers
88812330|NCT05525533|Experimental|Private feedback|Biweekly summarized reports of AGYW customer feedback will be given directly to shopkeepers
88812331|NCT05525533|Experimental|Public feedback|Shopkeepers will get biweekly summarized reports of AGYW customer feedback, gold stars reflecting the level of AGYW customer feedback (e.g., 1-5 star rating) will be placed in the shop in a visible location, and shopkeepers will be invited to an awards ceremony every 6 months to recognize shopkeepers who receive high levels of positive AGYW customer feedback
88812332|NCT05503693|Experimental|AP303|AP303
88812333|NCT05503693|Placebo Comparator|Placebo|Placebo
88812334|NCT05502016|Experimental|Intervention|Family model diabetes self-management education and support
88812335|NCT05502016|Active Comparator|Wait-list Control|Family model diabetes self-management education and support
88812336|NCT05493826||Group 1|Patients treated with cemiplimab for laCSCC or mCSCC who were not suitable for curative surgery or curative radiation
88812337|NCT05479916|Experimental|Low glycated milk protein|40 grams of low glycated milk protein, blocked lysine level ~5%
88812338|NCT05479916|Experimental|High glycated milk protein|40 grams of high glycated milk protein, blocked lysine level ~50%
88812339|NCT05453526||Race - American Indian or Alaska Native|Being identified as American Indian or Alaska Native
88812340|NCT05453526||Race - Asian|Being identified as Asian
88812341|NCT05453526||Race - Black or African-American|Being identified as Black or African-American
88812342|NCT05453526||Race - Native Hawaiian or Other Pacific Islander|Being identified as Native Hawaiian or Other Pacific Islander
88812343|NCT05453526||Race - White|Being identified as White
88812344|NCT05453526||Ethnicity - Spanish/Hispanic/Latino|Being identified as Spanish/Hispanic/Latino
88812345|NCT05451940|Experimental|Erythropoietin|Subjects on a stable dose of hydroxyurea will be treated with increasing doses of subcutaneous erythropoietin (EPO) as tolerated for an initial 12 weeks, during which the main safety and efficacy endpoints (including the primary endpoint of hemoglobin response) will be assessed. Subjects may continue on treatment for an additional 12 weeks as clinically indicated, with assessment of additional endpoints at the end of the 24-week study period.
88812346|NCT05451914|Experimental|My Diabetes Care|Patients have access to an existing patient web portal (i.e., Epic's MyChart) embedded with My Diabetes Care.
88812347|NCT05451914|No Intervention|Usual Care|Patients will have access to an existing patient web portal (i.e., Epic's MyChart) NOT embedded with My Diabetes Care (i.e., usual care)
88812348|NCT05448560|Experimental|Multi-level Intervention of shared model of survivorship care|"Patient survivorship education via telehealth with the cancer center~Ongoing patient-tailored education program by MyChart within the EHR patient portal~Structured interactive phone communication between the research RN at the cancer center and community PCP clinic~In-person visit with the PCP clinic for survivorship care."
88812349|NCT05448560|Active Comparator|"Gold standard cancer center-based survivorship clinic"|In-person visit at specialty survivorship clinic
88812350|NCT05447559|Placebo Comparator|Intraoperative only Surgical Antimicrobial Prophylaxis Arm|Placebo administered every 8-hours following the preoperative dose (time=0) for a total of five postoperative doses
89557564|NCT05906043|No Intervention|The effect of treating anaemia on fatigue in IBD|A longitudinal study assessing anaemia and the effect of treatment on fatigue in those subjects with inactive IBD.Patients with anaemia and fatigue will be followed prospectively while undergoing treatment for anaemia with the IBD team. The study outcomes will be assessed at recruitment and when their anaemia has resolved (this may occur in parallel with the disease activity arm). If their fatigue resolves, they will exit the study at this point. If their fatigue persists, they will be further assessed as detailed below.
89557565|NCT05906043|Other|Assessing exercise therapies in IBD subjects with fatigue|A longitudinal study assessing of dietary and exercise therapies for IBD subjects with fatigue using a single case study (SCS) design. They will have their physical activity levels assessed at recruitment and as needed after active disease/anaemia/nutritional deficiencies have been adequately treated. Those with fatigue despite optimisation will be offered a physical activity intervention. Each participant will be assessed initially and subsequently assigned a physical activity intervention with a physical therapist.
88964029|NCT02029053|Other|Single Arm Study|Vaginal Lubrication Ring for Vaginal Dryness
89557566|NCT05906043|Other|Acceptance and commitment therapy (ACT) in IBD subjects with fatigue|A longitudinal study of acceptance and commitment therapy (ACT) in IBD subjects with psychological disability and fatigue using a single case study (SCS) design. All patients will undergo psychological assessment as detailed above at recruitment and as needed after active disease/anaemia/nutritional deficiencies have been adequately treated. Those with fatigue and psychological disability will be referred to the IBD psychology service or recruited to a psychological intervention. Participants will receive an online intervention with a psychologist from the School of Psychology in University College Dublin to address psychological disability and associated fatigue.
89557567|NCT05906043|Other|ACT for IBD subjects with sleep disturbance and fatigue|A longitudinal study of ACT for IBD subjects with sleep disturbance using a single case study (SCS) design. Patients will have their sleep quality assessed at recruitment and as needed after active disease/anaemia/nutritional deficiencies have been adequately treated. Those with sleep disturbance will undergo sleep studies at home both at the start and end of the intervention. This device will be a non-invasive, widely available sleep device worn on the wrist or the patient's index finger for one to three consecutive nights. They will be referred to the sleep medicine unit in SVUH if sleep apnea or another diagnosis that requires medical intervention is identified. Otherwise they will undergo an online intervention with a psychologist from the School of Psychology in University College Dublin to address their sleep quality.
88964030|NCT02029066|Experimental|SR-T100 gel|dosage form: topical gel dosage: 2g of 2.3% SR-T100 frequency: once duration: 24 hours
88964031|NCT02029079|Experimental|E+ drink, enriched with energy and nutrients.|The intervention consists of 300 ml E+ per day for 35 days in addition to a normal food intake. This means 525 kcal, and 22.5 gram protein extra per day for five weeks.
88964032|NCT02029079|No Intervention|Control|Subjects in the control group will be assessed in the same way and same time as the intervention group.
88964033|NCT02029092||Orsiro|
88964034|NCT02029105||Mesothelin, hyaluronan, osteopontin, syndecan|The patients with pleural diseases
88964035|NCT02029118|Experimental|Herbal application on acupoint group|Containing the herbal medicine application on the specific acupoints plus foundation treatment
88964036|NCT02029118|Placebo Comparator|Placebo application on acupoint|Not containing herbal medicine application on the specific acupoints plus foundation treatment
88964037|NCT02029118|Placebo Comparator|Herbal application on non-acupoint group|Containing the herbal medicine application on the non-acupoints plus foundation treatment
88964038|NCT02029118|Sham Comparator|Placebo application on non-acupoint|Not containing herbal medicine application on the non-acupoints plus foundation treatment
88964039|NCT02029131|Experimental|Exercise|
88964040|NCT02029131|No Intervention|Controls|
89208344|NCT04046510|Active Comparator|High doses|the patients of this group recieved conventionnal doses of ocytocin after foetal extraction in C section: 5IU in bolus followed by 15IU in continuous infusion
88964041|NCT02029157|Experimental|ARQ 197|Daily oral dose
88964042|NCT02029157|Placebo Comparator|Placebo|Daily oral dose
88964043|NCT02029170|Experimental|Early weightbearing|After operative reduction and fixation of the fractures, patients allocated to the early weightbearing group start weightbearing after stitch out at 2 weeks and the application of a walking cast.
88964044|NCT02029170|Active Comparator|Non-weightbearing|Patients allocated to non-weightbearing group are kept non-weightbearing till 6 weeks post-operative
88964045|NCT02029183|Experimental|bi-level positive airway pressure|bi-level positive airway pressure for 6 hour per night，total 7 days
88964046|NCT02029209|Experimental|Anlotinib|Anlotinib QD orally and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
88964047|NCT02029209|Placebo Comparator|Placebo Capsule|Placebo capsule QD orally and it should be continued until disease progression or patients withdrawal of consent
89557568|NCT05906043|Other|A longitudinal study of probiotics for IBD subjects with fatigue|Participants will have their stool analysed to assess the diversity of their microbiome. They will receive a twelve-week course of a probiotic which will be taken once daily. They will then have their stool re-assessed at the completion of the intervention.
89557569|NCT05905770||Sickle cell disease patients aged 16 years and older with an available matched sibling donor.|Alemtuzumab 1mg/kg/TBI 3Gy conditioning
89557570|NCT05905627||breathing exercise group|breathing exercise group
89557571|NCT05905627||relaxation exercise group|relaxation exercise group
89557572|NCT05905627||control group|control group
89557573|NCT05905510|Active Comparator|Control Group|Patients will receive spinal anesthesia alone (30 ml bupivacaine 0. 25%).
89208345|NCT04046510|Experimental|Intermediate doses|the patients of this group recieved after foetal extraction in C section: 2IU in bolus followed by 10IU in continuous infusion
89208346|NCT04046510|Experimental|Low doses|the patients of this group recieved after foetal extraction in C section: 2IU in bolus followed by 5 IU in continuous infusion
88812351|NCT05447559|Other|Intraoperative and 24-hours Postoperative Surgical Antimicrobial Prophylaxis Arm|Cefazolin (2g) administered 8-hourly following the preoperative dose (time=0) for two doses then placebo 8-hourly for three doses (total of 5 postoperative doses of cefazolin/placebo)
88812352|NCT05447559|Active Comparator|Intraoperative and 48-hours Postoperative Surgical Antimicrobial Prophylaxis Arm|Cefazolin (2g) administered every 8-hours following the preoperative dose (time=0) for a total of five postoperative doses
88812353|NCT05444595|Experimental|Behavioral and Plant-based Dietary Intervention|In this arm, participants will receive the behavioral plant-based intervention from community health workers.
88812354|NCT05444595|Active Comparator|Standard Care|In this arm, participants will receive the standard care intervention from community health workers.
88812355|NCT05444309|Active Comparator|Quadratus lumborum block group|"The child will be positioned in the lateral position, with the operative side non-dependent. Under complete aseptic precautions, QL block will be given by anterior approach at the level of L4. A linear high-frequency probe of Sonosite M Turbo ultrasonography will be applied vertically above the iliac crest, and a 22G, 80 mm spinal needle will be inserted in the plane from the posterior edge of the probe through the QL muscle in an anteromedial direction. The needle tip will be placed between the Psoas major (PM) muscle and the QL muscle.~After negative aspiration, injection of 0.5 mL of normal saline to the space between PM and QL muscles .~An injection of 0.5 mg/kg of 0.25% bupivacaine into the fascial plane and the local anesthetic appears to press down the PM muscle in the ultrasound image, the patients will be repositioned to a supine position immediately after the block."
88812356|NCT05444309|Active Comparator|Pericapsular Nerve Group (PENG) block group|"PENG block will be done while the child in supine position. Then, a high-frequency (8-15 MHz) ultrasound linear probe of Sonosite M Turbo ultrasonography (FUJIFILM Sonosite, Inc., Bothell, WA, USA) will be placed over the anterosuperior iliac spine and then rotating it 45 degrees to acquire images from lateral to medial of the anterior inferior iliac spine, iliopubic eminence, psoas tendon, and the femoral artery.~Then, a 22G, 80 mm spinal needle will be inserted from lateral to medial in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly.~After negative aspiration and a test does (0.5 mL of normal saline), an injection of 0.5 mg/kg of 0.25% bupivacaine into the space between the psoas tendon and the iliopubic eminence."
88812357|NCT05444309|No Intervention|control group|The child will not receive any block.
88812358|NCT05441852||Ambulatory Emergency Department Patients at risk for hyperkalemia|Patients who are at elevated risk for hyperkalemia identified during a visit to the emergency department. Elevated risk individuals are defined in this study as: >50 years of age, eGFR <45, or prior K >5.2
88812359|NCT05431608|Experimental|Dose Level -1B|MCARH125 dose 50 million total CAR+ cells MCARH109 dose 50 million total CAR+ cells
88812360|NCT05431608|Experimental|Dose Level -1A|MCARH125 dose 50 million CAR+ cells MCARH109 dose 0 total CAR+ cells
88812361|NCT05431608|Experimental|Dose Level 0|MCARH125 dose 150 million total CAR+ cells MCARH109 dose 0 total CAR+ cells
88812362|NCT05431608|Experimental|Dose Level 1|MCARH125 dose 150 million total CAR+ cells MCARH109 dose 50 million total CAR+ cells
88812363|NCT05431608|Experimental|Dose Level 2|MCARH125 dose 150 million total CAR+ cells MCARH109 dose 150 million total CAR+ cells
88812364|NCT05429879|Experimental|Preferred Music Arm|This arm will allow patients to listen to their preferred music choice during their cystoscopy.
88812365|NCT05429879|Experimental|Classical Music Arm|Patients will listen to a standard playlist of copyright free classical music.
88812366|NCT05429879|No Intervention|No music Arm|Patients will not listen to music during cystoscopy.
88812367|NCT05428033|Experimental|Weight Based High Dose Centanafadine Capsules|High dose - weight-based dosing
88812368|NCT05428033|Experimental|Weight Based Low Dose Centanafadine Capsules|Low dose - weight-based dosing
88812369|NCT05428033|Placebo Comparator|Matching Placebo|Children (4 to 12 years of age, inclusive) to receive Placebo capsules will be matching in size and color.
88812370|NCT05418608|Experimental|Aim 1|A PET study of the novel SV2A imaging tracer [11C]UCB-J in participants, to characterize the distribution of [11C]UCB-J in cortical and subcortical areas in experienced meditators compared to non-meditating controls. Subjects will undergo one PET scan with [11C]UCB-J and one MRI scan for anatomical identification of brain regions.
88812371|NCT05413941|Experimental|Internet-based Cognitive Behavioral Therapy|
88812372|NCT05399537|Experimental|Prismocitrate 18|
88812373|NCT05397431||Lanadelumab|Participants will receive 300 milligram (mg) of Lanadelumab Subcutaneous (SC) injection once every 2 weeks.
88812374|NCT05389631||Trifecta VinV|VinV TAVI procedure in patients who have previously received a Trifecta valve
88964048|NCT02029222||25 NSCLC patients|25 NSCLC patients who received curative radiotherapy. Re-irradiation can either be indicated for primary or secondary cancers in the lung. All patients referred for primary radiotherapy or chemoradiation after curative radiation therapy more or equal to one year ago with overlapping CTV will be included. The organs at risk of the primary tumor are the same organs at risk at the secondary treatment.
88964049|NCT02029248||Children 6-7|Patients who are between 6 and 7 years old
88964050|NCT02029248||Children 8-11|Patients who are between 8 and 11 years old
89208347|NCT00788762||Villagers in Taxiarchis|
89557574|NCT05905510|Active Comparator|Lumbar Erector spinae plane block (L-ESPB)|Patients will receive spinal anesthesia and then ipsilateral lumbar erector spinae plane block (30 ml bupivacaine 0. 25%) at the level of the lumbar region in the operating room after the end of the surgery.
88964051|NCT02029248||Children 12-16|Patients who are between 12 and 16 years old
88964052|NCT02029248||Patients 17-30|Patients who are between 17 and 30 years old
88964053|NCT02029287|Experimental|Subjects with CHF follow-up|Subjects with Hospital-Community-Family-Care Management Platform online and those with the clinic follow up.In the program, participants were educated on the use of smart health-tracking devices and mobile application (APP) to collect and upload comprehensive data elements related to the risk of CHF self-care management. They were also instructed to send text messages, view notifications, and receive individualized guidance on the mobile APP. The general practitioners viewed index of each participant on mobile APP and provided primary care periodically, and cardiologists in regional central hospital offered remote guidance and management if necessary. Outcomes assessed included accomplishments of the program, usability and satisfaction, engagement with the intervention, and changes of heart failure-related health behaviors.
88964054|NCT02029287|Active Comparator|Subjects with CHF conventional clinic visit|Subjects with standardized treatment according to latest guidelines via conventional visit.
88964055|NCT02029300|Other|Nasal Route|The nasal route will be when the airway is acquired and secured with a fiberoptic bronchoscope through one of the nares.
88964056|NCT02029300|Other|Oral Route|The oral route will be when the airway is acquired and secured with a fiberoptic bronchoscope through the patient's mouth.
88964057|NCT02029313|Experimental|MKT-N2|Montelukast
88964058|NCT02029313|Active Comparator|Singulair|Montelukast sodium
88964059|NCT02029339|Experimental|triple-tube group|The patients were treated with continuous topical triple-tube irrigation and suction
88964060|NCT02029339|Active Comparator|SOC group|The patients were treated with standard of care (SOC) without topical irrigation
88964061|NCT02029352|Experimental|Sinecatechins 10%|Patients are instructed to apply a thin layer of the sinecatechins 10% ointment twice daily (morning and evening) in a thin layer to the tumour including 5mm of the surrounding skin. Before applying a new layer patients are advised to wipe off the remnants. Sinecatechins 10% ointment has to be applied for six weeks. Patients are advised to wash their hands after each application to prevent spreading of the ointment.
88964062|NCT02029352|Placebo Comparator|Placebo|Patients are instructed to apply a thin layer of the placebo ointment twice daily (morning and evening) in a thin layer to the tumour including 5mm of the surrounding skin. Before applying a new layer patients are advised to wipe off the remnants. Sinecatechins 10% ointment has to be applied for six weeks. Patients are advised to wash their hands after each application to prevent spreading of the ointment.
88964063|NCT02029365|Other|Without eating disorders|Women consulting for infertility but without diagnosis of eating disorder.
88964064|NCT02029365|Other|With Eating disorders|Womenconsulting for infertility for which eating disorder is diagnosed.
88964065|NCT02029378|Experimental|Eculizumab|Eculizumab, 900 mg intravenously once a week
88964066|NCT02029378|Placebo Comparator|Placebo|Matched placebo, intravenously once a week
88964067|NCT02029391|Active Comparator|Myofascial pain syndrome patients|Manual pressure release only
88964068|NCT02029391|Experimental|Myofascial pain syndrome|One session of manual pressure release and kinesio tape
88964069|NCT02029404|Active Comparator|Tibial nerve group|In the TN (tibial nerve ) group probe will be placed in popliteal cave to identify the popliteal artery and laterally the tibial nerve. Identified the tibial nerve we will proceed , previous local anaesthesia, to insert a catheter medially to tibial branch of the sciatic nerve according to in plane approach.
88964070|NCT02029404|Active Comparator|Tibial peroneal nerve group|"In the TPN (tibial -peroneal nerve) group the probe will be placed in popliteal cave to identify the popliteal artery and laterally the tibial nerve. Afterwards, proceeding cranially with the probe according to in plane approach, we will identify the confluence of tibial with peroneal branch and in this point, previous local anaesthesia, we will position the catheter within the confluence of peroneal and tibial nerve."
88964071|NCT02029456|Experimental|Low dose prolonged infusion arm|Low dose prolonged infusion of tPA arm (25mg Actilyse in 6 hours)
88964072|NCT02029469|Experimental|HRA Device|Patients who will be treated with Ascension HRA device.
88964073|NCT02029482|Experimental|ACT-128800|ACT-128800 tablets, once daily for 3 days at each dose level: 10 mg, 20 mg, 40 mg, 60 mg, 80 mg, and 100 mg.
88964074|NCT02029482|Placebo Comparator|Placebo|Matching placebo tablets, once daily, for 18 days
88964075|NCT02029508|Active Comparator|Epley maneuver|The group using modified Epley maneuver for PSCC BPPV
88964076|NCT02029508|Active Comparator|Semont maneuver|The group using Semont maneuver for PSCC BPPV
88964077|NCT02029508|Sham Comparator|Sham|The group using Reverse Epley maneuver for PSCC BPPV
88964078|NCT02029534|Active Comparator|Atorvastatin 20 mg|atorvastatin 20 mg daily 2 to 7 days prior to surgery and up to 7 post surgery
88964079|NCT02029534|Experimental|Atorvastatin 80 mg|atorvastatin 80 mg daily 2 to 7 days prior to surgery and up to7 days post surgery
88964080|NCT02029547|Experimental|Physician Readers|Physician readers will interpret 60 Amyvid scans using qualitative analysis followed by the use of quantitation. No subjects will be exposed to florbetapir (18F) as part of this study.
88964081|NCT02029573|Experimental|Atorvastatin in Combination With Radiotherapy and Temozolomide|
88964082|NCT02029586|Experimental|MB12066|
88964083|NCT02029586|Placebo Comparator|Placebo|
88964084|NCT02029599|Experimental|High dose group|Fang yi qing feng shi granule, Oral,10g, 3 times a day, Oral,for 3 months Methotrexate,Oral,7.5-15mg per week Acetaminophen tablets,Oral,0.5g, 1~2 times a day, when vas=10.
89208348|NCT00506350|Experimental|GSK1562902A non-AD F1 Primed Group|Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 1 (F1) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated intramuscularly (IM) in the deltoid region of the non-dominant arm.
89208349|NCT00506350|Experimental|GSK1562902A non-AD F2 Primed Group|Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 2 (F2) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.
89208350|NCT00506350|Experimental|GSK1562902A non-AD F3 Primed Group|Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 3 (F3) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.
89026059|NCT03272789|Other|interviews and questionnaires|Realization of interviews (at day 0, and at 1, 2, 3 6 and 12 months) and questionnaires delivery (at day 0, and at 3, 6 and 12 months)
89026060|NCT01327300|Active Comparator|Mesalamine|This group received the drug Mesalamine for 12 weeks then a wash out for 3 weeks prior to crossing over to the placebo arm.
89026061|NCT01327300|Placebo Comparator|Placebo|This group will receive the Placebo for 12 weeks then a wash out for 3 weeks prior to crossing over to the drug arm.
89026062|NCT00491673|Active Comparator|Uncemented|Uncemented primary bipolar hemiarthroplasty of the hip
89026063|NCT00491673|Active Comparator|Cemented|Cemented primary bipolar hemiarthroplasty of the hip
89026064|NCT04380727||Almitrine|Administration of 4 mcg/kg/min iv almitrine bismesylate (Vectarion®, Servier Laboratory, France), over 30-45 min followed by 12 mcg/kg/min infusion rate. Because of a shortage of drug store at national level, a protocol using continuous infusion was not considered. Some patients may receive the drug for 36 hours depending on availability..
89026065|NCT04380727||Control|To eliminate the eventuality of a spontaneous evolution of hypoxia, these patients were matched to control COVID-19 patients treated without almitrine (time control).
89026066|NCT04379440||" Acute Ward Patients  care setting cohort"|Acute Ward Hospitalised patients with suspected or known SARS-CoV-2 infection
89208351|NCT00506350|Experimental|GSK1562902A non-AD F4 Primed Group|Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 4 (F4) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.
89557575|NCT05905510|Active Comparator|Fascia iliaca compartment block (FICB)|Patients will receive spinal anesthesia and then ipsilateral suprainguinal fascia iliaca compartment block (30 ml bupivacaine 0. 25%) in the operating room after the end of the surgery.
89557576|NCT05904964|Experimental|Disitamab Vedotin|Disitamab Vedotin, 2mg/kg, every 2 weeks
89557577|NCT05904964|Active Comparator|Endocrine therapy|Doctors choose endocrine therapy independently
89026067|NCT04379440||" Nursing Homes (RSA)  care setting cohort"|Nursing Home Resident Older Adult suffering from Suspected or known SARS-CoV-2 infection
89557578|NCT05904483|Experimental|Pinwheel Group|In the pinwheel group, a windmill made of colored cardboard is introduced to the children, and then they are asked to blow on the pinwheel during the blood sampling procedure.The blood sampling is terminated at the same time by blowing the pinwheel.
89557579|NCT05904483|Experimental|Finger Puppet Group|In the finger puppet group, a finger puppet made of felt is introduced to the children, and they are told a story (Brave Little Rabbit) by the same researcher using the finger puppet.The blood sampling is terminated at the same time by reading story with finger puppet.
89557580|NCT05904483|Experimental|Abeslang Puzzle Group|In the abeslang puzzle group, a puzzle made of colorful abeslang pieces with animal images (sheep, duck) is introduced to the children, and then they are asked to complete the puzzle using their non-dominant hand during the blood sampling procedure.The blood sampling is terminated at the same time by completing abeslang puzzle.
89557581|NCT05904483|No Intervention|Control|Children in the control group are monitored during the blood sampling procedure if their informed consent is obtained by the researcher. They have the routine blood draw procedure, and do not receive any distraction techniques and other pharmacological interventions.
89557582|NCT05904418|Other|Young, healthy volunteers|"Medical History (20 minutes)~Clinical examination (20 minutes)~Clothes changing time (15 minutes)~ULD CT scan of the vertebra L1 to S1 (30 minutes)~Clothes changing time (15 minutes)~Handheld US scan of the vertebra L1 to S1 (20 minutes)~Platform changing time (15 minutes)~Path planning and robot-assisted US Scan of the vertebra L1 to S1 (40 minutes)~Clothes changing time (15 minutes)~Volunteer Questionnaire (10 minutes)~Total study time per volunteer: 3 Hours 20 minutes"
89557583|NCT05904353|Experimental|Cluster randomized intervention regions|Patients from the intervention regions will be followed the protocol of ambulant nurse-assisted administration of zoledronic acid
89557584|NCT05904353|Active Comparator|Cluster randomized control regions|Patients from the control regions are followed as usual. General practitioners are requested to take care of the follow-up, through the patients and the discharge summary, with annual infusions of zoledronic acid.
89557585|NCT05903469|Experimental|Patient with explicit suicidal ideation and suicide attempt|
89557586|NCT05903469|Experimental|Patient with explicit suicidal ideation without suicide attempt|
89557587|NCT05903469|Active Comparator|Patient without explicit suicidal ideation|
88812375|NCT05389631||Epic VinV|VinV TAVI procedure in patients who have previously received an Epic valve
89026068|NCT04379440||" Home and Outpatients' Care  cohort"|Outpatients at risk of SARS-CoV-2 infection
89026069|NCT04379440||" Dementia Outpatients  cohort"|Outpatients suffering from Dementia according to NIA-AA criteria, at risk of SARS-CoV-2 infection and on Treatment with anti-cholinesterase- dugs and/or anti-psychotics
89026070|NCT04379440||" At home  cohort"|Outpatients at risk of SARS-CoV-2 infection
89557588|NCT05903274|Experimental|JSP191|This study will explore up to 5 ascending dose levels (Cohorts 1, 2, 3, 4, and 5) and subjects will receive JSP191 on Day 1 on each 8-week cycle for 4 consecutive cycles.
89557589|NCT05903014|Experimental|Experimental|3600 mg NAC per day in 12 weeks
89557590|NCT05903014|Placebo Comparator|Placebo|Placebo
89557591|NCT05901818|Experimental|Autologous induced neural stem cell-derived DA precursor cells|The patients will receive transplantation of autologous induced neural stem cell-derived DA precursor cells.
89557592|NCT05896098||Easy laryngoscopy|Cormack Lehane Classification 1-2a
89557593|NCT05896098||Difficult laryngoscopy|Cormack Lehane Classification 2b-3-4
89557594|NCT05895500||Tablet|Tablets (50mg/tablet), oral
89557595|NCT05895500||Injection|Injection for SC administration (120mg/syringe)
89557596|NCT05893680|Experimental|Group to play online games|The child's pain was evaluated 4 hours after the surgery, and then he/she was allowed to play an online game that he/she knew, loved, and wanted to play for 20 minutes.
89557597|NCT05893680|Experimental|Group that received cold application|The child's pain was evaluated 4 hours after the surgery, and then a clean gauze wrapped cold gel pack was applied to the surgical site for 20 minutes.
89557598|NCT05893680|Placebo Comparator|Group that received placebo|The child in the relevant group had their pain evaluated 4 hours after the surgery, and then was given 2 cc of 0.9% saline (isotonic) solution intravenously, while being told that it was a painkiller administered to both the child and the parent.
89557599|NCT05893680|Active Comparator|"Group that played an online game and received cold application at the same time"|Pain assessment was performed on the child in the relevant group 4 hours after surgery, and then while playing an online game that the child knew, liked, and wanted to play, a clean gauze-wrapped cold gel pack was applied to the surgical site for cold therapy. The interventions lasted for 20 minutes.
89026071|NCT04379440||" Outcomes  cohort"|Age≥65 years as target population Hospitalised patients diagnosed with SARS-CoV-2 infection
89557600|NCT05891756||CD patients requiring surgical treatment (ileocecal resection)|
89557601|NCT05891756||Control group|Patients requiring an ileocecal resection for a cause other than CD
89557602|NCT05888753||Yes Textbook Outcome|Patients undergoing scheduled adrenal neoplasm surgery with a R0 resection, no Clavien-Dindo ≥IIIa complications, no prolonged stay, no readmissions, and no mortality in the first 30 days
89557603|NCT05888753||No Textbook outcome|Patients undergoing scheduled colon cancer surgery without any of the following items: R0 resection, no Clavien-Dindo ≥IIIa complications, no prolonged stay, no readmissions, and no mortality in the first 30 days
89557604|NCT05887739||GLUT1DS|Patients affected by GLUT1 deficiency syndrome
89557605|NCT05887739||Healthy controls|Age and sex matched healthy controls
89026072|NCT04328389|Placebo Comparator|Placebo Comparator: electric toothbrush|Participats will be instructed to used electric toothbrush for home supragingival plaque removal
89557606|NCT05881447||RenalTWO screening cohort|Approximately 1200 patients seeking primary care in the Bagamoyo District Hospital and in two of its associated dispensaries are randomly selected to participate in the RenalTWO cohort study. This includes a longitudinal health check-up over three visits: at the date of enrolment, after a minimum of 90 days for confirmation, and finally after one full calendar year.
89557607|NCT05880771|Experimental|Immediate implant placement with buccal gap grafted with Allograft|Following tooth extraction immediate implant will be placed in the palatal bone and the buccal gap between the implant and the buccal bone will be grafted with Allograft
89557608|NCT05880771|Experimental|Immediate implant placement with buccal gap grafted with Xenograft|Following tooth extraction immediate implant will be placed in the palatal bone and the buccal gap between the implant and the buccal bone will be grafted with Xenograft
89557609|NCT05879224|Experimental|Revised case management package|
89026073|NCT04328389|Experimental|Professional oral hygiene|Full-Mouth professional oral hygiene consisting in scaling and root planing, four quadrants in one session.
89026074|NCT00467207|Active Comparator|BoNT A|Botulinum toxin A injections in muscles of the arm (biceps brachii and brachialis)
89026075|NCT00467207|Experimental|Resistance training|8 weeks resistance training
89026076|NCT04378504||ACS|All patients admitted in the ICU for ACS after coronary angiography evaluation between May 2019 and May 2020
89026077|NCT00592111|Experimental|1|
89026078|NCT00592111|Experimental|2|
89026079|NCT00592111|Experimental|3|
89026080|NCT00592150|Experimental|1|Fenoldopam infusion
89557610|NCT05877716|Active Comparator|Treatment as Usual|Participants will be treated as usual in their early psychosis CSC program and will not complete cognitive training or use the Personalized Real-Time Motivational Enhancement App.
89557611|NCT05877716|Experimental|Cognitive Training plus Personalized Real-Time Intervention for Motivational Enhancement|The Mobile Intervention. 20 hours of training consisting of 10 hours of cognitive training exercises plus 10 hours of social cognitive training exercises will be delivered over the course of 12 weeks. Participants will also engage in the PRIME app on a smart phone and will receive personalized support from a motivation enhancement coach.
89557612|NCT05877625||open ICU|open ICU: open ICU
89557613|NCT05877625||negative ICU|negative ICU: negative-pressure laminar flow ward
89557614|NCT05877625||positive ICU|positive ICU: laminar flow ward
89557615|NCT05874492|Active Comparator|Immediate spa treatment|The spa treatment must be carried out within a maximum of 6 weeks after the inclusion visit.
89557616|NCT05874492|Sham Comparator|Late spa treatment|The spa treatment must be carried out after the 6-month visit.
89557617|NCT05873361||Adult patients with a papillary microcarcinoma asymptomatic|Adult patients who have had a papillary microcarcinoma asymptomatic and who are followed.
89557618|NCT05872321||Per-operative Complication|
89557619|NCT05871840||Treatment duration of RLRL therapy (≥ 6 months and < 12 months)|
89557620|NCT05871840||Treatment duration of RLRL therapy (≥12 months and < 24 months)|
89557621|NCT05871840||Treatment duration of RLRL therapy (≥24 months and < 36 months)|
89557622|NCT05871840||Treatment duration of RLRL therapy (≥36 months)|
89557623|NCT05869149|Experimental|Restaurants receiving FRESH intervention|Restaurants enrolled in the experimental arm of will FRESH undergo activities aimed to improve their healthy food offerings at their restaurants.
89026081|NCT00592150|Placebo Comparator|2|Placebo infusion
89026082|NCT00592189|Experimental|1|Amnion tissue and blood collection
89557624|NCT05869149|No Intervention|Restaurants not receiving FRESH intervention|Restaurants will be enrolled in the study, but not receive the FRESH intervention.
89557625|NCT05868057|Experimental|Treatment group ARM 1|SHR7280 dry suspension then SHR7280 tablets
89557626|NCT05868057|Experimental|Treatment group ARM 2|SHR7280 tablets, then SHR7280 dry suspension
89557627|NCT05862909|Experimental|Intervention group (IG 1)|CHD-specific web-based emotion regulation intervention
89557628|NCT05862909|Active Comparator|Intervention group (IG 2)|General web-based emotion regulation intervention
89557629|NCT05862909|No Intervention|Waitlist control group (CG)|8-week waiting period
89557630|NCT05856656|Experimental|Music therapy arm|A music therapy will be offered to patients before the first 3 chemotherapy cycles
89557631|NCT05856656|No Intervention|Standard care arm|Standard patient care, no intervention
89557632|NCT05856058|Experimental|Treatment group ARM 1|SHR0302 tablets, then SHR0302 oral solution
89557633|NCT05856058|Experimental|Treatment group ARM 2|SHR0302 oral solution, then SHR0302 tablets
89026083|NCT00592228|Other|1|Fractional flow guided drug-eluting stent implantation arm
89026084|NCT00592228|Other|2|Routine drug-eluting stent implantation
89026085|NCT00592306|Active Comparator|thymoglobulin (intraoperative)|we plan to blindly randomize these 25 lung transplant patients to intraoperative dosing of thymoglobulin followed by 3 additional postoperative doses (the first of these 3 postoperative doses will be placebo)
89026086|NCT00592306|Placebo Comparator|thymoglobulin (postoperative dosing)|We plan to blindly randomize these 25 lung transplant patients to 3 postoperative doses of thymoglobulin (the intraoperative dose will be placebo)
89026087|NCT04376749||preterm infants received caffeine|preterm infants aged between 28 to 34 weeks gestational age who received caffeine therapy either for prophylaxis or treatment
89026088|NCT04376749||preterm infants received no caffeine|preterm infants aged between 28 to 34 weeks gestational age who received no caffeine therapy
89557634|NCT05855421|Experimental|Experimental: Specific Auricular Acupuncture|12 sessions in 6 weeks, 6 ear points of Chinese Tradicional Medicine - liver, kidney, shenmen, subcortex, heart and lung, with a semi-permanent needle (0,2x2,5mm). Participants will be instructed to stimulate the area 3 times a day.
89557635|NCT05855421|Sham Comparator|Inespecific Auricular Acupuncture|12 sessions in 6 weeks, 6 ear points not related to chinese specific points - cheek, outer ear, 4 points non-reactive on the ear helix, with a semi-permanent needle (0,2x1,0mm). Participants will be instructed to stimulate the area 3 times a day.
89557636|NCT05854069|Experimental|FAMS-T1D|"Participants will receive FAMS-T1D components (monthly phone coaching and text message support for goals) for 6 months. Support persons will receive text messages that are tailored to the goal set by the person with type 1 diabetes.~All persons with diabetes will receive text messages regarding how to access their HbA1c results and receive links providing information to assist them in self-care behaviors related to their diabetes. All support persons will also receive materials about type 1 diabetes and how to provide helpful support to the person with diabetes."
89557637|NCT05854069|Placebo Comparator|Digital resources for diabetes|All persons with diabetes will receive text messages regarding how to access their HbA1c results and receive links providing information to assist them in self-care behaviors related to their diabetes. All support persons will also receive materials about type 1 diabetes and how to provide helpful support to the person with diabetes.
89557638|NCT05847608|Experimental|Omega-3 Supplementation|This groups will supplement their regular diet with 1 tsp of fish oil containing 1.5 grams combined omega-3 fatty acid (EPA/DHA) supplement in liquid form on a daily basis until they are recovered or have been enrolled for 6 weeks.
89557639|NCT05847608|Placebo Comparator|Placebo|This group will supplement their regular diet with 1 tsp olive oil in liquid form on a daily basis until they are recovered or have been enrolled for 6 weeks.
89557640|NCT05846776|Experimental|elderly subjects at risk of fall|
89557641|NCT05843019||Cross sectional|"The patients in the cross sectional study will have done a synactenstest to investigate how their own product of kortisol os after longterm use of systemic steroids.~The group consists of patients referred to the Respiratory Clinic, ENT, RH, for evaluation of CRS/CRSwNP/CRSnNP and with or without asthma for biological treatment. They are classified according to the type of inflammation they have (type-2 or non-type-2), whether they have CRSwNP or CRSsNP, their adherence, comorbidity with asthma, and finally the severity of the disease. All patients are given standard questionnaires to assess CRS/CRSwNP/CRSnNP and asthma (STARR-15, SNOT22, ACQ, ACT, MARS-5-L/N, Fosterscore - routine questionnaires for all patients in the Respiratory Clinic)."
89557642|NCT05840666|Active Comparator|Conventional Physical Therapy (CPT) Group|Conventional Physical Therapy will consist of Therapeutic Ultrasound, Moist Heat-pack, TENS and standard exercises. Participants will receive 15 sessions of Conventional Physical Therapy (CPT) at a frequency of 5 sessions per week.
89026089|NCT04376398||COVID-19|Any pediatric or adult patient with COVID-19 or suspected of COVID-19 scheduled for any intervention
89026090|NCT02893111|Experimental|Bortezomib (Velcade)|A proteasome inhibitor
89557643|NCT05840666|Experimental|Conventional Physical Therapy (CPT) plus Mulligan SNAGs Group|Besides Conventional Physical Therapy, Mulligan Mobilizations will be provided in this group. It consist of Extension SNAGS in prone, and Lumbar flexion SNAGS in sitting. The techniques will be applied in 3 sets with 10 repetitions and 60 seconds rest between sets.
89557644|NCT05840666|Experimental|Conventional Physical Therapy plus McKenzie MDT Group|Along with Conventional Physical Therapy, McKenzie MDT will be be given in this group. It consist of Prone lying, Prone lying Elbow popups, Prone elbow Extension. Standing Extension, supine Both Knee to Chest, Sitting on chair with forward flexion. The techniques will be applied in 3 sets with 8-10 repetitions and 60 seconds rest between sets.
89557645|NCT05839184|No Intervention|CONTROL GROUP|All newborns in the study will be monitored during IV catheter placement. Newborns in the control group will not be given any therapeutic toy and IV catheter will be placed and their comfort levels and vital signs will be monitored.
89557646|NCT05839184|Active Comparator|therapeutic toy GROUP|All newborns in the study will be monitored during IV catheter placement. Newborns in the therapeutic toy group will be given an octopus-shaped therapeutic toy that they can hold in their hands throughout the procedure and IV catheter will be inserted and their comfort levels and vital signs will be monitored.
89557647|NCT05836792|Experimental|Cycle Ergometer Group (CEG)|Isometric exercises Transcutaneous electrical nerve stimulation Ultrasound Cycle ergometer
89557648|NCT05836792|Active Comparator|Control Group|Isometric exercises Transcutaneous electrical nerve stimulation Ultrasound
89557649|NCT05835895|Experimental|GNSC-001 (low dose)|
89557650|NCT05835895|Experimental|GNSC-001 (low dose) + transient immune-modulation|
89557651|NCT05835895|Experimental|GNSC-001 (high dose)|
89557652|NCT05835895|Experimental|GNSC-001 (high dose) + transient immune-modulation|
89557653|NCT05835895|Placebo Comparator|Placebo|
89557654|NCT05832411|Experimental|AI group|In the AI group, except for the original videos, there is additional information presented to endoscopists:（1）the virtual stomach model monitoring;（2）time;（3）scoring. Endoscopists will complete EGD examination without blind spots.
89557655|NCT05832411|No Intervention|Routine group|In the Routine group, only the original videos and there is no additional information, and inspection time will be no less than 7 minutes.
89557656|NCT05831904|Experimental|20 healthy children|20 healthy children aged 5 to 15 years , without any congenital or developmental abnormalities of their hip joint
89557657|NCT05830669|Experimental|Intervention Group|Remote ischemic preconditioning (RIPC) Three Cycles of 5-min upper limb ischemia. If there is no response this will be followed by 2 cycles of 10-min upper-limb ischemia.
89557658|NCT05830669|Sham Comparator|Control Group|Three cycles of 5- min upper limb sham ischemia.
89557659|NCT05825651||Exposure group|Group with history of COVID-19 infections and vaccines, as well as health-related, behavioral, socioeconomic exposures.
89557660|NCT05825651||Non-exposure group|Group without history of COVID-19 infections and vaccines, as well as health-related, behavioral, socioeconomic exposures.
89557661|NCT05824884|Experimental|Experimental 1|positive visual feedback during VR-height-exposure combined with SE-enhancement after exposure.
89557662|NCT05824884|Active Comparator|Active Comparator 1|positive visual feedback during VR-height-exposure, and a placebo intervention after exposure.
89557663|NCT05824884|Active Comparator|Active Comparator 2|no visual feedback during exposure but SE-enhancement after exposure.
89557664|NCT05824884|Placebo Comparator|Placebo Comparator|no visual feedback during exposure and placebo intervention after exposure.
89557665|NCT05824546|Active Comparator|Intervention Arm|Patients will undergo LP using uSINE-PAMS-guided technique
89557666|NCT05824546|Active Comparator|Control Arm|Patients will undergo LP using traditional landmark-based method
89557667|NCT05823896|Active Comparator|Nirmatrelvir/ritonavir|Oral nirmatrelvir/ritonavir (Paxlovid) 300/100 mg twice daily for 15 days
89557668|NCT05823896|Placebo Comparator|Placebo/ritonavir|Oral placebo/ritonavir 100 mg twice daily for 15 days
89557669|NCT05822154||elderly subjects|subjects aged 65 years and over
89557670|NCT05821413|Experimental|Data to Care|Clinics randomized to the intervention arm will implement the data to care strategy, which includes a 5-step process: (1) identify not-in-care PLWH using the a medical information system, (2) verify eligibility criteria, (3) contact patients and invite to visit the clinic, (4) determine care status and reengage into care, and (5) provide case management services and confirm engagement in care.
88964085|NCT02029599|Experimental|Low dose group|"Fang yi qing feng shi granule,Oral,10g, 2 time a day, taking morning and evening,for 3 months.~placebo,Oral,10g, 1 time a day, taking noon ,for 3 months. Methotrexate,Oral,7.5-15mg per week. Acetaminophen tablets,Oral,0.5g, 1~2 times a day, when vas=10."
88964086|NCT02029599|Placebo Comparator|The placebo group|placebo,Oral,10g, 3 time a day ,for 3 months. Methotrexate,Oral,7.5-15mg per week. Acetaminophen tablets,Oral,0.5g, 1~2 times a day, when vas=10.
88964087|NCT02029612|Other|Group 1 - Phone Call Support|Smoking cessation telephone hotline phone number provided to participants, along with a 10 week supply of nicotine patches. Each participant counseled on quitting smoking at baseline. Questionnaires completed at baseline, 3 months, and at 6 months. Participant receives 11 phone calls from study staff over a 6-month period. Breath test performed at 3 month and 6 month visit.
88964088|NCT02029612|Other|Group 2 - Text Messaging Support|Participants receive 10 week supply of nicotine patches. Each participant counseled on quitting smoking at baseline. Questionnaires completed at baseline, 3 months, and at 6 months. Participants receive text messages for support about quitting smoking over a 6 month period. Breath test performed at 3 month and 6 month visit.
88964089|NCT02029625|Experimental|NVP-1205|administration of NVP-1205(rosuvastatin+ezetimibe)
88964090|NCT02029625|Active Comparator|rosuvastatin and ezetimibe|coadministration of rosuvastatin and ezetimibe
88964091|NCT02029651|Experimental|E-glove system|E-glove rehabilitation system for upper extremity
88964092|NCT02029651|Active Comparator|Conventional occupational therapy|conventional occupational therapy
88964093|NCT02029664|Experimental|Visual feedback distortion|Visual distortion increment based on the gait pattern
88964094|NCT02029690|Experimental|ADI-PEG 20|Arginine deiminase formulated with polyethylene glycol
88964095|NCT02029742|Experimental|Community Health Worker Intervention|Community Health Workers will have scheduled interactions with subjects and will customize text messaging jointly with each youth and parent and initiate text message reminders to both parent and youth for months 4-6.
88964096|NCT02029742|Active Comparator|Education|Those randomized to the Education group will continue usual care, and will be provided with educational materials about sickle cell disease and hydroxyurea use for children.
88964097|NCT02029768||Women with burn injury|
88964098|NCT02029768||Men with burn injury|
88964099|NCT02029781|Other|LAPP score|Use of the LAPP score during a diagnostic laparoscopy.
88964100|NCT02029794|Experimental|HPV Self-collection|Subjects will self-collect a cervical-vaginal sample. One time use.
88964101|NCT02029794|Active Comparator|VIA arm|Standard of care in Uganda is visual inspection with acetic acid (VIA). Women randomized to this arm will undergo the following: Cervix examined by clinician using speculum and light source. Cervix then sprayed with 3-5% acetic acid, and then lesions described one minute after application of acetic acid. VIA negative no acetowhite lesions detected; positive is when dense aceto-white lesions are seen touching squamocolumnar junction
88964102|NCT02029807||Blood donors|Healthy adult volunteers donating blood
88964103|NCT02029820|Active Comparator|RenalGuard|Hydration with the device renalguard
88964104|NCT02029820|No Intervention|Saline|Hydration with saline 1ml/Kg/h for 12h
88964105|NCT02029859|Experimental|Prevalence of obstructive sleep apnea syndrome|"Determine the prevalence of obstructive sleep apnea syndrome (OSA) in late pregnancy in a population of obese patients .~Polygraphic examination between 30 and 36 weeks of amenorhea"
88964106|NCT02029885|Experimental|Investigational Therapy (Surround Sound)|Investigational Therapy using external focused ultrasound
88964107|NCT02029885|Sham Comparator|Sham Control|Blinded Sham Control Arm
88964108|NCT02029898|Active Comparator|Remifentanil|injectable solution, 0.5 microgramme/Kg for 30 seconds following by a continuous dose of 0.1 microgramme/kg/minute
88964109|NCT02029898|Placebo Comparator|Placebo|injectable solution 0.9% for the end of surgery
88964110|NCT02029924|Experimental|BioChaperone insulin lispro|BioChaperone insulin lispro
88964111|NCT02029924|Active Comparator|Humalog®|Humalog®
88964112|NCT02029937|Experimental|Proflavine, high resolution imaging|5-10 ml of proflavine hemisulfate (0.01%) will be sprayed on the esophageal mucosa. The HRME will then be inserted through the endoscope and gently placed against the mucosa. Imaging of abnormal tissues will be performed.
88964113|NCT02029937|No Intervention|Standard of care|No invention
88964114|NCT02029950|Experimental|Treatment (combination chemotherapy, pomalidomide)|See Detailed Description
88964115|NCT02030158||Early Goal-Directed Therapy (EGDT)|Protocolised resuscitation (termed Early Goal-Directed Therapy - EGDT)
88964116|NCT02030158||Usual resuscitation|Usual resuscitation
88964117|NCT02030171|Active Comparator|PLURIHOC|-Functionnal reeducation : in hospital, intensive, multidisciplinary.
88964118|NCT02030171|Active Comparator|KIPLURI|-Functionnal reeducation : ambulatory, no intensive multidisciplinary.
88964119|NCT02030171|Active Comparator|KIMONO|-Functionnal reeducation : ambulatory, low-intensity
89033051|NCT02922348|Experimental|Combined Oral Contraceptives|Patients will be given hormones in the form of: monophasic combined oral contraceptive containing ethinyl estradiol 0.035 mg and norgestimate 0.25 mg, 1 tablet daily (21 days of active pills and 7 days of inactive pills)
89557671|NCT05821413|Active Comparator|Standard of Care|Participants in the standard of care sites will receive existing case management and supportive services from the HIV clinic.
88964120|NCT02030236|Experimental|Cooling|
88964121|NCT02030249|Experimental|High Protein / Low Glycaemic Index|A 10-month weight maintenance diet, administered from the 2-month to the 12-month time point, where protein intake is 25% of energy intake, carbohydrate intake is 45% of energy intake, dietary glycaemic index is < 55. Please see parent study for further Arm details: http://clinicaltrials.gov/ct2/show/NCT01777893?term=preview&rank=1
88964122|NCT02030249|Active Comparator|Moderate Protein / High Glycaemic Index|A 10-month weight maintenance diet, administered from the 2-month to the 12-month time point, where protein intake is 15% of energy intake, carbohydrate intake is 55% of energy intake, dietary glycaemic index is > 65. Please see parent study for further Arm details: http://clinicaltrials.gov/ct2/show/NCT01777893?term=preview&rank=1
88964123|NCT02030470|Other|fotosan|
88964124|NCT02030561|Experimental|Trastuzumab + NK cells|"During cycle 1, Day 1 patient will receive intravenous trastuzumab and subcutaneous IL-2 on day 1, followed by NK cell infusion on day 2, followed by subcutaneous IL-2 for an additional 5 doses three times a week to support NK cell viability and expansion in vivo.~From cycles 2-4, patient will receive trastuzumab monotherapy alone every 21 days, except for patients who achieve objective tumor response after 2 cycles of therapy, who will then receive an additional infusion of NK cells along with trastuzumab during cycle 4 therapy at the same dose and schedule as in cycle 1.~Patients will be taken off study after cycle 4, unless the patient has objective tumor response after 4 cycles of therapy with only stable disease after cycle 2, in which case the patient will be given another 2 cycles of trastuzumab with an additional NK cell infusion during cycle 6 therapy at the same dose and schedule as in cycle 1."
88964125|NCT02030730|Experimental|Triple P Seminar Series|Intervention parents received the Seminar Series (Selected TripleP); three 90-minute seminars ('The Power of Positive Parenting', 'Raising Confident, Competent Children', and 'Raising Resilient Children'), including 60 minutes of scripted presentation material and 30 minutes question time for discussion. Parents received tip sheets with the material presented at the end of each seminar. The seminars were free of charge. The delivery of each seminar was 2 to 4 weeks apart.
89557672|NCT05821088|Experimental|Treatment (tafasitamab, lenalidomide, ICE regimen)|Patients receive tafasitamab IV, lenalidomide PO, etoposide IV, ifosfamide IV and carboplatin IV on study. Patients undergo PET or CT, and undergo blood sample collection throughout the study. Patients may undergo tissue biopsy on study.
89557673|NCT05802966||Mindfulness-Based Cognitive Therapy + Treatment as usual|Patients receive Mindfulness-Based Cognitive Therapy (MBCT) and treatment as usual (TAU). Measurements are administered before, half-way and after MBCT.
89557674|NCT05802966||Wait-list control (Treatment as usual)|Patients in the wait-list controlled group receive treatment us usual (TAU) during their waiting-period. After their waiting period, they receive MBCT in a similar fashion compared to the intervention group. Measurements are administered before, half-way and after their waiting period. In addition, a fourth and fifth measurement will be administered half-way and after MBCT.
89557675|NCT05802654|Experimental|Participants receiving SBRT|The participants enrolled will receive single fraction of ultra-high dose SBRT(30Gy/1F).
89557676|NCT05794581|Experimental|CT-868|SC injection of CT-868 Intervention
89557677|NCT05794581|Placebo Comparator|Placebo|SC injection of placebo matching CT-868 dose
89557678|NCT05794581|Active Comparator|Victoza|SC injection of active comparator
89557679|NCT05794438|Experimental|Adaptive Approach Bias Modification|
89557680|NCT05794438|Experimental|Static Approach Bias Modification|
89557681|NCT05794438|No Intervention|Control|
89557682|NCT05791318|Experimental|Cohort 1|10 total participants Cohort 1. 8 participants on VYD222 2 participants on placebo
89557683|NCT05791318|Experimental|Cohort 2|10 total participants Cohort 2. 8 participants on VYD222 2 participants on placebo
89557684|NCT05791318|Experimental|Cohort 3|10 total participants Cohort 3. 8 participants on VYD222 2 participants on placebo
89557685|NCT05790915||Group 1|Patients with SOFA score < 2 at admission. No intervention
89557686|NCT05790915||Group 2|"Patients with SOFA score equal to or > 2 on admission and who improved after 48 hours of treatment.~Intervention focused on identified organ dysfunction(s)"
89557687|NCT05790915||Group 3|"Patients with SOFA score equal to or > 2 on admission and who did not improve after 48 hours of treatment.~Intervention focused on identified organ dysfunction(s)"
89557688|NCT05785949|Experimental|Microfracture + Chondro-Gide®|Microfracture + Chondro-Gide® bilayer collagen membrane
89557689|NCT05785949|Active Comparator|Microfracture|Microfracture
89557690|NCT05776498|Experimental|immediate implant placement with particulate bone graft using the dual zone technique.|immediate implant placement with particulate bone graft using the dual zone technique.
89557691|NCT05776498|Experimental|immediate implant placement with connective tissue grafting|immediate implant placement with connective tissue grafting
89557692|NCT05770518|Experimental|Biofeedback|In office video biofeedback performed at the time of the diagnosis.
89557693|NCT05770518|Active Comparator|Laryngeal control therapy|A specific type of behavioral therapy performed by speech and language pathologists
89557694|NCT05767944|Experimental|Wide Awake Local Anesthesia (WALANT)|Study arm: (WALANT) patient received local anaesthesia (25ml of 2%lidocaine with 0.5 ml of adrenaline (1mg/mL) and 5 ml of 8.4% of sodium bicarbonate. the final 50 ml mixture contained 10 mg/ml Lidocaine and adrenaline 1:100,000 concentration) infiltration along rays at site of surgery (15 ml or more per ray (150 mg lidocaine) by 27G needle, 10 ml (or more) in the palm, then 2 ml in the proximal and middle phalanges and 1 ml in the distal phalanx (if required )) for hand flexor tendons repair.
89557695|NCT05767944|Active Comparator|Supra Clavicular- Brachial Plexus Block (SC-BPB)|Control arm:(SC-BPB): ultrasound-guided injection of local aesthetics (15 mL of 2% lidocaine and 15 mL of 0.5% bupivacaine were injected incrementally over 3-5 min) at supra-clavicular level where brachial plexus trunks are located this will provide anesthesia for the whole upper limb distal to shoulder joint.
89557696|NCT05766787|Other|LID022821/AOHP|Serafilcon A contact lenses worn first, with senofilcon A contact lenses worn second, as randomized. Each study lens type will be worn bilaterally (in both eyes) for approximately 14 days. CLEAR CARE will be used for daily cleaning and disinfection.
89557697|NCT05766787|Other|AOHP/LID022821|Senofilcon A contact lenses worn first, with serafilcon A contact lenses worn second, as randomized. Each study lens type will be worn bilaterally (in both eyes) for approximately 14 days. CLEAR CARE will be used for daily cleaning and disinfection.
89557698|NCT05764135|Experimental|Intervention Group|25 individuals will be randomized into the intervention group and download SCI-Lynx Mobile Application.
89557699|NCT05764135|No Intervention|Control Group|25 individuals will be randomized into the control group or usual care. They will then have an opportunity at the end of the 1-month to download the SCI-Lynx Mobile Application.
89557700|NCT05754190||Healthy Controls|[general study + sub study] No history of chronic pain
89557701|NCT05754190||Acute pain|[general study] Pain duration < 3 months
89557702|NCT05754190||Chronic pain|"[general study] Pain duration > 6 months~[sub-study] diagnosis of chronic low back pain, failed back surgery syndrome, or fibromyalgia"
89557703|NCT05753839|Experimental|Upfront cytoreductive nephrectomy|Cytoreductive nephrectomy±metastasectomy, followed by induction therapy with nivolumab plus ipilimumab combination and maintenance therapy with nivolumab.
89557704|NCT05753839|Experimental|Deferred cytoreductive nephrectomy|Cytoreductive nephrectomy±metastasectomy after induction therapy with nivolumab plus ipilimumab combination, followed by maintenance therapy with nivolumab.
89557705|NCT05753839|Active Comparator|No surgery|Induction therapy with nivolumab plus ipilimumab combination, followed by maintenance therapy with nivolumab.
89557706|NCT05753085|Experimental|Conavi Medical Novasight Hybrid System intervention|Patients who present with non-ST elevation myocardial infarction (NSTEMI) and require an angiogram and or PCI will have intravascular imaging assessment of the culprit vessel using the Conavi Medical Hybrid System (Novasight Hybrid Catheter, Novasight Hybrid PIM, Novasight Hybrid Hummingbird Console)
89557707|NCT05751265|Experimental|Tislelizumab combined with chemotherapy|
89557708|NCT05746988|Experimental|Carrageenan-based Mouthwash|Mouthwash with Carrageenan as an active ingredient
89557709|NCT05746988|Placebo Comparator|Placebo Mouthwash|"Mouthwash without Carrageenan but similar in colour, taste, and mouthfeel to the experimental mouthwash"
89557710|NCT05744687|Experimental|SPH4336 Tablets 400mg|SPH4336 Tablets； Letrozole tablets
89557711|NCT05744687|Placebo Comparator|SPH4336 Tablets Placebo|SPH4336 Placebo； Letrozole tablets
89026091|NCT00498771|Active Comparator|Aquatic Exercise arm|Participants will attend 12 classes of aquatic exercise program (2-3 classes/weekly). Each one hour class is held in warm water pool which is 89 degrees and 3.5'-4'deep.Classes include low impact, dynamic movements for warm up, stretching and breathing exercises, upper and lower body resistance training, and cool down activities. Participants will be evaluated for Circumference & volumetric measurement of the affected limb, BMI, weight and height at the baseline, at 3rd week and at 6th week. Participant will complete a quality of life survey (QOL)at baseline, 6 week, 6 and 12 month.
89557712|NCT05743413|Experimental|Armeo Spring|Study subjects randomized into this group will undergo physiotherapy sessions using the Armeo Spring device.
89557713|NCT05743413|Active Comparator|Standard physiotherapy|Study subjects randomized into this control group will undergo standard physiotherapy sessions.
89557714|NCT05737823|Experimental|Carers-ID online support programme|Participants in this arm will receive access to the Carers-ID online programme. Participants will be able to access the online programme for 2 weeks.
89557715|NCT05737823|Other|Wait-list Control|Wait-list control arm
89557716|NCT05733845|Other|Samples|The intervention is to collect blood; urine; saliva and stool samples but also mucosal biopsies at each protocol visits (baseline and follow up visits).
89557717|NCT05733520|Experimental|Brain CareNotes App|
89557718|NCT05733520|Active Comparator|Attention Control App|
89026092|NCT00498771|No Intervention|Control - No Exercise Arm|No exercise will be performed in Control arm. Participants will be evaluated for Circumference & volumetric measurement of the affected limb, BMI, weight and height at the baseline, at 3rd week and at 6th week. Participant will complete a quality of life survey (QOL) at baseline, 6 week, 6 and 12 month.
89557719|NCT05732896|No Intervention|control group|standard care group
89557720|NCT05732896|Active Comparator|study group|NOL guided group
89557721|NCT05727436|Experimental|Group 1 - probiotic|"Experimental: Group 1 - probiotic The use of Streptococcus salivarius M18 containing tablets (Dentoblis, registration number: AM.01.06.01.003.R.000061.07.20; 15.07.2020, MEDICO DOMUS, d.d.o.; 18116, Nis, Serbia)) once a day for 4 weeks (before bedtime after evening brushing).~Ingredients: basic active ingredients - Streptococcus salivarius M18 (≥5×108 CFU in 1 tablet), Vitamin D (320 IU (8 mcg) in 1 tablet); excipients - isomalt (sweetener), magnesium stearate (vegetable), mint flavoring."
89557722|NCT05727436|Placebo Comparator|Group 2 - placebo|"The use of placebo tablets once a day for 4 weeks (before bedtime after evening brushing).~Ingredients: isomalt (sweetener), magnesium stearate (vegetable), mint flavoring."
89557723|NCT05716854|Active Comparator|Part 1: Clarithromycin Administration Only|Subjects in this arm will be administered Clarithromycin only over 3 days of dosing.
89557724|NCT05716854|Active Comparator|Part 1: Pimozide Administration Only|Subjects in this arm will be administered Pimozide only over 3 days of dosing.
89557725|NCT05716854|Placebo Comparator|Part 1: Placebo|Subjects in this arm will not be administered any drug. Will serve as placebo comparator arm.
89557726|NCT05716854|Active Comparator|Part 2: Moxifloxacin Administration Only|Subjects in this arm will be administered Moxifloxacin only for 1 day of dosing.
89557727|NCT05716854|Active Comparator|Part 2: Cobicistat Administration Only|Subjects in this arm will be administered Cobicistat only for 1 day of dosing.
89557728|NCT05716854|Active Comparator|Part 2: Moxifloxacin and Cobicistat Administration|Subjects in this arm will be administered both Cobicistat and Moxifloxacin for 1 day of dosing.
89557729|NCT05716854|Placebo Comparator|Part 2: Placebo|Subjects in this arm will not be administered any drug. Will serve as placebo comparator arm.
89557730|NCT05714553|Experimental|Module 1 (NUC-3373 + LV + pembrolizumab)|"This Module is designed to evaluate the tolerability and the overall safety profile of NUC-3373 (1875 mg/m2) + LV (400 mg/m2) + pembrolizumab (200 mg) in the treatment of patients with advanced solid tumours (dose validation phase).~NUC-3373 and LV will be administered on Days 1, 8 and 15 and pembrolizumab will be administered on Day 1 of 21-day cycles. The dosing schedule may be adjusted based on emerging data with agreement from the Safety Review Committee. Following completion of the dose validation phase, expansion cohorts may be initiated at the selected dose level."
89033052|NCT02922270||Patients|Who have received PD as renal replacement therapy (RRT) over a period of 20 years.
89557731|NCT05714553|Experimental|Module 2 (NUC-3373 + LV + docetaxel)|"This Module is designed to assess NUC-3373 (750 mg/m2) + LV (400 mg/m2) + docetaxel (55 mg/m2) for the treatment of patients with advanced/metastatic NSCLC or pleural mesothelioma who have progressed on, or were unable to tolerate, 1 or 2 prior lines of cytotoxic chemotherapy-containing regimens for advanced/metastatic disease (dose validation phase).~NUC-3373 and LV will be administered on Days 1 and 22 and docetaxel will be administered on Day 8 of 28-day cycles. The dosing schedule may be adjusted based on emerging data with agreement from the Safety Review Committee. Following completion of the dose validation phase, expansion cohorts may be initiated at the selected dose level."
89557732|NCT05713760|Experimental|5 Day treatment course 1 with Tirbanibulin Ointment 1%|10 Subjects will be given one study kit containing single-dose packets of Tirbanibulin Ointment 1% and instructed to topically apply to the treatment area once daily for 5 consecutive days.
89557733|NCT05713760|Experimental|5 Day treatment course 2 with Tirbanibulin Ointment 1%|Subjects with unresolved lesion will be given an additional study kit containing single-dose packets of Tirbanibulin Ointment 1% and instructed to topically apply to the treatment area once daily for 5 consecutive days.
89557734|NCT05701488|Experimental|Durvalumab + Tremelimumab (Arm A)|"-Participants will be randomized into the treatment group in a 1:1 ratio and will receive interventions as outlined:~Neoadjuvant Treatment:~Cycle 1:~Day 1 of 28 Day Cycle: Pre-determined dose of Durvalumab and Tremelimumab~Day 28 of 28 Day cycle: Pre-determined dose of Durvalumab~Participants will undergo surgery on day 49 of Cycle 1. Surgery will be performed per institutional standard of care.~Adjuvant Treatment:~--Cycles 1 (28 days postoperatively) - 13:~---Day 1 of 28 Day Cycle: Pre-determined dose of Durvalumab"
89557735|NCT05701488|Experimental|Durvalumab + Tremelimumab + SIRT (Arm B)|"-Participants will be randomized into the treatment group in a 1:1 ratio and will receive interventions as outlined:~Neoadjuvant Treatment:~Cycle 1:~Day 3 of 28 Day Cycle: Pre-determined dose of Durvalumab and Tremelimumab~Day 31 of 28 Day Cycle: Pre-determined dose of Durvalumab~Day 1 of 28 Day Cycle: Yttrium-90~Participants will undergo surgery on Day 52 of Cycle 1. Surgery will be performed per institutional standard of care.~Adjuvant Treatment:~--Cycles 1 (28 days postoperatively) - 13:~---Day 1 of 28 Day Cycle: Pre-determined dose of Durvalumab"
88812376|NCT05380687|Experimental|Training A - PEEP 10-5-5-5|"The respiratory muscles of all participants will be trained in 4 consecutive blocks of 30 minutes during ventilation in neural pressure support mode (NPS) with a pressure support of 7 cmH2O.~During training A, the 4 blocks are~A1. PEEP 10 cmH2O | A2. PEEP 5 cmH2O | A3. PEEP *5* cmH2O | A4. PEEP 5 cmH2O~During the training, ventilator data will be recorded and respiratory muscles will be imaged using ultrasound.~Before and after each training block, an inspiratory and an expiratory hold (both ≤ 30 seconds) will be performed to assess fatigue."
88812377|NCT05380687|Experimental|Training B - PEEP 10-5-0-5|"The respiratory muscles of all participants will be trained in 4 consecutive blocks of 30 minutes during ventilation in neural pressure support mode (NPS) with a pressure support of 7 cmH2O.~During training B, the 4 blocks are~B1. PEEP 10 cmH2O | B2. PEEP 5 cmH2O | B3. PEEP *0* cmH2O | B4. PEEP 5 cmH2O~During the training, ventilator data will be recorded and respiratory muscles will be imaged using ultrasound.~Before and after each training block, an inspiratory and an expiratory hold (both ≤ 30 seconds) will be performed to assess fatigue."
88812378|NCT05348993|Experimental|50 mg dose of G03-52-01|150 subjects randomized to 50 mg of G03-52-01
88812379|NCT05348993|Experimental|100 mg dose of G03-52-01|150 subjects randomized to 100 mg of G03-52-01
88812380|NCT05348993|Placebo Comparator|Placebo|75 subjects randomized to placebo
88812381|NCT05341583|Experimental|Ensatinib|Ensatinib ( 225 mg, once daily), in accordance with the randomization schedule
88812382|NCT05341583|Placebo Comparator|Placebo|Placebo ( 225 mg, once daily), in accordance with the randomization schedule
88812383|NCT05340296|Experimental|Acute Youth Connect + TAU|Subjects will receive 12 weeks of post-discharge Acute Youth Connect intervention, in addition to regular post-discharge treatment as usual.
89519577|NCT05396651|Placebo Comparator|NICE guidelines group|"42 Children aged 5-15 years old fulfilling ROME IV criteria of IBS diagnosis and didn't have one of the following : o Abdominal pain or diarrhea that wakes the child from sleep~Delay in onset or progression of puberty.~Faltering growth.~Family history of inflammatory bowel disease, celiac disease.~History of significant weight loss .~Bleeding per rectum.~Persistence of severe vomiting or diarrhea~. Persistent joint pain.~Recurrent unexplained fever.~Unexplained pallor~they followed NICE guidelines for irritable bowel syndrome for 6 weeks"
89519578|NCT05396573|Experimental|RQ3013|
88812386|NCT05251896|Experimental|Plasma-free procedure|Use albumin solution, lactated Ringer's solution, normal saline as replacement fluid
89519579|NCT05396573|Active Comparator|Comirnaty|
89519580|NCT03812471|Experimental|Main study: 3D volumes acquisitions|3D volume acquisitions
89519581|NCT03812471|Experimental|Ancillary study: 2D and 3D acquisitions|2D standard measurements and 3D volumes acquisitions
89519582|NCT01093573|Experimental|Dose Level 1|Aza at 75 mg/m2 D1-7 & Midostaurin 25 mg BID D 8-21
89519583|NCT01093573|Experimental|Dose Level 2|Aza at 75 mg/m2 D1-7 & Midostaurin 50 mg BID D 8-21
89519584|NCT01093573|Experimental|Dose Level 3|Azacitidine 75 mg/m2 IV D1-7 & Midostaurin 75 mg PO BID D 8-21
89519585|NCT03484039|Experimental|Epilepsy Patients|The group will receive the module (a 1-2 hour course on either medication adherence, seizure documentation, memory improvement or stress management) right after a baseline assessment. A post assessment and delayed post assessment will be conducted after the module is administered.
89519586|NCT05396261|Experimental|Treatment arm|"Film forming silicone gel (7-0940) is an innovative gel that forms a full contact, flexible wound dressing for supporting mucosal conditions of the genital, rectal and perineal areas.~Film forming silicone gel (7-0940) is a semi-occlusive, non-resorbable, self-drying and transparent gel.~Film forming silicone gel (7-0940) may be directly applied to dry, wet, cracked and sensitive mucosal tissue.~Film forming silicone gel (7-0940) gel is bacteriostatic and inert. It contains no alcohols, parabens or fragrances."
88812387|NCT05215379|Other|neoadjuvant chemoradiation therapy|neoadjuvant chemoradiation therapy
88812388|NCT05215379|Experimental|neoadjuvant chemoradiation therapy +immunotherapy|neoadjuvant chemoradiation therapy +immunotherapy
88812389|NCT05212831|No Intervention|Standard of Care (SOC)|SOC is defined as the patient symptoms or complications based treatment.
88812390|NCT05212831|Experimental|Portable Oxygen Concentrator|"Inogen One® G4 Portable Oxygen Concentrator (POC) is used on a prescriptive basis by subjects requiring supplemental oxygen. It supplies a high concentration of oxygen and is used with a nasal cannula which channels oxygen from the concentrator to the subject.~Inogen One® G4 is designed to provide a flow of high purity oxygen. Inogen One® G4 may be used in home, institution, vehicle and various mobile environments."
88812391|NCT05192317|Experimental|Arm Sollievo Fisiolax|Sollievo Fisiolax
88812392|NCT05192317|Placebo Comparator|Arm Placebo|Placebo
88812393|NCT05183165|Other|Patients with Wilson's disease declaring pregnancy,|Patients with Wilson's disease declaring pregnancy.Followed in the reference, constituent, and competence centers for Wilson's disease and other rare copper-related diseases, spread over French national territory.
88812394|NCT05160805|Experimental|Treatment Group A|ONL1204 Ophthalmic solution (Dose A) administered by intravitreal injection
88812395|NCT05160805|Experimental|Treatment Group B|ONL1204 Ophthalmic solution (Dose B) administered by intravitreal injection
88812396|NCT05160805|Sham Comparator|Treatment Group C|Sham procedure without penetrating the eye
88812397|NCT05159063||Right heart catheterization|
88812398|NCT05155436|Experimental|Fixed-Dose Combination pill of Telmisartan and Amlodipine|Fixed-Dose Combination pill of Telmisartan 40 mg and Amlodipine 5 mg, once daily for 3 months
88812399|NCT05125900|Active Comparator|Resin modified glass ionomer|Group received proximal box elevation using resin modified glass ionomer
88812400|NCT05125900|Placebo Comparator|Glass hybrid|Group received proximal box elevation using glass hybrid
88812401|NCT05125900|Active Comparator|Bulk fill flowable resin composite|Group received proximal box elevation using bulk fill flowable resin composite
88812402|NCT05125900|Placebo Comparator|Ion-releasing material|Group received proximal box elevation using ion-releasing material
88812403|NCT05116514|Experimental|Case manager group|
88812404|NCT05116514|No Intervention|Control|
88812405|NCT05108311|Experimental|Treatment|The Treatment sequence including joint Manual therapy techniques and soft tissue release techniques is proposed.
88812406|NCT05103696|Experimental|Remimazolam group|Patients received remimazolam to maintain sufficient sedation (sufficient sedation as judged by MOAA/S ≤ 4 for 3 consecutive measurements) during endoscopy procedure. And patients were injected remifentanil 0.3μg/kg (infusion time > 1min) at the first time，When the analgesia was insufficient, Remifentanil can be added according to the situation.
88812407|NCT05103696|Active Comparator|EP group|Patients received Etomidate combined with propofol to maintain sufficient sedation (sufficient sedation as judged by MOAA/S ≤ 4 for 3 consecutive measurements) during endoscopy procedure. And patients were injected remifentanil 0.3μg/kg (infusion time > 1min) at the first time.When the analgesia was insufficient,Remifentanil can be added according to the situation
88812408|NCT05101915|Experimental|Interventional|Single arm trial involving all patients receiving IMP
88812409|NCT05078437|Experimental|Treatment optimization|Participants will undergo an evaluation of all the medications taken and changes will be proposed for treatment optimization.
88812410|NCT05072041|Experimental|Test group|Degradable embolic microsphere (Nexsphere™)
88812411|NCT05020366|Experimental|PrO-PEAR|This group will receive the optimized PrO-PEAR intervention (in addition to usual care).
88812412|NCT05020366|Active Comparator|Enhanced Usual Care|This group will serve as the control group and only receive a report of their child's performance and adherence to World Health Organization recommendations based on baseline data.
88812413|NCT05006261|Experimental|Tele-Tai Chi|Tele-Tai Chi intervention
88812414|NCT05004376|No Intervention|Non-adherent control|Control subjects will receive no text intervention and a 150 day follow-up phone call.
88812415|NCT05004376|Experimental|Non-adherent intervention|Intervention subjects will receive the text messaging intervention and a 150 day follow-up phone call.
88812416|NCT04992039|No Intervention|Control Arm|Participants of this arm will not receive the total WHO HEARTS package as an intervention. These participants will be screened in the designated area for universal BP screening via A&D arm-in device. Their diagnosis will be confirmed by measuring their BP by a Medical Officer via an Omron desktop oscillometer. The Medical Officers and UHC nurses of the control sites will be trained up on BP measurement using standard techniques, patient registration, data collection, etc.
88812417|NCT04992039|Experimental|Intervention Arm|Participants of this arm will receive all the components of WHO HEARTS technical package components as an intervention.
88812418|NCT04981418|Active Comparator|Control group|will receive standardised advice on management of pelvic girdle pain, through a discussion centred around 'Guidance for Mothers-to-be and New Mothers: Pregnancy-related Pelvic Girdle Pain' booklet (https://pogp.csp.org.uk/system/files/pogp-pgppat_3.pdf). This publicly available, specialist physiotherapy approved, standardised leaflet, provides information reflective of current best practice. The participant can use this as an ongoing resource. The physiotherapist will teach participants a standardised programme of exercises, typical of those provided within usual physiotherapy practice. Written explanation/illustrations of these exercises will be provided and the women asked to undertake these at home, three times/week.
88812419|NCT04981418|Experimental|Intervention group|"In addition to the control groups intervention of exercise and advice, women in the intervention group will be fitted with the customised pelvic support shorts (DM Orthotics Ltd, https://www.dmorthotics.com).~Prior to the first physiotherapy session, those women allocated to the intervention group will have recieved the support shorts in the post together with standardised written information on wear time/washing. At the first physiotherapy session (one hour), the woman will be asked to try them on so that the physiotherapist can review the fit and comfort of the shorts. The physiotherapist will reinforce the written advice about wear time and care of the shorts, and answer any queries / brainstorm any issues. At session two (30 minutes), ~10 days later, the physiotherapist will review the fit and wearing of the shorts, problem solve any issues that have arisen, and review exercises to ensure they are being performed correctly."
88964126|NCT02030730|No Intervention|Leaflets on child health and development|An attention control group received leaflet information on child health and development provided by the Greek National Health Services of the Ministry of Health. They cover topics such as vaccinations, common childhood illnesses, first aid guide on severe injuries and cuts, and nutrition. The topics did not overlap with the topics of the Seminar Series or the general purpose of the study. Control families received the seminar tip sheets after 6-month follow-up.
88964127|NCT02031224|Experimental|Keto-diet (KD)|Patients in the intervention arm (KD group) will receive a vegetarian very low protein diet (0.3 g proteins/kg ideal body weight per day) supplemented with ketoanalogues of essential amino acids (Ketosteril®, Fresenius Kabi, Bad Homburg, Germany), 1 capsule for every 5 kg of ideal dry body weight per day.
88964128|NCT02031224|Active Comparator|Low Protein Diet group (LPD)|"The patients in the control arm (LPD group) will continue their conventional low protein diet, with 0.6 g/kg per day (including high biological value proteins).~The total recommended energy intake is of 30 kcal/kg of ideal dry body weight per day in both arms."
89557736|NCT05700461|Experimental|Implantable microdevice (IMD) + Biopsy + Standard of Care Treatment|"Participants with confirmed or suspected metastatic Renal Cell Carcinoma (RCC) and who are candidates for standard of care metastatectomy or debulking/consolidative nephrectomy will be selected for study participation and will undergo study procedures as outlined:~Placement of 1-6 microdevice(s) 72 +/- 24 hours prior to scheduled, standard of care surgery. The number of microdevices implanted into a tumor will be made on a case-by-case basis based on tumor and participant factors before and during the procedure.~At the time of standard of care surgery, surgical removal of microdevice(s) along with surrounding tumor tissue.~Monitoring for safety endpoints during inpatient stay and at a follow-up clinic visit."
89557737|NCT05700279|Active Comparator|Stellate Ganglion Block Treatment|Participants randomly assigned to the Stellate Ganglion Block (SGB) condition will receive 2 SGB treatments separated by 2 weeks.
89557738|NCT05700279|Active Comparator|Cognitive Processing Therapy|Participants randomly assigned to the Cognitive Processing Therapy (CPT) condition will receive 1-week massed CPT treatment consisting of 10 CPT sessions given within a single 5-day period via telehealth.
89557739|NCT05700279|No Intervention|Usual Care|Participants randomly assigned to the Usual Care condition will not receive any active intervention.
89557740|NCT05698433||high Blood pressure variability team|The group with excessive blood pressure fluctuation during operation is high Blood pressure variability team
88964129|NCT02031367|Active Comparator|Corticosteroid|
88964130|NCT02031367|Experimental|Platelet Rich Plasma|
88964131|NCT02031497|Experimental|Drink with sweeteners|
89557741|NCT05696769||Youth with CTD Ages 8-12|"Youth (8-12 years) will be recruited for a qualitative interview using the exploratory questionnaire developed for the study. Parent/caregivers will also be asked questions related to their child's CTD. Participants will be asked for feedback on the ease of completion, content, readability and completion time.~After development of the TD Stigma scale, prior and new participants with CTD will be asked to complete the TD-Stigma scale with companion measures. Feedback on the scale will be elicited as well."
88964132|NCT02031497|Active Comparator|Drink without sweeteners|
88964133|NCT02031692|Active Comparator|Vitamin D and calcium supplement|
88964134|NCT02031692|No Intervention|Control|
88964135|NCT02031991|Experimental|A = PF-06439535|Intervention Description: Sterile vial 400mg, single-dose 5mg/kg administered as 90-minute infusion on day 1.
88964136|NCT02031991|Active Comparator|B = Bevacizumab-EU|Intervention Description: Sterile vial 400mg, single-dose 5mg/kg administered as 90-minute infusion on day 1.
89557742|NCT05696769||Supporters: Parents/Caregivers|Qualitative interviews will be administered and adapted to the caregiver's perspective. Parents/caregivers will also be asked to complete questionnaires child's CTD history, family history and impact of CTD on different aspects of the child's life. Participants will be asked for feedback on the ease of completion, content, readability and completion time.
89557743|NCT05696769||Provider/ advocate cohort|For providers and advocates, qualitative interview administered will begin with the participant's experience and qualifications in caring for individuals with CTD and adapted to the provider's perspective. Participants will be asked for feedback on the ease of completion, content, readability and completion time.
89557744|NCT05696769||Youth with CTD Ages 13-17|"Youth (13-17 years) will be recruited for a qualitative interview using the exploratory questionnaire developed for the study. Parent/caregivers will also be asked questions related to their child's CTD. Participants will be asked for feedback on the ease of completion, content, readability and completion time.~After development of the TD Stigma scale, prior and new participants with CTD will be asked to complete the TD-Stigma scale with companion measures. Feedback on the scale will be elicited as well."
88964137|NCT02031991|Active Comparator|C = Bevacizumab-US|Intervention Description: Sterile vial 400mg, single-dose 5mg/kg administered as 90-minute infusion on day 1.
88964138|NCT02032043||Annual MDA treated Group|This group will receive annual mass drug administration (Albendazole 400 mg plus Ivermectin) provided by the Ivorian Ministry of Health.
88964139|NCT02032043||Semiannual Mass Drug Administration|This group will receive semi-annual mass drug administration (Albendazole 400 mg plus Ivermectin) provided by the Ivorian Ministry of Health.
88964140|NCT02032134|Other|Patients with severe thrombocytopenia|Intervention Patients with severe thrombocytopenia with an active bleeding, in preparation for surgery, or after chemotherapy (prophylaxis of bleeding),will receive transfusion of Pooled Platelets Cryopreserved In DMSO With a New System
88964141|NCT02032186|Experimental|Mg++|Magnesium Citrate oral supplementation from early pregnancy; 160 mg twice per day.
88964142|NCT02032186|Placebo Comparator|Placebo|Placebo pills twice per day.
89026093|NCT00464984|Active Comparator|ILI-group|Intensive lifestyle intervention at a tertiary care rehabilitation center. Treatment included changes in both dietary habits (calori restriction) and physical activity with particularly high intensity the first 3 months.
88964143|NCT02032446|Experimental|Umbilical Cord Mesenchymal stromal cells (UC-MSC)|"Pentostatin will be given by intravenous infusion at a dose of 1 mg/m2 for 3 consecutive days. Thereafter, three Umbilical Cord Mesenchymal stromal cells (UC-MSC) infusions will be given at weekly interval starting from day 5. We will follow a dose escalating programme with progressively increasing doses of cells until the maximally tolerated dose (MTD) is achieved.~The dose escalating design will be characterised by the administration of 1x106 /kg UC-MSC per dose per three doses for the first three patients (total up to 3x106/kg). The second three patients will receive 2x106/kg UC-MSC per dose per three doses (total up to 6x106/kg). The third three patients will receive 3x106/kg UC-MSC per dose per three doses (total up to 9x106 cells/kg).~Since three dosages of cells are programmed for each group of 3 patients, a minimum of 9 patients should be studied, unless unacceptable acute infusion related toxicity is observed."
89557745|NCT05696769||Adults with CTD Ages (18-30)|"Adults with CTD (Ages 18-30) will be recruited for a qualitative interview using the exploratory questionnaire developed for the study.~Participants will be asked for feedback on the ease of completion, content, readability and completion time.~After development of the TD Stigma scale, prior and new participants with CTD will be asked to complete the TD-Stigma scale with companion measures. Feedback on the scale will be elicited as well."
89557746|NCT05696769||Supporters: Partners/Spouses/Significant others|For Partners/Spouses/Significant others, qualitative interview administered will begin with the participant's experience and qualifications in caring for individuals with CTD and adapted to the supporter's perspective. Participants will be asked for feedback on the ease of completion, content, readability and completion time.
89557747|NCT05692973|Experimental|Variable Test|Students will be taught a knowledge base comprised of 18 facts about Egypt. After learning the knowledge base to criterion, students will practice retrieving the knowledge base across four testing sessions spaced 24 hours apart. Students will receive different questions across testing sessions. Next, students will read 6 passages about Egypt and then answer literal and inferential questions about the passages. Immediately after reading the passages, students will get re-tested on their retention of the knowledge base and use of the knowledge base to form inferences. They will also get retested one week and one month later to examine students' long-term retention of the knowledge base and use to make inferences.
89557748|NCT05692973|Experimental|Repeated Test|Students will be taught a knowledge base comprised of 18 facts about Egypt. After learning the knowledge base to criterion, students will practice retrieving the knowledge base across four testing sessions spaced 24 hours apart. Students will receive the same questions repeated across testing sessions. Next, students will read 6 passages about Egypt and then answer literal and inferential questions about the passages. Immediately after reading the passages, students will get re-tested on their retention of the knowledge base and use of the knowledge base to form inferences. They will also get retested one week and one month later to examine students' long-term retention of the knowledge base and use to make inferences.
88964144|NCT02032537|Active Comparator|Callmax cream|
88964145|NCT02032537|Placebo Comparator|Placebo|
88964146|NCT02032576|Experimental|ECT for depressed patients|electroconvulsive therapy with a bipolar brief pulse square wave
88964147|NCT02032667|Experimental|Multi-player condition|The multi-player condition examines the aspect of online gaming and social interaction with adherence to the exergame.
88964148|NCT02032667|No Intervention|Single-player condition|This arm will look at whether those who play an exergame by themselves or with a computer generated player have the same adherence and use when compared to a multi-player condition.
88964149|NCT02033044|Experimental|cognitive remediation|Cognitive remediation programme in order to improve several cognitive domains.
88964150|NCT02033044|Active Comparator|Psychoeducation|Psychoeducation group in order to improve psychosocial functioning of patients.
88964151|NCT02033122|Active Comparator|Aerobic training|the intervention will be an aerobic training program. For the TG subjects, breathing exercises will have duration of 30 minutes and will be always followed by aerobic training sessions that will consist in 35 minutes divided in 5 minutes of warm-up, 25 minutes of aerobic training and 5 minutes of cool down. Initially, aerobic training will be performed at the heart rate (HR) corresponding to one third of the difference between the anaerobic threshold (AnT) and the respiratory compensation point (RCP) obtained in the incremental cardiopulmonary testing (CPET) and after two weeks of the adaptation, the intensity will increased to two thirds of the difference between AnT and RCP. The program will be performed twice a week, for 3 months.
88964152|NCT02033122|Sham Comparator|Breathing exercise|Patients from the control group will be taught breathing exercises with 30 min per session , twice a week , during 3 months. Every exercise will be performed in sets of 3 (2 min each) and 60 s of rest .
88964153|NCT02033356|Experimental|ACB with 30 ml lidocaine 1%|"Procedure/Surgery: Adductor canal block with lidocaine 1% The Continual Reassessment Method is used to calculate the dose level consecutively for every new cohort (2 subjects) in the study.~Possible dose levels are: 5, 10, 15, 20, 25 and 30 ml."
88964154|NCT02033356|Experimental|ACB with 25 ml lidocaine 1%|"Procedure/Surgery: Adductor canal block with lidocaine 1% The Continual Reassessment Method is used to calculate the dose level consecutively for every new cohort (2 subjects) in the study.~Possible dose levels are: 5, 10, 15, 20, 25 and 30 ml."
88964155|NCT02033356|Experimental|ACB with 20 ml lidocaine 1%|"Procedure/Surgery: Adductor canal block with lidocaine 1% The Continual Reassessment Method is used to calculate the dose level consecutively for every new cohort (2 subjects) in the study.~Possible dose levels are: 5, 10, 15, 20, 25 and 30 ml."
88964156|NCT02033356|Experimental|ACB with 15 ml lidocaine 1%|"Procedure/Surgery: Adductor canal block with lidocaine 1% The Continual Reassessment Method is used to calculate the dose level consecutively for every new cohort (2 subjects) in the study.~Possible dose levels are: 5, 10, 15, 20, 25 and 30 ml."
89026094|NCT00464984|Active Comparator|MLI|Moderate lifestyle intervention at a secondary care outpatient center. Treatment included moderate changes in dietary habits (calori restriction) and physical activity.
88964157|NCT02033356|Experimental|ACB with 10 ml lidocaine 1%|"Procedure/Surgery: Adductor canal block with lidocaine 1% The Continual Reassessment Method is used to calculate the dose level consecutively for every new cohort (2 subjects) in the study.~Possible dose levels are: 5, 10, 15, 20, 25 and 30 ml."
88964158|NCT02033356|Experimental|ACB with 5 ml lidocaine 1%|"Procedure/Surgery: Adductor canal block with lidocaine 1% The Continual Reassessment Method is used to calculate the dose level consecutively for every new cohort (2 subjects) in the study.~Possible dose levels are: 5, 10, 15, 20, 25 and 30 ml."
88964159|NCT02033720||Shockable arrest|Initial arrest rhythm shockable. This is either pulseless ventricular tachycardia (pulseless VT) or ventricular fibrillation (VF).
88964160|NCT02033720||Pulseless electrical activity|Initial arrest rhythm is pulseless electrical activity.
88964161|NCT02033720||Asystole|Initial arrest rhythm is asystole.
88964162|NCT02033733||Adequate cooling time|"Patients that reached target temperature within 4 hours of initiation of the hypothermia protocol will be in the adequate cooling time group."
88964163|NCT02033733||Inadequate cooling time|"Patients that did not reach target temperature within 4 hours of initiation of the hypothermia protocol will be in the inadequate cooling time group."
88964164|NCT02034045|Active Comparator|Usual Care|Patients randomized to the control group will continue to receive usual care from their Family Health Care Team. Usual care includes physician assessment and treatment and periodic augmentation of care in the community (CCAC or case manager, nurse practitioner) at the discretion of the treating physician.
88964165|NCT02034045|Experimental|Community Paramedicine|The intervention will consist of an initial visit and 3 follow-up visits at 3 month intervals over one year by a paramedic who has received additional training in chronic disease management, in addition to routine usual care and any additional visits prompted by the patient, the paramedic or the Family Health Care Team.
88964166|NCT02034136|Experimental|Ginsenoside|"Ginsenoside :~Intervention : ginsenoside, 3 gram / day, for 28 days in intervention group"
88964167|NCT02034136|Placebo Comparator|Dietary fiber fill|Dietary fiber fill manufactured to mimic Ginsenoside tablet
89557749|NCT05692973|Placebo Comparator|Placebo|Students will be taught a knowledge base comprised of 18 facts about Egypt. After learning the knowledge base to criterion, students will re-read the passages. They will not receive any questions. Next, students will read 6 passages about Egypt and then answer literal and inferential questions about the passages. Immediately after reading the passages, students will get re-tested on their retention of the knowledge base and use of the knowledge base to form inferences. They will also get retested one week and one month later to examine students' long-term retention of the knowledge base and use to make inferences.
89557750|NCT05690334|Experimental|Control group|No fluid coload was given. An initial infusion dose of prophylactic norepinephrine simultaneous with spinal anesthesia
89557751|NCT05690334|Experimental|Crystalloid - 5 ml/kg|5 ml/kg crystalloid coload combined with an initial infusion dose of prophylactic norepinephrine simultaneous with spinal anesthesia.
89557752|NCT05690334|Experimental|Crystalloid - 10 ml/kg|10 ml/kg crystalloid coload combined with an initial infusion dose of prophylactic norepinephrine simultaneous with spinal anesthesia.
88964168|NCT02034214|Experimental|Full Intervention|Life skills education vocational counseling Economic livelihoods reproductive health services social support
88964169|NCT02034214|Active Comparator|Education and health services alone|Life skills education Reproductive health services
88964170|NCT02034253||first episode psychosis|Unmedicated first episode psychosis patients that wish to enroll in a 16 week treatment regimen with the drug Risperidone.
88964171|NCT02034253||healthy demographic-matched controls|healthy controls will be matched to patients one to one based on: age, smoking status, parental socio-economic status, and gender. Healthy controls must be free from current or past Axis I mental disorders, 1st degree relative current or past Axis I mental disorders, and any other neurological conditions.
88964172|NCT02034279|Experimental|Intravenous infusion of albumin|Treatment arm will receive intravenous albumin on days 1 and 3 plus antibiotics
88964173|NCT02034279|No Intervention|No albumin|Only antibiotics
88964174|NCT02034370||Included patients|All ten patients included in this cohort. Shoulder surgery patients that are getting a nerve block and are at high risk for OSA. They will receive a Lung-function spirometry test and an overnight sleep test.
89557753|NCT05689411|Experimental|Musical Toy Group|The child and his parents in the experimental group were distracted by playing with the xylophone, a musical toy, 5 minutes before the peripheral vascular access procedure. The xylophone is a percussion wooden toy. There are two wooden bars on the xylophone that make melodious sounds when the metal plates are struck. The xylophone toy was introduced to the child and the parent, and they were given the opportunity to examine it. Before the procedure, one of the wooden sticks of the toy was given to the child and the other to the parent. Before, during and after the procedure, the child and his parents played together by making a melodic sound from the musical toy xylophone. While the child and his parents were playing with the toy, the researcher attached a tourniquet to the appropriate extremity of the child and determined the vein to which the vascular access would be performed.
89557754|NCT05689411|No Intervention|Control Group|No distraction technique was applied to the children in the control group before the vascular access procedure. After the procedure was explained according to the child's developmental level, the researcher applied the procedure to open a vascular access in accordance with the institutional policies.
89557755|NCT05685407|Experimental|Caffeine|During one of two counterbalanced experimental sessions, participants will ingest 300mg of caffeine orally via capsules.
89557756|NCT05685407|Placebo Comparator|Placebo|During one of two counterbalanced experimental sessions, participants will ingest placebo orally via capsules.
88964175|NCT02034812||Radiation Oncologists|"Radiation oncologists targeted for recruitment into the study must meet the following criteria:~Practicing, board-certified radiation oncologists~Perform consultations on at least 80 patients with prostate cancer annually~Each participant is asked to complete a questionnaire to assess the impact of Decipher on physicians' treatment recommendation. All participants use the same data collection instrument. Each participant's opinion is collected based on a random selection of cases."
89608661|NCT05582577|Active Comparator|Intravitreal bevacizumab injection alone|"After the eye examination, the eyes will be randomly divided into 2 groups {group A: intravitreal interjection of Bevacizumab and subthreshold micropulse laser, and group B: intravitreal injection of Bevacizumab alone}. For both groups, 3 intravitreal injections of bevacizumab with a dose of 1.25 mg will be performed, in sterile conditions at 1-month intervals as a loading dose.~A sham laser will be performed after the third injection in group B. Then, the intravitreal injection of Bevacizumab will be continued if the central thickness of the macula is equal to or greater than 300 microns.~The follow-up will be performed 2, 3, 4, 6, 8, 10, and 12 months after the first injection. In each follow-up (except for the first month), ophthalmological examinations and Optical Coherence Tomography will be performed."
89608662|NCT04149015|Experimental|POF|A 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and leucovorin (400 mg/m2), administered simultaneously over a 2-hour infusion period. Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating every 14 days for 4 cycles
89608663|NCT04140591|Placebo Comparator|Proton-pump inhibitor|PPI: Pariet EC 20 mg/QDAC
89608664|NCT04140591|Active Comparator|Propranolol+Proton-pump inhibitor|"Propranolol:~Propranolol 10mg BID initially and titrate dosage every week to achieve 25% drop of heart rate (keep heart rate>55 or systemic blood pressure>90mmHg)~PPI: Pariet EC 20 mg/QDAC"
89608665|NCT05582109|Experimental|Envafolimab, Lenvatinib Combined With TACE|Envafolimab, Lenvatinib Combined With TACE
88964176|NCT02034825||Practicing urologic surgeons|"US board-certified~Practicing urologic surgeons~Performing at least 40 radical prostate surgeries annually~Urologists will be excluded from participating in the study if:~They are unable to identify a the required number of eligible patient cases with available clinical data and tissue specimens;~They have spent less than 3 years in practice or perform less than 40 RP's per year~All participants will be asked to complete a questionnaire based on a random selection of retroactively selected cases."
88964177|NCT02034851||Dexamethasone|Intervention group
88964178|NCT02034851||Control|Placebo group (physiological saline)
88964179|NCT02034864|Experimental|Osteopathic manipulative treatment|6 sessions of standardized manipulative treatment
88964180|NCT02034864|Sham Comparator|Placebo of osteopathic manipulative treatment|6 sessions of standardized placebo of manipulative treatment
88964181|NCT02034942|Experimental|Non-sedation|"The experimental group will not receive sedatives. Patients are thoroughly and repeatedly informed by the staff of where they are, what have happened, and what type of treatment they are going to receive.~Participants will be awake and have a natural sleep rhythm. In case these patients develop and outward delirium, it is necessary to have a nurse or other caregiver at the bedside in order to calm the patient. Patients with delirium will be treated with haloperidol."
88964182|NCT02034942|Active Comparator|Sedation with daily wake-up|"The control group will be sedated to Ramsay score 3-4. The first 48 hours the patients will be sedated with propofol, after 48 hours midazolam will be used. During daytime, the patient will be awakened as the intravenous infusion of sedatives will be discontinued. The patient will be considered to be awake when he/she can perform at least three of the following four tasks:~Open the eyes to verbal commands.~Follow the examiner's instructions with the eyes.~Squeeze hands on request.~Stick out the tongue on request.~After a successful wake-up, the infusion of sedative will be resumed, starting on half of the pre-wake-up dose and adjusted to Ramsey score 3-4."
88964183|NCT02035020|Experimental|Gamma interferon|IFN gamma 1b (Immukin ®) will be administered by subcutaneous route at day 0, 14 and 28 at a dose of 100, 150 and 200 ug respectively.
88964184|NCT02035046|Other|study's population|
88964185|NCT02035059||Women with/without gestational diabetes|Women with/without gestational diabetes diagnosed by clinically routine 75 g oral glucose tolerance testing
88964186|NCT02035540||Decellularized human valves|Pulmonary heart valve replacement
88964187|NCT02035670||tradition diagnostic strategy|According to the current diagnistic procedures of FUO
88964188|NCT02035670||two-step diagnostic strategy|"First step is to differentiate FUO according to the onset of disease and invasive pathogens.~Second step is to further differentiate FUO according to trends of disease and inflammation scores."
88964189|NCT02035709|Active Comparator|TCI-PCA|Intravenous Patient-Controlled Analgesia with Target-Controlled Infusion
89608666|NCT04140123|Experimental|ZSP1601-Dose 1|ZSP1601-50mg once daily
89608667|NCT04140123|Experimental|ZSP1601-Dose 2|ZSP1601-50mg twice daily
89608668|NCT04140123|Experimental|ZSP1601-Dose 3|ZSP1601-100mg once daily
89608669|NCT04140123|Placebo Comparator|Placebo|Placebo
89557757|NCT05684276|Experimental|Experimental: Neodjuvant treatment + Adjuvant maintenance treatment|"Neodjuvant treatment:~Nivolumab: 360 mg intravenous Q3W Paclitaxel: 200mg/m2 infusion over 3 hours Carboplatin: AUC6 at the end of the Paclitaxel infusion~Neoadjuvant treatment will start within 1-3 days from enrollment. 3 cycles will be administered at 21-day (+/- 3 days) intervals (QW3) prior to surgery. Before surgery a tumor assessment will be done. Patients must leave the study if there is evidence of progression. Patients with stable disease or partial response may be considered for surgery.~Surgery: Surgery must be done within the 3rd-4th week (+7 days) from day 21 cycle 3 of neoadjuvant treatment (day 42-49 after day 1 of cycle 3)~Depending on surgery results the patient will receive:~Patients with degree of resection 'R0': Adjuvant treatment for 6 months with Nivolumab 480mg QW4~Patients with degree of resection 'R1' or 'R2': standard treatment according to local guidelines"
89557758|NCT05679427|Active Comparator|Arm A|Single fraction radiosurgery on bone metastases (21-24Gy x 1 fraction)
89557759|NCT05679427|Active Comparator|Arm B|Multi-fractioned stereotactic ablative radiotherapy (5 fractions delivered in 5 consecutive working days) with SIB on bone metastases (5Gy x 5 fractions + SIB up to 40-50Gy)
89557760|NCT05676385|Active Comparator|Dietary supplement/First concept Product 1 (containing 50 grams of carbohydrates)|All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
88812420|NCT04981041|Experimental|Potent P2Y12-Inhibition|Prasugrel 10mg (5 mg in patients ≥ 75 years old or weighing < 60 kg) q.d. per os or Ticagrelor 90mg bid per os
88812421|NCT04981041|Active Comparator|Clopidogrel|Clopidogrel 75mg q.d. per os
88812422|NCT04959422|Experimental|Active scheduling|Children who fail instrument vision screens will be scheduled at a community vision specialist office before departure from clinic and all no shows at the vision specialist office will be tracked and rescheduled.
88964190|NCT02035709|Active Comparator|PCA|Intravenous Patient-Controlled Analgesia
88964191|NCT02035774|Active Comparator|LSIB +SSNB|Patients will receive LSIB (31 ml ropivacaine 7.5 mg/ml)+ SSNB (4 ml Ropivacaine 5 mg/ml)
88964192|NCT02035774|Placebo Comparator|LSIB + placebo|Patients will receive LSIB (31 ml ropivacaine 7.5 mg/ml) + SSNB (4 ml saline)
88964193|NCT02035839|Other|Target Temperature Management of 34°C|In hospital target temperature management to achieve core body temperature of 34°C for 24 hours.
89519587|NCT03447613||elderly participants with surgery|The studied cohort were participants 50 years old or older, without a diagnosis of dementia, and scheduled to have orthopedic or urological surgery under spinal anesthesia at Shanghai 10th People's Hospital.
89519588|NCT05396183||3D-PCT group|Participant will receive three-dimensional printing co-planar template (3D-PCT) assisted CT-guided head and neck neoplasm biopsy and prospective accuracy and safety data will record.
88812423|NCT04912570|Experimental|Manual Thrombus Aspiration|Manual Thrombus aspiration in STEMI patients with Heavy thrombus burden (TIMI 0-1 or TB classification 4-5)
89519589|NCT03447535||classic oppositional defiant disorder|"CODD Group:  classic  oppositional defiant disorder~SDQ total difficulties score and the parents report SDQ total difficulties score:~Group CODD ( classic  oppositional defiant disorder): teacher report SDQ total difficulties score (≥ 12), parents report SDQ total difficulties score (≥14)"
88812424|NCT04912570|Active Comparator|Standard PCI|Conventional PCI according to the most recent guidelines in STEMI patients with no heavy thrombus burden (TIMI 0-1 or TB classification 4-5)
88812425|NCT04898725|Experimental|Vit D Group (randomized)|Subjects will be randomly assigned to receive a daily vitamin D supplementation (4800IU daily) for 8 weeks
88812426|NCT04898725|No Intervention|Control Group (randomized)|Subjects will be randomly assigned to receive a placebo for 8 weeks.
88812427|NCT04898725|Experimental|Preference Vit D Group (non-randomized)|Subjects with a strong preference to receive a daily vitamin D supplementation (4800IU daily) for 8 weeks.
88812428|NCT04898725|No Intervention|Preference no Vit D Group (non-randomized)|Subjects with a strong preference to receive usual care (not receiving vitamin D supplements) for 8 weeks.
88812429|NCT04891666|Experimental|Lactobacillus plantarum DSM 33464|1 sachet of Lactobacillus plantarum DSM 33464 (2 g) and 1 sachet of supplement YingKangWei per day for 12 weeks
88812430|NCT04891666|Placebo Comparator|placebo|1 sachet of placebo (2 g) and 1 sachet of supplement YingKangWei per day for 12 weeks
88812431|NCT04890145|Experimental|Mild to severe hearing loss|
88812432|NCT04879043|Experimental|HDP-101|"Participants will receive HDP-101 intravenously at one dose every 3 weeks (21 day cycle) until disease progression, intolerable toxicity, Investigator's discretion or patient withdrawal.~During the phase 1 tolerability of different dose levels will be evaluated. During the phase 2a dose expansion part the recommended phase 2 dose (RP2D) of HDP-101 will be administered."
88812433|NCT04875559||Breast cancer surgery patients.|Patients scheduled for day-case unilateral breast conserving surgery or mastectomy with or without axillary lymph node dissection or sentinel lymph node biopsy. No intervention.
89026095|NCT04328272|Experimental|Hydroxychloroquine|tablet hydroxychloroquine (HCQ). Day-1 (initial) 1st dose, 3 tablets (200 mg per tablet), 2nd dose after 6 hours, 3 tablets (200 mg per tablet) per oral. From day 2 to 7 (maintenance dose), 2 tablets twice a day.
89557761|NCT05676385|Active Comparator|Dietary supplement/First concept Product 2 (containing 50 grams of carbohydrates)|All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized
89557762|NCT05676385|Active Comparator|Reference product (containing 50 grams of carbohydrates)|All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized
89557763|NCT05669820|Active Comparator|Salovum|Salovum, an egg yolk powder will be orally at dose of 11 g 3 times daily.
89557764|NCT05669820|Placebo Comparator|Placebo|Placebo, an egg yolk powder will be orally at dose of 11 g 3 times daily.
89557765|NCT05665322|Active Comparator|Control|
89557766|NCT05665322|Experimental|Porto-scanner guidance with Angio-CT|
89557767|NCT05664698|Experimental|SKILLS-ER|Emotion regulation training
89026096|NCT04328272|Active Comparator|Azithromycin|Tablet azithromycin (AZC) 500 mg orally as a single dose on day 1, followed by 250 mg orally once a day on days 2 to 7.
89557768|NCT05663203|Experimental|Supportive care (CRCWeb intervention)|Patients and caregivers attend a CRCweb intervention over 8 weeks. Patients and caregivers complete interviews and surveys throughout the trial.
89557769|NCT05662540|Experimental|PET/MR|This is a prospective, single-arm clinical study. Subjects who meet the inclusion criteria will receive PET/MR examination within 28 days before treatment after signing the informed consent form for pre-treatment evaluation. Stage I/II patients received PET/MR again 21-35 days after 2 and 4 courses of standard treatment for mid-term and final efficacy evaluation. Stage III/IV patients received PET/MR again 21-35 days after 3 and 6 courses of standard treatment for mid-term and final efficacy evaluation. Follow-up assessments are then continued, every 12 weeks for the first year, and every 24 weeks thereafter (clinical symptoms, physical examination, enhanced CT of the cervix, abdomen, and pelvis, and enhanced MR of the nasopharynx) until disease progression (PD), death, withdrawal of informed consent, or study finish. For subjects with suspected PD, histopathological results should be obtained whenever possible to confirm or exclude PD status.
89557770|NCT05661006|Placebo Comparator|Control group|Subjects taking control product
89557771|NCT05661006|Experimental|Active group|Subjects taking active product
89557772|NCT05659797|Experimental|FES BPET-DBT|FES-BPET/DBT imaging session
89557773|NCT05659173||1- normotensive women|Women with vitamin D deficiency and normotensive during pregnancy
89557774|NCT05659173||2- women with hypertensive disorder in pregnancy|Women with Vitamin D deficiency and hypertensive disorder in pregnancy
89557775|NCT05658952|Active Comparator|Angiography-guided PCI|Patients will receive PCI according to the interpretation of angiography findings by the Interventional Cardiologist.
89557776|NCT05658952|Experimental|Microcatheter-derived FFR|Patients will receive PCI according to the plan derived from the interpretation of the FFR pullback obtained with microcatheter FFR performed by the Interventional Cardiologist before and after PCI.
89557777|NCT05658952|Experimental|Angiography-derived FFR|Patients will receive PCI according to the plan derived from the interpretation of the FFR pullback obtained with angiography-derived FFR performed by the Interventional Cardiologist before PCI. The angiography-derived FFR can be repeated after PCI to check the results and eventually apply correcting maneuvers.
89557778|NCT05641051|Experimental|Metoclopramide group|Patients will receive 10 mg intravenous metoclopramide / 6 hours.
89557779|NCT05641051|Placebo Comparator|Control group|Patients will receive the same volume of intravenous placebo / 6 hours.
89557780|NCT05633329|Experimental|single ESPB|single injection at level T8
89557781|NCT05633329|Experimental|dual ESB|dual injection at level T7 and T9
89557782|NCT05632926|Experimental|CBL-514 40mg|
89557783|NCT05632926|Experimental|CBL-514 60mg|
89557784|NCT05632926|Experimental|CBL-514 80mg|
89557785|NCT05631626|Active Comparator|25mg CTx-1301 (Dexmethylphenidate tablet)|All subjects will be titrated to their optimal dose during the dose-optimization phase. The starting dose for all subjects at Day 0 is 25mg. Each subject is expected to be on their optimal dose for 2 sequential weeks prior to the randomization phase. Subjects will be randomized (1:1) to their optimal dose or placebo in the 7-day, double-blind, randomization phase.
89557786|NCT05631626|Active Comparator|37.5mg CTx-1301 (Dexmethylphenidate tablet)|All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 25mg, 37.5mg, or 50mg . Each subject is expected to be on their optimal dose for 2 sequential weeks prior to the randomization phase. Subjects will be randomized (1:1) to their optimal dose or placebo in the 7-day, double-blind, randomization phase.
89557787|NCT05631626|Active Comparator|50mg CTx-1301 (Dexmethylphenidate tablet)|All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 25mg, 37.5mg, or 50mg . Each subject is expected to be on their optimal dose for 2 sequential weeks prior to the randomization phase. Subjects will be randomized (1:1) to their optimal dose or placebo in the 7-day, double-blind, randomization phase.
89557788|NCT05631626|Placebo Comparator|Placebo|Subjects will be randomized (1:1) to their optimal dose or placebo in the 7-day, double-blind, randomization phase.
89557789|NCT05627128|Experimental|Arm1: Crohn's disease patients + DAIN|Participants will have 10 weeks of DAIN intervention (From week 1 to week 10)
89026097|NCT04328272|Placebo Comparator|Suger Tablets|Placebo (sugar tablet) twice daily for 7 days
89026098|NCT04328194|Experimental|Study Group|80 patients with breast cancer
89026099|NCT04328194|Placebo Comparator|Control Group|20 healthy controls aged ( 19 to 69 years ) from healthy volunteers after informed consent.
89026100|NCT03272750|Experimental|Bioscalin® new formulation with Galeopsis Segetum|2 placebo capsules + 1 Bioscalin with Galeopsis Segetum table
89026101|NCT03272750|Active Comparator|REFERENCE PRODUCT|2 reference product capsules + 1 placebo tablet
89026102|NCT03272750|Placebo Comparator|PLACEBO|2 placebo capsules + 1 placebo tablet
89026103|NCT04371289||COVID-19 outpatients|Mild COVID-19 outpatients managed by General Practitioners in Northern Italy (Lombardy)
89557790|NCT05627128|No Intervention|Arm 2: Crohn's disease patients no intervention|Participants will continue consuming their usual diet, with no intervention
89026104|NCT04371289||COVID-19 inpatients|Mild, moderate and severe inpatients managed in different Italian Hospitals, mostly in Northern Italy (Lombardy)
89026105|NCT00465023|Experimental|Proton Beam Radiation|Proton radiation therapy
89026106|NCT00491790|Sham Comparator|1|Sterile Water
89026107|NCT00491790|Active Comparator|Montelukast|Dissolved granules in sterile water
89026108|NCT02892994|Experimental|Ultrasound|Subjects will receive 5 minutes of ultrasound treatment at 0.4 W/cm^2 and 100% duty cycle on each masseter muscle.
89026109|NCT02892994|Placebo Comparator|Placebo|Subjects will receive 5 minutes of ultrasound treatment at zero power on each masseter muscle.
89026110|NCT04369183||Study Group|Patients with primary focal segmental glomerulosclerosis or minimal change disease who were treated using rituximab (375 mg/m2/wk for 1-4 weeks) following resistance to or relapse after at least one set of prior therapies including corticosteroids, calcineurin inhibitors or mycophenolic acid derivatives.
89026111|NCT03272009|Experimental|Treatment A|oral EYP001a
89026112|NCT03272009|Experimental|Treatment B|oral EYP001a
89026113|NCT03272009|Experimental|Treatment C|oral EYP001a
89026114|NCT03272009|Experimental|Treatment D|oral EYP001a
89026115|NCT03272009|Placebo Comparator|Treatment E|oral placebo
89026116|NCT03272009|Active Comparator|Treatment F|oral Entecavir
89026117|NCT03272009|Experimental|Treatment G|oral EYP001a plus subcutaneous injection of Peg-INFα2a
89557791|NCT05626673|Experimental|Prayer app|Participants will be given the Pray.com app and directed to use it daily.
89557792|NCT05626218|Experimental|Stress ball group|A stress ball will be applied to pregnant women with anxiety during NST.
89557793|NCT05626218|No Intervention|Control group|Participants in this group will consist of people who do not routinely do any practice on their own to reduce anxiety symptoms.
89557794|NCT05623488|Experimental|Dose Level 1|3.00 x 10^7 CAR T cells administered intratumoral
89557795|NCT05623488|Experimental|Dose Level -1|3.00 x 10^6 CAR T cells administered intratumoral
89557796|NCT05621967|Experimental|Silent Breathing / Tonation Breathing Techniques (TBT)|"Twice a week during the patient's 8 weeks of pulmonary rehabilitation:~For first 4 weeks, twice a week - 20 min of silent quiet breathing while sitting.~Next 4 weeks, twice a week - 20 min of TBT guided by a facilitator virtually"
89557797|NCT05621967|Experimental|Silent Breathing / Music Driven Vocal Exercises (MDVE)|"Twice a week during the patient's 8 weeks of pulmonary rehabilitation:~For first 4 weeks, twice a week - 20 min of silent quiet breathing while sitting.~Next 4 weeks, twice a week - 20 min of MDVE guided by a facilitator in-person"
89557798|NCT05621967|Experimental|Tonation Breathing Techniques (TBT) / Silent Breathing|"Twice a week during the patient's 8 weeks of pulmonary rehabilitation:~For first 4 weeks, twice a week - 20 min of TBT guided by a facilitator virtually~Next 4 weeks, twice a week - 20 min of silent quiet breathing while sitting."
89557799|NCT05621967|Experimental|Music Driven Vocal Exercises (MDVE) / Silent Breathing|"Twice a week during the patient's 8 weeks of pulmonary rehabilitation:~For first 4 weeks, twice a week - 20 min of MDVE guided by a facilitator in-person~Next 4 weeks, twice a week - 20 min of silent quiet breathing while sitting."
89557800|NCT05618366|Experimental|Tazemetostat and Venetoclax|All participants will receive a combination of oral 800 mg tazemetostat BID and oral venetoclax. Since this is a phase 1 trial, the dose of venetoclax will be determined by the investigators per a sequential dose escalation (3+3). Participants will be provided study drug in the form of pills to take at home. Study participants will need to regularly come to the clinic for blood work, imaging, and to monitor and side effects. Participants may receive study drug until their cancer progresses or for up to 24 months.
89557801|NCT05610683|Experimental|SHFVE-HD group|Hemodialysis sessions using the VieX™ (Polysulfone, surface area: 2.1 m², sterilization gamma, ultrafiltration coefficient: 104.3 ml/h/mmHg, Asahi Kasei Medical, Japan).
89557802|NCT05610683|Experimental|MCO-HD group|Hemodialysis sessions using the Theranova 500™ (Baxter healthcare Corporation Deerfield, USA; surface area 2 m², ultrafiltration coefficient: 59 ml/h/mmHg).
89557803|NCT05609461||Chronic stroke patients with knee hyperextension|
89557804|NCT05600985||DED after FS-LASIK|patients with dry eye disease (DED) after refractive surgery (RS）
89557805|NCT05600985||DED without FS-LASIK|patients with dry eye who did not have refractive surgery
89557806|NCT05600985||normal control|subjects with no ocular symptoms and no previous ocular surgeries
89557807|NCT05599399|Active Comparator|Patients receiving gum acacia|Group one will receive gum acacia extract as an add-on therapy on daily basis
89557808|NCT05599399|No Intervention|Patients receiving no intervention|Group two will not receive add-on therapy; they will receive standard care only.
89557809|NCT05599373|Active Comparator|Active rTMS over bilateral dorsolateral prefrontal cortex|Active rTMS over bilateral dorsolateral prefrontal cortex. Participants will receive up to 20 rTMS sessions within the 4-week treatment period.
89026118|NCT03272009|Experimental|Treatment H|oral EYP001a plus subcutaneous injection of Peg-INFα2a
89026119|NCT03272009|Placebo Comparator|Treatment I|oral placebo plus subcutaneous injection of Peg-INFα2a
89026120|NCT00498888|Active Comparator|1|Women were prescribed a 3 month supply of Tolterodine SR 4 mg (Detrusitol SR 4 mg, Pfizer Pharmaceuticals Israel LTD) . After the randomization she needs to get the first prescription from her doctor, and followed this protocol every three weeks. Her doctor how already knows this research were explained how to take the drug. After finished this protocol she get the money she pay after sending the receipts and the empty boxes.
89033053|NCT02943512|Experimental|Discharge day of Procedure|Subjects in this arm will be discharged the same day of their cardiac device implant if deemed safe by treating physician.
89033054|NCT02943512|No Intervention|Control|Subjects in this arm will remain in the hospital overnight per standard of care and will be discharged the next day if deemed safe by treating physician.
89557810|NCT05599373|Active Comparator|Active rTMS over left dorsolateral prefrontal cortex|Active rTMS over left dorsolateral prefrontal cortex and sham rTMS over right dorsolateral prefrontal cortex. Participants will receive up to 20 rTMS sessions within the 4-week treatment period.
89557811|NCT05599373|Sham Comparator|Sham rTMS over bilateral dorsolateral prefrontal cortex|Sham rTMS over bilateral dorsolateral prefrontal cortex. Participants will receive up to 20 rTMS sessions within the 4-week treatment period.
89557812|NCT05591898|Experimental|Progressive relaxation exercises group|Participants will be randomly selected by a computer based system (Block randomization was used to keep the sample size of the groups similar. Random Allocation Software (Ver. 1.0.0) will be used to allocate the patients to groups). Selected participants will be invited to a meeting which will be held face-to-face and in a quiet environment. Progressive Relaxation Exercises will be explained to this group in a step-by-step manner whose surgery date is determined to undergo bariatric surgery by the relevant researcher. After this stage, participants will be followed to do the exercises regularly for a month by a researcher. Patients will fill the Amsterdam Preoperative Anxiety and Information Score Scale preoperatively at the hospital. After the surgery, the patients will be evaluated by the researchers in terms of pain scores and analgesic usage frequency in the recovery room and 1st, 4th, 8th, 12th, 24th, 36th and 48th hours data will be collected in the postoperative service.
89033055|NCT02925468|Experimental|Intervention group|A standard initial lateral cephalogram radiograph will be taken of all subjects, unless this is already available within the specified age range. An intra-oral scanner will be used to accurately record the occlusal relationships prior to insertion of the fixed anterior bite plane (bite turbos) (T0) and repeated immediately after placement (T1). Each subject will then be re-scanned on a six weekly basis for a period of six months (T2-T5). Conventional clinical photographs and three-dimensional stereophotogrammetry will be used to assess the vertical facial relationships at T0-T5. A further lateral cephalogram radiograph will be taken at T5.
89557813|NCT05591898|No Intervention|Control group|This group will be the randomized selected patients who will not get any intervention. Patients will fill the Amsterdam Preoperative Anxiety and Information Score Scale preoperatively at the hospital. After the surgery, the patients will be evaluated by the researchers in terms of pain scores and analgesic usage frequency in the recovery room and 1st, 4th, 8th, 12th, 24th, 36th and 48th hours data will be collected in the postoperative service.
89557814|NCT05589740|Experimental|Intervention|Intervention group consisting of culturally-tailored healthy eating advice through daily text messages for 2 months (delivery phase); a subsequent reinforcement phase of 2-months to repeat the text messages; and a subsequent maintenance phase of 2-months with no text messages.
89557815|NCT05589740|Active Comparator|Control|Control group consisting of general healthy eating advice through daily text messages for 2 months (delivery phase); a subsequent reinforcement phase of 2-months to repeat the text messages; and a subsequent maintenance phase of 2-months with no text messages.
89557816|NCT05588739|Experimental|Treatment Right-Away|Cognitive Behavioral Therapy using exposure, relaxation, and rescripting - Child utilizes behavioral and cognitive therapy techniques of exposure therapy and cognitive restructuring.
89557817|NCT05588739|No Intervention|Waitlist Control|Waitlist control group will complete pre and post assessments at beginning and end of wait period.
89557818|NCT05587998|Experimental|AZD4041 and morphine|Participants will receive an IV dose of morphine on Days 1 and 15. From Days 2 to 15, participants will receive an oral dose of AZD4041 once daily.
89557819|NCT05587998|Placebo Comparator|Placebo and morphine|Participants will receive an IV dose of morphine on Days 1 and 15. From Days 2 to 15, participants will receive an oral dose of placebo once daily.
89557820|NCT05585398|Experimental|LMRC (left with micro-/right with conv- needle)|
89557821|NCT05585398|Experimental|RMLC (right with micro-/left with conv- needle)|
89557822|NCT05585398|Experimental|LCRM (left with conv-/ right with micro-needles)|
89557823|NCT05585398|Experimental|RCLM (right with conv-/left with micro-needles)|
89557824|NCT05579860|Experimental|Olezarsen Dose Level 1|Participants will receive two doses of Dose Level 1 each, using one of the following two sequences: (i) AI on Day 1 of Treatment Period 1, followed by vial on Day 1 of Treatment Period 2; or (ii) vial on Day 1 of Treatment Period 1, followed by AI on Day 1 of Treatment Period 2. A washout period of 28-42 days will be maintained between the 2 treatment periods.
89557825|NCT05579860|Experimental|Olezarsen Dose Level 2|Participants will receive two doses of Dose Level 2 each, using one of the following two sequences: (i) AI on Day 1 of Treatment Period 1, followed by vial on Day 1 of Treatment Period 2; or (ii) vial on Day 1 of Treatment Period 1, followed by AI on Day 1 of Treatment Period 2 A washout period of at least 28 days will be maintained between the 2 treatment periods.
89557826|NCT05571735||TB cohort|"TB cohort - Bacteriologically confirmed TB patients (18 years and above)~One of the following three COVID-19 vaccines will be provided based on availability of supply from the Ministry of public health, Thailand as an intervention for the study."
89557827|NCT05571735||Healthy comparator|"Comparator- Clinically healthy individuals (54 in healthy comparator)~One of the following three COVID-19 vaccines will be provided based on availability of supply from the Ministry of public health, Thailand as an intervention for the study."
89557828|NCT05569005|Active Comparator|THS|Subjects who are not willing to quit smoking.
89557829|NCT05569005|Active Comparator|Cigarette|Subjects who are not willing to quit smoking.
89557830|NCT05569005|Active Comparator|Smoking Abstinence|Subjects who are willing to quit smoking.
89557831|NCT05561491|Experimental|ONCOS-102|ONCOS-102 will be administered by intratumoral (IT) injection at 1.0×10^12 VP/dose with the potential to de-escalate dosing to 3.0×10^11 VP/dose.
89608670|NCT04140201|Active Comparator|Receive oral hypoglycemic +omega 3|Eicosapentanoic acid + standard treatment
89608671|NCT04140201|Active Comparator|Receive oral hypoglycemic +statin|Simvastatin + standard treatment
89608672|NCT04140201|Active Comparator|Receive oral hypoglycemic +fibrate|Fenofibrate +standard treatment
89608673|NCT04140201|No Intervention|Receive oral hypoglycemic only|Standard treatment only
89608674|NCT05581875|Experimental|Part 1 : Dose finding|"Belantamab mafodotin will be administered by intravenous infusion as a combination therapy as a calculated dose on Day 1 of every other 28-day cycle.~Belantamab mafodotin starting dose for Part 1:~Cohort 1: 1.4 Q8W = 1.4 mg/kg on Day 1 of every other 28-day cycle~Cohort 2: 1.9 Q8W = 1.9 mg/kg on Day 1 of every other 28-day cycle~Daratumumab 1800mg SC (fixed dose) on:~Cycles 1-2: days 1, 8, 15, 22 Cycles 3-6: days 1, 15 Cycles 7+: day 1~Pomalidomide: 4 mg/d on days 1-21 of every 28-day cycle.~Dexamethasone: 40 mg/d on days 1, 8, 15, 22 of every 28-day cycle in participants < 75 years; 20 mg/d on days 1, 8, 15, 22 of every 28-day cycle in participants ≥ 75 years."
89608675|NCT03945045|Experimental|SCV|TIVAD implanted through subclavian vein under real-time ultrasound guidance
89608676|NCT03945045|Experimental|IJV|TIVAD implanted through internal jugular vein under real-time ultrasound guidance
89557832|NCT05561491|Experimental|ONCOS-102 and balstilimab|ONCOS-102 will be administered by IT injection at 3.0×10^11 VP/dose with planned dose escalation to 1.0×10^12 VP/dose. Balsitilmab will be administered at a fixed dose of 300 mg by intravenous (IV) injection.
89557833|NCT05558527|Experimental|Social support from a romantic partner|Participants will hold the hand of their romantic partner
89557834|NCT05558527|Active Comparator|Social support from a stranger|Participants will hold the hand of a stranger
89557835|NCT05558527|No Intervention|No social support|Participants will hold a stress ball
89557836|NCT05556252|Experimental|Intervention Group|
89033056|NCT02925468|No Intervention|Control group|A control group of subjects from the treatment waiting list who meet the inclusion criteria will be used. An intra-oral scanner will record the baseline occlusal relationship (T0) and will be repeated after six months (T5). The control group will also have a standard pre-treatment lateral cephalogram radiograph taken, as well as conventional and three-dimensional stereophotogrammetry at baseline (T0) and after six months (T5). This will allow changes resulting from growth to be assessed whilst no active orthodontic treatment has taken place.
89557837|NCT05556252|Placebo Comparator|Control Group|
89557838|NCT05554237|Experimental|PF-07612577|Part-1: Dose 1, Dose 2, Dose 4, Dose 5 Part-2: Cohort 2-5
89557839|NCT05554237|Placebo Comparator|Placebo|Part-1: Dose 1-5 Part-2: Cohort 2-4
89557840|NCT05554237|Experimental|PF-06264006|Part-1: Dose 3, Dose 5
89557841|NCT05550870|Experimental|Group 1|Group 1 will be given Raw Fenugreek seed powder. The dose will be 7.5grams two times a day i.e, before breakfast and before dinner for the period of three months.
89557842|NCT05550870|Experimental|Group 2|Group 2 will be given Roasted Fenugreek seed powder, 7.5 grams twice a day before breakfast and dinner for the period of three months.Total number of arms will be 2.
89557843|NCT05546151|Experimental|Cohort J1|
89557844|NCT05546151|Experimental|Cohort J2|
89557845|NCT05546151|Experimental|Cohort J3|
89557846|NCT05538312|Experimental|ARV-471 with and without itraconazole|ARV-471 administered as a single dose in Period 1 and Period 2. Itraconazole administered once a day for 11 days in Period 2.
89557847|NCT05529862|Experimental|Locally advanced or metastatic Breast Cancer Women|"Study Procedures:~Additional tumour sampling during the pre-treatment biopsy scheduled as per routine care,~A post-treatment tumour biopsy,~One pre-treatment and one post-treatment blood sampling."
89557848|NCT05529277||Dyad of person with cognitive impairment and caregiver|Households identified in routine care receiving a home-based Dementia Care Management.
89557849|NCT05529043|Active Comparator|MINISTOP app|Receives the MINISTOP app for 12-months.
89557850|NCT05529043|Experimental|MINISTOP Plus Program|Receives the MINISTOP app for 12-months and receives Community Group Mini.
89208352|NCT00506350|Experimental|GSK1562902A AD F1 Primed Group|Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of an adjuvanted (AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation1 (F1) in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.
89557851|NCT05520593|Experimental|Complex Carbohydrate Drink Group|The patients will drink a 400ml drink that contains 50g of complex carbohydrates, 3 hours prior to the surgery. The drink will be given once at the preoperative holding area. Patients are not allowed to eat solid foods after 12am the morning of surgery and can only drink clear fluids up to 3 hours prior to the surgery.
89557852|NCT05520593|No Intervention|No-Complex Carbohydrate Drink Group|These patients will follow normal institutional preoperative fluid management guidelines, this consist of no solid foods after 12am the morning of surgery. Patients are allowed to drink clear liquids (water, clear fruit juices, coffee) from 12am the morning of surgery up to 3 hours prior to the surgery.
89557853|NCT05516316|Experimental|EP395 high dose|EP395 in repeated doses. Orally, once-daily administration of 3 EP395 capsules for 21 days
89557854|NCT05516316|Experimental|EP395 low dose|EP395 in repeated doses. Orally, once-daily administration of 1 EP395 capsule and 2 placebo capsules for 21 days
89557855|NCT05516316|Placebo Comparator|Placebo|Matched placebo capsule, once-daily administration of 3 placebo capsules for 21 days
89557856|NCT05515393|Experimental|XY03-EA Tablet (300mg group)|XY03-EA 150 mg/tablet, 2 tablets，three times a day； XY03-EA Placebo 150 mg/tablet, 2 tablets，three times a day； For 90 days, continuous administration Other Name: low dose
89557857|NCT05515393|Experimental|XY03-EA Tablet (600mg group)|XY03-EA 150 mg/tablet, 4 tablets ,three times a day, For 90 days, continuous administration Other Name:high dose
89557858|NCT05515393|Placebo Comparator|XY03-EA Placebo Tablet|XY03-EA Placebo Tablet 150 mg/tablet, 4 tablets,three times a day, For 90 days, continuous administration Other Name: placebo
89557859|NCT05507476|Active Comparator|Desmopressin group|"The patient will receive two puffs of desmopressin acetate 10 µg/puff in the side of the nasal cavity ipsilateral to the obstructed lacrimal duct (20 μg totally) 60 minutes before surgery Minirin 10 μg/0.1 ml per spray, Ferring Pharmaceutical Company. Three normal saline-soaked packs will be placed in the middle meatus for 5 minutes immediately before the start of surgery."
89557860|NCT05507476|Active Comparator|Epinephrine group|"The patient will receive topical 1:100,000 epinephrine in the side of the nasal cavity ipsilateral to the obstructed lacrimal duct via 3 soaked packs placed in the middle meatus for 5 minutes immediately before the start of surgery. The patient will also receive two puffs of normal saline prepared in emptied Minirin bottle in the same nasal cavity 60 minutes before surgery."
89557861|NCT05507450|Experimental|V181 High-Potency Level Group|Participants will receive a single 0.5mL subcutaneous (SC) dose of V181 High-Potency vaccine.
89557862|NCT05507450|Experimental|V181 Mid-Potency Level Group|Participants will receive a single 0.5mL SC dose of V181 Mid-Potency vaccine.
89208353|NCT00506350|Experimental|GSK1562902A AD F2 Primed Group|Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of an adjuvanted (AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 2 (F2) in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.
89519590|NCT03447535||intrafamilial oppositional defiant disorder|"IODD group: intrafamilial oppositional defiant disorder~SDQ total difficulties score and the parents report SDQ total difficulties score:~Group IODD (Intrafamilial Oppositional Defiant Disorder): teacher report SDQ total difficulties score normal (<12), parents report SDQ total difficulties score abnormal (>16)"
89519591|NCT04454177||SMART watch|Medical records from patients aged 18 years or older undergoing Transcatheter Aortic Valve Replacement
89519592|NCT05320315|Other|ACTIVE and UNTREATED|This was an intraindividual comparison study. Active (DM sunscreen) treated zone and Untreated zone are compared
89519593|NCT04155203|Experimental|Perrigo active|
89519594|NCT04155203|Active Comparator|Reference Active|
89519595|NCT04155203|Placebo Comparator|Vehicle control|
89519596|NCT05320081|Experimental|Camrelizumab combined with CD30 CAR-T|This study have only one arm that is Camrelizumab combined with CD30 CAR-T experimental arm.
89519597|NCT04238143|Experimental|tSVF + PRP Arm1|Tissue Stromal Vascular Fraction (tSVF) + Platelet-Rich Plasma (PRP) Concentrate
89519598|NCT04238143|Experimental|tSVF + PRP + cSVF Arm 2|Tissue Stromal Vascular Fraction (tSVF) + Platelet-Rich Plasma (PRP) Concentrate + Cellular Stromal Vascular Fraction (cSVF)
89519599|NCT04238143|Experimental|Normal Saline IV + cSVF Arm 3|Cellular Stromal Vascular Fraction (cSVF); Sterile Normal Saline Intravenous (IV) Introduction
89519600|NCT05394467||Lipedema|Women with diagnosed lipedema
89519601|NCT03447457|Other|standard oxygen group|Patients are treated with standard oxygen delivered through nasal cannula, face mask or non-rebreathing reservoir
89519602|NCT03447457|Other|High-flow oxygen group|Patients are treated with high-flow nasal cannula oxygen continuously applied via large-bore nasal prongs with a gas flow rate of 50 L/min
89519603|NCT05392439|Experimental|taVNS treatment|The taVNS treatment is performed at auricular cymba concha. The stimulation parameters are set as follows: train on-time of 2 seconds and off-time of a 3-second pulse width of 0.5 ms, pulse frequency of 25 Hz, and amplitude of 0-2 milliamp (at the maximum level tolerated by the subject).
89519604|NCT05392439|Sham Comparator|sham-taVNS treatment|Sham-taVNS is performed with the same parameters as taVNS except that electrical stimulation is applied at the elbow area.
89519605|NCT03129529|Experimental|focused shock wave|Treatment was administered directly to the middle of muscle bellies of the spastic triceps surae muscle in three sessions, with one week interval. During each session, 3000 pulses (1500 shots in the gastrocnemius and 1500 shots in the soleus muscle) were delivered at 5 Hz. The intensities of FSWT were 0.10 mJ/mm2.
89519606|NCT03129529|Experimental|radial shock wave|Treatment was administered directly to the middle of muscle bellies of the spastic triceps surae muscle in three sessions, with one week interval. During each session, 3000 pulses (1500 shots in the gastrocnemius and 1500 shots in the soleus muscle) were delivered at 5 Hz.The intensities of RSWT were 2.0 bar.
89519607|NCT03447301|Experimental|Extra virgin olive oil|Extra virgin olive oil (30mL) daily
89519608|NCT03447301|No Intervention|Control|No consumption of extra virgin olive oil
89519609|NCT05320003|Other|Adults with pes planus|Detailed clinical examination of cases with pes planus will be performed. Inky foot analysis of both feet will be performed to confirm the diagnosis of pes planus in the subjects included in the study. Staheli arch index and Chippaux-Smirak Index will be calculated for each foot based on the footprints obtained. According to the Staheli Arc Index 1 and above, according to the Chippaux-Smirak Index 0.45 and above will be considered as pes planus, static foot pressure measurement will be performed with a pedobarography device in all cases. Peak pressure, maximum force and total foot area values will be obtained. Balance assessment of the patients will be performed with a computerized static posturography device. Individuals will be graded according to the fall index results, as low, medium and high risk. It will be determined whether there is a fall risk with the Timed Up and Go Test, which is one of the clinical balance tests.
89519610|NCT03447223||ADHD-patients|The children and adolescent 6-15 years old with ADHD. Diagnoses of the children with ADHD were made in Xijing Hospital according to criteria described in the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). Children with ADHD had an IQ score above 70.
89519611|NCT03447223||Controls-healthy children|Age- and gender- matched healthy 6-15 years old children and adolescent.
89519612|NCT03447145|Experimental|TQ-B3203|
89519613|NCT03127579|Experimental|Longer meal duration|Families eat longer as they usually do
89519614|NCT03127579|No Intervention|Usual meal duration|Families eat as long as they usually do
89519615|NCT03447067|Experimental|Conventional surgery|"comprised 9 patient undergoing surgical removal of deeply impacted mandibular third molar by regular manor.~(Based on :Panorama and CBCT ) technique : 1- flap design 2- bone removal 3- tooth division 4- closure flap (suture)"
89519616|NCT03447067|Experimental|computer guided surgery|"comprised 9 patient undergoing surgical removal of deeply impacted mandibular third molar using computer guided surgical cutting stent.~Based on (panorama , CBCT and fabricating computer guided stent technique: 1- flap design 2- accurate setting stent in a predesign site 3- bony window removing according to the stent design 4- surgical separation of the teeth with extraction the remaning part . 5- identify the nerve 6- replace the bony window in to original place with stability 7- closure and depridment"
89519617|NCT03057613|Experimental|Pembrolizumab + post operative radiotherapy|IMRT 60-66Gy for 6 weeks in combination with Pembrolizumab every 3 weeks for 16 weeks
89519618|NCT03446911|Active Comparator|SABR|Patients receive prior to surgery (lobectomy) SABR.
89519619|NCT03446911|Active Comparator|SABR + pembrolizumab|Patients receive prior to surgery (lobectomy) SABR + 2 rounds of pembrolizumab
89519620|NCT02974309|Experimental|Sleep Extension|All youth in this condition are asked to extend their sleep to 10 hours or at least one hour, whichever is longer.
89557863|NCT05507450|Experimental|V181 Low-Potency Level Group|Participants will receive a single 0.5mL SC dose of V181 Low-Potency vaccine.
89557864|NCT05507450|Placebo Comparator|Placebo|Participants will receive a single SC 0.5 mL dose of placebo.
89557865|NCT05507138|Experimental|AKL-T01|Participants in the intervention group will complete 25 minutes of AKL-T01 per day, 5 days/week, for 6 weeks. AKL-T01 trains rapid multitasking on an iPad in an immersive videogame-like environment. Participants complete go/no-go + navigation exercises by moving the iPad to navigate a character on a path while tapping when a certain stimulus is presented and ignoring other stimuli. Participants will also receive weekly 45-minute metacognitive strategy coaching sessions delivered by a clinician. Sessions use guided questions and worksheets (shared virtually) to help participants reflect on their experience with AKL-T01 and link it to daily functioning, generate strategies for daily activities, and explore any emotional responses that arise during gameplay.
88964194|NCT02035839|Other|Target Temperature Management of 32°C|In hospital target temperature management to achieve core body temperature of 32°C for 24 hours.
88964195|NCT02035839|Other|Target Temperature Management of 33°C|In hospital target temperature management to achieve core body temperature of 33°C for 24 hours.
88964196|NCT02035878|Active Comparator|Probiotics|400mg probiotic capsule taken once daily for ten weeks
88964197|NCT02035878|Placebo Comparator|Placebo (rice flour)|400mg placebo capsule containing rice flour taken once daily for ten weeks
88964198|NCT02035891|Active Comparator|colchicine|0.5mg/d colchicine
88964199|NCT02035891|Placebo Comparator|placebo|appearance is same as colchicine
88964200|NCT02035956|Experimental|IVAC MUTANOME RBL001/RBL002|All participants will be treated with the personalized IVAC MUTANOME vaccine with or without prior treatment with RBL001/RBL002 vaccine depending on expression of these two antigens. Vaccines will be administered intra-nodally.
88964201|NCT02036151|Experimental|Experimental, control|Mothers in the experimental group were instructed to chew 1 pellet of xylitol gum (Fennobon Oy, Yrittäjäntie, Finneland -gum, 3 times ) for a period of 3 months. control mothers did not receive any medications. All mothers received oral hygiene instructions and restorative treatment when needed. Offspring of both the experimental and control groups did not receive any medication and were followed for at 6,12, 18 and 24 month from initiation of mothers consumption. month
88964202|NCT02036151|Active Comparator|fluoride varnish application|The control group participated in a preventive program under the supervision of the Pediatric Dentistry Department. The program activities consisted of oral hygiene instructions, fluoride varnish application (Duraphat 5% Na F ,Ultradent Products, Utah, USA) and restorative treatment when needed.
88964203|NCT02036255|Experimental|Taurolidine Urokinase|Taurolock Urokinase is used weekly in this arm substituting the classic Taurolock HEP500
88964204|NCT02036255|Active Comparator|Taurolidine Heparin|Taurolock HEP 500 is used as locking solution after each dialysis session
88964205|NCT02036450|Experimental|ILR group|Receive implantable loop recorder (ILR, Medtronic Reveal LINQ(TM)) with continuous monitoring, and will be followed by daily automated remote transmissions. Study visits are scheduled annually until the 4th visit, and furthermore, endpoints are collected via lookup in medical records and registries on at least an annual basis until the finalization of the trial.
88964206|NCT02036450|No Intervention|Control group|Followed according to standard care, i.e. by their general practitioner. Study visits are scheduled at inclusion and after 3 years. Furthermore, the participants are contacted by telephone after 1 and 2 years of follow-up, and endpoints are collected via lookup in medical records and registries on at least an annual basis until the finalization of the trial.
88964207|NCT02037022|Experimental|Pivotal Response Treatment Package|Pivotal Response Treatment Package (PRT-P)
88964208|NCT02037022|No Intervention|Delayed Treatment Group|Delayed Treatment Group (DTG)
88964209|NCT02037113||Patient underwent PAD-Stent|Patient who underwent angioplasty and/or atherectomy with stent placement for Femoro-popliteal disease and Intravascular ultrasound was performed after stent deployment.
89608677|NCT04148469|Experimental|dry needling and TENS|A dry needling treatment was performed on trapezius trigger point number 2, and just after thar, a TENS curretn was applied. Patients will be reassed on fourth day after treatment.
89608678|NCT04148469|Placebo Comparator|Placebo|A placebo dry needling was performed on trapezius trigger point number 2. Patients will be reassed on fourth day after treatment.
89608679|NCT04148469|Experimental|dry needling|A dry needling treatment was performed on trapezius trigger point number 2. Patients will be reassed on fourth day after treatment.
89608680|NCT04406025||participation in Regional Anesthesia Seminar|this group consists of anesthesiologists that have attended a Regional Anesthesia Seminar taking place once a year
88964210|NCT02037269||All participants|Female patients ≥30 years of age with known breast cancer scheduled for breast-conserving surgery (BCS) +/- sentinel lymph node biopsy (SLNB) or axillary lymph node dissection (ALND)
88964211|NCT02037542|Experimental|Diet and Exercise|Prospective, observational, cohort study, with a proposed start date of May 2013 and proposed end date of June 2018. Our goal is to gather data on a total of 200 patients: 100 patients (study group) will be prospectively enrolled, while data on another 100 patients (control) will be accessed through retrospective data collection. Number of patients to be analyzed will depend on enrollment and patient compliance. We would like to enroll the proposed 100 patients in the first 1-3 years of the study (approximately 30 per year).
88964212|NCT02038062|Experimental|Sevoflurane|Sevoflurane Preconditioning
88964213|NCT02038062|No Intervention|No Sevoflurane|No Sevoflurane Preconditioning
88964214|NCT02038855|Active Comparator|IIDEA|Patients in the Integrated Intervention for Dual Problems and Early Action (IIDEA) arm will receive the 10 session intervention administered in person and via telephone.
88964215|NCT02038855|No Intervention|Usual Care|Patients in this arm receive usual care for dual-diagnosis symptoms of mental health and substance use. They receive 5 check-in calls from a care manager to assess safety.
89608681|NCT04406025||no participation in Regional Anesthesia Seminar|this group consists of anesthesiologists that have not attended a Regional Anesthesia Seminar taking place once a year
89608682|NCT04140045|Experimental|Hypohydrated|Participants will be required to restrict their water intake during cycling in the heat (90-120 minutes at 35°C), in order to achieve a body mass loss of approximately 3%.
88964216|NCT02039141|Experimental|Every Little Step Counts Intervention|Exercise classes (3/week) Lifestyle sessions (1/week)
88964217|NCT02039141|No Intervention|Delayed ELSC Intervention Group|Control group (delayed intervention group)
89557866|NCT05507138|Placebo Comparator|Enhanced Metacognitive Strategy Training|"In the control group, participants will complete-at the same frequency and duration as the intervention group-iPad-based games designed to provide general cognitive stimulation (word searches, checkers, and spot the differences between two pictures). Concurrently with these cognitive stimulation games, participants will receive weekly metacognitive strategy coaching sessions akin to that described above."
89557867|NCT05502757|Experimental|Provision of paper FV vouchers (VOUCHER) condition|Families in the VOUCHER condition will be provided 6, $15 paper vouchers ($90 total) for the purchase of fresh FV at a partnering Food City location in Knoxville, TN.
89557868|NCT05502757|Experimental|Home delivery of fresh FV (DELIVERY) condition|Families in the DELIVERY condition will be provided access to an online Food City account to purchase up to $90 fresh FV for home delivery, delivered by research staff at the time of their choosing.
89557869|NCT05495282|No Intervention|Group A: Traditonal Lecture|Group A (n=30) will receive a baclofen pump refill and programming instruction via the traditional lecture method performed by a single faculty member. The traditional lecture will consist of a PowerPoint lecture for 30 minutes, a demonstration of the refilling and programming technique for 10 minutes, and participant hands-on practice refilling and programming a baclofen pump for 20 minutes. Group A will have time to practice refilling and programming baclofen pumps with the guidance of a single faculty member during the traditional 60-minute lecture.
89608683|NCT04140045|Experimental|Euhydrated|Participants will be provided with water intake that matches their sweat losses during cycling in the heat (90-120 minutes at 35°C)
88964218|NCT02039193|Experimental|adherence priming|"To investigate various types of how to conduct a standardized CBT-protocol, all therapists are tutored in peer dyads (tandem peer tutoring). Immediate before sessions 1 to 5, the therapists are required to contact the tandem-partner face-to-face or via self-phone to deliberate the forthcoming session by a 5 to 10 minute brief communication (primings; comparable to Flückiger & Grosse-Holtforth, 2008).~Adherence priming: Immediately before sessions 1 to 5, therapists have a five-minute conversation about how to implement the disorderspecific interventions that are described in the treatment protocol. These communications are focused on therapists' understanding of patients GAD and the related comorbidities and how these issues can be addressed in the prescriptive treatment protocol."
88964219|NCT02039193|Experimental|resource priming|Resource priming: Immediately before sessions 1 to 5, therapists have a five-minute conversation about how to implement strengths-based micro-interventions in the forthcoming session. Strengths-based micro-interventions addresses therapists explicit focus on patients' preexisting strengths and abilities, subtle changes and improvements during therapy (potential recources) as well as motivational preparedness, readiness and goals (motivational resources; Grawe, 2006; Flückiger, et al., 2010).
88964220|NCT02039193|Experimental|supportive resource priming|Supportive resource priming: The supportive resource priming condition has the very same protocol as the resource priming condition (5 brief tandem peer tutorings). The only difference in the procedure is that the therapists are allowed to integrate a helpful significant person of the patients (such as the partners or the best friends) around session 1 and 7 to encourage and support the patient to realize their treatment plans (active integration of interpersonal resources). However, the integration of a significant other person does not touch the CBT-treatment protocol.
88964221|NCT02039453|Experimental|Fentanyl arm|The subjects of this arm will consist of the patients who undergo colonoscopy with sedative agents, propofol and fentanyl.
88964222|NCT02039453|Active Comparator|Pethidine arm|The subjects of this arm will consist of the patients who undergo colonoscopy with sedative agents, propofol and pethidine.
88964223|NCT02039492|Experimental|A|Denervation
89608684|NCT05586165|No Intervention|Holdout|
88964224|NCT02039492|Active Comparator|B|Treatment with aldactone
88964225|NCT02030769|Experimental|Pronase|Add pronase 20000 U in 80ml pretreatment mixture plus 5ml Dimethicone and 1g sodium bicarbonate.
88964226|NCT02030769|Sham Comparator|control|No pronase in 80ml pretreatment mixture plus 5ml Dimethicone and 1g sodium bicarbonate.
88964227|NCT02039583||full cohort|All singleton births in England. See 'statistical analysis' for denominator specification for individual outcomes.
89608685|NCT05586165|Experimental|Simple Reminder|
89608686|NCT05586165|Experimental|Flu Tag Along|
89608687|NCT05586165|Experimental|Covid-19 Booster + Flu Bundle|
89608688|NCT03944265|Experimental|Supportive care (treatment decision counseling session)|Patients complete a treatment decision counseling session/interview about genetic testing and supportive/palliative care with a qualified member of the research team in-person or via telephone. Health care providers receive a 1-page summary of session results for use in treatment shared decision making at the next office visit.
89608689|NCT04148547|Experimental|transcranial direct current stimulation|
89608690|NCT04148547|Placebo Comparator|Sham transcranial direct current stimulation|
89608691|NCT03588897|No Intervention|Normal Diet|Elderly patients receiving normal diet
89608692|NCT03588897|Experimental|Nutritional Support|Elderly patients receiving normal diet with nutritional support (Nutridrink Multi Fibre 2x100 ml per day)
89608693|NCT03941847|Experimental|music|The experimental group will benefit from musical listening during a classic period of induction of anesthesia
89608694|NCT03941847|No Intervention|silence|The control group will have a usual care.
89608695|NCT05582421|Sham Comparator|calcium hydroxide|calcium hydroxide will be placed as intracanal medication between visits.
89608696|NCT05582421|Active Comparator|diclofenac sodium|diclofenac sodium will be placed as intracanal medication between visits
89608697|NCT03897933||Erector spinae plane block group (ESP)|Single- shot ultrasound guided ESP block with 30 ml 0.25% bupivacain at the T10 vertebral level was performed preoperatively to patients in the ESP group (Group I).
89608698|NCT03897933||non- blocked Group|consists of the patient group without any procedure
89608699|NCT03588663|Experimental|Bionic Leg|Participants will wear the Bionic Leg during a series of different activities including a timed-up-and-go, balance tests, 6-min walk test and sit-to-stand exercises.
89033057|NCT00530036||Continent|"54% of 699 patients followed as outpatient by the Fondation des Services d'Aide et de Soins à Domicile in Geneva without urinary incontinence"
88964228|NCT02039596|Experimental|vegetarian breakfast|Diet: Vegetarian food items
88964229|NCT02039596|Experimental|Swedish Breakfast|Diet: Swedish food items
89557870|NCT05495282|Experimental|Group B: Microvideo|Group B (n=30) will receive an asynchronous 10-minute micro-video on the topic for which no face-to-face interaction with faculty will be conducted. The micro-video will be provided on a 12.9-inch iPad pro for each participant to view individually. The micro-video group will also have the opportunity to practice pump refilling before the post-evaluation. Participants in Group B will have the micro-video instruction available while practicing hands-on baclofen pump refilling and programming. The maximum time allowed to view the micro-video and practice hands-on baclofen pump refilling and programming will be 30-minutes. The time that each participant in group B spends reviewing the micro-video and practicing hands-on pump refilling and programming will be recorded. The participant may view and rewind the video as many times as needed in the 30-minute period. The live demonstration and the procedural video describe identical steps involved in refilling and programming the baclofen pump.
89517421|NCT03011528|Other|VDC - IE & TEMIRI & Surgery|"Patients in Arm B receive~VDC-IE & TEMIRI: Intensified induction phase:~4 cycles of VDC (Vincristine-Doxorubicine-Cyclophosphamide) association alternative with 4 cycles of IE (Ifosfamide-Etoposide) association if poor response after the 4th treatment, followed by:~4 cycles of TEMIRI (Temozolomide-Irinotecan) association~Local treatment by surgery of primary tumour/metastatic sites (outside pulmonary sites): indicated before of after consolidation phase (BuMel) among multidisciplinary decision. Radiotherapy can be added~Consolidation BuMel High dose chemotherapy (Busulfan-Melphalan) followed by Peripheral Blood Stem Cell Infusion~Maintenance phase~1st year : VC (Vincristine Cyclophosphamide) association~2nd year : Cyclophosphamide po 25 mg/m²"
89519621|NCT02974309|Sham Comparator|Routine|All youth in this condition are asked to follow the routine that their clinical team has established.
89519622|NCT03446833|Experimental|All Subjects|Subjects who meet the intraoperative criteria will receive The LFP Beta aDBS System.
89519623|NCT03446755|Experimental|Intrauterine balloon (Cook medical)|Insertion of a hearth shaped intrauterine balloon immediately after hysteroscopic adhesiolysis and left in place for 7 days under antibiotic prophylaxis.
89519624|NCT02733367|Experimental|Infacort|Infacort® granules
89519625|NCT03446677|Experimental|Asymptomatic persons with HIV|
89557871|NCT05494125|Experimental|ESP Catheters with Ropivacaine 0.2%|
89557872|NCT05494125|Placebo Comparator|ESP Catheters with Saline Solution|
89519626|NCT03446599|Experimental|Hydroxocobalamin|Participants in this arm will receive one intravenous 5-gram dose of hydroxocobalamin reconstituted in 200ml of normal saline over 10-15minutes at the time of initiation of cardiopulmonary bypass.
89519627|NCT03446599|Experimental|Methyelene blue|Participants in this arm will receive one intravenous 2mg/kg dose of methylene blue diluted in 200ml of normal saline over 10-15minutes at the time of initiation of cardiopulmonary bypass.
89557873|NCT05492422|Experimental|CET-then-BPT|Families receive CET in Phase 1 followed by BPT in Phase 2
89557874|NCT05492422|Experimental|BPT-then-CET|Families receive BPT in Phase 1 followed by CET in Phase 2
89557875|NCT05492422|Experimental|Waitlist then CET+BPT|Families do not receive either intervention in Phase 1 and then receive both CET and BPT concurrently in Phase 2
89557876|NCT05492422|Experimental|CET+BPT then 'waitlist' (follow-up)|Families receive CET and BPT concurrently in Phase 1, and then are followed in Phase 2 with not additional intervention
89557877|NCT05492006|Active Comparator|Group A: intentional contact with nature|Group A volunteers will take a light walk along the park with green space in a single 1-hour session with an emphasis on sense-directed appreciation guided by research team.
89557878|NCT05492006|Active Comparator|Group B: indirect contact with nature|The members of Group B will watch a video with the images of nature during 4 consecutive 15-minute sessions accompanied by the researcher, totaling 1 hour.
89557879|NCT05484401|Experimental|Test Product|Ibuprofen 200mg Oral Liquid Capsule, Placebo of Ibuprofen 200mg Oral Tablet
89557880|NCT05484401|Active Comparator|Reference Product|Ibuprofen 200mg Oral Tablet, Placebo of Ibuprofen 200mg Oral Liquid Capsule
89557881|NCT05484401|Placebo Comparator|Placebo|Placebo of Ibuprofen 200mg Oral Liquid Capsule, Placebo of Ibuprofen 200mg Oral Tablet
89557882|NCT05473117||Patient Group|A single cohort consisting of 230 patients referred for CT Coronary Angiography (CCTA) at risk of coronary artery disease. All patients will undergo both CCTA and CMRA
88964230|NCT02039596|Experimental|English breakfast|Diet: English food items
88964231|NCT02039596|Experimental|Lacto-vegetarian breakfast|Diet: Lacto-vegetarian food items
88964232|NCT02039596|Experimental|Swedish omnivore breakfast|Diet: Swedish breakfast with meat items
88964233|NCT02039609||Omnivores|No intervention, habitual diet
88964234|NCT02039609||Vegetarians|No intervention, habitual diet
88964235|NCT02039609||Vegans|No intervention, habitual diet
88964236|NCT02039609||Vegetarians consuming fish|No intervention, habitual diet
88964237|NCT02039622||Patient under study condition|Patient under study condition
88964238|NCT02039869|Experimental|Proton Pump Inhibitor|Patients will receive proton pump inhibitor therapy with omeprazole twice daily while we observe for improvement in reflux symptoms. We will compare the confocal endomicroscopy images in the responders to non-responders at the end of 8 weeks to determine if confocal endomicroscopy can select patient that would benefit most from proton pump inhibitor therapy.
89519628|NCT03446599|Placebo Comparator|Normal saline|Participants in this arm will receive an intravenous administration of 200ml normal saline over 10-15minutes at the time of initiation of cardiopulmonary bypass.
89519629|NCT05230225|Experimental|Notification Letter Arm|Providers that will receive an electronic Physician Notification Letter.
89519630|NCT05230225|No Intervention|Control Group|Providers that will not be contacted.
89519631|NCT02856451||Patients Treated with Nivolumab followed by Encephalitis Event|Case series reported to the sponsor from various health care facilities
89519632|NCT03979183|Experimental|Intervention|Therapeutic exercise
89519633|NCT03979183|No Intervention|Control|Usual care
89519634|NCT03684655|Experimental|[18F]F-AraG|"radiofluorinated imaging agent, [18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine)~Trade name: VisAcT"
89557883|NCT05469230||Typically developed children group|Typically developed children will be from both genders. the age range will be (8-16) years old and will be recruited from public governmental schools
89557884|NCT05469230||Beta thalassemia group|children diagnosed with beta thalassemia major and intermedia will be recruited from Abo-El-Rish Pediatric Hospital. the age will be (8-16) years and will be from both genders
89557885|NCT05468814|Experimental|Z-plasty|It is a surgical technique in which a Z-shaped section of the transverse carpal ligament is performed, to later join both ends with a resorbable stitch.
89557886|NCT05468814|Active Comparator|Conventional|It is a surgical technique in which a complete section of the transverse carpal ligament is performed, without subsequent closure.
89557887|NCT05461547|Other|Usual Care|
89557888|NCT05461547|Experimental|Lung Ultrasound|
89557889|NCT05457101|Experimental|with AI-based biliopancreatic EUS navigation system|The endoscopists in the experimental group will be assisted by EndoAngel, which can in real-time prompt standard stations and anatomical structures during EUS.
89033058|NCT00530036||Incontinent|"46% of 699 patients followed by the Fondation des Services d'Aide et de Soins à Domicile in Geneva and with an urinary incontinence"
89557890|NCT05457101|No Intervention|without AI-based biliopancreatic EUS navigation system|The endoscopists in the contrpl group performs the examination routinely without special prompts.
89557891|NCT05456139|Active Comparator|Treatment as Usual Only|"During 2 of the 3 six-month periods of participation, families will receive Treatment as Usual (TAU) only. Families in the TAU control condition will receive usual care and EI service in their community, which will be tracked with the BSRC Intervention History Form. Because all families join My Baby Navigator and will be screened by the SoCo CheckUp, families in both conditions will have access to the Seamless Path for Families which includes online tools about social communication developmental milestones. Families will also have access to Autism Navigator About Autism in Toddlers, the ASD Video Glossary, and the Autism Navigator How-to Guide for Families, a self-guided online course."
89557892|NCT05456139|Active Comparator|ESI-MC plus Treatment as Usual|During 1 of the 3 six-month periods of participation, families will receive 24 weekly sessions of Early Social Interaction via Mobile Coaching (ESI-MC) by a trained early intervention provider. ESI-MC is an evidence-based parent-implemented intervention for toddlers with ASD. ESI teaches parents how to support their child's social communication, language, play and behaviors in everyday routines, activities, and places. Program planning entails building consensus with families on priority targets for the child and teaching strategies and supports for the parents using manualized conversational steps, Baby Navigator social communication milestones, and ESI content for families to practice 25 hours per week. Families will be invited to participate in the online Autism Navigator How-To Guide, a self-guided web-based course and companion online group education meetings. Families will also receive Treatment as Usual (TAU).
89557893|NCT05454241|Experimental|anti-CD7 UCAR-T cells|
89608700|NCT03588663|Active Comparator|Control|Participants will complete a series of different activities including a timed-up-and-go, balance tests, 6-min walk test and sit-to-stand exercises without wearing the bionic leg (control condition).
89608701|NCT03580473|Experimental|SATURNO II|1 drop, 4 times a day, in the eye to be operated, 1 day before surgery until 15 days after surgery
89608702|NCT03580473|Active Comparator|Vigadexa®|1 drop, 4 times a day, in the eye to be operated, 1 day before surgery until 15 days after surgery
89608703|NCT03581721|No Intervention|The control group|"Control group according to usual practices: no active warming (no fluid warming). The fluid warmer device will be set up but not activated. The control group will receive IV fluid coload at room temperature through the fluid warmer set to off. The device is hidden"
89608704|NCT03581721|Experimental|The warming group|"IV fluid warming with the enFlow® or Fluido®Compact IV fluid warmer : Women will receive IV fluid coload warmed to 40°C through the enFlow® or Fluido®Compact device. The box will be also hidden. The fluid warmer will be turned off at the end of surgery, just before transfer to the PACU."
88964239|NCT02039869|Experimental|Sucralfate|Patients will receive sucralfate therapy four times a day while we observe for improvement in reflux symptoms. We will compare the confocal endomicroscopy images in the responders to non-responders at the end of 8 weeks to determine if confocal endomicroscopy can select patient that would benefit most from sucralfate therapy.
88964240|NCT02040012|Active Comparator|AZP-531|subcut administration once or twice daily
88964241|NCT02040012|Placebo Comparator|Mannitol|subcut administration once or twice daily
88964242|NCT02040038|Experimental|LIVE Arm|Participation in 3D virtual environment for DSMT/S for a period of 12 months.
88964243|NCT02040038|Active Comparator|Website|Participation in 2D website for DSMT/S for a period of 12 months.
88964244|NCT02040051|Active Comparator|GROUP A: Sound isolation / Music therapy|"PREINTERVENTION: First hour. The patient will remain under the usual conditions of intensive care unit~INTERVENTION: Second hour. Sound isolation~INTERVENTION: Third hour. Music therapy~POSTINTERVENTION: Fourth hour. The patient will remain under the usual conditions of intensive care unit"
88964245|NCT02040051|Active Comparator|GROUP B: Music therapy / Sound isolation|"PREINTERVENTION: First hour. The patient will remain under the usual conditions of intensive care unit~INTERVENTION: Second hour. Music therapy~INTERVENTION: Third hour. Sound isolation~POSTINTERVENTION: Fourth hour. The patient will remain under the usual conditions of intensive care unit"
88964246|NCT02040064|Experimental|Treatment|"Cohort 1: Tremelimumab 3 mg/kg every 4 Weeks plus Gefitinib 250 mg/daily, 6 patients (+ 6 patients if 3 mg/kg is the MTD)~Cohort 2: Tremelimumab 6 mg/kg every 4 Weeks plus Gefitinib 250 mg/daily, 6 patients (+ 6 patients if 6 mg/kg is the MTD)~Cohort 3: Tremelimumab 10 mg/kg every 4 Weeks plus Gefitinib 250 mg/daily, 6 patients (+ 6 patients if 10 mg/kg is the MTD)"
88964247|NCT02040103|Experimental|Intermittent Pneumatic Compression(IPC)|The intervention group will be receiving Intermittent Pneumatic Compression(IPC)
88964248|NCT02040103|No Intervention|No Intermittent Pneumatic Compression|patients will not receive Intermittent Pneumatic Compression
88964249|NCT02040129|Experimental|Acrysof toric IOL|Acrysof Toric intraocular lens in congenital cataract
89033059|NCT02922387|Experimental|Varenicline + Behavioral support|varenicline and behavioral support
89033060|NCT02922387|Active Comparator|Behavioral support|behavioral support
89608705|NCT04148859|Experimental|pregnant women|women who have to undergo amnioreduction due to TTTS
89557894|NCT05448196|Experimental|Intervention|Patients randomized to the intervention arm will be enrolled in a four-month coordinated financial navigation program. This program will take a more proactive, coordinated, and systematic approach and includes concrete action plans, and frequent and standardized follow-ups. All patients randomized to the intervention arm will meet with the nurse navigator (NN) for an intake. The NN will introduce navigation services and navigator's NN role and describe the financial navigation program (e.g., goals and expectations of the financial advocacy and social work programs). Next, the navigator will elicit from the patient their potential and current barriers to completing the diagnostic test or treatment. The navigator will then perform proactive outreach to these resources and coordinate an action plan with the patient.
89557895|NCT05448196|No Intervention|Usual Care|Patients are connected to financial advocacy and social work on an ad hoc basis, rather than systematically. We hypothesize that many patients who would qualify and benefit from these services are not using them or are being referred late in their treatment course, which is contributing to their financial hardship and adversely affecting their healthcare.
89557896|NCT05447676|Active Comparator|Dalfampridine (4-AP)+STDP+training|The effects of the functional recovery of the lower-limb muscles will be determined after 10 sessions of 4-AP, STDP stimulation and training.
89557897|NCT05447676|Placebo Comparator|Placebo+STDP+training|The effects of the functional recovery of the lower-limb muscles will be determined after 10 sessions of placebo drug, STDP stimulation and training.
89557898|NCT05447676|Experimental|Dalfampridine (4-AP)+STDP+training for extended sessions|The long-term effects of the functional recovery of the lower-limb muscles will be determined after 40 sessions of 4-AP, STDP stimulation and training.
89557899|NCT05442580|Experimental|Cohort A Dose Level 1: Relapsed/Refractory Acute Myeloid Leukemia (AML)|Cohort A Dose Level 1: Adult patients ages ≥ 18 with acute myeloid leukemia (AML) who have not achieved remission after at least two lines of prior therapy will receive a single fixed dose of 3x10(6) CART 38 Cells via intravenous infusion on Day 0, following lymphodepleting chemotherapy with cyclophosphamide or fludarabine based on physician discretion.
89557900|NCT05442580|Experimental|Cohort A Dose Level -1 :Relapsed/Refractory Acute Myeloid Leukemia (AML)|Cohort A Dose Level -1: Adult patients ages ≥ 18 with acute myeloid leukemia (AML) will receive a single fixed dose of 7x10(5) CART 38 Cells via intravenous infusion on Day 0, following lymphodepleting chemotherapy with cyclophosphamide or fludarabine based on physician discretion.
89557901|NCT05442580|Experimental|Cohort A Dose Level 2 :Relapsed/Refractory Acute Myeloid Leukemia (AML)|Cohort A Dose Level 2: Adult patients ages ≥ 18 with acute myeloid leukemia (AML) will receive a single fixed dose of 7x10(6) CART 38 Cells via intravenous infusion on Day 0, following lymphodepleting chemotherapy with cyclophosphamide or fludarabine based on physician discretion.
89557902|NCT05442580|Experimental|Cohort A Dose Level 3 :Relapsed/Refractory Acute Myeloid Leukemia (AML)|Cohort A Dose Level 3: Adult patients ages ≥ 18 with acute myeloid leukemia (AML) will receive a single fixed dose of 3x10(7) CART 38 Cells via intravenous infusion on Day 0, following lymphodepleting chemotherapy with cyclophosphamide or fludarabine based on physician discretion.
89557903|NCT05442580|Experimental|Cohort B Dose Level 1: Multiple Myeloma (MM)|Cohort B Dose Level 1 - Adult patients ages ≥ 18 with Multiple Myeloma (MM) who have not achieved remission after at least two lines of prior therapy will receive a single fixed dose of 3x10(6) CART 38 Cells via intravenous infusion on Day 0, following lymphodepleting chemotherapy with cyclophosphamide or fludarabine based on physician discretion.
89557904|NCT05442580|Experimental|Cohort B Dose Level -1: Multiple Myeloma (MM)|Cohort B Dose Level -1 - Adult patients ages ≥ 18 with Multiple Myeloma (MM) who have not achieved remission after at least two lines of prior therapy will receive a single fixed dose of 7x10(5) CART 38 Cells via intravenous infusion on Day 0, following lymphodepleting chemotherapy with cyclophosphamide or fludarabine based on physician discretion.
89557905|NCT05442580|Experimental|Cohort B Dose Level 2: Multiple Myeloma (MM)|Cohort B Dose Level 2 - Adult patients ages ≥ 18 with Multiple Myeloma (MM) who have not achieved remission after at least two lines of prior therapy will receive a single fixed dose of 7x10(6) CART 38 Cells via intravenous infusion on Day 0, following lymphodepleting chemotherapy with cyclophosphamide or fludarabine based on physician discretion.
89557906|NCT05442580|Experimental|Cohort B Dose Level 3: Multiple Myeloma (MM)|Cohort B Dose Level 3 - Adult patients ages ≥ 18 with Multiple Myeloma (MM) who have not achieved remission after at least two lines of prior therapy will receive a single fixed dose of 3x10(7) CART 38 Cells via intravenous infusion on Day 0, following lymphodepleting chemotherapy with cyclophosphamide or fludarabine based on physician discretion.
89557907|NCT05439603|Experimental|ANC-501|50 mg/day
89557908|NCT05436028|Experimental|LuX-Valve Plus transvenous tricuspid valve and delivery system（LuX-Valve Plus System）|The LuX-Valve Plus System is intended for the treatment of patients with severe TR who are determined by a Heart Team to be at high risk of traditional open-heart surgery.
89033061|NCT02922309|Experimental|experimental|Vocal Training via Telepractice
89557909|NCT05426863|Experimental|Psychosocial Counselling|A multi-component intervention counseling package to prevent the reoccurrence of IPV and address psychological distress among women experiencing violence. The DeVI intervention is structured into five weekly sessions.
89026121|NCT00498888|Active Comparator|2|The Bladder training protocol aims o to increase the time interval between voids, either by a mandatory or self-adjustable schedule, so that incontinence is ultimately avoided and continence regained. It is generally comprised of three components: 1) patient education that includes information about bladder and how continence is usually maintained, 2) scheduled voiding- a 'timetable for voiding' which may fixed or flexible to suit the participant's rate of increase in interval between voids, commonly the aim is to achieve an interval of three to four hours between voids and 3) positive reinforcement- - psychological support and encouragement is generally considered important and usually provided by health care professional . Frequency volume chart (FVC) records the time and volumes of voided for 24 hours by the women between the appointments. Four visits in 3 months with pelvic floor physical therapist, who is trained in the procedure, for educate and schedule voiding regimen.
89026122|NCT00498888|Active Comparator|3|The Pelvic floor muscle training (PFMT) protocol based on National Institute for health and clinical excellence (NICE clinical guideline 40, 2006), that the PFMT programs should comprise at least eight contractions performed three times per day, and the trial of supervised PFMT of at least 3 months' duration . Each appointment the women maid three sets of eight to 12 slow maximal contractions sustained for 6-8 second, and asked to made this protocol every day, and taught to contract these muscle to suppress urge filling. Four visits in 3 months with pelvic floor physical therapist, who is trained in the procedure, for reinforced pelvic floor muscles.
89026123|NCT00498888|Active Comparator|4|Four visits in 3 months with pelvic floor physical therapist, who is trained in the procedure, for pelvic floor muscle training and bladder training and lifestyle advice and information about good bladder and bowel habits.
89026124|NCT02893072|Experimental|Individualized medical nutrition therapy|A comparison of normal lifestyle and medical nutrition therapy after intervention in the same individual
89026125|NCT00491868|Experimental|1|
89026126|NCT00491868|Experimental|2|
89026127|NCT00491868|Active Comparator|3|
89026128|NCT00491868|Active Comparator|4|
89208354|NCT00506350|Experimental|GSK1562902A AD F3 Primed Group|Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of an adjuvanted (AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 3 (F3)in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.
89557910|NCT05426863|No Intervention|Standard Usual Care|Provide standard usual care and information booklet similar to that of the intervention group that contains updated contact information for the referral services.
89557911|NCT05426629|Experimental|Treatment|"4 sessions of treatment at 1-week interval for first 4 weeks 3 sessions of treatment each 4 weeks apart, at week 8, week 12 and week 16~1 Follow-up visit: Follow up 4 weeks after the last treatment at week 20"
89557912|NCT05425901|Experimental|IBD|active or quiescent
89557913|NCT05425901|Active Comparator|control|polyp screening
89557914|NCT05423340|Experimental|Use Own Brand of Flavored Product|Participants will use their current flavor of e cigarettes for 90 days
89557915|NCT05423340|Experimental|Use Provided Tobacco Flavor|Participants will use a new assigned flavor for 90 days
89557916|NCT05423340|Active Comparator|"Vaping Abstinence - use Tobacco Free Nicotine Pouches"|Participants will be asked to stop vaping for 90 days and instead only use the provided 'tobacco free' nicotine pouches.
89557917|NCT05418582|Experimental|DZD9008 and itraconazole|Subjects in arm 1 will receive DZD9008 single dose on Day 1, and the second dose of DZD9008 along with itraconazole after the wash-out period.
89557918|NCT05418582|Experimental|DZD9008 and carbamazepine|Subjects in arm 2 will receive DZD9008 single dose on Day 1, and the second dose of DZD9008 along with carbamazepine after the wash-out period.
89557919|NCT05417425|Experimental|Omeza combination therapy and SOC with total contact cast|"Omeza's products were developed to utilize the benefits of essential omega fatty acids to reduce chronic inflammation and disrupt biofilm colonization commonly found in chronic wounds. The Omeza combination treatment under investigation in this study includes two over the counter (OTC) drugs, Omeza® Lidocaine Lavage and Omeza® Skin Protectant, and a 510(K) medical device, Omeza® Collagen Matrix.~In combination with standard of care and total contact cast, the products will be applied on a weekly basis. There will be a 14-day screening period to assess chronicity from standard of care alone. At that time treatment will be applied weekly for 4 weeks. Further treatment will be at the discretion of the PI to continue for 8 more weeks or until wound closure."
89557920|NCT05414617|Experimental|Medical Device : Happyone|Hyaluronic acid associated with tranexamic acid ; 4.8 ml will be injected in one time
89557921|NCT05414617|Experimental|Medical Device : Happysoft|Hyaluronic acid associated with tranexamic acid ; 2.2 ml will be injected in three times (one injection per week)
89557922|NCT05414526|Experimental|InterCARE package|
89026129|NCT04367974||1|The dose of cefazolin and Ceftazidime co-administered were 20 mg /kg，they were given intraperitoneal twice daily in the first bag and the fourth bag for 5 days，and given 1g once daily in the fourth bag for 9 days. Total treatment duration was 2 weeks.
89026130|NCT04367974||2|The dose of cefazolin and Ceftazidime co-administered were 20 mg /kg，and were given once daily in the fourth bag. Total treatment duration was 2 weeks.
89557923|NCT05412628|Experimental|Esophageal cancer group|patients aged ≥ 20 years with esophageal cancer
89557924|NCT05412628|Experimental|Oropharyngeal cancer group|patients aged ≥ 20 years with oropharyngeal cancer
89557925|NCT05412628|Experimental|Synchronous cancer group|patients aged ≥ 20 years with synchronous oropharyngeal cancer and esophageal cancer
89557926|NCT05412628|Placebo Comparator|Control group|patients aged ≥ 20 years with symptoms of dysphagia without cancer
89557927|NCT05394103|Experimental|Dose escalation (Q901)|
89557928|NCT05394103|Experimental|Q901 Single-Agent Expansion Cohorts|
89557929|NCT05394103|Experimental|Q901 + KEYTRUDA® (pembrolizumab) Cohorts|
89557930|NCT05389618||Older adults 65-80 years|
89557931|NCT05389618||Older adults above 80 years|
88964250|NCT02040142|Experimental|HIPEC + Mitomycin C|HIPEC + 40mg of Mitomycin C. Mitomycin C, 30 mg, will be administered into the inflow line of the perfusion circuit once target temperature is reached. At the 60 minute time point of the perfusion, Mitomycin C, 10 mg, will be administered into the inflow line of the perfusion circuit. Once the 90-minute perfusion period has elapsed, the perfusate will be drained into the waste reservoir. The peritoneal cavity will be rinsed/washed-out.
88964251|NCT02040155|Experimental|Real time dosimetric monitoring of brachytherapy.|
89557932|NCT05388474||Cohort 1 (No ibalizumab or Pre-ibalizumab treatment):|This cohort will be comprised of Heavily treatment-experienced (HTE) patients with Multi Drug Resistant (MDR) HIV who are not receiving ibalizumab. These patients will roll-over into cohort 2 if a change to their ARV regimen is made to include ibalizumab.
89557933|NCT05388474||Cohort 2 (On ibalizumab treatment):|This cohort will be comprised of Heavily Treatment-Experienced patients (HTE) with Multi Drug Resistant (MDR) HIV who are starting treatment with an ARV regimen that includes ibalizumab. Patients already receiving ibalizumab prior to study entry may also be included in Cohort 2 if baseline viral load (VL) and cluster of differentiation 4 (CD4) count data are available prior to ibalizumab treatment. Recruited patients will be required to consent to provide their full retrospective ARV treatment and drug resistance history, as well as retrospective historical data from their medical records from 01 May 2018 to enrollment.
89557934|NCT05383976||Patients Residing in 18 zip codes in Western and Southwestern Philadelphia|The cohort will consist of patients residing in 18 zip codes in Western and Southwestern Philadelphia who have primary care providers in 4 Penn Medicine Internal Medicine practices and 3 Penn Medicine Family Medicine Practices.
89557935|NCT05379699|Active Comparator|1|Standard 4-hour live screener training with 1-on-1 live observation by a speech-language pathologist.
89557936|NCT05379699|Experimental|2|New eLearning training with 1-on-1 live observation by a speech-language pathologist.
89557937|NCT05379699|Experimental|3|New eLearning training with 1-on-1 live observation by a competency mentor.
89557938|NCT05379439|Experimental|Intervention|Intervention families will participate in the Structured Family Deliberation that includes a clinician-led review of a web-based decisional aid.
89557939|NCT05379439|No Intervention|Control|Control families will undergo the standard decisional process for home ventilation and will also review the web-based decisional aid independently.
89557940|NCT05374044||rectal cancer with NAT|The patients are planned to receive neoadjvant therapy, and then receive radical surgery.
89557941|NCT05372744|Experimental|Experimental group (anticipatory)|Participants receive a nasal spray that is in fact a placebo. However, they are told that it protects from experiencing intensive emotional reactions and consequent rumination tendencies. They take the nasal spray once in the laboratory.
88964252|NCT02040168||28 days - 18 yo|Children requiring mechanical ventilation for at least 24h from 28 days to 18 yo
88964253|NCT02040168||18 months - 18 yo|Post traumatic stress disorder evaluation in children requiring mechanical ventilation for at least 24h from 18 month to 18 Years old
88964254|NCT02040220||Group 1|Eylea treatment goup
88964255|NCT02040233|Active Comparator|BAY1067197 (10 mg)|
88964256|NCT02040233|Active Comparator|BAY1067197|
88964257|NCT02040233|Placebo Comparator|Placebo (10 mg)|
88964258|NCT02040233|Placebo Comparator|Placebo|
88964259|NCT02040246|Experimental|Repaglinide|Initial dose of repaglinide 0.5 mg once daily. During the dose titration period of 1 week, the dose of repaglinide could be titrated up to 1 mg three times daily, according to fasting glucose values. The minimal dose was repaglinide 0.5 mg three times daily.
88964260|NCT02040246|Active Comparator|Metformin|Initial dose of metformin 250mg once daily. During the dose titration period of 1 week, the dose could be titrated up to metformin 500 mg three times daily, according to fasting glucose values.
88964261|NCT02040272|Experimental|Surgery|(Extended) pleurectomy decortication
88964262|NCT02040272|No Intervention|no surgery|no surgery
88964263|NCT02040285|Active Comparator|Free laxative CTC|
89557942|NCT05372744|Experimental|Experimental group (reactive)|Participants receive a nasal spray that is in fact a placebo. Participants of this group are told, however, that it helps to regulate experienced intensive emotional reactions and to distance oneself from consequent ruminative thoughts. They take the nasal spray once in the laboratory.
89557943|NCT05372744|No Intervention|No-treatment control group|Participants do not receive the nasal spray and continue with the following task.
89557944|NCT05372159||Cognitively healthy adults|Eligible participants completed a 4-hour screening visit, and a consensus team determined cognitive status according to the National Institute on Aging and Alzheimer's Association Workgroup guidelines.
89557945|NCT05372159||Cognitively impaired adults|Eligible participants completed a 4-hour screening visit, and a consensus team determined cognitive status according to the National Institute on Aging and Alzheimer's Association Workgroup guidelines.
88964264|NCT02040285|Experimental|Low-dose laxative bowel preparation for CTC|
88964265|NCT02040311|Experimental|Topiramate 96 mg daily|
88964266|NCT02040311|Experimental|Topiramate 192 mg daily|
88964267|NCT02040311|Placebo Comparator|placebo|
88964268|NCT02040324|Active Comparator|Endotracheal Intubation|Clinical routine for longer lasting procedures
88964269|NCT02040324|Experimental|Laryngeal Mask|Laryngeal mask with gastric access and drainage as airway management instead of endotracheal intubation
88964270|NCT02040350|Placebo Comparator|Placebo|Placebo was given to compare the effects
88964271|NCT02040350|Active Comparator|Pralidoxime|Pralidoxime for treating organophosphorous poisoning patients
88964272|NCT02040363|Active Comparator|COPD Patients ~90% VO2max|COPD Patients ~90% VO2max
88964273|NCT02040363|Active Comparator|COPD patients ~60-65% VO2max|COPD patients ~60-65% VO2max
88964274|NCT02040363|Placebo Comparator|healthy volunteers|healthy volunteers
88964275|NCT02040389|Active Comparator|pictures book + standard education|arm with children undergoing urological procedures and their parents will receive standard preoperative education + pictures book with pictures of surgical wound in different stages of healing
89026131|NCT02893033|Experimental|Real stimulation|Real repetitive transcranial magnetic stimulation + swallowing training
88812434|NCT04852562|Experimental|Modified radical endoscopic sinus surgery(MRESS)|The experimental group intends to adopt a modified radical endoscopic sinus surger to remove the mucosa including ethmoid sinus and maxillary sinus, as well as a completly middle turbinate resection to achieve a radical cure of ethmoid sinus. Antrostomies of frontal and sphenoid sinuses were then performed with meticulous operation and preserve the mucosa intactly.
89557946|NCT05364086||Observational (questionnaire, biospecimen, medical records))|Patients complete questionnaires and undergo collection of blood and saliva samples before 1st and 2nd infusion of immunotherapy, 6 months after 1st infusion of immunotherapy, and then every year after 1st infusion of immunotherapy. Patients also undergo collection of saliva samples before 1st and 2nd infusion of immunotherapy. A tumor sample will also be collected at the beginning of the study and patients medical records will be reviewed.
89557947|NCT05363540|Active Comparator|Pre-incisional parasternal block|ultrasound guided parasternal intercostal block will be administrated before surgical incision.
89557948|NCT05363540|Active Comparator|Post-incisional parasternal block|under direct vision parasternal intercostal block will be administrated after surgical incision and before closure of the sternum.
89557949|NCT05360069|Experimental|Linear stapler group|Linear stapler is adopted in esophagojejunostomy.
89557950|NCT05360069|Active Comparator|Circular stapler group|Circular stapler is adopted in esophagojejunostomy.
89557951|NCT05347771|Experimental|Dupilumab|"Participants between 12-17 years of age, will receive an initial dose of 600 mg (two 300 mg injections) followed by 300 mg given every other week (Q2W).~Participants between 6-11 years of age will not complete a loading dose and will receive injections based on their body weight:~Participants with a body weight of 15 kg to less than 30 kg, will receive 100mg Q2W.~Participants with a body weight of 30 kg or more, will receive 200 mg Q2W."
88812435|NCT04852562|Experimental|Functional endoscopic sinus surgery (FESS)|FESS was performed by Messerklinger technique, operation procedures including full maxillary antrostomy, ethmoidectomy, sphenoidotomy and frontal sinusotomy, but with the middle turbinate preservation.
89208355|NCT00506350|Experimental|GSK1562902A AD Approved F4 Primed Group|Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of approved Formulation (F) of adjuvanted (AD) H5N1 vaccine (A/Vietnam/1194/04 strain) in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.
89557952|NCT05347771|Placebo Comparator|Placebo|"Participants between 12-17 years of age, will receive an initial dose of placebo (two injections) followed by a placebo injection given every other week (Q2W).~Participants between 6-11 years of age will not receive an initial loading dose of placebo and will receive injections Q2W based on their body weight."
89557953|NCT05343611|Active Comparator|Group A (Controls: HPro diet and HIT)|Subjects included in this group will serve as controls and will maintain the HPro Diet + HIT program prescribed to all the participants included in the randomization step of the study. The subjects' diet will be adjusted to receive the same overall intake of calories (+ 180 kcal) and macronutrients (+ 3 g of proteins, 4 g of carbohydrates, +11 g of fat, + 4 g of fibers) that the chocolate products will provide to groups B and C.
89557954|NCT05343611|Sham Comparator|Group B (Case 1: HPP Choko)|Individuals included in this group will undergo the same diet and physical exercise as Group A and additionally they will add to their diet 30g of 85% dark chocolate high in PP (HPP ≥ 500 mg of PP and corresponding to ≥ 60 mg of epicatechin).
89557955|NCT05343611|Experimental|Group C (Case 2: HPP/VE Chocolate)|Individuals included in this group will undergo the same diet and physical exercise as Group A and additionally they will add to their diet 30 grams of 85% dark HPP chocolate functionalized with 100 mg Vitamin E per day.
89557956|NCT05342844|No Intervention|Group-Control|After cession section, patients Will receive ultrasound (US)-guided bilateral transversus abdominis plane block with 10 mL bupivacaine 0.5% plus 10 mL normal saline 0.9% for each side
89557957|NCT05342844|Active Comparator|Group-Dexmedetomidine 0.5|After cession section, patients Will receive ultrasound (US)-guided bilateral transversus abdominis plane block with 10 mL bupivacaine 0.5% plus 10 mL normal saline containing 0.5 mcg/kg dexmedetomidine for each side
89557958|NCT05342844|Active Comparator|Group-Dexmedetomidine1|After cession section, patients Will receive ultrasound (US)-guided bilateral transversus abdominis plane block with 10 mL bupivacaine 0. 5% plus 10 mL normal saline containing 1 mcg/kg dexmedetomidine for each side
89557959|NCT05333133|Experimental|High calorie formula on IGF-1, TNF-alpha and total lymphocyte counts|Interventional study with pre-, post design after the subjects are diagnosed with TB and UTI, they will receive 400 ml (equal with 400 kcal) of high calorie formula per day, prescribed by the researcher (a pediatrician) for 90 days consumption. Body weight and body height will be monitored by the researcher group every 30 days to record the tolerance, acceptance and complaints (and the side effects) the blood will be withdraw at day 0 (before intervention) and day 90 (after intervention) to investigate the IGF-1, TNF-alpha and total lymphocyte counts
89557960|NCT05332509|Experimental|C-BRACE/SCO|The patient is first fitted during 2 months with the C-BRACE orthosis, them, after 2 weeks wash-out period, the patient is fitted with its Stance Controlled Orthosis (SCO).
89557961|NCT05332509|Other|SCO/C-BRACE|The patient is using its Stance controlled orthosis (SCO) during 2 months, then, after 2 weeks wash-out period, the patient is fitted with the C-BRACE orthosis.
89557962|NCT05328765||With HIV Infection|Patients with CCA with HIV infection,
89557963|NCT05328765||Without HIV Infection|Patients with CCA without HIV infection,
89557964|NCT05323617|Experimental|Arm 1: Previously Untreated IST|Participants with SAA/vSAA that are previously untreated with IST.
89557965|NCT05323617|Experimental|Arm 2: Refractory IST|Participants with SAA/vSAA that are refractory to IST.
89557966|NCT05322161|No Intervention|Control|Parents will experience usual care including all available parental support as practiced in the specific site NICU.
89557967|NCT05322161|Experimental|Yoga Group|In addition to usual care, the parents randomized to the intervention group will be provided a yoga mat and participate in 30-min online led yoga sessions done at least twice weekly at the parent's pace using a secure, virtual platform (website).
89557968|NCT05316012|Experimental|Residents|"5 residents - fase 1 Intervention device: smart diaper (diaper, sensor and strips, without alerting system).~15 residents -fase 2, of which 5 residents of study phase 1 Intervention device: smart diaper (diaper, sensor and strips, with alerting system)"
89557969|NCT05310877|Experimental|Values-affirmation|
89026132|NCT02893033|Sham Comparator|Sham stimulation|Sham repetitive transcranial magnetic stimulation + swallowing training
89026133|NCT04366765||COVID-19 suspects|Patients presenting with suspected COVID-19 to the emergency department of the University Hospital Basel.
89026134|NCT03271931|No Intervention|Usual care|Cardiologists in this arm will receive no interventions and will act as usual care
89557970|NCT05302765|No Intervention|No IV Fluids|The control arm consists of lumbar puncture performed in routine fashion without the administration of intravenous fluids prior to procedure.
89557971|NCT05302765|Experimental|Receives IV Fluids|The experimental arm will receive normal saline intravenous fluid administration (20 milliliters/kilogram) prior to lumbar puncture. Bolus to be complete prior to lumbar puncture in the experimental group.
89026135|NCT03271931|Experimental|Active choice|Cardiologists in this arm will be exposed to an active choice intervention through the electronic health record (EHR) using an alert to prompt recommendations for statin therapy for patients not on guideline-based therapy. Cardiologists will be have to make an active choice to prescribe a statin at the recommended dose or not.
89026136|NCT03271931|Experimental|Passive choice|Cardiologists in this arm will be exposed to a passive choice alert within the EHR, using the same evidence-based guidelines as in the active choice arm. The passive alert will not block clinician workflow and instead will be available in the background for the cardiologist to open and then use to make a prescribing decision.
89026137|NCT04365634||Diabetes|Diabetes mellitus was diagnosed according to the standards of American Diabetes Association which were briefly described as FPG ≥ 7.0 mmol/L (Fasting is defined as no caloric intake for at least 8 h) or 2-h plasma glucose ≥ 11.1 mmol/L during Oral glucose tolerance test (OGTT), or with classic symptoms of hyperglycemia or hyperglycemic crisis, a random plasma glucose (RPG) ≥ 11.1 mmol/L. And in this group, we have 129 COVID-19 patients with diabetes.
89026138|NCT04365634||Non-diabetes|Patients who do not meet the American Diabetes Association's standard diagnosis of diabetes are defined as non-diabetes. And in this group, we have 177 COVID-19 patients without diabetes.
89026139|NCT04365634||Survivors|COVID-19 patients who survived on the 28th day in hospital belong to survivors group. In the survivors group, we included 201 patients with complete data.
89033062|NCT02922309|Active Comparator|control|Vocal Training via face-to-face practice
89557972|NCT05293431|Experimental|Active Stimulation Group|This group will receive real tACS non-invasive brain stimulation
89557973|NCT05293431|Sham Comparator|Sham Control Group|This group will receive Sham tACS non-invasive brain stimulation
89557974|NCT05292508|Experimental|CRP Tests in addition to Usual Standard of Care|For the clusters (health posts) in this arm, the health worker will prick the finger of the eligible patient using a lancet device following aseptic precautions. A very small drop (10 microliters) of whole blood will be obtained which will be added to specimen dilution buffer and the dipstick will be placed into the diluted sample. It will be removed after the liquid rises and the timer will be started and result will be interpreted in 5 minutes. Interpretation of CRP levels: Only red color line (No blue line): <10 mg/L One blue line: 10-40 mg/L Two blue lines: 40-80 mg/L Three blue lines: >80 mg/L. CRP levels of 40 mg/L or above will be considered as increased CRP levels. The decision on antimicrobial use and other treatments will be made with the help of CRP results in addition to information obtained from the history and physical examination.
89557975|NCT05292508|No Intervention|Usual Standard of Care Alone|For the clusters (health posts) in this control arm, Usual Standard of Care Alone will be provided. This usual standard of care is given to patients with febrile illness at health posts. Commonly, this involves taking a brief history and conducting a simple physical examination followed by symptomatic treatment such as paracetamol, cough medication or analgesics such as NSAIDs. Often antimicrobial treatment is also prescribed based on clinical suspicion of bacterial infection.
89026140|NCT04365634||Non-survivors|COVID-19 patients who did not survive on the 28th day in hospital belong to non-survivors group. In the non-survivors group, we included 54 patients with complete data.
89026141|NCT00499005|Active Comparator|Primi|
89557976|NCT05291169|Experimental|Omeza Combination Therapy + SOC|The Omeza Combination Therapy under investigation includes two Over the Counter (OTC) drugs, Omeza®Lidocaine Lavage for periwound preparation and pain control, and Omeza® Skin Protectant to be applied to the skin from knee to ankle for increased perfusion. Omeza® Collagen Matrix is an FDA cleared 510(K) medical device which is applied directly to the wound bed. The combination treatment is applied on a weekly basis, followed by compression management
89557977|NCT05291169|No Intervention|SOC|Cleaning and debriding the Study ulcers and compression management on a weekly basis.
89557978|NCT05290766|Active Comparator|Control group|"will receive implant-supported mandibular fixed metal acrylic prosthesis on 4 implants that were placed according to the All on four concept."
89557979|NCT05290766|Active Comparator|Study group|"will receive implant-supported mandibular fixed metal acrylic prosthesis on two implants placed according to All On two concept."
89557980|NCT05290610|Other|Research IESM|Functional mapping for research application
89026142|NCT00499005|Active Comparator|Multi|
89026143|NCT04363567||CKD 1|"Patients with Chronic kidney disease stage 1: Normal kidney function but urine findings or structural abnormalities or genetic trait point to kidney disease. eGFR :90+.~20 patients, maximun 4 patients with diabetes."
89026144|NCT04363567||CKD 2|"Patients with Chronic kidney disease stage 2: Mildly reduced kidney function, and other findings (as for stage 1) point to kidney disease. eGFR: 60-89.~20 patients, maximun 4 patients with diabetes."
89026145|NCT04363567||CKD 3|"Patients with Chronic kidney disease stage 3: Moderately reduced kidney function. eGFR: 30-59.~20 patients, maximun 4 patients with diabetes."
89026146|NCT04363567||CKD 4|"Patients with Chronic kidney disease stage 4: Severely reduced kidney function. eGFR: 15-29.~20 patients, maximun 4 patients with diabetes."
89026147|NCT04363567||CKD 5|"Patients with Chronic kidney disease stage 5: Very severe kidney function. eGFR: <15.~20 patients, maximun 4 patients with diabetes."
89557981|NCT05278533|Experimental|BioPlete™ Advanced Formula|"BioPlete™ Advanced Formula in Capsule~Intervention: Dietary Supplement: Multi-Vitamin"
89557982|NCT05278533|Placebo Comparator|Placebo|"Rice Flour in a capsule~Intervention: Other: Placebo"
89557983|NCT05276674||ZNN Bactiguard Retrograde Femoral Nail|Patients implanted with a ZNN Bactiguard Retrograde Femoral Nail for fixing and stabilizing a femoral fracture.
89557984|NCT05275699|Experimental|68Ga-FAPI-04 PET/CT|All patients diagnosed with keloid underwent 68Ga-FAPI PET/CT.
89557985|NCT05263674|No Intervention|"Non-sedative medical treatment"|"The patient is treated with an additional high-dose intravenous antiepileptic drug, which is selected by the treating neurologist. If NCSE continues to be detected at cEEG or clinically> 3 hours after starting treatment, the patient should receive standard treatment (i.e. sedation in the intensive care unit or addition of additional intravenous antiepileptic drugs) in accordance with local guidelines and the assessment of the treating neurologist. The following preparations are permitted as additional treatment:~Levetiracetam (60 mg / kg as saturation dose followed by maintenance dose of 2-4 g / day), valproate (60 mg / kg as saturation dose followed by maintenance dose of 20 mg / kg / day), phosphenytoin (20 PE as saturation dose followed by maintenance dose 5 mg PE / kg / day), lacosamide (400 mg as a saturation dose followed by a maintenance dose of 200-400 mg / day), topiramate (200-400 mg per probe as a saturation dose followed by a maintenance dose of 200-400 mg / day)."
89557986|NCT05263674|Experimental|Fast sedation|Within a maximum of 60 minutes after the diagnosis of NCSE (EEG or clinical), the patient must be sedated with high-dose Propofol (bolus 3-5 g / kg, maintenance dose 5-10 mg / kg / hour) to - 5 on the Richmond agitation sedation scale (RASS) for 20 hours, and a single anti-epileptic drug should be added as adjunctive therapy. Addition of low-dose Midazolam (max. 0.1 mg / kg / h) is permitted if deep sedation (defined clinically by RASS -5) is not possible with Propofol alone. After 20 hours, the sedation should be completely phased out within 3 hours.
89557987|NCT05259085|Experimental|Cohort 1: Mild IHF|Participants will receive ALXN2050.
89557988|NCT05259085|Experimental|Cohort 2: Moderate IHF|Participants will receive ALXN2050.
89557989|NCT05259085|Experimental|Cohort 3: Severe IHF|Participants will receive ALXN2050.
89026148|NCT04363567||Dialysis|Patients with end stage renal disease in dialysis. 20 patients, maximun 4 patients with diabetes.
89026149|NCT04363567||Healthy|20 healthy people. Control group
89557990|NCT05259085|Experimental|Cohort 4: Healthy Control|Participants will receive ALXN2050.
89557991|NCT05257668|Active Comparator|Group 1|High intensity interval training
89557992|NCT05257668|Active Comparator|Group 2|Moderate intensity training
89557993|NCT05257668|No Intervention|Group 3|Control
89557994|NCT05251181|Active Comparator|Normal saline|Hypovolemic shock patients will be provided the standard of care. Following randomization 100 ml (equal volume to experimental arm) of normal saline will be administered intravenously over 1 hour.
89557995|NCT05251181|Experimental|Centhaquine|Hypovolemic shock patients will be provided the standard of care. Following randomization centhaquine (0.01 mg/kg) will be administered intravenously over 1 hour in 100 mL of normal saline.
89557996|NCT05248009|Experimental|Semi-Permanent Tattoo Ink|Semi-Permanent Tattoo Ink
88812436|NCT04841304||Patients receiving hemodialysis with diabetes|Patients receiving chronic hemodialysis with a diagnose of Type 1 diabetes or Type 2 diabetes (diagnosed according to the criteria of the World Health Organization) and receiving glucose-lowering treatment
89026150|NCT04327765|Experimental|Cohort 1|Single orally-inhaled dose
89026151|NCT04327765|Experimental|Cohort 2|Single orally-inhaled dose
89026152|NCT04327765|Experimental|Cohort 3|Single orally-inhaled dose
89557997|NCT05236348|Experimental|Patients 21-60yo with Aktiia.product-us|All study participants will wear the Aktiia.product-us during 9 visits that will be held over the span of seven days.
88812437|NCT04841304||Patients receiving hemodialysis without diabetes|Patients receiving chronic hemodialysis without diabetes (no known diagnosis of diabetes, and HbA1c < 48 mmol/mol at inclusion)
89557998|NCT05236348|Experimental|Patients 60-85yo with Aktiia.product-us|All study participants will wear the Aktiia.product-us during 9 visits that will be held over the span of seven days.
89557999|NCT05231837|Experimental|Fee Waiver|Fees for youth sports programs will be waived in this condition. Youth who enroll in youth sports programs in parks that are randomly assigned to this condition will pay no fee for program enrollment.
89558000|NCT05231837|Experimental|Fee Waiver Plus Intensive Outreach|"Parks randomly assigned to the Intensive Outreach and Fee Waiver:~Intensive Outreach consists of the formation and activity of a community advisory group who will engage with neighborhood community partners to support parents in the neighborhood to enroll their child and support the child's participation in the park youth sports programs offered at the neighborhood park and recreation center. Program marketing and materials and registration will be offered in both Spanish and English. Program coaches will be supported with technical assistance from study staff to implement the park youth sports program with high fidelity and with high communication and engagement with enrolled youth and their parents.~Fees for youth sports programs will be waived in this condition. Youth who enroll in youth sports programs in parks that are randomly assigned to this condition will pay no fee for program enrollment."
89558001|NCT05230030|No Intervention|Observational|
89558002|NCT05230030|Experimental|Improvisation Workshops|Participants will take part in an improvisation curriculum containing a uniquely designed series of flexibly-timed improvisation workshops administered during the study period. Using published guidelines, workshops will have groups of approximately 10 study participants and last on average 2 hours under the instruction of an expert medical improvisation facilitator.
89558003|NCT05229965|Active Comparator|Paracétamol Group|"In each study population, the patient will be assigned to one of three treatments (Paracetamol Group or Paracetamol Codéine Group or Paracétamol Caféine Group) .~In Paracetamol group , the patients will receive a pill containing 1000 mg of paracetamol 3 times a day for 7 days .~Paracétamol 1000 mg : 1 pill *3 / day"
89558004|NCT05229965|Active Comparator|Paracétamol Codéine Group|"In each study population, the patient will be assigned to one of three treatments (Paracetamol Group or Paracetamol Codéine Group or Paracetamol Caféine Group) .~In Paracetamol codéine group , the patients will receive a pill containing an association of paracetamol and codéine ( 500mg / 30mg ) 3 times a day for 7 days .~-Association of Paracétamol and Codéine ( 500mg / 30 mg) : 1 pill *2 /day"
89558005|NCT05229965|Active Comparator|Paracétamol Caféine Group|"In each study population, the patient will be assigned to one of three treatments (Paracetamol Group or Paracetamol Codéine Group or Paracetamol Caféine Group) .~In Paracetamol caféine group , the patients will receive a pill containing an association of paracetamol and caféine ( 500mg / 65 mg ) 3 times a day for 7 days .~-Association of Paracétamol and Caféine ( 500mg / 65 mg) : 1 pill *3 /day"
89558006|NCT05229120|Experimental|Episodic Future Thinking|Parents who are receiving residential substance use disorder (SUD) treatment will receive an adapted episodic future thinking focused condition. Parents will meet with peer recovery coaches (PRCs) who will administer the intervention, focused on generating future, pleasant events with their children. After the intervention session, parents will receive a daily postcard over the course of two weeks including a reminder cue generated as part of the episodic future thinking (EFT) intervention and a prompt to remember these episodes in vivid detail.
89558007|NCT05227391|Experimental|Letrozole-stimulated group|
89558008|NCT05227391|Active Comparator|Hormone replacement treatment group|
89558009|NCT05220631|Experimental|Cohort 1|Cohort 1 will start the intervention directly after randomization.
89558010|NCT05220631|Active Comparator|Cohort 2|Cohort 2 will serve as the control while cohort 1 is in the intervention stage. Cohort 2 will start the intervention after cohort 1 concludes the intervention.
89558011|NCT05209880|Experimental|Intervention Arm|The intervention will take place in the emergency department or days after an emergency department visit at home/hospital virtually using zoom or phone by our trained clinicians. At the time of follow-up assessments, participants may also receive additional counseling by our trained clinicians as needed.
89558012|NCT05209880|No Intervention|Control Arm|No intervention will be conducted (standard of care).
89558013|NCT05207709|Experimental|Ribociclib + Endocrine Therapy|Ribociclib + Fulvestrant or Letrozole
89558014|NCT05207709|Experimental|Palbociclib + Endocrine Therapy|Palbociclib + Fulvestrant or Letrozole
89558015|NCT05207709|Experimental|Paclitaxel +/- Tislelizumab - Exploratory cohort|Additional experimental Cohort that includes patients with Basal-Like intrinsic subtype.
89558016|NCT05203731|Experimental|Exercise Group|Participants who will be randomized to moderate intensity exercise after extinction (Day 1)
88812438|NCT04840550|Experimental|Tegoprazan 25mg|Tegoprazan 25mg tablets will be orally administered once a day, with NSAIDs, for up to 6 months.
88812439|NCT04840550|Active Comparator|Lansoprazole 15mg|Lansoprazole 15mg capsules will be orally administered, once a day, with NSAIDs, for up to 6 months.
88812440|NCT04817176|Experimental|MI-CBT KNA Program|The program is a 6-week group, telehealth intervention for older adults with possible MCI. The intervention uses Motivational interviewing and cognitive behavioral therapy strategies to enhance motivation and help participants overcome personal obstacles to following health-behavior recommendations. Specifically, the program examines the use of a Mediterranean ketogenic type of nutrition to target mild cognitive impairment. The intervention is designed to disseminate practical information to help older adults learn how to incorporate healthy Mediterranean ketogenic nutrition into their lifestyle.
88812441|NCT04817176|Active Comparator|KN Information-Only Program|6-week group, telehealth intervention for older adults. The intervention is designed to disseminate practical information to help older adults learn how to incorporate healthy Mediterranean ketogenic nutrition into their lifestyle.
89033063|NCT02922231||All Study Participants|Participants with congenital hemophilia B (FIX level ≤5%)
89558017|NCT05203731|Sham Comparator|Seated group|Participants who will be randomized to sitting after extinction (Day 1)
89026153|NCT04361539||Elite adolescent badminton players|The population was all the elite adolescent badminton players from a high-level club. We excluded players who had SSI in the 3 months prior to the isokinetic test or had shoulder surgery. They were included and followed from September 2018 to May 2019.
89026154|NCT03272048|Experimental|Low-Fear/Not-Temporary|
89558018|NCT05203315|Experimental|Treatment Group A|Subjects whose baseline Itch and/or Burning/Stinging Score is less than 2 (moderate), one tube of Duobrii along with one jar of CeraVe cream, will be dispensed to the subject at the Baseline visit. The study participant will be instructed to apply the CeraVe cream to the treatment area twice daily and advised to apply a thin layer of the Duobrii only to the affected skin once daily in the evening.
89558019|NCT05203315|Experimental|Treatment Group B|Subjects whose baseline Itch and/or Burning/Stinging Score is greater than or equal to 2 (moderate), in addition to one tube of Duobrii along with one jar of CeraVe cream, the participant will be given a tube of hydrocortisone 1% cream and instructed to apply to the treatment area twice daily for 5 days, along with CeraVe cream. Starting at day 6 and ongoing, subjects will be instructed to discontinue the hydrocortisone cream and initiate Duobrii application every night, while continuing the CeraVe cream twice daily.
89208356|NCT00506350|Experimental|Control Group|Healthy male or female adults, between and including 19 to 61 years of age, unprimed receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.
89208357|NCT00788840|Active Comparator|1. Insulatard|
89558020|NCT05203276|Experimental|Envafolimab+ Endostar Group|Envafolimab（300mg，SC，Q3W，d1） Endostar（210mg，CIV 72h，Q3W，d1-3）
89208358|NCT00788840|Active Comparator|2. Detemir|
89558021|NCT05186714|Active Comparator|Tai Chi|12 weeks of Tai Chi classes
89558022|NCT05186714|Placebo Comparator|Wellnes Education|12 weeks of Wellness Education classes
89558023|NCT05171348|Experimental|CM326 55mg Q2W|55mg for 6 doses, SC, Q2W
89558024|NCT05171348|Experimental|CM326 110mg Q2W|110mg for 6 doses, SC, Q2W
89558025|NCT05171348|Experimental|CM326 220mg Q2W|220mg for 6 doses, SC, Q2W
89558026|NCT05171348|Experimental|CM326 220mg Q4W|220mg for 3 doses, SC, Q4W
89558027|NCT05171348|Placebo Comparator|Placebo|Placebo
89558028|NCT05167487||Experimental: platinum-based neoadjuvant treatment and surgery.|Resectable stage IIIA non-small cell lung cancer patients treated with platinum-based neoadjuvant treatment and surgery.
89558029|NCT05162638|Other|'In-and-out' catheterization|"Safety and immune-cell profile of lymphatic fluid in MS patients with a single time-point sampling of lymphatic fluids and peripheral blood compared to healthy controls.~Two healthy controls and six patients with early MS (never treated or at least 90 days after discontinued treatment with glatiramer acetate or interferons), who consent to the 'In-and-out' catheter procedure. MS participants can also consent to OMB treatment with 2-year follow-up."
89558030|NCT05162638|Other|"Indwelling catheterization"|"immune-biology in people with MS before and during/after OMB treatment within thoracic duct and peripheral blood via indwelling catheter and multiple time-point sampling compared to healthy controls (without drug treatment).~Twelve patients with early MS (never treated or at least 90 days after discontinued treatment with glatiramer acetate or interferons), who consent to treatment with OMB and to the indwelling catheter procedure with serial sampling and up to four healthy controls (no drug treatment)"
89558031|NCT05159778|Experimental|Experimental|
89558032|NCT05152888|Experimental|Evolocumab|Informed consent will be obtained from study participants willing to participate in EMPOWER. Study participants will then undergo the baseline rest/stress cardiac PET scan along with CCTA. The final PET scan and CCTA will occur at 12 months after the intervention.
89558033|NCT05152888|No Intervention|Control|Informed consent will be obtained from study participants willing to participate in EMPOWER. Study participants will then undergo the baseline rest/stress cardiac PET scan along with CCTA. The final PET scan and CCTA will occur at 12 months after the baseline.
89558034|NCT05151484|Active Comparator|Group 1 Low Turnover|Teriparatide (anabolic) For 1 Year
89026155|NCT03272048|Experimental|Low-Fear/Temporary|
89026156|NCT03272048|Experimental|High-Fear/Not-Temporary|
89026157|NCT03272048|Experimental|High-Fear/Temporary|
89026158|NCT03272672|Experimental|Braced|Össür Unloading Knee Brace used during walking protocol
89026159|NCT03272672|No Intervention|Unbraced|Walking protocol without the use of brace
89208359|NCT00258895|Experimental|DAPTACEL Primed|Participants received Daptacel in Study P3T06.
89208360|NCT00258895|Experimental|Pentacel Primed|Participants received Pentacel in Study P3T06
89208361|NCT00742625|Experimental|Treatment (daunorubicin hydrochloride and bortezomib)|See Detailed Description
89208362|NCT00801710|Experimental|BridgePoint Medial System|
89208363|NCT00801788|Experimental|Egalet® oxycodone Treatment A|Single Dose Administration
89026160|NCT00592423|Other|1|"A convenience sample of children will be utilized for this study, which will include both genders and all ethnicities. There is no known predilection for any racial or gender inequalities with regard to subject recruitment or outcome variables related to this study."
89026161|NCT00592462||Whole Body MRI|
89026162|NCT00592540|Experimental|Unrelated Donor BMT|
89026163|NCT00491985|Experimental|Study Group 1|Subjects aged 9 to 17 years
89558035|NCT05151484|Active Comparator|Group 2 Low Turnover|"Standard of Care - Control:~Treated with Alendronate (antiresorber) For 1 Year"
89558036|NCT05151484|Active Comparator|Group 3 Normal-High Turnover|Standard of Care Treatment with Alendronate (antiresorber) For 1 Year
89558037|NCT05151380|Other|Women with CO2 laser MonaLisa Touch ® sessions|Women with 3 sessions of CO2 laser MonaLisa Touch ®
89558038|NCT05147324|Experimental|"MyPlan - Individualized Eating Pattern"|All youth enrolled in the study will receive the 6-month MyPlan behavioral intervention. Youth will be paired with a dietitian to individualize the eating plan and receive support in setting and refining action plans focused on adhering to the five eating behavior goals that define the eating plan.
89558039|NCT05132322|Active Comparator|Unlearning Only|Includes educational outreach and audit & feedback.
88812442|NCT04765072|Experimental|Survivorship care|Participants in rural areas will receive a telehealth (providing health-related services through electronic communication technologies) survivorship care plan in combination with assistance from a patient navigator.
89558040|NCT05132322|Experimental|Unlearning + Substitution|Includes educational outreach, audit & feedback, and an electronic health record-integrated clinical pathway to support appropriate use of pulse oximetry.
89558041|NCT05128227|Active Comparator|Pharm-SAVES|This is an approximately 30-minute self-guided online module that covers basic information about suicide prevention gatekeeper skills training that is relevant to community pharmacists.
89026164|NCT00491985|Experimental|Study Group 2|Subjects aged 3 to 8 years
89026165|NCT00491985|Experimental|Study Group 3|Subjects aged 6 to 35 months
89026166|NCT03272594|Experimental|Breastfeeding|
89558042|NCT05128227|Experimental|Interactive video case|An approximately 30-minute self-guided online suicide prevention gatekeeper skills training module, plus two approximately 5-minute interactive video cases in which participants are asked to respond to patients who exhibit suicidal warning signs.
89558043|NCT05124574||mothers infected with SARS-COV-2 at the time of delivery.|"Maternal-fetal transmission of SARS-COV-2 is likely and may require co-expression of the virus receptor (ACE2) and at least one activator of virus internalization (TMPRSS2 and/or cathepsin) in a cell to make it susceptible to SARS-COV-2 infection.~To confirm these hypotheses, it is necessary to explore these mechanisms of fetal transmission in a larger number of mothers infected with SARS -CoV-2 at the time of delivery.~Informed information will be given in the delivery room, initially orally by the midwives, to any mother presenting with an SARS-COV-2 infection (symptomatic or not) (whatever the variant involved). An information leaflet will also be given to the patient and consent will be systematically obtained."
89558044|NCT05121831|Experimental|Single Ascending Dose Cohort S1|Subjects will receive a single dose of either dose level 1 of DGX-001 or placebo
89558045|NCT05121831|Experimental|Single Ascending Dose Cohort S2|Subjects will receive a single dose of either dose level 2 of DGX-001 or placebo
89558046|NCT05121831|Experimental|Single Ascending Dose Cohort S3|Subjects will receive a single dose of either dose level 3 of DGX-001 or placebo
89026167|NCT03272594|Active Comparator|24% oral sucrose|
89026168|NCT02892916|Experimental|Ketamine|Patients in this experimental group will receive a bolus of low intravenous dose (sub-anaesthetic) 0.5 mg/kg ketamine following induction of anaesthesia.
89026169|NCT02892916|Placebo Comparator|Placebo|Patients in this control group will receive a bolus of an intravenous normal saline solution following induction of anaesthesia.
89026170|NCT01245309|Experimental|scratching|endometrial scratching prior ivf cycle
89026171|NCT01245309|Placebo Comparator|PLACEBO|PLACEBO PROCEDURE
89558047|NCT05121831|Experimental|Single Ascending Dose Cohort S4|Subjects will receive a single dose of either dose level 4 of DGX-001 or placebo
89026172|NCT02956304|Other|Group iTBS-cTBS-SHAM|PMv stimulation (iTBS) at session 2, PMv inhibition (cTBS) at session 3, and control (SHAM) at session 4
89026173|NCT02956304|Other|Group iTBS-SHAM-cTBS|PMv stimulation (iTBS) at session 2, control (SHAM) at session 3, and PMv inhibition (cTBS) at session 4
89026174|NCT02956304|Other|Group cTBS-iTBS-SHAM|PMv inhibition (cTBS) at session 2, PMv stimulation (iTBS) at session 3, and control (SHAM) at session 4
89026175|NCT02956304|Other|Group cTBS-SHAM-iTBS|PMv inhibition (cTBS) at session 2, control (SHAM) at session 3, and PMv stimulation (iTBS) at session 4
89026176|NCT02956304|Other|Group SHAM-iTBS-cTBS|control (SHAM) at session 2, PMv stimulation (iTBS) at session 3, and PMv inhibition (cTBS) at session 4
89026177|NCT02956304|Other|Group SHAM-cTBS-iTBS|control (SHAM) at session 2, PMv inhibition (cTBS) at session 3, and PMv stimulation (iTBS) at session 4
89026178|NCT00492102|Experimental|1|Nine VLBW pre-term infants older than 7 days will be enrolled in the study and receive one oral dose of Montelukast based on weight. Two blood samples will be obtained from each infant within 24 hours of the drug administration and plasma Montelukast levels will be determined.
89026179|NCT04354558||survival patients|The cohort will be dichotomised in survival/non-survival groups according to the issue during ICU stay
89026180|NCT04354558||non-survival patients|The cohort will be dichotomised in survival/non-survival groups according to the issue during ICU stay
89026181|NCT00465218||1|High dose aspirin (325 mg)
89026182|NCT00465218||2|Low dose aspirin (81 mgs) plus warfarin
89026183|NCT04354519||Confirmed Cases|"Diagnosed by health professional / Covid-19 test~Monitored through fortnightly questionnaires"
89026184|NCT04354519||Not Covid-19 cases|"Through self report no suspicion of COVID-19, tested by fortnightly questionnaire.~non Covid Cases can become COVID cases through self report."
89558048|NCT05121831|Experimental|Multiple Ascending Doses Cohort M1|Subjects will receive multiple doses of either dose level 1 of DGX-001 or placebo
89558049|NCT05121831|Experimental|Multiple Ascending Doses Cohort M2|Subjects will receive multiple doses of either dose level 2 of DGX-001 or placebo
89558050|NCT05121831|Experimental|Multiple Ascending Doses Cohort M3|Subjects will receive multiple doses of either dose level 3 of DGX-001 or placebo
89558051|NCT05121831|Experimental|Stress Exposure Resilience Panel Cohort 1|Subjects will receive any of the MAD dose panel or placebo
89558052|NCT05119400||COVID-19 group|"COVID-19 group will be made up of 30 patients that have a past diagnosis of COVID-19 with confirmed positive SARS-CoV-2 (Severe acute respiratory syndrome coronavirus 2) PCR (polymerase chain reaction) test in their electronic medical record and were previously hospitalized at NYP/WCM (NewYork Presbyterian/ Weill Cornell Medicine) between March 1 and December 31, 2020 for a minimum of three days.~Administration of study instruments, including self-report measures of mood, anxiety, post-traumatic stress and adjustment, and objective neuropsychological tests of cognitive function will be done via telephone interview, videoconference interview, and/or Redcap survey for both groups."
89558053|NCT05119400||Comparison group|"The subjects in comparison group will be 30 patients previously hospitalized at NYP/WCM between March 1 and December 31, 2020 for a minimum of three days. The recruited subjects would have undergone hospitalization secondary to a medical diagnosis that was not COVID-19.~Administration of study instruments, including self-report measures of mood, anxiety, post-traumatic stress and adjustment, and objective neuropsychological tests of cognitive function will be done via telephone interview, videoconference interview, and/or Redcap survey for both groups."
89558054|NCT05118009|Experimental|Intervention|Patients randomized to intervention will have access to the screening tool.
88964276|NCT02040389|Active Comparator|Standard preoperative education|Arm with children undergoing urological procedures and their parents will receive only standard preoperative education
88964277|NCT02040402|Active Comparator|4-Dose Regimen|"3+1 schedule of 7-valent pneumococcal conjugated vaccine:~Infants who are randomized for 3+1 schedule will be administrated one dose of PCV7 at the age of 2 months old, 4months old and 6 months old. A booster dose will be administrated at the age of 12 months old.~Infants will be followed up for 12-16 months starting from vaccination of first dose. There is no restriction on the use of other medications before or during the follow-up period."
88964278|NCT02040402|Active Comparator|3-Dose Regimen|"2+1 schedule of 7-valent pneumococcal conjugated vaccine:~Infants who are randomized for 2+1 schedule will be administrated with one dose of PCV7 at the age of 2 months old and 4months old. A booster dose will be administrated at the age of 12 months old.~Infants will be followed up for 12-16 months starting from vaccination of first dose. There is no restriction on the use of other medications before or during the follow-up period."
88964279|NCT02040415|Experimental|DW-1030(eperisone HCl)|DW-1030(eperisone HCl) 75mg BID
88964280|NCT02040415|Active Comparator|Myonal Tab.(eperisone HCl)|Myonal Tab.(eperisone HCl) 50mg TID
88964281|NCT02040441|Active Comparator|Spironolactone|High-risk pattern: Spironolactone 25 mg once daily + Standard care
88964282|NCT02040441|Placebo Comparator|Placebo|High-risk pattern: One placebo tablet once daily + Standard care
88964283|NCT02040441|Other|Observational|Low-risk pattern: Standard care
88964284|NCT02040454|Active Comparator|Standard Therapy Plus Paclitaxel|"Standard Therapy - heparin, angioplasty, stent~Paclitaxel - single intravascular dose up to 20 mg"
88964285|NCT02040454|Sham Comparator|Standard Therapy Alone|heparin, angioplasty, stent
88964286|NCT02040480|Experimental|Sequence 1|Participants will receive treatment in following sequence in each of the three study periods (one treatment per period): ABC
88964287|NCT02040480|Experimental|Sequence 2|Participants will receive treatment in following sequence in each of the three study periods (one treatment per period): ACB
88964288|NCT02040480|Experimental|Sequence 3|Participants will receive treatment in following sequence in each of the three study periods (one treatment per period): BAC
88964289|NCT02040480|Experimental|Sequence 4|Participants will receive treatment in following sequence in each of the three study periods (one treatment per period): BCA
88964290|NCT02040480|Experimental|Sequence 5|Participants will receive treatment in following sequence in each of the three study periods (one treatment per period): CAB
88964291|NCT02040480|Experimental|Sequence 6|Participants will receive treatment in following sequence in each of the three study periods (one treatment per period): CBA
88964292|NCT02040493|Experimental|Intra-operative radiation therapy (IORT)|IORT
88964293|NCT02040506|Experimental|IGN523|IGN523
88964294|NCT02040519|Experimental|Evaluation by voiding diaries|
88964295|NCT02040545||Infertility|Patients undergoing ovulation induction and controlled ovarian hyperstimulation at a participating infertility center
89026185|NCT04354519||Suspected Covid-19 Cases|"Participants that are suspected of having Covid-19 but this has not been confirmed by health professional or Covid-19 test has not been performed.~Fortnighly questionnaire"
89026186|NCT04353349||Patients operated with an open approach|
89558055|NCT05118009|No Intervention|Control|Patients randomized to control will continue routine practice.
89558056|NCT05113537|Experimental|Part A: Abemaciclib, 177Lu-PSMA-617|Patients receive abemaciclib lead-in on days 1-14 and lutetium Lu 177 vipivotide tetraxetan IV over 30 minutes on day 15. Treatment repeats every 6 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
89026187|NCT04353349||Patients operated with minimally invasive robotic approach|
89026188|NCT04353349||Patients operated with VATS approach|
89558057|NCT05113537|Experimental|Part B: Recommended Phase 2 dose of Abemaciclib, 177Lu-PSMA-617|Patients receive the recommended phase 2 dose of abemaciclib lead-in on days 1-14 and lutetium Lu 177 vipivotide tetraxetan IV over 30 minutes on day 15. Treatment repeats every 6 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
89558058|NCT05110300|Active Comparator|Body weight support system control group|The Body weight support system (BWSS) active comparator control group will conduct 2 to 6, 30 minute sessions, over two-weeks. To be as pragmatic and clinically relevant as possible, treatment sessions will be incorporated directly to the participants' normal care. Furthermore, participants are allowed to complete 2 to 6 sessions as dictated by short or unexpected changes to the discharge planning timeline. During each session, participants will conduct balance exercises, including: marching, side-stepping, retro-ambulation, step-taps, and step-ups. Participants will also conduct various standard gait exercises, including: ambulation over the ground, going up and down stairs, and performing sit-to-stand transitions.
89026189|NCT04352335||Cohort 1：ICI treatment with immunomodulator|Lung cancer patients received immunological checkpoint inhibitors (ICIs) and any immunomodulatory drugs.
89558059|NCT05110300|Experimental|Body weight support system with balance perturbations|The BWSS with balance perturbations (BWSS-P) experimental intervention group will also conduct 2 to 6, 30 minute sessions, over two-weeks. Participants in the BWSS-P group will conduct the same balance and gait exercises as the control group, including: marching, side-stepping, retro-ambulation, step-taps, step-ups, ambulation over the ground, going up and down stairs, and performing sit-to-stand transitions. However, each sessions will include eight, resistive or assistive, balance perturbations, two in each cardinal direction (lateral, anterior, and posterior).
89558060|NCT05092542|No Intervention|Random Sample of Latinx Immigrants|random sample comparison group of Latinx immigrants who are NOT randomly assigned to a treatment condition
89026190|NCT04352335||Cohort 2：ICI treatment without immunomodulator|Lung cancer patients received immunological checkpoint inhibitors (ICIs).
89026191|NCT00499044|Experimental|1|MATRICS Consensus Cognitive Battery
89026192|NCT00499044|Experimental|2|Cognitive Drug Research Computerized Cognitive Assessment System
89026193|NCT02892838|Experimental|mobile bearing knee prosthesis|use of the Scorpio mobile bearing knee system for total knee arthroplasty
89026194|NCT02892838|Active Comparator|fixed bearing|use of the Scorpio fixed bearing knee system for total knee arthoplasty
89026195|NCT00467636|Experimental|Insulin Glulisine|Blood glucose monitoring and treatment of hyperglycaemia with insulin. Insulin to be with-held if pre meal blood glucose < 4 mmol/l.
89026196|NCT00467636|Active Comparator|2|Blood glucose monitoring for comparison with treatment arm (1)
89026197|NCT00492141|Experimental|L9-NC + Temozolomide|Liposomal 9-nitro-20(S)-camptothecin (L9-NC) alone, total 10 ml of 0.4 mg/ml in aerosol reservoir once a day for 5 days in row each 2 weeks, followed by 2 weeks off; then in combination with Temozolomide 100 mg/m^2 oral/day for Cycle 2 Days 1-5.
89026198|NCT04327726|Placebo Comparator|Control group|received ultrasonic nebulization of 4mL 0.9% saline twice daily for 3 days
89026199|NCT04327726|Active Comparator|Dexmedetomidine group|received ultrasonic nebulization of 1 µg/kg dexmedetomidine diluted in 4mL 0.9% saline twice daily for 3 days. The intervention will be continued until achieving a VAS score ≤3 and Lybecker et al. classification score <2 and or for a maximum of 72 hours. Patients in this group who achieved the target scores before 72 hours will be given 4ml of saline 0.9% nebulization to maintain blinding.
89026200|NCT00499161|No Intervention|1|Control group received usual care
89208364|NCT00801788|Experimental|Egalet® oxycodone Treatment B|Single Dose Administration
89208365|NCT00801788|Experimental|Egalet® oxycodone Treatment C|Single Dose Administration
89208366|NCT00801788|Active Comparator|Active comparator|Single Dose Administration
89026201|NCT00499161|Experimental|2|Received intervention New model of nursing care
89026202|NCT04349449||Vedolizumab Participants|Participants diagnosed with moderate to severe CD from approximately 20 investigational sites will be observed over a period of 12 months after initiation of treatment with vedolizumab, intravenous infusion under standard clinical care.
89026203|NCT03271970||Patients with conductive hearing loss|
89208367|NCT01070485|Experimental|Radium-223 dichloride (Xofigo, BAY 88-8223)|Patients were to receive 4 intravenous administrations of Radium-223 at a dose of 50 kBq/kg body weight (b.w) at intervals of 4 weeks. Radium-223 was given as add-on therapy to existing bisphosphonate therapy.
89208368|NCT00618618|Experimental|Deoxycholic Acid Injection 0.2 mL/0.7 cm|Participants received deoxycholic acid administered in 0.2 mL injections, 0.7 cm apart, up to 9.6 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
89208369|NCT00618618|Placebo Comparator|Placebo 0.2 mL/0.7 cm|Participants received placebo administered in 0.2 mL injections, 0.7 cm apart, up to 9.6 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
89208370|NCT00618618|Experimental|Deoxycholic Acid Injection 0.2 mL/1.0 cm|Participants received deoxycholic acid administered in 0.2 mL injections, 1.0 cm apart, up to 4.8 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
89026204|NCT00492219|Active Comparator|1|Patients undergoing total knee replacement
89026205|NCT00492219|No Intervention|2|Healthy volunteers that are not undergoing knee replacement surgery
89026206|NCT00492219|Experimental|3|Patients undergoing partial knee replacement with the Oxford mobile bearing implant system
89026207|NCT00492219|Experimental|4|Patients undergoing partial knee replacement with the Vanguard M implant system
89026208|NCT04348084||who developed POPF|Patients undergone curative distal pancreatectomy for PDAC who developed POPF
89026209|NCT04348084||who did not develop POPF|Patients undergone curative distal pancreatectomy for PDAC who did not develop POPF
89026210|NCT04345354||Patient with continuous positive airway pressure treatment|
89026211|NCT04345354||without continuous positive airway pressure treatment|
88964296|NCT02040558|Experimental|MNK-010|Subjects will receive 1 dose of MNK-010 followed by a 7-day post dose assessment period per treatment cycle. Dose levels will be based upon the amount of active delivered per square meter of body surface area (mg/m2). Cycles will repeat every 3 weeks (21 days) based on toxicity and response, as determined by a Safety Review Committee (SRC). Subjects will continue treatment with MNK-010 until unacceptable toxicity, documented progression of disease, another criterion for discontinuation is met, or until 4 treatment cycles have been completed.
88964297|NCT02040571|Experimental|Closed Loop|
88964298|NCT02040571|Active Comparator|Open Loop|
88964299|NCT02040584|Experimental|Minimisation of TAC|Treatment with rTAC+EVR+corticosteroids
88964300|NCT02040584|Active Comparator|TAC + MMF + corticosteroids|Treatment with TAC + MMF + corticosteroids
88964301|NCT02040597|Experimental|CHF5993 pMDI|CHF 5993 pMDI (Beclometasone/Formoterol/Glycopyrrolate 100/6/25 mcg) 4 inhalations
88964302|NCT02040610|Active Comparator|Low Risk Prostate Cancer|Hypofractionated Proton Therapy 62 Gy (RBE) in 20 fractions of 3.1 Gy (RBE) over 4 weeks
88964303|NCT02040610|Active Comparator|Intermediate Risk Prostate Cancer|Hypofractionated Proton Therapy 62 Gy (RBE) in 20 fractions of 3.1 Gy (RBE) over 4 weeks
88964304|NCT02040636|Experimental|Study Group 1|Participants randomized to receive Tetanus and Diphtheria Toxoids Adsorbed Combined with Component Pertussis Vaccine and Inactivated Poliomyelitis Vaccine (TdcP-IPV) at month 0, Hepatitis B at months 1, 2 and 7.
88964305|NCT02040636|Active Comparator|Study Group 2|Participants randomized to receive Tetanus and Diphtheria Toxoids Adsorbed Combined with Component Pertussis Vaccine and Inactivated Poliomyelitis Vaccine (TdcP-IPV) + Hepatitis B at month 0, Hepatitis B at months 1 and 6.
88964306|NCT02040649|Experimental|Non-sedation|Non-sedation supplemented with pain management during mechanical ventilation.
88964307|NCT02040649|Active Comparator|Sedation|Current gold standard: Sedation with a daily wake-up trial.
88964308|NCT02040662|Experimental|Continuous Thoracic Paravertebral Block|"continuous thoracic paravertebral blockade 0,08 ml/kg/h with bupivacaine 0,25% + epinephrine 1:200.000~patient-controlled analgesia (morphine), bolus dose 2 mg, lockout time 10 min"
88964309|NCT02040662|Experimental|Continuous Thoracic Epidural Analgesia|"continuous thoracic epidural block 0,06 ml/kg/h with bupivacaine 0,25% + epinephrine 1:200.000~patient-controlled analgesia (morphine), bolus dose 2 mg, lockout time 10 min"
88964310|NCT02040688||Sleep Disorders|7-36 months old children with behavioral insomnia of childhood based on the International Classification of Sleep Disorders (ICSD) criteria will be recruited from the Pediatric Sleep Center at Dana Children's hospital
88964311|NCT02040688||Control|7-36 months old chidren of age who attend well-care clinics in the metropolitan of Tel Aviv for routine periodic medical examination.
88964312|NCT02040688||Feeding disorder|7-36 monthsold children with feeding disorders based on Chatoor criteria will be recruited from the clinic of feeding disorders at Dana Children's Hospital.
88964313|NCT02040701||SDB group|
88964314|NCT02040701||Control group|
88964315|NCT02040727|Active Comparator|Non-Resistance Trained|No Participation in Resistance Training
88964316|NCT02040727|Experimental|Resistance Trained|Participation in Resistance Training
88964317|NCT02040740||Observation|Healthy early pubertal boys
88964318|NCT02040753||Intensive Lifestyle Intervention|Former participants of intensive lifestyle intervention at Ubberup Folk High School.
88964319|NCT02040818|Experimental|Antibiotic Lock Solution|
88964320|NCT02040818|Active Comparator|Guide-wire Exchange|
88964321|NCT02040831|Experimental|RSV LID ΔM2-2 Vaccine|Participants will receive one dose of the RSV LID ΔM2-2 vaccine at study entry, delivered as nose drops.
88964322|NCT02040831|Placebo Comparator|Placebo Vaccine|Participants will receive one dose of placebo at study entry, delivered as nose drops.
88964323|NCT02040883|Active Comparator|Control Group|Treated with a stable dose of an AAPD for at least three months before enrollment; Atypical antipsychotic drugs(AAPDs): Risperidone/Olanzapine/Quetiapine/Ziprasidone/Aripiprazole
88964324|NCT02040883|Experimental|Study Group|Atypical antipsychotic drugs(AAPDs) and Tandospirone ; Atypical antipsychotic drugs(AAPDs) ,treated with a stable dose of an AAPD for at least three months before enrollment; AAPD: Risperidone/Olanzapine/Quetiapine/Ziprasidone/Aripiprazole; Tandospirone, 30mg per day;
88964325|NCT02040896||Group 1|All consecutive emergency department patients undergoing CT during study hours will be prospectively enrolled, except for those meeting pre-specified exclusion criteria.
88964326|NCT02040909|Experimental|Propofol|A predetermined propofol dose is used in every 5 consecutive patients per age group. Starting dose is 1.0 mg/kg. Dose is increased or decreased with 0.5 mg/kg
88964327|NCT02040922||Post-Campylobacter|Adults with symptoms of intestinal infection who submit a stool sample from which Campylobacter jejuni or coli is cultured
88964328|NCT02040935|Experimental|Trastuzumab|Participants will receive 600 milligrams (mg) trastuzumab SC by SID every 3 weeks (Q3W) for up to a total of 1 year, unless disease recurrence, unacceptable toxicity or participant withdrawal occurs. The first 3 administrations will be done at hospital, after that participants will be permitted to self-administer under the supervision of a healthcare professional (HCP).
88964329|NCT02040948|Experimental|Surgical patients|"Nexfin (Pulse Pressure Variation)~Radical 7 (Pleth Variability Index)~CardioQ (stroke volume)"
88964330|NCT02040961|Experimental|EtView|Use of ETVew double-lumen tube
88964331|NCT02040987|Experimental|AZD3293 dose A|AZD3293 therapeutic dose oral solution (low dose)
88964332|NCT02040987|Experimental|AZD3293 dose B|AZD3293 supratherapeutic dose oral solution (high dose)
88964333|NCT02040987|Placebo Comparator|Placebo|Placebo oral solution
88964334|NCT02040987|Active Comparator|Moxifloxacin|Moxifloxacin tablet
88964335|NCT02041013|No Intervention|No Talking Card|Usual care of asthma by study clinician, including evaluation of asthma using C-ACT and clinical history, treatment using asthma action planning
88964336|NCT02041013|Experimental|Taking Card|Usual care, as in comparison group, plus recordable Talking Card at each visit
88964337|NCT02041026|Experimental|probiotic yoghurt|the subject will be given 200ml of yogurt daily for 28 days
89558061|NCT05092542|Experimental|Refugee & Immigrant Well-being Project (RIWP) Intervention|6-month mental health intervention that pairs university students with newcomers to engage in mutual learning, resource mobilization, and social change efforts
89558062|NCT05092542|No Intervention|Treatment-as-usual Waitlist Control Group|participants recruited from community-based organizations receive usual services from community-based organizations and may participate in RIWP intervention in Year 3
89558063|NCT05088252|Experimental|Desflurane Inhalational Anesthesia|
89558064|NCT05088252|Active Comparator|Propofol Total Intravenous Anesthesia|
89558065|NCT05069298|Experimental|INTERVENTION|Silibinin (A) for three months, with an administration regimen of 3 oral doses of 300 mg per day, before each main meal.
89558066|NCT05069298|Placebo Comparator|CONTROL|Similar treatment regimen, but with a placebo.
88964338|NCT02041052|Active Comparator|Conventional Whipple procedure|Conventional Whipple procedure
89558067|NCT05068258|Experimental|Venous leg ulcers patients undergoing lymphovenous bypass|
89558068|NCT05065632||Groupe 1|[1-15[
88964339|NCT02041052|Experimental|Subtotal gastrectomy added to whipple procedure.|Subtotal gastrectomy added to Whipple procedure.
88964340|NCT02041065|Experimental|Waterjet induced dissection|Waterjet induced dissection of the liver during resection.Waterjet dissection device mechanically separates hepatic tissue from bile ducts and vessels, the latter two to be separately ligated.
88964341|NCT02041065|Active Comparator|CUSA induced dissection|CUSA transection of the liver. Ultrasound based destruction of the liver parenchyma to allow separate ligation of the bile duct and intrahepatic vessels.
88964342|NCT02041078|Placebo Comparator|Extrahepatic vein division|Conventional right sided hemihepatectomy with division of the liver parenchyma with CUSA.
88964343|NCT02041078|Experimental|Intrahepatic vein division|Conventional right sided hemihepatectomy with division of the liver parenchyma with CUSA and intrahepatic division of the right hepatic vein.
88964344|NCT02041117|Other|Rosuvastatin|
88964345|NCT02041130|Experimental|Renal Denervation and standard medical management|"Renal Denervation (RDN) is a simple catheter procedure removing excess nerve signals to and from the kidneys. The renal denervation system consists of a small steerable treatment catheter and an automatically-controlled treatment delivery generator.~A guiding catheter is inserted through a tiny incision in the groin into the femoral artery to direct the treatment catheter to the renal arteries. The treatment catheter delivers high -frequency radio waves, called radiofrequency wavees, to 4-6 locations within each of the two renal arteries. the energy delivered is about 8 watts and aims to disrupt the nerves and lower blood pressure over a period of months. The procedure takes 40-60 minutes."
88964346|NCT02041130|No Intervention|Contorl and Standard Medical Management|Continued medical management will comprise management of all cardiovascular risk factors (hypertension, diabetes, dyslipidaemia) in accord with international guidelines. Lifestyle and dietary counselling will also be part of the patient management. As there is no established evidence-based pharmacotherapy for HFPEF per se, therapy aimed at HF specifically will adopt treatments recommended for HFREF with prescription of diuretic, ACE inhibitor/ARB, beta blocker and mineralocorticoid antagonist accordingly.
89208371|NCT00618618|Placebo Comparator|Placebo 0.2 mL/1.0 cm|Participants received placebo administered in 0.2 mL injections, 1.0 cm apart, up to 4.8 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
89558069|NCT05065632||Group 2|[15- 30[
89558070|NCT05065632||Group 3|[30-45[
89558071|NCT05065632||Group 4|[45-60[
89558072|NCT05065632||Group 5|60+
89558073|NCT05062759|Experimental|Tezepelumab|Participants will be randomized to receive tezepelumab 210 mg administered at Weeks 0, 4, 8 and 12. Participants will also receive a single dose of inactivated quadrivalent seasonal influenza vaccine intramuscularly at Week 12, prior to the fourth dose of study intervention.
89558074|NCT05062759|Placebo Comparator|Placebo to Tezepelumab|Participants will be randomized to receive placebo SC Q4W, administered at Weeks 0, 4, 8 and 12. Participants will also receive a single dose of inactivated quadrivalent seasonal influenza vaccine intramuscularly at Week 12, prior to the fourth dose of study intervention.
89558075|NCT05057715|Active Comparator|Cohort 1|Single dose of 3.3x10(12) vp of VCN-01 on Day 0, followed by a single dose of 5x10(7) of huCART-meso cells on Day 14.
89558076|NCT05057715|Active Comparator|Cohort 2|Single dose of 1x10(13) vp of VCN-01 on Day 0, followed by a single dose of 5x10(7) of huCART-meso cells on Day 14.
89558077|NCT05057715|Active Comparator|Cohort -1|In the event that 2 DLTs occur in Cohort 1, then enrollment in Cohort 1 will be stopped and Cohort -1 will be opened for evaluation. Enrolled subjects will receive a single dose of huCART-meso cells on Day 0 followed by a single dose of 3.3x10(12) vp of VCN-01 on Day 14.
89558078|NCT05056454|No Intervention|Treatment as usual (TAU, a.k.a. Perinatal Psychiatric Care)|This treatment condition is modelled after the psychiatry-delivered treatment usually provided at the Maternal Outpatient Mental Health Services (MOMS) Clinic associated with the UCLA Westwood OB-GYN Clinic and Department of Psychiatry.
89558079|NCT05056454|Experimental|Screening and Treatment of Anxiety and Depression (STAND)|This treatment condition provides access to a system of care, in which type of treatment is allocated based on presenting symptomatology. Participants will learn their allocation from study staff or participants will create a secure account through STAND to learn about their allocation through the STAND online dashboard. Through their STAND online dashboard, they could also have access to a) their CAT-MH results over time from the start of treatment, b) assessment of their current diet/nutrition and psychoeducation about the relationship between diet/nutrition and mental health, and c) list of additional resources available to them.
89608706|NCT03588507|No Intervention|Papilla preservation flap techniques|Papilla preservation flap techniques will be conducted to gain access to the intrabony defects. In the narrow interproximal spaces (≤2 mm), incision with the preservation of the buccal papilla according to the simplified papilla preservation technique will be applied. Whereas, in the wide interdental spaces (>2 mm), the modified papilla preservation technique will be applied. Vertical or horizontal mattress sutures and additional interrupted single sutures will be performed to obtain primary closure of the interdental space.
89208372|NCT00618618|Experimental|Deoxycholic Acid Injection 0.4 mL/1.0 cm|Participants received deoxycholic acid administered in 0.4 mL injections, 1.0 cm apart, up to 9.6 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
89558080|NCT05050240|Experimental|Cold Exposure|The cold vest procedure: The first blood draw will be taken from participants before the cooling procedure (time 0, 30mL blood). Participants will then be requested to put on hospital scrubs and the cooling vest will be placed on them. Since muscle shivering is an alternative way of heat production (skeletal thermogenesis), we will first determine individual 'shivering threshold' for each participant (coldest tolerable temperature; typically 14°C / 57.2F), based on participant-report and direct observation. The cold vest will then be kept on for 3 hours with a temp set to the coldest tolerable temperature (shivering threshold +2°C (~16-17°C / 60.8F-62.6F) and body temperature will be monitored by a tympanic thermometer. Following 3 hours, 30mL of blood will be drawn (Time 180min). All participants will be re-warmed with blankets after cooling has been completed, and offered a warm drink and a snack.
89558081|NCT05050240|Active Comparator|Fasted procedure without cooling|"This arm has been added in order to exclude the effects of prolonged fasting on blood analytes. Previously enrolled participants will be re-invited to donate blood after 12hr fast and 3hrs later (15hr fast) without the cooling procedure. Participants will be re-consented for this lab appointment. The night prior the visit, the participants will be instructed to fast from 10:00pm. At the time of visit vital signs and anthropomorphic measurements will be taken.~Blood Draw: The first blood draw will take place in the morning. Participant will then be asked to sit in the procedure room for 3 hours at room temperature; second blood draw will take place after 3 hrs. Total of 38ml of blood will be drawn. Blood will be used for clinical labs (fasting glucose, Hba1c, TSH, TG) and research."
88964347|NCT02041143|Experimental|Milk protein|Study product will provide 25 g of protein to subjects. One single supplement will be taken.
89558082|NCT05047640|Experimental|BNT162b2 vaccine Group|Participants in this arm will receive one booster dose of the BNT162b2.
88964348|NCT02041143|Placebo Comparator|Placebo|Placebo (no protein)
89558083|NCT05047640|Experimental|JNJ-78436735 vaccine Group|Participants in this arm will receive one booster dose of the JNJ-78436735
89558084|NCT05047224|Experimental|Tele-assessment + in-person assessment|Participants in this group will receive a tele-assessment using the TAP and will attend a traditional, in-person evaluation for autism spectrum disorder in a clinic setting.
88964349|NCT02041156|Experimental|aerobic with resistance training|Regular aerobic activity combined with 3 sessions/week of resistance training totalling 150 minutes per week of physical activity
89558085|NCT05047224|Active Comparator|Tele-assessment only|Participants in this group will receive a tele-assessment using the TAP, followed by a second, shorter tele-assessment.
89558086|NCT05043714|Experimental|Intravenous|"Phase 1a Part A: One cycle (28 days) of NG-641 on Days 1, 3 and 5 and nivolumab on Day 15, followed by nivolumab every 4 weeks.~Phase 1a Part B: NG-641 on Days 1, 3 and 5 and one nivolumab on Day 15 in each of up to eight 28-day cycles."
89558087|NCT05039073|Experimental|Treatment (brentuximab vedotin, nivolumab)|Patients receive brentuximab vedotin IV over 30 minutes and nivolumab IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 16 cycles in the absence of disease progression or unacceptable toxicity. Patients who achieve complete response or partial response at any time after 4 cycles may discontinue study therapy to proceed to autologous or allogeneic stem cell transplant.
88964350|NCT02041156|Active Comparator|aerobic with balance training|Regular aerobic activity combined with 3 sessions/week of balance training totalling 150 minutes per week of physical activity
88964351|NCT02041182|Experimental|Intervention Pre-visit Questionnaire|Adolescents receive PVQ that includes questions about youth violence/bullying
88964352|NCT02041182|Active Comparator|Control Pre-visit Questionnaire|Adolescents received PVQ without youth violence/bullying items
88964353|NCT02041247|Active Comparator|VAC-3S 16µg/administration|VAC-3S 16µg/ml administered every 4 weeks for 3 months followed by 3 maintenance vaccinations every 12 weeks after the third initial vaccination.
88964354|NCT02041247|Placebo Comparator|VAC-3S Placebo|VAC-3S placebo administered every 4 weeks for 3 months followed by 3 maintenance vaccinations every 12 weeks after the third initial vaccination.
88964355|NCT02041247|Active Comparator|VAC-3S 32 µg/administration|VAC-3S 32µg/ml administered every 4 weeks for 3 months followed by 3 maintenance vaccinations every 12 weeks after the third initial vaccination.
88964356|NCT02041247|Active Comparator|VAC-3S 64 µg/administration|VAC-3S 64µg/ml administered every 4 weeks for 3 months without maintenance vaccination.
88964357|NCT02041260|Experimental|Open Label Cabozantimib|
88964358|NCT02041273|Experimental|Palbociclib given to healthy volunteers|
88964359|NCT02041312||Gastric cancer|No intervention
88964360|NCT02041338|Experimental|Luminal subtype test|Paclitaxel 175mg/m2, every 2 weeks as a cycle for 4-6 cycles
88964361|NCT02041338|Active Comparator|Luminal subtype control|Epirubicin 75mg/m2 plus paclitaxel 175mg/m2 every 3 weeks as a cycle for 4-6 cycles
88964362|NCT02041338|Experimental|Her2 positive subtype test|Paclitaxel 175mg/m2 plus carboplatin AUC 4 with or without trastuzumab every 2 weeks as a cycle for 4-6 cycles
88964363|NCT02041338|Active Comparator|Her2 positive subtype control|Epirubicin 75mg/m2 plus paclitaxel 175mg/m2 with or without trastuzumab every 3 weeks as a cycle for 4-6 cycles
88964364|NCT02041338|Experimental|Triple negative subtype test|Paclitaxel 175mg/m2 plus carboplatin AUC 4 every 2 weeks as a cycle for 4-6 cycles
88964365|NCT02041338|Active Comparator|Triple negative subypte control|Epirubicin 75mg/m2 plus paclitaxel 175mg/m2 every 3 weeks as a cycle for 4-6 cycles
88964366|NCT02041351|Experimental|docetaxel|measurement evaluation every 2 months tomography of all measurable lesions in millimeters, to assess response rate, partial and complete responses.
88964367|NCT02041364||Control: patients without fatigue|Patients whose scores on the brief fatigue inventory (BFI) (15) won't increase after having received the first cycle of chemotherapy will be considered as controls
88964368|NCT02041364||Patients with fatighe|Patients whose scores on the brief fatigue inventory (BFI) (15) increase after having received the first cycle of chemotherapy will be considered as having manifested fatigue
88964369|NCT02041390|Experimental|SMS group|Patients in SMS group will receive reminding by additional SMS messages monthly after stent implantation.
89558088|NCT05037669|Experimental|Cohort A: Acute Lymphoblastic Leukemia (ALL)|Adult patients aged >18 with relapsed or refractory B cell malignancies - Acute Lymphoblastic Leukemia (ALL)
89558089|NCT05037669|Experimental|Cohort B: Chronic Lymphocytic Leukemia (CLL) + Non-Hodgkin's Lymphoma (NHL)|Adult patients aged >18 with relapsed or refractory B cell malignancies - Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL).
89558090|NCT05033262|No Intervention|Control|Participants who are allocated to the control arm will complete baseline measures and then receive usual advanced care planning care and discussions with the nursing facility staff. Control arm participants will not review the Our Memory Care Wishes website. Participants will complete follow up measures one week after the baseline interview.
89558091|NCT05033262|Experimental|Intervention|Participants allocated to the intervention group will complete baseline measures. Then, the participant will review the Our Memory Care Wishes website and enter advanced care planning decisions and preferences into the website. Participants will complete follow up measures one week after the baseline interview. Participants receiving the intervention will complete additional follow up measures which include surveys measuring the ease of use of the website.
89558092|NCT05029999|Experimental|Cohort A|"PLD chemotherapy will be administered 40 mg/m2 as intravenous injection once per cycle until toxicity or progression.~CDX-1140 will be administered 1.5mg/kg as intravenous injection once per cycle until toxicity or progression for up to 24 months.~CDX-301 will be administered 75µg/kg as subcutaneous injection daily x 5 days cycles 1 and 2 only."
89558093|NCT05029999|Experimental|Cohort B|"PLD chemotherapy will be administered 40 mg/m2 as intravenous injection once per cycle starting on cycle 2 until toxicity or progression.~CDX-1140 will be administered 1.5mg/kg as intravenous injection once per cycle until toxicity or progression for up to 24 months.~CDX-301 will be administered 75µg/kg as subcutaneous injection daily x 5 days cycles 1 and 2 only."
89558094|NCT05029999|Experimental|Cohort C|"PLD chemotherapy will be administered 40 mg/m2 as intravenous injection once per cycle until toxicity or progression.~CDX-1140 will be administered 1.5mg/kg as intravenous injection once per cycle starting on cycle 2 until toxicity or progression for up to 24 months.~CDX-301 will be administered 75µg/kg as subcutaneous injection daily x 5 days cycles 2 and 3 only."
88964370|NCT02041390|Active Comparator|Conventional reminder group|Patients in control group will not receive additional SMS reminder monthly after stent implantation.
88964371|NCT02041403||Renal resistive Index|
88964372|NCT02041455|Experimental|Melatonin and Placebo|Melatonin 10mg and placebo, once in the evening, for 6 weeks.
88964373|NCT02041455|Experimental|Amitriptyline and placebo|Amitriptyline 25mg and placebo, once in the evening, for 6 weeks.
88964374|NCT02041455|Active Comparator|Melatonin and Amitriptylin|Melatonin 10mg and Amitriptylin 25mg, once in the evening, for 6 weeks.
88964375|NCT02041468||Pharmacoeconomic main study|Patients from Quebec and Ontario (first or second line treatment)
88964376|NCT02041468||Biomarker sub-study|Patients from Quebec only (first or second line treatment)
88964377|NCT02041481|Experimental|Arm I (continuous MEK inhibitor MEK162, FOLFOX)|Patients receive MEK inhibitor MEK162 PO BID on days 1-14, and leucovorin calcium IV over 2 hours, oxaliplatin IV over 2 hours, and fluorouracil IV continuously over 46 hours on days 1 and 2. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
88964378|NCT02041481|Experimental|Arm II (intermittent MEK inhibitor MEK162, FOLFOX)|Patients receive MEK inhibitor MEK162 PO BID on days 1-5, and leucovorin calcium IV over 2 hours, oxaliplatin IV over 2 hours, and fluorouracil IV continuously over 46 hours on days 6 and 7. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
88964379|NCT02041507|Active Comparator|Air insufflation method.|Colonoscopy performed in the standard fashion, with the minimal air insufflation required to aid insertion and allowing for washing as needed. Considered to be standard procedure.
89208373|NCT00618618|Placebo Comparator|Placebo 0.4 mL/1.0 cm|Participants received placebo administered in 0.4 mL injections, 1.0 cm apart, up to 9.6 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
89026212|NCT01245465|Experimental|Profermin|Daily oral intake of a food for special medical purposes (Profermin)
89208374|NCT00796250|Experimental|Group A|
89208375|NCT00796250|Active Comparator|Group B|
89208376|NCT01070563||Usual|CT angiography is performed 6 hours after the clinical diagnosis of brain death.
89558095|NCT05025956|Experimental|Fisetin group (investigational group)|"20mg/kg of Fisetin per day for days 1 and 2 prior to surgery and days 33, 34, 63, 64, 93, and 94 post surgery.~(The pills are 100mg each. For example, if a participant weighs 160 pounds (about 73 kg), the participant will need to take 15 pills per day)"
89558096|NCT05025956|Placebo Comparator|Placebo group (control group)|"20mg/kg of Placebo per day for days 1 and 2 prior to surgery and days 33, 34, 63, 64, 93, and 94 post surgery.~(The pills are 100mg each. For example, if a participant weighs 160 pounds (about 73 kg), the participant will need to take 15 pills per day)"
89558097|NCT05023967|Experimental|Arm I (fasting, glucose monitoring, counseling, metformin)|Patients fast for >= 16 hours every night and use the continuous glucose monitoring system for 4-6 weeks. Patients also receive nutritional counseling sessions on days 0 and 10. Beginning week 2, patients also receive metformin hydrochloride extended release PO QD until the day of surgery. Treatment continues for 4-6 weeks (until surgery) in the absence of disease progression or unacceptable toxicity. Patients undergo the collection of blood samples at baseline and at the final study visit (days 28-43), and the collection of tissue at the time of surgery (days 28-43).
88964380|NCT02041507|Experimental|Water Immersion method.|Infusion of water during the insertion phase of colonoscopy mainly to open the colonic lumen and progress to the cecum immersed in the water environment thus created, without attempting to clear the colon contents. Residual air in the colon will not be removed. Infused water and residual feces will be suctioned back predominantly during withdrawal. Insufflation not used until the cecum is reached. It will be allowed only 3 times and no more than 10 seconds each time (ITT failure if >3) if the lumen cannot be seen. Withdrawal phase done using air insufflation.
88964381|NCT02041507|Experimental|Water Exchange method.|Insufflation not used until the cecum is reached. Infusion of a sufficient amount of water to render the lumen of the colon a slit to progress with the colonoscope. Part of the infused water will be constantly suctioned back exchanging clean for dirty or hazy water. Air pockets will be always aspirated to collapse the lumen. After cecal intubation as much residual water as possible will be aspirated before beginning the withdrawal phase. During withdrawal residual water and feces will be suctioned. Withdrawal phase done using air insufflation.
88964382|NCT02041546|Active Comparator|Bolus surfactant|Bolus surfactant 100 mg/kg proctant alfa
88964383|NCT02041546|Active Comparator|Lung lavage with surfactant|Lung lavage with surfactant
88964384|NCT02041559||robot assisted prostatectomy|robot assisted prostatectomy
88964385|NCT02041572|Other|Attentional Bias Retraining|Each participant receives 12 sessions. The first three sessions are baseline (assessment only) sessions. The last four sessions must be treatment sessions. The attentional bias intervention starts randomly on sessions 4 - 8, and continues until the end of the 12 sessions.
88964386|NCT02041598|Experimental|Full CHW Intervention|5 monthly group educational sessions, 2 1v1 Visits with CHW, Phone Calls as Needed
89558098|NCT05023967|Active Comparator|Arm II (glucose monitoring)|Patients continue their usual dietary pattern and use the continuous glucose monitoring system for 4-6 weeks (until surgery). Patients undergo the collection of blood samples at baseline and at the final study visit (days 28-43), and the collection of tissue at the time of surgery (days 28-43).
89558099|NCT05022264||Participants|All participants will have their vital signs measured with conventional techniques as well as with the new experimental medical device (labelled RIA-VS)
89558100|NCT05012254|Experimental|Induction treatment + Maintenance|"Induction: 2 cycles of platinum-based chemotherapy plus (Nivolumab + Ipilimumab):~- Non-squamous NSCLC patients: Pemetrexed: 500 mg/m2 IV, Q3W Carboplatin: AUC 5 o 6 or Cisplatin: 75 mg/m2 IV, Q3W Nivolumab: 360 mg IV Q3W Ipilimumab: 1mg/kg IV Q6W~2 cycles will be administered at 21-day intervals (Q3W) for Pemetrexed, Carboplatin/Cisplatin and Nivolumab. Ipilimumab will be administered at 42 days interval (Q6W).~- Squamous NSCLC patients: Paclitaxel: 200 mg/m2 IV, Q3W Carboplatin: AUC 5 o 6, Q3W Nivolumab: 360 mg IV, Q3W Ipilimumab: 1mg/kg IV, Q6W~Maintenance: following two cycles of chemo-immunotherapy the patients will receive:~Nivolumab: 360 mg IV, Q3W Ipilimumab: 1mg/kg IV, Q6W~Immunotherapy will be administered until disease progression, unacceptable toxicity, loss of clinical benefit or up to a maximum of 2 years of treatment."
89558101|NCT05012241||Czech patients with multiple sclerosis|Czech patients with multiple sclerosis will be asked to fill in a questionnaire. Then they will be tested by the Nine Hole Peg Test. Video of their performance will be obtained.
89558102|NCT05009121||Czech adult people after stroke|Czech adult people after stroke will be asked basic questions about present feelings according to their condition using a questionnaire. Then they will be tested by the Box and Block Test in only one session. Video of their performance will be obtained. The Box and Block Test will be done during their regular rehabilitation by occupational therapist.
89558103|NCT05009108||Czech adult patients after a stroke|Czech adults patients after a stroke will be asked to fill in a informed agreement and as well to answer short questionnaire. Then they will be tested by the Purdue Pegboard Test in only one session. Video of their performance will be obtained as well.
89558104|NCT05005052|Experimental|Sulodexide arm|Name: Vessel (medicinal product registered in Italy) Dosage form: soft capsules Active substance: sulodexidum 250 LSU Dosage: 2 x 2 soft capsules daily (oral use), in line with the labelled posology (500 LSU twice a day) Duration: 24 ± 4 weeks
89558105|NCT05005052|Placebo Comparator|Placebo arm|Dosage form: soft capsules Appearance: undistinguishable from the active Dosage regimen: 2 x 2 soft capsules daily Duration of placebo intake: a total of 24 ± 4 weeks
89558106|NCT05001139|Experimental|Relizema ecofoam|Reizema ecofoam for 42 days, 2 times per day
89558107|NCT04995978|Experimental|Pioglitazone|
89558108|NCT04995978|Placebo Comparator|placebo|
88964387|NCT02041598|No Intervention|Control: Intro to Diabetes Session Only|One-time, Introduction to Diabetes educational session only
88964388|NCT02041611|Other|Standard Care Pts Eval of T-Cell Immune Status|Pts undergoing standard radiation/TMZ and adjuvant TMZ will have blood collections at 6 different time points throughtout their treatment to evaluate T Cell changes
88964389|NCT02041624||allergic rhino-conjunctivitis|Patient with proven allergic rhino-conjunctivitis due to grass pollen
88964390|NCT02041650|Other|Patients with ACS treated medically|
88964391|NCT02041676|Experimental|1: chest physiotherapy technique|Chest physiotherapy technique increasing inspiratory flow (IIF) 3 times per day
89558109|NCT04995952|Experimental|Gross motor training activity|Gross motor training activity It includes training of motor components of child grossly
88964392|NCT02041676|Active Comparator|2: Usual surveillance|Usual surveillance of the non invasive ventilation
88964393|NCT02041689||Participants|"Patients at St. Jude Children's Research Hospital between the ages of 7 and 11 years who have a working diagnosis or initial diagnosis of a bone or soft tissue sarcoma.~Interventions: two unstructured life-story interview sessions, observations, and guided activities."
88964394|NCT02041715|Experimental|TKM-100802 for Injection|
88964395|NCT02041715|Placebo Comparator|Placebo|
88964396|NCT02041741|Active Comparator|Weekly tips|Daily small and concrete happiness tips
88964397|NCT02041741|Active Comparator|Daily Tips|Weekly more in-depth happiness tips involving an active (doing and experiencing) task
88964398|NCT02041741|No Intervention|Wait-List Control|No intervention
88964399|NCT02041754|Active Comparator|IQP-AK-102|2 capsules per dose, 3 times daily, 30-60 mins before each main meal with a full glass (250 mL) of water
88964400|NCT02041754|Placebo Comparator|Placebo|2 capsules per dose, 3 times daily, 30-60 mins before each main meal with a full glass (250 mL) of water
88964401|NCT02041767|Experimental|group A|One single perfusion of 1g of ertapenem 1 hour prior to prostate surgical resection
88964402|NCT02041767|Experimental|group B|One single perfusion of 1g of ertapenem 12 hour prior to prostate surgical resection
88964403|NCT02041780|Experimental|Shearwave electrography|"Two experimental interventions will be realized in each patient in this population : Shearwave electrography (new diagnostic test of fibrosis) and Fibrotest .~Moreover, liver biopsies, the gold standard for the fibrosis diagnosis is also realized in each patient within usual cares."
89558110|NCT04995952|Experimental|Trunk targeted training|In this training group the particpiants were given the exercises that were focused the truck muscles
89558111|NCT04993781|Experimental|eSTEPS Clinical Decision Support|Use of clinical decision support to assist in exercise-related fall prevention care planning will be compared to usual care.
88964404|NCT02041793|Active Comparator|Laparoscopic cystogastrostomy|Laparoscopic cystogastrostomy will be performed by using a stapled cystogastrostomy
89558112|NCT04993781|No Intervention|Usual Care|Usual primary care practices regarding exercise-related fall prevention planning
89558113|NCT04993157|Experimental|Group 1: Healthy participants with normal hepatic function|Each participant will receive a single dose of FIA586
89558114|NCT04993157|Experimental|Group 2: Participants with mild hepatic impairment|Each participant will receive a single dose of FIA586
89558115|NCT04993157|Experimental|Group 3: Participants with moderate hepatic impairment|Each participant will receive a single dose of FIA586
89558116|NCT04988867|Experimental|Drug - trofinetide|Oral dose of trofinetide
89558117|NCT04987294|Experimental|ALLN-346 (Engineered Urate Oxidase)|ALLN-346 is novel urate oxidase provided as capsules for oral administration. ALLN-346 will be administered as 5 capsules thrice daily (15 capsules per day total) to each of two subject cohorts based on estimated glomerular filtration rate (eGFR). Treatment Period is 14 Days.
89558118|NCT04987294|Placebo Comparator|Placebo|Matching placebo capsules for oral administration. Placebo capsules will be administered as 5 capsules thrice daily (15 capsules per day total) to each of two subject cohorts based on estimated glomerular filtration rate (eGFR). Treatment Period is 14 Days.
89558119|NCT04987242|Experimental|ALLN-346 (Engineered Urate Oxidase)|ALLN-346 is novel urate oxidase provided as capsules for oral administration: 5 capsules thrice daily (TID) for a total of 15 capsules per day will be evaluated for 7 days
89558120|NCT04987242|Placebo Comparator|Placebo|Matching placebo capsules for oral administration: 5 capsules thrice daily (TID) for a total of 15 capsules per day will be evaluated for 7 days
89558121|NCT04984005|Experimental|Low intensity exercise training group|
89558122|NCT04984005|Experimental|Moderate intensity exercise training group|
89558123|NCT04984005|Experimental|Intermittent high intensity exercise training group|
88964405|NCT02041793|Active Comparator|Endoscopic cystogastrostomy|Endoscopic cystogastrostomy or cystoduodenostomy will be performed either under direct endoscopic or endosonography guidance.
88964406|NCT02041819|Experimental|Nimotuzumab nab-paclitaxel cisplatin|"Nimotuzumab: 200mg,IV once a week for 6 weeks during chemotherapy (days 1,8,15,22,29,36).~Cisplatin: 75mg/m2,IV on days 1，22.~Nab-paclitaxel: 125mg/m2,IV on days 1,8,22,29.~patients will receive radical operation 4-6 weeks after Neoadjuvant therapy."
88964407|NCT02041832|Other|Holter monitoring|Screening of patients with older age, arterial hypertension and diabetes for paroxysmal atrial fibrillation by using conventional Holter monitoring
88964408|NCT02041832|Other|Implantable loop recorder|Screening of patients with older age, arterial hypertension and diabetes mellitus for paroxysmal atrial fibrillation by using an implantable loop recorder
88964409|NCT02041858|No Intervention|Control|Control arm with organizational-based alarm parameter settings
88964410|NCT02041858|Experimental|Altered Alarm Settings|Altered set of alarm parameter settings.
88964411|NCT02041871|Experimental|Impact control|ORAL IMPACT Powder 74g within 250ml of water, 3 times per day during 7 days before surgery
88964412|NCT02041871|Placebo Comparator|Placebo|Placebo
88964413|NCT02041884|Experimental|iCBT|A skill training internet-based treatment program based on CBT and DBT interventions .
88964414|NCT02041884|Active Comparator|Internet stress-reduction|Internet-based psychoeducation, stress-reduction, and Applied Relaxation based on CBT (control group)
89558124|NCT04977050|Experimental|Intervention Site|All miners in the New Mexico intervention mine site who will be administered nasal swabs for antigen testing every other work shift, and serological testing 3 months.
89558125|NCT04977050|No Intervention|Controled site|All miners in the Wyoming Control mine site who will be administered serological testing 3 months.
89558126|NCT04973553|Experimental|participants with acute stroke|(a) a first-ever unilateral, diagnosed stroke by a neurologist as defined by the World Health Organisation, (b) been admitted to the acute hospital for rehabilitation, (c) Upper limb hemiparesis or hemiplegia with a trace of muscle contraction:≥grade 1 at shoulder (abductors or elevators) or wrist/finger extensors measured by the MRC Scale and a score of <61 on the Motricity Index and severely motor affected by score of 2 or 3 on item number 5 on the NIH Stroke Scale (NIHSS)[24], (d) the age of > 18 years and (e) the ability to provide informed consent.
89558127|NCT04970290|Experimental|Definisse threads free floating and Definisse threads double needle|"Definisse™ free floating threads will be used with the Soft Tissue Reshaping-2 (STR-2) Technique, to reposition the tissue of the malar area.~It is to be used for the face and neck. The thread presents a central area, free of barbs, and two distal areas with barbs. The 12 cm thread will be used in this study.~Definisse™ double needle thread (12 cm) that is equipped with barbs in the intermediate section, while the side and the central sections are smooth. The thread ends with two straight cut edge needles 10 cm long Definisse™ double needle threads will be used with the Jawline Reshaping (JR) Technique, to reshape the frame of the jawline, lifting the lower face. This is to be used for the face and the neck. The thread ends with two straight cut edge needles The 12 cm thread will be used in this study."
88964415|NCT02041884|Other|Treatment as usual (TAU)/waiting list|Treatment as usual (usually medications for ADHD), will be offered treatment after the FU3 (week 24)
89558128|NCT04967677||Czech healthy occupational therapy students|Czech healthy occupational therapy students will be asked to fill in a questionnaire. Then they will be tested by the Nine Hole Peg Test, the Purdue Pegboard Test and the Box and Block Test. Video of their performance will be obtained.
89558129|NCT04963062|Experimental|Participants treated with Holmium laser with the Moses laser|
89558130|NCT04963062|Experimental|Participants treated with Holmium laser with the thulium laser|
89558131|NCT04958486|Experimental|Treatment|
89558132|NCT04952961|Experimental|Single Arm Intervention|Participants will be shown how to perform vulval self-examination in a face-to-face intervention and provided with an information leaflet. They will be sent reminders to self-examine each month.
89558133|NCT04949165|Experimental|Iron Supplementation|
89558134|NCT04949165|No Intervention|Control|
88964416|NCT02041897|Other|EUS-FNA, Rate of chang on diagnosis|It is a single arm study. We will conclude by calculating the rate of change of diagnosis before and after getting the results of EUS-FNA.
88964417|NCT02041910|Experimental|Stem Cells|60 ml of Bone marrow will aspirated for stem cells isolation and preparation. 5 ml of stem cells prepared according to GMP rules injected into testis.
88964418|NCT02041910|Experimental|Stem Cells Injection|Stem Cell Dose 3-5 Million Autologous MSCs Injected into testis.
88964419|NCT02041975|Experimental|Prebiotic|Nutriose FB06 14g/day
88964420|NCT02041975|Placebo Comparator|Placebo|Maltodextrin
88964421|NCT02041988||0,2 mg/kg oral morphine|Patients have been assigned to two groups of 20 individuals, they have been premedicated with oral morphine sulfate, 0,2 mg/kg group A, 0,4mg/kg group B.During surgery analgesic administration will be monitored
88964422|NCT02041988||0,4 mg/ kg oral morphine|morphine and analgesic consumption throughout surgery will be monitored
88964423|NCT02042001|Experimental|Immediate Switch|Immediate switch to TDF/FTC/RPV
88964424|NCT02042001|Active Comparator|Deferred Switch|Switch to TDF/FTC/RPV after 24 weeks
88964425|NCT02042027|Active Comparator|Group A|Gamunex-C 50 mg subconjunctival injections, in addition to standard of care treatment (steroids and cyclosporine). One dose of Gamunex-C injection delivered four weeks prior to corneal transplant surgery and one dose at the time of corneal transplantation. Dose to be repeated if recurrence of corneal neovascularization
88964426|NCT02042027|Active Comparator|Group B|Gamunex-C 50 mg subconjunctival injections, one dose injected for patients with active disease from corneal melts (peripheral ulcerative keratitis; Mooren's ulcer), ocular cicatricial pemphigoid, or anterior uveitis refractory to conventional therapy.
88964427|NCT02042053|Experimental|PET/MR|Patients treated with SipT (standard of care) undergo FDG-PET/MRI, NaF-PET/CT and blood drawing at 3 time points: baseline, Day 7 after the last SipT infusion, Week 10 after the last SipT infusion.
89558135|NCT04944979|Experimental|Experimental: Kedrion IVIG 10%|Participants will receive intravenous infusion of Kedrion IVIG 10% at a dose of 200 to 800 milligram per kilogram (mg/kg) body weight every 21 or 28 days for period of 48 weeks.
89558136|NCT04942210|Experimental|vYF|1 injection of vYF at Day 1
89558137|NCT04942210|Active Comparator|YF-VAX|1 injection of YF-VAX at Day 1
89558138|NCT04940767|Experimental|Treatment Group A|Patients will concomitantly receive once daily treatment of oral isotretinoin and topical AMZEEQ® for 20 weeks, followed by a further 24 weeks of once daily AMZEEQ® only treatment.
89558139|NCT04940767|Experimental|Treatment Group B|Patients will receive once daily treatment of oral isotretinoin for 20 weeks, followed by a further 24 weeks of once daily AMZEEQ® only treatment.
88964428|NCT02042066|Experimental|Treated Group|This group will receive actual shockwave treatment
88964429|NCT02042079|Experimental|EFTR with LA|(Endoscopic full-thickness resection with laparoscopic assistance)
88964430|NCT02042092|Active Comparator|Color Doppler Ultrasound (CDUS)|The aorta, supraaortic large vessels and the temporal arteries of the sLVV patients will be evaluated by color Doppler ultrasound
88964431|NCT02042092|Active Comparator|Magnetic resonance angiography (MRA)|The aorta, supraaortic large vessels and the temporal arteries of the sLVV patients will be evaluated by Magnetic resonance angiography
88964432|NCT02042118|Experimental|Laryngeal Mask Airway|Laryngeal mask airway (LMA) ventilation will be provided for newborns in this arm during the first 2.5 minutes.
88964433|NCT02042118|Active Comparator|Face mask ventilation|Face-mask ventilation (FMV) will be provided for newborns in this arm during the first 2.5 minutes.
88964434|NCT02042144||Group 1|
88964435|NCT02042157|Experimental|Bidet use|This arm will have a bidet installed in their home bathroom and be instructed how to use it. This arm will use the bidet for usual toileting for a period of two years.
88964436|NCT02042157|Placebo Comparator|Usual Toileting|This group will toilet as usual.
89208377|NCT01070563||TCD|When the diagnosis of brain death is made, TCD is performed and then every 2 hours until the flow patterns compatible with brain death are found. Then a CT angiography is performed.
89558140|NCT04926623|Experimental|CGM with Structured Education|CGM with Structured Education
89558141|NCT04926623|Active Comparator|CGM with Standard Education|CGM with Standard Education
88964437|NCT02042157|Experimental|Caregivers of PT in Arm 1 (bidet use)|"Participants with functional impairment will be randomized into one of two arms (bidet use or usual toileting). Their caregivers will be enrolled and their randomization is bundled with the study participant who they care for. This arm will care for participants who have been randomized to bidet."
88964438|NCT02042157|Placebo Comparator|Caregivers of PT in Arm 2 (usual toileting)|"Participants with functional impairment will be randomized into one of two arms (bidet use or usual toileting). Their caregivers will be enrolled and their randomization is bundled with the study participant who they care for. This arm will care for participants who have been randomized to usual toileting."
88964439|NCT02042170|Experimental|Sr-hGH 0.5 mg/kg/wk|Patients inject Eutropin plus (Sr-hGH) 0.5 mg/kg/wk every week himself/herself.
88964440|NCT02042170|Experimental|Sr-hGH 0.7 mg/kg/wk|Patients inject Eutropin plus (Sr-hGH) 0.7 mg/kg/wk every week himself/herself.
88964441|NCT02042170|Active Comparator|Daily hGH 0.37 mg/kg/wk|Patients inject Eutropin (daily hGH) 0.37 mg/kg/wk everyday for the first 6days a week himself/herself.
88964442|NCT02042196|Experimental|Pre or Early perimenopausal 1|"Baseline experiment: Subjects randomized to either 1) KUVAN (10mg/kg body weight) crossover to placebo OR 2) placebo crossover to KUVAN~Hormone modification: GnRH antagonist with Cetrotide (0.25mg/d) + placebo transdermal patch, then subjects randomized again to either 1) KUVAN crossover to placebo OR 2) placebo crossover to KUVAN"
88964443|NCT02042196|Experimental|Pre or Early Perimenopausal 2|"Baseline experiment: Subjects randomized to either 1) KUVAN crossover to placebo OR 2) placebo crossover to KUVAN~Hormone modification: Estrogen add-back with Cetrotide + Climara (0.075mg/d), then subjects randomized again to either 1) KUVAN crossover to placebo OR 2) placebo crossover to KUVAN"
88964444|NCT02042196|Experimental|Late Perimenopausal and Postmenopausal|"Subjects randomized to either 1) KUVAN crossover to placebo OR 2) placebo crossover to KUVAN~No hormone modification."
88964445|NCT02042222|Active Comparator|Standard Arm|Half of the subjects initiating hydroxyurea will be randomly assigned to the standard treatment arm, consisting of escalation to the maximum tolerated dose (MTD) of hydroxyurea utilizing a previously published algorithm. Hydroxyurea dosing will commence at 20+/-2.5 mg/kg/day, given as a single daily oral dose. All patients will be offered the choice of a liquid formulation of hydroxyurea or hydroxyurea tablets, with the exact dose rounded up or down to the closest practical dose based on the chosen formulation but not differing from the intended dose by more than 2.5 mg/kg. It should take approximately 6 to 12 months for subjects to reach the MTD on this arm.
88964446|NCT02042222|Active Comparator|Alternative Treatment Arm|"Half of the subjects initiating hydroxyurea therapy will be assigned to the alternative treatment arm of the study. In this arm, the predicted hydroxyurea MTD will be calculated for each subject.~As in the dose-escalation arm, the exact dose will be rounded up or down to the closest practical dose based on the chosen formulation of hydroxyurea. Since the most common toxicity associated with hydroxyurea use is excessive myelosuppression, the maximum dose at which a subject in the dose-prediction arm will be started will be 30 mg/kg/day or 2000 mg/day. Patients with a higher predicted MTD will subsequently be escalated to this higher dose after four weeks on therapy if there is no evidence of toxicity."
88964447|NCT02042235|Experimental|Parent-implemented language intervention|In the intervention group, the techniques and attitudes favouring use of oral language will be taught to the parents during 15 sessions with the parent(s) and child.
88964448|NCT02042235|No Intervention|Control group|The control group will benefit from the actual routine care for children with language delay before the age of 3 years. In order to provide them the best routine care, the psychologist will provide some advice to the parents to enhance their child's language (e.g.: using life situations to talk with the child and encourage him/her to talk …).
88964449|NCT02042248|Experimental|Arm A: ART initiated during AHI|Arm A will enroll approximately 6 participants who initiated ART during AHI (acute HIV infection). The target dose of AGS -004 is delivered in three ID (intradermal) injections of 0.2 mL of AGS-004 (0.6 mL total volume) for a total of 1.2 x 107 viable cells. AGS-004 is administered every 4 weeks at weeks 0, 4, 8, and 12 for a total of 4 doses.
88964450|NCT02042248|Experimental|Arm B: ART initiated during CHI|Arm B will enroll approximately 6 participants who initiated ART during CHI (chronic HIV infection). The target dose of AGS -004 is delivered in three ID (intradermal) injections of 0.2 mL of AGS-004 (0.6 mL total volume) for a total of 1.2 x 107 viable cells. AGS-004 is administered every 4 weeks at weeks 0, 4, 8, and 12 for a total of 4 doses.
88964451|NCT02042313|Active Comparator|Epidural|Epidural catheters will be applied at the T6-8 level prior to the induction. 6 ml of 2% xylocaine with 1 in 200,000 epinephrine administered before surgery. During the surgery, 2% xylocaine with 1 in 200,000 epinephrine infusion will be administered at a rate of 2-10 ml/hour adjusted according to patient's blood pressure. After surgery, 0.125% levobupivacaine with 2.5μg fentanyl and 1 in 400,000 epinephrine will be given at a rate of 0.10-0.15 ml kg-1 h-1 (0.5 h lock and 2 ml bolus) through a patient-controlled infusion pump.
88964452|NCT02042313|Experimental|combined PVB TAP|"Paravertebral catheterization into the paravertebral region ipsilateral to the VATS incision as described by Murata at the level of T7-8 will be performed. 10 ml of 2% xylocaine with 1 in 200,000 epinephrine to initiate analgesia. During the surgery, 2% xylocaine with 1 in 200,000 epinephrine infusion will be administered at a rate of 2-10 ml/hour adjusted according to patient's blood pressure. After the surgery, 0.125% levobupivacaine with 2.5μg fentanyl and 1 in 400,000 epinephrine will be administered at the rate of 0.10-0.15 ml kg-1 h-1 (0.5 h lock and 2 ml bolus) through a patient-controlled infusion pump.~Ultrasound-guided (USG) subcostal TAP block will be performed at the end of surgery. Fifteen milliliters of 0.5% levobupivacaine with 1 in 400,000 epinephrine will be injected in incremental doses on each side of the abdomen."
88964453|NCT02042339|Experimental|Hyperbaric oxygen|Problem-wound schedule: 2.4 atmospheres, 100% oxygen for 90 minutes, two 10 - minute breaks (patients breathing pressurized air from the chamber atmosphere)
89558142|NCT04926623|Active Comparator|SMBG with Standard Education|SMBG with Standard Education
89558143|NCT04923334|Experimental|Brief Pain Teleconsult|Participants randomized to Brief Pain Teleconsult will receive the brief teleconsult intervention in Phase 1 (1-12 weeks) Responder status to the Phase 1 treatment will be examined at the 12 week assessment. Participants determined to be non-responders will receive the Telehealth Physical Therapy intervention. Responders receive no additional treatment.
89558144|NCT04923334|Experimental|Brief Pain Teleconsult plus Telehealth Physical Therapy|Participants randomized to Brief Pain Teleconsult plus Telehealth Physical Therapy will receive the brief teleconsult intervention in Phase 1 followed by the 10-week physical therapy intervention. No additional treatment is provided after the 12 week assessment.
89558145|NCT04914117|Experimental|RC118 for injection|"Part A (Dose Escalation): RC118 will be administered through IV infusion at the various dose levels, including 0.25, 0.5, 1.0, 1.5, 2, 2.5, and 3 mg/kg, 1-12 subjects for each dose level.~Part B (Dose Confirmation): RC118 will be administered at up to two dose levels, which is equal or lower than MTD/MAD, through IV infusion. Each dose level contains 3-6 subjects."
89558146|NCT04913805|Active Comparator|Potassium Nitrate|Potassium Nitrate (KNO3) 6 mmol three times daily
88964454|NCT02042339|Placebo Comparator|Sham Hyperbaric oxygen|The patients will be transferred into the chamber like the treatment group. Instead of 100% oxygen they will breathe normal air through the tight fitting masks, at an ambient pressure of 1.1 bar. During the two 10 - minute breaks patients will breathe pressurized air from the chamber atmosphere.
88964455|NCT02042352||pH test|VpH test gloves
88964456|NCT02042365||ERAS (Enhanced recovery after surgery)|This observational study evaluates the feasibility of ERAS pathway in six French departments of surgery located at Clermont-Ferrand, Bordeaux, Montpellier, Amiens, Strasbourg and Aurillac
88964457|NCT02042417|Experimental|INRatio2 and CoaguChek|one measuring per tool, in case of error: one repetiton
88964458|NCT02042456||Main Cohort|Subjects enrolled in this group will receive a full field digital mammogram, digital breast tomosynthesis exam and an automated whole breast ultrasound exam as part of their visit.
88964459|NCT02042469||Survey|Cross-sectional survey will be carried out using an interview questionnaire composed of close-ended questions to be completed by trained research coordinator.
88964460|NCT02042482|Experimental|Coenzyme Q10U, L-carnitine|Patients receive combination of coenzyme Q10U 180 milligram and L-carnitine 2000 milligram
88964461|NCT02042495|Experimental|Metformin|"Metformin 500 mg PO TID from time of entry to study until scheduled surgical staging operation.~In cases of unresolving side effects, the metformin will be dose reduced to metformin 500 mg PO BID with evaluation after 1 week followed by withdrawal from the study if side effects persist."
88964462|NCT02042508|Experimental|Paraplegic patients|
88964463|NCT02042521|Experimental|Healthy Smokers (Active then Placebo)|"Healthy individuals who smokes at least 20 cigarettes per day~Interventions: Dietary Supplement, Lactose Placebo"
89558147|NCT04913805|Active Comparator|Potassium Nitrate + Propionyl-L-Carnitine + Nicotinamide Riboside|Potassium Nitrate (KNO3) 6 mmol three times daily + Propionyl-L-Carnitine (PLC) 1000 mg twice daily + Nicotinamide Riboside (NR) 300 mg three times daily
89558148|NCT04913805|Placebo Comparator|Potassium Chloride|Potassium Chloride (KCl) 6 mmol three times daily
89558149|NCT04912713|Active Comparator|Arm 1|This group will be randomly immersed in ice water (2°C temperature) for preset times and instructed to remove their hand if they cannot withstand these times. In total there will be 5 attempts with durations of 90, 60, 60, 60, 90 and 60 s respectively. Between dive attempts they will be instructed to put their arm on a towel and immediately do the arithmetic task of counting backwards from the number 2043 as quickly and accurately as they can. Each time they make a mistake in the mental task, they will be given negative feedback and must start again from the number 2043. The duration of the 4 arithmetic tasks (between each of the 5 immersion attempts) will be fixed at 45, 60, 90 and 45 s respectively.
88964464|NCT02042521|Experimental|Healthy Smokers (Placebo then Active)|"Healthy individuals who smokes at least 20 cigarettes per day~Interventions: Dietary Supplement, Lactose Placebo"
88964465|NCT02042547||Patients about to undergo heart surgery|
88964466|NCT02042560||Patients with ITP|
88964467|NCT02042560||Controls|
88964468|NCT02042586||Patients|
88964469|NCT02042586||Controls|
88964470|NCT02042599|Experimental|sevoflurane|Determination of plasmatic concentrations of sevoflurane at different times of a 48h sedation of sevoflurane in ICU patients with acute kidney injury
88964471|NCT02042612|Experimental|sevoflurane|Determination of plasmatic concentrations of sevoflurane at different times of a 48h sedation of sevoflurane in obese ICU patients
88964472|NCT02042625|Other|nasopharyngeal|The nasopharyngeal probe will be inserted into the nostril. The nasopharyngeal temperature will initially be recorded 45 minutes after anesthetic induction. The nasopharyngeal probe will then be withdrawn 2 cm and after a 3-minute equilibration period, nasopharyngeal temperatures will again be recorded. The nasopharyngeal probe withdrawal sequence will be repeated, 2 cm at a time, until only 2 cm remains in the nostril. There will be a total of 10 sets of nasopharyngeal temperatures obtained.
88964473|NCT02042638||16 treatment naive Hypogonadotropic hypogonadism patients|Treatment naive 16 patients with idiopathic hypogonadotrophic hypogonadism
88964474|NCT02042651|Experimental|Low intensity extracorporeal shockwave therapy|Active treatment with low intensity extracorporeal shockwave therapy applied to the perineum.
88964475|NCT02042651|Sham Comparator|Sham low intensity extracorporeal shockwave therapy|Sham treatment with low intensity extracorporeal shockwave therapy applied to the perineum.
88964476|NCT02042664|Experimental|treatment BYETTA|
88964477|NCT02042664|Active Comparator|metformine|
88964478|NCT02041442|Experimental|All subjects|Electrical mapping of the urinary bladder
88964479|NCT02042690|Active Comparator|chemotherapy|"Drugs:~Drug:Methotrexate 1g/m2 d1,IV (in the vein) , used in cycle 1,3,5 Drug:arabinoside 2-3g/m2,q12h, d2-3, IV, used in cycle 1,3,5 Drug:cyclophosphamide:300mg/m2 q12h, d1-3, IV,used in cycle 2,4,6 Drug:Epirubicin 60mg/m2.d，d4,used in cycle 2,4,6 Drug:Vindesin 4mg/d，d4，d11, IV,in cycle 2,4,6 Drug:dexamethasone 40mg/d，d1-4，d11-14, IV, in cycle 2,4,6 Drug:Methotrexate 20 mg/m2/w,po, during maintenance treatment for 2 years Drug:6-mercaptopurine 60 mg/m2/d，po，d1-d28,during maintenance treatment for 2 years Drug:Vindesin 4mg/d，Predisone:1mg/kg, d1-7, every month during maintenance treatment for 2 years"
89558150|NCT04912713|Active Comparator|Arm 2|This group will not be falsely recorded or evaluated. They will be randomly immersed in warm water (35-37°C temperature) for preset times and instructed to remove their hand if they cannot withstand these times. In total there will be 5 attempts with durations of 90, 60, 60, 60, 90 and 60 s respectively. Between dive attempts they will be instructed to put their arm on a towel and immediately do the simple counting task, in which they will have to count consecutively from 1 to 25 at their own pace. If they reach 25 they must start again and will never be given negative feedback. The duration of the 4 arithmetic tasks (between each of the 5 immersion attempts) will be fixed at 45, 60, 90 and 45 s respectively
89558151|NCT04907968|Experimental|Dose Escalation - Module A (UPGRADE-A)|XMT-1536 (Upifitabmab Rilsodotin) + carboplatin is administered in groups of patients who will receive doses of XMT-1536 that increase over time.
89558152|NCT04907968|Experimental|Dose Expansion - Module A (UPGRADE-A)|Once the MTD or RP2D is achieved in dose escalation, a new group of patients will receive XMT-1536 (Upifitamab Rilsodotin) at this fixed-dose + carboplatin.
89558153|NCT04902794|Experimental|Light Emitting Diode|Light Emitting Diode in the Treatment of Menopause Genitourinary Syndrome
89558154|NCT04902794|Sham Comparator|Light Emitting Diode Sham|Light Emitting Diode device Sham - turned off
89558155|NCT04900220|Active Comparator|Betamethasone|betamethasone
89558156|NCT04900220|Active Comparator|Methylprednisolone|methylprednisolone
89558157|NCT04896684||Patient screened or followed-up for IBS or IBD or colorectal cancer|Blood and colon biopsy sampling
89558158|NCT04896320|Experimental|Gemcitabine + Tucatinib + Trastuzumab|Gemcitabine (1000 mg/m2) will be administered intravenously on Days 1 and 8 of each 21-day cycle. The investigational study drug (tucatinib) will be administered as 300mg by mouth taken twice a day of every day in each cycle. Trastuzumab will be administered per package insert on Day 1 of each cycle.
89558159|NCT04896320|Experimental|Vinorelbine + Tucatinib + Trastuzumab|Vinorelbine (25 mg/m2) will be administered intravenously on Days 1 and 8 of each 21-day cycle. The investigational study drug (tucatinib) will be administered as 300mg by mouth taken twice a day of every day in each cycle. Trastuzumab will be administered per package insert on Day 1 of each cycle.
89558160|NCT04887259|Experimental|LAVA-051|"Part 1 (dose escalation): LAVA-051 will be given to patients via intravenous (IV) infusion with dose escalation. A selected group of patients will also receive a low dose of interleukin 2 via subcutaneous injection.~Group A: LAVA-051~Group B: LAVA-051 + low dose interleukin 2~Part 2 (dose expansion): patients will receive LAVA-051 at the dose and regimen established in Part 1 of the study"
89558161|NCT04877613|Experimental|Cohort 1: single dose of 5x10^7 CART-GFRa4 cells via intravenous infusion|
88964480|NCT02042690|Experimental|Haplo-identical HSCT|Haplo-identical HSCT Protocol:G, donor treatment with recombinant granulocyte colony-stimulating factor (rhG-CSF); I, intensified immunologic suppression; A, antihuman thymocyte immunoglobulin (ATG) for the prevention of GVHD; C, combination of peripheral blood stem cell transplantation (PBSCT), and bone marrow transplantation (BMT)，named GIAC regimen. Graft versus-host disease(GVHD) prevention regimen: CSA/MMF/MTX, cyclosporine A(CSA) 1.25mg/kg/d, i.v administrated in two doses from day -109 until bowel function returned to normal, at which time patients receive oral CSA until 12months after HSCt and then gradually tapered. Every 12h, 0.5g mycophenolate mofetil (MMF)(0.25g for children) was administrated orally from day -10 to +30 and subsequently 0.25g from days +30 to +60. Methotrexate (MTX) was administrated at a dose of 15mg/m2 on day +1 and 10mg/m2 on days +3,+6, and +11.
88964481|NCT02042703||exfoliation syndrome|patients with exfoliation syndrome
88964482|NCT02042703||POAG|patients with primary open angle glaucoma (POAG)
88964483|NCT02042703||cataracts|patients with cataracts
88964484|NCT02042716|Experimental|diagnosis of white matter damage|Added value of supersonic shear imaging in the diagnosis of white matter damage in preterm infants
88964485|NCT02042729|Experimental|E2022- Tape Formulation|
88964486|NCT02042729|Placebo Comparator|Matching Placebo E2022|Matching Placebo
88964487|NCT02042729|Active Comparator|E2022- New Formulation|
88964488|NCT02042729|Placebo Comparator|Placebo E2022- New Formulation|Matching Placebo
88964489|NCT02042742|Experimental|Antioxidant supplement|Treatment consist of consuming 65g of punicalagin and 3,3g of hydroxytyrosol (plus 331,7g of maltodextrin) three times daily, during 8 weeks.
88964490|NCT02042742|Placebo Comparator|Control supplement|Treatment consist of consuming 400g of maltodextrin three times daily, during 8 weeks.
88964491|NCT02042781|Experimental|PG545|Once weekly, one hour IV infusion of PG545.
89558162|NCT04877613|Experimental|Cohort -1: single dose of 2x10^7 CART-GFRa4 cells via intravenous infusion|
89558163|NCT04877613|Experimental|Cohort 2: single dose of 1x10^8 CART-GFRa4 cells via intravenous infusion|
88964492|NCT02042820||Dry Eye Disease|"Confocal Imaging - In vivo confocal microscopy (IVCM)~Ophthalmic Examination:~Tear Break Up Time (TBUT)~Ocular Surface Disease Index (OSDI)~Schirmer's II test~Conjunctival staining with lissamine green~Corneal staining with fluorescein~Conjunctival redness assessment"
89558164|NCT04877613|Experimental|Cohort 3: single fixed dose of 3x10^8 CART-GFRa4 cells via intravenous infusion|
88964493|NCT02042820||Control|"Confocal Imaging - In vivo confocal microscopy (IVCM)~Ophthalmic Examination:~TBUT~OSDI~Schirmer's II test~Conjunctival staining with lissamine green~Corneal staining with fluorescein~Conjunctival redness assessment"
88964494|NCT02042833||Cohort|
88964495|NCT02042846|Experimental|SportWelding Fiji Anchor|
88964496|NCT02042885|Experimental|1: Regimen A Escalation|1: OPB-111001, orally, once weekly
88964497|NCT02042885|Experimental|2: Regimen A Extension|2: OPB-111001, orally, once weekly
89558165|NCT04871607|Experimental|Treatment (yttrium Y 90 basiliximab, chemotherapy, HPC-A)|Patients receive 'cold' basiliximab IV followed by yttrium Y 90 basiliximab IV on day -14. Patients also receive carmustine IV on over 4 hours day -6, etoposide IV over 1 hours QD and cytarabine IV over 2 hours BID or QD on days -5 to -2, and melphalan IV over 1 hours on day -1. Patients then receive HPC-A product via infusion on day 0. Beginning day 5, patients receive G-CSF (or biosimilar) SC or IV until ANC > 500 for 3 consecutive days or according to the treating physician's best clinical judgement.
89558166|NCT04869917|Experimental|Decision Aid intervention|Health Educators (HEs) will meet briefly with eligible participants after each office visit to review a prediabetes decision aid which reviews information about the benefits and risks of intensive lifestyle intervention and metformin.
89558167|NCT04869917|Experimental|Text Messaging intervention|Participants will receive biweekly messages throughout the 12-month trial. Automated messages will be sent using an existing secure text messaging platform.
89558168|NCT04869917|Experimental|Decision Aid intervention + Text Messaging intervention|Health Educators (HEs) will meet briefly with eligible participants after each office visit to review a prediabetes decision aid. Additionally, participants will receive biweekly messages throughout the 12-month trial. Automated messages will be sent using an existing secure text messaging platform.
89558169|NCT04869917|Placebo Comparator|Usual Care|Usual care includes no additional intervention above the care routinely provided at the clinical partner site, Erie Family Health Center.
89558170|NCT04869397|Experimental|Allogeneic Wharton's jelly-MSCs (WJ-MSC)|Intravenous administration, 1 dose, for 20 minutes
89558171|NCT04869397|Placebo Comparator|Placebo|Intravenous administration, 1 dose, for 20 minutes
89558172|NCT04865042|Experimental|Gabapentin|"GABAPENTIN per os*:~DAY 1:300 mg~DAY 2: 600 mg~DAY 3: 900 mg"
89558173|NCT04865042|Placebo Comparator|Placebo|"PLACEBO:~DAY 1:300 mg~DAY 2: 600 mg~DAY 3: 900 mg"
89558174|NCT04861441|Experimental|Continuous Cryotherapy|Subjects will use continuous cryotherapy post operative for pain control
89558175|NCT04861441|Active Comparator|Icepack|Subjects will use standard icepacks post operative for pain control
89558176|NCT04853368|Experimental|F508del Homozygous Cystic Fibrosis (CF) Participants|F508del homozygous cystic fibrosis (CF) participants receive galicaftor/navocaftor dual combination (28 days) followed by galicaftor/navocaftor/ABBV-119 triple combination therapy (28 days).
89558177|NCT04853368|Experimental|F508del Heterozygous CF Participants (Active Drug Group)|F508del heterozygous CF participants receive galicaftor/navocaftor/ABBV-119 combination therapy (28 days).
89558178|NCT04853368|Placebo Comparator|F508del Heterozygous CF Participants (Placebo Group)|F508del heterozygous CF participants receive placebo (28 days).
89558179|NCT04853368|Experimental|F508del Homozygous and Heterozygous CF Participants|F508del homozygous and heterozygous CF participants receive galicaftor/navocaftor/ABBV-576 triple combination therapy for 28 days.
89558180|NCT04838106||Covid19|Patients admitted to an adult (16 years or over), general ICU in England or Wales as an emergency with confirmed COVID-19 between 1st January to 1st July 2020.
88964498|NCT02042885|Experimental|3: Regimen B Escalation|3: OPB-111001, orally, 2 - 3 times per week
89558181|NCT04838106||Non Covid19|Patients admitted to an adult (16 years or over), general ICU in England or Wales as an emergency without confirmed COVID-19 between 1st July 2016 and 1st July 2020.
89558182|NCT04837365|Other|patients with neuropsychological disorders|
89558183|NCT04837365|Other|patients without neuropsychological disorders|
89558184|NCT04833790|Experimental|Free distribution of ORS + standardized patient with ORS preference|Providers assigned to this arm will receive 3 months supply of ORS. Roughly 4 weeks later, they will receive a visit from a standardized patient (outcomes assessor) who poses as a caretaker for their child with diarrhea and indicates a preference for ORS.
89558185|NCT04833790|Experimental|Free distribution of ORS + standardized patient with Antibiotic preference|Providers assigned to this arm will receive 3 months supply of ORS. Roughly 4 weeks later, they will receive a visit from a standardized patient (outcomes assessor) who poses as a caretaker for their child with diarrhea and indicates a preference for Antibiotics.
88964499|NCT02042885|Experimental|4: Regimen B Extension|4: OPB-111001, orally, 2 - 3 times per week
88964500|NCT02042898|Active Comparator|Restrictive transfusion strategy|Restrictive transfusion strategy: patients will receive a red cell transfusion if their hemoglobin is <75 g/L (<7.5 g/dL;<4.7mmol/L) intraoperatively and/or postoperatively
88964501|NCT02042898|Active Comparator|Liberal transfusion strategy|Liberal transfusion strategy: patients will receive a red cell transfusion if their hemoglobin concentration is <95 g/L (<9.5 g/dL<5.9mmol/L) intraoperatively, or postoperatively in the intensive care unit; and/or <85 g/L (< 8.5 g/dL;<5.3mmol/L) on the ward.
88964502|NCT02042937|No Intervention|Control|No intervention
88964503|NCT02042937|Experimental|Exercise|Exercise to improve gluteus maximus recruitment
88964504|NCT02042963||KNOW-KT|1000 Kidney transplant recipients in Korea
88964505|NCT02042976|Experimental|Mindfulness-based cognitive therapy + pulmonary rehabilitation|An 8-week manual-based programme developed by Segal, Williams and Teasdale (2013) adjusted to the COPD population. The programme is delivered as an add-on to an 8-week standardised rehabilitation programme consisting of physical exercise and COPD-specific patient education.
88964506|NCT02042976|Active Comparator|Pulmonary rehabilitation only|An 8-week standardised rehabilitation programme consisting of physical exercise and COPD-specific patient education.
89208378|NCT00788918|Experimental|Chronic hepatitis C treatment|30 Chronic HCV patients with pending antiviral treatment. A majority will have pending treatment with interferon and ribavirin, and the treated patients will be assessed 8-12 weeks after starting treatment for interferon-induced depression.
89208379|NCT00788918|No Intervention|Healthy Controls|50 age, sex and education matched controls (matched 1:1 to participants in the HCV patient groups (+/- treatment)
89558186|NCT04833790|Experimental|Free distribution of ORS + standardized patient with no preference|Providers assigned to this arm will receive 3 months supply of ORS. Roughly 4 weeks later, they will receive a visit from a standardized patient (outcomes assessor) who poses as a caretaker for their child with diarrhea and indicates no preference for treatment.
89558187|NCT04833790|Experimental|Free distribution of ORS + standardized patient with no preference + no financial incentive|Providers assigned to this arm will receive 3 months supply of ORS. Roughly 4 weeks later, they will receive a visit from a standardized patient (outcomes assessor) who poses as a caretaker for their child with diarrhea and indicates no preference for treatment and indicates that they will purchase whatever the provider recommends from a relative's drug shop.
89558188|NCT04833790|Experimental|Status quo ORS supply + standardized patient with ORS preference|Providers assigned to this arm will have status who ORS supply. Roughly 4 weeks later, they will receive a visit from a standardized patient (outcomes assessor) who poses as a caretaker for their child with diarrhea and indicates a preference for ORS.
89558189|NCT04833790|Experimental|Status quo ORS supply + standardized patient with Antibiotic preference|Providers assigned to this arm will have status who ORS supply. Roughly 4 weeks later, they will receive a visit from a standardized patient (outcomes assessor) who poses as a caretaker for their child with diarrhea and indicates a preference for Antibiotics.
88964507|NCT02043002|Experimental|18F-FDG-PET scan|An early evaluation 18F-FDG-PET scan after 7-10 days
89558190|NCT04833790|Experimental|Status quo ORS supply + standardized patient with no preference|Providers assigned to this arm will have status who ORS supply. Roughly 4 weeks later, they will receive a visit from a standardized patient (outcomes assessor) who poses as a caretaker for their child with diarrhea and indicates no preference for treatment.
89558191|NCT04833790|Experimental|Status quo ORS supply + standardized patient with no preference + no financial incentive|Providers assigned to this arm will have status who ORS supply. Roughly 4 weeks later, they will receive a visit from a standardized patient (outcomes assessor) who poses as a caretaker for their child with diarrhea and indicates no preference for treatment and indicates that they will purchase whatever the provider recommends from a relative's drug shop.
89558192|NCT04830592|Experimental|Part A|NG-641 monotherapy
89558193|NCT04830592|Experimental|Part B|NG-641 and pembrolizumab
88964508|NCT02043028|Experimental|Group 1|"Participants compress the chest of a manikin with kneeling posture using a kneeling stool for chest compression posture during 5 minutes~2 weeks later, They perform the chest compression with standing posture using a step stool during 5 minutes"
88964509|NCT02043028|Experimental|Group 2|"Participants compress the chest of a manikin with a standing posture using a step stool for chest compression posture during 5 minutes~2 weeks later, They perform the chest compression with a kneeling posture using a kneeling stool stool and bed height adjustment during 5 minutes"
88964510|NCT02043041||1 Dried Blood Spot (DBS)|Number of DBS Spots Participants will be asked to fill one spot on a dried blood spot collection card.
88964511|NCT02043041||3 DBS Spots|Number of DBS Spots Participants will be asked to fill three spots on a dried blood spot collection card.
89558194|NCT04827849|Experimental|Experiment group|The study group will be provided physical examination, pregnancy monitoring and training on transition to motherhood within the direction of nursing care based on Meleis's Transition Period Theory, in addition to the usual care provided by healthcare professionals.
89558195|NCT04827849|No Intervention|Control group|The control group continued to receive the routine care
89558196|NCT04824131|Experimental|CAB LA|In Step 1, participants will receive one CAB tablet orally every day for 5 weeks. In Step 2, participants will receive an intramuscular (IM) injection of CAB LA at Weeks 5, 9, 17, 25, and 33. In Step 3, participants will receive a TDF/FTC tablet orally every day for 48 weeks or join an open-label extension CAB study in their area, if available.
88964512|NCT02043041||5 DBS Sports|Number of DBS Spots Participants will be asked to fill five spots on a dried blood spot collection card.
89558197|NCT04815707|Other|Surgery|Occult hernia found will be repaired at the same time as the initial inguinal hernia
89558198|NCT04815707|No Intervention|Expectant Management|No surgery will be done if an occult hernia is found during the initial inguinal hernia surgery
89558199|NCT04810975|Other|The effect of exercise A on musculoskeletal health|
89558200|NCT04810975|Other|The effect of exercise B on musculoskeletal health|
89558201|NCT04803851|Experimental|Treatment group|Anlotinib plus AK105
89558202|NCT04781296|Experimental|Subject's Scanned with Investigational Device|
89608411|NCT04146363|Experimental|Escape Arm (Lebrikizumab Q2W)|"Maintenance Period (Week 16-Week 52):~Blinded loading doses based on prior treatment assignment will be administered, followed by one 250 mg Lebrikizumab SC injection Q2W until Week 50 in an open-label fashion.~For participants who received placebo in the Induction Period, the loading dose is:~Two 250 mg Lebrikizumab SC injections on Week 16.~Two 250 mg Lebrikizumab SC injections on Week 18.~To maintain the loading dose blind, for participants who received Lebrikizumab in the Induction Period, the loading dose is:~One 250 mg Lebrikizumab SC injection and one placebo SC injection on Week 16. One 250 mg Lebrikizumab SC injection and one placebo SC injection on Week 18.~For participants who do not maintain an acceptable response during the Maintenance Period and entered the Escape Arm, the loading doses will be administrated at entry and 2 weeks after entry based on the treatment assignment prior to entering escape arm."
88964513|NCT02043054|Experimental|Liraglutide|Liraglutide doses will be self-administered by the participant through daily subcutaneous injections. Liraglutide doses will be initiated at 0.6 mg and then increased to 1.2 mg in week two and 1.8mg in week three. The dose will then be maintained at 1.8 mg. Where 1.8 mg doses are not tolerated by the patient, the dose will be lowered to the maximum tolerated dose at the investigators discretion.
88964514|NCT02043054|Active Comparator|Sitagliptin|Sitagliptin doses will be self-administered by the participant orally at 100mg/day throughout the 26 week period of the study. Sitagliptin is licensed to be used either alone or in combination with other oral antihyperglycemic agents (such as metformin or a sulphonylurea)
88964515|NCT02043067||new HIV clinic enrollees|All new enrollees to a Lusaka HIV clinic will receive a full TB work-up.
88964516|NCT02043080|No Intervention|SOC: sputum smear and Chest x-ray|HIV-infected adult and pediatric TB suspects screened for TB according to current standard of care
88964517|NCT02043080|Experimental|Xpert MTB/RIF, sputum, chest xray &TB culture|HIV-infected adult and pediatric TB suspects screened for TB using the Xpert MTB/RIF Tuberculosis diagnostic tool (algorithm) which include chest x-ray, sputum TB culture
88964518|NCT02043093|No Intervention|Waiting|Surveys are administered to school students and staff, but Sources of Strength program is not implemented until the school year following two years of survey participation
89558203|NCT04776447|Experimental|Experimental: Atezolizumab plus induction chemotherapy plus CT-radiotherapy|"Induction Treatment:~Atezolizumab: 1200mg, IV infusion Carboplatin: AUC5, IV infusion Paclitaxel: 200 mg/m2 The treatment will start within 1-5 days from enrollment. The treatment will be 3 cycles administered at 21-day intervals.~Concurrent Chemotherapy (CT)-Radiotherapy Treatment:~Chemotherapy and radiotherapy treatment will be at the discretion of the principal investigator of each site. It is recommended to use as concurrent chemotherapy treatment a platinum based doublet.~After the 3rd cycle of the induction treatment, concurrent treatment will start, 1st concurrent cycle will be administered from day 1 of cycle 3 of induction treatment.~Concurrent chest radiotherapy will be administered starting at day 1 of cycle 1 of concurrent chemo-radiotherapy.~Maintenance with Atezolizumab:~Atezolizumab: 1200mg, IV infusion After the 3rd cycle of the concurrent treatment, Atezolizumab maintenance treatment will start from day 1 of cycle 6 and will be administered for 12 months."
89558204|NCT04768556|Experimental|ADHD group|ADHD group: 20 participants having received a positive diagnosis of ADHD
89608412|NCT01272154|Experimental|Primary cervical dystonia Patients|
88812443|NCT04736745|Experimental|Dose escalation|"One single injection of study medication (IPN59011 or Placebo) will be injected locally. IPN59011 is injected in a dose-escalation manner.~In total for this stage at least 40 subjects."
88964519|NCT02043093|Experimental|Intervention|School receives Sources of Strength Peer Leader training and implementation for two school years, beginning in fall of enrollment year. Peer leaders are actively implementing program across two school years. Students and school staff participate in surveys across the two implementing school years.
88964520|NCT02043106|Experimental|spinal cord injury|Individuals who have sustained an incomplete spinal cord injury
88964521|NCT02043106|Active Comparator|non-spinal cord injury|Individuals who have not sustained a spinal cord injury
88964522|NCT02043119|Active Comparator|Breastfeeding Clinic|A breastfeeding clinic that mothers can attend with their infants up to one month post delivery.
88964523|NCT02043119|No Intervention|Standard of Care|
88964524|NCT02043171|Placebo Comparator|Placebo Exercise|Placebo supplementation group with 3 days per week of exercise
88964525|NCT02043171|Placebo Comparator|Placebo Non-exercise|Placebo supplementation group without exercise
88964526|NCT02043171|Active Comparator|HMB plus Vitamin D Exercise|HMB plus Vitamin D supplementation group with 3 days per week of exercise
88964527|NCT02043171|Active Comparator|HMB plus Vitamin D Non-exercise|HMB plus Vitamin D supplementation group without exercise
88964528|NCT02043184|Active Comparator|Standard Care 12 weeks|Standard care. Standard supportive care and Toolkit given at 12 weeks.
88964529|NCT02043184|Experimental|Standard Care 8 wks, Daily IVR 4 wks|Interactive Voice Response (IVR) Reminders Daily delivery for the last 4 weeks of the study.
88964530|NCT02043184|Experimental|Daily IVR 8 weeks|Interactive Voice Response (IVR) Reminders daily for the first 8 weeks of the study.
88964531|NCT02043184|Experimental|Daily IVR 4 wk, Every other day IVR 4 wk|Interactive Voice Response (IVR) Reminders daily for the first 4 weeks of the study and every other day for weeks 4-8.
88964532|NCT02043210|Active Comparator|Standard Treatment as Usual|Treatment that would normally be received at the clinic typically consisting of individual or group counseling sessions focusing on substance abuse.
88964533|NCT02043210|Experimental|CBT4CBT plus Standard treatment as usual|A computerized program that teaches skills for stopping substance use by increasing coping skills such as how to understand patterns of drug use, coping with cravings, etc. plus standard treatment as usual.
88964534|NCT02043223|Experimental|Early postpartum vitamin A suppl.|Single dose 200,000 IU vitamin A supplementation at <3-day and placebo supplementation at 6-wk postpartum.
88964535|NCT02043223|Experimental|Late postpartum vitamin A suppl.|Placebo supplementation at <3-day and single dose 200,000 IU vitamin A supplementation at 6-wk postpartum.
88964536|NCT02043223|Experimental|Early & late postpartum vitamin A suppl|200,000 IU vitamin A supplementation, both at <3-day and 6-wk postpartum
88964537|NCT02043223|Experimental|No postpartum vitamin A suppl.|Placebo supplementation, both at <3-day and 6-wk postpartum.
88964538|NCT02043236|Active Comparator|Healthy bones pamphlet, letter to GP|Strategy 1: Written educational material to patient and GP
88964539|NCT02043236|Active Comparator|Healthy bones pamphlet, Bone Health Care Coordinator|Strategy 2: Written educational material to patient and counseling from a Bone Health Care Coordinator
88812444|NCT04736745|Experimental|Dose ranging|"Up to two IPN59011dose(s) groups will be included in parallel groups versus Azzalure group and placebo group. One single injection of study medication will be injected locally into several sites.~In total for this stage at least 70 subjects."
88812445|NCT04736745|Experimental|Additional dose ranging|"Dose-ranging for three additional placebo-controlled parallel groups. One single injection of study medication will be injected locally into several sites, concomitantly and non-concomitantly.~In total for this stage at least 110 subjects."
88964540|NCT02043236|No Intervention|Usual care|Control group gets usual care from their oncologist.
88964541|NCT02043249|No Intervention|CORD MILKING|WITHOUT MILKING
88964542|NCT02043262|Experimental|Reablement|Reablement is an intensive, multidisciplinary, client-centered, home-based type of rehabilitation, where ordinary activities of daily living are used for rehabilitative purposes. It is a rehabilitation alternative that may be offered to older adults, although there is no lower age limit. An occupational therapist and physical therapist, or nurse, constitutes the key personal, while home helpers, assistants and others with lower education, are the ones who work rehabilitative with the older person on a daily basis focusing on self-help.
88964543|NCT02043262|Active Comparator|Standard treatment|This arm consists of the standard treatment home-dwelling elderly persons receive when applying for home-based help. Some elderly may receive home-based nursing or home help services assisting them in daily activities, while others may receive occupational therapy or physical therapy measures for rehabilitative purposes.
89208380|NCT00788918|No Intervention|Former HCV infected|20 Subjects with prior HCV infection identified through positive HCV antibodies, but negative HCV RNA.
89208381|NCT00788918|No Intervention|Chronic HCV patient - no treatment|20 chronic HCV patients without pending antiviral treatment.
89208382|NCT02596373|Experimental|Mitoxantrone Hydrochloride Liposome Injection|Mitoxantrone Hydrochloride Liposome Injection 20 mg/m2 will be infused intravenously once over 1 hours in 250 ml 5％ glucose injection on the first day during a treatment phase of 4 weeks
89558205|NCT04768556|Other|Control group 1|Control group 1: 20 participants having received a negative diagnosis of ADHD
89558206|NCT04768556|Other|Control group 2|Control group 2: 20 participants as healthy volunteers
89558207|NCT04768504|Experimental|Treatment Arm|Tofacitinib 10 mg PO BID for 30 days
89558208|NCT04763967||PedSCath|Subjects in this arm will be catheterized with the PedSCath Pediatric Urinary Cather.
89208383|NCT02596373|Active Comparator|Mitoxantrone Hydrochloride Injection|Mitoxantrone Hydrochloride Injection 14 mg/m2 will be infused intravenously once over 30 minutes in 150 ml 5％ glucose injection on the first day during a treatment phase of 4 weeks
89558209|NCT04763967||Retrospective Control|Generated from 2016 and 2018 anonymized subject data from the clinical sites.
89558210|NCT04762342|Experimental|Training Group Multiple Sclerosis|"24 weeks of moderate to high-intensity power training (resistance training- emphasizing an explosive concentric phase of muscle contraction) performed twice weekly.~Balance- and functional exercises are included after week 8."
89558211|NCT04762342|No Intervention|Control Group Multiple Sclerosis|Habitual lifestyle including standard care.
89558212|NCT04755452|Experimental|Low Intra-abdominal pressure|Intra-abdominal pressure will be set at 7 mm Hg during the procedure.
89558213|NCT04755452|Active Comparator|High (standard) intra-abdominal pressure|Intra-abdominal pressure will be set at 12 mm Hg during the procedure.
89558214|NCT04748172||Study Group: Women who are planning to be vaccinated|Women that are planning to be vaccinated, before receiving the first shot of the vaccine
89558215|NCT04747041|Experimental|Alternating each month for 1 year between Phytocyst herbal tea and Cyscontrol|Alternating each month (From Day1 to DAY15) for 1 year between Phytocyst herbal tea and Cyscontrol = Preventive Treatment In case of episode of cystitis : AROMAFEMINA, Capsules for the comfort of the urinary tract Oleocaps 2 : 2 capsules before meals, 3 times a day for 5 consecutive days.
89558216|NCT04741646|Experimental|Treatment Arm|During the 12-month trial, participants will be given a fixed weight-based dose of Ferric Citrate (FC). The full medication dose will be 3g/day for participants weighing <31 kg, 5g/day for those weighing >31 - <51 kg, and 6g/day for participants >51 kg. These doses will be divided into three doses to be taken with meals.
89558217|NCT04741646|Placebo Comparator|Control Arm|During the 12-month trial, participants will be given a fixed weight-based dose of Placebo. The full medication dose will be 3g/day for participants weighing <31 kg, 5g/day for those weighing >31 - <51 kg, and 6g/day for participants >51 kg. These doses will be divided into three doses to be taken with meals.
89558218|NCT04736823|Experimental|Part1 Cohort1(AK112 + Pemetrexed or Paclitaxel+Carboplatin)|"non-Squamous NSCLC:Subjects receive AK112 plus Pemetrexed and Carboplatin on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by AK112 plus Pemetrexed until progression.~Squamous NSCLC:Subjects receive AK112 plus Paclitaxel and Carboplatin on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by AK112 until progression."
89558219|NCT04736823|Experimental|Part1 Cohort2(AK112 + Pemetrexed +Carboplatin)|Subjects receive AK112 plus Pemetrexed and Carboplatin on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by AK112 plus Pemetrexed until progression.
89558220|NCT04736823|Experimental|Part1 Cohort3(AK112 + Docetaxel)|Subjects receive AK112 plus Docetaxel on Day 1 of every 3-week cycle (Q3W) until progression.
89558221|NCT04736823|Experimental|Part2 (AK112 + Pemetrexed or Paclitaxel+Carboplatin)|"non-Squamous NSCLC:Subjects receive AK112 plus Pemetrexed and Carboplatin on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by AK112 plus Pemetrexed until progression.~Squamous NSCLC:Subjects receive AK112 plus Paclitaxel and Carboplatin on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by AK112 until progression."
88964544|NCT02043275|Experimental|Leg training|Lower body resistance training only
88964545|NCT02043275|Active Comparator|Arm training|Upper body resistance training only
88964546|NCT02043288|Experimental|NC-6004 and Gemcitabine combination|NC-6004 90mg/m2 i.v. on Day 1 and Gemcitabine 1000mg/m2 i.v. on Day 1 and Day 8 respectively
88964547|NCT02043288|Active Comparator|Gemcitabine monotherapy|Gemcitabine 1000mg/m2 i.v. on Day 1 ,8 and 15
88964548|NCT02043314|Active Comparator|Isoniazida-LAQFA®|3 coated tablet of 100mg
88964549|NCT02043314|Experimental|Isoniazida|coated tablet of 300mg
88964550|NCT02043327||Experienced in Colonoscopy|two tests on two different modalities of colonoscopy simulators
88964551|NCT02043327||Novices in colonoscopy|Two tests on each of trw colonoscopy simulators
88964552|NCT02043340|Experimental|Indocyanine green (ICG)|The study included 30 patients diagnosed with chronic periodontitis. Three sites from three different quadrants were selected and assigned to three groups namely, SRP group - scaling and root planing, LASER group - scaling and root planing with application of 810 nm diode laser and ICG group - scaling and root planing with application of 810 nm diode laser and ICG at a concentration of 5 mg/mL. Primary parameters included estimation of decrease in percentage of viable bacteria at baseline, immediate post treatment and end of 1 week and Lactate dehydrogenase (LDH) levels at baseline and end of 1 week. Secondary parameters included site-specific measures of plaque, gingivitis, pocket depth (PD) and clinical attachment loss (CAL) at specific time intervals.
88964553|NCT02043353||Winter Vs. Summer|All children that underwent PSG evaluation at the Tel Aviv Medical center between 2005-2010
88964554|NCT02043353||Primary snoring|All children that were diagosed with primary snoring at the Tel Aviv Medical center between 2005-2010
88964555|NCT02043353||Adenotonsillectomy Vs. Adenoidectomy|All children that underwent adenotonsillectomy or tonsillectomy at the Tel Aviv Medical center between 2005-2008
88964556|NCT02043353||repeated PSG|All children that underwent Adenoidectomy / Adenotonsillectomy and two PSG evaluations at the Tel Aviv Medical center between 2005-2012
88964557|NCT02043444|Experimental|secretory azoospermia|110 men with secretory azoospermia will have FDG PET-CT
88964558|NCT02043444|Active Comparator|excretory azoospermia|30 men with secretory azoospermia will have FDG PET-CT
89558222|NCT04736823|Experimental|Part3 group A(AK112 + Docetaxel)|Subjects receive AK112 plus Docetaxel on Day 1 of every 3-week cycle (Q3W) until progression.
88964559|NCT02043444|Placebo Comparator|normospermia|20 men with secretory azoospermia will have FDG PET-CT
88964560|NCT02043483||CPAP|Patients with moderate/severe OSAS will be treated with CPAP
88964561|NCT02043483||Control|Patients with snoring will not be subject to treatment with CPAP
88964562|NCT02043496|Experimental|CBT-Guided Self Help|Integrative Cognitive-Affective Therapy CBT-Guided Self Help
88964563|NCT02043496|Experimental|Integrative Cognitive-Affective Therapy|Integrative Cognitive-Affective Therapy is a psychotherapy treatment for binge eating that focuses on changing behaviors, feelings, thoughts, and relationships
88964564|NCT02043522|Experimental|Nuclear Imaging|Planar, conventional SPECT imaging and CZT SPECT imaging will be done. Imaging will begin immediately following radioisotope injection with CZT SPECT imaging for 15 minutes, followed by 1) planar anterior view imaging for 10 minutes, 2) conventional SPECT imaging for 12.5 minutes and 3) CZT SPECT imaging for 12 minutes. A low dose CT transmission scan will be acquired for attenuation correction (GE Infinia Hawkeye) with the initial conventional SPECT imaging and not repeated with subsequent imaging. Participants will undergo repeat imaging at 1, 2, 3 and 4 hours after radiotracer injection with each imaging session to include 1) planar anterior, 2) conventional SPECT and 3) CZT SPECT imaging.
88964565|NCT02043535|Other|Myocardial blood flow quantification|"The RA-MR™ Virtual Sequential Gas Delivery System. : delivery of CO2 in increasing levels.~Rubidium Elution System: delivery of Rb-82 through an automated pump system for myocardial PET perfusion imaging.~Persantine stress myocardial PET perfusion imaging: as a standard for comparison."
88964566|NCT02043561|Sham Comparator|no urge|rectal balloon deflated
88964567|NCT02043561|Experimental|moderate urge|moderate urge induced by rectal balloon
88964568|NCT02043561|Experimental|high urge|high urge induced by rectal balloon
88964569|NCT02043600|Experimental|Yoga|
88964570|NCT02043600|Active Comparator|Self-care|
88964571|NCT02043613|Active Comparator|Exercise in standard room|"Intervention: Exercise~Patients exercise in standard physical surroundings. The room is marked by years of use. The room is placed in the basement, has artificial lighting, poor acoustics and bare concrete walls."
88964572|NCT02043613|Experimental|Exercise in a contexually enhanced room|"Intervention: Exercise + contextually enhanced physical surroundings~Patients exercise in a contextually enhanced room. The room has both artificial lighting and daylight, view of a recreational park, better acoustics, decorations among other factors, which may cause or enhance the context effect."
88964573|NCT02043613|No Intervention|Waiting list|Patients on waiting list are included, baseline tested and placed on a waiting-list for a 8 week period and tested at 8 weeks follow-up. The group is representative of the natural cause of disease.
88964574|NCT02043626|Experimental|Physical Activity Only|Students in 3 designated study schools will receive educational intervention and increased opportunities for physical activity.
89608413|NCT01272154|Experimental|Primary upperlimb Dystonia Patients|
89608414|NCT01272154|Experimental|Secondary Cervical or Upperlimb Dystonia due to cerebral palsy|
89608415|NCT01272154|Other|Healthy volunteers|
89608416|NCT01277770||Kidney Transplant Recipients|Kidney Transplant Recipients at the University of Minnesota since 1984. The study looks at a 10 year followup of steroid-free maintenance immunosuppression, post-transplant infections and evaluation of the DGF nomogram in Thymoglobulin on patients at the University of Minnesota.
89608417|NCT02992210|Experimental|effectiveness of 4SCAR-GD2 T cells|The 4SCAR-GD2-modified T cells can recognize and kill tumor cells through the recognize of GD2 .This study will evaluate the side effects and effective doses of 4SCAR-GD2 T cells in treating refractory and recurrent solid tumors
89608418|NCT00721162|Experimental|Ramucirumab|
89608419|NCT01838941|Experimental|Betaine|Betaine will be given orally to all participants and dose will be adjusted to body weight.
89558223|NCT04736823|Experimental|Part3 group B(AK112)|Subjects receive AK112 on Day 1 of every 3-week cycle (Q3W) until progression.
89558224|NCT04736823|Experimental|Part3 group C(Docetaxel)|Subjects receive Docetaxel on Day 1 of every 3-week cycle (Q3W) until progression.
89558225|NCT04732676|Experimental|Experimental group|participants will receive and use during 4 weeks the full interventional version of the smartphone application (combining EMA + EMI) targeting craving and personal situations at risk for use
89558226|NCT04732676|Placebo Comparator|control group|: participants will receive and use a restricted version of the smartphone application (only EMA: 4 electronic questionnaires per day to assess main problematic substance use / addictive behavior) during 4 weeks
89558227|NCT04731571||Adaptive Radiotherapy|Patients treated using adaptive radiotherapy on the Varian Ethos linear accelerator
89558228|NCT04731571||Conventional Radiotherapy|Patients treated using conventional, non-adaptive radiotherapy on the Varian Truebeam linear accelerator
89558229|NCT04729946|Experimental|Pure-Vu Treatment|Participants in this arm will undergo colonoscopy using the Pure-Vu cleansing device.
89558230|NCT04729621|Experimental|TVB-009 main treatment period|TVB-009 (denosumab) pre-filled syringe, administered at weeks 1 and 26
89558231|NCT04729621|Active Comparator|PROLIA main treatment period|Prolia® (denosumab) pre-filled syringe, administered at weeks 1 and 26
88964575|NCT02043626|No Intervention|Delayed Interventions Only|Students in 3 designated schools will receive educational interventions on health topics not related to nutrition or physical activity (i.e. peer relations, sleep, dental care, etc.)
88964576|NCT02043626|Experimental|Nutrition and Physical Activity|Students in 3 designated schools will receive nutrition education, nutrition standards for foods sold, and opportunities for physical activity.
88964577|NCT02043626|Experimental|Nutrition Only Interventions|Students in 3 designated study schools will receive multiple interventions regarding nutrition education and nutrition standards for foods sold.
88964578|NCT02043717||CF patients|Both children and adults, with or without vitamin D deficiency.
88964579|NCT02043730|Experimental|nab-paclitaxel and gemcitabine|ARM A: nab-paclitaxel 125 mg/mq over 30 min and gemcitabine 1000 mg/mq weekly on days 1, 8 and 15 of a 28-day cycle
88964580|NCT02043730|Active Comparator|Gemcitabine|ARM B: Gemcitabine 1000 mg/mq over 30 minutes on days 1, 8 and 15 of a 28-day cycle.
88964581|NCT02043743|Experimental|Laboratory and Clinical|"Biological: Stem Cells 60 ml of bone marrow will aspirated and used for stem cells isolation. Then stem cells will cultured using autologous serum, characterized and prepared using GMP rules and finally injected into rete testis.~Stem Cell Dose:~•3-5 Million Autologous MSCs Injected into Ovarian tissue."
88964582|NCT02043756|Experimental|Mitoxantrone Hydrochloride Liposome|Dose escalation will begin at 6mg/m2 to 16mg/m2,4 weeks apart
88964583|NCT02043756|Active Comparator|Mitoxantrone ,injection|When the dose of experiment drup up 10mg/m2,10mg/m2 of Mitoxantrone as active comparator
88964584|NCT02043769||Prospective Cohort|"The prospective cohort surveillance will be built upon and support the routine clinical care, visit schedule and monitoring system at each study site. Eligible HIV-infected ART naïve children who are accessing care at study sites will be recruited sequentially for study enrollment. Children enrolled in the surveillance study will attend study visits co-scheduled to coincide with routine clinical visits. Study nurses will:~review routinely collected information;~conduct questionnaires with caregiver and child;~conduct additional assessments of child;~contact the caregiver by phone or through home visits for active follow-up for up to 24 months; and~conduct active follow-up including appointment reminders by means of phone calls and defaulter tracking."
88964585|NCT02043795|Other|Treated with BVS|Symptomatic patients would be screened with a duplex ultrasound as per clinical practice prior to intervention. After informed consent for a standard angiography/intervention, the patient will undergo a planned intervention under general or local anaesthesia in an angiographic facility.
88964586|NCT02043821|Other|Placebo|Placebo 1250mg/m2 tablet by mouth every 12 hours for 14 days
89558232|NCT04729621|Experimental|TVB-009 main / TVB-009 transition period|TVB-009 (denosumab) pre-filled syringe, administered at week 52 in patients that were randomized to TVB-009 in the main treatment period
89558233|NCT04729621|Active Comparator|PROLIA main / PROLIA transition period|Prolia® (denosumab) pre-filled syringe, administered at week 52 in patients that were randomized to PROLIA in the main treatment period
88964587|NCT02043821|Experimental|Capecitabine|Capecitabine 1250mg/m2 tablet by mouth every 12 hours for 14 days
88964588|NCT02043834|Experimental|Balance Training|"Balance training will be conducted individually two times per week for 4 weeks. Each training session will include virtual reality tasks such as ankle reaching and obstacle crossing using a virtual obstacle shown on a computer screen. Each session will last 30 - 45 minutes."
88964589|NCT02043834|No Intervention|Control|The control group will keep their normal activity without receiving any intervention.
88964590|NCT02043873||25 composite restorations replaced|25 composite replaced with clinically diagnosed secondary caries (Charlie) or undercontoured anatomical form defects (Bravo)
88964591|NCT02043873||25 composite repaired|25 composite repaired with clinically diagnosed secondary caries (Charlie) or undercontoured anatomical form defects (Bravo)
88964592|NCT02043886|Active Comparator|Acarbose|Acarbose 50mg by mouth at minute 0 of the Meal Test.
88964593|NCT02043886|Placebo Comparator|Placebo|Placebo 1 tablet at 0 minutes of Meal Test.
88964594|NCT02043912||patients treated with haloperidol|
89558234|NCT04729621|Experimental|PROLIA main / TVB-009 transition period|TVB-009 (denosumab) pre-filled syringe, administered at week 52 in patients that were randomized to PROLIA in the main treatment period
89558235|NCT04726514|Experimental|SleepFlex Treatment|
89558236|NCT04707885|Experimental|ECochG monitoring|For those randomized to the experimental group, the CI surgery will proceed in a standard fashion. However, the surgeon will utilize ECochG-guided monitoring by placing the external device coil and processor over the receiver/stimulator of the implanted components. Also, a sound applicator (i.e. speaker) will be placed in the external auditory canal by the surgeon. During electrode insertion the surgeon will utilize the ECochG feedback to adjust insertion if needed. That is, once the electrode has been inserted at least 75% (75% of the electrode contacts inside the cochlea), the surgeon may proceed to full insertion if indicated during ECochG feedback or may modify and/or cease electrode insertion if indicated by the ECochG feedback in attempts to preserve RH.
89558237|NCT04707885|No Intervention|Control Group|For those randomized to the control group, they will receive their CI per the standard of care. That is, all procedures that take place during a routine CI surgery will be the same for those in the control group. As such, no ECochG monitoring will be performed. However, all study surgeons will be asked to adhere to soft surgical principles (non-traumatic cochlear opening, slow electrode insertions) to enhance HP outcomes even in the absence of intraoperative ECochG monitoring. Further, the standard of care for cochlear implantation is to perform full electrode insertions with all electrode contacts inside of the cochlea. Thus, for subjects in the control group, surgeons will be asked to perform full electrode insertions.
89558238|NCT04695028||Persons with crystal related arthropathies|
89558239|NCT04694534|Experimental|"Remediation program via a serious game"|"Classic care (recommended by the French Haute Autorité de Santé) accompanied by cognitive remediation by serious game"
89558240|NCT04694534|Placebo Comparator|Classic care (French Haute Autorité de Santé)|Classic care (recommended by French Haute Autorité de Santé)
89558241|NCT04684836||Synchronous telemedicine alone|
89558242|NCT04684836||Telemedicine-supplemented in-person care|
89558243|NCT04684836||In-person care alone|
89558244|NCT04684121|Experimental|Granexin gel|"Within-subject comparison of Granexin® Gel versus vehicle gel (placebo).~Granexin® gel 200 μM will be applied daily over ten days. Granexin® will be applied to one of two selected target burns."
88964595|NCT02043925||psychiatric patients treated with QT-prolonging drugs|
88964596|NCT02043951||Single Arm: Lutonix Drug Coated Balloon|
88964597|NCT02043977|Experimental|propofol infusion|Induction of sleep is accomplished with a bolus of propofol (up to 0.5mg/kg over one minute, concurrently with a constant infusion of propofol starting at 25 ug/kg/min titrated to a maximum of 100ug/kg/min, to maintain the subject at a Modified Ramsay Score of 3-4 for a total of 120 minutes. An additional bolus may be given by the investigator in order to maintain the level of sleep. This procedure will be conducted over 5 consecutive nights.
88964598|NCT02043990|Experimental|Noninvasive NAVA Ventilation|Noninvasive NAVA Ventilation versus conventional noninvasive Pressure Support Ventilation
88964599|NCT02044003|Experimental|Post Angioplasty Dissection Repair|Implant of Innovasc Tack Intravascular Staple System (Tack) to repair post angioplasty dissections
88964600|NCT02044016||Observational study|To compare results of the ATLM with goniometry and Ultrasound measures of the achilles tendon.
88964601|NCT02044029||Age- and gender-matched controls|
88964602|NCT02044029||Patients with spinal muscular atrophy|
88964603|NCT02044042||HCV pregnant women|HCV chronically infected pregnant women, with a positive HCV RNA during pregnancy
88964604|NCT02044055||Children born to HBV-HDV women|"Children born to HBV-HDV co-infected women will be checked for:~HDV antibodies~if positive, HDV RNA"
88964605|NCT02044068||children born from HIV-HBV women|Studying retrospectively their status for HBs Ag and HBc Ab
88964606|NCT02044107|Experimental|Co-packaging and counseling messages|"Current standard care at public health center ( zinc ORS for treatment of diarrhea and antibiotics for treatment of of pneumonia).~The intervention consists of health center level co-packaging and visual counseling messages (zinc & ORS packaged at health center for diarrhea, and zinc & antibiotics co-packaged at health center for pneumonia) Co-packaging is done in a plastic bag, which is covered with pre-tested zinc treatment messages - a distinct packaging has been designed for diarrhea and for pneumonia"
88964607|NCT02044107|No Intervention|Control group|Current standard care at public health center (zinc & ORS for treatment of diarrhea and zinc & antibiotics for treatment of of pneumonia).
88964608|NCT02044120|Experimental|niraparib and temozolomide|Niraparib (capsule) and temozolomide (capsule) will be taken together.
88964609|NCT02044120|Experimental|niraparib and irinotecan|Niraparib will be taken orally and irinotecan will be administered intravenously.
88964610|NCT02044120|Experimental|niraparib, irinotecan and temozolomide|Niraparib and temozolomide will be taken orally. Irinotecan will be administered intravenously.
88964611|NCT02044133|Other|Dosage of vitamine D : inclusion and 6 month|Participant will have one dosage of vitamine D to entrance of prison and one dosage of vitamine D 6 month after entry
88964612|NCT02044133|Other|Dosage of Vitamine D 6 month|Participant will have one dosage of vitamine D 6 month after entry to prison
88964613|NCT02044146|Experimental|Personalized Therapy|"A point-of-care bedside genetic test for CYP2C19*2 and CYP2C19*3 using a buccal swab will be conducted.2 P2Y12 inhibitory drug therapy will be then be directed based on a risk algorithm (integrating genotyping and clinical variables). Patients with high ischemic risk are defined as having (*2 or *3) and/or diabetes and/or (having age>65 AND BMI>=28). High-risk patients will be switched to prasugrel at 10mg daily, while low ischemic risk patients be kept on clopidogrel 75 daily. For patients >age 75 or wt < 60 kg, prasugrel will be reduced to 5mg daily."
88964614|NCT02044146|Active Comparator|Ticagrelor|Patients will be treated with a 90mg twice daily regimen of Ticagrelor
89558245|NCT04684121|Placebo Comparator|Vehicle Gel|"Within-subject comparison of Granexin® Gel versus vehicle gel (placebo).~Vehicle gel will be applied daily over ten days. Vehicle will be applied to one of two selected target burns."
89558246|NCT04672369|Experimental|IBI939 in combination with Sintilimab|
88964615|NCT02044146|Other|Clopidogrel registry arm|A concurrent registry of patients (not randomized) who are receiving clopidogrel only (as decided by treating physician) will be followed as a comparator group.
89558247|NCT04672369|Active Comparator|sintilimab|
88964616|NCT02044185||high dose chemotherapy|group of using myeloablation regimen, autologous stell cell transplantation
88964617|NCT02044185||control group|normal population with health screening
88964618|NCT02044198|Active Comparator|Group 1 - FMP2.1/AS01B vaccine|"FMP2.1/AS01B vaccine administered at days 0, 28 and 56.~Blood-stage controlled human malaria infection (CHMI) at day 70."
88964619|NCT02044198|No Intervention|Group 2 - control|"Group 2 is an infectivity-control group for the malaria infection challenge procedures; these volunteers will not be vaccinated.~Blood-stage controlled human malaria infection (CHMI) at day 70."
88964620|NCT02044211|Active Comparator|Collaborative Care for Heart Failure + Depression|"Collaborative care program for heart failure and depression involving a nurse care manager providing counseling and treatment advice via telephone~Interventions:~Behavioral:~Counseling for heart failure self-care Counseling for depression~Drug:~Pharmacotherapy for heart failure Pharmacotherapy for depression"
89558248|NCT04672356|Experimental|Phase Ia: IBI939 in combination with Sintilimab|IBI939 10mg/kg combination with Sintilimab
88964621|NCT02044211|Active Comparator|Collaborative Care for Heart Failure Only|"Collaborative care program for heart failure and depression involving a nurse care manager providing counseling and treatment advice via telephone~Interventions:~Behavioral:~Counseling for heart failure self-care Usual care for depression~Drug:~Pharmacotherapy for heart failure~Usual Care for depression"
88964622|NCT02044211|No Intervention|Usual Care for Heart Failure and Depression|Control group will receive their doctors' usual care for heart failure and depression
88964623|NCT02044211|No Intervention|Non-Depressed Comparison Cohort|Control group will receive their doctors' usual care for heart failure
88964624|NCT02044224|Experimental|Dexmedetomidine|Dexmedetomidine infusion during anaesthesia for IRE procedure
88964625|NCT02044237|Experimental|Decoupling|specific technic to reduce hair pulling
88964626|NCT02044237|Active Comparator|progressive muscle relaxation|Progressive relaxation relaxation technic
88964627|NCT02044250|Active Comparator|Clopidogrel|Antiplatelet monotherapy : Clopidogrel 75mg P.O. daily
88964628|NCT02044250|Placebo Comparator|Aspirin|Antiplatelet monotherapy : Aspirin 100~200mg P.O. daily
88964629|NCT02044263|Experimental|Internet CBT-i|Participants will be instructed on the use of the internet CBT-i (SHUTi) intervention site, then use the program for six weeks.
88964630|NCT02044263|Active Comparator|face-to-face CBT-i|4 to 8 sessions of face-to-face CBT-i treatment with one of three clinicians (experienced CBT-i psychiatrists)
89558249|NCT04672356|Experimental|Phase Ia:IBI939 in combination with Sintilimab|IBI939 20mg/kg combination with Sintilimab
89558250|NCT04668170||hospitalized patients|"very well-defined population of COVID-19 patients with the following outcomes:~Patients with severe disease requiring on admission ICU management for SARS, Non-severe hospitalized patients with secondary clinical worsening requiring ICU management, Non-severe hospitalized patients without clinical worsening requiring ICU management."
89558251|NCT04668170||healthcare workers|mildly symptomatic patients among healthcare workers attending outpatient dedicated clinics will be recruited
89558252|NCT04665869|Experimental|Combined balance and brisk walking training|Week1-6: Supervised training in groups of 6-8 participant, once/week, 90 min/session 2. Week 7-26: Supervised training in groups of 6-8 participant, once/month, 90 min/session 3. Participants practice own balance exercise and brisk walking 2-3 times/week (to aim at 150 min of moderate intensity of brisk walking per week at 40-60% of heart rate reserve)
89558253|NCT04665869|Active Comparator|Flexibility and strengthening exercise|"Week1-6: Supervised training in groups of 6-8 participant, once/week, 90 min/session~Week 7-26: Supervised training in groups of 6-8 participant, once/month, 90 min/session~Participants practice own flexibility and strengthening exercise 2-3 times/week (to aim at 150 min of exercise per week)"
89558254|NCT04664023||Patients with severe SARS-CoV-2 infection|Patients with severe SARS-CoV-2 infection hospitalised in intensive care unit
89558255|NCT04664023||Patients with intermediate SARS-CoV-2 infection|Patients with intermediate SARS-CoV-2 infection hospitalised in infectious and tropical diseases department
89558256|NCT04664023||Little symptomatic patients with SARS-CoV-2 infection|Little symptomatic ambulatory patients with SARS-CoV-2 infection
88964631|NCT02044315|Sham Comparator|Conventional|Conventional ICD programming
88964632|NCT02044315|Experimental|High-zone|High-zone ICD programming
88964633|NCT02044354|Other|Do/Ca|Arm Do/Ca : Taxotere 75mg/m2/3w x 4 cycles, followed by Jevtana 25mg/m2/3w x 4 cycles
88964634|NCT02044354|Other|Ca/Do|Arm Ca/Do : Jevtana 25mg/m2/3w x 4 cycles, followed by Taxotere 75mg/m2/3w x 4 cycles
88964635|NCT02044406|Experimental|1 BI 1181181 single rising dose part|single rising doses of BI 1181181
88964636|NCT02044406|Experimental|2 BI 1181181 bioavailability part|bioavailability, food effect part of BI 11881181
88964637|NCT02044432|Experimental|Ginger compress|
88964638|NCT02044432|No Intervention|Wait list|
88964639|NCT02044445|Active Comparator|36 h group|Oocyte retrieval will be performed 36 hours after hCG administration
89558257|NCT04664023||Patients with SARS-CoV-2 infection hospitalised in geriatry department|Patients with SARS-CoV-2 infection hospitalised in geriatry department to study influence of age on the studied mechanisms
89558258|NCT04664023||Subjects above 65 years wishing to be vaccinated with anti-COVID-19 BioNTech Pfizer vaccine|Subjects above 65 years wishing to be vaccinated with anti-COVID-19 BioNTech Pfizer vaccine
88964640|NCT02044445|Active Comparator|38 h group|Oocyte retrieval will be performed 38 hours after hCG administration
88964641|NCT02044471|Experimental|Intervention|"Our intervention will be ischemic conditioning (IC) remotely applied using a sphygmomanometer. We will use the standard, validated protocol, which is inflation of the sphygmomanometer to 200 mmHg for 5 minutes, then deflation with 5 minutes of reperfusion, repeated for 3 cycles (total 30 minutes). This will be done in the dominant arm, twice daily.~Once patients are discharged home on a stable pharmacotherapy regimen, they will be expected to follow the above intervention for 6 weeks, followed by another 6 weeks in the control (no intervention) phase. Patients will be randomized as to which phase they begin the study."
88964642|NCT02044471|No Intervention|Control|standard care
88964643|NCT02044484|Experimental|Multi-component intervention|"Computer-based intervention (CBI) completed twice (separated by 2-4 months) among patients whose viral load exceeds 1000 copies/mL at time of enrollment.~One-on-one counseling from a project Health Coach (three 1-hour sessions at the clinic and two follow-up phone calls at 1 and 3 months after last session). The counseling is offered to patients who do not show a 1-log reduction in their viral load after the first CBI or whose viral load remains above 200 copies/mL after two administrations of the CBI.~Behavioral screening of patients at HIV primary care visits.~Dissemination of palm cards with empowering messages at HIV primary care visits."
88964644|NCT02044484|No Intervention|Standard of care control|HIV patients will continue to receive existing standard of care practices at the clinic without receiving the multi-component intervention.
88964645|NCT02044523||Hepatis C, Hepatitis B, NAFLD|"All patients enrolled will undergo:~Transient Elastography (Fibroscan)~Acoustic Radiation Force Impulse (ARFI)~Magnetic Resonance Elastography (MRE)"
88964646|NCT02044536||Faculty doctors|Experienced endoscopists (> 6000 cases). no intervention
88964647|NCT02044536||Trainees|Doctors on fellowship who are inexperienced endoscopists (< 4 months of endoscopy training) no intervention
88964648|NCT02044549|Active Comparator|carbetocin|single 100 μg IV dose of carbetocin (150 women) after fetal extraction and before placental removal.
88964649|NCT02044549|Active Comparator|Syntometrine|Intravenous combination of 5 IU oxytocin and 0.2 mg ergometrine (300 women) after fetal extraction and before placental removal.
88964650|NCT02044562|Experimental|nitrate supplementation|Patients will receive 7-day nitrate supplementation at the end of the radiotherapy.
88964651|NCT02044562|Placebo Comparator|Placebo|Patients will receive 7-day placebo supplementation at the end of the radiotherapy
88964652|NCT02044575||Critically ill patients|Intensive care unit patients with refractory septic shock
88964653|NCT02044588||HBsAg negative kidney allograft donor|
88964654|NCT02044588||HBsAg positive kidney allograft donor|HBsAg positive kidney allograft donor
88964655|NCT02044601|Experimental|Chemoradiation + Onartuzumab|"Participants with wild-type EGFR mutation to be randomized, and may receive this regimen.~Phase I: Starting dose of Onartuzumab 10 mg/kg by vein on Day 1 of each 3 week cycle. Paclitaxel 45 mg/m2 by vein once a week throughout radiation for 7 weeks. Carboplatin AUC 2 by vein once a week throughout radiation for 7 weeks. Radiation therapy at 66 Gy in 33 fractions delivered 5 days a week for 7 weeks, or proton therapy delivered at biological equivalent to 66 Gy (RBE) (RBE = 1.1) in 33 fractions 5 days a week for 7 weeks.~Phase II: Same regimen as in Phase I, but starting dose of Onartuzumab is maximum tolerated dose from Phase I."
88964656|NCT02044601|Experimental|Chemoradiation + Erlotinib + Onartuzumab|"Participants with EGFR mutation to receive this regimen. Participants with wild-type EGFR mutation to be randomized, and may receive this regimen.~Phase I: Erlotinib 150 mg by mouth every day throughout radiation, except for chemotherapy day. Starting dose of Onartuzumab 10 mg/kg by vein on Day 1 of each 3 week cycle. Paclitaxel 45 mg/m2 by vein once a week throughout radiation for 7 weeks. Carboplatin AUC 2 by vein once a week throughout radiation for 7 weeks. Radiation therapy at 66 Gy in 33 fractions delivered 5 days a week for 7 weeks, or proton therapy delivered at biological equivalent to 66 Gy (RBE) (RBE = 1.1) in 33 fractions 5 days a week for 7 weeks.~Phase II: Same regimen as in Phase I, but starting dose of Onartuzumab is maximum tolerated dose from Phase I."
88964657|NCT02044614|Other|icodextrin-based peritoneal dialysis to hemodialysis|12-week course of adjuvant low-frequency icodextrin-based peritoneal dialysis to ongoing thrice-weekly maintenance hemodialysis
88964658|NCT02044627|Experimental|1 dose of [14C-ETC-1002]|
88964659|NCT02044640||Appendectomy|Patients undergoing a laporascopic appendectomy
88964660|NCT02044653|Experimental|Group A (Part A)|GX-E2 : Subcutaneously injection every 2 weeks (Q2W) at dose 3ug/kg
88964661|NCT02044653|Experimental|Group B (Part A)|GX-E2 : Subcutaneously injection every 2 weeks (Q2W) at dose 5ug/kg
88964662|NCT02044653|Experimental|Group C (Part A)|GX-E2 : Subcutaneously injection every 2 weeks (Q2W) at dose 8ug/kg
88964663|NCT02044653|Experimental|Group D (Part A)|GX-E2 : Subcutaneously injection every 4 weeks (Q4W) at dose 3ug/kg
88964664|NCT02044653|Experimental|Group E (Part A)|GX-E2 : Subcutaneously injection every 4 weeks (Q4W) at dose 5ug/kg
88964665|NCT02044653|Experimental|Group F (Part A)|GX-E2 : Subcutaneously injection every 4 weeks (Q4W) at dose 8ug/kg
88964666|NCT02044653|Experimental|Group G (Part B)|GX-E2 : Subcutaneously injection every 2 weeks (Q2W) at dose 5ug/kg
88964667|NCT02044653|Experimental|Group H (Part B)|GX-E2 : Subcutaneously injection every 2 weeks (Q2W) at dose 8ug/kg
88964668|NCT02044653|Active Comparator|Group I (Part B)|MIRCERA : Subcutaneously injection every 2 weeks (Q2W) at dose 0.6ug/kg
89558259|NCT04664023||Subjects below 65 years wishing to be vaccinated with anti-COVID-19 BioNTech Pfizer vaccine|Subjects below 65 years wishing to be vaccinated with anti-COVID-19 BioNTech Pfizer vaccine
89558260|NCT04642781||healthy children aged 8-13years (schoolgrade 2-5)|Primary school children are asked to read a German text presented on a laptop screen
89558261|NCT04635995|Experimental|Monotherapy dose escalation|The monotherapy dose escalation phase includes 8 dose levels of LVGN7409. Route of administration is IV infusion, and the frequency of administration is once every 3 weeks (Q3W). One cycle is 3 weeks, and treatment can be up to 35 cycles if patients receive benefits.
89558262|NCT04633889|Experimental|Deferoxamine|Deferoxamine 30mg/kg (max dose, 6g) intravenous infusion (diluted in 240mL normal saline) administered over 12 hours
89558263|NCT04633889|Placebo Comparator|Placebo|Normal saline (240mL) intravenous infusion over 12 hours
89558264|NCT04630886|Experimental|Tranexamic acid|The TXA group will receive 2% lidocaine with 1:100,000 epinephrine mixed 50/50 with 50mg/ml TXA (with 50% dilution, this will yield 1% lidocaine with 1:200,000 epi).
89558265|NCT04630886|Active Comparator|Control|The control group will use the routine local anesthetic of buffered 1% lidocaine with 1:200,000 epinephrine.
89558266|NCT04626349|Experimental|FOCUS+|Dyads in the FOCUS+ arm will receive the face-to-face nurse-led FOCUS+ program.
89558267|NCT04626349|Experimental|iFOCUS|Dyads in the iFOCUS arm will receive the web-based iFOCUS program.
89558268|NCT04626349|No Intervention|Standard care|Dyads in the control group will receive standard care as usual, as determined by the healthcare system in the participating countries. The dose and frequency of usual care will be as deemed appropriate by the medical practitioner in charge of their treatment.
89558269|NCT04619316|Other|BRAF wild type|In BRAF wild type patients trametinib 2mg (1-0-0) is applied daily over a time span of 3 weeks, then the effect is evaluated via 123I whole-body scintigraphy
89558270|NCT04619316|Other|BRAF V600E Mutation|In BRAF wild type patients trametinib 2mg (1-0-0) and dabrafenib 75mg (2-0-2) are applied daily over a time span of 3 weeks, then the effect is evaluated via 123I whole-body scintigraphy
88964669|NCT02044653|Experimental|Group J (Part B)|GX-E2 : Intravenously injection every week (Q1W) at dose 5ug/kg
88964670|NCT02044653|Experimental|Group K (Part B)|GX-E2 : Intravenously injection every week (Q1W) at dose 8ug/kg
88964671|NCT02044653|Experimental|Group L (Part B)|GX-E2 : Intravenously injection every 2 weeks (Q2W) at dose 8ug/kg
88964672|NCT02044653|Active Comparator|Group M (Part B)|NESP : Intravenously injection every week (Q1W) at dose 30ug
88964673|NCT02044666|Experimental|Treatment|
88964674|NCT02044679|Experimental|A = Increase water intake 1|+ 1,5 to 2,0 L/day of water
88964675|NCT02044679|Experimental|B = Increase water intake 2|+ 1,0 to 1,5 L/day of water
88964676|NCT02044679|Other|C = no change|No change
89558271|NCT04618484|Experimental|Biomodulation|6-weeks post-operative cryo-, photo- and electro-biomodulation protocol after repair
89558272|NCT04618484|No Intervention|Control|standard rehabilitation after repair
89558273|NCT04618211|Other|Low dose/placebo|Single low dose of deucrictibant or placebo
89558274|NCT04618211|Other|Medium dose/placebo|Single medium dose of deucrictibant or placebo
89558275|NCT04618211|Other|High dose/placebo|Single high dose of deucrictibant or placebo
89558276|NCT04610528|Experimental|U3-1402|U3-1402 is an antibody drug conjugate (ADC) comprising a recombinant fully human anti-human epidermal growth factor receptor (HER) 3 immunoglobulin G1 (IgG1) monoclonal antibody (patritumab, U3-1287) covalently conjugated to a drug-linker (MAAA-1162a) containing a drug component (MAAA-1181a). MAAA-1181a is released after internalization and leads to apoptosis of the target tumor cells by the inhibition of topoisomerase I
89558277|NCT04609111|Active Comparator|No aspirin|To start prasugrel monotherapy before the index percutaneous coronary intervention (PCI) and to change into clopidogrel monotherapy at 1-month after the PCI.
89558278|NCT04609111|Active Comparator|1-month DAPT|To start dual antiplatelet therapy comprising of aspirin and prasugrel before the index percutaneous coronary intervention (PCI) and to change into aspirin monotherapy at 1-month after the PCI.
89558279|NCT04599062|Experimental|Talimogene Laherparepvec in combination with radiotherapy-Phase I Cohort|"Talimogene Laherparepvec Dose Levels:~Dose 0 = talimogene laherparepvec up to 8.0 mL of 108 PFU/mL dosed weekly~Dose -1 = talimogene laherparepvec up to 8.0 mL of 108 PFU/mL dosed every 2 weeks"
89558280|NCT04599062|Active Comparator|Talimogene Laherparepvec in combination with radiotherapy-Phase II Cohort|Dose 0 = talimogene laherparepvec up to 8.0 mL of 108 PFU/mL dosed weekly
89558281|NCT04597359|Experimental|Arm A (green tea catechins)|Patients receive green tea catechins PO BID for up to 6 months in the absence of disease progression or unacceptable toxicity.
89558282|NCT04597359|Placebo Comparator|Arm B (placebo)|Patients receive placebo PO BID for up to 6 months.
89558283|NCT04590196|Experimental|treatment|
89558284|NCT04590196|Placebo Comparator|control|
89558285|NCT04589208|Experimental|Ketamine|ketamine
89558286|NCT04582864|Experimental|Flotetuzumab|"Will start on cycle 1 day 1 on the dose escalation ramp schedule of flotetuzumab as a continuous intravenous (IV) infusion. Patients will be initiated at 30 ng/kg/day and have their dose increased daily to a target goal of 500 ng/kg/day by day 7~Patients will continue on flotetuzumab at 500 ng/kg/day for the remaining 21 days of the 28 day cycle.~On cycle 1 day 28, patients will undergo bone marrow biopsy for assessment of disease status. Patients who have achieved a CR/CRi will proceed to a second cycle per protocol, while patients with a PR or SD or better may proceed to cycle 2 with permission of the investigator. Patients with available donor lymphocytes may receive DLI concurrently with flotetuzumab during Cycle 1 and/or Cycle 2."
89558287|NCT04580524|Active Comparator|Phasix Mesh|Phasix mesh will be used in the repair of the hernia
89558288|NCT04580524|Active Comparator|Current Care|The hernia will be repaired with either synthetic mesh or suture repair, as determined by the operating surgeon.
89558289|NCT04566328|Active Comparator|Arm A (daratumumab, lenalidomide, dexamethasone)|INDUCTION: All patients receive standard induction therapy comprising the following: daratumumab subcutaneously (SC) on days 1, 8, 15, and 22 of cycles 1-2, days 1 and 15 of cycles 3-6, and day 1 of cycles 7-9, lenalidomide orally (PO) daily on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for 9 cycles in the absence of disease progression or unacceptable toxicity.
89558290|NCT04566328|Experimental|Arm B (bortezomib, daratumumab, lenalidomide, dexamethasone)|"CONSOLIDATION: Patients receive bortezomib SC on days 1, 8, and 15, daratumumab SC on day 1, lenalidomide PO daily on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for 9 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive lenalidomide PO daily on days 1-21 and daratumumab SC on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
89558291|NCT04566328|Active Comparator|Arm C (daratumumab, lenalidomide, dexamethasone)|"CONSOLIDATION: Patients receive daratumumab SC on day 1, lenalidomide PO daily on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for 9 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive lenalidomide PO daily on days 1-21, and daratumumab SC on day 1. Cycles repeats every 28 days in the absence of disease progression or unacceptable toxicity."
89558292|NCT04565795|Experimental|Placement of ureteral stent post ureteroscopy|Subjects with unilateral ureteral or renal stone fragments who have undergone an uncomplicated ureteroscopy (UURS)
89558293|NCT04559724|Experimental|Indego-Assisted Gait Rehabilitation|"Every session of Indego-assisted gait rehabilitation will last 30 minutes, excluding preparation times (dressing, measurements, and adaptation of the brace to the anthropological measures of the various patients). The Indego program will be set based on the patient's ambulatory abilities, assessed by the Functional Ambulation Classification (FAC):~subjects unable to walk or high-.assistance needed (FAC = 0-2): Motion + program;~Subjects able to walk with mid/mini assistance or with supervision only (FAC = 3-5): Therapy + program.~During the treatment, the program change from Motion + to Therapy + is allowed based on the experts' opinion."
89558294|NCT04559139|Active Comparator|Arm I (surgery, adjuvant therapy)|Within 4 weeks of randomization, patients undergo surgery to remove part of the liver, the lymph nodes around the liver, and possibly the bile ducts. Patients then receive gemcitabine IV over 30 minutes and cisplatin IV over 30 minutes-24 hours on days 1 and 8. Treatment repeats every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity.
89558295|NCT04559139|Experimental|Arm II (neoadjuvant therapy, surgery, adjuvant therapy)|Patients receive gemcitabine IV over 30 minutes and cisplatin over 30 minutes-24 hours on days 1 and 8. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Approximately 4-8 weeks after completion of chemotherapy, patients whose disease has not spread to other places in the body (metastasized), then undergo surgery as in Arm I. Patients with successful surgery then resume treatment with gemcitabine IV and cisplatin IV on days 1 and 8. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
89208384|NCT00246805|Experimental|1. VRS ON|"Patients with permanent atrial fibrillation implanted with VVI(R) pacemaker Vitatron model C20 SSIR or T20 SSIR were randomized to Function Ventricular Rate Stabilization (VRS) ON or OFF.~This arm (1) is randomized to Function Ventricular Rate Stabilization ON."
89558296|NCT04551222|Active Comparator|Probenecid|1 gr. orally of probenecid twice daily for 180 days
89558297|NCT04551222|Placebo Comparator|Placebo|identical placebo (to probenecid tablets) for 180 days
89558298|NCT04541056|Experimental|Goal Management Training (GMT)|"GMT will be administrated in a group-based format over 5 sessions (minimum three weeks between each session). Homework assignments between sessions are included. Following the fourth session, text messages reading Stop! (a key instruction in GMT) will be sent to all GMT participants every day to maximize adherence to training (approximately 12 per participant). Homework assignment will also include the logging of automatic thoughts and an examination of the relationship between situations, thoughts, and accompanying emotions."
88964677|NCT02044705|Experimental|Family group sessions|Active and Healthy Families
88964678|NCT02044705|No Intervention|Wait-list control|Controls may participate in Active and Healthy Families after the study
88964679|NCT02044731|Experimental|Family group sessions|Active and Healthy Families
88964680|NCT02044744|Experimental|Referral|Physical activity referral
88964681|NCT02044744|No Intervention|Wait-list control|Wait-list controls receive no intervention until after they provide follow-up measurements.
88964682|NCT02044757|Experimental|SSB withdrawal|
88964683|NCT02044783|Experimental|Behavioral Intervention|Behavioral Counseling Intervention: 6 telephone calls that include physical activity goal-setting, tracking,and problem-solving of barriers
88964684|NCT02044783|No Intervention|Usual Care|Monthly mailed print materials on aging topics (that would generally be administered by subjects' primary care clinic). No behavioral counseling.
88964685|NCT02044809|Placebo Comparator|Placebo|
88964686|NCT02044809|Experimental|Cannabidiol 200mg Oral|
88964687|NCT02044809|Experimental|Cannabidiol 400mg Oral|
88964688|NCT02044809|Experimental|Cannabidiol 800mg Oral|
88964689|NCT02044835|Placebo Comparator|OMT controll|placebo 20 ml every time, three times a day, combined with optimal medical therapy of internal medicine, including anti-platelet therapy and other protocol-driven medical therapies to control blood pressure and glucose and lipid levels in accordance with guidelines.
88964690|NCT02044835|Experimental|herbal treatment|Fu-zheng-qu-zhuo oral liquid ( herbal medicine) 20 ml every time, three times a day,combined with optimal medical therapy of internal medicine, including anti-platelet therapy and other protocol-driven medical therapies to control blood pressure and glucose and lipid levels in accordance with guidelines.
88964691|NCT02044861|Experimental|ACT-PFK-158|dose escalation
89558299|NCT04541056|Active Comparator|Waitlist/Brain Health Workshop (BHW)|The adults participating in the control condition will approximately one year from waitlist, be offered a psycho-educative training program, the BHW, in groups aimed at providing a better understanding of cognitive sequelae after treatment for childhood ALL. BHW will be administrated in a group-based format over 5 sessions (minimum three weeks between each session). Homework assignments between sessions are included. Homework assignments between sessions are included.
89558300|NCT04537208|Experimental|Cohort 1: Group 1: SARS-CoV-2 vaccine LD + AF03|Participants received a single intramuscular (IM) injection of SARS-CoV2 vaccine low-dose (LD) formulation along with adjuvant AF03 on Day 1.
88964692|NCT02044913|Experimental|Phone-based Aftercare-Coordination|After inpatient treatment patients receive six phone contacts of aftercare-coordination at intervals of two weeks carried out by therapists for 12 weeks. The intervention aims at supporting the patients in coordinating their aftercare treatment which can help to maintain or even improve longterm treatment outcome.
88964693|NCT02044913|No Intervention|Treatment as usual|After inpatient treatment patients receive treatment as usual within routine care.
88964694|NCT02044939|Experimental|Pulmonary rehabilitation|Sarcoidosis patients will realize a pulmonary rehabilitation program
88964695|NCT02044939|No Intervention|Controls|Sarcoidosis patients who do not achieve a respiratory rehabilitation program but will have physical activity counseling.
88964696|NCT02044952|Experimental|Mesalazine, Tripterygium glycosides|Mesalazine 4g/d and Tripterygium glycosides 2mg/kg/d for 12 weeks
88964697|NCT02044965|No Intervention|Antibiotic|This group will be prescribed a dose of antibiotics (Septra 2mg/kg)
88964698|NCT02044965|Placebo Comparator|Probiotic plus placebo|Receive probiotic plus an antibiotic placebo
88964699|NCT02044965|Active Comparator|probiotics plus antibiotic|This group will be on a dose of probiotics (2 capsules; 5 billion total organisms of L. rhamnosus GR-1 and L. reuteri RC-14 per capsule) plus a antibiotic (Septra)
88964700|NCT02044978|Active Comparator|Bisphosphonate implant|Dental implant coated with zoledronate Note: Both arms in each patient (2 implants)
88964701|NCT02044978|Placebo Comparator|control|Dental implant without coating Note: Both arms in each patient (2 implants)
88964702|NCT02045004||Surgery Group Sevoflurane|Patients aged ≥ 65 years undergoing major surgical procedures.
88964703|NCT02045004||Control Group|Healthy study participants aged ≥ 65 years (no surgical intervention).
88964704|NCT02045017|Experimental|Pomalidomide and low dose Dexamethasone|Pomalidomide 4mg, and low dose Dexamethasone, starting at 40mgs(≤ 75 years old) or 20 mg/day (> 75 years old)
88964705|NCT02045030|Experimental|aflibercept and FOLFIRI|aflibercept and FOLFIRI
88964706|NCT02045043||Cardiomyopathy patients with ICDs|
88964707|NCT02045056|Experimental|Gemfibrozil|Gemfibrozil 600 mg by mouth twice daily for 48 weeks
88964708|NCT02045056|Placebo Comparator|Sugar pill|Matching placebo capsule by mouth twice daily for 48 weeks
88964709|NCT02045069|Experimental|2 days Ivermectin|Ivermectin 200 - 400 µg/kg once daily for 2 days
88964710|NCT02045069|Experimental|3 days Ivermectin|Ivermectin 200-400 µg/kg once daily for 3 days
88964711|NCT02045069|Placebo Comparator|Placebo|Placebo
88964712|NCT02045082|Experimental|Flocked swab (Copan 519CS01)|Sampling of the cornea by the flocked swab
88964713|NCT02045082|Experimental|Traditionnal fiber swab (Copan 164KS01)|Sampling of the cornea by the traditional finer swab
88964714|NCT02045121|Experimental|Indwelling Pleural Catheter|Day-case IPC insertion. Attendance d10 for drainage, stitch removal and education in catheter care.
88964715|NCT02045121|Active Comparator|Talc Pleurodesis|Hospital admission for chest drain insertion and suction if needed, plus talc pleurodesis by slurry or poudrage if >75% of visceral and parietal pleura in direct contact on chest x-ray.
88964716|NCT02045134|Placebo Comparator|Placebo|Soluble corn flour not rich in anthocyanins
88964717|NCT02045134|Active Comparator|High-anthocyanin rich corn flour|Soluble corn flour at high content in anthocyanins
88964718|NCT02045147|Experimental|Grp 1 Low Cognition, Low Activation|Group 1: Subjects will receive an 8 week care transition intervention with an Advanced Practice Registered Nurse-Nurse Practitioner (APRN-NP) and Certified Nursing Assistant (CNA). The APRN-NP will guide the care transition intervention. This group will receive the most intense intervention.
88964719|NCT02045147|Experimental|Grp 2 Low Cognition, High Activation|Group 2: Subjects will receive an 8 week care transition intervention with an APRN-NP and CNA. The APRN-NP will guide the care transition intervention. This group will receive an intense intervention.
88964720|NCT02045147|Experimental|Grp 3 Normal Cognition, Low Activation|Group 3: Subjects will receive an 4 week care transition intervention with a Registered Nurse (RN) Coach. This group will be evaluated at four weeks, if the patient activation levels are still low, they will be referred to the 4 week APRN-NP and CNA.
88964721|NCT02045147|Experimental|Grp 4 Normal Cognition, High Activation|Group 4: Subjects will receive the least intensive intervention delivered by a RN coach.
89558301|NCT04537208|Experimental|Cohort 1: Group 2: SARS-CoV-2 vaccine LD + AS03|Participants received a single IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AS03 on Day 1.
89558302|NCT04537208|Experimental|Cohort 1: Group 3: SARS-CoV-2 vaccine HD + AF03|Participants received a single IM injection of SARS-CoV2 vaccine high-dose (HD) formulation along with adjuvant AF03 on Day 1.
89558303|NCT04537208|Experimental|Cohort 1: Group 4: SARS-CoV-2 vaccine HD + AS03|Participants received a single IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AS03 on Day 1.
89558304|NCT04537208|Placebo Comparator|Cohort 1: Group 5: Placebo|Participants received an IM injection of placebo matching to SARS-CoV2 vaccine on Day 1.
89558305|NCT04537208|Experimental|Cohort 2: Group 6: SARS-CoV-2 vaccine LD + AF03|Participants received IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AF03 on Day 1 and Day 22, respectively.
89558306|NCT04537208|Experimental|Cohort 2: Group 7: SARS-CoV-2 vaccine LD + AS03|Participants received IM injection of SARS-CoV2 vaccine LD formulation along with adjuvant AS03 on Day 1 and Day 22, respectively.
89558307|NCT04537208|Experimental|Cohort 2: Group 8: SARS-CoV-2 vaccine HD + AF03|Participants received IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AF03 on Day 1 and Day 22, respectively.
89558308|NCT04537208|Experimental|Cohort 2: Group 9: SARS-CoV-2 vaccine HD + AS03|Participants received IM injection of SARS-CoV2 vaccine HD formulation along with adjuvant AS03 on Day 1 and Day 22, respectively.
89558309|NCT04537208|Experimental|Cohort 2: Group 10: SARS-CoV-2 vaccine HD|Participants received a single IM injection of SARS-CoV2 vaccine HD formulation without adjuvant on Day 1 and Day 22, respectively.
89558310|NCT04537208|Placebo Comparator|Cohort 2: Group 11: Placebo|Participants received an IM injection of placebo matching to SARS-CoV2 on Day 1 and Day 22, respectively.
89558311|NCT04527549|Experimental|Arm A (dabrafenib, trametinib, hydroxychloroquine)|Patients receive dabrafenib mesylate PO BID, trametinib dimethyl sulfoxide PO QD, and hydroxychloroquine sulfate PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89558312|NCT04527549|Active Comparator|Arm B (dabrafenib, trametinib, placebo)|Patients receive dabrafenib mesylate PO BID, trametinib dimethyl sulfoxide PO QD, and placebo PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89558313|NCT04522414||Preterm infant|
89558314|NCT04514783|Other|Group 2|Use of scalpel and a spoon-shaped metal instrument (curette).
89558315|NCT04514783|Experimental|Group 1|Use of Debritom+ micro water jet technology
89558316|NCT04512950|Active Comparator|Ringer's lactate|administered as infusions or boluses as per the treating physician
89558317|NCT04512950|Active Comparator|0.9% Saline|administered as infusions or boluses as per the treating physician
89558318|NCT04512430|Experimental|Experimental: Neo-Adjuvant Immunotherapy|"Neoadjuvant treatment: (Atezolizumab: 1200 mg, IV infusion+Bevacizumab: 15mg/Kg mg, IV infusion+Carboplatin: AUC6, IV infusion+Pemetrexed: 500 mg/m2, IV infusion) will start within 1-3 days from enrollment. 3 cycles will be administered at 21-day (+/- 3 days) intervals (QW3) prior to surgery.Before surgery a tumor assessment will be done. Patients must leave the study if there is evidence of progression. Patients with stable disease or partial response may be considered for surgery.~Surgery: Surgery must be done within the 4th week (+7 days) from day 21 cycle 3 of neoadjuvant treatment (day 42-49 after day 1 of cycle 3).~Adjuvant treatment: Atezolizumab: 1200 mg, IV infusion Q4W (+/- 3 days) for 6 months (6 cycles) Patients that are R0 confirmed by surgical pathology evaluation will receive the first adjuvant administration within the 3rd to 8th week (+7 days) from surgery and for 6 months (6 cycles)."
88964722|NCT02045160||Sulfamethoxazole-trimethoprim treatment|
88964723|NCT02045173|Other|Apneascan TM|autoscoring algorithms of the Apneascan TM compared to the polysomnography or polygraphy
89558319|NCT04605458|Experimental|Contingency Management|
88964724|NCT02045186|Other|Assessment of Oral HPV Infection|Oral HPV infection will be assessed 14 times, once prior to starting CRT, weekly during CRT, and then serially post-treatment: 4-8 weeks, 3 months, 6 months, 12 months, 18 months, 24 months. Patients will provide samples of their saliva and exfoliated epithelial cells at these timepoints. Samples will be collected with supplies provided by and analyzed by OralDNA Labs.
89558320|NCT04605458|Active Comparator|Standard Care|
89558321|NCT04509128||A|Subjects hospitalized for a COPD acute exacerbation, undergoing arterial blood gas analysis, evaluation of presence and grade of dyspnea, handgrip strength test, and diaphragmatic and vastus lateralis muscle ultrasound assessment, at admission and discharge.
89558322|NCT04509128||B|Subjects referred for pulmonary rehabilitation (PR) after a hospitalized COPD exacerbation, undergoing pulmonary function test, arterial blood gas analysis, evaluation of presence and grade of dyspnea, handgrip strength test, and diaphragmatic and vastus lateralis muscle ultrasound assessment, before and after PR.
89558323|NCT04502433|No Intervention|Control|Patients treated with standard-of-care (SoC), as control cohort
89558324|NCT04502433|Experimental|Poractant alfa|Patients treated with CUROSURF® (poractant alfa), as an add-on to standard-of-care (SoC)
88964725|NCT02045199|Experimental|V0111|
89558325|NCT04499339|Experimental|All eligible patients|
89558326|NCT04495348||Open-label arm|Participants are switched to doravirine and then switched back to INSTI-based therapy.
89558327|NCT04485468||Parkinson's disease patients|Parkinson's disease patients and over 18 years old
89558328|NCT04484818|Active Comparator|Arm A (ADT, placebo)|Patients receive goserelin acetate, leuprolide acetate, or triptorelin via injection every 3 months for 12 months (4 injections), every 4 months for 12 months (3 injections), or every month for 12 months (12 injections) in the absence of disease progression or unacceptable toxicity. Patients also receive a placebo four times daily (QID) for 52 weeks in the absence of disease progression or unacceptable toxicity.
89558329|NCT04484818|Experimental|Arm B (ADT, darolutamide)|Patients receive goserelin acetate, leuprolide acetate, or triptorelin via injection every 3 months for 12 months (4 injections), every 4 months for 12 months (3 injections), or every month for 12 months (12 injections) in the absence of disease progression or unacceptable toxicity. Patients also receive darolutamide QID for 52 weeks in the absence of disease progression or unacceptable toxicity.
89558330|NCT04484012|Experimental|Treatment (CD19 CAR T cells, acalabrutinib)|Patients receive acalabrutinib PO BID on days -5 to 28 of cycle 1 and on days 1-28 of subsequent cycles. Patients also receive CD19 CAR T cells IV on day 0. Treatment with acalabrutinib repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients who have not attained CR after the first disease assessment and tolerated the initial CAR T cell infusion may receive a second CAR T cell infusion in cycle 2.
88964726|NCT02045199|Placebo Comparator|Placebo|
88964727|NCT02045225|Experimental|Cognitive behavioural therapy|Reduction of social anxiety & substance use in gay/bi men
88964728|NCT02045251|Experimental|Interventional Arm|This arm will have 100 patients receiving the proposed Pylera based regimen for 10 days.
88964729|NCT02045290|Placebo Comparator|Oral Placebo|"A central pharmacy will compound a placebo to match the metformin tablets.~The placebo product will contain the following components:~Micosolle™, silica based excipient~Silicified Micro Crystalline Cellulose, National Formulary~Safflower Oil, United States Pharmacopeia~K-30 Povidone Powder~Magnesium Stearate, National Formulary (Vegetable source)~Fumed Silica, National Formulary"
88964730|NCT02045290|Experimental|Metformin|Metformin 2000 mg per day
88964731|NCT02045316||Preeclamptic pregnants|pregnants with preeclampsia
88964732|NCT02045316||Normal pregnants|pregnants without obstetric complications
88964733|NCT02045329||Staphylococcus aureus nasal carriers|Patients who are treated with mupirocin to clear nasal colonization with Staphylococcus aureus
88964734|NCT02045342|Experimental|Carbohydrate drink|Ingest 500ml (1g/kg) prior to metabolic measures.
88964735|NCT02045342|Placebo Comparator|Placebo|Ingest 500ml of placebo prior to metabolic measures.
88964736|NCT02045355|Experimental|Fish intervention|The patients will receive one portion of salmon (150 g), one portion of cod (150 g), and two portions of sild (50g each) per week.
88964737|NCT02045355|No Intervention|Meat control group|The control food will be pork and chicken (150 g each) and two portions of cooked ham / liver pate for use in cold meals (50 g each).
88964738|NCT02045368|Experimental|Subject Treatment with IGF-Methotrexate conjugate|IV infusion at the assigned dose administered on days 1, 8, and 15 of a 28 day (4 week) cycle.
88964739|NCT02045394||Patients presenting with haemoptysis|
88964740|NCT02045420||Normal Participants|"The investigators will use normal age-matched volunteers to compare against the Idiopathic Parkinson's Disease Patients"
88964741|NCT02045420||Idiopathic Parkinson's Disease Patients|The investigators will observe the MR scans to determine the vascular flow, brain lesions and brain iron levels in this group.
88964742|NCT02045459|Experimental|Exercise Program and Medical Therapy|All subjects randomized to this arm will be given intensive medical therapy including - Isosorbide mononitrate, Lisinopril, Carvedilol, and Simvastatin. After 8 weeks of ONLY medication therapy, the subjects will begin a intensive exercise program. This will be supervised on site at UVA. Also, on days that the subject is not being supervised, they will be required to keep a journal of their exercise at home.
88964743|NCT02045472|Experimental|VIS410|VIS410 administered as a single infusion with ascending dose-escalation ranging from 2 to 50 mg/kg
88964744|NCT02045472|Placebo Comparator|Placebo|Placebo administered as a single infusion
88964745|NCT02045498|Experimental|capnography, feedback, quality of cpr|capnography feedback was used for management of the resuscitation and quality of cpr performance in rescuers and outcomes of the patients was measured.
88964746|NCT02045498|No Intervention|conventional cpr|conventional cpr
88964747|NCT02045537||Fractures|Patients in follow up from 1st Jan 1997 to 1st Jan 2012 with any fracture (pathologic)
88964748|NCT02045550|Placebo Comparator|Placebo Syrup|Placebo Syrup 2.5 ml twice daily for 4 weeks
88964749|NCT02045550|Active Comparator|Prospan Syrup|Prospan Syrup 2.5 ml twice daily for 4 weeks
89208385|NCT00246805|No Intervention|2. VRS OFF|"Patients with permanent atrial fibrillation implanted with VVI(R) pacemaker Vitatron model C20 SSIR or T20 SSIR were randomized to Function Ventricular Rate Stabilization (VRS)ON or OFF.~This arm (2) is randomized to Function Ventricular Rate Stabilization OFF."
89208386|NCT00801866|Experimental|Group 1|Panretinal Photocoagulation + Bevacizumab
89208387|NCT00801866|Experimental|Group 2|Panretinal Photocoagulation
89208388|NCT04088747||Fibromyalgia|Patients who display symptoms and have a history of Fibromyalgia, between 20-65 years of age.
88964750|NCT02045576|Experimental|Sleep position trainer|Nightbalance
88964751|NCT02045576|Active Comparator|Oral Appliance Therapy|Somnodent
88964752|NCT02045589|Experimental|Dose Escalation, Combination|Three intratumoral administrations of VCN-01 oncolytic adenovirus every 28 days in combination with Abraxane® and Gemcitabine.
88964753|NCT02045602|Experimental|Part I: Dose Escalation, Single Agent|Single intravenous injection of VCN-01 oncolytic adenovirus
88964754|NCT02045602|Experimental|Part II: Dose Escalation, Combination|Single intravenous injection of VCN-01 oncolytic adenovirus in combination with Abraxane®/Gemcitabine
88964755|NCT02045602|Experimental|"Part III: Dose Escalation, Combination, delayed schedule"|Single intravenous injection of VCN-01 oncolytic adenovirus in combination with Abraxane®/Gemcitabine
88812446|NCT04736745|Experimental|Total dose for Upper Facial Lines|"One single injection of study medication will be injected locally into Upper Facial Lines.~In total for this stage approximately 48 subjects."
88964756|NCT02045615||Conventional|Conventional technique for Wichita nail extraction
89558331|NCT04478227|Experimental|Arm A|"Arm A will include acquired bone marrow failure (BMF) disorders including aplastic anemia, refractory cytopenia of childhood/Myelodysplastic Syndrome(MDS) without monosomy 7 and 5q deletion abnormalities, toxin induced myelosuppression due to infection and inherited cytopenia with or without involvement of other cell lines who are transfusion dependent and or showing progression to bone marrow failure.~Arm A: Start at 5 microgram/kg/dose per week along with standard of care and escalate with 2.5 microgram/kg/dose increments (per week at physician's discretion depending on the clinical and laboratory response) (Maximum: 20 microgram/kg/dose) based on response for at least 24 weeks or until hematopoietic response is seen, whichever comes first. If patient shows response, therapy will be continued for a total of 52 weeks."
89558332|NCT04478227|Experimental|Arm B|"Arm B will include children with chemo and or radiotherapy induced thrombocytopenia/cytopenia and children undergoing stem cell transplantation (SCT).~Arm B: Starting dose 2 microgram/kg/dose per week with increments at 1 microgram/kg/dose (Maximum: 10 micrograms/kg/dose) depending on the laboratory response."
89558333|NCT04477200|Experimental|Phase 0 - Recurrent glioblastoma (GBM) / gliosarcoma (GS)|Mycophenolate mofetil
89208389|NCT04088747||Healthy Controls|Age-matched, healthy controls, between 20-65 years of age who present no signs of chronic pain.
89558334|NCT04477200|Experimental|Phase 1 - Recurrent GBM / GS|Mycophenolate mofetil; radiation therapy
89558335|NCT04477200|Experimental|Phase 1 - Newly Diagnosed GBM / GS|Mycophenolate mofetil; radiation therapy; temozolomide
89558336|NCT04455802|Active Comparator|Morphine|Infants randomized to the morphine arm will start at a dose of 0.06 mg/kg/dose every 4 hours. A buprenorphine placebo will also be given at the same frequency as a faux drug.
89558337|NCT04455802|Experimental|Buprenorphine|"Infants randomized to the buprenorphine arm will be started on a dose of 10 mg/kg/dose every 8 hours. A morphine placebo will also be given at the same frequency as a faux drug.~Patients can only be randomized to only one arm."
89558338|NCT04446052|Placebo Comparator|Placebo|
89558339|NCT04446052|Active Comparator|GM-CSF priming|
89558340|NCT04443088|Other|Dose Escalation|"Phase 1a: Subjects will receive escalating doses of INV-1120 orally once a day until un-acceptable toxicity or disease progression. Three to six patients will be enrolled per cohort to evaluate the safety and pharmacokinetics for each dose level. After the last patient in each cohort completes Cycle 1 (DLT observation period of 28 days), the Safety Evaluation Team (SET) will evaluate the safety data and pharmacokinetic collected from Cycle 1, and make the decision whether to escalate the dose before opening the second cohort.~Phase 1b: Subjects will receive escalating and de-escalating doses of INV-1120 orally once a day in combination with pembrolizumab until un-acceptable toxicity or disease progression, and DLT observation period of 21 days."
89558341|NCT04428658|Experimental|Supplemental video visits|Participants in this intervention arm will receive home-based video visits with a pediatric endocrinologist every month for the duration of 6 months in addition to usual care.
89558342|NCT04428658|Active Comparator|Standard of Care|The control group will receive usual care, consisting of quarterly visits with the UCD Pediatric Diabetes Clinic.
89558343|NCT04428658|Experimental|Supplemental remote monitoring|Participants in this intervention arm will receive remote glucose monitoring with monthly asynchronous outreach from a pediatric endocrinologist for a duration of six months in addition to usual care.
89558344|NCT04426890|Experimental|Arm 1|300 mg of CT-P39 as SC injections via PFS
89558345|NCT04426890|Active Comparator|Arm 2|300 mg of EU-approved Xolair as SC injections via PFS
89558346|NCT04426890|Experimental|Arm 2-1|300 mg of CT-P39 as SC injections via PFS
89558347|NCT04426890|Active Comparator|Arm 2-2|300 mg of EU-approved Xolair as SC injections via PFS
89558348|NCT04426890|Experimental|Arm 3|"Treatment period 1: 150 mg of CT-P39~Treatment period 2: 300 mg of CT-P39"
89558349|NCT04426890|Active Comparator|Arm 4|"Treatment period 1: 150 mg of EU-approved Xolair~Treatment period 2: 300 mg of EU-approved Xolair"
89558350|NCT04422132|Active Comparator|ARM 1 - 2 weeks|Patients will receive treatment to the prostate fossa +/- nodes in 32.5 Gy in 5 fractions. Patients receiving 32.5 Gy in 5 fractions cannot be treated on consecutive days.
88812447|NCT04731844|Experimental|Prostate Cancer|Curcumin plus Piperine at a dose of 4 gram/5mg orally BID for 12 months
88812448|NCT04731844|Experimental|Smoldering Multiple Myeloma (SMM)|Curcumin plus Piperine at a dose of 4 gram/5mg orally BID for 12 months
88812449|NCT04731844|Experimental|Monoclonal Gammopathy of Unknown Significance (MGUS)|Curcumin plus Piperine at a dose of 4 gram/5mg orally BID for 12 months
88812450|NCT04685291|Active Comparator|Group 1: Control|Systemic conventional pain management. Adult patients with acute fractures of the clavicle, who are scheduled to have internal fixation of the fracture within the next 24 hours receive oral and intravenous pain management.
88812451|NCT04685291|Active Comparator|Group 2: Nerve Block|Adult patients with acute fractures of the clavicle, who are scheduled for an internal fixation of the fracture within the next 24 hours will receive an ultrasound-guided block of the supraclavicular nerves using a maximum of 3 ml of a long-acting local anesthetic. The injection is carried out directly in the emergency department following a sonographic or radiological diagnosis.
88812452|NCT04672070|Active Comparator|Selective Caries Removal|The patient will be treated with Selective Caries Removal (SCR)
88812453|NCT04672070|Active Comparator|Pulpotomy|The patient will be treated with full coronal Pulpotomy.
88812454|NCT04618705|No Intervention|control group|Participants who have not smoked for at least 10 years
88812455|NCT04618705|No Intervention|smoking group|Participants who have smoked cigarettes (at least 5 cigarettes per day) for at least 2 years.
88812456|NCT04618705|Experimental|smoking cessation group|Participants who have smoked cigarettes (at least 5 cigarettes per day) for at least 2 years and who are planning to quit smoking.
88964757|NCT02045615||New|Proposed technique for Wichita nail extraction
88964758|NCT02045628|Experimental|Investment intervention|Those in the investment group will complete carefully framed questions designed to raise the salience of the investment they have made in their procedure at baseline and 3 months follow up. The content of this intervention will be tailored to the recent experiences of the patient (ie pre or post surgery).
88964759|NCT02045628|No Intervention|Control|Those in the control group will receive usual care.
88964760|NCT02045641|No Intervention|current postoperative regimen|The group will follow the current postoperative regimen at the surgical ward; screening for pleural effusions with x-ray and further diagnostic procedures in case of symptoms. Treatment will be entirely in the hands of the clinical personnel.
88964761|NCT02045641|Experimental|pleuracentesis|The group will follow the current postoperative regimen. In addition they will be followed with ultrasound examination, clinical examination, spirometry examination and 6 minute walk test. In case of either a) pleural effusion > 400ml OR b) pleural effusion< 400ml with symptoms in rest or during the walk test, the effusion will be drained and examinations will be repeated. In case of pericardial effusion of predefined size and location, either the surgeon on call or a cardiologist will be consulted.
88964762|NCT02045654||MDS patients|MDS patients who were treated with decitabine
88964763|NCT02045667|Placebo Comparator|Placebo|Placebo tablets three times daily orally
88964764|NCT02045667|Active Comparator|Mexiletine|Mexiletine 200mg three times daily orally
88964765|NCT02045680||deep block|deep block
88964766|NCT02045680||non deep block (historical control)|non deep block (historical control)
88964767|NCT02045693|Experimental|Part 1: Methadone + DCV 3DAA FDC + BMS-791325|"Methadone 40-120 mg tablet or solution orally once on Day 1~Methadone 40-120 mg tablet or solution orally once daily + DCV 3DAA FDC (Daclatasvir 30 mg/Asunaprevir 200 mg/BMS-791325 75 mg 3 direct-acting antiviral (3DAA) fixed dose combination tablet) orally twice daily + BMS-791325 75 mg tablet orally twice daily on Days 2 through 12"
88964768|NCT02045693|Active Comparator|Part 2: Buprenorphine/Naloxone + DCV 3DAA FDC + BMS-791325|"Buprenorphine/Naloxone 8/2 - 24/6 mg tablet or sublingual film orally once on Day 1~Buprenorphine/Naloxone 8/2 - 24/6 mg tablet or sublingual film orally once + DCV 3DAA FDC (Daclatasvir 30 mg/Asunaprevir 200 mg/BMS-791325 75 mg 3DAA fixed dose combination tablet) orally twice daily + BMS-791325 75 mg tablet orally twice daily on Days 2 through 12"
88964769|NCT02045706|Experimental|Community Health Worker Trainings|Trained community health workers (CHW) (one per 25 households), conducted a focus group and four quarterly meetings. CHWs were then responsible for 25 households where they would teach preventive health, track health data for the Ministry, and refer sick cases (700 households total). Staff and volunteers also conducted home visits and handed out printed summaries. We also worked with the local villagers and community health workers to construct 3 protected water sources in the Intervention areas.
88964770|NCT02045706|No Intervention|Control Group|The Control Group was comprised of similar households to the Intervention Group (n = 700). In these villages, however, we did not instill the community health worker program until after the trial was completed.
88964771|NCT02045719|Experimental|cat's claw|100 mg dose of a dry extract of U. tomentosa three times per day
88964772|NCT02045745|Experimental|Prolonged postoperative air leaks in risk patients.|Patients with prolonged postoperative air leaks
88964773|NCT02045758|Experimental|TAP20-C|TAP20-C
88964774|NCT02045758|Active Comparator|Fingerstick|Fingerstick
88964775|NCT02045771|Other|Support Group (Control Group)|In addition to usual care, the control group will be offered a support group therapy format delivered at the same place, same visit frequency and duration of program as the intervention group. This support group is intended to simulate the intervention group format to minimize risk of biased estimate of BA effectiveness by reducing the potential placebo effect which can be seen due to frequent clinic visits and having additional attention beyond usual care.
89208390|NCT03973879|Experimental|PVSRIPO + Atezolizumab|Single PVSRIPO infusion at a dose of 5x10^7 tissue culture infected dose (TCID50). Atezolizumab infusions at a dose of 1200 mg every three weeks for up to two years.
89558351|NCT04422132|Active Comparator|ARM 2 - 4 weeks|Patients will receive treatment to the prostate fossa +/- nodes in 55 Gy in 20 fractions.
89558352|NCT04411914|Experimental|Clavulanic Acid|Participants will receive 10 days of CLAV-- Period 1: 500 mg/day for days 1-3; Period 2: 750 mg/day for days 4-6; Period 3: 1000 mg/day for days 7-10.
88964776|NCT02045771|Experimental|Behavioral Activation|Originally a component of cognitive therapy, behavioural activation is the use of strategies such as activity scheduling, master/pleasure ratings, and graded task assignments to change one's perception of specific situations. It involves the use of activities to improve life situations or depressed mood.
88964777|NCT02045784|Experimental|Infant formula milk 60 µg iodine/day|Infant formula containing 57 µg/100 g powder, providing approximately 60 µg iodine/day (i.e. 55% of the current AI). Unrestricted consumption during 11 days.
88964778|NCT02045784|Experimental|Infant formula milk 110 µg iodine/day|Infant formula containing 92 µg/100 g powder, providing approximately 110 µg iodine/day (i.e. 100% of the current AI). Unrestricted consumption during 11 days.
88964779|NCT02045784|Experimental|Infant formula 220 µg iodine/day|Infant formula containing 217 µg/100 g powder, providing approximately 220 µg iodine/day (i.e. 200% of the current AI). Unrestricted consumption during 11 days.
88964780|NCT02045784|Other|Breast milk|Unrestricted consumption during 4 days
88964781|NCT02045797|Experimental|Treatment Group A|Subject will receive GSK2140944 750mg IV every 12 hours (q12h; twice daily [BID]) on Day 1 and Day 2. Subject may switch to GSK2140944 1500mg orally (PO) q12h (BID) at investigator's decision or will continue to receive GSK2140944 750mg IV q12h (BID) from Day 3 to Day 10.
88964782|NCT02045797|Experimental|Treatment Group B|Subject will receive GSK2140944 1000mg IV q12h (BID) on Day 1 and Day 2 . Subject may switch to GSK2140944 2000mg PO q12h (BID) at investigator's decision or will continue to receive GSK2140944 1000mg IV q12h (BID) from Day 3 to Day 10.
88964783|NCT02045797|Experimental|Treatment Group C|Subject will receive GSK2140944 1000mg IV q8h (TID) on Day 1 and Day 2. Subject may switch to GSK2140944 2000mg PO q8h (TID) at investigator's decision or will continue to receive GSK2140944 1000mg IV q8h (TID) from Day 3 to Day 10.
88964784|NCT02045810|Active Comparator|Treatment|Patients in group receive Ileoinguinal block before the start of surgery, and an injection of plasebo saline after surgery. Injectate is blinded from caregiver.
88964785|NCT02045810|Placebo Comparator|Control group|Patients receive a plasebo saline injetion at the site of ileoinguinal block prior to surgery and an injectio with local anesthetics after surgery. The treatment group is blinded for caregiver.
88964786|NCT02045849|Experimental|Part 1|Subjects will receive either GSK2140944 1500 mg (500 mg x 3) capsules under fasted conditions or GSK2140944 1500 mg (750 mg x 2) tablets under fasted conditions or GSK2140944 1500 mg (750 mg x 2) tablets under fed conditions as per the randomization schedule in each of the three periods with a washout period of at least 3 days between the doses. There will also be a follow-up visit within 5-7 days after the last dose of study drug.
88964787|NCT02045849|Experimental|Part 2|Subjects will receive a single dose of GSK2140944 1500 mg (tablet or capsule) on Day 1 followed by a repeat dose of Itraconazole 200 mg once daily for 6 days from Day 4 to Day 9. On Day 7, subjects will receive a single dose of GSK2140944 1500 mg (tablet or capsule) one hour after the dose of Itraconazole. There will also be a follow-up visit within 5-7 days after the last dose of study drug.
88964788|NCT02045849|Experimental|Part 3|Subjects in Group 1 will receive GSK2140944 1500 mg (750 mg x 2) tablets twice daily from Day 1 to Day 5 under fasting and fed conditions in Period I and Period II, respectively. Subjects in Group 2 will receive GSK2140944 1500 mg (750 mg x 2) tablets twice daily from Day 1 to Day 5 under fed and fasting conditions in Period I and Period II, respectively. There will be a washout of at least 7 days between the periods. Subjects will have a follow up visit 5-7 days after the last dose of study drug in both the groups.
88964789|NCT02045888|Experimental|Low Dose ADRC|ADRCs prepared by investigational Celution Device
88964790|NCT02045888|Experimental|High Dose ADRC|ADRCs prepared by investigational Celution Device
88964791|NCT02045888|Placebo Comparator|Placebo|Placebo
88964792|NCT02045914|No Intervention|control group|the patients who have no intervention with calcium ionophore during ICSI cycle
88964793|NCT02045914|Experimental|calcium ionophore|the patients whose oocytes are incubated with calcium ionophore solution during ICSI cycle
88964794|NCT02045927|Active Comparator|Intevention Group|sedation monitoring with RASS score plus sedation monitoring with BIS-Guided monitoring
89558353|NCT04411914|Placebo Comparator|Placebo|"Participants will receive 10 days of placebo and will have a dose escalation at the same time as the experimental group. They will be given additional placebo pills to match the number given to the experimental group (i.e. 2 PBO capsules/day for days 1-3, 3 PBO capsules/day days 4-6 and 4 PBO capsules/day for days 7-10)."
89558354|NCT04392635|Experimental|Trocar Placement Assist Device (TPAD)|Participants will receive investigational TPAD device during laparoscopic surgery
88964795|NCT02045927|Other|Control Group|sedation monitoring with RASS score
88964796|NCT02045940|Experimental|Cohort 1|Participants will receive one of the following four treatment sequences in four study period (one treatment per period). Sequence 1=Placebo, dose level (DL) 2, DL3, and DL4. Sequence 2=DL1, placebo, DL2, and DL4. Sequence 3=DL1, DL2, placebo, and DL4. Sequence 4=DL1, DL2, DL3, and placebo
89558355|NCT04389671|Experimental|Lyophilized Lucinactant|Lyophilized Lucinactant reconstituted with sterile water for injection
88964797|NCT02045940|Experimental|Cohort 2|Participants will receive one of the following four treatment sequences in four study period (one treatment per period). Sequence 5=Placebo, DL5, DL6, and DL7. Sequence 6=DL4, placebo, DL6, and DL7. Sequence 7=DL4, DL5, placebo, and DL7. Sequence 8=DL4, DL5, DL6, and placebo
88964798|NCT02045940|Experimental|Cohort 3|Participants will receive repeat doses of GSK2881078 or placebo in a 3:1 randomization ratio for 14 days. The dose level will depend upon results from Part A
89558356|NCT04388748|Experimental|SMART-D Intervention Group|Subjects will participate in Stress Management and Resiliency Training for Depression (SMART-D) therapy as well as treatment as usual which consists of any ongoing medication or psychotherapy based treatments that are currently in place.
89558357|NCT04388748|No Intervention|Standard of Care Group|Treatment as usual will consist of any ongoing medication or psychotherapy based treatments that are currently in place.
89558358|NCT04381494|Other|Observational/Other|Patients will be enrolled after their treating physician has prescribed durvalumab and before they start durvalumab treatment. Patients will receive mobile and wearable devices alongside their durvalumab treatment without any additional interventions.
89558359|NCT04364048|Experimental|Induction durvalumab, chemoradiation, consolidation durvalumab|Induction durvalumab at 1500 mg intravenously (IV) on Day 1 of a four week cycle for 1 cycle, followed by concurrent definitive chemoradiation, followed by consolidation durvalumab at 1500 mg IV Day 1 of every 4 week cycle for up to 12 cycles.
89558360|NCT04355819|Experimental|Disclosure before|Patients will be told that a hernia was found on CT before the follow-up survey is administered.
89558361|NCT04355819|Experimental|Disclosure after|Patients will be told that a hernia was found on CT after the follow-up survey was administered.
89558362|NCT04350359|Active Comparator|Variable-dose TTNS Protocol 5 x week|"TTNS protocol: Electrodes 2 inch by 2 inch will be placed according to anatomic landmarks, with the negative electrode behind the internal malleolus and the positive electrode 10cm superior to the negative electrode, verified with rhythmic flexion of the toes secondary to stimulation of the flexor digitorum and hallicus brevis. The intensity level will be set to the amperage immediately under the threshold for motor contraction. If there is no contraction seen, patients will be excluded. In addition, if the patient perceives pain, the intensity will be lowered until comfortable. Stimulation frequency of 20 Hz and pulse width of 200ms in continuous mode will be used.~All participants will be instructed to use the device for 30 minutes, 5 days per week for the first 4 months post-sci."
89558363|NCT04350359|Active Comparator|Fixed-dose TTNS protocol|"Fixed-dose protocol: Toe flexion will be attempted, as in the TTNS protocol. Then the stimulation will be reduced to 1 mA for 30 minutes.~Both variable-dose TTNS and fixed-dose TTNS protocol participants will be instructed to use the device for 30 minutes, 5 days per week."
89208391|NCT00519376|Experimental|GW642444M 25mcg|
89558364|NCT04350359|Active Comparator|Variable-dose TTNS Protocol 2 x week|At the 4 month CMG, subjects initially randomized into the variable dose protocol of 2 x weekly will start doing so for the remainder of the study.
89558365|NCT04315064|Experimental|Treatment with MTX110|
89558366|NCT04311580|Experimental|urothelial high risk non-muscle invasive bladder cancer|patients with urothelial high risk non-muscle invasive bladder cancer after failed intravesical bacillus Calmette-Guérin treatment.
89558367|NCT04303182|Active Comparator|Standard 3 port TEP|Group A will undergo laparoscopic TEP inguinal hernia repair with 3 ports (10 mm , and 2 ports of 5 mm ).
89558368|NCT04303182|Active Comparator|LESS TEP|Group B will undergo laparoscopic TEP inguinal hernia repair with a single skin incision 2-3cm.
89558369|NCT04301492|Experimental|Vortioxetine|first visit medical and pharmacological history will be collected and ECG, laboratory tests and clinical assessment will be performed. After verifying the absence of significant abnormalities at the ECG and laboratory tests and after confirming all inclusion and exclusion criteria, subjects will perform the second visit (Week 1 - Visit 2) to receive study drug (Brintellix drops 20 mg/ml). All subjects will be instructed to take Vortioxetine 1 drop every day after lunch, increasing of 1 drop per day arriving to 10 drops per day. After 5 days from the beginning of treatment, subject will be contacted by phone to check on tolerability and in absence of side effects, the dosage will be increased to 10 drops per day (Visit 3- Phone contact). At Week 4-8-12 (Visits 4-5-6) patients will return to the site to perform all clinical evaluations required and to receive study drug. Visit 7 subjects will return to the site to perform all the assessment required by protocol.
89558370|NCT04300816|Experimental|CBT-UT|Seven telephone-based sessions of cognitive behavioral therapy for uncertainty tolerance (CBT-UT) delivered over seven weeks.
89558371|NCT04300816|Active Comparator|tCBT|Seven telephone-based sessions of traditional cognitive behavioral therapy (tCBT) delivered over seven weeks.
89558372|NCT04300816|No Intervention|TAU|Participant continues with their lives as they normally would.
89208392|NCT00519376|Experimental|GW642444M 50mcg|
89208393|NCT00519376|Experimental|GW642444M 100mcg|
89208394|NCT00519376|Experimental|GW642444H 100mcg|
89208395|NCT00519376|Experimental|placebo|
89208396|NCT00860964|Placebo Comparator|Placebo|
89208397|NCT00860964|Experimental|estradiol valerate|
89208398|NCT00745121|Experimental|Group-A, Osteoporosis/osteopenia|Patients with osteoporosis/osteopenia.
88964799|NCT02045940|Experimental|Cohort 4|Participants will receive repeat doses of GSK2881078 or placebo in a 3:1 randomization ratio for 14 days. The dose level will depend upon results from Part A and preceding repeat dose Cohort
88964800|NCT02045940|Experimental|Cohort 5|Participants will receive repeat doses of GSK2881078 or placebo in a 3:1 randomization ratio for 14 days. The dose level will depend upon results from Part A and preceding repeat dose Cohorts
88964801|NCT02045953|Experimental|Sequence 1|Participant will receive study treatments in following sequence in four treatment periods (one treatment per period): ABCD, where A= FLIXOTIDE 250 Hydrofluoroalkane (HFA) with Aerochamber Plus spacer, B= FLIXOTIDE 250 HFA with VENTOLIN Mini-Spacer, C= SERETIDE 250/25 HFA with Aerochamber Plus spacer, D= SERETIDE 250/25 HFA with VENTOLIN Mini-Spacer
88964802|NCT02045953|Experimental|Sequence 2|Participant will receive study treatments in following sequence in four treatment periods (one treatment per period): BDAC, where A= FLIXOTIDE 250 HFA with Aerochamber Plus spacer, B= FLIXOTIDE 250 HFA with VENTOLIN Mini-Spacer, C= SERETIDE 250/25 HFA with Aerochamber Plus spacer, D= SERETIDE 250/25 HFA with VENTOLIN Mini-Spacer
88964803|NCT02045953|Experimental|Sequence 3|Participant will receive study treatments in following sequence in four treatment periods (one treatment per period): CADB, where A= FLIXOTIDE 250 HFA with Aerochamber Plus spacer, B= FLIXOTIDE 250 HFA with VENTOLIN Mini-Spacer, C= SERETIDE 250/25 HFA with Aerochamber Plus spacer, D= SERETIDE 250/25 HFA with VENTOLIN Mini-Spacer
88964804|NCT02045953|Experimental|Sequence 4|Participant will receive study treatments in following sequence in four treatment periods (one treatment per period): DCBA, where A= FLIXOTIDE 250 HFA with Aerochamber Plus spacer, B= FLIXOTIDE 250 HFA with VENTOLIN Mini-Spacer, C= SERETIDE 250/25 HFA with Aerochamber Plus spacer, D= SERETIDE 250/25 HFA with VENTOLIN Mini-Spacer
88964805|NCT02045966|Experimental|Arm 1: Cocktail + DCV 3DAA FDC + BMS-791325|"Treatment A: Cocktail of CYP and transporter probe substrates orally as a single dose on Day 1~Treatment B: DCV 3DAA FDC tablet administered orally BID on Days 6 to 15~Treatment C: DCV 3DAA FDC tablet administered orally BID on Days 16 to 20, plus the cocktail of CYP and transporter probe substrates administered orally as a single dose on Day 16 only~Treatment D: DCV 3DAA FDC tablet plus BMS-791325 75-mg single-agent tablet administered orally BID on Days 21 to 30~Treatment E: DCV 3DAA FDC tablet plus BMS-791325 75-mg single-agent tablet administered orally BID on Days 31 to 35, plus the cocktail of CYP and transporter probe substrates administered orally as a single dose on Day 31 only"
88964806|NCT02045992|Experimental|Caffeine|Caffeine 500mg
88964807|NCT02045992|Placebo Comparator|Placebo|Lactose 500mg
88964808|NCT02046018|Active Comparator|ICCM delivered by VHT|Health Outcomes in Communities where VHT's were trained in ICCM and given drugs.
88964809|NCT02046018|Active Comparator|ICCM delivered by VHT with cell phone|Health Outcomes in communities with VHT's who were trained in ICCM and given cell phones
88964810|NCT02046018|Active Comparator|Health outcomes in communities with no ICCM|Health outcomes in communities with VHT's who were not trained in ICCM
88964811|NCT02046031|Experimental|Ginkgolides Meglumine Injection|Intravenous drip slowly. A 1 (25 mg), will be taken slowly into the 0.9% sodium chloride injection diluted in 250 ml before use, then slow intravenous drip, once a day. The dripping speed must be strictly controlled. For the first time when using Ginkgolides Meglumine Injection, dripping speed should be controlled for 10 ~ 15 drops per minute. After 30 minutes treatment without discomfort, dripping speed can be appropriately increased, but no more than 30 drops per minute.
88964812|NCT02046044|Experimental|Ivabradine|Ivabradine: initial dose of 5 mg b.id. dose up-titration to 7,5 mg b.id. in 2 weeks due to the heart rate and maintaining the last dose during 6 months.
88964813|NCT02046044|Experimental|Digoxin|Digoxin: Digoxin 0,25 mg once a day 5 days per week during 6 months.
88964814|NCT02046083|Experimental|treatment|Prospective randomized double blind, placebo controlled, protocol in two phases: 1/ active treatment versus placebo for induction phase; 2/ long versus short maintenance
88964815|NCT02046083|Placebo Comparator|placebo|Prospective randomized double blind, placebo controlled, protocol in two phases: 1/ active treatment versus placebo for induction phase; 2/ long versus short maintenance
88964816|NCT02046109|Experimental|Repair|Subjects in the Repair group will be given a local anesthetic only if required (i.e. for restorations extending gingivally or on exposed dentin surface) as per usual clinical protocol. The existing restoration will not be removed. The surface of the existing restoration will be roughened with a Brasseler 8856 bur without extending to the surrounding enamel (except is the defect being repaired is adjacent to enamel). No accessory groves/pits for retention will be prepared. To repair the restoration, the surface will be etched using 35% phosphoric acid, and then 3M ESPE Scotchbond Universal Adhesive System followed by 3M ESPE Filtek Supreme Ultra Universal Restorative composite will be used as per the manufacturer's instructions.
88964817|NCT02046109|Active Comparator|Replace|Subjects in the Replace group will be given local anesthetic (an injection of 2% lidocaine with 1:100 000 epinephrine). The type of injection and dosage of anesthetics will be dependent on the tooth being treated, and will follow the usual protocol used in the Dalhousie Dentistry undergraduate clinics. The existing composite restoration will then be removed and the peripheral enamel beveled if not already beveled. To restore the tooth, the surface will be etched using 35% phosphoric acid, and then 3M ESPE Scotchbond Universal Adhesive System followed by 3M ESPE Filtek Supreme Ultra Universal Restorative composite will be used as per the manufacturer's instructions.
89208399|NCT00745121|Experimental|Group-B, Control|Control (non-osteoporotic/-osteopenic patients).
89558373|NCT04297787|Other|Treatment|The treatment protocol the study team will be following is as follows for all enrolled patients. First, a pulse spray tPA infusion with 20 cc of 8 mg tPA and saline will be administered to the thrombus with a 20-minute dwell time. Afterwards, an 8F curved sheath (Indigo 8 Torq Tip, ranges 85 to 115 cm) with CAT8 penumbra device will be used to aspirate the thrombus. If the operating physician deems necessary, they will have the option at that point to balloon plasty, stent, or use catheter-directed thrombolysis at this point. Clinical parameters such as areas of clinically-significant stenosis, extent of thrombus, (more parameters) will be tracked at the time of the procedure. The device is being used is FDA approved and being used according to FDA indications.
89558374|NCT04295473|Experimental|Reduced port laparoscopic gastrectomy|The definition of reduced port laparoscopic gastrectomy was 1-3 ports used in laparoscopic gastrectomy for gastric cancer.
89558375|NCT04295473|No Intervention|Standard laparoscopic gastrectomy|5 ports were used in standard laparoscopic gastrectomy
89558376|NCT04290039|Active Comparator|Low Dose Sublingual|"Atropine sulfate ophthalmic solution, USP 1% is a sterile topical anti-muscarinic indicated for cyclopegia, mydriasis, and penalization of the healthy eye in the treatment of amblyopia. Each mL of Atropine Sulfate Ophthalmic Solution USP, 1% contains active ingredient: atropine sulfate 10 mg equivalent to 8.3 mg of atropine. Inactive ingredients include benzalkonium chloride 0.1 mg (0.01%), dibasic sodium phosphate, edetate disodium, hypromellose (2910), monobasic sodium phosphate, hydrochloric acid and/or sodium hydroxide may be added to adjust pH (3.5 to 6.0), and water for injection, USP. Atropine Sulfate Ophthalmic Solution, USP 1% will be supplied in dropper bottles containing 2 mL.~Each bottle will only be used to administer a single dose, to a single subject."
88964818|NCT02046161|Experimental|colon cleansing room group|All patients in colon cleansing room group drink two liter PEG-ELS in the colon cleansing room which is a in-hospital setting for colon preparation at 8:00 AM on the day of colonoscopy.
88964819|NCT02046161|Placebo Comparator|standard colon preparation group|All patients in the standard colon preparation groupinitiate the standard colon preparation with PEG-ELS made from two sachets of PEG (Klean-PrepTM, Norgine Ltd. Harefield, Middlesex, United Kingdom) dissolved in 2 L of water at 8:00 AM on the day of colonoscopy.
88964820|NCT02046187|Experimental|Ketogenic Diet|Subjects will adhere to a ketogenic diet prior to the start of and through radiation therapy course until the time of first scan after radiation ends. During radiation course, patients also take temozolomide daily.
88964821|NCT02046213|Experimental|E2006|Single oral 10mg dose of 100 uCi [14C]E2006
88964822|NCT02046239|Other|Staple Group|Staple Group: At the end of the operation, the skin will be closed using stainless steel staples, which is standard clinical practice at St. James's University Hospital. Approximately ten days after the operation, the staples will be manually removed; this is normally performed by the patients GP.
88964823|NCT02046239|Experimental|Suture Group|Suture Group: At the end of the operation, the skin will be closed using absorbable surgical suture. Manual removal of this suture is not required because the thread is self-absorbable.
88964824|NCT02046278|No Intervention|Control arm - Standard of Care|The anastomosis will be created using Standard of Care only
88964825|NCT02046278|Experimental|Device arm - Standard of Care + LifeSeal™ Kit|The anastomosis will be created using SOC + LifeSeal™ Kit
88964826|NCT02046291|Experimental|Romiplostim treatment|Romiplostim at the assigned dose will be administered subcutaneously (SQ) once a week for 6 weeks (i.e. 6 doses) unless platelet count exceeds 100 x 10^9/L and at least 4 doses of therapy were given.After the initial dose, subsequent doses will be administered within a window of +/- 3 days.
88964827|NCT02046304|Experimental|Gemcitabine + Radiation Therapy|Patients receive concurrent chemoradiation (days 1 - 33) consisting of external beam radiotherapy (EBRT) plus gemcitabine, administered in a phase I dose escalation format until MTD is reached. EBRT delivered preoperatively (for patients with measurable disease) or postoperatively (for patients who have undergone pre-referral excisional biopsy) to a dose of 50 Gy in 25 fractions at 2.0 Gy per fraction. Radiotherapy given once daily (Monday through Friday) for 5 weeks. Surgical resection of the post-treatment tumor mass performed 4 to 8 weeks after the final dose of gemcitabine. Gemcitabine administered intravenously (IV) on days 1, 8, 22, 29, 43, and 50, concurrently with radiotherapy. Starting dose of gemcitabine 400 mg/m2 by vein once a week.
88964828|NCT02046343|Experimental|Physical Activity|Weekly promotora-led group sessions on physical activity (16 weeks) and followed by monthly telephone counseling and newsletters during the 24 week maintenance period. Promotoras will also implement environmental change strategies to increase the number of PA program offerings available to study participants.
88964829|NCT02046343|Placebo Comparator|Community Health and Safety|Weekly promotora-led group sessions on home safety/first aid (16 weeks) followed by and monthly generic health education materials and informational telephone calls during the 24 week maintenance period.
88964830|NCT02046356||Early-Stage HCC|Early-Stage hepatocellular carcinoma From January 2014 to January 2015, a total of 139 patients with early HCC from the First Affiliated Hospital, the Second Affiliated Hospital and the Third Affiliated Hospital of the Third Military Medical University were prospectively recruited according after MESS-RFA
88964831|NCT02046408|Experimental|Tablet Intervention|Primary care providers will be randomized into intervention or control conditions. The patients of intervention providers will be given a computer tablet that provides 5A's for smoking cessation counseling. Patients of control providers will not receive a tablet intervention.
88964832|NCT02046408|No Intervention|Control|Primary care providers will be randomized into intervention or control conditions. The patients of intervention providers will be given a computer tablet that provides 5A's for smoking cessation counseling. Patients of control providers will not receive a tablet intervention.
88964833|NCT02046421|Experimental|Treatment (mifepristone, carboplatin, gemcitabine)|Patients receive mifepristone PO QD on days 0, 1, 7, and 8, and carboplatin IV over 30 minutes and gemcitabine hydrochloride IV over 30-60 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89208400|NCT00864630|No Intervention|Wait list|
89208401|NCT00864630|Experimental|Computer-based problem solving therapy|
89026213|NCT03271892||Active surveillance|Patients under active surveillance choose to not have immediate thyroidectomy. Patients are closely monitored with respect to clinical status, ultrasound imaging, biochemical indices (thyroid function, thyroglobulin, and thyroglobulin antibodies) and any thyroid cancer-related treatments (if needed). Active surveillance is conducted at a participating study site. Criteria defining disease progression are established, and if such criteria are met, thyroid surgery is recommended to the patient. However, patients are free to choose to have thyroid surgery at any time, in the absence of disease progression. Thyroid cancer clinical and treatment outcomes are tracked by the study team.
89026214|NCT03271892||Immediate Surgery|Patients who choose surgery, undergo thyroidectomy, as per current standards of care, by a surgeon of their choice in an institution of their choice. The treating surgeon, in discussion with the patient, will choose the extent of thyroid surgery that may be appropriate for the individual case. Post-surgical follow-up is per the discretion of the treating surgeon, endocrinologist, or other healthcare providers involved in the patient's thyroid cancer care. Thyroid cancer clinical and treatment outcomes are tracked by the study team.
89026215|NCT04327648|Active Comparator|Social interaction treatment|During the treatment days, children in social interaction treatment group will have 30min social interaction each day for 3 months. ASD children are followed up closely.
89558377|NCT04290039|Active Comparator|High Dose Sublingual|"Atropine sulfate ophthalmic solution, USP 1% is a sterile topical anti-muscarinic indicated for cyclopegia, mydriasis, and penalization of the healthy eye in the treatment of amblyopia. Each mL of Atropine Sulfate Ophthalmic Solution USP, 1% contains active ingredient: atropine sulfate 10 mg equivalent to 8.3 mg of atropine. Inactive ingredients include benzalkonium chloride 0.1 mg (0.01%), dibasic sodium phosphate, edetate disodium, hypromellose (2910), monobasic sodium phosphate, hydrochloric acid and/or sodium hydroxide may be added to adjust pH (3.5 to 6.0), and water for injection, USP. Atropine Sulfate Ophthalmic Solution, USP 1% will be supplied in dropper bottles containing 2 mL.~Each bottle will only be used to administer a single dose, to a single subject."
89558378|NCT04290039|Active Comparator|Intravenous (IV)|"Atropine sulfate injection is indicated for temporary blockade of severe or life-threatening muscarinic effects, e.g., as an antisialagogue, an antivagal agent, an antidote for organophosphorus, carbamate, or muscarinic mushroom poisoning, and to treat symptomatic bradycardia.~Atropine sulfate injection, USP,8mg/20mL (0.4 mg per mL) is a sterile, nonpyrogenic, isotonic, clear solution of atropine sulfate in water for injection with sodium chloride sufficient to render the solution isotonic. Each mL contains atropine sulfate, 0.4 mg; benzyl alcohol, 9 mg; sodium chloride 9 mg; and may contain sulfuric acid for pH adjustment, pH 3.5 (3.0 to 3.8).~Atropine sulfate injection will be supplied in multidose vials containing 20 mL.~Each vial will only be used to administer a single dose, to a single subject."
89558379|NCT04282850|Experimental|Pulmonary Vein Isolation (PVI) Group|Subjects randomized to this treatment arm will undergo atrial fibrillation ablation, and undergo routine post-procedural follow-up.
89558380|NCT04282850|No Intervention|Medical Management|Subjects randomized to this treatment arm will undergo medical management of the arrhythmia, but will not undergo invasive electrophysiologic procedures to address subject's AF.
89558381|NCT04278339|Experimental|CONTROLLED SUBJECTS|In this arm, only controlled subjects (pathological-free) will be investigated.
89558382|NCT04278339|Experimental|PATIENTS|In this arm, only patients with scyzophrenic syndrome will be investigated.
89558383|NCT04267211|Experimental|Illustrated Consult|
89558384|NCT04267211|Experimental|Standard Consult|
89558385|NCT04266249|Experimental|Arm A (pCR after surgery)|"PRE-OPERATIVE/NEOADJUVANT THERAPY: Patients receive either paclitaxel or nab-paclitaxel IV on days 1, 8 and 15, or docetaxel IV on day 1 at the discretion of the treating oncologist. Patients also receive trastuzumab IV on day 1 or days 1, 8, and 15, and pertuzumab IV on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.~SURGERY: Within 42 days after last dose of neoadjuvant therapy, patients undergo standard of care lumpectomy and/or mastectomy.~POST-OPERATIVE.ADJUVANT THERAPY: Patients with pCR after surgery receive trastuzumab and pertuzumab IV on day 1. Treatment repeats every 21 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity. Patients may also undergo standard of care radiation therapy and receive hormone therapy if appropriate."
89558386|NCT04266249|Experimental|Arm B (residual invasive disease after surgery)|"PRE-OPERATIVE/NEOADJUVANT THERAPY: Patients receive either paclitaxel or nab-paclitaxel IV on days 1, 8 and 15, or docetaxel IV on day 1 at the discretion of the treating oncologist. Patients also receive trastuzumab IV on day 1 or days 1, 8, and 15, and pertuzumab IV on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.~SURGERY: Within 42 days after last dose of neoadjuvant therapy, patients undergo standard of care lumpectomy and/or mastectomy.~POST-OPERATIVE/ADJUVANT THERAPY: Patients with remaining tumor after surgery receive standard of care trastuzumab emtansine for 14 doses in the absence of disease progression or unacceptable toxicity. Patients may also receive additional standard of care chemotherapy, as well as hormone therapy if appropriate."
89558387|NCT04247997|Experimental|Group D|disconnect pulmonary vague nerve branches
89558388|NCT04247997|No Intervention|Group P|preserve the pulmonary vague nerve branches
89558389|NCT04246463||Thoracic - TEVAR|
89558390|NCT04246463||Abdominal - EVAR|
89558391|NCT04246463||Custom Device|
89558392|NCT04246463||Other indications|Isolated Iliac Artery Aneurysm (IIAA)
89558393|NCT04246333|No Intervention|Gastric Feeds|Patients in this arm will receive feeds via the standard route which is gastric feeds.
89558394|NCT04246333|Experimental|Duodenal Feeds|Patients in this arm will receive feeds via the experimental route which is duodenal feeds.
89026216|NCT04327648|Sham Comparator|Neuronal cognition treatment|Children in neuronal cognition treatment group will experienced neural cognition training 30min each day for 3 months. ASD children are followed up closely.
89026217|NCT04327648|Other|Routine treatment|Children in routine treatment group will keep the same initial treatment. ASD children are followed up closely.
89026218|NCT00467714|No Intervention|1|2.5 cm Cartilage as columella strut
89026219|NCT02892877||Complete Hydatidiform mole and Partial Hydatidiform mole|
89026220|NCT02892877||Invasive mole|
89026221|NCT02892877||Choriocarcinoma|
89026222|NCT02892877||Post-molar neoplasia|
89026223|NCT02892877||Placental Site Trophoblastic and Epithelioid Tumor|
89026224|NCT04344145||Target Group|This group includes frontline healthcare workers who are actively involved in the management of the Covid-19 outbreak: from emergency units, non-intensive Covid-19 and intensive Covid-19 units. They will fill self-reported questionnaires and scales upon their inclusion.
89558395|NCT04241757||Patient with indication of ElectroCardioGram (ECG)|Patient with indication of ElectroCardioGram (ECG) will be included. They will have a collection of results ElectroCardioGram (ECG).
89558396|NCT04239573|Experimental|Arm I (low intensity surveillance)|Patients undergo MRI or CT at the beginning of the trial and again in 1 year. Following the first year, patients with no abnormalities repeat MRI or CT every 2 years. Patients with positive imaging features on MRI and CT at 1 or 2 years and with negative EUS, repeat MRI or CT in 1 year. Patients with negative imaging repeat MRI or CT in 2 years.
89558397|NCT04239573|Experimental|Arm II (high intensity surveillance)|Patients undergo MRI or CT. Patients with 1-2 cm cyst undergo MRI or CT every 6 months for 1 year, then every 12 months for 2 years, and then every 24 months thereafter. Patients with 2-3 cm cyst undergo EUS within 6 months, and if EUS is negative, patients repeat MRI or CT in 1 year. If second EUS is negative, patients undergo alternate MRI or CT and EUS every 12 months. Patients with cyst > 3 cm undergo EUS within 6 months, and if EUS is negative, patients undergo alternate MRI or CT with EUS every 3-6 months.
89558398|NCT04235491||Micra AV leadless pacemaker therapy|All Medicare patients implanted with a Micra AV leadless pacemaker system
89558399|NCT04235491||Dual Chamber Transvenous pacemaker|All Medicare patients implanted with full system (e.g. lead and generator) dual-chamber transvenous pacemakers
89558400|NCT04233112|Placebo Comparator|Placebo/Mock|Placebo capsules; mock osteogenic loading
89026225|NCT04344145||Control group|"This group includes healthcare workers who are actively involved in usual medical care units, referred in this study as non-Covid-19 units. They will fill same self-reported questionnaires and scales than those filled in the Target group, also upon their inclusion.This group will be the comparator of the Target Group to assess the frontline Covid-19 condition."
89026226|NCT03272438|Active Comparator|No schedule control|This group will receive an accelerometer and daily step goal. They will monitor their steps over the 9 week duration of the study. They will also monitor their steps over the 9 week duration of the study. They will have the same level of contact as the other two conditions.
89026227|NCT03272438|Experimental|Consistent schedule condition|This group will receive an accelerometer and daily step goal. They will monitor their steps over the 9 week duration of the study. They will have the same level of contact as the other two conditions. In addition they will plan when, where, and how they will take steps in consistent contexts, i.e., that are very similar from day to day.
89558401|NCT04233112|Experimental|Melatonin/Mock|Melatonin capsules; mock osteogenic loading
89558402|NCT04233112|Experimental|Placebo/Osteogenic loading|Placebo capsules/osteogenic loading
89558403|NCT04233112|Experimental|Melatonin/Osteogenic loading|Melatonin capsules/osteogenic loading
89558404|NCT04226755|Experimental|Heart failure|After a run-in phase of 2 weeks, patients will add 3 g of sodium chloride to every meal, using a NaCl tablet of 1 g. They will continue the sodium tablet for 4 weeks with a study visit every 2 weeks. A skin biopsy will be performed before the start of the augmented salt intake and after 4 weeks.
89558405|NCT04226755|Active Comparator|Healthy volunteer|After a run-in phase of 2 weeks, volunteers will add 3 g of sodium chloride to every meal, using a NaCl tablet of 1 g. They will continue the sodium tablet for 4 weeks with a study visit every 2 weeks.A skin biopsy will be performed before the start of the augmented salt intake and after 4 weeks.
89558406|NCT04223596|Experimental|Experimental: Brigatinib Arm|Brigatinib 90 mg for the first 7 days and then 180 mg daily thereafter for QW4 cycles of duration (28 days +- 3 days)
89558407|NCT04222387|Experimental|Participants with hair dye|Hair dye product with pPD Type Aromatic Amines used up to 1 month before
89558408|NCT04217954|Experimental|OXA, 5-FU and Bev plus Toripalimab|the patients enrolled in this arm would receive hepatic arterial infusion chemotherapy with oxaliplatin, 5-fluorouracil and bevacizumab plus intravenous Toripalimab
89558409|NCT04210427|Experimental|Intervention with polyethylene glycol & SmartPill|Patients will ingest a Smart pill to obtain baseline motility within the GI lumen. All patients will undergo intervention with taking polyethylene glycol (PEG) or Miralax (brand name) 17 grams once daily. After two weeks of therapy, the patient will repeat the motility survey and again ingest a smart pill to assess the change in motility symptoms while on therapy.
89558410|NCT04201574|Placebo Comparator|Vehicle|Vehicle Ophthalmic Solution
89558411|NCT04201574|Experimental|ALY688 0.1%|ALY688 0.1% Ophthalmic Solution
89558412|NCT04201574|Experimental|ALY688 0.4%|ALY688 0.4%Ophthalmic Solution
89558413|NCT04194034|Experimental|TG6002 and flucytosine (5-FC) combination|
89558414|NCT04176133|Experimental|Entolimod 1 mcg|Subjects will receive entolimod as a single dose administered intramuscularly (1mcg)
89558415|NCT04176133|Experimental|Entolimod 3 mcg|Subjects will receive entolimod as a single dose administered intramuscularly (3mcg)
89558416|NCT04176133|Experimental|Entolimod 10 mcg|Subjects will receive entolimod as a single dose administered intramuscularly (10mcg)
89026228|NCT03272438|Active Comparator|Inconsistent schedule condition|This group will receive an accelerometer and daily step goal. They will monitor their steps over the 9 week duration of the study. They will have the same level of contact as the other two conditions. In addition they will plan when, where, and how they will take steps in inconsistent contexts, i.e., that vary from day to day.
89026229|NCT02955810|Experimental|CyBorD-DARA|
89026230|NCT04339387||Coronavirus Disease 2019 positive, suitable for discharge|Patients with Coronavirus Disease 2019 who do not require supplemental oxygen, do not require intensive care unit-level care, and do not die.
89026231|NCT04339387||Coronavirus Disease 2019 positive, not suitable for discharge|Patients with Coronavirus Disease 2019 who do require supplemental oxygen, do require intensive care unit-level care, or do die.
89558417|NCT04176133|Placebo Comparator|Placebo|Subjects will receive a placebo as a single dose administered intramuscularly (no study drug); placebo that looks exactly like the study drug, but contains no active ingredient.
89558418|NCT04175418|Experimental|Supervised Exercise Program Group|Participants in the supervised exercise group were included to a program that consisted of 16 individual physiotherapist supervised sessions (two 60-minutes sessions/week), which were prepared to improve physical activity.
89026232|NCT03272555|Other|Study Participants|The participants in this arm will engage in the WILD 5 Wellness activities combining five wellness elements including exercise, mindfulness, sleep, social connectedness and nutrition.
89026233|NCT00499200|Experimental|SRA-444 + Placebo|Experimental; Placebo
89026234|NCT04327492||Carotid endarterectomy|"This study is a non-interventional prospective cohort study. The population corresponds to patients submitted to CEA under regional anesthesia. Consecutive patients from a tertiary referral center who undergo CEA for carotid artery stenosis (CS) will be prospectively recruited. The expected patient follow-up will be of 5 years.~The demographics will be recorded in a prospective, protected database. Blood samples will be collected in clot activator serum tubes at three timepoints: timepoint 1 - before surgery (until 15 days before surgery); timepoint 2 up to 48h postoperatively; timepoint"
89026235|NCT04332484||Acute on Chronic Liver Failure|All patients of Acute on chronic liver failure according to CANONIC definition, aged more than 18 years were included. Sonoclot, TEG and conventional coagulation tests were done at baseline and at 72 hours. In case of clinically evident bleeding, Point of care tests were repeated to check for changes.
89026236|NCT04332484||Cirrhosis of Liver|All patients with cirrhosis of liver with age more than 18 years were included. Sonoclot, TEG and conventional coagulation tests were done at baseline and at 72 hours. In case of clinically evident bleeding, Point of care tests were repeated to check for changes.
89026237|NCT04327375||observational|observational
89558419|NCT04175418|Experimental|Online Education Program Group|Participants in the online education group were included to a program that consisted of 16 online sessions (two 60-minutes sessions/week), which were prepared to improve physical activity.
89558420|NCT04171908|Active Comparator|Conventional therapy|Conventional Physical therapy for the upper limb
89558421|NCT04171908|Experimental|semi-inmersive VR technology plus conventional therapy|Conventional Physical therapy for the upper limb plus semi-inmersive VR technology
89558422|NCT04166318|Active Comparator|Arm A (standard-dose chemoradiation)|Patients undergo 28 fractions of intensity-modulated radiation therapy (IMRT). Within 24 hours, patients also receive mitomycin IV over 30 minutes or less on day 1 and either fluorouracil IV over 24 hours on days 1-4 and 29-32 or capecitabine PO BID 5 days per week (Monday - Friday) until completion of IMRT in the absence of disease progression or unacceptable toxicity.
89558423|NCT04166318|Experimental|Arm B (de-intensified chemoradiation)|Patients undergo 20 or 23 fractions of IMRT. Within 24 hours, patients also receive mitomycin IV over 30 minutes or less on day 1 and either fluorouracil IV over 24 hours on days 1-4 or capecitabine PO BID 5 days per week (Monday - Friday) until completion of IMRT in the absence of disease progression or unacceptable toxicity.
89558424|NCT04165213|Experimental|Online training site|"Ten participating Trinity PACE Organizations will participate via webinar in a brief orientation/ training to the study and project logistics. Next, Trinity Health PACE organizations will be randomized into two groups using the re-randomization procedures described in the paragraph below; 5 PACE organizations will serve as the control site in which training will be provided via the traditional high intensity face-to-face.; 5 PACE organizations will serve as the comparison and be trained through the online training site. Prior to randomization, we will carefully examine PACE organizations on important variables such as size, location (urban; rural) percent of persons with dementia, and staff: participant ratio. In each site, one occupational therapist (OT) and one nurse (RN) will be trained (e.g., 5 OTs and 5 RNs in traditional sites; 5 OTS and 5 RNS in online training sites for a total of 10 OTs and 10 RNs or 20 health providers)."
89558425|NCT04165213|Experimental|COPE-PACE participant outcomes with online training|The efficacy of the COPE program training on PACE participant outcomes by type of COPE training will be evaluated in this arm. Each of the PACE organizations will enroll 5 persons with dementia and their caregivers in the study. This will yield 50 family dyads or 100 subjects (25 dyads in traditional training sites and 25 dyads in online training sites). Dyads will be followed for 4 months. Non-inferiority analysis will be used to assess whether dyads will yield the same or better outcomes regardless of how PACE staff were trained.
89558426|NCT04158921|Other|The Control:Diabetes mobile app for Diabetes self-management.|This is a single arm open label pilot clinical trial that will assess patient-reported blood glucose levels before and after using the Control:Diabetes mobile app.
89026238|NCT04327453|Experimental|XP-endo Finisher file|removal of double antibiotic paste intracanal medication with XP-endo Finisher file
89026239|NCT04327453|Experimental|Irrisafe Ultrasonic tip|removal of double antibiotic paste intracanal medication with passive ultrasonic irrigation
89026240|NCT04327453|Active Comparator|side vented needle|removal of double antibiotic paste intracanal medication with conventional syringe irrigation
89026241|NCT01245504||Lower-limb amputee|Subjects with at least one lower limb amputated at teh trans-tibial level
89026242|NCT00592579|Experimental|1|Open label, oral administration of 2ME2
89026243|NCT04327414|Experimental|Intervention group|Implementation of standing desks in classroom. To ensure that adolescents will spend sufficient time at the standing desks, 1/3 to half of the classroom will be provided with standing desks. The school will be asked to actually replace some traditional desks with these standing desks, instead of just adding standing desks to the classroom set-up to ensure as much as possible that the desks are being continuously used throughout the intervention period.
89026244|NCT04327414|No Intervention|Control group|No implementation of standing desks in classroom.
89208402|NCT04088903|Experimental|Daratumumab infusion|"Participants will receive an intravenous infusion of daratumumab weekly for 8 doses and then every other week for 2 doses.~For this dose-escalation study, the initial patients will receive a 2 mg/kg dose of daratumumab. In subsequent patients, the dose will be uptitrated to 16 mg/kg as tolerated.~Participants will undergo laboratory testing, including for circulating antibodies, at baseline, prior to each infusion session, and at the end of the study."
89208403|NCT02545140||UK (Lead Site)|"Data will be collected from 100 adolescents from each participating site providing clinical data for 500 adolescents providing a cross-sectional cohort from each of the following countries:~UK (Lead Site) Germany Portugal Greece Spain (Basque Country)"
89558427|NCT04152330|Other|Comparison between intervention and control group|"The subjects will be randomized to two groups, intervention group (IG) and control group (CG). Each day GI Parents-Baby receives guidance for 6 weeks of stimulation activities and will be instructed to keep an online execution diary, directly with the researcher of videos and messages via cell phone. Parents is understood as a generalist nomenclature and will be considered a parent, mother or principal.~GC subjects receive standard guidance from the pediatric and pediatric cardiology clinic."
89558428|NCT04150614|Active Comparator|Arm 1|ARM 1 -transdermal granisetron plus intravenous dexamethasone
88964834|NCT02046447||Primary Cervical Dystonia (Trihexyphenidyl)|"These subjects will receive the following: 1) data about clinical movement disorder history, age, gender, height, weight, and other medical conditions; 2) clinical neurological examination; 3) tests assessing cognitive abilities including: the Montreal Cognitive Assessment, Stroop, Digit Span, and Brief Test of Attention (BTA); 4) measures of anxiety and depression: the Beck Depression Index (BDI II). Only participants aged 18+ will be given the BDI; and 5) Functional magnetic resonance imaging (fMRI) and structural MRI will be performed.~After the above baseline testing these subjects will receive a dose of trihexyphenidyl 2 mg an hour prior to the second functional fMRI scan. The subjects will be done with the study after the second MRI scan has been completed."
88964835|NCT02046447||DYT 1 Dystonia (Healthy Control)|These subjects will receive the following: 1) data about clinical movement disorder history, age, gender, height, weight, and other medical conditions; 2) clinical neurological examination; 3) tests assessing cognitive abilities including: the Montreal Cognitive Assessment, Stroop, Digit Span, and Brief Test of Attention (BTA); 4) measures of anxiety and depression: the Beck Depression Index (BDI II). Only participants aged 18+ will be given the BDI; and 5) Functional magnetic resonance imaging (fMRI) and structural MRI will be performed.
88964836|NCT02046447||Primary Cervical Dystonia (Healthy Control)|These subjects will receive the following: 1) data about clinical movement disorder history, age, gender, height, weight, and other medical conditions; 2) clinical neurological examination; 3) tests assessing cognitive abilities including: the Montreal Cognitive Assessment, Stroop, Digit Span, and Brief Test of Attention (BTA); 4) measures of anxiety and depression: the Beck Depression Index (BDI II). Only participants aged 18+ will be given the BDI; and 5) Functional magnetic resonance imaging (fMRI) and structural MRI will be performed.
88964837|NCT02046447||DYT 1 Dystonia|These subjects will receive the following: 1) data about clinical movement disorder history, age, gender, height, weight, and other medical conditions; 2) clinical neurological examination; 3) tests assessing cognitive abilities including: the Montreal Cognitive Assessment, Stroop, Digit Span, and Brief Test of Attention (BTA); 4) measures of anxiety and depression: the Beck Depression Index (BDI II). Only participants aged 18+ will be given the BDI; 5) Functional magnetic resonance imaging (fMRI) and structural MRI will be performed; and 6) Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS) to assess dystonia severity.
88964838|NCT02046473|Other|Volumetric Flow in TIPS|Subjects who have TIPS (transjugular intrahepatic porto-systemic shunts) have measurements taken to determine if someone has increased blood pressure in the portal vein of the liver (portal hypertension). Subjects who have a TIPS receive clinical ultrasounds every 3 months to determine if the TIPS is working properly.
88964839|NCT02046486|Active Comparator|Ticagrelor 180mg whole tablets|Ticagrelor 180mg loading dose, in the form of 2 whole tablets administered per os in the supine position (standard administration)
88964840|NCT02046486|Experimental|Ticagrelor 180mg crushed and dispersed|Ticagrelor 180mg in the form of 2 tablets crushed and dispersed in purified water administered per os with 1-minute-stay in a 60-70 degrees semi-upright sitting position
88964841|NCT02046499|Active Comparator|Oxytocin arm|Oxytocin alone administered which is current standard of care
88964842|NCT02046499|Experimental|Oxytocin + syntometrine|Oxytocin plus syntometrine administered
88964843|NCT02046538|Experimental|Postoperative Chemo WITH Zaltrap|"Subjects will receive 3 months of chemotherapy consisting of either FOLFOX (oxaliplatin, leucovorin, 5-FU) or FOLFIRI (Irinotecan, leucovorin, 5-FU) in the case of liver limited CRC, or FOLFOX (in the case of rectal cancer). Zaltrap will be administered with chemotherapy every 2 weeks for the first 5 out of 6 planned treatment cycles. After a standard 3-4 week recovery period (i.e. 5-6 weeks from the last Zaltrap dose), patients will undergo standard resection. At the time of resection, the tumor will be collected for biomarker discovery.~Following resection, patients will receive chemotherapy with zaltrap for 3 additional months. Patients may continue zaltrap (without chemotherapy) until disease recurrence or up to an additional 15 months."
88964844|NCT02046538|Active Comparator|Postoperative chemo WITHOUT zaltrap|"Subjects will receive 3 months of chemotherapy consisting of either FOLFOX (oxaliplatin, leucovorin, 5-FU) or FOLFIRI (Irinotecan, leucovorin, 5-FU) in the case of liver limited CRC, or FOLFOX (in the case of rectal cancer). Zaltrap will be administered with chemotherapy every 2 weeks for the first 5 out of 6 planned treatment cycles. After a standard 3-4 week recovery period (i.e. 5-6 weeks from the last Zaltrap dose), patients will undergo standard resection. At the time of resection, the tumor will be collected for biomarker discovery.~Following resection, patients will receive chemotherapy (without zaltrap) for 3 additional months."
88964845|NCT02046551|Placebo Comparator|Placebo|placebo
88964846|NCT02046551|Experimental|Atomoxetine|atomoxetine (40 mg/day)
88964847|NCT02046577|Experimental|5600 IU Vitamin D3|Oral 5600 IU Vitamin D3 in liquid weekly during 6 months
88964848|NCT02046577|Experimental|Oral 11200 IU Vitamin D3 weekly|Oral 11200 IU Vitamin D3 in liquid weekly during 6 months
88964849|NCT02046577|Placebo Comparator|Placebo|Oral placebo in liquid weekly during 6 months
88964850|NCT02046629|Experimental|teriflunomide dose 1|Teriflunomide 14mg tablet, oral single dose, fast condition Cholestyramine power, 8 gram,oral three times a day for 4 days, fed condition
88964851|NCT02046642|Active Comparator|Maternal rest in left lateral position|"women in maternal rest in left lateral position group rested in the left lateral position for 15 minutes and then rested in the right lateral position for another 15 minutes."
89558429|NCT04150614|Active Comparator|ARM 2|ARM 2 -intravenous ondansetron plus intravenous dexamethasone
89558430|NCT04138940|Experimental|Distributed, Short Script|Participant practices for 1 hour, 2 days a week for 5 weeks using a 5 sentence-long script.
89558431|NCT04138940|Experimental|Distributed, Long Script|Participant practices for 1 hour, 2 days a week for 5 weeks using a 10 sentence-long script.
88964852|NCT02046642|Active Comparator|Maternal rest in right lateral position|"Women in maternal rest in right lateral position group started resting in the right lateral position for 15 minutes and then rested in the left lateral position for another 15 minutes."
88964853|NCT02046655|Experimental|Corifollitropin alfa group|"On day 2 of the cycle, a single subcutaneous (SC) dose of 150 μg Corifollitropin alfa (Elonva) will be administered.~GnRH antagonist (Orgalutran) 0.25 mg/day flexible initiation by a follicle of 14mm.~A daily dose of recFSH (450 IU/day) will be used from day 8 of stimulation until the day of hCG, if necessary.~Triggering of final oocyte maturation will be performed using 250 μg of rechCG."
88964854|NCT02046655|Active Comparator|rec FSH group|"On day 2 of the cycle, daily SC dose of min 450 IU recFSH (Puregon) will be administered.~GnRH antagonist (Orgalutran) 0.25 mg/day , flexible initiation by a follicle of 14mm.~Triggering of final oocyte maturation will be performed using 250 μg of rechCG."
88964855|NCT02046668|Active Comparator|spironolactone|25mg spironolactone daily
88964856|NCT02046668|Placebo Comparator|Placebo|Matched Placebo
88964857|NCT02046681||Acetam, acetam + codeine, Ibuprofen, Oxycodone|monitoring side effects of pain medication prescribed in patients over 65 acetaminophen 1000 mg tabs po q6h acetaminophen + codeine 500 mg tabs po q6h ibuprofen 200 mg tabs po q8h oxycodone 5 mg tabs po bid
88964858|NCT02046707|Experimental|Patients with chronic heart failure|
88964859|NCT02046707|Other|Controls|
88964860|NCT02046720|Experimental|propofol induced sedation|Propofol was administered using a commercially available target-controlled infusion with an incorporated pharmacokinetic model developed by Schnider (Base Primea , Fresenius-Kabi, Brezins, FRANCE)12. The initial effect-site target concentration of propofol (0.5 μg/ml) was incremented by 0.5 μg/ml every 5 minutes to ensure equilibration between plasma concentration and effect site, until loss of eyelash reflex. From the beginning of infusion until LOER patients received no other agent besides propofol for the duration of the trial.
88964861|NCT02046733|Experimental|Nivolumab + Ipilimumab|"- Induction: Nivolumab at a dose of 1 mg/kg i.v. followed (on the same day) by Ipilimumab at a dose of 3 mg/kg i.v. once every 3 weeks, 4 cycles~- Maintenance: Nivolumab 240 mg i.v. once every 2 weeks, for a maximum of 12 months from start of maintenance"
88964862|NCT02046733|No Intervention|Observation|no further treatment; tumour assessment, follow-up documentation and collection of biological material will be done according to the same schedule as Arm 1.
88964863|NCT02046746|Experimental|Oral Nutritional Supplement (ONS)|1-2 serving per day of a renal specific oral nutritional supplement
88964864|NCT02046759|Experimental|Pharmacist-Intervention|
88964865|NCT02046759|Active Comparator|Routine Care|
88964866|NCT02046785|Other|0.9% saline solution|comparing values obtained before and after administration of 500 ml of 0.9% saline
88964867|NCT02046798|Experimental|14C labeled ASP3652|
88964868|NCT02046811|Experimental|Patient activation and education|Patient activation and education (PAE)
88964869|NCT02046811|Experimental|PAE plus physician activation|PAE plus physician activation (PAE + MD)
88964870|NCT02046811|Experimental|PAE, MD, plus teledermoscopy|PAE physician activation, plus teledermoscopy (PAE +MD +TD)
88964871|NCT02046824|Experimental|Xtra®, Sorin cellsaver|when at least 750 mL of wound blood is collected in the reservoir during the operation, and when the patients has been allocated to the Xtra Sorin cellsaver group, the washing process will be started. Samples will be taken from before and after the washing process. Thereafter, the blood will be retransfused to the patient.
88964872|NCT02046824|Experimental|C.A.T.S.®, Fresenius cellsaver|when at least 750 mL of wound blood is collected in the reservoir during the operation, and when the patients has been allocated to the C.A.T.S. cellsaver group, the washing process will be started. Samples will be taken from before and after the washing process. Thereafter, the blood will be retransfused to the patient.
88964873|NCT02046824|Experimental|CardioPAT®, Haemonetics, cellsaver|when at least 750 mL of wound blood is collected in the reservoir during the operation, and when the patients has been allocated to the CardioPAT cellsaver group, the washing process will be started. Samples will be taken from before and after the washing process. Thereafter, the blood will be retransfused to the patient.
89208404|NCT05395871|Active Comparator|Usual Care|A text message sent 7 days prior then 48 hours before a booked/timed appointment. The content of the message will be the 'usual care' content that is currently sent by the London Breast Cancer Screening Programme. This includes a link to a YouTube hosted video.
89208405|NCT05395871|Experimental|Behavioural Message|A text message sent 7 days prior then 48 hours before a booked/timed appointment. The content of the message has been informed by previous co-design work, and incorporate behavioural change techniques. This will include the same link to a YouTube hosted video, as the usual care arm.
88964874|NCT02046824|Other|no use of cell saver|When less than 750 ml of wound blood is collected in the reservoir at the end of the operation, patients will be automatically allocated to the control group. The collected blood will be cast away according to daily clinical practice and recommendations of the manufacturers.
88964875|NCT02046837|Experimental|Supervised 1:1 exercise|This intervention arm will include 3 one-on-one, supervised sessions per week for 6 months with a certified exercise specialist. Flexibility training will include stretching for 5-10 minutes at the beginning and end of each session. Aerobic training will involve 30 minutes of low-impact step aerobics. Resistance training will be conducted using resistance bands, a stability ball, and an exercise mat with 8 prescribed exercises that target the major muscle groups. Participants will be encouraged to perform exercises independently on additional days, for a total of 4-5 days per week of exercise.
89026245|NCT00592657||1|Patients diagnosed with rhabdomyolysis and no history of jimsonweed ingestion
89026246|NCT00592657||2|Patients diagnosed with rhabdomyolysis and history of jimsonweed ingestion
89558432|NCT04138940|Experimental|Massed, Short Script|Participant practices for 1 hour, 5 days a week for 2 weeks using a 5 sentence-long script.
88964876|NCT02046837|Experimental|Supervised group exercise|This intervention arm will include 3 group, supervised sessions per week for 6 months with a certified exercise specialist. Supervised sessions will be delivered in a group format with 4-8 participants per group. Flexibility training will include stretching for 5-10 minutes at the beginning and end of each session. Aerobic training will involve 30 minutes of low-impact step aerobics. Resistance training will be conducted using resistance bands, a stability ball, and an exercise mat with 8 prescribed exercises that target the major muscle groups. Participants will be encouraged to perform exercises independently on additional days, for a total of 4-5 days per week of exercise.
88964877|NCT02046837|Experimental|Home-based exercise|The same protocol and training frequency as the supervised programs described above will be followed. However, all exercises will be completed independently by participants. Specific exercises in the aerobic program may be modified to accommodate patient preference (same target heart rate range as supervised groups). Participants will be supported with smartphone technology and remote 'health coaches' during the intervention phase. This will help to ensure participant adherence, appropriate progression, and safety.
88964878|NCT02046850|Experimental|selumetinib 75mg.|Volunteers will receive selumetinib 75mg administered by mouth, as a capsule
88964879|NCT02046850|Other|rifampicin 600mg.|Volunteers will receive rifampicin 600mg administered by mouth, as a capsule
88964880|NCT02046850|Experimental|selumetinib 75mg and rifampicin 600mg|Volunteers will receive selumetinib 75mg and rifampicin 600mg, by mouth, as a capsule
88964881|NCT02046876|Experimental|Multimodal Physiotherapy Program for Chronic Neck Pain Suffers|
88964882|NCT02046889|Experimental|Intervention group|The intervention group or experimental group will receive the bicycle training intervention during the first year of the study. The intervention is a 5 day/75 minutes per day bicycle training intervention which used specialized instruction and adapted equipment to teach independent bicycle riding skills to youth aged 9-18 years with autism spectrum disorder and Down syndrome.
88964883|NCT02046889|No Intervention|Control group|The control group will not receive the intervention during the first year of the study. Instead, this group will receive a delayed intervention during the second year of the study, after pre-post effects have been evaluated.
88964884|NCT02046915|Experimental|Pomalidomide, Dexamethasone, Cyclophosphamide|"Pomalidomide administered orally at the starting dose of 4 mg/day on Days 1-21 of a 28-day cycle~Low-dose Dexamethasone administered orally at the starting dose of 40 mg/day (≤ 75 years old) or 20 mg/day (> 75 years old) on Days 1, 8, 15, and 22 of a 28-day cycle~Cyclophosphamide administered intravenously 500 mg/m² on Days 1 and 15 of a 28-day cycle"
88964885|NCT02046928|Experimental|A6|A6 is administered subcutaneously two times a day for 6 cycles (1 cycle = 28 days).
88964886|NCT02046954||Study group|Patients monitored with hemodynamically focussed transesophageal echocardiography (placement within 12 hours of ICU admission)
88964887|NCT02046954||Control Group|Patients receiving conventional monitoring (e.g. transpulmonary thermodilution)
88964888|NCT02046967|Active Comparator|Endovenous laser ablation|Endovenous laser ablation with 940 nm bare fiber.
88964889|NCT02046967|Active Comparator|Endovenous steam ablation|Endovenous steam ablation with steam vein sclerosis system.
88964890|NCT02047006|Experimental|Rivaroxaban 10 mg|"Measurement of AUC of rivaroxaban and effect on coagulation assays:~Rivaroxaban is given as a single oral dose of 10 mg immediately after three subsequent dialysis sessions. Patients remain in the hospital from the intake of the first dose until 48 hours after the intake of the third dose.~Effect of dialysis on levels of rivaroxaban:~Rivaroxaban is given as a single oral dose of 10 mg in the morning when dialysis is scheduled in the afternoon, or the previous evening when dialysis is scheduled in the morning. The interval between the two doses was at least 48 hours. Dialysis is scheduled 6 to 8 hours after the intake of rivaroxaban."
88964891|NCT02047019|Active Comparator|Candesartan|Treatment with 1 capsule and 2 tablets once daily in the morning for 8 weeks (Candesartan 16 mg, Placebo combination A, Placebo combination B)
88964892|NCT02047019|Experimental|Nifedipine/Candesartan-30/16|Treatment with 1 capsule and 2 tablets once daily in the morning for 8 weeks (Candesartan placebo, Placebo combination A, Combination nifedipine / candesartan 30/16 mg)
88964893|NCT02047019|Experimental|Nifedipine/Candesartan-60/16|Treatment with 1 capsule and 2 tablets once daily in the morning for 8 weeks (Candesartan placebo, Placebo combination B, Combination nifedipine / candesartan 60/16 mg)
88964894|NCT02047058||high-risk|high-risk is determined by the evaluation of the biomarkers of Q cell.
88964895|NCT02047071|No Intervention|Standard Care|Conservative treatment. This group will be receive standard care for OSA consisting of hygienic-dietary advice and lifestyle counseling.
88964896|NCT02047071|Experimental|Continuous positive airways pressure|Optimal Continuous positive airways pressure treatment every night plus standard care for OSA consisting of hygienic-dietary advice and lifestyle counseling.
88964897|NCT02047123|Experimental|Raw Flaxseed|For 30 days, participants in group 1 took with 15g flaxseed mixed with yoghurt and diet,(the 15g of raw flaxseed that was provided in addition to the linen package spoon so all would take far it) group 2 took yoghurt and diet, and group 3 only received the diet.The energy intake of the designed diet was similar into the three groups (ranging 1900-2000 Kcal per day).
89026247|NCT01243710|Experimental|Taurolidine with heparin|
89026248|NCT01243710|Active Comparator|Heparin|
89026249|NCT00622843|Experimental|Group 1|PCV, 210 patients
89026250|NCT00622843|Active Comparator|Group 2|PPV, 110 patients
89558433|NCT04138940|Experimental|Massed, Long Script|Participant practices for 1 hour, 5 days a week for 2 weeks using a 10 sentence-long script.
89558434|NCT04131712|No Intervention|Ambulatory Control|Following baseline assessments, participants will be randomized into the ambulatory group for the remainder of the study. Atrophy will not be induced and massage intervention will not be applied. Ambulatory groups will be recruited following the immobilized groups.
89558435|NCT04131712|Sham Comparator|Ambulatory Massage|Following baseline assessments, participants will be randomized into the ambulatory group for the remainder of the study. No atrophy induction. Four massage treatments will be applied every other day until the end of the study. Ambulatory groups will be recruited following the immobilized groups.
89026251|NCT00622843|Active Comparator|Group 3|PPV, HIV-negative, 25 patients
89026252|NCT00592696||Observation|
89558436|NCT04131712|No Intervention|Immobilization Control|Following baseline assessments, participants will be randomized into the unilateral lower limb suspension group undergoing atrophy for the remainder of the study. Massage intervention will not be applied.
89558437|NCT04131712|Experimental|Immobilization Massage|Following baseline assessments, participants will be randomized into the unilateral lower limb suspension group undergoing atrophy for the remainder of the study. Four massage treatments will be applied every other day until the end of the study.
89558438|NCT04126096|Experimental|Study Group|Study team is developing a new diagnostic skin testing procedure for patients who receive beta lactam containing antibiotics during surgery (other than penicillin) in order to determine Negative Predictive Values and Non-Irritant Concentrations.
89558439|NCT04121455|Experimental|Cohort 1: 200 mg Olaptesed pegol + Radiotherapy|olaptesed pegol weekly for 26 weeks administered i.v. by continuous infusion plus radiotherapy during weeks 1-6
89558440|NCT04121455|Experimental|Cohort 2: 400 mg Olaptesed pegol + Radiotherapy|olaptesed pegol weekly for 26 weeks administered i.v. by continuous infusion plus radiotherapy during weeks 1-6
89026253|NCT03271736|Experimental|Freezer|All the subjects received 2 experiments. 2 experiments contain 20 mins stepping-in-place exercise and pre-/post assessments. The difference between 2 experiments is the application of auditory cues. One of the 2 experiment includes stepping-in-place exercise with auditory cues from the metronome (Stepping-in-place exercise with external auditory cues), in the other experiment we ask the subjects to follow their internal rhythm without external auditory cues (Stepping-in-place exercise without external auditory cues). Transcranial magnetic stimulation (TMS) is applied before and after the stepping-in-place exercise.
89208406|NCT05395871|Experimental|Behavioural Message + Video|An text message sent 7 days prior then 48 hours before a booked/timed appointment. The content of the message will be the same as the Behavioural text, however the link will be replaced with a weblink to an animated video. This video has been designed through an extensive co-design process involving several behavioural change techniques designed to overcome barriers highlighted in this qualitative work.
89208407|NCT01009372|Experimental|breaks during laparoscopic surgery|Intraoperative Breaks were instituted in the intervention group. The other group operated conventionally without breaks
89558441|NCT04121455|Experimental|Cohort 3: 600 mg Olaptesed pegol + Radiotherapy|olaptesed pegol weekly for 26 weeks administered i.v. by continuous infusion plus radiotherapy during weeks 1-6
89558442|NCT04121455|Experimental|Expansion group, Arm A: 600 mg Olaptesed pegol + Radiotherapy + 10 mg/kg Bevacizumab|olaptesed pegol weekly for 26 weeks administered i.v. by continuous infusion, bevacizumab every two weeks for 26 weeks plus radiotherapy during weeks 1-6, incompletely or not resected patients
89558443|NCT04121455|Experimental|Expansion group, Arm B: 600 mg Olaptesed pegol + Radiotherapy|olaptesed pegol weekly for 26 weeks administered i.v. by continuous infusion plus radiotherapy during weeks 1-6, completely resected patients
89558444|NCT04121455|Experimental|Expansion group, Arm C: 600 mg Olaptesed pegol + Radiotherapy + 200 mg Pembrolizumab|olaptesed pegol weekly for 26 weeks administered i.v. by continuous infusion, pembrolizumab every three weeks for 26 weeks plus radiotherapy during weeks 1-6, incompletely resected patients
89558445|NCT04117958|Experimental|Dose-exploration phase|The dose-exploration phase of the study will estimate the MTD (Maximum Tolerated Dose) of AMG 199 using a Bayesian logistic regression model (BLRM). A RP2D (Recommended Phase 2 Dose) may be identified based on emerging safety, efficacy, and PD (Pharmacodynamics) data prior to reaching an MTD. Alternative dosing schedule(s) may be explored based on emerging PK (Pharmacokinetics) and safety data.
89558446|NCT04117958|Experimental|Dose-expansion phase|The dose-expansion phase will be conducted to confirm safety, PK, and PD at the MTD or RP2D and to obtain further safety and efficacy data and enable correlative biomarker analysis.
89558447|NCT04117672|Placebo Comparator|Placebo|Egg yolk powder not enriched for antisecretory powder
89558448|NCT04117672|Experimental|Salovum|Egg yolk powder enriched for antisecretory powder
89558449|NCT04115631|Experimental|Arm A (bendamustine, rituximab, cytarabine)|Patients receive bendamustine IV on days 1 and 2 and rituximab IV on day 1 or 2. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Beginning cycle 4, patients receive rituximab IV on day 1 and cytarabine IV every Q12 hours on days 1 and 2. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
89026254|NCT03271736|Experimental|Non-freezer|All the subjects received 2 experiments. 2 experiments contain 20 mins stepping-in-place exercise and pre-/post assessments. The difference between 2 experiments is the application of auditory cues. One of the 2 experiment includes stepping-in-place exercise with auditory cues from the metronome (Stepping-in-place exercise with external auditory cues), in the other experiment we ask the subjects to follow their internal rhythm without external auditory cues (Stepping-in-place exercise without external auditory cues). Transcranial magnetic stimulation (TMS) is applied before and after the stepping-in-place exercise.
89026255|NCT00592735||1|
89026256|NCT00592813|Experimental|1|
89026257|NCT00592813|Placebo Comparator|cardiovascular education (attention control)|
89026258|NCT01245543|Experimental|AC480IV|Dose range finding study
89026259|NCT01245543|Experimental|Docetaxel|Dose range finding study in subjects with solid tumors
89026260|NCT00592891|Experimental|Hyperbaric oxygen therapy|Patients undergoing low pressure HBOT for chronic brain injury
89026261|NCT00592930|Experimental|1|olanzapine
89026262|NCT00592930|Placebo Comparator|2|matching placebo
89026263|NCT01245582|Experimental|SECOX regimen|Oxaliplatin (Eloxatin) 85mg/m2 , 2 hour infusion, day 1 Capecitabine (Xeloda) 850 mg/m2 BID orally daily, from day 1 to 7 Sorafenib (Nexavar) 400 mg BID orally daily, from day 1 to 14 (continuously)
89208408|NCT00864786|Experimental|Cohort 1|200 mcg
89208409|NCT00864786|Experimental|Cohort 2|600 mcg
89208410|NCT00864786|Experimental|Cohort 3|1000 mcg
89208411|NCT00864786|Experimental|Cohort 4|Dose to be decided
89558450|NCT04115631|Experimental|Arm B (acalabrutinib, bendamustine, rituximab, cytarabine)|Patients receive PO BID on days 1-28, bendamustine IV on days 1 and 2, and rituximab IV on day 1 or 2. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Beginning cycle 4, patients receive acalabrutinib PO BID on days 1-7 and 22-28, rituximab IV on day 1, and cytarabine IV Q12 hours on days 1 and 2. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
89558451|NCT04115631|Experimental|Arm C (acalabrutinib, bendamustine, rituximab)|Patients receive acalabrutinib PO BID on days 1-28, bendamustine IV on days 1 and 2, and rituximab IV on day 1 or 2. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
89558452|NCT04112667||Normal Macular Health|>=60 years old with no macular disease
89558453|NCT04112667||Early Macular Degeneration|>=60 years old with early age-related macular degeneration
89558454|NCT04112667||Young Normals|20-30 years old with normal macular health
89558455|NCT04109482|Experimental|Relapsed or Refractory BPDCN|Treatment with MB-102.
89558456|NCT04109196|Experimental|Intensive 5-day Cognitive Processing Therapy for PTSD|Participants who are eligible for and enrolled in the study will receive a 5-day CPT treatment for PTSD. All participants will be asked to complete clinician-rated and self-report assessments at multiple time points during the study. Participants will also be asked to provide fecal and saliva samples as part of the study, however, they may opt out of biological sample collection.
89558457|NCT04096859||PremiCron®|Assessment of PremiCron suture for cardiac valve reconstruction and replacement
89558458|NCT04094584|Experimental|Multimodal Intervention|"The intervention is multimodal and consists of:~Intramuscular injections of 380mg extended-release Naltrexone, given once monthly for 3 months.~Case Management services"
89558459|NCT04091308|Active Comparator|Usual Care|Usual care involves physiotherapeutic rehabilitation in an unknown format, and will, therefore, be monitored closely and described accordingly.
89558460|NCT04091308|Experimental|Usual Care with Protein Supl.|Usual care involves physiotherapeutic rehabilitation in an unknown format, and will, therefore, be monitored closely and described accordingly.
89558461|NCT04091308|Experimental|Individualized Physical Exercise Training with Protein Supl.|This group is also called EXER group, and will receive individually tailored physical exercise programs, based on their strength and weaknesses from the baseline testing.
89558462|NCT04082338|Experimental|VPN Toolkit+TM|The intervention will be delivered through virtual patient navigation (VPN) toolkit system (a web/mobile application) format.
89558463|NCT04082338|Active Comparator|Text Messages|Receive TM respectively once a week for 5 weeks for every 6 months in the 18-month study period
89558464|NCT04074616|Experimental|High Dose|
89558465|NCT04074616|Other|Control|Low dose TTNS
89558466|NCT04070560|Active Comparator|Early (≤ 60 seconds) cord clamping|If the infant don't breathe, the umbilical cord is clamped (≤ 60 seconds) and cut and resuscitation will be provided at a resuscitation table Other Name: Immediate clamping
89558467|NCT04070560|Active Comparator|Intact cord (≥ 180 seconds) resuscitation|"If the infant don't breathe, the umbilical cord is not clamped and cut until after 180 seconds. Initial resuscitation will be provided bedside to the mother~Other Names:~Late cord clamping Deferred cord clamping Optimal cord clamping"
89558468|NCT04053283|Experimental|Intravenous|"Phase 1a dose escalation: one cycle of treatment.~Phase 1a dose optimisation: up to 8 cycles of treatment"
89558469|NCT04023370|Experimental|BeGraft Peripheral Stent Graft System|Covered stent
89208412|NCT00864786|Experimental|Cohort 5|Dose to be decided
89208413|NCT00740051|Experimental|Linagliptin|52 week treatment
89558470|NCT04023370|Active Comparator|Bare metal stent system|bare metal stent
89558471|NCT04020341|Experimental|Gepotidacin|Participants will be administered oral doses of 1500 milligrams (mg) gepotidacin plus nitrofurantoin matching placebo twice daily (BID); approximately every 12 hours for 5 days
89558472|NCT04020341|Active Comparator|Nitrofurantoin|Participants will be administered oral doses of 100 mg nitrofurantoin plus gepotidacin matching placebo BID; approximately every 12 hours for 5 days.
89558473|NCT04015141|Experimental|Perampanel|Participants aged 1 month to less than 18 years with pediatric epileptic syndrome (Cohort 1) or aged 1 month to less than 2 years with POS (Cohort 2) will receive perampanel oral suspension or perampanel tablets, once daily up to 56 weeks.
89558474|NCT04014166|Experimental|15 refractory ITP patients|15 enrolled refractory ITP patients will be picked up to infuse hUC-MSCs at the indicated dose.
89558475|NCT04011280|Experimental|Low Dose Varenicline|0.5 mg twice daily with 0.5 mg daily titration over one full week
89558476|NCT04011280|Active Comparator|Standard Dose Varenicline|1.0 mg twice daily with standard titration
88964898|NCT02047136|Experimental|Treatment group (on low histamine diet)|78 subjects who come to Allergy Centre for treatment of idiopathic urticaria, with or without angioedema and pruritus (U/A/P), will be randomized into two parallel groups; treatment group (TG) will be asked to follow a histamine-restricted diet for 4 weeks and the control group (CG) will be asked to follow a well-balanced diet instructed by a dietitian for 4 weeks. A well-balanced diet for the CG subject is tailor-made by the dietitian according to subject's usual intake to ensure that the subject's energy requirement is met and all food groups are consumed.
89558477|NCT04002934|Experimental|Group A|"Group A is the early-start group and will receive a total of 6 months of BZA -- 3 months of BZA, followed by 3 months BZA"
88964899|NCT02047136|Active Comparator|Well-balanced diet|Diet tailor-made by the dietitian according to subject's usual intake to ensure that the subject's energy requirement is met and all food groups are consumed.
88964900|NCT02047149|Experimental|Zileuton/Dasatinib|zileuton/dasatinib: This is a traditional phase I design. Three dose levels of daily zileuton will be studied in conjunction with dasatinib to define the MTD
88964901|NCT02047162|Experimental|Bismuth subsalicylate|Bismuth subsalicylate, 262 mg/chewable tablet, 2 tablets every hour as needed up to 16 tablets per 24 hours, for up to 48 hours.
88964902|NCT02047162|Placebo Comparator|Placebo|Placebo chewable tablets, 2 every hour as needed up to 16 tablets per 24 h, for up to 48 h.
88964903|NCT02047175|Experimental|A(Telmisartan/S-Amlodipine)|"A(Telmisartan/S-Amlodipine)~: Telmisartan/S-Amlodipine 40/2.5mg 2T for 9days and Telmisartan/S-Amlodipine 40/2.5mg 2T + Rosuvastatin 20mg 1T for 5days"
88964904|NCT02047175|Experimental|B(Rosuvastatin)|"B(Rosuvastatin)~: Rosuvastatin 20mg 1T for 5days and Telmisartan/S-Amlodipine 40/2.5mg 2T + Rosuvastatin 20mg 1T for 9days"
88964905|NCT02047201|Experimental|Experimental|Induction chemotherapy (Docetaxel, Cisplatin and Fluorouracil) following radiochemotherapy (IMRT using PET/CT images after IC for treatment planning + cisplatin iv 40 mg/m2 weekly).
88964906|NCT02047266|Experimental|MICS CABG|"Minimally invasive cardiac surgery coronary artery bypass grafting (complete multivessel minimally invasive off-pump revascularization via left minithoracotomy), which is performed with a help of Octopus® Nuvo, Starfish® Non-Sternotomy, ThoraTrak®, Starfish®, Octopus®, Clearview® blower, ClearView® Shunt.~(MICS CABG group, n=50)"
88964907|NCT02047266|Active Comparator|OPCABG|"Off-pump coronary artery bypass grafting treatment which is performed with a help of Starfish®, Octopus®, Clearview® blower, ClearView® Shunt.~(OPCABG group, n=50)"
88964908|NCT02047266|Active Comparator|ONCABG|On-pump coronary artery bypass grafting treatment (ONCABG group, n=50)
88964909|NCT02047279|Active Comparator|MVS + maze|"Procedure: Maze procedure, mitral valve surgery~The scheme of lesion pattern: box lesion + line to mitral valve + line from box to left atrial appendage. The ablation procedure was performed by using a dry bipolar radiofrequency ablation clamp.~The left atrial appendage was excluded in all cases. For mitral regurgitation or stenosis, the procedures will be a valve repair in the majority of cases. For valves that are not amenable to repair, a valve replacement will be performed."
88964910|NCT02047279|Experimental|MVS + maze + LA reduction|"Procedure: maze procedure, mitral valve surgery, left atrial reduction~The scheme of lesion pattern: box lesion + line to mitral valve + line from box to left atrial appendage. The ablation procedure was performed by using a dry bipolar radiofrequency ablation clamp.~The left atrial appendage was excluded in all cases. For mitral regurgitation or stenosis, the procedures will be a valve repair in the majority of cases. For valves that are not amenable to repair, a valve replacement will be performed.~The enlarged left atria are plicated (suture technique) between the left and right pulmonary vein down to the inferior end of left atrial incision on the half-moon shape."
88964911|NCT02047292|Active Comparator|THA28|THA Corail PinnacleCoC28
88964912|NCT02047292|Active Comparator|THA36|THA Corail DeltaMotion36
88964913|NCT02047292|Active Comparator|THA40|THA Corail DeltaMotion40
88964914|NCT02047331|Active Comparator|group PI|group PI were performed periarticular drug injection during surgery.
88964915|NCT02047331|Active Comparator|group FI|group FI were performed fascia iliaca block before surgery
88964916|NCT02047357|Experimental|Intervention Arm|Learning Through Play Plus
88964917|NCT02047357|No Intervention|Control|This arm will receive no intervention
88964918|NCT02047370|Experimental|Diaphragm stretching|30 Patients with asthma are included in this group. They will receive a diaphragm stretching technique
88964919|NCT02047370|Placebo Comparator|Placebo group|Ultrasound disconnected in same position and with the same duration.
88964920|NCT00005817|Experimental|Arm I (becatecarin)|Patients receive rebeccamycin analogue IV over 60 minutes on day 1.
88964921|NCT00005817|Experimental|Arm II (becatecarin)|Patients receive rebeccamycin analogue IV over 60 minutes on days 1-5.
88964922|NCT00005820|Experimental|nitrocamptothecin|"Patients receive nitrocamptothecin orally daily for 5 consecutive days each week for 3 consecutive weeks. Treatment continues every 4 weeks in the absence of disease progression or unacceptable toxicity.~Patients are followed every 3 months until evidence of progression or relapse for a maximum of 2 years from the date of registration."
88964923|NCT00005829|Experimental|gemcitabine|Patients receive gemcitabine IV over 30 minutes on days 1 and 8. Treatment repeats every 4 weeks for a minimum of 3 courses. Patients achieving clinical complete remission, complete remission, nodular partial remission, or partial remission following 3 courses of therapy, receive 2 additional courses of therapy. Patients achieving complete remission or further improvement following the 2 additional courses of therapy, receive another 2 courses of therapy. Patients are followed every 3 months until disease progression or relapse. Patients achieving complete remission are followed every 6 months for 1 year.
88964924|NCT00005832|Experimental|R115777|300mg/dose BID, PO, Days 1-21, q 28days
89558478|NCT04002934|Experimental|Group B|"Group B is the delayed-start group and will receive a total of 3 months of BZA -- 3 months of placebo, followed by 3 months of BZA"
89026264|NCT01245582|Active Comparator|Sorafenib alone|Sorafenib (Nexavar) 400 mg BID orally daily, from day 1 to 14 (continuously)
89026265|NCT00593047|Placebo Comparator|1|Statin + placebo
89026266|NCT00593047|Experimental|2|Statin + KB2115 dose 1
89026267|NCT00593047|Experimental|3|Statin + KB2115 dose 2
89026268|NCT00593047|Experimental|4|Statin + KB2115 dose 3
89026269|NCT00593086|Active Comparator|A|Standard of care pain management
89026270|NCT00593086|Experimental|B|SnoWorld Virtual Reality Game
89026271|NCT02956200|Experimental|fingolimod with standard therapy|Patients will be treated with standard alteplase bridging and mechanical thrombectomy with fingolimod.
89026272|NCT02956200|No Intervention|standard therapy|Patients will be treated with standard alteplase bridging and mechanical thrombectomy.
89026273|NCT00593125|Experimental|1|levetiracetam
89558479|NCT03990428||Caregivers of Patients|This is an observational study of informal caregivers (ICs) of patients with Erdheim-Chester Disease (ECD) and other histiocytic diseases. That will collect data cross-sectionally, at a single time point. Caregiver-reported data will be completed in the form of online surveys by the participants themselves using the Research Electronic Data Capture Platform [RedCAP] platform.
89026274|NCT00593164|Experimental|1|Comatose post-resuscitation patients cooled with ThermoSuit and treated with intravenous magnesium sulfate (30 mg per kg IV over 15 min).
89026275|NCT00593164|Active Comparator|2|Comatose post-resuscitation patients cooled with ThermoSuit and treated with intravenous normal saline.
89026276|NCT01316107|Experimental|ASP group|Concomitant administration of ASP1941 and nateglinide
89558480|NCT03988764||Antibody-negative|"Patient has been found negative for at least three T1D antibodies.~The investigators will proceed with whole exome sequencing"
89558481|NCT03988764||Antibody-positive|"Patient has been found to be positive for at least one T1D autoantibody.~No further studies will be performed as part of the main study."
89558482|NCT03988621|Experimental|Intervention|Caregivers randomized to the intervention ViCCY will receive 10 front-loaded sessions of virtual health coaching by trained registered nurses over 6 months with content based on the theoretical framework (based on the Transactional Model of Stress and Coping) and prior research. Sessions are provided using tablets. Initially, sessions are weekly but the frequency decreases over time as needed. We help caregivers gain the knowledge and skills needed to achieve self-identified health goals through self-care using motivational interviewing. We focus on identifying personal values, solving problems, and transforming goals into action. ViCCY is standardized in a treatment manual. Because stress does not affect all people equally, the intervention is tailored to individual appraisals and the factors most likely to influence demand and perceived burden.
89558483|NCT03988621|No Intervention|Health Information|The Health Information (HI) group will receive health resource information delivered through the internet.
89558484|NCT03987711|Experimental|Warfarin|Individuals randomized to this arm will be exposed to dose-adjusted daily warfarin targeting an international normalized ratio (INR) of 2.0-3.0.
89558485|NCT03987711|Active Comparator|Apixaban|Individuals randomized to this arm will receive apixaban 5 mg twice daily (a reduced dose of 2.5 mg twice daily will be given to selected participants).
89558486|NCT03987711|Active Comparator|No oral anticoagulation|Individuals in this arm will be exposed to a treatment strategy in which no oral anticoagulation is prescribed.
89558487|NCT03983967|Experimental|Immuncell-LC group|Adjuvant adoptive immune therapy using a CIK cell agent(Cytokine-Induced Killer cells; Immuncell-LC) 3 times(3 treatments at a frequency of once per week) or 6 times(3 treatments at a frequency of once per week followed by 3 treatments every 2 weeks)
89026277|NCT00492453|Active Comparator|1|Laparoscopic cholecystectomy under spinal anesthesia
89026278|NCT00492453|Active Comparator|2|Laparoscopic cholecystectomy under general anesthesia
89026279|NCT01316185|Experimental|Group 1|Low Dose for 28 days: n=4
89026280|NCT01316185|Experimental|Group 2|High Dose for 28 days; n=4
89026281|NCT05654194|Experimental|AVA（Azacitidine Combined With Venetoclax and ATRA）group|(1)Inductive therapy: AZA 75mg/m² per day for days 1-7 and venetoclax 100mg orally for day 2 , 200mg orally for day 3, 300mg orally for day4-6, 400mg orally for day7-10,ATRA 45mg/m² for day 12-28,every 28 days for up to 2 cycles or progression; (2)Consolidate therapy:ATRA 45mg/m2 per day for d1-21 ,AZA 70mg/m² per day for days 1-7, every 28 days for up to 4 cycles or progression; (3) Maintenance therapy:ATRA 45mg/m2 for d1-21 every 28 days,AZA 70mg/m² per day for days 1-7, every 3 month untill progression;
89026282|NCT05654155|Experimental|Auricular acupressure group|The AAG participants received auricular acupressure three times a day for five days every week for three weeks. Using Dr. Huang's ear reflex theory, our AAG intervention included six acupoints (i.e., shenmen, subcortex, heart, kidney, anxious, and neurasthenia points) that have been demonstrated to be effective in improving sleep and emotional stability.
89026283|NCT05654155|Sham Comparator|sham auricular acupressure group|Participants in SAG received the same protocol of auricular acupressure as the AAG, but six acupoints were used near the treated acupoints (e.g., sacroiliac, neck, stomach, wrist, tonsil, and tongue), which would have had no effects on participants' sleep and mood status.
89026284|NCT00468065|Experimental|A|TO use Veinviewer to improve the effectiveness of IV starts in children
89026285|NCT00468065|No Intervention|B|Standard approach to placing IV s in children
89026286|NCT00492492|Other|trans-styloid and intrafocal pinning on the one side|trans-styloid and intrafocal pinning on the one side
89026287|NCT00492492|Other|volar fixed-angle plating on the other side|volar fixed-angle plating on the other side
89026288|NCT05653453|Experimental|Tumor treating fields combined with Gemcitabine hydrochloride and albumin binding paclitaxel|"Device: Tumor treating fields Subjects will use tumor treating fields each day~Drug: Gemcitabine hydrochloride and albumin binding paclitaxel 28 days is a cycle. On the 1st, 8th and 15th days of each cycle, 125 mg/m2 albumin binding paclitaxel will be administered intravenously，1000 mg/m2 gemcitabine hydrochloride will be administered immediately after the infusion of albumin binding paclitaxel."
89026289|NCT05653453|Active Comparator|Gemcitabine hydrochloride and albumin binding paclitaxel|Drug: Gemcitabine hydrochloride and albumin binding paclitaxel 28 days is a cycle. On the 1st, 8th and 15th days of each cycle, 125 mg/m2 albumin binding paclitaxel will be administered intravenously，1000 mg/m2 gemcitabine hydrochloride will be administered immediately after the infusion of albumin binding paclitaxel.
89558488|NCT03962348|Experimental|Specialized Early Engagement Support Service|The investigators will implement a Specialized Early Engagement Support Service (SEESS) in the same three jails. The SEESS will increase the likelihood that referred individuals found to have first-episode psychosis enroll in Coordinated Specialty Care upon release.
89558489|NCT03961893|Experimental|Arm A: Standard colonoscopy then colonoscopy with G-EYE|Arm A: Standard colonoscopy then colonoscopy with G-EYE
89558490|NCT03961893|Experimental|Arm B: G-EYE colonoscopy then standard colonoscopy|Arm B: G-EYE colonoscopy then standard colonoscopy
89558491|NCT03958760||Diabetic patients with CVD, CKD or at risk|The group A include all diabetic patients with established cardiovascular disease, chronic kidney disease, or at high cardiovascular risk.
89558492|NCT03958760||Diabetic patients without CVD, CKD or at risk|The group B include all diabetic patients without established cardiovascular disease, chronic kidney disease, or at high cardiovascular risk.
89026290|NCT00468182||1|MS patients or patients with CIS (Clinically isolated syndrome) who decided to be treated with IFN-beta for 3 months (with the option to continue Rx)
89026291|NCT00468182||2|MS patients or patients with CIS(Clinically isolated syndrome)who decided to postpone the treatment with IFN-beta
89026292|NCT05653375|Experimental|mindfulness-based psychoeducation program|The group in which the mindfulness-based psychoeducation program was applied.
89558493|NCT03958760||Non-diabetic patients with CVD, CKD or at risk|The group C included all non-diabetic patients with established cardiovascular disease, chronic kidney disease, or at high cardiovascular risk.
89558494|NCT03958760||Health controls|The group D included non-diabetic patients without established cardiovascular disease, chronic kidney disease, and not at high cardiovascular risk.
89558495|NCT03945669|Active Comparator|Intramedullary Nail|Intramedullary Nailing: Alignment will be obtained by closed or limited open reduction of the fracture. A standard reamed intramedullary nail is inserted. Access above the patella, through the patella tendon or parapatellar access is used according to surgeon preferences. One or more cortical screws may be used if deemed appropriate due to fracture pattern. Patients are administered preoperative antibiotics (Dicloxacillin) 15 minutes before surgery commences. Postoperative antibiotics is administered by discretion of the surgeon based on individual patient considerations.
89558496|NCT03945669|Experimental|External Ring fixator|External Ring fixation: Closed or limited open reduction of the fracture is performed. A circular frame is attached on both sides of the fracture. Connection to the bone is obtained by hydroxyapatite coated half pins and/or k-wires with olives as needed according to surgeon preferences. One or more cortical screws may be used if deemed appropriate due to fracture pattern. After applying the ring fixator alignment is assessed radiologically and corrected both peri- and postoperatively. Patients are administered preoperative antibiotics (Dicloxacillin) preoperatively 15 minutes before surgery commences. Following surgery antibiotics are continued until wounds, pin- and wire perforations are dry.
89558497|NCT03940950|Experimental|SVF (Stromal Vascular Fraction) Group|Subjects with knee osteoarthritis (OA) will receive Autologous Adipose-Derived SVF (Stromal Vascular Fraction) cells
89558498|NCT03940950|Placebo Comparator|Placebo Group|Subjects with knee osteoarthritis (OA) will be treated with a placebo
89026293|NCT05653375|Active Comparator|control group|The group in which no intervention was made and only the pre-test and post-test were applied for comparison.
89208414|NCT00740051|Placebo Comparator|Placebo|First 18 weeks of treatment
89558499|NCT03938688|Other|Transfascial sutures for mesh fixation|Mesh will be placed in the retromuscular space, with wide overlap on all sides. Full thickness transfascial sutures will be placed circumferentially to secure the mesh using slowly absorbable no. 1 sutures. A total of at least six transfascial sutures will be placed universally for all patients with additional sutures allowed according to each surgeon's discretion. Additional bone or ligament sutures for mesh fixation will be allowed according to each surgeon's discretion.
89558500|NCT03938688|No Intervention|No mesh fixation|Mesh will be placed in the retromuscular space, with wide overlap on all sides. No fixation method will be used. Bone or ligament sutures for mesh fixation will not be allowed.
89558501|NCT03937635|Experimental|Arm I (daratumumab, lenalidomide, dexamethasone)|Patients receive daratumumab IV on days 1, 8, 15, and 22 of courses 1-2, days 1 and 15 of courses 3-6, and day 1 of courses 7-24. Patients also receive lenalidomide PO daily on days 1-21 and dexamethasone PO on days 1, 8, 15, and 22 in courses 1-12. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
89558502|NCT03937635|Experimental|Arm II (lenalidomide, dexamethasone)|Patients receive lenalidomide PO daily on days 1-21 and dexamethasone PO on days 1, 8, 15, and 22 of courses 1-12. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
89558503|NCT03933176|Experimental|Simplified restorative procedure|After selective carious tissue removal, the universal adhesive (Adper Universal; 3M ESPE, St. Paul, MN, EUA) will be applied on the cavity walls. The cavity will be restored using a single increment of Filtek One Bulk Fill (3M ESPE, St. Paul, MN, EUA).
89558504|NCT03933176|Active Comparator|Control|A thin layer of resin-modified glass ionomer (Ionoseal (Voco America Inc., Briarcliff Manor, NY, EUA) will be placed on the pulpal floor of the cavity. Then, the adhesive and composite will be used following the same directions defined for the experimental condition.
89558505|NCT03924778|Experimental|DASH diet|calorie-restricted DASH diet (25% fat; 57% carbohydrate; 18% protein; 34 g fiber
88964925|NCT00005838|Experimental|Arm I (shark cartilage extract AE-941)|"Patients receive oral AE-941 (Neovastat) twice daily beginning on day 1 or within 10 days of initiation of chemotherapy.~All patients receive induction chemotherapy with 1 of the following platinum-based regimens: cisplatin IV on days 1, 22, 50, and 71 and vinorelbine IV on days 1, 8, 22, 29, 50, 57, 71, and 78 carboplatin IV over 30 minutes and paclitaxel IV over 3 hours on days 1, 22, 50, 57, 64, 71, 78, and 85.~All patients receive radiotherapy beginning on day 50 for 6 weeks. Treatment in both arms continues in the absence of unacceptable toxicity."
88964926|NCT00005838|Placebo Comparator|Arm II (placebo)|"Patients receive oral placebo twice daily beginning on day 1 or within 10 days of initiation of chemotherapy.~All patients receive induction chemotherapy with 1 of the following platinum-based regimens: cisplatin IV on days 1, 22, 50, and 71 and vinorelbine IV on days 1, 8, 22, 29, 50, 57, 71, and 78 carboplatin IV over 30 minutes and paclitaxel IV over 3 hours on days 1, 22, 50, 57, 64, 71, 78, and 85.~All patients receive radiotherapy beginning on day 50 for 6 weeks. Treatment in both arms continues in the absence of unacceptable toxicity."
88964927|NCT00005850|Experimental|gemcitabine + cisplatin + fluoxetine|Patients receive gemcitabine and cisplatin. Treatment repeats every 21 days for a total of six cycles. Patients receive fluoxetine for 7 weeks. Further use of fluoxetine is at the discretion of the patient and physician.
88964928|NCT00005856|Experimental|Treatment (oxaliplatin)|Patients receive oxaliplatin IV over 2 hours on day 1. Treatment repeats every 14 days for a maximum of 6 courses in the absence of unacceptable toxicity or disease progression.
88964929|NCT00005862|Experimental|Arm I|atients receive SU5416 IV twice weekly for 4 weeks. Treatment continues every 4 weeks in the absence of disease progression or unacceptable toxicity.
88964930|NCT00386490|Experimental|Larazotide acetate 0.25 mg|larazotide acetate 0.25 mg capsule TID for 10 days
88964931|NCT00386490|Experimental|Larazotide acetate 1 mg|larazotide acetate 1 mg capsule TID for 10 days
88964932|NCT00386490|Experimental|Larazotide acetate 4 mg|larazotide acetate 4 mg capsule TID for 10 days
88964933|NCT00386490|Experimental|Placebo|Placebo capsule TID for 10 days
88964934|NCT00005922|Experimental|A|Participants will receive 100% of the dose of the medication on the same reinforcement schedule (100%) as received during the baseline (maintenance) period.
88964935|NCT00005922|Experimental|B|Participants will receive 100% of the dose of the medication on a partial reinforcement schedule (25% or 50%) as received during the baseline (maintenance) period
88964936|NCT00005922|Experimental|C|Participants will receive 25% or 50% of the dose of the medication on the same reinforcement schedule (100%) as received during the baseline (maintenance) period.
88964937|NCT00005940|Experimental|Treatment (radiolabeled BC8, chemotherapy, PBSCT)|"RADIOLABELED ANTIBODY: Patients receive iodine I 131 monoclonal antibody BC8 IV on day -13.~CHEMOTHERAPY: Patients receive busulfan PO every 6 hours on days -7 to -4 and cyclophosphamide IV on days -3 and -2.~TRANSPLANT: Patients undergo allogeneic PBSC or BM transplant on day 0.~GRAFT-VS-HOST DISEASE PREVENTION: Patients receive cyclosporine IV or PO every 12 hours on days -1 to 50 with a taper to day 180. Patients also receive methotrexate IV on days 1, 3, 6, and 11."
88964938|NCT00005949|Experimental|Treatment (gp100:209-217, aldesleukin )|Patients receive gp100:209-217(210M) emulsified in Montanide ISA-51 SC on day 1 and interleukin-2 SC on days 1-5 and 8-13. Courses repeat every 21 days in the absence of unacceptable toxicity or disease progression. Patients with a CR receive 3 additional courses after achieving CR.
88964939|NCT00005961|Experimental|Arm I|Patients receive O6-benzylguanine IV over 1 hour, followed 1 hour later by carmustine IV over 1 hour on day 1. Treatment continues every 6 weeks for a minimum of 2 courses in the absence of disease progression or unacceptable toxicity.
89026294|NCT05653297||Group A (Control Group)|will undergo conventional dressing daily until the wound is ready for reconstruction, Then coverage of the wound with conventional tie over for 4 days.
89208415|NCT00740051|Active Comparator|Glimepiride|Placebo patients switch to glimepiride week19-52
89208416|NCT00864864|Experimental|Sunitinib|
88964940|NCT00005964|Experimental|Chemotherapy + prednisone + filgrastim|Patients receive doxorubicin IV, etoposide IV, vincristine IV, and cyclophosphamide IV continuously over days 1-4. Patients also receive oral prednisone twice daily on days 1-5 and filgrastim (G-CSF) subcutaneously beginning on day 6 until blood counts recover. Treatment continues every 21 days for a maximum of 8 courses in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 2 years and then every 6 months for 3 years.
88964941|NCT00005967|Experimental|Arm I|Patients receive oral tipifarnib twice daily for 21 days. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. After 1 course of therapy, patients may receive subsequent therapy at the maximum tolerated dose at the investigator's discretion.
89558506|NCT03924778|Active Comparator|standard American diet|calorie-restricted standard American diet (35% fat; 51% carbohydrate; %15 protein; 14 g fiber
88964942|NCT00005970|Experimental|Arm I (AC, paclitaxel, tamoxifen, aromatase inhibitor)|Patients receive doxorubicin hydrochloride IV and cyclophosphamide IV over 20-30 minutes on day 1. Treatment repeats every 3 weeks for 4 courses. Patients then receive paclitaxel IV over 1 hour beginning on day 1 of week 13 and continuing weekly for 12 courses in the absence of disease progression or unacceptable toxicity. Within 5 weeks after completion of paclitaxel, patients may undergo radiotherapy. All postmenopausal ER- or PR-positive patients receive oral tamoxifen or an aromatase inhibitor once daily for 5 years beginning no later than 5 weeks after the last dose of paclitaxel. Patients may also receive an aromatase inhibitor once daily for 5 years after 5 years of daily tamoxifen. Patients who receive tamoxifen once daily for less than 4.5 years may receive an aromatase inhibitor daily until they have received a total of 5 years of adjuvant hormonal therapy.
89026295|NCT05653297||Group B (Experimental Group)|NPWT (MEDWAY GROUP VAC) will be applied on a continuous mode between -75 & -150 mm Hg for 4 days per session for indefinite number of sessions until the wound is ready for reconstruction, Then it will be applied after coverage of the wound for 1 session.
89026296|NCT05649163||Cohort1|Cohort1: About 186 patients with histologically or cytologically confirmed gastric/gastroesophageal junction (GEJ) adenocarcinoma with HER2 overexpression who received a regimen containing Disitamab Vedotin;
89026297|NCT05649163||Cohort2|Cohort2: About 80 patients with histologically or cytologically confirmed HER2-overexpressed gastric cancer /GEJ adenocarcinoma who received an investigator-selected regimen in addition to Disitamab Vedotin;
89558507|NCT03922971|Other|National comparison|Ability to view center's rate compared with all others
89026298|NCT05649163||Cohort3|Cohort3: Approximately 40 patients with other advanced solid tumors histologically or cytologically confirmed with HER2-overexpression and receiving a regimen containing Disitamab Vedotin.
89026299|NCT05652010|Experimental|New Coupling|
89558508|NCT03922971|Other|National comparison with benchmarking|Ability to view center's rate compared with the others with a similar patient comorbidity profile and in addition to viewing option 1
89558509|NCT03921554|Experimental|Aicardi Goutières Syndrome patients receiving Baricitinib|Baricitinib will be taken by mouth or via gastrostomy feeding tube or nasogastric tube as directed by the study doctor. Baricitinib will be dosed by patient age, weight range and estimated glomerular filtration rate (eGFR). Dosing formulations in use in this study will include 1 mg and 2 mg tablets and will be used without splitting. Dispersion will be permitted to aid in swallowing.
89558510|NCT03892044|Experimental|Treatment (duvelisib, nivolumab)|Patients receive duvelisib PO BID on days 1-28 and nivolumab IV over 60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89558511|NCT03886038|Active Comparator|RA patients on JAK inhibitors|RA patients treated with JAK inhibitors as a monotherapy or in combination with methotrexate/other DMARDs/prednisone for at least 3 months will receive two doses of Shingrix vaccine administrated with at least 2 months apart
89558512|NCT03886038|Active Comparator|healthy controls|healthy individuals without any rheumatic disease or not treated with any immunosupressive drug for any other condition will receive two doses of Shingrix vaccine administrated with at least 2 months apart
89558513|NCT03869749|Experimental|Learning to BREATHE Plus|It is a 6-week manualized program; each meeting is 1.5 hours, for a total of 9 contact hours. It will be administered in a classroom at Colorado State University. Adolescents will be sent ecological momentary intervention text messages several times a day (with reminders, encouragement, and guides to practice mindfulness), and also have access to an on demand online library of mindfulness resources.
89558514|NCT03869749|Active Comparator|Health and wellness|It is a 6-week program; each meeting is 1.5 hours, for a total of 9 contact hours. It will be administered in a classroom at Colorado State University.
89558515|NCT03868891|Experimental|EMST150|Subjects with or without cleft palate will use the EMST150 2 times a day for 8 weeks.
89558516|NCT03867851|Experimental|IBsolvMIR|Study drug IBsolvMIR administered intravenously at 18 mg/kg on day of transplantation and 3 mg/kg on post-operative days 1, 3, 6.
89558517|NCT03867851|Active Comparator|Heparin|Heparin treatment according to clinical praxis.
89558518|NCT03857490|Experimental|Intervention|Lower leg heat therapy via water immersion up to the knee in a circulated bath (water temperature 42°C, 4 times per week, 45 minutes per session) for 8 weeks.
89558519|NCT03857490|Placebo Comparator|Control|Lower leg immerse in a thermoneutral water bath (33°C), 4 times per week, 45 minutes per session for 8 weeks.
89558520|NCT03851458||Consumo de Opciones Mas Ideales De Alimento (COMIDA)|Participants will be placed in either individual or group interventions by convenience. Recruitment will be consecutive and participants will be placed in either intervention depending on what resource is available on a given day at the VDS, individual counselor or a group educator.
89558521|NCT03851458||SANOS|Conducting SANOS Focus Groups. We will conduct 3-5 focus groups (in Spanish) with 6-10 participants each, until saturation. Bilingual study staff will approach individuals visiting the VDS and VDS Mobile for potential participation. A brief screening questionnaire will be administered, and a BMI assessment conducted, to ascertain eligibility. Focus groups will be scheduled at the VDS Mobile unit at times convenient to participants. Participants will be verbally consented in Spanish, and will be apprised that their participation is purely voluntary and that their names will not be included in the final narrative. The 6-month follow-up and my plate dietary surveys can be done over phone. Study staff will access step counts (or obtain it through phone via the pedometer manual provided to the participant) and upload data onto the REDCap tracking tool. Staff may ask participants to report step counts captured by their personal devices (i.e., phone or smartwatch).
89026300|NCT05652010|Active Comparator|Comparator Device|
89026301|NCT05650684||"exclusive breastfeeding group"|Women initiating exclusive breastfeeding after birth
89558522|NCT03851458||ROADmAP schema|Participants will be randomly assigned to one of eight study groups which will be one or a combination of 4 conditions: (1) in person individualized diet and exercise counseling (2) diet and exercise text messages (3) weekly telephone support and (4) self-monitoring tools for diet and weight. For the first part of the study, Survey, approximately 64 drivers and 36 management staff will take pate in the feedback questionnaire. For the second part of the study, Interview, approximately 8 drivers and 12 management staff may be invited to take part in an interview via phone, in person, or teleconference (Zoom).
89558523|NCT03851250|Experimental|MRx-4DP0004|"MRx-4DP0004 is a Live Biotherapeutic Product containing 10^9 to 10^10 Colony Forming Units.~Participants randomised to this arm will take 2 capsules twice daily at approximately 12 hour intervals for 12 weeks."
89558524|NCT03851250|Placebo Comparator|Placebo|"Participants randomised to this arm will take 2 capsules of placebo twice daily at approximately 12 hour intervals for 12 weeks.~All participants will receive placebo in a single blind manner for two weeks in addition to the 12 weeks of double blind treatment."
89558525|NCT03850912|No Intervention|Activity 1: Stakeholder Feedback|"Obtain stakeholder feedback to inform eSyM finalization and implementation from:~patient advisory councils~health system leaders~clinicians~clinic support staff/administration~IT/Informatics"
89558526|NCT03850912|No Intervention|Activity 2: eSym Build|"Build and deploy eSyM~Finalize training materials based on findings from stakeholder engagement"
89558527|NCT03850912|Experimental|Activity 3: Pilot Test eSyM App|"Pilot testing of the eSyM app will include:~Activity 3a (eSyM app usage by patients)~Activity 3b (User acceptability testing)~Activity 3c (Medical record abstraction)"
89026302|NCT00465491|Experimental|1|Picoplatin
89026303|NCT00465491|Other|2|BSC
89026304|NCT00499512||Spirituality Questionnaire|Patients with newly diagnosed ovarian, primary peritoneal, or fallopian tube cancer.
89558528|NCT03850912|Experimental|Activity 4: eSyM+ Participants|"These patients (and/or proxy) will report their symptoms in eSyM~A subset of these patients will be asked to complete a research questionnaire called the SASS Questionnaire (eSyM+ version or eSyM-Non-Responder version)~A medical record abstraction will be completed for ALL eSyM+ patients"
89558529|NCT03850912|Experimental|Activity 4: eSyM- Participants|"These patients (and/or proxy) will NOT report their symptoms in eSyM~A subset of these patients will be asked to complete a research questionnaire called the SASS Questionnaire (eSyM- version)~A medical record abstraction will be completed for ALL eSyM- patients"
89026305|NCT01379521|Experimental|everolimus + TACE|everolimus 7.5mg/day by mouth + transcatheter arterial chemoembolization (TACE)
89558530|NCT03827655|Placebo Comparator|Placebo|TAK-954 placebo-matching, 60-minute infusion, intravenously (IV), once presurgery on Day 1 and once daily postsurgery until return of upper and lower GI function or for up to 10 days.
89558531|NCT03827655|Experimental|TAK-954 0.1 mg/100 mL|TAK-954 0.1 milligrams per 100 milliliters (mg/100 mL), 60-minute infusion, IV, once presurgery on Day 1 and once daily postsurgery until return of upper and lower GI function or for up to 10 days.
89558532|NCT03827655|Experimental|TAK-954 0.5 mg/100 mL|TAK-954 0.5 mg/100 mL, 60-minute infusion, IV, once presurgery on Day 1 and once daily postsurgery until return of upper and lower GI function or for up to 10 days.
89558533|NCT03827655|Experimental|TAK-954 0.1 mg/100 mL + Placebo|TAK-954 0.1 mg/100 mL, 60-minute infusion, IV, once presurgery on Day 1 and once daily placebo infusions postsurgery up to Day 10 or until resolution of upper and lower GI function.
89558534|NCT03827655|Experimental|TAK-954 0.5 mg/100 mL + Placebo|TAK-954 0.5 mg/100 mL, 60-minute infusion, IV, once presurgery on Day 1 and once daily placebo infusions postsurgery up to Day 10 or until resolution of upper and lower GI function.
89558535|NCT03810651|Other|Renal tumors|Any patient with Wilms tumor or clear cell sarcoma of the kidney who would require radiation therapy as standard of care. Patients may receive an investigation drug for Wilms or CCSK given concurrently or within the first four weeks of the first fraction of proton therapy administration.
89026306|NCT01379521|Placebo Comparator|placebo + TACE|Placebo by mouth + transcatheter arterial chemoembolization (TACE)
89026307|NCT01371994|Experimental|Solifenacin succinate|Participants received 5 mg solifenacin succinate tablets once a day for 12 weeks. At week 4, based on efficacy and safety and in agreement with the investigator, the dose might be increased to 10 mg (2 tablets of 5 mg) once daily.
89026308|NCT01371994|Placebo Comparator|Placebo|Participants received matching placebo tablets once a day for 12 weeks.
89026309|NCT00465608|Experimental|1|propranolol
89026310|NCT01245777|Experimental|ferric carboxymaltose|Hb> 11 g/dl and Ferritin < 35 (controlled by CRP): 500mg to correct iron deficiency Hb ≥ 10 and < 11g/dl; Ferritin < 35 (controlled by CRP): 700 mg Hb ≥9 and < 10 g/dl; Ferritin < 35 (controlled by CRP): 800 mg Hb < 9g/dl; Ferritin < 35 (controlled by CRP): 900 mg
89026311|NCT00468338||BIS monitor used for all subjects|BIS monitor applied to all subjects
89026312|NCT01371877|Experimental|Vitamin D3 4000 IU|"Subjects will be randomized 1:1 to high dose vitamin D defined as 4000 IU per day for 3 months.~Subjects will be given Vitamin D3 supplementation at 4000 IU daily."
89026313|NCT01371877|Active Comparator|Vitamin D3 600 IU|"Subjects will be randomized 1:1 to low dose vitamin D as defined as 600 IU per day for 3 months.~Subjects will be given Vitamin D3 supplementation at 600 IU daily"
89026314|NCT00492609||1|PATIENTS WITH COMPUTER-ASSISTED
89026315|NCT00492609||2|PATIENTS WITHOUT COMPUTER-ASSISTED
89026316|NCT01245816|Experimental|Eflornithine plus Sulindac|Eflornithine 500 mg and Sulindac 150 mg
89026317|NCT01245816|Active Comparator|Elfornithine plus Placebo|Eflornithine 500 mg and Placebo
89026318|NCT01245816|Active Comparator|Sulindac plus Placebo|Sulindac 150 mg and Placebo
89026319|NCT01371838|Experimental|Ceftaroline|
89026320|NCT01371838|Active Comparator|Ceftriaxone plus placebo|
89026321|NCT01245855|No Intervention|PGE1 group and control group|the control group: received only the conventional medications, the PGE1 group: received additional 20 micrograms/day of lipo-PGE1 intravenously, starting at least 24 hours before PCI and continuing for 5 days
89558536|NCT03809780|Experimental|Lenalidomide,dexamethasone|"High dose for intermediate risk group: lenalidomide 25mg day 1-21 plus dexamethasone 20mg weekly, every 4 weeks~Low dose for high risk group: lenalidomide 15mg day 1-21 plus dexamethasone 10mg weekly, every 4 weeks Schedule"
89558537|NCT03802604|Experimental|Talimogene laherparepvec + Atezolizumab|"Talimogene laherparepvec: Cycle 1 - 10^6 PFU/mL. Cycle 2, 3, 4 & 5 - 10^8 PFU/mL.~Atezolizumab 840 mg"
89558538|NCT03801382|Other|Digital / Paper|Phase 1: Participants' cognition is measured using digital tests. Phase 2: Participants' cognition is measured using paper-pencil tests.
89558539|NCT03801382|Other|Paper / Digital|Phase 1: Participants' cognition is measured using paper-pencil tests. Phase 2: Participants' cognition is measured using digital tests.
89558540|NCT03801382|Other|Digital / Digital|Phase 1: Participants' cognition is measured using digital tests. Phase 2: Participants' cognition is measured using digital tests.
89558541|NCT03801382|Other|Paper / Paper|Phase 1: Participants' cognition is measured using paper-pencil tests. Phase 2: Participants' cognition is measured using paper-pencil tests.
88964943|NCT00005970|Experimental|Arm II (AC, paclitaxel, trastuzumab, tamoxifen)|Patients receive doxorubicin hydrochloride, cyclophosphamide, and paclitaxel as in arm I. Patients then receive trastuzumab (Herceptin®) IV over 30-90 minutes beginning on day 1 of week 25 and continuing weekly for 52 courses in the absence of disease progression or unacceptable toxicity. Within 5 weeks after completion of paclitaxel, patients may undergo radiotherapy. All postmenopausal ER- or PR-positive patients receive oral tamoxifen or an aromatase inhibitor once daily for 5 years beginning no later than 5 weeks after the last dose of paclitaxel. Patients may also receive an aromatase inhibitor once daily for 5 years after 5 years of daily tamoxifen. Patients who receive tamoxifen once daily for less than 4.5 years may receive an aromatase inhibitor daily until they have received a total of 5 years of adjuvant hormonal therapy.
89026322|NCT00473603|Experimental|LHI|to perform an i.v. lipid heparin infusion for 4 h
89026323|NCT00473603|Sham Comparator|SHI|to perform an i.v. saline heparin infusion for 4 h
89026324|NCT00492765|Experimental|1|interferon beta-1a and Simvastatin
89558542|NCT03801382|Other|Digital|Phase 1: Participants' cognition is measured using digital tests. Phase 2: N/A
89558543|NCT03800680|No Intervention|Usual Care (Arm 1)|Participants will receive usual care by their diabetes clinics.
89558544|NCT03800680|Experimental|DMP (Arm 2)|Participants will receive usual care by their diabetes clinics and the Diabetes Management Package (DMP).
89558545|NCT03800680|Experimental|DMP + M-POWER Rewards (Arm 3)|Participants will receive usual care by their diabetes clinics, the Diabetes Management Package (DMP), and the financial incentive program, M-POWER Rewards.
89558546|NCT03793361|Experimental|Arm A|Regorafenib
89558547|NCT03793361|Placebo Comparator|Arm B|Placebo
89026325|NCT00492765|Placebo Comparator|2|Interferon beta-1a and Placebo
89026326|NCT00499629|Active Comparator|1|Arm 1: FXR 450
89026327|NCT00499629|Placebo Comparator|2|Placebo
89026328|NCT01371721|Experimental|Desvenlafaxine Succinate Sustained-Release|
89558548|NCT03786406||T2DM patients seen in routine practice|All anti-diabetic and cardiovascular (CV) medication will be prescribed at the physician's discretion under routine clinical practice conditions.
89558549|NCT03785873|Experimental|Nal-Irinotecan and Nivolumab|
89558550|NCT03783507|Experimental|Order 1|Meal 1, Meal 2, Meal 3, Meal 4
89558551|NCT03783507|Experimental|Order 2|Meal 2, Meal 3, Meal 4, Meal 1
89558552|NCT03783507|Experimental|Order 3|Meal 3, Meal 4, Meal 1, Meal 2
89558553|NCT03783507|Experimental|Order 4|Meal 4, Meal 1, Meal 2, Meal 3
89558554|NCT03783195|Experimental|High GRS group|This group consists of individuals who are in the highest quartile of the genetic risk score (GRS) and will ingest one sugar drink (equal to 2 soft drinks) per day for 3 weeks. The GRS is computed by adding the number of alleles that increase the risk for liver lipogenesis or fatty liver.
89558555|NCT03783195|Experimental|Low GRS group|This groups consists of individuals who are in the lowest quartile of the genetic risk score (GRS) and will ingest one sugar drink (equal to 2 soft drinks) per day for 3 weeks. The GRS is computed by adding the number of alleles that increase the risk for liver lipogenesis or fatty liver.
89558556|NCT03782064|Experimental|Nivolumab+DC/myeloma fusions/GM-CSF|"Nivolumab will be given every two weeks~The DC/myeloma fusion vaccine/GM-CSF is administered 4 days per cycle"
89558557|NCT03773471|No Intervention|Control Arm|Standard of care
89558558|NCT03773471|Experimental|Intervention Arm|Mobile Health App
89558559|NCT03772522|Experimental|Immediate dk Leadership Intervention|"Participants allocated to the immediate intervention group are assessed for study outcomes immediately prior to the 6-week dk Leadership intervention and immediately after the intervention.~Outcomes measured immediately post-intervention are compared with participants who have not received the intervention during the 6 weeks.~After the delayed intervention group takes the intervention, the two groups are joined into a single arm."
89026329|NCT00473720|Experimental|satraplatin abraxane|Satraplatin and abraxane will be given in escalating cohorts on a 3 + 3 design from satraplatin 40mg/m2 and abraxane 80mg/m2
89026330|NCT00492804|Other|Neurectomy|
89558560|NCT03772522|Placebo Comparator|Delayed dk Leadership Intervention|"Participants allocated to this arm receive 6 weeks of no intervention. Outcomes are measured immediately before and immediately after the 6 week period. The change in outcomes are compared with participants who have received the intervention during the 6 week period.~This group then receives the same dk Leadership intervention; after this point, the two groups are joined into a single arm for subsequent analyses."
89558561|NCT03764488|Experimental|BIIB067 High Dose + 99mTc-MAG3-BIIB067 in 15 mL aCSF|Participants will receive intrathecal injection consisting of unlabeled BIIB067 and 99mTc-MAG3-BIIB067 in 15 milliliter (mL) artificial cerebrospinal fluid (aCSF).
88964944|NCT00005970|Experimental|Arm III (AC, paclitaxel, trastuzumab, tamoxifen)|"Patients receive doxorubicin hydrochloride and cyclophosphamide as in arm I. Patients then receive paclitaxel IV over 1 hour and trastuzumab IV over 30-90 minutes beginning on day 1 of week 13 and continuing weekly for 12 courses. Patients then receive trastuzumab IV over 30 minutes beginning on day 1 of week 25 and continuing weekly for 40 courses in the absence of disease progression or unacceptable toxicity.~Within 5 weeks after completion of paclitaxel, patients may undergo radiotherapy. All postmenopausal ER- or PR-positive patients receive oral tamoxifen or an aromatase inhibitor once daily for 5 years beginning no later than 5 weeks after the last dose of paclitaxel. Patients may also receive an aromatase inhibitor once daily for 5 years after 5 years of daily tamoxifen. Patients who receive tamoxifen once daily for less than 4.5 years may receive an aromatase inhibitor daily until they have received a total of 5 years of adjuvant hormonal therapy."
88964945|NCT00005973|Experimental|Treatment|Patients receive BMS-214662 IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity.
88964946|NCT00005976|Experimental|Arm I|"Patients receive carboplatin IV over 30 minutes and pyrazoloacridine IV over 3 hours on day 1. Treatment continues every 28 days in the absence of unacceptable toxicity or disease progression.~Cohorts of 3-6 patients receive escalating doses of carboplatin and pyrazoloacridine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity."
88964947|NCT00005976|Experimental|Arm II|Patients receive the same treatment as given in study 1. Dose escalation is performed as in study 1 to determine the MTD in patients not receiving concurrent anticonvulsants.
88964948|NCT00005976|Experimental|Arm III|Patients receive the same treatment as given in studies 1 and 2 without dose escalation.
88964949|NCT00005982|Experimental|Treatment (nelarabine)|Patients receive 506U78 IV over 2 hours on days 1, 3, and 5. Treatment continues every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
88964950|NCT00005988|Experimental|in vitro-treated bone marrow transplantation|"Donor bone marrow will be harvested on Day -2~Bone Marrow incubated with irradiated recipient cells and anti-B7.1 and anti-B7.2 for 36 hours.~Bone marrow will be infused intravenously~Cyclophosphamide will be administered IV once daily~Total Body Irradiation (TBI) will be delivered per institutional practice~Methylprednisolone will be administered IV as 4 doses separated by 12 hours,"
88964951|NCT00006003|Experimental|Treatment (semaxanib)|Patients receive SU5416 IV over 60 minutes twice weekly for 4 weeks. Treatment continues for a minimum of 2 courses in the absence of unacceptable toxicity or disease progression.
89558562|NCT03764488|Experimental|BIIB067 Low Dose + 99mTc-MAG3-BIIB067 in 15 mL aCSF|Participants will receive intrathecal injection consisting of unlabeled BIIB067 and 99mTc-MAG3-BIIB067 in 15 mL aCSF.
89558563|NCT03764488|Experimental|BIIB067 Low Dose + 99mTc-MAG3-BIIB067 in 5 mL aCSF|Participants will receive intrathecal injection consisting of unlabeled BIIB067 and 99mTc-MAG3-BIIB067 in 5 mL aCSF.
88964952|NCT00006006|Experimental|Arm I|Patients receive oral thalidomide once daily. Patients on a stable dose of thalidomide for at least 4 weeks with evidence of progressive disease receive interferon alfa subcutaneously twice daily. Treatment continues in the absence of disease progression after initiation of interferon alfa therapy or unacceptable toxicity.
88964953|NCT00006012|Experimental|topotecan + paclitaxel + filgrastim + TRT + radiation|"Patients receive topotecan IV on days 1-5 and paclitaxel IV over 3 hours on day 5. Patients receive filgrastim (G-CSF) subcutaneously (SC) daily beginning 24 hours after the last dose of chemotherapy and continuing until blood counts recover. Treatment repeats every 3 weeks for 2 courses.~After 2 courses of treatment, patients undergo TRT twice daily for 5 consecutive days for 5 weeks. During TRT, patients receive cisplatin IV, oral etoposide, and amifostine SC daily prior to TRT.~At 4 weeks after completion of TRT, patients receive 2 additional courses of topotecan, paclitaxel, and G-CSF every 3 weeks followed by prophylactic cranial irradiation.~Patients are followed every 3 months for 1 year, every 4 months for 1 year, and then every 6 months for 3 years."
88964954|NCT00006015|Experimental|Combination Chemotx|Combination chemotherapy for metastatic colorectal cancer in patients who have disease progression after 5-FU and/or irinotecan-containing therapy
88964955|NCT00006024|Experimental|Pre and Post radiation Chemotherapy|
88964956|NCT05681013|Experimental|Laughter Therapy Group|A pre-test was administered to all students. In the pre-test application, the Descriptive Information Form, General Health Questionnaire-28, Pittsburgh Sleep Quality Index and Perceived Stress Scale were applied. Experimental and control groups were formed randomly among the students who filled all the scales. Communication groups were established for the students in both groups without being told which group they belonged to. Considering the hours suitable for the experimental group, 8 sessions of laughter therapy were applied for an average of 45 minutes. At the end of the therapy in the last session, a post-test was administered to all of the students. In the post-test application, the Descriptive Information Form, General Health Questionnaire-28, Pittsburgh Sleep Quality Index, and Perceived Stress Scale were applied.
88964957|NCT05681013|No Intervention|Control Group|In the pre-test application, the Descriptive Information Form, General Health Questionnaire-28, Pittsburgh Sleep Quality Index, and Perceived Stress Scale were applied. At the end of the therapy in the last session, a post-test was administered to all students. In the post-test application, the Descriptive Information Form, General Health Questionnaire-28, Pittsburgh Sleep Quality Index, and Perceived Stress Scale were applied.
88964958|NCT05680935|Experimental|atherosclerosis of the brachiocephalic arteries|The recruitment of patients will be carried out at the University Clinical Hospital No. 1 of the Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University). The study will include up to 50 people - the study group with atherosclerosis of the brachiocephalic arteries.
88964959|NCT05680935|Experimental|No brachiocephalic atherosclerosis|The recruitment of patients will be carried out at the University Clinical Hospital No. 1 of the Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University). Up to 30 people - the control group without brachiocephalic atherosclerosis.
88964960|NCT05680701|Active Comparator|real tACS|The investigators will administer the transcranial alternating current stimulation (tACS) intervention at 10 Hz to the participants. This intervention will utilize 6 electrodes; electrode placement and current parameters for each electrode have been optimized using a standard brain to generate an average electric field of 0.25 V/m. To ensure adherence to current safety recommendations for tACS, optimizations will be constrained to a maximum of total injected current 4.0 mA and a max. current per electrode of 2.0 mA. Stimulation will start and end with a 60 s ramp up/down to maximize comfort. This standard approach is both well-tolerated and safe in older adults. In a separate visit, we will use an active sham in which very low-level currents (0.5 mA total) will be transferred between electrodes in close proximity on the scalp throughout the entire 20-minute session.
88964961|NCT05680701|Sham Comparator|sham tACS|The investigators will administer the sham tACS intervention to the participants. They will use an active sham in which very low-level alternating currents (0.5 mA total) will be transferred between electrodes in close proximity on the scalp throughout the entire 20-minute session.
88964962|NCT05680662|Experimental|adjuvant quadruple thearpy of quercetin , zinc, EGCG, metformin for 100 breast cancer cases|experimental study of adjuvant quadruple therapy of quercetin, zinc, EGCG, and metformin for 100 cases of different types of breast cancer women daily dose as follows daily 500 mg orally quercetin OD daily 50 mg zinc sulfate orally OD daily 300 mg EGCG orally OD daily metformin 850 mg orally OD during chemotherapy courses and until last stage of treatment
88964963|NCT05680662|Experimental|no adjuvant thearpy for 100 cases of breast cancer breast for this group ( controlled group )|this arm ( 100 cases controlled group not taken adjuvant therapy only was taken the regular chemotherapy as prescription
88964964|NCT05680506|Experimental|Pain neuroscience education group|Pain neuroscience education 10- 15min Hot pack(10 min) TENS Kaltenborn Moilization technique at L4-L5 segment stretchings and stabilization exercises. (5 reps/1 set) Total duration:40 min/session
88964965|NCT05680506|Active Comparator|Standard therapy group|Hot pack(10 min) TENS Kaltenborn Mobilization technique at L4-L5 segment stretchings and stabilization exercises (5 reps /1 set) Total duration:30 min/session
88964966|NCT05680389|Experimental|Minocycline|100 mg twice daily for 3 months
88964967|NCT05680389|Placebo Comparator|Placebo|twice daily for 3 months
88964968|NCT05680350|Active Comparator|Study group|"Study group Patients with unexplained infertility had estimated their Plasma Expression level for GeneMicro RNA 203 & 210 by qRT-PCR followed by laparoscopic exploration"
88964969|NCT05680350|Active Comparator|Control Group|Control group Patients with unexplained infertility underwent laparoscopy only
88964970|NCT05679687|Experimental|Treatment|In this study, allogeneic anti-CD19 CAR T cells (ThisCART19A) infusion is used as a bridge therapy to hematopoietic stem cell transplantation to treat patients with refractory or relapsed CD19 positive B cell acute lymphoblastic leukemia. Lymphodepletion conditioning before CAR T cell infusion consists of fludarabine, CTX and VP-16.
88964971|NCT05679609|Experimental|group 1|participants would use incentive spirometry for 2 months together with ordinary medical treatment
88964972|NCT05679609|No Intervention|group 2|participants would receive only ordinary medical treatment for 2 months
88964973|NCT00386841|Active Comparator|A Escitalopram 10 mg|Escitalopram 10 mg
88964974|NCT00386841|Placebo Comparator|Placebo|Placebo
88964975|NCT05679453|Active Comparator|Etodolac|Etodolac, 400 mg tid per a day for four days
88964976|NCT05679453|Active Comparator|Lornoxicam|Lornoxicam, 8 mg twice per day for four days
88964977|NCT05679414||Study group|Covid 19 patients in which MTHFR C677T genotypes was determined by RT- PCR of 2 ml EDTA blood sample.Follow up patient for 28 days as regard development of vascular thrombotic manifestation
88964978|NCT05679414||Control group|Healthy subjects in which MTHFR C677T genotypes was determined by RT- PCR of 2 ml EDTA blood sample.
88964979|NCT05679375|Active Comparator|Intrathecal Ketamine|Patients will receive intrathecal Ketamine 0.1mg/kg added to bupivacaine and morphine.
88964980|NCT05679375|Active Comparator|Intravenous ketamine|Patients will receive IV Ketamine 0.25mg/kg after spinal anesthesia with bupivacaine and morphine.
88964981|NCT05679336|Experimental|Rituximab, Cyclophosphamide, and Corticosteroids group|The experimental treatment group: 40 participants will receive combined immunosuppressive therapy with Rituximab, Cyclophosphamide, and Corticosteroids.
88964982|NCT05677191|Experimental|proximal femoral nail|20 patient with trochanteric fractures , unstable type will use proximal femoral nail
88964983|NCT05677191|Active Comparator|Dual Mobility Arthroplasty|20 patient with trochanteric fractures , unstable type will use dual mobility arthroplasty
88964984|NCT05677035|Experimental|Pharmacokinetic evaluation|LINO-1713 (Estetrol 15mg/Drospirenone 3mg)
88964985|NCT05677035|Experimental|Pharmacodynamic evaluation|LINO-1713 (Estetrol 15mg/Drospirenone 3mg)
88964986|NCT05676957|Experimental|Study group|The subjects will be considered to be enrolled in the study group of the trial when all inclusion and exclusion criteria have been met, the informed consent form has been signed, and randomization to the study group of the trial to allow endovascular therapy with the Thermogard XP3 Intravascular Temperature Management (IVTM) System after recanalization.
88964987|NCT05676957|No Intervention|Control group|The subjects will be considered to be enrolled in the control group of the trial when all inclusion and exclusion criteria have been met, the informed consent form has been signed, and randomization to the control group of the trial.
88964988|NCT05675280||Iron deficiency at diagnosis|
88964989|NCT05675280||No iron deficiency at diagnosis|
88964990|NCT05670522|Experimental|Transcranial direct current stimulation group|Children assigned to the transcranial direct current stimulation group received active transcranial direct current at their primary motor cortex (Active dose 11, ser. No 13070350, Active Tek Inc., USA). Stimulation was conducted at an intensity of 1 mA for 20 min per session, 5 times/week for 2 successive weeks (total of 10 sessions). 1 mA was shown to be appropriate in children's investigations. The anode (+) was positioned on the midline sagittal plane of the skull, corresponding to the motor area of lower limbs, and the cathode (-) was positioned over the inion. In addition to their assigned intervention, the children received the standard-of-care gait training. During the two-week intervention phase, gait training was administered immediately after each intervention session. Training was delivered in one hour increments 5 times/week for those first two weeks, then 3 times/week for the next 10 weeks.
88964991|NCT05670522|Experimental|Virtual reality group|Children assigned to the virtual reality group received virtual balance training using Nintendo Wii and Wii Balance Board, with a custom training program developed from activities on the Wii Fit Plus game. Training was conducted for 30 minutes, 5 sessions/week for 2 successive weeks (total of 10 sessions). Two sessions with Wii Fit Plus were conducted before the treatment protocol to help the children familiarize with the VR setup. In addition to their assigned intervention, the children received the standard-of-care gait training. During the two-week intervention phase, gait training was administered immediately after each intervention session. Training was delivered in one hour increments 5 times/week for those first two weeks, then 3 times/week for the next 10 weeks.
88964992|NCT05632770|Experimental|Stepped Collaborative Care (Intervention)|Patients in the intervention condition will receive a stepped collaborative care intervention that includes posttraumatic concern elicitation, proactive care management, medication, and psychotherapy elements targeting posttraumatic stress disorder (PTSD) and related comorbidity.
88964993|NCT05632770|Active Comparator|American College of Surgeons (ACS) Required Screening and Referral (Usual Care)|Patients in the control condition will receive usual trauma center care with American College of Surgeons (ACS) required psychosocial screening and referral.
88964994|NCT05626725||Observationnal cohort|Patients with type 1 diabetes and using an AID system.
88964995|NCT05611203|Experimental|Oropharyngeal swab only including the posterior oropharyngeal wall|An Oropharyngeal swab is performed with the collection of specimens from the posterior oropharyngeal wall only
88964996|NCT05611203|Experimental|Oropharyngeal swab including the posterior oropharyngeal wall and both palatine tonsils|An Oropharyngeal swab is performed with the collection of specimens from the posterior oropharyngeal wall and both palatine tonsils
88964997|NCT05597163|Experimental|0.01% atropine|0.01% atropine eye drop
88964998|NCT05597163|Experimental|0.025% atropine|0.025% atropine eye drop
88964999|NCT05597163|Experimental|0.05% atropine|0.05% atropine eye drop
88965000|NCT05597163|Other|cross-over|first year: placebo second year: 0.05% atropine eye drop
88965001|NCT03983772|Experimental|RS10-10-10|First 2 weeks is for baseline variability measurement (no product). Second 2 weeks is 10 g resistant starch (RS) blend. Third 2 weeks is 10 g RS blend. Fourth 2 weeks is 10 g RS blend.
88965002|NCT03983772|Experimental|RS10-20-20|First 2 weeks are for baseline variability measurement (no product). Second 2 weeks is 10 g resistant starch (RS) blend. Third 2 weeks is 20 g RS blend. Fourth 2 weeks is 20 g RS blend.
88965003|NCT03983772|Experimental|RS10-20-30|First 2 weeks are for baseline variability measurement (no product). Second 2 weeks is 10 g resistant starch (RS) blend. Third 2 weeks is 20 g RS blend. Fourth 2 weeks is 30 g RS blend.
88965004|NCT03983772|Placebo Comparator|Placebo10-10-10|First 2 weeks are for baseline variability measurement (no product). Second 2 weeks is 10 g placebo. Third 2 weeks is 10 g placebo. Fourth 2 weeks is 10 g placebo.
88965005|NCT05550129|Experimental|AMG 510 + Metformin|
88965006|NCT05508204|Experimental|Cohort A|A single dose of BION-1301 will be administered subcutaneously on Day 1 at dose level A
88965007|NCT05508204|Experimental|Cohort B|A single dose of BION-1301 will be administered subcutaneously on Day 1 at dose level B
88965008|NCT05508204|Experimental|Cohort C|A single dose of BION-1301 will be administered subcutaneously on Day 1 at dose level C
88965009|NCT05489835||Employees|Employees in Austrian companies affected by digitalization
88965010|NCT05482698|Experimental|MC2-25 cream|MC2-25 cream Twice daily applications for 12 weeks
88965011|NCT05482698|Placebo Comparator|MC2-25 vehicle|MC2-25 vehicle Twice daily applications for 12 weeks
88965012|NCT05470101|Experimental|Cohort A1: ITI-333 2.25 mg|
88965013|NCT05470101|Experimental|Cohort A2: ITI-333 dose to be determined based on Cohort A1|
89026331|NCT00492804|Other|Nerve preservation|
89558564|NCT03764488|Experimental|BIIB067 Low Dose + 99mTc-MAG3-BIIB067 in up to 20 mL aCSF|Participants will receive intrathecal injection consisting of unlabeled BIIB067 and 99mTc-MAG3-BIIB067 in up to 20 mL aCSF.
89558565|NCT03763708|Experimental|Spinal Cord Stimulation|Each subject will be programmed to different settings.
89558566|NCT03761160|Experimental|Mobile Health App|"The developed mobile health app will include the following facets:~Physical activities~Dietary regimen.~The physical activities facet will encourage patients to engage in physical activities, with daily prompts, encouragement, and tips.~Users will be asked to record the type of physical activity they engaged in during the week, and for how long.~The dietary aspect will ask patients to log what they ate during the day and to rate how 'healthy' it is"
89558567|NCT03761160|Active Comparator|Usual Care|Usual care per hospital guideline
89558568|NCT03755518|Experimental|Administration of Fedratinib 400mg/day|Self-administered Investigational Product (IP) (400 mg/day) on an outpatient basis, once daily preferably with food during an evening meal at the same time each day in consecutive 4-week (28-day) cycles.
89026332|NCT01605448|Experimental|MBSR|Mindfulness Based Stress Reduction
89558569|NCT03753490|Other|ABC score guided therapy|Individual treatment recommendations based on the ABC-scores for stroke and bleeding.
89558570|NCT03753490|Other|Standard care|Management according to local practice, national and international guidelines.
89558571|NCT03739112|Experimental|Quadrivalent VLP Vaccine|Participants received one intramuscular (IM) injection of 0.5 mL of 30 μg/strain of the Quadrivalent VLP Influenza Vaccine on Day 0.
89558572|NCT03739112|Active Comparator|Fluarix Quadrivalent® Comparator Vaccine|Participants received one IM injection of 0.5 mL of 15 μg/strain of the Fluarix Quadrivalent® comparator vaccine on Day 0.
89558573|NCT03738072|Experimental|StiMic stimulation condition|StiMic stimulation condition will be evaluate during stereo-electro-encephalography and this condition will be compare to standard stimulation condition
89558574|NCT03724071|Experimental|Phase 1, Arm A - Dose escalation and safety of TG6002 and flucytosine combination|Dose escalation with repeated administrations of TG6002 in combination with flucytosine in patients with advanced gastro-intestinal (GI) tumors.
89558575|NCT03724071|Experimental|Phase 1, Arm B - Dose escalation and safety of TG6002 and flucytosine combination|Dose escalation with closer administrations of TG6002 in combination with flucytosine in patients with advanced gastro-intestinal (GI) tumors.
89558576|NCT03724071|Experimental|Phase IIa - Efficacy of TG6002 and flucytosine combination|Repeated administrations of TG6002 in combination with flucytosine in patients with colorectal cancer and liver metastases
89558577|NCT03709446|Experimental|Leflunomide|"Women with HER2-negative metastatic and/or locally advanced, inoperable breast cancer.~Leflunomide tablet orally daily"
89558578|NCT03708965|Experimental|JR-141|"Subjects will be assigned to 1.0, 2.0 or 4.0 mg of JR-141 per kg of body weight once every week (the same dose taken during the previous study) in the beginning of the study.~During the study, the dose of all subjects will be switched to the selected one*.~* The dose was determined to be 2.0 mg/kg/week based on the safety and efficacy data of JR-141-BR21 study."
89558579|NCT03708809|Experimental|Immediate insertion|The intrauterine system will be inserted immediately after surgical termination of pregnancy, before awakening from anesthesia
89558580|NCT03708809|Experimental|Delayed insertion|The intrauterine system will be inserted on the first menstruation after termination of pregnancy. Women allocated to this arm will be asked to contact the study coordinator in order to visit the hospital on the proper timing for IUD insertion.
89558581|NCT03708809|Other|Control|Women who refuse to actively participate in the intervention groups will be offered consultation on other options for contraception during gynecological clinic visit after fist menstruation from termination of pregnancy.
89558582|NCT03705910|Active Comparator|Perceptive Rehabilitation (PR-group)|"This treatment will include small latex cones with different resistance. In each session, over one hundred cones will be placed on a rigid wooden base using elastic strips. The patient will be asked to lie down supine on the material. Patients weigh will create pressure and reaction force to his/her body. Treatments will be 2 times a week till 8 weeks.~The therapist will ask the patient firstly to breathe normally and feel the pressure. The patient will then perform breathing exercises and active exercises (including stretching, warming up, and cooling down) under supervision. During the session, the therapist will ask about the pressure of the cones and will correct the patient's posture."
88965014|NCT05470101|Experimental|Cohort A3: ITI-333 dose to be determined based on Cohort A1 and A2|
88965015|NCT05470101|Experimental|Cohort A4: ITI-333 dose to be determined based on Cohort A1, A2 and A3|
88965016|NCT05320770|Experimental|TMD patients with joint hyper mobility|
88965017|NCT03940131|Experimental|Single Arm|Panitumumab with FOLFOX6/FOLFIRI
88965018|NCT05257044|Experimental|CBG|Participants will ingest 20 mg of CBG tincture in this arm
88965019|NCT05257044|Placebo Comparator|Placebo|Participants will ingest 20 mg of placebo tincture in this arm
88965020|NCT03939390|No Intervention|follicular phase stimulation|
88965021|NCT03939390|Experimental|luteal phase stimulation|
88965022|NCT05230173|Other|Switching Targeted Immunomodulators Treatment|"Participants randomized to a strategy of switching TIM will be switched to one of the preferred agents recommended by clinical guidelines and covered by the participants' insurance formulary as part of routine care, and at the discretion of the site investigator and treating provider. No study-related medications will be provided.~For participants randomized to switch to an alternative TIM, selection of alternative agent will be determined at the discretion of the local site physician in accordance with clinical guidelines on the management of moderate to severe ulcerative colitis, and management of moderate to severe CD from the AGA and ACG.9, 34, 35 These guidelines include recommendations on positioning of TIMs for first line use (TIM-naïve patients) and second-line use (in patients with prior exposure to TIMs)."
88965023|NCT05230173|Other|Continuing Index Targeted Immunomodulators Treatment|Participants randomized to a strategy of continuing TIM will continue on their concomitant therapy.
89558583|NCT03705910|Active Comparator|Mobilisation Techniques (Mob-group)|"A certified physiotherapist will perform mobilisation techniques. All participants in this group will receive treatment protocol according to the list on below. Treatments will be 2 times a week till 8 weeks.~For this treatment, the participant should lie on a bed and change their position according to the technique (supine, position or side-lying). Also, the therapist will be changing her position according to the technique. All technique will be on the range of motion limit. For releasing techniques the therapist will apply three-dimensional pressures till 3-5 minutes, with the feeling of relaxing therapist will change the limit for the next point."
89558584|NCT03705910|No Intervention|Control Group (C-group)|This group will not receive any intervention during this period. C-group will attend assessments.
89558585|NCT03701646||arterial line|Pediatric patients admitted to the ICU with a medically indicated arterial line.
89558586|NCT03701646||cardiac output|Pediatric patients requiring cardiac output measurement by thermodilution through cardiac catheterization.
88965024|NCT05196828|Active Comparator|Arm 1 - Direct Roll-Over Extension|24-wks of Active neurostimulation - Noninvasive peripheral nerve stimulation device programmed to deliver active stimulation; followed by 8-wks of No Intervention
88965025|NCT05196828|No Intervention|Arm 2 - Control Group|24-wks of No Intervention
88965026|NCT05178810|Experimental|FAB122|
88965027|NCT05178810|Placebo Comparator|Placebo|
88965028|NCT05173935|Active Comparator|PEG Group|Subjects will gastrostomy tube placement via percutaneous endoscopic gastrostomy (PEG) method.
88965029|NCT05173935|Active Comparator|RIG Group|Subjects will have the placement of a gastrostomy tube via radiologically-inserted gastrostomy (RIG) method.
88965030|NCT05173116||prospective study|API-VIGIE program adult participant who agreed to participate in the study
88965031|NCT05173116||retrospective study|Any stay for adults patients in the emergency room of the ARRAS hospital for API during the period covered (from 1 year before to 1 year after the installation of the APIVIGIE program) (main diagnosis or associated with an API (F10.0 according to the ICD-10 classification used by Department of Medical Information)
88965032|NCT05160519|Experimental|Experimental|30 participants will be irradiated with Class IV laser therapy over the left parasternal area to examine the effectiveness of Class IV laser.
88965033|NCT05160519|Sham Comparator|Sham Controlled|30 participants will subject to irradiation but the equipment will be kept off.
89026333|NCT01605448|No Intervention|Control Group|Continue in Usual care; offered the intervention at the end of the study
89208417|NCT00868686|Active Comparator|Volar aluminum splint|
89558587|NCT03689296||Users|Person with a long-term mental disorder
89558588|NCT03689296||Caregivers|Adult helping a person with a long-term psychological disorder
88965034|NCT05146167|Experimental|Bodhi AIM|Participants randomized to the intervention group will receive the Bodhi AIM app
88965035|NCT05146167|Active Comparator|HIB|Participants randomized to the health promotion control group will receive the HIB app
88965036|NCT05142540||blood and saliva sampling|blood and saliva samples will be taken
88965037|NCT05120037|Experimental|Active|
88965038|NCT05120037|Sham Comparator|Sham|
88965039|NCT05000307|Experimental|Volunteers, infected with COVID-19|
88965040|NCT00387270|Experimental|A|Dimebon
88965041|NCT00387387|Experimental|FOLFOX 6 + Pazopanib|Subjects will receive escalating doses of Pazopanib in combination with FOLFOX 6.
88965042|NCT00387387|Experimental|CapeOx + Pazopanib|Subjects will receive escalating doses of Pazopanib in combination with CapeOx. CapeOx treatment consisted of IV oxaliplatin (130 mg/m^2) on Day 1 plus oral capecitabine (1000 mg/m^2) twice daily on Days 2 through 14 of every 21-day cycle. Reduced CapeOx treatment was administered according to the same schedule as the CapeOx treatment, but the dose of capecitabine was reduced to 850 mg/m^2 twice daily.
88965043|NCT03865719|Other|Healthy Habits for Life Intervention|Participants will receive the Healthy Habits for Life Intervention
88965044|NCT04920825|Active Comparator|Sacha Inchi Oil softgel|Oral Sacha Inchi oil softgel supplement
88965045|NCT04920825|Placebo Comparator|Corn oil softgel|Oral corn oil softgel
88965046|NCT04833387|Experimental|PD-1 antibody + capecitabine + radiation|
88965047|NCT04831008|Active Comparator|Figure-of-eight|Using the figure-of-eight closure technique when closing access for structural heart therapies.
88965048|NCT04831008|Active Comparator|Perclose Device|Using the Perclose device when closing access for structural heart therapies.
89208418|NCT00868686|Active Comparator|Dorsal aluminum splint|
88965049|NCT04793685|Experimental|Active Drug|Prazosin (16mg/day) versus Placebo comparator, administered in t.i.d schedule, in capsules, over a 12 week period, with 2 weeks titration in weeks 1-2 and a 5-day taper in week 12.
88965050|NCT04793685|Placebo Comparator|Placebo Drug|Placebo for 12 weeks.
88965051|NCT04745676|Experimental|Experimental|The SICG program consists of the Serious Illness Conversation Guide as well as training and system-level support for physicians to conduct ACP conversations.
88965052|NCT04552080|Active Comparator|Test: Amoxicillin|
88965053|NCT04552080|Placebo Comparator|Comparator: Placebo|
88965054|NCT03834909|Active Comparator|Standard Dose Truvada®|Standard Dose Truvada® - Tenofovir disoproxil fumarate (TDF) 300 mg/Emtricitabine (FTC) 200 mg fixed dose combination (Truvada®), one tablet each day
88965055|NCT03834909|Experimental|Pregnancy-Adjusted Truvada®|Pregnancy-Adjusted dose Truvada® - Tenofovir disoproxil fumarate (TDF) 300 mg/Emtricitabine (FTC) 200 mg fixed dose combination (Truvada®), two tablets each day
88965056|NCT04380480|Experimental|Experiment|"One or two weeks before CCRT, all patients will undergo a percutaneous endoscopic gastrostomy (PEG) to be administered enteral nutrition support(30-35 kcal/kg of energy, 1.2-1.5g/kg of protein and electrolyte supplementation each day). Nutritional supplements will be administered till 1 month after CCRT.~All patients will receive definitive radiotherapy combined with three cycles of S-1 (40mg/2, BID, po) on D1-14, D22-35, D43-56."
88965057|NCT04330989|Experimental|Group 1a: iNSC and Adherence supporter training|HIV-positive women randomly assigned to the intervention arm will receive a multi-component support strategy comprising iNSC and adherence supporter training for ART.
88965058|NCT04330989|No Intervention|Group 1b: Standard of Care|HIV-positive participants randomly assigned to the control arm will antiretroviral educational material about HIV prevention and treatment (as appropriate to this arm).
88965059|NCT04330989|Experimental|Group 2a: iNSC and Adherence supporter training|HIV-negative women randomly assigned to the intervention arm will receive a multi-component support strategy comprising iNSC and adherence supporter training for PrEP.
88965060|NCT04330989|No Intervention|Group 2b: Standard of Care|HIV-negative participants randomly assigned to the control arm will receive educational material about HIV prevention and treatment (as appropriate to this arm).
88965061|NCT00423384|Experimental|1|Ibandronate
88965062|NCT00423384|Placebo Comparator|2|
88965063|NCT03988257|Experimental|Experimental group|Imunoglukan PH4 syrup (10 mg of pleuran and 10 mg of vitamin C in 1 ml of syrup) in a dose 1 ml / 5 kg body weight, once a day.
88965064|NCT03988257|Placebo Comparator|Control group|A vitamin C syrup (10 mg of vitamin C in 1 ml of syrup) in a dose 1 ml / 5 kg body weight.
88965065|NCT03913221|Active Comparator|Low Dose Caffeine (5 mg/kg)|Within 24 hours of delivery, participants will receive low dose administration of Caffeine citrate.
88965066|NCT03913221|Active Comparator|High Dose Caffeine (10 mg/kg)|Within 24 hours of delivery, participants will receive high dose administration of Caffeine citrate.
88965067|NCT03903549|Experimental|Brain uptake and kinetics in Parkinson patients|
88965068|NCT03903549|Experimental|Brain uptake and kinetics in healthy volunteers|
88965069|NCT03903549|Experimental|Dosimetry in healthy volunteers|
88965070|NCT03869736|Experimental|Nitrous Oxide 50% or 25%|Nitrous oxide at an inhaled concentration of 50% or 25%
88965071|NCT03869736|Sham Comparator|Placebo|Oxygen-air mixture
88965072|NCT03741933|Experimental|Apremilast|30 mg twice daily to be administered for a period of 6 months
88965073|NCT03584646|Experimental|Arm 1 - Control Arm|Usual care, nutrition and exercise counseling at baseline, use of the Nokia GO wearable step tracker device and end-of-study assessment at the end of the 14-week study period. Participants will receive the Nokia GO wearable step tracker to monitor daily step counts, but they will not be provided with personalized walking goals or automated feedback on goal attainment via text message.
88965074|NCT03584646|Experimental|Arm 2 - Intervention arm|Physical activity program supported by financial incentives for meeting walking goals and participating in weekly check-in appointments with study team members via telephone calls. Participants in the intervention arm will also receive twice-daily medication reminders via bidirectional text messages to promote medication adherence. Participants in Arm 2 will also receive personalized nutrition and exercise counseling, daily feedback on step counts via the Nokia GO wearable step tracker and their smartphones, and an end-of-study assessment.
88965075|NCT03408717||Persistent post surgical pain (PPSP)|Questionnaires, Mechanical Temporal Summation assessment and pain threshold assessment will be assigned to patient. Within this cohort, some patients will have high pain score recorded (persistent pain) during the follow-up evaluations at 4 and 6 months.
88965076|NCT03385239|Placebo Comparator|Pooled Placebo|Participants in each cohort (A, B, C and D) were randomized to receive placebo at a dose-matched volume of study drug (ISIS 678354).
88965077|NCT03385239|Experimental|Cohort A: ISIS 678354: 10 mg Q4W|Cohort A participants received 10 milligrams (mg) ISIS 678354, subcutaneous (SC) injection, once every 4 weeks (Q4W), for up to 49 weeks and a maximum of 13 doses.
89026334|NCT00468572|Experimental|1|Participants will receive treatment with affectionate writing
88965078|NCT03385239|Experimental|Cohort C: ISIS 678354: 15 mg Q2W|Cohort C participants received 15 mg ISIS 678354, SC injection, once every 2 weeks (Q2W) for up to 51 weeks and a maximum of 26 doses.
88965079|NCT03385239|Experimental|Cohort D: ISIS 678354: 10 mg QW|Cohort D participants received 10 mg ISIS 678354, SC injection, once weekly (QW) for up to 52 weeks and a maximum of 52 doses.
88965080|NCT03385239|Placebo Comparator|Cohort B: ISIS 678354: 50 mg Q4W|Cohort B participants received 50 mg ISIS 678354, SC injection, once Q4W for up to 49 weeks and a maximum of 13 doses.
88965081|NCT03079401|Experimental|Treatment Arm|"Those randomized to the treatment arm will receive MPCs injected directly into the LV endocardium following clinical surgical maneuvers to recruit the LV (mitral valve repair, aortic valve repair, and/or resection of endocardial fibroelastosis) or BDG.~MPCs will be delivered directly into the LV endocardium via a 23-25 gauge needle following completion of all surgical procedures. A total dose of 20 million cells will be delivered, divided evenly into ~11 injections of 50 µL each. The total volume is not to exceed 2.0 mL."
88965082|NCT03079401|No Intervention|Control Arm|Those subjects randomized to the control arm will receive standard LV recruitment or BDG with no injection.
88965083|NCT03073395|Experimental|Dynamic group|Dynamic imaging of suspected metastatic lesions with the investigation drug [68Ga]P16-093 in patients with a history of histologically confirmed cancer.
88965084|NCT03073395|Experimental|Biodistribution group|Whole body imaging to determine human dosimetry of the investigational drug [68Ga]P16-093
88965085|NCT03020160|Experimental|Emicizumab: PK Run-in Cohort|Participants received emicizumab subcutaneously (SC) at a dose of 6 mg/kg once every 4 weeks, with no loading dose, for at least 24 weeks.
88965086|NCT03020160|Experimental|Emicizumab: Expansion Cohort|Participants received emicizumab subcutaneously (SC) at a loading dose of 3 mg/kg once every week for the first 4 weeks followed by a maintenance dose of 6 mg/kg emicizumab SC once every 4 weeks for at least 24 weeks.
89026335|NCT00468572|Active Comparator|2|Participants will receive treatment with meaningless writing
89026336|NCT00499668|Experimental|ARM A|
88965087|NCT03002259|No Intervention|Control|No placebo required
88965088|NCT03002259|Active Comparator|Dexamethasone|Dexamethasone, 1 mg/kg (maximal dose 100 mg), single dose administration before cardiopulmonary bypass
88965089|NCT02936505|Active Comparator|Arm A:Cyclosporine|Group A: Cyclosporine A, Mycophenolate mofetil (MMF) and corticosteroids according to local practice and approved label.
88965090|NCT02936505|Experimental|Arm B:Tacrolimus|Group B: Tacrolimus (Advagraf), Mycophenolate mofetil (MMF) and corticosteroids.
88965091|NCT02931903|Experimental|Hybrid superstructure|Vita Enamic is a hybrid ceramic, consisting of composite and ceramic. The ceramic; compatible and high aesthetics while the composite; resilient material with low modulus of elasticity which will absorb stress and therefore decrease load on bone and eventually decrease crestal bone loss
88965092|NCT02931903|Active Comparator|Ceramic superstructure|IPS Emax, is the mostly used ceramic superstructures in implant supported restorations.
88965093|NCT02917980||surgical treatment|patients with structural heart disease received surgical treatment
88965094|NCT02917980||interventional treatment|patients with structural heart disease received interventional treatment
88965095|NCT02917980||surgical combined with interventional treatment|patients with structural heart disease received surgical combined with interventional treatment
88965096|NCT02851758|Experimental|Autologous mitochondria injection|All subjects will have autologous mitochondria injected into ischemic areas of the myocardium (via injection or infusion).
88965097|NCT02792478||RAS wild-type subjects|The blood samples will be collected according to the site's routine clinical practice usually prior to each treatment cycle and at the follow-up visits. Analysis of the RAS mutation status will be carried out on blood samples taken at baseline, on those carried out at 20 +/-2 weeks after the start of treatment (in any case, prior to the second tumour assessment) and on the sample obtained upon progression, coinciding with routine clinical practices for collecting blood. Blood Samples will be collected to all subjects participating (119 subjects.)Objective to evaluate the RAS mutation status at baseline in liquid biopsies in subjects with RAS wild type metastatic colorectal cancer.
88965098|NCT02792478||Patient RAS WT|As in cohort 1 blood samples will be collected for all subjects participating (119) 10 ml will be used for analysis of the RAS mutation status. The mutation status of BRAF and EGFR will be also analysed with the IdyllaTM (Biocartis) tests in this Cohort 2. In 20 patients included in Cohort 2, 10 ml additional taken at baseline will be used in order to determine the RAS mutation status by the BEAMing technique and 10 ml additional taken at disease progression will be used to determine the mutational profile in genes other than RAS by a NGS technique.
88965099|NCT02593110|Active Comparator|Telmisartan + Supervised Treadmill Exercise Therapy|Participants in this group will receive both daily telmisartan and supervised treadmill exercise three days weekly for six months.
89026337|NCT00499668|Experimental|ARM B|
89026338|NCT00468611|Experimental|1|
89026339|NCT00468611|Placebo Comparator|2|
89026340|NCT03270995|Experimental|Group 1|Behavioral:Cognitive Existential Therapy Group 1- Weekly two-hour group sessions
89026341|NCT03270995|Active Comparator|Group 2|Behavioral: Supportive Therapy Group 2- Weekly two-hour group sessions
89026342|NCT00499785||patients admitted with acute leukemia|
89208419|NCT00868686|Active Comparator|Custom thermoplastic|
89208420|NCT00868764|Experimental|Sancuso® patch|Subjects receiving 1 Sancuso® patch worn for 7 days
89558589|NCT03689296||Primary care professionals|Primary care professional in practice following at least one person with a long-term mental disorder
89558590|NCT03689296||Psychiatric professionals|Psychiatric specialist working in a hospital or in private practice
89558591|NCT03679338|Other|Ablation Therapy With Bipolar Radio Frequency|
89558592|NCT03671525|Experimental|Nimodipine|One 60mg capsule of nimodipine on first or second study visit
88965100|NCT02593110|Active Comparator|"Telmisartan + No Exercise Control Group"|Participants in this group will receive daily telmisartan and attend weekly educational lectures at the medical center for six months.
88965101|NCT02593110|Active Comparator|Placebo + Supervised Treadmill Exercise Therapy|Participants randomized to this group will receive daily placebo and supervised treadmill exercise three times weekly for six months.
88965102|NCT02593110|Placebo Comparator|"Placebo + No Exercise Control Group"|Participants randomized to this group will receive daily placebo and health education lectures weekly for six months.
88965103|NCT02373813|Experimental|Open Label Run-In: Etanercept plus Methotrexate|Etanercept 50 mg weekly by subcutaneous injection plus oral methotrexate 10 to 25 mg weekly for 24 weeks. Participants also receive folic acid as standard of care.
88965104|NCT02373813|Experimental|Double-Blind Treatment: Methotrexate Monotherapy|"Oral methotrexate 10 to 25 mg weekly plus placebo for etanercept for 48 weeks. Participants also receive folic acid as standard of care.~After randomization, a participant experiencing protocol-defined disease worsening will initiate rescue treatment with etanercept 50 mg QW plus methotrexate (10 to 25 mg)."
88965105|NCT02373813|Experimental|Double-Blind Treatment: Etanercept Monotherapy|"Etanercept 50 mg weekly by subcutaneous injection plus placebo for methotrexate for 48 weeks. Participants also receive folic acid as standard of care.~After randomization, a participant experiencing protocol-defined disease worsening will initiate rescue treatment with etanercept 50 mg QW plus methotrexate (10 to 25 mg)."
88965106|NCT02373813|Experimental|Double-Blind Treatment: Etanercept plus Methotrexate|"Etanercept 50 mg weekly by subcutaneous injection plus oral methotrexate 10 to 25 mg weekly for 48 weeks. Participants also receive folic acid as standard of care.~After randomization, a participant experiencing protocol-defined disease worsening will continue on the assigned treatments (as rescue treatment)."
88965107|NCT02324907||Tibiotalocalcaneal arthrodesis with DynaNail|Procedure/Surgery: Tibiotalocalcaneal arthrodesis with a novel dynamic compression intramedullary nail
88965108|NCT02305641||Cohort|Method of continuous surveillance per standard of care
88965109|NCT01959204|Other|Active|Open label pharmacokinetic study of oxycodone.
88965110|NCT03795870|Active Comparator|Polymeric Tube Feeds|This arm will be receiving Polymeric Tube Feeds as a part of the regular HEN Protocol.
88965111|NCT03795870|Active Comparator|Blenderized Tube Feeds|This arm will be receiving Blenderized tube feeds as a part of the regular HEN Protocol.
89558593|NCT03671525|Placebo Comparator|Placebo|One placebo capsule on first or second study visit
88965112|NCT03778983||Pediatric Live Transplantation Group|Children who underwent pediatric Ltx at RenJi Hospital before 12 month, and now age between 2 and 7 years;
88965113|NCT04712331|Experimental|The Study group A|they received graduated abdominal strengthening exercises for 30 min., 3 times per week for 6 weeks preoperatively.
88965114|NCT04712331|Experimental|The Study group B|they received Russian stimulation on abdominal muscles for 30 min., 3 times per week for 6 weeks preoperatively.
88965115|NCT04712331|Experimental|The Study group C|they received combination between graduated abdominal strengthening exercises and Russian stimulation on abdominal muscles for 30 min., 3 times per week for 6 weeks preoperatively.
88965116|NCT04712331|No Intervention|The Control group D|they were instructed to presume in normal activities of daily living preoperatively, without abdominal exercises or Russian stimulation.
88965117|NCT00006081|Experimental|Bryostatin-1 + Taxol|
88965118|NCT00006102|Experimental|Arm I|"Patients with solid tumors are stratified according to tumor histology (neuroblastoma vs Ewing's sarcoma [closed to accrual as of 5/19/03]/peripheral primative neuroectodermal tumor [PNET] vs osteosarcoma [closed to accrual as of 5/19/03] vs rhabdomyosarcoma vs non-Hodgkin's lymphoma vs other solid tumors). Patients with CNS tumors are stratified according to tumor histology (medulloblastoma/PNET vs ependymoma vs brainstem glioma vs other CNS tumors).~Patients receive rebeccamycin analogue IV over 1 hour on day 1. Treatment continues every 21 days for a total of 16 courses in the absence of disease progression or unacceptable toxicity."
88965119|NCT00006105|Experimental|Administration of Cisplatin, Gemcitabine, and Amifostine|Subjects receive the study drug combination in 29-day cycles. Gemcitabine (1000 mg/m2) is given by IV infusion on Days 1, 8, and 15 of each cycle. Cisplatin (70 mg/m2) is given by IV infusion on Day 1 of each cycle. Immediately prior to each cisplatin infusion amifostine (910 mg/m2) will be given by IV infusion.
88965120|NCT00006111|Experimental|resectable disease|
88965121|NCT00006111|Experimental|unresectable disease|
88965122|NCT00006213|Experimental|Treatment (BMS-214662)|Patients receive BMS-214662 IV over 1 hour weekly for 4 weeks. Treatment continues every 4 weeks for a maximum of 12 courses in the absence of unacceptable toxicity or disease progression.
88965123|NCT00006222|Experimental|Arm I|Patients receive EMD 121974 IV twice a week for four weeks. Courses repeat every 4 weeks in the absence of disease progression. Cohorts of 3-6 patients receive escalating doses of EMD 121974 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which no more than 1 of 6 patients experiences dose limiting toxicities.
89558594|NCT03653611||Clinician Participants|Two Aim 2 practices are selected by each of their 5 affiliated PBRNs based upon willingness to participate and variability of primary care practice type within the PBRN. Differences in practice size, staffing, ownership, prior quality improvement engagement, geography, patient population socioeconomic status (SES) or languages spoken are among the among the selection criteria the PBRNs will utilize to choose.
89558595|NCT03653611||Patient Participants|200 patients, who are enrolled in Aim 1 (approximately 40 from each PBRN) will be invited to take a CAPTURE opinion survey
89558596|NCT03648437|Experimental|Pedea 5mg/mL and Paracetamol 10mg/mL|Intravenous (IV) ibuprofen 5mg/mL q 24h for 3 days, dosages: 10mg/kg + 5mg/kg + 5mg/kg and IV paracetamol 10mg/mL for 3 days: loading dose 20mg/kg, following 7.5mg/kg q 6h (up to12 doses)
89558597|NCT03648437|Placebo Comparator|Pedea 5mg/mL and 0.45 sodium chloride|IV ibuprofen 5mg/mL q 24h for 3 days, dosages: 10mg/kg + 5mg/kg + 5mg/kg and NaCl 0.45% for 3 days, the same amount in mL as would have been given IV paracetamol
89558598|NCT03648437|Experimental|Indomethacin 25mg/mL and Paracetamol10mg/mL|Intravenous (IV) indometahcin 25mg/mL q 24h for 3 days, dosages: 0.2mg/kg + 0.1mg/kg + 0.1mg/kg and IV paracetamol 10mg/mL for 3 days: loading dose 20mg/kg, following 7.5mg/kg q 6h (up to12 doses)
89558599|NCT03648437|Placebo Comparator|Indomethacin 25mg/mL and 0.45 sodium chloride|Intravenous (IV) indomethacin 25mg/mL q 24h for 3 days, dosages: 0.2mg/kg + 0.1mg/kg + 0.1mg/kg and NaCl 0.45% for 3 days, the same amount in mL as would have been given IV paracetamol
89208421|NCT00518986|Active Comparator|1|armodafinil 200 mg/day
89208422|NCT00518986|Placebo Comparator|2|Placebo
89558600|NCT03643042|Experimental|Restrictive group|Transfusion with: Hb < 80g/L and Hb maintain between 80 and 100g/L
89558601|NCT03643042|Experimental|Liberal group|Transfusion with: Hb < 100g/L and Hb maintain between 100 and 120g/L
89558602|NCT03622593|Experimental|A: Faricimab 6 mg Q8W|Participants randomized to Arm A received 6 milligrams (mg) faricimab intravitreal (IVT) injections once every 4 weeks (Q4W) to Week 20, followed by 6 mg faricimab IVT injections once every 8 weeks (Q8W) to Week 96, followed by the final study visit at Week 100.
89558603|NCT03622593|Experimental|B: Faricimab 6 mg PTI|Participants randomized to Arm B received 6 milligrams (mg) faricimab intravitreal (IVT) injections Q4W to at least Week 12, followed by a personalized treatment interval (PTI) dosing of 6 mg faricimab IVT injections up to once every 16 weeks (Q16W) through Week 96, followed by the final study visit at Week 100.
89208423|NCT00870324||1. Control|Patients will receive the Tendril (wide-spaced) lead as part of their ICD implant
89208424|NCT00870324||2. Experimental|Patients will receive the OptiSense (narrow-spaced) lead as part of their ICD implant
89208425|NCT00917423||Inpatients with anorexia nervosa|Hospital inpatients with anorexia nervosa
89208426|NCT00917423||Normal weight controls|Healthy, normal-weight volunteers
89558604|NCT03622593|Active Comparator|C: Aflibercept 2 mg Q8W|Participants randomized to Arm C received 2 milligrams (mg) aflibercept intravitreal (IVT) injections Q4W to Week 16, followed by 2 mg aflibercept IVT injections Q8W to Week 96, followed by the final study visit at Week 100.
88965124|NCT00387582|Experimental|I|Lucentis injections for the first three months of the study and then per the protocol for the duration of the trial.
89558605|NCT03620058|Experimental|CART22-65s monotherapy|
89558606|NCT03620058|Experimental|CART22-65s in combination with huCART19|
89558607|NCT03618186|Experimental|Normal control|Cognitively normal volunteers
89558608|NCT03618186|Experimental|Mild Cogntive impairment|Person with cognitive impairment that meet Peterson Criteria
89558609|NCT03618186|Experimental|Demented|Patient's that meet dementia criteria
89558610|NCT03614260|Experimental|Renal Denervation|Renal Angiogram and Renal Denervation (Paradise Renal Denervation System)
89558611|NCT03614260|Sham Comparator|Sham Control|Renal Angiogram
89558612|NCT03593655|Experimental|Sequence A: Dapivirine vaginal ring + FTC/TDF|Participants will receive one 25 mg dapivirine vaginal ring inserted vaginally each month for 24 weeks, followed by one FTC/TDF oral tablet taken by mouth daily for 24 weeks, followed by participant's choice of either or neither study product for 24 weeks.
89558613|NCT03593655|Experimental|Sequence B: FTC/TDF + Dapivirine vaginal ring|Participants will receive one FTC/TDF oral tablet taken by mouth daily for 24 weeks, followed by one 25 mg dapivirine vaginal ring inserted vaginally each month for 24 weeks, followed by participant's choice of either or neither study product for 24 weeks.
88965125|NCT00387582|Active Comparator|II|Argon Laser treatment at enrollment and then per the protocol for the duration of the study.
88965126|NCT03765177|Experimental|CLIC-1901|A single Intravenous infusion of CLIC-1901 will be given.
88965127|NCT00006228|Experimental|Treatment (trastuzumab and aldesleukin)|Patients receive trastuzumab IV over 30-90 minutes on days 1 and 8 and aldesleukin SC on days 2-7 and 9-21. Beginning on day 22, patients receive trastuzumab IV over 30 minutes every 14 days. Patients also receive aldesleukin SC daily on days 1-14. Treatment continues for 1 year in the absence of disease progression or unacceptable toxicity.
88965128|NCT02972463|Placebo Comparator|Placebo|9 maltodextrin capsules, once daily for 12 weeks
88965129|NCT02972463|Experimental|IgY Max Low-Dose (1g IgY Max)|2 Immunoglobulin Y capsules and 7 maltodextrin capsules, once daily for 12 weeks
88965130|NCT02972463|Experimental|IgY Max Mid-Dose (2g IgY Max)|4 Immunoglobulin Y capsules and 5 maltodextrin capsules, once daily for 12 weeks
88965131|NCT02972463|Experimental|IgY Max High-Dose (4.5g IgY Max)|9 Immunoglobulin Y capsules, once daily for 12 weeks
88965132|NCT00006243|Experimental|Arm I (vaccine therapy)|Patients receive tyrosinase peptide, MART-1:27-35 peptide vaccine, and gp100 antigen admixed in incomplete Freund's adjuvant SC on day 1 of weeks 0, 3, 6, 9, 12, and 24.
88965133|NCT00006243|Experimental|Arm II (vaccine therapy and lower-dose sargramostim)|Patients receive tyrosinase peptide, MART-1:27-35 peptide vaccine, and gp100 antigen admixed in incomplete Freund's adjuvant SC and lower-dose sargramostim SC on day 1 of weeks 0, 3, 6, 9, 12, and 24.
88965134|NCT00006243|Experimental|Arm III (vaccine therapy and higher-dose sargramostim)|Patients receive tyrosinase peptide, MART-1:27-35 peptide vaccine, and gp100 antigen admixed in incomplete Freund's adjuvant SC and higher-dose sargramostim SC on day 1 of weeks 0, 3, 6, 9, 12, and 24.
88965135|NCT00006249|No Intervention|observation|5 years observation + 5 years follow up
88965136|NCT00006249|Experimental|pegylated interferon alfa|5 years pegylated interferon alfa + 5 years follow up
88965137|NCT00006252|Experimental|Allogeneic Stem Cell Tx|minimal ablation and cellular immune therapy with allogeneic donor stem cell therapy
88965138|NCT00006294||Chlorthalidone|Participants will take chlorthalidone at recommended doses to control hypertension
88965139|NCT00006294||Amlodipine|Participants will take Amlodipine at recommended doses to control hypertension
88965140|NCT00006294||Lisinopril|Participants will take Lisinopril at recommended doses to control hypertension
88965141|NCT00006294||Doxazosin|Participants will take Doxazosin at recommended doses to control hypertension
88965142|NCT03728595||Patients with lung disease having HAST|"Patients with chronic respiratory diseases who had a hypoxic altitude simulation test (HAST) for clinical purposes will have for research purposes:~venepuncture~spirometry."
88965143|NCT00005818|Experimental|Treatment (irinotecan hydrochloride, semaxanib)|Patients receive irinotecan IV over 90 minutes on day 1 of weeks 1-4 and SU5416 IV over 60 minutes on days 1 and 4 of weeks 1-6. Treatment continues every 6 weeks in the absence of unacceptable toxicity or disease progression.
88965144|NCT00005830|Experimental|Treatment (doxorubicin, cisplatin, radiation therapy)|Patients receive doxorubicin IV and cisplatin IV on day 1. Treatment repeats every 3 weeks for 3 courses. Patients then undergo whole abdominal radiotherapy 5 days a week for 4-6 weeks.
88965145|NCT00005833|Experimental|R115777|R115777, 300mg PO BID on Days 1-21. 1 cycle=28 days.
88965146|NCT00005842|Experimental|Arm I|Patients receive trastuzumab (Herceptin) IV over 90 minutes on days 1, 8, 15, and 22 plus oral R115777 twice daily for 3 weeks. Treatment continues every 28 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of R115777 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which no more than 1 of 6 patients experiences dose limiting toxicities.
88965147|NCT00005845|Experimental|Treatment (tipifarnib)|Patients receive tipifarnib PO BID on weeks 1, 3, 5, and 7. Treatment repeats every 8 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity.
88965148|NCT00006333||Subjects with known or suspected arthritis|Subjects with known or suspected arthritis will be evaluated longitudinally
88965149|NCT00005851|Experimental|Treatment (nonmyeloablative donor PBSC transplantation)|"CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo low-dose TBI on day 0.~TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell transplant on day 0.~IMMUNOSUPRESSION: Patients receive cyclosporine PO BID or IV QD or BID on days -3 to 35 with taper to day 56, and mycophenolate mofetil PO or IV over 2 hours TID on days 0-40.~DLI: Patients with stable mixed chimerism on day 56 with no evidence of GVHD may receive escalating doses of non-mobilized DLI over 30 minutes. Patients may receive up to 4 DLIs at escalating doses if there is disease progression with no evidence of GVHD."
89208427|NCT04089683||Doctors|Swabs collected from Web space, Scrub, Anterior nares before entering Operation theatre and while exit from operation theatre
89558614|NCT03591133|Other|Step1:3㎎ QD|Drug: TS-143 3mg Drug: Placebo
89558615|NCT03591133|Other|Step2:6㎎ QD|Drug: TS-143 6mg Drug: Placebo
89558616|NCT03591133|Other|Step3-1:11㎎ QD|Drug: TS-143 11mg Drug: Placebo
89558617|NCT03591133|Other|Step3-2:11㎎ QD（Fed)|Drug: TS-143 11mg Drug: Placebo
89558618|NCT03591133|Other|Step4:20㎎ QD|Drug: TS-143 20mg Drug: Placebo
89558619|NCT03591133|Other|Step5:36㎎ QD|Drug: TS-143 36mg Drug: Placebo
89558620|NCT03577106|Experimental|Transcranial magnetic stimulation (TMS)|
89558621|NCT03572530|Experimental|group 1|5-Azacytidine (5-AZA) group 1: Enrolled patients will undergo surgical placement of a ventricular catheter into the fourth ventricle that will be attached to a subcutaneously placed reservoir. Patients will be divided into 3 dose groups and receive 8 weeks of intraventricular 5-AZA (12 mg) into the fourth ventricle. Patients in Group 1 will receive two 5-AZA infusions every week.
89558622|NCT03572530|Experimental|group 2|5-Azacytidine (5-AZA) group 2: Enrolled patients will undergo surgical placement of a ventricular catheter into the fourth ventricle that will be attached to a subcutaneously placed reservoir. Patients will be divided into 3 dose groups and receive 8 weeks of intraventricular 5-AZA (12 mg) into the fourth ventricle. Patients in Group 2 will receive three 5-AZA infusions every week.
89558623|NCT03572530|Experimental|group 3|5-Azacytidine (5-AZA) group 3: Enrolled patients will undergo surgical placement of a ventricular catheter into the fourth ventricle that will be attached to a subcutaneously placed reservoir. Patients will be divided into 3 dose groups and receive 8 weeks of intraventricular 5-AZA (12 mg) into the fourth ventricle. Patients in Group 3 will receive four 5-AZA infusions every week.
89558624|NCT03569280|Experimental|KPG-121|Safety and Antitumor Activity of KPG-121 capsules at different dose level for 21 days
89558625|NCT03558087|Experimental|Gemcitabine, Cisplatin and Nivolumab|Combination Therapy: Nivolumab 360mg IV, Gemcitabine 100mg/m^2 IV ,Cisplatin 70mg/m^2 IV for four 21-day cycles. At restaging, subjects with cT0 or cTa status may undergo cystectomy or continue maintenance Nivolumab 240mg IV for up to 8 14-day cycles. Subjects with > cTa status will undergo cystectomy.
89558626|NCT03549442|Experimental|Phase A|Safety Run-in to test the safety of CART-BCMA + huCART19 as split-dose infusions after lymphodepleting chemotherapy with cyclophosphamide + fludarabine in patients who have relapsed/refractory myeloma after two prior regimens but who are responding to their current therapy.
89558627|NCT03549442|Experimental|Phase B|Randomization Phase in which patients responding to first or second-line therapy will receive either CART-BCMA alone (Cohort 1) or CART-BCMA + huCART19 (Cohort 2) as split-doses after lymphodepleting chemotherapy with cyclophosphamide + fludarabine.
89558628|NCT03549442|Experimental|Phase C|Single-dose infusion phase to test the safety of single-dose infusion of CART-BCMA alone (Cohort 1) and CART-BCMA + huCART19 (Cohort 2) as single-dose infusions after lymphodepleting chemotherapy with cyclophosphamide + fludarabine in patients responding to first- or second-line therapy.
89558629|NCT03549442|Experimental|Phase A Expansion|Once safety of CART-BCMA/huCART19 combination therapy is established in Phase A, an expansion of Phase A will occur in which the Phase A target population (patients with relapsed/refractory multiple myeloma responding to a standard salvage therapy regimen) will receive both CART-BCMA and huCART19. Enrollment into the Phase A Expansion may occur concurrently with Phase B once opened.
88965150|NCT00005866|Experimental|treatment|
88965151|NCT00005881||Quality of life forms|Completion of the development of an instrument [Minneapolis-Manchester Quality of Life (MM-QOL)] that measures HRQOL in the survivors of childhood cancer in a standardized, valid way and to assess the feasibility of incorporating this endpoint in a variety of clinical trials.
89558630|NCT03542695|Experimental|Diagnostic (64Cu-DOTA-alendronate, PET/CT scan)|Participants receive 64Cu-DOTA-alendronate IV and undergo PET/CT imaging 60 minutes after injection. Participants with sufficient levels of residual radioactivity may undergo repeat imaging on day 1 as determined by the study team.
89558631|NCT03541876||children with H. pylori infection|
89558632|NCT03524183|Active Comparator|Control|The children will receive the standard of care at their respective afterschool programs. As with the treatment group, all children will be asked to wear their Fitbits for one year following the intervention period, for the mid- and long-term follow up. Fitbit data will be recorded tracked year-round through the automated Fitbit data syncing stations at the afterschool program site. All participants will be assessed for PA and psychosocial variables at the same four measurement points for the treatment group.
88965152|NCT00005914||Probands and family members|Individuals with major depressive disorder who meet study criteria, and members of their families. No intervention. This is a genetic study only.
88965153|NCT00386542|Experimental|ID-JI-0.1|"Group ID-JI-0.1 (n = 16) - reduced 0.1 mL INF doses administered intradermally (ID) by needle-free jet injector (JI) (Biojector® 2000 subcutaneous syringe no. 2 [green color code], with 2 cm investigational spacer, Bioject Medical Technologies, Inc., Portland, OR, USA)"
88965154|NCT00386542|Active Comparator|IM-NS-0.1|"Group IM-NS-0.1 (n = 16) - reduced 0.1 mL INF doses administered intramuscularly (IM) needle-syringe (NS) (via 22-25 gauge needle, minimum 25 mm/1-inch length)"
88965155|NCT00386542|Active Comparator|IM-NS-0.25 control|"Group IM-NS-0.25 (controls) (n = 16) - full 0.25 mL INF doses administered intramuscularly (IM) by needle-syringe (NS) (22-25 gauge needle, minimum 25 mm/1-inch length)"
88965156|NCT00386620||Survey + ED|"Part 1: Survey + Electronic Diaries (ED)~Part 2: 3 Month, 6 Month Survey + ED"
88965157|NCT00006348|Experimental|Arm 1: ondansetron + placebo|Patients receive oral ondansetron twice daily on days 1-7 and oral placebo twice daily on days 8-14 in the absence of unacceptable toxicity.
88965158|NCT00006348|Experimental|Arm 2: ondansetron + placebo|Patients receive oral placebo twice daily on days 1-7 and oral ondansetron twice daily on days 8-14 in the absence of unacceptable toxicity.
88965159|NCT00005950|Experimental|Treatment|Patients receive 506U78 IV over 2 hours on days 1, 3, and 5. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
88965160|NCT00387738|Experimental|1|TOLAMBA™ dose-intense regimen
88965161|NCT00387738|Experimental|2|TOLAMBA™ lower-dose regimen
88965162|NCT00387738|Placebo Comparator|3|
88965163|NCT03658551||Liver cirrhosis|Patients with liver cirrhosis are included in this arm. Liver cirrhosis is diagnosed by ultrasound, CT - scan oder by clinical signs.
88965164|NCT03658551||Control group|Patients with abdominal symptoms with the indication for endoscopy without liver cirrhosis and portal Hypertension.
88965165|NCT00005977|Experimental|STAGE III NHL (Trt 1)|"A: Cyclophosphamide (CTX), Doxorubicin hydrochloride, Vincristine sulfate (VCR), Dexamethasone IT Therapy. B: HD-Methotrexate(MTX), Cytarabine(Ara-C), Dexamethasone IT Therapy.~Treatment ABABA"
88965166|NCT00005977|Experimental|STAGE IV NHL, -CNS (Trt 2)|"A: Cyclophosphamide (CTX), Doxorubicin hydrochloride, Vincristine sulfate (VCR), Dexamethasone IT Therapy. B: HD-Methotrexate(MTX), Cytarabine(Ara-C), Dexamethasone IT Therapy.~Treatment ABABAB"
88965167|NCT00005977|Experimental|STAGE IV, +CNS (Trt 3)|"A: Cyclophosphamide (CTX), Doxorubicin hydrochloride, Vincristine sulfate (VCR), Dexamethasone IT Therapy. B: HD-Methotrexate(MTX), Cytarabine(Ara-C), Dexamethasone IT Therapy. C: Etoposide, Ifosfamide, Dexamethasone IT Therapy.~Treatment ABCABAB"
89558633|NCT03524183|Experimental|Treatment|The virtual pet functions as a personalized fitness buddy to encourage children to set and meet physical activity goals, promote physical activity self-efficacy, and foster mutually supportive relationships among children, parents, and the virtual pet. Concurrently, the kiosk sends a text message to parents on the child's physical activity progress. Parents are then able to send words of encouragement and communicate with their children via the kiosk, using the text messaging feature of their mobile phones. Parents will also receive text messages from the kiosk with a security code to access a website that provides detailed records of the child's physical activity over time. Participants will be assessed for post-treatment measurements immediately after 3 months, 6 months after, and 12 months after the intervention.
89558634|NCT03512405|Experimental|Treatment (pembrolizumab, blinatumomab)|Participants receive pembrolizumab IV over 30 minutes on day 15 of course 1 and days 1 and 22 of courses 2 -4, and blinatumomab IV on days 1-28. Treatment repeats every 35-42 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
89558635|NCT03508934|Active Comparator|Intervention group (Continuous Glucose Monitroring and POC)|Hospitalized patients with DM2 will be monitored with Glucose Telemetry System (GTS) and Point of Care (POC) finger-stick blood glucose levels with application of hypoglycemia prevention protocol (activated based the GTS lower glucose alarms)
89558636|NCT03508934|Placebo Comparator|Control group (Point of Care-POC)|Hospitalized patients with DM2 will be monitored with POC blood glucose levels and application of hypoglycemia prevention protocol (activated based the POC values)
89558637|NCT03491215|Experimental|Ruxolitinib|All patients received ruxolitinib in addition to corticosteroids +/-calcineurin inhibitor (CNI)
89558638|NCT03490565|Active Comparator|EX group|Exercise training
89558639|NCT03490565|No Intervention|CON-group|Usual Care
89558640|NCT03458416|Experimental|Cannabidiol Oral Solution: 20-40 mg/kg/day|Participants will receive total daily doses between 20 milligrams per kilograms per day (mg/kg/day), 30 mg/kg/day, and 40 mg/kg/day. The two equivalent doses will be administered twice a day with a standard meal approximately every 12 hours.
89558641|NCT03441308|Active Comparator|Educational method of group treatment|Educational method of group treatment based on regular meals and food based on Nordic nutrition recommendations. The method has been developed by a district nurse at Ljungby. Ten meetings in groups of 6-8 participants over 6 months. Group meeting number 5 includes short individual consultations. In addition, individual consultation after group meeting 1 and 10.
89558642|NCT03441308|Placebo Comparator|Dietary advice|The control group is offered dietary advice according to the Swedish National Food Agency's guidelines for overweight and obesity (including brochures) at one occasion.
89558643|NCT03441113|Other|Cohort 1: Study GS-US-352-0101|Participants will continue to receive the same dosage regimen as in the previous MMB study GS-US-352-0101 until MMB receives regulatory approval and is commercially available, or development of the product ceases.
89558644|NCT03441113|Other|Cohort 2: Study GS-US-352-1214|Participants will continue to receive the same dosage regimen as in the previous MMB study GS-US-352-1214 until MMB receives regulatory approval and is commercially available, or development of the product ceases.
89558645|NCT03441113|Other|Cohort 3: Study GS-US-352-1154|Participants will continue to receive the same dosage regimen as in the previous MMB study GS-US-352-1154 until MMB receives regulatory approval and is commercially available, or development of the product ceases..
89558646|NCT03441113|Other|Cohort 4: Study SRA-MMB-301|Participants will continue to receive the same dosage regimen as in the previous MMB study SRA-MMB-301 until MMB receives regulatory approval and is commercially available, or development of the product ceases.
89558647|NCT03430219||Subchondroplasty Procedure|The SCP Procedure targets and fills bone defects with AccuFill bone substitute material utilizing an arthroscopic / percutaneous approach
89558648|NCT03428009||Dystonia group|Both groups will have blood drawn, undergo clinical assessments, the collection of medical and family history, and an Magnetic Resonance Imaging. This is an observational study and there is no intervention.
89558649|NCT03428009||Control Group|Both groups will have blood drawn, undergo clinical assessments, the collection of medical and family history, and an Magnetic Resonance Imaging. This is an observational study and there is no intervention.
89558650|NCT03419234|Experimental|Arm A (abiraterone acetate, prednisone, cabazitaxel)|Patients receive abiraterone acetate PO QD on days 1-21, prednisone PO BID on days 1-21. Courses of abiraterone acetate and prednisone repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients receive cabazitaxel IV over 1 hour on day 1, and treatment with cabazitaxel repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients also receive standard of care antiandrogen therapy with either LHRH agonist or antagonist, or surgical castration with bilateral orchiectomy.
89558651|NCT03419234|Active Comparator|Arm B (abiraterone acetate, prednisone)|Patients receive abiraterone acetate and prednisone as in Arm A. Patients also receive standard of care antiandrogen therapy with either LHRH agonist or antagonist, or surgical castration with bilateral orchiectomy.
88965168|NCT00005977|Experimental|B-ALL, -CNS (Trt 2)|"A: Cyclophosphamide (CTX), Doxorubicin hydrochloride, Vincristine sulfate (VCR), Dexamethasone IT Therapy. B: HD-Methotrexate(MTX), Cytarabine(Ara-C), Dexamethasone IT Therapy.~Treatment ABABAB"
88965169|NCT00005977|Experimental|B-ALL, +CNS (Trt 3)|"A: Cyclophosphamide (CTX), Doxorubicin hydrochloride, Vincristine sulfate (VCR), Dexamethasone IT Therapy. B: HD-Methotrexate(MTX), Cytarabine(Ara-C), Dexamethasone IT Therapy. C: Etoposide, Ifosfamide, Dexamethasone IT Therapy.~Treatment ABCABAB"
88965170|NCT00387855|Experimental|1|receive SOS program
88965171|NCT00005983|Active Comparator|surgery|surgery followed by observation
88965172|NCT00005983|Experimental|surgery followed by RT|Surgery followed by radiation therapy
88965173|NCT03642912||ECMO patients|ECMO patients treated on the intensive care units of the Department of Anesthesiology of LMU Munich
88965174|NCT00006001|Experimental|Arm I|Patient receive SU5416 IV over 60 minutes twice weekly for 4 weeks. Treatment continues for a minimum of 2 courses in the absence of unacceptable toxicity or disease progression.
88965175|NCT00006007|Experimental|gemcitabine + pemetrexed|"Patients receive gemcitabine IV over 30 minutes on days 1 and 8. pemetrexed disodium IV is administered over 10 minutes 90 minutes following gemcitabine on day 8. Treatment continues every 21 days for a minimum of 6 courses in the absence of unacceptable toxicity or disease progression. Patients achieving a complete response receive 2 additional courses.~Patients are followed every 3 months for 5 years."
88965176|NCT00006010|Experimental|docetaxel + gemcitabine|"Patients receive docetaxel IV over 15-60 minutes and gemcitabine IV over 30 minutes on days 1 and 8. Treatment repeats every 3 weeks. Patients achieving complete response after 2 courses of therapy receive 2 additional courses of therapy. Patients with stable disease or partial response continue therapy until disease progression.~Patients are followed every 3 months for 1 year and then every 6 months for 4 years."
88965177|NCT00006016|Experimental|Treatment (thalidomide, chemoembolization)|Patients receive oral thalidomide daily beginning 4 weeks before the first planned chemoembolization procedure. Thalidomide administration is stopped 24 hours before each chemoembolization procedure, and then restarted at 24 hours after completion of each procedure OR when blood counts and levels of bilirubin and transaminases recover, whichever occurs later. Thalidomide treatment continues in the absence of disease progression or unacceptable toxicity. Patients undergo placement of a visceral arterial catheter. Patients receive doxorubicin as a chemoemulsion via the arterial catheter into 1 hepatic lobe only under angiographic guidance. Immediately after delivery of the chemoemulsion, patients undergo particulate embolization. The opposite lobe, if involved, is treated within 3-5 weeks of treatment of the initial lobe. Patients are reevaluated for repeat chemoembolization within 8-12 weeks of the last chemoembolization.
88965178|NCT00387933|Experimental|Gleevec + PTK787/ZK 22584 + Hydroxyurea|Patients with recurrent or relapsing glioblastoma multiforme (GBM) will be given daily doses of Gleevec and PTK787/ZK 22584 orally in combination with fixed doses of hydroxyurea.
88965179|NCT00006031|Active Comparator|I: Radioactive Seed Localized Breast Biopsy|Arm I: Patients undergo radiographic placement of a radioactive seed (either iodine I 125 or palladium Pd 103) into the suspicious lesion. Patients then undergo surgery to remove the lesion along with the seed and a small margin of surrounding breast tissue followed 3 months later by a postoperative mammogram.
88965180|NCT00006031|Active Comparator|Arm II: Needle Localized Breast Biopsy|Arm II: Patients undergo a needle localized breast biopsy with a specimen x-ray.
88965181|NCT00006034|Experimental|Arm I|Patients receive a sensitizing dose of keyhole limpet hemocyanin (KLH) intradermally in week 2 followed by induction KLH IV once weekly in weeks 1-6. Patients with partial or no response receive IV KLH reinduction therapy once weekly in weeks 13-18. Patients with complete response receive IV KLH maintenance therapy monthly in weeks 13, 17, and 21, and then in months 6-12.
88965182|NCT00006034|Active Comparator|Arm II|Patients receive doxorubicin IV once weekly in weeks 1-6.
88965183|NCT00006363|Experimental|Induction Arm I|Patients receive cytarabine IV continuously on days 1-7 and daunorubicin IV over 5-10 minutes followed by etoposide IV over 2 hours on days 1-3. Patients with 20% or greater bone marrow cellularity and greater than 5% leukemia blasts at the end of the first course receive a second course of cytarabine IV continuously on days 1-5 and daunorubicin IV over 5-10 minutes followed by etoposide IV over 2 hours on days 1 and 2.
88965184|NCT00006363|Experimental|Induction Arm II|Patients receive PSC 833 IV continuously on days 1-3 and cytarabine, daunorubicin, and etoposide as in arm I. Patients with 20% or greater bone marrow cellularity and greater than 5% leukemia blasts at the end of the first course receive a second course of PSC 833 IV continuously on days 1 and 2 and cytarabine, daunorubicin, and etoposide as in arm I.
88965185|NCT00006363|Experimental|Intensification Favorable|Patients receive HiDAC IV over 3 hours every 12 hours on days 1, 3, and 5. Treatment repeats no earlier than 28 days after the prior course and no later than 14 days after hematopoietic recovery for two more courses.
88965186|NCT00006363|Experimental|Intensification Unfavorable PBSCT Group|Patients receive etoposide IV continuously and HiDAC IV over 2 hours every 12 hours on days 1-4. Patients also receive G-CSF SC daily beginning on day 14 and continuing until PBSC collection is completed. Patients who are not able to undergo PBSCT after HiDAC/etoposide continue treatment in the non-PBSCT group. At least 4 weeks after HiDAC/etoposide recovery, patients receive oral busulfan every 6 hours on days -7 to -4 and etoposide IV over 4 hours on day -3 prior to PBSCT. Patients receive autologous PBSC infusion on day 0. Patients also receive G-CSF SC beginning on day 0 and continuing until hematopoietic recovery.
88965187|NCT00006363|Experimental|Intensification Unfavorable Non-PBSCT Group|Patients receive etoposide, HiDAC, and G-CSF as in the PBSCT group. After hematopoietic recovery, patients then receive HiDAC IV over 3 hours every 12 hours on days 1, 3, and 5. Treatment repeats no earlier than 28 days after prior course and no later than 14 days after hematopoietic recovery for one more course.
88965188|NCT00006363|Experimental|Immunotherapy Arm I|Patients begin therapy no later than 120 days after the first day of the last course of HiDAC treatment OR day 0 of PBSCT. Patients receive low-dose IL-2 SC on days 1-14, 19-28, 33-42, 47-56, 61-70, and 75-90. In addition, patients receive high-dose IL-2 SC on days 15-17, 29-31, 43-45, 57-59, and 71-73.
89026343|NCT01366534|Experimental|Ad35.CS.01 Group|Healthy male or non-pregnant female subjects, aged 18 to 50 years, were administered one dose of Ad35.CS.01 vaccine at Month 0, and 2 doses of GSK257049 at Months 1 and 2 intramuscularly in the deltoid of the non-dominant arm. The duration of the study was approximately 11 months for vaccinated subjects.
89026344|NCT01366534|Experimental|GSK257049 Group|Healthy male or non-pregnant female subjects, aged 18 to 50 years, were administered 3 doses of GSK257049 vaccine at Months 0, 1 and 2 intramuscularly in the deltoid of the non-dominant arm. The duration of the study was approximately 11 months for vaccinated subjects.
89026345|NCT01366534|Experimental|Control Group|Healthy male or non-pregnant female subjects, aged 18 to 50 years, were volunteers who did not receive any immunization but were subjected to the sporozoite challenge. The duration of the study was approximately 8 months for infectivity control subjects.
89558652|NCT03392480||Adult non-haptoglobin 2-2 group|Patients are 45 to 65 years old.
89558653|NCT03392480||Adult haptoglobin 2-2 group|Patients are 45 to 65 years old.
89558654|NCT03392480||Elder non-haptoglobin 2-2 group|Patients are elder than 65 years.
89026346|NCT00492843|Experimental|A|Intravenous infusion of either 6mg Bondronat on three consecutive days
89558655|NCT03392480||Elder haptoglobin 2-2 group|Patients are elder than 65 years.
89558656|NCT03388242||Normal control people|These people are age-matched with the patients with MCI. No intervention is applied.
89558657|NCT03388242||Patients with MCI|These patients have met the criteria for diagnosing MCI. No intervention is applied.
89558658|NCT03388242||Patients with AD|These patients are diagnosed with AD. No intervention is applied.
89558659|NCT03364231|Experimental|Marginal Zone Lymphoma (MZL): Umbralisib|Participants with non-follicular indolent non-Hodgkin's lymphoma (iNHL) with MZL as the histology type received umbralisib, 800 milligrams (mg), orally, once daily (QD), until disease progression, unacceptable toxicity, or withdrawal from the study whichever occurred first.
89558660|NCT03364231|Experimental|Waldenstrom's Macroglobulinemia (WM): Umbralisib|Participants with non-follicular iNHL with WM as the histology type received umbralisib, 800 mg, orally, QD, until disease progression, unacceptable toxicity, or withdrawal from the study whichever occurred first.
89558661|NCT03347162||Cohort 1 - Resectable patients|These patients will undergo 3 assessments: a baseline-assessment prior to surgery, a post-surgery assessment (2 week post-surgery) and a follow-up assessment 6 months after surgery (after adjuvant oncology treatment).
89558662|NCT03347162||Cohort 2 - Non-resectable patients|These patients will undergoing 3 assessments: a baseline-assessment prior to palliative treatment, an acute measurement 4 weeks after initiation of palliative treatment, and a 6-month long-term assessment.
89558663|NCT03343093|Experimental|Intervention Evaluation Control Group|Surveys at 3 month intervals
89558664|NCT03343093|Experimental|Intervention Evaluation Test Group|We will evaluate the effects of an educational, tailored, online rehabilitation program addressing sexual and urinary outcomes after treatment by surveying at 3 month intervals
89558665|NCT03335228|Experimental|Eclipse Easy Spin for PRP Treatment|Assessing the safety and efficacy of platelet rich plasma for treating frontal fibrosing alopecia. This will be accomplished by the production of platelet rich plasma by the Eclipse Easy Spin centrifuge. Subjects will receive treatment once a month for 6 months. Platelet rich plasma will be administered via injections into the affected areas of the scalp.
89558666|NCT03303625|Experimental|Cohort 0: Adults (Ad26.RSV.preF)|Participants aged greater than or equal to (>=) 18 to lesser than or equal to (<=) 50 years will receive vector Ad26.RSV.preF at 1*10^11 viral particles (vp) via intramuscular (IM) route (Group 1) on Day 1 and 29.
89558667|NCT03303625|Placebo Comparator|Cohort 0: Adults (Placebo)|Participants aged >= 18 to <= 50 years will receive placebo via IM route (Group 2) on Day 1 and 29.
89558668|NCT03303625|Experimental|Cohort 1: RSV seropositive Toddlers (Ad26.RSV.preF)|RSV seropositive participants aged >=12 to <=24 months will receive Ad26.RSV.preF at 5*10^10 vp via IM route (Group 3) on Day 1 and 29.
89558669|NCT03303625|Placebo Comparator|Cohort 1: RSV seropositive Toddlers (Placebo)|RSV seropositive participants aged >= 12 to <= 24 months will receive placebo via IM route (Group 4) on Day 1 and 29.
89558670|NCT03299816|Active Comparator|Self-Shopping DASH group (S-DASH)|The Self-Shopping DASH group will receive printed patient-centered materials on the DASH diet and chronic kidney disease. Participants will also receive $30/week allowance for the purchase of food and drinks of their choosing from a local grocer (Klein's ShopRite stores of Maryland) during the first four months. During the remainder of the study (months 5-12), the participants in this group will be asked to continue to follow the dietary advice provided but will not receive the food allowance.
89558671|NCT03299816|Experimental|Coaching DASH group (C-DASH)|The C-DASH group intervention will be a patient-tailored program, delivered by a study coach that is trained by a dietitian, which emphasizes key self-management behaviors - diet and self-monitoring. This group will receive advice from the study coach and purchase $30 worth of fresh fruits, vegetables, nuts and beans that are high in potassium on a weekly basis for the first four months.
89558672|NCT03287349||Patients with severe reactions to radiation|Two 12.5 mL blood draws and photograph of severe reaction, and autoimmune testing in patients without prior testing.
89558673|NCT03267433|Experimental|Group I (auto-HCT, rituximab)|Patients receive standard of care preparative chemotherapy and undergo auto-HCT. Beginning 60-120 days after transplant, patients receive rituximab IV once every 8 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.
89558674|NCT03267433|Experimental|Group II (rituximab alone)|Patients receive standard of care induction chemotherapy. Beginning 40-120 days after completion of chemotherapy, patients receive rituximab as in Group I.
89026347|NCT00492843|Active Comparator|B|Intravenous infusion of 6mg Bondronat on one day
89026348|NCT01605487|Other|Rupatadine 20mg - Placebo - Rupatadine 40mg|
89026349|NCT01605487|Other|Rupatadine 20mg - Rupatadine 40mg - Placebo|
89558675|NCT03238690|Experimental|Controlled Cardiac Reloading|Heart failure patients with recent LVAD implantation after an optimum unloading phase, will undergo controlled cardiac reloading through LVAD speed adjustment reductions in a controlled reloading phase
89558676|NCT03238300|Experimental|N-Acetylcysteine, then Placebo|Participants first received N-Acetylcysteine 600mg capsules by mouth, two pills twice daily will be taken for 10 days. After washout for 11 days, they then received placebo capsules mimicking N-Acetylcysteine (two pills, twice daily) will be taken for 10 days.
89558677|NCT03238300|Experimental|Placebo, then N-Acetylcysteine|Participants first received placebo capsules mimicking N-Acetylcysteine (two pills, twice daily) will be taken for 10 days. After washout for 11 days, they then received N-Acetylcysteine 600mg capsules by mouth, two pills twice daily will be taken for 10 days.
89558678|NCT03233191|Experimental|Arm A (digital mammography)|Patients undergo bilateral screening DM with standard CC and MLO views at baseline, 12, 24, 36, and 48 months if pre-menopausal or at baseline, 24, and 48 months if post-menopausal.
89558679|NCT03233191|Experimental|Arm B (digital tomosynthesis mammography)|Patients undergo manufacturer-defined screening TM at baseline, 12, 24, 36, and 48 months if pre-menopausal or at baseline, 24, and 48 months if post-menopausal.
89558680|NCT03214003|Experimental|SIB group|Patients in this group will receive concurrent twice-daily radiotherapy by SIB technique (95%PGTV 54Gy, 95%PTV 45Gy,both in 30 twice-daily fractions over 3 weeks, 5 days per week) and chemotherapy (etoposide and cisplatin).
89558681|NCT03214003|Active Comparator|BID group|Patients in this group will receive concurrent twice-daily standard radiotherapy (95%PTV 45Gy in 30 twice-daily fractions over 3 weeks, 5 days per week, without SIB) and chemotherapy (etoposide and cisplatin).
89558682|NCT03186417|Experimental|Cohort 1|2 million human MSC (hMSC)/kg infusion versus placebo infusion
89558683|NCT03186417|Experimental|Cohort 2|4 million hMSC/kg infusion versus placebo infusion
89558684|NCT03186417|Experimental|Cohort 3|6 million hMSC/kg infusion versus placebo infusion
89558685|NCT03178045||Team Monitoring|Team Monitoring is the current standard of care for patients at Josie Robertson Surgery Center (JRSC).
89558686|NCT03178045||Enhanced Feedback|The electronic system will provide tailored normative data visualizations that offer context and education to patients regarding expected symptom severity.
89558687|NCT03175744|Experimental|Stellarex DCB|Spectranetics Stellarex Drug Coated Balloon
89558688|NCT03175744|Active Comparator|PTA Catheter|Standard Uncoated Balloon Angioplasty Catheter
89558689|NCT03171311|Active Comparator|Angiographic guided PCI|Angiographic guided PCI is revascularization by percutaneous coronary intervention (PCI) and optional use of intravascular ultrasound (IVUS).
89558690|NCT03171311|Experimental|OCT guided PCI|OCT guided PCI is percutaneous coronary intervention (PCI) guided by systematic use of intravascular optical coherence tomography (OCT)
89558691|NCT03168750||Femoral Component:Medacta Masterloc Stem and Medacta MPACT cup|All patients enrolled will receive the Medacta Masterloc Stem and MPACT cup with Highcross PE liner.
89558692|NCT03154307|Experimental|Group 1: Weekly TMS|LF-rTMS intervention for 2 weeks (5 days per week for total of 10 days) , LF-rTMS 1 session/week for 1 month (4 days), and LF-rTMS 1 session/month for 11 months
89558693|NCT03154307|Experimental|Group 2: Monthly TMS|LF-rTMS intervention for 2 weeks (5 days per week for total of 10 days), LF-rTMS 1 session/month for 12 months
88965189|NCT00006363|Active Comparator|Immunotherapy Arm II|Patients are observed and receive no further therapy.
88965190|NCT05680909||SaCo VLM evaluation|"Prospective group of morbidly obese patients scheduled for elective bariatric procedure with the use of SaCo VLM for airway management.~The following features related to SoCo VLM use will be recorded: insertion of SaCo VLM, evaluation of ventilation parameters, attempt of endotracheal intubation via SaCo VLM's lumen under continuouis visualisation of entrance to larynx using videoscope intergatred system"
88965191|NCT05680870|No Intervention|Control group|Control grp will not receive omeprazole . They will receive chemotherapy protocols only
88965192|NCT05680870|Experimental|Intervention group|Intervention group will receive omeprazole plus chemotherapy protocols
88965193|NCT05680831|Experimental|0.070 ppm ozone concentration|Exposure to 0.070 ppm ozone for 6.6 hours while performing moderate intermittent exercise.
88965194|NCT05680831|Experimental|Clean air (0.0 ppm ozone)|Exposure to clean air (0.0 ppm ozone) for 6.6 hours while performing moderate intermittent exercise.
88965195|NCT05680753|Experimental|Stratified Blended Approach arm|First, physiotherapists will use two stratification tools to decide the most suitable content and intensity as well as mode of care delivery of primary care physiotherapy. The content and intensity of physiotherapy will be matched to the patient's risk of persistent disabling pain as assessed with the Keele STarT MSK tool. The mode of care delivery of physiotherapy will be matched to the patient's suitability for blended care as assessed using the Dutch Blended Physiotherapy Checklist (i.e. yes or no). Second, physiotherapists will receive two practical tools to provide the matched treatment of the mode of care delivery. If considered suitable for blended care, the patient will receive a blended physiotherapy treatment (e-Exercise), in which a smartphone app with personalized information, exercises and physical activity modules is an integral part of physiotherapy treatment. If patients are considered not to be suitable for blended care, a paper-based workbook will be integrated.
88965196|NCT05680753|Active Comparator|Usual physiotherapy arm|Patients in the usual physiotherapy arm will be offered usual care (face-to-face or video consults) based upon the recommendations of the guidelines of the Royal Dutch Association for Physiotherapy (KNGF). The clinical guideline for neck pain, recommends categorization in treatment profiles based on: the severity of neck pain, the course of symptoms (normal vs. deviant) and the presence of psychosocial factors that may hinder recovery (yes vs. no). The clinical guideline for complaints of the arm, neck and shoulder recommends categorization in treatment profiles based on the region of complaints indicated as most problematic and the relationship between complaints, disabilities, and limitations in participation. No stratification tools to identify patient subgroups and subsequently match them to a treatment are recommended by the guidelines.
88965197|NCT05680714||FALLERS IN THE INTERVENTION BOROUGHS|"Fallers 65+ years from the borough of Nordstrand from January 1. 2015 Fallers 65+ years from the borough of Østensjø from September 1. 2016~Fall injury will be included as a time-varying exposure variable. The individuals are all registered as non-fallers until they are registered with a fall injury in the NPR database, when they shift status to fallers."
88965198|NCT05680714||FALLERS IN THE CONTROL BOROUGHS|"Fallers 65+ years from all the 13 other boroughs of Oslo.~Fall injury will be included as a time-varying exposure variable. The individuals are all registered as non-fallers until they are registered with a fall injury in the NPR database, when they shift status to fallers."
89026350|NCT01605487|Other|Placebo - Rupatadine 20mg - Rupatadine 40mg|
89026351|NCT01605487|Other|Rupatadine 40mg - Placebo - Rupatadine 20mg|
89026352|NCT01605487|Other|Placebo - Rupatadine 40mg - Rupatadine 20mg|
89558694|NCT03154307|Sham Comparator|Group 3: Sham TMS|Sham LF-rTMS for 2 weeks (5 days per week for a total of 10 days), sham LF-rTMS 1 session/week for 1 month (4 days), and sham LF-rTMS 1 session/month for 1 month. After the sham stimulation real LF-rTMS intervention sessions will be delivered as follows: 50% of placebo group will follow group 1 protocol and the other 50% will follow group 2 protocol
88965199|NCT05680714||NON-FALLERS|All non-fallers 65+ years from all Oslo boroughs.
88965200|NCT05680402|Experimental|Group 1|Soft tissue mobilization
88965201|NCT05680402|Active Comparator|Group 2|Piriformis Stretching
88965202|NCT05680363|Active Comparator|Standard Sperm Preparation|Sperm samples in the control group will undergo traditional processing in the lab prior to insemination.
88965203|NCT05680363|Experimental|HyperSperm|Sperm samples in the experimental group will undergo product-specific processing in the lab prior to insemination.
88965204|NCT05680324|Active Comparator|Abdominoplasty with Monsplasty|
88965205|NCT05680324|Active Comparator|Abdominoplasty without monsplasty|
88965206|NCT05680285|Experimental|diode laser pulpotomy|"Diode laser (Solase-976 Dental Diode Laser)~With a wavelength of 980 nm and a frequency of 110 Hz~In pulse mode, working for 1 ms and stopping for 8 ms~With a power output of 1 W during each laser pulse from the 400 µm fiber optic tip~By touching the fiber optic tip to the remaining pulp tissue~for 3 seconds~With 3 J energy to each root pulp during the process"
88965207|NCT05680285|Experimental|low level diode laser pulpotomy|"Diode laser (Solase-976 Dental Diode Laser)~It has a wavelength of 980 nm and a frequency of 165 Hz.~In pulse mode by setting it to run for 2 ms and stop for 4 ms~At a power of 0.2 W during each laser pulse from a 400 µm fiber optic tip~Without the fiber optic tip touching the remaining pulp tissue~for 10 seconds~With 2 J Energy to each root pulp"
88965208|NCT05680207|Active Comparator|Intervention group|Type 2 Diabetes Mellitus patients who received a empowerment training program for 6 weeks, 2 hours a week
88965209|NCT05680207|No Intervention|Control group|Type 2 Diabetes Mellitus patients who did not receive a empowerment training program
88965210|NCT05680090||Eligible participants for AI-based ophthalmic emergency triage and primary diagnosis|
88965211|NCT05679973|Experimental|Polybutester|Polybutester suture is a copolymer of polyglycol terephthalate and polybutylene terephthalate. It is a synthetic, non-resorbable, monofilament suture material. Polybutester is stronger than other monofilaments. Suture memory is poor and packaging does not retain its shape. Therefore, this suture is easier to work with and the knot security is higher. Polybutester suture adapts better to tensile strength than other synthetic sutures. This suture adapts to the increasing wound edema and returns to its original shape when the edema subsides. Also, this suture reduces the risk of hypertrophic scar formation due to its ability to adapt to the edema and changing configuration of a healing wound. It produces better cosmetic results.
88965212|NCT05679973|Active Comparator|Polypropylene|Polypropylene, used as suture material, is formed by bringing isotactic stereoisomers of a linear hydrocarbon crystalline polymer into sterile monofilament form. Polymer polypropylene is a non-resorbable, synthetic, monofilament suture. It has high compressive strength and low tissue reactivity. It is resistant to infection formation. In general, the ability to close and protect the wound is good. The suture memory is high, therefore it is difficult to use and the knot security is less than other sutures. Allergic reaction due to polypropylene sutures is very rare.
88965213|NCT05679934|Experimental|Home-Based Exercise|Patients who perform home-based exercise program
88965214|NCT05679934|Experimental|Telerehabilitation|Patients who perform telerehabilitation exercise program
88965215|NCT05679934|No Intervention|Control Group|No intervention
88965216|NCT05679856|Experimental|Single vocal cord hypofractionated radiotherapy|Hypofractionated radiotherapy 58.08Gy/16 fractions to affected vocal cord plus margins to account for motion and setup errors using IMRT/VMAT technique
88965217|NCT05679856|Active Comparator|Whole laryngeal radiotherapy|Radiotherapy 63Gy/28 fractions to whole larynx from lower border of hyoid bone to lower border of cricoid cartilage using IMRT/VMAT technique
88965218|NCT05679817|Experimental|D-GAE group|This group received a 12-week aerobic training in addition to the traditional physical rehabilitation.
88965219|NCT05679817|Active Comparator|Control group|This group received the traditional physical rehabilitation only
88965220|NCT05679739|Experimental|Individualized blood pressure strategy|Hemodynamic optimization performed to an individualized target mean arterial pressure in the first 72 hours post ROSC based on cerebral perfusion assessed serially.
89026353|NCT01605487|Other|Rupatadine 40mg - Rupatadine 20mg - Placebo|
89558695|NCT03154307|Experimental|Short-term protocol|LF-rTMS intervention daily for up to 5 days in medically refractory status epilepticus participants only
89558696|NCT03144700||Compensated Cirrhosis|
88965221|NCT05679739|No Intervention|Standard-of-care group|Hemodynamic optimization to a target mean arterial pressure of ≥65mmHg throughout the first 72 hours post-ROSC.
88965222|NCT05679583|Experimental|Preoperative SBRT arm|Patients with resectable pancreatic cancer will receive preoperative SBRT 2 to 4 weeks before surgery. And 4 weeks after surgery, adjuvant CTx will be administered for 6 months.
88965223|NCT05679466|Active Comparator|ReCOV|
88965224|NCT05679466|Placebo Comparator|ReCOV placebo|
88965225|NCT05442619|Experimental|Portable therapeutic baby nest group|Blood will be drawn from newborns using the portable therapeutic baby nest.
88965226|NCT05442619|Active Comparator|Control group|Blood collection from newborns will be done according to the clinical routine.
88965227|NCT05678296||control group|platelet-rich fibrin placed into the socket of extracted tooth and no antibiotic is prescribed.
88965228|NCT05678296||group 1|platelet-rich fibrin + 0.5 ml amoklavin I.V. 1.2 gr placed into the socket of the extracted tooth.
88965229|NCT05678296||group 2|platelet-rich fibrin + 0.5 ml Clin 600 mg/4 ml IM/IV, 0.5 ml placed into the socket of the extracted tooth.
88965230|NCT05675293|Experimental|EXPERIMENTAL ARM|
88965231|NCT05675293|Active Comparator|CONTROL ARM|
88965232|NCT05675176||Group 1|Patients with non muscle invasive bladder cancer undergoing intravesical instillation with the use of self lubricated silicon tiemann 10 fr urinary catheter.
89558697|NCT03139825|Other|Adolescent with suicidal behavior and personality disorder|
89558698|NCT03139370|Experimental|KITE-718|"Phase 1A: Participants will receive cyclophosphamide and fludarabine conditioning chemotherapy followed by the investigational treatment, KITE-718.~Phase 1 B: Participants will receive cyclophosphamide and fludarabine conditioning chemotherapy followed by the investigational treatment, KITE-718, at a dose selected based on Phase 1A."
88965233|NCT05675176||Group 2|Patients with non muscle invasive bladder cancer undergoing intravesical instillation with the use of straight tipped latex foley 14 fr urinary catheter
88965234|NCT03996148|Active Comparator|Remifentanil, Propofol, and Desflurane|Study group A: no midazolam given; maintenance drugs started immediately after induction and airway is secured.
88965235|NCT03996148|Active Comparator|Remifentanil, Dexmedetomidine, and Desflurane|Study group B: no midazolam given; maintenance drugs started immediately after induction and airway is secured.
88965236|NCT03996148|Active Comparator|Remifentanil and Desflurane|Study group C (control group): no midazolam given; maintenance drugs started immediately after induction and airway is secured.
88965237|NCT05660200|Experimental|IBSA Iron ODF|A single dose of IBSA Iron ODF containing 30mg Iron and 400ug folic acid will be admistered to healthy female volounteers in one of the two consecutive study periods with a 7-day washout interval between the two administrations.
88965238|NCT05660200|Active Comparator|SiderAL® FORTE|A single dose of SiderAL® FORTE containing 30mg Iron and 70mg vitamin C will be admistered to healthy female volounteers in one of the two consecutive study periods with a 7-day washout interval between the two administrations.
88965239|NCT05656183|Experimental|Single Arm|To investigate the diagnostic efficacy of WGS and its impact on clinical management compared to usual care in individuals with cardiovascular disease. Diagnostic yield and changes of management (CoM) will be assessed both within the WGS group and compared to a contemporaneous, matched (2:1) usual care (UC) group sourced from EHR records.
88965240|NCT05643781||Co-TB Group|Follow up all participants from hospital discharge until 12 months post-Covid-19 infection. Conduct investigations assessing cardiopulmonary, socioeconomic, quality of life outcomes. No interventions.
88965241|NCT03986203|Experimental|Active|Subjects in this group will receive the active treatment for each daily treatment session.
88965242|NCT03986203|Sham Comparator|Sham|Subjects in this group will receive the sham treatment for each daily treatment session.
88965243|NCT05552404|Other|Conservative therapy|will receive conservative therapy such as bed rest, fluids, abdominal binder, oral paracetamol, and caffeine
88965244|NCT05552404|Active Comparator|Aminophylline|will receive conservative therapy plus Aminophylline (250mg of Aminophylline dissolved in 100ml normal saline for intravenous infusion over 30 minutes)
88965245|NCT05552404|Active Comparator|transnasal spheno-palatine ganglion block|will receive the conservative therapy plus transnasal spheno-palatine ganglion block under strict protective and safety measures against COVID-19, using a hollow cotton swab soaked in lidocaine 2% for 5 minutes in each nostril then 0.5ml of lidocaine 2% will be injected slowly through the hollow swab and repeated once after another 5 minutes where the patient will stay in the supine position for 10 minutes.
88965246|NCT05546320|Active Comparator|Migraine Medication Group|Patients randomized into migraine medication group will be given Metoprolol 25mg twice a day as the control group.
88965247|NCT05546320|Experimental|Anticoagulation or anti-platelet medication Group 1|Patients randomized into anticoagulation or anti-platelet medication group will be given aspirin.
88965248|NCT05546320|Experimental|Anticoagulation or anti-platelet medication Group 2|Patients randomized into anticoagulation or anti-platelet medication group will be given clopidogrel.
88965249|NCT05546320|Experimental|Anticoagulation or anti-platelet medication Group 3|Patients randomized into anticoagulation or anti-platelet medication group will be given Rivaroxaban.
88965250|NCT05535595|Experimental|Experimental|This group will perform genetic study for predicting adverse reaction to ACEI. Based on the result of genetic study, participants will receive ACEI or ARB.
88965251|NCT05535595|Active Comparator|Control|Participants will receive ACEI without genetic study.
88965252|NCT05470816|Active Comparator|Tranexamic Acid|12 mg/kg, before surgical incision, and then an infusion of 3 mg/kg/h until the end of surgery.
88965253|NCT05470816|Placebo Comparator|Placebo|12 mg/kg, before surgical incision, and then an infusion of 3 mg/kg/h until the end of surgery.
88965254|NCT00386893|Other|Treatment as usual|simultaneous EEG/fMRI
88965255|NCT00386971|Active Comparator|1|L-carnitine
88965256|NCT00386971|Placebo Comparator|2|Placebo
88965257|NCT00387049|Experimental|Anxiety-specific smoking cessation care|
88965258|NCT00387049|Active Comparator|Standard smoking cessation care|
89026354|NCT03271775|No Intervention|control group|Patients in the control group will follow the doctor's instructions (medications and etc.) and will not participate in any physical therapy program.
89558699|NCT03133221|Experimental|Oral Zydelig 150 mg BID|Zydelig given orally at 150 mg twice daily continuously on 28-day cycles starting 30 to 120 days after autologous stem cell transplantation for patients with indolent or transformed indolent B-cell NHL, for up to 1 year maintenance duration. Dose withhold/modification is allowed according to tolerability/toxicity.
88965259|NCT00387166||1|Mexican-American women, aged 40-65
88965260|NCT05431543|Experimental|Combination ophthalmic solution (LNZ101) dosed bilaterally|LENZ 101: Aceclidine/Brimonidine combination ophthalmic solution
88965261|NCT05431543|Experimental|Aceclidine Ophthalmic Solution (LNZ100) dosed bilaterally|LENZ 100: Aceclidine ophthalmic solution
88965262|NCT05431543|Experimental|Vehicle Ophthalmic Solution dosed bilaterally|Proprietary vehicle ophthalmic solution
89558700|NCT03112928|Experimental|Phantom Motor Execution (PME)|Phantom motor execution is decoded via myoelectric pattern recognition and promoted via serious gaming in virtual and augmented reality.
89558701|NCT03112928|Active Comparator|Phantom Motor Imagery (PMI)|Use the same device and visual stimulation as PME, with the difference that participants imagine to perform, rather than execute phantom movements. Myoelectric activity is used to monitor that the subjects do not produce muscular contractions but only imagine the movements.
89558702|NCT03089203|Experimental|Cohort 1|CART-PSMA-TGFβRDN cells 1-3x10^7 Day 0
89558703|NCT03089203|Experimental|Cohort 2|CART-PSMA-TGFβRDN cells 1-3x10^8 Day 0
89558704|NCT03089203|Experimental|Cohort -3|CART-PSMA-TGFβRDN cells 1-3x10^7 Day 0
89558705|NCT03089203|Experimental|Cohort 4|CART-PSMA-TGFβRDN cells 0.70-1.00 x 10^8 Day 0
89558706|NCT03089203|Experimental|Cohort 3|CART-PSMA-TGFβRDN cells at the MTD (established by Cohorts 1-2) on day 0
89558707|NCT03079037||Stimulation|Traditional deep brain stimulation
89558708|NCT03072602|Experimental|African-American|Healthy self-identified African-American participants will be enrolled and each will undergo a physical exam and screening tests to determine participants' eligibility. Participants will consume the study diet for 3 days provided by the clinical research unit's metabolic kitchen (at UAB). On 4th day, participants will come to the clinic in fasting state and drink 75 gm of oral glucose solution, followed by blood collection every hour for 8 hours.
89558709|NCT03072602|Active Comparator|White|Healthy self-identified white participants will be enrolled and each will undergo a physical exam and screening tests to determine participants' eligibility. Participants will consume the study diet for 3 days provided by the clinical research unit's metabolic kitchen (at UAB). On 4th day, participants will come to the clinic in fasting state and drink 75 gm of oral glucose solution, followed by blood collection every hour for 8 hours.
89558710|NCT03070366|Active Comparator|Chemotherapy combined with stereotactic radiotherapy (RT)|"Chemotherapy is based on patient Performance Status (PS) and comorbidities:~PS 0-1: standard treatment: 6 cycles, every 3 weeks cisplatin (100 mg/m² iv on D1), 5FU (4000 mg/m² total dose starting on Day 1 to Day 4 and during 96h in continuous infusion)~PS 2/cardiac contra-indication to 5 Fluorouracil (5FU): 6 cycles, every 3-4 weeks cisplatin (100 mg/m² iv on Day 1) or carboplatin Area Under Curve (AUC) 4 or 5 on Day 1 In both case: Cetuximab (loading dose 400 mg/m² iv on Day1, then 250 mg/m² weekly or 500mg/m² every 2 weeks).~Cycle 1 of systemic treatment will be administered before the start of the stereotactic RT. Then, following cycles will be performed after the end of stereotactic irradiation.~Cetuximab maintenance: 250 mg/m² iv weekly. It will be given only if at least disease stabilization is observed at the end of chemotherapy, and will be continued until progression or unacceptable toxicity."
89608707|NCT03588507|Active Comparator|PPF+NCHA bone graft substitute|intervention: papilla preservation flap techniques + nanocrystalline hydroxyapatite bone graft substitute Same surgical techniques and procedures will be performed. Before suturing the flap, nanocrystalline hydroxyapatite bone graft substitute(Dentaurum, Germany) will be placed within the defect up to the existing level of the alveolar crest and care will be taken not to overfill the defect. The mucoperiosteal flaps will be repositioned and secured in place using non-resorbable # 6-0-suturing material. Vertical or horizontal mattress sutures and additional interrupted single sutures will be performed to obtain primary closure of the interdental space.
89608708|NCT03897309|Experimental|Monovalent GI.1|Monovalent GI.1 tableted vaccine group
89608709|NCT03897309|Experimental|Monovalent GII.4|Monovalent GII.4 tableted vaccine group
89608710|NCT03897309|Experimental|Bivalent GI.1 and GII.4 vaccine group|Bivalent vaccine group consisting of co-administration of GI.1 and GII.4 vaccine
89608711|NCT03897309|Placebo Comparator|Placebo|Placebo tablets
89608712|NCT03588429|Experimental|Sevoflurane|Anesthesia was maintained with sevoflurane.
89608713|NCT03588429|Experimental|Isoflurane|Anesthesia was maintained with isoflurane.
89608714|NCT03581019|Experimental|Uterus transplantation|Uterus transplantation
89608715|NCT03580161||18-F FDG PET/CT|Patients receiving routine diagnostic scan
89608716|NCT03580161||Ga-68 PSMA PET/CT|Patients receiving routine diagnostic scan
89608717|NCT03580161||68-Ga Dotatate PET/CT|Patients receiving routine diagnostic scan
89608718|NCT03580161||99mTc Pertechnetate Thyroid Scan|Patients receiving routine diagnostic scan
89608719|NCT03580161||99mTc DMSA(III) Renal Scan|Patients receiving routine diagnostic scan
89608720|NCT03580161||99mTc MAG3 Renal Scan|Patients receiving routine diagnostic scan
89608721|NCT03580161||99mTc MDP/HDP Bone Scan|Patients receiving routine diagnostic scan
89608722|NCT03583437|Experimental|Healthy male volunteers|Behavioral: Exercise Moderate Intensity Exercise (50 % af VO2max) for 90 minutes before and after PET scanning.
89608723|NCT03583437|Experimental|Healthy female volunteers|Behavioral: Exercise Moderate Intensity Exercise (50 % af VO2max) for 90 minutes before and after PET scanning.
89608724|NCT03588351|Active Comparator|chlorhexidine gluconate|GROUP I: - 15 teeth will be treated with specially prepared gel containing chlorhexidine gluconate as intracanal medicament .
89608725|NCT03588351|Experimental|chitosan nanoparticles gel|GROUP II: - 15 teeth will be treated with specially prepared gel containing chitosan nanoparticles that ready to use as intracanal medicament.
89608726|NCT03588351|Experimental|chitosan gel|Group III: 15teeth will be treated with specially prepared gell containing chitosan that ready to use as intra medicament .
89608727|NCT03588273|Other|Amoxil 500 mg Oral Capsule Time 0|In each period (before the surgery and 2 months after the bariatric surgery) the obese volunteers received a single oral dose of amoxicillin 500 mg capsule (Amoxil®, GlaxoSmithKline Brazil Ltda.) with 200 mL water after an overnight fast (approximately 8 h).
89608728|NCT03588195|Experimental|Education Group|
89608729|NCT03588195|Active Comparator|Control Group|
89608730|NCT03585621|Experimental|SBRT to the Primary Breast Tumour|SBRT to the breast using 4 sequentially escalating dose levels from 9Gy to 12 Gy.
89608731|NCT03588819|Experimental|2-fraction SABR|
89558711|NCT03070366|Experimental|stereotactic radiotherapy|Splitting will be based on the tumor diameter, and proximity of organs at risk which constitutes any limiting toxicities. It will be 3 or 5 fractions based on the recommendations (CARO-Stereotactic Body Radiation Therapy (SBRT) 2012) and for the purpose of harmonization practices. The prescription dose is 3 x 10 = 30 Gy 3 x 11 = 33 Gy or 3 x 15 = 45 Gy (if 3 fractions) with the possibility of 3 x 20 Gy to the peripheral lung nodules with tracking in Cyberknife or 5 x 7 = 35 Gy or 5 Gy x 10 = 50 (if 5 fractions). Beyond 3 cm of tumor diameter and / or to a distance of less than 1 cm from the GTV in an organ critical risk (eg spinal cord), a splitting up into 5 sessions must be privileged.
89558712|NCT03049540|Active Comparator|Tadalafil|Tadalafil 20 MG, p.o., once per day for 3 years
89558713|NCT03049540|Placebo Comparator|Placebo|Placebo 20 MG, p.o., once per day for 3 years
89558714|NCT03039712||Micra leadless pacemaker therapy|All Medicare patients implanted with Micra leadless pacemaker system
89558715|NCT03039712||Single Chamber Transvenous pacemaker|All Medicare patients implanted with full system (e.g. lead and generator) single- chamber ventricular transvenous pacemakers
89026355|NCT03271775|Experimental|PT treatment group for balance disorder|Patients in this research group will join to a 3 months' physical therapy treatment group designed to improve balance. The service for the group is provided by laboratory.
89026356|NCT03271775|Experimental|independant home computerized exercises|Patients in this group will be treated by 3 months' independent home computerized exercise program. Each patient will receive a personal access code for the exercise program. The duration of each practice is 5-10 minutes per day.
89026357|NCT00499824|Experimental|1|Medical Practitioners who receive education on diabetes management following the guidelines of the International Diabetes Federation Western Pacific Region
89026358|NCT00499824|No Intervention|2|Medical practitioners who follow standard practice for management of their patients with type 2 diabetes
89026359|NCT01365910|Experimental|Treatment (enzyme inhibitor)|Patients receive linifanib PO QD. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89026360|NCT00473798||A|Women who are eligible to participate in a study of the technical feasibility of optical spectroscopy will be invited to participate in this study.
89026361|NCT00473798||A'|Women who are eligible to participate in a study of the technical feasibility of optical spectroscopy will be invited to participate in this study.
89026362|NCT00473798||B|Patients who have consented to participate in a randomized trial of optical spectroscopy.
89026363|NCT00473798||C|Women who are eligible to participate in a study of the technical feasibility of optical spectroscopy will be invited to participate in this study.
89026364|NCT00473798||D|Health care providers.
89026365|NCT01605526|Experimental|Single Arm|
89026366|NCT02274480||Breast cancer patients with cardiotoxicity|Each patient will undergo a cardiac MRI with DWI. The standard of care in patients with declining LVEF is a cardiac MRI. For this study, those patients will also have the added DWI sequence. For patients who are not already scheduled for a cardiac MRI by their referring physician, and therefore do not have an upcoming standard of care cardiac MRI, a research cardiac MRI with DWI will be added. They will not be charged for the DW-MRI of the heart or any additional images taken as part of that scan. Patients unable to tolerate lying flat for this length of time or to tolerate the scan for any reason will be withdrawn and replaced in the study. After their cardiac MRI, their participation in the study is complete.
89026367|NCT02274480||Breast cancer patients without cardiotoxicity|Each patient will undergo a cardiac MRI with DWI. The standard of care in patients with declining LVEF is a cardiac MRI. For this study, those patients will also have the added DWI sequence. For patients who are not already scheduled for a cardiac MRI by their referring physician, and therefore do not have an upcoming standard of care cardiac MRI, a research cardiac MRI with DWI will be added. They will not be charged for the DW-MRI of the heart or any additional images taken as part of that scan. Patients unable to tolerate lying flat for this length of time or to tolerate the scan for any reason will be withdrawn and replaced in the study. After their cardiac MRI, their participation in the study is complete.
89026368|NCT00499902|Other|2 stages|This is a two-stage study. The first stage is in a three-tier dose escalation format, followed by a second stage during which subjects will be randomized in an equal proportion to up to 3 qualifying dose arms.
89026369|NCT00473954|Experimental|EGEN-001|
89558716|NCT03012880|Experimental|Treatment (ixazomib, lenalidomide, daratumumab, dexamethasone)|"INDUCTION PHASE: Patients receive ixazomib citrate PO on days 1, 8, and 15 and lenalidomide PO on days 1-21. Patients receive daratumumab IV over 3-7 hours on days 1, 8, 15, and 22 of courses 1 and 2, on days 1 and 15 of courses 3, 4, and 5, and on day 1 of courses 7 and beyond. Patients also receive dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE PHASE: Patients receive ixazomib citrate PO on days 1, 8, and 15 and daratumumab IV over 3-7 hours on day 1. Courses repeat every 28 days for up to 36 months from registration in the absence of disease progression or unacceptable toxicity."
89026370|NCT00468767|Experimental|1|Atrial fibrillation (AF) duration of 3 hours to 7 days.
89026371|NCT00468767|Experimental|2|AF duration of >7 days to <45 days
89026372|NCT00493077|Experimental|1|
89558717|NCT02999087|Active Comparator|Arm A Patient FIT|"Lead-in phase (Day-8) : no treatment~Concomitant radiotherapy phase : Radiotherapy by IMRT + cisplatin 100mg/m2~Maintenance phase : no treatment until follow-up phase"
89026373|NCT00500019||1.|Elective Cesarean sections
89558718|NCT02999087|Experimental|Arm B Patient FIT|"Lead-in phase (Day-8) : Cetuximab 400mg/m2 and avelumab 10mg/kg~Concomitant radiotherapy phase : Radiotherapy by IMRT + cetuximab 250mg/m2 and avelumab 10mg/kg~Maintenance phase : avelumab 10mg/kg every 2 weeks during 12 months"
89558719|NCT02999087|Experimental|Arm C Patient UNFIT|"Lead-in phase (Day-8) : Cetuximab 400mg/m2 and avelumab 10mg/kg~Concomitant radiotherapy phase: Radiotherapy by IMRT + cetuximab 250mg/m2 and avelumab 10mg/kg~Maintenance phase : avelumab 10mg/kg every 2 weeks during 12 months"
89558720|NCT02999087|Active Comparator|Arm D Patient UNFIT|"Lead-in phase (Day-8): Cetuximab 400mg/m2~Concomitant radiotherapy phase: Radiotherapy by IMRT + cetuximab 250mg/m2~Maintenance phase : no treatment until follow-up phase"
89558721|NCT02983461|Placebo Comparator|Placebo|Double Blind Placebo 3 times a day for 10 weeks.
89558722|NCT02983461|Active Comparator|Sildenafil|Double Blind Sildenafil, 20mg x 3 times a day, 10 weeks.
89558723|NCT02950987|Experimental|Whole Body MRI|"Magnetic resonance imaging will be performed on participants~Participants who are two young to tolerate the scans awake, can receive sedation/anesthesia"
89558724|NCT02945085|Experimental|Home Based Care Team|Primarily in-home treatment provided by team led by nurse practitioner with geriatrics and geriatric psychiatry expertise.
89026374|NCT00500019||2.|Non-elective cesarean section
89026375|NCT00474110|Experimental|1|Ketamine and hydromorphone for patient-controlled relief in children's mucositis.
89208428|NCT04089683||Nurses|Swabs collected from Web space, Scrub, Anterior nares before entering Operation theatre and while exit from operation theatre
89558725|NCT02945085|Active Comparator|Telephone Based Care Team|Primarily telephone-based treatment provided by existing care management program offered by collaborating Medicare Advantage insurer.
89558726|NCT02935543|Experimental|CART19|CART19 cells transduced with a lentiviral vector to express anti-CD19 scFv TCRz:41BB administered by IV infusion.
89558727|NCT02925364||No pain|patients who are enrolled in the parent study and report no chest pain at their 6 month post-cardiac surgery follow-up will undergo functional and anatomical MRI
89558728|NCT02925364||Pain|Patients who are enrolled in the parent study and report chest pain at their 6 month post-cardiac surgery follow-up will undergo functional and anatomical MRI
89558729|NCT02924727|Experimental|LCZ696 (sacubitril/valsartan)|"Following randomization, patients will receive LCZ696 in titrated doses from level 1 up to level 3 (50, 100 and 200 mg twice daily).~Patients will be required to take a total of two pills, (one tablet from the LCZ696 pack and one capsule from ramipril matching placebo pack) twice a day for the duration of the study.~Patients randomized to LCZ who were previously treated with ACE inhibitors receiving the last dose of that agent during the last 36 hours prior to randomization will receive a valsartan bridge for one day. These patients will receive two doses of valsartan for 1 day in a blinded manner prior to beginning double-blind LCZ696 treatment."
89558730|NCT02924727|Active Comparator|Ramipril|"Following randomization, patients will receive the Ramipril in titrated doses from level 1 up to level 3 (1.25, 2.5 and 5 mg twice daily).~Patients will be required to take a total of two pills, (one capsule from the ramipril pack and one tablet from LCZ696 matching placebo pack) twice a day for the duration of the study.~Patients randomized to ramipril who were previously treated with ACE inhibitors receiving the last dose of that agent during the last 36 hours prior to randomization will immediately start on double-blind ramipril; however, to maintain double blind/double dummy of the valsartan bridge, these patients will receive two doses of matching valsartan placebo for 1 day in a blinded manner prior to beginning double-blind LCZ696 placebo."
89558731|NCT02905110|Experimental|Methotrexate / Etoposide Infusion|12 infusions of intraventricular Methotrexate and 15 infusions of intraventricular Etoposide into implanted fourth ventricle catheter/Ommaya reservoir following surgical catheter placement into fourth ventricle. Methotrexate will be infused twice weekly for 6 weeks and etoposide will be infused 5 times a week on weeks 1, 3 , and 5.
89558732|NCT02901626|Experimental|Arabin Cervical Pessary|Arabin pessary. Participants will also receive vaginal progesterone to be administered daily, if it is the local standard of care.
89558733|NCT02901626|No Intervention|No Pessary|Participants will also receive vaginal progesterone to be administered daily, if it is the local standard of care.
89558734|NCT02893163|Experimental|CHANGE Intervention|The CHANGE intervention is a personalized approach to nutrition and exercise modification supported by a interdisciplinary team. The FD will recruit patients, complete baseline measurements and stabilize medication. The RD will create a diet plan tailored to the individual patient based on the intervention protocol. The ES will create an exercise plan tailored to the individual patient based on the intervention protocol. At the start, patients will meet weekly with the RD and ES in order to monitor progress, ascertain barriers and facilitators to change, and ensure adherence for the first 12 weeks of the intervention. Meetings will then occur monthly for the remaining 9 months of the intervention. Visits with the FD will occur every 3 months for the 12 month intervention to monitor progress, encourage behaviour change. A follow-up visit with the Research Coordinator will take place at 18 months.
88965263|NCT05401786|Experimental|Anti-CTLA-4, SBRT and PD1|"Participants will receive 1 dose of ipilimumab (1mg/kg intravenously) on day 1. After 1 week the participants will receive SBRT (3x8Gy) on at least 1 but no more than 4 tumor lesions.~Within 1 week of the last radiation fraction participants will start with cemiplimab (350mg intravenously every 3 weeks) until disease progression, unacceptable toxicity, patient request for discontinuation, or up to 2 years of treatment"
88965264|NCT00006420||Observational, no interventions|
88965265|NCT05391763|Other|Right: removal of fascia pectoralis, left: preservation of fascia pectoralis|
88965266|NCT05391763|Other|Left: removal of fascia pectoralis, right: preservation of fascia pectoralis|
88965267|NCT03957733|Experimental|Experimental arm|Long course CRT is followed by 4 cycles of combination chemotherapy of modified FOLFOX6 or 3 cycles of XELOX (capecitabine and oxaliplatin) and surgery. Consolidation chemotherapy will start 2-4 weeks after the end of CRT. Surgery will be performed 2-4 weeks after the last chemotherapy cycle. After surgery, patients with pT0-2 N0 will not receive adjuvant chemotherapy. Patients with higher pathological stage will receive adjuvant chemotherapy (4 cycles of modified FOLFOX6 or 3 cycles of XELOX).
88965268|NCT03957733|No Intervention|Standard arm|Long course CRT will be followed by surgery 10-12 weeks after the end of CRT. After surgery, patients with pT0-2 N0 will not receive adjuvant chemotherapy. Patients with higher pathological stage will receive adjuvant chemotherapy (8 cycles of modified FOLFOX6 or 6 cycles of XELOX).
88965269|NCT05314309||mtFIT|Individuals who consent to participate in the study, will be asked to take two stool samples from the same bowel movement. In a central laboratory these two samples then will be analyzed. One with the standard of care faecal immunochemical test (FIT) and the other with the multi-target faecal immunochemical test (mtFIT). If either one of these two tests is positive, individuals will be referred to undergo a colonoscopy procedure. The performance of mtFIT, in comparison to FIT, will be evaluated against the colonoscopy findings.
88965270|NCT00387205|Experimental|Arm 1|Pazopanib monotherapy or in combination with lapatinib or other approved anti-cancer medications
88965271|NCT05285683|Active Comparator|Methylphenidate|0.5mg/kg
88965272|NCT05285683|Active Comparator|Carbidopa/levodopa,|25mg/100mg
88965273|NCT05285683|Placebo Comparator|Placebo|Oral Pill
88965274|NCT05247970|Experimental|Part 1: S-309309|Participants will receive S-309309 at specific timepoints in a fasted state.
88965275|NCT05247970|Experimental|Part 2: S-309309 and Midazolam|Participants will receive S-309309 and Midazolam at specific timepoints fed state.
88965276|NCT05247970|Placebo Comparator|Part 1 and 2: Placebo|Participants will receive a matching placebo to S-309309 at specific timepoints in either a fed or fasted state.
88965277|NCT05180656|Experimental|Yoga Intervention Group|All participants will be assigned to the yoga intervention group (single arm).
88965278|NCT00006441|Experimental|A|Patients beginning IL-2 treatment regimens after 4 weeks of study
88965279|NCT00006441|Active Comparator|B|Patients beginning IL-2 treatment after some delay based on specified criteria
89558735|NCT02893163|Active Comparator|Usual Care|The usual care arm of the study will involve regular care from the patients' FD. This may involve discussions regarding nutrition and exercise. The FD will still recruit patients, complete baseline measurements and stabilize medication. Visits to the FD will occur as usual care dictates. Participating PCNs randomized to usual care will still have interdisciplinary team members available but the referral arrangements are and will continue to be ad hoc. For the study, we will mandate that control patients have follow-up with the Research Coordinator at 3, 12 and 18 months for the purpose of assessing outcomes. At these time points, appointments will not be scheduled with the FD to manage their disease; rather, the purpose of the visit is to just conduct the outcome assessment.
89558736|NCT02872337|Experimental|Experimental (Intervention): PreopPT Group|This group will undergo the group preoperative education session. Following this session (intervention) this group underwent a one-time, one-on-one preoperative PT session. They also were given access to a web-based microsite which was customized to surgeon
89558737|NCT02872337|Placebo Comparator|Control (standard of care): No PreopPT Group|This group underwent the current of standard of care at our institution. This only includes the group preoperative education session. No further preoperative education was given.
89558738|NCT02856815|Experimental|Immuncell-LC group|Adjuvant adoptive immune therapy using a CIK cell agent(Immuncell-LC) 12 times(5 treatments at a frequency of once per week, followed by 5 treatments every 2 weeks, and finally 2 treatments every 4 weeks.
89558739|NCT02856815|No Intervention|Non-treatment group|Non-treatment
89558740|NCT02808507|Experimental|Facility-based screening|This strategy will be implemented at all clinics (n=28) within this arm for 18 months. Study staff will encourage providers at each of the clinics to screen all consenting patients attending the clinic, regardless of the original reason for clinic presentation. Upon presenting for care (e.g., while waiting for their healthcare provider), patients will be informed about the study and screened for cough of any duration, fever, weight loss, or night sweats. Participants who are symptomatic and provide a sputum specimen (according to the clinic standard of care) will be given a study flyer informing them that they may be contacted by study staff, and a brief summary of the study. Per standard of care, all sputum samples will be sent to the local National Health Laboratory Service laboratory for Xpert testing.
89558741|NCT02808507|Experimental|Contact screening|"This arm is comprised of two sub-arms:~In the household contact screening sub-arm, a mobile field team visits the household of each consenting newly diagnosed pulmonary TB index case. Each visit consists of a household census, consent of all eligible household members for TB screening, administration of a brief questionnaire, sputum collection for testing with Xpert Mycobacterium tuberculosis (MTB)/rifampin (RIF) and the offer of HIV testing.~In the incentive-based contact screening sub-arm, all consenting newly diagnosed active TB cases are provided with 10 coupons for free TB screening to give to close contacts. When a contact presents at clinic with a coupon, they and the index case each receive a small amount of money. If the contact is diagnosed with active TB and starts treatment, the index case receives an additional larger amount of money. Each contact receives a brief questionnaire, TB symptom screen, optional HIV testing, and sputum sample collection for Xpert MTB/RIF."
89558742|NCT02798523|Experimental|Up to 2 hours post infusion|Healthy volunteers received a single intravenous dose of 250 mg of methylprednisolone and blood was collected between one to two hours after the start of the infusion.
89558743|NCT02798523|Experimental|Up to 4 hours post infusion|Healthy volunteers received a single intravenous dose of 250 mg of methylprednisolone and blood was collected between two hours to four hours after the start of the infusion.
89558744|NCT02797977|Experimental|Standard-Dose Triplet Combination|SRA737 will be administered orally on Days 2, 3, 9, and 10 of each 21-day cycle. Subjects will receive a single dose of SRA737 between 4 to 7 days prior to starting the first cycle for PK profiling. Gemcitabine will be administered intravenously on Days 1 and 8 of each 21-day cycle. Cisplatin will be administered on Day 1 of each 21-day cycle. Subjects can continue taking the study treatment if they are safely receiving clinical benefit and able to follow the requirements of the study.
89208429|NCT04089683||OT Technicians|Swabs collected from Web space, Scrub, Anterior nares before entering Operation theatre and while exit from operation theatre
89558745|NCT02797977|Experimental|Low-Dose Gemcitabine Combination|SRA737 will be administered orally on Days 2, 3, 9, 10, 16, and 17 of each 28-day cycle. Subjects will receive a single dose of SRA737 between 4 to 7 days prior to starting the first cycle. Gemcitabine will be administered intravenously on Days 1, 8, and 15 of each 28-day cycle. Subjects can continue taking the study treatment if they are safely receiving clinical benefit and able to follow the requirements of the study.
89558746|NCT02786589|Experimental|Blood-stage infection of P. vivax|This is a single arm study that enrolls 30 patients to receive Plasmodium immunotherapy.
89558747|NCT02767973|Experimental|Woodsmoke Exposure|
89558748|NCT02748668||ECMO|No intervention. Blood specimen collection.
89558749|NCT02748668||Control|No intervention. Blood specimen collection.
88965280|NCT02972671|Experimental|MiStent (MT005) Coronary Artery Stent|A balloon expandable crystalline sirolimus eluting stent with an absorbable polymer coating will be implanted.
88965281|NCT02972671|Active Comparator|Xience Coronary Artery Stent|Balloon expandable drug eluting stents using everolimus with a non-erodible or durable polymer coating will be implanted
88965282|NCT05147233|Experimental|Active Treatment Arm|OCS-01 (Ophthalmic Suspension) - topical use
88965283|NCT05147233|Placebo Comparator|Vehicle Placebo Arm|Vehicle
88965284|NCT05088109||SI|adult patients with septic shock will be enrolled,At the time of admission (before the start of vasopressors), age of patients, source of sepsis, baseline systolic (SBP), diastolic (DBP), mean blood pressure (MAP), heart rate (HR), shock index (SI), adjusted shock index (ASI), modified shock index (MSI), diastolic shock index (DSI), baseline lactate, ABG, capillary refill time and body temperature will be recorded. Subsequent recordings will be at 0 (before starting vasopressors), 1, 2, 4, 8, and 12, 24, 48, 72 hours for all parameters except for lactate and ABG will be every 12 hours. SOFA scores, APACHE II, GCS, Charlson Comorbidity Index, will be recorded at admission; and mean total vasopressor dose, urine output will be recorded daily. Cause of death will be documented. All readings will continue for 72 after admission.
88965285|NCT05079139|Other|surgical technique of Musset|
88965286|NCT05054647||family caregivers of palliative patients|psychometric questionnaires
88965287|NCT03926845|Active Comparator|Isobutylamido-thiazolyl-resorcinol Cream 0.2%|The cream contains 0.2% Isobutylamido-thiazolyl-resorcinol.
88965288|NCT03926845|Placebo Comparator|Vehicle|The cream contains no active ingredients.
88965289|NCT05000515|Experimental|High-resistance inspiratory muscle strength training|Using a handheld device, participants will perform 30 breaths a day at 75% of maximal inspiratory pressure, six days a week, for three months.
88965290|NCT05000515|Active Comparator|Aerobic exercise|Participants will walk for 25 minutes a day, six days a week, for three months at a target heart rate of 40-60% heart rate reserve. Heart rate will be monitored with a heart rate monitor.
88965291|NCT00387322|Experimental|Group 1|Patients receive oral erlotinib hydrochloride once on days 2, 9, and 16 and pemetrexed disodium IV over 10 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of unacceptable toxicity or disease progression
88965292|NCT00387322|Experimental|Group 2|Patients receive oral erlotinib hydrochloride once daily on days 2-16 and pemetrexed disodium IV over 10 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of unacceptable toxicity or disease progression.
88965293|NCT00387361|Experimental|1|
88965294|NCT00387361|No Intervention|2|
88965295|NCT03923296||HCPs|Health care professional interviews (market research)
88965296|NCT03923296||Patients or caregivers|Patients or caregivers interviews
88965297|NCT03918343|Other|All patients|
89558750|NCT02742025|Other|Standard Care|"Patients randomized to this arm will have standard care with no extra interventions.~Intervention: Inclusion visit~Intervention: Coronarography on day 0"
89558751|NCT02742025|Experimental|HEARTLINK|"Patients randomized to this arm will participate in the HEARTLINK program, which includes a specific nurse consultation and telephone contact.~Intervention: Inclusion visit~Intervention: Nurse consultation~Intervention: Telephone contact~Intervention: Coronarography on day 0"
89558752|NCT02720692|Experimental|N1539 30mg|N1539 (Intravenous meloxicam) 30mg every 24 hours for up to 7 doses.
88965298|NCT03906604|Other|Dominant hand-open Carpal Tunnel Release|Standard mini-open carpal tunnel release (standard of care) on the dominant hand.
88965299|NCT03906604|Other|Dominant hand-Incisionless thread carpal tunnel release|Incisionless thread carpal tunnel release on the dominant hand.
88965300|NCT03876106|Experimental|LUT014 dose level 1|LUT014 will be topically applied to the face, neck, and upper portion of the anterior and posterior chest once a day for 4 weeks.
88965301|NCT03876106|Experimental|LUT014 dose level 2|LUT014 will be topically applied to the face, neck, and upper portion of the anterior and posterior chest once a day for 4 weeks.
88965302|NCT03876106|Experimental|LUT014 dose level 3|LUT014 will be topically applied to the face, neck, and upper portion of the anterior and posterior chest once a day for 4 weeks.
88965303|NCT00388011|Experimental|1|Intranasal morphine 3.75 mg
88965304|NCT00388011|Experimental|2|Intranasal morphine 7.5 mg
88965305|NCT00388011|Experimental|3|Intranasal morphine 15 mg
88965306|NCT00388011|Experimental|4|Intranasal morphine 30 mg
88965307|NCT00388011|Active Comparator|5|Intravenous morphine 7.5 mg
88965308|NCT00388011|Placebo Comparator|6|Intranasal placebo
88965309|NCT04918381|Experimental|CellFX Procedure|Treatment of the BCC with CellFX System
88965310|NCT00388050|Experimental|Diabetes Medication Choice decision aid|Patients in this arm will discuss diabetes medication for glucose control with the help of a decision aid that covers five commonly prescribed anti-hyperglycemic medications.
88965311|NCT00388050|Other|Usual Care|Patients and clinicians in this arm will discuss anti-hyperglycemic agents in their usual manner.
88965312|NCT04852978|Experimental|Wave 1 Dose 1|
88965313|NCT04852978|Experimental|Wave 1 Dose 2|
89558753|NCT02720692|Placebo Comparator|IV Placebo|IV Placebo every 24 hours for up to 7 doses.
88965314|NCT04852978|Experimental|Wave 1 Dose 3|
88965315|NCT04852978|Experimental|Wave 1 Vaccine only|
88965316|NCT04852978|Experimental|Wave 2 Dose 1|
89026376|NCT00500058|Experimental|SB-485232+Rituximab|Rituximab 375 milligrams per square meter (mg/m^2) will be administered to subjects with CD20+ B cell lymphoma by intravenous (IV) infusion once a week for four consecutive weeks on Day 1 of Weeks 1 to 4. SB-485232 will be administered by IV infusion over a 2 hour period, at doses ranging from 1 microgram (μg)/kilogram (kg) to 100 μg/kg. SB-485232 will be given once a week for 12 consecutive weeks on Day 2 of Weeks 1 to 4 and Day 2 (± 1 day) of Weeks 5 to 12. SB-485232 will be infused at least 24 hours after the Rituximab infusion was started.
89026377|NCT00468923|Placebo Comparator|Rosuvastatin|Rosuvastatin 10 mg vs placebo
89026378|NCT00468923|Placebo Comparator|Candesartan/HCT|Candesartan 16 mg/HCT 12.5 mg vs placebo
89026379|NCT01365481|Experimental|valsartan|Valsartan starting dose: ≥18 kg to <35 kg is 40 mg, ≥35 kg to <80 kg is 80 mg, ≥80 kg to ≤160 kg is 160 mg for 1 week then Valsartan maintenance dose: ≥18 kg to <35 kg is 80 mg, ≥35 kg to <80 kg is 160 mg, ≥80 kg to ≤160 kg is 320 mg after Week 8 if the Mean Sitting Systolic Blood Pressure (MSSBP) and/or Mean Sitting Diastolic Blood Pressure (MSDBP) was higher than 95th percentile for age, gender and height under the maintenance valsartan dose then add amlodipine and/or Hydrochlorothiazide (HCTZ). The valsartan +antihypertensive group includes patients who received background antihypertensive medication or received antihypertensive medication including amlodipine or HCTZ during the study.
89026380|NCT03271619||Transvenous ICD|Patients with a transvenous ICD undergoing defibrillation testing.
89026381|NCT03271619||Subcutaneous ICD|Patients with a subcutaneous ICD undergoing defibrillation testing.
89558754|NCT02712151|Active Comparator|Abdominal Wall Block with Ropivacaine 0.2%|Patients will receive bilateral transversus abdominis plane and rectus sheath blocks via ultrasound guidance. A total of 1.0ml/kg distributed between the four blocks (0.4+0.4+0.1+0.1) of 0.2% Ropivacaine (max 50ml) will be injected, as a one time single shot injection, into the fours sites. Surgical infiltration of the four port sites will receive 0.4ml/kg of sterile saline.
89558755|NCT02712151|Active Comparator|Surgical Infiltration with Ropivacaine 0.5%|Patients will receive surgical infiltration of local anesthetic into the 4 laparoscopic port sites. A total of 0.4 ml/kg (0.1+0.1+0.1+0.1) of 0.5% Ropivacaine, divided between the four port sites (max 20 ml), will be used. A total of 1ml/kg, divided between the TAP (0.4ml/kg on each side) and RS (0.1ml/kg on each side), of sterile saline will be used for the nerve blocks.
89558756|NCT02707484|Experimental|Thalidomide Group（100mg）|Generic name:Thalidomide Dosage form:tablet, 25mg Dosage:100mg/day Frequency: 25mg, QID, Oral Duration:120 days
89558757|NCT02707484|Experimental|Thalidomide Group（50mg）|Generic name:Thalidomide Dosage form:tablet, 25mg&Placebo Dosage:50mg/day Frequency: 25mg BID &Placebo, BID, Oral Duration:120 days
89558758|NCT02707484|Placebo Comparator|placebo -controlled Group|Generic name:Thalidomide Placebo Dosage form:tablet, Placebo Dosage:Placebo Frequency: Placebo, QID, Oral Duration:120 days
89026382|NCT01605604|Experimental|recieves Buddhist mindfullness|
89026383|NCT00493116|Experimental|1|
89026384|NCT01605682|Experimental|Berry extract 125|Fresh berry extract containing 125mg of polyphenols
89026385|NCT01605682|Experimental|Berry extract 250|Fresh berry extract containing 250mg of polyphenols
89026386|NCT01605682|Experimental|Berry extract 500|Fresh berry extract containing 500mg of polyphenols
89026387|NCT01605682|Placebo Comparator|Placebo|Berry flavoured juice containing no polyphenols
89026388|NCT00493155|Experimental|1|
89558759|NCT02687243|Experimental|Interactive Virtual Application|Online application
89558760|NCT02687243|No Intervention|Standard of Care|No intervention and Hospital Standard of Care
89026389|NCT01357915|Experimental|GSK149203A S- Group|Male subjects who received 3 doses of GSK Biologicals' candidate GSK149203A vaccine according to a 0-1-6 month schedule in the primary study 108890 (NCT00435396).
89558761|NCT02674971|Active Comparator|INCREASE|This condition will be instructed to make food consumption decisions based solely upon the ED of a food. The goal of the ED condition will be to consume at least 10 foods ≤ 1.0 kcal/g (i.e., fruits and vegetables, broth based soups, non-fat yogurts, some legumes, egg substitutes, some white fish, etc.) per day.
89558762|NCT02674971|Active Comparator|COMBINATION|This condition will be identical to the INCREASE condition, except it will also have a goal regarding the number of high-ED foods to consume and substituting low-ED foods for high-ED foods. Thus, this condition will have ED goals to consume at least 10 foods ≤ 1.0 kcal/g (i.e., fruits and vegetables, broth based soups, non-fat yogurts, some legumes, egg substitutes, some white fish, etc.) and no more than 2 foods ≥ 3.0 kcal/g (i.e., crackers, chips, cookies, hard cheeses, hot dogs, salad dressings, etc.) per day. Foods with an ED >1.0 kcal/g but < 3.0 kcal/g will be unlimited; however, lower ED foods will be strongly encouraged. Furthermore, additions to beverages (i.e., sugar, cream) will count toward the > 3.0 kcal/g goal if the additions meet that ED criteria.
89558763|NCT02660476||QUDOS 1|Aims to recruit 1,700 diabetic patients (including 200 with type 1 diabetes mellitus (independent of healthcare setting)) attending the hospitals and primary care
89558764|NCT02660476||QUDOS 2|To further characterise 500 patients, from the total 1500 patients with T2DM recruited in QUDOS 1, who accept to continue with QUDOS 2 (a more detailed study and assessment).
89558765|NCT02659215|Experimental|Hyalofast with BMAC|A hyaluronan-based scaffold (Hyalofast®) is utilized together with autologous bone marrow aspirate concentrate (BMAC) in a one-step arthroscopic/mini-arthrotomic procedure.
89558766|NCT02659215|Active Comparator|Microfracture|Microfracture is an arthroscopic surgical technique involving placement of microfracture penetrations within the cartilage defect to provide stem cells and growth factors from the bone marrow to aid cartilage repair.
89026390|NCT01357915|Other|GSK149203A S+ Group|Male subjects who were assessed as being naturally infected with Cytomegalovirus (CMV) at the screening visit of the primary study 108890 (NCT00435396).
89026391|NCT00474227|Experimental|A|behavioral intervention, group therapy including nutritional guidance and physical exercise
89026392|NCT00474227|No Intervention|B|comparison group, one time explanation of importance of proper nutrition. This group receives no group therapy or organized exercise sessions or nutritional guidance. They are wait listed for this program.
89026393|NCT01350973|Experimental|TAK-085 2 g|TAK-085 2 g, orally, once daily for up to 12 weeks.
89026394|NCT01350973|Experimental|TAK-085 4 g|TAK-085 2 g, orally, twice daily for up to 12 weeks.
89558767|NCT02656303|Experimental|Parent Study Arm B|Participants from Arm B of the parent trial (UTX-TGR-304) received ublituximab, 150 milligrams (mg), intravenously (IV), on Day 1, 750 mg on Day 2, followed by 900 mg on Days 8 and 15 of Cycle 1 (cycle length=28 days), Day 1 of Cycles 2-6, and once every 3 months thereafter, along with umbralisib, 800 mg, orally, once daily during each cycle until disease progression, lack of tolerability, or until the treatment is commercially available or up to 78 months.
89558768|NCT02656303|Experimental|Parent Study Arm C|Participants from Arm C of the parent trial (UTX-TGR-304) received ublituximab, 900 mg, IV, on Day 1 of Cycles 1-6 (cycle length=28 days), and once every 3 months thereafter, along with umbralisib, 800 mg, orally, once daily during each cycle until disease progression, lack of tolerability, or until the treatment is commercially available or up to 78 months.
89558769|NCT02656303|Experimental|Parent Study Arm D|Participants from Arm D of the parent trial (UTX-TGR-304) received ublituximab, 150 mg, IV, on Day 1, 750 mg on Day 2, followed by 900 mg on Days 8 and 15 of Cycle 1 (cycle length=28 days), Day 1 of Cycles 2-6, and once every 3 months thereafter, along with umbralisib, 800 mg, orally, once daily during each cycle until disease progression, lack of tolerability, or until the treatment is commercially available or up to 78 months.
89026395|NCT01350973|Experimental|EPA-E 1.8 g|Eicosapentaenoic acid-ethyl (EPA-E) capsule 0.6 g, orally, three-times daily for up to 12 weeks.
89026396|NCT03270722|Experimental|patients with scleroderma and trouble swallowing|
89026397|NCT03270722|Experimental|patients with scleroderma but no trouble swallowing|
89026398|NCT03270722|Active Comparator|patients without scleroderma undergoing endoscopy|
89558770|NCT02650622||Cohort 1-Newborns aged 1-2 days|No intervention will be applied specifically for this cohort. Blood samples will be collected from this cohort by piggybacking the state-mandated newborn screening test.
89558771|NCT02650622||Cohort 2-Children aged 0-18 years|No intervention will be applied specifically for this cohort. Blood samples will be collected from this cohort by piggybacking the blood draw of patient's standard of care.
89558772|NCT02650622||Cohort 3-Diseased childrens and families|Blood samples will be collected from this cohort by piggybacking the blood draw of patient's standard of care. Skin biopsy will be performed on the proband children with the agreement from parents or guardians.
89558773|NCT02646683|Other|Early Crohn's disease|"VEDOLIZUMAB 300 mg at week 0,2,6, (10), 14, 22, 30,(34), 38, (42), 46, (50)~week 10 = only required for subjects not responding week 34, 42 and 50- only required for subjects who have no endoscopic improvement at week 26"
89558774|NCT02646683|Other|Late Crohn's disease|"VEDOLIZUMAB 300 mg at week 0,2,6, (10), 14, 22, 30,(34), 38, (42), 46, (50)~week 10 = only required for subjects not responding week 34, 42 and 50- only required for subjects who have no endoscopic improvement at week 26"
89558775|NCT02640586|Experimental|Assessing response with MRI|"Preoperative chemo-radiotherapy as standard treatment. Neoadjuvant therapy (long course intensity modulated radio-chemotherapy, GTV 50.6Gy, totally 22 fractions; Capecitabine 825mg/m2 /bid by oral administration).~Three MR examinations: first MRI taken within 1 week before preoperative chemo-radiotherapy; second MRI taken between 14-16days after the initiation of radio-chemotherapy; third MRI taken 7-9 weeks after the completion of preoperative chemo-radiotherapy.~All patients are scheduled to receive total mesorectal excision surgery 12-14 weeks after the completion of preoperative chemo-radiotherapy."
89026399|NCT01350544|No Intervention|Wait-list control|Participants in the wait-list control group will not receive the intervention until after the 6-month follow-up assessment.
89026400|NCT01350544|Experimental|treatment advocacy|Treatment advocacy is a 24-week intervention with booster sessions, including a 4-week intensive intervention followed by a 20-week maintenance period. In the first 4 weeks, all participants receive 4 individual weekly 60-minute sessions and 1 group HIV education session. In the next 20 weeks, all participants receive booster sessions in weeks 12 and 20, and a counselor check-in phone call in week 8 regarding need for new referrals and adherence barriers. Participants who have not demonstrated good adherence (≥90%) during the prior 2 weeks receive ≤4 additional booster sessions at weeks 14, 16, 22, and 24. Clients receive additional linkage with AIDS Project Los Angeles' (APLA) social service programs, as necessary.
89026401|NCT01350505|Experimental|All subjects|13 minutes of light at night (2 hours after bedtime)
89026402|NCT01605721|Experimental|XIENCE PRIMETM everolimus-eluting coronary stent|
89558776|NCT02640209|Experimental|Arm 1|
89558777|NCT02628626|Placebo Comparator|Placebo|Participants in this arm will receive placebo for 4 weeks.
89558778|NCT02628626|Active Comparator|Colesevelam and Clonidine|Participants in this arm will receive a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) for 4 weeks.
89558779|NCT02617797|Experimental|Radiofrequency|Experimental group: women with urinary incontinence are subjected to standard treatment kinesiotherapy perineal ( pelvic muscle exercises ) every day in home and one session per week in the clinic in beyond the RF application in the genital area once a week to total 5 sessions.
89026403|NCT01605760|No Intervention|non immunotherapy treatment|
89026404|NCT01605760|Active Comparator|sublingual immunotherapy course|
89026405|NCT00469040|Experimental|GW642444M 25mcg|In Cohort 1 if subjects meet the stopping criteria the dose of GW642444M will changed to one inhalation of 25 mcg.
89026406|NCT00469040|Experimental|GW642444M 50mcg|Subjects after randomization will receive two inhalations of 25 mcg GW642444M in Cohort 1.
89026407|NCT00469040|Experimental|GW642444M 100mcg|In Cohort 2 if subjects meet the stopping criteria the dose of GW642444M will changed to one inhalation of 100 mcg.
89026408|NCT00469040|Experimental|GW642444M 200mcg|Subjects after randomization will receive two inhalations of 100 mcg GW642444M in Cohort 2.
89026409|NCT00469040|Experimental|GW642444M 400mcg|Subjects after randomization will receive two inhalations of 200 mcg GW642444M in Cohort 3.
89026410|NCT01350271|Placebo Comparator|Placebo|Placebo tablets produced by the State Pharmaceutical Manufacturing Corporation of Sri Lanka
89026411|NCT01350271|Active Comparator|Mebendazole polymorph A and C 500 mg|Mebendazole tablets produced by the State Pharmaceutical Manufacturing Corporation of Sri Lanka, containing 500mg of mebendazole as a 50:50 mixture of Polymorphs A and C
89026412|NCT01350271|Experimental|Mebendazole polymorph C 500 mg|Mebendazole tablets manufactured by the State Pharmaceutical Manufacturing Corporation of Sri Lanka, containing 500mg dose of mebendazole as Polymorph C alone
88965317|NCT04852978|Experimental|Wave 2 Dose 2|
88965318|NCT04852978|Experimental|Wave 2 Vaccine only|
88965319|NCT04852978|Experimental|Wave 3 Dose 1|
88965320|NCT04852978|Experimental|Wave 3 Dose 2|
88965321|NCT04852978|Experimental|Wave 3 Vaccine only|
88965322|NCT04852978|Experimental|Wave 4 Dose 1|
88965323|NCT04852978|Experimental|Wave 4 Vaccine only|
88965324|NCT04759456|Experimental|Intervention group|Participants will undergo 12-week comprehensive remotely-supervised rehabilitation program along with individually titrated CPAP therapy.
88965325|NCT04759456|No Intervention|Control group|Participants will undergo individually titrated CPAP therapy.
88965326|NCT00388128|Placebo Comparator|A|
88965327|NCT04689646|Experimental|Mind-Body Intervention 1|Participants will receive a mind body educational based intervention to learn the techniques comprising intervention 1.
88965328|NCT04689646|Active Comparator|Mind-Body Intervention 2|Participants will receive a mind body educational based intervention to learn the techniques comprising intervention 2.
88965329|NCT04689646|No Intervention|Usual Care|Participants will continue their usual care for 26 weeks
88965330|NCT00006462|Experimental|Relapsed acute lymphoblastic and acute Myelogenous leukemia|Gemcitabine hydrochloride will be given as 10 mg/m2/min x 360 minutes weekly for three weeks. After a one-week rest period it may be repeated in patients without progressive disease or limiting toxicity.
88965331|NCT04604197|Experimental|Angiography and Clinical Follow up|After PCI. The patient is randomized to an angiographic follow-up at 6 months and a Clinical Follow to 36 months
89558780|NCT02617797|Sham Comparator|Radiofrequency Off|Control group: women with stress urinary incontinence will be submitted to the treatment of kinesiotherapy standard perineal ( pelvic muscle exercises ) every day in home and one session per week in the clinic beyond the application of radiofrequency off in genital area once a week with the total of 5 sessions.
89558781|NCT02609542||STOL group|"STOL children will be recruited in the neuropediatric unit at the GHICL in Lille. Children will be followed and we will determine if capacities of verbal memory of the children presenting STOL diagnosed at an early stage of their development (before 6 years) are predictive of the evolution of the disorder according to their cognitive profile and more specifically, their language profile as well as their tests performances. The participants' eye movements ( visual world paradigm or eye tracking) will be recorded in order to determine the interplay between linguistic and visual information processing.~Patients with a persistent STOL will be identified at the end of the follow up."
89558782|NCT02609542||Control group|Children with no language development disorder willing to participate in the study will be recruited at school. The participants' eye movements ( visual world paradigm or eye tracking) will be recorded in order to determine the interplay between linguistic and visual information processing.
89558783|NCT02588456|Experimental|Single Arm|
89558784|NCT02559609|Active Comparator|job activity contracting|Standard services plus job activity contracting and alcohol monitoring
88965332|NCT04604197|Active Comparator|Clinical Follow up|After PCI. The patient is randomized to a Clinical Follow to 36 months
88965333|NCT03863509||Exclusive Smokers|Smokes Daily; >/= 5 cigarettes/day for last 6 months
88965334|NCT03863509||Exclusive E-Cig users|E-cig usage >/= 5 days/week for last 3 months
88965335|NCT03863509||Never users|< 100 cigarettes in lifetime, none for > 5 years; < 3 E-cig usage in lifetime
88965336|NCT00387439|Experimental|standard medical treatment|standard medical treatment
88965337|NCT00387439|Experimental|standard medical treatment + anoperineal physiotherapy|standard medical treatment + anoperineal physiotherapy
89558785|NCT02559609|Experimental|reinforcement for negative alcohol samples|Standard services plus job activity contracting and alcohol monitoring plus reinforcement for negative breath alcohol recordings
88965338|NCT03832309|Active Comparator|Group 1|Packet 1: The Physician will be asked to instruct the patient as empathetically and confidently as possible, that the drug the patient will be given will make them feel no pain, cause them to forget the procedure, and allow them to dream the dream of their choice.
88965339|NCT03832309|Other|Control Arm|Half of the participants will receive the sedation medication with the usual conversation while the physician is giving the medication to the patient. The other half of the participants will have a more positive conversation, (which is the study intervention), with the physician while being given the medication. Both group's emergence reactions, if any, will be compared to see if the positive conversation reduced the side effect.
88965340|NCT00006471|Experimental|Fenretinide|
88965341|NCT04428619|Active Comparator|Peripheral Electrical Nerve Field Stimulation (PENFS) Device|The PENFS device has a battery activated generator and wire harness. Four leads are attached to the generator, each with a sterile 2 mm, titanium needle. The patient's ear is trans-illuminated to identify neurovascular bundles that are avoided during needle placement. The generator is attached with adhesive to the skin behind the patient's ear. Needles are inserted into the dorsal and ventral aspects of the ear, within 1-1.5 mm of the vascular branches to create a field effect. The device settings are standardized and deliver 3.2 volts with alternating frequencies (1 ms pulses of 1 Hz and 10 Hz) every 2 s. This stimulation targets central pain pathways through branches of cranial nerves V, VII, IX, and X, which innervate the external ear. The device is worn for 5 days/week for a total of 4 weeks. Patients remove devices at home on day 6 of each treatment cycle. Patients will be asked to wear a SmartWatch during the study to monitor heart rate.
89026413|NCT01605955||Fingertip Pulse Oximeter|SPO2 measurement range: 70%-99%
88965342|NCT04428619|Sham Comparator|Sham Device|The sham devices will be identical to the active devices but will not administer electrical charges. Per manufacturer design and patient anecdotal experience from previous studies, both active stimulation and sham are below detectable sensation threshold. Per report from previous studies, some patients may experience a sensation around the ear after percutaneous needle placement; however, this sensation can occur with equal likelihood in the active or sham device. The device is worn for 5 days a week for a total of 4 weeks. Patients remove devices at home on day 6 of each treatment cycle. Patients will also be asked to wear a SmartWatch as above.
88965343|NCT04371172||Patients with TAVI|cognitive research battery, MRI, laboratory values
88965344|NCT04370119||(1) Healthcare workers|All healthcare workers at University Medicine Greifswald who were enrolled in the study between 04/2020-08/2020
88965345|NCT04370119||(2) Healthcare workers in high-risk areas of the hospital (intensive care, emergency medicine)|Healthcare workers at University Medicine Greifswald who were enrolled in the study between 01/2021-03/2021
88965346|NCT04370119||(3) Healthcare workers after SARS-CoV-2 vaccination|Healthcare workers at University Medicine Greifswald who received a SARS-CoV-2 vaccination within the last 7-21 days
88965347|NCT04359121||Physicians|Questionnaires
88965348|NCT04359121||Medical staff|Questionnaires
89558786|NCT02559609|Experimental|reinforcement for completing activities|Standard services plus job activity contracting and alcohol monitoring plus reinforcement for completing job-related activities
89558787|NCT02559609|Experimental|reinforcement for negative alcohol samples & activities|Standard services plus job activity contracting and alcohol monitoring plus reinforcement for negative breath alcohol recordings and for completing job-related activities
88965349|NCT04359121||General public|Questionnaires
88965350|NCT04359121||Patients with psychiatric disorders|Questionnaires
88965351|NCT03815851|Other|Drain group|Place prophylactic drainage after surgery.
88965352|NCT03815851|Other|No-drain group|Not place prophylactic drainage after surgery.
88965353|NCT04232293|Experimental|Blood tests|Two diagnostic tests (eLift and FibroMeter) will be performed to evaluate liver fibrosis
88965354|NCT04205149||Pre-ERAS implementation arm|
88965355|NCT04205149||Post-ERAS implementation arm|
88965356|NCT04192435|Active Comparator|Tranexamic acid|At induction of anesthesia and prior to surgical incision a bolus of 0.15 ml/kg ( up to a maximum of 15 ml) , and then commence an infusion of 0.05 ml/kg/h until the end of surgery. The total maximal administered study drug volume will be 30 ml.
88965357|NCT04192435|Placebo Comparator|Placebo|At induction of anesthesia and prior to surgical incision a bolus of 0.15 ml/kg ( up to a maximum of 15 ml) , and then commence an infusion of 0.05 ml/kg/h until the end of surgery. The total maximal administered study drug volume will be 30 ml.
88965358|NCT04185454|Experimental|First design level|Three Healthy Voluntary (HV) women were give the same starting daily dose of 100 g Jarlsberg
88965359|NCT04185454|Experimental|Second design level|Based on the results from the starting dose 5 + 5 HV get a new daily doses of Jarlsberg cheese
88965360|NCT04185454|Experimental|Third design level|Based on the results from the second design level, the daily dose of Jarlsberg cheese for the next 7 HVs was given
88965361|NCT04130269||Patients with MCI|Patients with myocardial infarction (STEMI/NSTEMI) aged 19-90
89558788|NCT02555384|Active Comparator|crowded drawing task|children will be asked to draw on a pattern presented under crowded viewing conditions.
89558789|NCT02555384|Placebo Comparator|uncrowded drawing task|children will be asked to draw on a pattern presented under uncrowded viewing conditions
89558790|NCT02554812|Experimental|Cohort A1|NSCLC patients treated with avelumab + utomilumab (Dose level 1)
89558791|NCT02554812|Experimental|Cohort A2|NSCLC patients treated with avelumab + utomilumab (Dose level 2)
89558792|NCT02554812|Experimental|Cohort A3|NSCLC patients treated with avelumab + utomilumab (Dose level 3)
89558793|NCT02554812|Experimental|Cohort A4|Melanoma patients treated with avelumab +utomilumab
89558794|NCT02554812|Experimental|Cohort A5|SCCHN patients treated with avelumab + utomilumab
89558795|NCT02554812|Experimental|Cohort A6|TNBC patients treated with avelumab + utomilumab
89558796|NCT02554812|Experimental|Cohort A7|SCLC that has progressed after at least 1 line of platinum-containing therapy treated with avelumab +utomilumab
89558797|NCT02554812|Experimental|Cohort A8|NSCLC first-line Stage IV treated with avelumab +PF-05082566
89558798|NCT02554812|Experimental|Combination B Dose Escalation|PF-04518600 + avelumab in selected tumor types
89558799|NCT02554812|Experimental|Combination B Expansion Cohorts|PF-04518600 + avelumab in selected tumor types
89558800|NCT02554812|Experimental|Combination C Dose escalation cohorts|PD 0360324 + avelumab in selected tumor types
89558801|NCT02554812|Experimental|Combination C Dose expansion cohorts|PD 0360324 + aveluamb in selected tumor types
89558802|NCT02554812|Experimental|Combination D Dose escalation cohorts|PF-05082566 + PF-04518600 + avelumab in selected tumor types
89558803|NCT02554812|Experimental|Combination D Dose expansion cohorts|PF-05082566 + PF-04518600 + avelumab in selected tumor types
89558804|NCT02554812|Experimental|Cohort A9|NSCLC first-line Stage IV treated with avelumab +utomilumab (sequential starting with utomilumab monotherapy followed by combination)
89558805|NCT02554812|Experimental|Cohort A10|NSCLC first-line Stage IV treated with avelumab + utomilumab (sequential starting with avelumab monotherapy followed by combination)
88965362|NCT04121728|Other|Group Ginkgo-Placebo|Cross-over design: In Group Ginkgo-Placebo participants are allocated first to the IMP Symfona® during 6 months and after 2 months of wash-out period are allocated to the placebo for 6 months.
89026414|NCT01605955||CO-oximeter|SaO2 measurement range: 70%-99%
89558806|NCT02554812|Experimental|Cohort F1|CMP-001 +avelumab in SCCHN
89558807|NCT02554812|Experimental|Cohort F2|CMP-001+avelumab+utomilumab in SCCHN
89558808|NCT02554812|Experimental|Cohort F3|CMP-001 +avelumab+PF-04518600 in SCCHN
89558809|NCT02546167|Experimental|Cohort 1|will receive 1-5x10^7 CART-BCMA cells given as a split dose infusion over 3 days.
89558810|NCT02546167|Experimental|Cohort 2|Cyclophosphamide infusion prior to 1-5x10^7 CART BCMA cells given as a split dose infusion over 3 days.
89558811|NCT02546167|Experimental|Cohort 3|Cyclophosphamide infusion prior to 1-5x10^8 CART BCMA cells given as a split dose infusion over 3 days.
88965363|NCT04121728|Other|Group Placebo-Ginkgo|Cross-over design:In Group Placebo-Ginkgo participants are allocated first to the placebo during 6 months and after 2 months of wash-out period are allocated the IMP Symfona® for 6 months.
88965364|NCT03746587|Experimental|Arimoclomol I|Arimoclomol, oral capsule
88965365|NCT03746587|Experimental|Arimoclomol II|Arimoclomol, oral capsule
88965366|NCT03746587|Experimental|Arimoclomol III|Arimoclomol, oral capsule
88965367|NCT03746587|Placebo Comparator|Placebo|Placebo oral capsule matching experimental arm
88965368|NCT03609385||Stroke patients with elevated troponin|Patients with acute ischemic stroke (confirmed by cerebral imaging) and cardiac troponin values > 52 ng/l or troponin values > 14 ng/l and dynamic change > 20% will undergo coronary angiography
88965369|NCT03558958|Experimental|P-188 NF|P-188 NF, 5 mg/Kg administered subcutaneously daily for 1 year
88965370|NCT03542773|Experimental|18F-DCFPyL|A bolus of less than or equal to 9 mCi (331 MBq) of IV injection of 18F-DCFPyL
88965371|NCT03427918|Experimental|patient-partner|patients and their partners will receive a weekly Mindfulness-Based Sex Therapy program. The treatments will deliver by a group of facilitators to groups of women consisting of 4-7 women.
88965372|NCT03427918|Experimental|patient-partner and health care providers|patients and their partners as well as health care providers will receive a weekly Mindfulness-Based Sex Therapy program. Th treatments will deliver by a group of facilitators to groups of women consisting of 4-7 women.
88965373|NCT03427918|No Intervention|Control group|The control group will receive a routine counseling
88965374|NCT03407794|No Intervention|Control|Participants randomized into the control group will be asked to follow their usual diet during the 6 weeks of the intervention.
89558812|NCT02527707|Experimental|lonafarnib/ritonavir|Lonafarnib starting at 50 mg BID in combination with ritonavir 100 mg BID and escalating to lonafarnib 75 mg BID and then 100 mg BID as tolerated. The duration of the study for each patient is 6 months of treatment and 6 months follow-up.
89558813|NCT02470754|Active Comparator|EC Block1/TC Block 2|Participants will be randomized into one of two groups. In this group, participants will be assigned to Electronic Cigarettes only for Study Block #1, then crossover to Tobacco Cigarettes only for Study Block #2.
89558814|NCT02470754|Active Comparator|TC Block 1/EC Block 2|Participants will be randomized into one of two groups. In this group, participants will be assigned to Tobacco Cigarettes only for Study Block #1, then crossover to Electronic Cigarettes only for Study Block #2.
89558815|NCT02453191|Experimental|Treatment|"Talimogene Laherparepvec in combination with radiotherapy~Talimogene Laherparepvec Dose Levels:~• Initial dose for all = talimogene laherparepvec up to 4.0 mL of 106 PFU/mL"
89558816|NCT02386371|Experimental|surgery and Intra Operative Radiotherapy|"Surgery :~Tumorectomy will be performed according to the current standards, obtaining clear margins. The axillary lymph node control will depend on the initial management (clinical and ultrasound) of these N0 patients, chosen by the teams.~Intra Operative Radiotherapy (IORT):~After the excision of the tumor, IORT will be delivered. A single dose of 20 Gy by 50 kV photons (Intrabeam™) will be administered in tumor bed. The addition of IORT does not modify the surgical procedure."
89558817|NCT02367924||Yondelis|The administration of chemotherapy regimen with trabectedin (according to Summary of Product Characteristics (SmPC)) will be determined by the Investigator's discretion depending on the patients' conditions and previous chemotherapy.
89558818|NCT02364726|Experimental|Acupuncture|"As part of routine clinical care, a chemotherapy nurse, research nurse, or physician will assess the patient's symptoms including CIPN based on the NCI-CTC 4.0 criteria to determine the grade of CIPN. Once these patients develop National Cancer Institute-Common Toxicity Criteria (NCI-CTC) grade 2 CIPN, they will be recruited for the intervention phase of the study. Severity of CIPN as defined by NCI-CTC is listed in Appendix A. Patients who consent to the intervention phase of the study will then be treated with weekly acupuncture until the end of chemotherapy. No concomitant anti-neuropathy medication will be permitted.~Subjects will receive acupuncture in bilateral ear points: shen men, point zero, two additional auricular acupuncture point where electrodermal signal is detected and bilateral body acupuncture points: LI4, TE5, LI11, ST40, Ba Feng, Ba xie."
89558819|NCT02352090|Experimental|Synthetic estrogen + progestin|Ethinyl estradiol / dienogest
89558820|NCT02352090|Experimental|Natural estrogen + progestin|Estradiol valerate / dienogest
89558821|NCT02352090|Active Comparator|Progestin-Only|Dienogest
89558822|NCT02280460||VA ECMO|Patients who are placed on VA ECMO.
89558823|NCT02280460||VV ECMO|Patients who are placed on VV ECMO.
89558824|NCT02277522|Experimental|RNA autologous T cells (anti CD19 CAR T cells)|
89558825|NCT02236143||MRI|Subjects undergoing MRI
89558826|NCT02226432|Sham Comparator|Kinesics|- Classic Rehabilitation and Kinesic Therapy
89558827|NCT02226432|Sham Comparator|surgery|"- Surgery:~Selective Peripheral Neurotomy is surgical a method of section on suplying peripheral nerves of motor fascicles to relieve harmful spasticity. An intraoperative stimulation of motor fascicles is done, and those which abnormal spreading on far placed myotomes are more evident are chosen to be sectioned."
89558828|NCT02226432|Active Comparator|Magnetic Stimulation|- Postoperative Antagonistic Peripheral Magnetic Stimulation with 1.5 tesla intensity, infrathreshold 80 per cent of minimal intensity able to produce always muscle contraccion. Trials repeated twice a week in sessions of 30 minutes during 6 months
89558829|NCT02159742||Cohort 1|
89558830|NCT02135107|Experimental|Arm A|
88965375|NCT03407794|Experimental|Fermented vegetable|Participants randomized into the fermented vegetable group will receive 1/2 cup per day of fermented vegetables, including cabbage, carrots or pickles, for 6 weeks.
88965376|NCT03407794|Active Comparator|Non-fermented vegetable|Participants randomized into the non-fermented vegetable group will receive 1/2 cup per day of non-fermented vegetables, including cabbage, carrots or pickles, for 6 weeks.
88965377|NCT03292198|Active Comparator|Compression Group|"Subjects in the Compression Group will wear 20-30 mmHg sleeves and gauntlets daily for a maximum of 4 weeks. L-dex will be performed at the end of each week. If the L-dex score has reversed back into normal range, intervention (garment wearing) will be discontinued and the subject will resume the surveillance schedule of screenings. If the L-dex score is still abnormal, garment wearing continues. If L-dex score is abnormal even at the end of the 4 weeks, the subject will be removed from the study and referred to standard lymphedema therapy.~An abnormal L-dex is defined by 7 or more units change compared to the subject's pre-surgical baseline."
89558831|NCT02135107|Experimental|Arm B|
89558832|NCT02135107|Experimental|Arm C|
89558833|NCT02135107|Experimental|Arm D|
89558834|NCT02097706|Active Comparator|NMDA receptor antagonist|20mg/daily for 12 weeks (84 days)
89558835|NCT02097706|Placebo Comparator|Placebo tablet|1 capsule/daily for 12 weeks (84 days)
89558836|NCT02030847|Experimental|Arm1|"phase II study to determine the efficacy and safety of a single infusion of autologous T cells expressing CD19 chimeric antigen receptors expressing tandem TCRζ and 4-1BB (TCRζ/4-1BB) co-stimulatory domains (referred to as CART-19 cells) in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia."
89558837|NCT02030834|Experimental|Cohort A|murine CART19
89558838|NCT02030834|Experimental|Cohort B|T cell/histiocyte-rich Diffuse Large B Cell Lymphoma (DLBCL) treated with murine CART19
89558839|NCT02030834|Experimental|Cohort C|Diffuse Large B Cell Lymphoma (DLBCL) treated with humanized CART19
89558840|NCT01982448|Experimental|Arm A: Cisplatin|Cisplatin given by IV infusion at a dose of 75 mg/m2 every 3 weeks (1 cycle) for 4 cycles as preoperative chemotherapy. Participants with inadequate clinical response after 12 weeks (as judged either clinically or radiologically by a provider) were able to crossover to an alternative provider-selected preoperative chemotherapy regimen. Definitive breast surgery following no later than 42 days after administration of last chemotherapy.
89558841|NCT01982448|Experimental|Arm B: Paclitaxel|Paclitaxel given by IV infusion at a dose of 80 mg/m2 weekly for 12 weeks (4 cycles) as neoadjuvant chemotherapy. Participants with inadequate clinical response after 12 weeks (as judged either clinically or radiologically by a provider) were able to 'crossover' to an alternative provider-selected preoperative chemotherapy regimen. Definitive breast surgery following no later than 42 days after administration of last chemotherapy.
89558842|NCT01980264|Experimental|Diagnostic imaging|Harmonic Generation Microscopy
88965378|NCT03292198|Experimental|Therapy Group|"Subjects in the Therapy Group will wear 20-30 mmHg sleeves and gauntlets daily and receive Manual Lymphatic Drainage 3x/week for a maximum of 4 weeks. L-dex will be performed at the end of each week. If the L-dex score has reversed back into normal range, intervention will be discontinued and the subject will resume the surveillance schedule of screenings. If the L-dex score is abnormal, intervention continues. If L-dex score is abnormal even at the end of the 4 weeks, the subject will be removed from the study and referred to standard lymphedema therapy.~An abnormal L-dex is defined by 7 or more units change compared to the subject's pre-surgical baseline."
88965379|NCT03265405|Active Comparator|Low dose prednisolone|An initial dose of 20 mg/day will be administered for 8 weeks, followed by 15 mg/day for 8 weeks, 10 mg/day for 4 weeks, and 5 mg/day for 4 weeks, after which the drug will be tapered over 2 weeks and discontinued.
88965380|NCT03265405|Active Comparator|Medium dose prednisolone|An initial dose of 40 mg/day will be administered for 4 weeks, followed by 30 mg/day for 4 weeks, 20 mg/day for 4 weeks, 15 mg/day for 4 weeks, 10 mg/day for 4 weeks, and 5 mg/day for 4 weeks, after which the drug will be tapered over 2 weeks and discontinued.
88965381|NCT03808480|Experimental|CA and Nivolumab|"After 1 cycle of cyclophosphamide and doxorubicin (CA) induction therapy, Nivolumab 360mg flat dose will be given on day 1 with CA chemotherapy in a 21-day cycle.~After the completion of 4 cycles of CA chemotherapy, Nivolumab will be continued as a single agent at a dose of 480mg flat dose every 4 weeks until loss of clinical benefit"
88965382|NCT03185728|Experimental|iLookOut|Online, interactive learning program developed by study team.
88965383|NCT03185728|Active Comparator|Standard|Online mandated reporter training developed by the state of Maine during Y1, then recruited to complete iLookOut during Y2 and Y3.
88965384|NCT03185728|No Intervention|Control|No active recruitment or incentivizing of participants to complete any training on mandated reporting during Y1 and Y2, then recruited to complete iLookOut during Y3.
88965385|NCT03116347|Experimental|EPOCH 1|Ramp up period for participants who were not treated with HyQvia prior to this study
88965386|NCT03116347|Experimental|EPOCH 2|Participants who were treated with HyQvia prior to this study, and those who completed the ramp up period (Epoch 1). After one year in Epoch 2, participants with anti-rHuPH20 antibody titer <160 at all time-points during the study will complete the study termination/completion visit at the next possible occasion. Participants with anti-rHuPH20 antibody titer >=160 during the study and/or at the last measurement will continue for an additional two years of HyQvia treatment and observation.
88965387|NCT03116347|Experimental|Epoch 3|Safety follow-up for participants whose anti-rHuPH20 antibody titer was >= 160 during Epoch 1 or Epoch 2 and who experience either a related serious adverse event (SAE) or a related severe adverse event (AE)
88965388|NCT00387478|Experimental|1|modified Tree pollen allergen absorbed to Tyrosine and containing MPL adjuvant
88965389|NCT00387478|Experimental|2|modified Tree pollen allergen absorbed to Tyrosine
88965390|NCT00387478|Placebo Comparator|Placebo|4 injections of placebo 0.5 ml (2% tyrosine)
88965391|NCT03078361|Active Comparator|LATINOS CARES Toolkit|Participants assigned to the LATINOS CARES condition will receive an I-FOBT kit, DVD and photonovella booklet from the study coordinator. The participant will view the DVD in a private area (headphones are available) using a portable DVD player in clinic before seeing the provider. The DVD will be about 8-10 minutes long. The participant will take the LATINOS CARES toolkit and I-FOBT home after the clinic visit. The participant will be instructed to re-review the materials and complete the I-FOBT stool sampling at home.
88965392|NCT03078361|Active Comparator|Standard Intervention (SI)|Participants assigned to the standard brochure (SI) will be provided a packet containing the CDC Spanish-language tri-fold brochure titled Screen for Life and an I-FOBT card. The participant will be instructed to review the materials in clinic and complete the I-FOBT stool sampling at home. This brochure describes CRC, risk factors, symptoms, screening tests, benefits of screening, and insurance coverage.
88965393|NCT02890069|Experimental|CRC - PDR001 + LCL161|Enrollment to this combination arm is closed to further enrollment.
89558843|NCT01967160||XGEVA inception cohort|Patients with cancer who are naïve to oral or IV bisphosphonate treatment at the dose indicated for SRE prevention and who begin treatment with XGEVA at any time during the treatment cohort identification period
88965394|NCT02890069|Experimental|NSCLC - PDR001 + LCL161|Enrollment to this combination arm is closed to further enrollment.
88965395|NCT02890069|Experimental|TNBC - PDR001 + LCL161|Enrollment to this combination arm is closed to further enrollment.
89558844|NCT01967160||Zoledronic acid inception cohort|Patients with cancer who are naïve to oral or IV bisphosphonate treatment at the dose indicated for SRE prevention and who begin treatment with IV zoledronic acid at any time during the treatment cohort identification period
89558845|NCT01967160||XGEVA-switch cohort|Patients with cancer who switch to XGEVA during treatment cohort identification period after having started antiresorptive therapy at the dose indicated for SRE prevention of no more than 2 years duration with bisphosphonates (<24 IV infusions or <24 monthly oral prescriptions)
89558846|NCT01839838|Experimental|APBI with protons|
89558847|NCT01837602|Experimental|cMet positive breast cancer patients|Metastatic breast cancer patients with an accessible tumor (cutaneous, subcutaneous, or superficial) and/or a palpable adenopathy/mass, with ≥ 30% tumor cells expressing cMet as demonstrated on immunohistochemical analysis . The intensity for cMet IHC should be greater than or equal to 1+. The targeted tumor must be accessible (i.e. is not near a great vessel or the spinal cord) and can be surgically excised or biopsied.
88965396|NCT02890069|Experimental|CRC - PDR001+ Everolimus|Enrollment to this combination arm is closed to further enrollment.
88965397|NCT02890069|Experimental|NSCLC - PDR001+ Everolimus|Enrollment to this combination arm is closed to further enrollment.
88965398|NCT02890069|Experimental|TNBC - PDR001+ Everolimus|Enrollment to this combination arm is closed to further enrollment.
88965399|NCT02890069|Experimental|CRC - PDR001 + Panobinostat|Enrollment to this combination arm is closed to further enrollment.
88965400|NCT02890069|Experimental|NSCLC - PDR001 + Panobinostat|Enrollment to this combination arm is closed to further enrollment.
88965401|NCT02890069|Experimental|TNBC - PDR001 + Panobinostat|Enrollment to this combination arm is closed to further enrollment.
88965402|NCT02890069|Experimental|CRC - PDR001 + QBM076|Enrollment to this combination arm is closed to further enrollment.
88965403|NCT02890069|Experimental|TNBC - PDR001 + QBM076|Enrollment to this combination arm is closed to further enrollment.
88965404|NCT02890069|Experimental|NSCLC- PDR001 + QBM076|Enrollment to this combination arm is closed to further enrollment.
88965405|NCT02890069|Experimental|CRC - PDR001 + HDM201|Dose escalation completed, expansion arm.
88965406|NCT02890069|Experimental|RCC - PDR001 + HDM201|Dose escalation completed, expansion arm.
88965407|NCT02425501||Aflibercept (Eylea,BAY86-5321)|Decision of EYLEA treatment is made by attending investigator according to the Japanese Package Insert
88965408|NCT02409238|Experimental|Lifestyle Intervention and Metformin|Intensive lifestyle interventions at Lifestyle Intervention Centres and Metformin (if Diabetic)
88965409|NCT02409238|Active Comparator|Standard Level of Care|Standard lifestyle recommendations for the Control groups
88965410|NCT00006483|Experimental|aerosolized sargramostim|"Patients receive aerosolized sargramostim (GM-CSF) by nebulizer over 10-15 minutes twice daily on days 1-7 and 14-21. Treatment repeats every 28 days in the absence of disease progression or unaceptable toxicity.~Patients are followed for disease progression and then every 3 months thereafter."
88965411|NCT00006486|Experimental|Arm I (carboxyaminoimidazole)|"Patients receive oral CAI daily for 4 weeks. Treatment repeats for 4 courses in the absence of disease progression or unacceptable toxicity. After 4 courses, patients experiencing complete or partial response continue treatment until disease progression or unacceptable toxicity.~Patients receive oral CAI as above."
88965412|NCT00006486|Experimental|Arm II (carboxyamidotriazole, placebo)|"Patients receive oral CAI daily for 4 weeks. Treatment repeats for 4 courses in the absence of disease progression or unacceptable toxicity. After 4 courses, patients experiencing complete or partial response continue treatment until disease progression or unacceptable toxicity.~Patients receive a placebo."
88965413|NCT00006501||ECG recording|After the tests are completed, people who enroll in this study are followed by telephone, 1, 4, 8, 12 16, 20 and 24 months. During these follow-up telephone calls a research coordinator asks about the participant's health condition and about cardiovascular medications that are being taken.
88965414|NCT00006708|Active Comparator|ICE Chemotherapy|Etoposide 100 mg/m2 IV Days 1-3 Carboplatin AUC=5 IV Day 2 Ifosfamide 5 g/m2 IV Day 2 Mesna 5 g/m2 IV Day 2 Filgrastim 5ug/kg/day SQ Days 5-12 Q 21 days x 3 cycles
88965415|NCT00006708|Experimental|Rituximab-ICE Chemotherapy|Etoposide 100 mg/m2 IV Days 2-4 Carboplatin AUC=5 IV Day 3 Ifosfamide 5 g/m2 IV Day 3 Mesna 5 g/m2 IV Day 3 Filgrastim 5ug/kg/day SQ Days 6-13 Q 21 days x 3 cycles Rituximab 375 mg/m2 IV Days 1 and 8 Cycle 1 Rituximab 375 mg/m2 IV Day 1 Cycles 2-3
88965416|NCT00006747|Experimental|chemotherapy + stem cell transplantation|"Patients receive carmustine, etoposide, cytarabine and melphalan on day -1. Patients undergo allogeneic peripheral blood stem cell (PBSC) transplantation on day 0. Patients also receive tacrolimus on day -2 and then orally twice daily until day 120 and methotrexate on days 1, 3, and 6 as graft-versus-host disease (GVHD) prophylaxis. Patients receive sargramostim daily beginning on day 7 and continuing until blood counts recover.~Patients with no active GVHD who have persistent disease on day 150 or progressive disease at any time after PBSC transplantation receive donor lymphocytes IV over 2 hours. Patients may receive additional donor lymphocytes at least 8 weeks later if disease persists.~Patients are followed at 6 and 12 months post-transplantation and then annually for 4 years."
88965417|NCT00006942|Experimental|Treatment (bryostatin 1, cisplatin)|Patients receive bryostatin 1 IV continuously over 72 hours immediately followed by cisplatin IV over 1 hour. Treatment continues every 3 weeks for a minimum of 2 courses in the absence of disease progression.
88965418|NCT02972541|Experimental|Stenting with neoadjuvant chemotherapy|After clinical success of colonic stenting, patients will receive neoadjuvant chemotherapy with mFOLFOX6 regimen for 3 cycles or CapeOx regimen for 2 cycles. Patients will undergo surgery 3-5 weeks after the last cycle of chemotherapy, type and extent of the surgery will be selected by the surgeon.
88965419|NCT02972541|Active Comparator|Stenting with Immediate Surgery|After clinical success of colonic stenting, patients will undergo surgery 7-14 days after inclusion. Type and extent of the elective surgery will be selected by the surgeon.
88965420|NCT02109523|Experimental|Intervention|Patients enrolled in the intervention arm will receive two educational sessions on the importance of medication and barriers to adherence
89558848|NCT01809041|Experimental|Sevoflurane & remifentanil|sevoflurane at 0.5 to 1.5 minimum alveolar concentrations plus remifentanil (0.1 - 0.5 µg/kg/min) during the surgery.
88965421|NCT02109523|Active Comparator|Usual Care|The usual care group received routine discharge counseling performed by the cardiologists and nurses.
88965422|NCT01955356|Experimental|Scratching|induced endometrial injury
88965423|NCT01955356|No Intervention|No scratching|None intervention
88965424|NCT00387556|Experimental|Ketamine + Ondansetron|ketamine 1 mg/kg IV (maximum single dose 100 mg)+ondansetron (0.15 mg/kg/dose; maximum dose 4 mg)
88965425|NCT00387556|Placebo Comparator|Ketamine + Placebo|ketamine 1 mg/kg IV (maximum single dose 100 mg)+2 ml normal saline solution IV (placebo
88965426|NCT03780790|Active Comparator|Quadratus Lumborum Block|US-guided quadratus lumborum block will be performed with 0,5 ml/kg 0.25% Bupivacaine in the anterior layer of the thoracolumbar fascia between psoas major and quadratus lumborum muscles
88965427|NCT03780790|Active Comparator|Transversus Abdominis Plane Block|US- guided transversus abdominis plane block will be performed with 0,5 ml/kg 0.25% Bupivacaine into the fascial plane between internal oblique muscle and transversus abdominis muscle
88965428|NCT03780790|Active Comparator|Caudal Block|US-guided caudal epidural block will be applied to 0.7 ml/kg 0.25 % Bupivacaine up to a maximum of 20 mL
88965429|NCT04712227||difficult intubation|patients with a difficult intubation score of 5 or more
88965430|NCT04712227||easy intubation|patients with difficult intubation score less than 5
88965431|NCT04712227||difficult mask ventilation|group 3 and 4 by han mask ventilation grouping
88965432|NCT04712227||easy mask ventilation|group 1 and 2 according to han mask ventilation grouping
88965433|NCT00388167||1|Caspofungin
88965434|NCT01541839|Experimental|Septal Stapler|This group will have closure of their nasal septal flaps via septal stapler.
88965435|NCT01541839|No Intervention|Control (Suture)|This arm will have closure of their nasal septal flaps as routinely performed with suture passed in a quilting fashion.
88965436|NCT00388323|Experimental|1|
88965437|NCT00786760||1. Men ages 18 - 44 years|
88965438|NCT00786760||2. Men ages 45 - 70 years|
88965439|NCT00006079|Experimental|Arm I|Arm I-II: Patients receive one of two different doses of oral eflornithine daily. Treatment continues for 28 days.
89208430|NCT04089683||House keeping staff and cleaners|Swabs collected from Web space, Scrub, Anterior nares before entering Operation theatre and while exit from operation theatre
88965440|NCT00006079|Experimental|Arm II|Arm I-II: Patients receive one of two different doses of oral eflornithine daily. Treatment continues for 28 days.
89558849|NCT01809041|Active Comparator|propofol & remifentanil|propofol (50 - 150 µg/kg/min) and remifentanil (0.1 - 0.5 µg/kg/min)
88965441|NCT00006079|Placebo Comparator|Arm III|Arm III: Patients receive oral placebo daily. Treatment continues for 28 days.
88965442|NCT00006094|Experimental|Treatment (oxaliplatin, fluorouracil, EBRT)|Patients receive oxaliplatin IV over 1 hour on day 1, fluorouracil IV continuously on days 1-7, and radiotherapy on days 1-5. Treatment repeats weekly for a maximum of 6 courses in the absence of disease progression or unacceptable toxicity.
88965443|NCT00006103|Experimental|irinotecan + leucovorin + fluorouracil|"Patients receive irinotecan IV over 90 minutes, leucovorin calcium IV, and fluorouracil IV on days 1, 8, 15, and 22. Treatment repeats every 6 weeks for a total of 5 courses in the absence of disease progression or unacceptable toxicity.~Patients are followed every 3 months for 1 year and then every 6 months thereafter."
88965444|NCT00006124|Experimental|Arm I (celecoxib)|Patients receive oral celecoxib twice daily.
88965445|NCT00006124|Placebo Comparator|Arm II (placebo)|Patients receive oral placebo twice daily.
88965446|NCT00006154|Experimental|A|Patients will receive combination antiretroviral therapy with a protease inhibitor
88965447|NCT00006154|Active Comparator|B|Patients will receive combination antiretroviral therapy without a protease inhibitor
88965448|NCT00006172|Active Comparator|bright light box|60 min light therapy shortly after awakening
88965449|NCT00006172|Active Comparator|high-output negative ion generator|60 min high-density exposure shortly after awakening
88965450|NCT00006172|Placebo Comparator|low-output negative ion generator|60 min low-density exposure shortly after awakening
88965451|NCT00006205|Experimental|Ondansetron|Ondansetron + cognitive behavioral therapy
88965452|NCT00006205|Experimental|Topiramate|Topiramate + cognitive behavioral therapy
88965453|NCT00006205|Placebo Comparator|Placebo|Placebo + cognitive behavioral therapy
88965454|NCT00006205|Experimental|Ondansetron + Topiramate|Ondansetron + Topiramate + cognitive behavioral therapy
88965455|NCT00006214|Experimental|flutamide|"Patients receive oral flutamide once daily.~Treatment continues for 1 year in the absence of disease progression or unacceptable toxicity. Quality of life is assessed before study, at 1, 6, and 12 months, and then annually therafter. Patients are followed annually for up to 10 years."
88965456|NCT00006214|Other|placebo|"Patients receive an oral placebo once daily.~Treatment continues for 1 year in the absence of disease progression or unacceptable toxicity. Quality of life is assessed before study, at 1, 6, and 12 months, and then annually therafter. Patients are followed annually for up to 10 years."
88965457|NCT00006220|Experimental|Phase I|Starting dose of arsenic trioxide of 0.15 mg/kg/day
88965458|NCT00006220|Experimental|Phase II|MTD of arsenic trioxide
88965459|NCT00006220|Experimental|Treatment Failure|Arsenic trioxide and tretinoin
88965460|NCT03761953|Experimental|Oritavancin|Single IV infusion of 1200mg of oritavancin
88965461|NCT00387634|Active Comparator|Arm 1|Blood draw only, no vaccine
88965462|NCT00387634|Active Comparator|Arm 2|Blood draw only, no vaccine
88965463|NCT00387634|Active Comparator|Arm 3|Blood draw only, no vaccine
88965464|NCT00387634|Active Comparator|Arm 4|Blood draw only, no vaccine
89208431|NCT00864942|Experimental|BL-NHL|Bendamustine and lenalidomide for NHL
89558850|NCT01805466|Experimental|EVADO|"The E.V.A.D.O. system is made of the following components:~The ADMIRAL oxygenator, that requires low priming volumes (, has a limited contact surface and contains an accessory independent cardiotomy reservoir, allowing separation of pericardial suction blood.~The HARMONY Smart Suction System, which allows automatic regulation of a pumpless extracavity blood sucker, whose rates and pressures depend on whether suction is required for blood/air surfaces (skimming), or for fluids (pooled).~Paediatric circuits with 3/8 tubing for both arterial and venous lines."
89558851|NCT01805466|Active Comparator|Conventional CPB|conventional cardiopulmonary by-pass (CPB) system
89558852|NCT01773421|Experimental|Part A|
89558853|NCT01773421|Experimental|Part B|
89558854|NCT01747486|Experimental|Target dose of 1-5x10e8|Arm 1: Target dose of 1-5x10e8 CART-19 cells (calculated as range of 10-50% transduced cells in 1 x10e9 total cells)
89558855|NCT01747486|Experimental|Target dose of 1-5x10e7|Arm 2: Target dose of 1-5x10e7 CART-19 cells (calculated as the range of 10-50% transduced cells in 1 x10e8 total cells)
89558856|NCT01733238|Experimental|PNT2258|PNT2258 120 mg/m2 will be administered as a 2-hour intravenous infusion on days 1-5 of a 21-day cycle. Treatment may continue (unless there is disease progression or the occurrence of unacceptable toxicity) for a total of 6 cycles of therapy.
88965465|NCT00006226|Experimental|Treatment (thalidomide)|Patients receive oral thalidomide daily for 4 weeks. Courses repeat every 4 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity.
88965466|NCT00006253|Experimental|Nurse|Receives symptom management assistance from an oncology nurse via the telephone
88965467|NCT00006253|Experimental|Non-nurse coach|Receives symptom management assistance from a non-nurse coach via telephone
88965468|NCT00006265|Experimental|Cohort I|Immunotherapy with gemtuzumab
88965469|NCT00006265|Experimental|Cohort II|Gemtuzumab + ara-C
88965470|NCT00006265|Experimental|Cohort IA|Gemtuzumab + ara C
88965471|NCT00006265|Experimental|Cohort IV|Gemtuzumab + ara-C
88965472|NCT00007605|Active Comparator|1|Amiodarone or Sotalol
88965473|NCT00007605|Active Comparator|2|Sotalol
88965474|NCT03709888||Observation Group|Subjects will be identified from patients with chemotherapy induced peripheral neuropathy (CIPN) that are planning to be treated with memantine XR-pregabalin combination therapy.Patients who agree to participate will be asked to complete study questionnaires prior to the start of their CIPN treatment and once per week for six weeks during their treatment.
88965475|NCT03682744|Experimental|anti-CEA CAR-T cells|One intraperitoneal infusion of gene-modified anti-CEA T cells are administered to patients with CEA-expressing peritoneal metastases or malignant ascites
88965476|NCT00006295||Pedigree 1|
88965477|NCT00006295||Pedigree 2|
88965478|NCT00006295||Pedigree 3|
88965479|NCT00006295||Pedigree 4|
88965480|NCT00006295||Pedigree 5|
88965481|NCT00006295||Pedigree 6|
88965482|NCT00006295||Pedigree 7|
88965483|NCT00006295||Pedigree 8|
88965484|NCT00006295||Pedigree 9|
88965485|NCT00006295||Pedigree 10|
88965486|NCT00006295||Pedigree 11|
88965487|NCT00006295||Pedigree 12|
88965488|NCT00007683|Active Comparator|1|Warfarin Titrated to an INR of 2.5-3.0
88965489|NCT00007683|Active Comparator|2|Aspirin 182 mg
88965490|NCT00007683|Active Comparator|3|Clopidogrel 75 mg
88965491|NCT00007722||1|
89558857|NCT01689727|Other|Technetium Tc 99m EC20|
88965492|NCT00007761|Experimental|1|Bipolar Disorder Program
88965493|NCT00007761|Active Comparator|2|Usual (psychiatric) Care
88965494|NCT03677011|Other|category 1|Low responder
88965495|NCT03677011|Other|category 2|Medium Responder and High Responder
88965496|NCT00006229|Experimental|BMS-275291|
88965497|NCT00006229|Placebo Comparator|Placebo|
88965498|NCT00387868|Other|Registration|Cisplatin, Etoposide & concurrent radiotherapy
88965499|NCT00387868|Other|Surgical Resection|No distant Progression post Registration Arm
88965500|NCT00387868|Other|Post Resection|Assessment post surgical procedure to determine if at higher risk of recurrence or if complete resection could not be achieved.
88965501|NCT03616717|Active Comparator|modafinil 100 mg|"Drug: modafinil, Provigil, Alertec, Modavigil~Dosage form, frequency and duration: Each participant receives a single pill of placebo or active drug (modafinil 100 mg or 200 mg) 30 minutes after arriving at the lab. The participant then completes approximately 6 hours of testing in the laboratory. The participant stays at the lab for 7.5 hours in order to monitor physical condition in case the participant received the active pill. One week later, that participant receives a single pill of an alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and two active pills, each time separated by one week."
88965502|NCT03616717|Active Comparator|modafinil 200 mg|"Drug: modafinil, Provigil, Alertec, Modavigil~Dosage form, frequency and duration: Each participant receives a single pill of placebo or active drug (modafinil 100 mg or 200 mg) 30 minutes after arriving at the lab. The participant then completes approximately 6 hours of testing in the laboratory. The participant stays at the lab for 7.5 hours in order to monitor physical condition in case the participant received the active pill. One week later, that participant receives a single pill of an alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and two active pills, each time separated by one week."
88965503|NCT03616717|Placebo Comparator|placebo|"Drug: modafinil, Provigil, Alertec, Modavigil~Dosage form, frequency and duration: Each participant receives a single pill of placebo or active drug (modafinil 100 mg or 200 mg) 30 minutes after arriving at the lab. The participant then completes approximately 6 hours of testing in the laboratory. The participant stays at the lab for 7.5 hours in order to monitor physical condition in case the participant received the active pill. One week later, that participant receives a single pill of an alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and two active pills, each time separated by one week."
89208432|NCT00864942|Experimental|BLR-CLL|Bendamustine, lenalidomide, rituximab for CLL
89558858|NCT01689714|Experimental|Tc 99m EC20|Patients received 2 intravenous (IV) injections: 1 mg of folic acid (to reduce the uptake of FolateScan in normal tissues), followed 1 to 3 minutes later by 0.1 mg of EC20 labeled with 15 to 25 mCi of technetium-99m (99mTc) over 30 seconds in a total injection volume of 1 to 2 mL.2 Each injection was given as a slow IV push via a free-flowing indwelling IV catheter in an upper extremity vein (i.e., in the antecubital fossa).
89558859|NCT01689662|Experimental|Tc 99m EC20|"Subjects will receive two intravenous injections 1-3 minutes apart:~1 mg of folic acid~1-2 mL injection of 0.1 mg of EC20 labeled with 15-25 mCi of technetium-99m"
88965504|NCT00006349|Experimental|donepezil + vitamin E|"Patients receive oral donepezil daily and vitamin E twice daily.~All patients begin treatment within 2 weeks after completion of prophylactic cranial irradiation. Treatment continues for a minimum of 1 month in the absence of disease progression, unacceptable toxicity, or a 3.0 point drop on the Mini Mental State Examination (MMSE) and/or a 5 point drop on the Blessed Dementia Scale.~Cognition is assessed using the Blessed Dementia Scale and the MMSE at baseline and then every 3 months during study.~Quality of life and depression are assessed at baseline and then every 3 months during study.~Patients are followed every 6 months."
88965505|NCT00006349|Placebo Comparator|placebo|"Patients receive oral placebo twice daily.~All patients begin treatment within 2 weeks after completion of prophylactic cranial irradiation. Treatment continues for a minimum of 1 month in the absence of disease progression, unacceptable toxicity, or a 3.0 point drop on the Mini Mental State Examination (MMSE) and/or a 5 point drop on the Blessed Dementia Scale.~Cognition is assessed using the Blessed Dementia Scale and the MMSE at baseline and then every 3 months during study.~Quality of life and depression are assessed at baseline and then every 3 months during study.~Patients are followed every 6 months."
88965506|NCT00007878|Experimental|Treatment (bortezomib, fluorouracil, leucovorin calcium)|Patients receive bortezomib IV on days 1 and 4 and fluorouracil IV and leucovorin calcium IV on day 1 weekly for 2 weeks. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.
88965507|NCT00006364|Experimental|Treatment (omacetaxine mepesuccinate)|"Remission induction therapy: Patients receive remission induction therapy comprising homoharringtonine IV continuously over 24 hours on day 1 and then subcutaneously (SC) twice daily on days 2-14 for course 1. Subsequent courses of remission induction therapy comprise homoharringtonine SC twice daily on days 1-14. Treatment continues monthly for at least 2 courses.~Maintenance therapy: Patients with complete hematologic remission receive maintenance therapy comprising homoharringtonine SC twice daily on days 1-7 monthly for 3 years in the absence of disease progression or unacceptable toxicity."
88965508|NCT00007917|Experimental|Arm I|"Patients receive gemcitabine IV over 1-2.5 hours on days 1 and 8 and flavopiridol IV continuously over 24 hours on days 2 and 9. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of gemcitabine and flavopiridol until the maximum tolerated dose (MTD) is reached. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
88965509|NCT00006373|Experimental|TIME|Topotecan, Ifosfamide, Mesna and Etoposide
88965510|NCT00006388|Experimental|Radiation plus Tamoxifen|
88965511|NCT03586479|Experimental|Low Testing|Children will receive 0 testing (talking) exposures and 6 listening exposures for a total of 6 exposures to each word. This is a listening only condition with minimal testing.
88965512|NCT03586479|Experimental|Mid Testing|Children will receive 2 testing (talking) exposures and 4 listening exposures for a total of 6 exposures to each word. This is a listening and talking condition with mostly listening.
88965513|NCT03586479|Experimental|High Testing|Children will receive 4 testing (talking) exposures and 2 listening exposures for a total of 6 exposures to each word. This is a listening and talking condition with mostly talking.
88965514|NCT00388024||cancer patients about to be treated with radiation therapy|Patienta with histologically confirmed squamous cell or lymphoepithelioma of oral cavity, oropharynx, hypopharynx, larynx, nasopharynx, or unknown primary of the head and neck about to be treated with radiation therapy
88965515|NCT00006463|Experimental|Therapy ECTEINASCIDIN 743 (1100 ug/m2 )|
88965516|NCT00006463|Experimental|ECTEINASCIDIN 743 (1300 ug/m2)|
88965517|NCT00006469|Other|Single arm study|Concurrent Paclitaxel, Carboplatin, and External-Beam Radiation Followed by Surgical Resection in Locally Advanced Non-Small-Cell Lung Cancer
88965518|NCT00006472|Other|Single arm study|Taxol® (Paclitaxel), Carboplatin and 5-Fluorouracil with Simultaneous Radiotherapy Followed by Surgical Resection
88965519|NCT00008346|Other|SFM then FFDM|Screen Film Mammography (SFM) followed by Full Field Digital Mammography (FFDM)
88965520|NCT00008346|Other|FFDM then SFM|Full Field Digital Mammography (FFDM) followed by Screen Film Mammography (SFM)
88965521|NCT00006487|Active Comparator|chemo/RT with tirapazamine|induction and consolidation: cisplatin, etoposide, tirapazamine, radiation therapy
88965522|NCT05448261|Experimental|Emotion-centered problem-solving intervention (EPi)|The EPi comprises four weekly 60 minutes individual face-to-face session (45 minutes of emotion-centered problem-solving intervention and 15 minutes of stroke education), followed by two bi-weekly telephone follow-ups (30 minutes) and one face-to-face round up session (60 minutes). The content of the stroke education will be based on a developed booklet for local family caregivers (please refer to control group).
88965523|NCT05448261|Sham Comparator|Stroke education|The CG will receive basic education on stroke caregiving, as research indicates that basic education is not effective in improving problem-solving coping abilities and depressive symptoms. Four weekly individual stroke education (60 minutes/session) will be conducted by a trained research nurse. It will be based on a developed information booklet for local stroke caregivers. The participants will received three biweekly phone calls for general greetings. Questions relating to stroke caregiving raised by the caregivers will be answered according to the educative content. Any extra information provided will be documented.
89558860|NCT01689636|Experimental|Single-center, open-label|"The study was designed as a single-center, open-label clinical study to evaluate the safety, pharmacokinetics, dosimetry and metabolism of Tc 99m EC20 in normal volunteers and in patients with known or suspected ovarian cancer.~Eight subjects were to be enrolled at one center: four normal subjects, four patients with ovarian cancer. Each subject was to receive a single injection of Tc 99m EC20 complex composed of 0.1 mg ligand (EC20) and 15 - 20 mCi of Tc 99m. Two (2) of the 4 normal subjects and 2 of the 4 patients were to receive an injection of 0.25-2.0 mg folic acid 1-2 minutes prior to the injection of Tc 99m EC20."
89558861|NCT01686256|Experimental|Tc 99m EC20|A Phase 1, multi-center, open-label, single-treatment group, baseline-controlled (for safety) study designed to verify product safety, determine optimal imaging time, gather efficacy data for the radioactive drug product (Technetium Tc 99m EC20), and assay masses for presence of folate receptors, in women with suspected ovarian or endometrial cancer. Twelve subjects will be enrolled, with a minimum of five malignant cases, as determined by histopathological evaluation.
89558862|NCT01684098|Other|Tc 99m EC20|
89558863|NCT01593254|Active Comparator|Arm 1: Imatinib (≥400 mg)|Imatinib ≥400 mg tablets by mouth once daily (QD) or twice daily (BID) up to 60 months
89558864|NCT01593254|Active Comparator|Arm 2: Dasatinib (100 mg)|Dasatinib 100 mg tablet by mouth QD up to 60 months
89558865|NCT01581489||Early cord clamping (ECC)|Early cord clamping consisted of early (=< 10 s) clamping of the umbilical cord at birth.
89558866|NCT01581489||Delayed cord clamping (DCC)|Delayed cord clamping consisted of delayed (>= 180 s) clamping of the umbilical cord at birth.
89558867|NCT01570998|Experimental|Treatment (IORT)|Patients undergo IORT in a single fraction over 15-40 minutes at the time of standard of care lumpectomy.
89558868|NCT01559818|Experimental|IMM-101|IMM-101 1.0 mg administered intradermally
89558869|NCT01537601|Other|Antibiotic prophylaxis alone|Children will be on antibioprophylaxis and will not have a circumcision.
89558870|NCT01537601|Experimental|Circumcision and antibiotic prophylaxis|Children will have a circumcision at the time of valve resection and will be on antibioprophylaxis
89558871|NCT01525394|Experimental|Lenvatinib Capsules|
89558872|NCT01525394|Active Comparator|Moxifloxacin tablets|
89558873|NCT01525394|Placebo Comparator|Placebos|
89558874|NCT01510678|Experimental|Decrease Condition|In the Decrease Snack Foods condition participants will reduce intake of SFs (i.e., candy, cookies, cakes, ice cream, chips, nuts) to < 3 servings/week (for children aged 6 to 12 years, the solid fats and added sugar energy limit is 840 kcals/week and the DECREASE goal will help with meeting this limit). Children and parents will gradually work towards meeting these goals and self-monitor these behaviors.
89558875|NCT01510678|Experimental|Increase + Decrease Condition|Families will be encouraged to increase fruits and vegetables and decrease snack foods.
89558876|NCT01510678|Experimental|Increase Condition|A parent and child will be encouraged to increase fruits and vegetables. Children will be encouraged to consume 1 cup/day and 1.5 cups/day of whole fruit, and 1.5 cups/day and 2 cups/day of vegetables for children aged 6 to 8 years and 9 to 12 years, respectively. Children will gradually work towards these goals. Parents will also work towards F&V goals, with 2 cups/day of whole fruit and 2.5 cups/day of vegetables.
89558877|NCT01454934|Experimental|Arm A|
89558878|NCT01454934|Active Comparator|Arm B|
89558879|NCT01442246|Experimental|Adjuvant treatment|Leuproreline acetate
89558880|NCT01442246|No Intervention|Surveillance|Surveillance
89558881|NCT01439282|Experimental|Eribulin + Capecitabine|
89558882|NCT01391026|No Intervention|Usual care|Patients will receive usual care by their primary care physicians without automated referral to specialized providers.
89558883|NCT01391026|Experimental|Enhanced patient-centered care|Patients will be evaluated and treated in the advanced illness management clinic
89558884|NCT01326312|Experimental|GTx- 758 1000mg|GTx-758/Experimental/ nonsteroidal selective ER alpha agonist
89558885|NCT01326312|Experimental|GTx-758 2000mg|GTx-758/Experimental/ nonsteroidal selective ER alpha agonist
89558886|NCT01326312|Active Comparator|Lupron Depot|Luteinizing Hormone Releasing Hormone Agonist
89558887|NCT01321554|Experimental|Lenvatinib (Randomization Phase)|Participants randomly assigned in a 2:1 ratio to receive blinded study drug (lenvatinib or matching placebo) until documentation of disease progression (confirmed by IIR), development of unacceptable toxicity, or withdrawal of consent.
88965524|NCT00006505|Experimental|Transplant|Islet cell transplantation
88965525|NCT03612154|Experimental|Lorlatinib|Subjects will be treated with lorlatinib 100mg PO daily. A cycle will be defined as 28-days for the convenience of analysis.
88965526|NCT00008502||18 years of age or older|without keloids
88965527|NCT00008502||family members over 12 years of age|who have either classic or non-classic keloids
88965528|NCT00008502||Probands|original participants who have had a classic (butterfly-shaped or wound-overflowing) keloidfor at least one year
88965529|NCT00006517|Active Comparator|bright light box|30 min exposure shortly after wake-up
88965530|NCT00006517|Active Comparator|high-output negative ion generator|90 min exposure prior to wake-up
88965531|NCT00006517|Placebo Comparator|low-output negative ion generator|90 min exposure prior to wake-up
88965532|NCT00006517|Active Comparator|dawn simulator|naturalistic incremental light exposure 90 min prior to wake-up
88965533|NCT00006517|Experimental|dawn light pulse|rectangular pulse light exposure 13 min before wake-up, matched for total illuminance with dawn signal
88965534|NCT00006565|Experimental|1|HEPA Air Cleaners
88965535|NCT00006565|Placebo Comparator|2|Inactive (placebo) filtration unit
88965536|NCT00008697|Experimental|Phase 1|"Cohort 1 Arsenic trioxide = 0.1 mg/kg/day x 28 days with 14 day rest for 3 cycles (each cycle = 6 weeks)~Cohort 2 Arsenic trioxide = 0.15 mg/kg/day x 28 days with 14 day rest for 3 cycles (each cycle = 6 weeks)~Cohort 3 Arsenic trioxide = 0.20 mg/kg/day x 28 days with 14 day rest for 3 cycles (each cycle = 6 weeks)~Cohort 4 Arsenic trioxide = 0.25 mg/kg/day x 28 days with 14 day rest for 3 cycles (each cycle = 6 weeks)~Cohort 5 Arsenic trioxide = 0.30 mg/kg/day x 28 days with 14 day rest for 3 cycles (each cycle = 6 weeks)"
88965537|NCT00008697|Experimental|Phase 2|Arsenic trioxide = MTD found in Phase 1 mg/kg/day x 28 days with 14 day rest for 3 cycles (each cycle = 6 weeks)
88965538|NCT00388141|Experimental|NIDCAP|In the intervention NIDCAP group the staff has been introduced and trained in the principles of the NIDCAP-care, where main core is to see, organize and conduct the care of the preterm infant on behalf of the childs actually resources and competences
88965539|NCT00006760|Experimental|Treatment (ifosfamide, vinorelbine, filgrastim)|Patients receive ifosfamide IV over 24 hours on days 1-4 and vinorelbine tartrate IV over 6-10 minutes on days 1 and 5. Patients also receive filgrastim (G-CSF) subcutaneously or IV over 15-30 minutes beginning 24-36 hours after completion of vinorelbine and continuing daily until blood counts recover. Treatment repeats at least every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients may receive a third course of therapy at the discretion of the investigator. Heavily pretreated, high-risk patients who achieve a complete response are eligible for stem cell transplantation. Patients undergo peripheral blood stem cell (PBSC) collection during hematopoietic recovery after the second course of chemotherapy. Patients with sufficient PBSCs collected may undergo PBSC transplantation on protocol COG-AHOD0121.
88965540|NCT00006994|Active Comparator|L-glutamine in suspension + radiation|20 cc three times daily for 60 days plus radiation therapy.
88965541|NCT00006994|Placebo Comparator|Placebo in suspension + radiation|20 cc three times daily for 60 days plus radiation therapy.
88965542|NCT00388375|No Intervention|CVC Internal Jugular or Subclavian Vein|
88965543|NCT05636046||transseptal catheterization performed without auxiliary tools|patients in whom transseptal catheterization have been performed without auxiliary tools
88965544|NCT05636046||transseptal catheterization performed with auxiliary tools|patients in who transseptal catheterization have been performed with the use of auxiliary tools
88965545|NCT00007267|Experimental|1|Participants will receive individual cognitive behavioral therapy
88965546|NCT00007267|Experimental|2|Participants will receive self-help cognitive behavioral intervention facilitated by a psychologist
88965547|NCT00007267|Active Comparator|3|Participants will receive a disease/health education intervention
88965548|NCT00007501|Experimental|Arm 1|varicella-zoster vaccine
88965549|NCT00007501|Placebo Comparator|Arm 2|vaccine placebo
88965550|NCT00007579||1|
88965551|NCT00007618||1|
88965552|NCT00007657|Experimental|1|Percutaneous Coronary Intervention (PCI) plus intensive medical therapy
88965553|NCT00007657|Active Comparator|2|Intensive medical therapy
88965554|NCT00007696||1|
88965555|NCT00007774|Experimental|1|Olanzapine
88965556|NCT00007774|Active Comparator|2|Haloperidol
88965557|NCT00007813|Experimental|Arm 1|
88965558|NCT00007852|Experimental|Arm I|Rituxan and BEAM with autologous stem cell transplant
88965559|NCT00008320|Experimental|ceramide cream|Topical ceramide cream is applied to all cutaneous lesions twice daily. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Quality of life is assessed at baseline and then at 1 and 3 months. Patients are followed every 3 months for 1 year and then every 6 months for 4 years.
88965560|NCT05636254||Chronic Meningitis|"Chronic meningitis : Case definition~Headache with or without fever, nuchal stiffness and systemic symptoms AND~CSF suggestive of meningitis Pleocytosis (>20 cells per μL) with lymphocyte predominance (>50%) OR Protein concentration greater than age-specific normal value; especially >1•0 g/L OR Glucose concentration less than 60% of concentration in blood OR MRI suggestive of meningeal enhancement on contrast enhanced T1 sequences AND~Deemed by the treating physician that the syndrome is consistent with chronic meningitis~Patients who are positive for antibodies to HIV and pregnant females will also be included."
88965561|NCT05636553|Experimental|Massage|Women will receive four 60 minute massage consultations within a four-month period at intervals of their choosing.
88965562|NCT05636566|Active Comparator|Group (S)|sevoflurane inhalational anaesthesia for induction, then sevoflurane and fentanyl infusion for maintenance ,
88965563|NCT05636566|Active Comparator|Group P|propofol infusion for induction afterward propofol and fentanyl infusions for maintenance of anaesthesia
88965564|NCT05636566|Active Comparator|Group D|dexmedetomedine infusion for induction after that dexmedetomedine and fentanyl infusions for maintenance
88965565|NCT05636644||Group A|anthracyclines+cyclophosphamide+other paclitaxel drugs
88965566|NCT05636644||Group B|anthracyclines+cyclophosphamide+nab paclitaxel
88965567|NCT05447143|Other|Control Group (CG)|The control group will be queued to be included in the exercise program and participants' routine treatment will continue.
88965568|NCT05447143|Experimental|Video Group (VG)|The exercise will be given as a video and participants will be asked to continue the exercises for 8 weeks, 3 days a week. Patients will be contacted by phone every week to ask if participants have any problems with the exercise program and their compliance.
88965569|NCT05447143|Experimental|Brochure Group (BG)|Exercise will be given as a brochure and participants will be asked to continue the exercises given for 8 weeks, 3 days a week. Visual feedback will be provided by asking participants to mark the exercise tracking chart on the exercise brochures.
88965570|NCT05636631||Patients with Pneumonia (1)|Patients presented with symptoms suggestive of pneumonia as fever, tachypnea, cough with sputum. These patients will receive IV fluids & antibiotics with follow up of sepsis parameters
88965571|NCT05636631||Patients with decongestive heart failure (2)|Patients presented with symptoms suggestive of acute congestive heart failure as dyspnea, orthopnea, bilateral lower limb edema. These patients will receive anti-failure treatment as diuretics, ACE inhibitors & Beta blockers with follow up of resolving signs of decompensated heart failure
88965572|NCT05636761||group EliteHRV|the group (Elite) that started the assessment with the EliteHRV mobile application
88965573|NCT05636761||group Polar|the (Polar) group that started the evaluation with the Polar V800 watch
88965574|NCT05636839|Experimental|UVB treatment|"UVB treatment 3 times per week for 10 weeks~Before treatment starts, researchers will collect 20 ml of blood from participants. After 10-week treatment, researchers will collect 20 ml of blood from participants again."
88965575|NCT05636917||radiculopathy|Patients with suspected radiculopathy who are prescribed the nerve conduction test at the Lozano-Blesa University Hospital and who have undergone or are awaiting an MRI scan.
89558888|NCT01321554|Placebo Comparator|Placebo (Randomization Phase)|Participants randomly assigned in a 2:1 ratio to receive blinded study drug (lenvatinib or matching placebo) until documentation of disease progression (confirmed by IIR), development of unacceptable toxicity, or withdrawal of consent.
89558889|NCT01321554|Experimental|Lenvatinib 24 mg (OOL Lenvatinib Treatment Period)|Participants will receive lenvatinib 24 mg, orally once daily until documentation of disease progression (confirmed by investigator's assessment), development of unacceptable toxicity, or withdrawal of consent. Placebo treated participants in the Randomization Phase who have progressive disease confirmed by IIR could request to receive lenvatinib treatment in the OOL Treatment Period.
89558890|NCT01321554|Experimental|Lenvatinib 20 mg (OOL Lenvatinib Treatment Period)|Participants will receive lenvatinib 20 mg, orally once daily until documentation of disease progression (confirmed by investigator's assessment), development of unacceptable toxicity, or withdrawal of consent. Placebo treated participants in the Randomization Phase who have progressive disease confirmed by IIR could request to receive lenvatinib treatment in the OOL Treatment Period.
89558891|NCT01308437|Experimental|Wosulin (N or 70/30 with R)|Basal bolus conventional Insulin viz. Wosulin (N or 70/30 with R) to be injected subcutaneously.
88965576|NCT05636670||SLE group|"The researcher signed the informed consent voluntarily;~Male or female patients aged 14-55 years;~Patients diagnosed with systemic lupus erythematosus are classified according to the European League against Rheumatism (EULAR)/American College of Rheumatology (ACR) joint classification criteria for SLE in 2019.~Patients who need to undergo head imaging examination according to the judgment of treating doctors, and the results of head imaging examination are not consistent with changes in cerebrovascular disease.~no antibiotics have been taken in the past 2 weeks;"
88965577|NCT05636670||NPSLE epilepsy group|"The researcher signed the informed consent voluntarily;~Male or female patients aged 14-55 years~Patients diagnosed with systemic lupus erythematosus are classified according to the European League against Rheumatism (EULAR)/American College of Rheumatology (ACR) joint classification criteria for SLE in 2019.~Patients who need MRI according to the judgment of the treating doctor, and reveal that the MRI suggests cerebrovascular disease;~no antibiotics have been taken in the past 2 weeks;"
88965578|NCT05636670||Healthy control group|"Male or female patient volunteers aged 14-55 from the Health Examination Center of Nanfang Hospital,~Voluntary signing of informed consent;~no systemic disease;~According to the judgment of the researchers, healthy volunteers matching SLE group in age, gender and education level were selected as the control group;"
88965579|NCT05636956|Experimental|Patients who receive education and counseling program|Patients with CIEDs and low health literacy received education and counseling program by researchers.
88965580|NCT05636956|No Intervention|Patients who receive clinical routine care|Patients with CIEDs and low health literacy received only clinical routine care.
88965581|NCT05637034|Experimental|68Ga-DOTA-F2 PET/CT and 18F-FDG|Each subject receive a single intravenous injection of 68Ga-DOTA-F2 and 18F-FDG, and undergo PET/CT imaging within the specified time.
88965582|NCT05637268|Experimental|treatment group|"Treatment with camrelizumab combined with chemotherapy was planned for 4 to 6 cycles, after which carrilizumab monotherapy was maintained until disease progression, unacceptable toxicity, or patient withdrawal.~A total of 4 to 6 cycles, after carrilizumab maintenance treatment for one year."
88965583|NCT05637385|Experimental|central vision loss|will receive behavioral intervention
88965584|NCT05637385|Active Comparator|normal vision|using simulated central scotomas, will receive behavioral intervention
88965585|NCT05637580||combined well responder|Both primary tumor and nodal response achieve major pathological response (MPR).
88965586|NCT05637580||poor responder|Primary tumor or/and nodal response can not achieve MPR.
88965587|NCT05637736|Experimental|Mindfulness-based Stress Reduction by Therapeutic VR|
88965588|NCT05637736|Active Comparator|mindfulness-based therapy|
89026415|NCT00469118|Experimental|DRX Treatment|20 treatments of spinal decompression over a six week period. Each session lasts about 45 minutes and consists of a 28-minute treatment on the DRX9000™ machine followed by 15 minutes of cold therapy to the lumbar paravertebral muscles.
89026416|NCT00469118|No Intervention|Conservative Care|Conservative non surgical therapy for 6 weeks prior to beginning DRX9000 treatment
89026417|NCT00493233|Experimental|1|
89026418|NCT00493233|Placebo Comparator|2|
89208433|NCT00864942|Experimental|BLR-NHL|Bendamustine, lenalidomide, and rituximab for NHL
89208434|NCT00864942|Experimental|BL-CLL|bendamustine and lenalidomide in patients with CLL
89208435|NCT00870402|Experimental|1|
89558892|NCT01308437|Active Comparator|Novolin® (N or 70/30 with R)|Basal bolus conventional Insulin viz. Novolin® (N or 70/30 with R) to be injected subcutaneously.
89558893|NCT01269346|Experimental|1|
89558894|NCT01268293|Experimental|1|
89558895|NCT01268150|Experimental|Experimental|
89558896|NCT01267175|Experimental|X54 pump|All subjects transferred from current pump to X54
89558897|NCT01259908||Laparoscopic vs open Ygraft|Patients with advanced atherosclerosis in aorto iliac segment operated with either laparoscopic aortobifemoral bypass or open aortobifemoral bypass shall be compared on the basis of the operative procedure for the primary endpoint, composite endpoint (all-cause mortality, systemic morbidity and graft thrombosis).
89208436|NCT00870402|Placebo Comparator|2|
89208437|NCT00742391|Active Comparator|1|PEP005 (ingenol mebutate) Gel
89208438|NCT00742391|Placebo Comparator|2|Vehicle gel
89558898|NCT01231841|Experimental|rATG + Cyclosporine|Patients receive anti-thymocyte globulin IV daily over 4-24 hours on days 1-5. Beginning on day 6, patients receive oral cyclosporine twice daily for 6 months followed by a taper. Treatment continues in the absence of disease progression or unacceptable toxicity
89558899|NCT01133756|Experimental|Lenvatinib plus carboplatin + gemcitabine|Phase IB and Phase II
89558900|NCT01133756|Active Comparator|Carboplatin + gemcitabine|Phase II
89558901|NCT01126736|Experimental|Low Dose E7389 in Combination with Pemetrexed|
89558902|NCT01126736|Active Comparator|Pemetrexed|
89558903|NCT01126736|Experimental|High Dose E7389 in Cominbation with Pemetrexed|Eribulin mesylate (eribulin; E7389) administered as a 2-5 minute intravenous (IV) bolus in one of two dosing schedules for both the Phase Ib and Phase 2 portions: either Days 1 and 8 of a 21 day cycle in ascending doses of 0.7, 1.1, or 1.4 mg/m2 or on Day 1 of the 21-day cycle at doses at ascending doses of 0.9, 1.4, or 2.0 mg/m2.
89558904|NCT01117844|Experimental|Proton radiation|
89558905|NCT01111461|Experimental|Lenvatinib 24 mg|Participants with advanced endometrial cancer and disease progression following platinum-based, first line chemotherapy.
88965589|NCT05637853||HFrEF patients (diagnosed within 3 months or hospitalized for worsening of HFrEF)|"Standardized sequencing of all for main HFrEF drugs: Betablockers, RAASi, SGLT2i, MRA.~All patients will be started on an SGLT2i (Empagliflozin or Dapagliflozin) and a betablocker (Metoprolol, Bisoprolol or Carvedilol) right after study inclusion. In the second week, RAASi will be introduced with either angiotensin converting enzyme inhibitor (ACEi)(Ramipril or Enalapril) or angiotensin receptor neprilisyn inhibitor (ARNI)(Sacubitril/Valsartan). If the patient is intolerant to either of these, an angiotensin receptor blocker (ARB)(Candesartan, Losartan, Valsartan) will be introduced. During the following weeks, both BB and ACEi/ARNI/ARB will be up titrated every second week according to the sequencing algoritm. MRA (Spironolactone, Eplerenone) will be introduced and up titrated in week 3 and 7 respectively. If the patient is already on either BB or ACEi/ARNI/ARB/MRA they will continue with the previous prescription and dose until the titration scheme indicates uptitration."
88965590|NCT05637931||adult polymyositis and dermatomyositis|
88965591|NCT05637931||juvenile dermatomyositis|
88965592|NCT05637931||healthy controls|
89558906|NCT01104155|Active Comparator|eribulin mesylate, 21 day cycle|
89558907|NCT01104155|Active Comparator|eribulin mesylate, 28 day cycle|
89558908|NCT01067287|Active Comparator|Group 1|Monoclonal antibody CT-011 will be given 1-3 months following autologous transplant. 3 doses will be given at 6 week intervals.
89558909|NCT01067287|Active Comparator|Group 2|Vaccination with DC/myeloma fusion cells will be given 1-3 months following autologous transplant. Vaccination will be given at 6 weeks intervals. The monoclonal antibody CT-011 will be given 1 week following each vaccination. 3 doses of CT-011 will be given at 6 week intervals.
89558910|NCT01065597|Experimental|Nonconvulsive electrotherapy|Open label single arm study of nonconvulsive electrotherapy
89558911|NCT01051856|Active Comparator|SEAMGUARD with bioabsorbable staple|In this arm pancreatic transection will be executed using an endoscopic linear stapling device. The individual staple depth can be chosen by the operating surgeon. Bioabsorbable Mesh sleeves specifically manufactured for the chosen staple depth and cartridge length will be placed over the stapler before firing.
89558912|NCT01051856|Active Comparator|TissueLink with radiofrequency ablation|After pancreatic transection, with any method chosen by the operating surgeon, the pancreatic remnant will be treated with TissueLink alone for an ablation depth (thickness) of approximately 7 mm using electrosurgical generator settings of 100 W and a saline drip rate of 1-2 drops per second.
89558913|NCT01029366|Experimental|CART-19 CLL|CART-19 (autologous T cells transduced with CD19 TCR-ζ/4-1BB vector) administered as an IV infusion days 0, 1, 2 and 11 in the absence of disease progression or unacceptable toxicity.Minimum/maximum total dose: 1.5x10^7 / 5x10^9 administered to patients with chronic Lymphocytic Leukemia (CLL) and Acute Lymphoblastic Leukemia (ALL).
89558914|NCT01029366|Experimental|CART-19 ALL|CART-19 (autologous T cells transduced with CD19 TCR-ζ/4-1BB vector) administered as an IV infusion days 0, 1, 2 and 11 in the absence of disease progression or unacceptable toxicity.Minimum/maximum total dose: 1.5x10^7 / 5x10^9 administered to patients with chronic Lymphocytic Leukemia (CLL) and Acute Lymphoblastic Leukemia (ALL).
89558915|NCT00879086|Active Comparator|Eribulin mesylate|
89558916|NCT00879086|Active Comparator|Ixabepilone|
89558917|NCT00796263|Other|HAART|"The proposed HAART regimen consists of:~2 nuceloside/nucleotide analog reverse-transcriptase inhibitor (NRTI) class medications~Dolutegravir(DTG) 50 mg orally once daily"
89558918|NCT00715442|Experimental|Sunitinib + Nephrectomy|Sunitinib 50 mg by mouth daily for 28 consecutive days. Nephrectomy will occur approximately 24 hours after the last dose of sunitinib.
89558919|NCT00675922|Experimental|Sulfamylon 5% and Silver Nitrate Soaks|Application of Sulfamylon 5% Solution and Silver Nitrate soaked dressings to two different burned area. Sites were then monitored for infections during hospitalization.
89558920|NCT00591812|Experimental|1 - ComPreSs system|
89558921|NCT00466531|Experimental|Patients with CLL or indolent B-cell lymphoma|The first stage is a standard 3-step phase I dose escalation trial to assess the safety of 19-28z CAR expressing autologous T cells with or without prior conditioning chemotherapy.Step 1, a cohort of pts will receive the lowest planned dose of 19-28z+ modified T cells. Step 2, a cohort of pts will receive cyclophosphamide conditioning chemotherapy followed by the lowest planned dose of 19-28z+ modified T cells. If less than 33% of pts in the cohort experience unanticipated dose-limiting toxicity,Step 3, a cohort of pts will be treated with the investigator's choice conditioning chemotherapy followed by the higher dose of 19-28z+ modified T cells. If less than 33% of pts in the initial cohort (Step 3) experience unanticipated dose-limiting toxicity, the cohort in Step 3 may be expanded to include up to 15 pts. In Step 3, an additional cohort of Waldenstrom's Macroglobulinemia (WM) pts will be treated with the investigator's choice conditioning chemotherapy followed by 19-28z+ T cells.
89558922|NCT00458653|Experimental|Group A|Post-transplant vaccination
89558923|NCT00458653|Experimental|Group B|Pre- and post-transplant vaccination
89558924|NCT00244933|Experimental|Gemcitabine, genistein (Novasoy), Tumor biopsy|Gemcitabine IV-1000mg/m2: Days 1 & 8 every 21 days Novasoy Orally-100 mg 2 times/day for 7 days; 2 times/day on Days 1-21 every 21 days.
89026419|NCT00469157|Other|1.|
89026420|NCT03270410||Neonates|Babies born in Rennes University Hospital
89026421|NCT00493272|Placebo Comparator|Placebo|Nacl
89026422|NCT00493272|Active Comparator|Fibrinogen|Fibrinogen
89026423|NCT00500253|Active Comparator|1|children with asthma with FeNO monitored treatment (study group)
89026424|NCT00500253|Other|2|group of children with treatment monitored by GINA's grade of disease clinical control (control group)
89026425|NCT03270566|Experimental|Domestic ion-exchange water softener|The intervention group will have a domestic ion-exchange water softener installed prior to birth.
89026426|NCT03270566|No Intervention|Usual hard water supply|The control group will receive their usual domestic water supply.
89558925|NCT00165425|Experimental|Cardiac screening|"Interventions:~Participants will~meet with study cardiologist~undergo cardiac risk factors screening~undergo resting and stress echocardiogram (echo and stress echo)"
89558926|NCT00121719|Experimental|1|
89558927|NCT00053209|Experimental|Pemetrexed Disodium and Gemcitabine|Pemetrexed disodium 500 mg/m2 followed by gemcitabine 1000 mg/m2 on day 1 and gemcitabine 1000 mg/m2 on day 8 of a 21-day cycle for a maximum of 6 cycles
89558928|NCT00003800|No Intervention|Laboratory/CT evaluation|Observation following orchiectomy
89558929|NCT00002934|No Intervention|Pathology Review, Observation and Follow-up|Pathology review, observation and follow-up
89558930|NCT00002668|Active Comparator|Observation|Standard pain management interventions usually given by hospital staff
89558931|NCT00002668|Experimental|Educational Intervention and Behavioral Skills Training|Patients participated in a program including video presentations, written materials, and coaching in behavioral skills to improve pain control (not to reduce analgesic use).
89558932|NCT03145987|Experimental|Vitis vinifera extract|Vitis vinifera extract 250 mg/day orally administered for 12 weeks.
89558933|NCT03145987|Placebo Comparator|Placebo|Placebo orally administered once a day for 12 weeks.
89558934|NCT05007665||Chronic Liver Diseases Patients/Healthy People|Chronic hepatitis (B OR C) , autoimmune hepatitis, liver cirrhosis, primary hepatocellular carcinoma
89558935|NCT04477915|Experimental|Core stabilization Exercise|Core stabilization exercise include, plank, lateral plank, swimmer, flutter kick and bridge exercises. Exercises will be carried out under the supervision of a physiotherapist 3 days in a week separate time periods. Our study will take 6 weeks.
89558936|NCT04477915|Experimental|Auxiliary respiratory exercises|Auxiliary respiratory exercises include, strengthening and stretching exercises for trapezius, sternocleidomastoideus, pectoralis major and serratus anterior muscles. exercises will be carried out under the supervision of a physiotherapist 3 days in a week separate time periods. Our study will take 6 weeks.
89558937|NCT04477915|No Intervention|Control|Control Group
89558938|NCT05007353|Experimental|Structured Lifestyle Intervention|Structured lifestyle modification program developed for participants targeting diet, physical exercise, cognitive training, and social stimulation.
89558939|NCT05007353|Experimental|Self-Guided Intervention|General health information provided to participants.
89558940|NCT03146065|Experimental|PF-06730512|Study Drug being used in the study
89558941|NCT03146065|Placebo Comparator|Placebo|Placebo for IV/SC administration
89558942|NCT03088397|Experimental|Patient decision aid|Group receives the patient decision aid, POCO (POstpartum Contraceptive Options), a grid with various contraceptive options across the columns and characteristics of each option in rows. Group receives Shared Decision Making counseling afterwards.
89558943|NCT03088397|Active Comparator|Website information|Group receives directions on how to get to bedsider.org information pages regarding contraceptive choices. Group receives Shared Decision Making counseling afterwards.
89558944|NCT03088397|Active Comparator|Standard of care|Group receives standard brochure on contraception in their postpartum packet. Group receives Shared Decision Making counseling afterwards.
89558945|NCT03146455||Health adults|(1) 18< Age <65, and Han Chinese residents living in Hunan more than 3 years. (2) Health examination population who physical examination, assistant examination and serological examination were normal; Not suffer from other diseases last 3 months; Not take any medication last 7 days.
89558946|NCT03078725|Active Comparator|Glyburide|hypoglycemic agent approved for treatment of GDMA2
89558947|NCT03078725|Active Comparator|Metformin|hypoglycemic agent approved for treatment of GDMA2
89558948|NCT02346409|Experimental|LFP-MEG recording with tACS of the cerebellum|To explore how cerebellar stimulation (using tACS) will alter oscillations and coupling along the CTC pathway, relating these changes in brain activity to clinical improvement.
89558949|NCT02346409|Active Comparator|tACS of the cerebellum vs VIM-DBS|To evaluate the differential effects of non invasive high-frequency stimulation tACS of the cerebellum, as compared to high-frequency stimulation of the thalamus (using DBS of the VIM).
89558950|NCT05007119|Active Comparator|Control Group|"It includes participants receiving conventional physical therapy for low back pain female patients for a period of 6 months.~McKenzie extension exercise Protocol Moist Heat Pack for 10 mins McKenzie Extension Protocol Sequence~Static:~Lying Prone~Lying prone in extension~Sustained extension~Posture correction~Dynamic:~Extension in lying~Extension in lying with clinician overpressure~Extension mobilization~Extension in standing"
89026427|NCT00469235|Placebo Comparator|1|50ng dose group
89026428|NCT00469235|Placebo Comparator|2|200ng dose group
89026429|NCT01243788|Active Comparator|Ipratropium/Albuterol|Ipratropium/Albuterol 36/206ug QID
89026430|NCT03270605||CS with myomectomy|Women having uterine myoma with pregnancy and subjected to myomectomy during delivery by CS
89026431|NCT03270605||CS without myomectomy|Women having uterine myoma with pregnancy and delivered by CS without myomectomy
89558951|NCT05007119|Experimental|Experimental Group|"Group (A) Involves participants receiving cupping therapy along with conventional physicla therapy for a period of 6 months .~Moist Heat Pack for 10 mins McKenzie Extension Exercise Protocol"
89558952|NCT02346487|Experimental|LPV/RTV pellets and AZT/3TC or ABC/3TC|Only 1 arm. No comparator
89558953|NCT03086837|Experimental|Mobile phone based intervention|Participants in the intervention group will receive a 12 week mobile phone based program via a mobile phone application specifically designed for this study. The program will include information, advice and strategies to increase active transportation. Feedback will be provided on personal goals.
89558954|NCT03086837|No Intervention|Control|No information
89558955|NCT02341963|Experimental|Oral Ketamine|Subjects will receive Oral Ketamine (1.0 mg/kg) ) presurgery and 3 days postsurgery (including surgery day).
89026432|NCT01243827|Experimental|carvedilol|carvedilol is administered after randomization at a dose of 10 mg once daily, and if needed, titrated to 15 mg and to a maximum of 20 mg to achieve a clinic BP <140/90 mmHg.
89026433|NCT01243827|Experimental|bisoprolol|bisoprolol is administered after randomization at a dose of 2.5 mg once daily, and if needed, titrated to 3.75 mg and to a maximum of 5.0 mg to achieve a clinic BP <140/90 mmHg.
89026434|NCT00500409|Experimental|Drug Group|Osteoform
89026435|NCT00500409|Active Comparator|Control group|SHELCAL
89558956|NCT05007197|Experimental|Intervention Group|"After controlling the metabolic values of the individuals in the intervention group, the education were carried out according to the learning modality of the people.~Group-specific diabetes trainings were completed in two training sessions. Each training session lasted an average of one and a half hours and a fifteen minute break was given.~The auditory group in the intervention group, calling by phone; visual group by SMS and WhatsApp tactile group, reminder alerts were made by phone+SMS+WhatsApp."
89558957|NCT05007197|No Intervention|Control Group|The learning modality of the control group were determined and standard group training was provided with the education booklet.
89558958|NCT05006651|No Intervention|Laryngoscope|Intubation with traditional laryngoscope
89558959|NCT05006651|Active Comparator|McGrath MAC|Intubation with video laryngoscope
89558960|NCT05006651|Active Comparator|Trachway|Intubation with video stylet
89558961|NCT05014685|Experimental|RA group|
89558962|NCT05014685|Experimental|RAM group|
89558963|NCT05014685|Experimental|RAB group|
89558964|NCT05014685|Active Comparator|RABM group|
89558965|NCT03111823|Experimental|Supportive Care (aerobic exercise)|Patients undergo aerobic exercise sessions consisting of cycling or walking at a low-moderate intensity and progressing to moderate intensity for 30 minutes 2 times a week for up to 8 weeks.
89558966|NCT02346097|Experimental|Optimal electrical resynchronization|"Cardiac Resynchronization Therapy: LV lead implant according to electrical activation mapping of available epicardial veins to identify the latest electrical activated myocardial region. Post-implant interventricular (VV) electrical optimization for narrowing the paced QRS width. Post-implant standard pacemaker settings: Atrioventricular (AV) interval 100-130 ms and VV interval settings with simultaneous biventricular pacing.~Day 1 after implantation: ECG, AV-optimization guided by echocardiography, high-pitch cardiac CT to verify LV lead position.~Programming of the VV interval to obtain the narrowest QRS-width"
89558967|NCT02346097|Active Comparator|Routine CRT-strategy, imaging guided|"Cardiac Resynchronization Therapy: LV lead implant guided by echocardiography and Rb-PET towards the latest mechanically activated myocardial segment and separate from scar. Post-implant VV electrical optimization for narrowing the paced QRS width. Standard pacemaker settings for both groups: AV-interval 100-130 ms and VV-interval settings with simultaneous biventricular pacing.~Day 1 after implantation: ECG, AV-optimization guided by echocardiography, high-pitch cardiac CT to verify LV lead position.~Continue standard interventricular pacing interval settings with simultaneous pacing in both ventricular leads."
89558968|NCT05014763|Active Comparator|CTG from deep palate|The connective tissue graft harvested from the deep palate during flap elevation for implant placement
89558969|NCT05014763|Experimental|CTG from tuberosity|The connective tissue graft harvested from the tuberosity
89558970|NCT02341885||One Group|This is an observational study, aimed at collecting an adequate dataset on a large cohort of patients admitted to a large number of ICUs.
89558971|NCT05015309|Experimental|SH3765 tablet|Daily oral administration of SH3765 tablet
89558972|NCT04433819||Cushing syndrome|Male and female patients diagnosed as Cushing syndrome caused by ACTH-producing pituitary adenoma or cortisol producing adrenal adenoma
89558973|NCT04433819||Controls|Healthy controls matched for age, gender, and body mass index
89558974|NCT02345785||Group 1|pediatric patients who need urologic surgery and caudal block
89558975|NCT05006495|Experimental|C3 laminectomy with C4-6 laminoplasty|Cervical myelopathy patients who underwent C3 laminectomy with laminoplasty.
89558976|NCT05006495|Active Comparator|C3-6 laminoplasty|Cervical myelopathy patients who underwent C3-6 laminoplasty.
89558977|NCT03111901|Experimental|Level 1|Pembrolizumab (200 mg) administered intravenously (day 2 of cycle 1; day 1 of cycles 2 and beyond); Low dose-interleukin 2 (LD-IL2) 12 MIU/m2 administered subcutaneously (days 1-5 and 8-12 of each cycle); each cycle is 21 days.
89558978|NCT03111901|Experimental|Level -1|Pembrolizumab (200 mg) administered intravenously (day 2 of cycle 1; day 1 of cycles 2 and beyond); Low dose-interleukin 2 (LD-IL2) 5 MIU/m2 administered subcutaneously (days 1-5 and 8-12 of each cycle); each cycle is 21 days.
89558979|NCT02345941|Experimental|Invervention|The intervention group will get tailored information on the Parent Action Report and the Parent Portal about child safety seats and booster seats.
89558980|NCT02345941|Active Comparator|Control|The control group will get tailored information in the Parent Action Report and the Parent Portal about smoke alarms.
89558981|NCT04816357||Endometriosis & Migraine|"Premenopausal women aged 18-55 years, at time of operation~Endometriosis confirmed with surgery and histologic staging (Report of the surgery available)~For the cases migraine needs to be confirmed during the interview according to the IHS criteria."
89558982|NCT04816357||Endometriosis|"Premenopausal women aged 18-55 years, at time of operation~Endometriosis confirmed with surgery and histologic staging (Report of the surgery available)"
89558983|NCT05014529||Control group|Polysomography show AHI less than 15 events/h and participants do not receive any intervention include CPAP, oral appliance, or surgery for 6 months.
89558984|NCT05014529||OSA without CPAP group|Polysomography show AHI greater than 15 events/h and participants do not receive any intervention include CPAP, oral appliance, or surgery for 6 months.
89026436|NCT01243866|Experimental|Early treatment|comprehensive dental treatment
89026437|NCT01243866|No Intervention|Regualr treatment|Regular treatment consisted of children who would be on a waiting list for regular dental treatment at KFAFH for at least 8 months
89026438|NCT00469430|No Intervention|Op|traditional surgery
89026439|NCT00469430|Experimental|Ab|antibiotic treatment
89026440|NCT00500487|Experimental|1|
89026441|NCT00500487|Active Comparator|2|
89026442|NCT00500487|Active Comparator|3|
89026443|NCT01243905|Active Comparator|Family psychoeducation plus TAU|Family psychoeducational therapy in addition to treatment as usual for the child (TAU)
89558985|NCT05014529||OSA with CPAP group|Polysomography show AHI greater than 15 events/h and participants receive CPAP more than 6 months.
89558986|NCT02341729|Other|starting with ticagrelor|"Patients, after CPR because of an ACS, will receive 2 crushed tablets of ticagrelor (180mg) through a gastric tube. After this dose twice a day 90mg is given for the duration of 1 year. The 1st blood sample is taken before administration. In total 10 blood samples are taken for determination of platelet aggregation and plasma concentrations.~When patients receive a semi-urgent CABG, ticagrelor has been interrupted for 3 days. Postoperative the patients get crushed tablets of ticagrelor, the 1st dose will be 90mg, and every 12h 90mg is given, for the duration of 1 year. The 1st blood sample is taken before the 1st dose. In total 9 blood samples are taken for determination of platelet aggregation and plasma concentrations."
89558987|NCT05014373|Active Comparator|Experimental: Favipiravir + Best supportive Care|Favipiravir (or Avigan) 1800 mg tablet 2x a day on Day 1 then 800 mg 2x a day from Day 2 to maximum of Day 14
89558988|NCT05014373|Placebo Comparator|Comparator: Best Supportive Care|Best supportive care or Standard Treatment includes oral or intravenous rehydration, electrolyte correction, antipyretics, analgesics, antibiotics and antiemetic drugs & the medication any patient is on due to any concomitant diseases
89026444|NCT01243905|Placebo Comparator|Treatment as usual|Treatment as usual for the child (TAU)
89558989|NCT02039245|Experimental|Canagliflozin/Metformin XR|Each patient will receive 2 tablets of CANA/MET XR combination of total dose 300/2000 mg
89558990|NCT03083951|Experimental|Complete Mesocolon Excision|A high tie of the inferior mesenteric artery (IMA) should be attempted. The inferior mesenteric vein section at the Treitz angle should be performed. The lymphatic tissue that accompanies the inferior mesenteric vein should be added.
89558991|NCT03083951|Active Comparator|Conventional Locoregional Lymphadenectomy|A high tie of the inferior mesenteric artery (IMA) should be attempted. Lymphadenectomy of the lymphatic tissue that accompanies the IMA will be performed. The inferior mesenteric vein section could be performed at the discretion of the surgeon.
89558992|NCT04762459|Active Comparator|Almonertinib|Drug: Almonertinib 110 mg A cycle of treatment is defined as 21 days of once daily treatment. Number of Cycles: The patient continues to receive treatment until the disease progresses or reaches termination criteria. The overall treatment last for 3 years.
89558993|NCT04762459|Experimental|Almonertinib/Pemetrexed/Cisplatin|"Drug: Almonertinib 110 mg Drug: Pemetrexed 500 mg/m² IV on day 1 of each 21 day cycle. Number of cycles until disease progression or unacceptable toxicity develops.~Drug: Cisplatin 75mg/m2 IV on day 1 of each 21 day cycle. Number of cycles until disease progression or unacceptable toxicity develops.~A cycle of treatment is defined as 21 days of once daily treatment. Number of Cycles: The patient continues to receive treatment until the disease progresses or reaches termination criteria. The overall treatment last for 3 years."
89558994|NCT04762459|Active Comparator|Pemetrexed/Cisplatin|"Drug: Pemetrexed 500 mg/m² IV on day 1 of each 21 day cycle. Number of cycles until disease progression or unacceptable toxicity develops.~Drug: Cisplatin 75mg/m2 IV on day 1 of each 21 day cycle. Number of cycles until disease progression or unacceptable toxicity develops.~A cycle of treatment is defined as 21 days of once daily treatment. Number of Cycles: The patient continues to receive treatment until the disease progresses or reaches termination criteria. If disease progresses during the treatment period and conditions required for the cross-treatment are met according to the assessment process, the patient can start to receive the open cross-treatment of Almonertinib. The overall treatment last for 3 years."
89558995|NCT03078569|Experimental|testosterone gel|testosterone gel treatment group
89558996|NCT03078569|No Intervention|Control group|without testosterone treatment
89558997|NCT03078335|Experimental|Glove based care|The intervention is the use of non-sterile gloves, after standard hand hygiene for all routine patient care needs.
89558998|NCT03078335|Active Comparator|Standard care|The control group will provide standard care, that is, hand hygiene before all patient, bed, and intravenous catheter contact.
89558999|NCT02345863|Experimental|Bendamustine + GA101 + Ibrutinib|"Bendamustine 70mg/m² i´v~GA101: 1000 mg iv~Ibrutinib: 420 mg po daily"
89559000|NCT03078257|Experimental|dual antiplatelet therapy|clopidogrel +aspirin
89559001|NCT03078257|Experimental|tirofiban in PV|clopidogrel +aspirin + tirofiban in PV
89559002|NCT03078257|Experimental|tirofiban in IC|clopidogrel +aspirin +tirofiban in IC
89559003|NCT03078257|Experimental|antiplatelet thrombolysin|clopidogrel +aspirin +antiplatelet thrombolysin
89559004|NCT03078257|Placebo Comparator|placebo|clopidogrel +aspirin +placebo
89559005|NCT02341573|Experimental|chinese medicine group|Children of chinese medicine group will be treated with experienced chinese herbal formula based on different stages and different symptoms.Patients at the acute stage of asthma will be given Shegan mixture ,at the remission stage, will be treated with Huangqi Bushen mixture-based formulation with modification according to their symptoms,10-30 mL , 2 times a day, for 3 months.
89559006|NCT02341573|Active Comparator|western medicine group|Children of western medicine group will be treated with leukotriene receptor antagonist and a bronchial relaxant.Children at the acute stage of asthma will be treated with etinoline,twice a day for 7 days.At the remission stage, they will be given leukotriene receptor antagonist Singulair, once daily for 3 months.
89559007|NCT02346019|Experimental|Surgical: Medial thighplasty|Perform a standard medial thighplasty with our without additional thigh liposuction on up to three obese transfemoral amputee subjects. The surgery will consist of medial excision of excess adipose and cutaneous tissue with circumferential liposuction.
89559008|NCT05005715|Active Comparator|Dexmedetomidine group|After the induction of anesthesia, the dexmedetomidine group received intravenous dexmedetomidine at a loading dose of 1µg/kg for 10 min, followed by a maintenance dose of 0.5µg/kg/h until the end of surgery.
89026445|NCT00474461|Experimental|Treatment group|Patients in this arm received intracoronary expanded autologous c-kit positive cardiac stem cells.
89559009|NCT05005715|Placebo Comparator|Control group|After the induction of anesthesia, the control group received intravenous normal saline at the same loading volume for 10 min, followed by the same volume until the end of surgery.
89559010|NCT02341651|Experimental|"Multicomponent combination"|Multicomponent intervention is a combination of the following 1) community health worker (CHW)- led blood pressure (BP) screening and referral to provider, plus 2) home health education (HHE) adapted to the local diet by trained CHW plus 3) trained primary health center mid-level providers (MLP) and physicians using evidence-based treatment algorithm of BP lowering in all and lipid lowering for high risk, plus 4) process-based incentives
89559011|NCT02341651|No Intervention|Usual Care|No active intervention
89559012|NCT03083795|Experimental|Social relationships intervention|"Participants randomized to the social interaction cohort will be split into two groups of 12. Each group of 12 will meet together once a month for a two-hour support group. Each participant will be allowed five minutes to check-in with the support group. During the 5 minute period the participant is encouraged to share their innermost thoughts and feelings in the knowledge that this information will not be shared outside the group.~Participants will additionally be paired with another study participant in the same cohort and will be asked to meet outside group sessions once a week for a minimum of 45 minutes. The pairing process will take place by study investigators and will be sensitive to gender, age, and neighbourhood of residence. Participants who find that their paired partner is not suitable may ask the facilitators to help find a more suitable match.~These participants will continue to receive BC Diabetes standard care."
89559013|NCT03083795|No Intervention|Control cohort|Patients in the control group will receive BC Diabetes standard care.
89559014|NCT02345707|Experimental|Part A|Subjects will receive reference cabotegravir 30 mg current formulation (Treatment A), Cabotegravir 30 mg micronized new formulation 500 M (Treatment B) and Cabotegravir 30 mg unmicronized new formulation 500 U (Treatment C) in one of six sequences ABC, ACB, BCA, BAC, CAB, CBA in three treatment periods under fasting condition
89559015|NCT02345707|Experimental|Part B|Subjects will receive reference Cabotegravir 30 mg current formulation (Treatment A), Cabotegravir 30 mg micronized new formulation 650 M (Treatment D) and Cabotegravir 30 mg unmicronized new formulation 650 U (Treatment E) in one of six sequences ADE, AED, DAE, DEA, EAD, EDA in three treatment periods under fasting condition
89559016|NCT02341339|Experimental|Fallopian Tube Co-culture|fallopian tube biopsy for co-culture of embryos
89559017|NCT02337049||Previously early onset preeclampsia|Women with a history of early onset preeclampsia 10 years ago
89559018|NCT02337049||Previously late onset preeclampsia|Women with a history of late onset preeclampsia 10 years ago
89559019|NCT02337049||Previously normotensive pregnancy|Women with a history of normotensive pregnancies 10 years ago
89559020|NCT02345473||Cystectomy patients|Arm of patients undergoing radical cystectomy for bladder cancer providing peripheral blood samples for detection of circulating cancer cells
89559021|NCT02345473||Healthy volunteers|Arm of healthy subjects not undergoing radical cystectomy providing peripheral blood samples for detection of circulating cancer cells
89559022|NCT05005637|Experimental|Anti Tuberculosis Therapy|"Dosage form: ATT fixed-dose combination (FDC). FDC intensive phase containing 150 mg rifampicin, 75 mg isoniazid, 400 mg pyrazinamide, and 275 mg ethambutol), while FDC continuation phase containing rifampicin-isoniazid.~Dosage: according to body weight, 30-37 kg: 2 tablets, 38-54 kg: 3 tablets, 55-70 kg: 4 tablets, more than 70 kg: 5 tablets.~Frequency: Intensive phase: once daily. Continuation phase: 3 times/week. Duration: 6 months (2 months of FDC intensive phase + 4 months of FDC continuation phase)"
89559023|NCT05005637|Active Comparator|Oral Steroid|Dosage form: Oral prednisone Dosage: 1 mg/kgBW/day (max 60 mg/day) Duration: until the uveitis is controlled or up to 4 weeks of administration, after that the dose will be tappered off gradually.
89559024|NCT03078179|Experimental|Commercial Cow Milk with Probiotic|"Probiotic enriched cow milk:~200 ml of commercial nutritive milk fortified with probiotic Lactobacillus rhamnosus and Bifidobacterium longum once a day."
89559025|NCT03078179|Placebo Comparator|Commercial Dairy Cow Milk|200 ml of commercial nutritive milk without probiotic, once a day,
89559026|NCT02341183|Active Comparator|A: Treatment order: tPAD treatment, then no treatment|Subjects will receive one overnight treatment with 7% hypertonic saline administered via the tPAD device. They will then have one overnight stay without treatment.
89559027|NCT02341183|Active Comparator|B: Treatment order: no treatment, then tPAD treatment|Subjects will have overnight stay w/o treatment, and one overnight treatment with 7% hypertonic saline administered via the tPAD device.
89559028|NCT05013515|Experimental|Salivary Gland Carcinomas|Patients with Salivary Gland Carcinomas were given Surufatinib .
89559029|NCT02345551|Experimental|Exercise|The behaviour change intervention to promote an increase in moderate-vigorous physical activity (to meet the cancer prevention guidelines of 150 min/week) will be guided by the Health Action Process Approach (HAPA) model. This model aims to promote behaviour change through increasing self-efficacy for intention, planning and maintenance of physical activity. As a compliment to the behavioural counseling sessions, participants will be asked to track their physical activity using the FitBit, a wrist-worn activity monitor (www.fitbit.com) which monitors step counts, distance covered, and active minutes and also tracks sleep. The FitBit synchronizes wirelessly to the participants' computer and/or smartphones, thus minimizing the need for daily data entry tracking by participants.
89559030|NCT05013671|Active Comparator|residents with BPPV|
89559031|NCT05013671|Other|residents without BPPV|
89559032|NCT02341261|Experimental|Standard Care Counseling|Participants randomized to the control group will receive diet and exercise counseling at baseline and 9 months. Participants will wear an ActivePAL for 7 days at baseline, 9 months, and 18 months without stimulation.
89026446|NCT00474461|No Intervention|Control group|Patients in this arm did not receive any intervention.
89026447|NCT00500526|Experimental|1 Singing Group|Patients who will receive singing classes
89026448|NCT00500526|Other|2 Control group|Patients who will attend hand craft classes
89026449|NCT03270488|Experimental|Laser Group|Laser application three times a week for 4 weeks.
89026450|NCT03270488|Placebo Comparator|Placebo group|The same equipment was used with a pen that emits a red guide light and a warning sound, but without the emission of a laser beam.
89026451|NCT00493350||1|Patients with newly diagnosed stage IV breast cancer scheduled to start systemic therapy.
88965593|NCT05638048|Active Comparator|The control group|Patients were routinely implanted with PICC and received routine health education. The content of health education included face-to-face language explanation of the whole process of catheter knowledge, issuing catheter maintenance manual, issuing ordinary grip ball and telling how to use it, and follow-up.
89559033|NCT02341261|Experimental|Supervised Exercise and Counseling|"Participants randomized to the intervention will perform supervised aerobic, resistance and balance training twice weekly for 12 weeks, and weekly thereafter. Actigraphy-based counseling to reduce sedentary behavior will follow a similar taper. Daily text messages, tweets, emails, and social media posts at random times during waking hours will be used to provide reminders and motivational messages. Participants will have 11 separate 7-day continuous ActivePAL training session incorporating vibrostimulatory feedback spread across the treatment period."
89559034|NCT02336893|No Intervention|Pre-intervention|Family members of patients admitted to the ICU from August to December 2013 that consented to participate in the satisfaction survey and had been in the ICU for 72 h.
89559035|NCT02336893|Experimental|Post-intervention|Family members of patients admitted to the ICU from March to August 2014 that consented to participate in the satisfaction survey and had been in the ICU for 72 h.
89559036|NCT05013203||Aseptic (uninfected) Revision Spine Surgery|Aseptic revision for indications including but not limited to hardware failure, adjacent segment pathology, radiculopathy, instability, cord compression.
89559037|NCT05013203||Spine Surgery for Degenerative Disease|Primary degenerative pathology surgery where a disc sample is extracted to enable spinal decompression or fusion. The potential primary surgeries include but are not limited to microdiscectomy, laminectomy, and lumbar and cervical fusion
89559038|NCT05013203||Septic (infected) Revision Spine Surgery|Spine surgery for known infection specifically: epidural abscess or septic revision. Epidural abscess must be managed surgically for inclusion. Septic revision cases include any surgery to address infected hardware from a previous spinal surgery.
89559039|NCT03082469|Active Comparator|CytoSorb|CytoSorb therapy for 48h
89559040|NCT03082469|No Intervention|Matched controls|60 matched controls with SAP and transpulmonary thermodilution monitoring
89559041|NCT02336659|Placebo Comparator|Saline|Mixed meal test and ad libitum meal test duing infusion of saline
89559042|NCT02336659|Experimental|Exendin 9-39|Mixed meal test and ad libitum meal test duing infusion of exendin 9-39, 900 pmol/kg/min
89559043|NCT02336659|Experimental|DPP-4 Inhibition|Mixed meal test and ad libitum meal test during intake of sitagliptin 100 mg * 2
89559044|NCT02336659|Experimental|Exendin 9-39 / DPP 4-Inhibition|Mixed meal test and ad libitum meal test duing infusion of exendin 9-39, 900 pmol/kg/min and intake of sitagliptin 100 mg * 2
89559045|NCT03082625|Experimental|Transdermal Magnesium|5 sprays each on the 2 most effected areas for muscle cramps twice a day
89559046|NCT03082625|Placebo Comparator|Placebo|5 sprays each on the 2 most effected areas for muscle cramps twice a day
89559047|NCT02336581|Experimental|Acceptance and Commitment Therapy (ACT)|ACT which includes individual and group sessions during hospitalization and follow-up phone contacts the first month following hospital discharge.
89559048|NCT02336581|Active Comparator|Enhanced Treatment as Usual (eTAU)|Enhanced treatment as usual (eTAU) which includes other individual and group sessions during hospitalization and follow-up phone contacts the first month following hospital discharge.
89559049|NCT03081923|Experimental|Durvalumab|Durvalumab, 1500 mg IV, q4 weeks, until disease progression or onset of unacceptable toxicity
89559050|NCT03081923|Experimental|Duralumab and Tremelimumab|Durvalumab, 1500 mg IV, on day 1 and q4 weeks, until disease progression or onset of unacceptable toxicity Tremelimumab, 75 mg IV, both on day 1 and q4 weeks, until disease progression or onset of unacceptable toxicity
89559051|NCT02345395|Experimental|Transpalpebral Approach|Aneurysm Clipping - Patients will be submitted to a Transpalpebral Approach to Unruptured Anterior Circulation Aneurysm and they will be discharged from the hospital on the next day.
89559052|NCT02345395|Experimental|NanoPterional Approach|Aneurysm Clipping - Patients will be submitted to a Modified MiniPterional Approach (Nanopterional) to Unruptured Anterior Circulation Aneurysm and they will be discharged from the hospital on the next day.
89559053|NCT02345395|Sham Comparator|Classical Pterional Craniotomy|Aneurysm Clipping - Patients will be submitted to a Classical Pterional Approach to Unruptured Anterior Circulation Aneurysm and they will be discharged from the hospital 4-5 days after the procedure.
89559054|NCT03081845|Experimental|Sequence A1-A2|Oral consumption of milk A1 in study phase 1. Oral consumption of milk A2 in study phase 2.
89559055|NCT03081845|Experimental|Sequence A2-A1|Oral consumption of milk A2 in study phase 1. Oral consumption of milk A1 in study phase 2.
88965594|NCT05638048|Experimental|Experiment 1 set|Patients were routinely implanted with PICC, and the optimal duration-relaxation time of grip strength training was adopted on the basis of health education in the control group.
88965595|NCT05638048|Experimental|Experiment 2 set|"On the basis of control group~Determine the best grip strength On the basis of the control group, color Doppler ultrasound and electronic grip force were used to record the optimal grip strength of patients to achieve effective blood flow velocity before and 24 hours after PICC insertion.~Design precise grip strength training guidance program On the basis of the control group, the patients were instructed to perform grip strength training according to the determined best grip strength and the best duration of clenching and relaxation time."
88965596|NCT05638243||High-risk residents|
88965597|NCT05637372||Study group|Patients without any disorders and diseases in age range ensuring full temporomandibular joint development.
88965598|NCT05638477|Experimental|Parkinson's disease|Eye tracking using Eyelink 1000 during free-viewing of videos
88965599|NCT05638477|Experimental|Progressive Supranuclear Palsy|Eye tracking using Eyelink 1000 during free-viewing of videos
88965600|NCT05638477|Experimental|Multiple System Atrophy|Eye tracking using Eyelink 1000 during free-viewing of videos
88965601|NCT05638477|Experimental|Corticobasal Syndrome|Eye tracking using Eyelink 1000 during free-viewing of videos
89026452|NCT00500565|Experimental|On-Q pump with Saline|On-Q Pump with Saline
89559056|NCT02341105|Active Comparator|Medical therapy|Amiodarone treatment. Amiodarone will be given at a loading dose of 400 mg per day for two week and then lowered to 200 mg daily for 6 months at which point the dose will be lowered to 1000 mg per week. The dose of amiodarone will then be lowered every six, as long as the patient has a satisfactory response. The minimum dose will be 700 mg per week.
88965602|NCT05637411||Retrospective cohort|The clinical data, socioeconomical data and environmental exposure data from 800.000 asthmatic patients attended in our region from 2007 to 2021 will be analysed to train and validate a risk predictive model for exacerbation (defined as emergency visits)
88965603|NCT05637411||Prospective cohort|The same inclusion/exclusion criteria were applied prospectively. This is an external validation cohort.
89559057|NCT02341105|Active Comparator|Catheter ablation|A standard pulmonary vein isolation procedure will be done. Additional ablation will be permitted (roof and mitral lines/ CFAE )
89559058|NCT03078101|Experimental|Group A|Diabetic CKD patients receiving Empagliflozin 10 MG [Jardiance]
89559059|NCT03078101|Placebo Comparator|Group B|Diabetic CKD patients receiving Placebo Oral Tablet
89559060|NCT03078101|Experimental|Group C|Non-diabetic CKD patients receiving Empagliflozin 10 MG [Jardiance]
89559061|NCT03078101|Placebo Comparator|Group D|Non-diabetic CKD patients receiving 'Placebo Oral Tablet
89559062|NCT03082079|Experimental|ESD group|Patient in this group undergo ESD for GIST, and regular follow-up are carried out for these patients on 72 ±3h,7±2d,14±2d,3 month,6 month,1 year,2 year,3 year,4 year,5 year after the treatment. The investigators record the success rate of operation,en bloc resection,operation time,complication rate,hospitalization days,hospitalization expenses,pathology results and tumor recurrence rate.
89559063|NCT03082079|No Intervention|Follow-up group|Patient in this group are given no intervention,the investigators record the tumor size and EUS features of the first endoscopic examination.Regular follow-up are carried out for these patients on 3 month,6 month,1 year,2 year,3 year,4 year,5 year after this check.Then,tumor size and EUS features of each time are collected accurately.
89559064|NCT02345239|Experimental|Pantoprazole|Pantoprazole
88965604|NCT05637450|Experimental|Fish protein supplement|Blue Whiting Protein Hydrolysate
88965605|NCT05637450|Placebo Comparator|Placebo|Isocalorific Maltodextrin Citrus Flavoured Powder
88965606|NCT05638711||Before group|"Patient: ICU patients received CVVH between 2019/01/01 - 2020/10/01 (before utilization of built-in calculator)~received regular protocol of ICU patient care (same in two groups)"
88965607|NCT05638711||After group|"Patient: ICU patients received CVVH between 2020/10/01 - 2021/12/31 (after utilization of built-in calculator)~received regular protocol of ICU patient care (same in two groups)"
88965608|NCT05638789|Active Comparator|EST alone|
88965609|NCT05638789|Active Comparator|EST + EPLBD|
88965610|NCT05638828|Experimental|Cell injection|
88965611|NCT05638984|Experimental|low-dose decitabine combined with tirelizumab|Injection site citabine, 10 mg/ bottle, 10 mg/d, Q3W, D1-D5 intravenous infusion; Tirelizumab injection 200mg D5 intravenous infusion.
88965612|NCT05638984|Active Comparator|tirelizumab|Tirelizumab injection, 10ml: 100mg/1 bottle, 200mg, Q3W, D1 IV infusion.
88965613|NCT05637528||MagTrace patients|Patients who underwent sentinel lymph node biopsy with MagTrace one year ago.
88965614|NCT05639023|Experimental|Manipulation Techniques Group|Subjects will be received orthopedic manipulation and Physiotherapy Scoliosis-Specific Exercise(PSSE). For orthopedic manipulation, Subjects will received 12 times orthopedic manipulation. Three times of treatment per months, and less than twice a week. For PSSE, subjects will receive 14 supervise training, 5 times of intensive supervise training for first two weeks and then 1-2 trainings per month for the rest. Subjects are encouraged to perform home exercise everyday on their own throughout the study.
88965615|NCT05639023|Experimental|Control Group|Subjects will be received sham orthopedic manipulation and Physiotherapy Scoliosis-Specific Exercise(PSSE). For orthopedic manipulation, Subjects will received 12 times orthopedic manipulation. Three times of treatment per months, and less than twice a week. For PSSE, subjects will receive 14 supervise training, 5 times of intensive supervise training for first two weeks and then 1-2 trainings per month for the rest. Subjects are encouraged to perform home exercise everyday on their own throughout the study.
89026453|NCT00500565|Experimental|On-Q Pump with Bupivicaine|On-Q Pump with bupivicaine
89026454|NCT03270293|Experimental|Profhilo|"The intradermal procedure was performed bilaterally on the face, at level of the following five points:~zygomatic protuberance~nostril's angle~inferior margin of tragus~lip marionette lines~mandibular angle. The amount of product injected, was 0.2 ml for each injection-point."
89026455|NCT01243983|Experimental|LX211|
89026456|NCT01243983|Placebo Comparator|Placebo|
89559065|NCT02340871||Genetic Neurological Diseases|The group consists of patients with a neurological disease that are tested for finding the genetic basis of their disease.The neurological signs and symptoms include ataxia, intellectual disability, seizures, movement disorders, migrational disorders, macrocephaly, microcephaly and various other signs and symptoms. The group consists of patients from 1-year-old until 90 years who are having a neurological disease as stated above or who are the parents or siblings of the affected patients. Blood specimens will be taken from them and DNA will be extracted for next generation studies like whole exome sequence or whole genome sequence. This process is called genetic testing. The current proposal will assist in diagnosing children and families with a neurological disease for genetic counseling.
89026457|NCT00469547|Experimental|1|62% ethanol in emollient gel
89559066|NCT03081767|Other|Patients undergoing digital PET/CT|Single arm prospective study of paired imaging studies. Patients who are referred to Nuclear Medicine and are scheduled to undergo imaging on the standard PET/CT will also have imaging performed on the digital PET/CT.
89559067|NCT02340793|Experimental|Counterweight Plus Dietary Intervention|Weight management programme including total diet replacement with soups and shakes; approximately 800 calories/day
89559068|NCT03081065|Experimental|Mediterranean Diet+ extra virgin olive oil|Free supply with extra virgin olive oil and nuts plus educational advice
89559069|NCT03081065|Experimental|Mediterranean Diet+ tree nuts|Free supply with tree nuts plus educational advice
89026458|NCT00469547|Placebo Comparator|2|15% ethanol in emollient gel
89559070|NCT03081065|No Intervention|Control|Usual care
89559071|NCT04688203|Active Comparator|Magnesium sulfate infudsion|patients will receive IV bolus dose of 40mg/kg magnesium sulfate in 100 ml saline solution over ten minutes then continuous infusion of 10-15mg/kg/h will be titrated till achieve target mean arterial blood pressure (55-65 mmHg) and will be terminated by the end of surgery.
89559072|NCT04688203|Active Comparator|Labetalol infusion|will receive IV bolus does of labetalol 0.25 mg/kg over ten minutes then continuous infusion of 0.5-1mg/kg/h will be titrated till achieve target mean arterial blood pressure (55-65 mmHg) and will be terminated by the end of surgery.
89559073|NCT03145753|Experimental|HIV/HCV Education plus Testing|In this arm education should be provided and also resources for testing, HIV/HCV rapid tests and Testing staff different from clinical practice resources
89026459|NCT00500604|Experimental|A|"period 1: Hydrochlorothiazide 12.5 mg for 3-5 weeks~period 2: One 150/12.5mg tablet every morning for 8 weeks.~period 3: One 300/12.5mg tablet every morning for 8 weeks.~period 4: Two 150/12.5mg tablets every morning for 8 weeks."
89026460|NCT00500604|Active Comparator|B|"period 1: Hydrochlorothiazide 12.5 mg for 3-5 weeks~period 2: One 80/12.5mg tablet every morning for 8 weeks.~period 3: One 160/12.5mg tablet every morning for 8 weeks.~period 4: Two 80/12.5mg tablets every morning for 8 weeks."
89559074|NCT03145753|Active Comparator|HIV/HCV Education|In this arm only education should be provided
89559075|NCT04679233|Experimental|Arm 1: Intervention Arm|Arm 1 will receive the aerobic prescription exercise intervention. As this is a feasibility and safety study, there will not be a second arm.
89559076|NCT03145597|Experimental|Laminate veneer of composite|Laminate veneer of composite (Estenia, Kuraray Dental), composite laminate veneer, 2-4-6 veneers per patient will be made.
89559077|NCT03145597|Experimental|Laminate veneer of ceramic|laminate of ceramic (Empress Esthetic, Ivoclar Vivadent), ceramic laminate veneer, 2-4-6 veneers per patient will be made.
89559078|NCT02336035|No Intervention|Cast immobilization|"Cast immobilization for 5 weeks from primary injury/reduction. Thereafter active exercise within the range of pain.~Both groups will be followed after 3, 6 and 12 months, and after 2 and 5 years."
89559079|NCT02336035|Experimental|Operation|"Operation with a volar plate. Cast immobilization for 2 weeks after operation, thereafter active motion without weight for 4 weeks. 6 weeks after operation the patients are allowed active exercise within the range of pain.~Both groups will be followed after 3, 6 and 12 months, and after 2 and 5 years."
89559080|NCT05254561|Active Comparator|purified protein derivative (PPD)|Group A
89559081|NCT05254561|Active Comparator|Candida antigen.|Group B
89559082|NCT05254561|Active Comparator|Measles, Mumps and Rubella vaccine (MMR).|Group C
89026461|NCT01348828|Other|Single Arm|All patients meet study criteria receives a single use Ventana Fenestrated System, which requires administration of intravascular contrast. Catheter advancement is performed under fluoroscopic guidance and Ventana Fenestrated System is placed.
89026462|NCT03270254|No Intervention|root surface debridement (RSD)|Standard care - root surface debridement (RSD)
89559083|NCT05254561|Active Comparator|Triple combination of PPD, Candida antigen and MMR|Group D
89559084|NCT04536025||Prosthetists|Up to 24 prosthetists who are actively providing prosthetic care to people with lower limb amputation will be recruited for participating in focus groups to describe their decisional needs for providing prostheses to people with lower limb amputation.
89559085|NCT04536025||People with lower limb amputation|An estimated 14 people within 1 year from lower limb amputation, receiving their first prosthesis will be recruited for individual semi-structured interviews to describe their decisional needs for provision of a prosthesis.
89559086|NCT04536025||Expert working group|The expert working group will consist of at least 5 and up to 12 people with LLA actively receiving prosthetic care, and at least 5 and up to 12 prosthetic care providers with greater than 5 years of experience. Individuals will be invited to join the expert working group based on expertise, and representation of key stakeholders relevant to the prosthetic design process.
89559087|NCT04509973|Experimental|Dexamethasone 12 mg|Intravenous bolus injection of dexamethasone 12 mg once daily in addition to standard care for up to 10 days. We will allow the use of betamethasone 12 mg at sites, where dexamethasone is not available.
89026463|NCT03270254|Active Comparator|light activated dye (PDT)|light activated dye photodynamic therapy (PDT)
89026464|NCT01348789|Experimental|Hair2Go (Mē)|Treatment with Hair2Go (Mē)device
89026465|NCT01605994|Experimental|Panel 1:BMS-933043(2mg)/Placebo+Antacid Buffer Solution|"BMS-933043 2 mg solution by mouth twice daily for 10 days~OR~Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days~Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days"
89559088|NCT04509973|Active Comparator|Dexamethasone 6 mg|Intravenous bolus injection of dexamethasone 6 mg once daily in addition to standard care for up to 10 days. We will allow the use of betamethasone 6 mg at sites, where dexamethasone is not available.
89559089|NCT02637557|Placebo Comparator|Control|Matching placebo twice daily
89559090|NCT02637557|Experimental|500 mg IW-3718|500 mg IW-3718 twice daily
89559091|NCT02637557|Experimental|1000 mg IW-3718|1000 mg IW-3718 twice daily
89559092|NCT02637557|Experimental|1500 mg IW-3718|1500 mg IW-3718 twice daily
89559093|NCT04491253|Experimental|Intervention|The intervention is defined as informational support (transmission of information for health care, knowledge of DM2, nutrition, physical activity), instrumental (physical care) and emotional (management of anxiety, empowerment and decision-making).
89559094|NCT04491253|No Intervention|Control|Control group will receive usual care treatment at the diabetes mellitus nursing consultation in primary care.
89559095|NCT04480645|Experimental|Treatment|Radioactive bandage applied to surface of the body worn for approximately one week.
89559096|NCT05254249|Active Comparator|Treatment Group|In the treatment group, intervention was given in the form of standard therapy and probiotic Lactobacillus plantarum IS 10605 in the amount of 2x1010 CFU for 12 weeks.
89559097|NCT05254249|Placebo Comparator|Placebo Group|In the placebo group, intervention was given in the form of standard therapy and placebo 2x1 sachets for 12 weeks.
89559098|NCT05254249|No Intervention|Healty Control Group|Healthy control group was not given any treatment. Stool samples were taken to examine the gut microbiota profile.
89559099|NCT03145909|Experimental|Dose Escalation Cohort|ABBV-176 will be administered via intravenous infusion at escalating dose levels until the maximum tolerated dose is reached.
89559100|NCT03145909|Experimental|Expanded RPTD Cohort|ABBV-176 via intravenous administration in participants with breast cancer at the Recommended Phase Two Dose (RPTD) determined during the Dose Escalation Cohort
89559101|NCT02344927|Active Comparator|Non-Clinically Assisted Hydration arm|"The interventions utilised within this trial are representative of standard clinical practice~Continuance of oral intake (if appropriate)~Regular (4 hourly) mouth care~Standard management of pain and other symptoms in the terminal phase."
89559102|NCT02344927|Active Comparator|Clinically Assisted Hydration arm|"The interventions utilised within this trial are representative of standard clinical practice~Continuance of oral intake (if appropriate)~Regular (4 hourly) mouth care~Clinically-assisted hydration~Standard management of pain and other symptoms in the terminal phase"
89559103|NCT02344849|Experimental|Mesenchymal stem cell|Patients will receive single intracavernous injection of Mesenchymal stem cell. Oral PDE5-inhibitor can take on demand.
89559104|NCT02336113|No Intervention|Control group|Standard care during hospital stay, without pharmacist involved
89559105|NCT02336113|Experimental|Pharmacist intervention|A pharmacist is included in the multidisciplinary treatment team during the hospital stay
89559106|NCT03145363|Experimental|Intervention|receive interactive text messages
89559107|NCT03145363|Active Comparator|Control|Receive informational text messages
89559108|NCT02336191||LDLT Recipients|Patients subjected to living donor liver transplantation
89559109|NCT02336347|Experimental|Group 1 - Period 1|Twice daily dosing of AVP-786 orally for 8 days
89559110|NCT02336347|Active Comparator|Group 1 - Period 2|Twice daily dosing of AVP-923 orally for 8 days
89559111|NCT02336347|Active Comparator|Group 2 - Period 1|Twice daily dosing of AVP-923 orally for 8 days
89559112|NCT02336347|Experimental|Group 2 - Period 2|Twice daily dosing of AVP-786 orally for 8 days
89559113|NCT02341027|Active Comparator|Levonorgestrel (LNG) implants immediately postpartum|LNG contraceptive implants provided within 5 days of delivery
89559114|NCT02341027|Active Comparator|Levonorgestrel (LNG) implants 6 weeks postpartum|LNG contraceptive implants provided 6-8 weeks postpartum
89559115|NCT03112291|Experimental|permanent teeth apexification|They should have one permanent tooth with traumatic necrosis, which in turns should show color alteration, fistulae, periapical lesion, and/or internal or external root resorption, pain, or absence of pulp response to sensitivity tests at a clinical examination to be considered necrotic. Male and female patients who had not undergone antibiotic therapy 3 months before the treatment were included and clinical and radiographic examinations confirmed pulp necrosis. This study analyzed the clinical and microbiological results of the endodontic treatment performed on permanent teeth with necrosis caused by traumatic injury and treated using revascularization technique, double antibiotic paste, intra-canal medication, and an MTA cervical plug.
89559116|NCT02340637|Experimental|Coping Kids|"A Program for Managing Anxiety and Depression (P.C Kendall et al., 2013) is a newly developed group intervention targeting children aged 8 to 13 years who experience difficulty with symptoms of anxiety, depression, or both. The program is designed as an indicated prevention intervention to reduce the symptom levels and reduce the likelihood of the development of an anxiety disorder and/or depression.~The youth-focused sessions are designed for implementation in school settings, and the program includes parent group meetings.~All groupleaders participate in a three days training, followed by supervision. Manuals and workbooks are provided by the project. In addition is the same presentation as in TAU offered to the schools."
89559117|NCT02340637|Active Comparator|TAU|The teachers and school-nurses in the control schools will conduct treatment as usual (TAU).The project offers a 2,5 hours presentation to the schools, providing general information about the research study, the prevalence of emotional disorders and how to handle emotional disorders in treatment as usual. No materials are provided by the project.
89559118|NCT02335879|Experimental|Recombinant Human Follitropin|
89559119|NCT05005325|Active Comparator|Experimental group(Male)|Participants will be included in the study after screening from inclusion criteria. Each participant will perform FMS during a single session before competition as pre testing. It consists of 7 movement tasks and 3 clearance screens. Movement task will include deep squat, hurdle step, inline lunge, shoulder mobility, active straight-leg raise, trunk stability push-up and rotary stability. Five of the 7 tasks (hurdle step, inline lunge, shoulder mobility, active straight-leg raise and rotary stability) will be performed on both right and left sides. In addition to these, 3 clearance screen will assess the presence of pain with shoulder internal rotation/flexion, end range spinal flexion and end range spinal extension. Participants will be instructed for each task performance and will perform 3 attempts for each task.
89026466|NCT01605994|Experimental|Panel 2:BMS-933043(5mg)/Placebo+Antacid Buffer Solution|"BMS-933043 5 mg solution by mouth twice daily for 10 days~OR~Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days~Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days"
89559120|NCT05005325|Experimental|Experimental group(Female)|Participants will be included in the study after screening from inclusion criteria. Each participant will perform FMS during a single session before competition as pre testing. It consists of 7 movement tasks and 3 clearance screens. Movement task will include deep squat, hurdle step, inline lunge, shoulder mobility, active straight-leg raise, trunk stability push-up and rotary stability. Five of the 7 tasks (hurdle step, inline lunge, shoulder mobility, active straight-leg raise and rotary stability) will be performed on both right and left sides. In addition to these, 3 clearance screen will assess the presence of pain with shoulder internal rotation/flexion, end range spinal flexion and end range spinal extension. Participants will be instructed for each task performance and will perform 3 attempts for each task.
89559121|NCT03077945|Experimental|Intervention Condition|This group will receive the heart rate variability biofeedback intervention in addition to the cognitive reappraisal of stress intervention
88965616|NCT05637346|Experimental|Patients scheduled for laparotomy|This is a single-center observational feasibility study to develop an automatic segmentation and registration algorithm based on ultrasound imaging of the pelvic arteries. The duration of this study will be approximately 1 year. Patients scheduled for a laparotomy at the NKI are eligible for inclusion. Patients are informed about the study before the planned surgery and, after being provided with the necessary information regarding participation in the study, will be asked for informed consent. The ultrasound acquisitions for this study will be performed intra-operatively with CE marked equipment for intra-operative ultrasound. There is no impact on the standard surgical procedure or decision making of the surgery. After surgery, no further participation or cooperation of the patient is required.
88965617|NCT05639062|Active Comparator|Narrative-based card game|
88965618|NCT05639062|No Intervention|PUKE card game|
89559122|NCT03077945|Placebo Comparator|Control Condition|This group will complete control tasks, including viewing neutral videos.
89559123|NCT02039479|Placebo Comparator|TAU + Placebo|Treatment as Usual + Placebo
89559124|NCT02039479|Active Comparator|TAU + Lithium|Treatment as Usual + Lithium
89559125|NCT05013125|No Intervention|Conventional Colonoscopy - ENDO-AID assisted Colonoscopy|Patients will undergo usual colonoscopy as per usual practice, followed back to back by ENDO-AID assisted colonoscopy
89559126|NCT05013125|Active Comparator|ENDO-AID assisted Colonoscopy - ENDO-AID assisted Colonoscopy|Patients will undergo ENDO-AID assisted colonoscopy with all polyps treated as per usual practice, followed back to back by ENDO-AID assisted colonoscopy
89559127|NCT02340481|Experimental|Loperamide Hydrochloride + Simethicone|Participant will take 2 loperamide hydrochloride and simethicone chewable tablets + 2 loperamide hydrochloride placebo capsules orally, as their first dose, and subsequently 1 loperamide hydrochloride and simethicone chewable tablet + 1 loperamide hydrochloride placebo capsule orally, in the event of unformed stool (provided that no more than 4 tablets/capsules are taken within a 24-hour period) up to 48 hours.
89559128|NCT02340481|Active Comparator|Loperamide Hydrochloride|Participant will take 2 loperamide hydrochloride capsules + 2 loperamide hydrochloride and simethicone chewable placebo tablets orally, as their first dose, and subsequently 1 loperamide hydrochloride capsule + 1 loperamide hydrochloride and simethicone chewable placebo tablet orally, in the event of unformed stool (provided that no more than 4 capsules/tablets are taken within a 24-hour period) up to 48 hours.
89559129|NCT03077867|Experimental|test HA|synthetic hydroxyapatite alone sinus floor augmentation with bone graft
89559130|NCT03077867|Experimental|test HA vicryl|synthetic hydroxyapatite mixed with polylactic-polyglycolic acid sinus floor augmentation with bone graft
89559131|NCT03077867|Experimental|test HA-PRF|synthetic hydroxyapatite mixed with i-PRF sinus floor augmentation with bone graft
89559132|NCT03077867|Active Comparator|control|anorganic bovine bone sinus floor augmentation with bone graft
89559133|NCT04426279||patient with chronic inflammatory rheumatism|
89559134|NCT05012501||PVT group|（1) Patients with cirrhosis diagnosed in accordance with the 2019 Guidelines for the Diagnosis and Treatment of Cirrhosis;(2) In accordance with the diagnostic criteria of portal vein thrombosis in the 2015 European Society of Hepatology Clinical Practice Guidelines: Hepatic Vascular Diseases. Color ultrasound, CT, MRI, and other imaging studies confirmed the presence of portal vein thrombosis and the specific location of the thrombosis.
89559135|NCT05012501||without PVT group|(1) Patients with cirrhosis diagnosed in accordance with the 2019 Guidelines for the Diagnosis and Treatment of Cirrhosis;(2)Color ultrasound, CT, MRI, and other imaging studies confirmed the absence of portal vein thrombosis and the specific location of the thrombosis.
88965619|NCT05639101|Other|Intervention group|Clinicians will use a Clinical decision support system to better manage their patients. Asthmatic patients will use a smartphone app for their self management.
88965620|NCT05639101|No Intervention|Control|Asthmatic patients that will not be subject to any intervention
88965621|NCT05639140||Color discrimination deficit|
88965622|NCT05639140||Without Color discrimination deficit|
88965623|NCT05637684|Experimental|low intensity pulsed ultrasound group|low intensity pulsed ultrasound application The following parameters will be used: intensity of 0.3 W/cm2 at a 1megahertz frequency for 20 minutes and pulsed (20%) ultrasound waves and conventional physical therapy program will be used for this group in a form of wrist hand Splint ,Medical Massage (effleurage),Passive stretching for wrist flexor, Carpal mobilization and Strengthening exercise
88965624|NCT05637684|Sham Comparator|control group|conventional physical therapy program will be used for this group in a form of wrist hand Splint ,Medical Massage (effleurage),Passive stretching for wrist flexor, Carpal mobilization and Strengthening exercise
88965625|NCT05639257|Active Comparator|Lamotrigine|"An escalation phase of 28 days:~- tablet Lamotrigine 25 mg once daily in 14 days followed by 50 mg once daily in 14 days.~A treatment phase of 30 days:~- tablet Lamotrigine 100 mg, once daily in 10 days, twice daily in 10 days, followed by third daily in 10 days."
88965626|NCT05639257|Active Comparator|Namuscla|"A placebo phase of 28 days:~- tablet placebo 25 mg once daily in 14 days followed by 50 mg once daily in 14 days.~A treatment phase of 30 days:~- tablet Namuscla 167 mg, once daily in 10 days, twice daily in 10 days, followed by third daily in 10 days."
89559136|NCT03077633|Active Comparator|Cervical Cerclage + Progesterone|Placement of a Cervical Cerclage plus the daily administration of vaginal progesterone (200mg tab)
89559137|NCT03077633|Placebo Comparator|Progesterone|Daily administration of vaginal progesterone (200mg tab)
89559138|NCT05005169|Experimental|intrapartum streptococcal B detection by PCR|The automatons will be installed by the laboratory in the delivery rooms and used delocalized by the obstetrical teams. Verification and validation of results will be ensured by the microbiology laboratory team, according to the recommendations and procedures already in use for off-site biology.
89559139|NCT05005169|Active Comparator|"intrapartum streptococcal B detection by SGB culture strategy"|
89559140|NCT05253781|Experimental|Intervention|Low dose aspirin (LDA) group will receive 100mg aspirin daily taken at once just before bedtime from 12 weeks gestational age or enrollment till 36 weeks gestational age.
89559141|NCT05253781|Placebo Comparator|Control|Placebo group will receive one tablet of the placebo which has same shape, size, thickness and colour as the LDA daily taken at once just before bedtime from 12 weeks gestational age or enrollment till 36 weeks gestational age.
89559142|NCT05012423|Placebo Comparator|SAD Cohorts 1 to 7: Participants Receiving Placebo|Participants in each SAD cohort will be randomized to receive placebo.
89559143|NCT05012423|Experimental|SAD Cohorts 1 to 7: Participants receiving ECC0509|Participants in each SAD cohort will be randomized to receive 1 of 7 escalating doses (1 mg, 4 mg, 10 mg, 20 mg, 40 mg, 60 mg, or 80 mg).
89559144|NCT05012423|Placebo Comparator|MAD Cohorts 1 to 3: Participants receiving Placebo|Participants will be randomized to receive a once-daily dose of placebo for 14 days.
89559145|NCT05012423|Experimental|MAD Cohorts 1 to 3: Participants receiving ECC0509|Participants will be randomized to receive a once-daily dose of 1 of 3 escalating doses (8 mg, 20 mg, or 40 mg) for 14 days.
89559146|NCT03077477|Placebo Comparator|SAD|"Cohort will have a total 6 subjects: SAD (2 subjects receiving placebo and 4 subjects receiving active AMXT 1501 dicaprate);~SAD cohorts are defined as follows:~Cohort 1: One placebo and one AMXT 1501 dicaprate subject will be treated as sentinel subjects receiving one tablet each of their assigned treatment. Assuming no intolerance is noted after at least 3 days, the remaining cohort subjects (placebo, 1 subject and AMXT 1501 dicaprate, 3 subjects) will be treated.~Cohort 2: 2 subjects 2 placebo each and 4 subjects 2 AMXT 1501 dicaprate tablets each~Cohort 3: 2 subjects 4 placebos each and 4 subjects 4 AMXT 1501 dicaprate tablets each~Cohort 4: 2 subjects 8 placebos each and 4 subjects 8 AMXT 1501 dicaprate tablets each"
89559147|NCT03077477|Placebo Comparator|MAD|"Each cohort will have a total 6 subjects: MAD (2 subjects receiving placebo and 4 subjects receiving active AMXT 1501 dicaprate); MAD cohorts will receive dosing once daily for 14 consecutive days. Dosing will be contingent on adequate tolerance in Cohorts 1-5.~Cohort 6: 2 subjects 2 placebos each; 4 subjects 2 AMXT 1501 dicaprate tablets each~Cohort 7: 2 subjects 4 placebos each; 4 subjects 4 AMXT 1501 dicaprate tablets each~Cohort 8: 2 subjects 8 placebos each; 4 subjects 8 AMXT 1501 dicaprate tablets each"
89559148|NCT03077477|Active Comparator|FE|"Each cohort will have a total 6 subjects: FE crossover (6 subjects receiving active AMXT 1501 dicaprate).~FE Crossover:~• Cohort 5: 6 new subjects will be randomized to a fed (n=3 standard meal) or fasted (n=3) group and administered the highest dose of AMXT 1501 dicaprate tolerated by previous cohorts. First dose and accompanying assessments will be referred to as Period 1. Subjects will then crossover to the opposite diet plan (fed or fasted) and receive a second administration of study treatment at the same dose level. The second dose and assessments are referred to as Period 2. There will be a 7-day washout between doses administered in Periods 1 and 2."
89559149|NCT02344615|Active Comparator|NS-guided infraclavicular block|NS-guided infraclavicular block is performed using 35 ml of 0.5% ropivacaine.
89559150|NCT02344615|Experimental|US-guided infraclavicular block|US-guided infraclavicular block is performed using 35 ml of 0.5% ropivacaine.
89559151|NCT03145519|Experimental|OptiVein|Placement of IV-catheter and administration of treatment using OptiVein catheter.
89559152|NCT03145519|Active Comparator|Vasofix Certo|Placement of IV-catheter and administration of treatment using Vasofix Certo catheter.
89559153|NCT02638493||HIV positive TDF/FTC|8 HIV positive men taking TDF/FTC as treatment
89559154|NCT02638493||HIV negative|8 HIV negative men taking TDF/FTC as pre-exposure prophylaxis
89559155|NCT02638493||HIV Positive TAF|8 HIV positive men taking TAF as treatment
89559156|NCT02340559|Experimental|Meta-cognitive Training|"The metacognitive training program is comprised of eight modules targeting common cognitive errors in schizophrenia. The modules are : attributional distortions (module 1), a jumping to conclusions bias (module 2 and 7), a bias against disconfirmatory evidence (module 3), deficits in theory of mind (module 4 and 6), over-confidence in memory errors (module 5) and depressive cognitive patterns (module 8).~The treatment group consist of 8 weekly sessions of 45-60 minutes with a total of 4 to 8 patients per group."
89559157|NCT02340559|Active Comparator|Psychoeducational group|In the control group the modules worked were: 1. Healthy Habits, 2. Risk Behaviors, 3. Prevention of relapse, 4 and 5.Videoforum, 6. Resources of work and development of curriculum vitae 7. Leisure activities, and 8. Resources of the community. The psychoeducational group consist of 8 weekly sessions of 45-60 minutes with a total of 4 to 8 patients per group.
88965627|NCT05639608|Experimental|systemically healthy females with gingivitis|scaling will be done at baseline
88965628|NCT05639608|No Intervention|systemically and periodontally healthy females|data will be recorded at baseline and no intervention will be done
88965629|NCT05639725|Experimental|EXTRACTION OF MAXILLARY IST PREMOLARS|Experimental: EXTRACTION treatment of class II div 1 malocclusion with bilateral maxillary premolar extraction
88965630|NCT05639725|Experimental|DISTALIZATION|Experimental: DISTALIZATION treatment of class II div 1 malocclusion with distalization using zygomatic miniplates
89026467|NCT01605994|Experimental|Panel 3:BMS-933043(10mg)/Placebo+Antacid Buffer Solution|"BMS-933043 10 mg solution by mouth twice daily for 10 days~OR~Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days~Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days"
89026468|NCT01605994|Experimental|Panel 4:BMS-933043(25mg)/Placebo+Antacid Buffer Solution|"BMS-933043 25 mg solution by mouth twice daily for 10 days~OR~Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days~Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days"
89559158|NCT02340325|Other|Acute Sensitivity Test to FS2 cream|Twenty (20) healthy volunteers will be assigned volunteer numbers and will have a testing areas identified by permanent marker on their backs. Pouches containing 0.00% (placebo), 0.15%, 0.25%, 0.4% and 0.5% of FS2 will be randomly applied to an occlusive, transparent dressing (Tegaderm) and applied to each test area once for 24 hours. The pouch order will be random, generated by the www.random.org list generator each application. Patients will be evaluated at 24 hours post application for skin reactions and adverse reactions by a blinded observer recorded. Before and after photographs will be taken.
89559159|NCT02340325|Other|Chronic Sensitivity Test to FS2 cream|Twenty (20) randomized healthy volunteers will be assigned numbers and will have a single testing area identified by permanent marker on either shoulder or upper back. Volunteers will be educated how to apply a pouch of cream to an occlusive, transparent dressing (Tegaderm) and place it on the test site every 24 hours for 30 days. The date and time of first application will be recorded. Baseline urine and serum measurements of drug concentration (presumed absent), as well as complete blood count, liver enzymes, blood urea nitrogen, and creatinine will be taken on Day 0 (the initial enrollment of each part). The volunteers will be seen in follow-up at day 1, day 5, day 15, and day 30.
89559160|NCT05229367|Experimental|Eccentric isokinetic group|In this group, eccentric isokinetic training of hamstring muscle was performed.
89559161|NCT05229367|Active Comparator|Concentric isokinetic group|In this group, concentric isokinetic training of hamstring muscle was performed.
89559162|NCT02340247|Experimental|Placebo|150mL water
89559163|NCT02340247|Experimental|Ursodeoxycholic acid|Ursodeoxycholic acid (750mg) dissolved in 150mL water
89559164|NCT02340247|Experimental|Chenodeoxycholic acid|Chenodeoxycholic acid (1250mg) dissolved in 150mL water
89559165|NCT02340013|Active Comparator|Medroxyprogesterone acetate|Medroxyprogesterone acetate 10mg per os x 10 days prior to starting clomiphene citrate 50mg once daily days 3 - 7 of bleeding after stopping medroxyprogesterone acetate
89559166|NCT02340013|No Intervention|Control|Women are assigned to start clomiphene citrate 50mg tabs x 5 days on an assigned day, without any vaginal bleeding
89559167|NCT02339857||No-touch vein grafts to LAD|
89559168|NCT02638337|Experimental|Ospemifene|Participants will take one tablet of ospemifene 60 mg orally, once a day for 12 weeks.
89559169|NCT02638337|Placebo Comparator|Placebo|Participants will take one tablet of matching placebo, orally, once a day for 12 weeks.
89559170|NCT02339935|Experimental|ABA Treatment Group|20 Children - 10 hospitalized at Vanderbilt Children's Hospital and 10 hospitalized at Vanderbilt Psychiatric hospital - will receive Brief Analogue Functional Analysis (Brief AFA) targeted to their most problematic behavior(s) while hospitalized
89559171|NCT02339935|Other|Control Group|20 Children - 10 hospitalized at Vanderbilt Children's Hospital and 10 hospitalized at Vanderbilt Psychiatric hospital - will receive all typical standard of care procedures while hospitalized, but will not receive Brief AFA
89559172|NCT02339623||threatened preterm labour|"Women who are diagnosed as having threatened preterm labour based on the American college of obstetricians and gynaecologists guidelines (ACOG,2003) :~Presence of uterine contractions ( at least 4 in 20 minutes or 8 in 60 minutes )~Cervical dilataion >1cm, &/or~Cervical effacement ≥ 80%"
89559173|NCT05178823|Active Comparator|Corsodyl|Chlorhexidine
89559174|NCT05178823|Experimental|Solumium Oral|Chlorine dioxide
89559175|NCT05178823|Experimental|Listerine Total Care|Essential oils, sodium fluoride, zinc chloride
89559176|NCT05178823|Experimental|BioGate Si*CLEAN|Microsilver
89559177|NCT03105583||Pregnant women visiting the obstetrics department|
89559178|NCT03105115|Active Comparator|intrathecal fentanyl|heavy bupivacaine 14mg and fentanyl 20mcg will be injected intrathecally during spinal anesthesia
89559179|NCT03105115|Experimental|bupivacaine only|heavy bupivacaine 14mg will be injected intrathecally during spinal anesthesia
89559180|NCT03080831|Active Comparator|NaCl 0.9% in Glucose 5% + 40mmol/L Potassium|
89559181|NCT03080831|Active Comparator|Glucion 5%|
89026469|NCT01605994|Experimental|Panel 5:BMS-933043(50mg)/Placebo+Antacid Buffer Solution|"BMS-933043 50 mg solution by mouth twice daily for 10 days~OR~Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days~Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days~CSF sampling required"
89559182|NCT03105349|Experimental|Single arm|16 weeks treatment with elbasvir/grazoprevir plus sofosbuvir and ribavirina
89559183|NCT03077555|Active Comparator|Meliane ED|20 mcg ethinyl estradiol/70 mcg gestodene
89559184|NCT03077555|Experimental|Zoely|1.5 mg estradiol/2.5 mg nomegestrol acetate
89559185|NCT02335723|Active Comparator|Alteco LPS Adsorber|Hemoperfusion and Standard therapy
89559186|NCT02335723|Placebo Comparator|Placebo|Placebo and Standard therapy. The placebo comparator device differs from Alteco® LPS Adsorber only in that no peptide component (i.e. active component) has been attached to the matrix.
89559187|NCT05005091|Active Comparator|oral carbohydrate|the patients drunk oral carbohydrate two hours ago preoperatively
89559188|NCT05005091|No Intervention|no oral carbohydrate|the patients did not drink oral carbohydrate preoperatively
89559189|NCT02335645||Body Weight Supported Treadmill|Post surgical ACL patients who will complete standard ACL protocol with the addition of body weight supported treadmill use.
89559190|NCT03080285|Active Comparator|Conventional patch|"The patients were prescribed 2 hours of patching per day for the sound eye and the spectacles were to be worn full-time.~Conventional patch is occlusion treatment sticker (Opticlude Eye Patch, 3M, Maplewood, MN, USA) with an adhesive material attached to the skin and serves to cover the eyes."
89559191|NCT03080285|Experimental|over-glasses patch|"the patients were prescribed 2 hours of patching per day for the sound eye and the spectacles were to be worn full-time.~Over-glasses patch (Tomato Eye Patch, Tomato Inc., Busan, South Korea) is made of fabric and covers the glasses, hence serves to cover the eyes."
89559192|NCT03077321|Active Comparator|CARE|The parent-child dyads in the CARE arm will receive the standard CARE program.
89559193|NCT03077321|Experimental|CARE plus peer mentor|The parent-child dyads in the CARE plus peer mentor arm will receive the CARE program that is delivered with the peer mentor.
89559194|NCT03077321|No Intervention|Control|Wait list control
89559195|NCT02335255|Experimental|Naftifine Hydrochloride Gel 2%|Naftifine Hydrochloride Gel 2% (Taro Pharmaceuticals Inc.)
89559196|NCT02335255|Active Comparator|Naftin® Gel 2%|Naftin® (Naftifine Hydrochloride) Gel 2% (Merz Pharmaceuticals, LLC)
89559197|NCT02335255|Placebo Comparator|Placebo Topical Gel|Placebo Topical Gel (Taro Pharmaceuticals Inc.)
89559198|NCT02344459|Experimental|80mL double balloon catheter (Cook catheter®)|
89559199|NCT02344459|Active Comparator|30mL single Foley balloon catheter|
89559200|NCT05012345|Experimental|4 Weeks cast immobilisation|Patients with fracture distal radius ( indicated for conservative treatment) will stay in a below-elbow cast for 4 weeks. Following immobilisation, treatment will be the same for both groups, in which additional physiotherapy after removal of the cast is advised and exercises to train wrist function will be given. As extra structured advice programmes may cause no extra benefit for the patient, this was not generally prescribed. However, during FU visits, patients will be asked if they were treated by a physiotherapist. If this is the case, details on the number of sessions per week and the total number of weeks the patient received physiotherapy, will be collected.
89559201|NCT05012345|Experimental|6 Weeks cast immobilisation|Patients with fracture distal radius ( indicated for conservative treatment) will stay in a below-elbow cast for 6 weeks. Following immobilisation, treatment will be the same for both groups, in which additional physiotherapy after removal of the cast is advised and exercises to train wrist function will be given. As extra structured advice programmes may cause no extra benefit for the patient, this was not generally prescribed. However, during FU visits, patients will be asked if they were treated by a physiotherapist. If this is the case, details on the number of sessions per week and the total number of weeks the patient received physiotherapy, will be collected.
89559202|NCT02344381|Experimental|Sucrose|Sucrose ingestion post-exercise
88965631|NCT05639764|Experimental|specific Immersive virtual reality (VRi) software|"Intervention group will perform active treatment using Virtual Reality software based on pain education and gamified exercise for gradual exposure to shoulder movement. The game involves visual stimuli and shoulder movement exercises in the shoulder flexion and abduction ranges in real time using immersive glasses located on the head and two controls on both hands. Patients will inhabit an avatar from an egocentric perspective.~The intervention will last 3 sessions / week of 15 minutes, therefore carrying a total duration of two weeks of treatment. Within the intervention will consist of a pill of education in pain neuroscience (PNE) of 1 minute duration, followed by an exposure level that will last 2:30 minutes where a progression will be made in number of ranges of motion and speed. Each session will consist of 2 intervention blocks (PNE + Gradual Exposure pill). The content of the PNE educational pills have been selected according to the objective of the study."
88965632|NCT05639764|Active Comparator|non specific Immersive virtual reality (VRi) software|"The control group will perform a VRi intervention with the game Tsuro, which consists of a puzzle-based strategy game where the patient will have to solve a maze by placing pieces. This intervention will attempt to assess the influence of the immersive context and the playful component compared to the intervention group. This treatment will last 3 sessions / week of 15 minutes, therefore taking a total duration of two weeks of treatment with a total of 6 sessions."
89559203|NCT02344381|Active Comparator|Glucose|Glucose ingestion post-exercise
89559204|NCT05012033||Group A|Patients started acutely on high dose prednisolone (>30mg for any inflammatory condition)
89559205|NCT05012033||Group B|Patients on longer term anti-inflammatory doses of prednisolone to treat any medical condition warranting their use, including post COVID.
89559206|NCT05012033||Group C|Patients receiving multiple high doses of methylprednisolone or dexamethasone in association with oral prednisolone.
89559207|NCT03145831|Experimental|Somavaratan|fusion protein, subcutaneous bolus injection, 3.5 mg/kg twice monthly
89559208|NCT05011877||Acute Hypercapnic Respiratory Failure patients with Sleep Disorders|Acute Hypercapnic Respiratory Failure patients with Sleep Disorders
89559209|NCT05011877||Acute Hypercapnic Respiratory Failure patients without Sleep Disorders|Acute Hypercapnic Respiratory Failure patients without Sleep Disorders
89559210|NCT03080051|Experimental|[18F]MNI-952|To evaluate [18F]MNI-952 (also known as [18F]UCB-K), a tau targeted PET radioligand.
89559211|NCT02344303|Experimental|Part A|Fixed sequence, open label
89559212|NCT02344303|Experimental|Part B|4 way cross over, double blind
88965633|NCT05639803|Experimental|PEGIFNα1b 1.5 μg/kg|8 randomized participants receive one dose PEGIFNα1b 1.5 μg/kg, 2 randomized participants receive one dose placebo, subcutaneous administered
88965634|NCT05639803|Experimental|PEGIFNα1b 3.0 μg/kg|8 randomized participants receive one dose PEGIFNα1b 3.0 μg/kg, 2 randomized participants receive one dose placebo, subcutaneous administered
89559213|NCT05011955|Experimental|Mindfulness, compassion and intercare based Intervention|Four week, one hour peer week, online group intervention plus home work based on mindfulness, compassion and intercare based programs.
89559214|NCT05011955|Active Comparator|Psychoeducational based intervention|Four week, one hour peer week, online group intervention plus home work based on psychoeducation about stress, anxiety, selfcare and effective communication.
89559215|NCT05011955|Other|General curricular intervention|All participants were offered psychological sessions if a high score on depression or anxiety symptoms were detected. Participants also have academic breaks of two week per semester, apart from holidays, and academic flexibility in submitting work, attending practical activities and taking exams.
89559216|NCT02335177|Active Comparator|Interventionnal arm|Interventional arm : patients at home with technologies for autonomy and tailored physical activity program.
89559217|NCT02335177|No Intervention|Control arm|Control arm : patients with usual care home
89559218|NCT03076931|Experimental|Study: Airway Reconstruction Patients|These participants have significant airway abnormalities that require invasive surgery, such as Laryngotracheoplasty, to rectify, and whose voice quality may suffer as a result of the surgery. The goal of this study is to improve voice outcomes of these patients, and their clinical data will be collected.
89559219|NCT03076931|Experimental|Control: Normal Airway Patients|These participants have normal airways and voice who will undergo a microlaryngoscopy and voice evaluation, the data from which will be compared to study patients.
89559220|NCT02339467|Experimental|GO-OUT program|An outdoor walking workshop with stations to learn various outdoor walking skills and information, followed by a supervised, group based outdoor walking program, twice a week for 60 minutes, for 3 months.
89559221|NCT02339467|Active Comparator|Task-oriented outdoor walking workshop|An outdoor walking workshop with stations to learn various outdoor walking skills and information.
89559222|NCT02343991|Experimental|Transcranial ExAblate|MR Guided Focused Ultrasound
89559223|NCT02334943|Experimental|Treated HIV-1 infected patients|Treated HIV-1 infected patients for Blood test
89559224|NCT02334943|Experimental|No treated HIV-1 infected patients|No treated HIV-1 infected patients for Blood test
88965635|NCT05639803|Experimental|PEGIFNα1b 5.0μg/kg|8 randomized participants receive one dose PEGIFNα1b 5.0 μg/kg, 2 randomized participants receive one dose placebo, subcutaneous administered
88965636|NCT05639803|Experimental|PEGIFNα1b 6.0 μg/kg|8 randomized participants receive one dose PEGIFNα1b 6.0 μg/kg, 2 randomized participants receive one dose placebo, subcutaneous administered
88965637|NCT05639803|Experimental|PEGIFNα1b 7.0 μg/kg|8 randomized participants receive one dose PEGIFNα1b 7.0 μg/kg, 2 randomized participants receive one dose placebo, subcutaneous administered
88965638|NCT00000136|Experimental|Foscarnet|The induction dose for foscarnet is 60 mg/kg every 8 hours. Full dose maintenance therapy for foscarnet is 90 mg/kg/day
88965639|NCT00000136|Experimental|Ganciclovir|The induction dose for ganciclovir is 5 mg/kg every 12 hours. Full dose maintenance therapy for ganciclovir is 5 mg/kg every 24 hours, 7 days a week.
88965640|NCT00000142|Experimental|treatment deferral|"IV (in the vein) treatment deferred until retinitis progressed, either:~5 mg/kg IV (in the vein) of body weight once weekly for two weeks, then maintenance therapy with cidofovir, 3mg/kg once every 2 weeks, or~5mg/kg IV (in the vein) once weekly for 2 weeks, then maintenance therapy with cidofovir, 5mg/kg once every two weeks."
88965641|NCT00000142|Experimental|Cidofovir (low dose)|5 mg/kg IV (in the vein) of body weight once weekly for two weeks, then maintenance therapy with cidofovir, 3mg/kg once every 2 weeks
88965642|NCT00000142|Experimental|Cidofovir (high dose)|5mg/kg IV (in the vein) once weekly for 2 weeks, then maintenance therapy with cidofovir, 5mg/kg once every two weeks.
88965643|NCT00000145|Experimental|1|Antioxidants
88965644|NCT00000145|Experimental|2|Zinc
88965645|NCT00000145|Experimental|3|Antioxidants and zinc
88965646|NCT00000145|No Intervention|4|
88965647|NCT00000256|Active Comparator|Placebo + 20% N2O|0% N2O inhaled during psychomotor testing, 20% N2O inhaled during psycho motor testing, then subject's choice of the 2.
88965648|NCT00000256|Active Comparator|Placebo + 40% N2O|0% N2O inhaled during psychomotor testing, 40% N2O inhaled during psycho motor testing, then subject's choice of the 2.
88965649|NCT00000256|Active Comparator|Placebo + 60% N2O|0% N2O inhaled during psychomotor testing, 60% N2O inhaled during psycho motor testing, then subject's choice of the 2.
88965650|NCT00000256|Active Comparator|Placebo + 80% N2O|0% N2O inhaled during psychomotor testing, 80% N2O inhaled during psycho motor testing, then subject's choice of the 2.
88965651|NCT03582085|Experimental|Bacillus Calmette-Guerin (BCG)|3 BCG vaccinations spaced 1 year apart.
88965652|NCT03582085|Placebo Comparator|Placebo Comparator: Saline injections|3 saline injections spaced 1 year apart.
88965653|NCT03573739|Experimental|Low group|"Patients randomized in the low group will receive a low-calorie low-protein nutrition regimen during the acute phase."
88965654|NCT03573739|Active Comparator|Standard group|"Patients randomized in the standard group will receive a standard-calorie/standard-protein nutrition regimen during the acute phase."
88965655|NCT05637957|Experimental|Physiotherapy + Active tDCS|20 minutes of active anodal tDCS immediately prior to physiotherapy intervention, twice a week for total of 10 sessions.
88965656|NCT05637957|Active Comparator|Physiotherapy + Sham tDCS|20 minutes of sham anodal tDCS immediately prior to physiotherapy intervention, twice a week for total of 10 sessions.
88965657|NCT03562156|Experimental|Oteseconazole (VT-1161) 150mg capsule|Once daily for 7 days starting at Day 1, followed by once weekly for 11 weeks
88965658|NCT03562156|Placebo Comparator|Placebo capsule|Once daily for 7 days starting at Day 1, followed by once weekly for 11 weeks
88965659|NCT05638035||non-obese women|After obtaining demographic information for women with a BMI of 18-27.9 kg/m2 for at least 6 months, Body Mass Index (BMI) will be calculated and the relationship between rectus femoris muscle thickness, sarcopenia, gait and balance will be evaluated and will be compared with obese group.
88965660|NCT05638035||obese women|After obtaining demographic information in women with a BMI of 30-39.9 kg/m2, Body Mass Index (BMI) will be calculated and the relationship between obesity and rectus femoris muscle thickness, sarcopenia, gait and balance will be evaluated.
88965661|NCT00000409|Active Comparator|Surgery|Decompressive Laminectomy Fusion-Instrumented Fusion-Non-instrumented
88965662|NCT00000409|Active Comparator|Non-surgical intervention|Other. Non-surgical treatments
88965663|NCT05638074||With cervical facet tropism|
88965664|NCT05638074||Without cervical facet tropism|
89026470|NCT01605994|Experimental|Panel 6:BMS-933043(100mg)/Placebo+Antacid Buffer Solution|"BMS-933043 100 mg solution by mouth twice daily for 10 days~OR~Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days~Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days"
89559225|NCT02334943|Experimental|Healthy witness|Healthy witness for Blood test
89559226|NCT02335021|Experimental|Sucralose|Participants will rate sweetness, sourness, saltiness, bitterness and umami intensity of various taste stimuli. Next they will consume a flavored beverage with sucralose.
89559227|NCT02335021|Experimental|Sucrose|Participants will rate sweetness, sourness, saltiness, bitterness and umami intensity of various taste stimuli. Next they will consume a flavored beverage with sucrose.
89559228|NCT02335021|Experimental|Sucralose + maltodextrin|Participants will rate sweetness, sourness, saltiness, bitterness and umami intensity of various taste stimuli. Next they will consume a flavored beverage with Splenda + maltodextrin .
89026471|NCT01605994|Experimental|Panel 7:BMS-933043(200mg)/Placebo+Antacid Buffer Solution|"BMS-933043 200 mg solution by mouth twice daily for 10 days~OR~Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days~Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days"
89559229|NCT02335021|Experimental|Sucralose + Sucrose|Participants will rate sweetness, sourness, saltiness, bitterness and umami intensity of various taste stimuli. Next they will consume a flavored beverage with Splenda + sucrose.
89559230|NCT02344069|Active Comparator|Fibrinogen|Immediate intravenous administration as a single dose of fibrinogen concentrate (Riastap®, CSL Behring), when haemostatic resuscitation is deemed necessary by the clinician.
89559231|NCT02344069|Placebo Comparator|Placebo|Saline 0.9%
89559232|NCT02343913|Experimental|PAC checklist|Pictorial checklist which illustrates these signs and symptoms
89559233|NCT02334475|Experimental|GROUP (P)|Ultrasound guided sacroiliac joint injection of 3 ml of leukocyte free platelet rich plasma with 0.5 ml of calcium chloride(total volume 3.5 ml) per course. Single injection per course is being given.
89559234|NCT02334475|Active Comparator|GROUP (S)|Ultrasound guided sacroiliac joint injection of 1.5 ml of methylprednisolone (40mg/ml) and 1.5 ml of 2% lidocaine (20mg/ml) with 0.5 ml of saline (total volume 3.5 ml). Single injection per course is being given.
89559235|NCT02343835|Experimental|NanoKnife LEDC System|90 pulses of 70 microseconds each in duration will be administered per electrode pair.
89559236|NCT02343835|No Intervention|Control|The patients without treatment
89559237|NCT02334553|Active Comparator|S1226 (8%)|The drug S1226(8%), consists of Perflubron and 8% CO2 in a medical gas mixture. The dosage is 3ml delivered as an aerosol/vapour/gas mixture with a Circulaire nebulizer.
89559238|NCT02334553|Placebo Comparator|Placebo|The comparator is normal saline delivered as an aerosol with compressed medical air with a Circulaire nebulizer.
89559239|NCT02334709|Experimental|SBRT + fixed dose Tyrosine Kinase Inhibitor|Single arm phase I trial with 3 dose-escalation arms
89559240|NCT02334631|Experimental|High volume simethicone|High volume simethicone is defined as 1125 mg simethicone in 750 ml of water (1.5 mg/ml).
89559241|NCT02334631|Active Comparator|Standard volume simethicone|Standard volume simethicone is defined as 300 mg simethicone in 200 ml of water (1.5 mg/ml).
89559242|NCT02334397|Active Comparator|Total Control Program|Women will be enrolled in Total Control, which is a fitness and education program. Specifically, Total Control is a comprehensive pelvic fitness and wellness program designed by board-certified female pelvic medicine and reconstructive surgery (FPMRS) practitioners as well as physical therapists that combines pelvic floor and core muscle strengthening. Subjects will participate in 1 standardized class per week during their second trimester for a total of 6 weeks. Women will also participate in a weekly educational session which will include keynote speakers who are experts in various aspects of the labor and delivery process. Women in this group will complete questionnaires and consent to use of their delivery outcomes. Women will also wear pedometers to track daily general activity.
89559243|NCT02334397|No Intervention|Control Group|This group will consist of eligible women who were not randomized to the fitness and education program. Participants will complete questionnaires and consent to use of their delivery outcomes. Women will also wear pedometers to track daily general activity.
89559244|NCT02334319|Experimental|Treatment (ganetespib, surgery)|Patients receive ganetespib IV over 1 hour twice weekly for 2 weeks in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery the day after the last dose of ganetespib.
89559245|NCT02338765|Experimental|Buddy|Physical activity plus having a buddy
89559246|NCT02338765|Active Comparator|Control|Physical activity only
89559247|NCT02338531|Experimental|Therapeutic regimen|oral administration of PF-03084014, 9 days at 150 mg q.d. (day 1 and 9) and 150 b.i.d. (day 2 till 8)
89559248|NCT02338453|Active Comparator|Attention Bias Modification Treatment|Participants will receive an attention bias modification protocol designed to divert attention away from socially-threatening stimuli via repeated trials of a dot-probe task.
89559249|NCT02338453|Placebo Comparator|placebo-control condition|Participants will receive an placebo control protocol using the same task and stimuli but not designed to change attention patterns
89559250|NCT02332213||1. Colorectal cancer|Patients with histologically confirmed colorectal cancer (adenocarcinoma)
89559251|NCT02332213||2. Colorectal high-risk lesions|Patients without colorectal adenocarcinoma, but carrying high-risk adenomatous polyps being described by one of the following: 1) size≥1 cm; 2) high-grade dysplasia; 3) villous component. Prior to removal of the lesions.
89559252|NCT02332213||3. Colorectal low-risk adenoma|Patients without colorectal adenocarcinoma and without colorectal high-risk lesions as described under Group 2 criteria
89559253|NCT02332213||4. Group of control (colorectal)|Patients having undergone colonoscopy without an evidence for colorectal lesions fulfilling Group 1 or Group 2 or Group 3 criteria. Prior to removal of the lesions.
89559254|NCT02332213||5. Gastric cancer|Patients with histologically confirmed gastric cancer (adenocarcinoma)
89559255|NCT02332213||6. Gastric dysplasia|Patients without gastric adenocarcinoma but with histologically confirmed dysplasia (either high- or low-grade) of the stomach
89559256|NCT02332213||7. High-risk gastric lesions|Patients graded Stage III-IV according to OLGIM (Operative Link of Gastric Intestinal Metaplasia Assessment) staging system, but excluding those with dysplasia (Group 5)
89559257|NCT02332213||8. Normal and low-risk gastric lesions|Staged 0-III according to OLGIM. Dysplasia should be excluded
88965665|NCT00000421|Active Comparator|Prednisone arm|Patients who remained clinically stable but showed serologic evidence of a lupus flare (elevation of both the anti-dsDNA level by 25% and the C3a level by 50% over the previous 1-2 monthly visits) were randomized receive either prednisone or placebo therapy at a dosage of 30 mg/day for 2 weeks, 20 mg/day for 1 week and 10 mg/day for 1 week.
88965666|NCT00000421|Placebo Comparator|Placebo|Patients who remained clinically stable but showed serologic evidence of a lupus flare (elevation of both the anti-dsDNA level by 25% and the C3a level by 50% over the previous 1-2 monthly visits) were randomized receive either prednisone or placebo therapy at a dosage of 30 mg/day for 2 weeks, 20 mg/day for 1 week and 10 mg/day for 1 week.
88965667|NCT00000457|Placebo Comparator|Placebo|Subjects who achieved smoking abstinence and give a bupropion-placebo (sugar) pill for 44 weeks in order to prevent relapse to smoking. Brief Behavioral Counseling is also given during this time.
88965668|NCT00000457|Active Comparator|Bupropion|Subjects who achieved smoking abstinence and give bupropion (300 mg/day) for 44 weeks in order to prevent relapse to smoking. Brief Behavioral Counseling is also given during this time.
88965669|NCT00000460||Low intensity exercise|
88965670|NCT00000460||High intensity exercise|
89559258|NCT02332213||9. Average risk population|Average risk population of both genders aged 40-64 at the time of inclusion lacking alarm symptoms for gastrointestinal cancer.
89559259|NCT02332135|Experimental|microwave ablation group|patients in ultrasonic ablation will be treated by ultrasound guided percutaneous parathyroid gland microwave ablation
89559260|NCT02332135|Active Comparator|control group|patients in control group will be treated by active vitamin D and other general treatments according to the suggestions in K/DOQI guidelines
89559261|NCT03518359|Experimental|Mental Training for Residents|The intervention will be the modified form of Mindfulness-Based Stress Reduction (MBSR). For this study investigator named the experimental arm Enhanced Stress Resilience Training (ESRT).
89559262|NCT03518359|Active Comparator|Active Control|"Active control that emphasizes externalized attention via the shared reading and listening model."
89559263|NCT05134675||Consumption|Patients consuming homemade beer
89559264|NCT05134675||Not consumption|Patients are not consuming homemade beer
89559265|NCT04987177|Experimental|Workload conditions to be tested|The intervention is the external workload a participant propels against. Participants will propel against N=20 different external workloads.External workload will be controlled by the wheelchair ergometer.
89559266|NCT02334241|Experimental|Sorbact®|The basic Sorbact® presentation is an antimicrobial, non-adhesive absorbent wound dressing. It consists of a highly absorbent hydropolymer matrix with an antimicrobial Sorbact® mesh (Sorbact® acetate fabric coated with dialkyl carbamoyl chloride - DACC) and is covered by a semipermeable polyurethane film.
89559267|NCT02334241|Active Comparator|Best local cares|Dressing requirements in this study have to be consistent with international guidelines.
89559268|NCT02334163|Experimental|Nitazoxanide group|"12 patients will receive the following for 7 days:~Oral lactulose~500 mg nitazoxanide tablets twice daily"
89559269|NCT02334163|Active Comparator|Metronidazole group|"12 patients will receive the following for 7 days:~Oral lactulose~250 mg metronidazole tablets every 8 hours"
89559270|NCT02334163|Active Comparator|Rifaximine group|"12 patients will receive the following for 7 days:~Oral lactulose~Two 200 mg rifaximine tablets every 8 hours"
89559271|NCT02039635|Experimental|Korean Red Ginseng|"Patients receive oral Korean Red Ginseng twice daily for 16 weeks. Treatment repeats every 4 weeks for 4 courses.~Intervention: Dietary Supplement: Korean Red Ginseng"
89559272|NCT02039635|Placebo Comparator|Placebo|"Patients receive oral placebo twice daily for 16 weeks. Treatment repeats every 4 weeks for 4 courses.~Intervention: Other: Placebo"
89559273|NCT02332057|Active Comparator|Diclofenac plus lidocaine|Diclofenac(100 mg) is administered 1 hour before IUD insertion and lidocaine gel is placed on cervix three minutes before IUD insertion
89559274|NCT02332057|Placebo Comparator|Placebo|Placebo tablets is administered 1 hour before IUD insertion and placebo gel is placed on cervix three minutes before IUD insertion
89559275|NCT02331745|Experimental|Granulocyte colony-stimulating factor|"Granulocyte colony-stimulating factor(G-CSF) was given 5 ug/kg subcutaneously qd for 6 doses,then qod for other 6 doses(total 12 doses).~Standard treatment includes reduced glutathione, glycyrrhizin, ademetionine,polyene phosphatidylcholine, alprostadil, and human serum albumin) on the day of admission. HBV associated ACLF patients receive entecavir at the same time"
89559276|NCT02331745|Active Comparator|standard treatment|Standard treatment alone
89559277|NCT02638259|Experimental|50mg GP2015|Group 1 will receive treatment with 50mg GP2015 by subcutaneous injection every week up to 24 weeks (Treatment Period 1) after which patients achieving at least a moderate clinical response continue treatment with 50mg GP2015 subcutaneous injection every week up to 48 weeks (Treatment Period 2).
89559278|NCT02638259|Active Comparator|50mg EU-authorized Enbrel|Group 2 will receive treatment with 50mg EU-authorized Enbrel by subcutaneous injection every week up to 24 weeks (Treatment Period 1) after which patients achieving at least a moderate clinical response will be switched to 50 mg GP2015 subcutaneous injection every week up to 48 weeks (Treatment Period 2).
89559279|NCT02333929||VTE prevention|Prophylaxis of VTE in patients undergoing knee or hip replacement surgery (10 mg OD): orthopaedic department of the hospital will be in charge of the sample collection.
88965671|NCT00388843||Dose Increased|Patients presenting with symptoms of coronary artery disease or stroke/suspected stroke, with carotid plaque > 1.1 mm, and whose statin dose is increased to moderate to high dose by their clinicians.
88965672|NCT00388843||Dose Maintained|Patients presenting with symptoms due to coronary artery disease or stroke/suspected stroke, with carotid plaque > 1.1 mm, on no statins or whose statin dose was unchanged by their clinicians.
88965673|NCT05638191||Experiemental: Surgical Arm|Individuals in this group will receive nerve transfer surgery 6 - 9 months post cervical spine injury and be observed for two years post-operatively.
88965674|NCT05638191||Control: Non-surgical|Individuals in this group will not have undergone nerve transfer surgery. They will be observed for two years post injury while receiving standard of care including medical and rehabilitation. We want to reinforce that individuals are not being randomized to surgery versus non-surgery. Rather individuals this group will either have made the decision not to undergo surgery, independent their participation in this study.
88965675|NCT00388999|Other|0 mg/kg|
88965676|NCT00388999|Other|0.5 mg/kg|
88965677|NCT00388999|Other|1.0 mg/kg|
88965678|NCT05638230||HIgh HFA-PEFF points (≥5)|
88965679|NCT05638230||Low to intermediate HFA-PEFF points (<5)|
88965680|NCT05638308|Other|FAZA PET/MRI scan|FAZA PET/MRI scan before the standard of care biopsy for case group
88965681|NCT05638425||Group 1|
88965682|NCT05638464|Experimental|Multisite HD-tDCS group|Constant current will be applied for 20min and the electrodes will be placed over the target area
88965683|NCT05638464|Active Comparator|Conventional tDCS Group|Constant current (1mA) will be applied for 20min and the anode will be placed over the standard C3/C4 position
88965684|NCT05638464|Sham Comparator|Sham HD-tDCS group|The stimulator will be applied for 20 minutes with only 30s ramp-up and ramp-down stimulation delivered.
89559280|NCT02333929||DVT/PE treatment|Treatment of deep vein thrombosis (DVT), pulmonary embolism (PE), and risk reduction of DVT and PE recurrence; (15 mg BID for 3 weeks then 20 mg OD): different departments of the hospital will be in charge of the sample collection (samples can come e.g., from emergency room, vascular lab or cancer unit).
89559281|NCT02333929||SPAF|Stroke prevention and reduction of systemic embolism in non-valvular patients with atrial fibrillation (SPAF) (20 mg OD): cardiology department of the hospital will be in charge of the sample collection.
89559282|NCT02333851|Experimental|Premixed insulin|Mixtard 30:70 Novonordisk® twice daily, before breakfast and before dinner.
89559283|NCT02333851|Experimental|Basal-bolus|'Lantus® once daily and Apidra® before meals
89559284|NCT02334085||HOW study participants|
89559285|NCT02334007|Experimental|LMWH: Dalteparin|Consenting patients undergoing lung resection will receive standard postoperative thromboprophylaxis in hospital until the time of discharge. Subsequently, patients will be administered LMWH for duration of 30 days as outpatients.
89559286|NCT02334007|Placebo Comparator|Placebo|After undergoing lung resection these patients will research standard post-op TE prophylaxis and upon discharge will be administered a placebo injection of subcutaneous saline for 30 days duration.
89559287|NCT02333695|Experimental|Spinal Magnetic Stimulation|Spinal Magnetic Stimulation (SMS) is a relatively new way to use magnetism to affect the spinal cord. It is non-invasive, meaning that the procedure does not require any type of surgery; rather, it is conducted by transmitting magnetic pulses through the Spinal Cord by pressing a machine against the back.
88965685|NCT05638464|Experimental|multisite HD-tDCS with EMG-driven robot hand group|The stimulation electrodes are fixed on the ipsilesional sensorimotor cortex according to the brain activation map detected by task based fMRI.
88965686|NCT05638464|Sham Comparator|Sham HD-tDCS EMG-driven robot hand group|The stimulator will be applied for 20 minutes with only 30s ramp-up and ramp-down stimulation delivered.
88965687|NCT05638503||Hypertension with left ventricular hypertrophy group|"2015 ASE/EACVI guideline standard: Eccentric hypertrophy, EH: LVMI>115g/ m2（male）or LVMI>95g/ m2（female）and RWT≤0.42 Concentric hypertrophy, CH: LVMI>115g/ m2（male）or LVMI>95g/ m2（female）and RWT>0.42~Reference Values for Chinese (EMINCA) and Configuration Analysis Based on Ganau Typing:~Eccentric hypertrophy, EH: LVMI>108g/ m2（male）and RWT≤0.51or LVMI>99g/ m2（female）and RWT≤0.49 Concentric hypertrophy, CH: LVMI>108g/ m2（male）and RWT>0.51 or LVMI>99g/ m2（female）and RWT>0.49"
88965688|NCT05638503||Hypertension with left ventricular non-hypertrophy group|"2015 ASE/EACVI guideline standard: Normal left ventricular geometry, NG: LVMI≤115g/m2（male）or LVMI≤95g/m2（female）and RWT≤0.42 Concentric remodeling, CR: LVMI≤115g/m2（male）or LVMI≤95g/ m2（female）and RWT>0.42~Reference Values for Chinese (EMINCA) and Configuration Analysis Based on Ganau Typing:~Normal left ventricular geometry, NG: LVMI≤108g/ m2（male）and RWT≤0.51 or LVMI≤99g/ m2（female）and RWT>0.49 Concentric remodeling, CR: LVMI≤108g/ m2（male）and RWT>0.51 or LVMI≤99g/ m2（female）and RWT>0.49"
88965689|NCT05638659|Experimental|Experimental group|Twice a week for 8 weeks, total of 16 sessions course of computerized dual-task balance and home program.
88965690|NCT05638659|Active Comparator|Control group|Medical consultation and traditional balance training, and assessed after 8 weeks.
88965691|NCT00000607|Experimental|Left ventricular assist device|Subjects received Thermo Cardiosystems, Inc. (TCI) vented electric (VE) left ventricular assist device (LVAD) and were followed for at least two years
88965692|NCT00000607|Active Comparator|Optimal medical therapy|Subjects received optimal medical therapy (OMM) and were followed for at least two years
88965693|NCT00389038|Active Comparator|Coping Skills Training + Amitriptyline|Behavioral coping skills training--Behavioral Treatment session 1 and 2: Doses are one session a week for 8 weeks, followed by one session a month for 2 months, followed by 1 session every three months for 1 year.
88965694|NCT00389038|Active Comparator|Headache Education + Amitriptyline|Behavioral headache education
88965695|NCT00389116|Experimental|1|
88965696|NCT00389116|Placebo Comparator|2|
88965697|NCT03503695|Active Comparator|Auricular Acupuncture|Sterile acupuncture semi-permanent (ASP) gold needles will be administered in the following acupuncture points: Cingulate Gyrus, Thalamus point, Omega 2, Point Zero, and Shen Men starting in either ear and alternating left and right until 10 ASP needles are placed. The needles may remain in the AA points for 3-4 days.
88965698|NCT03503695|No Intervention|Comparison Group|There will be no intervention. The participants will be instructed to return on Day 8.
89559288|NCT02338375|Experimental|Cartistem|For control group patients currently standard treatment of arthroscopic curettage and microfracture is performed, and for study group patients allogenic umbilical cord blood-derived mesenchymal stem cell product(Cartistem®) is added on the lesion after above mentioned procedure.
89559289|NCT02338375|Active Comparator|standard treatment|standard treatment of arthroscopic curettage and microfracture for osteochondral lesion of talus
88965699|NCT00000817|Experimental|1|Participants will receive standardized or alternate point acupuncture treatment twice weekly for the first 6 weeks, then once weekly for the next 8 weeks, plus either oral amitriptyline or placebo daily for the entire 14 weeks.
88965700|NCT00389233|Experimental|1|2L gut cleansing solution
88965701|NCT00389233|Active Comparator|2|4L preparation
88965702|NCT05638971|Experimental|Sensor Group|The first half sample size Peripheral intravenous canula will be enrolled in a non-alarming group. ivWatch will monitor the Peripheral intravenous canula insertion site collecting data without notifications. The goals of the study on the nonalarming group are: a) to evaluate ivWatch sensitivity to detect infiltration in comparison with nurse standard of care; b) to estimate the difference in terms of time to detection of ivWatch in comparison with nurse standard of care
88965703|NCT05639049|Experimental|Enova GF3|Patient will receive the monofocal IOL in one eye during cataract surgery
88965704|NCT05639049|Experimental|Tecnis 1-piece ZCB00|Patient will receive the monofocal IOL in one eye during cataract surgery
88965705|NCT03474445|Active Comparator|Control group|Volar Plate Osteosynthesis Aptus 2.5
88965706|NCT03474445|Active Comparator|Study Group|Volar Plate Osteosynthesis Inteos 2.5
88965707|NCT05639127|Experimental|Low dose, wash out, high dose|
88965708|NCT05639439|Active Comparator|Group A- Fastrach|"Group of 40 patients scheduled for elective surgery under general anesthesia are planned to be ventilated through the intubating laryngeal mask airway Fastrach, while the laryngeal view through Fastrach will be evaluated using a flexible fiberoptic bronchoscope"
88965709|NCT05639439|Active Comparator|Group B- Proseal|"Group of 40 patients scheduled for elective surgery under general anesthesia are planned to be ventilated through the Proseal laryngeal mask airway, while the laryngeal view through Proseal will be evaluated using a flexible fiberoptic bronchoscope"
88965710|NCT05639439|Active Comparator|Group C- I-gel|"Group of 40 patients scheduled for elective surgery under general anesthesia are planned to be ventilated using the I-gel supraglottic airway device, while the laryngeal view through I-gel will be evaluated using a flexible fiberoptic bronchoscope"
88965711|NCT05639439|Active Comparator|Group D- Protector|"Group of 40 patients scheduled for elective surgery under general anesthesia are planned to be ventilated using the Protector laryngeal mask airway, while the laryngeal view through Protector will be evaluated using a flexible fiberoptic bronchoscope"
88965712|NCT00389311|Active Comparator|Nonoxynol-9|Gynol-II, 2% N-9, 5 mL
88965713|NCT00389311|Other|Normosol-R|Normosol-R, 5 mL, single administration, negative control
88965714|NCT00389311|Experimental|Normosol with simulation, endoscopy and biopsy|Normosol-R, 5 mL following simulation, endoscopy and biopsy
88965715|NCT00001183||Group 1|Pulmonary Patients
88965716|NCT00001213|Experimental|Cysteamine topical solution|Cysteamine topical solution administered hourly while awake in both eyes
88965717|NCT00001219||Patients undergoing MRI in the Clinical Center|All patients who, by virtue of the NIH protocol in which they are enrolled, who qualify for MRI will be eligible for participation in this protocol.
88965718|NCT03444727|Experimental|Ice Pre-treatment|Participants will hold an exam glove filled with ice to intended biopsy area for 30 seconds prior to preparation and local anesthetic injection.
88965719|NCT03444727|Placebo Comparator|Room Temperature Water Pre-Treatment|Participants will hold an exam glove filled with room temperature water to intended biopsy area for 30 seconds prior to preparation and local anesthetic injection.
88965720|NCT00000135|Experimental|MSL-109|The dose MSL-109 administered by intravenous infusion every 2 weeks 60 mg.
88965721|NCT00000135|Placebo Comparator|Placebo|Placebo administered intravenous infusion every 2 weeks 60 mg.
89559290|NCT02338063|Experimental|1|Virtual Reality
88965722|NCT00388557|Experimental|1|
88965723|NCT00001651|Experimental|HIV-infected subjects|HIV-infected adults
88965724|NCT00001651|Experimental|HIV-negative subjects|HIV-negative adults
88965725|NCT00001723|Placebo Comparator|Placebo|Matching placebo 120 mg TID x 6 months plus a behavioral weight loss program
88965726|NCT00001723|Experimental|Orlistat|Orlistat 120 mg TID for 6 months plus a behavioral weight loss program
88965727|NCT00001756||Healthy Volunteers|Healthy Volunteers
88965728|NCT00001756||Patients|Patients have mast cell hyperplasia compatible with a diagnosis of systemic mastocytosis (applicable to systemic mastocytosis patients only) or other allergic, hematologic, orimmunologic condition.
88965729|NCT05641636||childhood cancer survivors - the main group|childhood cancer survivals after complex management of cranial and craniospinal tumors formed the main group
89559291|NCT02338063|Experimental|2|Health Promotion
89559292|NCT02637323|Experimental|FX006 32 mg|Single 5 mL intra-articular (IA) injection Extended-release formulation
88965730|NCT05641636||the control group|healthy people formed the control group
88965731|NCT05641558|Experimental|611 dose 1 plus placebo|One subcutaneous injections of 611 150 mg on Day 1, followed by a 4-week observation period. Two subcutaneous injections of 611 150 mg (for a total of 300 mg) as a loading dose on Week 0 Day 29, followed by one 150 mg injection quaque week (QW) from Week 1 to Week 15 (15 cycles).
88965732|NCT05641558|Experimental|611 dose 2 plus placebo|Two subcutaneous injections of 611 150 mg (for a total of 300 mg) on Day 1, followed by a 4-week observation period. Four subcutaneous injections of 611 150 mg (for a total of 600 mg) as a loading dose on Week 0 Day 29, followed by one 300 mg injection quaque 2 week (Q2W) from Week 1 to Week 15 (8 cycles).
89559293|NCT02637323|Active Comparator|TCA IR 40 mg|Commercially available triamcinolone acetonide, single 1 mL intra-articular (IA) injection Immediate-release formulation
89559294|NCT02338141|Experimental|Portable colposcopy|Diagnostic evaluation with 8x magnification portable colposcopy after visual inspection with acetic acid
89559295|NCT02338141|Active Comparator|Conventional colposcopy|Diagnostic evaluation with standard 25x magnification conventional colposcopy after visual inspection with acetic acid
89559296|NCT02338297|Experimental|TACE+EGM|Occlude APS with EGM and perform TACE sequentially
89559297|NCT02338297|Active Comparator|TACE+PVA|Occlude APS with PVA and perform TACE sequentially
89559298|NCT02338219|Active Comparator|vaginal delivery|postpartum female pelvic floor muscle affection postpartum sexual function in Egyptian women.
89559299|NCT02338219|Active Comparator|elective cesarean section|postpartum female pelvic floor muscle affection postpartum sexual function in Egyptian women.
89559300|NCT02338219|Active Comparator|urgent cesarean section|postpartum female pelvic floor muscle affection postpartum sexual function in Egyptian women.
89559301|NCT05011643||Symptomatic statin users|Statin users with self-reported muscle symptoms
89559302|NCT05011643||Asymptomatic statin users|Statin users without muscle symptoms
89559303|NCT05011643||Non-statin using controls|Participants not using statins
89559304|NCT03111979|Experimental|Beta-alanine supplementation|Participants will be supplemented with 4.8g·d-1 β-alanine (CarnoSyn™, NAI, USA). The β-alanine dosing regimen will consist of two 800 mg tablets three times per day at 3-4 hour intervals or the same regimen for placebo tablets. The use of multiple small doses throughout the day has been used in numerous studies using β-alanine in solutions or gelatine capsules (Hoffman et al., 2008; Sale et al., 2011; Saunders et al., 2012; Sale et al., 2012; Tobias et al., 2013) in order to circumvent potential symptoms of paraesthesia (see box xii for possible risks and discomforts). Overall increases have been shown to be between 40% and 80% depending upon dose (between 3.2 and 6.4 g·d-1) and duration of administration (between 4 and 10 weeks) (Sale et al., 2012).
89559305|NCT03111979|Placebo Comparator|Placebo|Participants will be supplemented with 4.8 g·d-1 placebo (maltodextrin; NAI, USA). The regimen will consist of two 800 mg tablets three times per day at 3-4 hour intervals the same regimen for beta-alanine tablets
89559306|NCT05004623|Other|Sentinel Lymph Node Biopsy|Sentinel lymph node biopsy by indocyanine green (ICG) fluorescent dye technique, using a prototype of the Easy Light device. Lymph node dissection in each hemipelvis should be performed as standard if no sentinel lymph node is detected. Decision of proceeding with complementary lymph node dissection after sentinel lymph node detection is a surgeon decision, according to his/her usual practice.
89559307|NCT02331901||MTBI SYMP|Mild Traumatic Brain Injury subjects with symptoms
89559308|NCT02331901||MTBI NO SYMP|Mild Traumatic Brain Injury subjects without symptoms
88965733|NCT05641558|Experimental|611 dose 3 plus placebo|Four subcutaneous injections of 611 150 mg (for a total of 600 mg) on Day 1, followed by a 4-week observation period. Four subcutaneous injections of 611 150 mg (for a total of 600 mg) as a loading dose on Week 0 Day 29, followed by one 300 mg injection QW from Week 1 to Week 15 (15 cycles).
88965734|NCT05641168|Experimental|Ostomy Adhesive material|Newly designed ostomy adhesive material
88965735|NCT05641168|Other|comparator adhesive material|Adhesive material already on the market e.g adhesive material from SenSura Mio ostomy product
88965736|NCT05641090|Experimental|Nordic walking in water|The groups trained Nordic walking in water
88965737|NCT05641090|No Intervention|No exercise intervention|The groups did not receive exercise
88965738|NCT00000252|Sham Comparator|0% N2O|Subjects will inhale 0% N2O
88965739|NCT00000252|Active Comparator|10% N2O|Subjects will inhale 10% N2O
88965740|NCT00000252|Active Comparator|20% N2O|Subjects will inhale 20% N2O
88965741|NCT00000252|Active Comparator|30% N2O|Subjects will inhale 30% N2O
88965742|NCT00000252|Active Comparator|40% N2O|Subjects will inhale 40% N2O
88965743|NCT05641012||metastatic melanoma group|adult with metastatic melanoma treated by immunotherapy
88965744|NCT05640856||Group D|STOP BANG Score <3
88965745|NCT05640856||Group Y|STOP BANG Score ≥ 3
88965746|NCT05640817|Active Comparator|Group 1 as control group|cisplatin with standard hydration with normal saline
88965747|NCT05640817|Active Comparator|Group two as Pentoxifylline|receive cisplatin with standard hydration with normal saline and Pentoxifylline 400 mg SR tablets twice daily for three cycles.
89559309|NCT05004779|Experimental|human stem cell media apply lesion|human media apply after non ablative laser treatment
89559310|NCT05004779|Sham Comparator|control condition lesion|normal saline apply after non ablative laser treatment
88965748|NCT00000255|Placebo Comparator|0% Nitrous oxide|
88965749|NCT00000255|Active Comparator|10% nitrous oxide|
88965750|NCT00000255|Active Comparator|20% nitrous oxide|
88965751|NCT00000255|Active Comparator|30% nitrous oxide|
88965752|NCT00000255|Active Comparator|40% nitrous oxide|
88965753|NCT05640739|No Intervention|Control group patients|Data will be collected from the patients in the control group without any application and their ability to use MDI will be evaluated.
88965754|NCT05640739|Experimental|Demonstration group patients|Patients in the demonstration group will be given inhaler training (practically) by the researcher. The training will include steps compatible with the video. After the training, the patients will be asked to use inhaler drugs again, and their skill scores will be re-evaluated and the mistakes made by the patients will be shown by the researcher in the demonstration group. On the 7th day of the study, the patients will be called by the researcher with a video call, and the patients will be asked to use their MDI drugs again, and the MDI use skill chart will be filled again.
89026472|NCT01605994|Experimental|Panel 8:BMS-933043(25mg)/Placebo+Antacid Buffer Predose|"MAD Phase: Japanese Subjects. Cerebrospinal fluid (CSF) sampling not required~BMS-933043 25 mg solution by mouth twice daily for 10 days~OR~Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days~Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days"
89559311|NCT02331823|Experimental|arm A: super-short retreatment regimen|A regimen of 5 drugs is to be administered. Isoniazid Aminosalicylate Tablets,0.3g tid po for 5 mon moxifloxacin tab, 0.4g qd po for 5 mon rifabutin capsule,0.3g qd po for 5 mon ethambutol tab, 0.75g qd po for 5 mon pyrazinamide tab, 0.5g tid po for 5 mon
89559312|NCT02331823|Active Comparator|arm B:standardized retreatment regimen|8-9 months of standardized regimen is to be administered. regimen 1.2SHREZ/6HRE streptomycin injectable,0.75g qd intramuscular for 2 mon isoniazid tab,0.3g qd po for 8 mon rifampicin capsule,0.45-0.6g po for 8 mon ethambutol tab, 0.75g qd po for 8 mon pyrazinamide tab, 0.5g tid po for 2 mon or regimen 2.3HREZ/6HRE isoniazid tab,0.3g qd po for 9 mon rifampicin capsule,0.45-0.6g po for 9 mon ethambutol tab, 0.75g qd po for 9 mon pyrazinamide tab, 0.5g tid po for 3 mon
89026473|NCT01605994|Experimental|Panel 9:BMS-933043(200mg)/Placebo+Antacid Buffer Predose|"Japanese Subjects. CSF sampling not required.~BMS-933043 200 mg solution by mouth twice daily for 10 days~OR~Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days~Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days"
89559313|NCT05011097|Experimental|Y150|Subjects who meet the enrollment criteria will enter the core treatment period and receive a cycle of treatment with Y150 (once weekly for 4 weeks) via intravenous infusion. And eligible subjects who complete the core treatment period will receive a cycle of extended treatment (once weekly for 4 weeks) until disease progression or toxicity intolerance.
89559314|NCT02890459|Active Comparator|Aim 1 - Fixed Incentive|Fixed Incentive - Prize Prize incentive - Low Prize incentive - High
89559315|NCT02890459|Experimental|Aim 1 - Loss Aversion|Loss Aversion - Prize Prize incentive - Low Prize incentive - High
89559316|NCT02890459|Experimental|Aim 1 - Lottery|Lottery - Prize Prize incentive - Low Prize incentive - High
89559317|NCT02890459|Active Comparator|Aim 2 - Standard Care|Standard care Travel voucher
89559318|NCT02890459|Experimental|Aim 2 - Enhanced Care (Intervention)|Escalating payment incentive Travel voucher
89559319|NCT02890459|Experimental|Aim 3 Pilot - Loss Aversion|Loss Aversion - Deposit
89559320|NCT02890459|Experimental|Aim 3 Pilot - Fixed Incentive|Fixed Incentive - Voucher
89559321|NCT02890459|No Intervention|Aim 3 Pilot - No incentive|Participants will be encouraged to come for repeat HIV testing, but no incentive will be offered.
89559322|NCT02890459|Experimental|Aim 3 Trial - Loss Aversion|Loss Aversion - Deposit
89559323|NCT02890459|Experimental|Aim 3 Trial - Fixed Incentive|Fixed Incentive - Voucher
89559324|NCT02890459|No Intervention|Aim 3 Trial - No incentive|Participants will be encouraged to come for repeat HIV testing, but no incentive will be offered.
89559325|NCT03077009|Experimental|Treatment arm|Patients with confirmed plantaris friction syndrome will be offered hyaluronic acid injection into the space between the Plantaris and Achilles tendons
89559326|NCT02333773|Experimental|Group A|irreversible electroporation with voltage in level A for Unresectable Portal Venous Tumor Emboli
89559327|NCT02333773|Experimental|Group B|irreversible electroporation with voltage in level B for Unresectable Portal Venous Tumor Emboli
89559328|NCT02333773|Experimental|Group C|irreversible electroporation with voltage in level C for Unresectable Portal Venous Tumor Emboli
89559329|NCT05011175||Individuals with Parkinson's Disease|Individuals that have been diagnosed with Parkinson's Disease will be enrolled to participant in the survey research.
89559330|NCT02331979|Experimental|Stimulation of Non-Naive|Evaluate neuromodulation in 6 subjects with prior motor training.
89559331|NCT02331979|Experimental|Stimulation of Naive|Evaluate neuromodulation in 6 naive subjects.
89559332|NCT02331979|Experimental|Stimulation|Apply parameters discovered in Arm 1 and Arm 2 to evaluate neuromodulation in 12 naive subjects.
89559333|NCT03079817|Active Comparator|Proprioceptive Drills|Includes drills during which participants perform multiplestances on a pillow, a number of different cone and line drills, reaching drills, object retrieval drills and drills using balls to disturb balance.
89026474|NCT01605994|Experimental|Panel 10:BMS-933043(350mg)/Placebo+Antacid Buffer Predose|"BMS-933043 350 mg solution by mouth twice daily for 10 days~OR~Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days~Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days"
89026475|NCT01605994|Experimental|CSF Panel:BMS-933043(MTD)/Placebo+Antacid Buffer Predose|"If Panel 5 does not run. CSF Sampling at steady state~BMS-933043 maximum tolerated dose (MTD), solution by mouth twice daily for 10 days~OR~Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days~Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days"
89559334|NCT03079817|Experimental|Yoga Meditation|The meditation program will use simple poses during which the participant will not move and will concentrate on each of the participant's body parts and where they are in space.
89559335|NCT04477525|Experimental|ESP nerve block|
89559336|NCT04477525|No Intervention|Standard of Care|Standard of care includes IV opioids, NSAIDs (commonly ketorolac), +/- acetaminophen. No regional anesthesia will be given to control patients.
89559337|NCT03079973|Experimental|P-3073|
89559338|NCT03079973|Placebo Comparator|Vehicle|
89559339|NCT03076853||Patients with Pharmaceutical Record|
89559340|NCT05004545|Experimental|group 1 Profol Infusion to CABG patients to check lactate level|Propofol infusion according to bodyweight will be given to check lactate level on CPB
89559341|NCT05004545|Active Comparator|sevoflurane will be given to group 2 to check lacate level|Sevoflurane MAC % will be given to CABG patients to check lactate level
89559342|NCT03079895|No Intervention|Control Arm|After enrollment in the study, the subject will continue to receive treatment as usual for their depression from their primary care physician. They then will be asked to complete 2-month and 6-month assessments about their emotional well-being.
89559343|NCT03079895|Experimental|Intervention Arm|"After enrollment in the study, the subject will be granted 8 weeks of access to Thrive, an online self-help tool designed to assess for depressive symptoms and give therapeutic suggestions based on Cognitive Behavioral Therapy. During the first 4 weeks, they will receive 4 coaching emails and/or phone calls encouraging their participation in the study, and answering any program-related questions. The subject will also continue to receive treatment as usual for their depression from their primary care physician. They then will be asked to complete 2-month and 6-month assessments about their emotional well-being."
89559344|NCT05003999|Experimental|Intermittent catheterization starting with a hydrophilic catheter (HPC)|The investigators measure the time taken to perform intermittent catheterization using a 13 step pre-determined intermittent catheterization protocol using a hydrophilic catheter i.e. SpeediCath ® (Coloplast A/S, Humlebæk, Denmark)
89559345|NCT05003999|Active Comparator|Intermittent catheterization starting with a non-hydrophilic catheter (non-HPC)|The investigators measure the time taken to perform intermittent catheterization using a 13 step pre-determined intermittent catheterization protocol using a non-hydrophilic catheter i.e. Self-Cath ® (Coloplast A/S, Humlebæk, Denmark); Lubrication jelly (MUKO ®, 3.5g package, Cardinal Health Canada Inc, Toronto, ON, Canada) was provided
89559346|NCT02337439|Experimental|Sensory Information Processing Training|Computerized training designed to improve sensory processing
89559347|NCT02337439|Active Comparator|Active Control Training|Commercially available computer exercises that were not designed specifically to improve sensory information processing.
89559348|NCT05003765|No Intervention|Saline injection (CTRL)|Arm 1- 50 Patients-Control Group (CTRL): No Block (Saline) Post-operatively patients will receive 20 mL of Saline (on each side) between the pectoralis major and external intercostal muscle aponeurosis at 2 cm lateral to the right and left of the sternal edge, corresponding to the fifth rib.
89559349|NCT05003765|Experimental|SPIP Block|Arm 2-50 Patients-Post-operatively patients will receive bilateral SPIP blocks by injecting 20 mL of 0.25% bupivacaine (on each side) between the pectoralis major and external intercostal muscle aponeurosis at 2 cm lateral to the right and left of the sternal edge, corresponding to the fifth rib.
89559350|NCT05003765|Experimental|SPIP Block + Magnesium|Arm 3-50 Patients-Post-operatively patients will receive bilateral SPIP blocks by injecting 20 mL of 0.25% bupivacaine + 200mg of magnesium sulfate (on each side) between the pectoralis major and external intercostal muscle aponeurosis at 2 cm lateral to the right and left of the sternal edge, corresponding to the fifth rib.
89559351|NCT05003765|Experimental|SPIP Block + Magnesium + Buprenorphine|Arm 4-50 Patients-Post-operatively patients will receive bilateral SPIP blocks by injecting 20 mL of 0.25% bupivacaine+ 200mg of magnesium sulfate + buprenorphine (300mcg) (on each side) between the pectoralis major and external intercostal muscle aponeurosis at 2 cm lateral to the right and left of the sternal edge, corresponding to the fifth rib.
89559352|NCT05010863||Patients with early gastric cancer|
89559353|NCT05010863||Patients with advanced gastric cancer|
89559354|NCT05010863||healthy person|
89559355|NCT05010863||Patients with colorectal cancer|
89026476|NCT01606033|Other|phase II non randomized study|"phase II non randomized study, Case : 40 patients description of patients feeling by questionnaires :~Anxiety and depression questionnaire, life quality questionnaire, adjustment strategy questionnaire, emotional regulation questionnaire, satisfaction Survey~understanding of the implications of participating in a clinical trial"
89026477|NCT01606033|Other|blind randomized phase II or III study|"blind randomized phase II or III study: control : 40 patients description of patients feeling by questionnaires :~Anxiety and depression questionnaire, life quality questionnaire, adjustment strategy questionnaire, emotional regulation questionnaire, satisfaction Survey~understanding of the implications of participating in a clinical trial"
89559356|NCT05010863||Liver cancer patients|
89559357|NCT05010863||Breast cancer patient|
89026478|NCT01606033|Other|open randomized phase II or III study|"open randomized phase II or III study : 40 patients description of patients feeling by questionnaires : Anxiety and depression questionnaire, life quality questionnaire, adjustment strategy questionnaire, emotional regulation questionnaire, satisfaction Survey~-understanding of the implications of participating in a clinical trial"
89026479|NCT01606033|Other|receiving standard treatment|"receiving standard treatment : 120 patients description of patients feeling by questionnaires :~-understanding of the implications of participating in a clinical trial"
89026480|NCT00469586|Experimental|A|
89559358|NCT05010863||Patients with atrophic gastritis|
89559359|NCT05003375||Multiple Sclerosis (MS)|People with MS diagnosis, aged 18-55 years, Relapsing Remitting type, EDSS < 6.0, normal vision (if necessary corrected), Dutch speaking.
89559360|NCT05003375||Healthy Controls (HC)|Healthy controls without relevant health conditions (diabetes, thyroid diseases, neurological disorders), non-pregnant, aged 18-55 years, normal vision (if necessary corrected), Dutch speaking.
89559361|NCT05010239|Active Comparator|Intervention group|Patients in the intervention group will receive a 30-minute MBST session by a palliative care physician trained in mindfulness practice. The MBST consists of a session that involves interviewing patients with open-ended questions on suffering experiences. During the session, the practitioner will practice mindful breathing simultaneously while listening to patients. The practitioner will acknowledge the distress of patients when it is appropriate, but without losing their attention on mindful breathing. Outcomes will be measured at baseline and at minute 30.
89559362|NCT05010239|Placebo Comparator|Control group|Patients in the control group will receive a 30-minute supportive listening session by a palliative care physician who has no experience in mindfulness practice. The session involves interviewing patients with the same open-ended questions on suffering experiences. The practitioner will acknowledge the distress of patients when it is appropriate. Outcomes will be measured at baseline and at minute 30.
89559363|NCT03111589|Experimental|SCD patients under regular chronic exchange transfusion|Sickle cell disease patients (SCD) under regular chronic exchange transfusions. Pediatric and adult patients from the HUDERF and CHU-Brugmann Hospitals.
89559364|NCT03111589|Experimental|SCD patients under HU treatment alone|Sickle cell disease patients (SCD) under hydroxyurea (HU) alone. Pediatric and adult patients from the HUDERF and CHU-Brugmann Hospitals.
89559365|NCT03111589|Experimental|SCD patients under HU treatment+sporadic transfusion|Sickle cell disease patients (SCD) under hydroxyurea (HU) and receiving sporadic transfusions.Pediatric and adult patients from the HUDERF and CHU-Brugmann Hospitals.
89559366|NCT03111589|Active Comparator|Control group|Pediatric and adult patients from the HUDERF and CHU-Brugmann Hospitals.
89559367|NCT05003297||patients whom were hospitalized for 3 days or less|
89559368|NCT05003297||patients hospitalized for more than 3 days|
89559369|NCT02337283|Experimental|BI 425809 very low dose - part I|Part I only - very low dose tablet, oral administration with 240 ml water, over 14 days
89559370|NCT02337283|Placebo Comparator|Placebo - part I|Part I only - placebo tablet, oral administration with 240ml water, over 14 days
89559371|NCT02337283|Experimental|BI 425809 low dose - part I|Part I - low dose tablet, oral administration with 240 ml water, over 14 days
89559372|NCT02337283|Experimental|BI 425809 medium dose - part I|Part I only - medium dose tablet, oral administration with 240 ml water, over 14 days
89559373|NCT02337283|Experimental|BI 425809 high dose -part I|Part I only - high dose tablet, oral administration with 240 ml water, over 14 days
89559374|NCT02337283|Experimental|BI 425809 low dose - part II|Part II - one low dose tablet on day 1 of visit 2 and 2a
89559375|NCT02337283|Experimental|BI 425809 very high dose -part I|Part I only - very high dose tablet, oral administration with 240 ml water, over 14 days
89559376|NCT05010395|No Intervention|Control|Individuals in this arm did not receive a letter.
89559377|NCT05010395|Experimental|Arm 1: Basic Letter|Individuals received a letter with information about the benefits of enrolling, the February 15th sign-up deadline, the HealthCare.gov website, and the call center phone number.
89559378|NCT05010395|Experimental|Arm 2: Action|"Individuals in this arm received a letter that emphasized only minimal marginal effort is required; and used adjectives and verbs connoting action (e.g., almost done, quick, act now, and fast)."
89559379|NCT05010395|Experimental|Arm 3: Action, Implementation|Individuals in this arm received a letter similar to Arm 2, but with the addition of a calendar that draws attention to the February 15th deadline; and provided fill-in blanks in which the recipient can write the planned month, day, and time when they intend to enroll.
89559380|NCT05010395|Experimental|Arm 4: Action, Implementation, Picture|Individuals in this arm received a letter similar to Arms 2 and 3, but with the addition of an image of then HealthCare.gov Chief Executive Officer Kevin Counihan
89559381|NCT05010395|Experimental|Arm 5: Norm|"Individuals in this arm received a letter that included the following social norm sentence: Americans are enrolling but you haven't joined them."
89559382|NCT05010395|Experimental|Arm 6: Norm, Pledge|"Individuals in this arm received a letter that included a statement, to be checked in agreement, that I pledge to Get Covered at Healthcare.gov."
89559383|NCT05010395|Experimental|Arm 7: Loss Aversion|"Individuals in this arm received a letter that warned You risk paying a fee of $325 or 2% of your income-whichever is higher."
89559384|NCT05010395|Experimental|Arm 8: Kitchen Sink|Individuals in this arm received a letter that includes all behavioral dynamics except for the pledge (due to space limitations).
89559385|NCT02331433|Experimental|Experimental: 1|
89026481|NCT00469586|Experimental|B|
89559386|NCT02331433|Placebo Comparator|Placebo Comparator: 2|
89559387|NCT02327221|Active Comparator|Ovasave - Dose 10e4|
89559388|NCT02327221|Active Comparator|Ovasave - Dose 10e6|
89559389|NCT02327221|Active Comparator|Ovasave - Dose 10e7|
89559390|NCT02327221|Placebo Comparator|Placebo|
89559391|NCT02327065|Active Comparator|EUS-FNA Group|FNA,Fine needle aspiration
89559392|NCT02327065|Active Comparator|EUS-FNB Group|FNB,Fine needle biopsy
89559393|NCT02333539|Experimental|Tailored feedback|Participants are provided a Tailored Feedback report based on data downloaded from their insulin pumps. Summaries are provided about insulin pump adherence behaviors and recommendations for improvement are made.
89559394|NCT02333539|Experimental|Problem Solving|Participants receive a problem-solving session based on data downloaded from their insulin pumps. An insulin pump adherence behavior that needs improvement is targeted; goals are set and solutions generated.
89559395|NCT02333539|No Intervention|Treatment as Usual|Standard of care as provided by the endocrinologist occurs.
89559396|NCT02333617|Experimental|Dry Needling and Exercise|Dry Needling to treat gluteus medius trigger points followed by hip and core exercises.
89559397|NCT02333617|Active Comparator|Soft Tissue Mobilization|Soft tissue mobilization to treat gluteus medius trigger points followed by hip and core exercises.
89559398|NCT02333617|Placebo Comparator|Placebo Control|Placebo to control for hands on time and attention from therapist followed by hip and core exercises.
89559399|NCT02333305|Experimental|1|Coenzyme Q10 (CoQ10) - is a Dietary complement that contains Coenzyme Q10 (Ubidecarenone) well characterized nano particles.
89559400|NCT02333305|Placebo Comparator|2|Placebo of CoQ10 is a translucent nano-emulsion of well characterized nano particles. Lecithin (and) Alcohol (and) Glycerin (and) Aqua
89559401|NCT02326909|Experimental|optical coherence tomography|A single 1300 nm OCT measurement will be performed during ureterorenoscopy in patients with upper urinary tract tumour(s)
89559402|NCT02326987|Experimental|GLA5PR GLARS-NF1 tab.150mg(fasted)|GLA5PR GLARS-NF1 tab. 150mg/day(Pregabalin 150mg once a day)
89559403|NCT02326987|Experimental|GLA5PR GLARS-NF1 tab.150mg(after high fat meal)|GLA5PR GLARS-NF1 tab. 150mg/day(Pregabalin 150mg once a day)
89559404|NCT02326987|Active Comparator|Lyrica Capsule 75mg(after high fat meal)|Lyrica Capsule 150mg/day(Pregabalin 75mg twice a day)
89559405|NCT02039713||IRIS DeSyne|DeSyne drug eluting stent group
89559406|NCT03105037||Study group|CTM assessed with supraglottic airway in situ and without
89559407|NCT02333461|Placebo Comparator|Placebo|333 mg capsule comprised of silicified microcrystalline cellulose, magnesium stearate, modified cellulose gum, silicon dioxide, dextrose, corn starch, and caramel color. Consumed as six capsules once daily (total of 2 g/day) with the morning meal for a period of seven days.
89559408|NCT02333461|Experimental|Apple|333 mg capsule comprised of apple peel extract (115:1, standardized to 80% polyphenol and 5% phlorizin). Consumed as six capsules once daily (total of 2 g/day) with the morning meal for a period of seven days.
89559409|NCT02333461|Experimental|Grape|333 mg capsule comprised of grape extract (8000:1, standardized to 75% total polyphenol, 50% oligomeric proanthocyanidin). Consumed as six capsules once daily (total of 2 g/day) with the morning meal for a period of seven days.
89559410|NCT02333461|Experimental|Red Raspberry|333 mg capsule comprised of red raspberry leaf extract (4:1, standardized to 6% ellagic acid). Consumed as six capsules once daily (total of 2 g/day) with the morning meal for a period of seven days.
89559411|NCT02333461|Experimental|Apricot/Nectarine|333 mg capsule comprised of apricot/nectarine extract (40:1, standardized to 50% polyphenol).
89559412|NCT02332837|Experimental|Digital informed consent|"Traditional digitally signed text based informed consent~Intervention A: questionnaire accuracy Intervention B: Questionnaire speed of completion Intervention C: Questionnaire completion rate"
89559413|NCT02332837|Experimental|Multi-media informed consent|"Informed consent with images, text and auditory presentation~Intervention A: questionnaire accuracy Intervention B: Questionnaire speed of completion Intervention C: Questionnaire completion rate"
89559414|NCT02332837|Experimental|Test to train informed consent|"Informed consent with images, text, auditory presentation and test to train feature where participants get feedback on comprehension responses throughout the consent and can change them~Intervention A: questionnaire accuracy Intervention B: Questionnaire speed of completion Intervention C: Questionnaire completion rate"
89559415|NCT02326753|Experimental|No. 7 oral airway|
89559416|NCT02326753|Experimental|No. 8 oral airway|
89559417|NCT02326753|Active Comparator|No. 9 oral airway|
89559418|NCT02332993||Supplementation Group|15 Type 2 Diabetics receiving Negative Wound Pressure Therapy will receive the FPP supplementation to take 3 times a day for 12 weeks (3g/dose).
89559419|NCT02332993||Control Group|15 Type 2 Diabetics receiving Negative Wound Pressure Therapy will receive no supplementation for 12 weeks.
89559420|NCT03104881|Experimental|3D exoskeleton type robot|3 dimension exoskeleton type upper extremity robot
89559421|NCT03104881|Experimental|2D end-effector type robot|2 dimension end-effector type upper extremity robot
89559422|NCT02326675|Active Comparator|Cryotherapy Group (Group A)|Subjects in the intervention group will receive both standard oral care and cryotherapy. During the 30 minute cryotherapy periods, subjects will eat ice chips, and/or consume very cold or frozen foods. Cryotherapy will begin 15 minutes prior to the start time of each etoposide infusion. After 30 minutes of cryotherapy, subjects will begin the saline rinses. The subject should perform 3 saline rinses over 15 minutes. After 15 minutes of saline rinses, the 30-minute cryotherapy / 15-minute saline rinse cycles will be repeated until 30 min after completion of etoposide infusion (approximately 150 minutes). In addition, an oral care diary will be completed by the subject, and a daily oral assessment will be performed by the investigators.
89559423|NCT02326675|Active Comparator|Standard Oral Care Group (Group B)|Subjects in the control group will receive standard oral care only. At the beginning of each etoposide infusion, the subject will begin the saline rinses. The subject will perform 3 saline rinses over 15 minutes followed by 30 minutes of rest (no rinses). The 15-minute saline rinse / 30-minute rest cycles will be repeated until 30 minutes after the completion of the etoposide infusion (approximately 150 minutes). In addition, an oral care diary will be completed by the subject, and a daily oral assessment will be performed by the investigators.
89559424|NCT02331667|Experimental|Seafood|Intervention with meals consisting of seafood (herring and mackrell).
89559425|NCT02331667|Experimental|Non-seafood|Intervention with meals constisting of non-seafood (meat).
89559426|NCT02331511|Placebo Comparator|placebo|No antiplatelet drug
89559427|NCT02331511|Active Comparator|Aspirin|Aspirin 80 mg daily
89559428|NCT02331511|Active Comparator|Clopidogrel|Clopidogrel 75mg daily
89559429|NCT02326441|Experimental|KX2-361|
89559430|NCT03144271|Experimental|NNC 0113-0217|Dose-escalation trial
89559431|NCT03144271|Placebo Comparator|Placebo|Dose-escalation trial
89559432|NCT02332525|Experimental|Intervention|20 elders (10 mild cognitive impairment, 10 cognitive normal elders) those who received oral vibrational stimulation
89559433|NCT02039791|Experimental|Nimotuzumab plus chemoradiotherapy|
89559434|NCT06276296||PFA group|Patients undergoing pulsed field ablation
89559435|NCT06276296||RFA group|Patients undergoing radiofrequency ablation
89026482|NCT00469586|Active Comparator|C|
89559436|NCT06276283|Experimental|DZD9008 plus Bevacizumab|This single-arm study includes two parts (dose escalation [Part A] and dose expansion [Part B]).
89559437|NCT06276270|Experimental|Device is administered directly onto the area affected by mucositis.|
89559438|NCT06276257|Experimental|Paravertebral block|Preoperative paravertebral block on the side of mastectomy in addition to usual analgesia.
89559439|NCT06276257|Active Comparator|Usual analgesia|Usual analgesia, as per anesthesiologist's preferences.
89559440|NCT06276244||Congenital Myotonic Dystrophy (CDM)|"CDM group:~Age 0-17 years, 11 months of age~A diagnosis of CDM, which is defined as children having symptoms of myotonic dystrophy in the newborn period (&lt;30 days), such as hypotonia, feeding or respiratory difficulty, requiring hospitalization to a ward or to the neonatal intensive care unit for more than 72 hours; and a genetic test confirming an expanded trinucleotide (CTG) repeat in the DMPK gene in the child or mother. An expanded CTG repeat size in the child is considered greater than 200 repeats or E1-E4 classification (E1= 200-500, E2=500-1,000, E3=1,000-1,500, E4&gt;1,500)."
89026483|NCT01606111|Placebo Comparator|0.9% NaCl, saline|
89559441|NCT06276244||Childhood Muscular Dystrophy (ChDM)|"ChDM group:~Age 0-17 years, 11 months of age~A diagnosis of ChDM, which is defined as children having symptoms of myotonic dystrophy after day 30 from birth. These may include any delay in psychomotor development, attention deficit disorder, behavioral abnormalities within the spectrum of autistic spectrum disorders, gastrointestinal dysfunction such as persistent constipation or diarrhea and gastroesophageal reflux; and a genetic test confirming an expanded trinucleotide (CTG) repeat in the DMPK gene in the child or mother. An expanded CTG repeat size in the child is considered greater than 200 repeats."
89559442|NCT06276218|Experimental|self-adjustable clavicular brace|
88965755|NCT05640739|Experimental|Video group patients|The patients in the video group will be shown the video of using MDI prepared by the researchers. The training will be completed by watching the MDI usage video prepared by the researchers in the patients in the video group. After the training, the patients will be asked to use the inhaler again and their skill scores will be re-evaluated. Their mistakes will be shown by making them watch it again from the video. On the 7th day of the study, the patients will be called by the researcher with a video call, and the patients will be asked to use their MDI drugs again, and the MDI use skill chart will be filled again.
89559443|NCT06276218|Active Comparator|standard clavicular brace|
89559444|NCT06276205|Experimental|Vitamin D + Levothyroxine|
89559445|NCT06276205|Active Comparator|Levothyroxine Alone|
89559446|NCT06276192|Experimental|Digital Physiotherapy (diSAID)|The digital physiotherapy group receives the digital Shoulder Aid (diSAID) strategy available via a web application. For three months, this group will complete a home-based rehabilitation programme containing education and evidence based exercises for patients with subacromial pain tutored by videos, images and instructions.The treatment is standardized but can be customized by a responsible physiotherapist during the whole treatment period. The Physiotherapist also deliver progression in the education and in the exercises during the whole treatment period and can support the patient via a messenger function in the web application.
89559447|NCT06276192|Active Comparator|Traditional Physiotherapy|The traditional physiotherapy group receives current practice provided by physiotherapist in primary care with no predefined directives. The treating physiotherapist are instructed to treat their patient as they usually do.
89559448|NCT06276114||Consecutive patients with stent underexpantsion treated with IVL|
89559449|NCT06276114||Consecutive patients with stent underexpantsion treated ELCA|
89559450|NCT06276101|Experimental|NWRD08 administered by electroporation|Patients will be assigned to three dose groups:1mg, 4mg, and 8mg. Each patient will be administered NWRD08 by electroporation in entire study period. The Maximum Tolerated Dose of NWRD08 will be determined by the classical 3+3 dose escalation schedule. The number of patients will be ranged from 9 to 18.
88965756|NCT00000258|Active Comparator|Informed group|Group inhaled placebo and varying doses of nitrous oxide in pairs then chose which they wanted for a third inhalation.
88965757|NCT00000258|Active Comparator|Non-informed Group|Group and technician were blinded as to which gas they were inhaling in pairs with third inhalation subject's choice.
88965758|NCT05640544|Experimental|Sound and light stimulation in Gamma band|
88965759|NCT05640505|Experimental|Experimental|This group received 03 gratitude interventions for 4 weeks
88965760|NCT05640505|No Intervention|Control Group|This group did not receive any intervention during active phase. Only the scores on dependent variables were measured. After completion of study, the same interventions were repeated with this group.
88965761|NCT05640427|Placebo Comparator|Group C|Group C received general anesthesia with intravenous normal saline. The cognitive function of this groups was assessed with the Mini Mental State Scale (MMSE) on the day before surgery. the anxiety of this groups was assessed with Self-rating Anxiety Scale (SAS) on the day before, one day after and three days after surgery.
88965762|NCT05640427|Experimental|Group D1|groups D1 received general anesthesia with intravenous pump of 0. 2μg/kg/h dexmedetomidine. The cognitive function of this groups was assessed with the Mini Mental State Scale (MMSE) on the day before surgery. the anxiety of this groups was assessed with Self-rating Anxiety Scale (SAS) on the day before, one day after and three days after surgery.
88965763|NCT05640427|Experimental|Group D2|groups D2 received general anesthesia with intravenous pump of 0. 5μg/kg/h dexmedetomidine. The cognitive function of this groups was assessed with the Mini Mental State Scale (MMSE) on the day before surgery. the anxiety of this groups was assessed with Self-rating Anxiety Scale (SAS) on the day before, one day after and three days after surgery.
88965764|NCT03312868|Experimental|Prospective Arm|Prospective arm with patients being treated with SBRT
88965765|NCT05640388||RV3278A arm : Treated group|This group will receive the RV3278A - ET0943 product
88965766|NCT05640388||RV4632A arm : Control group|This group will receive the RV4632A - RY1845 product
89559451|NCT06276075|Experimental|Conventional rehabilitation|patients performed daily physiotherapy, which included intensive preparatory training for standing and sitting positions, strengthening exercises, weight-bearing exercises, and balance and coordination exercises (from 40 to 60 minutes of therapy).
88965767|NCT05640349||Case|Patients with positive blood culture recorded at the microbiology laboratory of University Hospital of Nice during the Covid-19 Pandemic lockdown (between 23/03/2020 and 24/05/2020).
88965768|NCT05640349||Control|Patients with positive blood culture recorded at the microbiology laboratory of University Hospital of Nice between 23/03/2019 and 24/05/2019.
88965769|NCT05640154|Experimental|Educational program|aged patients 60 years and more, able to communicate, diagnosed with hypertension, diabetes mellitus and cardiac diseases. they will receive the nursing educational program which will be implemented in small groups from (5-7) in outpatient clinics. It includes nutrition, exercise, control hypertension , engage in weight control measures, smoking cessation, stress management, breathing exercise, appropriate treatment of diseases, control of diabetes, control of cholesterol in blood and routine follow up).also they will receive health-promoting lifestyle that includes (spiritual growth, interpersonal relations, nutrition, physical activity, health responsibility and stress management).
88965770|NCT05640154|No Intervention|control group|aged patients 60 years and more, able to communicate, diagnosed with hypertension, diabetes mellitus and cardiac diseases. the will not receive educational program and life style promotion.
88965771|NCT03295747|Experimental|180 mg|180 mg of peppermint oil
89559452|NCT06276075|Experimental|Erigo®Pro|effective therapy included 1 session on a tilting table at an angle of 42° for 20 minutes, 5 times a week (Monday to Friday) at a speed of 32 steps per minute, followed by a physiotherapy session for two weeks.
89559453|NCT06276075|Experimental|motor imagery (MI)|in addition to conventional physiotherapy, activity imagery during passive walking on the Erigo®Pro table was introduced. During the exercises on the table, the patients wore headphones that blocked out any external sounds, closed their eyes and their task was to imagine the sensation of their body moving (first-person imagination), differentiating the idea of walking in various real environments (park, forest, beach, snow, streets). in the city, walking at different speeds, going up and down stairs, running, etc.)
89559454|NCT06276049|Experimental|Intervention group|Engage in 12 weeks of SDL task-based training with LearnGuide&#39;s support.
89559455|NCT06276049|No Intervention|control group|the control group engaged in SDL task-based training without the support of LearnGuide or any similar artificial intelligence (AI) assistance.
89559456|NCT06275997|No Intervention|Parallel arm 1|patients will undergo standard high-definition and high-quality upper-GI endoscopy for the detection of gastric lesions with histological mapping according to Sydney system
88965772|NCT03295747|Experimental|360 mg|360 mg of peppermint oil
88965773|NCT03295747|Experimental|540 mg|540 mg of peppermint oil
88965774|NCT05639998|Experimental|Group 1(COVAXIN® + COVAXIN®)|"Group 1 (COVAXIN® + COVAXIN®):~In this group, 152 participants will be recruited who will receive COVAXIN® on day 0 and on day 28 via the intramuscular route"
89559457|NCT06275997|Active Comparator|Parallel arm 2|patients will undergo high-definition and high quality upper-GI endoscopy with real-time assistance by real-time artificial intelligence for the detection of early gastric cancer and gastric dysplasia.
89559458|NCT06275997|Other|Cross-over arm 1 (control)|patients will undergo two standard high-definition and high-quality upper-GI endoscopies in tandem: the first will be without Artificial Intelligence assistance, and the second with Artificial Intelligence in order to define the miss rate for standard unassisted upper-GI endoscopy.
89559459|NCT06275997|Active Comparator|Cross-over arm 2|patients will undergo two standard high-definition and high-quality upper-GI endoscopies in tandem: the first will be with Artificial Intelligence assistance, and the second without Artificial Intelligence in order to define the decrease of miss rate when assistance by Artificial Intelligence is implemented.
89559460|NCT06275984|Other|Online training|Participants will perform an online training in CPR-AED
89559461|NCT06275971|Experimental|CGM arm|Glycemic control was monitored using CGM data for seven days following cardiac surgery
89559462|NCT06275971|Active Comparator|SMBG or venous/arterial glucose arm|Glycemic control was monitored using SMBG or venous/arterial glucose data for seven days following cardiac surgery
89559463|NCT06275958|Active Comparator|Doublet therapy, full dose (low toxicity risk based on G8)|Low risk of toxicity: G8-score of 15 or higher
89559464|NCT06275958|Experimental|Doublet therapy, dose-reduced (low toxicity risk based on G8)|Low risk of toxicity: G8-score of 15 or higher
89559465|NCT06275958|Active Comparator|Fluoropyrimidine monotherapy, full dose (high toxicity risk based on G8)|"High risk of toxicity: G8-score of 14 or lower or judged as high toxicity risk by their treating oncologist"
89559466|NCT06275958|Experimental|Fluoropyrimidine monotherapy, dose-reduced (high toxicity risk based on G8)|"High risk of toxicity: G8-score of 14 or lower or judged as high toxicity risk by their treating oncologist"
89559467|NCT06275945|Experimental|Voro Urologic Scaffold Group|"Subjects undergo radical prostatectomy procedure as part of their stand of care treatment for their prostate cancer. The Voro Urologic Scaffold is placed during the prostatectomy procedure after prostate removal. The device is placed over the urethral stump in its compressed configuration. With the device compressed at the pelvic floor, the urethral stump is anastomosed with the bladder neck. The device is expanded and positioned over the anastomosed urethra and bladder neck. The distal end of the device is sutured in place and the proximal end of the device is sutured to the bladder.~The time of Voro Urologic Scaffold insertion and time of completion of device placement (i.e., final sutures placed) will be recorded.~Incision closure will proceed per institution standard of care for the radical prostatectomy procedure."
89559468|NCT06275932|Experimental|Interventional group|All the enrolled newborns will make the skin-to-skin contact with the use of a thermal blanket after birth.
89559469|NCT06275932|Active Comparator|Standard of care group|All the enrolled newborns will make the skin-to-skin contact according to local procedure after birth.
89559470|NCT06275906|Experimental|Intervention arm 1|"The 1st arm involves a low-calorie diet, which respects the criteria of the Mediterranean diet, with the following macronutrient percentage: carbohydrates 50% of total calories, lipids 30% of total calories, proteins 20% of total calories.~The dietary intervention will be combined with moderate intensity exercise (outdoor walking)."
89559471|NCT06275906|Experimental|Intervention arm 2|"The 2nd arm involves a low-calorie diet, which respects the criteria of the Mediterranean diet, with the following percentage of macronutrients: carbohydrates 30% of total calories, lipids 50% of total calories, proteins 20% of total calories.~The dietary intervention will be combined with moderate intensity exercise (outdoor walking)."
89026484|NCT01606111|Experimental|Cerebrolysin|
89026485|NCT01606267|No Intervention|Routine HEP|This arm includes routine care provided under the health extension program provided to rural Ethiopian villages with limited access to health facilities.
88965775|NCT05639998|Experimental|Group 2(COVAXIN® + BBV154)|"Group 2 (COVAXIN® + BBV154):~In this group, 152 participants will be recruited who will receive COVAXIN® (Intramuscular) on day 0 and BBV154 (Intranasal) day 28.~*Post 56 days of vaccination, participants with seroconversion rate less than 3 folds will receive another dose of COVAXIN® via intramuscular route"
88965776|NCT05639998|Experimental|Group 3(BBV154 + COVAXIN®)|"Group 3 (BBV154 + COVAXIN®):~In this group, 152 participants will be recruited who will receive BBV154 (Intranasal) on day 0 and COVAXIN® (Intramuscular) on day 28.~*Post 56 days of vaccination, participants with sero-conversion rate less than 3 folds will receive another dose of COVAXIN® via intramuscular route"
88965777|NCT05639998|Experimental|Group 4(BBV154 + BBV154)|"Group 4 (BBV154 + BBV154):~In this group, 152 participants will be recruited who will receive BBV154 on day 0 and on day 28 via the intranasal route."
88965778|NCT05639959||Commercial product group|group who are taking commercial nasal spray products
88965779|NCT05639959||New formulation product group|who are taking new formulation nasal spray product with same strength
88965780|NCT05639920||Group A|
89559472|NCT06275893|Experimental|IC14 (atibuclimab)|IC14 (atibuclimab) 20 mg/kg intravenously every 3 weeks for 12 weeks (4 doses)
89559473|NCT06275880|Experimental|GROUP A|Patients who received intra-articular infiltration of PVP Collagen
89559474|NCT06275880|Active Comparator|GROUP B|Patients who received conservative treatment through rehabilitation with a home program for one month
89559475|NCT06275867|No Intervention|Control group|In this group, participants will have free access to government facilities (usual care)
89559476|NCT06275867|Experimental|Convenient group|In this group, for the duration of the study, participants will be given free access to a small number of private providers located relatively close by (less than 30 minutes).
89559477|NCT06275867|Experimental|Inconvenient group|In this group, for the duration of the study, participants will be given free access to a small number of private providers located relatively far (about one hour).
89559478|NCT06275828|No Intervention|control|
89559479|NCT06275828|Experimental|intervention|
89559480|NCT06275815|No Intervention|Untreated Control|Caregivers read to child as usual over 15 week period.
89559481|NCT06275815|Experimental|STAR Only|Typical implementation of Sit Together and Read (STAR)
89559482|NCT06275815|Experimental|STAR + Reward|Typical implementation of Sit Together and Read (STAR) plus additional small monetary incentives for caregivers
89559483|NCT06275815|Experimental|STAR + text encouragement|Typical implementation of Sit Together and Read (STAR) plus caregivers receive encouraging text messages
89559484|NCT06275802|Experimental|Intervention schools (educated about nutrition)|The research will be conducted in six high schools, three of which are intervention schools . Schools in the district will be divided into 3 layers as 1- Anatolian High Schools, 2- Technical and Vocational High Schools, 3- Imam Hatip High Schools.
89559485|NCT06275802|Sham Comparator|Control schools (non-educated about nutrition)|The research will be conducted in six high schools, three of which are control schools. Schools in the district will be divided into 3 layers as 1- Anatolian High Schools, 2- Technical and Vocational High Schools, 3- Imam Hatip High Schools, and a control school will be determined from each layer by means of a random numbers table
89559486|NCT06275789|Experimental|Test Group|This group will receive the grafting material that is a combination of DFDBA + DBBM + collagen matrix seal during the alveolar ridge preservation procedure.
89559487|NCT06275789|Active Comparator|Control Group|This group will receive the grafting material that is a Tutoplast® processed mineralized particulate allograft + collagen matrix seal during the alveolar ridge preservation procedure.
89559488|NCT06275763|Experimental|Eplerenone (+placebo of Spironolactone and placebo of Torasemide)|Phase C. Participants randomly assigned to this arm take Eplerenone and placebos of Spironolactone and Torasemide
89559489|NCT06275763|Experimental|Spironolactone (+placebo of Eplerenone and placebo of Torasemide)|Phase C. Participants randomly assigned to this arm take Spironolactone and placebos of Eplerenone and Torasemide
89559490|NCT06275763|Experimental|Torasemide (+placebo of Eplerenone and placebo of Spironolactone )|Phase C. Participants randomly assigned to this arm take Torasemide and placebos of Eplerenone and Spironolactone
89559491|NCT06275763|Active Comparator|Open-label|Phase B Replacement of ineffective antihypertensive treatment based on 3 or more antihypertensive drugs (single or dual drug preparations) with a triple single pill combination (SPC) based on optimally combined antihypertensive drugs: perindopril + indapamide + amlodipine (P+I+A) or olmesartan + hydrocholothiazide + amlodipine (O+H+A).
89559492|NCT06275763|Other|Screening|Phase A. Confirmation of the true ineffectiveness of antihypertensive therapy based on 3 or more antihypertensive drugs (single or dual drug preparations) using ABPM and home BP measurements.
89608732|NCT03588117||Participants of a weight management program|Participants of a physician-supervised nonsurgical weight management program were observed as they received weekly in-person coaching sessions with licensed clinicians. In-person coaching sessions were focused on educating participants on strategies to manage their weight and adopt a healthy lifestyle. Prescribed diets were individualized based on each participant's behavior, level of physical activity, and total energy expenditure. Supplements, appetite suppressant medications, and compounded injections were used to control appetite and/or boost energy during a period of low-caloric intake. The program was generally divided into three phases: Acute, Short-Term Maintenance, and Wellness.
89608733|NCT03545607|Experimental|MultiStem|1.2 billion cells
89608734|NCT03545607|Placebo Comparator|Placebo|
88965781|NCT03575208|Experimental|HBIG followed by Peginterferon alfa-2a|HBIg x 12 weeks followed by peginterferon alfa-2a 180mcg x 24 weeks
88965782|NCT03575208|Active Comparator|Peginterferon alfa-2a|Peginterferon alfa-2a 180mcg x 24 weeks
88965783|NCT03295552|Experimental|DC|DNA demethylating agent decitabine plus carboplatin
88965784|NCT05637541|Experimental|Low-dose group|Drug 1 is a vial of 130 tablets of the experimental drug, and drug 2 is a vial of 130 tablets of the placebo
88965785|NCT05637541|Experimental|High-dose group|Drug 1 and 2 are each a vial of 130 tablets of the experimental drug
88965786|NCT05637541|Placebo Comparator|Placebo group|Drug 1 and drug 2 are each a vial of 130 tablets of the placebo
88965787|NCT05634187||Patients suffering from symptoms suggestive for gastroesophageal reflux disease|Patients suffering from dysphasia, heartburn, laryngitis or pharyngitis suggestive for gastroesophageal reflux disease
88965788|NCT05632744|Experimental|CG-100 Intraluminal Bypass Device|Subjects will be treated with CG-100 Intraluminal Bypass Device
88965789|NCT05631379||All patients meeting inclusion criteria|All patients meeting inclusion criteria
88965790|NCT05631379||Subgroup of patients with available preoperative CT/MRI scans|Subgroup of patients with available preoperative CT/MRI scans will be detected and body composition measurements will be assessed min order to detect nutrition-related syndromes
88965791|NCT05629468|Active Comparator|Azithromycin and Topical|group A (n=25) received tab. azithromycin 250mg oral on alternate days and topical cream benzoyl peroxide 4% twice a day daily for a period of 3 months
88965792|NCT05629468|Experimental|Probiotics and Topical|group B (n=25) received Probiotic sachet oral once a day everyday and topical cream benzoyl peroxide 4% twice a day daily for a period of 3 months
88965793|NCT05629468|Other|Azithromycin and Probiotics and Topical|combination group C (n=25) received tab. azithromycin 250mg oral on alternate days, Probiotic sachet oral once a day everyday and topical cream benzoyl peroxide 4% twice a day daily for a period of 3 months
89559493|NCT06275750|Experimental|Patients treated with non-surgical spinal decompression|The patients were positioned in supine with adjustable lumbar, and thoracic belts attached to the traction cord. After tightening the belts, the M7 position was selected to achieve hip and knee flexion, and posterior pelvic tilt of 25° was added. Before starting the therapy, the weight of the subject was entered in the panel, and a short tolerance test was carried out. Patients were provided with a manual switch to stop treatment any time. Preset lumbar disc herniation protocol was used. Each session lasted fifteen minutes, applied force had 100-gram step increments, and did not exceed 50% of the weight of the patient. At the end of the therapy, the cord was disconnected and belts were removed. Participants were asked to sit for three minutes to identify any adverse reaction.
89559494|NCT06275737|Other|Cohort 1 and Cohort 2|"Cohort 1 - Patients with PDAC~Cohort 2 - Patients with OGC"
88965794|NCT00000378|Active Comparator|sertaline|patients randomized to sertraline 12 week trial does up to 200mgs
88965795|NCT00000378|Active Comparator|nortriptyline|patients randomized to nortriptyline dose adjusted to therapeutic level
89559495|NCT06275711|Experimental|Therapeutic communication|Therapeutic communication methods were applied. Pre-test and post-test measurements were made
89559496|NCT06275698|Experimental|Treatment|Manuka honey, 15ml, three times a day, for 14 days. To be kept on the tongue for at least 10 seconds prior to swallowing.
89559497|NCT06275698|Placebo Comparator|Placebo|"Sugar-based syrup, thickened with sodium alginate and flavoured with honey flavouring, 15ml, three times a day, for 14 days.~To be kept on the tongue for at least 10 seconds prior to swallowing."
88965796|NCT05618041|Experimental|CAR-T Autologous T cell injection|Patients will be treated with CAR-T cells
88965797|NCT05631925|Active Comparator|Group bolus|Propofol will be administered in bolus doses of 0.5mg/kg. Doses will be determined according to the clinical condition of the patient.
88965798|NCT05631925|Active Comparator|Group infusion|Propofol will be administered as 10mg/kg/hour infusion. The infusion dose will be adjusted so that the Bispectral index (BIS) is in the range of 40-60.
89559498|NCT06275685|Active Comparator|Control|The control arm will receive multi-day visualizations of their sensor derived data but not receive SeizureWise
89559499|NCT06275685|Experimental|Personalized seizure risk score|The personalized seizure risk score arm will receive multi-day visualization of their sensor derived data and also SeizureWise, an investigational algorithm which enables forecasting of future seizure probabilities based on the pattern and frequency of previous generalized tonic-clonic seizure (GTCS) events, as well as changes in physiological and behavioral variables
89559500|NCT06275672|Active Comparator|Cohort 1|An Ugandan adapted version of the mhGAP-IG child and adolescent mental health module will be used for identification, assessment, and management of common mental disorders in children and adolescents at primary schools.
88965799|NCT05611606||DanFunD baseline|"Data from the DanFunD baseline cohort will be included (11). It comprises a total of 9,656 (33.7% of the invited participants) men and women aged 18-76 years born in Denmark and living in the Western part of greater Copenhagen.~Individuals with FSD are identified by means of self-reported questionnaires (n=9,656) (2) and diagnostic research interviews (n=1,590) (12).~Participants with FSD will be defined as follows:~FSD operationalised by the Bodily Distress Syndrome single- and multi-organ type will be defined with both self-reported questionnaires (14) and diagnostic interviews (3)~Three functional somatic syndromes, i.e. irritable bowel (15), chronic widespread pain (16), and chronic fatigue (17) will be defined with questionnaires.~Severe physical disease will be defined as having received at least one of the following five diagnoses: Cancer, stroke, myocardial infarction, other heart disease, and obstructive pulmonary disease."
88965800|NCT05606926|Other|Group I|15 Children with spastic diplegia in this group will a designed physical therapy program for 60 minutes per session in addition to WBV for 10 minutes, three times a week, for three consecutive months.
88965801|NCT05606926|Experimental|Experimental group|15 Children with spastic diplegia in this group will receive the same designed physical therapy program while WBV will be conducted while wearing a weighted vest.
88965802|NCT05601778|Experimental|HSK31858 20mg|multiple oral doses: 20mg/d for 24w
88965803|NCT05601778|Experimental|HSK31858 40mg|multiple oral doses: 20mg/d for 24w
88965804|NCT05601778|Placebo Comparator|placebo|multiple oral doses for 24w
88965805|NCT00000408|Experimental|email discussion group|
88965806|NCT00000408|No Intervention|rancomized control group|usual care
88965807|NCT00000411|Active Comparator|Surgery|Decompressive laminectomy
88965808|NCT00000411|Active Comparator|Non-surgical treatments|Active physical therapy modality, Education/Counseling with home exercise instruction, and an NSAID if tolerated
89559501|NCT06275672|Active Comparator|Cohort 2|Same as arm 1
89559502|NCT06275672|Active Comparator|Cohort 3|Same as arms 1-2
89559503|NCT06275672|Active Comparator|Cohort 4|Same as arms 1-3
89559504|NCT06275672|Active Comparator|Cohort 5|Same as arms 1-4
89559505|NCT06275672|Active Comparator|Cohort 6|Same as arms 1-5
89559506|NCT06275646|Experimental|A dartos flap and PRP layer|dartos flap and PRP layer was applied in hypospadias surgery as additional layer
89559507|NCT06275646|Experimental|preputial dartos flap layer|preputial dartos flap layer applied as additional layer
89608735|NCT04148235||Patients|Patients who have been diagnosed with Celiac Disease
89559508|NCT06275633|Experimental|Effect of levodopa|"Patients with PD are first being tested off medication~After examination OFF, the same group is being tested after adm of 200 mg Madopar Q"
89559509|NCT06275607|Experimental|Cognitive Behavioral Affective Therapy|Group receiving CBAT.
89559510|NCT06275607|Placebo Comparator|Emotional Education|Group receiving general emotion psychoeducation.
89559511|NCT06275594|Experimental|Remimazolam|American Society of Anesthesiologists (ASA) I-II: initial dosing 5mg, maintenance dosing: 2.5mg, interval ≥2minutes ASA III: initial dosing 2.5mg, maintenance dosing: 1.25mg, interval ≥2minutes Remimazolam dose limitation: none Fentanyl: 25-50mcg, interval ≥5mintues, max: 200mcg
89559512|NCT06275594|Active Comparator|Real world Midazolam|Initial dosing 2-3mg, maintenance dosing: 0.5-1mg, interval ≥2minutes Remimazolam dose limitation: 7.5mg Fentanyl: 25-50mcg, interval ≥5mintues, max: 200mcg
89559513|NCT06275594|Active Comparator|On label Midazolam|"<60years old and healthy: initial dosing 1.75mg, maintenance dosing: 1.0mg, interval ≥2minutes~≥60years old or debilitated/chronically ill: initial dosing 1.0mg, maintenance dosing: 0.5mg, interval v2minutes Remimazolam dose limitation: 7.5mg Fentanyl: 25-50mcg, interval ≥5mintues, max: 200mcg"
89559514|NCT06275581|Experimental|Ketac Universal test group|intra-individual (split-mouth) study
89559515|NCT06275581|Active Comparator|Ketac Molar Quick control group|intra-individual (split-mouth) study
89559516|NCT06275568|Active Comparator|Usual care Fresh Connect cardholder engagement|
89559517|NCT06275568|Experimental|Usual care Fresh Connect cardholder engagement plus Enhanced engagement communication|
89559518|NCT06275542|Experimental|Clinical extubation strategy without TOF monitoring|Extubation without TOF monitoring strategy: the administration of neostigmine reversal with a dose based on the degree of blockade without TOF monitoring, and extubation is performed at least 15 minutes after reversal if the patient can maintain SpO2 > 95% for 3 minutes after receiving room air without oxygen supplementation.
88965809|NCT05582746|Other|COVID-19 mHealth Intervention|We are using a pre-post study design, given the low risk of the educational intervention and expected benefit.
88965810|NCT00000414|Experimental|Arthritis Self-Management Program|small group self-management program
88965811|NCT00000414|Experimental|SMART Program|Self-Managed Arthritis Relief Therapy: mailed self management material
88965812|NCT05563792|Experimental|OPTIONS Intervention Coaching|Intervention participants will participate in a series of four coaching sessions focused on helping patients clarify their values and treatment goals, aligning these values and goals and their lifestyle with nonpharmacological treatment options, working on overcoming barriers to use and adherence of nonpharmacological treatment options (using motivational interviewing), and preparing patients to discuss these options with their primary care providers. A decision aid will be used during these coaching sessions.
88965813|NCT05563792|No Intervention|OPTIONS Waitlist Control|Participants randomized into waitlist control group will receive the intervention decision aid after completing the last survey at 9 months. Participants will also be offered the opportunity to have a brief 20-minute session with a member of the OPTIONS study staff to help walk them through this decision aid.
88965814|NCT05530174|Experimental|Treatment A, Single-dose practice|"One preoperative single dose of either Dicloxacillin/Cloxacillin 2g OR Cefuroxime 1.5g administered intravenously prior to surgical incision.~As the study is a non-inferiority trial, we have chosen the Experimental design category."
88965815|NCT05530174|Active Comparator|Treatment B, Multiple-dose practice|One preoperative dose of either Dicloxacillin/Cloxacillin 2g OR Cefuroxime 1.5g administered intravenously prior to surgical incision followed by 3 postoperative doses of Dicloxacillin/Cloxacillin 1g x 3 OR Cefuroxime 750mg x 3 within 24 hours after the preoperative dose.
88965816|NCT05519683|Experimental|TEA at location A|The TEA device administers a mild electrical shock through the skin, similar to acupuncture. Stimulation will be performed twice daily, morning and evening for 45 minutes for 8 weeks. Location sets are described in the protocol, which will be shared with results reporting but are not provided here to maintain masking and, therefore, to safeguard scientific integrity.
89026486|NCT01606267|Experimental|HEP+ICCM|This arm includes routine care provided under the Health Extension Program plus the HEWs will be assessing and treating childhood pneumonia cases in rural Ethiopian villages with limited access to health facilities.
89559519|NCT06275542|Active Comparator|Clinical extubation strategy with TOF monitoring|Extubation with quantitative TOF monitoring strategy: neostigmine reversal dosing is determined based on the degree of blockade observed through quantitative TOF monitoring, and extubation is performed when the measured TOF ratio is ≥ 0.90.
89559520|NCT06275529|Experimental|MSU Classification 1A|Transforaminal Epidural Steroid Injection, MSU classification according to MRI images 1A
89559521|NCT06275529|Experimental|MSU Classification 1B|Transforaminal Epidural Steroid Injection, MSU classification according to MRI images 1B
89559522|NCT06275529|Experimental|MSU Classification 1C|Transforaminal Epidural Steroid Injection, MSU classification according to MRI images 1C
89026487|NCT01342510|Experimental|Lidocaine|Lidocaine 50 mg in a 10 cc syringe
89026488|NCT01342510|Experimental|Magnesium|Magnesium sulfate 0.25 g (2 mOsmol) in a 10 cc syringe
89026489|NCT01342510|Experimental|Lidocaine/Magnesium|Lidocaine 50 mg and 0.25 g (2 mOsmol) magnesium sulfate in a 10 cc syringe
89026490|NCT01342510|Placebo Comparator|Control|0.9% saline in a 10 cc syringe
89026491|NCT01606345|Experimental|Phase I Dose Escalation|Dose escalation: 200 mg/75 ml effluent, 400 mg/75 ml effluent, 800 mg/75 ml effluent
89026492|NCT01244022||Colorectal cancer patients|Patients with pathohistologically verified colorectal cancer or adenoma with epithelial dysplasia
89026493|NCT01245894|Active Comparator|Low-dose Rosuvastatin|5mg Rosuvastatin/day
89026494|NCT01245894|Active Comparator|High-dose Rosuvastatin|Rosuvastatin 40mg/day
89026495|NCT01316367|Active Comparator|Conventional Health Promotion Education (CHPE).|The CHPE model was defined according to the recommendations of the Spanish Ministry of Health National Conference on Diabetes Mellitus, which was complemented by criteria for good care of the Madrid Primary Healthcare Service for the promotion of healthy lifestyles among adults (2004-2007). The model is based on the following aspects: self-monitoring of glycaemic control, physical exercise, diet, weight management, and times of the day when the patient was most vulnerable to overeating, and given improved understanding of the relative effects of certain food choices on blood glucose control, medication adherence and smoking cessation.
89026496|NCT01316367|Experimental|PRECEDE HPE model|
89026497|NCT01244100|Experimental|PL2200|
89026498|NCT04697888|Experimental|Overall Study|Use of Omegaven for patients with parenteral nutrition associated liver disease.
89026499|NCT01340872|Experimental|ST10|ST10 (Ferric Maltol) 30mg capsules, taken orally twice a day
89026500|NCT01340872|Placebo Comparator|Placebo|Matching placebo capsules for ST10 (Ferric Maltol), taken orally twice a day
89026501|NCT00469781|Active Comparator|1|
89026502|NCT00469781|Other|2|
89026503|NCT01244139|Experimental|Active study drug|Treatment
89559523|NCT06275529|Experimental|MSU Classification 2A|Transforaminal Epidural Steroid Injection, MSU classification according to MRI images 2A
89559524|NCT06275529|Experimental|MSU Classification 2B|Transforaminal Epidural Steroid Injection, MSU classification according to MRI images 2B
89559525|NCT06275529|Experimental|MSU Classification 2C|Transforaminal Epidural Steroid Injection, MSU classification according to MRI images 2C
89559526|NCT06275529|Experimental|MSU Classification 3A|Transforaminal Epidural Steroid Injection, MSU classification according to MRI images 3A
89559527|NCT06275529|Experimental|MSU Classification 3B|Transforaminal Epidural Steroid Injection, MSU classification according to MRI images 3B
89559528|NCT06275529|Experimental|MSU Classification 2AB|Transforaminal Epidural Steroid Injection, MSU classification according to MRI images 2AB
89559529|NCT06275529|Experimental|MSU Classification 3AB|Transforaminal Epidural Steroid Injection, MSU classification according to MRI images 3AB
89559530|NCT06275516|Experimental|VR+treadmill training group|Multi-sensory stimulation immersive VR+ treadmill training with suitable for training intensity. 20 minutes a day for 30 days, a total of 600 minutes (training frequency is adjusted according to the patient's own conditions).
89026504|NCT01244139|Experimental|Comparator|Dummy drug
89026505|NCT01340794|Experimental|Treatment (pazopanib hydrochloride)|Patients receive pazopanib hydrochloride PO QD on days 1-28 (days 1-14 of courses 1 and 2). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89026506|NCT00500838|Experimental|1|Transthoracic impedance device implanted.
89026507|NCT00474695||1|Active approved treatment
89559531|NCT06275516|Active Comparator|treadmill training group|Only treadmill training similarly with suitable for training intensity in the control group. 20 minutes a day for 30 days, a total of 600 minutes (training frequency is adjusted according to the patient's own conditions).
89026508|NCT00500877|Active Comparator|Mood Management Phone counseling|Mood management phone counseling for smoking cessation
89026509|NCT00500877|Placebo Comparator|Phone Counseling Standard|Phone counseling standard
89026510|NCT03271502|Experimental|Total intravenous anesthesia|Total intravenous anesthesia with propofol and remifentanil
89026511|NCT03271502|Active Comparator|Inhalation anesthesia|Inhalation anesthesia with sevoflurane and remifentanil
89026512|NCT03271463||Reliability/Validity of SCALE Assessment|Reliability + validity of the Selective Control Assessment of Lower Extremity (SCALE) in people with chronic stroke.
89026513|NCT00501072|Experimental|Open|Real-Time Continuous Glucose monitoring System (RT-CGMS) with alarm setting active and ability to view glucose trend profiles
89026514|NCT00501072|No Intervention|Blind|RT-CGMS is applied without alarm setting and without the ability to watch glucose trend profiles
89026515|NCT01340482|Experimental|KRN23|Escalating doses of KRN23 (0.05, 0.10, 0.30 and 0.60 mg/kg) will be administered SC every 28 days (up to 4 doses)
89026516|NCT03271697|Experimental|AM group|Treatment group will accept Astragalus Membranaceus(AM) t.i.w treatment for 14 days from second day of admission, in addition to standard ordinary treatment.
89026517|NCT03271697|Placebo Comparator|Placebo group|Control group will accept placebo t.i.w treatment for 14 days from the second day of admission, in addition to standard ordinary treatment.
89026518|NCT00501111|No Intervention|1|Placebo
89026519|NCT00501111|Active Comparator|2|donepezil
89026520|NCT00501111|Experimental|3|AZD3480
89026521|NCT00475007|Experimental|1|The experimental group will have an investigational medical device implanted in their lungs with an instrument known as a bronchoscope. This procedure is done without an incision
89026522|NCT00475007|Sham Comparator|2|The sham comparator group will be tested, treated and followed in an identical manner as the experimental group, except that no valves will be placed during the diagnostic bronchoscopy, the sham procedure.
89559532|NCT06275503|Other|Systematic screening group|Individuals aged 75/76 randomized to systematic screening are invited through a centralized screening facility to participate in prolonged ECG screening.
89559533|NCT06275503|Other|Opportunistic screening group|Individuals aged 75/76 randomized to opportunistic screening are invited to participate when they visit their primary care facility to prolonged ECG screening.
89608736|NCT03587649|Experimental|[18F]MNI-1126|To measure the dynamic uptake and washout of [18F]MNI-1126 in the brain using positron emission tomography (PET) in subjects with AD, PD, and healthy volunteers.
89026523|NCT03271541|Experimental|Bitopertin|"Part 1 - The main study - 16 weeks in total:~Participants will undergo a 6-week dose-escalation period followed by 10 weeks of treatment at the attained target dose of bitopertin.~Part 2 - Open Label Extension (OLE) - up to an additional 12 months:~Participants will be given the option to enroll into the OLE once the 16-week treatment of Part 1 has been completed.~Participants who decide not to enroll in the OLE, at the end of Part 1 will enter a 6-week follow-up period."
89026524|NCT00501189||1|Those getting Gardasil vaccination for low grade Pap abnormality.
89026525|NCT00501189||2|Historical group that did not get Gardasil.
89026526|NCT01340209|Experimental|Tiotropium Respimat (low dose)|Tiotropium low dose once daily delivered with Respimat inhaler
89026527|NCT01340209|Experimental|Tiotropium Respimat (high dose)|Tiotropium high dose once daily delivered with Respimat inhaler
89026528|NCT01340209|Placebo Comparator|Placebo Respimat|Tiotropium placebo once daily delivered with Respimat inhaler
89026529|NCT01246089|Experimental|Ranabizumab|Myopic eyes with retinal neovascularization
89026530|NCT00598897|Experimental|clarithromycin and rifabutin/rifampin|Clarithromycin and rifabutin/rifampin with ethambutol given three times weekly.
89026531|NCT04326400||Hospital de la Princesa employees|
89026532|NCT04697732||Adult patients age above 18 years|ASA I-IV adult patients over 18 years of age who will receive general anesthesia and are scheduled to be extubated postoperatively, who can give informed consent, have no known psychological or psychiatric problems, and who are suitable for postoperative follow-up.
89026533|NCT00598936||Cardiac Surgery or Hospitalization|"Patients scheduled for a Cardiac Surgery procedure, two types of cerebral oximetry devices were compared at the same time during the surgical procedure.~The second group were patients hospitalized (in the Intensive Care Unit or ICU, with any diagnosis, excluding head trauma patients. Those patients were monitored using two types of cerebral oximetry devices at the same time for up to 72 hours."
89026534|NCT04326244||Snoring obesity patient|Constitution in Chinese Medicine Questionnaire, physical examination, blood test and genetic test are provided to subjects. The blood test includes High-density lipoprotein- cholesterol, Low-density lipoprotein- cholesterol, Total cholesterol, Triglyceride, Leptin, Glucose AC, Hemoglobin A1C, Insulin; the DNA test includes FTO、MC4R、BDNF、PPARG、ADRB3、UCP1. Epworth Sleepiness Scale, laryngoscope and polysomnography are also performed in the patients enrolled
89026535|NCT00599209|Experimental|A - coded unit ID|Nursing home units provided the CDS intervention
89026536|NCT00599209|No Intervention|B - coded unit ID|Nursing home units not provided the CDS intervention
89026537|NCT01326910|Experimental|19306-127|Experimental Topical cream applied twice daily (or as needed)
89559534|NCT06275490|Experimental|Partially Demineralized Dentin Block|"The extracted tooth will undergo grinding using the tooth transformer device. The produced dentin graft will be of a particle size 400-800 μm. Afterwards.~-Prepare the partially demineralized dentin block, the L-PRF membranes will be cut into small pieces and mixed with the dentin particles at a ratio of 2 membranes to 0.5 g of dentin, providing a 1:1 volume ratio. The liquid fibrinogen will be added to the homogeneous mixture, and while shaping the mixture into the desired form it will be gently stirred for approximately 10 seconds. Within a few minutes, the fibrinogen will convert into fibrin primarily from the activated blood platelets in the chopped L-PRF membranes. This process will effectively trap the biomaterial and the L-PRF pieces, forming a sturdy block known as the dentin block, which serves as a convenient and compact graft .The extracted socket will be filled with partially demineralized autogenous dentin graft."
89559535|NCT06275490|Active Comparator|L- PRF Block|"The same procedure will be performed for preparing the L-PRF block by mixing the L-PRF membranes with xenograft. In both groups, the placed graft will be covered with a L-PRF membrane .The L-PRF clots obtained after 12 min of centrifugation will be placed in the Xpression box (IntraSpin, Intra-Lock, Florida, USA) for 5 min to gently compress (by gravity) into membranes.~Finally, tension free wound closure will be attained after periosteal releasing incision and suturing using 5/0 proline interrupted sutures.~An immediate postoperative CBCT scan will be done following the surgical procedure."
89559536|NCT06275477|Experimental|Ga68-FAPI46 TEP scan|In addition to the usual routine care, the study adds the performance of a [68Ga] Ga-FAPI PET/CT scan
89559537|NCT06275464|Active Comparator|5mg SAD|
89559538|NCT06275464|Placebo Comparator|5mg SAD placebo|
89559539|NCT06275464|Active Comparator|10mg SAD|
89559540|NCT06275464|Placebo Comparator|10mg SAD placebo|
89559541|NCT06275464|Active Comparator|5mg MAD|
89026538|NCT01326910|Other|19306-137|Marketed Topical cream applied twice daily (or as needed)
89026539|NCT00469937|Experimental|Therapeutic Intervention|
89026540|NCT00599287|No Intervention|1|No intervention
89026541|NCT00599287|Experimental|2|Methylphenidate
89026542|NCT00599287|Experimental|3|Rivastigmine
89026543|NCT00599287|Experimental|4|Haloperidol
89026544|NCT00599365|Experimental|Pharmacy Care arm|"The pharmacist:~will take all the patient's medication bottles, and give medication boxes filled with medications in the order the patient should take them in.~will need to obtain a complete list of medications.~will teach the patient about the medications.~will provide a medication schedule, and other papers about the medications.~will count the pills in the medication boxes.~will review all the medications with the patient and answer any question.~will check to see if the medication is working for the patient.~will work with the patient's kidney doctor to adjust medications if needed.~will give the medication boxes filled with medications to take home."
89026545|NCT00599365|No Intervention|Control|"The pharmacist:~will obtain a complete list of medications.~will count the pills in the patients' medication bottles.~will inform patients to take their medications from these bottles."
89026546|NCT00475124|Experimental|1|Home Monitoring ON
89559542|NCT06275464|Placebo Comparator|5mg MAD placebo|
89559543|NCT06275464|Active Comparator|10mg MAD|
89559544|NCT06275464|Placebo Comparator|10mg MAD placebo|
89608737|NCT04148313||Patients|Patients with diagnosis of Multiple Sclerosis.
89608738|NCT03589755|Active Comparator|mindful meditation|Behavioral intervention, providing meditation
89608739|NCT03589755|No Intervention|Waiting list|Patient on a waiting list
89608740|NCT03589599|Experimental|Flavored tobacco|All participants will be completing a lab visit where they smoke flavored waterpipe tobacco ad lib for up to 45 min.
89559545|NCT06275438|Active Comparator|experimental group|The group consists of mothers who meet the inclusion criteria specified in the study, have an 8cm dilation at term, and undergo cesarean section delivery.
88965817|NCT05519683|Sham Comparator|TEA at location B|The TEA device administers a mild electrical shock through the skin, similar to acupuncture. Stimulation will be performed twice daily, morning and evening for 45 minutes for 8 weeks. Location sets are described in the protocol, which will be shared with results reporting but are not provided here to maintain masking and, therefore, to safeguard scientific integrity.
88965818|NCT05519683|Experimental|TEA at location C|The TEA device administers a mild electrical shock through the skin, similar to acupuncture. Stimulation will be performed twice daily, morning and evening for 45 minutes for 8 weeks. Location sets are described in the protocol, which will be shared with results reporting but are not provided here to maintain masking and, therefore, to safeguard scientific integrity.
88965819|NCT05519683|Experimental|Escitalopram treatment|This arm will receive treatment with the chemical neuromodulator escitalopram (Lexapro) at 10 mg once per day for 8 weeks. Lexapro is often used as a standard treatment for IBS.
89559546|NCT06275438|No Intervention|control group|The group comprises healthy mothers who meet the inclusion criteria specified in the study, have an 8cm dilation at term, and give birth vaginally.
89559547|NCT06275425|Experimental|Intervention|General anesthesia is maintained with intravenous administration of Byfavo.
88965820|NCT05510635|Experimental|interactive bibliotherapy|All adolescents enrolled in the experimental group will receive two times of interactive bibliotherapy with an interval of 7 to 14 days. The researcher will read the story to the participant and then discuss it with him/her.
88965821|NCT05510635|Active Comparator|reading bibliotherapy|All adolescents enrolled in the comparison group will receive two times of reading bibliotherapy with an interval of 7 to 14 days. The participant will read the story alone.
88965822|NCT05507944||Healthcare workers at Oslo University Hospital|"Occupational control.~Environmental exposure during commuting."
88965823|NCT05507944||Hairdressers|"Occupational exposure for airway irritants during hairdressing.~Environmental exposure during commuting."
89559548|NCT06275425|Active Comparator|Control|
89559549|NCT06275412|Active Comparator|Educational Attention Control (EAC) + Standard Medical Care|
88965824|NCT05486611|Experimental|W-GenZD Mobile Application Group|Participants assigned to the W-GenZD mobile application group will be asked to download and use the W-GenZD mobile application that will provide information and tools through a chatbot (a computer program designed to communicate with users). Participants will be invited to use the mobile application as often as they like during the 4-week treatment period - we will encourage 5 to 10 minutes of daily use.
88965825|NCT05486611|Sham Comparator|Digital Education Application Group|Participants assigned to the Digital Education mobile app group will be given instructions on how to download and access the application that will provide general health information. A new article will be provided to the participant at a rate of once per week across the 4 weeks (4 articles total) and they will receive a weekly notification when a new article is available. Each article will be available for one week from release date. We expect a target dosage of roughly 30 minutes per week (120 min), which would make it comparable to Woebot (about 5 min per day X 28 days = 140 min).
88965826|NCT05486455|Experimental|CT scan|
88965827|NCT05455060|Experimental|Chinese herbal formula (CHF)|The patients in CHF group will take CHF capsules, 12 capsules (6 gm) twice a day, total 12 gm a day for 12 weeks, and the dosage will be modified according to patients' body weight. (3gm BID for 20kg≦BW<40kg; 1.5gm BID for BW<20kg)
88965828|NCT05455060|Placebo Comparator|Control|The patients in control group will take the placebo capsules, which has the similar look, smell, and taste. The dosage, frequency, and duration are the same as CHF group, in which 12 capsules (6 gm) twice a day, total 12 gm a day for 12 weeks, and the dosage will be modified according to patients' body weight. (3gm BID for 20kg≦BW<40kg; 1.5gm BID for BW<20kg)
88965829|NCT05442268|Experimental|Acetaminophen group|patients will receive intravenous 500 mg acetaminophen(every 6 hours postoperatively.
88965830|NCT05442268|Experimental|Duloxetine group|Patients will receive duloxetine 30 mg every 12 hours for 3 days before surgery, 30 mg 2 hours preoperatively and 30 mg 12 hours postoperatively and intravenous 500 mg acetaminophen (every 6 hours postoperatively)
88965831|NCT05451355|Active Comparator|Control Group|Participants receive a link to review an educational webpage (e.g., the AAP Firearm Storage Web Page)
88965832|NCT05451355|Experimental|Intervention Group|Participants receive the newly developed prototype (e.g., the Family Safety Check In)
88965833|NCT05448820|Experimental|P1 Cohort 1A: Dose 1 YH001 + Dose 1 Envafolimab Q3WK|Dose 1 of YH001 will be dosed in combination with Dose 1 Envafolimab every 3 weeks.
88965834|NCT05448820|Experimental|P1 Cohort 2A: Dose 2 YH001 + Dose 1 Envafolimab Q3WK|Dose 1 of YH001 will be dosed in combination with Dose 1 Envafolimab every 3 weeks.
88965835|NCT05448820|Experimental|P1 Cohort 1B: Dose 1 YH001 + Dose 1 Envafolimab + Doxorubicin Q3WK|Dose 1 of YH001 will be dosed in combination with Dose 1 of Envafolimab with Doxorubicin every 3 weeks.
88965836|NCT05448820|Experimental|P1 Cohort 2B: Dose 2 YH001 + Dose 1 Envafolimab + Doxorubicin Q3WK|Dose 1 of YH001 will be dosed in combination with Dose 1 of Envafolimab with Doxorubicin every 3 weeks.
88965837|NCT05448820|Experimental|P2: Sarcoma Subtype 1 RP2D YH001 + Dose 1 Envafolimab Q3WK|Recommended Phase 2 Dose of YH001 in combination with Dose 1 of Envafolimab every 3 weeks
88965838|NCT05448820|Experimental|P2: Sarcoma Subtype 2 RP2D YH001 + Dose 1 Envafolimab Q3WK|Recommended Phase 2 Dose of YH001 in combination with Dose 1 of Envafolimab every 3 weeks
88965839|NCT05448820|Experimental|P2: Sarcoma Subtype 3 RP2D YH001 + Dose 1 Envafolimab + Doxorubicin Q3WK|Recommended Phase 2 Dose of YH001 in combination with Dose 1 of Envafolimab every 3 weeks and Doxorubicin every 3 weeks for a maximum of 6 doses
89559550|NCT06275412|Experimental|The 3Ms 2.0 Intervention + Standard Medical Care|
89608741|NCT03589599|Experimental|Non-flavored tobacco|All participants will be completing a lab visit where they smoke non-flavored waterpipe tobacco ad lib for up to 45 min.
89608742|NCT02984865|Active Comparator|group S|Patients were attach with PCA containing 100ml combination of sulfentanyl 2.5ug/kg and flubiprofen axetil 100mg after receiving the loading dose of sulfentanyl 5 ug and flubiprofen axetil 50mg intravenously 30 mins before the end of the operation .
88965840|NCT05448820|Experimental|P2: Sarcoma Subtype 4 RP2D YH001 + Dose 1 Envafolimab + Doxorubicin Q3WK|Recommended Phase 2 Dose of YH001 in combination with Dose 1 of Envafolimab every 3 weeks and Doxorubicin every 3 weeks for a maximum of 6 doses
88965841|NCT05446012||women diagnosed with ectopic pregnancy (n: 40)|thyroid function tests (TSH, sT3, sT4, TT3, TT4, thryoglobulin, Anti-Peroxidase Antibody, Anti- thryoglobulin Antibody, TSH receptors antibody levels) will be done in women diagnosed with ectopic pregnancy
88965842|NCT05446012||Control group pregnants (n:40)|thyroid function tests (TSH, sT3, sT4, TT3, TT4, thryoglobulin, Anti-Peroxidase Antibody, Anti- thryoglobulin Antibody, TSH receptors antibody levels) will be done in pregnant women in early pregnancy week.
88965843|NCT02972476|Active Comparator|1: Symbicort 400/12 & Eklira Genuair|Budesonide 400mcg & formoterol fumarate 12mcg: 1 inhalation twice daily, inhalation powder and Aclidinium bromide 322mcg: 1 inhalation twice daily, inhalation powder for 3 months
88965844|NCT02972476|Active Comparator|2: Seretide 500/50 & Eklira Genuair|Fluticasone propionate 500mcg & salmeterol 50mcg: 1 inhalation twice daily, inhalation powder and Aclidinium bromide 322mcg: 1 inhalation twice daily, inhalation powder for 3 months
88965845|NCT02972476|Active Comparator|3: Seretide 250/50 & Eklira Genuair|Fluticasone propionate 250mcg & salmeterol 50mcg: 1 inhalation twice daily, inhalation powder and Aclidinium bromide 322mcg: 1 inhalation twice daily, inhalation powder for 3 months
88965846|NCT02972476|Active Comparator|4: Duaklir Genuair|Aclidinium bromide 340mcg & formoterol fumarate 12mcg: 1 inhalation twice daily, inhalation powder for 3 months
88965847|NCT05409079|Experimental|Abilitech Assist|The Abilitech™ Assist device is a passively powered orthotic device designed to support and assist the arms of patients with neuromuscular weakness for activities of daily living.
88965848|NCT05398003|Experimental|Study population|12 patients with neck and upper limb pain who have failed multidisciplinary treatment and are candidates for cervical medullary stimulation will be included.
88965849|NCT02972320|Experimental|temozolomide maintain therapeutic|Lobaplatin combined with etoposide for first-line treatment of extensive stage small cell lung cancer,then clinical benefit patients for temozolomide maintain therapeutic.This study have only one arm which temozolomide maintain at dose of 150mg/m2 D1-5 Q4W.
88965850|NCT05349838|Experimental|DTG/RPV FDC Regimen|One combined Dolutegravir 50mg /Rilpivirine 25mg FDC tablet taken orally once daily
88965851|NCT05349838|Active Comparator|Continued ART Regimen|Patients will continue the current boosted PI regimen (or other antiretroviral combination) for 48 weeks. Patients will then be switched to one combined Dolutegravir/Rilpivirine FDC tablet taken orally once daily for 48 weeks.
88965852|NCT05346289||Women|
88965853|NCT05346289||Men|
88965854|NCT05314816|Experimental|Blood culture identification panel|BioFire BCID2 (Blood culture identification panel) will be performed on positive blood culture specimens.
88965855|NCT05314816|No Intervention|Concurrent control|Standard blood culture process will be performed concurrently on select positive blood culture specimens during the study period. BCID2 will NOT be performed on these specimens.
88965856|NCT05314816|No Intervention|Retrospective control|Standard blood culture process was performed prior to the study period.
88965857|NCT05313763|Experimental|Conventional physical therapy group|Conventional physical therapy is the first line of treatment in cervical spondylosis.
88965858|NCT05313763|Active Comparator|Kinesio-tape Group|Conventional rehabilitation program will be applied five days a week, 3 weeks, a total of 15 sessions. Kinesio-tape applications will be applied in 6 sessions during conventional physical therapy, twice a week at four-day intervals.
89559551|NCT06275399||Patients with chronic coronary syndrome and coronary stenosis (30% - 90%) amenable to OCT imaging|"Patients with chronic coronary syndrome and coronary stenosis (30% - 90%) amenable to OCT imaging. The groups will be assessed at the time of angiography with:~OCT for evaluation of plaque morphology within the coronary stenosis~Computational fluid dynamics with vFFR and estimation of value and distribution of shear rate and shear stress~Impedance aggregometry based platelet reactivity~Single-particle high-resolution flow cytometry analysis of pMVs and sEVs as well as additional platelet activation and inflammatory biomarkers~Proteomic and metabolomic characterization - in the subset of patients~Biomarker assessment will be done in the blood sampled directly from coronary artery (proximal and distal segment) arteries. Shear rate/shear stress distribution and biomarkers profile will be compared between the stenotic vessel and the non-stenotic vessel (stenoses <30%) in the same patient."
89559552|NCT06275386|Experimental|Drug-coated balloon|Patients will undergo PCI of the native coronary CTO with a DCB.
88965859|NCT05313763|Sham Comparator|Sham kinesio-tape Group|Conventional rehabilitation program will be applied five days a week, 3 weeks, a total of 15 sessions. Sham kinesio-tape applications will be applied twice a week at four-day intervals, 6 sessions during conventional physical therapy.
88965860|NCT05305456|Experimental|Tanreqing capsule|3 capsules per time, 3 times a day，7 days of treatment
88965861|NCT05305456|Placebo Comparator|Tanreqing capsule simulator|3 capsules per time, 3 times a day，7 days of treatment
88965862|NCT05247658|Active Comparator|Therapeutic lens alone|
88965863|NCT05247658|Experimental|Therapeutic lens + amniotic membrane (Visio-AMTRIX)|
88965864|NCT00388986|Experimental|1|
88965865|NCT00388986|Experimental|2|
89208439|NCT05227560|Experimental|Emotional Freedom Technique group|"Personal characteristics questionnaire, State Anxiety Scale (SQS) and Stress Coping Styles Scale (SST) were applied to the intervention group at the pre-test stage. Subjective discomfort level scale (ERDS) was also applied to the intervention group before EFT was applied. After four sessions of EFT, DKO, SBO, ORDS were applied to the intervention group again in the post-test phase."
88965866|NCT00388986|Experimental|3|
88965867|NCT05234203|Experimental|HTB Rejuvenate|4 capsules of study interventional supplement delivered as 2 capsules two times a day for 90 days.
89026547|NCT00475124|Active Comparator|2|Home Monitoring OFF
89208440|NCT05227560|No Intervention|Control|Participants in the control group received no intervention throughout the study.
89559553|NCT06275360|Experimental|Chemoimmunotherapy followed by radiotherapy|Nivolumab (Opdivo) + plus platinum-doublet chemotherapy followed by radiotherapy
89559554|NCT06275347|Experimental|Intervention Very low calorie ketogenic low-fat diet (VLCKLFD)|"Frank ketosis: between 650 and 730 kcal/day in 5 mealtimes. This stage in the nutritional intervention was done during the first 4 weeks.~Mixed Ketosis: in this stage, one intake of commercial preparations was replaced by proteins, which discreetly increased by 100 to 150 Kcal/day. This stage was done during the next 4 weeks."
89559555|NCT06275347|Active Comparator|Low-Calorie Diet (LCD)|The usual caloric intake of a balanced LCD is between 1,200 and 1,500 kcal per day with a macronutrient distribution of 50% carbohydrates, 25% proteins and 25% fats, according to the Diogenes study
89559556|NCT06275321|Experimental|Synchronous-supervised online home-baased group|Group following a supervised exercise program with an exercise cancer specialist
89559557|NCT06275321|Active Comparator|Exercise recommendation group|Group following general recommendations of physical exercise
89559558|NCT06275308|Experimental|Observational Group|Manipulation of end tidal carbon dioxide in subjects
89559559|NCT06275269|Experimental|Ultrasound-Guided Triamcinolone Injection Treatment Group|Ultrasound-Guided Triamcinolone Injection for the Treatment of Subglottic Stenosis
89559560|NCT06275269|Experimental|Translaryngeal Endoscopic Mucosal Injection of Triamcinolone Treatment Group|Translaryngeal Endoscopic Mucosal Injection for the Treatment of Subglottic Stenosis
89559561|NCT06275256|Experimental|Rezum|This arm will receive the Rezum procedure.
89559562|NCT06275256|Experimental|iTind|This arm will receive the iTind Procedure
89559563|NCT06275243|Active Comparator|Group of cases diagnosed with Alzheimer's disease|Participants: Men and women with age between 60 and 90 years
89026548|NCT04326166||Group A|Patients who receive Double therapy or Insulin
89026549|NCT04326166||Group B|Patients who receive DPP-4 inhibitor
89026550|NCT04326166||Group C|Drug-naïve patients
89026551|NCT00599443|Experimental|1|
89026552|NCT00599443|Placebo Comparator|2|
89026553|NCT00599482|Other|1|Far Infrared Radiation
89026554|NCT00599560|Experimental|1. Meniere's disease|Patients were eligible for enrollment if they had received a clinical diagnosis of Meniere's disease according to the 1995 AAO-HNS criteria (Committee, 1995). These criteria can be briefly described as follows: 1) Repeated attacks of vertigo: A definitive spell is spontaneous vertigo lasting at least 20 minutes. A mixed type of spontaneous nystagmus is observed during attacks. 2) Fluctuating cochlear symptoms: The hearing test usually reveals a marked fluctuation of the threshold in the low and middle tone range.
89026555|NCT00599560|No Intervention|2. Acoustic neurinoma|Diagnosed by CT and/or MRI
89026556|NCT00599599|Experimental|1|Prolonged Exposure Therapy.
89026557|NCT00599599|No Intervention|2|Weekly monitoring/Waitlist Control Group.
89026558|NCT02891668||Hypothyroid|Levothyroxine treatment
89559564|NCT06275243|Sham Comparator|Control group of healthy individuals without a diagnosis of Alzheimer's disease|Participants: Men and women with age between 60 and 90 years
89559565|NCT06275230||chronic obstructive pulmonary disease|Patients with COPD undergoing bronchoscope.
89559566|NCT06275217|Experimental|Mindful yoga group|The participants in experimental group will receive a 10-week mindfulness-based yoga program, one session per week with 1.5 hours in each session.
89026559|NCT02891668||Healthy volunteers|Matched on age and BMI 18 persons
89026560|NCT02956343||AF|Five minutes pulse wave recording in patients with atrial fibrillation at the time of recruitment
89559567|NCT06275217|Active Comparator|Psychoeducation group|The participants in the psychoeducation group will receive a 10-week psychoeducation program, one session per week with 1.5 hours in each session.
89559568|NCT06275139|No Intervention|Control group (No-integrated group)|The control group adopt the traditional diagnosis and treatment mode, and only head CT plain scan and carotid artery ultrasound shall be performed. If necessary, relevant disciplines would be consulted but no integrated assessment of cervicocerebral vessels be arranged. The final treatment plan would be decided by the surgeon alone.
89608743|NCT02984865|Experimental|group N1|Patients were attach with PCA containing 100ml combination of nalbuphine 1.5mg/kg and flubiprofen axetil 100mg after receiving the loading dose of nalbuphine 5 mg and flubiprofen axetil 50mg intravenously 30 mins before the end of the operation .
89608744|NCT02984865|Experimental|group N2|Patients were attach with PCA containing 100ml combination of nalbuphine 2mg/kg and flubiprofen axetil 100mg after receiving the loading dose of nalbuphine 5 mg and flubiprofen axetil 50mg intravenously 30 mins before the end of the operation .
89026561|NCT02956343||SR|Five minutes pulse wave recording in patients with sinus rhythm at the time of recruitment
89026562|NCT00599677|Experimental|group 1|specific acupoints of Stomach meridians
89026563|NCT00599677|Experimental|group 2|Non-specific acupoints of Stomach meridians
89026564|NCT00599677|Experimental|group 3|alarm and transport points
89026565|NCT00599677|Experimental|group 4|acupoints of the other meridian
89026566|NCT00599677|Sham Comparator|group 5|non-acupoints
89026567|NCT00599677|Active Comparator|group 6|Itopride
89026568|NCT00599716|Experimental|1|study drug
89026569|NCT00599716|Placebo Comparator|2|vehicle control
89026570|NCT00599794||1|Healty volunteers who are euvolemic.
89026571|NCT00599794||2|Critically ill patients who will be having a central venous catheter with a monitor to measure central venous pressure placed as part of their planned care independent of this study.
89026572|NCT01246284|Active Comparator|A|Please note that the letter are assigned to different areas of injections within the same patient. All patients will be receiving the same treatment
89026573|NCT01246284|Active Comparator|B|Please note that the letter are assigned to different areas of injections within the same patient. All patients will be receiving the same treatment
89559569|NCT06275139|Experimental|Experimental group (Integrated group)|The experimental group adopt the multidisciplinary collaboration and integrated evaluation mode. In addition to routine diagnosis and treatment as above-mentioned, integrated assessment of cervicocerebral vessels shall be performed, including transcranial color-coded doppler, cerebral perfusion with multislice CT, and cognitive function assessment. Based on the above results, surgical plans will be formulated jointly by multiple disciplines including neurologists, vascular surgeons, ICU physicians and cardiac surgeons.
89559570|NCT06275074|Experimental|Dry Needling and Therapeutic Exercise|
89559571|NCT06275074|Active Comparator|Therapeutic Exercise Alone|
89559572|NCT06275061||Metabolic and Bariatric Surgery|Metabolic and bariatric surgery is weight loss surgery that results in weight loss and resolution of metabolic disorders.
89559573|NCT06275048|Experimental|Wrist/hand immobilization|Participants will have their wrist and hand immobilized using a rigid splint continuously for 7 days. The splint will restrict all wrist and hand movement and must be worn at all times for the full 7 day period, and may only be removed under supervision of the research participants.
88965868|NCT05233696|Experimental|RT followed by nab-paclitaxel/paclitaxel plus pembrolizumab|Nab-paclitaxel/paclitaxel plus pembrolizumab will be started within 7 days of completion of RT.
88965869|NCT05213299|Experimental|First auricular acupuncture, then sham acupuncture in left ear|Participants are experienced two phases of our study. The first phase, participants are received auricular acupuncture at TF4, AT4, LO1, LO3 points in the left ear. The second phase, participants are received sham acupuncture at the same points. The facial pain threshold will be recorded before and after performing auricular acupuncture.
88965870|NCT05213299|Experimental|First auricular acupuncture, then sham acupuncture in right ear|Participants are experienced two phases of our study. The first phase, participants are received auricular acupuncture at TF4, AT4, LO1, LO3 points in the right ear. The second phase, participants are received sham acupuncture at the same points. The facial pain threshold will be recorded before and after performing auricular acupuncture.
88965871|NCT05212363|Experimental|Calf Compression|Subjects will wear calf compression garments while video gaming for 2 hours. All subjects will undergo blood flow assessments before and after wearing lower leg graduated compression gear during their gaming session (i.e. compression during uninterrupted sitting).
88965872|NCT05212363|Experimental|6- minute Walk|Subjects will game for 2 hours sitting and take a 6 minute walking break at the one hour period before resuming game play. All subjects will undergo blood flow assessments before and after taking an active break (i.e. 6-minute walk) during their gaming session.
88965873|NCT05212363|No Intervention|Continuous video game play|Subjects will game for 2 hours sitting with no break. All subjects will undergo blood flow assessments without wearing lower leg graduated compression gear or taking an active break during their gaming session (i.e. during uninterrupted sitting).
88965874|NCT05199805|Experimental|Mindfulness-based pain management|The program consists of sessions of 150 minutes once a week over the course of 8 weeks. Treatment as usual is allowed.
88965875|NCT05199805|No Intervention|Waiting-List|The control group will receive no active intervention in addition to treatment as usual during the study period.
88965876|NCT05192590|No Intervention|Control|These providers will complete two rounds of three simulated patient cases (CPVs). Control arm physicians will continue to have access to standard of care diagnostic tools, but not the CDMT test results.
88965877|NCT05192590|Experimental|Educational Materials and CDMT Test Results (Intervention 1)|Participants will care for the same set of CPV patients as the control arm, but will be educated on and will receive the CDMT test results whether they select it or not. Investigators will compare intervention participants' clinical recommendations to those in the control arm.
88965878|NCT05192590|Experimental|Educational Materials and CDMT Test Results when Selected (Intervention 2)|Participants will care for the same set of CPV patients as the control arm, but will be educated on and will receive the CDMT test results only if they select it. Investigators will compare intervention participants' clinical recommendations to those in the control arm.
88965879|NCT05183152|Experimental|NMES-BCI|Sensory-threshold electrical stimulation is delivered to the flexors/extensors of the forearm contingent to the voluntary activation of the motor cortex by motor imagery of hand flexion/extension as detected by a closed-loop BCI.
88965880|NCT05183152|Active Comparator|Visual-BCI|Bar-based visual feedback is provided on a screen contingent to the voluntary activation of the motor cortex by motor imagery of hand flexion/extension as detected by a closed-loop BCI.
88965881|NCT05174299|Experimental|double active magnetic stimulation|the multi-target magnetic stimulation on motor cortex combined with spinal cord
88965882|NCT05174299|Active Comparator|single active magnetic stimulation|the active magnetic stimulation on motor cortex and sham stimulation on spinal cord
88965883|NCT05174299|Sham Comparator|double sham magnetic stimulation|the sham magnetic stimulation on motor cortex and sham stimulation on spinal cord
88965884|NCT05157607|Experimental|Family Connections Protocol for Relatives of Patients with SBD.|"The intervention lasts three months and includes 12 sessions with a weekly two-hour group format. The FC program is divided into six modules:~Module 1: Up-to-date information and research on suicide (Epidemiology, frequency, Risk factors, protective factors).~Module 2: Psychoeducation on the development of suicide, explanatory theories, available treatments, comorbidity.~Module 3: Emotional regulation skills, skills of acceptance, validation, approach, awareness, and to decrease emotional reactivity.~Module 4: Skills to improve the quality of relationships in family interactions (letting go of guilt and anger, acceptance skills in relationships).~Module 5: Communication skills and effective self-expression. Module 6: Problem management and making safe plans for crisis management."
89026574|NCT01246284|Active Comparator|C|Please note that the letter are assigned to different areas of injections within the same patient. All patients will be receiving the same treatment
89559574|NCT06275022|Experimental|Macro/mixed cystic lymphatic A|Inflow occlusion assisted by indocyanine green-fluorescence imaging combined with perforation of septation and sclerotherapy
89559575|NCT06275022|Active Comparator|Macro/mixed cystic lymphatic B|Perforation of septation and sclerotherapy
88965885|NCT05157607|Active Comparator|Treatment as Usual Optimized Protocol (TAU-O).|"Family members in this condition will continue to receive their treatment as usual in their care center of reference. In addition, we will optimize the treatment based on the recommendations of the international guidelines for the treatment of suicide. There will be one three-hour session in group format with the following component:~Module 1: Updated information and research on suicide (Epidemiology, frequency, Risk factors, protective factors). Psychoeducation on the development of Suicide, Explanatory theories. Available treatments, and comorbidity."
88965886|NCT05148013|Experimental|Pilates exercise group|Pilates exercise group will receive a total of 20 sessions of 30 minute Pilates exercises 5 days a week which will be performed under the supervision of a physiotherapist.
88965887|NCT05148013|Experimental|PNF exercise group|A total of 20 sessions of PNF exercises for 30 minutes, 5 days a week, will be performed individually with a physiotherapist.
88965888|NCT00389935|Experimental|Treatment|
88965889|NCT05116930|Experimental|Postpartum dural puncture headache following dural puncture from Tuohy needle|Subjects identified as experienced a post dural puncture headache after a confirmed dural puncture from a Tuohy needle will receive an IV administration of the study medications neostigmine and atropine
88965890|NCT00423475|Active Comparator|I|Exclusive Radiation Therapy 66 Gy (prostatic bed) / 46 Gy (Pelvis with lymph nod involvement) in treating patients who have undergone surgery for recurent or refractory Prostate Cancer
88965891|NCT00423475|Experimental|II|Radiation Therapy 66 Gy (prostatic bed) / 46 Gy (Pelvis with lymph nod involvement) and GOSERELIN ACETATE in treating patients who have undergone surgery for recurent or refractory Prostate Cancer
88965892|NCT05054608||COVID-19 ICU cohort|All patients, 18 to 63 years old, admitted to a Swedish ICU with COVID-19 with at least one year of follow up. COVID-19 defined by the ICD-10 diagnosis U07.1 in the nationwide Swedish intensive care registry.
88965893|NCT05054608||COVID-19 hospital admission control cohort|Four random control patients per ICU patient matched on age legal gender and region. Controls selected from all patients admitted to a Swedish hospital with COVID-19 with at least one year of follow up. Not including patients in the COVID-19 ICU cohort. COVID-19 defined by the ICD-10 diagnosis U07.1 in the nationwide Swedish national patient registry.
88965894|NCT05054608||General population control cohort|Four general population controls per ICU patient, matched on age, legal gender and region drawn from the total population register of Sweden. Not including ICU and hospital admitted COVID-19 patients.
88965895|NCT03126799|Active Comparator|A: Erlotinib only|"Standard therapy arm:~Erlotinib 150mg. po, qd, daily, q 3weeks"
88965896|NCT03126799|Experimental|B: Erlotinib plus Bevacizumab|Study treatment arm; Erlotinib 150mg, po. qd, daily, q 3weeks plus Bevacizumab 15mg/kg, iv, on D1, q 3weeks.
89208441|NCT02596139||Healthy people|
89559576|NCT06275022|Experimental|Microcystic lymphatic A|Indocyanine green-fluorescence imaging-guided partial resection and sclerotherapy
89559577|NCT06275022|Active Comparator|Microcystic lymphatic B|Partial resection and sclerotherapy
89559578|NCT06274970|Experimental|ERAS Group|Those patients who follow ERAS protocols preoperatively, intraoperatively and post operatively
89559579|NCT06274970|Active Comparator|Conventional Group|Those patients who conventional protocols preoperatively, intraoperatively and post operatively
89559580|NCT06274957|Experimental|control|Conventional training was applied to the patients
89559581|NCT06274957|Experimental|Positive Expiratory Pressure|We applied PEP (positive expiratory pressure) therapy in adddition to the conventional exercises
89559582|NCT06274957|Experimental|High Frequency Chest Wall Oscillation|We applied HFCWO (High Frequency Chest Wall Oscillation) in addition to the conventional exercises
89559583|NCT06274931||ICU patients|Patients admitted to the Intensive Care Unit with a diagnosis of acute respiratory failure
89559584|NCT06274931||non ICU patients|Outpatient patients with a diagnosis of pneumonia
89559585|NCT06274931||Controls|In the control group, an alveolar bronchial lavage was performed directly on lung tissue taken from deceased individuals who did not have any known lung pathologies.
89559586|NCT06274918||Usual care|Patients undergoing surgery requiring general anesthesia. Usual hand hygiene devices and products will be accessible which will include but are not limited to those mounted to the wall outside of the operating room entrance and those present on the anesthesia cart.
89559587|NCT06274918||Personalized body worn alcohol dispenser|Anesthesia providers (attending anesthesiologist and their assistant (resident physician/Certified-Registered Nurse Anesthetist (CRNA), or student nurse assistant (SRNA) will receive a personalized, body worn alcohol dispenser in addition to usual hand hygiene devices/products for hand decontamination during surgery requiring general anesthesia.
88965897|NCT05020483|Experimental|FEIBA Group|Pediatric patients ≤15 kg of weight, undergoing cardiac surgery with cardiopulmonary bypass will receive activated prothrombin complex concentrate (aPCC) FEIBA to be incorporated into standard treatment of post-bypass coagulopathic bleeding.
88965898|NCT05020483|Placebo Comparator|Placebo Group|Pediatric patients ≤15 kg of weight, undergoing cardiac surgery with cardiopulmonary bypass will receive a placebo to be incorporated into standard treatment of post-bypass coagulopathic bleeding.
89026575|NCT01246284|Placebo Comparator|D|Please note that the letter are assigned to different areas of injections within the same patient. All patients will be receiving the same treatment.
89026576|NCT00599911|Experimental|Lu AA24530: 5 mg|
89026577|NCT00599911|Experimental|Lu AA24530: 10 mg|
89208442|NCT03843762||Adolescents|Adolescents, male or female, ages 11 - 17. Participants will complete 7 days/nights of actigraphy and sleep-based EEG and questionnaires.
89559588|NCT06274905|Experimental|EMLA cream|EMLA cream 5% 25g lidocaine, 25g prilocaine; Astra Zeneca. Topically applied followed by Tegaderm dressing to cover. Length of duration monitored and recorded as part of study
89559589|NCT06274905|Placebo Comparator|EMLA placebo|Aqueous cream ((Ultrapure Laboratories®️, Mayo, Ireland) applied topically followed by covering with Tegaderm dressing. Length of duration monitored and recorded as part of study
89559590|NCT06274905|Experimental|Ethyl chloride spray|Ethyl chloride spray (Cryogesic®, Fannin Ltd, Dublin, Ireland). Applied topically to surgical site prior to LA injection. Spray at distance of 5-10cm for 4-8 seconds until skin slightly blanched and the fluid allowed to evaporate.
89559591|NCT06274905|No Intervention|Control group|No intervention administered
89559592|NCT06274892|Experimental|Remote monitoring PROs|All participants allocated to the interventional arm will receive the RT technique, dose and fractionation according to institutional standards. Once per week, participants will use a mobile phone 'app' to enter mPROs, and indicate a need for review for any other reason. The treatment Radiation Therapists will triage the participant to either attend or skip that week's on-treatment review based on this information and established criteria. After RT completion, Advanced Practice Radiation Therapists (apRTs) will triage the participant to receive a virtual follow-up visit when necessary. Participants will be seen once by a Radiation Oncologist 4 to 12 weeks after last radiation treatment. The participants will also complete the following questionnaires: 1) Baseline (patient factors); 2) 'During treatment' (review quality); 3) 'Post acute phase' (satisfaction with care). Circle-of-care HCP will comment on the impact of the PROMOTE process on the quality of care for that participant.
88965899|NCT04997434|Experimental|Intervention|After 5-10 minute interview with the patient to define his or her tastes and contraindications to certain techniques. The patient will have 15 to 20 minutes to carry out an artistic activity, accompanied by the art therapist according to his/her needs. During the activity, verbal exchanges will continue. After the session, 5 minutes will be devoted to the patient's self-evaluation of the past moment, of his level of anxiety, of the intensity of his pain and of his feelings in relation to his passage in the Emergency Department and the art therapy session.
89559593|NCT06274892|No Intervention|Standard of Care|All participants allocated to the standard of care arm will receive all RT treatment activities according to institutional standards. Participants will attend the weekly in-person review session with a Radiation Oncologist during treatment and will be seen once between 4 and 12 weeks after last RT treatment. Documentation of radiation-related toxicity will be performed by the radiation HCPs according to standard of care. Participants will be asked to complete the following study questionnaires: 1) Baseline evaluation (patient factors); 2) 'During treatment' evaluation (need/usefulness of review); 3) 'Post acute phase' evaluation (satisfaction with care).
88965900|NCT04997434|No Intervention|Control|The questionnaires and VAS will be offered to the control group at the beginning of the wait, then after 30 minutes of waiting under usual conditions.
88965901|NCT04997044|Other|control group|control group
88965902|NCT04997044|Experimental|Experimental group|selective dorsal rhizotomy group
88965903|NCT03067636|Active Comparator|Physical exercise + stress management activity A|Eight week program of concurrent exercise and stress management training.
88965904|NCT03067636|Active Comparator|Physical exercise + stress management activity B|Eight week program of concurrent exercise and stress management training.
88965905|NCT03067636|No Intervention|Lifestyle as usual|"Eight weeks period with no alteration of usual lifestyle.~Participants randomized to this arm are eligible for re-randomisation to one of the active conditions at the conclusion of week eight."
88965906|NCT04935814|Experimental|Continuous vasopressin infusion|After general anesthesia, patients will receive a continuous infusion of vasopressin in order to improve mean arterial pressure by 20 mmHg.
88965907|NCT00390052|Experimental|Arm I|Patients will receive a 2-hour infusion of 3-AP once in week 1. Beginning in week 2, they will receive 3-AP by mouth twice a day 3 days a week for 3 weeks. Treatment with 3-AP by mouth may repeat every 4 weeks for as long as benefit is shown.
88965908|NCT04842253|Experimental|High flow nasal cannula|Participants in the high flow nasal cannula group will receive high flow nasal cannula oxygen during deep sedation.
88965909|NCT04842253|No Intervention|Low flow nasal cannula|Participants in the current standard of care will receive low flow nasal cannula during deep sedation.
88965910|NCT04841629|Experimental|PreBioGyn Gel|Topical administration to forearm
89208443|NCT00742235|Experimental|1|Vitamin D insufficient (treated with ergocalciferol 50,000 IU every other day x 5 doses)
88965911|NCT04841629|Active Comparator|Trimosan Gel|Topical administration to forearm
88965912|NCT04841629|Active Comparator|RepHresh Gel|Topical administration to forearm
88965913|NCT04833283|Experimental|the intervention group intermittent hypoxic-hyperoxic training|"the intervention group is patients performing intermittent hypoxic-hyperoxic training before operation. ReOxy Cardio device, intermittent hypoxic-hyperoxic training ( IHHT)~Intervention Description: Perform 4 trainings daily of intermittent hypoxic hyperoxic trainings before surgery, using 40 min trainings periods, the patient will receive air with reduced oxygen content (12 %) through a mask under constant monitoring of heart rate (HR) and SpO2. As a safety measure, minimal SpO2 was set at 82 % and maximal accepted increase of heart rate was set to + 50 % of the initial HR. When these values would be reached, the supply of oxygen automatically switched to a hyperoxic gas mixture (35% - 40% O2), inhaling of which would be continued until SpO2 reached 100% (even if SpO2 would be lower before the procedure), which, depending on the rate of saturation reduction, will takes 1 to 3 min (mean 1 min and 50 s)."
88965914|NCT04833283|Placebo Comparator|the control group|intermittent hypoxic-hyperoxic training control group will be identical to the main group, also underwent four daily procedures before surgery using 40 min training periods with simulation of intermittent hypoxic-hyperoxic trainings by using the same equipment, whereas moistened air will be delivered through a placebo mask
88965915|NCT04820335|Experimental|Immediate Treatment Group|Participants will complete 7, 60-minute SEMAT sessions over 7 weeks with their group.
88965916|NCT04820335|No Intervention|Delayed Treatment Control|Participants will not receive the intervention immediately. After 8 weeks, participants in this arm will complete the SEMAT. This is not a crossover design, because the treatment effects from those in the immediate treatment group can not be taken away.
88965917|NCT04806685|Experimental|Intervention|Diet therapy plus sleep education
88965918|NCT04806685|Other|Control|Diet therapy
88965919|NCT04782505|Experimental|Cohort 1 (Part 1)|DWJ1248 100mg (100mg 1tab) PO
89559594|NCT06274879|Active Comparator|Control arm|Standard of care consisting of chemotherapy + durvalumab + endoscopic stenting
89559595|NCT06274879|Experimental|Biliary radiofrequency ablation|Standard of care consisting of chemotherapy + durvalumab + endoscopic stenting plus intraductal radiofrequency ablation (bRFA)
89559596|NCT06274866|Experimental|Study Group|After total hip arthroplasty, participants who take supervised home based exercised program which consists especially early weight bearing hip specific mobilization and strengthening exercises.
88965920|NCT04782505|Experimental|Cohort 2 (Part 1)|DWJ1248 200mg (100mg 2tab) PO
88965921|NCT04782505|Experimental|Cohort 3 (Part 1)|DWJ1248 300mg (100mg 3tab) PO
88965922|NCT04782505|Experimental|Group A (Part 2)|DWJ1248 100mg 2tab PO - Wash out - DWJ1248 200mg 1tab PO
88965923|NCT04782505|Experimental|Group B (Part 2)|DWJ1248 200mg 1tab PO - Wash out - DWJ1248 100mg 2tab PO
88965924|NCT04762225|Experimental|RPTR-168|Escalating doses of RPTR-168 as a monotherapy in HPV-16 E6/E7 positive tumors and melanoma.
88965925|NCT03011593|Experimental|Nutrition Support Product|Participants were asked to take a nutrition support product twice per day for a period of 6 weeks.
88965926|NCT00000588|Experimental|Chronic therapy of PIH according to medical condition|"Half of overall participants will get one of the following doses according to their medical condition:~Reducing the body iron burden to near-normal levels in non- transfusion-dependent patients with iron-loading anemias (requires chelate- induced iron excretion of at least 0.10 to 0.20 mg Fe/kg/day);~Maintaining near-normal body iron stores in transfusion-dependent patients who have previously been well-chelated with chronic subcutaneous or intravenous desferrioxamine (requires chelate-induced iron excretion of at least 0.25 to 0.40 mg Fe/kg/day);~Reducing the body iron burden to near-normal levels in iron-loaded, transfusion-dependent patients (requires chelate-induced iron excretion greater than 0.40 mg Fe/kg/day)."
89559597|NCT06274866|Other|Control group|After total hip arthroplasty, participants who take an educational booklet (about exercise program) at hospital stay
89559598|NCT06274853|Experimental|SAD Cohort 1|A single oral dose of 100 mg GS-441524 under fasted conditions
89559599|NCT06274853|Placebo Comparator|SAD Placebo|Matching Placebo under fasted conditions
89559600|NCT06274853|Experimental|SAD Cohort 2|A single oral dose of 300 mg GS-441524
89559601|NCT06274853|Experimental|SAD Cohort 3|A single oral dose of 600 mg GS-441524
89559602|NCT06274853|Experimental|SAD Cohort 4|A single oral dose of 1000 mg GS-441524
89559603|NCT06274853|Experimental|SAD Cohort 5|Optional Cohort - dose TBD
89559604|NCT06274853|Experimental|Food Effect|Randomized, balanced, single-dose, two-treatment (fed vs fasting), two-period, two sequence crossover study part in healthy human subjects Treatment A: a single oral dose of TBD mg GS-441524 under fasted conditions Treatment B: a single oral dose of TBD mg GS-441524 under fed conditions
88965927|NCT00000588|Placebo Comparator|Placebo|"Half of the participants will receive a Placebo:~Non-transfusion-dependent patients~Transfusion-dependent patients~Iron-loaded, transfusion-dependent patients"
88965928|NCT04749238|Experimental|Treatment with NucleoCapture device|Device: 100 ml NucleoCapture selective DNA adsorber. Treatment with NucleoCapture in one arm.
88965929|NCT04709224|Experimental|Cohort 1: LAI Lumateperone 50 mg SC in the abdomen|
88965930|NCT04709224|Experimental|Cohort 2: LAI Lumateperone 100 mg SC in the abdomen|
88965931|NCT04709224|Experimental|Cohort 3: LAI Lumateperone 200 mg SC in the abdomen|
88965932|NCT04709224|Experimental|Cohort 4: LAI Lumateperone 100 or 200 mg SC in the outer area of the upper arm|
88965933|NCT04688242|Experimental|Treatment Arm|Anal dilatation plus probiotics per anus Q3D, starting from 2 weeks after proctectomy until reduction of ileostomy.
88965934|NCT04688242|No Intervention|Control Arm|No anal dilatation or probiotics per anus was allowed, from 2 weeks after proctectomy until reduction of ileostomy.
88965935|NCT04677400|Experimental|Experimental Group|Participants in the Experimental group start the MBA intervention immediately (Time 0; T0).
88965936|NCT04677400|Active Comparator|Waiting-list group|Participants in the waiting-list group start the MBA intervention at Time 1 (T1; 15 days after the Experimental group).
88965937|NCT00390130|Active Comparator|Pentacel|The subjects in this arm will be vaccinated with Pentacel
88965938|NCT00390130|Active Comparator|Prevnar|The subjects in this arm will be vaccinated with Prevnar
88965939|NCT02978755|Experimental|GM102 escalating doses|8 successive cohorts
88965940|NCT02978755|Experimental|GM102 escalating doses + carboplatin+paclitaxel|2 successive cohorts
88965941|NCT02978755|Experimental|GM102 recommended dose|3 parallel cohorts in sex cord stromal, epithelial ovarian and cervix cancers
88965942|NCT04650880|Active Comparator|Vitamin D|Vitamin D 50,000 IU/ week for 4 weeks, followed by 50,000 IU once every 2 weeks for 52 weeks Those who remain anovulatory after 6 months will be treated with a 6-month course of letrozole (2.5mg to 7.5mg for 5 days per cycle titrated according to response) for ovulation induction.
88965943|NCT04650880|Placebo Comparator|Placebo|Placebo tablets with same external appearance for 52 weeks Those who remain anovulatory after 6 months will be treated with a 6-month course of letrozole (2.5mg to 7.5mg for 5 days per cycle titrated according to response) for ovulation induction.
88965944|NCT04601077|Active Comparator|Nitric Oxide|Nitric Oxide (NO) lozenges taken twice daily by mouth for 30 days
88965945|NCT04601077|Placebo Comparator|Placebo|Placebo of Nitric Oxide (NO) lozenges taken twice daily by mouth for 30 days
88965946|NCT02972281|Other|Patients with bacterial infections|Patients with recurrent and/or severe bacterial infections
88965947|NCT04547530|Active Comparator|Vitamin D|"Vitamin D 50,000IU per week for 4 weeks from recruitment, followed by 50,000IU per week every 2 weeks throughout the IVF cycle. Subjects to stop own supplements and folic acid will be provided. If pregnant and fetal viability confirmed at 6 weeks gestation, switch to Materna until delivery.~If not pregnant, to continue vitamin D 50,000IU once every 2 weeks until 6 months from recruitment.~The rest of the IVF, embryo transfer procedure and antenatal care will be the same as usual practice."
89026578|NCT00599911|Experimental|Lu AA24530: 20 mg|
89026579|NCT00599911|Active Comparator|Duloxetine: 60 mg|
89026580|NCT00599911|Placebo Comparator|Placebo|
89026581|NCT00501462|Other|Mild renal impairmnent|
89026582|NCT00501462|Other|moderate renal impairment|
89559605|NCT06274853|Experimental|MAD Cohort 1|Multiple oral doses of TBD mg GS-441524under fasted or fed conditions twice daily for 5 days (Days 1 to 5) and only a morning dose on Day 6
89559606|NCT06274853|Experimental|MAD Cohort 2|Multiple oral doses of TBD mg GS-441524under fasted or fed conditions twice daily for 5 days (Days 1 to 5) and only a morning dose on Day 6
89559607|NCT06274853|Experimental|MAD Cohort 3|Multiple oral doses of TBD mg GS-441524under fasted or fed conditions twice daily for 5 days (Days 1 to 5) and only a morning dose on Day 6
89559608|NCT06274853|Placebo Comparator|MAD Placebo|Matching Placebo under fasted or fed conditions
89559609|NCT06274801|Experimental|Seralutinib 90 mg|Seralutinib inhaled orally twice per day (BID)
89559610|NCT06274788|Other|Single arm OMEGAVEN® (fish oil triglycerides; injectable emulsion)|The dose of investigational drug (study treatment), as well as all other components of the overall nutritional regimen is solely at the discretion of the Investigator. It is assumed the Investigator will use sound medical judgement, follow institutional standards of care regarding the nutrition provided to each patient, and review applicable prescribing information indicating the maximum and recommended dose of Omegaven of 1 g/kg/day infused intravenously over 8 to 24 hours as long as the infusion rate does not exceed 1.5 mL/kg/hour.
89559611|NCT06274775|Experimental|Educational Video Group|Group A (intervention group), which will be shown an educational video about the nail biopsy procedure in addition to standard of care, which includes verbal information about the procedure and pre-operative and post-operative handouts with instructions provided via quick-response (QR) code.
88965948|NCT04547530|Placebo Comparator|Placebo|"Placebo tablets identical to the active drug for 4 weeks from recruitment, followed by placebo tablets once every 2 weeks throughout the IVF cycle. Subjects to stop own supplements and folic acid will be provided. If pregnant and fetal viability confirmed at 6 weeks gestation, switch to Materna until delivery.~If not pregnant, to continue placebo tablets once every 2 weeks until 6 months from recruitment.~The rest of the IVF, embryo transfer procedure and antenatal care will be the same as usual practice."
89559612|NCT06274775|No Intervention|Standard of Care Group|Standard of care only, which includes verbal information about the procedure and pre-operative and post-operative handouts with instructions provided via quick-response (QR) code.
89559613|NCT06274762|Experimental|Experimental group|A pre-test will be conducted to determine socio-demographic data and to assess breast cancer awareness (champion health belief model scale). Experimental and control groups will be formed. The 45 people in the experimental group will be divided into 5 groups of 8 people. Each group will receive 45 minutes of theoretical training and 60 minutes of BSE application and will be explained and applications will be provided on the model. Question - Answer - 20 minutes will be allocated for feedback. 5 groups will be allocated one day each.4 weeks after the training, the experimental group will be called again in 5 groups and the champion health belief model scale will be repeated, they will be asked to perform the BSE application on the model and evaluation will be made according to the BSE evaluation form prepared by the researcher. 6 months after the study, the whatsapp group will be questioned about whether individuals have BSE.
89559614|NCT06274762|Active Comparator|Control Group|A pre-test will be conducted to determine socio-demographic data and to assess breast cancer awareness (champion health belief model scale). Experimental and control groups will be formed.The control group will not be intervened until the study is over.
89559615|NCT06274736||Women who will undergo a breast augmentation or reconstruction with Motiva® Sizer during surgery.|
89559616|NCT06274736||Women who will undergo a breast augmentation or reconstruction without Motiva® Sizer during surgery.|
88965949|NCT04531696|Other|Standard|"UPTIDER consists of 8 substudies:~Pilot phase~Invasive Lobular Carcinoma (ILC) substudy~Inflammatory Breast Cancer (IBC) substudy~Molecular heterogeneity and treatment response substudy~Patient-derived xenograft (PDX) / Patient-derived Organoid (PDO) substudy~Metabolomics substudy~Liquid biopsy substudy~Hereditary cancer syndromes substudy The intervention, consisting of sample collection only, is identical in all substudies, however, the focus of downstream analysis of the samples may be different."
88965950|NCT04495504|Experimental|Ropivacaine group|Administration of a bolus dose of ropivacaine, followed by a continuous infusion of ropivacaine during the first 48 hours postoperatively.
88965951|NCT00390208|Other|Group 1|Combination triple therapy of Lucentis, Dexamethasone and Visudyne Therapy
88965952|NCT00390208|Other|Group 2|Monotherapy: One 0.5 mg intravitreal Ranibizumab injection
88965953|NCT04466956|Active Comparator|Virtual reality for reduction of pain and anxiety during MVA|25 participants randomised to use VR headset during MVA and complete questionnaire and short interview regarding experience
88965954|NCT04466956|No Intervention|Control group- no VR|25 participants randomised to not use VR headset during MVA and complete questionnaire and short interview regarding experience
88965955|NCT00389103|Placebo Comparator|placebo|
88965956|NCT04438447|Experimental|ERAS plus artificial nutrition|"Patients randomised in the treatment arm will be treated with a full ERAS protocol that establishes oral food at will plus parenteral nutrition (PN) from postoperative day 1. A 3-bag compartment peripheral parenteral solution (mOsm < 800) containing carbohydrate, lipids and proteins will be infused to deliver 20/25 total Kcal/kg for a total of 5 days after the operation. In case of the occurrence of any complication impairing the full or partial recovery of oral food, the treatment will be continued until clinically indicated"
88965957|NCT04438447|Active Comparator|Enhanced recovery protocol|"Patients randomised in the control arm will be treated with a full ERAS protocol that establishes oral food at will. In case of the occurrence of any complication impairing the full recovery of oral food within postoperative day 7, patients will receive parenteral nutrition as in the treated arm until clinically indicated"
88965958|NCT04384003|Active Comparator|Shear Wave Ultrasound Elastography|Shear Wave Ultrasound Elastography (SWUE, AplioTM 300 Platinum, Toshiba Medical System Corp, Japan, 6I) to examine the morphology and mechanical properties (μ = ρVs2, μ is the shear modulus of the tissue, ρ is the density of muscle (1000 kg m-3), Young's modulus )
88965959|NCT04384003|Active Comparator|The 3-D Motion Analysis|An optoelectronic-based 3D motion analysis system, including cameras, force plates, and an EMG system will be used in this study. A lower limb model (pelvis included) will be established through commercial motion analysis software (VICON Corp, UK). We will use this model to measure joint kinematics, joint kinetics, and ground reaction forces during functional activities, such as level walking.
89026583|NCT00501462|Other|Normal renal function|
89026584|NCT00599950|Experimental|1|Topical mitomycin C on the corneal epithelium of patients undergoing photorefractive keratectomy (PRK)
89026585|NCT00599950|Placebo Comparator|2|Photorefractive keratectomy (PRK)without mitomycin C.
89026586|NCT00600145|Experimental|1|Mirtazapine
89026587|NCT00600145|Placebo Comparator|2|Placebo
89559617|NCT06274723|Experimental|Source|Participants in source arm will receive e-cigarette education messages manipulated in one of two source types.
89559618|NCT06274723|Experimental|Sidedness|Participants in sidedness arm will receive e-cigarette education messages manipulated in one of two sidedness types.
89026588|NCT00600223||1|Patients undergoing laryngectomy and pharyngeal reconstruction
89026589|NCT00470015|Experimental|MART1 Analog, gp100 and Survivin|
89026590|NCT04325971|Experimental|Healthy Subjects|All healthy subject are gathered in one arm
89026591|NCT04326127||Control|Healthy volunteers
89559619|NCT06274710|Experimental|ODYSSEE-KH|Participants in the intervention arm of the trial will have full access to digital counselling materials for CKD self-care and RRT education. Program engagement is dynamic with videos, digital handouts, animated charts, infographics, interactive digital trackers, and self-assessment forms. Patients will receive weekly email links to digital sessions (Supplements 1 and 2). Initial sessions will build motivation for therapeutic change. Subsequent sessions follow CBT guidelines. Finally, a monthly video posted on ODYSSEE will address common challenges and patient comments or queries.
89559620|NCT06274710|No Intervention|Usual care (UC)|UC is the standard of usual care which provides patients with conventional digital CKD education
89559621|NCT06274697|Experimental|Magnetic sensor|The CapMagic device is a small magnetic sensor, whose technology is derived from magnetocardiography, with a very weak field identical to that of a refrigerator magnet, which is placed on the foot or toe to record curves reflecting the state of the arterial network. It does not require direct skin contact.
89559622|NCT06274671||Clinically Isolated Syndrome|Patients with a diagnosis of Clinically Isolated Syndrome
89559623|NCT06274671||Healthy Controls|Age- and gender-matched healthy controls.
89559624|NCT06274658||Spinal Cord Injury|This group includes people with spinal cord injury and the level of injury is at the 6th thoracic vertebra or above.
89559625|NCT06274658||Non-injured Controls|This group includes age- and sex-matched non-injured control participants.
89559626|NCT06274632|Experimental|ADELANTE|Participants will receive 5, individualized problem solving sessions delivered by a community health worker over 6 months. The intervention content is framed around a bi-lingual film about HIV.
89559627|NCT06274632|No Intervention|Enhanced Care Condition|Participants in the enhanced care control group will receive 5 locator phone calls confirming contact information at the same interval as CHW sessions in the ADELANTE group. They will be offered routine HIV health promotion materials as is available in the clinic. If a participant requests support for navigation or case management, they will be encouraged to contact their HIV team
89559628|NCT06274606|Experimental|Exercise Group (EX-group)|The EX-group will complete 8 weeks of supervised aerobic exercise training. The EX-group will also continue normal care with bariatric doctors and nurses along with the exercise intervention.
89559629|NCT06274606|No Intervention|Standard Care Only Group (SC-group)|The SC-group will only complete the orientation visit and testing visits. The participants that are randomized to this group will continue normal care with bariatric doctors and nurses. They will participate in study assessment visits only.
89026592|NCT04326127||Case|Volunteers with diagnosed sleep apnea
89026593|NCT00600379|Experimental|A,|Virtual Reality training for an overall of 18 sessions 2/week + usual care.
89026594|NCT00600379|No Intervention|B,|Usual care
89026595|NCT02891707|Active Comparator|Control Group|The investigators will recruit 20 healthy subjects at Walter Reed National Military Medical Center (WRNMMC) with the goal of consenting and enrolling 15 healthy subjects to assess the reliability and validity the wearable Rehabilitative Lower-limb Orthopedic Accommodating-feedback Device (ReLOAD) system.
89026596|NCT02891707|Active Comparator|Amputee Group|The investigators will recruit a total of 130 subjects (65 at WRNMMC and 65 at the Miami VA) with the goal of consenting and enrolling 100 subjects (50 and WRNMMC and 50 at the Miami VA) with lower limb amputation to utilize the ReLOAD system.
89026597|NCT00501618|Other|Fazaclo|open label switch from generic clozapine to Fazaclo
89026598|NCT00600457||A,1|
89026599|NCT02891434|Experimental|Acquisition on TouchScreen|Subjects practice the task and retention TouchScreen, transfer 1 on LeapMotion and transfer 2 on Kinect
89559630|NCT06274580|Experimental|Embolization of the middle meningeal artery|Endovascular treatment of chronic subdural hematoma
89559631|NCT06274580|No Intervention|standard of care|"control group will managed according to the current standard of care with wait and see approach and best medical treatment"
89559632|NCT06274567|Experimental|Active intermittent theta burst stimulation (iTBS)|The Active intermittent theta burst stimulation (iTBS) arm will receive active iTBS applied to the inferior parietal lobule (IPL)
89559633|NCT06274567|Placebo Comparator|Sham intermittent theta burst stimulation (iTBS)|The Sham intermittent theta burst stimulation (iTBS) arm will receive sham iTBS applied to the inferior parietal lobule (IPL)
89559634|NCT06274554|Experimental|IL-23 Therapy with Fluconazole|"Fluconazole will be blindly administered as capsules for oral consumption. On the first day, 200 mg will be given. Subjects will then take 100 mg once daily for thirteen days.~Subjects will have the option to take open-label fluconazole beginning at Week 12. (200 mg on the first day and 100 mg once daily for the next thirteen days)"
89559635|NCT06274554|Placebo Comparator|IL-23 Therapy with Placebo|"Placebo will be blindly administered as capsules for oral consumption. On the first day, 200 mg will be given. Subjects will then take 100 mg once daily for thirteen days.~Subjects will have the option to take open-label fluconazole beginning at Week 12. (200 mg on the first day and 100 mg once daily for the next thirteen days)"
89559636|NCT06274541||Patients with HGSEC|
89559637|NCT06274515|Experimental|Mechanisms of Acquired Resistance|Participants with breast cancer who have a newly appearing or recurrent metastatic lesion while on anti-cancer therapy will be assigned to one of 3 cohorts.
89559638|NCT06274515|Experimental|Mechanisms of Primary Resistance|Participants with breast cancer who have a progressing tumor lesion while on anti-cancer therapy will be assigned to one of 2 cohorts.
89559639|NCT06274476|Experimental|maxillary atrophic ridge|received ridge splitting done by piezo surgery and implant placement in maxillary arch
89559640|NCT06274476|Active Comparator|mandibular atrophic ridge|received ridge splitting done by saw technique using ridge expanders and implant placement in maxillary arch
89559641|NCT06274463|Experimental|Brain disease|
89559642|NCT06274450|Experimental|Drinks with active ingredients Rosa Roxburghii and Pomegranate|Take drinks with active ingredients such as Rosa Roxburghii and Pomegranate. Drink every morning on an empty stomach, 20ml/2 sachets/day.
89559643|NCT06274450|Other|Blank Group|Not taking drinks
89559644|NCT06274437|Experimental|BND-35 Dose Escalation (Sub-Part 1A)|"Accelerated titration followed by standard 3 + 3 dose escalation design with enrollment of at least 3 participants per dose level cohort. BND-35 will be administered at escalating doses of 0.3 mg/kg to 20 mg/kg intravenously (IV), every 2 weeks (Q2W)"
88965960|NCT04384003|Active Comparator|EMG acquisition system|Electromyographic signals measures will be focused on the Abductor Hallucis (AbdH), Peroneus Longus (PL) and Previous Brevis (PB), Gluteus Medius (Glut Med), and Gluteus Maximus (Glut Max). In order to reduce the cross-talk of other muscles in the foot, a miniature wireless surface EMG sensor (TrignoTM Mini Sensor, Delsys Inc. USA) will be used after confirmation of our previous research results.
89559645|NCT06274437|Experimental|BND-35 in Combination with Nivolumab Dose Escalation (Sub-Part 1B)|"Standard 3 + 3 dose escalation design with enrollment of at least 3 participants per dose level cohort. BND-35 will be administered at escalating doses of 3 mg/kg to 20 mg/kg intravenously (IV) every 2 weeks (Q2W). Nivolumab will be administered at a dose of 240 mg IV, every 2 weeks (Q2W)."
89559646|NCT06274437|Experimental|BND-35 in Combination with Cetuximab Dose Escalation (Sub-Part 1C)|"Standard 3 + 3 dose escalation design with enrollment of at least 3 participants per dose level cohort. BND-35 will be administered at escalating doses of 3 mg/kg to 20 mg/kg intravenously (IV) every 2 weeks (Q2W). Cetuximab will be administered intravenously (IV) at a dose of 500 mg/m2, every 2 weeks (Q2W)"
89559647|NCT06274437|Experimental|BND-35 in Combination with Nivolumab Dose Optimization (Sub-Part 2A)|BND-35 dose optimization in combination with nivolumab. The indications for the combination cohorts will be selected following completion of Part 1. Enrollment will start after the recommended dose(s) of BND-35 have been determined based on data from Sub-Parts 1A, 1B, and 1C. Nivolumab will be administered at a dose of 240 mg IV, every 2 weeks (Q2W).
88965961|NCT04384003|Active Comparator|Foot intrinsic muscle assessment and training device|"Schematic diagram of the novel modified foot intrinsic muscle (FIM) assessment and training device, which consists of one controller unit (signal generators, amplifier and A/D converter; signal generators provide noise-enhanced vibration to facilitate the muscle activation), 2 voice coil motor & server, 2 optical rulers, 2 rail scale, and 7 load cells.~The main concept for this design is to provide the quantitative assessment of the foot intrinsic muscles and facilitation of intrinsic muscles of the fool during functional sporting activities such single-leg-standing and kicking."
88965962|NCT04350073||COVID-19 ICU Patients|COVID-10 patients with respiratory failure admitted to the ICU
88965963|NCT04350073||ICU Patients (Control)|Non-COVID-19 respiratory failure patients requiring mechanical ventilation > 48 h receiving similar ICU standards of care at Duke
88965964|NCT04321954|Experimental|LENVATINIB|"Study procedures include screening for eligibility and study treatment, evaluations, and follow up visits~Lenvatinib will be administered orally daily at a predetermined dose for 2, 4, or 6 cycles, dependent on response. 1 cycle is 28 days.~Surgery per standard of care will follow lenvatinib treatment."
88965965|NCT04540159||Case|Advanced stage Colorectal cancer patients with intraabdominal ascites
88965966|NCT04540159||Control|Liver cirrhosis and congestive heart failure patients with intraabdominal ascites
88965967|NCT00390481|Other|Intervention|EC-IC Bypass
88965968|NCT00390481|No Intervention|Control|Best Medical Therapy
88965969|NCT01350115|Active Comparator|LDE225|Participants received 400 mg once daily.
88965970|NCT01350115|Placebo Comparator|Placebo|Participants received matching placebo.
88965971|NCT02903212|Experimental|Rheumatoid arthritis|Patients with rheumatoid arthritis. An injection of autologous apoptotic cells is performed on the D0.
88965972|NCT04227106|Experimental|EB-101|One-time surgical application of EB-101 on up to 6 chronic, RDEB wounds
88965973|NCT04142983|Experimental|Study Group|Participants will receive a single dose of Tdap vaccine (Adacel) every 3 months for a total of 5 immunizations over a period of 12 months.
88965974|NCT03509181|Experimental|CBM|Cognitive Bias Modification for Interpretation delivered via smartphone
88965975|NCT03509181|Active Comparator|Symptom Tracking|Weekly symptom monitoring smartphone app with anxiety and depression symptom scores
88965976|NCT04084795|Active Comparator|EMDR plus MtCS|MtCS stimulation will consist of 1mA MtDCS for 20 minutes applied immediately before EMDR sessions.
88965977|NCT04084795|Placebo Comparator|EMDR plus sham-MtCS|Sham stimulation will consist of inactive MtDCS for 20 minutes applied immediately before EMDR sessions
88965978|NCT04084795|No Intervention|Treatment as Usual|Patients in this condition will not receive EMDR nor MtCS sessions, and will continue to attend their regular visits with rheumatology and psychiatry. The patients from the TAU group will have the choice to attend 10 sessions of EMDR group therapy when the research project finishes.
88965979|NCT04082299||Pregnant women|pregnant women expected to be vaccinate with Tdap vaccine during their 3th trimester
88965980|NCT04082299||Non pregnant women|Non pregnant women expected to be vaccinate with Tdap vaccine
89026600|NCT02891434|Experimental|Acquisition on Kinect|Subjects practice the task and retention Kinect, transfer 1 on TouchScreen and transfer 2 on LeapMotion.
89559648|NCT06274437|Experimental|BND-35 in Combination with Cetuximab Dose Optimization (Sub-Part 2B)|BND-35 dose optimization in combination with cetuximab. The indications for the combination cohorts will be selected following completion of Part 1. Enrollment will start after the recommended dose(s) of BND-35 have been determined based on data from Sub-Parts 1A, 1B, and 1C. Cetuximab will be administered intravenously (IV) at a dose of 500 mg/m2, every 2 weeks (Q2W)
89559649|NCT06274424|Experimental|Group Cognitive Behavioral Therapy Intervention|The Friends Program
89559650|NCT06274411|Experimental|Standby cannulated ECMO|For standby cannulated ECMO procedures, femoral cannulas are inserted either by percutaneous approach or surgical approach. The primed circuit is connected to the inserted ECMO cannulas, clamps are kept on circuit, and ECMO is on standby during PCI. When PCI cause hemodynamic instability, clamps on circuit are removed, and VA-ECMO is initiated to maintain maintain adequate systemic pressure and perfusion.
89559651|NCT06274411|Active Comparator|Prophylactic ECMO|Prophylactic ECMO procedures are performed in the catheterization laboratory before PCI. Femoral cannulas are inserted either by percutaneous approach or surgical approach. Following cannula placement, VA-ECMO is initiated to maintain adequate systemic pressure and perfusion during PCI.
88965981|NCT04020172|Experimental|Dobutamine + Goal-Directed Fluid Therapy|All patients will receive a baseline infusion of Ringer's lactate at 2 ml/kg/h to satisfy maintenance fluid requirements. The intervention will commence at anesthesia induction and continue for up to 4 hours postoperatively. In addition to maintenance fluids, patients will receive 250 ml fluid challenges with crystalloid as required until they are no longer fluid responsive. The absence of fluid responsiveness will be defined as the absence of a sustained rise in stroke volume index of at least 10% for 20 minutes or more, at which point, the patient will be considered fluid optimized. At this point, a low-dose dobutamine infusion at a fixed rate (2.5 μg/kg/min) will be commenced and maintained until 4 hours postoperatively. The infusion rate will be halved and/or discontinued if the patient develops tachycardia (heart rate ≥ 100 bpm) for more than 30 minutes despite adequate anesthesia/analgesia and fluid status.
88965982|NCT04020172|No Intervention|Standard of care|Patients in the control group will also receive a baseline infusion of Ringer's lactate at 2 ml/kg/h to satisfy maintenance fluid requirements, which will be commenced upon admission to the operating room. The anesthetic management will otherwise be according to standard practice. No specific cardiac output monitoring device will be used to guide fluid therapy. Likewise, perioperative dobutamine will not be used unless clinically indicated to improve cardiac function.
88965983|NCT04011202|Experimental|VR Group|Receives the VR protocol
89559652|NCT06274398|Experimental|Active|2 TAF/EVG (20/16mg) rectal inserts
88965984|NCT04011202|No Intervention|Control Group|Receives regular care
88965985|NCT03991741|Experimental|melanoma|
88965986|NCT03991741|Experimental|head and neck cancer|
88965987|NCT03962374|Experimental|Frova|Frova will be used to facilitate the endotracheal intubation.
88965988|NCT03962374|Active Comparator|Stylet|Stylet will be used to facilitate the endotracheal intubation.
88965989|NCT03937609|Other|Standard dosing|All eligible patients will receive an intravenous infusion of IFX at 5 mg/kg IFX at week 0. The control group will continue with 5 mg/kg IFX at week 2 and 6, followed by every 8 weeks.
88965990|NCT03937609|Experimental|Intervention group|All eligible patients will receive an intravenous infusion of IFX at 5 mg/kg IFX at week 0. The intervention group will receive model based dosing of infliximab with 5mg/kg at various timepoints based on the dashboard model.
88965991|NCT02858284|Experimental|TUG Device|1 time external application - device powered on
88965992|NCT02858284|Sham Comparator|Sham|1 time external application - device powered off
88965993|NCT00390598|Active Comparator|senna 36 mG + PEG 2L|Bowel preparation with senna tablets 36 mG and PEG 2L prior to colonoscopy.
88965994|NCT00390598|Active Comparator|4 L PEG|Bowel preparation with 4 L PEG prior to colonoscopy.
88965995|NCT03872479|Experimental|Adults Low Dose|Single dose of EDIT-101 administered by subretinal injection surgery
88965996|NCT03872479|Experimental|Adults Middle Dose|Single dose of EDIT-101 administered by subretinal injection surgery
88965997|NCT03872479|Experimental|Adults High Dose|Single dose of EDIT-101 administered by subretinal injection surgery
88965998|NCT03872479|Experimental|Pediatric Middle Dose|Single dose of EDIT-101 administered by subretinal injection surgery
89559653|NCT06274398|Placebo Comparator|Placebo|2 Matching placebo inserts
89559654|NCT06274385|Experimental|Betalain-rich Concentrate|A single dose of a BRC supplementation
88965999|NCT03872479|Experimental|Pediatric High Dose|Single dose of EDIT-101 administered by subretinal injection surgery
88966000|NCT03801031|Active Comparator|Lidocaine|Patients being treated for gynecologic cancer assigned aqueous lidocaine solution as intervention to use during sexual encounters.
88966001|NCT03801031|Placebo Comparator|Placebo|Patients being treated for gynecologic cancer assigned placebo solution as intervention to use during sexual encounters.
88966002|NCT03797560|Experimental|Ba-Duan-Jin group|"Ba-Duan-Jin therapy: The participants will be guided by a research staff to do the Ba-Duan-Jin therapy for 50 minutes twice weekly for 12 weeks, in the outpatient section of the hospital.~Placebo pregabalin capsules: Pregabalin placebo treatment will be administered at bedtime once a day, starting at 150 mg for the first week, and increase to the dose of 300 mg from the second week. After one week, if 300 mg dose is tolerable, then maintain it for 10 additional weeks, if not, then go back to the 150 mg dose for 10 additional weeks."
88966003|NCT03797560|Active Comparator|Pregabalin group|"Wellness education and muscle relaxation exercise program: This program will be held for 50 minutes twice weekly for twelve weeks, containing 10-minute wellness education, 10-minute doctor-patient discussion, and 30-minute guided muscle relaxation exercise.~Active pregabalin capsules: As same usage as the placebo pregabalin capsules."
88966004|NCT03495414||Healthy Controls (HC)|Controls will be physically and psychologically healthy and will show no indication of clinical hypersexuality.
88966005|NCT03495414||Patients with hypersexual disorder (HD)|Patients will meet diagnostic criteria for HD as defined in the DSM-5 proposed criteria for hypersexual disorder (Kafka, 2010) and CSBD according to ICD-11.
88966006|NCT00390637|Experimental|1|Low Protein, Low GI Diet
88966007|NCT00390637|Experimental|2|Low Protein, High Glycemic Index Diet
88966008|NCT00390637|Experimental|3|High Protein, Low Glycemic Index diet
88966009|NCT00390637|Experimental|4|High Protein, High glycemic index diet
88966010|NCT00390637|Experimental|5|Control diet (current recommendations)
88966011|NCT03574402|Experimental|Arm1: Avitinib Maleate|Patients with EGFR de novo T790m mutation receive Avitinib 300mg orally (PO) twice daily (BID) on day 1-28.
88966012|NCT03574402|Experimental|Arm2: Chidamide plus Afatinib|"Patients with EGFR sensitive mutation with BIM deletion polymorphism receive Afatinib plus Chidamide.~Chidamide will be administered 30mg orally twice weekly, 28 days as one cycle. Afatinib will be administered 40mg orally once a day, 28 days as one cycle."
88966013|NCT03574402|Experimental|Arm3: crizotinib|Patients with MET 14 exon mutation receive crizotinib 250mg PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88966014|NCT03574402|Experimental|Arm4: X396|Patients with MET amplification receive X396 225mg PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88966015|NCT03574402|Experimental|Arm5: X396|Patients with ROS1 fusion receive X396 225mg PO QD on days 1-28. 28 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity.
88966016|NCT03574402|Experimental|Arm6: X396|Patients with Ntrk1/2/3 fusion receive X396 225mg PO QD on days 1-28. 28 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity.
88966017|NCT03574402|Experimental|Arm7: Pyrotinib Maleate|Patients with HER2 mutation receive Pyrotinib Maleate 400mg PO QD on days 1-28. 28 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity.
88966018|NCT03574402|Experimental|Arm8: AZD3759|EGFR sensitive mutation with brain/meningeal metastasis receive AZD3759 200mg PO BID on days 1-28. 28 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity.
88966019|NCT03574402|Experimental|Arm9: Pirotinib|"Patients with EGFR20ins mutation positive receive Pirotinib.~This arm was divided into three groups:~Group 1, 60mg PO QD on days 1-28. 28 days as one cycle. Group 2, 40mg PO BID on days 1-28. 28 days as one cycle. Group 3, Dosage was determined according to the number of PR patients in Group 2."
88966020|NCT03574402|Experimental|Arm10: Nimotuzumab plus gemcitabine and carboplatin|"Lung squamous cell carcinoma with EGFR amplification. Nimotuzumab 400mg, iv gtt. on day 1,8,15. Gemcitabine 1250mg/m^2, iv gtt. on day 1,8. Carboplatin AUC5, iv gtt. Q3W on day 1.~21 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity."
88966021|NCT03574402|Experimental|Arm11: Nimotuzumab plus pemetrexed and cisplatin|"Lung adenocarcinoma with EGFR amplification. Nimotuzumab 400mg, iv gtt. on day 1,8,15. pemetrexed 500mg/m^2, iv gtt. on day 1. Cisplatin 75mg/m^2, iv gtt. Q3W on day 1.~21 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity."
88966022|NCT03574402|Experimental|Arm12: Pirotinib|"Patients with rare EGFR mutation receive Pirotinib.~This arm was divided into two groups:~Group 1, 40mg PO BID on days 1-28. 28 days as one cycle. Group 2, Dosage was determined according to the number of PR patients in Group 1."
88966023|NCT03574402|Experimental|Arm13: Avitinib|Patients with EGFR sensitive mutation receive Avitinib 300mg PO BID on days 1-28. 28 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity.
88966024|NCT03574402|Experimental|Arm14: Sintilimab|Patients with PD-L1(TPS)≥50% without EGFR mutation or ALK rearrangement. Sintilimab 200mg iv gtt. Q3W on day1. 21 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity.
88966025|NCT03574402|Experimental|Arm15: Sintilimab|"Patients with TMB≥10 mut/Mb，1%≦PD-L1<50% without EGFR mutation or ALK rearrangement.~Sintilimab 200mg iv gtt. Q3W on day1. 21 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity."
88966026|NCT03574402|Experimental|Arm16: Sintilimab|"Patients with KRAS and TP53 mutation, 1%≦PD-L1<50%, TMB<10 mut/Mb without EGFR mutation or ALK rearrangement.~Sintilimab 200mg iv gtt. Q3W on day1. 21 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity."
88966027|NCT03574402|Experimental|Arm17: Sintilimab plus pemetrexed and cisplatin|"Patients with PD-L1<1%, TMB<10 mut/mb without EGFR mutation, ALK rearrangement, KRAS or TP53 mutation.~Sintilimab 200mg iv gtt. Q3W on day1. Pemetrexedb 500mg/m^2 iv gtt. Q3W on day1. Cisplatin 75mg/m^2 iv gtt. Q3W on day1. 21 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity."
88966028|NCT03574402|Experimental|Arm18: Sintilimab plus Gemcitabine and carboplatin|"Patients with PD-L1<1%, TMB<10 mut/mb without EGFR mutation, ALK rearrangement, KRAS or TP53 mutation.~Sintilimab 200mg iv gtt. Q3W on day1. Gemcitabine 1g/m^2 iv gtt. on day1,8. Carboplatin AUC5 iv gtt. Q3W on day1. 21 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity."
88966029|NCT03524989|Active Comparator|Treatment|Hyperbaric Oxygen Therapy: 2 months of treatment consisting of 40 daily sessions, 60 minutes of 100% oxygen at pressure of 2 ATA each, five days a week
88966030|NCT03524989|Sham Comparator|Control/Crossover|SHAM therapy: 2 months of treatment consisting of 40 daily sessions, 60 minutes of 21% oxygen at pressure of 1.01 ATA each, five days a week
88966031|NCT03479203|Experimental|Healthy, Non-Smokers|Non-nicotinized electronic cigarette aerosol (16 2-second long puffs)
88966032|NCT03460483|Experimental|Comprehensive LS genetic testing|Testing for inherited forms of cancer and tumor sequencing
88966033|NCT03458533||Group 1|Obese patients with indication to bariatric surgery
89559655|NCT06274385|Placebo Comparator|Placebo|A single dose of a placebo
89559656|NCT06274372|Other|control group|volume controlled ventilation
89559657|NCT06274372|Experimental|fcv|flow controlled ventilation
89559658|NCT06274359|Experimental|Digital storytelling group|Caregivers will receive a series of digital stories by text message designed to increase influenza vaccine confidence.
89559659|NCT06274359|No Intervention|Control group|Caregivers will receive standard care.
89608745|NCT02984865|Experimental|group N3|Patients were attach with PCA containing 100ml combination of nalbuphine 2.5mg/kg and flubiprofen axetil 100mg after receiving the loading dose of nalbuphine 5 mg and flubiprofen axetil 50mg intravenously 30 mins before the end of the operation .
89608746|NCT02984865|Other|Group ESRD|30 patients with ESRD who underwent PD catheter placement using left lateral transversus abdominis plane (TAP) block combined with rectus sheath (RS) block from our center. The TAP and RS blocks were respectively conducted with 15 ml of 0.5% ropivacaine and 10 ml of 0.5% ropivacaine. Pain intensity was evaluated by verbal rating scale (VRS), and the degree of patient and surgeon satisfaction was qualified by a categorical scale.
88966034|NCT03458533||Group 2|Overweight or obese patients without indication to bariatric surgery, able to obtain weight loss trough diet and lifestyle changes
88966035|NCT03458533||Group 3|Overweight or obese patients without indication to bariatric surgery, not able to obtain weight loss trough diet and lifestyle changes
88966036|NCT03404986|Other|Standardized ureteroscopy group|
88966037|NCT03404986|Other|Ultrasonography ureteroscopy group|
88966038|NCT03399136|Experimental|Moderate-intensity aerobic exercise|In the moderate-intensity aerobic exercise group, participants performed a self-paced 1-mile walk (3-5 METs) on an indoor track in the same exercise center as the high-intensity exercise group. Initial sessions lasted 20-30 minutes and were increased weekly to 45 minutes in parallel to the duration of the high-intensity exercise group.
88966039|NCT03399136|Experimental|High-intensity aerobic exercise|In the high-intensity aerobic exercise group, exercise training was performed on a motorized treadmill with occasional substitution with the elliptical machine as needed for joint pain. Target heart rate was based on the baseline treadmill test and was calculated as percentage of the heart rate reserve (HRR=maximal HR-resting HR). Initially, participants trained for 20-30 minutes at 50-60% of HRR. Duration and intensity was increased by 10% weekly so that within 5-7 weeks the aerobic exercise sessions lasted 30-45 minutes at 70-85% of HRR and at the end of the 16 weeks lasted 40-45 minutes at 75-90% of HRR.
88966040|NCT03357952|Experimental|Part 1: JNJ-63723283 + Daratumumab|Participants in Safety Run-in cohort will receive daratumumab IV and JNJ-63723283 IV for 1 cycle (28 days). Participants will continue to receive study treatment until confirmed disease progression, unacceptable toxicity, or any other treatment discontinuation criteria are met. Participants who were previously receiving JNJ-283 plus daratumumab have the opportunity to continue daratumumab therapy alone.
88966041|NCT03357952|Experimental|Part 2 and Part 3: Daratumumab/ JNJ-63723283 + Daratumumab|Participants in Treatment Arm A will receive daratumumab IV and in Treatment Arm B will receive daratumumab IV and JNJ-63723283 IV for cycles of 28 days each. All participants will continue to receive study treatment until confirmed disease progression, unacceptable toxicity, or any other treatment discontinuation criteria are met. Participants who were previously receiving JNJ-283 plus daratumumab have the opportunity to continue daratumumab therapy alone.
88966042|NCT03285880|Experimental|Declarative memory|Napping v. wake effect on a declarative memory task (storybook)
88966043|NCT03285880|Experimental|Procedural memory|Napping v. wake effect on a procedural memory task (motor sequence learning or mirror tracing)
88966044|NCT03285880|Experimental|Emotional memory|Napping v. wake effect on an emotional memory task (emotional faces or storybook)
88966045|NCT00390754|Experimental|Pregnancy Test Group|Group got free home pregnancy test kits
88966046|NCT00390754|No Intervention|2|Group did not receive free home pregnancy test kits
88966047|NCT00390832|Active Comparator|A|recombinant human erythropoietin beta
88966048|NCT00390832|Placebo Comparator|B|0.9% NaCl solution
88966049|NCT00390871|Active Comparator|Fentanyl/Propofol sedation first|Patient given fentanyl only first, then sedated with fentanyl/propofol as needed to have Richmond Agitation Sedation Scale (RASS) Score 0 to -1. After washout with fentanyl only, patient sedated with fentanyl/dexmedetomidine to have RASS Score 0 to -1.
88966050|NCT00390871|Active Comparator|Fentanyl/Dexmedetomidine sedation first|Patient given fentanyl only first, then sedated with fentanyl/dexmedetomidine as needed to have RASS Score 0 to -1. After washout with fentanyl only, patient sedated with fentanyl/propofol to have RASS Score 0 to -1.
88966051|NCT03134833|Experimental|Automated Messaging & Monitoring|"Youth randomized to the Automated Messaging and Monitoring Intervention (AMMI) arm will receive daily texts to motivate, inform, and refer youth to health care and HIV services. Message banks will focus on the HIV Prevention Continuum, with libraries of text messages dedicated to healthcare, wellness, sexual health, drug use and medication reminders (e.g., for PrEP) for young men-who-have-sex-with-men (MSM) and non-MSM.~Youth will also receive a weekly monitoring survey that covers seven domains, including: use of PrEP/PEP, condomless sex, potential symptoms of acute HIV infection, potential symptoms of STI, excessive use of alcohol and/or drugs, feelings of sadness or depression, and housing or food insecurity."
88966052|NCT03134833|Experimental|Peer Support|Youth randomized to the Peer Support arm will be enrolled in private, online peer support groups, where they can post information and have discussions with other participants, guided broadly by topics relevant to the HIV Prevention Continuum. Peer Supporters will post to encourage and broadly guide discussion, while Coaches and Project Coordinators will be available to provide factual information (as needed), and remove inappropriate content. All youth will also receive AMMI messages.
88966053|NCT03134833|Experimental|Coaching|Youth randomized to the Coaching arm will have access to a dedicated Coach for crisis management, problem-solving, linkage to HIV and related services, and care coordination. The Coach's primary means of contact with youth will be electronic - using e-mail, social media, text messages - and phone calls. In person contacts may also occur. AMMI is also provided to all youth.
88966054|NCT03134833|Experimental|Coaching + Peer Support|Youth randomized to the Coach + Peer Support arm will be enrolled in online, private peer support groups and have access to a Coach. As well as AMMI messages.
88966055|NCT03129061|Experimental|Cohort 1 Patients with M/R SCCHN|"Patients with unresectable and metastatic SCCHN cancer who will receive anti-PD-1 treatment under SOC. SOC treatments currently include nivolumab and pembrolizumab (anti-PD-1 treatment). The protocol may be amended to include other agents should they become SOC. Patients will receive a baseline [18F]F-AraG PET/CT scan and another [18F]F-AraG PET/CT scan 6 to 12 weeks after anti-PD-1 dose."
89026601|NCT02891434|Experimental|Acquisition on LeapMotion|Subjects practice the task and retention LeapMotion, transfer 1 on TouchScreen and transfer 2 on Kinect.
89608747|NCT03696069||Patients treated with immunotherapy and BRAF/MEK inhibitors|
89559660|NCT06274346|Active Comparator|Multiangular Isometric exercise group:|Each patient was allowed to warm up for 10 minutes on the bicycle ergometer before each isometric exercise session. For this part of the study we position the patient on isokinetic device with the hip joint flexed at 90˚ the back supported with a backrest and the pelvis stabilized with a strap. The distal of the thigh was rested on a lifted support in the front of the seat and was wrapped with a strap. The center of rotation of the dynamometer was placed opposite the center of the femur lateral epicondyle. The lever arm of the dynamometer was set so that the load cell pad was comfortable against the lower part of the leg close to the lateral malleolus.
89559661|NCT06274346|Experimental|Retrograde walking group:|Each patient was allowed to warm up for 10 minutes on the bicycle ergometer before each retrograde walking session. The patients were instructed to walk backwards for 10 min on a flat surface for a distance of 30 m at a comfortable speed supervised by the physiotherapist. Patients were required to walk backwards without looking behind. Safety measures were taken to ensure patients' well-being during retro walking. The physiotherapist stood beside the patients, gave them moral support, and guided them through the walking path till the patients are confident to walk on their own. The patient is also encouraged to increase their speed throughout the 4 weeks of rehabilitation.
89559662|NCT06274346|Other|Pulsed short wave diathermy:|Patient is in supine lying, contra planer (transverse) method was used. The electrodes were placed over opposite aspects of the part i.e. knee. Timing: was applied for 20 minutes, 3 days/ week for duration of 4 weeks. After pulsed SWD, both groups were given static quadriceps exercise, dynamic quadriceps exercise, straight leg raise, prone knee bending, side lying hip abduction, prone hip extension for 10 repetitions with 5 seconds hold followed by 2 seconds rest for each exercise for a period of 3 days per week for duration of 4 weeks.
88966056|NCT03129061|Experimental|Cohort 2 Patients with de novo SCCHN|Patients with de novo SCCHN prior to initiation of anti-cancer treatment (e.g., radiation, chemoradiation, or surgery). Patients will receive ONE DOSE of the anti-PD-1 treatment, after the baseline [18F]F-AraG PET/CT scan, baseline blood and tumor tissue collection. Patients will receive a second [18F]F-AraG PET/CT scan 2 - 3 weeks after the one dose of anti-PD-1 treatment.
88966057|NCT03055858|Experimental|PDA closure|
88966058|NCT02972203|Experimental|Mindfulness Training for Primary Care|• Mindfulness Training for Primary Care (MPTC) is a primary care adaptation that includes core common Mindfulness-Based Intervention (MBI) elements. MTPC is a referral-based, insurance-reimbursable 8-week group psychotherapy delivered primarily by Patient-Centered Medical Home-integrated behavioral clinicians. MTPC groups are 2 hours long for 8 weeks, with a 7-hour day of silent group practice on a weekend. MTPC also emphasizes psychoeducational skills for self-regulation including a collaborative primary care provider (PCP) action-planning appointment during week 6.
88966059|NCT02972203|Active Comparator|Mindfulness Intro. +resources +waitlist|Control arm: Participants receive a 60-minute introduction to mindfulness group plus referral to a list of community mindfulness resources such as private-pay community mindfulness classes, mobile mindfulness applications, books, and online recordings. These participants are added to a 6-month waitlist for a Cambridge Health Alliance (CHA) mindfulness-based intervention group. All participants are scheduled to meet with their primary care provider during week 6 for a collaborative action planning visit.
88966060|NCT02987335||Lean Diabetes Subjects|N=20 subjects with BMI 16-22.5 kg/m2, with a history of low birth weight and malnutrition documented on at least one occasion. Will undergo pancreatic clamp.
88966061|NCT02987335||Type 2 Diabetes Mellitus Subjects|N=13 subjects with BMI 22.5-27 kg/m2. Will undergo pancreatic clamp
88966062|NCT02987335||Type 1 Diabetes Mellitus Subjects|N=15 subjects with BMI 16-22.5 kg/m2. Will undergo pancreatic clamp
88966063|NCT02987335||Lean Nondiabetic Subjects|N=16 nondiabetic with BMI 16-22.5 kg/m2 subjects 19-45 years of age and in general good health, taking no medications, with normal glucose tolerance and no family history of diabetes. These subjects will be similar in age, ethnicity and BMI with the lean DM group, and will be recruited through various means of community outreach, including notices in shops and newspapers. Will undergo pancreatic clamp
88966064|NCT02987335||Obese Nondiabetic Subjects|N=9 nondiabetic with BMI 16-22.5 kg/m2 subjects 19-45 years of age and in general good health, taking no medications, with normal glucose tolerance and no family history of diabetes. These subjects will be similar in age, ethnicity and BMI with the Type 2 diabetes Mellitus group, and will be recruited through various means of community outreach, including notices in shops and newspapers. Will undergo pancreatic clamp
88966065|NCT02939365|Experimental|Belatacept patients|"Forty patients who are previously enrolled in belatacept based regimens with a minimum of 7 years of follow up at 4 transplant centers and who are maintained on belatacept, an antiproliferative ± steroids will be approached for enrollment.~Drug withdrawal of steroids (in patients on steroids) and of antiproliferatives (MPAs or mTor inhibitors). Patients who continue to be stable for 3 months on belatacept monotherapy will be converted from q 4 weeks to q 8 weeks belatacept administrations."
88966066|NCT00389181|Experimental|Medical management|Patients with unruptured BAVMs will receive symptomatic medical management alone.
88966067|NCT00389181|Active Comparator|Interventional therapy|Patients with unruptured BAVMs will receive symptomatic medical management with invasive therapies (any combination of surgery, endovascular embolization, or radiotherapy).
88966068|NCT00389220|Active Comparator|BioMatrix Flex stent|Coronary stent placement with Biolimus A9 coated stent with biodegradable polymer
88966069|NCT00389220|Active Comparator|Cypher Select stent|Coronary stent placement with Sirolimus coated stent with durable polymer
88966070|NCT02650258||Young Adult|80 Adults 21-40 years of age: 10 Male and 10 Female in each 5 year increment (21-25, 26-30, 31-35, 36-40).
88966071|NCT02650258||Middle Aged Adults|80 Adults 41-60 years of age: 10 Male and 10 Female in each 5 year increment (41-45, 46-50, 51-55, 56-60).
88966072|NCT02650258||Older Adults|100 Adults 61-85 years of age: 10 Male and 10 Female in each 5 year increment (61-65, 66-69, 70-75, 76-80, 81-85).
89026602|NCT02891434|Active Comparator|Acquisition on TouchScreen Control Group|Subjects practice the task and retention TouchScreen, transfer 1 on LeapMotion and transfer 2 on Kinect
89026603|NCT02891434|Active Comparator|Acquisition on Kinect Control Group|Subjects practice the task and retention Kinect, transfer 1 on TouchScreen and transfer 2 on LeapMotion.
89026604|NCT02891434|Active Comparator|Acquisition on LeapMotion Control Group|Subjects practice the task and retention LeapMotion, transfer 1 on TouchScreen and transfer 2 on Kinect.
89026605|NCT00600535|Experimental|Abiraterone acetate (non-fasting)|
89026606|NCT00600535|Experimental|Abiraterone acetate (fasting)|
89026607|NCT00600574|Active Comparator|S|physiotherapy in warm pool by means of stretching
89559663|NCT06274307|Active Comparator|Active Comparator: Transversus abdominis plane (TAP) block performed in operating room|The treatment group will have a transversus abdominis plane (TAP) block performed prior to closing surgical port sites post-operatively in an insufflated abdomen in the operating room (OR). The local anesthetic used for the TAP block will be 30 to 40ml of Ropivacaine 0.375%, not to exceed a max dose of 3mg/kg of 0.375% divided equally bilaterally. Each study participant will receive standard post-operative pain medication orders of morphine 2mg q5mins times 4 doses followed by hydromorphone. 0.5mg q10mins times 4 doses.
89026608|NCT00600574|Experimental|AI|physiotherapy in warm pool by means of Ai Chi
89026609|NCT00600652||1|glucocorticoid-resistant patients
89026610|NCT00600652||2|glucocorticoid-sensitive patients
89026611|NCT00600652||3|normal controls
89026612|NCT00600691|Experimental|1|5mg finasteride orally, daily for 2 weeks prior to prostate biopsy and one week following prostate biopsy.
89026613|NCT00623077|Experimental|Total Marrow Irradiation (MTI) with Tomotherapy|TMI given prior to alkylator intensive conditioning regimen (Busulfan 9.6 mg/kg intravenously (IV) (>4 yrs of age) or 13.2 mg/kg IV (< 4 years of age), Melphalan 100 mg/m^2, Thiotepa 500 mg/m^2 for high risk solid tumor patients, Whole lung radiation 1500cGy in 10 fractions by Day 60, stem cell transplantation on day 0. Ifosfamide, etoposide, and mesna are given Days 0-4 followed by filgrastim for 3 doses. Cohorts of patients (n=3) will be treated with increasing doses of TMI (600, 1000, 1200 cGy) directed toward the bones.
89026614|NCT00623155|No Intervention|1|Control group
89026615|NCT00623155|Experimental|2|Test group
89026616|NCT00600730|Experimental|1|Hyperinsulinemic euglycemic clamp with fMRi
89026617|NCT00600730|Experimental|2|Hyperinsulinemic hypoglycemic clamp with fMRI
89026618|NCT00600769|Other|treatment of MAC and other NTM|Clarithromycin drug given twice daily.
89026619|NCT00470210|Experimental|1|Peginterferón alfa-2a (40 KD) (Pegasys®) 180 ug/week Ribavirin (Copegus®) 1600 mg/day Epoetin β (450 UI/kg/week)
89026620|NCT00600847|Active Comparator|1|desloratadine 20 mg
89026621|NCT00600847|Active Comparator|2|desloratadine 5 mg
89026622|NCT00600847|Placebo Comparator|3|
89026623|NCT04325932|Experimental|Urinary Kallikrein group|Urinary Kallikrein for injection, 0.15PNA IU,qd, for 2 weeks, administered within 96 hours after TIA or acute ischemic stroke, with basic therapies like dual antiplatelet therapy, blood pressure-lowering therapy and lipid-lowering therapy.
89026624|NCT04325932|No Intervention|control group|with basic therapies like dual antiplatelet therapy, blood pressure-lowering therapy and lipid-lowering therapy.
89026625|NCT00501657|Experimental|Sitagliptin (100mg)|Active drug (sitagliptin)
89026626|NCT00501657|Placebo Comparator|Placebo (sugar pill)|Inactive drug (placebo)
89026627|NCT00600964|Experimental|GX15-070MS|GX15-070MS at various doses and schedules
89026628|NCT02891512|Experimental|ELF and Xinepa®|The very low frequency magnetic fields (ELF) are magnetic fields already use for orthopedics pathology that have shown to be able to repair, to reduce pain, inflammation and edema in the damaged tissues. Xinepa® is a dietary supplement containing alpha-lipoic acid, N-acetyl-L-carnitine, turmeric, vitamins B, E and C. They have an antioxidant and anti-inflammatory action on nervous system and they act on cellular energy metabolism.
89026629|NCT02891512|Placebo Comparator|ELF and Placebo Xinepa®|The very low frequency magnetic fields (ELF) are magnetic fields already use for orthopedics pathology that have shown to be able to repair, to reduce pain, inflammation and edema in the damaged tissues. Xinepa® without its specific activity for the condition being treated.
89026630|NCT00601042|Experimental|1|Swedish snus ad libitum as a substitute for cigarettes
89026631|NCT00601042|Placebo Comparator|2|Tobacco-free, nicotine-free placebo snus ad libitum as a substitute for cigarettes
89026632|NCT00601081||1|Very low birth weight and preterm infants who will likely receive fortification of breast milk with HMF
89026633|NCT00501696|Other|1|A randomized placebo-controlled, parallel-group study, crossover-design
89026634|NCT00501696|Other|2|A randomized placebo-controlled, parallel-group study, crossover-design
89026635|NCT00475436|Experimental|Arm 1|
89026636|NCT04326322|Experimental|Methionine Intake|Oral consumption of eight hourly experimental meals- Includes 4 tracer-free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein free cookies and 4- labeled amino acid experimental meals.
89026637|NCT04326088||head and neck cancer with free flap reconstruction|patients with head and neck cancer who underwent tumor wide excision and primary free flap reconstruction or secondary free flap reconstruction between March 2008 and February 2017
89026638|NCT00601237|Experimental|A|Participants will receive HIV-related text messages
89026639|NCT00601237|Active Comparator|B|Participants will receive nutrition-related text messages
89026640|NCT00601237|No Intervention|C|Participants will attend a 90-minute focus group to develop messages for the cell-phone program
89026641|NCT00475475|Experimental|1|Fructose-sweetened beverage Subjects will be asked to drink 4 servings of a beverage sweetened with 100% fructose per day for 8 days, while consuming an ad libitum diet (same solid food for all three diet periods).
89026642|NCT00475475|Experimental|2|Glucose-sweetened beverage Subjects will be asked to drink 4 servings of a beverage sweetened with 100% glucose per day for 8 days, while consuming an ad libitum diet (same solid food for all three diet periods).
89559664|NCT06274307|Active Comparator|Transversus abdominis plane (TAP) block performed in PACU|The treatment group will have a transversus abdominis plane (TAP) block performed post-operatively after the patient has been transferred from the Operating Room to the Post Anesthesia Care Unit (PACU). The local anesthetic used for the TAP block will be 30 to 40ml of Ropivacaine 0.375%, not to exceed a max dose of 3mg/kg of 0.375% divided equally bilaterally. Each study participant will receive standard post-operative pain medication orders of morphine 2mg q5mins times 4 doses followed by hydromorphone. 0.5mg q10mins times 4 doses
88966073|NCT02638987|Experimental|Dry needling|After the second computer task, a single dry needling session will be performed with the subject lying on the non painful side. After palpation of a taut band and detection of MTrP 2 in the upper trapezius muscle, a trained physiotherapist will penetrate the needle into the MTrP and will move the needle up and down in multiple directions. When local twitch responses are elicited, this will be repeated until the local twitch responses are extinct.
88966074|NCT02638987|No Intervention|Rest|After the first computer task, participants will rest in sidelying position for 10 minutes.
88966075|NCT00389259|Experimental|A|IV Scopolamine 0.25mg in adults and 0.006mg/kg in children Q4h
88966076|NCT00389259|Placebo Comparator|B|IV Look alike drug Q 4h
89559665|NCT06274294|Experimental|SC CT-P13 induction|Experimental arm: SC induction of 240 mg of CT-P13 at week 1, then 120 mg at weeks 2, 3, 4 then every 2 weeks until week 24.
89559666|NCT06274294|Other|IV CT-P13 induction|Control arm: IV induction of 5 mg/kg of CT-P13 at weeks 1 and 2 then SC (120 mg) every 2 weeks until week 24.
89559667|NCT06274281|Experimental|Experimental Group Training|After the intensive 5-days rehabilitation treatment (2 hours/day, 5 days/week, for 1 week), the EG pa-tients will be encouraged to perform the self-management plan at home with the same duration and in-tensity as the CG (1 hour/session, 3 sessions/week, 12 weeks) through a Digital Telemedicine platform (Phoema GPI Platform, GPI Spa, Trento, Italy). The platform will be implemented with wearable digital devices Axivity AX3, 3-axis Logging Accel-erometer to gather objective and subjective information on the patient's motor activity. At discharge (T1), each patient in the experimental group will receive 2 wearable sensors (Axivity AX3,) for moni-toring of movement data (i.e., activity level, number of steps, distance travelled). The data will be transmitted periodically to the research center and processed. The subjective assessment of the patient's motor activity will be collected by clinical diaries focusing on gait and activity level.
88966077|NCT02471053|Experimental|Moderate Intensity Exercise|All consenting patients will participate in an aerobic training program, twice-weekly over a 12-week period. Assessments will be performed at baseline (pre-training) and post-program (12-weeks). All participants will continue to receive standard care for their cancer diagnosis.
89559668|NCT06274281|Active Comparator|Control Group Training|After the intensive 5-days rehabilitation treatment (2 hours/day, 5 days/week, for 1 week), the CG patients will be encouraged to perform the self-management plan at home with the same duration and intensity as the EG (1 hour/session, 3 sessions/week, 12 weeks) without a Digital Telemedicine platform and wearable devices use.
89559669|NCT06274268|Experimental|Interventionnal|"Hand Grip Dynamometer Chair rise test measurement of impedance SEFI Nutritional Intake Assessment Questionnaire GPAQ questionnaire SARC-F questionnaire"
89559670|NCT06274255||Controlle group|healthy children presenting to the pediatric neurology clinic at the same times were enrolled as the control group. The demographic characteristics (age, sex, and body mass index) of the patient group and their clinical (attack durations and frequencies, symptoms during attacks, and treatments) and laboratory (hemoglobin (Hb), hematocrit (Hct), platelet, glucose, calcium (Ca), magnesium (Mg), vitamin D, folate and ferritin levels) characteristics were recorded.
88966078|NCT02393716|Other|Endovascular repair|Endurant Evo AAA Stent Graft System
88966079|NCT02312011|Experimental|IONIS-DMPKRx|"IONIS DMPKRx is administered subcutaneously over the course of 6 weeks for dose levels 1, 2, 3, 4, and 5.~IONIS DMPKRx is administered subcutaneously over the course of 12 weeks for dose levels 4 or 5."
88966080|NCT02312011|Placebo Comparator|Placebo|A placebo is administered subcutaneously over the course of 6 weeks. A placebo is administered subcutaneously over the course of 12 weeks.
88966081|NCT02304913|Experimental|Hypoglossal acupuncture|Single treatment of hypoglossal needle acupuncture during the chemotherapy administration: Treated points will be Jinjin (Golden Liquid/EX-HN12) left beside the lingual frenulum and Yuye (Jade Fluid/EX-HN13) right beside the lingual frenulum. Both points are treated in quick succession with immediate removal of the needle.
88966082|NCT02304913|Sham Comparator|Sham acupuncture|Single treatment of hypoglossal sham acupuncture uring the chemotherapy administration: Treated points will be 1 to 1.5 cun (a cun is defined as the width of the patient's thumb at the knuckle) beside the verum acupuncture points Jinjin and Yuye using the dull side of the needle.
88966083|NCT02304913|Active Comparator|Dietary recommendations|This group adheres to specific dietary recommendations for dysgeusia of the German Cancer Society.
88966084|NCT02225392|Active Comparator|Delayed bronchial thermoplasty|"After randomisation they will wait for 25 weeks (control group) and then start with bronchial thermoplasty.~Bronchial thermoplasty (BT) will be performed using the Alair system (Boston Scientific, USA). Patients will undergo 3 bronchoscopy procedures with BT at least 3 weeks apart. Treatment sessions are designed to address different lobes of the lung with the right lower lobe treated during the first bronchoscopy, the left lower lobe treated during the second bronchoscopy, and both the right and left upper lobes treated in the third and final bronchoscopy. The right middle lobe and proximal airways including RC2 are left untreated."
88966085|NCT02225392|Experimental|Immediate bronchial thermoplasty|"After randomisation they start immediate with bronchial thermoplasty treatment.~Bronchial thermoplasty (BT) will be performed using the Alair system (Boston Scientific, USA). Patients will undergo 3 bronchoscopy procedures with BT at least 3 weeks apart. Treatment sessions are designed to address different lobes of the lung with the right lower lobe treated during the first bronchoscopy, the left lower lobe treated during the second bronchoscopy, and both the right and left upper lobes treated in the third and final bronchoscopy. The right middle lobe and proximal airways including RC2 are left untreated."
89559671|NCT06274255||Patients diagnosed with migraine were included as the study group|"Patients diagnosed with migraine were included as the study group The demographic characteristics (age, sex, and body mass index) of the patient group and their clinical (attack durations and frequencies, symptoms during attacks, and treatments) and laboratory (hemoglobin (Hb), hematocrit (Hct), platelet, glucose, calcium (Ca), magnesium (Mg), vitamin D, folate and ferritin levels) characteristics were recorded.~Patients and controls in whom Mg therapy was contraindicated (renal failure or nephrolithiasis), with non-migraine headaches, with substance/drug addiction (abuse), with psychiatric and/or chronic systemic diseases, and cases with histories of drug use (antidepressants, neuroleptics, tranquilizer group, antiepileptic medications (lithium and carbamazepine), using headache prophylaxis (beta blockers and calcium antagonists), and patients with deficient file data were excluded from the study."
89559672|NCT06274242|Experimental|Prebiotic arm|
89559673|NCT06274242|Placebo Comparator|Placebo arm|
89559674|NCT06274229||Aarhus, installation site|Residents of Aarhus (DK), living at or nearby the site of the installed Intervention
89559675|NCT06274229||Aarhus, control site|Residents of Aarhus (DK), living at or nearby the control site
89559676|NCT06274229||Bucharest, intervention site|Residents of Bucharest (RO), living at or nearby the site of the installed Intervention
89559677|NCT06274229||Bucharest, control site|Residents of Bucharest (RO), living at or nearby the control site
89559678|NCT06274229||Castelló, intervention site|Residents of Castelló (ES), living at or nearby the site of the installed Intervention
89559679|NCT06274229||Castelló, control site|Residents of Castelló (ES), living at or nearby the control site
89559680|NCT06274229||Orvieto, intervention site|Residents of Orvieto (IT), living at or nearby the site of the installed Intervention
89559681|NCT06274229||Orvieto, control site|Residents of Orvieto (IT), living at or nearby the control site
89559682|NCT06274229||Potsdam, intervention site|Residents of Potsdam (DE), living at or nearby the site of the installed Intervention
89559683|NCT06274229||Potsdam, control site|Residents of Potsdam (DE), living at or nearby the control site
89559684|NCT06274216|Experimental|Group A|Patients in group A received 5000 IU of vitamin D3 orally every day for 12 weeks
89559685|NCT06274216|Active Comparator|Group B|Patients in group B received 400mg of vitamin E orally every day for 12 weeks
89559686|NCT06274203|Experimental|Oral vitamin D3|Monthly oral vitamin D3 dose (100,000 IU,150,000 IU, and 200,000 IU)
89559687|NCT06274190||First patient focus group|"During these focus groups, we aim to achieve various goals:~To gain insight into the bowel symptoms and the consequences patients experienced after treating rectal cancer~To understand the expectations of the patients regarding an electronic bowel diary~To determine whether the questions/items derived from the literature study for the bowel diary are clear and understandable for the patients~To explore other relevant questions/items that should be added to the bowel diary~We will include 10-12 patients in this focus group."
89559688|NCT06274190||Delphi survey|"In this Delphi survey, a multidisciplinary group of experts and patients will score each item of the long list on a 1-9-point Likert scale from 'Not Important' (1) to 'Essential' (9) for inclusion in the bowel diary. Finally, a consensus meeting will be held for the participants who completed the Delphi survey.~We will recruit 10-18 Delphi panelists per area of expertise. These panelists are experts with international expert recognition in treating bowel symptoms in the following health care categories (abdominal surgeons, digestive/radiation oncologists, specialized pelvic floor muscle physiotherapists, nursing specialists). In addition, we will include one group comprising 10-18 patients in the Delphi survey, ensuring a comprehensive and holistic perspective on treating bowel symptoms across various healthcare categories."
89559689|NCT06274190||Second patient focus group|"Content validation of the newly developed bowel diary, will be tested in different international patient focus groups.~We will include 10-12 patients in each focus group."
89559690|NCT06274190||Usability of e-diary|"The participants will be asked to use a newly developed electronic bowel diary for 7 consecutive days.~During and after these 7 days, several questionnaires will be administered regarding the use of the application: complexity, need for additional support, coherence of the application, user-friendliness, and the need for prior knowledge.~Additionally, a questionnaire that explores the differences and/or similarities between the paper and electronic versions of the bowel diary will be conducted."
89559691|NCT06274190||Validation of e-diary|To evaluate the validity of the e-diary, encompassing both construct and criterion validity, participants will be requested to utilize the e-diary for 7 consecutive days. Additionally, to assess test-retest reliability and responsiveness, participants will be instructed to use the e-diary for two separate 7-day periods.
89559692|NCT06274177|Experimental|Treatment with BTL-785-7|Treatment with BTL-785F device (BTL-785-7 applicator)
88966086|NCT00391183|Active Comparator|Endoscopic stenting|patients with biliary obstruction will undergo endoscopic stenting.
89208444|NCT00742235|No Intervention|Vitamin D sufficient|Subjects who did not receive ergocalciferol and had a 25-OH vitamin D level >32 ng/ml
89208445|NCT00868920|Experimental|1|"The Graseby 3300 PCA pump will be loaded with a mixture of propofol 10 mg/cc containing 10 µg/cc remifentanil. The loading and demand doses will be individualized based on patient weight, height, age, and gender.~The initial loading phase of sedation will be performed by the anesthesiologist to permit estimation of patient sensitivity. Following the initial loading dose, a series of button presses will be issued by the anesthesiologist to achieve a state of moderate sedation, as determined by a decrease in BIS to the range of 75-80. Once this state has been reached, the button will be transferred to the patient for Patient C0ntrolled Sedation."
88966087|NCT00391183|No Intervention|Best supportive care|
88966088|NCT00005828|Experimental|green tea extract|Patients receive oral green tea extract six times daily for 4 months. Patients with a 50% decline in PSA, complete or partial response, or stable disease after 4 months continue treatment in the absence of disease progression or unacceptable toxicity. Patients with disease progression after 4 months receive no further treatment. Patients are followed every 3 months for 5 years or until disease progression. If disease progression, patients are followed every 6 months for 5 years.
89559693|NCT06274151|Experimental|Anti-inflammatory medicine|Week 2 after muscle strain injury Naproxen 500mg 2x daily
89559694|NCT06274151|Placebo Comparator|Placebo|Week 2 after muscle strain injury Placebo pill, no active compounds 2x daily
88812457|NCT04578925|Experimental|Happy, Healthy, Loved|"Both parents will complete surveys on a tablet during the postpartum hospital stay. Surveys cover three topic areas related to breast-feeding; modeling and feedback, partner support, and stress coping. For the next 6 weeks participants' will receive 4 personalized text messages per week based on their tablet survey responses. Participants will be asked one yes/no question each week (still breastfeeding? Text Y for yes, N for no). Once a no response has been received from a participant, all remaining text messages will emphasize coping and partner support rather than breastfeeding."
88966089|NCT01776229|Experimental|Behavioral|Exposure, Relaxation, & Rescripting Therapy-Child utilizes behavioral and cognitive therapy techniques of exposure therapy and cognitive restructuring.
88966090|NCT01776229|No Intervention|Waitlist Control|All potential participants will be evaluated and some will be randomly placed in the control group, following the five-week treatment phase, participants in the control group will be re-evaluated and offered the treatment
89208446|NCT00868920|Experimental|2|"The Graseby 3300 PCA pump will be loaded with a mixture of propofol 10 mg/cc containing 10 µg/cc remifentanil. The loading and demand doses will be individualized based on patient weight, height, age, and gender.~The initial loading phase of sedation will be performed by the anesthesiologist to permit estimation of patient sensitivity. Following the initial loading dose, a series of button presses will be issued by the anesthesiologist to achieve a state of moderate sedation, as determined by a decrease in BIS to the range of 75-80. Once this state has been reached,the anesthesiologist will control the sedation."
89208447|NCT00742079|Experimental|1 D-cycloserine, placebo|Participants will receive D-cycloserine 1 hour before a cognitive behavioral therapy (CBT) session on Week 1, and they will receive placebo 1 hour before a CBT session on Week 2.
89208448|NCT00742079|Experimental|2 Placebo, D-cycloserine|Participants will receive placebo 1 hour before a CBT session on Week 1, and they will receive D-cycloserine 1 hour before a CBT session on Week 2.
89559695|NCT06274125||NGAL measurement for evaluating kidney damage in patients undergoing robotic radical prostatectomy.|For the evaluation of kidney damage in patients undergoing robotic radical prostatectomy, blood samples will be collected at preoperative and perioperative 2nd and 6th hours to measure NGAL values.
89559696|NCT06274112|Experimental|TMS A|Active continuous thetaburst stimulation administered over right dorsolateral prefrontal cortex for 40 seconds (600 pulses total)
89559697|NCT06274112|Sham Comparator|TMS B|Sham continuous thetaburst stimulation administered over right dorsolateral prefrontal cortex for 40 seconds (600 pulses total)
89559698|NCT06274099|Experimental|EXPERIMENTAL GROUP|This group will be given designated nursing care.
89559699|NCT06274099|Active Comparator|CONTROL GROUP|Routine nursing care will be provided to this group.
89559700|NCT06274086|Experimental|Two-session catheter-directed sclerotherapy|Each patient received two sessions of catheter-directed sclerotherapy for endometrioma 1 day apart with the catheter left in situ overnight.
89559701|NCT06274073|Experimental|Single injection palmar digital block|The needle was inserted into the subcutaneous region from the palmar side to the root of the proximal phalanx, perpendicular to the frontal plane and the finger. For anesthesia, 3 ml of anesthetic agent (prilocaine hydrochloride) was applied to the described point with this single injection and the needle was slowly removed.
89559702|NCT06274073|Experimental|Double injection dorsal digital block|The needle was inserted into the proximal dorsal root of the proximal phalanx, into both the medial and lateral parts, perpendicular to the fingers and the frontal plane. After the aspiration, the injection was performed slowly and the needle was withdrawn concurently. A total of 3 ml of anesthetic agent (prilocaine hydrochloride) was injected into both the medial and lateral parts of the finger, 1.5 ml for each side.
89559703|NCT06274034|Experimental|Supportive Care (MUSE S headband, meditation)|Patients wear the MUSE S headband to bed every night for 8 weeks and meditate using the MUSE phone app during day hours for at least 5 minutes over 8 weeks.
89559704|NCT06274008|Experimental|Exparel|Adductor Canal Block with Bupivacaine Liposome Injectable Suspension Admixture bupivacaine 0.5 % 10 cc with Bupivacaine Liposome Injectable Suspension 10cc total 20
89559705|NCT06274008|No Intervention|Standard ACB with bupivacaine|Standard Adductor Canal Block (ACB) with Bupivacaine Standardized amount of 0.5% bupivacaine 20 cc
89559706|NCT06273982|Experimental|STEP-UP|
89559707|NCT06273982|Active Comparator|ARC|
88966091|NCT00005831|Experimental|Treatment (trastuzumab, combination chemotherapy)|Patients receive trastuzumab (Herceptin) IV over 30-90 minutes on days 1, 8, and 15; paclitaxel IV over 3 hours and carboplatin IV over 15 minutes on day 1; and gemcitabine IV over 30 minutes on days 1 and 8. Courses repeat every 3 weeks. Patients achieving a complete response (CR) receive 3 courses past CR. Patients achieving a partial response or stable disease continue on therapy until CR or disease progression or unacceptable toxicity.
88966092|NCT00005834|Experimental|chemo with thalidomide|chemo with thalidomide
88966093|NCT00005834|Active Comparator|chemo without thalidomide|chemo without thalidomide
88966094|NCT00005840|Experimental|Treatment (paclitaxel, cisplatin, abdominal radiotherapy)|"Patients receive paclitaxel IV over 1 hour and cisplatin IV on days 1, 8, 15, 22, 29, and 36. Patients also undergo whole abdominal radiotherapy for 5 consecutive days weekly for 6 weeks.~Cohorts of 3-6 patients receive escalating doses of paclitaxel and cisplatin until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, additional patients are treated at that dose level."
88966095|NCT00005843|Experimental|Arm I|Patients receive oral R115777 twice daily for 21 consecutive days. Treatment continues every 28 days in the absence of disease progression or unacceptable toxicity.
89559708|NCT06273969|Experimental|Osteopathic Manipulative Treatment|The OMT protocol is designed to target the somatic dysfunction associated with TOS.
89559709|NCT06273943|Active Comparator|Oral PrEP with daily or on-demand TDF/FTC|Participants randomly assigned to the oral PrEP regimen will be instructed to take a single dose combination of TDF 300 mg + FTC 200 mg (TDF/FTC), either daily or on-demand, according to their preferences.
89559710|NCT06273943|Experimental|Long-acting injectable PrEP with cabotegavir|Participants assigned to the cabotegravir group will initially take a 30mg oral tablet of cabotegravir daily for a four-week period. Following this initial phase, they will receive 13 intramuscular injections of 600mg (3mL) long-acting injectable cabotegravir (CAB-LA) administered every two months after an initial loading dose given one month after the last oral tablet.
89208449|NCT04730362|Active Comparator|Control group|20 patients in which a Guedel oral airway will be inserted for airway management and to conduct inhalational anesthetic through face mask fixed with harness to the head and then connected to anesthesia breathing circuit of MRI compatible anesthesia machine for maintenance of anesthesia of O2 and sevoflurane 2-4% .
88966096|NCT00005849|Experimental|Arm A|Paclitaxel (90 mg/m2, days 1, 8 and 15 of every 28 day cycle), Bryostatin-1 (50 mcg/m2, days 2, 9 and 16 of every 28 day cycle)
88966097|NCT00005858|Experimental|Arm I|"Patients receive LMB-9 immunotoxin IV continuously for 10 days. Treatment continues every 30 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of LMB-9 immunotoxin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
88966098|NCT00001077||1|Participants will receive peptamen drinks and multivitamin and mineral supplements, taken in addition to a regular diet for 4 months
88966099|NCT00001077||2|Participants will receive NuBasics drinks or equivalent amounts of NuBasics soups or bars and daily multivitamin and mineral supplements, taken in addition to a regular diet for 4 months
88966100|NCT00001077||3|Participants will receive multivitamin and mineral supplements, taken in addition to a regular diet for 4 months
88966101|NCT00700258||1|Patients treated with Temsirolimus for metastatic renal cell carcinoma (mRCC) under usual care settings.
88966102|NCT00700258||2|Patients treated with Temsirolimus for mantle cell lymphoma (MCL) under usual care setting
88966103|NCT00700258||3|Patients treated with Sunitinib for metastatic renal cell carcinoma (mRCC) under usual care setting
88966104|NCT00700258||4|Patients treated with Sunitinib for gastro-intestinal stroma tumor (GIST) under usual care setting
88966105|NCT00700258||5|Patients treated with Axitinib after treatment with Sunitinib or Cytokine for metastatic renal cell carcinoma (mRCC)
89208450|NCT04730362|Active Comparator|supraglottic group|20 patients in which supraglottic airway laryngeal mask airway (LMA) will be used and then connected to anesthesia breathing circuit of MRI compatible anesthesia machine for maintenance of anesthesia of O2 and sevoflurane 2-4% .
89208451|NCT00876096|Other|1|precocious diagnosis and taken care therapeutics of the systematic athlete's feet
89559711|NCT06273930|No Intervention|Control|"Superiority parallel 3-arm randomized control trial. The intention behind a superiority trial is that CSPS & Arginine are superior to commercially available desensitizing agents.~Double blinded study (Participants and Outcome Assessor)~Allocation ratio 1:1:1~Patients are chosen based on inclusion criteria. Patients undergo non-surgical periodontal therapy as part of their treatment. DH is assessed using the Schiff scale evaluation and tactile test Visual analogue Score (VAS) after treatment.~2 groups of patients receiving desensitizing agents applied for two consecutive 3-second applications, while others are placed in a control group.~DH is evaluated again immediately using the Schiff scale and tactile test VAS after the application of desensitizing agents Patients are instructed to maintain their oral hygiene by brushing their teeth twice daily with a specific dentifrice provided to them along with a soft toothbrush."
89559712|NCT06273930|Active Comparator|5% CSPS group|"Superiority parallel 3-arm randomized control trial. The intention behind a superiority trial is that CSPS & Arginine are superior to commercially available desensitizing agents.~Double blinded study (Participants and Outcome Assessor)~Allocation ratio 1:1:1~Patients are chosen based on inclusion criteria. Patients undergo non-surgical periodontal therapy as part of their treatment. DH is assessed using the Schiff scale evaluation and tactile test Visual analogue Score (VAS) after treatment.~2 groups of patients receiving desensitizing agents applied for two consecutive 3-second applications, while others are placed in a control group.~DH is evaluated again immediately using the Schiff scale and tactile test VAS after the application of desensitizing agents Patients are instructed to maintain their oral hygiene by brushing their teeth twice daily with a specific dentifrice provided to them along with a soft toothbrush."
89559713|NCT06273930|Active Comparator|8% arginine group|"Superiority parallel 3-arm randomized control trial. The intention behind a superiority trial is that CSPS & Arginine are superior to commercially available desensitizing agents.~Double blinded study (Participants and Outcome Assessor)~Allocation ratio 1:1:1~Patients are chosen based on inclusion criteria. Patients undergo non-surgical periodontal therapy as part of their treatment. DH is assessed using the Schiff scale evaluation and tactile test Visual analogue Score (VAS) after treatment.~2 groups of patients receiving desensitizing agents applied for two consecutive 3-second applications, while others are placed in a control group.~DH is evaluated again immediately using the Schiff scale and tactile test VAS after the application of desensitizing agents Patients are instructed to maintain their oral hygiene by brushing their teeth twice daily with a specific dentifrice provided to them along with a soft toothbrush."
89559714|NCT06273917|Experimental|PRIDE Patients|Community-dwelling adults (age 18+) in the ED with prior outpatient visits within the NM system and a history of dementia or mild cognitive impairment recorded in the NM EHR will be eligible for inclusion. We will include 290 patients across 3 sites to have medication reconciliation conducted by the clinical pharmacist. Patients who were previously prescribed CNS PIMs will have deprescribing recommendations communicated by the clinical pharmacist to the outpatient prescriber.
89559715|NCT06273904|Experimental|Group Receiving Active Stimulation and Sham Stimulation on Separate Days (All Participants)|All participants will receive active stimulation and non-active (sham) stimulation on different days. Before the stimulation sessions, all participants will complete experimental tasks during functional magnetic resonance imaging. On the next two study days, all participants will complete tasks before and after receiving active transcranial focused ultrasound (tFUS) on one day and sham (non-active) tFUS on another day. Stimulation (active or sham) is conducted briefly (< 10 minutes) in between tasks, not during tasks.
89559716|NCT06273865||Healthy volunteers|
89559717|NCT06273865||Hemophilia A patient|
89208452|NCT00662792|Experimental|T+S_PE/ Tio18GEL / Salm50DPI / T18GEL+S_DPI|7.5 µg/ 25 µg Tiotropium/Salmeterol (T+S_PE)/ 18 µg Tiotropium (Tio18GEL) / 50 µg Salmeterol MDPI (Salm50DPI) / 18 µg Tiotropium (T18GEL) plus 50 µg Salmeterol MDPI (S_DPI) BID
89559718|NCT06273852|Experimental|PBA-0405|Patients who are scheduled for surgical biopsy or tumor resection surgery will be injected at 1-2 days prior to surgery using the CIVO device. Each needle of the CIVO device will deliver up to 8.3 microliters of solution, including a vehicle control (sterile saline) or subtherapeutic microdoses of PBA-0405, as single agents. Each microdose is simultaneously injected in a columnar fashion through each of 8, or 5, (in a device configuration determined by tumor dimensions) into a single solid tumor or effaced metastatic lymph node.
89559719|NCT06273839|Experimental|Test 1 tablet followed by Test 2 tablet followed by Reference capsule|On Day 1 of each period, participants will receive a single dose of 1 of the tafamidis formulations. Each period is separated by a washout of at least 16 days between administration of study drug
88966106|NCT00584233|Experimental|Breast CT and Breast MRI|Four hundred women who will be having breast biopsy as part of their standard care (BIRADS 4 and 5) will undergo pre- and post- contrast breast computed tomography and pre- and post- contrast magnetic resonance imaging.
88812458|NCT04578925|No Intervention|Control|Control group participants will complete surveys on a tablet during the postpartum hospital stay. Surveys cover three topic areas related to breast-feeding; modeling and feedback, partner support, and stress coping. The control group participants will be sent 4 text messages per week for the first 6 weeks, but the content of the texts will be non-breastfeeding related. The content will instead summarize infant development facts.
88812459|NCT04512365|Placebo Comparator|Placebo oral capsule|Participants will receive a placebo at their first or second laboratory visit.
88812460|NCT04512365|Experimental|THC|Participants will receive THC (7.5 mg) at their first or second laboratory visit.
88812461|NCT04501796|Experimental|NT-I7|NT-I7 will be administered once by IM injection within 24 hours of baseline (day 0). The treatment course pursued in all enrolled participants will be a single dose. Dosing will be staggered with at least 72 hours between each study participant.
88812462|NCT04501796|Placebo Comparator|Placebo|Placebo will be administered once by IM injection within 24 hours of baseline (day 0). The treatment course pursued in all enrolled participants will be a single dose. Dosing will be staggered with at least 72 hours between each study participant.
88812463|NCT04480853|Experimental|Fingolimod|Open label Fingolimod 0.5 mg capsule taken once daily, oral.
88812464|NCT04452214|Experimental|CAN04 and pembrolizumab (Part 1)|Subjects will receive weekly doses of CAN04 in combination with pembrolizumab given as standard regimen
88812465|NCT04452214|Experimental|CAN04 + pembrolizumab + carboplatin + pemetrexed (Part 2)|Subjects will receive doses of CAN04 on Days 1 and 8 (Cycles 1 thru 4), and on Day 1 (Cycle 5 onwards) in combination with pembrolizumab given as standard regimen and carboplatin and pemetrexed standard of care
88812466|NCT04448171|Active Comparator|Activated TENS Unit with standard pain control measures|Activated TENS Unit with standard pain control measures during Office Based Cystoscopic Intra-detrusor Onabotulinumtoxin A Injection
88812467|NCT04448171|Placebo Comparator|Sham TENS Unit with standard pain control measures|Sham TENS Unit with standard pain control measures during Office Based Cystoscopic Intra-detrusor Onabotulinumtoxin A Injection
88812468|NCT04437706||Participants|Participants completing COVID-19 testing
88812469|NCT04430010|Experimental|Implementation|Teachers will implement the BEST in CLASS treatment in their classrooms
88812470|NCT04417283||Mother-infant dyads|Mother and/or infant participants will provide a series of biological specimens, including blood, urine, and microbiome samples. Additionally, each participant will wear a silicone wrist band each trimester to capture environmental exposures and will fill out study surveys related to diet, environmental exposures, and social factors.
88812471|NCT04402008|Experimental|Phase 1: Once Daily Dosing|Dose finding at 8 mg, 12 mg, or 16 mg of poziotinib once daily in 28-day treatment cycles.
88812472|NCT04402008|Experimental|Phase 1: Twice Daily Dosing|Dose finding at 4 mg, 6 mg, or 8 mg of poziotinib twice daily in 28-day treatment cycles.
88812473|NCT04402008|Experimental|Phase 2: Once Daily Dosing or Twice Daily Dosing|"Once Daily or Twice Daily Dosing as determined in Phase 1 in 28-day treatment cycles.~Cohort 1: EGFR exon 20 insertion mutations~Cohort 2: HER2 exon 20 insertion mutations"
88812474|NCT04398719|Active Comparator|CBD|
88812475|NCT04398719|Placebo Comparator|Placebo|
88812476|NCT04339270|Active Comparator|Azithromycin according to symptoms|Patients randomized to this arm will be prescribed azithromycin in function of their symptoms.
88812477|NCT04339270|Experimental|Azithromycin according to rheology|Patients randomized to this arm will be prescribed azithromycin in function of their sputum rheology.
88812478|NCT04318340|Active Comparator|Standard Applicators|All patients will be fitted with the 2.6 cm applicator and sized up to the 3.0 cm applicator if tolerable.
88812479|NCT04318340|Experimental|Tapered Applicator|All patients will be fitted with the novel tapered 3.0 cm applicator. Patients have the option of having magnetic resonance imaging with the tapered applicator in place.
88812480|NCT04277819||Patients with cystic fibrosis related liver disease|Patients with cystic fibrosis, who meet the criteria for diagnosis of liver disease according to the European Cystic Fibrosis Society best practice guidelines
88812481|NCT04277819||Patients without cystic fibrosis related liver disease|
88812482|NCT04276558|Experimental|Dose 1 - 0.5 µg/day|Dose of study drug per day: 0.5 µg/day Study drug concentration: 5 µg/mL MT8 given 1 drop QID
88812483|NCT04276558|Experimental|Dose 2 - 2.5 µg/day|Dose of study drug per day: 2.5 µg/day Study drug concentration: 25 µg/mL MT8 given 1 drop QID
88812484|NCT04276558|Experimental|Dose 3 - 5 µg/day|Dose of study drug per day: 5 µg/day Study drug concentration: 50 µg/mL MT8 given 1 drop QID
88812485|NCT04276558|Placebo Comparator|Vehicle|Dose of study drug per day: 0 µg/day Study drug concentration: Vehicle given 1 drop QID
88812486|NCT04223505|Active Comparator|TEE arm|TEE will be performed as per clinical routine using multiple standard tomographic planes to rule-out LA/LAA thrombus. Echocardiographic analysis will include: LAA-emptying velocity, and grading the severity of LAA spontaneous ECHO. The severity of the SEC will be graded on a 4 point scale with 1 = minor homogeneous contrast enhancement, 2 = significant homogeneous contrast enhancement, 3 = significant, dense, and inhomogeneous, slow-moving contrast, and 4 = dense slow-moving contrast.
89559720|NCT06273839|Experimental|Test 1 tablet followed by Reference capsule followed by Test 2 tablet|On Day 1 of each period, participants will receive a single dose of 1 of the tafamidis formulations. Each period is separated by a washout of at least 16 days between administration of study drug
89559721|NCT06273839|Experimental|Test 2 tablet followed by Reference capsule followed by Test 1 tablet|On Day 1 of each period, participants will receive a single dose of 1 of the tafamidis formulations. Each period is separated by a washout of at least 16 days between administration of study drug
89559722|NCT06273839|Experimental|Test 2 tablet followed by Test 1 tablet followed by Reference capsule|On Day 1 of each period, participants will receive a single dose of 1 of the tafamidis formulations. Each period is separated by a washout of at least 16 days between administration of study drug
89559723|NCT06273839|Experimental|Reference capsule followed by Test 1 tablet followed by Test 2 tablet|On Day 1 of each period, participants will receive a single dose of 1 of the tafamidis formulations. Each period is separated by a washout of at least 16 days between administration of study drug
88966107|NCT00556972|Experimental|Fecal Incontinence management system|Fecal Incontinence Management System is based on the same principle as fecal pouches. A barrier around anus to ensure adhesion and prevent leakage.
89559724|NCT06273839|Experimental|Reference capsule followed by Test 2 tablet followed by Test 1 tablet|On Day 1 of each period, participants will receive a single dose of 1 of the tafamidis formulations. Each period is separated by a washout of at least 16 days between administration of study drug
89559725|NCT06273826||Colorectal Leakage App group|"This group comprises patients who will be monitored using the Colorectal Leakage App based on the Dutch leakage score for early detection of anastomotic insufficiency after colorectal surgeries."
89559726|NCT06273813|Experimental|Ketorolac tromethamine|Cohort 1 - All subjects receive one Ketorolac tromethamine injection, followed by Ketorolac tromethamine gel topical Cohort 2 and 3 - Ketorolac tromethamine gel topical
88966108|NCT00009217|Active Comparator|Haloperidol-Haloperidol|Haloperidol for 20 weeks followed by haloperidol for 24 weeks
88966109|NCT00009217|Placebo Comparator|Haloperidol-Placebo|Haloperidol for 20 weeks followed by placebo for 24 weeks
88966110|NCT00009646|Experimental|Indomethacin|Indocid P.D.A., Merck Frosst, Kirkland, Que., Canada, and Merck, West Point, Pa.
88966111|NCT00009646|Placebo Comparator|Placebo|Saline solution
88966112|NCT00009919|Experimental|Treatment (semaxanib)|Patients receive SU5416 IV over 1 hour twice weekly. Treatment continues every 6 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients with CR receive an additional 6 months of therapy after achieving CR.
88966113|NCT00009958|Experimental|Stage I|Patients receive fCEA-TRI vaccine SC once daily on days 1, 29, 57, and 85.
88966114|NCT00009958|Experimental|Stage II|Patients receive vCEA-TRI vaccine intradermally once on day 1 and fCEA-TRI vaccine SC at the MTD determined in stage I once daily on days 29, 57, and 85.
88966115|NCT00009958|Experimental|Stage III|A single cohort of 6-10 patients receive both vaccines as in stage II, at the MTDs determined in stages I and II, and sargramostim (GM-CSF) SC once daily on days 1-4, 29-32, 57-60, and 85-88.
88966116|NCT00010114||Newly diagnosed embryonal tumors|The participants in this study are infants (< 3 years of age) with newly diagnosed medulloblastoma, primitive neuroectodermal tumor, or other embryonal tumor, atypical teratoid/rhabdoid tumor, intracranial germ cell tumor, or choroid plexus carcinoma who have received no prior therapy with the exception of steroids and have consented to allow research studies on banked tissue specimens
88966117|NCT00010192|Experimental|Treatment (rituximab and aldesleukin)|Patients receive rituximab IV on days 1, 8, 15, and 22. Patients then receive low-dose aldesleukin SC on days 29-39, 43-53, 57-67, and 71-81, and intermediate-dose aldesleukin SC on days 40-42, 54-56, 68-70, and 82-84.
88966118|NCT02122354|Experimental|Survey + videogame|"Hide and Seek videogame"
88966119|NCT00386516|Experimental|GM-CT-01, 5-FU|GM-CT-01 (280 mg/m2) combined with 5-FU (600 mg/m2) given 4 consecutive days in a 28 days cycle until disease progression.
89559727|NCT06273787|Experimental|diaphragmatic release|diaphragmatic myofascial release
89559728|NCT06273787|Active Comparator|positioning|positioning instruction for sleep apnea
89559729|NCT06273761|Experimental|Intervention|Participants who join the trial will have have a control period (no intervention) of 3 to 12 months before receiving medication management service (MMS) at 8 NGO community pharmacies. Since there are 8 NGO community pharmacies, 2 NGO community pharmacies will start delivering MMS by phase at 3, 6, 9 and 12 month intervals. Therefore, all participants who join the trial will receive MMS by month 12 from recruitment date. During the MMS service, pharmacists will review the participants' medication history and conduct medication reconciliation, refer them to doctors for reviewing the prescribing decision if necessary, as well as provide education and lifestyle advice on medication management.
89559730|NCT06273761|No Intervention|Control|Participants who join the trial will have have a control period of 3 to 12 months before receiving medication management service (MMS) at 8 NGO community pharmacies. Participants will have no MMS intervention during the control period. Since there are 8 NGO community pharmacies, two NGO community pharmacies will start delivering MMS by phase at 3, 6, 9 and 12 month intervals. Therefore, all participants who join the trial will receive MMS by month 12 from recruitment date.
88966120|NCT00011362|Active Comparator|Dexamethasone|Dexamethasone
88966121|NCT00011362|Placebo Comparator|Placebo|Saline
88966122|NCT00011713||Infertility patients|Patients undergoing infertility treatment at Massachusetts General Hospital Infertility Clinic.
88966123|NCT02972645|Experimental|LY3305677|Single escalating doses of LY3305677 administered subcutaneously (SC)
88966124|NCT02972645|Placebo Comparator|Placebo|Placebo administered SC
88966125|NCT00012025|Experimental|fulvestrant|"Patients receive fulvestrant intramuscularly on day 1. Courses repeat approximately every 28 days in the absence of disease progression or unacceptable toxicity.~Patients are followed every 3 months for 5 years or until disease progression. After disease progression, patients are followed every 3 months for 2 years and then every 6 months for 3 years."
89026643|NCT00475475|Placebo Comparator|3|Beverage sweetened with a non-caloric sweetener Subjects will be asked to drink 4 servings of a beverage sweetened with a non-caloric sweetener per day for 8 days, while consuming an ad libitum diet (same solid food for all three diet periods).
89559731|NCT06271993|Other|Collagen wound dressing with positive and negative controls|Application of test dressing, histamine, and saline with glycerin to volar forearm skin
89559732|NCT06271980||Survivors of early-onset colorectal cancer, with recurrent disease (Training Cohort)|Survivors of early-onset colorectal cancer who developed recurrent CRC within 60 months from primary tumor treatment, in the first cohort
89559733|NCT06271980||Survivors of early-onset colorectal cancer, with no recurrent disease (Training Cohort)|Survivors of early-onset colorectal cancer who did not develop recurrent CRC within 60 months from primary tumor treatment, in the first cohort
89559734|NCT06271980||Survivors of early-onset colorectal cancer, with recurrent disease (Validation Cohort)|Survivors of early-onset colorectal cancer who developed recurrent CRC within 60 months from primary tumor treatment, in the second, independent, validation cohort
89559735|NCT06271980||Survivors of early-onset colorectal cancer, with no recurrent disease (Validation Cohort)|Survivors of early-onset colorectal cancer who did not develop recurrent CRC within 60 months from primary tumor treatment, in the second, independent, validation cohort
89559736|NCT06271850|Active Comparator|Ergonomic breastfeeding training (control group)|They will receive ergonomics breastfeeding training only.
88966126|NCT00005942|Experimental|Treatment (liposomal danorubicin citrate, semaxanib)|Patients receive daunorubicin liposomal IV over 6 hours on days 1-3 and SU5416 IV twice a week for 2 months. The second course is administered for 1 month, then treatment continues every 4-6 weeks in the absence of disease progression or unacceptable toxicity.
88966127|NCT00012064|Experimental|Biological/Vaccine|"Biological/Vaccine: therapeutic autologous dendritic cells.~Apheresis procedure collects peripheral blood mononuclear cells (PBMC) for the production of dendritic cell, which are admixed with irradiated tumor cells from autologous tumor cell line for vaccine product."
88966128|NCT00012181|Experimental|Treatment (alvocidib)|Patients receive flavopiridol IV over 1 hour on days 1-3. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
89208453|NCT00662792|Experimental|Tio18GEL/ T18GEL+S_DPI/ T+S_PE/ Salm50DPI|18 µg Tiotropium (Tio18GEL) / 18 µg Tiotropium (T18GEL) + 50 µg Salmeterol MDPI (S_DPI) BID / 7.5 µg/ 25 µg Tiotropium/Salmeterol (T+S_PE) / 50 µg Salmeterol MDPI (Salm50DPI)
88966129|NCT00005945|Experimental|Induction Not Randomized|Standard Induction (28 Days). M3 Marrow at Day 28 and Off Protocol Therapy.
88966130|NCT00005945|Experimental|Induction and Oral MTX, Double Delayed Intensification CNS|Patients with CNS disease at diagnosis, without other unfavorable characteristics. Standard Induction (28 Days). Consolidation (28 days) and in remission Day 21 and at time of randomization, Interim maintenance I (2 months), Delayed intensification I (2 months), Interim maintenance II (2 months), Delayed intensification II (2 months), then Maintenance (12 week cycles). Cranial radiation therapy during the Consolidation phase.
88966131|NCT00005945|Experimental|Induction and Augmented regimen (IV MTX, Double DI)|Patients with unfavorable characteristics. Standard Induction (14 Days), Augmented Induction (Days 14-35), Consolidation (9 weeks), Interim Maintenance I (56 Days), Delayed Intensification I (2 months), Interim Maintenance II (2 months), Delayed Intensification II (2 months), then Maintenance (84 day courses).
88966132|NCT00005945|Experimental|Induction and Oral MTX, Single Delayed Intensification|Patients without CNS disease at diagnosis, with favorable cytogenetics. Standard Induction (28 Days). Consolidation (28 days) and in remission Day 21 and at time of randomization, Interim maintenance I (2 months), Delayed intensification I (2 months), Interim maintenance II (2 months) then Maintenance (12 week cycles). Biopsy-proven testicular leukemia pts at diagnosis will receive testicular radiation therapy during the consolidation phase.
88966133|NCT00005945|Experimental|Induction and Oral MTX, Double Delayed Intensification|Patients without CNS disease at diagnosis, with favorable cytogenetics. Standard Induction (28 Days). Consolidation (28 days) and in remission Day 21 and at time of randomization, Interim maintenance I (2 months), Delayed intensification I (2 months), Interim maintenance II (2 months), Delayed intensification II (2 months), then Maintenance (12 week cycles). Biopsy-proven testicular leukemia pts at diagnosis will receive testicular radiation therapy during the consolidation phase.
88966134|NCT00005945|Experimental|Induction and IV MTX, Single Delayed Intensification|Patients without CNS disease at diagnosis, with favorable cytogenetics. Standard Induction (28 Days). Consolidation (28 days) and in remission Day 21 and at time of randomization, Interim maintenance I (2 months), Delayed intensification I (2 months), Interim maintenance II (2 months) then Maintenance (12 week cycles). Biopsy-proven testicular leukemia pts at diagnosis will receive testicular radiation therapy during the consolidation phase.
88966135|NCT00005945|Experimental|Induction and IV MTX, Double Delayed Intensification|Patients without CNS disease at diagnosis, with favorable cytogenetics. Standard Induction (28 Days). Consolidation (28 days) and in event free remission Day 21 and at time of randomization, Interim maintenance I (2 months), Delayed intensification I (2 months), Interim maintenance II (2 months), Delayed intensification II (2 months), then Maintenance (12 week cycles). Biopsy-proven testicular leukemia pts at diagnosis will receive testicular radiation therapy during the consolidation phase.
88966136|NCT01929811|Experimental|Metformin arm|Docetaxel: 75mg/m2, d1, q3w*6 Epirubicin: 75mg/m2, d1, q3w*6 Cyclophosphamide: 500mg/m2, d1, q3w*6 Metformin: 500mg tid, orally (500mg daily in first cycle)
88966137|NCT01929811|Other|TEC|Docetaxel: 75mg/m2, d1, q3w*6 Epirubicin: 75mg/m2, d1, q3w*6 Cyclophosphamide: 500mg/m2, d1, q3w*6
88966138|NCT00012220|Active Comparator|Gemcitabine|Standard treatment
88966139|NCT00012220|Experimental|Gemcitabine + cisplastin|Addition of cisplastin to gemcitabine
88966140|NCT00012220|Experimental|Gemcitabine + docetaxel|Addition of docetaxel to gemcitabine
88966141|NCT00012220|Experimental|Gemcitabine + Irinotecan|Addition of irinotecan to gemcitabine
88966142|NCT00012259|Experimental|troxacitabine|
89026644|NCT00601276|Experimental|1|
89026645|NCT00601276|Active Comparator|2|
89208454|NCT00662792|Experimental|Salm50DPI/ T+S_PE/ T18GEL+S_DPI/ Tio18GEL|50 µg Salmeterol MDPI (Salm50DPI) / 7.5 µg/ 25 µg Tiotropium/Salmeterol (T+S_PE) / 18 µg Tiotropium (T18GEL) + 50 µg Salmeterol MDPI (S_DPI) BID / 18 µg Tiotropium (Tio18GEL)
89559737|NCT06271850|Experimental|Pilates exercises and ergonomic breastfeeding training (study group)|They will receive Pilates exercises, in addition to ergonomics breastfeeding training.
89559738|NCT06271811|Active Comparator|Control group|"The intervention protocol is centered on neuromuscular training, targeting the strengthening of key muscle groups including the quadriceps, hamstrings, and hip abductors, which are vital for knee stabilization. This approach is supported by previous research, emphasizing the importance of these muscle groups in knee joint health. Complementing this, proprioceptive exercises, such as single-leg balances and controlled knee bends, were incorporated to enhance joint position sense, aligning with the guidelines set forth by Powers et al., 2010.~The intensity of these exercises is progressively increased, tailored to each patient's tolerance and improvement. The protocol stipulates two sessions per week over eight weeks."
89559739|NCT06271811|Experimental|Intervention group|The application of flossing to the knee commences with a preliminary evaluation of the joint range of motion and pain perception. The band is wrapped around the knee, starting with an approximate tension of 50% for the first wrap and escalating to a tension of 60-80% in subsequent wraps. It is essential to overlap the band with each wrap, moving from a distal to the proximal direction (bottom to top), which aids in enhancing drainage. Continuous monitoring of the patient is critical to ensure that excessive pressure is not being applied. This can be achieved by palpating the pulse on the dorsum of the foot or inner ankle, and observing if the skin regains its normal color after pressing the area with fingers. Should the patient experience strong tingling or pain, the bandage must be immediately removed. The duration of the band's application varies between 2 to 5 minutes, depending on patient tolerance, a methodology informed by existing research.
89559740|NCT06271096|Experimental|Group A IM-Midazolam|Group A received IM midazolam at a dose of 0.2 mg/kg gently injected into the vastus lateralis muscle
89559741|NCT06271096|Experimental|Group B IV Diazepam|Patients in group B were cannulated in the dorsum of the hand or foot, or the great saphenous vein at the ankle first and then administered diazepam at a dose of 0.2mg/kg
89559742|NCT06270745||Indocyanine Green|Indocyanine green infusion during digestive system surgery
89559743|NCT06270745||non-Indocyanine Green|No indocyanine green infusion during digestive system surgery
89559744|NCT06269926|Experimental|Education-CBT|The Education-CBT group will receive pain education (a pain education booklet in addition to usual medical care) followed by Cognitive Behavioral Therapy for Chronic Pain (CBT-CP; the primary intervention-a 12-week group therapy course).
89559745|NCT06269926|Experimental|CBT-Education|The CBT-Education group will receive Cognitive Behavioral Therapy for Chronic Pain (CBT-CP; the primary intervention-a 12-week group therapy course) followed by pain education (a pain education booklet in addition to usual medical care).
88966143|NCT00012376|Experimental|Treatment (bryostatin 1 and sargramostim)|Patients receive bryostatin 1 IV continuously and GM-CSF subcutaneously once daily on days 1-21. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients with disease stabilization or improvement may continue treatment for up to 12 courses.
88966144|NCT00012610|Other|Arm 1|
88966145|NCT00012649||Group 1|
88966146|NCT00012688|Other|Arm 1|
88966147|NCT00012727|Other|Arm 1|
88966148|NCT00012766|Other|Arm 1|
88966149|NCT00012805|Other|Arm 1|
88966150|NCT00012844|Other|Arm 1|
88966151|NCT00012883|Other|Arm 1|Homewalking Exercise Program
88966152|NCT00012922|Other|Arm 1|
88966153|NCT00012961||Group 1|
88966154|NCT00013000|Other|Arm 1|
88966155|NCT00013039|Other|Arm 1|
88966156|NCT00013078|Other|Arm 1|
88966157|NCT00005963|Experimental|docetaxel + carboplatin|This is a multicenter study. Patients receive docetaxel IV over 1 hour and carboplatin IV over 30 minutes on day 1. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients who achieve stable disease (SD), partial response (PR), or complete response (CR) may receive 4 additional courses past SD, PR, or CR. Patients are followed every 6 months for 2 years and then annually for 3 years.
88966158|NCT00013117|Other|Arm 1|
88966159|NCT00013156|Other|Arm 1|
88966160|NCT00013195|Other|Arm 1|
88966161|NCT00013234|Other|Arm 1|
88966162|NCT00013390|Active Comparator|1|Tinnitus Masking
88966163|NCT00013390|Other|2|Tinnitus Retraining Therapy
88966164|NCT00001305|Experimental|Growth Hormone|Treatment of children with types III and IV osteogenesis imperfecta with Humatrope
88966165|NCT00005969|Experimental|Liposomal Tretinoin|Liposome by vein (IV) over 30 minutes every other day for 28 days and Chemotherapy.
88966166|NCT00005972|Experimental|gemcitabine + irinotecan|Patients are stratified according to prior response duration (progression 90 days or more after initial therapy vs progression less than 90 days after initial therapy or no response to initial therapy). Patients receive gemcitabine IV over 30 minutes and irinotecan IV over 90 minutes on days 1 and 8. Treatment continues every 21 days in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 1 year, then every 6 months for 2 years, and then annually for 3 years.
88966167|NCT00014170|Experimental|Treatment (gefitinib)|Patients receive oral gefitinib daily. Courses repeat every 8 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
88966168|NCT02972164|No Intervention|Control|Each year, 100 school children age 9-12 who meet inclusion criteria are selected from 5 randomly chosen schools to participate in the control group. Control children are assessed for the same measures as the intervention group at the beginning and end of the intervention but receive none of the intervention modules.
88966169|NCT02972164|Experimental|Weight loss program for school children|Each year, 100 school children age 9-12 who meet inclusion criteria are selected from 5 randomly chosen schools to participate in the intervention group. The intervention children take part in the integrated approach for weight management consisting of (1) intensive weight loss camp (2) twelve weeks of after school clubs for consolidation purposes, and (3) social media and wearable sensors for support and monitoring.
88966170|NCT00005975|Active Comparator|Megestrol Acetate/Placebo 20 mg/day|Double blinded Megestrol Acetate 20 mg/day or Megestrol Acetate Placebo 20 mg/day taken for 3 months
88966171|NCT00005975|Active Comparator|Megestrol Acetate/Placebo 40 mg/day|Double blinded Megestrol Acetate 40 mg/day or Megestrol Acetate Placebo 40 mg/day taken for 3 months
88966172|NCT02971930||Prophylaxis treatment of BAY94-9027_1|2 infusions per week during the extension study
88966173|NCT02971930||Prophylaxis treatment of BAY94-9027_2|infusion every 5 days during the extension study
88966174|NCT02971930||Prophylaxis treatment of BAY94-9027_3|every 7 days during the extension study
88966175|NCT00391534|Experimental|Oxcarbazepine MR|Patients who are pre-treated with a total daily dose of exactly 900 or exactly 1200 mg or exactly 1500 mg oxcarbazepine (as OXC IR) will increase dosage of OXC by 300 mg to a daily dose of 1200 mg / 1500 mg / 1800 mg OXC MR. Dosage will be titrated to a maximum tolerated total daily dose, maximally to 2700 mg in steps of 300 mg every 6th day.
88966176|NCT00391534|Active Comparator|Oxcarbazepine IR|Patients who are pre-treated with a total daily dose of exactly 900 or exactly 1200 mg or exactly 1500 mg oxcarbazepine (as OXC IR) will increase dosage of OXC by 300 mg to a daily dose of 1200 mg / 1500 mg / 1800 mg OXC IR (divided in two daily doses). Dosage will be titrated to a maximum tolerated total daily dose, maximally to 2700 mg in steps of 300 mg every 6th day.
88966177|NCT00005984|Experimental|Patients with CML|Patients treated for chronic accelerated phase and/or chronic myelogenous leukemia (CML)
88966178|NCT00391612|Sham Comparator|2|subject receives optimal medical management, supervised pulmonary rehabilitation therapy and undergoes bronchoscopy but no stents are placed
88966179|NCT00391612|Experimental|1|subject receives optimal medical management, supervised pulmonary rehabilitation therapy and undergoes bronchoscopy during which up to six Exhale drug-eluting stents are placed in the lungs
88966180|NCT00391651|Active Comparator|1|Nitrofurantoin 100mg BID x 5 days
88966181|NCT00391651|Active Comparator|2|TMP/SMX DS BID x 3 days
88966182|NCT05442450|Experimental|Diet+excercise+oral semaglutide|Participants will receive individual counselling sessions for reduced-calorie diet and physical activity (with 150 minutes per week of physical activity, such as walking). Participants in this group will receive oral Semaglutide drug along with diet and exercise. Treatment will be initiated with the 3 mg once-daily dose. The dose will be increased to 7 mg and then maximum of 14mg per day in 2-4weeks interval based on your symptoms (nausea, vomiting, constipation etc)
88966183|NCT05442450|No Intervention|Diet+excercise|Participants in this group will receive individual counselling sessions for reduced-calorie diet and increased physical activity (with 150 minutes per week of physical activity, such as walking).
88966184|NCT00391729|Placebo Comparator|1|
88966185|NCT00391729|Experimental|2|
88966186|NCT00015340|Experimental|Buprenorphine/Naloxone|
88966187|NCT00006002|Experimental|Arm B|dexamethasone followed by SU5416 done twice weekly (Monday and Thursday or Tuesday and Friday) every week for 4 weeks (a total of 8 doses). Four weeks of treatment (8 doses) is considered 1 cycle of treatment if tumor grows.
88966188|NCT00006002|Experimental|Arm A|SU5416 done twice weekly (Monday and Thursday or Tuesday and Friday) every week for 4 weeks (a total of 8 doses). Four weeks of treatment (8 doses) is considered 1 cycle of treatment
88966189|NCT00015964|Experimental|Daily administration of ZD1839|
88966190|NCT01630213|Active Comparator|Vitamin D3 + fish oil/placebo|Vitamin D3 2000 IU/day and fish oil (840 omega 3-fatty acids; Omacor)(or fish oil placebo)/day
88966191|NCT01630213|Placebo Comparator|Vitamin D3 placebo + fish oil/placebo|Vitamin D3 placebo + fish oil (840 mg of omega 3-fatty acids; Omacor)/fish oil placebo
88966192|NCT00016276|Experimental|Arm I (chemoprotection, monoclonal antibody, radiotherapy)|Patients receive dexrazoxane IV over 10-20 minutes, doxorubicin IV over 5-10 minutes, and cyclophosphamide IV over 30 minutes on days 1, 22, 43, and 64. Patients receive paclitaxel IV over 1 hour and trastuzumab (Herceptin) IV over 30-90 minutes on days 85, 92, 99, 106, 113, 120, 127, 134, 141, 148, 155, and 162. Approximately 1-2 weeks after completion of neoadjuvant chemotherapy, patients undergo breast conservation surgery, modified radical mastectomy, or mastectomy. Patients with unacceptable toxicity or locoregional disease progression may undergo surgery prior to week 24 (i.e., completion of neoadjuvant chemotherapy). Beginning 2-4 weeks after breast conservation surgery or 3-5 weeks after mastectomy, patients undergo radiotherapy daily 5 days a week for 6-8 weeks. Patients receive long-term trastuzumab IV over 30-90 minutes weekly for 40 weeks beginning on week 36 (day 254).
88966193|NCT00016276|Experimental|Arm II (chemoprotection, radiotherapy, surgery, trastuzumab)|Patients receive dexrazoxane, doxorubicin, and cyclophosphamide as in arm I. Patients receive paclitaxel (without trastuzumab) as in arm I. Patients undergo surgery and radiotherapy as in arm I. Patients receive long-term trastuzumab as in arm I.
88966194|NCT00016276|Experimental|Arm III (chemoprotection, monoclonal antibody, radiotherapy)|Patients receive dexrazoxane, doxorubicin, and cyclophosphamide as in arm I. Patients receive paclitaxel and trastuzumab as in arm I. Patients undergo surgery and radiotherapy as in arm I. Patients undergo observation only for 40 weeks after completion of radiotherapy.
88966195|NCT00016276|Experimental|Arm IV (chemoprotection, paclitaxel, surgery, radiotherapy)|Patients receive dexrazoxane, doxorubicin, and cyclophosphamide as in arm I. Patients receive paclitaxel as in arm II. Patients undergo surgery and radiotherapy as in arm I. Patients undergo observation as in arm III.
88966196|NCT00016276|Experimental|Arm V (combination chemo, radiotherapy, long term trastuzumab)|Patients receive doxorubicin and cyclophosphamide (without dexrazoxane) as in arm I. Patients receive paclitaxel and trastuzumab as in arm I. Patients undergo surgery and radiotherapy as in arm I. Patients receive long-term trastuzumab as in arm I.
88966197|NCT00016276|Experimental|Arm VI (combination chemo, paclitaxel, surgery, radiotherapy)|Patients receive doxorubicin and cyclophosphamide as in arm V. Patients receive paclitaxel as in arm II. Patients undergo surgery and radiotherapy as in arm I. Patients receive long-term trastuzumab as in arm I.
88966198|NCT00016276|Experimental|Arm VII (combination chemo, monoclonal antibody, radiotherapy)|Patients receive doxorubicin and cyclophosphamide as in arm V. Patients receive paclitaxel and trastuzumab as in arm I. Patients undergo surgery and radiotherapy as in arm I. Patients undergo observation as in arm III.
88966199|NCT00016276|Experimental|Arm VIII (combination chemotherapy, paclitaxel, radiotherapy)|Patients receive doxorubicin and cyclophosphamide as in arm V. Patients receive paclitaxel as in arm II. Patients undergo surgery and radiotherapy as in arm I. Patients undergo observation as in arm III.
88966200|NCT00016315|Experimental|Arm 1|Sequence A: Gemcitabine 300 mg/m2/week plus radiation therapy (RT)
88966201|NCT00016315|Experimental|Arm 2|Sequence B: Gemcitabine 300 mg/m2/week plus paclitaxel 30 mg/m2/week and RT
88966202|NCT00016315|Experimental|Arm 3|Sequence A: Gemcitabine 300 mg/m2/week plus carboplatin 2 AUC and RT
88966203|NCT00016315|Experimental|Arm 4|Sequence B: Gemcitabine 450 mg/m2/week plus paclitaxel 30 mg/m2/week and RT
89559746|NCT06269874|Active Comparator|Intravenous Adenosine|Invasive microvascular function assessment will be conducted by administering intravenous hyperemic agent adenosine.
89559747|NCT06269874|Experimental|Intracoronary Adenosine|Invasive microvascular function assessment will be conducted by administering intracoronary hyperemic agent adenosine.
89559748|NCT06269419||Type 2 diabetes patients with no diabetic retinopathy|
89559749|NCT06269419||Type 2 diabetes patients with mild to moderate diabetic non-proliferative retinopathy|
89559750|NCT06269380|Experimental|Normal esophagogastroduodenoscopy|Patients with normal esophagogastroduodenoscopic findings and biopsy samples were obtained.
89559751|NCT06269081|Experimental|Supportive-Expressive Peer Social Support Group + Individual Strengths-Based Case Management|
89559752|NCT06269081|Experimental|Supportive-Expressive Peer Social Support Group|
89559753|NCT06269081|Experimental|Individual Strengths-Based Case Management|
89559754|NCT06269081|No Intervention|HIV Information Only|This arm will not receive either of the interventions but will receive information on successfully aging with HIV.
89559755|NCT06268600|Experimental|Modified neck target volume delineation|For patients with negative lymph nodes in regions III and IVa (accounting for about 60% of the total patients), a modified neck target volume delineation method was used to define the inner boundary of regions III and IVa as the outer edge of the common carotid artery.
89559756|NCT06268600|No Intervention|Routine neck target volume delineation|For patients with positive lymph nodes in regions III and IVa (accounting for about 40% of the total patients), the inner boundary of regions III and IVa is defined as the inner edge of the common carotid artery or the outer edge of the thyroid.
89559757|NCT06266065|Experimental|Coronary Sinus Reducer|
89559758|NCT06264999|Active Comparator|Journey II CR|Implantation of Journey II CR sacrificing the anterior cruciate ligament.
89559759|NCT06264999|Active Comparator|Journey II XR|Implantation of Journey II XR retaining the anterior cruciate ligament.
89559760|NCT06264934||Part A|Twenty healthy participants will be recruited to examine the ability of the Z-scanner to identify healthy breast tissue and assess repeatability and reproducibility of the device.
89559761|NCT06264934||Part B|70 participants (35 benign and 35 malignant) will be recruited to investigate the ability of the Z-scanner to correctly identify and differentiate malignant and/or benign lesions from healthy breast tissue.
89559762|NCT06262997|Active Comparator|Pilates|Participants will receive an average of 1 hour of pilates training accompanied by a physiotherapist for 8 weeks, 2 days a week in groups of 2-3 people.
89559763|NCT06262997|Experimental|Pilates and Kinesiotape|They will receive exactly the same Pilates training as the patients in the Pilates group and in addition kinesio tape will be applied.
89559764|NCT06258746|Experimental|160 mg/100 μCi [14C]HSK31679|[14C]HSK31679
88966204|NCT00016315|Experimental|Arm 6|Sequence B: Gemcitabine 450 mg/m2/week plus paclitaxel 40 mg/m2/week and RT
88966205|NCT00016315|Experimental|Arm 8|Sequence B: Gemcitabine 600 mg/m2/week plus paclitaxel 40 mg/m2/week and RT
88966206|NCT00016315|Experimental|Arm 10|Sequence B: Gemcitabine 600 mg/m2/week plus paclitaxel 50 mg/m2/week and RT
88966207|NCT00016315|Experimental|Arm 12|Sequence B: Gemcitabine 750 mg/m2/week plus paclitaxel 50 mg/m2/week and RT
88966208|NCT00016315|Experimental|Arm 14|Sequence B: Gemcitabine 900 mg/m2/week plus paclitaxel 50 mg/m2/week and RT
88966209|NCT00016315|Experimental|Arm 5|Sequence A: Gemcitabine 450 mg/m2/week plus carboplatin 2 AUC and RT
88966210|NCT00016315|Experimental|Arm 7|Sequence A: Gemcitabine 600 mg/m2/week plus carboplatin 2 AUC and RT
88966211|NCT00016315|Experimental|Arm 9|Sequence A: Gemcitabine 750 mg/m2/week plus carboplatin 2 AUC and RT
88966212|NCT00016315|Experimental|Arm 11|Sequence A: Gemcitabine 900 mg/m2/week plus carboplatin 2 AUC and RT
88966213|NCT00006014|Experimental|Arm I|Patients receive SU5416 IV over 1 hour twice weekly. Courses repeat every 4 weeks for a minimum of 2 courses in the absence of disease progression or unacceptable toxicity.
88966214|NCT00006017|Active Comparator|Rebeccamycin 1 day|Patients receive rebeccamycin analogue IV over 1 hour on day 1.
88966215|NCT00006017|Active Comparator|Rebeccamycin 5 day|Patients receive rebeccamycin analogue IV over 1 hour on days 1-5.
88966216|NCT00016432|Experimental|Group 1|Exemestane
88966217|NCT00016432|Placebo Comparator|Group 2|Placebo
88966218|NCT00389376|Other|Group 1|Placebo and 140 mg single dose + every 8 hours
88966219|NCT00389376|Other|Group 2|Placebo and 280 mg single dose
88966220|NCT00389376|Other|Group 3|Placebo and 280mg every 8 hours
88966221|NCT00389376|Other|Group 4|Placebo and 280 single dose + every 8 hours
88966222|NCT00389376|Other|Group 5|Placebo and 560 mg single dose + every 8 hours
88966223|NCT00389376|Other|Group 6|Placebo and 560 mg single dose + every 8 hours
88966224|NCT00389376|Other|Group 7|Placebo and 700 mg single dose + every 8 hours
88966225|NCT00001464||Group 1|Smokers exposed to oxygen
88966226|NCT00016744|Active Comparator|1|"Subjects will be randomized to receive either the Phenylbutyrate or placebo tablets for 4 days~Every participant will receive Genistein during the NPD."
88966227|NCT00016744|Placebo Comparator|2|
88966228|NCT00386633|Other|1|Lower dosage: 10E7_TCID50
88966229|NCT00386633|Active Comparator|2|10E8_TCID50
88966230|NCT00386672|Experimental|Lite OJ with Ca and VitD|240ml of reduced energy (lite) OJ beverage fortified with 350mg Ca and 100U VitD, 3 times per day.
89559765|NCT06256991|Experimental|Patiromer|All participants will receive patiromer 8.4g/d (powder for oral suspension) during one of the two 12-week study periods. Following a 6-week washout, participants will switch from the patiromer arm to the placebo arm or vice versa (cross-over design).
89559766|NCT06256991|Placebo Comparator|Placebo|All participants will receive placebo 8.4g/d (powder for oral suspension) during one of the two 12-week study periods. Following a 6-week washout, participants will switch from the patiromer arm to the placebo arm or vice versa (cross-over design).
89559767|NCT06256562|Experimental|GZR18|GZR18 injection s.c.
89559768|NCT06256562|Placebo Comparator|Placebo|Placebo injection s.c.
89559769|NCT06256549|Experimental|GZR18|GZR18 injection s.c.
89559770|NCT06256549|Active Comparator|Semaglutide|Semaglutide injection s.c.
89559771|NCT06256536|Experimental|GZR18|GZR18 injection s.c.
89559772|NCT06256536|Placebo Comparator|Placebo|Placebo injection s.c.
88966231|NCT00386672|Active Comparator|Lite OJ without Ca and VitD|240ml of reduced energy (lite) OJ beverage, 3 times per day.
88966232|NCT00016978|Experimental|Arm I|Patients receive oxaliplatin IV over 2 hours on days 1 and 15 and leucovorin calcium and fluorouracil IV on days 1, 8, and 15. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a confirmed complete response for 2 consecutive courses may discontinue study treatment at the investigators discretion. Quality of life is assessed at baseline, approximately every 6-8 weeks during treatment, and then after the last course of treatment.
88966233|NCT00017095|Active Comparator|non taxane based chemotherapy|either FEC 100 or Canadian CEF or Tailored FEC for 6 cycles
89559773|NCT06256523|Experimental|GZR18|GZR18 injection s.c.
89559774|NCT06256523|Placebo Comparator|Placebo|Placebo injection s.c.
89559775|NCT06255912|Experimental|LTC004 + MIL-97|
88966234|NCT00017095|Experimental|taxane based chemotherapy|Docetaxel for 3 cycles followed by Epirubicin/Docetaxel for 3 cycles
88966235|NCT00006029|Active Comparator|vinorelbine + gemcitabine + doxorubicin - higher doses|"Patients who have not undergone prior transplantation receive vinorelbine, gemcitabine, and doxorubicin HCl liposome.~Patients are followed every 6 months for 2 years and then annually for 6 years."
88966236|NCT00006029|Experimental|vinorelbine + gemcitabine + doxorubicin - lower doses|"Patients who have undergone prior transplantation receive lower doses of vinorelbine, gemcitabine, and doxorubicin HCl liposome.~Patients are followed every 6 months for 2 years and then annually for 6 years."
88966237|NCT04734418|Experimental|Remifentanil group|
88966238|NCT04734418|Active Comparator|Dexmedetomidine|
88966239|NCT00017173|Experimental|surgery with INGN 201 followed by chemo/RT|intraoperative and postoperative injections of INGN 201 into the tumor bed, followed by cisplatin and radiation therapy
88966240|NCT04734223||Group 1|The first group consisted of 46 patients whose neuroimaging findings demonstrated acute/subacute infarction, bleeding, encephalitis, and venous sinus thrombosis
88966241|NCT04734223||Group 2|The 2nd group (N=390) was obtained by subtracting the 1st group from all cases.
88966242|NCT04734223||Group 3|The third group (N = 189) consisted of patients of the first group and patients with chronic ischemic changes observed in neuroimaging
88966243|NCT04734223||Group 4|The 4th group (N=247) was obtained by subtracting the 3rd group from all cases.
88966244|NCT04734340|Experimental|EIT-guided group|Treatment based on EIT
88966245|NCT04734340|Placebo Comparator|Control group|Treatment based on ARDS-net Peep setting
88966246|NCT00017251|Experimental|Treatment (oblimersen sodium, carboplatin, etoposide)|Patients receive G3139 IV continuously on days 1-8, carboplatin IV over 30 minutes on day 6, and etoposide IV over 1 hour on days 6-8. Treatment repeats every 3 weeks for up to 6 courses in the absence of unacceptable toxicity or disease progression.
88966247|NCT00017368|Experimental|All Patients|
88966248|NCT02971813|Experimental|Facebook group|The Facebook group will receive peer support, education and provider support via social media.
88966249|NCT02971813|Active Comparator|Comparison group|The comparison group will receive the same educational materials as the Facebook™ group but will receive it in handout form, or via email if the patient misses cardiac rehabilitation on a particular week.
88966250|NCT05680961||Parkinson's patients|Cohort of patients with clinical diagnosis of Parkinson's diseases with varied symptoms and severity.
88966251|NCT04734067||observational group|Patients receiving ICIs for the first time
89559776|NCT06255912|Experimental|LTC004 + MIL-97+ chemotherapy|
89559777|NCT06254976|Active Comparator|2 week home exercise program|Joint range of motion exercises, four-way straight leg raises, isotonic quadriceps strengthening, hamstring and quadriceps stretching exercises were given. The exercise program was demonstrated by the same physiotherapist. The patients' exercise compliance was questioned and noted.
89559778|NCT06254976|Active Comparator|2 doses of intraarticular PRP application, 1 week apart|2 doses of intra-articular 3 cc LP-PRP were applied to the patients, 1 week apart, from the inferolateral aspect of the patella, in accordance with antisepsis conditions, by a physical medicine and rehabilitation specialist.
89559779|NCT06254859||Normal Signal Group.|During the surgical procedure, there was no occurrence of a decrease in recurrent laryngeal nerve signals or a decrease of less than 10%.
89559780|NCT06254859||Signal Decrease 10-50%.|During the surgical procedure, the signal of the recurrent laryngeal nerve decreased by 10-50%.
89559781|NCT06254859||Signal Decrease 50-90%.|During the surgical procedure, the signal of the recurrent laryngeal nerve decreased by 50-90%.
89559782|NCT06254859||Signal Absence Group.|During the surgical procedure, the signal of the recurrent laryngeal nerve decreased by more than 90% or completely disappeared.
88966252|NCT00018148|Experimental|1|Transdermal nicotine plus nortriptyline
88966253|NCT00018148|Active Comparator|2|Transdermal nicotine plus placebo
88966254|NCT00001563|Experimental|1|EPOCH-R every 3 weeks for up to 6 cycle
88966255|NCT05680766|Experimental|Intervention arm|IBS subjects fulfilling the eligibility criteria will follow a structured and personalised cardiovascular endurance training (CET).
89026646|NCT02274714||Case (with IBD)|Women aged 18-48 years with regular menstrual cycles AND with an established diagnosis of CD or UC involving the small bowel, colon or both
89559783|NCT06254508|Active Comparator|FITT to CON|Online program that includes exercise guided by the FITT-VP principle and dietary advice for 16 weeks, followed by conventional in-clinic nutrition and exercise advice and self-control for 16 weeks.
89559784|NCT06254508|Active Comparator|CON to FITT|Conventional in-clinic nutrition and exercise advice and self-control for 16 weeks, followed by online program that includes exercise guided by the FITT-VP principle and dietary advice for 16 weeks.
89559785|NCT06254261|Experimental|RAY1225 (cohort 1)|Participants received dose1 or dose2 RAY1225 administered subcutaneously (SC) once two week for 24 weeks.
89559786|NCT06254261|Placebo Comparator|Placebo (cohort 1)|Participants received Placebo administered SC once two weeks for 24 weeks.
89559787|NCT06254261|Experimental|RAY1225 (cohort 2)|Escalating doses of RAY1225 administered subcutaneously (SC) once two week
89559788|NCT06254261|Placebo Comparator|Placebo (cohort 2)|Participants received Placebo administered SC once two week
89559789|NCT06254001|Active Comparator|Nicotine replacement therapy|Nicotine replacement therapy (Nicotine patches) plus counseling and cognitive behavioral therapy
89026647|NCT02274714||Control (without IBD)|Women aged 18-48 years with regular menstrual cycles and without a diagnosis of CD will qualify for the study
89026648|NCT00601393|Active Comparator|1|Participants will receive treatment as usual followed by 8 weeks of Internet-based cognitive behavioral therapy treatment
89026649|NCT00601393|Experimental|2|Participants will receive 8 weeks of Internet-based cognitive behavioral therapy treatment
89026650|NCT00470249|Experimental|Patients with (HER-2)-negative and anthracycline- and taxane-resistant|Patients with human epidermal growth factor 2 (HER-2)-negative locally advanced or metastatic breast cancer that was anthracycline- and taxane-resistant
89026651|NCT04325893|Active Comparator|Hydroxychloroquine|
89026652|NCT04325893|Placebo Comparator|Placebo|
89026653|NCT00501813|Active Comparator|surgery|initial palliative hepatectomy followed by TACE and/or local regional treatment
89026654|NCT00501813|Experimental|no surgery|TACE combined with local regional treatment without hepatectomy
89026655|NCT00601471|Experimental|1|proximal tibiofibular manipulation
89026656|NCT00601471|Experimental|2|distal tibiofibular manipulation
89026657|NCT00601471|No Intervention|3|no treatment
89026658|NCT00601510|Experimental|Imatinib mesylate|Imatinib mesylate 300mg/day(maximum dose will be 800 mg) on day -4, -3, -2, -1, 1, 2, 3 through d21 in combination with capecitabine 1250 mg/m2 twice daily (d1-d14) and iv cisplatin 60mg/m2
89026659|NCT00601549|Experimental|1|Patients with low rectal cancer after CCRT undergoing laparoscopic surgery
89208455|NCT00662792|Experimental|T18GEL+S_DPI/ Salm50DPI/ Tio18GEL/ T+S_PE|18 µg Tiotropium (T18GEL) + 50 µg Salmeterol MDPI (S_DPI) BID / 50 µg Salmeterol MDPI (Salm50DPI) / 18 µg Tiotropium (Tio18GEL) / 7.5 µg/ 25 µg Tiotropium/Salmeterol (T+S_PE)
89559790|NCT06254001|Experimental|Nicotine replacement therapy and Bupropion|Nicotine replacement therapy (Nicotine patches) plus Bupropion and counseling and cognitive behavioral therapy
89559791|NCT06253923|Active Comparator|MR-301|"On first day, patient will receive MR-301 at 100 mg intravenous infusion BID. On second day, the dose is elevated to 150 mg intravenous infusion BID.~On third day, the dose is further elevated to 200 mg intravenous infusion BID and maintained up to Day 21"
89559792|NCT06253923|Placebo Comparator|Placebo|
89559793|NCT06251661|Active Comparator|Group 1 (GA)|20 Egyptian ischemic stroke patients receive 12 sessions of CMR and traditional physical therapy each session lasts for 40 minutes of CMR and 30 minutes of traditional physical therapy.
89559794|NCT06251661|Sham Comparator|Group 2 (GB)|20 Egyptian ischemic stroke patients receive 12 sessions of traditional physical therapy each session lasts for 30 minutes.
89026660|NCT00601549|Active Comparator|2|Patients with low rectal cancer after CCRT undergoing traditional open surgery
89559795|NCT06249776|Experimental|Supernova revascularization device|Mechanical thrombectomy with Supernova Stent Retriever
89559796|NCT06247683|Experimental|trifocal intraocular lens|Bilateral Implantation of new trifocal intraocular lens
89559797|NCT06241677|Active Comparator|IVT group|For patients enrolled into the IVT group from participating centers that allow IVT in patients with last DOAC intake 12-48 hours before presentation (PWH, QEH, QMH, UCH, TMH): Either alteplase (0.6 or 0.9mg/kg, maximum dosage 90mg, intravenous infusion) or tenecteplase (0.25mg/kg, maximum dosage 25mg, intravenous infusion) will be given at discretion of the treating physician.
89559798|NCT06241677|No Intervention|Control|For patients enrolled into the control group from participating centers that exclude eligible patients from IVT (PMH, PYNEH): no IVT will be given unless specific antidote can be administered before IVT.
89559799|NCT06238115|Experimental|Tirofiban group|After femoral artery puncture, initial infusion of 0.4μg/kg body weight/minute over 30 minutes, followed by a continuous infusion of 0.1μg/kg body weight/minute for 24 hours.
89026661|NCT00601744||Patient|Diagnosis of orbital or head and neck cancer and a history of orbital exenteration.
89026662|NCT00601744||Family Member/Friend|Family member or close friend of a patient with a diagnosis of orbital or head and neck cancer and a history of orbital exenteration.
89026663|NCT01246362|Placebo Comparator|Control|Given placebo tablets preoperatively
89026664|NCT01246362|Active Comparator|Etoricoxib|Given etoricoxib preoperatively
89026665|NCT04325854||Ectopic pregnancy population|The data have been collected from the Humanitas Fertility Center' Department database (ART.it) from all ART procedures (both I and II level) performed between 2009 and 2018.
89026666|NCT00470405|Experimental|Therapeutic Intervention|
89026667|NCT04207372|Experimental|Whey protein isolate|
89026668|NCT04207372|Experimental|Zein|
89026669|NCT04207372|Placebo Comparator|Protein-free|
89026670|NCT00601822|Experimental|1|Group receiving cognitive behavioral therapy for anorexia nervosa (CBT-AN)
89026671|NCT00601822|Experimental|2|Group receiving cognitive behavioral therapy for anorexia nervosa, plus cognitive remediation therapy (CBT-AN+CRT)
89026672|NCT00601861|Experimental|A|
89026673|NCT00470444|Active Comparator|1|Liberal transfusion strategy
89026674|NCT00470444|Active Comparator|2|Restrictive transfusion strategy
89026675|NCT00601978|Active Comparator|1|Immediate-Release Carbidopa/Levodopa
89026676|NCT00601978|Active Comparator|2|Carbidopa/Levodopa/Entacapone
89026677|NCT00601159|Experimental|gemcitabine and cisplatin|cisplatin and gemcitabine in the management of triple negative metastatic breast cancer
89026678|NCT00470483|Active Comparator|arm 1|Paroxetine treatment during 8 weeks
89026679|NCT00470483|Placebo Comparator|arm 2|Placebo treatment during 8 weeks
89026680|NCT00602056|Experimental|1|Redesigned immunization card
89026681|NCT00602056|Experimental|2|Center based education to mothers/caregivers
89026682|NCT00602056|Experimental|3|Redesigned immunization card with center based education to mothers/caregivers
89026683|NCT00602056|No Intervention|4|Standard care only
89026684|NCT00602095|Experimental|1|Labour induction with misoprostol
89026685|NCT00602095|Active Comparator|2|Labour induction with dinoprostone
89026686|NCT00602095|Experimental|3|Labour induction with bard
89026687|NCT00502086|Experimental|I|Viusid, three sachets daily during 96 weeks
89026688|NCT00502086|Placebo Comparator|2|Placebo three sachets daily during 96 weeks
89026689|NCT00475553|Other|Group 2|Subject will use the nuvaring and if they developed breakthrough bleeding or spotting for more than 5 days on the 6th day the ring would be removed and would leave it out for 3 full days and reinsert the same ring the next day. All subjects would be filling out a daily diary or calendar which would rate their blood flow, pelvic pain, headaches, moods, how many pain pills were taken and how many pads, liners or tampons would be used.
89026690|NCT00475553|Other|Group 1|Subject is using the nuvaring continuously and it would be changed out monthly. If she develops breakthrough bleeding or spotting she does not remove the ring until it is her time to change it. All subjects would be filling out a daily diary or calendar which would rate their blood flow, pelvic pain, headaches, moods, how many pain pills were taken and how many pads, liners or tampons would be used.
89026691|NCT01326481|Experimental|Single|All patients received TRC105 + capecitabine
89026692|NCT00502125||Patients with oral lesions|
89026693|NCT00475592|Experimental|Capsule Endoscopy|
89026694|NCT00475592|Active Comparator|Upper Gastrointestinal Endoscopy|
89026695|NCT00502281|Active Comparator|Group A|COS followed by TI
89026696|NCT00502281|Active Comparator|Group B|COS followed by IUI
89026697|NCT01244178|Experimental|Tight Glucose Control Hyperinsulinemic Group|
89026698|NCT01244178|Experimental|Non-Tight Glucose Control Hyperinsulinemic Group|
89026699|NCT01244178|Active Comparator|Standard Insulin Protocol Group|
89026700|NCT00470561|Active Comparator|Aspirin|
89026701|NCT00470561|Placebo Comparator|Placebo|
89026702|NCT00470678|Experimental|1|Ranibizumab
89026703|NCT00470756||evertors, invertors|
89026704|NCT00470795|Experimental|A|Acupuncture - 2 treatments weekly, 4 weeks (8 treatment)
89026705|NCT00470795|Placebo Comparator|B|Placebo/sham treatment; twice weekly for 4 weeks (total 8 treatments)
89026706|NCT00470873||Group 1|
89026707|NCT00493584|Experimental|1|Primary PCI in patients with acute Non-STEMI
89026708|NCT00493584|Active Comparator|2|Standard medical treatment and coronary angiography after 3 days in patients with Non-STEMI.
89026709|NCT00493623|Experimental|1|
89026710|NCT00493623|Placebo Comparator|2|
89026711|NCT02955849|Experimental|SLT laser group|"selective laser trabeculoplasty for 360 degrees the study eye.~Patients having 1 or 2 quadrants of angle with trabecular meshwork not visible will undergo Laser peripheral iridotomy prior to selective laser trabeculoplasty to maximize the amount of angle visible;~Cataract surgery will be offered if indicated and completed within 3 months of selective laser trabeculoplasty , if accepted by the patient.~Patients will be re-examined every 4 months and selective laser trabeculoplasty performed again according to the above protocol if intraocular pressure exceeds the target (25% reduction from the original intraocular pressure or < 21 mmHg, whichever is lower)."
89026712|NCT02955849|No Intervention|Standard care group|"Trabeculectomy as usually performed by the operative surgeon in one eye (study eye).~Both Mitomycin and releasable sutures are permitted if indicated in the opinion of the surgeon and s/he can perform and/or has access.~Simultaneous cataract surgery is permitted if indicated in the opinion of the operating surgeon.~Patients will be re-examined every 4 months， and Timolol 0.5% added bid if intraocular pressure exceeds the target (25% reduction from the original intraocular pressure or < 21 mmHg, whichever is lower)"
89026713|NCT02955849|No Intervention|Drug treatment group|Patients not accepting the offered treatment for the study eye within 3 months will receive topical Timolol 0.5% bid at the usual price, with the prescription to be refilled per usual practice at the hospital (usually monthly).
89026714|NCT00476099|Experimental|Beclomethasone 100 µg plus formoterol 6 µg (CHF1535) pMDI|
89559800|NCT06238115|Placebo Comparator|Standard medical care|Routine dual antiplatelet therapy (aspirin 100 mg/day, clopidogrel 75 mg/day)
89559801|NCT06237179|Experimental|Exercise Training Intervention|The exercise program (ET) is tailored to each participant depending on his initial functional capacity, cardiorespiratory fitness and strength, to achieve ≥150 moderate to vigorous physical activity
89559802|NCT06237179|Active Comparator|Healthy Living Education Control|Educational modules delivered remotely (or manual and telephone call) in a group-based setting to approximately match contact frequency and structure with the ET arm.
89559803|NCT06236451|Experimental|Aripiprazole group|Aripiprazole will be started at dose of 10 mg/day and increased to a stable dose of 20 mg/day over 2-3 weeks and will be continued till 12 weeks.
89559804|NCT06236451|Active Comparator|Risperidone group|Risperidone will be started at dose of 2 mg/day and increased to a stable dose of 6 mg/day over 2-3 weeks and continued till 12 weeks.
89026715|NCT00476099|Active Comparator|Budesonide 200 µg plus formoterol 6 µg DPI|
89026716|NCT00476099|Active Comparator|Formoterol 12 µg DPI|
89026717|NCT02274519|Experimental|Tai Chi|Group randomized to participate in Tai Chi intervention
89026718|NCT02274519|Active Comparator|Educational|Group randomized to participate in educational intervention
89026719|NCT02955888|Experimental|PBI4050|Four 200 mg capsules (total 800 mg) administered orally, once daily.
89026720|NCT02955888|Placebo Comparator|Placebo|Four 200 mg capsules (total 800 mg) administered orally, once daily.
89026721|NCT00470951|Active Comparator|open rectal resection|conventional open resection
89026722|NCT00470951|Active Comparator|laparoscopic rectal resection|laparoscopic rectal resection
89559805|NCT06234969|Experimental|Continuous theta burst stimulation to the intraparietal sulcus|Continuous theta burst stimulation will be delivered to the individually targeted intraparietal sulcus site at 100% RMT.
89559806|NCT06234969|Placebo Comparator|Sham continuous theta burst stimulation|We will use the coil's electric stimulation functionality that allows for the delivery of a brief electric pulse to the scalp simultaneous to the pulse to mimic actual stimulation.
89559807|NCT06234475|Experimental|Mobile health group|Smartphone mHealth support for smoking cessation by scheduled age-friendly multimedia e-messages and real-time personalized behavioral supports for 3 months.
89026723|NCT02956083|Active Comparator|Lipid based artificial tears|Patients use lipid based artificial tears
89026724|NCT02956083|Active Comparator|Non-lipid based artificial tears|patients use non-lipid based artificial tears
89026725|NCT02956083|Placebo Comparator|Saline|patients use saline
89026726|NCT01246440|Experimental|Catumaxomab|
89026727|NCT03271112|Other|Exercise program|Participation to the 12-wks exercise program
88966256|NCT00001566|Experimental|Peptide vaccine/autologous T cell transplant/indinavir therapy|Patients receive oral indinavir sulfate 350 mg/m^2 administered every 8 hours; maximum dose i.e. 800 mg every 8 hours; peptide pulsed dendritic cells 1 x 10^6 injection; harvested autologous T cells (minimum dose 1 x 10^6/kg will be thawed rapidly in 37 degree water bath and infused sequentially over 5-15 minutes.
88966257|NCT04394572||colorectal cancer|Patients with and without colorectal cancer
88966258|NCT00001575|Experimental|Anti-Tac yttrium 90-labeled humanized anti-Tac (90 Y-HAT)|"10 mCi (if a bone marrow transplant was part of the patient's previous therapy) or 15 mCi of yttrium labeled anti-TAC; followed by calcium trisodium Inj (Ca DTPA).~Ca-DTPA will be administered intravenously on Days 1-3 to clear the radioactive agent from the body"
88966259|NCT05680649|Experimental|Intervention|Breathing exercise
88966260|NCT05680649|No Intervention|Control|Standard practice
88966261|NCT00001596|Active Comparator|Pirfenidone|Subjects received pirfenidone 801 mg (3 pills of 267 mg each), three times daily.
88966262|NCT00001596|Placebo Comparator|Placebo|Subjects received placebo (3 pills), three times daily.
88966263|NCT05680571||Parkinson|Patients suffering from PD of both genders above 18 years of age and Gender- and age-matched HC without any eye- or neurological disorder.
88966264|NCT05680571||Ataxia|Patients suffering from AT of both genders above 18 years of ageand Gender- and age-matched HC without any eye- or neurological disorder.
88966265|NCT05680532|Experimental|BR group|Experimental group AZ subjects were requested to take 50 g of BR powder dissolved in 240 ml of water for 4 weeks.
88966266|NCT05680532|Placebo Comparator|Placebo group|Placebo group AZ subjects were requested to take 50 g of dextrin powder dissolved in 240 ml of water for 4 weeks.
88966267|NCT04733872|Placebo Comparator|placebo group|subjects drank 50 ml , 1 bottle a day for 8 week
88966268|NCT04733872|Experimental|Vegetable and Berry Drink|subjects drank 50 ml , 1 bottle a day for 8 week
88966269|NCT05576545|Experimental|general routine care and the Breast Cancer Self-Care App|
88966270|NCT05576545|No Intervention|general routine care|
88966271|NCT05680493|Experimental|Dry needling|Total 12 sessions of trigger point dry needling at lumbar muscles with Hot pack,with 3 sessions per week
88966272|NCT05680493|Active Comparator|manual pressure release|Hot pack for 15 min then manual pressure release
88966273|NCT05680376||Recurrent Pregnancy loss|patients with a diagnosis of recurrent miscarriage
88966274|NCT05680376||Healthy Controls|healthy women at same age and similar demographics
88966275|NCT00392080|Placebo Comparator|3|
88966276|NCT00392080|Experimental|1|75 mg BID
88966277|NCT00392080|Experimental|2|
88966278|NCT05680259|Experimental|Maela connected follow-up|patient will benefit of the Maela connected follow-up
88966279|NCT05680259|Active Comparator|control group|control group with a traditional follow-up
88966280|NCT05574595|Experimental|The Mean of the Hemodialysis Comfort Scale scores of the experimental and group patients|To the Experimental Group; The information form and the short form of the comfort scale will be applied to the patient who is taken to the dialysis unit to start HD treatment.
88966281|NCT05574595|No Intervention|The mean of the Hemodialysis Comfort Scale scores of the control group patients|No procedure was performed on the patients in the control group.
88966282|NCT05574556||myoelectric activity of the quadriceps muscle|electromyography myoelectric activity of the quadriceps muscle
88966283|NCT05680220|Experimental|Active Neurostimulation System (NSS)|Exposure to the NSS device set to 40 Hz invisible spectral flicker 1 hour a day
88966284|NCT05680220|Placebo Comparator|Sham Neurostimulation System (NSS)|Exposure to the NSS device set to continuous color-matched white light for 1 hour a day
88966285|NCT05574283|Experimental|ESPB group|ESPB group: 30 patients will receive bilateral ultrasound-guided erector spinae plane block using 20 ml of bupivacaine 0.25% with 4 mg dexamethasone for each side.
88966286|NCT05574283|Experimental|TQLB group|TQLB group: 30 patient will receive bilateral ultrasound-guided transmuscular quadratus lumborum block using 20 ml of bupivacaine 0.25% with 4 mg dexamethasone for each side.
88966287|NCT05574205|Experimental|High Quality Protein|Participants will consume four high-quality protein containing meals per day (amounting to 1g/kg/day of protein) over a 10-day period. Each meal will contain 75:25 animal:plant protein with most of the animal protein from supplemental high-quality protein powder.
88966288|NCT05574205|Experimental|Low Quality Protein|Participants will consume four low-quality protein containing meals per day (amounting to 1g/kg/day of protein) over a 10-day period. Each meal will contain 25:75 animal:plant protein with most of the plant protein from supplemental low-quality protein powder.
88966289|NCT05574166|Experimental|SP-8356 powder|Part1 will consist of escalating single doses in five sequential cohorts. Each dose level cohort will consist of 8 subjects: 6 subjects will receive SP-8356 and 2 subjects will receive placebo in fasted state according to the randomization schedule. Subjects in Cohort 3 will receive a single dose of SP-8356 or placebo in the fasted then fed state on separate dosing occasions.
88966290|NCT05574166|Placebo Comparator|Placebo|Part1 will consist of escalating single doses in five sequential cohorts. Each dose level cohort will consist of 8 subjects: 6 subjects will receive SP-8356 and 2 subjects will receive placebo in fasted state according to the randomization schedule. Subjects in Cohort 3 will receive a single dose of SP-8356 or placebo in the fasted then fed state on separate dosing occasions.
88966291|NCT02971774||questionnary|self administered questionnary
88966292|NCT05574049|Active Comparator|Single Dose|Once daily mouth strip containing 8mg of THCV and 10mg of CBD
88966293|NCT05574049|Active Comparator|Double Dose|Once daily mouth strip containing 16mg of THCV and 20mg of CBD
88966294|NCT05574049|Placebo Comparator|Placebo|Once daily mouth strip containing nothing
88966295|NCT05573971|Experimental|with verbal encouragement|
88966296|NCT05573971|No Intervention|without verbal encouragement|
88966297|NCT05573854|Sham Comparator|Overnight Fast|After an overnight fast period of eight hours, the 6 participants will attend the Radiology Service of the Hospital de Câncer, Cuiaba, Brazil to perform MRI images of the upper abdomen with the objective of measuring the fasting GRV. GRV will be evaluated by tracking the region of interest (ROI) in each slice, forming a volume by the sum of all ROIs (phase 1).
88966298|NCT05573854|Active Comparator|Oral Supplement|Each of the 6 participants while still inside the MRI exam room just after the MRI in fast condition, will ingest 200mL of the study oral supplement (OS). The individual will be immediately positioned in the supine position and another MRI scan will be carried out. In this second phase, GRV will be evaluated again as in phase 1 (phase 2).
88966299|NCT05573854|Active Comparator|3h after ingestion|Finally, phase 3 will be performed after a 3-hour pause. All volunteers, while still in the Radiology Service and fasted after the ingestion of the OS described in phase 2, will be submitted to a third MRI scan of the upper abdomen to measure again the GRV as previously described.
88966300|NCT05573815|Experimental|Positive group|A patient diagnosed with brain metastasis after a brain MR
88966301|NCT05573815|Experimental|Negative group|A normal person or a patient not diagnosed with brain metastasis after a brain MR
88966302|NCT05573776|Experimental|Exercise Therapy, High Protein supplement|
88966303|NCT05573386||Filgrastim to Pegfilgrastim|Participants in this group will receive filgrastim treatment, followed by pegfilgrastim treatment at the 8-week mark.
88966304|NCT05573386||Pegfilgrastim to filgrastim|Participants in this group will receive pegfilgrastim treatment, followed by filgrastim treatment at the 8-week mark
88966305|NCT00001656|Active Comparator|Olanzapine|
88966306|NCT00001656|Active Comparator|Clozapine|
88966307|NCT05573347||Bone marrow harvest from side-lying patient|This group will have bone marrow harvested from the PSIS extraction site while lying in the lateral decubitus position.
88966308|NCT05573347||Bone marrow harvest from patient lying prone|This group will have bone marrow harvested from the PSIS extraction site while lying in the prone position.
88966309|NCT05573308|Experimental|Clear Aligners with Dental Monitoring|"Experiment group: DM (Remote Dental Monitoring approach). Remote Dental Monitoring by DMTM will be implemented in the patient's orthodontic treatment. Pretreatment, 3D digital intra-oral scans will be uploaded to the DMTM dashboard, so they serve as the baseline for 3D tracking of tooth movement. Patients will be trained on how to use the DMTM application and do DM remote scans using their smartphones DM scan box and rector.~They will be instructed to do the DM scan after the initial tray insertion. Replacement of the aligners trays will be based on DM GO tracking function, which is specifically targeted at clear aligner treatment."
88966310|NCT05573308|Active Comparator|Clear Aligners replaced every 7 days|Group 2:Control group. All subjects will have conventional aligner treatment with aligners replaced every 7 days, and standard in-office visits every 8 weeks.
88966311|NCT05573308|Active Comparator|Clear Aligners replaced every 14 days|Group 3: (n=40) Control group. All subjects will have conventional aligner treatment with aligners replaced every 14 days, and standard in-office visits every 8 weeks.
88966312|NCT05679869|Active Comparator|VR Simulated Outdoor Environment|Exposure to recorded outdoor environmental sounds
88966313|NCT05679869|Experimental|VR Simulated Outdoor Environment with Masking Sounds|Exposure to recorded outdoor environmental sounds augmented with masking sounds
88966314|NCT05573269|Experimental|FOPE group|"Dietary supplement, Polyphenolic extract from pine bark (Oligopin® 100mg) and fish oil capsule contained EPA 350mg + DHA 250mg. This group will receive a nutritional supplement for a period of 6 months.~The participants will have a capsule of polyphenolic extract and a capsule of fish oil a day."
88966315|NCT05573269|Active Comparator|FO group|This group will have placebo capsule and fish oil capsule. Placebo capsule contained maltodextrin and magnesium stearate, while fish oil contained EPA 350mg + DHA 250mg. The participants will receive the supplements for a period of 6 months and have a capsule of placebo and a capsule of fish oil a day.
88966316|NCT05573191|Experimental|LP group|The experimental group received 1.5 mg/kg lidocaine intravenously,after 90s, the corresponding dose of propofol was injected intravenously at 30mg/kg/h, and to observe Whether consciousness disappears or not，recording NTI values, heart rate, oxygen saturation, mean arterial pressure and drug side effects in the baseline state, 90s after lidocaine administration, 60s and 120s after propofol administration
88966317|NCT05573191|Placebo Comparator|P group|Replace lidocaine with equal volume normal saline,Others are the same as the experimental group.
88966318|NCT05573152|Experimental|Nursing|Nursing Group (Nurse): the nursing team will use of the warming device air flow device from the moment the patients enter the operating room until anesthesia induction. The warming device will be set up connected to the patient and to the motor with the activation of the system at 43°C by the nursing team. The monitoring of the times since the entrance of the patient in the operating room until the induction of the anesthesia will be controlled by a member of the anesthesia team (regardless of the room process);
88966319|NCT05679830|Experimental|160mg Cannabidiol Isolate|320mg of CBD Isolate BID for 5 days every month starting the day that participants believed they were having menstrual-related symptoms (MRS).
88966320|NCT05679830|Experimental|320mg Cannabidiol Isolate|160mg of CBD Isolate BID for 5 days every month starting the day that participants believed they were having menstrual-related symptoms (MRS).
88966321|NCT05679791||Group 1|
88966322|NCT05679791||Group 2|
88966323|NCT05572801|No Intervention|ARM A: HPV positive standard of care follow-up|The national follow-up program + collection of blood samples for retrospective translational research
88966324|NCT05572801|Experimental|ARM B: HPV positive ctDNA guided imaging in follow-up|The national follow-up program + ctDNA guided additional imaging + collection of blood samples for retrospective translational research
88966325|NCT05572801|No Intervention|ARM O: HPV negative observational arm|"Patients with HPV negative disease will be included in an observational arm (ARM O)~ARM O: The national follow-up program + collection of blood samples for retrospective translational research"
88966326|NCT05572762|Experimental|Atraumatic Peribulbar Technique|a cannula is used to apply ophthalmic block
88966327|NCT05572762|Active Comparator|Conventional peribulbar block|a 24 or 25 gauge needle is used to provide regional o anesthesia to the study group
88966328|NCT05572723|Active Comparator|Group Remifentanil|Remifentanil group was initially to receive remifentanil (group R), 0.01-0.2 g/kg/min without intraoperative loading.
88966329|NCT05572723|Active Comparator|Group Dexmedetomidine|Dexmedetomidine group, dexmedetomidine (group D) was initiated with a bolus of 1 mg/kg and received 0.2-0.7 g/kg per hour as an infusion during surgery.
88966330|NCT05570071|Experimental|vaginal radiofrequency|vaginal radiofrequency therapy 4 times
89026728|NCT00476216|Experimental|Combination of Arixtra with chemotherapy|Carboplatin 6 AUC q 21 days; Paclitaxel 200 mg/m2 q 21 days. Cohort I: Arixtra 2.5 mg SQ qd x 21 days; Cohort II: Arixtra weight-based dose (D1-2)followed by Arixtra 2.5 SQ q day (D3-21)
89026729|NCT00502632|Experimental|1|"Intrapleural administration of:~Urokinase 40,000 in 40ml normal saline, twice daily for 4 days~Dornase alfa 2,500 IU in 25ml normal saline, twice daily for 4 days"
89559808|NCT06234475|Experimental|Financial incentive group|An escalating incentive scheme for smoking abstinence: HK$500 for using any SC services within 6 months, and HK$1000, 1500 and 2000 for biochemically validated abstinence at 3-, 6- and 12-month, respectively.
89559809|NCT06234475|Experimental|Combined intervention group|Smartphone mHealth support for smoking cessation by scheduled age-friendly multimedia e-messages and real-time personalized behavioral supports for 3 months and an escalating incentive scheme for smoking abstinence: HK$500 for using any SC services within 6 months, and HK$1000, 1500 and 2000 for biochemically validated abstinence at 3-, 6- and 12-month, respectively.
89559810|NCT06234475|Active Comparator|Control group|Brief advice
89559811|NCT06231498||Overall Cohort|The study will include 300 adult (>18yo) patients with Eosinophilic Granulomatosis with Polyangiitis (EGPA). All patients will be recruited at Meyer Children's Hospital and Careggi University Hospital, which are referral centers for EGPA and have a large cohort of prevalent cases under long-term follow-up. They will represent the cases for the case-control epigenome-wide association study. Patients are expected to be untreated or under glucocorticoids at the time of sampling. A blood sample will be drawn for each participant. Among this cohort, 50 patients will be identified that will undergo treatment with Mepolizumab, and they will form the sub-cohort in which we will search for epigenetic predictors of the response to Mepolizumab treatment (predictive epigenomic study). These 50 patients will also be analyzed with regard to the transcriptomic and proteomic profile. Written informed consent from all participants and approval from the local ethical committees will be obtained.
88966331|NCT05570071|Active Comparator|electromyography biofeedback|electromyography combined with biofeedback therapy 15 times
88966332|NCT04733716|Active Comparator|Total Knee Arthroplasty with using Tourniquet|A pneumatic tourniquet was used before surgery at the proximal thigh and inflated before the skin incision until skin closure in this group. The tourniquet was inflated to either 275 or 325 mmHg, depending on the patient's systolic blood pressure.
88966333|NCT04733716|Active Comparator|Total Knee Arthroplasty without using Tourniquet|A pneumatic tourniquet was not used in this group during the total knee arthroplasty.
88966334|NCT05563753||ABT in the first week of life|VLBWI with gestational age between 24+0 and 31+6 weeks of gestation with antibiotic treatment in the first week of life
88966335|NCT05563753||no antibiotic therapy (ABT) in the first week of life|VLBWI with gestational age between 24+0 and 31+6 weeks of gestation without antibiotic treatment in the first week of life
88966336|NCT05560984|Experimental|study population|Women with previous one or more cesarean sections with placenta previa and focal accrete
88966337|NCT05557786||Real CB-tACS (10 days cerebellar tACS)|Real cerebellar tACS, 70Hz,2mA (peak to peak), 40min/day (10s ramp up and 10s ramp down), (10 sessions, 5 days/week for 2 weeks)
88966338|NCT05557786||Sham CB-tACS (10 days sham cerebellar tACS)|Sham cerebellar tACS,10Hz, 2mA (peak to peak) for 40s, and then no current 40min/day (10s ramp up and 10s ramp down), (10 sessions, 5 days/week for 2 weeks)
88966339|NCT05455099||obese group|Participants will be assigned to obese group (body mass index 24.0-27.9 kg/m²). Based on the inclusion criteria, 1200 overweight Han people（body mass index 24.0-27.9 kg/m²）and both sexes will be recruited in the analysis. The values of ultrafast pulse wave velocity will be obtained.
88966340|NCT05455099||overweight group|Participants will be assigned to overweight group (body mass index ≥ 28.0 kg/m²). Based on the inclusion criteria, 1200 obese Han people（body mass index ≥28.0 kg/m²） and both sexes will be recruited in the analysis. The values of ultrafast pulse wave velocity will be obtained.
88966341|NCT04733794|Experimental|Surgery for Stoma Reversal|All study participants will receive stoma reversal, complete baseline questionnaire, pelvic floor training and follow up questionnaires
88966342|NCT04733755|Experimental|Beauty Image|
88966343|NCT04733755|Placebo Comparator|Placebo Control|
88966344|NCT05676983|Experimental|Spiky balance disc study group|Bobath therapy will be studied with the children in this group and balance training will be given on the rough (spiky) surface of the extra balance disc.
88966345|NCT05676983|Experimental|Smooth balance disc study group|Bobath therapy will be studied with the children in this group and balance training will be given on the smooth (flat) surface of the extra balance disc.
88966346|NCT05311618|Experimental|NGM438 Monotherapy Dose Escalation|Part 1a Single Agent Dose Escalation
88966347|NCT05311618|Experimental|NGM438 Combination Dose Finding with Pembrolizumab|Part 1b NGM438 plus pembrolizumab
88966348|NCT05311618|Experimental|Biopsy Cohort with NGM438 Monotherapy Lead-in Followed by Combination Therapy with Pembrolizumab|Part 1C NGM438 followed by NGM438 plus pembrolizumab
88966349|NCT05266183|Experimental|Simultaneous Variety, Small Portion|3 different foods served in a small portion.
88966350|NCT05266183|Experimental|Simultaneous Variety, Large Portion|3 different foods served in a large portion.
88966351|NCT05266183|Experimental|Single-Food, Small Portion|1 food served in a small portion.
88966352|NCT05266183|Experimental|Single-Food, Large Portion|1 food served in a large portion.
88966353|NCT02972047|Experimental|Diaphragmatic Breathing|"Subjects randomized to the experimental intervention arm will receive instructions and rationale for Diaphragmatic Breathing in the postprandial state and receive detailed instruction in diaphragmatic breathing.~Following the office visit the patients with upright GERD and healthy persons will undergo a further 24 hours of pH impedance monitoring. This group will practice diaphragmatic breathing for 30 minutes after each meal.~During the second 24 hour period patients with GERD and healthy persons will again consume the standard pH neutral refluxogenic meal note this with an event marker~After 48 hours patients with GERD and healthy persons will present to the esophageal laboratory for probe removal"
89026730|NCT00502632|Placebo Comparator|2|"Intrapleural administration of:~Urokinase 40,000 in 40ml normal saline, twice daily for 4 days~25ml normal saline, twice daily for 4 days"
89026731|NCT00471185|Experimental|A|Subjects will receive progressively increasing doses of 10, 20 and 40 mg of oral acyline, on 3 occasions, each separated by 1 week
89026732|NCT01325701|Experimental|PCI-32765: 560 mg|Treatment Group 1: Subjects received 560 mg of ibrutinib once daily, on a continuous basis.
89026733|NCT01325701|Experimental|PCI-32765: 840 mg|Treatment Group 2: Subjects received 840 mg of ibrutinib once daily, on a continuous basis.
89026734|NCT00493857|Experimental|2|Nimotuzumab 400mg every week or every two weeks
89026735|NCT00476255|Active Comparator|Enhanced Standard Care|Instructional materials
89026736|NCT00476255|Experimental|Motivational Intervention|Motivational interview
89026737|NCT00476294||Group 1: G + Placebo|G-CSF plus Placebo Arm (G + Placebo)
89026738|NCT00476294||Group 2: G + AMD3100|G-CSF plus AMD3100 Arm (G + AMD3100)
89026739|NCT01325623|Other|Model 106 VNS Therapy System|Model 106 VNS Therapy System includes a new Seizure Detection Algorithm (SDA) and corresponding Automatic Magnet Mode (AMM) feature.
89559812|NCT06224426|Experimental|Normobaric high-concentration oxygen (NBHO) group|After preoxygenating (FiO2=100%, 6 L/min) with a face mask for 3 min, patients will be sequentially administered intravenous sufentanil 0.2 µg/kg followed by propofol 2 mg/kg. Once the eyelash reflex was absent, all patients received 0.6 mg/kg rocuronium, with an endotracheal tube inserted approximately 90 seconds later. Mechanical ventilation is set to volume-controlled ventilation (VCV) mode, fresh gas flow 4 L/min, tidal volume (Vt) 6-8 ml/kg, respiratory rate (RR) 12-14 breaths/min, and positive end-expiratory pressure (PEEP) 5 cmH2O. End-tidal carbon dioxide (PetCO2) will be continuously monitored, maintaining it between 35-40 mmHg. Based on group allocation, the NBHO group will adjust the FiO2 at 80% throughout the surgery. Anesthesia will be maintained through total intravenous anesthesia, continuously infusing remifentanil 0.05-0.1 µg/kg/min and propofol 4-6 mg/kg/min, with intermittent 10 mg rocuronium as needed.
89608748|NCT03589521|Experimental|ABCT_Military|ABCT_Military manual will address alcohol use, couple issues and military specific issues. Required interventions include: routine interventions, overview of treatment, reintegration issues, motivational techniques, patient-focused interventions for abstinence, partner-related interventions for abstinence, couple interventions, general coping skills, social skills and relapse prevention. In addition, to personalize each treatment plan, interventions from optional modules (e.g., intimate partner violence (IPV), depression, trauma, and traumatic brain injury (TBI)) will be integrated into each couple's treatment plan depending on clinical presentation.
89026740|NCT00494052|Experimental|1|Heart to Heart intervention
89026741|NCT00494052|No Intervention|2|Usual care
89026742|NCT01246518|Active Comparator|MOB015 for 3 months|
89026743|NCT01246518|Active Comparator|MOB015 for 9 months|
89026744|NCT01325584|Experimental|Omegaven (compassionate use)|This is a compassionate use study. All participants will receive intravenous Omegaven (10% fish oil emulsion) with parenteral nutrition for 4 weeks.
89026745|NCT04207294|Experimental|Vitamin D-enriched pork|One portion of Vitamin D-enriched pork
89026746|NCT04207294|Placebo Comparator|Control pork|One portion of control pork
89026747|NCT04207294|Active Comparator|Vitamin D supplement|Equivocal dose of Vitamin D supplement
89026748|NCT04207294|Experimental|Vitamin D-enriched chicken|One portion of Vitamin D-enriched chicken
89026749|NCT04207294|Placebo Comparator|Control chicken|One portion of control chicken
89026750|NCT00502749|Experimental|Exercise program|Daily (Monday-Friday) 45-minute group physical exercise program during each hospital admission for three months or individual 20 minute session bedside.
89026751|NCT02891551||Patients receiving Azacitidine per daily clinical practice|
89026752|NCT02891473|Experimental|Mézières Method group|Sessions of exercises for the recovery of midline symmetry, diaphragmatic breathing exercises, stretching of the latissimus dorsi respecting the global elongation according to the Mézières Method.
89026753|NCT02891473|Active Comparator|Home based exercise program group|Sessions of home based exercises performed by the patients at their domicile after a training session about the exercise program made by a physiotherapy. The exercises aimed at promoting trunk control in static and dynamic position according to the specific guidelines for Parkinson's disease and proprioceptive exercises for the recovery of balance. An illustrated exercises booklet was given to the patient.
89026754|NCT00476372||Parkinson's disease|Pt with parkinsons disease
89026755|NCT00471224||Patients who have received drug.|Patients who have received drug.
89026756|NCT02891590|Experimental|DTRMWXHS-12|DTRMWXHS-12 only: oral capsules (50 mg and 150 mg strengths), successive administration, dose escalation from 50mg to 100, 200, 400, 600, 800mg daily until MTD. During successive administration, orally once a day, 28 days as a cycle.
89026757|NCT00502827|Other|Recommended Standard of Care|Recommended Standard of Care (RSOC) = Physician Advice + Written Materials
89026758|NCT00502827|Other|RSOC + Cell Phone Intervention|Recommended Standard of Care (RSOC) + Cell Phone Intervention
89026759|NCT00502866||breastfed children|children, 6-15 months old, predominately breastfed for at least 6 months without supplemental vitamin D
89026760|NCT00494208|Active Comparator|1|
89026761|NCT00494208|Active Comparator|2|
89026762|NCT00494208|Active Comparator|3|
89026763|NCT00494208|Active Comparator|4|
89026764|NCT00494208|Active Comparator|5|
89026765|NCT01325428|Experimental|Afatinib once daily (OD)|Patients receive afatinib monotherapy once daily until progression of their disease
89026766|NCT00502983||Interview|AML Patients & Healthy Controls
89026767|NCT00476411|Experimental|1|HBV vaccine
89026768|NCT01325350|Experimental|bimatoprost Formulation A|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
89026769|NCT01325350|Experimental|bimatoprost Formulation B|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
89026770|NCT01325350|Experimental|bimatoprost Formulation C|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
89026771|NCT01325350|Placebo Comparator|bimatoprost vehicle solution|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
89559813|NCT06224426|Experimental|Normobaric low-concentration oxygen (NBLO) group|After preoxygenating (FiO2=100%, 6 L/min) with a face mask for 3 min, patients will be sequentially administered intravenous sufentanil 0.2 µg/kg followed by propofol 2 mg/kg. Once the eyelash reflex was absent, all patients received 0.6 mg/kg rocuronium, with an endotracheal tube inserted approximately 90 seconds later. Mechanical ventilation is set to volume-controlled ventilation (VCV) mode, fresh gas flow 4 L/min, tidal volume (Vt) 6-8 ml/kg, respiratory rate (RR) 12-14 breaths/min, and positive end-expiratory pressure (PEEP) 5 cmH2O. End-tidal carbon dioxide (PetCO2) will be continuously monitored, maintaining it between 35-40 mmHg. Based on group allocation, the NBLO group will adjust the FiO2 at 30% throughout the surgery. Anesthesia will be maintained through total intravenous anesthesia, continuously infusing remifentanil 0.05-0.1 µg/kg/min and propofol 4-6 mg/kg/min, with intermittent 10 mg rocuronium as needed.
89559814|NCT06223373|Experimental|Blood Flow Restriction (BFR)|Blood Flow Restriction (BFR) pressurized per standard protocols in addition to our institutional rehabilitation protocol
89559815|NCT06223373|Sham Comparator|"sham Blood Flow Restriction (BFR)"|"rehabilitation using sham BFR as well as our institutional rehabilitation protocol"
89559816|NCT06220773|Experimental|BR1019A + BR1019B + BR1019C-1|
89559817|NCT06220773|Active Comparator|BR1019A + BR1019B-1 + BR1019C-1|
89559818|NCT06220773|Active Comparator|BR1019A-1 + BR1019B + BR1019C-1|
89559819|NCT06220773|Other|BR1019A-1 + BR1019B + BR1019C|
89559820|NCT06214793|Experimental|Taletrectinib|Taletrectinib 600mg will be given po daily every day within 2 hours of meals on days 1-21, on a 21-day cycle. Study drug will be given until intolerance, consent withdrawal, progression per RECIST 1.1, or death (i.e., no maximum number of cycles).
89559821|NCT06208371|Experimental|Liver-localized treatment group|Participants in this group will undergo liver-localized interventions, which may include surgical resection and/or ablation therapy and/or SBRT, aiming to achieve NED.
89559822|NCT06208371|Active Comparator|Palliative chemotherapy only group|Participants in this group will receive standard palliative chemotherapy. The focus is on managing symptoms and controlling the progression of the disease.
89559823|NCT06206902|Experimental|Assigned Interventions|
89559824|NCT06204029|Experimental|Everyone can sing|Students from 0-3rd grade receive class choir two lessons every week as part of their regular school schedule
89559825|NCT06201689|Placebo Comparator|Placebo Control 1|Energy Product Form 1 - control
88966354|NCT02972047|Sham Comparator|Life style counseling|"Subjects randomized to the Sham Comparator intervention arm will engage in sham therapy (listening to music/watching TV for 30 minutes after each meal)~Following the office visit the patients with upright GERD and healthy persons will undergo a further 24 hours of pH impedance monitoring. This group will will engage in sham therapy (listening to music/watching TV for 30 minutes after each meal)~During the second 24 hour period patients with GERD and healthy persons will again consume the standard pH neutral refluxogenic meal note this with an event marker~After 48 hours patients with GERD and healthy persons will present to the esophageal laboratory for probe removal"
88966355|NCT05673356|Experimental|Main arm of the study|Arthroscopic anterior cruciate ligament reconstruction with quadriceps tendon bone autograft (QTB) will be performed in these patients.
89559826|NCT06201689|Experimental|Active Product 1.1|Energy Product Form 1 - active product 1
89559827|NCT06201689|Experimental|Active Product 1.2|Energy Product Form 1 - active product 2
88966356|NCT05233384||Patients with hereditary dysfibrinogenemia|Patient, male or female, aged over 18, with confirmed hereditary dysfibrinogenemia
88966357|NCT05668364|Experimental|Exposition group|Outdoor cold air exposure (<10°C or <50°F) for 30 minutes. On completion of the intervention, participants remained under observation at indoor ambient air from 30 minutes to 60 minutes from the intervention.
88966358|NCT05668364|No Intervention|Control group|Indoor ambient air exposure (24-25°C or 75-77°C). Participants remained under observation at indoor ambient until 60 minutes from triage.
88966359|NCT05144269|Experimental|Multimodal exercises group|Multimodal exercise-based telerehabilitation will be implemented with video conference method. For telerehabilitation, a program including pilates, breathing, progressive relaxation training, posture and pelvic floor strengthening exercises was created. Sessions consist of 45 minutes. Telerehabilitation will take place 2 days a week for 8 weeks.
88966360|NCT05144269|No Intervention|Education group|30 minutes of training will be given about postpartum and exercises. As exercise, only aerobic walking exercise, which can be started for 15 minutes a day and 3 days a week according to the guide, gradually increasing, up to 30 minutes and up to 4 days a week will be applied. There will also be a warm-up and a cool-down period before the walking exercise. *Exercise intensity is determined in the 12-14 score range according to the Borg Scale, and how to apply it will be explained.
89559828|NCT06198374|Experimental|PA Intervention.|The group which receives the PA as a dietary food supplement. A single capsule contains 500mg of sodiumpropionate, which is taken twice daily for 28 days.
89559829|NCT06198374|Placebo Comparator|Placebo Intervention|The control-group receives a placebo instead of propionate. The placebo contains maltodextrin and the same amount of sodium chloride as compared to the PA intervention. The placebo is taken twice per day for 28 days.
89608749|NCT03589443|Experimental|Multiplexed heptapeptides|QRH & KSP sprayed onto area of interest and imaged before and after application
89608750|NCT03589365|Other|Preterm group|young adults born preterm will performed an Magnetic resonance imaging (MRI)
89608751|NCT03589365|Other|control group|young adults born at term will performed an Magnetic resonance imaging (MRI)
89608752|NCT03587415||Polycyctic ovary sendrome (PCOS)|these women who have PCOS, we will use their blood samples
89608753|NCT03587415||Healty groups|These women who have reguler menstrual cycle, no akne or hirsutism, we will use their boold samples
89608754|NCT03020433|Active Comparator|rTMS Contralesional M1 Inhibition|
89608755|NCT03020433|Active Comparator|rTMS Contralesional PMC facilitation|
89608756|NCT03020433|Active Comparator|rTMS Ipsilesional PMC facilitation|
89608757|NCT03020433|Sham Comparator|rTMS Sham at Ipsilesional M1|
89608758|NCT01797445|Experimental|E/C/F/TAF (Double-Blind)|"E/C/F/TAF plus E/C/F/TDF placebo for 144 weeks~After 144 weeks, participants will continue to take their blinded study drug until treatment assignments have been unblinded."
89559830|NCT06194929|Experimental|Phase II, Defactinib and Avutometinib (Cohort A)|"Avutometinib will be administered at 3.2 mg biweekly orally (e.g., Monday/Thursday, Tuesday/Friday, or Wednesday/Saturday) for 3 weeks, followed by a 1-week rest period, in each 4-week (28-day) cycle.~Defactinib will be administered at 200 mg twice a day orally for 3 weeks, followed by a 1-week rest period, in each 4-week (28-day) cycle."
89559831|NCT06194929|Experimental|Phase Ib, Defactinib, Avutometinib, and Encorafenib (Cohort B)|"Avutometinib will be administered at 3.2 mg biweekly orally (e.g., Monday/Thursday, Tuesday/Friday, or Wednesday/Saturday) for 3 weeks, followed by a 1-week rest period, in each 4-week (28-day) cycle.~Defactinib will be administered at 200 mg twice a day orally for 3 weeks, followed by a 1-week rest period, in each 4-week (28-day) cycle.~Encorafenib will be administered orally to a small cohort to a limited dose escalation cohort using a Bayesian optimal interval (BOIN) design to evaluate safety, toxicity, and recommended phase II dose for dosage of encorafenib when combined with avutometinib and defactinib.~Dose escalation levels for Encorafenib:~Dose Level -1: 225 mg Daily (three 75mg capsules) Dose Level 0: 300 mg Daily (four 75mg capsules) Dose Level 1: 450 mg Daily (six 75mg capsules)"
89559832|NCT06194929|Experimental|Phase II, Defactinib, Avutometinib, and Encorafenib (Cohort B)|"Avutometinib will be administered at 3.2 mg biweekly orally (e.g., Monday/Thursday, Tuesday/Friday, or Wednesday/Saturday) for 3 weeks, followed by a 1-week rest period, in each 4-week (28-day) cycle.~Defactinib will be administered at 200 mg twice a day orally for 3 weeks, followed by a 1-week rest period, in each 4-week (28-day) cycle.~Encorafinib will be administered orally at doses defined in the dose escalation portion (225mg - 450mg) Daily continuously (days 1-28 of a 28 day cycle) for Cohort B."
89559833|NCT06185465|Experimental|Prontosan Wound Irrigation Solution rinse|The test group is selected according to the randomization number of enrollment. For experimental group, Prontosan Wound Irrigation Solution is extracted with syringe (Dosage 1-2ml/cm2), and the wound is rinsed 1 cm from the wound. Then, Prontosan wound irrigation solution is used to saturate the gauze, and the gauze is applied to the wound for 15 minutes. After removing the gauze, cover it with oil gauze, then cover it with 8 layers of gauze and wrap it with a bandage.
89559834|NCT06185465|Active Comparator|Normal Saline rinse|For control group, Normal saline is extracted with syringe (Dosage 1-2ml/cm2), and the wound is rinsed 1 cm from the wound. Then, Normal saline is used to saturate the gauze, and the gauze is applied to the wound for 15 minutes. After removing the gauze, cover it with oil gauze, then cover it with 8 layers of gauze and wrap it with a bandage.
89559835|NCT06184750|Experimental|Prevention (tamoxifen)|Participants receive tamoxifen 5mg PO QD for 6 months. Participants with aDAR >= 10% on mammogram at 6 months continue receiving tamoxifen 5mg PO QD for 12 months. Participants with aDAR < 10% at 6 months are escalated to receive tamoxifen 10mg PO QD for 6 months. Participants with aDAR >= 10% after 6 months of tamoxifen 10mg continue receiving tamoxifen 10 mg PO QD for 6 months. Participants with aDAR < 10% after 6 months of tamoxifen 10mg are given the option of continuing tamoxifen 10mg or escalating to receive tamoxifen 20mg PO QD for 6 months. Participants undergo mammography and collection of blood samples at screening and on study. Participants may optionally undergo biopsy at screening and on study.
88966361|NCT05095441|Experimental|Part 1: Dose Escalation|C5252 single agent dose escalation in participants with glioblastoma
88966362|NCT05095441|Experimental|Part 2: Dose Expansion|Recommended dose of C5252 as determined in Part 1 Dose Escalation in participants with glioblastoma
88966363|NCT05080738|Experimental|Intervention group|The patients in the intervention group will be asked to practice upper extremity home exercises including stretching, mobility and strengthening, as home exercises, 5 days a week for 8 weeks, which will be taught by the physiotherapist.
88966364|NCT05080738|No Intervention|Control|Education group:Patients will be informed about joint protection principles by a physiotherapist for once.
88966365|NCT05650853|Experimental|Study intervention|Transrectal ultrasound and Urethroscopy
88966366|NCT05026333|Experimental|High Stress Group|Group of high stress participants based on cutoff scores on the Perceived Stress Scale (PSS) and the STAI - State Anxiety Scale.
88966367|NCT05026333|Experimental|Low Stress Group|Group of low stress participants based on cutoff scores on the Perceived Stress Scale (PSS) and the STAI - State Anxiety Scale.
88966368|NCT04981639|Active Comparator|I (IVPCA)|Intravenous patient controlled analgesia will be performed.
88966369|NCT04981639|Active Comparator|II (IVPCA+TAP)|Intravenous patient controlled analgesia and transversus abdominis plane block will be performed.
88966370|NCT04981639|Active Comparator|III (IVPCA, IMS, and TAP)|Intravenous patient controlled analgesia, transversus abdominis plane block, and intramuscular muscular stimulation will be performed.
88966371|NCT04971343||Unselected blood donors|
88966372|NCT04971343||Hospitalized patients|
88966373|NCT04971343||Known HIV-1 Ab positive|
88966374|NCT04971343||Known HIV-2 Ab positive|
88966375|NCT04971343||Known Acute HIV-1 p24 Ag positive|
88966376|NCT00001788||1|patients with primary immunodeficiency disorders
88966377|NCT04962256||Study group|Patients with degenerative CSM or OPLL undergoing C3-7 open-door laminoplasty
88966378|NCT05620628|Experimental|Savoritinib and Durvalumab|A fixed dose of 1500 mg Q4W durvalumab (equivalent to 20 mg/kg Q4W) is used in the present study for patients >30 kg (dosing by bodyweight only required for patients ≤30 kg).And Savolitinib will be administered orally 600mg once a day for 28 days as one cycle.
88966379|NCT04935307|Experimental|Patients with multiple chemical sensitivity (MCS)|MCS is characterized by odour intolerance and various somatic symptoms attributed to the influence of toxic environmental chemicals in low usually harmless doses.
88966380|NCT04935307|Experimental|Patients with multi-systemic functional somatic disorders (FSD)|Based on empirical research, a phenotype of multi-systemic FSD or multi-organ bodily distress syndrome (multi-organ BDS) has been identified in the most severely affected patients who have symptoms from multiple organ systems, thus fulfilling the criteria for multiple FSS. Multi-organ BDS is a research diagnosis, and the terms FSD and BDS are used as synonyms. This diagnosis is defined by an identifiable physical symptom pattern with symptoms from four groups (a cardiopulmonary, a gastrointestinal, a musculoskeletal, and a general symptom group).
88966381|NCT04935307|Experimental|Healthy controls|Healthy participants
88966382|NCT00001806|Experimental|Group|Group education and counseling
88966383|NCT00001806|Active Comparator|Individual|Individual education and counseling
88966384|NCT04905121|Experimental|Psilocybin|
88966385|NCT05583812|Experimental|SAD Dose 1|Subjects will receive FB2001 or placebo for inhalation once on DAY 1
88966386|NCT05583812|Experimental|SAD Dose 2|Subjects will receive FB2001 or placebo for inhalation once on DAY 1
88966387|NCT05583812|Experimental|MAD Dose 1|Subjects will receive FB2001 or placebo for inhalation twice daily during the dosing period
88966388|NCT05583812|Experimental|MAD Dose 2|Subjects will receive FB2001 or placebo for inhalation twice daily during the dosing period
88966389|NCT00392314|Experimental|Early favorable|patients with early favorable disease Ia IIA will have a PET/CT following 2 cycles of ABVD
88966390|NCT00392314|Experimental|Early Unfavorable|Patients with early favorable disease Ia or IIa with risk factors :large mediastinal mass extra nodal disease elevated esr, three or more involved areas, age equal or >50 , lymphocytic depleted or mixed cellularity
88966391|NCT00392314|Experimental|advanced disease|patients with advanced disease low IPS score 0-2 will start chemotherapy with ABVD for 2 cycles followed by PET/CT further therapy will be given according to PET/CT results
88966392|NCT00392314|Experimental|advanced disease IPS 3-7|Patients with advanced disease IPS score 3-7 will start chemotherapy with escalated beacopp. following 2 cycles PET/CT will be carried out and according to results further chemotherapy will be given
88966393|NCT04872127|Experimental|CAS with proximal protection|using proximal embolism protection device during CAS
88966394|NCT04872127|Active Comparator|CAS with distal protection|using distal protection device during CAS
88966395|NCT04837027|Experimental|Aerobic training|Participants will be given a stationary exercise bike for home use. They will be instructed to use the exercise bike five times a week for thirty-minute sessions. The exercise intensity prescription will be based on the subject's VO2max determined on pre-test day. The exercise program will start at 60% of intensity per session, and then will be increased by steps of 5% intensity every 2 sessions until participants reach 30 minutes of training at 80% intensity. Participants will be contacted weekly by e-mail or phone to answer any questions about the exercise protocol and will be instructed to log each training session. Subjects will record duration of exercise, perceived exertion, average heart rate, maximum heart rate, and distance.
88966396|NCT04837027|Active Comparator|Balance training|Balance Training A physical therapist will tailor a home balance training program for each participant based on pre- training capabilities. Subjects will be asked to perform exercises five times a week for thirty-minute sessions. Both dynamic and static exercises will be performed in sitting and standing positions. Exercises will start with stabilizing in a challenging static position and progress to dynamic arm and leg movements in the same or modified position. Participants will be contacted weekly by e-mail or phone to answer any questions about the exercise protocol and will be required to log their exercise effort in terms of frequency and level of balance challenge. Individuals will be instructed to perform more difficult exercises if balance
88966397|NCT05641545|Experimental|IVAC-RCC-001|Individual peptide vaccination with adjuvant GM-CSF and Imiquimod Intradermal injection of a cocktail of 3-5 individual HLA-binding peptides. Subcutaneous injection of adjuvant GM-CSF at vaccination site. Topical administration of Imiquimod at vaccination site.
88966398|NCT05641506|Experimental|Arm|Participants received Niraparib 200mg or 300mg QD PO continually combined with Yangzheng Xiaoji capsule， 0.36g*4 tid，28 days as one cycle，up to 3 cycles.
88966399|NCT04747600||serous cystic neoplasms|
88966400|NCT04747600||mucinous cystic neoplasms|
88966401|NCT04747600||intra-papillary mucinous neoplasms|
88966402|NCT04747600||solid pseudo-papillary neoplasms|
88966403|NCT04727710|Experimental|Part 2: Couples-based mindfulness intervention|Mindfulness-based intervention + Usual care
88966404|NCT04727710|Active Comparator|Part 2: Usual care|Usual care
88966405|NCT05641428|Experimental|Arm A (ARI-0001)|Infusion with Point of Care CAR T-cells
88966406|NCT05641428|Active Comparator|Arm B (Axi-cel)|Infusion with Standard of Care CAR T-cells
88966407|NCT04723108|Experimental|Virtual reality arm|Participants will be asked to use virtual reality during their infusion for a duration of at least 10 minutes.
88966408|NCT05641389||Monitoring Group|Participants will be monitored via a transdermal monitor for four weeks. They will give four breath samples a day for these weeks as well as 5 Blood spot samples.
88966409|NCT04591834||Observational|No Intervention
88966410|NCT04733365|Experimental|Training group|Patients admitted due to decompensated heart failure who will perform the training protocol - ERIC protocol
88966411|NCT04733365|No Intervention|Control group|Patients admitted due to decompensated heart failure who will perform the standard rehabilitation nursing care for this type of patients
88966412|NCT04551664|Experimental|EVT group|Patients in this group will receive best medical management plus EVT including mechanical thrombectomy, aspiration thrombectomy, intra-arterial thrombolysis, angioplasty or stenting.
88966413|NCT04551664|Active Comparator|Best medical management group|Patients in this group will receive best medical management alone.
88966414|NCT05536310||Trilogy TAVI|Patients receiving JenaValve Trilogy Heart Valve System for management of symptomatic, severe aortic stenosis (AS)/ aortic regurgitation (AR) who are at high risk for surgical aortic valve replacement (SAVR)
88966415|NCT04526119|Experimental|Z-338|
88966416|NCT04526119|Placebo Comparator|Placebo|
88966417|NCT04452331|Experimental|OAA Intervention|Visit recorded, both patient and provider aware, both patient and provider have access to audio post-visit
88966418|NCT04452331|Sham Comparator|OAA Physician Aware Control|Visit recorded, both patient and provider aware, neither patient nor provider have access to audio post-visit
88966419|NCT04452331|Placebo Comparator|OAA Physician Unaware Control|Visit recorded, patient aware but provider unaware, neither patient nor provider have access to audio post-visit
88966420|NCT02972086|Experimental|Parent|Parent of a child who is a patient at the NYU Bellevue Attention Deficit Hyperactivity Disorder (ADHD) Clinic
88966421|NCT04172506|Experimental|AK105|AK105 200 mg, every 2 weeks
88966422|NCT04134169||Rheumatoid arthritis|
88966423|NCT05641233|Experimental|Intervention arm|
88966424|NCT00392509|Experimental|2|Unfractionated Autologous Mononuclear Bone Marrow
88966425|NCT05641038|Active Comparator|Group 1 Peloid treatment|The patients in the first group; Peloid was applied to both feet at 42 °C for 2 weeks, 5 days a week, 10 sessions in total, 20 minutes each session.
89559836|NCT06183684|Experimental|Tricuspid Valve Replacement|Transcatheter replacement of the native tricuspid valve with the Laplace bioprosthesis
89559837|NCT06181760|Active Comparator|Fenretinide 300 mg/m2|Single oral dose of fenretinide, 300 mg/m2
89559838|NCT06181760|Active Comparator|Fenretinide 600 mg/m2|Single oral dose of fenretinide, 600 mg/m2
89559839|NCT06181760|Active Comparator|Fenretinide 900 mg/m2|Single oral dose of fenretinide, 900 mg/m2
89559840|NCT06181760|Placebo Comparator|Placebo|Single oral dose of placebo capsules
89559841|NCT06171191|Experimental|Intervention group|Intervention group receives intervention between prétest and posttest. Three months after posttest they undergo a follow-up test
89559842|NCT06171191|Other|Control group|Waiting group. Control group receives intervention after all test (prétest, posttest and follow-up test)
89559843|NCT06170944|Experimental|Remote ischemic preconditioning and guideline-based treatment|5 cycles of cuff inflation (200mmHg for 5 minutes) and deflation (for 5 minutes), once or twice daily for 12 months.
89559844|NCT06170944|No Intervention|Guideline-based treatment|Guideline-based treatment.
89559845|NCT06170736|Active Comparator|Doppler-Guided Haemorrhoidal Artery Ligation|Patients will be treated by DGHAL procedure.
89559846|NCT06170736|Experimental|Radiofrequency Ablation|Patients will be treated by radiofrequency ablation.
89559847|NCT06170216||iNHL|Different immunochemotherapies in small B-cell non-Hodgkin lymphoma
89559848|NCT06167265|Other|Treatment RTRT (R: Cilostazol, T: PMR)|"Treatment R: One Cilostazol Tablet 100 mg in the morning and another at an interval of 12 hours of the morning dose~Treatment T: Two PMR Tablet 145 mg in the morning~Four-period dosing following the sequence of Treatment RTRT"
89559849|NCT06167265|Other|Treatment TRTR (T: PMR, R: Cilostazol)|"Treatment R: One Cilostazol Tablet 100 mg in the morning and another at an interval of 12 hours of the morning dose~Treatment T: Two PMR Tablet 145 mg in the morning~Four-period dosing following the sequence of Treatment TRTR"
89559850|NCT06162221|Experimental|Subprotocol A: KRAS G12C-Mutated Solid Tumors|RMC-6291 (BID) and Pembrolizumab (Q3W) with or without Chemotherapy (Q3W-Q4W)
89559851|NCT06162221|Experimental|Subprotocol B: RAS-mutated NSCLC|RMC-6236 (QD) and Pembrolizumab (Q3W) with or without Chemotherapy (Q3W-Q4W)
89559852|NCT06161610|Experimental|LITT|LITT+potential other treatment
89559853|NCT06161610|Active Comparator|Control|Best medical management under guidelines
89559854|NCT06160466|Experimental|Artificial intelligence arm Patients undergoing colonoscopy with artificial intelligence.|Patients undergoing colonoscopy with artificial intelligence.
89559855|NCT06160466|Active Comparator|Conventional Colonoscopy|Standard Colonoscopy with white light
89559856|NCT06158100|Experimental|VEN/AZA Dose Escalation/De-Escalation Cohort|"Participants in this group will begin Venetoclax and Azacitidine (VEN/AZA) combination therapy between day +42 and day +100 following hematopoietic cell transplant (HCT) infusion. VEN/AZA combination therapy will be administered for up to six (6) cycles, followed by up to six (6) additional cycles of Venetoclax monotherapy in the absence of disease progression or unacceptable toxicity. Each cycle is 28 days.~Participants may also receive donor lymphocyte infusions (DLI) at the discretion of the treating physician, if certain criteria are met.~Participants will receive up to one year (12 cycles) of study therapy, followed by up to one year of follow-up. Total participation duration is up to two years."
89559857|NCT06158100|Experimental|VEN/AZA Expansion Cohort|"Participants in this group will receive VEN/AZA therapy at the most appropriate dose determined in Part 1. Participants may also receive donor lymphocyte infusions (DLI) at the discretion of the treating physician, if certain criteria are met.~Participants will receive up to one year (12 cycles) of study therapy, followed by up to one year of follow-up. Total participation duration is up to two years."
89559858|NCT06157866|Experimental|Cognitive Training|Participants will meet with a pain specialist who will conduct a specific form of cognitive training targeting fibromyalgia.
89559859|NCT06157866|Active Comparator|Education Training|Participants will meet with a pain specialist to receive education training related to fibromyalgia.
89559860|NCT06153537||Insulin degludec + dose check|Participants will be treated with commercially available insulin degludec used with Dose Check app according to local label and routine clinical practice at the discretion of the treating physician.
89559861|NCT06149494|Experimental|Vapendavir Cohort|"VPV will be dispensed by the study team on Day 0 at the clinical study visit at the study site. Participants will be given enough VPV for the 7-day treatment phase, (eg. Days 2 to 8). Treatment is twice daily, am and pm, 12 h apart ± 2 h. VPV micronized free base tablets (250 mg each) will be given orally beginning with a 1,000 mg loading dose (4 tablets) as soon as symptoms are present or the subject answers yes to do you think you have a cold today followed by 500 mg (2 tablets) either on the same day (eg day 2) or the next day. Treatment will therefore be for a total of 7 days consisting of an initial 1,000 mg dose (4-tablets) followed by thirteen 500mg doses (2-tablets). Treatment may occur within the home, on non-clinical study days."
89559862|NCT06149494|Placebo Comparator|Placebo Cohort|"Placebo will be dispensed by the study team on Day 0 at the clinical visit at the study site. Participants will be given enough Placebo for the 7-day treatment phase, (eg. Days 2 to 8). Treatment is twice daily, am and pm, 12 h apart ± 2 h. Placebo tablets will be matched to the active treatment and will be administered orally for 7 days as follows: 4 tablets for the initial dose as soon as symptoms are present or the subject answers yes to do you think you have a cold today on the first day of dosing (eg. Day 2), and 2 tablets, either on the same day (eg Day 2) or the next day. Treatment will therefore be for a total of 7 days (consisting of an initial 4-tablet dose followed by thirteen 2-tablet doses). Treatment may occur within the home, on non-clinical study days."
89608759|NCT01797445|Active Comparator|E/C/F/TDF (Double-Blind)|"E/C/F/TDF plus E/C/F/TAF placebo for 144 weeks~After 144 weeks, participants will continue to take their blinded study drug until treatment assignments have been unblinded."
89608760|NCT01797445|Experimental|Open-Label E/C/F/TAF|After the unblinding visit, in countries where E/C/F/TAF is not commercially available, participants (except in UK) who complete 144 weeks of study will be given the option to receive open-label E/C/F/TAF and attend study visits every 12 weeks until it becomes commercially available, or until Gilead terminates the study in that country.
89608761|NCT04765683||Patients|Attending surgical outpatients
89608762|NCT04765683||Surgeons|Running surgical outpatients
89559863|NCT06148311|Experimental|Sublingual dexmedetomidine|Participants will be administered 120 micrograms sublingual film following start of an autonomic crisis. In case the crisis has not subsided after 2 hours, the patient will be instructed to take the second dose. The maximum amount for the study is two oral films within two hours for each episode but not more than 24 hours apart, one at the beginning of the crisis and if needed, one additional within two hours.
89559864|NCT06148311|Placebo Comparator|Matching Sublingual Placebo|Participants will be administered the matching placebo sublingual film following start of an autonomic crisis. In case the crisis has not subsided after 2 hours, the patient will be instructed to take the second dose. The maximum amount for the study is two oral films within two hours for each episode but not more than 24 hours apart, one at the beginning of the crisis and if needed, one additional within two hours.
89559865|NCT06146257|Experimental|Dose Escalation of GLB-001 as a Monotherapy in Participants with R/R AML and R/R HR-MDS-Phase 1a|Part 1a (Dose Escalation) of the study will enroll R/R AML and R/R HR-MDS participants and will evaluate the safety, tolerability, PK, PD and preliminary efficacy of GLB-001 administered orally, and determine the maximum tolerated dose/maximum administered dose (MTD/MAD) in R/R AML or R/R HR-MDS patients who are eligible for dose limiting toxicity (DLT) evaluation.
89559866|NCT06146257|Experimental|Dose Expansion of GLB-001 as a Monotherapy in Participants with R/R AML and R/R HR-MDS-Phase 1b|Part 1b (Dose Expansion) will confirm tolerability of the selected doses and schedules and evaluate whether efficacy is in a range that warrants further clinical development for R/R AML and R/R HR-MDS participants.
89559867|NCT06141889|Experimental|Single dose, 2-way crossover in Part 1, then daily dosing for 14 days in Part 2|"Study Part 1:~Participants will receive a single Dose A or B on Day 1 and then followed by a crossover to a single Dose B or A on Day 8.~Study Part 2:~Participants in Study Part 2 will receive either a single Dose C or equivalent of Dose C administered twice daily, starting on Day 1 and through Day 14"
89559868|NCT06134557||flow diverter stents|single flow diverter(FD) stents or flow diverter assisted coil
89559869|NCT06134557||conventional stents|stent-alone or overlapping stent treatment ,stent-assisted coiling techniques
89559870|NCT06127810||3T Contrast Enhanced Images First|
89559871|NCT06127810||0.064 Contrast Enhanced Images First|
89559872|NCT06125145|Experimental|Feasibility Arm|All enrolled participants will receive the pilot Geriatric Assessment and Promotora Coaching intervention.
89559873|NCT06124040||Radio-chemotherapy|Cervical cancer patients undergoing radio-chemotherapy.
89559874|NCT06124040||Surgery|Cervical cancer patients undergoing surgery.
89559875|NCT06123052||Patients unwilling to receive information|Interview
89559876|NCT06123052||Patients not interested in IBD-CE after receiving information|Interview
89559877|NCT06123052||Patients interested in IBD-CE after receiving information|Interview
89559878|NCT06121882|Experimental|Micro Fragmented Adipose Tissue (MFat)|"Injection of Microfragmented Adipose Tissue derived using Lipogems® Kit~The cases assigned to this group will be injected intra-articularly with Lipogems®. The patients will undergo lipoaspiration of their own adipose tissue for MFat then this MFat will be injected intra-articularly in the knee. It will be administered once at the baseline visit of the study."
89559879|NCT06121882|Active Comparator|Saline Injection|The cases assigned to this group will be injected intra-articularly in the knee with saline. It will be administered once at the baseline visit of the study.
89559880|NCT06118034|Experimental|Experimental group (colchicine group)|The experimental group take 0.5mg of colchicine tablets orally for 3 days before surgery, and continue to take 0.5mg every other day (qod) for 10 days after tracheal extubation.
89559881|NCT06118034|Placebo Comparator|Control group|The control group take 0.5mg of placebo tablets orally for 3 days before surgery, and continue to take 0.5mg every other day (qod) for 10 days after tracheal extubation.
89559882|NCT06114732|Experimental|Walking exercise behaviour change intervention + TENS|Participants in the Intervention groups will be asked to attend four telehealth appointments with a physiotherapist. They will also be provided with a TENS machine and training at the baseline appointment on how to use it. They will be instructed to use it daily as their symptoms require for 12 weeks. The device will be set at High Frequency-TENS (120 Hz, 200µs and a patient-determined intensity of ''strong but comfortable'').
89559883|NCT06114732|No Intervention|Usual Care control|Usual Care at NHS Lanarkshire Vascular Services and/or Intermittent Claudication service.
89559884|NCT06111807||Chemo-radiotherapy|Stage 3 NSCLC eligible for chemoradiotherapy
89559885|NCT06111807||Neoadjuvant and surgery|Stage 3 NSCLC eligible for neoadjuvant chemo-immunotherapy followed by surgery
89559886|NCT06111807||Surgery and adjuvant immunotherapy|Stage 3 NSCLC eligible for surgery followed by immunotherapy
89559887|NCT06108674|Experimental|Telepharmacy|Pharmaceutical care via telepharmacy
88966426|NCT05641038|Active Comparator|Group 2 Paraffin treatment|The patients in the second group were given paraffin treatment on both feet by dipping method, for 2 weeks, 5 days a week, 10 sessions in total, 20 minutes each session.
88966427|NCT03960190|Experimental|1K expression kit|Subjects will be using the breastpump with the with 1K expression kit.
88966428|NCT03960190|Experimental|2K expression kit|Subjects will be using the breastpump with the with 2K expression kit.
88966429|NCT03960151|Experimental|Rolapitant|Rolapitant plus Olanzapine, Palonosetron, and Dexamethasone
89559888|NCT06108674|Active Comparator|In-person|In-person pharmaceutical care
89559889|NCT06106100|Active Comparator|Antireflux mucosal ablation|In patients fulfilling the inclusion criteria and being randomized for ARMA, retroflexion endoscopy to visualize the cardia is performed, followed by mucosa markings with straight-fire APC catheter (ERBE Electromedizin, Tübingen, Germany) in forced coagulation mode (VIO300D, ERBE Electromedizin, Tübingen, Germany, 20W). The marking site at 1-cm and 2-cm distal to squamocolumnar junction at anterior-posterior and lesser curvature site, respectively, sparing the greater curvature site of cardia, is done. After marking, mucosal ablation (forced coagulation mode, 1L/min, 80W) is performed at marking site in a hoarse-shoe shape. Adequate ablation depth is defined as reaching the submucosal layer with blackish discolored tissue with carbonization
89559890|NCT06106100|Sham Comparator|Sham procedure|In patients fulfilling the inclusion criteria and being randomized for sham procedure, retroflexion endoscopy to visualize the cardia is performed. Using the straight-fire APC catheter to touch the marking sites similar to the treatment group without electrocauterization is performed
89559891|NCT06098404||Cancer Patients|Patients diagnosed with cancer undergoing standard of care treatment.
89559892|NCT06094504|Experimental|Lighting cycling (Spectral vs Conventional)|A washout period of one week will commence the Monday after study subject enrollment, followed by alternating periods of 3 days of daytime full spectrum lighting (FS) including violet and blue light wavelengths and 4 days of daytime conventional (CON) hospital lighting.
89559893|NCT06093282|Experimental|ARCH|4-month health outreach intervention to improve depressive symptoms, physical activity, and weight management
88966430|NCT04733326|Experimental|Cryothrapy|5 ml Saline at low temperature (2.5°C) will be used as intra-canal irrigantion during single visit endodontics treatment, to study the effect on reduction of post-operative pain and expression of IL-8.
88966431|NCT04733326|Experimental|Ketroloc tromethamine|2ml 30 mg Ketroloc tromethamine will be used as intra-canal irrigantion during single visit endodontics treatment, to study the effect on reduction of post-operative pain and expression of IL-8.
89559894|NCT06093282|Active Comparator|Traditional Health Outreach|4-month health outreach intervention focused on screening, referral to healthcare resources, and support
88966432|NCT04733326|Placebo Comparator|Saline at room temperature|30 ml Saline at room temperature will be used as intra-canal irrigantion during single visit endodontics treatment, to study the effect on reduction of post-operative pain and expression of IL-8.
89559895|NCT06088979|Experimental|TOUR006 - 20 MG|In part A of the study, participants will receive a total of three 20 mg subcutaneous injections: 1 injection every 8 weeks (Day 1, Week 8, Week 16) followed by treatment in part B of the study based on proptosis response and rescue therapy use.
89559896|NCT06088979|Experimental|TOUR006 - 50 MG|In part A of the study, participants will receive a total of three 50 mg subcutaneous injections: 1 injection every 8 weeks (Day 1, Week 8, Week 16) followed by treatment in part B of the study based on proptosis response and rescue therapy use.
88966433|NCT05640921|Experimental|Group-integrated Cognitive Behavioural Therapy (Gi-CBT)|The Gi-CBT sessions will cover relevant aspects of tackling trauma, and the CBT component will involve addressing negative thoughts, building more positive ones and building resilience through post-traumatic situations and adversities.
89559897|NCT06088979|Placebo Comparator|Placebo|In part A of the study, participants will receive a total of three Placebo subcutaneous injections: 1 injection every 8 weeks (Day 1, Week 8, Week 16) followed by treatment in part B of the study based on proptosis response and rescue therapy use.
89559898|NCT06088680||Open Label- Glycar Pericardial Patch|patients undergoing cardiovascular repair or reconstruction surgery under standard clinical care with the commercially available Glycar Pericardial Patch.
89559899|NCT06084533||Parkinson Disease|
88966434|NCT05640921|Active Comparator|Media Intervention|The second group will receive Media Orientation (MO). The MO sessions will embed media content to create awareness of the government's approaches to reintegration.
88966435|NCT03960112|Experimental|mpMRI|mpMRI in the detection of prostate cancer in a per patient analysis using cystoprostatectomy specimen
88966436|NCT03959995|Experimental|exercise|Exercise group
88966437|NCT03959995|Sham Comparator|control|active control group
88966438|NCT00386945|Other|1|Non-Experiment Intervention consisting of an intervention based on the Clinical Practice Guideline: Treating Tobacco Use and Dependence and modified for use in chiropractic settings.
88966439|NCT03959839|Experimental|Endoscopic Treatment|Rectal Endoscopic Submucosal Dissection
88966440|NCT03959839|Experimental|Minimally Invasive Laparoscopic Local Surgical Treatment|Transanal Minimally Invasive Surgery (TAMIS) or Transanal Endoscopic Operation (TEO)
88966441|NCT03959761|Experimental|Treatment Group|Intraperitoneal (IP) nivolumab treatment, after extensive debulking surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
88966442|NCT03959722|Experimental|Probiotics:Healthy male endurance athletes with GI symptoms|14 weeks of supplementation with a multispecies probiotics: Ecologic® PERFORMANCE ( 1*1010 CFU(Colony forming units)/daily dose, Winclove Probiotics B.V., Amsterdam).
88966443|NCT03959722|Placebo Comparator|Placebo: Healthy male endurance athletes with GI symptoms|14 weeks of supplementation with a placebo comparator (Winclove Probiotics B.V., Amsterdam)
88966444|NCT05640882|Experimental|VRET|VRET - 10 week protocol using VR
88966445|NCT05640882|Active Comparator|VRET Olfaction|VRET olfaction - 10 week protocol using VR with olfaction
88966446|NCT03959449|Experimental|Action Observation and Motor imagery|
88966447|NCT03959449|Active Comparator|Motor Imagery|
88966448|NCT03959449|Experimental|Exercise plus motor imagery and action observation|
88966449|NCT00387179|Experimental|Dim Light Melatonin and/or methylxanthine|Dim Light Melatonin and/or methylxanthine
88966450|NCT00387179|Experimental|Placebo and Dim Light or bright light|Placebo and Dim Light or bright light
88966451|NCT00387179|Experimental|Bright light melatonin and/or methylxanthine|Bright light, melatonin, and/or methylxanthine
88966452|NCT03959332|Experimental|Baloxavir Marboxil 40 mg|
88966453|NCT03959332|Experimental|Baloxavir Marboxil 80 mg|
88966454|NCT05441072||Diabetic Retinopathy (DR)|Patients suffering from DR of both genders above 18 years of age with different disease degree. Each patient will be measured with BulbiCam device 6 times within three days
88966455|NCT05441072||Healthy controls DR|Gender- and age-matched healthy controls without any eye disease to the DR patients
88966456|NCT05441072||Age related macular degeneration (AMD)|Patients suffering from AMD of both genders above 18 years of age with different disease degree.
88966457|NCT05441072||Healthy controls AMD|Gender- and age-matched healthy controls without any eye disease to the AMD patients
89026772|NCT01325350|Active Comparator|minoxidil 2% solution|Approximately one mL dose applied evenly onto pre-specified area on scalp, twice daily for 6 months.
89559900|NCT06084533||Healthy Control|
89559901|NCT06084117|Experimental|High Flow Nasal Oxygen (HFNO)|Patients will start at a flow of 50 L/min and a temperature of 37°C, FiO2¬ will start at 25%, and titrated to target SpO2 (88-92%, as in usual care).
89559902|NCT06084117|Active Comparator|Non-Invasive Ventilation (NIV)|"Patients will be started at~Using the facemask interface: EPAP/PEEP set at 5-7 cmH2O and PS of 5-7 cmH2O (equal to IPAP of 10-14 cmH2O).~Using the helmet interface; EPAP/PEEP set at least 10 cmH2O and PS of 10 cmH2O (equal to IPAP of 20 cmH2O).~PEEP/EPAP and IPAP/PS can be titrated to effectiveness, tolerance and comfort~FiO2 should be set to achieve a SpO2 of 88-92%"
89559903|NCT06080009|Experimental|Patients diagnosed with Ca sebaceous of the ocular adnexa.|adult patients diagnosed with Ca sebaceous of the ocular adnexa.
89559904|NCT06078280|Experimental|Study Group|"The study group will use the CardioPulmonary Management (CPM) device daily for 6 months (beginning at visit 1 and ending at visit 2). The ADI (Analog Devices, Inc) triaging team will monitor the CPM device data and call the patient as indicated by the data.~The ADI care team will then forward the device data and patient symptomology collected to the patient's care team where that team will device if intervention is necessary. The patient's care team will also have access to view device data at any time using the CPM website."
89559905|NCT06078280|No Intervention|Control Group|The control group will not receive a device and will continue their normal standard of care.
89559906|NCT06078267|Experimental|Study Group|"The study group will use the CardioPulmonary Management (CPM) device daily for 6 months (beginning at visit 1 and ending at visit 2). The ADI (Analog Devices, Inc) triaging team will monitor the CPM device data and call the patient as indicated by the data.~The ADI care team will then forward the device data and patient symptomology collected to the patient's care team where that team will device if intervention is necessary. The patient's care team will also have access to view device data at any time using the CPM website."
89559907|NCT06078267|No Intervention|Control Group|The control group will not receive a device and will continue their normal standard of care.
89559908|NCT06076044|Experimental|healthy subjects|healthy male subjects aged 20-30 years
89559909|NCT06075849|Experimental|PB101|A total of 6 cohorts are planned, and each dose escalation will proceed in a traditional 3+3 scheme.
89559910|NCT06073665|Active Comparator|Lower TSH Group|Target TSH level of 0.5-2.0 mU/L
89559911|NCT06073665|Experimental|Higher TSH group|Target TSH level of 5.5-7.0 mU/L
89559912|NCT06071286|Experimental|Interventional|Patients with suspected advanced OC, based on preoperative imaging/clinical evaluation, will undergo blood samples in different timepoints
89559913|NCT06070376|Active Comparator|Group A|placement of the esophageal prostheses fully covered in the palliative treatment of malignant esophageal obstructions.
89559914|NCT06070376|Active Comparator|Group B|placement of the partially covered esophageal prostheses in the palliative treatment of malignant esophageal obstructions.
89559915|NCT06057779|Other|Slow and heavy exercise therapy|Participants perform eccentric heel drop exercises into maximal dorsiflexion at slow speed.
88966458|NCT03959254|Experimental|Intervention Group|Application of a protocol of active exercises for recovery after arthroscopic hip surgery, adapted to the femoroacetabular shock characteristics.
89559916|NCT06057779|Other|Slow and light exercise therapy|Participants perform eccentric heel drop exercises into neutral ankle position at slow speed.
88966459|NCT03959254|Active Comparator|Control Group|Usual post-surgical general guidelines for hip interventions described by Gocen et al
88966460|NCT04733521|Experimental|NSCLC|
88966461|NCT04733521|Experimental|BTC|
88966462|NCT05640726|Experimental|(SCRT) followed by PD-1+ standard therapy|
88966463|NCT03959059|Experimental|PKP of traditional procedure|traditional method of PKP
88966464|NCT03959020||Patients, undergoing anti-reflux surgery|Patients having undergone anti-reflux surgery at the Department of Surgery, Kolding Hospital, a part of Hospital Lillebaelt, from 1th January 2002 - 31th December 2013
88966465|NCT03958981|Experimental|castor oil group|60 mL of castor oil in 140 mL of orange juice
88966466|NCT03958981|Placebo Comparator|placebo group|Patients will receive sunflower oil as a placebo
88966467|NCT03958942|Active Comparator|quadratus lumborum block|received pre-emptive ultrasound-guided quadratus lumborum block with 25 mL of 0.25% bupivacaine on each side of the abdominal wall before induction of GA.
88966468|NCT03958942|Active Comparator|lumbar epideural block|received pre-emptive lumbar epidural block with 15 mL of 0.25% bupivacaine before induction of GA.
88966469|NCT03958864|Experimental|CC-90001 100 mg|100 mg of CC-90001 (once daily [QD] x 7 days) will be given orally
88966470|NCT03958864|Experimental|CC-90001 200 mg|200 mg of CC-90001 (once daily [QD] x 7 days) will be given orally
89026773|NCT01324999|Experimental|Sarcoid Associated Pulm. Hypertension|Single-arm open-label proof of concept study of tadalafil in patients with sarcoidosis associated pulmonary hypertension.
89026774|NCT02891356||Anorexia patient|Dual Energy X-ray Absorptiometry (DEXA)
89026775|NCT03273335||Surgical patients|Surgical patients will undergo CSF biomarker assays, cognitive testing and fMRI scans.
89026776|NCT00494286|Experimental|AF-CBT|Participants will receive abused-focused cognitive behavioral therapy
89026777|NCT00494286|Active Comparator|TAU|Participants will receive treatment as usual
89026778|NCT03271385||hypertrophic cardiomyopathy group|The hypertrophic cardiomyopathy was diagnosed by left ventricular hypertrophy via echocardiography (wall thickness >15 mm) with either genetic determination of a pathogenic mutation or ) left ventricular hypertrophy (LVH) (end-diastolic wall thickness >15 mm) with resting left ventricular outflow tract obstruction or hypertrophy in a recognisable pattern, i.e., ventricular bulge in apical-variant HCM. And then patients with hypertrophic cardiomyopathy were evaluated by the predetermined differentiating formula.
89026779|NCT03271385||hypertensive heart disease group|The diagnosis of hypertensive heart disease was based on medical history and conventional echocardiography. Long durations of uncontrolled hypertension for at least 5 years with systolic blood pressure [BP] ≥150 mm Hg or diastolic BP ≥90 mm Hg or both in the absence of other cardiac or systemic diseases were used as criteria. And then patients with hypertensive heart disease were evaluated by the predetermined differentiating formula.
89026780|NCT03271385||control group|The healthy age-matched controls were generally volunteers with a normal electrocardiogram, normal echocardiographic examination, and overall normal CMR findings. And then patients with normal findings were were evaluated by the predetermined differentiating formula.
89026781|NCT01324570|Experimental|Overall BTDS|Buprenorphine transdermal system
89026782|NCT05645653|Experimental|Educational treatment|The medication self-management intervention consists of three face-to-face education sessions and two weekly telephone follow-up over 6 weeks. Intervention components are derived from an extensive review of the literature, including the related theoretical framework and current practice. Based on the extended IMB model of medication adherence, this intervention is designed to offer information related to medication treatment, motivate patients to adhere, help build medication self-management skills, and develop adherence improvement plans. The face-to-face meeting will take place in the clinical nurse specialist counselling room in NCCCR.
89026783|NCT05645653|No Intervention|Standard Care|Participants in the control group will continue to receive standard care from Physicians, nurses, and clinical pharmacists in the NCCCR. Physicians are the primary providers and coordinators of care for patients with chronic conditions. Physicians provide patients consultations and education regarding their diseases and treatments (typically clinician-centred) at each patient visit to the chronic disease clinic.
89026784|NCT03271229|Active Comparator|Stem Cells|Participants will have Concentrated Bone Marrow Aspirate (BMAC) injections into symptomatic knee
89026785|NCT03271229|Active Comparator|Plasma|Participants will have Platelet-Rich Plasma (PRP) injections into symptomatic knee
89026786|NCT04325698|Experimental|Arm A|PF-06439535 (CN) + paclitaxel + carboplatin
89026787|NCT04325698|Active Comparator|Arm B|Bevacizumab-EU + paclitaxel + carboplatin
89026788|NCT00503100||NICU full-term early pain group|
89026789|NCT00503100||NICU premature early pain group|
89026790|NCT00503100||NICU premature control group|
89026791|NCT00503100||Soroka- full-term control group|
89026792|NCT02273882||Preterm Infants 29-35 Weeks Gestation <12 months of age|Preterm Infants 29-35 Weeks Gestation <12 months of age
89559917|NCT06057779|Other|Fast and heavy exercise therapy|Participants perform eccentric heel drop exercises into maximal dorsiflexion at fast speed.
89559918|NCT06057727|No Intervention|Control|Clinics randomized to the control arm will receive standard of care.
89026793|NCT01324141|Experimental|1/Chemo + Radiation|Chemo + Radiation
89026794|NCT01324102|Active Comparator|1. Yoga therapy|The intervention is an 8 week Yoga therapy class adapted to the specific needs of the veteran. The class meets two times per weeks for 90 minutes. A series of poses are instructed, with adaptations used as provided by a physical therapist.
89208456|NCT01009450|Active Comparator|LC was done using traditional method|LC was done using traditional method by dissection of calot's triangle and clipping of both cystic duct and artery by metal clips. Then dissection of gall bladder from its bed by hook using electrocautery technique. Finally we insert abdominal drain in Morrison pouch.
88966471|NCT03958864|Experimental|CC-90001 400 mg|400 mg of CC-90001 (once daily [QD] x 7 days) will be given orally
88966472|NCT03958825|Active Comparator|open left hepatic sectionectomy|patients undergoing open left hepatic sectionectomy within an enhanced recovery after surgery programme
88966473|NCT03958825|Experimental|laparoscopic hepatic sectionectomy|patients undergoing a laparoscopic left hepatic sectionectomy within an enhanced recovery after surgery programme
88966474|NCT03958786|Experimental|single arm|500 HIV-1 infected patients, aged 70 years and older
88966475|NCT03958708|Experimental|Treatment Arm|
88966476|NCT05640609|Experimental|Capeox regimen combined with Sintilimab and Bevacizumab|Capeox regimen combined with Sintilimab and Bevacizumab
88966477|NCT03958669||Sorafenib treated HCC patients|No intervention is performed. This is an observational study.
88966478|NCT03958591|Experimental|Intensive-de-escalation group with intelligent management|Short-term continuous subcutaneous insulin infusion and thereafter the combination therapy of basal insulin, metformin and vildagliptin will be applied. Then the oral hypoglycemic therapies will be prescribed. Wearable devices and smart apps will be used to manage and follow-up patients.
89559919|NCT06057727|Experimental|Intervention Arm|Clinics randomized to the intervention arm will receive the toolkit of clinician and patient facing nudges. Patient nudges will be pre-visit text message reminders (standard messaging content). Clinician nudges will be monthly peer comparison feedback and default pended orders.
89559920|NCT06057727|Experimental|High Risk Intensification Arm|Patients in the intervention clinics identified as high risk for noncompletion of the flu vaccine will be randomized 1:1 to receive the high risk intensification arm or remain in the standard intervention arm. Patients in the high risk intensification arm will receive an additional bidirectional texting component.
89559921|NCT06057064|Placebo Comparator|Placebo|Single dose of Placebo IM (0.9% sodium chloride)
88966479|NCT03958591|Experimental|Intensive-de-escalation group without intelligent management|Short-term continuous subcutaneous insulin infusion and thereafter the combination therapy of basal insulin, metformin and vildagliptin will be applied. Then the oral hypoglycemic therapies will be prescribed. Traditional ways such as telephone contact will be used to follow-up patients.
88966480|NCT03958591|Active Comparator|Traditionally upgrading group|The combination therapy of basal insulin, metformin and vildagliptin for the entire 12 weeks and thereafter the oral hypoglycemic therapies will be applied. Traditional ways will be used to follow-up patients.
88966481|NCT05411861|Experimental|CPL-01|Low dose of CPL-01
89559922|NCT06057064|Experimental|AZD3152|Single dose of 300 mg IM
89559923|NCT06054269|Experimental|FLUAD Quadrivalent|Participants administered a single dose of adjuvanted egg-based quadrivalent influenza vaccine (FLUAD Quadrivalent by Seqirus, 15 µg of HA from each strain).
89559924|NCT06054269|Active Comparator|FluQuadri|Participants administered a single dose of standard dose egg-based quadrivalent influenza vaccine (FluQuadri by Sanofi-Pasteur, 15 µg of HA from each strain).
89559925|NCT06052072|Experimental|PADN with Gradient Denervation System|Procedure using the Gradient Denervation System to ablate nerves within the pulmonary artery using ultrasonic ablation.
89559926|NCT06049849|Experimental|Treatment Group|Active Biophoton Generators are placed under the hotel bed.
89559927|NCT06049849|Placebo Comparator|Control Group|Placebo-products are placed under the hotel bed.
89559928|NCT06049563||Enrolled subjects|An additional MRI scan of the upper abdomen will be performed on all the subjects with the low-field 0.4 T MRI system.
89559929|NCT06045117|Experimental|Study Group|"The study group will use the CardioPulmonary Management (CPM) device daily for 6 months (beginning at visit 1 and ending at visit 2). The ADI (Analog Devices, Inc) triaging team will monitor the CPM device data and call the patient as indicated by the data.~The ADI care team will then forward the device data and patient symptomology collected to the patient's care team where that team will device if intervention is necessary. The patient's care team will also have access to view device data at any time using the CPM website."
89559930|NCT06045117|No Intervention|Control Group|The control group will not receive a device and will continue their normal standard of care.
88966482|NCT05411861|Active Comparator|Ropivacaine HCl|Low dose of Ropivacaine HCl
88966483|NCT05411861|Placebo Comparator|Placebo|Low volume of placebo
88966484|NCT03958513|Placebo Comparator|Placebo|0.9% normal saline, 1.5 ml for 1 inch incision, before closure of ports in patients undergoing Laparoscopic Cholecystectomy
88966485|NCT03958513|Experimental|Intervention|0.25% Bupivacaine, 1.5 ml per 1 inch incision, before closure of ports in patients undergoing Laparoscopic Cholecystectomy
88966486|NCT05640570|Experimental|The individualized Jade Wind-Barrier Herbal Tea Bag (JWBT) arm|
88966487|NCT05640570|No Intervention|Control arm|
88966488|NCT03958396|Active Comparator|OSA Group|a) Children 8-14 years old, b) ASA physical status 1or 2, c) undergoing tonsillectomy or tonsillectomy and adenoidectomy for known obstructive sleep apnea
88966489|NCT03958396|Active Comparator|Control (non-OSA) Group|a) Children 8-14 years old, b) ASA physical status 1or 2, c) no known obstructive sleep apnea presenting for any procedure requiring general anesthetic
88966490|NCT03958357||Treatment arm|Single arm study, 40 participants will undergo brachytherapy with the Advanced Gynecological Applicator Venezia Configuration
88966491|NCT03958318|Experimental|Exercise|Multi-modal exercise program
88966492|NCT03958318|Experimental|Exercise plus nutritional suplementation|Multi-modal exercise program plus nutritional suplementation
88966493|NCT03958318|No Intervention|Control|No interventions
88966494|NCT03958279||primipara giving birth|"The investigators involve every primipara giving birth in a period of two years.~Exclusion criteria:~a) Unwilling to participate~b) Minors (under 18 years old)~c) Foetus mortus or perinatal death of the newborn~d) Admission of the newborn to the ICU~e) Unfamiliar with slovak language~f) Multiple pregnancy"
88966495|NCT05640531|Experimental|WCK 771|WCK 771 600mg, 800mg, and 1000mg WCK 771 BID. Dosage form : IV Infusion
88966496|NCT05640531|Placebo Comparator|Placebo infusion|Matching Placebo administered as IV infusion
88966497|NCT03958162|Experimental|uniportal and tubeless video assisted thoracic surgery|lung biospy by the uniportal and tubeless video assisted thoracic surgery
88966498|NCT03958162|Experimental|transbronchial lung cryobiopsy|transbronchial lung cryobiopsy
89026795|NCT01324102|No Intervention|2. Wait list|The comparative intervention is an 8 week wait list control group for which there is no intervention provided within the study protocol.
89026796|NCT00503256||CLL - Linkage Families|Gene identification related to Chronic lymphocytic leukemia (CLL) development
89559931|NCT06040346|Experimental|Intervention Groups|Up to 60 participants will be enrolled into 1 of 3 meplazumab dose levels (20 participants/dose level).
89559932|NCT06039514|Experimental|GGTCA-AD mobile app|The experimental group uses the GGTCA-AD module for 14 days after the first assessment.
89559933|NCT06039514|Active Comparator|GGNeutra mobile app|The control group uses GGNeutra for 14 days after the first assessment.
89559934|NCT06026891|Experimental|MG-K10 Humanized Monoclonal Antibody Injection|Every four weeks, subcutaneous injection ，total of 52W
89559935|NCT06026891|Placebo Comparator|MG-K10 placebo|Every four weeks, subcutaneous injection，The drug was transferred to the trial after 16 weeks
89559936|NCT06024824|Experimental|Radiation; IMRT|"Fifteen fractions of external beam radiation therapy (EBRT) delivered via IMRT/ VMAT. Cohort 1 (n = 3-6) Single PTV 40.05 Gy/15#, homogenous dose* Cohort 2 (n = 3-6) High Risk PTV 45 Gy/15# SIB to PTV tumour, Elective PTV 40.05 Gy/15# to nodal regions* Cohort 3 (n = 3-6) High risk PTV 48 Gy/15# SIB to PTV tumour, Elective PTV 40.05 Gy/15# to nodal regions~* Progression to the next dose in successive cohorts depends on the number of patients experiencing DLTs within 4 weeks post-RT treatment in each patient cohort."
89559937|NCT06024369|Experimental|Using wearable CPM Device daily|The patients will be using the wearable device once daily at home for 6 months.
89559938|NCT06014515|Experimental|Experimental: PET/CT scans|Each subject will undergo a dynamic 18F-FDG PET/CT scan and a dynamic 11C-butanol PET/CT scan on the EXPLORER total-body PET/CT system
89559939|NCT06013995|Experimental|Cohort A: BMS-986326 Dose 1 IV|
89559940|NCT06013995|Experimental|Cohort B: BMS-986326 Dose 2 IV|
89559941|NCT06013995|Experimental|Cohort C1: BMS-986326 Dose 3 IV|
89559942|NCT06013995|Experimental|Cohort C2: BMS-986326 Dose 3 SC|
89559943|NCT06013995|Experimental|Cohort D1: BMS-986326 Dose 4 IV|
89559944|NCT06013995|Experimental|Cohort D2: BMS-986326 Dose 4 SC|
89559945|NCT06013995|Experimental|Cohort E1: BMS-986326 Dose 3 IV|
89559946|NCT06013995|Experimental|Cohort E2: BMS-986326 Dose 3 SC|
89559947|NCT06008626|Experimental|Cryosa Procedure|The purpose of this study is to evaluate the safety and effectiveness of Cryosa System applied to the tongue and soft palate in patients with clinically diagnosed obstructive sleep apnea (OSA).
89559948|NCT06007131|Experimental|Study Group|The study group will use the CPM device daily for 6 months (beginning at visit 1 and ending at visit 2). The ADI triaging team will monitor the CPM device data and call the patient as indicated by the data. The ADI care team will then forward the device data and patient symptomology collected to the patient's care team where that team will device if intervention is necessary. The patient's care team will also have access to view device data at any time using the CPM website.
88966499|NCT03958123|Experimental|Treatment Group 1: Cebranopadol|"Supratherapeutic dose (1600 μg) of cebranopadol:~Participants received placebo once a day for 2 days (Days -3 and -1); 200 μg of cebranopadol once a day for 3 days; 400 μg once a day for 3 days; 600 μg once a day for 3 days; 900 μg once a day for 3 days; 1300 μg once a day for 3 days; 1600 μg once a day for 14 days; and placebo once a day on the last dosing day.~Participants received capsules under fasting conditions on Days -3, -1, 1, 29 and 30, and under fed conditions on all other dosing days. Participants received four encapsulated cebranopadol/ placebo tablets and 1 encapsulated moxifloxacin/ placebo tablet (5 capsules in total) on Day -3, Day -1, and from Day 1 to Day 30. Capsules were taken with 240 mL of water."
89559949|NCT06007131|No Intervention|Control Group|The control group will not receive a device and will continue their normal standard of care.
88966500|NCT03958123|Experimental|Treatment Group 2: Cebranopadol|"Therapeutic dose (600 μg) of cebranopadol:~Participants received placebo once a day for the first 11 days (Days -3, -1 and 1-9); 200 μg of cebranopadol once a day for 3 days; 400 μg once a day for 3 days; 600 μg once a day for 14 days; and placebo once a day on the last dosing day.~Participants received capsules under fasting conditions on Days -3, -1, 1, 29 and 30, and under fed conditions on all other dosing days. Participants received 4 encapsulated cebranopadol/ placebo tablets and 1 encapsulated moxifloxacin/ placebo tablet (5 capsules in total) on Day -3, Day -1, and from Day 1 to Day 30. Capsules were taken with 240 mL of water."
88966501|NCT03958123|Experimental|Treatment Group 3A: Placebo and Moxifloxacin|"Placebo / Moxifloxacin:~Participants received placebo once a day for 31 days (Days -3, -1 and 1-29) and moxifloxacin 400 mg once on the last dosing day. Participants received capsules under fasting conditions on Days -3, -1, 1, 29 and 30, and under fed conditions on all other dosing days.~Participants received 4 encapsulated cebranopadol/ placebo tablets and 1 encapsulated moxifloxacin/ placebo tablet (5 capsules in total) on Day -3, Day -1, and from Day 1 to Day 30. Capsules were taken with 240 mL of water."
89026797|NCT01324024|Experimental|Lisdexamfetamine, then placebo|Participants first received titrated doses of Lisdexamfetamine 20 to 60 mg/d each day for 4 weeks followed by a 2-week washout, then they received Placebo tablets (matching Lisdexamfetamine tablets) each day for 4 weeks.
89208457|NCT01009450|Active Comparator|LC was done using harmonic ACE|LC was done using harmonic ACE (Ethicon Endo-Surgery) by dissection of calot's and then occlusion of both cystic duct and artery using harmonic ACE. For closure of and division of cystic pedicle we set the instrument at a power 2 i.e. more coagulation. And when dissecting the gall bladder from the bed we set it to the level 5 i.e. more cutting power. And control of any bleeding from the bed using the active blade of harmonic ACE. Finally we insert abdominal drain in Morrison pouch.
89208458|NCT00870480|Experimental|A|Finasteride 5 mg single dose tablet, single dose
89208459|NCT00870480|Active Comparator|B|Proscar® 5 mg Tablet, single dose
89559950|NCT06007079|Experimental|Device Use|Patients will be given the CPM device to take home and use once daily
89559951|NCT06006520|Active Comparator|control group|No exercises will be given.
89559952|NCT06006520|Experimental|oropharyngeal|oropharyngeal exercises will be given.
89559953|NCT06006520|Experimental|aerobic|In addition to oropharyngeal exercises, 50 minutes of moderate-intensity aerobic exercise will be given at least 3 days a week.
89559954|NCT06002763||Vaginal delivery|Patients who have vaginal deliveries with neuraxial labour analgesia.
89559955|NCT06002763||Cesarean delivery|Patients who have a scheduled cesarean delivery with neuraxial anesthesia.
89559956|NCT06001541|Experimental|Web-SUCCEED+Enhanced Usual Care|web-SUCCEED, usual care, psychoeducational materials and resources for caregivers.
89559957|NCT06001541|Active Comparator|Enhanced Usual Care|Usual care, enhanced by psychoeducational materials and resources for caregivers.
89559958|NCT06000475|Active Comparator|Cognitive Processing Therapy (CPT)|Standard CPT as described in the treatment manual
89559959|NCT06000475|Experimental|Cognitive Processing Therapy (CPT) + Memory Support|CPT+Memory support will also incorporate frequent and intentional use of strategies to enhance learning and memory of this content.
89559960|NCT05998408|Experimental|Subjects with hypoplastic MDS|Subjects are defined as patients with a diagnosis of hMDS clinically confirmed by a licensed physician or an advanced practitioner who meets the inclusion and exclusion criteria and can provide informed consent.
89559961|NCT05998408|Experimental|Subjects with MAA|Subjects are defined as patients with a diagnosis of MAA clinically confirmed by a licensed physician or an advanced practitioner who meets the inclusion andexclusion criteria and can provide informed consent.
89559962|NCT05998408|Experimental|Subjects with PRCA|Subjects are defined as patients with a diagnosis of PRCA clinically confirmed by a licensed physician or advanced practitioners who meet the inclusion and exclusion criteria and can provide informed consent.
89559963|NCT05998408|Experimental|Subjects with SAA|Subjects are defined as patients with a diagnosis of SAA clinically confirmed by a licensed physician oran advanced practitioner who meets the inclusion andexclusion criteria and can provide informed consent.
89559964|NCT05998408|Experimental|Subjects with TLGL|Subjects are defined as patients with a diagnosis of TLGL clinically confirmed by a licensed physician or advanced practitioner who meets the inclusion and exclusion criteria and can provide informed consent.
89559965|NCT05995847|Experimental|harmonica combination group|These patients will participate in a six-month harmonica playing program, in addition to receiving basic pulmonary rehabilitation (PR) care, which includes self-management education, exercise training, and breathing training, as well as routine follow-up. All training sessions are home-based and will take place five days per week for six months.
89559966|NCT05995847|Active Comparator|basic-PR-care group|These patients will receive basic pulmonary rehabilitation (PR) care, which includes self-management education, exercise training, and breathing training, as well as routine follow-up. All training sessions are home-based and will take place five days per week for six months.
89559967|NCT05993481|Active Comparator|5 min. BP|"Clinicians will carry out randomized treatments in coordination with research staff.~The treatments will be: 1) Ephedrine treatment to maintain intraoperative MAP ≥60 mmHg, delayed resumption of chronic antihypertensive medications as monitoring with 5 min. Blood pressure management. The staff anesthesiologist will administer an ephedrine sulfate injection. An initial dose of 5 to 10 mg given as an intravenous bolus is advised for the treatment of clinically significant hypotension during anesthesia to provide an increase in blood pressure in case of MAP< 60 mmHg. However, the dose of each will be titrated as necessary to reach the target mean arterial pressures."
89559968|NCT05993481|Active Comparator|2.5 min. BP|"Clinicians will carry out randomized treatments in coordination with research staff.~The treatments will be: 2) Ephedrine treatment to maintain intraoperative MAP ≥60 mmHg, delayed resumption of chronic antihypertensive medications as monitoring with 2.5 min. Blood pressure management.~The staff anesthesiologist will administer an ephedrine sulfate injection. An initial dose of 5 to 10 mg given as an intravenous bolus is advised for the treatment of clinically significant hypotension during anesthesia to provide an increase in blood pressure in case of MAP< 60 mmHg. However, the dose of each will be titrated as necessary to reach the target mean arterial pressures."
89559969|NCT05989841|Experimental|RISE Guide|Brief cognitive behavioral intervention completed in the 3 weeks post-assault delivered via Internet on participants' smartphones targeting anxiety sensitivity, or fear of anxious arousal. Patients learn psychoeducation regarding the nature of stress, cognitive retraining to reduce negative interpretations of stress, and how to complete interoceptive exposures to reduce anxiety sensitivity. These skills are supported by 6 concurrent then subsequent weeks of ecological momentary intervention to deliver personalized intervention reminders based on symptoms.
89559970|NCT05989841|Active Comparator|Relaxation|"Patients will download the Breathe2Relax app, which delivers information about how to use diaphragm breathing (taking slow, deep breaths through the diaphragm) to manage stress. Participants will receive reminders to engage with the intervention. Participants will also receive ecological momentary intervention reminders to engage with the relaxation intervention."
89559971|NCT05980585|Experimental|Study Group|The Study group will use the CPM device once daily (in the morning) for 60 days.
89559972|NCT05978518|Experimental|Study Group|The study group will use the device one time daily (in the morning). The data will be reviewed and sent to the provider as detailed by the protocol.
89559973|NCT05978518|Sham Comparator|Control Group|The control group will use the device one time daily (in the morning). The data will not be reviewed or acted upon.
89559974|NCT05960305|Active Comparator|Tobacco Flavor|Can choose between 2 different tobacco flavor variants at 2 different nicotine levels (1.5% and 5%)
89559975|NCT05960305|Active Comparator|Menthol Flavor|Can choose between 2 different menthol flavor variants at 2 different nicotine levels (1.5% and 5%)
89559976|NCT05960305|Active Comparator|NTNM Flavor|Can choose between 2 different non tobacco/non menthol flavor variants at 2 different nicotine levels (1.5% and 5%)
88966502|NCT03958123|Experimental|Treatment Group 3B: Moxifloxacin and Placebo|"Moxifloxacin / Placebo:~Participants received placebo once a day for 2 days (Days -3 and -1); moxifloxacin 400 mg once for 1 day; and placebo once a day for the following 29 days. Participants received capsules under fasting conditions on Days -3, -1, 1, 29 and 30, and under fed conditions on all other dosing days.~Participants received four encapsulated cebranopadol/ placebo tablets and 1 encapsulated moxifloxacin/ placebo tablet (5 capsules in total) on Day -3, Day -1, and from Day 1 to Day 30. Capsules were taken with 240 mL of water."
88966503|NCT03933865|Other|Buprenorphine Maintained Patients|All participants will be maintained on buprenoprhine for the treatment of opioid use disorder. All participants will be exposed to all 8 study drug combinations
88966504|NCT03921385||Single cohort - navigated cranial and spine surgery|
89026798|NCT01324024|Experimental|Placebo, then Lisdexamfetamine|Participants first received Placebo tablets (matching Lisdexamfetamine tablets) each day for 4 weeks followed by a 2-week washout, then they received titrated doses of Lisdexamfetamine 20 to 60 mg/d each day for 4 weeks.
89026799|NCT00494520|Experimental|Errorful training condition|A type of anomia rehabilitation paradigm which allows for errors. The intervention involves providing minimal auditory cues to allow for errors in picture naming.
89208460|NCT01009528|Experimental|Intervention|Admission to electronic feedback system
89559977|NCT05960240|Experimental|Part 1|
89559978|NCT05960240|Experimental|Part 2|
89559979|NCT05960240|Experimental|Part 3|
89559980|NCT05954325|Experimental|Immunoadsorption|5 immunoadsorption treatments
89559981|NCT05954325|Sham Comparator|Sham immunoadsorption|5 sham immunoadsorption treatments
89559982|NCT05951881||Urgent care unit patients with medication|All patients admitted to the emergency department who agree to describe their medication
89559983|NCT05949684|Experimental|Luspatercept|
89559984|NCT05949684|Active Comparator|Epoetin Alfa|
89559985|NCT05949333|Active Comparator|Day1 Group|Eflapegrastim administration on day 1 (24 hours after completion of chemotherapy)
89559986|NCT05949333|Experimental|Day 3 Group|Eflapegrastim administration on day 3 (the third day after completion of chemotherapy
89559987|NCT05946447|Experimental|Gastric Ultrasound|Ultrasound measurements of the antrum will be recorded.
89559988|NCT05943509|Experimental|Alternative Rehabilitation Strategies|Patients who screened positive for hearing loss and were randomized into the counselling on alternative rehabilitation strategies intervention arm.
89559989|NCT05943509|Active Comparator|Usual Care|Patients who screened positive for hearing loss and were randomized into the usual care audiology pathway control arm alone.
89559990|NCT05938426|Active Comparator|ET-101|Treatment group
89208461|NCT01009528|No Intervention|control|Control group. No special attention
89208462|NCT00742001|Experimental|Mirasol Illumination Dose #1|Whole blood units treated with Mirasol at Illumination dose #1 (A1) of 22 Joules per milliliter of red blood cells (J/mL RBCs)
88966505|NCT03878953|Experimental|rhPTH(1-84)|Participants will receive a SC injection of initial dose of 50 mcg of rhPTH(1-84) once daily (QD) in the thigh (alternate thigh every day). If albumin-corrected serum calcium (ACSC; [mg/dL] = serum calcium [mg/dL] +0.8*[4-serum albumin (g/dL)]) is >2.25 mmol/L (>9.0 mg/dL), a starting dose of 25 mcg will be considered. At 4 week intervals the rhPTH(1-84) dose may be increased in 25 mcg increments to a maximal dose of 100 mcg SC QD. At any time during the study as needed for safety reasons, rhPTH(1-84) doses may be decreased in 25 mcg decrements to a minimum of 25 mcg QD. If the ACSC is >2.97 mmol/L (>11.9 mg/dL), then the investigational product should be stopped until the calcium level is corrected.
88966506|NCT03830671|Experimental|investigational arm|the arm was given investigational regimen:3Am-Mfx-PZA-X-Y-Z/3Am3-Mfx-PZA-X-Y-Z/12 Mfx-PZA-X-Y-Z.X、Y、Z are the drugs susceptible or possibly susceptible to mycobacterial bacilli(The candidated drugs to be selected are:Cs-Cycloserine,Pto-Protionamide,Clr-Clarithromycin,PAS-sodium para-aminosalicylate,E-ethambutol,Bdq-Bedaquiline,Cfz-Clofazimine,Lzd-linezolid).The abbreviation of the name of each drug in the regimen is explained as follows: PZA-pyrazinamide，Am-Amikacin，Mfx-moxifloxacin）and the total duration of the regimen is 18 months.
88966507|NCT05292326|Experimental|PacePress|the patients will be dressed with PacePress medical device instead of a standard compression device
88966508|NCT05292326|Active Comparator|standard compression band/tourniquet|standard treatment with respect to preventing hemorrhagic complications and implantation site inflammation, the patients will be dressed with a standard compression device/sand bag
88966509|NCT03806491|Experimental|CBT-I + AUD-TAU|Individual Cognitive Behavioral Therapy for Insomnia (CBT-I) delivered once a week for five (5) weeks.
88966510|NCT03806491|Active Comparator|Sleep Hygiene + AUD-TAU|Sleep hygiene education delivered once to all participants
88966511|NCT05640141||Control|Control group composed of 80 healthy aged volunteers.
88966512|NCT05640141||Motoric Cognitive Syndrom|MCR group composed of 80 MCR participants.
88966513|NCT03618784|Experimental|FURESTEM-RA Inj.|
88966514|NCT03618784|Placebo Comparator|Placebo Comparator: Placebo|
89559991|NCT05938426|Sham Comparator|Sham Device|Sham group
89559992|NCT05930041|Experimental|CSP|
89559993|NCT05930041|Active Comparator|HS-EMR|
89559994|NCT05929222|Active Comparator|Standard Arm|Radiotherapy alone
89559995|NCT05929222|Experimental|Experimental Arm|Radiotherapy plus Obinutuzumab
89559996|NCT05922124|Experimental|Cefiderocol + ampicillin-sulbactam|Cefiderocol 2 gram intravenous (IV) q8 hours and ampicillin-sulbactam 3 gram IV q6 hours for patients with normal creatinine clearance, both administered as extended infusion of 3 hours. Dosing adjusted according to reduced and augmented renal clearance and to renal replacement therapies.
89559997|NCT05922124|Active Comparator|Colistin or colistin + meropenem|Colistin 9 million units (MIU) intravenous (IV) loading dose followed by 4.5 MIU for patients with normal creatinine clearance +/- meropenem 2 gram IV administered as extended infusion of 3 hours. Dosing adjusted according to reduced and augmented renal clearance and to renal replacement therapies.
89559998|NCT05918211|Experimental|Drug|Approximately 218 subjects dosed with udenafil will be enrolled at approximately 30 sites.
89559999|NCT05918211|Experimental|Placebo|Approximately 218 subjects dosed with matching placebo will be enrolled at approximately 30 sites.
89560000|NCT05916235|Experimental|Experimental: Active PBM|PBM has been used clinically in the treatment of musculoskeletal and other pain conditions for over 30 years. Despite the low quality of the existing evidence, PBM has been increasingly used in other countries for the treatment of TMD. However, in the US PBM is not widely used for the treatment of TMD pain. Due to the multifactorial nature of chronic TMD pain, we propose that a multimodal PBM protocol targeting multiple pathophysiological mechanisms will be the optimal approach for PBM implementation in patients with TMD.
89560001|NCT05916235|Sham Comparator|Sham PBM|When applying PBM therapy, there are some heating elements in the treatment device, and most of the sham treatment devices available do not offer this feature, which increases the likelihood of unblinding both the patient and the interventionist. The THOR® LX2.3 PBM machine includes this new feature, such that the sham condition mimics the heating activity of the active treatment.
89560002|NCT05910489||Control|"Biomonitoring studies to detect MNPLs in biological samples and study of health effects.~Determination of MNPLs levels, genotoxic damage, and immunological effects"
89560003|NCT05910489||Greenhouse workers|"Biomonitoring studies to detect MNPLs in biological samples and study of health effects.~Determination of MNPLs levels, genotoxic damage, and immunological effects"
89560004|NCT05910229|No Intervention|Patient with standard care|Consultation with the onco radiotherapeutic and submission of the recommendations to follow before the simulation CT Scan before the radiotherapy
89560005|NCT05910229|Experimental|Patient with personalized support|Consultation with the onco radiotherapeutic and submission of the recommendations to follow before the simulation CT Scan before the radiotherapy and a phone call by a radiotherapy technician
88966515|NCT05206175|Experimental|Primary Arm|Components of the Affect Therapeutic Program for MUD Components of the treatment services include: contingency management (CM; monetary incentives for drug tests negative for stimulants), the digital behavioral therapy curriculum (based on CBT) delivered via the Affect app on smartphones, weekly one-on-one telemedicine-based addiction counseling with clinical personnel, twice-weekly group therapy, and monthly psychiatrist appointments for evaluation and management and medication support, as needed.
89560006|NCT05902533|Experimental|Reduced Elective Dose + Concurrent Capecitabine/Mitomycin C|Reduced elective nodal dose (30.6 Gy); (28- 30 fractions given M-F for approximately 5.5 to 6 weeks) Capecitabine 825 mg/m2 BID on days with RT Mitomycin C 10 mg/m2 slow IV push Days 1 and 29
89560007|NCT05893641|Active Comparator|A regular training volume|They will maintain their training volume of 35 h/week
89560008|NCT05893641|Active Comparator|A lower exercise volume group|They will conduct 85% of the control group weekly training volume (i.e., 30h/week)
89560009|NCT05893641|Active Comparator|A longer rest group|They will maintain the 35 h/week of exercise training, but with longer rest between exercise sessions
89560010|NCT05885828|Experimental|Plant-based diet|Participants in this arm will be recommended to consume more fiber-rich foods, including whole grains, fruits, legumes and vegetables; to moderate their intake of fish, eggs and dairy products; and to avoid other animal products. All participants are instructed not to modify their exercise habits during the intervention period.
89560011|NCT05885828|Experimental|Conventional diabetic diet|Participants in this arm will be recommended to have a diet following 2023 Chinese Diabetes Society guidelines. All participants are instructed not to modify their exercise habits during the intervention period.
89560012|NCT05885347|Placebo Comparator|Control group|This caregivers group will not receive any intervention different to the routinely practice.
89560013|NCT05885347|Experimental|Video Intervention|Caregivers will be taught by a video intervention about how to develop their home tasks during an hour.
88966516|NCT00392743||pet/spect scan|
88966517|NCT00392899|Active Comparator|UFT adjuvant therapy group|UFT is given at a dose of 500-600 mg/day as tegafur in 2 divided doses after meals for 5 days, followed by a 2-day rest. This one-week cycle is repeated for one year. During protocol treatment, clinical findings and laboratory values are evaluated every month. After the completion of protocol treatment, patients are followed-up, according to the schedule defined in the study protocol, for 5 years until recurrence, other malignancy or death is confirmed.
88966518|NCT00392899|No Intervention|Observation group|Patients are followed-up without adjuvant treatment, according to the schedule defined in the study protocol, for 5 years until recurrence, other malignancy or death is confirmed.
88966519|NCT05190419|Experimental|Orismilast modified release tablets 20 mg BID|Oral, twice daily morning and evening
88966520|NCT05190419|Experimental|Orismilast modified release tablets 30 mg BID|Oral, twice daily morning and evening
88966521|NCT05190419|Experimental|Orismilast modified release tablets 40 mg BID|Oral, twice daily morning and evening
88966522|NCT05190419|Placebo Comparator|Placebo tablets BID|Oral, twice daily morning and evening
88966523|NCT05638893|Experimental|Placebo group|Placebo tablet twice daily + celecoxib 200mg capsule once daily for 12 weeks.
88966524|NCT05638893|Experimental|Metformin group|Metformin 500mg tablet twice daily + celecoxib 200mg capsule once daily for 12 weeks.
88966525|NCT05190302||Phase I - Patients undergoing regional anesthesia with a block allowing a neurostimulation.|The investigators propose to conduct a single-blind, prospective observational study on all eligible patients undergoing regional anesthesia with a peripheral nerve block allowing a neurostimulation.
88966526|NCT00393055|Experimental|xylitol lozenge|1g xylitol lozenge. Five/day, dissolved in mouth
89208463|NCT00742001|Experimental|Mirasol Illumination Dose #2|Whole Blood units treated with Mirasol at Illumination dose #2 (A2) of 33 J/mL RBCs
88966527|NCT00393055|Placebo Comparator|inactive lozenge|1g placebo lozenge. Five/day, dissolved in mouth
88966528|NCT05162651|Active Comparator|Contingency management group|Randomized to receive individual motivational interviewing therapy and contingency management
89560014|NCT05885347|Experimental|Virtual reality|Caregivers will be taught by a VR intervention during 20minutes about how to develop their home tasks.
89560015|NCT05885347|Experimental|Augmented reality|Caregivers will be taught by a AR intervention during 20minutes about how to develop their home tasks.
89560016|NCT05885334|Placebo Comparator|Naturalistic Intervention|Natural intervention (actual provision of information and answering of questions). This arm will evaluate the natural learning during the action.
89560017|NCT05885334|Experimental|Virtual Reality|Virtual Reality intervention specifically designed for this study. Using VR to learn procedures will encourage caregivers to learn in a fully immersive and participatory environment where they will have to interact with the virtual content, enhancing their learning experience.
89560018|NCT05885334|Experimental|Augmented Reality|Augmented Reality Intervention specifically designed for this study. This intervention will increase participants' skills through active learning as they interact with real-world care situations while receiving simultaneous support from AR devices.
89560019|NCT05885334|Active Comparator|Videos with 360 degrees|Intervention using immersion 360 degrees specifically designed for this study. Participants enrolled in this arm, by completing it, is assumed that will experience a form of learning more participatory and immersive than conventional videos, as they can interact with the content by changing the camera angle.
89560020|NCT05884931|Active Comparator|Conventional Treatment|Conventional Treatment
89560021|NCT05884931|Experimental|Conventional Treatment + Nexpowder|Conventional Treatment + Nexpowder
89560022|NCT05884762|Experimental|Interventional group|electroencephalographic neurofeedback + traditional reference rehabilitation programme
89560023|NCT05884762|Sham Comparator|Control group|SHAM electroencephalographic neurofeedback + traditional reference rehabilitation programme
89560024|NCT05881395||Women with epidural analgesia experiencing pain during labor|Patients reporting pain will have their sensory block checked using ice and pinprick tests, prior to, and following and epidural top-up.
89560025|NCT05878184|Experimental|SC291 Plus Chemotherapy Regimen|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by investigational treatment with SC291
89560026|NCT05868083|Experimental|SNC-109 CAR-T Cells|After the operation and pre-infusion evaluation, SNC-109 CAR-T Cells will be evaluated.
89560027|NCT05864209|Experimental|Intervention Group|Half of the participants will be randomly assigned to the intervention group and will receive a three-month supply of phthalate- and bisphenol-free baby products (e.g., wipes, diaper cream) and a subscription to a cloth diaper service. Participants will be contacted after 2 and 6 weeks over the phone and administered a brief adherence survey.
89560028|NCT05864209|Active Comparator|Control Group|Half of the participants will be randomly assigned to the control group and provided with a three-month supply of conventional disposable diapers (e.g., Huggies or Pampers) and baby products (e.g., wipes, diaper cream). Participants will be contacted after 2 and 6 weeks over the phone and administered a brief adherence survey.
89560029|NCT05860569|Experimental|Cohort 1|1.0x10^13 vg/kg of GC304 delivered one-time intravenously (n=3)
89560030|NCT05860569|Experimental|Cohort 2|3.0x10^13 vg/ kg of GC304 delivered one-time i intravenously (n=3)
89560031|NCT05860569|Experimental|Cohort 3|5.0x10^13 vg/ kg of GC304 delivered one-time i intravenously (n=3)
89560032|NCT05856916|Experimental|Creatine Supplementation|Participants randomized to receive creatine. Study participants will be asked to track their daily administration on a log provided by the study team.
89560033|NCT05856916|Placebo Comparator|Placebo|Participants randomized to receive placebo. Study participants will be asked to track their daily administration on a log provided by the study team.
89560034|NCT05856760|Experimental|sparsentan|Sparsentan will be administered daily as a 200-mg oral tablet. The goal is to titrate from the initial dose of 200 mg (Day 1) to the target dose of 400 mg at Week 2.
89560035|NCT05843981|Experimental|Ks dental implant|Innovative dental implant with lasting, internal conical connection of 15° and strengthened implant walls.
89560036|NCT05843981|Active Comparator|TSIII dental implant|Standard dental implant with internal conical connection of 11°.
89560037|NCT05842876||Caregiver + Low Risk neonates|Participants in the nursery who are expected to be lower risk for CoA
89560038|NCT05842876||Caregiver + Medium to High Risk neonates|Participants in the NICU who are expected to be at a higher risk for CoA
89560039|NCT05842876||Nurses in the Newborn Nursery|Nurses who work at the Meriter Hospital, Inc. Newborn Nursery
89560040|NCT05832151|Experimental|CIN-102 Dose 1|Dose 1 twice daily for 12 weeks
89560041|NCT05832151|Experimental|CIN-102 Dose 2|Dose 2 twice daily for 12 weeks
89560042|NCT05832151|Placebo Comparator|Placebo|Placebo twice daily for 12 weeks
89560043|NCT05830864||Main cohort|Adult patients with refractory status epilepticus treated by Isoflurane as third anticonvulsive therapy
89560044|NCT05826041|Experimental|INSPIRE Group|90-minute support group; 9 content sessions over 18 weeks; co-led by a professional facilitator and peer.
89560045|NCT05826041|Active Comparator|Intervention as Usual: Traditional Domestic Violence Support Group|75-minute support group; 18-weeks; led by a domestic violence service provider counselor or advocate
89560046|NCT05815979|Experimental|Experimental Group:virtual reality, low-reality simple simulation dummy/model|Presentation of the From this point of view, the research was planned as a randomized, control group, experimental study to evaluate the effect of virtual reality-based nasogastric tube application skill on the knowledge, skills and self-confidence of graduate nursing students. glasses and an information meeting will be held for all students in the experimental group, and the working procedure of the virtual reality glasses will be introduced. Afterwards, students will monitor the practice skill at least once using virtual reality glasses. After the completed follow-up, the students will be asked to practice their nasogastric tube application skill on a simple simulation mannequin/model with low reality in the laboratory environment.
89560047|NCT05815979|No Intervention|Control Group:low-reality simple simulation dummy/model|Students will be shown the ability to apply a nasogastric tube on a low-reality simple simulation mannequin/model in the laboratory with a demonstration method by the same researcher. Afterwards, students will be asked to practice the skill of applying a nasogastric tube on a simple simulation manikin/model. While practicing on a low simple simulation mannequin/model, students will be evaluated according to the 'Nasogastric Catheter Application Skill Checklist' by a person who works as a nurse and has a graduate education in the field of Nursing Fundamentals, and the application time of the student's nasogastric tube will be recorded. After the application, the students will be asked to fill the 'Nasogastric Catheter Application Skill Knowledge Test' and 'Self-Confidence Evaluation Form'. In addition, students will be required to fill in the Anxiety, Stress, Satisfaction and Motivation Evaluation Form.
89560048|NCT05813587|Experimental|Meplazumab|First dose: 0.2 mg/kg - Day 1; second dose: 0.2 mg/kg - Day 8
89560049|NCT05813587|Placebo Comparator|Placebo|First dose: control - Day 1; second dose: control - Day 8
89560050|NCT05810363|Experimental|EP group|Patients in this group will receive etomidate- propofol mixture during induction and maintenance.
89560051|NCT05810363|Experimental|P group|Patients in this group will receive propofol during induction and maintenance.
89560052|NCT05810285||VITAMIN E|Patients who received cemented total knee arthroplasty with vitamin E blended polyethylene mobile bearing
89560053|NCT05810285||POLYETHYLENE|Patients who received cemented total knee arthroplasty with conventional polyethylene mobile bearing
89560054|NCT05807204|Experimental|Multi-ingredient of L-histidine, L-serine, L-carnosine and N-Acetylcysteine|Participants will daily consume the multi-ingredient (L-Histidine, L-Serine, L-Carnosine and N-Acetylcysteine) for 12 weeks.
89560055|NCT05807204|Placebo Comparator|Placebo|Participants will daily consume the placebo (maltodextrin) for 12 weeks.
89026800|NCT00494520|Experimental|Errorless training condition|A type of anomia rehabilitation paradigm in which the situation surrounding the performance of the desired task (i.e., picture naming) is controlled to prevent errors. The intervention involves providing maximal auditory cues to prevent errors in picture naming.
89026801|NCT00476567|Experimental|exercise|Regular exercise 45-60 minutes minimum three times per week
89026802|NCT00476567|Active Comparator|control|standard antenatal care
89560056|NCT05804903|Experimental|TAVI in severe calcified aortic stenosis or in failed surgical aortic bioprosthesis|
89026803|NCT00502554|No Intervention|1|Observation with standard care (macrolides, exercise, oxygen therapy etc.) alone.
89026804|NCT00502554|Active Comparator|2|2-day cycles of photopheresis every 3 weeks for 3 months
89026805|NCT00471614|Experimental|1|NucleomaxX
89026806|NCT00471614|Placebo Comparator|2|Placebo
89026807|NCT01244217|Experimental|Age 6 months - 2 years|Patients between 6 months and 2 years old
89026808|NCT01244217|Experimental|Age 2 - 11 years|Patients between 2 and 11 years (and under 10.5 kg)
89026809|NCT01244217|Experimental|Age 2 - 11 years (and over 10.5 kg)|Patients between 2 and 11 years (and over 10.5 kg)
89026810|NCT00471692|Placebo Comparator|placebo|Normal saline placebo
89026811|NCT00471692|Active Comparator|Ropivocaine|Ilioinguinal nerve block with ropivocaine
89026812|NCT01244295|Experimental|Complicated Grief Treatment|Targeted psychotherapy for complicated grief
89026813|NCT01244295|Active Comparator|Interpersonal Therapy|Standard IPT is a comparator treatment
89026814|NCT00476684|Experimental|radiofrequency neurotomy|Radiofrequency-neurotomy of the medial branch at 80 degr. C for 70 seconds, after diagnostic blocks
89026815|NCT00476684|Sham Comparator|sham controls|Radiofrequency-neurotomy of the medial branch at 37 degr. C needle temperature for 70 seconds, after diagnostic blocks
89026816|NCT00494559|Experimental|Actos|Actos group: pioglitazone 15mg or 30mg
89026817|NCT00494559|Placebo Comparator|Placebo|Placebo group: placebo without active medication
89026818|NCT00503334|Experimental|preOP booster|
89026819|NCT00503334|Placebo Comparator|preOP booster placebo|
89560057|NCT05804396|Experimental|Active stimulation|Relivion® device- Active stimulation
89560058|NCT05800366|Experimental|Polatuzumab + Glofitamab + R-CH|"-Participants will receive treatment interventions as outlined: Experimental: Safety Lead-In Phase of 6 Participants, Total Enrollment of 40 Participants~Polatuzumab, once, predetermined day and dosage per cycle, per protocol Cycles 1 - 6~R-CHP (Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Prednisone~Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride once, predetermined day and dosage per cycle, per protocol Cycles 1 - 6:~Prednisone) 5 days, predetermined day and dosage per cycle, per protocol Cycles 1 - 6:~Glofitamab~twice, predetermined day and dosage per cycle, per protocol Cycle 3-6~once, predetermined day and dosage per cycle, per protocol Cycle 7-8~Participants who need urgent therapy are also allowed to proceed with one cycle of R-CHOP for 1 cycle per standard of care.~Participants will be followed for up to 5 years post-treatment."
89026820|NCT00471770||1|1.Core group: enrolled subjects who have isolated pneumococcal
89026821|NCT00471770||2|2.SPN group:enrolled subjects who have no isolated pneumococcal
89026822|NCT00471770||3|3.DCF group: Subjects screened but not enrolled
89026823|NCT00476723||1|HIV/Hepatitis coinfected patients who use at least one hepatitis activity drug or medications
89026824|NCT00503451|Experimental|LBH589|
89026825|NCT00503490|Experimental|1|Inhaled Levofloxacin
89026826|NCT00503490|Placebo Comparator|2|Placebo
89026827|NCT00476801|Experimental|UVA1 irradiation|The dose and scheduling will be similar to those being successfully used in Germany: up to 130J/cm2 from a UVA1 Sellamed irradiation device (German manufactured UVA1 light emitting device) with irradiations up to 5 times per week for up to 14 weeks on one side of the face. Then a cross-over treatment an equal length of time.
89026828|NCT00476801|No Intervention|Control|No treatment on the opposite side of the face as the UVA1 treatment for up to 14 weeks. Then a cross-over treatment an equal length of time.
89026829|NCT04696965|Experimental|Correct/recheck strategy|Patients of study arm will be asked to show how they use their two inhalers and identify errors using a device-specific checklist by research assistant. Research assistant then show the patient how to use these devices correctly and give the checklist including the steps patients did wrong. After teaching by the research assistant, patients were asked to demonstrate the correct way of wrong step(s) they made at beginning.
89026830|NCT04696965|Active Comparator|Usual verbal instruction|Patients of control arm will be asked to show how thy use their two inhalers and identify errors using specific check list by research assistant. The educational nurse will give verbal instruction.
89026831|NCT00471965|Experimental|A|Oxaliplatin + 5-Fluorouracil/Leucovorin
89026832|NCT00471965|Active Comparator|B|Doxorubicin
89026833|NCT00472004|Active Comparator|1|17B Estradiol (1mg) / (0.125 mg) Trimegestone (TMG) Continuous combined, 1 Daily, 1 year duration
89026834|NCT00472004|Active Comparator|2|Tibolone 2.5 mg 1 daily, 1 year duration
89026835|NCT00494715|Experimental|Benazepril|
89026836|NCT00494715|Experimental|valsartan|
89026837|NCT00494715|Experimental|benazepril/valsartan|
89026838|NCT02273999|No Intervention|Control Group (no device)|No devices were delivered after third molar tooth extraction
89026839|NCT02273999|Placebo Comparator|Placebo group (Inactivated device)|Inactivated devices were delivered after third molar tooth extraction
89026840|NCT02273999|Experimental|Test (activated device)|Activated devices were delivered after third molar tooth extraction
89026841|NCT01323946|Experimental|GSK1562902A 6 to 12 M Group|Subjects between 6 and 12 months of age (6 to 12 M), who received 2 primary doses of A/Indonesia/05/2005 GSK1562902A vaccine on Days 0 and 21 and 1 booster dose of the A/turkey/Turkey/1/2005 GSK1562902A vaccine on Day 182.
89208464|NCT00742001|Experimental|Mirasol Illumination Dose #3|Whole Blood units treated with Mirasol at Illumination dose #3 (A3) of 44 J/mL RBCs
89560059|NCT05798117|Experimental|YTB323|Single infusion of YTB323
88966529|NCT05162651|Other|Control group|Randomized to receive individual motivational interviewing therapy alone
89560060|NCT05797285|Experimental|Weekly Human Keratin Graft Application|Patients randomized into this arm will receive standard of care (offloading, debridement, and three-layer outer dressing) with the test material, the human keratin graft, reapplied weekly to the target wound.
89560061|NCT05797285|Experimental|Bi-Weekly Human Keratin Graft Application|Patients randomized into this arm will receive standard of care (offloading, debridement, and three-layer outer dressing) with the test material, the human keratin graft, reapplied every other week to the target wound.
89560062|NCT05793723||Cases|Infants with confirmed neonatal COVID-19 infection
89560063|NCT05793723||Controls|Infants born to mothers with no history of COVID-19 infection during pregnancy and no neonatal COVID-19 infection
89560064|NCT05785741|Experimental|DB-1310 Dose Level 1|Enrolled Subjects will receive a single-dose of DB-1310 at Dose Level 1 on Day 1 of each cycle Q3W
89560065|NCT05785741|Experimental|DB-1310 Dose Level 2|Enrolled Subjects will receive a single-dose of DB-1310 at Dose Level 2 on Day 1 of each cycle Q3W
89560066|NCT05785741|Experimental|DB-1310 Dose Level 3|Enrolled Subjects will receive a single-dose of DB-1310 at Dose Level 3 on Day 1 of each cycle Q3W
89560067|NCT05785741|Experimental|DB-1310 Dose Level 4|Enrolled Subjects will receive a single-dose of DB-1310 at Dose Level 4 on Day 1 of each cycle Q3W
89560068|NCT05785741|Experimental|DB-1310 Dose Level 5|Enrolled Subjects will receive a single-dose of DB-1310 at Dose Level 5 on Day 1 of each cycle Q3W
89560069|NCT05785741|Experimental|DB-1310 Dose Expansion 1|Enrolled Subjects with advanced/unresectable, or metastatic adenocarcinoma NSCLC with EGFR activating mutation who have progressed on or after standard systemic treatments will receive a single-dose of DB-1310 on a selected dose level (RP2D) Day 1 of each cycle Q3W
89560070|NCT05785741|Experimental|DB-1310 Dose Expansion 2|Enrolled Subjects with advanced/unresectable, or metastatic NSCLC without EGFR activating mutation who have progressed on or after standard systemic treatments will receive a single-dose of DB-1310 on a selected dose level (RP2D) Day 1 of each cycle Q3W
89560071|NCT05785741|Experimental|DB-1310 Dose Expansion 3|Enrolled Subjects with advanced/unresectable, or metastatic CRPC who have progressed on or after standard systemic treatments will receive a single-dose of DB-1310 on a selected dose level (RP2D) Day 1 of each cycle Q3W
89560072|NCT05785741|Experimental|DB-1310 Dose Expansion 4|Enrolled Subjects with advanced/unresectable, or metastatic HNSCC who have progressed on or after standard systemic treatments will receive a single-dose of DB-1310 on a selected dose level (RP2D) Day 1 of each cycle Q3W
89560073|NCT05785741|Experimental|DB-1310 Dose Expansion 5|Enrolled Subjects with advanced/unresectable, or metastatic BC with HER2-positive (IHC3+, or IHC2+ and ISH+) who have progressed on or after HER2 targeted systemic treatments will receive a single-dose of DB-1310 on a selected dose level (RP2D) Day 1 of each cycle Q3W
89560074|NCT05785741|Experimental|DB-1310 Dose Expansion 6|Enrolled Subject with other advanced/unresectable, or metastatic solid tumors who have progressed on or after standard systemic treatment, or for which no standard systemic treatment is available will receive a single-dose of DB-1310 on a selected dose level (RP2D) Day 1 of each cycle Q3W
89560075|NCT05777291|Experimental|Experimental arm|Patients will be given physical activity recommendations ABD will be using the study devices: activity watch (Fitbit Sense) and a sleep monitoring mattress (Withings, Sleep Analyzer)
89560076|NCT05777291|Active Comparator|Control arm|Patients will be given physical activity recommendations only
89560077|NCT05775354|Experimental|Early diagnosis strategy|RED-CVD early diagnosis questionnaire, physical examination, laboratory testing, electrocardiography, echocardiography
89560078|NCT05775354|No Intervention|Usual primary care|No measurements
89560079|NCT05771688|Experimental|FETO therapy|FETO therapy
89560080|NCT05770882|Experimental|Part I safety; and Part II cohort expansion|"Part I: The safety of drug combination will be studied.~Part II: The drug combination will be further evaluated in the cohort expansion phase."
89560081|NCT05762471|Experimental|Cohort 1|Patients will receive once daily doses of study drug (GSBR-1290 or Placebo) for a total of 4 weeks
89560082|NCT05762471|Experimental|Cohort 2|Patients will receive once daily doses of study drug (GSBR-1290 or Placebo) for a total of 4 weeks
88966530|NCT03435484|Active Comparator|Arm A|Participants in this group will receive one version (out of two) of instructions for completing the Health Assessment Questionnaire.
88966531|NCT03435484|Active Comparator|Arm B|Participants in this group will receive another version (out of two) of instructions for completing the Health Assessment Questionnaire.
88966532|NCT05636475|Experimental|Manuel hand massage group|According to the hand massage training received, the patient coming out of the surgery is in diamond shape for ten minutes for each hand.
89208465|NCT00870558|Experimental|Arm I|Patients receive an intra-arterial infusion of iodine I 131 ethiodized oil.
89208466|NCT00870558|Placebo Comparator|Arm II|Patients receive an intra-arterial infusion of unlabeled ethiodized oil.
89560083|NCT05762471|Experimental|Cohort 3|Patients will receive once daily doses of study drug (GSBR-1290 or Placebo) for a total of 4 weeks
89560084|NCT05762471|Experimental|Cohort 4|HOV participants (Cohort 4) will receive multiple-ascending doses of GSBR-1290 or placebo for a total of 12 weeks
89560085|NCT05762471|Experimental|Cohort 5|Participants with T2DM(Cohort 5) will be randomized to placebo, low-dose, or high-dose arms. Participants in the low-dose, high-dose or placebo arms will receive multiple-ascending doses for 12 weeks
89560086|NCT05760573|No Intervention|Usual care plus school supplies and resources|This group will not be enrolled in the Family Wellness Program. They will receive usual care from their regular clinician plus a backpack with schools supplies and a list of resources.
89560087|NCT05760573|Experimental|Famliy Wellness Program|This group will be enrolled in the Family Wellness Program which consists of 8 weekly parent-child workshops prior to the children entering kindergarten as well as 4 booster sessions during the child's kindergarten year. As part of the program families will receive school supplies, books and resources.
89560088|NCT05750758|Experimental|DAPT+rivaroxaban|Rivaroxaban 2.5 mg bid + aspirin 100 mg qd + ticagrelor 90 mg bid was used for 1 month after operation, and then aspirin 100 mg + ticagrelor 90 mg bid was used for 5 months.
89560089|NCT05750758|No Intervention|DAPT|aspirin 100 mg qd + ticagrelor 90 mg bid for 6 months.
89560090|NCT05739981|Experimental|Chemotherapy + BEV + IMNN-001 (Experimental)|"Chemotherapy (neoadjuvant and adjuvant): Paclitaxel 175 mg/m2 IV followed by carboplatin AUC 5-6 IV starting on C1D1. During the neoadjuvant period, there will be from 4 to 6 cycles repeated every 21 days.~BEV 15 mg/kg IV administration will be included with each cycle except during the cycles around time of surgery. During maintenance, BEV will be administered every 3 weeks as a single agent until disease progression or unacceptable toxicity for a maximum of an additional 18 cycles. In total, BEV may be administered up to 24 cycles. FDA approved BEV biosimilars may be used in this study in place of BEV.~IMNN-001 80 mg/m2 IP will be administered weekly beginning C1D15 and continue weekly through the last cycle of adjuvant therapy. At the conclusion of chemotherapy, GEN-1 will be administered every 21 days with BEV in subjects who are BRCA-/HRP until disease progression or unacceptable toxicity for up to an additional 18 cycles."
89560091|NCT05739981|Other|Chemotherapy + BEV (Control)|"Chemotherapy (neoadjuvant and adjuvant): Paclitaxel 175 mg/m2 IV followed by carboplatin AUC 5-6 IV starting on C1D1. During the neoadjuvant period, there will be from 4 to 6 cycles (at the Investigator's discretion, having an additional C4+1 and C4+2) repeated every 21 days.~BEV 15 mg/kg IV administration will be included with each cycle EXCEPT the following cycles: [1] Cycle 1, [2] the last cycle of neoadjuvant therapy immediately preceding ICS, and [3] the first cycle of adjuvant chemotherapy (i.e., first cycle after ICS). During the maintenance phase, BEV 15 mg/kg will be administered every 3 weeks as a single agent until disease progression or unacceptable toxicity for a maximum of an additional 18 cycles. In total, BEV may be administered up to 24 cycles. FDA approved BEV biosimilars may be used in this study in place of BEV."
89560092|NCT05739708|Other|Asthma patients|
89560093|NCT05738655|Placebo Comparator|Placebo group|Placebo capsule, one capsule/day (300 mg/day) for 3 months
89560094|NCT05738655|Experimental|Low dose|Pumpkin seed extract capsule, one capsule/day (300 mg/day) for 3 months
89560095|NCT05738655|Experimental|High dose|Pumpkin seed extract capsule, two capsules/day (600 mg/day) for 3 months
89560096|NCT05737524|Experimental|Telerehabilitation (VAST 2)|
89560097|NCT05733702||Single arm study:|Patients with IBD requiring a treatment change at the time of inclusion
89560098|NCT05732870||Participant undergoing orthopaedic surgery|"Patients with osteoarthritis undergoing total joint arthroplasty, osteotomy or arthrodesis of any joint (including hip, knee, shoulder, elbow, ankle).~Patients with fractured neck of femurs undergoing hemiarthroplasty or total hip arthroplasty, or other internal fixation procedure.~Patients undergoing acute low-velocity or fragility fracture fixation surgery."
89560099|NCT05728918|Placebo Comparator|Placebo|Placeo group
89560100|NCT05728918|Experimental|Treatment|Experimental group
89560101|NCT05728814||Case-only|The study population consists of adult female patients with diagnosis of dMMR/MSI-H recurrent or advanced endometrial cancer with progression to a previous platinum regimen, who were treated within the Spanish dostarlimab Expanded Access Program (EAP).
89560102|NCT05723835|Experimental|Somapacitan|Participants will receive Somapacitan for 26-week main phase followed by 130-week extension phase.
89560103|NCT05719441|Experimental|Arm 1: VRC07-523LS + PGT121.414.LS + ART|
89560104|NCT05719441|Placebo Comparator|Arm 2: Placebo + ART|
89560105|NCT05718570||Participants with Adult Growth Hormone Deficiency (AGHD)|Participants will be treated with commercially available Sogroya according to routine clinical practice at the discretion of the treating physician. The decision to treat a participant with Sogroya has been made prior to and independently from the decision to include the participant in this study.
89560106|NCT05713266||Severe COVID-19 survivors|Adult COVID-19 survivors who had 'severe COVID-19' during the acute phase and have at least one of the following pre-existing conditions: Hypertension, Asthma, COPD, Heart Failure, Chronic kidney disease and/or Diabetes. 'Severe COVID-19' is defined as requiring hospital or intensive level care for treatment of the infection and its complications.
89560107|NCT05709067|Experimental|Probiotic Arm|
89560108|NCT05709067|Placebo Comparator|Control|
89560109|NCT05707806||healthy controls|generally healthy volunteers
89560110|NCT05701735|No Intervention|Routine care|Routine in-house workflow for initial and follow-up consultation, disclosure of diagnosis, and apprisal and counseling regarding treatment options
89560111|NCT05701735|Experimental|Patient decision aid|Routine in-house workflow for initial and follow-up consultation, disclosure of diagnosis, and apprisal and counseling regarding treatment options plus provision of a decision aid after the initial consultation
89026842|NCT01323946|Experimental|GSK1562902A 12 to 24 M Group|Subjects between 12 and 24 months of age (12 to 24 M), who received 2 primary doses of A/Indonesia/05/2005 GSK1562902A vaccine on Days 0 and 21 and 1 booster dose of the A/turkey/Turkey/1/2005 GSK1562902A vaccine on Day 182.
89560112|NCT05688852|Experimental|VTX958 Dose A|
89560113|NCT05688852|Experimental|VTX958 Dose B|
89560114|NCT05688852|Placebo Comparator|VTX958 Placebo|
89560115|NCT05688371|Active Comparator|standard dose morphine|children will receive 0.05 mg morphine /kg.as a bolus dose dissolved in 50 ml normal saline.
89560116|NCT05688371|Active Comparator|low dose morphine and dexmedetomidine|children will receive 0.02 mg morphine /kg bolus dose plus 0.2 µg/kg dexmedetomidine dissolved in 50 ml normal saline .
89560117|NCT05687149||Fanconi anemia|A prospective cohort of individuals with Fanconi anemia (FA) at very high risk of squamous cell carcinoma (SCC)
89560118|NCT05685303|Experimental|Treatment|Subjects randomized to the treatment arm will undergo cardiac imaging, femoral vein access and receive the Alleviant ALV1 System device procedure.
89560119|NCT05685303|Sham Comparator|Control|Subjects randomized to the control arm will undergo cardiac imaging and sheath placement in femoral vein.
89560120|NCT05684588|Other|Instrumental diagnostic evaluation|After enrollment all patients will undergo an instrumental evaluation including a radiography (according to clinical practice) and a magnetic resonance (experimental procedure outside clinical practice), at 1 year from previous hospitalization
89560121|NCT05679479|Experimental|Meplzaumb|First dose: 0.2 mg/kg - Day 1; second dose: 0.2 mg/kg - Day 8
89560122|NCT05679479|Placebo Comparator|Placebo|First dose: control - Day 1; second dose: control - Day 8
89560123|NCT05678257|Experimental|NUFIRI-bev on a Q1W NUC-3373 schedule|"Arm A: Study treatment will be administered in 28-day cycles as follows:~Bevacizumab 5 mg/kg on Days 1 and 15:~90 minutes for the first dose~60 minutes for the second dose (if first dose is tolerated)~30 minutes for subsequent doses (if second dose is tolerated)~LV 400 mg/m2 (or equivalent levo-LV) over 120 minutes on Days 1, 8, 15, and 22.~Irinotecan 180 mg/m2 over 90 minutes (concurrently with the LV infusion) on Days 1 and 15.~NUC-3373 1500 mg/m2 over 120 minutes on Days 1, 8, 15, and 22."
89560124|NCT05678257|Experimental|NUFIRI-bev on a Q2W NUC-3373 schedule|"Arm B: Study treatment will be administered in 28-day cycles as follows:~Bevacizumab 5 mg/kg on Days 1 and 15:~90 minutes for the first dose~60 minutes for the second dose (if first dose is tolerated)~30 minutes for subsequent doses (if second dose is tolerated)~LV 400 mg/m2 (or equivalent levo-LV) over 120 minutes on Days 1 and 15.~Irinotecan 180 mg/m2 over 90 minutes (concurrently with the LV infusion) on Days 1 and 15.~NUC-3373 1500 mg/m2 over 120 minutes on Days 1 and 15."
89560125|NCT05678257|Active Comparator|FOLFIRI-bev on a Q2W schedule|"Arm C: Study treatment will be administered in 28-day cycles as follows:~Bevacizumab 5 mg/kg on Days 1 and 15:~90 minutes for the first dose~60 minutes for the second dose (if first dose is tolerated)~30 minutes for subsequent doses (if second dose is tolerated)~LV 400 mg/m2 (or equivalent levo-LV) over 120 minutes on Days 1 and 15.~Irinotecan 180 mg/m2 over 90 minutes (concurrently with the LV infusion) on Days 1 and 15.~5-FU 400 mg/m2 bolus on Days 1 and 15.~5-FU 2400 mg/m2 infusion over 46 hours on Days 1 and 15."
89560126|NCT05676970|Experimental|Telehealth Arm: Wellness with Vaccine Education|Individuals in this arm will complete standardized telehealth interventions that focus on nutrition, work-life balance, mental health, diabetes and hypertension. In addition, they will complete education and counseling on vaccination. All educations will be completed one-on-one as well as small group.
89560127|NCT05676970|Active Comparator|Telehealth Arm: Wellness Only|Individuals in this arm will complete standardized telehealth interventions that focus on nutrition, work-life balance, mental health, diabetes and hypertension. All educations will be completed one-on-one as well as small group.
89560128|NCT05673187|Experimental|Treatment Arm|Adagrasib to be administered at a dose of 600 mg orally, twice daily until progression or unacceptable toxicity.
89560129|NCT05668260|Experimental|Biodegradable Stent|An internal biodegradable pancreatic stent (ArchimedesTM) will be placed at the level of the pancreatic anastomosis in patients undergoing pancreatoduodenectomy.
88966533|NCT05636475|Experimental|machine-based hand massage|The pressure setting of the machine is made according to the manual massage application method. In manual massage and machine massage, machine adjustments are made to keep the temperature and pressure difference as low as possible. A hand massage is done for ten minutes for each hand.
88966534|NCT05636475|No Intervention|Control group|The control group will be treated only according to the clinical analgesia protocol.
88966535|NCT03339505|Active Comparator|Treatment group|Patients in treatment group will receive Salovum according to g/kg body weight/24 hours/divided into 6 doses, during a maximum of 5 days
88966536|NCT03339505|Placebo Comparator|Placebo group|Patients in treatment group will receive Placebo (egg yolk powder) according to g/kg body weight/24 hours/divided into 6 doses, during a maximum of 5 days
88966537|NCT05636085||Eligible subjects|Subjects ≥45 years of age and at average risk of colorectal cancer.
88966538|NCT03216421|Other|Low/Intermediate Grade DCIS|Subjects with Low/Intermediate Grade DCIS will complete quality of life questionnaires before and after the IORT.
88966539|NCT03216421|Other|High Grade DCIS|Subjects with High Grade DCIS will complete quality of life questionnaires before and after the IORT.
88966540|NCT05635188||Open Surgery|
88966541|NCT05635188||Laparoscopic Surgery|
88966542|NCT05635188||Trephine Surgery|
88966543|NCT03152305||Women with menstrual migraine|Womens presenting with regular menstrual migraine treated with triptans will be included in the study.
88966544|NCT03152305||Matched control|The potential variations will be compared to the measures done on matched healthy women outside and during menses.
88966545|NCT05012930|Experimental|Study Provided Diet - Meat|A group of complementary foods provided to participants by researchers.
88966546|NCT05012930|Experimental|Study Provided Diet - Plant|A group of complementary foods provided to participants by researchers.
88966547|NCT05012930|Experimental|Study Provided Diet - Dairy|A group of complementary foods provided to participants by researchers.
88966548|NCT05012930|Placebo Comparator|Traditional Diet|No study foods provided to participants by researchers. Participants will eat a typical diet provided by caregivers.
88966549|NCT05634564|Experimental|Concurrent radiochemotherapy combined with immunotherapy|Participants will receive tislelizumab plus gemcitabine and nab-paclitaxel in cycles of 21 days. Non-progressors will plus concurrent radiotherapy during the 3rd cycle of chemotherapy. After 4-6 cycles treatment, Multiple disciplinary team (MDT) will evaluate whether to undergo radical surgery.
88966550|NCT03152227|Experimental|ACGG & ATONU|ACGG high-producing chicks to households along with provision of technical input on production and ATONU Nutrition sensitive BCC on poultry-specific aspects of nutrition, WASH, women's empowerment, and use of income combined with home gardening.
89208467|NCT00869076|Experimental|Pharmacist Management|In this arm the Pharmacist managed the Diabetes in collaboration with the primary care physician
89560130|NCT05668260|No Intervention|Non Stent|No stent will be placed at the level of the pancreatic anastomosis in patients undergoing pancreatoduodenectomy.
89560131|NCT05664074|Experimental|Rectal indomethacin|"Dosage based on subject's weight:~>=50 kg, 100 mg; 30-49 kg, 50 mg; 10-29 kg, 25 mg"
88966551|NCT03152227|Active Comparator|ACGG only|ACGG high-producing chicks to households along with provision of technical input on production
88966552|NCT03152227|No Intervention|Control|ACGG eligible households in non-ACGG villages receiving standard of care agricultural and health services as provided in Ethiopia
89026843|NCT01323946|Experimental|GSK1562902A 24 to 36 M Group|Subjects between 24 and 36 months of age (24 to 36 M), who received 2 primary doses of A/Indonesia/05/2005 GSK1562902A vaccine on Days 0 and 21 and 1 booster dose of the A/turkey/Turkey/1/2005 GSK1562902A vaccine on Day 182.
89026844|NCT03271073|Experimental|Apatinib plus S1|patients with advanced gastric cancer enrolled after failure of first-line systemic chemotherapy will be given Apatinib plus S1 till progressive disease,death or non-tolerable toxicity
89026845|NCT00476879|Experimental|1|12 hours of fasting and a GH bolus
89026846|NCT00476879|Experimental|2|36 hours of fasting and a GH bolus
89026847|NCT00476879|Experimental|3|36 hours of fasting and Pegvisomant
89026848|NCT00476879|Experimental|4|36 hours of fasting and NaCl injection
89560132|NCT05664074|Experimental|IV ketorolac|Dosage based on subject's weight: 0.5 mg/kg (maximum: 15 mg)
89560133|NCT05659927|Experimental|MG-ZG122 first dose group|4 cases in the 52.5 mg dose group (2 cases of placebo, 2 cases of experimental drug)
89560134|NCT05659927|Experimental|MG-ZG122 second dose group|10 cases in the 105 mg dose group (2 cases of placebo, 8 cases of experimental drug)
89560135|NCT05659927|Experimental|MG-ZG122 third dose group|10 cases in the 210 mg dose group (2 cases of placebo, 8 cases of experimental drug)
89560136|NCT05659927|Experimental|MG-ZG122 forth dose group|10 cases in the 420 mg dose group (2 cases of placebo, 8 cases of experimental drug)
89560137|NCT05659784|Experimental|Telerehabilitation|
89560138|NCT05657639|Experimental|CAV regimen|
89560139|NCT05657639|Active Comparator|MEC regimen|
89560140|NCT05650541|Experimental|Study Group|The study group will use the CPM device daily for 6 months (beginning at visit 1 and ending at visit 2). The ADI triaging team will monitor the CPM device data and call the patient as indicated by the data. The ADI care team will then forward the device data and patient symptomology collected to the patient's care team where that team will device if intervention is necessary. The patient's care team will also have access to view device data at any time using the CPM website.
89560141|NCT05650541|No Intervention|Control Group|The control group will not receive a device and will continue their normal standard of care.
89560142|NCT05640466|Other|Adult patient with displaced metatarsal head fractures|"A Kirschner wire with its distal end is placed showing a small bend into the medullar cavity through the lateral margin of the proximal metaphysis of the affected metatarsal using a 5mm skin incision at that level. The skin incision was made over the interosseus space, so as to use one incision for the two neighbouring metatarsal bones. The diameter of the Kirschner wires to be used should be related to the size of the fractured metatarsal medullar cavity. Kirschner wire will be driven anterograde, with the help of an X-ray image intensifier.~Subsequently, the wire will be rotated 180 to direct its end to the dorsum of the foot so as to provoke a translation effect on the metatarsal head in order to obtain the head reduction, and maintained this reduction with the Kirschner wire."
89560143|NCT05634954|Experimental|[18F]GEH121224 - Group 1 - Biodistribution|
89560144|NCT05634954|Experimental|[18F]GEH121224 - Group 2 - Reproducibility|
89560145|NCT05625932|No Intervention|Control Arm|Those patients allocated in the control arm will receive no interventions related to VTE risk. No placebo will be administered to avoid discomfort of these patients who are already under treatment for their cancer.
89560146|NCT05625932|Experimental|Experimental arm|"Those patients allocated to the experimental arm will receive prophylactic Tinzaparin at a fixed dose according to their weight:~Patients < 80 kg will receive a fixed dose of 4500 IU daily. Patients between 80-100 kg will receive a fixed dose of 6000 IU daily. Patients > 100 kg will receive a fixed dose of 8000 IU daily.~Accordingly, the effective dose of tinzaparin is estimated to be in the range of 56-90 IU/kg. Tinzaparin dose will be adjusted according to the dose levels specified above in patients who experience changes in body weight greater than 10% during treatment period."
89560147|NCT05624684||ICU patients with severe pneumonia|Critically ill patients with severe pneumonia under mechanical ventilation including ventilator-associated pneumonia, community-acquired or hospital-acquired pneumonia.
89560148|NCT05615714|Experimental|Paresthesia-Free Stimulation|Duration: 2 weeks
89560149|NCT05615714|Sham Comparator|Sham Stimulation|Duration: 2 weeks
89560150|NCT05615415||NP-PASC (neuropsychiatric post-acute sequelae of SARS-CoV-2)|Individuals with new onset a) cognitive and/or b) psychiatric symptoms following SARS-CoV-2 infection. Participants will undergo PET/MR scanning, during which a TSPO PET tracer and a Gadolinium-based MRI tracer will be administered intravenously and blood samples will be collected from an arterial line. In addition, blood samples will be taken at screening. Participants can elect to provide an optional cerebrospinal fluid (CSF) sample.
89560151|NCT05615415||CC (COVID Control)|Individuals with a history of SARS-CoV-2 infection who do not meet the criteria for any DSM-5 diagnosis and perform within normal limits on cognitive tests. Participants will undergo PET/MR scanning, during which a TSPO PET tracer and a Gadolinium-based MRI tracer will be administered intravenously and blood samples will be collected from an arterial line. In addition, blood samples will be taken at screening. Participants can elect to provide an optional cerebrospinal fluid (CSF) sample.
89560152|NCT05611801|Experimental|marstacimab (PF-06741086)|Weekly subcutaneous injections.
89560153|NCT05603754|Experimental|Lorecivivint|Healthcare professional-administered intra-articular injection; performed on Day 1.
89026849|NCT00472121||1: AMG|
89026850|NCT00472121||2: MMG|
89026851|NCT00494793|Other|VAWC and mesh mediated fascial traction|This is a study aiming to evaluate one technique for temporary abdominal closure for open abdomen therapy in all patients applicable according to the inclusion criteria
89026852|NCT01246635|Experimental|TRUFIT CB with accelerated rehab.|
89026853|NCT01246635|Experimental|TRUFIT CB with standard rehab.|
89026854|NCT01246635|Active Comparator|• Microfracture with rehabilitation|
89026855|NCT00472160|Experimental|1|Non Invasive Ventilation
89026856|NCT00472238|Experimental|1, Training|Group for training therapy
89026857|NCT00472238|Active Comparator|2, Control|
89208468|NCT00869076|Active Comparator|Usual Care|The patient was managed by the primary care physician
89208469|NCT01565278|Experimental|Soybean oil + Fish oil|Intralipid (0.25 g/kg/TPN day) + Omegaven (0.4 g/kg/TPN day) for a period of 6 months.
89026858|NCT01246674||Hypothesis generating study|Consecutive total hip arthroplasty patients
89026859|NCT01323790|Experimental|1|Oral treatment
89560154|NCT05603754|Placebo Comparator|Vehicle|Healthcare professional-administered intra-articular injection; performed on Day 1.
89560155|NCT05596955|Experimental|Buprenorphine|Study participants receive three once-a-month injections of buprenorphine and complete weekly monitoring visits.
89560156|NCT05596955|Active Comparator|Naltrexone|Study participants receive three once-a-month injections of naltrexone and complete weekly monitoring visits.
89560157|NCT05595447|Experimental|Brentuximab plus PD-1 blocked plus ASCT plus maintenance Brentuximab plus PD-1|Brentuximab plus PD-1 blocked x 8 cycles plus ASCT plus maintenance Brentuximab plus PD-1 x 8 cycles
89560158|NCT05581147||Klinefelter syndrome|Males affected by 47,XXY non-mosaic Klinefelter syndrome. Subgroups according to pubertal stage: pre-pubertal, pubertal and adults. Subgroups according to gonadal status: eugonadal, hypogonadal and receiving testosterone replacement therapy (TRT).
89560159|NCT05581147||Healthy controls|Euthyroid, age- and pubertal stage-matched males Subgroups according to pubertal stage: pre-pubertal, pubertal and adults.
89560160|NCT05581147||Chronic lymphocytic thyroiditis|Adult males affected by chronic lymphocytic thyroiditis
89560161|NCT05573867|Experimental|Intervention group|"Individualized, digital coaching twice a week for 12 weeks with Physical activity on prescription (FaR) to increase physical activity and reduce PSF after stroke."
89560162|NCT05573867|No Intervention|Control group|Control group receive routine written and verbal information about PSF and information about recommended level of physical activity.
89560163|NCT05571553|Experimental|Intervention group|"Phase 1~Participants will assess their health status, at home, at recruitment (M0) and at 3 months (M3) with CARE© with the help of their family caregivers.~The principal investigator or a representative will contact them by phone within 5 days of the CARE© assessment to complete ESOGER.~Phase 2~Participants will assess their health status, at home, at recruitment (M0), at 3 months (M3), and at 6 months (M6) on the CARE© application with the help of their family caregivers. An additional assessment will take place over the phone by the principal investigator or one of his representatives.~If their health status is considered fragile, then individuals will be contacted by phone by the PI or one of his representatives to complete the ESOGER© questionnaire (at M0, M3 and M6)."
89560164|NCT05571553|No Intervention|Control group|"Phase 1~Participants will assess their health status, by telephone, at recruitment (M0) and at 3 months (M3) with CARE© with the help of their family caregivers.~The principal investigator or a representative will contact them by phone within 5 days of the CARE© assessment to complete ESOGER.~Phase 2~Participants will assess their health status, at home, at recruitment (M0), at 3 months (M3), and at 6 months (M6) on the CARE© application with the help of their family caregivers. An additional assessment will take place over the phone by the principal investigator or one of his representatives.~If their health status is considered fragile, then individuals will be contacted by phone by the PI or one of his representatives to complete the ESOGER© questionnaire (at M0, M3 and M6)."
89560165|NCT05571267|Experimental|Zimura and Avastin|Participants receive three monthly Avastin treatments (Day 1, Month 1, and Month 2) followed by Zimura administered on the same day. All participants will receive treatment every 3 months for a total of 18 months. If there is a loss of visual acuity during the intervening visits, participants may be retreated with Avastin and Zimura.
89560166|NCT05571267|Experimental|Zimura and Lucentis|Participants receive three monthly Lucentis treatments (Day 1, Month 1, and Month 2) followed by Zimura administered on the same day. All participants will receive treatment every 3 months for a total of 18 months. If there is a loss of visual acuity during the intervening visits, participants may be retreated with Lucentis and Zimura.
89560167|NCT05571267|Experimental|Zimura and Eylea|Participants receive three monthly Eylea treatments (Day 1, Month 1, and Month 2) followed by Zimura administered on the same day. All participants will receive treatment every 3 months for a total of 18 months. If there is a loss of visual acuity during the intervening visits, participants may be retreated with Eylea and Zimura.
89560168|NCT05568264|Experimental|Physical Therapy Intervention|Infants enrolled in this arm will receive the intervention in addition to standard of care
89560169|NCT05568264|No Intervention|Standard of Care|Infants enrolled in this arm will receive standard of care
89560170|NCT05567887|Experimental|maplirpacept (PF-07901801)|maplirpacept (PF-07901801)
89560171|NCT05562570|Experimental|Physical activity intervention coupled with standard post-cancer directed treatment care group|
89560172|NCT05562570|Other|Standard post-cancer directed treatment care control group|
88966553|NCT03152188|Experimental|FMT|Fecal Microbiota Transplantation (FMT) capsules
88966554|NCT03152188|Placebo Comparator|Placebo|Placebo capsules
88966555|NCT03152149|Active Comparator|1. Spiolto Respimat|Spiolto Respimat (Tiotropium 2.5 micrograms,olodaterol 2.5 micrograms) 2 puffs once daily for 6 months
88966556|NCT03152149|Active Comparator|2. Relvar Ellipta|Relvar Ellipta (fluticasone furoate 92 micrograms, vilanterol 22 micrograms) 1 puff once per day for 6 months
88966557|NCT03152071|Experimental|Robot assisted thoracic surgery|RATS
88966558|NCT03152071|Active Comparator|Video assisted thoracic surgery|VATS
88966559|NCT04999826||Observational (questionnaire, biospecimen collection)|Participants complete questionnaires over 10 minutes and undergo blood, urine, saliva, and fecal samples collection.
88966560|NCT03152032|Experimental|In-House Vocational Training Programs|The In-House Vocational Training Programs were government-funded services offered to newly discharged inpatients or current outpatients with chronic psychiatric disorders in four regional psychiatric hospitals of Taiwan. The programs emphasized the utilization of the hospitals' existing spaces, facilities and manpower alongside the community sources to train participants in various job options including bakery training, culinary skill, barista training, computer data processing, auto wash and detailing, janitorial training, and wash and fold laundry service. Each program was staffed with occupational therapists and paid or volunteer job coaches, along with cross-disciplinary support from psychiatrists, psychologists, social workers, nurses, vocational specialists or others.
88966561|NCT03151993|Experimental|Recombinant staphylokinase|Lyophilizate for solution making for intravenous injection, 5 mg (745000 ME). 10 mg of drug reconstituted in 10 ml of 0.9% solution of NaCl given as single i.v. bolus over 5 - 10 seconds
88966562|NCT03151993|Active Comparator|Actilyse|Intravenous alteplase 0.9 mg/kg (10% bolus and 90% as IV infusion over 1 hour, maximum 90 mg)
88966563|NCT05633472|Experimental|Experimental: Treatment group|Vitamin D (2000IU/day) for 6 months
89026860|NCT01323790|Experimental|2|Oral treatment
89026861|NCT01323790|Placebo Comparator|3|Oral treatment
88966564|NCT05633472|Placebo Comparator|Placebo Comparator: Control group|placebo
88966565|NCT04996238|Other|Blood and nasal fluid sampling before and after COVID-19 vaccination|Blood and nasal fluid will be collected just before the first vaccination (T1: pre-vaccination), between 14 and 30 days after the second vaccination (T2: post-vaccination), 6 months after the second vaccination (T3: 6 months post-vaccination), between 14 and 30 days after the third/booster vaccination (T4: post-booster-vaccination) and 6 months after the third/booster vaccination (T5: 6 months post-booster-vaccination)
89026862|NCT00477035|Experimental|Autologous Cytokine-induced Killer Cells|
89560173|NCT05562193|Experimental|Physical activity intervention coupled with standard post-cancer directed treatment care group|
89560174|NCT05562193|Other|Standard post-cancer directed treatment care control group|
89560175|NCT05560646|Experimental|Group A: OG-6219 Dose 1|Group A: OG-6219 Dose 1 BID
89026863|NCT00494832|Active Comparator|Dexmedetomidine|Dexmedetomidine infusion
89560176|NCT05560646|Experimental|Group B: OG-6219 Dose 2|Group B: OG-6219 Dose 2 BID
89560177|NCT05560646|Experimental|Group C: OG-6219 Dose 3|Group C: OG-6219 Dose 3 BID
89560178|NCT05560646|Placebo Comparator|Group D: Placebo|Group D: Placebo BID
89560179|NCT05556473|Experimental|[18F]FETrp PET radiotracer|All participants will receive the tracer to evaluate the uptake of [18F]FETrp PET/CT on intra- and extracranial cancers.
89560180|NCT05553197|Experimental|Cognitive Behavior Therapy + Ecological Momentary Assessment (CBT + EMA)|Cognitive Behavior Therapy + Ecological Momentary Assessment
89560181|NCT05553197|Active Comparator|Treatment as Usual (TAU)|Cognitive Behavioural Therapy (Treatment as Usual)
89560182|NCT05549323|Experimental|Treatment Group 1|Oral PF-07054894
89560183|NCT05549323|Placebo Comparator|Treatment Group 2|Matched Placebo
89560184|NCT05542160|Placebo Comparator|Placebo|Placebo capsule
89560185|NCT05542160|Experimental|Treatment|IRK-19 capsule
89560186|NCT05540262|Experimental|Edaravone|
89560187|NCT05537688||Control group|"Participants will complete a graphic task included in a validated test for language impairment in adults and the elderly (DTLA).~They must not have a diagnosis of minor or major neurocognitive disorder."
89560188|NCT05537688||Alzheimer's Disease group|"Participants will complete a graphic task included in a validated test for language impairment in adults and the elderly (DTLA).~They must have mild stage Alzheimer's disease: 1/ Be diagnosed according to ICD-10 criteria for the following conditions: Alzheimer's disease and 2/ Have an MMSE score between 20 and 27, corresponding to a major TNC of mild stage or have a diagnosis of minor TNC with an MMSE score between 25 and 30, the validity period of a previously done MMSE is 3 months."
89560189|NCT05537688||PPA group|"Participants will complete a graphic task included in a validated test for language impairment in adults and the elderly (DTLA).~They must have Primary Progressive Aphasia according to the Gorno-Tempini criteria (Gorno-Tempini et al., 2011) and have an MMSE score between 20 and 27, corresponding to mild stage major CND or have a diagnosis of minor CND with an MMSE score between 25 and 30, the validity period of a previously made MMSE is 3 months."
89560190|NCT05521997|Active Comparator|Control Arm: Standard of Care Chemoradiation|-Participants will receive 7 weeks of standard of care chemoradiation.
89560191|NCT05521997|Experimental|Experimental Arm #1: Telaglenastat + Standard of Care Chemoradiation|-Participants will receive 2 weeks of telaglenastat and 7 weeks of standard of care chemoradiation plus telaglenastat.
89560192|NCT05521061|Experimental|1.5 g/day 2-fucosyllactose|1.5 g/day of human milk oligosaccharides will be supplemented in the first intervention group.
89560193|NCT05521061|Experimental|3 g/day 2-fucosyllactose|3 g/day of human milk oligosaccharides will be supplemented in the second intervention group.
89026864|NCT00494832|Placebo Comparator|Placebo|Normal Saline infusion
89560194|NCT05521061|Placebo Comparator|Maltodextrine|The placebo group will receive maltodextrin as a placebo at a dose with no effect on metabolic control.
88966566|NCT03151954|Experimental|nasal polyps|"Explore the degree of abnormal proliferation in NESCs,and analyze the relationship between the proliferation and the activation of hippo-YAP pathway,then explore the levels of LPS and Th2/17 cytokines in nasal polyps,and the relation between cytokines and the activation of hippo-YAP pathway through Immunohistochemistry and Immunofluorescence （P63、Ki67、YAP、LATS1/2 and MST1/2），as well as Western Blot and the Flow cytometry.~Explore if the LPS and LPS and Th2/17 cytokines, as well as the epidermal growth factors can effect the hippo-YAP pathway of NESCs through cell culture, Western Blot and Real time PCR,and test the YAP expression and location through Immunohistochemistry.~Explore that how the hippo-YAP effect the proliferation and differentiation of NESCs through cell transfection;~Explore the regulation of hippo-YAP pathway in NESCs."
88966567|NCT03151954|Placebo Comparator|inferior turbinate|Compared with nasal polyps,explore the levels of LPS and Th2/17 cytokines in nasal polyps,and the relation between cytokines and the activation of hippo-YAP pathway through Immunohistochemistry and Immunofluorescence（P63、Ki67、YAP、LATS1/2 and MST1/2），as well as Western Blot and the Flow cytometry.
88966568|NCT03151915||Patients who underwent fetoscopic laser coagulation with TTTS|This is an retrospektive trial. We use data of patients who underwent fetoscopic laser coagulation with TTTS retrospectively. All patients meet eligibility criteria and give written informed consent before therapy. As part of the ongoing quality control we were able to safely store patient data relating to fetoscopic laser coagulation with TTTS.
89608763|NCT03589131|Active Comparator|Robotic-assisted Surgery Group|In this arm the investigators use a robotic system to perform resection of the rectum harboring the tumor trying to do that while being oncologically safe. The robotic system that we use is the da Vinci Si (Intuitive Surgical, Inc.,Sunnyvale,CA) Interventions used are total operative time, margin assessment, conversion rate to open surgery, baseline demographics, preoperative data and postoperative data
89608764|NCT03589131|Active Comparator|Laparoscopic Surgery Group|"In this arm the investigators use a Laparoscopy system to perform resection of the rectum harboring the tumor trying to do that while being oncologically safe.~Interventions used are total operative time, margin assessment, conversion rate to open surgery, baseline demographics, preoperative data and postoperative data"
89560195|NCT05515536|Experimental|Vatiquinone|Participants with FA who were previously treated with vatiquinone at an investigational site and completed participation in a prior PTC Therapeutics (PTC)-sponsored clinical study (PTC743-NEU-003-FA or PTC743-NEU-005-FA) will continue to receive the same dose/formulation of vatiquinone (unless there has been a change in age and/or weight that meets the criteria for a different dose/formulation as described below; dose/formulation will also be changed if participants meet the criteria for a different dose/formulation during study treatment): If <7 years of age, participants will receive an oral solution (100 milligrams [mg]/milliliter [mL]) 3 times a day (TID) at one of the following doses: 15 mg/kilogram (kg) if body weight <13 kg, or 200 mg if body weight ≥13 kg. If ≥7 years of age, participants will receive a capsule formulation (200 mg) orally TID at one of the following doses: 200 mg if body weight ˂25 kg, or 400 mg if body weight ≥25 kg.
89560196|NCT05512169||Newly diagnosed ALL Children with age group of >1 and ≤18 years old|Newly diagnosed ALL Children who are likely to receive anti-cancer drugs or chemotherapy as a part of IciCLE treatment protocol.
89560197|NCT05497284|Experimental|LTP001|Participants will receive LTP001 orally once daily in the morning for approximately 26 weeks
89560198|NCT05497284|Experimental|Placebo|Participants will receive LTP001 placebo capsules matching LTP001 orally once daily in the morning for approximately 26 weeks
89560199|NCT05494866|Experimental|Arm 1|CYP3A Inhibitor Cobicistat and the cytostatics Gemcitabine and nab-Paclitaxel
89560200|NCT05492448|Placebo Comparator|Placebo|
89560201|NCT05492448|Experimental|L. salivarius AP-32 and L. reuteri GL-104|
89560202|NCT05492448|Experimental|L. reuteri GL-104|
89560203|NCT05487001|Experimental|dexamethasone group|a iliopsoas plane block before surgery
89560204|NCT05487001|Sham Comparator|sham group|sham block before surgery
89560205|NCT05484661|Experimental|Exercise + BCAA|Exercise will include a 3x/wk for eight weeks exercise protocol is designed to provide a high-volume, moderate-intensity whole body training stimulus. BCAA will include ~7-10 g of BCAAs (100 mg/kg) daily for eight weeks.
89560206|NCT05484661|Placebo Comparator|Exercise + Placebo|Exercise will include a 3x/wk for eight weeks exercise protocol is designed to provide a high-volume, moderate-intensity whole body training stimulus. Placebo will include ~7-10 g of maltodextrin (100 mg/kg) daily for eight weeks.
89560207|NCT05478252|Experimental|Semaglutide J|Participants will initially receive 0.25 milligrams (mg) subcutaneous injections of semaglutide J once weekly (OW) and the dose will be then escalated once in 4 weeks for 8 weeks until the target maintenance dose of 1.0 mg is reached which will be maintained for a period of 20 weeks. Metformin will be considered as background therapy during the trial.
89560208|NCT05478252|Active Comparator|Semaglutide B|Participants will initially receive 0.25 mg subcutaneous injections of semaglutide B OW and the dose will be then escalated once in 4 weeks for 8 weeks until the target maintenance dose of 1.0 mg is reached which will be maintained for a period of 20 weeks. Metformin will be considered as background therapy during the trial.
89560209|NCT05473182|Other|Single arm: All participants receive the intervention|All participants receive power wheelchair skills training using the IndieTrainer system.
89560210|NCT05466877|Experimental|MG-K10 Regimen 1|subcutaneous injection every 4 weeks (placebo injections at 2, 6, 10, 14 weeks to maintain blindness)
89560211|NCT05466877|Experimental|MG-K10 Regimen 2|subcutaneous injection every 2 weeks
89560212|NCT05466877|Experimental|MG-K10 Regimen 3|subcutaneous injection every 4 weeks (placebo injections at 2, 6, 10, 14 weeks to maintain blindness)
89560213|NCT05466877|Placebo Comparator|Placebo|subcutaneous injection every 2 weeks
89560214|NCT05464082|Experimental|Treatment: All Patients|"Patient derived xenografts (PDX) are grown in mice. Organoids may generated from patient tumor(PDO) and PDX(PDxO). Organoids will be used for drug profiling. PDX, organoid establishment and drug profiling will occur while patient is undergoing preoperative chemo, surgery, radiation, and may extend into disease-free interval. Patients receive first line therapy in the metastatic setting per SOC or in separate clinical trial. Results of PDM drug profiling, tumor genomic, and circulating tumor DNA results will be returned to treating physician to inform 2nd line therapy. At progression on the first line therapy, the patient will begin new therapy as directed by the treating physician. Any subsequent therapy (aligned or unaligned with report recommendations) that a patient starts after the return of results will be deemed informed."
89560215|NCT05464082|No Intervention|Physician Questionnaire|"Prior to the return of results, treating physicians will be asked to complete the PRE-Information Provider Survey on Functional Precision Oncology. After review of the FPO results, treating physicians will be asked to complete the POST-Information Provider Survey on Functional Precision Oncology to assess the potential effect that the FPO results have on the selection of therapy. These surveys will be administered to assess the impact the results have on the selection of therapy.~Physicians are not mandated to select the treatment recommended by the FPO data since the FPO results are not from a CLIA certified laboratory. Information regarding whether the physician chose to switch to the recommended drug or not for the next line of therapy and patient outcomes (progression-free survival) according to treatment selection (treatment selected aligned with FPO recommendation vs. not) will be captured."
89560216|NCT05457634|Experimental|blu Disposable Flavor A|
89560217|NCT05457634|Experimental|blu Disposable Flavor B|
88966569|NCT03151876|Experimental|ChiCGB|"Experimental: ChiCGB~Chidamide administered orally on D-7, -4, 0,+3~Cladribine administered at 10mg on D-6 to D-2~Gemcitabine administered at 2500 mg/m2 on days -6 and -2.~Busulfan administered at 3.2 mg/kg (adjusted ideal body weight) on days -6 to -3.~Dexamethasone 10 mg by vein daily from day -6 to day -1. Caphosol oral rinses 30 mL four times a day used from day -8.~Interventions:~Drug: Chidamide Drug: Cladribine Drug: Gemcitabine Drug: Busulfan Drug: Dexamethasone Procedure: Stem Cell Transplant"
88966570|NCT04984655|Other|30-minute Virtual Reality (VR) Experience delivered through Oculus Quest 2 VR headset|
88966571|NCT03151837|Experimental|Momordica charantia|Subjects will take the capsule of Greenyn Momordica charantia extracts 600 mg/day orally for three months.
88966572|NCT03151837|Placebo Comparator|Placebo control|Subjects will take the capsule of Placebo 600 mg/day orally for three months.
88966573|NCT03151759||No radiotherapy|Surgery only
88966574|NCT03151759||25 Gray radiotherapy|Surgery after short term radiotherapy
88966575|NCT03151759||50 Gray radiotherapy|Surgery after long term radiotherapy
89026865|NCT01323673|Active Comparator|Clobetasol Propionate 0.05%|
89560218|NCT05457634|Experimental|blu Disposable Flavor C|
89560219|NCT05457634|Experimental|blu Disposable Flavor D|
89560220|NCT05457634|Experimental|blu Disposable Flavor E|
89560221|NCT05457634|Active Comparator|Combustible cigarette|
89560222|NCT05454137|Experimental|participate in shared medical appointment|The POTS shared medical appointment will occur once monthly for four months. Each visit will last 1.5 hours. The group will meet in our clinic group space and lifestyle management therapies will be taught by a physician and another provider ie occupational therapist, dietician etc
89560223|NCT05454137|No Intervention|Do not participate in shared medical appointment|participants will only have one-on-one traditional visit with the physician
89560224|NCT05454124|Experimental|Training visual sensitivity|A standard Perceptual Learning approach to train early visual processes of discriminating the orientation of Gabor patches presented at threshold- level contrast. Preliminary data, using this method, in normally seeing and MD participants show both feasibility and preliminary evidence that this training gives rise to improvements in acuity.
89560225|NCT05454124|Experimental|Combination training|In combination training, investigators test the extent to which a combined training gives rise to the joint benefits of each training individually, or integrative benefits potentially surpassing benefits of the individual training alone. The visual sensitivity task will alternate across blocks with the spatial integration task, using the timing of targets and location switches from spatial attention training.
89560226|NCT05447403|Experimental|Chewing gum combined with WeChat enhanced instructions group|Patients in the chewing gum and WeChat group are advised to chew one piece of sugarless gum for 20 minutes after drinking each 1 liter PEG. They also receive enhanced instructions via WeChat before two days and one day of colonoscopy to further inform how to chew gum and highlight the importance of adequate bowel preparation.
89560227|NCT05447403|No Intervention|Control group|Patients in the control group are guided by regular instructions.
89560228|NCT05446675||eTEP|First 30 participants who meet the inclusion criteria and do not exhibit any of the exclusion criteria will be investigated. The option for endoscopic eTEP repair, if feasible, is given preoperatively as a standard for the treatment of symptomatic midline abdominal wall hernias with concomitant rectus abdominis diastasis as an alternative to open Rives-Stoppa mesh repair. The modality of operative treatment is made in cooperation with the participant.
89560229|NCT05446675||Rives-Stoppa, control|Thirty participants will be selected out of all patients who underwent an open Rives-Stoppa (midline repair with sublay mesh) in the investigators' center and who do not meet any of the exclusion criteria. Participant selection will consist of matching to participants in group 1 according to gender and age (e.g. a male participant in group 1 will be matched to a male participant (group 2) out of the investigators' records who underwent an open Rives-Stoppa repair and whose age most closely resembles the age of the matched participant in group 1).
89560230|NCT05446142|Experimental|Four Period Treatment Sequence: PPI Effect|Participants will receive a single encorafenib dose formulation, a single encorafenib dose of the formulated capsule (CAP), and a single encorafenib dose of the formulation after administration of 20 mg rabeprazole every evening for 5 days.
89560231|NCT05446142|Experimental|Four Period Treatment Sequence: PPI Effect Second Formulation|Participants will receive a single encorafenib dose of the second formulation, a single encorafenib dose of the second formulation, a single encorafenib dose of the formulated capsule (CAP), and a single encorafenib dose of the second formulation after administration of 20 mg rabeprazole every evening for 5 days.
89560232|NCT05445453|Experimental|Intervention|"Physicians participating in the research project will be able to prescribe a visit to the Museum to any of their patients for whom they deem this museum prescription necessary. Only patients who meet the inclusion criteria will be offered to participate in the research.~If patients refuse or do not meet the inclusion criteria, they may be prescribed a museum visit but will not be offered the study.~After obtaining informed consent, the patient will be asked to complete 2 sets of self-administered questionnaires: in the 2 days prior to the visit and in the 2 days following the MBAM visit."
89560233|NCT05444907||DBS-induced Mania Cohort|Patients diagnosed with Parkinson's Disease (PD) who were submitted to deep brain stimulation (DBS) surgery irrespective of its target and who developed a manic episode or mixed affective state diagnosed after surgery and associated to DBS modulation, i.e., after switching on the device or changing modulation parameters.
89560234|NCT05444907||DBS Control Cohort|Patients diagnosed with PD who were submitted to DBS surgery irrespective of its target and who did not develop DBS-induced mania.
89560235|NCT05441969||Current major depressive episode group|Adult individuals (18-65 yrs) diagnosed with current major depressive episode (MDE), under treatment or medication naif, starting a new antidperessant strategy (n≈30).
89560236|NCT05441969||Maintenance antidepressant treatment group|Adult individuals (18-65 yrs) previously diagnosed with major depressive episode (MDE) currently remitted under continuation or maintenance antidepressant treatment (n≈30).
89560237|NCT05441969||Healthy subjects group|Adult individuals (18-65 yrs) without current diagnosis of major neuropsychiatric disorders, inlcluding MDE, hence not under any antidepressant medication. The same exclusion criteria will be applied as in the two clincial groups.
89560238|NCT05439954||Case group|（a）patients fulfilling the Diagnostic Criteria of the Diagnostic and Statistical Manual of Mental Disorders 5th Edition（DSM-V); (b)age:14 and under 14 years old; (c)first clinic visit, never-treated; (d)without injury to head and other diseases of the nervous system.
89560239|NCT05439954||Control Group|（a）healthy subject of same ages;(b)without injury to head and diseases of the nervous system; (c)without family history of mental disorders; (d)without other somatic illness.
88811894|NCT01390259|Experimental|Closed Loop Control (CLC)|"The CLC used a computer to make recommendations for their insulin treatment. This study arm was designed to demonstrate management of glucose using a modular insulin management system based on continuous glucose monitoring and targeted towards the avoidance of hypoglycemic and prolonged hyperglycemic episodes (i.e. control to range). This system was designed to both:~monitor the meal boluses of the patient and correct it in case of observed/predicted under insulinization (avoidance of prolonged hyperglycemia), based on a coarse and subjective knowledge of the meal amount, a precise understanding of the subject's day to day insulin treatment, continuous glucose monitoring, and past insulin injections;~predict and avoid hypoglycemic events, based on continuous glucose reading and past insulin injection."
89026866|NCT01323673|Placebo Comparator|Vehicle|
89026867|NCT00494949|Experimental|Hemospan (MP4OX)|4.3 g/dL MalPEG-Hb solution
89560240|NCT05439759|Experimental|Condition 1: Training visual sensitivity|A standard Perceptual Learning approach to train early visual processes of discriminating the orientation of Gabor patches presented at threshold- level contrast. Preliminary data, using this method, in normally seeing and MD participants show both feasibility and preliminary evidence that this training gives rise to improvements in acuity.
89560241|NCT05439759|Experimental|Condition 2: Training spatial integration|Most visual tasks involve integrating features to discriminate objects, therefore requiring brain areas that can integrate features from multiple receptive fields from early visual areas. Thus spatial integration involves what investigators refer to as mid-level vision. Spatial integration is a particular concern in developing a PRL since an area of the visual periphery that is best suited to discriminate a simple visual feature may not be appropriate to integrate information across objects, such as in reading or recognizing facial identity or expression. Investigators address this issue with a targeted spatial integration training approach developed by MPI Seitz and based on contour integration tasks used in previous PL studies to train mid-level visual processes. Target stimuli consist of contours formed by spaced Gabors. Difficulty of detecting the target is manipulated by varying orientation jitter of Gabors making up the target.
89560242|NCT05439759|Experimental|Condition 3: Training spatial attention|A key attribute of most real-world visual tasks is that individuals alternate shifting and holding attention and eye movements to different objects in the visual field while searching for and discriminating possible sources of visual information. To train this, investigators will implement a task structure that requires participants to alternate between holding and switching attention and making targeted eye movements. The basic task is to press a key whenever a red circle appears in a series of other colored circles, with a target presented every 2 to 4s. Participants must maintain vigilance for relatively long periods, detect objects in the near periphery, switch attention based upon exogenous and endogenous cues, and make eye- movements to move areas of spared vision to those locations. These are aspects of attention and eye movements not incorporated in Conditions 1 and 2.
89560243|NCT05439759|Experimental|Condition 4: Combination training|In Condition 4, investigators combine the elements of Conditions 1-3. The investigators test the extent to which a combined training gives rise to the joint benefits of each training individually, or integrative benefits potentially surpass the benefits of the individual training alone. The visual sensitivity task from Condition 1 will alternate across blocks with the spatial integration task from Condition 2, using the timing of targets and location switches from Condition 3; Gabors or contours are used as targets instead of the red- circle in Condition 3 and a fixation point is presented instead of distractors to maintain a similar stimulus configuration as Conditions 1 and 2.
89560244|NCT05436418|No Intervention|Donors (Haplo HCT)|Research on collected samples
89560245|NCT05436418|No Intervention|Donors (Matched HCT)|Research on collected samples
89560246|NCT05436418|Experimental|Phase I Dose De-escalation (Haplo HCT)|PTCy at de-escalating doses to assess for safety and determine Phase II dose
89560247|NCT05436418|Experimental|Phase I Dose De-escalation (Matched HCT)|PTCy at de-escalating doses to assess for safety and determine Phase II dose
89560248|NCT05436418|Experimental|Phase I Pilot for Comparative Data (Haplo HCT)|Standard PTCy 50 mg/kgday on days +3 and +4
89560249|NCT05436418|Experimental|Phase I Pilot for Comparative Data (Matched HCT)|Standard PTCy 50 mg/kg/day on days +3 and +4
89560250|NCT05436418|Experimental|Phase II Efficacy (Haplo HCT)|PTCy at shortest duration, safe dose (from Phase I)
89560251|NCT05436418|Experimental|Phase II Efficacy (Matched HCT)|PTCy at shortest duration, safe dose (from Phase I)
89560252|NCT05415072|Experimental|Phase I: Dose Escalation|Patients with metastatic uveal melanoma or other GNAQ/11 mutant melanomas
89560253|NCT05415072|Experimental|Phase II: Tebe naive group|Patients with metastatic uveal melanoma that has not received prior treatment with tebentafusp
89560254|NCT05415072|Experimental|Phase II: Tebe pre-treated|Patients with metastatic uveal melanoma that have been previously treated with tebentafusp
89560255|NCT05415072|Experimental|Phase II: Non-uveal melanoma|Optional Arm: To explore patients with non-uveal melanoma that harbor GNAQ or 11 mutations, based on emerging data from dose escalation
89560256|NCT05415007|Experimental|GOLD Psychosocial Program|Participant will receive a 2-hour interventional session. Its content will consist of two modules: (1) psychoeducation and coping, providing information in content areas such as side effects of cancer treatments, fever protocols, role disruption and (2) stress, triggers, and self care, where caregivers will be briefed on symptoms of and reactions to traumatic stress in order to help parents accurately label thoughts and emotions related to their child's cancer diagnosis.
88811895|NCT01390259|Placebo Comparator|Open Loop|The subject were in charge of their insulin treatment.
88811896|NCT04091516|Other|Low-fat plant-based diet|For 12 weeks, participants will follow a diet comprised of whole grains, vegetables, legumes, and fruits, with no restriction on energy intake. Animal products and added oils will be excluded. Except for light refreshments and tastings at the group sessions, no meals will be provided. Participants will handle their own food preparation and purchases, with guidance from the education team, with no restriction on energy intake.
88811897|NCT01391273|Experimental|bimatoprost solution 0.03%|One drop of bimatoprost solution 0.03% applied along each upper eyelid margin once daily in the evening for 4 months.
88811898|NCT01391273|Placebo Comparator|bimatoprost vehicle solution|One drop of bimatoprost vehicle solution applied along each upper eyelid margin once daily in the evening for 4 months.
88811899|NCT05235230|Experimental|Test product (T) 25 mg Film Coated Tablets|Single oral dose of 25 mg tablet
88811900|NCT05235230|Active Comparator|Reference product (R) 25 mg Film Coated Tablets (first dose)|Single oral dose of 25 mg tablet
88811901|NCT05235230|Active Comparator|Reference product (R) 25 mg Film Coated Tablets (second dose)|Single oral dose of 25 mg tablet
88811902|NCT01429259|Experimental|Meropenem 3 hour prolonged infusion|All 30 participants will receive meropenem as a 3 hour infusion.
88811903|NCT05177198|Experimental|Test group (M-MIST + Clindamycin augmented PRF)|Patients will be selected with probing pocket depth PD ≥ 5 mm and clinical attachment level (CAL) ≥ 5 mm, with vertical defects as detected in periapical radiographs will be treated with modified minimally invasive surgical technique with Clindamycin (at concentration of 150 mg/ml) augmented platelet-rich fibrin.
89560257|NCT05415007|Active Comparator|Treatment-as-Usual (TAU)|
89560258|NCT05413629|No Intervention|Group1 (n=33)|Control 1: Pretest negative and post test positive group
89560259|NCT05413629|No Intervention|Group 2 (n=33)|Control 2: Pretest positive and post test positive
89560260|NCT05413629|Experimental|Group 3 (n=33)|Experimental 1: Pretest negative and post test positive
89560261|NCT05413629|Experimental|Group 4 ( n=33)|Experimental 2: Pretest positive and post test positive
89560262|NCT05404854||chronic low back pain patients|Physical Activity by wearing an accelerometer for 7 days before and after the rehabilitation program sedentarity by wearing an accelerometer for 7 days before and after the rehabilitation program Measurement of explicit motivation Measurement of implicit attitudes
89560263|NCT05394155|Experimental|Leucine intake|For this study, each participant will be randomly assigned to receive up to 7 intake levels of leucine, ranging from 10 to 75 mg/kg/d.
89560264|NCT05385237|Experimental|4D-MRI assessment for patients with liver diseases|patients with chronic liver diseases, acute liver inflammation or cardiac blood congestion to the liver will be assessed by MRI
89026868|NCT00494949|Active Comparator|Control|Ringer's lactate
89026869|NCT01246752|Experimental|Human Stem Cell Transplantation|Patients receive an allogenic stem cell transplantation from an HLA-matched unrelated or related donor
89560265|NCT05385237|Experimental|4D-MRI assessment for healthy volunteers (control group)|healthy control subjects will be assessed by MRI
89560266|NCT05384496|Experimental|Axitinib and Nivolumab for the Treatment of Mucosal Melanoma|This is a single center trial enrolling up to 20 total evaluable patients with unresectable primary or advanced mucosal melanomas arising from the head and neck, gastrointestinal, or genitourinary tract to receive frontline therapy with nivolumab IV 480mg q4 weeks plus axitinib 5mg PO twice daily. A Simon 2-stage design will be utilized. Upon progression with good tolerance, addition of stereotactive body radiation therapy (SBRT) or CTLA-4 blockade to continued nivolumab plus axitinib will be offered to patients depending on the type of progression. For patients with local or oligometastatic progression, stereotactic body radiotherapy (SBRT) will be added; for patients with progression in a site of prior radiotherapy or with multifocal or distant progression not amenable to SBRT, ipilimumab 1mg/kg IV q3 weeks for up to 4 doses will be added.
89560267|NCT05379985|Experimental|Experimental: RMC-6236|"Enrollment into dose exploration may be from any advanced solid tumor type with KRAS p.G12 mutations.~Enrollment into dose expansion/optimization may be from groups consisting of patients with a single histotype/genotype (for example, KRAS G12-mutated NSCLC, PDAC, CRC, RAS mutant NSCLC, PDAC, CRC, Melanoma, gynecological cancer or other solid tumors not previously specified).~RAS mutant is defined as any nonsynonymous mutation of KRAS, NRAS, or HRAS at codons 12, 13, or 61 (G12, G13, or Q61)"
89560268|NCT05371028||Participants With SBS-IF|Participants with SBS-IF who as part of standard or routine clinical practice, must have received teduglutide (Revestive®) treatment and were dependent on parenteral support prior to teduglutide treatment initiation will be observed in this retrospective observational study for up to 48 months.
89560269|NCT05370274|Experimental|strength training intervention|Strength training of the affected upper limb in chronic stroke survivors
89560270|NCT05370274|Experimental|Cranial nerve non-invasive neuromodulation (CN-NINM)|CN-NINM will be applied during each session of the strength training intervention
89560271|NCT05366790|Experimental|CEASE Intervention arm|"The CEASE and CEASE-A interventions are tobacco and vaping cessation interventions delivered in pediatric practices, leveraging existing healthcare and community resources. They integrate evidence-based tobacco use screening and cessation assistance into routine visits to pediatric clinics. CEASE and CEASE-A are based on the 5A's model of smoking cessation: Ask about smoking, Advise to quit, Assess readiness to quit, Assist with a quit plan and Arrange follow-up. Given that CEASE and CEASE-A are one-time interventions, Arrange is removed, and the fourth step Assist is divided into two parts: a) providing phone/text/app quit support and b) providing NRT.~CEASE-A follows the same format at CEASE, but is modified slightly to address smoking and vaping in the adolescent target population"
89560272|NCT05366790|No Intervention|Control: Usual care condition|The control condition will be care as is usually delivered in participating clinics with the possibility of receiving direct linkage with cessation services delivered via CEASE/CEASE-A at the end of the 6-month study period. Current practice does not include routine provision of assistance for parental/adolescent smoking or e-cigarette cessation (e.g., referral to quitlines, NRT prescription).
89560273|NCT05357898|Experimental|Part 1A Monotherapy Dose Escalation Phase|"In Part 1A, SQZ-eAPC-HPV as a monotherapy is administered every 3 weeks for up to a year.~There are 3 groups (Cohorts) in this Phase as follows:~Cohort 1: low dose SQZ-eAPC-HPV~Cohort 2: intermediate dose SQZ-eAPC-HPV~Cohort 3: high dose SQZ-eAPC-HPV~Additional provisional cohorts may be opened prior to starting Part 1B."
89560274|NCT05357898|Experimental|Part 1B Combination Phase|In Part 1B, SQZ-eAPC-HPV is administered in combination with immune checkpoint inhibitor pembrolizumab. SQZ-eAPC-HPV will be administered on Day 1 of Cycle 1 and 200 mg of pembrolizumab will be administered on Day 8 of Cycle 1. In future cycles, patients will be first administered SQZ-eAPC-HPV and then pembrolizumab on the first day of each cycle, every 3 weeks for a maximum of 1 year for SQZ-eAPC-HPV, and 2 years for pembrolizumab.
89560275|NCT05357898|Experimental|Part 2 Lead-in Combination Phase|In Part 2, SQZ-eAPC-HPV will be administered on Day 1 of each treatment cycle. Treatment with 200 mg of pembrolizumab will begin in Cycle 3. Starting at Cycle 3, patients will be administered SQZ-eAPC-HPV and then pembrolizumab every 3 weeks for a maximum of 1 year for SQZ-eAPC-HPV, and 2 years for pembrolizumab.
89560276|NCT05350748||Cohort 1|Participants with myelodysplastic syndromes and associated malignancies
89560277|NCT05350748||Cohort 2|Participants (controls) without MDS or associated malignancies, contributing bone marrow
89560278|NCT05346198|Experimental|Subjects will receive CART-BCMA|"Biological: CART-BCMA Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) to produce CART-BCMA.~During CART-BCMA production, subjects may receive bridging chemotherapy for disease control. Upon successful generation of CART-BCMA product, subjects will receive treatment with CART-BCMA therapy.~Study treatment will include lymphodepleting chemotherapy followed by one dose of CART-BCMA administered by intravenous (IV) injection."
89560279|NCT05345938|Experimental|Mitoxantrone Hydrochloride Liposome Injection|"Stage 1: Subjects with R/R AML will receive one of three dose-escalation (30 mg/m^2, 36 mg/m^2, 40 mg/m^2) Mitoxantrone Hydrochloride Liposome, IV, on day 1 of each 28-day cycle (q4w).~Stage 2: Subjects with R/R AML or unfit AML will receive one dose Mitoxantrone Hydrochloride Liposome every 28 days (a cycle) for a maximum of 6 cycles."
89560280|NCT05341128||Pediatric Participants With CPP|Pediatric participants who have been diagnosed with CPP per criteria set in the 2015 version of The Consensus on the Diagnosis and Treatment of Central Precocious Puberty and have received treatment or medical services in China between 07 August 2015 and 31 December 2024 will be assessed retrospectively using the Chinese CPP Big Data Platform database.
89560281|NCT05328180|Other|Non-buffered local anaesthetic|The investigators allocate 58 patients in this arm. It serves as the control group, who receives currently used local anaesthetic solution.
89560282|NCT05328180|Experimental|Buffered local anaesthetic|The investigators allocate 58 patients in this arm. It serves as the experimental group, who receives currently used anaesthetic solution that has been buffered.
89560283|NCT05321095||Screening|Only one group will be evaluated during the SALINE study. Everyone that meets the inclusion criteria of having a high risk for albuminuria is invited to participate. During participation, subjects are asked to collect one or more urine samples for albuminuria determination. If albuminuria is high (>= 3,0 mg/mmol) subjects are invited for a visit. During the visit non-invasive measurements (BMI, PoC HbA1c, eGFR, blood pressure and heart rate) are taken to determine the cardiovascular risk. Furthermore, medication use is reviewed.
89560284|NCT05305365|Experimental|Patients with Breast Cancer Parenchymal brain metastasis (Cohort 1)|All participants in Cohort 1 will receive QBS72S IV injections once monthly until disease progression.
89560285|NCT05305365|Experimental|Patients with Breast Cancer Leptomeningeal Disease (Cohort 2)|All participants in Cohort 2 will receive QBS72S IV injections once monthly until disease progression.
89560286|NCT05305365|Experimental|Patients with any Primary Cancer Leptomeningeal Disease (Cohort 3)|All participants in Cohort 3 will receive QBS72S IV injections once monthly until disease progression.
89560287|NCT05304936|Experimental|HCW9218|Experimental Arm: HCW9218
89560288|NCT05293808|Experimental|aspirin 100 mg bis in die|aspirin 100 mg twice daily for the first month after acute coronary syndrome
89560289|NCT05293808|Active Comparator|aspirin 200 mg|aspirin 200 mg once daily for the first month after acute coronary syndrome
89560290|NCT05293808|Active Comparator|aspririn 100 mg|aspirin 100 mg once daily
89560291|NCT05290129|Experimental|Oxytocin infusion rate 4 IU/h|The maintenance infusion rate of oxytocin will be 4 IU/h.
89560292|NCT05290129|Experimental|Oxytocin infusion rate 6 IU/h|The maintenance infusion rate of oxytocin will be 6 IU/h.
89560293|NCT05290129|Experimental|Oxytocin infusion rate 8 IU/h|The maintenance infusion rate of oxytocin will be 8 IU/h.
89560294|NCT05290129|Experimental|Oxytocin infusion rate 10 IU/h|The maintenance infusion rate of oxytocin will be 10 IU/h.
89560295|NCT05290129|Experimental|Oxytocin infusion rate 12 IU/h|The maintenance infusion rate of oxytocin will be 12 IU/h.
89560296|NCT05290129|Experimental|Oxytocin infusion rate 14 IU/h|The maintenance infusion rate of oxytocin will be 14 IU/h.
89560297|NCT05290129|Experimental|Oxytocin infusion rate 16 IU/h|The maintenance infusion rate of oxytocin will be 16 IU/h.
89560298|NCT05289167|Experimental|Participants with hematological malignancies|Participants undergoing Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) will receive a combination of cyclophosphamide, known commercially as Cytoxan®, abatacept, known as Orecia® and bortezomib commercially known as Velcade®, to reduce the rate of graft-versus-host disease (GvHD). These medications will be given for GvHD prevention during the transplant process.
89560299|NCT05287113|Experimental|Treatment Group 1: Retifanlimab Monotherapy|Retifanlimab will be administered intravenously every 4 weeks. Placebos for INCAGN02385 and INCAGN02390 will be administered intravenously every 2 weeks.
89560300|NCT05287113|Experimental|Treatment Group 2: Retifanlimab + INCAGN02385|Retifanlimab will be administered intravenously every 4 weeks. INCAGN02385 and Placebo for INCAGN02390 will be administered intravenously every 2 weeks.
89560301|NCT05287113|Experimental|Treatment Group 3: Retifanlimab + INCAGN02385 + INCAGN02390|Retifanlimab plus INCAGN02385 and INCAGN02390 will be administered intravenously. Retifanlimab will be administered intravenously every 4 weeks. INCAGN02385 and INCAGN02390 will be administered every 2 weeks.
89026870|NCT01246752|Active Comparator|Consolidating Chemotherapy|Patients receive a standard chemotherapy as consolidation therapy
89026871|NCT01323634|Experimental|Fluticasone Furoate / GW642444 (vilanterol)|Inhaled Corticosteroid (ICS)/ Long acting Beta Agonist (LABA)
89026872|NCT01323634|Active Comparator|Fluticasone Propionate / salmeterol|Inhaled Corticosteroid (ICS)/ Long acting Beta Agonist (LABA)
89026873|NCT05645302||Patients using Lidocaine Cataplasms|
89026874|NCT01323478|Experimental|Vortioxetine|
88811904|NCT05177198|Experimental|Control group (M-MIST + PRF)|Patients will be selected with probing pocket depth PD ≥ 5 mm and clinical attachment level (CAL) ≥ 5 mm, with vertical defects as detected in periapical radiographs will be treated with modified minimally invasive surgical technique with platelet-rich fibrin alone .
89026875|NCT04325581|Experimental|Post LSG with Liraglutude|Liraglutide in incremental dose upto maximum of 1.8 mg per day subcutaneously once a day.
89026876|NCT04325581|Placebo Comparator|Post LSG without Liraglutide|Normal Saline in equivalent per day subcutaneously once a day
89026877|NCT02956161|Experimental|Up phase stimulation|Auditory stimulations are delivered in synchrony with the up phase of slow oscillations during N3 sleep stage.
89026878|NCT02956161|Experimental|Random phase stimulation|Auditory stimulations are randomly delivered during N3 sleep stage.
89026879|NCT02956161|Sham Comparator|No stimulation|The device is worn without any auditory stimulations delivered.
89208470|NCT01565278|Active Comparator|Soybean oil (Standard treatment)|Standard treatment: Intralipid (0.25 g/kg/TPN day) for a period of 6 months
89208471|NCT02596295||Mothers for term infants|Lactating mothers
89208472|NCT02596295||Mothers for preterm infants|Lactating mothers
89560302|NCT05287087|Active Comparator|My Symptoms 1 (MySt-1)|"GPs will receive an introduction to the overall content of the eHealth programme MySt-1. The information will be given to participating GPs and their staff during a 1½-hour session in the practice. The research assistant will go through the logistics of the patient recruitment and evaluation step-by-step and GPs and relevant staff will subsequently have access to the programme.~The patients will get access to a basic eHealth programme (My Symptoms 1). The programme is an internet-delivered self-help programme supporting patients' selfefficacy and behavioural changes. The programme is activated by the patient after prescription by the GP."
89560303|NCT05287087|Experimental|My Symptoms 2 (MySt-2)|"GPs will attend a one-day training course of 7 hours including: in depth insight into the My Symptoms 2 eHealth programme, comprehensive understanding of PPS, training of communication skills and the use of contextual (non-specific/common psychological) factors. The training programme has been developed in cooperation with the national GP association offering CME (PLO-e). Lecturers and trainers will be GPs and psychologists from the research team.~The patients will get access to an advanced eHealth programme (My Symptoms 2). The programme is an internet-delivered self-help programme supporting patients' selfefficacy and behavioural changes. The programme is activated by the patient after prescription by the GP."
89560304|NCT05286047|Experimental|Bifidobacterium longum CCFM1029|
89560305|NCT05286047|Placebo Comparator|Placebo|
89560306|NCT05282732||aHD: Acute haemodialysis patients|
89560307|NCT05282732||cHD: Chronic haemodialysis patients|
88966576|NCT03151720|Experimental|Cohort 1: Sequence 1 (ABAB)|Participants will receive 10 milligram (mg) loratadine (1*10 mg oral tablet) as Xisimin (Treatment A) on Day 1 of Period 1 and Period 3 and 10 mg loratadine (1*10 mg oral tablet) administered as Clarityne (Treatment B) on Day 1 of Period 2 and Period 4 under fasted condition. A washout period of at least 7 days will be maintained between each treatment administration.
88966577|NCT03151720|Experimental|Cohort 1: Sequence 2 (BABA)|Participants will receive Treatment B on Day 1 of Period 1 and Period 3 and Treatment A on Day 1 of Period 2 and Period 4 under fasted condition. A washout period of at least 7 days will be maintained between each treatment administration.
88966578|NCT03151720|Experimental|Cohort 2: Sequence 1 (ABAB)|Participants will receive Treatment A on Day 1 of Period 1 and Period 3 and Treatment B on Day 1 of Period 2 and Period 4 under fed condition. A washout period of at least 7 days will be maintained between each treatment administration.
88966579|NCT03151720|Experimental|Cohort 2: Sequence 1 (BABA)|Participants will receive Treatment B on Day 1 of Period 1 and Period 3 and Treatment A on Day 1 of Period 2 and Period 4 under fed condition. A washout period of at least 7 days will be maintained between each treatment administration.
88966580|NCT03151603|Experimental|Uva Ursi|"placebo to fosfomycin: 3 g granules orally 1x1 (day 0)~and~Uva Ursi: 105 mg (Arctuvan®) 3x2 tablets orally from day 0 for 5 days"
88966581|NCT03151603|Active Comparator|fosfomycin|"fosfomycin (Monuril®): 3 g granules orally 1x1 (day 0),~and~placebo to Uva Ursi: 3x2 tablets orally from day 0 for 5 days~If the patient returns with persistent/recurrent symptoms, antibiotic therapy according to the sensitivity test."
88966582|NCT03151525|Experimental|Azathioprine|Azathioprine 2-2.5 mg/kg/day, according to approved indication
88966583|NCT03151525|Active Comparator|Infliximab|Infliximab 5 mg/kg every 8 weeks
88966584|NCT03151486|Experimental|Cohort 1:JNJ-55308942 0.5 mg or Placebo (SAD Part)|Participants will be randomized to receive a single dose of JNJ-55308942 0.5 milligrams (mg) or matching placebo as an oral solution after an overnight fast on Day 1 of Cohort 1 after single ascending dose (SAD).
88966585|NCT03151486|Experimental|Cohort 2: JNJ-55308942 1.5 mg or Placebo (SAD Part)|Participants will be randomized to receive a single dose of JNJ-55308942 1.5 mg or matching placebo as an oral solution after an overnight fast on Day 1.
88966586|NCT03151486|Experimental|Cohort 3: JNJ-55308942 4 mg or Placebo (SAD Part)|Participants will be randomized to receive a single dose of JNJ-55308942 4 mg or matching placebo as an oral solution after an overnight fast on Day 1.
88966587|NCT03151486|Experimental|Cohort 4: (JNJ-55308942 12 mg or Placebo (SAD Part))|Participants will be randomized to receive a single dose of JNJ-55308942 12 mg or matching placebo as an oral solution after an overnight fast on Day 1.
88966588|NCT03151486|Experimental|Cohort 5: JNJ-55308942 36 mg or Placebo (SAD Part)|Participants will be randomized to receive a single dose of JNJ-55308942 36 mg or matching placebo as an oral solution after an overnight fast on Day 1.
88966589|NCT03151486|Experimental|Cohort 6: JNJ-55308942 100 mg or Placebo (SAD Part)|Participants will be randomized to receive a single dose of JNJ-55308942 100 mg or matching placebo as an oral solution after an overnight fast on Day 1.
88966590|NCT03151486|Experimental|Cohort 7: JNJ-55308942 or Placebo (SAD Part)|Participants will be randomized to receive a single dose of JNJ-55308942 or matching placebo as an oral solution in a fed state on Day 1. The dose selected for this cohort will be based on the data obtained from the single ascending dose cohorts.
88966591|NCT03151486|Experimental|Cohort 1: JNJ-55308942 or Placebo (MAD Part)|Participants will be randomized to receive JNJ-55308942 or matching placebo once daily as an oral solution for 10 consecutive days (Day 1 to 10). The doses for the multiple ascending doses (MAD) will be determined based on the data from the SAD part.
88966592|NCT03151486|Experimental|Cohort 2: JNJ-55308942 or Placebo (MAD Part)|Participants will be randomized to receive JNJ-55308942 or matching placebo once daily as an oral solution for 10 consecutive days (Day 1 to 10). The doses for the MAD will be determined based on the data from the SAD part.
88966593|NCT03151486|Experimental|Cohort 3: JNJ-55308942 or Placebo (MAD Part)|Participants will be randomized to receive JNJ-55308942 or matching placebo once daily as an oral solution for 10 consecutive days (Day 1 to 10). The doses for the MAD will be determined based on the data from the SAD part.
88966594|NCT00387374|Experimental|Stratum I (radiotherapy, bevacizumab, chemotherapy)|Patients undergo prophylactic radiotherapy on days 1-5 and 8-12. Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30-60 minutes on day 15. Patients also receive paclitaxel IV over 3 hours or carboplatin IV over 30-60 minutes and bevacizumab IV over 30-90 minutes on day 36 (course 2).
89560308|NCT05281640|Experimental|Affect Dysregulation intervention|"The AD module focuses on skills training in relation to identifying and labelling feelings, emotion management, distress tolerance, and acceptance of feelings and experiencing positive emotions.~The module will be delivered by a trained therapist,in each site. Sessions are one hour long and six sessions will be delivered over an 8-week therapy window."
89560309|NCT05281640|No Intervention|Treatment as usual (1)|TAU will include ongoing standard care - antipsychotic medication as well as monitoring by psychiatrists and community psychiatric nurses (CPNs).
89560310|NCT05281640|Experimental|Negative Self Concept intervention|"The NSC module focus on the impact of trauma on one's self concept, how to stay in the present moment and combat dissociation, introduce self - compassion and mindfulness skills, challenge thinking patterns including tackling negative thoughts rules and assumptions that relate to ones-self, how to be more nurturing towards one's self, explore personal qualities and develop a balanced view of self.~The module will be delivered by a trained therapist,in each site. Sessions are one hour long and six sessions will be delivered over an 8-week therapy window."
89560311|NCT05281640|No Intervention|Treatment as usual (2)|TAU will include ongoing standard care - antipsychotic medication as well as monitoring by psychiatrists and community psychiatric nurses (CPNs).
89560312|NCT05281640|Experimental|Disturbed Relationships intervention|"The DR module will focus on exploration and revision of maladaptive schemas, effective assertiveness, awareness of social context, and flexibility in interpersonal expectations and behaviours that are displayed in social interactions.~The module will be delivered by a trained therapist,in each site. Sessions are one hour long and six sessions will be delivered over an 8-week therapy window."
89560313|NCT05281640|No Intervention|Treatment as usual (3)|TAU will include ongoing standard care - antipsychotic medication as well as monitoring by psychiatrists and community psychiatric nurses (CPNs).
89560314|NCT05270278||1. Eosinophilic AB - initiated biological treatment against IL-5 or IL-5R|"initiated biological treatment - mepolizumab or benralizumab~judged by the treating physician, the patient cannot indicated treatment of type anti IgE or anti IL-4R"
89560315|NCT05270278||2. Eosinophilic AB - initiated biological treatment against IgE or IL-4R|"initiated biological treatment - omalizumab or dupilumab~judged by the treating physician, patient cannot indicated treatment type anti IL-5 or anti IL-5R"
89560316|NCT05270278||3. Eosinophilic AB - initiated biological treatment against IgE or IL-4R, or against IL-5 or IL-5R|"initiated biological treatment - omalizumab or dupilumab, or mepolizumab or benralizumab~judged by the treating physician, the patient could be potentially indicated to treatment with all 4 alternatives"
89560317|NCT05270278||4. Non-eosinophilic AB - without indication for biological treatment|"no biological treatment initiated~judged by the treating physician, the patient cannot be indicated to biological treatment"
89560318|NCT05263388|Experimental|REKOVELLE (Follitropin Delta)|
89560319|NCT05263388|Active Comparator|GONAL-F (Follitropin Alfa)|
88966595|NCT00387374|Experimental|Stratum II (radiotherapy, chemotherapy, bevacizumab)|Patients undergo prophylactic radiotherapy and receive paclitaxel and carboplatin as in stratum I. Patients also receive bevacizumab IV over 30-90 minutes on day 15 (course 1). In both strata, treatment with paclitaxel, carboplatin, and bevacizumab repeats every 21 days for 5-6 courses in the absence of disease progression or unacceptable toxicity. Patients with complete or partial response or stable disease may continue to receive single-agent bevacizumab every 21 days in the absence of disease progression or unacceptable toxicity.
89560320|NCT05248165||Coronary artery disease requiring percutaneous coronary intervention|Chronic or acute coronary syndrome requiring percutaneous myocardial revascularization.
89560321|NCT05240638|Experimental|TD Drainage|Short term TD drainage
89560322|NCT05235555||Patients with symptomatic severe AS undergoing TAVI.|
89560323|NCT05232071|Experimental|Lanifibranor (IVA337) (800 mg/day)|2 Lanifibranor tablets 400 mg with food --> once a day (quaque die, QD)
88966596|NCT03151447|Experimental|SBRT in combined with anti-PD-1 antibody|Patients will receive stereotactic body radiation therapy to metastatic lesions of liver, lung, bone, brain or lymph nodes and concurrent anti-PD-1 antibody treatment.
88966597|NCT03151369|Other|Morphine|patients with the visual analog scale over 3 will receive morphine
89560324|NCT05232071|Placebo Comparator|Matching placebo|2 Placebo to match tablets with food --> once a day (quaque die, QD)
89560325|NCT05232071|Experimental|Lanifibranor (IVA337) (800 mg/day) plus Empagliflozin (10mg/day)|2 Lanifibranor tablets 400 mg plus 1 Empagliflozin tablet 10mg with food --> once a day (quaque die, QD)
89560326|NCT05230082|Experimental|Immediate Start|Patients will receive acupuncture treatment two times per week for 12 weeks.
88966598|NCT03151330|Other|Screened arm|This will be an arm of women who are prospectively screened and receive a risk score for preterm birth. They will be recommended treatment strategies and their outcomes compared to an historical control.
89560327|NCT05230082|Active Comparator|Delayed start|Patients will act as control group for the first 12 weeks then will receive acupuncture treatment two times per week for 12 weeks.
89560328|NCT05222022|Experimental|Design validation of mechanism of action of an eye movement measurement device|Participants have retinal images captured with the Retitrack device to measure eye movements. The eye movement measurements are intended to validate the mechanism of action of the device.
89560329|NCT05193929|Experimental|OptiPulse™|The OptiPulse™ is designed to enhance blood circulation in the venules and arterioles in subjects with diabetic foot ulcers of the lower extremities. OptiPulse™ is supplied as a pair of footwear. One side is fitted with an offloaded and shin pumping unit and the other acts as pressure reducing footwear. Both active and non-active footwear should be worn to give balanced gait.
89560330|NCT05193929|Active Comparator|Standard of care offloading device|Diabetic CAM boot
89560331|NCT05183633||One single trial|
89560332|NCT05156060|Experimental|Gabapentin plus Ketamine|Gabapentin and Ketamine will be taken 3 times per day.
89560333|NCT05155189|Experimental|C-CAR031|Autologous C-CAR031 administered by intravenous (IV) infusion
89560334|NCT05155189|Experimental|C-CAR031 combined with Lenvatinb|Autologous C-CAR031 combination with Lenvatinib
89560335|NCT05155189|Experimental|C-CAR031 combined with PD-1(L1) antibody|Autologous C-CAR031 combination with PD-1(L1) monoclonal antibody
89560336|NCT05153395|Experimental|Insulin (Doppler)|Human insulin (160 IU) will be administered as a bolus using an intra-nasal device.
89560337|NCT05153395|Experimental|Insulin (MRI)|Human insulin (160 IU) will be administered as a bolus using an intra-nasal device.
89560338|NCT05153395|Other|Time Control (Doppler)|Time control only
89560339|NCT05152615|Experimental|New Onset Rheumatoid Arthritis (NORA) Patient|NORA patients receiving methotraxate as first line therapy (standard of care) will take additional oral SCFA supplementation for the purposes of the study.
88811905|NCT01392053|No Intervention|Control group|Control Group (CG) that will receive the routine procedures of motherhood, but will be monitored and evaluated at the same time in the intervention group
89560340|NCT05144750|Experimental|Fruit and Vegetable Prescription Program Cohort|All participants received the program intervention.
89560341|NCT05143671||Hybrid coronary revascularization strategy (HCR)|Patients who undergo a combination of coronary artery bypass grafting and PCI.
89560342|NCT05143671||Hybrid valve and coronary disease correction|Patients who undergo a combination of surgical valve replacement and PCI.
89560343|NCT05143671||Hybrid coronary and carotid artery disease treatment|Patients who undergo a combination of coronary artery bypass grafting and carotid stenting.
89560344|NCT05139173|Experimental|Experimental: Injured Worker Population|Participants that have a confirmed rotator cuff pathology, and are undergoing physiotherapy at the Holland Centre for a work-related shoulder injury as part of the Working Condition Program.
89560345|NCT05139173|Active Comparator|Active Comparator: OHIP (funded) Patient Population|Participants that have a confirmed rotator cuff pathology, and are undergoing physiotherapy at the Holland Centre as part of the Shoulder Program.
89560346|NCT05135559|Experimental|Concizumab-naïve patients|Concizumab-naïve participants below 12 years of age at the time of consent/assent
89560347|NCT05135559|Experimental|Patients coming from compassionate use|Patients previously treated with concizumab via compassionate use, either on an individual patient basis or through the concizumab compassionate use programme NN7415-4807
89560348|NCT05124873|Experimental|Experimental Prosthetic Liner|
89560349|NCT05124249||Invasive coronary angiography (ICA)|Patients who undergoing invasive coronary angiography with intravascular imaging or invasive physiologic assessment
89560350|NCT05124249||Percutaneous coronary intervention (PCI)|Patients who undergoing percutaneous coronary intervention with intravascular imaging or invasive physiologic assessment
89560351|NCT05116787|Experimental|BCX9930 monotherapy|"In Part 1, participants are randomized to 2:1 to receive BCX9930 monotherapy or placebo under double-blind conditions~In Part 2, all participants receive open-label BCX9930 monotherapy"
89208473|NCT00616902|Active Comparator|Paricalcitol Injection 4 mcg/mL|Paricalcitol Injection 4 mcg/mL given intravenously 3 times per week during dialysis
89560352|NCT05116787|Placebo Comparator|Placebo|In Part 1, participants are randomized to 2:1 to receive BCX9930 monotherapy or placebo under double-blind conditions
89560353|NCT05116774|Experimental|BCX9930 monotherapy|"In Part 1, participants are randomized 2:1 to receive BCX9930 monotherapy or continue with current C5 inhibitor~In Part 2, all subjects receive BCX9930 monotherapy"
89560354|NCT05116774|Active Comparator|Continued C5 inhibitor therapy|In Part 1, participants are randomized 2:1 to receive BCX9930 monotherapy or continue with current C5 inhibitor
89560355|NCT05113303||navigation assisted knee revision surgery|
89560356|NCT05113303||manual procedure|
89560357|NCT05101551|Experimental|Talazoparib with topotecan and gemcitabine|Talazoparib will be administered orally on Days 1 to 5 concurrently with topotecan and a single dose of gemcitabine on Day 1 of 28 day cycle for 1 or 2 cycles. Subjects on dose level 5 will receive an additional 5 day treatment course of talazoparib on days 15-19.
89560358|NCT05097989|Experimental|LN Cohort: ALXN2050 180 mg|Participants diagnosed with LN with an active flare will receive ALXN2050 in addition to standard-of-care background therapy.
89560359|NCT05097989|Experimental|LN Cohort: ALXN2050 120 mg|Participants diagnosed with LN with an active flare will receive ALXN2050 in addition to standard-of-care background therapy.
89560360|NCT05097989|Placebo Comparator|LN Cohort: Placebo|Participants diagnosed with LN with an active flare will receive matched placebo in addition to standard-of-care background therapy.
89560361|NCT05097989|Experimental|IgAN Cohort: ALXN2050 180 mg|Participants diagnosed with IgAN will receive ALXN2050 in addition to standard-of-care background therapy.
89560362|NCT05097989|Experimental|IgAN Cohort: ALXN2050 120 mg|Participants diagnosed with IgAN will receive ALXN2050 in addition to standard-of-care background therapy.
89560363|NCT05097989|Placebo Comparator|IgAN Cohort: Placebo|Participants diagnosed with IgAN will receive matched placebo in addition to standard-of-care background therapy.
89560364|NCT05090085|Active Comparator|3M Adper Single Bond2|O.I. will clean the labial surface of the tooth with polishing paste and brush Roughening of the surface may be needed by the diamond point The tooth will be isolated by a rubber dam. Apply etchant for 30 s for enamel and 15 s for dentin. Rinse thoroughly with water for 15 s. blot-drying with paper tissue was carefully performed leaving the dentin surface slightly moist. Active application of consecutive coats of the adhesive for 15 s. Gently air for 5 s. Light cure for 10 s. Composite build ups (Filtek Z350 XT, 3 M ESPE, St Paul, MN, USA) were performed in increments and individually light-cured for 20 s. Light curing of all resin materials was performed using (3M Elipar Curing Light) delivering 1100 mW/cm2.
89560365|NCT05090085|Experimental|DMSO application before 3M Adper Single Bond2, etch and rinse adhesive|The same steps of the comparator group with an additional step, after dentin etching and humidity control, dentin pretreatments were performed consisting of active application of 10% DMSO/H2O (OT Primer, OT Dent) solutions on etched-dentin for 1 minute followed by 20 seconds of air drying then apply adhesive.
89560366|NCT05085067|No Intervention|Group A: no auto-cross linked hyaluronic acid gel|no auto-cross linked hyaluronic acid gel into intrauterine cavity after hysteroscopic treatment because of retained products of conception
88811906|NCT01392053|Experimental|Massage Group|Massage Group (GM):receive lumbosacral massage for 30 minutes, during uterine contractions between 4-5 cm of cervical dilation
88811907|NCT02979821|Experimental|Poziotinib|The study drug(poziotinib) will be administered orally as one 12 mg tablet once a day until disease progression or manifestation of unacceptable toxicity. The initial dose of the study drug 12 mg daily can be reduced to 8 mg once daily according to dose reduction criteria.
88811908|NCT02204657|Active Comparator|Continuous Glucose Monitoring System|Patients in this arm will receive Continuous Glucose Monitoring System (CGMS) at 28,32 and 36 weeks of gestation and their insulin titrated according to the CGMS results.
88811909|NCT02204657|No Intervention|Control|Patients in this arm will not receive any Continuous Glucose Monitoring System( CGMS) and the insulin titration will be made based on their fingerstick sugar readings.
88811910|NCT03008603|Experimental|Procedures with XACT Robotic System|CT-guided minimally invasive percutaneous procedures using the XACT Robotics system
88966599|NCT03151291|No Intervention|Control group|"usual care control group receives individualized nutritional support (dietary advices: daily protein intake > 1.0 g/kg bodyweight)"
88966600|NCT03151291|Experimental|EMS group|"physical exercise group performing a regular WB-EMS Training (two WB-EMS trainings per week; each session for 20 min)~+ individualized nutritional support (dietary advices: daily protein intake > 1.0 g/kg bodyweight)"
88966601|NCT03151291|Experimental|HMB group|HMB supplemented group receives individualized nutritional support (dietary advices: daily protein intake > 1.0 g/kg bodyweight) + specific dietary supplementation with HMB (3 g/d)
88966602|NCT03151291|Experimental|HMB+EMS group|"HMB supplemented physical exercise group performing a regular WB-EMS Training (two WB-EMS trainings per week; each session for 20 min)~+ individualized nutritional support (dietary advices: daily protein intake > 1.0 g/kg bodyweight) + specific dietary supplementation with HMB (3 g/d)"
88966603|NCT03151291|Experimental|LC group|LC supplemented group receives individualized nutritional support (dietary advices: daily protein intake > 1.0 g/kg bodyweight) + specific dietary supplementation with LC (4 g/d)
88966604|NCT03151291|Experimental|LC+EMS group|"LC supplemented physical exercise group performing a regular WB-EMS Training (two WB-EMS trainings per week; each session for 20 min)~+ individualized nutritional support (dietary advices: daily protein intake > 1.0 g/kg bodyweight) + specific dietary supplementation with LC (4 g/d)"
88966605|NCT03151291|Experimental|EPA group|EPA supplemented group receives individualized nutritional support (dietary advices: daily protein intake > 1.0 g/kg bodyweight) + specific dietary supplementation with EPA (2.2 g/d)
88966606|NCT03151291|Experimental|EPA+EMS group|"EPA supplemented physical exercise group performing a regular WB-EMS Training (two WB-EMS trainings per week; each session for 20 min)~+ individualized nutritional support (dietary advices: daily protein intake > 1.0 g/kg bodyweight) + specific dietary supplementation with EPA (2.2 g/d)"
88966607|NCT04712266|Active Comparator|Insulin IV|calculated insulin rate
88966608|NCT04712266|Experimental|Insulin and Glucagon IV|calculated molar ratio insulin:glucagon
88966609|NCT03151252|Other|Food allergy|Patients with confirmed foodspecific- IgE antibodies in blood
88966610|NCT03151252|Other|healthy controls|participants without foodspecific- IgE antibodies in blood and other gastrointestinal symptoms
88966611|NCT03151252|Other|gastointestinal symptoms without foodallergy in blood|Patients without foodspecific- IgE antibodies in blood, but with gastrointestinal symptoms
88966612|NCT03151213|Active Comparator|Pregabalin|Pregabalin 150 mg before intervention
88966613|NCT03151213|Placebo Comparator|Placebo|Placebo before intervention
88966614|NCT03151174|Experimental|Vitamin D - 10000IU|These individuals have been categorized as Vitamin D deficient and will receive 10000IU of Vitamin D per day.
88966615|NCT03151174|Experimental|Vitamin D - 5000IU|These individuals have been categorized as Vitamin D insufficient and will receive 5000IU of Vitamin D per day.
88966616|NCT03151174|No Intervention|Placebo|These individuals have been categorized as Vitamin D sufficient and will receive placebo.
88966617|NCT00393172|Experimental|exercise|5 days per week exercise for 4 months
88966618|NCT00393172|No Intervention|no exercise|
89560367|NCT05085067|Experimental|Group B: infusing auto-cross linked hyaluronic acid gel|infusing auto-cross linked hyaluronic acid gel into intrauterine cavity after hysteroscopic treatment because of retained products of conception
89560368|NCT05078593|Experimental|HLX26|The initial dose of HLX26 is 60 mg, and 7 dose levels are designed: 60 mg, 150 mg, 300 mg, 500 mg, 800 mg , 1200mg, and 1600mg(Q3W).
88966619|NCT03151135||AN patients|Patients with Anorexia Nervosa (AN). No intervention, observation at end of inpatient treatment
88966620|NCT03151096|Experimental|treatment arm|5mg Riboflavin pills
88966621|NCT03151096|Placebo Comparator|Placebo arm|Placebo pills
88966622|NCT03906539|Placebo Comparator|Control Group|The patients in control groups will receive tablet atorvastatin (10 mg/day) and a placebo capsule.
88966623|NCT03906539|Experimental|VCO Group|The VCO group will receive capsule VCO (1000mg/day) as an add-on to tablet atorvastatin (10 mg/day).
89560369|NCT05078190||Doxorubicin|Patients treated with doxorubicin (Adriamycin) for breast cancer
89560370|NCT05078190||Trastuzumab|Patients treated with trastuzumab (Herceptin) for breast cancer
88966624|NCT03151018||Onyx|The patients who received PCI with Resolute Onyx stent(s)
88966625|NCT03150979|Experimental|Provision of a cane|The experimental group will receive a single-point cane, with ergonomic handgrip, which will be individually adjusted to the participant's height. A physiotherapist will provide instructions on how to walk with the cane and the participants will practice for about 15 minutes or until they feel comfortable with the device. Then, they will take the cane home and will be instructed to use it all the time during locomotion. Weekly, they will receive a phone call, to ensure that they are using the cane and to clarify any doubts. A home visit may be conducted, if necessary.
89560371|NCT05078190||Doxorubicin and Trastuzumab|Patients treated with both doxorubicin (Adriamycin) and trastuzumab (Herceptin) for breast cancer
88966626|NCT03150979|Other|Control|The control group will be instructed to to perform stretching of the lower limb muscles daily and keep their daily activities, without the use of a cane. They will also receive weekly phone calls, to ensure similar level of attention to that of the the participants in the experimental group.
88966627|NCT03150940||Duke University Athletes|"Division 1 Athletes, participating in obligatory screening prior to athletic competition every summer. The investigators are observing required study outcomes (ECGs, history and physicals, and ultrasounds) to see what is useful in the screening.~ECG: 12 lead electrocardiogram that visualizes cardiac activity~history and physical: background information about athlete's and their family history~ultrasound: bedside cardiac ultrasound to visualize 2D imaging of structural cardiac function"
88966628|NCT05608512||hospice care nurses|nurses who have worked in a palliative care or hospice unit
89026880|NCT05645263|Experimental|Cola 1（3d）|The patients in intervention group 1 dieted Coca-cola to treat gastric phytobezoars, 250ml-500ml/2 h till to sleeping time according to the health conditions and life habits. Pay more attention to the stools and assess if the bezoars had excreted. The dieting Coca-cola period is 3 days.The patients will go through an endoscopy once the Coca-cola dieting therapy is over.
89208474|NCT00616902|Placebo Comparator|Placebo Injection 4 mcg/mL|Placebo Injection 4 mcg/mL given intravenously three times a week during dialysis
89560372|NCT05069766|Experimental|BioXmark™|
88966629|NCT03150901||diabetic patients|"In a prospective study, we will collect wound edge tissue specimens from 75 patients with DF during surgical debridement. From each patient, 1-4 specimens will be obtained per debridement. To evaluate debrided tissue, each specimen will be processed for paraffin embedding and stained with haematoxylin and eosin. Histopathology analysis of multiple specimens acquired from the same wound will be analysed. Full-thickness epidermis biopsies will be followed by biomarker assessment such as:~Expression of insulin-like growth factor 1 receptor (IGF-1R)~Adiponectin~Leptin~Resistin~Osteocalcin~Osteoprotegerin~Insulin, c-peptid~HOMA-IR"
89560373|NCT05062590|Experimental|Group Intervention|Experimental: Group 1 The intervention group will take the ESOGER questionnaire at month 0 and month 3 ( beginning and end) and receive recommendations following their needs.
89560374|NCT05062590|No Intervention|Group control|The participants will only take the ESOGER questionnaire at month 0 and month 3 without recommendations
89560375|NCT05059327|Experimental|Arm A (Basimglurant to Placebo)|Basimglurant to Placebo
89560376|NCT05059327|Placebo Comparator|Arm B (Placebo to Basimglurant)|Placebo to Basimglurant
89560377|NCT05056077|Experimental|Condition I (text, health kit, health coach, support coach)|Patients receive a personal report comparing their nutrition and physical activity to ACS guidelines and a booklet on nutrition and physical activity for patients with a history of cancer. Patients receive text messages and use digital health tool kit for 48 weeks. Patients also receive 15 health coaching sessions over 30-45 minutes each for 48 weeks. Support persons receive four coaching sessions lasting 30-45 minutes each, approximately every 12 weeks for 48 weeks.
89560378|NCT05056077|Experimental|Condition II (text, health kit, health coach)|Patients receive a personal report comparing their nutrition and physical activity to ACS guidelines and a booklet on nutrition and physical activity for patients with a history of cancer cancer. Patients receive text messages and use digital health tool kit for 48 weeks. Patients also receive 15 health coaching sessions over 30-45 minutes each for 48 weeks.
89560379|NCT05056077|Experimental|Condition III (text, health kit, support coach)|Patients receive a personal report comparing their nutrition and physical activity to ACS guidelines and a booklet on nutrition and physical activity for patients with a history of cancer. Patients receive text messages and use digital health tool kit for 48 weeks. Support persons receive four coaching sessions lasting 30-45 minutes each, approximately every 12 weeks for 48 weeks.
89560380|NCT05056077|Experimental|Condition IV (text, health kit)|Patients receive a personal report comparing their nutrition and physical activity to ACS guidelines and a booklet on nutrition and physical activity for patients with a history of cancer. Patients receive text messages and use digital health tool kit for 48 weeks.
89560381|NCT05056077|Experimental|Condition IX (health kit, health coach, support coach)|Patients receive a personal report comparing their nutrition and physical activity to ACS guidelines and a booklet on nutrition and physical activity for patients with a history of cancer. Patients use digital health tool kit for 48 weeks. Patients also receive 15 health coaching sessions over 30-45 minutes each for 48 weeks. Support persons receive four coaching sessions lasting 30-45 minutes each, approximately every 12 weeks for 48 weeks.
89560382|NCT05056077|Experimental|Condition V (text, health coach, support coach)|Patients receive a personal report comparing their nutrition and physical activity to ACS guidelines and a booklet on nutrition and physical activity for patients with a history of cancer. Patients receive text messages for 48 weeks. Patients also receive 15 health coaching sessions over 30-45 minutes each for 48 weeks. Support persons receive four coaching sessions lasting 30-45 minutes each, approximately every 12 weeks for 48 weeks.
89560383|NCT05056077|Experimental|Condition VI (text, health coach)|Patients receive a personal report comparing their nutrition and physical activity to ACS guidelines and a booklet on nutrition and physical activity for patients with a history of cancer. Patients receive text messages for 48 weeks. Patients also receive 15 health coaching sessions over 30-45 minutes each for 48 weeks.
89560384|NCT05056077|Experimental|Condition VII (text, support coach)|Patients receive a personal report comparing their nutrition and physical activity to ACS guidelines and a booklet on nutrition and physical activity for patients with a history of cancer. Patients receive text messages for 48 weeks. Support persons receive four coaching sessions lasting 30-45 minutes each, approximately every 12 weeks for 48 weeks.
89560385|NCT05056077|Experimental|Condition VIII (text)|Patients receive a personal report comparing their nutrition and physical activity to ACS guidelines and a booklet on nutrition and physical activity for patients with a history of cancer. Patients receive text messages for 48 weeks.
89560386|NCT05056077|Experimental|Condition X (health kit, health coach)|Patients receive a personal report comparing their nutrition and physical activity to ACS guidelines and a booklet on nutrition and physical activity for patients with a history of cancer. Patients use digital health tool kit for 48 weeks. Patients also receive 15 health coaching sessions over 30-45 minutes each for 48 weeks.
89560387|NCT05056077|Experimental|Condition XI (health kit, support coach)|Patients receive a personal report comparing their nutrition and physical activity to ACS guidelines and a booklet on nutrition and physical activity for patients with a history of cancer. Patients use digital health tool kit for 48 weeks. Support persons receive four coaching sessions lasting 30-45 minutes each, approximately every 12 weeks for 48 weeks.
89560388|NCT05056077|Experimental|Condition XII (health kit)|Patients receive a personal report comparing their nutrition and physical activity to ACS guidelines and a booklet on nutrition and physical activity for patients with a history of cancer. Patients use digital health tool kit for 48 weeks.
89560389|NCT05056077|Experimental|Condition XIII (health coach, support coach)|Patients receive a personal report comparing their nutrition and physical activity to ACS guidelines and a booklet on nutrition and physical activity for patients with a history of cancer. Patients receive 15 health coaching sessions over 30-45 minutes each for 48 weeks. Support persons receive four coaching sessions lasting 30-45 minutes each, approximately every 12 weeks for 48 weeks.
88966630|NCT03150823|Experimental|Upward Direct Current (Ascending Effect)|Group subjected to a direct current application (Longitudinal Galvanization) in which the anode is placed at the distal level and the cathode at the proximal level. This would be an excitatory effect of the nervous system.
89208475|NCT00869154|Active Comparator|Primary care follow up|Multidisciplinary examination and follow up by the family doctor.
88966631|NCT03150823|Experimental|Downward Direct Current (Descending Effect)|Group subjected to a direct current application (Longitudinal Galvanization) in which the cathode is placed at the distal level and the anode at the proximal level. This would be an inhibitory effect of the nervous system.
88966632|NCT03150823|Sham Comparator|Sham Direct Current|Group to which an electrical installation will be carried out without emission of part of the electrotherapy equipment. The electrodes will be applied longitudinally to the participants with the equipment switched off.
88966633|NCT03150784|Experimental|Motor coordination difficulties|"Type: Experimental main~EPIC club: 60min session / 2 times weekly / 7 weeks"
88966634|NCT03150784|Other|Non motor coordination difficulties|"Type: Experimental comparator~EPIC club: 60min session / 2 times weekly / 7 weeks"
88966635|NCT05605665|Active Comparator|Low-dose interleukin-2|One million IU of IL-2 was injected subcutaneously once every other day for 4 weeks.
88966636|NCT05605665|Active Comparator|Rapamycin|Rapamycin 0.5ml once per day for 4 weeks.
88966637|NCT05605665|Experimental|Low-dose interleukin-2 and rapamycin|One million IU of IL-2 was injected subcutaneously once every other day and rapamycin 0.5ml once per day for 4 weeks.
88966638|NCT03150745|Other|Colposcopic group|
88966639|NCT03150745|Other|office hysteroscopic group|
88966640|NCT03150706|Experimental|Avelumab|"The mismatch repair deficient or microsatellite instable, or POLE mutated metastatic colorectal cancer patients who were progressed after at least one prior systemic treatment for metastatic setting.~After checking the eligibility for the study entry, patients will be entered into the study treatment with avelumab monotherapy."
88966641|NCT03150667|Active Comparator|Ticagrelor Arm|Eligible patients randomized to the Ticagrelor arm will receive open label drug at a dose selected by their providers along with 81mg aspirin. These patients will be followed for 1 year through chart review for events. For event free patients, a phone follow-up will be done at the end of 1 year to record events These events be documented in the medical records.
88966642|NCT03150667|Active Comparator|Clopidogrel|Eligible patients randomized to the Clopidogrel arm will receive open label drug at a dose selected by their providers along with 81mg aspirin. These patients will be followed for 1 year through chart review for events. For event free patients, a phone follow-up will be done at the end of 1 year to record events These events be documented in the medical records
88966643|NCT03150628|Experimental|Study population|
88966644|NCT00393250|Experimental|1|Hypnosis
88966645|NCT00393250|Active Comparator|2|Control
88966646|NCT03150550|Experimental|Relapse Prevention|Each patient will perform 12 classic psychotherapeutic sessions over a period of 6 weeks.
88966647|NCT03150550|Experimental|Mindfulness Practice|Each patient will perform 12 mindfulness psychotherapeutic sessions over a period of 6 weeks.
88966648|NCT03150472|Experimental|Ivory Dentin Graft (Ivory Graft Ltd.)|"Ivory Dentin Graft is a bone graft material for the repair or augmentation of bone defects in dental procedures. It consists of sterile 300 - 1200 μm porous particles or granules of hydroxyapatite which retain the natural form of the source porcine dentin and also the natural protein matrix which consists largely of porcine collagen.~This type of Graft Matrix will be administered as the intervention."
88966649|NCT03150472|Active Comparator|OsteoBiol Gen-Os ® (Tecnoss)|"A natural replicate of autologous bone, Gen-Os® conserves the same intimate structures (matrix and porous form) and presents a highly osteoconductive properties.~It is biocompatible and bioavailable, as recognized by tests made according to the ISO 10993 method conducted at Eurofins Biolab.~This type of Graft Matrix will be administered as the intervention."
88966650|NCT04895852|Experimental|TEAS group|30 minutes TEAS therapy on DU20, EX-HN3, LI4, LR3 once per day for three days before surgery.
88966651|NCT04895852|Sham Comparator|Control group|The control group selects the same acupoints as the TEAS group and other intervention measures are the same as the TEAS group except for the current intensity is set to 0-mA.
88966652|NCT03150394|Experimental|Treatment of quadruple eradication therapy with GASTRUS|
88966653|NCT03150394|Placebo Comparator|Treatment of quadruple eradication therapy with PLACEBO|
88966654|NCT03150355||open reduction and internal fixation|outcome of open reduction and internal fixation of fractures of proximal femur and acetabulum in patients aged 65 years and older
88966655|NCT03150355||Arthroplasty|outcome of arthroplasty of fractures of proximal femur and acetabulum in patients aged 65 years and older
88966656|NCT03150355||conservative management|outcome of conservative management of fractures of proximal femur and acetabulum in patients aged 65 years and older
88966657|NCT03150316|Experimental|Treat Regimen|CKD-581(investigational Drug) Lenalidomide Dexamethasone
88966658|NCT03150277|Experimental|Plyometric-Resistance|This group will perform plyometric exercise first and then heavy resistance exercise
88966659|NCT03150277|Experimental|Resistance-Plyometric|This group will perform resistance exercise first and then plyometric exercise
88966660|NCT02972125|Experimental|Treatment A - B|Single administration of the reference drug (Treatment A, a single dose of Lacosamide (LCM) 100 mg tablet), followed by a Wash-Out Period of at least 7 days and a single administration of the test drug (Treatment B, a single dose of LCM 100 mg given as dry syrup).
88966661|NCT02972125|Experimental|Treatment B - A|Single administration of the test drug (Treatment B, a single dose of LCM 100 mg given as dry syrup), followed by a Wash-Out Period of at least 7 days and a single administration of the reference drug (Treatment A, a single dose of Lacosamide (LCM) 100 mg tablet).
88966662|NCT05597553|Experimental|Premixed MTA|The premixed bioceramics putty are ready to use materials, fast setting, with superior handling properties and hydrophilic in nature that necessitate moisture from the adjacent tissues to set. They have advantage of insensitive to moisture and blood contamination with less technique sensitive.
88966663|NCT05597553|Active Comparator|Powder/liquid MTA|Mineral trioxide aggregate (MTA) is a bioactive, biocompatible, antibacterial material with good stability, and excellent sealing ability that has been used as a dressing material in pulp capping procedures in permanent teeth, although it has good properties, it has many limitations, including long setting time, handling property and tooth discoloration making the use of this material challenging for many clinicians.
88966664|NCT03150238||Post-operative Crohn Disease patients|Adult patients, with a defined diagnosis of CD, who underwent a surgery for CD in the previous 6 months
89208476|NCT00869154|Experimental|Multidisciplinary follow up|Multidisciplinary examination and follow up by a multidisciplinary outpatient team.
89208477|NCT00801944|Experimental|I|Solifenacin succinate 5/10mg
88966665|NCT03086044|Experimental|HCV NAT Positive Donor|"Intervention: 2 week treatment course with a direct acting antiviral, sofosbuvir 400mg / velpatasvir 100mg daily~Participants who receive allografts from a donor who is HCV NAT positive will receive treatment with a direct acting antiviral, sofosbuvir 400mg / velpatasvir 100mg daily, beginning on the day of transplant."
88966666|NCT03086044|Experimental|HCV NAT Negative, HCV Ab Positive Donor|"Intervention: HCV viral load monitoring~Participants who receive allografts from a donor who is HCV Ab positive and NAT negative will have close serial HCV viral load monitoring and will be treated with a direct acting antiviral, 400mg / velpatasvir 100mg daily, for 6 weeks if HCV viremia develops."
88966667|NCT05588973|Experimental|Intervention group|"50 patients will be randomized to the MEDISKIN group and 50 to the panthenol group. Everyone will start using their cream from the start of the treatment and will continue for 2 weeks after the end of the radiation therapy (twice a day). If there are cases of patients using panthenol and it is deemed necessary based on symptoms to use MEDISKIN then they will automatically change group. Before starting to use the skin cosmetic products, patients will be asked to test the product for any allergic reactions. The mini-patch test which is standard of practice is carried out by using the substance on the inner elbow or wrist for 24 hours and observing for any reactions."
88966668|NCT05588973|Placebo Comparator|Control group|The group will be using panthenol istead of the MEDISKIN product
88966669|NCT04712344|Experimental|COVID-19 convalescent plasma|A total of three units of COVID-19 convalescent plasma administered on three separate occasions during Day 1 and Day 2 and standard treatment.
88966670|NCT04712344|No Intervention|Standard treatment|Standard treatment.
88966671|NCT05585853|Experimental|Virtual Reality application group|Virtual reality glasses (VR Box Virtual Reality Headset 3D Vr Glasses V2.0 2020 model) compatible with the mobile phone (Lenovo P2a42) with the Android operating system will be worn and the patient will be watched (underwater world, open-air museum tours, beach trips and nature scenes) by patients for an average of 10 minutes during chest tube removal.
88966672|NCT05585853|No Intervention|Standard of care|Only standard care will be given and no application will be made.
88966673|NCT02866006|Experimental|BVAC-C mono(High dose)|BVAC-C IV injection at 0, 4, 8th weeks.(HIgh dose)
88966674|NCT02866006|Experimental|BVAC-C mono(Intermediate dose)|BVAC-C IV injection at 0, 4, 8, 12th weeks.(Half dose)
88966675|NCT02866006|Experimental|BVAC-C + Topo Combi|BVAC-C IV injection at 0,4,8,12th weeks.(Half dose) Topotecan IV injection at 2, 6, 10, 14th weeks
88966676|NCT05575752|Experimental|high temperature (32℃) group|Subjects in exposure group will be exposed to high temperature (32℃) for about 2 hours in a chamber.
88966677|NCT05575752|Sham Comparator|moderate temperature (22℃) group|Subjects in exposure group will be exposed to moderate temperature (22℃) for about 2 hours in a chamber.
88966678|NCT04826159|Experimental|IMB-1018972 200 mg|
88966679|NCT02766166||Predictive Monitoring|
88966680|NCT02766166||No Predictive Monitoring|
88966681|NCT02633098|Experimental|Artesunate|Artesunate 200mg oral tablets once daily for 14 days.
88966682|NCT02633098|Placebo Comparator|Matching placebo|Matching placebo oral tablets once daily for 14 days.
88966683|NCT04796831|Experimental|All Participants|Participants who will receive a single, oral dose of 60 mg quizartinib and a single, IV administration of 50 μg 14C-quizartinib solution for infusion at 4 hours post-oral dosing.
89208478|NCT00801944|Experimental|II|Placebo
89208479|NCT00741611|Experimental|Mesh|Ablation with HD Mesh Ablation System
89208480|NCT00741611|Active Comparator|Drug|Treatment with anti-arrhythmic drugs
88966687|NCT02285179|Experimental|tamoxifen and GDC-0032|20 mg tamoxifen QD and 4 MG GDC-0032 QOD
88966688|NCT02285179|Placebo Comparator|tamoxifen and placebo|20 mg tamoxifen QD and placebo QOD
88966689|NCT04744220|Experimental|Yoga Training Group|"Training: Before the yoga program, the patients will be informed about the bronchiectasis disease and its symptoms, as well as all the parameters used in the evaluation, tests and the content of the yoga session.~During the program, the perceived fatigue intensity of the patients will be questioned with the Modified Borg Scale.~Yoga Session~1-8 weeks and duration~Breathing Exercises 5 min~Instant Relaxation Technique 2 min~Warm-up Exercises 10 min~Quick Relaxation Technique 3 min~Asanas (Posture Exercises) 15 min~Alternative Breathing Exercises 10 min~Deep Relaxation Technique 3 min"
88966690|NCT04744220|No Intervention|Control group|"Training: The exercise program will include respiration exercises that they can do at home.~Before the exercise program, the patients will be informed about the bronchiectasis disease and its symptoms, as well as all the parameters and tests used in the evaluation. Respiratory control, breathing exercises, relaxation techniques and the reasons, importance and effects of exercise training in the treatment program will be explained.~Breathing Exercises (10 min) Pursed-lip breathing training, Chest breathing exercise (10 repetitions), Diaphragmatic breathing exercise (10 repetitions), Bilateral basal expansion breathing exercises (10 repetitions)"
88966691|NCT02122081|Experimental|Treatment (OSMI, allogeneic transplant)|"CONDITIONING REGIMEN: Patients undergo organ-sparing marrow irradiation BID on days -6 to -4 and receive cyclophosphamide IV over 1-2 hours every 24 hours on days -3 to -2. Patients with an unrelated donor also receive anti-thymocyte globulin every 24 hours on days -4 to -2.~GVHD PROPHYLAXIS: Patients receive tacrolimus IV or PO beginning on day -1 and continuing for at least 6 months and methotrexate IV on days 1, 3, 6, and 11.~TRANSPLANT: Patients undergo allogeneic peripheral blood progenitor cell or bone marrow transplant on day 0."
88966692|NCT04710173||ARDS children|children with severe ARDS
88966693|NCT00393328|Active Comparator|A|
89208481|NCT00876252|Active Comparator|IC43 100 mcg|IC43 100 mcg with Aluminum hydroxide
89208482|NCT00876252|Active Comparator|IC43 200 mcg|IC43 200 mcg with Aluminum hydroxide
89208483|NCT00876252|Active Comparator|IC43 100 mcg w/o|IC43 100 mcg without Aluminum hydroxide
89208484|NCT00876252|Placebo Comparator|Placebo|phosphate-buffered saline solution containing 0,9 % NaCl and 400 mcg Aluminum hydroxide as an adjuvant
89208485|NCT00870714|Experimental|A|Eligible patients with high-risk prostate cancer who are scheduled to undergo radical prostatectomy will receive four cycles of therapy with ketoconazole and docetaxel prior to surgery resection
89208486|NCT00796484|Experimental|1|
89208487|NCT02596217|Experimental|Stage 1 (low dose SC)|Low dose administered by subcutaneous (SC) injection
89560390|NCT05056077|Experimental|Condition XIV (health coach)|Patients receive a personal report comparing their nutrition and physical activity to ACS guidelines and a booklet on nutrition and physical activity for patients with a history of cancer. Patients receive 15 health coaching sessions over 30-45 minutes each for 48 weeks.
89560391|NCT05056077|Experimental|Condition XV (support coach)|Patients receive a personal report comparing their nutrition and physical activity to ACS guidelines and a booklet on nutrition and physical activity for patients with a history of cancer. Support persons receive four coaching sessions lasting 30-45 minutes each, approximately every 12 weeks for 48 weeks.
89560392|NCT05056077|Experimental|Condition XVI (study booklet)|Patients receive a personal report comparing their nutrition and physical activity to ACS guidelines and a booklet on nutrition and physical activity for patients with a history of cancer.
89560393|NCT05051124|Experimental|Patients Enrolled in the AMPATH CDM Program|
89560394|NCT05046275||MCR syndroms|Summarize of participants' characteristics using means and standard deviations or frequencies and percentages First, prevalence of MCR syndrome will be determined by classifying participants into MCR and non-MCR syndrome groups. Second, between-group comparisons of participants' characteristics will be performed using unpaired t-test, Mann-Whitney, analysis of variance with LSD correction or Chi-square test, as appropriate. Third, multiple regressions will be performed to examine the association between MCR syndrome (dependent variable) and cardio-vascular risk factors and/or diseases (independent variables) adjusted on participants' characteristics. Fourth, the incidence of MCR syndrome during the follow-up period of NuAge study will be reported. Fifth, regression will be performed to examine the association between MCR syndrome (dependent variable) and cognitive decline as well cognitive impairment (independent variables, separated model) adjusted on participants' characteristics.
89560395|NCT05046275||Non MCR syndroms|Summarize of participants' characteristics using means and standard deviations or frequencies and percentages First, prevalence of MCR syndrome will be determined by classifying participants into MCR and non-MCR syndrome groups. Second, between-group comparisons of participants' characteristics will be performed using unpaired t-test, Mann-Whitney, analysis of variance with LSD correction or Chi-square test, as appropriate. Third, multiple regressions will be performed to examine the association between MCR syndrome (dependent variable) and cardio-vascular risk factors and/or diseases (independent variables) adjusted on participants' characteristics. Fourth, the incidence of MCR syndrome during the follow-up period of NuAge study will be reported. Fifth, regression will be performed to examine the association between MCR syndrome (dependent variable) and cognitive decline as well cognitive impairment (independent variables, separated model) adjusted on participants' characteristics.
89560396|NCT05043649|Experimental|Camsirubicin + pegfilgrastim|Camsirubicin phase 1b dose escalating to determine MTD
89560397|NCT05038150|Experimental|Cohort|"In part 1&2, cohorts of 3 patients will be enrolled. The first patient of each cohort in Part 1 will be admitted to an infusion unit and treated with an IV infusion of SGN1 over 2 hours. Patients in Part 1 will enter Part 2 for extension treatment after completing the 28-day DLT observation period. Up to 5 cohorts will be evaluated.~Part 3 is an open-label, dose expansion phase.There will be at least 2 tumor types selected, expand between second to four dose level in each tumor type ."
89560398|NCT05025007||Cohort 1|The study cohort will consist of patients with spastic diplegic cerebral palsy who were admitted to our outpatient and inpatient clinics of the Physical Medicine and Rehabilitation Department.
89560399|NCT05014412|Experimental|Part 1|Evaluation of step-up priming dosing
89560400|NCT05014412|Experimental|Part 2A|Dose determination
89560401|NCT05014412|Experimental|Part 2B|Dose expansion
89560402|NCT05014412|Experimental|Part 2C|To explore higher dose intensity
89560403|NCT05014347||Health Care Professionals|Health Care Professionals (HCP) working in PancreatoBiliary Endoscopy and EUS Division of IRCCS San Raffaele (both endoscopists and nurses)
89560404|NCT05014347||"Expert patients"|a set of at least 30 outpatients undergoing EUS, who already underwent this procedure at least once
89560405|NCT05014347||Patients|100 consecutive patients undergoing EUS
89560406|NCT05013879|Experimental|Kinesiotape leg plus standard rehabilitation|Kinesio(R)Tape for edema management applied to a randomly selected lower extremity plus standard inpatient rehabilitation after bilateral total knee arthroplasty
89560407|NCT05013879|No Intervention|Control leg with standard rehabilitation alone|Control leg receiving standard inpatient rehabilitation alone.
89560408|NCT05013229|Experimental|IcoSema|Participants will receive once weekly subcutaneous (s.c) injections of IcoSema during the 52-week treatment period.
89560409|NCT05013229|Active Comparator|Insuling glargine/insulin aspart|Participants will receive subcutaneous (s.c) injections of insulin glargine once daily combined with 2-4 times daily injections of insulin aspart.
89560410|NCT05007782|Experimental|Part A - GS-1811 Dose Escalation|
89560411|NCT05007782|Experimental|Part B - Mandatory Paired Tumor Biopsy|
89560412|NCT05007782|Experimental|Part C: GS-1811 + Zimberelimab dose escalation|
89560413|NCT05007782|Experimental|Part D: GS-1811 + Zimberelimab dose expansion|
89560414|NCT05007782|Experimental|Part E: GS-1811 Monotherapy Dose Expansion|
89560415|NCT04982848||Talzenna treated group|Talzenna treated gBRCA Breast cancer patients in the real world setting in Korea
89560416|NCT04976322|Experimental|Dapirolizumab pegol|Subjects will receive dapriolizumab pegol throughout the Treatment Period.
88966694|NCT00393328|Active Comparator|B|
88966695|NCT05530551|Experimental|Treatment A, Single-dose practice|"One preoperative single dose of either Dicloxacillin/Cloxacillin 2g OR Cefuroxime 1.5g administered intravenously prior to surgical incision.~As the study is a non-inferiority trial, we have chosen the Experimental design category."
88966696|NCT05530551|Active Comparator|Treatment B, Multiple-dose practice|One preoperative dose of either Dicloxacillin/Cloxacillin 2g OR Cefuroxime 1.5g administered intravenously prior to surgical incision followed by 3 postoperative doses of Dicloxacillin/Cloxacillin 1g x 3 OR Cefuroxime 750mg x 3 within 24 hours after the preoperative dose.
88966697|NCT01843504|Active Comparator|Platelet Rich Plasma|Subjects in Group 1 (PRP) will receive a single US-guided injection of 5 mL autologous platelet-rich plasma at week 0 (baseline).
88966698|NCT01843504|Placebo Comparator|Group 2|Subjects in Group 2 (saline control) will receive a single injection of 5 mL 0.9% normal saline at week 0.
89560417|NCT04966715|Experimental|Patients planned for complete cytoreductive surgery|Only one arm in the study. All patients operated for complete cytoreductive surgery and who signed informed consent form
89560418|NCT04950712||Overall Study Group|Patients aged 18 years old or above, with HSV-2 genital herpes, who are recruited in specific community settings in the United States and in Europe.
89560419|NCT04946032|Active Comparator|4 cm epidural catheter|The epidural catheter will be thread into the epidural space at a length of 4 cm.
89560420|NCT04946032|Active Comparator|5 cm epidural catheter|The epidural catheter will be thread into the epidural space at a length of 5 cm.
89560421|NCT04939506|Experimental|Participants Which Receive COVID-19 Vaccine Education at the Point of COVID-19 Testing|Vaccine education will be focused on addressing misinformation and concerns in a culturally competent manner with referral to resources. The vaccine education model will be translated to reach minority groups including African Americans, Vietnamese Americans and Hispanic Americans.
89560422|NCT04937751||Invasive fusariosis|
89560423|NCT04937751||Fusarium keratitis|
89560424|NCT04927481|Experimental|Mitoxantrone Hydrochloride Liposome Injection|Patients with advanced HER2 negative breast cancer will receive 20 mg/m2 Mitoxantrone Hydrochloride Liposome injection every 21 days (a cycle) for about 6 cycles.
89560425|NCT04914286|Experimental|GFH018+Toripalimab|Patient will be dosed in GFH018 in combination with Toripalimab. In the PhaseIb part, the dose levels will be escalated following the Bayesian optimal interval (BOIN) design. In the Phase II part, patients will be assigned based on tumor type(s).
89560426|NCT04894435|Active Comparator|Group 1: Moderna, Moderna - 28 Days apart|"Participants will be blinded and receive two doses (0.20 mg/mL each) of mRNA-1273 SARS-CoV-2 vaccine via intramuscular injection in the deltoid muscle 28 days apart.~Vaccine-exposed participants will only be blinded to, and receive, the second injection."
89560427|NCT04894435|Active Comparator|Group 2: Moderna, Moderna - 112 days apart|"Participants will be blinded and receive two doses (0.20 mg/mL each) of mRNA-1273 SARS-CoV-2 vaccine at 0.20 mg/mL via intramuscular injection in the deltoid muscle 112 days apart.~Vaccine-exposed participants will only be blinded to, and receive, the second injection."
89560428|NCT04894435|Active Comparator|Group 3: Moderna, Pfizer/BioNTech - 28 days apart|"Participants will be blinded and receive one dose (0.20 mg/mL) of mRNA-1273 SARS-CoV-2 vaccine via intramuscular injection in the deltoid muscle followed by one dose (0.3mL) of BNT162b2 vaccine after 28 days.~Vaccine-exposed participants will only be blinded to, and receive, the second injection."
89560429|NCT04894435|Active Comparator|Group 4: Moderna, Pfizer/BioNTech - 112 days apart|"Participants will be blinded and receive one dose (0.20 mg/mL) of mRNA-1273 SARS-CoV-2 vaccine via intramuscular injection in the deltoid muscle followed by one dose (0.3mL) of BNT162b2 vaccine after 112 days.~Vaccine-exposed participants will only be blinded to, and receive, the second injection."
89560430|NCT04894435|Active Comparator|Group 5: Pfizer/BioNTech, Pfizer/BioNTech - 28 days apart|"Participants will be blinded and receive two doses (0.3mL each) of BNT162b2 vaccine via intramuscular injection in the deltoid muscle 28 days apart.~Vaccine-exposed participants will only be blinded to, and receive, the second injection."
89560431|NCT04894435|Active Comparator|Group 6: Pfizer/BioNTech, Pfizer/BioNTech - 112 days apart|"Participants will be blinded and receive two doses (0.3mL each) of BNT162b2 vaccine via intramuscular injection in the deltoid muscle 112 days apart.~Vaccine-exposed participants will only be blinded to, and receive, the second injection."
89560432|NCT04894435|Active Comparator|Group 7: Pfizer/BioNTech, Moderna - 28 days apart|"Participants will be blinded and receive one dose (0.3mL) of BNT162b2 vaccine via intramuscular injection in the deltoid muscle followed by one dose (0.20 mg/mL) of mRNA-1273 SARS-CoV-2 vaccine after 28 days.~Vaccine-exposed participants will only be blinded to, and receive, the second injection."
89560433|NCT04894435|Active Comparator|Group 8: Pfizer/BioNTech, Moderna - 112 days apart|"Participants will be blinded and receive one dose (0.3mL) of BNT162b2 vaccine via intramuscular injection in the deltoid muscle followed by one dose (0.20 mg/mL) of mRNA-1273 SARS-CoV-2 vaccine after 112 days.~Vaccine-exposed participants will only be blinded to, and receive, the second injection."
89560434|NCT04894435|Active Comparator|Group 9: Astra Zeneca, Moderna - 28 days apart|"Participants will be blinded and receive one dose (0.5 ml) of ChAdOx1-S [recombinant] vaccine via intramuscular injection in the deltoid muscle followed by one dose (0.20 mg/mL) of mRNA-1273 SARS-CoV-2 vaccine after 28 days.~Vaccine-exposed participants will only be blinded to, and receive, the second injection."
89560435|NCT04894435|Active Comparator|Group 10: Astra Zeneca, Moderna - 112 days apart|"Participants will be blinded and receive one dose (0.5 ml) of ChAdOx1-S [recombinant] vaccine via intramuscular injection in the deltoid muscle followed by one dose (0.20 mg/mL) of mRNA-1273 SARS-CoV-2 vaccine after 112 days.~Vaccine-exposed participants will only be blinded to, and receive, the second injection."
89560436|NCT04894435|Active Comparator|Group 11: Astra Zeneca, Pfizer/BioNTech - 28 days apart|"Participants will be blinded and receive one dose (0.5 ml) of ChAdOx1-S [recombinant] vaccine via intramuscular injection in the deltoid muscle followed by one dose (0.3 mL) of BNT162b2 vaccine after 28 days.~Vaccine-exposed participants will only be blinded to, and receive, the second injection."
89560437|NCT04894435|Active Comparator|Group 12: Astra Zeneca, Pfizer/BioNTech - 112 days apart|"Participants will be blinded and receive one dose (0.5 ml) of ChAdOx1-S [recombinant] vaccine via intramuscular injection in the deltoid muscle followed by one dose (0.3 mL) of BNT162b2 vaccine after 112 days.~Vaccine-exposed participants will only be blinded to, and receive, the second injection."
89560438|NCT04894435|Active Comparator|Group 1b|Participants will be blinded and receive one dose (0.3mL) of BNT162b2 vaccine via intramuscular injection in the deltoid muscle.
89560439|NCT04894435|Active Comparator|Group 2b|Participants will be blinded and receive one half dose (0.25mL) of mRNA-1273 vaccine via intramuscular injection in the deltoid muscle.
89560440|NCT04894435|Active Comparator|Group 3b|Participants will be blinded and receive one half dose (0.25mL) of mRNA-1273 vaccine via intramuscular injection in the deltoid muscle.
89560441|NCT04894435|Active Comparator|Group 4b|Participants will be blinded and receive one dose (0.3mL) of BNT162b2 vaccine via intramuscular injection in the deltoid muscle.
88966699|NCT01807468|Experimental|HaploSC+NK|
88966700|NCT01807429|Experimental|Ketamine-midazolam|300 to 500 mcg/kg ketamine plus 0.03 mg/kg midazolam
88966701|NCT01807429|Active Comparator|Morphine|0.05 to 0.1 mg/kg morphine
88966702|NCT01807312|Experimental|CO2 insufflation|CO2 insufflations was applicated in routine colonoscopy examination with Endoscopic CO2 regulation unit and accessories
89560442|NCT04894435|Active Comparator|Group 5b|Participants will be blinded and receive one half dose (0.25mL) of mRNA-1273 vaccine via intramuscular injection in the deltoid muscle.
89560443|NCT04894435|Active Comparator|Group 6b|Participants will be blinded and receive one dose (0.3mL) of BNT162b2 vaccine via intramuscular injection in the deltoid muscle.
88966703|NCT01807312|Placebo Comparator|Air insufflation|Air insufflations is applicated in Routine Colonoscopy Examination
88966704|NCT01807273||Hemiplegic subjects|60 hemiplegic outpatients walking test
88966705|NCT01807195||the medical records of those in whom a contrast medium|
88966706|NCT01807078|Active Comparator|Ezetimibe|Patients will receive for 6 months ezetimibe (10 mg/day)
88966707|NCT01807078|Active Comparator|Nutraceuticals|Patients will receive for 6 months a commercially available nutraceutical combined pill (1 capsule/day containing monacolin K 10 mg, policosanol 10 mg, and phytosterols 300 mg
88966708|NCT01807039||patients after surgery with isolated proximal femur fracture|Patients between 18-110 years admitted to Faculty Hospital Brno with isolated injury of proximal femur (ICD dg. S72.0 a S72.1)who underwent surgery between 1.1. 2011 00:00 - 31.12. 2012 23:59 in Faculty hospital Brno (tertiary care university hospital).
88966709|NCT05526885|Experimental|Approach 1 - CAD4TB screening|Participants with a CAD4TB version 7 (Delft Imaging, NL) score above the overall threshold (as defined for study approach 1) are eligible for Xpert MTB/RIF Ultra testing.
88966710|NCT05526885|Experimental|Approach 2 - CAD4TB screening with POC-CRP triage testing|Participants with a CAD4TB version 7 (Delft Imaging, NL) score within the threshold window (between lower and upper limit threshold as defined for study approach 2), a POC-CRP LumiraDx (LumiraDx Limited, UK) test will follow as a triage test. If CRP is above the determined threshold as defined for approach 2, Xpert MTB/RIF Ultra will be performed. If the CAD4TB score is above the upper limit threshold as defined for approach 2, Xpert MTB/RIF Ultra will be performed (without further CRP testing).
88966711|NCT01349803|Experimental|PT005 MDI|PT005 MDI
88966712|NCT01349803|Experimental|PT001 MDI|PT001 MDI
88966713|NCT01349803|Experimental|PT003 MDI|PT003 MDI
88966714|NCT01349803|Active Comparator|Formoterol Fumarate 12 μg (Foradil® Aerolizer®)|Formoterol Fumarate 12 μg (Foradil® Aerolizer®)
88966715|NCT01807000|Experimental|Radiolabeled Prucalopride Succinate|
88966716|NCT04636853|Experimental|Affected Individual|A subretinal injection of umbilical cord blood platelet-rich plasma (CB-PRP) will be performed only in one eye, the other eye will be considered as a control group.
88966717|NCT01806922|Experimental|Yoga training, Tradiational physiotherapy|Experimental Group(20 people) receive tradiational physiotherapy(4 times in a week, every time 1 hour), and 8-weeks yoga training(2 time in a week, every time 1 hour)
88966718|NCT01806922|No Intervention|Tradiational physiotherapy|Control Group(20 people)only receive tradiational rehabiliation( 4 times in a week, every time 1 hour ) for 8 weeks.
88966719|NCT01806883|Experimental|Rehabilitation using Nintendo-Wii|30 patients will receive rehabilitation using Nintendo-Wii.
88966720|NCT01806883|Active Comparator|Traditional physiotherapy|30 patients will receive traditional physiotherapy.
88966721|NCT05520060|Experimental|experimental|The experimental group will be placed in continuous midwifery care. The continuous and supportive care stages to be presented at birth are planned within the framework of Kolcaba's comfort theory. According to this theory, interventions will be applied according to the physical, psychospiritual, environmental and sociocultural comfort needs of women.
88966722|NCT05520060|Placebo Comparator|Control|The experimental group will be placed in routine midwifery care.
88966723|NCT01806805|Experimental|Zonegran|Zonegran / Placebo Zonisamide (Zonegran ®) and its placebo appear under the shape of virgin capsules of size 1. Each drug will be dispensed successively in a box containing blister packs of 14 capsules. For every period (A and B), box will contain 26 blister packs. A phase of progressive increase of doses by stages of 50 mg / week is planned before reaching the fixed dose of 300 in the daytime during 4 weeks. Then, a progressive diminution over two weeks is planned before the stop.
88966724|NCT01806805|Placebo Comparator|placebo|Placebo /Experimental Zonisamide (Zonegran ®) and its placebo appear under the shape of virgin capsules of size 1. Each drug will be dispensed successively in a box containing blister packs of 14 capsules. For every period (A and B), box will contain 26 blister packs. A phase of progressive increase of doses by stages of 50 mg / week is planned before reaching the fixed dose of 300 in the daytime during 4 weeks. Then, a progressive diminution over two weeks is planned before the stop.
88966725|NCT01806766|Active Comparator|Ceramic on Ceramic|Ceramic on Ceramic bearing coupled side of a single patient undergoing bilateral total hip arthroplasty
89026881|NCT05645263|Experimental|Cola 2（5d）|The patients in intervention group 2 dieted Coca-cola to treat gastric phytobezoars, 250ml-500ml/2 h till to sleeping time according to the health conditions and life habits. Pay more attention to the stools and assess if the bezoars had excreted. The dieting Coca-cola period is 5 days. The patients will go through an endoscopy once the Coca-cola dieting therapy is over.
89560444|NCT04894435|Active Comparator|Group 7b|Participants will be blinded and receive one dose (0.3mL) of BNT162b2 vaccine via intramuscular injection in the deltoid muscle.
89560445|NCT04894435|Active Comparator|Group 8b|Participants will be blinded and receive one half dose (0.25mL) of mRNA-1273 vaccine via intramuscular injection in the deltoid muscle.
89560446|NCT04894435|Experimental|Group 9b|Participants will receive one dose (0.5mL) of Covifenz vaccine via intramuscular injection in the deltoid muscle.
88966726|NCT01806766|Active Comparator|Ceramic on HXPE|Ceramic on HIghly crosslinked polyethylene bearing coupled side of a single patient undergoing bilateral total hip arthroplasty
88966727|NCT01806727|Active Comparator|Diabetes Self Management (DSM)|Diabetes Self Management education, delivered in the clinics, using group-based visits and targeting improved control of hemoglobin A1c and related risk factors.
88966728|NCT01806727|Experimental|Community Lifestyle Weight Loss (LWL)|Participants with type 2 diabetes will be enrolled in a 12 month lifestyle intervention designed to achieve a mean >7% weight loss induced through caloric restriction and increased physical activity. The intervention will be delivered via supervised Community Health Workers (CHWs). Most meetings will be at a community location.
88966729|NCT01806688|Experimental|Experimental Snack #1|One of three interventions to be administered at each visit, an experimental snack, a placebo comparator reference product or a placebo comparator non-caloric control. The experimental snack #1 is a gluten-free high protein snack comprised of a 30g serving of buckwheat groats. The placebo comparator reference product is a gluten-free snack with similar energy density, but 1/2 the protein as snack #1, comprised of a 32g serving of corn nuts. The placebo comparator non-caloric control is water.
88966730|NCT01806688|Experimental|Experimental Snack #2|One of three interventions to be administered at each visit, an experimental snack, a placebo comparator reference product or a placebo comparator non-caloric control. The experimental snack #2 is a gluten-free high protein and high fibre snack comprised of a 50g serving of a buckwheat and pinto bean flour pita bread. The placebo comparator reference product is a gluten-free snack with similar energy density, but less protein and fibre than snack #2, comprised of a 50g serving of rice bread. The placebo comparator non-caloric control is water.
88966731|NCT00387413|Experimental|Treatment Arm A1|In treatment Arm A1 Period 1 subject will receive 50 mcg GSK189254 plus Duloxetine Placebo in Week 1, in Week 2 subject will receive 100 mcg GSK189254 plus Duloxetine Placebo and in Week 3 subject will receive GSK189254 Placebo plus Duloxetine Placebo. In treatment Arm A1 Period 2 subject will receive GSK189254 Placebo plus Duloxetine Placebo for all 3 Weeks. There will be a washout of approximately one week between periods 1 and 2.
88966732|NCT00387413|Experimental|Treatment Arm A2|In treatment Arm A2 Period 1 subject will receive GSK189254 Placebo plus Duloxetine Placebo for all 3 Weeks. In treatment Arm A2 Period 2 subject will receive 50 mcg GSK189254 plus Duloxetine Placebo in Week 1, in Week 2 subject will receive 100 mcg GSK189254 plus Duloxetine Placebo and in Week 3 subject will receive GSK189254 Placebo plus Duloxetine Placebo. There will be a washout of approximately one week between periods 1 and 2.
88966733|NCT00387413|Experimental|Treatment Arm B1|In treatment Arm B1 Period 1 subject will receive 30 milligram (mg) Duloxetine plus GSK189254 Placebo in Week 1, in Week 2 60 mg Duloxetine plus GSK189254 Placebo and in Week 3 30 mg Duloxetine plus GSK189254 Placebo. In treatment Arm B1 Period 2 subject will receive GSK189254 Placebo plus Duloxetine Placebo for all 3 Weeks. There will be a washout of approximately one week between periods 1 and 2.
88966734|NCT00387413|Experimental|Treatment Arm B2|In treatment Arm B2 Period 1 subject will receive GSK189254 Placebo plus Duloxetine Placebo for all 3 Weeks. In treatment Arm B2 Period 2 subject will receive 30 milligram (mg) Duloxetine plus GSK189254 Placebo in Week 1, in Week 2 60 mg Duloxetine plus GSK189254 Placebo and in Week 3 30 mg Duloxetine plus GSK189254 Placebo. There will be a washout of approximately one week between periods 1 and 2.
88966735|NCT01806649|Experimental|BKM120|BKM120, starting at 100 mg oral once daily
88966736|NCT01806610|Experimental|BPS804|Single dose BPS804 administration.
88966737|NCT01806610|Placebo Comparator|Placebo|Single dose placebo administration.
88966738|NCT05517291|Experimental|DCB|participants in this group will be received drug-coated balloon angioplasty
88966739|NCT05517291|Active Comparator|stenting|participants in this group will be received primary selective stenting
88966740|NCT03852836|Other|1.5T magnetic field|For each patient who undergo a 1.5T MRI, 3 sequences will be done: (i) a conventional SPACE sequence, (ii) an ultra-rapid sequence (sequence CS-SPACE) acquired in apnoea and (iii) an accelerated sequence (sequence CS-SPACE) but remaining synchronized with the breath.
88966741|NCT03852836|Other|3T magnetic field|For each patient who undergo a 3T MRI, 3 sequences will be done: (i) a conventional SPACE sequence, (ii) an ultra-rapid sequence (sequence CS-SPACE) acquired in apnoea and (iii) an accelerated sequence (sequence CS-SPACE) but remaining synchronized with the breath.
88966742|NCT05492955|Active Comparator|Standard of Care (SOC)|Participants will receive clinic-based standard of care
88966743|NCT05492955|Experimental|Community Health Worker Care Model (CHW)|Participants will be given a standard blood pressure cuff (Omron) for at-home BP monitoring, and will be assigned to a CHW for follow-up visits and medication delivery.
88966744|NCT05492955|Experimental|Enhanced Community Health Worker + Mobile Health Monitoring (eCHW+)|Participants will be given a blood pressure cuff with cellular capability (Blipcare) for at-home BP monitoring which automatically transmit BP data to our server for nurse review. These participants will also be assigned to a CHW for follow-up visits and medication delivery.
88966745|NCT01806532||18F-FDG PET-CT|A total of 10 patients with acute respiratory distress syndrome (ARDS) will be imaged with 2-18F-fluoro-2-deoxy-D-glucose (18F-FDG) and PET-CT scan.
88966746|NCT01806493||obese subjects|One hundred and three overweight or obese subjects were included in the study: 74 women (aged 41.5±10 years) and 29 men (aged 43.8±8 years);
88966747|NCT01806454|Active Comparator|calcium A|tablets, 600mg per day,till birth
88966748|NCT01806454|Active Comparator|calcium B|tablets,1200mg per day,till birth
88966749|NCT03846089||Retrograde reperfusion|After completion of the inferior vena cava anastomosis, the clamps were removed to allow retrograde reperfusion of the graft.
88966750|NCT03846089||Antegrade reperfusion|After completion of the inferior vena cava anastomosis, the portal vein anastomosis is completed and then the clamps were removed to allow antegrade reperfusion of the graft.
88966751|NCT01806415|Experimental|Fenobam 50 mg|Treatment regimen 1: Fenobam [1-(3-chlorophenyl)-3-(1-methyl-4-oxo-2-imidazolidinylidine) urea hydrate], oral administration of one 50 mg gelatin capsule.
88966752|NCT01806415|Experimental|Fenobam 100 mg|Treatment regimen 2: Fenobam, oral administration of one 100 mg gelatin capsule.
88966753|NCT01806415|Experimental|Fenobam 150 mg|Treatment regimen 3: Fenobam, oral administration of one 150 mg gelatin capsule.
88966754|NCT01806415|Placebo Comparator|Placebo arm|Treatment regimen 4: Placebo (lactose), oral administration of one 150 mg gelatin capsule.
88966755|NCT01806376|Experimental|Subutinib Maleate capsules|Dose escalation will be dependent on any dose limiting toxicities
88966756|NCT01806337|Experimental|Alemtuzumab, antibody|alemtuzumab - anti CD 52 antibody administered as consolidation, total dose 133 mg
89026882|NCT05645263|Experimental|Cola 3（7d）|The patients in intervention group 3 dieted Coca-cola to treat gastric phytobezoars, 250ml-500ml/2 h till to sleeping time according to the health conditions and life habits. Pay more attention to the stools and assess if the bezoars had excreted. The dieting Coca-cola period is 7 days. The patients will go through an endoscopy once the Coco-cola dieting therapy is over.
89208488|NCT02596217|Experimental|Stage 1 (medium dose SC)|Medium dose administered by subcutaneous (SC) injection
89560447|NCT04894435|Active Comparator|Group 1c|Participants will be blinded and receive one dose (0.3mL) of BNT162b2 vaccine via intramuscular injection in the deltoid muscle.
89560448|NCT04894435|Active Comparator|Group 2c|Participants will be blinded and receive one dose (0.5mL) of Covifenz vaccine via intramuscular injection in the deltoid muscle.
89560449|NCT04894435|Active Comparator|Group 3c|Participants will be blinded and receive one half dose (0.25mL) of mRNA-1273 vaccine via intramuscular injection in the deltoid muscle.
89560450|NCT04894435|Active Comparator|Group 4c|Participants will be blinded and receive one dose (0.5mL) of Covifenz vaccine via intramuscular injection in the deltoid muscle.
89560451|NCT04894435|Active Comparator|Group 5c|Participants will be blinded and receive either one dose (0.3mL) of BNT162b2 or one half dose (0.25mL) of mRNA-1273 via intramuscular injection in the deltoid muscle.
89560452|NCT04894435|Active Comparator|Group 6c|Participants will be blinded and receive one dose (0.5mL) of Covifenz vaccine via intramuscular injection in the deltoid muscle.
89560453|NCT04894435|Experimental|Group 7c|Participants will receive one dose (0.5mL) of Covifenz vaccine via intramuscular injection in the deltoid muscle.
89560454|NCT04892043|Experimental|Part 1 Monotherapy Dose Escalation Phase|"In Part 1, SQZ-AAC-HPV as a monotherapy is administered every 3 weeks for up to a year.~There are 3 groups (Cohorts) in this Phase as follows:~Cohort 1a: low dose SQZ-AAC-HPV~Cohort 1b: high dose SQZ-AAC-HPV~Cohort 1c: higher or lower dose SQZ-AAC-HPV"
89560455|NCT04892043|Experimental|Part 2 Combination Safety Phase|"In Part 2, SQZ-AAC-HPV in combination with immune checkpoint inhibitors (1) ipilimumab, (2) nivolumab, or (3) nivolumab plus ipilimumab is administered every 3 weeks up to a year, but the immune checkpoint inhibitors may be administered up to 2 years. There are 3 groups (Cohorts) in this Phase as follows:~Cohort 2a: SQZ-AAC-HPV RP2D (Recommended Phase 2 Dose) plus ipilimumab~Cohort 2b: SQZ-AAC-HPV RP2D plus nivolumab~Cohort 2c: SQZ-AAC-HPV RP2D plus nivolumab and ipilimumab"
89560456|NCT04888091|Active Comparator|Cervical mucus removal with cotton swab|Cervical mucus will be removed with cotton swab before embryo transfer
89560457|NCT04888091|Active Comparator|Cervical mucus removal with cannula|Cervical mucus will be removed with cannula before embryo transfer
89560458|NCT04888091|No Intervention|No cervical mucus removal|Cervical mucus will not be removed prior to embryo transfer
89560459|NCT04871893|Other|Treatment with the blood-gas exchanger multiECCO2R for CO2 removal|Treatment of patients suffering from hypercapnia due to acute lung failure and acute kidney injury (AKI). Patients will be treated up to 72 hours with CVVHD/HDF with a standard multiFiltrate blood line kit (multiFiltrate or multiFiltrate Pro). In order to perform an ECCO2R procedure during CVVHD/HDF treatment, the blood-gas exchanger multiECCO2R is inserted in a specifically designed blood line kit downstream of the hemodialyzer.
89560460|NCT04852432|No Intervention|Control group|Nasal prong is applied, but sedation is performed without oxygen administration.
89560461|NCT04852432|Experimental|Low flow group|Oxygen administration by nasal cannula
89560462|NCT04852432|Experimental|High flow group|Oxygen is administered at a rate of 2L/kg/min using an Optiflow device
89560463|NCT04837716|Experimental|Treatment (ensartinib, carboplatin, pemetrexed, bevacizumab)|"INDUCTION THERAPY: Patients receive ensartinib PO QD on days 1-21, carboplatin IV over 15-60 minutes on day 1, pemetrexed IV over 10 minutes on day 1 and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive ensartinib PO QD on days 1-21 and bevacizumab IV over 30-90 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity."
89560464|NCT04833829|Active Comparator|Clinic Patients During the Pre-implementation Period|Patients visiting one of the study clinics prior to implementation of the CHIMES intervention. The Baseline time period consists of study Months 1 - 12. Data are retroactively abstracted from medical records of patients who had clinic visits that occurred between January 1, 2019 and December 31, 2019.
89560465|NCT04833829|Experimental|Clinic Patients During the Implementation Period|Patients visiting one of the study clinics during the Implementation period of the CHIMES intervention. Data will be abstracted from medical records of visits that occur during study Months 13 - 27.
89560466|NCT04833829|Experimental|Clinic Patients During the Maintenance Period|Patients visiting one of the study clinics during the Maintenance period of the CHIMES intervention. Data will be abstracted from medical records of visits that occur during study Months 28 - 33.
89560467|NCT04826250|Experimental|Hypertensive patients - nighttime medication|Hypertensive patients will be instructed to take their medication in the evening for four consecutive weeks. At the end of this period, participants will switch the timing of medication to the morning for four weeks.
89560468|NCT04826250|Experimental|Hypertensive patients - morning medication|Hypertensive patients will be instructed to take their medication in the morning for four consecutive weeks. At the end of this period, participants will switch the timing of medication to the evening for four weeks.
89560469|NCT04820257|Experimental|Home based exercise|Home based exercise with health coaching
89560470|NCT04820257|No Intervention|Usual care|Usual care, waiting list
89560471|NCT04813055||Therapeutic EUS|Procedures involving Linear Echoendoscopes to create a communication between the gastrointestinal tract and a target organ (biliary tree, pancreatic duct, fluid collection, gallbladder, downstream gastrointestinal tract) through plastic or metal stents.
89560472|NCT04813055||Controls|Patients eligible for T-EUS procedures, but undergoing alternative surgical interventions, percutaneous interventions (e.g. Percutaneous Biliary Drainage) or non-EUS based endoscopic procedures (e.g. enteral stenting)
89560473|NCT04809311||Lifestyle intervention ± metformin|Patients will continue their antidiabetic treatment as per usual clinical practice at the discretion of their own treating physician.
89560474|NCT04809311||Other oral antidiabetic drugs (OADs) ± metformin|Patients will continue their antidiabetic treatment as per usual clinical practice at the discretion of their own treating physician
89560475|NCT04809311||Basal insulin ± OADs|Patients will continue their antidiabetic treatment as per usual clinical practice at the discretion of their own treating physician
89560476|NCT04809311||Glucagon-like peptide-1 (GLP-1) ± Basal insulin (loose and fixed combination) ± OADs|Patients will continue their antidiabetic treatment as per usual clinical practice at the discretion of their own treating physician
89560477|NCT04809311||Basal + Bolus or premixed insulin ± OADs|Patients will continue their antidiabetic treatment as per usual clinical practice at the discretion of their own treating physician
89560478|NCT04803994|Experimental|Systemic therapy with atezolizumab + bevacizumab|"Patients receive atezolizumab 1200 mg flat dose plus bevacizumab 15 mg/kg given intravenously every 3 weeks until failure of strategy, participant request, or withdrawal of consent for a maximum of up to 24 months.~The discontinuation of one of the study drugs for toxicity reasons does not qualify as failure of treatment strategy as long as the other drug can be continued according to protocol."
89560479|NCT04803994|Active Comparator|Locoregional therapy with TACE|"Patients will receive initial TACE and - if required to achieve or improve an objective response - a second TACE after 8 weeks (±7 days window). Thereafter, additional TACE can be applied on demand until failure of strategy, participant request, or withdrawal of consent for a maximum of up to 24 months.~TACE must be discontinued in cases of technical difficulties making additional TACE impossible.~Only conventional TACE (cTACE) and drug-eluting bead TACE (DEB-TACE) approaches are accepted as TACE therapy. However, consistency in the TACE procedure and the use of the chemotherapeutic agent has to be maintained for each individual patient."
89560480|NCT04790110||Studie A ESO - monitoring|Patients that present themselves at the clinic through referral from their dentist with tooth wear, who have no request for help, receive a non-restorative 'counseling & monitoring' strategy , in which appropriate preventive measures are recommended and wear and tear is monitored and recorded by periodically taking intra-oral photographs and 3D scans
89560481|NCT04781192|Experimental|Dose Finding Regorafenib|We will use a 3 + 3 design with two dose levels of 80 mg and 120 mg to discover the Maximum Tolerated Dose (MTD) for regorafenib
89560482|NCT04774887|Experimental|HPV vaccination|Children receiving HPV vaccine will be studies for seroconversion to HPV types, and aflatoxin levels in blood will be measured and compared to seroconversion.
89560483|NCT04748445||All participants|
89560484|NCT04742777|Experimental|Rapamycin|Rapamycin 1mg for 8 weeks
89560485|NCT04740541|Experimental|Threonine Requirement in CD Patients|Males aged 18 - 49 with stable Crohn's disease will be seen for pre-study They will be studied up to 5 times for different levels of threonine intakes.
89560486|NCT04737720||1|This is an expanded use protocol for a named subject.
89560487|NCT04721977|Experimental|Tucatinib + Trastuzumab + Capecitabine|Participants will receive tucatinib plus trastuzumab plus capecitabine. Tucatinib 300 mg will be administered orally twice daily (BID). Trastuzumab 8 mg/kg loading dose followed by 6 mg/kg maintenance dose thereafter, will be administered intravenously (IV) on Day 1 of each 21-day cycle. Capecitabine 1000 mg/m^2 will be administered orally BID on Days 1-14 of each 21-day cycle. Tucatinib, trastuzumab and capecitabine treatment will continue until unacceptable toxicity, disease progression, death, withdrawal of consent or study closure.
89560488|NCT04720781|Active Comparator|Vonoprazan|Vonoprazan (20mg/day) is prescribed for patients with erosive esophagitis
89560489|NCT04720781|Placebo Comparator|Esomeprazole|Esomeprazole (20mg/day) is prescribed for patients with erosive esophagitis
89560490|NCT04718896|Experimental|Bimekizumab Dose A|Study participants randomized to this arm will receive bimekizumab (BKZ) Dose A at pre-specified time points during the study.
89560491|NCT04718896|Experimental|Bimekizumab Dose B|Study participants randomized to this arm will receive bimekizumab (BKZ) Dose B at pre-specified time points during the study.
89560492|NCT04716881|Experimental|Vivitrol (naltrexone)|Intramuscular injection of Vivitrol (naltrexone), 380 mg. Six doses given 28 days apart.
89560493|NCT04709341|Experimental|Group A|
89560494|NCT04709341|Active Comparator|Group B|
89560495|NCT04707872||Heart transplant protocol and for cause biopsies|The study population includes patients with a functioning heart transplant undergoing a biopsy for clinical indications as standard of care, or protocol biopsies of heart in high-risk patients, or follow-up after treatment.
89560496|NCT04706026|Experimental|Open Inguinal Repair- Local anesthesia|This arm will receive local anesthesia for their open inguinal hernia repair.
89560497|NCT04706026|Active Comparator|Inguinal Hernia Repair- General Anesthesia|This arm will receive general anesthesia for their open inguinal hernia repair.
89560498|NCT04704258|Experimental|TAVI + Embolic protection|Subjects with severe native aortic valve stenosis who meet the clinically approved indications for aortic valve interventions such as TAVI
89560499|NCT04698187|Experimental|CMP-001 and Nivolumab|All enrolled subjects will receive CMP-001 IT and nivolumab IV according to the treatment schedule until a reason for treatment discontinuation is reached.
89560500|NCT04695197|Active Comparator|Artemether-lumefantrine|Artemether-lumefantrine, standard 3-day antimalarial treatment regimen.
89560501|NCT04695197|Experimental|Pyronaridine-artesunate|Pyronaridine-artesunate, standard 3-day antimalarial treatment regimen.
89560502|NCT04678986||ER2 participants|all participants of ER2 database will be included in the analysis
89560503|NCT04666922|Experimental|1 mg BI 765080|BI 765080
89560504|NCT04666922|Placebo Comparator|Placebo group|Placebo group
89560505|NCT04666922|Experimental|10 mg BI 765080|BI 765080
89560506|NCT04666922|Experimental|25 mg BI 765080|BI 765080
89560507|NCT04666922|Experimental|50 mg BI 765080|BI 765080
89560508|NCT04666922|Experimental|100 mg BI 765080|BI 765080
89026883|NCT05645263|No Intervention|Fragmentation 1|The patients who chose emergently endoscopic fragmentation was enrolled in control group 1. All patients endorsed the informed consent paper, no diet for at least 4 hours, no drink for 2 hours and bring the medical records before endoscopy and go on a mechanical fragmentation through gastroendoscopy
89560509|NCT04666922|Experimental|200 mg BI 765080|BI 765080
89560510|NCT04660214|Active Comparator|Vessel sealing device|Endoscopic diverticulectomy is performed with the LigaSure (TM) device
89560511|NCT04660214|Active Comparator|Dissecting Knife device|Endoscopic diverticulectomy is performed with the SB-Knife(TM) device
89608765|NCT03589053|Experimental|LRIC group|Participants in the experimental group receive both LRIC and standard clinical therapy. The LRIC treatment is composed of 5 cycles of bilateral upper limb ischemia for 5 minutes followed by reperfusion for another 5 minutes performed twice a day for a total of 90 consecutive days.The procedure was performed by using an electric autocontrol device with cuffs that inflated to a pressure of 200 mmHg during the ischemic period and deflated during the reperfusion (Patent No.CN200820123637.X, China).
89560512|NCT04658472|Experimental|SOC-Refractory Initial Dose|"Part A: Eligible participants will receive SAR445088 for 24 weeks. Participants who do not enroll into Part B will be asked to attend a final safety follow-up visit that will take place 22 weeks after Week 24 (approximately (~)at Week 46).~Part B: Participants who successfully complete Part A, will be reassessed for continuing eligibility and will be given the option of rolling into Part B, where they will continue receiving SAR445088 for an additional 52 weeks. At the end of the Part B treatment period, participants will be asked to attend a safety follow-up visit that will take place 22 weeks after the last SAR445088 dose (approximately week 98) if they will not continue in Part C.~Part C: Participants from Part B who enter Part C will continue receiving SAR445088 until the end of study.~Participants who discontinue at any time during Part C will be asked to attend a safety follow-up visit that will take place 22 weeks after the last SAR445088 dose."
89208489|NCT02596217|Experimental|Stage 1 (high dose SC)|High dose administered by subcutaneous (SC) injection
89560513|NCT04658472|Experimental|SOC-Refractory Low Dose|"Part A: Eligible participants will receive SAR445088 for 24 weeks. Participants who do not enroll into Part B will be asked to attend a final safety follow-up visit that will take place 22 weeks after Week 24 (approximately at Week 46).~Part B: Participants who successfully complete Part A, will be reassessed for continued eligibility and will be given the option to roll into Part B, where they will continue receiving SAR445088 for an additional 52 weeks. At the end of the Part B treatment period, participants will be asked to attend a safety follow-up visit that will take place 22 weeks after the last SAR445088 dose (approximately week 98) if they do not continue in Part C.~Part C: Participants from Part B who enter Part C will continue receiving SAR445088 until the end of study.~Participants who discontinue at any time during Part C will be asked to attend a safety follow-up visit that will take place 22 weeks after the last SAR445088 dose."
89560514|NCT04658472|Experimental|SOC-Treated Initial Dose|"Part A: Eligible participants will receive SAR445088 for 24 weeks. Weeks 1-12 (overlap period): Participants will be given SAR445088 with superimposing effects of SOC therapy; Weeks 13-24: SAR445088 given.~Participants who do not enroll into Part B will attend final safety follow-up visit at 22 weeks after Week 24 (~Week 46).~Part B: Participants who successfully complete Part A, will be reassessed for continuing eligibility and will be given option of rolling into Part B, and continue receiving SAR445088 for 52 weeks. At the end of the Part B treatment period, participants will be asked to attend a safety follow-up visit that will take place 22 weeks after the last SAR445088 dose (~week 98) if they do not continue in Part C.~Part C: Participants from Part B who enter Part C will continue receiving SAR445088 until end of study.~Participants who discontinue at any time during Part C will be asked to attend a safety follow-up visit at 22 weeks after the last SAR445088 dose."
89560515|NCT04658472|Experimental|SOC-Naive|"Part A: Eligible participants will receive SAR445088 for 24 weeks. Participants who do not enroll into Part B will be asked to attend a final safety follow-up visit that will take place 22 weeks after Week 24 (approximately at Week 46).~Part B: Participants who successfully complete Part A, will be reassessed for continuing eligibility and will be given the option of rolling into Part B, where they will continue receiving SAR445088 for an additional 52 weeks. At the end of the Part B treatment period, participants will be asked to attend a safety follow-up visit that will take place 22 weeks after last SAR445088 dose (approximately week 98) if they do not continue in Part C.~Part C: Participants from Part B who enter Part C will continue receiving SAR445088 until the end of study. Participants who discontinue at any time during Part C will be asked to attend a safety follow-up visit that will take place 22 weeks after last SAR445088 dose."
89560516|NCT04658472|Experimental|SOC-Treated Low Dose|"Part A: Eligible participants will receive SAR445088 for 24 weeks. Weeks 1-12 (overlap period): Participants will be given SAR445088 with superimposing effects SOC therapy; Weeks 13-24: SAR445088. Participants who do not enroll into Part B will attend a final safety follow-up visit that will take place 22 weeks after Week 24 (~Week 46).~Part B: Participants who successfully complete Part A, will be reassessed for continued eligibility, will be given the option of rolling into Part B, and continue receiving SAR445088 for 52 weeks. At the end of the Part B treatment period, participants will attend a safety follow-up visit that will take place 22 weeks after the last SAR445088 dose (~week 98) if they do not continue in Part C.~Part C: Participants from Part B who enter Part C will continue receiving SAR445088 until end of study. Participants who discontinue at any time in Part C will attend a safety follow-up visit that will take place 22 weeks after the last SAR445088 dose."
89560517|NCT04634812|Experimental|[14C]-KBP-5074|
89560518|NCT04630665|Other|thin buccal bone|immediate implant placement in thin buccal bone wall socket
89560519|NCT04630665|Other|≥1 buccal bone|immediate implant placement in 1 mm or more buccal bone thickness socket
89560520|NCT04624698|Experimental|Implantation|Subjects will undergo cataract surgery and then implantation of the iStent Inject trabecular micro-bypass device.
89560521|NCT04606537|Experimental|Cohort 1 (Effects of CYP3A4 inhibition on KBP-5074)|
89560522|NCT04606537|Experimental|Cohort 2 (Effects of CYP3A4 induction on KBP-5074)|
89560523|NCT04601428|Experimental|Investigational Arm|
89608766|NCT03589053|Sham Comparator|Control group|Participants in the control group receive both sham LRIC and standard clinical therapy.
89608767|NCT03587103|Experimental|Protocol initiate with A|Eligible participants will be randomized to receive one of the protocols initiated with A, or the protocols initiated with two-drug combination therapy with full dose A.
89608768|NCT03587103|Experimental|Protocol initiate with C|Eligible participants will be randomized to receive one of the protocols initiated with C, or the protocols initiated with two-drug combination therapy with full dose C.
89608769|NCT03587103|Experimental|Protocol initiate with D|Eligible participants will be randomized to receive one of the protocols initiated with D, or the protocols initiated with two-drug combination therapy with full dose D.
89608770|NCT01611259|Experimental|Rituximab and Lenalidomide|Single arm: 6 cycles for patients with complete response, 8 cycles for subjects with stable disease or partial remission; cycles duration: 28 days Rituximab (Mabthera®): 375 mg/m² i.v. day 1 Lenalidomide (Revlimid®): 20 mg p.o. daily for 21 days
88966757|NCT04581317|Experimental|Phase 1 (meals only)|Participants will receive meals delivered to them by the Meals oN wheels(MOW) program for 6 weeks.MOW will once a week deliver in-person enough frozen meals to cover lunch for 5 days and breakfast for 7 days. Study staff will call the participants twice a week to ask 5 questions about their health, mood, and meal consumption.At the end of the 6 weeks, a study team member will make an in-person visit to the participants' homes to measure Fried Frailty Phenotype(FFP), MHS, CES-D, MOCA, Activities of Daily Living (ADL)/Instrumental activities of daily living(IADL)s, NSI, and ZCBI. Caregivers will not receive meals during this first phase as the focus is on the nutritional status of the cognitively impaired older adult.
88966758|NCT04581317|Experimental|Phase 2 (Meals + Amazon Echo Show 8 (AES 8) basic usage)|Participants will have meals delivered and the AES device installed for basic usage
88966759|NCT04581317|Experimental|Phase 3 (meals + AES 8 advanced )|Participants will have meals delivered and the AES device installed for advanced usage
88966760|NCT01806259|Experimental|ketorolac 30 mg|Active drug to be compared with placebo
88966761|NCT01806259|Placebo Comparator|NaCl 0.9% 3mL|Placebo looking like the Active drug
88966762|NCT01806220|Active Comparator|biopsy of retrocrycoid laryngeal mucosa|"During upper digestive endoscopy a biopsy specimen of the retrocrycoid laryngeal mucosa was obtained with a forceps introduced by the working channel of the scope.~Intervention: biopsy of retrocrycoid laryngeal mucosa"
88966763|NCT01806220|Active Comparator|biopsy of distal esophagus mucosa|"during upper digestive endoscopy a biopsy specimen of the distal esophageal mucosa was obtained~Intervention:biopsy of distal esophagus mucosa"
88966764|NCT00393445|Experimental|Intravenous infusion|intravenous infusion of test substances
88966765|NCT01806181|Other|Cancer Treatment|
88966766|NCT01806142|Experimental|Medium-chain triglycerides|During Medium-Chain Triglycerides (MCT period), participant will asked to consume two pastries per day that will provide a total of 20 g of MCT/day for 4 weeks.
88966767|NCT01806142|Active Comparator|Corn oil|During Corn oil period (Control period), participant will asked to consume two pastries per day that will provide a total of 20 g of corn oil/day for 4 weeks.
88966768|NCT00387452|Active Comparator|1|
88966769|NCT00387452|Active Comparator|2|
88966770|NCT00387452|No Intervention|3|No intervention, only testing during 6 months.
88966771|NCT01806103|Experimental|Antimicrobial Stewardship Bundle|"An intervention bundle to reduce outpatient antibiotic use in children will include education, creation of and access to guidelines, and audit of and feedback on individual prescribing within the context of achievable benchmarks."
88966772|NCT01806103|No Intervention|Control|Control sites will be within strata to maintain balance of treatment arm within strata
88966773|NCT01806025||Cystic Fibrosis Patients|Patients with Cystic Fibrosis with two known severe (class I and class II) mutations
88966774|NCT01805986||MS patient|
88966775|NCT01805947||Lifestyle Modification|"All patients with chronic pain conditions participate in a 8-weeks structured group program. Detailed information on the mindfulness based program can be found in the publication by Paul, A. et al. An Integrative Day Care Clinic for chronically ill patients: Concept and case presentation in the European Journal of Integrative Medicine, 2012, 4(4):e455-e459."
88966776|NCT01805908|Experimental|111In-Pertuzumab + SPECT-CT|Radiopharmaceutical 111In-labeled Pertuzumab given intravenously prior to SPECT-CT imaging.
88966777|NCT01805830|Experimental|MP513 group|
88966778|NCT01805830|Placebo Comparator|Placebo group|
88966779|NCT01805791|Placebo Comparator|Placebo|Placebo, oral tablets, three times a day
88966780|NCT01805791|Experimental|HMPL-004 1800 mg/day|1 600 mg HMPL-004 tablet, 2x400 mg placebo tablets taken 3 times a day
88966781|NCT01805791|Experimental|HMPL-004 2400 mg/day|2 x 400 mg HMPL tablets, 1 x 600 mg placebo tablet, taken 3 times per day
88966782|NCT01805752|Experimental|Integrated family-focused PMTCT arm|"Intervention package includes: 1) task-shifting to lower-cadre providers at PMTCT sites; 2) POC CD4+ cell count testing; (3) integrated mother-infant care; and (4) a prominent role for influential family members (male partners), working in close partnership with community-based health workers/volunteers.~Patients attending sites randomized to this arm will also receive group health education; opt-out HIV testing, same-day HIV test results; infant feeding counseling; HBC services; infant prophylaxis, early infant diagnosis, and linkage to family spacing services, if desired."
88966783|NCT01805752|No Intervention|Standard of care|Arm will receive standard of care activities, namely: group health education; opt-out HIV testing, same-day HIV test results; infant feeding counseling; HBC services; infant prophylaxis, early infant diagnosis, linkage to family spacing services, if desired.
88966784|NCT01805713||CF Infant Cohort|Infants with CF followed for the first two years of life.
88966785|NCT01805713||CF Child/Adult Cohort|CF patients > 8 years of age followed during hospitalization for pulmonary exacerbation and when well for two years.
88966786|NCT01805674||isoflavones combined with magnolia|A food supplement containing soy isoflavones, lactobacillus sporogenous, Ca,vitamin D3, magnesium and magnolia extract will be administered once a day during 12 weeks.
88966787|NCT05437887|Experimental|Fucoidan|All patients are in the experimental group.
88966788|NCT01805635||Children suspected of allergic diseases|Children suspected of allergic diseases No intervention
89560524|NCT04595604|Experimental|Trimodal prehabilitation + ERAS|"Patients receiving a formal preoperative preparation on:~Physical status (walking, respiratory training) Nutrition (nutritional supplements) Mental status (weekly groups led by clinical psychologist on anxiety and depression management).~Each patient will be treated in an ERAS program preoperatively."
88966789|NCT01805596|Experimental|clopidogrel-ticagrelor|21 days clopidogrel followed by 21 days ticagrelor
89560525|NCT04595604|Active Comparator|ERAS + nutritional prehabilitation|Each patient will be treated in an ERAS program preoperatively. No specific preoperative training will be involved apart from nutritional status assessment and nutritional supplements.
89560526|NCT04581785|Experimental|Dose Level 1 Part A|3 year-olds to 12 year-olds
89560527|NCT04581785|Experimental|Dose Level 1 Part B|6 month to 2 year-olds
89560528|NCT04581785|Experimental|Dose Level 1 Part C|6 month to 12 year-olds
89560529|NCT04581785|Experimental|Dose Level 2 Part A|3 year-olds to 12 year-olds
89560530|NCT04581785|Experimental|Dose Level 2 Part B|6 month to 2 year-olds
89560531|NCT04576156|Experimental|Imetelstat|Participants will receive imetelstat at 9.4 mg/kg intravenous (IV) every 21 days (±3 days), until disease progression or unacceptable toxicity, treatment discontinuation or study end.
89560532|NCT04576156|Active Comparator|Best Available Therapy (BAT)|"Participants will receive BAT (investigator-selected non-JAK-inhibitor treatment), until disease progression or unacceptable toxicity, treatment discontinuation or study end.~Participants on BAT who meet protocol-defined criteria for progressive disease may crossover to receive imetelstat treatment after sponsor's approval."
89560533|NCT04567719||Changes in Taste Perception After Exposure to Chemotherapy|A total of 20 participants with histologically-proven MIBC planning to receive pre-surgery chemotherapy followed by radical cystectomy will be recruited.
89560534|NCT04567433||CHEST Study|Participants in the CHEST trial long term sepsis cohort
89560535|NCT04567433||ARISE Study|Participants in the ARISE study long term follow-up cohort
89560536|NCT04567433||ADRENAL study|Participants in the ADRENAL study
89560537|NCT04560699|Active Comparator|Physiotherapeutic group|medical care and physiotherapeutic treatment
89560538|NCT04560699|Active Comparator|medical care group|Medical care
89560539|NCT04556890|Experimental|Active rTMS/Active iTBS DFPLC/Sham Pain M1|
89560540|NCT04556890|Experimental|Active rTMS/Active iTBS|
89560541|NCT04536012|No Intervention|Control|Via the Way to Health platform, all patients will receive daily text messages that inform them of their previous day's step count for 24 weeks.
89560542|NCT04536012|Experimental|Intervention|"Participants have a 4-week ramp-up towards their step goal and are asked to maintain the goal for the rest of the study. They receive daily texts informing them if they met their step goal and biweekly texts to encourage walking for exercise.~Participants are entered into a game. Each week they receive 70 points. If the step goal was met they keep their points. If not, they lose 10 points. At the end of the week if they have at least 40 points they move up a level. If not, they drop a level. Participants start in the middle of 5 levels.~Participants choose a support partner who gets a weekly email with the participant's progress. We hold a 3-way phone call with the participant and partner to discuss ways they can help the participant meet their goal. Every 8 weeks, we have a follow up call if the participant is stuck in a lower level and restart them back at the middle level.~In the follow-up period, participants continue to get a daily text stating if they met their step goal."
89560543|NCT04534699|Experimental|Hepatic Impaired|KBP-5074 0.5mg tablet orally, Single dose
89560544|NCT04534699|Experimental|Matched-control Healthy|KBP-5074 0.5mg tablet orally, Single dose
89560545|NCT04533451|Experimental|Group A (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89560546|NCT04533451|Experimental|Group B (pembrolizumab, pemetrexed, carboplatin)|Patients receive pembrolizumab IV over 30 minutes, pemetrexed IV over 10 minutes, and carboplatin IV per institutional guidelines on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89560547|NCT04532957|Experimental|Group 1|Multiple doses 100mg Healthy subjects receive multiple doses of KBP-7072 (100mg) or Placebo (100mg) QD capsules daily for a total of 10 days
88966790|NCT01805596|Experimental|ticagrelor-clopidogrel|ticagrelor for 21 days followed by clopidogrel for 21 days
88966791|NCT01805557|Active Comparator|R-DHAP|R-DHAP x 2, restaging, mobilization and harvest of peripheral stem cell + R-DHAP x 2, restaging with PET evaluation
88966792|NCT01805557|Experimental|BR-DHAP|Bortezomib + R-DHAP x 2, restaging, mobilization and harvest of peripheral stem cell + Bortezomib + R-DHAP x 2, restaging with PET evaluation
88966793|NCT00389727|Experimental|Group 1 Patients|Radiotherapy Patients
88966794|NCT00389727|No Intervention|Group 2|
88966795|NCT01805518|Active Comparator|Scelectium Tortuosum|S Tortuosum
88966796|NCT01805518|Placebo Comparator|Sugar pill/placebo|Sugar pill/placebo
88966797|NCT01805479|Placebo Comparator|stretching-flexibility|This group will use a stretching and flexibility program designed to utilize minimal levels of aerobic capacity. It was chosen in place of a education-based control group due to the high level of personal interaction that is found in the active arm.
88966798|NCT01805479|Active Comparator|aerobic exercise group|aerobic activity targeting 60% peak heart rate for 12 weeks is the active group.
88966799|NCT04474223|Experimental|Mothers with Fetuses Who Have 2° AVB or AV interval > 170ms|
88966800|NCT01805440|Active Comparator|Uridine|Subjects randomized to this study arm will receive uridine 500 mg twice daily by mouth for 6 weeks.
88966801|NCT01805440|Placebo Comparator|Placebo|Subjects randomized to this arm of the study will receive placebo 500 mg twice daily by mouth for 6 weeks.
89560548|NCT04532957|Experimental|Group 2|Multiple doses 200mg Healthy subjects receive multiple doses of KBP-7072 (200mg) or Placebo (200mg) QD capsules daily for a total of 10 days
89560549|NCT04532957|Experimental|Group 3|Multiple doses dose tbd Healthy subjects receive multiple doses of KBP-7072 (tbd) or Placebo(tbd) QD capsules daily for a total of 10 days
89560550|NCT04530110|Experimental|Fremanezumab|The dose of Fremanezumab to be administered will be confirmed or adjusted, as appropriate, based on the participant's weight every 3 months.
89026884|NCT05645263|No Intervention|Fragmentation 2|The patients who chose emergently endoscopic fragmentation was enrolled in control group 2. All patients endorsed the informed consent paper, no diet for at least 4 hours, no drink for 2 hours and bring the medical records before endoscopy and go on a mechanical fragmentation through gastroendoscopy
89026885|NCT05645263|No Intervention|Fragmentation 3|The patients who chose emergently endoscopic fragmentation was enrolled in controlled Group 3. All patients endorsed the informed consent paper, no diet for at least 4 hours, no drink for 2 hours and bring the medical records before endoscopy and go on a mechanical fragmentation through gastroendoscopy
89026886|NCT04325776|Experimental|AL2846+An analog of zoledronic acid injection|AL2846 capsules 150 mg given orally, once daily in 28-day cycle, an analog of zoledronic acid injection (5ml:0mg) administered intravenously (IV) on Day 1 of each 28-day cycle.
89208490|NCT02596217|Experimental|Stage 2 (low dose IV)|Low dose administered by intraveneous (IV) infusion
89560551|NCT04530006|Experimental|GBM Patients|"This cohort of patients will be asked to orally ingest 200mg dose of FDA approved drug amantadine hydrochloride. This will be done at the following timepoints:~Within 4 weeks of the start of treatment; but as close to commencement of treatment (Day 1 of radiotherapy) as possible for newly diagnosed patients.~Cycle 1, Day 1 of chemotherapy (temozolomide or lomustine) +/- 7 days~Day 1 +/- 7 days for each visit where MRI is obtained (typically every 8-12 weeks - pre-cycles 4, 7, 10, for temozolomide or pre-cycles 3, 5, and 7 for lomustine)"
89560552|NCT04522947|Experimental|fMRI|Participants are delivered sips of appetizing tastes (milkshake) and tasteless solution throughout the task while in the MRI scanner.
89560553|NCT04519320|Other|SARS-COV 2 Patients|
89560554|NCT04489732|Experimental|Treatment with MSCs|A single dose of MSCs injected into the submandibular glands of patients with radiation-induced xerostomia
89560555|NCT04482933|Experimental|Experimental: HSV G207|All subjects will receive G207 at 1 x 10^8 plaque-forming units (pfu), intratumorally via controlled rate infusion through up to 4 silastic catheters over a 6 hour period. The subject will then receive a single 5 Gy dose of radiation to the tumor within 24 hours of virus inoculation.
89560556|NCT04472117|Experimental|Usual care and usual care plus video|Phase I (completed 3/31/2021): A sample of patients in phase I will complete a qualitative interview prior to or after surgery. Twenty-five evaluable patients (15 pre-operatively and a separate 10 post-operatively) will be selected to participate in an in-person/phone interview. Phase II: A separate group of women will compose phase II. All patients (N = 100) in phase II will complete discrete-choice surveys. Patients in phase III of the study will be randomized evenly to usual care plus video or usual care only. Phase III: One hundred participants will be randomized via CRDB to receive standard pre-operative counseling or standard pre-operative counseling with the additional of an educational video. Those randomized to view the video will also complete the post-video survey. All patients will complete the post-op survey.
89560557|NCT04462276|Experimental|Arm A: Atezolizumab + thoracic radiotherapy|Atezolizumab at a fixed dose of 1,200 mg as an IV infusion, on day 1, to be repeated every 3 weeks (Q3W) Thoracic radiation therapy (TRT), 30 Gy in 10 fractions
89560558|NCT04462276|Experimental|Arm B: Atezolizumab|Atezolizumab at a fixed dose of 1,200 mg as an IV infusion, on day 1, to be repeated every 3 weeks (Q3W)
89560559|NCT04458207|Experimental|Experimental group (EG), the immediate rehabilitation group|The experimental group will begin with the rehabilitation immediately after the first measurement of cognitive tests (pre-test). Three months after complete rehabilitation the first post-test (post-test 1) will be conducted on all participants. Participants will be recalled after about a year for a long-term follow up (post-test 2). The OHIP-14, chewing function test, saliva samples, neuropsychological assessments together with MRI assessments will also be recorded at different time points (i.e., pre-test, post-test 1 and post-test 2).
88966802|NCT01805440|No Intervention|Healthy Comparison|Subjects are not randomized, and do not receive any treatment intervention.
88966803|NCT01688011||Newly diagnosed Lower-Risk Myelodysplastic Syndromes (LR-MDS)|Newly diagnosed lower risk MDS patients as determined by International Prognostic Scoring System (IPSS).
88966804|NCT01688011||Newly diagnosed Higher-Risk Myelodysplastic Syndromes (HR-MDS)|Newly diagnosed higher risk MDS patients as determined by International Prognostic Scoring System (IPSS).
88966805|NCT01688011||Newly diagnosed Acute Myeloid Leukemia (AML)|Newly diagnosed AML patients (≥55 years old, excluding patients with acute promyelocytic leukemia (APL).
88966806|NCT01688011||Treated Myelofibrosis (MF)|Newly treated MF patients receiving treatment for MF or MF-related cytopenias. This cohort also includes patients with myelodysplastic syndrome (MDS)/myeloproliferative neoplasm (MPN) overlap syndromes, excluding juvenile myelomonocytic leukemia (JMML).
89560560|NCT04458207|Active Comparator|Control group (CG), the test-retest group|The control group will be tested with the cognitive tests two times (pre-test + post-test 1) at an interval of about three months or more inbetween tests and before the onset of the prosthodontic rehabilitation. Three months after complete rehabilitation the post-test (post-test 2) will be conducted on all participants. Further, participants will be recalled after about a year for a long-term follow up (post-test 3). The OHIP-14, chewing function test, saliva samples, neuropsychological assessments together with MRI assessments will also be recorded at these time points (i.e., pre-test, post-test 1, post-test 2 and post-test 3).
89026887|NCT04325776|Active Comparator|An analog of AL2846+ zoledronic acid injection|An analog of AL2846 capsules 0 mg given orally, once daily in 28-day cycle, zoledronic acid injection (5ml:4mg) administered intravenously (IV) on Day 1 of each 28-day cycle.
89026888|NCT03276845|Other|1|
89026889|NCT01322386|Experimental|Oral Vancomycin|Vancocin
89560561|NCT04435366|Experimental|Avacincaptad Pegol Treatment Group|Monthly avacincaptad pegol 2mg intravitreal injections through Month 11 (Year 1) NOTE: At Month 12, participants are re-randomized to receive monthly injections or every other month injections (alternating with sham) from Month 12 to Month 23 (Year 2) - Year 2 is not included in the primary analysis.
89560562|NCT04435366|Sham Comparator|Sham Treatment Group|Monthly sham administration through Month 11 (Year 1) NOTE: At Month 12, participants continue to receive monthly sham administration from Month 12 to Month 23 (Year 2) - Year 2 is not included in the primary analysis.
89560563|NCT04428944|Active Comparator|PV antral isolation alone (PVAI)|PV antral isolation alone (PVAI)
89560564|NCT04428944|Active Comparator|PV antral isolation plus ablation of drivers|PV antral isolation plus ablation of drivers (PVAI+drivers)
89560565|NCT04428944|Active Comparator|PV antral isolation plus isolation of posterior wall|PV antral isolation plus isolation of LA posterior wall (PVAI+Box)
89560566|NCT04428450|Experimental|Deprexis (unguided)|web-based self-help program without any support from a therapist during the 10-week treatment period
89026890|NCT03275909|Experimental|Study procedure|An experimental group the psychological treatment includes 50 sessions of integrated psychological therapy (IPT) (focused on attentional skills training, social perception skills training, verbal communication skills, social skills training, interpersonal problems solving skills) and 10 sessions of specific emotional management therapy (EMT), designed for this research and based on the contents developed by Hodel, Kern and Brenner.
89560567|NCT04428450|Experimental|Deprexis (guided, with therapist)|web-based self-help program plus scheduled e-mail contact with a therapist during the 10-week treatment period
89560568|NCT04428450|No Intervention|Wait-list|Wait-list group (subjects receive access to Deprexis after 10 weeks)
89560569|NCT04425148|Experimental|tACS|40 Hz transcranial alternating current stimulation (tACS), 30 daily (Monday-Friday) 1-hour sessions
89560570|NCT04425148|Sham Comparator|Sham tACS|Sham transcranial alternating current stimulation (tACS), 30 daily (Monday-Friday) 1-hour sessions
89560571|NCT04408313|Experimental|XR-B|Extended-release buprenorphine
89026891|NCT03275909|No Intervention|Treatment as usual|The treatment as usual is pharmacological treatment and activities in a Day Care Center.
89026892|NCT00477308|Other|salvage therapy|Children with drug resistance were treated using the drug resistant profile
89026893|NCT01246908|Experimental|CX157 (TriRima)|CX157 (TriRima) in a reversible monoamine oxidase inhibitor (MAOI)
89026894|NCT01246908|Placebo Comparator|Placebo|
89026895|NCT00495105|Experimental|Two Servings of Dairy Snacks|Intervention group received two servings of dairy food per day as a snack at school for 6 months as well as nutrition education.
89026896|NCT00495105|No Intervention|No Dairy Snacks|Control Group did not receive any snacks or education.
89560572|NCT04408313|Active Comparator|XR-NTX|Extended-release naltrexone
89560573|NCT04393649||Older patients / community dwellers|"The inclusion criteria are:~Older (i.e., 70-years-old and over) adults OR caregiver living at home with an adult answering to inclusion criteria~Living and staying at home because of physical and social distancing~Understanding and writing the different languages of the recruitment centre (i.e., French, English, Chinese.)~Agree to participate in the study~The exclusion criteria are:~A concomitant participation to another medical trial~Living in semi-autonomous residence or CHSLD"
89026897|NCT00472472|Placebo Comparator|1|PTA
89026898|NCT00472472|Active Comparator|2|PTA with Paccocath
89026899|NCT01247025||Veterans|Veterans receiving mental health services at the Eastern Colorado Healthcare System (ECHCS)/Denver Veterans Affairs Medical Center (VAMC)
89026900|NCT00477347|Active Comparator|1|Manual administration
89026901|NCT00477347|Experimental|2|Closed-loop administration
89026902|NCT01244568|No Intervention|Usual care|
89026903|NCT01244568|Experimental|Prostate cancer treatment DESI|
89026904|NCT00503568|Experimental|DS-1: gp96-ig Dose Schedule 1|Dose Schedule 1 (DS-1): Ad100-gp96Ig-HLA A1 Vaccine 4x10^7 cells bi-weekly, maximum 9 vaccines/patient;
89026905|NCT00503568|Experimental|DS-2: gp96-ig Dose Schedule 3|Dose Schedule 2 (DS-2): Ad100-gp96Ig-HLA A1 Vaccine 2X10^7 cells weekly, maximum 18 vaccines/patient;
89026906|NCT00503568|Experimental|DS-3: gp96-ig Dose Schedule 3|Dose Schedule 3 (DS-3): Ad100-gp96Ig-HLA A1 Vaccine 1x10^7 cells twice weekly, maximum 36 vaccines/patient
89026907|NCT01244607|Placebo Comparator|Placebo|
89026908|NCT01244607|Experimental|NI-0801|
89026909|NCT00472589||1|Healthy women
89560574|NCT04373265|Experimental|Relacorilant in Combination with Pembrolizumab|Participants will be treated on Day -3 to Day 1 (Cohort 1 under fasting conditions) or Day -6 to Day 1 (Cohort 2 under fed conditions) for Cycle 1 only. During the lead-in period, 300 mg relacorilant will be administered daily for 4 -7 days. Patients will receive their first pembrolizumab infusion on Cycle 1 Day 1. The participants will then receive combined treatment from Cycle 1 Day 1 until confirmed PD or unacceptable toxicity. Pembrolizumab will be administered every 6 weeks (on Day 1 of each 42-day cycle) and relacorilant will be administered daily. Optional Cohort 3 will lead-in with 400 mg relacorilant once daily for 7 days and combined treatment of relacorilant and pembrolizumab, depending on PD and toxicity.
89560575|NCT04368663|Active Comparator|TJ-134 group|The traditional Japanese medicine, Keishi-ka-shakuyaku-daio-to（TJ-134, 7.5g/day), which consists of a mixture of a compound of peony root (6 g), cinnamon bark (4 g), jujube (4 g), glycyrrhiza (2 g), rhubarb (2 g), and ginger (1 g) is administered to enrolled patients for 8 weeks.
89560576|NCT04368663|Placebo Comparator|Lactomin group|Lactomin (3g/day) is administered to enrolled patients for 8 weeks.
89560577|NCT04366024||Observed group|COVID-19 disease patients who were detected by RT-PCR and CT imaging.
89560578|NCT04347369||Observed group|The patients who were detected COVID-19 disease by RT-PCR and CT imaging.
89560579|NCT04344860|Active Comparator|rVWF plus TA|Subjects randomized to this arm will receive recombinant von Willebrand factor 80 IU/kg IV within 5-10 minutes of delivery (or epidural anesthesia) plus Tranexamic Acid 1 gm IV within 3 hours of delivery; and recombinant Von Willebrand factor 80 IU/kg on day 1 and day 2 postpartum.
89560580|NCT04344860|Active Comparator|rVWF alone|Subjects randomized to this arm will receive recombinant von Willebrand factor 80 IU/kg IV within 5-10 minutes of delivery (or epidural anesthesia); and recombinant Von Willebrand factor 80 IU/kg on day 1 and day 2 postpartum.
89560581|NCT04344717|Experimental|Anticoagulation and teduglutide naive short bowel syndrome|Apixaban-, vitamin K antagonist- and teduglutide naive patients with short bowel syndrome requiring long term parenteral support
89560582|NCT04344717|Experimental|Healthy volunteers|Apixaban- and vitamin K antagonist naive healty volunteers
89560583|NCT04344717|Other|Short bowel syndrome on apixaban|Patients with short bowel syndrome requiring long term parenteral support and taking apixaban 2.5 mg twice daily or 5 mg twice daily
89560584|NCT04344717|Other|Patients with a normal gastrointestinal tract on apixaban|Patients with a normal gastrointestinal tract taking apixaban 2.5 mg twice daily or 5 mg twice daily
89560585|NCT04344717|Experimental|Anticoagulation naive short bowel syndrome on teduglutide|Apixaban- and vitamin K antagonist naive patients with short bowel syndrome requiring long term parenteral support and initiated on teduglutide
89560586|NCT04332744|Active Comparator|Control Arm (Arm A)|Patients will receive enzalutamide capsules orally once daily continuously (160 mg) in addition to standard ADT (unless surgical castration).
89560587|NCT04332744|Experimental|Interventional Arm (Arm B)|Patients will receive enzalutamide capsules 160 mg in combination with talazoparib (PF-06944076) capsules 0.5 mg, both orally daily and continuously in 28-day cycle, in addition to standard ADT (unless surgical castration).
89208491|NCT02596217|Experimental|Stage 2 (medium dose IV)|Medium dose administered by intraveneous (IV) infusion
89560588|NCT04310397|Experimental|Treatment (dabrafenib, trametinib, surgery, spartalizumab)|"NEOADJUVANT TREATMENT: Patients receive dabrafenib PO BID and trametinib PO QD on days 1-28. Treatment repeats every 28 days for 2 cycles in the absence of disease progression or unacceptable toxicity.~SURGERY: Patients undergo surgical resection of melanoma.~ADJUVANT TREATMENT OF pCR PATIENTS: Patients receive dabrafenib PO BID and trametinib PO QD on days 1-28. Cycles repeats every 28 days for 44 weeks in the absence of disease progression or unacceptable toxicity.~ADJUVANT TREATMENT OF NON pCR PATIENTS: Patients receive spartalizumab IV over 30 minutes on day 1, dabrafenib PO BID and trametinib PO QD on days 1-28. Cycles repeats every 28 days for 44 weeks in the absence of disease progression or unacceptable toxicity."
89560589|NCT04309110|No Intervention|Standard care with geko™ T3 device|Current geko™ device incorporating hydrogel adhesive designated KM10T
89560590|NCT04309110|Active Comparator|geko™ X-T3|Next generation geko™ device incorporating new hydrogel adhesive designated KM40C
89560591|NCT04298047|Experimental|Intervention group|The participants in the Intervention group will be participants of the MMFA participatory art-based activity.
89560592|NCT04298047|No Intervention|Control Group|The Control arm will be composed of older community dwellers matched on age and sex compared to the Intervention group but who will not be participants at the MMFA participatory art-based activity.
89560593|NCT04294641|Experimental|Intervention|Determine response rate via continuous daily dose by mouth to determine efficacy
89560594|NCT04282915|Active Comparator|Implementation as Usual|Primary care providers will be trained in the 7-day curriculum of the mental health Gap Action Programme adapted by the Nepal Ministry of Health.
89026910|NCT00472589||2|Women with breast cancer
89026911|NCT01244646||1|Patients with Diabetes Mellitus Type 2
89026912|NCT00477503|Active Comparator|Group A|Ga-67 citrate injection alone for individuals with cancer cells in cerebral spinal fluid (CSF), no earlier treatment for disease.
89026913|NCT00477503|Active Comparator|Group B|Ga-67 + In 111 DTPA injection for individuals who have cancer cells in CSF, no earlier treatment for disease.
89026914|NCT00477503|Active Comparator|Group C|Individuals with tumors in the CSF that have been treated and are now cleared from the CSF, receive standard follow-up care (baseline injection of Ga-67 citrate and In-111 DTPA).
89026915|NCT01244334|Active Comparator|Difluprednate Ophthalmic Emulsion 0.05%|
89208492|NCT02596217|Experimental|Stage 2 (high dose IV)|High dose administered by intraveneous (IV) infusion
89208493|NCT02596217|Placebo Comparator|Placebo SC (Stage1)|Placebo administered by subcutaneous (SC) injection
89208494|NCT02596217|Placebo Comparator|Placebo IV (Stage2)|Placebo administered by intraveneous (IV) infusion
89208495|NCT00876330|Experimental|1|Receives Hypertension and Hyperlipidemia Intervention using Clinical Decision Support.
89208496|NCT00876330|Experimental|2|Receives Hypertension and Hyperlipidemia Intervention with automated telephone outreach.
89560595|NCT04282915|Experimental|RESHAPE|Primary care providers will be trained in the 7-day curriculum of the mental health Gap Action Programme, plus they will have co-facilitation by mental health service users providing recovery testimonials as well as aspirational figures presenting testimonies and conducting myth-busting sessions.
89560596|NCT04261309||Elderly with back pain in primary healthcare|Consecutive women and men 55 years of age or older who seek primary care (GP, physiotherapist or chiropractor) with a new episode of back pain (preceded by 6 months without visiting a primary care provider for similar complaints)
89560597|NCT04257032|Experimental|Reference 1 (R1)|
89560598|NCT04257032|Experimental|Test 1 (T1)|
89560599|NCT04257032|Experimental|Reference 2 (R2)|
89560600|NCT04257032|Experimental|Test 2 (T2)|
89560601|NCT04254133||Case Ascertainment|Men with prostate cancer
89560602|NCT04254133||Family Recruitment|Male relatives of men with prostate cancer
89560603|NCT04240028||Individuals with prefrailty|"This is defined as a co-existing prefrailty using the Fried criteria. Frailty defined by the CHS index as proposed by Fried et al. will be identified by the presence of ≥ 3 of the following 5 components: 1) Shrinking as identified by an unintentional weight loss of ≥ 5% between two assessments, 2) Weakness as identified by a maximal grip strength in the lowest quintile stratified by body mass index quartile; 3) Poor energy as identified by an answer of no to the question Do you feel full of energy? from the 30-item Geriatric Depression Scale; 4) Slowness as identified by an average walk speed in the lowest quintile stratified by median standing height, and 5) Low physical activity level as identified by a PASE score in the lowest quintile. Participants with none of the above components will be considered to be vigorous and those with 1 or 2 components will be considered to be in a prefrail stage."
89560604|NCT04240028||Individuals with cognitive-prefrailty|"A combination of prefrailty stage using Fried criteria and subjective cognitive impairment (SCI).~The IANA/IAGG consensus defines cognitive frailty as CDR = 0.5 and frailty by the Fried criteria.SCI will be defined using a proxy for subjective cognitive complaint (i.e. memory complaint) and following the procedure used in previous multicenter prevalence studies on MCR syndrome. Memory complaint used to define MCR syndrome was based on standardized memory loss question on the 15-item or 30-item Geriatric Depression Scale (GDS; Do you feel you have more problems with memory than most?). Memory complaint in our study will be elicited from this item of 30-item GDS."
89560605|NCT04240028||Individuals with MCR|The diagnosis of MCR syndrome will be made following the criteria of Verghese et al. 5: a combination of subjective cognitive complaint, in particular of memory complaint, with the presence of an objective slow gait and the absence of dementia or mobility disability. MCR syndrome will be defined at baseline assessment and each year of follow-up period. Slow gait speed will be defined as gait speed that is one standard deviation (SD) or more below age-and sex-appropriate mean values established in the present cohort like in previous studies. The mean value and SD of female and male will be determined separately. Gait speed was determined from the 3-meter walking test using the best time of the two trials recorded and expressed as meters per second.
89560606|NCT04210284|Experimental|Nutritional supplementation|Given Ensure Max Protein Nutrition shake 2 weeks before surgery and continued 2 weeks after surgery.
89560607|NCT04210284|No Intervention|No Nutritional supplementation|Treatment as usual
89560608|NCT04177810|Experimental|Cemiplimab and Plerixafor|All participants will receive Cemiplimab and Plerixafor.
89560609|NCT04175119|Experimental|Main study group|All participants signed up for experiment 1, 2, or 3 complete the same protocol (1 study arm) with an intent for intra-subject correlational analyses.
89560610|NCT04174001||Neuro group|"Patients who meet the following criteria:~18 years of age or younger~diagnosed with one or more of the following neurological disorders: moyamoya disease, congenital anomalies of the brain, hypoxic-ischemic encephalopathy, brain tumor, Chiari malformation, epilepsy and stroke~planned for any surgical procedures that require general anesthesia~planned to receive intraoperative and/or postoperative invasive arterial blood pressure monitoring~Patients who have a surgical procedure that contraindicates the placement of a NIRS probe on the forehead or are scheduled for a cardiac procedure will be excluded."
89560611|NCT04174001||Control group|"Patients who meet the following criteria:~18 years of age or younger-planned for any surgical procedures that require general anesthesia~planned postoperative invasive blood pressure monitoring~Patients who have a surgical procedure that contraindicates the placement of a NIRS probe on the forehead or have symptoms of neurological disorders will be excluded."
89560612|NCT04168879|Active Comparator|bupivacaine group|
89560613|NCT04168879|Placebo Comparator|saline group|
89560614|NCT04135989|Other|Cre8 AES and personalized DAPT duration|"Percutaneous coronary intervention with implantation of a Cre8 amphilimus- eluting stent for coronary artery disease.~Personalized duration of dual antiplatelet therapy for 3-, 6-, or 24-month after percutaneous coronary intervention based on the DAPT score."
89026916|NCT01244334|Active Comparator|Prednisolone acetate suspension 0.1%|
89026917|NCT00472667|Experimental|1|Procalcitonin guided strategy
89026918|NCT00477581|Experimental|Sequence A|
89026919|NCT00477581|Experimental|Sequence B|
89026920|NCT00503802|Active Comparator|1|Active RF treatment
89026921|NCT00503802|Sham Comparator|2|Sham RF treatment
88966807|NCT01688011||Newly diagnosed Idiopathic cytopenia of undetermined significance (ICUS)|Newly diagnosed ICUS patients.
89026922|NCT00504621||sarcoidosis|Sarcoidosis known by the ild care team of the outpatient clinic of the department of Respiratory Medicine of the University Hospital Maastricht as well as new patients attending the out-patient clinic from August 2007 to January 2009
89026923|NCT00504621||pulmonary fibrosis|Idiopathic pulmonary fibrosis (IPF) patients known by the ild care team of the outpatient clinic of the department of Respiratory Medicine of the University Hospital Maastricht as well as new patients attending the out-patient clinic from August 2007 to January 2009
88966808|NCT01688011||Treated Lower-Risk Myelodysplastic Syndromes (LR-MDS)|Treated LR-MDS patients receiving first active treatment regimen containing at least one non-ESA therapy
88966809|NCT01515124|No Intervention|Lymphedema Care Only|"All 4 groups receive lymphedema care as follows:~2 custom fitted compression garments (baseline and 6 months)~evaluations for flare-ups at request (and at each measurement time point)~lymphedema treatment by a certified lymphatic therapist upon detection of a flare-up, paid for by the study. No limit was placed on number of sessions."
89026924|NCT01247103|Placebo Comparator|Part A: single ascending dose|AZD4316: single oral dose, with 1 group with/without food
89026925|NCT01247103|Placebo Comparator|Part B: multiple ascending dose|AZD4316: multiple oral doses
89026926|NCT00477776|Active Comparator|a|Mother with diet-controlled diabetes receive Metoclopramide 10 mg 3 times a day for the first 7 days, and 2 times a day for day 8 to 10, and once a day from day 11 to day 12
89026927|NCT00477776|Placebo Comparator|b|Placebo 10 mg 3 times a day for 7 days, 2 times a day from day 8 to day 10, and once a day for day 11 to 12
89560615|NCT04135989|Other|Cre8 AES and standard DAPT duration|"Percutaneous coronary intervention with implantation of a Cre8 amphilimus- eluting stent for coronary artery disease.~Standard duration of dual antiplatelet therapy for 12-month after percutaneous coronary intervention."
89560616|NCT04135989|Other|Synergy EES and personalized DAPT duration|"Percutaneous coronary intervention with implantation of a Synergy everolimus-eluting stent for coronary artery disease.~Personalized duration of dual antiplatelet therapy for 3-, 6-, or 24-month after percutaneous coronary intervention based on the DAPT score."
89560617|NCT04135989|Other|Synergy EES and standard DAPT duration|"Percutaneous coronary intervention with implantation of a Synergy everolimus-eluting stent for coronary artery disease.~Standard duration of dual antiplatelet therapy for 12-month after percutaneous coronary intervention."
89560618|NCT04129528|Active Comparator|CFZ533|Randomized in a 2:1 ratio: 2 Active / 1 Placebo
89560619|NCT04129528|Placebo Comparator|Placebo|Similar in appearance to active study drug
89560620|NCT04125095||Head Scans|Includes patients receiving proton therapy for tumors in the brain, skull, and head and neck region. The same patient could potentially contribute to both cohorts if he/she receives radiation to both head and body sites.
89560621|NCT04125095||Body Scans|Includes proton irradiation to shoulders, thorax, abdomen, pelvis, spine (thoracic or lumbar), extremities, and other body sites. The same patient could potentially contribute to both cohorts if he/she receives radiation to both head and body sites.
89560622|NCT04124341|Experimental|Prefrontal Cortical Stimulation (PCS)|Stereotactically implanted bilateral PCS
89560623|NCT04111510|Experimental|LN-145|LN-145 will be delivered as a single therapy in patients with Metastatic Triple Negative Breast Cancer.
89560624|NCT04110262|Experimental|High-low dietary sodium|High sodium diet (3400 mg/day) feeding period followed by low sodium diet (2300 mg/day) feeding period
89560625|NCT04110262|Experimental|Low-high dietary sodium|Low sodium diet (2300 mg/day) feeding period followed by high sodium diet (3400 mg/day) feeding period
89560626|NCT04091451|Experimental|HZ/su Group|Subjects randomized to the HZ/su group will receive 2 doses of HZ/su vaccine at visit day 1 and visit month 2 and will be followed up until the study end.
89560627|NCT04091451|Placebo Comparator|Placebo Group|Subjects randomized to Placebo group will receive placebo at visit day 1 and visit month 2 and will be followed up until the study end.
89560628|NCT04072458|Experimental|BP1002 monotherapy|L-Bcl-2 Antisense oligonucleotide (BP1002) is given in a sequential, dose escalation design. Starting dose is 20mg/m^2.
89560629|NCT04069624|Active Comparator|Services as Usual (SAU)|Substance abuse program (SAP) managed by the Kentucky Department of Corrections, with the option to initiate MOUD prior to jail release.
89560630|NCT04069624|Experimental|MOUD Pre-Treatment Telehealth|Telehealth connection to a community MOUD provider.
89560631|NCT04069624|Experimental|MOUD Pre-Treatment Telehealth and Peer Navigator|Telehealth connection to a community MOUD provider, in addition to a peer navigator
89560632|NCT04064086|Active Comparator|Comprehensive Pre-ESRD Patient Education (CPE)|These patients will receive CPE for a total of up to 3 session in an intent-to-teach format, either via Face-to-face or telemedicine delivery.
89026928|NCT00477776|Active Comparator|c|Metoclopramide 10 mg 3 times a day for 7 days, 2 times a day from day 8 to day 10, and once a day from day 11 to 12
89026929|NCT00477776|Placebo Comparator|d|Placebo 10 mg 3 times a day for 7 days, 2 times a day for day 8 to 10; and once a day from day 11 to 12
89026930|NCT01247142||Invasive pulmonary aspergillosis (IPA)|Patients with proven or probable invasive pulmonary aspergillosis (IPA) (EORTC/MSG criteria) or putative IPA (Blot et al. Am J Respir Crit Care Med 2012)
89026931|NCT01247142||Controls|Patients without signs of infection.
89026932|NCT00504699|Experimental|letrozole|ovarian stimulation after breast cancer diagnosis and before breast cancer treatment
89026933|NCT00504699|No Intervention|control|No ovarian stimulation before breast cancer treatment
89560633|NCT04064086|Active Comparator|Enhanced Usual Care|This group will receive usual care. This care will be enhanced by providing them with the freely available education material for the Kidney Disease Education
89560634|NCT04055207|Experimental|VVC|Option to receive VA Video Connect (VVC) delivery of HIV care.
89560635|NCT04055207|No Intervention|Usual Care|All HIV care available at MEDVAMC will be delivered as usual.
89560636|NCT04047303|Experimental|Administration of CC-90010|During the preoperative period, all subjects will be given a course of orally administrated CC-90010 at 30 mg once daily for 4 consecutive days on Cycle 1 Day 1 to Day 4. The last CC-90010 dose (Day 4) will be administrated 6-24 hours prior to brain tumor resection. Following recovery from surgery and a minimum of 4 weeks from the first CC-90010 dose (Cycle 1 Day 1), subjects who are fit to continue study treatment my restart CC-90010 on Day 1 of Cycle 2 at 45 mg given orally once daily for 4 consecutive days followed by 24 consecutive days off (4 days on/24 days off), in each 28 day cycle.
89026934|NCT00477815|Experimental|Rituximab + Zevalin|Determine the dose level that is both tolerable and achieves the greatest B cell recovery in patients with multiple myeloma.
89026935|NCT01247181|Experimental|Mobile phone text message|
89560637|NCT04038983||Observational|"ER2 is a simple and standardized clinical tool composed of two sequential components: an assessment followed by recommendations for intervention. The assessment component of ER2 consists of 6 very simple closed-ended format questions (i.e., yes versus no) which are: Age category (≥ 85), male, polypharmacy (≥ 5 different medications per day), use of formal (health care or social professional) and/or informal (family and/or friend) home support, use of a walking aid regardless of its type, and temporal disorientation (inability to give the current month and/or year). A score of five points is assigned to the items use of walking aid and temporal disorientation, whereas, for the other items, the assigned score is one point. The weighting of points for ER2 items is based on the results of our previous studies (21-24). Scores range from 0 (lowest risk) to 14 (highest risk). ER2 scores stratify the risk for short-term ED adverse events into three levels: low, moderate and high."
89560638|NCT04036006|Experimental|Group-Based|The Group-based Program uses an ecologically valid setting in which participants exercise, prepare foods, and eat together to facilitate the emergence of old habits and replace them with healthy alternatives. The intervention team consists of a health psychologist, registered dietitian, and health coach. They co-facilitate group meetings for 15 participants that are held weekly for 3 months, bi-weekly for 3 months, and then monthly in participant-led maintenance meetings. Each session includes: weigh-in and physical activity (20 min), cooking demonstration (20 min), and a shared vegetable dish with discussion (50 min). The maintenance phase (months 7 to 24 post randomization) consists of support and health-related topics of the participants' own choosing. Progress reports with lab results are sent to participants and primary care physicians.
89026936|NCT01247181|Active Comparator|No Mobile phone text message|Usual care provided at clinic
89026937|NCT01244685|Active Comparator|probe|Patients in the 'goal-directed fluid' Lactated Ringers solution according to ideal body weight for the first 24 hours. The fluids will be changed after the first 24 hours and continued until the patient is tolerating a regular diet. The Deltex CardioQ esophageal probe will be evaluated every 15 minutes in the Post Anesthesia Care Unit (PACU) by the Anesthesia service. Stroke Volume (SV), Flow Time Corrected (FTc), and Peak Velocity (PV) will be measured. A short FTc (<330 ms) indicative of hypovolemia will receive a 3cc/kg fluid challenge with Lactated Ringers crystalloid solution over 5 minutes. A SV increase of >10% will receive a further 3cc/kg fluid challenge. A SV increase of <10% will not receive further fluid challenge.
89026938|NCT01244685|No Intervention|Standard Fluid|Patients in the 'standard fluid' group will receive Lactated Ringers solution for 24 hours post-operatively at 1 times maintenance rate according to ideal body weight. Then the fluids will be changed to physiologic maintenance with D5½NS at the same rate. Fluids will be decreased by ½ once the patient is tolerating a clear liquid diet, and then discontinued once the patient is tolerating a regular diet.
89026939|NCT00477854|Experimental|Visual Analogue Scale Ratings|Food intake data and its coefficients, including total food intake, food not eaten, duration of the meal, and bite rate. A mixed model analysis of variance will also be conducted on ratings of food cravings and eating atttudes. Changes in hunger and satiety ratings between, before, and after the meals will be compared for difference across treatment conditions.
89560639|NCT04036006|Active Comparator|Self-Directed|The Self-Directed lifestyle program represents enhanced usual care based upon what is currently offered in primary care in the United States for lifestyle treatments for adults with metabolic syndrome. Usual care is enhanced by: 1) lifestyle education for management of metabolic syndrome provided in evidence-based tip sheets from nationally recognized organizations; 2) provision of a Fitbit for self-monitoring physical activity; 3) access to a website containing all education materials; and 4) progress report letters with lab results sent to participants and primary care physicians after completion of each assessment
89560640|NCT04029714|Active Comparator|Arm 1: Current practice for active surveillance|In this arm, patients are monitored according to current practice for active surveillance at the trial centre. Repeat biopsies (and/or other examinations) and initiation of curative treatment are performed according to the urologist's judgement.
89560641|NCT04029714|Experimental|Arm 2: Standardized triggers for treatment|In this arm, patients are monitored according to a standardized active surveillance protocol with specific triggers for treatment. Repeat biopsies and curative treatment are only initiated if/when specific criteria are fulfilled.
89560642|NCT04024436|Experimental|Futibatinib|"Group/Cohort 1 Description HR+ HER2- Measurable Disease w/ FGFR2 Amplification~Group/Cohort 2 Description TNBC Measurable Disease w/ FGFR2 Amplification~Group/Cohort 3 Description HR+ HER2- or TNBC Non-Measurable Disease w/ FGFR2 Amplification"
89560643|NCT04024436|Experimental|Futibatinib plus Fulvestrant|Group/Cohort 4 Description HR+ HER2- Measurable Disease w/ FGFR1 Amplification
89560644|NCT04022551||Observational|"At Emergency nurses will carry out a test called: Emergency Room Evaluation and Recommendation which contents the following statements:~Being 85 years older and over (Yes/No)~Male (Yes/No)~Home services (Yes/No)~Taking 5 different medication daily (Yes/No)~Use of walking aid (Yes/No)~Disoriented (Yes/No)"
89210574|NCT00927498|Experimental|Arm B Daunorubicin and Cytarabine and Mylotarg|"Daunorubicin(DNR) induction : 60 mg/m2/day IV (30 min), Days 1,2,3 Daunorubicin (DNR)first consolidation : 60 mg/m2 day 1. Daunorubicin (DNR)second consolidation : 60 mg/m2 day 1 and day 2.~Cytarabine induction :200 mg/m2/day by continuous infusion, Days 1 to 7. Cytarabine (AraC)first and second consolidation: 1g/m2/12h days 1 to 4.~Mylotarg® (GO)induction : 3 mg/m2 IV (2 hours) Days 1, 4, 7. Mylotarg® (GO) First consolidation and Second Consolidation:3 mg/m2 day 1."
89560645|NCT04018898||Observational|Each participant will be evaluated at Emergency Department based on ER2 screening tool (Emergency Room Evaluation and Recommendation Form). Six closed-ended format questions (i.e., yes versus no) composed ER2 assessment: Age category (≥ 85), male, polypharmacy (≥ 5 different medications per day), use of formal (health care or social professional) and/or informal (family and/or friend) home support, use of a walking aid regardless its type, and temporal disorientation (inability to give the current month and/or year).
89560646|NCT04018248|Experimental|Treatment (BR101801): Phase Ia (dose escalation)|Patients will receive BR101801 capsules orally, QD in 28-day cycles. The regimen may be changed to BID dosing based on emerging data.
89560647|NCT04018248|Experimental|Treatment (BR101801):Phase Ib (dose expansion)|• Subjects with PTCL NOS, PTCL AITL, Nodal PTCL with TFH and PTCL FTCL
89026940|NCT00477854|Experimental|Consuming less Lunch allows consumption of more dinner|Test whether chromium picolinate supplementation affects food cravings, eating attitudes, and satiety in healthy, overweight and/or obese, adult women who are determinded to be carbohydrate cravers. Whether participants who eat less at a lunch test meal consume more food at an ad lib dinner test meal with a diversity of foods.
89026941|NCT01247259|Active Comparator|SLIT-mono|
89026942|NCT01247259|Active Comparator|SLIT-poly|
89560648|NCT04017273||Observational|The participants of this study will be seen at Emergency Department, and a nurse will perform a test called ER2 ( Emergency Room Evaluation and Recommendation).
89560649|NCT04009447|Other|Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia (CBT-I) 6 sessions of Cognitive Behavioral Training for Insomnia (1 hour each).
89560650|NCT04002063|Experimental|CBT-D augmented with CBT MobileWork-V|Patients randomized to this condition will receive CBT-D as usual plus access to CBT MobileWork-V, a comprehensive tailored smartphone app for CBT skills practice for OEF/OIF Veterans.
89560651|NCT04002063|Active Comparator|CBT-D|Patients randomized to CBT-D will receive CBT-D as usual only.
89560652|NCT03986021||At-risk girls|Girls with first degree relative diagnosed with Polycystic Ovary Syndrome (PCOS) age 8-<15
89560653|NCT03986021||early post-menarche girls|Healthy, early post-menarchal girls age 8-<15
89560654|NCT03986021||Healthy control women|Women age >18-34 without PCOS at least 3-years post-menarchal with regular menstrual cycles every 21-35 days
89560655|NCT03986021||late post-menarche girls|Late post-menarchal girls age 11-<17.5 (gynecological age 2-5)
89560656|NCT03986021||pre-menarche girls|Healthy, pre-menarchal girls age 8-<14.5
89560657|NCT03986021||Women with PCOS|Women diagnosed with PCOS >18-34 at least 3-years post-menarchal with irregular menstrual cycles
89560658|NCT03971669|Experimental|Vaccination with Oral Typhoid Vaccine (Vivotif)|Volunteers receive immunization with Vivotif oral typhoid vaccine. Blood, saliva, and stool specimens are collected at subsequent visits.
89560659|NCT03964311|Other|Emergency Room Evaluation Tool (ER2)|Patients who are 75 years and over, and who are brought to Emergency in stretchers will be evaluated based on the Emergency Room Evaluation Tool (ER2).
89560660|NCT03962985|Other|Intervention|The 41 participants will attend the guided tours at the Montreal Museum of Fine Arts.
89026943|NCT00477893|Placebo Comparator|Placebo|
89026944|NCT00477893|Active Comparator|Adalimumab|
89026945|NCT01245426|Experimental|GW870086 2mg|GW870086 2mg once daily in the morning for 27 ± 2 days
89210575|NCT00909636|Active Comparator|1. ABT-333 Tablet|Three 400mg ABT-333 Tablets, BID
89210576|NCT00909636|Active Comparator|2. ABT-333 Tablet|Four 400mg ABT-333 Tablets, BID
89560661|NCT03961750|Experimental|Intervention|A feasibility study examining a single patient group undertaking a 12 week, student-led, OTAGO exercise class for community dwelling older adults at Glasgow Caledonian University. OTAGO consists of progressive strength and balance exercises.
89560662|NCT03933202||Cladribine Tablets|No intervention will be administered as a part of this study. Participants who had decided prior to enrollment to transition from any oral or infusion DMD to treatment with cladribine tablets under routine clinical care and who meet all eligibility criteria will receive an initial treatment course with cladribine tablets in Year 1 and are planned to receive a second course in Year 2, as per the approved United States Prescribing Information (USPI). Data sources for this study will include data extracts from participants' medical records performed by site personnel as well as questionnaires directly filled out by participants.
89560663|NCT03911141|No Intervention|Control|Participants receive a daily text message stating whether or not they achieved their step goal on the prior day during the 12 months of intervention and 6 months of follow-up.
89026946|NCT01245426|Experimental|GW870086 4mg|GW870086 4mg once daily in the morning for 27 ± 2 days
89026947|NCT01245426|Placebo Comparator|Placebo|Placebo once daily in the morning for 27 ± 2 days
89026948|NCT01245426|Experimental|GW870086 1mg|GW870086 1mg once daily in the morning for 27 ± 2 days
89026949|NCT01245426|Experimental|GW870086 3mg|GW870086 3mg once daily in the morning for 27 ± 2 days
89026950|NCT01247337|Experimental|Single arm chemotherapy treatment|
89026951|NCT00478049|Active Comparator|1|Docetaxel
89026952|NCT00478049|Experimental|2|Gefitinib
89026953|NCT01248975|Experimental|FP/SAL 250/50mcg BID plus GSK2190915 300mg QD (AM)|FP/SAL 250/50mcg BID plus GSK2190915 300mg QD (AM)
89026954|NCT01248975|Active Comparator|FP/SAL 250/50mcg BID plus montelukast 10mg QD (PM)|FP/SAL 250/50mcg BID plus montelukast 10mg QD (PM)
89026955|NCT01248975|Placebo Comparator|FP/SAL 250/50mcg BID plus placebo BID|P/SAL 250/50mcg BID plus placebo BID
89026956|NCT01247415||Anaphylaxis|Anaphylaxis: these patients will have to meet at least level 3 of diagnostic certainty according to the Brighton Collaboration criteria for anaphylaxis
89210577|NCT00909636|Placebo Comparator|3. Placebo|Three or four placebo tablets, BID
89026957|NCT01247415||Allergic-like reactions|Allergic-like reactions: These patients will have to have displayed at least one sign or symptom of an allergic reaction (any of the minor or major criteria of anaphylaxis) but will exclude patients with conjunctivitis who will belong to the ORS group
89026958|NCT01247415||ORS cases|ORS cases: According to the Public Health Agency case definition, these patients should have presented a bilateral conjunctivitis plus ≥1 of the seven respiratory symptoms (cough, wheeze, chest tightness, difficulty breathing, difficulty swallowing, hoarseness or sore throat) that started within 24 hrs of vaccination, with or without facial oedema (no restriction for duration) (ref: Public Health Agency of Canada: User Guide: Report of Adverse Events Following Immunization (AEFI) Appendix III National Case Definitions of AEFIs of Special Interest: oculo-respiratory Syndrome. http://www.phac-pc.gc.ca/im/aefi_guide/ann3-eng.php
89210578|NCT05711355|Active Comparator|Use of Platelet-Rich Plasma after meningomyelocele sac repair|Paitents treated with platelet-rich plasma injection and treated with according to guidelines
89560664|NCT03911141|Experimental|Gamification Intervention|"Participants have an 8-week ramp-up period where daily goals increase from baseline to the step target, and sign a pledge agreeing to try their best to meet their goals.~Participants are entered into a game. Each week they receive 70 points. Each day they're told their step count and points. If the step goal was met they keep their points, but if not, they lose 10 points. At the end of the week if they have at least 40 points they move up a level, but if not, they drop a level. Participants start in the middle of 5 levels.~Participants choose a support partner who gets a weekly email with the participant's progress. We hold a 3-way phone call with the participant and supportive sponsor to discuss ways they can help the participant meet their goal. Every 8 weeks, have a follow up call if the participant is stuck in a lower level and restart them back at the middle level.~In the follow-up period, participants continue to get a daily text stating if they met their step goal."
89560665|NCT03911141|Experimental|Financial Incentive Intervention|"Participants are informed that each week that money is placed in a virtual account for them. Each day the participant is informed of their step count on the prior day. If the step goal was achieved, the balance remains. Each day the goal is not achieved, the participant is informed that some of the money was taken away. We will use an 8-week ramp-up period in which daily goals are increased gradually from baseline to targets.~During the follow-up period, participants in this arm will continue to receive a daily text message stating whether or not they achieved their step goal on the prior day."
89560666|NCT03911141|Experimental|Gamification and Financial Incentive Intervention|Participants receive both of the interventions described in the Gamification Intervention arm and the Financial Incentive Intervention arm.
89560667|NCT03910075|Experimental|I-ACQUIRE High Dose|High Dose I-ACQUIRE (6hrs/day, 5 days/wk X 4 wks)
89560668|NCT03910075|Experimental|I-ACQUIRE Moderate Dose|Moderate Dose I-ACQUIRE (3 hrs/day, 5 day/wk X 4 wks)
89560669|NCT03910075|Active Comparator|Usual & Customary Treatment|Usual & Customary Treatment
89560670|NCT03903172|Experimental|Binder Arm|Abdominal binder + standard of care postpartum pain management
89560671|NCT03903172|No Intervention|Standard of Care|Standard of care postpartum pain managment
89560672|NCT03900624|No Intervention|Methylprednisolone Arm|Non-randomized, prospective, observational arm of children receiving standard care for status asthmaticus in the PICU with intravenous methylprednisolone.
89560673|NCT03900624|Experimental|Dexamethasone Arm|Non-randomized, open-label, prospective use of intravenous dexamethasone for children admitted to the PICU with status asthmaticus.
89560674|NCT03896568|Experimental|Part I (oncolytic adenovirus Ad5-DNX-2401)|Patients receive oncolytic adenovirus Ad5-DNX-2401 IA over 20-30 minutes on day 0.
89560675|NCT03896568|Experimental|Part II (oncolytic adenovirus Ad5-DNX-2401, surgery)|Patients receive oncolytic adenovirus Ad5-DNX-2401 as in part I. After 2 weeks, patients undergo surgery, then receive oncolytic adenovirus Ad5-DNX-2401 IA over 20-30 minutes.
89560676|NCT03895320|Experimental|Intervention Program|The intervention and control programs will consist of similar, but not identical components. The intervention will include a) a brief self-assessment (also called 'quiz'), b) score, and c) personalized messaging. For the intervention program, the self-assessment ('Sexual Health Quiz'), score ('Sexual Health Score') and messaging ('Sexual Health Messaging') will pertain to sexual and reproductive health. For the intervention program, the self-assessment, will include a valid clinical prediction tool, established to predict STI positivity. Short messages that indicate key steps the person can take to lower their risk for STIs will be displayed on the screen after the risk score. The program will be delivered via tablet. All participants regardless of randomization group, will be offered a STI screening kit immediately after receipt of their respective program.
89560677|NCT03895320|Other|Control Program|The intervention and control programs will consist of similar, but not identical components. The Control Program will include a) a brief self-assessment (also called 'quiz'), b) score, and c) personalized messaging. For the Control Program, the self-assessment ('Water Sugar Sweetened Beverages (SSB) Quiz'), score ('Water SSB Score') and messaging ('Water SSB Messaging') will pertain to consumption of water, soda and sugar sweetened beverages. There will not be a comparable clinical prediction tool in the control self-assessment. However, based on the answers given on the control quiz, steps the control participant can take to meet the recommended daily intake of water and sugar sweetened beverages will be displayed on the screen after they complete the quiz. The control program will be delivered via tablet. All participants regardless of randomization group, will be offered a STI screening kit immediately after receipt of their respective program.
89560678|NCT03892746|Active Comparator|Active tDCS + task oriented practice|
89560679|NCT03892746|Sham Comparator|Sham tDCS + task oriented practice|
89560680|NCT03892694|Active Comparator|Treatment|MCS
89560681|NCT03892694|Sham Comparator|Sham Control|Sham
88966810|NCT01515124|Experimental|Exercise only|The Exercise Intervention combines 60-90 minute twice-weekly supervised weight-lifting sessions with 180 minutes of weekly aerobic exercise. Women will be trained by certified fitness professionals in both the weight-lifting intervention and in safely increasing their aerobic exercise activity over 6 weekly sessions, and then monitored through phone contact, and monthly in-person sessions. All exercise participants will be provided with 'Power Blocks' which are adjustable dumbbells with which they can increase resistance in 1-2 pound increments from 1-21 pounds. All weight training will be done in their homes except for the first 6 weekly session and monthly check-in sessions. Exercise only group members also received the Lymphedema care intervention described above.
88966811|NCT01515124|Experimental|Weight loss only|The Weight Loss Intervention begins with a 24 week intensive phase that includes weekly meetings and provision of all meals and snacks from a commercial manufacturer (NutriSystem®, Inc., Fort Washington, PA). Daily caloric intake will be strictly controlled during this first 24 weeks at 1200-1500 calories per day. Participants will be guided to stay at the same number of calories per day until reaching goal weight, followed by a gradual increase in caloric intake (of approximately 500 calories/d) to maintain their weight throughout the remainder of the intervention. The treatment groups will be led by registered dietitians and will receive ongoing supervision via telephone and email contact. Weight loss only group members also received the Lymphedema care intervention described above.
89560682|NCT03871036|Experimental|Tremelimumab 75 (R1)|"Run-in phase-1 (R1): n=3 patients will be treated with:~paclitaxel 70 mg/m2 on day 1, 8, 15 of cycles 1-6~tremelimumab 75 mg on day 1 of cycles 2-6 and then every 12 weeks until week 45"
89560683|NCT03871036|Experimental|Tremelimumab 225 (R2)|"Run-in phase-2 (R2): n=3 patients will be treated with:~paclitaxel 70 mg/m2 on day 1, 8, 15 of cycles 1-6~tremelimumab 225 mg on day 1 of cycles 2-6 and then every 12 weeks until week 45"
88966812|NCT01515124|Experimental|Exercise and Weight loss combined|Participants in this group will receive a combination of the supervised twice-weekly weight training sessions and the weight loss program. Combined group members also received the Lymphedema care intervention described above.
89560684|NCT03871036|Experimental|Tremelimumab vs Tremelimumab+Durvalumab (R3)|"Run-in phase-3 (R3): n=2 x 3 patients will be randomized over 2 arms:~paclitaxel 70 mg/m2 on day 1, 8, 15 of cycles 1-6~tremelimumab 750 mg on day 1 of cycles 2-6 and then every 12 weeks until week 45~OR~paclitaxel 70 mg/m2 on day 1, 8, 15 of cycles 1-6~tremelimumab 75 mg on day 1 of cycles 2-5~durvalumab 1500 mg on day 1 of cycles 2-12, every four weeks (until week 49)"
89560685|NCT03871036|Experimental|Tremelimumab 300 (R4)|"Run-in phase-4 (R4): n=3 patients will be treated with:~paclitaxel 70 mg/m2 on day 1, 8, 15 of cycles 1-6~tremelimumab 300 mg once on day 1 of cycle 2~durvalumab 1500 mg on day 1 of cycles 2-12, every four weeks (until week 49)"
89560686|NCT03871036|Experimental|Tremelimumab 750 (A)|"Arm A:~paclitaxel 70 mg/m2 on day 1, 8, 15 of cycles 1-6~tremelimumab 750 mg on day 1 of cycles 2-6 and then every 12 weeks until week 45"
89560687|NCT03871036|Experimental|Tremelimumab+Durvalumab (B)|"Arm B:~paclitaxel 70 mg/m2 on day 1, 8, 15 of cycles 1-6~tremelimumab 300 mg once on day 1 of cycle 2~durvalumab 1500 mg on day 1 of cycles 2-12, every four weeks (until week 49)"
89560688|NCT03871036|Experimental|Tremelimumab without paclitaxel (C)|"Arm C (control arm):~• tremelimumab 750 mg on day 1 of cycles 1-5 and then every 12 weeks until week 41"
89560689|NCT03870672|Active Comparator|CCFES + rTMS facilitating cHMC|"This rTMS paradigm is the New Approach. Facilitation of the intact hemisphere target (cHMC) will be achieved using 5Hz rTMS. After rTMS, the participant will participate in one hour of CCFES-mediated functional task practice. The therapist will instruct and guide the participants in practicing functional tasks with their paretic hand with the assistance of CCFES. Tasks will involve using the paretic hand to pick up, manipulate, and release objects commonly used in daily life. Early sessions will focus on simpler tasks, such as practicing opening the hand adequately to acquire an object."
89560690|NCT03870672|Active Comparator|CCFES + rTMS facilitating iM1|"This rTMS paradigm is the Conventional Approach.Facilitation of M1 will be achieved using 5Hz rTMS. After rTMS, the participant will participate in one hour of CCFES-mediated functional task practice. The therapist will instruct and guide the participants in practicing functional tasks with their paretic hand with the assistance of CCFES. Tasks will involve using the paretic hand to pick up, manipulate, and release objects commonly used in daily life. Early sessions will focus on simpler tasks, such as practicing opening the hand adequately to acquire an object."
89560691|NCT03870672|Sham Comparator|CCFES + Sham rTMS|"This rTMS paradigm is the Sham Approach. Immediately after sham rTMS, the participant will participate in one hour of CCFES-mediated functional task practice. The therapist will instruct and guide the participants in practicing functional tasks with their paretic hand with the assistance of CCFES. Tasks will involve using the paretic hand to pick up, manipulate, and release objects commonly used in daily life. Early sessions will focus on simpler tasks, such as practicing opening the hand adequately to acquire an object."
89560692|NCT03830580|Experimental|Sung voice|
89560693|NCT03830580|No Intervention|Control|
89560694|NCT03818022|Experimental|Experimental|Patients receiving Cryoneurolysis (Iovera) prior to total knee arthroplasty
89560695|NCT03818022|No Intervention|Control|
89560696|NCT03796364|Active Comparator|control group|standard SRILI treatment
89560697|NCT03796364|Experimental|observation group|Endostar® plus standard treatment
88966813|NCT01466569|Experimental|AbGn-7 phase 1a cohort 1|
88966814|NCT01466569|Experimental|AbGn-7 phase 1a cohort 2|
88966815|NCT01466569|Experimental|AbGn-7 phase 1a cohort 3|
88966816|NCT01466569|Experimental|AbGn-7 phase 1b cohort 1|
88966817|NCT01466569|Experimental|AbGn-7 phase 1b cohort 2|
88966818|NCT01466530|Placebo Comparator|Placebo|sublingual two moistened white coated placebo tablets
88966819|NCT01466530|Active Comparator|Misoprostol|sublingual misoprostol (400 µg)
88966820|NCT01466452|Active Comparator|Aspirin 100|
88966821|NCT01466452|Active Comparator|Aspirin 200|
88966822|NCT01466452|Active Comparator|Aspirin 100 x 2|
88966823|NCT04404257|Experimental|ControlRad System|Participant will undergo Cardiac catheterization or electrophysiology implant procedures with the ControlRad system installed in Cath lab room 5
88966824|NCT04404257|Active Comparator|Without ControlRad System|Participant will undergo the cardiac catheterization or electrophysiology implant procedures per standard of care. Meaning, without the ControlRad system installed in Cath lab room 5.
89560698|NCT03791944|Experimental|3DV+TPS/VARIAN|Use 3DV+TPS to map targets and develop treatment plans. The intervention is 3DV+TPS and VARIAN.
89560699|NCT03791944|Active Comparator|TPS/VARIAN|Use imported Varian TPS to map targets and develop treatment plans.
89560700|NCT03791944|Experimental|3DV+TPS/ Domestic accelerator|Use 3DV+TPS to map targets and develop treatment plans.
89560701|NCT03791944|Active Comparator|TPS/ Domestic accelerator|Adopt domestic TPS hook target and develop treatment plan.
89560702|NCT03788499|No Intervention|Control arm|routine oral care and functional exercise.
89560703|NCT03788499|Experimental|Massage arm|Massage of Maxillofacial and oral cavity plus routine oral care and functional exercise
89560704|NCT03784924||Initial prostate biopsy|Men who have never had a prostate biopsy, but have an elevated risk for prostate cancer such as elevated PSA who are scheduled or considered candidate for an initial prostate biopsy.
89560705|NCT03753555|Active Comparator|Routine-dose statin group|Routine-dose statin group will be gaven the treatment of atorvastatin 20mg Qd for 12 months
89560706|NCT03753555|Experimental|high-dose statin or PCSK9 inhibitor group|"high-dose statin group will be gaven the treatment of atorvastatin 40-80mg Qd till 6 months at the moment the subjects will be followed up to determine plaques status by HRMRI examination, among which the subjects presenting culprit plaque progression with the significant increasing of plaque burden including intraplaque hemorrhage will be again randomized into two groups at a ratio of 1:1 as followed: atorvastatin-probucol group will be administrated atorvastatin 40-80mg Qd plus probucol 0.5g Bid till 12 months, the other group will maintain the original scheme till 12 months.~PCSK9 inhibitor group will receive the subcutaneous injection of Evolocumab (140mg, 2 / month) for one year."
89560707|NCT03749187|Experimental|Arm A (BGB-290, temozolomide)|Patients with grades III-IV newly diagnosed IDH1/2 mutant glioma receive 60mg PARP inhibitor BGB-290 PO BID on days 1-28 and 20mg temozolomide PO daily on days 1-21. Courses repeat every 28 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
89560708|NCT03749187|Experimental|Arm B (BGB-290, temozolomide)|"Patients with grades I-IV recurrent IDH1/2 mutant glioma receive 60mg PARP inhibitor BGB-290 PO BID on days 1-28 and 20mg temozolomide PO daily on days 1-21. Courses repeat every 28 days for up to 24 months in the absence of disease progression or unacceptable toxicity.~Cohort B0: Patients who are surgical candidates with grades I-IV recurrent IDH1/2 mutant glioma receive 60mg PARP inhibitor BGB-290 PO BID for 7 days, pre-surgery. After recovery from surgery, patients receive PARP inhibitor BGB-290 PO BID on days 1-28 and 20mg temozolomide PO daily on days 1-21. Courses repeat every 28 days for up to 24 months in the absence of disease progression or unacceptable toxicity."
89560709|NCT03734679|Experimental|Surveil drug coated balloon|
89560710|NCT03734588|Experimental|SPK-8016|All participants who meet the eligibility criteria will receive an outpatient single intravenous (i.v.) administration of SPK-8016.
89560711|NCT03733041|Active Comparator|rTMS|This group will be randomized to receive rTMS
89560712|NCT03733041|Sham Comparator|Sham|This group will be randomized to receive sham treatment
89560713|NCT03733041|Other|No intervention|This group will receive no intervention
89560714|NCT03725202|Experimental|Arm A|Upadacitinib dose A administered daily + 26-week CS taper regimen
89026959|NCT01247415||Controls|Controls will be individuals who received the pH1N1 vaccine but did not present any of the above mentioned adverse events after their vaccine.
89560715|NCT03725202|Experimental|Arm B|Upadacitinib dose B administered daily + 26-week CS taper regimen
89560716|NCT03725202|Placebo Comparator|Arm C|Placebo administered daily + 52-week CS taper regimen
89560717|NCT03709706|Experimental|Arm A: lete-cel monotherapy|In Arm A, participants with NSCLC (lacking actionable genetic aberrations) will receive lete-cel monotherapy. Participants who subsequently progress by Week 25 will be offered pembrolizumab.
89560718|NCT03709706|Experimental|Arm B: lete-cel plus pembrolizumab|In Arm B, participants with NSCLC (lacking actionable genetic aberrations) will receive lete-cel followed by pembrolizumab.
89560719|NCT03709706|Experimental|Arm C: lete-cel plus pembrolizumab|In Arm C, participants with NSCLC (with actionable genetic aberrations) will receive lete-cel followed by pembrolizumab.
89560720|NCT03691987|Experimental|Preprocessed thawed donor FMT|"The active transplants are processed in a 2-3 weeks period before treatment of the first participant. Fifty to eighty grams of freshly delivered feces from donors is mixed with 100 mL isotonic saline and 25 mL 85% glycerol, homogenized and poured through a 0.5 mm mesh steel strainer, and transferred to 60 ml luerlock syringes and stored at -40°C.~Frozen transplants are slowly thawed 2 hours prior to administration by transferring the FMT-syringes to a waterbath (+30°C). The transplant is then mixed with 125 mL 12°C isotonic saline in an enema bag prior to installation."
89560721|NCT03691987|Placebo Comparator|Preprocessed thawed autologous FMT|"The placebo transplant from each participant is prepared during the inclusion process four to six weeks before intervention and stored at -40°C. Fifty to eighty grams of freshly delivered feces from participants is mixed with 100 mL isotonic saline and 25 mL 85% glycerol is homogenized and poured through a 0.5 mm mesh steel strainer, and transferred to 60ml Luerlock syringes.~Frozen transplants are slowly thawed 2 hours prior to administration by transferring the Luerlock syringes to a waterbath (+30°C). The transplant is then mixed with 125 mL 12°C isotonic saline in the enema bag prior to installation."
89560722|NCT03679221||Group 45-54 years old|divided in two subgroups: individuals with and without cardio-vascular risk factors and diseases
89560723|NCT03679221||Group 54-64 years old|divided in two subgroups: individuals with and without cardio-vascular risk factors and diseases
89560724|NCT03679221||Group 65-74 years old|divided in two subgroups: individuals with and without cardio-vascular risk factors and diseases
89560725|NCT03679221||Group 75-85 years old|divided in two subgroups: individuals with and without cardio-vascular risk factors and diseases
89560726|NCT03676907|No Intervention|single layer suturation technique|in this arm we use single layer suturation technique to suture uterine incision
89560727|NCT03676907|Experimental|double layer suturation technique|in this arm we use double layer suturation technique to suture uterine incision
88966825|NCT01466413|Experimental|Restylane|"Patients with an even subject identification number (SIN) (02, 04, 06, 08, 10, 12, 14, 16) will have ELAPR to the right arm and the control to the left, where patients with an odd subject identification number (01, 03, 05, 07, 09, 11, 13, 15) will have the ELAPR to the left arm and the control to the right.~Patients will receive either device ELAPR002c or ELAPR002e. This will alternate to minimise bias between the right and left arms.~The first group of eight patients (01 - 08) will have their biopsy performed at day 169. The second group of eight patients (09 - 16) will have their biopsy at day 85."
89560728|NCT03674723|Experimental|Arms|Methionine bioavailability in Mung beans Participants will be seen initially for pre-study assessment (3 hour). They will then be studied for up to 10 times. levels of phenylalanine intake (7 Study periods). You could be expected to participate in up to 10 different sets of experiments which will take 11 weeks to 6 months. Each set of experiment consists of a 3 day period. During the first 2 days (Adaptation Days) you will be expected to consume 4 meals per day consisting of a protein liquid drink and protein freecookies and/or a Mung bean stew with or without rice or wheat, which will be provided by the investigators
89560729|NCT03671967|Experimental|piperacillin tazobactam|
89560730|NCT03671967|Active Comparator|meropenem|
88966826|NCT01466374|Experimental|Cohort 1: Induction|Placebo
88966827|NCT01466374|Experimental|Cohort 2: Induction|Anti-IP-10 Antibody
88966828|NCT01466374|Experimental|Cohort 3: Induction|Anti-IP-10 Antibody
89560731|NCT03668769|Experimental|Prevention (smoking reduction, Quitting Schedule mobile app)|"AIM I: Participants follow an individually tailored gradual reduction of smoking schedule for 5 weeks while MDACC eHealth adapts WebCASSI into a smartphone app: Quitting Schedule.~AIM II: Participants pre-test the Quitting Schedule mobile smartphone app for 5 weeks."
89560732|NCT03654079|Active Comparator|Simulation Arm|Subjects in this arm will participate in Interventions (In- Utero Simulation, Cesarean Section Simulation, and Pushing Simulation).
89560733|NCT03654079|No Intervention|Control Arm|Subjects in this arm will not participate in any simulations.
89560734|NCT03633253||MCR syndroms|
89560735|NCT03633253||Non MCR syndroms|
89560736|NCT03628768||Healthy / Non fallers|Older cognitively healthy individuals Non fallers
89560737|NCT03628768||Healthy / Fallers without injuries|Older cognitively healthy individuals Fallers without injuries
89560738|NCT03628768||Healthy / Fallers with injuries|Older cognitively healthy individuals Fallers with injuries
89560739|NCT03628768||MCI / Non fallers|Older individuals with MCI and mild dementia Non fallers
89560740|NCT03628768||MCI / Fallers without injury|Older individuals with MCI and mild dementia Fallers without injuries
89560741|NCT03628768||MCI / Fallers with injury|Older individuals with MCI and mild dementia Fallers with injuries
89560742|NCT03626103|Experimental|+ Brief ED Intervention (BI), + Text|Participants receive both the Brief ED Intervention component (a 20-minute Motivational Interviewing- and Cognitive Behavioral Therapy-based in-Emergency Department session delivered by a bachelors'-level Research Assistant) and the Text Message Intervention component (8 weeks of an automated, tailored, two-way text-message curriculum started after the ED visit, which reinforces cognitive reappraisal, emotional regulation, and self-efficacy skills).
89560743|NCT03626103|Experimental|+ Brief ED Intervention (BI), no Text|Participants receive the Brief ED Intervention component only (which is a 20-minute Motivational Interviewing- and Cognitive Behavioral Therapy-based in-Emergency Department session delivered by a bachelors'-level Research Assistant).
89560744|NCT03626103|Experimental|No Brief ED Intervention (BI), + Text|Participants receive the Text Message Intervention component only (8 weeks of an automated, tailored, two-way text-message curriculum started after the ED visit, which reinforces cognitive reappraisal, emotional regulation, and self-efficacy skills). Participants receive a brochure containing online and community resources for violence and depression prevention instead of the Brief ED Intervention component.
89560745|NCT03626103|No Intervention|No Brief ED Intervention (BI), no Text|Participants receive neither the Brief ED Intervention component, nor the Text Message Intervention component. Participants receive a brochure containing online and community resources for violence and depression prevention, instead of the Brief ED Intervention component.
89560746|NCT03598608|Experimental|Part A: Favezelimab Dose A+pembrolizumab|Participants receive 200 mg pembrolizumab by intravenous (IV) infusion followed by favezelimab Dose A by IV infusion on Day 1 of each 3-week cycle for up to 35 cycles (up to approximately 2 years).
89560747|NCT03598608|Experimental|Part A: Favezelimab Dose B+pembrolizumab|Participants receive 200 mg pembrolizumab by IV infusion followed by favezelimab Dose B by IV infusion on Day 1 of each 3-week cycle for up to 35 cycles (up to approximately 2 years).
88966829|NCT01466374|Experimental|Cohort 1: Maintenance|Placebo
88966830|NCT01466374|Experimental|Cohort 2: Maintenance|Anti-IP-10 Antibody
88966831|NCT01466374|Experimental|Cohort 3: Maintenance|Anti-IP-10 Antibody
88966832|NCT01466374|Experimental|Cohort 1: Open Label|Anti-IP-10 Antibody
88966833|NCT01466335|Experimental|Ronacaleret 100mg once daily|1 x 100mg oral tablet
88966834|NCT01466335|Experimental|Ronacaleret 100mg twice daily|1 x 100mg oral tablet twice daily
89210579|NCT05711355|Active Comparator|Control group of meningomyelocele sac repair|Paitents treated according to guidelines
89210580|NCT00816296||Controls|Obese (BMI>30) and normal AST and ALT. Between the ages of 5 and 18 years old.
89210581|NCT00816296||Liver Disease|Obese (BMI>30) and elevated AST and/or ALT (evidence of NAFLD). Between the ages of 5 and 18 years old.
89560748|NCT03598608|Experimental|Part A: Favezelimab Dose C+Pembrolizumab|Participants receive 200 mg pembrolizumab by IV infusion followed by favezelimab Dose C by IV infusion on Day 1 of each 3-week cycle for up to 35 cycles (up to approximately 2 years).
88966835|NCT01466335|Experimental|Ronacaleret 200mg once daily|2 x 100mg oral tablet
88966836|NCT01466335|Experimental|Ronacaleret 200mg twice daily|2 x 100mg tablets twice daily
88966837|NCT01466335|Experimental|Ronacaleret 400mg once daily|4 x 100mg tablets
88966838|NCT01466335|Placebo Comparator|Placebo|Matching number of identical placebo tablets
89560749|NCT03598608|Experimental|Part B: cHL-Combination Therapy|Participants with cHL receive 200 mg pembrolizumab by IV infusion followed by the recommended Phase 2 dose (RP2D) of favezelimab by IV infusion on Day 1 of each 3-week cycle for up to 35 cycles (up to approximately 2 years).
89560750|NCT03598608|Experimental|Part B: DLBCL-Combination Therapy|Participants with DLBCL receive 200 mg pembrolizumab by IV infusion followed by the RP2D of favezelimab by IV infusion on Day 1 of each 3-week cycle for up to 35 cycles (up to approximately 2 years).
89560751|NCT03598608|Experimental|Part B: iNHL-Combination Therapy|Participants with iNHL receive 200 mg pembrolizumab by IV infusion followed by the RP2D of favezelimab by IV infusion on Day 1 of each 3-week cycle for up to 35 cycles (up to approximately 2 years).
89560752|NCT03598608|Experimental|Part B: Randomized cHL-Monotherapy|Participants with cHL receive either pembrolizumab by IV infusion or the RP2D of favezelimab by IV infusion on Day 1 of each 3-week cycle (Q3W) for up to 35 cycles (up to approximately 2 years).
89560753|NCT03597438||Patient|patients scheduled for elective surgery who are patients either as an inpatient or arriving to the hospital on the day of scheduled surgery
88966839|NCT01466296|Experimental|Re-Step|"Mechatronic shoe with a sole made to change slopes in the swing phase of walking.~This unpredictable change will introduce a situation of necessary adaptation to keep balance"
89560754|NCT03597438||Volunteer|Volunteers who are employees, trainees and students at the Children's Hospital of Philadelphia (CHOP) will be introduced to the study via an informational study flyer to determine eligibility and desire to participate in the study
89560755|NCT03558867|Placebo Comparator|Metformin + Healthy diet|Metformin (1500 mg/d, Extended Release) + Healthy, low fat diet
89560756|NCT03558867|Active Comparator|Metformin + Personalized diet|Metformin (1500 mg/d, Extended Release) + Personalized diet based on an algorithm developed at the Weizmann Institute of Science (Zeevi et al, Cell 2015)
89560757|NCT03528694|Experimental|Durvalumab plus BCG (induction + maintenance)|Durvalumab (MEDI4736) plus Bacillus Calmette-Guerrin (BCG) combination therapy
89560758|NCT03528694|Experimental|Durvalumab plus BCG (induction only)|Durvalumab (MEDI4736) plus Bacillus Calmette-Guerrin (BCG) combination therapy
89560759|NCT03528694|Active Comparator|BCG treatment (Standard of care therapy)|Bacillus Calmette-Guerrin (BCG) standard of care treatment
89560760|NCT03523390|Experimental|Avelumab 3 mg/kg Q2W|
89560761|NCT03523390|Experimental|Avelumab 10 mg/kg Q2W|
89560762|NCT03523390|Experimental|Avelumab 20 mg/kg Q2W|
89560763|NCT03523390|Experimental|Avelumab 10 mg/kg QW|
89560764|NCT03510442||adult-onset Still's disease (AOSD)|Composed of patients with known or suspected AOSD as defined by Yamaguchi criteria.
89560765|NCT03510442||family members|Composed of family members of patients with systemic juvenile idiopathic arthritis, adult-onset Still's disease and related conditions.
89560766|NCT03510442||healthy volunteers|Composed of healthy adults and children (above the age of 6 years) who volunteer to participate in this protocol.
89560767|NCT03510442||related inflammatory conditions|Composed of patients with suspected inflammatory disease as indicated by the presence of episodic fever and/ or arthritis.
88966840|NCT01466296|Experimental|Dummy shoes|The shoes are in the same shape and weight of the Re-Step without the perturbations.
88966841|NCT01466296|Active Comparator|treadmill|A treadmill with safety adaptation and all the usual characteristics of speed and slopes of fitness treadmills.
88966842|NCT03818204|Experimental|Experimental Group|"The purpose of the experimental group is to test the intervention. Participants will have their acuity measured (refraction as needed), slit lamp with Nafl & NEI scale, visual functioning questionnaire (VFQ), cognitive assessment (MOCA).The eye lid will be prepped and video recorded.The masked clinical staff will then apply the polarized magnets and perform a number of measurements to ascertain effectiveness of intervention.~-Intervention - Magnetic Levator Prosthesis (MLP)"
88966843|NCT03818204|Other|Control/Normal Vision Group|"The purpose of the normal vision group is to test the experimental setup prior to enrolling ptosis patients. If the measurements of the normal vision group are found to be non-different to the experimental group, the data will be pooled.~-Intervention - Magnetic Levator Prosthesis (MLP)"
88966844|NCT01466218||WTC Volunteers and Workers|Any current participant of the World Trade Center Health Program-Clinical Center of Excellence, formerly known as World Trade Center Medical Monitoring and Treatment Program
88966845|NCT01466140|No Intervention|Control group|Patients in the control group were asked to participate in a patient satisfaction study. They were asked to fill in a questionnaire with respect to patient satisfaction.
89026960|NCT02955927|Experimental|ortho-k and 0.01% atropine eye drops|participants will receive treatment of ortho-k and 0.01% atropine eye drops
89560768|NCT03510442||systemic juvenile idiopathic arthritis (sJIA)|Composed of patients with known or suspected sJIA as defined by the international league of Associations for Rheumatology (ILAR) criteria
89560769|NCT03503344|Experimental|Arm I (apalutamide, SBRT)|Participants receive apalutamide PO QD on days 1-28. Courses repeat every 28 days for up to 52 weeks in the absence of disease progression or unacceptable toxicity. Beginning 60 days after first dose of apalutamide, participants also undergo stereotactic body radiation therapy for 1-5 fractions.
89560770|NCT03503344|Active Comparator|Arm II (SBRT)|Participants receive apalutamide PO QD on days 1-28. Courses repeat every 28 days for up to 52 weeks in the absence of disease progression or unacceptable toxicity.
89560771|NCT03501576||Inactivated Influenza Vaccine|Patients will be vaccinated with an FDA approved seasonal inactivated influenza vaccine
89560772|NCT03501576||Qualifying subjects to receive a SARS-CoV2 vaccine.|Patients receive a SARS-CoV2 vaccine.
89560773|NCT03501576||Clinical Group Receiving SARS-CoV2 Booster Vaccines|Patients receive a SARS-CoV2 vaccine.
89560774|NCT03439046|Experimental|ribociclib+letrozole|Ribociclib oral (3weeks on/1week off) in combination with oral once daily letrozole: 600mg tablets ribociclib QD + 2.5 mg tablets letrozole QD
89560775|NCT03439046|Experimental|alpelisib+fulvestrant|Alpelisib 300 mg oral daily on a continuous dosing schedule in combination with fulvestrant 500 mg intramuscular on Days 1 and 15 of Cycle 1, and on Day 1 of each cycle thereafter in a 28 days cycle
89560776|NCT03429543|Placebo Comparator|Placebo - DINAMOᵀᴹ & DINAMOᵀᴹ Mono|Patients treated with metformin and/or insulin or patients who do not tolerate metformin or treatment-naïve patients or patients who are not on active treatment took 1 film-coated tablet of either Linagliptin or Empagliflozin matched placebo once daily, until end of treatment.
89560777|NCT03429543|Experimental|Placebo - Linagliptin 5 mg - DINAMOᵀᴹ & DINAMOᵀᴹ Mono|Patients treated with metformin and/or insulin or patients who do not tolerate metformin or treatment-naïve patients or patients who are not on active treatment took 1 film-coated tablet of either Linagliptin or Empagliflozin matched placebo once daily, until end of treatment.
89560778|NCT03429543|Experimental|Placebo - Empagliflozin 10 mg - DINAMOᵀᴹ & DINAMOᵀᴹ Mono|Patients treated with metformin and/or insulin or patients who do not tolerate metformin or treatment-naïve patients or patients who are not on active treatment took 1 film-coated tablet of either Linagliptin or Empagliflozin matched placebo once daily. At week 26, patients were re-randomised to receive 10 milligram (mg) empagliflozin, taken once daily, until end of treatment.
89560779|NCT03429543|Experimental|Placebo - Empagliflozin 25 mg - DINAMOᵀᴹ & DINAMOᵀᴹ Mono|Patients treated with metformin and/or insulin or patients who do not tolerate metformin or treatment-naïve patients or patients who are not on active treatment took 1 film-coated tablet of either Linagliptin or Empagliflozin matched placebo once daily. At week 26, patients were re-randomised to receive 25 milligram (mg) empagliflozin, taken once daily, until end of treatment.
89560780|NCT03429543|Experimental|Linagliptin 5 mg - DINAMOᵀᴹ & DINAMOᵀᴹ Mono|Patients treated with metformin and/or insulin or patients who do not tolerate metformin or treatment-naïve patients or patients who are not on active treatment took 1 film-coated tablet of 5 milligram (mg) Linagliptin once daily, until end of treatment.
89560781|NCT03429543|Experimental|Empagliflozin 10 mg - DINAMOᵀᴹ & DINAMOᵀᴹ Mono|Patients treated with metformin and/or insulin or patients who do not tolerate metformin or treatment-naïve patients or patients who are not on active treatment took 1 film-coated tablet of 10 milligram (mg) Empagliflozin once daily, until Week 14. Responder patients were not re-randomised at week 14 and continued 10 mg empagliflozin, taken once daily, until end of treatment. Non responder patients were re-randomised at Week 14 to receive 10 mg empagliflozin, taken once daily, until end of treatment.
89560782|NCT03429543|Experimental|Empagliflozin 10 mg - Empagliflozin 25 mg - DINAMOᵀᴹ & DINAMOᵀᴹ Mono|Patients treated with metformin and/or insulin or patients who do not tolerate metformin or treatment-naïve patients or patients who are not on active treatment took 1 film-coated tablet of 10 milligram (mg) Empagliflozin once daily until Week 14. Non responder patients were re-randomised at Week 14 to receive 25 mg empagliflozin, taken once daily, until end of treatment.
89560783|NCT03427463|Active Comparator|receiving 0.1 mg IT morphine|Patients will receive the standard of care dose 0.1 mg of intrathecal morphine
89560784|NCT03427463|Experimental|recieving 0.05 mg IT morphine|Patients will receive 0.05 mg of intrathecal morphine
89560785|NCT03425526|Experimental|Treatment (allogeneic adenovirus-specific CTLs)|Within two weeks of enrollment, patients receive allogeneic adenovirus-specific CTLs IV over 30 minutes. Patients may receive additional allogeneic adenovirus-specific CTL infusions at the discretion of the investigator in the absence of disease progression or unacceptable toxicity.
89560786|NCT03413254|Active Comparator|2nd look DLS + routine FU|Follow-up after curatively resected pT4 colon cancer, consisting of second look DLS after negative CT abdomen at 6-9 months and normal CEA, with subsequent routine follow-up according to the Dutch colorectal cancer guideline until 5 years.
89560787|NCT03413254|Experimental|2nd and 3rd DLS + routine FU|Follow-up after curatively resected pT4 colon cancer, consisting of second look DLS after negative CT abdomen at 6-9 months and normal CEA, with subsequent routine follow-up and third look DLS after negative CT abdomen at 18 months and normal CEA. Third look DLS is not performed in patients with evidence of disease that is not curable, or in those already diagnosed with PM in the preceding period.
89560788|NCT03393884|Experimental|NACT + IMNN-001|The NACT regimen will be paclitaxel 175 mg/m2 IV over 3 hours followed by carboplatin AUC 6 IV over 1 hour on Day 1. This will be repeated every 3 weeks for 6 cycles. IMNN-001 100 mg/m2 IP will be administered on Days 8 and 15 of the first NACT cycle and then on Days 1, 8, and 15 of the subsequent 21 day NACT cycles for a total of 17 treatments.
89560789|NCT03393884|Active Comparator|NACT Alone|The NACT regimen will be paclitaxel 175 mg/m2 IV over 3 hours followed by carboplatin AUC 6 IV over 1 hour on Day 1. This will be repeated every 3 weeks for 6 cycles.
89560790|NCT03362190|Experimental|Cohort 1|Zimura dosage 1 + Lucentis 0.5 mg
89560791|NCT03362190|Experimental|Cohort 2|Zimura dosage 2 + Lucentis 0.5 mg
89560792|NCT03362190|Experimental|Cohort 3|Zimura dosage 3 + Lucentis 0.5 mg
89560793|NCT03362190|Experimental|Cohort 4|Zimura dosage 4 + Lucentis 0.5 mg
89560794|NCT03356860|Experimental|Durvalumab|"Patients will received paclitaxel 80 mg/m2 IV weekly from week 1 to 12 and then an association of epirubicin 90 mg/m2 IV and cyclophosphamide 600 mg/m2 IV Q 2 weeks from week 14 to 20.~Durvalumab will be administered at 1500 mg IV at week 14 and week 18."
88966846|NCT01466140|Experimental|Use of request card|Patients in the intervention group were told that the practice was participating in a patient satisfaction study, and they were given an envelope with information about the 'doorknob phenomenon' and a request card. The envelope for the control group only consisted of information about a patient satisfaction study, without any information on the 'doorknob phenomenon', and without a request card. Both groups received the same letter with patient information about the study.
88966847|NCT01466101|Active Comparator|Pregabalin administration|Administration of pregabalin
88966848|NCT01466101|Placebo Comparator|Placebo|Administration of placebo
88966849|NCT00393640|Active Comparator|A|Breast pump given and used on regular intervals
88966850|NCT00393640|No Intervention|B|
88966851|NCT00393640|Active Comparator|c|Breast pump given to be used on regular interval
88966852|NCT00393640|No Intervention|D|
89026961|NCT02955927|Active Comparator|ortho-k|participants will receive treatment of ortho-k alone
89026962|NCT01247454|Other|academic detailing|All arms will receive this intervention
89026963|NCT01247454|Experimental|Electronic Health Record (EHR) prompt|One intervention arm will receive the EHR prompt along with the academic detailing
89026964|NCT01247454|Experimental|EHR prompt and patient prompt|The final arm will receive this combined intervention plus the academic detailing
89026965|NCT00478322|Experimental|INCB013739|
89560795|NCT03356860|Active Comparator|Standard|Patients will received paclitaxel 80 mg/m2 IV weekly from week 1 to 12 and then an association of epirubicin 90 mg/m2 IV and cyclophosphamide 600 mg/m2 IV Q 2 weeks from week 14 to 20.
89560796|NCT03333044|Experimental|CHW-led health coaching|Group sessions
89560797|NCT03333044|Experimental|HIT-enabled & CHW led|Supportive care enabled by mobile devices.
89560798|NCT03333044|Experimental|CHW & Physician Feedback|Patient setting progress communicated to physician via PHI
89560799|NCT03322345||Dopamine Added|Patients with protein losing enteropathy (PLE) that have an exacerbation such that their treating physicians decide to add continuous dopamine infusion to their current therapies.
89560800|NCT03322345||No dopamine added (control)|Patients with protein losing enteropathy (PLE) that have an exacerbation such that their treating physicians decide to add new therapies to their current therapies but that do not require the addition of continuous dopamine infusion.
89560801|NCT03319082||CXL Group|Patients with corneal ectasia following refractive surgery who had corneal collagen cross-linking in one or both eyes according to the Photrexa Viscous and Photrexa prescribing information
89560802|NCT03314584|Experimental|Transcranial Magnetic Stimulation|Active-repetitive transcranial magnetic stimulation (rTMS) at the left motor cortex.
89560803|NCT03314584|Sham Comparator|Sham Transcranial Magnetic Stimulation|Sham rTMS will consist of the same parameters as active, however, the subject will not receive the actual magnetic stimulation to the left motor cortex.
89560804|NCT03312400|Active Comparator|200 mg Arm|100 mg twice a day
89560805|NCT03312400|Active Comparator|400 mg Arm|200 mg twice a day
89560806|NCT03283826|Experimental|ATA188|Participants in Parts 1 and 2 will receive ATA188 intravenously as described in the Detailed Description.
89560807|NCT03283826|Placebo Comparator|Placebo|Participants in Part 2 will receive placebo matching to ATA188 intravenously as described in the Detailed Description (i.e., will receive placebo only in the first year, and thereafter will receive ATA188 for the remainder of the study).
89560808|NCT03269136|Experimental|PF-06863135|BCMA-CD3 bispecific antibody
89560809|NCT03269136|Experimental|PF-06863135 + dexamethasone|BCMA-CD3 bispecific antibody + dexamethasone
89560810|NCT03269136|Experimental|PF-06863135 + lenalidomide|BCMA-CD3 bispecific antibody + lenalidomide
89560811|NCT03269136|Experimental|PF-06863135 + pomalidomide|BCMA-CD3 bispecific antibody + pomalidomide
89560812|NCT03269058|Experimental|Patients not treated with statins|
89560813|NCT03269058|Experimental|Patients treated with statins|
89560814|NCT03254667||Brodalumad exposed|1500 subjects exposes to brodalumab
89560815|NCT03254667||Comparator Subjects|2000 comparator subjects
89560816|NCT03246061|Active Comparator|BVN Ablation|BVN ablation with continued standard care
89560817|NCT03246061|Active Comparator|Standard Care Control|Continue with non-surgical standard care
89026966|NCT00478322|Placebo Comparator|Matching Placebo|
89560818|NCT03217357|Active Comparator|Transcranial stimulation in direct current(tDCS)active|30 minutes of active Transcranial stimulation in direct current
89560819|NCT03217357|Placebo Comparator|Transcranial stimulation in direct current(tDCS) placebo|30 minutes of placebo stimulation
89560820|NCT03194971||TTField at Recurrence|
89560821|NCT03194971||TTField at New Diagnosis|
89560822|NCT03182244|Experimental|ASP2215|ASP2215 will be administered orally once daily.
89560823|NCT03182244|Active Comparator|Salvage chemotherapy|Options for salvage chemotherapy are limited to the following: Low-dose Cytarabine (LoDAC) will be administered twice daily by subcutaneous or intravenous injection for 10 days. Mitoxantrone, Etoposide, Cytarabine (MEC Induction Chemotherapy) will each be administered intravenously for 5 days (days 1 through 5). Granulocyte colony-stimulating factor (G-CSF) will be administered intravenously for 5 days (days 1 through 5) and also recommended 7 days after completing chemotherapy, Fludarabine and Cytarabine administered intravenously for 5 days (days 2 through 6) (FLAG Induction Chemotherapy). Based on the outcome of interim analysis, participants will be evaluated for eligibility for crossover extension (COE). In COE participants will be administered ASP2215 orally once daily.
89560824|NCT03182244|Experimental|ASP2215 PK in Chinese population|PK samples will be collected after single and multiple doses in Chinese subjects.
89560825|NCT03158896|Experimental|MSCTC-0010 Dose Escalation|"Cohort 1: First 5 participants will receive a lower dose of cord-blood derived Wharton's jelly mesenchymal stem cells (MSCTC-0010) and they will be observed for 42 days after the dose for treatment-related serious adverse events (TRSAE) and response.~Cohort 2: Second 5 participants will receive an increased dose of MSCTC-0010 and will be observed for 42 days after the dose for TRSAE and response."
89026967|NCT00478400||Participants who have had a TBI|"(recruited by invitation only)~Must be between 1- and 6-years post-injury~Closed head injury~Evidence of loss of consciousness~Must have an informant (friend, spouse, child etc.)~Audit-C < 7, PCL < 65 and PHQ-9 < 15"
89026968|NCT00478400||Participants with No history of TBI|"(Recruited by invitation only)~No history of TBI~Must have an informant (friend, spouse, child etc.)"
89026969|NCT00478400||Veterans with History of TBI|"Must be between 1- and 6-years post-injury~Closed head injury~Evidence of loss of consciousness~Must have an informant (friend, spouse, child etc.)~Audit-C < 7, PCL < 65 and PHQ-9 < 15"
89560826|NCT03137160|Experimental|Ixekizumab (Taltz)|We have received funding for only a small pilot study to prove a benefit from Interleukin-17 inhibition in Pyoderma Gangrenosum . Therefore, there is only one treatment arm. The primary outcome will be a comparison of week 12 to baseline regarding a two-point improvement in the Investigator Global Assessment.
89560827|NCT03136705|Active Comparator|Lanthanum + Nicotinamide|Lanthanum Carbonate 1000mg orally three times daily with meals for 2 weeks and Nicotinamide 750mg orally twice daily for 2 weeks
89560828|NCT03136705|Active Comparator|Lanthanum + Nicotinamide Placebo|Lanthanum Carbonate 1000mg orally three times daily with meals for 2 weeks and Nicotinamide Placebo orally twice daily for 2 weeks
89560829|NCT03136705|Active Comparator|Lanthanum Placebo + Nicotinamide|Lanthanum Carbonate Placebo orally three times daily with meals for 2 weeks and Nicotinamide 750mg orally twice daily for 2 weeks
89560830|NCT03136705|Placebo Comparator|Lanthanum Placebo + Nicotinamide Placebo|Lanthanum Carbonate Placebo orally three times daily with meals for 2 weeks and Nicotinamide Placebo orally twice daily for 2 weeks
88966853|NCT05420025|Experimental|CHILDREN APPLIED WITH VIRTUAL REALITY GLASSES|Before the first dressing (5 minutes before the dressing) of the children who were accepted to the Organ Transplantation A Service from the intensive care unit after the transplantation, the introductory characteristics form and scales will be applied and the physiological parameters of the child (heart rate, respiratory rate, blood pressure) will be applied by the researcher. , oxygen saturation) will be taken. Then the children will be put on SGG and the glasses will be synchronized. During the dressing, children will be shown a video with SGG, which received expert opinion beforehand. After the dressing, the physiological parameters of the children will be measured again and the scales will be applied again.
88966854|NCT01465984|Experimental|IV Paracetamol|
89560831|NCT03134196|Placebo Comparator|Placebo|Encapsulated masked placebo
89560832|NCT03134196|Active Comparator|Masked Oral Valacyclovir 1000 mg daily|Valacyclovir, 500 mg, oral pill, two 500mg pills daily
88966855|NCT01465984|Active Comparator|IV Morphine Sulfate|
88966856|NCT04328246|Experimental|IES Device + Standard of Care|Intermittent electrical stimulation system. Charged pulses will be administered to bilateral gluteus maximus through surface electrodes. Stimulation occurs at 30 Hz for 10s every 10 minutes. The intervention is administered 24/7 and added to the standard of care management. Standard of care is defined as turning the patient every two hours.
88966857|NCT04328246|Active Comparator|Standard of Care|Standard of care treatment for pressure injuries is turning the patient every two hours.
88966858|NCT01465945|Other|Rectal Defect Sutured|The subject will have his/her defect sutured after the rectal tumors have been removed.
88966859|NCT01465945|Other|Rectal Defect Unsutured|The defect will be left open and let naturally close after the rectal tumor has been removed by TEM.
88966860|NCT01465906|Experimental|tulobuterol combined with tiotropium bromide|
88966861|NCT01465906|Active Comparator|Tiotropium bromide|
88966862|NCT01465867|Experimental|Selenium|
89560833|NCT03130127|Experimental|Continuous infusion of terlipressin|In our clinical practice, continuous infusion of terlipressin is being employed.
89560834|NCT03130127|Active Comparator|Bolus infusion of terlipressin|Traditionally, a bolus infusion of terlipressin is recommended.
89560835|NCT03127007|Experimental|Arm A|"Protracted IV 5-FU 225 mg/m2 is given from day 1 to 5 in parallel with radiotherapy 1.8 to 2 Gy from day 1 to 5 during 5 consecutive weeks.~Atezolizumab is given on day 1 of week 3, 6, 9 and 12 at 1200 mg IV. Rectal surgery is planned during week 15"
89560836|NCT03127007|Active Comparator|Arm B|"Protracted IV 5-FU 225 mg/m2 is given from day 1 to 5 in parallel with radiotherapy 1.8 to 2 Gy from day 1 to 5 during 5 consecutive weeks.~Rectal surgery is planned during week 15"
89560837|NCT03110432||Standard lipid lowering therapy|Statins, ezetimibe, nicotinic acid, fibrates, cholestagel, omega-3 fatty acids (and any combinations of these agents)
89560838|NCT03110432||PCSK9 Inhibitor [EPC]|Evolocumab or alirocumab.
89560839|NCT03071913||Observational (biospecimen collection)|As part of pre-operative standard of care, patients receive levetiracetam by injection and cefazolin by injection. Patients are also offered lorazepam in the pre-operative area. At the time of surgery, patients undergo approximately 2 tissue biopsies from 3-4 tumor locations. This tissue is removed as part of the planned surgery, but it is also tested for research purposes. During surgery, a blood sample is collected every 20-30 minutes beginning at the time of skin incision until all of the research tumor samples have been removed. A minimum of 3 blood samples are collected up to a maximum of 12.
89560840|NCT03046251|Other|natalizumab|Participants in this group are those who opt to receive treatment with natalizumab IV 300mg/day given q 4 weeks for 48 weeks.
89560841|NCT03046251|No Intervention|Control|Participants in this group may initiate any FDA approved DMT at any time post delivery or remain on no therapy.
89560842|NCT02989662|Active Comparator|Mifepristone|Mifepristone is a high affinity antagonist of the glucocorticoid receptor (GR). It is FDA approved to treatment hyperglycemia caused by high cortisol levels in adults with endogenous Cushing's syndrome.
89560843|NCT02989662|Placebo Comparator|Placebo - Cap|This is an inactive compound which appears physically identical to active medication.
89560844|NCT02944617|Experimental|Arm I (probiotic yogurt supplement)|Patients receive probiotic supplement Activia yogurt QD during weeks 2-13 of VEGF-TKI treatment.
89560845|NCT02944617|Active Comparator|Arm II (no intervention)|Patients avoid any intake of yogurt or yogurt-containing foods and refrain from taking/consuming other probiotic supplements for 3 months.
89560846|NCT02940301|Experimental|Treatment (ibrutinib, nivolumab)|Patients receive ibrutinib PO QD on days 1-21 and nivolumab IV continuously over 60 minutes on day 1. Treatment with nivolumab repeats every 21 days for up to 16 courses and treatment with ibrutinib continues in the absence of disease progression or unacceptable toxicity.
89560847|NCT02890849|Experimental|a prospective, open, self-controlled phase I clinical study|The project is planned to explore the consistency analysis of PD-L1 expression level detected in cancer tissues and pExo.We have designed to detected the expression levels of PD-L1 mRNA and protein in cancer tissue and detected the expression levels of PD-L1 mRNA in pExo.by using variance analysis of repeated measures design information.
89560848|NCT02869685|Other|a prospective, open,phase I clinical study|The investigators have designed five kinds of radiation-division with bioequivalent doses, and detected the expression levels of PD-L1 in pExo after 24h, 48h of each stage of radiotherapy.
89560849|NCT02867124|Experimental|Vivitrol at place of residence|One injection of long-acting naltrexone (XR-NTX) in prison, followed by 6 monthly injections post-release at the participants's place of residence utilizing mobile medical treatment
89560850|NCT02867124|Active Comparator|Vivitrol at opioid treatment program|One injection of long-acting naltrexone (XR-NTX) in prison, followed by 6 monthly injections post-release at a community opioid treatment program.
89560851|NCT02837965||diagnosed bullous pemphigoid|
89560852|NCT02815696|Experimental|lumbar spine segmental instability|Patients with a segmental instability of the lumbar spine having undergone surgery. Lumbar spine instability diagnosis is based on imaging (Magnetic resonance imaging, standard radiography, and EOS imaging). Surgical treatment is indicated if the pain is relieved by wearing a brace during at least three months.
89560853|NCT02813369||naloxegol|patients exposed to naloxegol
89560854|NCT02813369||non-PAMORA laxative|patient exposed to non-peripherally acting mu-opioid receptor antagonist (PAMORA) laxative
89560855|NCT02806440|Active Comparator|Low dose naltrexone|Low dose naltrexone 4.5 mg/tablet, 1 tablet a day for 21 days
89560856|NCT02806440|Placebo Comparator|Placebo|"Placebo tablet~1 tablet a day for 21 days"
89560857|NCT02798276|Experimental|AGTP-treatment|Patients in which the non-revascularizable area will be covered by the adipose graft and the revascularizable area will be treated with the normal procedure.
89560858|NCT02798276|Other|Control|Patients in with the non-revascularizable area will be left untouched and the revascularizable area will be treated normally.
89560859|NCT02788006|Experimental|Regorafenib 160 mg|
89560860|NCT02693548||Familial hypercholesterolaemia patients|Index cases with genetic diagnosis of FH and their relatives over 15 years old with a genetic diagnosis of FH.
89560861|NCT02693548||Unaffected relatives|Relatives of FH patients without FH (genetically defined)
89560862|NCT02686658|Experimental|Zimura 1 mg [Part 1]|Participants received 1 mg of Zimura in the study eye administered via IVT injection (50 µL) on Day 1 and monthly up to 18 months.
89560863|NCT02686658|Experimental|Zimura 2 mg [Part 1]|Participants received 2 mg of Zimura in the study eye administered via IVT injection (100 µL) on Day 1 and monthly up to 18 months.
89560864|NCT02686658|Sham Comparator|Sham [Part 1]|Participants received a Sham injection of an empty, needleless syringe administered in the study eye on Day 1 and monthly up to 18 months.
89560865|NCT02686658|Experimental|Zimura 2 mg (Zimura 2mg+Sham) [Part 2]|Participants received 2 mg of Zimura in the study eye administered via IVT injection (100 µL) and a subsequent Sham administration on Day 1 and monthly up to 18 months.
89560866|NCT02686658|Experimental|Zimura 4 mg (Zimura 2mg+Zimura 2mg) [Part 2]|Participants received 4 mg of Zimura in the study eye administered via two consecutive IVT injections (2 x 100 µL) on Day 1 and monthly up to 18 months.
89560867|NCT02686658|Sham Comparator|Sham (Sham+Sham) [Part 2]|Participants received two consecutive Sham injections of empty, needleless syringes administered in the study eye on Day 1 and monthly up to 18 months.
89560868|NCT02684669|Experimental|High-dose naloxone|naloxone 4 mg/ml i.v. infusion, total 3.25 mg/kg, target controlled infusion with three infusion rates (0.25 mg/kg; 0.75 mg/kg; 2.25 mg/kg) each of 25 min duration.
89560869|NCT02684669|Placebo Comparator|Normal saline|0.9% physiological saline, i.v. infusion, total 0.81 ml/kg, target controlled infusion with three infusion rates (0.06 ml/kg; 0.19 ml/kg; 0.56 ml/kg) each of 25 min duration.
89560870|NCT02654626|Experimental|KBP-7072: Cohort 1|Healthy Volunteers will receive multiple dose of KBP-7072 and placebo
89560871|NCT02654626|Experimental|KBP-7072: Cohort 2|Healthy Volunteers will receive multiple dose of KBP-7072 and placebo
89560872|NCT02654626|Experimental|KBP-7072: Cohort 3|Healthy Volunteers will receive multiple dose of KBP-7072 and placebo
89560873|NCT02654626|Experimental|KBP-7072: Cohort 4|Healthy Volunteers will receive multiple dose of KBP-7072 and placebo
89560874|NCT02653014|Experimental|Cohort 1|Healthy Volunteers will receive 2.5mg of KBP-5074, QD, 14 days
88966863|NCT01465867|Placebo Comparator|Sugar Pill Placebo|
88966864|NCT01465867|Experimental|Selenium + L-Thyroxine (LT4)|
88966865|NCT01465867|Experimental|Sugar Pill Placebo + L-Thyroxine (LT4)|
88966866|NCT04244864|Active Comparator|Treatment as usual (TAU)|8-12 months of treatment
88966867|NCT04244864|Experimental|Cross-sectoral social intervention|8-12 months of treatment
88966868|NCT01465828|Active Comparator|high clopidogrel dose|Patients will be randomized to this arm to receive before high clopidogrel dose and after crossover they will receive standard dose of prasugrel
88966869|NCT01465828|No Intervention|prasugrel standard dose|Patients will be randomized to this arm to receive before standard dose of prasugrel and after crossover they will receive high clopidogrel dose.
89560875|NCT02653014|Experimental|Cohort 2|Healthy Volunteers will receive 5.0mg of KBP-5074, QD, 14 days
89560876|NCT02653014|Experimental|Cohort 3|Subjects with mild to moderate renal impairment will receive 0.5mg of KBP-5074, QD, 56 days
89560877|NCT02653014|Experimental|Cohort 4|Subjects with mild to moderate renal impairment will receive 2.5mg of KBP-5074, QD, 56 days
89560878|NCT02642744|Other|Attending nurse model|The attending nurse model of in-hospital care delivery aims to improve patient understanding, shared decision making, medication adherence, and reduce early readmissions after discharge to improve quality of life. On the inpatient stroke unit, the attending nurse will take ownership of essential aspects of an individual stroke patient's care, education, and transition out of the hospital. To further contribute to the patient's plan of care, the attending nurse will be present on daily teaching rounds.
89560879|NCT02642744|No Intervention|Conventional inpatient nursing care|Standard of care nursing care patients receive while inpatient
89560880|NCT02639026|Experimental|Cohort 1|Subjects will receive 20 mg/kg MEDI4736 and 1 mg/kg tremelimumab in combination every 4 weeks for 4 doses, followed by 10 mg/kg MEDI4736 monotherapy every 2 weeks for 18 doses. The total duration of therapy is 12 months. Cohort 1 tests 8 Gy x 3 fractions
88966870|NCT05408052|Active Comparator|Standard Epidural|Standard epidural technic will be applied before the anesthesia induction for perioperative analgesia
88966871|NCT05408052|Active Comparator|Dural Puncture Epidural (DPE)|Dural Puncture Epidural technic will be applied before the anesthesia induction for perioperative analgesia
88966872|NCT01465750||Ovarian Cancer|
88966873|NCT01465672||neurosurgical patients|Patients undergoing transphenoidal pituitary adenoma resection and patients with transcranial surgery of tumors close to the pituitary gland and hypothalamus.
88966874|NCT01465633|Active Comparator|with iodine|
88966875|NCT01465633|Experimental|without iodine|
89026970|NCT00478400||US Veterans with No history of TBI|"No history of TBI~Must have an informant (friend, spouse, child etc.)"
89560881|NCT02639026|Experimental|Cohort 2|Subjects will receive 20 mg/kg MEDI4736 and 1 mg/kg tremelimumab in combination every 4 weeks for 4 doses, followed by 10 mg/kg MEDI4736 monotherapy every 2 weeks for 18 doses. The total duration of therapy is 12 months. Cohort 2 tests 17 Gy x 1 fraction.
89560882|NCT02616640|Experimental|Durvalumab monotherapy|Intravenous (IV) durvalumab at assigned dose level (750, 1500, 2250, or 3000 mg) over 1 hour on day 1 of a 28-day cycle
89560883|NCT02616640|Experimental|Durvalumab + pomalidomide (POM)|IV durvalumab at assigned dose level (750, 1500, 2250, or 3000 mg) over 1 hour on day 1 of a 28-day cycle and Oral POM 4 mg/day on Days 1 to 21 of each 28-day treatment cycle
89560884|NCT02616640|Experimental|Durvalumab + pomalidomide (POM) + dexamethasone (dex)|IV durvalumab at assigned dose level (750, 1500, 2250, or 3000 mg) over 1 hour on day 1 of a 28-day cycle with Oral POM 4 mg/day on Days 1 to 21 of each 28-day treatment cycle and Oral dex 40 mg/day (≤ 75 years old) or 20 mg/day (> 75 years old) on Days 1, 8, 15, and 22 of a 28-day cycle
89560885|NCT02598349|Experimental|Proton Radiation with capecitabine|The following will be performed in this group: Proton Radiation Therapy with concomitant oral chemotherapy, capecitabine taken on radiation treatment days for 6 weeks. A surgical resection will be performed between 8 and 16 weeks if radiographic studies suggest operability.
89560886|NCT02574728|Experimental|Oral sirolimus, celecoxib, etoposide, and cyclophosphamide|Participants in this group will receive oral sirolimus and celecoxib in addition to cycles of oral etoposide and cyclophosphamide for up to two years.
89560887|NCT02527746|Experimental|F-627 80 µg/kg|F-627 at the dose of 80 µg/kg administrated by s.c. injection on Day 3 of each cycle for 4 cycles.
89560888|NCT02527746|Experimental|F-627 240 µg/kg|F-627 at the dose of 240 µg/kg administrated by s.c. injection on Day 3 of each cycle for 4 cycles.
89560889|NCT02527746|Experimental|F-627 320 µg/kg|F-627 at the dose of 320 µg/kg administrated by s.c. injection on Day 3 of each cycle for 4 cycles.
89560890|NCT02397954|Experimental|Zimura + Anti-VEGF|Subjects will receive monthly intravitreous injections of Zimura in combination with either Lucentis, Avastin or Eylea.
89560891|NCT02390765||All participants|All participants in the study will be evaluated as one group
89560892|NCT02387957|Experimental|Fovista® plus bevacizumab|Fovista® 1.5 mg intravitreal injection + bevacizumab 1.25 mg intravitreal injection
89560893|NCT02387957|Experimental|Fovista® plus ranibizumab|Fovista® 1.5 mg intravitreal injection + 0.5 mg ranibizumab intravitreal injection
88811020|NCT04722224|Experimental|Intervention: Home-based pulmonary rehabilitation|Patients will be treated for 12 weeks. The intervention consists in a strategic mixture of home visits and phone calls. The program includes exercise training and the self-management educational program Living Well with COPD.
88811021|NCT04714892||Healthy control|BMI of 18.5-29.9 kg/m2
89560894|NCT02387957|Experimental|Fovista® plus aflibercept|Fovista® 1.5 mg intravitreal injection + 2.0 mg aflibercept intravitreal injection
89560895|NCT02327897||asthmatic|study group
89560896|NCT02327897||non-asthmatic|controls
89560897|NCT02251704|Other|Study Group|Subjects 6 months to <10 years of age enrolled in HDSS catchment areas at the sites participating in the EPI-MAL-002 and EPI-MAL-003 studies of the candidate malaria vaccine RTS,S/AS01E in sub-Saharan Africa.
89560898|NCT02214628|Experimental|Fovista® plus anti-VEGF Simultaneous|"Subjects will be administered Fovista® (anti-PDGF BB) plus anti-VEGF as a Simultaneous regimen followed by quarterly administration."
89560899|NCT02214628|Experimental|Fovista® plus anti-VEGF Pre-Treatment|"Subjects will be administered Fovista® (anti-PDGF BB) plus anti-VEGF as a Pre-Treatment regimen followed by quarterly administration."
89560900|NCT02192619||observational|
89560901|NCT02163694|Active Comparator|Veliparib Placebo with Carboplatin and Paclitaxel|Placebo capsules for veliparib (120 mg) administered by mouth twice daily (BID) on Days -2 through 5 of a 21-day cycle. Carboplatin administered intravenously over approximately 15 to 30 minutes at AUC 6 mg/ml/min immediately following paclitaxel infusion on Day 1 of every cycle. Paclitaxel administered intravenously over approximately 1 hour at a dose of 80 mg/m² on Days 1, 8, and 15 of every cycle.
89560902|NCT02163694|Experimental|Veliparib with Carboplatin and Paclitaxel|Veliparib capsules (120 mg) administered by mouth twice daily (BID) on Days -2 through 5 of a 21-day cycle. Carboplatin administered intravenously over approximately 15 to 30 minutes at AUC 6 mg/ml/min immediately following paclitaxel infusion on Day 1 of every cycle. Paclitaxel administered intravenously over approximately 1 hour at a dose of 80 mg/m² on Days 1, 8, and 15 of every cycle.
89560903|NCT02153957|Experimental|1|enhanced PA home intervention group for the first 12 weeks; followed by 12 weeks of PA maintenance on their own.
89560904|NCT02153957|Active Comparator|2|usual physical activity (no intervention) for 12 weeks; followed by the enhanced PA home intervention for 12 weeks.
88811022|NCT04714892||Obese|BMI of 30-39.9 kg/m2
88811023|NCT04714281|Other|Hemodiafiltration HDF|Three consecutive treatment periods of four weeks, one last study week where the patient is re-assigned to the same type of dialyzer used before beginning the study and one follow-up week per patient. Each treatment period includes 12 hemodiafiltration HDF sessions and is assigned to one type of dialyzer: FX CorAL 600 Fresenius Medical Care, comparator FX CorDiax 600 Fresenius Medical Care and comparator xevonta Hi 15 (B. Braun).
88811024|NCT04711057|Experimental|Pulmonary Rehabilitation + Community-based PA program|After PR, the experimental group will integrate a community-based PA program.
88811025|NCT04711057|Active Comparator|Pulmonary Rehabilitation|The control group will only receive pulmonary rehabilitation, which integrates PA recommendations.
88811026|NCT04710043|Experimental|Part 1 group A BNT153|Monotherapy dose escalation.
88811027|NCT04710043|Experimental|Part 1 group B BNT152|Monotherapy dose escalation.
88811028|NCT04710043|Experimental|Part 2A - BNT152+153|Escalating dose levels up to RP2D
88811029|NCT04710043|Experimental|Part 2B - BNT152+153|Escalating dose levels up to RP2D
88811030|NCT04710043|Experimental|Part 2C - BNT152+153|Escalating dose levels up to RP2D
88811031|NCT04710043|Experimental|Part 2 - BNT152+153 - biomarker cohort|
88811032|NCT04691570|Experimental|ANX005|Participants will receive two once-weekly doses of ANX005 at specific time points
88811033|NCT04682379||AIS with Proprioceptive Defect|AIS subjects possessing statistically significant difference on testing outcomes compared with healthy controls.
88811034|NCT04682379||AIS without Proprioceptive Defect|AIS subjects with similar testing results compared with healthy controls.
89026971|NCT01322347|Active Comparator|Soluble Ferric Pyrophosphate (SFP) in dialysate|11 micrograms (µg) of iron / deciliter (dL) of dialysate.
89026972|NCT01322347|Placebo Comparator|Standard Dialysate|0 micrograms (µg) of iron / deciliter (dL) of dialysate.
89560905|NCT02107976|Experimental|Stage 1|Upon admission, diabetic subjects maywill discontinue their oral hypoglycemic medications and/or insulin regimen per investigators discretion. Oral hypoglycemic agents and/or insulin doses will be adjusted and may be supplemented with a correction scale and/or and transitioned to a basal-bolus insulin regimen. In order to achieve optimal glycemic monitoring and for safety reasons, subjects may be fitted with a Dexcom continuous glucose monitor (CGM) upon inpatient admission. CGM will be used to supplement, rather than replace, fingerstick glucose measurements. CGM monitoring will include a sensor fitted subcutaneously, a wireless transmitter that allows for remote glucose monitoring by the research team.
89560906|NCT02107976|Experimental|Stage 2|Subjects may be considered for arm stage 2 inpatient study no less than 8 weeks duration from arm stage 1 study. Once the RBC vitamin C concentrations are optimal (>30 uM), subjects may be re-admitted to Clinical Center metabolic unit and undergo the same protocol as described above in arm stage 1. Oral vitamin C and E supplementation may be discontinued on admission. The inpatient diet, glucose monitoring and sampling scheme will be the same as described for the first inpatient study.
89560907|NCT02064764|Active Comparator|Cryoablation only|Pulmonary vein isolation
89560908|NCT02064764|Experimental|Cryoablation and renal nerve denervation|Pulmonary vein isolation plus renal nerve denervation
89560909|NCT02019706|Experimental|Imaging|All subjects will be imaged
89560910|NCT02013648|Active Comparator|Standard arm|"Patients will receive induction therapy with daunorubicin 60 mg/m2/day administered on days 1-3 (when daunorubicin is not available due to supply shortage: Idarubicin 12mg²/day on days 1,3,5) and cytarabine 200 mg/m2/day administered by continuous IV infusion on days 1-7.~Patients achieving PR only at the end of cycle 1 will receive a second induction cycle with daunorubicin 50 mg/m2/day (when daunorubicin is not available due to supply shortage: Idarubicin 10 mg²/day on days 1 and 3) administered on days 1-3 and cytarabine 200 mg/m2/day administered by cont. IV infusion daily on days 1-5.~Patients will receive 4 cycles of consolidation therapy. Consolidation therapy consists of high-dose cytarabine 3 g/m2 (>60 years: 1 g/m2) q12h, days 1-3 administered intravenously over three hours.~Follow-up period: There is no maintenance therapy in the standard arm. Patients will be closely followed, in particular for molecular disease persistence or molecular relapse."
89560911|NCT02013648|Experimental|Investigational arm|"Patients will receive induction therapy with daunorubicin 60 mg/m2/day on days 1-3 (when daunorubicin is not available due to supply shortage: Idarubicin 12mg²/day on days 1,3,5) and cytarabine 200 mg/m2/day by cont. IV infusion on days 1-7. Patients will receive dasatinib 100 mg QD on days 8-21. Patients achieving PR only at the end of cycle 1 will receive a 2nd induction cycle with daunorubicin 50 mg/m2/day on days 1-3 (when daunorubicin is not available due to supply shortage: Idarubicin 10 mg²/day on days 1 and 3) and cytarabine 200 mg/m2/day by cont. IV infusion on days 1-5. Patients will receive dasatinib 100 mg QD on days 6-21.~Consolidation therapy (4 cycles). Treatment consists of high-dose cytarabine 3 g/m2 (>60 years: 1 g/m2) q12h, days 1-3 iv over 3 hours. Patients will receive dasatinib 100 mg QD on days 4-21. Maintenance therapy: Patients completing consolidation therapy will continue to receive single agent dasatinib 100 mg QD for one year (or until relapse)."
89560912|NCT01958086|Experimental|Neural Communication System|The Neural Communication System consists of two Neuroport Multi-Port Arrays, which are descried in detail in the intervention description. One Neuroport Multi-Port Array is inserted into the posterior parietal cortex, an area of the brain used in reach planning. The second Neuroport Multi-Port Array is inserted into the motor cortex, which is primarily responsible for controlling movement. The arrays are inserted and the percutaneous pedestal is attached to the skull during a surgical procedure. Following surgical recovery the subject will participate in study sessions 3-5 times per week in which they will learn to use thought to control a simple computer environment or a tablet computer.
89560913|NCT01944839|Experimental|E10030 + ranibizumab|E10030 1.5 mg intravitreal injection + ranibizumab 0.5 mg intravitreal injection
89560914|NCT01944839|Active Comparator|Sham + ranibizumab|E10030 sham intravitreal injection + ranibizumab 0.5 mg intravitreal injection
89560915|NCT01940900|Experimental|E10030 + ranibizumab|E10030 1.5 mg intravitreal injection + ranibizumab 0.5 mg intravitreal injection
89560916|NCT01940900|Active Comparator|Sham + ranibizumab|E10030 sham intravitreal injection + ranibizumab 0.5 mg intravitreal injection
89560917|NCT01940887|Experimental|E10030 + bevacizumab or aflibercept|E10030 1.5 mg intravitreal injection + bevacizumab 1.25 mg intravitreal injection or aflibercept 2 mg intravitreal injection
89560918|NCT01940887|Active Comparator|Sham + bevacizumab or aflibercept|E10030 sham injection + bevacizumab 1.25 mg intravitreal injection or aflibercept 2 mg intravitreal injection
89560919|NCT01905046|Experimental|Arm I: metformin hydrochloride|Patients receive metformin hydrochloride PO QD or BID for 24 months. Patients will continue metformin 850 mg PO BID for months 13-24. Patients will undergo RPFNA at 24 months. Follow up visits will be performed at 36 and 48 months after the start of treatment.
89560920|NCT01905046|Placebo Comparator|Arm II: placebo|Patients receive placebo PO QD or BID for 12 months. Patients may crossover to Arm I for months 13-24.
89560921|NCT01697371|Experimental|Proton Radiation|
89560922|NCT01684904|Experimental|Proton radiation|Proton radiation
89560923|NCT01423474|Experimental|Short treatment time (11 days)|
89560924|NCT01423474|Experimental|Long treatment time (29 days)|
89560925|NCT01326104|Experimental|Group A|High dose chemotherapy plus peripheral blood stem cell transplant followed by TTRNA-xALT and TTRNA-DCs.
89560926|NCT01326104|Experimental|Group B|NMA Salvage chemotherapy plus peripheral blood stem cell transplant followed by TTRNA-xALT and TTRNA-DCs.
89560927|NCT01081431|Experimental|Lenalidomide|
89560928|NCT00783510||HUMIRA® Treatment Arm|For patients taking HUMIRA®
89026973|NCT00478439|Placebo Comparator|Placebo Comparator|
89560929|NCT00783510||Methotrexate Treatment Arm|For patients taking Methotrexate
89026974|NCT04325425|Experimental|mFOLFIRINOX|mFOLFIRINOX will be administered once every 14 days for up to 12 cycles. One cycle consists of 14 days (2 weeks) with injection on D1 of each cycle (D1=D15). Patients are eligible for repeated treatment cycles in the absence of disease progression and undue adverse events.
89560930|NCT00712881|Experimental|Doxorubicin (MYOCET) + Cyclophosphamide + Trastuzumab (MCH) and Docetaxel + Trastuzumab (TH)|Participants will receive MCH (liposomal doxorubicin hydrochloride [60 milligrams {mg}/square meter {m^2}], cyclophosphamide (600 mg/m^2), and trastuzumab (8 or 6 mg/kilogram {kg}), administered as intravenous (IV) infusion on Day 1 of each of 4 consecutive 21-day cycles. For the first cycle, the loading dose of trastuzumab will be 8 mg/kg; 6 mg/kg will be used for the remaining cycles. After 4 cycles of MCH, the treatment will be changed to 4 consecutive 21-day cycles of TH (docetaxel [100 mg/m^2] and trastuzumab [6 mg/kg]).
89560931|NCT00712881|Active Comparator|Doxorubicin (Anthracycline) + Cyclophosphamide (AC) and Docetaxel + Trastuzumab (TH)|Participants will receive AC (free doxorubicin hydrochloride [60 mg/m^2] and cyclophosphamide [600 mg/m^2]), administered as IV infusion on Day 1 of each of 4 consecutive 21-day cycles. After 4 cycles of AC, the treatment will be changed to 4 consecutive 21-day cycles of TH (docetaxel [100 mg/m^2] and trastuzumab [8 or 6 mg/kg]). For the first cycle, the loading dose of trastuzumab will be 8 mg/kg; 6 mg/kg will be used for the remaining cycles.
89560932|NCT00568997||1|Single-group Open Label Registry of patients exposed to Elidel/Pimecrolimus
89560933|NCT00216294|Experimental|Currently treated with SSRI|
89560934|NCT00216294|Experimental|Not currently treated with SSRI|
89560935|NCT00001337|Experimental|Arm A|EPOCH + Rituximab every 3 weeks for 6 cycles.
89560936|NCT02332681||With insufficiency fracture|Patients with acute pain that sustained a knee insufficiency fracture
89560937|NCT02332681||Without insufficiency fracture|Patients with acute pain that did not sustained a knee insufficiency fracture
89560938|NCT02330887|Experimental|Intervention Cohort|We will use a cohort of 60 women from intervention village clusters for the group antenatal care intervention.
89560939|NCT02330887|Active Comparator|Control Cohort|We will use a cohort of 60 women from control village clusters as an active comparison.
89560940|NCT03573817|Experimental|Period 1: Revefenacin + Formoterol (Sequential)|Days 1 to 21: Revefenacin and formoterol will be sequentially administered in the morning. Formoterol will be administered again in the evening.
89560941|NCT03573817|Experimental|Period 2: Revefenacin + Formoterol (Combo Solution)|Days 22 to 42: After a 21 day period, the participants from the Revefenacin + Formoterol (Sequential) Arm will be dosed for 21 days with a combination of revefenacin and formoterol administered as a combined solution. Formoterol will be administered again in the evening.
89560942|NCT03573817|Placebo Comparator|Period 1: Placebo + Formoterol (Sequential)|Days 1 to 21: Placebo versions of revefenacin and formoterol will be sequentially administered in the morning. Formoterol will be administered again in the evening.
89560943|NCT03573817|Placebo Comparator|Period 2: Placebo + Formoterol (Combo Solution)|Days 22 to 42: After a 21 day period, the participants from Placebo + Formoterol (Sequential) Arm the will be dosed for 21 days with a combination of placebo revefenacin and formoterol administered as a combined solution. Formoterol will be administered again in the evening.
89560944|NCT03112057|Experimental|Healthy subjects|Healthy subjects of different ages (20 persons), Interventions: harmonic generation microscopy
89560945|NCT03112057|Experimental|peripheral neuropathy|the participant have symptoms and diagnosed with peripheral neuropathy (90 persons), Interventions:harmonic generation microscopy
89560946|NCT03112057|Experimental|diabetic neuropathy|the participant have symptoms and diagnosed with diabetic neuropathy (20 persons), Interventions:harmonic generation microscopy
89560947|NCT03112057|Experimental|chemotherapy induced neuropathy|before chemotherapy, during chemotherapy, after peripheral nerve lesions were cured (30 persons). Interventions:harmonic generation microscopy
89560948|NCT03112057|Experimental|Polydactyly|Abandoned extra digit specimen of polydactyly(10 persons): the normal skin and nerve endings in extra digit: Interventions: harmonic generation microscopy
89560949|NCT02331043|Placebo Comparator|Placebo biscuit|Biscuit without plant stanol ester
89560950|NCT02331043|Experimental|Plant stanol ester biscuit|Biscuit with plant stanol esters
89560951|NCT03111511|Experimental|Drospirenone/Ethinylestradiol + Midazolam + JNJ-56136379|Participants will receive single dose of drospirenone/ethinylestradiol 3 milligram (mg)/0.02 mg (oral contraceptive [OC]) and single dose of midazolam 2 mg under fasted conditions on Day 1. JNJ-56136379 250 mg twice daily will be administered on Days 6, 7 and JNJ-56136379 170 mg once daily on Days 8 to 25 under fed conditions, except on Day 21 on which Single dose of JNJ-56136379 170 mg + single dose of OC and single dose of midazolam 2 mg will be administered on fasted state. A single dose of drospirenone/ethinylestradiol 3 mg/0.02 mg and midazolam 2 mg on Day 21 under fasted conditions.
89026975|NCT04325425|Active Comparator|platinum - etoposide|Platinum-Etoposide regimen will be administered once every 21 days. Treatment will be continued for 6 to 8 cycles or 24 weeks maximum. One cycle consists of 21 days (3 weeks) with injection on D1 of each cycle (D1=D22). Patients are eligible for repeated treatment cycles in the absence of disease progression and undue adverse events.
89210582|NCT00909714|Experimental|Anodal tDCS|Direct Current (DC)-Stimulator to apply tDCS + Training
89560952|NCT03144427||Burns|Patients with burns to 20% or more of their BSA (body surface area) require resuscitation with intravenous crystalloid fluids in order to avoid organ failure and death
89560953|NCT02330965||Subjects Assigned to BAF312|Patients with secondary progressive multiple sclerosis (SPMS) randomized to receive BAF312 (siponimod). Refer to ClinicalTrials.gov record NCT01665144 for more information.
89560954|NCT02330965||Subjects Assigned to Placebo (Controls)|Patients with secondary progressive multiple sclerosis (SPMS) randomized to receive placebo. Refer to ClinicalTrials.gov record NCT01665144 for more information.
89560955|NCT03144505|No Intervention|Control|The control group will be invited to an orientation session, where it will be provided detailed information concerning their home base exercise program. Additionally, once in every 4 weeks, the control group will meet for thematic sessions regarding diabetes topics, such as, nutrition, physical activity, and clinical complications. Due to ethical reasons, the control group needs to be provided with a standard counseling approach, as suggested in this research project.
89560956|NCT03144505|Experimental|MCT combined with RT Group|"MCT Group is designed to have equal energy expenditure when compared with HIIT Group. We standardized the exercise prescription according to body weight (kg), predicting that physical activity guidelines of 150 min peer week moderate intensity is equivalent to 10 kcal/kg of a combined session of RT and MCT. The MCT group will perform continuous cycling 3 days per week, with an exercise intensity of 40 to 59% of the heart rate reserve (HRR).~Participants will also perform an RT circuit: 1 set of two pull upper body exercises (seated row and lat pulldown); 1 set of two push upper body exercises (chest press and shoulder press); 1 set of two leg exercises (leg press and one leg lunge); and 1 set of two core exercises (dead bug and regular plank). Each set consisting in 10 to 12 repetitions."
89560957|NCT03144505|Experimental|HIIT combined with RT Group|"The HIIT program will perform cycle ergometer 3 days a week, and it will be divided into three phases: preparation phase (weeks 1-4), where the participants perform MCT (40-59% of the HRR); transition phase (weeks 5-8), in which the HIIT program is introduced progressively, starting with bouts of 2 minutes at 70% of the HRR, followed by 1 minute at 40-59% of the HRR (weeks 5-6), and finishing with bouts of 80% of the HRR, followed by 1 minute at 40-59% of the HRR (weeks 7-8); training phase (weeks 9-42), where the participants perform 1 minute of exercise at 90% of the HRR, followed by 1 minute resting at 40-59% of the HRR.~The HIIT session will have the same energy expenditure as the MCT group, using the 10kcal/kg week target. Participants will also fulfill the same RT as the MCT group."
89560958|NCT03144115|Experimental|oxytocin fertility|intranasal oxytocin administration (24IU) in women's fertility phase (LH>40 mIU/ml)
89560959|NCT03144115|Placebo Comparator|placebos fertility|intranasal placebo administration (24IU) in women's fertility phase (LH>40 mIU/ml)
89026976|NCT02891395|Experimental|open-label|"Induction phase: Imatinib mesylate - starting with 100 mg/day with increase of 100 mg/day each other week up to maximum tolerable dose or 400 mg/day whichever occurred first. For the responders and in absence of toxicity, the treatment will be maintained up to one year.~Salvage phase:~Nilotinib - starting with 200 mg/day with increase of 200 mg/day each other week up to maximum tolerable dose or 800 mg/day whichever occurred first. In absence of toxicity, the treatment will be maintained up to one year."
89026977|NCT00478478||Acute Ischemic Stroke patients|Patients presenting with signs and symptoms consistent with a diagnosis of Acute Ischemic Stroke, who are treated with the Merci Retrieval System during a Mechanical Thrombectomy procedure.
89026978|NCT05645185||Patient with Ma2 antibody|"This is a non-interventional study involving biological samples. Samples are already stored in biobank repositories and collected as part of good clinical practice in the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population. Patients have already gave explicit written consent for biological specimens sampling and storage at the Centre de Ressources Biologiques des Hospices Civils de Lyon (CRB-HCL) (including tissue, cells or biological fluids)."
89026979|NCT01247532|Experimental|Waitlist|
89026980|NCT01247610||ADHD group|
89026981|NCT01247610||Control group|
89026982|NCT03273218|Experimental|Tiger catheter|Tiger simple multipurpose catheter compared to Judkins catheters
89026983|NCT03273218|Active Comparator|Judkins catheter|Judkins right and judkins left catheter
89026984|NCT01321879|Experimental|Telavancin|10 or 7.5 mg/kg intravenous daily
89026985|NCT03271853||SBS II|
89026986|NCT01321723|Experimental|PTH analog tablet|PTH(1-31) 5 mg tablet, once daily
89026987|NCT01321723|Placebo Comparator|Placebo|Placebo matching tablet, once daily
89026988|NCT01321723|Active Comparator|Forsteo|Forsteo (teriparatide) 20 mcg SC Injection, once daily
89026989|NCT01247649|Experimental|Study group|Patients will be monitored to assess continuous blood glucose levels using the study device (Physical Logic) and reference methods, during 2-3 clinic visits, lasting 6-8 hours each
89026990|NCT00478634|Experimental|A1: RAD001 + cetuximab + irinotecan|RAD001 30mg weekly oral, 400mg/m2, loading i.v. (250mg/m2 for subsequent weekly dose i.v.), 350mg/m2 every 3 weeks i.v.
89560960|NCT03144115|Experimental|oxytocin luteal|intranasal oxytocin administration (24IU) in women's luteal phase (LH<30 mIU/ml)
89560961|NCT03144115|Placebo Comparator|placebos luteal|intranasal placebos administration (24IU) in women's luteal phase (LH<30 mIU/ml)
89560962|NCT02326519|Other|Intracardiac electrode catheter|All patient in the study will have same data collected during the procedure using the Steerable intracardiac electrode catheter.
89026991|NCT00478634|Experimental|B1 dose: RAD001 + cetuximab + irinotecan|RAD001 30mg weekly oral, 400mg/m2 loading i.v (250mg/m2 for subsequent weekly dose i.v.), 250mg/m2 every 3 weeks i.v.
89026992|NCT01247688|Experimental|Umbilical Cord Blood Transplant Treatment Plan|Cytoxan, Fludarabine, Total Body Irradiation (TBI), Cord Blood Stem Cell Infusion
89026993|NCT01321606|Experimental|Arm 1: Probiotic|subjects will be given a capsule formulation of a 1x10^10 colony-forming units of probiotic L. rhamnosus HN001 to be taken once a day, for 4 weeks
89026994|NCT01321606|Placebo Comparator|Arm 2: Placebo|Placebo identical to the active product will be given
89026995|NCT00503919|Experimental|MDC|Multi-spectral Digital Colposcopy for Fluorescence Spectroscopy
89026996|NCT00478790|Experimental|1|ologen™ collagen matrix will be placed on top of the scleral flap under the conjunctiva after the trabeculectomy. After operation with ologen™ Collagen Matrix, anti-inflammatory eye-drops will be prescribed
89026997|NCT02956187|Experimental|Biofeedback for constipation|Constipation will be treated by correcting functional outlet obstruction.
89026998|NCT02956187|Active Comparator|Fiber supplementation|Constipation will be treated by a fiber supplement
89026999|NCT01247766||Patients with rheumatoid arthritis (RA) who receive abatacept|
89027000|NCT01247766||Patients with RA who receive BDM drugs|biologic disease-modifying (BDM)
89027001|NCT01247766||Patients with RA who receive non-biologic DMARDs|disease-modifying anti-rheumatic drugs (DMARDs)
89027002|NCT04517682||Positive for SARS-CoV-2|Individuals who are symptomatic for COVID 19 disease, at high risk of infection or part of a screening program will provide samples for analysis which may reveal a positive result.
89027003|NCT04517682||Negative for SARS-CoV-2|Individuals who are symptomatic for COVID 19 disease, at high risk of infection or part of a screening program will provide samples for analysis which may reveal a negative result.
89027004|NCT01320943|Experimental|Stop TDF|Participants randomized to this arm will stop TDF therapy at baseline.
89027005|NCT01320943|Active Comparator|Continue TDF|Participants randomized to this arm will continue TDF therapy.
89027006|NCT04519008|Experimental|Treatment as usual plus mobile app|Those who will receive naturalistic treatment in outpatient setting and also the mobile app
89027007|NCT04519008|Active Comparator|Treatment as usual|Those who will receive naturalistic treatment in outpatient setting but not the mobile app
89027008|NCT04325347|Experimental|Virtual reality|Virtual Reality will be provided to all participants, just before sleeping.
89027009|NCT04325347|No Intervention|Control|No specific intervention will be provided.
89027010|NCT00472706|Active Comparator|1|Excision
89027011|NCT00472706|Active Comparator|2|Photodynamic therapy
89027012|NCT02955459|Experimental|VNRX-5133|IV infusion
89027013|NCT02955459|Placebo Comparator|Placebo|IV infusion
89027014|NCT02275377|Experimental|Inspiratory muscle training (IMT)|Participants will be submitted to a linear pressure resistance (PowerBreathe) with an inspiratory load of 40% of maximal inspiratory pressure (adjusted weekly), seven days a week, session duration of 30 minutes for 8 weeks.
89027015|NCT02275377|Placebo Comparator|Sham IMT|Participants will be submitted to inspiratory muscle training with the same equipment as the intervention group, but without a load generating resistance.
89027016|NCT02275377|No Intervention|Normotensive|The normotensive control group (healthy) will go through the same initial evaluation without performing inspiratory muscle training.
89027017|NCT00478946|Experimental|1|Picoplatin, 150 mg/m2, 5-FU and leucovorin (q 4 weeks, Schedule B). Leucovorin, 400 mg/m2 in D5W and leucovorin (± picoplatin) will be followed by a 5-FU bolus of 400 mg/m2 and then by 5-FU, 2,400 mg/m2 in D5W administered as a 46-hour continuous infusion.
89027018|NCT00478946|Active Comparator|2|FOLFOX Oxaliplatin 85 mg/m2, as a 2-hour infusion Leucovorin (400 mg/m2 in D5W) and Oxaliplatin. Leucovorin + oxaliplatin will be followed by a 5-FU bolus of 400 mg/m2 and then by 5-FU, 2400 mg/m2 in D5W administered as a 46-hour continuous infusion.
89027019|NCT01247844|Other|Day 7|removal of Shang Ring at 7 days
89027020|NCT01247844|Other|Day 14|removal of Shang Ring at 14 days
89027021|NCT01247844|Other|Day 21|removal of Shang Ring at 21 days
89027022|NCT01247961|Experimental|10 mg intravenous dexamethasone|Subjects randomized to intervention arm will receive single dose of 10 mg intravenous dexamethasone.
89027023|NCT01247961|Placebo Comparator|Placebo|Equal volume of normal saline administered as a single intravenous dose at enrollment.
89027024|NCT01248000||classical Hodgkin lymphoma|All cases of classical Hodgkin lymphoma diagnosed between 2006 and 2008 in the province of Modena, Reggio Emilia, Parma and Ferrara will be considered eligible for this study.
89027025|NCT01248078|Active Comparator|Cefazolin A|administered before skin incision
89027026|NCT01248078|Active Comparator|Cefazolin B|after umbilical cord clamping
89027027|NCT01248078|Placebo Comparator|saline solution|administered before skin incision
89560963|NCT02326285|Experimental|Treatment phase|Enrolled patients will be treated with 250mg/day Gefitinib for 11 days (day -12 until day -1) followed by 3 cycles (length 21 days) of chemotherapy with docetaxel (75mg/m2 d1) and cisplatin (50 mg/m2 d1+2) combined with intercalated gefitinib (250mg/day, d4-20 (cycle 1 and 2) and d4-17 (for cycle3). Surgery is planned in the 4th week after d1 of the last cycle.
89560964|NCT02332603|Active Comparator|Methylprednisolone|Preoperative single high dose of Solu-Medrol 125 mg iv.
89027028|NCT00472823|Experimental|vitamin D3 400 IU daily|vitamin D3 400 IU daily
89027029|NCT00472823|Experimental|vitamin D3 800 IU daily|vitamin D3 800 IU daily
89027030|NCT00472823|Experimental|vitamin D3 1600 IU daily|vitamin D3 1600 IU daily
89027031|NCT00472823|Experimental|vitamin D3 2400 IU daily|vitamin D3 2400 IU daily
89027032|NCT00472823|Experimental|vitamin D3 3200 IU daily|vitamin D3 3200 IU daily
89027033|NCT00472823|Experimental|vitamin D3 4000 IU daily|vitamin D3 4000 IU daily
89027034|NCT00472823|Experimental|vitamin D3 4800 IU daily|vitamin D3 4800 IU daily
89027035|NCT00472823|Placebo Comparator|placebo|matched to vitamin D tablet
89027036|NCT02275416|Experimental|Ipilimumab & UV1 vaccine & GM-CSF|Ipilimumab (3 mg/kg) every 3rd week for a total of 4 doses. GM-CSF (75 μg) followed by UV1 vaccine (300 μg) will be injected intradermally in the lower abdomen before and between treatments of ipilimumab and thereafter every 4th week up to 28 weeks, and thereafter at week 36 and 48.
89027037|NCT00472862|Experimental|2|Cognitive training
89027038|NCT00472862|Active Comparator|1|OPUS psychosocial treatment alone
89027039|NCT00479024||observation|patients enrolled in previous trial IOP 104; collecting clinical outcome data on these same patients
89027040|NCT02482233|Experimental|ENDD|"6-week supply of disposable NJOY ENDDs (e-cigarettes)~the number of e-cigarettes will be determined by equating the number of e-cigarettes to the number of cigarettes smoked per day (1 pack per day = 2 e-cigarettes per day = 14 e-cigarettes/week)~veterans will be given detailed instructions for use and also instructed to start with the high nicotine content (4.5%) strength for three weeks, then decrease to the low nicotine content (2.4%) for two weeks, then switch to nicotine-free for the final week~Both groups will receive:~i) referral to the California Smokers' Helpline, ii) brief advice lasting less than 2 minutes, iii) a brochure from the ASA about quitting smoking before surgery"
89027041|NCT02482233|Active Comparator|NRT (NicoDerm CQ)|"A prescription for 6 weeks of transdermal nicotine replacement (on-formulary at the VA) in the following doses: For smokers of 10 cigarettes per day or more, a 3-week supply of 21 mg/d, 1-week supply of 14 mg/d, 1-week supply of 7 mg/d, and 1-week of 0mg/d. Smokers of <10 cigarettes per day, 3 weeks of 14 mg/d patches 2 weeks of 7 mg/d patches, and 1-week of 0mg/d.~Both groups will receive:~i) referral to the California Smokers' Helpline, ii) brief advice lasting less than 2 minutes, iii) a brochure from the ASA about quitting smoking before surgery"
89027042|NCT00479063||Cases|All subjects screened for this study were aged 30 to 50 years, had been referred to participating Radiology services, and underwent a lumbar MRI. Cases had been referred for a lumbar MRI for LBP lasting > 90 days.
89210583|NCT00909714|Sham Comparator|Sham tDCS|Direct Current (DC)-Stimulator to apply Sham tDCS (Placebo) + Training
89210584|NCT00816374|Other|1|Group I
89210585|NCT00816374|Other|2|Group II
88966876|NCT01465594|Active Comparator|transurethral catheter after EERPE/ RALP|Recording of QoL measured by visual analogue ( pain )scale,EORTC QlQ -C 30 and QLQ - PR 25 questionnaires, incontinence rate, complication rate regarding insufficiency and strictures of vesicourethral anastomoses and urinary tract infection; demand of re-catheterization due to urinary retention and demand of antispasmodics
88966877|NCT01465594|Active Comparator|suprapubic catheter after EERPE /RALP|Recording of QoL measured by visual analogue ( pain )scale,EORTC QlQ -C 30 and QLQ - PR 25 questionnaires, incontinence rate, complication rate regarding insufficiency and strictures of vesicourethral anastomoses and urinary tract infection; demand of re-catheterization due to urinary retention and demand of antispasmodics
88966878|NCT01465516||Hispanic, HCV genotype 1|Historical group will be a continuous group of Hispanic patients with genotype 1 who were naive to treatment and completed or initiated 48 weeks of pegylated interferon and ribavirin. Patients, who discontinued the treatment due to side effects, adherence issues, or treatment failure, will be included and analyzed based on intention to treat analysis. All patients will be stratified according to their SVR, relapse and no response rate. RVR, EVR, and ETR will be also collated and compared to the study group.
88966879|NCT05394636||cerebral amyloid angiopathy (CAA)|Clinical and 1.5T MRI T2*-weighted imaging characteristics analyses from sporadic probable CAA patients (according to the modified Boston criteria) presenting with acute symptoms related to acute ICH, acute subarachnoid haemorrhage, or cortical SS,
88966880|NCT01465477|Experimental|Fibromyalgia arm|Patients fulfilling ACR 1990 Criteria for classification of Fibromyalgia, receiving the vaccination.
88966881|NCT01465477|Experimental|Heathy controls|Healthy controls receiving Influenza vaccination
88966882|NCT01465438|Experimental|Adalimumab|Responders at week 24 continue treatment with adalimumab. Non-responders at week 24 stops treatment with adalimumab.
88966883|NCT01465399|Experimental|PRGF-Endoret|
88966884|NCT01465399|Active Comparator|Conventional treatment|
88966885|NCT01465360||Study patients|Patients newly referred to a Reference Memory Center with a complaint of memory impairment for AD diagnostic workup.
88966886|NCT01465282|Experimental|0.05% (w/w) CT327 ointment|0.05% (w/w) CT327 ointment applied BID for up to 8 weeks.
88966887|NCT01465282|Experimental|0.1% (w/w) CT327 ointment|0.1% (w/w) CT327 ointment applied BID for up to 8 weeks.
88966888|NCT01465282|Experimental|0.5% (w/w) CT327 ointment|0.5% (w/w) CT327 ointment applied BID for up to 8 weeks.
88966889|NCT01465282|Placebo Comparator|Placebo ointment|Placebo ointment
88966890|NCT05393505|Experimental|Fast-tRack Absolute Neutrophil Count (FRANC) Protocol|"Patient's blood sample will be expedited for complete blood count with differentials. Intravenous antibiotic is given depending on absolute neutrophil count. If neutropenia is present, broad-spectrum antibiotic (meropenem 1 g or levofloxacin 500 mg) will be given after septic workup within 1 hour of registration in emergency department before transfer to wards. If absent, antibiotic according to Hospital Authority Interhospital Multi-disciplinary Programme on Antimicrobial ChemoTherapy (IMPACT) with reference to previous bacterial sensitivity pattern, or amoxiclav 1.2 g if not specified, will be given. Other interventions are given according to clinical needs. The regimen is continued until clinicians recommend an alternative antimicrobial based on clinical grounds, or detection of other pathogens which indicate another antimicrobial."
88966891|NCT05393505|Active Comparator|Standard of Care|"The control group refers to the existing clinical pathway which guides management of adult patients with suspected NF in ED. Without information of absolute neutrophil count, Meropenem 1 g IV bolus (or Levofloxacin 500 mg IV infusion over 1 hour if Penicillin-allergic) will be given within 1 hour of ED registration after septic workup. Other interventions are given according to clinical needs.~Subsequent treatment in wards will be determined by doctor's clinical judgement, on a personalised basis. Each patient will be assessed by a parent team member. There is no standardised antibiotic de-escalation protocol in place, but it is a usual practice to continue Meropenem or Levofloxacin injections until clinical improvement, rising ANC, and negative culture results. After that it will be replaced with an antibiotic with a narrower spectrum, such as oral Amoxiclav, before discharge."
88966892|NCT01465243|Experimental|Icotinib|This is a single arm study.
88966893|NCT01465204|No Intervention|Control|
88966894|NCT01465204|Experimental|Handwashing Intervention|scaling up handwashing with soap
88966895|NCT01465204|Experimental|Sanitation Intervention|total sanitation and sanitation marketing
88966896|NCT01465204|Experimental|Combined|combined scaling up handwashing with soap and total sanitation and sanitation marketing interventions
88966897|NCT04712188||Arcing|"10 patients with traumatic spinal cord injury using the arcing stroke pattern to propel manual wheelchair"
88966898|NCT04712188||Semicirculer|"10 patients with traumatic spinal cord injury using the semicirculer stroke pattern to propel manual wheelchair"
88966899|NCT04712188||Single loop|"10 patients with traumatic spinal cord injury using the single loop stroke pattern to propel manual wheelchair"
89560965|NCT02332603|Placebo Comparator|Isotonic Sodium Chloride|Preoperative single dose of isotonic Sodium Chloride
88966900|NCT04712188||Double loop|"10 patients with traumatic spinal cord injury using the double loop stroke pattern to propel manual wheelchair"
88966901|NCT04712149|Experimental|intervention arm|In the intervention arm, 15 patients will receive a weekly questionnaire. Alerts will be sent to the multidisciplinary care team, who will undertake follow-up actions. In the control arm, 15 patients will receive the standard care pathway without weekly questionnaire and without automatic alerts to the care team. The standard care pathways and the care team are the same in both groups. In this pilot study, the weekly follow-up will be evaluated by a validation questionnaire, semi-structured interviews with patients and the care team, and workload registration of the care team during a six-month period.
88966902|NCT04712149|No Intervention|Control arm|
88966903|NCT01465165||Depressed, unmedicated|Participants with MDD who are not treated with any antidepressant medication
88966904|NCT01465165||Depressed, on antidepressant|Participants with MDD, currently depressed but on a stable dose of an SSRI antidepressant
88966905|NCT01465165||Healthy control|Healthy participant with no MDD or other psychiatric condition, matched by age and gender to MDD participants
88966906|NCT01465087|Experimental|Diagnosis|Diagnosis, breath and confounding factor
88966907|NCT01465048|Experimental|Plasmodium falciparum sporozoites 2sites|2,500 sporozoites intradermally
88966908|NCT01465048|Experimental|Plasmodium falciparum sporozoites 1 site|2,500 sporozoites intramuscularly
88966909|NCT01465048|Experimental|Plasmodium falciparum sporozoites 1site|25,000 sporozoites intramuscularly
88966910|NCT01465009|Experimental|Arm 1|
88966911|NCT01465009|Active Comparator|Arm 2|
88966912|NCT01465009|Placebo Comparator|Arm 3|
88966913|NCT01464970|Active Comparator|SIE Vessels Both Clamped|
88966914|NCT01464970|Active Comparator|SIE Vessels both Unclamped|
88966915|NCT01464970|Active Comparator|SIE Artery Unclamped; Vein Clamped|
88966916|NCT01464970|Active Comparator|SIE Artery Clamped, SIE Vein Unclamped|Superficial Inferior Epigastric Artery Clamped; Vein Unclamped
88966917|NCT04169477|Experimental|cTENS-mTENS|Patients randomized in this arm will test cTENS mode first, the subjects will be crossed over to the mTENS form
88966918|NCT04169477|Experimental|mTENS-cTENS|Patients randomized in this arm will test mTENS mode first, the subjects will be cross over to the cTENS mode
88966919|NCT01464892|Experimental|Imagery Rescripting|
88966920|NCT01464892|Active Comparator|STAIR plus Imagery Rescripting|
88966921|NCT01464892|No Intervention|Wait-list control|Participants from this arm are randomized to the two active conditions after 8 weeks of waiting.
88966922|NCT01464853|Experimental|Specialized Enteral Nutrition|Enteral Feeding to provide 25 kcal/Kg/day
88966923|NCT01464853|Active Comparator|Standard Enteral Nutrition|Enteral Feeding to provide 25 kcal/Kg/day
88966924|NCT01465711||Control|Admission to the Intensive Care Unit (ICU) after abdominal surgery without suspicion / evidence of peritonitis.
88966925|NCT01465711||Peritonitis|Admission to the Intensive Care Unit (ICU) after abdominal surgery with suspicion / evidence of peritonitis
88966926|NCT03226548|Experimental|Experimental|Paycheck Plus: Participants will receive four times the standard Earned Income Tax Credit after filing their annual taxes
88966927|NCT03226548|No Intervention|Control|Control participants will receive the standard Earned Income Tax Credit after filing their annual taxes
88966928|NCT01464814|Experimental|Probiotic|Lactobacillus casei in fish oil capsule
89560966|NCT02332447|Experimental|NALOXONE|
89560967|NCT02332447|Placebo Comparator|PLACEBO|
89560968|NCT02331199|Experimental|preterm labour|200 women with preterm prelabour ruptured membranes or undergoing preterm CS
89560969|NCT02331121|Active Comparator|Text-only Online Training|Text-only evidence-based training content on CPR, choking relief & first aid
89560970|NCT02331121|Experimental|Family First Aid Online Training|Interactive multimedia evidence-based training content on CPR, choking relief & first aid
89560971|NCT02330809|Experimental|Daily extra water intake 2L|"Timing of daily extra water intake intervention-A: extra water intake: 8 8oz glasses of water a day (2L) - 2 first thing in the morning before breakfast, 2 before midday or midday meal, 2 before afternoon meal and 2 before evening meal.~Intervention-B: Drink extra water at anytime over 24 hours"
88966929|NCT01464814|Placebo Comparator|Placebo|Fish oil capsule
89560972|NCT02330809|Experimental|Daily extra water intake 1L|"Timing of daily extra water intake Intervention-A: 4 8oz glasses of water a day (1L) - 1 first thing in the morning before breakfast, 1 before midday or midday meal, 1 before afternoon meal and 1 before evening meal.~Intervention-B: Drink extra water at anytime over 24 hours"
88966930|NCT01464775|Experimental|Narrow Band Imaging (NBI)|Women will be randomized to white light/NBI versus white light/white light laparoscopy
88966931|NCT01464775|Active Comparator|Standard White Light Laparoscopy|Women will be randomized to white light/NBI versus white light/white light laparoscopy
88966932|NCT01464736|Experimental|Physical Training Group|This group performed aerobic physical training in treadmill.
88966933|NCT01464736|Experimental|NIV Trained|"This group performed aerobic physical training associated with ventilation in the bilevel modality (BiPAP®), using a nasal mask as an interface.~On evaluation day, the levels of inspiratory positive airway pressure (IPAP) (between 10 and 15cmH2O) and expiratory positive airway pressure (EPAP) (between 4 and 6cmH2O) were defined, varying according to the comfort level of each patient."
88966934|NCT04120610||Healthy|Healthy cohort is an age-matched population (over 40 years old) without history of PAD or suspected PAD. Healthy cohort will receive FlowMet-R measurement, Ankle Brachial Index (ABI), and Toe Brachial Index (TBI) measurements.
88966935|NCT04120610||PAD|PAD cohort is all-comers to the vascular lab that are scheduled to undergo assessment for Peripheral Artery Disease (PAD) or have a planned endovascular or surgical intervention to address PAD. PAD cohort patients will receive FlowMet-R measurement in addition to their routine standard of care.
88966936|NCT01464697|Experimental|oral micronized progesterone|Oral micronized progesterone is Prometrium 300 mg at bedtime daily
88966937|NCT01464697|Placebo Comparator|Placebo Comparator|Placebo
88966938|NCT04109846|Experimental|Non-euploid Transfer|Patients desiring pregnancy who have no acceptable euploid embryos available for transfer who chose to undergo embryo transfer of a non-euploid embryo (either aneuploid or mosaic).
88966939|NCT04109846|Active Comparator|Euploid Transfer|Patients desiring pregnancy who are undergoing euploid embryo transfer
88966940|NCT01464658|Other|panniculectomy|surgical intervention
88966941|NCT01464541|Experimental|orbital fractures size|patients who undergo surgical repair of orbital fracture with measuring the fracture size intraoperatively and had available orbital Ct scan preoperatively.
88966942|NCT01464502|Active Comparator|Standard CRT Implant|
88966943|NCT01464502|Active Comparator|Pressure-wire guided CRT Implant|
88966944|NCT00393679|Experimental|1|AS-AQ
88966945|NCT00393679|Experimental|2|"DHAPQ~TO BE NOTED: since the batches of the study drug DHAPQ expire at the end of October 2008, and because of the unavailability of a new batch of DHAPQ from the manufacturer, the recruitment in the DHAPQ arm had to be discontinued on 30th October 2008. A formal amendment has been submitted to all the concerned ECs and competent authorities."
88966946|NCT00393679|Experimental|3|AL
88966947|NCT00393679|Experimental|4|"Lapdap + AS~TO BE NOTED: following GlaxoSmithKline decision to discontinue the clinical development of the fixed-doses combination of Lapdap (Chlorproguanil-Dapsone) and artesunate, the Lapdap plus Artesunate arm was immediately discontinued in this study, on 17th February 2008. A formal amendment has been submitted to all the concerned ECs and competent authorities.The leading EC approval was obtained on 2nd June 2008."
88966948|NCT04712032|Experimental|Image Guided Bowel Anastomosis group|ICG-guided perfusion assessment
88811035|NCT04674254|Active Comparator|Anti-vascular endothelial growth factor agent|Intravitreal injections of 1.25 mg/0.05 ml of Bevacizumab every 4 weeks through 12- week visit then pro re nata to complete 12 months according to Protocol S.
88966949|NCT04712032|No Intervention|Conventional Bowel Anastomosis group|conventional perfusion assessment
89560973|NCT02330809|Experimental|Daily extra water intake 500ml|"Timing of daily extra water intake Intervention-A: 2 8oz glasses of water a day (500ml) - each half an hour before a meals~Intervention-B: Drink extra water at anytime over 24 hours"
89560974|NCT02330809|Experimental|Daily extra water intake 120ml|"Timing of daily extra water intake Intervention-A: 1/2 a glass of water on waking (120ml). If you forget to drink your water first thing, do not drink it later in the day, just skip this day and drink ½ a glass the next day on waking.~Intervention-B: Drink extra water at anytime over 24 hours"
89560975|NCT05077813|Active Comparator|13 cis retinoic acid, Minocycline, Chicroic Acid and Vitamin D for (MDR-TB)|50 Subjects will be randomly assigned to receive A) Minocycline i.v. 4,5 mg/kg gradual in 2 divided doses increases from 4,5 mg/kg from the first week to 7.5 and 10 mg/kg to the last week. In addition to Aerosolized 13 cis retinoic acid in gradual 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled retinoic acid therapy for 30 days. Moreover, the patients will receive Echinacea Purpurea Extract Capsules Polyphenols Chicoric Acid. Echinacea phytochemical profile Each tablet is comprised of the equivalent of 1275 mg of echinacea root, as follows: A) Echinacea purpurea - 675 mg root yields 112.5 mg dried extract, standardized to contain 2.1mg alkamides. Each batch of tablets contain choric acid = 3.4 to 8.5 mg/tablet. Furthermore, the patients will receive Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
89560976|NCT05077813|Active Comparator|9 cis retinoic acid , Minocycline,Chicroic Acid and Vitamin D for (MDR-TB)|50 Subjects will be randomly assigned to receive A) Minocycline i.v. 4,5 mg/kg gradual in 2 divided doses increases from 4,5 mg/kg from the first week to 7.5 and 10 mg/kg to the last week. In addition to Aerosolized 9 cis retinoic acid in gradual 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled retinoic acid therapy for 30 days. Moreover, the patients will receive Echinacea Purpurea Extract Capsules Polyphenols Chicoric Acid. Echinacea phytochemical profile Each tablet is comprised of the equivalent of 1275 mg of echinacea root, as follows: A) Echinacea purpurea - 675 mg root yields 112.5 mg dried extract, standardized to contain 2.1mg alkamides. Each batch of tablets contain choric acid = 3.4 to 8.5 mg/tablet. Furthermore, the patients will receive Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
89560977|NCT05077813|Active Comparator|All trans retinoic acid , Minocycline,Chicroic Acid and Vitamin D for (MDR-TB)|50 Subjects will be randomly assigned to receive A) Minocycline i.v. 4,5 mg/kg gradual in 2 divided doses increases from 4,5 mg/kg from the first week to 7.5 and 10 mg/kg to the last week. In addition to Aerosolized All trans retinoic acid in gradual 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled retinoic acid therapy for 30 days. Moreover, the patients will receive Echinacea Purpurea Extract Capsules Polyphenols Chicoric Acid. Echinacea phytochemical profile Each tablet is comprised of the equivalent of 1275 mg of echinacea root, as follows: A) Echinacea purpurea - 675 mg root yields 112.5 mg dried extract, standardized to contain 2.1mg alkamides. Each batch of tablets contain choric acid = 3.4 to 8.5 mg/tablet. Furthermore, the patients will receive Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
89560978|NCT05077813|Active Comparator|13 cis retinoic acid, Minocycline, Chicroic Acid and Vitamin D For (COVID-19 and MDR-TB)|50 Subjects with confection of COVID-19 and multidrug-resistant tuberculosis (MDR-TB) will be randomly assigned to receive A) Minocycline i.v. 4,5 mg/kg gradual in 2 divided doses increases from 4,5 mg/kg from the first week to 7.5 and 10 mg/kg to the last week. In addition to Aerosolized 13 cis retinoic acid in gradual 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled retinoic acid therapy for 30 days. Moreover, the patients will receive Echinacea Purpurea Extract Capsules Polyphenols Chicoric Acid. Echinacea phytochemical profile Each tablet is comprised of the equivalent of 1275 mg of echinacea root, as follows: A) Echinacea purpurea - 675 mg root yields 112.5 mg dried extract, standardized to contain 2.1mg alkamides. Each batch of tablets contain choric acid = 3.4 to 8.5 mg/tablet. Furthermore, the patients will receive Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
88811036|NCT04674254|Active Comparator|Targeted retinal photocoagulation|Targeted retinal photocoagulation guided by fundus fluorescein angiography will be administered after topical anesthesia, directed to areas of nonperfused peripheral retina plus a 1-disc area margin using the Mainster lens. Subsequent treatments if needed will be delivered at 3 monthly intervals for a minimum follow-up of 12 months. The extent of the laser applied will be determined based on areas of nonperfusion identified by fundus fluorescein angiography.
88966950|NCT05352867|Experimental|50μg group|
88966951|NCT05352867|Experimental|100μg group|
88966952|NCT05352867|Placebo Comparator|Placebo|
88966953|NCT01373515|Experimental|Cohort 1; 1x10E7 DCP-001|n=3; patients receiving 4 bi-weekly vaccinations of 1x10E7 DCP-001.
88966954|NCT01373515|Experimental|Cohort 2; 2.5x10E7 DCP-001|n=3; patients receiving 4 bi-weekly vaccinations of 2.5x10E7 DCP-001.
88966955|NCT01373515|Experimental|Cohort 3; 5x10E7 DCP-001|n=3; patients receiving 4 bi-weekly vaccinations of 5x10E7 DCP-001.
88966956|NCT01373515|Experimental|Cohort 4; 5x10E7 DCP-001|n=3; patients, matched for HLA-A2, receiving 4 bi-weekly vaccinations of 5x10E7 DCP-001. Or, in case this turned out toxic, this group will receive the Maximum Tolerated Dose.
88966957|NCT01057069|Experimental|HRD; 1x ddAC, 2x tCTC|HRD positive tumors; irrespective of response; - a fourth course of AC followed by Peripheral Blood Progenitor Cell (PBPC) harvest and tandem intermediate-dose alkylating therapy (miniCTC, carboplatin 800 mg/m2, thiotepa 250 mg/m2, and cyclophosphamide 3000 mg/m2) with PBPC-reinfusion.
88966958|NCT01057069|Active Comparator|HRD; 3x CP|HRD tumors; any response to 3x ddAC; 3 courses of CP
89560979|NCT05077813|Active Comparator|All trans retinoic acid, Minocycline, Chicroic Acid and Vitamin D For (COVID-19 and MDR-TB)|50 Subjects with confection of COVID-19 and multidrug-resistant tuberculosis (MDR-TB) will be randomly assigned to receive A) Minocycline i.v. 4,5 mg/kg gradual in 2 divided doses increases from 4,5 mg/kg from the first week to 7.5 and 10 mg/kg to the last week. In addition to Aerosolized All trans retinoic acid in gradual 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled retinoic acid therapy for 30 days. Moreover, the patients will receive Echinacea Purpurea Extract Capsules Polyphenols Chicoric Acid. Echinacea phytochemical profile Each tablet is comprised of the equivalent of 1275 mg of echinacea root, as follows: A) Echinacea purpurea - 675 mg root yields 112.5 mg dried extract, standardized to contain 2.1mg alkamides. Each batch of tablets contain choric acid = 3.4 to 8.5 mg/tablet. Furthermore, the patients will receive Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
89560980|NCT05077813|Placebo Comparator|The standard therapy|The standard therapy 100 infected patients with confection of COVID-19 and MDR-TB will receive the standard therapy for tuberculosis for 30 days 50- 50-
89560981|NCT02326051|Active Comparator|Early Enoxaparin initiation|Women will start Enoxaparin therapy once positive pregnancy test is established
89560982|NCT02326051|Active Comparator|Later Enoxaparin initiation|Women will start Enoxaparin therapy after sonographic confirmation of fetal cardiac pulsation
89560983|NCT02325973|Other|IMR evaluation|Assessment of IMR index in coronaries through PressureWire Certus guidewire
89560984|NCT00914251|Active Comparator|Hesperidin, 500 mg per day|500 mg daily of oral Hesperidin for 3 weeks
89560985|NCT00914251|Placebo Comparator|Placebo|
89560986|NCT02330731|Other|N-butyl-2-cyanoacrylate|injection sclerotherapy for gastric varices
89560987|NCT02330731|Other|iso-amyl-2-cyanoacrylate|injection sclerotherapy for gastric varices
89560988|NCT02330731|Other|72% chromated glycerin|injection sclerotherapy for gastric varices
89560989|NCT05076955|Experimental|Treatment of Diabetic Foot Ulcer|Participants with diabetic foot ulcers will be treated with a compounded, anti-infective irrigation therapy daily until closure of the ulcer or up to a maximum of 3 months. This is an irrigating foot bath with a compounded medication of vancomycin-tobramycin-itraconazole. This medication with combined 3/4 gallon of water. Participant will soak foot in solution for 10 minutes per day. Daily until wound is healed for a minimum of 4 weeks and a maximum of 3 months.
89560990|NCT02330575|Active Comparator|Standard Care|Participants in this group will receive standard education on the importance of physical activity in the recovery from cancer and how to become more active. Participants assigned to this group will have the option to participate in the exercise program after the 16-week follow-up assessment.
89560991|NCT02330575|Experimental|Supervised Community-based Exercise|Participants in this group will take part in an 8-week supervised exercise program at the YMCA. Following the 8-week intervention, participants will have the option to continue for an additional 8-weeks at the YMCA (fee for service) or follow an 8-week self-directed program.
89560992|NCT05076721|Experimental|Simulation group|The simulation training group will receive a simulation training of a sepsis case which will see the participants implementing one-hour bundle sepsis with a high-fidelity manikin.
89560993|NCT05076721|Experimental|Conventional group|The conventional training group will receive a case-based discussion of a sepsis case which will see the participants implementing one-hour bundle sepsis.
89560994|NCT03144193|Experimental|Experimental|Topical anti-aging cosmetic cream (active)
89560995|NCT03144193|Placebo Comparator|Placebo|Basic formulation without active ingredients (vehicle)
89560996|NCT05077111|Experimental|Group A|sole Thoracic Epidural Anesthesia
89560997|NCT05077111|Active Comparator|Group B|General Anesthesia with One Lung Ventilation
89560998|NCT02330497|Experimental|Radiofrequency|Procedure/Surgery Thermal Radiofrequency Ablation under endoscopic ultrasonography guidance of the pancreatic neuro endocrine tumor or mucinous cyst.
89560999|NCT05075863|Experimental|Clomiphene Citrate|A total of 39 women were given clomiphene citrate, 100mg from 3 to 7 days of menstrual cycle. All patients underwent transvaginal scan (TVS) so that efficacy could be evaluated (ovulation occurs on 14 day of menstrual cycle after a treatment of 5 days of both groups. Induction of ovulation was assessed by TVS. If follicle of >2cm is found on 12 days TVS and smaller/collapsed on 16 days TVS, ovulation induction was labeled.
89561000|NCT05075863|Experimental|Letrozole|A total of 39 women were given letrozole, 5mg from day 3 to 7 of menstrual cycle. All patients underwent transvaginal scan (TVS) so that efficacy could be evaluated (ovulation occurs on 14 day of menstrual cycle after a treatment of 5 days of both groups. Induction of ovulation was assessed by TVS. If follicle of >2cm is found on 12 days TVS and smaller/collapsed on 16 days TVS, ovulation induction was labeled.
89561001|NCT05072119||Patients with PM|All patients underwent PM implantation
89561002|NCT05072119||Patients with ICD|All patients undeerwent ICD implantation
89027043|NCT00479063||Controls|All subjects screened for this study were aged 30 to 50 years, had been referred to participating Radiology services, and underwent a lumbar MRI. Controls were headache patients who had been referred for a cranial MRI, which turned out to be normal, and who either had no history of LBP or had only experienced one episode in their life, which had lasted for less than 7 days.
89027044|NCT02489526|Experimental|VVZ-149 Injections|
89027045|NCT02489526|Placebo Comparator|Placebo|
89210586|NCT00906906||1|Patient to receive CPB
89561003|NCT05072119||Patients with ILR|All patients underwent ILR implantation
89561004|NCT02330419|Placebo Comparator|Placebo|Placebo 50mg, as needed
89561005|NCT02330419|Active Comparator|Naltrexone|Naltrexone 50mg, as needed
89561006|NCT03143803|Active Comparator|Polyherbal|Polyherbal capsule contains leaves of 3 herbs namely C. indica, B. spectabilis and C. rosea.
89561007|NCT03143803|Placebo Comparator|Placebo|Placebo will contain an inert substance
89561008|NCT05076331||Health and Aging Brain Study Cohort|Health and Aging Brain Study participants age 50 and older.
89561009|NCT05070325|Experimental|Cold application group (Group 1)|In the children in this group, the injection site was cleaned before the injection using antiseptic cotton and then the gel pad was placed on the injection site. In line with the literature, the cold gel pad was applied to the intramuscular injection site for 30-45 seconds before the injection and then the injection was delivered. The children were told to breathe deeply and not to tense up during the injection.
89561010|NCT05070325|Experimental|Shotblocker group (Group 2)|The injection site was cleaned using antiseptic cotton. The surface of the Shotblocker with the contact points was placed on the site just before the injection in a way not to contaminate the injection point. Injection was carried out through the opening in the middle of ShotBlocker. The children were told to breathe deeply and not to tense up during the injection. After the injection was completed, ShotBlocker was removed from the skin.
89561011|NCT05070325|Experimental|Control Group (Group 3)|The routine IM injection was applied to the children in this group. The injection site was cleaned using antiseptic cotton. The children were told to breathe deeply and not to tense up during the injection.
89561012|NCT05068141|Experimental|SG001 plus Nab-Paclitaxel|Patients will receive SG001 intravenously at a dose of 240 mg on Days 1 and 15 of every 4-week cycle in combination with nab-paclitaxel at a dose of 100 mg/m^2 on Days 1, 8, and 15 of every 4-week cycle until disease progression, or unacceptable toxicity, or other discontinuation or termination criteria are met.
89561013|NCT03142477|Other|Control|Control group patients will not receive any interventions with therapeutic touch. Two different quality of life questionnaires (WHOQOL-Bref and EORTC QLQ-C30) will be applied before and after treatment. Levels of cortisol, salivary IgA, hematological index results and telomerase activity before and after the use of therapeutic touch will be measured.
89561014|NCT03142477|Placebo Comparator|Placebo|Placebo patients group patients will receive the therapeutic touch intervention by a graduate student without any therapeutic touch training. Two different quality of life questionnaires (WHOQOL-Bref and EORTC QLQ-C30) will be applied before and after treatment. Levels of cortisol, salivary IgA, hematological index results and telomerase activity before and after the use of therapeutic touch will be measured.
89561015|NCT03142477|Experimental|Treatment|Treatment patients group patients will receive the therapeutic touch interventions with a trained therapeutic touch professional. Two different quality of life questionnaires (WHOQOL-Bref and EORTC QLQ-C30) will be applied before and after treatment. Levels of cortisol, salivary IgA, hematological index results and telomerase activity before and after the use of therapeutic touch will be measured.
89561016|NCT02330263|Experimental|carbohydrate group|Randomly selected patients of the carbohydrate group are given 400ml of 12.8 g/100 ml carbohydrate beverage in the evening before their surgery and in the morning of the operation day (3 hours before their scheduled operation).
89561017|NCT02330263|No Intervention|control group|Patients in the control group consume no food or drink after midnight before surgery.
89561018|NCT05050435||Early extubated (in operating room) patients after valvular cardiac surgery|
88966959|NCT01057069|Active Comparator|non-HRD;3x CP|non-HRD tumors; unfavourable response to 3x ddAC; 3 courses of Carboplatin and Paclitaxel
88966960|NCT01057069|Active Comparator|non-HRD; response; 3x ddAC|non-HRD tumors; favourable response to 3x ddAC; 3 more courses of ddAC
88966961|NCT01057069|Active Comparator|non-HRD; response; 3x CP|non-HRD tumors; favourable response to 3x ddAC; 3 courses of Carboplatin and Paclitaxel
88966962|NCT04060316|Experimental|GLS-1200|3 ml of GLS-1200 (1 mg/ml in 0.9% saline)
88966963|NCT04060316|Placebo Comparator|Sterile Saline|3 ml of 0.9% saline
88966964|NCT00847990||Pregnant women|Pregnant women who are scheduled to undergo an amniocentesis or CVS procedure and will receive the fetal FISH and/or karyotype results from the procedure.
88966965|NCT00847951|Other|Renal perfusion in Neonates|Ultrasound scanning with power Doppler is used to determine the fractional blood volume of the kidneys.
88966966|NCT00847873|Experimental|Combined SU/IPV treatment|A combined treatment containing cognitive behavioral therapy addressing partner violence and cognitive behavioral therapy addressing substance abuse
88966967|NCT00847873|Active Comparator|control condition|Cognitive behavioral therapy addressing substance abuse
88966968|NCT00847834|Experimental|1|"4 weeks of one tablet Irbesartan 150mg / Hydrochlorothiazide 12.5mg followed by:~If DBP<85mmHg: 4 weeks of one tablet of Irbesartan 150mg / Hydrochlorothiazide 12.5mg~If DBP≥85mmHg: 4 weeks of one tablet of Irbesartan 150mg / Hydrochlorothiazide 12.5mg + one tablet of Irbesartan 150mg"
88966969|NCT00847834|Experimental|2|"2 weeks of one tablet Irbesartan 150mg / Hydrochlorothiazide 12.5mg followed by 2 weeks of one tablet Irbesartan 150mg / Hydrochlorothiazide 12.5mg + one tablet Irbesartan 150mg followed by:~If DBP<85mmHg: 4 weeks of of one tablet Irbesartan 150mg / Hydrochlorothiazide 12.5mg + one tablet Irbesartan 150mg~If DBP≥85mmHg: 4 weeks of two tablets Irbesartan 150mg / Hydrochlorothiazide 12.5mg"
88966970|NCT00847795|Experimental|1|5ng Avotermin
88966971|NCT00847795|Experimental|2|50ng Avotermin
88966972|NCT00847795|Experimental|3|100ng Avotermin
88966973|NCT00847795|Placebo Comparator|4|Placebo
88966974|NCT00847795|No Intervention|5|Standard Care
88966975|NCT00847756||rAOM|Children 0-5 years of age suffering from recurrent acute otitis media and waiting for tympanostomy tube insertion.
88966976|NCT00847756||COME|Children 0-5 years of age suffering from chronic otitis media with effusion and waiting for tympanostomy tube insertion.
88966977|NCT00847756||CSOM|Children 0-5 years of age suffering from chronic suppurative otitis media and waiting for tympanostomy tube insertion. Note: Only 3 patients with CSOM were recruited and therefore not suitable for publication.
88966978|NCT00847717|Experimental|1|IIb preserving neck dissection
88966979|NCT00847717|Other|2|Conventional neck dissection
88966980|NCT00847678|Experimental|1|Mycograb + Amphotericin B + 5 flucytosine
88966981|NCT00847678|Placebo Comparator|2|Placebo + Amphotericin B + 5 flucytosine
88966982|NCT00847678|Experimental|3|Mycograb + Amphotericin B
88966983|NCT00847639|Experimental|Lenalidomide|Lenalidomide maintenance therapy will start within 60 to 180 days after allogeneic HCT at a starting dose of 10mg PO once daily. Dose escalation and de-escalation are performed depending on tolerability of lenalidomide. The dose range is 5mg every other day and 5 to 25 mg daily from days 1-21 followed by 7 days of rest for 12 cycles (each cycle 28 days).
88966984|NCT00847600|Experimental|1 Pregnenolone|50 mg/day
88966985|NCT00847600|Placebo Comparator|2 Placebo|1 caps.
88966986|NCT00847522|Experimental|All patients|All participants enrolled.
88966987|NCT04039139|No Intervention|Usual Care|Participants will continue their usual care for 26 weeks
89027046|NCT01248117|Experimental|Previously Treated|With prior anti-vegf therapy, only, no sooner than 30 days prior to enrollment into trial
89561019|NCT05050435||Later extubated (in ICU) patients after valvular cardiac surgery|
89561020|NCT03142165|Experimental|BMS-986263|
89561021|NCT03142165|Placebo Comparator|Placebo|
89561022|NCT02330029|Active Comparator|TCM (Traditional Chinese medicine)|Formula for pain and diarrhea, Atractylodes (~10-15g), Paeonia Lactiflora (~15-30g), Tangerine Peel (~10g), Ledebouriella Root (~10g), Radix codonopsitis (~10-15g), Radix curcumae (~10g), Fingered citron (~10g), Tuckahoe (~15g), etc.
89561023|NCT02330029|Active Comparator|Pinaverium|
89561024|NCT02330029|Placebo Comparator|Placebo|Placebo is blindly given to patients
89561025|NCT03142555|Experimental|Health talk plus intensive social media intervention|"Subjects in this group will receive:~General health talk;~Phone follow-up/counselling service (15 - 30 minutes);~Social media (intensive reminders);~Regular personalized what's app interaction ( up to 2 months duration)"
89561026|NCT03142555|Placebo Comparator|Health talk plus less intensive social media intervention|"Subjects in this group will receive:~General health talk;~Phone follow-up/counselling service (15 - 30 mintues);~Social media ( less intensive reminders)"
89561027|NCT02638103|Experimental|TEV-48125 225 mg Monthly: New/Placebo Rollover Participants|Participants with CM who were randomized to the placebo treatment group or participants who do not rollover from the pivotal efficacy study, will receive fremanezumab 675 milligrams (mg) SC as loading dose (3 injections of fremanezumab 225 mg/1.5 milliliters [mL] on Day 0) followed by 11 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5 mL and 2 injections of placebo 1.5 mL on Days 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5mL on Days 28, 56, 112, 140, 196, 224, 280, and 308). Participants with EM who were randomized to the placebo treatment group or participants who do not rollover from the pivotal efficacy study, will receive 12 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5 mL and 2 injections of placebo 1.5 mL on Days 0, 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308).
89561028|NCT02638103|Experimental|TEV-48125 225 mg Monthly: Active Rollover Participants|Participants with CM who were randomized to the active treatment group (Fremanezumab 675/225 mg) in the pivotal efficacy study, will receive fremanezumab 675 mg SC as loading dose (3 injections of fremanezumab 225 mg/1.5 mL on Day 0) followed by 11 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5mL and 2 injections of placebo 1.5 mL on Days 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5mL on Days 28, 56, 112, 140, 196, 224, 280, and 308). Participants with EM who were randomized to the active treatment group (Fremanezumab 225 mg) in the pivotal efficacy study, will receive 12 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5 mL and 2 injections of placebo 1.5 mL on Days 0, 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308).
89561029|NCT02638103|Experimental|TEV-48125 675 mg Quarterly: New/Placebo Rollover Participants|Participants with CM or EM who were randomized to the placebo treatment group or participants who do not rollover from the pivotal efficacy study, will receive fremanezumab 675 mg SC once every 3 months for 12 months for a total of 4 doses (3 injections of fremanezumab 225 mg/1.5 mL on Days 0, 84, 168, and 252; and 1 injection of placebo 1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308).
89561030|NCT02638103|Experimental|TEV-48125 675 mg Quarterly: Active Rollover Participants|Participants with CM or EM who were randomized to the active treatment group (Fremanezumab 675 mg) in the pivotal efficacy study, will receive fremanezumab 675 mg SC once every 3 months for 12 months for a total of 4 doses (3 injections of fremanezumab 225 mg/1.5 mL on Days 0, 84, 168, and 252; and 1 injection of placebo 1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308).
89561031|NCT02330107|Experimental|Treatment arm 1|"Subjects will receive MAT and placebo LA. The magnetic pellets will be applied to the six selected acupoints as detected by an acupoint finder. To achieve a blinding and placebo effect of the subject, the laser device will be switched to power off mode (i.e. deactivated laser) for acupoint stimulation before the application of MAT. Subjects will be asked to wear a pair of laser protective goggles to blind them during treatment."
88966988|NCT04039139|Experimental|Mind Body Intervention 1: Mind-Body-Syndrome-Therapy (MBST)|Participants will receive a mind body educational-based intervention to learn the techniques comprising intervention 1. Further details are not provided for blinding purposes.
88966989|NCT04039139|Active Comparator|Mind Body Intervention 2|Participants will receive a mind-body educational-based intervention to learn the techniques comprising intervention 2. Further details are not provided for blinding purposes.
88966990|NCT00847483|Active Comparator|Latanoprost|
88966991|NCT00847483|Active Comparator|Travoprost|
88966992|NCT00847483|Active Comparator|Bimatoprost|
88966993|NCT00847444|Active Comparator|AA|Drug intervention
88966994|NCT00847444|Active Comparator|BA|Lifestyle intervention
88966995|NCT00847444|No Intervention|BB|No individualized lifestyle intervention program.
88966996|NCT00847366|Experimental|Perifosine 201|"Perifosine 201: A Phase 1/2 trial of Perifosine in the Treatment of Non-Small Cell Lung Cancer.~Perifosine dosage:~Arm A: 50 mg p.o. 3 times daily with meals. Arm B: 150 mg p.o. daily at bedtime. Arm C: 300 mg p.o. 3 times a day (900 mg) once a week."
88966997|NCT00847366|Experimental|Perifosine 206|"Perifosine 206: A Randomized Phase II Trial of Three Doses of Perifosine in Combination with Trastuzumab.~Arm A: Perifosine 50 mg p.o. daily + 6 mg/kg Trastuzumab on day 1 of a 21-day cycle or 2 mg/kg on days 1, 8 and 15 of a 21 day cycle.~Arm B: Perifosine 50 mg p.o three times a day + 6 mg/kg Trastuzumab on day 1 of a 21-day cycle or 2 mg/kg on days 1, 8 and 15 of a 21 day cycle.~Arm C: Perifosine 300 mg three times on one day + 6 mg/kg Trastuzumab on day 1 of a 21-day cycle or 2 mg/kg on days 1, 8 and 15 of a 21 day cycle."
88966998|NCT00847366|Experimental|Perifosine 207|Perifosine 207: a Phase IIA Trial of Two Schedules of Perifosine Arm A: 50 mg daily with food. Arm B: 50 mg twice daily with food.
88966999|NCT00847366|Experimental|Perifosine 208|Perifosine 208: A Phase II Trial of Two Schedules of Perifosine in Combination with Endocrine Therapy (Tamoxifen) for Patients with Estrogen Receptor or Progesterone Receptor Positive Metastatic Breast Cancer Dosage: Arm A: 50 mg Perifosine /day p.o. .Endocrine therapy continued at same dose and schedule. Arm B: 900 Perifosine weekly. Endocrine therapy continued at same dose and schedule.
89561032|NCT02330107|Experimental|Treatment arm 2|Subjects will receive a combined approach that includes the use of MAT and LA. A laser device (Pointer Pulse™) will be used in this study. This device has a wavelength of 650 nm, an average output power of 2.5 mW, an energy density of 1 minute with 0.54 J/cm2, and a pulse of 10 Hz, which is a common acceptable dosage for clinical use (King et al., 1990; Round et al., 2013). This application is a low-energy laser therapy (LLLT), in which the energy level emitted from the device is approximately comparable to a teaching pointer. A 1-minute treatment using the continuous mode of the device will be directly applied to the reactive region of each of the six selected acupoints on the ear. Laser protective goggles will be provided to the subjects and the researchers for eye protection.
88967000|NCT00847366|Experimental|Perifosine 209|Perifosine 209: A Phase II Trial of Perifosine in Patients with Sarcomas. Perifosine 900 mg weekly (This dose should be divided so that the maximum dose rate is 300 mg in any 4-hour interval).
89208497|NCT02598011|Experimental|Toca 511/Toca FC at 170 mg/kg/day|"Toca 511: 4 mL administered by intracranial parenchymal injection into the walls of the resection cavity following tumor resection or, for those subjects who are not candidates for resection, via stereotactic injection into their tumor using a standard Nashold-type side cutting biopsy needle.~Toca FC: Approximately 4 to 6 weeks after tumor resection, subjects will begin temozolomide concurrent with radiation therapy. During concurrent chemoradiation at the start of the second and sixth week of concurrent chemoradiation and every 28 days thereafter, a 7-day course of oral Toca FC will be dosed at 170 mg/kg/day"
89561033|NCT02330107|Placebo Comparator|Treatment arm 3|"Subjects will serve as a placebo control and will receive LA at power off mode (i.e. deactivated laser) for acupoint stimulation before the application of plasters centred with a small portion of Junci Medulla (mimicking the MAT treatment)."
88967003|NCT00847327|Experimental|Parental Support|
88967004|NCT00847327|Active Comparator|Diabetes Education|
88967005|NCT00847288|Experimental|Monthly Review Arm|Patients enrolled at centers that are assigned to the monthly review arm will have their device data reviewed monthly
88967006|NCT00847288|Active Comparator|Quarterly Review Arm|Patients enrolled at centers that are assigned to the quarterly review arm will have their device data reviewed every 3 months
88967007|NCT00847249|Experimental|1|Solution for nebulisation, inhaled
88967008|NCT00847249|Placebo Comparator|2|Solution for nebulisation, inhaled
88967009|NCT03969641|Experimental|RIV4|The first recombinant inactivated influenza vaccine (RIV) using an insect baculovirus expression system and recombinant DNA technology
88967010|NCT03969641|Active Comparator|IIV4|Standard inactivated influenza vaccine (IIV) manufactured involving the use of embryonated hen eggs.
89027047|NCT01248117|Experimental|Treatment-Naive|Treatment-Naive: no previous treatment for PCV
89027048|NCT00479141|Experimental|1|HIV infected participants and their families
89027049|NCT00479141|Experimental|2|Popular Opinion Leaders (POL) participants
89561034|NCT02330185|Experimental|spinal anesthesia for knee arthroscopy|The intervention is spinal anesthesia. Tenth rib line or Tuffier's line will be examined as application landmarks by ultrasonography for spinal anesthesia.
89561035|NCT03143725|Experimental|Treatment A|GLPG1972 oral solution after overnight fast
89561036|NCT03143725|Experimental|Treatment B|GLPG1972 oral DC tablet after breakfast
89561037|NCT03143725|Experimental|Treatment C|GLPG1972 oral WG tablet after overnight fast
89561038|NCT03143725|Experimental|Treatment D|GLPG1972 oral WG tablet after breakfast
89561039|NCT04988971|Experimental|Group C|during the current cycle of chemotherapy (need to be the same regimens as the previous cycle of chemotherapy, the same dose), patients take a compound glutamine capsules, from the first day of chemotherapy, orally 3 times a day after meals, 3 tablets each time, the course of treatment is 3 weeks.
88967011|NCT00847210|Experimental|Dexlansoprazole MR 30 mg QD|
88967012|NCT00847210|Experimental|Dexlansoprazole MR 60 mg QD|
88967013|NCT00847171|Experimental|Trastuzumab, Cyclophosphamide, and a Breast Tumor Vaccine|Participants receive Trastuzumab (T), Cyclophosphamide (CY), and an allogeneic GM-CSF-secreting whole cell breast cancer vaccine
88967014|NCT05314608||Subjects with subchondral bone pathology|Subjects with subchondral bone pathology
88967015|NCT00847093|Experimental|Cream|Experimental group receiving either medicated topical cream or placebo cream
88967016|NCT04733482|No Intervention|Control group|Participants in the control group received usual care during adjuvant chemotherapy. The usual care consisted of written information and verbal guidance on the adverse effects of chemotherapy and related psychological reactions.
88967017|NCT04733482|Experimental|Cosmetic care group|Participants in the intervention group received cosmetic care in combination with usual care. The cosmetic care was a 3-hour, free-of-charge beauty activity, including face moisturizing steps, make-up, wigs, and breast prostheses wearing. It was provided by professional cosmeticians at a cosmetic training base before the patients finished half of their chemotherapy cycle.
88967018|NCT05313633|Experimental|Wii group|Children in this group will receive a designed physical therapy and occupational therapy programs prescribed individually for each child based on the functional capacity of each child (each program lasted for 30 minutes). Additionally, a 30- minute rest period will be implemented before receiving the allocated intervention. This group will receive a Wii training program for 45 minutes The treatment will be implemented three sessions a week for three months period.
88967019|NCT05313633|Experimental|plyometric group|Children in this group will receive a designed physical therapy and occupational therapy programs prescribed individually for each child based on the functional capacity of each child (each program lasted for 30 minutes). Additionally, a 30- minute rest period will be implemented before receiving the allocated intervention. This group will receive a plyometric training program for 45 minutes The treatment will be implemented three sessions a week for three months period.
88967020|NCT04733248|Active Comparator|Kinesiotaping group|Hot pack, Tens, stretching exercises, Kinesiotaping (I-O) and Home plan
88967021|NCT04733248|Experimental|stretching group|Hot pack, Tens, stretching exercises and Home plan
88967022|NCT00847054|Experimental|MORAb-004|
88967023|NCT00846976|Experimental|200 mg Casodex|
89561040|NCT04988971|Placebo Comparator|Group D|during the current cycle of chemotherapy (need to be the same regimens as the previous cycle of chemotherapy, the same dose), patients take a compound glutamine capsule simulated placebo, from the first day of chemotherapy, orally 3 times a day after meals, 3 tablets each time, the course of treatment is 3 weeks.
88967024|NCT03147768|Experimental|Distal Pancreatectomy Sealing using LTW|At the completion of pancreatic resection, the cut surface of the pancreas is covered with two layers of Albu-Green solder and one layer of D-Albumin lamina, all welded with the laser. The 60 Watt custom 810nm diode laser, is set to deliver continuous energy with laser irradiation power of approximately 150 W/cm2 with a Fluence of 90 J/cm2. During soldering the tip of the custom hand piece with top hat beam profile is held 1-2 cm from the wound surface to generate a 5mm spot size. Albu-Green Solder is observed to convert from a liquid green state to a solid white crust when the laser is activated indicating the completion of welding and providing a visual cue to the operator. The amount of Albu-Green solder and size of the denatured albumin lamina used is documented. The total laser tissue welding time for the three layers and the laser tissue welding time in seconds per cm2 is documented.
88967025|NCT00846898|Experimental|cinnamon|Subjects in this group will receive cinnamon capsules for 12 weeks period. The 2 g dose of cinnamon will be spread over the day as 500 mg (1 capsule) after breakfast, 1000 mg (2 capsules) after lunch and 500 mg (1 capsule) after dinner. The subjects will be instructed to take the capsules immediately after the meals.
88967026|NCT00846898|Placebo Comparator|Control|Subjects in this group will receive placebo capsules (starch flour) for 12 weeks period. The 2 g dose of starch capsules will be spread over the day as 500 mg (1 capsule) after breakfast, 1000 mg (2 capsules) after lunch and 500 mg (1 capsule) after dinner. The subjects will be instructed to take the capsules immediately after the meals.
88967027|NCT00846859|Experimental|varenicline|
88967028|NCT00846859|Placebo Comparator|placebo|
88967029|NCT03885830||Bosutinib|Subjects who have been prescribed or administered bosutinib (Bosulif) for treatment of chronic-phase CML for less than 12 months.
88967030|NCT03885830||Dasatinib|Subjects who have been prescribed or administered dasatinib (Sprycel) for treatment of chronic-phase CML for less than 12 months.
89561041|NCT03076619||Clinical ophthalmoscopy in PIH|"An observational study in which the patients for the study are selected from antenatal clinic, antenatal ward and preeclampsia and eclampsia room in Department of Obstetrics and Gynecology and general ophthalmic OPD in case of ambulatory patients during the period of November 2003 to June 2006 randomly."
89561042|NCT02329873|Experimental|Experimental group|Respiratory rehabilitation exercise training 2 times/day, 10-30 minutes per session for 4 days.
89561043|NCT02329873|No Intervention|Control group|Control group received usual care and health education.
89561044|NCT05003219||ERAS group|patients received posterior cervical open-door laminoplasty under ERAS mode
89561045|NCT05003219||Conventional group|patients received posterior cervical open-door laminoplasty under routine perioperative management mode
89561046|NCT03143881|Experimental|Intervention|Intervention patients will receive personalized education regarding their condition, pre- and post-testing of their HF knowledge base, and ED standard of care during the enrollment (index) visit. Patients will then be contacted via telephone 30 days post-index visit for re-testing and reinforcement of previously learned material.
89561047|NCT03143881|No Intervention|Control|Control patients will receive ED standard of care.
89561048|NCT03076541||patients with restless legs syndrome|
88967031|NCT03885830||Imatinib|Subjects who have been prescribed or administered imatinib (Gleevec) for treatment of chronic-phase CML for less than 12 months.
89561049|NCT04931875||Total-body PET/CT (uExplorer)|The diagnostic value of dynamic parameters(K1、Ki etc) to evaluate the prognosis of lymphoma compared to the static ones(SUV、MTV、TLG etc).
89561050|NCT03076463|Experimental|GRAPOM|Daily consumption for 6 weeks of 10 g of dried and milled grape pomaces solved in water. Samples will be collected at the beginning and the end of this period
89561051|NCT03076463|No Intervention|CTR|Follow-up for 6 weeks without intervention. Samples will be collected at the beginning and the end of this period
89561052|NCT02329795||Standard chemoradiotherapy|Group to receive 60 Gy radiotherapy in 30 fractions with concomitant and adjuvant temozolomide.
88967032|NCT03885830||Nilotinib|Subjects who have been prescribed or administered nilotinib (Tasigna) for treatment of chronic-phase CML for less than 12 months.
88967033|NCT00846781|Experimental|Denufosol tetrasodium Inhalation Solution|
88967034|NCT00846703|Active Comparator|Protocol A (MM)|
88967035|NCT00846703|Experimental|Protocol B (MM/VD)|
88967036|NCT00846664|Experimental|Group 1|Group 1 wil perform short arc banding twice a week for four weeks and have diagnostic ultrasound of multifidus measured before and after intervention
88967037|NCT03772964|Experimental|500mg exposure|Subjects will be exposed to 500mg of daily MetFORMIN Hydrochloride ER for up to 90 days.
88967038|NCT03772964|Experimental|1000mg exposure|Subjects will be exposed to 1000mg of daily MetFORMIN Hydrochloride ER for up to 90 days.
88967039|NCT03772964|Experimental|1500mg exposure|Subjects will be exposed to 1500mg of daily MetFORMIN Hydrochloride ER for up to 90 days.
88967040|NCT03772964|Placebo Comparator|Placebo|Subjects will be exposed to placebo for up to 90 days.
88967041|NCT00846625|Experimental|1|Ranibizumab (0.5 mg)
88967042|NCT00846625|Active Comparator|2|Triamcinolone (4 mg/0.1 ml)
88967043|NCT00846547|Experimental|Arbaclofen|
88967044|NCT00846508|Experimental|ciaplantin,cancer,survival|
89561053|NCT05002907||General adult population living along the Maroni River in French Guiana and Suriname|General adult population living along the Maroni River in French Guiana and Suriname, upstream from Apatou. All adults (men and women) 18 years or older of both sexes will be able to participate in the study, in French Guiana and Suriname. Participation will be based on volunteering and signing informed consent. The acceptability and diversity of recruitment will be improved by seeking community support through community leaders and local associations and through appropriate communication (radio spots, posters in health centers and public establishments) before the survey .
89561054|NCT02329561|Active Comparator|Tramadol extended release and CP/T|Tramadol extended release: 200mg Single-dose, extended-release, once-daily, tablet; Current Perception and Tolerance (CP/T)
88967045|NCT00394030|Experimental|Group A|In Group A healthy subjects will be randomized to receive 16 milligram (mg) of GSK716155 to abdomen.
88967046|NCT00394030|Experimental|Group B|In Group B healthy subjects will be randomized to receive 64 mg of GSK716155 to abdomen.
88967047|NCT00394030|Experimental|Group C|In Group C Type II diabetes subjects will be randomized to receive 16 mg of GSK716155 to abdomen.
88967048|NCT00394030|Experimental|Group D|In Group D Type II diabetes subjects will be randomized to receive 16 mg of GSK716155 to arm.
89561055|NCT02329561|Placebo Comparator|Placebo and CP/T|Single-dose, placebo identical in appearance to an extended release once-daily tablet; Current Perception and Tolerance (CP/T)
88967049|NCT00394030|Experimental|Group E|In Group E Type II diabetes subjects will be randomized to receive 16 mg of GSK716155 to leg.
88967050|NCT00394030|Experimental|Group F|In Group F Type II diabetes subjects will be randomized to receive 64 mg of GSK716155 to abdomen.
88967051|NCT00394030|Experimental|Group G|In Group G Type II diabetes subjects will be randomized to receive 64 mg of GSK716155 to arm.
89561056|NCT05000879|Experimental|MMB for Moms|Subjects will receive digital delivery of Mindful Mood Balance for Moms for 12 weeks. Subjects will be unconstrained in the types of treatments or other wellness activities they could receive while participating in the study.
89561057|NCT05000879|No Intervention|Waitlist Control|Subjects will be unconstrained in the types of treatments or other wellness activities they could receive while participating in the study.
89561058|NCT02329639||case group|genetic interaction analysis of women with HER2 negative metastatic breast cancer performing a first-line chemotherapy with bevacizumab
89561059|NCT02329639||control group|genetic interaction analysis of women with HER2 negative metastatic breast cancer performing a first-line chemotherapy without bevacizumab
89561060|NCT05003063|Active Comparator|Donepezil|5mg Donepezil will be administered in pill form.
89561061|NCT05003063|Placebo Comparator|Placebo|5mg placebo will be administered in pill form.
89561062|NCT03143491|Experimental|SOR007 0.15%|1 mL of 0.15% SOR007 Ointment
89561063|NCT03143491|Experimental|SOR007 1.0%|1 mL of 1.0% SOR007 Ointment
89561064|NCT03143491|Experimental|SOR007 2.0%|1 mL of 2.0% SOR007 Ointment
89561065|NCT05002673|Experimental|SLEEPERONE|
89561066|NCT05002673|Experimental|COMFORTIN|
89561067|NCT02329717|Experimental|PBI 05204|PBI 05204 capsules dosed at 0.2255 mg/kg/day, continuous dosing
89561068|NCT05001035|Experimental|Zinc carbonated hydroxy apatite|Toothpaste to be added on white spot lesions in dental enamel
89561069|NCT05001035|Experimental|Bioactive glass|Toothpaste to be added on white spot lesions in dental enamel
88967052|NCT00394030|Experimental|Group H|In Group H Type II diabetes subjects will be randomized to receive 64 mg of GSK716155 to leg.
88967053|NCT05291949|Experimental|ATLASense RAPHAEL monitoring|All patients receive monitoring by ATLASense RAPHAEL PolyMonitor for duration of surgery.
88967054|NCT00846469|Experimental|chest pain|CCTA (Coronary computed tomography angiography)
88967055|NCT00846352|Active Comparator|Early Bronch|This group will receive bronchoscopy within 36 hours of enrollment into the study.
88967056|NCT00846352|Active Comparator|Late bronch|This group will receive bronchoscopy within 5 days of enrollment.
88967057|NCT05288985|Experimental|Erector spinae plane catheter group in addition to Systemic Analgesia|
88967058|NCT05288985|Active Comparator|Systemic Analgesia Only Group|
88967059|NCT00846274|Active Comparator|Antithrombin III|
88967060|NCT00846274|Experimental|SK Antithrombin III|
88967061|NCT00846235|Experimental|Moisturising cream|
88967062|NCT00846196|Experimental|2|one commercial risedronate 35 mg DR tablet
88967063|NCT00846196|Active Comparator|1|one Phase III risedronate 35 mg DR tablet
88967064|NCT00846157|No Intervention|control|Rituximab 375mg/m2 IV administered on day 1. Cyclophosphamide 750mg/m2 IV for 2hours,Adriamycin 50mg/m2 ,Vincristine 1.4mg/m2 IV respectively. Prednisone 60mg P.O. per day for 5 days.
89561070|NCT05001035|Experimental|Poly amido amine|Resinous material to be painted on white spot lesions in dental enamel
89561071|NCT05001035|No Intervention|Control|No material to be added
89561072|NCT03076151|Experimental|Tacrolimus monohydrate (ADOPORT®)|patients with de novo Kidney Transplantation under Tacrolimus (ADOPORT®) treatment.
89561073|NCT05032651|Experimental|GROUP A-AI (model) Arm Description:|Artificial intelligence assisted platform supported system for the clinical physicians to prescribe ESA dose to maintain hemoglobin at the treatment target of 10 g/dl to 12 g/dl.
89561074|NCT05032651|Experimental|GROUP B-AI (model) Arm Description:|ESA dose prescribed by clinical physicians as regular care to maintain hemoglobin at the treatment target of 10 g/dl to 12 g/dl.
89561075|NCT02329483||High responder infertile patients|Ovarian high responder patients who are being planned for low-dose step-up protocol ovulation induction and intrauterine insemination.
89561076|NCT05002517|Experimental|Tociliziumab group|Patients assigned to this arm will receive an intravenous dose of tocilizumab. Patients weighing 75 kg or more will receive 600 mg. Those weighing less than 75 kg will receive 400 mg.
89561077|NCT05002517|Active Comparator|Metilprednisolone group|Patients in this arm will receive a daily intravenous dose of 250 mg methylprednisolone for 3 days.
89561078|NCT03473275||1: control|"Healthy normotensive participants. Cold pressor test on feet 3 times for 40 seconds during brain BOLD fMRI (2 runs), renal ultrasound and contrast-enhanced ultrasound.~PinPrick test on feet 3 times for 40 seconds during brain BOLD fMRI (2 runs), renal ultrasound and contrast-enhanced ultrasound."
89561079|NCT03473275||2: untreated hypertensive|"Untreated (or off antihypertensive drugs) hypertensive patients (ABPM proven essential hypertension).~Cold pressor test on feet 3 times for 40 seconds during BOLD fMRI (2 runs), renal ultrasound and contrast-enhanced ultrasound."
89561080|NCT03473275||3. resistant hypertensive|"Patients with proven resistant hypertension and not renal denervated or for whom a renal denervation is planned according to the criteria of the CHUV.~Cold pressor test on feet 3 times for 40 seconds during BOLD fMRI (2 runs), renal ultrasound and contrast-enhanced ultrasound."
89561081|NCT03473275||4. renal denervation|Patients with a renal denervation. Cold pressor test on feet 3 times for 40 seconds during BOLD fMRI (2 runs), renal ultrasound and contrast-enhanced ultrasound.
89561082|NCT05002205||COVID-19|exposed cohort with a diagnosis of COVID-19 in the last 6 months
89561083|NCT05002205||no history of COVID-19|non-exposed cohort without a diagnosis of COVID-19. Tested for COVID-19 because of symptoms at the same time (+/- 1 month) as the exposed cohort.
89561084|NCT05002361|Active Comparator|Treatment A+B|24 mg dexamethasone i.v. perioperatively
89561085|NCT05002361|Placebo Comparator|Placebo|Placebo (isotonic saline) i.v. perioperatively
89561086|NCT02329405|Experimental|Rifampicin|Rifampicin 600 mg tablet once a day orally for a week.
89561087|NCT02329405|Placebo Comparator|Placebo|Placebo tablet once a day orally for a week.
89561088|NCT05002283|Experimental|Study group|the patients undergo free gingival graft harvest from the palate using a patient specific guide
89561089|NCT02329171|Experimental|Imiquimod treatment arm|Patients in this group will be treated with imiquimod during 16 weeks. Colposcopy with diagnostic biopsies will be performed after 10 weeks. In case of progressive disease, the treatment will be ended and appropriate surgical excision will be performed. Treatment efficacy will be evaluated after 20 weeks, by colposcopy with diagnostic biopsies.
89561090|NCT02329171|Active Comparator|Standard treatment arm|Large loop excision of the transformation zone (LLETZ) will be performed in this group, as standard treatment.
89561091|NCT05001971|Experimental|Anlotinib Plus Penpulimab|Anlotinib (10mg qd po d1-14, 21 days per cycle) and Penpulimab (200mg ivgtt d1)
89561092|NCT05000801|Experimental|DC vaccine|Vaccination with autologous or HLA-matched donors' WT1/TERT/survivin loaded DCs plus follow-up care.
89561093|NCT02329093|Experimental|Bone Signal Changes|
89561094|NCT02329249|Experimental|Smokefree Partners: 21 Days to Freedom|Smoking cessation website program with live personal coach
89561095|NCT02329249|Other|Wait-list control|120-day wait-list and then provided access to the smoking cessation website
89561096|NCT05001893||The use of a mixture of BonAlive® putty and autologous bone|A retrospective case-controlled study will be created to compare the use of a mixture of BonAlive® putty and autologous bone to autologous bone alone for clinical safety and efficacy.
89561097|NCT03143335|Active Comparator|Retropectoral immediate breast reconstruction|Participants are randomized to immediate breast reconstruction with the implant placed retropectoral.
89561098|NCT03143335|Active Comparator|Prepectoral immediate breast reconstruction|Participants are randomized to direct to immediate breast reconstruction with the implant placed prepectoral using acellular dermal matrix for support.
89561099|NCT05001659|Other|computer simulator|training students ACLS by one computer simulator
89561100|NCT05001659|Other|mannequin simulator|training students ACLS by one mannequin simulator
89561101|NCT02328781|Experimental|Experimental|Drug-eluting stent
88967065|NCT00846157|Active Comparator|Active|R-CHOP plus Natural Killer Cell therapy
88967066|NCT00846118|Active Comparator|Pitavastatin|Pitavastatin in addition to optimal standard care
88967067|NCT00846118|No Intervention|optimal standard care|
88967068|NCT00846001|Active Comparator|CABG alone|Standard coronary artery bypass grafting according guidelines
88967069|NCT00846001|Experimental|CABG+CRT|Standard coronary artery bypass grafting according guidelines with concomitant three bipolar epicardial leads implantation for cardiac resynchronization therapy
88967070|NCT03651401||rotator cuff related shoulder pain|Participants were assessed for SME, pain (rest, activity, night, measurement), and upper extremity function (FIT-HaNSA).
88967071|NCT03651401||age gender matched healthy controls|Participants were assessed for SME, and upper extremity function (FIT-HaNSA).
88967072|NCT00845962|Active Comparator|Chloroprocaine|
88967073|NCT00845962|Active Comparator|Bupivacaine|
88967074|NCT00845923|Other|Civamide Patch 0.015%|All subjects in study will receive the Civamide Patch 0.015%
88967075|NCT03620942|Experimental|ADIVA system|Vasopressor delivery automated system administering phenylephrine and ephedrine using a three-step algorithm vasopressor delivery technique
88967076|NCT03620942|Active Comparator|DIVA system|Vasopressor delivery automated system administering phenylephrine and ephedrine using a two-step algorithm vasopressor delivery technique
88967077|NCT04711798||Patients receiving cardiac surgery|Patients receiving cardiac surgery will be included. All patients received a passive leg raising maneuver (PLR) for preload status evaluation using the PICCO system, a lung recruitment maneuver (LRM) and an echographic evaluation of the right cardiac function.
88967078|NCT00276991|Other|"Kallunk oxide (Immunotherapy)"|"The participants were received a daily regimen of Kallunk oxide(Immunotherapy) ."
88967079|NCT00276874|Experimental|Aripiprazole|Subjects receive oral aripiprazole.
88967080|NCT00276874|Placebo Comparator|Placebo|Subjects receive oral placebo
88967081|NCT00276835|Experimental|Genistein and Interleukin-2|
88967082|NCT00276523|Active Comparator|Control|Control (no treatment), conventional surgery.
88967083|NCT00276523|Experimental|PEG-Intron 0.5 mg/kg|PEG-interferon alfa-2b 0.5 mg/kg subcutaneously (SQ) once a week for 3 weeks, plus surgery.
88967084|NCT00276523|Experimental|PEG-Intron 2.5 mg/kg|PEG-interferon alfa-2b 2.5 mg/kg SQ once a week for 3 weeks, plus surgery.
88967085|NCT00276523|Experimental|PEG-Intron 5.0 mg/kg|PEG-interferon Alfa-2b 5 mg/kg SQ once a week for 3 weeks, plus surgery.
88967086|NCT05198778|Experimental|Test group 1: Renal impairment patient|Administer URC102, single-dose
88967087|NCT05198778|Experimental|Test group 2: Renal impairment patient|Administer URC102, single-dose
88967088|NCT05198778|Experimental|Control group: Healthy adult people|Administer URC102, 2 doses
88967089|NCT00276406|Experimental|Pyridostigmine|Oral pyridostigmine, starting with 60 mg capsules three times per day (TID), increasing by 60 mg every third day (i.e., over 10 days) up to the maximum tolerated dose or 120 mg TID (a total of 360 mg per day). This dose was maintained for 7 days.
88967090|NCT00276406|Placebo Comparator|Placebo|Placebo (sham) capsules, matching the appearance of the active drug comparator and taken TID.
88967091|NCT00389883|Active Comparator|1|propofol et remifentanil
89561102|NCT05000099||phone calls|patients choosing phone calls as preferred communication technique
89561103|NCT05000099||video call|patients choosing video calls as preferred communication technique
88967092|NCT00389883|Experimental|2|sevoflurane et sufentanil
88967093|NCT00389922|Experimental|A (Daily Dosing)|"Oral lapatinib given daily for 28 days plus IV vinorelbine given weekly (3 out of 4 weeks)~Cohorts of 3-6 patients receive escalating doses of lapatinib ditosylate until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity during course 1. At least 6 patients are treated at the MTD. Once the MTD of lapatinib has been determined, patients may be accrued to group B or to a separate pharmacokinetics cohort in group A."
88967094|NCT00389922|Experimental|B (Intermittent Dosing)|"Oral lapatinib given days 2-5, 9-12 and 16-25 plus IV vinorelbine given weekly (3 out of 4 weeks)~Cohorts of 3-6 patients receive escalating doses of lapatinib ditosylate until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity during course 1. At least 6 patients are treated at the MTD. Once the MTD of lapatinib has been determined, patients may be accrued to group B or to a separate pharmacokinetics cohort in group A."
88967095|NCT00276250|Experimental|Efalizumab Followed by Abatacept Regimen|Participants with Type 1 diabetes with onset of disease at < 40 years of age and insulin-dependence for > 5 years received efalizumab-based immunosuppression regimen after islet-cell transplantation. During the course of the study, efalizumab was withdrawn from the US market due to safety concerns. The protocol was subsequently amended to alter the immunosuppressive regimen to abatacept for these participants.
88967096|NCT00276250|Experimental|Abatacept Regimen|Participants with Type 1 diabetes with onset of disease at < 40 years of age and insulin-dependence for > 5 years received abatacept immunosuppresion regimen after islet-cell transplantation.
88967097|NCT00276250|Experimental|Belatacept Regimen|Participants with Type 1 diabetes with onset of disease at < 40 years of age and insulin-dependence for > 5 years received Belatacept immunosuppresion regimen after islet-cell transplantation.
88967098|NCT03813290|Experimental|Neuro-Technological Intervention|"Participants will attend a total of 8 x 30 minutes intervention sessions (twice a week) for four consecutive weeks, starting within 1 week after baseline assessment.~Participants will also be required to fill up some questionnaires at baseline and post-intervention visits."
88967099|NCT00276172|Experimental|Natalizumab|Open-label natalizumab
88967100|NCT03230006|Active Comparator|Unified Protocol|The Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (UP) consists of 5 core skills modules based on cognitive behavioral treatment elements of proven effectiveness. As noted above, these core skills modules were designed to target (and have been shown to address) negative emotionality and aversive reactivity to emotional experiences when they occur (Boswell et al., 2013; Carl et al., 2014; Sauer-Zavala et al., 2012). These modules are preceded by an introductory session that reviews the patient's presenting symptoms and provides a therapeutic rationale, as well as a module on motivational enhancement. A final module consists of relapse prevention. As the treatment proceeds, the domains of thoughts, feelings, and behaviors are each explored in detail, focusing specifically on elucidating dysfunctional emotion regulation strategies that the patient has developed over time within each of these domains, and teaching patients more adaptive emotion regulation skills.
88967101|NCT03230006|Placebo Comparator|Take Control|TC is a psychotherapy platform derived from the National Institute on Alcohol Abuse and Alcoholism's (NIAAA) self-help approach, Rethinking Drinking. In this study, TC, originally designed as a computerized treatment has been modified to be administered by the therapist to control for effects that may be related to patient-therapist interaction (as opposed to elements of the treatment itself). Specifically, on a weekly basis, therapists will review material from TC and offer general advice on implementation of the alcohol reduction skills in daily life.
88967102|NCT00276055|Experimental|Cohort 1|1000mg/m2 gemcitabine
88967103|NCT00276055|Experimental|Cohort 2|1250 mg/m2 gemcitabine
88967104|NCT00276055|Experimental|Cohort 3|1500 mg/m2 gemcitabine
89561104|NCT05000255|Experimental|Intervention 1: According to DGP|For the first group, a psychological intervention for psychoeducational measures and psychosocial support, was designed according to the recommendations of the DGP - Deutsche Gesellschaft für Pneumologie und Beatmungsmedizin e.V. for the rehabilitation of post-COVID-19 patients (DGP, 2020). The interventions start approximately two days after data collection at T0. The second measurement time point (T1) is scheduled at the time of patient discharge after the interventions have been implemented. Only patients who scored 8 or higher on the Hospital Anxiety and Depression Scale (HADS) at admission will participate in the interventions. This psychological intervention will be applied to both groups of patients (non-Covid/Covid patients)
89561105|NCT05000255|Active Comparator|"Intervention 2: According to Cacioppo E.A.S.E."|The second intervention was designed after Cacioppo's intervention EASE, for processing loneliness. This psychological intervention will be applied to both groups of patients (non-Covid/Covid patients), too. The interventions start approximately two days after data collection at T0. The second measurement time point (T1) is scheduled at the time of patient discharge after the interventions have been implemented. Only patients who scored 8 or higher on the Hospital Anxiety and Depression Scale (HADS) at admission will participate in the interventions.
89561106|NCT05000255|No Intervention|Care as Usual; Standard psychological Support|The patients receive standard care from the psychologists, as is usual in this unit. No intervention is carried out.
89561107|NCT04498741|Experimental|EDP-938 and tacrolimus interaction (Part 1)|
88967105|NCT03226028|Experimental|Music|"The recruiter will give the patient an ipod with earphone, in which the ipod is equipped with saved playlists of different music genres. Patient will choose the desired playlists and listen to the music for about 30 minutes, seated in a quiet environment in pre-operative waiting area before her turn for the scheduled surgery. Hospital Anxiety and Depression Scale (HADS) and EQ-5D-3L questionnaire will be conducted during this period.~Patient will be sent to the recovery room after the surgery, and will start the music listening again for 30 minutes once she is ready and feel comfortable to start the session. Pain score, HADS and EQ-5D-3L will be collected from the patient, as well as interview on her satisfaction and experience on the music listening."
88967106|NCT05149599|Experimental|Treated patients|
88967107|NCT00276640|Active Comparator|vincristine, carboplatin|standard chemotherapy group
88967108|NCT00276640|Active Comparator|vincristine, carboplatin, etoposide|intensified induction chemotherapy group
88967109|NCT00276640|Active Comparator|radiation|radiation therapy group
89561108|NCT04498741|Experimental|EDP-938 and dabigatran interaction (Part 2)|
88967110|NCT00276640|No Intervention|Control|Control group: wait and see strategy
88967111|NCT00275548|Other|The Preventative (Prophylaxis) Group:|This group of patients will receive study drugs for the treatment of recurring (or returning) hepatitis C before they actually develop clinical symptoms of hepatitis C.
88967112|NCT00275548|Other|The Observational Group:|This group of patients will receive the study drugs for the treatment of recurring hepatitis C only if they develop the clinical symptoms of hepatitis C infection.
88967113|NCT05567107|Experimental|experimental group: applied foot massage|Scales were applied preoperative to the patients. After being discharged from the intensive care unit in the postoperative period, the scales were applied without any intervention on the first day of hospitalization (day 0). Pain intensity was evaluated according to the Visual Comparison Pain Scale and classical foot massage was applied to patients who stated that they had 4 or more pain. After leaving the intensive care unit in the postoperative period, the scales were applied on the 2nd day (day 1) when the patient came to the service. After the scales, foot massage was applied again. After leaving the intensive care unit in the postoperative period, the scales were applied on the third day (day 2) when the patient came to the service. After the scales, foot massage was applied again. After the patient was discharged from the intensive care unit in the postoperative period, the scales were applied on the fourth day (3rd day) when they came to the service.
89561109|NCT04498741|Experimental|EDP-938 and rosuvastatin interaction (Part 3)|
89561110|NCT04498741|Experimental|EDP-938 and midazolam interaction (Part 4)|
89561111|NCT04999943|Active Comparator|Hypomemylating agent monotherapy|Azacitidine 100mg/ times. d × for 10 days (28 days for one cycle) or Decitabine 25mg/ times. d × 5 days ( 28 days is one cycle)
88967114|NCT05567107|No Intervention|control group: unapplied foot massage|Each data collection tool was collected without applying foot massage, as in the experimental group patients. While the patients in the control group received only analgesic treatment postoperatively, the patients in the experimental group received foot massage in addition to the analgesic treatment. Only routine nursing care was given to the patients in the control group postoperatively.
88967115|NCT05566990|Experimental|LIV-GAMMA SN Inj.10%|
88967116|NCT05559970|Active Comparator|Conventional sedation|Conventional sedation receiving analgosedation with fentanyl
88967117|NCT05559970|Experimental|Inhalational sedation|Inhalational sedation receiving isoflurane for sedation for 12 hours
88967118|NCT05140746|Experimental|PET/CT for prediction of NAC efficacy|68Ga-FAPI-04 PET/CT and 18F-FDG PET/CT will be scanned before, during or after NAC.
88967119|NCT05495971|Experimental|Presbyopia|Subject's baseline vision will be compared with vision wearing treatment product
88967120|NCT05132205|Experimental|Radiofrequency Ablation|Patients will receive RFA as a one-time intervention, with a possible second treatment after 6 months if adequate resolution is not noted on ultrasound.
89027050|NCT01248156||Intervention|Patients with persistent, long standing persistent and paroxysmal AF, who will receive ablation at sites that potentially maintain human AF.
89561112|NCT04999943|Experimental|Combined cellular immunotherapy（eDC）with Hypomemylating agent therapy|Azacitidine 100mg/ times. d × for 10 days (28 days for one cycle) or Decitabine 25mg/ times. d × 5 days ( 28 days is one cycle) with Dendritic Cell (DC) Vaccination Expressing WT1/hTERT/Survivin
89210587|NCT00159913|Experimental|Sildenafil Low dose|
89561113|NCT04938635|Experimental|VIT-2763 60 mg QD|VIT-2763 60 mg administered once daily
89561114|NCT04938635|Experimental|VIT-2763 60 mg BID|VIT-2763 60 mg administered twice daily
89561115|NCT04938635|Experimental|VIT-2763 120 mg BID|VIT-2763 120 mg administered twice daily
89561116|NCT04938635|Placebo Comparator|Placebo|Placebo capsule administered twice daily
89561117|NCT03551743|Experimental|Module 4 (600 mg bolus)|600 mg PRT064445 given as a single IV bolus
89561118|NCT03551743|Experimental|Module 4 (800 mg bolus + 480 mg infusion) 8mg/min|1280 mg PRT064445: 800 mg IV at ~30 mg/min, followed by a continuous infusion of 480 mg (4 mg /min over 60 minutes)
89561119|NCT03551743|Experimental|Module 4 (800 mg bolus)|800 mg PRT064445 as a single IV bolus
89561120|NCT03551743|Placebo Comparator|Module 4 Placebo|Placebo administered intravenously (IV) as a bolus or a bolus followed by continuous infusion.
89561121|NCT04932395|Experimental|Anshen Buxin Liuwei Pills|15 pills/time, 2 times/day, orally，for 8 weeks
89561122|NCT04932395|Placebo Comparator|Placebo|15 pills/time, 2 times/day, orally. for 8 weeks
89561123|NCT04932239|Experimental|Road traffic crashes first aid education module|It is an education module aiming to address the topics related to first aid: Recognizing emergency, Call for help, Scene safety, Airway and breathing, Haemorrhage control, First aid kit, Immobilization of fractures and transport of injured people.
89561124|NCT04932239|Placebo Comparator|Tuberculosis prevention education module|This education module covers the definition of the disease, types ways of prevention in working place, and its management
89561125|NCT04714879|Experimental|Slow oscillating transcranial direct current stimulation (so-tDCS)|7 experimental daytime naps with so-tDCS of different frequencies (fixed frequency of 0.75 Hz versus individually adapted frequency) and durations (5 min, 2 min, 30 sec) (Crossover assignment, applicable for each participant)
89561126|NCT04714879|Sham Comparator|Sham stimulation|sham so-tDCS during a daytime nap (Crossover assignment, applicable for each participant)
89561127|NCT04698811|Other|VIRTUAL ENEAGRAM: QUALITY OF LIFE, STRESS AND ANXIETY.|Training and testing battery.
89561128|NCT03142399|Experimental|whey protein|The whey protein group will receive whey protein supplementation 30g/day of whey protein during three months (12 weeks)
89561129|NCT03142399|Placebo Comparator|placebo group|The placebo group (maltodextrin) will receive 30g/day of maltodextrin during three months (12 weeks)
89561130|NCT03076307|Experimental|Parkinson's disease|
89561131|NCT03076307|Active Comparator|Control group|
89561132|NCT03076229|Experimental|Healthy Marriage: Treatment|Intervention: Behavioral: Healthy Marriage Program
89561133|NCT03076229|Experimental|Healthy Marriage: Wait-list Control|Intervention: Behavioral: Healthy Marriage Program
89561134|NCT03076073|No Intervention|Evaluating Tendons Structures|Ultrasound measurements of Patellar Tendon and Achilles Tendon Structures
89561135|NCT03076073|Active Comparator|Impact of physical activity on tendons|Ultrasound measurements of Patellar Tendon and Achilles Tendon Structures following different types and different intensity of physical activity
89561136|NCT02328859|Experimental|Virtual reality gait rehabilitation|Subjects will be trained using a custom treadmill with a virtual environment
89561137|NCT02328859|Active Comparator|Treadmill training gait rehabilitation|Subjects wil be trained using a standard treadmill without any visual display
89561138|NCT04993937|Active Comparator|Control group|Control group will follow their daily routine activities.
89561139|NCT04993937|Experimental|Experimental group|Interventional group will receive 6 weeks of plyometric training and receive training for week and three sessions in a week.
89561140|NCT03143257||Subjects|Diagnosed with CHL, SSD and mixed HL who currently have or have had the Sophono implant
89561141|NCT04993547|Experimental|Parents present, peers present|The children are accompanied by their parents during the COVID-19 testing, and a visible covid-19 swab test waiting line is set-up enabling the children to observe their peers being tested.
89561142|NCT04993547|Active Comparator|Parent present, peers absent|The children are also accompanied by their parents, but a covered COVID-19 swab test waiting line is set-up whereby the children are unable to observe their peers being tested.
89561143|NCT04993547|Active Comparator|Parents absent, peers present|Parents are absent during the COVID-19 testing, and a visible COVID-19 swab test waiting line is set-up enabling the children to observe their peers being tested.
89561144|NCT04993547|Active Comparator|Parents absent, peers absent|Parents are absent, and a covered COVID-19 swab test waiting line is set-up whereby the children are not able to observe their peers being tested.
88967121|NCT05464732|Experimental|Monovision|"The target refraction is plano (0.00 D) for the dominant eye and between -0.50 D and -0.75 D for the non-dominant eye. The Vivity IOL will be implanted bilaterally.~Corrected vision will involve correcting the dominant eye for emmetropia and the non-dominant eye for -0.50 D."
89561145|NCT04654429|Placebo Comparator|Lower OT temperature with placebo (LP)|Lower OT temperature with placebo This group function as a main control arm. Incidence of PSS will be documented usual / standard OT temperature which is 17-19 degree celsius, and without giving any pharmacological intervention to prevent PSS.
89561146|NCT04654429|Active Comparator|Higher OT temperature with placebo (HP)|Higher OT temperature with placebo This group will receive one non-pharmacological intervention, which is higher OT temperature 19-22 degree celsius. The aim of this intervention is to reduce heat loss therefore incidence of PSS for obstetric population coming for lower segment cesarean section (LSCS) by reducing the temperature gradient between the body and environment.
89561147|NCT04654429|Active Comparator|Lower OT temperature with IV Ondansetron 4mg (LO)|Lower OT temperature with Ondansetron 4mg intravenous. This group also will receive one pharmacological intervention, which is IV ondansetron 4mg to prevent incidence of PSS under standard OT temperature 17-19 degrees.
89561148|NCT04654429|Active Comparator|higher OT temperature 19-22 and IV ondansetron 4mg (HO)|This group will receive 2 interventions - higher OT temperature 19-22 and IV ondansetron 4mg. This group is designed to see if when both intervention combined, will further reduce the incidence of PSS among obstetrics population.
89561149|NCT03075683|Experimental|Cognitive behavioural therapy|Internet-based cognitive behavioural therapy for insomnia
89561150|NCT03075683|Active Comparator|Applied relaxation|Internet-based applied relaxation
89561151|NCT03075995|Experimental|lapatinib administered with hight-fat breakfast|
89561152|NCT04639999||Fabry's disease|Fabry's disease patients who were confirmed by enzyme assay and gene study
89561153|NCT03111355|Experimental|Brazil Nut supplementation|Consumption of one Brazil nut a day for 2 months followed by 2 months without intervention
89561154|NCT03075605||Subjects with acute pancreatitis|Subjects with acute pancreatitis
88967122|NCT05464732|Active Comparator|Emmetropia|Subject's vision will be tested with both eyes corrected for emmetropia.
88967123|NCT05428657|Experimental|Eye-tracking Training Group|EC Brain After-school Program- computerised eye-tracking training program
88967124|NCT05428657|Active Comparator|Conventional Training Group|Conventional intervention program for special educational needs
88967125|NCT05415163|Experimental|vascular photobiomodulation|Laser will be applied with the spot located in the radial artery of the participant's arm (right or left), and fixed to the wrist with a specific bracelet.
88967126|NCT05415163|Sham Comparator|photbiomodulation-sham|The device will be placed with the spot located in the radial artery of the participant's arm (right or left), and fixed to the wrist with a specific bracelet no laser apllied.
89561155|NCT03075605||Subjects with previous attack|Subjects with previous attack
89561156|NCT03075605||Controls|Controls
89561157|NCT02328703|Experimental|Reiki Therapy by a Reiki Master|The Reiki Master will take approximately 30 minutes to perform a hand placement sequence that will allow the direction of energy toward the site of pain.
89561158|NCT02328703|Placebo Comparator|Sham Reiki Therapy by a Clinician|The Clinician, who has not trained in Reiki, will mimic the same 30 minute hand placement protocol as the Reiki Master.
89561159|NCT04999007|No Intervention|Control|Whether the patients in the control arm will receive a temporary ileostomy depends on surgeons' experience.
88967127|NCT05351359|Active Comparator|Active control|The patients from the active control group will receive brief physical activity advice from their general practitioners at baseline, and they will also receive the Fitbit tracker to self-monitor their daily steps.
89561160|NCT04999007|Experimental|Intervention|Whether the patients in the intervention arm will receive a temporary ileostomy depends on the risk of anastomotic leakage calculated by the artificial intelligence algorithm.
89561161|NCT03979339|Experimental|blood sample collection|For all participants whatever the group Groups 0 and 4: Healthy volunteers Group1: Metastatic HER2-positive breast cancer Group 2: Advanced CA-125 positive ovarian cancer Group 3: Metastatic PSA-positive castrate-resistant prostate cancer Participants will receive the following interventions because they are enrolled in the study: blood sample collection of 32mL (4x8mL in EDTA tubes)
89561162|NCT03073499|Experimental|Intervention|(Partial) Oncological Home Hospitalization
89561163|NCT03073499|No Intervention|Control|Standard oncological treatment at the hospital day care unit
89561164|NCT03970993|Experimental|Group 1a|Volunteers will receive 3 doses of 10μg R21/50μg Matrix-M 4 weeks apart and an optional booster vaccination 12 months after the third dose
89561165|NCT03970993|Experimental|Group 2a|Volunteers will receive 3 doses of 10μg R21/50μg Matrix-M at 0, 4 and 24 weeks, followed by CHMI by sporozoite challenge (mosquito bite) 4 weeks later. If protected from malaria, volunteers will receive an optional booster vaccination 28 days prior to malaria rechallenge
89561166|NCT03970993|Experimental|Group 3a|Volunteers will receive 3 doses of 10μg R21/50μg Matrix-M 4 weeks apart, followed by CHMI by sporozoite challenge (mosquito bite) 4 weeks later. If protected from malaria, volunteers will receive an optional booster vaccination 28 days prior to malaria rechallenge
89561167|NCT03970993|Experimental|Group 4a|Volunteers will receive 2 doses of 50μg R21/50μg Matrix-M 4 weeks apart and a 3rd fractional dose of 10μg R21/50μg Matrix-M at 24 weeks. This is followed by optional CHMI by sporozoite challenge (mosquito bite) 4 weeks later
89561168|NCT03970993|Experimental|Group 5|Volunteers will receive 2 doses of 10μg R21/50μg Matrix-M 4 weeks apart and a 3rd fractional dose of 2μg R21/50μg Matrix-M at 24 weeks. This is followed by optional CHMI by sporozoite challenge (mosquito bite) 4 weeks later
88967128|NCT05351359|Experimental|Intervention|The patients in the intervention group will be exposed to the same procedures as those from the active control group, but will also receive a mHealth-enabled just-in-time adaptive intervention and regular monthly phone counselling in the first 6 months.
88967129|NCT02921555|Experimental|methylprednisolone & prednisone|Intravenous bolus of methylprednisolone followed by a decreasing conventional course of oral prednisone
88967130|NCT02921555|Active Comparator|prednisone|A decreasing conventional course of oral prednisone
88967131|NCT05282446|Experimental|INV-202|INV-202 25mg by mouth once daily
88967132|NCT05282446|Placebo Comparator|Placebo|Matching placebo by mouth once daily
88967133|NCT05070585|Experimental|Isothiocyanate Rich Juice|The juices will contain 37,5g isothiocyanate rich sprouts and be delivered frozen to the subjects. The subjects will be instructed to consume two juices per day.
88967134|NCT05070585|Placebo Comparator|Placebo Juice|The juices will contain 37,5g alfalfa sprouts and be delivered frozen to the subjects. The subjects will be instructed to consume two juices per day.
88967135|NCT05223049||Psoriatic Arthritis patients with neuropathic pain|Patients diagnosed with Psa according to The Classification Criteria for Psoriatic Arthritis (CASPAR) psoriatic arthritis criteria. Who has a DN4 score of ≥4 or PainDETECT score of ≥13.
88967136|NCT05223049||Psoriatic Arthritis patients with nonneuropathic pain|Patients diagnosed with Psa according to The Classification Criteria for Psoriatic Arthritis (CASPAR) psoriatic arthritis criteria. Who has a DN4 score of ≤4 or PainDETECT score of ≤13.
88967137|NCT05197855|Experimental|Technological innovations and CPAP|Patients will be equipped with 4 devices: a Dreem 3 Headband, a pulse oximeter, a continuous glucose sensor, and a pedometer. In parallel they will be equipped by the CPAP at home by Icadom.
88967138|NCT02965222|Experimental|Intervention arm|After injecting HCG 38- 40 hours , the patient's oocytes will be taken with ICSI , then placed in the Time-Lapse. The oocytes will be IVF after 4 hours and will be stripped surrounding cumulus cell ,then will be placed in the Time-Lapse.The third day the top-grade embryo will be selected by time-lapse imaging (TLI) . The cleavage pattern and time parameters for marker embryo development were recorded daily after insemination.
89561169|NCT03970993|No Intervention|Group 6|They are infectivity control volunteers for the sporozoite challenge procedures: these volunteers are not vaccinated.
89561170|NCT03970993|No Intervention|Group 7|They are infectivity control volunteers for the sporozoite challenge procedures: these volunteers are not vaccinated.
88967139|NCT02965222|Experimental|Control arm|The development of the embryos at time-lapse was recorded directly and was not disturbed by temperature changes.
88967140|NCT05065476||Study Group|"Participants signed up for the webinar will be learning and practicing the Isha Kriya practice (meditation for beginners) taught by the Isha Foundation."
89027051|NCT01248156||Control|Patients with persistent, long standing persistent and paroxysmal AF, who receive conventional ablation as determined by the operator at each site, and based upon Heart Rhythm Society guidelines.
89561171|NCT03970993|Experimental|Group 1b|Volunteers will receive 3 doses of 10μg R21/50μg Matrix-M, 4 weeks apart followed by an optional vaccination booster 12 months after the third dose.
89561172|NCT03970993|Experimental|Group 2b|Volunteers will receive 3 doses of 10μg R21/50μg Matrix-M at 0, 4 and 24 weeks.
89561173|NCT03970993|Experimental|Group 3b|Volunteers will receive 3 doses of 10μg R21/50μg Matrix-M 4 weeks apart.
89561174|NCT03970993|Experimental|Group 4b|Volunteers will receive 2 doses of 50μg R21/50μg Matrix-M 4 weeks apart and a 3rd fractional dose of 10μg R21/50μg Matrix-M at 24 weeks.
89561175|NCT04998695|Experimental|Olive pomace oil|Intake of 45 g/d of olive pomace oil as the only source of oil in the diet
89561176|NCT04998695|Active Comparator|Sunflower oil|Intake of 45 g/d of sunflower oil as the only source of oil in the diet
89561177|NCT04998461||Obese patients with normal renal function|"estimated Glomerular Filtration Rate (eDFG) ≥ 60 ml/min/1.73 m2~Body Mass Index (BMI) > 30 kg/m2~Microalbuminuria / creatinuria ≤ 3mg / mmol and / or proteinuria < 0.15 g/24h"
89561178|NCT04998461||Obese patients with impaired renal function|"estimated Glomerular Filtration Rate (eDFG) < 60 ml/min/1.73 m2~Body Mass Index (BMI) > 30 kg/m2~Microalbuminuria / creatinuria ≤ 3mg / mmol and / or proteinuria < 0.15 g/24h"
89561179|NCT04998461||Non-obese patients with impaired renal function|"estimated Glomerular Filtration Rate (eDFG) < 60 ml/min/1.73 m2~Body Mass Index (BMI) between 18 and 30 kg/m2~Microalbuminuria / creatinuria ≤ 3mg / mmol and / or proteinuria < 0.15 g/24h"
89561180|NCT04998461||Non-obese patients with normal renal function (control group)|"estimated Glomerular Filtration Rate (eDFG) ≥ 60 ml/min/1.73 m2~Body Mass Index (BMI) between 18 and 30 kg/m2~Microalbuminuria / creatinuria ≤ 3mg / mmol and / or proteinuria < 0.15 g/24h"
89561181|NCT03111121|Active Comparator|Group 1|Reversal of Paralysis in Microlaryngoscopy procedures: Inhaled anesthetics: sevoflurane at 1 MAC, remifentanil and intubation with rocuronium at 0.6-1.2 mg/kg (vitals maintained within 20% of baseline). Standard anti-nausea prophylaxis - Ondansetran and Decadran intraoperative.After induction; amount of inhaled anesthetic and remifentanil used will be titrated based on hemodynamic parameters (maintained within 20% from baseline) and a BIS monitor.TOF testing done every 5 minutes:Group 1 will receive reversal with neostigmine (0.04 mg/kg and glycopyrrolate (0.01 mg/kg)
89561182|NCT03111121|Active Comparator|Group 2|Reversal of Paralysis in Microlaryngoscopy procedures: Inhaled anesthetics: sevoflurane at 1 MAC, remifentanil and intubation with rocuronium at 0.6-1.2 mg/kg (vitals maintained within 20% of baseline). Standard anti-nausea prophylaxis - Ondansetran and Decadran intraoperative.After induction; amount of inhaled anesthetic and remifentanil used will be titrated based on hemodynamic parameters (maintained within 20% from baseline) and a BIS monitor.TOF testing done every 5 minutes: Group2 will receive reversal with sugammadex 4mg/kg
89561183|NCT03073421|Other|HIV positive pregnant women|HIV positive pregnant women who took part in the P3 program will take part in a 2-hour qualitative interview.
89561184|NCT04998383|Experimental|HVNI|High velocity nasal insufflation (Fisher &Paykel, Auckland, New Zealan High-velocity nasal insufflation (Precision Flow;Vapotherm, Inc, Exeter, NH) (Figure 2) using a smallborenasal cannula was initiated with a flow rate set to 35 L/min, with a starting temperature between 35C and 37C and FiO2 at 1.0. Adjustments in flow (up to 40 L/min) and temperature (typically between 35C and 37C) were made to alleviate respiratory distress and optimize comfort
89561185|NCT04998383|Experimental|Noninvasive ventilation|Respiratory assistance is provided by a NIV either Puritan Bennet 840 (Covidien, U.S.A.), EngströmCarestation (GE Healthcare, Finland) or Hamilton-G5 (Hamilton Medical, Germany), will be used for conventional non-invasive ventilation via an oronasal mask that helps patients to cope with their Breathlessness. Settings will be adjusted based on the clinical assessment of the respiratory therapist as per standard practice.
89561186|NCT02328469||unidentified aseptic meningitis|Patients with etiologically unidentified aseptic meningitis will be treated with symptomatic therapy and will be asked to complete a questionnaire.
89561187|NCT02328469||tick-borne encephalitis|Patient with aseptic meningitis in whom serological diagnosis of tick-borne encephalitis will be established. Patients will be treated with symptomatic therapy and will be asked to complete a questionnaire.
89561188|NCT02328469||Lyme neuroborreliosis|Patients with acute aseptic meningitis in whom Lyme neuroborreliosis will be proven or suspected according to microbiological criteria. Patients will be treated with antibiotic therapy (ceftriaxone or doxycycline) and will be asked to complete a questionnaire.
89561189|NCT02328469||healthy controls|Patients will be asked to refer a spouse to serve as a control . If unmarried they will be asked to refer a family member or a friend of +/- 5 years to serve as a control.
89561190|NCT02328469||identified aseptic meningitis|Patients with microbiologically identified cause of acute aseptic meningitis/meningoencephalitis will receive symptomatic therapy. If the identified causative agent will be Herpes Simplex Virus or Varicella Zoster Virus, patients will be treated with acyclovir and will be asked to complete a questionnaire.
89561191|NCT03073187||Students: Step 1 Interviews|20 adolescents with uncontrolled asthma and poor sleep [10 from New York City (NYC); 10 from Rhode Island (RI)] will provide information regarding their asthma and sleep routines, and on what they would like to see in an intervention targeting co-morbid asthma and poor sleep.
89561192|NCT03073187||Caregivers: Step 1 Interviews|The caregivers of the 20 adolescents in this step [10 from NYC; 10 from RI] will be asked to provide information regarding their teenager's asthma and sleep routines, and on what they would like to see in an intervention targeting co-morbid asthma and poor sleep.
89561193|NCT03073187||Teachers: Step 2 Interviews|4 high school teachers, 2 from NYC and 2 from RI, will review the developed intervention. They will provide their opinions about the appropriateness of the teaching methods and literacy level for adolescents.
89561194|NCT03073187||Students: Step 3 Focus Groups|20 adolescents with uncontrolled asthma and poor sleep [10 from NYC; 10 from RI] will review the intervention providing feedback on its appropriateness and utility.
89561195|NCT03073187||Caregivers: Step 3 Focus Groups|The caregivers of the 20 adolescents in this step [10 from NYC; 10 from RI] will review the intervention providing feedback on its appropriateness and utility in small groups.
89561196|NCT03141853|Experimental|Equine-assisted Therapy Group|This group will interact and ride horses for 1 hour each week for 6 weeks. Horses will remain at a walk and an standard Therapeutic Riding curriculum will be used including safety, mounting, riding, tasks while riding, dismount, bonding with the horse.
88967141|NCT05184439||Study group after surgery|33 children and adolescents (39 knees) with recurrent patellar dislocation were treated with MPFL reconstruction using the adductor magnus tendon between 2010 and 2012. The group is under clinical observation with evaluation being made.
88967142|NCT00387530|Other|Single Arm Study of Biopsy|
88967143|NCT04729660|Active Comparator|Study group|Evaluate of the Kinesio tex gold tape that applied to anterior neck localised.
88967144|NCT04729660|Sham Comparator|Sham group|Evaluate of the Kinesio tex gold tape that applied to different neck localised as no-stretched.
89027052|NCT00479180|Experimental|AVG1|Vascugel
89027053|NCT00479180|Placebo Comparator|AVG2|Gelfoam
89027054|NCT00479180|Experimental|AVF3|Vascugel
89027055|NCT00479180|Placebo Comparator|AVF4|Gelfoam
89027056|NCT01248234|Active Comparator|Propofol|Propofol alone will be used to put an elderly hypertensive patient to sleep for surgery.
89027057|NCT01248234|Active Comparator|Etomidate|Etomidate alone will be used to put an elderly hypertensive patient to sleep.
89027058|NCT01248234|Active Comparator|Propofol and Etomidate|A combination of Etomidate and Propofol will be used to put an elderly hypertensive patient to sleep for surgery.
89027059|NCT00479219|Experimental|A|
89027060|NCT00479219|Placebo Comparator|B|
89027061|NCT00473135|Experimental|1|Two subcutaneous vaccinations with rDEN1delta30 into the deltoid region or either arm. One vaccination is given on Day 0 and one vaccination is given on Day 120.
89027062|NCT00473135|Experimental|2|Two subcutaneous vaccinations with rDEN1delta30 into the deltoid region or either arm. One vaccination is given on Day 0 and one vaccination is given on Day 180.
89027063|NCT00473135|Placebo Comparator|3|Two subcutaneous vaccinations with placebo into the deltoid region or either arm. One vaccination is given on Day 0 and one vaccination is given on either Day 120 or 180, depending on arm assignment.
89027064|NCT01248273|Experimental|immunization|This trial will investigate the safety and immune responses following immunization with the unimolecular pentavalent Globo-H-GM2-sTn-TF-Tn-KLH conjugate, plus the immunological adjuvant QS-21. This is a phase I study to assess toxicity and immunogenicity.
89027065|NCT01248312||morbidly obese|BMI >45
89027066|NCT01248312||thin patients|BMI <45
89027067|NCT01248351|Experimental|autologous stored platelets|
89027068|NCT00473174|Active Comparator|1|Ramipril on awakening
89027069|NCT00473174|Active Comparator|2|Ramipril at bedtime
89027070|NCT01248390|Experimental|Interactive Metronome therapy|Fifteen one-hour training sessions using Interactive Metronome system, in addition to treatment as usual.
89027071|NCT01248390|No Intervention|Treatment as Usual|Standard of care symptom management.
89027072|NCT02274831|Experimental|Email Group|Includes receiving standard of care discharge instructions plus an email after being discharged home from the emergency department, reinforcing their discharge instructions. Included in the email is their physician's name and recommended timing of follow-up visit.
89027073|NCT02274831|No Intervention|Standard of Care|Includes standard of care discharge instructions after being discharged from the emergency department. This included receiving paper copies of their discharge instructions.
89561197|NCT03141853|Placebo Comparator|Arthritis Exercise Education Group|This group will receive exercise education that targets arthritis symptoms for 1 hour each week for 6 weeks. This will be based on the exercise education from the Arthritis foundation How-to Exercise With Arthritis. (n.d.).
89561198|NCT03075371|Active Comparator|intragastric glucose administration|
89561199|NCT03075371|Placebo Comparator|intragastric water administration|
89027074|NCT01320202|Active Comparator|Soluble Ferric Pyrophosphate (SFP) in dialysate|11 micrograms (µg) of iron / deciliter (dL) of dialysate.
89027075|NCT01320202|Placebo Comparator|Standard Dialysate|0 micrograms (µg) of iron / deciliter (dL) of dialysate.
89561200|NCT04998071|Active Comparator|ROUTINE DRUG - CONCENTRATION QLB|The patients will receive bilateral posterior quadratus lumborum block using 0.25% bupivacaine 0.4 ml/kg. in each side.
89561201|NCT04998071|Active Comparator|ALTERNATIVE DRUG - CONCENTRATION QLB|The patients will receive bilateral posterior quadratus lumborum block using 0.125% bupivacaine 0.4 ml/kg. in each side.
89027076|NCT00479570|Experimental|Study period 1, 2 or 3|
89027077|NCT00479570|Placebo Comparator|Placebo Study period 1, 2 or 3|
89027078|NCT01319383|Experimental|Open Label, Translational Research|Vorinostat will be administered to all eligible participants in each step of each phase (period) of the study
89027079|NCT00473252||Hemodialysis patients|
89027080|NCT00473252||Renal transplant patients|
89027081|NCT00479609|Placebo Comparator|1|Placebo gel
89027082|NCT00479609|Active Comparator|2|Transdermal testostrone therapy
89027083|NCT04325113|Placebo Comparator|NaCl 0,9%|patients receive 5ml of NaCl 0,9% at the level of the tonsils lodge
89027084|NCT04325113|Active Comparator|Xylocaine 2%|patients receive 5ml of Xylocaïne 2% at the level of the tonsils lodge
89027085|NCT04325113|Active Comparator|Levobupivacaine 0,5%|patients receive 5ml of Levobupivacaine 0,5% at the level of the tonsils lodge
89027086|NCT02891317||Cataract Surgery Only|Twenty-five participants with mild or moderate open angle glaucoma (OAG) controlled by medication with a visually significant cataract that meets clinical criteria for cataract surgery will be recruited from the glaucoma clinics at the UNC Kittner Eye Center. Patients who are consented for cataract surgery only (Group 1) will be recruited to this group. Each procedure will be completed in a standardized fashion with standardization of the post-operative medications. An effort will be made to gender and age match each surgical group as well as provide reasonable racial and ethnic diversity.
89027087|NCT02891317||Cataract Surgery with iStent|Twenty-five participants with mild or moderate open angle glaucoma (OAG) that meets clinical criteria for cataract surgery with implantation of an iStent trabecular micro-bypass shunt will be recruited from the glaucoma clinics at the UNC Kittner Eye Center. Patients who are consented for cataract surgery with iStent (Glaukos Corp., Laguna Hills, CA) implantation (Group 2) will be recruited to this group. Each procedure will be completed in a standardized fashion with standardization of the post-operative medications. An effort will be made to gender and age match each surgical group as well as provide reasonable racial and ethnic diversity.
89210588|NCT00159913|Experimental|Sildenafil Medium dose|
89210589|NCT00159913|Experimental|Sildenafil High dose|
89210590|NCT00159913|Placebo Comparator|Placebo|
89561202|NCT03734263|Experimental|open label|sodium phenylbutyrate
89561203|NCT03075293||Children with appendicitis|All children who came to the ER with appendicitis
89561204|NCT03145051|Experimental|Respimer Netiflow mineral salts solution|Nasal irrigation with Respimer Netiflow mineral salts solution, 4 times/day during 8 weeks using Respimer Netiflow class I medical device
89561205|NCT03145051|Active Comparator|Saline solution|Nasal irrigation with saline solution , 4 times/day during 8 weeks using Respimer Netiflow class I medical device
89561206|NCT03075059|Experimental|Intervention|For patients randomized to the intervention group, the Child Life specialist will reach out via telephone to offer support and expertise in helping prepare their child and themselves for outpatient surgery to help decrease anxiety and increase coping. Concepts covered will include: developmentally appropriate language for explaining surgery and related procedures, potential coping skills to ease separation for caregivers and pediatric patients. Additionally, written materials (attached) covering the same information will be sent via mail or email covering the same information discussed in the phone conversation to serve as a refresher and resource before the day of surgery. On the day of surgery, the patient will receive standard of care (SOC) Child Life Services available to all patients.
89561207|NCT03075059|No Intervention|Control|Patients randomized to the control group will not receive the preoperative phone call or written materials and will only receive SOC Child Life services on the day of surgery.
89561208|NCT03671473|Experimental|Focused|fESWT (0.05-0.29 mJ/mm2, 2000 shocks, 5 Hz)
89561209|NCT03671473|Active Comparator|Radial|rESWT (2000shocks, 4 Bar, 5Hz)
89561210|NCT03073343|Active Comparator|diabetic patients with NAFLD|Patients will be prescribed 4 grams of betaine/day (2 grams PO BID) for the first 4 weeks of the study. After 4 weeks, patients in each cohort will be randomized (1:1) to continue receiving betaine 4 grams per day or increase to 8 grams per day for an additional 8 weeks.
89561211|NCT03073343|Active Comparator|non-diabetics with NAFLD|Patients will be prescribed 4 grams of betaine/day (2 grams PO BID) for the first 4 weeks of the study. After 4 weeks, patients in each cohort will be randomized (1:1) to continue receiving betaine 4 grams per day or increase to 8 grams per day for an additional 8 weeks.
89561212|NCT03075137|Experimental|External Counter Pulsation (ECP) group|A standard ECP protocol involves 35 one-hour sessions (once per day, 5 days a week) and continuous for 7 weeks. ECP consists of three sets of pneumatic cuffs attached to each of the patient's legs at the calf and lower and upper thigh. The inflation of the cuffs is triggered by a computer, and timing of the inflation is based on the R wave of the electrocardiogram. The ECP therapist adjusts the inflation and deflation timing to provide optimal blood movement per a finger plethysmogram waveform reading.
89561213|NCT03075137|No Intervention|Control group|Guideline-driven standard medical treatment
89561214|NCT03074981|Experimental|Combined TopClosure & Vcare Alpha Treatment|"The investigators will debride the wound if necessary. Wound biopsies will be taken to determine the existing pathogens and direct the antibiotic treatment.~Wound measurements will be taken. Afterwards the wound will be approximated by the TopClosure device and the patient will be connected to a Negative Wound pressure device Vcare Alpha.~The investigators will change dressings according to schedule. If the wound is clean the investigators will change dressings every 3-5 days, If the wound is infected the investigators will change dressings every 2-4 days, If the investigators encounter a severe infected wound with a lot of pus the investigators will change dressings every 1-3 days, The investigators will determine the time to heal when the wound is clean and there is no further need for Negative Pressure Wound Treatment (ROI-NPT) up to 10 weeks."
89561215|NCT03340051|Active Comparator|EFT group|Episodic Future Thinking (EFT) is the intervention in this arm. EFT participants will generate positive future events they are looking forward to and that could happen at different future time points (e.g., in 2 weeks, 1 month, 6 months, 1 year). Participants will be instructed to use and think about their episodic cues as they make decisions.
89561216|NCT03340051|Placebo Comparator|ERT group|Episodic Recent Thinking (ERT) is the intervention in this arm. ERT participants will list positive recent events (events that have already happened) that they enjoyed that occurred at different past time points (e.g., 12 hours ago, 24 hours ago, a week ago). Participants will be instructed to use and think about their episodic cues as they make decisions.
89561217|NCT03073265||Patients on apixaban|Patients currently on apixaban who meet inclusion/exclusion criteria A blood draw will be done on each patient to measure apixaban concentration in plasma using anti-Xa assay and LCMS.
89561218|NCT03145129||POAG group|Patients diagnosed with POAG and OSA who require treatment with CPAP
89561219|NCT03145129||Control group|Patients with OSA and without POAG who require treatment with CPAP
89561220|NCT04998227||suspect acute coronary syndrome|"Subjects with the diagnosis of suspected acute coronary syndrome (ACS), age between 20 to 80.~Exclusion criteria: pregnant women, patients with end-stage renal disease (eGFR <15 mL/min/1.73 m2), cardiogenic shock."
89561221|NCT04438915|No Intervention|Average weight .control group|Average weight BMI (18.5_25)
88967145|NCT04996069|Experimental|All Participants|This is a single arm study. All subjects enrolled will be apart of the experimental group. Subjects in this group will use Crest Whitening Emulsions on their teeth up to 4 times a day for 7 days in order for the study team to evaluate if the study intervention product increases saliva production in this Xerostomic population.
88967146|NCT02680184|Experimental|Part 1: Dose-Escalation - CMP-001 and Pembrolizumab|Participants will receive up to 5 escalating dose levels (1 milligram [mg], 3 mg, 5 mg, 7.5 mg and 10 mg) of CMP-001 via intratumoral injection according to one of 2 schedules (Schedule A: once weekly for 7 weeks, followed by every 3 weeks thereafter until participant is discontinued; Schedule B: once weekly for 2 weeks, followed by every 3 weeks thereafter until participant is discontinued) in combination with pembrolizumab at its labelled dose and schedule.
88967147|NCT02680184|Experimental|Part 1: Dose-Expansion - CMP-001 and Pembrolizumab|Participants will receive CMP-001 10 mg via intratumoral injection by Schedule A (once weekly for 7 weeks, followed by every 3 weeks thereafter until participant is discontinued) in combination with pembrolizumab at its labelled dose and schedule. As of 05 October 2018, the dose and schedule for Part 1 Dose Expansion Phase was selected based on all available safety, efficacy and pharmacodynamic data from the Part 1 Dose Escalation Phase. Participants who were enrolled prior to 05 October 2018 to receive CMP-001 doses less than (<) 10 mg will have the option to receive CMP-001 doses up to 10 mg on Schedule A in combination with pembrolizumab.
88967148|NCT02680184|Experimental|Part 2: CMP-001 Monotherapy and Crossover to Combination|Participants will receive CMP-001 10 mg via intratumoral injection by Schedule A (once weekly for 7 weeks, followed by every 3 weeks thereafter until participant is discontinued). Participants who were enrolled prior to 05 October 2018 to receive CMP-001 doses <10 mg will have the option to receive CMP-001 doses up to 10 mg on Schedule A. Participants with documented progression while on CMP-001 monotherapy treatment will have the option to crossover to the combination treatment of CMP-001 10 mg plus pembrolizumab, at the discretion of the Investigator.
88967149|NCT00390000|Experimental|Arm I|See Detailed Description
89561222|NCT04438915|Active Comparator|Overweight|Overweight BMI ( 25_30 )
89561223|NCT04438915|Active Comparator|Mild obese|Mild obese BMI (30_35 )
89561224|NCT04997837|Experimental|PD-1 inhibitor and chemoradiotherapy|"PD-1 inhibitor+CapeOX/SOX/FOLFOX for 6 weeks, followed by chemoradiotherapy; 6 weeks of PD-1 inhibitor and CapeOX/SOX/FOLFOX for 6 weeks after chemoradiotherapy, followed by PD-1 inhibitor, till 12 months after chemoradiotherapy.~PD-1 inhibitor Nivolumab/Toripalimab 240mg solution intravenously once daily, Q2W. OR Nivolumab/Toripalimab 360mg solution intravenously once daily, Q3W; OR Pembrolizumab/Tilelizumab/Sintilimab/Carrelizumab, 200mg solution intravenously once daily, Q3W.~Chemotherapy: CapeOx or SOX or FOLFOX therapy determined by investigator.~Chemoradiotherapy Radiotherapy: 1.8 Gy/fx, 45-50.5Gy Chemotherapy: Capecitabine 625mg/m2 bid orally with radiotherapy; OR Tegafur-gimeracil-oteracil potassium combination drug 40-60mg bid orally with radiotherapy."
89561225|NCT04997837|Active Comparator|Chemotherapy|"Chemotherapy: CapeOx or SOX or FOLFOX therapy determined by investigator.~CapeOX:~Oxaliplatin 130 mg/m2 (body surface area) solution intravenously once-daily, followed by 20 days off.~Capecitabine 1000 mg2 (body surface area) bid orally in 14 days, followed by 7 days off.~SOX:~Oxaliplatin 130 mg/m2 (body surface area) solution intravenously once-daily, followed by 20 days off.~Tegafur-gimeracil-oteracil potassium combination drug 40 - 60 mg bid orally in 14 days, followed by 7 days off.~FOLFOX:~Oxaliplatin 85 mg/m2 (body surface area) solution intravenously once-daily, followed by 13 days off.~5-FU 2400-2800mg/m2/d continuous intravenous pumping for 48h, Q2W."
89561226|NCT04299295|Experimental|YVOIRE Y-Solution 360|Hyaluronic acid dermal filler
89561227|NCT04299295|Active Comparator|Juvéderm VOLBELLA|Hyaluronic acid dermal filler
89561228|NCT04997603|Other|Athletes wearing an accelerometer continuously for 2 weeks|High school students: 50% male, 50% female
89561229|NCT04997603|Other|Non-athletes wearing an accelerometer continuously for 2 weeks|High school students: 50% male, 50% female
89561230|NCT02328157|Experimental|Cataract with ERM and astigmatism|Eyes that have cataract and ERM with a preoperative corneal cylinder of more than 0.75 diopter.
89561231|NCT02328313|Experimental|Intervention Cohort|Breast cancer patients 65 and older undergoing chemotherapy and participating in a home-based physical activity intervention.
89561232|NCT04202263|Placebo Comparator|Placebo|Placebo cream without minocycline
89561233|NCT04202263|Active Comparator|Minocycline Arm|Minocycline cream (1%,2%,3%)
89561234|NCT04996979|Placebo Comparator|Control|Only standard care
89561235|NCT04996979|Experimental|Intervention group|The PENG block was performed for intervention group with local anaesthetic solution composed of 20 ml of ropivacaine 0.5%.
89561236|NCT03145285|Experimental|Cohort 1|"Patients locally advanced/metastatic ACC patients with uncontrolled Cushing's syndrome despite Mitotane +/- chemotherapy.~Treatment with single agent Abiraterone Acetate (AA) until progression"
89561237|NCT03145285|Experimental|Cohort 2|"Mitotane-naïve patients with newly diagnosis of ACC associated with Cushing's syndrome not amenable to surgical resection.~Treatment with single agent Abiraterone Acetate (AA) for 4 weeks followed by AA + Mitotane +/- first-line chemotherapy. AA in association with Mitotane will be administered for 3 months. If the primary endpoint is obtained before 1 month, then Mitotane +/- chemotherapy can be started upon the clinician's decision."
89561238|NCT04997291|Experimental|Dexrazoxane|
89561239|NCT02328079|Active Comparator|Steroid Group|prednisolone 60 mg /day IM /IV for 6 consecutive days then reduced by 10 mg /day (for a total treatment time for 12 days)
89561240|NCT02328079|Active Comparator|Steroid + Antiviral Group|Prednisolone IM/ IV 60 mg /day + IV acyclovir 500 mg three time /day for 6 consecutive days) then reduced by 10 mg /day (for a total treatment time for 12 days)
89561241|NCT04190641|Other|Flexible cystoscopy|Visualization of the urethra and bladder with the Ambu® aScope™ 4 Cysto and aView™ Urologia
88967150|NCT04955275|Experimental|Parkinson's Disease Patients receiving Cognitive Remediation Therapy|Parkinson's Disease Subjects will undergo 10 weeks of Brain HQ training, 2 times a week an hour at a time. Also patients pre- and post-intervention RBANS and PDQ-39 scores.
88967151|NCT04955275|No Intervention|Parkinson's Disease Patients not receiving Cognitive Remediation Therapy|Parkinson's Disease Subjects will receive no intervention, but still undergo pre- and post-intervention RBANS and PDQ-39 scores.
89210591|NCT05498259|Experimental|Orelabrutinib+R-CHOP-like|Orelabrutinib plus Rituximab for 21 days; Following Imaging examinations, patients with ≥25% tumor reduction, treat with orelabrutinib 150mg qd orally plus R-CHOP-like for 6 cycles; whereas, patients with <25% tumor reduction, withdraw from the study，treat with R-CHOP-like alone for 6 cycle
89561242|NCT03074903||Early cycle insertion|Participants in this group have the intrauterine system inserted during the first seven days of their menstrual cycle.
89561243|NCT03074903||Late cycle insertion|Participants in this group have the intrauterine system inserted during the remainder of their cycle.
89561244|NCT04992377|Experimental|R-EPOCH plus IBR for RT|
89561245|NCT02747329|Experimental|1st month OCT group implanted BuMA Supreme™ stent|This group contains 20 subjects. All subjects in this group will undergoing implantation of BuMA Supreme™ stent. The Primary Endpoint of this group is 1st month QCA and OCT assessment.
89561246|NCT02747329|Active Comparator|1st month OCT group implanted Xience V/Prime stent|This group contains 20 subjects. All subjects in this group will undergoing implantation of Xience V/Prime stent. The Primary Endpoint of this group is 1st month QCA and OCT assessment.
89561247|NCT02747329|Experimental|2st month OCT group implanted BuMA Supreme™ stent|This group contains 20 subjects. All subjects in this group will undergoing implantation of BuMA Supreme™ stent. The Primary Endpoint of this group is 2st month QCA and OCT assessment.
88967152|NCT04941781|Experimental|PIPE-307|Subjects will receive an oral dose of PIPE-307 and 3 intravenous injections of [11C] PIPE- 307.
88967153|NCT04899622|Experimental|Combined MBSR and exercise|Group A will take part in live online weekly mindfulness sessions based on the Mindfulness Based Stress Reduction (MBSR) programme, in addition to supervised exercise classes.
88967154|NCT04899622|Active Comparator|Online Self-Management Guide|Group B will be invited to interact with an online self-management guide accessible in the members area of the study website.
88967155|NCT02632760|Active Comparator|ferric carboxymaltose|ferric carboxymaltose 1000 mg or Iron isomaltoside 1000 mg given Intravenously
88967156|NCT02632760|Placebo Comparator|Placebo|Placebo intravenous infusion
89561248|NCT02747329|Active Comparator|2st month OCT group implanted Xience V/Prime stent|This group contains 20 subjects. All subjects in this group will undergoing implantation of Xience V/Prime stent. The Primary Endpoint of this group is 2st month QCA and OCT assessment.
88967157|NCT02505074||Mitral Valve Replacement|Review of retrospective data of those patients who have had surgical replacement of the mitral valve with the Melody valve.
88967158|NCT02505074||Tricuspid Valve Replacement|Review of retrospective data of those patients who have had surgical replacement of the tricuspid valve with the Melody valve.
88967159|NCT04574245||Resectable group|
88967160|NCT04574245||Potentially resectable group|
88967161|NCT04574245||Unresectable group|
88967162|NCT04556617|Experimental|PLX2853 + Abiraterone Acetate + Prednisone|"Phase 1b (PLX2853 + Abiraterone Acetate + Prednisone Combination): Up to 15 evaluable subjects with mCRPC will be enrolled.~Phase 2a (PLX2853 + Abiraterone Acetate + Prednisone Combination): Up to 19 evaluable subjects with mCRPC will be enrolled."
88967163|NCT04556617|Experimental|PLX2853 + Olaparib|"Phase 1b (PLX2853 + Olaparib Combination): Up to 18 evaluable subjects with homologous recombination repair (HRR) gene-mutated mCRPC will be enrolled.~Phase 2a (PLX2853 + Olaparib Combination): Up to 58 evaluable subjects with homologous recombination repair (HRR) gene-mutated mCRPC will be enrolled."
89561249|NCT04992533|Active Comparator|Long-duration tourniquet|Tourniquets inflated before arthroscopic exploration and deflated after high tibial osteotomy
89561250|NCT04992533|Experimental|Short-duration tourniquet|Tourniquet should be inflated before arthroscopic exploration and deflated immediately after the exploration
89561251|NCT04997213|Experimental|Interventional group|Biofeedback system is a center of pressure-controlled video game-based exercise system designed for patients with neurological and orthopedic diseases and provides balance training using auditory, visual, and pressure biofeedback. The system contains several games, each designed to focus on a different component of balance. Biofeedback is provided by means of a monitor in front of the patient. The balance exercises program involved a total of 18 sessions, each lasting 20 min, three times a week for six weeks, and were individually tailored based on the patient's tolerance and current motor and sensorial capacities. All patients performed conventional exercises.
89561252|NCT04997213|Active Comparator|Control group|Classic balance exercises were performed (two-leg stance, semi-tandem stance, tandem stance, standing on one leg, tandem walking, turning completely around, heel-to-toe stance, and standing with the eyes closed). Patients with balance disorder first were commenced balance training in a seated position before progressing to standing exercises, to the extent that these could be tolerable.
89561253|NCT02328001|No Intervention|Pre-intervention phase/phase 1|No intervention will be applied in phase 1
89561254|NCT02328001|Other|Post-intervention phase/phase 2|Intervention will be applied in phase 2 i.e; Debriefing endoscopists of the procedure accessory costs and pathology specimen costs
89561255|NCT04996745|Experimental|Intervention Group|Patients randomized to the intervention group of the RCT will be given tablet-based education. The first clinic follow-up visit will consist of screening for consent, providing a QR code for Orthokids, and conducting the pre-intervention questionnaire. The pre-intervention questionnaire has two sections with questions pertaining to demographics and orthopedic knowledge. The second clinic follow-up visit will be provided with the tablet for repeat education, with Orthokids and the post-intervention questionnaire will be distributed. The post-intervention questionnaire has two sections with questions pertaining to orthopedic knowledge and satisfaction with care.
89561256|NCT04996745|No Intervention|Control Group|"Patients randomized to the control group of the RCT will receive the standard clinic experience. This group will not be exposed to any education enrichment about their child's fracture except for the physician's explanation within the exam room.~The first clinic follow-up visit will consist of screening for consent and conducting the pre-intervention questionnaire. The pre-intervention questionnaire has two sections with questions pertaining to demographics and orthopedic knowledge. The second clinic follow-up visit will consist of conducting the post-intervention questionnaire. The post-intervention questionnaire has two sections with questions pertaining to orthopedic knowledge and satisfaction with care."
89561257|NCT02578069|Experimental|Experimental|NOVA Intracranial sirolimus eluting stent system
89561258|NCT02578069|Active Comparator|Control|Apollo Intracranial stent system
89561259|NCT03141775||Treatment of CDI|Treatment of CDI for hospitalized patients with Clostridium difficile associated diarrhea
89561260|NCT04996589||Lean subjects|BMI 18.5-22
89561261|NCT04996589||Obese subjects|BMI>30
89561262|NCT03142087|Active Comparator|virtual reality exercises|Nintendo Wii Fit Plus Game Console is used in these group. The one session included:warm-up exercises in 5-10 minutes, games (soccer heading, ski jump, ski slalom, etc.) in 30-40 minutes, and cooling exercises in 5 minutes.
89561263|NCT03142087|Active Comparator|conventional exercises|Physiotherapy and rehabilitation session included: warm-up exercises in 5-10 minutes, balance exercises (balance board, balance ball, two and one leg stand exercises, weight bearing exercises, balance in different type of surfaces, etc.) in 30-40 minutes, and cooling exercises in 5 minutes.
89561264|NCT03074825|Experimental|chiauranib|Patients take Chiauranib capsules 50mg, orally once daily, 28 days as a cycle.
89561265|NCT02327767|Experimental|Resonating Arm Exerciser|The treatment group will participate in supervised Resonating Arm Exerciser (RAE) group sessions of 45 minutes, three times a week, for a total of eight sessions for three consecutive weeks. During each treatment session, the affected upper extremity will be used to push on the lever of the RAE in the sagittal plane. Upon pushing and pulling on the lever, the wheelchair moves a total of 20 cm from a neutral position, which indicated a repetition counted by a programed iphone.
88967164|NCT04554862|Active Comparator|the intervention group (M) magnesium sulfate|a 6ml of magnesium sulfate 10% (600mg) will be added to 25ml of bupivacaine 0.5% for supraclavicular brachial plexus block
88967165|NCT04554862|Active Comparator|the intervention group (K) ketorolac|a 2ml of ketorolac (30mg) will be added to 4ml of normal saline and 25ml of bupivacaine 0.5% for supraclavicular brachial plexus block
88967166|NCT02241863|Experimental|Multifaceted intervention|Patients, their caregivers and family members will received the educational and motivational interventions
88967167|NCT02241863|Active Comparator|Active Comparator|Usual Care The usual care group received routine counseling performed by the psychiatrist and nurses.
88967168|NCT03802097|Experimental|A group (treatment group)|No use of antimicrobial prophylaxis
89210592|NCT00820274|Experimental|amniotic membranes|
89210593|NCT00821600|Experimental|001|risperidone IR and LAI formulation 1 mg risperidone IR single injection followed after 7 to 14 days with 75mg risperidone 4-week-LAI single injection
89561266|NCT02327767|No Intervention|Physical Therapy|The control group will continue with existing physical therapy treatment of passive range of motion (PROM) and therapeutic exercise to their involved upper extremity by the physical therapist.
89561267|NCT03110887||Preterm neonate with thrombocytopenia|Preterm neonates (GA<34 weeks) with severe thrombocytopenia
89561268|NCT03072485|Other|Sirolimus, metformin, diclofenac|First five enrolled participants
89561269|NCT03072485|Other|Metformin, diclofenac|Sixth to tenth enrolled participants
89561270|NCT05080543|Active Comparator|Group AT|will receive a bolus of albumin (1gm/kg) and terlipressin loading dose of 1 mg over 20 minutes followed by infusion at rate (2 μ g/kg/h)
89561271|NCT05080543|Placebo Comparator|Controlled|will receive the routine management of septic shock patients as culture-based IV antibiotics, IV fluids and intropic support plus a placebo (as lactated ringer solution in the same infusion rates for blinding).
89561272|NCT03074591|Active Comparator|Treatment|Active treatment: Ferric Carboxymaltose solution (Ferinject®) for parenteral application, 50 mg/mL iron. Medication will be given as a short time infusion over 15 minutes in 100mL NaCl.
89561273|NCT03074591|Placebo Comparator|Placebo|Placebo: Normal saline (0.9% weight/volume (w/v) NaCl) administered in analogy to active treatment procedures.
89561274|NCT03143413||Systemic sclerosis|Systemic sclerosis is an autoimmune connective tissue disease with undefined etiology and characterized by progressive fibrosis of the skin and major organs. Dry eyes and / or buccal syndrome is commonly reported in patients with systemic sclerosis.
89561275|NCT03143413||Gougerot-Sjogren syndrome|Goujerot-Sjogren syndrome is a chronic autoimmune disorder that is characterized by dryness of the eyes (xerophthalmia) and / or mouth (xerostomia).
89561276|NCT03143413||Sicca-Asthenia-Polyalgia syndrome|It may be primary or secondary to another connective tissue disease (such as lupus, rheumatoid arthritis or other).
89561277|NCT03074669|Experimental|ACT program|Participants from the active treatment group will be granted access to seven modules that are structured like chapters of a self-help book adapted for the online environment. In addition, participants from the experimental arm will be guided by an on-line therapist throughout the program duration. The on-line therapists are graduate students in clinical psychology who work under the supervision of an experienced psychotherapist. Participants will be asked to fill in a series of self-report measures to monitor their anxiety and some ACT specific processes (i.e., acceptance, mindfulness, experiential avoidance) throughout the intervention.
89561278|NCT03074669|No Intervention|Wait-list control group|During the first seven weeks, participants in the wait-list control group will only be asked to fill in a series of self-report measures to monitor their anxiety and some ACT specific processes (i.e., acceptance, mindfulness, experiential avoidance). Following the experimental group's completion of the program, participants in this group will also receive the intervention. All participants will be contacted 6 months after the intervention has concluded in order to conduct a follow-up assessment.
89561279|NCT05080309|Sham Comparator|Control|During labor the women will have free access to water only but not fruit juice or other calory source.
89561280|NCT05080309|Experimental|Carbohydrate|During labor the women will have free access to water and 20 ml commercial fruit juice bricks containing between 430 or 660 kcal/l. Every 2 hours the midwife or the nurse will measure the fruit juice oral intake volume and will advise women to drink the planned volume (1 brick/2hours)
89561281|NCT04991675|Active Comparator|pelvic floor muscle exercises|Exercises were taught in the supine position, as described by Kegel (1948), and it was confirmed that the women learned to use the correct muscles with vaginal palpation. During the exercise, the participants were informed not to pull the abdomen inwards, not to tighten their legs and hip muscles, and not move their pelvis.
89561282|NCT04991675|Active Comparator|diaphragmatic breathing exercises|Diaphragmatic breathing exercise was taught in supine position. The movement of the symphysis pubis was examined to confirm that the pelvic floors' movement was also involved breathing. Abdominal palpation was used to elicit unawareness of the diaphragmatic breathing and to assess whether contractions were performed correctly.
89561283|NCT04991909|Experimental|Treatment group A|
89561284|NCT04991909|Placebo Comparator|Treatment group B|
88967169|NCT03802097|Experimental|B group (control group)|Use of antimicrobial prophylaxis
88967170|NCT04230499|Experimental|Cohort 1|Cohort 1 will receive 0.5mg of eRapa every other day.
88967171|NCT04230499|Experimental|Cohort 2|Cohort 2 will receive 0.5mg of eRapa daily with 7 days on therapy, followed by 7 days off therapy.
88967172|NCT04230499|Experimental|Cohort 3|Cohort 3 will receive 0.5 mg of eRapa daily.
88967173|NCT04712435|Experimental|Experimental: N-acetylcysteine|Sachets containing N-acetylcysteine 200 mg Powder for Oral Solution administered every 8 hours (Daily dose 600 mg/day). is administered on the first day of conditioning and will continue until Day +30 post HSCT or hospital discharge, whichever is sooner
88967174|NCT04712435|Placebo Comparator|Placebo Comparator: Placebo|200mg granulated solution of matching placebo administered every 8 hours (Daily dose 600 mg/day), is administered on the first day of conditioning and will continue until Day +30 post HSCT or hospital discharge, whichever is sooner
88967175|NCT04712513||Patients with coronary artery disease and hemodynamically stable|
88967176|NCT03979729||3D + 2D-Mammogram Recipients (Patient Group A)|Women presenting for mammographic screening who selected 3D + 2D- mammogram. These women will undergo in-person or telephone interviews.
88967177|NCT03979729||2D-Mammogram Recipients (Patient Group B)|Women presenting for mammographic screening who selected 2D- mammogram alone (declined 3D + 2D- mammogram). These women will undergo in-person or telephone interviews.
88967178|NCT03979729||Women Who Have Never Received a Mammogram (Patient Group C)|Women who have never undergone recommended mammographic screening. These women will participate in a onetime facilitated focus group.
89561285|NCT04082377|Experimental|Recruitment maneuver with tidal volume (RM TV)|RMs were conducted under volume controlled ventilation with initial settings of a limit of peak inspiratory pressure at 40cmH2O, TV at 6 mL/kg PBW ,RR at 7 breaths/min, PEEP at 5 cmH2O, and I:E ratio at1:1. The TV was then increased by steps of 4 mL/kg PBW until plateau airway pressure (Pplt) was 40 cmH2O, after which 3 breaths were allowed. Finally, the limit of peak inspiratory pressure, TV, RR, and I:E ratio were reset at values equal to those preceding the RM. The ventilation protocol could be changed at any time when concerned about patient safety.
89561286|NCT04082377|Active Comparator|Recruitment maneuver by PEEP (RM PEEP)|"The ventilation protocol consisted of volume controlled mechanical ventilation, FiO2 0.4, inspiratory-to-expiratory (I:E) ratio at 1:2, and respiratory rate (RR) set to normocapnia 5 cmH2O PEEP.~RMs was conducted under pressure controlled ventilation so ventilation technique will be changed, pressure-control mode will be started and inspiratory time is increased to 50% (inspiratory: expiratory ratio will be set to 1:1). Peak airway inspiratory pressure (Ppeak) will be initially set to 20 cmH2O for three breaths, and then PEEP will be increased in steps from 5 to10 cmH2O for five breaths, from 10 to 15 cmH2O for seven breaths, from 15 to 20 cmH2O for ten breaths while Ppeak increased to 40 cmH2O and will be maintained for three more breaths. Following ARM, volume control will be re-established using Vt 6 mL/kg and step-wise reductions in PEEP from 20 to 15 cmH2O for three breaths,and then to 5 cmH2O until the end of recruitment maneuver."
89561287|NCT04073875||Bioprosthetic aortic valve|Single 18F-GP1 PET-CT
89561288|NCT04073875||Bioprosthetic aortic valve thrombus - repeat imaging|18F-GP1 PET-CT at baseline and 3 months
89561289|NCT03144739|Active Comparator|Control|Children enrolled during the control phase will receive care under the Current collaborative care protocol. Participating general practitioners are currently trained to recognize child mental health problems and refer them to partner community mental health centers for treatment.
89561290|NCT03144739|Experimental|Intervention|Children enrolled during the intervention phase will receive Training in management of children's mental health problems. This will involve treatment by their general practitioner in collaboration with a partner community mental health center; children meeting certain criteria for severity, or whose parents prefer center treatment, will be immediately referred.
89561291|NCT03072407|Placebo Comparator|PB-119 injection placebo|totally 8 subjects will have PB-119 injection placebo once per weekly for 4 weeks.
89561292|NCT03072407|Experimental|PB-119 injection 25ug|totally 8 subjects will have PB-119 injection 25 ug once per weekly for 4 weeks
89561293|NCT03072407|Experimental|PB-119 injection 50ug|totally 8 subjects will have PB-119 injection 50 ug once per weekly for 4 weeks
89561294|NCT03072407|Experimental|PB-119 injection 100ug|totally 8 subjects will have PB-119 injection 100 ug once per weekly for 4 weeks
88967179|NCT03979729||Providers|Primary care providers (physicians, physicians assistants, and advanced nurse practitioners) working in clinics providing primary care for underserved patient populations in New Mexico, including primary care providers at a RIOSNET-affiliated and UNM-affiliated clinics
89561295|NCT03072407|Experimental|PB-119 injection 200ug|totally 8 subjects will have PB-119 injection 200 ug once per weekly for 4 weeks
89561296|NCT03144895|Other|Arterial catheter|by anatomical placement alone
89561297|NCT03144895|Other|Placement|of an arterial catheter by ultrasound tracking
89561298|NCT03144661|Experimental|Part 1|Subjects with HCC, cholangiocarcinoma, or esophageal, nasopharyngeal, or serous ovarian cancers, regardless of FGF/FGFR alteration status.
89561299|NCT03144661|Experimental|Part 2 Cohort A|Subjects with HCC with FGF19 amplification.
89561300|NCT03144661|Experimental|Part 2 Cohort B|Subjects with HCC without FGF19 amplification.
89561301|NCT03144661|Experimental|Part 2 Cohort C|Subjects with cholangiocarcinoma or esophageal, nasopharyngeal, or serous ovarian cancers (regardless of FGF/FGFR status), or other solid tumor malignancies with documented FGF19/FGFR4 alteration.
88967180|NCT04991376||Vancomycin|Critically ill patients who suffered from sepsis, treated with vancomycin.
88967181|NCT04991376||Gentamicin|Critically ill patients who suffered from sepsis, treated with gentamicin.
88967182|NCT04991376||Other antibiotic groups|Critically ill patients who suffered from sepsis, treated by other antibiotic groups except for vancomycin or aminoglycoside (gentamicin).
88967183|NCT04712084|No Intervention|Control group|Extubation procedure following standard of care
88967184|NCT04712084|Experimental|Pressure support group|Extubation procedure is performed with 100% of O2 but with application of positive pressure before and after extubation
88967185|NCT04729465|Active Comparator|Active Comparator|"Active Comparator: Control Patients with cardiac disaese receive general anesthesia with Propofol~Interventions:~Drug: Propofol"
88967186|NCT04729465|Experimental|Experimental|"Experimental: Bispectral Index Monitor Patients with cardiac disease receive a general anesthesia with Propofol where the amount of anesthetics administered is decided taking into consideration the Bispectral Index Monitor.~Interventions:~Drug: Propofol Device: Bispectral Index Monitor"
88967187|NCT04712162|Other|D: maintain anesthesia with desflurane|D: maintain anesthesia with Suprane® (Desflurane) at 6%. Volatile concentration was titrated according to end-tidal MAC to maintain 0.7-1.3 MAC using end-tidal monitor of Dräger Primus anesthesia machine.
88967188|NCT04712162|Other|S: maintain anesthesia with sevoflurane.|S: maintain anesthesia with Sevorane® (Sevoflurane) at 2%. Volatile concentration was titrated according to end-tidal MAC to maintain 0.7-1.3 MAC using end-tidal monitor of Dräger Primus anesthesia machine.
88967189|NCT02965183|Experimental|Temperature measurements|
88967190|NCT04729309|Experimental|Mass Balance (MB) Cohort|Participants will receive oral [14C] RO7049389 under fasted conditions, followed by intravenous IV [13C] after a two-hour period.
88967191|NCT04729309|Experimental|Absolute Bioavailability (BA) Cohort|In Periods 1 and 2, participants will receive oral [12C] RO7049389 under fasted conditions, followed by IV [13C] RO7049389. There is a minimum 7-day washout between periods.
88967192|NCT04712357|Placebo Comparator|Placebo (Vitamin C)|Control placebo (Vitamin C - 500mg / day, for 10 days)
88967193|NCT04712357|Active Comparator|Tenofovir disoproxyl fumarate (TDF)|Tenofovir disoproxyl fumarate (TDF; 300 mg / day, for 10 days)
88967194|NCT04712357|Active Comparator|TDF + FTC|Tenofovir disoproxyl fumarate (TDF; 300 mg / day, for 10 days) plus emtricitabine (FTC; 200 mg / day, for 10 days)
88967195|NCT03041844|Experimental|Low Frequency, Low Intensity Ultrasound|Low Frequency, Low Intensity therapeutic ultrasound applied weekly for up to 16 weeks.
89210594|NCT00987207|Experimental|cyclosporine|A single bolus of 2.5 mg/kg cyclosporine is administered before aortic cross-declamping
89561302|NCT04991441|Experimental|Control|Participants will follow their usual or normal diet for 5 months (CON) followed by an Controlled Dietary Sodium Restriction (INT) diet for 2 months. During the sodium restricted diet, participants will be provided with 2 meals and snacks daily, for 30 days (Month 5 - days 1-30) and 1 meal and snacks daily, for 30 days (Month 6 - days 31-60). These meals should meet the National Kidney Foundation's Kidney Disease Outcomes Quality Initiative (KDQOI) guidelines for energy and protein (30-35 kcal/kg & 1.2 g/kg) as well as low phosphorus, potassium, and sodium. The meals are formulated to less than 600-800 mg sodium each (<2,000g/day) and will be ordered and delivered through momsmeals.com
89561303|NCT04991441|Experimental|Intervention|Participants will be provided with 2 meals and snacks daily, for 30 days (days 1-30) and 1 meal and snacks daily, for 30 days (days 31-60). These meals should meet KDQOI guidelines for energy and protein (30-35 kcal/kg & 1.2 g/kg) as well as low phosphorus, potassium, and sodium. The meals are formulated to less than 600-800 mg sodium each (<2,000g/day) and will be ordered and delivered through momsmeals.com
89561304|NCT03111433|Experimental|Group I|this group of patients will receive their standard insulin treatment in addition to 100 mg of coenzyme Q10 soft gelatin capsule once daily for three month
89561305|NCT03111433|Active Comparator|Group II|this group of patients will receive their standard insulin treatment only
89561306|NCT04915313|Experimental|Intervention group|Subjects in the intervention group will recieve remote ischemic conditioning (RIC) treatment twice a day for 4 weeks.
89561307|NCT04915313|Sham Comparator|Sham control group|Subject in the sham control group will recieve sham remote ischemic conditioning (Sham-RIC) treatment twice a day for 4 weeks..
89561308|NCT03143023|Experimental|arginine toothpaste|
89561309|NCT03143023|Active Comparator|fluoride toothpaste|
89561310|NCT04914455||Fluid responsiveness groups (responders and non-responders)|Fluid responsiveness is defined as an increase in stroke volume of 10% and more form baseline.
89561311|NCT05079529|Experimental|β-1,3/1,6-D-Glucan From Mycelia Extract of Indonesia's Ganoderma Lucidum Group|This group will receive capsule contains 180 mg of β-1,3/1,6-D-Glucan From Mycelia Extract of Indonesia's Ganoderma lucidum which will be taken 3 times daily for 90 days
89561312|NCT05079529|Placebo Comparator|Placebo Group|This group will receive empty capsule which will be taken 3 times daily for 90 days
89561313|NCT03074435|No Intervention|Control|No intervention
89561314|NCT03074435|Experimental|insecticidal paint|The insecticidal paint contains two organophosphates, chlorpyriphos(1.5%) and diazinon (1.5%), and an insect growth regulator (IGR),pyriproxyfen (0.063%), as active ingredients.
89561315|NCT03074435|Experimental|Larvicides|The larvicide is a slow release formulation containing Bacillus thuringiensis Var Israelensis.
89561316|NCT03074435|Experimental|Ivermectin|This arm consists in an injectable dose of Ivermectin given to peri-domestic animals.
89561317|NCT03074435|Experimental|Information, Education, Communication|After a sociological study during the pre-intervention year, this arm will consist in a reinforced communication strategy relative to the nationwide current one
89210595|NCT00987207|Other|Control|No cyclosporine A is administered before aortic cross-declamping
89561318|NCT03142945|Active Comparator|Traditional Physical Therapy Group|Traditional Physical Therapy Group Physical therapy-based interventions: home exercises (not repeated motions), stretching, modalities, and posture instruction.
89561319|NCT03142945|Experimental|MDT based physical therapy|MDT based physical therapy Physical therapy-based interventions: home exercises (including repeated motions), stretching, modalities, and posture instruction.
89561320|NCT04996277|Experimental|Fractional Flow Reserve|Patients with FFR ≤ 0.8 will undergo PCI Patients with FFR > 0.8 will be treated with medication For study purposes, all patients will undergo OCT (subject's treatment strategy will be based on FFR results, e.g., stent-implanted OCT).
89561321|NCT04996277|Experimental|Optical CoherenceTomography|Patients with MLA < 4.5mm² will undergo PCI Other patients will be treated with medication For study purposes, all patients will undergo FFR (subject's treatment strategy is based on OCT results; reference to FFR results is not recommended)
88967196|NCT03041844|Sham Comparator|Sham Ultrasound|Sham ultrasound applied weekly for up to 16 weeks.
88967197|NCT03794908|Experimental|Light therapy A (Bright) via the Re-Timer®|"60 minutes/day~For the first hour after waking"
88967198|NCT03794908|Active Comparator|Light therapy B (Dim) via the Re-Timer®|"60 minutes/day~For the first hour after waking"
88967199|NCT04712201|Experimental|En bloc|En bloc transurethral resection of the bladder
88967200|NCT04712201|Active Comparator|Conventional|Conventional transurethral resection of the bladder
88967201|NCT00390039|Experimental|A|MNS075 7.5mg
88967202|NCT00390039|Placebo Comparator|B|Placebo
88967203|NCT00390039|Active Comparator|C|IV Morphine
88967204|NCT00390039|Experimental|E|MNS075 15mg
88967205|NCT00390039|Placebo Comparator|D|Placebo
88967206|NCT00390039|Placebo Comparator|F|Placebo
88967207|NCT01838369|Experimental|BI-505|
88967208|NCT03675022|Experimental|Dupilumab|Dupilumab injections every 2 weeks.
88967209|NCT00399919|Experimental|PLC|Investigational drug
88967210|NCT00399919|Placebo Comparator|Placebo|
88967211|NCT04935801|Sham Comparator|LD Vehicle_GNP|Low dose (LD) comparator (2.5nmol) - gold nanoparticle (14.8ug) without peptides
88967212|NCT04935801|Experimental|LD PepGNP-Dengue|Low dose (LD) peptide vaccine (2.5nmol) - gold nanoparticle (14.8ug) plus peptides
88967213|NCT04935801|Sham Comparator|HD vehicle-GNP|High dose (HD) comparator (7.5nmol) - gold nanoparticle (44.5ug) without peptides
88967214|NCT04935801|Experimental|HD PepGNP-Dengue|High dose (HD) peptide vaccine (7.5nmol) - gold nanoparticle (44.5ug) plus peptides
88967215|NCT03393013|Experimental|KZR-616 45 mg + standard of care therapy (Phase 1b)|"Dose escalation cohort of patients with SLE with and without nephritis to receive 45 mg dose level of KZR-616 in combination with standard of care therapy.~Two Phase 1b cohorts received 45 mg at some point during the study.~Cohort 1 received 45 mg zetomipzomib frozen maleate weekly for 13 weeks.~Cohort 2a followed a step-up dosing procedure. Patients received zetomipzomib frozen maleate, 30 mg weekly for 2 weeks, followed by 45 mg weekly for 2 weeks then followed by 60 mg weekly for 9 weeks.~KZR-616 was administered as a SC injection."
89561322|NCT04996277|Experimental|angiography|Appropriate treatment (implantation of stents) will be given according to the evaluation of the physician.
89561323|NCT03111199|Placebo Comparator|Control Placebo Group|The subjects of this group will be submitted to TENS bound in placebo mode in the lumbar spine.
89561324|NCT03111199|Experimental|Cryotherapy Group|The subjects of this group will be submitted to Cryotherapy in the lumbar spine.
89561325|NCT03111199|Experimental|TENS Burst Group|The subjects of this group will be submitted to TENS Burst in the lumbar spine.
89561326|NCT03111199|Experimental|TENS Burst and Cryotherapy Group|The subjects of this group will be submitted to TENS Burst and Cryotherapy in the lumbar spine.
89561327|NCT04991519||Stroke Survivors|Participants have had a left-hemisphere stroke with or without aphasia, or a stroke elsewhere in the brain causing aphasia. They are given a series of standardized and in-house tests of language and cognition to provide a detailed profile of strengths and weaknesses, plus an MRI.
89561328|NCT04991519||Controls|Participants are matched to aphasia cohort in age, educational background, race, and gender but have no history of brain injury. They are also given a series of standardized and in-house tests of language and cognition to provide a detailed profile of strengths and weaknesses, plus an MRI.
89561329|NCT03833089|No Intervention|Control|ICD recipients in optimal Medical treatment as per guidelines according to their comorbidity
89561330|NCT03833089|Experimental|Targeted serum potassium levels|ICD recipients recipients in optimal Medical treatment as per guidelines according to their comorbidity. In addition to guideline recommended treatment, this cohort will be treated to increase serum potassium levels to 4.5-5.0 mEq/L.
89561331|NCT03071939|Other|patients with schizophrenia and their designated relatives|Evaluation of the patient's insight (an inclusion phase, followed by two evaluation phases on D0 and D7) by the patient, his / her close and two caregivers (inter-judicial fidelity)
89561332|NCT03142789|Active Comparator|Certa Catheter|"A Certa-catheter (suture method) is inserted under ultrasound guidance at the midthigh level in the adductor canal, using an in plane technique, short/oblique axis view.~A bolus of ropivacaine will be administered during real time US imaging to ensure correct placement of the catheter (initial bolus). An infusion pump will be connected immediately following catheter insertion, delivering intermittent boluses every 8 hours until 12 pm on POD2.~2 dressings will be applied (medial and lateral) to obscure which catheter has been placed."
89561333|NCT03142789|Active Comparator|Standard Catheter|"A Standard-catheter is inserted under ultrasound guidance at the midthigh level in the adductor canal, using an in plane technique, short/oblique axis view.~A bolus of ropivacaine will be administered during real time US imaging to ensure correct placement of the catheter (initial bolus). An infusion pump will be connected immediately following catheter insertion, delivering intermittent boluses every 8 hours until 12 pm on POD2.~2 dressings will be applied (medial and lateral) to obscure which catheter has been placed."
89561334|NCT03142789|Active Comparator|Single Bolus|"A bolus of ropivacaine will be injected into the adductor canal, at the midthigh level, using a 80 mm x 22G Pajunk needle during real time US imaging (initial bolus).~A sham catheter (25 Certa and 25 standard catheters according to randomi-zation) will be fixed externally and covered by dressings as in the catheter groups groups (Certa and standard). Care will be taken to use approximately the same amount of time as used in the catheter groups (Certa and standard) An infusion pump will be connected immediately following catheter insertion, delivering intermittent boluses into the dressing every 8 hour until 12 PM on POD2."
89561335|NCT03072329|Experimental|Pudendal nerve block|Bilateral pudendal nerve block with the administration of 0.1 mL/kg Bupivacaïne 0.5%, regardless of neurostimulation response.
89561336|NCT02327689|Experimental|compensated HBV related cirrhosis patients|Chinese naive compensated HBV related cirrhosis patients were treated with generic emtricitabine capsule(200 mg one time per day) plus adefovir dipivoxil(10 mg one time per day) for 96 weeks
89561337|NCT02327689|Experimental|decompensated HBV related cirrhosis patients|Chinese naive decompensated HBV related cirrhosis patients were treated with generic emtricitabine capsule(200 mg one time per day) plus adefovir dipivoxil(10 mg one time per day) for 96 weeks
89210596|NCT04044326|Experimental|microwave ablation (MWA)|20 patients with liver cancer, considered for local treatment of liver tumors of size measuring <5 cm and without any signs of extra-hepatic metastasis, will be enrolled to be treated with microwave ablation (MWA)
89561338|NCT03141697|Experimental|Carbon Dioxide|Colonoscopy with Insufflation of Carbon Dioxide
89561339|NCT03141697|Placebo Comparator|Room Air|Colonoscopy with Insufflatioin of Room Air
89561340|NCT03072017|Experimental|MBAT|Monitored breathing awareness therapy administered using a mobile device on a nightly basis during sleep onset.
89561341|NCT02327923|Active Comparator|Lidocaine|Intravenous bolus administration of lidocaine at the time of induction followed by infusion till the last suture.
89561342|NCT02327923|Active Comparator|Esmolol|Intravenous bolus administration of esmolol at the time of induction followed by infusion till the last suture.
89561343|NCT04991207|Experimental|BIA 5-1058|Treatment Period 1: Subjects were admitted to the clinical unit on Day 1. Subjects received a single oral dose of BIA 5 1058 400 mg (4 x 100 mg tablets) on Day 1 after an overnight fast of at least 8 hours. Subjects were discharged from the clinical unit on Day 4 (approximately 72 hours after dosing) barring any medical reasons for an extended clinical stay.
89561344|NCT04991207|Active Comparator|Bosentan|Treatment Period 2: Subjects were admitted to the clinical unit on Day 1. Subjects received multiple (twice daily [b.i.d.]) oral doses of bosentan (Tracleer® 1 x 125 mg film coated tablet) approximately 30 minutes before each meal (breakfast and dinner) from Days 1 to 5. On Day 6 after an overnight fast of at least 8 hours, subjects received a single morning dose of bosentan (Tracleer® 1 x 125 mg film coated tablet). Subjects were discharged from the clinical unit on Day 9 (approximately 72 hours after last dosing) barring any medical reasons for an extended clinical stay.
89561345|NCT04991207|Experimental|BIA 5-1058 and Bosentan|Treatment Period 3: Subjects were admitted to the clinical unit on Day 1. Subjects received multiple b.i.d. oral doses of bosentan (Tracleer® 1 x 125 mg film coated tablet) approximately 30 minutes before each meal (breakfast and dinner) from Days 1 to 5. On Day 6 after an overnight fast of at least 8 hours, subjects received a single concomitant dose of BIA 5 1058 400 mg (4 x 100 mg tablets) and bosentan (Tracleer® 1 x 125 mg film coated tablet). Subjects were discharged from the clinical unit on Day 9 (approximately 72 hours after last dosing) barring any medical reasons for an extended clinical stay.
89561346|NCT03072173|Experimental|PSG with Xylometazoline then placebo|"Patients are administered nasal CPAP with humidifier prior to PSG~Patients in this arm receive Xylometazoline on night 2 of PSG and placebo on night 3 of PSG."
89561347|NCT03072173|Experimental|PSG with placebo then Xylometazoline|"Patients are administered nasal CPAP with humidifier prior to PSG~Patients in this arm receive placebo on night 2 of PSG and Xylometazoline on night 3 of PSG."
89561348|NCT03141463|Experimental|Vvax001 therapeutic cancer vaccine|Patients will receive three consecutive doses of Vvax001, with an interval of 3 weeks
89561349|NCT03072095|Experimental|Text-only|Text-only outreach
89561350|NCT03072095|Experimental|Text + Lottery|Text outreach + financial incentive
89561351|NCT02327611|Experimental|Custodiol|Renal perfusion with Custodiol (cold crystalloid solution enriched with histidine-tryptophan-ketoglutarate).
89561352|NCT02327611|Active Comparator|enriched Ringer's lactate solution|Renal perfusion with cold Ringer's lactate solution enriched with methylprednisolone 125 mg /L and mannitol 12.5 g /L.
89561353|NCT03826849|No Intervention|Waitlist Control|Assessment only condition for all 12 weeks of participation.
89561354|NCT03826849|Experimental|Insomnia Coach|Intervention condition that involves use of the Insomnia Coach app for 6 weeks.
89561355|NCT03072641|Experimental|ProBion Clinica|Probiotic tablets yielding a daily dose of 1.4 x 10 ˄ 10 Bifidobacterium lactis Bl-04 (ATCC SD5219), 7x10 ˄ 9 Lactobacillus acidophilus NCFM (ATCC 700396), and 0.63 g inulin.
89561356|NCT03072641|No Intervention|Control|
89561357|NCT03074279||Cases|Patient with epilepsy who died as a result of confirmed or probable SUDEP and NEAR SUDEP during the study period.
89561358|NCT03074279||Controls|Patient with epilepsy matched by: âge, etiology and type of epilepsy, level of seizure control
89561359|NCT02327533||Patients with Aggressive Periodontitis|The periodontal diagnosis of subjects with GAgP was established on the basis of clinical and radiographic criteria and was defined by the 1999 International World Workshop for a Classification of Periodontal Diseases and Conditions.(Lang et al., 1999)
89561360|NCT02327533||Controls|Control subjects had no radiographic evidence of bone loss or any sign of past and present periodontitis.
89561361|NCT04991363|Experimental|Patients|
89561362|NCT03764371||sMPLC|Lung cancer related genes in tumor tissues and patients with at least 2 tumors that were confirmed as invasive adenocarcinoma by pathology after sMPLC resection (residual non-resectable or non-qualitative pulmonary nodules).
89561363|NCT03074123|Experimental|healthy subjects|20 healthy subjects will undergo low dose cosyntropin stimulation test. Serum and salivary cortisol will be measured just before cosyntropin administration and 30 minutes later.
89561364|NCT05078749|Active Comparator|Exercise training group|Continuous progressive exercise training will be applied to the treatment group. The exercises will be performed every day, twice a day, for an average of 10 minutes/session, for eight weeks. Exercise training will be updated regularly at two-week intervals. A different and progressive new exercise will be sent to the patients as a Youtube link. The patients will be interviewed by video every week.
89561365|NCT05078749|Sham Comparator|Control training group|The control group will be followed up as a home program by explaining the exercises and giving a brochure. They will be asked to do the exercises regularly for 7 days/week, 2 sessions/day, for eight weeks. Patients in the control group will be followed up by phone once a week.
89027088|NCT02891317||Glaucoma Drainage Device|Twenty-five participants with moderate or severe open angle glaucoma (OAG) that meets clinical criteria for implantation of a glaucoma drainage device (Group 3) will be recruited from the glaucoma clinics at the UNC Kittner Eye Center. Patients who are consented for implantation of a glaucoma drainage device (Group 3) will be recruited to this group. There will be 25 participants in each of the groups. Each procedure will be completed in a standardized fashion with standardization of the post-operative medications. An effort will be made to gender and age match each surgical group as well as provide reasonable racial and ethnic diversity.
89027089|NCT00473291||Patients with pleural effusion|Patients diagnosed with pleural effusion and presenting for treatment
89027090|NCT02275104||Ventricular arrhythmias|
89027091|NCT02275104||Persistent atrial fibrillation|
89027092|NCT05644717|Experimental|Ertugliflozin|Ertugliflozin 5/15mg once daily with standard of care
89027093|NCT01248429||Patient treated by TKI|Any patient with solid tumor and treated by Thyrosine Kinase Inhibitor for at least 1 week
89561366|NCT04433663|Experimental|Mentalization-based Intervention|Participants in the intervention group, received mentalization-based psychotherapy with the developed ECOSA axis. Therapist received mentalization-based supervision.
89561367|NCT04433663|Active Comparator|IPT-Inter Personal Therapy|The control group's participants received IPT - interpersonal psychotherapy that focused on resolving interpersonal problems and symptomatic recovery. The control group's therapist received regular supervision - with no emphasis on mentalization or tool's usage.
89561368|NCT02327299|Experimental|FePP|Bouillon fortified with 4mg FePP
89561369|NCT02327299|Experimental|FePP + Stabilizer|Bouillon fortified with 4mg FePP + Stabilizer
89561370|NCT02327299|Experimental|FeSO4|Bouillon fortified with 4mg FeSO4
89561371|NCT02327299|Experimental|FeSO4 + Stabilizer|Bouillon fortified with 4mg FeSO4 + Stabilizer
89561372|NCT03071627|Active Comparator|News with Spin|News items reporting results of animal studies with spin.
89561373|NCT03071627|Experimental|News without spin|News items reporting results of animal studies without spin.
89561374|NCT03071783|Experimental|Vacuum extraction intelligent system|Measurement and intra-operative feed back of vacuum extraction data: notification signal based an algorithm calculation using traction force (peak and time force integral) and time.
89561375|NCT03071783|No Intervention|conventional|conventional handle
89561376|NCT02327377|Experimental|Online Cognitive Behavior Therapy|Online cognitive behavior therapy for coping with pain
89561377|NCT02327377|Active Comparator|Online Education|Educational information about pain
89561378|NCT03071549|Active Comparator|combined azaleic and salicylic acids|Combined azaleic acid 20% with salicylic acid 20% peel every 2 weeks for 4 sessions
89561379|NCT03071549|Active Comparator|Trichloroacetic acid peel|Trichloroacetic acid 25% peel every 2 weeks for 4 sessions
89561380|NCT03144817|No Intervention|Control Group|
89561381|NCT03144817|Experimental|Intervention Group|Intervention group will dialyze with dialysate Na 135 mEq/L.
89561382|NCT03074201|Experimental|Cholangioscopy|Participants in this arm undergo radiation-free ERCP facilitated by cholangioscopy
89561383|NCT03734965|Active Comparator|AWAKEN INTUBATION FIBEROPTIC|awaken intubation
89561384|NCT03734965|Experimental|AWAKEN INTUBATION VIDEOLARYNGOSCOPY|awaken intubation
89561385|NCT04994951|Experimental|Qing-Re-Liang-Xue Decoction.|One dose of granules is mixed, poured into 500ml of boiling water, and taken twice in the morning and afternoon. Women stop taking Chinese medicine during the first 3 days of menstruation. Triamcinolone Acetonide Acetate and Urea Cream,10g/tube and Calcipotriol Ointment,10g/tube are used alternately. The period of treatment will be 10 weeks.
89561386|NCT04994951|Active Comparator|control group|Topical steroids. Triamcinolone Acetonide Acetate and Urea Cream,10g/tube and Calcipotriol Ointment,10g/tube are used alternately. The period of treatment will be 10 weeks.
89561387|NCT03073889|Experimental|Block|Scalp nerve block with 10ml solution of 0.75% ropivacaine before skin incision, n=15
89561388|NCT03073889|Active Comparator|Infiltration|Scalp infiltration with 10ml solution of 0.75% ropivacaine before incision, n=15
89561389|NCT03073889|No Intervention|Control|the control group has no treatment, n=15
89561390|NCT03645967|Other|ReadyCleanse for IUC|ReadyCleanse Cloths will be used for the standard of care for indwelling urinary catheter care and maintenance. The old standard of care will no longer be used.
89561391|NCT03570931|Experimental|RT001|RT001, oral, 3.84 g/day
89561392|NCT05078515||Patients with recurrence after TME|Patients who developed local recurrence after TME of rectal cancer
89561393|NCT05078515||Patients without recurrence after TME|Patients who did not develop local recurrence after TME of rectal cancer
89561394|NCT03142633||Women with Polycystic Ovary Syndrome|"Participants of the PICOLO study~Inclusion criteria:~Women aged 18-40 years when included in the PICOLO-cohort, PCOS based on the Rotterdam 2003 consensus criteria Exclusion criteria: Contraceptive pills within 6 weeks from examination, endocrinological disease (i.e. diabetes, thyroid dysfunction), endometriosis and premature ovarian insufficiency, breastfeeding women and pregnancy."
89561395|NCT04477369|Other|Sequence A|7 subjects assigned to Sequence A will receive a single dose of 300mg DWJ1439 in period 1, 300mg DWC202003 in period 2 and 300mg DWJ1464 in period 3.
89561396|NCT04477369|Other|Sequence B|7 subjects assigned to Sequence B will receive a single dose of 300mg DWJ1464 in period 1, 300mg DWC202004 in period 2 and 300mg DWC202003 in period 3.
89561397|NCT04477369|Other|Sequence C|7 subjects assigned to Sequence C will receive a single dose of 300mg DWC202003 in period 1, 300mg DWJ1439 in period 2 and 300mg DWC202004 in period 3.
89561398|NCT04477369|Other|Sequence D|7 subjects assigned to Sequence D will receive a single dose of 300mg DWC202004 in period 1, 300mg DWJ1464 in period 2 and 300mg DWJ1439 in period 3.
89561399|NCT05080933||COVID-19|
89561400|NCT05080933||H1N1|
89561401|NCT02636699|Experimental|Viaskin Peanut 250mcg|
89561402|NCT02636699|Placebo Comparator|Placebo|
89561403|NCT05080855|Active Comparator|the cleft lip will be repaired by modified Millard technique|In the modified Millard technique, points (nasal and Vermilion border points) and lines (rotational and advancement flap lines and mucosal lines) were drawn. Then, we cut the submucosal layer and created three flaps: advancement flap, rotational flap, and c flap. The orbicular muscle was dissected and freed from the columellar base on the non-cleft side and from the alar base on the cleft side. Using a vicryl 5-0, we sutured the anterior nasal floor; then, using vicryl 4-0, we sutured the alar base and muscle. Using vicryl 6-0, we sutured top of philtral column with point a, the peak of Cupid's bow, and tip of c flap with alar base. The suturing of mucosal lip was carried out using a vicryl 5-0.
89561404|NCT05080855|Active Comparator|the cleft lip will be repaired by Tennison-Randall technique.|In the Tennison-Randall technique, points (nasal and Vermilion border points) and lines (Skin triangle flap lines and mucosal lines) were drawn. Then, we cut the submucosal layer and created equilateral triangle flap and releasing incision. The orbicular muscle was dissected and freed from the columellar base on the non-cleft side and from the alar base on the cleft side. The suturing of the anterior nasal floor, alar base, and muscle followed the same principles of the modified Millard technique. The cutaneous repair was done by suturing the top of philtral column, the peak of Cupid's bow, point a, the line between the top of philtral column and the peak of Cupid's bow with b-8 and 3-a with b-a.
89561405|NCT03140839|Experimental|Imaginal Rescripting|"Imaginal Rescripting (IR) targets imagery-based mental representations embedded within patients negative autobiographical memories related to social anxiety. In IR, patients progress through 3 distinct phases: (1) They relive a past negative event in their imagination, (2) are guided to actively change the original memory in their imagination to create more satisfying outcomes, and (3) relive the memory again while incorporating the new information. The IR intervention will be administered in one 90 minute session."
89561406|NCT03140839|Active Comparator|Imaginal Exposure|"Imaginal Exposure (IE) involves repeatedly reliving a negative autobiographical memory related to social anxiety from a first-person perspective and actively considering alternative meanings of the memory, but differs from IR in that the original memory itself is never explicitly modified in any way. The IE intervention will be administered in one 90 minute session."
89561407|NCT03140839|Placebo Comparator|Supportive Counselling|Supportive counselling (SC) provides patients with empathic support regarding a negative autobiographical memory related to social anxiety. The SC condition controls for non-specific clinical factors such as therapeutic attention and alliance. SC will be administered in one 60-90 minute session.
89561408|NCT03071705|Experimental|Intervention|TKI plus Metformin
89561409|NCT03071705|Active Comparator|Control|TKI
89561410|NCT04995185|Experimental|PET/CT imaging|Intravenous injection of 370MBq ± 10% (18)F-fluoromisonidazole
89561411|NCT03351439|Active Comparator|Group 1|Oxycodone-acetaminophen 5 mg/325 mg, 1-2 tabs every 6 hours as needed for 60 tabs Naprosyn 500 mg twice daily x 3 weeks
89561412|NCT03351439|Experimental|Group 2|Oxycodone-acetaminophen 5 mg/325 mg, 1-2 tabs every 6 hours as needed for 60 tabs Naprosyn 500 mg twice daily for 3 weeks Zopiclone 7.5 mg nightly for 7 days
89561413|NCT03351439|Experimental|Group 3|Oxycodone-acetaminophen 5 mg/325 mg, 1-2 tabs every 6 hours as needed for 60 tabs Naprosyn 500 mg twice daily for 3 weeks Gabapentin 600 mg pre-operatively for one dose and 600 mg post-operatively for one dose
89561414|NCT03351439|Experimental|Group 4|Oxycodone-acetaminophen 5 mg/325 mg, 1-2 tabs every 6 hours as needed for 60 tabs Naprosyn 500 mg twice daily for 3 weeks Celebrex 400 mg pre-operatively for one dose
89561415|NCT04990661|Experimental|Intervention group (massage group)|intradialytic massage for lower extremity was applied to the intervention group in three sessions a week and a total of six sessions for two weeks
89561416|NCT04990661|No Intervention|Control group|not administered except nursing interventions in the HD unit.
89561417|NCT03141385|Experimental|RIPC intervention|Remote ischemic preconditioning (RIPC) will be induced after the general anesthesia prior to the cardiopulmonary bypass by four cycles of right limber ischemia (5-min blood pressure cuff inflation to a pressure of 200mmHg or a pressure that is 50 mmHg higher than SAP and 5-min cuff deflation)
89561418|NCT03141385|Sham Comparator|Control|Four cycles of right upper limb pseudo ischemia and reperfusion, which will be induced by 5-minute blood pressure cuff inflation to a low pressure of 20 mmHg followed by 5-minute cuff deflated.
89561419|NCT03139747|Experimental|Single Arm|
89561420|NCT04433429||RYR plus CoQ|333 mg of red yeast rice (RYR, equivalent to 10 mg of Monacolin K) plus 30 mg of Coenzyme Q10 (CoQ10) in a single pill once daily
88967216|NCT03393013|Experimental|KZR-616 60 mg + standard of care therapy (Phase 1b)|"Dose escalation cohort of patients with SLE with and without nephritis to receive 60 mg dose level of KZR-616 in combination with standard of care therapy.~Four Phase 1b cohorts received 60 mg at some point during the study.~Cohort 2 received 60 mg zetomipzomib frozen maleate weekly for 13 weeks.~Cohorts 2a, 2b, and 2c all followed a step-up dosing procedure. Patients in Cohort 2a received zetomipzomib frozen maleate, 30 mg weekly for 2 weeks, followed by 45 mg weekly for 2 weeks then followed by 60 mg weekly for 9 weeks. Patients in Cohort 2b received zetomipzomib lyophile, 30 mg weekly for 1 week, followed by 60 mg weekly for 12 weeks. Patients in Cohort 2c (tolerability strategies cohort) received zetomipzomib lyophile, 30 mg weekly for 1 week, followed by 60 mg weekly for 12 weeks.~KZR-616 was administered as a SC injection."
88967217|NCT03393013|Experimental|KZR-616 75 mg + standard of care therapy (Phase 1b)|"Dose escalation cohort of patients with SLE with and without nephritis to receive 75 mg dose level of KZR-616 in combination with standard of care therapy.~One Phase 1b cohort received 75 mg at some point during the study.~Cohort 3 followed a step-up dosing procedure. Patients in Cohort 3 received zetomipzomib lyophile, 30 mg weekly for 1 week, followed by 75 mg weekly for 12 weeks.~KZR-616 was administered as a SC injection."
88967218|NCT03393013|Experimental|KZR-616 60 mg + standard therapy (Phase 2)|"60 mg dose level of KZR-616 selected based on data from the phase 1b dose escalation and administered to patients with active lupus nephritis in combination with standard therapy including at least one immunosuppressive agent.~KZR-616 was administered as a SC injection weekly at a dose of 60 mg for 24 weeks (including a step-up from an initial Week 1 dose of 30 mg).~** See Limitations/Caveats for additional information"
89210597|NCT00604188|Experimental|Direct Suboxone Induction|Participants received 8 mg of Suboxone and placebo Subutex on Day 1, 16 mg of Suboxone and placebo Subutex on Day 2, and all participants received open label Suboxone from Day 3 to Day 28. Suboxone dosage may be titrated from Day 4 to Day 28 up to 24 mg per day.
89027094|NCT01316614|Experimental|With Stylet & Without Stylet|There will only be one arm in this study. This arm will undergo EUS-guided FNA with the use of a stylet for half of their FNA passes and without a stylet for the other half. Patients will be exposed to an equal number of passes with and without a stylet. Each pass will be individually assessed by a skilled cytopathologist who is blinded to the technique used. We will compare the adequacy of both techniques to determine whether or not a stylet leads to a higher diagnostic accuracy rate in patients with solid lesions.
89027095|NCT00479648|Active Comparator|1|Inactivated trivalent influenza vaccine
89027096|NCT00479648|Experimental|2|CSL412 formulation
89027097|NCT00479648|Experimental|3|CSL412 formulation
89027098|NCT00479648|Experimental|4|CSL412 formulation
89027099|NCT01316575|Experimental|nCPAP|The experimental group will receive nasal CPAP at 10cmH20 for one hour in the Post Anesthetic Care Unit.
89027100|NCT01316575|Active Comparator|Low Flow Oxygen|The control group will receive standard therapy of low flow oxygen via simple mask at 8 litres per minute.
89027101|NCT02955771|Experimental|PDT-Deuteporfin（6 hour）plus stenting|Deuteporfin (7.5mg/kg) was injected intravenously 6 hours before intraluminal photoactivation (wavelength,630 nm;light dose, 180 J/cm(2)). After PDT, endoscopic or percutaneous stenting will be performed.The second treatment may be given after 3 months.
89210598|NCT00604188|Active Comparator|Subutex-to-Suboxone Induction|Participants received 8 mg Subutex and placebo Suboxone on Day 1, 16 mg Subutex and placebo Suboxone on Day 2, and all participants received open label Suboxone from Day 3 to Day 28. Suboxone dosage may be titrated from Day 4 to Day 28 up to 24 mg per day.
89561421|NCT04990583|Experimental|Carium Condition|Participants assigned to the Carium condition will receive a single session intervention and receive 12 months of access to the Carium adherence application.
89561422|NCT04990583|Active Comparator|Control Condition|Participants assigned to the Control condition will receive a single session intervention only.
89561423|NCT04990271|Experimental|Conbercept intravitreal Injection|
89561424|NCT05191459||Heart failure and preserved ejection fraction|42 patients 50-90 years with preserved ejection fraction (EF ≥50%)
89561425|NCT05191459||Heart failure and reduced ejection fraction|42 patients 50-90 years with reduced ejection fraction ((EF≤40%)
89561426|NCT04990193|Active Comparator|Control group|Children in the control group received the conventional physical therapy protocol which was designed to improve axial stability and trunk steadiness during standing and walking.
89561427|NCT04990193|Experimental|Study group|The children in the study group received the conventional protocol given to the control group. Moreover, they wore TheraTog orthotic undergarment with its strapping system eight hours every day for twelve consecutive weeks.
89561428|NCT03141541|No Intervention|Usual care|All patients receive a thorough physical examination by a rheumatologist or a chiropractor with a subsequent examination by a physiotherapist.The patients receive general information about the nature back pain, adjustment of analgesic treatment and clarification of any need of further diagnosing or assessment by a surgeon. The physiotherapist furthermore makes an assessment of the patients' physical capacity and function and provides guidelines for any exercise programme. Based on the physiotherapist's judgement, the patient may be referred to rehabilitation in the local community
89561429|NCT03141541|Experimental|Group based pain management intervention|In addition to usual care as described for the control group, the patients in the intervention group will participate in a cognitive group-based pain management intervention. The aim of the intervention is to improve the patients' understanding of their back pain problem, and that they learn different pain coping strategies. The intervention is based on cognitive behavioural therapy including elements of acceptance and commitment therapy, and furthermore uses different relaxation and breathing exercises.
89561430|NCT03071315||CCT participants|Center-based compulsory treatment (CCT) participants who were placed into compulsory treatment centers for two years for a range of punitive treatment such as education, moral teaching, labor work. Very basic health care is provided in the CCT centers.
89561431|NCT03071315||MMT participants|Methadone maintenance treatment (MMT) participants who have been receiving MMT treatment. In Hai Phong City, during the period of this study, voluntary MMT was provided in the community free for people who were assessed as dependent on heroin.
89561432|NCT02888821|Experimental|CLS-FUERTE|Families will receive the CLS-FUERTE intervention in the fall of the 2016-2017 school year. CLS-FUERTE includes caretaker, child and teacher components implemented during a 6 week period. All content of group sessions will be derived from the manualized CLS-FUERTE treatment protocol developed by the PI and study staff.
89561433|NCT02888821|Other|Business as Usual (BAU) Waitlist Control|Families will receive school services as usual while on a waitlist to receive CLS-FUERTE in the spring of the 2016-2017 school year.
89561434|NCT03073655|Experimental|Group 1|it has been limited evidence of KT is effective
89561435|NCT03073655|Experimental|Group 2|it has been not known that KT is effective or not
89561436|NCT03073655|Experimental|Group 3|it has been known that KT has excellent result
89561437|NCT04770805|Experimental|Fetoscopic repair|Sacral Myelomeningocele and Mye-LDM Fetoscopic repair
89561438|NCT03139591|Active Comparator|lidocaine inhalation|Lidocaine inhalation group: 1.5 mg/kg body weight (BW) of 2% lidocaine inhalation, diluted with 2-3 ml of normal saline until the total volume was 6 ml, and intravenous normal saline injection
89561439|NCT03139591|Active Comparator|intravenous dexamethasone|Intravenous dexamethasone group: normal saline inhalation and 10 mg of intravenous dexamethasone
89561440|NCT03071237||Observational group|Patients who would receive total gastrectomy or distal gastrectomy are enrolled in to the study and this group. An optional reconstruction of IPA by enhanced CT scan can be performed before surgery but not a definite require. During the operation, IPA origin location will be photo-taken or video-recorded before its transection.
89561441|NCT02553967|Experimental|Immediate breast reconstruction|"Total mastectomy + immediate reconstructive surgery~6 months after surgery : Functional MRI and questionnaires"
89561442|NCT02553967|Experimental|Secondary breast reconstruction|"Within 2 months before surgery : Functional MRI~Reconstructive surgery~6 months after surgery : Functional MRI and questionnaires"
89561443|NCT04990115|Active Comparator|rotation|root canal preparation performed using rotating instruments
89561444|NCT04990115|Active Comparator|reciprocation|root canal preparation performed using reciprocating instruments
89561445|NCT04756375|Experimental|INTERVENTION|Use of virtual reality in the management of sickle cell patients with VOS
88967219|NCT03239041|Active Comparator|Intervention Arm|"The intervention group will have access to the services of a social navigation team. The social navigation team will consist of trained community health liaisons, a clinician and a social worker.~The social navigation team will function as follows:~The research assistant will then instruct the community health intern to review the results of the completed computerized survey. The community health intern will review the results, create a plan of action, i.e. specific referrals to community agencies and next steps needed by the caregiver and or adolescent (e.g., documents to gather, appointments to make, etc.), following pre-developed protocols for each risk area. Each plan will be reviewed with the social worker prior to presentation to the family. Each family will also receive a packet of community resources relevant to each social domain covered in the screening survey, similar to that provided to the enhanced usual care group."
88967220|NCT03239041|No Intervention|Enhanced Usual Care Arm|The enhanced usual care arm will only receive printed information regarding community resources.
89561446|NCT04756375|Other|NO INTERVENTION|
89561447|NCT04987619|Experimental|BJR|70 mL of beetroot juice (BEET It Sport®; James White Drinks Ltd., Ipswich, UK)
89561448|NCT04987619|Placebo Comparator|PLA|70 mL of blackcurrant beverage Capri-Sun.
89561449|NCT03139357||Primary care patients|Patients ages 20-65 who score 5 or greater on the GAD-7 will be given the SF12, GAD7, medial utilization, and helpfulness questionnaires at 6 month intervals for a 2 year period.
89561450|NCT04469101|Experimental|Left Uterine Displacement|Supine with left tilt for uterine displacement
89561451|NCT04469101|Experimental|Left Lateral|Left lateral decubitus position
89561452|NCT04469101|Experimental|Right Lateral|Right lateral decubitus position
89561453|NCT04469101|Experimental|Upright|Upright seated position
89561454|NCT04987853||Acute COVID patients|Patients in the acute phase of the course of the disease
89561455|NCT04987853||Long Covid Patients|Patients with chronic symptoms after a previous Covid-19 (4-12 weeks)
89561456|NCT04987853||Postcovid patients|Patients with chronic symptoms after a previous Covid-19 (more than 12 weeks)
89561457|NCT05154565|Experimental|Immediate intervention (Group A)|Meditation intervention applied during Phase 1 of the study. During Phase 2, the formal meditation intervention is not completed, but participants are followed for outcome measurement. Participants may continue to use meditation in their daily routines or return to their usual routines.
89561458|NCT05154565|Other|Delayed intervention (Group B)|No intervention is applied in Phase 1 of the study. This group serves as the control group for Phase 1. The meditation intervention is applied in Phase 2 of the study.
89561459|NCT02634983|Experimental|QVA149 110/50 mcg then Matching placebo|Single daily dose of 110/50 μg QVA149 for 8-10 days.
88967221|NCT02965105|Experimental|First Coloplast Test Catheter; then Speedicath|The subjects allocated to this arm first test Coloplast Test Catheter and then after cross over test the comparator Speedicath Catheter
88967222|NCT02965105|Experimental|First Speedicath; then Coloplast Test Catheter|The subjects allocated to this arm first test Speedicath Catheter and then after cross over test Coloplast Test Catheter
88967223|NCT00379652|Active Comparator|A|Patient-based intervention
88967224|NCT00379652|Active Comparator|B|Health center-based intervention
88967225|NCT00379652|Active Comparator|C|Combination of patient and health center-based intervention
88967226|NCT00379652|No Intervention|D|Control group: Neither patient-based nor center-based intervention
88967227|NCT02832544|Experimental|Rivaroxaban (20 mg)|Rivaroxaban 20 mg od (n ~ 2250); 15 mg od (once daily) in patients with creatinine clearance (CrCl) 15-49 ml/min
88967228|NCT02832544|Active Comparator|Vitamin K antagonists (VKA)|Any approved VKA in the participating country (n ~ 2250); VKA titrated to achieve an INR of 2.0-3.0
88967229|NCT02395705|Experimental|Neo-adjuvant chemotherapy group|"Neo-adjuvant chemotherapy(cisplatin and paclitaxel):~Paclitaxel, 175mg/m2, d1, Cisplatin, 25mg/m2, d2-d4, 3 week, 2 cycles.~Paclitaxel, 87.5mg/m2, d1,d8, Cisplatin, 25mg/m2, d2-d4, 3 week, 2 cycles.~Paclitaxel, 175mg/m2, d1, Cisplatin, 75mg/m2, d1, 3 week, 2 cycles.~Surgery:~2-3weeks after Neo-adjuvant chemotherapy~Surgeons: the operation shall be performed by senior thoracic surgeons. Try to achieve the consistency of operation quality.~Operation: the thoracic esophagectomy must be through right thoracic cavity. (open and minimally invasive McKeown or Ivor Lewis). Total two-field lymphadenectomy (right and left recurrent laryngeal nerve lymph nodes must be included)."
88967230|NCT02395705|No Intervention|Surgery alone group|"Surgery:~2-3weeks after Neo-adjuvant chemotherapy~Surgeons: the operation shall be performed by senior thoracic surgeons. Try to achieve the consistency of operation quality.~Operation: the thoracic esophagectomy must be through right thoracic cavity. (open and minimally invasive McKeown or Ivor Lewis). Total two-field lymphadenectomy (right and left recurrent laryngeal nerve lymph nodes must be included)."
88967231|NCT00006047|Experimental|Combination Therapy|Combination Therapy with Oral 9-Nitrocamptothecin & Oral Etoposide. Patients receive oral nitrocamptothecin on days 1-3 and oral etoposide on days 4-5 each week. Treatment continues in the absence of disease progression or unacceptable toxicity.
89561460|NCT02634983|Placebo Comparator|Matching placebo then QVA149 110/50 mcg|Single daily dose of matching placebo for 8-10 days.
89561461|NCT05115799|Experimental|Patients with Axilliary Web Syndrome and manual therapy and scar massage.|"These users will come from the first moment of the diagnosis of the thrombus in our unit, to receive manual therapy by the physical therapist. They will receive 15 sessions of manual therapy by the physiotherapist, 5 days a week, each session being approximately 40 minutes long. The session will begin with pendulum exercises of the shoulder to warm up the joint and give proprioceptive stimulation to the joint capsule. The physiotherapist will perform passive stretches looking to put tension on the cord lymphatic, never exceeding grade 6 VAS pain. Mainly the shoulder will be worked affected, and if the cord reaches the crease of the elbow or thumb, the extension-supination of the elbow, and ulnar deviation of the wrist.~Scar massage will be done in the area where the lymphatic cord originates at the proximal level while maintaining the tolerable tension of the lymphatic cord (during the massage also pain grade 6 VAS will be exceeded)."
88967232|NCT00083824|Placebo Comparator|Sugar Pill|Placebo
89561462|NCT05115799|Other|Patients with Axilliary Web Syndrome and health education and kinesiotherapy.|These users will be instructed in hygienic-postural care and active auto-kinesitherapy assisted to perform daily for 30 minutes. The investigators will value following the instructions every 30 days
89561463|NCT02405845|Other|CT Angiogram|A research CTA scan may be required if there is no change of the imaging on the 3 CTA scans prior.
89561464|NCT04037215|Other|COGNITIVE TREATMENT OF DIETARY STIMULI AND BODY IMAGE|In order to explore the cognitive treatment of patients with early onset anorexia nervosa in front of images of silhouettes and food, it is currently used in the child psychiatry department of the Robert Debré Hospital, the eye-tracking method. Eye tracking is a non-invasive and painless method of recording the path of vision on images presented on a computer screen. In order to understand the specificities of the eye path in sick patients, we will compare the data with those of controls without eating disorders.
89561465|NCT04987151|Experimental|Strength training|Each session lass 60 minutes, during which time 20 minutes are allocated for warming up and cooling down (stretching) and 40 minutes are allocated to strength training exercise involving the major muscle groups.
89561466|NCT04987151|Experimental|Aerobic training|Each session lass 60 minutes, during which time 20 minutes are allocated for warming up and cooling down (stretching) and 40 minutes are allocated to brisk walking,
89561467|NCT04987151|Experimental|Strength/Aerobic training|Each session lass 60 minutes, during which time 20 minutes are allocated for warming up and cooling down (stretching), 15 minutes are allocated to brisk walking and 25 minutes are allocated to strength training involving the major muscle groups
89561468|NCT04987151|No Intervention|Control Group|All the patients in the wait-list control group will receive one of the three trainings immediately after the intervention.
89561469|NCT03141229|Experimental|Intervention|One school semester MBSR training for teacher; followed by one school semester mindfulness training for children and one school semester follow-up period.
89561470|NCT03141229|Other|Waitlist|One school semester waitlist; followed by one school semester MBSR training for teacher and one school semester MBSR training for children.
89561471|NCT04412291|Active Comparator|Standard-of-care Treatment (SOC)|"SOC according to local recommendations at the Karolinska University Hospital:~Oxygen supplementation so to achieve SpO2>93%. Thrombosis prophylaxis (Fragmin or Innohep or Klexane or new oral anticoagulants incl. dabigatran, apixaban or rivaroxaban).~Steroids (Betapred)"
89561472|NCT04412291|Active Comparator|Anakinra + SOC|"Anakinra: A total dose of 400mg per day (divided in 4 doses of 100 mg iv every 6 hours) for 7 days.~SOC according to local recommendations at the Karolinska University Hospital. Oxygen supplementation so to achieve SpO2>93%. Thrombosis prophylaxis (Fragmin or Innohep) Steroids (Betapred) Prophylactic broad spectrum antibiotics for seven days.."
89561473|NCT04412291|Active Comparator|Tocilizumab + SOC.|Tocilizumab: 8mg/kg for a single infusion iv up to max 800 mg. If no clinical response is obtained, another dose of 8mg/kg may be administered after earliest 2 days SOC according to local recommendations at the Karolinska University Hospital. Oxygen supplementation so to achieve SpO2>93%. Thrombosis prophylaxis (Fragmin or Innohep) Steroids (Betapred) Prophylactic broad spectrum antibiotics for seven days.
89561474|NCT03141073|Experimental|HMS5552|75mg BID
89561475|NCT03141073|Placebo Comparator|Placebo|BID
89561476|NCT04456361|Experimental|COVID-19 patients|Treatment consistsof Mesenchymal Stem Cells administered as a one-time, single-dose therapy via IV infusion at a dose of 1 X 10 8 cells.
89561477|NCT03139513||Metastatic Melanoma|Participants with BRAF V600 mutation-positive unresectable or metastatic melanoma, having started treatment with cobimetinib in combination with vemurafenib as per local guidelines and/or routine clinical practice in context of TAU program, will be observed.
89561478|NCT03071081|Experimental|TOP1288 200mg BID|1 day dosing
89561479|NCT03071081|Placebo Comparator|Placebo to TOP1288 200mg BID|1 day dosing
89561480|NCT03071081|Experimental|TOP1288 1g BID|1 day dosing
89561481|NCT03071081|Placebo Comparator|Placebo to TOP1288 1g BID|1 day dosing
89561482|NCT03071081|Experimental|TOP1288 Xg (where X is <=1g) BID|7 days dosing
89561483|NCT03071081|Placebo Comparator|Placebo to TOP1288 Xg|7 days dosing
89561484|NCT04986995|Experimental|Opicapone|50 mg hard capsules
89561485|NCT04987073|Experimental|patients with CYP24A1 mutation|
89561486|NCT03139435|Experimental|Diagnostic (ultrasound)|Patients undergo peripheral nerve ultrasound. Patients also undergo skin biopsy.
89561487|NCT03070067||Mild ACVS-definite|Clinical diagnosis of ACVS, and imaging positive (either DWI+ or CT/CTA+).
89561488|NCT03070067||Mild ACVS-possible|Clinical diagnosis of ACVS, and DWI- and/or CTA-.
89561489|NCT03070067||Mimic|Clinical diagnosis of mimic and imaging negative.
89561490|NCT03971929|Experimental|SHR0532 tablet|up to 3 cohorts of subjects will receive multiple dose of oral tablets
89561491|NCT03971929|Placebo Comparator|SHR0532 placebo|up to 3 cohorts of subjects will receive multiple dose of oral SHR0532 placebo
89561492|NCT03971929|Active Comparator|Hydrochlorothiazide|up to 3 cohorts of subjects will receive multiple dose of oral Hydrochlorothiazide 25mg
89561493|NCT03071159|Other|cases|children (4-18 years) with type 1 diabetes mellitis using the FreeStyle Flash Libre glucose monitoring system (standard care)
89561494|NCT03626389||Patients receiving physiotherapy in primary care|Physiotherapy, without predetermined selection of specific modalities
89561495|NCT03071003|Experimental|Cohort 1 SENS 401 & Placebo|12 subjects will receive 29 mg SENS-401 (approximately 4 male and 4 female subjects) or placebo (approximately 2 male and 2 female subjects) once daily for 7 days.
89561496|NCT03071003|Experimental|Cohort 2 SENS 401 & Placebo|12 subjects will receive 29 mg SENS-401 (approximately 4 male and 4 female subjects) or placebo (approximately 2 male and 2 female subjects) twice daily for 6 days and a single dose of 29 mg SENS-401 or placebo in the morning on Day 7.
89561497|NCT03071003|Experimental|Cohort 3 SENS 401 & Placebo|12 subjects will receive 43.5 mg SENS-401 (approximately 4 male and 4 female subjects) or placebo (approximately 2 male and 2 female subjects) twice daily for 6 days and a single dose of 43.5 mg SENS-401 or placebo in the morning on Day 7.
89561498|NCT03139201|Experimental|OxyAqua|OxyAqua (olifilcon D) daily disposable
89561499|NCT03139201|Active Comparator|Si-Hy|Si-Hy (olifilcon B) daily disposable
89561500|NCT04986761|Experimental|Workflows|Digital and conventional workflows for treatment of implant single crowns
89561501|NCT04986761|Experimental|Materials|Materials for treatment of implant single crowns (polymer-infiltrated ceramic networks, PICNs and lithium disilicate, LS2).
89561502|NCT03139123||Patients with acute kidney injury|Intensive care unit patients with acute kidney injury. Patients under continuous renal replacement therapy and hemodynamic monitoring.
89561503|NCT05067829|Active Comparator|Ideal Body weight|"ROCURONIUM PRIMING DOSE 0,06 MG/KG FOR IDEAL BODY WEIGHT BEFORE 3 MINUTES BEFORE INDUCTION.~AFTER INDUCTION, ROCURONIUM 0,94 MG/KG FOR IDEAL BODY WEIGHT WILL BE GIVEN."
89561504|NCT05067829|Active Comparator|Total Body Weight|"ROCURONIUM PRIMING DOSE 0,06 MG/KG FOR TOTAL BODY WEIGHT BEFORE 3 MINUTES BEFORE INDUCTION.~AFTER INDUCTION, ROCURONIUM 0,94 MG/KG FOR TOTAL BODY WEIGHT WILL BE GIVEN."
89561505|NCT05067829|Active Comparator|Corrected Body Weight|"ROCURONIUM PRIMING DOSE 0,06 MG/KG FOR CORRECTED BODY WEIGHT BEFORE 3 MINUTES BEFORE INDUCTION.~AFTER INDUCTION, ROCURONIUM 0,94 MG/KG FOR CORRECTED BODY WEIGHT WILL BE GIVEN."
89561506|NCT05066971|Experimental|Participants in gradual self-adjustment rate control medication|Patients receive a weekly simplified version of the information transmitted by the HM system. In the first 3 months, using that information, the physician changes or not the rate control medication posology (i.e. if the mean heart rate is 60bpm, betablocker dose is cut to half, and another heart rate evaluation is done a week later, and if heart rate is now 120bpm the dose is increased to a 3/4 of the initial dose, and so on). After those three initial months where physician guide titration, the patient is allowed to make self-adjustment of their medication accordingly to the information received (i.e. increasing or decreasing their rate control medication depending on heart rates and activity hours per day.
89561507|NCT05021965|Experimental|group 1: have two weeks of at-home tooth bleaching|Participants will receive two weeks of at-home tooth bleaching with 10% Carbamide peroxide(Opalescence PF 10%) for the maxillary anterior teeth.
89561508|NCT05021965|Experimental|group 2 : have two sessions of in-office tooth bleaching|Participants will receive two sessions（with a 1- week interval ） of in-office tooth bleaching with 40% hydrogen peroxide (Opalescence Boost PF 40%)for the maxillary anterior teeth.
89561509|NCT05021965|Experimental|group 3 : one week of at-home and then have one session of in-office tooth bleaching|Participants will receive one week of at-home tooth bleaching with 10% Carbamide peroxide(Opalescence PF 10%) and then receive one session of in-office tooth bleaching with 40% hydrogen peroxide (Opalescence Boost PF 40%)for the maxillary anterior teeth.
89561510|NCT05021965|Experimental|group 4 : one week of in-office and then have one session of at-home tooth bleaching|Participants will receive one session of in-office tooth bleaching with 40% hydrogen peroxide (Opalescence Boost PF 40%) and a week later receive one week of at-home tooth bleaching with 10% Carbamide peroxide(Opalescence PF 10%)for the maxillary anterior teeth.
89561511|NCT03069833|Experimental|Computer-aided diagnosis|
88967233|NCT00083824|Experimental|Estrogens, Conjugated (USP)|Conjugated Equine Estrogen 0.625 mg/day for 3 years, drug
88967234|NCT00083824|Experimental|Medroxyprogesterone 17-acetate|Conjugated Equine Estrogen 0.625 mg/day plus Medroxyprogesterone Acetate 2.5 mg/day
88967235|NCT00083863||Framingham Heart Study Offspring|
88967236|NCT00083863||FHS Gen 3|
88967237|NCT00083980|Active Comparator|active antidepressant drug comparator|Venlafaxine ER
88967238|NCT00083980|Placebo Comparator|Sugar pill|Inert placebo pills as duble dummy - up to 4 per day for kava and 3 per day for venlafaxine
88967239|NCT00083980|Experimental|Herbal treatment kava|Kava
88967240|NCT04889352|Experimental|Access to colonoscopy web app|Approximately half of the consenting individual endoscopy physicians in the city (gastroenterologists and surgeons) will be randomized (stratified by physician specialty) to the intervention group where they are provided access to an application which indicates recommended timing of follow-up colonoscopy given values for various entered factors. In the intervention group, the application can be downloaded to smart phones for portability which will allow access in an endoscopy suite or in clinic or used as a reference at other times. It can also be accessed online (all endoscopy rooms in Winnipeg have computers with internet access for the endoscopy physicians' use). Access to the application will be password-protected, thereby avoiding exposure of the non-intervention group to the application. The clusters of patients will be defined by the endoscopy physician providing the colonoscopy.
88967241|NCT04889352|No Intervention|Control|Approximately half of the consenting individual endoscopy physicians in the city (gastroenterologists and surgeons) will be randomized (stratified by physician specialty) to the group where they are not provided access to the application (control group).
88967242|NCT00084370|Experimental|Group 1|Group I: Patients receive oral celecoxib twice daily for 3 months and then undergo prophylactic oophorectomy.
88967243|NCT00084370|Experimental|Group II|Group II: Patients undergo immediate prophylactic oophorectomy.
88967244|NCT00084604|Experimental|Treatment (bevacizumab, cisplatin, irinotecan)|Patients receive bevacizumab IV over 30-90 minutes on day 1. Patients also receive cisplatin IV over 30 minutes followed by irinotecan IV over 30 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
88967245|NCT00084643|Experimental|Treatment (GTI-2040, capecitabine, oxaliplatin)|Patients receive GTI-2040 IV continuously on days 1-14, oral capecitabine twice daily on days 2-15, and oxaliplatin IV over 2 hours on day 2 of the first course. In all subsequent courses, capecitabine is administered on days 1-14, oxaliplatin is administered on day 1, and GTI-2040 is administered as in course 1. Courses repeat every 21 days in the absence of disease progression and unacceptable toxicity.
88967246|NCT00084877|Experimental|Treatment (triapine, irinotecan hydrochloride)|"Patients receive irinotecan IV over 1 hour on day 1 and 3-AP (Triapine®) IV over 2 hours on days 1-3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of irinotecan and 3-AP (Triapine®) until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, 6 additional patients are treated at that dose."
89561512|NCT03069833|No Intervention|traditional diagnosis|
89561513|NCT04986007|Experimental|digital Cognitive Behavioral Therapy for Insomnia|Following baseline evaluation, participants in this group will receive 8 weeks of digital Cognitive Behavioral Therapy for Insomnia delivered using Sleep Healthy Using the Internet (SHUTi). After the interim assessment, participants will then crossover to 8 weeks of active monitoring.
89561514|NCT04986007|No Intervention|Waitlist Control|Following baseline evaluation, participants in this group will undergo weekly monitoring of insomnia and suicidal ideation for 8 weeks. Participants will continue whatever treatments they are currently receiving, but will receive no specific instructions or behavioral interventions for insomnia. After the interim assessment, participants will then crossover to receive digital Cognitive Behavioral Therapy for Insomnia.
89561515|NCT03070847|Experimental|Very low dose|Will receive single bolus of Tranexamic acid. Dose: 5mg/kg diluted in 0,9% sodium chloride (0,9% NaCl), administered IV (in the vein), 15 min before admission to operation theatre.
89561516|NCT03070847|Active Comparator|Low dose|Will receive single bolus of Tranexamic acid. Dose: 10mg/kg diluted in 0,9% sodium chloride (0,9% NaCl), administered IV (in the vein), 15 min before admission to operation theatre.
89561517|NCT03140995|Active Comparator|Exercise Intervention|The walking programme will consist of a total of 21 aerobic walking sessions, with 1 per week being supervised by a trained physiotherapist, spread over a maximum of eight weeks (2-3 times/week). During the first 4 weeks the intention is to increase frequency and the final 4 weeks the intensity, using the Borg Rate of Perceived exertion 6-20 or distance from 2km to 6km. The participants will attend the University of Limerick for a final assessment at week 9.
89561518|NCT03140995|No Intervention|Control Group|The control group will be given verbal and written instructions regarding the benefits of exercise in RA.
89561519|NCT03069911|Experimental|Intervention|One injection of onabotulinumtoxinA (29 units for women and 40 units for men) will be injected into two facial muscles - the corrugator and procerus.
89561520|NCT03069911|Placebo Comparator|Control|One injection of saline solution will be injected into two facial muscles - the corrugator and procerus.
89561521|NCT04109521|Experimental|Trained vendors|"The intervention consists of a Training, Certification and Marketing scheme for dairy vendors operating in the informal sector. This scheme includes a 12hr training offered at the beginning of the study, followed by 2 quarterly visits where milk will be tested for microbiological quality and results will be discussed with participants.~The training will include three main components: (i) milk hygiene and quality; (ii) business skills; (iii) milk marketing.~Trainings will be offered free of charge. The trainings will be given by business development service (BDS) providers, who will be trained through a training of trainers ahead of the intervention. Quarterly visits will involve the collection of a milk sample from each participant in the experimental arm in an unannounced visit and results on the microbiological quality of the milk reported back individually and explained to each vendor."
89561522|NCT04109521|No Intervention|Untrained vendors|Participants in the no-intervention arm will receive the same unannounced quarterly visits, where milk will be sampled and tested for microbiological quality, but results will not be shared with the participants. The participants in this arm will only receive the training upon completion of the endline survey (i.e. when the study is finished).
89561523|NCT04989257|Experimental|Ticagrelor-based dual-antiplatelet therapy|Aspirin with ticagrelor
89561524|NCT04989257|Active Comparator|Clopidogrel-based dual-antiplatelet therapy|Aspirin with clopidogrel
89561525|NCT03140527|Active Comparator|SAD HV PTI-801 Active - Complete|The safety, tolerability, and pharmacokinetic profile of PTI-801 will be evaluated following a single dose of PTI-801. Three cohorts are planned for evaluation where subjects will be randomized to PTI-801 or placebo.The subjects will be followed for 7 days post dose.
89561526|NCT03140527|Placebo Comparator|SAD HV PTI-801 Placebo - Complete|The safety, tolerability, and pharmacokinetic profile of PTI-801 will be evaluated following a single dose of PTI-801. Three cohorts are planned for evaluation where subjects will be randomized to PTI-801 or placebo.The subjects will be followed for 7 days post dose.
89561527|NCT03140527|Active Comparator|MAD HV PTI-801 Active - Complete|Following the conclusion of the respective SAD level dose groups and after sufficient review of study data and approval by the SRC, a second set of healthy adult subjects will participate in an assigned MAD treatment group. The MAD treatment group is comprised of 3 cohorts. Subjects will be randomized to either PTI-801 or placebo. Each dose will be administered once daily (QD) for a total of 7 days. Follow up visits will occur on Days 10, 12 and 14.
89561528|NCT03140527|Placebo Comparator|MAD HV PTI-801 Placebo - Complete|Following the conclusion of the respective SAD level dose groups and after sufficient review of study data and approval by the SRC, a second set of healthy adult subjects will participate in an assigned MAD treatment group. The MAD treatment group is comprised of 3 cohorts. Subjects will be randomized to either PTI-801 or placebo. Each dose will be administered once daily (QD) for a total of 7 days. Follow up visits will occur on Days 10, 12 and 14.
89561529|NCT03140527|Active Comparator|FE HV PTI-801 Active - Complete|Following the conclusion of SAD groups and after sufficient review of study data and approval by the SRC, a third set of healthy adult subjects will participate in the Food Effect cohort. Subjects will be randomized to Fed or Fasted on Days 1 and 12. Follow up visits will occur 7 days post Day 12 dose.
89561530|NCT03140527|Active Comparator|DDI HV PTI-801 Active - Complete|Following the conclusion of HV MAD Cohort 2 and after sufficient review of study data and approval by the SRC, a fourth set of healthy adult subjects will participate in the Drug-Drug Interactions cohort. Subjects will receive a 3-drug cocktail consisting of caffeine, bupropion, and midazolam on Day 1. On Day 4, subjects will be randomized to receive either PTI-801 or placebo QD for a total of 12 days. On Day 17, subjects will receive the 3-drug cocktail in combination with PTI-801 or placebo. Subjects will remain in clinic until Day 20. A follow up visit will occur on Day 24.
89561531|NCT03140527|Placebo Comparator|DDI HV PTI-801 Placebo - Complete|Following the conclusion of HV MAD Cohort 2 and after sufficient review of study data and approval by the SRC, a fourth set of healthy adult subjects will participate in the Drug-Drug Interactions cohort. Subjects will receive a 3-drug cocktail consisting of caffeine, bupropion, and midazolam on Day 1. On Day 4, subjects will be randomized to receive either PTI-801 or placebo QD for a total of 12 days. On Day 17, subjects will receive the 3-drug cocktail in combination with PTI-801 or placebo. Subjects will remain in clinic until Day 20. A follow up visit will occur on Day 24.
88967247|NCT03038373||Group I|Morbid Obese Type 2 Diabetics, undergo Laparoscopic Sleeve Gastrectomy
89561532|NCT03140527|Active Comparator|MAD Cohort 1-3 CF PTI-801 Active - Complete|Adult subjects diagnosed with CF currently on stable ivacaftor/lumacaftor background therapy for a minimum of three months will participate in the Part 2 complementary CF MAD cohort. The CF MAD treatment group is comprised of 3 cohorts. Subjects will be randomized to receive either PTI-801 or placebo QD for a total of 14 days. A follow up visit will occur on Day 21.
89561533|NCT03140527|Placebo Comparator|MAD Cohort 1-3 CF PTI-801 Placebo - Complete|Adult subjects diagnosed with CF currently on stable ivacaftor/lumacaftor background therapy for a minimum of three months will participate in the Part 2 complementary CF MAD cohort. The CF MAD treatment group is comprised of 3 cohorts. Subjects will be randomized to receive either PTI-801 or placebo QD for a total of 14 days. A follow up visit will occur on Day 21.
89561534|NCT03140527|Active Comparator|Cohort 4 CF PTI-801 Active co-admin PTI-808 Active - Complete|Adult subjects diagnosed with CF not currently receiving a CFTR modulator therapy within 30 days prior to Day 1 will participate in the Part 2 CF Cohort 4. Subjects will be randomized to receive either PTI-801 co-administered with PTI-808 or placebos QD.
89561535|NCT03140527|Placebo Comparator|Cohort 4 CF PTI-801 Placebo co-admin PTI-808 Placebo- Complete|Adult subjects diagnosed with CF not currently receiving a CFTR modulator therapy within 30 days prior to Day 1 will participate in the Part 2 CF Cohort 4. Subjects will be randomized to receive either PTI-801 co-administered with PTI-808 or placebos QD.
89561536|NCT03140527|Active Comparator|Cohort 5 CF PTI-801 Active co-admin with PTI-808 Active|Adult subjects diagnosed with CF not currently receiving a CFTR modulator therapy within 30 days prior to Day 1 will participate in the Part 2 CF Cohort 5. Subjects will be randomized to receive either PTI-801 co-administered with PTI-808 or placebos QD.
89561537|NCT03140527|Placebo Comparator|Cohort 5 CF PTI-801 Placebo co-admin with PTI-808 Placebo|Adult subjects diagnosed with CF not currently receiving a CFTR modulator therapy within 30 days prior to Day 1 will participate in the Part 2 CF Cohort 5. Subjects will be randomized to receive either PTI-801 co-administered with PTI-808 or placebos QD.
89561538|NCT03140527|Active Comparator|Cohort 6 CF PTI-801 Active|Adult subjects diagnosed with CF currently on stable tezacaftor/ivacaftor background therapy for a minimum of one month will participate in the Part 2 complementary CF MAD cohort. Subjects will be randomized to receive either PTI-801 or placebo QD.
89561539|NCT03140527|Placebo Comparator|Cohort 6 CF PTI-801 Placebo|Adult subjects diagnosed with CF currently on stable tezacaftor/ivacaftor background therapy for a minimum of one month will participate in the Part 2 complementary CF MAD cohort. Subjects will be randomized to receive either PTI-801 or placebo QD.
89561540|NCT03070769||Control|Subjects without Obstructive sleep apnea (Apnea-hypopnea index-AHI<5). Venous blood collection for biomarkers measurements.
89561541|NCT03070769||Obstructive sleep apnea (OSA) patients|Patients with Obstructive sleep apnea (AHI> or =5). Venous blood collection for biomarkers measurements.
89561542|NCT03069443|Experimental|IHG+Hypertension lifestyle guidelines|Participants in this group will follow a home-based IHG training protocol. The IHG training will be structured with four sets of 2-minute contractions for each hand, 3 days per week for 20 weeks. In addition, the IHG group will receive information about hypertension-guidelines on lifestyle changes.
89561543|NCT03069443|No Intervention|Hypertension lifestyle guidelines|The usual care group will receive information about hypertension-guidelines on lifestyle changes. The usual care group will have the same amount of hospital visits for measurements of blood pressure and maximal muscle tests as the intervention group in order to ensure similar attention provided by the healthcare professionals.
89561544|NCT04025983|Experimental|GastimunHp Plus|1 sachet of GastimunHp Plus twice daily during or after meals.
89561545|NCT04025983|Placebo Comparator|Placebo|1 sachet of placebo twice daily during or after meals.
89561546|NCT04892069||Ryzodeg®|Participants are patients with Type 2 Diabetes (T2D) treated with Ryzodeg® (Insulin Degludec/Insulin Aspart) in a real-world adult population in Lebanon
89561547|NCT04986059|Experimental|Pre-event massage|
89561548|NCT04986059|No Intervention|Control|
89561549|NCT03140449|Experimental|Rapamycin|Rapamycin(0.1%)
89561550|NCT03140449|Experimental|Calcitriol|Calcitriol(3mcg/g)
89561551|NCT03140449|Experimental|Rapamycin-calcitriol combination|Rapamycin(0.1%) with Calcitriol(3mcg/g)
89561552|NCT03137875||Patient with sputum smear positive 2+|patient who will have a positive diagnostic of tuberculosis using microscopy with a 2+ grade
89561553|NCT03137875||patient smear positive scanty or 1+|patient who will have a positive diagnostic of tuberculosis using microscopy with a scanty or 1+ grade
89561554|NCT03137875||patient smear negative|patient with a negative TB microscopy result
89561555|NCT04986215||Benign pancreatic space occupying group|
88967248|NCT03038373||Group II|Morbid Obese Non Diabetics, undergo Laparoscopic Sleeve Gastrectomy
89210599|NCT03913377|Experimental|Observational|Eligible subjects that are habitual spectacle wearers will use their habitual optical correction and undergo ocular evaluations and questionnaires at the baseline and 1-week visit.
89561556|NCT04986215||Malignant pancreatic space occupying group|
89561557|NCT03138811|Experimental|CSJ117|low dose, medium dose, or high dose administered as a once daily inhaled dose
89561558|NCT03138811|Placebo Comparator|Placebo|placebo comparator administered as once daily inhaled dose
89561559|NCT02895451|Experimental|Extended behavioral intervention|Specific goal-setting, self-monitoring and feed-back
89561560|NCT02895451|No Intervention|Usual care|Hospital-based or home-based aerobic exercise 3 times a week with a duration of 30-60 minutes and an intensity of 40-80 % of Vo2max and resistance exercise 2 times a week of 1-3 sets of 10-15 repetitions. The exercise period is 16 weeks.
88967249|NCT03038373||Group III|Lean Diabetics, No surgery
88967250|NCT03038373||Group IV|Lean Non Diabetics, No surgery
88967251|NCT00084916|Experimental|Treatment (temsirolimus)|Patients receive CCI-779 IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88967252|NCT00085111|Experimental|Arm I|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
88967253|NCT00400114|Experimental|sunitinib|
89561561|NCT02659813|Experimental|Firewire|Experimental Group 1. Novel orthodontic archwire.
88967254|NCT00085189|Experimental|Cohort I (melanoma peptide vaccine, Montanide ISA-51)|Patients receive multi-epitope peptide melanoma peptide vaccine with incomplete Freund's adjuvant and agatolimod sodium SC at 0, 2, 4, 6, 8, 10, 14, 18, 22, 26, 38, and 50 weeks and then every six months for two years for up to 16 vaccinations in the absence of disease progression or unacceptable toxicity.
88967255|NCT00085189|Experimental|Cohort II (melanoma peptide vaccine, Montanide ISA 51 VG)|Patients receive multi-epitope peptide melanoma peptide vaccine with Montanide ISA 51 VG and agatolimod sodium SC at 0, 2, 4, 6, 8, 10, 14, 18, 22, 26, 38, and 50 weeks and then every six months for two years for up to 16 vaccinations in the absence of disease progression or unacceptable toxicity.
88967256|NCT00085306|Experimental|Recombinant interferon beta|
88967257|NCT04838028||Standard polypropylene mesh|Density > 50 g/square meter
88967258|NCT04838028||Lightweight mesh|"A mesh based on either polypropylene or polyester. Some variants contain purely 1 polymer. Others are composite, ie, contain also an absorbable material.~The density < 50 g/square meter (when applicable, after partial absorption)"
88967259|NCT04838028||Fixation with metal tacks|Non-absorbable metal staples or tacks
88967260|NCT04838028||Fixation with absorbable tacks|Absorbable synthetic staples or tacks
88967261|NCT04838028||Fibrin glue fixation|Biologic glue/sealant produced from human donor blood
88967262|NCT04838028||Non-fixation|Mesh is deployed without fixation
88967263|NCT04838028||3D mesh|"A polypropylene mesh with a preformed anatomic shape corresponding to the inner preperitoneal curvature of the groin.~The category does not differentiate between standard and lightweight variants."
88967264|NCT04838028||Progrip fixation|Absorbable (Velcro type of) microhooks. The particular meshes come with prefabricated Progrip microhooks. Progrip = Registered trademark.
88967265|NCT04838028||Polyester mesh|Polyester-based mesh. This category does not differentiate between standard and lightweight variants
88967266|NCT00085384|Experimental|PEG-interferon alfa-2b|Patients receive PEG-interferon alfa-2b (PEG IFN-α) subcutaneously (SC) on days 1, 8, 15, and 22.
88967267|NCT00085384|Experimental|Arm II|Patients receive PEG IFN-α SC (at a higher dose than in arm I) on days 1, 8, 15, and 22.
88967268|NCT00085384|Experimental|Arm III|Patients receive PEG IFN-α SC (at a higher dose than in arm II) on days 1, 8, 15, and 22.
88967269|NCT00085501|Active Comparator|1|
88967270|NCT00085501|Active Comparator|2|
88967271|NCT00006083|Experimental|Fragmin|Fragmin at 5000 IU injected subcutaneously daily
88967272|NCT00006083|Placebo Comparator|placebo|placebo injected subcutaneously daily
88967273|NCT04729426|Experimental|Position Group|Position group
88967274|NCT04729426|No Intervention|Control group|No Position group
88967275|NCT04798638|Experimental|Arm1: TY-9591 + Osimertinib + TY-9591|Participants will receive TY-9591 tablets under fasted condition in period 1 , followed by Osimeritinib Mesylate tablet under fasted condition in period 2. In period 3, participants will receive TY-9591 tablet in fed state (high-fat meal). The washout will be no less than 21 days between each treatment.
89027102|NCT02955771|Experimental|PDT-Deuteporfin（9 hour）plus stenting|Deuteporfin (7.5mg/kg) was injected intravenously 9 hours before intraluminal photoactivation (wavelength,630 nm;light dose, 180 J/cm(2)). After PDT, endoscopic or percutaneous stenting will be performed.The second treatment may be given after 3 months.
89561562|NCT02659813|Experimental|CNiTi|Experimental Group 2. Current best available orthodontic archwire
89561563|NCT04095143||New onset of stage ≥2 acute kidney injury|"Either:~A ≥ 2-fold increase in serum creatinine OR~A serum creatinine ≥ 354 μmol/L with evidence of a minimum increase of 27 μmol/L OR~Urine output < 6.0 mL/kg over the preceding 12 hours OR~Initiation of RRT for severe acute kidney injury less than 72 hours before recruitment"
89561564|NCT04917445|Experimental|SPIKES Protocol Compassionate Call|Nurses trained to contact IVF patients with negative pregnancy test results who were trained on the SPIKES-focused bad news delivery script.
89561565|NCT04917445|No Intervention|Control: Standard of Care Call|Nurses who will continue to deliver bad news as they have been in the past without a script.
89561566|NCT04904653|Experimental|Hemopatch Group:|Hemopatch + suction drainage
89561567|NCT04904653|Other|Control group|No sealant (liquid, gel or patch) + suction drain
89561568|NCT03070691|Active Comparator|LDE225 0.75% cream|
89561569|NCT03070691|Placebo Comparator|Vehicle|
89561570|NCT03137953|Experimental|Clinical and Imaging|Subjects in this arm would undergo clinical evaluation of skin involvement followed by Radiological Imaging (CT/MRI) based evaluation of the distance between the base of the tumor and the skin. Based on this distance, the skin would either be conserved or not during tumor resection.
89561571|NCT04985591|Experimental|liposuction group|
89561572|NCT04985591|Placebo Comparator|Other plastic surgery group|
89561573|NCT02594683||Key Group of Interest|Exclusively formula fed subjects since 1 month of age
89561574|NCT02594683||Other-Fed Group|Mixed feeding of formula and breast milk
89561575|NCT02594683||Breastfeeding Group|Exclusively breastfeeding at least until 4 months of age
89561576|NCT02513173||Low back pain group|No intervention
89561577|NCT02513173||Control|No intervention
89561578|NCT04985435|Active Comparator|Choice group|50 patients will be randomized to the choice group, they will view a neutral information video on anti TNF and Filgotinib and will be given the opportunity to choose between these two treatments
89561579|NCT04985435|Active Comparator|Randomization group anti TNF|A total of 50 patients will be randomized to the randomization group: 25 of those will start treatment with antiTNF
89561580|NCT04985435|Active Comparator|Randomization group Filgotinib|A total of 50 patients will be randomized to the randomization group: 25 of those will start treatment with Filgotinib
89561581|NCT03070457|Experimental|Early discharge group|Patients with a shorter hospital stay, 23 hours after surgery
89561582|NCT03070457|Active Comparator|Conventional discharge|Patients with conventional protocol and 48-72 hours of hospital stay
89561583|NCT03070613|Experimental|Fluorescent Lectin Application|Fluorescein conjugated wisteria floribunda will be sprayed onto the colonic surface during colonoscopy or TEM surgery.
89561584|NCT03441139|Experimental|Cryotherapy + medical analgesics|Percutaneous Cryotherapy and medical analgesics according to the investigator's discretion
89561585|NCT03441139|Active Comparator|Medical analgesics|Medical analgesics alone according to the investigator's discretion
89561586|NCT04985279|Active Comparator|Standard clinical practice|"Lumbar ultrasound scan will be performed to identify the desired needle insertion site, followed by demarcation using skin markers.~The angulation of the ultrasound probe will be adjusted to optimise the image of the simulated patient's lumbar spine.~The ultrasound probe will be removed and needle insertion simulated by touching the tip of a blunt needle to the patient's back, at the desired angle.~A usability questionnaire regarding the procedure will be completed."
89561587|NCT04985279|Experimental|Position and Angle Marking System (PAMS)|"PAMS will be attached to the ultrasound probe.~Lumbar ultrasound scan will be performed to identify the desired needle insertion site, followed by demarcation by gentle pressing PAMS into the simulated patient's back to create skin indentations.~The angulation of the ultrasound probe will be adjusted to optimise the image of the simulated patient's lumbar spine, and the angle read off a graduated scale.~The ultrasound probe will be removed and needle insertion simulated by touching the tip of a blunt needle to the patient's back, at the desired angle.~A usability questionnaire regarding the procedure will be completed."
88967276|NCT04798638|Experimental|Arm2: Osimertinib + TY-9591 + TY-9591|Participants will receive Osimeritinib Mesylate tablet under fasted condition in period 1 , followed by TY-9591 tablets under fasted condition in period 2. In period 3, participants will receive TY-9591 tablet in fed state (high-fat meal). The washout will be no less than 21 days between each treatment.
88967277|NCT00085852|Experimental|Single|Treatment with BLVR
88967278|NCT00006089|Experimental|Treatment (trastuzumab)|Patients receive trastuzumab (Herceptin) IV over 30-90 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88967279|NCT00085969|Placebo Comparator|A1 - Placebo 0.04 mL twice daily|
88967280|NCT00085969|Placebo Comparator|A2 - Placebo 0.04 mL once daily|
88967281|NCT00085969|Placebo Comparator|A3 - Placebo 0.08 mL once daily|
88967282|NCT00085969|Experimental|B - Exenatide 10 mcg twice daily|
88967283|NCT00085969|Experimental|C - Exenatide 10 mcg once daily|
88967284|NCT00085969|Experimental|D - Exenatide 20 mcg once daily|
88967285|NCT00006092|Experimental|Arsenic Trioxide Treatment|Patients receive arsenic trioxide IV over 2-3 hours daily for 28 days. Patients who respond may receive a second course of therapy beginning 28 days from the last dose of the first course.
88967286|NCT00086125|Experimental|1|AP23573 12.5 mg IV as monotherapy once daily for 5 days, every 2 weeks
88967287|NCT00006095|Experimental|Vincristine Sulfate 1.5 mg/m2/wk and Irinotecan|
88967288|NCT00006095|Experimental|Vincristine sulfate 2.0 mg/m2/wk and Irinotecan|
89027103|NCT02955771|Other|Stenting|Endoscopic or percutaneous stenting alone will be performed.
89561588|NCT04985669|Experimental|prucalopride group|prucalopride group will receive prucalopride 2 mg once daily
89561589|NCT04985669|Active Comparator|Lubiprostone group|lubiprostone group will receive lubiprostone 8 microgram twice daily
89561590|NCT05083897||30 patients in 1 group|measuring the effect of isometric hip adduction with knee extension on the peak torque of knee extensors
89561591|NCT04988711|Experimental|Hb Oxymeter|Hb mesurment
89561592|NCT04753957|Active Comparator|Vaginal progesterone|200mg micronized vaginal progesterone placed 7am prior to scheduled cesarean delivery
89561593|NCT04753957|No Intervention|Control|No intervention, scheduled cesarean delivery
89561594|NCT03070379|Experimental|Experimental group|Topical lidocaine pharyngeal anesthesia was performed.
89561595|NCT03070379|No Intervention|Control group|No topical lidocaine pharyngeal anesthesia was performed.
89561596|NCT03227263|Experimental|Bevacizumab|Intravenous infusion of Bevacizumab at a dose of 5 mg/kg
89561597|NCT03227263|Placebo Comparator|Placebo|0.9% of sodium chloride is infused every 14 days for 6 consecutive administrations
89561598|NCT04985201|Experimental|Simvastatin + Irinotecan|received intravenous infusions of Irinotecan 60 milligrams per square meter (mg/m^2) on Day 1,8 of every 21-day cycle (4 cycles) in combination with oral simvastatin (20mg daily) (10 months)
89561599|NCT04985201|Active Comparator|Irinotecan|received intravenous infusions of Irinotecan 60 milligrams per square meter (mg/m^2) on Day 1,8 of every 21-day cycle (4 cycles)
89561600|NCT03156595|Placebo Comparator|Nurse interview|Personal interview with nurses to evaluate the relief of neuropathic pains with the reference treatment. (If necessary send to the medical team ) It's a listening time around neuropathic pain which altered the quality of life.
89561601|NCT03156595|Experimental|Hypnosis session|Hypnosis sessions with nurses or psychologists, with deepening sessions to facilitate self-hypnosis learning.
89561602|NCT04985123||Silicone Block patients|All subjects who received a successful penile implantation with the Silicone Block by the surgeons at the centers in this study.
89561603|NCT03092713|Active Comparator|Cognitive Intervention and Supported Employment (CCI-SE)|Combined cognitive and vocational rehabilitation in a mixed design.
89561604|NCT03092713|Active Comparator|Control group|Usual follow-up assessment and treatment provided by the multidisciplinary TBI rehabilitation team.
89561605|NCT04985045||Control group|Healthy women will be included
89561606|NCT04985045||Cerebral palsy group|Women with cerebral palsy will be included
89561607|NCT04988243|Other|Prospective and retrospective study of subjects undergoing aortic valve surgery|This study is a prospective / retrospective, multicenter, and observational study after listing. The researchers can initially determine that they can be enrolled in the study according to the history diagnosis of the subjects. After fully informed, they sign informed consent form. After the evaluation of the researchers, they meet the TAVR selection requirements, and register the subjects in multiple centers at the same time
89561608|NCT02031601|Experimental|Combination therapy|"Interventions:~Drug: Erlotinib [Tarceva] or Gefitinib [Iressa] or Icotinib [Conmana] plus Drug: Docetaxel for patients of lung squamous cell carcinoma; Pemetrexed for patients of lung adenocarcinoma plus Drug: Platinum (cisplatin or carboplatin)"
89561609|NCT02031601|Other|TKI alone therapy|"Interventions:~Drug: Erlotinib [Tarceva] or Gefitinib [Iressa] or Icotinib [Conmana]"
89561610|NCT04988165|Experimental|Treatment arm|
89561611|NCT02772679|Experimental|PolyTregs+IL-2|Patients with type 1 diabetes mellitus will receive ex vivo expanded human autologous polyclonal regulatory T cells plus IL-2
89561612|NCT04456127|No Intervention|Standard of Care|Scar section does not receive CO2 laser therapy.
89561613|NCT04456127|Experimental|Factional CO2|Scar section receives fractional CO2 laser therapy.
89027104|NCT02891161|Experimental|Arm A: Safety Run In Phase Ib|Subjects will receive durvalumab 1500mg Q4 weekly with RT to gross disease over 36 fractions. Durvalumab will start on Day 1. RT to start on Day 1 or 2. Subjects will receive adjuvant durvalumab monotherapy Q4 week, up to 12 months. Durvalumab monotherapy to start 4 weeks post completion of durvalumab and RT.
89561614|NCT04984187|Other|Laser group|High Intensity Laser Therapy only , this group will receive laser for 4 weeks three times /week
89561615|NCT04984187|Other|Exercise group|Exercise , selected physiotherapy exercises will receive for 4 weeks ,3times/week
89561616|NCT04984187|Experimental|High intensity laser grouo|High intensity laser plus exercise will receive the selected exercises and laser 4 weeks, 3 times/week
89561617|NCT05088343|Experimental|Treatment|rosuvastatin alone and then in combination with hetrombopag
89561618|NCT04984265|Experimental|Stereotactic Body rRadiotherapy (SBRT)|SBRT targeting the area of the circuit of Ventricular Tachycardia
89561619|NCT03070145|Experimental|Exercise Intervention|"12-weeks brisk walking and strength training~150 minute moderate aerobic activities, such as brisk walking~Strength training 3 days /week~One on one sessions with exercise physiologist~Optional group sessions"
89561620|NCT03070145|No Intervention|Usual Care|Usual Care provided
89561621|NCT03137485|Active Comparator|Conventional|Patients in this arm will have conventional open lumbar discectomy operation.
89561622|NCT03137485|Active Comparator|Endoscopic|Patients in this arm will have Percutaneous Endoscopic Translaminar lumbar discectomy operation using Easy Go system Endoscopy
89561623|NCT03068507|Experimental|Prehabilitation group|Trimodal prehabilitation management
89561624|NCT03068507|No Intervention|Control group|The patients will receive the conventional clinical guidance according to Peking Union Medical College Hospital, including preoperative anesthesia assessment, drug treatment recommendations for chronic disease, quit smoking and abstinence.
89561625|NCT03137641||Nurses in contact with chemotherapies|"It is a nurses cohort, who administer chemotherapies or are in charge of patients treated by chemotherapie. Three urine samples are collected:~first : between 0 to 3h before the beginning of the workday second : between 0 to 2h after the end of the workday third : between 7 to 10h after the end of the workday"
89561626|NCT04983641|No Intervention|Control - No Pre-Visit Message|o Patients were assigned PROMIS forms in the domains of Depression (PROMIS-D) and Pain Interference (PROMIS-PI) in addition to Upper Extremity Function (PROMIS-UE) and/or Physical Function (PROMIS-PF). These forms were available for remote completion in each respective patient's MyChart portal at 1 week prior to their clinic appointment. Patients in this arm were not sent any reminder e-mails or MyChart messages concerning PROMIS form completion at any timepoint prior to their scheduled clinic visit.
89561627|NCT04983641|Experimental|E-mail Arm|o Patients were assigned PROMIS forms in the domains of Depression (PROMIS-D) and Pain Interference (PROMIS-PI) in addition to Upper Extremity Function (PROMIS-UE) and/or Physical Function (PROMIS-PF). These forms were available for remote completion in each respective patient's MyChart portal at 1 week prior to their clinic appointment. Patients in this arm were sent an initial reminder e-mail message at 1 week prior to their scheduled clinic visit regarding PROMIS form completion. If patient's did not fill out PROMIS forms by 3 days prior to their visit, they were sent a second reminder e-mail message.
89561628|NCT04983641|Experimental|"Digital Patient Portal MyChart Arm"|o Patients were assigned PROMIS forms in the domains of Depression (PROMIS-D) and Pain Interference (PROMIS-PI) in addition to Upper Extremity Function (PROMIS-UE) and/or Physical Function (PROMIS-PF). These forms were available for remote completion in each respective patient's MyChart portal at 1 week prior to their clinic appointment. Patient's in this arm were sent an initial reminder MyChart message at 1 week prior to their scheduled clinic visit regarding PROMIS form completion. If patients did not fill out PROMIS forms by 3 days prior to their visit, they were sent a second reminder MyChart message.
89561629|NCT03068429|Experimental|Sertraline open label|Sertraline hydrochloride up to 200mg/day or maximum tolerated dosage for 4-weeks.
89561630|NCT03068351|Experimental|RO6870810|Participants will be administered RO6870810 monotherapy at ascending-dose levels during the dose escalation phase followed by an expansion phase during which RO6870810 will be administered as monotherapy at the recommended dose. Participants will continue to receive study drug as long as they experience clinical benefit in the opinion of the Investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression, as determined by the Investigator after an integrated assessment of IMWG response criteria, biopsies/aspirate (if applicable), and clinical status, or withdrawal of consent.
89561631|NCT03068351|Experimental|RO6870810 + Daratumumab|Participants will be administered RO6870810 at ascending-dose levels in combination with daratumumab at the recommended dose during the dose escalation phase followed by an expansion phase during which both RO6870810 and daratumumab will be administered each at their recommended dose. Participants will continue to receive the study drugs as long as they experience clinical benefit in the opinion of the Investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression, as determined by the Investigator after an integrated assessment of IMWG response criteria, biopsies/aspirate (if applicable), and clinical status, or withdrawal of consent.
89561632|NCT03137563||Women eligible for cervical cancer screening|French women aged 25 to 65 years living in the Department of Hérault or Aude (France), attending one of the 8 centers where the questionnaire will be distributed
89561633|NCT03140293|Active Comparator|Lidocaine Injection|Injection of lidocaine which is given prior to chorionic villus sampling
89027105|NCT02891161|Experimental|Arm B: Investigational Treatment Phase II|Subjects will receive durvalumab 1500mg Q4 weekly with RT to gross disease over 36 fractions. Durvalumab will start on Day 1. RT to start on Day 1 or 2.. Subjects will receive adjuvant durvalumab monotherapy Q4 week, up to 12 months. Adjuvant durvalumab monotherapy to start 4 weeks post completion of durvalumab and RT.
89027106|NCT00478985|Experimental|1|Imatinib treatment ending
89027107|NCT02955732|Experimental|Intranasal dex|Dexmedetomidine 2-4 µg/kg alone
89027108|NCT01315678|Experimental|Arikayce™|Arikayce™ is liposomal amikacin for inhalation
89027109|NCT01315678|Active Comparator|TOBI®|TOBI® is tobramycin inhalation solution
89027110|NCT02955693|Other|Sequence A (n=8)|Fumaderm® 120 mg fed (Period 1) - LAS41008 120 mg fasting (Period 2) -Fumaderm® 120 mg fasting (Period 3) - LAS41008 120 mg fed (Period 4)
89027111|NCT02955693|Other|Sequence B (n=8)|LAS41008 120 mg fasting (Period 1) - LAS41008 120 mg fed (Period 2) - Fumaderm® 120 mg fed (Period 3) - Fumaderm® 120 mg fasting (Period 4)
89561634|NCT03140293|Experimental|Gebauer Ethyl Chloride Spray|Topical anesthesia will be Gebauer Ethyl Chloride sprayed continuously from 3 - 7 seconds from a distance of 3-9 inches until the skin turns white (not frosting the skin) as per Gebauer package insert instructions.
89561635|NCT04983563|Experimental|Actigraphy|
88967289|NCT00086242|Experimental|Psychosocial Telephone Counseling (PTC)|Eligible patients are randomized to receive psychosocial telephone counseling (PTC) or usual care.The PTC intervention was specifically designed to help women cope with the stressful events and feelings of distress associated with cervical cancer. The PTC arm of the study received six counseling sessions, ~45 to 50 min in length, in their preferred language, consisting of five consecutive weekly sessions and a 1-month booster session, delivered by a psychologist. A review letter, generated by the counselor after each session, recapitulated the session's contents and reinforced adaptive coping strategies.
88967290|NCT00086242|No Intervention|Usual Care|Eligible patients are randomized to receive either psychosocial telephone counseling (PTC) or usual care. The usual care are were only contacted by the study team to collect data in an identical frame to subjects receiving PTC.
88967291|NCT00086359|Experimental|A|One pill of abacavir/lamivudine/zidovudine twice daily
88967292|NCT00086359|Experimental|B|One pill of zidovudine/lamivudine and four pills of lopinavir/ritonavir twice daily.
88967293|NCT04788771|Sham Comparator|Tracheal intubation in laparoscopic extraperitoneal hernia repair|Tracheal intubation in laparoscopic extraperitoneal hernia repair
88967294|NCT04788771|Active Comparator|laryngeal mask airway in laparoscopic extraperitoneal hernia repair|laryngeal mask airway in laparoscopic extraperitoneal hernia repair
88967295|NCT00387569|Experimental|Cohort 1|Experimental (20ug); Active Comparator/Placebo
88967296|NCT00387569|Experimental|Cohort 2|Experimental (60ug); Active Comparator/Placebo
88967297|NCT00387569|Experimental|Cohort 3|Experimental (200ug); Active Comparator/Placebo
88967298|NCT04784637|Experimental|Group 1|AID + Auto Titration Module (ATM) and Web Simulation Tool (WST) for 6 weeks
88967299|NCT04784637|Experimental|Group 2|AID + Auto Titration Module (ATM) and Web Simulation Tool (WST) +Behavioral Adaptation Module (BAM) for 6 weeks
88967300|NCT00086749||Tamoxifen group|
89561636|NCT03137329|Other|Weight Loss Surgery (WLS) Arm|Subjects enrolled in the WLS arm will undergo WLS as part of the routine care provided by the respective WLS centers. During routine care patients typically meet with their dietician at least twice prior to WLS and are placed on a higher protein meal replacement supplement and calorie controlled diet. For weeks 1-52, the investigators will ensure that patients are receiving 1500mg of elemental calcium and 3000 IU of vitamin D based on recent best practice guidelines. In addition, participants will complete an individualized pragmatic exercise program for the first 52 weeks after surgery. Patients will begin the program after receiving clearance from their surgeon. Patients will meet with a physical therapist at BIDMC for individual sessions.
89561637|NCT03137329|Other|Lifestyle Arm|Subjects enrolled in the lifestyle group will be prescribed a balanced high protein diet (1g high quality protein/kg body weight/day) that provides an energy deficit of 500 to 750 kcal /day from their daily energy requirements[58] and prescribed a weight loss goal of 10% over the course of 6 months. Participants will meet with a trained dietician/nutritionist at the BIDMC General Clinical Research Unit. The investigators will incorporate the HMR (Health Management Resources) high protein meal replacement supplements into participants' diet regimen for the first 24 weeks. In addition, participants will complete a comparable 52-week exercise program consisting of an individualized pragmatic exercise program.
89561638|NCT04452695||Intervention arm|Patients presenting to the emergency department are triaged using a novel robotic telehealth triage system. Once triage is complete, patients complete a quantitative assessment to measure their acceptance and willingness to interact with the robotic telehealth system.
89561639|NCT04584541|Other|case|Index cases (RA and SpA patients under immunosuppressive treatments)
89561640|NCT04584541|Other|controls|Members of index cases family cluster infected with the same viral strain
89561641|NCT04982861|Experimental|Cefixime trihydrate 100 mg/5 mL dry syrup|Cefixime trihydrate 100 mg/5 mL dry syrup was dissolved by 20 mL of water split in 2 portions. Then the drug was shaken well for at least 30 seconds at each addition of water.
89561642|NCT04982861|Active Comparator|Suprax® 100 mg/5 mL dry syrup|Suprax® 100 mg/5 mL dry syrup was dissolved by 33 mL of water split in 2 portions. Then the drug was shaken well for at least 30 seconds at each addition of water.
89561643|NCT04456049|Experimental|Enzalutamide (Xtandi®)|Interventional treatment
89561644|NCT04456049|Active Comparator|Standard of care (SOC)|Supportive treatment
89561645|NCT04572217|Experimental|Medication Group|"Adolescent patients post vertical sleeve gastrectomy who have had inadequate weight loss, who consented for use of off-label medications prescribed at the discretion (one or both) of physician.~Patients will be followed every 2-12 weeks over one year.~All patients in this group will continue to follow the standard of care procedures of our multidisciplinary bariatric clinic, including frequent follow-up appointments, nutrition guidance, vitamin supplementation, exercise instruction, and healthy lifestyle education."
89561646|NCT04572217|No Intervention|Non-Medication Group|"Adolescent patients post vertical sleeve gastrectomy who had inadequate weight loss and did not consent for use of off-label medications.~All patients in this group will continue to follow the standard of care procedures of our multidisciplinary bariatric clinic, including frequent follow-up appointments, nutrition guidance, vitamin supplementation, exercise instruction, and healthy lifestyle education."
89561647|NCT04553809|Active Comparator|Kontrol|Patients undergoing examination for lung cancer with the use of electromagnetic navigation bronchoscopy for biopsy sampling
89561648|NCT04553809|Experimental|Intervention|Patients undergoing examination for lunge cancer with the use of electromagnetic navigation bronchoscopy and radial endobronchial ultrasound for biopsy sampling.
89561649|NCT05083195|Experimental|Telerehabilitation Group|This group will perform their exercises with pre-prepared personalized exercise videos over the telerehabilitation system 3 times a week for 8 weeks.
89561650|NCT05083195|Experimental|Control Group|This group will perform exercises with personalized exercise brochures defined over the telerehabilitation system 3 times a week for 8 weeks.
89027112|NCT02955693|Other|Sequence C (n=8)|Fumaderm® 120 mg fasting (Period 1) - Fumaderm® 120 mg fed (Period 2) - LAS41008 120 mg fed (Period 3) - LAS41008 120 mg fasting (Period 4)
89561651|NCT03137251|Experimental|TENS 1|"This group will receive TENS continuously for 30 minutes starting at the beginning of the active phase of labour.~Dose TENS 1: Biphasic asymmetric pulse, pulse width of 100 µs and a frequency of 100 Hz. The intensity is individually titrated according to the sensitivity of the parturient."
89561652|NCT03137251|Experimental|TENS 2|"This group will receive TENS continuously for 30 minutes starting at the beginning of the active phase of labour.~Dose TENS 2: Biphasic asymmetric pulse, pulse width of 350 µs and a variable frequency between 80 and 100Hz. The intensity is individually titrated according to the sensitivity of the parturient."
89561653|NCT03137251|Sham Comparator|Placebo TENS|This group will receive TENS continuously for 30 minutes starting at the beginning of the active phase of labour. However, TENS has been modified, so that it emits light and sound but does not transmit electrical current.
89561654|NCT05635955|Experimental|Remimazolam|Intravenous Remimazolam will be co-administrated with esketamine.
89561655|NCT05635955|Active Comparator|Propofol|Intravenous Propofol will be co-administrated with esketamine.
89561656|NCT03137017|Experimental|GRT7014 fasted|"Abuse deterrent formulation of a fixed dose combination of hydrocodone bitartrate 5 mg/acetaminophen 325 mg tablet (GRT7014 - Abuse Deterrent Tablet) under fasted conditions.~Participant must fast from approximately 10:00 pm pre-dosing day until 4 hours after the administration of the Investigational medicinal product (IMP)."
89561657|NCT03137017|Experimental|GRT7014 fed|"Abuse deterrent formulation of a fixed dose combination of hydrocodone bitartrate 5 mg/acetaminophen 325 mg tablet (GRT7014 - Abuse Deterrent Tablet) under fed conditions.~Participant must fast from approximately 10:00 pm pre-dosing day until they consume a high-calorie and high-fat breakfast the following morning.~The IMP must be administered as soon as the meal has been eaten."
89561658|NCT03137017|Active Comparator|Norco fasted|"Norco fixed dose combination Hydrocodone bitartrate 5 mg/acetaminophen 325 mg tablet (Norco 5Mg-325Mg Tablet) under fasted conditions.~Participant must fast from approximately 10:00 pm pre-dosing day until 4 hours after the administration of the IMP."
89561659|NCT03137017|Active Comparator|Norco fed|"Norco fixed dose combination Hydrocodone bitartrate 5 mg/acetaminophen 325 mg tablet (Norco 5Mg-325Mg Tablet) under fed conditions.~Participant must fast from approximately 10:00 pm pre-dosing day until they consume a high-calorie and high-fat breakfast the following morning.~The IMP must be administered as soon as the meal has been eaten."
89561660|NCT04412681|Experimental|PE Enhanced Screening|"The PE screening program entails the following for all participants:~provision of additional demographic and risk factors~provision of mean arterial pressure~standard nuchal translucency scan as part of their first trimester screening (FTS) with the addition of the measurement of the uterine artery Doppler by a certified sonographer~standard blood sample (as part of the FTS)~results of the PE screening (in the format of a screening report) will be provided to the study team and participant's healthcare provider"
89561661|NCT05635565|Active Comparator|Individualized goal training|This group will be submitted to individualized goal training, 3 hours/day, 5 times/week, over the course of two weeks, totaling 30 hours. Training will happen in a clinical setting. Adolescents will select their functional goals to be trained during the intervention period.
89561662|NCT05635565|Experimental|Individualized goal training with educational strategies|This group will be submitted to individualized goal training with their caregivers, for 2 weeks, with 5 face-to-face meetings lasting 3 hours a day at the rehabilitation center. The other 5 meetings will be held online with the adolescent and their caregiver at the same time, via video communication platform. Adolescents will select their functional goals to be trained during the intervention period.
89561663|NCT05635253|Other|GROUP GSEM|In-office whitening treatment with 35% Hydrogen Peroxide
89561664|NCT05635253|Experimental|GROUP GP|In-office whitening treatment with 35% Hydrogen Peroxide + Polishing of whitened teeth
89561665|NCT03069599||10 IRE locally advanced|patients undergoing in situ IRE for locally advanced pancreatic
89561666|NCT03069599||10 IRE borderline resection|patients undergoing margin accentuation IRE for borderline resectable disease
89561667|NCT03069599||10 resection only|patients undergoing surgical resection only
89561668|NCT05634941|Active Comparator|Active ON-tDCS|The active group will receive the active transcranial direct current stimulation via a saline-soaked pair of surface sponges. Patients received this treatment protocol for 5 consecutive days.
89561669|NCT05634941|Sham Comparator|Sham ON-tDCS|The sham group will also receive the transcranial direct current stimulation for 5 consecutive days on sham procedure. The rationale behind this sham procedure was to mimic the transient skin sensation at the beginning of active ON-tDCS without producing any conditioning effects on the brain.
89561670|NCT05074069||Neovaginal reconstruction|Neovaginal reconstruction post-vulvovaginal resection
89561671|NCT05074069||Flap Reconstruction|Flap closure of perineal defect post-gynaecological organ resection
88967301|NCT00086827|Experimental|Treatment (romidepsin)|Patients receive FR901228 (depsipeptide) IV over 4 hours on days 1, 8, and 15. Treatment repeats every 28 days for at least 6 courses in the absence of disease progression or unacceptable toxicity. Patients who have continuing tumor response or stable disease after 6 courses receive 2 additional courses beyond best response.
88967302|NCT00086944|Experimental|Treatment (genase, combination chemotherapy)|See detailed description.
88967303|NCT00006107|Experimental|Taxotere|"Taxotere: (1 hour infusion once a week for four weeks)~Radiation Therapy (5 days/week for 6-7 weeks)~Surgery (if required) 14 -12 weeks after radiotherapy~Follow-up"
88967304|NCT00086983|Experimental|Treatment (becatacarin, oxaliplatin)|"Patients receive rebeccamycin analogue IV over 1 hour on days 1-5 and oxaliplatin IV over 2 hours on day 5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of rebeccamycin analogue and oxaliplatin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. At least 6 patients are treated at the MTD."
88967305|NCT00087217|Experimental|Treatment (tanespimycin, paclitaxel)|Patients receive 17-AAG IV over 1 hour on days 1*, 4, 8, 11, 15 and 18 and paclitaxel IV over 1 hour on days 1, 8, and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
88967306|NCT00087256|Placebo Comparator|Arm 1: placebo|one placebo capsule taken orally twice a day for 3 years
88967307|NCT00087256|Experimental|Arm 2: celecoxib|one 400 mg capsule taken orally twice a day for 3 years
88967308|NCT00087295|Experimental|Treatment|Depsipeptide
89027113|NCT02955693|Other|Sequence D (n=8)|LAS41008 120 mg fed (Period 1) - Fumaderm® 120 mg fasting (Period 2) - LAS41008 120 mg fasting (Period 3) - Fumaderm® 120 mg fed (Period 4)
89027114|NCT04697121|Placebo Comparator|Placebo|
89561672|NCT05074069||No reconstruction/Primary closure|Primary closure of defect post-multivisceral, gynaecological organ-involving, resection
89561673|NCT04262479|Experimental|GAD-vaccination with vitamin D suppletion|"Each study participant will receive 3 injections of 4 µg GAD-alum (Diamyd). The first, second and third injection will be one month apart.~Vitamin D (Divisun 2000 IE) will be given from one month before the first injection of GAD-alum until one month after the third injection (120 days in total)."
89561674|NCT04275323|Experimental|investigational produc|Patients in this treatment group will receive 8mg NL003 respective in D0、14、28
89561675|NCT04275323|Placebo Comparator|Placebo|Patients in this group will receive normal saline respective in D0、14、18
89561676|NCT04133311|Active Comparator|DE-130A|Instillation of one drop, once daily in the evening (9 pm ±1 hour) in the conjunctival sac of the affected eye(s). Both eyes will be treated unless the patient suffers from unilateral OAG/OHT
89561677|NCT04133311|Active Comparator|Xalatan®|Instillation of one drop, once daily in the evening (9 pm ± 1 hour) in the conjunctival sac of the affected eye(s). Both eyes will be treated unless the patient suffers from unilateral OAG/OHT
89561678|NCT04237025|Experimental|Nordic walking exercise group|Supervised Nordic walking exercise training 3 times per week for the first two weeks and 2 times per week for next four weeks (total 6 weeks). In addition to independent Nordic walking exercise twice weekly during intervention phase and three times weekly during the 3-month followup phase.
89561679|NCT03217825|Experimental|Rostafuroxin 6 micrograms capsules|1 capsule of ROSTAFUROXIN (6 micrograms) once a day before breakfast.
89561680|NCT03217825|Experimental|Rostafuroxin 50 micrograms capsules|1 capsule of ROSTAFUROXIN (50 micrograms) once a day before breakfast.
89561681|NCT03217825|Experimental|Rostafuroxin 500 micrograms|1 capsule of ROSTAFUROXIN (500 micrograms) once a day before breakfast.
89561682|NCT03217825|Active Comparator|Losartan 50 mg encapsulated|1 capsule containing one cpr of Losartan 50 mg once a day before breakfast.
89561683|NCT05183009|Experimental|Therapy|Neuromuscular electrical stimulation
89561684|NCT05183009|No Intervention|No Therapy|Under the care of the referring physician, with no therapy applied
89561685|NCT04014829||Control group for CPHP|Preoperative assessment with questionnaires, Mechanical Temporal Summation, Pain-Pressure Threshold, and heart rate variability. All patients will undergo elective abdominal or laparoscopic hysterectomy. Patients will be assigned to this group if no significant pain is noted during the follow up evaluations at 4 and 6 months.
89561686|NCT04014829||Chronic Post-Hysterectomy Pain (CPHP)|Preoperative assessment with questionnaires, Mechanical Temporal Summation, Pain-Pressure Threshold, and heart rate variability. All patients will undergo elective abdominal or laparoscopic hysterectomy. Patients will be assigned to this group if significant pain is noted during the follow up evaluations at 4 and 6 months.
89561687|NCT04014829||Control group for significant postoperative pain|Preoperative assessment with questionnaires, Mechanical Temporal Summation, Pain-Pressure Threshold, and heart rate variability. All patients will undergo elective abdominal or laparoscopic hysterectomy. Patients will be assigned to this group if no significant pain is noted during the follow up evaluations at 24 and 48 hours.
89561688|NCT04014829||Significant postoperative pain|Preoperative assessment with questionnaires, Mechanical Temporal Summation, Pain-Pressure Threshold, and heart rate variability. All patients will undergo elective abdominal or laparoscopic hysterectomy. Patients will be assigned to this group if significant pain is noted during the follow up evaluations at 24 and 48 hours.
89561689|NCT05634629|Active Comparator|Anterior Lamellar Recession|
89561690|NCT05634629|Active Comparator|Bilamellar Tarsal Rotation|
89561691|NCT05088031||1- Group ( A): 20 patients underwent shock wave therapy|1-Group (A): 20 patients would undergo shock waves plus traditional physical therapy. One thousand shock waves (7 times per sec) were applied at 2.5 Hz at low energy flux densities of 0.01-0.16 mJ/mm2 using a 17 mm head for 15 minutes on alternate days for four weeks for a total of 12 sessions14.
89561692|NCT05088031||2-Group (B): 20 patients would undergo intermittent mechanical traction|"2-Group (B): 20 patients would undergo intermittent mechanical traction plus conventional physical therapy. Participants would undergo 30 minutes of mechanical traction (with 10-second pull and 5-second rest) 3 times weekly day after day for four weeks for a total of 12 sessions."
89027115|NCT04697121|Active Comparator|Combined Bergamot Phytosome and Artichoke leaf dry extract|600 mg of Bergamot Phytosome and 100 mg of Artichoke leaf standardized dry extract
89027116|NCT01315249|Experimental|QVA149|Participants received indacaterol and glycopyrronium (QVA149) and placebo to fluticasone/salmeterol.
89027117|NCT01315249|Active Comparator|fluticasone/salmeterol|Participants received fluticasone/salmeterol and placebo to indacaterol and glycopyrronium (QVA149).
89561693|NCT05088031||Group (C): (Control group) 20 patients would underwent conventional physical therapy|"3-Group (C): (Control group) 20 patients would underwent conventional physical therapy consisted of hyperthermia using hot packs (20 minutes), ultrasound (5 minutes), and electrotherapy using TENS (15 minutes) in addition to stretching exercises for the back, iliopsoas, and hamstring muscles and strengthening exercises for the abdominal muscles for 30 minutes."
89561694|NCT05087953||FAC group|Patients with familial amyloidotic cardiomyopathy.
89561695|NCT05087953||Non-FAC group|Patients with transthyretin gene mutations who do not have FAC.
89561696|NCT05087953||Control group|Healthy subjects.
89561697|NCT05087797|Experimental|nicorandil group|
89561698|NCT05087797|No Intervention|control group|
89561699|NCT05087719|Experimental|experimental group|The patients in the experimental group will get the hot pack initially for 15 minutes .Then for proprioception training of graphesthesia for 15 mints, therapist repeatedly draw some letter, figures, digit, shapes ,alphabets on the palm of hand/digits of patient.For Stereognosis therapist command the patient to close his or her eyes, then on affected hand put some different kinds of objects and shapes then ask the patient to identify that object, the object might be of any kind like a key, rubber a block or a coin etc. Total time for stereognosis was 15 minutes. For motor training patients were guided by the therapist to use his or her affected hand more. Then patient practiced some task like drawing writing his or her name, folding the towel or a paper, eating something with different speed, picking small objects like nails and put them in to small boxes, organize the cards etc. This training session required 15 minutes.
89561700|NCT05087719|Active Comparator|conventional treatment|baseline treatment of hot pack for 15 minutes will be given.The patients in this group will get muscle strengthening exercise of the hand, Range of motion, and stretching of the hand muscles, 3 sets of 8 repetitions were given to the patient, gap of 2 minutes will be given between regimes. For 20 minutes this session will be given to patient by the therapist.
89561701|NCT05087017||Intervention Group|Patients with COPD or Lung Fibrosis following rehabilitation program will be invited to participate and answer the questionnaires in the beginning and after eight weeks of rehabilitation.
89561702|NCT05087017||Control group|Patients with COPD or Lung Fibrosis who do not do any regular activity will be invited to participated and answer the questionnaires just once.
89561703|NCT05086861|Experimental|Oesophageal Pacing Arm|Patients undergoing atrial fibrillation ablation to isolate the left atrial posterior wall via catheter or staged hybrid ablation.
89561704|NCT05086783|Experimental|Video-based coaching|Participants in the intervention arm will receive the standard surgical teaching while in the operating room (master-apprentice model (MAM)), plus the intervention of reviewing the recorded video with the surgical coach after performing their first attempt at laparoscopic closure of the vaginal vault.
89561705|NCT05086783|Placebo Comparator|Standard surgical teaching|Participants in the control arm will receive the standard surgical teaching while in the operating room (master-apprentice model-(MAM)).
89561706|NCT05070949|Experimental|Mindful Self-Compassion|Participants will meet every 2 weeks via zoom application or equivalent online meeting platforms, for 12 weeks. The sessions will be led by a clinical psychologist. The curriculum will follow mindful compassion program by Neff KD
88967309|NCT00087373|Experimental|Treatment (recombinant fowlpox-TRICOM vaccine)|Patients receive fowlpox-TRICOM intratumorally on day 1 of weeks 1, 4, and 7 (maximum of 3 injections for a single lesion) (course 1). After 3 injections (course 1), patients with stable or responding disease receive additional injections into new lesions following the same schedule as above. Treatment repeats every 9 weeks for a maximum total of 9 injections (3 injections total into a maximum of 3 different tumors) (total of 3 courses) in the absence of disease progression or unacceptable toxicity
88967310|NCT00087412|Experimental|Treatment|Patients receive oral erlotinib once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
88967311|NCT00390078|Active Comparator|1|20 Subjects, 1x 10E8_TCID50 MVA-mBN32
88967312|NCT00390078|Placebo Comparator|2|10 Subjects 1x 10E8_TCID50 IMVAMUNE
88967313|NCT00087802|Active Comparator|Stratum 1|Subjects will be randomized in a 1:1 allocation to either GEMOX or CP after signed consents and baseline evaluations are completed, allowing for safe entry into the study. In order to avoid an unbalanced distribution by baseline characteristics, randomization will be stratified by one factor: disease stage (in a 1:4 proportion for Stage IIIb vs. Stage IV or relapsed disease). Randomization schedules will be produced for each stratum, and treatment allocation will be carried out centrally
88967314|NCT00087802|Active Comparator|Stratum 2|Subjects will be randomized in a 1:1 allocation to either GEMOX or CP after signed consents and baseline evaluations are completed, allowing for safe entry into the study. In order to avoid an unbalanced distribution by baseline characteristics, randomization will be stratified by one factor: disease stage (in a 1:4 proportion for Stage IIIb vs. Stage IV or relapsed disease).
88967315|NCT00006125|Experimental|Doxorubicin + topotecan|"Patients receive doxorubicin IV over 5-10 minutes on day 1 and topotecan IV over 30 minutes on days 3-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression.~Patients are followed every 6 months for 2 years and annually for the next 3 years."
88967316|NCT04747470|Experimental|GS-3583 Dose Escalation|Participants will receive an escalating dose of GS-3583 for up to 52 weeks or until the participant meets study treatment discontinuation criteria.
89561707|NCT05070949|No Intervention|Wait List Control|Wait list control group will not participate in the MSC program during the first 12 weeks of the protocol but will be given an opportunity to participate after 12 weeks, using the same curriculum.
89561708|NCT04011787|Active Comparator|Intervention|bolus NGT feeding
89561709|NCT04011787|Other|Control|Continuous NGT feeding (standard care)
89561710|NCT03867799|Experimental|Nivolumab and Relatlimab|Nivolumab 480mg and Relatlimab 160mg will be administered intravenously every 4 weeks
89561711|NCT05085925|Experimental|Cognitive behavioral mindfulness intervention at entry|Cognitive behavioral mindfulness intervention at entry
89561712|NCT05085925|Active Comparator|Cognitive behavioral mindfulness intervention after 3 months|Cognitive behavioral mindfulness intervention after 3 months of wait list
89561713|NCT05085769||Study group|15 patients who had bariatric surgery
89561714|NCT05085769||Control group-1|8 morbidly obese participants who did not have bariatric surgery
89561715|NCT05085769||Control group-2|11 participants who were non-obese
88967317|NCT00087880|Active Comparator|Brief Treatment|Participants will start with a 21 mg nicotine patch, tapering to 14 mg patch and finally tapering to 7 mg patch. The nicotine patch will be administered on Week 3 of the program. Participants will meet with medical staff during Weeks 1, 2, 5, and 11. Five group counseling sessions must be attended by the participants. Assessments will be conducted on Weeks 12, 24, 36, 52, 64, and 104.
88967318|NCT00087880|Active Comparator|Extended Bupropion/Low Contact|Participants will receive the Brief Treatment followed by ongoing Bupropion treatment through Week 52. Participants will meet with medical staff once a month.
88967319|NCT00087880|Placebo Comparator|Extended Placebo/Low Contact|Participants will receive the Brief Treatment followed by placebo medication (sugar-pill) through Week 52 and meet with medical staff once a month.
88967320|NCT00087880|Active Comparator|Extended Bupropion/High Contact|Participants will receive Brief Treatment followed by ongoing bupropion treatment through Week 52. Participants will attending counseling session 20-40 minutes in duration and will be scheduled at weeks 12, 14, 16, 18, 20, 24, 28, 32, 36, 44, and 52. The contents of these sessions will introduce additional information focusing on motivation, social support, mood management, weight gain, and dependence/withdrawal. Subjects will be contact by phone between counseling sessions (at Weeks 13, 15, 18, 22, 26, 30, 34, 36, 40, 48) for a brief check-in.
88967321|NCT00087880|Placebo Comparator|Extended Placebo/High Contact|Participants receive the Brief Treatment followed by a placebo medication through Week 52 and meet with medical staff once per month. Participants will attending counseling session 20-40 minutes in duration and will be scheduled at weeks 12, 14, 16, 18, 20, 24, 28, 32, 36, 44, and 52. The contents of these sessions will introduce additional information focusing on motivation, social support, mood management, weight gain, and dependence/withdrawal. Subjects will be contact by phone between counseling sessions (at Weeks 13, 15, 18, 22, 26, 30, 34, 36, 40, 48) for a brief check-in.
88967322|NCT00088231|Experimental|PTK 787 + Imatinib|For 1 week prior to receipt of study combination regimen, all patients will receive single agent PTK 787 at dose specified for that dose level of the study combination regimen to allow stabilization of PTK 787 levels. Patients should not have a grade 3 or 4 PTK 787-related adverse events in order to begin study combination therapy with a imatinib on day 8. On Day 8, PTK 787 250 mg by mouth every day and imatinib 600 mg by mouth every day (for Acute Myelogenous Leukemia (AML), Chronic Myelogenous Leukemia- blastic phase (CML-BP) and imatinib 400 mg by mouth every day (for Agnogenic Myeloid Metaplasia (AMM). Length of therapy is four courses; each course equals 28 days. Patients assessed for response after each course.
88967323|NCT00088231|Experimental|PTK 787 (vatalanib) Alone|For 1 week prior to receipt of study combination regimen, all patients will receive single agent PTK 787 at dose specified for that dose level of the study combination regimen to allow stabilization of PTK 787 levels. Patients should not have a grade 3 or 4 PTK 787-related adverse events in order to begin study combination therapy with a imatinib on day 8. PTK 787 250 mg by mouth for Days 1 - 7.
88967324|NCT00088426||Control|Control group of Williams-Beuren (also known as Williams) syndrome
88967325|NCT00088426||Family|Direct blood relatives (typically parents, and occasionally siblings of affected individuals) ofpatients with HPE are also eligible to participate.
88967326|NCT00088426||HPE|Patients with HPE
88967327|NCT04700865|Other|Examination|Continuous ECG monitoring for minimum 3 days
88967328|NCT00088543|Experimental|1 Low dose|total dose 4.5 mg/kg Thymoglobulin
88967329|NCT00088543|Experimental|2 High dose|total dose 8.5 mg/kg Thymoglobulin
88967330|NCT00088582|Experimental|Sandostatin s.c. (Octreotide)|
88967331|NCT00088582|Experimental|Pasireotide (SOM230)|
88967332|NCT04695444|Active Comparator|conventional PVC tube|When performing nasotracheal intubation, clinicians use the conventional PVC tube.
88967333|NCT04695444|Experimental|PVC tube with rubber suction catheter|When performing nasotracheal intubation, clinicians use the conventional PVC tube + rubber suction catheter.
88967334|NCT04695444|Experimental|velvet soft PVC tube|When performing nasotracheal intubation, clinicians use the velvet soft PVC tube.
88967335|NCT00088777|Experimental|MET|
88967336|NCT00088777|Experimental|CSE|
88967337|NCT00088855|Experimental|Treatment (bortezomib and pegylated liposomal doxorubicin)|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11 and pegylated liposomal doxorubicin hydrochloride IV over 1 hour on day 4. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
88967338|NCT00088894|Experimental|Arm I (gemcitabine hydrochloride, bevacizumab)|Patients receive gemcitabine IV over 30 minutes on days 1, 8, and 15 and bevacizumab IV over 30-90 minutes on days 1 and 15.
88967339|NCT00088894|Active Comparator|Arm II (gemcitabine hydrochloride, placebo)|Patients receive gemcitabine IV as in arm I and placebo IV over 30-90 minutes on days 1 and 15.
88967340|NCT00088933|Experimental|Arm I|Three weeks after treatment with vaccinia-CEA-TRICOM vaccine, patients receive fowlpox-CEA-TRICOM vaccine SC on day 1 and GM-CSF SC into each vaccination site on days 1-4.
88967341|NCT00088933|Experimental|Arm II|Patients receive fowlpox-CEA-TRICOM vaccine and GM-CSF as in arm I and lower-dose docetaxel IV over 30 minutes on days 1 and 8.
88967342|NCT00088933|Experimental|Arm III|Patients receive fowlpox-CEA-TRICOM vaccine and GM-CSF as in arm I and standard-dose docetaxel IV over 30 minutes on days 1 and 8.
88967343|NCT00088933|Experimental|Arm IV|Patients receive fowlpox-CEA-TRICOM vaccine and GM-CSF as in arm I and full-dose docetaxel IV over 1 hour on day 1.
88967344|NCT00088933|Experimental|Arm V|Patients receive full-dose docetaxel IV over 1 hour on day 1, fowlpox-CEA-TRICOM vaccine SC on day 8, and GM-CSF SC into each vaccination site on days 8-11.
88967345|NCT00088933|Experimental|Arm VI|Patients receive full-dose docetaxel as in arm V, fowlpox-CEA-TRICOM vaccine SC on day 15, and GM-CSF SC into each vaccination site on days 15-18.
88967346|NCT04664205|Experimental|High intensity interval training, then Moderate Intensity Continuous Training|Participants randomly assigned to this arm will first receive high intensity interval training followed by moderate intensity continuous training.
89561716|NCT05085457|No Intervention|Control Group|On group I (T-ayre and standard protocol), SBT must begin with the pacient in T-ayre, oxygen support that is proprotional to the fraction of inspired oxygen in invasive mechanical ventilation (IMV), during 30 minutes. If the pacient does not show any sign of SBT failure, the rapid shallow beathing index (RSBI) will be calculated and pacients with RSBI lower than 105 L/min will be extubated, meanwhile pacients with RSBI higher than 105 L/min will return to MV for at least 24 hours until the perfomance of a new SBT.
89561717|NCT05085457|Experimental|ExPreS Group|On group II (T-ayre and ExPreS protocol), the pacient will be submitted to the SBT with T-ayre, with oxygen support that is proprotional to the fraction of inspired oxygen in IMV, during 30 minutes. If the pacient does not show any sign of SBT failure, ExPreS will be calculated. If punctuation is lower than or equal to 44, it indicates weaning failure and the pacient mjust return to MV for 24 hours at least. Punctuation between 45 and 58 must be evaluated if the pacient presents chronic obstructive pulmonary desease (COPD), obesity or heart desease. In this case, non invasive ventilation (NIV) should be scheduled or the weaning must be continued if there isn't any risck factors. Punctuation higher than or equal 59 indicates that the pacient can be extubated.
89561718|NCT03726073|Experimental|Intervention group|Electrical stimulation will be given 30min before anesthesia and during surgery, auricular acupressure will be given in postoperative 3 days
89561719|NCT03726073|Sham Comparator|Non-intervention group|Usual care
89561720|NCT04873297|Experimental|Metoclopramide Group|One group will be given metoclopramide 10mg TDS
89561721|NCT04873297|Placebo Comparator|Placebo Group|This group will be given placebo (normal saline 10ml via NG TDS)
89561722|NCT02633501|Experimental|Subset 1 Arm 1|One of the two doses of P03277 (0.05 or 0.1 mmol/kg)-enhanced MRI then gadobenate dimeglumine (0.1 mmol/kg)-enhanced MRI
89561723|NCT02633501|Experimental|Subset 1 Arm 2|Gadobenate dimeglumine (0.1 mmol/kg)-enhanced MRI then one of the two doses of P03277 (0.05 or 0.1 mmol/kg)-enhanced MRI
89561724|NCT02633501|Experimental|Subset 2 Arm 1|One of the four doses of P03277 (0.025, 0.05, 0.1 or 0.2 mmol/kg)-enhanced MRI then gadobenate dimeglumine (0.1 mmol/kg)-enhanced MRI
89561725|NCT02633501|Experimental|Subset 2 Arm 2|Gadobenate dimeglumine (0.1 mmol/kg)-enhanced MRI then one of the four doses of P03277 (0.025, 0.05, 0.1 or 0.2 mmol/kg)-enhanced MRI
89561726|NCT05634473|Experimental|Patients with asthma/healthy subjects|
89561727|NCT05634317|Experimental|Behavioral activation|The SD-BA, consisting of 16 sessions (30 minutes each) twice a week over 8 weeks, will be delivered by the trained instructor through a videoconference mobile app. Participants will be asked to review their daily activity patterns and then choose activity goals and review their successes and areas of improvement. They will also be taught how to fill out the daily monitoring record, which will involve noting down their activities on the day of the session for each hour before the session, and rating the importance and degree of enjoyment associated with each activity.
89561728|NCT05634317|Active Comparator|Mindfulness|A mindfulness instructor will deliver the program through a videoconference mobile app, and include various mindfulness practices (e.g., mindful walking, body scanning) and sharing. To standardize the interventions in this study, the previous approach will be changed from 7 weekly 120-minute sessions to 16 sessions (30 minutes each) twice a week over 8 weeks. The participants will also be encouraged to perform 30 minutes of mindfulness practice every day. All participants will be given an audio (mp3) recording of guided mindfulness activities to enhance their daily practice, and a logbook via a mobile app or in hardcopy (according to their preference) to record the frequency of their self-practice at home and monitor their compliance rate. Our volunteers will provide support via smartphone to answer questions and address difficulties.
89561729|NCT05085145|Experimental|Coronavirus vaccination|Patients in the experimental need to accept the coronavirus vaccination
89561730|NCT05634239|Experimental|Health check|
89561731|NCT04858711|Active Comparator|ketamine-lidocaine-dexmedetomidine (KLD) group|combination of ketamine-lidocaine-dexmedetomidine in one syringe
88967347|NCT04664205|Experimental|Moderate Intensity Continous Training, then High Intensity Training|Participants randomly assigned to this arm will first receive moderate intensity continuous training followed by high intensity interval training.
88967348|NCT04664205|No Intervention|Control: No exercise|Participants will complete the same pre- post measurements, with no exercise in between.
88967349|NCT00089089|Experimental|Treatment (decitabine)|"Patients receive decitabine IV over 1 hour on days 1-5 or on days 1-5 and 8-12. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.~Cohorts of 6 patients receive escalating doses of decitabine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity."
89561732|NCT04858711|Active Comparator|fentanyl (control) group|syringe of fentanyl
89561733|NCT03138187|No Intervention|control|without physical exercise sessions
89561734|NCT03138187|Experimental|Moderate exercise group|The training phase of the moderate exercise group (MEG) will consist of 4 sets of 10 minutes walking/running at moderate intensity, with 5 minutes walking at low intensity for recovery between sets
89561735|NCT03138187|Experimental|Vigorous exercise group|The training phase of the vigorous exercise group (VEG) will consist of 4 sets of 10 minutes running at vigorous intensity, with 5 minutes walking at low intensity for recovery between sets
89561736|NCT03069209|Experimental|Stem Cells|Intervention: Intraovarian transplantation of autologous purified bone marrow-derived stem cells and mesenchymal stem cells.
89561737|NCT04771819|Experimental|SoftOx Wound Irrigation Solution (SWIS)|Blister wounds will be irrigated and soaked for 15 minutes.
89561738|NCT04771819|Active Comparator|Normal Saline|Blister wounds will be irrigated and soaked for 15 minutes.
89561739|NCT03068975|Experimental|Alvimopan|Patients in the study group will be administered a post operative dose of Alvimopan
88967350|NCT00400231|Active Comparator|1|Metformin
88967351|NCT00400231|Active Comparator|2|Fenofibrate
88967352|NCT00400231|Active Comparator|3|Fenofibrate and Metformin
88967353|NCT00400231|Placebo Comparator|4|
88967354|NCT00423865|Experimental|cisplatin & RAD001|This will be a single institution phase I study of low dose weekly cisplatin (20 mg/m2 intravenously on Days 1, 8, and 15) plus escalating doses of daily RAD001 tablets (per oral or via percutaneous gastrostomy tube, Days 1 -21 of a 28-Day Cycle) for patients with advanced solid tumors
89561740|NCT03068975|Placebo Comparator|Placebo|Patients in the Placebo group will receive a placebo pill and will be compared with the study group
89561741|NCT02034331|Active Comparator|Acetylcholine Iontophoresis|For acetylcholine iontophoresis, the anode electrode will contain 0.2 ml of 1% acetylcholine chloride; the cathode electrode will contain a medical grade adhesive for skin placement and last 20 minutes. Preparation, instrumentation and data collection for this intervention are the same as the insulin iontophoresis.
89561742|NCT02034331|Active Comparator|Heat Application|For the provocation with heat, an insulated thermal heat pack (~106°F) will be applied to the exposed arm or leg for 18 minutes. The thermal heat pack is comparable to what is routinely used as a heat therapy in conventional rehabilitation settings. LDF leads and temperature sensors will be placed in the previously specified locations to evaluate the changes.
89561743|NCT02034331|Experimental|Insulin Iontophoresis|For insulin iontophoresis, the cathode electrode will contain 0.2 ml of liquid insulin. For preparation and instrumentation, the arms will be uncovered below the elbow; the participant's lower extremities will be uncovered below knee for leg evaluations. The laser Doppler flowmetry (LDF) lead will be placed bilaterally, 2 inches proximal to the lateral malleolus over the peroneus longus muscle. For arm evaluations, a lead will be placed (and secured with dual-sided transparent tape) bilaterally, 2 inches distal to the lateral epicondyle over the flexor carpi ulnaris muscle along the midline with the ulnar process. Baseline and peak cutaneous blood flow responses to application of insulin iontophoresis will be determined for each LDF lead during the evaluation.
89561744|NCT02034331|Placebo Comparator|Placebo Iontophoresis|For placebo iontophoresis, the cathode electrode will contain 0.2 ml of preservative-free normal saline; the anode electrode will contain a medical grade adhesive for skin placement and last 20 minutes. Preparation, instrumentation and data collection for this intervention are the same as the insulin iontophoresis.
89561745|NCT03592225|Other|Educational workshop intervention arm|The group of general practitioners (GP) from Lyon (France), about 300, that will be invited to attend the 3 hours educational workshop about HPV vaccination. After the workshop, the GPs will return to their normal health care practice.
89561746|NCT03592225|No Intervention|Control arm|The group of general practitioners (GP) from Lyon (France), about 300, that will NOT be invited to attend the 3 hours educational workshop about HPV vaccination. These GPs perform their normal health care practice.
89561747|NCT04166981|Active Comparator|Non-instrumented arm|Decompression with concomitant non-instrumented posterolateral fusion with autologous(obtained from the decompression) and allogenic bone graft.
89561748|NCT04166981|Experimental|Instrumented arm|Decompression with concomitant instrumented posterolateral fusion with autologous(obtained from the decompression) and allogenic bone graft and supplementary pedicle screw fixation.
89561749|NCT03068117|Experimental|RESSCT plus Standard Care/Therapy|"Regular Early Specialist Symptom Control Treatment (RESSCT) and Standard Therapy.~Participants will be seen within three weeks of randomisation by the Specialist Palliative Care Team (SPCT), (regardless of, and in addition to, all other treatments being offered). The initial meeting will be an approximately 1 hour consultation with a member of the Specialist Palliative Care team. This may be either a Consultant or Specialist Palliative Care Clinical Nurse Specialist (SPCCNS).~Patients will then continue to be seen regularly on at least a 4 weekly basis (regardless of other treatments, interventions and symptoms) by a member of the SPCT, with consultations lasting approximately 30 minutes. These monthly reviews will continue until end of trial (EOT) or patient death."
88967355|NCT00423982|Active Comparator|Rifampicin-combination therapy|Cloxacillin or vancomycin in combination with Rifampicin. Treatment of early staphylococcal prosthetic joint infections in addition to debridement and retention of the prosthesis.
88967356|NCT00423982|Active Comparator|Monotherapy|Cloxacillin or vancomycin in the treatment of early staphylococcal prosthetic joint infections in addition to debridement and retention of the prosthesis.
88967357|NCT02965261|Experimental|Test|Torrent's Fluoxetine Tablets 20 mg
88967358|NCT02965261|Active Comparator|Reference|Warner Chilcott LLC's Sarafem® Tablet 20 mg
88967359|NCT00089323|Other|1: Bone Marrow Aspiration|
88967360|NCT00089362|Experimental|Treatment (alvespimycin hydrochloride)|"Patients receive alvespimycin hydrochloride IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 1-2 patients receive accelerated escalating doses of alvespimycin hydrochloride until at least 1 of 2 patients experience DLT. Cohorts are then expanded to 3-6 patients who receive escalating doses (in a standard manner) of alvespimycin hydrochloride until MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience DLT. Once the MTD is determined, 10 additional patients are treated at that dose."
88967361|NCT02958397|Experimental|Myeloid Malignancies|The trial will be conducted in a manner of simon two-stage design with anti-CD33-CAR-transduced T cells, beginning in the first stage with the aim of over 30% reaction rate among 15 patients with myeloid malignancies. Only when the expected reaction rate is achieved the 30 patients left can be recruited.
88967362|NCT02965300||Primary lung cancer|patients newly diagnosed with lung cancer by tissue biopsy and did not receive any treatment aiming at the tumor, including chemotherapy and radiotherapy.
88967363|NCT02965300||Benign lung lesion|Patients diagnosed with pulmonary benign diseases.
88967364|NCT02965300||Healthy control|Patients without any pulmonary abnormal symptoms or diseases
88967365|NCT00089908|Experimental|1|One subcutaneous vaccination with rDEN1delta30 vaccine (10^3 PFU dose) into the deltoid region of either arm.
88967366|NCT00089908|Experimental|2|One subcutaneous vaccination with rDEN1delta30 vaccine (10^5 PFU dose) into the deltoid region of either arm. This arm may enroll after Arm 1 depending on the effect of the vaccine on subjects in Arm 1.
89561750|NCT03068117|No Intervention|Standard Care/Therapy|The standard care/therapy control group will continue to receive all appropriate, standard treatment for Malignant Pleural Mesothelioma (MPM) currently available to them and will be initiated by the patient's General Practitioner (GP), the cancer MDT or lead respiratory physician as required.
89561751|NCT03538873|Active Comparator|Physical activity|"The assessment of physical activity in the prevention of depression. The intervention program being implemented in this study consists of four steps, lasting three months each:~Step 1 - Watchful waiting Step 2 - Physical Activity Intervention 1 Step 3 - Physical Activity Intervention 2 Step 4 - Referral to primary care In the case of the CES-D scores remain high, participants will receive orientation to discuss with their doctors the need to receive a specific medication."
89027118|NCT03270800|Experimental|IMX101 vaccine as intradermal and sublingual application|IMX101 vaccine will be administered intradermally and sublingually
89027119|NCT03270800|Experimental|CTA control as intradermal and sublingual application|CTA mucosal adjuvans will be administered intradermally and sublingually
89027120|NCT04207411|Experimental|Bupivacaine|The dose received at each injection will be 5 mg. One injection per week will be carried out over 4 consecutive weeks
89027121|NCT04207411|Sham Comparator|Lidocaine|The dose received at each injection will be 1.25mg. An injection unique per week will be carried out over 4 consecutive weeks.
89027122|NCT01248663|Active Comparator|antecolic reconstruction|After completion of pancreaticoduodenectomy and reconstruction of the pancreaticojejunostomy and hepaticojejunostomy, the reconstruction of the intestinal passage will be conducted by performing an antecolic duodeno-jejunostomy
89027123|NCT01248663|Experimental|retrocolic reconstruction|After completion of pancreaticoduodenectomy and reconstruction of the pancreaticojejunostomy and hepaticojejunostomy, the reconstruction of the intestinal passage will be conducted by performing a retrocolic duodeno-jejunostomy
89561752|NCT03538873|No Intervention|Usual care|Participants in the usual care group will have unrestricted access to usual care for depressive and / or anxiety symptoms.
89027124|NCT00473486|Active Comparator|1|Pemetrexed, Carboplatin plus Sorafenib in the first-line treatment of patients with stage IIIb or IV NSCLC
89027125|NCT00473486|Placebo Comparator|2|Pemetrexed, Carboplatin plus placebo in the first-line treatment of patients with stage IIIb or IV NSCLC
89027126|NCT05644483|Experimental|remimazolam group|patients who receive remimazolam-remifentanil based total intravenous anesthesia
89027127|NCT05644483|Active Comparator|propofol group|patients who receive propofol-remifentanil based total intravenous anesthesia
89027128|NCT01315132|Experimental|Allogeneic Transplantation|Matched Sibling Allogeneic Transplantation
89027129|NCT00504036|Experimental|Intra-gastric balloon|Patients will receive either an air-filled or water-filled intra-gastric balloon.
89027130|NCT00504036|No Intervention|Usual care|Usual care will be given to the patients.
89027131|NCT01248702|Experimental|Critical Pathway|
89027132|NCT01248702|No Intervention|Standard Practice|
89027133|NCT01248819|Active Comparator|Instillation|Instillation of Ropivacaine 100 mg in the abdominal cavity
89027134|NCT01248819|Experimental|Nebulization|Nebulization of Ropivacaine 60 mg in the abdominal cavity
89027135|NCT01313767|Experimental|Meditoxin®|Botulinum toxin type A
89027136|NCT01313767|Active Comparator|Botox®|Botulinum Toxin type A
89027137|NCT01248858|Experimental|GSK2126458 and GSK1120212|The first combination schedule that will be tested involves giving both GSK2126458 and GSK1120212 continuously once a day in the morning until the subjects withdraw from the study. Other dosing schedules with both drugs will also be tested and these schedules are described below GSK2126458 will be dosed twice per day (morning and evening) continuously and GSK1120212 will be dosed once a day in the morning on a continuous schedule. Subjects will be treated with both drugs and remain in the study as long as they are benefiting from therapy. Another schedule that will be tested involves giving GSK2126458 twice each day (morning and evening) on an intermittent schedule (4 days of treatment, 10 days rest, then 4 days treatment, 10 days rest). GSK1120212 will be dosed once each day in the morning on a continuous schedule. Subjects will be treated with both drugs as long as they are benefiting from therapy.
89027138|NCT00481286|Experimental|Group Clinic|Patients in Group Clinic arm will meet every 3rd week for 12 weeks, for a total of 4 visits. At each visit, BP will be measured, home BP and glucose measurements collected. Each visit will include group-based education and feedback sessions, with an individualized process of selecting and modifying process of care goals for systolic BP, H1C, and LDL cholesterol. Short-term health behavior change goals will also be discussed.
89027139|NCT00481286|Placebo Comparator|Uusual Care|Older diabetes patients will attend regular clinician visits and one targeted primary care physician visit during the 12 weeks post-enrollment. They will be enrolled in a diabetes education class. Blood pressure, H1C and lipids will be measured at enrollment, 6 weeks , and 12 weeks.
89027140|NCT01313728|Experimental|Dapsone plus Tretinoin Gel|Dapsone gel, followed by tretinoin gel one hour later, applied once daily to the assigned side of the face for 2 weeks - all subjects participate in both arms in a split-face model
89027141|NCT01313728|Active Comparator|Tretinoin Gel Alone|Tretinoin gel applied once daily to the assigned side of the face for 2 weeks - all subjects participate in both arms in a split-face model
89027142|NCT01248897||erbB2+/Her2 Breast Cancer Patients|erbB2+/Her2 Breast Cancer Patients Treated with Lapatinib and Other Anti-erbB2/Her2 Therapy
89027143|NCT00481364|Active Comparator|Statin|Atorvastatin 40 mg/day
89561753|NCT05077189||Study Group|Patients with CV-19 and not in the acute period. This group were then divided into two subgroups each according to ASA (American Society of Anesthesiologist) classification (ASA 1 and ASA 2).
89561754|NCT05077189||Control Group|Patients without CV-19 This group were then divided into two subgroups each according to ASA (American Society of Anesthesiologist) classification (ASA 1 and ASA 2).
89027144|NCT00481364|Placebo Comparator|Placebo|placebo
89027145|NCT01249014|No Intervention|Control|No peri-operative warming.
89027146|NCT01249014|Experimental|Warmed fluids|Patients will receive warmed i.v. fluids administered pre- and intra-operatively.
89561755|NCT04766957|Experimental|Idracare|The treatment will be applied 2 times a week, preferably at night before going to bed.
89561756|NCT03068039|Active Comparator|OATS PORRIDGE|Oats breakfast porridge 220 kcal served with 240 mL water
89027147|NCT01249014|Experimental|Warmed fluids and warm air|Patients will receive warmed i.v. fluids administered pre- and intra-operatively, and warmed air blown into a blanket covering the body intra-operatively.
89027148|NCT01240460|Experimental|1|Twice-daily dosing (every 12 hours) XL765
89027149|NCT01240460|Experimental|2|Once-daily dosing XL147
89027150|NCT01240460|Experimental|3|Once-daily dosing XL765
89027151|NCT01249170|Other|First year fellow|
89027152|NCT01249170|Other|Second Year Fellow|
89027153|NCT01249209|Other|lifestyle advice|
89027154|NCT01249248||Male basketball players|
89027155|NCT01249248||Female basketball players|
89027156|NCT01249248||Baseball players|
89561757|NCT03068039|Active Comparator|PEARL (BAJRA) MILLET PORRIDGE|Pearl (bajra) millet breakfast porridge isoenergetic (220 kcal) served with 300 mL water to make it also isovolumteric with the Oats arm
89561758|NCT05632991|Active Comparator|External oblique intercostal plane block|Ultrasound-guided External oblique intercostal plane block before surgery
89561759|NCT05632991|Active Comparator|Subcostal Transversus Abdominis Plan Block Group|Ultrasound-guided Subcostal Transversus Abdominis Plan Block Group
89561760|NCT05073601||control group|group of subjects with healthy cornea
89561761|NCT05073601||keratoconus group|group of keratoconus patients with no history of thyroid dysfunction
89561762|NCT03068195|Experimental|laparoscopic microwave ablation|laparoscopic microwave ablation will be performed before the renal cysts are decorticated
89561763|NCT03068195|Experimental|percutaneous microwave ablation|percutaneous microwave ablation will be performed to treat the renal cysts without decorticating.
89561764|NCT03068195|Active Comparator|laparoscopic decortication|conventional laparoscopic decortication will be performed to treat the renal cysts.
89561765|NCT03140059|Active Comparator|Open flap debridement|In this group (n = 22), patients will receive open flap debridement will be performed to treat residual pockets.
89561766|NCT03140059|Active Comparator|Repeated application of aPDT|In this group (n=22), patients will receive 5 applications of antimicrobial photodynamic therapy after the scaling and root planing.
89561767|NCT03067883|Experimental|interventional Qurevo group|"A total of 40 HCV treatment naïve patients with or without compensated cirrhosis on regular hemodialysis will be enrolled in the study.~These patients will receive intervention of '25 mg ombitasvir, 150 mg paritaprevir, and 100 mg ritonavir' (2 capsules Qurevo®) plus ribavirin 200 mg daily for 12 weeks.~Qurevo will be given once daily (on the day of dialysis, it will be given after dialysis session).~Ribavirin will be given once daily (on the day of dialysis, it will be given 4 hrs before dialysis session )."
89561768|NCT05631821|Active Comparator|Prospective Range Spinal System|Adolescent (between the ages of 10-18 years of age), with Idiopathic Scoliosis Range Spinal System: rod contour changes utilizing Differential Rod Bending and pre-operative templating in Adolescent Idiopathic Scoliosis: A pilot study. The prospective arm consented subjects will use the Rod Counour measurement system
89561769|NCT05631821|No Intervention|Retrospective|Retrospective matched cohort of subjects from the investigating surgeon are subjects that have not used the Rod contour measurement system. There is no intervention because the second arm is retrospective chart review.
89561770|NCT03404245|Active Comparator|Immediate Intervention Group|Education, Fitbit/self-management web app, physiotherapist counselling. These 3 components will be delivered to the participants in Months 1 and 2. The session will include a short presentation about physical activity in everyday life, an individual goal-setting session with a registered physical therapist (PT), and an orientation to the Fitbit device and the web app. Participants will be provided access to a Fitbit and an app account. The PT will review physical activity goals with participants via bi-weekly phone calls and progressively modify their activities. In Month 3-6, participants will continue using Fitbit and the app and have access to a PT via email as needed, but no phone call. In Months 7-12, participants may keep their Fitbit and app account, but will not have access to a PT.
89561771|NCT03404245|Placebo Comparator|Delayed Intervention Group|Same intervention with a 6 month delay: The full intervention will be initiated in Month 7 and 8 with a brief education session, use of a Fitbit paired with the self-management web app, and counseling by a physical therapist (PT). In Month 9-12, participants will continue the intervention without the PT phone calls, but will have email access to PT, if needed.
89561772|NCT03285763|Experimental|Atezolizumab|Participants with Stage IIIb or State IV NSCLC who have progressed after standard systemic chemotherapy will receive atezolizumab until Investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or participant's decision to withdraw from therapy, or death (whichever occurs first).
89561773|NCT03231631|Experimental|Education plan and adherence to exercise|"Educational talk about the importance of nutrition and exercise as an important strategy to change cardiovascular risk factors at the start of the study.~It will be sent via text, whatsapp, and / or e-mail on a weekly basis three text messages that remind them of the importance of doing the exercise and how often they should do it, it will be a predetermined text."
89561774|NCT03231631|No Intervention|Control|"The blood sample will be taken for the collection of serum HDL and the aerobic capacity test measured in MET will be recorded at the beginning of the study.~A survey will be conducted at week 12 of monitoring where adherence to exercise is measured during the 12-week study."
88967367|NCT00089908|Placebo Comparator|3|One subcutaneous vaccination with placebo into the deltoid region of either arm.
88967368|NCT04656990|Experimental|Gross motor and social-emotional integrated intervention group|Participants will receive a nine-month intervention which focuses on gross motor skills, physical activity, and social-emotional skills.
88967369|NCT04656990|No Intervention|Control|Participants will receive the center's everyday business as usual curriculum.
88967370|NCT00090025|Experimental|becatecarin|becatecarin
88967371|NCT00090025|Active Comparator|5-FU Plus Leucovorin (LV)|5-Fluorouracil (5-FU) Plus Leucovorin (LV)
88967372|NCT00090337|Experimental|Arm I|Patients undergo acupuncture for 20-30 minutes once weekly for 4 weeks.
88967373|NCT00090337|Active Comparator|Arm II|Patients undergo standard of care for 4 weeks.
88967374|NCT00090415|Experimental|1|Child participants with autism will undergo intensive behavioral therapy.
88967375|NCT00090415|No Intervention|2|Child participants without autism will receive no treatment and will undergo assessments to determine brain functioning only.
88967376|NCT04633902|Experimental|Olaparib + Pembrolizumab|This arm will enroll patients who has advanced melanoma with a genetic HR mutation/ alteration including mutation/ deletion in ARID1A/B, ARID2, ATM, ATR, BARD1, BRCA1/2, BAP1, BRIP1, CHEK2, FANCA, FANCD2, MRN11A, PALB2, RAD50, RAD51, RAD54B.
88967377|NCT04729153||Chronic HCV patients previously treated by DAADs.|
89561775|NCT03138109||grade1&2 diastolic dysfunction|lower diastolic dysfunction exposure
88967378|NCT04729153||Chronic HCV patients not treated by DAADs yet.|
88967379|NCT00090961|Experimental|12-week exercise program + education|A 12-week supervised exercise program consisting of 3 days a week on a stationary bike or treadmill. In addition, at the time of enrollment patients are provided educational materials focusing on breathing and energy conservation.
89027157|NCT01249248||Softball players|
89027158|NCT01249248||Football players|
89561776|NCT03138109||grade 3 diastolic dysfunction|higher diastolic dysfunction exposure
89561777|NCT03067805|Experimental|Oxytocin|Oxytocin nasal spray
89561778|NCT03067805|Placebo Comparator|Placebo|Placebo nasal spray
89561779|NCT05393011||Pregnant group|A female is considered pregnant when an explicit gestational sac inside the uterus is seen by ultrasound 4 weeks after embryo transfer.
89561780|NCT05393011||Non-pregnant group|A female is considered not pregnant when no explicit gestational sac is seen inside the uterus by ultrasound 4 weeks after embryo transfer.
89561781|NCT05034835|Experimental|With compression garments|Usual care in day hospitals, i.e. 3 occupational therapy sessions / week for 3 months, with the usual protocol of desensitization by Aquaroll (hydro-massage ball device) and by Vibralgic (device generating electronic transcutaneous vibrations) + wearing a compression garment for 3 months.
89561782|NCT05034835|Other|Without compression garments|Usual care in day hospitals, i.e. 3 occupational therapy sessions / week for 3 months, with the usual protocol of desensitization by Aquaroll (hydro-massage ball device) and by Vibralgic (device generating electronic transcutaneous vibrations).
89561783|NCT03138421|Experimental|ABX-1431 HCl|
89561784|NCT03138421|Placebo Comparator|Placebo|
89561785|NCT03110497|Experimental|Single application brachytherapy|After external beam radiotherapy with or without chemotherapy as per standard, each study patient will undergo single application brachytherapy to deliver 3 High Dose Rate (HDR) fractions [1st, 2nd and 3rd fractions of doses 9 Gy, 7 Gy and 7 Gy respectively] keeping 6-12 hours of interval. All patients will undergo an inter-fraction Computed Tomography (CT) scan before delivery of second fraction. Plan will be re-optimized to reduce the dose to Organs at Risk (OAR's), only if the dose exceeds the dose constraints. Dose constraints being exceedingly hard in 1st fraction or before 2nd fraction even after re-planning will deem patient non-feasible but optimization will be done to give preference to OAR's while accepting some compromise in target doses.
89561786|NCT03110731|Experimental|Intervention group|Physical training (2x / week) was performed for 12 weeks
89561787|NCT03110731|No Intervention|Control Group|no intervention
89561788|NCT03085771|Active Comparator|Desferal treatment|Patients will be randomized (by block randomization) to Desferal (DFO) treatment.
89561789|NCT03085771|Placebo Comparator|Isotonic saline treatment|Patients will be randomized (by block randomization) to isotonic saline treatment.
89561790|NCT05619965|Active Comparator|Awake Glidoscope Videolaryngoscope|Awake endotracheal intubation of cervical trauma patients by Glidoscope Videolaryngoscope
89561791|NCT05619965|Active Comparator|Awake Fiberoptic bronchoscope|Awake endotracheal intubation of cervical trauma patients by Fiberoptic bronchoscope
89561792|NCT02985619|Active Comparator|IVB randomised group I|"Randomised patients [intravitreal bevacizumab (IVB) group I] with central foveal thickness >300µm on OCT will be submitted to 6 months treatment with 0.05ml (1.25mg) intravitreous injection of Bevacizumabe prn (pro re nata, or as needed), with monthly visits for central subfoveal thickness map more than 300µm by Optic Coherence Tomography. Care will be take in all cases to insure that the needle do not touch the lids or lashes. Bevacizumab (1.25 mg/0.05 cc; F. Hoffmann- La Roche Ltd., Basel, Switzerland) will be inject into the vitreous cavity using a 29-gauge 0.5- inch needle insert through the superotemporal pars plana 3.0-3.5 mm posterior to the limbus."
89561793|NCT02985619|Active Comparator|IVT randomised group II|Randomised patients [intravitreal triamcinolone (IVT) group II] with central foveal thickness >300µm on OCT will be submitted to 6 months treatment with 0.03ml (1.20mg) intravitreous injection of triamcinolone each 3 months (prn, as needed) for central sufoveal thickness map more than 300µm by Optic Coherence Tomography. Care will be take in all cases to insure that the needle do not touch the lids or lashes. Triamcinolone (1.20 mg/ 0.03 cc; Opthaac, Ophthalmos, São Paulo, Brazil) will be inject into the vitreous cavity using a 29-gauge 0.5- inch needle insert through the superotemporal pars plana 3.0-3.5 mm posterior to the limbus.
89561794|NCT02985619|Active Comparator|IVB group III (not randomised)|Patients with central foveal thickness ≤300µm at week visit 24 will be allocated to group III (IVB, intravitreal bevacizumab). So, it won't get IVB injection at week visit 24 due OCT regular thickness (≤300µm) but will do regular monthly follow-up visits and prn-IVB therapy if central foveal thickness >300µm on OCT until last visit of study (48 week-visit). Care will be take in all cases to insure that the needle do not touch the lids or lashes. Bevacizumab (1.25 mg/0.05 cc; F. Hoffmann- La Roche Ltd., Basel, Switzerland) will be inject into the vitreous cavity using a 29-gauge 0.5- inch needle insert through the superotemporal pars plana 3.0-3.5 mm posterior to the limbus.
89561795|NCT05587205|Experimental|Treatment at time of surgery|EO2002 intracameral injection
89561796|NCT05587205|Experimental|Treatment post surgery|EO2002 intracameral injection
89561797|NCT05587205|Active Comparator|Treatment at time of or post surgery|EO2002 intracameral injection
89561798|NCT05587205|Sham Comparator|Sham injection at time of or post surgery|Sham injection
89561799|NCT04958005||Children with early chilhood caries|Early chilhood caries group
89561800|NCT04958005||Without early chilhood caries|Control group
89561801|NCT05583929||Spastic Cerebral Palsy|Children with spastic cerebral palsy
89561802|NCT05583929||Healthy Developing Peers|Children with healthy developing peers
89561803|NCT03110419|Experimental|Intervention|The training group will perform a Physical Exercise as multicomponent training.
89561804|NCT03110419|No Intervention|Control|The control group will only be evaluated, without any intervention.
89561805|NCT04123613|Experimental|2.0 µg/kg, multiple dose|n=45 with 15 Participants from cohort 1, 15 from cohort 2, and 15 from cohort 3
89561806|NCT04123613|Experimental|5.0 µg/kg, multiple dose|n=45 with 15 Participants from cohort 1, 15 from cohort 2 and 15 from cohort 3
89561807|NCT03110653|Active Comparator|Remifentanil|Remifentanil TCI: gradual withdrawal: reduction of 30% / 15 mins (2 -> 1.4 -> 1 -> 0.7-> 0.5 -> 0.35 -> 0.25 -> 0 ng/ml)
89561808|NCT03110653|Placebo Comparator|NaCl 0.9%|Remifentanil abrupt discontinuation / NaCl 0.9% (control group with a reduction of 30% /15 mins) (2 -> 1.4 -> 1 -> 0.7-> 0.5 -> 0.35 -> 0.25 -> 0 ng/ml)
89027159|NCT01249248||Female vollyball players|
89027160|NCT01249248||Male soccer players|
89561809|NCT04116593|Experimental|Intervention|
89561810|NCT04116593|No Intervention|Control|
89561811|NCT05392387||peg-IFN-alpha alone|Patients with chronic HBV infection only treated with peg-IFN-alpha
89561812|NCT05392387||nucleos(t)ide analogues alone|Patients with chronic HBV infection only treated with nucleos(t)ide analogues
89561813|NCT05392387||combination|Patients with chronic HBV infection treated with nucleos(t)ide analogues and peg-IFN-alpha
89561814|NCT04583579|Experimental|New Scleral Lens Wearers|All patients will be asked to wear scleral lenses for the duration of this study.
89561815|NCT04450199|Active Comparator|Vitamin D|12 over encapsulated 50,000 IU Vitamin D2
89561816|NCT04450199|Placebo Comparator|Placebo|12 over encapsulated placebo tablets
89561817|NCT03067649|Experimental|Motivational Interview|After the assessment, parents were provided with a 90-minute intervention aimed at increasing the likelihood that the parent would seek treatment for psychiatric problems for themselves.
89561818|NCT03067649|Other|Information only control|After the assessment, parents were given pamphlet with referral information for psychiatric services.
89561819|NCT01884259|Active Comparator|A|"Patients receive 3 cycles (cycle duration 21 days) of docetaxel (75mg/m²), cisplatin (75mg/m²) and 5-fluorouracil (750mg/m²) followed by Cetuximab (weekly, starting with 400mg/m² then continuing with 250 mg/m²) with radiotherapy (concomitant boost for 6 weeks).~Active comparator is 5-fluorouracil for first three cycles."
89027161|NCT01249248||Female soccer players|
89561820|NCT01884259|Experimental|B|"All patients receive 3 cycles (cycle duration 21 days) of docetaxel (75mg/m²), cisplatin (75mg/m²) Cetuximab (weekly, starting with 400mg/m² and continuing with 250 mg/m²), followed by Cetuximab (weekly 250 mg/m²) with radiotherapy (concomitant boost for 6 weeks).~Experimental: cetuximab for the first three cycles."
89561821|NCT04930549|Experimental|Dapagliflozin 10Mg Tab|Dapagliflozin 10 mg film-coated tablets
89561822|NCT04930549|Placebo Comparator|Placebo|Identical film-coated tablets without dapagliflozin
89561823|NCT05392153|Experimental|Myofascial therapy group|The myofascial therapy group (n=26) will receive 12 sessions of 6-weekly lower extremity posterior muscle myofascial therapy.
88967380|NCT00090961|Other|Education|At the time of enrollment patients are provided educational materials focusing on breathing and energy conservation.
88967381|NCT00091078|Experimental|Treatment (oblimersen sodium and imatinib mesylate)|Patients receive oblimersen IV continuously on days 1-14. Patients also receive oral imatinib mesylate on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88967382|NCT00091117|Experimental|Treatment|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
88967383|NCT00091195|Experimental|Treatment (single-agent depsipeptide)|Patients receive depsipeptide (romidepsin) IV over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88967384|NCT00091351|Experimental|surgery|"Patients undergo surgery.~Treatment continues in the absence of disease progression or unacceptable toxicity.~Patients are followed at 28 days, 4 months, every 6 months for 5 years, and then annually for 5 years."
88967385|NCT00091351|Experimental|radiation + surgery|"Patients undergo preoperative radiotherapy once daily, 5 days a week, for 5.5 weeks. Within 28-63 days after the completion of radiotherapy, patients undergo surgery.~Treatment continues in the absence of disease progression or unacceptable toxicity.~Patients are followed at 28 days, 4 months, every 6 months for 5 years, and then annually for 5 years."
88967386|NCT04619706|Experimental|Arm A: FSD201 600 mg|Participants will receive 600 milligrams (mg) FSD201 tablet twice daily (BID) orally along with the placebo matched to 600 mg FSD201 tablet from Day 1 to Day 14.
88967387|NCT04619706|Experimental|Arm B: FSD201 1200 mg|Participants will receive 1200 mg (2x600 mg) tablets FSD201 BID orally from Day 1 to Day 14.
89561824|NCT05392153|No Intervention|Control group|The control group (n=23) will not receive lower extremity posterior muscle myofascial therapy. They will continue the routine exercise program.
88967388|NCT04619706|Placebo Comparator|Arm C: Placebo|Participants will receive placebo matched to 600 mg FSD201 tablets (2xplacebo tablets) from Day 1 to Day 14.
88967389|NCT00091468|Placebo Comparator|Placebo Group|Placebo for first six months of study; moved to open-label active nicotine for second six months
88967390|NCT00091468|Experimental|Active Nicotine Group|Blinded active nicotine for first six months of study; open-label active nicotine for second six months
88967391|NCT00400309|Experimental|REPEVAX® after REVAXIS®|REVAXIS® at Visit 1 (Day 0) and REPEVAX®) at Visit 2 (Day 28).
88967392|NCT00400309|Active Comparator|REPEVAX® after Placebo|Placebo at Visit 1 (Day 0) and REPEVAX®) at Visit 2 (Day 28).
88967393|NCT02972307||caregiver|dyad of caregiver and the wheelchair user to whom they provide care
88967394|NCT00091858|Experimental|Darbepoetin alfa 6.75 mcg/kg Q4W|
88967395|NCT00091858|Placebo Comparator|Placebo Q4W|
88967396|NCT00390195|Experimental|1. Daily|Taking orally the investigational drug daily
89561825|NCT03067727|Experimental|Dinoprostone vaginal insert|
89561826|NCT03067727|Placebo Comparator|Placebo|
89561827|NCT01794793|Experimental|Pasireotide subcutaneous|0.3mg, 0.6mg and 0.9mg. Doses to be taken BID or TID, dependent on parent study guidelines. Cabergoline may be combined in this arm for Cushing's Disease and Acromegaly patients.
89561828|NCT01794793|Experimental|Pasireotide Long Acting Release (LAR)|10mg, 20mg, 40mg and 60mg. All doses to be taken q28days. Strength is dependent on parent study guidelines.
89561829|NCT03067103|Active Comparator|tramadol|Tramadol group will receive 2 mg/kg (2 ml) through the peritonsillar fossa. For each tonsil 1 ml will be applied to upper pole, lower pole and between the upper and lower pole with 25-G needle. The depth of the infiltration will be as superficial as 3 mm of needle injected and ballooned out the submucosal tissues of the tonsillar pillar, intratonsillar injection as avoided.
88967397|NCT00390195|Experimental|2. Weekly|Taking orally the investigational drug weekly
88967398|NCT00091897|Experimental|Rituximab or placebo|Rituximab or placebo is administered through intravenous access on day 1 and again on day 15 (+/- 2 days)
89561830|NCT03067103|Active Comparator|ketamine|Ketamine group will receive 0.5 mg/kg (2cc) through the peritonsillar fossa. For each tonsil 1 ml will be applied to upper pole, lower pole and between the upper and lower pole with 25-G needle. The depth of the infiltration will be as superficial as 3 mm of needle injected and ballooned out the submucosal tissues of the tonsillar pillar, intratonsillar injection as avoided.
89561831|NCT03067103|Placebo Comparator|Placebo|Placebo group will receive 2mL of saline solution through the peritonsillar fossa. For each tonsil 1 ml will be applied to upper pole, lower pole and between the upper and lower pole with 25-G needle. The depth of the infiltration will be as superficial as 3 mm of needle injected and ballooned out the submucosal tissues of the tonsillar pillar, intratonsillar injection as avoided.
89561832|NCT01398319|Experimental|Group Brief Alcohol Booster Intervention|The 1-hour booster intervention was delivered using MI to extend the effective elements found in the original BAI intervention with elements from behavioral economic theory. A behavioral economic approach to alcohol use suggests that decisions to drink are more likely when 1) there is a lack of access to or engagement in alternative alcohol-free reinforcing activities, and 2) there is a greater relative focus on immediate, relative to delayed, rewards (i.e., steep delayed reward discounting). The intent of the intervention is to bring important long-term goals into the present so that the immediate awareness of this goal might diminish the relative benefit of drinking. Another goal was to have the Airmen identify enjoyable and goal-consistent alcohol-free activities they could engage in during their free time. The booster also included a reminder of the U.S. Air Forces rules and policies on alcohol use and harm reduction drinking strategies.
89561833|NCT01398319|Active Comparator|Bystander Intervention|"The 1-hour Bystander intervention was a non-alcohol related briefing that served as the control condition. The intervention focused on increasing Airmen's awareness of the qualities of being a good wingman (e.g., watching for their peers) and how those are tied to the Air Force Core Values. It aimed to increase participants' perceived responsibility to act in certain situations. The intervention draws on the philosophy that members in a community have a role in shifting social norms to prevent violence. While the intervention did not directly discuss alcohol use, the focus on military values and taking responsibility for one's self and others could contribute to healthier drinking-related choices."
89561834|NCT03068585|Experimental|Neovasculgen|DNA encoding the 165-amino-acid isoform of human vascular endothelial growth factor (pCMV - VEGF165)
89561835|NCT03068585|No Intervention|Control|Control therapy
89561836|NCT01305889|Experimental|problem solving therapy|subjects will receive 12 weeks of weekly problem solving therapy
89561837|NCT01305889|Experimental|sertraline|12 weeks of sertraline
89561838|NCT03138265|Experimental|High intensity exercise training|HIT training protocol.
89561839|NCT05391997|Experimental|Modified Cervical and Shoulder Retraction exercises|Cervical extension traction protocol will be added as standard treatment. Then, patients either sit or stand in an upright position while pushing their chin backward and simultaneously raising their head within the pain-free range, then, in a seated or standing position, patients will maintain an upright posture and try to pull back their shoulders and extend their neck within the pain-free range.
89561840|NCT05391997|Active Comparator|Cervical Extension Traction exercises|Here, patients will receive Cervical Extension Traction exercises as standard treatment. Cervical extension traction includes a protocol in which traction will be applied within the extension range of the cervical region in full spine position.
89561841|NCT03136939||type 1 diabetes|
89561842|NCT03136939||type 2 diabetes|
89561843|NCT03136939||healthy people|
89561844|NCT03591107|Experimental|PTSD Care Management (PCM)|In addition to the education and feedback components for both conditions the PCM intervention provides access to a trained Care Manager (CM) who will engage the patient into care, monitor progress over 6 months, coordinate care with primary care and behavioral healthcare providers and social services, and receive monthly supervision by the study psychiatrist.
89561845|NCT03591107|Active Comparator|Minimally Enhanced Usual Care (MEU)|The MEU condition will consist of only clinician education, patient education (Information Sheet) and feedback about having a probably diagnosis of PTSD to both the clinician and patient.
89561846|NCT00223171|Active Comparator|Arm 1 : 36 months AB + RT|Androgen blockade : 36 months of androgen blockade : bicalutamide 50 mg die for one month, goserelin 10.8 mg x 12 Q 3 months + radiation therapy : pelvis 44 grays , prostate 70 grays (2 grays/fraction)
89561847|NCT00223171|Experimental|Arm 2 : 18 months AB + RT|Androgen blockade 18 months : bicalutamide 50 mg die for one month, goserelin 10.8 mg x 6 Q 3 months + radiation therapy ( pelvis 44 grays , prostate 70 grays ,2 grays/fraction)
89561848|NCT04563481|Experimental|Telerehabilitation|Stretching and strengthening exercises, functional exercises, massage techniques, sensory training and breathing exercises will be applied to the patients via telerehabilitation for 3 sessions per week.
89561849|NCT04563481|Experimental|Rehabilitation by Physiotherapist in the Clinic|Stretching and strengthening exercises, functional exercises, massage techniques, sensory training and breathing exercises will be applied to the patients by physiotherapist in the clinic for 3 sessions per week.
89561850|NCT04497493|Experimental|tDCS group|participants receive 20 min sessions of 2 mA direct current delivered over the dorsolateral prefrontal cortex, 5 days per week, for 4 weeks combine a selective serotonin reuptake inhibitor (SSRI) or a serotonin and norepinephrine reuptake inhibitors(SNRI)
89561851|NCT04497493|Sham Comparator|Sham group|Participants receive sham stimulation that administered similarly, but with current turned off after 30s combine a selective serotonin reuptake inhibitor (SSRI) or a serotonin and norepinephrine reuptake inhibitors(SNRI)
89561852|NCT05391685|Experimental|therapeutic ultrasound|Control group will be treated by therapeutic ultrasound only
89561853|NCT05391685|Experimental|therapeutic ultrasound+scar release techniques|Study group will be treated by various scar release techniques in addition to therapeutic ultrasound
88967399|NCT02972346|Experimental|ACTH(+)|routine treatment + ACTH
88967400|NCT02972346|No Intervention|ACTH(-)|routine treatment
89027162|NCT00480038|Other|1|Measurement characteristics of WHODAS II (World Health Organization Disability Assessment Schedule)
89027163|NCT04697537|Active Comparator|Ultrasound guided regional anesthesia|Patient will be given a peripheral nerve block from their treating anesthesiologist before the operation (in the OR) with an conventional ultrasound guided femoral and sciatic block of each 15 ml ropivacaine 0,5% and 0,5 ml dexmedetomidine (100µg/ml).
89027164|NCT04697537|Active Comparator|Local infiltration analgesia|Patient will be given a local infiltration analgesia from their treating surgeon during the operation (in the OR) with 60 ml ropivacaine 0,5% and 1 ml dexmedetomidine (100µg/ml).
89027165|NCT01313650|Experimental|GSK573719/GW642444|62.5/25mcg
89027166|NCT01313650|Experimental|GSK573719|62.5mcg
89027167|NCT01313650|Experimental|GW642444|25mcg
89027168|NCT01313650|Placebo Comparator|Placebo|Placebo
89027169|NCT02274909|No Intervention|control group|The subjects received no intervention and continued with their daily activities.
89027170|NCT02274909|Active Comparator|Pilates group|The exercise protocol of Pilates method consisted of muscle stretching of the upper limbs, trunk and lower limbs before the exercises. Then, exercises involving range of motion and strength of upper limbs, trunk and lower limbs were performed, always associated with breathing in different positions and with increasing repetitions and resistance along the weeks of training.
89027171|NCT02274909|Active Comparator|PNF group|The exercises from the PNF method were performed with stretching, associated to hold-relax technique, for upper and lower limbs. Then, subjects carried out exercises with the upper limbs, in a bilaterally symmetrical pattern, and with the lower limbs, in the asymmetric bilateral pattern. Additionally, scapular and pelvic girdle exercises were done with symmetrical and reciprocal combination.
89561854|NCT03138031|Experimental|Percutaneous Ethanol Injection (PEI)|"Those participants receive percutaneous ethanol alcohol injection for the large and unresectable HCC. Absolute alcohol; weekly sessions; under close monitoring; maximum of 30 mls; no anaesthesia needed and a maximum pain score of 8 during the procedure. Postprocedure analgesia may be required."
89561855|NCT04433507|Active Comparator|Sleeve Gastrectomy group|This group will receive a Sleeve Gastrectomy only, a mainly restrictive procedure which consists in creating a narrow tube-like stomach based on its lesser curvature.
89561856|NCT04433507|Experimental|Sleeve Gastrectomy + Hiatal Hernia repair group|This group will receive a Sleeve Gastrectomy combined with hiatal hernia repair. Hiatal Hernia repair consists of a peri-esophageal dissection proximal to the diaphragmatic crura to achieve an intra-abdominal esophageal length of 2-3 cm. The pillars will then be closed anteriorly and posteriorly using nonabsorbable sutures.
89561857|NCT04363385|Other|Collection of blood sample|
89561858|NCT04800991|Experimental|Rhexium Onco Nutrition(HDT-202)|"subject mobile application and Investigator web portal with no invasive action on the human body"
89561859|NCT04795921||Patients with haemophilia|This investigation includes patients with haemophilia of all seventies (mild, moderate, severe), as well as female carriers and patients with Von-Willebrand-Disease (Typ III)
89561860|NCT04795921||Healthy controls|The control group consists of adult healthy female and male subjects.
89561861|NCT04790851|Experimental|Experimental group|Experimental Group (384 subjects) will receive: 1st dose : combined vaccination of COVAX+IIV4; 2nd dose: combined vaccination of COVAX+PPV23
89561862|NCT04790851|Active Comparator|Control group A|Control Group A (384 subjects) will receive: 1st dose: COVAX only; 2nd dose: COVAX only
89561863|NCT04790851|Active Comparator|Control group B|Control Group B (384 subjects) will receive: 1st dose: IIV4 only; 2nd dose: PPV23 only
89561864|NCT05391529||Colonoscopy|Patients awaiting colonoscopy
89561865|NCT05391529||CCE|Patients awaiting colon capsule endoscopy
89561866|NCT03208985|Experimental|Use Phase (Ulipristal Acetate, 30 mg)|One tablet of 30 mg of ulipristal acetate for emergency contraception
89561867|NCT03644953|Experimental|Hydroxyurea and Transfusion (HAT)|Combination hydroxyurea and simple chronic transfusion therapy
89561868|NCT03630835|Experimental|99mTc-Annexin-V-128 uptake on scintigraphy|
89027172|NCT04697615||Algometry|In the test stage, pain threshold evaluations were started through the algometer in a randomized manner by two different examiners trained and experienced in the application of the test, following the same order of evaluation of the muscles (middle deltoid, upper trapezius, pectoralis major, biceps brachii , triceps, lumbar multifidus, rectus femoris, biceps femoris, tibialis anterior and soleus, bilaterally), with an interval between each assessment of five minutes in which the participants remained at rest. After the interval described, the retest stage was initiated, which had the same procedures as the test stage.
89027173|NCT00504114||1|Healthy volunteers without knee pain.
89027174|NCT00504114||2|Patients with mild arthritic symptoms and radiographic changes (Kellgren Lawrence score of 1, 2)
89027175|NCT00504114||3|Patients with severe pain and functional limitations associated with knee arthritis (Kellgren Lawrence score of 3, 4).
89027176|NCT00504114||4|Patients with acute anterior cruciate ligament (ACL) injuries with associated osseous contusion.
89027177|NCT00504114||5|Patients with posttraumatic knee injury or degenerative condition and will have cartilage resurfacing procedures.
89027178|NCT00481481|Experimental|1|
89027179|NCT04516317||Group intravenous artesunate (around 300 patients)|Period 2011-2019
89027180|NCT04516317||Group intravenous quinine (around 300 patients)|Period 2000-2010
89561869|NCT03067337|Experimental|Stainless Steel Crowns (Group A)|Groups that received Stainless Steel Crowns
89561870|NCT03067337|Experimental|Zirconia crowns (Group B)|Groups that received Zirconia crowns
89561871|NCT04764097|Experimental|Dapagliflozin|Dapagliflozin, Oral Tablet,10mg, od, 24 months.
89561872|NCT04764097|Placebo Comparator|Placebo|Placebo, Oral Tablet, od, 24 months.
89561873|NCT02922023|Active Comparator|Chronotherapy|Chronotherapy group automatically receives a shift in 1 anti-hypertensive medication to night-time without assessment of ambulatory blood pressure monitor results.
89561874|NCT02922023|Active Comparator|ABPM|ABPM group will have their ambulatory blood pressure monitor results reviewed prior to deciding to change regimen.
89561875|NCT04761211|Experimental|smart bra|The patients who were going to take breast ultrasound in the breast surgery clinic were enrolled into the group. The patients were put on the device for about 3 minutes, and the breast was photographed at 5 sites. After that, the artificial intelligence learning was carried out on the photos of the training stage. For the photos of the verification stage, the algorithm obtained by the training stage was compared with the existing artificial intelligence algorithms of ultrasound and molybdenum target.
89561876|NCT03605017|Experimental|VREFT: Wonderkin Treatment|Administered by computer
89561877|NCT03605017|Active Comparator|VREFT: Attention Control|Administered by computer
89561878|NCT05391451|Experimental|Quadratus lumborum block (QLB) group|
89561879|NCT05391451|Active Comparator|Control group|
89561880|NCT03520309|Experimental|International Dental Federation|Dental Treatment: according to the decision based on the International Dental Federation (FDI) criteria
89561881|NCT03520309|Experimental|Caries Around Restorations System|Dental Treatment: according to the decision based on the Caries Around Restorations System (CARS) and treatment decision proposed by the International Caries Classification and Management System (ICCMS)
89561882|NCT03110341|Experimental|Erythropoietin|Erythropoietin is administered 750U/kg intravenously every other day for 2 weeks (a cumulative dose of 5,250U/kg over the course of 7 separate intravenous injections regardless of gestational age), starting with the first dose within 72 hours after birth. A single dose consisted of 750U EPO per kg of birth weight dissolved in 3mL/kg normal saline was administered intravenously during a period of 5 minutes.
89561883|NCT03110341|Placebo Comparator|Normal saline|Normal saline is administered 3ml/kg intravenously every other day for 2 weeks, starting with the first dose within 72 hours after birth. Similarly, the placebo dose consisted of 3mL of normal saline per kilogram birth weight was administered intravenously during a period of 5 minutes.
89561884|NCT03140215|Active Comparator|Baska Device ventilation group|Device: laryngeal mask insertion (Baska)
89561885|NCT03140215|Active Comparator|I-Gel device ventilation group|Device: laryngeal mask insertion ( I-gel )
89561886|NCT04720729|Experimental|Single arm|Patients with HER2-negative metastatic breast cancer, starting a second line of chemotherapy
89561887|NCT03511417|Experimental|Middle-aged adults|Participants will use an over-the-counter hearing device in one ear until asymptotic speech perception performance is noted (maximum 12 weeks). The same individuals will use over-the-counter hearing devices in each ear until asymptotic performance is noted (the order of these two phases will be randomized across participants). They will be asked to use these devices at least 4 hours/day.
89561888|NCT03273751|Experimental|Remote Ischemic Preconditioning (RIPC)|Four cycles of upper arm ischemia/reperfusion
89561889|NCT03273751|Sham Comparator|Sham control|Placement of a blood pressure cuff around upper arm without inflation.
89561890|NCT03136315|Experimental|INFERNAL Arm|The INFERNAL Arm will have serum and urinary dosage for creatinine and cystanin C at the beginning and at the end of the 110 km race.
89561891|NCT03152539|Experimental|Development of MRI protocols|MRI exam to grade differents interventions for future research
89561892|NCT03152539|Experimental|Development of EEG protocols|EEF exam to grade differents interventions for future research
89561893|NCT03152539|Experimental|Development of NIRS protocols|NIRS exam to grade differents interventions for future research
89561894|NCT03136549|Placebo Comparator|Room temperature|The nasotracheal tube, sized 6.0 -7.0 mm inner diameter (ID), were put into a bottle of sterilized normal saline (1 L, 25 °C) at room temperature.
89561895|NCT03136549|Experimental|Thermo-softening|The naso tracheal tube, sized 6.0 -7.0 mm inner diameter (ID), were put into a bottle of sterilized normal saline (1 L) at warm cabinet set to 45°C (approximately 117°F).
89561896|NCT05377801|Experimental|The intervention group|The intervention group of this study is a multi-dimensional intervention conducted by nursing students over a 12-week period, consisting of four parts: individualized balance and strength training, vision screening, drug evaluation, home risk assessment and home repair and transformation. These components were carried out through a combination of personal home visits and telephone interviews.
89561897|NCT05377801|No Intervention|The control group|The control group would receive the same amount of health education.
89561898|NCT04543513|Experimental|Active Left Dorsolateral Prefrontal Cortex rtfMRI-nf|Real-time functional magnetic resonance imaging neurofeedback (rtfMRI-nf) will target left dorsolateral prefrontal cortex. Participants in this arm will receive active feedback while attempting to modulate their neural activity during an emotional cognitive control task.
88967401|NCT00006221|Experimental|Arm I|"Patients receive BMS-247550 IV over 1 hour once weekly on weeks 1-4. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of BMS-247550 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, additional patients are treated at that dose level. Patients treated at the MTD receive treatment once weekly on weeks 1-3 of each 4-week course."
89561899|NCT04421053||women with GDM|After participants enrollment, we conducted follow-up visit every two weeks. Blood glucose values, body weight, life style record and clinical information are collected. Blood samples and stool samples are collected from participants in Beijing.
89561900|NCT04405063|Experimental|Genoss® DCB|Paclitaxel Coated PTCA Balloon Catheter
89561901|NCT04405063|Active Comparator|SeQuent® Please|Paclitaxel Coated PTCA Balloon Catheter
89561902|NCT04400305|No Intervention|Control|No Intervention: Control Group This group will complete baseline and final questionnaires (online). At the end of the study this group will have the option to receive access to the other group's materials (online platform) if they wish, for the 6 week period following the study.
88967402|NCT00093223|Experimental|1|35mg/m^2 infusion time is 3.5 minutes
88967403|NCT00093223|Experimental|2|2 doses of 35mg.m^2 with the second dose given 2 months later
89027181|NCT02891239|Experimental|PicoWay laser treatment|3 wavelength tattoo treatment with picosecond laser (PicoWay)
89027182|NCT02891083|Experimental|Adjuvant chemotherapy group|Surgery followed by adjuvant chemotherapy,with Paclitaxel and Cisplatin.
89027183|NCT02891083|Experimental|Adjuvant radiotherapy group|Surgery followed by 50Gy adjuvant radiotherapy
89027184|NCT02891083|Other|Control group|Surgery alone
89027185|NCT02890966|Experimental|Cohort 1|1mg SHR4640 or placebo
88967404|NCT00093262|Experimental|clevidipine|Clevidipine was administered in a blinded fashion intravenously, starting with an infusion rate of 0.4 μg/kg/min (non weight-based equivalent is 2 mg/hr), titrating upward, as tolerated by the patient, in doubling increments approximately every 90 seconds up to an infusion rate of 3.2 μg/kg/min (16 mg/hr) to achieve the desired blood pressure-lowering effect. Up-titration to infusion rates above 3.2 μg/kg/min could be used, guided by the patient's response, by increasing the infusion rate in serial increments of 1.5 μg/kg/min, up to the maximum recommended clevidipine infusion rate of 8.0 μg/kg/min. Clevidipine was to be administered for a minimum of 30 minutes, unless bailout occurred, and up to a maximum of one hour.
88967405|NCT00093262|Placebo Comparator|placebo|Placebo consisted of 20% lipid emulsion (the same lipid vehicle used for clevidipine) administered in a blinded fashion intravenously following the same study drug administration guidelines as with clevidipine study drug administration guidelines. As with clevidipine, placebo was to be administered for a minimum of 30 minutes, unless bailout occurred, and up to a maximum of one hour.
88967406|NCT00093418|Experimental|Arm I|Arm I: Patients receive oral tipifarnib twice daily on days 1-21. In all arms, courses repeat every 28 days in the absence of unacceptable toxicity or disease progression. Patients who achieve a complete remission (CR) receive up to 3 additional courses beyond CR. Patients in CR who develop recurrent disease after the completion of therapy are eligible to receive tipifarnib again.
88967407|NCT00093418|Experimental|Arm II|Patients receive oral tipifarnib twice daily on days 1-7 and 15-21. In all arms, courses repeat every 28 days in the absence of unacceptable toxicity or disease progression. Patients who achieve a complete remission (CR) receive up to 3 additional courses beyond CR. Patients in CR who develop recurrent disease after the completion of therapy are eligible to receive tipifarnib again.
88967408|NCT00093418|Experimental|Arm III|Patients receive tipifarnib as in arm I, but at a lower dose. In all arms, courses repeat every 28 days in the absence of unacceptable toxicity or disease progression. Patients who achieve a complete remission (CR) receive up to 3 additional courses beyond CR. Patients in CR who develop recurrent disease after the completion of therapy are eligible to receive tipifarnib again.
88967409|NCT00093418|Experimental|Arm IV|Patients receive tipifarnib as in arm II, but at a lower dose. In all arms, courses repeat every 28 days in the absence of unacceptable toxicity or disease progression. Patients who achieve a complete remission (CR) receive up to 3 additional courses beyond CR. Patients in CR who develop recurrent disease after the completion of therapy are eligible to receive tipifarnib again.
88967410|NCT00093613|Experimental|Treatment (sorafenib tosylate)|"Patients receive oral sorafenib twice daily on days 1-28 (once daily on day 1 of course 1 only). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients per stratum receive escalating doses of sorafenib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 3 of 6 patients experience dose-limiting toxicity."
88967411|NCT02964832|Active Comparator|PocketCPR;Grasp method|Subject grasp a smartphone in the hand and compress the chest of manikin.
88967412|NCT02964832|Active Comparator|PocketCPR;Armband-in-hand method|Grab the smartphone-contained-armband in hand when performing chest compression
88967413|NCT02964832|Active Comparator|PocketCPR;Armband-on-arm method|Fix the smartphone-contained-armband on upperarm when performing chest compression
88967414|NCT00093730|Experimental|BMS-59926|
88967415|NCT00093769|Experimental|bortezomib + rituximab|"Arm I: Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Patients also receive rituximab IV on days 1, 8, and 15 of course 1 only and on day 1 of course 2 only. Treatment with repeats every 21 days for up to 5 courses in the absence of disease progression or unacceptable toxicity.~Arm II: Patients receive bortezomib IV over 3-5 seconds on days 1, 8, 15 and 22. Patients also receive rituximab IV on days 1, 8, 15, and 22 of course 1 only. Treatment repeats every 35 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.~Patients in either arm may crossover to the other arm if treatment is found to be ineffective."
88967416|NCT02964715|Experimental|Interventional arm|Patients with NAFLD and Type 2 Diabetes prescribed 25mg empagliflozin(JARDIANCE) daily for 6 months
88967417|NCT00093886|Experimental|clevidipine|Clevidipine (0.5 mg/mL in 20% lipid emulsion) was initiated after insertion of an arterial line upon the occurrence of perioperative hypertension, as determined by the investigator, and was administered intravenously (IV) at an initial infusion rate of 0.4 μg/kg/min (non weight-based equivalent is 2 mg/h). Clevidipine was titrated to blood pressure lowering effect by doubling increments approximately every 90 seconds up to a maximum infusion rate of 3.2 μg/kg/min (16 mg/h). Infusion rates above 3.2 μg/kg/min were permitted up to the maximum infusion rate of 8.0 μg/kg/min. Treatment was maintained as long as was deemed clinically necessary or until discharge from the ICU. Infusion rates between 4.4 and 8.0 μg/kg/min were to be administered for no more than 2 hours.
88967418|NCT00093886|Active Comparator|nitroglycerin|Nitroglycerin (NTG) was initiated after insertion of an arterial line upon the occurrence of perioperative hypertension, as determined by the investigator, and was administered intravenously as per institutional practice. Treatment was maintained as long as was deemed clinically necessary or until discharge from the ICU.
88967419|NCT00093925|Experimental|clevidipine|Clevidipine (0.5 mg/mL in 20% lipid emulsion) was initiated after insertion of an arterial line upon the occurrence of postoperative hypertension, as determined by the investigator, and was administered intravenously (IV) at an initial infusion rate of 0.4 μg/kg/min (non weight-based equivalent is 2 mg/h). Clevidipine was titrated to blood pressure lowering effect by doubling increments approximately every 90 seconds up to a maximum infusion rate of 3.2 μg/kg/min (16 mg/h). Infusion rates above 3.2 μg/kg/min were permitted up to the maximum infusion rate of 8.0 μg/kg/min. Treatment was maintained as long as was deemed clinically necessary or until discharge from the ICU. Infusion rates between 4.4 and 8.0 μg/kg/min were to be administered for no more than 2 hours.
88967420|NCT00093925|Active Comparator|nicardipine|Nicardipine (NIC) was initiated after insertion of an arterial line upon the occurrence of postoperative hypertension, as determined by the investigator, and was administered intravenously as per institutional practice. Treatment was maintained as long as was deemed clinically necessary or until discharge from the ICU.
89027186|NCT02890966|Experimental|Cohort 2|2.5mg SHR4640 or placebo
89027187|NCT02890966|Experimental|Cohort 3|5mg SHR4640 or placebo
89027188|NCT02890966|Experimental|Cohort 4|10mg SHR4640 or placebo
89027189|NCT02890927|Experimental|Cardio-geriatric co-management|A geriatric co-management intervention will be implemented on the cardiology units of the University Hospitals Leuven. Geriatric co-management is defined as a shared responsibility and decision making between the cardiology team and the geriatric team who provides complementary medical care in the prevention and management of geriatric problems. Patients included in the co-management program will undergo a comprehensive geriatric assessment within 24 hours of hospital admission.
89027190|NCT02890927|No Intervention|Standard of care|The control group will receive the standard of care on the cardiology units. This includes multidisciplinary care with a one weekly multidisciplinary team meeting. Team members include a cardiology resident (supervised by a cardiologist), ward nurses, a physical therapist, a social worker and a dietician. A geriatric consultation team is available for consultation services if requested by the cardiology team.
89027191|NCT02891005|Experimental|paclitaxel controlled release balloon catheter|Patients treated with paclitaxel controlled release balloon catheter
89027192|NCT02891005|Experimental|common balloon catheter|Patients treated with common balloon catheter
89027193|NCT02891044|Experimental|BAY987517|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
89027194|NCT00504816|Other|Brevicon|Oral contraceptive used to determine pharmacokinetics when given with GSK189075 to look for interaction.
89027195|NCT00504816|Experimental|GSK189075|Given in conjunction with Brevicon to see if GSK189075 interfered with Brevicon drug levels.
89027196|NCT00623350|Active Comparator|1|Acute Stroke Telephone consult for the decision of tPA within 3 hours of symptoms onset.
89027197|NCT00623350|Active Comparator|2|Acute Stroke consult via audio video telemedicine for the decision of tPA within 3 hours of symptom onset.
89027198|NCT00480116|Active Comparator|1|
89027199|NCT00480116|Active Comparator|2|
89027200|NCT00480116|Active Comparator|3|
89027201|NCT00504855|Active Comparator|Gortex (Waterproof) Cast Padding|Randomized application of one of two cast padding materials
89027202|NCT00504855|Active Comparator|Cotton/Cotton-Poly Cast Padding|Randomized application of one of two cast padding materials
89027203|NCT00504933|Experimental|A|Bilastine
89027204|NCT00504933|Active Comparator|B|Cetirizine
89027205|NCT00504933|Placebo Comparator|C|Placebo
89027206|NCT01313299|Experimental|Dysport 500 U|
89561903|NCT04400305|Other|Intervention|Participants will complete a baseline questionnaire, and receive access to the our online platform for 6 weeks. Completing the online platform is designed to encourage participants to engage in physical activity. At 3 weeks, a check-in session will occur over the phone. At 6 weeks the participant will be contacted to complete the final questionnaire, and do a wrap up interview. The end-of-trial qualitative interview will evaluate participant satisfaction and feasibility of the intervention. For this reason a lab employee unaffiliated with this study will complete these in person interviews.
89561904|NCT04381039|Experimental|customized insole group|
89561905|NCT01672853|Experimental|Treatment Arm A|Simtuzumab 75 mg for 96 weeks
89561906|NCT01672853|Experimental|Treatment Arm B|Simtuzumab 125 mg for 96 weeks
89561907|NCT01672853|Placebo Comparator|Treatment Arm C|Placebo for 96 weeks
89561908|NCT05090449|Active Comparator|A1: Individual formulation of chlorthalidone|(Higroton 50, product of Sandoz, S.A. de C.V.)
89561909|NCT05090449|Active Comparator|A2:Individual formulation Losartan|(COZAAR, product of Schering Plough, S.A. de C.V., S.A. de C.V.)
89561910|NCT05090449|Active Comparator|A3: Co-administration of individual formulations|Co-administration of individual formulations of chlorthalidone and losartan potassium
89561911|NCT05090449|Experimental|B: Fixed combination of chlorthalidone and losartan potassium|B: Fixed combination of chlorthalidone and losartan potassium (product of Laboratorios Silanes S.A. de C.V.)
89561912|NCT05090137|Other|Diuretic cessation|Participants will be asked to withhold their diuretic therapy (loop diuretics and mineralocorticoid receptor antagonists) 48 hours prior to visit
89561913|NCT05090137|Other|Usual diuretic regimen|Participants will take their usual diuretic regimen prior to study visit. At least one week is required between cross-over visits
89561914|NCT03067025||30 youth with MS|
89561915|NCT03067025||30 healthy control participants|
89561916|NCT05090059|Experimental|Lower limb myofascial trigger points f-ESWT group|3 total sessions, one per week, of focused extracorporeal shockwave treatment with a frequency of 5 Hz, an energy flux density of 0.05-0.167 mJ (millijoule)/mm2 administered on 3 or 4 myofascial points (identified based on Fascial Manipulation principles), 1500 shocks per point.
89561917|NCT05090059|Active Comparator|Plantar fascia insertion f-ESWT group|3 total sessions, one per week, of focused extracorporeal shockwave treatment, with a frequency of 5 Hz, an energy flux density of 0.32 mJ(millijoule)/mm2, for a total of 2000 shocks administered on the area of the painful heel on the medial calcaneal tubercle.
89027207|NCT01313299|Experimental|Dysport 1000 U|
89027208|NCT01313299|Placebo Comparator|Placebo|
89027209|NCT00480155|Active Comparator|1|FluMist
89027210|NCT00480155|Placebo Comparator|2|Placebo
89561918|NCT03067415|Experimental|D565H(Latanoprost 25㎍/㎖)|D565H(Latanoprost 25㎍/㎖)
89561919|NCT03067415|Active Comparator|D565(Latanoprost 50㎍/㎖)|D565(Latanoprost 50㎍/㎖)
89561920|NCT05089981|Active Comparator|NAC group|IV N acetyl cysteine 300mg will be administered in doses as described in protocol
89561921|NCT05089981|Placebo Comparator|NAC Placebo group|IV Placebo of N acetyl cysteine will be administered in doses as described in protocol (Placebo will be normal saline in a look alike preparation with same volume as active NAC arm)
89561922|NCT03349801||no AMD|No interventions
89561923|NCT03349801||early AMD|No interventions.
89561924|NCT03349801||intermediate AMD|No interventions.
89561925|NCT03349801||late AMD|No interventions.
89561926|NCT03066401||obese patients with dysmetabolic hyperferritinemia|"PATIENTS: obese patients with dysmetabolic hyperferritinemia undergoing a therapeutic bleeding.~INTERVENTIONS: The investigators performed ultrasound measurements (echography) and collected clinical parameters before and after a 300 to 500ml therapeutic bleeding, during a standardized respiratory maneuver."
89027211|NCT00504972|Experimental|Study Treatment|This study is a single arm study
89027212|NCT01313221|Active Comparator|Etanercept 50 mg BIW|Following 12 weeks of etanercept 50 mg twice weekly, participants were randomized to 50 mg etanercept twice weekly for 12 weeks.
89027213|NCT01313221|Experimental|Etanercept 50 mg QW + Topical|Following 12 weeks of etanercept 50 mg twice weekly, participants were randomized to 50 mg etanercept once weekly plus as needed topical agents.
89027214|NCT01313182|Active Comparator|3M Skin and Nasal Antiseptic|Povidone-iodine solution 5% w/w (0.5% available iodine) USP Patient Preoperative Skin Preparation
89027215|NCT01313182|Active Comparator|Bactroban Nasal|Mupirocin calcium ointment, 2%
89027216|NCT04516512|Experimental|Investigated arm|Participants included in the study who met inclusion criteria
89561927|NCT05089591|Active Comparator|Study eyes|Study eye receives the standard energy dose as recommended by the manufacturer (between 8 and 12J/cm2, in accordance with the manufacturer's recommendations).
89561928|NCT05089591|Sham Comparator|Control eyes|The control eye is treated using low energy dose energy (1J/ cm2) as sham treatment, ensuring blinding of the respective patient.
89561929|NCT04206059|Experimental|CLASS-D Cohort|Within-subject crossover cohort with intervention, acoustic stimulation delivered in phase with the anticipated trough of EEG slow wave oscillation, and 0 dB stimulation.
89561930|NCT05377645|Experimental|Cervical mobilization|Mobilization Cyriax's cervical mobilization technique and traditional physiotherapy were applied to the intervention group. For Cyriax Mobilization technique, the patient was asked to lying supine position. Cervical ROM applied all directions. Also AP and ML glides applied to the cervical region. The treatment was done 3 times a week for 2 weeks. Also traditional physiotherapy techniques were applied to the experimental group. Traditional physiotherapy techniques were applied to the intervention group. Conventional TENS type was used. Continuous ultrasound type was applied with full contact technique.. And; isometric cervical strengthening exercises applied. The treatment was done 3 times a week for 2 weeks.
89561931|NCT05377645|Active Comparator|Traditional physiotherapy|Traditional physiotherapy techniques were applied to the intervention group. Conventional TENS type was used. Current transition time was set as 50-100 µs. TENS application is performed at a frequency of 100 Hertz for 20 minutes in amplitude that does not cause muscle contraction in the patient and creates a feeling of numbness and tingling. Continuous ultrasound type was applied with full contact technique. Ultrasound treatment was applied over the suboccipital area with circular movements towards the proximal and distal at a speed of 1-2.5 cm per second, at a dose of 1 W / cm2, for 6 minutes, with a frequency of 3 MHz. And; isometric cervical strengthening exercises applied. The treatment was done 3 times a week for 2 weeks.
89561932|NCT05430737|Experimental|stereotactic body radiotherapy|Long-term ADT of 2-3years were administered. Neoadjuvant ADT within 6 months was allowed.Then patients with high-risk prostate cancer recieve stereotactic body radiotherapy with pelvic radiation and GTV boost based on multiparameter magnetic resonance image.
89561933|NCT05431049||combined spino-epidural anesthesia (CSEA)|Percutaneous nephrolithotomy under combined spino-epidural anesthesia
89561934|NCT05431049||general anesthesia (GA)|Percutaneous nephrolithotomy under general anesthesia
89561935|NCT04148573|Active Comparator|Arm NFX88 - 1|1.05 g/day NFX88
89561936|NCT04148573|Active Comparator|Arm NFX88 - 2|2.10 g/day NFX88
89561937|NCT04148573|Active Comparator|Arm NFX88 - 3|4.20 g/day NFX88
89561938|NCT04148573|Placebo Comparator|Arm PLACEBO - 4|Placebo
89561939|NCT03136783|Other|Patient with stage IV melanoma|
89561940|NCT05430503||Long COVID|Caucasian subjects with a history of SARS CoV-2 infection confirmed by nasopharyngeal swab with real-time polymerase-chain reaction were included in the study. They were referred to investigators' pulmonary function laboratory after being tested negative for SARS-CoV-2, because of dyspnea, fatigue, and exercise intolerance persisting or occurring at least 3 months after the COVID-19 acute phase and lasting ≥2 months.
89561941|NCT05430503||Healthy controls|Anthropometrically-matched healthy subjects, without history of COVID-19 and vaccinated against SARS-CoV-2 infection.
89561942|NCT03110263|Experimental|Multicomponent internet-based self-help|Multicomponent internet-based self-help
89561943|NCT03110263|Experimental|Internet-based sleep restriction|Internet-based sleep restriction
89561944|NCT03110263|No Intervention|Waiting control group|Access to internet-based intervention after 8-weeks
89561945|NCT05730023|Experimental|Active tDCS plus individualized language training|The group will receive five consecutive days a week for two weeks of 25 minutes sessions of Active tDCS combined with an individualized language training
89561946|NCT05730023|Active Comparator|Placebo tDCS plus individualized language training|The group will receive five consecutive days a week for two weeks of 25 minutes sessions of Placebo tDCS combined with an individualized language training
89561947|NCT05089045|Experimental|Population Ⅰ|
89027217|NCT04512495|Other|Patients with sarcoma|
89027218|NCT00481637||Cancer patients|SCLC and gynecological cancer patients and unrelated cancer patients with presence of PND-specific CTLs.
89027219|NCT00481637||Normal|Normal volunteers
89027220|NCT00505050|No Intervention|1|Standard follow-up medical visits and treatment for control group were performed during the study period by the same cardiologist team that was not informed of the randomization.
89027221|NCT00505089|Experimental|1|ACZ885 10mg/kg subcutaneous
89027222|NCT00505089|Experimental|2|ACZ885 5mg/kg intravenous
89027223|NCT00505089|Experimental|3|ACZ885 2mg/kg subcutaneous
89027224|NCT00505089|Experimental|4|ACZ885 1mg/kg intravenous
89027225|NCT00481715|Experimental|1|Web-based weight loss program
89027226|NCT00481715|Experimental|2|Cash incentive weight loss program
89027227|NCT00481715|Experimental|3|Web-based program plus the cash incentive program
89027228|NCT00481715|No Intervention|4|No intervention
89027229|NCT00505128|Other|1|to test the interest of early bile duct decompression by endoscopic sphincterotomy after early non invasive diagnosis by endosonography or MR cholangiography
89027230|NCT00505167|Active Comparator|1|Patients randomized to receive memantine
89561948|NCT04132817|Experimental|Group A Target class A-1: Nivolumab+nab-paclitaxel|The CA048-001 clinical study will utilize a master protocol and subprotocols representing distinct mechanisms of actions. Each subprotocol will contain 1 Group, representing a particular mechanism of action, and will consist of 3 treatment arms that will be simultaneously evaluated. One treatment within a group will be selected to move forward to the next sub-protocol based on safety and tolerability, pharmacodynamic and efficacy data. Thus, the number of treatments within each group is increased by one for each subsequent group, with the intent to simultaneously impact a wide range of mechanisms thought to be important for generating anti-tumor immune responses.
89561949|NCT04132817|Experimental|Group A Target Class A-2: Nivolumab+nab-paclitaxel+ipilimumab|The CA048-001 clinical study will utilize a master protocol and subprotocols representing distinct mechanisms of actions. Each subprotocol will contain 1 Group, representing a particular mechanism of action, and will consist of 3 treatment arms that will be simultaneously evaluated. One treatment within a group will be selected to move forward to the next sub-protocol based on safety and tolerability, pharmacodynamic and efficacy data. Thus, the number of treatments within each group is increased by one for each subsequent group, with the intent to simultaneously impact a wide range of mechanisms thought to be important for generating anti-tumor immune responses.
89561950|NCT04132817|Experimental|Group A Target Class A-3: Nivolumab+nab-paclitaxel+ipilimumab|The CA048-001 clinical study will utilize a master protocol and subprotocols representing distinct mechanisms of actions. Each subprotocol will contain 1 Group, representing a particular mechanism of action, and will consist of 3 treatment arms that will be simultaneously evaluated. One treatment within a group will be selected to move forward to the next sub-protocol based on safety and tolerability, pharmacodynamic and efficacy data. Thus, the number of treatments within each group is increased by one for each subsequent group, with the intent to simultaneously impact a wide range of mechanisms thought to be important for generating anti-tumor immune responses.
89561951|NCT05088811||Liver cirrhosis|Group (1): Thirty patients having liver cirrhosis and hepatocellular carcinoma diagnosed by tripahsic CT.
89561952|NCT05088811||Hepatocellular Carcinoma|Group (2): Thirty liver cirrhosis patients without hepatocellular carcinoma diagnosed by abdominal ultrasound examination
89561953|NCT05088811||Control|Group (3): Twenty normal subjects (control group) matching in age and sex with patients in groups 1 and 2.
89561954|NCT03066635|Experimental|Botulinum Toxin 25 IU|5 patients will be injected with 25 IU of Botulinum Toxin Type A towards the otic ganglion in the symptomatic side (ipsilateral to the pain)
89561955|NCT03066635|Experimental|Botulinum Toxin 12.5 IU|5 patients will be injected with 12.5 IU of Botulinum Toxin Type A towards the otic ganglion in the symptomatic side (ipsilateral to the pain)
89561956|NCT05077267|Experimental|ABNCoV2 100ug single dose|ABNCoV2 100ug single dose. Intervention type: Biological/Vaccine
89561957|NCT05077267|Experimental|ABNCoV2 50ug single dose|ABNCoV2 50ug single dose. Intervention type: Biological/Vaccine
89561958|NCT05077267|Experimental|ABNCoV2 100ug two doses|ABNCoV2 100ug two doses 4 weeks apart. Intervention type: Biological/Vaccine
89561959|NCT05075083|Experimental|Experimental Group|A total 400 subjects receive two doses inactivated COVID-19 vaccine with the interval of 21 days
89561960|NCT04073771||Cohort study|Patients with septic shock undergoing continuous renal replacement therapy
89561961|NCT03136237|Experimental|Cohort 1|Day 1: Digoxin 0.25 mg oral dose Day 11-18: BCX7353 350 mg oral dose Day 19: Digoxin 0.25 mg oral dose and BCX7353 350 mg oral dose Day 20-21: BCX7353 350 mg oral dose
89561962|NCT03136237|Experimental|Cohort 2|Day 1: Rosuvastatin 10 mg oral dose Day 7-14: BCX7353 350 mg oral dose Day 15: Rosuvastatin 10 mg oral dose and BCX7353 350 mg oral dose Day 16: BCX7353 350 mg oral dose
89561963|NCT03136237|Experimental|Cohort 3|Day 1: BCX7353 350 mg oral dose Day 14: single oral dose of Cyclosporine 600 mg and BCX7353 350 mg
89561964|NCT05430425||body weight|(grup VA; igel=n:40 clasic lma n=40),
89561965|NCT05430425||thyromental distance|grup T; igel=n:40 clasic lma n=40)
89561966|NCT05430425||resize with 3 fingers|grup p; igel=n:40 clasic lma n=40
89561967|NCT04001309|Experimental|Infectious diseases physician led|"Prospective audit and feedback of antimicrobial therapy by infectious disease physicians twice weekly~Also including standard of care~infectious disease consultant on demand~hospital antimicrobial stewardship program as usual (education, general information, feedback on prescribing)"
89561968|NCT04001309|Experimental|Multiprofessional team|"Prospective audit and feedback of antimicrobial therapy by infectious disease physicians once weekly, ward clinical pharmacists thrice weekly and engagement of ward nurses in the stewardship intervention~Also including standard of care~infectious disease consultant on demand~hospital antimicrobial stewardship program as usual (education, general information, feedback on prescribing)"
88967421|NCT04540887|Experimental|Treatment|Treatment will be provided via self-administration of pulsed electromagnetic field (PEMF) therapy using the B. Body (whole body mat), B. Pad (targeted pelvic mat), and Control Unit. The participant will lay the B. Body mat on any flat surface (i.e. floor, bed, reclining chair, etc.) and lie down on the mat with the smaller B. Pad placed directly over their pelvic area. Then, the participant will turn the PEMF device on using the attached control unit, which has been pre-programmed to deliver the same level of energy every time. Participants will be instructed to administer this home treatment twice a day (morning and evening) for 8-minute sessions over a four-week period. As this is a single-group assignment, all participants will be given the PEMF device.
89027231|NCT00505167|Active Comparator|2|Patients randomized to receive donepezil
89561969|NCT03136081||Septic shock and candidiasis|"The realized analyses will be two types:~1/an immunological analysis that is the characterization of the capacities of defense against germs and 2/a search(research) of Candida by microscopic examination and culture on circles of growth but also the research for the genome of the mushroom by a state-of-the-art technique of the laboratory of mycology ( PCR). Usual takings of research for bacteria."
89561970|NCT03135925|Other|Intervention|Exercise program
89561971|NCT05729789|Experimental|Group Written Exposure Therapy|"Patients will be invited to participate in group Written Exposure Therapy (described in the Interventions section)."
89027232|NCT00480272|Experimental|group A|"adalimumab 40 mg subcutaneous injections every other week from baseline to month 12~methotrexate orally weekly at initial dose of 10 mg rising to 20 mg weekly over 4 weeks in 2.5 mg increments, continued up to month 24.~prednisone orally 50 mg daily, gradually tapered up to 6.25 mg at week 7 and stopped at month 6"
89027233|NCT00480272|Placebo Comparator|group B|"adalimumab 40 mg subcutaneous injections every other week from baseline to the end of month 12~methotrexate orally oweekly at an initial dose of 10 mg rising to 20 mg weekly over 4 weeks in 2.5 mg increments, continued up to month 24.~placebo orally, stopped at month 6"
89027234|NCT00481754||Females with ovarian cancer|Recruited from Magee Women's Hospital
89027235|NCT04517058||epilepsy patients with depression group|the score of HAMD-17>7
89027236|NCT04517058||epilepsy patients without depression group|the score of HAMD-17≤7
89027237|NCT00480311||1|Measurement characteristics of WHODAS II (World Health Organization Disability Assessment Schedule).
89027238|NCT04519788|Active Comparator|AT-301B|AT-301B consists of edetate disodium, glyceryl monooleate, polysorbate 80, benzalkonium chloride, microcrystalline cellulose and sodium carboxymethylcellulose (vivapur), trisodium citrate dihydrate, and purified water (HCl to adjust pH to 5.0)
89027239|NCT04519788|Placebo Comparator|AT-301A|AT-301A consists of sodium chloride, benzalkonium chloride and purified water (NaOH/HCl to adjust pH to 5.0)
89027240|NCT04519593|Experimental|Laparoscopic myomectomy with temporary blood supply occlusion|Laparoscopic myomectomy is performed with prior visualization and temporary bilateral clipping of uterine/internal iliac arteries and suspensory ligaments of ovaries.
89027241|NCT04519593|Active Comparator|Conventional laparoscopic myomectomy|Laparoscopic myomectomy is performed without prior temporary blood supply occlusion.
89561972|NCT04021381|Experimental|Potassium and magnesium citrate|Patients are treated with potassium and magnesium citrate
89561973|NCT04021381|Placebo Comparator|Placebo|Patients are treated with placebo
89027242|NCT00480389|Experimental|Sorafenib|"All patients on study will be accrued to this arm. Sorafenib (200 mg tablets x 2) will be administered orally twice a day for 12 weeks (full daily dose of 800 mg). Patient visits for safety will be conducted at least every 4 weeks. Sorafenib dose reductions for drug-related toxicity will be applied based on considerable prior clinical experience. Surgery will be performed at the completion of the 13th week, allowing for a one-week washout period. Sorafenib will be continued post operatively (around 6 weeks post surgery or when complete wound healing has occurred) until patient progresses or unacceptable toxicity occurs."
89561974|NCT04020523|Experimental|Patient with an injected breast MR exam|
89561975|NCT04158401||Control group|Pregnant patients between 12w0d and 22w0d who present for prenatal care.
89561976|NCT04158401||Cerclage group A|Patients who present for a history-indicated cerclage placement.
89561977|NCT04158401||Cerclage group B|Patients who present for an ultrasound-indicated cerclage placement.
89561978|NCT04158401||Cerclage group C|Patients who present for an exam-indicated cerclage placement.
89561979|NCT03066479|Experimental|Fitbit|Patients will wear a Fitbit bracelet during their sleep study.
89561980|NCT03066791|Active Comparator|Turmeric group|"Turmeric Tablets:~Each tablet contains 1,000 mg of Turmeric (Curcuma Longa) per tablet. Dose: subjects will take 6 tablets per day, with a total daily dose of 6,000 mg.~Supplied by Sabinsa Corporation"
89561981|NCT03066791|Active Comparator|Curcumin Group|"Curcumin and Bioperine tablets:~Each tablet contains 1,000mg Curcumin + 1.25mg black pepper. Dose: subjects will take 6 tablets per day, with a total dose of 6,000mg curcumin.~Supplied by Sabinsa corporation"
89561982|NCT03066791|Placebo Comparator|Placebo Group|"Placebo tablets made to look like the turmeric and curcumin tablets~Each placebo tablet will contain: microcrystalline cellulose, dicalcium phosphate, PVPK30, sodium starch glycolate, magnesium stearate, OpaDry orange coating.~Dose: subjects in this group will take 6 placebo tablets per day"
89561983|NCT03066869|Experimental|H.P. ACTHAR GEL|
89561984|NCT04200131|Experimental|Moray micro-forceps|
89561985|NCT05729633|Experimental|Robot mediated Impairment-oriented training(RMIT)|Participant receives 20 hours of robot mediated impairment-oriented training applied via the Optimo Regen
89561986|NCT05729633|Experimental|Robot mediated impairment-orientyed and task-specific training (RMIT+RMTT)|Participant receives a total of 20 hours of robotic therapy. 10 hours will be in the form of RMIT and 10 hours in the form of RMTT
89027243|NCT04519554|Other|5FR + 7FR|Each woman is its own control and had biopsies with the 2 size of forceps. In this group first with 5FR then 7 FR
89027244|NCT04519554|Other|7FR + 5FR|Each woman is its own control and had biopsies with the 2 size of forceps. In this group first with 7FR then 5FR
89027245|NCT00482027|Active Comparator|1 AAV-2 HIV Vaccine|64 volunteers receiving AAV-2 HIV vaccine tgAAC09 at 3 dosage levels, dose escalation and dose optimization
89561987|NCT05729555|Experimental|Ibuprofen and Diphenhydramine Hydrochloride Modified-Release Tablets|Specification: Each tablet containing ibuprofen 400 mg, diphenhydramine hydrochloride 50 mg Batch number: 22082801 Content: Ibuprofen 96.9%, diphenhydramine hydrochloride 102.4% Effective: August 27,2024 S torage conditions: sealed, room temperature. Manufacturers: Overseas Pharmaceuticals, Ltd. Usage and dosage：Once a day, one tablet at a time
89561988|NCT05729555|Active Comparator|Motrin® IB (ibuprofen tablets USP) 200mg and BENADRYL® (diphenhydramine hydrochloride tablet) 25 mg|"Specification: 200 mg Batch number: 2CE2330 Content: 100.5% Expiry date: December 2023 Storage conditions; Storage in 20℃ -25℃~Specification: 25 mg Batch number: BCC009 Content: 99.2% Effective to: December 2023 storage conditions; storage at 20℃ -25℃, shading~Distributed by: Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division Usage and dosage：Once a day, two tablets at a time"
89561989|NCT01603459|Experimental|IncobotulinumtoxinA (Xeomin) (up to 800 Units)|"IncobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection"
89561990|NCT03066245|Experimental|MSC-PLGA|The lesion will be treated with curettage then 1 million of bone marrow derived MSC seeded on 5x5 mm2 PLGA scaffold will be engrafted in the cyst of ABC patient.
89561991|NCT03066323|Active Comparator|Tea extract|Rice with tea extract
89561992|NCT03066323|Placebo Comparator|No tea extract|Rice without tea extract
89561993|NCT05424185||type 1 scapular dyskinesis|type 1 scapular dyskinesis classified by dyskinesis classification test
89561994|NCT05424185||type 2 scapular dyskinesis|type 2 scapular dyskinesis classified by dyskinesis classification test
89561995|NCT05424185||type 3 scapular dyskinesis|type 3 scapular dyskinesis classified by dyskinesis classification test
89561996|NCT05424185||type 4 scapular dyskinesis|type 4 scapular dyskinesis classified by dyskinesis classification test
89561997|NCT02926027|Active Comparator|Active subjects|Vascepa (4 gm/day), oral dose
89561998|NCT02926027|Placebo Comparator|Placebo subject|oral dose of placebo
89561999|NCT05037305|Other|Intervention arm|All individuals in the Intervention arm will undergo pharmacogenetic testing, which will be performed in our CLIA-CAP certified clinical laboratory using the panel-based clinical pharmacogenomic assay used at Vanderbilt University Medical Center. Upon completion of the testing, they will be provided a link to an educational video about pharmacogenetic testing and results. Surveys will be performed before and after the pharmacogenetic testing.
88967422|NCT00006242|Experimental|Treatment (BMS-214662)|"Single patient cohorts receive BMS-214662 IV over escalating periods of 2, 4, 8, 16, and 24 hours weekly for 3 weeks followed by 1 week of rest. If no patient experiences DLT, dose escalation proceeds in the single patient cohorts.~Treatment repeats every 4 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity. Individual patient cohorts may increase their duration of BMS-214662 infusion in subsequent courses to the current duration safely reached.~Beginning with the infusion level at which DLT is first encountered by a single patient, cohorts of 3-6 patients receive escalating doses of BMS-214662 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience DLT. An additional cohort of 10 patients is treated at the MTD."
88967423|NCT04538430|Other|Axial Low Back Pain|Patient diagnosed with axial low back pain not responding to conservative measures and no symptoms of radiculopathy, that is scheduled to have a SPRINT percutaneous peripheral nerve stimulator placed as standard of care.
88967424|NCT00094276|Experimental|1|Breathmobile intervention combined with a Facilitated Asthma Communication intervention (FACI)
88967425|NCT00094276|Active Comparator|2|FACI intervention
88967426|NCT00094276|Active Comparator|3|Breathmobile intervention
88967427|NCT00094276|No Intervention|4|Control group
88967428|NCT00094354||1|HIV-infected FPDs
88967429|NCT00094354||2|Family members of HIV-infected FPDs
88967430|NCT00094354||3|Local healthcare workers
88967431|NCT00094354||4|Villagers not related to an HIV-infected individual
88967432|NCT00094432|Active Comparator|A1|
88967433|NCT00094432|Placebo Comparator|A2|
88967434|NCT00094705|Experimental|1|One subcutaneous vaccination with a 10^3 PFU dose of rDEN2/4delta30(ME) vaccine given in the deltoid region of either arm.
88967435|NCT00094705|Experimental|2|One subcutaneous vaccination with a 10^5 PFU dose of rDEN2/4delta30(ME) vaccine given in the deltoid region of either arm.
88967436|NCT00094705|Placebo Comparator|3|One subcutaneous vaccination with a placebo vaccine given in the deltoid region of either arm.
88967437|NCT00006251|Experimental|Treatment (fludarabine phosphate, TBI, PBSC transplant, DLI)|"CONDITIONING REGIMEN : Patients receive fludarabine phosphate IV on days - 4 to -2 and undergo low-dose TBI on day 0. (Note: Patients who have had an autologous transplant within 90 days prior to day 0 will not receive fludarabine phosphate.)~PBSC INFUSION: Patients undergo allogeneic PBSC transplant on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine PO BID on days -3 to 35 with a taper to day 56. Patients receive mycophenolate mofetil PO BID on days 0-27.~POST TRANSPLANT DLI: Patients with stable mixed chimerism on day 56, and without evidence of GVHD, undergo DLI IV over 30 minutes on day 65. Patients without a complete response, full donor chimerism, and GVHD after 2 months undergo further DLI at higher cell numbers. Up to 6 DLIs may be given 65 days apart."
88967438|NCT04515030||Primary glaucoma|"Primary glaucoma patients were diagnosed based on guidelines [1-2]. Patients with a confirmed diagnosis of primary glaucoma were enrolled and classified into the acute angle-closure crisis (AACC), primary angle-closure glaucoma (PACG), and primary open-angle glaucoma (POAG) subgroups.~Prum BE, Herndon LW, Moroi SE, et al. Primary Angle Closure Preferred Practice Pattern® Guidelines. Ophthalmology 2016;123:P1-40. doi:10.1016/j.ophtha.2015.10.049~Prum BE, Rosenberg LF, Gedde SJ, et al. Primary Open-Angle Glaucoma Preferred Practice Pattern® Guidelines. Ophthalmology 2016;123:P41-111. doi:10.1016/j.ophtha.2015.10.053"
88967439|NCT04515030||Senile cataract|"Senile cataract patients were diagnosed based on guideline [3]. Patients with a confirmed diagnosis of senile cataract were enrolled and considered as controls for aqueous humor-related analysis.~[3] Olson RJ, Braga-Mele R, Chen SH, et al. Cataract in the Adult Eye Preferred Practice Pattern®. Ophthalmology 2017;124:P1-119. doi:10.1016/j.ophtha.2016.09.027"
88967440|NCT04515030||Normal control|Normal people without ocular diseases were enrolled as normal control.
88967441|NCT00094744|Active Comparator|6hrs daily patching|6 hours per day of patching in the sound eye
88967442|NCT00094744|Active Comparator|Full-time daily patching|Patching of the sound eye all but one waking hour
88967443|NCT00094822||Pegfilgrastim|
88967444|NCT00094822||PLACEBO|
88967445|NCT02964754|Experimental|the observation group|32 patients with complex long bone fractures will be randomized to undergo digital three-dimensional models will be established by CT scan for internal fixation in the observation group.
88967446|NCT02964754|Experimental|the control group|31 patients will be randomized to undergo conventional internal fixation in the control group.
88967447|NCT00095251|Active Comparator|Dexmedetomidine group|Patients in the dexmedetomidine arm will receive a bolus dose of 1 μg/kg infused over 10 minutes followed by an infusion started at 0.15- 0.45 μg/kg/hr. The patient's managing physician will have the option of beginning the dexmedetomidine infusion without a bolus in circumstances where the patient's sedation level is adequate at enrollment or in the presence of baseline bradycardia /hypotension. Dexmedetomidine will be titrated every 10 minutes to achieve set target RASS score. The maximum dexmedetomidine infusion will be 1.5 μg/kg/hr.
89027246|NCT00482027|Placebo Comparator|2|16 volunteers receiving formulation buffer consisting of a buffered salt solution with potassium phosphate, calcium chloride, magnesium chloride, and HEPES
89562000|NCT05037305|Other|Delayed intervention arm|All individuals in the Delayed intervention arm will undergo pharmacogenetic testing, which will be performed in our CLIA-CAP certified clinical laboratory using the panel-based clinical pharmacogenomic assay used at Vanderbilt University Medical Center. Surveys will be performed before and after the pharmacogenetic testing. Upon completion of the first follow up survey, they will be provided a link to an educational video about pharmacogenetic testing and results. A second follow up survey will then be completed.
89027247|NCT02275455|Experimental|Participants with autism|
89027248|NCT02275455|Experimental|Aged-matched controls|
89027249|NCT03272243|Active Comparator|Short Segment posterior spine fixation|Short segment transpedicular screw fixation with inclusion of the index level
89027250|NCT03272243|Active Comparator|Long Segment posterior spine fixation|Long segment transpedicular screw fixation with escape of the index level
89027251|NCT03270137|Active Comparator|Condition A: rTMS on L-DLPFC|"Repetitive transcranial magnetic stimulation- IDLPFC. The intervention will be rTMS delivered on left dorsolateral prefrontal cortex (L-DLPFC).~Every patient will receive 15 rTMS sessions (in weekdays) along three weeks at 5 Hz of frequency and at its 100% of motor threshold. Each session will consist of 30 trains separated by 10 seconds inter-train interval and 1500 total pulses per session.~Equipment to rTMS includes a Magpro R30 stimulator (Magventure, Denmark) with an 8-shape coil model MCF-B70."
89027252|NCT03270137|Active Comparator|Condition B: rTMS on six regions|"Repetitive transcranial magnetic stimulation - Six regions. Two sub-conditions will alternate each session, starting with day 1: rTMS on Broca and Wernicke area and lDLPFC and then day 2: rTMS on left and right parietal association cortex (lPAC; rPAC) and right dorsolateral prefrontal cortex (rDLPFC).~Patients will receive 15 intervention sessions (in weekdays) along three weeks at 5 Hz frequency and 100% of motor threshold. Each area will receive 10 trains (500 pulses) separated by 10 seconds of inter-train interval that correspond to 1500 total pulses per session.~Equipment to rTMS includes a Magpro stimulator (Dantec, Denmark) with an 8-shape coil model MC-B70."
89027253|NCT04519398||COVID-19 patients with proved venous thrombosis|"1st group includes COVID-19 patients with proved~venous thrombosis (deep vein thrombosis, pulmonary embolism or venous thrombosis occurring in more atypical places such as in the veins of the brain, liver, kidney, mesenteric vein and the veins of the arms)~or arterial thrombosis (heart attacks, strokes)"
89027254|NCT04519398||Asymptomatic COVID-19 & those with mild or moderate disease|2nd group encompasses asymptomatic patients and those with mild or moderate disease, according to current guidelines, without thrombosis: no symptoms or evidence of lower respiratory disease by clinical assessment or imaging and a SpO2 > 94%
89027255|NCT04519398||Severe disease, according to Guidelines, without thrombus|3rd group includes severe disease, according to current guidelines, without thrombosis: respiratory frequency > 30 breaths per minute, SpO2 < 94%, PaO2/FiO2 < 300 mmHg, or lung infiltrates >50%
89027256|NCT00482066|Active Comparator|1|Abatacept (Orencia)
89562001|NCT03136003|Experimental|Arm A: DDAVP followed by exercise|"Intervention #1: DDAVP. The participant will take either 1 or 2 nasal sprays of IN DDAVP. For patients weighing <50 kg: 150 ug (i.e. 1 spray into one nostril) and patients weighing ≥50 kg: 300 ug (i.e. 2 sprays - one into each nostril).~Intervention #2: Exercise"
89562002|NCT03136003|Active Comparator|Arm B: DDAVP alone|"Intervention #1: DDAVP. The participant will take either 1 or 2 nasal sprays of IN DDAVP. For patients weighing <50 kg: 150 ug (i.e. 1 spray into one nostril) and patients weighing ≥50 kg: 300 ug (i.e. 2 sprays - one into each nostril).~Intervention #2: no further intervention (rest)"
89562003|NCT03136003|Experimental|Arm C: Exercise alone|"Intervention #1: Exercise~Intervention #2: no further intervention (rest)"
89562004|NCT03136003|Experimental|ARM D: Exercise followed by DDAVP|"Intervention #1: Exercise~Intervention #2: DDAVP. The participant will take either 1 or 2 nasal sprays of IN DDAVP. For patients weighing <50 kg: 150 ug (i.e. 1 spray into one nostril) and patients weighing ≥50 kg: 300 ug (i.e. 2 sprays - one into each nostril)."
89562005|NCT03798353|Experimental|Experimental group|"The patient will undergo surgery by sternotomy to perform the surgical revascularization of the arteries candidates for revascularization.~In addition, the matrix-cell (PeriCord) construct will be placed on the ischemic area of the non-candidate revascularization area and will be fixed using surgical glue.~PeriCord: Expanded and cryopreserved allogeneic umbilical cord Wharton´s jelly-derived adult mesenchymal stem cells colonized on human pericardial matrix ."
89562006|NCT03798353|Active Comparator|Control group|The patient will undergo surgery by sternotomy to perform the surgical revascularization of the arteries candidates for revascularization. No additional procedure will be performed.
89562007|NCT04962685|Experimental|Unilateral Posterior Crossbite|
89562008|NCT04962685|No Intervention|Normal occlusion|
89562009|NCT05410847|Experimental|Experimental|"Camrelizumab: 200mg，iv，30min, q3w, 4 cycles. Nab-Paclitaxel: intraperitoneal nab-paclitaxel 80 mg/m2 and intravenous nab-paclitaxel 180 mg/m2 on days 1, q3w, 4 cycles.~S-1：According to the body surface area, BSA <1.25m2，40mg bid; 1.25m2≤BSA≤1.5m2，50mg bid; BSA >1.5m2, 60mg bid. Take the medicine twice daily for 2 weeks, then suspend for 1 week, q3w, 4 cycles.~For patients who were operable, the original regimen was continued for 4 cycles of adjuvant treatment after operation, followed by maintenance of carrelizumab monotherapy to 1 year.~Inoperable patients were selected for follow-up treatment according to guidelines recommended by the investigator."
89562010|NCT04750291|Experimental|Botulinum toxin|Infiltration with botulinum toxin
89562011|NCT04750291|Placebo Comparator|Placebo|Infiltration with placebo or sterile saline
89562012|NCT04708951|Active Comparator|ECV colonoscopy|EndoCuff Vision® device (ECV)
89562013|NCT04708951|Experimental|G-EYE® colonoscopy|G-EYE® colonoscope (G-EYE)
89562014|NCT03726749|Experimental|Tocilizumab and prednisone|"TCZ 162 mg administered by subcutaneous injection weekly for 52 weeks.~Prednisone taper over 8 weeks with a starting dose between 20 and 60 mg."
89027257|NCT00482066|Placebo Comparator|2|saline placebo
89027258|NCT04519047|Experimental|Rejoint|Rejoint+PRP
89027259|NCT04519047|Active Comparator|Control|Saline+PRP
89562015|NCT04593745|Other|ALL AIEOP-BFM induction|Intraocular pressure messured in children treated with steroids
89562016|NCT03812575||Active eosinophilic esophagitis|
89562017|NCT03812575||Eosinophilic esophagitis in remission|
89562018|NCT03812575||No eosinophilic esophagitis|
89562019|NCT03756337|Experimental|Neuro 2 Upgrade|Participant wears Neuro 1 sound processor and is tested, then is upgraded with the new sound processor Neuro 2 and tested.
89562020|NCT03756337|Experimental|Neuro 1 Downgrade|Participant wears Neuro 2 sound processor and is tested, then is downgraded with the sound processor Neuro 1 and tested.
89562021|NCT03066713|Experimental|Experimental: A|Skin On French Fry - breakfast Skin On French Fry - lunch Mashed Potatoes - dinner
89562022|NCT03066713|Experimental|Experimental: B|Skin Off French Fry - breakfast Skin Off French Fry - lunch Mashed Potatoes - dinner
89562023|NCT03066713|Experimental|Experimental: C|Hash brown - breakfast Hash brown - lunch Mashed Potato - dinner
89562024|NCT03066713|Experimental|Experimental: D|Pancake - breakfast Pretzels - lunch Macaroni - dinner
89562025|NCT03066557|Active Comparator|study group|TACE and Apatinib
89562026|NCT03066557|Experimental|control group|TACE alone
89562027|NCT04574401|Experimental|Dose escalation|Dose-cohort escalation of a single intravenous injection of IS-002 at four different dose levels
89562028|NCT05729087|Experimental|Blended Intervention Group|A 10-week lifestyle intervention will be provided, addressing physical activity (PA) and healthy diet simultaneously. The program mode is a web- and center-based blended intervention. The web-based lifestyle behavior intervention will be developed based on the Health Action Process Approach.
89562029|NCT05729087|No Intervention|Control Group|No treatment will be provided during the intervention period. Relevant intervention materials are accessible and available for all participants in the control group after the completion of data collection.
89562030|NCT05308667|Experimental|iTBS + mCIMT group|
89562031|NCT05308667|Sham Comparator|Sham iTBS+ mCIMT group|
89562032|NCT05308667|Active Comparator|mCIMT group|
89562033|NCT02529943||Surgery Group|Consecutive patients from a two surgeon practice
89562034|NCT05737927|Active Comparator|SINGLE DOSE- TEST PRODUCT 1 (T1)|Oral coated beads 8 g glucose (content glucose/bead 47% w/w)
89562035|NCT05737927|Active Comparator|SINGLE DOSE- TEST PRODUCT 2 (T2)|Oral coated beads 12 g glucose (content glucose/bead 47% w/w)
89562036|NCT05737927|Active Comparator|SINGLE DOSE- TEST PRODUCT 3 (T3)|Oral coated beads 16 g glucose (content glucose/bead 47% w/w)
89562037|NCT05737927|Active Comparator|SINGLE DOSE- TEST PRODUCT 4 (T4)|Oral uncoated beads 12 g glucose
89562038|NCT05737927|Active Comparator|SINGLE DOSE- TEST PRODUCT 5 (T5)|Oral coated beads 12 g glucose (content glucose/bead 60% w/w)
89562039|NCT05737927|Active Comparator|MULTIPLE DOSE- TEST PRODUCT 2 (T2)|Oral coated beads 12 g glucose (content glucose/bead 47% w/w)
89562040|NCT04152967|Experimental|new-designed PTFE valved conduit|In this group, new-designed PTFE valved conduits will be applied for patients.
89562041|NCT04152967|Active Comparator|Bovine jugular valved conduit|In this group, bovine jugular vein valved conduits will be applied for patients.
89562042|NCT05737771|Other|Group A|administrate DWP16001 + DWC202213 at first period, and administrate DWJ1563 at second period
89562043|NCT05737771|Other|Group B|administrate DWJ1563 at first period, and administrate DWP16001 + DWC202213 at second period
89562044|NCT05728697||Patients with nonalcoholic fatty liver disease and elevated body mass index|Patients who have BMI >=25 and suspected nonalcoholic fatty liver disease based on imaging, laboratory workup, or clinical history. Patients are included in the study if they have been selected for routine clinical endoscopic ultrasound (can be for any indication) with liver biopsy either during the same session or within 6 months.
89562045|NCT04477135|Other|perinatologists|perinatologists working actively and performing ultrasonography every day
89562046|NCT05737537|Other|infected pediatric cancer patients|
89562047|NCT05737459||Group K|Those who have been administered ketamine for perioperative sedation
89210600|NCT03913377|Experimental|Interventional|Eligible subjects that are habitual contact lens wearers who own spectacles will be randomized into 1 of 2 sequences (Spectacle/ACUVUE OASYS 1-Day or ACUVUE OASYS 1-Day/Spectacle)
89562048|NCT05737459||Group D|Those who have been administered dexmedetomidine for perioperative sedation.
89562049|NCT05737303|Experimental|Nab-Paclitaxel/carboplatin for systemic therapy after surgery|Nab-Paclitaxel/carboplatin q3 weeks Nab-Paclitaxel 260 mg/m² IV followed by carboplatin AUC（area under the curve） 5 IV Day1 Repeat every 21 days x 6 cycles Nab-Paclitaxel/carboplatin weekly Dose-dense Nab-Paclitaxel 100 mg/m2 IV followed by carboplatin AUC（area under the curve）2 IV Davs 1. 8, and 15 ·Repeat every 21 days x 6 cycles
89562050|NCT05737303|Active Comparator|Paclitaxel/carboplatin for systemic therapy|"Paclitaxel 175 mg/m² IV followed by carboplatin AUC（area under the curve）5 IV Day·1Repeat every 21 days x 6 cycles~Paclitaxel weekly/carboplatin weekly Paclitaxel 60 mg/m2 followed by carboplatin AUC（area under the curve） 2 IV Days 1.8. and 15: repeat every 21 days 6 cycles (18 weeks)"
89562051|NCT03066089|Experimental|Group A|Fenfuro 500 mg capsule by mouth, BD (two times a day), till next follow-up
89562052|NCT03066089|No Intervention|Group B|Investigational product is not being administered to this arm. This arm will regularly be observed on follow-up and laboratory investigations will be performed.
89562053|NCT04648501|Experimental|Dual-task group|Dual-task (CIBT- experimental) group participants will receive 10 minutes of warm up, 40 minutes of CIBT training and 10 minutes of cool down exercises. CIBT program includes performing four types of cognitive tasks during sit to stand, standing with feet apart, one leg, tandem standing, multidirectional reaching, stair climbing and walking (10 metres) tasks. The four cognitive tasks will include: counting backwards by subtracting 4 numbers (for mental tracking ), naming fruits, vegetables, or animals (for working memory), auditory cues for performing activities, example, perform heel raise when you hear the alphabet H (for improving attention and auditory discrimination), short story telling (for verbal fluency). In addition, falls prevention strategies will be taught.
89562054|NCT04648501|Active Comparator|Single-task group|Single-task (conventional balance, coordination and cognitive training- active control) group participants will receive 10 minutes of warm-up, 20 minutes of conventional balance and coordination exercises that are in accordance to previously published literature, 20 minutes of cognitive training as single-task (same 4 tasks provided for the CIBT) and 10 minutes of cool down. In addition, falls prevention strategies will also be taught.
89562055|NCT03066167||Patients|Patients with oesophageal cancer and dysphagia
89562056|NCT03066167||Controls|Healthy Controls with no known dysphagia
89608771|NCT04147767|Experimental|Phytosterols Arm|"The investigational food product Cholesterol Reducing Strawberry Yogurt Drink (Tesco) is a strawberry yogurt drink with added plant sterols. A 100g bottle (one serving) of cholesterol lowering strawberry yogurt drink contains 2g of free plant sterols. The magnitude of the effect given by this enriched food product, providing a daily intake of 1,5-2,4 g plant sterols/stanols, refers to the lowering/reducing blood cholesterol effects in the range 7 % to 10 % within 2 to 3 weeks of treatment, as specified by Commission Regulation (EU) 384/2010 of 05/05/2010.~The dietary intervention will consist in 8 weeks consumption of PSS enriched Yogurt Drink, which provide a daily PSS intake of 3.4g/100g bottle plant sterols ester equivalent to 2g/100g bottle of free plant sterols."
89562057|NCT04599049|Other|six sessions of online classes and virtual training day camps through Zoom in two days|"The Smoke-free teens will join six sessions of online classes via an e-platform in October 2020 and followed by virtual training day camps through Zoom in two days in December 2020 organized by COSH. The online classes will educate students the knowledge on smoking hazards, tobacco control and smoking cessation. In addition, the teens will be taught how to deliver a brief smoking cessation intervention using the AWARD Model. After the online classes, the teens will then break down into groups to organize smoke-free programmes in their schools or in the community.~All Smoke-free Teens will be invited to respond to the structured questionnaire at baseline (T1), immediately after the online classes (T2), and 3 months later (T4). They will be asked to complete a process evaluation form immediately after the training camp (T3). Each group of teens will have to submit the written proposal and final report regarding the smoke-free programme to COSH at 3 months (T4), respectively."
89562058|NCT03065699|No Intervention|Standard of Care|For patients with ACLF grade 1 or 2 and randomised to the 'Standard of care' arm, the location of treatment (ICU or general ward) will be determined by their clinical need and will be decided by the site Principal Investigator. They will receive standard of care.
89562059|NCT03065699|Active Comparator|DIALIVE Liver Dialysis Device treatment arm|Patients with ACLF grade 1 and ACLF grade 2 on the background of alcoholic cirrhosis randomized to the DIALIVE arm will receive treatment in an intensive care (ICU) or renal dialysis unit setting. They will receive DIALIVE treatment according to a fixed treatment schedule over a period of 10 days post-randomization.
89562060|NCT03065855|Experimental|Early removal group|All participants are to have a urethral catheter placed following successful placement of an epidural catheter for analgesia prior. Following urethral catheter placement participants will be randomly assigned to either the experimental arm or the control arm. Participants assigned to the experimental arm will have their urethral catheters removed at 2 days following surgery.
89562061|NCT03065855|Active Comparator|Normal removal group|All participants are to have a urethral catheter placed following successful placement of an epidural catheter for analgesia prior. Following urethral catheter placement participants will be randomly assigned to either the experimental arm or the control arm. Participants assigned to the control group will have their urethral catheters removed at 7days following surgery, as is standard practice in our institution.
89562062|NCT01678807|Experimental|MK-8237 6 DU|MK-8237 6 DU rapidly dissolving tablet administered sublingually once daily for 28 days
89562063|NCT01678807|Experimental|MK-8237 12 DU|MK-8237 12 DU rapidly dissolving tablet administered sublingually once daily for 28 days
89562064|NCT01678807|Placebo Comparator|Placebo|Placebo rapidly dissolving tablet administered sublingually once daily for 28 days
89562065|NCT05188313|Active Comparator|Chemoradiation according to the CROSS regimen|"Paclitaxel 50 mg/m2 and carboplatin AUC = 2 will be given by intravenous infusion on days 1, 8, 15, 22 and 29.~A total dose of 41.4 Gy will be given in 23 fractions of 1.8 Gy, 5 fractions per week, starting the first day of the first cycle of chemotherapy."
89562066|NCT05188313|Experimental|Chemoradiation according to the CROSS regimen combined with trastuzumab and pertuzumab|"Paclitaxel 50 mg/m2 and carboplatin AUC = 2 will be given by intravenous infusion on days 1, 8, 15, 22 and 29.~A total dose of 41.4 Gy will be given in 23 fractions of 1.8 Gy, 5 fractions per week, starting the first day of the first cycle of chemotherapy.~Pertuzumab will be administered intravenously first, on Day 1, 22, 43, 64, and 85 using a fixed dose of 840 mg.~Trastuzumab will be administered intravenously on Day 1 of each treatment cycle, using an initial dose of 4 mg/kg on day 1, followed by doses of 2 mg/kg weekly up to week 6. From week 7 onwards trastuzumab will be administered at a dose of 6 mg/kg, every three weeks."
89562067|NCT04540315|Experimental|Intervention - MobiMD app|Intervention group will receive notifications to their smart device through MobiMD app. Participants will be asked to fill out reports and upload all clinically relevant data using the app. Engaging with the app will be in addition to the standard of care follow-up.
89562068|NCT04540315|No Intervention|Standard of Care|The standard of care control group will receive conventional postoperative care. Participants will receive reported outcome survey by email.
89562069|NCT03065777|Experimental|ONE ENDO|Single file rotary system
89562070|NCT03065777|Experimental|F6 SKYTaper|Single file rotary system
89562071|NCT03065777|Active Comparator|ProTaper Universal|Muti-file rotary system
89562072|NCT04310137|Experimental|Therapist-Directed Re-loading|Participants in this arm will be instructed to increase their activity by walking 10% more steps per day than the steps recorded in the most recent activity monitoring (i.e. StepWatch) measurement (e.g. 10% more than the initial monitoring values and 10% more than the second monitoring values once they are completed).
89562073|NCT04310137|No Intervention|Self-Directed Re-loading|Participants in this arm will be instructed to slowly increase their walking.
89562074|NCT02514655|Experimental|1: Nosten® monitoring|One experimental group with the control of the cuff pressure by Nosten® device
89562075|NCT02514655|Active Comparator|2: Manual monitoring|One control group with the manual monitoring of the cuff pressure and inflation of the balloon
89562076|NCT03188731||Pregnant Women|
89562077|NCT03066011||Isavuconazonium sulfate Group|Oral and Intravenous
89562078|NCT03066011||Voriconazole Group|Oral and Intravenous
89562079|NCT03066011||Posaconazole Group|Oral and Intravenous
89562080|NCT03135769|Experimental|Avelumab|Avelumab administration at 10 mg/kg every 14 days during 6 months maximum
89562081|NCT03781297|Active Comparator|Intervention: NET+G|In addition to usual care, participants will receive six sessions of Narrative Exposure Therapy over six weeks plus the option to receive genealogical services.
89562082|NCT03781297|Active Comparator|Intervention: NET|In addition to usual care, participants will receive six sessions of Narrative Exposure Therapy over six weeks.
89562083|NCT05728463|Experimental|Single-incision laparoscopic cholecystectomy|SILC was defined as laparoscopic surgery done through a single trans-umbilical incision
89562084|NCT05728463|Active Comparator|Conventional laparoscopic cholecystectomy|CLC was defined as three or four port surgery carried out with either French or American position.
89210601|NCT00820352|Active Comparator|bosentan|Patients in this arm receive bosentan twice a day for 12 weeks
89210602|NCT00820352|Placebo Comparator|placebo|patients in this arm receive 12 placebo twice a day for 12 weeks
89210603|NCT00927654|Experimental|Iloprost|
89210604|NCT00927654|Placebo Comparator|Isotonic Sodium Chloride solution 0.9 %|
89562085|NCT05527457|Placebo Comparator|Placebo|Placebo (saline) nasal spray, taken before bedtime. Dosage is taken on one instance for one night only.
89562086|NCT05527457|Experimental|BAY2586116 (oro-nasal breathing night)|BAY2586116 nasal spray, taken before bedtime. Dosage is taken on one instance for one night only for the oro-nasal breathing night.
89562087|NCT05527457|Experimental|BAY2586116 (nasal breathing only night)|BAY2586116 nasal spray, taken before bedtime. Dosage is taken on one instance for one night only for the nasal only breathing night.
89562088|NCT05520749||Luspatercept treated patients|Adult patients (i.e. aged >=18 years) with diagnosis of MDS according to WHO 2016 classification that met IPSS-R criteria for very low, low, or intermediate-risk MDS treated with Luspatercept
89562089|NCT05092243|Experimental|real tDCS|In transcranial direct current stimulation, the anodal pad was tapped over the primary motor cortex and the cathode pad was adhered of the contralateral frontal region. A constant current of 2.0 mA will be apply for up to 20 mins.
89562090|NCT05092243|Sham Comparator|sham tDCS|In transcranial direct current stimulation, the sham stimulation will be 30s stimulation with ramp up and ramp off for 10s at 2.0 mA.
89562091|NCT03609697|Experimental|Community-based lifestyle intervention|Participants will attend 7 community-based group intervention sessions plus 2 individual face-to-face dietician consultation sessions during the first 6 months, followed by a 6-month maintenance phase which they will receive monthly phone support from the research team.
89562092|NCT03609697|Other|Minimal intervention (SMS intervention)|Participants will receive one SMS per month during the first 6 months, followed by a 6-month maintenance phase which participants will receive one SMS every 2 months.
89562093|NCT03073525|Experimental|Part 1: Vigil + Atezo|This was a safety run in and intervention was combined. The first three participants received Vigil immunotherapy at a concentration of 1x10e7 cells/dose given via intradermal injection every 3 weeks for a minimum of 4 doses and a maximum of 12 doses. Atezolizumab was administered at a dose of 1200 mg as an intravenous infusion every 3 weeks. 1 cycle = 21 days.
89562094|NCT03073525|Experimental|Part 2: Vigil first then combination Vigil + Atezo|"After Part 1 participants completed completed combination therapy without dose-limiting toxicity, then Part 2 participants randomized to Vigil first received two cycles of Vigil alone, then Vigil and atezolizumab given in sequence (Vigil administered first, followed 30 minutes later by atezolizumab)~Vigil immunotherapy was administered at a concentration of 1 x 10e6 or 1 x 107 cells/dose given via intradermal injection every 3 weeks for a minimum of 4 doses and a maximum of 12 doses. Atezolizumab was administered at a dose of 1200 mg as an intravenous infusion every 3 weeks, with a maximum of 12 doses. When Vigil and atezolizumab was given together, Vigil~1 cycle = 21 days"
89562095|NCT03073525|Experimental|Part 2: Atezo first then combination of Vigil + Atezo|"After Part 1 participants completed completed combination therapy without dose-limiting toxicity, then Part 2 participants randomized to atezolizumab first received two cycles of atezolizumab alone, then Vigil and atezolizumab given in sequence (Vigil administered first, followed 30 minutes later by atezolizumab).~Vigil immunotherapy was administered at a concentration of 1 x 10e6 or 1 x 107 cells/dose given via intradermal injection every 3 weeks for a minimum of 4 doses and a maximum of 12 doses. Atezolizumab was administered at a dose of 1200 mg as an intravenous infusion every 3 weeks, with a maximum of 12 doses. 1 cycle = 21 days"
89562096|NCT03073525|Other|Part 3: Atezo Only|Participants who completed all cycles of Part 2 were pre-approved by the sponsor for inclusion into Part 3. Atezolizumab alone was administered at a dose of 1200 mg as an intravenous infusion every 3 weeks. 1 cycle = 21 days
89562097|NCT05728307||Intervention Group|The intervention group consists of patients admitted to the 4 neonatal subunits where neoGuard was installed: the preterm units (category A and category B), and the high dependence units (HDU-1 and HDU-2).
89562098|NCT05728307||Comparison Group|The comparison group consists patients admitted 4 subunits where neoGuard was not installed: the neonatal intensive care unit (NICU), the KMC/category C room, the isolation room and the stable full-term room. These subunits will receive the standard-of-care/current practice, which consists of either a bedside cardiac monitor or intermittent monitoring every 3 hours using manual equipment such as hand-held pulse oximeters for pulse rate and oxygen saturation, digital axillary thermometers for temperature, and manual counting of breaths for respiratory rate.
89562099|NCT02563015|Experimental|Cholecalciferol 400|400 IU orally per day
89562100|NCT02563015|Experimental|Cholecalciferol 1000|1000 IU orally per day
89562101|NCT02563015|Active Comparator|Reference 400|400 IU orally per day
89562102|NCT02382445|Experimental|Anesthesia depth monitor|Anesthesia depth is aimed to be between BIS 50-60
89562103|NCT02382445|Sham Comparator|Control group|Anesthesia depth is monitored but blinded to the anesthesiologist
89562104|NCT05094973|Experimental|Canine and molar distalization and molar derotation|Evaluating the canine and molar distalization and molar derotation in dental Class II patients who where submitted to Carriere Motion Appliance® for a mean of 4 months.
89562105|NCT02875535|No Intervention|Usual Care|Standard school nurse care for suicide prevention.
89562106|NCT02875535|Experimental|RLAS|Through the RLAS, the investigators will train school nurses statewide. Using the Dynamic Adaptation Process, the nurses will then convene and lead Implementation Resource Teams (IRTs). With the assistance of RLAS coaches, the school nurse-led IRTs will engage in an iterative process of assessment and planning to build school capacity and implement up to six evidence-base strategies to reduce adolescent suicide.
89562107|NCT05736757|No Intervention|Control group|Control group (no tissue fibrinogen activator)
89562108|NCT05736757|Experimental|Drug group|Drug group (injection of 50 ug tissue fibrinogen activator into the suprachoroidal cavity or subretinal space )
89562109|NCT04483817|Experimental|A: Transcutaneous tibial nerve stimulation|The transcutaneous electrostimulation of the posterior tibial nerve (ETNTP) will be applied to group A: place two surface electrodes, one 32 mm in diameter, 5 cm cephalad of the internal malleolus and 1 cm medial posterior of the tibia; and another 50x50 mm electrode in the calcaneous. The flexion of the first toe will indicate the correct placement of the electrodes. Stimulation is performed according to the Stoller method with a stimulator programmed at 20Hz and 200 µs, with a continuous current, 12 sessions, 2 weekly are completed. The intensity of the current will be tolerance by the subject.
89562110|NCT04483817|Active Comparator|B: Percutaneous tibial nerve stimulation|The percutaneous electrostimulation of the posterior tibial nerve (EPNTP) will be applied to group B: inserting a 0.25x30mm surgical steel needle at a 60º angle, 5 cm cephalad to the malleolus and 1 cm posterior of the tibia , and a surface electrode of 50x50 mm in the calcaneous. The flexion of the first finger will indicate its correct placement. The stimulation parameters will also follow the Stoller method.
89562111|NCT05733481|Other|Patients with the presence of coronary arterial de novo or restenotic chronic total occlusion.|Successful crossing of the targeted chronic total occlusion, defined as angiography confirmed guidewire placement in the true lumen without utilization of a re-entry device.
89562112|NCT05732233|Experimental|Ultivision AI colonoscopy (CADe Arm)|Ultivision AI is used to aid in real-time detection of adenomas.
89562113|NCT05732233|Active Comparator|Standard colonoscopy (Control Arm)|Patients will undergo standard colonoscopy without AI.
89562114|NCT05092087||Control group/ non-regularity group|those who completed 8 consultations by average interval time more than 3 weeks were in the non-regularity group
89562115|NCT05092087||test group/ regularity group|those who completed the consultations and interval time within in 3 weeks were in the higher regularity
89562116|NCT04413643|Experimental|Noninvasive Ventilation|Subjects will be introduced to NIV and educated on sleep disordered breathing. NIV will be initiated during hospitalization following resolution of acute respiratory failure. NIV settings will be based on inspiratory and expiratory positive airway pressures (IPAP, EPAP), rates, and tidal volumes tolerated during the acute phase of treatment. Initial settings will be set with goals of tolerance and acceptance of therapy. Minimum pressure difference between IPAP and EPAP settings will be 5cmH20. Volume assured pressure support mode with a target tidal volume (Vt) of 8ml/kg ideal body weight will be used. Final device settings and patient parameters will be documented after 10 minutes of acclimation to the device. Data from the device will be reviewed the following day. Tolerance, mask comfort, and acceptance of therapy will be assessed. Changes to settings, mask interface, or other comfort features will be performed at this initial reassessment period.
89562117|NCT05094583||Intervention Arm|Patients who expressed wish to quit smoking and accept use of the SmokeFree app
89562118|NCT05094583||Control Arm|Patients who expressed wish to quit smoking but declines all support or use of SmokeFree app
89562119|NCT05091775|Placebo Comparator|Standard management of acute fissure(Diltiazem Jelly,supportive care,placebo suppository, sitz bath)|Patients in the first group underwent for 14 consecutive days treatment with diltiazem gel 2 times a day, a basin of warm water 2 times a day and drink daily 8-12 a glass of water will be placed with a placebo suppository.
89562120|NCT05091775|Experimental|Intervention group (Asacol suppository, supportive care, placebo suppository, sitz bath)|Patients in the second group or treatment group will be treated with diltiazem gel topically 3 times a day for 14 consecutive days, pelvis of warm water 2 times a day and drink daily 8-12 glasses of water plus Asacol anal suppository (mesalazine) are taken 1 piece every night.
88967448|NCT00095251|Active Comparator|Lorazepam group|Patients in the lorazepam arm will receive a bolus dose of 1-3 mg followed by an infusion started at 1-3 mg/hr. Lorazepam infusion will be titrated every 10 minutes to achieve set target RASS score. The maximum lorazepam infusion will be 10 mg /hr.
88967449|NCT00095329|Experimental|sirolimus|
88967450|NCT04504149|Experimental|PRIMED|Shared decision making session
88967451|NCT04504149|No Intervention|Usual Care|The investigators will characterize usual care using chart review and administrative data to identify medications (prescribed, filled), number of mental health sessions received, types of providers seen, and the content of treatment sessions as captured in chart notes.
88967452|NCT02964793|Experimental|Intervention group|The intervention consists in the standardization of current practices. Clinicians in the intervention maternity units will follow a standardized protocol, and will be asked to measure SFH at each antenatal appointment, collect EFW from the 3rd trimester US, report these values on the chart, and monitor fetal growth according to the protocol guidelines
88967453|NCT02964793|No Intervention|Control group|In the control arm women will benefit from the current routine screening practice for growth failure. The management of pregnancies will remain unchanged. Consultants will be free to monitor growth according to their usual practice. In each maternity unit in the control arm, an information session will be organized on site but its content will be limited to the rational, the objectives of the trial and the study logistics.
88967454|NCT00095680|Experimental|001|SCIO-469 two 30-mg capsules three times daily
88967455|NCT00095680|Active Comparator|002|SCIO-469 and bortezomib The addition of bortezomib (treatment regimen or bolus) to monotherapy of SCIO-469 or bortezomib combination with SCIO-469 will be dependent upon clinical response or disease progression during the study
88967456|NCT00095719|Active Comparator|A1|
88967457|NCT00095719|Placebo Comparator|B1|
88967458|NCT00095758|Placebo Comparator|A1|
88967459|NCT00095758|Active Comparator|A2|
88967460|NCT02964637||Progressive supranuclear palsy|Observational Study
88967461|NCT02964637||Corticobasal syndrome|Observational Study
88967462|NCT02964637||Behavoral variant FTD|Observational Study
88967463|NCT02964637||Semantic variant PPA|Observational Study
88967464|NCT02964637||Non-fluent variant PPA|Observational Study
89210605|NCT05709327|Other|Single-arm observational study|All participants in the study will be provided a smart ring to wear for the entire duration of the pregnancy.
88967465|NCT02964637||FTD-motor neuron disease|Observational Study
88967466|NCT02964637||Healthy controls|Observational Study
88967467|NCT00095797|Experimental|Treatment (XK469R)|Patients receive XK469R IV over 30-60 minutes on days 1, 3, and 5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
88967468|NCT04432428|Experimental|sufentanil sublingual tablet|sufentanil sublingual 15µg tablets
88967469|NCT00096070|Experimental|Arm I|Patients undergo radiotherapy once daily, 5 days a week, for 5.5 weeks. Beginning concurrently with radiotherapy, patients receive oxaliplatin IV over 2 hours on days 1, 15, and 29 and fluorouracil IV continuously for 5.5 weeks. Beginning 4-6 weeks after the completion of chemoradiotherapy, patients receive gemcitabine IV over 30 minutes on days 1 and 8. Treatment with gemcitabine repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
88967470|NCT00096148|Experimental|Arm I (idarubicin, cytarabine)|"Arm I: Patients receive idarubicin IV over 1 hour on days 1-3 and cytarabine IV continuously over 24 hours on days 1-4.~Post-CR therapy: All patients receive 4 post-CR chemotherapy courses approximately every 28 days in the absence of disease progression or unacceptable toxicity.~Course 1: Patients receive cytarabine IV continuously over 24 hours on days 1-5.~Course 2 and 4: Patients receive idarubicin IV over 1 hour and cytarabine IV continuously over 24 hours on days 1-4."
89562121|NCT05091541|Experimental|CT120 in relapsed/refractory B-cell non-Hodgkin's lymphoma patients|Fully Human Anti-CD19/CD22 Dual Target Chimeric Antigen Receptor Autologous T Cell Injection（CT120）will be infused at 1.0 x 10^6 CAR+ T cells/kg、3.0 x 10^6 CAR+ T cells/kg、6.0 x 10^6 CAR+ T cells/kg in relapsed/refractory B-cell non-Hodgkin's lymphoma patients
89562122|NCT05376085|Experimental|RT|"T: DA-5215 R: DA-5215-R"
89562123|NCT05376085|Experimental|TR|"T: DA-5215 R: DA-5215-R"
89562124|NCT05091463|Experimental|Transcutaneous spinal stimulation|Participants with chronic SCI will receive 60 sessions of activity based-locomotor training (AB-LT) combined with transcutaneous stimulation (scTS).
89562125|NCT05091385||Severe asthma patients treated with mepolizumab|Patients having received mepolizumab 100 mg SC every 4 weeks for at least 12 months in six severe-asthma clinics in Poland between December 2017 and December 2019
89562126|NCT02631551|Experimental|GSP 301 NS|
89562127|NCT02631551|Active Comparator|Olopatadine HCl NS|
89562128|NCT02631551|Active Comparator|Mometasone furoate NS|
89210606|NCT02550704|Experimental|Irritable Bowel Syndrome with diarrhea|Colonoscopy with eleven biopsies in the left colon to assess intestinal permeability. Intestinal permeability is not routinely performed and is assessed in colonic biopsies (occludin, claudin and ZO-1 by western blot, qPCR and immunofluorescence)
89210607|NCT00927732|Experimental|hydroquinidine|As it is a cross-over study, patient will taken treatment 1 for 18 months (ex: hydroquinidine) and then treatment 2 (placebo in this case) for 18 months.
89562129|NCT02631551|Placebo Comparator|GSP 301 Placebo NS|
89562130|NCT05094193|Experimental|Trocar-site infiltration|Trocar-site infiltration with 20 mL of ropivacaine 0.375% (6 mL in 10 mm trocar site and 4 mL in 5 mm trocar site) associated with bilateral TAP block with 20 mL of normal saline in each side
89562131|NCT05094193|Active Comparator|TAP block|Trocar-site infiltration with 20 mL of normal saline associated with bilateral TAP block with 20 mL of ropivacaine 0.375% in each side
89562132|NCT04165811|Experimental|Aerobic Dance based Exercise|The exercise program will be administered 60 minutes, 2 days a week for 8 weeks. The exercise program will be created by physiotherapists as a group exercise program.
89562133|NCT04165811|Experimental|Counseling of physical activity|Physical activity counseling is aimed at increasing the physical activity levels of the individuals who are waiting for bariatric surgery in the preoperative period.
89562134|NCT05091151|Active Comparator|Intranasal dexmedetomidine at dose of 2 mcg/kg|Subjects in IND 2 group received Intranasal dexmedetomidine at dose of 2 mcg/kg, before the MRI procedure through both nostrils using a 1 mL syringe. Patient was maintained in supine position for 1-2 minutes to maximize absorption.
88967471|NCT00096148|Experimental|Arm II (idarubicin, cytarabine, bevacizumab)|"Patients receive idarubicin and cytarabine as in arm I. Patients also receive bevacizumab* IV over 30-90 minutes on day 1. Patients who do not achieve complete remission (CR) after the first induction course may receive a second induction course approximately 28 days* later. Patients who do not achieve CR after 2 courses are removed from the study.~NOTE: *Patients in arm II receive bevacizumab, independently of chemotherapy administration schedule, once every 21 days for 1 year from CR date.~Post-CR therapy: All patients receive 4 post-CR chemotherapy courses approximately every 28 days in the absence of disease progression or unacceptable toxicity.~Course 1: Patients receive cytarabine IV continuously over 24 hours on days 1-5.~Course 2 and 4: Patients receive idarubicin IV over 1 hour and cytarabine IV continuously over 24 hours on days 1-4."
88967472|NCT04431960|Active Comparator|low-BC Group|consume: 1) one tablet containing 392 mg blackcurrant (BC) extract per capsule and 2) one calcium citrate caplet containing 400 mg calcium and 500 IU vitamin D
88967473|NCT04431960|Active Comparator|high-BC Group|consume: 1) two capsules containing 392 mg BC extract per tablet (total 784 mg/day) and 2) one calcium citrate caplet containing 400 mg calcium and 500 IU vitamin D
89562135|NCT05091151|Active Comparator|Intranasal dexmedetomidine at dose of 4 mcg/kg.|Subjects in IND 4 group received Intranasal dexmedetomidine at dose of 4 mcg/kg, before the MRI procedure through both nostrils using a 1 mL syringe. Patient was maintained in supine position for 1-2 minutes to maximize absorption.
89562136|NCT04752917|Experimental|Intervention|Headphones
89562137|NCT04752917|No Intervention|Control|Standard of care
89562138|NCT05377021|Active Comparator|"Diet group"|
89562139|NCT05377021|Experimental|"Diet and exercise combination group"|
89562140|NCT05093647||patient|"The women who followed up for HrP (high-risk pregnancy ) were invited to participate and women with HrP in the second trimester (14th to 28th gestational weeks), between 20 to 40 years old, and followed up at our perinatology department with a diagnosis of IUGR (intrauterine growth retardation~), cholestasis, diabetes, preeclampsia, or hypertension were included."
89562141|NCT05093647||control|The pregnant women admitted for routine second-trimester ultrasonography assessment but with no risk for pregnancy formed the control group.
89562142|NCT05093257||Group I|age and sex matched healthy control individuals.
89562143|NCT05093257||Group II|available number of ITP patients.
89562144|NCT05093179|Experimental|Deep tissue massage group|"The one session of deep tissue massage was performed. The patient's positions were changed depending on the specificity of used techniques.~The following techniques were used:~Shifting the rectus abdominis m.,~Stretching of the fascia within the costal arches,~trigger points compression (30-60 s).~Stretching of the chest fascia, superficially with forearm or fingertips on intercostal muscles,~filleting the pectoral muscles,~hook and stretch with the proximal phalanges of the fingers 2-4 and the forearm~filleting between the pectoral muscles and the deltoids,~Releasing the lateral edge of the scapula using the fingers and stretching the tissues, Releasing the medial edge of the scapula using the fingers and the weight of the patient,~hook and stretch of the trapezius muscle,~Subsequently, the patient took a prone position.~Stretching of the levator scapulae and supraspinatus muscles using the fist, forearm and elbow were performed."
89562145|NCT05093179|Active Comparator|Classic massage group|The one session of classic massage was performed. The massage was performed with moderate force. The entire procedure took about 15-20 min. The sequence of standard classic massage techniques was used in standard way and patterns.
88967474|NCT04431960|Placebo Comparator|Control Group|consume: 1) one placebo capsule and 2) one calcium citrate caplet containing 400 mg calcium and 500 IU vitamin D
89562146|NCT04626167|Experimental|Intervention group|Patients will undergo a cadaveric donor bladder transplant in addition to or after their kidney transplant rather than using intestinal segments for bladder reconstruction or construction.
89562147|NCT04538989|Experimental|RZ358 Cohort 1|
88967475|NCT00096343|Experimental|Paclitaxel IV followed by Carboplatin IV|paclitaxel IV over 3 hours followed by carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
88967476|NCT00096499|Experimental|Treatment (ispinesib)|Patients receive SB-715992 IV over 1 hour on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
88967477|NCT04381182|Other|Biostrap/Apollo Device Use|Participants wear a Biostrap wearable device which measures steps, heart rate, heart rate variability, sleep metrics, and quantitative data in typical day-to-day activities of residents. Participants then again wear Biostrap except now also with the Apollo device which is worn around the ankle and is suggested to modulate heart rate variability and perceived stress of participants.
88967478|NCT00096733||Donors|Living liver donors. This label may also refer to those evaluated for liver donation who did not go on to donate, i.e., potential living liver donors.
89562148|NCT04538989|Experimental|RZ358 Cohort 2|
89562149|NCT04538989|Experimental|RZ358 Cohort 3|
89562150|NCT04538989|Experimental|RZ358 Cohort 4|
89562151|NCT05704907|Other|gallblader ultrasound|
89562152|NCT04413175|Experimental|a music group|Patients in the music group were provided music therapy that was prepared by the Turkish Psychological Association. They listened to the music that has a calming and relaxing effect for 20 min before and during the procedure.
89562153|NCT04413175|No Intervention|control group|control group
89562154|NCT05421689|Experimental|Experimental: 150 x 10⁶ AMDC-GIR dosage|31 subjects will be receiving two doses of 150 x 10⁶ AMDC-GIR spaced 4-6 weeks apart.
89562155|NCT05421689|Sham Comparator|Experimental: Identical Placebo composed of the same cryopreservation medium used for AMDC-GIR|31 subjects will be receiving two doses of identical placebo composed of the same cryopreservation medium used for AMDC-GIR. Doses will be spaced 4-6 weeks apart.
89562156|NCT05663333||DOCTA cohort|Patients > 50 years of age with suspected giant cell arteritis requiring temporal artery biopsy in the dermatology department
89562157|NCT04447469|Active Comparator|10 mg/kg (Cohort 1)|Non-mechanically ventilated participants administered mavrilimumab 10 mg/kg as a single IV infusion
89562158|NCT04447469|Active Comparator|6 mg/kg (Cohort 1)|Non-mechanically ventilated participants administered mavrilimumab 6 mg/kg as a single IV infusion
89562159|NCT04447469|Placebo Comparator|Placebo (Cohort 1)|Non-mechanically ventilated participants administered placebo as a single IV infusion
89562160|NCT04447469|Active Comparator|10 mg/kg (Cohort 2)|Mechanically ventilated participants administered mavrilimumab 10 mg/kg as a single IV infusion
89562161|NCT04447469|Active Comparator|6 mg/kg (Cohort 2)|Mechanically ventilated participants administered mavrilimumab 6 mg/kg as a single IV infusion
89562162|NCT04447469|Placebo Comparator|Placebo (Cohort 2)|Mechanically ventilated participants administered placebo as a single IV infusion
89562163|NCT04447235|Placebo Comparator|ARM A: Placebo|Patients will receive ivermectin-placebo single dose on the day of confirmed diagnosis of COVID-19, followed by losartan-placebo daily for 15 days.
89562164|NCT04447235|Experimental|ARM B: Ivermectin plus losartan|Patients will receive a single dose of 12mg of ivermectin on the day of the confirmed diagnosis of COVID-19, followed by losartan 50mg orally once daily for 15 consecutive days
89562165|NCT01680991|Experimental|CLL: 1000 mg Obinutuzumab|Participants with chronic lymphocytic leukemia (CLL) will receive 1000 milligrams (mg) obinutuzumab as an intravenous (IV) infusion, on Day 1 of each 21-day cycle for a maximum of 8 cycles. The first infusion on Cycle 1 Day 1 will be given over two days: Day 1 and Day 2. Additional doses of obinutuzumab will be administered on Cycle 1 Day 8 and Day 15.
89562166|NCT01680991|Experimental|DLBCL: 1000 mg Obinutuzumab|Participants with diffuse large B-cell lymphoma (DLBCL) will receive 1000 mg obinutuzumab as an IV infusion, on Day 1 of each 21-day cycle for a maximum of 8 cycles. Additional doses of obinutuzumab will be administered on Cycle 1 Day 8 and Day 15.
88967479|NCT00096733||Recipients|Liver transplant recipients (either living or deceased donor). This label may also refer to those who were evaluated for liver transplantation, but never received a transplant, i.e., potential recipients.
89210608|NCT00927732|Placebo Comparator|capsules of sugar|As it is a cross-over study, patient will taken treatment 1 for 18 months (ex: hydroquinidine) and then treatment 2 (placebo in this case) for 18 months.
89562167|NCT01680991|Experimental|FL: 1000 mg Obinutuzumab|Participants with follicular lymphoma (FL) will receive 1000 mg obinutuzumab as an IV infusion, on Day 1 of each 21-day cycle for a maximum of 8 cycles. Additional doses of obinutuzumab will be administered on Cycle 1 Day 8 and Day 15.
89562168|NCT01700569|Experimental|Folinic Acid|"Folinic acid is given orally every day during the radiation therapy (47 days), then 5 days at each of the 6 maintenance cycle of temozolomide. The dose is escalated in a 3x3 method and the levels are: 5mg, 10mg, 15mg, 30mg, 60mg."
89562169|NCT04442867|Experimental|Intervention group|Subjects will receive nurse-led case management supported by a social service team.The nurse, functioning as a case manager, is involved in the initial assessment of the participant using the Omaha system. After the initial assessment, the NCM will equip participants with the skills required to perform self-care in health maintenance, including self-monitoring of vital signs, medication adherence, and sources of help if needed.
89562170|NCT04442867|Other|Control group|Participants in the control group will receive a monthly social control call from a trained research assistant
89562171|NCT05090761|Active Comparator|SAPB|40 Patients - Patients will receive 30 mL of 0.25% bupivacaine injected below the serratus anterior muscle in the caudal direction using ultrasound guidance.
89562172|NCT05090761|Active Comparator|SAPB with Mg|40 Patients - Patients will receive 30 mL of 0.25% bupivacaine with 150 mg of Mg injected below the serratus anterior muscle in the caudal direction using ultrasound guidance.
89562173|NCT05090761|Active Comparator|SAPB with Mg and Buprenorphine|40 Patients - Patients will receive 30 mL of 0.25% bupivacaine with 150 mg of Mg and 300 mcg of buprenorphine injected below the serratus anterior muscle in the caudal direction using ultrasound guidance.
89562174|NCT05084443|Placebo Comparator|Placebo/Control|Placebo drink-- Orally (200 ml/day)
89562175|NCT05084443|Experimental|Roselle Based drink (Test)|Roselle-Based Drink--- Orally (200 ml/day)
89562176|NCT03064529|Experimental|Accelerometer Participants|All participants receive an accelerometer to wear around their wrist to measure physical activity continuously beginning 1 week before surgery (when the accelerometer is put on the wrist) and ending 2 weeks after surgery (when the accelerometer is removed from the wrist).
89562177|NCT05608109|Experimental|Alcohol personalized normative feedback (APNF)|"Participants will receive feedback about their consumption, what they think the average student at their university drinks, and actual drinking statistics at their university.~Participants in this condition will participate in a baseline survey and afterwards will receive the feedback intervention. They will then complete follow-up surveys at 3-months and 6-months."
89562178|NCT05608109|Experimental|Social media personalized normative feedback (SMPNF)|"Participants will receive feedback about their consumption and alcohol related consumption posts, what they think the average student at their university drinks, and actual drinking statistics at their university.~Participants in this condition will participate in a baseline survey and afterwards will receive the feedback intervention. They will then complete follow-up surveys at 3-months and 6-months."
89562179|NCT05608109|Experimental|Alcohol and social media personalized normative feedback (APNF + SMPNF)|"Participants will go through the alcohol personalized normative feedback process and the social media personalized normative feedback.~Participants in this condition will participate in a baseline survey and afterwards will receive the feedback intervention. They will then complete follow-up surveys at 3-months and 6-months."
89562180|NCT05608109|No Intervention|Attention control|"Participants will receive feedback about their consumption of desserts, what they think their peers consume, and actual dessert consumption statistics are for individuals in their age group in the United States.~Participants in this condition will participate in a baseline survey/feedback intervention. They will then complete follow-up surveys and feedback interventions at 3-months and 6-months."
89562181|NCT04139057|Experimental|EBV TCR-T|EBV-specific TCR-T cell with anti-PD1 auto-secreted element
89562182|NCT04127903|Experimental|the Length of Right Main Stem Bronchus >=15mm|
88967480|NCT00096850|Experimental|1|From Days 1 to 8, participants will receive 600 mg RIF every 24 hours. From Days 9 to 19, participants will receive 300 mg ATV and 100 mg RTV every 12 hours and 600 mg RIF every 24 hours. From Days 20 to 27, participants will receive 400 mg ATV and 100 mg RTV every 12 hours and 600 mg RIF every 24 hours.
88967481|NCT04310709|Experimental|REGONIVO|"Nivolumab - 480 mg IV on Day 1, every 4 weeks~Regorafenib~- 80 mg per oral once daily for 21 consecutive days starting on Day 1, every 4 weeks."
88967482|NCT00390312|Active Comparator|4|Intravenous morphine
88967483|NCT00390312|Experimental|1|Intranasal morphine 7.5 mg
88967484|NCT00390312|Experimental|2|Intranasal morphine 15 mg
88967485|NCT00390312|Active Comparator|3|Oral morphine 60 mg
88967486|NCT00390312|Placebo Comparator|5|Intranasal placebo
88967487|NCT00390312|Placebo Comparator|6|Oral placebo
88967488|NCT00390312|Placebo Comparator|7|Intravenous placebo
88967489|NCT00400387|Other|Multivitamin supplement|
88967490|NCT00400387|Experimental|Multivitamin supplement + dalteparin sodium|
88967491|NCT00400465|Active Comparator|Control group|Pressure dressing
88967492|NCT00400465|Experimental|Experimental group|Normal dressing
88967493|NCT00097747|Placebo Comparator|Placebo|Single injection administered intravenously
88967494|NCT00097747|Experimental|Peginesatide 0.025 mg/kg|Single peginesatide dose of 0.025 milligram per kilogram (mg/kg) administered intravenously.
88967495|NCT00097747|Experimental|Peginesatide 0.05 mg/kg|Single peginesatide dose of 0.05 mg/kg administered intravenously.
88967496|NCT00097747|Experimental|Peginesatide 0.10 mg/kg|Single peginesatide dose of 0.10 mg/kg administered intravenously.
88967497|NCT00097903|Experimental|1|Karenitecin IV/ Karenitecin tablet
88967498|NCT00006341|Experimental|Implant|A total of 62 patients with early oral cancer will be recruited; in addition, 22 patients requiring a partial maxillectomy and 40 requiring a partial lateral mandibulectomy will be enrolled. The mandibular defects will be reconstructed with fibula free flap surgery. Following a healing period, implants will be placed and permitted to heal unloaded for six months. Conventional dental prostheses will be fabricated and used by patients for at least 16 weeks during Phase I healing before the implants are exposed and loaded. A few weeks after Phase II surgery, the patients will receive implant-supported dental prostheses.
88967499|NCT04294836|Experimental|Curcumin|Chemotherapy (cisplatin) plus concomitant radiation therapy (teletherapy + high or low rate brachytherapy) + Curcugreen (BCM95) 2000mg daily (each 6h)
88967500|NCT04294836|Placebo Comparator|Placebo|Chemotherapy (cisplatin) plus concomitant radiation therapy (teletherapy + high or low rate brachytherapy) + Placebo Capsules 500mg 2000mg daily (each 6h)
88967501|NCT00098137|Experimental|Olmesartan|Olmesartan tablet, 1 in the morning
88967502|NCT00098137|Placebo Comparator|Placebo|Placebo tablets, 1 in the morning
88967503|NCT04294680|Experimental|Opiate Sparing|Cryotherapy one hour daily four times per day for two weeks postoperative Acetaminophen 1000 milligrams every six hours by mouth for fourteen days postoperative Gabapentin 100 milligrams three times per day by mouth for thirty days postoperative Celecoxib 100 milligrams two times per day by mouth for thirty days postoperative Esomeproazole 20 milligrams daily by mouth for thirty days postoperative Ondansetron 4 milligrams every eight hours by mouth as needed for nausea and/or vomiting for fourteen days postoperative Oxycodone 5 milligrams every six hours by mouth as needed for uncontrolled pain for fourteen days postoperative
89210609|NCT04423575|Experimental|Outpatients|Health care pathway: patient education, communication to liberal nurses, first-position surgical planning, bariatric surgery (bypass or sleeve) as outpatient procedure, follow-up by home nurse twice-a-day, standardized communication to surgeons, management of possible complications
89562183|NCT04127903|Experimental|the Length of Right Main Stem Bronchus <15mm|
89562184|NCT03065309|Experimental|Single Arm|Patients will receive bolus dose of remifentanil before intubation
89562185|NCT02819479|Experimental|Low-dose Intra-arterial Bevacizumab|A single intra-arterial targeted dose of 2.5 mg/kg bevacizumab will be administered after osmotic blood-brain-barrier disruption with intra-arterial 25% mannitol at rate of 4-12 ml/sec for 30 seconds.
89027260|NCT00482105|Other|A|"This research study proposes to use a non-invasive method to capture superficial cells on pigmented skin lesions that are suspected of being early melanomas. This non-invasive biopsy technology has been developed and patented by DermTech International. RNA in skin cells captured by this method will be profiled in order to diagnose the nature of the lesion (i.e. malignant melanoma or not). A successful outcome of this proposal would create a candidate non-invasive diagnostic assay based on a gene expression profile for identifying early stage melanomas"
89027261|NCT04519242|Active Comparator|Patients enrolled in the ORIF group|Open reduction and internal fixation (ORIF), ORIF will be done by using bridge plate (variable angle locking plate and/or locking plate and/or dynamic compression plate - 3.5mm, 2.7mm or 2.4mm) and/or transarticular screw osteosynthesis (4.0mm cannulated screws and/or solid small fragment screws and/or HCS). For fixation, TMT4 and/or TMT5 K-wires (1.6 or 2.0mm) can be used instead.
89027262|NCT04519242|Active Comparator|Patients enrolled in the PA group|PA will be done by removal of the articular surface and subsequent stabilization with bridge plate (variable angle locking plate and/or locking plate and/or dynamic compression plate - 3.5mm, 2.7mm or 2.4mm) and/or transarticular screw osteosynthesis (4.0mm cannulated screws and/or solid small fragment screws and/or HCS).
89027263|NCT00482144|Active Comparator|Treatment: PDL 450 microseconds|The scar will be randomly divided into three equal fields. One third of the scar will receive PDL using a 7 mm spot size at 4.0 J (Joules) for 450 microseconds. First treatment will be immediately after suture removal, and then monthly for 3 months.
89027264|NCT00482144|Active Comparator|Treatment: PDL 1.5 milliseconds|The scar will be randomly divided into three equal fields. One third of the scar will receive PDL using a 7 mm spot size at 4.0 J (Joules) for 1.5 milliseconds. First treatment will be immediately after suture removal, and then monthly for 3 months.
89027265|NCT00482144|No Intervention|Control|The scar will be randomly divided into three equal fields. One third of the scar will not receive treatment
89027266|NCT04519359|Experimental|Stop Arm|Stop NAs therapy
89562186|NCT05095285|No Intervention|The control group|• In addition to incubator cover and nesting, no other non-pharmacological intervention was applied to the control group.
89562187|NCT05095285|Experimental|The swaddling group|•Babies in this group were wrapped with a white cheesecloth 2 minutes before ES in addition to incubator cover and nesting.
89562188|NCT05095285|Experimental|The oropharyngeal colostrum group|• In addition to incubator cover and nesting, babies in this group were given 0.4 ml of colostrum with an insulin injector on the inside of the cheeks and on the tongue.
89562189|NCT04081025||Adults|Age Groups 35, 50, 65, 75 and 85
89562190|NCT05376943||Patients diagnosed with HCC after receiving direct acting antiviral HCV treatment|In this group there will be patients with the diagnosis of hepatocellular carcinoma, who underwent direct acting antiviral treatment. We will collect both epidemiological (age, gender, comorbidities, alcohol abuse) and clinical data (serum bilirubin, alanine, aspartate aminotransferase, gammaglutamyltransferase, alkaline phosphatase and alpha-fetoprotein level, Child-Pugh and MELD score, imaging tests, liver biopsy and elastography, if performed). The HCV infection and co-infections will be assessed and also the composition of therapy and the response to treatment will be evaluated.
89562191|NCT05376943||Patients diagnosed with HCC who were not receiving direct acting antiviral HCV treatment|In this group there will be patients with the diagnosis of hepatocellular carcinoma, who were not receiving direct acting antiviral treatment. We will collect both epidemiological (age, gender, comorbidities, alcohol abuse) and clinical data (serum bilirubin, alanine, aspartate aminotransferase, gammaglutamyltransferase, alkaline phosphatase and alpha-fetoprotein level, Child-Pugh and MELD score, imaging tests, liver biopsy and elastography, if performed). The HCV infection and co-infections will also be assessed.
89562192|NCT04074785|Experimental|Safety Run-In|Abemaciclib 150 mg po bid PLUS Bevacizumab 10 mg/kg IV every 2 weeks, then continue treatments for 2 cycles
89027267|NCT04519359|No Intervention|Continue Arm|Continue NAs therapy
89027268|NCT04518774|Experimental|Allogeneic γδT cell immunotherapy|Patients will receive 3 cycles of ex-vivo expanded allogeneic γδT cells treatments, at four-weeks' intervals, each cycle has 2 infusions. Ex-vivo expanded γδT cells are transfused to patients in a dosage escalated manner (Dose escalation, 1×107, 3×107, 9×107 per kg of body weight).
89027269|NCT01312909|Experimental|Varenicline 1mg BID|Oral Varenicline 1mg BID, or 1/2 that dose (0.5mg BID) for those subjects that weigh less than or equal to 55kg at baseline, for twelve weeks, follow-up through Week 52
89027270|NCT01312909|Experimental|Varenicline 0.5mg BID|Oral Varenicline 0.5mg BID, or 1/2 that dose (0.5 QD) for those subjects that weigh less than or equal to 55kg at baseline, for twelve weeks, follow-up through Week 52
89027271|NCT01312909|Placebo Comparator|Placebo|Oral placebo for twelve weeks,follow-up through Week 52
89027272|NCT00482222|Active Comparator|OxMdG / IrMdG chemotherapy|OxMdG / IrMdG chemotherapy for 12 weeks Followed by surgery OxMdG / IrMdG chemotherapy for 12 weeks
89027273|NCT00482222|Experimental|OxMdG / IrMdG chemotherapy with cetuximab|OxMdG / IrMdG chemotherapy with cetuximab for 12 weeks Followed by Surgery OxMdG / IrMdG chemotherapy with cetuximab for 12 weeks
89562193|NCT04074785|Experimental|Abemaciclib with Bevacizumab|Abemaciclib 100 mg po bid PLUS Bevacizumab 10 mg/kg IV every 2 weeks, then continue treatments for 2 cycles
89562194|NCT04533841|Active Comparator|Misoprostol + propranolol|Patient who receive misoprostol then after 30minutes receive propranolol
89562195|NCT04533841|Placebo Comparator|Misoprostol + placebo|Pt who will receive misoprostol then after 30minutes receive placebo
89562196|NCT04537663|Experimental|Bacille Calmette-Guérin (BCG)|Intradermal injection of BCG-Vaccine SSI [Statens Serum Institut]) - Danish strain 1331.
89562197|NCT04537663|Placebo Comparator|Placebo|Intradermal injection of sterile 0.9% NaCl.
89562198|NCT05376865|Experimental|Intervention|Vitamin D3 supplement every week
89562199|NCT05376865|Placebo Comparator|Control|Placebo every week
89562200|NCT04064411|Active Comparator|abaloparatide-SC|Participants self-administered daily doses of abaloparatide 80 mcg SC for 12 months using a single-participant, multiple-use, prefilled injection pen that delivers 30 doses. Participants received a new injection pen every 30 days.
89562201|NCT04064411|Experimental|abaloparatide-sMTS|Abaloparatide-sMTS 300 mcg applied to the thigh for 5 minutes once daily for 12 months.
89562202|NCT05086159|Active Comparator|Traditional Education|"Traditional biomedical education for back pain and standard stress education. Education was developed from Back School, National PTSD Center, and PTSD Coach."
89562203|NCT05086159|Experimental|Pain Neuroscience Education|Pain neuroscience education (PNE) was developed for this research comparing pain and stress symptoms to a radar that can become hypervigilant to threat.
89562204|NCT03064685||Group I - Cases|Patients older than 18 years of age with a history of liver transplantation since January 2002 for any cause and who have undergone medical follow-up at HIBA and had at least one event of pyogenic liver abscess after transplantation.
89562205|NCT03064685||Group II - Controls|Patients older than 18 years with a history of liver transplantation since January 2002 for any cause and who have performed their medical follow-up at HIBA without developing any event of pyogenic liver abscess after transplantation
89562206|NCT03064997|Active Comparator|Prebiotic Synergy 1-supplemented GFD|The application of a prebiotic Synergy 1 together with a strict gluten-free diet
89562207|NCT03064997|Placebo Comparator|Placebo-supplemented GFD|The application of a placebo together with a strict gluten-free diet
89562208|NCT05083663|Experimental|Group I|received bupivacaine 0.375 % 15 mL + normal saline 4ml +hyaluronidase 800 IU in 1 ml.
89562209|NCT05083663|No Intervention|Group II|received bupivacaine 0.375% 15 mL + normal saline5 ml.
89562210|NCT05082415||Brolucizumab|Participants received brolucizumab injection during the index period
89562211|NCT05050825|Experimental|CDSA strategy|Children and adolescents presenting with non-severe acute febrile illness or diarrhea managed by healthcare workers trained on the CDSA strategy
89562212|NCT05050825|No Intervention|Routine practice|Children and adolescents presenting with non-severe acute febrile illness or diarrhea managed by healthcare workers according to routine practice at the health facility
89562213|NCT04012931|Experimental|Rilpivirine (RPV) (25 mg or adjusted weight-based dose)|Participants will receive rilpivirine (RPV 25 milligram [mg], adjusted weight-based dose) orally once daily in combination with an investigator selected background regimen (that is investigator-selected antiretrovirals [ARVs] such as nucleoside/nucleotide reverse transcriptase inhibitor [N{t}RTIs] and integrase inhibitors) for 48 weeks.
88967504|NCT04294680|No Intervention|Opiate Based|Oxycodone 5 to 10 milligrams every four to six hours by mouth as needed for pain for fourteen days postoperative Acetaminophen 1000 milligrams every six hours by mouth for fourteen days postoperative Gabapentin 100 milligrams three times per day by mouth for thirty days postoperative Celecoxib 100 milligrams two times per day by mouth for thirty days postoperative Esomeprazole 20 milligrams daily by mouth for thirty days postoperative Ondansetron 4 milligrams every eight hours by mouth as needed for nausea and/or vomiting for fourteen days postoperative
89562214|NCT05331287|Experimental|snifing Position|Nasotracheal intubation via fiberoptic bronchoscope under snifing position.The snifing position was obtained by placement of a 7-cm cushion under the head of the patient. When the FOB was inserted into Nasal cavity, and the epiglottis and glottis were identified by the FOB. The anterior of FOB was inserted deep into tracheal after the glottis was exposed sufficiently then the tracheal tube was pushed into the trachea via the FOB.
89562215|NCT05331287|Experimental|neutral position|Nasotracheal intubation via fiberoptic bronchoscope under snifing position.The Head Extension was obtained by the occiput of the patient close to the operating table. When the FOB was inserted into Nasal cavity, and the epiglottis and glottis were identified by the FOB. The anterior of FOB was inserted deep into tracheal after the glottis was exposed sufficiently then the tracheal tube was pushed into the trachea via the FOB.
89562216|NCT05331287|Experimental|Head Extension|Nasotracheal intubation via fiberoptic bronchoscope under snifing position.The extension position with a 7-cm pillow underneath the shoulder and the occiput close to the operating table. When the FOB was inserted into Nasal cavity, and the epiglottis and glottis were identified by the FOB. The anterior of FOB was inserted deep into tracheal after the glottis was exposed sufficiently then the tracheal tube was pushed into the trachea via the FOB.
88967505|NCT02958358|Experimental|Pulmonary Hypertension|Patients with Group I pulmonary arterial hypertension to undergo CT imaging, functional PET imaging before and after 3 months of treatment with ambrisentan
88967506|NCT00098488|Experimental|Treatment (17-AGG and rituximab)|Patients receive 17-AAG IV over 2 hours on days 1, 4, 8, 11, 15 and 18 (course 1). Patients achieving ≥ 25% reduction in measurable disease after course 1 receive an additional course of single-agent 17-AAG approximately 10 days later in the absence of disease progression or unacceptable toxicity and provided absolute lymphocyte count continues to decrease. Patients failing to achieve a 25% reduction in measurable disease after course 1 OR with disease progression after courses 1 or 2 of single-agent 17-AAG proceed to combination therapy comprising 17-AAG IV over 2 hours on days 1, 4, 8, 11, 15, 18, and 22; and rituximab IV over 4 hours on days 1 and 2 and over 1 hour on days 4, 8, 15, and 22 in the absence of disease progression or unacceptable toxicity.
88967507|NCT00098527|Experimental|Treatment (romidepsin)|Patients receive FR901228 (depsipeptide) IV over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89027274|NCT01312129|Experimental|Sulfasalazine|Sulfasalazine 1500 mg
89562217|NCT03063359|Experimental|Intranasal fentanyl + Oral placebo|Administration of intranasal fentanyl (1.5µg/kg) and oral placebo in children with acute pain in traumatic context on arrival in emergency pediatric department.
88967508|NCT00098605|Experimental|Treatment (lapatinib ditosylate)|Patients receive oral lapatinib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88967509|NCT04284345|Experimental|Saline Pd/Pa|Eligible subjects will undergo invasive coronary physiology measurements including whole cycle resting Pd/Pa, iFR, RFR, cFFR, Saline Pd/Pa and FFR
88967510|NCT04273464|Experimental|Brava-group|External tissue expanders will be used 3 weeks prior to operation and 2 weeks postoperatively in order to enhance the volume and survival of fat cells. We expect that each patient in the fat transplantation group will need 4-6 transplantation sessions of about 1.5 to 2 hours each to achieve satisfactory volume and shape of the breast.31 participants.
88967511|NCT04273464|Active Comparator|DIEP-group|26 participants. We expect 1-2 operative sessions of respectively 5-7 and 2-3 hours duration in the DIEP group. The risk of reoperation (second operation during the first postoperative week) in the DIEP group is 5-10 %
88967512|NCT03633305|Active Comparator|Treatment as usual|Hypnotics - Medication used 1 to 7 nights/week for 6 to 8 weeks
88967513|NCT03633305|Experimental|Online cognitive behavior therapy|Online CBT- Internet self-help program for insomnia with 6 cores
88967514|NCT03633305|Experimental|Treatment as usual + Online CBT|Hypnotics - Medication used 1 to 7 nights/week for 6 to 8 weeks Online CBT- Internet self-help program for insomnia with 6 cores
88967515|NCT03633305|Experimental|Medication|Hypnotics - Medication used 1 to 7 nights/week for 6 to 8 weeks (arms 1, 3, 4)
88967516|NCT03633305|Experimental|In-person cognitive behavior therapy|Face-to-face CBT- Face-to-face therapy with 3 to 4 individual sessions in a period of 6 to 8 weeks.
88967517|NCT03633305|No Intervention|No additional treatment|
88967518|NCT02907372|Other|cognitive tests|
88967519|NCT04728763||Cases|"Patients for whom bronchial endoscopy with BAL is performed as part of an exploration of invasive pulmonary aspergillosis (IPA) or Chronic pulmonary aspergillosis (CPA) in current care :~Probable or proven invasive pulmonary aspergillosis according to the criteria of the EORTC (2019) or~Chronic pulmonary aspergillosis according to the criteria of ESCMID / ERS (2016)"
88967520|NCT04728763||Control Group|Patients for whom bronchial endoscopy with BAL is performed as part of an exploration of diffuse interstitial lung disease or a lower respiratory infection other than Aspergillus in routine care
88967521|NCT04728568|Experimental|Sintilimab|Sintilimab will be administered every 3 weeks Sintilimab will be administered through IV infusion
88967522|NCT04728529|Experimental|USSM protocol|patient in the intervention group receive fluid resuscitation and inotropic-vasoactive agent, if needed, in accordance to USSM protocol of fluid resuscitation.
88967523|NCT04728529|Experimental|ACCM protocol|patient in the control group receive fluid resuscitation and inotropic-vasoactive agent, if needed, in accordance to ACCM protocol of fluid resuscitation.
88967524|NCT04253730|No Intervention|Control Condition|Subjects will sit at rest wearing a liquid perfused suit containing thermoneutral water for 60 min. The suit will not be turned on during this period.
88967525|NCT04253730|Experimental|Cold Condition|Subjects will be cooled for 60-90 min at ~ 4-10°C using a liquid perfused suit. Subjects will then be rewarmed for 30 min at ~ 41°C using the liquid perfused suit.
88967526|NCT00099502|Experimental|Arm 1|
88967527|NCT00099502|Experimental|Arm 2|
88967528|NCT00099502|Active Comparator|Arm 3|
88967529|NCT00387920|Experimental|Treatment (enzyme inhibitor therapy)|"PART A: Patients receive oral sunitinib malate once daily on days 1-28 days. Treatment repeats every 42 days for up to 18 courses in the absence of disease progression or unacceptable toxicity.~PART B: Patients receive sunitinib malate capsule contents sprinkled over applesauce or yogurt once daily on days 1-28. Treatment repeats every 42 days for up to 18 courses in the absence of disease progression or unacceptable toxicity. After the first course, patients may switch to capsule formulation for convenience."
88967530|NCT00400660|Experimental|Subjects receiving treatment sequence 1: Part 1|Eligible subjects will receive placebo followed by GSK615915A with a starting dose of 250 micrograms.
88967531|NCT00400660|Experimental|Subjects receiving treatment sequence 2: Part 1|Eligible subjects will receive GSK615915A with a starting dose of 250 micrograms followed by placebo.
88967532|NCT00400660|Experimental|Subjects receiving treatment sequence 1: Part 2|Eligible subjects will receive placebo followed by GSK615915A with a starting dose of 250 micrograms.
88967533|NCT00400660|Experimental|Subjects receiving treatment sequence 2: Part 2|Eligible subjects will receive GSK615915A with a starting dose of 250 micrograms followed by placebo.
88967534|NCT00400660|Experimental|Subjects receiving GSK615915A: Part 3|Eligible subjects will receive GSK615915A with a starting dose of 250 micrograms.
88967535|NCT00400660|Experimental|Subjects receiving placebo: Part 3|Eligible subjects will receive placebo.
88967536|NCT00400699|Other|REview|
88967537|NCT00400738|Experimental|1|different dose per arm
88967538|NCT00400738|Experimental|2|different dose per arm
88967539|NCT00400738|Experimental|3|different dose per arm
88967540|NCT00400738|Experimental|4|different dose per arm
88967541|NCT00099580|Experimental|1|
88967542|NCT00099580|Placebo Comparator|2|
88967543|NCT00099619|Experimental|exenatide/insulin glargine|Arm that first receives exenatide, then crosses over to insulin glargine
88967544|NCT00099619|Experimental|Insulin glargine/exenatide|Arm that first receives insulin glargine, then crosses over to exenatide
88967545|NCT00099658|Experimental|1|HIV-uninfected infants born to HIV-uninfected mothers
88967546|NCT00099658|Experimental|2|HIV-infected infants in CDC Disease Category 1 who were randomly assigned to the delayed therapy arm (Arm 1) of CIPRA SA-Project 2
88967547|NCT00099658|Experimental|3|HIV-infected infants in CDC Disease Category 1 who were randomly assigned to the first early therapy arm (Arm 2) of CIPRA SA-Project 2
88967548|NCT00099658|Experimental|4|HIV-infected infants in CDC Disease Category 2 or 3 who were randomly assigned to the second early therapy arm (Arm 3) of CIPRA SA-Project 2
88967549|NCT00099658|Experimental|5|HIV-uninfected infants born to HIV infected mothers
88967550|NCT00006359|Experimental|Androgen suppression + EBRT + Brachytherapy|Androgen suppression with external beam radiation therapy followed by brachytherapy boost
89562218|NCT03063359|Active Comparator|Oral morphine + Intranasal placebo|Administration of oral morphine (0.4mg/kg) and intranasal placebo in children with acute pain in traumatic context on arrival in emergency pediatric department.
89210610|NCT04423575|No Intervention|Inpatients|Standard care pathway with bariatric surgery (bypass or sleeve) as inpatient procedure (at least one night in the hospital)
89210611|NCT00227539|Experimental|Neoadjuvant therapy, PET scan and surgery|
89562219|NCT02629133|Experimental|SHE Program|"Participants received a 50 minute intervention on the computer immediately after their baseline assessment and a 15 minute booster session on the computer within 2 weeks after the intervention. There was also a 3 and 6 month follow-up after completion of the SHE program."
89562220|NCT02629133|No Intervention|Control Condition|Control condition consisted of a series of questions regarding television show preferences and viewing a brief series of videos of popular entertainers/shows, with subsequent requests for rating of subjective preference. Participants in this condition completed a baseline assessment as well as a television show booster and a follow-up assessment 3 and 6 months later.
89562221|NCT02660359|Experimental|600 U Dysport® Group|
89562222|NCT02660359|Placebo Comparator|600 U Dysport® Placebo Group|
89562223|NCT02660359|Experimental|800 U Dysport® Group|
89562224|NCT02660359|Placebo Comparator|800 U Dysport® Placebo Group|
88967551|NCT00099736|Experimental|FTY720 5 mg + reduced-dose Neoral (RDN) + corticosteroids,|
88967552|NCT00099736|Experimental|FTY720 2.5 mg + full dose Neoral (FDN) + corticosteroids|
88967553|NCT00099736|Experimental|MMF 2 g + full-dose Neoral (FDN) + corticosteroids|
88967554|NCT00006365|Experimental|EBRT to the prostate followed by brachytherapy|Patients received 45 Gy of external beam radiation therapy (EBRT)to the prostate followed (within 2 to 6 weeks) by permanent iodine (I-125) brachytherapy 108 Gy.
88967555|NCT00100477|Other|Arm 1|
88967556|NCT00006371|Active Comparator|Hydrocortisone with Ketoconazole|Patients are stratified according to prior antiandrogen therapy (yes vs no). Patients with prior antiandrogen therapy begin study therapy after appropriate antiandrogen withdrawal, while those without such prior therapy begin study therapy immediately. Patients undergo medical adrenalectomy using hydrocortisone combined with ketoconazole. Oral hydrocortisone is administered twice daily. Oral aminoglutethimide is administered twice daily for 1 week and then 4 times daily during subsequent weeks. Oral ketoconazole is administered three times daily.
88967557|NCT00006371|Active Comparator|Hydrocortisone with Aminoglutethimide|Patients are stratified according to prior antiandrogen therapy (yes vs no). Patients with prior antiandrogen therapy begin study therapy after appropriate antiandrogen withdrawal, while those without such prior therapy begin study therapy immediately. Patients undergo medical adrenalectomy using hydrocortisone combined with aminoglutethimide. Oral hydrocortisone is administered twice daily. Oral aminoglutethimide is administered twice daily for 1 week and then 4 times daily during subsequent weeks. Oral ketoconazole is administered three times daily.
88967558|NCT04728685|Active Comparator|Group A|One-fifth of body weight traction force will be given
88967559|NCT04728685|Active Comparator|Group B|One-third of body weight traction force will be given
88967560|NCT04728685|Active Comparator|Group C|One-half of body weight traction force will be given
88967561|NCT04728490|Experimental|Allogenic transplantation using treosulfan in conditioning regimen|"Haplo-identical transplantation using treosulfan in conditioning regimen Treosuflan, in the conditioning regimen will be administrated as followed 10 gr/m2 per day -4, -3 and -2 IV route~In combination with:~Thiotepa 5 mg/kg on day -6 Fludarabine 30 mg/m2 per day from day -5 to day -1"
88967562|NCT02958592||study group|patients with liver tumor intend to perform hepatectomy
88967563|NCT00100750|Experimental|Treatment (gemcitabine hydrochloride, tipifarnib)|Patients receive tipifarnib PO BID on days 1-14 and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89562225|NCT03063281||SLE patient|165 SLE patients. Subgroup : 77 with active lupus and 88 in disease remission. in the active subgroup : 36 with lupus nephritis and 41 without. Biological analysis were performed.
89562226|NCT03063281||healthy patients|48 healthy patients. Biological analysis were performed.
89562227|NCT05287373|Active Comparator|PNS Therapy plus Conventional Medical Management|peripheral nerve stimulator plus conventional medical management
89562228|NCT05287373|Other|Conventional Medical Management|Control arm conventional medical management only
89562229|NCT04757311||Metastatic Colorectal Cancer Patients|All RAS wild type metastatic colorectal cancer patients
89562230|NCT03065153||Healthy|Healthy individuals without any neurological or orthopaedic disorder that could influence motor performance and balance
89562231|NCT03065153||Stroke|Individuals suffered from a haemorrhagic or ischaemic stroke. Diagnosis has to be confirmed on the basis of CT or MRI imaging.
89562232|NCT04626505|Experimental|Ziltivekimab 15 mg|Participants will receive ziltivekimab 15 mg for 12 weeks.
89562233|NCT04626505|Experimental|Ziltivekimab 30 mg|Participants will receive ziltivekimab 30 mg for 12 weeks.
89562234|NCT04626505|Placebo Comparator|Placebo (ziltivekimab)|Participants will receive placebo (ziltivekimab) for 12 weeks.
89562235|NCT05276609|Experimental|HS-20093 (Phase Ia: Dose escalation)|There are seven escalating dose cohorts.
89562236|NCT05276609|Experimental|HS-20093 (Phase Ib: Dose expansion)|The recommended dose from the dose-escalation stage and other potential doses will be further explored.
89562237|NCT04909099||Knee Ostearthritis/ Low Bakc Pain|Patients referred for physical therapy rehabilitation
88967564|NCT01350102|Active Comparator|Bacitracin wound care dressing alone|Bacitracin wound care dressing alone
88967565|NCT01350102|Active Comparator|Bacitracin with Vit C|Bacitracin wound care dressing with Vitamin C supplementation
88967566|NCT01350102|Active Comparator|AmeriGel® wound care dressing alone|AmeriGel® wound care dressing alone
89027275|NCT01312129|Placebo Comparator|Placebo|Placebo capsule x 3 doses 12 hours apart
89562238|NCT05068297|Experimental|Germanium-Embedded Knee Brace|Following surgery the patients effected limb would be placed in an Germanium-Embedded Knee Brace
89027276|NCT04518852|Experimental|Treatment group|The participants will receive the combined treatment of local therapy (TACE, oxaliplatin and epirubicin), anti-angiogenic therapy (sorafenib), and immunotherapy (PD-1 monoclonal antibody)
89562239|NCT05068297|Active Comparator|Replica Knee Brace|Following surgery the patients effected limb would be placed in a replica knee brace
89562240|NCT05067985||SARS-CoV-2 pregnant women|After receiving approval from the local ethics committee and permission to use the hospital archives, we included records of spinal anesthesia performed on confirmed SARS- CoV-2 patients in the Ankara City Hospital between April 2020 and February 2021, as well as related data, in our study. Patients who did not have their data gathered, or whose operation took more than 3 hours due to any reason, were excluded from the study
89562241|NCT02672761|Experimental|MBSR|Subjects enrol and complete a standardized and licensed meditation program developed by Jon Kabat-Zinn. The program includes a weekly 200 min group session, daily meditation training from 20-40 min and one 4 h retreat within the study period. The individual daily and overall training volume is noted in min.
89562242|NCT02672761|Experimental|MBT|Subjects while being on the waiting list for MBSR are allocated to a web-based training program (MBT- My Brain Training) for working, episodic and general memory functions. The individual daily and overall training volume is noted in min.
89562243|NCT02672761|Active Comparator|Wellness|Subjects while being on the waiting list for MBSR are allocated to a free accessable wellness program including sessions in a computerized chair delivering Shiatzu massage and relaxation music. The individual daily and overall training volume is noted in min.
89562244|NCT02672761|Placebo Comparator|Control|Subjects while being on the waiting list for MBSR are requested to do no special program for stress reduction or memory improvement. The individual daily and overall training volume of sports or recreational activity is noted in min.
89562245|NCT04449913|Experimental|Active group|10 days intensive meditation retreat
89562246|NCT04449913|Other|Control group|Waiting for a 10 days intensive meditation retreat
89562247|NCT04437901||COVID-19 patients|Patients admitted at one of the participating centres with highly suspected/confirmed infection with SARS-CoV-2.
89562248|NCT04262869|Experimental|Arm I (squamous NSCLC)|Patients receive carboplatin IV over 15-60 minutes, paclitaxel IV over 3 hours and durvalumab IV over 1 hour on day 1. Treatment repeats every 3 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients who do not progress receive durvalumab IV every 4 weeks for up to 35 cycles in the absence of disease progression or unacceptable toxicity.
89562249|NCT04262869|Experimental|Arm II (non-squamous NSCLC)|Patients receive carboplatin IV over 15-60 minutes, pemetrexed IV over 10 minutes and durvalumab IV over 1 hour on day 1. Treatment repeats every 3 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients who do not progress receive durvalumab IV and pemetrexed IV every 3 weeks for up to 35 cycles in the absence of disease progression or unacceptable toxicity.
89562250|NCT02628743|Experimental|Olesoxime|"Participants who have consented to the dose increase will receive 10 milligrams per kilogram (mg/kg) suspension twice a day (BID) either orally or via a naso-gastric or gastrostomy tube with breakfast and dinner, preferably at the same time of the day throughout the study. If the drug administration does not coincide with one of the scheduled meals, a snack should be taken prior to drug administration. Preferably there should be at least 10 hours between the morning and evening dose. The total dose in this study will not exceed 2000 mg.~Participants who do not consent to the dose increase will continue with the previous dosage and receive a dose of 10 mg/kg suspension once a day orally or via a naso-gastric or gastronomy tube with the main meal, preferably at the same time of the day."
89562251|NCT04682821|Experimental|with Artificial intelligence assistant system|The experiment group would receive the training with the help of artificial intelligence assistant system in addition to the common training. The system is an non-invasive AI system which could help the endoscopists to diagnosis and monitor the blind spot during the gastroscope.
89562252|NCT04682821|No Intervention|without Artificial intelligence assistant system|The control group would receive the training without the help of artificial intelligence assistant system. That is, they would receive the common training process.
89562253|NCT03062813|Experimental|Tacrolimus & entecavir|Tacrolimus capsule, 0.5mg/capsule,1.0mg/capsule, 0.05-0.1mg/kg.d by mouth , every 12 hours for a day.Entecavir 0.5mg tablet by mouth every night.
89027277|NCT02955615|Experimental|ILT-101|Subcutaneous administrations for 3 to 6 months according to clinical responder status at week 12
89027278|NCT02955615|Placebo Comparator|Placebo|Subcutaneous administrations for 3 to 6 months according to clinical responder status at week 12
89210612|NCT00816530||Asymptomatic Women who have Dense Breast Tissue|Women who have no signs or symptoms of breast cancer who have > 50% parenchymal density on mammography.
89562254|NCT03062813|Active Comparator|placebo & entecavir|Tacrolimus capsule, 0.5mg/capsule,1.0mg/capsule, 0.05-0.1mg/kg.d by mouth , every 12 hours for a day.Entecavir 0.5mg tablet by mouth every night.
89562255|NCT05088577|Experimental|Whole egg|Two whole eggs (50g each) to be eaten daily during 8 weeks
89562256|NCT05088577|Experimental|Annatto-enriched egg|Two whole eggs (50g each) enriched with annatto (Bixa orellana L.) to be eaten daily during 8 weeks. Dose of annatto: 1,2 mg bixin/kg of body weight.
88967567|NCT01350102|Active Comparator|AmeriGel® with Vit C|AmeriGel® wound care dressing with Vitamin C supplementation
89562257|NCT05088577|Placebo Comparator|Egg whites - Control|Two egg whites to be eaten daily during 8 weeks
88967568|NCT00100906|Active Comparator|ATRA Followed by IL-2 - Dose Level A|"Patients were assigned to one of three ATRA dose levels, at a 1:1:1 ratio, using a randomly permuted list assignments, with the assignment generally being made on the initial day of treatment.~Week 1: One dose daily of IL-2 for 5 days followed by 2 days off.~Weeks 2-6: One dose daily of IL-2 for 5 days followed by 2 days off.~After the IL-2: 2-3 weeks rest, with no treatment. During this time a repeat physical exam, history and X-ray scans will be performed. If there has not been progression (worsening) of the patient's tumor, they will continue to a second 8-week treatment schedule.~This schedule will be the same as the first, unless the patients dose had to be reduced. If so, patient's will get that reduced dose. It consists of 1 week of ATRA, 1 week of rest, followed by 6 weeks of IL-2. The same blood tests are collected during that second cycle."
89210613|NCT05706519||Control Group|Six hundred volunteers. This group has to be without any type of cardiovascular Disease.
89562258|NCT04942327|Other|Interview|This will be evaluated through a specific questionnaire that will be systematically gone over with the participants during an interview in the first and third phases.
89562259|NCT04601311|Experimental|Guided self-determination|3 to 5 one-hour digital or analogue guided self-determination sessions
89562260|NCT04601311|Active Comparator|Personal support in goal-pursuing|Up to five personal goal pursuing support sessions
89562261|NCT04582981|Experimental|Arm A|Combination treatment of Fruquintinib and Raltitrexed
89562262|NCT04582981|Experimental|Arm B|Monotherapy of Fruquintinib
89562263|NCT03760627|Experimental|Refugees Mindfulness Resiliency Training|The Collateral Repair Project (CRP) will conduct a Mindfulness Resiliency Training Program (MRTP) for refugees residing in Amman, Jordan. A small support group will demonstrate to participants techniques that they can use to self-manage their own stress and trauma.
89562264|NCT03760627|Placebo Comparator|Control arm|The control group will receive the training after the study group at 2 months and the control group will then become the study group for the new session. A new group of 20 participants will be recruited who will act as a control for that session. The surveys from the control group will be compared with the study group at 0 and 2 months. Each session will last for two months. The control group will receive the training at the end of the two months. This process will be repeated for a total of nine sessions over a total period of 12 months.
88967569|NCT00100906|Active Comparator|ATRA Followed by IL-2 - Dose Level B|"Patients were assigned to one of three ATRA dose levels, at a 1:1:1 ratio, using a randomly permuted list assignments, with the assignment generally being made on the initial day of treatment.~Week 1: One dose daily of IL-2 for 5 days followed by 2 days off.~Weeks 2-6: One dose daily of IL-2 for 5 days followed by 2 days off.~After the IL-2: 2-3 weeks rest, with no treatment. During this time a repeat physical exam, history and X-ray scans will be performed. If there has not been progression (worsening) of the patient's tumor, they will continue to a second 8-week treatment schedule.~This schedule will be the same as the first, unless the patients dose had to be reduced. If so, patient's will get that reduced dose. It consists of 1 week of ATRA, 1 week of rest, followed by 6 weeks of IL-2. The same blood tests are collected during that second cycle."
88967570|NCT00100906|Active Comparator|ATRA Followed by IL-2 - Level C|"Patients were assigned to one of three ATRA dose levels, at a 1:1:1 ratio, using a randomly permuted list assignments, with the assignment generally being made on the initial day of treatment.~Week 1: One dose daily of IL-2 for 5 days followed by 2 days off.~Weeks 2-6: One dose daily of IL-2 for 5 days followed by 2 days off.~After the IL-2: 2-3 weeks rest, with no treatment. During this time a repeat physical exam, history and X-ray scans will be performed. If there has not been progression (worsening) of the patient's tumor, they will continue to a second 8-week treatment schedule.~This schedule will be the same as the first, unless the patients dose had to be reduced. If so, patient's will get that reduced dose. It consists of 1 week of ATRA, 1 week of rest, followed by 6 weeks of IL-2. The same blood tests are collected during that second cycle."
88967571|NCT00100945|Experimental|gefitinib|"Patients receive oral gefitinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease recurrence or unacceptable toxicity.~Quality of life is assessed at baseline, 4 weeks, every 12 weeks during study treatment, and then at the end of study treatment.~Patients are followed every 3 months for up to 5 years."
88967572|NCT04059549|Active Comparator|A-CHESS Drinker|Patients randomized to the A-CHESS group will receive the A-CHESS app on a smartphone.
88967573|NCT04059549|Experimental|PartnerCHESS Drinker|Patients randomized to the PartnerCHESS group will receive all A-CHESS services listed above, plus learning modules and resources from Alcohol-based Couple Therapy.
88967574|NCT04059549|Active Comparator|A-CHESS Partner|Patient's partner randomized to the A-CHESS group will receive the A-CHESS app on a smartphone.
88967575|NCT04059549|Experimental|PartnerCHESS Partner|Patient's partner randomized to the PartnerCHESS group will receive all A-CHESS services listed above, plus learning modules and resources from Alcohol-based Couple Therapy.
88967576|NCT00006386|Experimental|External beam radiotherapy with stereotactic boost|External beam radiotherapy (EBXRT): 50 Gy in 25 daily fractions of 2 Gy. Stereotactic radiotherapy (SRT) boost: 4 treatments of 5 or 7 Gy, once per week during weeks 3-6. Patients will not receive EBXRT on the SRT treatment days.
88967577|NCT00101179|Experimental|Arm I|"Patients receive azacitidine subcutaneously on days 1-10 and oral MS-275 on days 3 and 10. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses* of MS-275 until the maximum tolerated dose (MTD) is determined. Patients receive adjusted doses of azacitidine based on clinical response. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Up to 9 additional patients are treated at the MTD."
88967578|NCT04041570|Experimental|Group 1: cAd3-EBO S vaccine (1x10^10 PU)|cAd3-EBO S vaccine (1x10^10 PU) administered intramuscularly (IM) with needle and syringe in a volume of 1 mL
88967579|NCT04041570|Experimental|Group 2: cAd3-EBO S vaccine (1x10^11 PU)|cAd3-EBO S vaccine (1x10^11 PU) administered IM with needle and syringe in a volume of 1 mL
88967580|NCT00400816|Experimental|Temozolomide|Temozolomide, 150 mg/m2/d x days 1-7 and 15-21
88967581|NCT00400855|Experimental|Arm 1|study drug
89562265|NCT03579667|Experimental|Diet intervention|
89562266|NCT03579667|No Intervention|Control|
89562267|NCT03278821|Experimental|Self Match|The patient must choose between the five possible treatment options.
89562268|NCT03278821|Active Comparator|Expert Match|The Patient is referred to treatment by standard procedure which is Expert Match based on patient data.
89562269|NCT04873427||early metastatic prostate cancer patients|Reconstruction of local PCa heterogeneity in multi-needle diagnostic biopsy with different Gleason scores (6-10) using high-coverage whole exome sequencing (WES) and DP-based clonal analysis
89562270|NCT04873427||non-relapsing/non-metastatic patients with indolent malignant disease|Reconstruction of local PCa heterogeneity in multi-needle diagnostic biopsy with different Gleason scores (6-10) using high-coverage whole exome sequencing (WES) and DP-based clonal analysis
89562271|NCT04518787||Control|Healthy child
89562272|NCT04518787||Experimental|Patients with language disorder
89562273|NCT04862741|Experimental|NX-13 250mg IR|Oral
89562274|NCT04862741|Experimental|NX-13 500mg IR|Oral
89562275|NCT04862741|Experimental|NX-13 500mg MR|Oral
89562276|NCT04862741|Placebo Comparator|Placebo|Oral
89562277|NCT04683055|Active Comparator|Phacoemulsification combined with trabeculectomy|Patients will undergo Two site phacoemulsification combined with trabeculectomy with Mitomycin C
89562278|NCT04683055|Active Comparator|Phacoemulsificaiton combined with ab-externo trabeculotomy|Patients will undergo two phacoemulsification combined with deep sclerectomy and ab-externo trabeculotomy
89562279|NCT04474249||COVID-19|Patients with PCR-confirmed COVID-19 who were treated in the intensive care unit.
89562280|NCT02508493||Major Depressive Disorder Population|100 Individuals with DSM-5-defined MDD, aged 18-65
89562281|NCT02508493||Healthy Control Population|100 healthy controls matched on age, sex and years of education
89562282|NCT04613089||CLN1 Disease, Haltia-Santavuori Disease|Patients with genetic mutations in the CLN1/PPT1 gene, causing a lysosomal enzyme deficiency of PPT1.
89562283|NCT04613089||CLN2 Disease, Jansky-Bielschowsky Disease|Patients with genetic mutations in the CLN2/TPP1 gene, causing a lysosomal enzyme deficiency of TTP1.
89562284|NCT04613089||CLN2 Disease - ERT (Brineura) treated|Patients with genetic mutations in the CLN2/TPP1 gene, causing a lysosomal enzyme deficiency of TTP1, previously and/or currently receiving enzyme-replacement therapy (ERT) with Cerliponase alpha (Brineura).
89562285|NCT04613089||CLN3 Disease, Spielmeyer-Vogt-Sjögren-Batten Disease|Patients with genetic mutations in the CLN3 gene.
89562286|NCT04613089||CLN4 disease, Parry disease|Patients with genetic mutations in the CLN4/DNAJC5 gene.
88967582|NCT00400933|Experimental|psycho-education|six session psycho-educational group program for family members and close friends of persons with eating disorders and co-morbid personality disorders
88967583|NCT00101296|Experimental|Treatment (tipifarnib)|Patients receive oral tipifarnib twice daily on days 1-7 and 15-21. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression. Patients achieving a CR receive 2 additional courses beyond CR. Patients experiencing relapse after previously achieving CR may receive additional tipifarnib at the current dose level for newly registered patients.
88967584|NCT00006398|Experimental|Timolol Maleate|Dose titrated from 5 mg per day to up to 80 mg per day depending on heart rate
88967585|NCT00006398|Placebo Comparator|Placebo|Timelol placebo
88967586|NCT00101491|Experimental|1|
88967587|NCT00101491|Other|2|Attention Control Comparator
88967588|NCT00006401|Experimental|Inhaled Nitric Oxide (iNO)|Nitric Oxide study gas will be initiated at 5 ppm using the INOvent delivery system. The delivery system provides for masked delivery of the treatment gas. This dose will be used for a 21-day period or until extubation.
89562287|NCT04613089||CLN5 Disease|Patients with genetic mutations in the CLN5 gene.
88967589|NCT00006401|Placebo Comparator|Placebo|
88967590|NCT00101569|Experimental|A1|
88967591|NCT00101569|Experimental|A2|
88967592|NCT00101725|Experimental|125 mg crofelemer|
88967593|NCT00101725|Experimental|250 mg crofelemer|
88967594|NCT00101725|Experimental|500 mg crofelemer|
88967595|NCT00101725|Placebo Comparator|placebo|
88967596|NCT04729036||mandibular fracture group|
88967597|NCT00101881|Active Comparator|Monophasic Shock|Administration of monophasic waveform defibrillation
88967598|NCT00101881|Active Comparator|Biphasic Shock|Administration of biphasic waveform defibrillation
88967599|NCT00101920|Experimental|ABX-EGF|Open-label, single arm panitumamab monotherapy
88967600|NCT00102388|Experimental|vildagliptin|
89562288|NCT04613089||CLN6 Disease, Kufs Disease Type A|Patients with genetic mutations in the CLN6 gene.
89562289|NCT04613089||CLN7 Disease|Patients with genetic mutations in the CLN7/MFSD8 gene.
89562290|NCT04613089||CLN8 Disease|Patients with genetic mutations in the CLN8 gene.
89562291|NCT04613089||CLN10 Disease|Patients with genetic mutations in the CLN10/CTSD gene, causing a lysosomal enzyme deficiency of Cathepsin D.
88967601|NCT00102388|Active Comparator|Gliclazide|
88967602|NCT00006425||1|25 women undergoing ductal lavage
88967603|NCT00102622|Experimental|Arm 1: Paclitaxel + tgDCC-E1A|80 mg/m^2 intravenous Paclitaxel and intraperitoneal (IP) tgDCC-E1A starting dose 1.8 mg DNA/m^2 weekly for six treatments every 7 days.
88967604|NCT00102622|Active Comparator|Arm 2: Paclitaxel Alone|Weekly single agent intravenous Paclitaxel 80 mg/m^2 for six treatments every 7 days.
88967605|NCT00102661|Experimental|CAMPATH-1H|15 mg infused daily for continuous infusion x 7 days; starting day 10, CAMPATH-1H 30 mg subcutaneously three times weekly for 11 additional weeks.
88967606|NCT03923049|Other|PET/MRI|Diagnostic testing with simultaneous PET/MRI for cardiac sarcoidosis diagnosis
88967607|NCT00101998|Experimental|Alvimopan 0.5 mg Twice Daily (BID)|0.5 milligrams (mg) of alvimopan was administered orally BID for 3 weeks.
88967608|NCT00101998|Experimental|Alvimopan 1 mg Once Daily (QD)|"0.5 mg of alvimopan was administered orally QD for 3 days, then 1 mg of alvimopan QD for the remaining 3 weeks. Placebo was administered orally QD to maintain the blind.~A protocol amendment dropped this arm because another study had demonstrated 1 mg QD treatment to have similar efficacy but a less favorable gastrointestinal-related safety profile compared with 0.5 mg BID treatment."
88967609|NCT00101998|Experimental|Alvimopan 1 mg Twice Daily (BID)|0.5 mg of alvimopan was administered orally BID for 3 days, then 1 mg of alvimopan BID for the remaining 3 weeks.
89562292|NCT04613089||CLN11 Disease|Patients with genetic mutations in the CLN11/GRN gene.
89562293|NCT04613089||CLN12 Disease|Patients with genetic mutations in the CLN12/ATP13A2 gene.
89562294|NCT04613089||CLN13 Disease, Kufs Disease Type B|Patients with genetic mutations in the CLN13/CTSF gene, causing a lysosomal enzyme deficiency of Cathepsin F.
89562295|NCT04613089||CLN14 Disease|Patients with genetic mutations in the CLN14/KCTD7 gene.
89608772|NCT04147767|Placebo Comparator|Placebo Arm|"The investigational food product Low Fat Strawberry Yogurt Drinks (Morrisons) is a strawberry flavoured yogurt drink with sweetener and sugar, vitamin C, B6 and D, British milk.~Placebo intervention consists in 8 weeks consumption of PSS non-enriched Yogurt Drinks. The placebo intervention is needed for the study design chosen (randomized double-blind placebo-controlled cross-over clinical trial). Placebo will be used in order to determine the efficacy of PSS intervention, comparing the effects of the two compounds (PSS and placebo) in the same experimental conditions and then avoiding bias."
88967610|NCT00101998|Placebo Comparator|Placebo|Placebo was administered orally BID for 3 weeks.
88967611|NCT00401089|Experimental|Ginsana-115|Ginsana-115 (Panax Ginseng formulation obtained from Boehringer Ingelheim Pharmaton Inc. Switzerland )is available in oral dosage form of capsules. Two dosages of Ginsana-115 will be tested: 100 mg once daily oral dosage ( 1 100-mg Ginsana-115 capsule) and 200 mg once daily dosage ( 2 100-mg Ginsana-115 capsule). The total duration of each dosage is 8 weeks.
88967612|NCT00401089|Placebo Comparator|Sugar Pill|Placebo capsules formulated identical to the active drug: Ginsana-115 are to be obtained from Boehringer Ingelheim Pharmaton, Switzerland. Two dosages of Placebo capsules will be administered once daily for 8 weeks : a) Placebo 100 mg capsule: 1 placebo capsule daily; b) Placebo 200 mg capsule: 2 placebo-capsule daily
88967613|NCT00102934|Experimental|1|Participants will receive enfuvirtide for 6 months
88967614|NCT00102973|Experimental|TLK286 in Combination with Carboplatin|
88967615|NCT00102973|Active Comparator|Doxorubisin HCl Liposome Injection|
88967616|NCT00103168|Experimental|Imatinib mesylate|400 mg/day for 2 years
88967617|NCT00103168|No Intervention|Control|
88967618|NCT02697474|Experimental|Hexaxim® Group|Subjects that received Hexaxim® in Study A3L12
88967619|NCT02697474|Experimental|Infanrix® hexa Group|Subjects that received Infanrix® hexa in Study A3L12
88967620|NCT00103246|Experimental|Topical silicon phthalocyanine 4 (Pc 4) + photodynamic therapy|Topical silicon phthalocyanine 4 (Pc 4) followed by photodynamic therapy.
88967621|NCT00103324|Experimental|Treatment|Patients receive oral lapatinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88967622|NCT00103519|Experimental|DITPA 180 mg/day|DITPA 180 mg/day BID
88967623|NCT00103519|Experimental|DITPA 360 mg/day|DITPA 360 mg/day BID
88967624|NCT00103519|Placebo Comparator|Placebo|Placebo BID
88967625|NCT00103792|Experimental|1|mycophenolate and steroids as remission induction, followed by azathioprine maintenance therapy
88967626|NCT00103792|Active Comparator|2|cyclophosphamide
88967627|NCT03879408|Experimental|440 mg naproxen sodium with 1000 mg acetaminophen|440 mg naproxen sodium with 1000 mg acetaminophen administered as a single dose of two naproxen sodium 220 mg tablets and two acetaminophen 500 mg tablets
88967628|NCT03879408|Experimental|220 mg naproxen sodium with 650 mg acetaminophen|220 mg naproxen sodium with 650 mg acetaminophen administered as a single dose of one naproxen sodium 220 mg tablet and two acetaminophen 325 mg tablets and one placebo tablet
88967629|NCT03879408|Active Comparator|10 mg hydrocodone + 650 mg acetaminophen|10 mg hydrocodone + 650 mg acetaminophen administered as a single dose of two hydrocodone 5 mg + acetaminophen 325 mg tablets and two placebo tablets
88967630|NCT03879408|Active Comparator|440 mg naproxen sodium|440 mg naproxen sodium administered as a single dose of two naproxen sodium 220 mg tablets and two placebo tablets
88967631|NCT03879408|Placebo Comparator|Placebo tablet|Single dose of four placebo tablets
88967632|NCT00387998|Experimental|Risk primer|"Booklet written by investigators know your chances"
88967633|NCT00387998|Active Comparator|Control booklet|AHRQ staying healthy booklet
88967634|NCT00388076|Experimental|Part 1|pazopanib and paclitaxel
88967635|NCT00388076|Experimental|Part 2|pazopanib, paclitaxel, and carboplatin
88967636|NCT00388076|Experimental|Part 3|pazopanib, paclitaxel, and lapatinib
88967637|NCT03872583|Experimental|Understanding MRI in MS (website)|Participants will receive access to a newly developed, innovative, interactive and evidence-based education tool about magnetic resonance imaging in multiple sclerosis.
88967638|NCT03872583|Active Comparator|Control website|Participants will receive access to a specifically designed control website containing the information about magnetic resonance imaging in multiple sclerosis, that is freely available on the websites of major European multiple sclerosis self help organization (Australia, Belgium, Canada, France, Germany, Great Britain, Netherland, USA).
88967639|NCT00104494|Experimental|1|CF, Zinc acetate
88967640|NCT00104494|Experimental|2|CF, Placebo
88967641|NCT00104494|No Intervention|3|Controls
88967642|NCT00388115|Experimental|RFA prior to surgery|
88967643|NCT00390585|Experimental|A|Iodixanol 320
88967644|NCT00390585|Active Comparator|B|Iomeprol 350
88967645|NCT00104611|Active Comparator|TMS|Repetitive Transcranial Magnetic Stimulation (rTMS) Treatment 5 days/week for up to 6 weeks
88967646|NCT00104611|Placebo Comparator|Placebo|Treatment 5 days/week for up to 6 weeks
88967647|NCT00104689|Experimental|Capecitabine + Oxaliplatin|Patients receive oral capecitabine once daily on days 1-14 and oxaliplatin IV on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity
88967648|NCT00006461|Other|Chemotherapy, surgery, radiation therapy|Patients receive induction chemotherapy consisting of vincristine sulfate IV on days 1, 8, and 15; cisplatin IV over 6 hours on day 1; cyclophosphamide IV over 30 minutes on day 2; and oral etoposide daily on days 2-22. Treatment repeats every 28 days for a total of 4 courses. After completion of induction chemotherapy, patients with residual disease undergo a therapeutic conventional surgery (second resection). Within 4 weeks after completion of induction chemotherapy or second resection, patients receive 3-dimensional conformal radiation therapy daily, 5 days a week, for 6 weeks. Four weeks after completion of 3-dimensional conformal radiation therapy, patients receive alternating treatments of maintenance chemotherapy. Patients receive vincristine sulfate IV on days 1, 8, and 15 and cyclophosphamide IV over 30 minutes on day 1 of courses 1, 3, 5, and 7 and oral etoposide daily on days 1-21 of courses 2, 4, 6, and 8. Treatment continues every 28 days for 8 courses.
88967649|NCT00104767|Experimental|celecoxib|
88967650|NCT02972268|Experimental|Group I|Tamsulosin 0.2mg + Solifenacin 5mg
88967651|NCT02972268|Placebo Comparator|Group II|Tamsulosin 0.2mg + Placebo(Solifenacin)
88967652|NCT00104845|Experimental|human gp100 DNA vaccine|Patients receive human gp100 DNA vaccine intramuscularly (IM) once in weeks 1, 4, and 7. Patients then receive mouse gp100 DNA vaccine IM once in weeks 10, 13, and 16.
88967653|NCT00104845|Experimental|mouse gp100 DNA vaccine|Patients receive mouse gp100 DNA vaccine IM once in weeks 1, 4, and 7. Patients then receive human gp100 DNA vaccine IM once in weeks 10, 13, and 16
89608773|NCT03586869|Experimental|NANT Pancreatic Cancer Vaccine|A combination of agents will be administered to subjects in this study: Aldoxorubicin HCl, ALT-803, ETBX-011 (CEA), ETBX-021 (HER2), ETBX-051 (Brachyury), ETBX-061 (MUC1), GI-4000, GI-6207, GI-6301, haNK for infusion, avelumab, bevacizumab, capecitabine, cyclophosphamide, fluorouracil, leucovorin, nab-paclitaxel, oxaliplatin, and Stereotactic Body Radiation Therapy (SBRT).
89608774|NCT04147377|Experimental|PD with FOG|Patients with Parkinson's disease who complain of freezing of gait
89027279|NCT01311661|Experimental|Olodaterol medium daily dose|Olodaterol medium daily dose given either as once daily or split into two low doses daily or placebo only in randomised sequence of three cross-over treatment phases
89027280|NCT01311661|Experimental|Olodaterol high daily dose|Olodaterol high daily dose given either as once daily or split into two medium doses daily or placebo only in randomised sequence of three cross-over treatment phases
89027281|NCT04518735||Patients on previous oral anticoagulant treatment|Patients receiving chronic anticoagulation with vitamin K antagonists (VKA, warfarin or acenocumarol) or with DOACs (dabigatran, rivaroxaban, apixaban or edoxaban) for any indication
89027282|NCT04518735||Patients on previous antiplatelet therapy|Patients receiving chronic antiplatelet therapy (aspirin, clopidogrel, prasugrel, ticagrelor, cangrelor, dipyridamol) for any indication
89027283|NCT04518735||Patients without antithrombotic therapy|Patients receiving nor chronic oral anticoagulation neither chronic antiplatelet therapy
89027284|NCT00482261|Experimental|len-dex|Drug: Lenalidomide 15mg daily, days 1-21 of a 28 day cycle for 4 cycles. Patients who get stable disease or better will then receive 15mg on days 1-21 from cycle 5 onwards; Drug: dexamethasone 20mg day 1-4, 9-12, 17-20 for 4 cycles. Patients who get stable disease or better will then get dexamethasone 20mg on days 1-4 of a 28 day cycle, from cycle 5 onwards
89027285|NCT04518618|Experimental|Group F|Patients in this group will receive spinal anesthesia with 10 mg hyperbaric bupivacaine (2 ml) plus 25 ugs of fentanyl (0.5 ml).
89027286|NCT04518618|Experimental|Group FN|Patients in this group will receive spinal anesthesia with 10 mg hyperbaric bupivacaine (2 ml) plus 25 ugs of fentanyl (0.5 ml) plus 20 ugs naloxone.
89027287|NCT00480584|Experimental|GemCap-T Dose Escalation|GemCap-T, capecitabine in combination with gemcitabine. Dose Escalation 6 Cycles @ 28 Days.
89027288|NCT01311505|Active Comparator|A|Test
89027289|NCT01311505|Active Comparator|B|Reference
89027290|NCT04518423||Elderly people over the age of 65 years|The study group will comprise community dwelling elderly individuals over the age of 65 years who get around by themselves. The subjects will be followed up for 5 years to investigate the frailty and disability development, and survival.
89027291|NCT05644366|Experimental|Balance Assessment Children with Autism|Postural Stability Testing Each subject was instructed to stand in a static bipedal posture on the MatScan® pressure mat and performed 8 balance tasks.
89027292|NCT01240538|Experimental|Treatment (virus and chemotherapy)|Patients receive wild-type reovirus IV over 60 minutes QD on days 1-5. Some patients also receive cyclophosphamide PO on days 1-21. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
89027293|NCT04518579|Active Comparator|Group (EP)|Group (EP) received epidural (fentanyl and bupivacaine) - propofol based anesthetic technique and postoperative analgesia through patient controlled analgesia device (PCA)
89027294|NCT04518579|Active Comparator|Group (EH)|Group (EH) received epidural (fentanyl and bupivacaine)- inhalational based anesthetic technique and postoperative analgesia through patient controlled analgesia device (PCA)
89027295|NCT01310803|Experimental|Maintenance therapy|Chemotherapeutic: EN3329-301 (VALSTAR)
89027296|NCT01310803|Other|No Maintenance (Standard of care)|Subjects randomized to No Maintenance (Standard of Care) will not receive any additional intravesical therapy
89027297|NCT04518540|Experimental|lipoic acid group|The patients will take lipoic acid by intravenous. At the same time, the patients will take take riluzole tablets orally everyday.
89027298|NCT04518540|Experimental|control group|The patients will take riluzole tablets orally everyday.
89027299|NCT01240655|Experimental|LCL161 + Paclitaxel|
89027300|NCT04518189|Experimental|lidocaine patch|5% lidocaine patch applied at 3 hours before the procedure
89027301|NCT04518189|Placebo Comparator|Sham patch|Sham patch containing no study medication applied 3 hours before the procedure
89027302|NCT00505401|Other|A|Subjects were immunized subcutaneously with Tat, 3 dosage groups (7.5, 15 or 30 microgrammi), in association with Alum as adjuvant, or with Saline + Alum, as placebo.
89027303|NCT00505401|Other|B|Subjects were immunized intradermally with Tat, 3 dosage groups (7.5, 15 or 30 microgrammi), or with Saline, as placebo.
89027304|NCT00505440|Experimental|Computerized screening and referral|Computerized screening and referral: Intervention is a web-based screening and assessment tool completed by adolescents during primary care visits. Patient reported screening provided to primary care physicians in real time with recommendations for behavioral referrals.
89027305|NCT00505440|Active Comparator|Delayed feedback from screening|Active comparator is Usual pediatric care plus mailed screening results from computerized waiting room screens that arrive three days after screening.
89027306|NCT00482378|Experimental|Sm 153 lexidronam|
89027307|NCT01310413|Experimental|Influenza A (H5N1) adjuvanted 6-<36M Group|Subjects aged at enrolment between 3 and 36 months, 36 months excluded, received 2 doses of Influenza A (H5N1) Virus monovalent vaccine (GSK1557484A vaccine or GSK Biologicals' monovalent A/Indonesia/5/2005 (H5N1) vaccine adjuvanted) at Days 0 and 21. Influenza A (H5N1) Virus monovalent vaccine was administered intramuscularly. For children aged up to 12 months, 12 months excluded (< 12 months), Dose 1 was administered in the left anterolateral thigh and Dose 2 in the right anterolateral thigh. For children older than (>=) 12 months, Dose 1 was administered in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) and Dose 2 in the deltoid region of the dominant arm (or right arm).
89210614|NCT05706519||Case Group|Six hundred volunteers. In this group, participants must present a diagnosis of ischemic heart disease at least 1 year but less than 5 years from recruitment
89210615|NCT00927966|Experimental|RAD001 in combination with figitumumab|
89210616|NCT00816608||type 2 diabetes|
89608775|NCT03581253|Experimental|peripheral facial palsy patients|"peripheral facial palsy patients will performed questionnaires of quality of life (Facial disability Index (FDi) and Facial Clinimetric Evaluation (FaCE)"
89027308|NCT01310413|Experimental|Influenza A (H5N1) Virus monovalent vaccine 3-<9Y Group|Subjects aged at enrolment between 3 and 9 years, 9 years excluded, received 2 doses of Influenza A (H5N1) Virus monovalent vaccine (GSK1557484A vaccine or GSK Biologicals' monovalent A/Indonesia/5/2005 (H5N1) vaccine adjuvanted) at Days 0 and 21. Influenza A (H5N1) Virus monovalent vaccine was administered intramuscularly, Dose 1 in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) and Dose 2 in the deltoid region of the dominant arm (or right arm).
89027309|NCT01310413|Experimental|Influenza A (H5N1) Virus monovalent vaccine 9-<18Y Group|Subjects aged at enrolment between 9 and 18 years, 18 years excluded, received 2 doses of Influenza A (H5N1) Virus monovalent vaccine (GSK1557484A vaccine or GSK Biologicals' monovalent A/Indonesia/5/2005 (H5N1) vaccine adjuvanted) at Days 0 and 21. Influenza A (H5N1) Virus monovalent vaccine was administered intramuscularly, Dose 1 in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) and Dose 2 in the deltoid region of the dominant arm (or right arm).
89027310|NCT01310413|Placebo Comparator|Placebo 6-<36M Group|Subjects aged at enrolment between 3 and 36 months, 36 months excluded, received 2 doses of saline placebo at Days 0 and 21. The saline placebo was administered intramuscularly. For children aged up to 12 months, 12 months excluded (< 12 months), Dose 1 was administered in the left anterolateral thigh and Dose 2 in the right anterolateral thigh. For children older than (>=) 12 months, Dose 1 was administered in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) and Dose 2 in the deltoid region of the dominant arm (or right arm).
89027311|NCT01310413|Placebo Comparator|Placebo 3-<9Y Group|Subjects aged at enrolment between 3 and 9 years, 9 years excluded, received 2 doses of saline placebo at Days 0 and 21. The saline placebo was administered intramuscularly, Dose 1 in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) and Dose 2 in the deltoid region of the dominant arm (or right arm).
89027312|NCT01310413|Placebo Comparator|Placebo 9-<18Y Group|Subjects aged at enrolment between 9 and 18 years, 18 years excluded, received 2 doses of saline placebo at Days 0 and 21. The saline placebo was administered intramuscularly, Dose 1 in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) and Dose 2 in the deltoid region of the dominant arm (or right arm).
89027313|NCT01310413|Experimental|Placebo/Influenza A (H5N1) adjuvanted Group|Subjects in this group were those who were administered the saline placebo solution in the Blinded Phase of the study (either in the Placebo 6-<36M, Placebo 3-<9Y or Placebo 9-<18Y Group). These were subjects aged at enrolment between 6 months and 18 years, 18 years excluded, who had received 2 doses of saline placebo at Days 0 and 21 in the Blinded Phase of the study, as per described in the descriptions of the Placebo 6-<36M, Placebo 3-<9Y and Placebo 9-<18Y groups. After consenting to participating to the Unblinded Phase of the study, these subjects received in addition 2 doses of Influenza A (H5N1) Virus monovalent vaccine at Days 385 (Day U0) and Day 385 + 21 days (Day U21). Influenza A (H5N1) Virus monovalent vaccine was administered intramuscularly. Dose 1 of was administered in the deltoid region of the non-dominant arm and Dose 2 in the deltoid region of the dominant arm.
89027314|NCT02275572|Experimental|Pharmacist Intervention|Primary care pharmacist apply the GP-GP algorithm to each drug with the support of STOPP criteria, Beers and / or recommendations CatSalut. The pharmacist submit to doctor his findings and reach a consensus and decide which recommendations will be presented to patient.
89027315|NCT02275572|No Intervention|Control|Usual procedure.
89027316|NCT02275689|Active Comparator|Arthrocopic acromioplasty|Surgical intervention with arthroscopic acromioplasty, bursectomy and subacromial decompression
89027317|NCT02275689|Active Comparator|Radiofrequency microtenotomy|Surgical intervention With arthroscopic radiofrequency microtenotomy
89562296|NCT05098639|Active Comparator|BASICS|Participants in the active control will receive a modified single session BASICS. BASICS is a well-documented and empirically supported prevention/intervention program for college student drinkers. BASICS targets heavy drinking students that have experienced or are at an increased risk for a variety of alcohol-related problems linked to college student life. The program is designed to help students make better alcohol-use decisions based on a broader understanding of the risks associated with problem drinking. It enhances motivation to change and promotes the development of skills to moderate drinking. The overall style of the program uses motivational interviewing and emphasizes empathy and non-judgmental interaction. The aims of BASICS are to (1) reduce alcohol consumption and consequences, (2) promote healthier and more responsible choices, and (3) provide information and coping skills.
89562297|NCT05098639|Experimental|Deviance Regulation Theory|DRT participants receive an initial intervention session that is consistent with their current (pre-intervention) PBS frequency norm beliefs. For the initial intervention session, participants discuss their perception of the use of alcohol and use of protective behavioral strategies among campus peers. They are given feedback on the injunctive norms of alcohol use and PBS use by their peers which is tailored to each individuals normative perceptions. Following the initial intervention session, participants will carry a mobile device that allows for individuals to report current drinking environments. They then receive DRT consistent feedback based on the norms reported in their current drinking environment.
89562298|NCT05098639|Experimental|Deviance Regulation Theory+BASICS|DRT participants receive an initial intervention session that is consistent with their current (pre-intervention) PBS frequency norm beliefs but also follows the framework of BASICS. For the initial intervention session, participants discuss their perception of the use of alcohol and use of protective behavioral strategies among campus peers. They are given feedback on both descriptive and injunctive norms of alcohol use and PBS use by their peers which is tailored to each individuals normative perceptions. Following the initial intervention session, participants will carry a mobile device that allows for individuals to report current drinking environments. They then receive DRT consistent feedback based on the norms reported in their current drinking environment.
89562299|NCT04469179|Experimental|Cohort 1|10mg/kg SAB-185 in normal (0.9%) saline; concentration 4mg/mL (0.4%)
89562300|NCT04469179|Experimental|Cohort 2|25mg/kg SAB-185 in normal (0.9%) saline; concentration 20mg/mL (2%)
89562301|NCT04469179|Experimental|Cohort 3|50mg/kg SAB-185 in normal (0.9%) saline; concentration 20mg/mL (2%)
89562302|NCT04469179|Placebo Comparator|Placebo|Normal (0.9%) saline in approximately the same volume as each cohort in the experimental drug arm.
89562303|NCT04437121||Parents of children aged 2-18 years|Parents of children aged 2-18 years during the lockdown due to the COVID-19 pandemic, following their informed consent form prior to their participation to the study.
89562304|NCT04531579|Experimental|VPA plus SOC|A single dose of 140 mg/kg of VPA plus standard of care
89562305|NCT04531579|Placebo Comparator|Placebo plus SOC|A single dose of isotonic saline solution plus standard of care
89562306|NCT04362085|Experimental|Therapeutic Anticoagulation|Therapeutic anticoagulation with LMWH or UFH (high dose nomogram). The choice of LMWH versus UFH will be at the clinician's discretion and dependent on local institutional supply. Therapeutic anticoagulation will be administered until discharged from hospital, 28 days or death. If the patient is admitted to the ICU or requiring ventilatory support, we recommend continuation of the allocated treatment as long as the treating physician is in agreement.
89562307|NCT04362085|No Intervention|Standard Care|Administration of LMWH, UFH or fondaparinux at thromboprophylactic doses for acutely ill hospitalized medical patients, in the absence of contraindication, is considered standard care.
89562308|NCT04354597|Experimental|Study Arm A (HCQ & AZ)|Subjects will receive weekly HCQ 400mg X 1 Day PO and AZ 500mg PO X 3 Days; weekly for 16 weeks.
89562309|NCT04354597|No Intervention|Study Arm B (No treatment)|Subjects will receive no treatment in this group and will be serving as control.
88967654|NCT00104962|Experimental|Treatment (lenalidomide)|Patients receive oral lenalidomide once daily on days 1-21. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
88967655|NCT00006467|Experimental|gemcitabine + ISIS 2503|Patients receive gemcitabine IV over 30 minutes on days 1 and 8 and ISIS 2503 IV continuously on days 1-14. Treatment continues every 21 days in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 1 year and then every 6 months for 4 years.
88967656|NCT00105040|Experimental|Levetiracetam (LEV)|Oral tablets or oral solution at 20-60 mg/kg/d, divided into twice daily dosing.
88967657|NCT00105040|Placebo Comparator|Matching Placebo (PBO)|Oral tablets and oral solution.
88967658|NCT00105547|Experimental|1|800 mg BID
88967659|NCT00105547|Placebo Comparator|2|BID dosing
88967660|NCT00105625||Group 1|
88967661|NCT00105664|Other|Arm 1|
88967662|NCT00105703|Other|Arm 1|
88967663|NCT00006473|Experimental|Treatment (oxaliplatin)|Patients receive oxaliplatin IV over 2 hours on day 1. Treatment repeats every 21 days for a maximum of 6 courses in the absence of disease progression or unacceptable toxicity.
88967664|NCT00105742|Other|Arm 1|
88967665|NCT00105781|Other|Arm 1|
88967666|NCT00105859|Other|1|
88967667|NCT00105898|Experimental|Arm 1|Intervention group
88967668|NCT00105898|Active Comparator|Arm 2|Comparator
88967669|NCT00105898|Sham Comparator|Arm 3|Comparator
88967670|NCT03815682|Experimental|RPTR-147:1|Arm A: Escalating doses of RPTR-147:1 as a monotherapy in solid tumors and lymphomas
88967671|NCT03815682|Experimental|RPTR-147:1 and Pembrolizumab|Arm B: Escalating doses of RPTR-147:1 in combination with Pembrolizumab in patients with solid tumors and lymphomas
88967672|NCT03815682|Experimental|RPTR-147:2|Arm C: Escalating doses of RPTR-147:2 in patients with HPV-16 positive tumors
88967673|NCT00106210|Experimental|1|Behavioral Intervention (experimental)
88967674|NCT00106210|Active Comparator|2|Behavioral Intervention 2
88967675|NCT00106288|Experimental|1|
88967676|NCT00106288|Active Comparator|2|
88967677|NCT00106327|Experimental|1|6-month supervised treadmill exercise program
88967678|NCT00106327|Experimental|2|6-month supervised lower extremity progressive resistance training program
88967679|NCT00106327|Active Comparator|3|Diet/nutrition control group
88967680|NCT00106483||Coronary Artery Risk Development in Young Adults|There were no interventions.
88967681|NCT04728256|Experimental|İntervention group|A six-session antenatal care program included both music listening and laughter therapy, and was designed for those in the study group as a session every week. The program was carried out by arranging a session of music listening for one week and a laughter therapy session over the following week. Also, the notes uttered by pregnants women were discussed at the week laughter listening sessions were performed. Data from the intervention group was collected four times as pretest (after providing informed contest), first-interval measurement (fourth week of the intervention), second-interval measurement (the first month following the birth) and post-test (the third month following the birth).The data were collected through Beck depression Inventery (BDI), Edinburg postpartum depressıon scale EPDS, Brief semptom ınventory(BSI) and maternal attachment scale(MAS) evaluate overall mental health status comprehensively. All participants responded to the questionnaire prepared for the study.
88967682|NCT04728256|No Intervention|Control group|Mothers receiving standard antenatal care in the prenatal period, giving birth, and having a three-month-old baby constituted the control group. The Control group was created after the procedures were completed for those in the intervention group. Only the post test was applied to the control group.The data were collected through Beck depression Inventery (BDI), Edinburg postpartum depressıon scale EPDS, Brief semptom ınventory(BSI) and maternal attachment scale(MAS) evaluate overall mental health status comprehensively. All participants responded to the questionnaire prepared for the study.
89027318|NCT02275689|No Intervention|Physical therapy|Muscle strength training, home trainings programme
89027319|NCT00480896|Experimental|1|
89027320|NCT00480896|Placebo Comparator|2|
89210617|NCT00720941|Active Comparator|Sunitinib|Control arm
89210618|NCT00720941|Experimental|Pazopanib|Experimental arm
89562310|NCT04413409|Experimental|surgical group|The metastatic sites are firstly treated by surgery then followed by systemic treatment
89562311|NCT04413409|No Intervention|systemic group|After confirmation of puncture, receive systemic treatment
89562312|NCT05375461|Experimental|TQB3616 capsules plus fulvestrant|"The dose of TQB3616 capsules is 180mg, taken orally on an empty stomach, once a day for 28 consecutive days as one treatment cycle.~Fluvestrin injection was given at a fixed dose of 500mg on day 1, day 15 of the first treatment cycle and day 1 of each subsequent treatment cycle, and a treatment cycle of 28 days."
89562313|NCT05375461|Placebo Comparator|TQB3616-matching placebo plus fulvestrant|"The dose of placebo is 180mg, taken orally on an empty stomach, once a day for 28 consecutive days as one treatment cycle.~Fluvestrin injection was given at a fixed dose of 500mg on day 1, day 15 of the first treatment cycle and day 1 of each subsequent treatment cycle, and a treatment cycle of 28 days."
89562314|NCT05097781|Experimental|Treatment arm|Local irradiation + immunotherapy
88967683|NCT03803826|Experimental|CRT-D re-programming|"The ineffective previously implanted CRT-D is reprogrammed under supervision of transthoracic echocardiography to:~adjust the atrioventricular interval so that E and A waves do not overlap~the interventricular interval is subsequently optimized to yield maximum improvement of the sum of longitudinal+radial+circumferential strains.~Transthoracic echocardiography is performed prior to optimization and 3 months after optimization (i.e., 3 and 6 months after the CRT implantation) and and New York Heart Association Classification (NYHA Classification; total score range 1-4) is being determined in accordance with the standard NYHA methods re-programming of the interventricular interval"
88967684|NCT03803826|No Intervention|Control Group|Only trans-thoracic echocardiography is performed during follow-ups at 3 and 6 months from CRT implantations performed and New York Heart Association Classification (NYHA Classification; total score range 1-4) is being determined in accordance with the standard NYHA methods
88967685|NCT00106522|Experimental|1|
88967686|NCT00106522|Experimental|2|
88967687|NCT00106522|Placebo Comparator|3|
88967688|NCT00105820|Other|Arm 1|
88967689|NCT00401323|Experimental|docetaxel plus cisplatin|Taxotere 75 mg/m², one-hour IV infusion on Day 1 of each 3-week cycle followed by cisplatin 75 mg/m² administered as a 30-minute to 3-hour infusion on Day 1
88967690|NCT00401323|Active Comparator|cisplatin plus 5-FU|Cisplatin 100 mg/m², 30-minute to 3-hour infusion on Day 1 of each 3-week cycle followed by the continuous infusion of 5-FU 1000 mg/m²/day from Day 1 to Day 5
88967691|NCT00401323|Experimental|docetaxel plus 5-FU|"Taxotere 85 mg/m², one-hour IV infusion on Day 1 of each 3-week cycle followed by the continuous infusion of 5-FU 750 mg/m²/day from Day 1 to Day 5~Arm only in the phase II part of the study"
88967692|NCT00401362|Experimental|Arm 1|
88967693|NCT00401362|Placebo Comparator|Arm 3|
88967694|NCT00401362|Experimental|Arm 2|
88967695|NCT00106678||Infected through risk behaviors|
88967696|NCT00106678||Infected perinatally or through blood/blood products.|
88967697|NCT00107107|Active Comparator|Pramlintide Acetate|Pramlintide acetate injection is a clear, colorless, sterile solution for SC injection. It consists of pramlintide in sodium acetate buffer, pH 4.0, containing 43 mg/mL mannitol as an iso-osmolality modifier and 2.25 mg/mL metacresol as a preservative. The concentration of pramlintide injection to be used in this study is 0.6 mg/mL.
88967698|NCT00107185|Experimental|Vaccine|
88967699|NCT00107263|Experimental|Arm I: letrozole + zoledronate|"Patients receive oral letrozole once daily. Patients also receive zoledronate IV over 15 minutes once every 6 months.~Treatment continues for up to 5 years in the absence of disease progression or unacceptable toxicity."
88967700|NCT00107263|Experimental|Arm II: letrozole + zoledronate|"Patients receive oral letrozole once daily. Patients with radiologic evidence of bone loss after 1 year of letrozole therapy receive zoledronate as in arm I.~Treatment continues for up to 5 years in the absence of disease progression or unacceptable toxicity."
88967701|NCT02964949|Experimental|Edoxaban 75 mg|Edoxaban 60 mg + edoxaban 15 mg orally, once daily, at the same time (preferably morning) for up to 12 months, with a 2-4 week follow-up period. If needed when the patient completes or discontinues the study, an open-label transition dose of 30 mg and 15 mg edoxaban tablets will be provided.
88967702|NCT02964949|Active Comparator|Edoxaban 60 mg|Edoxaban 60 mg + placebo 15 mg orally, once daily, at the same time (preferably morning) for up to 12 months, with a 2-4 week follow-up period. If needed when the patient completes or discontinues the study, an open-label transition dose of 30 mg and 15 mg edoxaban tablets will be provided.
88967703|NCT00107341|Experimental|bortezomib + paclitaxel + carboplatin|"Patients receive bortezomib IV over 3-5 seconds on days 1, 4, and 8 and paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 2. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~After completion of study treatment, patients are followed every 3 months until disease progression and then every 6 months for up to 3 years."
88967704|NCT00107419|Experimental|pemetrexed|pemetrexed
88967705|NCT03683667|Placebo Comparator|Placebo & Control|Placebo / Nutrition education
88967706|NCT03683667|Experimental|Placebo & Protein Supplement|Placebo / Protein-rich blended food / Nutrition education
88967707|NCT03683667|Placebo Comparator|Placebo & Isocaloric Supplement|Placebo / Isocaloric blended food / Nutrition education
88967708|NCT03683667|Experimental|Placebo & Egg|Placebo / Egg / Nutrition education
88967709|NCT03683667|Experimental|Azithromycin & Control|Azithromycin / Nutrition education
88967710|NCT03683667|Experimental|Azithromycin & Protein Supplement|Azithromycin / Protein-rich blended food / Nutrition education
88967711|NCT03683667|Experimental|Azithromycin & Isocaloric Supplement|Azithromycin Isocaloric blended food Nutrition education
88967712|NCT03683667|Experimental|Azithromycin and Egg|Azithromycin Egg Nutrition education
88967713|NCT00107458|Experimental|Treatment 1|VPA Target Trough Concentration 75-100 mcg/mL, week 1 VPA dose: 15 mg/kg/day, divided tid
88967714|NCT00107458|Experimental|Treatment 10|VPA Target Trough Concentration 100-150 mcg/mL, week 1 VPA dose: 15 mg/kg/day, divided tid
88967715|NCT00107458|Experimental|Treatment 20|VPA Target Trough Concentration 150-200 mcg/mL
88967716|NCT00107497|Active Comparator|Control|50Gy in 25 fractions of radiation therapy over 5 weeks
88967717|NCT00107497|Active Comparator|Test group 1|30Gy in 5 fractions of radiation therapy over 5 weeks
88967718|NCT00107497|Active Comparator|Test group 2|28.5Gy in 5 fractions of radiation therapy over 5 weeks
88967719|NCT02964988|Experimental|uPAR PET/CT|Injection of 68Ga-NOTA-AE105 followed by PET/CT scan. Administration will be performed twice in approximately 8 weeks.
88967720|NCT04712396|Experimental|Capivasertib + Itraconazole|Subjects will receive a single oral dose of capivasertib on Day 1 during treatment period 1, itraconazole on Days 3, 4, and 5 during treatment period 2, and single oral dose of capivasertib plus a dose of itraconazole on Day 6, followed by itraconazole alone on Day 7 during treatment period 3.
88967721|NCT00107770|Other|1|ALS patient
88967722|NCT00107887|No Intervention|1|Subjects in clinics that have not received the intervention
88967723|NCT00107887|Experimental|2|Subjects at clinics that have received the intervention
88967724|NCT00006695|Experimental|Arm I|Iodine-131 Anti-B1 Antibody/BEAM/autologous hematopoietic stem cell transplantation (AHSCT)
88967725|NCT00107926|Experimental|licarbazepine|
88967726|NCT00107926|Placebo Comparator|Placebo|
89562315|NCT04524481||Patients with mild haemophilia A or B|(FVIII or IX >5 %, ≥ 18 years' old)
89562316|NCT04524481||Patients with moderate haemophilia A or B|(FVIII or IX 1-5 %, ≥ 18 years' old)
89562317|NCT04524481||Patients with severe haemophilia A or B|(FVIII or IX <1 %, ≥ 18 years' old)
89562318|NCT05374213|Experimental|Mindfulness-based intervention|Participants will take part in an adapted and abbreviated version of the traditional eight-week MBCT protocol, conducted virtually via Zoom. Participants will meet for five, weekly, two-hour sessions. The group size will be larger than traditional MBCT groups (i.e. 16-20 participants rather than 12 participants).
89562319|NCT05374213|No Intervention|Waitlist|Participants will be placed in a group with no treatment interventions for the duration of five weeks. Once these five weeks are complete, these participants will be placed in the next mindfulness clinic session to receive treatment. This does not the typical wait-list time for clinical services, which currently exceeds eight weeks
89562320|NCT03062969||Cleavage stage biopsy group|Patients undergoing a PGS cycle with single blastomere biopsy on day 3 and analysis using comparative genomic hybridation bacterial artificial chromosome (BAC) arrays (aCGH) If euploid blastocysts were available, patients underwent fresh blastocyst transfer on day 5.
89562321|NCT03062969||Trophectoderm biopsy group|Patients undergoing a PGS cycle with blastocyst biopsy on day 5-7 and analysis using comparative genomic hybridation bacterial artificial chromosome (BAC) arrays (aCGH). If euploid blastocysts were available, patients underwent frozen-thawed blastocyst transfer.
89562322|NCT01129297||BMI ≥ 35 kg/m2 and diabetes|BMI (Body Mass Index) ≥ 35 kg/m2 and diabetes defined by a fasting blood glucose ≥ 7 mmol/l and/or ≥ to 11.1 mmol/l, 120 minutes after ingestion of glucose (oral glucose tolerance test)
89562323|NCT01129297||BMI ≥ 35 kg/m2 with intolerance glucose|BMI (Body Mass Index) ≥ 35 kg/m2 with intolerance glucose defined by a fasting blood glucose> 6 mmol/L and <7 mmol/l and / or> 7.8 mmol/l and <11.1 mmol/l , 120 minutes after ingestion of glucose (oral glucose tolerance test)
89562324|NCT01129297||BMI ≥ 35 kg/m2 without diabetes|BMI (Body Mass Index)≥ 35 kg/m2 without diabetes defined by a blood glucose ≤ 6 mmol/L and / or ≤ 7.8 mmol/l, 120 minutes after ingestion of glucose (oral glucose tolerance test)
89562325|NCT01129297||BMI <27 kg/m2 without diabetes|BMI (Body Mass Index) <27 kg/m2 without diabetes defined by a blood glucose ≤ 6 mmol/L and / or ≤ 7.8 mmol/l, 120 minutes after ingestion of glucose (oral glucose tolerance test)
89562326|NCT01129297||27 < BMI < 35 kg/m2 without diabetes|BMI (Body Mass Index) <27 kg/m2 without diabetes defined by a blood glucose ≤ 6 mmol/L and / or ≤ 7.8 mmol/l, 120 minutes after ingestion of glucose (oral glucose tolerance test)
89562327|NCT04245475|No Intervention|Control Group|No treatment, side study to test the assumptions of our quantitative sensory testing pain paradigm
89562328|NCT04245475|Active Comparator|Low Tech/passive Virtual Reality first|Low Tech VR first brief test phase thermal stimulus + High Tech VR during a second test phase pain stimulus
89562329|NCT04245475|Experimental|High Tech/interactive Virtual Reality first|High Tech/Interactive VR during first brief test phase thermal stimulus + Low Tech VR during a second brief thermal stimulus.
89562330|NCT05097547|Experimental|Contingency management|This arm will include data from participants who received CM
89562331|NCT03987139|Other|All patients|Patients included in the study.
89562332|NCT01117441|Active Comparator|R1 control arm|see detailed protocol description
89562333|NCT01117441|Experimental|R1 experimental arm|see detailed protocol description
89562334|NCT01117441|Active Comparator|R2 control arm|see detailed protocol description
89562335|NCT01117441|Experimental|R2 experimental arm|see detailed protocol description
89562336|NCT01117441|Active Comparator|R-HR control arm|see detailed protocol description
89562337|NCT01117441|Experimental|R-HR experimental arm|see detailed protocol description
89562338|NCT04829123|Experimental|Single dose of 0.5 mg HEC88473|Healthy subjects, receiving a single dose of 0.5 mg HEC88473 (N=6) or placebo(N=2) after meal.
89562339|NCT04829123|Experimental|Single dose of 1.7 mg HEC88473|Healthy subjects, receiving a single dose of 1.7 mg HEC88473 (N=6) or placebo(N=2) after meal.
88967727|NCT00107965|Experimental|1|
88967728|NCT00107965|Experimental|2|
88967729|NCT00107965|Experimental|3|
88967730|NCT00107965|Placebo Comparator|4|
88967731|NCT00107965|Experimental|5|
88967732|NCT00107965|Experimental|6|
88967733|NCT00107965|Experimental|7|
88967734|NCT00107965|Placebo Comparator|8|
89562340|NCT04829123|Experimental|Single dose of 5.1 mg HEC88473|Healthy subjects, receiving a single dose of 5.1 mg HEC88473 (N=6) or placebo(N=2) after meal.
89562341|NCT04829123|Experimental|Single dose of 10.2 mg HEC88473|Healthy subjects, receiving a single dose of 10.2 mg HEC88473 (N=6) or placebo(N=2) after meal.
89562342|NCT04829123|Experimental|Single dose of 17.0 mg HEC88473|Healthy subjects, receiving a single dose of 17.0 mg HEC88473 (N=6) or placebo(N=2) after meal.
89562343|NCT04829123|Experimental|Single dose of 25.5 mg HEC88473|Healthy subjects, receiving a single dose of 25.5 mg HEC88473 (N=6) or placebo(N=2) after meal.
89562344|NCT04829123|Experimental|Single dose of 34.0 mg HEC88473|Healthy subjects, receiving a single dose of 34.0 mg HEC88473 (N=6) or placebo(N=2) after meal.
89562345|NCT04829123|Experimental|Single dose of 44.2 mg HEC88473|Healthy subjects, receiving a single dose of 44.2 mg HEC88473 (N=6) or placebo(N=2) after meal.
89562346|NCT04829123|Experimental|Multiple doses of 1.7 mg HEC88473|Healthy subjects, receiving a weekly dose of 1.7 mg HEC88473 (N=10) or placebo (N=2) for 5 consecutive weeks after meal.
89562347|NCT04829123|Experimental|Multiple doses of 5.1 mg HEC88473|Healthy subjects, receiving a weekly dose of 5.1 mg HEC88473 (N=10) or placebo (N=2) for 5 consecutive weeks after meal.
89562348|NCT04829123|Experimental|Multiple doses of 10.2 mg HEC88473|Healthy subjects, receiving a weekly dose of 10.2 mg HEC88473 (N=10) or placebo (N=2) for 5 consecutive weeks after meal.
89562349|NCT05177159||Postoperative delirium|
89562350|NCT05177159||Non postoperative delirium|
89562351|NCT03939949|Experimental|High Mindfulness|All participants in this condition will complete all measures online at four different points in time, including one narrative response at T1. They will also be instructed to complete a mindfulness intervention at home and respond to diary-type text messaging questions (all including questions about pain) twice daily for six days.
89562352|NCT03939949|Experimental|Low Mindfulness|All participants in this condition will complete all measures online at four different points in time, including one narrative response at T1. They will also be instructed to respond to diary-type text messaging questions (some related to pain) twice daily for six days.
89562353|NCT03939949|Active Comparator|Active control|All participants in this condition will complete all measures online at four different points in time, including one narrative response at T1. They will also be instructed to respond to diary-type text messaging questions (none about pain) twice daily for six days.
89562354|NCT04434599|Active Comparator|Fluoroscopically guided ablation|These patients will receive one catheter ablation of typical atrial flutter by fluoroscopically guided radiofrequency ablation catheters
89562355|NCT04434599|Active Comparator|Contact force guided ablation|These patients will receive one catheter ablation of typical atrial flutter by contact force guided radiofrequency ablation catheters using the CARTO 3D electroanatomic mapping system
89562356|NCT04434599|Active Comparator|Local impedance guided ablation|These patients will receive one catheter ablation of typical atrial flutter by local impedence guided radiofrequency ablation catheters using the Rhythmia Ultra-high density 3D electroanatomic mapping system
89562357|NCT01101451|Active Comparator|Arm I (EBRT, IMRT)|Patients undergo pelvic EBRT or IMRT once daily, 5 days a week, for 5.5 weeks.
89562358|NCT01101451|Experimental|Arm II (cisplatin, EBRT, IMRT)|Patients receive cisplatin IV over 1-2 hours on day 1 and undergo radiotherapy as in Arm I. Treatment with cisplatin repeats every 7 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
89562359|NCT03064919|Experimental|Curriculum Testing|Test an evidence-based curriculum for teaching preschool children to eat in response to internal hunger and fullness signals.
89562360|NCT03656627|Experimental|Nivolumab: Autoimmune Diseases Cohort 1|"Arms determined by autoimmune type. First cohort consists of patients with:~Rheumatoid arthritis, psoriasis, giant cell arteritis/polymyalgia rheumatica, systemic lupus erythematosis~If a patient has more than one autoimmune condition, if all the conditions are within either cohort 1 or 2 above, the patient will be assigned to that cohort. If the patient has conditions from both cohort 1 and 2, the patient will be grouped in cohort 2."
89562361|NCT03656627|Experimental|Nivolumab: Autoimmune Diseases Cohort 2|"Arms determined by autoimmune type. Second cohort consists of patients with:~Other autoimmune diseases (ulcerative colitis, Crohn's disease, multiple sclerosis). Patients must be discussed with PI prior to enrollment.~If a patient has more than one autoimmune condition, if all the conditions are within either cohort 1 or 2 above, the patient will be assigned to that cohort. If the patient has conditions from both cohort 1 and 2, the patient will be grouped in cohort 2."
89562362|NCT04773665|Experimental|Phase 1a, Group G1|20 participants age 18-54 will receive VBI-2902a at a dose of 5 μg of S protein at Day 1 and placebo at Day 28
89562363|NCT04773665|Experimental|Phase 1a, Group G2|20 participants age 18-54 will receive VBI-2902a at a dose of 5 μg of S protein at Days 1 and 28
89562364|NCT04773665|Placebo Comparator|Phase 1a, Group G3|20 participants age 18-54 will receive placebo at Days 1 and 28
89562365|NCT04773665|Experimental|Phase 1b, Group G4|27 participants age 18-54 will receive VBI-2905a at a dose of 5 μg of S protein at Day 1
89562366|NCT04773665|Placebo Comparator|Phase 1b, Group G5|27 participants age 18-54 will receive placebo at Day 1
89562367|NCT03064607||pregnant women|Women undergoing c-section or EXIT procedure
89562368|NCT04759703|Experimental|Pramipexole|Medication arm; 0.25 or 0.5 mg of pramipexole
89562369|NCT04759703|Placebo Comparator|Placebo|Placebo arm; 0.25 or 0.5 mg of placebo
89562370|NCT03595787|Experimental|Prehabilitation program|Program based on nutritional support, physical activity program and coaching. Home-based monitoring will be done thanks to connected watches (step counter pedometer) and a connected body fat weight scale
89562371|NCT05087407|Experimental|decomprssion and drainage seton|
89562372|NCT05087407|Active Comparator|Cutting seton|
89562373|NCT05086003|Experimental|Kidney and bone marrow transplantation|Combined kidney and bone marrow transplantation after preparation with thymoglobuline and total lymphoid irradiation
89562374|NCT05026801|Active Comparator|Azithromycin plus hydroxychloroquine|Azithromycin 500 mg plus hydroxychloroquine 600 mg by mouth daily for six consecutive days
89562375|NCT05026801|Placebo Comparator|Placebo|Placebo
89562376|NCT03063047|Active Comparator|PD21871AA, PD21872AA|Subjects will use PD21871AA for 1 week and then PD21872AA for 1 week.
89562377|NCT03063047|Active Comparator|PD21872AA, PD21871AA|Subjects will use PD21872AA for 1 week and then PD21871AA for 1 week.
89562378|NCT05020795|Experimental|Balloon inflation|Endovascular thrombectomy with simultaneous balloon inflation using a balloon guide catheter
89562379|NCT05020795|Active Comparator|No balloon inflation|Endovascular thrombectomy without simultaneous balloon inflation using a balloon guide catheter
89562380|NCT03062735|Experimental|Inspiratory Muscle Training|Inspiratory Muscle Training intervention (Sham-IMT) groups during a 3 months training season. A pressure threshold device (POWERbreathe - HaB International Ltd., UK) will be used to IMT. The IMT group will perform 30 inspiratory efforts, 5 times a week, twice daily, for 12 weeks, against a pressure threshold load equivalent to 50% of maximal inspiratory pressure (MIP).
89562381|NCT03062735|Sham Comparator|Sham Inspiratory Muscle Training|Sham-IMT group will follow a similar protocol, except the inspiratory effort that will be made against 15% MIP. The duration of each IMT session will be 30 inspirations. After the initial setting of training loads, the IMT group will be instructed to periodically increase load so that only 30 maneuvers could be completed. The Sham-IMT group will not receive these instructions. All the IMT sessions, in both groups will take place before swimming training and will be supervised throughout the intervention period to ensure that technique and load will be appropriate.
89608776|NCT03581175||Cycle1|Patients undergoing colonoscopy with full bowel cleansing before the improvement phase
89608777|NCT03581175||Cycle2|Patients undergoing colonoscopy with full bowel cleansing after the improvement phase
89608778|NCT03586791|Experimental|Pupillometry group|In this group, anesthesia is performed using Pupillometry guided anesthesia.
89608779|NCT03586791|Active Comparator|SPI group|In this group, anesthesia is performed using SPI guided anesthesia.
89608780|NCT03586791|Sham Comparator|Control group|In this group, remifentanil concentration is controlled by the discretion of the anesthesiologist in charge of the patients (Standard management).
89562382|NCT03818659|Active Comparator|Self-Guided|Active Clinics randomized to the Self-Guided Arm will receive access to an AHA/AMA web platform that includes the posted M.A.P. materials and limited access to AMA Staff who are available to answer questions. The study team will facilitate access to staff by hosting a kick-off webinar for program participants that will include an orientation to the materials on the website, general advice and practical tips about what works for implementation, and time for answering questions and discussion with the group.
88967735|NCT00108004|Experimental|Pramlintide|"Pramlintide acetate injection is a clear, colorless, sterile solution for SC injection.~It consists of pramlintide in sodium acetate buffer, pH 4.0, containing 43-mg/mL mannitol as an iso-osmolality modifier and 2.25 mg/mL metacresol as a preservative"
89208498|NCT02598011|Experimental|Toca 511/Toca FC at 220 mg/kg/day|"Toca 511: 4 mL administered by intracranial parenchymal injection into the walls of the resection cavity following tumor resection or, for those subjects who are not candidates for resection, via stereotactic injection into their tumor using a standard Nashold-type side cutting biopsy needle.~Toca FC: Approximately 4 to 6 weeks after tumor resection, subjects will begin temozolomide concurrent with radiation therapy. During concurrent chemoradiation at the start of the second and sixth week of concurrent chemoradiation and every 28 days thereafter, a 7-day course of oral Toca FC will be dosed at 220 mg/kg/day"
89208499|NCT00869310|Experimental|1|Dexamethasone plus Aprepitant
89208500|NCT00869310|Active Comparator|2|dexamethasone plus metoclopramide
89208501|NCT00662558|Experimental|celecoxib|
89208502|NCT00662558|Active Comparator|tramadol|
89208503|NCT00869388|Experimental|Arm 1|rBBX-01 1.0 mg/m2 SC on 5 consecutive days on weeks 1, 3, 5, and 7
89208504|NCT00869388|Experimental|Arm 2|rBBX-01 2.0 mg/m2 SC on 5 consecutive days on weeks 1, 3, 5, and 7
89208505|NCT00869388|Experimental|Arm 3|rBBX-01 4.0 mg/m2 SC on 5 consecutive days on weeks 1, 3, 5, and 7
89208506|NCT00869388|Experimental|Arm 4 (optional)|rBBX-01 8.0 mg/m2 SC on 5 consecutive days on weeks 1, 3, 5, and 7
89208507|NCT00870792|Active Comparator|Received report|
89027321|NCT01309828|Experimental|Azilsartan Medoxomil + Chlorthalidone|United States and Europe: Azilsartan medoxomil 20 mg plus chlorthalidone 12.5 mg fixed dose combination tablets, titrated up to azilsartan medoxomil 40 mg plus chlorthalidone 25 mg orally, once daily for up to 52 weeks.
89208508|NCT00870792|Placebo Comparator|Routine care|Patients receive usual, routine, care.
89208509|NCT05226546|Other|control group|Patient underwent simple olfactive training for one month.
89208510|NCT05226546|Experimental|PRP injected group|Patient had one injection in each olfactory cleft.
89208511|NCT00869544||HIV|Those positive for HIV and those negative but at high risk for HIV. Both positive and negative for HIV who smoke and those who do not smoke. Both HIV positive and negative with and without asthma and/or COPD
89208512|NCT00788996|Experimental|Lifestyle counseling|Usual care
89208513|NCT00869856|Experimental|1|HX575, EPO Hexal
89208514|NCT00802256|Experimental|A|teeth which are treated with Mineral Trioxide Aggregate (MTA) material
89208515|NCT00802256|Experimental|B|teeth which are treated with new Endodontic Cement (NEC) material
89562383|NCT03818659|Experimental|Full Support|"Active Clinics randomized to the Full Support Arm will receive online access to M.A.P. materials and orientation webinar and also a Practice Change Facilitator who will lead the health center clinical staff, site champions and physician leads at each clinic over the course of 6 months to support the implementation of the MAP Program. With support from an AMA Improvement Advisor, the Practice Change Facilitators will perform a baseline assessment of current workflows and assess each domain of M.A.P. The goal of the Full Support program is to help care teams develop skills and sustainable workflows that are effective at attaining and maintaining high levels of BP control."
89562384|NCT03818659|No Intervention|Usual Care|"The investigators will also conduct non-randomized comparisons of BP control in the Full Support and Self-Guided intervention arms to BP control in non-participating Usual Care institutions in PCORnet."
89208516|NCT00876486|Experimental|Genexol®-PM|This is a open-labeled, randomized, parallel, phase III Trial. Up to 106 elgible patients will be enrolled in each treatment arm(Total 212 subjects will recruited) according to the trial design. Patients will be randomly allocated to arm A (Genexol-PM) or arm B (Paclitaxel).
89208517|NCT00876486|Active Comparator|Genexol®|This is a open-labeled, randomized, parallel, phase III Trial. Up to 106 elgible patients will be enrolled in each treatment arm(Total 212 subjects will recruited) according to the trial design. Patients will be randomly allocated to arm A (Genexol-PM) or arm B (Paclitaxel).
89208518|NCT00802334|Experimental|1|
89208519|NCT00876564|Other|Trauma patients|Included in trauma registry
89208520|NCT00876642|Experimental|1|
89208521|NCT00876642|No Intervention|2|
89208522|NCT00796796|Experimental|Cohort 1 (Starting Dose)|"Temsirolimus 20 mg IV weekly for 4 weeks~Radiation therapy will begin on Day 2, one day after the initial dose of temsirolimus. Treatment will consist of daily fractions of 250 cGy, 5 days per week to a total cumulative dose of 3500 cGy for a total of 14 days."
89208523|NCT00796796|Experimental|Cohort 2|"Temsirolimus 25 mg IV weekly for 4 weeks~Radiation therapy will begin on Day 2, one day after the initial dose of temsirolimus. Treatment will consist of daily fractions of 250 cGy, 5 days per week to a total cumulative dose of 3500 cGy for a total of 14 days."
89208524|NCT03794076|Active Comparator|Cromoglycate|Cromoglycate nasal spray
89208525|NCT03794076|Placebo Comparator|Placebo|Saline nasal spray
89208526|NCT00802490|Active Comparator|Intervention|20 sessions of EEG biofeedback training
89208527|NCT00802490|Placebo Comparator|Control|Only 1 session of EEG biofeedback training
89208528|NCT00870948|Experimental|Regimen A|One 100 mg ABT-874 (pre-filled syringe liquid formulation from the 6000 L process) injected subcutaneously in the abdominal region at a 45 degree angle
89208529|NCT00870948|Experimental|Regimen B|One 100 mg ABT-874 (pre-filled syringe liquid formulation from the 6000 L process) injected IV in an arm vein
89208530|NCT00870948|Experimental|Regimen C|One 100 mg ABT 874 (reconstituted lyophilized powder from the 3000 L process) injected subcutaneously in the abdominal region at a 45 degree angle
89208531|NCT00870948|Experimental|Regimen D|One 100 mg ABT-874 (reconstituted lyophilized powder from the 1000 L process) injected subcutaneously in the abdominal region at a 45 degree angle
89562385|NCT03789877|Experimental|Group I (home-based walking program, rTMS)|Patients participate in a home-based exercise program of at least 10,000 steps per day (about 30 minutes of daily exercise) for 5 days weekly (150 minutes per week) for 12 weeks. Patients also undergo repetitive transcranial magnetic stimulation over 1 hour for 8 sessions during the first 2 weeks of the walking program.
89562386|NCT03789877|Active Comparator|Group II (home-based exercise program, sham rTMS)|Patients participate in a home-based exercise program of at least 10,000 steps per day (about 30 minutes of daily exercise) for 5 days weekly (150 minutes per week) for 12 weeks. Patients also undergo sham repetitive transcranial magnetic stimulation over 1 hour for 8 sessions during the first 2 weeks of the walking program.
89562387|NCT03786991||Organ donors|Organ donors after neurologic death (NDD) of 18 years old and older for whom consent to organ donation has been obtained.
89562388|NCT03786991||Liver and kidney Recipients|Liver and kidney recipients of 18 years old and older.
89562389|NCT03943693|Active Comparator|Single Shock Group|Patients randomized to single shock will then be treated initially with a 200 Joule shock through the antero-posterior pads only.
89562390|NCT03943693|Active Comparator|Double Shock Group|Patients randomized to the dual shock group will have two near-simultaneous 200-Joule shocks delivered through the two sets of pads (antero-posterior position and right infraclavicular-axillary position). The first of these shocks will be synchronized.
89562391|NCT03493061|Experimental|Systemic CPT-11 + HAI (FUDR+L-OHP)|"Patients will receive Systemic CPT-11 + HAI (FUDR+L-OHP) every 28 days:~Irinotecan 150 mg/m2 IV over 90 minutes on Day 1; followed by Oxaliplatin 85 mg/m2 over 3 hours through the HAI pump on Day 1 and 0.12 mg/kg/day floxuridine (FUDR) and 25 mg dexamethasone in normal saline to a total volume of 300 ml will be administered through the HAI pump.~then Irinotecan 150 mg/m2 IV over 90 minutes on Day 15, followed by Oxaliplatin 85 mg/m2 IV over 3 hours on Day 15.~This will be repeated on Day 1 of each 28-day cycle. FUDR will be administered through a 14-day continuous infusion with the HAI pump."
89562392|NCT03410017||Normally-hearing|Children with normal hearing
89562393|NCT04110613|Active Comparator|noFast: Start tube feeds within 1 hour of procedure|The noFAST group will have post-PEG tube feeds initiated <1 hour after the procedure. Feeds are to be initiated at the rate and with the formula the patient was tolerating prior to the procedure.
89562394|NCT04110613|No Intervention|FAST: Start tube feeds 4 hours after procedure|The FAST group will have post-PEG tube feeds initiated 4 hours after the procedure. Feeds are to be initiated at the rate and with the formula the patient was tolerating prior to the procedure.
89562395|NCT03516877|Experimental|ESRT|"Volunteer surgery and anesthesia faculty from UCSF working at Parnassus Hospital site and interested in training.~Volunteer surgery and anesthesia faculty from UCSF working at Zuckerberg San Francisco General Hospital site and interested in training.~Volunteer surgery and anesthesia faculty from UCSF working at Mission Bay Hospital site and interested in training."
89562396|NCT04800523|Experimental|Arm 1 - Non-functional Device|a non-functional UroMonitor will be inserted by urologist.
89562397|NCT04654897|Experimental|Elinzanetant (NT-814, BAY3427080)|Subjects received a single dose of 120 mg radioactive labeled elinzanetant ([14C]-NT-814) orally.
89562398|NCT03236077|No Intervention|Control|
89562399|NCT03236077|Experimental|Intervention|
89562400|NCT04554043|Experimental|SHR7280 dose 1(male)|oral administration for 14 days,Phase I(PART 1)
89562401|NCT04554043|Experimental|SHR7280 dose 2(male)|oral administration for 14 days,Phase I(PART 1)
89562402|NCT04554043|Experimental|SHR7280 dose 3(male)|oral administration for 14 days,Phase I(PART 1)
89562403|NCT04554043|Experimental|SHR7280 dose 4(male)|oral administration for 14 days,Phase I(PART 1)
89562404|NCT04554043|Experimental|SHR7280 dose 5(male)|oral administration for 14 days,Phase I(PART 1)
88967736|NCT03638427||High Risk HPV Positive Cohort|This group of women have tested positive for HR-HPV at annual cervical cancer screening and have been invited to participate in the study. They will be asked to use a menstrual pad we provide that collects a sample of their menstrual blood (strip). The strip will be mailed back to us for analysis (Menstrual Blood Analysis). These women will also be asked to conduct a self-swab vaginally to be sent back to us for analysis. These women will return 6-months after their positive HR-HPV for standard of care testing. All results of the standard of care tests, menstrual blood tests, and self-swab tests will be compared.
88967737|NCT00108316|Other|Arm 1|
89562405|NCT04554043|Experimental|SHR7280 dose 1(female)|oral administration for 21 days,Phase I(PART 2)
89562406|NCT04554043|Experimental|SHR7280 dose 2(female)|oral administration for 21 days,Phase I(PART 2)
89562407|NCT04554043|Experimental|SHR7280 dose 3(female)|oral administration for 21 days,Phase I(PART 2)
88967738|NCT00401440|Active Comparator|A|400 microgram vaginal misoprostol tablet will be applied every 6 hours with a maximum of 4 doses
88967739|NCT00401440|Active Comparator|B|400 microgram vaginal misoprostol tablet will be applied every 12 hours with a maximum of 4 doses
88967740|NCT00006773|Experimental|Treatment (bortezomib)|Patients receive bortezomib IV over 3-5 seconds twice weekly for 2 weeks. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
88967741|NCT00108901|No Intervention|Control|Children were not provided with an after-school exercise intervention. They were free to do their usual activities. Families were offered a monthly healthy lifestyle class.
88967742|NCT00108901|Experimental|Low Dose|This group was assigned to receive a 20 min/day aerobic exercise program offered 5 days/week after school. Families were offered a monthly healthy lifestyle class.
88967743|NCT00108901|Experimental|High dose|This group was assigned to receive a 40 min/day aerobic exercise program offered 5 days/week after school. Families were offered a monthly healthy lifestyle class.
88967744|NCT00006890|Experimental|Prednisone plus Thalidomide|After Autologous Stem Cell Infusion
88967745|NCT03608397|Experimental|DAXI for injection low dose|Low Dose Group
88967746|NCT03608397|Experimental|DAXI for injection high dose|High Dose Group
89562408|NCT04554043|Experimental|SHR7280 dose 4(female)|oral administration for 21 days,Phase I(PART 2)
89562409|NCT04554043|Experimental|SHR7280 dose 6(male)|oral administration for 14 days,Phase I(PART 1)
89562410|NCT04554043|Experimental|SHR7280 dose 7(male)|oral administration for 14 days,Phase I(PART 1)
89562411|NCT04523935|Placebo Comparator|Placebo-Sequence 1|The placebo contained fructose powder in packets identical to the medicines.
89562412|NCT04523935|Active Comparator|Drug-Sequence 2|GABA-B agonists, muscarinic acetylcholine receptor antagonists, inhibitors of the vesicular monoamine transporter, benzodiazepines, antiepileptics, and tricyclic antidepressants were used.
89562413|NCT05059301|Experimental|RSV OA_Lot 1|Participants received 1 dose of a combination of the RSVPreF3 antigen Lot 1 and AS01E adjuvant Lot A at Day 1 and were followed up until the study end (Month 6).
89562414|NCT05059301|Experimental|RSV OA_Lot 2|Participants received 1 dose of a combination of the RSVPreF3 antigen Lot 2 and AS01E adjuvant Lot B at Day 1 and were followed up until the study end (Month 6).
89562415|NCT05059301|Experimental|RSV OA_Lot 3|Participants received 1 dose of a combination of the RSVPreF3 antigen Lot 3 and AS01E adjuvant Lot C at Day 1 and were followed up until the study end (Month 6).
89562416|NCT03450473|Other|SurgiMend® MP|Patients will not be randomized as this is a case series study involving the evaluation of only 1 type of mesh (SurgiMend MP®).
89562417|NCT01938430|Experimental|Cohort A, Group 1 (12 wk): CPT Class B (7-9)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class B (CPT score 7-9)
89562418|NCT01938430|Experimental|Cohort A, Group 1 (24 wk): CPT Class B (7-9)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class B (CPT score 7-9)
89562419|NCT01938430|Experimental|Cohort A, Group 2 (12 wk): CPT Class C (10-12)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class C (CPT score 10-12)
89562420|NCT01938430|Experimental|Cohort A, Group 2 (24 wk): CPT Class C (10-12)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class C (CPT score 10-12)
89562421|NCT01938430|Experimental|Cohort B, Group 3 (12 wk): F0-F3 Fibrosis|LDV/SOF (90/400 mg) plus RBV (weight-based: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with Fibrosis Stage F0-F3.
89562422|NCT01938430|Experimental|Cohort B, Group 3 (24 wk): F0-F3 Fibrosis|LDV/SOF (90/400 mg) plus RBV (weight-based: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with Fibrosis Stage F0-F3
89562423|NCT01938430|Experimental|Cohort B, Group 4 (12 wk): CPT Class A (5-6)|LDV/SOF (90/400 mg) plus RBV (weight-based: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with CPT Class A (CPT score 5-6)
89208532|NCT00870948|Experimental|Regimen E|700 mg ABT-874 (reconstituted lyophilized powder from the 3000 L process) in 100 mL 5% dextrose solution IV infusion in an arm vein
89562424|NCT01938430|Experimental|Cohort B, Group 4 (24 wk): CPT Class A (5-6)|LDV/SOF (90/400 mg) plus RBV (weight-based: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with CPT Class A (CPT score 5-6)
89562425|NCT01938430|Experimental|Cohort B, Group 5 (12 wk): CPT Class B (7-9)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class B (CPT score 7-9)
89562426|NCT01938430|Experimental|Cohort B, Group 5 (24 wk): CPT Class B (7-9)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class B (CPT score 7-9)
89562427|NCT01938430|Experimental|Cohort B, Group 6 (12 wk): CPT Class C (10-12)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class C (CPT score 10-12)
89562428|NCT01938430|Experimental|Cohort B, Group 6 (24 wk): CPT Class C (10-12)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class C (CPT score 10-12)
88967747|NCT03608397|Placebo Comparator|Placebo|Placebo Group
88967748|NCT00006929|Experimental|Treatment (suramin, paclitaxel, carboplatin)|Patients receive suramin IV over 30 minutes on days 1 and 2. Patients also receive paclitaxel IV over 3 hours and carboplatin IV over 1 hour on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
88967749|NCT00109213|Active Comparator|1|Lumbar Laminectomy without Fusion
88967750|NCT00109213|Active Comparator|2|Lumbar Laminectomy with Pedicle Screw Instrumented Fusion
88967751|NCT03598920||AspireAssist|Patients undergoing the endoscopic bariatric procedure using the AsspireAssist device
89562429|NCT01938430|Experimental|Cohort B, Group 7 (12 wk): FCH|LDV/SOF (90/400 mg) plus RBV (weight-based: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with FCH
88967752|NCT03598920||Nutritional consulting|Patients undergoing nutritional consulting
88967753|NCT00109291|Placebo Comparator|Placebo|Single injection of placebo administered intravenously
88967754|NCT00109291|Experimental|Peginesatide 0.025 mg/kg|Single peginesatide dose of 0.025 milligram per kilogram (mg/kg) administered intravenously.
88967755|NCT00109291|Experimental|Peginesatide 0.05 mg/kg|Single peginesatide dose of 0.05 mg/kg administered intravenously.
89562430|NCT01938430|Experimental|Cohort B, Group 7 (24 wk): FCH|LDV/SOF (90/400 mg) plus RBV (weight-based: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with FCH
89562431|NCT01937884|Experimental|Early Parenteral Nutrition|Patients receive supplemental parenteral nutrition within 12 hours of enrollment. Titrated with enteral nutrition to achieve target goal calories and protein.
89562432|NCT01937884|Active Comparator|Late Parenteral Nutrition|Patients receive supplemental parenteral nutrition 96 hours after enrollment. Titrated with enteral nutrition to achieve target goal calories and protein.
89562433|NCT01916824|Experimental|Participants with Major Depressive Disorder|Persons with a primary diagnosis of Major Depressive Disorder who start taking any FDA-approved antidepressant prescribed within standard dose range for 6 weeks
89562434|NCT01916824|No Intervention|Healthy Controls|Persons without a history of Major Depressive Disorder and without a current diagnosis of any mental illness
89562435|NCT01915732|Experimental|Duac™Once Daily Gel|Subjects will use Duac™Once Daily Gel (once daily in the evening)for 12 weeks. The subjects will be evaluated for change in lesion counts, ISGA, SGA , local tolerability, and AEs/SAEs at Weeks0, 1, 2, 4, 8, and 12 (or at early withdrawal). In addition, quality of life measures will be performed at every study visit
89562436|NCT01915732|Active Comparator|1% clindamycin phosphate gel|Subjects will use 1% clinidamycin phosphate gel (twice daily in the morning and evening)for 12 weeks. The subjects will be evaluated for change in lesion counts, ISGA, SGA , local tolerability, and AEs/SAEs at Weeks0, 1, 2, 4, 8, and 12 (or at early withdrawal). In addition, quality of life measures will be performed at every study visit
89562437|NCT04634968|Experimental|intervention group|The interactive Brief MI-based text message communication via instant messaging apps (e.g., WhatsApp, WeChat) will be applied in the intervention group. The chatting function of WhatsApp and WeChat will be used as the intervention platform. The intervention will start on the first day after the participants join the follow-up group. The whole interactive text-communication intervention lasts for 1 month. The frequency of message communication will be at least twice a week. After completing the intervention, participants will be invited to complete an individualized telephone-based interview for collecting further information on the intervention content.
89562438|NCT04634968|Placebo Comparator|control group|The participants in the control group will receive general health communication twice every week via SMS. The communication lasts for 1 month. After completing the intervention, participants will be invited to complete an individualized telephone-based interview for collecting further information on the intervention content.
89562439|NCT04634266|Experimental|Experimental intervention|Transcatheter tricuspid valve treatment (TTVT) plus optimal medical therapy (OMT)
89562440|NCT04634266|No Intervention|Control intervention|OMT for severe tricuspid regurgitation in right-sided heart failure
89562441|NCT01936948|Active Comparator|Clip closure + EndoCut|Clipping of the mucosal defect after resection of a ≥20mm non-pedunculated study polyp using clips. Resection is done using the EndoCut electrocautery mode.
89562442|NCT01936948|Active Comparator|Clip closure + Coagulation|Clipping of the mucosal defect after resection of a ≥20mm non-pedunculated study polyp using clips. Resection is done using the Coagulation electrocautery mode.
89562443|NCT01936948|No Intervention|No clip closure + EndoCut|No clipping of the mucosal defect after resection of a ≥20mm non-pedunculated study polyp. Resection is done using the EndoCut electrocautery mode.
89562444|NCT01936948|No Intervention|No clip closure + Coagulation|No clipping of the mucosal defect after resection of a ≥20mm non-pedunculated study polyp. Resection is done using the Coagulation electrocautery mode.
89562445|NCT01936870||Fesoterodine (Toviaz)|
89562446|NCT01618864|Other|Luxe|
89562447|NCT01618708|Experimental|Synvisc-One|Single intraarticular (IA) injection of Synvisc-One (48 mg of Hylan G-F 20 polymer) at Day 1. Participants were observed for 26 weeks in follow up period.
89562448|NCT01618708|Placebo Comparator|Placebo|Single IA injection of placebo matched to Synvisc-One at Day 1. Participants were observed for 26 weeks in follow up period.
89562449|NCT04615234||Experimental: Treated with Genetic Test Guide (TGTG)|Antidepressant monotherapy treatments according to good clinical practice for major depressive disorder guided with the pharmacogenomic test (PGs)
89562450|NCT04615234||Control: Treated as Usual (TAU)|Antidepressant monotherapy treatments according to good clinical practice for major depressive disorder.
89562451|NCT03315455|Active Comparator|Arm C (Control): No Prophylaxis, Then Emicizumab|Participants ≥12 years old with hemophilia A (with or without FVIII inhibitors) who are randomized to Arm C will not receive any prophylactic treatment for at least 24 weeks. After 24 weeks, participants will have the opportunity to switch to receive emicizumab prophylaxis at 3 mg/kg QW via SC injection for 4 weeks, followed by 6 mg/kg Q4W until marketing authorization as part of this study or a separate extension study, as long as they derive clinical benefit. Participants will continue to receive standard-of-care treatments on an episodic basis for the treatment of breakthrough bleeds during the study.
89208533|NCT00739973|Placebo Comparator|Placebo|Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 5 of the 5 pills taken were placebos.
89562452|NCT03315455|Experimental|Arm A: Emicizumab Prophylaxis at 1.5 mg/kg QW|Participants ≥12 years old with hemophilia A (with or without FVIII inhibitors) who are randomized to Arm A will receive prophylactic emicizumab at a dose of 3 mg/kg via SC injection QW for first 4 weeks, followed by 1.5 mg/kg via SC injection Q4W for at least 24 weeks. After 24 weeks treatment, participants will be allowed to continue emicizumab until marketing authorization as part of this study or a separate extension study, as long as they derive clinical benefit. Participants will continue to receive standard-of-care treatments on an episodic basis for the treatment of breakthrough bleeds during the study.
89562453|NCT03315455|Experimental|Arm B: Emicizumab Prophylaxis at 6 mg/kg Q4W|Participants ≥12 years old with hemophilia A (with or without FVIII inhibitors) who are randomized to Arm B will receive prophylactic emicizumab at a dose of 3 mg/kg via SC injection QW for first 4 weeks, followed by 6 mg/kg via SC injection Q4W for at least 24 weeks. After 24 weeks treatment, participants will be allowed to continue emicizumab until marketing authorization as part of this study or a separate extension study, as long as they derive clinical benefit. Participants will continue to receive standard-of-care treatments on an episodic basis for the treatment of breakthrough bleeds during the study.
89562454|NCT03315455|Experimental|Arm D: Emicizumab Prophylaxis at 1.5 mg/kg QW|Participants <12 years old with hemophilia A and FVIII inhibitors who are enrolled to Arm D will receive prophylactic emicizumab at a dose of 3 mg/kg via SC injection QW for first 4 weeks, followed by 1.5 mg/kg via SC injection QW for at least 24 weeks. After 24 weeks treatment, participants will be allowed to continue emicizumab until marketing authorization as part of this study or a separate extension study, as long as they derive clinical benefit. Participants will continue to receive standard-of-care treatments on an episodic basis for the treatment of breakthrough bleeds during the study.
89562455|NCT03064139|Experimental|MCG - Mindful Walking|Participants will be trained in mindful walking technique
89562456|NCT03064139|Active Comparator|SCG - Education and Self-Care|Participants will receive education in self-management of knee OA
89562457|NCT02229149|Experimental|Triple Therapy|"Physician's choice of chemotherapy plus trastuzumab plus pertuzumab~trastuzumab, given as a loading dose of 8 mg/kg intravenously (IV, or through the vein) on Day 1 followed by 6 mg/kg IV every 3 weeks thereafter, AND~physician's choice of chemotherapy:~Vinorelbine 25 mg/m2 IV weekly times 3 with 1 week off; OR~Paclitaxel 80 mg/m2 IV weekly times 3 with 1 week off; OR~Nab-Paclitaxel 100 mg/m2 IV weekly times 3 with 1 week off; OR~Docetaxel 75 mg/m2 IV every 3 weeks; OR~Capecitabine 1500 mg by mouth twice a day (PO BID) 14 days on and then 7 days off.~AND pertuzumab given as a loading dose of 840 mg IV on Day 1 followed by 420 mg IV every 3 weeks."
88967756|NCT00109291|Experimental|Peginesatide 0.10 mg/kg|Single peginesatide dose of 0.10 mg/kg administered intravenously.
88967757|NCT02964871|Active Comparator|LTCF with RIDT|Nasal swabs will be tested by nursing personnel at each intervention site using SOFIA Fluorescent Immunoassay Analyzer Influenza A+B (LTCF with RIDT). Anonymous results will be sent, via wireless transmission, for daily review by the study team and public health personnel. A positive influenza detection will trigger direct communication with LTCF personnel with advice on antiviral treatment, antiviral prophylaxis, and appropriate infection control practices. We will collect data from each site regarding the prescribing of influenza antivirals for treatment and prophylaxis, number of hospitalizations, number of deaths, and associated healthcare costs during annual, dynamic, 4-month risk windows, based on Wisconsin surveillance of influenza patterns.
88967758|NCT02964871|Placebo Comparator|LTCF Control|"Usual care.~Data will be collected from each site regarding the prescribing of influenza antivirals for treatment and prophylaxis, number of hospitalizations, number of deaths, and associated healthcare costs during annual, dynamic, 4-month risk windows, based on Wisconsin surveillance of influenza patterns."
88967759|NCT00109369|Experimental|Active|Provider and patient receive Diabetes Information System services
88967760|NCT00109369|No Intervention|Control|Usual Care
88967761|NCT00007007|Experimental|Whole brain radiation therapy + neurocognitive assessments|Whole brain radiation therapy (WBRT) with neurocognitive assessments done pre and post WBRT.
88967762|NCT00109408|Experimental|1|
88967763|NCT00109408|Active Comparator|2|
88967764|NCT03581760|Experimental|Cycling Exercise|Patients randomized into this arm will undergo cycling exercise once a day while on mechanical ventilation at intensive care unit.
88967765|NCT03581760|Active Comparator|Conventional Physiotherapy|Patients randomized into this arm will undergo conventional physiotherapy twice a day while on mechanical ventilation at intensive care unit.
88967766|NCT00109486|Experimental|Arm 1|
88967767|NCT03513042||Cohort|"Intervention:~- Standard of care Intensity Modulated Proton Therapy (IMPT) +/- Chemotherapy.~Baseline measurements:~- All patients undergo baseline FDG PET-CT and FAZA PET-CT of the head-neck area.~Interim measurements conventional):~FDG PET-CT will be repeated at the end of the second week of IMPT.~FAZA PET will only be repeated at the end of the second week of IMPT if a hypoxic tumour volume was found at baseline scanning.~A subcohort will also undergo activation PET imaging three times during IMPT."
88967768|NCT00109720|Experimental|1|Patients in the experimental group received the services of a Diabetes Self-Management Consultant (DSC)
88967769|NCT00109720|Active Comparator|2|This Arm was a Enhanced Usual Care Control group who continued with their usual care but also they and their physicians received the results of all metabolic assessments obtained during the study.
88967770|NCT00109759|Experimental|RagweedMATAMPL|
88967771|NCT00109759|Placebo Comparator|Placebo|
88967772|NCT00109798|Experimental|Temozolomide, Topotecan|Patient will take on days 1-5 of a 28-days schedule. Take Topotecan on days 2-6 of the 28 day schedule
88967773|NCT00110032|Experimental|Group 1 (fluorine F 18 EF5, PET)|Patients receive fluorine F 18 EF5 (^18F-EF5) IV followed by whole brain and whole body PET scanning OR whole body PET scanning only. Patients then receive nonradioactive EF5 IV over 1-2 ½ hours.
88967774|NCT00110032|Experimental|Group 2 (EF5, PET)|Patients receive nonradioactive EF5 IV over 1-2½ hours followed by ^18F-EF5 IV. Patients then undergo whole brain and whole body PET scanning.
88967775|NCT00110032|Experimental|Group 3 (EF5, PET)|Patients receive nonradioactive EF5 and ^18F-EF5 as in group 2. Patients then undergo whole brain PET scanning.
88967776|NCT03472716||Samples|Included patients will undergo 2 biological samples : a 5-ml blood sample included in the standard care and a tumoral sample (from the surgical exeresis or from the initial diagnosis biopsy). Patients with a confirmed pancreatic carcinoma will be followed during 18 months in this cohort. In case of relapse, patients will have 2 new biological samples (blood and tumoral).
88967777|NCT00110071|Experimental|Treatment (chemoradioimmunotherapy)|Patients receive a dosimetric dose of iodine I 131 tositumomab IV over 40-60 minutes on day -24 followed by gamma camera imaging over the next 6 days. Patients then receive a therapeutic dose of iodine I 131 tositumomab via central line over 40-60 minutes on day -14. Patients also receive fludarabine phosphate IV QD on days -11 to -9 OR days -11 or -7. Patients undergo autologous or syngeneic peripheral blood stem cell transplantation on day 0.
88967778|NCT00110188|Experimental|Ridaforolimus|50 mg of ridaforolimis intravenously over 30 minutes, weekly
88967779|NCT00110227|Experimental|Tai Chi|12-week tai chi program
88967780|NCT00110227|Active Comparator|Heart Health Education|12-week attention control
88967781|NCT00110344|Experimental|Arm 1|
88967782|NCT00110344|Placebo Comparator|Arm 2|
88967783|NCT00110383|Experimental|1|Supervised therapy
88967784|NCT00110383|No Intervention|2|Inhaled steroid use as usual care
88967785|NCT00110656||Kidney Transplant|All patients entered into the study will have received a kidney transplant.
88967786|NCT00388193|Experimental|1|
88967787|NCT00110695|Experimental|A|
88967788|NCT00110773|Experimental|S-Caine Peel|
88967789|NCT00110773|Placebo Comparator|Placebo Peel|
88967790|NCT00388271|Active Comparator|1|xatral
88967791|NCT00388271|Placebo Comparator|2|standard treatment
88967792|NCT00111085|Experimental|Clazosentan 1 mg/h|intravenous clazosentan at 1 mg/h starting within 56 hours maximum after aneurysm rupture and continuing until Day 14 post-aneurysm rupture
88967793|NCT00111085|Experimental|Clazosentan 5 mg/h|intravenous clazosentan at 5 mg/h starting within 56 hours maximum after aneurysm rupture and continuing until Day 14 post-aneurysm rupture
89562458|NCT02229149|Active Comparator|Double Therapy|"Physician's choice of chemotherapy plus trastuzumab~trastuzumab, given as a loading dose of 8 mg/kg intravenously (IV, or through the vein) on Day 1 followed by 6 mg/kg IV every 3 weeks thereafter, AND~physician's choice of chemotherapy:~Vinorelbine 25 mg/m2 IV weekly times 3 with 1 week off; OR~Paclitaxel 80 mg/m2 IV weekly times 3 with 1 week off; OR~Nab-Paclitaxel 100 mg/m2 IV weekly times 3 with 1 week off; OR~Docetaxel 75 mg/m2 IV every 3 weeks; OR~Capecitabine 1500 mg PO BID 14 days on and then 7 days off."
89562459|NCT03259295|Experimental|Skin tag removal initial visit plus follow-up|Removal of skin tags 1 cm or less using Digiclamp and follow-up 2-3 months after skin tag removal to assess functionality and effectiveness of the device.
89562460|NCT04871399|Active Comparator|Conventional Right hemicolectomy (Non-CME)|Patients will undergo conventional non-CME procedure.
89562461|NCT04871399|Experimental|Right hemicolectomy with CME+CVL|Patients will undergo Right hemicolectomy CME+CVL procedure.
89562462|NCT04432025|Active Comparator|Control|Patients will undergo bariatric surgery- either roux en y gastric bypass or sleeve gastrectomy. Long term diabetes care will be under the supervision of their primary care provider/general practitioner
89562463|NCT04432025|Experimental|Intervention|Patients will undergo bariatric surgery- either roux en y gastric bypass or sleeve gastrectomy and will have ongoing goal directed medical treatment for their T2DM, titrated to specific end points for BP, HbA1c and lipids.
89562464|NCT04867889|Active Comparator|Active Treatment iTBS|Magnetic pulses of 120% of visual motor threshold applied in triplets of 50 Hz bursts, repeated at 5 Hz; 2 seconds on and 8 seconds off; 600 pulses per session; total duration of 3 min 20 s over the left DLPFC (F3), given in 20 sessions on 20 week days, one session per day.
89562465|NCT04867889|Sham Comparator|Sham treatment|Sham treatment given either with a sham stimulation coil or by flipping an active coil 90 degrees.
89562466|NCT04440371|Active Comparator|Tacrolimus|Phototherapy NBUVB will be given 3 times per week and Tacrolimus 0.1% ointment will be applied twice a day
89562467|NCT04440371|Active Comparator|calcipotriol / betamethasone|Phototherapy NBUVB will be given 3 times per week and calcipotriol & betamethasone containing cream will be applied once a day
89562468|NCT04430543|Experimental|CBM Group|This group will receive Cognitive Bias Modification training
89562469|NCT04430543|Sham Comparator|Control Group|This group will receive Sham (control) training
88967794|NCT00111085|Experimental|Clazosentan 15 mg/h|intravenous clazosentan at of 15 mg/h starting within 56 hours maximum after aneurysm rupture and continuing until Day 14 post-aneurysm rupture
88967795|NCT00111085|Placebo Comparator|Placebo|intravenous placebo starting within 56 hours maximum after aneurysm rupture and continuing until Day 14 post-aneurysm rupture
88967796|NCT03429114||Binge eating/purging|Adolescents engaging in recurrent binge eating and/or purging behavior.
88967797|NCT03429114||Healthy comparison|Adolescents who do not have a history of eating disorders
88967798|NCT00388310|Active Comparator|Cephalexin|Cephalexin 250 mg PO q6h x5 days
88967799|NCT00388310|Active Comparator|Clindamycin|Clindamycin 300 mg PO q6h x5 days
88967800|NCT00388310|Active Comparator|trimethoprim/sulfamethoxazole|trimethoprim/sulfamethoxazole 160 mg/800 mg PO q12h x 5 days
88967801|NCT00388310|Placebo Comparator|Placebo|
89027322|NCT01309828|Active Comparator|Olmesartan Medoxomil + Hydrochlorothiazide|United States: Olmesartan medoxomil 20 mg plus hydrochlorothiazide 12.5 mg fixed dose combination tablets, titrated up to olmesartan medoxomil 40 mg plus hydrochlorothiazide 25 mg orally, once daily for up to 52 weeks. Europe: Olmesartan medoxomil 20 mg plus hydrochlorothiazide 12.5 mg fixed dose combination tablets, titrated up to olmesartan medoxomil 20 mg plus hydrochlorothiazide 25 mg orally, once daily for up to 52 weeks.
89027323|NCT00482820|Experimental|1|attention training away from threat
89027324|NCT00482820|Placebo Comparator|2|placebo attention training
89562470|NCT02087267||1- or 2-level spinal fusion|Patients suffering from symptomatic degenerative disc disease or degenerative spondylolisthesis grade 1 or 2 with chronic low back pain, pain in the leg or buttock, muscle weakness, sensation abnormalities and/or neurogenic claudication requiring 1- or 2-level lumbar or lumbar-sacral spinal fusion.
89562471|NCT03213119|Experimental|Caloric Vestibular Stimulation, Left-Warm|Caloric Vestibular Stimulation (CVS) stimulates the vestibular system through thermic currents applied through small quantity of water injected in the external ear. The Left-Warm condition uses water with a temperature of 44°. It induces a nystagmus with its slow phase towards the right.
89562472|NCT03213119|Experimental|Caloric Vestibular Stimulation, Left-Cold|Caloric Vestibular Stimulation (CVS) stimulates the vestibular system through thermic currents applied through small quantity of water injected in the external ear. The Left-Cold condition uses water with a temperature of 30°. It induces a nystagmus with its slow phase towards the left.
89562473|NCT03213119|Sham Comparator|Caloric Vestibular Stimulation, SHAM|The SHAM condition uses water with a temperature of 37°. It does not induce nystagmus
89562474|NCT04432649|Experimental|Effectiveness of 4SCAR-276 T cells|The 4SCAR-276 T cells can recognize and kill tumor cells through the recognition of CD276 .This study will evaluate the side effects and effective doses of 4SCAR-276 T cells in treating refractory and recurrent solid tumors
89562475|NCT03125447|Experimental|Prematurely born children|Speed and accuracy answer to visual stimuli evaluated in 3 distinct posture/mobility situations
89562476|NCT03125447|Active Comparator|Term born children|Speed and accuracy answer to visual stimuli evaluated in 3 distinct posture/mobility situations
89562477|NCT04602923|Experimental|XEN Gel Stent implantation|Participants suffering from glaucoma who are candidates for XEN Gel Stent implantation
89562478|NCT04602923|Experimental|Trabeculectomy|Participants suffering from glaucoma who are candidates for trabeculectomy
89531996|NCT04246593|No Intervention|Control - Planning|At Control - Planning (comparison) sites, engagement will focus on involving community members in food access program planning and research. It is anticipated that each organization will create one or more community advisory committees to oversee their food access work. At comparison sites, engagement efforts will be more generally centered on food access and understanding what types of programs would be most acceptable. Examples of community engagement activities include community forums and listening sessions, informational tables at community events, and establishment of text, e-mail or social media sites for ongoing communication and feedback around food access issues. As part of this community engagement work, partners will collect contact information from community members that will assist in the data collection process.
89531997|NCT04226495|Active Comparator|Sufentanil Bolus|medication in scheduled doses (bolus)
89531998|NCT04226495|Experimental|Sufentanil Infusion|medication in a slow trickle (infusion)
89562479|NCT04602923|Experimental|GDD implantation|Participants suffering from glaucoma who are candidates for GDD implantation (BGI or AGV)
89562480|NCT04432805|Experimental|Pregnant women|Pregnant women suspected of COVID-19
88967802|NCT00111358|Active Comparator|Lifestyle Modification|Goals derived from the AACE and NCEP-ATP III guidelines and the Diabetes Prevention Program are as follows: <35% calories from fat, < 7% calories from saturated fat, up to 10% calories from polyunsaturated fat, reduction of trans fatty acid intake, up to 20% calories from monounsaturated fat, and 25-35g of fiber per day. 3 hrs of physical activity/week at moderate intensity, >10,000 steps in daily activity, measured by pedometer. The curriculum is modeled after the Diabetes Prevention Program. Subjects will complete lifestyle sessions in the offices of the Program in Nutritional Metabolism or in the Clinical Research Center at MGH with protocol study staff trained to implement the curriculum.
88967803|NCT00111358|Placebo Comparator|Control|
88967804|NCT00111436|Experimental|50 mg|50 mg once weekly
88967805|NCT00111436|Experimental|100 mg|50 mg twice weekly
88967806|NCT00111592|Active Comparator|1|current usual care
88967807|NCT00111592|Experimental|2|treatment protocol with clear indications for therapy
88967808|NCT00111631|Experimental|1|
88967809|NCT00111631|Experimental|2|
88967810|NCT00111631|Experimental|3|
88967811|NCT00111631|Placebo Comparator|4|
88967812|NCT00111670|Experimental|1|
88967813|NCT00111670|Experimental|2|
88967814|NCT00111670|Experimental|3|
89208534|NCT00739973|Experimental|Aliskiren 150 mg tablet|Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos.
89531999|NCT04203641|Experimental|L-DOS47 + doxorubicin|Patients will be recruited into escalating dosing cohorts of 3, 6 and 9 µg/kg of L-DOS47, with a minimum of 3 and a maximum of 6 patients per cohort. A fixed dose of intravenous doxorubicin [20 mg/m2/week] will be administered in combination with L-DOS47 across all cohorts.
88967815|NCT00111670|Experimental|4|
88967816|NCT00111670|Placebo Comparator|5|
88967817|NCT00111748|Active Comparator|1|"Stratification:~CA13/hypodiploidy at diagnosis versus no CA13/hypoploidy at diagnosis~Prior Velcade vs. No prior Velcade~TREATMENT:VTD Velcade 1.0 mg/m2 Days 1,4, 8,11 Thalidomide 100 mg Daily qhs Dexamethasone 20 mg Days 1, 2, 4,5, 8, 9, 11, 12 Lovenox 40 mg Days 1-14 Every 21 days"
88967818|NCT00111748|Active Comparator|2|"Stratification:~CA13/hypodiploidy at diagnosis versus no CA13/hypoploidy at diagnosis~Prior Velcade vs. No prior Velcade~TREATMENT:~VATD Velcade 1.0 mg/m2 Days 1,4, 8,11 Thalidomide 100 mg Daily qhs Dexamethasone 20 mg Days 1, 2, 4,5, 8, 9, 11, 12 Adriamycin 2.5 mg/m2 Days 1-4 & Days 9-12 Lovenox 40 mg Days 1-14 Every 21 days"
89532000|NCT06338683|Experimental|Arm I (ONS group)|Patients receive olanzapine 2.5mg PO until disease progression. Intervention: Patients received olanzapine and nutritional advice and standard antitumor treatment.
89532001|NCT06338683|Placebo Comparator|Arm II (NS group)|No Intervention: Patients received nutritional advice and standard anti-tumor treatment.
89532002|NCT06338670|Experimental|Cochlear™ Osia® System|Participants will receive the Osia 3 and Osia® 2 sound processors. They will then complete a series of assessments designed to evaluate the clinical performance of these two sound processors. These assessments will take place across four study visits.
89532003|NCT06338657|Experimental|Treatment (FID-007)|Patients receive FID-007 IV over 30 minutes once a week for 3 weeks on days 1, 8, and 15 of a single 28 day cycle in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgery. Patients undergo CT or MRI during screening and blood sample collection throughout the study.
89532004|NCT06338644||Primary resistant to endocrine therapy|Primary endocrine resistance is defined as a relapse within 2 years of adjuvant endocrine treatment or disease progression during the first 6 months of first-line endocrine therapy for advanced or MBC
89532005|NCT06338644||Secondary resistant to endocrine therapy|Secondary resistance is defined in early BC as a relapse that occurs after at least 2 years of endocrine therapy and during or within the first year of completing adjuvant endocrine therapy. In advanced BC or MBC, secondary resistance is defined as disease progression after more than 6 months of endocrine therapy
89532006|NCT06338631||Adults with weight excess|
89532007|NCT06338618|Experimental|liver treatment protocol|The liver treatment protocol consists of performing twelve visceral manual techniques in an approximate time of 30 minutes twice a week for 4 weeks.
89532008|NCT06338618|No Intervention|placebo comparator|This group will not receive any type of treatment
89532009|NCT06338592|No Intervention|Study 1 (Study of Patients with Uncertain LCS Eligibility) Control Arm|In Study 1 (Study of Patients with Uncertain LCS Eligibility), patients allocated to the control arm will not be exposed to the project intervention unless their EHR data change during the trial so that they have documented LCS eligibility. In these rare cases, these patients will be exposed to the intervention provided to patients in the control arm of Study 2 but will not be considered participants in Study 2.
89562481|NCT04982939|Experimental|Experimental Group-Sintilimab in combination with SOX|Preoperative treatment: three cycles of sintilimab in combination with SOX. Radical gastrectomy and lymphadenectomy (D2). Postoperative treatment: five cycles of SOX, Sintilimab up to one year.
89562482|NCT04982939|Active Comparator|Active Comparator-SOX|Preoperative treatment: three cycles of SOX. Radical gastrectomy and lymphadenectomy (D2). Postoperative treatment: five cycles of SOX.
89562483|NCT04982549|Experimental|Durvalumab + platinum-based chemotherapy and radiation|"All patients will receive 1 of the following platinum-based standard of care chemotherapy options, based on Investigator discretion, in addition to radiation therapy:~cisplatin/etoposide carboplatin/paclitaxel pemetrexed/cisplatin pemetrexed/carboplatin At the completion of standard of care chemoradiation therapy (SoC CRT), patients with complete response, partial response or stable disease will continue to receive durvalumab as consolidation treatment."
89562484|NCT04982627|Experimental|Brief Negotiation Interview Chatbot (BNI Chatbot)|Participants will receive a link to register for the chatbot. Following registration, they will complete the initial chat, which includes instructions for the entire study. The chatbot will then guide the participant through multiple BNIs focused on the goal of bup engagement, with the following steps: 1) Raise the Subject/Establish Rapport; 2) Enhance Motivation; 3) Provide & Elicit Feedback; and 4) Negotiate a Plan. The chatbot then reminds the participant of their reasons why they might engage in OUD treatment based on their responses to Steps 2 & 3, and their negotiated plan. The chatbot will electronically connect participants to a treatment provider of their choice, based on available options.
89562485|NCT04982627|Active Comparator|Standard Care (OUD Education & Referral Resources)|• SC: The RA will provide participants with an electronic link, which provides OUD and bup education, and lists OUD treatment options and descriptions and locations, including bup prescribers. After reviewing, participants will be asked to choose from among the list of and a referral will be made based on the receiving treatment providers' procedures. These participants will not have access to the BNI chatbot. However, the referral facilitation, the electronic link will direct participants to a short Feasibility, Acceptability and Satisfaction (FAS) Assessment to obtain feedback on the process.
89562486|NCT03064061|Sham Comparator|Virtual Reality Neutral|neutral VR session before oocytes retrieval
89562487|NCT03064061|Active Comparator|Virtual reality Anxiety|VR session with the goal of reducing anxiety before oocytes retrieval
89562488|NCT04981691|Experimental|anti-MESO CAR-T cells|"The subjects in this arm will receive Cyclophosphamide 300mg/m2/d and Fludarabine 30mg/m2/d from day-4 to day-2. Subjects will be treated with six administrations of anti-MESO CAR-T cells three times weekly (Monday-Wednesday-Friday) for two weeks. In the first week, total 1×109 or 3×109 will be infused, the second week is to plan three times consecutive infusions of 1x109 or 3×109 anti-MESO CAR-T cells each time.~Subjects will be enrolled serially. For subject safety, the preceding subject must have completed therapy and be 28 days from their last infusion before the next subject can be treated.~Interventions:~Drug: anti-MESO CAR-T cells~Drug: Fludarabine~Drug: Cyclophosphamide"
89562489|NCT03062423|Experimental|T test|Test drug (Sofodelevier)1 tablet contains 400 mg Sofosbuvir
89562490|NCT03062423|Active Comparator|B reference (first dose)|Reference drug (Sovaldi)1 tablet contains 400 mg Sofosbuvir
89562491|NCT03062423|Active Comparator|B reference (second dose)|Reference drug (Sovaldi)1 tablet contains 400 mg Sofosbuvir
89562492|NCT00790933|Experimental|Vedolizumab 300 mg|Vedolizumab 300 mg, 30-minute intravenous (IV) infusion every 4 weeks, starting at Week 0 for approximately up to 510 weeks.
89562493|NCT04981457|Active Comparator|patients who recieve misoprostol alone|Group A (n =30 ) will receive only vaginal Misoprostol 800mcg (4 tablets Cytotec 200mcg ) ) every 3 hours to a maximum of two doses or until reaching cervical ripening or uterine contractions or bleeding assessed by the same doctor who made evaluation at the beginning.
89562494|NCT04981457|Active Comparator|patients who recieve misoprostol and iso sorbide mononitrate|Group B (n =30 ) will receive combined vaginal Misoprostol 800mcg (4 tablets Cytotec ) ) every 3 hours to a maximum of two doses or until reaching cervical ripening or start of uterine contractions or bleeding. with Isosorbide-5-mononitrate (20 mg). Effox 20 mg )once at the beginning with misoprostol until reaching cervical ripening or start of and uterine contractions assessed by the same doctor who made the evaluation at the beginning.
89562495|NCT02161211|Experimental|De-coupling|Six sessions of CBT for anxiety-alcohol de-coupling
89562496|NCT02161211|Experimental|Anxiety Reduction|Six sessions of CBT for anxiety reduction.
89562497|NCT02161211|Experimental|Combined|Three sessions devoted to anxiety reduction and to anxiety-alcohol de-coupling each.
89027325|NCT01309282||Rituximab|Sero-positive [Rheumatoid Factor (RF) and/or anti-Cyclic Citrullinated Peptide (CCP+)] rheumatoid arthritis (RA) patients, who had initiated therapy with Rituximab (MabThera) following lack of response or intolerance to a single tumour necrosis factor (TNF)-inhibitor will be included in this arm
89562498|NCT01676701|Experimental|Tabalumab Auto-Injector|Tabalumab 180 milligram (mg) loading dose administered using auto-injectors at Week 0 as 2 subcutaneous (SC) injections (90 mg each), followed by a 90 mg SC injection every 2 weeks (Q2W) up to Week 12.
89608781|NCT01795495|Active Comparator|Remifentanil|This arm will receive remifentanil alone as is the current practice.
89608782|NCT01795495|Experimental|Remifentanil plus methadone|This arm will receive the current analgesic remifentanil plus and adjunct dose of methadone hydrochloride.
89608783|NCT01795495|Experimental|Remifentanil plus magnesium|This arm will receive the current analgesic remifentanil plus an adjunct dose of magnesium sulfate.
89027326|NCT00480935|Experimental|Sunitinib Malate (Sutent)|Sutent will be given at 50 mg once daily for 4 consecutive weeks followed by a 2 week rest period to comprise a complete cycle of 6 weeks. Patients will then continue on Sutent for another cycle of 4 consecutive weeks
89027327|NCT02955264|Experimental|D-Galactose|D-Galactose is an oral powdered supplement to be taken by mouth. For the first 6 weeks galactose will be given at the dose 0.5g per kg, then from weeks 7-12 at 1.0g per kg, lastly from weeks 13 to 18 at 1.5g per kg (with a maximum daily dose of 50g).
89027328|NCT00480974||1|Patients with Sickle cell anemia treated by Hydroxyurea
89608784|NCT04765527|Experimental|Turmeric|Dietary supplement, Turmeric Strength for Joint, containing turmeric root extract (with 350 mg curcumin), black pepper extract, boswellia gum resin extract, devil's claw root extract, and ginger root; 2 tablets each day in the morning prior to breakfast, 2 weeks, and Monday through Friday of exercise and recovery.
89562499|NCT01676701|Experimental|Tabalumab Prefilled Syringe|Tabalumab 180 mg loading dose administered using prefilled syringes at Week 0 as 2 SC injections (90 mg each), followed by a 90 mg SC injection Q2W up to Week 12.
89562500|NCT04981379|Active Comparator|Hydroxychloroquine + Favipiravir|Hydroxychloroquine 2x200 mg 5 days and favipiravir 2 x 1600 mg loading, then 4 days 2 x 600 mg maintenance (5 days)
89027329|NCT04518150|Experimental|study group|patients with placenta previa undergoing cesarean section underwent bilateral uterine artery ligation plus insertion of Bakri balloon
89027330|NCT04518150|Active Comparator|control group|patients with placenta previa undergoing cesarean section underwent insertion of Bakri balloon
89562501|NCT04981379|Active Comparator|Favipiravir + Placebo (Hydroxychloroquine)|Favipiravir 2 x 1600 mg loading, then 4 days 2 x 600 mg maintenance (5 days) + Placebo (Hydroxychloroquine ) 2x200 mg (5 days)
89562502|NCT04981379|Active Comparator|Hydroxychloroquine + Placebo (Favipiravir)|Hydroxychloroquine 2x200 mg (for 5 days) + placebo (favipiravir) 2 x 1600 mg loading, then 4 days 2 x 600 mg maintenance (5 days)
89562503|NCT04981379|Placebo Comparator|Placebo (Favipiravir) + Placebo (Hydroxychloroquine)|Placebo (favipiravir) 2 x 1600 mg loading, then 4 days 2 x 600 mg maintenance (5 days) + Placebo (Hydroxychloroquine) 2x200 mg (5 days)
89562504|NCT04389775|Experimental|Cohort A|Subcutaneously administer a single dose of XW003, ranging from 0.03mg to 1.0mg, every cohort by the body weight.
89562505|NCT04389775|Placebo Comparator|Placebo A|Subcutaneously administer a single dose of volume-matching placebo, ranging from 0.03mg to 1.0mg, every cohort by the body weight.
89562506|NCT04389775|Experimental|Cohort B|Subcutaneously administer multiple SC doses of XW003, ranging from 0.2mg to 0.6mg, once weekly for 6 weeks.
89562507|NCT04389775|Placebo Comparator|Placebo B|Subcutaneously administer multiple SC doses of volume-matching placebo, ranging from 0.2mg to 0.6mg, once weekly for 6 weeks.
89562508|NCT05375383|Active Comparator|Streptococcus salivarius K12 lozenge|Streptococcus salivarius K12 lozenge
89562509|NCT05375383|Active Comparator|Probiotic S. salivarius K12 lozenges containing prebiotic A|Streptococcus salivarius K12 lozenge with prebiotic
89562510|NCT05375383|Active Comparator|Probiotic S. salivarius K12 lozenges containing prebiotic B|Streptococcus salivarius K12 lozenge with prebiotic
89562511|NCT05375383|Active Comparator|Probiotic S. salivarius K12 lozenges containing prebiotic A and B|Streptococcus salivarius K12
89562512|NCT05375383|Active Comparator|Probiotic S. salivarius K12 powder|Streptococcus salivarius K12 powder
89562513|NCT05375383|Active Comparator|Probiotic S. salivarius K12 powder containing prebiotic A|Streptococcus salivarius K12 powder with prebiotic
89562514|NCT05375383|Active Comparator|Probiotic S. salivarius K12 powder containing prebiotic B|Streptococcus salivarius K12 powder with prebiotic
89562515|NCT05375383|Active Comparator|Probiotic S. salivarius K12 powder containing prebiotic A and B|Streptococcus salivarius K12 powder with prebiotic
89562516|NCT05375383|Active Comparator|Probiotic S. salivarius M18 lozenges|Streptococcus salivarius M18 lozenge
89562517|NCT05375383|Active Comparator|Probiotic S. salivarius M18 lozenges containing prebiotic A|Streptococcus salivarius M18 lozenge with prebiotic
89562518|NCT05375383|Active Comparator|Probiotic S. salivarius M18 lozenges der containing prebiotic B|Streptococcus salivarius M18 lozenge with prebiotic
89562519|NCT05375383|Active Comparator|Probiotic S. salivarius M18 + lozenges containing prebiotic A and B|Streptococcus salivarius M18 lozenge with prebiotic
89562520|NCT03062501|No Intervention|Control (No Hydroxyurea)|Patients in VOC will be treated according to the center's usual practice and analgesia protocol.
89562521|NCT03062501|Experimental|Hydroxyurea|Patients in VOC will receive up to three daily doses of 30-40 mg / kg hydroxyurea.
89562522|NCT02987803|No Intervention|Control Group|Participants in the control group will receive educational articles about obstetric hospitals. The articles will prompt the participant to look up hospitals in their geographic location. Participants will not know they are participating in a trial.
89562523|NCT02987803|Experimental|Data Group|"Participants in the intervention group will receive an educational module designed to support them in selecting a delivering hospital, which will include an educational video, articles, and a data tool with cesarean delivery rate data for hospitals in their geographic location.~Participants will not know they are participating in a trial."
89562524|NCT02998879|Experimental|Velmanase Alfa|velmanase alfa 1mg/kg body weight infusion
89562525|NCT02926651|Active Comparator|Conventional Oral TXA, Total Hip Arthroplasty (THA)|THA patients will be given three 650mg tablets of oral TXA 2 hours prior to incision with three 250mg tablets of ascorbic acid (oral TXA placebo) given 6 hours postoperatively and a final 750mg ascorbic acid dose given the morning of postoperative day 1.
89562526|NCT02926651|Active Comparator|Conventional Oral TXA, Total Knee Arthroplasty (TKA)|TKA patients will be given three 650mg tablets of oral TXA (Tranexamic Acid) 2 hours prior to incision with three 250mg tablets of ascorbic acid (oral TXA placebo) given 6 hours postoperatively and a final 750mg ascorbic acid dose given the morning of postoperative day 1.
89562527|NCT02926651|Experimental|Multi-Dose Oral TXA, Total Hip Arthroplasty (THA)|THA patients will be given three 650mg tablets of oral TXA 2 hours prior to incision with a second 1950mg oral TXA dose given 6 hours postoperatively and a final 1950mg oral TXA dose given the morning of postoperative day 1.
89562528|NCT02926651|Experimental|Multi-Dose Oral TXA, Total Knee Arthroplasty (TKA)|TKA patients will be given three 650mg tablets of oral TXA 2 hours prior to incision with a second 1950mg oral TXA dose given 6 hours postoperatively and a final 1950mg oral TXA dose given the morning of postoperative day 1.
89562529|NCT04271059||TBI without polytrauma|Subjects who have experienced a severe traumatic brain injury (Glasgow Coma Scale (GCS) 3-13) within the last 12 hours, without additional polytrauma.
89562530|NCT04271059||TBI with polytrauma|Subjects who have experienced a severe traumatic brain injury (Glasgow Coma Scale (GCS) 3-13) and polytrauma, including major trauma to the chest, abdomen, pelvis or extremities. within the last 12 hours.
89562531|NCT04271059||Healthy Control|Subjects who have not experienced any TBIs within the last six months.
89562532|NCT04248673|Placebo Comparator|carbohydrate rich bread|
89562533|NCT04248673|Experimental|carbohydrate reduced bread|
89562534|NCT01670279|Experimental|Cohort 1|14 day titration phase and two fixed dose phases. The first fixed dose phase is 14 days with a daily dose of 2mg brexpiprazole/placebo. The second fixed dose phase is 14 days with a daily dose of 3 mg brexpiprazole/placebo.
89562535|NCT01670279|Experimental|Cohort 2|14 day titration phase and a 14 day fixed dose phase a daily dose of 3mg brexpiprazole/placebo.
89562536|NCT01670279|Experimental|Cohort 3|21 day titration phase and a 14 day fixed dose phase a daily dose of 3mg brexpiprazole/placebo.
89562537|NCT01670279|Placebo Comparator|Placebo|Placebo
89562538|NCT04226677|Experimental|aerobic exercise group|Aerobic exercise group is received treadmill training.
89562539|NCT04226677|Experimental|Video based exercise group|Video based exercise group is received exergame training.
89562540|NCT04226677|Experimental|Control group|Control group
88967819|NCT00111787|Experimental|Overall study|A Single arm study with 2 cohorts of participants. Cohort A consists of participants with tumors overexpressing HER2 and/or EGFR. Cohort B consists of participants with tumors expressing EGFR without overexpressing HER2.
89562541|NCT03062579|Experimental|ACTEMRA® (Tocilizumab)|Tocilizumab will be intravenously administered as the dosage of 8 mg/kg every 4 weeks, 6 weeks if possible.
89562542|NCT04188145|Active Comparator|Fluoropyrimidine|
89562543|NCT04188145|Active Comparator|Fluoropyrimidine + Bevacizumab|
89562544|NCT04981769||Patients|Patients presenting to clinical sites for Covid-19 testing who are 2 years of age or older.
89562545|NCT04532125|Experimental|ARGX-117 IV|Subjects receiving ARGX-117 IV
89562546|NCT04532125|Placebo Comparator|Placebo IV|Subjects receiving placebo IV
89562547|NCT04532125|Experimental|ARGX-117 PH20 SC|Subjects receiving ARGX-117 PH20 SC
89562548|NCT04532125|Placebo Comparator|Placebo PH20 SC|Subjects receiving placebo PH20 SC
89562549|NCT04532125|Experimental|ARGX-117 + rHuPH20|Subjects receiving ARGX-117 + rHuPH20
89562550|NCT04532125|Placebo Comparator|Placebo + rHuPH20|Subjects receiving placebo + rHuPH20
89562551|NCT04980989|Experimental|Mobile software|Patient with early breast cancer were followed-up by mobile software for the first six months. At six months they crossed-over to be followed-up by telephone calls for the next six months.
88967820|NCT00111865|Experimental|Exercise|Aerobic Exercise Training
88967821|NCT00111865|No Intervention|Usual Care|
88967822|NCT00111982|Experimental|Liatermin|Bilateral continuous infusion of liatermin for up to 24 months.
88967823|NCT00401674|Experimental|SINGLE ARM|
88967824|NCT00112021|Experimental|Pramlintide Acetate|
88967825|NCT00112021|Placebo Comparator|Placebo|
88967826|NCT00007358|Experimental|1|Depending on patient and physician decision, a steroid may be administered during pregnancy.
88967827|NCT00112099|Active Comparator|1|Procedure/Surgery: Surgery: Splenectomy
89210619|NCT00928044||control groups|They had regular menstrual cycles and no history of pelvic surgery. None had any endocrine disorders (e.g. PCOS) and received any kind of medication that could affect the results within the preceding 6 months, and any woman who had a suspected pathologic lesion in the ovary or menopausal symptoms was excluded.
89562552|NCT04980989|Active Comparator|Telephone calls|Patient with early breast cancer were followed-up by telephone calls for the first six months. At six months they crossed-over to be followed-up by mobile software for the next six months.
88967828|NCT00112099|Experimental|2|Procedure/Surgery: Surgery: Spleen-preservation
88967829|NCT03330639|Experimental|Experimental Group|This group will receive the capsaicin. The Study Drug ICX72 or sinus buster which is a homeopathic blend of capsicum annum and eucalyptol, that is readily available over the counter.
88967830|NCT03330639|Placebo Comparator|Placebo Group|This group will receive saline. The Placebo formulation contained saline and eucalyptol in a concentration that matched the control.
89562553|NCT04117321||Pregnant women|Women who are being pregnant and plan to give birth in local hospital. Pregnant women who plan to stay in the same local area for at least 7 years post-delivery.
89562554|NCT04117321||New Born Baby|new born baby of an enrolled pregnant woman.
89562555|NCT04117321||Father of new born baby|Biological father of an enrolled new born baby.
89562556|NCT04102813|Experimental|Functional Therapy (FT)|The FT includes a variety of functional techniques such as diaphragmatic breathing, and thoracic and abdominal manipulation, designed to stimulate the neurofunctional interconnection between body, mind and immune system. The FT session will last 30 minutes.
89562557|NCT04102813|No Intervention|Attention Control (AC)|The AC group will listen an audiobook lasting for 30 minutes, which will be used as attention control activity
89562558|NCT03063983|Experimental|Maintenance therapy|104 weeks of continuous oral low dose chemotherapy with cyclophosphamide (CPM) and methotrexate (MTX) following 31 weeks of MAP
89562559|NCT03063983|No Intervention|Control|31 weeks of MAP
89562560|NCT03945721|Experimental|Niraparib|"Niraparib will be administered orally on a daily basis~Radiation Therapy will be administered concurrently with Niraparib"
89562561|NCT01876355|Experimental|Clonidine|
89562562|NCT01876355|Placebo Comparator|Sodium chloride|
89562563|NCT03943303|Experimental|Natural gamma radiation from the monazite sands|Patients selected for the study will have their knee (s) affected by osteoarthrose fully submerged in the monazite beach sand 2 (two) times per week for 30 (thirty) minutes each session at the same location and at the same time of day. The natural gamma radiation doses of the monazite sands will be monitored, the radiation measurements gamma will be associated with the atmospheric and climatic measurements of each group. It is understood here as atmospheric measurements, level of solar radiation, spectrum of sunlight at the time of exposure, humidity, wind speed, ultraviolet radiation level, amount of ions present in the air and measurements of the magnetic field in the place.
89562564|NCT03943303|Placebo Comparator|Normal sands exposure patients|Patients selected for the study will have their knee (s) affected by osteoarthrose fully submerged in the no-monazite beach sand 2 (two) times per week for 30 (thirty) minutes each session at the same location and at the same time of day. To ensure the absence of radiation, mesuaraments of possible radiation will be monitored.
89562565|NCT03062345|Experimental|Single-User Mode first, Multi-User Mode second|
89562566|NCT03062345|Experimental|Multi-User Mode first, Single-User Mode second|
89562567|NCT02747407||Basic Science Group II (vaccination at 9 months)|Patients undergo standard of care treatment and collection of blood samples as in Group I. Patients then receive hepatitis A and tetanus toxoid vaccinations at month 9.
89562568|NCT02747407||Basic Science Groups I (vaccination pre-treatment)|Patients receive standard of care hepatitis A or B vaccine, tetanus toxoid vaccine, and trivalent influenza vaccine and then undergo standard of care treatment external beam radiation therapy and receive standard of care temozolomide. Patients also undergo collection of blood Samples monthly for the first 8 months and then bimonthly for up to 12 months for analysis via flow cytometry, (CFSE) assay, live cell/dead cell distinction assay, and determination of naïve and memory immune response.
89562569|NCT01870193|Active Comparator|Young controls|Young controls will be studied before and after receiving cysteine and glycine for 2 weeks
89562570|NCT01870193|Active Comparator|Elderly active|Elderly subjects in the active group will receive glycine plus cysteine (as n-acetylcysteine) for 4 months, and be studied at baseline, 2 weeks and 4 months
89562571|NCT01870193|Placebo Comparator|Elderly placebo|Elderly subjects in the placebo group will receive alanine for 4 months, and be studied at baseline, 2 weeks and 4 months
89562572|NCT04531501||Patients suspected to have Covid-19|Individuals suspected to have COVID-19 who are admitted to Gloucestershire Hospitals NHS Foundation Trust facilities for treatment for COVID-19. Individuals with full mental capacity.
89562573|NCT04531501||Patients tested positive for Covid-19|Individuals tested positive for COVID-19 at Northern Care Alliance NHS Group using an NHS NPS test who are accessible within 24 hours and consent to providing a saliva sample and further NPS sample for Chronomics.
89562574|NCT03063905||Opioid Taper|Patients tapering off their buprenorphine treatment
89562575|NCT03063905||Opioid Maintenance|Patients starting their buprenorphine treatment
89562576|NCT05096455||severe acute pancreatitis|Patients 18 years of age or older admitted to intensive care or resuscitation for severe acute pancreatitis (AP) with hypertriglyceridemia (HTG)
89562577|NCT04432415|Experimental|Group Silver Diamine Fluoride|Participants receive Annual applications of 38% SDF solution and semestral applications of artificial saliva and a personalized dental health education program.
89562578|NCT04432415|Experimental|Group Sodium Fluoride Varnish|Participants receive semestral applications of Sodium Varnish Fluoride and a personalized dental health education program.
89562579|NCT04432415|Placebo Comparator|Placebo|Participants receive semestral apllications of artificial saliva and a personalized dental health education program.
89562580|NCT05331937|Experimental|real rTMS|verum rTMS condition, 1500 continuous 1-Hz pulses to the pre-SMA
89562581|NCT05331937|Sham Comparator|sham rTMS|sham rTMS condition, 1500 continuous 1-Hz pulses to the pre-SMA
89562582|NCT02627495|Experimental|tDCS intervention (open label)|Subjects will undergo tDCS stimulation
89562583|NCT04980755|Experimental|Phase one|"Participants will be asked to attend four weekly sessions of Body Reprogramming via group video call.~Each session will include up to 8 patients and will consist of a 25-30 minute live presentation"
89562584|NCT04980755|Experimental|Phase two|We anticipate that participant sin phase two will complete the same intervention, but it may be somewhat modified following participant feedback in phase one.
89562585|NCT03485053|Experimental|IOP Injection / MPB-1514|Administered IV infusion
89562586|NCT02356939|Experimental|Intraductal stent (IST)|"For intervention : intraductal removable stent In the IST group, the surgeon will place the IST in the bile duct, which is a custom-made segment (2 cm) of a 8 French T-tube. The stent is inserted in the biliary duct without suture fixation.~In the IST group, an endoscopic retrograde cholangio-pancreatography (ERCP) with sphincterotomy will be planned between the 4th and the 6th month post-transplantation."
89562587|NCT02356939|Experimental|Without intraductal stent (no IST)|For intervention : stent extraction by endoscopic retrograde cholangio-pancreatography (ERCP) Each center will perform its habitual postoperative follow up.
89562588|NCT01670045||Rheumatoid Arthritis Participants|Participants with moderate to severe rheumatoid arthritis (RA) according to the American College of Rheumatology (ACR) criteria and the Disease Activity Score based on 28 Joint Count (DAS28) who were on tocilizumab treatment within 8 weeks prior to start of study will receive tocilizumab in accordance with the licensed label recommendations, and will be observed for 6 months. The study is designed as non-interventional, no additional intervention in terms of follow-up visit, complementary examination or medication is required.
89562589|NCT05102461|Placebo Comparator|Placebo|Subjects randomized in the Placebo Arm will take one placebo capsule daily. Each capsule will also contain 32 mg of riboflavin as a tracer substance for tracking compliance.
89562590|NCT05102461|Active Comparator|Treatment|Subjects randomized in the Treatment Arm will take one placebo capsule daily. One Florajen Digestion capsule contains 15 billion live cultures of Lactobacillus acidophilus (7.5 billion), Bifodobacterium lactis (6.0 billion), and Bifidobacterium longum (1.5 billion). Each capsule will also contain 32 mg of riboflavin as a tracer substance for tracking compliance.
89562591|NCT05375227|Experimental|Electric Toothbrush|Electric toothbrush + manufacturer's instructions + professional recommendations + sodium monofluorophosphate (1450 ppm F) toothpaste (elmex® SENSITIVE PROFESSIONAL)
89562592|NCT05375227|Active Comparator|Manual toothbrush|Manual toothbrush + manufacturer's instructions + professional recommendations + sodium monofluorophosphate (1450 ppm F) toothpaste (elmex® SENSITIVE PROFESSIONAL)
89562593|NCT04980131|Experimental|Group C|Group C were received PPSF with pointed lotus-style regulator
89562594|NCT04980131|Experimental|Group B|Group B were received PPSF with Flat ended lotus root regulator
89562595|NCT04980131|No Intervention|Group A|Group A were received traditional PPSF
88967831|NCT00112372|Experimental|Ridaforolimus|10 mg tablet of ridaforolimus administered orally according to one of several different dosing regimens for a four-week treatment cycle.
88967832|NCT00112528|Experimental|gemcitabine + bevacizumab + oxaliplatin|"Patients receive gemcitabine IV over 100 minutes and bevacizumab IV over 30-90 minutes on days 1 and 15. Patients also receive oxaliplatin IV over 120 minutes on days 2 and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 2 courses of therapy beyond CR.~After completion of study treatment, patients are followed every 3-6 months for up to 5 years."
88967833|NCT02972190|Experimental|Bilateral decompression with TLIF|Patients undergoing bilateral decompression with TLIF
88967834|NCT02972190|Active Comparator|laminectomy with PLIF|Patients undergoing laminectomy with PLIF
88967835|NCT03288090||Treated|
89562596|NCT04974203|Experimental|CT Value <25|Patients with CT value <25
89562597|NCT04974203|Experimental|CT Value 25+|Patients with CT value of 25 or higher
89562598|NCT04974203|Experimental|Negative|Patients with negative PCR test result
89562599|NCT05102227||LBBAP|Patients implanted with a dual-chamber DF-1 cardioverter-defibrillator. Ventricular tachy sensing is performed via an IS-1 pacing lead placed in the interventricular septum.
89562600|NCT03063671|Active Comparator|bupivacine group|preoperative insertion of thoracic epidural at T4-5 and adminstration of 12 ml bupivacine 0.125% as one shot 15 minutes before general anesthesia postoperative analgesia done by infusion of bupivacaine 0.125% (5ml/hour through thoracic epidural catheter for 12 hours).
89562601|NCT03063671|Active Comparator|ketamine group|preoperative insertion of thoracic epidural at T4-5 and adminstration of 12 ml bupivacine 0.125% plus ketamine in a dose 0.5 mg/kg 15 minutes before general anesthesia postoperative analgesia will be preformed by infusion of mixture of (bupivacaine 0.125% plus ketamine 0.5 mg/ml ml) in a rate of 5ml/hour through thoracic epidural catheter for 12 hours
89562602|NCT03063671|Active Comparator|dexmedetomidine group|preoperative insertion of thoracic epidural at T4-5 and adminstration of 12 ml bupivacine 0.125% plus dexmedetomidine in a dose 1 ug/kg 15 minutes before general anesthesia Postoperative analgesia will be performed using infusion of mixture of (bupivacaine 0.125% plus dexmedetomedine 2μg/ ml) in a rate of 5ml/hour through thoracic epidural catheter for 12 hours.
89562603|NCT03063671|Active Comparator|ketamine-dexmedetomidine group|preoperative insertion of thoracic epidural at T4-5 and adminstration of 12 ml bupivacine 0.125% plus both ketamine in a dose 0.3 mg/kg and dexmedetomidine in a dose 0.1 ug/kg 15 minutes before general anesthesia Postoperative analgesia will be performed using infusion of mixture of (bupivacaine 0.125% plus dexmedetomedine 2μg/ ml and and ketamine 0.5 mg/ml) in a rate of 5ml/hour through thoracic epidural catheter for 12 hours.
89562604|NCT05375149||LTx rejection|Lung transplanted patients with acute or chronic rejection
89562605|NCT05375149||LTx non-rejection|Lung transplanted patients without any form of rejection
89562606|NCT03063827||Treatment group|Patients with chronic SCI causing NDO and urinary incontinence
89562607|NCT03063827||Control group|Female patients who underwent anti-incontinence suregery without lower urinary tract symptoms
89562608|NCT05101837|Experimental|MIND-GROUP|Daily mindfulness sessions on android
89562609|NCT04980209||Ultrasonic and c-arm combination group|Ultrasound and c-arm were combined to evaluate intraoperatively conditions
89562610|NCT04980209||c-arm group|c-arm group was used to evaluate intraoperatively conditions
89562611|NCT03334201|Other|Western diet first|To receive Western diet controlled feeding first, followed by non-Western diet controlled feeding
89562612|NCT03334201|Other|Non-Western diet first|To receive non-Western diet controlled feeding first, followed by Western diet controlled feeding
89562613|NCT01669421|Experimental|Alpha-1 Antitrypsin (human) standard dose baseline|Alpha-1 Antitrypsin (human) 60 mg per kg per week for 4 weeks. Study week 4
89562614|NCT01669421|Experimental|Alpha-1 Antitrypsin (human) Double dose|Alpha-1 Antitrypsin (human) 120 mg/kg per week for 4 weeks. Study week 8
89562615|NCT01669421|Experimental|Alpha-1 Antitrypsin (human) standard dose|4 weeks on A1PI at 60 mg/kg per week after the other 2 phases. Collected@ study week 12
89562616|NCT03210571|Experimental|eyeWatch device|
89562617|NCT05104021|Experimental|game group|"Children who accepted to participate in the game were taken to the playground with minimum two and maximum four people. After the children were introduced to each other, the rules of the game were explained. Between the children playing, dice were rolled to determine the starting order of the game. The player who scored the highest number had the right to start the game first. With the help of the stopwatch, the playing time was started, and the children played the game in accordance with the rules.~For the child who first reached the square of the world, the time was stopped and recorded in the Child Follow-up Form. The game was played with a maximum game duration of 15 minutes. In the same way, the times of the children who reached the world square in the second, third and fourth places were recorded on the Follow-up Form."
89562618|NCT05104021|No Intervention|control group|"Children in the control group were allowed to walk for 15 minutes on a flat surface in the clinic accompanied by the researcher and their parents. As soon as the child came out of his room, the time was started with the help of a stopwatch. The time was stopped when the child went back to bed.~The pain and fear scores of each child who completed the game and mobilization were evaluated separately and simultaneously by the child, parent and researcher with the help of the Visual Analog Scale and the Child Fear Scale, and then the physiological parameter measurements were made by the researcher and the Child Follow-up Form was evaluated after the procedure. and data collection was terminated."
89562619|NCT05103865|Experimental|Experimental group (EG)|
89562620|NCT05103865|Active Comparator|Control group|
89562621|NCT01671059||Tocilizumab|Participants with rheumatoid arthritis (RA) receiving tocilizumab either as combination therapy or monotherapy through routine clinical practice.
89562622|NCT05103787|Active Comparator|deep parasternal plane block|Subjects will receive bilateral deep parasternal intercostal plane block after induction of anesthesia.
89562623|NCT05103787|Placebo Comparator|control|subjects will receive skin puncture with needle on the same location as the treatment group without administration of local anesthetics after induction of anesthesia,
89562624|NCT03115021|Experimental|Active tPCS / Sham tDCS|All subject will receive active tPCS and sham tDCS for 20 minutes simultaneously.
89562625|NCT03115021|Experimental|Sham tPCS / Active tDCS|All subject will receive sham tPCS and active tDCS for 20 minutes simultaneously.
89562626|NCT03115021|Experimental|Sham tPCS / Sham tDCS|All subject will receive sham tPCS and sham tDCS for 20 minutes simultaneously.
89562627|NCT04980053|Experimental|Back Massage|"Back massage will be initiated in the first 2 hours after birth and it will be performed every 6 hours for 15 minutes until the mother is discharged from the hospital. After the mother's outfits are removed and the mother is situated in a suitable position, the back of the mother will be massaged by euphlorage, petrissage, friction methods. Then, the participants breast will be milked by hand every 3 hours and will be measured in the breast milk storage bag and delivered to the baby nurses until the 5th-7th day."
89562628|NCT04980053|Experimental|Breast Massage|Breast massage will be initiated in the first 2 hours after delivery and it will be practised every 6 hours until being discharged. After the researcher washes her hands, the participant's outfits are removed and she is situated in a sitting position, the massage will be practised on both breasts for 10 minutes by the researcher herself. After the mother's breast will be milked by hand every 3 hours and the milk obtained from the breast will be measured in the breast milk storage bag and delivered to the baby nurses.
89562629|NCT04980053|No Intervention|Control Group|No intervention will be made to the control group, standard hospital procedures will be applied and the relevant forms will be filled out. Until the mother is discharged from the hospital, the amount of milk obtained from the mother will be measured every 3 hours by the researcher.
89562630|NCT04973969|Other|study group|The participants will recieve decapeptyl 0.2 mg on day 2/3 of the follicular phase.At that day, and at the day after, hormonsl profile will be documented. The hormonal profile of the day after follicular decapeptyl administration will be compared to the hormonal profile to test the predictive value.
89562631|NCT02961205|Experimental|Oral Nutritional Supplementation|Patients randomized to the interventional arm will receive Ensure Enlive (Abbott Nutrition), a high energy, high protein oral supplement.
89562632|NCT02961205|No Intervention|Standard of care|Patients randomized to the control arm will continue their usual diet.
89562633|NCT04979975|Experimental|Placebo|placebo matching UB-621
89562634|NCT04979975|Experimental|UB-621 low-dose|low-dose of UB-621
89562635|NCT04979975|Experimental|UB-621 high-dose|high-dose of UB-621
89562636|NCT02958709|Experimental|high dose RIF, INH, PZA, EMB|Arm 1 participants will receive high-dose rifampicin for 8 weeks plus ethambutol at standard doses, in addition to standard doze pyrazinamide (PZA) and isoniazid.
89562637|NCT02958709|Experimental|high dose RIF, INH, PZA, LEVO|Arm 2 participants will receive high-dose rifampicin plus levofloxacin for 8 weeks, in addition to standard doze pyrazinamide and isoniazid.
89562638|NCT02958709|Active Comparator|standard dose RIF, INH, PZA, EMB|Arm 3 participants will receive standard of care dose rifampicin plus ethambutol for 8 weeks, in addition to standard doze pyrazinamide and isoniazid.
89562639|NCT04979663|Experimental|experimental group|Combination of Gemox, Donafenib and Tislelizumab
88967836|NCT03288090||Non-treated|
88967837|NCT00007631|Active Comparator|1|Topical Tretinoin
88967838|NCT00007631|Placebo Comparator|2|Placebo
89562640|NCT05307367|Experimental|WP1-3|WP1+2: no intervention WP3: exercise training as intervention
88967839|NCT00112684|Experimental|Treatment (chemotherapy, biological therapy)|Patients receive alvocidib IV over 4½ hours once weekly in weeks 1-4. Treatment repeats every 6 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
89562641|NCT04979819|Experimental|Multiple Sclerosis|Patients with multiple sclerosis will perform the UULEX and fill in the other mentioned parameters. Validity and reliability of the UULEX will be measured.
88967840|NCT02972229|Experimental|partial body group|10x(3-5) Gy IMRT on partial vertebral body
88967841|NCT02972229|Active Comparator|whole body group|10x3 Gy IMRT on whole vertebral body
88967842|NCT00112996|Experimental|Arm I: Alpha-Lipoic Acid|Oral alpha-lipoic acid three times daily for at least 24 weeks in the absence of unacceptable toxicity.
88967843|NCT00112996|Placebo Comparator|Arm II: Placebo|Oral placebo three times daily for at least 24 weeks in the absence of unacceptable toxicity.
88967844|NCT00113035||Patients with late onset Pompe Disease|
88967845|NCT00007709||1|
88967846|NCT00113074|Active Comparator|1|Weight management and BP control program
88967847|NCT00113074|Active Comparator|2|Self-help materials targeting lifestyle modification
88967848|NCT00390702|Experimental|VSD occluder|transcatheter implantation of a VSD occluder (Nitinol coil)
88967849|NCT02972528|Active Comparator|Platelet Lysate|Patients will receive 5ml peri-lesional injections of Platelet Lysate at weekly intervals, for 4 consecutive times (week 0,1,2,3).
88967850|NCT02972528|Placebo Comparator|Platelet Poor Plasma|Patients will receive 5ml peri-lesional injections of Platelet Poor Plasma at weekly intervals, for 4 consecutive times (week 0,1,2,3).
89562642|NCT04979585|Experimental|Experimental|Patients with untreated advanced mucosal melanoma
89562643|NCT05101603|Active Comparator|Control|Only non surgical periodontal treatment
89562644|NCT05101603|Experimental|Test|Nd:YAG Laser and air abrasive combined application addition to non surgical periodontal treatment
89562645|NCT04400513||Aortic Stenosis|Subjects with echo-confirmed AS graded moderate-to-severe or worse
89562646|NCT04400513||Mitral Regurgitation|Subjects with echo-confirmed MR graded moderate-to-severe or worse
89562647|NCT04400513||Tricuspid Regurgitation|Subjects with echo-confirmed TR graded moderate-to-severe or worse
89562648|NCT04400513||Innocent Murmur|Subjects with echo-confirmed trace/trivial valve disease severity
89562649|NCT04400513||Diastolic Murmur|Subjects with pathology associated with diastolic murmur (e.g. AR, PR, MS, TS)
89562650|NCT04400513||Continuous Murmur|Subjects with pathology associated with continuous murmur (e.g. congenital shunts, PDA)
89562651|NCT02481817||iSGS patients|Participants will receive standard of care treatment at the respective center and will be followed longitudinally for symptom changes, need for further treatment, complications, and will have Patient-reported outcomes (PROs) administered at a priori determined intervals.
89562652|NCT05103709|Experimental|MULTI-FORTIFIED|The product to be evaluated is bread made from wheat flour fortified according to Peruvian national standards [Riboflavin (0.18 mg), niacin (2.25 mg), thiamine (0.18 mg), folic acid (60ug), iron (4.2 mg)] and a previtamin mix [Vitamin A (240 ug), Vitamin b12 (0.72 ug), zinc (5.25 mg) per daily serving]. Participants will receive 2 slices of bread a day for 120 days. It is supplied by Panificadora Bimbo del Peru S.A.
89562653|NCT05103709|Active Comparator|FORTIFIED|The active comparator is bread fortified according to Peruvian national standards [Riboflavin (0.18 mg), niacin (2.25 mg), thiamine (0.18 mg), folic acid (60ug), iron (4.2 mg)]. Participants will receive 2 slices of bread a day for 120 days. It is supplied by Panificadora Bimbo del Peru S.A.
89562654|NCT05103709|No Intervention|CONTROL|The control group will be followed for 120 days. No product will be provided.
89562655|NCT04979897||Intensive care unit stay during high bed occupancy in the COVID-19 pandemic|Adult patients (≥18 years old) who are mechanically ventilated for at least 48 hours in one of the participating ICUs during a high bed occupancy in the pandemic
89562656|NCT04979897||Intensive care unit stay during low bed occupancy in the COVID-19 pandemic|Adult patients (≥18 years old) who are mechanically ventilated for at least 48 hours in one of the participating ICUs during a low bed occupancy in the pandemic
89562657|NCT05103553|Experimental|Annual screening at outpatient clinic|After signing informed consent, patients with low risk for disease progression (in the low or intermediate risk group) wil be randomized into the intervention group (annual assessment at the outpatient clinic). Due to the nature of the intervention, the randomization will not be blinded, as this is not possible.
89562658|NCT05103553|No Intervention|Annual screening at Care Pathway Systemic Sclerosis|After signing informed consent, patients with low risk for disease progression (in the low or intermediate risk group) will be randomized into the control group (annual assessment at the care pathway). Due to the nature of the intervention, the randomization will not be blinded, as this is not possible.
89562659|NCT04979195||Group 1|patients with stable renal function.
89562660|NCT04979195||Group 2|Patients who developed AKI.
89562661|NCT05101525|Experimental|Patient with effective tendon healing|
89562662|NCT05101525|Active Comparator|Patient without tendon healing|
89562663|NCT05103397|Active Comparator|low dose group|low dose group. Group (A) (25 patients) patients will receive 10 mg/Kg methyl prednisolone after induction before separation to (CPB).
89562664|NCT05103397|Active Comparator|high dose group|high dose group. Group (B) (25 patients) patients will receive 30 mg/Kg methyl prednisolone after induction before separation to (CPB).
89562665|NCT05103397|Placebo Comparator|Placebo group|placebo group. Group (C) (control group)(25 patients) patients will receive placebo in form of normal saline.
89562666|NCT05101447|Experimental|MMF PK|
88967851|NCT00007787|Experimental|Antibody plus delayed cyclosporine therapy|Anti-human thymocyte globulin (rabbit) (Thymoglobulin®) is admistred at the time of transplant followed delayed clyclosporine A therapy post tranplant.
88967852|NCT00007787|Active Comparator|Standard cyclosporine A therapy|Cyclosporine A therapy (either Cyclosporine or Tacrolimus) will be initiated pre-transplantations
88967853|NCT00113347|Experimental|Erlotinib + Docetaxel|Erlotinib 100, 125, or 150 mg orally daily except days receive Docetaxel 15 mg/m^2 or 20 mg/m^2 intravenously with Concomitant Boost Radiation to Head/Neck
88967854|NCT00113503|Active Comparator|Azathioprine weight-based dose|
88967855|NCT00113503|Experimental|Azathioprine individualised dose|
88967856|NCT00113698|Placebo Comparator|1|
88967857|NCT00113698|Active Comparator|2|Ace inhibition (enalapril)
88967858|NCT03272295|Experimental|Arm A|Reference product (product 1) x 2, Single ingredients products 2, 3, 4, 5, 6 and Multiple ingredient product (product 12). Single cigarette each for nicotine PK assessment and smoking behaviour assessment.
89562667|NCT05101447|Active Comparator|MMF BSA|
89562668|NCT05101291|Experimental|Fractional spinal anaesthesia|"After FIC block or femoral nerve block with ropivacaine 3.5mg/ml 20-40ml. The LiDCOplus was calibrated with 0.3-0.45 mmol lithium based on body weight. After calibration and baseline parameter registration, the LiDCOplus system provided cardiac output variables A dural puncture by a 18G Tuohy needle was performed either between the L2 - L3 or the L3 - L4 interspaces, preferably using a mid-line approach. A catheter 20G was then inserted 4-5 cm into the intrathecal space. A solution (10 ml) of 1.5 mg/ml bupivacaine and 10 µg/ml fentanyl was prepared. Intrathecal anaesthesia was induced by giving 1,5 ml (2.25 mg of bupivacaine and 15 µg of fentanyl) of the solution, followed by a second 1.5 ml injection after 25 min.~MAP was maintained with a norepinephrine to target a MAP >65mmHg or to avoid a > 30% decline in MAP from baseline. Invasive haemodynamic parameters were recorded every 5 min for 45 min after initial intrathecal dose was given."
89562669|NCT04342169|Experimental|HCQ|Participants randomized to the HCQ arm will receive HCQ 400mg po BID x 1 day, then 200mg po BID x 4 days. The drug dose (2.4 gm over 5 days) falls at the lower end of doses proposed in various international trials, but it has proven in vitro efficacy, with a ratio of lung tissue trough concentrations to the EC50 (effective concentration to suppress 50% of viral activity) of >20.
89562670|NCT04342169|Placebo Comparator|Placebo|Those randomized to placebo will receive a placebo to be taken on the same schedule.
89608785|NCT04765527|Placebo Comparator|Placebo|Placebo tablets; 2 tablets each day in the morning prior to breakfast, 2 weeks, and Monday through Friday of exercise and recovery.
89608786|NCT04570111|Active Comparator|Standard Care Diet|After the controlled feeding study, participants in this group will follow the standard care diet for the remainder of pregnancy with the assistance of a study dietitian. The standard care study diet will provide the standard 40% Carb/20% Pro/40% Fat as energy, distributed consistently across 3 meals and 2 snacks.
89562671|NCT05103163|Experimental|Foot reflexology group|Before the reflexology application, a personal information form was applied to the patients who had abdominal surgery. As a pre-test, satisfaction levels in terms of pain and nursing were evaluated. Then, vital signs (systolic blood pressure, diastolic blood pressure, pulse, respiration and saturation) were measured. Foot warming movements were started and then the warming movements were terminated by applying pressure to the solar plexus area of the left foot. Then in order; Reflexology was applied to the brain, lymphatic system, blood pressure area, lung, adrenal gland, thyroid, diaphragm, stomach and joint areas. Afterwards, relaxation movements were made for the foot, pressure was applied to the solar plexus and the reflexology application was completed within 30 minutes. Immediately after the application, vital signs were re-measured as a post-test, and the numerical pain scale and care satisfaction scale were applied again.
89562672|NCT05103163|No Intervention|No treatment group|To the patients in the control group; Personal Information Form, Numerical Pain Scale (NPS) and Newcastle Nursing Care Satisfaction Scale (NNCSS) were applied as pre-test. After the questions were answered, NNCSS with NPS was applied again 40 minutes later as a final test, without any intervention other than the clinical protocol.
89562673|NCT04979273|Active Comparator|Control Group|Patients within control group will be given adrenaline 1:20.000 injection, followed by thermocoagulation or hemoclip
89562674|NCT04979273|Experimental|Dextrose group|Patients within this group will be given adrenaline 1:20.000 injection, followed by dextrose 40% spray
89562675|NCT04973423|No Intervention|CALM|Tight control of inflammatory activity by calprotectin.
89562676|NCT04973423|Other|CALM + IRM|Tight control of inflammatory activity by calprotectin associated with transmural evaluation.
89562677|NCT05073991||Lung surgery|Patients underwent lung surgery.
89562678|NCT05073991||Open aortic suregry|Patients underwent open aortic surgery.
89562679|NCT05073991||Thoracic endovascular aortic repair (TEVAR)|Patients underwent TEVAR.
89562680|NCT05073991||Endovascular aneurysm repair (EVAR)|Patients underwent EVAR.
89562681|NCT03062033||Cohort 1|Patients without visible signs of involuntary movements (possible TD) at time of clinician assessment
89562682|NCT03062033||Cohort 2|Patients with visible signs of involuntary movements (possible TD) at the time of clinician assessment
89562683|NCT05099887|Other|wound application|Application of Procenta as wound cover
89562684|NCT03061799|Experimental|HPC-03|"To experimental arm randomly assigned, HPC-03 will administrated twice a day , two capsules each time (total dose of HPC-03: 2g/day) for 12 weeks (84days).~*(HPC-03: extracts of angelica gigas nakai, cnidium rhizome, and cinnamon bark.)"
89562685|NCT03061799|Placebo Comparator|Placebo|To control arm randomly assigned, placebo will administrated twice a day , two capsules each time for 12 weeks (84days).
89562686|NCT05036473|Experimental|25/100mg treatment group|25/100mg WD-1603
89562687|NCT05036473|Experimental|25/150mg treatment group|25/150mg WD-1603
88967859|NCT03272295|Experimental|Arm B|Reference product (product 1), Single ingredients products 7, 8, 9, 10, 11 and Multiple ingredient product (product 12). Single cigarette each for nicotine PK assessment and smoking behaviour assessment.
88967860|NCT00007904|Experimental|Arm A: Combination Chemotherapy|Paclitaxel IV continuously over 72 hours on days 1-3 and cyclophosphamide IV on days 1-3. Filgrastim subcutaneously (SC) beginning on day 5 and continuing until blood counts recover or pegfilgrastim SC on day 5. Treatment repeats every 21 days for 3 courses. Then doxorubicin hydrochloride IV on day 1 and filgrastim SC beginning on day 2 and continuing until blood counts recover or pegfilgrastim SC on day 2. Treatment repeats every 21 days for 4 courses. Patients with hormone-receptor positive tumors receive oral tamoxifen citrate or oral anastrozole daily for 5 years following chemotherapy. Beginning 3-6 weeks after completion of chemotherapy, patients undergo radiation therapy 5 days a week for 6-7 weeks.
88967861|NCT00113815|Experimental|003|topiramate 25 mg/kg/day
88967862|NCT00113815|Experimental|002|topiramate 15 mg/kg/day
89208535|NCT00739973|Experimental|Aliskiren 300 mg tablet|Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos.
88967863|NCT00113815|Experimental|001|topiramate 5 mg/kg/day
88967864|NCT00113815|Experimental|004|placebo placebo
88967865|NCT03109431|Experimental|Enhanced Standard Care|"Youth randomized to the Enhanced Standard Care arm will receive an Automated Messaging and Monitoring Intervention (AMMI), which involves receiving 1-5 texts per day to motivate, inform and refer to HIV care and health services. Message banks will focus on the HIV Treatment Continuum, with libraries dedicated to healthcare, wellness, sexual health, drug use and ARV adherence for YLH.~Youth will also receive a weekly monitoring survey that covers six domains related to the HIV Treatment Continuum, including: ARV adherence, condomless sex, potential symptoms of STI, excessive use of alcohol and/or drugs, feelings of sadness or depression, and housing or food insecurity."
89208536|NCT00739973|Experimental|Amlodipine 5 mg capsule|Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos.
89210620|NCT00928044||operation group|1. They had regular menstrual cycles and no history of pelvic surgery. None had any endocrine disorders (e.g. PCOS) and received any kind of medication that could affect the results within the preceding 6 months, and any woman who had a suspected pathologic lesion in the ovary or menopausal symptoms was excluded. 2. Operations were performed for benign ovarian tumors, leiomyoma or adenomyosis
89562688|NCT05036473|Experimental|2x25/100mg treatment group|2x25/100mg WD-1603
89562689|NCT05036473|Placebo Comparator|placebo group|placebo are tablets-matching with the same active groups.
89562690|NCT04979351|Experimental|Abdominal Massage Group|Abdominal massage for 15 minutes twice a day application.
89562691|NCT04979351|No Intervention|Placebo Group|Abdominal massage was not applied.
89208537|NCT00739973|Experimental|Amlodipine 10 mg capsule|Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos. Amlodipine 10 mg arm starts with 1 week of Amlodipine 5 mg, then force titrated to 10 mg
89562692|NCT04985851|Experimental|maintenance treatment durvalumab + anlotinib|"Durvalumab 1500 mg monotherapy will be continued q4w. Anlotinib will be administered according to prescribing information in general use. The dose is 12mg, QD, PO, 14 days-on and 7 days-off.~N.B. If a patient's weight falls to 30 kg or below (≤30 kg) the patient should receive weight-based dosing equivalent to 20 mg/kg of durvalumab until the weight improves to >30 kg, at which point the patient should start receiving the fixed dosing of durvalumab 1500 mg.~Anlotinib is available at three dose levels, 12 mg, 10 mg, and 8 mg. Dose reduction may take place whenever toxicity that is not controlled with optimal supportive care is noted during the study. If a subject subsequently tolerates treatment well at that level in the judgment of the investigator, the dose may be increased to the next dose level. If a subject cannot tolerate treatment after dose reduction to 8 mg, treatment will be discontinued"
89562693|NCT04985851|Active Comparator|maintenance treatment durvalumab|Durvalumab 1500 mg monotherapy will be continued q4w.
89562694|NCT04929769|Experimental|1|the group of LRH
89562695|NCT04929769|Active Comparator|2|the group of ARH
89562696|NCT04930861|Experimental|Covidir|Patient (adults aged ≥18 years) with mild or moderate COVID-19 and flu-symptoms onset within 72 hours prior to inclusion. Treatment begins at the hospital. On the 4th day, participants who are well will be discharged and continue treatment up to Day 10 at home. All participants will receive Codivir 20 mg SC 2 x daily.
89562697|NCT04979507|Experimental|Experimental Group|
89562698|NCT04979507|Active Comparator|Control group|
89562699|NCT05099575||Pregnant women who receive oxytocin|
89562700|NCT05099575||Pregnant Women who receive carbetocin|
89562701|NCT05099575||Pregnant women who receive misoprostol|
89562702|NCT05099575||Pregnant women who receive ergometrine|
89562703|NCT04979039||normal pregnancy|Adult pregnant women scheduled for cesarean section under spinal anesthesia
89562704|NCT04919551|Experimental|KGD|Oral administration after fasting/high-fat meal/low-fat meal
89562705|NCT04919551|Experimental|GDK|Oral administration after high-fat meal/low-fat meal/fasting
89562706|NCT04919551|Experimental|DKG|Oral administration after low-fat meal/fasting/high-fat meal
89562707|NCT03063515|No Intervention|IVGTT without pyridostigmine|An intravenous glucose tolerance test (IVGTT) will be performed without any medication for baseline comparison.
89562708|NCT03063515|Active Comparator|IVGTT with pyridostigmine|An IVGTT will be performed 2 hours after taking one single dose of pyridostigmine 60 mg
89562709|NCT04907773|Other|Potassium measurement|
89562710|NCT04973813|Experimental|Guideline + Active Choice + action&coping planning (GA+)|Participants received a web-based intervention consisting of information (including the national physical activity guideline) and several assignments. Assignments included: completing a decision balance sheet; indicating the importance of personal values and the time, effort and energy spent on these personal values; action planning; identifying barriers to physical activity; coping planning.
89562711|NCT04973813|Experimental|Guideline + Active Choice (GA)|Participants received a web-based intervention consisting of information (including the national physical activity guideline) and several assignments. Assignments included: completing a decision balance sheet; indicating the importance of personal values and the time, effort and energy spent on these personal values; identifying barriers to physical activity.
88967866|NCT03109431|Experimental|Stepped Care|Youth randomized to the Stepped Care arm will receive up to three levels of intervention, depending on whether or not they have achieved viral suppression at each four-month assessment point. All youth will begin at Level 1 which is the same as the Enhanced Standard Care arm. If they fail to achieve viral suppression at a reassessment in four months, they will be moved to Level 2, which includes both Level 1 and enrollment in private, online peer support groups. If they fail to achieve viral suppression at another four-month assessment point, they will be moved to Level 3, which includes both Levels 1-2 and Coaching. Coaches will provide support using a strengths-based coaching approach.
89210621|NCT00821756|Experimental|1|Assertive intervention in OPAC-style: Outreach,problem solving,adherence,continuity
89562712|NCT04973813|Experimental|Guideline + Information (GI)|Participants received the national physical activity guideline, and information about pros and cons of physical activity, and possible barriers to physical activity.
89210622|NCT00821756|No Intervention|2|Control arm: Treatment as usual
89562713|NCT04973813|Other|Guideline (G)|Comparison arm. Participants received the national physical activity guideline.
89562714|NCT04894981|Experimental|Immersive condition|Performance driving wheelchair in immersive condition (in Cave automatic environment or with HMD)
89562715|NCT04894981|Experimental|Non Immersive condition|Performance driving wheelchair in non immersive condition (with screen and physical simulator or screen only)
89562716|NCT04973501|Experimental|Manual physiotherapeutic correction (MFK) Method|The MFK was chosen for our clinical experience- it was developed in Czech Republic.The MFK Method consists of five established steps: anamnesis, assessment, diagnoses, treatment and checkup. In the course of all those steps, the computer MFK System software is used. This software allows us to display and visualize the patient´s functional muscle imbalance at the day of the assesment based on the assessment of muscle strength by manual muscle tests. Hereafter the physiotherapist performs muscle test and records results in the software. Then, the software visually describes the patient´s imbalance at the day of the assessment. Based on these diagnostic maps and the software suggestions the therapist chooses the body areas where the therapeutic techniques may be applied.
89562717|NCT04973501|Experimental|Dynamic Neuromuscular Stabilization (DNS) Method|Dynamic Neuromuscular Stabilization (DNS) is a neurophysiological rehabilitative approach encompassing a set of functional tests assessing the quality of postural stabilization patterns and a treatment approach based on developmental kinesiology models. DNS diagnosis is based on comparison of the individual's postural stabilization pattern to the developmental stabilization pattern of healthy infants. The assessor uses DNS evaluation sheet to screen client's posture in 11 developmental positions if the patient can perform them all. If not, only the tests that the patient can perform sufficiently and safely serve for functional assessment. The strategy of DNS manual treatment is to utilize only those functional exercises in developmental positions that are the most suitable for the specific client. The goal is to improve spinal and joint stability by focusing on the global stabilization system consequently improving quality of movement and mobility.
89562718|NCT04858945|Experimental|Teach-back group|The first education session will be arranged at the day or the following day of admission before delivery, with a group meeting involving three women and one educator. The main purpose of the first session is to help women understand and prepare for the labor. On the day of discharge after delivery, women will receive the second group education session hosted by an educator. The main purpose of the second session is to help women understand postpartum health issues, get to know the practice of postpartum recovery and learn newborn care skills. At two-week postpartum, a short online meeting will be arranged. During the meeting, the educator answers questions raised by the woman and gives advices on the challenges and difficulties in postpartum recover and caring newborn faced by the woman.
89562719|NCT04858945|Active Comparator|Control group|Teach-back group and control group share some education content and communication methods, e.g. power-point presentation, educational video clips, live demonstration, information booklet, group discussion, and Q&A, expect that before the end of each education session.
89562720|NCT04973735|Experimental|30mg LY-CovMab|LY-CovMab is diluted with 0.9% sodium chloride to a total volume of 250 mL for IV infusion
89562721|NCT04973735|Experimental|150mg LY-CovMab|LY-CovMab is diluted with 0.9% sodium chloride to a total volume of 250 mL for IV infusion
89027331|NCT00482573|Experimental|Group LE|Seventeen (54.8%) patients, composed group LE, were randomly assigned for the infusion of 1.8 mL (one cartridge) by the modified anesthesia into the periodontal ligament (PDLm injection) of 2% lidocaine solution with epinephrine 1:100,000. Their ages were ranging from 18 to 44 years (mean:29.6), they were diagnosed as having rheumatic valve disease, in a functional class I or II according to classification of the NYHA. Gestation age ranged from 28 to 36 weeks (mean:31.8), and the BMI from 18.7 to 32.9 (mean:23.8) kg/m2. All the patients had the restauration done in their inferior premolar and/or molar teeth.
89027332|NCT00482573|Active Comparator|Group LNE|Fourteen (45.2%) patients, composed group LNE, were randomly assigned for the infusion of 1.8 mL (one cartridge) by the modified anesthesia into the periodontal ligament (PDLm injection) of 2% lidocaine solution without epinephrine. Their ages were ranging from 22 to 33 years (mean:26.6), they were diagnosed as having rheumatic valve disease, in a functional class I or II according to classification of the NYHA. Gestation age ranged from 29 to 37 weeks (mean:32.1), and the BMI from 18.5 to 38.1 (mean:22.8) kg/m2. All the patients had the restauration done in their inferior premolar and/or molar teeth.
89562722|NCT04973735|Experimental|600mg LY-CovMab|LY-CovMab is diluted with 0.9% sodium chloride to a total volume of 250 mL for IV infusion
89562723|NCT04973735|Experimental|1200mg LY-CovMab|LY-CovMab is diluted with 0.9% sodium chloride to a total volume of 250 mL for IV infusion
89562724|NCT04973735|Experimental|2400mg LY-CovMab|LY-CovMab is diluted with 0.9% sodium chloride to a total volume of 250 mL for IV infusion
89562725|NCT04973735|Placebo Comparator|Placebo|Placebo is diluted with 0.9% sodium chloride to a total volume of 250 mL for IV infusion
89562726|NCT04973579||Simultaneous cardiac surgery and carotid stenting|Patients with Heart Team and NeuroVascular Team recommendation to perform simutaneous (single anaesthesia) carotid artery stenting with MicroNet covered stent (CGuard) including proximal or distal neuroembolic protection and cardiac surgery (CABG or surgical valve replacement / repair procedure)
89562727|NCT04834063||NAFLD Cases|Non- alcoholic fatty liver disease
89562728|NCT04834063||control|healthy individual with normal liver on abdominal ultrasound
89027333|NCT00482651|Experimental|UAP, SAP|
89027334|NCT00481013|Placebo Comparator|1a|For six months, half of patients are randomized into placebo . After 6 months, all patients are on treatment.
89027335|NCT00481013|Active Comparator|1b|Cohort 1b patients are randomized onto treatment. After 6 months, all patients are on drug.
89027336|NCT00482768|Experimental|1|Intervention clinics will receive practice facilitation visits at regular intervals over a 12-month period.
89562729|NCT04978961|Experimental|Focused Acceptance and Commitment Therapy (FACT)|"Focused Acceptance & Commitment Therapy (FACT): FACT is a brief type of cognitive behavioral therapy that helps patients reduce disability through increased acceptance, reconnection with values, and reduced unhelpful control/coping strategies. Patients randomized to the intervention group received FACT per the study manual, delivered by an integrated Behavioral Health Consultant (BHC). Patients had one individual visit (30 minutes) and three consecutive weekly group visits (one hour) followed by a booster visit two months later. These classes (group visits) were rolling, not cohort-driven, meaning new and returning patients will be attending together. After the individual BHC visit and each class, patients had behavioral homework to complete."
89027337|NCT00482768|No Intervention|2|Control clinics will deliver usual care for patients with diabetes.
89027338|NCT01309243|Experimental|FTC/RPV/TDF|
89027339|NCT01309243|Experimental|EFV/FTC/TDF|
89027340|NCT01240070|Active Comparator|Usual Care|Clinical practice in type 2 diabetes treatment
89562730|NCT04978961|Active Comparator|Enhanced Treatment as Usual (ETAU)|"Patients randomized to the Enhanced-Treatment As Usual (ETAU) group received enhancement of usual primary care via 1-page (2-sided) educational handouts on four topic areas: Sleep, Pacing, Relaxation and Goal Setting. All topics have an evidence base in standard Cognitive Behavioral Therapy treatment of pain. One handout per assessment visit was given to each patient. Patients will continue to see their primary care clinicians and have access to all routine clinical services throughout the study."
89027341|NCT01240070|Active Comparator|Intensive Care|Intensive multi-factorial treat-to-target intervention, according to international guidelines, that includes both lifestyle intervention and a step-wise strategy for pharmacological treatment with a treat-to-target approach.
89562731|NCT04794205|Experimental|Low Dose BCP|Subjects will receive low dose of BCP.
89562732|NCT04794205|Experimental|Medium Dose BCP|Subjects will receive a medium dose of BCP
89562733|NCT04794205|Experimental|High Dose BCP|Subjects will receive high dose of BCP.
89562734|NCT04794205|Experimental|Placebo|Subjects will receive placebo drug.
89562735|NCT04973033|Experimental|Tofactitinib|Tofacitinib 5mg twice a day
89562736|NCT04436653|Experimental|Tricuspid Valve Replacement System|Subjects who received transcatheter tricuspid valve replacement with LuX-Valve and delivery system will be included in this arm.
89562737|NCT02660281|Other|Full Intensity TBI-based Conditioning|Total Body Irradiation 1200 cGy of 150 cGy over 4 or 5 days, days -5 or -4 to -1 Fludarabine 30 mg/m2/day x 3 days, days -6, -5, -4 Stem Cell Infusion, day 0 Post- Stem Cell Infusion Cyclophosphamide 50 mg/kg/day x 2 days, days +3 and +4 Mesna 50 mg/kg/day x 2 days, days +3 and +4
89562738|NCT02660281|Other|Full Intensity Chemo-Only Conditioning|Fludarabine 25 mg/m2/day x 5 days, days -6, -5, -4, -3, -2 Busulfan 130 mg/m2/day x 4 days, days -6, -5, -4, -3 Pre-Stem Cell Infusion Cyclophosphamide 14.5 mg/kg/day x 2 days, days -3 and -2 Pre-Stem Cell Infusion Mesna 14.5 mg/kg/day x 2 days, days -3 and -2 Stem Cell Infusion, day 0 Post-Stem Cell Infusion Cyclophosphamide 50 mg/kg/day x 2 days, days +3 and +4 Post-Stem Cell Infusion Mesna 50 mg/kg/day x 2 days, days +3 and +4
89562739|NCT02660281|Other|Reduced Intensity Conditioning|Fludarabine 30 mg/m2/day x 5 days, days -6 to -2 Melphalan 140 mg/m2/day x 1 day, day -2 Stem Cell Infusion, day 0 Post-Stem Cell Infusion Cyclophosphamide 50 mg/kg/day x 2 days, days +3 and +4 Post-Stem Cell InfusionMesna 50 mg/kg/day x 2 days, days +3 and +4
89562740|NCT02660281|Other|Non-Myeloablative Conditioning|Fludarabine 30 mg/m2/day x 5 days, days -6 to -2 Pre-Stem Cell Infusion Cyclophosphamide 14.5 mg/kg/day x 2 days, days -3 and -2 Pre-Stem Cell InfusionMesna 14.5 mg/kg/day x 2 days, days -3 and -2 Total Body Irradiation 200 cGy, day -1 Stem Cell Infusion, day 0 Post-Stem Cell Infusion Cyclophosphamide 50 mg/kg/day x 2 days, day +3 and +4 Post-Stem Cell Infusion Mesna 50 mg/kg/day x 2 days, day +3 and +4
89562741|NCT02660281|Other|Reduced Intensity Conditioning with Addition of Thiotepa|Fludarabine 30 mg/m2/day x 5 days, days -6 to -2 Thiotepa 8 mg/kg, day -3 Melphalan 140 mg/m2/day x 1 day, day -2 Stem Cell Infusion, day 0 Post-Stem Cell Infusion Cyclophosphamide 50 mg/kg/day x 2 days, days +3 and +4 Post-Stem Cell InfusionMesna 50 mg/kg/day x 2 days, days +3 and +4
89562742|NCT03061487||Group I|"Patients affected by central and peripheral aneurismatic disease with maximum statin daily dose ( Atorvastatin 80 mg, Simvastatin 40 mg, Rosuvastatin 40 mg).~Patients will undergo Open Surgical Treatment of Aneurysm (Aneurysmectomy).~The investigation consist in:~taking a preoperative blood sample to evaluate the MMPs circulating levels~taking an aneurismatic vassel wall istological sample with an intraoperative biopsy to evaluate the tissue MMPs and miRNAs levels"
89562743|NCT03061487||Group II|"Patients affected by central and peripheral aneurismatic disease with minimum statin daily dose.~Patients will undergo Open Surgical Treatment of Aneurysm (Aneurysmectomy).~The investigation consist in:~taking a preoperative blood sample to evaluate the MMPs circulating levels~taking an aneurismatic vassel wall istological sample with an intraoperative biopsy to evaluate the tissue MMPs and miRNAs levels"
89562744|NCT02438995|Experimental|Cetuximab with Radiation Therapy|For subjects receiving radiation therapy, the treatment schedule will consist of a re-irradiation dose of approximately 70 Gy over 6-7 weeks. This experimental treatment arm will add IA Cetuximab administration every three weeks up to 2 doses to this radiation schedule.
89562745|NCT02438995|Experimental|Cetuximab Alone|For subjects who are not candidates for re-irradiation, this experimental treatment arm will include only IA Cetuximab administration every three weeks up to 2 doses.
89562746|NCT03061409|Experimental|Pharmavite Nature Made Multi for Him 50+|A supplement containing vitamins and minerals
89562747|NCT03061409|Placebo Comparator|placebo|tablets contain microcrystalline cellulose containing 0.5% magnesium stearate
89562748|NCT04978883||pSS-ILD|diagnosis of pSS-ILD was based on abnormal HRCT and PFTs
89562749|NCT04978883||pSS non-ILD|pSS patients after exclusion of pSS-ILD and concomitant pulmonary diseases were considered as pSS non-ILD
89562750|NCT04662307|Experimental|Intelligent cardiopulmonary rehabilitation system (ICRS)|The intelligent cardiopulmonary rehabilitation system is designed to improve the user's adherence to pre-determined training intensity. The training intensity is pre-determined using the 60%-80% heart rate reserve which is obtained from the cardiopulmonary exercise test at prestest. The system allows dynamically auto-adjust the paddling resistance in accordance to the patient's current hear rate and paddling rate, with the goal to maintain the patient's heart rate at the pre-determined heart rate zone through the training period.
89562751|NCT04526041|Other|Professional beatboxer singer|1 professional beatboxer singer will be asked to produced different sounds while undergoing the different procedures. Researchers wil then select the most interesting sounds to be studied.
89562752|NCT04526041|Other|Experimented beatboxer singer|10 experimented beatboxer singer will be asked to reproduced the sounds record by the first subject (professional singer) while undergoing the different procedures.
89562753|NCT01669811|Experimental|D961H 20mg twice daily|Double-blinded
89562754|NCT01669811|Active Comparator|D961H 20mg once daily|Double-blinded
89608787|NCT04570111|Experimental|Macro-Optimized Diet (MOD)|After the controlled feeding study, participants in this group will follow the MOD diet for the remainder of pregnancy with the assistance of a study dietitian. The MOD diet will differ from control by macronutrient distribution at breakfast specifically, but also at each eating occasion, although the daily macronutrient distribution is equal to the control diet. At breakfast, the MOD diet will provide 10% Carb/30% Pro/60% Fat.
89608788|NCT03156699||STEMI patients treated with primary PCI|Database analysis only
89210623|NCT00924222|Experimental|Sevoflurane|
89210624|NCT00924222|Experimental|Propofol|
89608789|NCT04170907|Other|Nicotine salt 20 mg/mL|Vaping of nicotine salt e-liquids with a nicotine concentration of 20 mg/mL.
89608790|NCT04170907|Other|Nicotine salt 40 mg/mL|Vaping of nicotine salt e-liquids with a nicotine concentration of 40 mg/mL.
89608791|NCT04170907|Other|Free-base nicotine 20 mg/mL|Vaping of free-base nicotine e-liquids with a nicotine concentration of 20 mg/mL.
89562755|NCT05173285|Experimental|Brief Online ACT Intervention|Intervention Condition: Participants in this arm will take part in a brief ACT intervention delivered online via Qualtrics across 4-weeks; one session per week. The first two weeks will focus on mindfulness, with participants being invited to practice formal (i.e. 3-minute breathing exercise) and informal mindfulness practices (e.g. mindful walking, mindful drink etc.) during the week. The final two weeks will focus on values, specifically supporting participants to identify their personal values and set goals relating to these values. Participants have up to 6 weeks to complete the 4-week intervention.
89562756|NCT05173285|Other|Waitlist Control|Control Condition: Participants in this arm will not receive an intervention. They will however, been given access to the brief online ACT intervention at the end of study.
89562757|NCT04972877|Active Comparator|Treatment group|Treatment group protocol：participants will receive electro-acupuncture twice or three times a week with a maximum of 24 times in 2-3 months. Each treatment session lasts for 30 minutes.
89562758|NCT04972877|Sham Comparator|Control group|Control group protocol：participants will receive sham electro-acupuncture twice or three times a week with a maximum of 24 times in 2-3 months. Each treatment session lasts for 30 minutes.
89562759|NCT03061877||Anxiety or depression|
89562760|NCT03061877||Non-anxiety or depression|
89562761|NCT04601935|Experimental|LCAR-BCX cells product|Each subject will be given a single-dose infusion in each dose levelThe dose-finding phase of this study is designed primarily using the Bayesian optimal interval (BOIN) method, which is combined with accelerated titration at the beginning of the study to assess incidence of DLT (dose-limiting toxicity) and estimate MTD (maximum tolerated dose).
89562762|NCT04220723||End-Stage Liver Disease|End-stage liver disease patients who are being followed up at the Department of Gastroentereology of Hacettepe University Faculty of Medicine will be included in the study. When the participants come to the gastroenterology department for control, they will be directed to us and the assessment will begin after written and verbal approval is obtained. The Liver Frailty Index will be used to assess the frailty of the participants. Accordingly, hand grip test, 5 repeat sit-up test and side, semi-tandem and tandem balance measurements will be made and a total frailty score will be obtained. Submaximal aerobic capacities and functional capacities will be evaluated by 6 Minute Walk Test. Then, maximal inspiratory muscle pressure and maximal expiratory muscle pressure of the participants will be measured and respiratory muscle strength will be evaluated. Finally, maximal aerobic capacity will be measured by Shuttle Walk Test.
89562763|NCT04978025|Experimental|Silver Group|"Orally: the colloidal agent 1 dose of 30ml, 3 times a day for 5 days (use a plastic measuring cup and not a measuring cup or a metal spoon)~By inhalation: nebulization of 5ml of colloidal silver solution once, 3 times a day for 5 days."
89562764|NCT04978025|Placebo Comparator|Placebo Group|"Orally: EPPI 1 dose of 30 ml, 3 times a day for 5 days~By inhalation: nebulization of 5ml of EPPI solution once a day, 3 times a day for 5 days."
89562765|NCT05127811|Experimental|100mg(on empty)|
89562766|NCT05127811|Experimental|200mg(on empty)|
89562767|NCT05127811|Experimental|400mg(on empty)|
89562768|NCT05127811|Experimental|600mg(on empty)|
89562769|NCT05127811|Experimental|600mg（with a meal）|
89562770|NCT05127811|Experimental|800mg(with a meal)|
89562771|NCT04978103|Experimental|Single Arm|Hundred postmenopausal women were enrolled and received therapeutic dose of Gum Arabic (0.5 gm/kg/day) and followed for 12 weeks then the intended outcomes will be compared before and after completion of the study
89562772|NCT04437173|Experimental|Virtual Reality Arm|Patients undergo interventional pain procedure with virtual reality distraction
89562773|NCT04437173|No Intervention|No Intervention Arm|Patients undergo interventional pain procedure without virtual reality distraction
89562774|NCT04154579|Experimental|HeRe We Arts|This is an 8 week, arts-based session that includes educational & experiential components. Topics include: Introduction to Arts & Health; Music, Well-Being, & Resilience; Movement & Physical Activity; Art & Well-Being; Writing & Communication/Self-Expression; Theater & Socialization; Art Appreciation & a Healthy Brain; & Summary/Integration of the Arts into Daily Lives.
89562775|NCT04154579|Active Comparator|HeRe We Ed (Health Education Group)|This is an 8 week, non-arts-based health education session that includes educational & some experiential components. Topics include: Introduction to Health, Resilience, & Well-Being; Nutrition & Healthy Eating; Exercise, Chair Yoga, & Sleep; Mental Health, Stress Management, & Life Satisfaction; Holistic Approaches: Wellness, Integrative Medicine, & Complementary & Alternative Medicine; Chronic Illnesses & Chronic Pain; Health & Behaviors; Summary & Navigating the Healthcare System.
89562776|NCT04508179|Experimental|7HP349 Capsules|Part A: 7HP349 Capsules (5 cohorts); Part B: 7HP349 Capsules (2 cohorts); Part C: 7HP349 Capsules (3-period cross-over)
89027342|NCT04517409|Experimental|GDHT|After hepatic resection (Dynamic phase), the patients received an initial hemodynamic assessment based on PPV, CI and MAP. First, preload was optimized by fluid loading until PPV was <14% or VVS <12%, subjects were given 4 ml kg-1 boluses colloid solution every 5 minutes. At this point, the patient's individual preload optimized CI was determined and used as the hemodynamic goal until the end of surgery. Only if this value was below 2.5 L/min/(m2), inotropes were applied to reach this minimum CI, serving as a safety parameter to prevent patients from low cardiac output. If PPV and CI were within the target range but MAP was below 65 mmHg or PPV/VVS>1,2, vasopressors were started. After the initial assessment, patients were reassessed every 15 minutes intraoperatively to maintain values.
89210625|NCT00987285|Experimental|Computer Assisted Self Management plus Social Support|an interactive, automated self-management (ASM) program that uses web and interactive voice recognition (IVR) media combined with enhanced support in the form of group Diabetes Care Management visits and live follow up phone calls from Diabetes Care Managers
89562777|NCT04508179|Placebo Comparator|Placebo Capsules|Part A: Placebo Capsules (5 cohorts); Part B: Placebo Capsules (2 cohorts)
89608792|NCT03156387|Experimental|Diode laser|A 2.8 W, 980 nm diode laser(Sirona Advanced) in continuous wave mode with an air cooling handpiece was used in the alternative frenectomy technique. The frenulum was held with a hemostat, and a repeated continuous wave mode was applied for the excision. It was also used to remove the periosteal adhesion. The remnants of the ablated tissue were removed with saline, and no sutures were placed after the diode laser treatment.
89562778|NCT04400149||1|amniotic fluid progesterone (this group will be evaluated by the amniotic fluid which was received via amniocentesis). This group consisted of pregnant women who had high risk in the antenal test and give consent to perform amniocentesis. Notwithstanding, amniocentesis detects chromosome abnormalities, neural tube defects, and genetic disorders for the fetuses. İn a routine amniocentesis, 1-2 ml amniotic fluid which was taken in the first place was discarded in order to prevent maternal contamination. Then 15-20 ml amniotic fluid was taken from all of the patients to diagnose genetic disorders of the fetuses. İn this study we evaluate the amniotic fluid progesterone in this 1-2 ml amniotic fluid which was discarded and throw away. Therefore, we are not performing an extra invasive procedure for pregnant women
89210626|NCT00987285|No Intervention|Usual care|will receive a health-risk appraisal, interactive CD-ROM program that provides standardized advice on behavior change, but not the hypothesized key intervention processes of goal setting, barriers identification, problem solving, or social environmental support.
89562779|NCT04400149||2|serum progesterone (this group consisted of the pregnant women who have amniocentesis procedure and blood samples were taken in the same procedure )
89562780|NCT04437017|Experimental|Olanzapine+NK-1 RA+5-HT3 RA|Using one of the 5-HT3 receptor antagonists (a. Palonosetron: 0.25 mg d1 intravenous; b. Granisetron: 1 mg d1 intravenously, or 2 mg d1 orally; c. Ondansetron: 8-16 mg d1 intravenous or oral. the specific agent is chosen by the primary clinician, and is only delivered on the first day) within 30 minutes before cisplatin. Using one of the NK-1 receptor antagonists(a. Aprepitant: 125 mg orally, d1, 80 mg orally, d2-3; b. Fosaprepitant: 150 mg intravenously, d1) within 1 hour before cisplatin. On day 1-4, Olanzapine (5mg) is delivered orally after dinner.
89562781|NCT04437017|Active Comparator|Dexamethasone+NK-1 RA+5-HT3 RA|Using one of the 5-HT3 receptor antagonists (a. Palonosetron: 0.25 mg d1 intravenous; b. Granisetron: 1 mg d1 intravenously, or 2 mg d1 orally; c. Ondansetron: 8-16 mg d1 intravenous or oral. the specific agent is chosen by the primary clinician, and is only delivered on the first day) within 30 minutes before cisplatin. Using one of the NK-1 receptor antagonists (a. Aprepitant: 125 mg orally, d1, 80 mg orally, d2-3; b. Fosaprepitant: 150 mg intravenously, d1) within 1 hour before cisplatin. On first day, dexamethasone (12 mg) is given orally/intravenously within 30 minutes before cisplatin administered, and on day 2-4, the given dose of dexamethasone is 8 mg.
89562782|NCT03061253|Experimental|Nicotine-inclusive e-cigarettes|Participants will receive e-cigarettes (nicotine-inclusive) combined with behavioural change support over a 3 month period.
89562783|NCT03061253|Experimental|Nicotine-free e-cigarettes|Participants will receive e-cigarettes (nicotine-free) combined with behavioural change support over a 3 month period.
89562784|NCT03061253|Active Comparator|Nicotine Replacement Therapy (NRT)|Participants will be referred to smoking cessation services where they will be expected to receive Nicotine Replacement Therapy combined with behavioural change support over a 3 month period.
89562785|NCT04972643|Experimental|EPA and DHA intervention|EPA 1000mg and DHA 1000mg capsule twice a day, the total exposure to the intervention for each subject is 24 months.
89562786|NCT04972643|Experimental|EPA intervention|EPA 2000mg capsule twice a day, the total exposure to the intervention for each subject is 24 months.
89562787|NCT04972643|Experimental|DHA intervention|DHA 2000mg capsule twice a day, the total exposure to the intervention for each subject is 24 months.
89562788|NCT04972643|Placebo Comparator|Placebo|Placebo 2000mg capsule twice a day, the total exposure to the intervention for each subject is 24 months.
89562789|NCT05107141|Active Comparator|xenograft and a collagen membrane|
89562790|NCT05107141|Active Comparator|allograft and a collagen membrane|
89562791|NCT05107063||Dyslipidemic participants with Type 2 diabetes|Dyslipidemic participants with Type 2 diabetes who received a routine initiation dose of pravastatin 10 mg, 20 mg or 40 mg single dose once daily and maintained a low cholesterol diet throughout the study period.
89562792|NCT04977713|Experimental|Acupressure group|In the acupressure uterine contractions were checked before the care application began. Acupressure was applied when the women's cervical dilation reached 4-5 cm, 6-7 cm and 8-10 cm. This method was applied 18 times during uterine contractions. The application stopped at the end of each contraction and resumed once another contraction started. No application was performed between contractions.
89562793|NCT04977713|Experimental|Shower Group|The shower group, uterine contractions were checked before the care application began. A shower was applied when the women's cervical dilation reached 4-5 cm, 6-7 cm and 8-10 cm. This method was applied 18 times during uterine contractions. The application stopped at the end of each contraction and resumed once another contraction started. No application was performed between contractions.
89562794|NCT04977713|No Intervention|Control group|The women in the control group underwent routine hospital care. They were administered neither pharmacological nor nonpharmacological methods to reduce labour pain.
89562795|NCT05106907|Experimental|ThisCART19 cells injections|In this study, allogeneic anti-CD19 CAR T Cells(ThisCART19 cells) is used to treat patients with refractory or relapsed CD19 positive B cell malignancies.
89562796|NCT05106829|Active Comparator|Physical therapy program with treadmill training without using of ankle weights.|Cerebral palsied children will receive the physical therapy program from 45- 60 min./ session in addition to gait training on treadmill for 30 min./ session.
89562797|NCT05106829|Experimental|Physical therapy program with treadmill training with using of ankle weights.|Cerebral palsied children will receive the physical therapy program from 45- 60 min./ session in addition to gait training on treadmill with ankle weights for 30 min./ session.
89562798|NCT04432181||Group 1, astigmatic patients with amblyopia|astigmatic children with amblyopia
89562799|NCT04432181||Group 2, astigmatic patients without amblyopia|astigmatic children without amblyopia
89562800|NCT04422613|Experimental|characterization of pulmonary damage|This clinical trial will be characterized the pulmonary damage after COVID-19 pneumonia
89562801|NCT04971317|Experimental|Sugar-Sweetened Beverage (SSB) Video|
89562802|NCT04971317|Experimental|Water Video|
89562803|NCT04971317|Active Comparator|Control|
89562804|NCT05106751|Experimental|YVOIRE Classic plus|
89562805|NCT05106751|Active Comparator|Restylane Lidocaine|
89562806|NCT04383379|Experimental|Intervention group|6 NICUs in the intervention group . The participating units of the intervention group determine the improvement items (one or more) in each quarter from the list of best practices of breast feeding quality improvement of Jiangsu Province, and report the improvement plan to the supervision unit, and recommend the application of PDSA (plan-do-study-act) for the implementation of quality improvement loop. Report the implementation of quality improvement to the supervision unit on a quarterly basis.
89562807|NCT04383379|No Intervention|control group|Continue current practices
89562808|NCT05106673|Experimental|clinical centers that receive implementation support|These clinical centers receive support during the implementation of the CHIMPS-intervention. There are three different implementation interventions.
89562809|NCT05106673|Experimental|No Intervention: Treatment as usual|These clinical centers will be the control group and will not get a specific implementation support during the implementation of CHIMPS.
89027343|NCT04517409|Other|Control|"Before hepatic resection (Static phase) all patiens received continuous infusion of balanced crystalloid with the goal of CVP of 5 mmHg.~After hepatic resection (Dynamic phase), the patiens received colloid solution, vasopressors, and inotropes at the discretion of the anaesthetist, acording to CVP, MAP and orine output. In this group, CO monitoring was not performed. Intraoperative treatment goals in the control arm were flexible to avoid both extremes of clinical practice and practice misalignment"
89562810|NCT04977557|Other|single arm|"its a quasi experimental study where single group is used (self controlled clinical trial).~clinical features were compared before iand after intervention"
89562811|NCT04316143|Experimental|50 mg zamicastat|50 mg zamicastat once daily (half a tablet of 100 mg)
89562812|NCT04316143|Experimental|100 mg zamicastat once daily|100 mg zamicastat once daily (one tablet of 100 mg)
89562813|NCT04316143|Experimental|150 mg zamicastat once daily|150 mg zamicastat once daily (one and a half tablet of 100 mg)
89562814|NCT04316143|Experimental|200 mg zamicastat once daily|200 mg zamicastat once daily (two tablets of 100 mg)
89027344|NCT01240109|Active Comparator|propofol|
89027345|NCT01240109|Active Comparator|sevoflurane|
89027346|NCT04517526|Experimental|1|pemetrexed (500 mg/m2/d1) + cisplatin/carboplatin (20-25 mg/m2 × 3 days/AUC 5) + bevacizumab (7.5 mg/kg) + durvalumab (10 mg/kg) every 3 weeks for 4 to 6 cycles , followed by bevacizumab and/or durvalumab anti-maintenance therapy until the emergence of treatment-related toxicity or disease progression in the patient, followed by stereotactic radiotherapy to appropriate oligometastatic or oligoprogressive sites
89210627|NCT00987285|Experimental|Computer Assisted Self Management|An interactive, automated self-management (ASM) program that uses web and interactive voice recognition (IVR) media.
89562815|NCT04977323|Experimental|TICK-B group as intervention group|TICK-B group: The children will receive the pictures they want. They will be asked to trace and color the pictures that need coloring. The nurse will color with children during the procedure. And after the procedure, the child will take his or her picture which he colored during the procedure.
89562816|NCT04977323|Experimental|Watching cartoons|Watching cartoons: In this group, children will watch cartoons as they like. Watching will continue until the procedure is complete.
89562817|NCT04977323|Experimental|Group listening to music|Listening to music: In this group, children will listen to cartoon music as they like. Listen will continue until the procedure is complete.
89562818|NCT04977323|No Intervention|Standard care provided group as control group|Control group. The kids in this group will be allowed to keep their family near. The routine blood taking
89562819|NCT04977089||Ischemic heart disease patients .|Study of lipid profile of patients with chronic coronary syndromes who recieve drugs of anti hyperlipidemia at the cardiology clinic of sohag university hospital.
89562820|NCT05104801|Experimental|Arm A: tislelizumab+sitravatinib|Patients will receive sitravatinib 100 mg orally once daily in combination with tislelizumab 200 mg IV once every 3 weeks until disease progression, unacceptable toxicity, or withdrawal of consent.
89562821|NCT05104801|Experimental|Arm B: sitravatinib|Patients will receive sitravatinib 100 mg orally once daily until disease progression, unacceptable toxicity, or withdrawal of consent.
89562822|NCT04977011|Experimental|experimental group|30 minutes music intervention for 3 days on bedside
89562823|NCT04977011|No Intervention|control group|usually care
89562824|NCT04530877|Experimental|Exclusive enteral nutrition|the administration of a liquid formula diet with the exclusion of all other regular food for 8 weeks， the volume was determined according to the energy needs of the patient. All patients received high energy intakes (>110%-120% of the average requirement).
89562825|NCT04530877|Active Comparator|Infliximab|the participants with active CD accept anti-TNF therapy (Infliximab) at 0week, 2week, 6week, 14week. Infliximab, a monoclonal antibody-targeting tumor necrosis factor (TNF), is one of the primary treatment strategies for active pediatric CD
89562826|NCT04971083|No Intervention|Usual Care|"Control (CG): receives Usual Care. Observational data regarding energy and fluid intake, weight, quality of life, symptoms, and distress status will be recorded in the Electronic Health Platform. They will have to ability to print and share this documentation with their HCP at their own discretion.~Inflammation status will be recorded when data from routine blood draws is available"
89608793|NCT03156387|Active Comparator|Scalpel|(1) topical anesthesia (20% benzocaine), (2) local anesthesia using the bilateral vestibular infiltration technique, with 0.6 ml (1/3 of the carpule contents) of 4% articaine and 1:200,000 epinephrine, (3) hemostatic clamping of the frenulum, (4) excision of the whole band of tissue, together with its alveolar attachment, with a 15C scalpel blade, (5) relaxation and unbending of any fibrous adhesions to the underlying periosteum, and (6) simple suturing with 5-0 silk thread
89562827|NCT04971083|Active Comparator|Intervention Group|"Intervention Group (IG): The intervention consists of a built-in automated analysis that provide patient-tailored nutrition recommendations and behavioural tipps. Described in detail this means that dependent on the severity of the nutrition related symptom burden (NRSB) recorded, the patients in the intervention group only are, for example provided with detailed written nutrition information and cooking recipes and/or asked to discuss the symptoms with their health care provider, dietitian, and/or physician, or even asked to seek immediate medical care.~Analog to the control group, observational data regarding energy and fluid intake, weight, quality of life, symptoms, and distress status will be recorded in the Electronic Health Platform. They will have to ability to print and share this documentation with their HCP at their own discretion.~Inflammation status will be recorded when data from routine blood draws is available"
89562828|NCT04971239|Active Comparator|topical methotrexate microemulsion|Group(A): topical methotrexate micro emulsion formulation, each patient will be instructed to apply a very thin film of 0.5 ml of it over the three psoriatic plaques three times weekly .
89562829|NCT04971239|Experimental|combination of topical methotrexate microemulsion and excimer light|Group(B) : excimer laser will be done twice weekly on a different psoriatic plaques in combination with topical methotrexate micro emulsion for a total treatment course of 12 weeks.
89562830|NCT04971239|Experimental|combination of topical methotrexate microemulsion and narrow band-ultraviolet B|Group(C) : Narrow band ultraviolet B will be done twice weekly on a different psoriatic plaques in combination with topical methotrexate micro emulsion for a total treatment course of 12 weeks
89562831|NCT03062111|Active Comparator|ProTouch Laser Enucleation of Prostate|The intervention for this group is that the patient will undergo endoscopic ProTouch Laser Enucleation of Prostate (LEP).The laser is used to enucleate large pieces of prostatic tissue which is followed by further ablation of the tissue so that no fragments are left in the bladder
89562832|NCT03062111|Active Comparator|Transurethral Resection of Prostate|The intervention for this group that the patient will undergo endoscopic Transurethral Resection of Prostate (TURP) using bipolar cautery. The prostate is essentially shaved down using sequential cuts and cautery.
89562833|NCT04903093|Experimental|Part A: Abrocitinib Tablet|
89562834|NCT04903093|Experimental|Part A: Abrocitinib Suspension F1|
89562835|NCT04903093|Experimental|Part A: Abrocitinib Tablet + Famotidine|
89562836|NCT04903093|Experimental|Part B: Abrocitinib Suspension F1|
89562837|NCT04903093|Experimental|Part B: Abrocitinib Suspension F2|
89562838|NCT04903093|Experimental|Part B: Abrocitinib Suspension F3|
89562839|NCT04903093|Experimental|Part B: Abrocitinib Suspension F4|
89562840|NCT04903093|Experimental|Part B: Abrocitinib Suspension F5|
89562841|NCT04903093|Experimental|Part B: Abrocitinib Suspension F6|
89562842|NCT04903093|Experimental|Part B: Abrocitinib Suspension F1 + Famotidine|
89562843|NCT04903093|Experimental|Part B: Abrocitinib Suspension F2 + Famotidine|
89562844|NCT04903093|Experimental|Part B: Abrocitinib Suspension F3 + Famotidine|
88967867|NCT00114283|Experimental|Treatment (lapatinib ditosylate)|Patients receive lapatinib ditosylate PO QD. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88967868|NCT00114361|Active Comparator|1|Ribavirin + Peg IFN
88967869|NCT00114361|Active Comparator|2|Peg IFN + Placebo
88967870|NCT03079440|Experimental|TEMCAP|Temozolomide plus Capecitabine
88967871|NCT04728178|Active Comparator|study group|In the control group, fluid management was set as MAP (Mean arterial pressure) 65 mmHg and above and diuresis 0.5ml/kg/hour and above. Crystalloid infusion at 7ml/kg/hour was started. When SVV value increased to 13% and over in the study group, 250 ml of crystalloid was given in the first stage, and if it continued to be 13% and over, 250 ml of colloid bolus was given. Vasoconstrictor agent was used when SVV was below 13% and MAP was below 65 mmHg.
88967872|NCT04728178|Placebo Comparator|control group|In the control group, fluid management was set as MAP (Mean arterial pressure) 65 mmHg and above and diuresis 0.5ml/kg/hour and above. Crystalloid infusion at 7ml/kg/hour was started. They were given 250 ml of crystalloid in the first stage if the MAP was below 65 mmHg, and 250 ml of colloid bolus if the hypotensive episode continued. If hypotension persisted despite these fluid boluses, a vasoconstrictor agent was used. In addition, when the diuresis of the patients was detected at 0.5mg/kg/hr or less, 250 ml of colloid bolus was administered.
89562845|NCT04903093|Experimental|Part B: Abrocitinib Suspension F4 + Famotidine|
89562846|NCT04903093|Experimental|Part B: Abrocitinib Suspension F5 + Famotidine|
89562847|NCT04903093|Experimental|Part B: Abrocitinib Suspension F6 + Famotidine|
89562848|NCT04970849||one group that is IBD endoscopist who perform the endoscopy for IBD patients|Complete the questionnaire online
89562849|NCT04529785|Active Comparator|SVC only|Patients in Group 1 will receive an SVC isolation only
89562850|NCT04529785|Active Comparator|SVC isolation with substrate modification and VoM inf|Patients in Group 2 will receive an SVC isolation with substrate modification and vein of Marshal ethanol infusion
89562851|NCT04970615||Two-dimensional images|Patients who receive pre-operativeinformation while the two-dimensional MR images are being shown to them by the neurosurgeon.
89562852|NCT04970615||Three-dimensional printed model|Patients who receive pre-operative information while the three-dimensional printed models are being shown to them by the neurosurgeon.
89562853|NCT04271293||Patients with PEG and oral anticoagulan treatment|Patients with PEG and indication for treatment with long-term oral anticoagulant therapy due to non valvular atrial fibrillation (FNAV), according to the current guidelines.
89562854|NCT04208659|Experimental|Self-administration of Auricular Acupuncture Group|There is only one arm in this pilot project, whose purpose is to determine safety of self-administration of Battlefield Acupuncture over a six month period and how well a prosthesis facilitates needle insertion. Five ASP (Aiguille D'acupuncture semi-permanente) needles will be self-inserted into each participant's ear every two weeks according to the standardized acupuncture points in Battlefield Acupuncture.
89562855|NCT03060239|Experimental|Experimental arm|Patients with Parkinson's disease with severe REM sleep behaviour disorder according to International Classification of Sleep Disorders (ICSD2) criteria.
89562856|NCT03059927|Active Comparator|Knee arthroplasty, Cruciate retaining|Total knee replacement with preserved posterior cruciate ligament and a cruciate retaining insert.
89562857|NCT03059927|Active Comparator|Knee arthroplasty, Anterior stabilized|Total knee replacement with sacrificed posterior cruciate ligament and an anterior stabilized insert.
89562858|NCT03059927|Active Comparator|Knee arthroplasty, Posterior stabilized|Total knee replacement with sacrificed posterior cruciate ligament and a posterior stabilized design.
89562859|NCT03059849|Active Comparator|Temporary increase in adalimumab|
89562860|NCT03059849|No Intervention|Continued monitoring as per standard of care|
89562861|NCT04822441||Patients who contracted dengue fever before 34 weeks of amenorrhea|Patients who contracted biologically proven dengue fever during pregnancy before 34 weeks outside the peri-partum period (more than 12 days before childbirth)
89562862|NCT04822441||Patients who contracted dengue fever after 34 weeks of amenorrhea|Patients who contracted biologically proven dengue fever during pregnancy after 34 weeks outside the peri-partum period (more than 12 days before childbirth)
89562863|NCT04822441||Patients who have contracted dengue during the peripartum period|Patients who have contracted dengue during the peripartum period or who have a suspicion of dengue (in the 12 days preceding childbirth)
89562864|NCT04976075||Adults|Patients of 18 or more years old
89562865|NCT04976075||Pediatrics|Patients less than 18 years old
89562866|NCT04796701|Experimental|Follow Home Intervention|If possible, all included participants are physically followed home by a hospital-based project worker on the day of discharge. During the visit, the focus is on: basic human needs, medication review reconciliation, and a comprehensive geriatric assessment. Problems, challenges and concerns are discussed. Finally, a conference for the following working day is arranged either as a physical visit or a video conference. The patient, relatives, community-based nurse and project worker are invited to participate and health status and challenges are discussed They are recommended to contact the project worker about health and practical issues up to 7 days after discharge where the intervention ends. Subsequently, the responsibility for treatment and care is assigned to the GP and home healthcare provider.
89562867|NCT04796701|No Intervention|Control|On the day of discharge, the hospital-based nurse digitally sends a summary of the hospital stay and a treatment and care plan to the community-based nurse. If needed, the hospital-based nurse contacts the community-based nurse by phone as a supplement to the plan. Finally, a discharge letter conducted by the hospital-based doctor is digitally sent to the GP
89562868|NCT04156165|Active Comparator|VLCD-Control|Very low calorie diet, 600 kcal pr day for eight weeks.
89562869|NCT04156165|Experimental|VLCD-Active|Very low calorie diet plus additional 25 g protein powder, 700 kcal pr day for eight weeks.
89562870|NCT04156165|Active Comparator|Maintenance-Control|"12-week weight maintenance diets: Moderate protein weight maintenance diet (MP-WMD): Recommended healthy diet including 25 g beef daily.~The diet is ad libitum and will be high in fibre (40 g/10 MJ) and whole grain (150 g/day) and allow inclusion of free/added sugar up to the recommended level (<10E% sugar)."
89562871|NCT04156165|Experimental|Maintenance-Active|12-week weight maintenance diets: High protein weight maintenance diet (HP-WMD): The macronutrient distribution will be 25 energy percentage (E%) from protein, 45 E% from carbohydrate and 30 E% from fat. The diet will include 150 g beef as a daily source of protein, The diet is ad libitum and will be high in fibre (40 g/10 MJ) and whole grain (150 g/day) and allow inclusion of free/added sugar up to the recommended level (<10E% sugar).
89562872|NCT04970693|Experimental|Furmonertinib 80mg combined with radiotherapy|This group will enroll NSCLC patients who are oligoprogressive after first/second generation EGFR-TKI therapy. These patients will receive furmonertinib 80mg combined with radiotherapy as following therapy.
89562873|NCT04970693|Experimental|Furmonertinib 160mg combined with radiotherapy|This group will enroll NSCLC patients who are oligoprogressive after third generation EGFR-TKI therapy. These patients will receive furmonertinib 160mg combined with radiotherapy as following therapy.
89562874|NCT04918537|Experimental|Intervention walnuts|During the 3 last weeks of the study, the participants will eat a 30g daily walnut serving
89562875|NCT04970303||Case group|investigator will recruit 60 patients with ADHD (aged between 6 and 16). Blood (10 ml) and urine (10 ml) will be obtained from each participant to analyze the levels of EDCs (Phthalates, Phenols and Parabens), growth hormone and thyroid function (TSH, T3, Free T4, T4, growth hormone, IGF-1and IGF-BP3). Behavior symptoms (ADHD-RS and SNAP-IV) and neuropsychological function (WISC, CPT and CATA) of each participant will be assessed. Patients with ADHD will receive treatment in a clinical practice and then will be followed up for 12 months. At the 12th month, the same procedures as those performed at the baseline will be replicated for patients with ADHD.
89562876|NCT04970303||Control group|investigator will recruit 60 age- and gender-matched control subjects. Blood (10 ml) and urine (10 ml) will be obtained from each participant to analyze the levels of EDCs (Phthalates, Phenols and Parabens), growth hormone and thyroid function (TSH, T3, Free T4, T4, growth hormone, IGF-1and IGF-BP3). Behavior symptoms (ADHD-RS and SNAP-IV) and neuropsychological function (WISC, CPT and CATA) of each participant will be assessed.
89562877|NCT03942835|Experimental|Healthy participants aged from 6 to 90 year-old|
89562878|NCT03942835|Experimental|patients with ADHD with no treatment|patients with ADHD aged from 6 to 90 year-old with no treatment
89562879|NCT03942835|Experimental|patients with ADHD with treatment|patients with ADHD aged from 6 to 90 year-old with psychostimulant treatment (Methylphenidate)
89562880|NCT04975529|Experimental|Intervention Arm|Participants in intervention schools received access to daily, online after school programming, including live sessions with sports providers (via Zoom; rotating to provide exposure to multiple sports over the course of the intervention), weekly team meetings with a health coach (via Zoom), text-messages via the Remind app, and monthly delivery of Activity Kits with sports equipment, activity books, fresh produce, and incentives directly to their homes over 6-months.
89562881|NCT04975529|Experimental|Comparison Arm|Participants in comparison schools received access to the Game on Philly app with workout and sports content that could be used asynchronously, and received one activity kit delivery with sports equipment and a self-guided activity book at the start of the program.
89027347|NCT01309204|Experimental|Brinz/Brim|Vehicle, 1 drop instilled in each eye, followed by Brinzolamide 1%/brimonidine tartrate 0.2% fixed combination ophthalmic suspension, 1 drop instilled in each eye. A 10-minute waiting period separated the instillations. Study drugs were instilled twice a day for 6 months.
89027348|NCT01309204|Active Comparator|Brinz+Brim|Brimonidine tartrate 0.2% ophthalmic solution, 1 drop instilled in each eye, followed by Brinzolamide 1% ophthalmic suspension, 1 drop instilled in each eye. A 10-minute waiting period separated the instillations. Study drugs were instilled twice a day for 6 months.
89027349|NCT01309165|Experimental|CO-OP|CO-OP, a client-centred, performance-based, problem solving approach has 7 key features including: client-chosen goals, dynamic performance analysis, cognitive strategy use, guided discovery, and a specific 10 one-hour sessions intervention format. Participants randomized to the CO-OP group will continue to receive usual out-patient services, such as physiotherapy or speech-language therapy, but will receive CO-OP instead of usual occupational therapy.
89562882|NCT04902547|Experimental|Multidisciplinary Tapering Program Only|Patients in this arm will take part in the clinical multidisciplinary opioid tapering program (MTP).
89562883|NCT04902547|Experimental|Patient Education Workshop & Multidisciplinary Tapering Program|As above, though patients in this group will also take part in an opioid education workshop
89210628|NCT03972319|Experimental|Omega-3 Supplementation|Proof of Concept and Safety Study of 4 weeks of Omega-3 supplementation pre- Bariatric Surgery
89210629|NCT00928122|Experimental|1 / Presbyopia|Presbyopic patients, slightly hyperopes
89562884|NCT04969679|Active Comparator|E. coli Nissle 1917 (Mutaflor®)|Active group will receive E. coli Nissle 1917 (Mutaflor®).
89562885|NCT04969679|Placebo Comparator|Placebo|Placebo group will receive placebo drug.
89562886|NCT04969757|Experimental|Predigraft|"Patients in the interventional arm will use Predigraft (Class 1 medical device under MDD 93/42/EEC Cibiltech Society) to receive therapeutic education content (videos, facts sheets, short messages, questionnaires), exchange documents with their doctors and interact via messaging with them.~Physicians will be able to calculate their iBox score to predict their patients' allograft survival at 3, 5 and 7 years."
89562887|NCT04432259|Experimental|Arm B: Oral Dexamethasone|Participants will be randomly assigned to receive 4 mg Oral Dexamethasone taken twice daily for 4 days
89562888|NCT04432259|Placebo Comparator|Arm A: Placebo|Participants will be randomly assigned to receive 4 mg placebo taken twice daily for 4 days
89562889|NCT03933085|Experimental|MCI Group|A within-subject, multiple baseline design, with each subject serving as their own control,4 will be implemented to get the maximum number of participants trained in the use of the MSS during the proposed funding period. This 2-year study will involve four phases: a 4-month translation and cultural adaptation development phase, a 12-month recruitment and treatment implementation phase, a 6-month post data collection only phase, and a 2-month data analysis and result writing phase. Data analyses will be conducted using the Statistical Package for the Social Sciences (SPSS) program.
89562890|NCT04969523|Experimental|es-ketamine|es-ketamine 0.5mg/kg iv
89562891|NCT04969523|Placebo Comparator|saline|iv saline with the same volume of es-ketamine
89562892|NCT03578107|Other|Improvement intervention1|receive the following improvement intervention for 18 months：
89562893|NCT03578107|Other|Improvement intervention2|receive the following improvement intervention for 12 months：
89562894|NCT03578107|Other|Improvement intervention3|receive the following improvement intervention for 6 months：
89562895|NCT03059771|Experimental|Mobile Enhancement of Motivation (MEMS)|Facilitators will first collaboratively help participants set personal recovery-goals using Collaborative Goal Technology (Clarke et al., 2006). Participants will then receive three sets of interactive text messages each weekday for eight weeks to reinforce and cue goal completion.
89562896|NCT03059771|Active Comparator|Control|Participants will only engage in a goal-setting session where facilitators will collaboratively help participants set personal recovery-goals using Collaborative Goal Technology (Clarke et al., 2006).
89562897|NCT03918031|Active Comparator|PFI for Smoking & Distress Tolerance|A brief, one-session computer-delivered personalized feedback intervention (PFI) that addresses smoking and distress tolerance.
89562898|NCT03918031|Active Comparator|PFI for Smoking Only|A brief, one-session computer-delivered personalized feedback intervention (PFI) that addresses smoking only (no distress tolerance component).
89562899|NCT03059693|Experimental|HAT1 topical cream|HAT1 medicated cream will come in a blinded tube. The research team will provide instructions for the correct application of the treatment. The medicated cream will be applied twice daily (morning and evening) at least 4 hours apart to all lesions. Treatment will continue daily until next visit. If a lesion disappears, patients will continue applying the cream twice daily to the area.
89562900|NCT03059693|Placebo Comparator|Vehicle cream|Vehicle cream will come in a blinded tube. The research team will provide instructions for the correct application of the treatment. The vehicle cream will be applied twice daily (morning and evening) at least 4 hours apart to all lesions. This will be continued daily until next visit.
89562901|NCT05090683|Experimental|Mind-body mobile application|Participants are asked to engage with a user-guided mobile application (app) that employs mind-based techniques that include: expressive writing, meditation, cognitive behavioural therapy, and pain education. The app also includes access to podcasts that focus on pain counselling and pain education.
89562902|NCT05090683|No Intervention|Control|Participants are asked to continue with usual care for pain treatments. They are asked not to start any new forms of treatment.
89562903|NCT04964219|Experimental|S-ketamine group|"After anesthesia induction, a bolus of 0.15 mg/kg S-ketamine is injected intravenously about 30 min before incision; this is followed by a continuous infusion at a rate of 0.15 mg/kg/h until 1 hour before the end of surgery.~After surgery, patient-controlled analgesia is provided. The pump is established with S-ketamine 25 mg, dexmedetomidine 100 microgram, and sufentanil 100 microgram, diluted with normal saline to 100 ml. The pump is programmed to deliver 2-ml boluses with a background infusion rate at 1 ml /h and a 10-min lockout interval."
89562904|NCT04964219|Placebo Comparator|Control group|"After anesthesia induction, a bolus of placebo (normal saline) in the same volume is injected intravenously about 30 min before incision; this is followed by a continuous infusion of placebo at the same rate until 1 hour before the end of surgery.~After surgery, patient-controlled analgesia is provided. The pump is established with placebo, dexmedetomidine 100 microgram and sufentanil 100 microgram, diluted with normal saline to 100 ml. The pump is programmed to deliver 2-ml boluses with a background infusion rate at 1 ml /h and a 10-min lockout interval."
89562905|NCT04975451|Experimental|ADCb|Anlotinib (anlotinib 12mg qd p.o. d1-14/21day/cycle)and Docetaxel (75 mg/m2 administered intravenously every 3 weeks) and carboplatin (area under the concentration-time curve [AUC] 6, intravenously every 3 weeks) for six cycles
89562906|NCT04975373|Other|study group|study group women in this group will receive intrauterine hyaluronic acid injection after operative hysteroscopy
89562907|NCT04975373|No Intervention|control group|women will not receive hyaluronic acid after operative hysteroscopy
89562908|NCT04974983||A|Treatment without bevacizumab
89562909|NCT04974983||B|Treatment with bevacizumab
89562910|NCT04968977||UPLM-ISR|
89562911|NCT04968665||healthy volunteers|gait testing and MRI at baseline for healthy volunteers
89562912|NCT04968665||ACL-deficient patients|gait testing and MRI at pre-operation, 6 months post-operation, 1 year post-operation, 2 years post-operation
89027350|NCT01309165|Active Comparator|Standard Occupational Therapy|Participants randomized to the SOT group will receive usual out-patient rehabilitation services, with slight modifications. Specifically, a research assistant will administer the COPM to assist participants to self-select 4 personally meaningful skills. The treating SOT occupational therapists will be asked to log the activities completed in each session, and the amount of time spent in therapy.
89562913|NCT04963829|Active Comparator|Study Group (SG)|Participants who used the abovementioned gel combined with lemongrass (Cymbopogon citratus) oil at 0.1% concentration.
89562914|NCT04963829|Active Comparator|Control Group 1 (CG1)|Participants who were subjected to a standardized treatment (collagenase ointment was selected for this treatment),
89562915|NCT04963829|Active Comparator|Control Group 2 (CG2)|Participants who used a gel made of 10% peel powder of unripe banana (M. sapientum)
89562916|NCT04963985|Experimental|Tafamidis group|During the treatment period, each participant will receive 20 mg tafamidis meglumine once daily for 24 weeks.
89562917|NCT04974905|Other|patients with infrainguinal arterial occlusive disease after failed antegrade approach|
89562918|NCT01669577||severe trauma patients|analysis of blood samples and clinical features
89027351|NCT01308853|Other|Macrolane|Open label
89027352|NCT02890888|Experimental|Hyperbaric oxygen treatment|HBO for 1 hour at 2 ATA 10 times, administered 5 times per week over 2 consecutive weeks
89027353|NCT04517331|Active Comparator|Group S (single injection TPVB group)|Patients received bilateral single injection ultrasound-guided TPVB at the level of T3-T4 with 20 mL bupivacaine 0.375% per injection/side.
89027354|NCT04517331|Active Comparator|Group D (double injection TPVB group)|Patients received bilateral double injection ultrasound-guided TPVB at the level of T2-T3 and T4-T5 with 10 mL bupivacaine 0.375% per injection (20 mL bupivacaine 0.375% per side as the single injection group).
89027355|NCT01240148|Experimental|1|150 μL intradermal injection of 1 μmol/L AZD3161
89562919|NCT04974827|Experimental|Camrelizumab , Cisplatin or Carboplatin|Participants will be given intravenous administration of Camrelizumab (200mg) ,Cisplatin(40mg/m²) or Carboplatin(AUC 2) and Radiotherapy. After completing 5 cycles of concurrent chemoradiation, the Participants will continue to use camrelizumab as maintenance therapy until one year.
89562920|NCT04963595|Experimental|Pyrotinib and Vinorelbine with Inetetamab|
89562921|NCT04963595|Experimental|Pyrotinib and Vinorelbine without Inetetamab|
89562922|NCT04963907|Active Comparator|Active CES Therapy|Participants will be asked to use Alpha-Stim 60 minutes daily for 8 weeks. Active devices are programmed to emit a current intensity of 100 uA at 0.5 Hz and will be programmed to run for 60 minutes. Participants will not be able to adjust the settings on the devices.
89562923|NCT04963907|Sham Comparator|Sham CES Therapy|Participants will be asked to use Alpha-Stim 60 minutes daily for 8 weeks. Sham devices are programmed to display a current intensity of 100 uA at 0.5 Hz and will be programmed to run for 60 minutes, but no current will be emitted from the device. Participants will not be able to adjust the settings on the devices.
89562924|NCT04963361||fear of movement group|The score of fear of movement scale was more than 37
89562925|NCT04963361||non-fear of movement group|The score of fear of movement scale was no more than 37
89562926|NCT04968431||Mitral Stenosis patient|
89562927|NCT04955015||patients|patients with caotid atherosclerosis refering to carotid endarterectomy
89562928|NCT04963049|Experimental|With Mask|
89562929|NCT04954235||Exposed to Anti-SARS-CoV-2 hyperimmune equine immunoglobulin F[ab']2 fragments|Group of patients with severe pneumonia who received treatment with 2 infusions of 4 mg / Kg each of hyperimmune anti-SARS-CoV-2 serum (INM005, CoviFab®) separated by 48 hours
89562930|NCT04954235||Not Exposed to Anti-SARS-CoV-2 hyperimmune equine immunoglobulin F[ab']2 fragments|Group of patients with severe pneumonia not exposed to hyperimmune anti-SARS-CoV-2 serum (INM005, CoviFab®) during hospitalization corresponding to the period prior to the approval of the hyperimmune anti-SARS-CoV-2 serum for its use.
89562931|NCT03060941|Experimental|Group 1|Physical activity education
89562932|NCT03060941|Experimental|Group 2|Physical activity education and facility access
89562933|NCT03060941|Experimental|Group 3|Physical activity education and supervised exercise sessions
89562934|NCT03060941|Experimental|Group 4|Physical activity education and self-monitoring (Fitbit)
89562935|NCT03060941|Experimental|Group 5|Physical activity education and active living counseling
89562936|NCT03060941|Experimental|Group 6|Physical activity education, facility access, and supervised exercise sessions
89562937|NCT03060941|Experimental|Group 7|Physical activity education, facility access, and self-monitoring (Fitbit)
89562938|NCT03060941|Experimental|Group 8|Physical activity education, facility access, and active living counseling
89562939|NCT03060941|Experimental|Group 9|Physical activity education, supervised exercise sessions, and self-monitoring (Fitbit)
89562940|NCT03060941|Experimental|Group 10|Physical activity education, supervised exercise sessions, and active living counseling
89562941|NCT03060941|Experimental|Group 11|Physical activity education, self-monitoring (Fitbit), and active living counseling
89562942|NCT03060941|Experimental|Group 12|Physical activity education, facility access, supervised exercise sessions, and self-monitoring (Fitbit)
89562943|NCT03060941|Experimental|Group 13|Physical activity education, facility access, supervised exercise sessions, and active living counseling
89562944|NCT03060941|Experimental|Group 14|Physical activity education, facility access, self-monitoring (Fitbit), and active living counseling
89562945|NCT03060941|Experimental|Group 15|Physical activity education, supervised exercise sessions, self-monitoring (Fitbit), and active living counseling
89562946|NCT03060941|Experimental|Group 16|Physical activity education, facility access, supervised exercise sessions, self-monitoring (Fitbit), and active living counseling
89562947|NCT04962425||The case group|Trastuzumab for the treatment of breast cancer patients with cardiotoxicity.
89562948|NCT04962425||The control group|Trastuzumab is used to treat patients with breast cancer who do not present with cardiotoxicity
89562949|NCT04962269||prostate cancer|The patient was pathologically diagnosed with prostate cancer
89562950|NCT04962269||benign prostatic hyperplasia|The patient was pathologically diagnosed with benign prostatic hyperplasia
89562951|NCT03060707|Experimental|Continuous infusion|The group of participants who are designated to receive continuously infused rocuronium.
89562952|NCT03060707|Active Comparator|Bolus administration|The group of participants who are designated to receive bolus administered rocuronium.
89562953|NCT03060863|No Intervention|1. Comparison|Families in this group will not receive any of the interventions.
89562954|NCT03060863|Experimental|2. Executive functioning|"Children in this arm will have the opportunity to use a computer-based working memory training game to practice recalling stimuli with an increasing number of presentations prior (n-back task)."
89562955|NCT03060863|Experimental|3. Food Bias|Children in this arm will use a computer-based approach avoidance task to reduce attentional biases for food by using a joystick to push away images of nonhealthy foods and pull closer images of healthy foods.
89027356|NCT01240148|Experimental|2|150 μL intradermal injection of 6 μmol/L AZD3161
89562956|NCT03060863|Experimental|4. Emotion Regulation|Children in this arm will use a computer-based, game-like relaxation training to teach emotion regulation and coping strategies.
89562957|NCT03060863|Experimental|5. Future orientation|Children in this arm will participate in an interview training protocol to promote their capacity to utilize and articulate a future oriented perspective.
89562958|NCT04953533||patients with gout|"age:year of 25~60;~consistent with the 2015 ACR gout diagnostic criteria ,and serum uric acid >420umol/L;~The patient are willing to take part in our study."
89562959|NCT04953533||patients with hyperuricemia|"age:year of 25~60;~A medical record in our hospital showed that the person is healthy, without key disease;~serum uric acid >420umol/L without gout flares."
89562960|NCT04953533||healthy controls|"age:year of 25~60;~A medical record in our hospital showed that the person is healthy, without key disease;~serum uric acid ≤420umol/L."
89562961|NCT04953611||Group A in GOLD|CAT<10、mMRC 0-1、FEV1%≥50%、the frequency of acute exacerbations in the past year<2；
89562962|NCT04953611||Group B in GOLD|CAT≥10、mMRC≥2、FEV1%≥50%、the frequency of acute exacerbations in the past year<2
89562963|NCT04953611||Group C in GOLD|CAT<10、mMRC 0-1、 FEV1%<50%、the frequency of acute exacerbations in the past year≥2 or leading to hospital admission≥1
89562964|NCT04953611||Group D in GOLD|CAT≥10、mMRC≥2、FEV1%<50%、the frequency of acute exacerbations in the past year≥2 or leading to hospital admission≥1
89562965|NCT04953611||Control Group|not COPD
89562966|NCT04966949|Experimental|lateral prostate capsule sparing group|Patients will be preverved the lateral prostate capsule during the resection of bladder and prostate of the operation.
89562967|NCT04966949|Active Comparator|nerve sparing group|Patients will be preverved the neurovascular bundles during the resection of bladder and prostate of the operation.
89562968|NCT04432103|Experimental|Severe COVID-19 pneumonia|Hospitalized patients with SARS-CoV 2 severe infection will receive an anti SARS-CoV 2 Convalescent Plasma
89027357|NCT01240148|Experimental|3|150 μL intradermal injection of 30 μmol/L AZD3161
89027358|NCT01240148|Active Comparator|4|150 μL intradermal injection of 10 mg/mL Lidocaine
89027359|NCT01240148|Placebo Comparator|5|150 μL intradermal injection of AZD3161 placebo
89210630|NCT00928122|Experimental|2 / Myopia|Myopic patients without Astigmatism
89210631|NCT00928122|Experimental|3 / Hyperopia|Hyperope patients without Astigmatism
89562969|NCT04432103|Experimental|Critical COVID- 19 pneumonia|Hospitalized patients with SARS-CoV 2 critical infection will receive an anti SARS-CoV 2 Convalescent Plasma
89608794|NCT03586713|Other|ICDAS-II|According to the international caries detection and assessment system (ICDAS-II). The visual examination was performed using the ICDAS-II criteria, which provides a standardized method of lesion detection. The ICDAS-II detection codes for coronal categories the score will be 0 =surface not restored or sealant then according to caries categories range from 0 to 6 depending on the severity of the lesion with the corresponding clinical views.
89608795|NCT01794949|Experimental|Non-diabetic patients receiving the Resolute stent|Non-diabetic patients presenting with Acute Coronary Syndrome (ACS), receiving the Resolute stent.
89608796|NCT01794949|Experimental|Diabetic patients receiving the Resolute stent|Non-insulin dependent diabetes mellitus (NIDDM) patients presenting with Acute Coronary Syndrome (ACS), receiving the Resolute stent.
89562970|NCT02658175|Experimental|Treatment-naïve Group|Treatment naïve group included combined group of ISIS 304801-CS7 (CS7-New) study participant and participant on placebo in index studies (ISIS 304801-CS6 [NCT02211209] and ISIS 304801-CS16 [NCT02300233]), were to receive 300 mg of volanesorsen as single SC once weekly for Weeks 1-52 of this study. Participants were allowed dose adjustment/dose reduction based on monitoring rules. Following Week 52 visit, participants had option of participating in expanded access program or continuing treatment with 300 mg of volanesorsen as single SC once-weekly for up to additional 52 weeks (Weeks 53-104) and in France participants, up to additional 104 weeks for total of 156 weeks (Weeks 105 to Week 156) until expanded access program was approved and available in their country. Participants who were not participating in expanded access program were to enter 13-week post-treatment (PT) evaluation period and in France, participants not continuing treatment were to enter 26-week PT follow-up period.
89562971|NCT02658175|Experimental|CS6-Volanesorsen|Participants with FCS rolling over from the ISIS 304801-CS6 (NCT02211209) index study after receiving volanesorsen, were to receive 300 mg of volanesorsen as a single SC injection once weekly for Weeks 1-52 of this study. Participants were allowed dose adjustment/dose reduction based on monitoring rules. Following the Week 52 visit, participants had the option of participating in an expanded access program or continuing treatment with 300 mg of volanesorsen as a single SC injection once-weekly for up to an additional 52 weeks (Weeks 53-104) and in France participants, up to an additional 104 weeks for total of 156 weeks of treatment (Weeks 105 to Week 156) of this study until an expanded access program was approved and available in their country. Participants who were not participating in an expanded access program were to enter a 13-week post-treatment evaluation period and in France, participants not continuing treatment were to enter a 26-week post-treatment follow-up period.
89562972|NCT02658175|Experimental|CS16-Volanesorsen|Participants with FCS rolling over from the ISIS 304801-CS16 (NCT02300233) index study after receiving volanesorsen, were to receive 300 mg of volanesorsen as a single SC injection once weekly for Weeks 1-52 of this study. Participants were allowed dose adjustment/dose reduction based on monitoring rules. Following the Week 52 visit, participants had the option of participating in an expanded access program or continuing treatment with 300 mg of volanesorsen as a single SC injection once-weekly for up to an additional 52 weeks (Weeks 53-104) and in France participants, up to an additional 104 weeks for total of 156 weeks of treatment (Weeks 105 to Week 156) of this study until an expanded access program was approved and available in their country. Participants who were not participating in an expanded access program were to enter a 13-week post-treatment evaluation period and in France, participants not continuing treatment were to enter a 26-week post-treatment follow-up period.
89562973|NCT03060005|Experimental|primary Sjögren's syndrome|The female patients with primary Sjögren's syndrome receive the Tears Naturale Forte and Liposic.
89562974|NCT03060005|Experimental|secondary Sjögren's syndrome|The female patients with secondary Sjögren's syndrome receive Tears Naturale Forte and Liposic.
89562975|NCT03060005|Experimental|meibomian gland dysfunction|The female patients with meibomian gland dysfunction receive the Tears Naturale Forte and Liposic.
89562976|NCT03060005|Experimental|control|the female had no history of autoimmune disease receive the Tears Naturale Forte and Liposic.
89562977|NCT02774785|Experimental|Device Arm|Randomized for MarginProbe device to be used during surgical procedure
89562978|NCT02774785|No Intervention|Control Arm|Randomized for surgical procedure to happen as per standard care
89027360|NCT04325191|Experimental|High Salt and Melatonin|Subjects will consume sodium pills throughout the day achieving a total of 6900 mg sodium/day (4600 mg of sodium from pills and 2300 mg from diet) and will supplement with 10 mg (single dose) of melatonin at night.
89562979|NCT04953455||pre-operation|Within one month before operation of diagnoses with a ligament rupture, patella dislocation, meniscus injury, or total knee replacement surgery
89562980|NCT04953455||early after operation|Within three months after operation of ligament rupture, patella dislocation, meniscus injury, or total knee replacement surgery
89562981|NCT04953455||lately after operation|within three months to one year after operation of ligament rupture, patella dislocation, meniscus injury, or total knee replacement
89562982|NCT04953455||healthy volunteers|Healthy people without abnormalities
89562983|NCT03234361|Experimental|High Phosphate Phase|All subjects will be on a low Pi diet containing 700mg/day of phosphate and 2 capsules of sodium phosphate with 500mg/day of phosphate for 4 weeks.
89562984|NCT03234361|Placebo Comparator|Low Phosphate Phase|All subjects will be on a low Pi diet containing 700mg/day of phosphate and 2 capsules of sodium chloride for 4 weeks.
89562985|NCT04953299|Experimental|Functional Imagery training|The FIT sessions will occur weekly for four weeks and last an hour per session. The sessions will be conducted over Zoom. Sessions will be facilitated by the PI who is trained in FIT, and attended by 4 participants.
89562986|NCT04953299|Active Comparator|Control|The control condition will ask participants to complete the 12 week NHS weight loss plan.
89027361|NCT04325191|Placebo Comparator|High Salt and Placebo|Subjects will consume sodium pills throughout the day achieving a total of 6900 mg sodium/day (4600 mg of sodium from pills and 2300 mg from diet) and will supplement with a lactose placebo (single dose) at night.
89027362|NCT04324879|Experimental|TQ-B3525 tablet|TQ-B3525 tablet administered orally.
89027363|NCT04517292|Experimental|Eribulin,cisplatin|EP (Eribulin and cisplatin combination)
89027364|NCT04517292|Active Comparator|Gemcitabine,cisplatin|GP (gemcitabine and cisplatin combination)
89208538|NCT00739973|Experimental|Aliskiren/amlodipine 150/5 mg tablet|Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos.
89562987|NCT04210141|Active Comparator|Standard of care|Patients will receive an initial antivenom dose of 80mL lyophilized BPI viper antivenom, as per current national guidelines
89562988|NCT04210141|Experimental|Adaptive arm|Patients will receive an initial dose of lyophilized BPI viper antivenom determined by the adaptive model.
89562989|NCT04966793||Bronchiectasis patients group|Bronchiectasis patients group: Sputum specimens from bronchiectasis patients aged 18 to 79 years old .
89562990|NCT04966793||Healthy control group|Healthy control group: Sputum specimens from healthy people.
89562991|NCT04962191||Lung Cancer|The Idylla EGFR Mutation Test, performed on the BioCartis Idylla System, is an in vitro diagnostic test for the qualitative detection of exon mutations. One of the biggest challenges in oncology biomarker testing is the ability to obtain samples of sufficient size and quality. This study can help test the BioCartis Idylla System against standard of care (SoC) pathology results from tissue biopsies in the same setting, ultimately being able to diagnose with a fraction of the tissue previously needed.
89562992|NCT04186117|Experimental|Biological collection|"For all the patients include in the study :~- Blood samples collected at before any treatment~In parallel to this biological collection, standardized clinical data will be entered into a database"
89562993|NCT04953221||M1 Test group|YJ001 for spray, topical application on the skin, drug concentration 100mg/mL, 2 times/day (interval 11-13h), 8 sprays each time, a total of 12 weeks.
89562994|NCT04953221||M1 control group|YJ001 simulant for spray, topical application on the skin, drug concentration 100mg/mL, 2 times/day (interval 11-13h), 8 sprays each time, a total of 12 weeks.
89562995|NCT04953221||M2 Test group:|YJ001 for spray, topical application on the skin, drug concentration 150mg/mL, 2 times/day (interval 11-13h), 8 sprays each time, a total of 12 weeks.
89562996|NCT04953221||M2 control group:|YJ001 simulant for spray, topical application on the skin, drug concentration 150mg/mL, 2 times/day (interval 11-13h), 8 sprays each time, a total of 12 weeks.
88967873|NCT03057288|Experimental|fiducial markers placement|Prospective study with one arm evaluating the feasibility of fiducial markers placement under echoendoscopic guidance, for patients with esophageal or rectal cancer
88967874|NCT00114790|Experimental|BNCT.|Boronophenylalanine-based BNCT.
88967875|NCT00114868|Active Comparator|Vitamin A|48,000 IU vitamin A oral dose spread over 2 days as soon as possible after birth.
88967876|NCT00114868|Placebo Comparator|Placebo|placebo
88967877|NCT03034200|Experimental|ONC201 phase 2 d1d2 weekly cohort|625 mg ONC201 by mouth daily for 2 consecutive days weekly
88967878|NCT00008177|Experimental|Treatment ( I 131 BC8, chemotherapy, TBI, PBSCT, CSP, MMF)|"CONDITIONING REGIMEN: Patients receive iodine I 131 monoclonal antibody BC8 IV on day -12 and fludarabine phosphate IV on days -4 to -2. Patients undergo total-body irradiation on day 0.~TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell transplantation on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine PO or IV BID on days -3 to 56 with taper to day 80 (for patients with a related donor) OR days -3 to 100 with taper to day 177 (for patients with an unrelated donor) in the absence of GVHD. Patients also receive mycophenolate mofetil PO or IV TID on days 0 to 27 (for patients with a related donor) OR on days 0 to 40 with taper to day 96 (for patients with an unrelated donor) in the absence of GVHD."
89562997|NCT04953221||M3 Test group|YJ001 for spray, topical application on the skin, drug concentration 200mg/mL, 2 times/day (interval 11-13h), 8 sprays each time, a total of 12 weeks.
89562998|NCT04953221||M3 control group|YJ001 simulant for spray, topical application on the skin, drug concentration 200mg/mL, 2 times/day (interval 11-13h), 8 sprays each time, a total of 12 weeks.
88967879|NCT03007407|Experimental|durvalumab and tremelimumab|
88967880|NCT00115180||Hispanic|Hispanic patients with long bone fractures no intervention
88967881|NCT00115180||White|White patients with long bone fractures no intervention
88967882|NCT00115180||African-American|African-American patients with long bone fracture no intervention
88967883|NCT00008216||alloSCT group|Patients undergoing allogeneic blood or marrow stem cell transplantation (alloSCT).
88967884|NCT00115258|Experimental|parenteral nutrition titrated to measured REE|parenteral nutrition titrated to measured REE
88967885|NCT00115258|No Intervention|standard of care|
88967886|NCT00390936|No Intervention|1|4 dosages
89562999|NCT04006951|Experimental|Biological collection|"For all the patients include in the study :~Paraffin tissue samples (if applicable) collected during pre-therapeutic rectal biopsy~Blood samples collected at different times : Before any treatment and Before surgery if the patient received pre-operative radiochemotherapy~In parallel to this biological collection, standardized clinical data will be entered into a database"
89563000|NCT05106439|Experimental|Competition arm|"Programs with at least five interns were grouped into program-based teams. Interns within the same residency institution in programs that did not meet this criterion were grouped into institution-based teams, with a minimum of five participants per team.~For each week, an eligible team is randomized to either competition or non-competition group with 50/50 chance. For those randomized to competition arm, teams were assigned an opponent team according to a weekly equally randomly selected rule from three options: 1. total randomization, by which the opponent team was assigned regardless of institution and specialty; 2. within-institution randomization, by which two competing teams were from the same institution; 3. within-specialty randomization, by which two paired teams were from the same specialty. For each pair of competing teams, there was a 50/50 chance that they would compete on average daily step counts or average daily sleep minutes."
89563001|NCT05106439|Experimental|Non-competition group|For each week, an eligible team is randomized to either competition or non-competition group with 50/50 chance.
89563002|NCT04418531|Experimental|Experimental antibodies (immunoglobulins) infusion|Anti-coronavirus obtained with double-filtration plasmapheresis (DFPP) from convalescent patients
89563003|NCT05037019|Experimental|Single fraction radiotherapy|Single fraction of 21 Gy stereotactic radiation therapy delivered to a single malignant lesion of the breast prior to any other treatment for breast cancer.
89563004|NCT02555293|Experimental|film-coated Rifaximin (550 mg)|(550 mg) tablet twice daily for at least 14 days but up to 28 days dependent on the need for a PVE and the period between PVE (portal vein embolization) or randomization and surgery. Preoperative Rifaximin treatment in case of a PVE will start the day after PVE and will last for 14-21 days. In case patients are not pre-treated with a PVE they will receive Rifaximin for 7-10 days prior to surgery. Regardless of PVE, patients will receive additional Rifaximin treatment the first 7 days postoperatively.
89563005|NCT02555293|No Intervention|standard therapy|Patients directed to the control group will not receive Rifaximin.
89563006|NCT05087251|Experimental|Intervention: Five Psycho-educational Sessions|Approximately 6 weeks after the patient's cancer treatment is complete, participants in the intervention arm will proceed to receive up to 5 study sessions (approximately weekly, ~50 minutes each) with a trained interventionist focused on psychoeducational topics. This arm was designed to enhance patient skills to address key concerns during the transition from treatment to surveillance, using a cognitive-behavioral approach. Sessions will be based on an intervention manual.
89563007|NCT05087251|Experimental|Enhanced Usual Care: One Psycho-educational Session|At approximately 6 weeks after treatment completion (as defined by our eligibility criteria), control patients will attend one study session (~50 minutes) with a study clinician. This session is designed to control for patient access and connection to psychosocial resources as recommended in recent work.
89563008|NCT03293017|Experimental|Baclofen 30 mg/day|baclofen 30 mg/day
89563009|NCT03293017|Experimental|Baclofen 60 mg/day|
89563010|NCT03293017|Placebo Comparator|Placebo|
89563011|NCT04436809|Other|SNB only|"cT2 patients scheduled for primary chemotherapy (with or without a clinically involved axilla - cN0/1) who have disease-free sentinel nodes (pN0) after primary chemotherapy, are directed to SNB only: i.e. no further treatment to the axilla."
89563012|NCT04436809|Other|SNB + AD|cT2 patients scheduled for primary chemotherapy (with or without a clinically involved axilla - cN0/1) who have metastatic sentinel nodes (pN1) on sentinel node biopsy (SNB) will undergo axillary dissection (AD) i.e. surgical removal of most axillary lymph nodes.
89563013|NCT04658251||Patients with an intronic variant unknown in a gene implicated in cone disorders.|
89563014|NCT04859491|Active Comparator|Carbohydrate|Carbohydrate in the amount of 1.2 g/kg of body weight (bw). Gatorade®, Chicago, IL, USA.
89563015|NCT04859491|Active Comparator|Carbohydrate-Protein|Carbohydrate in the amount of 0.8 g/kg bw (Gatorade®, Chicago, IL, USA) plus protein in the amount of 0.4 g/kg bw (biPro Elite, Agropur Inc., Appleton, WI, USA).
89563016|NCT04859491|Placebo Comparator|Placebo|Flavored water (G Zero, Gatorade®, Chicago, IL, USA).
89208539|NCT00739973|Experimental|Aliskiren/amlodipine 150/10 mg tablet|150/5 for 1 week, then up-titrated to 150/10 mg. Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos.
89208540|NCT00739973|Experimental|Aliskiren/amlodipine 300/5 mg tablet|Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos.
89563017|NCT05106049||cases|non-alcoholic fatty liver patients
89563018|NCT05106049||control|healthy persons
89563019|NCT04523545|Experimental|Treatment|
88967887|NCT00115453|Experimental|A|Active treatment arm.
88967888|NCT02993406|Experimental|Bempedoic Acid 180 mg|Bempedoic acid 180 mg tablet taken orally, once daily.
88967889|NCT02993406|Placebo Comparator|Placebo Comparator|Matching placebo tablet taken orally, once daily
88967890|NCT00115531|Experimental|Arm 1|Standard Dose Influenza Vaccine Fluzone® (15 µg HA / viral strain; 45 µg/0.5 mL dose) will be administered to Arm 1: 200 subjects intramuscularly on day 0.
89563020|NCT05105815|Experimental|IPM001|A neoantigen/tumor-specific antigen sensitized autoimmune cell injection
89563021|NCT02625623|Experimental|Physician choice chemotherapy+Best Supportive Care (BSC)|Participants received BSC plus physician's choice chemotherapy. Chemotherapy comprises of one of the following: paclitaxel at a dose of 80 milligram per meter square (mg/m^2) on Days 1, 8, and 15 of a 4-week treatment cycle until confirmed progressive disease or unacceptable toxicity OR irinotecan at a dose of 150 mg/m^2 on Days 1 and 15 of a 4-week treatment cycle until confirmed progressive disease or unacceptable toxicity. Participants who are not deemed eligible to receive paclitaxel or irinotecan at the dose and schedule specified above receive BSC alone once every 3 weeks. BSC is defined as treatment administered with the intent to maximize quality of life without a specific antineoplastic regimen and is based on investigator's discretion.
89563022|NCT02625623|Active Comparator|Avelumab+BSC|Participants received avelumab as a 1-hour intravenous (IV) infusion at 10 milligram per kilogram (mg/kg) once every 2-week treatment cycle until confirmed progressive disease or unacceptable toxicity along with BSC. BSC is defined as treatment administered with the intent to maximize quality of life without a specific antineoplastic regimen and is based on investigator's discretion.
89563023|NCT05105893|Other|Dates group|The experimental group of women was given several dates orally and instructed to take seven a day and record their consumption until the beginning of the active phase of labor. Seven pieces of dates are about 80g of daily consumption
89563024|NCT05105893|Other|No dates|This group wasnt provided dates.
89563025|NCT02749513|Experimental|Itraconazole|Itraconazole 300 mg po bid for 14-17 days
89563026|NCT03058523||Non-Pregnant|30 non-pregnant women of childbearing age
89563027|NCT03058523||Pregnant|30 pregnant women
89563028|NCT05110339|Experimental|Ropivacaine plus Dexmedetomidine|In addition to standard general anesthesia, patients receive erector spinae block with ropivacaine at a dose of 0.5% plus dexmedetomidine at 0.3 mcg / kg corrected in a volume of 20 ml at the level of thoracic vertebra number 4, guided with ultrasound and under sterile technique, the date and time of application are recorded on the data collection sheet.
89563029|NCT05110339|Active Comparator|Control group|In addition to standard general anesthesia, patients receive erector spinae block with ropivacaine at a dose of 0.5% in a volume of 20 ml at the level of thoracic vertebra number 4, guided with ultrasound and under sterile technique, the date and time of application are recorded on the data collection sheet.
89563030|NCT05111665|Experimental|Mindfulness-based Cognitive Therapy (MBCT)|Remitted depressed participants received eight-weekly, two-hour MBCT sessions (Segal et al., 2013). This program combines MBSR meditation practices (e.g., body scan, mindful stretching, mindfulness of breath/body/sounds/thoughts) with traditional CT techniques (e.g., psychoeducation about depression symptoms and automatic thoughts, exercises designed to demonstrate how the nature of one's thoughts change with one's mood, questioning of automatic thoughts and creating a relapse prevention plan). Finally, participants engaged in a daily meditation practice and homework exercises directed at integrating the application of awareness skills into daily life. Each MBCT group was led by a masters-level clinician who was an active MBCT/Mindfulness-Based Stress Reduction (MBSR) instructor.
89563031|NCT05111665|Active Comparator|Relaxation Group Therapy (RGT)|The revised edition of the Changeways Relaxation Programme (Paterson, 1997) served as the active control condition to control for non-specific group factors including group participation, expectation of change or therapeutic contact and attention. The rationale was that relaxation can be used to better manage life stressors which precipitate depressive episodes. Participants received eight-weekly, two-hour relaxation training sessions. This group program combines psychoeducation regarding the effects of stress, diaphragmatic breathing, progressive muscle relaxation, passive relaxation and imagery. It also incorporates time for participants to discuss the events of the week to facilitate the supportive aspect of group participation. Finally, participants were asked to engage in daily exercises to practice the various relaxation strategies. Each RGT group was led by a doctoral-level therapist.
89563032|NCT05111665|Placebo Comparator|Treatment as usual (TAU)|Participants randomized to the TAU group were instructed that participants would receive MBCT at the end of the follow-up period and to seek help from their family doctors or other sources as the normally would, should the participants encounter symptomatic deterioration or other difficulties over the course of the study. At the end of the follow-up phase, participants in the TAU and RGT group were offered the opportunity to receive MBCT.
89608797|NCT04414501|Active Comparator|Tablet study group|Anxiety at separation from caregiver was measured by the modified Yale Preoperative Anxiety Scale (mYPAS). Caregiver anxiety was measured using the State-Trait Anxiety Inventory for Adults (STAI), a validated self-evaluation questionnaire. Mask acceptance, a functional evaluation of stress at the time of induction, was determined using the Mask Acceptance Scale.
88967891|NCT00115531|Experimental|Arm 2|High Dose Influenza Fluzone® Vaccine (60 µg HA / viral strain; 180 µg/0.5 mL dose) will be administered to Arm 2: 200 subjects intramuscularly on Day 0.
88967892|NCT00115570|Experimental|Insulin Glulisine|Insulin Glulisine (100UI/ml), at least twice daily, in association with basal insulin therapy (NPH insulin or insulin glargine for a maximum of 26 weeks
88967893|NCT00115570|Active Comparator|Insulin Lispro|Insulin Lispro (100UI/ml) Subcutaneous (SC) injection , at least twice daily, in association with basal insulin therapy (NPH insulin or insulin glargine ) for a maximum of 30 weeks
88967894|NCT00115648|Active Comparator|A|Single dose NVP + ZDV daily for the first week.
88967895|NCT00115648|Experimental|C|Arm A plus NVP + ZDV daily to age 14 weeks.
88967896|NCT00115648|Experimental|B|Arm A plus oral NVP daily to age 14 weeks.
88967897|NCT00115687|Placebo Comparator|A|placebo
88967898|NCT00115687|Experimental|B|2 mg nicotine gum
88967899|NCT00115726|Experimental|1|furosemide
88967900|NCT00115726|Placebo Comparator|2|placebo
88967901|NCT00008333|Experimental|vinorelbine|Patients receive oral vinorelbine on days 1, 8, 15, and 22. Treatment repeats every 28 days for 4-6 courses in the absence of disease progression or unacceptable toxicity. Quality of life is assessed at baseline and after 8 weeks of therapy. Patients are followed every 3 months for 5 years.
88967902|NCT00115882|Experimental|1|proactive smoking-cessation telephone counseling
88967903|NCT00115882|No Intervention|2|no-intervention control
88967904|NCT00115960|Experimental|1|Group 1 will receive 3 vaccinations of the HIV-1 gag DNA vaccine, or placebo. Vaccinations will be given at Months 0, 1, and 3.
88967905|NCT00115960|Experimental|2|Group 2 will receive 3 vaccinations of either the HIV-1 gag DNA vaccine with a low dose of IL-15 adjuvant, or a placebo. Vaccinations will be given at Months 0, 1, and 3.
88967906|NCT00115960|Experimental|3|Group 3 will receive 3 vaccinations of either the HIV-1 gag vaccine with a medium dose of IL-15 adjuvant, or a placebo. Vaccinations will be given at Months 0, 1, and 3.
88967907|NCT00115960|Experimental|4|Group 4 will receive 3 vaccinations of either the HIV-1 gag vaccine with a high dose of IL-15 adjuvant, or a placebo. Vaccinations will be given at Months 0, 1, and 3.
88967908|NCT00115960|Experimental|5|In Part B, Group 5 will receive 5 vaccinations of either the HIV-1 gag vaccine plus IL-15 DNA, or placebo. Vaccinations will occur at Months 0, 1, 3, 6, and 9.
88967909|NCT00115960|Experimental|7|In Part B, Group 7 will receive 3 vaccinations of the HIV-1 gag vaccine with a high dose of IL-15 adjuvant (maximum tolerated dose from Part A) followed by 2 vaccinations of the gag DNA vaccine with IL-12 DNA adjuvant. Some participants will receive placebo instead of this vaccine regimen. For Group 7, the HIV-1 gag vaccine with IL-15 adjuvant vaccinations will be given at Months 0, 1, and 3, and booster vaccinations will be given at Months 6 and 9.
88967910|NCT00008411|Experimental|Docetaxel Weekly|Arm I: Docetaxel IV over 1 hour on day 1. Courses repeat every 21 days.
88967911|NCT00008411|Experimental|Docetaxel Every 3 Weeks|Arm II: Docetaxel IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days.
89210632|NCT00928122|Experimental|4 / Myopia with Astigmatism|Myopic patients incl. Astigmatism
89210633|NCT00928122|Experimental|5 / Hyperopia with Astigmatism|Hyperope patients incl. Astigmatism
88967912|NCT00008450|Experimental|Treatment (cyclosporine, mycophenolate mofetil, transplant)|Patients receive cyclosporine PO or IV on days -3 to 100 followed by a taper until day 180 and mycophenolate mofetil PO or IV on days 0-40 with a taper until day 96 in the absence of unacceptable toxicity. Unrelated donor recipients also undergo TBI on day 0. Patients undergo bone marrow transplant on day 0.
88967913|NCT00116350|Experimental|Misoprostol|800 mcg sublingual misoprostol
89563033|NCT04966403|Experimental|standard physical therapy|Participants in the standard physical therapy received the standard physical therapy (sPT) program, which was conducted according to the needs of each participant and was generally concerned with building strength, enhancing developmental skills, boosting balance, coordination, and postural control, improving physical fitness, and minimizing the development of the compensatory movement patterns that children with DS are likely to develop.
89563034|NCT04966403|Experimental|trampoline-based stretch-shortening cycle exercises|In addition to the sPT, the SSC group received 15-minute SSC exercise sessions, twice weekly, with a total of 24 sessions over 12 successive weeks.
89563035|NCT04952831||Patients with mild CSM|mJOA score ≥15
89563036|NCT04952831||Patients with moderate CSM|mJOA score 13~14
89563037|NCT04952831||Patients with severe CSM|mJOA score ≤ 12
89563038|NCT04952831||Controls|health volunteers
89563039|NCT04965545||Wilson's disease cohort|Patients were clinically diagnosed according to the Leipzig Score and included in the study when they were confirmed to carry ATP7B pathogenic variants in 2 different alleles.
89563040|NCT04965467||Screening population|Screening for Fabry disease with early symptoms
89563041|NCT04795375|Experimental|Intervention|The intervention group will receive Physical activity counseling and guidance by a certified Nurse during the six months after the surgery, additional to the routine follow-up after bariatric surgery at Hadassah-Ein Kerem Hospital.
89563042|NCT04795375|No Intervention|Control|"The control group will receive the routine follow-up followed at Hadassah-Ein Kerem Hospital after bariatric surgery, which includes long term follow-up with the surgeon and a dietitian.~Participants at the Control group will receive Physical activity counseling by a certified nurse at the end of trial."
89563043|NCT04961411||published cases of patients with gallstone ileus|We will observe clinical signs, diagnostic procedures and therapeutic procedures and options
89563044|NCT04425785|Experimental|Physical Exercise Group|A structured exercise program for 12 weeks
89563045|NCT04425785|Experimental|Cognitive Behavioural Therapy|Cognitive Behavioural Therapy for 12 weeks
88967914|NCT00116350|Active Comparator|Oxytocin|40 IU Oxytocin IV
88967915|NCT02986386|Experimental|Intervention 1|Dental occlusion restoration by placement of dental implants and prosthesis on missing teeth.
88967916|NCT02986386|Other|Wait list control 1|Group of patients that will be evaluated until they receive the dental occlusion restoration procedure.
88967917|NCT02986386|Experimental|Intervention 2|Orthodontic treatment of malocclusion.
88967918|NCT02986386|Other|Wait list control 2|Group of patients that will be evaluated until they receive the orthodontic treatment of malocclusion.
88967919|NCT02909322|Active Comparator|Continuous Epidural Analgesia|Analgesic medications will be given via epidural, the standard of care.
88967920|NCT02909322|Experimental|Paravertebral Block Analgesia|Analgesic medications will be given via the paravertebral space.
88967921|NCT00116818|Experimental|Arm 1|
88967922|NCT04727905|Experimental|energy drink|Intake after exercise
89563046|NCT04425785|No Intervention|Standard Clinical Care|Standard Clinical Care
89563047|NCT05105659||B thalassemia Major patients|
89563048|NCT05105659||B thalassemia Intermedia patients|
89563049|NCT05105659||Healthy Controls|
89563050|NCT05105581||Group 1 (Patients)|"Patients: 37 patients with OCD diagnosed according to DSM-5~Inclusion criteria:~both sex~age groups : 18 : 60 are included~accept to participate in the study~Exclusion criteria~presence of major neurological disease as head trauma and sensory or motor defect as blindness or deafness~Active psychiatric disordes~patients refuse to participate in the study"
89563051|NCT05105581||Group 2 (Controlled)|37 healthy populations matched with PT group in age , sex , socioeconomic state
89563052|NCT05111275|Experimental|Group MEMO|Patients will perform cognitive exercises on the MEMO site at least 4 times per week for a month. During this month, patients will be contacted by phone on a weekly basis in order to maintain their motivation and ensure their treatment compliance. The time spent on the site during the month of evaluation will be quantified by the study investigator, via the professional profile created on the MEMO site, allowing to see the patient's activity on this same site.
89563053|NCT05111275|No Intervention|Control Group|Patients will not change their habits or perform cognitive exercises during the same assessment period.
89563054|NCT05105347|Experimental|Medium dose group (Adalimumab plus medium dose oral glucocorticosteroid)|Patients will be given adalimumab with 30mg daily prednisone or equivalent with a fixed slow tapering plan.
89563055|NCT05105347|Active Comparator|High dose group (Adalimumab plus high dose oral glucocorticosteroid)|Patients will be given adalimumab with 60mg daily prednisone or equivalent with a fixed slow tapering plan.
88967923|NCT04727905|Placebo Comparator|Seasoned water|Intake after exercise
89563056|NCT04436341||Patients with Alzheimer's disease|No treatment interventions. Investigations: physical examination, ear EEG, cranial MR, cognitive tests, blood samples
89563057|NCT04436341||Patients with Lewy body dementia|No treatment interventions. Investigations: physical examination, ear EEG, cranial MR, cognitive tests, blood samples
88967924|NCT02752815|Active Comparator|6R-CHOP+2R|"6 cycles of R-CHOP Rituximab 375 mg/m2 IV d1 Cyclophosphamide 750mg/m2 IV d2 Epirubicin 70mg/m2 IV d2 Vincristine 1.4 mg/m2 IV d2 Prednisone 60 mg/m2 PO d2-6 Frequency 21days~2 cycles of Rituximab monotherapy Rituximab 375 mg/m2 IV d1 Frequency 21days"
89563058|NCT04436341||Healthy controls|No treatment interventions. Investigations: physical examination, ear-EEG cranial MR, cognitive tests, blood samples
89563059|NCT04952675||low-risk group|Risk Index∈[0,0.5)
89563060|NCT04952675||high-risk group|Risk Index∈[0.5,1)
89563061|NCT05110963|Placebo Comparator|Uniform Standard of Care Counseling|Routine HIV counseling services available to patients with protocol delivered services. Three sessions of patient education monitored for protocol adherence.
88967925|NCT02752815|Experimental|4R-CHOP+4R|"4 cycles of R-CHOP Rituximab 375 mg/m2 IV d1 Cyclophosphamide 750mg/m2 IV d2 Epirubicin 70mg/m2 IV d2 Vincristine 1.4 mg/m2 IV d2 Prednisone 60 mg/m2 PO d2-6 Frequency 21days~2 cycles of Rituximab monotherapy Rituximab 375 mg/m2 IV d1 Frequency 21days"
88967926|NCT00116935|Active Comparator|1|1 year of adjuvant imatinib mesylate 400 mg/day orally
88967927|NCT00116935|Experimental|2|3 years of adjuvant imatinib mesylate 400 mg/day orally
88967928|NCT00388388|Experimental|1|Losartan treatment
88967929|NCT00388388|Active Comparator|2|Hydrochlorothiazide, 12.5-25 mg per day once a day for 6 months
88967930|NCT00116974|Experimental|1|
88967931|NCT00116974|Placebo Comparator|2|
88967932|NCT00117052|Active Comparator|During dialysis visit|Cinacalcet is given during the dialysis visit
88967933|NCT00117052|Active Comparator|Post-dialysis meal|Cinacalcet is administered with a post-dialysis meal
88967934|NCT02972450|Experimental|Injection only: Active:placebo (3:1)|"GTU-MultiHIV B-clade + MVA HIV-B:~GTU-MultiHIV B-clade - 2 mg of DNA in 1ml encoding a multi HIV antigen (synthetic fusion protein) administered intramuscularly into the non-dominant deltoid muscle at weeks 0 and 4 and MVA HIV-B 0.5ml(1 x108 pfu/ml) MVA encoding the full-length codon-optimized sequence of Gag administered intramuscularly into the non-dominant deltoid muscle at week 12."
88967935|NCT02972450|Experimental|Infusion only: Active:placebo (3:1)|Vedolizumab will be administered in the participant's dominant arm as an intravenous infusion over 30 mins.
88967936|NCT02972450|Experimental|Injection and Infusion: Active:placebo (3:1)|GTU-MultiHIV B-clade + MVA HIV-B + Vedolizumab
88967937|NCT02972450|Placebo Comparator|Placebo|"Placebo1 for DNA: Sodium chloride for injection, 0.9% in 1ml administered intramuscularly into the non-dominant deltoid muscle at weeks 0 and 4.~Placebo 2 for MVA: S08 buffer in 0.5ml administered intramuscularly into the non-dominant deltoid muscle at week 12.~Placebo for mAb: Sodium Chloride (NaCl) for infusion, 0.9% in 250 ml infusion bags."
88967938|NCT00117208|Experimental|1|
88967939|NCT00117208|Active Comparator|2|DNase daily for 12 weeks
88967940|NCT00117208|Other|3|combination
88967941|NCT00388427|Other|Advanced Solid Malignancies|
88967942|NCT00117403|Experimental|1|vitamin E 800 IU, vitamin C 200 mg, and alpha-lipoic acid 600 mg formulated into three capsules, one capsule given three times per day with meals, plus two placebo wafers three times per day with meals
88967943|NCT00117403|Experimental|2|CoQ 400 mg, compounded as a wafer, two wafers three times per day with meals, plus one placebo capsule three times per day with meals
88967944|NCT00117403|Placebo Comparator|3|two placebo wafers three times per day with meals, plus one placebo capsule three times per day with meals
88967945|NCT00423410|Experimental|EPC2407 (crinobulin)|
88967946|NCT00117442|Experimental|Pegfilgrastim 18 mg|Pegfilgrastim 18 mg given once for mobilization
88967947|NCT00117442|Active Comparator|Filgrastim|Filgrastim given daily for mobilization
88967948|NCT00117442|Experimental|Pegfilgrastim 12 mg|Pegfilgrastim 12 mg given once for mobilization
88967949|NCT00117442|Experimental|Pegfilgrastim 6 mg|Pegfilgrastim 6 mg given once for mobilization
88967950|NCT04728022|Experimental|Students|Education program
88967951|NCT05441371|Experimental|Test; Parodontax toothpaste|1.st quadrant of subject
88967952|NCT05441371|Placebo Comparator|Control; Regular toothpaste|2.nd quadrant of subject
88967953|NCT00117481|Experimental|1|
88967954|NCT00117481|Experimental|2|
88967955|NCT00117481|Placebo Comparator|3|
88967956|NCT00000113|Experimental|Progressive Addition Lenses (PALs)|
88967957|NCT00000113|Active Comparator|Single Vision Lenses|
88967958|NCT04727515|Experimental|General anesthesia|Patients will receive general anesthesia
88967959|NCT04727515|Experimental|Axillary Block|Patients will receive axillary nerve block
88967960|NCT00118066|Experimental|Arm I|Patients receive oral calcitriol once daily for 8 weeks. Treatment repeats every 8 weeks for 2 courses. After completion of course 2 (week 16), patients undergo biopsy. Patients continue to receive calcitriol for up to 3 additional weeks while the biopsy is being evaluated. Patients with persistent high-grade prostatic intraepithelial neoplasia (HGPIN) by biopsy receive 2 additional courses of calcitriol.
88967961|NCT00118066|Other|Arm II|Patients undergo observation for 16 weeks. At week 16, patients undergo biopsy. Patients with persistent HGPIN by biopsy receive 2 courses of calcitriol as in arm I.
88967962|NCT05636150|Experimental|Fruquintinib plus S-1|"Cohort A: Fruquintinib 3 mg QD, oral dosing, 2 weeks on/1 weeks off+ S-1 40-60mg/time bid po d1-14 q3w.~Cohort B: Fruquintinib 4 mg QD, oral dosing, 2 weeks on/1 weeks off+ S-1 40-60mg/time bid po d1-14 q3w.~Cohort C: Fruquintinib 5 mg QD, oral dosing, 2 weeks on/1 weeks off+ S-1 40-60mg/time bid po d1-14 q3w."
88967963|NCT00118105|Experimental|Chemotherapy + Surgery + Chemotherapy|"Preoperative Neoadjuvant Chemotherapy~Bevacizumab, 7.5 mg/kg, IV, Day 1 of cycles 1,2,3~Oxaliplatin, 130 mg/m^2, IV, Day 1 of cycles 1,2,3,4~Capecitabine, 1,700 mg/m^2/day divided, PO at 12 hr intervals, Days 1-14 of cycles 1,2,3,4~Conventional surgery: After 4 cycles of chemotherapy~Postoperative Neoadjuvant Chemotherapy~Bevacizumab, 7.5 mg/kg, IV, Day 1 of cycles 1,2,3,4~Oxaliplatin, 130 mg/m^2, IV, Day 1 of cycles 1,2,3,4~Capecitabine, 1,700 mg/m^2/day divided, PO at 12 hr intervals, Days 1-14 of cycles 1,2,3,4"
88967964|NCT00118183|Experimental|Arm I|Patients receive docetaxel IV over 30 minutes on days 1, 8, and 15 and cetuximab IV over 1-2 hours on days 1, 8, 15, and 22. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients with responding or stable disease after 4 courses receive cetuximab alone as above in the absence of disease progression or unacceptable toxicity.
89027365|NCT00482846|Experimental|Palifermin & Melphalen|"Palifermin 60 mcg/kg/d of the actual body weight unless actual body weight is >40% of the Ideal body weight (IBW), then adjusted body weight (AdBW) will be used for dose calculations - administered on Day - 5,-4, - 3 and then repeated on Day +1, +2 and +3~Dose of Melphalan + Palifermin (Normal Renal Function): All given on Day -2:~Dose Level 1- 200 mg/m2 I.V; Dose Level 2- 220 mg/m2 I.V; Dose Level 3- 240 mg/m2 I.V; Dose Level 4- 260 mg/m2 I.V; Dose Level 5- 280 mg/m2 I.V;~Dose of Melphalan + Palifermin (Renal Dysfunction CrCl. <60)adm. via I.V.:~Dose Level 1- 140 mg/m2; Dose Level 2- 160 mg/m2; Dose Level 3- 180 mg/m2; Dose Level 4- 200 mg/m2; Dose Level 5- 220 mg/m2;"
89563062|NCT05110963|Active Comparator|Behavioral Self-Regulation Skills Counseling|Mobile phone-delivered counseling grounded in Behavioral Self- Regulation Theory to improve retention in HIV care and HIV viral suppression. Counseling is delivered by lay counselors in differentiated health care context. This is a culturally tailored adaptation of CDC disseminated Phone-Delivered Support Counseling for HIV treatment Adherence.
89563063|NCT05110963|Experimental|Behavioral Self-Regulation Skills Counseling + Stigma Management|Mobile phone-delivered counseling grounded in Behavioral Self- Regulation Theory with stigma management to improve retention in HIV care and HIV viral suppression. Counseling is delivered by lay counselors in differentiated health care context with added components directly targeting stigma-related experiences and concerns.
89563064|NCT04424537|Placebo Comparator|Control|"A control group will consume 2 meal replacement beverages(MRBs) made with whey protein~The control diet group will be provided with a protein powder which will provide all Amino Acids. Diets will be provided in unmarked containers, to ensure subjects will be blinded to the dietary group assignment.~No overall calorie reduction will be implemented for any group.~All subjects will receive recipes developed by clinical nutritionist in the study team. Theses recipes will maximize palatability and match energy density across all diets and total protein content.~The subjects will be able to use multiple different recipes over the course of the study to prevent taste fatigue and dropout. Each subject is anticipated to replace 2 meals per day with a beverage."
89563065|NCT04424537|Active Comparator|Low protein(LP) diet|"This group will consume 2 meal replacement beverages(MRBs) containing low protein (goal to reduce total protein by 2/3rds).~LP diet group will be provided with a protein powder which will provide all Amino Acids. Diets will be provided in unmarked containers, to ensure subjects will be blinded to the dietary group assignment.~No overall calorie reduction will be implemented for any group.~All subjects will receive recipes developed by clinical nutritionist in the study team. Theses recipes will maximize palatability and match energy density across all diets and total protein content.~The subjects will be able to use multiple different recipes over the course of the study to prevent taste fatigue and dropout. Each subject is anticipated to replace 2 meals per day with a beverage."
89563066|NCT04424537|Experimental|Low branched-chain amino acids (BCAA)|"The group on low-BCAA diet will consume 2 meal replacement beverages (MRBs) per day made with BCAD2 (branched chain amino acid) powder (lacking BCAAs).~BCAD2 powder(Mead Johnson) is a fortified medical food powder that does not contain the BCAAs isoleucine, leucine, or valine, but provides all other essential and nonessential AAs, carbohydrates, fat, vitamins, and minerals.~No overall calorie reduction will be implemented for any group.~All subjects will receive recipes developed by clinical nutritionist in the study team. Theses recipes will maximize palatability and match energy density across all diets and total protein content.~The subjects will be able to use multiple different recipes over the course of the study to prevent taste fatigue and dropout. Each subject is anticipated to replace 2 meals per day with a beverage."
89027366|NCT01308736|Active Comparator|varenicline|
89027367|NCT01308736|Placebo Comparator|placebo pill|
89027368|NCT04517214|Experimental|Toripalimab Combined with GP Arm|Systemic chemotherapy for 6 cycles: Toripalimab 240mg d1+Gemcitabine 1.0g/m2 d1, Cisplatin 80mg/m2 d1, q3w; Followed by Radiotherapy to the nasopharynx and neck; Then maintenance therapy of Toripalimab with Capecitabine: Toripalimab 240mg d1+Capecitabine 1000mg/m2 bid d1-14, q3w
89027369|NCT04517214|Active Comparator|GP Arm|Systemic chemotherapy for 6 cycles: Gemcitabine 1.0g/m2 d1, Cisplatin 80mg/m2 d1, q3w; Followed by Radiotherapy to the nasopharynx and neck; Then maintenance therapy of Capecitabine: Capecitabine 1000mg/m2 bid d1-14, q3w
89027370|NCT01240187|Experimental|Experimental 1|
89027371|NCT01240187|Experimental|Experimental 2|
89027372|NCT00483054|Experimental|Efavirenz|Efavirenz 600 mg/day + stavudine +lamivudine
89027373|NCT00483054|Experimental|Nevirapine|Nevirapine 400 mg/day + stavudine +lamivudine
89027374|NCT01240226|Experimental|A|
89027375|NCT01240226|Experimental|B|
89027376|NCT01240824|Experimental|BCG + aminophylline|Bacillus Calmette-Guerin (BCG) plus one of three escalating doses of aminophylline administered intravesically.
89027377|NCT00482924||Overweight/obese|"The cohort consists of age and sex matched normal weighted controls and overweight/obese persons.~Definition for overweight: BMI >90th and <97th percentile, if under 18 years of age, and BMI >25 and <29.9 kg/m2 if over 18 years of age.~Definition for obese: BMI >97th percentile, if under 18 years of age, and BMI >30kg/m2, if over 18 years of age."
89027378|NCT00482924||Interventional branch|A lifestyle intervention following a holistic schedule was done in a subgroup of obese juveniles.
89027379|NCT01240941|Experimental|MK-2206|MK-2206 maximum tolerated dose found from Phase Ib trial (under a separate NCT number) taken orally on a weekly basis
89027380|NCT04517097||patient group|patients treated in the french anti-cancer center of the study
89027381|NCT04517097||salaried staff group|all salaried staff of the french anti-cancer center of the study
89027382|NCT00482963|Experimental|levonorgestrel, efavirenz|healthy HIV-negative women of reproductive age were given levonorgestrel, efavirenz
89027383|NCT01240980|Experimental|BMS-903452 (0.1 mg) or Placebo - A1|(Healthy Subjects)
89027384|NCT01240980|Experimental|BMS-903452 (0.6 mg) or Placebo - A2|(Healthy Subjects)
89027385|NCT01240980|Experimental|BMS-903452 (3.0 mg) or Placebo - A3|(Healthy Subjects)
89027386|NCT01240980|Experimental|BMS-903452 (10 mg) or Placebo - A4|(Healthy Subjects)
89027387|NCT01240980|Experimental|BMS-903452 (30 mg) or Placebo - A5|(Healthy Subjects)
89027388|NCT01240980|Experimental|BMS-903452 (60 mg) or Placebo - A6|(Healthy Subjects)
89027389|NCT01240980|Experimental|BMS-903452 (120 mg) or Placebo - A7|(Healthy Subjects)
89563067|NCT04952441|Experimental|Intervention Group|Intervention group will attend the RISE program which consists of eight 90-minute weekly psychoeducational group sessions facilitated by a licensed mental health counselor
89563068|NCT04952441|Active Comparator|Wait-list Control Group|The control group will attend the RISE program after the 3 month wait-list period (study months 6-7)
89563069|NCT05110651|Active Comparator|Hydroxychloroquine|Oral hydroxychloroquine 200mg once daily
89563070|NCT05110651|No Intervention|No treatment|No treatment
89563071|NCT03060785|Experimental|TFV/FTC dosing in Transgender women|Single daily dose of oral Tenofovir Disoproxil Fumarate/Emtricitabine (Truvada)for 7days in transgender women taking feminizing hormones
89563072|NCT03060785|Active Comparator|TFV/FTC dosing in Cis men|Single daily dose of oral Tenofovir Disoproxil Fumarate/Emtricitabine (Truvada) for 7days in cis men
89563073|NCT05104879|Experimental|Biosketch Card|Patients within the experimental group received a biosketch card during rooming, pre-clinician encounter, and were not informed about their involvement. To blind the outcome measure, the research assistant did not explain the reason for the card upon rooming the patient nor did they inform the midlevel provider.
89563074|NCT05104879|No Intervention|No Card|No bio sketch card was provided to these participants.
89563075|NCT04952363|Experimental|HFCWO+WBVT|Subjects received HFCWO+WBVT intervention twice a week for a period of 8 weeks
89563076|NCT04952363|Active Comparator|HFCWO only|Subjects received HFCWO intervention twice a week for a period of 8 weeks
89563077|NCT04961333|Experimental|Rehabilitation group|Rehabilitation group will be provided multidisciplinary interventions online and individually by ExorLive app. The screening with self-scored questionnaires and physical tests will be performed before and after 8 weeks rehabilitation.
89563078|NCT04961333|No Intervention|Waiting list controls|Passive waiting list or control group, which will be offered to participate in rehabilitation after at least 8 weeks of waiting time. The group will fulfil screening twice, following the time schedule of intervention group. When invited to rehabilitation a new screening will be asked to be completed if the waiting time after the last screening will be longer than 2 weeks.
89563079|NCT05110573||Laparoscopic pancreatoduodenectomy|Cohort of patients that underwent a Whipple-procedure through a laparoscopic approach.
89563080|NCT05110573||Open pancreatoduodenectomy|Cohort of patients that underwent a Whipple-procedure through a traditional open approach.
89563081|NCT04952207||DAA Group|Chronic hepatitis C patients treated with DAA
88967965|NCT00118183|Experimental|Arm II|Patients receive docetaxel as in arm I and bortezomib IV over 3-5 seconds on days 1, 8, and 15. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients with responding or stable disease after 4 courses receive bortezomib alone as above in the absence of disease progression or unacceptable toxicity.
88967966|NCT00118222|Active Comparator|Low light dose during surgery|Arm I: During surgery, patients receive low light dose photodynamic therapy.
88967967|NCT00118222|Active Comparator|High light dose during surgery|Arm II: During surgery, patients receive high light dose photodynamic therapy.
89563082|NCT04632589|Experimental|Losartan|6 weeks of daily (50mg/day) oral losartan potassium tablet
88967968|NCT00118261|Experimental|Erlotinib, modified FOLFOX6, and bevacizumab|
88967969|NCT02733081|No Intervention|Arm 1: Traditional IUD Insertion|Standard IUD insertion according to package insert. Bimanual pelvic exam to assess uterine size and position will be performed. Uterine sound will be used to measure depth of uterus prior to insertion.
88967970|NCT02733081|Experimental|Arm 2: Simplified IUD Insertion|Simplified, investigational IUD insertion performed. No bimanual pelvic exam or uterine sounding.
88967971|NCT05636384|Experimental|Intervention|Patients enrolled in the intervention cluster (institution) are given specialized home-based medical care based on a specialized home-based medical team approach.
88967972|NCT05636384|No Intervention|Control|"Patients enrolled in the control cluster (institution) are only given the educational materials.~Except for the home-based care intervention, usual care for advanced cancer patients was not restricted for these patients."
88967973|NCT00118456|Experimental|1|Continuous daily dosing
88967974|NCT00118456|Experimental|2|Monday, Wednesday, Friday Dosing
88967975|NCT00118573|Experimental|EVAR|AAA repair with endografting
88967976|NCT00118573|Active Comparator|Surveillance|Not AAA repair; surveillance
88967977|NCT00118612|Experimental|Therapeutic Regimen|
88967978|NCT00118612|Experimental|Intermediate dose|
88967979|NCT00118612|Experimental|Low dose|
88967980|NCT00118612|Placebo Comparator|Placebo|
88967981|NCT00118651||Positive cases|"Positive radiographic findings were defined as the presence of a new air space opacities in the setting of acute respiratory symptoms. Patients with equivocal radiographic findings interpreted as possible pneumonia were considered positive cases"
88967982|NCT00118651||Control|Acute respiratory symptoms, negative chest radiographs, and a date of birth within five years of that of the positive case
88967983|NCT00402142|Active Comparator|Pulsed dendritic cells untreated patients|Untreated patients receiving a dendritic cell based vaccine pulsed with autologous heat iactivated virus
88967984|NCT00402142|Placebo Comparator|non pulsed dendritic cells untreated patients|
88967985|NCT00402142|Active Comparator|pulsed dendritic cell treated patient|treated patients will be immunized with a dendritic cell vaccine pulsed with heat inactivated autologous virus immediately before art interruption
89563083|NCT04632589|Placebo Comparator|Placebo|6 weeks of daily oral placebo tablet
88967986|NCT00402142|Active Comparator|pulsed dendritic cell in treated patients|patients will be immunized with a dendritic cell vaccine pulsed with heat inactivted autologous virus immediately after interruption of art
88967987|NCT00402142|Placebo Comparator|non pulsed dendritic cells|
88967988|NCT00118729|Experimental|Arm 1|
89563084|NCT04952285||Normal saline（I）|Intravenous infusion of 0.9% saline when start to cut the skin，do not intravenous tranexamic acid during the surgery
89563085|NCT04952285||Tranexamic acid（II）|Intravenous infusion of tranexamic acid 1g when start to cut the skin in 1 hour
89563086|NCT04961099|Experimental|low-dose group|low-dose group: HY01 10mg（20mg/ml）
89563087|NCT04961099|Experimental|high-dose group|high-dose group: HY01 20mg（40mg/ml）
89563088|NCT04965233||Participants recruited in Denmark|Participants recruited in Denmark will consist of 63 healthy individuals and 187 individuals with atopic dermatitis
89563089|NCT04965233||Participant recruited in the United States of America|Participants recruited in the US will consist of 125 healthy individuals, 3000 individuals with atopic dermatitis
89563090|NCT04975009|Experimental|PTSD group|Participants will be screened and diagnosed using typical screening procedures and diagnostic criteria (e.g., the clinically administered PTSD scale). Participants also screened for contraindications for MRI. The learning paradigm inside the MRI scanner occurs over 3 days. The first two days are consecutive (back-to-back) and the third MRI visit is 1 month later. Participants are asked to look at a screen and listen to simple tones over headphones, while the experimenter measures brain activity and physiological measures of arousal (e.g., sweating from sensors on the hand). These visits will be scheduled within two weeks from the baseline and assessment visit.
89563091|NCT04975009|Experimental|Healthy control group|Participants will be healthy adults without a history of psychiatric illness. Participants also screened for contraindications for MRI. The learning paradigm inside the MRI scanner occurs over 3 days. The first two days are consecutive (back-to-back) and the third MRI visit is 1 month later. Participants are asked to look at a screen and listen to simple tones over headphones, while the experimenter measures brain activity and physiological measures of arousal (e.g., sweating from sensors on the hand). These visits will be scheduled within two weeks from the baseline and assessment visit.
89563092|NCT04964999|Experimental|Exercise|Participants will perform aerobic and strength exercises for 2 weeks.
89563093|NCT04964999|No Intervention|No exercise|Participants will not perform any exercises.
89563094|NCT05108701|Experimental|I-MBCT|"Participants randomized to I-MBCT (Mindfulness-Based Cognitive Therapy) receive 12 weekly 60- minute sessions of I-MBCT according to the protocol of Segal et al. (2002), integrated with the theme, rationale, intention and practice skills (TRIP) protocol (Woods et al. 2016, 2019). The original MBCT protocol, created for eight group sessions lasting two hours, is adapted to twelve individual sessions."
89563095|NCT05108701|Active Comparator|CBT|Participants randomized to Individual Cognitive Behavioural Therapy (CBT) receive 12 weekly 60-minute individual sessions of standard CBT strategies following Beck et al. (1979). Participants receive a copy of Greenberger and Padesky's Mind over Mood (The Guilford Press, 1995) for use during the intervention.
89563096|NCT05108545|Experimental|Amphotericin B liposomes|Patients with suspected fungal neutropenia and fever will receive amphotericin B liposome 3 mg/kg intravenously. Treatment will be continued until the ANC≥500 /mm^3 (0.5×10^9 /L) for more than 72 hrs in terms of patients without evidence of baseline fungal infection and breakthrough fungal infection; or treatment will be continued according to investigator's judgement with a duration ranging from 14 days to 12 weeks in terms of patients with evidence of baseline fungal infection and breakthrough fungal infection.
89563097|NCT03060395|Sham Comparator|A1/A2 milk|"Commercial conventional A1/A2 semi-skimmed fresh pasteurised cow milk. Progressive intake of intervention milk as follows:~Days 1 and 2: 100 mL twice a day~Days 3 and 4: 150 mL twice a day~Days 5 and 6: 200 mL twice a day~Days 7 to 14: 250 mL twice a day"
89563098|NCT03060395|Active Comparator|A2 milk|"Commercial A2 semi-skimmed fresh pasteurised cow milk.~Progressive intake of intervention milk as follows:~Days 1 and 2: 100 mL twice a day~Days 3 and 4: 150 mL twice a day~Days 5 and 6: 200 mL twice a day~Days 7 to 14: 250 mL twice a day"
89563099|NCT05081323|Experimental|Self-applied treatment with THERA|Participants in this group will use the Self-applied treatment with THERA for a maximum period of one month.
89563100|NCT05081323|No Intervention|Control without treatment|Participants in this group keep on a waiting list, after one month, they will receive the self-applied treatment
89563101|NCT04431791||Regorafenib|
89563102|NCT04431791||Fruquintinib|
89563103|NCT05007769|Experimental|Ramucirumab + Atezolizumab + N-803|-Ramucirumab intravenously (IV) on Day 1, atezolizumab IV on Day 1, and N-803 subcutaneous (SC) on Day 1 of each cycle. Cycles are 21 days.
89563104|NCT04952051|Experimental|Enalapril Folic Acid Tablets Combined With amlodipine|Enalapril Folic Acid Tablets 10.8mg Combined With amlodipine 5 or 10mg
89563105|NCT04952051|Active Comparator|Enalapril Folic Acid Tablets Combined With hydrochlorothiazide|Enalapril Folic Acid Tablets 10.8mg Combined With hydrochlorothiazide 12.5 or 25mg
89563106|NCT04979143|Other|HoLVP with the use of Moses 2.0 technology|HoLVP with the use of Moses 2.0 technology
89563107|NCT04979143|Other|HoLVP without the use of Moses 2.0 technology|HoLVP without the use of Moses 2.0 technology
89563108|NCT04960943|Experimental|Pyrotinib|Pyrotinib with or without paclitaxel/trastuzumab treatment
89563109|NCT03058367|Experimental|High dose IQP-AE-103 (1980mg)|2 capsules IQP-AE-103 by mouth, three times a day after main meals for 12 weeks
89563110|NCT03058367|Experimental|Low dose IQP-AE-103 (990mg)|2 capsules IQP-AE-103 by mouth, three times a day after main meals for 12 weeks
89563111|NCT03058367|Placebo Comparator|Placebo|2 capsules IQP-AE-103 by mouth, three times a day after main meals for 12 weeks
89563112|NCT03060317||Validation group DOC|Examination with neurological scales.
89563113|NCT04964531||Adults|group of adults includes all patients aging 19 years or more
89563114|NCT04964531||children|group of children includes all patients aging less than 19 years
89563115|NCT04964687||Transplanted patients seen by an addictionology team|Adult patients with alcohol-related liver disease, possibly complicated by hepatocellular carcinoma, that required liver transplantation in participating centers from January 2000 to December 2015, and seen by an addictology team before and after the transplantation.
89563116|NCT04964687||Transplanted patients not seen by an addictionology team|Adult patients with alcohol-related liver disease, possibly complicated by hepatocellular carcinoma, that required liver transplantation in participating centers from January 2000 to December 2015, and seen by an addictology team before and after the transplantation.
89563117|NCT03058445|Experimental|Main group|This the only arm in the study Intervention: Echocariography and assessing T2T and CXR CVC tip to carina distance
89563118|NCT04431713|Experimental|Exenatide|
89563119|NCT04431713|No Intervention|Standard of care|
89563120|NCT04773925|Experimental|Mindfulness group|As this is a pilot feasibility trial, there is only one arm. All subjects will receive the mindfulness intervention if they consent to participate in the study.
89563121|NCT05104333|Experimental|0-1-4 schedule group|Subjects receive the booster vaccine 3 months after the second dose.
89563122|NCT05104333|Experimental|0-1-6 schedule group|Subjects receive the booster vaccine 5 months after the second dose.
89563123|NCT03058055|Placebo Comparator|Placebo|Usual lifestyle activities
89563124|NCT03058055|Experimental|Origami|Origami lessons (one hour/week) with daily take home Origami activities to complete
89563125|NCT03058055|Experimental|Reading|Daily reading (out loud into a voice recorder) for one hour
89563126|NCT04951895||control group|patients with normal TMJ
89563127|NCT04951895||Study group|Patients with TMJ internal deragement
89563128|NCT05094895|Active Comparator|Stretta Treatment|Patients will receive the Stretta treatment
89563129|NCT05094895|Sham Comparator|Sham treatment|Patients will receive the sham treatment
89563130|NCT04819763|Experimental|Physical training of the lateral pterygoid muscle|Static stretching and isometric contraction exercises of the lateral pterygoid muscle are used to strengthen and restore a physiological lateral movement of the mandible.
88967989|NCT05636579|Experimental|EO2002 with Ripasudil|EO2002 + topical Ripasudil daily, then reinjection at week 6 + topical Ripasudil daily
88967990|NCT05636579|Experimental|EO2002 without Ripasudil|EO2002 injection at Day 0 and re-injection at Week 6
88967991|NCT00118924|Experimental|1|One subcutaneous vaccination with a 10^3 PFU dose of LGT(TP21)/DEN4 vaccine given in the deltoid region of either arm. A second booster vaccination will be given 6 months after the first vaccination.
89208541|NCT00739973|Experimental|Aliskiren/amlodipine 300/10 mg tablet|300/5 for 1 week, then up-titrated to 300/10 mg. Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos.
89208542|NCT00876720|Experimental|1|Combined frontal and temporal transcranial magnetic stimulation
89208543|NCT00876720|Experimental|2|Temporal transcranial magnetic stimulation
89563131|NCT04819763|Active Comparator|Stabilization appliance therapy|Hard acrylic splint with anterior canine guidance for the lower jaw.
89563132|NCT04960631||Clinical diagnosis of suspected malignant tumor by dual site CT guided needle biopsy|
89563133|NCT03059615|Experimental|Nerofe 48mg/m2|48mg/m2 IV Nerofe - three times a week
89563134|NCT03059615|Experimental|Nerofe 96mg/m2|96mg/m2 IV Nerofe - three times a week
89563135|NCT03059615|Experimental|Nerofe 48mg/m2 + Doxorubicin 10mg/m2|48mg/m2 IV Nerofe + Doxorubicin 10mg/m2 - once a week
89563136|NCT03059615|Experimental|Nerofe 96mg/m2 + Doxorubicin 10mg/m2|96mg/m2 IV Nerofe + Doxorubicin 10mg/m2 - once a week
89563137|NCT04951505|Experimental|cefepime-taniborbactam|
89563138|NCT04951349|Experimental|Treatment of hospitalized patients with laboratory-confirmed COVID-19|Hospitalized patients with laboratory-confirmed COVID-19 using GX-03 administered intranasally TID for 5 days.
89563139|NCT04951349|Placebo Comparator|Placebo Treatment of hospitalized patients with laboratory-confirmed COVID-19|Hospitalized patients with laboratory-confirmed COVID-19 using placebo (petrolatum emulsion) administered intranasally TID for 5 days.
89563140|NCT04951349|Experimental|Prevention of SARS-COV-2 in Health Care Providers|Health care providers with laboratory-confirmed negative COVID-19 using GX-03 administered intranasally TID for 10 days.
89563141|NCT04951349|Placebo Comparator|Placebo Prevention of SARS-COV-2 in Health Care Providers|Health care providers with laboratory-confirmed negative COVID-19 using placebo (petrolatum emulsion) administered intranasally TID for 10 days.
89563142|NCT02658019|Experimental|Pembrolizumab in Advanced HCC|Patients will be treated in three-week cycles, with intravenous (IV) administration of 200 mg of pembrolizumab on day 1 of each 3-week cycle. Trial therapy will last until withdrawal of consent, disease progression and/or unacceptable toxicity, whichever occurs first.
89563143|NCT03059303|Experimental|Part 1: Treatment A: FDC [SMV(75mg)+ODV(25mg)+AL-335(800mg)]|Participants will receive single oral dose of simeprevir (SMV) 75 milligram (mg), odalasvir (ODV) 25 mg, and AL-335 800 mg, given as a fixed-dose combination (FDC) tablet (G008 formulation) after a standardized breakfast on Day 1.
89563144|NCT03059303|Experimental|Part 1: Treatment B: FDC [SMV(75mg)+ODV(12.5mg)+AL-335(800mg)]|Participants will receive single oral dose of SMV 75 mg, ODV 12.5 mg, and AL-335 800 mg, given as an FDC tablet (G007 formulation) after a standardized breakfast on Day 1.
89563145|NCT03059303|Experimental|Part 1: Treatment C: Simeprevir, Odalasvir, and AL-335|Participants will receive single oral dose of 75 mg SMV, 25 mg ODV, and 800 mg AL-335, given as 3 single agents after a standardized breakfast on Day 1.
89563146|NCT03059303|Experimental|Part 1: Treatment D: Lansoprazole + FDC [SMV+ODV+AL-335]|Participants will receive 30 mg lansoprazole once daily in the morning under fasted conditions on Days 1 to 4, and together with a single oral dose of an FDC containing 75 mg SMV, 25 mg ODV, and 800 mg AL-335 (G008 formulation) after a standardized breakfast, which is served 2 hours after lansoprazole dosing, on Day 5.
88967992|NCT00118924|Experimental|2|One subcutaneous vaccination with a 10^5 PFU dose of LGT(TP21)/DEN4 vaccine given in the deltoid region of either arm. A second booster vaccination will be given 6 months after the first vaccination. This arm may enroll after Arm 1 depending on the immunological response of Arm 1.
88967993|NCT00118924|Placebo Comparator|3|One subcutaneous vaccination with a placebo vaccine given in the deltoid region of either arm. A second placebo vaccination will be given 6 months after the first vaccination.
88967994|NCT00118963|Active Comparator|3|BIAsp30 plus Metformin plus Placebo-Repaglinide. Double-Masked and randomized. Duration: 12 months.
88967995|NCT00118963|Active Comparator|2|BIAsp30 plus Repaglinide plus Placebo-Metformin. Double-masked and randomized. Duration: 12 months.
88967996|NCT00118963|Other|1|Run-in period of four months duration with Repaglinide 6 mg daily plus Metformin 2000 mg daily. No masking of interventions.
88967997|NCT00119002|Active Comparator|Dexamethasone|1mg of Dexamethasone/kg
88967998|NCT00119002|Placebo Comparator|Placebo|1mg/kg placebo
88967999|NCT00119197|Experimental|1|Killed Whole Cell Oral Cholera Vaccine
88968000|NCT00119197|Placebo Comparator|2|Heat-killed E. coli
89208544|NCT00789230|Active Comparator|primary suture|
89208545|NCT00789230|Active Comparator|mesh enforced closure|
89208546|NCT00869934|Active Comparator|1. Cognitive-Behavior Therapy|
89208547|NCT00869934|Experimental|2. Behavior Therapy|
89563147|NCT03059303|Experimental|Part 1: Treatment E: Omeprazole + FDC [SMV+ODV+AL-335]|Participants will receive 20 mg omeprazole once daily in the morning immediately before a (non-standardized) breakfast on Days 1 to 4, and immediately before a standardized breakfast and within 1 hour before a single oral dose of an FDC containing 75 mg SMV, 25 mg ODV, and 800 mg AL-335 (G008 formulation) after a standardized breakfast on Day 5. Treatment E will only be started in case a drug-drug interaction (DDI) is observed for Treatment D.
89563148|NCT03059303|Experimental|Part 2: Treatment Sequence A2-F|Participants will receive single oral dose of simeprevir (SMV) 75 milligram (mg), odalasvir (ODV) 25 mg, and AL-335 800 mg, given as an FDC (Treatment A2 - G008 formulation) on Day 1 of Period 1, and then single oral dose of SMV 75 mg, ODV 25 mg, and AL-335 800 mg, given as an FDC (Treatment F - G012 formulation) on Day 1 of Period 2, under fed condition (after a standardized breakfast). A washout period of at least 2 weeks will be maintained between each treatment.
89563149|NCT03059303|Experimental|Part 2: Treatment Sequence F-A2|Participants will receive Treatment F on Day 1 of Period 1 and then Treatment A2 on Day 1 of Period 2 under fed condition (after a standardized breakfast). A washout period of at least 2 weeks will be maintained between each treatment.
89563150|NCT03059303|Experimental|Part 2: Treatment Sequence C2-F|Participants will receive single oral dose of 75 mg SMV, 25 mg ODV, and 800 mg AL-335, given as 3 single agents (Treatment C2) on Day 1 of Period 1 and then Treatment F on Day 1 of Period 2 under fed condition (after a standardized breakfast). A washout period of at least 2 weeks will be maintained between each treatment.
89563151|NCT03059303|Experimental|Part 2: Treatment Sequence F-C2|Participants will receive Treatment F on Day 1 of Period 1 and then Treatment C2 on Day 1 of Period 2 under fed condition (after a standardized breakfast). A washout period of at least 2 weeks will be maintained between each treatment.
89563152|NCT03059303|Experimental|Part 2: Treatment Sequence C2-G|Participants will receive Treatment C2 on Day 1 of Period 1 and then 2 tablets of SMV 37.5 mg, ODV 37.5 mg, and AL-335 400 mg, given as FDC (Treatment G - G013 formulation) on Day 1 of Period 2 under fed condition (after a standardized breakfast). A washout period of at least 2 weeks will be maintained between each treatment.
89563153|NCT03059303|Experimental|Part 2: Treatment Sequence G-C2|Participants will receive Treatment G on Day 1 of Period 1 and then Treatment C2 on Day 1 of Period 2 under fed condition (after a standardized breakfast). A washout period of at least 2 weeks will be maintained between each treatment.
89563154|NCT03059303|Experimental|Part 2: Treatment Sequence F-G|Participants will receive Treatment F on Day 1 of Period 1 and then Treatment G on Day 1 of Period 2 under fed condition (after a standardized breakfast). A washout period of at least 2 weeks will be maintained between each treatment.
89563155|NCT03059303|Experimental|Part 2: Treatment Sequence G-F|Participants will receive Treatment G on Day 1 of Period 1 and then Treatment F on Day 1 of Period 2 under fed condition (after a standardized breakfast). A washout period of at least 2 weeks will be maintained between each treatment.
88968001|NCT00119236|Experimental|Arm I|Patients receive irinotecan IV over 30 minutes followed by 17-N-allylamino-17-demethoxygeldanamycin (17-AAG)* IV over 2 hours on days 1 and 8. Treatment repeats every 21 days for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients achieving stable or improved disease after course 2 may receive additional courses of treatment.
89563156|NCT04593199|Sham Comparator|Physical Activity Tracking App Only|Over a four week period, participants were asked to use the Fitbit app to track their daily physical activity.
89563157|NCT04593199|Active Comparator|Physical Activity Tracking + Gamified Smartphone App|Over a four week period, participants were asked to use the Fitbit app to track their daily physical activity. Additionally, they were asked to use the gamified smartphone app, Draco, during the intervention period.
89563158|NCT03059225|Experimental|Experimental|repetitive transcranial magnetic stimulation (rTMS) intervention of contralesional 1Hz-rTMS for 10 daily sessions.
89563159|NCT03059225|Sham Comparator|Sham stimulation|Sham treatment for 2-week inhibitory non-dominate hemisphere rTMS program.
89208548|NCT00869934|Experimental|3. Cognitive Therapy|
89563160|NCT03059225|Experimental|High frequency rTMS|High-frequency rTMS to ipsilesional region for 10 daily sessions.
89563161|NCT03059537|Experimental|Stimulation Test|Study meal plus chenodeoxycholic acid: 1,250 mg single dose stimulation
89563162|NCT04416685|Other|Level 1|Those tumors located superior to the portal confluence were classified as Level I,
89563163|NCT04416685|Other|Level II|those tumors located on the confluence (involving the confluence) located on the portal confluence
89563164|NCT04416685|Other|Level III|those tumors located inferior to the portal confluence
89563165|NCT04944407|Experimental|LHP GROUP|patients recieved minimal invasive LHP procedure with diode laser
89563166|NCT04944407|Active Comparator|MM GROUP|patients received conventional MM hemorroidectomy
89563167|NCT04428775|Experimental|Group I (Low Dose)|Group I (n=40) will receive treatment regimen of ALZT-OP1a (cromolyn) 17.1 mg/twice a day (bid) (total of 34.2 mg/day)
89563168|NCT04428775|Experimental|Group II (High Dose)|Group II (n=40) will receive treatment regimen of ALZT-OP1a (cromolyn) 34.2 mg/bid (total of 68.4 mg/day)
89563169|NCT04944329||COLCOVID|adults undergoing hip fracture surgery
88968002|NCT05636735||midwife students group|midwife students in France
88968003|NCT00119548|Other|Arm 1|Randomized, controlled trial with three intervention models: Model A (traditional counseling/testing);
88968004|NCT00119548|Other|Arm 2|Model B (nurse-initiated screening, traditional counseling/testing);
88968005|NCT00119548|Other|Arm 3|Model C (nurse-initiated screening, streamlined counseling/rapid testing).
88968006|NCT05636813|Experimental|Training|Program of training of use of assistive technology
88968007|NCT00119782|Experimental|1|Comprehensive worksite intervention
88968008|NCT00119782|Experimental|2|Delayed intervention control group
89208549|NCT00870012|Active Comparator|Lepicol probiotic & prebiotic formula+simple lifestyle advice|
89208550|NCT00870012|Placebo Comparator|Simple lifestyle advice alone|
89563170|NCT04436263|Experimental|Supplement|Ethanol-water extract of winery by-products
89563171|NCT04436263|Placebo Comparator|Placebo|Maltodextrin-based placebo
89563172|NCT04951271|Experimental|Intervention (SFA) group|solution-focused approach intervention was applied for 7 weeks
89563173|NCT04951271|No Intervention|Control (no intervention) group|No intervention was made.
89563174|NCT04950569|Experimental|Levosimendan|Receive standard heart failure treatment, plus levosimendan treatment.
89563175|NCT04950569|No Intervention|Control|Receive standard heart failure treatment, without levosimendan treatment.
89563176|NCT04944251|Experimental|aerobic exercise group|the patients in the aerobic group started to exercise at a heart rate corresponding to 60% of the maximal VO2, by adjusting the pedal resistance of the exercise bike, consistent with the Karvonen formula. This was followed by exercise cycling at a heart rate corresponding to 70% of maximal VO2 in the second month, and 80% of maximal VO2 in the third month, for 30 minutes, 3 days a week
89563177|NCT04944251|Experimental|strength exercise group|The patients included in the strength exercise group performed weight training exercises involving 10 large muscle groups (leg press, chest press, leg curl, lateral pull down, leg extension, dumbbell lateral raise, calf press, upright row, sit up, quadruped arm opposite leg raise), 3 days a week; including 1 set of 12-15 repetitions in the first month, 2 sets of 12-15 repetitions in the second month, and 3 sets of 12-15 repetitions in the third month (Figure 1). Participants' working weights were set as 60% of the maximum weight they could lift.
89517422|NCT03011528|Other|VDC - IE x2 & Radiotherapy|"Patients in Arm C receive~VDC-IE x2: Intensified induction phase:~4 cycles of VDC (Vincristine-Doxorubicine-Cyclophosphamide) association alternative with 4 cycles of IE (Ifosfamide-Etoposide) association if good response after the 4th treatment, followed by:~4 cycles of VDC (Vincristine-Doxorubicine-Cyclophosphamide) association alternative with 4 cycles of IE (Ifosfamide-Etoposide) association~Consolidation BuMel High dose chemotherapy (Busulfan-Melphalan) followed by Peripheral Blood Stem Cell Infusion~Local treatment by radiotherapy of primary tumour/metastatic sites (outside pulmonary sites): indicated before of after consolidation phase (BuMel) among multidisciplinary decision.~Consolidation BuMel High dose chemotherapy (Busulfan-Melphalan) followed by Peripheral Blood Stem Cell Infusion~Maintenance phase~1st year : VC (Vincristine Cyclophosphamide) association~2nd year : Cyclophosphamide po 25 mg/m²"
89517423|NCT03011528|Other|VDC - IE & TEMIRI & Radiotherapy|"Patients in Arm D receive~VDC-IE & TEMIRI: Intensified induction phase:~4 cycles of VDC (Vincristine-Doxorubicine-Cyclophosphamide) association alternative with 4 cycles of IE (Ifosfamide-Etoposide) association if poor response after the 4th treatment, followed by:~4 cycles of TEMIRI (Temozolomide-Irinotecan) association~Local treatment by radiotherapy of primary tumour/metastatic sites (outside pulmonary sites): indicated before of after consolidation phase (BuMel) among multidisciplinary decision.~Consolidation BuMel High dose chemotherapy (Busulfan-Melphalan) followed by Peripheral Blood Stem Cell Infusion~Maintenance phase~1st year : VC (Vincristine Cyclophosphamide) association~2nd year : Cyclophosphamide po 25 mg/m²"
88968009|NCT05636891|Experimental|Stimus|Treatment: Nanogen's Darbepoetin alfa 10µg/0.4mL, 20µg/0.5mL, 40µg/0.4mL, 60µg/0.3mL, prefilled syringe
89517424|NCT03010163|Active Comparator|Health Fair + Pedometer|Participants will get free weight, height, waist, and blood pressure testing at health fairs stationed at NYC taxi garage bases and airport taxi holding lots. Health fair staff will follow up with participants who need to see a doctor due to a high blood pressure reading or other unusual result that needs a physician follow-up. All participants will be given a pedometer with instructions on how to use it to track their daily step counts. Participants will be randomized by envelope provided by Memorial Sloan Kettering's Department of Epidemiology and Biostatistics during an in person meeting after the completion of the 1 month run-in or by phone in case we are unable to meet them in person.
89563178|NCT04944251|No Intervention|control group|The patients who didn't want to exercise were included in the control group.
89563179|NCT04944641|Experimental|A: Routine AED group|Routine and proper antiepileptic drugs group
89563180|NCT04944641|Experimental|B: AED and education group|Routine, proper antiepileptic drugs and education group
89563181|NCT04436419|Placebo Comparator|Placebo|Patients benefited from a complete hospitalization including dietary monitoring (food intake was controlled in order to provide 30% less of their estimated daily energy expenditure) with a personalized food plan and an adapted physical activity program (5 sessions per week supervised by a graduated health physical activity coach), plus placebo administration (2x per day) apart from meal.
89563182|NCT04436419|Active Comparator|ALA|Patients benefited from a complete hospitalization including dietary monitoring with a personalized food plan and an adapted physical activity program, plus R-ALA enantiomer administration (2x300mg per day) apart from meal.
89563183|NCT02624687|Active Comparator|Intervention|These subjects will participate in a behavioral intervention that will focus on reducing sedentary behavior and improving self-management of pain. This will include an initial, in-person behavioral intervention and then monthly follow-up calls. In addition, subjects will receive a sit-stand desk attachment and a wrist-worn activity prompter to aid in sedentary behavior reduction.
88968010|NCT05636891|Active Comparator|Aranesp|Control: Amgen's Aranesp® 10µg/0.4mL, 20µg/0.5mL, 40µg/0.4mL, 60µg/0.3mL, prefilled syringe
88968011|NCT00119821|Experimental|I|Behavioral Weight Reduction
88968012|NCT00119821|Other|II|Exercise
88968013|NCT00119821|Other|III|Smoking Cessation
88968014|NCT00119977|Active Comparator|1|
88968015|NCT00120016|Experimental|1|Mediterranean diet
88968016|NCT00120016|No Intervention|2|non-intervention diet
88968017|NCT05636930||smart bracelet|Type and specification:FRA-B39
88968018|NCT00402181|Experimental|Treatment Plan A|Siltuximab 6 milligram per kilogram (mg/kg) as intravenous (directly into the vein) infusion once every 2 weeks for 12 cycles and duration of each cycle is 28 days (if participant have complete or partial response) along with dexamethasone (starting from Cycle 2, If participant do not have complete or partial response) 40 mg tablet orally on Day 1 to 4, 9 to 12 and 17 to 20 for maximum 4 cycles after that on Day 1 to 4 up to 12 cycles.
88968019|NCT00402181|Experimental|Treatment Plan B|Siltuximab 6 mg/kg as intravenous infusion once every 2 weeks along with dexamethasone 40 mg tablet orally on Day 1 to 4, 9 to 12 and 17 to 20 for maximum 4 cycles (duration of each cycle is 28 days) after that on Day 1 to 4 up to 12 cycles.
88968020|NCT04727437|Active Comparator|Control|Full dose anticoagulation treatment as standard care for at least 3 months.
88968021|NCT04727437|Experimental|Intervention|Withholding anticoagulation for Isolated Sub-Segmental Pulmonary Embolism (ISSPE) for at least 3 months.
88968022|NCT00120211|Experimental|Radiotherapy: 6 Fractions|
88968023|NCT00120211|Active Comparator|Radiotherapy: 5 fractions|
88968024|NCT04727320|Experimental|patient+TUDCA|
88968025|NCT04727320|Placebo Comparator|patient+placebo|
89517425|NCT03010163|Experimental|Health Fair, Pedometer + Text Messaging|In addition to the health fair services with general follow-up, and giving each driver a pedometer with instructions on how to use the devise to track daily step counts, all participants in this group will receive daily healthy living advice and encouraging messages about walking through text messages sent by study staff to participants' cellular phone. Participants will be randomized by envelope provided by Memorial Sloan Kettering's Department of Epidemiology and Biostatistics during an in person meeting after the completion of the 1 month run-in or by phone in case we are unable to meet them in person.
89517426|NCT03010163|Experimental|Health Fair, Pedometer, Social Network Support|Each participant in this group will receive the health fair services with general follow-up along with a pedometer with instructions on how to use the device to track daily step counts. Additionally, participants in this group will be asked to provide the names of family or friends who will form a social support network team. This team will provide encouragement and remind participants to maintain a healthy lifestyle and increase daily walking activities. Participants will be given a social network guide to train their family and/or friends on how to best motivate the participants . Participants will be randomized by envelope provided by Memorial Sloan Kettering's Department of Epidemiology and Biostatistics during an in person meeting after the completion of the 1 month run-in or by phone in case we are unable to meet them in person.
89517427|NCT03010163|Experimental|Health Fair, Pedometer, Text Msg, Social Network Support|Participants in this group will receive the health fair service with general follow-up, along with a pedometer with instructions on how to use the device to track daily step counts. Participants will also receive daily healthy living advice through encouraging text messages about walking through text messages sent by our staff to participants' cellular phones. Participants will also be asked to provide the names of family or friends who will form a social support network team. This team will provide encouragement and remind participants to maintain a healthy lifestyle and increase daily walking activities. Participants will be given tools to train their family and/or friends on how to best motivate the drivers. Participants will be randomized by envelope provided by Memorial Sloan Kettering's Department of Epidemiology and Biostatistics during an in person meeting after the completion of the 1 month run-in or by phone in case we are unable to meet them in person.
89517428|NCT03004547||Chronic hemodialysis patients|Patients on standard in-centre 3 times a week hemodialysis
89517429|NCT03004547||Peritoneal dialysis patients|Patients on peritoneal dialysis
89563184|NCT02624687|Placebo Comparator|Control|These subjects will receive no intervention.
88968026|NCT05637125|Active Comparator|Group A|Group A received aerobic exercise for upper limb in the form of arm ergometer 3 session/week for 12 weeks.
88968027|NCT05637125|Active Comparator|Group B|received aerobic exercise for lower limb in the form of cycling 3session/week for 12 weeks.
88968028|NCT00120445|Active Comparator|2|air vs perfluoropropane gas in pneumatic retinopexy
88968029|NCT00391014|Experimental|1|"AML patients in induction chemotherapy treatment will received prophylaxis with nebulized liposomal amphotericin B (24 mg/week). It will be maintained during the intensification chemotherapy and in periods between cycles.~If patient required ALO-TPH, the prophylaxis should be followed."
88968030|NCT00120796|Active Comparator|1|Lamivudine alone
88968031|NCT00120796|Experimental|2|Lamivudine + Vaccine
88968032|NCT02398734|Experimental|Sonolysis|In patients randomized into sonolysis group, middle cerebral artery segment in a depth of 55 mm will be continuously monitored during intervention using a diagnostic 2-MHz transcranial Doppler probe with a maximal diagnostic energy. The probe will be fixed in a required position using a special helmet and sonolysis will start before the carotid intervention and will be stopped after the intervention, but at latest after 120 minutes. Transcranial Doppler machine with a 2-MHz diagnostic transcranial Doppler probe will be used. This non-diagnostic transcranial Doppler monitoring will be performed without detection of microembolic signals or detection of changes in blood flow. Device sound and Doppler wave imaging will be switched off. Only sonographer will be unblinded to the procedure.
89027390|NCT01240980|Experimental|BMS-903452 (0.6 mg) or Placebo - B1|(Subjects with type 2 Diabetes Mellitus)
89027391|NCT01240980|Experimental|BMS-903452 (10 mg) or Placebo - B2|(Subjects with type 2 Diabetes Mellitus)
89517430|NCT03004547||Adult and paediatric patients with CKD stage 1-5|Patients with chronic kidney disease stage 1-5 (not dialysis dependent)
89027392|NCT01240980|Experimental|BMS-903452 (120 mg) or Placebo - B3|(Subjects with type 2 Diabetes Mellitus)
89027393|NCT01240980|Experimental|BMS-903452 (10 mg) or Placebo - A11|(Healthy Subjects)
89517431|NCT03004547||Healthy adult and paediatric controls|Subjects without kidney disease
89517432|NCT03004547||Heart failure patients with and without renal dysfunction|Heart failure patients (atrial fibrillation etc ...) with and without renal dysfunction
89517433|NCT03000387|Experimental|Experimental Condition|Participants unable to quit smoking after 2 weeks of treatment with 21mg nicotine patch will get 21mg nicotine patches plus additional active nicotine patches until achieving 7 consecutive days of abstinence over the next 5 weeks; maximum daily patch dose, 84mg/day
89517434|NCT03000387|Placebo Comparator|Placebo Condition|Participant unable to quit smoking after 2 weeks of treatment with 21mg nicotine patch will get 21mg nicotine patches plus placebo patches until 7 consecutive days of abstinence over the next 5 weeks; Maximum daily patch dose, 21mg active nicotine patch plus 3 placebo 21mg patches.
89517435|NCT03000387|Active Comparator|Quit condition|Participants able to quit for 7 consecutive days during the first 2 weeks of treatment with 21mg nicotine patch will continue open label 21mg active nicotine patches for the remaining 10 weeks.
89517436|NCT02994927|Active Comparator|Prednisone group|Avacopan-matching placebo plus cyclophosphamide/azathioprine or rituximab plus a full starting dose of prednisone.
89517437|NCT02994927|Experimental|Avacopan group|Avacopan plus cyclophosphamide/azathioprine or rituximab plus prednisone-matching placebo.
89517438|NCT02828098|Experimental|Part 1: BO-112 IT|BO-112 dose 1 (starting dose) intratumoral injection. BO-112 dose 2, 3 and 4 are expected to be tested, upon confirmation of the safety profile of the starting dose.
89517439|NCT02828098|Experimental|Part 2: BO-112 IT|"Combination treatment of BO-112 intratumoral injections with standard of care nivolumab intravenous treatment~Or Combination treatment of BO-112 intratumoral injections with standard of care pembrolizumab intravenous treatment"
89517440|NCT02721459|Experimental|Dose Escalation|Escalating Doses of XL888 with Vemurafenib plus Cobimetinib.
89027394|NCT01240980|Experimental|BMS-903452 (60 mg) or Placebo - A12|(Healthy Subjects)
89563185|NCT04943705|Experimental|Yin and Yang Regulating Moxibustion|1.The acupoints will be selected as Shenque and Mingmen.The location of the acupoints were based on the national GB/T 12346-2006 acupoints standard.Each treatment was 60min, once a week, Wenyang Yishen moxibustion and Peiyuan Guben moxibustion were performed alternately. Each patient received WenYang Yishen moxibustion and then Peiyuan Guben moxibustion for a total of 12 weeks of treatment and 12 weeks of follow-up at the end of the treatment. 2.The diet and exercise control implementation plan is as follows:Participants weighed ≤113.6 kg (250 lbs) and had a prescription diet of 1200-1499 kcal/day, including traditional foods, of which protein was about 15-20 kcal, fat was about 20-35%, and the rest came from carbohydrates. People weighing ≥113.6 kg are prescribed 1500-1800 kcal per day. They were also instructed to continue moderate-intensity physical activities (such as jogging, brisk walking) at least 5 days a week, at least 210 minutes a week, preferably ≥270 minutes a week。
89563186|NCT04943705|Active Comparator|Mild Moxibustion|1.The acupoints will be selected as Zhongwan, Guanyuan, Sanyinjiao (double).The location of the acupoints were based on the national GB/T 12346-2006 acupoints standard.Light one end of the moxa stick and hang it about 2-3cm above the skin, taking the patient's local skin redness and conscious warmth as the degree. Moxa-box moxibustion will be used for 20 minutes each treatment, once every other day, 3 times a week, for a total of 12 weeks of treatment, and 12 weeks of follow-up after the treatment. 2.Lifestyle modification:It will be performed as the same as the Yin and Yang Regulating Moxibustion group.
89563187|NCT04950491|Experimental|Test group (s-CAIS)|The test group workflow used a fully computer-guided implant surgical protocol.
89563188|NCT04950491|Other|Control group (CIS)|The control group workflow used a conventional implant surgical protocol.
89563189|NCT04950335||AOPT|patients underwent AOPT to treat large cystic OLTs (>10mm)
89563190|NCT04950335||AOCT|patients underwent AOCT to treat large cystic OLTs (>10mm)
89563191|NCT04960319|Experimental|Intravascular Lithotripsy|Study Device Treatment: IVL balloon catheter size is chosen in a 1:1 ratio to the distal reference vessel diameter. If the IVL balloon cannot be delivered into the target lesion a Guide catheter extension is recommended. The balloon catheter is then inflated to 4 ATM and 10 impulses are delivered. The balloon is then inflated to 6 ATM and deflated to reestablish blood flow. Up to 80 impulses can subsequently be delivered and the balloon can be repositioned within the lesion. In multiple lesions with different reference vessel diameters different sizes of IVL balloon can be used.
89563192|NCT04960319|Active Comparator|Rotational Atherectomy|Control group treatment: Rotablation should be performed as described in the ESC-Consensus document. Burr/vessel-ratio is 0.5 - 0.75. The use of different burr sizes as well as the use of a temporary pacemaker is left to the operator's discretion.
89563193|NCT04950647|Experimental|Test group 1|Nitroketazine tablet 600 mg group
89563194|NCT04950647|Experimental|Test group 2|Nitroketazine tablets 1200 mg group
89563195|NCT04950647|Placebo Comparator|Control group|placebo group
89563196|NCT01675765|Experimental|Immunotherapy plus chemotherapy|"Weeks 1 and 3: CRS-207 (1 × 10^9 CFU)~Weeks 5, 8, 11, 14, 17 and 20 (up to 6 cycles every 21 days): pemetrexed (500 mg/m^2) and cisplatin (75 mg/m^2)~Weeks 23 and 26: CRS-207~Maintenance Vaccinations: CRS-207 every 8 weeks (starting at Week 34) until disease progression"
89563197|NCT01675765|Experimental|Immunotherapy with cyclophosphamide plus chemotherapy|"Weeks 1 and 3: cyclophosphamide (200 mg/m^2), CRS-207 (1 × 10^9 CFU)~Weeks 5, 8, 11, 14, 17 and 20 (up to 6 cycles every 21 days): pemetrexed (500 mg/m^2) and cisplatin (75 mg/m^2)~Weeks 23 and 26: cyclophosphamide one day before CRS-207~Maintenance Vaccinations: cyclophosphamide one day before CRS-207 every 8 weeks (starting at Week 34) until disease progression"
89563198|NCT04522453|Active Comparator|paper mental health Gap Action Program-Intervention Guide|This arm will be training and supervision as usual employing the standard paper version of the mental health Gap Action Program-Intervention Guide. Primary care workers will be trained to use the paper version of this tool and will use the paper version when evaluating patients.
89563199|NCT04522453|Experimental|digital mental health Gap Action Program-Intervention Guide|This arm will be training and supervision in an experimental approach using a digital version of version of the mental health Gap Action Program-Intervention Guide. The digital version allows for interactive decision making on diagnoses and care, and it allows for entering of patient data. Primary care workers in this arm will be trained to use the digital version of this tool and will use the digital version when evaluating patients.
89563200|NCT05011435||Users|users of the web-application
89563201|NCT04950413|Active Comparator|Traditional Treatment Arm|conventional physical therapy program (infrared, stretching exercise, isometric strengthening exercise)
89563202|NCT04950413|Experimental|IASTM treatment arm|Instrument-assisted soft tissue mobilization (IASTM) is a therapeutic technique that is based on the soft tissue mobilization rationale introduced by James Cyriax.
89563203|NCT04950413|Experimental|Phonophoresis treatment arm|It will be consisted of 1 MHz pulsed mode with an intensity set at 1.5 W/cm2.
89027395|NCT01240772|Experimental|DGALM|doppler-guided arterial ligation with mucopexy
89563204|NCT04950413|Experimental|Combined IASTM and phonophoresis treatment arm|Combined phonophoresis and M2t Blade
89563205|NCT04285255|Active Comparator|Opioids anesthesia|received propofol-fentanyl induction of anaesthesia plus ultrasound-guided Bilateral oblique subcostal TAP block using 20ml of bupivacaine hydrochloride 0.25% (Marcaine, Astra Zeneca UK) in each side (total volume of 40 ml) deposited equally on each side
89027396|NCT01240772|Active Comparator|SH|stapled haemorrhoidopexy according to Longo
89027397|NCT01241019|Experimental|Topiramate|Newborns with hypoxic ischemic encephalopathy treated with mild hypothermia and topiramate
89563206|NCT04285255|Active Comparator|OFA|received preinduction with dexmeditomidine 0.1µg.kg-1 over 10 min. Induction with propofol 1.5 mg.kg-1-ketamine (ketofol 3:1 mixture) induction plus maintenance mixture of dexmedetomidine 0.5µg.kg-1.h-1, ketamine 0.5mg.kg-1.h-1, and lidocaine 1 mg.kg-1.h-1 plus ultrasound-guided Bilateral oblique subcostal TAP block using 20ml of bupivacaine hydrochloride 0.25% (Marcaine, Astra Zeneca UK) in each side (total volume of 40 ml) deposited equally on each side
89563207|NCT04943003|Experimental|Active tDCS|"SimNIBS will be used for modeling. It is a free and open source software package for the simulation of electric field induced by tDCS in the individual brain.~Modeling will be done using T1-weighted anatomical images of each subject to reconstruct a high-resolution head model of each individual. For electrode placement, we will simulate areas F5 and F6, according to the EEG 10-20 system, for the anode and cathode, respectively, targeting the left and right Dorsolateral Prefrontal Cortex (DLPFC). This group will receive active tDCS, for 30 minutes and for 5 consecutive days, in two weeks, with an anode positioned on the left DLPFC and a cathode electrode placed on the right supraorbital area."
89563208|NCT04943003|Sham Comparator|Sham tDCS|The electrodes will be placed in the same way as in the Active tDCS group. However, individuals in this group will receive a stimulation that will last only 20-30 seconds. Afterwards, the device will be turned off, no longer emitting current.
89563209|NCT04963543|Experimental|FID123238|FID123238 applied to the ocular surface, 1 application per day, for five consecutive days
89563210|NCT04943081|Experimental|Case group|Adult patients with age group ≥ 18 years old with renal stones candidate for PCNL with pre-operative estimated GFR less than 90 ml/min/1.7 m2 and ≥ 15 ml/min/1.7 m2.
89563211|NCT04942691|No Intervention|non-exercise group (control group)|The control group not performed physical activity for a total of 20-weeks.
89563212|NCT04942691|Experimental|exercise group|The exercise group performed SuperJump® training that will be performed for three times a week, each session lasting 60 minutes for a total of 20-weeks.
89563213|NCT04942847|No Intervention|The control group|The control group received routine nursing, including diet nursing, life nursing, direct and indirect training, health education and so on. Patients were followed up regularly by telephone after discharge
89563214|NCT04942847|Experimental|Dual task training group|On the basis of routine swallowing function training, the use of sucking training rehabilitation device is mainly used for tongue muscle training and lip muscle training to improve the control and delivery ability of tongue muscle to food.At the same time,adopt Troup's playing and comprehensive analysis ability training.Disrupt the three sets of cards, instruct the patient to read words or say colors, and measure the patient's reaction time with an electronic timer.Comprehensive analysis ability training: including digital training or item classification training.
89563215|NCT04121299|Experimental|Carvedilol 40mg Extended Release Once Daily|participants will be randomized to carvedilol 40 mg extended release once daily for the 1st or 2nd 4 week treatment period
89563216|NCT04121299|Active Comparator|Amlodipine 10mg Once Daily|participants will be randomized to amlodipine 10 mg once daily for the 1st or 2nd 4 week treatment period
89563217|NCT04942769|Experimental|selenium|selenium was administered to patients with autoimmune thyroiditis
89563218|NCT04253665|No Intervention|Usual care|Discharge teaching is usually not delivered in a systematic or consistenly way, nor by relying on a particular intervention model.
89563219|NCT04253665|Experimental|Discharge teaching|Receiving tailored discharge teaching by nurses during hospital stay.
89563220|NCT04942301|Experimental|Endostar pump for three days|Group A: The first cycle, Endostar 7.5mg/m2/day, intravenous infusion for 4 hours, D1-14 First 2-4 cycles, Endo 105mg/m2/cycle D1 starts intravenous pump for 72 hours;
88968033|NCT02398734|Sham Comparator|Shame sonolysis|In patients randomized into control group, the transcranial Doppler probe will be fixed in a required position using a special helmet as in sonolysis group patients, but middle cerebral artery segment in a depth of 55 mm will be only localized using a diagnostic 2-MHz transcranial Doppler probe with a maximal diagnostic energy and the transcranial Doppler monitoring will be stopped afterwards. Patients in the control group will undergo a sham procedure in which further sonolysis (transcranial Doppler monitoring) will not be conducted.
88968034|NCT04727164|Experimental|HBM4003+Toripalimap|HBM4003 combined with toripalimab in patients with advanced melanoma and other solid tumors
88968035|NCT02377830|Experimental|Early Cycling and routine physiotherapy|Patients will receive 30 minutes of in-bed cycling in addition to routine physiotherapy, 5 days per week, for the duration of their ICU stay
88968036|NCT02377830|Active Comparator|Routine physiotherapy|Patients will receive routine physiotherapy per current institutional practice
88968037|NCT05637320|Experimental|Intervention Arm|Treatment will be administered to participants in this arm.
88968038|NCT05637320|No Intervention|Control Arm|No treatment will be administered to participants in this arm until post-test assessment has been completed.
88968039|NCT00121264|Experimental|Treatment (sorafenib tosylate, tanespimycin)|Patients receive oral sorafenib twice daily on days -14 to 28 in course 1 and on days 1-28 in all subsequent courses. Patients also receive 17-AAG IV over 3 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88968040|NCT00121303|Active Comparator|Arm A low dose Dauno|Induction 45 mg Dauno
88968041|NCT00121303|Experimental|ARM B high dose Dauno|Induction 90 mg Dauno
88968042|NCT00121303|No Intervention|Arm 1 no further treatment|
88968043|NCT00121303|Experimental|Arm 2 Mylotarg|Post induction treatment with Mylotarg
89563221|NCT04942301|Experimental|Endostar pump for seven days|Group B: Cycle 1, Endo 7.5mg/m2/day, intravenous infusion for 4 hours, D1-14 First 2-4 cycles, Endo 105mg/m2/cycle D1 starts intravenous pump injection for 168 hours;
89563222|NCT04960007||Group A|Sarcopenia patients.
88968044|NCT05637359||Patients scheduled for navigated abdominal cancer surgery|Patients are 18 years old or older. Patients are scheduled for tumor surgery in the abdominal/pelvic area and navigation surgery with a scheduled Cone Beam CT-scan in the operating room. Patients provide written 'informed consent'. The to be administered intervention is a percutaneous tracked ultrasound measurement of the patient's pelvic bone on the operating room after anesthesia.
89563223|NCT04960007||Group B|Dynapenia patients.
89563224|NCT04960007||Group C|Age and gender matched non-sarcopenia and non-dynapenia patients.
89563225|NCT04959539|Active Comparator|endoscopic transcanal tympanoplasty with attico-antrostomy|
89563226|NCT04959539|Active Comparator|endoscopic assisted canal wall up mastoidectomy|
89608798|NCT04414501|Active Comparator|VR study group|Anxiety at separation from caregiver was measured by the modified Yale Preoperative Anxiety Scale (mYPAS). Caregiver anxiety was measured using the State-Trait Anxiety Inventory for Adults (STAI), a validated self-evaluation questionnaire. Mask acceptance, a functional evaluation of stress at the time of induction, was determined using the Mask Acceptance Scale.
89563227|NCT04184479|Active Comparator|A-LEVAmetoden by Bertz et al|Individual dietary advices for weight loss, based on the participants' food record of 4 consecutive days aimed to achieve an energy intake reduction of 500 kcal/d with a nutrient composition according to the Nordic Nutrition Recommendations. Follow up visits after 3 months, 1 year and 2 years after baseline. Follow up by electronic platform every other week until 3 months after baseline and each month after 3 months until 1 year after baseline.
89563228|NCT04184479|Placebo Comparator|B-Ordinary treatment|Dietary advices for weight loss aimed to achieve calorie restriction. Follow up visits after 3 months, 1 year and 2 years after baseline. Additional visits, up to 4 times in the first year after baseline.
89563229|NCT04959227||whirling dervish group|Beck Anxiety Inventory Beck Depression Inventory International Physical Activity Questionnaire
89563230|NCT04959227||control group|Beck Anxiety Inventory Beck Depression Inventory International Physical Activity Questionnaire
89563231|NCT04725175|Experimental|PIPE-307|
89563232|NCT04725175|Placebo Comparator|Placebo|
89563233|NCT02625233|Experimental|senofilcon C|Vistakon Investigational Contact Lens (Test)
89563234|NCT02625233|Active Comparator|comfilcon A|Marketed Monthly Wear Contact Lens (Control)
89563235|NCT04704349|Experimental|Scintigraphy acquisitions|All patients will undergo scintigraphy on 2 distinct devices and the images obtained will be compared.
89563236|NCT03059069|Experimental|Glitamin|800mg/day
89563237|NCT03059069|Placebo Comparator|Placebo|same shape, color, size tablet as Glitamin
89563238|NCT04942223|Other|Subjects undergoing virtually planned GBR for extended and complex alveolar defects.|"Subjects undergoing virtually planned GBR for extended and complex alveolar defects.~The subjects were selected from the population of patients referring to the Oral & Maxillofacial Surgery Unit of S.Orsola-Malpighi University Hospital for oral function rehabilitation. Eligibility criteria were: the presence of horizontal and vertical alveolar defects in both jaws, inadequate for the placement of at least two fixtures, even ≤6 mm long ones; ≥ 18 years; informed consent signed."
89563239|NCT04950023||early COPD|1) <60 years old; 2) smoking ≥ 10 pack years. 3) with any of the following anomalies: a. Post-bronchodilator FEV1/FVC< 0.7. b. CT image abnormalities: emphysema, air trapping or bronchial wall thickening; c.Rapid decrease of FEV1 (>60 ml/yr).
89563240|NCT04950023||Control|1) <60 years old; 2) Pre-bronchodilator FEV1/FVC≥70% and FEV1 ≥ 80% predicted; 3) no exposure to harmful factors such as cigarettes and dust pollution.
88968045|NCT00121381|Experimental|1|Pimecrolimus 1 % cream plus topical corticosteroid (TCS)
88968046|NCT00121381|Placebo Comparator|2|Pimecrolimus vehicle (Placebo) plus topical corticosteroid (TCS)
88968047|NCT00391131|Experimental|Ig NextGen 16%|
88968048|NCT05637437|Active Comparator|Control Group|Participants in the control group will receive the usual care of the hospital.
88968049|NCT05637437|Experimental|Intervention Group|Participants in the intervention group will receive a peer supported diabetes self-care intervention through digital media
88968050|NCT04711096||Group A|TAB group formed of 65 patients
88968051|NCT04711096||Group B|"Group B : The Infiltration Group formed of 65 patients.~• This group will B wills provided with single-shot local anesthetic wound infiltration with 20 ml of 0.25% bupivacaine injected subcutaneously above and below skin incision before closure of skin."
88968052|NCT04711096||Group C|"Group C : Narcotics only group formed of 20 patients~• routine analgesic was taken only without any intervention"
88968053|NCT04705948|Experimental|ketamine group|ketamine gargle (0.5 mg/kg up to 30 ml dextrose water) 15 minutes before the operation
88968054|NCT04705948|Experimental|magnesium sulfate group|magnesium sulfate gargle (20 mg/kg up to 30 mL G5%) 15 minutes before the operation.
88968055|NCT00391287||erythropoietin treatment in CRF|Patients exposed to EPREX or other marketed erythropoietin products administered by the subcutaneous route of administration for the treatment of anemia of Chronic Renal Failure
88968056|NCT00121654|Active Comparator|1|paresthesic SCS
88968057|NCT00121654|Active Comparator|2|subliminal SCS (75-80% of paresthesic threshold)
88968058|NCT00121654|Sham Comparator|3|low stimulation, consisting of an hour of SCS a day at 0.05 mV intensity, which does not have any significant stimulator effect (sham stimulation)
89563241|NCT03710785|Experimental|forward neck posture syndrome patients|Patients diagnosed with forward neck posture syndrome in cervical plain X-ray have a cervical spine extension exercise for 4 weeks
89563242|NCT04949945|Experimental|CHF patients who will receive guided self help culturally adapted cognitive behavioral therapy|CHF(Chronic heart failure patients)(experimental group) will receive guided self help culturally adapted cognitive behavioral therapy.
88968059|NCT00121693|Experimental|Music Listening 1|Intervention: Listen to Music type 1
88968060|NCT00121693|Experimental|Music Listening 2|Intervention: Listen to Music type 2
88968061|NCT00121693|Experimental|Music LIstening 3|Intervention: Listen to Music type 3
88968062|NCT00121693|No Intervention|Control|Intervention: Listen to White noise
88968063|NCT00121732|Experimental|A|
88968064|NCT00121732|Experimental|B|
88968065|NCT05637827||children with hyperopia|The refractive error and axial length of eye were observed
88968066|NCT05637827||children with emmetropia|The refractive error and axial length of eye were observed
89563243|NCT04949945|No Intervention|CHF patients will not receive guided self help culturally adapted cognitive behavioral therapy|CHF(Chronic heart failure patients) (control group) will not receive Self Help Culturally Cognitive Behavior Therapy.
89563244|NCT04563715|Active Comparator|Standard of Care|HIV counseling and testing
89563245|NCT04563715|Experimental|Standard of Care plus Network Intervention|Network intervention
89563246|NCT04941677||schizophrenia group|No intervention age between 20-65, diagnosed schizophrenia by DSM-5.
89563247|NCT03057899|Experimental|fenugreek seed and Lespedeza cuneata (TFG)|Patients who received investigational products (200 mg TFG) twice per day for 8 weeks at least 30 minutes after food intake
89563248|NCT03057899|Placebo Comparator|Placebo|Patients who received placebo twice per day for 8 weeks at least 30 minutes after food intake
89563249|NCT03284827|Experimental|NOAC|60 mg once daily
89563250|NCT03284827|Active Comparator|DAPT|clopidogrel (75 mg OD) plus acetylsalicylic acid (ASA, 75-100 mg OD)
89563251|NCT04959071|Experimental|Group A|Group A included participants who underwent VAC therapy for diabetic Foot ulcers
89563252|NCT04959071|Active Comparator|Group B|Group B included participants who underwent conventional dressings for diabetic foot ulcers
89563253|NCT04949321|Experimental|Gadovist (gadobutrol) / two MRI|60 Meniere's Disease patients and 20 healthy volunteers (sample of 5 volunteers per MRI machine)
89027398|NCT01241019|No Intervention|Control|Newborns with hypoxic ischemic encephalopathy treated with mild hypothermia
89563254|NCT04434001|Experimental|ZEPLAST|"In case of bleeding and:~CT INTEM > CT HEPTEM by 25% : give protamine 0.25 mg/kg;~MCF FIBTEM < 8 mm : give Fibrinogen Concentrate 30 mg/kg;~CT EXTEM > 100 s : give Prothrombin Complex Concentrate 20 mg/kg."
89563255|NCT04434001|Active Comparator|Control|"In case of bleeding and:~CT INTEM > CT HEPTEM by 25% : give protamine 0.25 mg/kg;~fibrinogen and/or thrombin generation deficiency : give FFP 10-20 ml/kg."
89563256|NCT04958993|Experimental|Anlotinib combined with concurrent chemoradiotherapy|"Radiotherapy: 1.8-2.0Gy, qd, 54-66Gy, 5 days a week Chemotherapy: squamous cell cancer: paclitaxel + platinum;Adenocarcinoma: pemetrexed + platinum;A cycle of 3W was used, and the appropriate chemotherapy dose was selected by the researcher according to the patient's situation without any restriction on the chemotherapy dose.Pre-induction chemotherapy is allowed.~Anlotinib: QD, take 2 weeks and stop for 1 week (radiotherapy 1, 2, 4, 5 weeks)"
89563257|NCT04683913|Experimental|Immediate Intervention: Telerehabilitation|Immediate entry into the gait modification intervention delivered using teleconferencing methods
89563258|NCT04683913|Experimental|Delayed Intervention: Telerehabilitation|Delayed (6 weeks) entry into the gait modification intervention delivered using teleconferencing methods
89563259|NCT03603925||PET/MR + PET/CT|The interventions for participating in this research are centered around steps needed to safely and ethically collect a research PET/MR scan following a standard-of-care PET/CT scan. The patient will be imaged in at least one of several standard anatomic areas: head/neck, thorax, abdomen, pelvis or whole-body.
89563260|NCT04958603||Traditional surgery group|Traditionally loosen the lateral support belt proximally
89563261|NCT04958603||New surgery group|"Laterally loosen the outer support belt, that is, L-shaped loosen"
89563262|NCT03540901|Active Comparator|ACETAZOLAMIDE oral capsule|375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3100m until the morning after the second night at 3100m
89563263|NCT03540901|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3100m until the morning after the second night at 3100m.
89563264|NCT03517735|Experimental|Automated postoperative sedation|Automated administration of Propofol and Remifentanil.
89027399|NCT01240928|Experimental|MK-2206 + exemestane +/- goserelin|Oral MK-2206 and oral exemestane and subcutaneous goserelin (for pre-menopausal participants only)
89027400|NCT04517175||Myelodysplastic syndrome (MDS) patients|MDS patients will be divided according to prognostic parameters in sub-cohorts.
89027401|NCT04517175||Acute myeloid Leukemia (AML) patients|AML patients will be divided according to prognostic parameters in sub-cohorts.
89027402|NCT04517175||Myelodysplastic syndrome/neoplasm (MDS/MPN) patients|MDS/MPN patients will be divided according to prognostic parameters in sub-cohorts.
89027403|NCT04516980||Participants with ankle sprain.|Participants with ankle sprain
89027404|NCT04516980||Participants without ankle sprain|Participants without ankle sprain
89027405|NCT04516863|Active Comparator|Patients with depression|"Major depression according to DSM-V and ICD-10 (ICD F32.1, F32.2, F32.3, F33.1, F33.2, F33.3)~Hamilton Depression Rating Scale > 17"
89563265|NCT03517735|Active Comparator|Manual postoperative sedation|Manual administration of Propofol and Remifentanil.
89563266|NCT04958915||30 ° flexion position|Scan the knee at 30° flexion
89563267|NCT04958915||conventional flexion position|Routine body scan of the knee joint
89563268|NCT03489811|Experimental|Test Essential Oil Blend|Participants in this arm receive the test essential oil inhaler to administer during the 4-week intervention.
89563269|NCT03489811|Active Comparator|Active Essential Oil Blend|Participants in this arm receive an active essential oil inhaler to administer during the 4-week intervention.
89563270|NCT03489811|Placebo Comparator|Control|Participants in this arm receive a control inhaler to administer during the 4-week intervention.
89027406|NCT04516863|Active Comparator|Healthy controls|- Mental health
89027407|NCT04517019|Experimental|Arm A (Tracker/daily step-count suggestion)|"Patients receive a fitness tracker, a booklet Physical training, exercise and cancer and an in-person briefing on physical activity during cancer therapy. We suggest a daily step-count which should improve the patients phyiscal activity during radiotherapy of breast cancer. Patients receive weekly feedback and a new goal with the aim to reach a total of 6000 daily steps, which should be then maintained during radiotherapy."
89027408|NCT04517019|Experimental|Arm B (Tracker/no daily step-count suggestion)|"Patients receive a fitness tracker, a booklet Physical training, exercise and cancer and an in-person briefing on physical activity during cancer therapy.~The patients self-document their daily step count during radiotherapy, there will be no recommendation for the daily count of steps."
89563271|NCT04941131|Experimental|chlorhexidine digluconate mouthwash|
89563272|NCT04941131|Experimental|chlorhexidine digluconate lozenges|
89563273|NCT04941131|Experimental|povidone iodine mouthwash|
89563274|NCT04941131|No Intervention|tap water|
89563275|NCT03400501|Experimental|subjects receiving insulin degludec|Youth aged 8-18 years with T1D whose diabetes is poorly-controlled (A1c ≥8.5%) will receive insulin degludec injections.
89563276|NCT03400501|Active Comparator|Subjects receiving insulin glargine|Youth aged 8-18 years with T1D whose diabetes is poorly-controlled (A1c ≥8.5%) will receive insulin glargine injections.
89563277|NCT04940975|Experimental|Occupation-based sleep intervention program|A program composed of four occupation-based interactive workshops on sleep, insomnia, lifestyle, and change strategies, plus two individual coaching sessions on lifestyle and sleep hygiene.
89563278|NCT04940975|Active Comparator|Insomnia educational program (Treatment as Usual Group)|A program composed of four educational talks on sleep hygiene and relaxation training, plus two individual sessions for the reviewing of sleep patterns.
89563279|NCT04383847|Experimental|Main study|There is only 1 arm because this is a feasibility and acceptability pilot.
89563280|NCT03231475|Experimental|SPH1188-11|SPH1188-11 dose escalation, 50mg/100mg/200mg/300mg/450mg/600mg
89563281|NCT04415957|Experimental|Elastic Tape Group (ETG)|The ET placement was previously described by Pinto et al. (2020). Briefly, the subject's trunk was passively extended for ET placement. The ET was placed considering the origins and insertions of the following muscles: rectus abdominis, internal oblique, and internal intercostal. ET has shown six days of durability on average, so the participants were asked to return to change the ET after seven days.
89563282|NCT04415957|No Intervention|Control Group (CG)|CG received instructions about the importance of becoming physical activity. Furthermore, the participants included in CG were invited to place the ETs at the end of the protocol.
89563283|NCT04958681||Covid-19 history positive|
89563284|NCT04958681||Covid-19 history negative|
89563285|NCT04949009||Patients with primary immune thrombocytopenia (ITP)|"Ever been diagnosed as ITP patients. The diagnostic criteria comply with the Chinese Guidelines for the Diagnosis and Treatment of Adult Primary Immune Thrombocytopenia (2020 Edition)"
89563286|NCT04948541|Experimental|treatment|
89563287|NCT04948541|Experimental|no treatment|
89563288|NCT04948229||Control Group|This group will be included subjects who had no history or diagnosis of any disease, no infection history within last two weeks, no history of any particular medication, who were admitted to emergency department (ED) with complaints other than infectious issues, and who gave their written consent to participate in the study.
89563289|NCT04948229||Moderate Disease Group|This group will be consisted of the patients whose diagnoses of moderate COVID-19 infection were confirmed by positive RT-PCR in ED according to WHO guidelines and who gave their written consent were included in the study.
89563290|NCT04948229||Severe/Critical Disease Group|This group will be consisted of the patients whose diagnoses of severe/critical COVID-19 infection were confirmed by positive RT-PCR in ED according to WHO guidelines and who gave their written consent were included in the study.
89563291|NCT04940819|Experimental|Mobile Application Intervention|Participants in this arm will receive mobile application dietary intervention as well as usual CKD dietary care.
89563292|NCT04940819|No Intervention|Care as Usual|Participants in this arm will receive usual CKD dietary care.
89563293|NCT03058211||pneumococcal pneumonia|Patients with community-acquired pneumonia due to S.pneumoniae. An Echocardiography will be performed to all patients (one per day during 7 days). A Cardiac magnetic resonance (MRI) will be performed during an acute episode and at month 6 since ICU admission. In addition a blood sample will be drawn daily (one per day during 7 days) to measure myocardial injury and inflammation systemic (interleukins) biomarkers.
89563294|NCT03058211||non-pneumococcal pneumonia|Patients with community-acquired pneumonia due to S.pneumoniae. An Echocardiography will be performed to all patients (one per day during 7 days). A Cardiac magnetic resonance (MRI) will be performed during an acute episode and at month 6 since ICU admission. In addition a blood sample will be drawn daily (one per day during 7 days) to measure myocardial injury and inflammation systemic (interleukins) biomarkers.
89563295|NCT04940429||Roux n Y Gastric Bypass (RYGB)|"Participants in this arm will include patients who will be having a RYGB after their assessment by their bariatric surgeon. After reviewing and signing the consent form, participants will perform the paper-based standard psychometric tests (number connection test A and B, line tracing test, and digital subtraction test, and serial dotting test, which take about 20 minutes) at their preoperative visit.~After completion of paper-based standard psychometric tests, participants will then perform the computer application test which takes about 5 minutes at their preoperative visit.~These will also be performed at their post operative visits 2 weeks, 3, 6 and 12 months."
89563296|NCT04940429||Sleeve gastrectomy (SG)|"Participants in this arm will include patients who will be having a SG after their assessment by their bariatric surgeon. After reviewing and signing the consent form, participants will perform the paper-based standard psychometric tests (number connection test A and B, line tracing test, and digital subtraction test, and serial dotting test, which take about 20 minutes) at their preoperative visit.~After completion of paper-based standard psychometric tests, participants will then perform the computer application test which takes about 5 minutes at their preoperative visit:~These will also be performed at their post operative visits 2 weeks, 3, 6 and 12 months."
89563297|NCT02656693|Experimental|Online Program Only|Patients will use an online weight management program called BMIQ, with minimal additional support.
89563298|NCT02656693|Experimental|Combined Intervention|Patients will use an online weight management program called BMIQ, but will also receive additional monitoring and support from a population health manager who works with their primary care practices.
89563299|NCT02656693|No Intervention|Usual Care|Patients will continue receiving usual care but will also be mailed some general written information about weight management (very minimal intervention.)
89563300|NCT04940273|Experimental|remifentanil|Continuous infusion of remifentanil at a dose of 0.02、0.04、0.06、0.08 ug/kg/min for 30 minutes in sequence.
89563301|NCT04958525||Endoscopic Surgery Group|After a full evaluation of the patient's condition, the informed consent was signed to perform keyhole neuroendoscopic ultrasound-guided hematoma removal for the patient.
89563302|NCT04958525||Microsurgery group|After a full evaluation of the patient's condition, the informed consent was signed to perform small bone window craniotomy for hematoma removal under microscope for the patient.
89563303|NCT02642107|Experimental|Elective neck irradiation|Whole neck irradiation is given in the involved neck. Elective neck irradiation of Level II,III and Va lymph node area is given in the uninvolved neck, and Level IV and Vb lymph node area were not irradiated in the uninvolved neck.
89563304|NCT02642107|Active Comparator|Whole neck irradiation|Whole neck irradiation is given regardless of the involved or uninvolved neck.
89563305|NCT04948385|Active Comparator|Patients|Deep sedation for digestive endoscopy.
89563306|NCT04948385|Other|Escorts|Accompanying persons are the adults who accompany the patients home. They do not receive any medication or intervention.
89563307|NCT03057821|No Intervention|Control|The control group will not receive any hydrogen peroxide skin preparation
89563308|NCT03057821|Experimental|Treatment|The treatment group will also undergo skin preparation with 3% hydrogen peroxide.
89563309|NCT04947761|Experimental|modified Cheonwangbosimdan Hydrogel patch|Group receiving modified Cheonwangbosimdan Hydrogel patch
89563310|NCT04947761|Placebo Comparator|Placebo patch|Group receiving placebo patch
89563311|NCT04958213|Other|Conventional physical therapy|Conventional physical therapy (Hotpack, TENS and Ultrasound) and home exercise program (isometric and isotonic exercises) will be applied to this group for 4 weeks (20 sessions).
89563312|NCT04958213|Active Comparator|Dextrose prolotherapy treatment|This group will be treated with 15% dextrose prolotherapy around and inside the knee, 2 times with a two-week interval, and home exercise program (isometric and isotonic exercises).
89563313|NCT04958135|Experimental|Sequence 1: Acoramidis|"Participants will receive acoramidis once each period as a single dose under fasted or fed conditions as follows:~Period 1: Acoramidis as an immediate-release tablet under fasted conditions.~Period 2: Acoramidis as an immediate-release tablet under fed conditions.~There will be a washout period of at least 14 days between acoramidis dosing."
89563314|NCT04958135|Experimental|Sequence 2: Acoramidis|"Participants will receive acoramidis once each period as a single dose under fasted or fed conditions as follows:~Period 1: Acoramidis as an immediate-release tablet under fed conditions.~Period 2: Acoramidis as an immediate-release tablet under fasted conditions.~There will be a washout period of at least 14 days between acoramidis dosing."
89563315|NCT04948151|Experimental|Sildenafil Cream, 3.6%|
89563316|NCT04948151|Placebo Comparator|Placebo Cream|
89563317|NCT04939493|Experimental|Rhythmic Auditory Cueing|Group (B): Patients in this group will receive the same designed physical therapy program given to the control group in addition to auditory cueing during bilateral arm training using the metronome.
89563318|NCT04939493|Active Comparator|Bilateral arm training|Patients in this group will receive a standard physical therapy program in addition to Bilateral arm training.
89563319|NCT04947995||Gastric cancer group|
89563320|NCT04947995||Precancerous lesion group|
89563321|NCT04947995||Healthy group|
89563322|NCT04939337|Experimental|TH-SC01|TH-SC01 24 mL suspension of 120 million cells as a perilesional injection, once on Day 0.
89563323|NCT04939025|No Intervention|Historic cohort|
89563324|NCT04939025|Other|Multi-interventional program cohort|
89563325|NCT04947371|Experimental|Anlotinib Hydrochloride|Oral anlotinib 12 mg/d
89563326|NCT04957121||on-hours|"Hip surgeries with the start time of anesthesia between 8:00 and 17:59 were coded as on-hours."
89563327|NCT04957121||off-hours|"Hip surgeries with anesthesia beginning between 18:00 and 7:59 were coded as off-hours. Besides, taking the long duration of hip surgery into account, if the anesthesia began before 18:00 but ended after 20:00, it was also defined as off-hours."
89563328|NCT02633293|Experimental|Inhaled Treprostinil|Open-label access
89563329|NCT04938713|Active Comparator|AB group|"If A = Ketamine and B = Esketamine, each patient included in the study will be randomized in a sequence of administration of the two products. The AB sequence consists of patients starting with intravenous Ketamine 0,3 mg/kg in 1 hour (2 infusions separated by 6 weeks; Period 1) and continuing with intravenous Esketamine 0,15 mg/kg in 1 hour (2 infusions separated by 6 weeks; Period 2). Each patient will be monitored during the IV perfusion, and then, the next hour.~The patient will receive a total of two infusions of Ketamine and two infusions of Esketamine. Each patient will be his own witness because having received the two products without knowing which he started with. A wash-out period of one week will be observed between the two administration periods to avoid so-called carry-over effects according to which the administration of the first drug could influence the effect of the second drug administered."
89563330|NCT04938713|Other|BA group|"If A = Ketamine and B = Esketamine, each patient included in the study will be randomized in a sequence of administration of the two products. The BA sequence consists of patients starting with intravenous Esketamine 0,15 mg/kg in 1 hour (2 infusions separated by 6 weeks; Period 1) and continuing with intravenous Ketamine 0,3 mg/kg in 1 hour (2 infusions separated by 6 weeks; Period 2). Each patient will be monitored during the IV perfusion, and then, the next hour.~The patient will receive a total of two infusions of Esketamine and then two infusions of Ketamine. Each patient will be his own witness because having received the two products without knowing which he started with. A wash-out period of one week will be observed between the two administration periods to avoid so-called carry-over effects according to which the administration of the first drug could influence the effect of the second drug administered."
89563331|NCT04938401||epistaxis|Postoperative pituitary tumor group with epistaxis
89563332|NCT04938401||no epistaxis|Postoperative pituitary tumor group without epistaxis
89563333|NCT04938011|Experimental|Progesterone + 7|the transfer of day 6 blastocyst on the 7th day of progesterone supplementation
89563334|NCT04938011|Active Comparator|Progesterone + 6|the transfer of day 6 blastocysts on the 6th day of progesterone supplementation
89563335|NCT04296019|Experimental|Fruquintinib|Patients who achieved stable disease (SD) or partial response (PR) or complete response (CR) following palliative first-line treatment will receive maintenance therapy with fruquintinib.
89563336|NCT04296019|No Intervention|Observation|Patients who achieved SD or PR or CR following palliative first-line treatment will receive treatment-free observation.
89608799|NCT03586557|Experimental|Corticosteroid & Plasma Exchange|1000mg intravenous methylprednisolone daily for 3~5 days and subsequent taper, combined with plasma exchange every other day for five times in all
89563337|NCT04947215||Cases group|It includes 100 neonates who are admitted in the neonatal intensive care unit in Assiut University children hospital suffering from RDS. The cases will be subdivided into subgroups according to1. Full term or preterm, 2. Type of pregnancy (normal or complicated), 3. Mode of delivery, and 4. LPCAT1 genetic polymorphism.
89563338|NCT04947215||control group|include 60 neonates without RDS.
89563339|NCT05115565|No Intervention|Control group|When the patients are admitted to the clinic, the patient identification form and the SF-36 Quality of Life Scale will be filled by face-to-face interview method. On the morning of the operation, before the operation, the GCS, EHA and WOMAC index will be filled. After the operation, the pain during rest and movement (24., 48., 72., 96. hours and 15. days) will be evaluated with VAS. The total amount of analgesics used by the patients will be recorded by looking at the nurse observation form records where the nurses recorded the drugs they administered at the 24th, 48th, 72nd, and 96th hours after the surgery, and by asking the patients on the 15th day after discharge. The WOMAC Index will be re-administered at discharge and on the 15th day, and the VCS, ROM, and the SF-36 Quality of Life Scale on the 15th day.
89563340|NCT05115565|Experimental|Intervention group|Unlike the control group, the patients in the intervention group will be informed about TENS and the application will be made. The electrodes of TENS will be placed 2 cm below and 2 cm above the incision site. TENS settings Frequency: 100 Hz; Pulse width (duration): 150 μs; Flow Intensity (Amplitude): By adjusting it to be 30 mA, TENS will be applied 3 times a day (09.00, 13.00, 17.00) for 20 minutes during the time the patients stay in the clinic (3 days).It is planned to start the TENS application the day after the surgery.
89563341|NCT04003675||Adolescent elite athletes|Adolescent boys and girls elite athletes over 16 years of age studying at elite sport high schools in Norway.
89563342|NCT04003675||Adolescent controls|Adolescent boys and girls over 16 years of age studying at regular high schools in Norway.
89563343|NCT04003675||Trainers and leaders|Trainers (with more than 20 percent employment status) at elite sport high schools, and leaders/principals at elite sport high schools and regular high schools.
89563344|NCT03057665||Pregnant Women|Measure magnetic field versus time for fetus, using atomic biomagnetometer.
89563345|NCT04677907|Active Comparator|Cemented knee replacement|total knee replacement with cemented modular knee replacement as per current standard for total knee replacements.
89563346|NCT04677907|Experimental|Uncemented knee replacement|total knee replacement with uncemented modular knee replacement, which is CE certified and accepted in the field.
89563347|NCT03057509|Experimental|Gallium PET/MR Imaging|"Siemens PET/MR scanner at Martinos Center for Biomedical Imaging will be use.~Standard Siemens software will be used to perform image analysis and measure parameters such as SUVmean, SUVmax and MTV.~Standard LAR Octreotide will be administered.~Ga-68-DOTA-TOC that will be administered prior to PET/MR imaging at 7 days after standard LAR octreotide administration and again at 28 day.~Ga-68-DOTA-TOC will be administered as a single intravenous dose at a pre-determine dosage."
89563348|NCT05115487||Sjögren's syndrome|Subjects diagnosed with primary sjögren's syndrome according to the 2016 ACR/EULAR primary sjögren classification criteria will be included in the study.
89563349|NCT05115487||Healthy controls|
89563350|NCT04957199||Community|Individuals with or without COVID-19 in society
89563351|NCT04436887|No Intervention|Primary closure|Primary closure of midline laparotomy
89563352|NCT04436887|Experimental|Mesh closure|Sub-lay permanent mesh supported the closure
89563353|NCT05115175|Experimental|Intervention immediately|The intervention was delivered via a teen MBSR workbook and online communication across the 10-week intervention period. Participants were assigned weekly readings and activities from an MBSR workbook for teens. Topics included understanding stress, introduction to mindfulness, mindful eating and other mindfulness-based intervention principles and were recommended to be completed daily. Mindfulness-based exercises were either self-led per instructions provided in the workbook or to be completed using an audio recording directing participants' behaviors during the exercise.
89563354|NCT05115175|Experimental|Intervention in ten weeks following waitlist|This group received the same intervention as the first arm, however, the participants in arm 2 received the intervention after a 10-week waitlist period. The intervention was delivered via a teen MBSR workbook and online communication across the 10-week intervention period. Participants were assigned weekly readings and activities from an MBSR workbook for teens. Topics included understanding stress, introduction to mindfulness, mindful eating and other mindfulness-based intervention principles and were recommended to be completed daily. Mindfulness-based exercises were either self-led per instructions provided in the workbook or to be completed using an audio recording directing participants' behaviors during the exercise.
89563355|NCT03800329|Active Comparator|Snap40 Monitor|Patients randomly assigned to wear the Snap40 monitor will wear the device for 48 hours following discharge from the hospital.
89563356|NCT03800329|Placebo Comparator|No Monitor|Patients randomly assigned to not wear the Snap40 monitor will continue with their follow-up surgical care in the ordinary fashion.
89563357|NCT04946513||Group 1|Patients with femoroacetabular impingement syndrome and underwent hip arthroscopy。
89563358|NCT03058133|Other|fMRI study|
89563359|NCT04798495|Experimental|HAPPY|Single arm longitudinal design.
89563360|NCT05114707|Experimental|camrelizumab group|
89563361|NCT04937621||SARS-CoV-2 infection|This group includes patients prospectively included during their follow-up at the Bordeaux University Hospital for COVID-19, as well as retrospectively included patients whose follow-up for COVID-19 has been completed.
89563362|NCT04937855||Control group|25 gender and age matching healthy controls
89563363|NCT04937855||ARDS group 1|100 ARDS patients at the time of check in hospital
89563364|NCT04937855||ARDS group 2|100 ARDS patients at the time of 24h after check in hospital
89563365|NCT04937855||ARDS group 3|100 ARDS patients at the time of 48h after check in hospital
89563366|NCT04937855||ARDS group 4|100 ARDS patients at the time of 72h after check in hospital
89563367|NCT03572413|Experimental|Low pressure PNP, deep NMB|Low pressure pneumoperitoneum of 8 mmHg with deep neuromuscular block (post tetanic count of 1-2) reached by titration with continuous infusion of Rocuronium bromide.
89563368|NCT03572413|Active Comparator|Normal pressure PNP, moderate NMB|Normal pressure pneumoperitoneum of 12 mmHg with moderate neuromuscular block (TOF count of 1-2) reached by titration with bolus or continuous infusion of a low dose of Rocuronium bromide.
89563369|NCT04946747|Active Comparator|Trained|"Both groups will be shown how to use the Virtual Reality goggles. The Trained group will have the conditioned stimulus (CS, images of opposing players approaching) and the unconditioned stimulus (US, a voice cue to stiffen the neck by the coach) always being delivered with a consistent timing relationship (e.g. a 250 msec delay between the CS and the US), causing the conditioned response (neck stiffening) to emerge.~Both groups will also wear our smart head-impact sensor system to measure their response to training."
89563370|NCT04946747|Active Comparator|Control|Both groups will be shown how to use the Virtual Reality goggles. The Control group will also receive the same CS and the same US, but the CS and the US will bear no consistent timing relationship, therefore never causing any CR to emerge. Both groups will also wear our smart head-impact sensor system to measure their response to training.
89563371|NCT04937933|Active Comparator|Coolant spray group|Coolant spray (Cryos ®Spray, Phyto Performance, Italy) was applied as suggested by the manufacturer (at a distance of 20 cm from the injured area for 5-10 s). Saline solution was sprayed for the same duration and at the same distance from the injured area as well. The first spray application was performed after the initial assessment, and the second spray application was performed at the end of the 30th minute (immediately after the pain level/score measurement). All patients were given intravenous (IV) dexketoprofen (50 mg in 50 ml standard saline solution) in 5 minutes simultaneously with the first spray application. The physicians applied the designated treatment protocol for each treatment group. As a rescue analgesic treatment, patients were scheduled to be given IV fentanyl at a dose of 1 mcg/kg.
89563372|NCT04937933|Placebo Comparator|Placebo group|A standard saline solution in a bottle covered with opaque white paper and refrigerated at 4°C was prepared. Saline solution was sprayed for the same duration and at the same distance from the injured area as well like coolant spray application. The first spray application was performed after the initial assessment, and the second spray application was performed at the end of the 30th minute (immediately after the pain level/score measurement). All patients were given intravenous (IV) dexketoprofen (50 mg in 50 ml standard saline solution) in 5 minutes simultaneously with the first spray application. The physicians applied the designated treatment protocol for each treatment group. As a rescue analgesic treatment, patients were scheduled to be given IV fentanyl at a dose of 1 mcg/kg.
89563373|NCT04956419|Experimental|Treatment group A|SHR8008 capsule
89563374|NCT04956419|Active Comparator|Treatment group B|Fluconazole capsule
89563375|NCT04956653||Patients diagnosed with Cervical Degenerative Disease|Patients who suffered from Cervical Degenerative Disease, treated by operation for the first time and aged 18 years old or over were assigned to CDD group.
89563376|NCT04956653||Patients diagnosed with Thoracic Degenerative Disease|Patients who suffered from Thoracic Degenerative Disease, treated by operation for the first time and aged 18 years old or over were assigned to TDD group.
89563377|NCT04956653||Patients diagnosed with Lumbar Degenerative Disease|Patients who suffered from Lumbar Degenerative Disease, treated by operation for the first time and aged 18 years old or over were assigned to LDD group.
89563378|NCT04615429|Experimental|Mesenchymal Stromal cells|Approximately 1x10E6 MSC/kg
89563379|NCT04615429|Placebo Comparator|Control group|Solution identical to experimental treatment, without the MSC
89563380|NCT04956965|Active Comparator|Patient free cardiac amyloidosis|Patient with heart disease (related with rhythm disorders or conduction disorders) but free cardiac amyloidosis.
89563381|NCT04956965|Experimental|Patient with Transthyretin cardiac amyloidosis|Patient with transthyretin cardiac amyloidosis plus heart disease (related with rhythm disorders or conduction disorders).
89027409|NCT04517019|No Intervention|Arm C (no activity tracker)|"Patients receive a booklet Physical training, exercise and cancer and an in-person briefing on physical activity during cancer therapy. A fitness tracker will not be provided."
89563382|NCT05114395|Experimental|Telerehabilitation Group|"The intervention group includes a hybrid program of face-to-face sessions and video sessions. In the first consultation, a face-to-face one, patients will be instructed with behavioral and lifestyle measures and it will be prescribed a 12-week exercise program, including exercises to be performed three times a day and two weekly exercise sessions - three face-to-face sessions (2 initial and one at 8 weeks) and video sessions of 30 minutes, divided into 3 phases with gradual addition of exercises of increasing difficulty in terms of duration, number of repetitions and positions.~In the middle of the treatment (at 6 weeks) a medical teleconsultation is performed for reassessment. In the end of the 12-week program there will also be a face-to-face consultation."
89563383|NCT05114395|Active Comparator|Face-to-Face Group|The control group develops the entire program in face-to-face consultations and exercise sessions.
89563384|NCT04946669|Experimental|Refractory Dermatomyositis|Patients who have been receiving glucocorticoids in combination with at least one immunosuppressive therapy for at least 3 months and who have failed therapy or are intolerant to therapy
89563385|NCT03219775|Experimental|Nivolumab/Ipilimumab|"Induction: Mono-Therapy with Nivolumab~If CR/PR: Nivolumab Maintenance Mono-Therapy~If SD/PD: Nivolumab/Ipilimumab Boost 1+2-Combination Therapy~If CR/PR: Nivolumab Maintenance Mono-Therapy~If SD/PD: Nivolumab/Ipilimumab Boost 3+4-Combination Therapy~If CR/PR/SD: Nivolumab Maintenance Mono-Therapy"
89027410|NCT01241045||misoprostol|"2 groups:-~Group 1:-those with Ph<5. (n=50).~Group 2:-those with Ph > or=5. (n=50). -Each group is subdivided into another two groups:-~Group 1A (n=25). - Group 1B (n=25).~Group 2A (n=25). - Group 2B (n=25).~All the women in group 1A and group 2A will receive intravaginal misoprostol tablets moistened with 3 ml of 5% acetic acid, and all the women in group 1B and group 2B will receive intravaginal misoprostol tablets moistened with water, 400 micrograms every 4 hours for a maximum of 5 doses within 24 hours. If the patient will not have adequate uterine contractions, the same regimen will be repeated over the following 24 hours"
89563386|NCT05114317||Women with Lipoedema|No interventions administered.
89027411|NCT00483093|Experimental|A|
89608800|NCT03586557|Active Comparator|Corticosteroid|1000mg intravenous methylprednisolone daily for 3~5 days, and subsequent corticosteroid decrement.
89027412|NCT00483080|Experimental|A: NGR-hTNF|NGR-hTNF: 0.8 mcg/m² as 60-minutes intravenous infusion every 3 weeks or weekly
89027413|NCT00487994|Experimental|Lapaquistat Acetate 100 mg QD|
89027414|NCT00487994|Experimental|Lapaquistat Acetate 100 mg QD + Atorvastatin 10 mg QD|
89563387|NCT04946045|Experimental|İntervention (Tactile/Kinesthetic Stimulation+Nonnutritive Sucking) Group|"Tactile/Kinesthetic Stimulation (15 min): It was applied 3 times a day, once every 3 hours for 10 days.~Nonnutritive Sucking: It was applied 8 times a day for 10 days with Orogastric (OG) feeding throughout the feeding."
89563388|NCT04946045|No Intervention|Control (Nonnutritive Sucking) Group|1) Nonnutritive Sucking: Administered during feeding with Orogastric (OG) 8 times a day for 10 days.
89563389|NCT03057587||NIRS Monitoring|A NIRS sensor will be placed on the forehead of the patient upon entry to the operating room and will remain on, as tolerated, for the duration of surgery
89563390|NCT03100045|Experimental|ART 200 mg, 2 cycles|Two five-day cycles of Artesunate suppositories, 200 mg/day
89027415|NCT00487994|Active Comparator|Atorvastatin 10 mg QD|
89563391|NCT03100045|Experimental|ART 200 mg, 3 cycles|Three five-day cycles of Artesunate suppositories, 200 mg/day
89563392|NCT03100045|Experimental|ART 400 mg, 2 cycles|Two five-day cycles of Artesunate suppositories, 400 mg/day
89563393|NCT03100045|Experimental|ART 400 mg, 3 cycles|Three five-day cycles of Artesunate suppositories, 400 mg/day
89563394|NCT03100045|Experimental|ART 600 mg, 2 cycles|Two five-day cycles of Artesunate suppositories, 600 mg/day
89563395|NCT03100045|Experimental|ART 600 mg, 3 cycles|Three five-day cycles of Artesunate suppositories, 600 mg/day
89563396|NCT04956107||HIPEC cohort|Patients undergoing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal cancer with peritoneal metastases
89563397|NCT04956107||PE cohort|Patients undergoing pelvic exenteration (PE) for colorectal cancer with involvement of the urinary bladder
89563398|NCT04946123|No Intervention|methimazole (control)|Patients with hyperthyroidism under methimazole treatment
89563399|NCT04946123|Experimental|methimazole+L-carnitine+selenium (intervention)|Patients with hyperthyroidism under methimazole treatment + supplementation with L-carnitine and Selenium
89563400|NCT04945889||Geriatric inpatients at risk for sepsis|"Consecutive patients admitted to an Acute Geriatric Unit for any reason presenting at least one National Institute for Health and Care Excellence (NICE) risk factor for sepsis (age ≥75 years, impaired immune function, long-term corticosteroid therapy, immunosuppressive or antineoplastic drug treatment, surgery or other invasive procedures within 6 weeks, any breach of skin integrity, intravenous drug misuse, indwelling lines or catheters).~In those with suspected infection (i.e. antibiotic prescription and a culture test within 24 hours before-72 hours after), clinical parameters (respiratory rate, blood pressure, heart rate, body temperature, peripheral oxygen saturation, mental status) were assessed at least twice daily throughout hospital stay and used by study investigators to determine the qSOFA, NEWS and MEWS."
89563401|NCT04945811|Experimental|Interlukein 6 and procalcitonin|Interlukein 6 and procalcitonin levels in COVID 19 patients
88968067|NCT05637827||children with myopia|The refractive error and axial length of eye were observed
88968068|NCT02013492|Experimental|Treatment (propranolol hydrochloride)|Patients receive propranolol hydrochloride PO BID for 4 months in the absence of disease progression or unacceptable toxicity. Propranolol will be administered on an out-patient basis. Blood for correlative studies (30 ml - green top tube) will be drawn at baseline and at each clinic visit. Tumor tissue for analysis will be obtained via core needle biopsy (or other appropriate modality) pre-study and at approximately the two month time point.
89563402|NCT04945265||Women aged <30|
89563403|NCT04945265||Women aged 30-36|
89563404|NCT04945265||Women aged 37-40|
89563405|NCT04945265||Women aged >40|
89563406|NCT04945265||Women undergoing egg freezing/male factor infertility/genetic testing|
89563407|NCT04945265||unidentified cause of infertility|
89563408|NCT04945265||PCOS|
89563409|NCT04945265||endometriosis|
89563410|NCT04945265||tubal disorders|
88968069|NCT00122122|Other|Arm 1|
88968070|NCT00122161|Other|Arm 1|
88968071|NCT05637905||psoriatic arthritis patients group|
88968072|NCT05637905||health control group|
88968073|NCT00122356|Other|Anastrozole and alendronate|Patients will receive anastrozole for 5 years and alendronate for 3 years or anastrozole and alendronate treatment for 5 years.
88968074|NCT01720407|Experimental|Imiquimod|
88968075|NCT01720407|Placebo Comparator|Placebo|
88968076|NCT05637983|Experimental|US-guided femoral puncture|US-guided femoral puncture and Perclose ProGlide/Prostyle implantation during transcatheter aortic valve replacement (TAVR)
88968077|NCT05637983|Active Comparator|Fluoroscopy-guided puncture|Fluoroscopy-guided puncture and Perclose ProGlide/Prostyle implantation during transcatheter aortic valve replacement (TAVR)
88968078|NCT00402220|Active Comparator|1|active TMS
88968079|NCT00402220|Placebo Comparator|2|Sham TMS
88968080|NCT05638022||Newborns|Newborns matching inclusion criteria
88968081|NCT05637164|Experimental|Norepinephrine|
88968082|NCT01345578|Experimental|Hepatocyte Transplantation|See Below
88968083|NCT00129493|Other|Arm 1|
88968084|NCT00129454|Experimental|Telemedicine treatment|Psychotherapy delivered by telephone
89563411|NCT04945265||ovulatory disorders|
89563412|NCT04945265||other causes of infertility e.g., fibroids.|
88968085|NCT00129454|Active Comparator|In-Person treatment|Psychotherapy delivered in-person
88968086|NCT00129454|No Intervention|Assessment only|No intervention
88968087|NCT00129415|Experimental|UVA1 Irradiation|UVA 1 Irradiation (Sellemed UVA1 light source) up to 130 J/cm2
88968088|NCT00129415|Experimental|UVB Irridiation|UVB Irradiation maximum dose of 4000 mJ/cm2
88968089|NCT00129337|Experimental|1|0.1 mg/kg
88968090|NCT00129337|Experimental|2|0.3 mg/kg
88968091|NCT00129337|Experimental|3|1 mg/kg
88968092|NCT00129337|Experimental|4|3 mg/kg
88968093|NCT00129298|Experimental|1|Tiagabine
88968094|NCT00129298|Placebo Comparator|2|Matching placebo
88968095|NCT00936078||Non-donors/controls|Healthy normotensive people who have not donated a kidney including relatives or friends of the donor, or candidates who were ineligible to donate due to blood group or cross-match incompatibility. These non-donor/controls must meet all screening criteria (same as standard criteria donors).
89027416|NCT04516824||Trauma,Spine cases,Arthroplasty,Arthroscopy, Miscellaneous|
89027417|NCT00483158|Placebo Comparator|A|Rising Single Dose
89027418|NCT00483158|Placebo Comparator|B|Rising Multiple Dose
89027419|NCT00483158|Experimental|C|Open Label H. pylori cohort
89027420|NCT00488111|Active Comparator|1|Participants were treated with normal Ringer's solution 15 min before the operation.
89027421|NCT00488111|Active Comparator|2|6% Starch was used 15min before operation followed epidural anesthesia.
89027422|NCT02955381|Experimental|Restylane Silk, 1.0 ml|Subjects must have at least 1 but up to 3 acne scars ≥3 mm and ≤ 10 mm located on the cheeks or forehead. Subjects will receive one treatment (Restylane® Silk) in each scar (up to 3 acne scars) at day 0, and Month 1 (2 total treatments per scar during the study). Subjects will remain blinded to the treatment administered to them during these visits.
89027423|NCT02955381|Placebo Comparator|Placebo (Saline), 1.0 ml|Subjects must have at least 1 but up to 3 acne scars ≥3 mm and ≤ 10 mm located on the cheeks or forehead. Subjects will receive one treatment (Placebo (Saline)) in each scar (up to 3 acne scars) at day 0, and Month 1 (2 total treatments per scar during the study). Subjects will remain blinded to the treatment administered to them during these visits.
89563413|NCT04955561|Experimental|Randomised to begin with oxygen-supplementation at 10L/min during ESWT|Randomised order of tests starting with the 10L/min O2, during the ESWT followed by prescribed O2 flow rate or medical air in randomised order on seperate days
89563414|NCT04955561|Experimental|Randomised to begin with medical air supplementation at prescibed O2 flow rate during ESWT|Randomised order of tests starting with the medical air during the ESWT followed by prescribed O2 flow rate or 10L/min O2 in randomised order on seperate days
89563415|NCT04955561|Experimental|Randomised to begin with oxygen supplementation at prescibed O2 flow rate during ESWT|Randomised order of tests starting with the prescribed O2 flow rate, during the ESWT followed by 10L/min O2 or medical air in randomised order on seperate days
89563416|NCT04945577||Experimental: Mild Clinical Group|patients showing mild clinical symptoms without pneumonia.
89563417|NCT04945577||Experimental: Moderate Clinical Group|patients with fever, other respiratory symptoms, and pneumonia findings based on radiological imaging
89563418|NCT04945577||Experimental: severe/critical clinical group|severe one of these as follows; patients with hypoxia (≤93% oxygen saturation), respiratory distress (RR >30 times per minute), partial pressure of arterial blood oxygen (PaO 2 )/the fraction of inspired oxygen (FiO 2 ) ≤ 300 mmHg, patients whose chest imaging shows that lung damage develops significantly within 24 to 48 hours, or critical one of these as follows; respiratory failure requiring mechanical ventilation, signs of septic shock with multiple organ failure requiring intensive care unit admission.
89563419|NCT04945343|Other|Children who had growing rods instrumentation for correction of Early Onset Scoliosis|Growing spine profiler instrumentation
89563420|NCT02623829|Experimental|Botulinum Toxin|50 units of botulinum toxin diluted in 1ml of normal saline will be administered. The forehead will be injected with 12, evenly spaced and symmetrical aliquots of 0.05ml(2.5 units) and the glabella will be injected at the nasal root and the medial aspect of the corrugators with 0.1ml(5 units) each in addition to the lateral aspect of each corrugator with 0.05ml(2.5 units). The injections will be administered with a 30G needle perpendicular to the skin.
89563421|NCT02623829|Sham Comparator|Saline|1ml of normal saline will be injected with 12, evenly spaced and symmetrical aliquots of 0.05ml and the glabella will be injected at the nasal root and the medial aspect of the corrugators with 0.1ml each in addition to the lateral aspect of each corrugator with 0.05ml. The injections will be administered with a 30G needle perpendicular to the skin.
89563422|NCT04945499|Other|D-glucose|During the dynamic glucose scan, a brief hyperglycemic state was established by intravenous infusion of hospital-grade D50 glucose (D50, 25 g of dextrose in 50 mL of water sterile solution), followed by 20 mL of saline solution in 1 arm. The glucose infusion was performed using a power injector at an infusion rate of 0.2 mL/s, corresponding to total infusion times 250 seconds.
89563423|NCT04944875|Active Comparator|Group I; group headphone|In the first group of the patients in the isolation group wear the headphones but do not listen to music during the procedure. Then patients were sedated by midazolam and propofol.
89563424|NCT04944875|Active Comparator|Group II; group music|"In the second group of the patients wear the headphones and listen to Vivaldi's The Four Seasons violin concertos by sound isolating headphones during the procedure.~Then patients were sedated by midazolam and propofol."
89563425|NCT04944875|Active Comparator|Group III; group maternal voice|In the third group of the patients wear the headphones and listen the maternal voice during the procedure.Then patients were sedated by midazolam and propofol.
89563426|NCT02655679|Experimental|VTP-38543 0.05%|VTP-38543 0.05% administered topically every 12 hours for 28 days.
89563427|NCT02655679|Experimental|VTP-38543 0.15%|VTP-38543 0.15% administered topically every 12 hours for 28 days.
89563428|NCT02655679|Placebo Comparator|Vehicle without Transcutol®P|Vehicle without Transcutol®P administered topically every 12 hours for 28 days.
89563429|NCT02655679|Experimental|VTP-38543 1%|VTP-38543 1% administered topically every 12 hours for 28 days.
89563430|NCT02655679|Placebo Comparator|Vehicle with Transcutol®P|Vehicle with Transcutol®P administered topically every 12 hours for 28 days.
89563431|NCT04936295|Experimental|Fulvestrant plus Anlotinib|Each participant receives fulvestrant combined with anlotinib.
89033064|NCT02921724|Experimental|Cancer patients undergoing oral therapy|At the time of therapy prescription, patients candidate for oral therapy with capecitabine or sunitinib will be provided with informations on the side-effects of therapy and on the use and functions of the mobile diary app TreC-Onco. Patients are required to manually insert data into the mobile diary app at least once a day. Patients will be visited every 6 weeks. During the visit, the clinician will compare adherence and toxicity data entered into the mobile diary app with those directly reported by the patient and by drug accountability.
89563432|NCT04955873|Experimental|Test - Group A - Dentsply biomaterials|"Dental extraction socket treated with the combined use of the xenogenic bone granules Dentsply Sirona Symbios Xenograft Granules and the resorbable collagen membrane Dentsply Sirona Symbios Collagen Membrane SR."
89563433|NCT04955873|Active Comparator|Active comparator - Group B - Geistlich biomaterials|"Dental extraction socket treated with the combined use of the xenogenic bone granules Geistlich Bio-oss Collagen and the resorbable collagen membrane Geistlich BioGide."
89563434|NCT04955873|No Intervention|Control - Group C - Spontaneous healing|Spontaneous postextraction alveolar healing
89563435|NCT05114239|Experimental|Timolol|Timolol 0.25% applied to distal or posterior half of wound edge twice daily prior and adjunct to prior wound care.
89563436|NCT05114239|Placebo Comparator|Standard Wound Care|Petrolatum ointment
89563437|NCT04945031||cannabis-induced psychosis|
89033065|NCT04691882|Experimental|Diaphragmatic contraction|
89033066|NCT04691882|Active Comparator|Diaphragmatic relaxation|
89033067|NCT02925507||Healthy Controls|Healthy patients with no neurologic impairments or disease
89563438|NCT05113849|Experimental|Cohort A (Low-dose group)|IN-B009 (Low-dose)
89563439|NCT05113849|Experimental|Cohort B (High-dose group)|IN-B009 (High-dose)
89563440|NCT04935827||Patients initiating dialysis for end-stage kidney disease|"Patients whose start of dialysis is from 12/1/2007-11/30/2017. We use the following inclusion criteria:~Adult (>= 18 years old)~Did not die or have a transplant prior to the 90th day of dialysis~Valid medical evidence form~Medicare Part A/B as primary payer in the 30 days prior to initiating dialysis~Initiating dialysis in the USA"
89563441|NCT04944719||chronically ill adult patients colonized by streptococcus pneumoniae|At baseline, adult patients with chronic disease who are colonized with Streptococcus pneumoniae will be identified. Then, after determining the colonized subjects, monthly telephone follow-up and clinical outcome will be determined to identify patients who develop CAP or IPD. Additionally, follow-up samples similar to baseline will be taken to determine colonization by other serotypes or resolution of colonization status in these patients.
89563442|NCT04944719||chronically ill adult patients not colonized by streptococcus pneumoniae|Subjects who are not colonized with S. pneumoniae will be followed by monthly telephone follow-up and clinical outcome will be determined to identify patients who develop CAP or IPD. Additionally, follow-up samples similar to baseline will be collected every six months to determine colonization during the follow-up time in the study.
89563443|NCT04469725|Experimental|Thymic carcinoma|enrolled subjects will receive KN046 every 2 weeks.
89563444|NCT04418999|Experimental|Dexamethasone insert|Per participant, one eye will be randomized to receive the intracanalicular dexamethasone insert at the baseline visit (study eye). DEXTENZA is an ophthalmic insert that is inserted in the lower lacrimal punctum into the canaliculus at the day 1 visit by pulling the lower lid taught and using a forceps to insert the medication into the lower canaliculus through the lower punctum.
89563445|NCT04418999|Active Comparator|Loteprednol etabonate ophthalmic gel 0.38%|Per participant, one eye will be randomized to receive the standard of care topical lotemax etabonate ophthalmic gel 0.38% (control eye). Patients will be prescribed a loteprednol etabonate ophthalmic gel 0.38% and will instill one drop into the eye following a 4x/day,3x/day,2x/day,1/xday weekly taper
89563446|NCT04427527|Experimental|Multi-level Intervention|Receives the project intervention first
89563447|NCT04427527|No Intervention|Delayed Multi-level Intervention|Offered the intervention later in the project
89563448|NCT02623361|Placebo Comparator|Sham|
89563449|NCT02623361|Active Comparator|Fascia Iliaca Compartment Block|
89033068|NCT02925507||Stroke Subjects|Patients with new onset stroke for ischemic, hemorrhagic or TIA
89563450|NCT05113459|Experimental|disitamab vedotin + PD-1+Capecitabine|disitamab vedotin：2.5mg/kg,iv,d1,q2w ,6cycle PD-1: 200mg,iv,d1,q2w，6cycle Capecitabine：1000mg/m2 ,po, bid,d1-14,q3w, 4cycle
89563451|NCT04944485|Active Comparator|class V cavities treated with putty nanohybrid resin composite|Selective enamel etching will be done and a universal adhesive (Prime&Bond universal™ ,Dentsply)will be applied to both enamel and dentin. After gentle dryness and solvent evaporation the bonding agent will be cured for 20 seconds. Composite (Neo Spectra™ST, Dentsply, Sirona, USA) will be placed incrementally and light cured for 20 seconds
89563452|NCT04944485|Experimental|class V cavities treated with Self adhesive giomer containing nanohybrid flowable composite|Cleaning and gentle air blowing of the preparation. Then applying FIT SA F03 (Low Flow), SHOFU, USA. Spread in a thin layer (≤0.5mm) on the prepared surface with needle tip, microbrush and gently air-blow leave for 20 seconds then light cure for 5 seconds. Then,apply additional increments (≤2mm) of FIT SA and light cure each increment for 10 seconds then finish and polish
89563453|NCT04935983|Active Comparator|High CHO|High CHO diet for 36 h
89563454|NCT04935983|Experimental|Low CHO|Low CHO diet for 36 h
89563455|NCT04955483||Virtual single-energy imaging reconstruction group|Rebuild a virtual single energy map (70-140Kev, interval 10Kev)
89563456|NCT04955483||Virtual single energy (70-140Kev, interval 10Kev) combined with MAR reconstruction group|Rebuild a virtual single energy map (70-140Kev, interval 10Kev) combined with MAR reconstruction group
89563457|NCT04447963|Experimental|Non-invasive treatment of wrinkles and rhytids|"The subjects will be enrolled and assigned into one experimental study arm. The subjects will be required to complete three (3) treatment visits and two follow-up visits.~At the baseline visit health status will be assessed and, if needed, additional tests will be performed. Inclusion and exclusion criteria will be verified and informed consent will be signed.~The treatment administration phase consists of three (3) treatment visits, delivered 1 week apart.~At every treatment visit after the first, prior to the procedure, the participants will be assessed for adverse effects resulting from the previous treatment(s) with the BTL-785F device."
89563458|NCT04933019|Other|Clindamycin Resistance Genes among Staphylococcus Isolates by Using Real Time PCR|
89563459|NCT04933019|Other|Clindamycin sensetive Antibiotic Genes among Staphylococcus Isolates by Using Real Time PCR|
89563460|NCT05068531||Observational|We plan to recruit up to 100 mCRC patients with baseline resectable liver-restricted metastases (mCRC-LR) without evidence of extra-hepatic metastases, with primary tumor already or to be resected (metachronous or synchronous disease), planned to receive upfront FOLFOX-based preoperative neoadjuvant systemic chemotherapy, who achieved no-evidence of disease (NED) in the abdomen by standard imaging.
89563461|NCT04955093|Experimental|Intervention|
89563462|NCT04955093|No Intervention|Control|
89563463|NCT04935281||percutaneous repair with an intraoperative assissted ultrasound|a radiologist did an intraoperative ultrasound before the repair for identification the course of sural nerve and outline the medial and lateral edges of torn tendon.
89563464|NCT04935281||percutaneous repair without an intraoperative assissted ultrasound|the course of the sural nerve was determined according to the technique described by Blackmon et al .This technique depends on the leg length for location the point where the nerve crosses the lateral edge of the tendon
89563465|NCT04935515|Experimental|Mild|Patients with mild symptoms and normal CRP.
89563466|NCT04935515|Experimental|Moderate|Patients with mild symptoms and less than 10 fold increase in CRP.
89563467|NCT04935515|Experimental|Severe|Patients with high grade fever persisting even on the third or fourth day after onset of symptoms or 10 fold or more increase in CRP.
89563468|NCT04447729|Experimental|fremanezumab|Two doses, each dose consists of 4 injections with prefilled syringes
89563469|NCT04090645|Other|TheraShere in treatment of primary & secondary liver carcinoma|TheraSphere® is delivered into the liver tumor through a catheter placed into the hepatic artery. The hepatic artery provides the main blood supply to the tumor in the liver, whereas the portal vein supplies blood to normal liver parenchyma. TheraSphere® is embolized within the tumor and exerts a local beta radiation radiotherapeutic effect with a relatively limited concurrent injury to surrounding normal tissue.
89563470|NCT04932551||Physician|
89563471|NCT05110885||Individuals living in Turkey|Individuals from different regions of Turkey who meet inclusion criteria
89563472|NCT03951883|Active Comparator|Typical Diet (TD)|Participants will be instructed to continue habitual dietary intake.
89033069|NCT00531323|Other|1|Group 1 (n =12): subjects will receive TMC125 400 mg once daily for 14 days followed by 14 days of washout followed by efavirenz 600 mg once daily for 14 days followed by 14 days of TMC125 400 mg once daily
89563473|NCT03951883|Experimental|Increased Egg Consumption (IE)|Participants will be prescribed an additional 2 eggs per day to their diet.
89563474|NCT04376281|Experimental|Noradrenaline group|
89563475|NCT04932629|Experimental|Experimental Group|The eligible patients will undergo corneal transplant surgery, when the central corneal epithelium will be removed using a surgical sponge. 0.1ml of stromal cells in a concentration of 0.5x106 cells/µl diluted in the thrombin component of fibrin glue (TISEEL, Baxter) will be applied to the debrided corneal stroma.
89563476|NCT04332445|Experimental|Experimental|subjects, 18-70 y, healthy
89563477|NCT04954703|Experimental|Muscle energy technique of gluteus maximus and tensor fascia lata|INTERVENTIONAL GROUP (muscle energy technique of gluteus maximus and tensor fascia lata)
89563478|NCT04954703|Active Comparator|Myofascial release of iliotibial band|CONTROL GROUP(Myofascial release of iliotibial band)
89563479|NCT04932863||Subjects with cancer of any type and stage under active or prior medical treatment|BNT162b2 mRNA Covid-19 Vaccine as two injections, 21 days apart, of 30 μg per dose in the deltoid muscle.
89563480|NCT04278313|Experimental|PRP group|Platelet RICH Plasma prepared using RegenLab FDA approved device.
89563481|NCT04278313|Placebo Comparator|PPP group|Platelet POOR Plasma prepared using RegenLab FDA approved device.
89563482|NCT04934735|Active Comparator|The intervention group: received a complex case-management rehabilitation program|The intervention group was followed at 6, 12, 18, 24 months after entering the study. The follow-up was conducted by the case manager for patients in the intervention group, and by a research assistant for patients in the control group. Medical data were retrieved from the computerized medical records in the relevant hospitals.
89563483|NCT04934735|No Intervention|The control: group received the standard care|The control group received regular care.
88968096|NCT00936078||Living Kidney Donors|"Living kidney donors who went on to donate their kidney. All donors were recruited and are divided into 2 groups:~Standard criteria donors (meet all screening criteria)~Expanded-criteria donors (did not meet one or more of the screening criteria)~Expanded criteria donors will be examined in a separate protocol and analysis."
88968097|NCT05638100||Rivaroxaban-H|elderly patients (≥75-year-old) with NVAF administered Rivaroxaban(20mg/15mg)
89563484|NCT04232839|Experimental|T1 (Test 1)|
89563485|NCT04232839|Experimental|T2 (Test 2)|
89563486|NCT04232839|Experimental|T3 (Test 3)|
89563487|NCT04232839|Experimental|T4 (Test 4)|
89563488|NCT04232839|Experimental|T5 (Test 5)|
89563489|NCT04232839|Experimental|T6 (Test 6)|
89563490|NCT04232839|Experimental|R1 (Reference 1)|
88968098|NCT05638100||Rivaroxaban-M|elderly patients (≥75-year-old) with NVAF administered Rivaroxaban(10mg)
88968099|NCT05638100||Rivaroxaban-L|elderly patients (≥75-year-old) with NVAF administered Rivaroxaban(7.5mg)
88968100|NCT00819780|Experimental|Panitumumab Plus mFOLFOX6|Participants received 6 mg/kg panitumumab administered by intravenous (IV) infusion and modified FOLFOX6 (mFOLFOX6) chemotherapy regimen consisting of oxaliplatin (85 mg/m^2), leucovorin (400 mg/m^2) and 5-fluorouracil (5-FU) (2400 mg/m^2) administered on Day 1 of every 14-day cycle until disease progression, unacceptable toxicity, withdrawal of consent, or death.
89563491|NCT04934813|Experimental|Alveolar ridge preservation with particulated allograft covered with collagen sponge.|Alveolar ridge preservation after tooth extraction. Freeze-dried bone allograft (FDBA) was applied in the socket immediatelly after tooth extraction and it was covered with collagen sponge (CS).
89563492|NCT04934813|Experimental|Alveolar ridge preservation with particulated allograft covered with autogenous soft tissue punch|Alveolar ridge preservation after tooth extraction. Freeze-dried bone allograft (FDBA) was applied in the socket immediatelly after tooth extraction and it was covered with free gingival graft (FGG).
89563493|NCT04934813|Experimental|Alveolar ridge preservation with particulated xenograft covered with autogenous soft tissue punch|Alveolar ridge preservation after tooth extraction. Demineralized bovine bone mineral xenograft (DBBM) was applied in the socket immediatelly after tooth extraction and it was covered with free gingival graft (FGG).
89563494|NCT04934813|Experimental|Alveolar ridge preservation without bone grafting covered with socket sealing mean|Alveolar ridge preservation after tooth extraction. No bone graft was applied and the socket was covered with free gingival graft (FGG).
89563495|NCT04934423|Experimental|active tDCS|tDCS active, for 30 minutes for 5 consecutive days, with an anode positioned in the left dorsolateral prefrontal cortex and cathode electrode placed over the right supraorbital area. The EEG International 10-20 system will be taken as a reference. The current intensity will be defined from computational modeling, using Nuclear Magnetic Resonance (MRI) to estimate and individualize a dose to be administered.
88968101|NCT00819780|Active Comparator|Bevacizumab Plus mFOLFOX6|Participants received 5 mg/kg bevacizumab administered by IV infusion and the mFOLFOX6 regimen consisting of oxaliplatin (85 mg/m^2), leucovorin (400 mg/m^2), followed by 5-FU (2400 mg/m^2) administered on Day 1 of every 14-day cycle until disease progression, unacceptable toxicity, withdrawal of consent, or death.
88968102|NCT00128908|Active Comparator|Continuous triple-class therapy|Patients will be treated with a regimen containing antiretroviral agents from 3 different classes
88968103|NCT00128908|Experimental|Alternating therapy|Patients will be assigned to weekly alternating dual-class regimen
89563496|NCT04934423|Sham Comparator|Sham tDCS|The electrodes will be positioned in the same way as in the intervention group. However, individuals in this group will receive a stimulation that will last only 20-30 seconds. Subsequently, the device is switched off, no longer emitting current.
89563497|NCT03890887|Experimental|All subjects: Reference followed by Test treatments|Reference - BI 1291583 alone. Test - BI 1291583 + Itraconazole
88968104|NCT05638178||Adult|18+
88968105|NCT05638178||Pediatric|Under 18
88968106|NCT05638256|Experimental|68Ga-NY104|
89563498|NCT05098951|Experimental|Patients with stiffness of joint receive acupuncture therapy|This is a single arm study. All the enrolled patients will receive acupuncture twice weekly for 6 weeks then once weekly for another 6 weeks.
89563499|NCT04934501||PAD patients|The entire cohort exists of patients recently treated with an endovascular stent placement in the superficial femoral artery (SFA).
88968107|NCT05638451|Experimental|Sintilimab and Bevacizumab and Temozolomide|single arm study
88968108|NCT05638685||Dutch-speaking people living or working in Belgium|Every participant was asked to complete a questionnaire about the impact of a COVID-19 infection and/or the impact of lockdown measures as a result of the COVID-19 pandemic on fatigue and musculoskeletal complaints.
88968109|NCT00128713|Active Comparator|1|Lower Dose Prophylactic Platelets
88968110|NCT00128713|Active Comparator|2|Medium Dose Prophylactic Platelets
88968111|NCT00128713|Active Comparator|3|Higher Dose Prophylactic Platelets
88968112|NCT05638763|Experimental|Dasatinib and ketoconazole|Patients will receive dasatinib at a dose of 25mg orally daily for one year and ketoconazole 200mg orally two times per day for one year.
88968113|NCT00128557|Placebo Comparator|Placebo|Supplement containing soybean oil with a small amount of vitamin E as an antioxidant
88968114|NCT00128557|Active Comparator|Vitamin A|15,000 ug retinol equivalents (50,000 International Units)
88968115|NCT00128518|Experimental|Group A : T1+P2 ● P1+P2 ● T2+P1 ● P1+P2|T1 = perindopril T2 = Indapamide P1 = Placebo of T1 P2 = Placebo of T2
88968116|NCT00128518|Experimental|Group B : P1+P2 ● T1+P2 ● P1+P2 ● T2+P1|T1 = perindopril T2 = Indapamide P1 = Placebo of T1 P2 = Placebo of T2
88968117|NCT00128518|Experimental|Group C : T2+P1 ● P1+P2 ● T1+P2 ● P1+P2|T1 = perindopril T2 = Indapamide P1 = Placebo of T1 P2 = Placebo of T2
88968118|NCT00128518|Experimental|Group D : P1+P2 ● T2+P1 ● P1+P2 ● T1+P2|T1 = perindopril T2 = Indapamide P1 = Placebo of T1 P2 = Placebo of T2
89563500|NCT04111861|Experimental|Intevention|To see if singing can be used as a detractive method from patients experiencing ongoing pain.
89563501|NCT04932161|Experimental|Titanium Granules as a bone graft in intrabony defects|In test group, after reflection of flap and degranulation, bone graft i.e., titanium particles will be placed in the void created by the defect and sutures will be placed.
89563502|NCT04932161|Active Comparator|Hydroxyapatite as a bone graft in intrabony defects|In control group, after reflection of flap and degranulation, bone graft i.e., hydroxyapatite will be placed in the defect and sutures will be placed.
89563503|NCT05073523|Other|Meal A|Diet: meal proportion 1
89563504|NCT05073523|Other|Meal B|Diet: meal proportion 2
89563505|NCT05073523|Other|Meal C|Diet: meal proportion 3
89563506|NCT04934345||FC administration|"All the patients receive crystalloids at 4 ml/kg/hour as maintenance fluid during surgery, according to standard practice.~After the first episode of hypotension (MAP < 65 mmHg) the PPV is checked.~PPV ≥ 13% - FC (4 ml/kg of crystalloids administered in 10')~PPV < 13% - start norepinephrine (starting dose - 0.05 mcg/kg/min). In this group, the FC will be administered during an episode of intraoperative hypotension during NE infusion."
89563507|NCT04922177|Experimental|CAD/CAM Group|For the CAD/CAM group, an indirect ceramic restoration will be made using an optical impression.
89563508|NCT04922177|Active Comparator|Direct method Group|For the direct method group, a restoration using a Glass Ionomer Cement will be performed.
89563509|NCT03817957|Experimental|Polyglucoferron|once intravenously, dosing according to Hb-levels and body weight, 500 - 2000 mg
89563510|NCT03817957|Active Comparator|Ferric Carboxymaltose|Once intravenously (a second administration is allowed), dosing according to Hb-levels and body weight (500 - 2000 mg, max. single dose of 1000 mg)
89563511|NCT03817957|Active Comparator|Ferrous sulfate|capsules, orally, dosing 50 mg - 200 mg (50 mg: 1 capsule in total, 200 mg: 4 capsules in total, taken as 2 capsules twice daily), duration of treatment 28 days
89208551|NCT00510874|Experimental|Pumarix Formulation 1 Group|Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of formulation 1 of Pumarix™ vaccine at Day 0 and Day 21. The vaccine was administered intramuscularly in the deltoid region of the arm (non-dominant arm for the first injection and dominant arm for the second one).
89208552|NCT00510874|Experimental|Pumarix Formulation 2 Group|Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of formulation 2 of Pumarix™ vaccine at Day 0 and Day 21. The vaccine was administered intramuscularly in the deltoid region of the arm (non-dominant arm for the first injection and dominant arm for the second one).
89208553|NCT00510874|Experimental|Pumarix Formulation 3 Group|Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of formulation 3 of Pumarix™ vaccine at Day 0 and Day 21. The vaccine was administered intramuscularly in the deltoid region of the arm (non-dominant arm for the first injection and dominant arm for the second one).
89208554|NCT00510874|Experimental|Pandemrix Formulation A Group|Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of formulation A of Pandemrix™ vaccine at Day 0 and Day 21. The vaccine was administered intramuscularly in the deltoid region of the arm (non-dominant arm for the first injection and dominant arm for the second one).
89563512|NCT04922489||Patients with Astra Tech EV|Patients who has receive Astra Tech dental implant system placement.
88968119|NCT00394459|Active Comparator|A|Perifix Standard
88968120|NCT00394459|Experimental|B|Perifix New
88968121|NCT00128479|Experimental|mifepristone 300 mg|
88968122|NCT00128479|Placebo Comparator|placebo|
88968123|NCT00128479|Experimental|mifepristone 600 mg|
88968124|NCT00128479|Experimental|mifepristone 1200 mg|
88968125|NCT05638958|Experimental|Test group|A customized PEEK abutment mimicking the subgingival emergence of the extraction site will be screw-retained on the implant to seal the extraction site and to support healing of buccal soft tissues.
88968126|NCT05638958|Active Comparator|Control group|A commercially available healing abutment will be screwed on top of the implant and a collagen sponge will be used to protect the graft.
88968127|NCT05638997|Experimental|Instrument Assisted Manipulation Group|Instrument Assisted Manipulation + Core exercises
88968128|NCT05638997|Experimental|Mulligan Mobilization with Movement Group|Mulligan Mobilization with Movement + Core exercises
88968129|NCT05638997|Active Comparator|Control group|Core exercises
88968130|NCT00128401|Active Comparator|D-Cycloserine|An antibiotic, d-cycloserine (DCS) was given to one group and the group is evaluated to see if the drug boosts the effectiveness of cognitive behavior therapy (CBT) for social anxiety.
88968131|NCT00128401|Placebo Comparator|Placebo|Another group was given the placebo and tested for effectiveness of cognitive behavior therapy (CBT) for social anxiety.
89208555|NCT00510874|Experimental|Pandemrix Formulation B Group|Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of formulation B of Pandemrix ™ vaccine at Day 0 and Day 21. The vaccine was administered intramuscularly in the deltoid region of the arm (non-dominant arm for the first injection and dominant arm for the second one).
89563513|NCT04955171|Active Comparator|BEOVU|Intravitreal injection of BEOVU 3 loading injections( monthly) then under treat and extent regimen
89563514|NCT04955171|Active Comparator|Eylea|Intravitreal injection of Eylea 3 loading injections( monthly) then under treat and extent regimen
89563515|NCT05015335|Experimental|Adalimumab|Adalimumab administered subcutaneously at 40mg every 2 weeks
89563516|NCT05015335|Active Comparator|Methotrexate|Methotrexate given 10mg orally once a week.
89563517|NCT03805243|Experimental|test of sensors for somnonaute device|monitoring with sensors
89563518|NCT03805243|Experimental|test of sensors for uronaute device|monitoring with sensors
89563519|NCT03805243|Experimental|test of sensors for toconaute device|monitoring with sensors
89563520|NCT03805243|Experimental|test of sensors for cardioskin device|monitoring with sensors
89563521|NCT03805243|Experimental|test of sensors for neuronaute device|monitoring with sensors
89563522|NCT03056261|Experimental|Combined general and epidural|Combined general and epidural anesthesia in infants UNDERGOING INTESTINAL SURGERY
89563523|NCT03056261|Placebo Comparator|General anaesthesia|General anesthesia in infants UNDERGOING INTESTINAL SURGERY
89563524|NCT03534817|Experimental|Early Access CR|Participants begin cardiac rehabilitation (CR) after 1-week following discharge post-MI.
89208556|NCT00510874|Experimental|Pumarix Formulation 4 Group|Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of formulation 4 of Pumarix™ vaccine at Day 0 and Day 21. The vaccine was administered intramuscularly in the deltoid region of the arm (non-dominant arm for the first injection and dominant arm for the second one).
89208557|NCT00510874|Experimental|Pumarix Formulation 5 Group|Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of formulation 5 of Pumarix™ vaccine at Day 0 and Day 21. The vaccine was administered intramuscularly in the deltoid region of the arm (non-dominant arm for the first injection and dominant arm for the second one).
89208558|NCT00802724|Experimental|1 Classification-directed treatment|People in the Classification-directed treatment will be treated based on their direction-specific LBP classification. Treatment will consist of 3 primary components. The first component of treatment will be analysis and instruction in modification of the person's direction-specific alignment and movement strategies during symptomatic functional activities and activities in which the person uses similar strategies to those displayed with symptomatic functional activities. The second component is education about the principles of tissue injury and healing and the need to keep active. The third component is exercise prescription that consists of practice in performance of modified versions of the direction-specific impairment tests from the exam, with an emphasis on impairments that can be modified to eliminate symptoms.
89208559|NCT00802724|Active Comparator|2 Non-specific treatment|People in the Non-specific treatment will be provided treatment that incorporates treatment commonly cited in the literature for people with chronic LBP. The first component of treatment will consist of training in functional activities based on biomechanical principles. The second component will include general education about low back pain. The third component is exercise prescription that is directed at improving the strength and flexibility of the trunk and limbs.
89208560|NCT00871026|Experimental|1|CAD/CAM group, customized archwires
89208561|NCT00871026|Active Comparator|2|prefabricated archwires (superelastic)
88968132|NCT00128362|Experimental|Radio guided Sentinle node biopsy|The radiolabeled Tc-99 colloid or phytate (500 Mbq) will be injected into the primary tumor 2 hours before surgery. A localized scintiscan will then be performed to confirm the radiolabeling of the sentinel node before surgery and for documentation. Isosulphan blue dye will be injected subdermal (0.5ml) over the tumor and intraparenchymal (3-4ml) towards the axilla 10-15mins before incision.
88968133|NCT00394576|Experimental|usual care plus Internet-based nutrition module|usual care plus Internet-based nutrition module
88968134|NCT00394576|Active Comparator|usual care|usual care
88968135|NCT05639075|Experimental|Gait analysis|A gait analysis test will be performed in each patient after cataract surgery to test peripheral vision
88968136|NCT00018616|Other|1|
88968137|NCT00018655|Experimental|Arm 1|Twelve Step Facilitation
88968138|NCT00018655|Experimental|Arm 2|Integrated Cognitive Behavioral Treatment
88968139|NCT00018694|Other|Arm 1|
88968140|NCT00009789|Experimental|Radiotherapy|"Patients receive accelerated 3-dimensional (3-D) conformal radiotherapy daily 5 days a week for 3.5-6 weeks.~Cohorts of 8 patients receive escalating fractions of accelerated 3-D conformal radiotherapy until the maximum tolerated course is determined. The maximum tolerated course is defined as the course at which no more than 2 patients develop at least grade 3 dose-limiting toxicity and no more than 1 patient develops at least grade 4 dose-limiting toxicity.~Patients are followed at 3 weeks, 6 weeks, 3 months, every 3 months for 2 years, and then every 6 months for 3 years."
88968141|NCT05639387|Experimental|Group of healthy volunteers (part I)|Participants will undergo active tVNS.
88968142|NCT05639387|Sham Comparator|Group of healthy volunteers (part II)|Participants will undergo sham tVNS.
88968143|NCT00009867|Experimental|Treatment (arsenic trioxide)|Patients receive arsenic trioxide IV over 1 hour on days 1-5. Treatment repeats every 28 days for a minimum of 2 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve complete response receive 2 additional courses.
88968144|NCT05639504||NEWS2 score of 2-4|Bio-sample collection
88968145|NCT05639504||NEWS2 score of 5-6|Bio-sample collection
88968146|NCT05639504||NEWS2 score of ≥7|Bio-sample collection
89208562|NCT00802802|Experimental|Cohort I, Step 1|HIV-infected children 3 months to 36 months of age, receiving EFV and two NRTIs
89208563|NCT00802802|Experimental|Cohort II|HIV/TB-coinfected children 3 months to 36 months of age, receiving EFV, two NRTIs, and rifampin-containing anti-tuberculosis (anti-TB) therapy
89208564|NCT00802802|Experimental|Cohort I, Step 2|HIV-infected children from Cohort I who become coinfected with TB during the study. They will receive EFV, two NRTIs, and rifampin-containing anti-TB therapy
89208565|NCT00870246||1|High mobility
89208566|NCT00870246||2|Lower mobility
89208567|NCT00802958||Cohort Group 1|Subjects number 1 to 30
89208568|NCT00802958||Cohort Group 2|Subjects number 31 to 56
89208569|NCT00802958||Cohort Group 3|Subject Numbers 57 to 76
89208570|NCT00876876|Placebo Comparator|Placebo QD or BID|Placebo QD or BID
89208571|NCT00876876|Experimental|Lixivaptan QD or BID|Lixivaptan QD or BID
89208572|NCT00876954|Placebo Comparator|Placebo|Warming without increase in core temperature
89208573|NCT00876954|Active Comparator|Hyperthermia|Hyperthermia for 2,5 hours (39 °C core temperature)
89208574|NCT04898036|Experimental|Sham First, then Experimental|Participants in this group will receive the sham treatment first, then the experimental treatment.
89208575|NCT04898036|Experimental|Experimental First, then Sham|Participants in this group will receive the experimental treatment first, then the sham treatment.
89208576|NCT01565512|Placebo Comparator|saline injection|saline injection
89208577|NCT01565512|Active Comparator|Bupivacaine injection|penile block with bupivacaine
89208578|NCT00739661|Experimental|Vismodegib 150 mg|Patients received vismodegib 150 mg orally once daily until radiographically confirmed disease progression, intolerable toxicity, or withdrawal from the study.
89208579|NCT00739661|Placebo Comparator|Placebo to vismodegib|Patients received placebo to vismodegib orally once daily until radiographically confirmed disease progression, intolerable toxicity, or withdrawal from the study.
89208580|NCT04895930|Experimental|Furmonertinib Plus Anlotinib|Furmonertinib (80mg) plus Anlotinib (10mg)
89208581|NCT00615030|Experimental|Indacaterol Morning,Indacaterol Evening, Salmeterol|In period I, indacaterol 300 μg once a day in the morning delivered via single dose dry powder inhaler (SDDPI) with a placebo to salmeterol delivered via dry powder inhaler (DPI). Patients were also instructed to take evening doses of a placebo to indacaterol via SDDPI and placebo to salmeterol via DPI. In period II, patients were instructed to take morning doses of a placebo to indacaterol delivered via SDDPI and placebo to salmeterol delivered via DPI. Indacaterol 300 μg once a day in the evening delivered via SDDPI with placebo to salmeterol delivered via DPI. In period III, Salmeterol 50 μg twice daily delivered via DPI. One of the two daily doses of salmeterol was administered in the morning and second dose in the evening along with placebo matching indacaterol delivered by SDDPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
89563525|NCT03534817|No Intervention|Standard Access CR|Participants begin CR after 7-weeks following discharge post-MI, similar to the average Canadian wait time.
89563526|NCT04933799|Active Comparator|PF-06650833 + Standard of Care treatment|Subjects randomized to the PF-06650833 arm of the study will receive 400 mg PF-06650833 (2 x 200 mg tablets) of the MR formulation orally QD under fasted conditions (preferably at least 4 hours after and 1.5 hours before a meal). Subjects who cannot take tablets PO will receive PF-06650833 200 mg IR suspension formulation every 6 hours (NG tube or OG tube, or equivalent). Subjects for whom concomitant administration of a strong inhibitor of CYP3A4 (eg, ritonavir) will have the dose reduced to either 200 mg MR or IR QD. All dosing of study drug will be in addition to current hospital SOC treatment that must include treatment targeting SARS-CoV-2.
89563527|NCT04933799|Placebo Comparator|Placebo + Standard of Care treatment|Placebo will match the Active comparator in dosage form, dosage, frequency and duration.
89563528|NCT03921619|No Intervention|No Sling|Participants will perform the balance tests without any added equipment.
89563529|NCT03921619|Experimental|Sling (Dominant)|Participants will perform the balance tests with a sling on the dominant arm.
89563530|NCT04985383|Experimental|AKST1210 device|AKST1210 column will be connected in series for the duration of each hemodialysis session.
89563531|NCT03533257|Active Comparator|Active (AMX0035)|AMX0035--a combination of TUDCA and Phenylbutyrate
89563532|NCT03533257|Placebo Comparator|Placebo|Taste-matched Placebo
88968147|NCT00019708|Experimental|Treatment (tanespimycin)|Patients will receive infusions of tanespimycin analogue twice a week in weeks 1 and 3.
89563533|NCT04933409|Experimental|3D printed replica of Donor tooth|3D printed replica of Donor tooth
89563534|NCT04933409|Active Comparator|Conventional|Conventional method of autotransplantation.
89563535|NCT04574479|Placebo Comparator|Placebo|Placebo group: patients have multimodal analgesia without fascia-iliaca compartment block
89563536|NCT04574479|Experimental|Fascia iliaca block|Patients in this arm have multimodal analgesia with supra-inguinal fascia iliaca compartment block before surgery
89563537|NCT04933487|Experimental|Ankoris IOL Implantation experimental|Monolateral implantation of toric intraocular lenses Ankoris
89563538|NCT03338257|Experimental|Husky Reads Intervention|The Husky Reads curriculum includes a series of 10 lessons designed to introduce preschool-age children to MyPlate while improving fruit and vegetable literacy. Each lesson includes reading at least one children's book, an activity or game, and sometimes food tasting to complement the learning objectives. Undergraduate students enrolled in the Husky Reads service-learning course at UCONN or college students participating in a paid summer internship deliver the program. Each team of 2-3 students is assigned 2-3 early care classrooms to visit and deliver Husky Reads on a weekly basis.
89563539|NCT03338257|No Intervention|Wait list Control|Programs on the wait list for Husky Reads, participate in the pre and post intervention testing but do not receive the program.
89563540|NCT04933955|Active Comparator|biodentine|pulptomy with biodentine
89563541|NCT04933955|Active Comparator|Theracal PT|pulpotomy with Theracal PT
89563542|NCT04933955|Active Comparator|Neo Putty|pulpotomy with Neo putty
89563543|NCT02925013|Experimental|Study group|Pregnant women at delivery
89563544|NCT02925013|Other|Control group|Women in fertility age not pregnant
88968148|NCT00009906|Experimental|Arm I (imatinib mesylate)|Patients receive oral imatinib mesylate once daily.
88968149|NCT00009906|Experimental|Arm II (imatinib mesylate)|Patients receive oral imatinib mesylate twice daily.
88968150|NCT05639621|Experimental|Meaningful accompaniment|Patient who is going to undergo an endoscopic procedure and who will have a significant accompaniment by a person freely chosen by the patient and who will escort him in a visual and tactile way during the pre-procedure, intra-procedure, and post-procedure endoscopic stage.
88968151|NCT05639621|No Intervention|Usual care|Patient who is going to undergo an endoscopic procedure and who receives regular care provided by the service during the pre-procedure, intra-procedure and post-procedure stage.
88968152|NCT00009984|Experimental|Arm I (thalidomide)|Patients receive oral thalidomide once daily in the absence of disease progression or unacceptable toxicity.
88968153|NCT00009984|Experimental|Arm II (thalidomide, fludarabine phosphate)|Patients receive thalidomide as in arm I and fludarabine IV over 30 minutes on days 1-5. Treatment with fludarabine repeats every 28 days for 6 courses. Once fludarabine is completed, patients continue to receive thalidomide alone as in arm I.
89210634|NCT01075711||NIS in-house doctors|This group will be assigned to general physicians, practicing doctors and interns (in-house doctors) with an observation period of 3 months. Three subjects are expected per in-house doctor therefore altogether, 1000 in-house doctors will be obtained or appointed for the observation study.
89563545|NCT04933175|Experimental|fluzopali combined with anlotinib|Patients 18 years of age or older, 75 years of age or younger with histologically proven small cell carcinoma of the lung were assessed by radiography as having an extensive stage (according to the American Veteran Lung Cancer Association). Patients received first-line two-drug chemotherapy with standard cisplatin, carboplatin, or lobaplatin, combined with or without immunotherapy, and developed radiologically evaluated disease progression during treatment or within 6 months of completion of treatment.
89210635|NCT01075711||NIS specialists|This group will be assigned to specialists (rheumatologist) with an observation period of 9 months. Ten subjects per rheumatologist are expected therefore altogether, 500 rheumatologists will be obtained or appointed for the observation study.
89563546|NCT02370901|Experimental|Helmet|Patients will be referred to a cranial orthotist who will create a custom cranial orthotic device. They will undergo adjustments monthly. At these appointments anthropometric measurements will be done by the cranial orthotist. The orthotist will be blinded and will not be informed of which patient is involved in the study.
89563547|NCT02370901|Experimental|home therapies|Patients will be referred to a physical therapist. They will be offered education, neck stretching exercises, and repositioning techniques, and reassurance.
89563548|NCT04431167|Experimental|Living well with Lupus Group|A newly developed intervention focused on promoting lifestyle change through recommendations for structured and unstructured physical activity and healthy eating.
89563549|NCT04431167|No Intervention|Usual Care Group|This group will receive all regular medical care and advice healthy
89563550|NCT04921709||IBD Patients with Renal Involvement|"Inclusion criteria: - patients with IBD diagnosed by colonoscopy and histopathology will classify the activity of the case to mild ,moderate and severe according to Mayo classification and have renal problems .~Age (18-65 years)~Exclusion criteria: 1-patients underage of 18 2-HCV or HBV patients 3- renal patients diagnosed before diagnosis of IBD 4- diabetic or hypertensive patients 5- other autoimmune diseases such as Rheumatoid Arthritis, SLE. 6- Malignancy"
89563551|NCT04921709||IBD Patients without Renal Involvement|"Inclusion criteria: - patients with IBD diagnosed by colonoscopy and histopathology will classify the activity of the case to mild ,moderate and severe according to Mayo classification and have no renal problems .~Age (18-65 years)~Exclusion criteria: 1-patients underage of 18 2-HCV or HBV patients 3- renal patients diagnosed before diagnosis of IBD 4- diabetic or hypertensive patients 5- other autoimmune diseases such as Rheumatoid Arthritis, SLE. 6- Malignancy"
89563552|NCT04930835|Active Comparator|Conventional Loading|implants are loaded at least after two months of healing
89563553|NCT04930835|Experimental|Immediate Loading|implants are loaded the same day of surgery
89563554|NCT04976725|Experimental|Ostepathic manipulative treatment|The effects of osteopathy treatment method on the migraine
89563555|NCT04976725|Experimental|Myofascial relaxation Treatment|The effects of myofascial treatment method on the migraine
89563556|NCT04976725|Experimental|Control treatment|Control group will have just medication treatment
89563557|NCT02195947|Experimental|Antagonist and Growth hormone|HMG IM daily was administrated from day 2 of the cycle. The GnRH antagonist (Cetrotide, Serono, Geneva, Switzerland) was given when the leading follicle was from 12 to 14 mm, at a daily dose of 0.25 mg SC. Growth hormone (Norditropin, Novo nordisk) was administrated on day 6 of HMG stimulation daily in a dose of 2.5 mg S.C. till the day of hCG administration.
89563558|NCT02195947|No Intervention|Antagonist|HMG IM daily was administrated from day 2 of the cycle. The GnRH antagonist (Cetrotide, Serono, Geneva, Switzerland) was given when the leading follicle was from 12 to 14 mm, at a daily dose of 0.25 mg SC
89563559|NCT04913207|Sham Comparator|Traditional echo-fluoroscopy guided group|LAA angiography is performed with a 6F pigtail catheter in LAA at the view of RAO 30°, CAU 20° and RAO 30°, CRA 20°. Next, the outline of the LAA will be drawn on the screen according to the LAA angiography. LAmbre device size selection is based on diameters of LAA ostium and landing zone measured on LAA angiography. The process of device implantation, assessment, releasing will be carried out at RAO 30°, CAU 20°. TEE is used to check whether the residual peri-device leaks is less than 5mm. The device will be released if it passes the 'COST' standard; otherwise readjusting the implantation position, change the device size and even re-puncturing transseptal to achieve a better axis will be proceeded.
89563560|NCT04913207|Experimental|3D-CTA guided group|Patients in 3D-CTA based perimeter group will undergo CCTA examination before LAAO and a 3D model of the left atrium is reconstructed by a workstation. LAmbre device size selection is based on perimeters of LAA ostium and landing zone which are obtained by the measurement method shown previously in this protocol. After transseptal puncture, LAA angiography is performed with a 6F pigtail catheter in LAA at the tangent angle view which is obtained preoperatively by 3D-CCTA. Then, the outline of the LAA will be drawn on the screen according to the LAA angiography. The process of device implantation, assessment, releasing will be carried out at this tangent angle view. TEE is used to check whether the residual peri-device leaks is less than 5mm. The device will be released if it passes the 'COST' standard; otherwise readjusting the implantation position, change the device size and even re-puncturing transseptal to achieve a better axis will be proceeded.
89608801|NCT03586401||Childhood Cancer Survivors|"The study will be attended by 1000 families with children who have completed treatment for cancer at least 6 months before the start of the trial and undergo rehabilitation courses at the Medical and Rehabilitation Research Center Russkoe pole at least twice a year."
88968154|NCT05639660||Aflibercept group|Single arm, Aflibercept 2.0mg/0.05ml, intravitreal injection
88968155|NCT00020566|Experimental|Group 1|Patients receive 2 additional courses of VIDE induction chemotherapy (courses 5 and 6). Patients requiring radiotherapy to the axial tumor also undergo concurrent radiotherapy 5 days a week. Some patients may then undergo surgical resection of the tumor. All patients will then receive vincristine IV on day 1 and dactinomycin IV and ifosfamide IV over 3 hours on days 1 and 2 (VAI). Treatment repeats every 21 days for 8 courses (courses 7-14). Patients requiring radiotherapy to the brain and/or spinal cord also undergo concurrent radiotherapy.
88968156|NCT00020566|Experimental|Group 2, arm I|Patients undergo 2 additional courses of VIDE induction chemotherapy (courses 5 and 6). Some patients may then undergo surgical resection of the tumor. All patients receive VAI chemotherapy as in group 1 for 1 course. Patients then receive 7 additional courses of VAI chemotherapy (courses 8-14). Patients with unresectable, partially resected, or inadequately resected disease undergo concurrent whole-lung radiotherapy for 6-12 days.
89033070|NCT00531323|Other|2|Group 2 (n = 12): TMC125 200 mg twice daily for 14 days followed by 14 days of washout followed by efavirenz 600 mg once daily for 14 days followed by 14 days of TMC125 200 mg twice daily
89210636|NCT00820508|Experimental|1|Oral, once daily administration of CHR-2845 to determine safety and tolerability
89210637|NCT00907062|Experimental|Gingko biloba|60 mg of Ginkgo biloba (standardized to 15 mg ginkgofavonglycosides) given 2 times per day, with food, for 12 weeks.
89210638|NCT01073371|Active Comparator|liposome-encapsulated 3% prilocaine|
88968157|NCT00020566|Experimental|Group 2, arm II|Patients undergo 2 additional courses of VIDE induction chemotherapy (courses 5 and 6). Some patients may then undergo surgical resection of the tumor. All patients receive VAI chemotherapy as in group 1 for 1 course. Patients then receive high-dose chemotherapy comprising oral busulfan every 6 hours on days -6 to -3 and melphalan IV over 30 minutes on day -2. Patients receive autologous PBSC IV on day 0. Patients with unresectable, partially resected, or inadequately resected disease undergo concurrent radiotherapy 5 days a week for at least 5 weeks.
88968158|NCT00020683|Experimental|Arm I (low dose incyclinide)|"Patients receive low-dose oral COL-3 once daily.~Treatment on both arms continues in the absence of disease progression or unacceptable toxicity. Quality of life is assessed."
88968159|NCT00020683|Experimental|Arm II (high dose incyclinide)|"Patients receive high-dose oral COL-3 once daily.~Treatment on both arms continues in the absence of disease progression or unacceptable toxicity. Quality of life is assessed."
88968160|NCT05639738|Other|All subject|Clinical and instrumental measurements
88968161|NCT00020761|Experimental|Gastro Esophogeal cohort|"Patients with adenocarcinoma of the esophagus, gastroesophageal (GE) junction and gastric cardia (GE cohort)~The course length is 3 weeks. Treatment will continue until one or more of criteria listed in the protocol are met.~Irinotecan 225 mg/m2 will be infused over 90 minutes every three weeks.~Paclitaxel 100 mg/m2 will be infused over three hours following irinotecan infusion every three weeks."
88968162|NCT00020761|Experimental|Distal Stomach cohort|"Patients with adenocarcinoma of the rest of the stomach (Distal Stomach cohort)~The course length is 3 weeks. Treatment will continue until one or more of criteria listed in the protocol are met.~Irinotecan 225 mg/m2 will be infused over 90 minutes every three weeks.~Paclitaxel 100 mg/m2 will be infused over three hours following irinotecan infusion every three weeks."
88968163|NCT05639816|Experimental|saline irrigation group|The patients received saline irrigation of common bile duct after complete ERCP stone removal confirmed by occluded cholangiogram
88968164|NCT05639816|No Intervention|control|The patients whom complete ERCP stone removal confirmed by occluded cholangiogram were follow up according to standard treatment
88968165|NCT00020878|Experimental|Study|See intervention description.
88968166|NCT05639855|Experimental|Third year students of the Bachelor's Degree in Occupational Therapy|Third-year students of the Bachelor's Degree in Occupational Therapy will receive training on a specific module on mental health and stigma in the university curriculum.
88968167|NCT05639855|No Intervention|Students of University of A Coruña|The students of the University of A Coruña will take part in an online survey to find out the attitudes and beliefs of future professionals from different areas of knowledge regarding mental health.
88968168|NCT05639855|No Intervention|People with mental health disorder|Users of a Psychosocial and Labor Rehabilitation Centers in the A Coruña Health Care Area will take part in interviews to find out their experiences regarding the attributions made towards them by citizens and health professionals.
88968169|NCT00021073|Experimental|Treatment (alvocidib, combination chemotherapy)|"Group I: Patients receive FLAVO IV over 24 hours on day 1 and CF IV and 5-FU IV over 1.5 hours daily on days 2-5. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of FLAVO and 5-FU until the MTD are determined. The MTD is defined as the dose preceding that at which at least 2 of 6 patients experience dose-limiting toxicity.~Once the MTDs for FLAVO and 5-FU are determined, patients receive FLAVO, CF, and 5-FU as in group I plus irinotecan IV over 1.5 hours on day 1. Courses repeat as in group I. Cohorts of 3-6 patients receive escalating doses of irinotecan until the MTD is determined. The MTD is defined as in group I."
88968170|NCT00021151|Experimental|Alemtuzumab|
88968171|NCT00010218|Experimental|karenitecin|"Patients receive karenitecin IV over 60 minutes on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with responding disease after 6 courses may receive 2 additional courses beyond best response.~Patients are followed every 3 months for 1 year and then every 6 months thereafter."
88968172|NCT00010335|Experimental|1|Participants will receive a stem cell transplant.
88968173|NCT00000134|Experimental|intravenous foscarnet|intravenous foscarnet reinduction at 90 mg/kg twice daily for 2 weeks, followed by maintenance therapy at 120 mg/kg/day
88968174|NCT00000134|Active Comparator|intravenous ganciclovir|intravenous ganciclovir reinduction at 5 mg/kg twice daily for 2 weeks followed by maintenance at 10 mg/kg/day
88968175|NCT00000134|Active Comparator|combination therapy|combination therapy, wherein patients continued their previous therapy and were reinduced with the second drug and then placed on maintenance therapy with foscarnet at 90 mg/kg/day and ganciclovir at 5 mg/kg/day.
88968176|NCT00394810|Experimental|1|
88968177|NCT00388544|Experimental|1|
88968178|NCT00388544|Experimental|2|
88968179|NCT00388544|Experimental|3|
88968180|NCT00388544|No Intervention|4|Recreational activities are not tailored to either style of interest or function
88968181|NCT00021814|Placebo Comparator|Placebo|Doxazosin and Finasteride placebos
88968182|NCT00021814|Experimental|Doxazosin|Doxazosin and Finasteride placebo
88968183|NCT00021814|Experimental|Finasteride|Doxazosin placebo and Finasteride
88968184|NCT00021814|Experimental|Combination|Doxazosin and Finasteride
88968185|NCT00388661|Active Comparator|Melatonin|melatonin 3mg
88968186|NCT00388661|Placebo Comparator|Placebo|
88968187|NCT00022087|Experimental|Zoledronic acid initial tx|Zoledronic acid + calcium + Vit D for 2 years, followed by Calcium + vit D for 1 year
88968188|NCT00022087|Experimental|Calcium + Vit D initial Tx|Calcium + vitamin D for 1 year followed by zoledronic acid + calcium + vit D for 2 years
88968189|NCT00388700|Experimental|GM-CT-01|
88968190|NCT00022126|Experimental|Modified Augmented BFM Therapy|
88968191|NCT00022165|Placebo Comparator|Placebo|Selenium yeast
88968192|NCT00022165|Experimental|Selenium yeast 100 micrograms per day|100 micrograms per day
88968193|NCT00022165|Experimental|Selenium yeast 200 micrograms per day|200 micrograms per day
89563561|NCT01698307|Active Comparator|Enhanced Treatment Algorithm|The Enhanced algorithm features the early use of combined antimetabolite/adalimumab therapy, and treatment intensification based on ileocolonoscopic findings. Failure to achieve or sustain Deep Remission, which includes sustained normalization of the imaging studies, will result in treatment intensification, according to the steps outlined in the algorithm, irrespective of symptoms.
89563562|NCT01698307|Other|Conventional Step-care Algorithm|Step-care algorithm that specifies treatment escalation solely on the basis of symptoms quantified using the Harvey Bradshaw Index (HBI).
89563563|NCT03054545|Experimental|Iguratimod treating group|Iguratimod 25mg twice a day, oral administrated.
89563564|NCT04111757|Experimental|Technolas TENEO 317 Model 2|One or both eyes of participants will undergo LASIK surgery with the Technolas® TENEO 317 Model 2 (version 1.28 US software) Excimer Laser on Day 0.
89563565|NCT05119153|Placebo Comparator|Placebo Comparator|Placebo composed of water and caramel color.
89563566|NCT05119153|Experimental|Light Roasted Coffee|12 oz light roast coffee beverage prepared at 55 g ground coffee/L water
89563567|NCT05119153|Experimental|Medium Roasted Coffee|12 oz medium roast coffee beverage prepared at 55 g ground coffee/L water
89563568|NCT05119153|Experimental|Dark Roasted Coffee|12 oz dark roast coffee beverage prepared at 55 g ground coffee/L water
88968194|NCT00022165|Experimental|Selenium yeast 300 micrograms per day|300 micrograms per day
88968195|NCT00388739|Active Comparator|Usual care|Systemic steroids (4 days of prednisone, 1mg/kg/dose to a maximum of 40 mg/dose to be given twice a day). Subjects will also receive standardized discharge medication instructions for using albuterol nebulizer treatments: they will receive a prescription for 2.5mg of albuterol in 3cc Normal Saline for aerosol use via compressor every 3 times a day as a chronic care regimen if they are either in the treatment arm and 1-5 years of age or if they are in the control group and already own a nebulization compressor. Children in the control group that do not own a nebulization compressor will be given a prescription for an albuterol MDI with mask and spacer with instructions to deliver 2 puffs (90mcg per actuation) 3 times a day as a standard chronic care regimen. Instructions to follow-up with their primary care physician in 3-5 days (as is standard care practice) will be given at discharge for patients in the control or treatment arm.
88968196|NCT00388739|Experimental|Usual care + 6 months of inhaled steroids|In addition to the usual care described above, patients randomized to the intervention/experimental arm will also be given a one month supply as well as a prescription (for a 6 month supply) for Budesonide respules (children with mild persistent disease will receive 0.25 mg bid whereas children with moderate or severe persistent disease will receive 0.5 mg bid).
88968197|NCT00010608|Experimental|Transcendental Meditation program|A mental technique for stress reduction which is natural, easy and effortless and is practiced sitting in a chair with eyes closed for 20 minutes twice a day.
88968198|NCT00010608|Active Comparator|Health Education|A lifestyle modification program for improving diet, exercise, salt intake and substance use.
88968199|NCT00022399|Experimental|Celecoxib|Participants receive celecoxib 400mg by mouth twice daily for 4 to 6 weeks prior to standard-of-care prostatectomy.
89563569|NCT04930757||Patients with SARS-CoV-2 infection confirmed by RT-PCR from a nasopharyngeal swab.|Patients hospitalized in intensive care with SARS-CoV-2 infection confirmed by RT-PCR from a nasopharyngeal swab.
88968200|NCT00022399|Placebo Comparator|Placebo-control|Participants receive placebo for 4 to 6 weeks prior to standard-of-care prostatectomy.
88968201|NCT00000143|Experimental|Ganciclovir implant and oral ganciclovir|Ganciclovir device and oral dose of Ganciclovir 1 gm three times daily
88968202|NCT00000143|Experimental|Cidofovir IV (Intravenous)|cidofovir intravenous (IV) start off with 5 mg/kg once weekly for two doses then followed by 5 mg/kg every other week
88968203|NCT00022477|Experimental|BMS-247550|IV administration of BMS-247550 once every 21 days
88968204|NCT00022555|Experimental|Treatment (bryostatin 1, vincristine sulfate)|Patients receive bryostatin 1 IV continuously on days 1 and 15 and vincristine IV over 5 minutes on days 2 and 16. Treatment continues every 4 weeks for a minimum of 2 courses in the absence of disease progression or unacceptable toxicity.
89210639|NCT01073371|Active Comparator|3% plain prilocaine|
89210640|NCT01073371|Active Comparator|3% prilocaine with 0,03IU/mL felypressin|
89563570|NCT04954339|Experimental|Atezolizumab plus Bevacizumab|Two cycles of naeoadjuvant atezolizumab (1200 mg) plus bevacizumab (15 mg/kg) prior to surgical resection and four cycles of adjuvant atezolizumab (1200 mg) plus bevacizumab (15 mg/kg) after the surgery will be administered.
89563571|NCT04930523|Active Comparator|Decompression|It include the pre- Physiotherapy treatment than decompression and post physiotherapy treatment.
89563572|NCT04930523|Experimental|Experimental|It includes the Pre physiotherapy treatment than ELDOA positions are guided and performed by patients before decompression Low back exercises guided i.e. knee to chest, pelvic rolling, bridging, SLR, piriformis exercises is guided for home plan along with precaution and Decoarctation of (C0/C1/C2),(C4/C5),(C5,C6),(C6/C7),(T4/T5),(T6/T7),(T8,/T9),(L4/L5),(L5/S1) then Neuro-oxy motorized lumbar spinal decompression therapy for 25 minutes and at last Post physiotherapy treatment
89563573|NCT04304833|Active Comparator|Provider-Based Care Model Arm|Non-connected home vital sign equipment will be given to patients in this group. The patients in the group will be instructed to record their daily readings on a paper log provided by the research team. These monitoring devices will not transmit readings to a centralized location and no one will be alerted to out-of-range readings or compliance with taking daily vital sign measures. At the front page of the log, normal ranges will be described with brief instructions about what participants/caregivers should do if their readings are out-of-range. Logs will be collected at baseline, 3-months and 6-months.
89563574|NCT04304833|Experimental|mHealth Model Arm|Connected home vital sign equipment (mHealth) will be given to patients in this group. The patients will be instructed to take their daily readings, which will automatically be sent to the secure cloud-based software. If the readings are out-of-range, the Registered Nurse (RN) Call Center will be automatically alerted and the event will be triaged. Daily measures and medical follow-up from the measures will be counted and collected at baseline, 3-months, and 6-months.
89563575|NCT04912661|Active Comparator|Immediate iron treatment|intravenous iron carboxymaltose before vaccination
89563576|NCT04912661|No Intervention|No iron treatment|no intravenous iron carboxymaltose before vaccination
89563577|NCT04391959|Experimental|AZR-MD-001 Vehicle|AZR-MD-001 Vehicle will be dosed up to twice weekly.
89563578|NCT04391959|Experimental|AZR-MD-001 Active|AZR-MD-001 Active will be dosed up to twice weekly.
89563579|NCT03429985|Experimental|FRRM Intervention|The experimental arm will receive the FRRM intervention.
89563580|NCT03429985|No Intervention|Control|The control arm will not receive the FRRM intervention.
89563581|NCT04921319|Experimental|VExUS-Guided Arm|Will receive 24 hour fluid balance target based on daily VExUS score.
89563582|NCT04921319|No Intervention|Usual Care Control Arm|Treating team will be blinded to results of daily VExUS score and will set 24 hour fluid balance target based on usual care.
89563583|NCT04939831|Experimental|1|the group of LRH
89563584|NCT04939831|Active Comparator|2|the group of ARH
89563585|NCT04921085||adult inpatients|adult inpatients with 7 categories of diseases (including digestive system, respiratory system, cardiovascular and endocrine system, tumor, nervous system, and urinary system)
89563586|NCT03357523|Experimental|Red LED|Light emitting diodes, 633 nm, 70 mW/cm2, Omnilux new-U (Red LED) (Photomedex, Horsham, PA, USA); RESPeRATE; Heating bag
89563587|NCT03357523|Active Comparator|Near Infrared LED|Light emitting diodes, 830 nm, 55 mW/ cm2, Omnilux new-U (Near infrared LED) (Photomedex, Horsham, PA, USA); RESPeRATE metronome; Heating bag
88968205|NCT04733287|Experimental|Effect of High Intensity Interval Training|"Young and older subjects will participate in single-leg, high-intensity interval training of the right knee extensors (4 intervals of 4 minutes at 80% of max aerobic power with 4 minute rest intervals between, 3x per week for 6 weeks).~Muscle function and knee extensor critical power will be measured before and after the 6 weeks of treatment."
88968206|NCT04733287|Experimental|Effect of Muscle Heat Therapy|"Young and older subjects will participate in single-leg,heat therapy training of a single leg ( quadriceps femoris, 120 minutes of shortwave diathermy to raise the muscle temperature to ~39C) 3 times a week for 6 weeks.~Muscle function and knee extensor critical power will be measured before and after the 6 weeks of treatment."
88968207|NCT04733287|Sham Comparator|Effect of Sham Muscle Heat Therapy|"Young and older subjects will participate in a sham treatment of single-leg,heat therapy training of the right knee extensors (120 minutes with shortwave diathermy unit positioned on leg, but not turned on) 3 times a week for 6 weeks.~Muscle function and knee extensor critical power will be measured before and after the 6 weeks of treatment."
88968208|NCT04733287|Sham Comparator|Effect of Immobilization with Daily Sham Heat Therapy|"Young subjects (18-35 years) will undergo 2 weeks of leg immobilization while receiving 2 hours of a sham heat therapy treatment each day. For the sham treatment, the heating device will be applied to the limb, but, unbeknownst to the participant, it will not be turned on.~Muscle function and knee extensor critical power will be measured before and after the 2 weeks of leg immobilization."
88968209|NCT04733287|Experimental|Effect of Immobilization with Daily Heat Therapy|"Young subjects (18-35 years) will undergo 2 weeks of leg immobilization while receiving 2 hours of heat therapy treatment each day. Heat therapy will consist of 120 minutes of shortwave diathermy to raise the quadriceps femoris muscle temperature to ~39C.~Muscle function and knee extensor critical power will be measured before and after the 2 weeks of leg immobilization."
88968210|NCT00394849|Experimental|suture one tonsillar fossa|Intervention: one tonsillar fossa was sutured. One side was not sutured. Pain was compared side to side.
88968211|NCT00394849|No Intervention|One side not sutured|Intervention: one tonsillar fossa was sutured. One side was not sutured. Pain was compared side to side.
88968212|NCT00022711|Experimental|Temozolomide|Temozolomide 150mg/m2/day daily. Repeat cycles every 28days for maximum of six months
88968213|NCT00394966|Experimental|SCH 619734 Dose 1|
88968214|NCT00394966|Experimental|SCH 619734 Dose 2|
88968215|NCT00394966|Experimental|SCH 619734 Dose 3|
88968216|NCT00394966|Experimental|SCH 619734 Dose 4|
88968217|NCT00394966|Placebo Comparator|Placebo|
88968218|NCT00000170|Active Comparator|Patching|
88968219|NCT00000170|Active Comparator|Atropine|Atropine
88968220|NCT00023374|Experimental|Rifampin+PZA+Ethambutol|6 mos of intermittent (2 or 3 times weekly) therapy with REZ
88968221|NCT00023647|Experimental|Synchrotope TA2M, 800 micrograms|Tyrosinase peptides, 800 micrograms
88968222|NCT00023647|Experimental|Synchrotope TA2M, 200 micrograms|Tyrosinase peptides, 200 micrograms
88968223|NCT00023647|Experimental|Synchrotope TA2M, 400 micrograms|Tyrosinase peptides, 400 micrograms
88968224|NCT00023686|Experimental|surgery|"Patients undergo radical prostatectomy.~Patients are followed every 6 months for 5 years and then annually thereafter."
89563588|NCT04912349|Experimental|Test Group|Patients received the transurethral split of the prostate(TUSP) treatment.
89563589|NCT04912349|Active Comparator|Control Group|Patients received the transurethral resection of the prostate(TURP) treatment.
89563590|NCT04406207||Patients|Patients relapsing or not after hematopoietic stem cell transplantation.
89563591|NCT04509739|Experimental|Music intervention|"At 9 months of age, families will start the 12 - session intervention in a controlled laboratory space. In the initial session, caregivers will be given a brief orientation to intervention, including introducing them to the musical toys they will be using during the sessions with their infants and the lab environment. They will also be trained techniques through which they can synchronize the infant's movements to the experimenter's movements, such as clapping hand, tapping feet.~The remaining sessions will be scheduled in groups of 2-3 infant/parent dyads. In each session, a music CD with 15 minutes of selected children's music will be played and a musically trained experimenter will facilitate the sessions to engage the infants and parents to move to musical beats, using different musical toys, such as infant drums and maracas. Parents will be instructed to not to repeat any of these activities outside of the lab setting for the period of the study."
89563592|NCT01966263|Active Comparator|Local Infiltration Analgesia (LIA)|local infiltration analgesia is an anesthetic technique that consists of the infiltration of operated tissue with a long acting local anesthetic during surgery to achieve postoperative pain relieve. In this study LIA of the knee will exist of: 1. local infiltration analgesia (LIA) of the posterior capsule of the knee, 2. LIA of the anterior capsule of the knee and 3. LIA of the subcutaneous tissue of the knee
89563593|NCT01966263|Active Comparator|Femoral Nerve Block (FNB)|"a femoral nerve block is an anaesthetic technique that consists of anesthetizing the femoral nerve proximal of the operating area to achieve numbness distal of the block puncture site. A catheter can be placed, so the nerve can be anesthetized continuously or repeatedly for post-operative pain relieve.~In this study the FNB with catheter will be combined with local infiltration analgesia (LIA) of the posterior capsule of the knee"
89563594|NCT04930679|Experimental|Group I|1 capsule of Andiabet x 3 times/ day . Taken 30 minutes before meals in 28 days
89563595|NCT04930679|Experimental|Group II|2 capsule of Andiabet x 3 times/ day . Taken 30 minutes before meals in 28 days
89563596|NCT04436185|No Intervention|Characteristics of newborns included|Characteristics of newborns included in the randomized controll
89563597|NCT04436185|Experimental|Intraclass Correlation between the NIPS Score of Parent, Nurse|Intraclass Correlation between the NIPS Score of Parent, Nurse
89563598|NCT04436185|Experimental|Comparisons of procedural pain scores among groups|Comparisons of procedural pain scores among groups
89563599|NCT04400201|Experimental|Remimazolam Tosilate|
89563600|NCT04400201|Active Comparator|Propofol|
89563601|NCT05434845|No Intervention|UA and PC ratio on original sample|Original urine sample
88968225|NCT00023686|Experimental|radiation|"Patients undergo brachytherapy with implanted iodine I 125 or palladium Pd 103 seeds.~Patients are followed every 6 months for 5 years and then annually thereafter."
88968226|NCT00391404|Active Comparator|Alendronate|Oral alendronate 70 mg weekly
88968227|NCT00391404|Placebo Comparator|Placebo|Conventional drug treatment
89563602|NCT05434845|Active Comparator|UA and PC ratio with 1 mL of whole blood added|1 mL of whole blood added to 20 mLs of urine
89563603|NCT05434845|Active Comparator|UA and PC ratio with 2 mL of whole blood added|2 mL of whole blood added to 20 mLs of urine
88968228|NCT00011037|Experimental|1|Participants will receive ALVAC-HIV vCP1452 at 0, 1, 3, and 6 months and MN rgp120 and Months 3 and 6
88968229|NCT00011037|Experimental|2|Participants will receive ALVAC-HIV vCP1452 at 0, 1, 3, and 6 months and MN rgp120 placebo and Months 3 and 6
88968230|NCT00011037|Placebo Comparator|3|Participants will receive ALVAC-HIV vCP1452 placebo at 0, 1, 3, and 6 months and MN rgp120 placebo and Months 3 and 6
88968231|NCT00023920|Experimental|Treatment (bevacizumab, idarubicin, cytarabine)|Patients receive bevacizumab IV over 90 minutes once on day -13. Patients then receive bevacizumab IV over 90 minutes and idarubicin IV on days 1 and 15 and cytarabine subcutaneously (SC) once daily beginning on day 1. Treatment repeats every 4 weeks for a maximum of 3 courses. Patients with responding disease receive maintenance therapy comprising bevacizumab IV over 90 minutes on days 1 and 15, idarubicin IV on day 1, and cytarabine SC once daily beginning on day 1. Treatment repeats every 4 weeks for 2 years in the absence of disease progression or unacceptable toxicity.
88968232|NCT00023959|Experimental|Treatment (hydroxyurea, fluorouracil, bevacizumab, radiation)|Patients receive oral hydroxyurea every 12 hours on days 1-6, fluorouracil IV continuously on days 1-5, and bevacizumab IV over 90 minutes on day 1. Patients also undergo radiotherapy once daily on days 1-5. Patients receive G-CSF subcutaneously on days 6-12. Treatment repeats every 2 weeks for up to 7 courses in the absence of disease progression or unacceptable toxicity.
88968233|NCT00023998|Experimental|Treatment (combination chemotherapy)|See detailed description.
88968234|NCT00024154|Experimental|Treatment (trastuzumab, gefitinib)|"Phase I (completed): Patients receive trastuzumab (Herceptin) IV over 30-90 minutes once weekly and oral gefitinib once daily beginning on day 1.~Cohorts of 3-6 patients receive escalating doses of gefitinib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is established, additional patients are accrued to the phase II portion of the study and are treated at that dose.~Phase II: Patients receive oral gefitinib once daily (at the MTD established in phase I) and trastuzumab IV weekly until week 24, at which time trastuzumab is given every 3 weeks (with daily gefitinib) until disease progression or unacceptable toxicity."
88968235|NCT00000251|Placebo Comparator|Placebo|Subjects inhale 100% oxygen
88968236|NCT00000251|Active Comparator|30% N2O|Subjects inhale 30% N2O
89563604|NCT05434845|Active Comparator|UA and PC ratio with 5 mL of whole blood added|5 mL of whole blood added to 20 mLs of urine
89563605|NCT04920773|Experimental|Ayurveda Care Group|Practice guidelines to follow physical distancing, respiratory and hand hygiene, wear mask Samshamani vati or Giloy Ghanavati
89563606|NCT04920773|Active Comparator|Usual Care Group|Practice guidelines to follow physical distancing, respiratory and hand hygiene, wear mask
89563607|NCT04423107|Active Comparator|No opioid|Acetaminophen every 6 hours and Ibuprofen every 6 hours
89563608|NCT04423107|Active Comparator|Opioid|Acetaminophen every 6 hours, Ibuprofen every 6 hours, and Oxycodone every 6 hours as needed for breakthrough pain for 10 doses.
89563609|NCT01675531|Experimental|Targin|Targin
89563610|NCT04920851||Covid with sepsis|Covid patient with sepsis
89563611|NCT04920851||covid without sepsis|Covid patient without sepsis
89563612|NCT05406999|Active Comparator|ADT alone + prostatectomy|A total of 100 subjects receive ADT for 6 cycles (28 days per cycle) before prostatectomy. Robot-assisted radical prostatectomy was performed within 2 weeks after the end of the therapy.
89563613|NCT05406999|Experimental|ADT plus Abiraterone|A total of 150 subjects in this group received abiraterone acetate + prednisolone acetate daily for 6 cycles along with ADT. Robot-assisted radical prostatectomy was performed within 2 weeks after the end of the therapy.
89563614|NCT05406999|Experimental|ADT plus Enzalutamide|A total of 50 subjects in this group received enzalutamide daily for 6 cycles along with ADT. Robot-assisted radical prostatectomy was performed within 2 weeks after the end of the therapy.
89563615|NCT05406999|Experimental|ADT plus Apalutamide|A total of 150 subjects in this group received apalutamide daily for 6 cycles along with ADT. Robot-assisted radical prostatectomy was performed within 2 weeks after the end of the therapy.
89563616|NCT05406999|Experimental|ADT plus Darotamide|A total of 150 subjects in this group received darotamide daily for 6 cycles along with ADT. Robot-assisted radical prostatectomy was performed within 2 weeks after the end of the therapy.
89563617|NCT05406999|Experimental|ADT plus Rizvilutamide|A total of 150 subjects in this group received rizvilutamide daily for 6 cycles along with ADT. Robot-assisted radical prostatectomy was performed within 2 weeks after the end of the therapy.
89563618|NCT05406999|Experimental|PARP inhibitor + abiraterone + ADT|A total of 100 subjects in this group received Poly ADP-ribose Polymerase (PARP) Inhibitor plus abiraterone along with ADT. Robot-assisted radical prostatectomy was performed within 2 weeks after the end of the therapy.
88968237|NCT00000251|Active Comparator|0.2% isoflurane|Subjects inhale 0.2% isoflurane
88968238|NCT00000251|Active Comparator|0.4% isoflurane|Subjects inhale 0.4% isoflurane
88968239|NCT00000251|Active Comparator|0.2% isoflurane + 30% N2O|Subjects will inhale a combination of 0.2% isoflurane and 30% N2O
88968240|NCT00000251|Active Comparator|0.4% isoflurane + 30% N2O|Subjects will inhale a combination of 0.4% isoflurane and 30% N2O
88968241|NCT00000257|Active Comparator|Light drinkers|
88968242|NCT00000257|Active Comparator|Moderate drinkers|
88968243|NCT00024466|Experimental|Vaccine|Participants are vaccinated with GVAX one month or more after finishing induction therapy (which is given as per standard of care). Two weeks later, participants go through leukapheresis on protocol, then receive autologous transplant as per standard of care. GVAX is administered eight subsequent times after the autologous transplant.
88968244|NCT04733131||converted to a belatacept based immunosuppression|Belatacept: infusion on Days 1, 15, 29, 43, 57 then every 28 days. All patients received a background maintenance immunosuppressive regimen of mycophenolate mofetil or mycophenolic acid, with adjunctive corticosteroids, according to their immunosuppressive regimen at the time of enrollment.
88968245|NCT00000359|Experimental|Canalith repositioning maneuver|Repositioning treatment for posterior canal BPPV
88968246|NCT00000359|Experimental|Modified Epley maneuver|
88968247|NCT00000359|Sham Comparator|Sham|The subject sat in a chair; the head was passively tilted downward, turned away from the involved side, turned back to center, upward, away from the involved side, twice, slowly.
89563619|NCT05406999|Experimental|PARP inhibitor + ADT|A total of 50 subjects in this group in this group received Poly ADP-ribose Polymerase (PARP) Inhibitor along with ADT mentioned above. Enrolled patients carry homologous recombination repair (HRR) gene mutation verified by molecular testing. Robot-assisted radical prostatectomy was performed within 2 weeks after the end of the therapy.
88968248|NCT00000359|Active Comparator|Liberatory maneuver|The standard liberatory maneuver (also known as the Semont maneuver) was used.
89563620|NCT05118607|Other|Intervention (IG1)|application of low intensity transcutaneous penile electrical stimulation for 45 minutes using frequency
89563621|NCT04930211|Active Comparator|Modic Type-1 changes|Transforaminal Epidural Steroid Injection will be performed on patients at the pathology detected level bilaterally. The Kambin approach will be preferred in order to reach the intervertebral disc.
89563622|NCT04930211|Active Comparator|Degenerative disc disease without Modic Type-1 changes|Transforaminal Epidural Steroid Injection will be performed on patients at the pathology detected level bilaterally. The Kambin approach will be preferred in order to reach the intervertebral disc.
88968249|NCT00000359|Active Comparator|Brandt Daroff exercise|Modified Brandt Daroff exercise performed as a self-liberatory exercise.
88968250|NCT00011349||Group 1|
88968251|NCT00395200|Experimental|MSC Treatment|
88968252|NCT00395239|Experimental|1|
88968253|NCT00395278||HIV negative|HIV negative without Kaposi sarcoma
88968254|NCT00395278||HIV positive|HIV positive without Kaposi sarcoma
88968255|NCT00395278||HIV positive KS|HIV positive with Kaposi sarcoma
88968256|NCT02971618||Total group|Patients T2D with dapagliflozin treatment
88968257|NCT00000380|Experimental|GHRH|Growth-hormone-releasing hormone (GHRH), also known as growth-hormone-releasing factor (GRF, GHRF), somatoliberin or somatocrinin, is a releasing hormone for growth hormone.
88968258|NCT00000380|Placebo Comparator|Placebo|Placebo
88968259|NCT00025207|Experimental|Treatment (gefitinib)|Patients receive oral gefitinib once daily on days 1-21. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
89563623|NCT03177265|Experimental|Text to Engage|This group will get 8 text messages that target common misperceptions around quitting and use of quit services prior to receiving the first counseling phone call.
89563624|NCT03177265|Other|Mail Notice|This group will only get a mailing indicating that they will receive a call from a quitline counseling in two weeks.
89563625|NCT03177265|Experimental|Text to Enhance|Text-to-Enhance condition will receive SMS appointment reminders for telephone counseling appointments and 5 texts per week with tips and suggestions for quitting for a duration of 8 weeks.
89563626|NCT03177265|Active Comparator|Telephone Counseling|Telephone counseling condition will receive standard 8 weeks of telephone counseling only.
89563627|NCT03054311|Experimental|Lifestyle Matters intervention|
89563628|NCT04912271|Experimental|Granisetron transdermal patch (other name: sancuso), aprepitant or fosaprepitant, dexamethasone|Patients received granisetron transdermal patch plus dexamethasone followed by oral aprepitant or fosaprepitant infusion Granisetron transdermal patch Aprepitant 125 mg PO D1, 80 mg PO D2-D3; Fosaprepitant 150 mg IV D1 Dexamethasone 7.5-10 mg IV/PO D1
89563629|NCT04912271|Active Comparator|Palonosetron, aprepitant or fosaprepitant, dexamethasone|Patients received intravenous palonosetron plus dexamethasone followed by oral aprepitant or fosaprepitant infusion Palonosetron 0.25 mg IV D1 Aprepitant 125 mg PO D1, 80 mg PO D2-D3; Fosaprepitant 150 mg IV D1 Dexamethasone 7.5-10 mg IV/PO D1
89563630|NCT02807779|Experimental|Dexamethasone|Participants randomized to the Dexamethasone group will receive dexamethasone infusion to the adventitia of the artery following plain-old-balloon-angioplasty (POBA).
89563631|NCT02807779|Active Comparator|Drug Coated Balloon|Participants randomized to the Drug Coated Balloon (DCB) group will not receive dexamethasone infusion to the adventitia of the artery following (POBA). They will receive additional angioplasty with a paclitaxel coated balloon.
89563632|NCT02807779|Active Comparator|Plain Balloon Angioplasty|Participants randomized to the Plain Balloon Angioplasty will receive balloon angioplasty (POBA) only. They will not receive adventital dexamethasone or paclitaxel.
89563633|NCT03057197|No Intervention|Group A|Conventional method group (n=85): caudal injection after advancement of the needle into the sacral canal. Ultrasound is used to achieve accurate needle placement and we will check intravascular injection using digital subtraction angiography.
89563634|NCT03057197|Experimental|Group B|New method group (n=85): same as conventional method group except caudal injection right after penetrating the sacrococcygeal ligament.
89563635|NCT02769091|Experimental|TEV-45478|80 mg (2x40mg) tablets once daily for up to 24 weeks
89563636|NCT02769091|Placebo Comparator|Placebo|Matching placebo
89563637|NCT04912193||antithrombin III < 50 %|preoperative antithrombin III levels <50%
89563638|NCT04912193||Antithrombin III ≥ 50 %|preoperative antithrombin III levels ≥ 50 %
89563639|NCT02680561|Experimental|Treatment A: Fp MDPI|Single inhalation dose of Fluticasone Propionate Multidose Dry Powder Inhaler (Fp MDPI) on Day 1 into 1 of 6 treatment sequences (ABC, BCA, CAB, ACB, BAC, or CBA)
89563640|NCT02680561|Experimental|Treatment B: FS MDPI|Single inhalation dose of Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler (FS MDPI) on Day 1 into 1 of 6 treatment sequences (ABC, BCA, CAB, ACB, BAC, or CBA)
89563641|NCT02680561|Active Comparator|Treatment C: Comparator|Single inhalation dose of fluticasone propionate/salmeterol (ADVAIR DISKUS) on Day 1 into 1 of 6 treatment sequences (ABC, BCA, CAB, ACB, BAC, or CBA)
89563642|NCT02532543|Active Comparator|Group A- Allograft, Membrane|Symbios mineralized cortical-cancellous granule mix, Symbios OsteoShield Collagen Resorbable Membrane
89563643|NCT02532543|Active Comparator|Group B- Alloplast, Membrane|Symbios OsteoGraf/LD-300, Symbios OsteoShield Collagen Resorbable Membrane
89563644|NCT02532543|Active Comparator|Group C- Xenograft, Membrane|OsteoGraf/N-300 , Symbios OsteoShield Collagen Resorbable Membrane
89563645|NCT02532543|Active Comparator|Group D- Membrane|Symbios OsteoShield Collagen Resorbable Membrane
89563646|NCT03057353||lumbar CT imaging|Collecting lumbar CT imaging data of 104 patients with lumbar spinal stenosis to observed the incidence of ligamentum flavum hypertrophy of patients with different nationalities, sexes, heights, ages, and weights and explored risk factors affecting ligamentum flavum hypertrophy.
89563647|NCT03054389||Participants/ Patients|Participants/ Patients from the AskBio009-101 Study
89210641|NCT00820586|Experimental|Mononuclear bone marrow derived cells|Intramyocardial injection of total mononuclear bone marrow derived cells
89563648|NCT03054389||Investigators and Study Coordinators|Investigators and Study Coordinators from the AskBio009-101 Study
89563649|NCT05118373|Other|Exposure|The campaign targets 3 TV stations, 8 radio stations, 2 billboard companies and social media platforms including YouTube, Twitter, Facebook, Instagram and LinkedIn with an anticipated reach of 1,433,201 people in Lusaka and Copperbelt provinces. Of the targeted TV and radio media houses, two each are national stations and will reach beyond these two intervention provinces including to Central and Southern province with an estimated 8% and 11% mass-media penetration compared to 21% and 38% for Copperbelt and Lusaka respectively.
89563650|NCT03057275||Threatened PTL|abdominal fetal/maternal monitoring
89563651|NCT03057275||Delivered PTL|abdominal fetal/maternal monitoring
89563652|NCT05116111|Experimental|SYHA1402 1000 mg plus placebo 500 mg|Eligible patients will be randomly assigned to receive SYHA1402 1000 mg and placebo 500 mg twice daily for 16 weeks of treatment after a placebo introduction period.
89563653|NCT05116111|Experimental|SYHA1402 1500 mg|Eligible patients will be randomly assigned to receive SYHA1402 1500 mg twice daily for 16 weeks of treatment after a placebo introduction period.
89563654|NCT05116111|Placebo Comparator|Placebo 1500 mg|Eligible patients will be randomly assigned to receive placebo 1500 mg twice daily for 16 weeks of treatment after a placebo introduction period.
89563655|NCT04929977|Other|Wearable device with smart mobile phone|20 mother/care provider-infant pairs practicing Kangaroo Mother Care, from a tertiary super-specialty hospital selected to wear the device ( few days in the hospital and for a week at home when discharged)
89563656|NCT05095051|Experimental|Healthy subjects|To assess safety and tolerability of limb cryocompression, as well as to determine the optimal temperature and pressure to be used. The occurrence or lack of core hypothermia will be studied.
89563657|NCT05095051|Experimental|Cancer patients|Once the optimal temperature and pressure of limb cryocompression is established in healthy subjects, a group of cancer patients will undergo limb cryocompression over multiple cycles of chemotherapy to establish safety and tolerability of repeated therapy.
89563658|NCT05597631|No Intervention|Control|Control
89563659|NCT05597631|Experimental|G-IVF PLUS|G-IVF PLUS
89563660|NCT04912037|Experimental|with AI-assisted system|The novice doctors are trained in colonoscopy with an artificial intelligence assisted system that can indicate abnormal lesions and the speed of withdrawal in real time, as well as feedback on the percentage of overspeed.
89563661|NCT04912037|No Intervention|without AI-assisted system|The novice doctors receive routine colonoscopy training without artificial intelligence assistance system and no special tips
89563662|NCT04824469|Experimental|web based training|"Patients on the first day; Patient Information Form (1st and 2nd part), Memorial Symptom Assessment Scale, Covid-19 Symptom Assessment Inventory, Morisky Compliance Scale, World Health Organization Quality of Life Scale Short Form Turkish Version, E-Health literacy scale on website or mobile devices Google via the form or by sending a phone link.~Morisky Compliance Scale will be applied on the 7th day by sending a link to the website or mobile devices via google form.~Patients in the intervention group will be asked to fill out the Covid-19 Symptom Assessment Inventory on the website when they experience changes in their symptoms.~Patients in the intervention group will be provided with web-based training and telephone (SMS) reminder service for 4 weeks.~All questionnaires and web site evaluation form will be filled in the pre-test after 4 weeks."
89563663|NCT04824469|No Intervention|standard care|The scales applied to the intervention group on the first day, by sending the E-Health literacy scale form or phone link via Google on mobile devices. The symptoms of the patients in the control group will be evaluated at the end of the 1st day, 7th day, 14th day and 4th day. No intervention was planned for the patients in the control group during the follow-up. In the standard practice protocol, after patients are informed for follow-up and treatment at home, they are called by the Ministry of Health and family physicians for symptom follow-up. The standard hospital protocol does not include a scheduled training program, telephone monitoring, or web-based training. After collecting the data in the intervention group, the website will be opened to the use of the control group.
89563664|NCT04258059|Active Comparator|Active UV Device|A household water treatment device with a lamp emitting germicidal UV. The device will be operated at 50 millijoule per square centimeter to treat >99.9% of all bacteria, protozoa, and most viruses in water supplies.
89563665|NCT04258059|Sham Comparator|Inactive UV Device|A device that appears identical to the active comparator device except the lamp will not emit germicidal UV.
88968260|NCT00025246|Experimental|Treatment (imatinib mesylate)|Patients receive oral imatinib mesylate daily beginning within 84 days of surgical resection. Treatment continues for 1 year in the absence of disease recurrence or unacceptable toxicity.
88968261|NCT00000383|Experimental|Trauma-Focused CBT|Trauma -Focused CBT provides 12 sessions (45 minutes child, 45 minutes parent) of CBT treatment. This includes therapist-directed trauma-focused skills training, exposure, parenting, conjoint parent-child sessions, and safety component provided to child and parent.
88968262|NCT00000383|Active Comparator|Child Centered Therapy|Child Centered Therapy provides 12 sessions (45 minutes child, 45 minutes parent) of supportive interventions. This includes client-directed activities focused on the needs and interests of the child or parent, respectively.
88968263|NCT00025363|Experimental|Arm I|Patients receive vincristine IV on days 1 and 8 and irinotecan IV over 1 hour on days 1-5 and 8-12. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.
89563666|NCT05406063|Experimental|SBRT with 9 Gy x 3 fractions to the treatment site.|Patients will be treated with SBRT delivering 9 Gy x 3 fractions (BED10: 51.3 Gy) to the treatment site.
88968264|NCT00025363|Experimental|Arm II|Patients receive vincristine IV on days 1 and 8 and irinotecan IV over 1 hour on days 1-5. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.
88968265|NCT00000392|Active Comparator|Peptide T|Peptide T given intranasally at a dosage of 2mg 3 times a day for 6 months
88968266|NCT00000392|Placebo Comparator|Placebo|Placebo given intranasally at a dosage of 2mg 3 times a day for 6 months
88968267|NCT00011583|Experimental|1|1 hour/day of mechanically-assisted upper limb therapy
88968268|NCT00011583|Active Comparator|2|1 hour/day of upper limb therapy that includes exposure to, but no manipulation by the robot
88968269|NCT00000395|Experimental|Group 1 - Folinic acid|Subjects receiving Methotrexate for 6 weeks and 5 mg of Folinic acid daily for 1 week.
88968270|NCT00000395|Experimental|Group 2: Folic acid|Subjects receiving Methotrexate for 6 weeks and 5 mg of Folic acid daily for 1 week.
89517441|NCT02718716|Experimental|UCB7665 4 mg/kg|Participants in this arm received 5 subcutaneous (sc) doses of UCB7665 (rozanolixizumab) 4 milligram per kilograms (mg/kg) at 1-week intervals.
89517442|NCT02718716|Experimental|UCB7665 7 mg/kg|Participants in this arm received 3 sc doses of UCB7665 (rozanolixizumab) 7 mg/kg at 1-week intervals.
89517443|NCT02718716|Experimental|UCB7665 10 mg/kg|Participants in this arm received 2 sc doses of UCB7665 (rozanolixizumab) 10 mg/kg at 1-week intervals.
88968271|NCT00000410|Active Comparator|Surgery|Diskectomy
88968272|NCT00000410|Active Comparator|Non-surgical intervention|Non-surgical treatments
88968273|NCT00025675|Active Comparator|p450|p450 inhibitor
88968274|NCT00025675|Active Comparator|nonp450|not on p450 inhibitor
88968275|NCT00000416|Experimental|Rehabilitation counseling|"Rehabilitation counseling~Experimental~Rehabilitation counseling was provided by rehabilitation counselors. They administered the Work Experience Survey; provided and discussed disability rights and responsibilities and provided career counseling they as needed."
88968276|NCT00000416|Active Comparator|printed information|"Active comparator~Control group participants received relevant printed information in the mail only; no rehabilitation counseling"
88968277|NCT00026104|Experimental|Arm I (radiation therapy, paclitaxel, gemcitabine)|Patients receive radiotherapy once daily, 5 days a week, for 5.5 weeks, beginning on day 1. Patients also receive paclitaxel IV over 1 hour and gemcitabine IV over 30 minutes on days 1, 8, 15, 22, 29, and 36.
88968278|NCT00026104|Experimental|Arm II (radiation therapy, tipifarnib)|Patients receive chemoradiotherapy as in arm I. Within 3-8 weeks after completion of chemoradiotherapy, patients without disease progression receive oral tipifarnib twice daily for 21 days.
88968279|NCT00026143|Experimental|Arm I|Patients receive interleukin-12 IV over 5-15 seconds on day 1 and interferon alfa subcutaneously on days 2-6. Treatment repeats every 2 weeks in the absence of unacceptable toxicity. Patients are reassessed after 6 courses. Patients with a complete response receive 2 additional courses. Patients with a partial response or stable disease continue treatment in the absence of disease progression.
88968280|NCT00026182|Experimental|Arm I (rituximab and recombinant interleukin-12)|Patients receive rituximab IV on days 1, 8, 15, and 22. Patients receive interleukin-12 SC twice weekly beginning on day 2 and continuing until disease progression.
88968281|NCT00026182|Experimental|Arm II (rituximab and recombinant interleukin-12)|Patients receive rituximab as in arm I. Patients are evaluated at week 12. Patients with stable or progressive disease receive interleukin-12 SC twice weekly until disease progression or for 24 weeks. Patients with a complete or partial response after rituximab are monitored until disease progression and then begin interleukin-12 SC twice weekly until further disease progression.
89517444|NCT02718716|Experimental|UCB7665 15 mg/kg|Participants in this arm received 1 sc dose of UCB7665 (rozanolixizumab) 15 mg/kg.
89517445|NCT02718716|Experimental|UCB7665 20 mg/kg|Participants in this arm received 1 sc dose of UCB7665 (rozanolixizumab) 20 mg/kg.
89517446|NCT02629120|Active Comparator|1|There is only one treatment arm for this study
89517447|NCT02627742|Experimental|METANEB|Patients will receive standard care with the addition of therapy with The MetaNeb® System.
89517448|NCT02617563||Minimally invasive lumbar fusion|A single or double level instrumented fusion using minimally invasive PLIF, TLIF, MIDLF, DLIF, OLIF, ALIF procedures for the treatment of the degenerative lumbar spine.
89517449|NCT02513186|Experimental|Isatuximab|"VCDI cohort: Isatuximab (escalating dose) + bortezomib + cyclophosphamide + dexamethasone (VCDI): Induction phase will be 50 weeks (12 cycles). The duration of a cycle will be 42 days (6 weeks) for Cycle 1 (C1) and 28 days (4 weeks) for subsequent cycles. The duration of a cycle of the maintenance phase will be 28 days (4 weeks). After C12, isatuximab will be administered at its initial assigned dose and dexamethasone once every 28 days.~VRDI cohort parts A and B: Isatuximab + bortezomib + dexamethasone + lenalidomide (VRDI): Induction phase will be 24 weeks (4 cycles at 6 weeks/cycle). The duration of a cycle of the maintenance phase will be 28 days (4 weeks). Maintenance therapy may continue until disease progression, unacceptable AE or patient willingness to discontinue.~VRDI Part A: Enrollment to begin after the VCDI cohort is completed.~VRDI Part B: Enrollment to begin after the VRDI part A is completed."
89517450|NCT02476838|Other|traumatic amputation of the hand|may be male or female patients between the ages of 18 and 60 who are missing all or part of one or both hands and forearms
89517451|NCT02435810||Family Member|A family member of a patient with known or suspected infection or inflammation of the nervous system based on clinical or imaging data provided
89517452|NCT02435810||Patient|Patient with known or suspected infection or inflammation of the nervous system based on clinical or imaging data provided
89517453|NCT02428985||Riociguat|Riociguat treatment group
89517454|NCT02333162|Experimental|Treatment (IMTMI, combination chemotherapy, PBSCT or BMT)|"CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV over 30 minutes daily on days -7 to -3 and melphalan IV on day -2. Patients also undergo IMTMI BID for 2 to 5 days between days -7 to -3.~TRANSPLANT: Patients undergo allogeneic PBSCT or BMT on day 0.~GVHD PROPHYLAXIS: Patients receive tacrolimus IV continuously over 24 hours or PO BID on days -2 to 180 with taper thereafter and mycophenolate mofetil IV every 8 hours or PO on days 0-28 (for matched donors) or days 0-40 (for alternative donors) with taper to day 60."
89517455|NCT02310867|Experimental|Hand transplant with Belatacept|
89563667|NCT05406063|Active Comparator|SBRT with 7 Gy x 5 fractions to the treatment site|Patients will be treated with SBRT delivering 7 Gy x 5 fractions (BED10: 59.5 Gy) to the treatment site.
89563668|NCT05037097|Experimental|Study Group 1, Adult Participants Not Previously Vaccinated randomized to receive ARCT-165|Participants will receive one dose of ARCT-165 on Day 1 and one dose of ARCT-165 on Day 29
89563669|NCT05037097|Experimental|Study Group 2, Adult Participants Not Previously Vaccinated randomized to receive ARCT-154|Participants will receive one dose of ARCT-154 on Day 1 and one dose of ARCT-154 on Day 29
88968282|NCT00026299|Experimental|Phase 2: Oxaliplatin plus ZD1839|Oxaliplatin will be administered by IV infusion once every 21 days at a fixed dose of 130 mg/m2 and ZD1839 will be taken orally at a dose of 250 mg or 500 mg daily (as determined during phase 1). Subjects can continue to receive the combination for 6 cycles (each cycle is 21 days). After 6 cycles of the combination, subjects can continue to take ZD1839 alone until their cancer worsens.
88968283|NCT00026299|Experimental|Phase 2: Oxaliplatin alone|Oxaliplatin will be administered by IV infusion once every 21 days at a fixed dose of 130 mg/m2 for up to 6 cycles. Each cycle will last 21 days.
88968284|NCT00026299|Experimental|Phase I: Oxaliplatin with ZD1839|Oxaliplatin will be administered by IV infusion once every 21 days at a fixed dose of 130 mg/m2. ZD1839 will be taken orally at a dose of 250 mg or 500 mg daily.
88968285|NCT00026338|Active Comparator|OSI-774 plus Gemcitabine|
88968286|NCT00026338|Active Comparator|Placebo plus gemcitabine|
88968287|NCT00026377|Experimental|SU5416 in combination with hormone and radiation therapy|Subjects receive 5 months of hormone suppression therapy consisting of 1 month of Bicalutamide or Flutamide followed by 4 months of leuprolide or goserlin injections. After completion of at least 12 weeks of hormone therapy, subjects will receive 7 1/2 weeks of radiation therapy. SU5416 will be given by IV infusion starting 4 weeks before beginning radiation treatment and continuing until 4 weeks after completion of radiation. Multiple doses of SU5416 will be studied.
88968288|NCT00026689||1/Cohort 1|Patients suspected of having, or with biopsy proven malignant disease or patients with a benign condition for whom radiotherapy is a potential treatment
88968289|NCT04733209|Experimental|Mobilization with movement|"Mobilization with movement technique and traditional physiotherapy were applied to the intervention group. For mobilization with movement technique, the patient was asked to actively flex and extend the wrist with the forearm in neutral in a sitting position on a treatment table, and the pain was asked. The painful side was determined according to the patient's statement.~In a patient whose painful side was flexion, the wrist joint was shifted manually (with the help of the web space of both hands of the therapist) to the lateral and medial at the same time while the patient actively flexed the wrist. The treatment was done 3 times a week for 4 weeks."
88968290|NCT04733209|Active Comparator|Conventional|Traditional physiotherapy techniques were applied to the intervention group. Conventional TENS type was used. Current transition time was set as 50-100 µs. TENS application is performed at a frequency of 100 Hertz for 20 minutes in amplitude that does not cause muscle contraction in the patient and creates a feeling of numbness and tingling. Continuous ultrasound type was applied with full contact technique. Ultrasound treatment was applied over the transverse carpal ligament in the wrist with circular movements towards the proximal and distal at a speed of 1-2.5 cm per second, at a dose of 1 W / cm2, for 6 minutes, with a frequency of 3 MHz. And; tendon-nerve gliding exercises, night splint, stretching and strengthening exercises applied. The treatment was done 3 times a week for 4 weeks.
88968291|NCT00000428|Experimental|1|Patients received each intervention multiple times in random-order crossover design.
88968292|NCT00027586|Experimental|Imatinib Mesylate|400 mg twice a day orally
88968293|NCT00027703|Experimental|Arm I|Patients receive gemcitabine IV over 30 minutes on days 1 and 8 and cisplatin IV over 30-60 minutes (beginning after gemcitabine infusion) and bevacizumab IV over 30-90 minutes (beginning after cisplatin infusion) on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve stable disease (SD), complete response (CR), or partial response (PR) after the sixth course may receive bevacizumab as a single agent once every 3 weeks in the absence of disease progression or unacceptable toxicity.
88968294|NCT00027703|Experimental|Arm II|Patients receive gemcitabine and cisplatin as in arm I and placebo IV over 30-90 minutes (beginning after cisplatin infusion) on day 1. Treatment repeats as in arm I. Patients who achieve SD, CR, or PR after the sixth course may receive placebo as a single agent once every 3 weeks in the absence of disease progression.
88968295|NCT00027820|Experimental|Treatment (PBSCT)|"REDUCED-INTENSITY CONDITIONING: Patients receive fludarabine phosphate IV on days -4, -3, and -2 and undergo TBI on day 0.~TRANSPLANT: Patients undergo allogeneic PBSCT on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine PO BID on days -3 to 100 with taper to day 177 and mycophenolate mofetil PO every 8 hours on days 0-40 with taper to day 96."
89210642|NCT00820586|Experimental|Selected CD34+ bone marrow derived cells|Intramyocardial injection of selected CD34+ bone marrow derived cells
89210643|NCT00928278|Experimental|Treatment A - PF-04764793|PF-04764793 using inhaler A
89563670|NCT05037097|Experimental|Study Group 3, Adult Participants Not Previously Vaccinated to receive ARCT-021|Participants will receive one dose of ARCT-021 on Day 1 and one dose of ARCT-021 on Day 29
89563671|NCT05037097|Experimental|Study Group 4, Adult Participants Previously Vaccinated randomized to receive ARCT-165|Participants will receive one dose of ARCT-165 on Day 1
89563672|NCT05037097|Experimental|Study Group 5, Adult Participants Previously Vaccinated randomized to receive ARCT-154|Participants will receive one dose of ARCT-154 on Day 1
89563673|NCT05037097|Experimental|Study Group 6, Adult Participants Previously Vaccinated randomized to receive ARCT-021|Participants will receive one dose of ARCT-021 on Day 1
89563674|NCT05025163|No Intervention|control group|no intervention in the control group
89563675|NCT05025163|Experimental|fluoride foam group|intervention; fluoride foam application (with 1.23% fluoride foam application on teeth )
89563676|NCT05025163|Experimental|fluoride varnish group|intervention; fluoride varnish application (with 2.26% fluoride varnish application on teeth)
89563677|NCT02674321|Experimental|SD-809|• SD-809 tablets taken once or twice daily for 8 weeks, includes a dose titration period and a maintenance period.
89563678|NCT05070637|Experimental|No-touch laparoscopic radical nephrectomy|Group A patients will undergo a no-touch laparoscopic radical nephrectomy, with the dissection being done through the Gerota's fascia plane until exposure of the corresponding great vessel (vena cava on the right side, and aorta on the left side) is obtained. The renal pedicle will be directly isolated, and ligated using Weck® clips with no kidney manipulation.
89563679|NCT05070637|Active Comparator|Conventional laparoscopic radical nephrectomy|Group B patients will undergo a conventional laparoscopic radical nephrectomy approach, starting with opening of the Gerota's fascia, identification of the ureter, traction on the peri-renal fat below the ureter while dissecting cephalad until the renal pedicle is reached. The renal pedicle will then be isolated while maintaining traction on the kidney, and peri-renal fat, and ligated using Weck® clips.
89563680|NCT05070637|Other|Laparoscopic total nephrectomy control arm|Control arm in which a laparoscopic total nephrectomy will be performed in patients with hypo-functioning kidneys, and no renal cell carcinoma.
89563681|NCT02532465|Active Comparator|Air-Q|The Air-Q is composed of an airway tube that connects to an elliptical mask with a cuff which is inserted through the patient's mouth, down the windpipe, and once deployed forms an airtight seal on top the glottis (unlike tracheal tubes which pass through the glottis) allowing a secure airway to be managed by a health care provider.
89563682|NCT02532465|Experimental|i-gel|The i-gel is designed to create a non-inflatable anatomical seal of the pharyngeal, laryngeal and perilaryngeal structures whilst avoiding the compression trauma that can occur with inflatable supraglottic airway devices.
89563683|NCT02665507|Active Comparator|LLLI|Subjects from this group will receive 6 biweekly physiotherapy treatment and in addition LLLI (low level laser irradiation) treatment performed with Gallium-Aluminium-Arsenide 808 nm laser ( GaAlAs 808nm laser ).
89210644|NCT00928278|Active Comparator|Treatment B - PF-04764793|PF-04764793 using inhaler B
89210645|NCT00928278|Experimental|Treatment C - PF-04764793|PF-04764793 using inhaler A
89210646|NCT00928278|Active Comparator|Treatment D - PF-04764793|PF-04764793 using inhaler B
89563684|NCT02665507|Sham Comparator|Sham|Subjects from this group will receive 6 biweekly physiotherapy treatment and in addition sham LLLI treatment
89563685|NCT02528331|Experimental|rTMS and Cognitive Behavior Therapy|
89563686|NCT02919241|Experimental|Diagnostic interview|Intervention for this group include diagnostic interview. Oral health Impact Profile (OHIP 14) and Spielberg State and Trait Anxiety (STAI-1) questionnaires and behaviour analyses are used in diagnostic interview.
89563687|NCT02919241|Experimental|Combined interview and treatment|Intervention for this group include both the diagnostic interview and one session treatment.
89563688|NCT02592031|Experimental|XM17|XM17 will be administered by 1 mL syringes in graduated steps of 0.01 mL.
89563689|NCT02592031|Experimental|Gonal-f®|Gonal-f® will be provided in pens with integrated vials of 0.5 mL
89563690|NCT02592031|Active Comparator|Zoladex®|Zoladex® 3.6 mg will be administered by subcutaneous injection
89563691|NCT05002231|Experimental|Losmapimod 15 mg oral tablet in healthy subjects (Treatment Regimen A)|Subjects will be randomized to 1 of 6 treatment sequences to receive one 15 mg tablet of losmapimod administered orally under fasted conditions. Subjects will fast overnight (nothing to eat or drink except water) for at least 10 hours before each study drug administration. Subjects will remain fasted for 4 hours after dosing with study drug. Washout period of 48 hours between dosing.
88968296|NCT00027898|Experimental|Treatment (bortezomib, carboplatin, and etoposide)|Patients receive bortezomib IV on days 1 and 8, carboplatin IV over 30 minutes on day 1, and etoposide IV over 60 minutes on days 1-3. Treatment repeats every 21 days for at least 2 courses in the absence of disease progression or unacceptable toxicity.
88968297|NCT00027976|Experimental|Group 1 active arm|receipt of active drug
88968298|NCT00027976|Experimental|Group 2 active arm|receipt of active drug
88968299|NCT00027976|Experimental|group 2 placebo arm|receipt of placebo
88968300|NCT00000479|Experimental|1|Vitamin E (600 IU every other day) and aspirin (100 mg every other day)
88968301|NCT00000479|Experimental|2|Vitamin E (600 IU every other day) and placebo
88968302|NCT00000479|Experimental|3|Aspirin (100 mg every other day) and placebo
88968303|NCT00000479|Placebo Comparator|4|Placebo and placebo
88968304|NCT00395551|Active Comparator|ranibizumab|ranibizumab 0.5mg intravitreal injection
88968305|NCT00028522|Experimental|Treatment (chemotherapy)|"SCHEDULE A: Patients receive R(+)XK469 IV over 30 minutes on days 1, 3, and 5. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of R(+)XK469 until the recommended phase II dose or MTD is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, additional patients are accrued and treated at the recommended phase II dose (for a maximum of 20 patients treated at that dose).~SCHEDULE B: Once the recommended phase II dose is determined on schedule A, additional patients are accrued and receive escalating doses of R(+)XK469 IV over 30-60 minutes on day 1, beginning at a reduced dose. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Dose escalation continues as in Schedule A."
89210647|NCT03970369|Experimental|Monitor|Activity monitoring with feedback. Participants in the Monitor group will wear a step counter to track if the activity prescription is being met.
89210648|NCT03970369|Active Comparator|Usual care|All children will receive the usual care, which includes personalized goals and an activity prescription. Participants in the usual care group will not receive a step counter.
89563692|NCT05002231|Experimental|Losmapimod two 7.5 mg oral tablets in healthy subjects (Treatment Regimen B)|Subjects will be randomized to 1 of 6 treatment sequences to receive two 7.5 mg tablets of losmapimod administered orally under fasted conditions. Subjects will fast overnight (nothing to eat or drink except water) for at least 10 hours before each study drug administration. Subjects will remain fasted for 4 hours after dosing with study drug. Washout period of 48 hours between dosing.
89563693|NCT05002231|Experimental|Losmapimod one 15 mg oral tablet in healthy subjects (Treatment Regimen C)|Subjects will be randomized to 1 of 6 treatment sequences to receive one 15 mg tablet of losmapimod administered orally under fed conditions. Subjects will fast overnight (nothing to eat or drink except water) for at least 10 hours before breakfast and will receive a high-fat breakfast approximately 30 minutes before dose administration. Subjects must consume the meal within 25 minutes or less. Washout period of 48 hours between dosing.
89563694|NCT04423263|Experimental|Intervention|Receives bilateral internal iliac artery occlusion
89563695|NCT04423263|Active Comparator|Control|Does not receive bilateral internal iliac artery occlusion
89563696|NCT02857543|Active Comparator|plant-based diet|Plant-based diet with as few added oils and fats as possible
89563697|NCT02857543|Active Comparator|American Heart Association|Diet encourages fruits, vegetables, whole grains, and low sodium intake but permits non-whole grains, low-fat dairy, selected plant oils, and lean meat and fish in moderation.
89563698|NCT02857543|Active Comparator|Mediterranean|Diet encourages fruits, vegetables, whole grains, and low sodium intake but permits non-whole grains, low-fat dairy, selected plant oils, with more emphasis on fish and extra virgin olive oil and/or nuts.
89563699|NCT05377671|Experimental|Cognitive deficit group|All patients will undergo task MRI and standard clinical assessments, including neuropsychological examination. The MRI includes, in addition to structural task sequences, diffusion imaging and resting state fMRI.
89563700|NCT05377671|Experimental|Without cognitive group|All patients will undergo task MRI and standard clinical assessments, including neuropsychological examination. The MRI includes, in addition to structural task sequences, diffusion imaging and resting state fMRI.
89563701|NCT04784299|Experimental|YVOIRE volume plus|Hyaluronic acid dermal filler
89563702|NCT04784299|Active Comparator|Restylane Lyft with Lidocaine|Hyaluronic acid dermal filler
89563703|NCT02765659|Other|Community 1|Receives Mzake ndi Mzake T1 immediately after baseline
88968306|NCT00028561|Experimental|Treatment (ixabepilone, carboplatin)|Patients receive BMS-247550 IV over 1 hour on days 1, 8, and 15 followed by carboplatin IV over 1 hour on day 1. Treatment repeats every 28 days for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients with a CR receive 2 additional courses after achieving CR or up to a total of 6 courses
88968307|NCT00028600|Experimental|Autologous + Allogeneic Transplant|autologous PB stem cell transplant followed by non-myeloablative allogeneic transplant fr multiple myeloma
89563704|NCT02765659|Other|Community 2|Receives Mzake ndi Mzake T2 immediately after Post-T1 evaluation
89563705|NCT02765659|Other|Community 3|Receives Mzake ndi Mzake T3 immediately after Post-T2 Evaluation
89563706|NCT02333149|Experimental|Melatonin|Dietary supplement: Melatonin 3 mg or 6 mg
89563707|NCT02333149|Placebo Comparator|Placebo|Drug: Placebo
89563708|NCT02315131|Experimental|TV46017- Healthy Volunteers|Stage 1 includes a single-dose treatment period
88968308|NCT04732741||Oral Cancer|patients diagnosed clinically and histopathologically with oral cancer who have yet to receive any treatment.
88968309|NCT04732741||Premalignant lesions|patients diagnosed clinically and histopathologically with oral potentially malignant lesions who have not yet to receive treatment or had a month wash-out period from any previous treatment.
88968310|NCT04732741||Control Group|healthy individuals who will be examined clinically through conventional visual and tactile examination to ensure no oral lesions are present and through thorough medical history
88968311|NCT00028756|Active Comparator|Arm I (immediate chemotherapy)|Beginning within 90 days of radical cystectomy, patients receive a total of 4 courses of adjuvant chemotherapy.
88968312|NCT00028756|Experimental|Arm II (deferred chemotherapy)|Beginning at the time of clinical relapse, patients receive a total of 6 courses of adjuvant chemotherapy.
89563709|NCT02315131|Placebo Comparator|Placebo - Healthy Volunteers|Some healthy subjects will be randomized to receive placebo.
89563710|NCT02315131|Experimental|TV46017 15 μg- COPD|Stage 2 includes two 24 hour treatment periods with approximately 7 days of washout in between each treatment period; and open label ipratropium bromide pressurized metered-dose inhaler hydrofluoroalkane (HFA) will be administered
89563711|NCT02315131|Experimental|TV46017 60 μg- COPD|Stage 2
89563712|NCT02315131|Experimental|TV46017 120 μg- COPD|Stage 2
89563713|NCT02315131|Experimental|TV46017 240 μg- COPD|Stage 2
89563714|NCT02029963|Experimental|Cluster rTMS|Two weeks of daily repetitive Transcranial Magnetic Stimulation (total of 10 rTMS sessions), six months following completion of regular six-week rTMS treatment.
89563715|NCT02029963|Experimental|Taper rTMS|Immediately following completion of regular six-week repetitive Transcranial Magnetic Stimulation treatment, patients in this group will receive three sessions of rTMS a week for two weeks followed by two sessions of rTMS a week for two weeks (total of 10 rTMS sessions tapered in 4 weeks)
88968313|NCT00028795|Experimental|Chemoradiotherapy|
88968314|NCT00012363|Experimental|Gemcitabine + Irinotecan|Gemcitabine 1000mg/m2 IV over 30 min on Days 1,8 q21days; Irinotecan 100mg/m2 IV over 90 min on Days 1,8 q21days
88968315|NCT00028834|Experimental|Treatment (gemcitabine hydrochloride, bevacizumab)|Patients receive gemcitabine IV over 30 minutes on days 1, 8, and 15 and bevacizumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
89563716|NCT02029963|Experimental|Treatment as Usual|Following their last session of regular six-week rTMS treatment, patients in this group will follow an individually-tailored maintenance plan as determined by their own psychiatrist or primary care provider
89563717|NCT04514965||PBC patients offered bezafibrate treatment|"All patients started on bezafibrate treatment are offered inclusion in the study.~First visit is before start of treatment. Afterwards patients will be seen at 4 weeks, 6 months, 1 year, 2 years and 3 years after inclusion.~At all visits blood samples will be taken and liver stiffness will be measured using FibroScan. Further, they will be asked about pruritus."
89563718|NCT05122429|Experimental|myCompass Only|Self-guided e-health treatment
89563719|NCT05122429|Experimental|myCompass + Delayed Text Therapy Support|Self-guided e-health treatment with delayed (44min) text support from a therapist.
89563720|NCT05122429|Experimental|myCompass + Delayed Video Therapy Support|Self-guided e-health treatment with delayed (44min) video support from a therapist.
89563721|NCT05122273||Children and adults with confirmed neuromuscular disease|Children and adults with confirmed genetic Duchenne muscular dystrophy (DMD) or Becker muscular dystrophy (BMD), limb-girdle dystrophy, spinal muscular atrophy (SMA), myopathy or neuropathy.
89563722|NCT01794715|Experimental|Ultrasound performed by nurses|Examinations including ultrasound examinations
89563723|NCT01794715|Active Comparator|Ultrasound not performed|Examinations not including ultrasound examinations, otherwise active
89563724|NCT01519141||HIV-negative controls|HIV-negative individuals
89563725|NCT01519141||HIV-infected patients|HIV-infected patients who are on a stable antiretroviral drug regimen for at least a year; all plasma HIV RNA levels within the past year must be below conventional levels of detection (< 50 copies RNA/mL).
89563726|NCT05118217||Clinical DPN without pain|"Score above 2.5 on the Michigan Neuropathy Screening Instrument~Score below 4 on the DN4"
89563727|NCT05118217||Painful DPN|"Score above 2.5 on the MNSI~Score above 4 on the DN4"
89563728|NCT02654977|Experimental|Metreleptin|Metreleptin open-label
89563729|NCT05117983|Active Comparator|MDD patient with HRSD score of at least 18|MDD patients who meet the DSM-5 diagnostic criteria of MDD and their current episode show a Hamilton Rating Scale for Depression (HRSD) score of at least 18
89563730|NCT05117983|Active Comparator|BD patient with HRSD score of at least 18|BD patients who meet the DSM-5 diagnostic criteria of BD and their current depression episode show a Hamilton Rating Scale for Depression (HRSD) score of at least 18
89563731|NCT05117437||Athletic group|Healthy male athletes who have been doing regular anaerobic sports (such as basketball, volleyball and handball) for at least 3 months
89563732|NCT05117437||Control group|Healthy sedentary (not doing regular sports for at least 3 months) men with age and physical characteristics similar to the athlete group
89563733|NCT02871115|Experimental|Pharmacy Intervention|"Patients randomized to the pharmacy intervention (PRIME) will undergo evaluation with a clinical pharmacist at their second or third chemotherapy infusion who will~Perform detailed medication reconciliation~Obtain allergy and vaccination history~Evaluate and document polypharmacy (number of medications)~Document their findings in the medical record and discuss their recommendations (in-person, phone call, email) with each patient's oncology team"
89563734|NCT02871115|Active Comparator|Usual Care|"Participants receiving Usual Oncology Care will not meet with the pharmacist unless indicated as part of their routine clinical care~Study staff will obtain all patient-reported measures from the patient.~Remind participant to complete self-report measures"
89563735|NCT02078947|Experimental|High Intensity Exercise|Patients perform interval- type endurance exercise at high intensity
89563736|NCT02078947|Active Comparator|Moderate Continuous Exercise|Patients perform endurance exercise at moderate intensity
89563737|NCT02078947|Sham Comparator|Usual Care|Patients receive advice on being physically active as well as usual care
89563738|NCT05122117|Experimental|Methylene blue mediated photodynamic therapy|Methylene blue (MB) with a concentration of 10 mg/mL was delivered inside the periodontal pocket. MB was injected inside in the selected periodontal pockets 4 - 6 mm with the help of a blunt needle and left for 1 min. Later, the periodontal pockets were flushed with distilled water for 3 min to remove the excess MB. The diode laser HELBO® TheraLite - Bredent Medical, Germany) of diameter 200 µm was used to deliver the light to initiate the disinfection process. Each participant underwent single session of laser exposure. The laser parameters such as wavelength, spot area, power output and laser energy were set at 660 nm, 0.028 cm2, 60 mW/cm2, and 150 mW, respectively. The laser was subjected for a period of 30 s in each pocket.
89563739|NCT05122117|Placebo Comparator|Scaling and root planing|A single session of full-mouth ultrasonic scaling using a sterilized scaler was rendered to the control group. Deep pockets were additionally approached and cleaned by using manual 'After Fives' Gracey curette for root planning (Hu Friedy Gracey After Five Vision curette; HuFriedy, Chicago, USA). This session was followed by a polishing session. A motivational session was conducted where the patients were educated on the importance of maintaining a good oral hygiene by brushing their teeth twice daily followed by the regular use of dental floss and chlorhexidine mouth wash twice daily, respectively.
89563740|NCT05117047||robot-assisted liver resection|In this study, the investigators included all HCC patients with BCLC stage 0-A (n=1669) who underwent hepatectomy over an 1 ½ year study period, and divided them into three study cohorts according to the operations they received. These were consecutive patients who met the inclusion criteria of the study. 71 HCC patients were included in robotic liver resection cohort.
89563741|NCT05117047||laparoscopic liver resection|In this study, the investigators included all HCC patients with BCLC stage 0-A (n=1669) who underwent hepatectomy over an 1 ½ year study period, and divided them into three study cohorts according to the operations they received. These were consecutive patients who met the inclusion criteria of the study. 141 HCC patients were included in laparoscopic liver resection cohort.
89563742|NCT05117047||open liver resection|In this study, the investigators included all HCC patients with BCLC stage 0-A (n=1669) who underwent hepatectomy over an 1 ½ year study period, and divided them into three study cohorts according to the operations they received. These were consecutive patients who met the inclusion criteria of the study. 157 HCC patients were included in open liver resection cohort.
89563743|NCT05116969|Experimental|Stage 1: PTX-35 Dose Level 1|Dose Level 1: PTX-35 0.1 mg/kg
89563744|NCT05116969|Experimental|Stage 1: PTX-35 Dose Level 2|Dose Level 2: PTX-35 0.3 mg/kg
89563745|NCT05116969|Experimental|Stage 1: PTX-35 Dose Level 3|Dose Level 3: PTX-35 1.0 mg/kg
89563746|NCT05116969|Experimental|Stage 1: PTX-35 Dose Level 4|Dose Level 4: PTX-35 3.0 mg/kg
88968316|NCT00388934|Experimental|Drug eluting stent (Cypher)|Percutaneous coronary intervention with implantation of drug eluting coronary stent (Cypher)
88968317|NCT00388934|Experimental|Drug eluting stent (Taxus)|Percutaneous coronary intervention with implantation of drug eluting coronary stent (Taxus)
89563747|NCT05116969|Experimental|Stage 1: PTX-35 Dose Level 5|Dose Level 5: PTX-35 10.0 mg/kg
89563748|NCT05116969|Experimental|Stage 2 Multiple Ascending Dose Regimen 6|4 doses of PTX-35 with each dose separated by 7 days
89563749|NCT05116969|Experimental|Stage 2 Multiple Ascending Dose Regimen 7|3 doses of PTX-35 with each dose separated by 14 days
89563750|NCT05116657||SARS-CoV2 OSA|Patients will be recruited from both Post-COVID19 and Sleep Clinics run through Beaumont Hospital, Beaumont, Dublin, Ireland. This will allow for the recruitment of patients with and without a history of SARS-CoV-2 infection.
89563751|NCT05116657||Non-SARS-CoV2 OSA|Patients will be recruited from both Post-COVID19 and Sleep Clinics run through Beaumont Hospital, Beaumont, Dublin, Ireland. This will allow for the recruitment of patients with and without a history of SARS-CoV-2 infection.
89563752|NCT05116501|Experimental|low VWF|In patients with low VWF levels, whole-exome sequencing will be performed to identity possible variants in the VWF gene or other genes that are associated with reduced VWF plasma levels. Furthermore, a correlation study between variants identified and the bleeding symptoms of patients will be performed.
89563753|NCT05116501|Other|Healthy controls|In healthy controls, the investigators will analyze the whole-exome sequencing to include the variants that are either not present in healthy controls or are present but with a significantly lower frequency than the patients.
89563754|NCT05116423||ITP inpatients|The study population included nonsplenectomized primary ITP inpatients 18 years of age or older. Patients who had a diagnosis of connective tissue disease, cancer (solid tumor or leukemia), or primary immune deficiency were excluded.
89563755|NCT05116345|Experimental|DEXTENZA|a single intracanalicular dexamethasone (0.4 mg) insert
89563756|NCT05116345|Active Comparator|Topical Dexamethasone Treatment|"Standard of care topical dexamethasone treatment through Month 2 dosing and tapering following:~6x/day week 1 4x/day weeks 2-4 2x/day weeks 5-8 Day of surgery dexamethasone ointment and patch will be applied post-surgically for overnight treatment and removed at post-operative day 1 visit in Group B eyes."
89563757|NCT05109013||NT group - normotensive children|
89563758|NCT05109013||HT group - hypertensive children|
88968318|NCT00395707|Active Comparator|1|Lucentis 0.3mg/0.05 ml
88968319|NCT00395707|Active Comparator|2|Lucentis 0.5mg/0.05 ml
89563759|NCT05120401||dry eye with presbyopia|dry eye with presbyopia , Intervention : glasses prescrubed
89563760|NCT05120401||dry eye with presbyopia without glasses use|no glasses use
89563761|NCT05096689|Experimental|Non-operative|Non-operative treatment of lateral humeral condyle fractures
89563762|NCT05076097|Experimental|Orelabtutinib in combination of rituximab and lenalidomide(OLR) Arm|Induction phase of mantle cell L lymphoma: Orelabrutinib: 150mg QD D1-28; Lenalidomide: Cycle 1: 15mg QD D1-21, if no dose-limiting toxicity occurred in Cycle 1, cycle 2-6: 20mg QD D1-21; Cycle 1: 375 mg/m2 d1, 8,15,22; Cycle 3, 5: 375 mg/m2 D1 Maintenance treatment phase: Orelabrutinib: 150mg QD D1-28; Lenalidomide: cycle 7-24: 15mg QD D1-21; Cycle 7, 9, 11, 13, 15, 17, 19, 21, 23: 375 mg/m2 D1
89563763|NCT04413019||Group (D): Planned domiciliary care.|Patients within this group will be counseled for home care with self-monitoring for any symptoms suggestive of preterm labor, maternal or fetal distress.
88968320|NCT00012597|Other|Arm 1|
88968321|NCT00012636|Other|Arm 1|
88968322|NCT00012675||Group 1|
89563764|NCT04413019||Group (H): Planned hospital care.|Patients within this group will be admitted at hospital for close monitoring of maternal & fetal wellbeing & finally the neonatal outcome
89563765|NCT05119933|Experimental|YL-15293|After a screening period of approximately 28 days, eligible patients will receive oral YL-15293 once daily until documented disease progression, unacceptable AEs, intercurrent illness prevents further administrations of study treatment, investigator's decision to withdraw the patient, the patient withdraws consent, pregnancy of the patient, or for administrative reasons. Following the end of treatment, patients will continue to be followed for safety for 30 days. Patients who permanently discontinue study treatment for reasons other than disease progression will have post-treatment follow-up for disease assessment until start of new anticancer treatment, patient withdraws consent, is lost to follow-up, death, or until the Sponsor stops the study, whichever comes first.
89563766|NCT05085847|Experimental|Mindfulness-based intervention (MBI)|Participants received mindfulness training for 8 weeks (two-hour meetings; 16 hours total)
88968323|NCT00030238|Other|Active Treatment|Subjects take calcium twice daily with meals
88968324|NCT00030238|Other|Control|Subjects take placebo twice daily with meals.
88968325|NCT00012714|Other|Arm 1|
88968326|NCT00030394|Experimental|Treatment (imatinib mesylate)|Patients receive oral imatinib mesylate once daily on days 1-28. Courses repeat every 28 days for 1 year in the absence of disease progression or unacceptable toxicity. Patients who fail to achieve a complete hematologic response after 3 courses or a partial or complete cytogenic response after 6 courses are removed from the study.
88968327|NCT00395941|Active Comparator|Control|Acitretin
88968328|NCT00395941|Experimental|Experimental|Pioglitazone
88968329|NCT00012753|Other|Arm 1|
88968330|NCT00012792|Other|Arm 1|
88968331|NCT00030628|Experimental|radiosurgery|"Patients undergo radiosurgery.~Quality of life is assessed at baseline, the beginning of each treatment, at week 6, every 3 months for 1 year, every 4 months for 1 year, and then every 6 months for 2 years."
89563767|NCT05085847|Active Comparator|Active control group|Participants received lectures for 8 weeks (two-hour meetings; 16 hours total)
89563768|NCT04932577|Experimental|Faecal microbiota transplantation|The patients will receive three applications of FMT consisting of 50 g cryopreserved, homogenized faeces from healthy donors. The faecal material will be dispensed into double-coated, acid-resistant enterocapsules or cryobags. Faeces will be screened according to international guidelines.
89563769|NCT04932577|Placebo Comparator|Placebo|The placebo products is produced from a suspension of glycerol, saline and food colouring and cannot be distinguished from the active FMT products.
89563770|NCT04882111|Experimental|Discharged Cancer Patients|25 patients, adults ≥ 18, with stage II - IV solid tumor malignancy discharging from an acute care hospital to a SNF in the metro Denver area who have decisional capacity to consent and are English speaking.
89563771|NCT05078281||Cases|Patients with severe eosinophilic asthma receiving benralizumab.
89563772|NCT05230069||Patients post emergency evaluation|Interview of patients post notification of emergency system
89563773|NCT04513639|Experimental|Arm A|Patients will be followed with MRD assessment every 4 month and start 2.L treatment at loss of MRD negative complete response.
89563774|NCT04513639|Active Comparator|Arm B|Patients will be followed up by standard criteria and start 2.L treatment at progressive disease.
89563775|NCT04746001||Infection|
89563776|NCT04746001||Tumours|
89563777|NCT04696549|Experimental|virtual visual art experience for individuals with dementia and their family care-partners|Individuals with dementia and their family care-partners will participate in three monthly one-hour virtual art sessions in which the facilitator uses Visual Thinking Strategies technique to facilitate participants' viewing and discussion about virtual art images.
89563778|NCT04675801||Bridging therapy with LMWH (n=475)|Bridging therapy with LMWH was performed after discontinuation of oral antiplatelet agents prior to non-cardiac surgery
89563779|NCT04675801||Bridging therapy with tirofiban (n=475)|Bridging therapy with tirofiban was performed after discontinuation of oral antiplatelet agents prior to non-cardiac surgery
88968332|NCT00030628|Experimental|radiosurgery + WBRT|"Patients undergo radiosurgery. Within 14 days, patients then undergo whole brain radiotherapy 5 days a week for 2.5 weeks.~Quality of life is assessed at baseline, the beginning of each treatment, at week 6, every 3 months for 1 year, every 4 months for 1 year, and then every 6 months for 2 years.~Patients are followed at weeks 6 and 12, every 3 months for 9 months, every 4 months for 1 year, every 6 months for 2 years, and then annually thereafter."
88968333|NCT00012831||Group 1|
88968334|NCT00030667|Experimental|Treatment (imatinib mesylate)|Patients receive oral imatinib mesylate once or twice daily on days 1-28. Courses repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
88968335|NCT00012870|Other|Arm 1|
88968336|NCT04711720|Experimental|Navigation|
89563780|NCT04186195||Diabetic children aged 1-16 years and their families|Diabetic children aged 1-16 years and their families. A child's disease duration must be over 1 year so that possible remission period is over.
89563781|NCT05119543||Grade|The changes in myopia rate in 3 years were compared by generalized estimation equation in different grades
89563782|NCT05229913|Placebo Comparator|The control group （Esketamine is not added）|Postoperative intravenous analgesia pump formula：Sufentanil 1ug/kg+ Flurbiprofen Axetil 200mg The intravenous analgesic pump in each group was supplemented with normal saline and matched to 100 ml, the background infusion rate is 2ml/h, the Self-controlled intravenous analgesia pressing once dose is 1ml, the locking time is 20min, and the analgesia lasted until 48h after surgery.
89563783|NCT05229913|Experimental|Esketamine experimental group(E0.2)|Postoperative intravenous analgesia pump formula：Esketamine 0.2mg/kg + Sufentanil 1ug/kg+ Flurbiprofen Axetil 200mg The intravenous analgesic pump in each group was supplemented with normal saline and matched to 100 ml, the background infusion rate is 2ml/h, the Self-controlled intravenous analgesia pressing once dose is 1ml, the locking time is 20min, and the analgesia lasted until 48h after surgery.
89563784|NCT05229913|Experimental|Esketamine experimental group (E0.4)|Postoperative intravenous analgesia pump formula：Esketamine 0.4mg/kg + Sufentanil 1ug/kg+ Flurbiprofen Axetil 200mg The intravenous analgesic pump in each group was supplemented with normal saline and matched to 100 ml, the background infusion rate is 2ml/h, the Self-controlled intravenous analgesia pressing once dose is 1ml, the locking time is 20min, and the analgesia lasted until 48h after surgery.
89563785|NCT05229913|Experimental|Esketamine experimental group (E0.6)|Postoperative intravenous analgesia pump formula：Esketamine 0.6mg/kg + Sufentanil 1ug/kg+ Flurbiprofen Axetil 200mg The intravenous analgesic pump in each group was supplemented with normal saline and matched to 100 ml, the background infusion rate is 2ml/h, the Self-controlled intravenous analgesia pressing once dose is 1ml, the locking time is 20min, and the analgesia lasted until 48h after surgery.
89563786|NCT05229913|Experimental|Esketamine experimental group (E0.8)|Postoperative intravenous analgesia pump formula：Esketamine 0.8mg/kg + Sufentanil 1ug/kg+ Flurbiprofen Axetil 200mg The intravenous analgesic pump in each group was supplemented with normal saline and matched to 100 ml, the background infusion rate is 2ml/h, the Self-controlled intravenous analgesia pressing once dose is 1ml, the locking time is 20min, and the analgesia lasted until 48h after surgery.
88968337|NCT04711720|No Intervention|Control|
88968338|NCT00012909|Other|Arm 1|
88968339|NCT00031096|Experimental|Arm 1|
88968340|NCT00031096|Placebo Comparator|Arm 2|
88968341|NCT00031174||1|Blood components collected using apheresis from normal volunteers.
88968342|NCT00031174||2|Blood components collected using apheresis from patients with rheumatic or kidney diseases.
88968343|NCT00012948|Other|Arm 1|
88968344|NCT00012987|Other|Arm 1|
89563787|NCT05229757|Experimental|Study Group|Children with cerebral palsy in the patient group received treatment in a special education and rehabilitation center two days a week for 8 weeks.
89563788|NCT05229757|Active Comparator|Control Group|Individuals in the control group were followed with a home program for 8 weeks.
89563789|NCT05229289|Experimental|FMT along with SMT|"FMT + Standard medical therapy (SMT):~Lactulose (Titrated to 2-3 soft bowel movements per day) Oral LOLA can be used as an alternative or additional agent to treat patients non-responsive to conventional therapy Oral BCAAs can be used as an alternative or additional agent to treat patients non-responsive to conventional therapy Diet Daily energy intakes of 35-40 kcal/kg ideal body weight Daily protein intake 1.2-1.5 g/kg/day Small meals or liquid nutritional supplements evenly distributed throughout the day Oral BCAA supplementation in patient's intolerant of dietary protein (to allow recommended nitrogen intake to be achieved and maintained)"
89608802|NCT05702775|No Intervention|Non-endoscopic treatment group (Group NE)|Antibiotic treatment will start from the moment of diagnosis in both arms of the study. Following the recommendations of the Clinical Practice Guideline for the Management of Acute Cholecystitis of Tokyo 2018, CAL will be classified into three groups according to severity (I,II,III) and empirical antibiotic treatment will be started according to the recommendations of said guideline
89563790|NCT05229289|Active Comparator|Standard Medical Treatment|"Standard medical therapy (SMT):~Lactulose (Titrated to 2-3 soft bowel movements per day) Oral LOLA can be used as an alternative or additional agent to treat patients non-responsive to conventional therapy Oral BCAAs can be used as an alternative or additional agent to treat patients non-responsive to conventional therapy Diet Daily energy intakes of 35-40 kcal/kg ideal body weight Daily protein intake 1.2-1.5 g/kg/day Small meals or liquid nutritional supplements evenly distributed throughout the day Oral BCAA supplementation in patient's intolerant of dietary protein (to allow recommended nitrogen intake to be achieved and maintained)"
89563791|NCT01362517|Experimental|Quinvaxem|
89563792|NCT05229133|Experimental|Refractive correction using CLEAR|Subjects 18+ years old with myopic (-0.50 to -10.00 D) astigmatism (up to -5.00 D) treated bilaterally with FEMTO LDV Z8 using CLEAR application.
89563793|NCT04330261||SARS-CoV-2 Positive Children|All children screened for SARS-CoV-2 and presenting to participating sites will be enrolled in this study. Children who are eventually test-positive for SARS-CoV-2 will be considered the exposed group in this study. These children will have exactly the same prospective follow-up as the other group.
89563794|NCT04330261||SARS-CoV-2 Negative Children|All children screened for SARS-CoV-2 and presenting to participating sites will be enrolled in this study. Children who are eventually test-negative for SARS-CoV-2 will be considered the unexposed (control) group in this study. These children will have exactly the same prospective follow-up as the other group.
89563795|NCT05108155||THA|Patient with primary total hip arthroplasty
89563796|NCT04375735|Experimental|BLES treatment|For patients randomized to the treatment arm, exogenous BLES will be administered as soon as possible and within 48 hours of intubation. BLES will be administered daily for up to 3 doses, or until the patient is liberated from the ventilator.
89563797|NCT04375735|No Intervention|Control|Patients will receive standard treatment and will not receive surfactant.
89563798|NCT01362439|Experimental|Paliperidone ER|
89563799|NCT05228743|Experimental|HIPEC plus Paclitaxel IP/IV, S-1|After laparoscopic exploration, HIPEC was started immediately, at least 4 HIPEC was completed.Three to six weeks after HIPEC was completed, chemotherapy was started.The curative effect was evaluated every 2-4 cycles. If the operation standard of R0 was met, the second laparoscopic staging was performed: if the peritoneal metastasis reached P 0 or P1a, the operator judged that R0 could be removed. Open radical gastrectomy (D2 / D2 +) was performed. For P1b / c cases, the original treatment was continued until the disease progressed.
89563800|NCT05228743|No Intervention|Paclitaxel IP/IV, S-1|Within one week after laparoscopic exploration, chemotherapy was started. The curative effect was evaluated every 2-4 cycles. If the operation standard of R0 was met, the second laparoscopic staging was performed: if the peritoneal metastasis reached P 0 or P1a, the operator judged that R0 could be removed. Open radical gastrectomy (D2 / D2 +) was performed. For P1b / c cases, the original treatment was continued until the disease progressed.
89563801|NCT05228665|Experimental|Prospective cohort|Participants will be shown a paced breathing programme and instructed to implement this for 10 minutes twice daily for 4 weeks. During the 10-minute breathing exercises, the participant will need to wear the Polar H10 chest strap and can remove this when finished. The breathing will ideally be a breathing pattern of a 4-second nasal inhale, and 6-second nasal exhale using the 'resonance' programme in the 'biofeedback' section of EliteHRV app. They will be advised to monitor the graph of HRV on EliteHRV which allows real-time assessment of HRV and to aim to breathe in and out deeply to raise the HRV graph reading as much as possible each time. They will be advised to perform the breathing programme lying down with minimal distractions on waking in the morning and just before bed in the evening, preferably in the same location each time.
88968345|NCT00396214|Experimental|1|
88968346|NCT00396214|Experimental|2|
88968347|NCT00396214|Active Comparator|3|
88968348|NCT00013026|Other|Arm 1|
88968349|NCT00031564|Experimental|Vaccine Therapy With Interleukin-2|At approximately 3-6 weeks after surgery, patients receive B7-1 gene-modified autologous tumor cell vaccine subcutaneously (SC) once on days 1, 29, and 57. At 6 weeks after the first vaccination, patients receive interleukin-2 (IL-2) SC five days a week for 6 weeks (days 43-82). Patients with stable or responding disease after day 106 may receive additional vaccinations in the absence of disease progression or unacceptable toxicity.
88968350|NCT00013065||Group 1|
88968351|NCT00031681|Experimental|Treatment (combination chemotherapy)|"PART I: Patients receive irinotecan hydrochloride IV over 90 minutes on days 1, 8, 15, and 22 and 7-hydroxystaurosporine IV over 3 hours on days 2 and 23. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of irinotecan hydrochloride and 7-hydroxystaurosporine until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Blood samples are collected periodically during study treatment.~PART II: (treatment of triple negative recurrent breast cancer): Patients receive irinotecan hydrochloride IV and 7-hydroxystaurosporine IV as in part I at the MTD and undergo blood sample collection."
88968352|NCT00031720|Experimental|Arm I|All patients receive placebo for 7 days as part of the run-in period. Patients being treated with tamoxifen were randomized to treatment arm I and received 40 gm soy protein and 90 mg isoflavones daily for 12 weeks.
88968353|NCT00031720|Placebo Comparator|Arm II|All patients receive placebo for a 7 day run in period. Patients being treated with tamoxifen randomized to Arm II received placebo daily for 12 weeks.
88968354|NCT00000569|Active Comparator|Triamcinolone|1200 micrograms of triamcinolone in daily divided doses
88968355|NCT00000569|Placebo Comparator|Placebo|Placebo
89563802|NCT05228587|Experimental|Liver Transplants|"Indocyanine Green will be injected in liver donors for measuring plasma disappearance rate with a non invasive measurement device.~Liver recipients will receive indocyanine green injection for measuring plasma disappearance rate at different time-points."
89563803|NCT03307915|Experimental|Group 1: Ad26.Mos4.HIV + MVA-Mosaic/Placebo|Participants will receive adenovirus serotype 26-Mosaic 4 -Human Immunodeficiency Virus (Ad26.Mos4.HIV) 5*10^10 virus particles (vp) as intramuscular (IM) injection at Weeks 0 and 12 (1 injection) followed by modified Vaccinia Ankara-Mosaic (MVA-Mosaic) 10^8 Plaque-forming unit (pfu) and placebo as IM injection at Weeks 24 and 36 (2 injections).
89563804|NCT03307915|Experimental|Group 2: Ad26.Mos4.HIV + Clade C gp140 + Mosaic gp140|Participants will receive Ad26.Mos4.HIV, 5*10^10 vp as IM injection at Weeks 0 and 12 (1 injection) followed by both Ad26.Mos4.HIV 5*10^10 vp plus Clade C gp140 (125 microgram [mcg]) plus Mosaic gp140 (125 mcg) with aluminum phosphate adjuvant or an equivalent dose of a bivalent vaccine that includes both Clade C gp140 and Mosaic gp140, and aluminum phosphate adjuvant in a single vial, via IM injection at Weeks 24 and 36 (2 injections).
89563805|NCT03307915|Placebo Comparator|Group 3: Placebo|Participants will receive 0.9 percent (%) saline as IM injection at Weeks 0, 12 (one injection) and at Week 24, 36 (two injections).
88968356|NCT00031759|Other|Ablative or excisional therapy|"Patients undergo ablative or excisional therapy.~Quality of life is assessed at baseline, 3-5 days after ablation or excisional therapy, at 3 months, and then annually thereafter.~Patients are followed every 3-4 months until 2 consecutive normal Pap smears or colposcopic exams, every 6 months for 2 years, and then annually until 5 years after completion of study therapy."
89563806|NCT04154059|Experimental|Intervention Group|Patients will receive a physical therapy intervention three times per week, for 8 weeks.
89563807|NCT04154059|No Intervention|Control Group|Patients will not receive any exercise treatment but they will keep their recommended clinical treatment.
89563808|NCT05227963|Experimental|Experimental Group(Group A)|Experimental Group received soft tissue mobilization with neck isometric strengthening exercises.
89563809|NCT05227963|Other|Control group (Group B)|Control group received neck isometric strengthening exercises alone.
89563810|NCT05010343|Active Comparator|carbon ion irradation group|All patients will receive carbon ion irradiation with 65.6 GyE in 16 fractions to the prostate with or without seminal vesicle
89563811|NCT05010343|Active Comparator|Carbon Ion Irradiation With SIB group|All patients will receive carbon ion irradiation with 65.6 GyE in 16 fractions to the prostate with or without seminal vesicle, and with simultaneous integrated boost (SIB) to the gross tumor in the PSMA PET/CT and mpMRI
89563812|NCT04990921|Experimental|Palliative Radiation in Combination with Pembrolizumab|"Stereotactic radiation therapy will be delivered using either linac-based SBRT using 10x flattening filter-free (FFF) photons or Cyberknife Pencil Beam Technology utilizing 6X photons. Treatment will be delivered in 1-5 fractions. Fractionation and total dose (1500 - 3000 cGy) will depend on the site of disease, previous radiation treatment, and patient symptomatology.~Pembrolizumab is supplied as pembrolizumab 100 mg/4 mL vials (25 mg/mL) solution for intravenous infusion. Pembrolizumab at a dose of 200 mg will be administered intravenously every 3 weeks (± 3 days)."
89563813|NCT02824237|Experimental|Improved cook stove|The investigators will conduct a pre-post intervention study to evaluate effectiveness of improved stoves and compare outcomes after two years
89563814|NCT04037059||Spinal Deformity Patients|For patients with disabling spinal deformities, long segment fusions have been shown to improve the health related quality of life (HRQOL). A consequence of spine fusion however is elimination of range of motion especially in the lumbar spine. Even in patients who report overall improvement in pain related domains, difficulty with some ADL's in this patient group has been well documented in previous studies. Complaints such as inability to dress independently, bathing of lower halves of their body, driving a motor vehicle, getting in and out of a chair/bed and performing perineal hygiene care following toileting have been reported.
89563815|NCT02673385||Brazelton scale|Procurement across Brazelton scale
89563816|NCT02673385||No test|usual care
89563817|NCT02628535|Experimental|MGD009|Orlotamab; Humanized B7-H3 x CD3 Dual-Affinity Re-Targeting (DART®) Protein
88968357|NCT00031759|Experimental|Ablative or excisional therapy + imiquimod|"Patients have topical imiquimod applied to the cervix for 6-10 hours twice weekly for a total of 5 doses. Within 3-4 weeks after the final application, patients undergo ablative or excisional therapy. Quality of life is assessed at baseline, after last dose of study drug, 3-5 days after ablation or excisional therapy, at 3 months, and then annually thereafter.~Patients are followed every 3-4 months until 2 consecutive normal Pap smears or colposcopic exams, every 6 months for 2 years, and then annually until 5 years after completion of study therapy."
88968358|NCT01791816|Experimental|Phenylephrine and L-Ng-monomethyl Arginine (L-NMMA)|
89563818|NCT04853407|Experimental|LY03005 extended-release tablets 80 mg group|orally once a day
89563819|NCT04853407|Experimental|LY03005 extended-release tablets 160 mg group|orally once a day
89563820|NCT04853407|Placebo Comparator|Placebo group|orally once a day
89563821|NCT02653495|Experimental|Influenza vaccine in metabolic syndrome|Influenza vaccine
89563822|NCT02653495|Experimental|Influenza vaccine in healthy controls|Influenza vaccine
89563823|NCT04218487|Experimental|XFZY group|2.4g (6 capsules) three times daily for 12 weeks
89563824|NCT04218487|Placebo Comparator|Control group|2.4g (6 capsules) three times daily for 12 weeks
88968359|NCT00031837|Experimental|Dalteparin|5,000 anti-Xa units of dalteparin subcutaneously once daily for six months in addition to gemcitabine at 1,000 mg/m2 as a 30-minute infusion weekly for 7 weeks followed by a week of rest for the first cycle and weekly for three weeks followed by a week of rest for each subsequent cycle.
88968360|NCT00000572|Experimental|Extracorporeal membrane oxygenation (CO2 removal)|Detailed Electronic Protocol Controlled Extracorporeal CO2 Removal with reduced positive-pressure ventilation
88968361|NCT00000572|Active Comparator|Protocol Controlled positive-pressure vent|Detailed Electronic Protocol Controlled positive-pressure ventilation
88968362|NCT00013104||Group 1|
88968363|NCT00013143|Other|Arm 1|
88968364|NCT00031993|Experimental|Treatment (erlotinib hydrochloride)|Patients receive oral erlotinib once daily for 4 weeks. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
88968365|NCT00000575|Active Comparator|1 Budesonide|Budesonide (Pulmicort), two 100 microgram puffs bid + two microgram puffs albuterol (Ventolin) prn
88968366|NCT00000575|Active Comparator|2 Nedocromil|Nedocromil (Tilade), four 2 mg puffs bid + two 90 microgram puffs albuterol prn
88968367|NCT00000575|Placebo Comparator|3 Placebo|Two 100 microgram puffs budesonide placebo bid + two 90 microgram puffs albuterol prn or four 2 mg puffs nedocromil placebo bid + two 90 microgram puffs albuterol prn.
89563825|NCT04507477|Experimental|Rituximab + Ex-vivo lung perfusion|Donor lungs deemed suitable for such patients will undergo ex vivo lung perfusion (EVLP) as per standard practice. In clinical practice almost all adult donor lungs are EBV seropositive. If in the rare case the donor lung is EBV seronegative, then the lung transplant candidate/recipient will no longer need to be part of the study. Therefore, for EBV seropositive lungs meant for an EBV seronegative recipient, one dose of rituximab (500mg) will be added to the EVLP perfusate and be allowed to circulate for 3-4 hours. Lungs will then be transplanted as per standard procedure.
89563826|NCT02472925|Other|Arm 1: Control|"MedSignals pill box will be set into quiet mode to track patient compliance. This mode sends daily adherence data to the Way to Health platform each time the participant opens the pill box, however, does not remind the participant to take the medication."
88968368|NCT00032032|Experimental|radiotherapy + paclitaxel + carboplatin|"Patients undergo radiotherapy once daily 5 days a week for 7 weeks and 2 days (a total of 37 fractions). Patients concurrently receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes once weekly for 7 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.~Beginning 3 weeks after completion of radiotherapy, patients receive paclitaxel and carboplatin as above. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed at baseline, once during the last week of radiotherapy, and then every 3 months for 2 years.~Patients are followed at 3 weeks, every 3 months for 21 months, and then every 6 months for 3 years."
89563827|NCT02472925|Experimental|Arm 2: Reminders/Feedback|MedSignals pill box will track patient compliance and the Way to Health platform will allow participants to receive tailored text message reminders to take the medication if in case the interval from last cap opening is >30 hours (greater than 6 hours overdue).
89563828|NCT02472925|Experimental|Arm 3: Reminders/Feedback/Incentives|MedSignals pill box will track patient compliance and in addition to reminders with missed doses and weekly adherence feedback, patients in this arm will be eligible to receive a small financial incentive each week they demonstrate perfect >85% adherence. The weekly adherence feedback message will also alert patients whether they earned the incentive for the past week.
89563829|NCT01391143|Experimental|MGA271|Fc-optimized, humanized monoclonal antibody
89563830|NCT01675141|Experimental|Lenalidomide Maintenance Therapy for Multiple Myeloma|10 mg oral daily, on days 1-21 of repeated 28 day cycles, to continue until disease progression or unacceptable toxicity.
88968369|NCT00032110|Experimental|Treatment (erlotinib hydrochloride)|Patients receive oral erlotinib once daily. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Patients with a CR receive 2 additional courses after CR is confirmed.
88968370|NCT00013182|Other|Arm 1|
88968371|NCT00032188|Experimental|Arm I (aldesleukin and lowest dose bryostatin 1)|Patients receive IL-2 subcutaneously on days 1-4, 8-11, and 15-18. For the second and subsequent courses of IL-2, patients also receive lowest dose bryostatin 1 IV over 1 hour on days 1, 8, and 15. Treatment repeats every 28 days for at least 3 courses in the absence of disease progression or unacceptable toxicity.
88968372|NCT00032188|Experimental|Arm II (aldesleukin and middle dose bryostatin 1)|Patients receive IL-2 subcutaneously on days 1-4, 8-11, and 15-18. For the second and subsequent courses of IL-2, patients also receive middle dose bryostatin 1 IV over 1 hour on days 1, 8, and 15. Treatment repeats every 28 days for at least 3 courses in the absence of disease progression or unacceptable toxicity.
89563831|NCT03915223|Experimental|"Arm Injection corticosteroids"|Single dose of Solumedrol 2 mg/kg
89563832|NCT03915223|Placebo Comparator|"Arm  injection physiological serum"|Single dose of physilogical serum
89563833|NCT05102149|Experimental|Test arm|PB-201: 100 mg each time, orally in the morning and evening respectively; Vildagliptin matched placebo: One tablet each time, orally in the morning and evening respectively;
89563834|NCT05102149|Active Comparator|Vildagliptin arm|Vildagliptin: 50 mg each time, orally in the morning and evening respectively; PB-201 matched placebo: One tablet each time, orally in the morning and evening respectively;
89563835|NCT05102149|Placebo Comparator|Placebo arm|PB-201 matched placebo: One tablet each time, orally in the morning and evening respectively; Vildagliptin matched placebo: One tablet each time, orally in the morning and evening respectively;
88968373|NCT00032188|Experimental|Arm III (aldesleukin and highest dose bryostatin 1)|Patients receive IL-2 subcutaneously on days 1-4, 8-11, and 15-18. For the second and subsequent courses of IL-2, patients also receive highest dose bryostatin 1 IV over 1 hour on days 1, 8, and 15. Treatment repeats every 28 days for at least 3 courses in the absence of disease progression or unacceptable toxicity.
88968374|NCT00032227|Experimental|1|Surgical release of CTS
88968375|NCT00032227|Active Comparator|2|Non-surgical treatment for CTS (splint, physical therapy, ultrasound)
88968376|NCT00013221|Other|Arm 1|
88968377|NCT00032344|Other|1|Phase I - Cross-sectional; Phase II - 5 year follow-up; Phase III - 10 year follow-up
88968378|NCT00013260|Other|Arm 1|
88968379|NCT00032539||1|
89210649|NCT04034394|Experimental|Electromoxibustion|Participants in this group will receive electromoxibustion using a knee-brace-like device which produces thermal stimulation with a moxa pad inside (Fort Mayer, Guangzhou, China).
89563836|NCT04019431|Experimental|Whey protein|VLCKD (780 kcal/day) low in carbohydrates (<50 g per day) and lipids (only 10 g of olive oil per day) for 45 days. High-biological-value protein preparations will be given four times per day, based on whey protein.
89563837|NCT04019431|Active Comparator|Vegetable proteins|VLCKD (780 kcal/day) low in carbohydrates (<50 g per day) and lipids (only 10 g of olive oil per day) for 45 days. High-biological-value protein preparations will be given four times per day, based on vegetal protein derived from soya or green peas or cereals.
89563838|NCT04019431|Active Comparator|Animal proteins|VLCKD (780 kcal/day) low in carbohydrates (<50 g per day) and lipids (only 10 g of olive oil per day) for 45 days.Patients will be given four meals per day containing natural animal protein (meat, fish, eggs, dairy products without whey protein).
89563839|NCT04922749|No Intervention|TAU|Treatment as usual (TAU); consist mainly of pharmacological treatment and psychotherapy.
89563840|NCT04922749|Experimental|MULTI+|Lifestyle treatment
89563841|NCT04412395|Active Comparator|Arm 01 (SOC + Lactoferrin 1200 mg QID)|Patients randomized to this group will receive two 600 mg Lactoferrin tablets QID plus the Standard of Care (SOC) treatment(s).
89563842|NCT04412395|Placebo Comparator|Arm 02 (SOC + Placebo QID)|Patients randomized to this group will receive two placebo tablets QID plus the SOC treatment(s).
89563843|NCT04016935||Patients with primary invasive ER+ HER2- breast cancer|Distant recurrence-free survival (DRFS) between years 5 and 10 post-diagnosis of women with ER+, HER2- breast cancer who are classified as low risk according to their EPclin score and who did not receive extended endocrine therapy
89563844|NCT04754269|Experimental|Beverage Intervention|Parents will watch a video that promotes optimal beverage practices for young children. Parents will receive that reinforce and expand on the messages in the video.
89563845|NCT04754269|Experimental|Reading Intervention|Parents will watch a video that promotes reading to children. Parents will receive text messages that reinforce and expand on the messages in the video.
89563846|NCT04987099|Experimental|Experimental Dose|Participants will consume a 15 mL grape juice cocktail solution that contains 550 mg of choline once daily for the duration of their pregnancy.
89563847|NCT04987099|Placebo Comparator|Control Dose|Participants will consume a 15 mL grape juice cocktail solution that contains 25 mg of choline once daily for the duration of their pregnancy.
89563848|NCT03906721|Experimental|Conditioning & Open-Label Placebo (COLP)|Days 1 to 3 will include the acquisition phase where oxycodone will be prescribed on a schedule of 3-4 times per day and paired with open-placebo and smelling the essential oil. Days 4 to 6 will be the evoked phase, and patients will receive full oxycodone dosage on alternating days with open placebo and smelling the essential oil.
89563849|NCT03906721|Other|Treatment-as-usual|For the duration of the study, days 1 to 6, oxycodone will be prescribed on a schedule of 3-4 times per day.
89563850|NCT03994081|Experimental|alpha Transcranial alternating current stimulation (tACS).|10 Hz tACS with a zero-to-peak amplitude of 1 mA for 40 minutes.
88968380|NCT00032617|Active Comparator|1|Prolonged Exposure
88968381|NCT00032617|Active Comparator|2|Present Centered Therapy
88968382|NCT00396370|Experimental|Group A: BCG ID/Placebo PO; Placebo ID/Placebo PO|Primary vaccination: BCG ID (Danish)/Placebo PO; secondary vaccination (1 year later): Placebo ID/Placebo PO.
88968383|NCT00396370|Experimental|Group B: BCG ID/Placebo PO; BCG ID/Placebo PO|Primary vaccination: BCG ID (Danish)/Placebo PO; secondary vaccination (1 year later): BCG ID (Danish)/Placebo PO.
88968384|NCT00396370|Experimental|Group C: Placebo ID/BCG PO; Placebo ID/Placebo PO|Primary vaccination: Placebo ID/BCG PO (Danish); secondary vaccination (1 year later): Placebo ID/Placebo PO.
88968385|NCT00396370|Experimental|Group D: Placebo ID/BCG PO; Placebo ID/BCG PO|Primary vaccination: Placebo ID/BCG PO (Danish); secondary vaccination (1 year later): Placebo ID/BCG PO (Danish).
88968386|NCT00396370|Experimental|Group E: BCG ID/BCG PO; Placebo ID/Placebo PO|Primary vaccination: BCG ID (Danish)/BCG PO (Danish); secondary vaccination (1 year later): Placebo ID/Placebo PO.
88968387|NCT00396370|Experimental|Group F: BCG ID/BCG PO; BCG ID/BCG PO|Primary vaccination: BCG ID (Danish)/BCG PO (Danish); secondary vaccination (1 year later): BCG ID (Danish)/BCG PO (Danish).
88968388|NCT00396370|Experimental|Group G: Connaught strain BCG ID|Primary vaccination: Connaught strain BCG ID; secondary vaccination (1 year later): none.
89210650|NCT04034394|Active Comparator|Knee health education|Participants in this group will attend 2 sessions (120 minutes each, 1-week apart) of health education related to knee OA symptom management.
89210651|NCT04005573|Experimental|VD3 group|dietary supplement : VD3 group treated with 50000 IU VD3/ week for 8 weeks
89563851|NCT03994081|Sham Comparator|Sham stimulation|20 seconds of ramp-up, 40 seconds of 10 Hz tACS with zero-to-peak amplitude of 1 mA, and 20 seconds of ramp-down for a total of 80 seconds of stimulation.
89563852|NCT04096573|Experimental|LC51-0255 low dose|Oral, daily, low dose for induction period, high dose for OLE period
89563853|NCT04096573|Experimental|LC51-0255 middle dose|Oral, daily, middle dose for induction period, high dose for OLE period
89563854|NCT04096573|Experimental|LC51-0255 high dose|Oral, daily, high dose for induction period, high dose for OLE period
89563855|NCT04096573|Placebo Comparator|placebo|Oral, daily, placebo for induction period, high dose for OLE period
89563856|NCT04919083||Non-exposed cohort (protective factor)|Group of patients operated on during the year 2021 in San Juan de Dios Hospital for hip fracture and to which the new programme implementing functional recovery and therapeutic exercise will be applied with follow-up for one year. The implementation of a functional recovery plan and subsequent follow-up is considered a protective factor in relation to the loss of functionality.
89563857|NCT04919083||Exposed cohort (retrospective)|Complete cohort of patients operated on during the year 2020 in San Juan de Dios Hospital for hip fracture and to whom no specific functional recovery plan was applied.
89563858|NCT04529863||Tocilizumab|Reference group
89563859|NCT04529863||Abatacept|Exposure group
89563860|NCT04441957||Group A, MOCA-group|Procedure/Surgery: MOCA Mechano-Chemical Ablation plus Elastic Compression
89563861|NCT04441957||Group B, Elastic Compression only group|Treatment: Elastic Compression only
89563862|NCT04432441|Active Comparator|Therapeutic physical exercise program for scapulo-humeral stabilitation|Therapeutic physical exercise program for scapulo-humeral stabilitation
89563863|NCT04432441|Active Comparator|Therapeutic physical exercise program for scapulo-humeral stabilitation + Electrostimulation|Therapeutic physical exercise program for scapulo-humeral stabilitation + Electrostimulation
89563864|NCT03883945|Placebo Comparator|Cohort 1 - vehicle|Subjects randomized to vehicle will receive vehicle administration to the target area.
88968389|NCT00000620|Experimental|Glycemia Trial: intensive control|Open label administration of oral anti-hyperglycemic agents and/or insulin in combination with dietary/lifestyle advice as needed to achieve glycated hemoglobin (HbA1c) levels <6.0%.
88968390|NCT00000620|Active Comparator|Glycemia Trial: standard control|Open label administration of oral anti-hyperglycemic agents and/or insulin in combination with dietary/lifestyle advice as needed to achieve glycated hemoglobin (HbA1c) levels of 7.0 - 7.9%.
88968391|NCT00000620|Experimental|BP Trial: intensive control|Open label administration of anti-hypertensive agents to reduce and maintain systolic blood pressure (SBP) level to <120 mmHg.
88968392|NCT00000620|Active Comparator|BP Trial: standard control|Open label administration of multiple anti-hypertensive agents to maintain SBP level <140 mm Hg.
88968393|NCT00000620|Experimental|Lipid Trial: fenofibrate|Double blind administration of 160 mg/day of fenofibrate in participants with estimated glomerular filtration rate (eGFR) ≥50 mL/min/1.73m2 or 54 mg/day in patients with eGFR <50 mL/min/1.73m2 in combination with open label simvastatin.
88968394|NCT00000620|Placebo Comparator|Lipid Trial: placebo|Double blind administration of placebo matching either 160 mg/day in participants with eGFR ≥50 mL/min/1.73m2 or 54 mg/day in participants with eGFR <50 mL/min/1.73m2 in combination with open label simvastatin.
88968395|NCT00033280|Experimental|Pre-RT temozolomide, RT plus temozolomide|Pre-radiation therapy (RT) temozolomide, RT plus temozolomide
88968396|NCT00033358|Experimental|Arm I (medroxyprogesterone)|Patients receive medroxyprogesterone intramuscularly once on day 1. Approximately 90 days after the injection, patients undergo a repeat transvaginal ultrasound and endometrial biopsy.
88968397|NCT00033358|Experimental|Arm II (ethinyl estradiol, norgestrel)|Patients receive OCP comprising ethinyl estradiol and norgestrel once daily on days 1-21. Treatment repeats every 28 days for 3-4 courses (3-4 packs of OCP) in the absence of unacceptable toxicity. Approximately 1 week after starting the fourth pack of OCP, patients undergo a repeat transvaginal ultrasound and endometrial biopsy.
88968398|NCT00013533|Experimental|1|Transplant with Induction Therapy
88968399|NCT00033397||Arm A|"Patients receive an injection of gadopentetate dimeglumine and undergo magnetic resonance imaging (MRI) of the breast before initiation, 1-3 days after initiation, and then after completion of neoadjuvant anthracycline-based chemotherapy and prior to surgery. Patients who previously received a taxane also undergo an additional contrast-enhanced MRI scan.~Mammograms and possibly ultrasounds are performed prior to and after chemotherapy (before surgery).~Patients are followed every 6 months for 5 years and then annually for up to 10 years."
88968400|NCT02971696|Experimental|HCC patients (Group 1)|Sorafenib will be administrated at a dose of 400 mg twice daily (consisting of two 200-mg tablets).Treatment interruptions and up to two dose reductions (first to 400 mg once daily and then to 400 mg every 2 days) will permitted for drug- related adverse effects. If further dose reductions will required, patients will withdraw from the study
88968401|NCT02971696|Active Comparator|HCC patients (Group 2)|Patient will take best supportive care
88968402|NCT00033553|Experimental|Paclitaxel + Carboplatin|Paclitaxel and carboplatin induction (2 cycles)followed by chemotherapy with the addition of radiotherapy for 7 cycles
88968403|NCT00033553|Experimental|Gemcitabine + Carboplatin|Gemcitabine and carboplatin induction (2cycles) followed by chemotherapy with the addition of radiotherapy for 7 cycles
89210652|NCT04005573|Experimental|omega 3- FA group|dietary supplement : omega 3- FA group 1000 mg wild salmon and fish oil complex (contain 300 mg of omega 3-FA) once daily for 8 weeks
89563865|NCT03883945|Active Comparator|Cohort 1 - 0.033%|Subjects randomized to vehicle will receive AIV001 0.033% administration to the target area.
89563866|NCT03883945|Placebo Comparator|Cohort 2 - vehicle|Subjects randomized to vehicle will receive vehicle administration to the target area.
89563867|NCT03883945|Active Comparator|Cohort 2 - 0.1%|Subjects randomized to vehicle will receive AIV001 0.01% administration to the target area.
89563868|NCT03883945|Placebo Comparator|Cohort 3 - vehicle|Subjects randomized to vehicle will receive vehicle administration to the target area.
89563869|NCT03883945|Active Comparator|Cohort 3 - 0.3%|Subjects randomized to vehicle will receive AIV001 0.03% administration to the target area.
89563870|NCT03883945|Placebo Comparator|Cohort 4 - vehicle|Subjects randomized to vehicle will receive vehicle administration to the target area.
89563871|NCT03883945|Active Comparator|Cohort 4 - 1%|Subjects randomized to vehicle will receive AIV001 0.03% administration to the target area.
89563872|NCT04582591|Experimental|Cannabidiol|Patients will receive cannabidiol in conjunction with their standard chemotherapy treatment
89563873|NCT04217239|Experimental|Ivor-Lewis group|minimally invasive esophagectomy (MIE) with intrathoracic anastomosis
89563874|NCT04217239|Active Comparator|McKeown group|minimally invasive esophagectomy (MIE) with cervical anastomosis
89563875|NCT04212481|Experimental|single port group|Uniport video-assisted thoracoscopic surgery for NSCLC
89563876|NCT04212481|Active Comparator|two ports group|video-assisted thoracoscopic surgery for NSCLC using two ports
89563877|NCT04212481|Active Comparator|three ports group|video-assisted thoracoscopic surgery for NSCLC using three ports
89563878|NCT03997669||experimental group|patients with malignant pleural effusion
89563879|NCT03997669||control group|patients with benign pleural effusion
89563880|NCT04497883|Experimental|Cohort A: Non-Hispanic, Caucasian|Non-Hispanic, Caucasian group participants will receive 400 milligram (mg) maribavir tablets orally once on Day 1 during treatment period 1.
89563881|NCT04497883|Experimental|Cohort B: Japanese Descent|Japanese descent group participants will receive 400 mg maribavir tablets orally once on Day 1 during treatment period 1 followed by 200 mg or 800 mg maribavir tablets orally once on Day 1 during treatment period 2 followed by 800 mg or 200 mg maribavir tablets orally once on Day 1 during treatment period 3 in cross-over fashion. A washout period of 72 hours will be maintained between treatment period 1, 2, and 3.
89563882|NCT03756103|Experimental|SPH3127 tablet Dose 1|Low-dose group
89563883|NCT03756103|Experimental|SPH3127 tablet Dose 2|Mid-dose group
89563884|NCT03756103|Experimental|SPH3127 tablet Dose 3|High-dose group
89563885|NCT03756103|Placebo Comparator|SPH3127 tablet Placebo|Placebo Control group
89563886|NCT04347655|Experimental|HFrEF|patients with heart failure with reduced ejection fraction
89563887|NCT04347655|Experimental|HFpEF|heart failure with preserved ejection fraction
89563888|NCT04347655|Active Comparator|Control|healthy (no heart failure) control participants
89563889|NCT03688633|Experimental|Candesartan|
89563890|NCT03688633|Active Comparator|Usual care|
89563891|NCT04436029|Experimental|Descartes 11|
89563892|NCT03743935|Experimental|Early cardiac MRI post-STEMI|Early stages post-STEMI (within the first 5 days)
89563893|NCT03736759|Experimental|Exercise and vaccine in same arm|20 min eccentric resistance exercise of deltoid and biceps brachii in non-dominant arm, followed immediately by intramuscular injection of seasonal quadrivalent influenza vaccine in non-dominant arm
89563894|NCT03736759|Active Comparator|Exercise and vaccine in different arms|20 min eccentric resistance exercise of deltoid and biceps brachii in dominant arm, followed immediately by intramuscular injection of seasonal quadrivalent influenza vaccine in non-dominant arm
89563895|NCT03736759|No Intervention|vaccine only|20 min rest followed immediately by intramuscular injection of seasonal quadrivalent influenza vaccine in non-dominant arm
89563896|NCT03662815|Experimental|iNeo-Vac-P01|"Personal Cancer Vaccine: iNeo-Vac-P01 (peptides)+ GM-CSF;~Peptides: 0.1 or 0.3 mg per peptide given on days 1, 4, 8, 15, 22, 78, and 162 for a total of 7 doses. Additional booster vaccines might be administered depending on ethics and patients' potential benefit.~GM-CSF: 40 mcg given 30 minutes before iNeo-Vac-P01."
89563897|NCT03490903|Experimental|VR with or without Moderate Sedation|"Patients randomized to receive a Virtual Reality Intervention will be fitted with a VR headset and headphones and undergo a continuous immersive meditation experience. This will begin immediately prior to the start of the procedure, and continue until the procedure is completed.~Patient pain and anxiety levels will be frequently assessed by procedure operator and circulating nurse, and pain medication or anxiolytic medications will be administered in the absence of contraindications. Baseline amounts of sedation pre-procedurally will not be used in either arm. Pain and Anxiety Scores will be assessed pre, intra, and post-procedurally. If no contraindications, the operator will decide upon how much sedation medication to administer if indicated or requested. This is the usual manner in which pain and anxiety is treated in the cath lab."
89563898|NCT03490903|Active Comparator|Moderate Sedation without VR|Subjects randomized to the comparison arm will not undergo the Virtual Reality Intervention. Baseline amounts of sedation pre-procedurally will not be used in either arm. Subjects will be assessed periodically by physicians and/or circulating nurses for their pain and anxiety levels. The patient may also prompt the staff that they are anxious or in pain, and if no contraindications, the operator will decide upon how much medication to administer. This is the usual manner in which pain and anxiety is treated in the cath lab.
89563899|NCT03438721|Experimental|Infant Obesity Prevention|The infant obesity prevention arm will provide parents with education on optimal infant feeding, sleep, and screen time practices.
89563900|NCT03438721|Experimental|Financial Coaching|The financial coaching arm will provide parents with education on basic financial literacy topics and coaching to help parents achieve financial goals.
89563901|NCT04435951||Group 1 (with TMJD)|Group 1, consists of 60 patients diagnosed with Temporomandibular Joint Dysfunction (TMJD) according to the Research Diagnostic Criteria for Temporomandibular Disorders by a specialist and experienced dentist in TMJD.
89563902|NCT04435951||Group 2 (without TMJD)|Group 2, consists of 60 individuals who did not exhibit TMJD symptoms and have not TMJD diagnosis.
89563903|NCT04253509||Lung cancer|
89563904|NCT04253509||Benign pulmonary disease|
89563905|NCT03712579|Experimental|SFA-Rich Meal|Participants will consume a SFA-rich test meal (75g test fat) and sequential blood and white adipose tissue samples will be collected
89563906|NCT03712579|Experimental|MUFA-Rich Meal|Participants will consume a MUFA-rich test meal (75g test fat) and sequential blood and white adipose tissue samples will be collected
89563907|NCT04248985||Pre-Intervention|Baseline measurement of timing and behavior in OOH cardiac arrest patients presenting with ongoing CPR.
89563908|NCT04248985||Post-Intervention|Timing and behavior in OOH cardiac arrest patents presenting with ongoing CPR
89563909|NCT03954613|Experimental|Group A|Donepezil/Memantin Combination
89210653|NCT04005573|Experimental|VD3 and omega 3 FA group|dietary supplement : VD3 and omega-3FA 50000 IU VD3/week for 8 weeks and 1000 mg wild salmon and fish oil complex (contain 300 mg of omega 3-FA) once daily for 8 weeks
89563910|NCT03954613|Experimental|Group B|Donepezil/Memantin Combination + Cognitive Exercises (BEYNEX Software)
89563911|NCT03954613|Active Comparator|Group C|Donepezil Mono
89563912|NCT03954613|Active Comparator|Group D|Donepezil Mono + Cognitive Exercises (BEYNEX Software)
89563913|NCT03954613|Active Comparator|Group E|Memantine Mono
89563914|NCT03954613|Active Comparator|Group F|Memantine Mono + Cognitive Exercises (BEYNEX Software)
89563915|NCT04504201||Early Breast Cancer Patients|Early breast cancer patients (Stage I-III) who have completed primary treatment with a current Body mass index (BMI) over 30.
89210654|NCT04005573|Other|control group|no intervention was given
89563916|NCT04504201||Medical Oncology Clinicians|Oncology providers associated with community-based practices
89563917|NCT04052893|Experimental|Study group|100 patients will be assigned into a study group.
89563918|NCT04052893|Active Comparator|Control group|100 patients will be assigned into a control group.
89563919|NCT03367819|Experimental|Phase 1: mCRPC/NSCLC|Isatuximab dose 1 and REGN2810 predefined dose
89563920|NCT03367819|Experimental|Cohort A-1: mCRPC, isatuximab and REGN2810 combination|Participants with mCRPC will be given isatuximab dose determined in Phase 1 arm of study and REGN2810 predefined dose
89563921|NCT03367819|Experimental|Cohort A-2: mCRPC, isatuximab monotherapy|Participants with mCRPC will be given isatuximab dose 2
89563922|NCT03367819|Experimental|Phase 2 Cohort B: NSCLC|Participants with NSCLC will be given isatuximab dose determined in Phase 1 arm of study and REGN2810 predefined dose
89563923|NCT03367819|Experimental|Possibly Phase 2 Cohort C: mCRPC|Isatuximab dose 3 will be given in combination with REGN2810 predefined dose or isatuximab dose 3 will be given as monotherapy in participants with mCRPC
89563924|NCT03367819|Experimental|Possibly Phase 2 Cohort D: NSCLC|Isatuximab dose 3 will be given in combination with REGN2810 predefined dose
89563925|NCT03044509||TB exposure|
89563926|NCT03044509||TB infection (latent TB)|
89563927|NCT03044509||TB disease (active TB)|
89563928|NCT03598387|Experimental|APD group|Subjects will receive PD catheter placement and subsequent automated peritoneal dialysis treatment.
89563929|NCT03598387|Active Comparator|IHD group|Subjects will receive un-tunneled hemodialysis catheter placement and subsequent intermittent hemodialysis.
89563930|NCT04781725|Experimental|INT230-6 Treated Arm|"Part I: Patients will receive up to 3 doses of INT230-6 injected weekly prior to breast surgery~Part II: Patients will receive up to 2 intratumoral doses of INT230-6 (over a 15-day period) prior to breast surgery"
89563931|NCT04781725|Placebo Comparator|Control Arm|"Part I: No intervention while awaiting surgery~Part II: Placebo saline injection"
89563932|NCT04761835|Active Comparator|Dietary Peanut|Participants in this group will be asked to continue peanut in their diet for 1 year at a dose determined from the double blind placebo controlled food challenge at baseline. After the 1 year period, participants will be given another double blind placebo controlled food challenge which will be used to determine their current peanut threshold. The current peanut threshold will be used to determine which participants will go into clinical care and which will get sustained unresponsiveness food challenges to peanut.
89563933|NCT04761835|No Intervention|Strict avoidance|Participants in this group will be asked to strictly avoid any peanut in their diet for 1 year. After the 1 year period, participants will be given another double blind placebo controlled food challenge which will be used to determine whether they will transition to daily dietary peanut or continue with clinical care.
89563934|NCT02550769|Experimental|TRANSANAL TOTAL MESORECTAL EXCISION|Transanal approach of total mesorectal excision.
88968404|NCT00033592|Experimental|Arm I: nicotine inhaler cartridges|"Participants receive 6-16 nicotine inhaler cartridges per day. Treatment continues for 12 weeks. After 12 weeks, participants are randomized a second time based on whether they continue to smoke or are smoke-free.~Participants randomized to arm I who continue to smoke are randomized to one of two treatment arms Arm IV or Arm V. Participants randomized to arm I who are smoke-free are randomized to one of two treatment arms Arm VIII or Arm IX."
88968405|NCT00033592|Experimental|Arm II: bupropion|"Participants receive oral bupropion 1-2 times daily.~Treatment continues for 12 weeks. After 12 weeks, participants are randomized a second time based on whether they continue to smoke or are smoke-free. After 12 weeks, participants are randomized a second time based on whether they continue to smoke or are smoke-free.~Participants randomized to arm II who continue to smoke are randomized to one of two treatment arms Arm VI or Arm VII. Participants randomized to arm II who are smoke-free are randomized to one of two treatment arms Arm Arm X or Arm XI."
89210655|NCT03970213|Placebo Comparator|Control Group|Intravenous normal saline (50cc) given over 15 minutes starting just prior to skin incision, and repeated 4 hours later
89210656|NCT03970213|Experimental|TXA Group|One gram of intravenous tranexamic acid (TXA) in normal saline (50cc) given over 15 minutes starting just prior to skin incision, and repeated 4 hours later
89563935|NCT02550769|Active Comparator|Laparoscopic-LAR|Type of surgical intervention as control group: Laparoscopic low anterior resection with total mesorectal excision for rectal cancer
89563936|NCT02320279||Women in labor|Pregnant women, women in labor, and women who are admitted to labor and delivery for scheduled c-sections will form the eligible population for recruitment into our study.
89563937|NCT03554707|Experimental|SGT-53 with radiation or drugs|"Radiation phase: SGT-53 will be given at 2.1 mg DNA/m2 twice weekly for the first week of radiation therapy, and then increase to 2.8 mg DNA/m2 twice weekly. Radiation therapy will be administered as per clinical care, with a target of fifteen (15) fractions, but patients with other clinically-determined radiation plans will be allowed.~Chemotherapy phase: SGT-53 will be administered at the highest tolerated dose given during radiation phase. Irinotecan will be given at a dose of 50mg/m2/dose IV daily for five days in a 4-week cycle. Temozolomide will be given at a dose of 100mg/m2 PO daily for five days in a 4-week cycle and bevacizumab will be given at a dose of 10mg/kg IV every two weeks in a 4-week cycle."
89563938|NCT02179333||Subjects with Ataxia|Patients with a diagnosis of ataxia (Friedreich's ataxia or Spinocerebellar ataxia type 1-30) aged 18-80 years old will be recruited for the study.
89563939|NCT03502759|No Intervention|Pre-intervention|Seizure patients receive usual care.
89563940|NCT03502759|Experimental|Post-intervention|Physicians provide care enhanced by computer based clinical decision support about SUDEP.
89563941|NCT04349605|Experimental|Meditation|This is a daily 15 minute meditation with guided breathing. Accessible through an app.
89563942|NCT04349605|Experimental|Kundalini Yoga|This is a daily 30 minute practice of Kundalini Yoga (stretching, guided breathing, and meditation). Accessible by smart phone, tablet or computer.
89563943|NCT04349605|No Intervention|Treatment as Usual|This group will serve as the comparison to assess the efficacy of the active treatments in that no study treatment will be provided. The participants will be asked to not start new treatments during the 8 weeks of the study.
89563944|NCT00790543||Observation|Children newly diagnosed with Crohn's disease.
89563945|NCT04299451|Experimental|Open dialogue about CAM (ODC-COC)|"Participation in an open dialogue about CAM with a nurse specialist. The dialogue will be based on the fundamentals of person-centered care and include patient preferences and wishes, reliable information and counselling, and advice about the potential risks and benefits of using CAM.~The dialogue is estimated to last approximately 60 minutes and all dialogues will be conducted by the same nurse. Depending on patient needs and wishes there may be a follow-up consultation one month after the first dialogue."
88968406|NCT00033592|Experimental|Arm III: nicotine inhaler cartridges|"Participants receive 6-16 nicotine inhaler cartridges per day and oral bupropion 1-2 times daily. Treatment continues for 12 weeks. After 12 weeks, participants are randomized a second time based on whether they continue to smoke or are smoke-free.~Participants randomized to arm III who continue to smoke do not receive any further therapy. Participants randomized to arm III who are smoke-free are randomized to one of four treatment arms Arm XII, Arm XIII, Arm XIV or Arm XV."
89563946|NCT04299451|No Intervention|Standard care|Standard care including referral to a homepage about complementary alternative medicine
89563947|NCT04264663|Experimental|furazolidone-tetracycline-containing quadruple|patients in furazolidone-tetracycline-containing quadruple group will receive Esomeprazole 40mg po bid, tetracycline 500mg po qid , bismuth subcitrate (Colloidal Bismuth Pectin) 200mg po bid, and furazolidone 100mg po bid for 14d
89563948|NCT04264663|Active Comparator|tinidazole-tetracycline-containing quadruple group|patients in tinidazole-tetracycline-containing quadruple group will receive Esomeprazole 40mg po bid, tetracycline 500mg po qid , bismuth subcitrate (Colloidal Bismuth Pectin) 200mg po bid, and tinidazole 500mg po tid for 14d.
89563949|NCT04264585|Experimental|Standard ICBT|Clients assigned to the Standard ICBT condition will receive the standard version of the ICBT course, which consists of four lessons spread across the span of five weeks. Clients will receive five weeks of therapist support.
89563950|NCT04264585|Experimental|ICBT with Motivational Interviewing|Clients assigned to the ICBT with Motivational Interviewing condition will receive the Planning for Change lesson before Lesson 1 of the UniWellbeing Course.
89563951|NCT04264585|Experimental|ICBT with Booster|Clients assigned to the ICBT with Booster condition will receive access to a booster session one month after the end of the ICBT course.
89563952|NCT04264585|Experimental|ICBT with Motivational Interviewing and Booster|Clients assigned to the ICBT with Motivational Interviewing and Booster condition will receive access to both the Motivational Interviewing content (before Lesson 1 of the UniWellbeing Course) and the booster session (one month after ICBT course).
89563953|NCT02827045||Depressive phase|Vestibular test
89563954|NCT02827045||Maniac phase|Vestibular test
89563955|NCT02827045||Euthimic phase|Vestibular test
89563956|NCT02827045||Healthy subject|Vestibular test
89563957|NCT02765737|Active Comparator|Group 1|Treatment 1 - dHACM plus Control Burn Area A Treatment 2 - Control Burn Area B
89563958|NCT02765737|Active Comparator|Group 2|Treatment 1 - dHACM plus Control Burn Area B Treatment 2 - Control Burn Area A
89563959|NCT04599751|Experimental|Hair removal treatment|Trio laser module (Alma Lasers)
89563960|NCT04563559|Other|DEXTENZA vs prednisolone acetate 1%)|Subjects will randomly receive Dextenza or prednisolone acetate 1% in the first eye after surgery. At the time of the second eye surgery, the other eye will receive the drug that the first eye did not receive. Subjects will receive both drugs during the course of the study and therefore there is only 1 ARM for this study.
88968407|NCT00033592|Experimental|Arm IV: bupropion|"Participants receive oral bupropion 1-2 times daily for 12 weeks.~All participants are followed every month for 6 months."
88968408|NCT00033592|Placebo Comparator|Arm V: placebo|"Participants receive oral placebo 1-2 times daily for 12 weeks.~All participants are followed every month for 6 months."
88968409|NCT00033592|Experimental|Arm VI: nicotine inhaler cartridges|"Participants receive 6-16 nicotine inhaler cartridges per day for 12 weeks.~All participants are followed every month for 6 months."
88968410|NCT00033592|Placebo Comparator|Arm VII: placebo inhaler|"Participants receive 6-16 placebo inhaler cartridges per day for 12 weeks.~All participants are followed every month for 6 months."
88968411|NCT00033592|Experimental|Arm VIII: nicotine inhaler cartridges|"Participants receive 6-16 nicotine inhaler cartridges per day for 40 weeks.~All participants are followed every month for 6 months."
89210657|NCT00821834|Experimental|Clopidogrel|"Patients received:~clopidogrel 300 mg as a loading dose, then 75 mg once daily as a maintenance dose,~ticlopidine matching placebo twice daily."
89563961|NCT02124187|Experimental|eCig 24 mg nicotine|eCig 24 mg nicotine for 12 weeks
89563962|NCT02124187|Sham Comparator|Ecig 0 mg nicotine|eCig 0 mg nicotine for 12 weeks
89563963|NCT02124187|Placebo Comparator|Nicotine free inhalator|nicotine free inhalator for 12 weeks
89563964|NCT05403073|No Intervention|No Nerve Blocking|Pain management at ER Department will be as usually with iv drugs and 3 kilogram soft traction.
89563965|NCT05403073|Active Comparator|Ultrasound Nerve blocking|Pain management at ER Department will be as usually with iv drugs and ultrasound guided Suprainguinal Iliac Fascia Nerve Block.
89563966|NCT02002819|Experimental|Levetiracetam-Placebo|This group receives levetiracetam for 4 weeks twice daily, then has a break where no treatment is given for 4 weeks, and then receives placebo for 4 weeks.
89563967|NCT02002819|Experimental|Placebo-Levetiracetam|This group receives placebo for 4 weeks twice daily, then has a break where no treatment is given for 4 weeks, and then receives levetiracetam for 4 weeks.
88968412|NCT00033592|Placebo Comparator|Arm IX: placebo inhaler cartridges|"Participants receive 6-16 placebo inhaler cartridges per day for 40 weeks.~All participants are followed every month for 6 months."
88968413|NCT00033592|Experimental|Arm X: bupropion|"Participants receive oral bupropion 1-2 times daily for 40 weeks.~All participants are followed every month for 6 months."
88968414|NCT00033592|Placebo Comparator|Arm XI: placebo|"Participants receive oral placebo 1-2 times daily for 40 weeks.~All participants are followed every month for 6 months."
88968415|NCT00033592|Experimental|Arm XII: nicotine inhaler cartridges|"Participants receive 6-16 nicotine inhaler cartridges per day and oral placebo 1-2 times daily for 40 weeks.~All participants are followed every month for 6 months."
88968416|NCT00033592|Placebo Comparator|Arm XIII: placebo inhaler cartridges|"Participants receive 6-16 placebo inhaler cartridges per day and oral bupropion 1-2 times daily for 40 weeks.~All participants are followed every month for 6 months."
88968417|NCT00033592|Experimental|Arm XIV: nicotine inhaler cartridges|"Participants receive 6-16 nicotine inhaler cartridges per day and oral bupropion 1-2 times daily for 40 weeks.~All participants are followed every month for 6 months."
89563968|NCT05399017|Experimental|EZVent|"Subjects who are involved in the clinical trial are already mechanically ventilated on traditional standard commercial ventilator. Baseline measurements (T0) will be taken from each patient before being transferred to EZVent ventilator. The following measurements will be taken: Vital Signs and hemodynamics (heart rate, blood pressure, temperature, Respiratory rate), Chest X-ray, Arterial blood gases as well as the ventilator mode parameters (dependent on each mode) and lung mechanics parameters (Peak, Plateau, Mean Airway Pressure, Tidal Volume, Airway Resistance and Static Compliance).~After taking the baseline measurements, subjects will be disconnected from their traditional standard ventilator and immediately connected to EZVent using the same previous original setting.~After 60 & 120 minutes of ventilation on EZVent (T1&T2) respectively, the same measurement will be taken (Vital signs and Hemodynamics will be continuously monitored and recorded every five minutes)."
89563969|NCT05123833|Active Comparator|Dartos Fascia|Dartos flap is used as a covering layer for urethra during repair of hypospadias
89563970|NCT05123833|Active Comparator|Tunica Vaginalis|Tunica Vaginalis Flap is used as a covering layer for urethra during repair of hypospadias
89563971|NCT05123677||Low Risk|These patients are screened to be low-risk for pre-eclampsia and fetal growth restriction by the guidelines set out by the National Institute for Health and Care Excellence; and the Royal College of Obstetricians & Gynaecologists, respectively.
89563972|NCT05123677||High Risk|These patients are screened to be high-risk for pre-eclampsia and fetal growth restriction by the guidelines set out by the National Institute for Health and Care Excellence; and the Royal College of Obstetricians & Gynaecologists, respectively.
89563973|NCT05123443||1 - Cross sectional genetics study|International, multicentre study assessing genetic predictors of chronic inflammation in 1000 MS patients with both susceptibility-based brain MRI scan and DNA from peripheral blood samples.The cross-sectional group will include 100 NUH participants who were previously scanned with iron sensitive sequences. These patients will be contacted by their clinical team and invited to participate. Blood samples will be stored in a -80° freezer until all 100 samples have been acquired. At this point, the samples will be shipped to the US for analysis, along with previously acquired MRI scans.
89563974|NCT05123443||2 - Longitudinal cohort MRI study|"The repeat MRI cohort group will be split into two phases. Phase 1: 30 participants who have consented to provide blood samples in the cross sectional genetics study will also be invited to participate by having an additional 7T MRI (funding already secured).~Phase 2: Following completion of phase 1 and securing additional funds we aim to perform more scans to complete our analysis. Exact number of phase 2 participants will be determined from analysis of pilot data."
89563975|NCT01597193|Experimental|enzalutamide (80-mg with increase to 160 mg)|enzalutamide be provided as two or four 40-mg capsules by mouth daily
89563976|NCT01597193|Experimental|enzalutamide and anastrozole|enzalutamide (160 mg) administered as four 40-mg capsules by mouth once daily in combination with anastrozole (1 mg) administered as one 1-mg tablet by mouth once daily.
89563977|NCT01597193|Experimental|enzalutamide and exemestane 25 mg|enzalutamide (160 mg) administered as four 40-mg capsules by mouth once daily in combination with exemestane administered as one 25-mg tablet daily
89563978|NCT01597193|Experimental|enzalutamide and exemestane 50 mg|enzalutamide (160 mg) administered as four 40-mg capsules by mouth once daily in combination with exemestane administered as two 25-mg tablets daily
88814934|NCT03024710|Experimental|Intervention cluster|"The study participants (the infant who has completed his/her 6 month of age from the date of birth along with their mother) will be enrolled from MNCH database according to criteria for the intervention group.All the mothers of the selected infants along with family member/s will receive training on standard complementary feeding practices . Refresher training will be arranged 3 months after the first training.~The CHRW will visit each infant house till the infant reaches at 12 month of age at every two month interval. During the visit CHRWs will measure weight through standard SECA digital weighing scale in nearest 100 gm (precision 20 gram) and length in nearest 0.1 cm by local made standard length board with movable foot board."
89563979|NCT01597193|Experimental|enzalutamide and fulvestrant|enzalutamide (160 mg) administered as four 40-mg capsules by mouth once daily in combination with fulvestrant (500 mg) administered as two 250-mg intramuscular injections every 28 days
89563980|NCT04920461|Experimental|Additional MRI sequences|
89563981|NCT04920305|Experimental|Phosphatidylserine group|subjects in the treatment group oral the PS (600mg/d, q.d.) for 6 months.
89563982|NCT04920305|Placebo Comparator|Bean powder group|Subjects in the control group were given a placebo, which was the same shape of bean powder(600mg/d, q.d.) for 6 months.
89563983|NCT04930133||Cohort A|T790M+ patients sequentially treated with osimertinib in cohort A
89563984|NCT04930133||Cohort B|T790M- patients treated with chemotherapy or other treatments in cohort B
89563985|NCT04930133||Cohort C|patients with unknown mutation status in cohort C
89563986|NCT04930133||Cohort D|Cohort D included patients who were still ongoing with afatinib.
89563987|NCT02649439|Experimental|A/PROSTVAC treatment|PROSTVAC treatment for 6 months with an additional optional year of maintenance for eligible patients
89563988|NCT02649439|Experimental|B/ Delayed PROSTVAC treatment|Surveillance for 6 months followed by PROSTVAC treatment for 6 months with an additional year of maintenance for eligible patients
89563989|NCT04911647|Active Comparator|The Plastic stent|Patient group with plastic stent inserted in biliary obstruction through endoscope
89563990|NCT04911647|Experimental|The metal stent|Patient group with metal stent inserted in biliary obstruction through endoscope
89563991|NCT03057041|Experimental|Fentanyl|
89563992|NCT03057041|Placebo Comparator|Placebo|
89563993|NCT04911569|Experimental|Cryoneurolysis|All 25 patients will receive cryoneurolysis
89563994|NCT05123209|Experimental|IM83 CAR-T cells|
89563995|NCT05123209|Experimental|IM83 CAR-T cells +The second-line treatment|
88968418|NCT00033592|Placebo Comparator|Arm XV: placebo inhaler cartridges|"Participants receive 6-16 placebo inhaler cartridges per day and oral placebo 1-2 times daily for 40 weeks.~All participants are followed every month for 6 months."
88968419|NCT00033748|Experimental|Combined Monoclonal Antibody Therapy|Patients with minimal metastatic colorectal cancer are treated with 2 anti-idiotype monoclonal antibodies
88968420|NCT02971462|Experimental|RIC group|Experimental: RIC group The upper limb ischemic conditioning is composed of five cycles of bilateral upper limb ischemia intervened by reperfusion, which is induced by two cuff placed around the upper arms respectively and inflated to 200 mm Hg for 5 minutes followed by 5 minutes of reperfusion by cuff deflation. This therapy started within 1 month after stroke. In addition, all participants receive a standard clinical therapy.
88968421|NCT02971462|No Intervention|Control group|The participants receive a standard clinical therapy after diagnosed ischemic stroke.
88968422|NCT02971423|Experimental|Part A; Cohort 1: 0.25 g IV ETX2514/placebo|Part A of the study will explore the safety and tolerability of a single ascending dose (SAD) of intravenous (IV) ETX2514. Participants in Cohort 1, aged 18 to 55 years, will receive 0.25 grams (g) IV ETX2514/placebo infused over 3 hours.
89563996|NCT03056807|Active Comparator|A - 25° head-up position|Participants will be positioned at a 25° head-up position for procedure.
89563997|NCT03056807|Active Comparator|B - 55° head-up position|Participants will be positioned at a 55° head-up position for procedure.
89563998|NCT04377685||COVID19 patients|Patient tested positive for SARS-CoV-2 who had a CT scan
89563999|NCT03056885|Experimental|Conventional One-lung ventilation|The patients received a Tidal volume of 10 ml/kg (based on Predicted body weight)
89564000|NCT03056885|Experimental|Protective One-Lung Ventilation|The patients received a Tidal volume of 5 ml/kg (based on Predicted body weight)
89564001|NCT03056105||Retreat|Participants registered for a one-month, residential Insight Meditation retreat held at Spirit Rock Meditation Center in either February or March, 2013
89564002|NCT03056105||Comparison|Experienced meditators from the Spirit Rock Meditation Community
89564003|NCT03949777|Experimental|Study Cohort|61 subjects will undergo colonoscopy
89564004|NCT03056963|Experimental|Positive Self-Reference Training|Participants in this arm will complete the Positive Self-Reference Training (PSRT).
89564005|NCT03056963|Placebo Comparator|Neutral Training Control|Participants in this arm will complete the neutral training paradigm.
89564006|NCT04184323|Active Comparator|EX-527|The drug will be administered daily for 5 days beginning with the start of progesterone therapy and ended 24 hours before embryo transfer
89564007|NCT04184323|Placebo Comparator|Placebo|The placebo will be administered daily for 5 days beginning with the start of progesterone therapy and ended 24 hours before embryo transfer
89564008|NCT03056027||Group Open|Patient submitted to open inguinal hernia repair
89564009|NCT03056027||Group extraperitoneal laparoscopic|Patients submitted to total extraperitoneal laparoscopic inguinal hernia repair
89564010|NCT03055949|No Intervention|pre-ERP|A group of the surgical ICU patients who had standard care before Asan medical center developed an early rehabilitation program (ERP)
89564011|NCT03055949|Experimental|post-ERP|A group of the surgical ICU patients who had an early rehabilitation program (ERP) within SICU care
89564012|NCT04202107||Urban|"Men and women between 18 and 49 years of age living in the selected urban communities in Rwanda and who are familiar with the diet.~Participants in this study should be acquainted with cooking practices to be able to cite all the ingredients that are used in the preparation of the dishes/ meals"
89564013|NCT04202107||Rural|"Men and women between 18 and 49 years of age living in the selected urban communities in Rwanda and who are familiar with the diet.~Participants in this study should be acquainted with cooking practices to be able to cite all the ingredients that are used in the preparation of the dishes/ meals"
89564014|NCT04911413|Experimental|low-dose group,|A bolus of 10 mg/kg Tranexamic Acid followed by a maintenance dose of 10 mg/kg/h Tranexamic Acid until the end of surgery
88968423|NCT02971423|Experimental|Part A; Cohort 2: 0.5 g IV ETX2514/placebo|Part A of the study will explore the safety and tolerability of a SAD of IV ETX2514. Participants in Cohort 2, aged 18 to 55 years, will receive 0.5 g IV ETX2514/placebo infused over 3 hours.
89564015|NCT04911413|Experimental|middle-dose group,|A bolus of 20 mg/kg Tranexamic Acid followed by a maintenance dose of 15 mg/kg/h Tranexamic Acid until the end of surgery
89564016|NCT04911413|Experimental|high-dose group|A bolus of 30 mg/kg Tranexamic Acid followed by a maintenance dose of 20 mg/kg/h Tranexamic Acid until the end of surgery
89208582|NCT00615030|Experimental|Indacaterol Evening,Indacaterol Morning, Placebo|In period I, patients were instructed to take morning doses of a placebo to indacaterol delivered via SDDPI and placebo to salmeterol delivered via DPI. Indacaterol 300 μg once a day in the evening delivered via SDDPI with placebo to salmeterol delivered via DPI. In period II, indacaterol 300 μg once a day in the morning delivered via SDDPI with a placebo to salmeterol delivered via DPI. Patients were also instructed to take evening doses of a placebo to indacaterol via SDDPI and placebo to salmeterol via DPI. In period III, during morning and evening, placebo matching indacaterol was delivered via SDDPI and placebo matching salmeterol was delivered via DPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
89208583|NCT00615030|Experimental|Salmeterol, Placebo, Indacaterol Morning|In period I, salmeterol 50 μg twice daily delivered via DPI. One of the two daily doses of salmeterol was administered in the morning and the second dose was in the evening along with placebo matching indacaterol delivered by SDDPI. In period II, during morning and evening, placebo matching indacaterol was delivered via SDDPI and placebo matching salmeterol was delivered via DPI. In period III, indacaterol 300 μg once a day in the morning delivered via SDDPI with a placebo to salmeterol delivered via DPI. Patients were also instructed to take evening doses of a placebo to indacaterol via SDDPI and placebo to salmeterol via DPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
89210658|NCT00821834|Active Comparator|Ticlopidine|"Patients received:~ticlopidine 100 mg twice daily,~clopidogrel matching placebo once daily."
89210659|NCT00924534|Placebo Comparator|1|
89564017|NCT04911725|Experimental|With device use|Volunteers included will use IMD during one of the two periods of the study.
89564018|NCT04911725|No Intervention|Without device use|Volunteers included will not use IMD during the other period of the study (reverse of experimental)
89564019|NCT04929665|Active Comparator|Thoracic Paravertebral Block|In patients who are planned to have a thoracic paravertebral block, the needle will be advanced to the paravertebral area with ultrasound-guided in-plane technique. 20 ml of 0.25% bupivacaine will be injected into this area.
89564020|NCT04929665|Active Comparator|Erector spinae block|Patients who are planned to have an erector spina block will be advanced to the interfacial area under the erector spinae muscle by ultrasound-guided in-plane technique. 20 ml of 0.25% bupivacaine will be injected into this area.
89564021|NCT04929665|Active Comparator|Thoracic Paravertebral block and Erector spinae Block|In patients who are planned to have combined erector spinae block and thoracic paravertebral block, the needle will be advanced to the paravertebral area with ultrasound-guided in-plane technique. 10 ml of 0.25% bupivacaine will be given to this area. Then, with the same needle, return 1-2 cm from the paravertebral area and inject 10 ml of 0.25% bupivacaine into the interfacial area under the erector spinae muscle.
89564022|NCT04911179|Experimental|Combined multicomponent physical exercise and cognitive stimulation (Vivfrail-Cog)|"The supervised multicomponent exercise training program (resistance, endurance, balance and flexibility) will be comprised of upper and lower body exercises tailored to the individual's functional capacity. Subjects will be encouraged at performing strength and endurance exercise at a moderate intensity. Exercise will progress in terms of intensity and difficulty upon individual adaptation.~The cognitive intervention will include the performance of different exercises with pencil and paper in order to train different cognitive areas, especially the executive functions."
89564023|NCT04911179|No Intervention|Usual care|The usual care group will receive normal outpatient care (including the evidence-based Otago exercise program).
89564024|NCT04919915|Other|Intervention group|Households are randomly assigned to the intervention group with asthma education and received two HEPA air cleaners designed to reduce PM and NH3.
89564025|NCT04919915|No Intervention|Control group|Households are randomly assigned to the control group. They only received the asthma education during the study period. These households receive a HEPA air cleaner at the end of the study.
89564026|NCT03830203|Experimental|BAT1806|BAT1806 injection: 8 mg/kg, intravenous infusion by 60 min
89564027|NCT03830203|Active Comparator|Actemra(EU-licensed)|Actemra(EU-licensed): 8 mg/kg, intravenous infusion by 60 min
89564028|NCT02622113|Experimental|Canagliflozin (TA-7284) ＋insulin|
89564029|NCT04920227|Experimental|CLASS+PHACO|CO2 Laser-Assisted Sclerectomy Surgery combined with phacoemulsification
89564030|NCT04920227|No Intervention|CLASS|CO2 Laser-Assisted Sclerectomy Surgery
89564031|NCT03860155|Experimental|allo-APZ2-ACLF|Application of IMP into peripheral vein (arm) by use of a perfusor.
89564032|NCT04430777|Placebo Comparator|Placebo group|No use of tranexamic acid. Subcutaneous infiltration of normal saline solution plus 1 mg of epinephrine as required for the procedure.
89564033|NCT04430777|Experimental|Intravenous group|A single dose of 1 gr of tranexamic acid (10 ml) IV, thirty minutes previous to the initiation of the surgery. Subcutaneous infiltration of normal saline solution plus 1 mg of epinephrine as required for the procedure.
89564034|NCT04430777|Experimental|Subcutaneous group|"A single dose of 1 gr of tranexamic acid (10 ml) in the total of the infiltration mixture, as follow:~4 liters of infiltration contents 2.5 ml of tranexamic acid plus 1 mg epinephrine 5 liters of infiltration contents 2 ml of tranexamic acid plus 1 mg epinephrine.~6 liters of infiltration contents 1.6 ml of tranexamic acid plus 1 mg epinephrine."
89564035|NCT04910789|Experimental|Thoracoabdominal approach|Radical surgery should be finished via Thoracoabdominal approach.
89564036|NCT04910789|Active Comparator|Transhiatal/transabdominal approach|Radical surgery should be finished via transhiatal/transabdominal approach.
89564037|NCT02651467|Experimental|Experimental Oral Rinse 1 (1.5% w/w KOX, 0ppm F, pH 7.0)|Participants will apply a strip of standard fluoride toothpaste to cover the full head of the toothbrush and brush their teeth for one timed minute and expectorate. They will then rinse with 20ml of tap water (using the dosing cap provided) for 10 seconds and expectorate, then rinse with 10ml of the experimental oral rinse 1 (using the second dosing cap provided) for one timed minute and expectorate. No further rinsing will be allowed. This regimen will be performed twice daily for 8 weeks.
89564038|NCT02651467|Experimental|Experimental Oral Rinse 2 (2.0% w/w KOX, 45ppm F, pH 4.5)|Participants will apply a strip of standard fluoride toothpaste to cover the full head of the toothbrush and brush their teeth for one timed minute and expectorate. They will then rinse with 20ml of tap water (using the dosing cap provided) for 10 seconds and expectorate, then rinse with 10ml of the experimental oral rinse 2 (using the second dosing cap provided) for one timed minute and expectorate. No further rinsing will be allowed. This regimen will be performed twice daily for 8 weeks.
89564039|NCT02651467|Placebo Comparator|Placebo Oral Rinse (0% w/w KOX 0ppm F, pH 4.5 )|Participants will apply a strip of standard fluoride toothpaste to cover the full head of the toothbrush and brush their teeth for one timed minute and expectorate. They will then rinse with 20ml of tap water (using the dosing cap provided) for 10 seconds and expectorate, then rinse with 10ml of the placebo oral rinse (using the second dosing cap provided) for one timed minute and expectorate. No further rinsing will be allowed. This regimen will be performed twice daily for 8 weeks.
89564040|NCT04910477|Experimental|Dexmedetomidine|Group D (patients will receive ultrasonic nebulization of dexmedetomidine (1 mg/kg diluted in 4 mL saline) twice daily for three days.
89564041|NCT04910477|Experimental|Neostigmine/atropine|Group N (patients will receive nebulization of 20 µ/kg neostigmine and 10 µ/kg atropine mixed in 4 ml) twice daily for three days.
89564042|NCT04910477|Placebo Comparator|Saline placebo|Group S (patients will receive nebulization of saline placebo in 4 ml)twice daily for three days.
89564043|NCT03487705|Other|child essential tremor|electromyogram with accelerometer
89564044|NCT04431089|Experimental|SHC014748M treatment|SHC014748M capsule, 200mg QD, 28 days for each cycle
89564045|NCT02468245|Active Comparator|Control Arm|"This is a usual care group. Patients in this arm will receive the standard pre-drug initiation training and 4 week clinic follow up visit."
89564046|NCT02468245|Experimental|Intervention arm|Patients in this arm will also receive the standard pre-drug initiation training followed by telephone follow up by an oncology certified chemotherapy nurse (OCN) at week one, two, and three. Patients will then have the standard 4 week follow up clinic visit.
89564047|NCT04910555||women over 65 years old with OAB|Community-dwelling women over 65 years old, with non-neurogenic OAB, with or without UI
89564048|NCT04910633||Solid Tumor and COVID-19|Patients with a solid tumor followed by an oncologist of Lyon University Hospital Cancer Institute (LUHCI) who have been hospitalized at LUHCI for the COVID-19 between March and May 2020 and who didn't oppose the reuse of their medical file data for research purpose.
88968424|NCT02971423|Experimental|Part A; Cohort 3: 1.0 g IV ETX2514/placebo|Part A of the study will explore the safety and tolerability of a SAD of IV ETX2514. Participants in Cohort 3, aged 18 to 55 years, will receive 1.0 g IV ETX2514/placebo infused over 3 hours.
89564049|NCT05099419|Experimental|High Frequency rTMS Protocol|High frequency with 10 Hz at 80% motor threshold intensity with figure-of-eight coil for a total of 2,000 pulses. Pulses will be delivered in 10-second trains with a 50-second pause between the trains.
89564050|NCT05099419|Experimental|Low Frequency rTMS Protocol|Low frequency 1 Hz at 80% motor threshold intensity with figure-of-eight coil for a total of 2,000 pulses. Pulses will be delivered continuously.
89564051|NCT04919603|Experimental|Enhanced physical activity group|the participants will take high-intensity exercise in accordance with High Intensity Interval Training (HIIT) prescriptions, with maximum heart rate and relative maximal oxygen uptake monitored. They will take both aerobic and resistance training exercise consecutively, and total training time will be expected to reach at least 150 minutes per week.
88968425|NCT02971423|Experimental|Part A; Cohort 4: 1.0 g IV ETX2514/placebo|Part A of the study will explore the safety and tolerability of a SAD of IV ETX2514. Participants in Cohort 4, aged 18 to 55 years, will receive 1.0 g IV ETX2514/placebo infused over 2 hours.
88968426|NCT02971423|Experimental|Part A; Cohort 5: 2.0 g IV ETX2514/placebo|Part A of the study will explore the safety and tolerability of a SAD of IV ETX2514. Participants in Cohort 5, aged 18 to 55 years, will receive 2.0 g IV ETX2514/placebo infused over 3 hours.
88968427|NCT02971423|Experimental|Part A; Cohort 6: 4.0 g IV ETX2514/placebo|Part A of the study will explore the safety and tolerability of a SAD of IV ETX2514. Participants in Cohort 5, aged 18 to 55 years, will receive 4.0 g IV ETX2514/placebo infused over 3 hours.
88968428|NCT02971423|Experimental|Part A; Cohort 7: 8.0 g IV ETX2514/placebo|Part A of the study will explore the safety and tolerability of a SAD of IV ETX2514. Participants in Cohort 7, aged 18 to 55 years, will receive 8.0 g IV ETX2514/placebo infused over 3 hours.
88968429|NCT02971423|Experimental|Part A; Cohort 8: 1.0 g IV ETX2514/placebo|Part A of the study will explore the safety and tolerability of a SAD of IV ETX2514. Participants in Cohort 8, aged 65 years or older, will receive 1.0 g IV ETX2514/placebo infused over 3 hours.
89210660|NCT00924534|Experimental|2|
89564052|NCT04919603|Experimental|Standard education group|the participants will receive no extra intervention but diabetes health education, which will be carried out in large classrooms, in groups, and over the telephone. The education is mainly consisted of instructions on diabetes prevention according to < Guidelines for prevention and treatment of type 2 diabetes in China (2017 edition)telephone. The education is mainly consisted of instructions on diabetes prevention according to < Guidelines for prevention and treatment of type 2 diabetes in China (2017 edition)>.
89564053|NCT05092633|Experimental|Control|Will have miniscrew only without laser application
89564054|NCT05092633|Experimental|Experimental|Will have miniscrew and laser application
89564055|NCT05079685||Cases-Control|Women aged 18-39 years, with BMI <30 and good ovarian reserve, undergoing study for primary sterility, subsidiary of conducting tubal patency studies to rule out pathology of the same and thus be able to perform Spousal or Donor IA.
89564056|NCT04929353|Other|ARM A|Self-Reporting by electronic survey consisting of 14 items selected by the NCI-PRO-CTCAE TM ITEMS-ITALIAN (Item Library Version 1.0)
89564057|NCT04929353|Other|Arm B|Standard symptom reporting following the conventional modalities of clinical oncology practice
89564058|NCT03843151|Experimental|All subjects: Reference followed by Test treatments|Reference - BI 1358894 alone. Test - BI 1358894 + Itraconazole
89564059|NCT04919759|Active Comparator|Rashakaty Basic (R-Basic)|Participants in the R-Basic intervention arm had access to a website that contained the study questionnaires and nutrition education materials
89564060|NCT04919759|Experimental|Rashakaty Enhanced (R-Enhanced)|Participants in the R-Enhanced intervention were given access to smart phones applications for monitoring diet and physical activity levels as well as an online access to a nutritionist
89564061|NCT03711019|Experimental|Magnetic Seizure Therapy (MST)|MST treatments will be administered using the MagPro MST with Cool TwinCoil.
89564062|NCT03711019|Active Comparator|RUL-UB ECT|ECT treatments will be administered using the MECTA spECTrum 5000Q or MECTA Sigma
89564063|NCT03711019|Active Comparator|Bitemporal ECT|ECT treatments will be administered using the MECTA spECTrum 5000Q or MECTA Sigma
89564064|NCT04919837|Experimental|Algorithm assisted group|Patients receive assisting devices fitting services from human doctors assisted by the machine learning model
89564065|NCT04919837|Experimental|Human doctor group|Patients receive assisting devices fitting services from humanr doctors
89564066|NCT02918305|Sham Comparator|PRDS-001 Renal Denervation Ultrasound System|Randomization will occur following the diagnostic renal angiogram. Blinded patients randomized to treatment will receive the renal denervation procedure using PRDS-001 System to deliver ultrasound energy to thermally ablate and disrupt the renal sympathetic nerves while sparing the renal arterial wall.
89564067|NCT02918305|Sham Comparator|Sham Procedure|Randomization will occur following the diagnostic renal angiography. For blinded patients randomized to control, the diagnostic renal angiography will be considered the sham procedure.
89564068|NCT04929509|Experimental|self-assembling peptide (P11-4)|"Curodont Repair; Credentis will be applied to the~white spot lesion at baseline."
89564069|NCT04929509|Active Comparator|nanosilver fluoride varnish|"(Study group) Nano-silver fluoride varnish will be applied to the~white spot lesion at baseline."
88968430|NCT02971423|Experimental|Part B; Cohort 9: 0.25 g IV EXT2514/placebo|Part B of the study will explore the safety and tolerability of multiple ascending doses (MAD) of IV ETX2514. Participants in Cohort 9, aged 18 to 55 years, will receive 0.25 g IV EXT2514/placebo infused over 3 hours, every 6 hours (4 times a day) for 7 consecutive days, and then will receive 1 dose on Day 8.
88968431|NCT02971423|Experimental|Part B; Cohort 10: 0.5 g IV EXT2514/placebo|Part B of the study will explore the safety and tolerability of MAD of IV ETX2514. Participants in Cohort 10, aged 18 to 55 years, will receive 0.5 g IV EXT2514/placebo infused over 3 hours, every 6 hours (4 times a day) for 7 consecutive days, and then will receive 1 dose on Day 8.
88968432|NCT02971423|Experimental|Part B; Cohort 11: 1.0 g IV EXT2514/placebo|Part B of the study will explore the safety and tolerability of MAD of IV ETX2514. Participants in Cohort 11, aged 18 to 55 years, will receive 1.0 g IV EXT2514/placebo infused over 3 hours, every 6 hours (4 times a day) for 7 consecutive days, and then will receive 1 dose on Day 8.
88968433|NCT02971423|Experimental|Part B; Cohort 12: 2.0 g IV EXT2514/placebo|Part B of the study will explore the safety and tolerability of MAD of IV ETX2514. Participants in Cohort 12, aged 18 to 55 years, will receive 2.0 g IV EXT2514/placebo infused over 3 hours, every 6 hours (4 times a day) for 7 consecutive days, and then will receive 1 dose on Day 8.
88968434|NCT02971423|Experimental|Part C; Cohort 13: ETX2514/placebo with sulbactam|Part C of the study will explore the safety and tolerability of IV ETX2514 when administered as a single dose in combination with sulbactam (1.0 g) and/or imipenem/cilastatin (0.5 g) to healthy participants. On Day 1, participants will receive a single dose of 1.0 g IV ETX2514/placebo infused over 3 hours. On Day 3, participants will receive a single dose of 1.0 g IV sulbactam infused over 3 hours. On Day 5, participants will receive a single dose of 1.0 g IV ETX2514/placebo plus 1.0 g sulbactam infused over 3 hours at the same time. The actual Day 1 and Day 5 ETX2514 dose and infusion time will be determined based on PK and safety data from Part A.
89033071|NCT02921880|Experimental|Cardiac Rehabilitation|Patients will return to the out-patient clinic at 4 weeks post - TAVR and research consent will be re-affirmed. Patients will be randomised to receive a programme of cardiac rehabilitation or routine care at this point. Patients randomised to receive cardiac rehabilitation will meet the cardiac rehab team and undergo baseline assessment for the programme. This involves recording height, weight, blood pressure, oxygen saturation and heart rate and rhythm. An individualised programme will be established to meet the needs of each patient. The patients will undergo a 6 week programme of cardiac rehab. Patients who are not allocated to the intervention group will not receive a cardiac programme and will have access to the TAVR nurse specialist team as would be usual care.
89210661|NCT00924534|Experimental|3|
89564070|NCT04929509|Placebo Comparator|sodium fluoride varnish|"(Control group) Fluoride varnish (Duraflor) will be applied to the~white spot lesion at baseline and 6 months follow up."
89564071|NCT04929119||Before wearing the Orthokeratology|OPD-Scan was performed and the following data were recorded: 4 mm high order strehl ratio (SR) , 4 mm high order corneal aberrations (Hoa ) , Spherical Aberrations (SA) , Coma Aberrations (Coma) , Trefoil Aberrations (RMS) , corneal aspheric index (Q, e) , corneal surface regularity index (SRI) , corneal surface asymmetry index (Sai)
89564072|NCT04929119||Wear Orthokeratology for a week|OPD-Scan was performed and the following data were recorded: 4 mm high order strehl ratio (SR) , 4 mm high order corneal aberrations (Hoa ) , Spherical Aberrations (SA) , Coma Aberrations (Coma) , Trefoil Aberrations (RMS) , corneal aspheric index (Q, e) , corneal surface regularity index (SRI) , corneal surface asymmetry index (Sai)
89564073|NCT04929119||Wear Orthokeratology for a month|OPD-Scan was performed and the following data were recorded: 4 mm high order strehl ratio (SR) , 4 mm high order corneal aberrations (Hoa ) , Spherical Aberrations (SA) , Coma Aberrations (Coma) , Trefoil Aberrations (RMS) , corneal aspheric index (Q, e) , corneal surface regularity index (SRI) , corneal surface asymmetry index (Sai)
89564074|NCT04929119||Wear Orthokeratology for three months|OPD-Scan was performed and the following data were recorded: 4 mm high order strehl ratio (SR) , 4 mm high order corneal aberrations (Hoa ) , Spherical Aberrations (SA) , Coma Aberrations (Coma) , Trefoil Aberrations (RMS) , corneal aspheric index (Q, e) , corneal surface regularity index (SRI) , corneal surface asymmetry index (Sai)
89564075|NCT04929119||Wear Orthokeratology for six months|OPD-Scan was performed and the following data were recorded: 4 mm high order strehl ratio (SR) , 4 mm high order corneal aberrations (Hoa ) , Spherical Aberrations (SA) , Coma Aberrations (Coma) , Trefoil Aberrations (RMS) , corneal aspheric index (Q, e) , corneal surface regularity index (SRI) , corneal surface asymmetry index (Sai)
89564076|NCT02798107||All patients treated with idarucizumab|
89564077|NCT04403867||Endometrial cancer patients|Patients submitted to Sentinel Lymph Node (SLN) procedure. Patients with lymph nodal disease (macrometastasis, micrometastasis, isolated tumor cells).
89564078|NCT04403867||Cervical cancer patients|Patients submitted to Sentinel Lymph Node (SLN) procedure. Patients with lymph nodal disease (macrometastasis, micrometastasis, isolated tumor cells).
89564079|NCT01865539|Active Comparator|Custom Foot Orthotic|Custom foot orthotic
89564080|NCT01865539|Sham Comparator|Sham Orthotic|Will be a sham orthotic that will be the same as the actual orthotic without the custom support pads.
89564081|NCT03054467|Active Comparator|CADUET 10mg-20mg|Patients are assigned to receive either amlodipine therapy (NORVASC 10 mg/day) for 6 months.
89564082|NCT03054467|Active Comparator|NORVASC|Patients are assigned to receive amlodipine/atorvastatin combination (CADUET 10/20mg) for 6 months
89564083|NCT05009485|Experimental|Intervention|Participants will be remotely monitored with the Current Health platform, respond to daily respiratory surveys, receive daily medication reminders and an action plan. Daily dashboard rounds and vital sign alarms from the continuously collected vital signs will be used to identify changes in health and escalated accordingly.
89027424|NCT02955420|Experimental|BC 007 (15, 50, 150, 300, 450, 750, 1350, 1200 mg)|"Part A:~BC 007 at doses of 15, 50 and 150 mg or matching placebo administered as i.v. bolus + infusion of 20 min (Cohorts 1 to 4). The sentinel pair of each cohort will be dosed without bolus.~NaCl 0.9% (matching placebo) administered as i.v. bolus + infusion of 20 min (Part A: Cohorts 1 to 4).~Part B:~BC 007 at doses of 50 and 150 mg administered (Cohort 1) or a single dose < 50 mg or 150 mg (Cohort 2) as i.v. bolus + infusion of 20 min is administered to GPCR autoantibody positive subjects. The first subject in each dosing period of Cohort 1 will be dosed without bolus.~Part C:~BC007 administered at doses of 300 mg (Cohort 1), 450 mg (Cohort 2), 750 mg (Cohort 3), 1350 mg (Cohort 4) as i.v. bolus + infusion of 40 min to GPCR autoantibody positive subjects. The first three subjects in each dosing period of Cohort 1-4 will be dosed without bolus. In Cohort 5 BC007 dose of 1200 mg will be administered as a continuous infusion of 20 min."
89210662|NCT00924534|Experimental|4|
89564084|NCT04910165|Experimental|Exparel|Liposomal Bupivacaine use as active ingredient in the block
89564085|NCT04910165|Active Comparator|Control|Ropivacaine use as active ingredient in the block
89564086|NCT02730325|Active Comparator|SBI 10 g BID|Serum-derived bovine immunoglobulin/protein isolate (SBI) 10.0 grams twice per day
89564087|NCT02730325|Placebo Comparator|Placebo BID|Placebo
89564088|NCT03054233|Experimental|Obese|Obese pregnant women received spinal anesthesia using Quincke Needle 25G/27G in crossed leg sitting position for caesarean section
89564089|NCT03054233|Experimental|Non-obese|Non-obese pregnant women received spinal anesthesia using Quincke Needle 25G/27G in crossed leg sitting position for caesarean section
89564090|NCT04928495|Placebo Comparator|Treatment group 1|Control placebo (Vitamin C - 500mg / day, for 10 days)
89564091|NCT04928495|Active Comparator|Treatment group 2|N-acetylcysteine (NAC; 1800 mg / day, for 10 days)
89564092|NCT04928495|Active Comparator|Treatment group 3|NAC (1800 mg / day) + bromhexine-BMX (32 mg / day for 10 days)
89564093|NCT03053921|Placebo Comparator|recession coverage|30 recession defects treated with Zucchelli's technique.
89564094|NCT03053921|Active Comparator|recession coverage and membrane|30 recession defects treated with Zucchelli's technique along with placental membrane.
89564095|NCT05015413|Experimental|shock wave group|Group A will receive shockwave therapy 2 session per week for 6 weeks
89564096|NCT05015413|Experimental|low level laser group|Group B will receive low level laser therapy 2 session per week for 6 weeks
89564097|NCT01636375||Direct Anterior Approach|
89564098|NCT01636375||Posterior Approach|
89564099|NCT04919213||Individuals with Intellectual Disabilities|Individuals will be invited to take part in an online survey (paper version will also be available). The participants will be recruited through advertisements on relevant platforms (e.g., Facebook, Twitter) and through relevant social care organisations. The study hopes to recruit 100 individuals from all over England (UK). A subgroup will be asked if they would like to take part in a one-to-one open-ended interview (n=20) and/or in direct observations (n=30).
89564100|NCT04919213||Family carers|Family carers (n=50) of people with intellectual disabilities in England, who use the internet, will be invited to take part in an online survey. A subgroup of family carers (n=7) will be asked if they would like to take part in a focus group.
89564101|NCT04919213||Paid carers|Paid carers (n=50) of people with intellectual disabilities in England, who use the internet, will be invited to take part in an online survey. A subgroup of paid carers (n=7) will be asked if they would like to take part in a focus group.
89564102|NCT04919213||Professionals with safeguarding responsibilities|Professionals with safeguarding duties (e.g., social workers, learning disability nurses, police and safeguarding adults board members) supporting people with ID in England who use the internet will also be invited to take part in an online survey (n=50). A subgroup (n=7) from London and Kent (England, UK) will be asked if they would like to take part in a focus group.
89564103|NCT01573429|Other|Dermal Carboxymethylcellulose arm|d-BPA administered dermally using a carboxymethylcellulose suspension
89564104|NCT01573429|Other|Dermal ethanol arm|d-BPA is administered dermally using an ethanol solution
89564105|NCT01573429|Other|Oral arm|d-BPA administered orally
89564106|NCT04928027||Persons with PD|Adults with PD will be provided with email link to complete the Comprehensive Executive Function Inventory-Self-Assessment
89564107|NCT04928027||Significant Others of those with PD|Adults whose significant other has a diagnosis of PD will be provided with email link to complete the Comprehensive Executive Function Inventory-Observer report
89564108|NCT03055559||Globifer Forte|
89564109|NCT04910009|No Intervention|Theoretical training group|Students participating in only theoretical training of the privacy education for two 40-minute sessions.
89564110|NCT04910009|Experimental|Digital story and ethical case analysis group|Students participating in 2 sessions of 40-minute theoretical training and then participating in 4 sessions of 60-minute digital story and ethical case analysis preparation and presentation.
89564111|NCT04910009|Experimental|Only ethical case analysis group|Students participating in 2 sessions of 40 minutes of theoretical training and then participating in 4 sessions of 60-minute ethical case analysis preparation and presentation only.
89564112|NCT01518673||X-rays|
89564113|NCT04909931|Experimental|vitamin D supplementation group|First arm ; add on vitamin D 40,000 IU/week for 12 weeks
89564114|NCT04909931|Experimental|second arm|add on placebo
89564115|NCT02360839|No Intervention|Early|Study subjects (patients) undergoing endoscopic ultrasound (with or without FNA/TCB) for clinical reasons during 2005-2011.
89564116|NCT02360839|Other|Late|"Study subjects (patients) undergoing endoscopic ultrasound with EUS-guided sampling of various lesions for clinical reasons during 20012-2015.~Subjects sampled with both EUS-FNA and EUS-FNB on the same lesion. Randomization on first needle order."
89564117|NCT04919291|Active Comparator|Topoguided LASIK|Topoguided ablation profile on dominant eye
89564118|NCT04919291|Active Comparator|Wavefront optimized LASIK|Wavefront optimized ablation profile on non-dominant eye
89564119|NCT04918589|Experimental|Tranexamic Acid|3 grams of tranexamic acid (30 mL of 100 mg/mL solution) diluted in 10 mL of normal saline
89564120|NCT04918589|Placebo Comparator|Normal Saline|40 mL topical of 0.9% normal saline
89564121|NCT05128981|Other|MI-CBT via the Internet|The MI-specific CBT will consist of 8 modules delivered via the Internet with home assignments that can be reviewed and reported in the research groups secure platform.
89564122|NCT04101643|Experimental|Evolocumab group|Eligible patients receive subcutaneous injections of evolocumab 420 mg
89564123|NCT02620787|Experimental|Diabetic Wound Infection|Participants with a documented medical history of Type 1 or Type 2 diabetes and a mild to moderate (Grade 2 or 3) wound infection of the lower limb will receive 3 to 6 doses of oral tedizolid 200mg once daily, followed by sampling of interstitial tissue fluid at the margin of the wound by a microdialysis probe over 24 hours following the last dose (e.g., 48-72 hours).
89564124|NCT02620787|Active Comparator|Healthy Volunteers|Participants will be male or female healthy adult volunteers with no significant medical or medication history. Participants will receive 3 to 6 doses of oral tedizolid 200mg once daily, followed by sampling of interstitial tissue fluid at the margin of the wound by a microdialysis probe over 24 hours following the last dose (e.g., 48-72 hours).
89564125|NCT04082455|Experimental|carbon ion radiotherapy|carbon ion radiotherapy
89564126|NCT04062799||Study cohort|
89564127|NCT04909619|Experimental|Ultrasound-guided bilateral suprazygomatic maxillary nerve block|Patients randomized to this arm will receive an ultrasound-guided bilateral suprazygomatic maxillary nerve block using 0.15 ml/kg of 0.2% ropivacaine per side, for a total of 0.3 ml/kg immediately after induction of general anesthesia and prior to incision. Participants will also receive local infiltration of the palate with an equivalent injection volume of 0.9% saline with 1:400,000 epinephrine at 2 ml/kg. Pediatric anesthesiologists with fellowship training in regional anesthesia will perform the nerve block. Local anesthetic infiltration will be performed by one of four board-certified pediatric plastic and craniofacial surgeons during repair of the palate. Patients, parents, surgeons, and the anesthesiologist will not be blinded to the specific intervention group due to the nature of the procedures involved. Nurses and the two key personnel responsible for data collection and analysis will be blinded throughout the entirety of the study.
89564128|NCT04909619|Active Comparator|Local anesthetic infiltration of the palate|Patients randomized to this arm will receive local infiltration of the palate using 0.125% bupivacaine + 1:400,000 epinephrine at a dose of 2 ml/kg intraoperatively. Local anesthetic infiltration will be performed by one of four board-certified pediatric plastic and craniofacial surgeons during repair of the palate. Patients, parents, surgeons, and the anesthesiologist will not be blinded to the specific intervention group due to the nature of the procedures involved. Nurses and the two key personnel responsible for data collection and analysis will be blinded throughout the entirety of the study.
89564129|NCT05128747|Active Comparator|group of intervention will receive nutritional program|group of type 2 diabetes on diabetic diet undergo nutritional program (low fat contents) to control the lipid profile (lowering cholesterol profile) in duration of 3 months.
89564130|NCT05128747|No Intervention|group of control will not receive nutritional program|group of type 2 diabetes on diabetic drugs without nutritional program to compare their lipid profile with the diabetic patients on nutritional program.
89564131|NCT03056729|Experimental|Cohort HV1|
89564132|NCT03056729|Experimental|Cohort HV2|
89564133|NCT03056729|Experimental|Cohort HV3|
89564134|NCT03056729|Experimental|Cohort HV4|
89564135|NCT03056729|Experimental|Cohort HV5|
89564136|NCT03056729|Experimental|Cohort AD1|
89564137|NCT03053999||Parathyroidectomy Tissue and Data|"Analyses includes genome sequencing based analysis to identify novel germline variations in blood DNAs and somatic changes in tumor DNAs, which may contribute to the development of pancreatic tumors.~Clinical information retrieved from the patients' medical record including: de-identified demographic data (age, gender, race/ethnicity), medical history, family history, disease status, treatment response, survival information, and selected clinical data from medical record (calcium levels, calcitonin levels)."
89564138|NCT03843073|Experimental|Connected Catheter Users|
89564139|NCT03053843|Experimental|Mediterranean diet plus extra virgin olive oil|These patients will receive 1 liter of EVOO per week free of charge and dietary advice on how to follow a Mediterranean diet with contacts every two months.
89564140|NCT03053843|No Intervention|no specific diet|The control group will be assigned to the usual care and patients assigned to this group will not receive any special intervention to follow a particular diet, as occurs in the current clinical practice.
89564141|NCT05128435||Positive Children|Children under 15 years old tested positive for SARS-CoV-2 by PCR on nasopharyngeal swab
89564142|NCT03055637|Active Comparator|patients with isolated cleft palate|Patients requiring isolated cleft palate repair
89564143|NCT03055637|Active Comparator|Patients with isolated cleft palate|Patients requiring isolated cleft palate repair
89564144|NCT03559855|Experimental|Real Essentials|The Real Essentials curriculum is delivered in class to students by the Center for Relationship Education staff. It consists of 5 to 6 hours of healthy relationship education.
89564145|NCT03559855|No Intervention|Class as Usual|For the Class-as-Usual condition, there is no change in class content. Teachers offer what they typically offer.
89564146|NCT04918901||Severe COVID-19|Comparative Analysis of Clinical Parameters and Radiographic Changes
89564147|NCT03520231|Experimental|Denosumab and Standard Chemotherapy|"Denosumab, given subcutaneously at a dose of 120 mg, every 4 weeks.~Gemcitabine, given intravenously at standard doses, on Days 1 and 8 of every 21 day cycle, for 3-4 cycles.~Carboplatin, given intravenously at standard doses, on Day 1 of every 21 day cycle, for 3-4 cycles.~OR Cisplatin, given intravenously at standard doses, on Day 1 of every 21 day cycle, for 3-4 cycles.~Calcium, orally at a dose of 1000 mg, once daily.~Vitamin D, orally at a dose of 400 IU, once daily."
89564148|NCT03520231|Placebo Comparator|Denosumab Placebo and Standard Chemotherapy|"Denosumab placebo, given subcutaneously, every 4 weeks.~Gemcitabine, given intravenously at standard doses, on Days 1 and 8 of every 21 day cycle, for 3-4 cycles.~Carboplatin, given intravenously at standard doses, on Day 1 of every 21 day cycle, for 3-4 cycles.~OR Cisplatin, given intravenously at standard doses, on Day 1 of every 21 day cycle, for 3-4 cycles.~Calcium, orally at a dose of 1000 mg, once daily.~Vitamin D, orally at a dose of 400 IU, once daily."
89564149|NCT05117749|Experimental|Mild UC-Saffron 100|Mild UC patients, receiving 100 milligram (mg)/day saffron for 8 weeks (50 mg two times (BID)), n=10
89564150|NCT05117749|Experimental|Moderate UC-Saffron 100|Moderate UC patients, receiving100 mg/day saffron for 8 weeks (50 mg BID), n=10
89564151|NCT05117749|Experimental|Mild UC-Saffron 50|Mild UC patients, receiving 50 mg/day saffron for 8 weeks (25 mg BID), n=10
89564152|NCT05117749|Experimental|Moderate UC-Saffron 50|Moderate UC patients, receiving 50 mg/day saffron for 8 weeks (25 mg BID), n=10
89564153|NCT05117749|Placebo Comparator|Mild UC-placebo|Mild UC patients, receiving 2 tablets of placebo for 8 weeks, n=10
89564154|NCT05117749|Placebo Comparator|Moderate UC-placebo|Moderate UC patients, receiving 2 tablets of placebo for 8 weeks, n=10
89564155|NCT04918667|Experimental|Berberine MetX™ Ultra Absorption|16 healthy subjects will receive orally 500 mg of berberine in two capsules of Berberine MetX™ Ultra Absorption.
89564156|NCT04918667|Active Comparator|Berberine MetX™|16 healthy subjects will receive orally 500 mg of berberine in one capsule of Berberine MetX™ (reference product).
89564157|NCT03456193|Experimental|LA transplantation|The left atrium and pulmonary veins will be transplanted into the recipient
89564158|NCT03056495|Experimental|Investigational drug|N-hydroxy-N'-phenyl-octanediamide (Vorinostat) capsules once a day, three weeks of treatment; dose escalation with different dosages per cohort; One cohort of three subjects
89564159|NCT03171805|Experimental|Propranolol group|Propranolol was given after patients with cirrhosis and isolated gastric varices underwent balloon occluded retrograde transvenous obliteration successfully.
89564160|NCT03171805|No Intervention|control group|Propranolol was not given after patients with cirrhosis and isolated gastric varices underwent balloon occluded retrograde transvenous obliteration successfully.
88968435|NCT02971423|Experimental|Part C; Cohort 14: ETX2514/placebo with SUL and/or IM/CIL|Part C of the study will explore the safety and tolerability of IV ETX2514 when administered as a single dose in combination with sulbactam (SUL: 1.0 g) and/or imipenem/cilastatin (IM/CIL: 0.5 g) to healthy participants. On Day 1, participants will receive a single dose of 1.0 g IV ETX2514/placebo infused over 3 hours. On Day 3, participants will receive a single dose of 0.5 g IV imipenem/cilastatin infused over 30 minutes. On Day 5, participants will receive a single dose of 1.0 g IV ETX2514/placebo infused over 3 hours plus 0.5 g imipenem/cilastatin infused over 30 minutes initiated at the same time as ETX2514/placebo. On Day 8, participants will receive a single dose of 1.0 g IV ETX2514/placebo plus 1.0 g sulbactam infused over 3 hours at the same time plus 0.5 g imipenem/cilastatin infused over 30 minutes initiated at the same time as ETX2514/placebo. The actual Day 1, Day 5, and Day 8 ETX2514 dose and infusion time will be determined based on PK and safety data from Part A.
88968436|NCT02971423|Experimental|Part D; Cohort 15: ETX2514/placebo with SUL and/or IM/CIL|Part D of the study will explore the safety and tolerability of multiple doses of combined IV ETX2514/sulbactam (1.0 g)/imipenem/cilastatin (0.5 g) to healthy participants. Participants in Cohort 15 will receive 1.0 g IV ETX2514/placebo and 1.0 g IV sulbactam both infused over 3 hours and 0.5 g IV imipenem/cilastatin infused over 30 minutes every 6 hours (4 times a day) for 10 days and will receive 1 dose on Day 11. The actual ETX2514 dose and infusion time will be determined based on PK and safety data from Part C.
88968437|NCT00033865|Experimental|1|Yoga treatment for 8 weeks
88968438|NCT00033865|No Intervention|2|Sleep hygiene instructions only
88968439|NCT00389090|Experimental|Temozolomide + O6BG|
89564161|NCT03098329|Experimental|Ct/GC screening|Community screening of men for Ct and GC is not normally done. We are testing to see if this intervention will impact the rates of Ct and GC among women
89564162|NCT03053531|Experimental|HERO-ED RCT|Subjects will be instructed on use of the HAD. The model that we will use is the PockeTalker Mini-Cog. This is a small (9.0cm X 5.5cm X 2.0cm) battery-powered electronic box that can be worn around the neck which connects via wires to both earphones and headphones (we will supply both earpieces, and let the patient choose). The RA, trained on use of the HAD by an experienced research audiologist, will instruct the patient in use of the HAD, and test the device to ensure proper functioning. The patient will also receive an instruction sheet (Appendix 3). Subjects will be encouraged to use the HAD during any encounters with ED staff.
89564163|NCT05117593|Experimental|FBL-MTX|"A single dose of FBL-MTX will be administered by slow intravenous injection in the morning, under fasted conditions.~A maximum of 4 dose levels (0.1 mg, 0.33 mg, 1 mg and 2.5 mg) are pre-planned."
89564164|NCT05117593|Placebo Comparator|Placebo|A single dose of placebo will be administered by slow injection in the morning, under fasted conditions.
89564165|NCT02787187|Active Comparator|Standard resection|Pancreaticoduodenectomy (child's digestive reconstruction); Standard lymphadenectomy: No 5 6 8a 12b1 12b2 12c 13a 13b 14a 14b 17a 17b
89564166|NCT02787187|Experimental|Extended resection|Pancreaticoduodenectomy (child's digestive reconstruction)extended lymphadenectomy No8p 12a 12p 14c 14d 16
89564167|NCT03053375|Experimental|Acute/subacute; active device|MDCure active device
89564168|NCT03053375|Placebo Comparator|Acute/subacute; sham|MDCure sham device
89564169|NCT03053375|Experimental|Chronic; active device|MDCure active device
89564170|NCT03053375|Placebo Comparator|Chronic; sham|MDCure sham device
89564171|NCT05405023|Experimental|Concentric exercises with wrist mobilization|concentric exercise including wrist flexion, extension, and abduction, adduction, supination and pronation plus wrist mobilizations with movements
89564172|NCT05405023|Active Comparator|Concentric exercises without wrist mobilization|concentric exercise including wrist flexion, extension, and abduction, adduction, supination and pronation
89564173|NCT04918433|Active Comparator|TRANSEVERSUS THORACIS MUSCLE PLANE BLOCK (TTPB)|After induction of anaesthesia, ultrasound guided transverses thoracis muscle plane block will be done using 0.25% bupivacaine
89564174|NCT04918433|Active Comparator|PECTO-INTERCOSTAL FACIAL PLANE BLOCK (PIFB)|After induction of anaesthesia, ultrasound guided pectointercostal facial plane block will be done using 0.25% bupivacaine
89564175|NCT05093803|Active Comparator|CONTROL GROUP|Recommendations on healthy eating habits based on the Mediterranean diet and moderate physical activity.
89564176|NCT05093803|Experimental|APP GROUP|Recommendations on healthy eating habits based on the Mediterranean diet and moderate physical activity through the use of an app based on machine learning, so they have constant stimuli for the improvement of the parameters.
89564177|NCT04926467|Experimental|Anakinra plus Chemotherapy|Patients will receive Anakinra during both pre-operative chemotherapy with Nab-paclitaxel, gemcitabine and cisplatin, followed by surgery and post-operative chemotherapy with 5-fluorouracil, oxaliplatin, and irinotecan.
89564178|NCT02302105|Active Comparator|Prostate Only|66-68 Gray (Gy) in 25 fractions will be prescribed for the prostate PTV
89564179|NCT02302105|Experimental|Whole Pelvis|66-68 Gray (Gy) in 25 fractions will be prescribed for the prostate PTV and 50 Gy in 25 fractions to nodal region .
89564180|NCT03055715||Locally advanced NSCLC-patients|Inoperable stage III (A and B) non-small-cell lung cancer (NSCLC) with indication for radical radiotherapy.
89564181|NCT04866043||NostraData Database|All prescriptions for lisdexamfetamine dimesylate available in the NostraData database at any time in the last 12 months will be collected in Australia.
89564182|NCT04866043||Physician Survey|Physician will provide de-identified data of participants who have been prescribed lisdexamfetamine dimesylate at least once during the study period for indications other than attention deficit hyperactivity disorder (ADHD) in Australia.
89564183|NCT05128045|Experimental|Experimental: NEW-R Intervention|NEW-R Intervention plus services as usual
89564184|NCT05128045|No Intervention|Control|Services as usual
89564185|NCT03053297||Patients with EGFR mutation (+) NSCLC|Patients with EGFR mutation-positive locally advanced or metastatic NSCLC who have progressed while on or after receiving front-line EGFR-TKI therapy (e.g., gefitinib, erlotinib, afatinib, or icotinib).
89564186|NCT03053297||Patients newly diagnosed NSCLC|Patients newly diagnosed with locally advanced or metastatic NSCLC who are treatment naive or patients who were diagnosed at an earlier stage but have progressed to metastatic NSCLC during the selection period.
89564187|NCT05127889|Experimental|Self-assembling peptide P11-4 varnish (study group)|"Test lesions will be wiped with NaOCl to remove pellicle,~Etched for 20 s with 35% H3PO4 Etching Gel to remove mineral deposits on the tooth surface and rinsed with water in accordance with the manufacturer's instructions.~The lesions will be dried and isolated with cotton rolls.~The varnish will be applied and left undisturbed for 5minutes (till disappearance) to allow diffusion of self-assembly."
89564188|NCT05127889|Experimental|Arginine-enriched Sodium Fluoride varnish (study group)|"The Arginine powder will be suspended at 2%.~A 10 mL of 5% sodium fluoride varnish tube dispensed in a sterile container.~200 mg of Arginine will be vigorously mixed with the varnish matrix for 60 sec using a sterile microbrush.~After dryness of the white spot lesion, the prepared varnish will be applied evenly using the micro brush.~After application the patient will be instructed to avoid rinsing, eating soft diet and avoid hot drinks for 2 hrs."
89564189|NCT05127889|Active Comparator|Tri Calcium Phosphate Fluoride varnish (positive control group)|"To limit undesirable oral ingestion, the appropriate dose for the patient will be determined with the help of the dosing guide.~The varnish will be mixed with the brush to avoid separation of the material during storage~However, to guarantee the best results suction will be used during application of the varnish.~A thin uniform layer of the varnish will be applied on the lesion surface by using the supplied brush~The applicator brush won't be moved through accumulated saliva to prevent premature setting on the bristles.~After application the patient will be instructed to close his mouth, avoid rinsing, eating soft diet and avoid hot drinks for 4 hrs.~All patients will be encouraged to maintain good oral hygiene through regular brushing."
88968440|NCT02971384|Experimental|Echinaforce Junior Tablets|Hydroalcoholic extract of Echinacea purpurea herb and radix
89564190|NCT04926935||Patients hospitalized in the ICU during the study period.|Patients hospitalized in the ICU during the study period with clinically suspected infection.
89564191|NCT03053219|Experimental|AC0010|each participant will be given AC0010 300mg bid
89564192|NCT04764019|Experimental|Patients|Patients with chronic digestive symptoms in whom intestinal dysmotility is suspected
89564193|NCT04583761||cases|Healthcare workers with mild symptoms of COVID-19 and a positive RT-PCR test for SARS-CoV-2
89564194|NCT04583761||controls|Healthcare workers with mild symptoms of COVID-19 and a negative RT-PCR test for SARS-CoV-2
89564195|NCT04531891|Experimental|All-out, high-intensity, intermittent exercise protocol|
89564196|NCT04531891|Experimental|5 min, high-intensity, intermittent exercise protocol|
89564197|NCT04926389|Experimental|low-level laser therapy applied on days 0, 3,7,14 & every 2 weeks|
89564198|NCT04926389|Active Comparator|low-level laser therapy applied every 3 weeks|
89564199|NCT04926155|Experimental|Metformin+ADT+abiraterone|Patients in this arm will be treatet with metformin plus ADT and abiraterone
89564200|NCT04926155|No Intervention|ADT+abiraterone|Patients in this arm will be treatet with ADT and abiraterone, Abiraterone 1000mg once daily until disease progression.
89564201|NCT05133583|Experimental|intervatonal|
89564202|NCT05133583|No Intervention|control|
89564203|NCT04918043||HUCS, NKL|Newborns and their mothers at the Helsinki University Central Hospital maternity ward.
89564204|NCT04917965||Healthy Term Neonates|Infants born at 37 weeks gestational age or greater born to mothers of any age with uncomplicated pregnancies. Following delivery, cord blood obtained from the placental portion of the umbilical cord will be used for analysis. To assure appropriate dilution, a hematocrit will be measured at the time of blood collection using a blood gas machine for prompt results. Sample blood will immediately be taken by the investigators from the delivery hospital to the children's hospital where the following clotting studies will be performed: PT, aPTT, fibrinogen, platelet count, platelet mapping, and TEG6s. Specimens will be transported utilizing Specimen Transport Guidelines.
89564205|NCT04917965||Term infants of diabetic mothers|Infants born at 37 weeks gestational age or greater to mothers of any age with gestational diabetes or Type 1 or Type 2 diabetes, managed with either diet or insulin. Following delivery, cord blood obtained from the placental portion of the umbilical cord will be used for analysis. To assure appropriate dilution, a hematocrit will be measured at the time of blood collection using a blood gas machine for prompt results. Sample blood will immediately be taken by the investigators from the delivery hospital to the children's hospital where the following clotting studies will be performed: PT, aPTT, fibrinogen, platelet count, platelet mapping, and TEG6s. Specimens will be transported utilizing Specimen Transport Guidelines.
89564206|NCT04909775|Experimental|Arm 1|Patients will receive 4 cycles of Tislelizumab (200mg per cycle) in combination with cisplatin-based chemotherapy before cystectomy discussion. The patients reach clinical complete remission will receive tislelizumab maintenance therapy for a year or 13 cycles.
89564207|NCT05133349|Experimental|Anlotinib|Anlotinib 12mg capsules given orally on once daily in 21-day cycle until disease progression or treatment intolerance(14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21), the dose can be adjusted to 10mg or 8mg according to the specific conditions of the patient.
89564208|NCT04925141|Experimental|Dasatinib tablets|Dasatinib tablets 100 mg orally once daily
89564209|NCT04908917|Experimental|PAC with HEPA|Intervention group (N=100) to use a portable air cleaner (with a HEPA filter in PAC)
89564210|NCT04908917|Sham Comparator|PAC without HEPA|control group (N=100) with a sham portable air cleaner (no HEPA filter in PAC)
89564211|NCT02651155|Experimental|Lubiprostone 24 μg|Lubiprostone 24 μg, capsules, orally, twice daily, under fed conditions, for 4 weeks.
88968441|NCT02971384|Active Comparator|Vitamin C Tablets|synthetically produced ascorbic acid
88968442|NCT02972567|Experimental|Probiotic|Lactobacillus strain
88968443|NCT02972567|Placebo Comparator|Control|Maltodextrin
89564212|NCT02651155|Placebo Comparator|Placebo|Lubiprostone placebo-matching capsules, orally, twice daily, under fed conditions, for 4 weeks.
89564213|NCT04925063|Experimental|Metformin+ADT+abiraterone|Drug: Metformin The starting daily dose of metformin is 500mg once daily, to be increased to 2000mg once daily if tolerated until disease progression Drug: Abiraterone Abiraterone 1000mg once daily until disease progression
88968444|NCT04711876||Test group with enterovirus meningitis|Level of Cytokine in blood and CSF for Patient with RT-PCR-EV +
88968445|NCT04711876||Control group with no enterovirus meningitis|Level of Cytokine in blood and CSF for Patient with RT-PCR-EV -
88968446|NCT02971540|Experimental|bupivacaine, LA, solution|an a local anesthetic administered for local wound infiltration on each side in a single dose of 10 ml of 0,2% solution per segment of vertrebral columne with potential duration time of up to 8 hours according to manufacturers data
89564214|NCT04925063|No Intervention|ADT+abiraterone|Drug: Abiraterone Abiraterone 1000mg once daily until disease progression
89564215|NCT04909151|Experimental|Robot-assisted gait training with walking speed of 0.5km/h|
88968447|NCT02971540|Experimental|ropivacaine, LA, solution|an a local anesthetic administered for local wound infiltration on each side in a single dose of 10 ml of 0,2% solution per segment of vertrebral columne with potential duration time of up to 8 hours according to manufacturers data
88968448|NCT02971540|Experimental|metamizol, analgesic, solution|an analgesic drug administered intravenously for pre-emptive analgesia in a initial dose of 1-1,25g with potential duration time of up to 6 hours according to manufacturers data
88968449|NCT02971540|Experimental|tramadol, analgesic, solution|a half-opioid drug administered intravenously for pre-emptive analgesia in a initial dose of 2 mg per kg of body weight with potential duration time of up to 6 hours according to manufacturers data
88968450|NCT02971540|Experimental|control group|no pre-emptive analgesia will be used.
89564216|NCT04909151|Experimental|Robot-assisted gait training with walking speed of 0.8km/h|
89564217|NCT04909151|Experimental|Robot-assisted gait training with walking speed of 1.1km/h|
89564218|NCT05127343|Active Comparator|Resin based sealant (Ultraseal XT Hydro)|
89564219|NCT05127343|Active Comparator|Glass ionomer based sealant (Fugi Triage)|
89564220|NCT05132959||Patient Group|Patients with supraspinatus tendinosis
89564221|NCT05132959||Control Group|Patients without shoulder pain
89564222|NCT04925297||Non-NS ( Non-neurological sequelae) group|Patients who do not develop neurological dysfunction after acute carbon monoxide poisoning
89210663|NCT04005417||Stannous fluoride dentifrice|Twice daily brushing
89564223|NCT04925297||NS (Neurological sequelae) group|Patients who develop neurological dysfunction after acute carbon monoxide poisoning
89564224|NCT04495777||students|students were assessed in order to have a risk for TMD in order to their status of having parafunctional habits and neck pain
88968451|NCT04711681|Experimental|PBS1|"This group will recieve an enhanced PBS intervention."
88968452|NCT04711681|Active Comparator|PBS 2|"This group will receive standard PBS with fewer training and coaching sessions than PBS 1."
88968453|NCT00034528|Experimental|Allogeneic stem cell transplantation|Participants will receive a nonmyeloablative conditioning regimen of fludarabine and busulfan prior to allogeneic peripheral blood stem cell (CD34+) infusions. FK506 and prednisone will be administered for graft versus host disease (GVHD) prophylaxis.
88968454|NCT04711642|No Intervention|No intervention|Control group.
88968455|NCT04711642|Experimental|Treatment 1|Sodium hyaluronate 0.1% eyedrops (Systane ultra plus), q.i.d from day 7 to day 30 after cataract surgery.
88968456|NCT04711642|Experimental|Treatment 2|Sodium hyaluronate 0.1% eyedrops (Hylo-comod), q.i.d from day 7 to day 30 after cataract surgery.
88968457|NCT00014079||Group 1|"DNA is examined for unstable elements (microsatellite instability and loss of heterozygosity) by analyzing at least 10 separate (CA)n-repeats localized to 5 separate chromosomes (5q, 8p, 15, 17p, and 18q). Loss of heterozygosity is analyzed for at least four chromosomal arms (5q, 8p, 17p, and 18q) and later other chromosomes (e.g., 1, 14, and 22). Immunohistochemistry is used to test for the presence or absence of the genes involved in DNA mismatch repair (hMLH1 and hMSH2).~Patients do not receive the results of the genetic testing and the results do not influence the type or duration of treatment."
89564225|NCT03055169||intensive care patients|patients with a least one organ dysfunction
89564226|NCT05132725|Experimental|Dietary intervention CHO counting combined with GFD|Carbohydrate counting diet will be prepared according to Kulkarni, (2005). Tailored diet plans according to patient's food preference, physical activity level and appropriate insulin: Carbohydrates ratio will be prescribed for each participants. Diets were based on each participants' recommended intakes of energy, protein (15-25%), fat (30-40%) and carbohydrate (40-50%) (Thomas and Gutierrez, 2005; Kleinwechter et al., 2014). Energy requirement will be determined in the participants' weight. The carbohydrate counts will be distributed into three main meals and 3 snacks, with the general dietary advice and diet that will be prescribed by hospital for participants
89033072|NCT02921880|No Intervention|Standard of care|15 patients will be randomised to receive a programme of cardiac rehabilitation, and 15 patients will receive standard of care which does not include a routine rehabilitation programme.
89033073|NCT04689126|Experimental|intervention|diagnosis and treatment plan before and after cone beam computed tomography scan
89033074|NCT00531362||Patients|All patients (acute or stable) presenting to a cardiovascular clinic and on aspirin.
89564227|NCT05132725|Experimental|Dietary intervention CHO Counting with GFD & DASH|The recommended intakes of energy, protein (15-25%), fat (30-40%) and carbohydrate (40-50%) will be similar to that in carbohydrate counting diet which mentioned above. DASH diet food choices will be inserted in the diet of the participants assigned for the combined diet of DASH and carbohydrate counting. The emphasis will be more on the fruits and vegetables group (>8 servings/day), whole grains (at least half of the amount of the total servings of cereals; 6-8 servings/day), fat free dairy products (2-3 servings/day), lean meat and plant proteins (0-2 servings/day) and nuts (5-7 servings/week). From the fat group olive oil will represent the main type of fat (20-25% of total fat %). Adequate intake of sodium (2000mg) will be applied into participants' diet, with the general dietary advice and diet that will be prescribed by hospital for participants
89564228|NCT05132725|No Intervention|General Dietary guidlines|the general dietary advice and diet that will be prescribed by hospital for participants
89564229|NCT04908527|Experimental|Walk group|Patients walked to operating room (OR)
89564230|NCT04908527|No Intervention|Bed group|Patients go to OR while in bed
89564231|NCT05132647||Cerebellar ataxia and Healthy adults|We will not administer any intervention to the patients in this study
89564232|NCT04924829||Tocilizumab|Group that received tocilizumab (8mg/kg, maximum dose 800 mg, only once) while being admitted with severe COVID-19 pneumonia.
89564233|NCT04924829||Non-tocilizumab|Group that did not receive tocilizumab but share the same indication according to the elegibility criteria for it as the tocilizumab group while admitted with severe COVID-19 pneumonia.
89564234|NCT05132413|Experimental|treatment group|
89564235|NCT05132413|Placebo Comparator|Placebo group 1|
89564236|NCT05132413|Placebo Comparator|Placebo group 2|
89564237|NCT04924751|Experimental|CEH-EUS-guided FNB group|In CEH-EUS-guided FNB group, needle puncture directly to the enhancing area 15-20 times without passing to the non-enhancing area was performed. After each pass, the needle is removed and the stylet will be introduced into the needle to extrude any aspirated material on a glass slide for inspection of the presence of a macroscopic visible core (MVC). The total length of the MVC will be measured before placement into a formalin bottle. EUS-FNB is completed if the obtained MVC is longer than 4mm and deemed adequate by endoscopist. If the obtained MVC is < 4mm, the procedure is repeated until a MVC of ≥ 4mm is obtained and deemed adequate by endoscopist. A maximum of 7 passes is allowed.
89564238|NCT04924751|Active Comparator|Conventional-EUS-guided FNB with fanning technique group|In conventional-EUS-guided FNB with fanning technique group, the needle was positioned at four different areas within the mass and then moved back and forth four times in each area to procure tissue (4 × 4). After each pass, the needle is removed and the stylet will be introduced into the needle to extrude any aspirated material on a glass slide for inspection of the presence of a macroscopic visible core (MVC). The total length of the MVC will be measured before placement into a formalin bottle. EUS-FNB is completed if the obtained MVC is longer than 4mm and deemed adequate by endoscopist. If the obtained MVC is < 4mm, the procedure is repeated until a MVC of ≥ 4mm is obtained and deemed adequate by endoscopist. A maximum of 7 passes is allowed.
89564239|NCT05126953|Experimental|samfilcon A Lenses with EPG01 Packaging Solution|
89564240|NCT05126953|Active Comparator|B+L Ultra Lenses|
89564241|NCT03052829|Experimental|Physical Activity Counseling|Subjects will be given counseling on the benefits of increasing activity, instructions on how to slowly increase their activity over 12 weeks with walking, record their daily step counts, and have bi-weekly phone calls with study staff to reinforce the training and help them overcome barriers to being physically active.
89027425|NCT02955303|Experimental|TECH protocol|Daily self-training using tablet apps facilitated by weekly group sessions. The self-training will take place independently at participants' home and will include mostly playing puzzle-apps to train different cognitive components. Participants will be requested to play (and log) various apps three to five times a week for 30-60 minutes each time, for a total of 15-20 training sessions. In addition they will use the tablets for a variety of everyday uses. The individual self-training will be accompanied by five weekly sessions (of 60-90 minutes) in a small group setting (5-6 participants) led by an experienced occupational therapist. For initial learning of the tablet's basic use, an individual session for each participant will take place.
89027426|NCT01308580|Experimental|Cabazitaxel 20 mg/m^2|Cabazitaxel 20 mg/m^2 intravenous (IV) infusion over 1 hour on Day 1 of each 21-day cycle in combination with Prednisone (or Prednisolone) 10 mg orally daily until disease progression (DP), unacceptable toxicity, participant's refusal of further study treatment or for a maximum of 10 cycles.
89027427|NCT01308580|Experimental|Cabazitaxel 25 mg/m^2|Cabazitaxel 25 mg/m^2 IV infusion over 1 hour on Day 1 of each 21-day cycle in combination with Prednisone (or Prednisolone) 10 mg orally daily until DP, unacceptable toxicity, participant's refusal of further study treatment or for a maximum of 10 cycles.
89027428|NCT00483444|No Intervention|2|Control group were recruited in the emergency department after concussion and received standard care as directed by the ED physician and PCP.
89027429|NCT00483444|Experimental|1|Persons with concussion recruited in the emergency department received 5-6 scheduled telephone counseling calls focused on symptom management and self-management.
89027430|NCT02890810|Experimental|Verum Electroacupuncture|Active Intervention
89027431|NCT02890810|Placebo Comparator|Placebo Electroacupuncture|Validated Control
89027432|NCT00483314|Experimental|1|
89027433|NCT04516629||Experimental|subjects with sub-health status
89027434|NCT04324918|Experimental|HCP1102|
89027435|NCT04324918|Active Comparator|HGP1408|
89027436|NCT00483483|Experimental|1|Healthy Relationships Intervention (HRI)
89027437|NCT00483483|Active Comparator|Attention-control group|health education & support
89027438|NCT01308424|Experimental|BTL TML HSV|
89027439|NCT01308424|Placebo Comparator|Matching Placebo|
89027440|NCT05644288|Experimental|Intervention group|"The proposed intervention is a telephonic telenursing program aimed at managing social isolation in the elderly, the HELPeN (Help eNursing) program.~The operational part of the intervention will be carried out by volunteers nursing students from the University of Murcia enrolled in the academic years 2020-2023. To ensure homogeneity in the intervention carried out by the volunteers they will receive a 15-hour training oriented to ensure the acquisition of essential communication skills for the implementation of the intervention and to know the specific interventions of support and counseling for the elderly in social isolation."
89027441|NCT05644288|No Intervention|Control group|No intervention will be performed in the control group and the subjects will be contacted on the same dates as the intervention group for data collection.
89027442|NCT00483522|Experimental|1|Scheduled telephone counseling over 2 years time.
89027443|NCT00483522|No Intervention|2|This control group will receive standard care after hospital rehabilitation discharge as directed by their physician.
89027444|NCT00483431|Placebo Comparator|PLACEBO|MK7 dosage 0 mcg, 4 capsules, orally, daily for 12 weeks.
89027445|NCT00483431|Active Comparator|MK7_10|MK7 dosage 10 mcg, 1 capsule of 10 mcg and 3 placebo-capsules, orally, daily for 12 weeks.
89027446|NCT00483431|Active Comparator|MK7_20|MK7 dosage 20 mcg, 2 capsules of 10 mcg and 2 placebo-capsules, orally, daily for 12 weeks.
89027447|NCT00483431|Active Comparator|MK7_45|MK7 dosage 45 mcg, 1 capsules of 45 mcg and 3 placebo-capsules, orally, daily for 12 weeks.
89027448|NCT00483431|Active Comparator|MK7_90|MK7 dosage 90 mcg, 2 capsules of 45 mcg and 2 placebo-capsules, orally, daily for 12 weeks.
89027449|NCT00483431|Active Comparator|MK7_180|MK7 dosage 180 mcg, 4 capsules of 45 mcg, orally, daily for 12 weeks.
89027450|NCT00483431|Active Comparator|MK7_360|MK7 dosage 360 mcg, 1 capsule of 360 mcg and 3 placebo-capsules, orally, daily for 12 weeks.
89027451|NCT00483600|Experimental|no arms/one group|
89027452|NCT00488189|No Intervention|1|baseline, collecting rectal swab samples
89027453|NCT00488189|Active Comparator|2|use pipercill/tazobact to replace 3rd generation cephalosporin and collect rectal swab
89027454|NCT04516551|Experimental|anti-CD19 allo-CAR-T|"The study will employ dose level cohorts of three patients that will be treated at each level described below, based on the number of T cells to be infused using the 3 + 3 dose-escalation strategy to find MTD followed by a dose-expansion phase at determining optimal dosage.~dosage: the number of anti CD19+CD22 CAR T cells~-1(if needed) 1×10^6/KG~3×10^6 /KG 6×10^6 /KG 1×10^7/KG Treatment follows a lymphodepletion, chemotherapy regimen that consists of Fludarabine (30 mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) for 3 days or bendamustione (90mg/m2 per day) for two days prior to cell infusion."
89027455|NCT00488228|Experimental|1|Participants in the behavioral self-regulation intervention will receive a modified standard treatment that incorporates daily weighing and training in self-regulation methods for weight loss. All treatment modules are adapted for a young adult age group.
89564242|NCT03052829|Placebo Comparator|Patient Usual Care|Subjects will undergo usual care without intervention in this study arm
89564243|NCT04140175||Women with suspected or confirmed endometriosis|Women with suspected or confirmed endometriosis undergoing standard of care treatments or interventions.
89027456|NCT00488228|Experimental|2|Participants in the Standard group will receive a brief version of standard behavioral weight loss treatment with treatment modules tailored to better meet the needs of young adults.
89027457|NCT02956421|Active Comparator|RABIPUR®|Comparator vaccine RABIPUR® Healthy volunteers received rabies vaccination intramuscularly on days 0,3,7 and 14
89027458|NCT02956421|Experimental|PIKA Rabies vaccine|PIKA Rabies vaccine with an accelerated regimen Healthy volunteers received rabies vaccination intramuscularly on days 0 (2 Doses), 3 (2 Doses), and day 7 (1 Dose)
89564244|NCT04924595|No Intervention|Regular treatment|
89564245|NCT04924595|Experimental|Exercise Intervention|
89564246|NCT03052907|Other|BSPAN Expansion|We will expand BSPAN's reach and sustainability by systematizing how to enable counties to assume responsibility for one or two of the components while Moncrief/UTSW continues to provide centralized financial review and reimbursement as the Texas BCCS contractor. We will prospectively identify which counties have the necessary program capacity, then test whether implementation of BSPAN tailored to a county's capacity and local needs can lead to equivalent program success in an additional 12 rural counties (BSPAN2 total= 17 counties). Findings will be used to develop a model by which BSPAN benefits can be brought to rural communities across the country.
89564247|NCT04133935|Experimental|Laparoscopic Obturator Urethropexy|Suspending the periurethral vaginal tissue to the obturator internus fascia bilaterally via sutures, creating a support for the bladder neck compartment
89564248|NCT04133935|Active Comparator|Burch Urethropexy|Suspending the periurethral vaginal tissue to Cooper's ligament bilaterally via sutures, creating a support for the bladder neck compartment
89564249|NCT04924049|Experimental|Experimental|The video-assisted education group also received routine treatment and care per protocol. Additionally, this patient group watched patient education through video in the patient room before TKR. The contents of the VE were developed by the researchers and included early postoperative care for TKR (knee positioning, early mobilization, pain control, and cold application), ADLs at home (bathing and toileting, eating, sleeping, vehicle driving, housekeeping, sexual life, praying, and maintaining home safety), and gradual exercise at home (for the first 90 days after discharge).
89564250|NCT04924049|No Intervention|Control|The control group received routine treatment and care per protocol.
89564251|NCT04435717|Experimental|TCZ 8 mg / kg one dose|TCZ 8 mg / kg (with a maximum of 800 mg) in single dose + usual treatment
89564252|NCT04435717|Experimental|TCZ 8 mg / kg in two|TCZ 8 mg / kg in two doses at 0 and 12 hours (with a maximum of 800 mg per dose) + usual treatment
89564253|NCT04435717|No Intervention|standard care treatment|Usual / standard care treatment
89564254|NCT04907981||Novel coronavirus infection|All patients were diagnosed according to the diagnostic criteria of the National Health Commission of China and confirmed by RT-PCR detection of viral nucleic acids.
89564255|NCT04907981||Not infected by novel coronavirus|Healthy controls and patients with liver disease
89564256|NCT04907981||Recovered patients with nucleic acid negative after infection with novel coronavirus|Novel coronavirus nucleic acid changed from positive to negative.
89564257|NCT05124223||Post-COVID-19|From May 2020 to May 2021, we retrospectively examined 104 clinical cardiac magnetic resonance (CMR) examinations performed in patients with suspected cardiac involvement post COVID-19. The mean time from first positive PCR to CMR was 112 +- 76 days. During their COVID-19 disease, 21% of patients required hospitalization, 17% supplemental oxygen and 7% mechanical ventilation.
89564258|NCT05124223||Post-COVID-19-Vaccination|Between May 2021 and August 2021, we examined 27 patients with suspected cardiac disease after COVID-19 vaccination.
89564259|NCT04075981|Experimental|Botulinum toxin|"All patients from the experimental group will receive botulinum toxin (Xeomin®, incobotulinumtoxin A, Merz Pharma GmbH & Co KGaA, Germany; 200 U dissolved in 4 mL of 0.9% normal saline and 50 U/1 mL will be injected at each fat pad).~Botulinum toxin will be injected into the entire visible area of the 4 major epicardial fat pads, during extra corporal circulation and before aortic cross clamping in order to reduce the time of ischemia.~The whole estimated dosage would be therefore 200 units of incobotulinumtoxin A,"
89564260|NCT04075981|Placebo Comparator|Placebo|All patients from the control group will receive placebo. Before the main stage of the surgery, during extra corporal circulation and before aortic cross clamping, the placebo dissolved in 4 mL of 0.9% normal saline will be injected into the entire visible area of the 4 major epicardial fat pads as follows (1 mL at each fat pad).
89564261|NCT05122195||Group A, compression therapy group|Elastic compression therapy with a thigh length stockings of 23-32 mmHg, at least 8 hours a day.
89564262|NCT05122195||Group B, control group|No compression therapy prescribed in the follow-up period.
89564263|NCT04917497||Levosimendan Treated Group|All patients consecutively admitted to the medical ICU of the University Hospital Zurich aged over 18 years, with an underlying cardiogenic shock, receiving Levosimendan.
89564264|NCT03933007|Other|Pharmacokinetic study|all participants will undergo pharmacokinetic study and take colchicine (1.5 mg over 1 hour), midazolam (1 mg) and fexofenadine (120 mg)
89564265|NCT04924439|Experimental|experimental group (foot reflexology group)|"Primiparas appropriate for the criteria, admitted to the clinic due to CS and accepting to participate in the study were randomly placed into groups. Reflexology was performed in the intervention group mothers, and the questionnaires and scales were self-reportingly filled in by the lead researcher (SC).~Different rooms were allocated for the participants in the intervention and control groups not to affect each other.~Foot reflexology was applied to the experimental group for 40 minutes once a week for postpartum 8 weeks."
89564266|NCT04924439|No Intervention|control group|"Primiparas appropriate for the criteria, admitted to the clinic due to CS and accepting to participate in the study were randomly placed into groups. Reflexology was performed in the intervention group mothers, and the questionnaires and scales were self-reportingly filled in by the lead researcher (SC).~Different rooms were allocated for the participants in the intervention and control groups not to affect each other."
89564267|NCT05126875|Experimental|Treatment arm|Treatment with stereotactic radiosurgery
89564268|NCT03056651|Other|DayCare-HF|Comprehensive service in day-care unit, including education, diagnostic tools (i.e. electrocardiography, transthoracic echocardiography, implanted cardioverter defibrillator (ICD) / cardiac resynchronization therapy device (CRT) interrogation and possibility of intravenous drug administration (i.e. loop diuretics, dobutamine).
89564269|NCT04917263||Retrospective|
89564270|NCT04917263||Prospective|
89564271|NCT03887143||Arterial ischemic stroke in patients less than 18 years old|"Patients < 18 years old~Suspected or confirmed cerebral infarction~With recanalization treatment in the acute phase: intra-venous thrombolysis +/- intra-arterial thrombolysis +/- thrombectomy~Patients treated between January 2015, 1st and May 2018, 31st"
89564272|NCT04907435||patient with simultaneous laparoscopic operations|
89564273|NCT04907435||patient with simultaneous open operations|
89564274|NCT05404399|Experimental|Free From Pain Exercise Book|"Participants in Group 1 will be asked to engage in the 3 sets of exercises within the exercise book for the following 12 weeks. They will be advised to engage in the exercises at least five times a week. The ideal plan would be as follows:~Monday - Otago exercises. Tuesday - Neck and Back exercises. Wednesday - Otago exercises. Thursday - Reading the weekly reading material. Friday - Neck and Back exercises. Saturday - Otago exercises. Sunday - Rest day.~Furthermore, it will be recommended that participants in Group 1 read one motivation/reason chapter and one metaphor each week for 12 weeks, to ensure that they absorb the information fully and do not overbear themselves with information.~Participants in Group 1 will also be asked to fill in the exercise diary, found at the back of the exercise book, each time they exercise as part of the Free From Pain programme."
89564275|NCT05404399|Active Comparator|Usual Care (physiotherapy)|"Those in Group 2 (control group) will not be provided with the Free From Pain Exercise Book, and will instead be referred to physiotherapy as part of standard / usual care. They will be asked to report when their physiotherapy commenced."
89564276|NCT04923503|Experimental|lean ramadan fasting|conduct ramadan fasting for 30 days
89564277|NCT04923503|Experimental|obese ramadan fasting|conduct ramadan fasting for 30 days
89564278|NCT04923503|Experimental|diabetics ramadan fasting|conduct ramadan fasting for 30 days
89564279|NCT03862729||Early minimally invasive surgery group|For patients in minimally invasive surgery group, intracranial hematoma will be removed by intraoperative stereotactic computer tomography-guided endoscopic surgery, or surgical aspiration followed by alteplase clot irrigation (1·0 mg every 8 h for up to nine doses). CTA will be performed before operation in all the patients for intraoperative navigation, and the minimally invasive surgery will be performed within 24 hours after intracerebral hemorrhage onset.
89564280|NCT03862729||conventional treatment group|Eligible patients not accepting early minimally invasive surgery are classified as the conventional treatment group. Conventional treatment includes medical treatment and conventional craniotomy. According to the intention-to-treat principle, patients treated by minimally invasive surgery beyond the 24 hours interval after ICH onset are also classified as conventional treatment group.
89564281|NCT04907747|Experimental|Group A: Vonoprazan taken with bismuth, amoxicillin, furazolidone for 10 days|Vonoprazan 20mg qd, Colloidal bismuth pectin 200mg bid, Amoxicillin 1.0g bid, Furazolidone 0.1g bid for 10days
89564282|NCT04907747|Experimental|Group B: Vonoprazan taken with bismuth, amoxicillin, furazolidone for 14 days|Vonoprazan 20mg qd, Colloidal bismuth pectin 200mg bid, Amoxicillin 1.0g bid, Furazolidone 0.1g bid for 14days
89564283|NCT04907747|Active Comparator|Group C: Esomeprazole taken with bismuth, amoxicillin, furazolidone for 14 days|Esomeprazole 20 mg bid, Colloidal bismuth pectin 200mg bid, Amoxicillin 1.0g bid, Furazolidone 0.1g bid for 14days
89564284|NCT03812263|Experimental|RP-L201|RP-L201 is a gene therapy product containing autologous genetically modified CD34+ hematopoietic cells transduced with Chim-CD18-WPRE lentiviral vector administered as a single intravenous infusion
89564285|NCT03052673|Active Comparator|Ketamine + Fentanyl Group|"Patients will receive pre-induction fentanyl 1-mcg/kg, ketamine 0.5-mg/kg after induction, followed by intraoperative fentanyl infusion of 0.5-mcg/kg/hr + ketamine infusion of 0.2-mg/kg/hr.~Postoperative analgesia will be provided with Intravenous Patient Controlled Analgesia (IV-PCA) pump containing fentanyl citrate-2.5 mcg/ml, which will be attached to all the patients upon shifting to the recovery room. The IV-PCA pump settings will be as follows: 0-ml basal dose; 4-ml PCA dose; 15-minutes lock out interval."
89564286|NCT03052673|Active Comparator|Fentanyl Group|"Patients will receive pre-induction fentanyl 1-mcg/kg,followed by intraoperative fentanyl infusion of 0.5-mcg/kg/hr.~Postoperative analgesia will be provided with Intravenous Patient Controlled Analgesia (IV-PCA) pump containing fentanyl citrate-2.5 mcg/ml, which will be attached to all the patients upon shifting to the recovery room. The IV-PCA pump settings will be as follows: 0-ml basal dose; 4-ml PCA dose; 15-minutes lock out interval."
89564287|NCT04907123|Experimental|UNa+ Driven Intensive Therapy|"Ask patient to empty bladder. Start treatment (step 1). Re-evaluate patient every 6 hours; if therapeutic goal is not met, treat according to the following step.~Therapeutic goal: Spot Urinary Sodium > 70 mEq/L AND mean diuresis > 1,5 ml/kg/h Step 1 Furosemide i.v. continuous infusion (2 times oral daily dose; minimum dose: 240 mg die) Step 2 Double furosemide i.v. continuous infusion (maximal dose: 720 mg die) Step 3 Add oral metolazone 5 mg b.i.d. Step 4 Add oral acetazolamide 250 mg b.i.d."
89564288|NCT04907123|Active Comparator|Standard Therapy|"Ask patient to empty bladder. Start treatment (step 1). Re-evaluate patient every 12 hours; if therapeutic goal is not met, treat according to the following step.~Therapeutic goal: mean diuresis > 1,5 ml/kg/h Step 1 Furosemide i.v. continuous infusion (2 times oral daily dose; minimum dose: 240 mg die) Step 2 Double furosemide i.v. continuous infusion (maximal dose: 720 mg die) Step 3 Add oral metolazone 5 mg b.i.d. Step 4 Add oral acetazolamide 250 mg b.i.d."
89564289|NCT05030857|Experimental|GLPG4716 and Midazolam|
89564290|NCT04917341||preoperative endometrial sampling result (secondary hospital)/1|Endometrial biopsy samples taken at the stage 2 state hospital
89564291|NCT04917341||preoperative endometrial sampling result (tertiary hospital)/2|Endometrial biopsy samples taken at the stage (tertiary hospital)
89564292|NCT04917341||final postoperative pathology/3|final postoperative pathology results with grade (endometrium cancer)
89564293|NCT03810859|Experimental|All patients|Blood sample
89027459|NCT04516239|Active Comparator|LDH THA|large diameter head total hip arthroplasty
89210664|NCT04005417||Positive control dentifrice|Twice daily brushing
89027460|NCT04516239|Active Comparator|HR|metal-on-metalhip resurfacing
89027461|NCT00483470|Experimental|1|
89210665|NCT04005417||Negative control dentifrice|Twice daily brushing
89210666|NCT01073839|Experimental|Cisplatin plus Gemcitabine|Patients after resection of cholangiocellular carcinoma will be allocated to treatment with cisplatin plus gemcitabine.
89210667|NCT00820742||Phase IV Post Marketing Surveillance Study|Open-label, observational study
89564294|NCT04917185|Experimental|Electro-Acupuncture group|The patients in this group will be treated with electro-acupuncture for 30 minutes twice a week in a month. We conduct Nei Guan (PC6), Shen Men (HT7), ZuSanli (ST36), SanYinjiao (SP6) as the major points. Each time treating, according to other symptoms, we will give no more than 2 additional points.
89564295|NCT04917185|No Intervention|Wait-list group|We give no intervention to the patients this group during the whole experiment. When finishing, the same ways of treatment will be given to these patients.
89564296|NCT03319459|Experimental|Regimen A|FATE-NK100 as a monotherapy in subjects with advanced solid tumor malignancies.
89564297|NCT03319459|Experimental|Regimen B|FATE-NK100 in combination with trastuzumab in subjects with human epidermal growth factor receptor 2 positive (HER2+) advanced breast cancer, HER2+ advanced gastric cancer or other advanced HER2+ solid tumors.
89564298|NCT03319459|Experimental|Regimen C|Regimen C: FATE-NK100 in combination with cetuximab in subjects with advanced colorectal cancer (CRC) or head and neck squamous cell cancer (HNSCC), or other epidermal growth factor receptor 1 positive (EGFR1+) advanced solid tumors.
89564299|NCT04923425||Exposure 1|commonly prescribed tricyclic antidepressants (Imipramine, Amitriptyline, Clomipramine HCL) administered for at least 3 months
89564300|NCT04923425||Exposure 2|commonly prescribed Selective Serotonin Re-uptake inhibitors antidepressants ( Fluoxetine, Fluvoxamine, Sertraline, Citalopram, Paroxetine) administered for at least 3 months
89564301|NCT04923425||Non exposure|Non-pharmacological treatment (psychotherapy)
89564302|NCT04430933|Experimental|NC318 + Pemetrexed/Carboplatin|NC318 at various dose strengths administered on the first day of each 21 day cycle in combination with pemetrexed/carboplatin
89564303|NCT04430933|Experimental|NC318 + Nab-paclitaxel/carboplatin|NC318 at various dose strengths administered on the first day of each 21 day cycle in combination with Nab-paclitaxel/carboplatin
89564304|NCT04430933|Experimental|NC318 + Docetaxel|NC318 at various dose strengths administered on the first day of each 21 day cycle in combination with Docetaxel
89564305|NCT04839133|Other|Feasibility study group|
89564306|NCT03056417|Experimental|Intervention|Participants in the Complete Health Improvement Program.
89564307|NCT03056417|No Intervention|No Change to Treatment|Participants who choose not to participate in the Complete Health Improvement Program.
89564308|NCT04815343|Experimental|Bilateral users|two implant systemswith two sound processors
89564309|NCT04815343|Experimental|Bimodal user|with one sound processor and one hearing aid
89564310|NCT04906733||Cancer patient|RAS/RAF wild-type metastatic right colon cancer patients receiving chemotherapy or chemotherapy combined target therapy treatment.
89564311|NCT03176095|Active Comparator|Probiotic Group|"The participants in the Probiotic group were provided with dietary supplements in the form as sachets with freeze dried bacteria (active lactobacilli culture) mixed with maltodextrin for daily intake (1 per day). The powder was dissolved in water or other non-alcoholic cold drink mixed with fruit before ingestion.~The probiotic product consisted of two different bacterial strains."
89564312|NCT03176095|Placebo Comparator|Placebo Group|The participants in the Placebo group were provided with dietary supplements in the form as sachets with maltodextrin for daily intake (1 per day).
89564313|NCT04906655|Experimental|Cohort A glycopyrronium 30 minutes cotton gloves|"Study drug should be applied to clean, dry skin. A single cloth will be used to apply study drug to both hands once daily, at bedtime. The subject will be instructed to apply the study drug as follows:~30 minutes residence time in cotton gloves~Complete daily diary.~Remove all jewelry.~Tear open the top of the pouch at the notch.~Wash hands thoroughly with warm water, and dry them.~Remove the wipe from the pouch and unfold the wipe.~Wipe both hands with the wipe continuously until the wipe is dry (up to 3 minutes).~Return the wipe to the pouch and put it back in the box.~Carefully put cotton gloves on both hands.~Set timer for 30 minutes.~After 30 minutes, remove gloves and throw them away. Immediately wash hands thoroughly with warm water and soap, and dry them."
89564314|NCT04906655|Experimental|Cohort B glycopyrronium 30 minutes under occlusion|"Study drug should be applied to clean, dry skin. A single cloth will be used to apply study drug to both hands once daily, at bedtime. The subject will be instructed to apply the study drug as follows:~30 minutes residence time under occlusion~Complete daily diary.~Remove all jewelry.~Tear open the top of the pouch at the notch.~Wash hands thoroughly with warm water, and dry them.~Remove the wipe from the pouch and unfold the wipe.~Wipe both hands with the wipe continuously until the wipe is dry (up to 3 minutes).~Return the wipe to the pouch and put it back in the box.~Carefully put gloves on both hands.~Set timer for 30 minutes.~After 30 minutes, remove gloves and throw them away. Immediately wash hands thoroughly with warm water and soap, and dry them."
89564315|NCT04906655|Experimental|Cohort C glycopyrronium overnight in cotton gloves|"Study drug should be applied to clean, dry skin. A single cloth will be used to apply study drug to both hands once daily, at bedtime. The subject will be instructed to apply the study drug as follows:~Overnight in cotton gloves~Complete daily diary~Remove all jewelry.~Tear open the top of the pouch at the notch.~Wash hands thoroughly with warm water, and dry them.~Remove the wipe from the pouch and unfold the wipe.~Wipe both hands with the wipe continuously until the wipe is dry (up to 3 minutes).~Return the wipe to the pouch and put it back in the box.~Carefully put on the cotton gloves on both hands and go to bed.~In the morning, after at least 4 hours of wearing the gloves , remove the cotton gloves and throw them away.~Immediately wash hands thoroughly with warm water and soap, and dry them."
89564316|NCT04906655|Experimental|Cohort D glycopyrronium overnight under occlusion|"Study drug should be applied to clean, dry skin. A single cloth will be used to apply study drug to both hands once daily, at bedtime. The subject will be instructed to apply the study drug as follows:~Overnight under occlusion~Complete daily diary~Remove all jewelry.~Tear open the top of the pouch at the notch.~Wash hands thoroughly with warm water, and dry them.~Remove the wipe from the pouch and unfold the wipe.~Wipe both hands with the wipe continuously until the wipe is dry (up to 3 minutes).~Return the wipe to the pouch and put it back in the box.~Carefully put on the occlusive gloves and go to bed.~In the morning, after at least 4 hours of wearing the gloves, remove the occlusive gloves and throw them away.~Immediately wash hands thoroughly with warm water and soap, and dry them."
89564317|NCT03130699|Experimental|Dulce Digital|The first of the three arms of the parallel design: The group of participants randomly assigned to this arm of the study receives one-size-fits-all educational text messages, with patient monitoring and transmission of blood glucose values.
89564318|NCT03130699|Experimental|Dulce Digital-Me (Automated Delivery)|The second of the three arms of the parallel design: The group of participants randomly assigned to this arm of the study receives educational text messages, with patient monitoring and transmission of blood glucose values, plus personalized goal-setting and tailored feedback delivered via automated algorithm-driven messaging, incorporated into existing primary care team processes.
89564319|NCT03130699|Experimental|Dulce Digital-Me (Medical Assistant)|The third of the three arms of the parallel design: The group of participants randomly assigned to this arm of the study receives educational text messages, with patient monitoring and transmission of blood glucose values, plus personalized goal-setting and tailored feedback delivered by Medical Assistants, incorporated into existing primary care team processes.
89564320|NCT03056183|Experimental|Treatment Group|Patients in the Depression Care Transitions intervention will have a Transitional Care Social Worker who will maintain daily phone contact, home visits, and will attend with the patient medical and psychiatric appointments for an average of three months following discharge. Patients in the usual care group will proceed as usual (scheduled follow-up visits). These subjects will also be asked to complete questionnaires relating to quality of life and physical and mental health status.
88968458|NCT04732819|No Intervention|Usual care|Facilities in the 'usual care' arm will be offered electronic messaging and education regarding the COVID-19 vaccine. This material stems from the Centers for Disease Control and Prevention (CDC) and AMDA - The Society for Post-Acute and Long-Term Care Medicine (AMDA) resources and represents a suggested approach to reduce vaccine hesitancy in staff and residents/proxies (e.g., legally authorized representatives, powers of attorney). This electronic quality improvement (QI) material will be developed as part of a QI initiative and disseminated by the American Health Care Association (AHCA) to the SNF chains and using social media.
88968459|NCT04732819|Experimental|High touch|Facilities in the 'high touch' arm will receive the same electronic messaging and educational material as in the 'usual care' arm but will receive an additional high touch multi-pronged behavioral intervention.
88968460|NCT00014196|Experimental|chemo/RT followed by consolidation chemo|cisplatin docetaxel radiation therapy
88968461|NCT00014235|Experimental|Arm I (indolent disease)|"CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.~TRANSPLANTATION: Patients undergo donor PBSCT on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine PO BID or IV every 8-12 hours on days -3 to 56 with a taper to day 180 and mycophenolate mofetil PO BID or IV every 8-12 hours on days 0 to 27."
88968462|NCT00014235|Experimental|Arm II (aggressive disease)|"CONDITIONING REGIMEN: Patients receive fludarabine phosphate and undergo TBI as in Arm I.~TRANSPLANTATION: Patients undergo donor PBSCT on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine PO BID or IV every 8-12 hours on days -3 to 56 with a taper to day 70 and mycophenolate mofetil as in Arm I."
88968463|NCT02972151|Experimental|Comprehensive treatment of TCM|The intervention is Comprehensive treatment of TCM,which including Oral medicine ,tradition chinese medicine enema, external treatment.
88968464|NCT02972151|Active Comparator|Expectant therapy|"Expectant treatment group patients were not treated during the observation period.~（3 months after the start of the trial and 1 months after the end of the trial.）"
88968465|NCT00035347|Experimental|Azithromycin plus ceftriaxone group (AZY+CEF group)|IV azithromycin (500 mg once daily) plus ceftriaxone (1 gram once daily) for 2 to 5 days followed by oral azithromycin (2 x 250 mg once daily) to complete a total of 7 to 10 days of therapy
88968466|NCT00035347|Experimental|Levofloxacin group (LEV group)|IV levofloxacin (500 mg once daily) for a minimum of 2 days followed by oral levofloxacin (500 mg once daily) to complete a total of 7 to 14 days of therapy.
88968467|NCT00035425|Experimental|A.|Patients will be stratified according to the use of prophylactic antibiotics. Both groups may receive open-label gram-negative coverage with either ceftazidime, aztreonam, and/or aminoglycosides (gentamicin, tobramycin, amikacin). Subjects will receive study medication intravenously every 12 hours for 7 to 28 days.
88968468|NCT00035425|Experimental|B.|
88968469|NCT00035464|Placebo Comparator|1|Placebo tablets
88968470|NCT00035464|Experimental|2|125 mg azimilide tablets
88968471|NCT00035581|Experimental|Ampligen|Ampligen (polyI-polyC12U) 200-400 mg IV infusions given twice weekly for 24 weeks
88968472|NCT00035581|No Intervention|No Ampligen|No Ampligen administered for first 24 weeks
88968473|NCT00035620|Active Comparator|Filgrastim|Filgrastim
88968474|NCT00035620|Experimental|Pegfilgrastim|Pegfilgrastim
88968475|NCT02971306|Active Comparator|Standard Medical therapy|standard medical therapy
88968476|NCT02971306|Experimental|G-CSF|standard medical therapy plus G-CSF- 5μg/Kg s.c every 12 hours for 5 consecutive days
88968477|NCT02971306|Experimental|G-CSF and NAC|standard medical therapy plus G-CSF- 5μg/Kg s.c every 12 hours for 5 consecutive days plus NAC (day 1: NAC at 150, 50, and 100 mg/kg in 250, 500, and 1000 ml of 5% glucose solution over 30 minutes, 4 hours, and 16 hours, respectively; days 2 through 5: 100 mg/kg/day in 1000 ml of 5% glucose solution)
88968478|NCT04732390|Placebo Comparator|GROUP(A) (CONTROL GROUP)|Patient will receive 20 ml 0.25% levobupivacaine into interfascial plane below erector spinae muscle at level of T5.
88968479|NCT04732390|Active Comparator|Group (M)|Patient will receive 20ml 0.25% levobupivacaine + 0.7 mg/kg MgSo4 into interfascial plane below erector spinae muscle at level of T5. .
88968480|NCT00035893|Experimental|Ampligen|Ampligen (poly I-poly C12U) 200-400 mg IV infusions given twice weekly for 64 weeks.
88968481|NCT00035893|No Intervention|No Ampligen|No Ampligen administered for first 64 weeks
88968482|NCT00000785||A|All eligible CPCRA subjects
88968483|NCT02971345|Experimental|Endovascular Brachytherapy&Stent&TACE|"Transarterial chemoembolization (TACE) is performed immediately following Iodine-125 seed strand and stent implantation.~Epirubicin,ultra-fluid lipiodol and gelatin sponge articles are used in TACE."
88968484|NCT02971345|Active Comparator|TACE alone|Only TACE is performed. Epirubicin, ultra-fluid lipiodol and gelatin sponge articles are used in TACE.
88968485|NCT00391521|Active Comparator|1|Regimen 1
88968486|NCT00391521|Active Comparator|2|Regimen 2
88968487|NCT00391521|Active Comparator|3|Regimen 3
88968488|NCT04732585|Experimental|Patient with PFPS or ACL injury|Physiotherapy intervention Surgical intervention
88968489|NCT04732585|No Intervention|Healthy control group|The healthy control group will not do any intervention
88968490|NCT00391638|Experimental|HIV antiretroviral therapy, TRUVADA , PEGASYS 180μg|Week-8 up Week0: HIV antiretroviral therapy Week 0 up Week 48: HIV antiretroviral therapy + TRUVADA + PEGASYS 180μg Week 48 up Week 72: HIV antiretroviral therapy + TRUVADA Week 72 up Week 144: HIV antiretroviral therapy
88968491|NCT02971189|Other|Librata endometrial ablation|Librata thermal balloon endometrial ablation treatment procedure will be performed in accordance with the physician's routine endometrial ablation practice and in accordance with the requirements of the LibrataTM IFU. The uterine cavity will be systematically inspected using hysteroscopy prior the ablative procedure (after any blind cervical dilatation) and post the ablative procedure to estimate the completeness of endometrial destruction and to exclude uterine trauma including uterine perforation. The patient will undergo standard post-operative monitoring and recovery according to usual hospital practices. An assessment will be made for any ablation procedure or device related serious adverse events.
89564321|NCT03056183|No Intervention|Control Group - Standard of Care|To be followed per standard of care and data from their medical records will be reviewed.
89564322|NCT03055091|Experimental|Treatment group|Participants in the treatment arm will receive a Xylitol syrup.
89564323|NCT03055091|Placebo Comparator|Placebo|Participants in the placebo arm will receive sorbitol syrup.
89564324|NCT02648581|Experimental|Subcutaneous Ustekinumab|
89564325|NCT04916717|Other|Counseling|Quasi-experimental design. Face-to-face and telephone counseling were applied to individuals in the intervention group.
89564326|NCT02609815|Experimental|gemigliptin/metformin|zemimet-SR 50/1000 mg x 1 tablet
89564327|NCT02609815|Active Comparator|glimepiride/metformin|amaryl-Mex 1/500 mg x 2 tablets
89564328|NCT01315639|Other|biomarkers, MRI and CSF|"Longitudinal multicenter study including 1300 subjects with amnestic impairment (MCI, n=650 and AD, n=650) derived from the main French national Memory Resources and Research Centers.~Participants will undergo at baseline and every 6 months a neurological examination, a neuropsychological assessment (and an oculomotor examination for those included from Broca Hospital).~Alzheimer disease biomarkers' measurements will be performed at inclusion and at the end of the study (or the conversion)."
89564329|NCT04662463|Experimental|CBM-I assignment|Patients will receive CBM-I assignments
89564330|NCT04662463|Placebo Comparator|Placebo assignment|Patients will receive placebo assignments
89564331|NCT04655521||COVID-19 patients|
89564332|NCT04655521||Healthy controls|
89564333|NCT04655521||Non-COVID-19 patients with respiratory tract infection|
89564334|NCT04906967|Active Comparator|modified sural flap|modified sural flap used to cover soft tissue defect around ankle
89564335|NCT04906967|Active Comparator|anterolateral thigh flap|anterolateral thigh flap used to cover soft tissue defect around ankle
89564336|NCT01118767|Experimental|Cell phone intervention|Participant receives short text messages
89564337|NCT01118767|No Intervention|Standard of care|Participant receives standard of care support but not short text messages
89564338|NCT04922879|Experimental|Individualized lung rehabilitation programme|Early respiratory function training, reasonable oxygen therapy to prevent hypoxemia, Positive pressure vibration training to promote coughing ability recovery, early exercise, Health education and psychological support.
88968492|NCT00036634|Active Comparator|Tenofovir DF|Participants received tenofovir DF 300 mg for 14 days
89027462|NCT00483470|Active Comparator|2|
89564339|NCT04906343|No Intervention|Group 1 (2 years)|Group 1, surveillance colonoscopy in two years after the last complete colonoscopy in SPS patient.
89564340|NCT04906343|Active Comparator|Group 2 (3 years)|Group 2, surveillance colonoscopy in three years after the last complete colonoscopy in SPS patient.
89564341|NCT05132023|Experimental|Empagliform|Test drug
89564342|NCT05132023|Active Comparator|Synjardy|Reference drug
89564343|NCT05404087||Pre-operative staging of breast cancer with CEBCT|Women who have been diagnosed with breast cancer and need to have a pre-operative staging and this will be done with contrast-enhanced breast CT.
89564344|NCT05404087||Follow-up of women with breast cancer treated with neo-adjuvant chemotherapy|Women who are selected for neo-adjuvant chemotherapy to reduce the size of the tumor need to be followed-up in order to evaluate the treatment response.
89564345|NCT04904159||Benign|Patients who have benign pathologies after thyroidectomy
89564346|NCT04904159||Malign|Patients who have malign pathologies after thyroidectomy
89564347|NCT04498663|Experimental|Therapeutic Interview Condition|The therapeutic interview for chronic pain will be a one-session interview lasting approximately 90 minutes. The goals of the therapeutic interview are to promote awareness of the role of trauma and interpersonal stress in pain, to encourage experience of emotions associated with interpersonal stressors and conflicts, and to encourage more adaptive interpersonal communication in current relationships.
89564348|NCT04498663|No Intervention|Waitlist Control Condition|Participants in the waitlist control condition will receive a delayed interview (after 6-week follow-up assessment), if they choose to do so.
89564349|NCT04916483|Experimental|Exploring the effectiveness of GCST in people with schizophrenia.|The experimental group will receive a total of 14 sessions, twice a week group cognitive stimulation therapy for 7 weeks.
89564350|NCT04916483|No Intervention|Control group|The control group maintains the usual care.
89564351|NCT05131711|Experimental|rGBM Group with combined stereotactic radiosurgery and enhanced immunotherapy|Patients with rGBMs will receive combined stereotactic radiosurgery and enhanced immunal adjuvants (GM-CSF, Sapylin, MnCl2). The safety and efficacy will be analyzed.
89564352|NCT05131711|No Intervention|rGBM Group with|After biopsy or tumor resection, this rGBM group was treated with FDA-approved strategies proposed by the MDT group.
89564353|NCT02619617|Experimental|SOM230 0.9mg|cohort 2
89564354|NCT02619617|Experimental|SOM230 1.5 mg|cohort 1
89564355|NCT04012957|Experimental|Darbepoetin Alfa Injection|Randomly assigned to receive Darbepoetin in a 1:1 ratio for 24 weeks.
89564356|NCT04012957|Active Comparator|Desidustat oral tablet|Randomly assigned to receive Desidustat 100 mg in a 1:1 ratio for 24 weeks.
89564357|NCT05125705|Experimental|Platelet rich plasma injection|Patients will be treated with a single PRP injection, where 8 mL of whole blood will be collected and 2.5 mL of PRP will be given to the patient. Routine physiotherapy regimens will be implemented, similar to placebo arm.
89564358|NCT05125705|Placebo Comparator|Saline injection|Patients will be treated with 2.5 mL saline 0.9%. Routine physiotherapy regimens will be implemented, similar to intervention arm.
89564359|NCT04906031|Experimental|Sodium stibogluconate|Sodium stibogluconate 900 mg/m2/day will be given on d1-5 and d15-19. 28 days per cycle.
89564360|NCT05131243|Experimental|ctDNA positive patients|Postoperative ctDNA-positive patients will receive chemotherapy for 6 months.The ctDNA dynamic detection and imaging examination will be completed every 3 months, and tumor markers will be detected in each chemotherapy cycle.
89564361|NCT05131243|Active Comparator|ctDNA negative patients|Postoperative ctDNA-negative patients will receive chemotherapy for 3 months. The ctDNA dynamic detection and imaging examination will be completed every 3 months, and tumor markers will be detected in each chemotherapy cycle.
89564362|NCT05125627|Experimental|Treatment A|"Progesterone 200 mg Soft Capsule (JSC Farmak, Ukraine)~Each dose was administered Intravaginally, the capsule introduced deeply into the vagina while lying down, after at least 10 hrs of fasting, under the direct supervision of the Principal and/ or clinical Investigator"
89564363|NCT05125627|Active Comparator|Treatment B|"Utrogestan® 200 mg Soft Capsule (Manufacturer: Cyndea Pharma, S.L., Spain, MAH: Laboratoires Besins International, France)~Each dose was administered Intravaginally, the capsule introduced deeply into the vagina while lying down, after at least 10 hrs of fasting, under the direct supervision of the Principal and/ or clinical Investigator"
89564364|NCT04399265|Experimental|Trehalose|Trehalose powder form to be dissolved in water, to be consumed by mouth, every day for 3 months.
89564365|NCT04399265|Placebo Comparator|Maltose placebo|Isocaloric maltose powder form to be dissolved in water, to be consumed by mouth, every day for 3 months.
89564366|NCT05125549|Experimental|Treatment A|Сlopidogrel bisulfate film-coated tablets, 75 mg (JSC Farmak, Ukraine)
89564367|NCT05125549|Active Comparator|Treatment B|Plavix® 75 mg film-coated tablets (Sanofi Winthrop Industrie, France)
89564368|NCT04903847|No Intervention|Dolutegravir/tenofovir disproxil/lamivudine|Continue dolutegravir 50 mg, tenofovir disproxil 245 mg, ,and lamivudine 300 mg once daily for 48 weeks.
89564369|NCT04903847|Experimental|dolutegravir/lamivudine|dolutegravir 50 mg/lamivudine 300 mg once daily for 48 weeks
89564370|NCT04903847|Experimental|doravirine/tenofovir disproxil/lamivudine|100 mg doravirin, 245 mg tenofovirdisoproxil and 300 mg lamivudine once daily for 48 weeks.
89564371|NCT05131009||Patients with pulmonary complications following abdominal surgery|
89564372|NCT05131009||Patients without pulmonary complications following abdominal surgery|
89564373|NCT03647917|Experimental|Platelet Rich Plasma, Left face and hands|"Subjects will receive PRP on left half of face and saline solution on right half of face through injections via filler injection technique followed by microneedling, and will also receive PRP on dorsal part of left hand and saline solution on dorsal part of right hand through injections via filler injection technique. Microneedling will not be performed on the hands.~Injections will take place every 4 weeks for a total of 3 treatments."
88968493|NCT00036634|Experimental|Tenofovir alafenamide 50 mg|Participants received tenofovir alafenamide 50 mg for 14 days
88968494|NCT00036634|Experimental|Tenofovir alafenamide 150 mg|Participants received tenofovir alafenamide 150 mg for 14 days
88968495|NCT02970994||Preterm neonates <34 wks|Haemodynamicaly stable preterm neonates <34 weeks with in 48 hours of admission
88968496|NCT00036751|Experimental|Treatment (imatinib mesylate)|Patients receive oral imatinib mesylate once daily in the absence of disease progression or unacceptable toxicity.
88968497|NCT00036868|Experimental|CMF + Herceptin|
88968498|NCT00037609|Experimental|Capecitabine + Exisulind|Capecitabine 1000 mg/m^2 taken by mouth twice daily. Exisulind 125 mg taken by mouth twice daily.
88968499|NCT00037648|Placebo Comparator|placebo|
88968500|NCT00037648|Experimental|anakinra|
88968501|NCT00037882|Experimental|SCH 54031|Peg Interferon Alpha-2B/PEG-Intron
88968502|NCT00037921|Other|1|
88968503|NCT00038038|Experimental|PET + 18F-fluoromisonidazole|
88968504|NCT00038116|Active Comparator|embryonic dopamine cell implant surgery|embryonic dopamine cell implant surgery
88968505|NCT00038116|Placebo Comparator|sham surgery|sham surgery (placebo)
88968506|NCT00038155|Other|1|
88968507|NCT00038194|Experimental|Imatinib + Docetaxel|
88968508|NCT00391677|Experimental|1|Participants will receive social skills training with attention shaping procedures
88968509|NCT00391677|Active Comparator|2|Participants will receive social skills training without attention shaping procedures
88968510|NCT00038233|Experimental|Thalidomide|200 mg at bedtime daily for 14 days (days 1-14), followed by an increase to 400 mg daily for 14 days (days 15-28), 600 mg daily for 14 days (days 29-42), up to a maximum 800 mg (days 43-completion)
88968511|NCT05434273|Experimental|Experimental Arm: Integrated Intervention|Receive an integrated exercise and cardiovascular health education programme (HE programme)
88968512|NCT05434273|Sham Comparator|Control|Receive usual care
88968513|NCT00000932||A|Participants currently enrolled in or currently being followed in an ongoing qualifying study. Qualifying studies can be found in the protocol.
89564374|NCT03647917|Experimental|Platelet Rich Plasma, Right face and hands|"Subjects will receive PRP on right half of face and saline solution on left half of face through injections via filler injection technique followed by microneedling, and will also receive PRP on dorsal part of right hand and saline solution on dorsal part of left hand, through injections via filler injection technique. Microneedling will not be performed on the hands.~Injections will take place every 4 weeks for a total of 3 treatments."
89564375|NCT04905875||Critically ill patients with COVID-19|n centres that obtained IRB approval for this prospective study, all critically ill adult patients (>18yrs) undergoing PP - that are homogeneous in terms of both clinical and treatment characteristics - will be prospectively observed.
89564376|NCT03637309|Experimental|BeReady2Smile Video and App|This arm will test the feasibility of the BeReady2Smile Video and App to promote dental health of young children with a parent education program.
89564377|NCT04905719||Patients with dyspnea|Patients who visit a general practitioner for dyspnea will undergo a Point-of-Care ultrasound examination of the lungs to identify the presence or the absence of A-profile, B-profile and pleural effusion.
89210668|NCT00928356|Experimental|Hybrid CABG/PCI|Patients undergo hybrid, same sitting CABG/PCI as described.
89564378|NCT04905719||Patients with abdominal pain|Patients who visit a general practitioner for abdominal pain in the right upper quadrant will undergo abdominal Point-of-Care ultrasound examination to identify cholecystolithiasis.
89564379|NCT04905719||Patients with suspected deep vein thrombosis|Patients who visit a general practitioner for pain and / or swelling of the lower extremity will undergo compression ultrasound testing to identify proximal deep vein thrombosis.
89564380|NCT03619681|Experimental|KN026|
89564381|NCT03609073|Experimental|Intervention|
89564382|NCT04916093|Experimental|Sitagliptin Group|Included 20 recently diagnosed type 2 diabetic subjects. They all received sitagliptin 100 mg therapy once daily before breakfast.
89564383|NCT04916093|Experimental|Vildagliptin Group|Included 20 recently diagnosed type 2 diabetic subjects. They all received vildagliptin 50 mg therapy twice daily before breakfast and supper.
89564384|NCT04916093|Active Comparator|Metformin Group|Included 20 recently diagnosed type 2 diabetic subjects. They all received control 1 gm twice daily
89564385|NCT03052205|Experimental|IMO-2125 at escalating dose levels|IMO-2125 at escalating dose levels by intratumoral injection
89564386|NCT03512119||Patient|Patient with cystic fibrosis homozygous for Phe 508 del CFTR having a glucose intolerance or newly diagnosis diabetes
89564387|NCT04903769|Other|Parkinson's Patients and Caregivers|Will participate in the 8-session SMART-PD program as a participant with Parkinson's disease or as a caregiver of a participant with Parkinson's disease
89564388|NCT05130541|Placebo Comparator|Control|Usual Care
89564389|NCT05130541|Experimental|Proning|Proning, rotating 90 degrees on long axis every 30 minutes - 2 hours
89564390|NCT04905485|Other|Intervention|All participants received the intervention in this trial. They received recommendations on their diets and supplements based on their results of microbiome expression.
89564391|NCT03052439|Active Comparator|Order 1|Subjects would introduce 5 different groups of FODMAPs in a blinded fashion (random order, 1 week on, one week off) while remaining on an otherwise low FODMAP diet while monitoring their IBS symptoms.
89564392|NCT03052439|Active Comparator|Order 2|Subjects would introduce 5 different groups of FODMAPs in a blinded fashion (random order, 1 week on, one week off) while remaining on an otherwise low FODMAP diet while monitoring their IBS symptoms.
89564393|NCT03052439|Active Comparator|Order 3|Subjects would introduce 5 different groups of FODMAPs in a blinded fashion (random order, 1 week on, one week off) while remaining on an otherwise low FODMAP diet while monitoring their IBS symptoms.
89564394|NCT03052439|Active Comparator|Order 4|Subjects would introduce 5 different groups of FODMAPs in a blinded fashion (random order, 1 week on, one week off) while remaining on an otherwise low FODMAP diet while monitoring their IBS symptoms.
89564395|NCT03052439|Active Comparator|Order 5|Subjects would introduce 5 different groups of FODMAPs in a blinded fashion (random order, 1 week on, one week off) while remaining on an otherwise low FODMAP diet while monitoring their IBS symptoms.
89564396|NCT04905329||"Patients with high and gray zone risk reccurrence early breast cancer"|
89564397|NCT04905329||Patients with gastointestinal cancers|
89564398|NCT04905329||Patients with gynecological malignancies|
89564399|NCT02767921|Experimental|Treatment (recombinant EphB4-HSA fusion protein, surgery)|Patients receive recombinant EphB4-HSA fusion protein IV over 60 minutes once weekly for 3 weeks (3 doses) in the absence of disease progression or unacceptable toxicity. Patients who agree may receive the fourth dose after an additional week as determined by the study medical oncologist. Two to four weeks after the last dose of recombinant EphB4-HSA fusion protein, patients undergo robotic-assisted radical cystectomy or robotic-assisted radical or partial nephrectomy.
89564400|NCT04903379|Other|Pain science education and self management strategies|The intervention will be educational in the form of the provision of contemporary pain science education and supportive advice from people with a history of persistent pain. The duration of the webinar will be 90 minutes.
88968514|NCT00000932||B|Participants previously enrolled in but not currently being followed in a qualifying study. Qualifying studies can be found in the protocol.
89564401|NCT02642809|Experimental|Arm 1: Pembrolizumab and Brachytherapy|"Brachytherapy dose=16 Gy delivered in 2 fractions of 8 Gy per fraction, separated by 7-10 days between fractions.~Pembrolizumab started within 1 week after completion of brachytherapy administered as an intravenous infusion over 30 minutes. It will be given every 3 weeks.~Standard of care endoscopic biopsy will take place at time of enrollment and 2-6 months (optional) after pembrolizumab initiation.~Research endoscopic biopsy for 8 consented patients will take place 1-2 weeks after initiation of brachytherapy.~Peripheral blood will be collected: Pre-brachytherapy, Post-brachytherapy but pre-pembrolizumab (on day 1), Day 22 after the start of pembrolizumab, 3, 6, and 12 months (+/- 2 weeks) after the start of pembrolizumab, and time of progression"
88968515|NCT00000932||C|Antiretroviral-naive participants not enrolling in a qualifying study (i.e., patients starting treatment outside the first study or patients deferring treatment)
88968516|NCT05434195|No Intervention|Normotensive|A sub-cohort of 32 normotensive women will be recruited to establish normal pregnancy values for the measures performed as well as validation of outcome measures.
88968517|NCT05434195|Placebo Comparator|Preeclampsia - Placebo|A sub-cohort of 32 preeclampsia women will be recruited taking the placebo.
88968518|NCT05434195|Active Comparator|Preeclampsia - low dosage|A sub-cohort of 32 preeclampsia women will be recruited taking the placebo low dose of 5-MTHF.
88968519|NCT05434195|Active Comparator|Preeclampsia - high dosage|A sub-cohort of 32 preeclampsia women will be recruited taking the placebo high dose of 5-MTHF.
88968520|NCT00014820||Patients with a diagnosis of asthma (new) (Cases)|Patients with a physician diagnosis of asthma during the 7.5 years being studied who were working at the time of diagnosis, as determined by patient interviews.
89033075|NCT02925585||Pre/post pelvic floor surgery imaging|
89033076|NCT02925273|Other|Standard|Prospective, grasp techniques will be compared in each patient from the experimental group using a palmar grasp without dorsal stimulation and a standard palmar grasp test with dorsal stimulation on the same patient as the control group
89033077|NCT04015011|Experimental|Low Calorie Diet (LCD) diet intervention|In person or video conference
89210669|NCT00928356|Other|Off-pump CABG|Standard of Care Off Pump CABG
88968521|NCT00014820||Patients with a diagnosis other than asthma (Controls)|Patients (age-matched to a case patient) with a physician diagnosis other than asthma who were working at the time of diagnosis.
88968522|NCT00014820||Patients with a diagnosis of asthma (previous)|Patients with a physician diagnosis of asthma prior to the 7.5 years being studied
89564402|NCT03052361|Experimental|Ondansetron|Patients allocated to this arm will receive ondansetron in the ED triage. Posology of ondansetron will be adapted to weight: doses of 2 mg for children weighting between 8 and 15 kg, 4 mg for children weighting between 15 to 30 kg and 8 mg for children heavier than 30 kg
89564403|NCT03052361|Placebo Comparator|control|Patients allocated to this arm will receive an identical looking/tasting placebo in the ED triage.
89564404|NCT05125393|Experimental|Linear stapler group|In the experimental group, indocyanine green was injected for development during the operation after ileocolic vessel and the middle colonic vessel were dissected. The tributary vessels of the Henle trunk were disconnected with a linear stapler if there was no obvious lymph node development, which means ligated not in the root. Otherwise, they were transferred to the experimental group.
89564405|NCT05125393|No Intervention|Conventional group|The branches of Henle trunk were dissected according to the conventional method and clamped at the root.
89564406|NCT05125315||low-hemosynamics|
89564407|NCT05125315||high-hemodynamics|
89564408|NCT05125159|Experimental|angioplasty guidewire-assisted transseptal group|Patients randomized to the angioplasty guidewire-assisted transseptal puncture (GW-TSP) group will undergo transseptal puncture with angioplasty guidewire-assistance.
89564409|NCT05125159|Sham Comparator|Conventional transseptal group|Patients randomized to the conventional transseptal group (Standard Group) will undergo transseptal puncture with BRK needle (St. Jude Medical).
89564410|NCT02532127|Experimental|Saliva sampling|Cells will be collected from consenting participants just before and after (30 min and 24 hr) exposure to CBCT, by brushing a swab against the inner cheek, which can be done by the patients themselves. Swab kits are provided together with an envelope for sending the swabs back.
89564411|NCT04915547|Experimental|Group-Based Exercise|The group-based exercise (GBE) programme will be delivered by a physiotherapist. The GBE comprises three sessions per week of group-based exercise in a local community centre, for 8 weeks.
89564412|NCT04915547|No Intervention|Control Group|Participants randomly allocated to the control group will remain on a waiting list. In addition, weekly contact will be made to ensure that they do not start treatment during the study protocol. After the end of the study, participants randomly allocated to the control group will receive the same intervention as the Group-Based Exercise.
89564413|NCT05079607|Experimental|Mitopure Topical Formula|
89564414|NCT02370589|Experimental|Group A|Day 0: Base Dose EBOV GP Vaccine; IM Day 21: Base Dose EBOV GP Vaccine; IM
89564415|NCT02370589|Experimental|Group B|Day 0: Base Dose EBOV GP Vaccine and Matrix-M Adjuvant; IM Day 21: Base Dose EBOV GP Vaccine and Matrix-M Adjuvant; IM
89564416|NCT02370589|Experimental|Group C|Day 0: Base Dose EBOV GP Vaccine and Matrix-M Adjuvant; IM Day 21: Placebo; IM
88968523|NCT05433922|Experimental|CSA + Avatrombopag|cyclosporine 3 mg/kg orally in two doses, with cyclosporine trough concentrations maintained at 200-250 ng/ml for 3 months to achieve maximum efficacy and then tapered by 25 mg every 3 months; Avatrombopag: two dosing groups, 40 mg orally once daily and 60 mg orally once daily, for a total of 24 weeks.If the 40 mg dose group trial meets the desired trial objectives, the 60 mg dose group trial will not be conducted.
88968524|NCT05433883|Experimental|treatment group|30 severe OSA patients (apnea/hypopnea >30)
88968525|NCT05433883|No Intervention|control group|15 simple snoring patients (apnea/hypopnea <5 )
88968526|NCT05433883|No Intervention|comparative group|15 mild cognitive impairment patients.
88968527|NCT05433805|Experimental|FMD first|"Patients receive nutritional counselling on the principles of the FMD diet and individual recommendations for optimising the micronutrient balance (vitamins, trace elements) based on their corresponding baseline values. A food diary is given to the patients to assess treatment adherence on FMD days.~This is followed by a combined nutritive and physiotherapeutic interventions from week 13 for a further 3 months. Patients will be instructed about ambulatory exercises during a physiotherapeutic counselling, scheduled in week 13. Physiotherapy exercises should only be carried out on FMD-free days. Patients also receive a diary in which they document daily physical activity."
89210670|NCT03743454||Men|
89564417|NCT02370589|Experimental|Group D|Day 0: 2x Base Dose EBOV GP Vaccine; IM Day 21: 2x Base Dose EBOV GP Vaccine; IM
89564418|NCT02370589|Experimental|Group E|Day 0: 2x Base Dose EBOV GP Vaccine and Matrix-M Adjuvant; IM Day 21: 2x Base Dose EBOV GP Vaccine and Matrix-M Adjuvant; IM
89564419|NCT02370589|Experimental|Group F|Day 0: 2x Base Dose EBOV GP Vaccine and Matrix-M Adjuvant; IM Day 21: Placebo; IM
89564420|NCT02370589|Experimental|Group G|Day 0: 4x Base Dose EBOV GP Vaccine; IM Day 21: 4x Base Dose EBOV GP Vaccine; IM
89564421|NCT02370589|Experimental|Group H|Day 0: 4x Base Dose EBOV GP Vaccine and Matrix-M Adjuvant; IM Day 21: 4x Base Dose EBOV GP Vaccine and Matrix-M Adjuvant; IM
89564422|NCT02370589|Experimental|Group J|Day 0: 4x Base Dose EBOV GP Vaccine and Matrix-M Adjuvant; IM Day 21: Placebo; IM
89564423|NCT02370589|Experimental|Group K|Day 0: 8x Base Dose EBOV GP Vaccine; IM Day 21: 8x Base Dose EBOV GP Vaccine; IM
89564424|NCT02370589|Experimental|Group L|Day 0: 8x Base Dose EBOV GP Vaccine and Matrix-M Adjuvant; IM Day 21: 8x Base Dose EBOV GP Vaccine and Matrix-M Adjuvant; IM
89564425|NCT02370589|Experimental|Group M|Day 0: 8x Base Dose EBOV GP Vaccine and Matrix-M Adjuvant; IM Day 21: Placebo; IM
89564426|NCT02370589|Placebo Comparator|Group N|Day 0: Placebo; IM Day 21: Placebo; IM
89564427|NCT04915625||Death group|Retrospective observational studies
89210671|NCT03743454||Women|
89027463|NCT00483678|Experimental|Intimacy-Enhancing Couples Therapy|Patients and their partners receive Intimacy-Enhancing Couples Therapy over 6 weeks comprising the following four 90-minute sessions: the Story of Cancer; Understanding the Couple, Ways of Relating and Key Influences; Intimacy; and Coping, Support, and Adaptation. Patients and their partners complete treatment satisfaction questionnaires after completion of study intervention.
89027464|NCT00483678|Active Comparator|standard psychosocial care|Patients and their partners receive standard psychosocial care. All participants complete questionnaires assessing psychological distress, intimacy, communication patterns, and overall relationship adjustment/satisfaction at baseline and at 1 month after completion of study intervention
89027465|NCT04516590||autoimmune antigen negative|treated with anti-epilepsy drugs
89564428|NCT04915625||Survival group|Retrospective observational studies
89564429|NCT05067673|Placebo Comparator|Control group|Placebo dry needling
89564430|NCT05067673|Experimental|Experimental group|Dry needling
89564431|NCT04904627||Polyehtylene vs Poliìycarbonate|super rigid vs rigid material
89564432|NCT04904627||Free pelvis vs classic pelvis|fixed pelvis versus free pelvis, allowing adjustment in the sagittal plane.
89564433|NCT05049265|Experimental|JS007|
89564434|NCT05013619||adolescent cerebral palsy|Demographical data, the subtypes of CP, Gross Motor Functional Classification System level, circumstances of pain, pain questionnaire will be analyzed.
89564435|NCT05013619||adolescent cerebral palsy's mother|pain questionnaire will be analyzed.
89564436|NCT04904783|Active Comparator|Study arm|10 patients of confirmed diagnosis of moderate COVID-19 who fulfil the inclusion criteria and give written informed consent would be in study arm. All patients, belong to both study and control groups would receive the same treatment (oxygen support, steroids, anticoagulant therapy, remdesivir and other supportive therapy) as per the Institute guidelines for management of moderate COVID-19 disease. Only low dose radiotherapy would be added to patients in the study arm.
89564437|NCT04904783|No Intervention|Control Arm|10 patients of confirmed diagnosis of moderate COVID-19 who fulfil the inclusion criteria and have not given written informed consent would be in study arm. These patients would receive the same treatment (oxygen support, steroids, anticoagulant therapy, remdesivir and other supportive therapy) as per the Institute guidelines for management of moderate COVID-19 disease except low dose radiotherapy.
89564438|NCT05136079|Experimental|Prophylactic lymphaticovenous anastomosis|Intervention participants will undergo prophylactic lymphaticovenous anastomosis as an addendum to axillary or ilioinguinal lymphadenectomy for treatment of cutaneous malignancy.
89564439|NCT05136079|No Intervention|Lymphadenectomy without lymphaticovenous anastomosis|Control participants will undergo axillary or ilioinguinal lymphadenectomy without lymphaticovenous anastomosis for treatment of cutaneous malignancy .
89564440|NCT04915469|No Intervention|Pre-standardization group|Pre intervention- patient level data are abstracted retrospectively from the charts of patients with VL >1000 copies/ml on demographic characteristics and clinical outcomes and facility level data from summary forms for up to 24 months prior to the implementation of the standardized EAC package.
89564441|NCT04915469|Other|Post-standardization group|This group of participants will receive the standardized enhanced adherence package. After implementation of the standardized EAC package, data will be prospectively collected from participants with high viral load (>1000 copies).
89564442|NCT04959877||1|Patients diagnosed with oropharyngeal dysphagia who require speech therapy treatment for this reason and who have voluntarily opted for the blended treatment modality.
89564443|NCT05124145||surveillance network|The surveillance network is made of 200 health professionals from 85 practices
89564444|NCT05136625|Active Comparator|Control|Troncular scalp blockade (Levobupivacaine 7,5%) Local site infiltration (Mepivacaine)
89564445|NCT05136625|Experimental|Treatment|Troncular scalp blockade (Levobupivacaine 7,5%) Local site infiltration (Mepivacaine) Transnasal sphenopalatine ganglion block (Levobupivacaine 7,5%)
89564446|NCT04402697|No Intervention|Normal-weight (NW)|Individuals with BMI<25 kg/m2
89564447|NCT04402697|Experimental|Overweight-Obese (OW-OB)|Individuals with BMI>25 kg/m2, submitted to a nutritional intervention (hypocaloric balanced diet) during 6 months and prescription of physical activity to achieve weigh loss
89027466|NCT04516590||autoimmune antigen positive|whether the patients receive immune therapy or not will depend on the type and titter of the autoimmune antibody as well as the severity of the symptom
89027467|NCT01307800|Experimental|80 milligrams (mg) LY2140023, BID|An 80-mg LY2140023 tablet administered orally, twice daily (BID) for 6 weeks. Prior to randomization, participants will complete a 1-week placebo lead-in period, during which time placebo tablets identical to LY2140023 are administered orally, BID.
89027468|NCT01307800|Experimental|40 mg LY2140023, BID|A 40-mg LY2140023 tablet administered orally, BID for 6 weeks. Prior to randomization, participants will complete a 1-week placebo lead-in period, during which time, placebo tablets identical to LY2140023 are administered orally, BID.
89027469|NCT01307800|Experimental|10 mg LY2140023, BID|A 10-mg LY2140023 tablet administered orally, BID for 6 weeks. Prior to randomization, participants will complete a 1-week placebo lead-in period, during which time, placebo tablets identical to LY2140023 are administered orally, BID.
89027470|NCT01307800|Placebo Comparator|Placebo|A placebo tablet administered orally, BID for 7 weeks.
89027471|NCT04516044||Video game|Patients treated by physicians who were randomized to either play an adventure-based video game that used narrative engagement to recalibrate physician heuristics in trauma triage or a puzzle-based video game that used analogical encoding to recalibrate physician heuristics in trauma triage.
89027472|NCT04516044||Control|Patients treated by physicians who were randomized either to nothing at all or to a text-based educational program.
89564448|NCT04402697|Experimental|Metabolically obese normal-weight (MONW)|Individuals with BMI<25 kg/m2, with metabolic alterations related to obesity (hypertriglyceridemia, hypercholesterolemia, hyperglycaemia, hypertension or high waist-hip ratio), submitted to an intervention to improve dietary habits and physical activity in order to achieve a better body composition and metabolic health. Mediterranean diet will be and aerobic and strength exercises will be advised to these individuals.
89564449|NCT04402619|Experimental|Online CBT|Ten modules with minimum therapist guidance
89564450|NCT04902001|Experimental|Adolescents with obesity|Adolescents with obesity aged 12-16 years old
89564451|NCT05124613||Patients waitlisted for Knee Surgery|Adults identified by a consultant orthopaedic surgeon at the study site as being on a waiting list for surgery on their knee and as experiencing a delay to their knee surgery as a result of the COVID-19 pandemic will be eligible to participate in this survey. The survey will include one validated questionnaire and a series of bespoke questions.
89564452|NCT05124535||Persons aged 18-29|
89564453|NCT05124535||Persons aged 30-39|
89564454|NCT05124535||Persons aged 40-65|
89564455|NCT04904237|Experimental|aza-ven +MBF|treatment with aza-ven debulking therapy followed by allo-HSCT with MBF conditioning
89564456|NCT05136469|Experimental|NEURAL GLIDING|with Sciatic nerve gliding which is done by applying force on the proximal point and releasing the force distally and then reversing the process. This process was achieved for 30 seconds, 6 times on each leg for a total time of 3 minutes (360 seconds).
89564457|NCT05136469|Active Comparator|DYNAMIC STRETCH|The stretch force was applied on the ankle in downward direction which was held for 30 seconds and was repeated 5 times total of 2.5 minutes (150 seconds). Stretch was given on both legs one at a time. Treatment was given for 3 weeks with 2 sessions per week
89564458|NCT04894487|No Intervention|Control Group|The babies have got sternum incision after the pediatric cardiac surgery. Experiment is about the dressing of the sternum incision. There is no extra intervention during sternum dressing at control group like routine of pediatric cardiovascular surgery intensive care clinic. Saved pain scores and physiological parameters and pain scores; just before the sternum dressing, just after sternum dressing and after the 15 minutes sternum dressing.
89564459|NCT04894487|Experimental|THE USE OF BABY MOBILE ACCOMPANIED WITH BRAHMS LULLABIES GROUP|Baby mobile and Brahms Lullaby started before the 10 minutes of sternum dressing process and controlled permanence of the baby mobile and Brahms Lullaby during sternum dressing. Saved pain scores and physiological parameters and pain scores; just before the sternum dressing, just after sternum dressing and after the 15 minutes sternum dressing.
89564460|NCT05136235|Other|Extremely preterm newborns|All extremely preterm newborns in Flanders will be included, it is a single arm study
89564461|NCT04902209||1- study group- patients after surgical treatment of acetabular fracture|1- study group- patients after surgical treatment of hip acetabular fracture
89564462|NCT04902209||2- control group- healthy subjects|2- control group- healthy subjects age, BMI matched
89564463|NCT04894409|Experimental|Experimental group|The experimental group was instructed to do mouthwash and nose rinse with the AgNPs solution.
89564464|NCT04894409|Active Comparator|Control group|"The control group was instructed to do mouthwashes and nose rinse in a conventional way."
89564465|NCT04901897|Experimental|kalifilcon A|kalifilcon A daily disposable contact lens
89564466|NCT04901897|Active Comparator|delefilcon A|DAILIES TOTAL1® (delefilcon A) daily disposable contact lenses
89564467|NCT04901897|Active Comparator|senofilcon A|Acuvue Oasys® 1-Day with HydraLuxe™ (senofilcon A) daily disposable contact lens
89564468|NCT04895371|Experimental|Tele-physiotherapy group|Allocated participants to this group will receive 18 physiotherapy sessions (three sessions per week) during six weeks. in these sessions, physiotherapist will prescribe aerobic, resistive, breathing and functional exercises and airway clearance techniques (if needed) based on result of assessment of patients at the discharge phase. the physiotherapist will use some educational contents for the patient and call him/her to guide the patient about how exercises should be performed (determining frequency, time, intensity and type of exercise). the patient should do exercises until next session and provide a feedback. The patient will be assessed weekly using a pre-designed questionnaire remotely. the progression of interventions will be based on the results of weekly assessment.
89564469|NCT04895371|Active Comparator|Control group|Allocated participants to control group will receive one consultation session by the physiotherapist. At this session, patients will be educated about how to perform their daily activities, breathing exercises, walking, using oxygen cylinder and dietary.
89564470|NCT05135065|Experimental|Artificial Intelligence-Assisted Supervision Protocol|Measurement-based supervision protocol that incorporates fidelity measurement from a machine learning tool and feedback reports from this tool into a standardized supervision protocol for behavior therapy to task-shift burdensome supervision tasks to a machine, reducing costs and improving precision of fidelity measurement for agencies.
89564471|NCT05135065|No Intervention|Enhanced Supervision as Usual (ESAU) Condition|ESAU therapists will be given standard, paper-based facilitation resources for STAND and will receive 4 hours of training on how to navigate these materials and self-assess fidelity. ESAU therapists will also be trained how to upload recordings into Care4 and complete self-assessments for each session. Supervisors will be given access to these data and recordings once uploaded (but not Lyssn scores or electronic facilitation resources).
89564472|NCT04894331||SNAS patients|Patients with (a) history of SNAS (coexistence of typical cutaneous and gastrointestinal symptoms); (b) positive Ni-patch test; (c) clinical improvement of at least 70% from baseline after 4 weeks of low-Ni diet; (d) positivity of a double-blind placebo-controlled oral Ni challenge (DBPCO). Exclusion criteria include (a) age < 18 years and >65 years; (b) other organic gastrointestinal diseases, such as peptic ulcer, inflammatory bowel diseases, celiac disease, gastrointestinal infections, and small intestinal bacterial overgrowth; (c) diabetes mellitus; (d) hepatic, renal or cardiac dysfunction; (e) thyroid disease or tumour; (f) concomitant treatment with steroids and/or antihistamines in the previous 4 weeks; (g) pregnancy and lactation; (h) smoking, abuse of alcohol, coffee, tea, and cola intake, and (i) inability to give written informed consent.
89564473|NCT05134909|Experimental|Study: Keratoconus|Customized contact lenses will be fitted to each study subject based on their own optical defects.
89564474|NCT04893941|Experimental|CM310 75mg arm|75mg for 3 doses, every 2 weeks, SC
89564475|NCT04893941|Experimental|CM310 150mg arm|150mg for 3 doses, every 2 weeks, SC
89564476|NCT04893941|Experimental|CM310 300mg arm|300mg for 3 doses, every 2 weeks, SC
89564477|NCT04893941|Experimental|CM310 600(1st)+300mg(2nd,3rd) arm|600mg for 1st dose, and then 300 mg for 2nd and 3rd doses, every 2 weeks, SC
89564478|NCT04893941|Placebo Comparator|placebo arm|placebo for 3 doses, every 2 weeks, SC
89564479|NCT05057845|Experimental|Cryoablation in combination with Tislelizumab plus lenvatinib|
89564480|NCT04901585||Totally intracorporeal distal gastrectomy|All patients who underwent minimally invasive distal gastrectomy with intracorporeal anastomosis for gastric cancer
89564481|NCT05109949|Experimental|Dapagliflozin 10 mg|Dapagliflozin is an oral medication used to treat Type 2 diabetes. It belongs to a sodium-glucose cotransporter 2 (SGLT2) inhibitors.
89564482|NCT05109949|Experimental|Empagliflozin 25 mg|Empagliflozin is an oral medication used to treat Type 2 diabetes. It belongs to sodium-glucose cotransporter 2 (SGLT2) inhibitors.
89564483|NCT05109949|Placebo Comparator|Placebo|Calcinated magnesium is a white powdery compound, MgO, used in pharmaceuticals as binder.
89564484|NCT04893473||Group 1|"Patients scheduled for limb (arm/leg) surgery with tourniquet where IscAlert is removed immediately after surgery.~All patients will receive 3 sensors in the limb undergoing surgery and two control sensors in the opposite limb. The sensor in the opposite extremity which is not to be operated serves as a reference value for carbon dioxide."
89564485|NCT04893473||Group 2|"Patients scheduled for limb (arm/leg) surgery with tourniquet where IscAlert is removed 72 hours after surgery.~All patients will receive 3 sensors in the limb undergoing surgery and two control sensors in the opposite limb. The sensor in the opposite extremity which is not to be operated serves as a reference value for carbon dioxide."
89564486|NCT04901429|Experimental|Truncal Vagotomy|Truncal vagotomy will be performed during other routine procedure.
89564487|NCT04901429|No Intervention|No Truncal Vagotomy|No truncal vagotomy will be performed during other routine procedure.
89564488|NCT04926259|Experimental|18F-T807, PET/CT|PET/CT perform after injecting 18F-T807
89564489|NCT04901663|Active Comparator|Omeprazole Group|Omeprazole 20 mg BD Amoxicillin 1000 mg BD Clarithromycin 500 mg BD
89564490|NCT04901663|Experimental|Vonoprazan Group|Vonoprazan 20 mg BD Amoxicillin 1000 mg BD
89564491|NCT05134597||Group 1 - Patients with Chronic Venous Disease (CVD)|Patients with CVD at different stages, according to CEAP Classification of Chronic Venous Disorders, will be recruited.
89564492|NCT05134597||Group 2 - Healthy subjects without Chronic Venous Disease (CVD)|Voluntary healthy subjects without Chronic Venous Disease (CVD) will be recruited.
88968528|NCT05433805|Experimental|Physiotherapy first|"Patients receive physiotherapy counselling, with structured ambulatory exercises shown and explained. The patients receive a diary where they have to document their physical activity every day.~This is followed by a combined nutritive and physiotherapeutic interventions from week 13 for a further 3 months. For this purposphe, nutritional counselling on the principles of the FMD diet is planned for week 13. In addition, individual recommendations for optimising the micronutrient balance (vitamins, trace elements) are given based on the respective baseline values. The physiotherapeutic exercises are to be carried out only on FMD-free days. Patients will also be given a food diary to assess treatment adherence on FMD days."
88968529|NCT02971150|Experimental|BBTI|Participants will receive Brief Behavioral Treatment for Insomnia (BBTI). This will be administered over the course of 4 weeks. BBTI is based on the concepts of sleep restriction and stimulus control. The first and third session are in person and the 2 and 4th session are conducted over the phone. Throughout the treatment, participants will complete daily sleep dairies. After 4 weeks of treatment, participants randomized to this group will cross over to the no intervention group and will be called once a week to assess mood and sleep symptoms.
88968530|NCT02971150|No Intervention|Control|Participants will not receive treatment. They will be contacted by phone once a week to complete assessments of mood and sleep. After 4 weeks, they will cross over to the experimental BBTI group.
88968531|NCT05433376|Experimental|IVL group|
88968532|NCT00396643|Experimental|A|
88968533|NCT00396643|Placebo Comparator|B|Coconut oil
88968534|NCT04732468|Experimental|Cohort 1- hAd5-S-Fusion+N-ETSD (Suspension for injection) and hAd5-SFusion+ N-ETSD (Oral capsule)|For subjects in cohort 1, hAd5-S-Fusion+N-ETSD (Suspension for injection) and hAd5-SFusion+N-ETSD (Oral capsule) will be administered on day 1 (prime) and hAd5-S-Fusion+N-ETSD (Suspension for injection) again on day 22 (boost).
89564493|NCT05134519|Experimental|RC48 for neadjuvant chemotherapy|RC48-ADC: 2.0 mg/kg, IV drip, Q2W
89564494|NCT04394663|Experimental|High-dose oral PPI|Omeprazole 80 mg/day (40 mg twice a day) per oral route for 72 hours
89564495|NCT04394663|Active Comparator|Standard IV PPI|Pantoprazole 8 mg/hour IV continuous drip for 72 hours
88968535|NCT04732468|Experimental|Cohort 2- hAd5-S-Fusion+N-ETSD (Suspension for injection) and hAd5-SFusion+ N-ETSD (Oral capsule)|For subjects in cohort 2, hAd5-S-Fusion+N-ETSD (Suspension for injection) and hAd5-SFusion+N-ETSD (Oral capsule) will be administered on day 1 (prime) and hAd5-S-Fusion+N-ETSD (Oral capsule) on day 22 (boost).
88968536|NCT04732468|Experimental|Cohort 3 - hAd5-S-Fusion+N-ETSD (Oral capsule)|For subjects in cohort 3, hAd5-S-Fusion+N-ETSD (Oral capsule) will be administered on days 1 (prime) and on day 22 (boost).
89564496|NCT05133193|Experimental|14d concomitant therapy|The eligible patients received 14-day concomitant therapy, including vonoprazan and three kinds of antibiotics according to the previous eradication regimens and antibiotic use. Antibiotics are selected from Amoxicillin, Tetracycline, Furazolidone, Levofloxacin, Clarithromycin, Tinidazole, Metronidazole.
89564497|NCT04901117|Experimental|10-day treatment group|"Use the following drug combination option for 10 days. Option 1: Amoxicillin + Clarithromycin + Bismuth + Vonoprazan fumarate Option 2: Amoxicillin + Tetracycline + Bismuth + Vonoprazan fumarate Option 3: Amoxicillin + Metronidazole + Bismuth + Vonoprazan fumarate Three options are selected according to the hospital's situation.~The dosage of each drug is:~Amoxicillin (Amoxicillin, United Laboratories Co., Ltd.) 1000mg bid Clarithromycin (Klacid, Abbott S.r.l) 500mg bid Tetracycline 500mg qid Metronidazole400mg qid Bismuth Potassium Citrate (Livzon Pharmaceutical Group Inc.) 220mg bid Colloidal Bismuth Pectin (North China Pharmaceutical Co., Ltd.) 200mg bid Vonoprazan fumarate (VOCINTI, Takeda Pharmaceutical Company Limited, Hikari Plant) 20mg bid"
89564498|NCT04901117|Active Comparator|14-day treatment group|"Use the following drug combination option for 14 days. Option 1: Amoxicillin + Clarithromycin + Bismuth + Vonoprazan fumarate Option 2: Amoxicillin + Tetracycline + Bismuth + Vonoprazan fumarate Option 3: Amoxicillin + Metronidazole + Bismuth + Vonoprazan fumarate Three options are selected according to the hospital's situation.~The dosage of each drug is:~Amoxicillin (Amoxicillin, United Laboratories Co., Ltd.) 1000mg bid Clarithromycin (Klacid, Abbott S.r.l) 500mg bid Tetracycline 500mg qid Metronidazole400mg qid Bismuth Potassium Citrate (Livzon Pharmaceutical Group Inc.) 220mg bid Colloidal Bismuth Pectin (North China Pharmaceutical Co., Ltd.) 200mg bid Vonoprazan fumarate (VOCINTI, Takeda Pharmaceutical Company Limited, Hikari Plant) 20mg bid"
89564499|NCT05121571|Experimental|HAIC of FOLFOX|Retreatment With hepatic arterial infusion chemotherapy of oxaliplatin , fluorouracil, and leucovorin
89564500|NCT05121571|Active Comparator|Sorafenib|
89564501|NCT03051269|Experimental|calcium chloride|Only one arm. All 6 enrolled patients are treated with calcium electroporation.
89564502|NCT05088733|Experimental|Yang Yin Fu Zheng Jie Du therapy|
89564503|NCT05088733|Placebo Comparator|Routine medical care|
89564504|NCT04924777|Experimental|Brisk walk|
89564505|NCT04924777|Experimental|Aerobic Training|
89564506|NCT04924777|Experimental|Strength Training|
89564507|NCT04861285|Experimental|RACESTYPTINE Solution with cord|The participant will receive RACESTYPTINE Solution into the sulcus. The solution is used in combination with a non-medicated gingival retraction cord.
89564508|NCT04861285|Experimental|RACEGEL with cord|The participant will receive RACEGEL into the sulcus. The gel is used in combination with a non-medicated gingival retraction cord.
88968537|NCT04732468|Experimental|Cohort 4 - hAd5-S-Fusion+N-ETSD (Suspension for injection) and hAd5-S-Fusion+N-ETSD (Oral capsule)|For subjects in cohort 4, hAd5-S-Fusion+N-ETSD (Suspension for injection) and hAd5-S-Fusion+N-ETSD (Oral capsule) will be administered on day 1 (prime) and hAd5-SFusion+N-ETSD (Oral capsule) will be administered on days 15 (boost) and 22 (boost).
88968538|NCT00396721|Active Comparator|A|
88968539|NCT00396721|Experimental|B|
88968540|NCT05432908|Experimental|Orofacial exercises and oropharyngeal functions|Orofacial exercises and oropharyngeal functions.
88968541|NCT02970838|Experimental|Intervention|Patients take part in a structured weight-loss program over 15 weeks including a fasting phase with formula diet over six weeks
88968542|NCT05432869|Experimental|Electrical stimulation (ES) group|ES group will be given additional external electrical stimulation to the lifestyle advices.
88968543|NCT05432869|Experimental|Control group|Control group will be given only lifestyle advices .
89564509|NCT04861285|Experimental|RACEGEL without cord|The participant will receive RACEGEL into the sulcus. No cord will be added.
89564510|NCT04725955|Placebo Comparator|Glucose Solution|
89564511|NCT04725955|Active Comparator|Wheat bread enriched with a-cyclodextrin|
89564512|NCT04725955|Experimental|Wheat bread enriched with hydroxytyrosol encapsulated in a-cyclodextrin|
88968544|NCT05432440|Experimental|Intervention group (the digital asthma education program)|"The intervention group receives the digital asthma education program (MIRACLE program). It consists of an asthma interactive narrative, a serious game, and an asthma action plan. It mainly covers asthma self-management and asthma attack prevention, such as asthma definition, asthma triggers and how to prevent asthma triggers exposures, asthma medications, proper inhaler technique, and asthma written action plan.~The time schedule will be described as:~Explain study purposes, program, procedures, and instructions (10 minutes).~Accompany children and parents to download and install the MIRACLE program on Google Play Store for free on their personal computers, tablets, or smartphones (5 minutes).~Asthma education will take place over one session lasting approximately 45 minutes."
88968545|NCT05432440|Active Comparator|Control group (the booklet asthma education program)|"For the control group, a pharmacist (same personnel) will provide an asthma education using a booklet for 45-60 minutes to children and parents. Patients will be asked to read the booklet at home for 15 minutes in 7 days. It mainly covered the same content as the MIRACLE program. The time schedule will be described as:~Explain study purposes, booklet, procedures, and instructions (10 minutes).~Asthma education will take place over one session lasting approximately 45 minutes."
88968546|NCT05432401|Experimental|T cell injection targeting FLT3 chimeric antigen receptor|The subjects, who sign the informed consent forms and been screened by inclusion/exclusion criteria, will be assigned into 1.0 × 10^8, 2.0 × 10^8 and 4.0 × 10^8 CAR-T groups in order of sequence. And the subjects will be administered once.
88968547|NCT05432128||Low-risk group|Combined with AI calculation of malignant probability and ctDNA methylation results, patients were divided into three groups. The high probability of malignancy calculated by AI was defined as positive, and vice versa. The methylation markers detected in specific peripheral blood of lung cancer were defined as positive, and vice versa. Negative for both items was considered as low risk group. Follow-up was conducted according to The Chinese Expert Consensus on the Diagnosis and Treatment of Pulmonary Nodules (2018 edition). 10ml peripheral blood was collected from each follow-up and stored for testing until the end of the study.
88968548|NCT05432128||medium-risk group|As above, one positive patient was considered to be in the medium-risk group and was reexamined every 6 months, with a total of 3 reexaminations expected
89027473|NCT05644210||RTX+TA group|"Screening stage：Patients received 200mg of rituximab intravenously at week 0 and week 2.~Follow-up period：Telitacicept 160mg once a week for 24 weeks Basic treatment： Hydroxychloroquine、Prednisone、Warfarin、Aspirin"
89027474|NCT05644210||RTX group|"Screening stage：Patients received 200mg of rituximab intravenously at week 0 and week 2.~Follow-up period Basic treatment：Hydroxychloroquine、Prednisone、Warfarin、Aspirin"
89027475|NCT00488384|Other|a|single arm only. Only open label treatment anticipated
89027476|NCT04325074|Experimental|Mental practice|The final sample therefore comprised of 35 participants (n=35), who were divided into three treatment groups. The sample of mental practice group was n=12.
89027477|NCT04325074|Experimental|Mental practice + skill training|The final sample therefore comprised of 35 participants (n=35), who were divided into three treatment groups. The sample of mental practice + skills training group was n=13.
89027478|NCT04325074|Active Comparator|Control group|The final sample therefore comprised of 35 participants (n=35), who were divided into three treatment groups. The sample of control group was n=10.
89027479|NCT00483834|Experimental|Bevacizumab, Irinotecan and Capecitabine|Evaluate the efficacy and toxicity of bevacizumab, irinotecan and capecitabine as first-line treatment for patients with metastatic colorectal cancer
89027480|NCT04324801|Experimental|Single arm|This is a within-subject repeated-measures design.
89027481|NCT01307449|Experimental|Older Group on PREVNAR|Participants between the ages of 60-89 received PREVNAR
89027482|NCT01307449|Experimental|Younger Group on PREVNAR|Participants between the ages of 25-40 years received PREVNAR
89027483|NCT01307449|Experimental|Older Group on PNEUMOVAX|Participants between the ages of 60-89 received PNEUMOVAX
89027484|NCT01307449|Experimental|Younger Group on PNEUMOVAX|Participants between the ages of 25-40 years received PNEUMOVAX
89027485|NCT00488423|Active Comparator|Lap-band|Patient undergoing Lap-band Bariatric Surgery
89027486|NCT00488423|Active Comparator|Gastric Bypass|Patient's undergoing Laparoscopic Roux-N Y Gastric Bypass surgery.
89027487|NCT01307020|Placebo Comparator|Placebo|
89027488|NCT01307020|Active Comparator|Ibuprofen|
89027489|NCT01307020|Active Comparator|TRAM.HCl high dose|
89027490|NCT01307020|Active Comparator|TRAM.HCl low dose|
89027491|NCT01307020|Active Comparator|DKP-TRIS high dose|
89027492|NCT01307020|Active Comparator|DKP-TRIS low dose|
89027493|NCT01307020|Experimental|DKP-TRIS low dose - TRAM.HCl low dose|
89027494|NCT01307020|Experimental|DKP-TRIS low dose - TRAM.HCl high dose|
89027495|NCT01307020|Experimental|DKP-TRIS high dose - TRAM.HCl low dose|
89027496|NCT01307020|Experimental|DKP-TRIS high dose - TRAM.HCl high dose|
89027497|NCT00483743|Experimental|TPI 1020|TPI 1020 500 mcg BID x 42 days
89027498|NCT00483743|Active Comparator|Budosenide cortico|Budesonide 800 mcg BID x 42 days
89027499|NCT00483743|Placebo Comparator|Placebo|Placebo inhaler
89027500|NCT04515654|Experimental|Audience participants|Community members viewed the performance (intervention) and completed pre/post stigma questionnaire
89027501|NCT04324996|Experimental|NK cells|The NK cells are going to be give by intravenous infusion (10E8 cells per kilogram of body weight, once a week) .
89027502|NCT04324996|Experimental|IL15-NK cells|The NK cells secreting super IL15 superagonist are going to be give by intravenous infusion (10E8 cells per kilogram of body weight, once a week) .
89027503|NCT04324996|Experimental|NKG2D CAR-NK cells|The NKG2D CAR-NK cells are going to be give by intravenous infusion (10E8 cells per kilogram of body weight, once a week).
89027504|NCT04324996|Experimental|ACE2 CAR-NK cells|The ACE2 CAR-NK cells are going to be give by intravenous infusion (10E8 cells per kilogram of body weight, once a week).
89027505|NCT04324996|Experimental|NKG2D-ACE2 CAR-NK cells|The NKG2D-ACE2 CAR-NK cells secreting IL15 superagonist and GM-CSF-neutralizing scFv are going to be give by intravenous infusion (10E8 cells per kilogram of body weight, once a week).
89027506|NCT00483951||Patients with known or suspected cardiovascular disease|Patients referred to protocol with known or suspected cardiovascular disease for further evaluation.
89027507|NCT00488462|No Intervention|Control|Clinics will collect data on patients experiencing shock due to obstetrical hemorrhage. In the control arm, half of the study clinics will not use the NASG but the NASG will be available at the referral hospital for patients transported there.
89564513|NCT04725955|Placebo Comparator|White wheat bread|
89027508|NCT00488462|Other|Intervention|Clinics will collect data on patients experiencing shock due to obstetrical hemorrhage. In the intervention arm, half of the study clinics will use the NASG on patients before transporting to the referral hospital.
89027509|NCT04516005|Experimental|foot reflexology|Foot reflexology was performed in every participant in the foot reflexology group after resting for 5 minutes in a sitting position by the same researcher who was trained and certified by the Department of Thai Traditional and Alternative Medicine, Ministry of Health.
89027510|NCT04516005|No Intervention|control|The control group received conventional treatment including anti-HT medications according to the standard HT guideline's recommendations. In the end of the follow-up visit, every participants were informed to adhere to their medication and were encouraged to have healthy lifestyles including salt restriction, regular exercise, and consuming healthy diets.
89027511|NCT02890732|Experimental|Appet HEART|smartphone application prototype of personalized care of patients after hospitalization for coronary artery disease
89027512|NCT02890771|Active Comparator|Tooth Brushing|Tooth brushing with dentifrice
89027513|NCT02890771|Experimental|Turmeric massaging|Tooth Brushing,massaging with whole turmeric powder
89027514|NCT02890771|Experimental|SRP with turmeric massaging|SRP with turmeric massaging on half arch
89027515|NCT01306201||In-patient Volunteers|In-patients from the hospital who choose to participate in the study
89027516|NCT01306162|Experimental|A: Dabigatran alone (Reference)|Capsule, oral administration with 240 mL water
89027517|NCT01306162|Experimental|B: Dabigatran plus Dronedarone (Test)|Capsule and Tablets, oral administration with 240 mL water
89027518|NCT01306162|Experimental|C: Dabigatran plus Dronedarone (Test)|Capsule and Tablets, oral administration with 240 mL water
89027519|NCT01306162|Experimental|D: Dabigatran plus Dronedarone (Test)|Capsule and Tablets, oral administration with 240 mL water
89027520|NCT01306162|Experimental|E: Dabigatran plus Dronedarone (Test)|Capsule and Tablets, oral administration with 240 mL water
89564514|NCT04674007||Healthy basketball, volleyball and handball players|Healthy basketball, volleyball and handball players
89564515|NCT05005585|Experimental|vestibuler socket therapy|immediate implant placement in esthatic zone with final crown placement after 2 months with VST technique
89564516|NCT05005585|Experimental|contour augmentation|Early implant placement in esthatic zone with contour augmentation and final crown after 3 months of implant placement
89564517|NCT04646239||Participants in the CROWN CORONATION trial|The CROWN CORONATION trial will randomly allocate adult participants to a single intramuscular injection of MMR vaccine or Placebo (0.9% saline). All participants in this sub-study receive SARS-CoV-2 specific vaccine subsequent to the MMR or Placebo injection.
89564518|NCT04934527|Experimental|Experimental|Patients with positive CMV serology at transplantation will receive 6 infusions of Cytotect every 15 days with the first injection on the day of transplantation. CMV infection will be monitored by quantitative PCR on whole blood every week during 3 months and then every 2 weeks until 4 months and then at months 5 and 6, 9 and 12.
89564519|NCT05288647|Experimental|Group A|Patients treated with four computer-guided sodium hyaluronate injections in superior TMJ space.
89564520|NCT05288647|Active Comparator|Group B|Patients treated with four conventional sodium hyaluronate injections in superior TMJ space.
89564521|NCT05287009|Experimental|ILM nonpeeling|
89564522|NCT05287009|Other|ILM peeling|
89564523|NCT04576663|Placebo Comparator|Control group|Normal saline infusion simultaneous with subarachnoid block
89564524|NCT04576663|Experimental|0.3125 μg/kg/min group|A maintenance dose of phenylephrine (0.3125 μg/kg/ min) infusion simultaneous with subarachnoid block
89564525|NCT04576663|Experimental|0.625 μg/kg/min group|A maintenance dose of phenylephrine (0.625 μg/kg/ min) infusion simultaneous with subarachnoid block
89564526|NCT04576663|Experimental|0.9375 μg/kg/min group|A maintenance dose of phenylephrine (0.9375 μg/kg/ min) infusion simultaneous with subarachnoid block
89564527|NCT04560517||Anorexia Nervosa|
89564528|NCT04560517||Healthy Control Subjects|
89564529|NCT04905199||Non-floating catheter|When using non-floating catheter.
89564530|NCT04905199||Floating catheter|When using floating catheter.
89564531|NCT04763005|No Intervention|Healthy controls|A cross-sectional investigation of 24h blood pressure, macro- and microvascular health, physical activity and fitness as well as anthropometry.
88968549|NCT05432128||High-risk group|Same as above, both positive are considered high-risk group.Part of high-risk nodules (5-10mm) will be reviewed every 3 months for the above two examinations, which is expected to be reviewed 6 times in total. Biopsy or surgical resection of high-risk nodules over 10mm will be performed after evaluation by the expert group and the patient's knowledge, and histopathological diagnosis will be made and compared with ctDNA methylation results. To analyze the sensitivity and specificity of ctDNA methylation markers in lung cancer.
88968550|NCT05403112|Active Comparator|Group I: autogenous bone rings|sinus lifting was augmented by bone rings were harvested from chin
88968551|NCT05403112|Active Comparator|GroupII : autogenous sticky bone|sinus lifting was augmented by autogenous sticky bone was harvested from chin and immediate implant placement
89564532|NCT04763005|Experimental|Hypertensive Patients|A cross-sectional investigation of 24h blood pressure, macro- and microvascular health, physical activity and fitness as well as anthropometry. In addition, randomization to an eight-week high-intensity interval intervention or control condition with physical activity recommendations.
89564533|NCT05281549|Active Comparator|Alteplase|Patients will receive intravenous Alteplase at the standard licensed dose of 0.9 mg/kg up to a maximum of 90mg, 10% as bolus and the remainder over 1 hour.
89564534|NCT05281549|Experimental|Tenecteplase 0.25mg/kg|Patients will receive intravenous Tenecteplase, 0.25mg/kg, maximum 25mg, administered as a bolus over 5~10 seconds
89564535|NCT05281549|Experimental|Tenecteplase 0.4mg/kg|Patients will receive intravenous Tenecteplase, 0.4mg/kg, maximum 40mg, administered as a bolus over 5~10 seconds
89564536|NCT05276479||Healthy subjects|Healthy subjects aged 18-30 years
89564537|NCT05255809|Experimental|Alexander Technique + Routine Physical Therapy|Routine Physical Therapy+Alexander Technique Verbal Instructions in Trunk stabilising exercises. The time duration will be 15 minutes. Verbal instructions in Stance Phase Time duration 15 minutes.Ankle Strategy. 40 minutes with rest of 5 minutes after 10 minutes. Lessons would be two days a week for 16 weeks.
89564538|NCT05255809|Placebo Comparator|Control Group|Routine Physical Therapy duration: two days a week for 16 weeks. Trunk stabilising exercises time duration will be 15 minutes. Stance Phase time duration will be 15 minutes.Ankle Strategy. 40 minutes with rest of 5 minutes after 10 minutes.
89564539|NCT05239351|Experimental|Jalucomplex 1|Sixteen patients will be administered Jalucomplex® 1 for the treatment of minor-sized facial and neck dermal tissue defects (scars, hypertrophic scars, depressed plaques, and lipodystrophy defects)
89564540|NCT05239351|Experimental|Jalucomplex 2|Sixteen patients will be administered Jalucomplex® 2 for the treatment of medium-sized facial and neck dermal tissue defects (scars, hypertrophic scars, depressed plaques, and lipodystrophy defects)
89564541|NCT05239351|Experimental|Jalucomplex 3|Sixteen patients will be administered Jalucomplex® 3 for the treatment of major-sized facial and neck dermal tissue defects (scars, hypertrophic scars, depressed plaques, and lipodystrophy defects)
89564542|NCT05214547|Experimental|Experimental Group|The patients received shock-wave exposure (energy flux density= 0.12 mJ/mm2, at 8 Hz), twice a week, for six weeks. Standard physiotherapy care was applied.
89564543|NCT05214547|Placebo Comparator|PlaceboGroup|In the placebo group, the device applicator was positioned in the same way as the experimental shock-wave group. The previously recorded 8 Hz pulsed shock wave sounds were played, as if the actual application was being performed, however the device itself was off during the session, and its pedal was not pressed. Standard physiotherapy care was applied.
89564544|NCT03965611||Patients with isolated severe traumatic brain injury (TBI)|TBI with initial Glasgow Coma Scale (GCS) ≤ 8 and AISextrahead score ≤3. Oropharyngeal and rectal swabs will be performed for each patient within the first 24 hours after ICU admission (day 0), then 48 hours (day 2) and 7 days (day 7) after ICU admission and weekly thereafter until ICU discharge.
89564545|NCT03965611||Patients with severe trauma without TBI|Patients with severe trauma without TBI (AISextrahead score > 3). Oropharyngeal and rectal swabs will be performed for each patient within the first 24 hours after ICU admission (day 0), then 48 hours (day 2) and 7 days (day 7) after ICU admission and weekly thereafter until ICU discharge.
89564546|NCT03965611||Healthy Controls|"Persons who have not had the conditions being studied or otherwise related conditions or symptoms, as specified in the eligibility requirements.~Oropharyngeal and rectal swabs will be taken only once, at inclusion, after that the participation of the control individual in the trial will be completed."
89564547|NCT05191225|Experimental|Rapid infusion group|After the administration of intravenous premedication (usually dexchlorpheniramine 5 mg IV and paracetamol 1 g IV), rituximab will be administered at standard dose (375 mg/m2 diluted in 250 ml of saline) administered in one hour, divided into: 10 first minutes at 450 mg/hour, and 50 minutes later at 720 mg/hour.
89564548|NCT05191225|Experimental|Ultrarapid infusion group|After the administration of intravenous premedication, the dose of rituximab will be administered at standard dose administered in half an hour, divided into: 10 first minutes at 450 mg/hour, and 20 minutes later at 1800mg/hour.
89564549|NCT05191225|Experimental|Ultrarapid plus infusion group|After the administration of oral premedication, the dose of rituximab will be administered at the standard dose administered in half an hour, divided into: 10 first minutes at 450 mg/hour, and 20 minutes later at 1800mg/hour.
89564550|NCT05187325||myofascial trigger point and disc displacement with reduction|the participants have myofascial trigger points in master muscle and also temporomandibular joint disc displacement with reduction.
89564551|NCT05187325||disc displacement with reduction|the participants have only temporomandibular joint disc displacement with reduction.
89564552|NCT05185921|Experimental|Cognitive-behavioral therapy virtual|The intervention will be provided by 2 psychotherapists. The total of sessions will be eight carried out weekly, for 2 to 3 months. They will also receive standard treatment, i.e. psychiatric management with or without drugs.
89564553|NCT05185921|No Intervention|Control|They will only receive standard treatment, i.e. psychiatric management with or without drugs.
89564554|NCT03914833||Patients|Patients aged 13 to 25 years old with a concussion in sports practice less than 72 hours previously
89564555|NCT03914833||Control - High-level athelete|healthy subjects aged 13 to 25 years students at one of the partner institutions
89564556|NCT03914833||Control - Non-high-level athelete|healthy subjects aged 13 to 25 years students at one of the partner institutions
89564557|NCT03909217|Experimental|TECAS|Patients will receive transcutaneous electrical cranial-auricular acupoint stimulation (TECAS) daily.
89564558|NCT03909217|Active Comparator|Anti-depressants|Each subject shall receive oral administration Escitalopram (10-20mg/day, q.d.), as prescribed by a clinical psychiatrist with respect to patients' conditions for 8 consecutive weeks.
89564559|NCT04769947||Cohort 1|Cohort 1 retrospective/prospective study: 293 patients enrolled and reported in Fava et al 2019 (1) with at least 1 year of follow up at the end of the study (February 2017) and 107 patients enrolled but not reported in Fava et al 2019 since their follow-up was shorter than 1 year. The data for these patients will be collected since the end of previous study.
89564560|NCT04769947||Cohort 2|Cohort 2 retrospective/prospective study: patient not enrolled in the previous study (Fava et al 2019). The data for these patients will be collected since patient diagnosis to the end of the study.
88968552|NCT05363254|Experimental|Cohort 1: Marlboro Gold Box|Subjects will self-assign to a Cohort 1 based on their self-reported use of Marlboro Gold as their usual brand of combustible cigarettes.
88968553|NCT05363254|Experimental|Cohort 2: Newport Box|Subjects will self-assign to a Cohort 2 based on their self-reported use of Newport as their usual brand of combustible cigarettes.
88968554|NCT05363254|Experimental|Cohort 3: HTP device with mode A (20023145) and non-combusted cigarette variant 42001401|Subjects will self-assign to one of 6 menthol flavor variant cohorts (Cohort 3 - 8) of non-combusted cigarette products based on their self-reported flavor usage history and a trial use of the 3 menthol flavor variants.
88968555|NCT05363254|Experimental|Cohort 4: HTP device with mode B (20022187) and non-combusted cigarette variant 42001401|Subjects will self-assign to one of 6 menthol flavor variant cohorts (Cohort 3 - 8) of non-combusted cigarette products based on their self-reported flavor usage history and a trial use of the 3 menthol flavor variants.
88968556|NCT05363254|Experimental|Cohort 5: HTP device with mode A (20023145) and non-combusted cigarette variant 42001399|Subjects will self-assign to one of 6 menthol flavor variant cohorts (Cohort 3 - 8) of non-combusted cigarette products based on their self-reported flavor usage history and a trial use of the 3 menthol flavor variants.
88968557|NCT05363254|Experimental|Cohort 6: HTP device with mode B (20022187) and non-combusted cigarette variant 42001399|Subjects will self-assign to one of 6 menthol flavor variant cohorts (Cohort 3 - 8) of non-combusted cigarette products based on their self-reported flavor usage history and a trial use of the 3 menthol flavor variants.
88968558|NCT05363254|Experimental|Cohort 7: HTP device with mode A (20023145) and non-combusted cigarette variant 40007386|Subjects will self-assign to one of 6 menthol flavor variant cohorts (Cohort 3 - 8) of non-combusted cigarette products based on their self-reported flavor usage history and a trial use of the 3 menthol flavor variants.
88968559|NCT05363254|Experimental|Cohort 8: HTP device with mode B (20022187) and non-combusted cigarette variant 40007386|Subjects will self-assign to one of 6 menthol flavor variant cohorts (Cohort 3 - 8) of non-combusted cigarette products based on their self-reported flavor usage history and a trial use of the 3 menthol flavor variants.
88968560|NCT05363254|Experimental|Cohort 9: HTP device with mode A (20023145) and non-combusted cigarette variant 42001402|Subjects will self-assign to one of 2 non-menthol flavor variant cohorts (Cohort 9 and 10) of non-combusted cigarette products based on their self-reported flavor usage history.
88968561|NCT05363254|Experimental|Cohort 10: HTP device with mode B (20022187) and non-combusted cigarette variant 42001402|Subjects will self-assign to one of 2 non-menthol flavor variant cohorts (Cohort 9 and 10) of non-combusted cigarette products based on their self-reported flavor usage history.
88968562|NCT00015210|Active Comparator|Nefazodone|Nefazodone 100 mg tablet, titrated to a maximum of 200 mg administered twice daily by treatment day 10. Drug tapered over 7 days at the conclusion of the treatment period. Treatment was administered for 8 weeks.
88968563|NCT00015210|Placebo Comparator|Matched Placebo Tablet|Matched placebo tablet, titrated up to 2 tablets twice daily by day 10 and tapered over 7 days at the conclusion of the study. Treatment period lasted 8 weeks.
89564561|NCT04769947||Cohort 3|Cohort 3 prospective study: patients who have discontinued TKI therapy after the study approval in each center. These patients will also participate in the validation process of Phase 2 of a questionnaire developed by an expert panel of eight CML patients with the purpose of capturing the experiences of people along all phases of the TFR.
89208584|NCT00615030|Experimental|Placebo, Salmeterol, Indacaterol Evening|In period I, during morning and evening, placebo matching indacaterol was delivered via SDDPI and placebo matching salmeterol was delivered via DPI. In period II, salmeterol 50 μg twice daily delivered via dry powder inhaler (DPI). One of the two daily doses of salmeterol was administered in the morning and the second dose was in the evening along with placebo matching indacaterol delivered by SDDPI. In period III, patients were instructed to take morning doses of a placebo to indacaterol delivered via SDDPI and placebo to salmeterol delivered via DPI. Indacaterol 300 μg once a day in the evening delivered via SDDPI with placebo to salmeterol delivered via dry DPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
89564562|NCT04914533|Experimental|Intervention Arm|Luminance Red Treatment Arm
89564563|NCT02650921|Experimental|Restylane Lyft with Lidocaine|
89564564|NCT02650921|No Intervention|No Intervention|
89564565|NCT04914143|Experimental|Experimental group|
89564566|NCT04914143|Placebo Comparator|placebo comparator group|
89564567|NCT04913987|Experimental|Total knee|Standard care
89564568|NCT04913987|Experimental|Partial knee|Intervention using relatively new partial knee.
89564569|NCT03054935||Subject-CD|Subjects with Crohn's Disease in active or quiescent phase, classified according to Crohn's Disease Activity Index (CDAI >150 active; CDAI < 150 quiescent)
89564570|NCT04914299|Experimental|A novel mobile-App based intervention|"An App-based positive intelligence intervention consisting of 6 weeks of weekly videos and support group sessions, and 6 weeks of daily App-guided practices."
89564571|NCT04914299|Active Comparator|Standard of Care|Standard prenatal care and follow up
89564572|NCT03801109|Experimental|Hyperbaric group|
89564573|NCT03801109|Experimental|Magnetic group|
89564574|NCT03801109|Active Comparator|Physical group|
89564575|NCT03801109|No Intervention|Baseline group|
89564576|NCT04914221|Experimental|Group I|Period I- comparator / Period II- comparator / Period III-JLP-2002
89564577|NCT04914221|Experimental|Group II|Period I- comparator / Period II- -JLP-2002 / Period III- comparator
89564578|NCT04914221|Experimental|Group III|Period I- JLP-2002/ Period II- comparator / Period III- comparator
89564579|NCT04739449|No Intervention|Control|Two facilities will follow their local protocols for infection prevention, including COVID-19 precautions. We will swab environmental surfaces at these sites to compare outcomes.
89564580|NCT04739449|Experimental|Intervention|"Using a cluster-randomized design, we will test a multimodal aging-friendly intervention including four components (4Cs):~Coaching staff~Cleaning protocols, standardized~Communication with staff and leadership~Collaboration with local expertise~We hypothesize that the implementation of this organizational QI educational program will be associated with lower odds of SARS-CoV-2 transmission to the environment."
88968564|NCT05195242|Experimental|Dexamethasone 12 mg|Intravenous bolus injection of dexamethasone 12 mg once daily in addition to standard care for up to 10 days. We will allow the use of betamethasone 12 mg at sites, where dexamethasone is not available.
88968565|NCT05195242|Active Comparator|Dexamethasone 6 mg|Intravenous bolus injection of dexamethasone 6 mg once daily in addition to standard care for up to 10 days. We will allow the use of betamethasone 6 mg at sites, where dexamethasone is not available.
89564581|NCT03711877|Experimental|scalp cooling system|'Scalp cooling device' will be used to prevent alopecia during chemotherapy regimen infusion.
89564582|NCT03711877|Active Comparator|cold cap|'Cold cap' will be used to prevent alopecia during chemotherapy regimen infusion.
89564583|NCT03054701|Experimental|Sidelying hip abduction exercise|"Participants will be lying on the side with both legs stretched and with their head resting on a pillow. Participants will be allowed to place their hand in front of them to fixate their body and maintain balance. The participants will be instructed to abduct their hip to 45 degrees and return to the resting position afterwards. An elastic band will be used as resistance. This exercise will be applied only on the test limb. A digital metronome will be used to maintain the pace during the exercise.~Load: 12 repetition maximum; Nr. of repetition: 12; Nr. of sets: 3; Rest between sets: 120 seconds; Time under tension: 8 seconds; Distribution of load: Concentric (3 seconds), Eccentric (3 seconds), Isometric (2 seconds)."
89564584|NCT03054701|Active Comparator|Sitting knee extension exercise|"Participants will be seated at the end of an examination couch with the hip and knee relaxed in a 90 degrees angel. Participants will be allowed to place their hands on the side of the couch and the stabilizing foot may have contact with the floor. The participants will be instructed to extend their knee to a 180-degree angle and return to the resting position afterwards. An elastic band will be used as resistance. This exercise will be applied only on the test limb. A digital metronome will be used to maintain the pace during the exercise.~Load: 12 repetition maximum; Nr. of repetition: 12; Nr. of sets: 3; Rest between sets: 120 seconds; Time under tension: 8 seconds; Distribution of load: Concentric (3 seconds), Eccentric (3 seconds), Isometric (2 seconds)."
89564585|NCT05124379|Other|Hemoclin Gel|
89564586|NCT03344263|Experimental|tests of attentional performance|
89564587|NCT04892615||Cohort A|The drainage tube was removed on the 5th day after surgery.
88968566|NCT05147077|Experimental|Integrated rehabilitation group|This group will include 94 patients. On the basis of standard care, patients in this group will receive acupuncture, traditional Chinese medicine, repetitive transcranial magnetic stimulation.
88968567|NCT05147077|Active Comparator|Standard care group|The patients were recommended to take one oral tablet of escitalopram oxalate (10 mg) every morning after a meal for 4 weeks. Internal medicine includes lipid regulation, blood sugar control, anti-hypertension, anticoagulation, and other drugs. Moreover, general duty nursing and motor therapy are also needed.
88968568|NCT05146882|Experimental|belcesiran|Participants who completed the DCR-A1AT-201 treatment period will receive open-label belcesiran administered subcutaneously
88968569|NCT05146882|No Intervention|Observational|Participants who completed the DCR-A1AT-201 Conditional Follow-up period will enter DCR-A1AT-202 for continued follow-up (will not receive open-label belcesiran)
89564588|NCT04892615||Cohort B|The drainage tube was removed on the 7th day after surgery.
88968570|NCT05118139|Experimental|1.5% nicotine cartridges|Subjects will self-assign to one of 7 flavor variants of 1.5% ENDS products based on their preferred flavor.
88968571|NCT05118139|Experimental|2.4% nicotine cartridges|Subjects will self-assign to one of 2 flavor variants of 2.4% ENDS products based on their preferred flavor.
88968572|NCT05118139|Experimental|5% nicotine cartridges|Subjects will self-assign to one of 7 flavor variants of 5% ENDS products based on their preferred flavor.
89027521|NCT04515732|Experimental|3a (apremilast intervention)|Apremilast in standard dosis (gradual increase 0-30 mg x 2 daily over the first 6 days, hereafter 30 mg x 2 daily) for 6 months, followed by 6 months observation.
89027522|NCT04515732|No Intervention|3b (non-intervention)|Observation
89027523|NCT01305577|Placebo Comparator|Placebo|Participants received placebo administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
88968573|NCT05114863|Experimental|Non-menthol smokers|Subjects will be randomized to one of ten product use sequences, such that one of the five IPs (A1,B,C,D,N) will be used in each of the five Test Sessions.
88968574|NCT05114863|Experimental|Menthol smokers|Subjects will be randomized to one of six product use sequences, such that one of the six IPs (A2,E,F,G,H,N) will be used in each of the six Test Sessions.
88968575|NCT05089903|Experimental|No Order|
88968576|NCT05089903|Experimental|No Order + Text (NO+T)|
88968577|NCT05089903|Experimental|Bulk Order (BO)|
88968578|NCT05089903|Experimental|Bulk Order + Text (BO+T)|
88968579|NCT05089903|Experimental|Clinician Endorsement (CE)|
88968580|NCT05089903|Experimental|Clinician Endorsement + Text (CE+T)|
88968581|NCT05089903|Experimental|Standard Messaging (SM)|
88968582|NCT05089903|Experimental|Standard Messaging (SM+T)|
88968583|NCT05076877|Experimental|Lazertinib + Probe Substrates of Midazolam, Rosuvastatin, and Metformin|Participants will receive a single oral dose of probe substrates of midazolam, rosuvastatin, and metformin on Day 1 under fasted conditions followed by a single oral dose of lazertinib under fed conditions from Day 5 to Day 14 except Day 13 which is under fasted conditions and co-administered with probe substrates under fasted conditions on Day 13.
88968584|NCT04976023|Active Comparator|Active Arm|14.55g of Yupingfeng Powder granules twice daily for 8 weeks
88968585|NCT04976023|Placebo Comparator|Placebo Arm|14.55g of placebo granules twice daily for 8 weeks
88968586|NCT04970836|Experimental|Low titer with two doses of HB Vaccines|anti-HBs titer 2.5-10 mIU/mL with two doses of HB Vaccines at Day 0 and Day 28
88968587|NCT04970836|Active Comparator|Low titer with one dose of HB Vaccine|anti-HBs titer 2.5-10 mIU/mL with one dose of HB Vaccine at Day 0
88968588|NCT04970836|Active Comparator|Extremely low titer with two doses of HB Vaccines|anti-HBs titer lower than 2.5 mIU/mL with two doses of HB Vaccines at Day 0 and Day 28
88968589|NCT04970836|Active Comparator|Extremely low titer with one dose of HB Vaccine|anti-HBs titer lower than 2.5 mIU/mL with one dose of HB Vaccine at Day 0
88968590|NCT04896541|Experimental|AZD7442|Single dose (IM injections or IV administration) of AZD7442 or saline placebo on Day 1.
88968591|NCT04896541|Experimental|placebo|Single dose (× 2 separate IM injections or IV administration) of AZD7442 or saline placebo on Day 1.
88968592|NCT04892407|Experimental|Algeness DF 3.5%|This arm is with the Sponsor's product. The product is already CE Marked and sold for this indication for the majority of participating countries.
88968593|NCT04892407|Active Comparator|Juvéderm Voluma|This arm is with a Control product that is already CE Marked and sold for this indication.
88968594|NCT01786434|Experimental|Routine medication arm|Fentanyl is given routinely to all patients before the procedure
88968595|NCT01786434|Active Comparator|Fentanyl on-demand arm|Fentanyl is given during the procedure if the patient experiences pain
88968596|NCT04815382|Experimental|Dynamic Upper Limb Orthosis group|"The dynamic upper limb orthosis group will receive a treatment based on the use of a dynamic upper limb orthosis.~Participants of this group will continue to receive their regular therapy"
88968597|NCT04815382|No Intervention|Control group|The control group will not receive any type of intervention Participants of this group will continue to receive their regular therapy
88968598|NCT04796155||labour arrest|Pregnant women whose labour progress is delayed and suspected or diagnosed as labour arrest according to the NICE guidelines. Intrapartum ultrasound will be performed at the suspicion of labour arrest in the active phase of the first and second stage of labour. Amniotomy will be performed as routine obstetric care according to the local clinical protocols in accordance with the NICE guideline. Later, diagnosis of labour arrest will be made in slow progress following amniotomy (<1cm cervical dilatation in 2 hours) where a sonographic examination will be repeated.
88968599|NCT04759807|Placebo Comparator|Placebo|The placebo designed for administration in the proposed clinical study consists of a dry powder composed of the same excipients as the active (sodium sulfate, mannitol and polysorbate 80), pre-metered into HPMC capsules at the same 5 mg powder fill weight as the active formulations. Subjects will receive 14 doses administered once daily in the morning.
88968600|NCT04759807|Active Comparator|PUR1800 250 μg|The PUR1800 drug product intended for use in the proposed clinical study comprises bulk powder containing 5 wt% or 10 wt% RV1162 pre-metered into HPMC capsules for oral delivery via a passive DPI. The capsules contain 5 milligrams (mg) of the powder formulation, corresponding to 250 μg and 500 μg nominal dose strengths of RV1162. Subjects will receive 14 doses administered once daily in the morning.
88968601|NCT04759807|Active Comparator|PUR1800 500 μg|The PUR1800 drug product intended for use in the proposed clinical study comprises bulk powder containing 5 wt% or 10 wt% RV1162 pre-metered into HPMC capsules for oral delivery via a passive DPI. The capsules contain 5 milligrams (mg) of the powder formulation, corresponding to 250 μg and 500 μg nominal dose strengths of RV1162. Subjects will receive 14 doses administered once daily in the morning.
88968602|NCT04529551|Experimental|1601A, 1601B product use order|Subjects will use 1601A for 1 week and then 1601B for 1 week.
88968603|NCT04529551|Experimental|1601B, 1601A product use order|Subjects will use 1601B for 1 week and then 1601A for 1 week.
88968604|NCT04511065|Experimental|Intervention Group|The intervention group will be provided with a survey to determine areas of interest to guide the 7-week literacy intervention plan of completing a newsletter. Students will complete the newsletter virtually using secure Zoom meetings 2x per week for 30 minutes per session. The results of the GORT 5 and TOC will be used to determine the baseline reading skills of the students and each researcher will use the results of the assessments to guide the intervention with the newsletter topic that is chosen by the student. For example, if the GORT 5 notes deficiency with reading accuracy, the focus of the intervention will be ensuring that reading accuracy is a focus of the summary that is crafted by the student for the newsletter.
88968605|NCT04511065|No Intervention|Control Group|The control group will not participate in the newsletter creation for the 7-week study period. These students will engage in the after-school programs at the Center, some of which may be literacy-based, but not the prescriptive model that is being followed by the researchers.
88968606|NCT03476135|Experimental|Group 1:MenACYW Conjugate Vaccine(Previous Exposed to MenACYW)|Participants who received a single dose of MenACYW conjugate vaccine 3 years earlier in a previous vaccine study (MET54), received a booster dose of MenACYW conjugate vaccine at Day 0 in this study (MET62).
88968607|NCT03476135|Experimental|Group2:MenACYW Conjugate Vaccine(Previous Exposed to Nimenrix)|Participants who received a single dose of Nimenrix® vaccine 3 years earlier in a previous vaccine study (MET54), received a booster dose of MenACYW conjugate vaccine at Day 0 in this study (MET62).
88968608|NCT04390867|Experimental|TOPS1 DBS|Participants receive TOPS1 for one week if it meets screening criteria, followed by one week each of TOPS2, TOPS3, and Standard in random order.
88968609|NCT04390867|Experimental|TOPS2 DBS|Participants receive TOPS2 for one week if it meets screening criteria, followed by one week each of TOPS1, TOPS3, and Standard in random order.
88968610|NCT04390867|Experimental|TOPS3 DBS|Participants receive TOPS3 for one week if it meets screening criteria, followed by one week each of TOPS1, TOPS2, and Standard in random order.
88968611|NCT04390867|Active Comparator|Standard DBS|Participants receive Standard for one week, followed by one week each of TOPS1, TOPS2, and TOPS3 in random order.
88968612|NCT04219618|Experimental|Off-Pump|
88968613|NCT04219618|Active Comparator|On-Pump|
88968614|NCT04189627||Participants Treated with GLE/PIB|Participants treated with all oral glecaprevir/pibrentasvir (GLE/PIB) and the decision to treat with GLE/PIB is made before the decision to offer an opportunity to join this study. Prescription of the treatment regimen is at the discretion of the physician and in accordance with local clinical practice and label.
88968615|NCT04185922|Experimental|Hemopatch|The RARP and BPLND are performed in the usual manner. Towards the end of the operation, Hemopatch is laid over the ends of raw truncated lymphatic tissue.
88968616|NCT04185922|No Intervention|Control|The RARP and BPLND are performed in the usual manner. Hemopatch will not be applied to control group.
88968617|NCT00015834|Experimental|Treatment (imatinib mesylate, cytarabine)|Patients who have not previously received imatinib mesylate receive oral imatinib mesylate daily on days 1-35. Patients who have previously received imatinib mesylate for at least 28 days receive oral imatinib mesylate on days 22-35. All patients receive cytarabine IV over 2 hours every 12 hours on days 29-32. Patients with more than 5% residual blasts in bone marrow on day 28 receive a second course in the absence of disease progression or unacceptable toxicity.
88968618|NCT04141423|Active Comparator|Tregopil 30 mg|Dose level cohort with a sentinel dosing design
88968619|NCT04141423|Active Comparator|Tregopil 45 mg|Dose level cohort with a sentinel dosing design
88968620|NCT04141423|Active Comparator|Tregopil 60 mg|Dose level cohort with a sentinel dosing design
88968621|NCT04141423|Active Comparator|Derived Dose level|Derived Dose level cohort with a sentinel dosing design (60 mg fixed preprandial dose plus an additional 30 mg postprandial rescue dose, if required)
88968622|NCT00015873|No Intervention|A no VIMARAM|No VIMARAM preceding maintenance treatment
88968623|NCT00015873|Experimental|B - VIMARAM|VCR i.v. 1.5 mg/m2/d - 4 days 6-MP p.o. 25 mg/m2/d - 15 days HD-MTX p.i.(24hr) 5 g/m2 - 2 days MTX + pred I.T. (age adapted) - 2 days HD-Ara-C p.i (3hr) 3 g/m2/12 hrs -8 days L-ASP p.i. (1hr) 5.000 U/m2 - 2 days
88968624|NCT03772210|Active Comparator|Current Intensity 1 mA|tDCS will be administered at an intensity of 1 mA to locations F3-F4, and fMRI response during performance of a 3-back/0-back memory task will be assessed.
88968625|NCT03772210|Sham Comparator|Sham 1 mA|Determine fMRI response during performance of a 3-back/0-back memory task with sham 1 mA tDCS.
88968626|NCT03772210|Active Comparator|Current Intensity 1.5 mA|tDCS will be administered at an intensity of 1.5 mA to locations F3-F4, and fMRI response during performance of a 3-back/0-back memory task will be assessed.
88968627|NCT03772210|Sham Comparator|Sham 1.5 mA|Determine fMRI response during performance of a 3-back/0-back memory task with sham 1.5 mA tDCS.
88968628|NCT03772210|Active Comparator|Current Intensity 2 mA|tDCS will be administered at an intensity of 2 mA to locations F3-F4, and fMRI response during performance of a 3-back/0-back memory task will be assessed.
88968629|NCT03772210|Sham Comparator|Sham 2 mA|Determine fMRI response during performance of a 3-back/0-back memory task with sham 2 mA tDCS.
88968630|NCT03772210|Experimental|Structural, Diffusion and MREIT Imaging|"Structural and High angular resolution diffusion weighted imaging will be performed.~Magnetic Resonance Electrical Impedance Tomography imaging will be performed using electrode locations F3-F4."
88968631|NCT00015912|Experimental|Treatment (interferon-alpha, thalidomide)|Patients receive interferon alfa subcutaneously every 12 hours and oral thalidomide daily in the absence of disease progression or unacceptable toxicity.
88968632|NCT03668431|Experimental|PDR001, Dabrafenib, Trametinib|"Patients who fulfill eligibility criteria will be entered into the trial to receive PDR001, Dabrafenib, Trametinib. Treatment will be administered on an outpatient basis.~After the screening procedures confirm participation in the research study:~Dabrafenib will be taken twice a day for 28 consecutive days~Trametinib will be taken once a day for 28 consecutive days~PDR001 will be administered IV every 28 days."
88968633|NCT02970721||Bipolar disorder-treated|Individuals in this group are taking any medication (mood stabilizer, antipsychotic, antidepressants, antianxiety) during pregnancy
89564589|NCT04892381||Lichen Planus group|Assessment of Programmed Cell Death Protein 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Tissue Expression Levels using ELISA in lesional and non lesional skin
89564590|NCT04892381||Control group|Assessment of Programmed Cell Death Protein 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Tissue Expression Levels using ELISA
89564591|NCT05100121|Experimental|Intervention|The intervention consists of standard care and an app for routine symptom reporting, weekly the first month and thereafter as mutually agreed, at minimum once a month in one year, with instant self-care advice in combination with supportive care with a district nurse. At coaching sessions with the district nurse, the patient-reported assessments in the app will be used to discuss the individual's current situation and to plan eventual additional actions needed. The intervention will last for 12 months.
89564592|NCT05100121|No Intervention|Control|The participants in the control group will only receive standard care. Usually after ended curative treatment the follow-up is a blood sample (PSA) every three or six months the first year, this can be handled either by a nurse or a physician in secondary care. Most hospitals also have one physical meeting with a physician three months after ended treatment (Regional Cancer Centers, 2020). All patients are allocated a contact nurse with a telephone number to contact when needed.
89564593|NCT04900961|Active Comparator|Intervention|A personalised, resistance-based exercise intervention for patients during the convalescence phase in-hospital through to 3-months post-discharge, a duration reflecting chronic, maintenance treatment studies. To maximise enrolment of eligible patients, the intervention may be initiated in-hospital or in the community post-discharge. Resistance bands may be used according to the exercise guideline.
89564594|NCT04900961|No Intervention|Control|Standard of care treatment
89564595|NCT03054623||DRIL procedure|Adult (>18 yo) patients with chronic kidney disease with functioning antecubital-based arteriovenous fistulae and evidence of ischemic steal symptoms
89564596|NCT04892225|Experimental|Intervention group|Individuals in this group will be randomly assigned to text message in Urdu language on dietary sodium and fluid restriction daily for 8 weeks.
88968634|NCT02970721||Bipolar Disorder-Not Treated|Individuals in this group are not taking any medications during pregnancy
88968635|NCT03636958|Active Comparator|control group|they will receive conventional antiepileptic treatment (antiepileptic combination therapy) without perampanel
88968636|NCT03636958|Experimental|experimental group|they will receive conventional antiepileptic treatment (antiepileptic combination therapy) with perampanel
88968637|NCT03531853|Experimental|Imaging patients|Get uveitis patients and ER patients to image their eyes
88968638|NCT03509896||Participants newly diagnosed with CML-CP|
89210672|NCT05698251|Experimental|Reducing uncertainty distress: Psychological therapy intervention|"Up to 16 sessions of psychological therapy delivered weekly either face to face or via telehealth . Based on empirically grounded models of anxiety/threat, illness uncertainty and intolerance of uncertainty.~Formulation driven and clinically responsive individualised treatment based on four intervention areas: information management, building safety, reducing overestimation of threat and tolerating uncertainty."
88968639|NCT00015990|Experimental|Treatment (thalidomide)|Patients receive oral thalidomide once daily. Treatment continues for 5 years in the absence of disease progression or unacceptable toxicity.
88968640|NCT03206476|Experimental|Intervention group|Nutritional intervention based on the SCT and the TM
89564597|NCT04892225|No Intervention|Control group|Randomly assigned Control group will not receive any text message.
89564598|NCT04900649|Experimental|study group|the study group has conducted chest resisted exercise combined with chest expansion exercise in addition to a usual chest physiotherapy. For chest resistance exercise, the children in the study group underwent sequential 12-week chest resistance exercise and chest expansion exercise, three sessions a week. Chest resistance exercises have been consisted of manual resistance exercise and resistance exercise via POWER breath KH2.
89564599|NCT04900649|Experimental|control group|12-week usual chest physiotherapy in form of bilateral vibration and gentle percussion for 3-5 minutes with distal finger phalanges to the upper apical lobes in modified drainage positions, placing the patient in a side-lying position or a prone position to increase oxygenation, at least 2-3 times a week
89564600|NCT04913909|Active Comparator|Dentoblis™ group|In Probiotic group; Dentoblis™, as a test lozenge, contains 4 billion CFU/g S. salivarius M18 strain probiotic isolated from a healthy oral microbiota, has been utilized one lozenge a day for 30 days.
89564601|NCT04913909|Placebo Comparator|Placebo group|The placebo was indistinguishable in form, size, color, smell and taste from the probiotic lozenge, but contained no bacteria and utilized one lozenge a day for 30 days . Placebo and probiotic lozenges were equivalent to 810 mg each and containing same amount of xylitol. Both were provided by the manufacturer, Bluestone Pharma GmbH, Baar, Switzerland, in equal white containers boxes, separated by production code.
89564602|NCT04891601|Active Comparator|Group II MA Mesh alone repair|patient use mesh alone as treatment of inguinal hernia
89564603|NCT04891601|Active Comparator|Group I CMD Combined Mesh & darn|patients utilize both mesh and darn repair
88968641|NCT03206476|Active Comparator|Control group|Nutritional information
88968642|NCT02970916|Experimental|FOLFIRI+aflibercept|
88968643|NCT00016107|Experimental|Treatment (chemotherapy, bevacizumab)|Patients receive oral estramustine 3 times daily on days 1-5 and docetaxel IV over 1 hour followed by bevacizumab IV over 30-90 minutes on day 2. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
88968644|NCT00016146|Experimental|vaccine|"This is a dose-escalation study of GPI-0100.~Patients receive glycosylated MUC-2-Globo H-KLH conjugate vaccine with adjuvant GPI-0100 subcutaneously weekly on weeks 0-2, 6, 14, and 26 in the absence of unacceptable toxicity or disease progression.~Cohorts of 5 patients receive escalating doses of GPI-0100 until the optimal dose, based on antibody response, is reached.~Patients are followed every 3 months."
88968645|NCT00001151|Experimental|Drug treatment|1,25-Dihydroxycholecalciferol 5 ug orally per day for 2 years
89564604|NCT01596335|Experimental|TA-650|
88968646|NCT00016302|Experimental|Regimen A|See detailed description.
89027524|NCT01305577|Experimental|Deoxycholic Acid Injection 1 mg/cm²|Participants received deoxycholic acid 1 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
89210673|NCT00585533|Other|A|
89210674|NCT00924690|Experimental|1|Behavioral Message Arm
89564605|NCT01596335|Active Comparator|VGIH|
89564606|NCT04891679|Active Comparator|Group A (Titrated OMS)|Titrated oral misoprostol solution
89564607|NCT04891679|Active Comparator|Group B (Static OMS)|Static oral misoprostol solution
89564608|NCT04913831|Experimental|Cerebrolysin|
89564609|NCT04913831|Placebo Comparator|Placebo|
89564610|NCT04900415|Experimental|Vitamin A and smell training|14-day course of daily oral vitamin A 7500µg RAE in combination with smell training three times per day for 4 weeks
89564611|NCT04900415|Active Comparator|Smell training|Smell training three times per day for 4 weeks
89564612|NCT04900415|No Intervention|Control|Observation
89564613|NCT03051035|Experimental|KO-947|
89564614|NCT04900571|Experimental|Nitrofurantoin|Measuring pain score using numerical pain scale post-operatively at different time intervals.
89564615|NCT04900571|Experimental|Calcium Hydroxide|Measuring pain score using numerical pain scale post-operatively at different time intervals.
89564616|NCT04900571|Experimental|Control|Measuring pain score using numerical pain scale post-operatively at different time intervals.
89564617|NCT04900727||Current smokers|Individuals who, at the time of the survey, smoke any forms of tobacco product either daily or occasionally.
89564618|NCT04900727||Ex-smokers|Individuals who were formerly smokers but, at the time of the survey, do not smoke at all.
89564619|NCT04900727||Never Smokers|Individuals who, at the time of the survey, have never smoked at all.
89564620|NCT04900181|Experimental|the same-day discharge surgery|Patients in the the same-day discharge surgery group were admitted to hospital, operated and discharged within 24 hour
89564621|NCT04900181|No Intervention|inpatient surgery|Patients in inpatient surgery follow routine procedures and do not need to be discharged on the same day.
89564622|NCT04913597||Recombinant human thrombopoietin (rh-TPO) group|Patients who fail previous steroids and avatrombopag and then switch to Rh-TPO will be enrolled. The reason for switch will be recorded. Patients will be given rh-TPO 300 U/kg once daily for 14 days as initial treatment. After initial treatment, maintenance therapy were performance. At initial therapy, rhTPO will be suspended when platelet counts ≥100×10^9 / L. During maintenance therapy, patients with platelet counts >150×10^9 / L will suspend treatment until platelet counts drop to ≤150×10^9 / L. Dosing interval will be prolonged when platelet count is ≥100×10^9 / L to ≤150×10^9 / L. Dose modification is not required when platelet count is ≥30×10^9 / L to <100×10^9 / L. The efficacy, safety, and patient/physician preference will be assessed.
89564623|NCT04913597||Avatrombopag group|Patients who fail previous steroids and rh-TPO and then switch to avatrombopag will be enrolled. The reason for switch will be recorded. Patients will be given avatrombopag 20mg once daily as initiate treatment, and adjust the dosage according to the count of platelets. The maximum dose of avatrombopag is 40mg daily.Avatrombopag will be terminated any time the platelet counts increased above 250×10^9/L. Dose adjustment of avatrombopag will be allowed to maintain platelet counts between 30×10^9/L and 150×10^9/L. The efficacy, safety, and patient/physician preference will be assessed.
89564624|NCT04891211|Active Comparator|Pediatric endocrinologist|Patient selection by pediatric endocrinologist on the basis of vitamin D
89564625|NCT04891211|No Intervention|Ophthalmologist|"Evaluation of the results by 2 different retina specialists during the examination of patients~Interpretation of the results without knowing the vitamin D level of patients"
89564626|NCT03050957|Experimental|menthol 10 mM (millimolar)|Patients were studied during the deglutition of one series of 5, 10 and 20 mL nectar control boluses and two series of 5, 10 and 20 mL nectar boluses supplemented with the corresponding concentration of menthol 10 mM
88968647|NCT00016302|Experimental|Regimen B|"Induction (weeks 1-9): Patients receive treatment as in induction of regimen A.~Consolidation (weeks 10-19): Patients receive treatment as in consolidation on regimen A.~Reinduction (weeks 20-29): Patients receive treatment as in reinduction on regimen A and nelarabine IV on days 162-166.~Maintenance (weeks 30-101): Patients receive oral mercaptopurine daily on days 1-28 and 36-56; oral methotrexate weekly; and nelarabine IV on days 29-33. Treatment repeats every 8 weeks for 4 courses. Beginning on week 62, patients receive vincristine IV once; oral prednisone three times daily for 5 days; oral mercaptopurine daily; and oral methotrexate weekly. Treatment repeats every 8 weeks for 5 courses."
88968648|NCT00016302|Experimental|Regimen C|"Induction (weeks 1-5): Patients receive treatment as in induction (weeks 1-5) on regimen A and nelarabine IV over 1 hour on days 29-33.~If bone marrow is M1, patients begin week 6 of induction therapy on day 36 or when peripheral blood counts recover. If bone marrow is M2, patients begin week 6 of induction therapy immediately. If bone marrow is M3, treatment discontinues.~Induction (weeks 6-9): Patients receive treatment as in induction (weeks 6-9) on regimen A.~Consolidation (weeks 10-19): Patients receive treatment as in consolidation on regimen A.~Reinduction (weeks 20-29): Patients receive treatment as in reinduction on regimen B.~Maintenance (weeks 30-101): Patients receive treatment as in maintenance on regimen B."
88968649|NCT00016302|Experimental|Regimen D|See detailed description.
88968650|NCT00016302|Experimental|Regimen E|Patients receive consolidation therapy, reinduction therapy, and maintenance therapy as in regimen D, but nelarabine is administered at a higher dose.
88968651|NCT00016302|Experimental|Regimen F|Patients receive nelarabine at a higher dose during induction therapy. Patients receive consolidation therapy, reinduction therapy, and maintenance therapy as in regimen E.
88968652|NCT01156545|Experimental|Treatment arm|BIBW 2992 plus simvastatin arm
88968653|NCT01156545|Active Comparator|control arm|BIBW 2992 arm
89210675|NCT00924690|Active Comparator|2|Generic Message Arm
89564627|NCT03050957|Experimental|menthol 1 mM|Patients were studied during the deglutition of one series of 5, 10 and 20 mL nectar control boluses and two series of 5, 10 and 20 mL nectar boluses supplemented with the corresponding concentration of menthol 1 mM
89564628|NCT04885049|Experimental|Group A|Group A (GA) will receive anti secretory 1.5mg/kg/dose three doses per oral in 24 hours for 3 days along with oral rehydration
89564629|NCT04885049|Experimental|Group B|Group B (GB) will receive a single dose of bovine colostrum and egg solids as 7 g of dry powder reconstituted in 30 mL of water and taken orally once daily for 3 days along with oral rehydration
89564630|NCT04884581|Experimental|GI Genius CADx device|
89564631|NCT04056533|Experimental|CMV CTLs|1x10^5 CMV-CTLs/kg
89564632|NCT04890587|Experimental|AL8326|"Part 1:(closed)Cohort 1 will initiate with AL8326 for single dose and multiple dose (28-Day cycles) . After three subjects have completed the first cycle of therapy without a DLT, additional cohorts may be enrolled sequentially. After the first cohort has completed one full cycle of therapy without a DLT, several additional cohorts will be sequentially for the same 28-day cycles.~Part 2 :(open)Each subject will receive a dose from Part 1 of this study for continuous 28-Day cycles of therapy.~Part 3:(open)Cohort 3 will initiate with AL8326(bid), for 28-Day cycles . After three subjects have completed the first cycle of therapy without a DLT, additional cohorts may be enrolled sequentially. After the first cohort has completed one full cycle of therapy without a DLT, two additional cohorts will be sequentially enrolled at decreased dose of AL8326 for the same 28-day cycles."
89564633|NCT04891055||patients treated with nivolumab|Patients candidates for II line therapy with Nivolumab from clinical practice
89564634|NCT04891055||patients treated with TKI|Patients candidates for II line therapy with TKI from clinical practice
89564635|NCT04890665|Experimental|Experimental: Self-applied psychological intervention for healthcare workers|Participants in this group will receive 9 sessions of a multi-component psychological intervention focused on the reduction of symptoms of anxiety, depression, stress, burnout, fatigue compassion, and post-traumatic stress, and the increase of the quality of sleep and perception of the quality of life. The participants will have the option to do 3 extra modules that are complimentary for the intervention.
89564636|NCT04890665|Active Comparator|Control: Self-applied psychological intervention for healthcare workers|The participants in this group will receive exactly the same intervention but delivered through a therapist in a weekly session through an online video call. The participants will be informed also about the 3 extra modules and briefly what it is the contents of these modules so they can accept or not receive these extra contents.
89564637|NCT04899713||Experimental group (neo-adjuvant chemotherapy combined with ZOMETA®) (zoledronic acid)|Patients treated every 3 weeks (+/- 2 days ) for 8 cycles in total. The 4 first cycles : zoledronic acid 4 mg (in a 15 min. infusion) + doxorubicin (60 mg/m²) + cyclophosphamide (600 mg/m²). The 4 last cycles with zoledronic acid 4 mg (in a 15 min. infusion) + docetaxel (100 mg/m²)
89564638|NCT04899713||Control group (neo-adjuvant chemotherapy alone)|Patients treated every 3 weeks (+/- 2 days) for 8 cycles in total. The 4 first cycles : doxorubicin (60 mg/m²) combined with cyclophosphamide (600 mg/m²). The 4 last cycles with docetaxel (100 mg/m²)
89564639|NCT04430621|Experimental|FSH|FSH, 300 IU s.c.
89564640|NCT04430621|Placebo Comparator|Control|Placebo, s.c.
89564641|NCT04900259||COVID-19 Bladder Cancer|Patients diagnosed with primary bladder cancer in the COVID-19 period
89564642|NCT04900259||PreCOVID-19 Bladder Cancer|Patients diagnosed with primary bladder cancer in the preCOVID-19 period
89564643|NCT04884503|Experimental|Patients diagnosed with BMS traeting with Clonazepam|Dosing of clonazepam was as follows: in the first week, 1 mg to be sucked for 2 minutes, then swallowed (once a day in the morning), in the second week, 1 mg to be sucked for 2 minutes, and then swallowed (twice a day in the morning and one hour before falling asleep), in the third week, 1 mg to be sucked for 2 minutes and in the fourth week 1 mg to be sucked for 2 minutes, then swallowed (once a day in the morning)
89564644|NCT04884503|Active Comparator|Patients diagnosed with BMS treating with tongue pads|patients wearing tongue pads 3 times a day for 20 minutes for 4 weeks to exclude parafunctions
89564645|NCT04884425|Active Comparator|PEMF Device Group|This arm will consist of participant's who have been randomly assigned to use the PEMF device daily for 30 mins for an overall 3 months
89564646|NCT04884425|No Intervention|Waiting List Control Group|These participants will be randomly selected to be on the waiting list group. All waiting list participants will be offered the use of the PEMF device after the study has completed
89564647|NCT03051893|Experimental|Part A1|Three formulations of Chronocort 30mg were administered to healthy volunteers, with a 7-day washout period between each dose. Each treatment was administered in a randomised, crossover manner.
89027525|NCT01305577|Experimental|Deoxycholic Acid Injection 2 mg/cm²|Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
89027526|NCT01304329|Experimental|treatment A, reference|1 tablet BI 10773, oral administration with 240 ml water
89027527|NCT01304329|Experimental|treatment B, reference|1 tablet simvastatin, oral administration with 240 ml water
89027528|NCT01304329|Experimental|treatment C, test|1 tablet BI 10773 + 1 tablet simvastatin, oral administration with 240 ml water
89027529|NCT04515420||Group A|"Group A for patients that will need an infusion of NA solution to meet the desired CPP.~Group A will be further divided into three sub-groups: A1 for patients that will receive NA in the dose of 0.06-0.12 μg/kg/min, A2 for patients that will receive a dose of 0.13-0.2 μg/kg/min, and A3 for patients that will receive a dose of NA > 0.2 μg/kg/min."
89564648|NCT03051893|Experimental|Part A2|Three additional formulations of Chronocort 30mg were administered to healthy volunteers, with a 7-day washout period between each dose. Each treatment was administered in a randomised, crossover manner.
89564649|NCT03051893|Experimental|Part B|The best formulation of Chronocort was then selected from Parts A1 & A2. This was then administered in four separate treatment periods, in dosages of 5mg, 10mg, 20mg and 30mg. Each treatment was administered in a randomised, crossover manner.
89564650|NCT04890197|Active Comparator|tahini|48 gr per day
89564651|NCT04890197|Placebo Comparator|control|no intervention
89027530|NCT04515420||Group B|Group B for patients that will not receive NA infusion.
89027531|NCT00488540|Active Comparator|Paracetamol (Acetaminophen)|Paracetamol (Acetaminophen) given at 2 and 8 hours post birth, measurement of EDIN-Score on day one of life, measurement of stress response after Guthrie-test on day 4 of life.
89027532|NCT00488540|Placebo Comparator|Placebo|Placebo given at 2 and 8 hours post birth, measurement of EDIN-Score on day one of life, measurement of stress response after Guthrie-test on day 4 of life.
89027533|NCT00483860|Experimental|Topotecan|once a day
89027534|NCT01241097|Experimental|high-dose simvastatin, combined, placebo|simvastatin 80 mg per days or simvastatin 10 mg and ezetimibe 10 mg, over a period of eight weeks, treatment consisted of tablets identical, or placebo
89027535|NCT00483899|Experimental|Cohort 1: Part A|Subjects in Cohort 1 will be randomized to receive 0.5, 2 and 6 mg GW870086X and placebo.
89564652|NCT04889963|Placebo Comparator|control group|rabbit with posterior cruciate ligament rupture and treated with fibrin glue (sacffold)
89564653|NCT04889963|Active Comparator|conditioned medium group|rabbit with posterior cruciate ligament rupture and treated with fibrin glue mix with ligament derived conditioned medium
89564654|NCT04889963|Active Comparator|stem cells group|rabbit with posterior cruciate ligament rupture and treated with fibrin glue mix with adypose mesenchymal stem cells in hypoxic culture condition
89564655|NCT04889963|Experimental|composite group|rabbit with posterior cruciate ligament rupture and treated with fibrin glue mix with adypose mesenchymal stem cells in hypoxic culture condition and ligament derived conditioned medium
89564656|NCT04412213||children of possitive family history of stuttering|
89564657|NCT04412213||children of negative family history of stuttering|
89564658|NCT04889885|Experimental|High-intensity laser therapy (HILT)|The participants in the intervention group were treated by HILT which was applied to the knee joint (2-3 sessions a week for a total of 10 sessions) plus conservative treatment.
89564659|NCT04889885|Sham Comparator|Sham laser|The control group received a sham laser by the same laser machine (2-3 sessions a week for a total of 10 sessions) plus conservative treatment.
89564660|NCT04899401|Experimental|Standard of care +PediaFlù®|
89564661|NCT04899401|Active Comparator|Standard of care|
89564662|NCT04889651|Experimental|A(TRTR)|"The selected subjects are randomized into two sequence group(Sequence A (TRTR) & Sequence B (RTRT)).~* Sequence A: T-R-T-R~T: BR9004, oral single-dose administration, 1 tablet per day~R: BR9004-1, oral single-dose administration, 1 tablet per day~Washout interval between periods: 7 days"
89564663|NCT04889651|Experimental|B(RTRT)|"The selected subjects are randomized into two sequence group(Sequence A (TRTR) & Sequence B (RTRT)).~* Sequence B: R-T-R-T~T: BR9004, oral single-dose administration, 1 tablet per day~R: BR9004-1, oral single-dose administration, 1 tablet per day~Washout interval between periods: 7 days"
89564664|NCT04898777|Active Comparator|ERCP-BD|ERCP Biliary Drainage by papillary approach with stent placement.
89564665|NCT04898777|Active Comparator|EUS-BD|Endoscopic Ultrasound guided Biliary Drainage by Choledochoduodenostomy with transmural stent placement.
89564666|NCT04889339|Experimental|Test group: Braces designed with growth modulation simulation|The braces will be designed using a growth modulation method.
89564667|NCT04889339|Active Comparator|Control group: Conventional method|The braces will be designed by an orthotist without growth modulation simulation.
89564668|NCT04884347|Experimental|Alline proMEN|The qualitative and quantitative formula is as follows: 500 mg Keratin, 225 mg Inactive dried yeast rich in vitamin (containing 200 mg Saccharomyces cerevisiae 100% inactivated, 11.218.4 mg Vitamin B3, 6.8-7.2 mg Vitamin B5, 1.6-1.8 mg Vitamin B6, 1.6-1.8 mg Vitamin B2, 1.6 -1.8 mg Vitamin B1, 0.2-0.4 mg Vitamin B9, 0.2 mg Vitamin B8, 5.6 μg Vitamin B12), 150 mg Venus hair fern extract, 117.6 mg Iron gluconate (containing 14.7 mg Iron), 84.2 mg Sodium ascorbate coated, 76.8 mg Zinc gluconate (11 mg Zinc) 24 mg Beta carotene 20%, 14.8 mg Vitamin E, 256.3 mg Acacia gum, 100 mg Microcrystalline cellulose, 11.3 mg Magnesium stearate, 78 mg White coating (containing: 23.4-39 mg Hydroxypropylmethylcellulose (E464), 15.6-23.4 mg Calcium sulfate anhydrous (E516), 15.6-23.4 mg Magnesium carbonate, light (E504), 7.8-15.6 mg Hydroxypropylcellulose (E463), 3.9-11.7 mg Stearic acid (E570)).
89564669|NCT04884347|Placebo Comparator|Placebo|1095 mg Microcrystalline cellulose, 5 mg Magnesium stearate, 55 mg White coating (containing: 16.5-27.5 mg Hydroxypropylmethylcellulose (E464), 11.0-16.5 mg Calcium sulfate anhydrous (E516), 11.0-16.5 mg Magnesium carbonate, light (E504), 5.5-11.0 mg Hydroxypropylcellulose (E463), 2.8-8.2 mg Stearic acid (E570).
89564670|NCT04883723|Experimental|Experiment I (Shotblocker) Group|Before the injection, the heart rate and blood pressure values of the patient were measured and recorded. The patient was placed in a prone position. The determined injection site was cleaned with a cotton pad with alcohol, with circular movements of 5 cm diameter from inside to outside, and the alcohol was allowed to dry. The protruding surface of the Shotblocker was placed in the area just before the injection, so that the needle entry point would not be contaminated. It was lightly pressed into the shotblocker with fingertips and the injection was performed. ShotBlocker has been removed after removing the needle. Visual comparison scale and injection satisfaction evaluation scale were applied to the patient in the first minute after the intramuscular injection. The obtained scores were recorded in the patient identification form. Pulse and blood pressure values were measured and recorded again. Finally, the patient introduction form was filled.
89564671|NCT04883723|Experimental|Experiment II (Manual Pressure) Group|Before the injection, the heart rate and blood pressure values of the patient were measured and recorded. The patient was placed in a prone position and the appropriate left or right ventrogluteal region was determined. Pressure was applied to the determined injection area with the thumb of the active hand for 10 seconds. Immediately after the application of pressure was terminated, the injection site was cleaned with an alcohol cotton pad with circular movements of 5 cm diameter from inside to outside and the alcohol was allowed to dry. With a single movement at a 90 ° angle, the compression area was entered quickly and the injection was performed. Visual comparison scale and injection satisfaction evaluation scale were applied to the patient in the first minute after the intramuscular injection. The obtained scores were recorded in the patient identification form. Pulse and blood pressure values were measured and recorded again. Finally, the patient introduction form was filled.
89564672|NCT04883723|No Intervention|Control Group|The patients in the Manual Pressure group were given detailed information about the procedure and the research, and the patients who agreed to participate in the study were signed by an informed consent form. Before the injection, the heart rate and blood pressure values of the patient were measured and recorded. The patient was placed in a prone position and the appropriate left or right ventrogluteal region was determined. Injection was given using the normal intramuscular injection procedure. Visual comparison scale and injection satisfaction evaluation scale were applied to the patient in the first minute after the intramuscular injection. The obtained scores were recorded in the patient identification form. Pulse and blood pressure values were measured and recorded again. Finally, the patient introduction form was filled.
89027536|NCT00483899|Experimental|Cohort 2: Part A|Subjects in Cohort 2 will be randomized to receive 3 mg GW870086X or placebo.
89564673|NCT04898699|Experimental|PrEP+|PrEP+ is an experimental pre-exposure prophylaxis (PrEP)-focused prevention strategy providing daily oral tenofovir/emtricitabine (TDF/FTC) in combination with two adherence self-management interventions: (1) real-time feedback from point-of-care urine drug-level assay, (2) HIV self-testing and (3) 2-way text message reminders in addition to standard of care HIV risk-reduction counseling among male clients (MC) of female sex workers in Kisumu, Kenya.
89564674|NCT04883801||COVID-19 case group|Newborns born to pregnant women diagnosed with COVID-19 during hospitalization for delivery
89564675|NCT04883801||Control group|Newborns born to pregnant women who were not diagnosed with COVID-19 in their medical history and hospitalization for delivery
89564676|NCT02618759|Experimental|DSXS1505|To evaluate the therapeutic efficacy and safety of DSXS topical spray, 0.15%.
89564677|NCT02618759|Placebo Comparator|Placebo|Eligible patients will be randomized in a 1:1 ratio to Test or Placebo product.
89564678|NCT04899011||Middle ear surgery|
89564679|NCT04888715|Experimental|DWN12088 and Pirfenidone|T1 - Pirfenidone A mg, Tablet, oral, once daily, T2 - 1) DWN12088 X mg, Tablet, oral, once daily, 2) DWN12088 X mg, Tablet, oral, twice daily, T3 - DWN12088 X mg, Tablet, oral, once daily+ Pirfenidone A mg, Tablet, oral, once daily
89027537|NCT00483899|Experimental|Part B|Subjects will be randomized to receive 1 and 3 mg of GW870086X or placebo.
89027538|NCT01303861|Active Comparator|varenicline|This group will consist of smokers who, based on smoking behavior, DO NOT respond favorably to pre-cessation nicotine patches (assessed at Session P2). They will receive varenicline.
89027539|NCT01303861|Active Comparator|Nicotine Patches only|This group will consist of smokers who, based on smoking behavior, respond favorably to pre-cessation nicotine patches(assessed at Session P2). They will continue to receive only nicotine patches.
89027540|NCT01303861|Active Comparator|Nicotine Patches with Nicotine Inhaler|This group will consist of smokers who, based on smoking behavior, respond favorably to pre-cessation nicotine patches (assessed at Session P2). They will continue to receive nicotine patches and will receive a nicotine inhaler to use as needed after their quit date.
89027541|NCT01303861|Active Comparator|varenicline with bupropion|This group will consist of smokers who, based on smoking behavior, DO NOT respond favorably to pre-cessation nicotine patches (assessed at Session P2). They will receive varenicline in combination with bupropion.
89027542|NCT05661136|Experimental|Warm air blower|Intra-operative lower-body forced-air warming after spinal anesthesia and co-loading 1000 mL liters of IV warmed-fluids started prior to performing spinal anesthesia
89027543|NCT05661136|Active Comparator|Control|Co-loading of 1000 mL liters of IV warmed-fluids started prior to performing spinal anesthesia
89564680|NCT04888715|Experimental|DWN12088 and Nintedanib|T1 - Nintedanib B mg, Tablet, oral, once daily, T2 - DWN12088 X mg, Tablet, oral, twice daily, T3 - DWN12088 X mg, Tablet, oral, once daily+ Nintedanib B mg, Tablet, oral, once daily
89564681|NCT04888871||Only Fundal Pressure (Kristeller Maneuver)|prolonged second stage phase and not prolonged second phase in pregnant women to singletons at the weeks between 37-42, applying Only Fundal Pressure (Kristeller Maneuver) and the postpartum evaluation of maternal episiotomy needs presence of second and third degree perineal tears, presence of postpartum hemorrhage and need for blood transfusion , cesarean rates and fetal first and fifth minute Apgar score , fetal blood gas parameters, presence of fetal trauma, need for neonatal intensive care will
89564682|NCT04888871||Only Vacuum Extraction|prolonged second stage phase and not prolonged second phase in pregnant women to singletons at the weeks between 37-42, applying only vacuum extraction and the postpartum evaluation of maternal episiotomy needs presence of second and third degree perineal tears, presence of postpartum hemorrhage and need for blood transfusion , cesarean rates and fetal first and fifth minute Apgar score , fetal blood gas parameters, presence of fetal trauma, need for neonatal intensive care will
89564683|NCT04888871||Both Fundal Pressure (Kristeller Maneuver) and Vacuum Extraction|prolonged second stage phase and not prolonged second phase in pregnant women to singletons at the weeks between 37-42, applying Both Fundal Pressure (Kristeller Maneuver) and Vacuum Extraction and the postpartum evaluation of maternal episiotomy needs presence of second and third degree perineal tears, presence of postpartum hemorrhage and need for blood transfusion , cesarean rates and fetal first and fifth minute Apgar score , fetal blood gas parameters, presence of fetal trauma, need for neonatal intensive care will
89564684|NCT04888559|Active Comparator|Whole grain breakfast product|
89564685|NCT04888559|Placebo Comparator|Reference|
89564686|NCT04897997||non smokers|never having smoked patients
89564687|NCT04897997||smokers|actively smoking patients
89564688|NCT04897997||acute coronary syndrome|patients with the coronary indication of ACS
89564689|NCT04897997||stable|patients with the coronary indication of stable or silent ischemia
89027544|NCT01241136|Placebo Comparator|Open traditional pilonidal cystectomy|traditional complete wide-excision pilonidal cystectomy
89027545|NCT01241136|Experimental|Minimal invasive pilonidal cystotomy|Using only Keyes Trephines to unroof and curette the pilonidal cyst cavity
89027546|NCT00488579|Active Comparator|routine iron prophylaxis|giving 60 mg ferrous sulphate daily (+folic acid)
89027547|NCT00488579|Active Comparator|screening and therapy|doing Hb measurement on each visit, Hb>9g/dl giving only folic acid, Hb<9g/dl giving 60-120 mg of ferrous sulphate daily (+folic acid)
89027548|NCT01303627|Active Comparator|ultiva,remifentanil,opioid,analgesic|Remifentanil:1.5ng/ml remifentanil infusion maintained at the end of the surgery
89027549|NCT01303627|No Intervention|control|Control:Remifentanil stopped at the end of the surgery
89027550|NCT01303510|Experimental|Group A|Adults from 18 to 60 years old inclusive
89027551|NCT01303510|Experimental|Group B|Elderly subjects aged over 60 years
89027552|NCT00488657|Experimental|1|In the ear device to provide altered auditory feedback
89210676|NCT04719741||O-4PI|4 mg Ondansetron given Pre-Induction
88968654|NCT03031873|Other|MRI perfusion imaging|"SWAN imaging on the GE 3 T has been attempted but the preliminary evidence suggest that the images are of low resolution and difficult to interpret. Similarly, early experience with TRMRA suggest poor spatial and temporal resolution using the standard out-of-the-box protocols.~Thus, there is a significant opportunity to improve SWAN and TRMRA, to evaluate the evolution of progressive obliteration of the AVM nidus. Specifically, this is attractive for brain AVMs that are treated with radiosurgery as MRI is required for clinical grounds for treatment planning purposes."
88968655|NCT02902900||Imnovid|Patients relapse/ refractory multiple myeloma who initiated pomalidomide in routine clinical practice
88968656|NCT02892955|Experimental|HeartMate 3 LVAS (HM3 LVAS)|The study was a single-arm, prospective, multi-center, study for continued evaluation of safety and clinical performance of the HM3 LVAS.
88968657|NCT02307253|Experimental|patients with solid lesions|Expect™19Flex needle (Boston Scientific Corp.,Natick,MA,USA)
88968658|NCT04732039|Experimental|LVAD recipients|Peak oxygen uptake vs VO2 measure during specific daily life activities in LVAD recipients
88968659|NCT04732039|Experimental|Healthy controls|Peak oxygen uptake vs VO2 measure during specific daily life activities in healthy controls.
88968660|NCT02179489|No Intervention|Control|surgery alone
88968661|NCT02179489|Experimental|Hipec|Surgery and Hyperthermic Intraperitoneal Chemotherapy with MMC
88968662|NCT00001262|Experimental|Copper histidine|
88968663|NCT02170363|Experimental|HeartMate 3|Left Ventricular Assist System (LVAS) to be used on Subjects with advanced refractory left ventricular heart failure
88968664|NCT00001277|No Intervention|Primary hyperparathyroidism|Patients with confirmed or suspected primary hyperparathyroidism or complications
88968665|NCT00001277|Experimental|DOTATATE and F-DOPA|Patients scanned using imaging agents 68GALLIUM-DOTATATE and 18F-DOPA
88968666|NCT02088190||Age group 1|Age > 60 years old
88968667|NCT02088190||Age group 2|Age < 60 years old
88968668|NCT02069743|Experimental|Intervention|The intervention group will use the study's mobile application during the 8-week study.
88968669|NCT02069743|No Intervention|Control|The control group will not use the study's mobile application during the study.
88968670|NCT00819793|Experimental|CentriMag Ventricular Assist System|All patients meeting the patient selection criteria will be treated with the CentriMag Ventricular Assist System.
88968671|NCT00038350|Experimental|1|8 week lingual strengthening exercise protocol
88968672|NCT00038389|Experimental|Vioxx MTD|
88968673|NCT00038623|Experimental|Yttrium-ibritumomab (Zevalin)|After Rituximab infusion (250 mg/m^2 intravenous) on Day 1, 111^In Zevalin on Day 1 followed by two whole body imaging performed on Day 1 then Day 2.
88968674|NCT00038701|Experimental|Gemzar Chemoradiation + TNP-470|
88968675|NCT00038779|Experimental|Megadose T cell depleted|
88968676|NCT00038818|Experimental|CD8 DLI|CD8 depleted DLI (Depleted Donor Lymphocyte Infusions)
88968677|NCT00017004|Experimental|Arm I|Patients undergo radiotherapy comprising pelvic external beam radiotherapy daily five days a week for 5 weeks, followed by either 1 or 2 implants of low-dose rate intracavitary brachytherapy or 5 fractions of high-dose rate intracavitary brachytherapy, followed by 3-5 days of parametrial boost radiotherapy. Patients receive cisplatin IV concurrently with pelvic external beam radiotherapy on days 1, 8, 15, 22, 29, and once during the week of parametrial boost radiotherapy.
88968678|NCT00017004|Experimental|Arm II|Patients undergo radiotherapy and chemotherapy as in arm I. Additionally, patients receive epoetin alfa subcutaneously once weekly concurrently with radiotherapy and chemotherapy.
88968679|NCT00396994|Experimental|Low magnitude mechanical stimulation|10 minutes per day of low magnitude mechanical stimulation using a vibrating platform set at 0.3 g and 30 Hz
88968680|NCT00396994|Placebo Comparator|2|10 minutes per day standing on sham low mechanical stimulation platform
88968681|NCT00038974|Experimental|Interferon and rivavirin|All patients received peginterferon alfa-2a in a dose of 180 μg weekly and ribavirin in a dose of 1000 (for patients with a body weight of ⩽75 kg) or 1200 mg (for those with a body weight of >75 kg) daily.
88968682|NCT00039013|Experimental|AC2993 5 mcg (0.02 mL)|Placebo, then AC2993 5 mcg, then AC2993 5 mcg
88968683|NCT00039013|Experimental|AC2993 10mcg (0.04 mL)|Placebo, then AC2993 5 mcg, then AC2993 10 mcg
88968684|NCT00039013|Placebo Comparator|Placebo 0.02 mL|Placebo 0.02 mL, then Placebo 0.02 mL, then Placebo 0.02 mL
88968685|NCT00039013|Placebo Comparator|Placebo 0.04 mL|Placebo 0.02 mL, then Placebo 0.02 mL, then Placebo 0.04 mL
89564690|NCT04888325|Experimental|Oral glucose|ORal glucose consumption 1.25 grams/kg in 200 ml water at time 0 and the same amount again at 3 hours
88968686|NCT00039091|Experimental|Treatment (ipilimumab)|Patients receive anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody IV over 90 minutes on day 1. Courses repeat every 2 months in the absence of disease progression or unacceptable toxicity.
88968687|NCT00001304|Experimental|PTH 1-34|All patients received twice daily synthetic Human Parathyroid Hormone 1-34.
88968688|NCT00001304|Experimental|Calcitriol & Calcium|All patients received twice daily Calcitriol and Calcium 1000mg divided into four doses daily.
89210677|NCT04719741||O-8PI|8 mg Ondansetron given Pre-Induction
89210678|NCT04719741||O-4PE|4 mg Ondansetron given Pre-Emergence
89564691|NCT04888325|Experimental|Intravenous glucose|0% intravenous glucose infusion at a rate of 3.6 ml/kg/h
88968689|NCT00017121|Experimental|sargramostim|"Patients receive aerosolized sargramostim (GM-CSF) twice a day on days 1-7 and 15-21. Treatment repeats every 28 days for 2 courses. Patients with no disease progression after completion of course 2 may continue on treatment until disease progression. Patients are grouped to 1 of 2 dose-escalation regimens (part A vs B).~After completion of study therapy, patients are followed at 3 months, every 2 months for 1 year, and then every 3-4 months for 5 years."
88968690|NCT00039286|Experimental|Positron Emission Tomography|Patients receive fludeoxyglucose F 18 IV. Approximately 1 hour later, patients undergo positron emission tomography imaging. Some patients may undergo a repeat scan in 4-6 months.
88968691|NCT00039325|Experimental|Group A - first dose for phase 1|A*0201 positive subjects will receive MART-1 adenovirus-transduced dendritic cells (DC)at dose of 10^6. Subjects will receive a total of three biweekly vaccinations given intradermally. If significant clinical or immunological response (to be defined later) is noted, subjects will be eligible for up to 6 additional monthly vaccine administrations.
89564692|NCT03050723|Other|Princess® FILLER|
89210679|NCT04719741||O-8PE|8 mg Ondansetron given Pre-Emergence
89564693|NCT04888403|Experimental|Toripalimab combined with neoadjuvant radiotherapy and chemotherapy Single arm study|"Induction period:~Toripalimab 240mg administered intravenously (IV) on Day 1 of each 21-day cycle for 1 cycles.~Neoadjuvant radiotherapy after 2W: The radiotherapy dose is 41.4Gy, completed in 23 times, 5 times a week, using intensity-modulated radiotherapy (IMRT) or volume-modulated radiotherapy (VMAT); In the same period, albumin paclitaxel combined with nedaplatin chemotherapy: albumin paclitaxel 60mg/m2 + nedaplatin 25mg/m2, performed once a week, 5 times in total; Simultaneous immunotherapy: 240 mg of Toripalimab (PD-1 antibody), once every 3 weeks, 4 times in total; Received radical resection of esophageal cancer within 7 weeks after radiotherapy and chemotherapy."
89564694|NCT04883567||AI arm|AI would be used to assist the trainee endoscopist
89564695|NCT04883567||Non-AI arm|Trainee endoscopist would perform OGD as usual.
89564696|NCT03050177|Experimental|Gefitinib Tablet 250mg of Hunan Kelun|During the study session, healthy subjects were orally administered a single dose of Gefitinib Tablet 250mg of Hunan Kelun under fed conditions.
89564697|NCT03050177|Active Comparator|Iressa® Tablet 250mg of AZN|During the study session, healthy subjects were orally administered a single dose of Iressa® Tablet 250mg of AZN under fed conditions.
89564698|NCT04882787|Experimental|BTE hearing aid model|BTE or SP-BTE (super power) hearing aid fitting
89564699|NCT03051581|Experimental|18F-FDG PET/CT-based prognostic model of PTCL|The new prognostic model is based on 18F-FDG PET/ CT scans, and combined with clinical and pathological prognostic factors.
89564700|NCT04882865||"healthy volunteers as patients"|"use of the device (AMMP) and the process on 5 healthy volunteers undergoing proning, as well as general care (movement up or down the bed, rotated laterally). As well, repositioning sheets will be used for general care. Surveys of the impressions of team members of the value (ease of use, efficiency, safety, physical demands) of using the AMMP and the repositioning sheets with these patients will be completed.~The impressions of the volunteers as patients will be surveyed, with particular reference to comfort and security during movement"
89564701|NCT04882865||ICU patients severe respiratory failure|patients with severe respiratory failure eligible for prone ventilation will be recruited with surveys provided to team members to gauge their impressions of the value of using the AMMP with the proning process for these patients. Surveys for 40 proning processes will be obtained. Movement from back to stomach or from stomach to back is considered a single process. A single patient may undergo multiple proning processes as prone ventilation is delivered for several days, with multiple healthcare team members participating in their care. We anticipate this will involve 10 patients, and 3 team members to be involved with each proning process.
89564702|NCT04882865||Patients admitted to the ICU|40 patients will have the AMMP used for general care. An additional 40 will have repositioning sheets used for general care. Healthcare team members involved with the care of these patients will be surveyed re their impressions of the value of using the AMMP or the repositioning sheets. We cannot predict the number of healthcare team members involved with the care of each patient s because of clinical conditions and length of stay
89564703|NCT04883021|Experimental|Dual Target Theta Burst Stimulation|The TMS intervention is open-label dual-target theta burst stimulation delivered in sequential fashion to the DLPFC and the MPFC.
89564704|NCT04897685|Experimental|Nature-based treatment group|The participants in the treatment group were offered 12 nature-based group therapy sessions in addition to standard care.
89564705|NCT04897685|No Intervention|Control group|The participants in the control group continued treatment as usual in the health care services.
89564706|NCT03050411|Experimental|Apatinib|Apatinib in combination with EGFR-TKIs
89564707|NCT03050567||Healthy Volunteers|Healthy volunteers with no previous history of cerebrovascular disease and aged over 18 years old.
89564708|NCT03050567||Subjects with symptomatic carotid artery stenosis|Patients with symptomatic cerebrovascular event (stroke, transient ischaemic attack or amaurosis fugax) and image confirmed carotid artery stenosis of >30%. This will include patients scheduled for carotid endarterectomy (>50% for men and >70% for women, by North American Symptomatic Carotid Endarterectomy Trial criteria) or treated conservatively with an optimal medical therapy (if patient declined surgical intervention or is outside surgical criteria for carotid endarterectomy).
89564709|NCT03050645||previous GDM|Women with previous GDM
89564710|NCT03050645||no previous GDM|Women without previous GDM matched on age, pregestational body mass index end time of pregnancy.
89564711|NCT04882943||patients with unexplained or refractory chronic cough|Patients with cough lasting for more than 8 weeks (duration corresponding to the definition of chronic cough)
89564712|NCT04887545||Thoracentesis|Patients who need removal of excess pleural effusion and assessed for the possibility of lung cancer.
89027553|NCT02890654||Teenagers with scoliosis|"Patients will be evaluated at three times during the study :~First time measure : 1 month before the scoliosis surgery~Second time measure : 3 months after the scoliosis surgery~Third time measure : 1 year after the scoliosis surgery"
89210680|NCT04719741||D-4PI|4 mg Dexamethasone given Pre-Induction
89210681|NCT04719741||D-8PI|8 mg Dexamethasone given Pre-Induction
89564713|NCT03050021||Delirium positive|delirium patients in critically ill surgical patients
89564714|NCT03050021||Delirium negative|non delirium patients in critically ill surgical patients
89564715|NCT03049943|Active Comparator|Laser wavelength of 830 nm|This group comprised 15 female patients with hyposalivation whose major salivary glands were treated for 10 consecutive days with low level laser therapy of 830 nm.The whole unstimulated and stimulated saliva was measured each day during 10 days, before and after laser treatment and 10th day after treatment was ended.
89210682|NCT04719741||D-4PE|4 mg Dexamethasone given Pre-Emergence
89210683|NCT04719741||D-8PE|8 mg Dexamethasone given Pre-Emergence
89210684|NCT04719741||O-4PI+D-8PI|4 mg Ondansetron pre-induction+ 8 mg Dexamethasone pre-induction
89210685|NCT04719741||O-4PI+D-8PE|4 mg Ondansetron pre-induction+ 8 mg Dexamethasone pre-emergence
89210686|NCT04719741||O-4PE+D-8PI|4 mg Ondansetron pre-emergence + 8 mg Dexamethasone pre-induction
89210687|NCT04719741||O-4PE+D-8PE|4 mg Ondansetron pre-emergence + 8 mg Dexamethasone pre-emergence
89210688|NCT04719741||Placebo Group|2 ml Saline 0.9%
89564716|NCT03049943|Experimental|Laser wavelength of 685 nm|This group comprised 15 female patients with hyposalivation whose major salivary glands were treated for 10 consecutive days with low level laser therapy of 685 nm.The whole unstimulated and stimulated saliva was measured each day during 10 days, before and after laser treatment and 10th day after treatment was ended.
89564717|NCT04896905||Isolation group with active Covid19|Patients assigned to rehab which had to be treated in isolation wards dur to active disease
89564718|NCT04896905||Post-Covid-group|Patients assigned to rehab after active disease, still having restrictions in activity and particiaption
89564719|NCT04896905||Control group|Pateints assigned to rehabilitation in the same time period without any signs of Sars-coV-2 infection
89564720|NCT03049709||cardiovascular disease|patients with cardiovascular disease, invasive and non-invasive determination of central blood pressure
89564721|NCT03049709||healthy controls|healthy controls, invasive and non-invasive determination of central blood pressure
89564722|NCT04887233|Experimental|Longan nasal spray|The patients will be received 2 puff of Longan nasal spray 2 times/day for 3 days.
89564723|NCT04887233|Placebo Comparator|Placebo nasal spray|The patients will be received 2 puff of placebo nasal spray 2 times/day for 3 days.
89564724|NCT04887311|Experimental|Cohort 1|"Group 1 Patients ≥13 years old will receive a total daily dose of 1200 mg/day.~Group 2 - Group 4~Patients 4-12 years old will receive group weight-tiered doses at 17 mg/kg:~Group 2~Patients aged 4-12 years weighing 15kg to <25 kg will take 340 mg/day. Group 3~Patients aged 4-12 years weighing 25kg to <35 kg will take 510 mg/day. Group 4~Patients aged 4-12 years weighing ≥35 kg will take 850 mg/day."
89564725|NCT03050255|Experimental|ESWT order 1|"Subject performs endurance shuttle walk tests (ESWT) under following conditions in the following order:~medical air (MA)~Oxygen (2 Liter/min)~Oxygen (4 Liter/min)"
89564726|NCT03050255|Experimental|ESWT order 2|"Subject performs endurance shuttle walk tests (ESWT) under following conditions in the following order:~medical air (MA)~Oxygen (4 Liter/min)~Oxygen (2 Liter/min)"
89564727|NCT03050255|Experimental|ESWT order 3|"Subject performs endurance shuttle walk tests (ESWT) under following conditions in the following order:~Oxygen (2 Liter/min)~Medical air (MA)~Oxygen (4 Liter/min)"
89564728|NCT03050255|Experimental|ESWT order 4|"Subject performs endurance shuttle walk tests (ESWT) under following conditions in the following order:~Oxygen (2 Liter/min)~Oxygen (4 Liter/min)~Medical air (MA)"
89564729|NCT03050255|Experimental|ESWT order 5|"Subject performs endurance shuttle walk tests (ESWT) under following conditions in the following order:~Oxygen (4 Liter/min)~Medical air (MA)~Oxygen (2 Liter/min)"
89564730|NCT03050255|Experimental|ESWT order 6|"Subject performs endurance shuttle walk tests (ESWT) under following conditions in the following order:~Oxygen (4 Liter/min)~Oxygen (2 Liter/min)~Medical air (MA)"
89564731|NCT04886921|Experimental|TRAM abdominal muscle training group|"Patients were recruited at least 6 months after the muscle-sparing (MS) pedicled Transverse rectus abdominis musculocutaneous (TRAM) flap procedure and at least 1 month after the conclusion of the last chemotherapy course, if any.~All subjects will receive 1-hr training sessions consisting of core stability exercises for 12 weeks for the TRAM group."
89564732|NCT04886921|No Intervention|TRAM control group|"Patients were recruited at least 6 months after the muscle-sparing (MS) pedicled Transverse rectus abdominis musculocutaneous (TRAM) flap procedure and at least 1 month after the conclusion of the last chemotherapy course, if any.~The control group was not received any exercise program."
89564733|NCT04886921|No Intervention|Healthy women group|A control group comprising female volunteers who were apparently healthy and had comparable socioeconomic backgrounds and physical conditions was recruited by convenience sampling from communities.
89564734|NCT04886843|Active Comparator|Cold Therapy|The patients have seated the knee joints in full extension and both ankle joints in a neutral position. Neuromuscular electrical stimulation (NMES) was applied to the non-affected side ankle dorsiflexors for five days, five sessions for a week. In addition to this application, a cold pack was applied on the affected side dorsiflexor muscle skin. The cold pack was applied on a moist towel for five minutes. A five-minute break was given and a further 5-minute cold application was repeated. The cold application was done simultaneously with NMES.
89564735|NCT04886843|Placebo Comparator|Control|The patients have seated the knee joints in full extension and both ankle joints in a neutral position. Neuromuscular electrical stimulation (NMES) was applied to the non-affected side ankle dorsiflexors for five days, five sessions for a week.
89564736|NCT03049631|Active Comparator|Raspberry and fructooligosaccharide|Red raspberries (1 cup equivalent) with fructooligosaccharide (8 g)
89564737|NCT03049631|Experimental|Raspberry|Red raspberries (1 cup equivalent)
89027554|NCT02890576||telemedicine|Setting up of a new organization of medical monitoring (ussing telemedicine) of patient having a cochlear implant
89564738|NCT04886765|Experimental|ALMB-0168|"Dose Escalation Cohort ：The accelerated titration and traditional 3+3 design will be used in the dose-escalation phase. Seven dose cohorts will be evaluated. ALMB-0168 will be administered intravenously once every 3 weeks until either the disease progresses or intolerable toxicity occurs.~Dose Expansion Cohort: Based on the results of Part I, 1-3 dose expansion cohorts will be started to further evaluate the safety and efficacy of ALMB-0168."
89564739|NCT04896671|Experimental|Intervention group|Each participant joins a total of 12 treadmill running sessions, two sessions per week and each session for 30 minutes.
89564740|NCT04896671|No Intervention|Waitlist control group|They receive no treatments.
89564741|NCT04396847|Experimental|Lorcaserin first, then placebo|Participants first receive lorcaserin (10 mg BID) for 7 days. After a washout period of 7 days, they then receive placebo tablets (BID) for 7 days.
89564742|NCT04396847|Placebo Comparator|Placebo first, then lorcaserin|Participants first receive placebo (BID) for 7 days. After a washout period of 7 days, they then receive lorcaserin (10 mg BID) for 7 days.
89564743|NCT03051503|Active Comparator|The Transdermal Therapeutic System-Fentanyl (TTS-F) group|(TTS-F) group (n=30) 50ug/h patch, placed 12 hs preoperatively.
89564744|NCT03051503|Placebo Comparator|Intravenous patient-controlled analgesia (PCA) morphine|IV (PCA) morphine for pain in the postoperative period.
89564745|NCT04886375|Active Comparator|esp group|The investigators performed erector spina plane block to that patient group for postoperative analgesia
89564746|NCT04886375|Active Comparator|pecs group|The investigators performed modified pectoral nerve block to that patient group for postoperative analgesia
89027555|NCT01241175|Experimental|magnesium sulfate|
89564747|NCT04882709|Active Comparator|Receiver-in-canal hearing aid 1 default|Receiver-in-canal hearing aid with current default compression strategy
89564748|NCT04882709|Active Comparator|Receiver-in-canal hearing aid 2|Receiver-in-canal hearing aid from a different manufacturer with default compression strategy
89564749|NCT04882709|Experimental|Receiver-in-canal hearing aid 1 strategy 1|Receiver-in-canal hearing aid with modified compression strategy 1
89564750|NCT04882709|Experimental|Receiver-in-canal hearing aid 1 strategy 2|Receiver-in-canal hearing aid with modified compression strategy 2
89564751|NCT04882709|No Intervention|No device|Stimuli recordings without hearing aid
89564752|NCT04896359|Experimental|Vitamin C|i.v. infusion of 12.5 g vitamin C 48 h before surgery, immediately before surgery, and 48 h after surgery
89564753|NCT04896359|Placebo Comparator|Control|i.v. infusion of placebo 48 h before surgery, immediately before surgery, and 48 h after surgery
89564754|NCT04896203||Group 1|Ulcerative Colitis or Crohn's Disease patients, in remission according to inclusion criteria
89564755|NCT04896203||Group 2|Ulcerative Colitis or Crohn's Disease patients, with activity defined by the inclusion criteria
89564756|NCT04895891|Experimental|EOS imaging|For each patient, EOS images are compared with computed tomography [CT] images
89564757|NCT04896125||Lumigan PF|Patients older than 20 years were recruited from the Glaucoma Clinic of National Taiwan University Hospital. Patients were considered eligible for enrolment if they were newly diagnosed with glaucoma and started to receive ocular hypotensive eye drops at our clinic. Eligible patients then received 0.03% bimatoprost (preservative-free) (Lumigan PF, Allergan Inc., CA, USA).
89027556|NCT01241175|Placebo Comparator|normal saline|
89033078|NCT02944526|Experimental|Ropivacaine Suprascapular Nerve Block|"Suprascapular nerve block realized in sterile conditions under live ultrasound guidance: injection of 5ml of Ropivacaine monohydrochloride 2mg/ml.~3 successive blocks are realized at 1 week interval."
89033079|NCT02944526|Placebo Comparator|Placebo Suprascapular Nerve Block|"Suprascapular nerve block realized in sterile conditions under live ultrasound guidance: injection of 5ml of physiological /isotonic saline.~3 successive blocks are realized at 1 week interval."
89564758|NCT04896125||Xalatan|Patients older than 20 years were recruited from the Glaucoma Clinic of National Taiwan University Hospital. Patients were considered eligible for enrolment if they were newly diagnosed with glaucoma and started to receive ocular hypotensive eye drops at our clinic. Eligible patients then received 0.005% latanoprost (containing 0.02% BAK as a preservative) (Xalatan, Pfizer, NY, USA).
89564759|NCT04896125||Control|Patients older than 20 years were recruited from the Glaucoma Clinic of National Taiwan University Hospital. Patients were not diagnosed with glaucoma.
89564760|NCT03049319|Experimental|Laser|All six interventions will be applied to patient's back.
89564761|NCT04895657|Other|Piperacillin/Tazobactam Intermittent infusion|4.5 gm Piperacillin/Tazobactam I.V intermittent over 30 min. every 8 hours.
89564762|NCT04895657|Other|Piperacillin/Tazobactam Continuous infusion|4.5 gm Piperacillin/Tazobactam I.V extended infusion over 4 hours every 8 hours.
89564763|NCT04885673|Active Comparator|Group A (High flow nasal cannula group)|(Vapotherm) will be used during the bronchoscopy time flow rate 50 L/min with 100% humidified oxygen and the temperature adjusted to be 38℃
89564764|NCT04885673|Active Comparator|Group B (Apeieoc oxygenation group)|The standard apneic oxygenation through the side port of rigid bronchoscope during the procedure
89564765|NCT04895423|Experimental|Group №1: Methotrexate therapy|
89564766|NCT04895423|Experimental|Group №2: Mycophenolate mofetil therapy|
89564767|NCT04895423|Experimental|Group №3: Cyclosporine therapy|
89564768|NCT04895423|Experimental|Group №4: Dupilumab therapy|
89033080|NCT04013763|Experimental|Atopic dermatitis with stop using product|case wheat allergy with atopic dermatitis and stop using wheat containing skin care products
89033081|NCT04013763|Experimental|Atopic dermatitis with containing using product|case wheat allergy with atopic dermatitis and continue using wheat containing skin care products
89564769|NCT03051425|Experimental|Test group|Probiotic yogurt supplementation
89564770|NCT03051425|Placebo Comparator|Placebo group|Placebo supplementation
89564771|NCT03050099||Mild ACVS-definite|Clinical diagnosis of ACVS, and imaging positive (either DWI+ or CT/CTA+).
89564772|NCT03050099||Mild ACVS-possible|Clinical diagnosis of ACVS, and DWI- and/or CTA-
89564773|NCT03050099||Mimic|Clinical diagnosis of mimic and imaging negative.
89564774|NCT04882163|Experimental|CC-220 + Polatuzumab vedotin + rituximab- Cohort A|Subjects with Relapsed or refractory (R/R) Aggressive B-cell lymphoma (a-BCL) will receive CC-220 at a dose specified by cohort dose level in combination with polatuzumab vedotin plus rituximab.
89564775|NCT04882163|Experimental|CC-220 + Tafasitamab- Cohort B|Subjects with R/R a-BCL will receive CC-220 at a dose specified by cohort dose level in combination with tafasitamab.
89564776|NCT04882163|Experimental|CC-220 + Rituximab + Chemo (Cohort C)|Subjects with R/R a-BCL will receive CC-220 at a dose specified by cohort dose level in combination with rituximab plus chemotherapy (Gemcitabine, cisplatin, dexamethasone).
89564777|NCT04882163|Experimental|CC-220 + Pola + Ritux vs Pola + Benda + Ritux (Cohort D)|Subjects will be randomized to receive either CC-220 + Pola (polatuzumab vedotin) + Ritux (rituximab) or polatuzumab vedotin + bendamustine + rituximab in 21-day treatment cycles. CC-220 will be given at the RP2D declared in Part 1 of this study. Polatuzumab vedotin and rituximab will be administered at the same levels as in part 1. Bendamustine will be given to subjects randomized in the control arm at a dose of 90 mg/m2 IV on Days 1 and 2 of each of the first 6 cycles.
89564778|NCT04882163|Experimental|CC-220 + tafasitamab vs Lenalidomide + Tafasitamab- Cohort E|Subjects will be randomized to receive either CC-220 + tafasitamab or lenalidomide + tafasitamab in 28-day treatment cycles. CC-220 will be given at the RP2D declared in Part 1 of this study and the tafasitamab will be at the same levels as in Part 1. Lenalidomide will be administered to subjects randomized in the control arm at a dose of 25 mg/day orally, for 21 days out of 28, for up to 12 cycles.
89564779|NCT04882163|Experimental|CC-220 + Rituximab + Chemo vs Rituximab + Chemo (Cohort F)|Subjects will be randomized to receive either CC-220 + rituximab + chemotherapy (Gemcitabine, Cisplatin, Dexamethasone) or rituximab + chemotherapy (Gemcitabine, Cisplatin, Dexamethasone) in 21-day treatment cycles. CC-220 will be administered at the RP2D declared in Part 1 of this study and the combination medicines will be at the same levels as in part 1.
89564780|NCT04882007|Experimental|OSE-127 High dose induction phase|OSE-127 mAb antagonist to CD127 receptor (or IL-7Rα) intravenous infusion 3 total infusions, weeks 0, 2, and 6
89564781|NCT04882007|Experimental|OSE-127 Low dose induction phase|OSE-127 mAb antagonist to CD127 receptor (or IL-7Rα) intravenous infusion 3 total infusions, weeks 0, 2, and 6
89564782|NCT04882007|Placebo Comparator|Placebo induction phase|Normal saline intravenous infusion 3 total infusions, weeks 0, 2, and 6
89564783|NCT04882007|Experimental|OSE-127 High dose optional extension phase|OSE-127 mAb antagonist to CD127 receptor (or IL-7Rα) intravenous infusion 7 total infusions, weeks 10, 14, 18, 22, 26, 30, and 34
89564784|NCT04885751|Experimental|eupatilin|take eupatilin to prevent NSAID induced gastroenteropathy
89210689|NCT04085861|Experimental|Dancers|Recruited group of professional dancers from the Norwegian University of dance
89564785|NCT04885751|Active Comparator|rebamipide|take rebamipide to prevent NSAID induced gastroenteropathy
89033082|NCT04013763|Experimental|Non atopic dermatitis with stop using product|case wheat allergy with normal skin and stop using wheat containing skin care products
89564786|NCT03051347|Other|Itch Questionnaire and Interview|Up to 30 dyads of patients ages 8-17 and their parents/caregivers, as well as up to 20 parents of children ages 6mo-7 years, will participate in semi-structured interviews to evaluate the new and modified items (questions) written for the PIQ-C questionnaire
89564787|NCT03051347|Other|Stigma Questionnaire and Interview|To assess stigma, up to 20 children ages 8-17 and 20 parents of children ages 5-12, will participate in semi-structured interviews to evaluate the modified Neuro-QoL stigma questionnaire. This questionnaire includes new skin-specific stigma items and existing items modified for use with children having a skin or other condition that may negatively affect their appearance
89564788|NCT03051347|Other|Validation Questionnaire and Interview-Moderate to Severe|For validation, up to 200 parent/child dyads ages 5-17 with a diagnosis of moderate to severe AD during the previous 6 months will participate in teledermatology or in-person semi-structured interviews as follow-up to validate PRO measures in a large cohort of itch-specific pediatric skin conditions, specifically AD. Furthermore, this portion of the study will validate generic PROMIS measures of AD subjects' environmental stressors, illness flares, socio-demographic differences based on race/ethnicity and family income status.
89564789|NCT03051347|Other|Validation Questionnaire and Interview-Mild|For validation, up to 90 parent/child dyads ages 0-17 with a diagnosis of mild AD will participate in teledermatology or in-person semi-structured interviews as follow-up to validate PRO measures in a large cohort of itch-specific pediatric skin conditions, specifically AD. Furthermore, this portion of the study will validate generic PROMIS measures of AD subjects' environmental stressors, illness flares, socio-demographic differences based on race/ethnicity and family income status for mild patients.
89564790|NCT04885517|Experimental|Spontaneous breathing, Venturi Mask FiO2 0.5, seated decubitus|Patient will be evaluated after 20 minutes of spontaneous breathing, with FiO2 0.5 (Venturi Mask), during seated decubitus. Respiratory, haemodynamics, and data on blood gas analysis will be obtained.
89564791|NCT04885517|Experimental|Spontaneous breathing, Non Rebreathing Mask, seated decubitus|Patient will be evaluated after 20 minutes of spontaneous breathing, with FiO2 1 (Non Rebreathing Mask), during seated decubitus. Respiratory, haemodynamics, and data on blood gas analysis will be obtained.
89564792|NCT04885517|Experimental|Continuous Positive Airway Pressure (CPAP) 7 cmH2O, FiO2 0.5, seated decubitus|Patient will be evaluated after 20 minutes of CPAP (7 cmH2O), with FiO2 0.5, during seated decubitus. Respiratory, haemodynamics, and data on blood gas analysis will be obtained.
89564793|NCT04885517|Experimental|Continuous Positive Airway Pressure (CPAP) 7 cmH2O, FiO2 0.5, supine decubitus|Patient will be evaluated after 20 minutes of CPAP (7 cmH2O), with FiO2 0.5, during supine decubitus. Respiratory, haemodynamics, and data on blood gas analysis will be obtained.
89564794|NCT04885517|Experimental|Continuous Positive Airway Pressure (CPAP) 7 cmH2O, FiO2 0.5, prone decubitus|Patient will be evaluated after 20 minutes of CPAP (7 cmH2O), with FiO2 0.5, during prone decubitus. Respiratory, haemodynamics, and data on blood gas analysis will be obtained.
89564795|NCT04885517|Experimental|Continuous Positive Airway Pressure (CPAP) 7 cmH2O, FiO2 1, seated decubitus|Patient will be evaluated after 20 minutes of CPAP (7 cmH2O), with FiO2 1.0, during seated decubitus. Respiratory, haemodynamics, and data on blood gas analysis will be obtained.
89564796|NCT04885517|Experimental|Continuous Positive Airway Pressure (CPAP) 12 cmH2O, FiO2 0.5, seated decubitus|Patient will be evaluated after 20 minutes of CPAP (12 cmH2O), with FiO2 0.5, during seated decubitus. Respiratory, haemodynamics, and data on blood gas analysis will be obtained.
89564797|NCT04885517|Experimental|Continuous Positive Airway Pressure (CPAP) 12 cmH2O, FiO2 1, seated decubitus|Patient will be evaluated after 20 minutes of CPAP (7 cmH2O), with FiO2 1.0, during seated decubitus. Respiratory, haemodynamics, and data on blood gas analysis will be obtained.
88968692|NCT00039325|Experimental|Arm B - dose increase for phase 1|A*0201 positive subjects will receive MART-1 adenovirus-transduced dendritic cells (DC)at dose of 10^7. Subjects will receive a total of three biweekly vaccinations given intradermally. If significant clinical or immunological response (to be defined later) is noted, subjects will be eligible for up to 6 additional monthly vaccine administrations.
88968693|NCT00039325|Experimental|Arm C - A*0201+/DR*04+ subjects - Phase II|Subjects will receive MART-1 adenovirus-transduced dendritic cells (DC)at dose of 10^7. Subjects will receive a total of three biweekly vaccinations given intradermally. If significant clinical or immunological response (to be defined later) is noted, subjects will be eligible for up to 6 additional monthly vaccine administrations.
88968694|NCT00039325|Experimental|Arm D - A*0201+/DR*04- - phase 2|Subjects will receive MART-1 adenovirus-transduced dendritic cells (DC)at dose of 10^7. Subjects will receive a total of three biweekly vaccinations given intradermally. If significant clinical or immunological response (to be defined later) is noted, subjects will be eligible for up to 6 additional monthly vaccine administrations.
88968695|NCT00039325|Experimental|Arm E - A*0201-/DR*04+ - phase 2|Subjects will receive MART-1 adenovirus-transduced dendritic cells (DC)at dose of 10^7. Subjects will receive a total of three biweekly vaccinations given intradermally. If significant clinical or immunological response (to be defined later) is noted, subjects will be eligible for up to 6 additional monthly vaccine administrations.
88968696|NCT00039403|Experimental|Treatment (UCN-01, gemcitabine hydrochloride)|"Patients receive gemcitabine IV over 1-2 hours on days 1 and 8 followed by UCN-01 IV over 3 hours on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.~Sequential dose escalation of UCN-01 is followed by sequential dose escalation of gemcitabine. Cohorts of 3-6 patients receive escalating doses of UCN-01 and then gemcitabine until the maximum tolerated dose (MTD) of the combination is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, at least 6 patients are treated at the recommended phase II dose."
88968697|NCT00039442|Experimental|Treatment|Patients receive oral capecitabine twice daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
88968698|NCT00039481|Experimental|Treatment (Oblimersen sodium, cytotoxic chemotherapy)|See detailed description.
88968699|NCT00001322|Experimental|Phase 1 - Lupron|Eight to 12 weeks of GnRH agonist treatment 3.75 mg given intramuscularly monthly.
89210690|NCT04085861|No Intervention|Control|Recruited group of professional art students from the Oslo Academy of the Arts (Norway)
89564798|NCT03051191||1: No ACVD/NIHF or cancers|The patients who do not have ACVD, NIHF or cancers
89564799|NCT03051191||2: Cancers but no ACVD/NIHF|The patients who have cancers but no ACVD/NIHF
89564800|NCT03051191||3: ACVD and cancers|The patients who have ACVD and cancers
89564801|NCT03051191||4: ACVD but no cancers|The patients who have ACVD but no cancers
89564802|NCT03051191||5: NIHF and cancers|The patients who have NIHF and cancers
89564803|NCT03051191||6: NIHF but no cancers|The patients who have NIHF but no cancers
89210691|NCT04085861|Experimental|Dance teachers|Recruited group of dance teachers from the Norwegian University of dance
89564804|NCT04895345|Experimental|TQB2450+Intensity modulated radiotherapy|TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day；The total dose of radiotherapy should meet PTVnx: 60Gy/27Fr/2.22Gy, PTVnd: 60-64Gy/27Fr/2.22-2.37Gy, PTV1: 54Gy/27Fr/2.00Gy, once a day, 5 times/week.
89564805|NCT04885361|Experimental|Arm 1 injection|The dose of 1 ml will be administered subcutaneously, preferably into deltoid region of the non-dominant arm.
89564806|NCT04885361|Experimental|Arm 2 injections separated by 21 days|The dose of 1 ml will be administered subcutaneously, preferably into deltoid region of the non-dominant arm.
89564807|NCT03049163|Other|vitrectomy under retrobulbar anesthesia|27-gauge vitrectomy for vitreous floaters under traditional retrobulbar anesthesia
89564808|NCT03049163|Experimental|vitrectomy under topical anesthesia|27-gauge vitrectomy for vitreous floaters under topical anesthesia
89564809|NCT04894955|Experimental|Main study group|
89564810|NCT04881695||Patients|Women aged 18-26 years with congenital (Turner syndrome or other determined or undetermined genetic cause) or acquired (post-therapeutic)
89564811|NCT04881695||Controls|Women aged 18-26 years who do not have a condition that compromises their fertility
89564812|NCT04885439|Experimental|NextSteps Intervention|Patients and caregivers will each receive their own tailored manual and six weekly 45-minute telephone calls that correspond to the manual, delivered by a Masters level trained interventionist.
89564813|NCT04885439|No Intervention|Usual Medical Care|UMC consists of standard oncologic care for the patient from the point of diagnosis of advanced cancer.
89564814|NCT04410809|Placebo Comparator|Placebo|The same composition as the active medication but without the active substance TA-46
89564815|NCT04410809|Experimental|TA-46|Decoy protein of the fibroblast growth factor receptor 3
89564816|NCT04894565|Experimental|intervention|effect of rehabilitation program in the intervention arm
89564817|NCT04881851|Experimental|Inositol + alpha lipoic acid|Inositol 1000 mg + alpha lipoic acid 400 mg + folic acid 200 ug: 1 sachet at breakfast and 1 sachet at dinner
89564818|NCT04881851|Experimental|Inositol|Inositol 1000 mg + folic acid 200 ug: 1 sachet at breakfast and 1 sachet at dinner
89564819|NCT04881851|Placebo Comparator|Folic acid|Folic acid 200 ug: 1 sachet at breakfast and 1 sachet at dinner
89564820|NCT04872335|Experimental|Gong's Mobilization|Subjects received gong's mobilization three times in a week for 4 weeks.
89564821|NCT04872335|Experimental|Gradually Graded Exercise Therapy|Subjects received gradually graded exercise therapy three times in a week for 4 weeks.
89564822|NCT03048929|Active Comparator|Typhoid Vi Polysaccharide Vaccine|Patients will receive one intramuscular 0.5 mL injection of Typhoid Vi Polysaccharide Vaccine containing 0.025 mg purified Vi polysaccharide.
89564823|NCT03048929|Placebo Comparator|Placebo|Patients will receive one intramuscular 0.5 mL injection of saline placebo.
89564824|NCT04871789||Patients with severe COVID-19 pneumonia|
89564825|NCT04871789||Patients who had an asymptomatic COVID-19 3 months ago|
89564826|NCT04871789||People who had close contact with patients with confirmed COVID-19 3 months ago but did not get sick|
89564827|NCT04881305||Cases|Adults recovered from COVID-19 (diagnosed using RT-PCR), 3-8 months after the onset of the acute stage of the disease, with cognitive/emotional complaints.
89564828|NCT04881305||Controls|Adults recovered from COVID-19 (diagnosed using RT-PCR), 3-8 months after the onset of the acute stage of the disease, reporting no cognitive/emotional complaints.
89564829|NCT04871633|Active Comparator|Remdesivir|patients having drug Remdesivir in addition to conventional treatment according to disease grade (steroids, anticoagulants, antibiotics if needed, oxygen therapy, paracetamol, antihistamine)
89564830|NCT04871633|Other|Conventional|patients having Standard Conventional therapy only.
89564831|NCT04880915|Experimental|SMOKE PROTECTION|Pre- and post-operative blood and urine samples of the surgical team (surgeon, surgical resident, anaesthesiologist, scrub nurse, circulating nurse, support staff and researcher), who worked in the standard practice, and the use of four different preventive measures that may affect the surgical smoke exposure during total mastectomy surgery in the operating room of the General Surgery Department of a University HospitaL. The surgical resident, anaesthesiologist, anaesthesia technician and support staff included in the study did not consist of the same people due to the change in the work schedules. Blood and urine samples were collected from a team of seven people before and after surgery [7 volunteers × 2 (blood and urine before and after surgery) = 14 (14 blood analysis + 14 urine analysis) 14 × 5 surgery = 70 (70 blood analysis + 70 urine analysis)].
89564832|NCT04880993|Experimental|Test Product|Manufactured by Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Drug: Dapagliflozin 10 mg tablets A single 10 mg dose (1 tablet) of the assigned drug product will be administered according to the randomization scheme with 240±5 mL of room temperature potable water.
89564833|NCT04880993|Active Comparator|Reference Product|Manufactured by AstraZeneca Pharmaceuticals LP Drug: Farxiga® 10 mg tablets A single 10 mg dose (1 tablet) of the assigned drug product will be administered according to the randomization scheme with 240±5 mL of room temperature potable water.
89564834|NCT04871555||mesio-temporal epilepsy|patients suffering from mesiotemporal epilepsy type
89564835|NCT04871555||basal temporal epilepsy|patients suffering from basal temporal epilepsy type
89564836|NCT04871555||temporal lateral epilepsy|patients suffering from temporal lateral epilepsy type
89564837|NCT04871555||operculo insular epilepsy|patients suffering from operculo insular epilepsy type
89564838|NCT04871555||temporo-insular epilepsy|patients suffering from temporo- insular epilepsy type
89564839|NCT04871555||healthy subjects|non epileptic patients
89564840|NCT04430231||Wait list time 0-2 weeks|Wait list time 0-2 weeks
89564841|NCT04430231||Wait list time 2-4 weeks|Wait list time 2-4 weeks
89564842|NCT04430231||Wait list time 4-6 weeks|Wait list time 4-6 weeks
89564843|NCT04430231||Wait list time > 6 weeks|Wait list time > 6 weeks
89564844|NCT04936997|Experimental|3rd COVID-19 vaccine (2nd booster)|Patients who were a part of the non-interventional portion of the study are eligible to receive a third COVID-19 Pfizer vaccine.
88968700|NCT00001322|Experimental|Phase 2, Arm 1 - Estradiol, then progesterone|12 weeks of GnRH agonist treatment 3.75 mg given intramuscularly monthly. Additionally, 4 weeks of transdermal Estradiol (100mcg/day by skin patch) and placebo suppositories. Week 5 involves 100mcg/day transdermal Estradiol and active Progesterone suppositories (200mg vaginally twice/day). Followed by 1-2 weeks (weeks 6-7) washout period. Then crossover to 5 weeks (week 8-12) of Progesterone suppositories (200mg vaginally twice/day) and placebo patches.
88968701|NCT00001322|Experimental|Phase 2, Arm 2 - Progesterone, then estradiol|12 weeks of GnRH agonist treatment 3.75 mg given intramuscularly monthly. Additionally, 5 weeks of Progesterone suppositories (200mg vaginally twice/day) and placebo patches. Followed by 1-2 weeks (weeks 6-7) washout period. Then crossover to 4 weeks (weeks 8-11) of transdermal Estradiol (100mcg/day by skin patch) and placebo suppositories. Week 12 involves 100mcg/day transdermal Estradiol and active Progesterone suppositories (200mg vaginally twice/day).
88968702|NCT00039559|Other|Early detection|
88968703|NCT00039832|Experimental|1|CT
88968704|NCT00039832|Experimental|2|MRI
88968705|NCT00039988|Experimental|1|Participants will receive Copaxone and albuterol placebo
88968706|NCT00039988|Experimental|2|Participants will receive Copaxone and albuterol
88968707|NCT00040105|Experimental|Zarnestra + Gleevec|
89564845|NCT04880525|Experimental|Study Group|The study group does reformer pilates for 45 minutes 3 days a week. The intensity of the workouts was gradually increased. Warm-up (10 minutes), main Pilates training activity (25 minutes), and cool-down (10 minutes) were the three parts of each session (10 minutes). In addition to pilates, the women in the SG followed a personalized weight loss diet. In accordance with Turkey Dietary Guidelines, these diet plans were designed to provide 45-60% of energy from carbohydrates, 10-20% from protein, and 20-35 percent from fat.
89564846|NCT04880525|No Intervention|Control Group|The control group does reformer pilates for 45 minutes 3 days a week. The intensity of the workouts was gradually increased. Warm-up (10 minutes), main Pilates training activity (25 minutes), and cool-down (10 minutes) were the three parts of each session (10 minutes). Individuals in the CG received no dietary or nutritional intervention. On any diet, the status of women in the CG was frequently questioned.
88968708|NCT04734249|Experimental|Advanced CRC|Patients with Advanced CRC were given Surufatinib Combined With Chemotherapy
88968709|NCT04734171|Placebo Comparator|Informational sheet (IS)|participant receives an informational sheet about COVID-19
88968710|NCT04734171|Active Comparator|IS + Video Solo|participants an informational sheet about COVID-19 and a 90 seconds video aimed at sensitizing participants to COVID-19 related stigma
89210692|NCT00628862|Experimental|F 4.5 bid|Formoterol 4.5 ug twice daily (bid)
89564847|NCT04880369|Experimental|Lignan capsule|1 capsule/day from baseline to end-of-follow-up (approx. 4 months)
89564848|NCT04880369|Experimental|Isoflavones capsule|1 capsule/day from baseline to end-of-follow-up (approx. 4 months)
89564849|NCT04880369|Placebo Comparator|Placebo capsule|1 capsule/day from baseline to end-of-follow-up (approx. 4 months)
89564850|NCT04870931||TEM-Group|All patients that underwent TEM
89564851|NCT04870931||TEM-ESD-Group|All patients that underwent TEM-ESD
89564852|NCT04879901|Experimental|Experimental group|Group measuring shoulder muscle activities by surface EMG with carrying backpacks forward
89564853|NCT04738175|Experimental|COVI-AMG|40 mg, 100 mg, or 200 mg of COVI-AMG will be administered
89564854|NCT04738175|Placebo Comparator|Placebo|Placebo will be administered
89564855|NCT03046979|Experimental|Apatinib|a molecular targeted anti-tumor drugs. Small molecule vascular endothelial growth factor receptor 2 inhibitor.
89564856|NCT04711187|Experimental|AT-527 Formulation 1 Dose 1|
89564857|NCT04711187|Experimental|AT-527 Formulation 2 Dose 1|
89564858|NCT04711187|Experimental|AT-527 Formulation 2 Dose 2|
89564859|NCT04711187|Experimental|AT-527 Formulation 1 Dose 3|
89564860|NCT04711187|Experimental|AT-527 Formulation 2 Dose 3|
89564861|NCT04711187|Experimental|AT-527 Formulation 2 Dose 1 Fast/Fed|
89564862|NCT04711187|Experimental|AT-527 Formulation 2 Dose 3 Fast/Fed|
89564863|NCT04676399|Experimental|Hydrochlorothiazide Pill (12.5 mg twice a day)|"Planned use in this study~Condition/disease indication(s): Hypertension~Subject population: Chronic pain~Dose(s): 12.5 mg twice per day for 14 days.~Administration: Oral~Dosing regimen: 12.5 mg twice per day"
89564864|NCT04676399|Placebo Comparator|Placebo|"Has no active ingredients but is made to look like the study drug.~2 pills/day for 14 days."
89564865|NCT04880213|Experimental|Japanese: M5049 Dose A (low dose)|
89564866|NCT04880213|Experimental|Japanese: M5049 Dose B (medium dose)|
89564867|NCT04880213|Experimental|Japanese: M5049 Dose C (high dose)|
89564868|NCT04880213|Experimental|Caucasian: M5049 Dose A (low dose)|
89564869|NCT04880213|Experimental|Caucasian: M5049 Dose B (medium dose)|
89564870|NCT04880213|Experimental|Caucasian: M5049 Dose C (high dose)|
89564871|NCT03047057|Experimental|Lidocaine|IV Lidocaine infusion
89564872|NCT03047057|Placebo Comparator|Control|IV normal saline infusion
89564873|NCT04630847|Experimental|Autism Subjects|These subjects will be administered fecal microbiota transplant by colonoscopy
89564874|NCT04430309|Experimental|Baduanjin exercise group|"The intervention group will practice Badunjin in a group which include 6-8 participants and one trained medical staff. The Baduanjin is an ancient Chinese mind-body exercise, which comprised of eight simple movements.~The sessions will take place twice a week, 60 minutes per session for a total duration of 12 weeks"
89564875|NCT04430309|Active Comparator|Control group|The control group will receive brisk walking activities. The sessions will take place twice a week, 60 minutes per session for a total duration of 12 weeks
89564876|NCT04567979||Patients with solid tumors|Patients with solid tumors under chemotherapy and / or radiotherapy treatment at our center.
89564877|NCT04567979||Healthcare workers|Healthcare workers at the chemotherapy and radiotherapy unit in our center.
89564878|NCT04880135|Experimental|Supervised stretching and strengthening exercise|Stretching and strengthening exercises will be performed under the supervision of Physical therapist for a period of one month
89564879|NCT04880135|Experimental|Home-based stretching and strengthening exercises|Stretching and strengthening exercises will be performed at home by individuals having musculoskeletal pain due to quarantine for a period of one month.
89564880|NCT04879667|No Intervention|group (1)|surgical management of gastrocutaneous fistula after laparoscopic sleeve gatrectomy by surgical exploration
89564881|NCT04879667|Active Comparator|group (2)|we performed upper GI endoscopy to all cases first to assess the site , size and cause of fistula . we used stents , clips , sutures and ballon dilatation to close the fistula according to size , site and cause of fistula.if the fistula had no track that was proved by CT with oral & I.V contrast , we used the endoscopic stent. if the fistula had track that was proved by CT with oral & I.V contrast , we used the OVASCO clip , endo suturing or ballon. Combined maneuvers may be used like ballon dilation and clipping or ballon dilatation and suturing if there was distal narrowing.
89564882|NCT04550195|Experimental|Part A Single Ascending Dose (SAD) Cohort A1|
89564883|NCT04550195|Experimental|Part A SAD Cohort A2|
89564884|NCT04550195|Experimental|Part A SAD Cohort A3|
89564885|NCT04550195|Experimental|Part A SAD Cohort A4|
89564886|NCT04550195|Experimental|Part A SAD Cohort A5|
89564887|NCT04550195|Experimental|Part A SAD Cohort A6|
89564888|NCT04550195|Experimental|Part B Multiple Ascending Dose (MAD) Cohort B1|
89564889|NCT04550195|Experimental|Part B MAD Cohort B2|
89564890|NCT04550195|Experimental|Part B MAD Cohort B3|
89564891|NCT04550195|Experimental|Part B MAD Cohort B4|
89564892|NCT04550195|Experimental|Part C MAD in Japanese Healthy participants Cohort C1|
89564893|NCT04550195|Experimental|Part C MAD in Japanese Healthy participants Cohort C2|
89564894|NCT04550195|Experimental|Part C MAD in Japanese Healthy participants Cohort C3|
89564895|NCT04525391|Experimental|Durvalumab+AZD2811 to SCLC patients|"Dosage and Schedule: AZD2811 500mg and durvalumab 1500mg via IV administered on Day 1 for every 3weeks (fixed dosing for subjects > 30 kg body weight for durvalumab). One cycle is consisted of 3 weeks.~The drug products must be dosed consecutively using different infusion lines. The sequence of infusions is as follows: durvalumab is administered first over 1 hour, followed by AZD2811 administered over 2 hours. A waiting time interval of at least 30 minutes between the end of durvalumab infusion and start of AZD2811 infusion should be adhered to."
89564896|NCT04870697|Experimental|ACT group|In addition to usual care, participants in the ACT group will receive ACT intervention. ACT intervention will be conducted in an individual-based format with four weekly sessions. The first session is a face-to-face format and the other three sessions are online live format.
89208585|NCT00615030|Experimental|Indacaterol Morning, Placebo, Indacaterol Evening|In period I, indacaterol 300 μg once a day in the morning delivered via SDDPI with a placebo to salmeterol delivered via DPI. Patients were also instructed to take evening doses of a placebo to indacaterol via SDDPI and placebo to salmeterol via DPI. In period II, During morning and evening, placebo matching indacaterol was delivered via SDDPI and placebo matching salmeterol was delivered via DPI. In period III, Patients were instructed to take morning doses of a placebo to indacaterol delivered via SDDPI and placebo to salmeterol delivered via DPI. Indacaterol 300 μg once a day in the evening delivered via SDDPI with placebo to salmeterol delivered via DPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
89564897|NCT04870697|Other|Control group|Participants in the control group will receive usual care in the study setting delivered by clinical staff. The rationale for adopting usual care as a control group is not only because it is more commonly used but also for practical and ethical considerations, as usual care is what is already being delivered clinically, therefore the results of the study can support any necessity of changes to clinical practice or not.
89564898|NCT04879511|Active Comparator|Receiving metformin|Active group receiving metformin with basal /bolus insulin
89564899|NCT04879511|Placebo Comparator|Placebo|Control group receiving Placebo with basal/bolus insulin
89564900|NCT03048695|Experimental|Goal Management Training|Cognitive rehabilitation
89564901|NCT03048695|No Intervention|Waiting list|
89564902|NCT03046901|Experimental|Vancomycin group|It is a single arm open label study and will constitute only one group that will be taking vancomycin for recurrent PSC post liver transplantation.
89564903|NCT03046745||Gastric cancer group|The patients aged more than 18 years who were diagnosed primary gastric adenocarcinoma.
89564904|NCT03046745||Control group|The participants aged more than 40 years without previous history of gastric cancer.
89564905|NCT03048539||Transoral endoscopic thyroidectomy|Patient who fit with the eligible criteria and choose endoscopic thyroidectomy by himself.
89564906|NCT03048539||Conventional thyroidectomy|Patient who fit with the eligible criteria and choose conventional thyroidectomy by himself.
89564907|NCT04879277|Other|Healthy subject|"The intervention, specific to the study, is to take blood samples on patients healthy volunteers.~Healthy subject will be paired to patient with phenylketonuria according to body mass index and sex."
89564908|NCT04879277|Other|Patient with phenylketonuria|The intervention, specific to the study, is to take blood samples on patients with phenylketonuria
89564909|NCT03046667|Experimental|Test drink|Test drink: Barley β-glucan
89564910|NCT03046667|Placebo Comparator|Control drink|Control drink: barley beverage
89564911|NCT03046589|Experimental|Treatment Period 1|DP13 capsules (dose level 1 ) and placebo capsules
89564912|NCT03046589|Experimental|Treatment Period 2|DP13 capsules (dose level 2) and placebo capsules
89564913|NCT03046589|Experimental|Treatment Period 3|DP13 capsules (dose level 3) and placebo capsules
89564914|NCT03046589|Experimental|Treatment Period 4|DP13 capsules (dose level 4) and placebo capsules
89564915|NCT03046589|Experimental|Treatment Period 5|DP13 capsules (dose level 5) and placebo capsules
89564916|NCT03046589|Experimental|Treatment Period 6|DP13 capsules (dose level 6) and placebo capsules
89564917|NCT04037813|Active Comparator|Laparoscopic tubal occlusion|54 patients will undergo laparoscopic tubal occlusion.
89564918|NCT04037813|Active Comparator|Hysteroscopic tubal occlusion|54 patients will undergo hysteroscopic tubal occlusion.
89564919|NCT02614079|Experimental|DSSEP|DSSEP testing after SCS trial lead placement
89564920|NCT03994679||cleft patient requiring bone graft|Patients presenting at the division of maxillofacial surgery at the AZ Sint-Jan Brugge-Oostende av (Belgium) or the 1st department of pediatrics at the USemmelweis (Hungary) for bone graft surgery of the unilateral cleft receive a complete routine work-up, including a cone-beam CT (CBCT).
89564921|NCT03871049|Placebo Comparator|group 1|intathecal bupivacaine
89564922|NCT03871049|Active Comparator|group 2|intrathecal bupivacaine with dexamethasone
89564923|NCT04878809|Experimental|Experimental group|People attending L'Horitzó School (students, teachers, administrative and service staff)
89564924|NCT04878809|Other|Control Group|Escola John Talabot, will provide the incidence rate of infections by SARS-CoV-2
89564925|NCT04430465|Experimental|High wholegrain then low wholegrain|Starting with high wholegrain intervention followed by low wholegrain intervention
89564926|NCT04430465|Experimental|Low wholegrain then high wholegrain|Starting with low wholegrain intervention followed by high wholegrain intervention
89564927|NCT04870541|Active Comparator|Patients receiving Ondansetron|
89564928|NCT04870541|Active Comparator|Patients receiving Nefopam|
89564929|NCT04870385|Experimental|Treatment|5-week online prevention program
89564930|NCT04870385|Other|Control|Waitlist control
89210693|NCT00628862|Experimental|F 9.0 bid|Formoterol 9.0 ug bid
89210694|NCT00628862|Placebo Comparator|PBO|Placebo
89564931|NCT04870073|Experimental|Retrograde autologous priming + mannitol|Priming solution (≥600 mL) will be removed from the extracorporeal circuit within 10 minutes before the initiation of cardiopulmonary bypass. Priming solution may be removed from 3 locations within the extracorporeal circuit (i.e. arterial, venous and cardioplegia lines) as determined by the perfusionist team. In addition, mannitol will be added as a bolus (0.3 g/kg) to the venous reservoir of the cardiopulmonary bypass machine within 5 min before the start of cardiopulmonary bypass.
89564932|NCT04870073|Experimental|Retrograde autologous priming alone|Priming solution (≥600 mL) will be removed from the extracorporeal circuit within 10 minutes before the initiation of cardiopulmonary bypass. Priming solution may be removed from 3 locations within the extracorporeal circuit (i.e. arterial, venous and cardioplegia lines) as determined by the perfusionist team.
89564933|NCT04870073|Experimental|Conventional priming + mannitol|Participants will receive conventional priming. In addition, mannitol will be added as a bolus (0.3 g/kg) to the venous reservoir of the cardiopulmonary bypass machine within 5 min before the start of cardiopulmonary bypass.
89564934|NCT04870073|Active Comparator|Conventional priming alone|Participants will receive conventional priming alone.
89564935|NCT02616029|Experimental|Part 1: E/C/F/TAF|"Participants with M184V and/or M184I mutations in reverse transcriptase and without any other NRTI resistance mutation switched from their current human immunodeficiency virus (HIV) treatment regimen consisting of FTC/TDF or ABC/3TC plus a third antiretroviral agent to E/C/F/TAF (150/150/200/10 mg) FDC tablet orally once daily for 48 weeks.~Allowed third agents include: lopinavir/ritonavir (LPV/r), atazanavir + ritonavir (ATV+RTV), atazanavir+cobicistat (ATV+COBI), darunavir + ritonavir (DRV+RTV), darunavir + cobicistat (DRV+COBI), fosamprenavir + ritonavir (FPV + RTV), saquinavir + ritonavir (SQV + RTV), atazanavir (ATV) (no booster) efavirenz (EFV), rilpivirine (RPV), nevirapine (NVP), etravirine (ETR), raltegravir (RAL) or dolutegravir (DTG)."
89564936|NCT02616029|Experimental|Part 2: E/C/F/TAF|"Participants with M184V and/or M184I mutations in reverse transcriptase and with or without 1 or 2 TAMs switched from their current HIV treatment regimen consisting of FTC/TDF or ABC/3TC plus a third antiretroviral agent to E/C/F/TAF (150/150/200/10 mg) FDC tablet orally once daily for 48 weeks.~Allowed third agents include: LPV/r, ATV+RTV, ATV+COBI, DRV+RTV, DRV+COBI, FPV + RTV, SQV + RTV, ATV (no booster) EFV, RPV, NVP, ETR, RAL or DTG."
89564937|NCT04878341|Experimental|Erector Spinae plane Block|After induction of general anesthesia, patients will be positioned in lateral decubitus with surgical site up and the transverse process of T5-T7 vertebrae and Erector Spinae (ES) fascia will be located with a linear ultrasound probe. A 19G or 20G epidural needle (according to age) will be positioned under the ES muscle and a bolus of of 0.3-0.5ml/kg of 0.2% ropivacaine will be administered; after hydrodissection, the catheter will be threaded, followed by an infusion of 0.2mg/kg/hr for the next 48 hours.
89564938|NCT04878341|Active Comparator|Thoracic Epidural Anesthesia|After induction of general anesthesia, patients will be positioned in lateral decubitus with surgical site up and a 19G or 20G epidural needle (according to age) will be positioned at T5-T7 level with cathether placement; a bolus of of 0.3-0.5ml/kg of 0.2% ropivacaine will be administered and followed by an infusion of 0.2mg/kg/hr for the next 48 hours.
89564939|NCT04878497||Warfarin|New users of warfarin
89564940|NCT04878497||Dabigatran|New users of dabigatran
89564941|NCT04878497||Rivaroxaban|New users of rivaroxaban
89564942|NCT04878497||Apixaban|New users of apixaban
89564943|NCT04878497||Edoxaban|New users of edoxaban
89564944|NCT03277703|Experimental|Group 1 - Booster|Group 1 subjects will receive a second booster dose of injectable influenza vaccine 4 weeks after initial vaccination in year 1 and year 2.
89564945|NCT03277703|Active Comparator|Group 2 - Standard|Group 2 subjects will be receive the standard single dose of influenza vaccine in year 1 but will receive a second booster dose of injectable influenza vaccine 4 weeks after initial vaccination in year 2.
89564946|NCT03257033|Experimental|IA Therapy|IA Treatments with 1,000 mg/m2 gemcitabine administered through RenovoCath every other week for a maximum of 8 treatments for approximately 16 weeks.
89564947|NCT03257033|Active Comparator|IV Therapy|IV gemcitabine and nab-paclitaxel will be administered for 16 weeks on days 1, 8, and 15 of a 28 day cycle. Nab-paclitaxel will be administered intravenously following pre-medication at a dose of 125 mg/m2 over 30 minutes followed by an infusion of gemcitabine at a dose of 1000 mg/m2 over 30 minutes.
89564948|NCT04429841||D1 Gastrectomy|Patients are managed by radical gastrectomy with D1 lymphadenectomy
89564949|NCT04429841||D2 Gastrectomy|Patients are managed by radical gastrectomy with D2 lymphadenectomy
89210695|NCT00907140|Other|Chemoradiation therapy|
89210696|NCT05420727|Experimental|Positive Ga-68-PSMA-11 PET/CT patients treated by Lu-177-ITG-PSMA-1|Positive Ga-68-PSMA-11 PET/CT prior to two cycles of Lu-177-ITG-PSMA-1 i scheduled six weeks apart.
89564950|NCT02614859|Active Comparator|Observation and Bicalutamide|Cycles 1-2: Observation without treatment Cycles 3-8: Bicalutamide 50 mg daily continuously to end of study
89564951|NCT02614859|Experimental|Metformin and Bicalutamide|Cycles 1-2: Metformin 1000mg BID Cycles 3-8: Bicalutamide 50 mg daily and Metformin 1000 mg BID
89564952|NCT04384445|Experimental|Zofin Plus Standard Care|Participants in this group will receive standard of care plus Zofin on day 0, day 4 and day 8.
89564953|NCT04384445|Placebo Comparator|Placebo Plus Standard Care|Participants in this group will receive standard of care plus placebo (Saline) on day 0, day 4 and day 8.
89564954|NCT04877795||Cardiac Surgery|Adult Patients undergoing elective on-pump cardiac surgery (i.e. Coronary artery bypass graft surgery (CABG) and/or valvular surgery)
89564955|NCT03046355|Experimental|Labor induction at 37.0 to 37.6 weeks of gestation|Diagnosis of FGR with induction at 37 weeks 0 days of gestation to 37 weeks and 6 days
89564956|NCT03046355|Active Comparator|Expectant monitoring until delivery|Diagnosis of FGR managed with expectant monitoring and delivery as indicated
89564957|NCT04877717|Experimental|SHR-A1904|
89564958|NCT04877951|Other|Effect of LSVT BIG therapy on Postural Control and Gait Parameters|LSVT BIG is a commonly used protocol to manage functional movement for those with Parkinson's Disease. This study measured postural control and gait parameters following a 4-week course of LSVT BIG therapy.
89564959|NCT04877171|Experimental|telemedicine neurology consultation|Starting on day 12-14 post-discharge, participants will receive a phone call for a drug conciliation. Participants at 1-month post-discharge will receive a telemedicine consultation, another at 3 months and 6 months.
89564960|NCT04877171|Active Comparator|in-person neurology consultation|Starting at 1-month post-discharge, participants will attend an in-person neurology consultation and the following consultations depend on their physician's criteria until completed 6 months post-discharge.
89564961|NCT03046277||Patients undergoing LTx|Retrospective analysis of clinical data
89564962|NCT03046277||Patients with pretransplant renal functional reserve testing|Prospective analysis of clinical data
89564963|NCT04876859|Active Comparator|Conventional Radiofrequency Group|Will be submitted to an anesthetic block of the sensory branches of femoral and obturator nerves to the hip, with 1 ml of 1% lidocaine with 1ml of steroid (Betamethasone Dipropionate 5 mg/ml + Betamethasone Sodium Phosphate 2 mg/ml) for each branch, followed by denervation with CRF (22¬gauge 5¬mm active tip cannula, 10cm in length) with the tip temperature set at 90° C in a single cycle of 90 min.
89564964|NCT04876859|Sham Comparator|Anesthetic plus steroid group|The sham group will be submitted to the same anesthetic block as described in the intervention group, followed by a simulation of CRF use.
89564965|NCT03049241||knee extensors|
89564966|NCT03049241||ankle plantar|
89564967|NCT03046043|Experimental|Low-Voltage & CFAE guided ablation|"Pulmonary isolation will be performed~Complex fractionated atrial electrogram(CFAE) and voltage mapping will be performed if atrial fibrillation the patient is still in atrial fibrillation after pulmonary vein isolation~CFAE and voltage mapping will be performed simultaneously using small electrode Pentaray® Catheter with CARTO®3 MEM version or CARTO®3 CONFIDENSE™~Automatic characterization of CFAE signals will be performed with an CARTO® CFAE software module.~CFAE areas within low voltage zone in the left atrium should be targeted first. If atrial fibrillation persist after left atrial ablation, target areas in the right atrium should be mapped and ablated. (Low-Voltage & CFAE guided ablation)"
89564968|NCT03046043|Active Comparator|PV Isolation Only|"Pulmonary vein isolation will be performed.~Electrical cardioversion to sinus rhythm will be performed if the patient is still in atrial fibrillation after pulmonary vein isolation."
89564969|NCT05257889||neonatal seizures cases|Cases of neonatal seizures
89033083|NCT04013763|Experimental|Non atopic dermatitis with continue using product|case wheat allergy with normal skin and continue using wheat containing skin care products
89564970|NCT05257889||seizure-free neonates|cases that are seizure free
89564971|NCT03047915|No Intervention|Control Group|All subjects enrolled will respond to questions assessing anxiety using the State Trait Anxiety Inventory (STAI), and pain using a 1-10 numerical score, and will have blood pressure and heart rate taken. Subjects randomized to the control group will continue the ED visit as usual.
89564972|NCT03047915|Experimental|Music Group|All subjects enrolled will respond to questions assessing anxiety using the State Trait Anxiety Inventory (STAI), and pain using a 1-10 numerical score, and will have blood pressure and heart rate taken. Subjects who are randomized to receive a music-listening intervention will listen to a choice of music for 30 to 60 minutes on a loaned iPad with disposable headphones. An hour after enrollment, participants will be asked the same questions assessing anxiety and pain, and will also have blood pressure and heart rate taken again.
89564973|NCT04876313|Experimental|Combined Drugs|Participants received 4x3 weekly cycles of 360 mg Nivolumab + 125 mg/m^2 Nab-paclitaxel IV on days 1 and 8, then they had cystectomy after that partecipants received adjuvant nivolumab 360 mg IV Q3W X13 cycles
89564974|NCT04876469|Active Comparator|Radiocontrast media group|"Pulsed radiofrequency (PRF) treatment will be applied to the dorsal root ganglion (DRG) by fluoroscopy-guidance at the level of nerve root compression due to disc herniation (L5 level) in both groups.~In patients in the Radiocontrast media group, contrast material will be given before the application, and primarily the localization of the DRG will be determined. After this stage, the needle will be directed towards the detected localization. Finally, the localization of the dorsal root ganglion will be confirmed by sensory and motor stimuli."
89564975|NCT04876469|Active Comparator|Non-radiocontrast media group|"Pulsed radiofrequency (PRF) treatment will be applied to the dorsal root ganglion (DRG) by fluoroscopy-guidance at the level of nerve root compression due to disc herniation (L5 level).~In patients in the Non-radiocontrast media group, the localization of the dorsal root ganglion will be determined just by sensory and motor stimuli."
89564976|NCT02615249|Experimental|Metal Allergen Epicutaneous Patch|8 allergens were tested. Not all subjects tested each allergen. Section reports number of subjects with positive responses to each allergen.
89033084|NCT04013763|No Intervention|Atopic dermatitis with no product use|case wheat allergy who does not use wheat containing skin care products and has atopic dermatitis
89033085|NCT04013763|No Intervention|Non atopic dermatitis with no product use|case wheat allergy who does not use wheat containing skin care products and no atopic dermatitis
89564977|NCT02615171|Active Comparator|Comprehensive Dietary Self-Monitoring|The intervention includes Facebook-delivered weight loss counseling and the use of MyFitnessPal, a comprehensive diet and exercise self-monitoring app. The intervention will last for 12 weeks. In addition to weight loss counseling in a private Facebook group, participants will be encouraged to use the self-monitoring app to enter everything they eat and do for exercise during the intervention period (12 weeks). Participants will receive a daily calorie goal directly from the app. Participants will receive a Fitbit scale to take their weight weekly and at assessments.
89564978|NCT02615171|Active Comparator|Simple Dietary Self-Monitoring|The intervention includes Facebook-delivered weight loss counseling and the use of Slip Buddy, an app created by the investigative team that only requires users to record instances of overeating by hitting a single button and then indicate the overeating trigger and stress and hunger levels. The intervention will last for 12 weeks. In addition to the weight loss counseling, participants will be asked to use the Slip Buddy app during the intervention period (12 weeks). Participants will receive a Fitbit scale to take their weight weekly and at assessments.
89564979|NCT03049085|Active Comparator|Aspirin group|a 75 mg uncoated aspirin is administered 2 hours prior to OPCAB
89564980|NCT03049085|Placebo Comparator|Placebo group|75 mg Vit. C is administered 2 hours prior OPCAB
89564981|NCT04876547||In pregnancy|Appendectomy in pregnancy (n=12)
89564982|NCT04876547||In postpartum|Appendectomy in postpartum first six week (n=20)
89564983|NCT04876001|Experimental|Face-to-face BBTI|"The BBTI consists of two in-person sessions on week 1 and 3 and two session on week 2 and 4 as the booster delivered by phone call."
89564984|NCT04876001|Experimental|Web-based BBTI|"The BBTI consists of two in-person sessions on week 1 and 3 and two session on week 2 and 4 as the booster delivered by phone call. All treatments will be delivered using pre-established web and telephone."
89564985|NCT04876001|No Intervention|Waiting-list|The participant in this arm will be asked to filled the online questionnaires at weeks 0 (baseline), 1 (mid-treatment), 2 (post-treatment), 4 and 12 (follow up). After the final follow up, all participants will be allowed to join the web-based BBTI treatment.
89564986|NCT04875845||6-hours fasting gastric volume|gastric volume measured after 6-hours fasting
89564987|NCT04875845||8-hours fasting gastric volume|gastric volume measured after 8-hours fasting
89564988|NCT04869293|Experimental|3D virtual reality|Use of Hypnosis 3D virtual reality headset
89564989|NCT04869293|No Intervention|Control|Standard of care : no hypnosis 3D virtual reality headset but a noise cancelling headphone
89564990|NCT04875611|Experimental|Experimental therapy:OPDIVO (Nivolumab)|
89564991|NCT04875689|Experimental|Group A (Experimental)|Patient receive laser therapy along with conventional therapy
89564992|NCT04875689|Other|Group B: Conventional treatment|patient will receive conventional therapy
89564993|NCT04369625|Experimental|CHIMPS-T|(Children of mentally ill parents) is a family-oriented lowfrequency brief therapy for diagnosis and treatment of mental disorders in children and adolescents. CHIMPS-T is based on a theory model, needs analyses and the pioneering studies of Williams Beardslee. The CHIMPS approach was tested, evaluated and manualized in an initial project (2007-2011).
89564994|NCT04369625|Experimental|CHIMPS-P|"CHIMPS-P is a family-oriented prevention for children and adolescents without signs of mental disorders in the initial screening. These families will receive the 3 family sessions from the modular CHIMPS intervention. The sessions will be carried out by a social worker (based on the Finnish model Let's talk about children (Solantaus), but in a family setting Let's talk WITH children)."
89564995|NCT04369625|Experimental|The CHIMPS-MFT-group|The CHIMPS-MFT-group is a prevention with a multi-family setting based on the CHIMPS approach. The multi-family intervention comprises 8 sessions for children and adolescents without psychiatric disorders and their families: preliminary talk, one additional session with the family (if needed), multifamily group with three to six other families, concluding session.
89564996|NCT04369625|Experimental|iCHIMPS|iCHIMPS is an online intervention. In terms of content, iCHIMPS is based on the CHIMPS program as well as on other evidence-based interventions of the study group. iCHIMPS will also be comprised of one module for children and adolescents as well as one module for parents; moreover; modules for the family system will be included. Overall, 8 consecutive online modules as well as elective modules will be included. These modules (e.g., dealing with difficult situations, emotion regulation, taboos and shame, self-worth) will be provided based on the specific constellation of children and adolescents of mentally ill parents. iCHIMPS will be completed by 2 booster session within a six months follow-up.
89564997|NCT04369625|No Intervention|Treatment as usual|The treatment as usual implies that families of the control group receive the treatment that is customary in regular care. Thus, these families normally don't receive any post-treatment. If, however, a member of a control group family appears to have an urgent need for treatment (every family receives a comprehensive diagnostic investigation at the beginning of the study), the respective family will be placed in the ambulatory care system.
89564998|NCT04366895|Experimental|control|Participants in control group (Group-A) received conventional manufactured implant overdenture
89564999|NCT04366895|Experimental|intervention|participants in intervention group (Group-B) received CAD-CAM manufactured implant overdenture.
89565000|NCT04429763|Experimental|Experimental|Usual tratment for COVID-19 plus MSC
89565001|NCT04429763|Placebo Comparator|Control|Usual treatment for COVID-19
89565002|NCT05256953|Active Comparator|Group ESP|bilateral ESPB (total of 40 ml, %0.25 bupivacaine) + IV morphine PCA
89565003|NCT05256953|Active Comparator|Group GA|only IV morphine PCA
89565004|NCT04875299||adalimumab TDM|Patients with active ankylosing spondylitis receiving adalimumab treatment.
89565005|NCT04875143|Placebo Comparator|PLACEBO|From a pre-established randomization, on the first day of collection, volunteers will be allocated to group I (Placebo) or group II (Citrus aurantium L.). In the first intervention, the volunteers allocated to group I will take a capsule containing 500mg of starch, at the end of this, another capsule containing 500mg of Citrus aurantium L. will be provided for the second intervention. Conversely, the volunteers allocated to group II will ingest a capsule containing 500mg of Citrus aurantium L. in the first intervention, and at the end of the experiment, another capsule containing 500mg of starch will be provided.
89565006|NCT04875143|Experimental|Citrus aurantium L.|From a pre-established randomization, on the first day of collection, volunteers will be allocated to group I (Placebo) or group II (Citrus aurantium L.). In the first intervention, the volunteers allocated to group I will take a capsule containing 500mg of starch, at the end of this, another capsule containing 500mg of Citrus aurantium L. will be provided for the second intervention. Conversely, the volunteers allocated to group II will ingest a capsule containing 500mg of Citrus aurantium L. in the first intervention, and at the end of the experiment, another capsule containing 500mg of starch will be provided.
89565007|NCT03045731||Kidney transplant recipients|Patients who have received kidney transplantation in Zhongshan Hospital.
89565008|NCT05256485|Active Comparator|cognitive behavioral therapy|Standard CBT comprises an array of approaches directed toward modifying dysfunctional thinking and behavior. The two critical components are analysis of thoughts, feelings, and behaviors, as well as skills training for achieving active behavior and thought modification.
89565009|NCT05256485|Active Comparator|mindfulness based relapse prevention|"MBRP training is based on a two-component process:~Attention to present moment experience, even if it includes craving or negative emotion.~An accepting attitude towards this experience letting it be exactly as it is, without judging it or reacting to it."
89565010|NCT05256485|Active Comparator|twelve-step therapy|12-step therapy was based on strengthening conscious contact with God and awakening spirituality through prayer and meditation
89565011|NCT04874675|Active Comparator|Diclofenac /Acetaminophen/Codeine|routine pain medication used in post extraction pain management
89565012|NCT04874675|Active Comparator|Ibuprofen/Acetaminophen/codeine|routine pain medication used in post extraction pain management
89565013|NCT04874363||smoker|active smokers
89565014|NCT04874363||non-smoker|Patients who have never smoked
89565015|NCT04868669|Experimental|Intervention|In this arm, pregnant women, along with their influential family members such as mothers, mothers-in-law, and husbands, will receive monthly in-home, intensive nutrition counseling during the prenatal period.
89565016|NCT04868669|No Intervention|Control|Pregnant women in this arm will receive standard antenatal care.
89565017|NCT03048851|Experimental|Low dosage SES group|Low dosage SES group received the low dosage SES training in addition to traditional rehabilitation. Each SES session involved electrical stimulation followed by UE training in addition to home program.
89565018|NCT03048851|Experimental|High dosage SES group|High dosage SES group received the high dosage SES training in addition to traditional rehabilitation. Each SES session involved electrical stimulation followed by UE training in addition to home program.
89565019|NCT03048851|Experimental|VRCIT group|VRCIT group received the VRCIT training in addition to traditional rehabilitation.Each VRCIT session involved practice of functional tasks with the more affected UE followed by virtual-reality based eye-hand coordination tasks with the more affected UE for, in addition to home program, and restraint of the less affected UE for 1.5 hours per day.
89565020|NCT03048851|Experimental|VRCIT+SES group|VRCIT+SES group received the VRCIT and SES training in addition to traditional rehabilitation.
89565021|NCT03048851|Active Comparator|traditional rehabilitation group|Shame control group received the shame SES and traditional rehabilitation programs.
89565022|NCT04868513|Experimental|Pregnant women to whom applied silane fluoride|We applied 0.1% silane fluoride (Fluor Protector, Ivoclar Vivadent AG™) as varnish in all teeth on all faces as a promotion strategy on the reduction of S. mutans.
89565023|NCT04868513|Experimental|Pregnant women to whom applied silane fluoride + 1% chlorhexidine|We applied 0.1% silane fluoride (Fluor Protector, Ivoclar Vivadent AG™) and 1% chlorhexidine (Cervitec, Ivoclar Vivadent AG™), both applied as varnish, with a 1 min interval between applications, in all teeth on all faces, using the standardized technique indicated by the manufacturer as a promotion strategy on the reduction of S. mutans.
89565024|NCT04868513|No Intervention|Children of the pregnant women to whom it was applied silane fluoride|The children not given any intervention, they were only subjected to a microbiological and clinical examination.
89565025|NCT04868513|No Intervention|Children of the pregnant women to whom it was applied silane fluoride + 1% chlorhexidine|The children not given any intervention, they were only subjected to a microbiological and clinical examination.
89565026|NCT05256407|Experimental|Intervention, digital support|Parents are offered participation in a digital channel consisting of video consultations, parental support gruops and parental education.
89565027|NCT05256407|No Intervention|Control, usual care|Usual child health care.
89565028|NCT04873973|No Intervention|Control|Participants in this group are routinely treated.
89565029|NCT04873973|Active Comparator|Telemedical support|Participants in this group are routinely treated with additional telemedical support and the use of the early warning system.
89565030|NCT04874129|Other|A Group|Two-way Crossover
89565031|NCT04874129|Other|B Group|Two-way Crossover
89565032|NCT05256329||Oncology patients|Patients suffering from specific solid cancers or hematological malignancies
89565033|NCT05256173|Experimental|Melatonin Tablets|
89565034|NCT05256173|Placebo Comparator|Lactasin Tablets|
89565035|NCT05256173|Experimental|transcutaneous vagus nerve stimulation|
89565036|NCT05256173|Sham Comparator|sham transcutaneous vagus nerve stimulation|
89565037|NCT03048071||Homograft in pulmonary position replacement|All patients having had the replacement of an homograft in pulmonary position between January 1999 and October 2016, within the Queen Fabiola Children Hospital of Brussels, Belgium.
89565038|NCT03048071||Contegra conduct replacement|All patients having had the replacement of a Contegra conduct between January 1999 and October 2016, within the Queen Fabiola Children Hospital of Brussels, Belgium.
89565039|NCT04868825|Experimental|Experimental (Intervention)|
89565040|NCT04868825|Active Comparator|Active Comparator|
89565041|NCT03048773|Experimental|shockwave therapy|"0.24mJ/mm2，1600 shots over 8 assigned sites of single knee with jelly between applicator pad (20) and handpiece~Physical therapy with TENS + MF + stretching + strengthening exercise, 3 times per week for 3 weeks"
89565042|NCT03048773|Placebo Comparator|placebo|"0.24mJ/mm2，1600 shots over 8 assigned sites of single knee without jelly between applicator pad (20) and handpiece~Physical therapy with TENS + MF + stretching + strengthening exercise, 3 times per week for 3 weeks"
89565043|NCT04868201|Experimental|0-anxiety|0-anxiety is based on the principles of VRT and CBT, which currently is the most researched and used treatment for anxiety disorders. The 0-anxiety intervention is an app-based intervention consisting of six modules that can be followed according to a user's own timing and without the intervention of a therapist.
89565044|NCT04868201|No Intervention|wait-list condition|
89565045|NCT04429997|Experimental|Removal of fibrosynovial tissue|Removal of fibrosynovial tissue in patellar non-resurfacing TKA
89565046|NCT04429997|Experimental|Non-removal of fibrosynovial tissue|Non-removal of fibrosynovial tissue in patellar non-resurfacing TKA
89565047|NCT05255939|Experimental|dTRA group|Investigators perform percutaneous coronary intervention by dTRA
89565048|NCT05255939|Other|TRA group|Investigators perform percutaneous coronary intervention by conventional TRA
89565049|NCT02648347|Experimental|Vadadustat|
88968711|NCT04734171|Active Comparator|IS + Video Friends|participants an informational sheet about COVID-19 and a 150 seconds video aimed at encouraging the use of a digital device (i.e. not in person contact) to meet with friends.
89565050|NCT02648347|Active Comparator|Darbepoetin alfa|
89565051|NCT05255783|Other|Critically ill adults requiring insulin|Patients admitted to the intensive care unit requiring insulin infusion to maintain blood glucose within target range
89565052|NCT02614703|Experimental|Chromoendoscopy using Acetic Acid 2.5%|Patient will have endoscopic examination of esophagus. Esophageal mucosa sprayed with 5cc solution of Acetic Acid 2.5% one time only. Esophageal mucosa examined again. Biopsies are obtained. Abnormal areas identified by Acetic Acid 2.5% will be submitted on separate containers for pathology review. If no abnormalities seen, random biopsies taken as per standard recommendations for Barrett's esophagus. Samples submitted for pathology review.
89565053|NCT02614703|Active Comparator|Standard random esophageal biopsies|Patient will have endoscopic examination of the esophagus. Esophageal mucosa will not be sprayed with Acetic Acid 2.5%. Random biopsies taken as per standard recommendations for Barrett's esophagus. Samples submitted for pathology review.
89565054|NCT03047525|No Intervention|control group|patients will just regularly chemotherapy
88968712|NCT04734171|No Intervention|Control|No intervention
89532033|NCT06338423|Experimental|Vacuum Mattress Arm|"Patients will be operated in a beach chair position. The patient will ley on vacuum mattresses during the surgery.~Patients' demographics, and perioperative data including age, gender, body mass index (BMI), smoking, ASA score, incidence of co-morbidities, compliance with ERABS protocol, amount of intraoperative blood loss, intraoperative complications, and surgery duration will be collected. Blood samples will be collected on first postoperative day to measure RML markers (myoglobin, creatine kinase, creatinine). Symptoms of RML, AKI and other complications were monitored for 30 days after surgery."
89565055|NCT03047525|Experimental|DC-CIK and CIK Immunotherapy|patients will receive chemotherapy with 4 cycles of DC-CIK treatment and 4 cycles of CIK treatment .
89565056|NCT04867967|Experimental|Iyengar Yoga Intervention|"8-week yoga class; once weekly; 90 minutes~Note: First administered face-to-face, due to Covid-restrictions changed to online classes"
89565057|NCT04867967|Active Comparator|Mindfulness-based stress reduction|"8-week MBSR class; once weekly; 90 minutes~Note: First administered face-to-face, due to Covid-restrictions changed to online classes"
89565058|NCT04867967|No Intervention|Waitlist control|Waitlist control, ususal care
89565059|NCT01669343|Other|Post-menopausal Women Using Adjuvant Letrozole|Part A Routine Care Letrozole; Part B Double Dose Letrozole in overweight/obese participants
89565060|NCT04867811|Experimental|group A|received conventional therapy
89565061|NCT04867811|Experimental|group B|received TENS in addition to conventional therapy
89565062|NCT04867811|Experimental|group C|received cupping therapy with conventional therapy
89565063|NCT04867811|Experimental|group D|TENS and cupping therapy plus conventional therapy
89565064|NCT05403619||Patients|Patients hospitalized for shortness of breath with realization of an enhanced FoCUS
89565065|NCT04678765|Active Comparator|Ultrasound-guided distal peripheral nerve block|Patients will receive the ultrasound-guided distal peripheral nerve block (locoregional anesthesia)
89565066|NCT04678765|Experimental|Ultrasound-guided quadruple-injection axillary nerve block|Patients will receive the ultrasound-guided quadruple-injection axillary nerve block (locoregional anesthesia)
89565067|NCT02675179|Experimental|EOS + Spiral CT pelvimetry|Women with an indication of pelvimetry will be included in this study. They will be their own control because they will benefit from the two methods of diagnosis : EOS new technique, and spiral CT (usual technique).
89565068|NCT04617067|Experimental|All Patients|Open Label: Paricalcitol 12mcg once daily, orally every day of each 28 day cycle PLUS GEM (1000mg/m2) and Nab-paclitaxel (Abraxane®) (125mg/m2) on days 1, 8 and 15 of each cycle.
89565069|NCT04600531|Experimental|Group 1a - Conventional tDCS - Anodal first|Half of all subjects will receive Conventional tDCS (randomly assigned). Within this Conventional tDCS condition, half of the subjects will receive active (anodal, real) tDCS in the first session. Following cross-over and a three-week washout-period, this half of the subjects will receive sham (placebo) tDCS.
89565070|NCT04600531|Sham Comparator|Group 1b - Conventional tDCS - Sham first|Half of all subjects will receive Conventional tDCS (randomly assigned). Within this Conventional tDCS condition, half of the subjects will receive sham (placebo) tDCS in the first session. Following cross-over and a three-week washout-period, this half of the subjects will receive active (anodal, real) tDCS.
89565071|NCT04600531|Experimental|Group 2a - HD tDCS - Anodal first|Half of all subjects will receive High Definition (HD) tDCS (randomly assigned). Within this HD tDCS condition, half of the subjects will receive active (anodal, real) tDCS in the first session. Following cross-over and a three-week washout-period, this half of the subjects will receive sham (placebo) tDCS.
89565072|NCT04600531|Sham Comparator|Group 2b - HD tDCS - Sham first|Half of all subjects will receive High Definition (HD) tDCS (randomly assigned). Within this HD tDCS condition, half of the subjects will receive sham (placebo) tDCS in the first session. Following cross-over and a three-week washout-period, this half of the subjects will receive active (anodal, real) tDCS.
89565073|NCT05023057|Experimental|Multidomain intervention|The participants in the intervention arm will receive all five components of the intervention: (1) monitoring and management of metabolic and vascular risk factors; (2) cognitive training and social activity; (3) physical exercise; (4) nutritional guidance; and (5) motivational training.
89565074|NCT05023057|No Intervention|Control|At baseline, the participants in the control group will meet a study doctor, be prescribed medication when necessary, and receive educational booklets corresponding to their risk factors and a booklet on lifestyle guidelines to prevent dementia. They will receive usual care during the study period and be informed that they could participate in the multidomain intervention program after this study end.
89565075|NCT04669015|Experimental|Active plus SOC|Inhaled Novaferon, given 20 ug BID, daily for 10 days, plus Standard of Care
89565076|NCT04669015|Placebo Comparator|Placebo plus SOC|Inhaled vehicle formulation (placebo), given BID, daily for 10 days, plus Standard of Care
89565077|NCT01594931|Experimental|pyronaridine/artesunate (6:2 mg/kg)|pyronaridine tetraphosphate 6 mg/kg and artesunate 2 mg/kg
89565078|NCT01594931|Experimental|pyronaridine/artesunate (9:3 mg/kg)|pyronaridine tetraphosphate 9 mg/kg and artesunate 3 mg/kg
89565079|NCT01594931|Experimental|pyronaridine/artesunate (12:4 mg/kg)|pyronaridine tetraphsophate 12 mg/kg and artesunate 4 mg/kg
89565080|NCT04981171|Experimental|Electro-thumbtack Needle Therapy (ETN) group|Electro-thumbtack needles (0.25×2 mm) will be inserted into acupoints of Dazhui (GV14), bilateral Wangu (GB12), bilateral cervical Jiaji (at C4 and C6 level), two Ashi points and bilateral Houxi (SI3) after sterilization. Then apply the gel electrodes and stimulation devices, turn on the device to produce a proper electric stimulation that the participant can tolerate.
88814935|NCT03024710|No Intervention|Controlled cluster|The participants for control clusters will be (the infant who has completed his/her 6 month of age from the date of birth along with their mother) will be enrolled from MNCH database according to criteria. The mother-infant pairs from control cluster will receive the usual care.
88814936|NCT03017144||Resuscitation team|Resuscitation pit crew model is educated to the resuscitation team.
88814937|NCT03017300|Experimental|COPD（threshold IMT training）|COPD patient use Inspiratory muscle trainer (Threshold IMT®)
88814938|NCT03017300|Experimental|COPD（resisive training）|COPD patient use Inspiratory muscle trainer (PFLEX®)
89565081|NCT04981171|Sham Comparator|Sham Electro-thumbtack Needle Therapy (ETN) group|Sham electro-thumbtack needles (0.25×0.2 mm) which are specially produced have blunt tips instead of sharp needle tip. They will be taped on acupoints of Dazhui (GV14), bilateral Wangu (GB12), bilateral cervical Jiaji (at C4 and C6 level), two Ashi points and bilateral Houxi (SI3) after sterilization. Then apply the gel electrodes and stimulation devices, produce a minimal level of electric stimulation for 30 seconds before turning off the device.
89565082|NCT04978831|Experimental|Respiratory exercise device group|
89565083|NCT04978831|Experimental|Reading aloud group|
89565084|NCT04978831|No Intervention|Control group|
89565085|NCT03045185|Experimental|Treatment Group|RET using Ciprofloxacin 100mg, and Metronidazole 100mg.
89565086|NCT03045497|Experimental|Diagnostic (contrast-enhanced ultrasound)|Patients receive perflutren lipid microspheres IV and then undergo contrast-enhanced ultrasound imaging over approximately 1 hour prior to transarterial chemoembolization with drug eluting beads, at 1-2 weeks and 1 month post transarterial chemoembolization with drug eluting beads. Patients also undergo contrast-enhanced MRI at 1 month post-treatment per standard of care.
89027557|NCT02890615|Experimental|Depression Self-care Intervention (SCI)|"Intervention group participants will receive the Depression Self-Care Toolkit for Cancer Survivors and will be supported by telephone by a coach who will help to activate them, guide them through the materials, help in selecting appropriate tools, and provide positive reinforcement. Coach contacts will be made every week for 3 months followed by 3 monthly contacts, up to a maximum of 15 contacts, lasting 10-20 minutes each.~The coach uses a stepped approach (i.e. educate about depression, initiate mood monitoring, determine participant's goals with respect to reducing depressive symptoms, and help with the use of specific tools). A suggested script is provided for the coach as a framework for each call. Tailoring of the SCI to different participants will be based on problems, depressive symptoms (from the PHQ-9), or concerns a participant may raise during the call."
89027558|NCT02890615|No Intervention|Control group|"Members of both groups will continue to receive usual care for their depression. We will not interfere with usual care beyond recommending that participants discuss their depressive symptoms with their doctor. If participants consent, a short progress report will be send to their treating physician at the end of the study. At each follow-up, we will ask participants about specific treatment they have received for depression since entering the study (antidepressant medication initiation, discontinuation, change of dose, or psychotherapy) and use of community resources. The Intervention group will receive the Depression SCI. The Control group will receive only usual care for 6 months after randomization; they will be given the Toolkit with a single coaching call upon completion of the final interview, to ensure their access to depression treatment."
89027559|NCT05644015|Experimental|experimental group (play group)|The experimental group played the escape room game. The experimental group played the game once in total.
89027560|NCT05644015|No Intervention|control group|No intervention was made in the control group.
89027561|NCT04324723|Experimental|Intervention|Participants in this group received a WhatsApp message reminding them to seek further medical attention for their measurement indicated hypertensive condition.
89027562|NCT04324723|No Intervention|Control|Participants in this group did not received a WhatsApp message reminding them to seek further medical attention for their measurement indicated hypertensive condition.
89027563|NCT05643937|Active Comparator|The control group|The control group received routine health education after catheterization, including introducing the purpose, method, advantages and complications of PICC insertion to patients before catheterization and signing informed consent. During catheterization, PICC assistant explained relevant matters needing attention and cooperative actions to the patient. After catheterization, patients were instructed to carry out grip training and limb activities.
89027564|NCT05643937|Experimental|Experimental group|On the basis of routine health education in the control group, the experimental group screened the high-risk behaviors of patients through the questionnaire of daily life behavior habits, and formulated the precise and concrete health education program for their high-risk behaviors
89027565|NCT02955498|Experimental|R-T|First period: administration of reference drug, Second period: administration of test drug
89027566|NCT02955498|Experimental|T-R|First period: administration of test drug, Second period: administration of reference drug
89027567|NCT05643898|Experimental|Mamá, te entiendo (Mom, I get you)|Participants assigned to this arm will receive a guided 8-week cognitive-behavioral app-based intervention for reducing postpartum depressive symptoms.
89033086|NCT00530309|Experimental|Subjects receiving GSK716155 + placebo|Eligible subjects will receive GSK716155 with doses of 15 milligrams once a week, 30 milligrams once a week, 50 milligrams biweekly or 100 milligrams once every four weeks. Subjects will also receive placebo.
89033087|NCT02917785|Experimental|Karman curettage|after a retained product of interception is observed in ultrasound examination, the women in this arm will undergo Karman curretage.
89033088|NCT02917785|No Intervention|Control|
89565087|NCT01687153||Traumatic Brain Injury (TBI)|65-100 Vietnam Veterans with Traumatic Brain Injury (TBI), but without PTSD, mild cognitive impairment (MCI)/dementia
89565088|NCT01687153||Post Traumatic Stress Disorder (PTSD)|65-100 Vietnam Veterans with PTSD, but without TBI, MCI/dementia
89565089|NCT01687153||Controls|65-100 Vietnam Veteran Controls without TBI or PTSD and comparable in age, gender, and education to the other cohorts
89565090|NCT01687153||TBI w/ MCI|65-100 Vietnam Veterans with TBI but without PTSD who meet the criteria for MCI but not dementia
89565091|NCT01687153||PTSD w/ MCI|65-100 Vietnam Veterans with PTSD but without TBI who meet the criteria for MCI but not dementia
89565092|NCT01687153||Controls w/ MCI|65-100 Vietnam Veteran Controls without TBI or PTSD who meet the criteria for MCI but not dementia, and are comparable in age, gender, and education to the other cohorts
89565093|NCT03047759|Active Comparator|Intervention A|water flosser
88814939|NCT00952718|No Intervention|Control|No intervention.
89565094|NCT03047759|Active Comparator|Intervention B|air floss
89565095|NCT04435639|Experimental|MLD + Adjustable Compression Sleeve.|Manual lymph drainage + Adjustable Compression Sleeve.
88814940|NCT00952718|Experimental|Inspiratory muscle training|With intervention.
88814941|NCT01010282|Active Comparator|Glycerin and Polysorbate 80 based artificial tear|Glycerin and Polysorbate 80 based artificial tear
89565096|NCT04435639|Active Comparator|MLD + Coban Compression Bandage.|Manual lymphatic drainage + Coban compression bandaging.
88968713|NCT04734093||Sohag university recruited patients|
89565097|NCT04969237||healthy subjects 2019|subjects with diseases not influencing vitamine D values without substitution nor post-COVID
89565098|NCT04969237||healthy subjects 2020|subjects with diseases not influencing vitamine D values without substitution nor post-COVID
89565099|NCT04969237||healthy subjects 2021|subjects with diseases not influencing vitamine D values without substitution nor post-COVID
89565100|NCT04969237||post-COVID subjects 2021|subjects with diseases not influencing vitamine D values without substitution with diagnosed post-COVID syndrome
89565101|NCT03045419||Patients group|"with small hepatic nodules (10-19mm) or atypical hepatic nodule (= or > 20mm) and high-risk group of HCC~scheduled for gadoxetic acid-enhanced liver MRI or liver nodule biopsy"
89565102|NCT03045419||Living liver donor candidates|"living liver donor candidates without history of liver disease~schedule for gadoxetic acid-enhanced liver MRI as preoperative workup~only used for control of normal liver parenchymal enhancement on hepatobiliary phase"
89565103|NCT01594853|Experimental|exercise|Female carriers as well as healthy age and gender matched individuals will participate in an exercise paradigm.
89565104|NCT03047681||Study group|patients undergoin transcatheter aortic valve implantation
89565105|NCT03047681||Control group|patient undergoing diagnostic coronary angiography
89565106|NCT05137561|Active Comparator|PSMA PET/CT guided biopsy arm|PSMA PET/CT guided biopsy will be done from PSMA avid lesion of the prostate after reviewing the whole body PSMA PET/CT scan.
89565107|NCT05137561|Active Comparator|MRI directed TRUS guided biopsy|The MRI-directed transrectal ultrasound-guided per-rectal prostate biopsy will be done by cognitive fusion.
89565108|NCT04341467|Experimental|Amisulpride group|The initial dose of amisulpride group is 50mg/d, and the maximum dose is 800mg/d.
89565109|NCT04341467|Active Comparator|Olanzapine group|The initial dose of olanzapine is 2.5 mg/d, and the maximum dose is 20 mg/d.
89565110|NCT04933591|Active Comparator|study group|Individuals aged 18-50 with varicose veins and CEAP C2-C4, Ep, As, Pr. Clinical and ultrasound examinations will be used to confirm varicose veins disease. It is planned to take blood samples from a varicose vein before and after administration of Venarus® (100 mg hesperidin + 900 mg diosmin) for 2 months
89565111|NCT04933591|No Intervention|control group|Individuals aged 18-50 with varicose veins and CEAP C2-C4, Ep, As, Pr vein. Clinical and ultrasound examinations will be used to confirm varicose veins disease. It is planned to take blood samples from a varicose vein at inclusion and 2 months later/
89565112|NCT04872881|Active Comparator|ETT Group|"ETT will be repositioned with direct laryngoscopy (ETT cuff will be inflated just above the vocal cords). The Reposition Time will start with the cuff deflation and end with successful ventilation after repositioning. If the ETT can not be repositioned within 5 minutes, it will be considered as a Failed Airway and tracheostomy will be continued with the usual method (ETT cuff will be inflated under the vocal cords)"
89565113|NCT04872881|Active Comparator|LMA Group|"After selecting the appropriate LMA size for the patient, the ET Tube will be removed and the LMA will be inserted. The LMA Insertion Time will start with the cuff deflation of the ETT and end with successful ventilation after LMA insertion. If the LMA cannot be inserted in 3 attempts, it will be considered as a Failed Airway and tracheostomy will be continued with the usual method (ETT cuff will be inflated under the vocal cords)"
89565114|NCT05137483||With cognitive impairment|Pulmonary function test, COPD assessment scale, Mini-Mental State Examination and Montreal Cognitive Assessment Scale, 6 min pegboard ring test, grip strength measurement, Fatigue Impact Scale and St.George Respiratory Questionnaire will be applied to the group.
89565115|NCT05137483||without cognitive impairment|Pulmonary function test, COPD assessment scale, Mini-Mental State Examination and Montreal Cognitive Assessment Scale, 6 min pegboard ring test, grip strength measurement, Fatigue Impact Scale and St.George Respiratory Questionnaire will be applied to the group.
89565116|NCT04872647|No Intervention|Usual Diabetic Care|Usual diabetic care for this study will include a diabetic visit with their primary care provider at the beginning and end of the 12 weeks. They will also be asked to continue their current level of physical activity and eating habits.
89565117|NCT04872647|Experimental|Usual Diabetic Care Plus Virtual Health Coaching|"For the duration of the 12 weeks, Healthy at Home will provide health coaching in 10-20 minute phone calls weekly. They will request daily blood glucose logs as this is part of Healthy at Home's normal procedure. The health coach and subject will choose a patient-directed overarching goal such as lose weight, or improve my blood sugar numbers, etc. that the health coach will then help the patient turn into a SMART goal. They will do this by utilizing a list of lifestyle change categories as top priority goals from which to choose from in their patient-directed health coaching sessions. Texting will be utilized to request daily blood glucose and provide real-time coaching via text."
89565118|NCT04591249|Other|Usual postoperative care|Participants randomized to usual care group will receive postoperative care as determined by their treating surgeon.
88968714|NCT04734093||Minia university recruited patients|
88968715|NCT04734093||Assuit university recruited patients|
88968716|NCT04734093||Kasr Elini recruited patients|
88968717|NCT04734093||Tanta university recruited patients|
88968718|NCT04734093||Monofia university recruited patients|
88968719|NCT04734093||Aswan university recruited patients|
88968720|NCT04734093||Ain shams university recruited patients|
89565119|NCT04591249|Experimental|Usual postoperative care + Physical activity intervention|Participants randomized to the physical activity intervention group will receive usual postoperative care as determined by their treating surgeon and novel physical activity intervention.
89565120|NCT03044873|Experimental|BMS 986165 and Rosuvastatin|
88968721|NCT00040378||Combination therapy|vitamin E (alphatocopherol) and selenium
88968722|NCT00040378||Vitamin E only|vitamine E (alphatocopherol) and placebo
88968723|NCT00040378||Selenium only|selenium and placebo (Placebo replacement for vitamin E)
88968724|NCT00040378||Placebo|placebo (Placebo replacement for vitamin E) and placebo (Placebo replacement for selenium)
89033089|NCT04000854|Active Comparator|Calcium hydroxide|Root canal dressing with Ca(OH)2 (Calasept)
89033090|NCT04000854|Active Comparator|Chlorhexidine|Root canal dressing with clorhexidine digluconate 2 % gel
89033091|NCT03994614|Experimental|the TEAS intervention group|Patients in this group will be given TEAS treatment for 12 weeks prior to COS.
88814942|NCT01010282|Experimental|Artificial Tears Formulation 1|Formulation 1: Carboxymethylcellulose sodium, glycerin and Polysorbate 80, based artificial tear
89565121|NCT03044951|Experimental|cryoballoon ablation|patients who accept cryoballoon ablation
89565122|NCT03044951|Active Comparator|radiofrequency ablation|patients who accept radiofrequency ablation
89565123|NCT03044795|Experimental|Part A|Patients with TNBC, platinum sensitive high grade serous ovarian cancer or BRCA-mutated (non-)breast and (non-)ovarian cancer will be included prior to the RAD51 assay and treated with veliparib irrespective of the assay result. All patients, including TNBC patients, will receive veliparib monotherapy until at least the first tumor assessment after 8 weeks of treatment.
89565124|NCT03044795|Experimental|Part B|Only patients with a RAD51 assay HR deficiency will be included. First there will be a pre-screening procedure followed by a tumor lesion biopsy on which the RAD51 assay will be performed. In case of a RAD51 assay indicating HR proficiency, patients will not be eligible for treatment in this study and cannot be included. Patients with a RAD51 assay indicating HR deficiency will be included. Eligible patients will be treated with veliparib monotherapy until at least the first tumor assessment after 8 weeks of treatment. In case of 0/15 patients within one patient subgroup having RAD51 tests showing HR-deficiency inclusion for this sub-group will be closed.
89565125|NCT04587583|Active Comparator|WeCareAdvisor|immediate use of the WeCareAdvisor tool for a 1 month period
89565126|NCT04587583|Active Comparator|WeCareAdvisor after 1 month|after a wait period of 1 month, use of the WeCareAdvisor tool for a 1 month period
89565127|NCT04581811|Experimental|Prolonged Proning Arm|Patients will receive 24 hours in the prone position followed by 8 hours in the supine position for the duration of the study
89565128|NCT04581811|Active Comparator|Traditional Proning Arm|Patients will receive standard 16 hour prone positioning followed by 8 hours in the supine position for the duration of the study
89565129|NCT05137249||patients with COVID 19 disease|Patients diagnosed with and hospitalized due to COVID-19. Subgroups: ICU admitted COVID-19 + patients vs COVID 19 pts. at normal ward-
89565130|NCT05137249||Healthy volunteers|healthy volnuteers
89565131|NCT04430153||Low match|A group with both low observed and perceived upper limb ability.
89565132|NCT04430153||Good match|A group with both good observed and perceived upper limb ability.
89565133|NCT04430153||Mismatch|A group with good observed but low perceived function.
89565134|NCT03047291|Placebo Comparator|Control group: placebo oral tablet|Placebo tablets. Intervention: 30 placebo tablets were given after the mechanical debridement of implants with mucositis and periimplantitis.
89565135|NCT03047291|Experimental|Test group: probiotic oral tablet|Probiotic tablets (Periobalance®, Sunstar, Switzerland). Intervention: 30 probiotic tablets were given after the mechanical debridement of implants with mucositis and periimplantitis.
89565136|NCT04487899||Instructors group|Group of flight instructors at the reactor school.
89565137|NCT04487899||Students group|Group of students at the reactor school.
89565138|NCT04865705|Experimental|Tilelizumab+Albumin Paclitaxel + Carboplatin/Cisplatin|Tilelizumab 200mg d1 Albumin Paclitaxel 260mg/m2 d1 Carboplatin/Cisplatin 75mg/m2/AUC5 d1IV,Q3W *2cycles
89565139|NCT04375111|Active Comparator|SAP block for management of post-mastectomy pain|the patients in this group shall undergo Serraturs anterior plane block for management of post-mastectomy pain.
89565140|NCT04375111|Active Comparator|TTP block combined with SAP block for post-mastectomy pain|the patients in this group shall undergo combined Serraturs anterior plane block, and Transversus thoracic plane block for management of post-mastectomy pain.
89565141|NCT03044717||Cardiology fellows and faculty|"Fill out a nutrition survey three times at 0, 3, and 6 months and be present at a prevention educational conference every 5 weeks until the end of the study.~This group will also complete a 3-hour nutrition module prior to study completion."
88814943|NCT01010282|Experimental|Artificial Tears Formulation 2|Formulation 2: Carboxymethylcellulose sodium, glycerin, and Polysorbate 80 based artificial tear
88814944|NCT03016988|Other|Bortezomib,Fludarabine and Cytarabine|Bortezomib(V) 1.3mg/m2, subcutaneously,day 1,4,8,11; Fludarabine(F) 25mg/m2, intravenously day 1-3; Cytarabine(A) 500mg/m2 for 3 days(day1-3).
88814945|NCT02245802||Low risk group|CU Prediction model < 3
88814946|NCT02245802||High risk group|CU Prediction model >=3
88814947|NCT00953654|Experimental|Strength Training|Lower-body strength training exercise twice weekly for 6 weeks at an intensity progressing from 50% to 75% predicted one-repetition maximum
88814948|NCT00953654|Experimental|Endurance Training|Six-week lower-body dynamic cycling exercise condition completed twice weekly and matched to the strength training arm on total work completed, total time actively engaged in exercise and load progression.
88814949|NCT00953654|No Intervention|Waiting List Control|Waiting list control condition in which participants will maintain their current lifestyle and will not enter a six-week exercise training intervention, but will complete outcome measures along the same time progression as the intervention arms.
88814950|NCT03017066|Experimental|Infant formula|Patients were given infant formula 6 hours prior to surgery. Gastric volume was assessed before ingestion, 1 hour prior to the surgery, and before the induction of general anesthesia using ultrasound.
88814951|NCT03017066|Experimental|Carbohydrate drink|Patients were given carbohydrate drink 2 hours prior to surgery. Gastric volume was assessed before ingestion, 1 hour prior to the surgery, and before the induction of general anesthesia using ultrasound.
88814952|NCT03016910||Type 2 diabetes|This group will consist of 300 patients with type 2 diabetes mellitus without symptoms or known coronary heart disease. The group will be followed for one year and CCTA will be performed at baseline and after one year.
88814953|NCT03016910||Type 1 diabetes|This group will consist of 50-100 patients with type 1 diabetes mellitus without symptoms or known coronary heart disease. The group will be followed for one year. CCTA will be performed at baseline and after one year.
88814954|NCT03016832|Experimental|Huangkui|Placebo drug that simulates Irbesartan tablets 150mg /qd, oral dosing; HuangKui Capsule 2.5g/tid, oral dosing
88814955|NCT03016832|Active Comparator|controlled|Placebo drug that simulates Irbesartan tablets 150mg /qd, oral dosing; HuangKui Capsule 2.5g/tid, oral dosing irbesartan tablets 150mg /qd, oral dosing; Placebo drug that simulates HuangKui capsule 2.5g/tid, oral dosing
88814956|NCT03016832|Other|combined treatment|irbesartan tablets 150mg /qd, oral dosing HuangKui Capsule 2.5g/tid, oral dosing.
89565142|NCT04898179||Telecare group|"When discharged, patients will be followed at home by a telecare nursing and specialist teleconsultation program for 3 months. The key element of the program will be a structured nurse-managed telephone support and, when necessary, video consultations, to follow patients, for the first month. During these contacts, the nurse will conduct a standardized interview enquiring about the general clinical condition of the patient. In the case of any symptom or problem, the patient will be able to call the service. At the end of the third month, patients will contact again to check their clinical condition and to close the program. Patients will be provided with a pulse oximeter to measure O2 saturation.~At the start and end of the program, patients were administered the SF-12 quality of life questionnaire."
89565143|NCT04898179||Control group|The patients in the control group will be followed by their general practitioner and they will be contacted after three months to check their clinical condition.
89565144|NCT04867577||vertebral osteoporotic compression fracture|Patients with osteoporotic vertebral compression receiving vertebroplasty or cemented screws reconstruction
89565145|NCT05137171|Experimental|AK105 and anlortinib|AK105 200mg iv q3w;anlotinib 12mg 2w on/1w off po qd;21 days as a cycle until PD,intolerable toxicity, investigator or patient decision to withdraw, non-adherence to treatment or trial procedures.
89565146|NCT04384679|Experimental|Hydrophilic polymer and potassium ferrate powder|Hydrophilic polymer with potassium ferrate powder is applied to the surgical wound with pressure until hemostasis is achieved
89565147|NCT04384679|No Intervention|Direct pressure with sterile gauze|Direct pressure with sterile gauze is applied to the surgical wound until hemostasis is achieved
89565148|NCT04866875|Active Comparator|Rapid weight loss|Participants in this group will be deprived in 1000 kcal/day (calculated based on their individual energy requirements) for 10 weeks
89565149|NCT04866875|Experimental|Slow weight loss|Participants in this group will be deprived in 500 kcal/day (calculated based on their individual energy requirements) for 20 weeks
89565150|NCT04858997|Experimental|Palbociclib-AI|ER(+)/HER2(-) patients with histologically or cytologically proven diagnosis of adenocarcinoma of the breast with evidence of locoregionally recurrent or metastatic disease receive palbociclib PO daily on days 1-21, combined with AI as first-line treatment Disease assessments measured by CT imaging will be performed at first 4 weeks, 8weeks, then every 8weeks (± 7 days) from the date of randomization until radiographic/clinical documentation of progressive disease per the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria.
89565151|NCT05135143|Active Comparator|Infertility male patients|Infertile male patients will receive the antioxidant formula for more than 172 days. Divided in two groups. One will take the active substance, to the other group placebo treatment will be given.
89565152|NCT05135143|Placebo Comparator|Control group|Placebo treatment and control and comparative variables will be measured.
89565153|NCT04865549|Experimental|TAD arm|Sentinel Node Biopsy + Targetted Axillary Dissection (Clipped cN1 node) extraction + lymphadenectomy.
89027568|NCT05643898|No Intervention|Waitlist|Participants in the WL condition will receive the same assessments as those in the intervention condition. Participants allocated to WL may access their local mental health services during their waiting period. In Chile, patients diagnosed with depression by a general practitioner have guaranteed access to treatment at low or no cost. Treatment varies according to depression severity, with group or individual therapy, alone or combined with pharmacotherapy. After the follow-up assessment, the WL group will be offered access to the intervention.
89027569|NCT01303159|Experimental|Radiofrequency probe (ENDOHPB)|"Intervention:~The EndoHPB is an endoscopic bipolar catheter designed to ablate tissue in malignant tumors within luminal structures, such as the biliary tree or pancreatic ducts. EndoHPB can be deployed via an ERCP or Percutaneous Transhepatic Cholangiographic (PTC) route. By using radiofrequency (RF) energy to heat the tissue in the duct prior to insertion of the stent, the surrounding tissue becomes coagulated and this may delay tumour growth and the time before the stent lumen becomes blocked. Thereby, allowing increased periods between the need for intervention and further stent deployment"
89027570|NCT00505596|Experimental|Computerized decision aid|Participants instructed to view the updated PT Tool and told that they can have whatever tests they would like (including no tests) and that tests that are not covered by their insurance will be paid for by the study (Informed free choice). They also participate in a baseline pre-randomization interview and one follow-up telephone interview.
89565154|NCT04867265|Active Comparator|Professional Adult Medium Skin CPR-AED Training Manikin with CPR Monitor (Prestan)|medical students trained BLS trainers and medical students trained in BLS will provide 2 minutes cycle of BLS according to ERC guidelines 2021 wearing the breathable self-sterilizing nanofiber respirators with accelerated copper
89565155|NCT04867265|Active Comparator|Resusci Anne QCPR AED (Laerdal)|medical students trained BLS trainers and medical students trained in BLS will provide 2 minutes cycle of BLS according to ERC guidelines 2021 wearing the breathable self-sterilizing nanofiber respirators with accelerated copper
89565156|NCT04867265|Active Comparator|Resusci Baby QCPR (Laerdal)|medical students trained BLS trainers and medical students trained in BLS will provide 2 minutes cycle of BLS according to ERC guidelines 2021 wearing the breathable self-sterilizing nanofiber respirators with accelerated copper
88814957|NCT00955916|Experimental|CLAG Regimen with Gleevec®|Combined chemotherapy treatment (CLAG regimen) with Gleevec® (imatinib mesylate).
89027571|NCT00505596|No Intervention|Usual care|Control group, in which participants receive no intervention beyond a baseline pre-randomization interview and one follow-up telephone interview.
89027572|NCT01302964|Experimental|Mirtazapine|The starting dose for subjects is 7.5 mg daily. The maximum daily dose will be 45 mg.
89027573|NCT01302964|Placebo Comparator|Placebo|Subjects randomized to placebo arm will receive capsules identical in size and appearance to those subjects receiving study drug. Placebo capsules contain inactive ingredients.
89033092|NCT03994614|No Intervention|No intervention group|Patients in this group will not be given any interventions for 12 weeks prior to COS.
89565157|NCT04858763||2020 Cohort|This is the 2020 MS cohort who experienced a clinician confirmed relapse during April - June 2020, during the first wave of the COVID-19 pandemic.
89565158|NCT04858763||2019 Cohort|2019 MS cohort who experienced a clinician confirmed relapse during April - June 2019.
88814958|NCT01010906|Experimental|Mild Hepatic Insufficiency (HI)|Participants with mild hepatic insufficiency (HI) administered a single 300 mg oral tablet of vaniprevir
89565159|NCT04863469|Experimental|B-POC high load Intervention|aerobic exercise [heartrate range (HRR) 70-75% of max HR, on treadmill] and a computerized high-load task for 45 minutes, 3 times per week, for 6 weeks
89565160|NCT04863469|Sham Comparator|B-POC low load intervention|aerobic exercise [heartrate range (HRR) 70-75% of max HR, on treadmill] and a computerized low-load task for 45 minutes, 3 times per week, for 6 weeks
88814959|NCT01010906|Experimental|Healthy Control to Mild HI|Healthy, matched to mild HI, control participants administered a single 300 mg oral tablet of vaniprevir
89027574|NCT04515381|Experimental|Therapeutic touch group|Each student from the Therapeutic touch (TT) group was given TT sessions via Krieger-Kunz method in a total of 8 times in the manner of twice a week for one group (Monday - Wednesday) and another group (Tuesday - Thursday) for a duration of 1 month (4 week). TT application procedure: The procedure was explained to the student, the student person was concentrated, concentrated practitioner for TT application, the student's entire body was evaluated from head to foot with the practitioner's hands at a distance of about 2 inc, hands were moved regularly and rhythmically to prevent imbalances in the energy field, the energy field was re-evaluated from top to bottom and rebalanced if there was a blocked area, finally, the student was left to rest and response to the treatment was observed. The TT sessions of 20 minutes were applied on the students and they were given a short rest at the end of the session
89027575|NCT04515381|Placebo Comparator|Placebo group|For students in the placebo group, the similar duration (20 minutes) and frequency (2 sessions a week, total of 8 sessions) of TT was applied with hands at a certain distance from the body (approximately 5 cm) and they were moved without a specific order. The application was performed by the other researcher in a separate room to the placebo group.
89027576|NCT04515381|Other|Control group|There was no attempt being made towards the students within the control group. At the end of the 4th week, all students were asked to repeat measurements
89027577|NCT00484055|Active Comparator|treatment|"Use of local CollagenGentamicin and enhanced sternal fixation according to the Clinical routine introduced 4 years earlier as a result of a previous RCT on 2000 patients. In that sense these patients did not receive any intervention but just the standard treatment introduced 4 years earlier.~The aim of the study was to PROSPECTIVELY include a defined number of patients to compare their complication rate with that from aControl Group of patients från a previous RCT to verify that the effect of the treatment was stable over time.~As the study did not include any intervention compared to the present standard treatment at that time ethical approval was Exempt."
89565161|NCT05306119|Active Comparator|Main group|Patients with low back pain who had undergone myocardial revascularization surgery within a year prior to admission to a sanatorium organization, admitted for a course of sanatorium treatment with an individual program of medical rehabilitation with the use of means, affecting both diseases lasting up to 21 days
89565162|NCT05306119|No Intervention|Comparison group|Patients with low back pain who had undergone myocardial revascularization surgery within a year prior to admission to a sanatorium organization, admitted for a course of sanatorium treatment lasting up to 21 days
89565163|NCT05306119|No Intervention|Control group|Healthy people aged 40-60 y.o.
89565164|NCT05305729||Subjects with a genetic disease|
89565165|NCT04488679|Experimental|PRF along with MTA|5 ml of the participant blood will be drawn into 10 ml test tubes without an anticoagulant and centrifuged immediately .centrifugation will be done using a tabletop centrifuge for 12 min at 2700 rounds per minute. The resultant product will exhibit three layers. platelet-poor plasma at the surface, PRF clot in the middle, and red blood cells at the bottom. Sterile tweezers inserted into a test tube to retrieve the PRF clot. The prepared fibrin membrane will be gently packed over the pulp
89565166|NCT04488679|Active Comparator|MTA direct pulp capping|MTA is primarily calcium oxide in the form of tricalcium silicate, dicalcium silicate and tricalcium aluminate. Bismuth oxide is added for radiopacity, MTA is considered a silicate cement rather than an oxide mixture, a so its biocompatibility is due to its reaction products. MTA elevates the expression of transcription factors, induces dentin bridge formation, possesses biocompatibility9, and sustains a high pH for a longer duration and a close physiochemical seal with dentin that forms an insoluble barrier to prevent microleakag
89565167|NCT05305417|Experimental|Regenerative Endodontic Treatment|This treatment consists of obturated the root canal preparations under an biological-based protocol using autologous biological elements and bioactive materials that allows restore the connective pulp-like tissue within the canals.
89565168|NCT05305417|Active Comparator|Conventional root canal treatment|This treatment consist on obturated the root canal preparations under the conventional protocol with an inert biomaterials like guttapercha and endodontics cements to seal the root canals.
89565169|NCT05305339||Group A (Control group)|Singleton pregnancies undergoing elective pre-labour CS at gestational age (34+0 to 40+0) that are otherwise healthy.
89565170|NCT05305339||Group B (Chronic hypertension)|It means systolic blood pressure of 140 mm Hg or more, a diastolic blood pressure of 90 mm Hg or more, or both, that is diagnosed or present before pregnancy or before 20 weeks of gestation on two occasions at least 4 hours apart. Hypertension that is diagnosed for the first-time during pregnancy and that does not resolve in the typical postpartum period also is classified as chronic hypertension
89565171|NCT05305339||Group C (Gestational hypertension)|It is usually diagnosed when systolic blood pressure is 140 mm Hg or more or a diastolic blood pressure of 90 mm Hg or more, or both, on two occasions at least 4 hours apart after 20 weeks of gestation, in a woman with a previously normal blood pressure. Gestational hypertension is considered severe when the systolic level reaches 160 mm Hg or the diastolic level reaches 110 mm Hg or both.
88814960|NCT01010906|Experimental|Moderate HI|Participants with moderate HI administered a single 300 mg oral tablet of vaniprevir
88814961|NCT01010906|Experimental|Healthy Control to Moderate HI|Healthy, matched to moderate HI, control participants administered a single 300 mg oral tablet of vaniprevir
88814962|NCT01010906|Experimental|Severe HI|Participants with severe HI administered a single 200 mg oral tablet of vaniprevir
88814963|NCT01010906|Experimental|Healthy Control to Severe HI|Healthy, matched to severe HI, control participants administered a single 200 mg oral tablet of vaniprevir
88814964|NCT01668017|Experimental|Part 1: Pimasertib 30mg in Solid Tumor|
88968725|NCT00040456|Placebo Comparator|Placebo|"A computer-generated randomization list will be created by a Baylor College of Medicine statistician (unrelated to study) prior to the study.~Patients are randomly assigned to either start with Mg pidolate or placebo and will continue that therapy for 24 weeks. Then, after a 2 month wash-out period, they will be switched to the other arm and continue on that arm for another 24 weeks, followed by 8 weeks of observation off study drug. Both patient and medical care provider(s) will be blinded to treatment assignment. Mg pidolate and placebo will be distributed through the pharmacy with labels that do not indicate the assignment."
88968726|NCT00040456|Active Comparator|MG Pidolate Administration|"A computer-generated randomization list will be created by a Baylor College of Medicine statistician (unrelated to study) prior to the study.~Patients are randomly assigned to either start with Mg pidolate or placebo and will continue that therapy for 24 weeks. Then, after a 2 month wash-out period, they will be switched to the other arm and continue on that arm for another 24 weeks, followed by 8 weeks of observation off study drug. Both patient and medical care provider(s) will be blinded to treatment assignment. Mg pidolate and placebo will be distributed through the pharmacy with labels that do not indicate the assignment."
88968727|NCT04734132|Experimental|Moringa|Six Moringa oleifera capsules (400 mg dry leaf powder /capsule) consumed daily during 12 weeks. Two capsules consumed with each of the three main meals.
88968728|NCT04734132|Placebo Comparator|Placebo|Six placebo capsules containing microcrystalline cellulose consumed daily during 12 weeks. Two capsules consumed with each of the three main meals.
88968729|NCT00040768|Experimental|Treatment (bortezomib)|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients who received prior bortezomib and achieved at least a partial response of at least 6 months duration may also receive therapy as above.
88968730|NCT00017238|Experimental|Treatment (KRN5500)|"Patients receive KRN5500 IV over 24-72 hours on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 1-3 patients receive KRN5500 at the starting dose over escalating infusion durations. After the longest duration of infusion time is safely reached, cohorts of 3-6 patients receive escalating doses of KRN5500 until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, additional patients are accrued to receive treatment with KRN5500 at the recommended phase II dose."
89565172|NCT05305339||Group D (Preeclampsia)|Women with PE fulfilled the criteria if they had hypertension (> 140/90 mmHg) and proteinuria (> 0.3 gm/day or ≥ +1 by dipstick urine analysis at ≥ 20 weeks of gestation or protein-to-creatinine ratio of 0.30 or more). If no proteinuria, hypertension associated with thrombocytopenia, renal or liver impairment, or pulmonary edema was sufficient to diagnose PE as per ACOG Practice Bulletin No .202
89565173|NCT04794283||Hand milking with Diabetes|93 women with DM1, DM2 and medically treated GDM who are patients in specialist maternity care at Soderhospital in Stockholm and who plan to hand milk are part of this group.
89565174|NCT04794283||Not hand milking with diabetes|A group of 93 women are then selected from 1 April 2021and back in the same number as the group1 (n=93) this group only gave milk substitute the first 24h.
89565175|NCT05305183|Active Comparator|Alendronate Sodium Tablets and Minodronate Tablets -matching placebo|subjects received 70 mg alendronate sodium tablet weekly and a minodronate tablet matching placebo monthly for 48 weeks.
89565176|NCT05305183|Experimental|Minodronate Tablets and Alendronate Sodium Tablets-matching placebo|subjects received 50mg minodronate tablets monthly and an alendronate sodium tablets -matching placebo weekly for 48 weeks.
88968731|NCT00040885|Experimental|infliximab + docetaxel|"Patients receive infliximab IV over 2 hours once weekly on weeks 1, 3, and 5 of the first course and once weekly on weeks 1 and 5 of all subsequent courses and docetaxel IV over 1 hour (immediately after completion of infliximab infusion once weekly on weeks 1-6 of each course.~Treatment repeats every 8 weeks for 2-3 courses in the absence of disease progression or unacceptable toxicity.~Quality of life, fatigue, appetite/anorexia, cachexia, and weight are assessed at baseline, weekly on weeks 1-8, and then monthly for the remainder of study treatment.~Patients are followed every 6 months for 5 years."
89027578|NCT01302691|Experimental|L50/H12.5/A5|Participants receive 1 tablet, containing 50 mg losartan potassium (L50), 12.5 mg hydrochlorothiazide (H12.5), and 5 mg amlodipine besylate (A5), orally, once daily, for 8 weeks.
89033093|NCT04689165|Experimental|Experimental Vaccine|Two doses of Experimental Group A meningococcal polysaccharide vaccine at the vaccination schedule of week 0, 12
89565177|NCT04782271|Experimental|Single administration Low Dose once daily|1 treatment day
89565178|NCT04782271|Experimental|Single administration Middle Dose once daily|1 treatment day
89565179|NCT04782271|Experimental|Single administration High Dose once daily|1 treatment day
89565180|NCT04782271|Experimental|Single administration High Dose twice daily|1 treatment day
89565181|NCT04782271|Experimental|Multiple administrations Low Dose once daily|7 treatment days
89565182|NCT04782271|Experimental|Multiple administrations Middle Dose once daily|7 treatment days
89565183|NCT04782271|Experimental|Multiple administrations High Dose once daily|7 treatment days
89565184|NCT04782271|Experimental|Multiple administrations High Dose twice daily|7 treatment days
89565185|NCT04781179|Experimental|CM-II Technique|
89565186|NCT04781179|Placebo Comparator|Psychoeducation|
89565187|NCT01668797|Placebo Comparator|Placebo|Placebo comparator for 52 weeks
89565188|NCT01668797|Experimental|Brexpiprazole (OPC-34712)|Brexpiprazole (OPC-34712) for 52 weeks
89565189|NCT05305027||IVF patients: first serum βHCG|IVF patients who undergo βHCG after fresh or frozen embryo transfer
89565190|NCT04767607||Breast cancer plus chemotherapy|Patients of the group will receive chemotherapy treatment.
89565191|NCT04767607||Breast cancer without chemotherapy|Patients of the group will not receive chemotherapy treatment.
89565192|NCT04759027||X-ray|Measurements of subacromial distance on standardized direct radiography
89565193|NCT04759027||ultrasound|Measurements of subacromial distance on ultrasound
89565194|NCT05304637|Experimental|Therapy Arm|Patient receive iTEAR100 treatment
89565195|NCT04511767||ASD group|the autism spectrum disorder group
89565196|NCT04511767||GDD group|the global developmental disorder group
89565197|NCT04511767||LD group|the language disorder group
89565198|NCT05304559|Experimental|Drug group|S-ketamine 0.1mg/kg was injected intravenously during anesthesia induction and esmolamine 0.1mg/ (kg.h) was injected intravenously during anesthesia maintenance.S-Ketamine was put into the analgesia pump as an adjuvant for continuous analgesia until 2 days after operation.
89565199|NCT05304559|Experimental|Device group|The hip fracture was diagnosed clinically on admission and ultrasound-guided iliofascial space block was performed after evaluation, and the analgesia lasted until 2 days after operation.
89565200|NCT05304559|Placebo Comparator|Normal saline group|normal saline 0.1ml/kg was injected intravenously during anesthesia induction and normal saline 0.1ml/ (kg.h) was injected intravenously during anesthesia maintenance.normal saline was put into the analgesia pump as an adjuvant for continuous analgesia until 2 days after operation.
89027579|NCT01302691|Active Comparator|L50 + A5|Participants receive tablet, containing 50 mg losartan potassium (L50), and tablet containing 5 mg amlodipine besylate (A5), orally, once daily, for 8 weeks.
89565201|NCT03045263|Active Comparator|Pivotal Response Treatment|Pivotal Response Training with children ages 3-6 years of age with an Autism Spectrum Disorder diagnosis
89565202|NCT03045263|No Intervention|Waitlist Control|Children in WL will be offered treatment following WL condition.
89565203|NCT04478851|Experimental|Intervention|All participants will be involved in group exercise classes, twice a week for 12 weeks.
89565204|NCT04866797|Active Comparator|cyclic merocyanine long-UVA absorber|
89027580|NCT01241084|Placebo Comparator|Placebo|Antileukotrienes+Placebo
89027581|NCT01241084|Active Comparator|Lactobacillus reuteri|Antileukotrienes+Lactobacillus reuteri
89027582|NCT05643820|Active Comparator|Group A|Patients prescribed with topical 5% Permethrin lotion two applications seven days apart and applied overnight.
89027583|NCT05643820|Active Comparator|group B|Patients weighing greater than 15kgs prescribed with oral ivermectin 200microgram/kg two doses seven days apart
89027584|NCT01302418||Symptomatic|Individuals with signs and symptoms of an acute respiratory tract infection where it is suspected that such signs and symptoms are caused by a respiratory virus infection.
89027585|NCT01241123|Placebo Comparator|Traditional Ambulation regimen|All patients will receive pedometers to record the total amount of ambulation. These patients will ambulate without limitations or goals. Most surgeons request that post-operative patients ambulate at least 2 to 3 times a day.
89027586|NCT01241123|Active Comparator|Walkers|All patients will receive pedometers to record the total amount of ambulation. Patients in the experimental group will have assigned nursing staff assisting in ambulation in these patients at least three times a day.
89027587|NCT00484263|Active Comparator|1|
89027588|NCT00484302|Experimental|CapOpus|
89027589|NCT00484302|Active Comparator|Treatment as usual|
89027590|NCT01241162|Experimental|Single arm study|Biological/Vaccine: Autologous dendritic cell vaccine with adjuvant
89027591|NCT00484341|Experimental|A: low-dose NGR-hTNF|0.8 mcg/m² of NGR-hTNF
89027592|NCT00484341|Experimental|B: high-dose NGR-hTNF|45 mcg/m² of NGR-hTNF
89027593|NCT00484341|Experimental|C: low-dose NGR-hTNF + doxorubicin|0.8 mcg/m² of NGR-hTNF + doxorubicin
89027594|NCT00484341|Experimental|D: high-dose NGR-hTNF + doxorubicin|45 mcg/m² of NGR-hTNF + doxorubicin
89027595|NCT01242566|Experimental|temozolomide|Administration of temozolomide 150-200 mg/m2/day for 5 consecutive days every 4 weeks for a maximum of 12 cycles or until disease progression or prohibited toxicity
89027596|NCT04515225||HIV-infected patients|All HIV-infected patients on active follow-up, whatever clinical and biological condition, on ARV treatment or not, and whatever ARV combination
89027597|NCT04514835|Experimental|Cisplatin+Capecitabine+Sintilimab|Cisplatin+Capecitabine+Sintilimab
89027598|NCT00484211|Experimental|A|
89565205|NCT04866797|Placebo Comparator|placebo|
89565206|NCT04476355|No Intervention|control group|In the same ICU, the former(2019-12~2020-12) patients were the control group, data collected through case system.
89565207|NCT04476355|Experimental|experimental group|In the same ICU, the patients in the study period were the experimental group
89565208|NCT04865471|Experimental|Liver transplantation|Auxiliary liver transplantation and staged hepatectomy
88814965|NCT01668017|Experimental|Part 1: Pimasertib 45 mg in Solid Tumor|
89027599|NCT00484458|Experimental|1|Wallis Stabilization System
89027600|NCT00484458|Active Comparator|2|Total Disc Replacement
89027601|NCT00488891||Paliperidone extended release (ER)|Drug: Paliperidone ER will be prescribed to the patients at the investigator's discretion. Patient receive their medication according to usual care in their treatment setting ie, no study drug is provided
89027602|NCT00488891||Atypical antipsychotics agent (AAP)|AAP includes quetiapine, risperidone, olanzapine, ziprasidone or aripiprazole. Dosage and administration of antipsychotics will be prescribed at the investigator's discretion
89027603|NCT00484328|Experimental|1|
89027604|NCT00484328|Experimental|2|
89033094|NCT04689165|Active Comparator|Active Comparator Vaccine|Two doses of Control Group A meningococcal polysaccharide vaccine at the vaccination schedule of week 0, 12
89565209|NCT04117711|Experimental|AT-007|
89565210|NCT04117711|Placebo Comparator|Placebo Comparator|
89565211|NCT02613221|Experimental|panitumumab + TAS-102 combination therapy|Panitumumab 6 mg/kg every 2 weeks, plus TAS-102 35 mg/m² given orally twice a day in 5 days followed by a 2-day rest period for 2-week cycle, and then a 14-day rest period (28 days per 1 course).
89565212|NCT05304325||Obese with type 2 diabetes|
89565213|NCT05304325||Obese insulin-sensitive|
89565214|NCT05304325||Obese insulin-resistant|
89565215|NCT05304169|Experimental|Leuprorelin Acetate (Eligard® 45 mg)|Patients received two subcutaneous injections of Eligard® 45 mg (leuprorelin acetate), with the first injection given at baseline (Visit 1) and the second after 168 ± 3 days at Visit 4.
89565216|NCT04867031|Experimental|White fish (cod)|Participants will consume 1 portion (~130g) of white fish (Bird's Eye Inspirations Cod Fillets with Tomato & Rosemary), providing approximately 140µg of iodine, alongside 452mL of water. Urine will be collected for 36 hours following test food consumption.
89565217|NCT04867031|Experimental|Semi-skimmed milk|Participants will consume 1 portion (~450mL) of milk (Tesco UHT Semi-Skimmed), providing approximately 140µg of iodine, alongside 452mL of water. Urine will be collected for 36 hours following test food consumption.
89565218|NCT04867031|Experimental|Dried seaweed sheets|Participants will consume 1 portion (~6g) of dried seaweed sheets (Itsu Crispy Seaweed Thins), providing approximately 140µg of iodine, alongside 452mL of water. Urine will be collected for 36 hours following test food consumption.
89565219|NCT03045107|Experimental|Intracorporeal ileocolic anastomosis (IIA)|After complete right colon mobilization and ileocolic and right colic vessels ligation, the proximal transverse colon and the terminal ileum are transected and a side-to-side anastomosis is fashioned with a laparoscopic stapler.
89565220|NCT03045107|Active Comparator|Extracorporeal ileocolic anastomosis|After complete right colon mobilization and ileocolic and right colic vessels ligation, the terminal ileum, right colon, and proximal transverse colon are exteriorized for bowel division through a small midline skin incision in the upper abdomen. Then, a primary ileocolic side-to-side handsewn or mechanical anastomosis is fashioned extracorporeally.
89565221|NCT05304091||Patients with bradykinin-mediated angioedema|Patients with bradykinin-mediated angioedema, aged 18 years or older, followed in the internal medicine department of the Lille University Hospital
89565222|NCT04865081|Experimental|VACCIN box group|The anesthesiologist will intubate the participants in the VACCIN box group while using the VACCIN box that will be placed over the participants' head.
89565223|NCT04865081|No Intervention|Control group|Enrolled participants in the control group will be intubated without the use of the VACCIN intubation box (standard anesthesia).
89565224|NCT04865003||DNI group|patients with infection of two or more deep neck spaces (DNI group)
89565225|NCT04865003||DNI + DNM group|patients with infection of two or more deep neck spaces with secondary descending necrotizing mediastinitis (DNI + DNM group)
89565226|NCT04864769|Experimental|Krill Protein Hydrolysate|Krill Protein Hydrolysate
89565227|NCT04864769|Active Comparator|Soy protein isolate|Soy Protein isolate
88968732|NCT00040885|Active Comparator|placebo + docetaxel|"Patients receive docetaxel IV over 1 hour (immediately after completion of infliximab infusion once weekly on weeks 1-6 of each course. Patients receive placebo IV over 2 hours once weekly on weeks 1, 3, and 5 of the first course and once weekly on weeks 1 and 5 of all subsequent courses.~Treatment repeats every 8 weeks for 2-3 courses in the absence of disease progression or unacceptable toxicity.~Quality of life, fatigue, appetite/anorexia, cachexia, and weight are assessed at baseline, weekly on weeks 1-8, and then monthly for the remainder of study treatment.~Patients are followed every 6 months for 5 years."
89033095|NCT04689087|Experimental|Second line conventional treatment|
89033096|NCT03989661||Test group|This group corresponds to patients who had undergone preoperative embolization (with resorbable material) before myomectomy.
89033097|NCT03989661||Control group|This group corresponds to patients with myomectomy without embolization.
89565228|NCT04864769|Active Comparator|Whey protein isolate|Whey protein isolate
89565229|NCT04864769|Sham Comparator|Control|Water
89565230|NCT03042455|Experimental|Robot and rTMS|Robot-Assisted upper arm training and Repetitive Transcranial Magnetic Stimulation group(intervention group 1)
89565231|NCT03042455|Experimental|Robot|Robot-Assisted upper arm training group(intervention group2)
89565232|NCT03042455|Active Comparator|Conventional|Conventional training group(control group)
89565233|NCT04451785|Active Comparator|Healthy individuals|20 healthy subjets aged 6 years minimum will be included in this study. This is the control group.
89565234|NCT04451785|Experimental|Patients with hereditary spherocytosis|60 patients with hereditary spherocytosis will be included in this study.
89565235|NCT03042065|Experimental|vibrating Mesh nebulizer|Receive in the same aerosol solution 5 mg of Salbutamol (Ventolin, Glaxo, 5 mg / ml solution for nebulization) mixed with 0.5 mg Ipratropium Bromide (0.25 mg / ml) by nebulization every 20 min For 3 doses during the first hour of treatment, using vibrating Mesh nebulizer
88968733|NCT00041041|Experimental|Treatment (imatinib mesylate)|Patients receive oral imatinib mesylate twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88968734|NCT00041197|Experimental|Arm I (imatinib mesylate)|Patients receive oral imatinib mesylate (Gleevec; STI571) once daily. Treatment continues for 1 year in the absence of unacceptable toxicity. Patients who develop a recurrence during the year of initial treatment receive imatinib mesylate (Gleevec; STI571) at an increased dose. Patients who develop a recurrence after the year of initial treatment restart imatinib mesylate (Gleevec; STI571) and continue taking the drug at the discretion of the principal investigator.
88968735|NCT00041197|Placebo Comparator|Arm II (placebo)|Patients receive oral placebo once daily. Treatment continues for 1 year in the absence of unacceptable toxicity. Patients who develop a recurrence at any time discontinue placebo and crossover to arm I. Treatment on arm I continues at the discretion of the principal investigator.
88968736|NCT00017316|Experimental|Arm I|Patients receive SU5416 IV over 1 hour twice weekly and oral thalidomide daily beginning 1 day after the first dose of SU5416. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.
88968737|NCT00397072|Experimental|ZK-EPO|administered iv for 3 h every 21 days; dose reductions to 12 or 9 mg/m2 ZK-EPO were allowed in order to manage any treatment-related toxicity.
88968738|NCT02972372|Active Comparator|CRT group|3-weekly cycles of cisplatin and 5-fluorouracil chemotherapy and radical radiotherapy delivered in IMRT mode (total of 50Gy given in 25 fractions) will be given over a period 5-6 weeks.
88968739|NCT02972372|Active Comparator|Surgery group|The patients randomized to receive either standard esophagectomy will have the operation performed in an open manner with two-field lymphadenectomy
89565236|NCT03042065|Active Comparator|jet nebulizer|Receive, in the same aerosol solution, 5 mg of Salbutamol (Ventolin, Glaxo, 5 mg / ml solution for nebulization) mixed with 0.5 mg Ipratropium Bromide (0.25 mg / ml) by nebulization every 20 min For 3 doses during the first hour of treatment, using a jet nebulizer
89565237|NCT04709107||Elective|Patients undergoing elective revascularisation (endovascular or surgical) for PAD.
89565238|NCT04709107||Emergent|Patients undergoing emergent revascularisation (endovascular or surgical) for PAD.
89565239|NCT04858919|Other|study group|virgins with genital tract lesion
89565240|NCT05303389|Experimental|Posterior plating group|Fix the posterior fragment using a buttress plate through a posterolateral approach by an interval between flexor hallucis longus and peroneii.
89565241|NCT05303389|Active Comparator|Anterior to posterior group|Fix the posterior fragment using anterior to posterior 4.0 mm cannulated screws under xray guidance.
89565242|NCT04858841|Experimental|Levetiracetam|The group receives oral levetiracetam.
89565243|NCT04858841|Experimental|Perampanel|The group receives oral perampanel.
89565244|NCT04858841|Placebo Comparator|Placebo|The group receives oral placebo.
89565245|NCT03997747||comprehensive genomic analysis group|Patients undergo collection of tissue samples for genomic analysis via mass spectrometry, PCR, and microarray. The therapy patients received would not be based on the results of the genomic analysis.
89565246|NCT03970915|Experimental|ON (standard warming process + body warmer)|Patients included during the ON periods will constitute the experimental group. Warming will be provided by the body warmer in addition to the standard warming procedure (survival blanket and heating in the emergency vehicle).
89565247|NCT03970915|Sham Comparator|OFF / Control group (standard warming process )|Patients included during the OFF periods will constitute the control group. Warming will be provided by the standard warming procedure : survival blanket and heating in the emergency vehicle.
89565248|NCT05303155||Patient with COVID 19|Pediatric patient infected by COVID 19
89565249|NCT05303155||Pediatric patient without infection of COVID 19|Pediatric patient without infection of COVID 19
89565250|NCT04379089||Children <18|"Infants, children, and young adults age < 18 years~Admitted to the hospital with confirmed or presumed COVID-19 infection (includes admissions to emergency, ward, intensive care etc.)"
89565251|NCT04363177|Experimental|Web-based psychosocial peer-to-peer support|"Web-based psychosocial peer-to-peer support, using Thinking Healthy two times during pregnancy"
89565252|NCT04363177|Active Comparator|Standard perinatal care|Perinatal standard care in Hong Kong, Shanghai
88814966|NCT01668017|Experimental|Part 1: Pimasertib 60 mg in Solid Tumor|
89565253|NCT05302843|Experimental|dose exploration and dose expansion|Patients receive BPI-28592 PO. Cycles repeat every 28 days.
89565254|NCT05302219|Experimental|Measurement of plethysmography curve|Calm measurement of plethysmography curve using pulse oximetry with simultaneous monitoring of the breath cycle. In this experimental arm, participants will vary their breath cycle (different respiratory rates and different tidal volumes).
89565255|NCT04690465|Experimental|Resistance training|In the 16 week resistance training, there will be 3 sessions per week, the duration of each session will be 60 minutes, which include 10min of warm-up, 40min of main exercise, and 10min of cool-down. The intensity will be light to somewhat hard (Rating of Perceived Exertion (RPE) 11 to 13; using the Cantonese version of RPE). In resistance training, the weights (resistance) will be from participants' own bodies, dumbbells, and adjustable ankle weights.
89565256|NCT04690465|Active Comparator|Eight-form Yang-style Tai Chi program|In Tai Chi, the 16-week program will be divided into cognitive, associated, and automatic stages. The coach will apply a group teaching with individual instruction on specific movements based on participant's needs in skills learning and acquisition. The same training principles of individuality and progression as well as training log-book used in resistance training will also be applied to Tai Chi training program.
89565257|NCT04690465|No Intervention|Non-treatment Concurrent Control|Participants in this group will not participate in any specific intervention during the whole study (the 16-week intervention and 12-week follow-up periods), but they will be asked to keep a daily log on their physical activity, medicine used, illness, diet, sleep quality and other health and physical activity related information (e.g., attending healthy eating workshops).
88814967|NCT01668017|Experimental|Part 1: Pimasertib 30 mg in Hepatocellular Carcinoma (HCC)|
88814968|NCT01668017|Experimental|Part 1: Pimasertib 45 mg in HCC|
88814969|NCT01010984|Experimental|Transcatheter Arterial Chemoembolization|TACE using LC beads loaded with Doxorubicin
88814970|NCT05710601||Tissue sealers|Procedures performed using a 5 mm diameter, 35 cm length curved branch radiofrequency tissue sealer connected to a dedicated electric generator
88814971|NCT05710601||Bipolar forceps|Procedures performed using a 5 mm diameter, 35 cm classic rotating bipolar forceps
88814972|NCT05710523|Experimental|I-ACE training|Participants will receive twenty-two sessions on the non-pharmacological therapies' methodology and on awareness of body language.
88814973|NCT05710523|Active Comparator|Standard non-pharmacological therapies (NPT) training|Participants will receive twelve sessions on the non-pharmacological therapies' methodology.
88814974|NCT05710523|No Intervention|As usual control group|Participants will continue the usual care activities and non-pharmacological interventions already in use in the Nursing Homes without participating in the training.
88814975|NCT01011218|Experimental|BBT-I + Armodafinil|"Two Brief Behavioral Therapy for Insomnia (BBT-I) sessions in person and additional brief BBT-I sessions over the phone.~Armodafinil 150 mg/day by mouth."
88814976|NCT01011218|Experimental|Behavioral placebo + Armodafinil|"Control behavioral intervention is a sleep hygiene handout completed by participant.~Armodafinil 150 mg/day by mouth."
88814977|NCT01011218|Sham Comparator|BBT-I without Armodafinil|"Two Brief Behavioral Therapy for Insomnia (BBT-I) sessions in person and additional brief BBT-I sessions over the phone.~No pharmaceutical intervention."
88814978|NCT01011218|Placebo Comparator|Behavioral placebo without Armodafinil|"Control behavioral intervention is a sleep hygiene handout completed by participant.~No pharmaceutical intervention."
88814979|NCT01670201|Experimental|Mepilex Transfer Ag|Mepilex Transfer Ag is a soft silicone wound contact layer that absorbs and transfers exudate, maintains a moist wound healing environment and has antimicrobial properties.
88814980|NCT02245217|Experimental|PET/CT Imaging arm|
89565258|NCT04682743|Sham Comparator|saline group|
89565259|NCT04682743|Active Comparator|ondansetron group|
89565260|NCT04682743|Active Comparator|paracetamol group|
89565261|NCT05301985|No Intervention|Fasting group|conventional preoperative fasting protocol The participants in the Fasting group stopped oral intake at 12:00 pm, the night before surgery. After surgery the participants fasted until the recovery of function of the bowel.
89532034|NCT06338423|Other|Standard Mattress arm|"Patients will be operated in a beach chair position. The patient will ley on standard mattresses during the surgery.~Patients' demographics, and perioperative data including age, gender, body mass index (BMI), smoking, ASA score, incidence of co-morbidities, compliance with ERABS protocol, amount of intraoperative blood loss, intraoperative complications, and surgery duration will be collected. Blood samples will be collected on first postoperative day to measure RML markers (myoglobin, creatine kinase, creatinine). Symptoms of RML, AKI and other complications were monitored for 30 days after surgery."
89532035|NCT06338410|Experimental|KMC group|Premature infants and their mothers who will be provided with kangaroo mother care on third day of life. baby will be placed on bare chest of mother and before and after KMC urine samples will be collected from premature infants.
89532036|NCT06338410|No Intervention|Control group|premature infants and their mothers who will be provided with same conventional incubator care in NICU on day third of life their urine samples will also be collected before and after conventional care
89532037|NCT06338397|Experimental|Social & affective cognition assessment|
89532038|NCT06338371|Experimental|Training Content|Group receiving training on pelvic floor exercise
89532039|NCT06338371|No Intervention|Control Group|Untrained group
89532040|NCT06338345|Experimental|Piperacillin Tazobactam|75 patients under VA-ECMO receiving a novel administration of Piperacillin Tazobactam.
89532041|NCT06338345|Experimental|Cefepime|75 patients under VA-ECMO receiving a novel administration of Cefepime.
89532042|NCT06338345|Experimental|Meropenem|75 patients under VA-ECMO receiving a novel administration of Meropenem.
89532043|NCT06338332||Nasogastric tube|Patients with right sided obstructive colon cancer will receive non-surgical decompression with a nasogastric probe. Prior to the definitive oncological resection, patients undergo preoperative optimisation which involves the engagement of a dietician and physiotherapist. Patients eligible for elective resection will have their resection 7-10 days after initial decompression.
89532044|NCT06338332||Ileostomy|Patients with right sided obstructive colon cancer will receive a ileostomy. Prior to the definitive oncological resection, patients undergo preoperative optimisation which involves the engagement of a dietician and physiotherapist. Patients eligible for elective resection will be operated at least 7 days after initial decompression and no later than 4 weeks after initial presentation.
89532045|NCT06338332||Right-sided stent|Patients with right sided obstructive colon cancer will receive a right-sided stent. Prior to the definitive oncological resection, patients undergo preoperative optimisation which involves the engagement of a dietician and physiotherapist. Patients eligible for elective resection will be operated at least 7 days after initial decompression and no later than 4 weeks after initial presentation.
89532046|NCT06338319|Experimental|BOOST Program|"Parents in the BOOST Program group will receive books to read with their children and send smartphone video recordings of their reading interactions.~To provide support, parents will participate in 3 remote, parent-focused book-sharing intervention sessions"
89532047|NCT06338319|No Intervention|Standard of Care Comparison Group|"Parents in the Standard of Care Comparison Group will receive books to read with their children and send smartphone video recordings of their reading interactions.~Parents in the comparison group will not participate in BOOST intervention sessions."
89532048|NCT06338306||De novo heart transplant patients|Twenty-five de-novo heart transplant recipients will be enrolled, male and female, aging 18-70 years, receiving TAC in combination with steroids and antiproliferative drugs (MMF; EC-MPS) or m-TOR inhibitors (Everolimus; Sirolimus).
89532049|NCT06338293|Experimental|Inclisiran＋rosuvastatin group|Inclisiran sodium＋rosuvastatin 20mg group: Rosuvastatin was given 20mg daily for one year, and Inclisiran was given three times in total. After the first injection, 284mg(1.5ml solution) was injected subcutaneously, the second injection was 3 months after the first injection, and the third injection was in the ninth month.
89532050|NCT06338293|Placebo Comparator|Rosuvastatin group|Rosuvastatin group: Rosuvastatin 20mg daily for one year.
89532051|NCT06338280|Experimental|Sonara-enabled|
89532052|NCT06338280|No Intervention|Treatment as usual|
89532053|NCT06338267||Main|Participants who are not in a separate interventional treatment trial
89532054|NCT06338267||Intervention|Participants who are also in a separate interventional treatment trial
89532055|NCT06338254|Experimental|PMT Group|Pregnant women included in this group received a total of 12 sessions of percussion massage therapy, applied to their bilateral lower extremities for four weeks.
89532056|NCT06338254|No Intervention|Control Group|No massage therapy was applied to the lower extremities of the pregnant women in this group.
89532057|NCT06338241|Experimental|Galibone Group|The Galibone+ experimental group includes participants receiving Galibone+ after impacted mandibular third molar extraction, testing its osteogenic properties. Galibone+ is prepared per manufacturer's instructions, potentially by immersing in sterile saline. Applied post-extraction into the socket using specialized instruments, it's compared to a control group receiving Bio-Oss, a standard xenograft material. Experimental group patients receive postoperative medications, including antibiotics and pain management. Follow-up assesses pain, inflammation, complications, and bone regeneration via radiological evaluation. Goal: Assess Galibone+'s efficacy in bone regeneration versus control.
88968740|NCT00017394|Experimental|Treatment (bevacizumab, vinorelbine tartrate)|Patients receive bevacizumab IV over 30-90 minutes once every other week and vinorelbine IV over 6-10 minutes once weekly for 8 weeks. Treatment repeats every 8 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Patients with complete or partial response or stable disease after completion of the fourth course may receive additional courses of concurrent bevacizumab and vinorelbine administered once every other week or may continue therapy on the schedule as above.
89565262|NCT05301985|Experimental|Carbohydrate group|preoperative nutrition The participants of experimental group consumed 400 ml of a clear carbohydrate drink (12,5 gr/100 ml carbohydrate, 50 kcal/100 ml, pH 5.0) at 10:00 pm the evening before surgery and 200 ml of the carbohydrate drink on the day of surgery, 2 hours before induction of anesthesia. After surgery the participants fasted until the recovery of function of the bowel.
89565263|NCT04331509||Symptom tracker users|No Intervention
89565264|NCT04649593|No Intervention|according to clinical guidlines|Dystocic progress and an observed low AFL value (< 12.0 mmol/l).
89565265|NCT04649593|Experimental|intevention|"At dystocic labor and an observed high AFL value, the woman is randomized to one of the intended two study groups.~Group 1) Delivery according to the clinic's guidelines in case labor dystocia, i.e., oxytocin stimulation Group 2) Two bags of Samarin mixed in a glass of water. After an hour, In case of lack of progress, oxytocin stimulation is started."
89565266|NCT04636333|Experimental|Middle-dose vaccine (18-59 years) & Two dose regimen|Two doses of middle-dose experimental vaccine at the schedule of day 0, 14.
89565267|NCT04636333|Experimental|Middle-dose vaccine (18-59 years) & Three dose regimen|Three doses of middle-dose experimental vaccine at the schedule of day 0, 14 28.
89565268|NCT04636333|Experimental|High-dose vaccine (18-59 years) & Two dose regimen|Two doses of high-dose experimental vaccine at the schedule of day 0, 14.
89565269|NCT04636333|Experimental|High-dose vaccine (18-59 years) & Three dose regimen|Two doses of High-dose vaccine at the schedule of day 0, 14, 28.
89565270|NCT04636333|Experimental|Middle-dose vaccine (> 59 years) & Three dose regimen|Three doses of middle-dose experimental vaccine at the schedule of day 0, 14, 28.
89565271|NCT04636333|Experimental|High-dose vaccine (> 59 years) & Three dose regimen|Three doses of high-dose experimental vaccine at the schedule of day 0, 14, 28.
89565272|NCT04636333|Placebo Comparator|Middle-dose placebo (18-59 years) & Two dose regimen|Two doses of middle-dose placebo at the schedule of day 0, 14.
89565273|NCT04636333|Placebo Comparator|Middle-dose placebo (18-59 years) & Three dose regimen|Three doses of middle-dose placebo at the schedule of day 0, 14, 28.
89565274|NCT04636333|Placebo Comparator|High-dose placebo (18-59 years) & Two dose regimen|Two doses of high-dose placebo at the schedule of day 0, 14.
89565275|NCT04636333|Placebo Comparator|High-dose placebo (18-59 years) & Three dose regimen|Three doses of high-dose placebo at the schedule of day 0, 14, 28.
89565276|NCT04636333|Placebo Comparator|Middle-dose placebo (> 59 years) & Three dose regimen|Three doses of high-dose placebo at the schedule of day 0, 14, 28.
89565277|NCT04636333|Placebo Comparator|High-dose placebo (> 59 years) & Three dose regimen|Three doses of high-dose placebo at the schedule of day 0, 14, 28.
89565278|NCT01362049|Active Comparator|'Eligible' Subject Group - STAB|"Subjects between the ages of 21-55 years with low back pain >12 months who are eligible for Treatment-Based Classification (TBC) stabilization exercises based on current criteria:~straight leg raise > 90 degrees~aberrant trunk movement with trunk forward flexion~positive prone instability test AND/OR~passive lumbar mobility testing that is judged to be hypermobile at any level."
89565279|NCT01362049|Active Comparator|'Ineligible' Subject Group - STAB|Subjects between the ages of 21-55 years with low back pain >12 months who are not eligible for the TBC-based stabilization exercises based on current criteria
89565280|NCT01362049|Active Comparator|'Eligible' Subject Group - MSI|"Subjects between the ages of 21-55 years with low back pain >12 months who are eligible for Treatment-Based Classification (TBC) stabilization exercises based on current criteria:~straight leg raise > 90 degrees~aberrant trunk movement with trunk forward flexion~positive prone instability test AND/OR~passive lumbar mobility testing that is judged to be hypermobile at any level."
89565281|NCT01362049|Active Comparator|'Ineligible' Subject Group -MSI|Subjects between the ages of 21-55 years with low back pain >12 months who are not eligible for the TBC-based stabilization exercises based on current criteria
89565282|NCT04435561|Experimental|Standard physiotherapy rehabilitation and dry needling|"In addition to the usual therapy, the experimental group will receive the application of dry needling technique in the hemiparetic limbs.~Dry needling intervention will take place over a period of one and a half months (6 weeks), with a total of 6 sessions. Each session will be performed once a week, where a single puncture will be made in each muscle to be treated, using Hong´s technique and lasting 60 seconds per muscle (or until the muscle is release).~The muscles that will receive dry needling are the following ones:~Upper limb: infraspinatus, teres minor, pectoralis major, deltoid.~Lower limb: gastrocnemius, soleus and anterior tibial muscles."
89565283|NCT04435561|Other|Standard physiotherapy rehabilitation|The control group will receive the usual therapy and treatment.
89565284|NCT04481737|Experimental|PDTA-IIMR|
89565285|NCT04481737|Active Comparator|Peer support|
89565286|NCT03103009|Experimental|pasireotide|Interventions - One patient will be given a drug, pasireotide (Signifor), on a compassionate use basis for treatment of post-gastric bypass hypoglycemia. The minimal dose will be 0.3 mg subcutaneous daily and the maximal dose will be 0.6 mg subcutaneous twice daily. The patient may continue treatment with pasireotide indefinitely unless the patient experiences unacceptable toxicity, disease progression and/or treatment is discontinued at the discretion of the treating physician or Novartis or withdrawal of consent.
89565287|NCT02839291|Experimental|quality of life questionaries|Patients should complete 3 quality of life questionaries (EORTC-QLQ C30 ; EORTC QLQ-BM22 and Euroqol EQ-5D) at many time points : at inclusion, every 3 months and at the end of study visit (2 years after inclusion)
89565288|NCT04485481|Experimental|Experimental: Cohort 1:1 - 1:6 ADX-914|ADX-914 single SC dose
89565289|NCT04485481|Placebo Comparator|Placebo Comparator: Cohort 1:1 - 1:6 placebo|Placebo single SC dose
89565290|NCT04485481|Experimental|Experimental: Cohort 2:1- 2:3|ADX-914 multiple SC dose once every 2 weeks for 6 weeks
89565291|NCT04485481|Placebo Comparator|Placebo Comparator: Cohort 2:1- 2:3|Placebo multiple SC dose once every 2 weeks for 6 weeks
89565292|NCT04274491||Pelvic Organ Prolapse Surgery Patients|Participants with greater than or equal to stage II pelvic organ prolapse who are scheduled for reconstructive surgery will be recruited. Participants will be asked to complete a preoperative online survey regarding their health, recovery expectancy, and different roles. Additional online surveys will be send on postoperative days 14 and 42 to measure postdischarge surgical recovery
89565293|NCT03852511|Experimental|Intravenous|Patients will receive three single doses of NG-350A by IV infusion, followed by multiple cycles of check point inhibitor treatment.
89565294|NCT03787381|Other|Intervention|Uterine scar will be evaluated by vaginal ultrasound examination
89565295|NCT03153787|Experimental|Not pregnancy|Vaginal probiotic administration
89565296|NCT04196335|Experimental|single-arm|
89565297|NCT03357367|Experimental|PAD patients|"Experimental: PAD patients Patients referred for vascular ultrasound investigation for suspicion of peripheral artery disease (PAD).~Intervention is measurement of microvascular response to current application on the skin by TiVi system"
89565298|NCT04183699|Experimental|MRI targeted + systematic random biopsy|
89565299|NCT03020875|Active Comparator|PO Acetaminophen|"Preop:~Eligible patients will receive oral acetaminophen within 3 hours of OR start time.~Postop:~Eligible patients will be administered oral acetaminophen following 1 and 2 level LLIFs supplemented with instrumented posterior fusion to evaluate pain management outcomes. Dosing for the group will be the following:~• Oral Acetaminophen 1,000 mg every 6 hours for 48 hours postoperative. Medication will be given at least 6 hours following initial preoperative dose of oral acetaminophen.~Postop supplemental pain medications:~All patients will receive a standardized hydromorphone IV-PCA order set for 24 hours postoperatively. The use of tramadol and tapentadol will specifically be discouraged due to challenges in determining morphine-equivalent dosing with these specific agents. Similarly, acetaminophen containing combination products (e.g. oxycodone/acetaminophen or hydrocodone/acetaminophen) will not be allowed due to overlap with the primary study medications."
89565300|NCT03020875|Active Comparator|Intravenous Acetaminophen|"Preop:~Eligible patients will receive IV acetaminophen within 3 hours of OR start time.~Postop:~Eligible patients will be administered IV acetaminophen following 1 and 2 level LLIFs supplemented with instrumented posterior fusion to evaluate pain management outcomes. Dosing for the group will be the following:~• IV Acetaminophen 1,000 mg [100 ml] every 6 hours for 48 hours postoperative. Medication will be given at least 6 hours following initial preoperative dose of IV acetaminophen.~Postop supplemental pain medications:~All patients will receive a standardized hydromorphone IV-PCA order set for 24 hours postoperatively. The use of tramadol and tapentadol will specifically be discouraged due to challenges in determining morphine-equivalent dosing with these specific agents. Similarly, acetaminophen containing combination products (e.g. oxycodone/acetaminophen or hydrocodone/acetaminophen) will not be allowed due to overlap with the primary study medications."
89027605|NCT04514640|Experimental|General Meditation|"Participants will be asked to meditate every day during the daytime for at least 10 min/session. Participants can use any general meditation including the Daily Calm which can be found on the homepage or by clicking on the meditate tab in the app. Participants will be asked to not choose any sleep meditations or Sleep Stories."
89027606|NCT04514640|Experimental|Sleep Meditation|"Participants will be asked to meditate every day just before going to bed for at least 10 min/session. Participants can use any sleep meditations which can be found by clicking on the meditate tab and then sleep. Particpiants will be asked to not choose any general meditations including the Daily Calm or Sleep Stories."
89565301|NCT03102931|Experimental|Reduced ROS/RNS content products|Participants will be given and asked to smoke research cigarettes for the first 4 weeks. For the final 4 weeks of the study they will be given and asked to smoke low ROS content cigarettes.
88814981|NCT03023228|Experimental|diabetes self-management education|Diabetes survival skills self-management education (DSME) program content was aligned with American Diabetes Association and Joint Commission suggested key areas for hospital diabetes education. Content areas were as follows: when and how to take diabetes medications; glycemic goals and self-blood glucose monitoring; definition, prevention, recognition, and treatment of hypoglycemia and hyperglycemia; what to do before you see the dietitian; sick day management; and when to call the doctor or go to the ED. Program content was created for delivery via either DVD or print format.
88814982|NCT03023306|Active Comparator|preemptive group|"The preemptive group will receive the anti-emetic regimen i.v. (4 mg of ondansetron) 1h before the start of surgery. During surgery, 30 min before the end of operation, this group will receive i.v. 0.9% NaCl in equal volumes.The intervention consists of the different time points of antiemetic treatment, thus 1h before surgery vs intraopertively.~Intervention: Antiemetic treatment 1h before surgery"
88814983|NCT03023306|Other|intraoperative group|"The preventive group will receive i.v. 0.9% NaCl 1h before surgery and ondansetron 4 mg 30 min before the end of surgery at equal volumes.~Intervention: Antiemetic treatment intraoperatively"
88814984|NCT05710367|Experimental|Dapagliflozin 10mg Tab|SGLT2is- Dapagliflozin (Forxiga): 10 mg/d, oral drug
88814985|NCT05710367|Placebo Comparator|Placebo|Placebo tablet will have the same color, taste, smell and package as the verum tablet
89027607|NCT04514640|Experimental|Sleep Stories|"Participants will be asked to listen to a Sleep Story every day just before going to bed for at least 10 min/session. Participants can listen to any Sleep Story which can be found by clicking on the sleep tab. Participants will be asked to not choose any general meditations including the Daily Calm or sleep meditations."
89027608|NCT00484575|Active Comparator|propofol|propofol for sedation minimum 2 hours in CTICU after CABG
89027609|NCT00484575|Experimental|sevoflurane|Sevoflurane via AnaConDa for minimum 2 hours in CTICU after CABG
89027610|NCT04697342|Active Comparator|NIS with pressure injury(PI) education|Clinical nurses use Nursing information system(NIS) to log in nursing records every day, and pressure injury (PI) education pops out of the NIS window for teaching
89027611|NCT04697342|Active Comparator|NIS with PI education, and microvideo|In addition to the built-in PI education in the NIS that nurses use every day, it also provides a flipped digital learning plan course unit, which can be self-study courses anytime, anywhere, without being restricted by time and space. And hold a 4-hour physical course for participants.
89027612|NCT04697342|Experimental|NIS with PI education, and workshop|In addition to the built-in PI education in the NIS that nurses use every day, an 8-hour physical course is also provided.
89027613|NCT04514796|Experimental|40 mg/0.4 mL of SB5|100 mg/mL of SB5
89027614|NCT04514796|Active Comparator|40 mg/0.8 mL of SB5|50 mg/mL of SB5
89027615|NCT00484367|Active Comparator|1 AGT|
89027616|NCT00484367|Active Comparator|2 TFT|
89027617|NCT00484614|Active Comparator|1 PEM|
89027618|NCT00484614|Active Comparator|2 MRI|
89027619|NCT00488969|Active Comparator|Modified-release morphine then Placebo|up to a ceiling dose of 120 mg
89565302|NCT02996305|Experimental|OV101 regimen 1|OV101 once daily
89565303|NCT02996305|Experimental|OV101 regimen 2|OV101 twice daily
89565304|NCT02996305|Placebo Comparator|Placebo|Twice daily
89565305|NCT02612909|Placebo Comparator|Phase 2: Placebo|Subjects participating in Phase 2 and assigned to receiving two injections of placebo administered intramuscularly as a single dose, separated by 21 days.
89565306|NCT02612909|Active Comparator|Phase 2: Vaccine (15 mcg)|Subjects participating in Phase 2 and assigned to receiving two injections of IVACFLU-A/H5N1 vaccine (15 mcg concentration) administered intramuscularly as a single dose, separated by 21 days.
89565307|NCT02612909|Active Comparator|Phase 2: Vaccine (30 mcg)|Subjects participating in Phase 2 and assigned to receiving two injections of IVACFLU-A/H5N1 vaccine (30 mcg concentration) administered intramuscularly as a single dose, separated by 21 days.
89565308|NCT02612909|Placebo Comparator|Phase 3: Placebo|Subjects participating in Phase 3 and assigned to receiving two injections of placebo administered intramuscularly as a single dose, separated by 21 days.
89565309|NCT02612909|Experimental|Phase 3: Vaccine|Subjects participating in Phase 2 and assigned to receiving two injections of IVACFLU-A/H5N1 vaccine (15 mcg concentration) administered intramuscularly as a single dose, separated by 21 days.
89565310|NCT02975479|Placebo Comparator|Intralymphatic placebo injections|ALK Diluent, ATC-code V07AB. 3 injections with 4-7 weeks interval.
89565311|NCT02975479|Active Comparator|Intralymphatic active injections|"ATC-code V01AA02. 3 injections with 4-7 weeks interval in an up-dosing protocol; 1000 SQ-U, 3000 SQ-U, 10000 SQ-U.~***IMPORTANT INFORMATION! The up-dosing protocol is changed due to an adverse event at the last injection. New regimen: 1000 SQ-U, 3000 SQ-U, 3000 SQ-U. ***"
89565312|NCT03102853|Active Comparator|Nordic diet|
89565313|NCT03102853|Other|Control diet|
89565314|NCT04866485|Experimental|HBM4003+pembrolizumab|HBM4003 combined with pembrolizumab in subjects with advanced NSCLC and other solid tumors
89565315|NCT04858373|Experimental|Glucose as reference food|Fourteen healthy, normal weight subjects (male: 6, female: 8) after 12hr fast, consumed 50g available carbohydrates from D-glucose, three times, in different visits as reference food along with 300ml water; and 50g available carbohydrates from emmer bread from Greek emmer seeds, emmer bread from Italian emmer seeds, and whole wheat commercial soft bread, tested once, in different visits. there was a washout period of 2 days between visits. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min after food consumption. The first glucose sample was taken exactly 15min after the first bite of food or drink.
89565316|NCT04858373|Experimental|Emmer bread from Greek emmer|Fourteen healthy, normal weight subjects (male: 6, female: 8) after 12hr fast, consumed 50g available carbohydrates from D-glucose, three times, in different visits as reference food along with 300ml water; and 50g available carbohydrates from emmer bread from Greek emmer seeds, emmer bread from Italian emmer seeds, and whole wheat commercial soft bread, tested once, in different visits. there was a washout period of 2 days between visits. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min after food consumption. The first glucose sample was taken exactly 15min after the first bite of food or drink.
89027620|NCT00488969|Placebo Comparator|Placebo then modified-release morphine|Matching placebo
89027621|NCT04697108|Other|Proprioception Test (TRMOPL)|In the Familiarization stage (1), the TRMOPL was applied by means of a single evaluator with the aim of knowledge and understanding of the test. After five minutes, step (2) test started. In this step, the test was applied twice, by different evaluators, with an interval of five minutes between applications (inter-rater reliability). Ten minutes after the end of the tests, step (3) retest (intra-rater reliability) was started, following the same procedures as in step 2. The order of the evaluators was randomized through a draw in Excel, the order of randomization of the steps (2) and (3) was the same in order not to influence intra-rater reliability.
88814986|NCT05710289||Primary series of mRNA-1273|Manufactured by ModernaTX
88814987|NCT05710289||Primary series of ChAdOx1 nCOV-19|Manufactured by Astrazeneca or Serum Institute of India Pvt., Ltd
88814988|NCT05710289||A single dose vaccination of Ad26.COV2.S|Manufactured by Janssen Pharmaceuticals/Johnson & Johnson
88814989|NCT05710289||Primary series of BNT162b2|Manufactured by Pfizer
88814990|NCT05710289||Primary series of BBIBP-CorV|Manufactured by Sinopharm
89027622|NCT00489008|Experimental|Cohort 1|Stereotactic Body Radiation Therapy (SBRT) Stage I NSCLC
89027623|NCT00489008|Experimental|Cohort 2|Stereotactic Body Radiation Therapy (SBRT) Selective Stage II NSCLC
89027624|NCT00489008|Experimental|Cohort 3|Stereotactic Body Radiation Therapy (SBRT) Isolated Peripheral Lung Recurrent NSCLC
89027625|NCT00484731|Placebo Comparator|Injection with Saline|Injection with Saline instead of Bupivacain
88968741|NCT00041509|Experimental|SB424323, 500 mg BID|
89565317|NCT04858373|Experimental|Emmer bread from Italian emmer|Fourteen healthy, normal weight subjects (male: 6, female: 8) after 12hr fast, consumed 50g available carbohydrates from D-glucose, three times, in different visits as reference food along with 300ml water; and 50g available carbohydrates from emmer bread from Greek emmer seeds, emmer bread from Italian emmer seeds, and whole wheat commercial soft bread, tested once, in different visits. there was a washout period of 2 days between visits. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min after food consumption. The first glucose sample was taken exactly 15min after the first bite of food or drink.
89565318|NCT04858373|Experimental|Whole wheat commercial bread|Fourteen healthy, normal weight subjects (male: 6, female: 8) after 12hr fast, consumed 50g available carbohydrates from D-glucose, three times, in different visits as reference food along with 300ml water; and 50g available carbohydrates from emmer bread from Greek emmer seeds, emmer bread from Italian emmer seeds, and whole wheat commercial soft bread, tested once, in different visits. there was a washout period of 2 days between visits. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min after food consumption. The first glucose sample was taken exactly 15min after the first bite of food or drink.
89565319|NCT02888041|Experimental|Dinoprostone|In case of failure of cervical ripening after a first intravaginal delivery device of Dinoprostone (Propess® 10 mg), patients receive a second Propess®, followed by Oxytocin 5U.I/ml (Syntocinon®) (if necessary) and epidural analgesia if desired by the patient.
89565320|NCT02888041|Active Comparator|Oxytocine|In case of failure of cervical ripening after a first intravaginal delivery device of Dinoprostone (Propess® 10mg), patients receive directly Oxytocin 5U.I/ml (Syntocinon®) and epidural analgesia if desired by the patient.
89565321|NCT04858139|Placebo Comparator|placebo|patients will be injected with placebo
89565322|NCT04858139|Active Comparator|Lactate|patients will be injected with lactate solution
89565323|NCT01688167|Experimental|Intervention|Experimental condition clinics offer the MC and sexual risk reduction intervention: four group counseling sessions focused on male circumcision and sexual risk reduction.
89565324|NCT01688167|No Intervention|Standard of Care|"Male participants in the standard of care control condition CHCs will receive counseling per the VCT protocol guidelines. Participants will attend four video-based time-equivalent attention-control group sessions on endemic disease prevention strategies (e.g., TB, malaria, cholera, waterborne diseases). Female partners will be invited to participate in a similar four session program devoted to endemic disease risk reduction."
89565325|NCT01688167|No Intervention|Observational|"3 CHC sites will be randomly assigned as observation only; only aggregated clinic VCT and circumcision data will be collected."
89565326|NCT04864691|Experimental|endovascular recanalization plus standard medical treatment|patients with symptomatic non-acute intracranial artery occlusion treated by endovascular recanalization and standard medical treatment after procedure
89565327|NCT04864691|Active Comparator|standard medical treatment|Patients take aspirin 100 mg/day or clopidogrel 75mg/day for the entire follow-up period (EVR patients take aspirin 100 mg/day and clopidogrel 75mg/day for 30-90 days after procedure)
89565328|NCT02838745|Experimental|Pemetrexed (300 mg/m2) and Cisplatin (175 mg/m2)|Pemetrexed and cisplatin will be admixed together in 1 liter of normal saline. The admixture of pemetrexed/cisplatin is stable for 4 hours and should be prepared and delivered immediately before use in the OR. The length of the pemetrexed/cisplatin lavage will be 1 hour.
88968742|NCT00041509|Experimental|SB424323, 125 mg BID|
88968743|NCT00041509|Placebo Comparator|Placebo|
88968744|NCT00041548|Experimental|1|Nitric Oxide for Inhalation
88968745|NCT00041548|Placebo Comparator|2|oxygen
88968746|NCT00017472|Experimental|Arm I|Patients receive apolizumab IV over at least 2 hours on days 1, 2, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients with a complete or partial response who relapse after 2 months may receive an additional course of therapy provided they still express the 1D10 antigen.
88968747|NCT00041782|Experimental|Dalteparin|
88968748|NCT00042211|Experimental|1|Problem Solving Treatment
88968749|NCT00042211|Active Comparator|2|Control
88968750|NCT02970643|Experimental|Olanzapine group|Palonosetron and Olanzapine Without Dexamethasone in moderate risk chemotherapy induced nausea and vomiting group
88968751|NCT00042601|Placebo Comparator|Placebo|A clear, colorless, sterile solution for SC injection manufactured by Amylin Pharmaceuticals, Inc. Placebo solution is the same, sterile preserved formulation, except the active ingredient, pramlintide, is omitted.
88968752|NCT00042601|Active Comparator|Pramlintide|Pramlintide acetate (AC137) injection is a clear, colorless, sterile solution for SC injection manufactured by Amylin Pharmaceuticals, Inc. It consists of pramlintide (AC137) 0.6 mg/mL in sodium acetate buffer, pH 4.0, containing 43 mg/mL mannitol as an iso-osmolality modifier and 2.25 mg/mL metacresol as a preservative.
88968753|NCT00042796|Experimental|Treatment (decitabine)|Patients receive decitabine IV over 1 hour on days 1-5 and 8-12. Treatment repeats every 4-6 weeks for a minimum of 4 courses in the absence of disease progression or unacceptable toxicity.
88968754|NCT00042835|Experimental|Group I (cisplatin, etoposide, erlotinib, and docetaxel)|Patients receive cisplatin IV over 2 hours on days 1, 8, 29, and 36; etoposide IV over 1 hour on days 1-5 and 29-33; and oral erlotinib once daily on days 1-49. Patients undergo concurrent radiotherapy 5 days a week for 7 weeks beginning on day 1. Patients receive consolidation therapy comprising docetaxel IV over 1 hour on days 50, 71, and 92. Some patients may also receive oral erlotinib once daily on days 50-112.
88968755|NCT00042835|Experimental|Group II (paclitaxel, carboplatin, and erlotinib|Patients receive induction chemotherapy comprising paclitaxel IV over 1 hour and carboplatin IV over 30 minutes on days 1 and 21. Patients receive consolidation therapy comprising paclitaxel IV over 1 hour and carboplatin IV over 30 minutes on days 43, 50, 57, 64, 71, 78, and 85 and oral erlotinib once daily on days 43-91. Patients undergo radiotherapy concurrently with consolidation therapy 5 days a week for 7 weeks beginning on day 43.
89027626|NCT00484731|Active Comparator|Injection with Bupivacaine|Injection with Bupivacaine
89027627|NCT04515069|Active Comparator|Traditional technique for tooth preparation.|Tooth preparation performed directly on the tooth structure
89208586|NCT00615030|Experimental|Indacaterol Evening,Salmeterol, Indacaterol Morning|In period I, patients were instructed to take morning doses of a placebo to indacaterol delivered via SDDPI and placebo to salmeterol delivered via DPI. Indacaterol 300 μg once a day in the evening delivered via SDDPI with placebo to salmeterol delivered via DPI. In period II, salmeterol 50 μg twice daily delivered via DPI. One of the two daily doses of salmeterol was administered in the morning and the second dose in evening along with placebo matching indacaterol delivered by SDDPI. In period III, indacaterol 300 μg once a day in the morning delivered via SDDPI with a placebo to salmeterol delivered via DPI. Patients were also instructed to take evening doses of a placebo to indacaterol via SDDPI and placebo to salmeterol via DPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
89208587|NCT00615030|Experimental|Salmeterol, Indacaterol Evening, Placebo|In period I, salmeterol 50 μg twice daily delivered via DPI. One of the two daily doses of salmeterol was administered in the morning and the second dose in evening along with placebo matching indacaterol delivered by SDDPI. In period II, patients were instructed to take morning doses of a placebo to indacaterol delivered via SDDPI and placebo to salmeterol delivered via DPI. Indacaterol 300 μg once a day in the evening delivered via SDDPI with placebo to salmeterol delivered via DPI. In period III, during morning and evening, placebo matching indacaterol was delivered via SDDPI and placebo matching salmeterol was delivered via DPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
89565329|NCT02838745|Experimental|Pemetrexed (400 mg/m2) and Cisplatin (175 mg/m2)|Pemetrexed and cisplatin will be admixed together in 1 liter of normal saline. The admixture of pemetrexed/cisplatin is stable for 4 hours and should be prepared and delivered immediately before use in the OR. The length of the pemetrexed/cisplatin lavage will be 1 hour.
89565330|NCT03102541||Cardiac Surgery|214 adult patients with estimated GFR ≥60 ml/min/1.73 m2 (CKD-Epidemiology Collaboration equation) undergoing elective cardiac surgery (coronary artery bypass, valve replacements, combined or other surgery, with cardiopulmonary bypass) between November 2014 and October 2015 at the San Bortolo Hospital, Vicenza, Italy
89565331|NCT04143919|Experimental|Subjects with CV risk factors|Subjects with 2 or more CV risk factors will be identified. Cardiovascular risk factors include hypertension, dyslipidemia, obesity, vascular disease, diabetes mellitus, chronic kidney disease, arrhythmia requiring therapy, moderate to severe valvular disease, history of alcohol abuse, smoking, cancer chemotherapy, or thoracic radiotherapy, and abnormal findings in the most recent ECG or thoracic X-ray.
89565332|NCT00136435|Other|Only Arm for this study|Only Arm for this study
89565333|NCT04857749|Active Comparator|Control group|Data from patients in the control group will be collected as in the experimental group. In the first interview, the patients in the control group will be given a training booklet. Apart from this, the standard approach, treatment and care of the clinic will be applied to all patients.
89565334|NCT04857749|Experimental|Navigation grup|While the standard treatment approaches of the hospital are applied to all patients, a nursing navigation program will be applied in addition to the patients in the experimental group. The navigation program will be started on the first day of radiotherapy by giving a 30-minute visual training and handbook related to expected side effects. Afterwards, patient follow-up will continue with phone reminders and weekly follow-up for seven weeks.
89565335|NCT05045209||Virtual rehabilitation|Virtual pulmonary rehabilitation will be provided by a tablet with connection to a physiotherapist for monitored exercise sessions with educational videos provided on the tablet.
89565336|NCT03041831||Older adult individual interviews|The investigators will conduct 8 semi-structured 60-minute interviews with patient participants.The goal of these interviews is to determine the acceptability, utility, and perceived value of mobile health (mHealth) in helping older adults overcome barriers to health behavior change.
89565337|NCT03041831||Clinician individual interviews|The investigators will conduct 6 semi-structured 60-minute interviews with primary care clinicians who care for older adult populations.The goal of these interviews is to determine the acceptability, utility, and perceived value of mobile health (mHealth) in helping older adults overcome barriers to health behavior change.
88814991|NCT05710289||Primary series of CoronaVac|Manufactured by Sinovac
88814992|NCT01012388|Experimental|Radiesse|
88814993|NCT01670825|Experimental|Pulsed radiofrequency + local anesthetic injection|Local anesthetic injection plus pulsed radiofrequency over each affected occipital nerve
88814994|NCT01670825|Active Comparator|Corticosteroid injection + sham pulsed radiofrequency|"Injection with corticosteroid and local anesthetic over the occipital nerve(s)plus sham pulsed radiofrequency"
88814995|NCT03016676|Experimental|Spinal manipulation|Spinal manipulation -High velocity low amplitude thrust (HVLA), Dosages : 2 repetition at the same time, Duration-10-20 minutes. total 2 weeks.
88814996|NCT03016676|Experimental|Exercise therapy|Exercise Therapy(ET): Exercise therapy (ET) 3 program: self education, supervised exercise visits, and home exercise. Duration-45 minutes,Total number of visits 12 for 2 weeks.
88814997|NCT03022994||NCWS patients|"Forty consecutive adult patients with an IBS-like clinical presentation, according to Rome III criteria, and a definitive diagnosis of NCWS. The patients will be recruited between January 2016 and February 2017 at 2 centers: the Department of Internal Medicine at the University Hospital of Palermo, Italy, and the Department of Internal Medicine of the Hospital of Sciacca, Agrigento, Italy. All subjects will undergo upper gastrointestinal endoscopy and proctoscopy at the Gastroenterology Unit at the University Hospital of Palermo, Italy. Duodenal and rectal biopsies will be evaluated at 2 centers: the Pathology Unit at the University Hospital of Palermo, Italy, and the Institute of Pathology at the Spedali Civili of Brescia, Italy."
88814998|NCT03022994||IBS patients|"Forty sex- and age-matched subjects with IBS unrelated to NCWS or other food 'intolerance', diagnosed according to standard criteria during the same study period and enrolled, at the same 2 centers, as control group. All subjects will undergo upper gastrointestinal endoscopy and proctoscopy at the Gastroenterology Unit at the University Hospital of Palermo, Italy. Duodenal and rectal biopsies will be evaluated at 2 centers: the Pathology Unit at the University Hospital of Palermo, Italy, and the Institute of Pathology at the Spedali Civili of Brescia, Italy."
89565338|NCT03041831||Community leader individual interviews|The investigators will conduct 4 semi-structured 60-minute interviews with community leaders.The goal of these interviews is to determine the acceptability, utility, and perceived value of mobile health (mHealth) in helping older adults overcome barriers to health behavior change.
89565339|NCT03041831||Focus group discussions|The investigators will lead four 90-minute focus group discussions consisting of 6-8 older adult participants each. The goal of these focus groups is to determine the acceptability, utility, and perceived value of mobile health (mHealth) in helping older adults overcome barriers to health behavior change.
89565340|NCT02612285|Experimental|SNX-5422|Open-label administration of SNX-5422 capsules to total 100 mg/m2 every other day for 21 days (total = 11 doses), followed by a 7-day drug-free period. Each treatment cycle will be 28 days. Subjects will repeat this 28-day schedule until the cancer progresses or the subject is unable to tolerate SNX-5422.
89565341|NCT02642185||Ablation|Patients that are primarily treated with microwave ablation of colorectal liver metastases
89565342|NCT02642185||Resection|Patients identified in the Swedish liver registry during the same time frame subjected to liver resection, propensity score matched to the ablation group
89565343|NCT02609633|Active Comparator|Control: Usual Care - Current Diabetes Management System (DMS)|Participants will perform self-monitoring of blood glucose (SMBG) for 6 months using the current DMS device. Follow-up office visits will be scheduled at Months 3 and 6 to review and discuss SMBG data and modify the type 1 diabetes (T1D) regimen as needed.
89565344|NCT02609633|Experimental|Interventional: Accu-Chek® CONNECT DMS|Participants will receive training on Day 1 with the Accu-Chek® CONNECT DMS and will thereafter perform SMBG for 6 months. Follow-up office visits will be scheduled at Months 3 and 6 to review and discuss SMBG data and modify the T1D regimen as needed.
89565345|NCT04053907|No Intervention|CCM:Standard of Care|Community Case Management (CCM), with passively monitored malaria incidence by community health workers using standard RDTs and artemisinin-based combination therapy (ACT), artemether-lumefantrine (AL) according to national guidelines.
89565346|NCT04053907|Experimental|CCM plus weekly fever screening and treatment|CCM plus active case detection (ACD) by fever screening and treatment if positive. Trained village health workers (VHW) recruited for this study will carry out weekly visits of all residents and screen for fever using research-grade thermometers. A standard RDT will be performed in all individuals with a body temperature ≥37.5°C or with reported fever in the last 24 hours. RDT positive individuals will be treated with AL according to national guidelines.
89565347|NCT04053907|Experimental|CCM plus MSAT|CCM plus monthly screening for malaria infection and treatment of positive individuals, regardless of symptoms. Screening will be performed by research staff and timed to ensure a gap of 25-35 days between screening rounds; Positive individuals will be treated with AL, according to national guidelines.
88968756|NCT00042874|Experimental|Treatment (combination chemotherapy)|Patients receive irinotecan hydrochloride IV over 90 minutes followed 5 hours later by leucovorin calcium IV over 2 hours and alvocidib IV over 1 hour immediately followed by 5-FU IV continuously over 48 hours beginning on day 1 of weeks 1, 3, and 5. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of alvocidib and 5-FU until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Ten additional patients are treated at the MTD.
88968757|NCT00042952|Experimental|Treatment (imatinib mesylate and surgical resection)|Patients receive oral imatinib mesylate once daily. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients who achieve a partial response or stable disease with normalization of human chorionic gonadotropin may undergo surgical resection of residual lesions at each tumor status assessment. If residual viable germ cell tumor is present in the resected specimen, patients may resume imatinib mesylate. If no viable germ cell tumor is present in the resected specimen, then no further therapy is administered.
88968758|NCT00043069|Active Comparator|Arm I: calcium + cholecalciferol + placebo + estrogen|"Patients receive oral calcium, oral cholecalciferol, oral risedronate placebo, and oral estrogen placebo daily.~Treatment in all arms continues for 2 years.~Quality of life is assessed at baseline, monthly for 6 months, and then at 1 and 2 years.~Bone mineral density is assessed at baseline, 6 months, and 1 and 2 years."
88968759|NCT00043069|Experimental|Arm II: calcium + cholecalciferol + risedronate + estrogen|"Patients receive oral calcium, oral cholecalciferol, oral risedronate, and oral estrogen placebo daily.~Treatment in all arms continues for 2 years.~Quality of life is assessed at baseline, monthly for 6 months, and then at 1 and 2 years.~Bone mineral density is assessed at baseline, 6 months, and 1 and 2 years."
88968760|NCT00043069|Placebo Comparator|Arm III: calcium + cholecalciferol + placebo + estrogen|"Patients receive oral calcium, oral cholecalciferol, low-dose oral conjugated estrogens, and oral risedronate placebo daily.~Treatment in all arms continues for 2 years.~Quality of life is assessed at baseline, monthly for 6 months, and then at 1 and 2 years.~Bone mineral density is assessed at baseline, 6 months, and 1 and 2 years."
88968761|NCT00043069|Experimental|Arm IV: calcium + cholecalciferol + risedronate + estrogen|"Patients receive oral calcium, oral cholecalciferol, low-dose oral conjugated estrogens, and oral risedronate daily.~Treatment in all arms continues for 2 years.~Quality of life is assessed at baseline, monthly for 6 months, and then at 1 and 2 years.~Bone mineral density is assessed at baseline, 6 months, and 1 and 2 years."
88968762|NCT04732234|Active Comparator|( Group A)|ultrasound guided superior hypogastric plexus block using 20 ml Bupivacaine 0.5% before skin incision.
88968763|NCT04732234|Placebo Comparator|(Group B)|ultrasound guided superior hypogastric plexus block using 20 ml normal saline 0.9% instead of bupivacaine.
88968764|NCT00043225||Cystic Fibrosis|Cystic Fibrosis patients
88968765|NCT02970604|Experimental|Aspirin|Non-enteric coated Aspirin 75mg once daily for 7 days
88968766|NCT02970604|No Intervention|No treatment|No treatment for 7 days
88968767|NCT00043420|Experimental|Phase I: 0.08 mg/kg|Escalating dose groups: 0.08 mg/kg PF-3512676 Injection
88968768|NCT00043420|Experimental|Phase I: 0.16 mg/kg|Escalating dose groups: 0.16 mg/kg PF-3512676 Injection
88968769|NCT00043420|Experimental|Phase I: 0.24 mg/kg|Escalating dose groups: 0.24 mg/kg PF-3512676 Injection
88968770|NCT00043420|Experimental|Phase I: 0.28 mg/kg|Escalating dose groups: 0.28 mg/kg PF-3512676 Injection
88968771|NCT00043420|Experimental|Phase I: 0.32 mg/kg|Escalating dose groups: 0.32 mg/kg PF-3512676 Injection
88814999|NCT03022760|Active Comparator|Work-related measures|"One-day training for GP:s and rehabilitation coordinators~A treatment protocol which includes contact with the patient's employer~Clinical support from the Institute of Stress Medicine"
88815000|NCT03022760|No Intervention|Treatment as usual|
88815001|NCT05710211|Experimental|CLONEMF cohort|
88815002|NCT00956540|Experimental|Deflating|Deflating tracheal cuff (total air suction under negative pressure using a syringe) during periods of disconnection from mechanical ventilation in the weaning phase in patients tracheostomized for prolonged weaning or ventilatory support. During ventilatory support the tracheal cuff remain pressurized (30 mmHg).
88815003|NCT00956540|No Intervention|Not deflating|The tracheal cuff remain inflated all the time during the weaning phase in patients tracheostomized for prolonged weaning or ventilatory support
88968772|NCT00043420|Experimental|Phase I: 0.36 mg/kg|Escalating dose groups: 0.36 mg/kg PF-3512676 Injection
88968773|NCT00043420|Experimental|Phase II: 10 mg|Phase II: 10 mg flat dose (random assignment in Phase II)
89565348|NCT04053907|Experimental|CCM plus dry season MDA|CCM plus plus 3 monthly rounds of MDA with a long-acting ACT (dihydroartemisinin-piperaquine, DP) starting in the dry season (April, May, June) (tablets of 320/40mg and 160/20mg piperaquine/ dihydroartemisinin per tablet. Administration of a full course of DP will be done as per manufacturer's guidelines once daily for 3 days and according to body weight).
89565349|NCT04857125|Active Comparator|Multicomponent intervention|Pre-, intra- and postoperative interventions applied using the Fast-IM method.
89565350|NCT04857125|No Intervention|Standard care|Patients are receiving standard care.
89565351|NCT04864379|Experimental|RFA+PD-1+iNeo-Vac-P01|Patients will undergo radiofrequency ablation. At Week 3, patients will receive PD-1 at a dose of 200mg administered by intravenous infusion (IV) every 2 weeks. At Week 12,all patients,regardless of their disease status,iNeo-Vac-P01(300mcg per peptide)+ GM-CSF (40mcg) on days 1, 4, 8, 15, 22, 52, and 82 from week 12. Additional booster vaccines might be administered depending on ethics and patients' potential benefit.
89565352|NCT04864379|Experimental|RFA+iNeo-Vac-P01+PD-1|Patients will undergo radiofrequency ablation. At Week 12, patients will receive iNeo-Vac-P01(300mcg per peptide)+ GM-CSF (40mcg) on days 1, 4, 8, 15, 22, 52, and 82 from week 12. Additional booster vaccines might be administered depending on ethics and patients' potential benefit. At Week 16, patients,regard of their disease status,will receive PD-1 at a dose of 200mg administered by intravenous infusion (IV) every 2 weeks.
89565353|NCT00759343||Control Group|"The control subjects of this study will be asked to undergo renal ultrasound examination, if available, or will be asked to complete a disease history form to determine the presence or lack of a kidney stone. Urine and serum will then be taken for storage until further analysis.~Controls will be asked to undergo a screening renal ultrasound to ensure they are stone free, this will take approximately 45 minutes. If the controls are asked to complete the history form, this will not take more than 20 minutes. They will also give a blood and urine sample during this time to bring the total extra time up to at most 60 minutes for controls."
89565354|NCT00759343||Stone Group|"The stone group will undergo standard diagnostic procedures for their condition and recovery process. Serum and urine for storage and analysis will be taken prior to stone treatment and 6 weeks following stone treatment. This will allow for the determination of differences in a stone patient's protein profile while they have their stone and after they are stone free. All patients will be required to have a stone patient metabolic evaluation which includes serum and urine testing. The analysis will focus on the serum and urine sample that they provide.~The stone patient will be asked to undergo one extra tube of blood during their preoperative assessment which should only add a few seconds to their visit."
89565355|NCT04864457||Normal|Patients without coronary atherosclerotic burden
89565356|NCT04864457||Chronic coronary syndrome (CCS)|"CCS covers the different stages of development of coronary heart disease in addition to the clinical manifestations dominated by acute coronary thrombosis, including asymptomatic myocardial ischemia, vasospasm, and microcirculatory lesions. The six most common types of CCS include:Suspected coronary heart disease and stable angina symptoms, whether or not patients with dyspnea; Patients with newly emerged heart failure or left ventricular dysfunction suspected of CAD; Patients with no symptoms or stable symptoms within 1 year after ACS, or patients with recent revascularisation; Patients with or without symptoms more than 1 year after initial diagnosis or revascularization; Patients with angina pectoris, suspected vasospasm or microcirculatory diseases; Asymptomatic patients with coronary heart disease are found during screening."
89565357|NCT04864457||Acute coronary syndrome (ACS)|ACS is a group of clinical syndromes commonly characterized by acute myocardial ischemia, including unstable angina pectoris (UA); Acute non-ST-segment elevation myocardial infarction (NSTEMI); Acute ST-segment elevation myocardial infarction (STEMI).
89565358|NCT04849559|Experimental|Tradipitant|Oral Capsule
89565359|NCT04849559|Placebo Comparator|Placebo|Oral Capsule
89565360|NCT03044561|Experimental|Sildenafil citrate|
89565361|NCT03044561|Placebo Comparator|placebo|
89565362|NCT03044405|Other|Responders and non-responders|Fluid challenge of 500 ml of crystalloids over 15 minutes is given. Positive fluid responsiveness is defined by an increase in stroke volume (SV) of at least 15% assessed by focused transthoracic echocardiography.
89565363|NCT02455141|Active Comparator|Taxanes|Epirubicin plus Cyclophosphamide followed by Paclitaxel or Docetaxel
89565364|NCT02455141|Experimental|Taxanes plus carboplatin|Epirubicin plus Cyclophosphamide followed by Paclitaxel or Docetaxel + Carboplatin
89565365|NCT03044639|Experimental|Provision of LCT emulsions in PN|Intervention: Lipid Emulsions, Intravenous. Daily provision of LCT-based lipid emulsion as a part of parenteral nutrition along with dextrose, amino acids, electrolytes, trace elements, vitamins and water in the dose of 0.8-1.0 g/kg/day.
89565366|NCT03044639|Experimental|Provision of MCT/LCT emulsions in PN|Intervention: Lipid Emulsions, Intravenous. Daily provision of MCT/LCT lipid emulsion as a part of parenteral nutrition along with dextrose, amino acids, electrolytes, trace elements, vitamins and water in the dose of 0.8-1.0 g/kg/day.
89565367|NCT03044639|Experimental|Provision of Olive oil emulsions in PN|Intervention: Lipid Emulsions, Intravenous. Daily provision of Olive-oil/ LCT lipid emulsion as a part of parenteral nutrition along with dextrose, amino acids, electrolytes, trace elements, vitamins and water in the dose of 0.8-1.0 g/kg/day.
89565368|NCT03044639|Experimental|Provision of SMOF lipid emulsions in PN|Intervention: Lipid Emulsions, Intravenous. Daily provision of SMOF lipid emulsion as a part of parenteral nutrition along with dextrose, amino acids, electrolytes, trace elements, vitamins and water in the dose of 0.8-1.0 g/kg/day.
89565369|NCT04864301|Active Comparator|Tumescent Stretching Measurement Technique|"The Tumescent Stretching Measurement Technique (TSMT) group (N=12) will be administered an intracorporal injection (ICI) of 20 microgram Alprostadil. Hegar 7 dilator will be introduced through the corporotomy until reaching a bone stopping point. The tumescent penis will stretched maximally, and the proximally inserted dilator measured externally to the coronal sulcus."
89565370|NCT04864301|Active Comparator|Conventional Measurement technique|The control group (N=12) will receive no intraoperative ICI. Following maximal corporal dilatation, cylinder length will be estimated conventionally by adding up the internally measured distal and proximal corpora to the length of the corporotomy.
89565371|NCT02439385|Experimental|Avastin/FOLFIRI with curcumin|Patients will receive first line Avastin/FOLFIRI in combination with curcumin-containing supplement
89565372|NCT04429529|Experimental|TY027 0.5 mg/kg|Subject will be administered with 0.5 mg/kg of TY027 via IV infusion over a period of 30 minutes.
89565373|NCT04429529|Placebo Comparator|Placebo 0.5 mg/kg|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes.
89565374|NCT04429529|Experimental|TY027 5mg/kg|Subject will be administered with 5 mg/kg of TY027 via IV infusion over a period of 30 minutes.
89565375|NCT04429529|Placebo Comparator|Placebo 5 mg/kg|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes.
89565376|NCT04429529|Experimental|TY027 10 mg/kg|Subject will be administered with 10 mg/kg of TY027 via IV infusion over a period of 30 minutes.
89565377|NCT04429529|Placebo Comparator|Placebo 10 mg/kg|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes.
89565378|NCT04429529|Experimental|TY027 20 mg/kg|Subject will be administered with 20 mg/kg of TY027 via IV infusion over a period of 30 minutes.
89565379|NCT04429529|Placebo Comparator|Placebo 20 mg/kg|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes.
89565380|NCT04429529|Experimental|TY027 30 mg/kg|Subject will be administered with 30 mg/kg of TY027 via IV infusion over a period of 30 minutes.
89565381|NCT04429529|Placebo Comparator|Placebo 30 mg/kg|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes.
89565382|NCT03104959|Placebo Comparator|Placebo|Healthy volunteers consume alcohol independently and estimate number of drinks then apply Vick's vapor rub under nose and take placebo capsules based on number of drinks consumed and fill out a Hangover Symptom Scale the next morning
89565383|NCT03104959|Experimental|N-acetyl cysteine|Healthy volunteers consume alcohol independently and estimate number of drinks then apply Vick's vapor rub under nose and take N-Acetyl Cysteine capsules based on number of drinks consumed and fill out a Hangover Symptom Scale the next morning
88968774|NCT00043420|Experimental|Phase II: 25 mg|Weekly subcutaneous injections of 25 mg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.
88968775|NCT00043537|Experimental|Social Effectiveness Therapy for Children|Social Effectiveness Therapy for Children includes social skills training, peer generalization experiences and exposure therapy
89565384|NCT04006015||Main study group|31 people with COPD and 31 controls in the main study group.
89565385|NCT04006015||six-minute walk substudy|We will aim to have 40 participants participating in the 6 minute walk sub-study.
89565386|NCT04006015||Qualitative dance substudy|We will aim for 20 participants.
89565387|NCT03044171|Experimental|G-FLUOR+LASER|The corresponding hemiarcade received the application of Low Level Laser Therapy as a desensitizing treatment prior to in-office dental bleaching, followed by the application of 1.1% sodium fluoride after dental bleaching.
89565388|NCT03044171|Experimental|G-FLUOR|The correspondent hemiarcade received only the positioning of the inactive laser tip (placebo), prior to in-office dental bleaching, followed by the application of 1.1% sodium fluoride as a desensitizing treatment after dental bleaching
89565389|NCT03102463|Sham Comparator|Water Control|
89565390|NCT03102463|Active Comparator|Milk derived hydrolysate|
89565391|NCT03102463|Active Comparator|Parent Protein|
89565392|NCT04863989|Experimental|Small sized chest tube|Insertion of small sized chest tube in patients with traumatic hemothorax, pneumothorax or hemopneumothorax.
89565393|NCT04863989|Active Comparator|Large sized chest tube|insertion of large sized chest tube in patients with traumatic hemothorax, pneumothorax or hemopneumothorax.
89565394|NCT03102385|Experimental|Motivational Interview|Complete an on-line motivational interview regarding participants' blood donation experience.
89565395|NCT03102385|Placebo Comparator|Knowledge Interview|Complete an on-line interview regarding participants' general knowledge about blood donation.
89565396|NCT04863755|Other|DASH diet only|Patients receive a DASH diet and orientation to maintain their physical activity
89565397|NCT04863755|Other|DASH diet with pedometer|Patients receive a DASH diet and orientation to increase their physical activity with a pedometer steps count
88815004|NCT00956540|Experimental|Deflating 2|Deflating tracheal cuff during periods of disconnection from mechanical ventilation in the weaning phase in patients tracheostomized for low level of consciousness or inability to adequate mange the airway.
88815005|NCT00956540|No Intervention|Not deflating 2|The tracheal cuff remain inflated all the time during the weaning phase in patients tracheostomized for low level of consciousness or inability to adequate mange the airway.
88815006|NCT03022136|Experimental|Epidural Block|Epidural block for patients undergoing urological surgery
88815007|NCT01671293|Experimental|Multicomponent remote care model|A remote intervention based on counseling (telephone-based).
88815008|NCT01671293|Active Comparator|Usual care|Usual care.
88815009|NCT01671605||CKD not on dialysis|Patients with CKD not on dialysis (CKD III-IV)
88815010|NCT01671605||Controls|Controls with normal kidney function (Control)
88815011|NCT00957242|Active Comparator|warfarin|Oral warfarin titrated to an international normalization ratio (INR) of 2-3
88815012|NCT00957242|Placebo Comparator|placebo|Oral placebo (1mg or 2.5mg)
88815013|NCT01671839|Experimental|Subcutaneous tissue release|Device: Subcutaneous tissue release with the Cabochon System
89532058|NCT06338241|Active Comparator|Control group|"The control group serves as an active comparator to the Galibone+ experimental group in this study. Participants undergo identical impacted mandibular third molar extraction procedures as the experimental group but receive a standard material, likely Bio-Oss, instead of Galibone+.~Bio-Oss, a widely used xenograft material in dental surgeries, acts as a benchmark due to its osteoconductive properties. Applied post-extraction into the socket with specialized instruments, it provides a reference for comparing Galibone+'s efficacy. Patients in the control group receive postoperative medications as per the study protocol, including antibiotics and pain management. Follow-up assesses pain, inflammation, complications, and bone regeneration via radiological evaluation."
89532059|NCT06338228||patients managed for Acetabular fracture|collect the data for all the patients managed and operated on between 01/01/2020 AND 31/01/2022 for Acetabular fracture
89532060|NCT06338215|Experimental|Moderation|Advice about alcohol intake following a Mediterranean Alcohol Drinking Pattern: Moderation (7 or less drinks/wk in women and 14 or less drinks/wk in men), avoidance of binge drinking, consumption of alcohol with meals and preference for red wine.
88968776|NCT00043537|Experimental|Fluoxetine|Fluoxetine given in 10mg doses, up to 40 mg as tolerated
88968777|NCT00043537|Placebo Comparator|Pill placebo|"Capsules identical to fluoxetine given in 10 mg. doses up to 40 mg."
88968778|NCT00043693|Experimental|1|Participants will undergo the Family Intervention for Dual Diagnosis (FIDD) program.
88968779|NCT00043693|Active Comparator|2|Participants will be placed in a family psychoeducation program.
88968780|NCT04734327|Experimental|Orthokine periradicular injection|Ultrasound guided injections
88968781|NCT04734327|Active Comparator|Orthokine epidural injection|Ultrasound guided injections
88968782|NCT00043810|Experimental|Gelonin Purging of ASCT|Gelonin Purging of Autologous Stem Cells for Transplantation (ASCT) + Fludara/Busulfan
88968783|NCT00001586|Experimental|Low-Intermediate Risk B-Cell Pts|Previously untreated low or intermediate risk B-cell chronic lymphocytic lymphoma (CLL)/small lymphocytic lymphoma (SLL) patients (pts) not requiring chemotherapy. No rituximab fludarabine administered. Eligible to donate cells.
88968784|NCT00001586|Experimental|Intermediate-high Risk B-Cell Pts|Previously untreated intermediate or high risk B-cell chronic lymphocytic lymphoma (CLL)/small lymphocytic lymphoma (SLL) patients requiring chemotherapy. Rituximab 375 mg/m^2 by infusion on day 1, cycle 1 followed by fludarabine on day 2-6, 25 mg/m^2 day x 5 days administered as an intravenous push or intravenous piggyback over 10-30 minutes, repeated every 28 days.
88968785|NCT00391755|Active Comparator|1|ramelteon 8 mg po qhs with sleep and migraine journal
89532061|NCT06338215|Active Comparator|Abstention|Advice on alcohol abstention.
88968786|NCT00391755|Placebo Comparator|2|Placebo po qhs with sleep and migraine journal
88968787|NCT04731727|Experimental|Cross linking treatment for corneal thinning|Cornea will be saturated with Vitamin B2 (Riboflavin) and then treated with 365 nm wavelength ultra violet light.
88968788|NCT00391794|Experimental|ESSG|eight weekly 90-minute sessions
88968789|NCT00391794|Active Comparator|ES|one 4-hour educational program
88968790|NCT00018096|Experimental|bronchoscopy|2 bronchoscopies 4 hours apart; The first to instill the 3 experimental biologic agents in separate airways (HDM, LPS and saline-placebo), the second to perform BAL and brush biopsies 4 hours later in the same airways.
88968791|NCT00044551|Experimental|Arm 1|
88968792|NCT00397384|Experimental|Treatment (cetuximab and erlotinib hydrochloride)|Patients receive cetuximab IV over 1-2 hours on days 1, 8, and 15 and erlotinib hydrochloride PO QD on days 8-21. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
88968793|NCT00397423|Active Comparator|1|1,G-CSF,intervention
89532062|NCT06338202||Patients treated with mavacamten|Patients with symptomatic obstructive hypertrophic cardiomyopathy (NYHA functional class II-III) who receive mavacamten as part of routine clinical care
89532063|NCT06338189|Active Comparator|The 5Ad Diet|Participants are required to follow the 5Ad diet for 7 days, followed by a washout phase for 7 days, before crossing over to the active phase of the low FODMAP diet for 7 days.
89532064|NCT06338189|Active Comparator|The Low FODMAP Diet|Participants are required to follow the active phase of the low FODMAP diet for 7 days, followed by a washout phase for 7 days, before crossing over to the 5Ad diet for 7 days.
89532065|NCT06338176|Experimental|OPTIMUS-SAB care pathway|Province-wide real time automated notifications of new SAB cases will be established and delivered to a centralized SAB care team electronically through Connect Care. The centralized SAB care team consists of a SAB clinical coordinator, ID specialists and other ad hoc representation depending on patient needs. Following patient chart review, the centralized SAB care team contacts the most responsible physician (MRP) to provide preliminary recommendations to optimize care, both verbally and in written format, facilitated by Connect Care (Alberta Health Services electronic medical record).
89532066|NCT06338176|No Intervention|Standard of care|
89532067|NCT06338163|Experimental|Treatment|"Once a day starting 5 days before the operation:~Total body washing with usual soap/shampoo and single-use washcloths impregnated with a mix of Polihexanide, surfactants, and excipients.~Nasal cleaning 3 times a day with a Polihexanide Nasal Gel Oral gargles 3 times a day using 10 mL of a Polihexanide oral solution. After the closure of fascia, 10 minutes subcutaneous irrigation with 50 to 250 mL (according to incision length) of antiseptic solution will be performed using a 0.04% sterile Polihexanide solution. After the end of the application time, a subcutaneous swab for culture will be taken. Before standard (according to local center clinical practice) wound(s) dressing(s), a 3 mm-thick antiseptic gel (a combination comprised of 0.1 % Polihexanide and 0.1 % propyl betaine (surfactant) that is used for cleansing, moistening and decontamination of post-operative wounds) will be applied on any wound(s)."
89532068|NCT06338163|Active Comparator|Control|"Once a day starting 5 days before the operation:~Total body washing with usual soap/shampoo. No oral and nasal MDRO-decolonization will be performed. After the closure of fascia, 10 minutes subcutaneous irrigation with 50 to 250 mL (according to incision length) NS will be performed. After the end of the application time, a subcutaneous swab for culture will be taken. Finally, standard wound(s) dressing(s) (according to local center clinical practice) will be applied."
89532069|NCT06338150||Participants with Multiple Myeloma|Participants who will undergo tumor biopsy for management of multiple myeloma (MM)
89532070|NCT06338137|Other|high-energy patients|Use high energy in stone management
89532071|NCT06338137|Other|Low energy patient|Use low energy in stone management
89532072|NCT06338124||survivor group|About 50 patients whom will be relifed from the sepsis and will be discharged from the Intensive Care Unit
89532073|NCT06338124||non-survivor group|About 50 patients whom will be died from the sepsis in the Intensive Care Unit
89532074|NCT06338111||1|09.11.2020-01.08.2021, patients with sepsis and septic shock
89532075|NCT06338111||2|13.07.2022-04.12.2022, patients with sepsis and septic shock
89532076|NCT06338098|Experimental|Heartfulness Group|Participants in the meditation program will be provided with guided meditation and relaxation audio clips to spend approximately 20 minutes per day on the meditation and relaxation activities and participate each week in a 20-30 minutes online meditation webinar with a certified meditation trainer. All meditation and relaxation exercises can be performed in the comfort of your own home or other place of your choosing. The intervention will be entirely online.
89532077|NCT06338098|No Intervention|Control Group|The control group had no change in their daily routines.
89532078|NCT06338085|Experimental|intervention group|The researcher will provide the intervention group with Emotional Freedom Technique (EFT) training, which will last for 2 sessions of 45 minutes with 1 day intervals.Participants will then be asked to continue the techniques taught during the training on their own once a day for 8 weeks.
88968794|NCT00397423|Placebo Comparator|2|2,NS,intervention
88968795|NCT00397501|Active Comparator|HER-2 positive subjects|HER-2 positive subjects treated with trastuzumab
88968796|NCT00397501|Active Comparator|HER-2 negative subjects|HER-2 negative subjects not treated with trastuzumab
88968797|NCT00018174|Experimental|1|
88968798|NCT00018174|Placebo Comparator|2|
88968799|NCT00044590||Cases|Patients with Parkinson's Disease
88968800|NCT00044590||Controls|Controls, subjects without Parkinson's Disease
88968801|NCT00044629|Experimental|Cognitive Behavioral Therapy and Ambien|Cognitive Behavioral Therapy and Ambien
88968802|NCT00044629|Placebo Comparator|Cognitive Behavioral Therapy and Placebo|Cognitive Behavioral Therapy and Placebo
88968803|NCT00044629|Active Comparator|Cognitive Behavioral Therapy alone (no drug)|Cognitive Behavioral Therapy alone (no drug)
88968804|NCT00044668|Experimental|AC2993|5 μg AC2993, twice daily, for 4 weeks followed by 10 μg AC2993, twice daily, during a maintenance period
88968805|NCT04734054|Experimental|Rapid maxillary expansion|The rapid maxillary expansion will be conducted using bonded modified Hyrax palatal expander. The expander will be activated twice daily (0.4 mm) until an overcorrection of 2-3 mm will be gained.
88968806|NCT04734054|Active Comparator|Slow maxillary expansion|The slow maxillary expansion using a removable plate with a midline screw will be accomplished. The expander will be activated twice weekly until an overcorrection of 2-3 mm will be gained.
88968807|NCT00044707|Active Comparator|Pramlintide acetate (AC137)|Pramlintide acetate (AC137) injection is a clear, colorless, sterile solution for SC injection. It consists of pramlintide in sodium acetate buffer, pH 4.0, containing 43 mg/mL mannitol as an iso-osmolality modifier and 2.25 mg/mL metacresol as a preservative. The strength of pramlintide injection is 0.6 mg/mL
88968808|NCT00044707|Placebo Comparator|Placebo|Placebo solution is the same, sterile preserved formulation, except the active ingredient, pramlintide, is omitted
88968809|NCT00044863|Experimental|1|Patients with metastatic EGFR-positive colorectal carcinoma
89532079|NCT06338085|No Intervention|control group|no intervention will be made to the control group
89532080|NCT06338072||Adult women of childbearing age using a loop system.|Adult women of childbearing age using the Minimed 780G loop system. Sixty-nine women of reproductive age will be recruited to assess variations in glycemic control across different stages of the menstrual cycle. Additionally, a subset of these women (n = 50) will wear a wearable device to collect temperature, photoplethysmography, and accelerometry data.
89532081|NCT06338072||Adult men under 50 years old using a closed loop system.|A control group of 50 men will wear a wearable device to collect temperature, photoplethysmography, and accelerometry data.
89532082|NCT06338059||painDETECT questionnaire scores> 13 likely or possible neuropathic pain (group 1)|lipedema patients showing NP symptoms
89532083|NCT06338059||painDETECT questionnaire scores13 unlikely neuropathic pain(group 2)|lipedema patients showing no NP symptoms
89532084|NCT06338046|Active Comparator|Sample A - Active treatment|28-day-treatment, with twice daily application (morning and evening) of a cosmetic formula containing NC65 - Vita D-Light at 0.5 %w/w. The cosmetic formula is a w/o emulsion done with cosmetic-grade ingredients according to GMP. The designed quantity to be applied on the face is approximately 2 mg.
89532085|NCT06338046|Placebo Comparator|Sample B - Placebo treatment|28-day-treatment, with twice daily application (morning and evening) of a cosmetic formula containing the same ingredient of the active treatment except for NC65 - Vita D-Light at 0.5 %w/w. The cosmetic formula is a w/o emulsion done with cosmetic-grade ingredients according to GMP. The designed quantity to be applied on the face is approximately 2 mg.
89532086|NCT06338033||VFA/BMI<5.49|
89532087|NCT06338033||VFA/BMI≥5.49|
89532088|NCT06338020|Experimental|Adaptive-VRT|Participants in this group received the adaptive variable-resistance training program in besides the standard physical therapy care.
89532089|NCT06338020|Active Comparator|Standard Physical Therapy|Participants in this group received the standard exercise program.
89532090|NCT06338007||Complications (No)|Patients who did not experience any postoperative complications within 90 days.
89532091|NCT06338007||Complications (Yes)|Patients who experienced any complications within 90 days after surgery.
89532471|NCT06239688|Experimental|essentiALZ + ECHO|Communities randomized to this arm will receive the essentiALZ training: a web-based training taken by AL staff that contains three hours of self-paced content separated into five modules, plus a final review. Modules include: 1) Alzheimer's disease and dementia; 2) person-centered care; 3) assessment and care planning; 4) activities of daily living; and 5) behaviors and communication. Staff will be encouraged to take the training over the course of four weeks. Additionally, they will receive access to Project ECHO. ECHO is a virtual tele-mentoring model grounded in case-based learning. It includes six weekly one-hour sessions of didactic and discussive learning. The first five sessions will reflect the content of the five essentiALZ modules, and the final session will address maintenance. ECHO sessions are group sessions that will be conducted via Zoom.
89565398|NCT03102229|Experimental|Activity Monitoring|"Enhanced Supportive Care - Status Checks Would occur everyday during treatment when a patient is deemed high-risk based on activity level. Other Names: •Daily Status Checks~Enhanced Supportive Care - Referrals On an as-need basis, high risk patients can be referred to our nutritionist or palliative care doctor. Other Names: •Referrals"
89565399|NCT04108429|Experimental|Mobile self-help intervention|Participants will have open access to the IntelliCare system.
89565400|NCT04857515||Cigarette Smokers|Adult cigarette smokers who only smoke combustible cigarettes
89565401|NCT04857515||Dual-Users|Adult smokers who smoke both combustible cigarettes and vape
89565402|NCT04857047|Experimental|Group A|"[Period1] administration of BR9003A 1mg twice a day for six days~- Wash out for 9days -~[Period2] administration of BR9003 2mg once a day for six days"
89565403|NCT04857047|Experimental|Group B|"[Period1] administration of BR9003 2mg once a day for six days~- Wash out for 9days -~[Period2] administration of BR9003A 1mg twice a day for six days"
89565404|NCT04856969|Active Comparator|Arm A|ATB-1011: 1tab/d for 5days , ATB-1011+ATB-1012: each 1tab/d for 5days
89565405|NCT04856969|Active Comparator|Arm B|ATB-1012: 1tab/d for 5days / ATB-1011+ATB-1012: each 1tab/d for 5days
89565406|NCT04856735|Active Comparator|IPLA:intraperitoneal local anesthetic|intraperitoneal local anesthetic:after the birth of the newborn and placenta, the uterus is closed and the blood accumulated in the pelvis is carefully wiped with surgical towels, after hemostasis is fully achieved, a total of 20 ml solution containing 10 cc of 0.5% bupivacaine +10 cc 2% lidocaine and 2 injectors containing 20ml saline and the 20ml solution were given to the surgeon. The 20 ml solution containing bupivacaine and lidocaine was injected into the uterine peritoneal region by spraying 5 mL to each quadrant of the uterus before closing the parietal peritoneum or fascia. The parietal peritoneal layer was sutured or left open at the surgeon's preference. At the end of the operation, 20 ml of saline solution was applied subcutaneously in the form of LWI instead of the incision before the skin was closed.
89565407|NCT04856735|Active Comparator|LWI:Surgical wound infiltration|Surgical wound infiltration:a solution containing 20 ml of saline was added to all four quadrants of the uterus in 5 ml volume and 20 ml solution containing lidocaine and bupivacaine were subcutaneously in the form of LWI before the skin was closed.
89565408|NCT04856735|Active Comparator|C: CONTROL GROUP|one of the two sterile injectors containing 20 ml of saline was applied to the uterine peritoneal region and the other was applied to the incision area as a local subcutaneous wound infiltration.
89565409|NCT04856501|Experimental|PALS intervention condition|
89565410|NCT04856501|Active Comparator|Control condition|
89027628|NCT04515069|Active Comparator|Aesthetic preevaluative temporary technique|Aesthetic pre-evaluative temporary (APT) was fabricated according the planned wax-up. Once the APT was approved both aesthetically and functionally, tooth preparation was performed through the APT.
89027629|NCT00484484|Experimental|1|Ketamine
89027630|NCT00484484|Experimental|2|Ketamine
89027631|NCT04514601||Pre-Intervention Group|The verbal and written handover of these patients was observed. This included 146 general orthopaedic admissions patients and 43 trauma patients. All patient data was anonymised.
89565411|NCT04856579|Other|Varicocelectomy|Subinguinal varicocelectomy under general anesthesia and complete aseptic condition
89027632|NCT04514601||Post-Intervention Group|The verbal and written handover of these patients was observed after the introduction of the intervention. This included 81 general orthopaedic admissions patients and 47 trauma patients. All patient data was anonymised.
89565412|NCT03104803|Experimental|Long-term PAS|The intervention is given to one hand only
89565413|NCT03104803|No Intervention|No intervention|Contralateral hand of the same patient
89565414|NCT03041519|Experimental|Zero-fluoroscopy ablation|Zero-fluoroscopy ablation will be performed under the guidance of Ensite NavX for mapping and ablation and fluoroscopy will not be used during the procedure.
89565415|NCT03041519|Active Comparator|Conventional fluoroscopy ablation|Conventional fluoroscopy ablation will be performed under fluoroscopic guidance plus Ensite NavX for mapping and ablation during the procedure.
89565416|NCT03938311|Experimental|very early rehabilitation|early mobilization initiates within 24h from the onset of the disease
89565417|NCT03938311|Experimental|relative early rehabilitation|early mobilization initiates between 24-72h from the onset of the disease
89565418|NCT03938311|Experimental|late mobilization group|early mobilization initiates after 72h from the onset of the disease
89027633|NCT00484562|Active Comparator|Standard oxygen delivery system|Standard oxygen tank with pulse dose regulator
89565419|NCT03041597|Experimental|Immediate loading|
89565420|NCT03041597|Active Comparator|delayed loading|
89565421|NCT04435171||Open renal transplantation|Patients who were performed open renal transplantation due to end stage renal disease.
89565422|NCT04435171||robot assisted renal transplantation|Patients who were performed robot assisted renal transplantation due to end stage renal disease
89565423|NCT04856345|Experimental|Music with synchronising|walking to music that one can synchronise to
89565424|NCT04856345|Active Comparator|Music without synchronising|walking to music that one cannot synchronise to
89565425|NCT04856345|Sham Comparator|No music|walking without music.
89565426|NCT04856267||Systemic AL Amyloidosis study cohort|"Eligible patients will undergo subcutaneous implantation of a cardiac monitor device (Brand name - LINQ device, Medtronic - referred to in the application as implantable loop recorder or ILR)"
89027634|NCT00484562|Active Comparator|Homefill oxygen delivery system|Homefill oxygen delivery system, pre-filled from a larger oxygen concentrator base unit.
89027635|NCT00484562|Active Comparator|Helios oxygen delivery system|Liquid oxygen portable system pre-filled from a larger liquid oxygen tank
89565427|NCT03919045|Experimental|Sodium chloride injection|Sodium chloride 9mg/ml by injection
89565428|NCT03919045|Placebo Comparator|Needle sting|Brief needle stings without injection
89565429|NCT04856111|Active Comparator|Pirfenidone|Pirfenidone will be started at a dose of 600 mg/day. The dose will be escalated by 600 mg/day every 3-7 days up to a targeted dose of 2400 mg/day. The subjects will be administered the maximum tolerated dose for a total period of 24 weeks from randomization.
89565430|NCT04856111|Active Comparator|Nintedanib|Subjects in this group will be administered nintedanib at a dose of 150 mg twice daily. The liver function tests will be monitored as above. The dose will be reduced to 100 mg twice daily, if there is intolerance to 300 mg/day dose.
89565431|NCT02053051|Experimental|MDI of insulin & ABC4D|Advanced Bolus Calculator for Type Diabetes (ABC4D)
89565432|NCT02053051|Active Comparator|MDI of insulin|Multiple daily injections(MDI) of insulin
89565433|NCT04856423||Us-qFIT group|People in this group will detect fecal hemoglobin concentration by us-qFIT before colonoscopy.
89565434|NCT03881683|Experimental|HRD and BRCA mutations|
89565435|NCT04856033|Experimental|TM|Transcendental Mediation
89565436|NCT04856033|Active Comparator|PCT|Present Centered Therapy
89565437|NCT04077541|Experimental|The experimental group|The trauma care bundles combined with the internet platform.
89565438|NCT04077541|No Intervention|The control group|Only trauma care bundles.
89565439|NCT04855565|Active Comparator|ALY688-SR|single dose subcutaneous injection
89565440|NCT04855565|Placebo Comparator|Matching placebo for ALY688-SR|single dose subcutaneous injection
89565441|NCT03864289|Experimental|Parent skills training|Parents of children with autism spectrum disorder attend the parental training course once a week, and there was a total of eight courses with each course lasting 3 hours.
89565442|NCT04855877|Active Comparator|Oral Tranexamic Acid|52 patients scheduled for primary anteriori cruciate ligament surgery by arthroscopy
89565443|NCT04855877|Placebo Comparator|Placebo|52 patients scheduled for primary anteriori cruciate ligament surgery by arthroscopy
89565444|NCT03102073||Radner test|reading speed evaluation
88968810|NCT04731805|Experimental|Moving On After Breast Cancer - Intervention Arm|Participants are randomized to the intervention arm after their breast cancer diagnosis (but before cancer surgery) and baseline measurements (T0) are taken. They are followed up again at 2 weeks after their breast cancer surgery (T1), and again at 3 months after surgery (T2). Participants are given the patient education materials (booklet, therapeutic exercise DVD, small ball, range of motion wand). The research assistant orients the participant to the education materials and summarizes each section of the booklet. The research assistant also teaches the participant how to do the therapeutic exercises in the booklet. All participants in the intervention also receive usual care.
89027636|NCT00484562|Active Comparator|FreeStyle oxygen system|portable battery-powered oxygen concentrator delivery system
89565445|NCT03041675|Experimental|Laser Acupuncture group|47 participants receive 10 seconds of Laser Acupuncture(808nM/300mW) on acupoints RN6, RN4, and RN12. The whole duration of treatment is 3 times a week, for 8 weeks.
89565446|NCT03041675|Sham Comparator|Sham Laser Acupuncture group|The investigators apply the Laser Acupuncture pen (without pressing the laser button) on other 47 participants' acupoints RN6, RN4, and RN12. The whole duration of treatment is 3 times a week, for 8 weeks.
89565447|NCT04855409||Bipolar Depression|Subjects with bipolar type I disorder depressive episode diagnosed by Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I)
89565448|NCT04855409||Healthy|Healthy control subjects matched with bipolar depressive patients by age and sex
89565449|NCT04849247|Experimental|177Lu-DOTA-FAPI dose escalation therapy study|Patients will be undergo 68Ga-DOTA-FAPI PET/CT scans to confirm eligibility for the 177Lu-DOTA-FAPI therapy. Patients with sufficient lesion uptake of 68Ga DOTA-FAPI PET/CT will be offered therapy. Escalating doses of 30-150 mCi of 177Lu-DOTA-FAPI will be administered in a traditional 3+3 dose escalation design. After escalation, 10 additional patients will be enrolled into a dose expansion cohort.
89565450|NCT04849247|Experimental|Recommended Phase 2 dose 177Lu-DOTA-FAPI therapy study|Patients will be undergo 68Ga-DOTA-FAPI PET/CT scans to confirm eligibility for the 177Lu-DOTA-FAPI therapy. 10 patients will be enrolled in the dose expansion cohort and received the highest dose achieved in the 177Lu-DOTA-FAPI dose escalation therapy study
89565451|NCT02845453|Experimental|Quetiapine|Quetiapine
89565452|NCT02845453|Placebo Comparator|Placebo|Placebo
89565453|NCT03041753||Intervention group|ischemic stroke patients in the anterior circulation territory (NIHSS ≥7) within 12 hours from last seen well, treated either with systemic thrombolysis or endovascular treatment.
89565454|NCT01799629|Experimental|Intervention|Intervention group will receive the glycerin suppository
89565455|NCT01799629|No Intervention|Control|Normal care
89565456|NCT04849403|Other|The group USG was applied|USG was applied to the patients who underwent Laparoscopic sleeve gastrectomy for research trocar site hernia after 2-4 years from the surgery. Carter Thomasson suture passer was used to close fascial defect in all patients.
89565457|NCT05431621||Digestive system cancer group|A total of about 1035 cases are expected to be enrolled, including 432 cases in stage I and 603 cases in II-IV.
89565458|NCT05431621||Negative group|985 healthy individuals.
89565459|NCT05431621||High risk group|410 cases with precancerous diseases.
89565460|NCT04848701|Other|uterocervical angle|uterocervical angle is the angle between lower segment of uterus and cervix
89565461|NCT04428827||Surgery|Patients treated with surgery
89565462|NCT04428827||Medications|Patients treated with mineralocorticoid antagonists or potassium sparing diuretics for primary aldosteronism
89565463|NCT03041129||Untreated PCOS|PCOS per NIH criteria. Obese Lifestyle treatment only.
89565464|NCT03041129||Metformin PCOS-(Study arm not funded)|PCOS per NIH criteria. Obese Taking 1500 mg of metformin or more per day for at least 6 months.
89565465|NCT03041129||Oral Contraceptive PCOS-(Study arm not funded)|PCOS per NIH criteria. Obese Taking 30 mcg of ethanyl estradiol or more per day for at least 6 months.
89565466|NCT03041129||Obese Control group-(Study arm not funded)|Obese Regular menses at least 18 months post-menarche Females only
89565467|NCT01597375|Experimental|Placebo then Prasugrel|"Subjects with AERD first received placebo oral tablet for 4 weeks prior to their aspirin challenge/desensitization. After aspirin challenge/desensitization subjects were discharged to home to washout the study drug from the first treatment phase. At the end of the 2-week washout period, subjects crossed over to the alternate treatment for 4 weeks of Prasugrel oral tablets [ (5 mg (for patients <60kg) or 10mg (> 60kg) daily, following a 60mg loading dose)] and returned for the second aspirin challenge.~Because no period effect was observed, data obtained from all subjects while on placebo from either visit 2 or 3 were combined."
89565468|NCT01597375|Experimental|Prasugrel then Placebo|"Subjects with AERD first received prasugrel oral tablets [ (5 mg (for patients <60kg) or 10mg (> 60kg) daily, following a 60mg loading dose)] prior to their aspirin challenge/desensitization. After aspirin challenge/desensitization subjects were discharged to home to washout the study drug from the first treatment phase. At the end of the 2-week washout period, subjects crossed over to the alternate treatment for 4 weeks of Placebo oral tablet.~Because no period effect was observed, data obtained from all subjects while on Prasugrel from either visit 2 or 3 were combined."
89565469|NCT03044093|Active Comparator|MISOPROSTOL alone|the common practice currently in our medical center for second trimester medical abortion/ Placebo
89565470|NCT03044093|Experimental|Mifepristone and Misoprostol|"in addition to the common practice currently in our medical center for second trimester medical abortion we will add Mifepristone before administering Misoprostol.~Mifepristone"
89565471|NCT04848545||Live-born sons (with and without testicular cancer diagnosis) from a Danish pregnancy Cohort|"Pregnancy cohort: Biological samples from 128,702 of pregnant women were stored for research purposes in the Danish National Biobank, in the period from 1976-2004.~Present study: live-born sons (with/without testicular cancer ascertained via data linkage in the Danish Cancer Registry)"
89565472|NCT01553071|Experimental|Investigational|Fenretinide (4-HPR) plus Intravenous Safingol
89565473|NCT03044327|Other|LPS challenge|LPS inhalation and bronchial instillation
89565474|NCT01506973|Experimental|Gemcitabine/Abraxane/Hydroxychloroquine|Abraxane: 125mg/m2 IV infusion over 30 minutes on Days 1, 8, 15 Gemcitabine: 1000mg/m2 IV infusion over 30-100 minutes on Days 1, 8, 15 Hydroxychloroquine: 1200 mg/day PO daily (600mg BID) Daily from D1
89565475|NCT01506973|Experimental|Gemcitabine/Abraxane|Abraxane: 125mg/m2 IV infusion over 30 minutes on Days 1, 8, 15 Gemcitabine: 1000mg/m2 IV infusion over 30-100 minutes on Days 1, 8, 15
89565476|NCT01322581||observational cohort|This observational-cohort study of individuals (3 months and 40 years of age) will be conducted in the rural village of Kalifabougou, Mali, where Pf transmission is intense and seasonal
89565477|NCT03041207||Pre-antibiotic guideline|Infants for whom antibiotics have been initiated for suspected ventilator-associated infection prior to the implementation of the antibiotic guideline
89565478|NCT03041207||After antibiotic guideline implementation|Infants for whom antibiotics have been initiated for suspected ventilator-associated infection after the implementation of the antibiotic guideline
89565479|NCT03041207||Microbiome Study Group|Infants intubated and anticipated to require mechanical ventilation for at least several days
89565480|NCT04848467|Experimental|Group 1: Co-ad group|Participants will receive CVnCoV at the same visit as QIV: first dose of CVnCoV and a dose of QIV in opposite arms at Day 1, the second dose of CVnCoV at Day 29, and a placebo injection at Day 57.
89565481|NCT04848467|Experimental|Group 2: Control group|Participants will receive QIV and CVnCoV at two different visits: one dose of placebo and one dose of QIV in opposite arms at Day 1, the first dose of CVnCoV at Day 29 and the second dose of CVnCoV at Day 57.
88968811|NCT04731805|No Intervention|Usual Care|Participants are randomized to the usual care arm after their breast cancer diagnosis (but before cancer surgery) and baseline measurements (T0) are taken. They are followed up again at 2 weeks after their breast cancer surgery (T1), and again at 3 months after surgery (T2). Usual care consists of pre-operative testing, pre-operative nursing education on care of the surgical incision and pain management followed by breast cancer surgery.
88968812|NCT00045019||discharged cancer patients|patients discharged from a surgery or medical ward of oncology institutes in Belgium, France, Germany, Italy, Poland, Spain, Sweden, Taiwan and United Kingdom (as part of a larger psychometric validation study) were asked to rate there level of satisfaction, using the EORTC QLQ-SAT32.
88968813|NCT00045175|Experimental|UCN-01 in combination with topotecan|
88968814|NCT02970682|Experimental|Aromatase Inhibitor|SFX-01 with Aromatase Inhibitor SFX-01 when used in combination with aromatase inhibitors. All patients will continue to receive their AI and, at the start of the study (D1), patients will take SFX-01, which is provided as 300 mg capsules, one to be taken twice daily, 12 hours apart, after food (preferably within 2 hours).
88968815|NCT02970682|Experimental|Fulvestrant|SFX-01 with Fulvestrant SFX-01 when used in combination with fulvestrant. All patients will continue to receive fulvestrant 500 mg IM in 28 day cycles. As patients will already have been taking this, a repeat loading dose is not necessary. Commencing on study D1 patients will take SFX-01, which is provided as 300 mg capsules, one to be taken twice daily, 12 hours apart, after food (preferably within 2 hours).
89565482|NCT03102307||CNB biopsy/clip placement not done|Clinically affected lymph nodes cannot be biopsied or clip labeled. Patients are not suitable for TAD
89565483|NCT03102307||CNB/clip placement done - benign|Clinically affected lymph nodes can be biopsied and clip labeled. Needle biopsy reveals no axillary tumor spread. Patients are suitable for TAD
89565484|NCT03102307||CNB/clip placement done - malignant|Clinically affected lymph nodes can be biopsied and clip labeled. Needle biopsy reveals axillary tumor spread. Patients are suitable for TAD
89565485|NCT02527161|Other|ShapeMatch Cutting Guides with Triathlon|"The ShapeMatch® Cutting Guides are intended to be used as patient-specific surgical instrumentation to assist in the positioning of knee arthroplasty components intra-operatively and in guiding the marking of bone before cutting.~They are intended for single use only."
89565486|NCT04848311|Experimental|ICG group|Patients in the ICG group will undergo endoscopic injection of ICG 4 hours before surgery. The ICG powder will be dissolved in 2.5mg/ml of sterile water. ICG will be injected along the submucosa at 4 points around the primary tumor,for a total volume of 10ml.
89208588|NCT00615030|Experimental|Placebo, Indacaterol Morning, Salmeterol|In period I, during morning and evening, placebo matching indacaterol was delivered via SDDPI and placebo matching salmeterol was delivered via DPI. In period II, indacaterol 300 μg once a day in the morning delivered via SDDPI with a placebo to salmeterol delivered via dry powder inhaler DPI. Patients were also instructed to take evening doses of a placebo to indacaterol via SDDPI and placebo to salmeterol via DPI. In period III, salmeterol 50 μg twice daily delivered via DPI. One of the two daily doses of salmeterol was administered in the morning and the second dose in evening along with placebo matching indacaterol delivered by SDDPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
88968816|NCT02970682|Experimental|Tamoxifen|SFX-01 with Tamoxifen SFX-01 when used in combination with tamoxifen All patients will continue to receive tamoxifen and, at the start of the study (D1), patients will take SFX-01, which is provided as 300 mg capsules, one to be taken twice daily, 12 hours apart after food (preferably within 2 hours).
88968817|NCT00045526|Experimental|Treatment (erlotinib hydrochloride)|Patients receive erlotinib hydrochloride PO QD. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
89532472|NCT06239688|No Intervention|No Intervention|Standard care will be provided.
89532473|NCT06238999|Experimental|Test goup TM Flow|The newly developed flowable composite TM Flow will be used for the restoration of NCCLs in the test group. The treatment workflow is very similar to other flowable composites.
89532474|NCT06238999|Active Comparator|Control group Tetric EvoFlow|The well-established Tetric EvoFlow will be used for the restorations of NCCLs in the control group.
89532475|NCT06238531|No Intervention|Control|Subjects will remain on their usual SLE medications
89532476|NCT06238531|Placebo Comparator|Placebo|Subjects will receive a placebo that looks similar to the interventional drug.
89532477|NCT06237491|Experimental|Experimental: 177Lu-LNC1003 Injection group 1|"177Lu-LNC1003 Injection, a single dose of 30mCi will be administered every 6 weeks, for a total of 2 cycles.~Interventions:~Drug: 177Lu-LNC1003 Injection group 1 radionuclide therapy"
89532478|NCT06237491|Experimental|Experimental: 177Lu-LNC1003 Injection group 2|"177Lu-LNC1003 Injection, a single dose of 50mCi will be administered every 6 weeks, for a total of 2 cycles.~Interventions:~Drug: 177Lu-LNC1003 Injection group 2 radionuclide therapy"
89532479|NCT06237491|Experimental|Experimental: 177Lu-LNC1003 Injection group 3|"177Lu-LNC1003 Injection, a single dose of 70mCi will be administered every 6 weeks, for a total of 2 cycles.~Interventions:~Drug: 177Lu-LNC1003 Injection group 3 radionuclide therapy"
89532480|NCT06232577|Experimental|5x-Multiplier Model|In this group, you will be given 5 times the amount of opioid medication you needed on your last day in the hospital. You would then use this supply plus standard non-narcotic pain medications.
89532481|NCT06232577|Experimental|3-Tier Model|The total amount of opioid medication you needed on your last day in the hospital to set a maximum number of opioid medications at discharge (up to 30).
89532482|NCT06231680|Experimental|Prevention Cohort 1 Group A|Camrelizumab + chemotherapy+Thalidomide(50mg)
89532483|NCT06231680|Experimental|Prevention Cohort 1 Group B|Camrelizumab + chemotherapy+Thalidomide(100mg)
89532484|NCT06231680|Experimental|Treatment Cohort 2 Group A|Thalidomide(100mg)
89532485|NCT06231680|Experimental|Treatment Cohort 2 Group B|Thalidomide(200mg)
89532486|NCT06229353||Under-immunized Emergency Department adult patients|"Adults attending the Emergency Department who are aged 18-45, without previous HPV vaccination history and without previously known infection from HPV high-risk strain, and in good functional capacity.~Eligible participants will receive Gardasil 9 (HPV) vaccination if interested."
89532487|NCT06228924|Experimental|Cohort 1|Dose for Cohort 1 will be 3E13 vg/kg
89532488|NCT06228924|Experimental|Cohort 2|Dose for Cohort 2 will be 6E13 vg/kg
89532489|NCT06228456|Experimental|Low-dose ticagrelor|Stable CAD patients undergoing elective PCI treated with standard of care clopidogrel will be randomly assigned in a 1:1 fashion to either switch to ticagrelor or continue with clopidogrel.
89532490|NCT06228456|Active Comparator|Clopidogrel|Stable CAD patients undergoing elective PCI treated with standard of care clopidogrel will be randomly assigned in a 1:1 fashion to either switch to ticagrelor or continue with clopidogrel.
89532491|NCT06228066|Experimental|Arm 1|Treatment with lurbinectedin
89532492|NCT06228066|Experimental|Arm 2|Treatment with lurbinectedin and avelumab
89532493|NCT06227338|Experimental|0.125 mg/kg|Patients who will be injected with 0.125 mg/kg Indocyanine green before their tumorectomy
89532494|NCT06227338|Experimental|0.25 mg/kg|Patients who will be injected with 0.25 mg/kg Indocyanine green before their tumorectomy
89532495|NCT06227338|Experimental|0.5 mg/kg|Patients who will be injected with 0.5 mg/kg Indocyanine green before their tumorectomy
89532496|NCT06227338|Experimental|1 mg/kg|Patients who will be injected with 1 mg/kg Indocyanine green before their tumorectomy
89532497|NCT06227338|Experimental|2 mg/kg|Patients who will be injected with 2 mg/kg Indocyanine green before their tumorectomy
89532498|NCT06223568|Experimental|Arm 1|DC (docetaxel + cisplatin)
89565487|NCT04848311|No Intervention|CLgroup|Patients in the CL group will undergo routine laparoscopic lymph nodes dissection instead of using any tracer.
88968818|NCT00045565|Experimental|Group A|Patients receive arsenic trioxide IV over 2 hours once weekly for 6 weeks. Patients in both groups also undergo radiotherapy once daily 5 days a week for 6 weeks.
88968819|NCT00045565|Experimental|Group B|Patients receive arsenic trioxide at a lower dose IV over 2 hours twice weekly for 6 weeks. Patients in both groups also undergo radiotherapy once daily 5 days a week for 6 weeks.
88968820|NCT00045682|Experimental|Treatment (polyglutamate paclitaxel)|Patients receive polyglutamate paclitaxel (CT-2103) IV over 10-20 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
88968821|NCT04731766|Active Comparator|Citrine 5% Sodium Fluoride|It was developed to prolong the contact between the tooth surface and fluoride to increase the resistance against caries attack and manage tooth hypersensitivity; the active ingredient of fluoride varnish is mostly 5% sodium fluoride.
88968822|NCT04731766|Experimental|concocuted Nano-silver fluoride|Nano-silver fluoride (NSF) is a laboratory synthesized solution
88968823|NCT00001703|Experimental|Group A-VHL peptide and ISA-51 adjuvant|Patients are vaccinated with 1000 micrograms of the mutant Von Hipple-Lindau (VHL) peptide administered subcutaneously along with ISA-51 adjuvant (Montanide ISA-51 adjuvant, Incomplete Freund's adjuvant) and injected subcutaneously every four weeks for a total of four vaccinations.
88968824|NCT00045799|Experimental|Omeprazole sodium bicarbonate immediate release PWD/FS|
88968825|NCT00045799|Active Comparator|Cimetidine IV|
89532499|NCT06223568|Experimental|Arm 2|DCP (docetaxel + cisplatin + PRGN-2009)
89532500|NCT06223555|Active Comparator|1|Fixed Mixed Meal Test
89532501|NCT06223555|Active Comparator|2|Adjusted Mixed Meal Test
89532502|NCT06222203||1 - High-Risk|Participants with clinical or genetic diagnosis of NF1 AND at least one of the eligibility-required high-risk characteristics
89532503|NCT06222203||2 - Low-Risk|Participants with clinical or genetic diagnosis of NF1 AND none of the eligibility-required high-risk characteristic
89532504|NCT06222203||3 - Caregiver|Parents or guardians of participants 8-17 years old in High-Risk or Low-Risk Cohorts
89532505|NCT06214923|Other|High impact TMD|"Other: TMD Phenotype~TMD participants will be clinically phenotyped into two between-subject groups based on their score on the Graded Chronic Pain Scale (GCPS). This group will have a GCPS grade 2b, 3, and 4."
89532506|NCT06214923|Other|Low impact TMD|"Other: TMD Phenotype~TMD participants will be clinically phenotyped into two between-subject groups based on their score on the Graded Chronic Pain Scale (GCPS). This group will have a GCPS grade 0, 1, and 2a"
89532507|NCT06213454|Active Comparator|TAP Block plus Laparotomy|
89532508|NCT06213454|Active Comparator|Laparotomy plus Local Wound Anesthetic|
89532509|NCT06212661||CGRP inhibitor|"Ubrogepant (Ubrelvy™)~Rimegepant (Nurtec®)~Atogepant (Qulipta™)~Eptinezumab (Vyepti®)~Fremanezumab (Ajovy®)~Galcanezumab (Emgality®)~Erenumab (Aimovig®) dosage and duration according to provider's clinical decision."
89532510|NCT06212661||BoNTA extracranial muscle injections|Botolinum toxin A (Botox) Injection into extracranial muscles to treat migraine. Dosage and duration according to provider's clinical decision
89532511|NCT06208306|Experimental|Itepekimab Q2W|Subcutaneous (SC) administration of Itepekimab every 2 weeks (Q2W) for up to 52 weeks
89532512|NCT06208306|Experimental|Itepekimab Q4W|SC administration of Itepekimab every 4 weeks (Q4W) for up to 52 weeks, with alternating SC administration of matching placebo at the 2-week interval between active IMP
89532513|NCT06207721|Experimental|Control group (A)|conventional treatment by diet regimen and laxatives
89532514|NCT06207721|Experimental|study Group (B)|physical therapy program in addition to conventional treatment by diet regimen and laxatives
89532515|NCT06203626||participant|we will collect an ULF-MRI from all participants.
89532516|NCT06199570|Experimental|Adapted Stress Management Program|The behavioral intervention consists of 3 brief coaching sessions delivered by a trained research interventionist (at baseline/orientation, pre-scan, and post-scan time points) and program modules consisting of psychoeducation and stress management skill activities/practice. They will also be provided with a list of mental health resources and crisis line information for use if needed.
89532517|NCT06199570|Active Comparator|Enhanced Usual Care|Those randomized to enhanced usual care in the pilot RCT (n=25) will receive a resource list, tablet for study assessments, and reminder calls, but will not receive the program modules. They will also be provided with a list of mental health resources and crisis line information for use if needed.
89532518|NCT06196060|Experimental|Visual perspective taking training|Participants will receive visual perspective taking training in this arm.
89532519|NCT06196060|Experimental|Block building training|Participants will receive block building training in this arm.
89532520|NCT06196060|Active Comparator|Thought-bubble training|Participants will receive thought-bubble training in this arm.
89532521|NCT06196060|Placebo Comparator|Treatment as usual|Participants will continue to receive routine therapy in this arm.
89532522|NCT06193889|Experimental|KYV-101 CAR-T cells with lymphodepletion conditioning|Dosing with KYV-101 CAR-T cells
89532523|NCT06192004||Prospective Cohort|NSCLC patients initiating an approved treatment with risk of pneumonitis/ILD.
89532524|NCT06191588|Experimental|infant cimt|"Other: Infant BIT Not use of unaffected hand containment. Both hand are use to improve the bimanual coordination~Other: Infant CIMT/BIT Use unaffected hand containment in part of the intervention and then, both hands in bimanual activities without containment.~Other: Conventional therapy Following the usual therapy in the baby."
89532525|NCT06191588|Active Comparator|Infant BIT|"Other: Infant CIMT/BIT Use unaffected hand containment in part of the intervention and then, both hands in bimanual activities without containment.~Other: Conventional therapy Following the usual therapy in the baby.~Other: infant cimt use of unaffected hand containment to improve the use of affected hand with unimanual activities"
89532526|NCT06191588|Active Comparator|Infant CIMT/BIT|"Other: Infant CIMT/BIT Use unaffected hand containment in part of the intervention and then, both hands in bimanual activities without containment.~Other: Conventional therapy Following the usual therapy in the baby.~Other: infant cimt use of unaffected hand containment to improve the use of affected hand with unimanual activities"
89027637|NCT00484601|Experimental|Ifosfamide and Doxorubicin|Single arm treatment with Ifosfamide and Doxorubicinin patients with Refractory Nasopharyngeal Carcinoma
89027638|NCT04514718|Active Comparator|low energy holmium laser|30 watts
89027639|NCT04514718|Active Comparator|high energy holmium laser|80-100 watts
89565488|NCT05431231||psychiatric ward|Adults consenting to treatment, who are admitted in the psychiatric ward at the Sheba Medical Health Center, whose first hospitalization has been up to five years before their current referral.
89565489|NCT05431231||Online hospitalization|adults consenting to treatment in their homes, who are found in an acute state that requires hospitalization, whose first hospitalization has been up to five years before their current referral. All the therapeutic treatments, assessment and follow-up meetings that are included in the service are provided online.
89565490|NCT05431231||Soteria|adults consenting to treatment in a house in the community, who are found in an acute state that requires hospitalization, whose first hospitalization has been up to five years before their current referral.
89565491|NCT03040583||ASSESS (PHRC) patients|Primary Sjögren's Syndrome Patients who have already participated to the study ASSESS
89565492|NCT03104335|Experimental|Study arm|every participant will recieve 750 mg daily once oral administration of apatinib for body surface area (BSA) > 1.5 and 500mg daily for BSA <1.5. Half an hour after meal and everyday at the same time is usually advised.
89565493|NCT04863365|Placebo Comparator|Placebo treatment|A matching placebo ophthalmic solution, TID
89565494|NCT04863365|Experimental|PHP-201 treatment|PHP-201 0.5% ophthalmic solution, TID
89565495|NCT04847765|Experimental|Combined pressure measurement and MRI|Gastric motility is evaluated simultaneously by means of the investigational medical device and by means of cine-MRI.
89565496|NCT03104179|Experimental|Treatment|CPB with Cytosorb
89565497|NCT03104179|No Intervention|Control|CPB without Cytosorb (Control)
89565498|NCT04855175|Active Comparator|Autograft group|The autologous group will receive bone harvested from the patient's own body
89027640|NCT04514094|Experimental|Silver Diamine Fluoride|"Gross debris will be removed with cotton pellets to allow better SDF contact with denatured dentin.~Cotton rolls will be used to protect surrounding gingival tissues and mucous membranes to avoid pigmentation or irritation.~Affected tooth surfaces will be dried with a gentle flow of air.~1-2 drops only of SDF will be used for the whole visit.~SDF will then be directly applied to affected tooth surfaces only using a micro sponge brush.~At least one minute will be needed to allow drying of SDF.~Excess SDF will finally be removed with cotton rolls to minimize systemic absorption.~When possible, isolation will be continued for up to three minutes.~After 2-4 weeks: reapplication will be done only to lesions that do not appear arrested (dark and hard)."
89027641|NCT04514094|Active Comparator|Atraumatic Restorative Treatment|"Caries removal by hand instruments with care not to expose the pulp.~Maximum excavation from the periphery of lesions will be done, to minimize leakage at the restoration margins.~Cotton roll isolation will then be carried out.~Cavities will be restored by glass ionomer cement.~Hand pressure should be applied by a gloved and petroleum jelly coated finger, then, excess material will be removed."
89027642|NCT00484796||1|Patients undergoing carotid surgery
89027643|NCT04514289||assesment SLND with enjection by using ICG|Patients who have endometrium cancer; undergo sentinel lymph node detection by using fluorescence imaging with an indocyanine green solution. Two different ways used to assess SLND. The first group in which the cervix is injected superficially with 1 mL of ICG ( indocyanine green) at 4 and 8 o'clock quadrans.
89027644|NCT04514289||assesment SLND with hysterescopy by using ICG|Patients who have endometrium cancer; undergo sentinel lymph node detection by using fluorescence imaging with an indocyanine green solution. Two different ways used to assess SLND. The second one which ICG has injected the uterine cavity during hysteroscopy. Our aim is to assess and compare the performance two approaches for sentinel lymph node ( SLND) biopsy.
89027645|NCT00484926|Active Comparator|Aspirin|Aspirin monotherapy (stopping clopidogrel at 1 year after DES)
89027646|NCT00484926|Experimental|Aspirin,Clopidogrel|Aspirin,Clopidogrel Dual antiplatelet therapy (continue aspirin and clopidogrel 1year after DES)
89027647|NCT01242683|Experimental|Case-Management for Behavior Change|Individual and group sessions devoted to behavioral strategies to facilitate weight loss conducted by a health educator. 12 month of intensive intervention followed by 12 months of maintenance intervention.
89027648|NCT01242683|Experimental|Case-Management plus Home Visits|Community health worker lifestyle support for weight loss strategies conducted in participants' homes and neighborhood. Also, receive individual and group sessions devoted to behavioral strategies to facilitate weight loss conducted by a health educator. 12 month of intensive intervention followed by 12 months of maintenance intervention.
89565499|NCT04855175|Active Comparator|Allograft group (ClearFit)|The allograft group will receive a synthetic bone known as ClearFit
89565500|NCT05430997|Active Comparator|Group A: conventional management|The ambient temperature of the operating room was set at 23±2 ℃ and the relative humidity was 50% to 60%. Intraoperative infusion fluids, blood products and rinsing fluid were warmed. Patients were given quilts to cover after entering the operating room, and the quilts covered from the neck to both the feet.
89565501|NCT05430997|Experimental|Group B: Hypothermia Risk Prediction Joint Active Insulation Management|"In the test group, after the assessment of the Intraoperative Hypothermia Risk Prediction APP, patients who were prompted/recommended to use active warming measures were actively warmed by inflatable warming (IOB Warming Unit (WU505) + Inflatable Warming Blanket) after admission to the room. Warming Unit (WU505) + Warming Blanket (IOB Warming Blanket)) was used for active warming. The air inlet was connected to the air catheter, and the host temperature was set at 38 ℃ with high air speed. During the operation, the thermal blanket is covered with non-surgical sterilization area (such as both shoulders, torso, healthy limbs, etc.), and the host temperature is adjusted to 38 ℃ for thermal insulation. The temperature and wind speed were adjusted in time to maintain the oropharyngeal temperature at 36.2℃～37.2℃ by monitoring the body temperature at any time during the operation."
89565502|NCT05376423|Experimental|OBI-833/OBI-821|"OBI-833 consists of Globo H, a unique tumor-associated carbohydrate antigen (TACA), covalently linked to cross-reacting material 197 (CRM197), an inactive and nontoxic form of diphtheria toxin (DT) acting as a carrier protein.~OBI-821 is a purified saponin adjuvant~Dosage form: solution Dosage:30 μg OBI-833/100 μg OBI-821, subcutaneous injection, Frequency: weekly for 4 doses (weeks 1, 2, 3, 4), then every 2 weeks for 2 doses (weeks 6, 8), then every 4 weeks for 4 doses (weeks 12, 16, 20, 24), and then every 8 weeks until disease recurrence, intolerable adverse events/toxicity, consent withdrawal, death, or up to 80 weeks from randomization."
89565503|NCT05376423|No Intervention|Observation|Patients will be randomized into OBI-833/OBI-821 (experimental) arm or observation arm.
89565504|NCT00484471|Experimental|1|
89565505|NCT00484471|Placebo Comparator|2|
89565506|NCT03041051|Experimental|PCV13|
89565507|NCT03041051|Experimental|PPV23|
89565508|NCT03103945||Patients with cardiac arrhythmias undergoing RF ablation|Patients with cardiac arrhythmias will be undergoing RF ablation using the Niobe Remote Magnetic Navigation System with CDS as their standard of care. System performance data will only be collected during the RF ablation procedure. Outcome measures will be evaluated with the CDS connected and without the CDS connected within all patients.
89565509|NCT05591547|Experimental|IMRT/VMAT-Based Accelerated Partial Breast Irradiation|Patients will be treated with a novel IMRT/VMAT-based accelerated partial breast irradiation regimen.
89565510|NCT04847999|Experimental|Conventional Dark Chocolate|A standard dark chocolate bar.
89565511|NCT04847999|Experimental|Ross Dark Chocolate|A dark chocolate bar sweetened with stevia, erythritol, and inulin.
89565512|NCT05430841|Experimental|18F-AlF-FAPI PET/CT|Each subject receives a single intravenous injection of 18F-FDG and 18F-AlF-FAPI, and undergo PET/CT imaging within the specified time.
89565513|NCT05375721|Experimental|ST36 acupoint injection group|Patients in this group will received bilateral ST36 injection with scopolamine 1ml/point
89565514|NCT05375721|Placebo Comparator|pharmacoprophylaxis group|Patients in this group will received bilateral ST36 acupoint injection with normal saline 1ml/point
89565515|NCT04863053||Stable CHD patient|Patients aged ≥ 18 years who have a history of stable coronary heart disease (CHD) receiving long-term mono-antiplatelet therapy with aspirin (80 mg once daily)
89565516|NCT05430763||Williams syndrome|Nerve conduction test (NCT) Nerve ultrasound Clinical evaluation GAITRite walkway Motor questionnaire
89565517|NCT05430763||Control, age matched|Nerve conduction test (NCT) Nerve ultrasound Clinical evaluation GAITRite walkway Motor questionnaire
89565518|NCT03104101|Active Comparator|TPTNS|Those who received Transcutaneous posterior tibial nerve stimulation sessions only
89565519|NCT03104101|Active Comparator|TPTNS+Drug|Those who received Transcutaneous posterior tibial nerve stimulation sessions plus 20 mg Trospium chloride
89565520|NCT05400525|Active Comparator|YMETA|Y META is a combination of gut health focused bioactives that target both the metabolic activity of existing microbiota (Bifidobacterium spp. targeting prebiotic galacto-oligosaccharides mixture)
89565521|NCT05400525|Placebo Comparator|Maltodextrin|
89565522|NCT03104023|Active Comparator|Staple line inversion|Patients will undergo a staple line inversion with a a running suture of Polypropylene 2/0.
89565523|NCT03104023|Experimental|Staple line buttressing|The gastric section will be performed with preloaded buttress material .
89565524|NCT04847687||Group 1|Patients who are started on 1 mg/kg/day methylprednisolone. Demographic data of the patients, length of hospital stay, follow-up in intensive care unit and prognosis will be recorded.
89565525|NCT04847687||Group 2|Patients who are started on 250 mg/day methylprednisolone. Demographic data of the patients, length of hospital stay, follow-up in intensive care unit and prognosis will be recorded.
89565526|NCT05430685|Experimental|Ashwagandha|Generic name: ashwagandha root extract Dose form: Chloroform capsule Dose: 1 capsule 350 mg ashwagandha root extract Frequency: 2 times per day (one capsule in the morning, one capsule in the evening). Total: 700 mg ashwagandha root extract per day Duration: 30 days
89565527|NCT05430685|Placebo Comparator|Placebo|Generic name: placebo Dose form: Glycerin equivalent weight to ashwagandha Dose: 1 capsule Frequency: one capsule, 2 times per day (one capsule in morning and one in evening) Duration: 30 dys
89565528|NCT01729455||BENLYSTA cohort|Participants with active, autoantibody-positive SLE treated with BENLYSTA at Baseline.
89565529|NCT01729455||Comparison cohort|Participants with active, autoantibody-positive SLE treated without BENLYSTA at Baseline.
89565530|NCT04854473|Experimental|Impedance measurement|Subjects with Exero's Smart Drain Device Attached This arm contains subjects which will have Exero's leak detection Device used: Exero Smart Drain is placed on their large bowel during colonic resection surgery (either open, laparoscopic or robotic). The study aims to demonstrate that the parameters measured by the device in in-vivo, non-disrupted tissue are different than parameters measured in ischemic tissue. Once this data is collected a detection algorithm can be trained. This procedure will add no more than 20 minutes to the existing procedure that is performed per hospital standard overall and will enable collection of control vs. ischemia induced clinical data, essential to developing the detection algorithms.
89565531|NCT03101839|Experimental|AZD4785|This is a single-arm study in which all patients will receive AZD4785 by IV infusion. Patients will continue to receive treatment with AZD4785 until disease progression, intolerable toxicity, or discontinuation criteria are met.
89027649|NCT01242683|Placebo Comparator|Usual Primary Care|Continuation of usual primary care managed by the participants' usual physician or nurse practitioner source of care.
89027650|NCT01242722||1|Two experimental and/or intervention groups under 1 arm.
89565532|NCT04428983|Experimental|Hericium erinaceus mycelium|Hericium erinaceus capsules 1 table tid orally per day for 24 months
89027651|NCT02275806|Other|All enrolled patients|"Induction Chemotherapy Cycle 1 - Irinotecan 65 mg/m2 and Cisplatin 30 mg/m2 on days 1 and 8~Concurrent Chemotherapy Cycles 2-4 - Irinotecan 65 mg/m2 and Cisplatin 30 mg/m2 on days 22 and 29, days 43 and 50, and days 64 and 71 along with radiation therapy of 60-70 Gy in 2 GY fractions on days 22 -71."
89027652|NCT01242761||Symptomatic rotator cuff tear|Patients with symptomatic rotator cuff tears presenting to hospital clinic after having ultrasound exam in community with indications for surgery
89027653|NCT01241370||Lean healthy subjects|Homeostasis Model Assessment score (HOMAs) ≤ 2, Body Mass Index (BMI) ≤ 28 kg/m2
89027654|NCT01241370||Insulin-resistnat subjects|HOMAs > 2, BMI > 28 kg/m2
89027655|NCT01241370||Type 2 diabetic patients|
89027656|NCT01241409|Experimental|Treatment sequence ABC|
89027657|NCT01241409|Experimental|Treatment sequence ACB|
89027658|NCT01241409|Experimental|Treatment sequence BAC|
89027659|NCT01241409|Experimental|Treatment sequence BCA|
89027660|NCT01241409|Experimental|Treatment sequence CAB|
89027661|NCT01241409|Experimental|Treatment sequence CBA|
89027662|NCT01242839|Experimental|CACICOL20|Arm that receives CACICOL20 treatment each 2 days for 3 months/until closure of the ulcer
89027663|NCT01242839|Placebo Comparator|Placebo|The placebo is applicated each 2 days on patient cornea for 3 months/ until ulcer closure.
89027664|NCT01242839|Experimental|CACICOL20 and Placebo|Patient applies the treatment each 2 days for 3 months or until closure of the ulcer. This treatment is alternatively CACICOL20 or Placebo : so the patient receives CACICOL20 each 4 days. CACICOL20 and placebo strips are strictly similar and cannot be identified.
89027665|NCT02275845|Experimental|intervention|Metformin twice daily 500 mg for the first week, after that twice daily 1000 mg. All the subjects are receiving a diet which contains a 2000 calories/day diet, with an adequate distribution of carbohydrates during the day.
89027666|NCT02275845|Active Comparator|control diet|a diet which contains a 2000 calories/day diet, with an adequate distribution of carbohydrates during the day.
89027667|NCT01241201|Placebo Comparator|Placebo|placebo for probiotic treatment
89027668|NCT02275884|Active Comparator|Dark chocolate (85% cocoa)|Patients will initially receive 50 grams of dark chocolate (85% cocoa) b.i.d. for one week. Patients will then cross over to intake of 50 grams of white chocolate (0% cocoa) b.i.d. for another week.
89027669|NCT02275884|Sham Comparator|White chocolate (0% cocoa)|Patients will initially receive 50 grams of white chocolate (0% cocoa) b.i.d. for one week. Patients will then cross over to intake of 50 grams of dark chocolate (85% cocoa) b.i.d. for another week.
89027670|NCT01241357||Observation only|This study has a single arm and no intervention.
89027671|NCT00485004|Experimental|Cutting balloon|Cutting balloon
89027672|NCT00485004|Active Comparator|Sirolimus-eluting stent|Sirolimus-eluting stent
89027673|NCT01241396||001|Any MMY treatment Any line of treatment for MMY
89027674|NCT00485030|Experimental|Cypher|sirolimus-eluting stent
89027675|NCT00485030|Active Comparator|Xience-V|everolimus-eluting stent
89027676|NCT00489515||patients with gastrointestinal cancer scheduled for surgery|
89027677|NCT01242878||healthy volunteers|ethnically matched people who do not have sickle cell disease
89027678|NCT01242878||patients|sickle cell disease patients
89027679|NCT04514172|Experimental|With exoskeleton|The experimental trial will be performed with exoskeleton.
89027680|NCT04514172|Experimental|Without exoskeleton|The experimental protocol will be performed without exoskeleton.
89027681|NCT00485108|Active Comparator|1|Prednisolone 1% eye drop
89027682|NCT00485108|Active Comparator|2|ketorolac 0.5% eye drop
89027683|NCT00485108|Placebo Comparator|3|Artificial Tears (methyl cellulose eye drop)
89027684|NCT00505713|Experimental|1|Dose Level 1 of escalating doses of Rexin-G i.v.
89027685|NCT00505713|Experimental|3|Dose Level 3 of escalating doses of Rexin-G i.v.
89027686|NCT00505713|Experimental|4|Dose Level 4 of escalating doses of Rexin-G i.v.
89027687|NCT00505713|Experimental|5|Dose Level 5 of escalating doses of Rexin-G i.v.
89027688|NCT00505713|Experimental|2|Dose Level 2 of escalating doses of Rexin-G i.v.
89027689|NCT04513704|Experimental|Oral Semaglutide A|Participants will receive oral semaglutide tablet once daily for 10 days (3 mg for first 5 days and 7 mg for the next 5 days), with a pre-specified timing for 2 hours of the pre-dose fast, followed by a 30 minutes post-dose fast.
89027690|NCT04513704|Experimental|Oral Semaglutide B|Participants will receive oral semaglutide tablet once daily for 10 days (3 mg for first 5 days and 7 mg for the next 5 days), with a pre-specified timing for 4 hours of the pre-dose fast, followed by a 30 minutes post-dose fast.
89027691|NCT04513704|Experimental|Oral Semaglutide C|Participants will receive oral semaglutide tablet once daily for 10 days (3 mg for first 5 days and 7 mg for the next 5 days), with a pre-specified timing for 6 hours of the pre-dose fast, followed by a 30 minutes post-dose fast.
89027692|NCT04513704|Experimental|Oral Semaglutide D|Participants will receive oral semaglutide tablet once daily for 10 days (3 mg for first 5 days and 7 mg for the next 5 days), with a pre-dose fasting time of 2 hours followed by a post-dose overnight fast.
89027693|NCT04513704|Active Comparator|Oral Semaglutide E|Participants will receive oral semaglutide tablet once daily for 10 days (3 mg for first 5 days and 7 mg for the next 5 days). Participants will be instructed to take the trial product in the morning after an overnight fast and wait 30 minutes before taking any food, water or other oral medication in accordance with the approved dosing schedule for oral semaglutide.
89027694|NCT01241474|Experimental|Fish oil|
89027695|NCT01241474|Placebo Comparator|Maize (corn) oil|
89027696|NCT01242956|Experimental|Verum group|video-based training after stroke
89027697|NCT01242956|Placebo Comparator|Placebo group|non-video group
89027698|NCT00485355|Active Comparator|1|Conventional Laparoscopic Hysterectomy
89027699|NCT00485355|Active Comparator|2|Robotic Assisted Laparoscopic Hysterectomy
89027700|NCT00485186||1|
89027701|NCT00485186||2|
89027702|NCT04513509|Experimental|rate control|
89565533|NCT04428983|Placebo Comparator|placebo|placebo capsules 1 table tid orally per day for 24 months
89565534|NCT03103867|Experimental|CGM augmented pump with PLGS (A)|Administration of Subcutaneous administration of Continuous subcutaneous insulin infusion with integrated continuous glucose monitoring and predicted low glucose suspense (PLGS) Randomised cross over treatment during 5 weeks
89565535|NCT03103867|Active Comparator|Insulin pump with CGM (B)|Administration of Subcutaneous administration of Continuous subcutaneous insulin infusion with second device measuring continuous glucose Randomised cross over treatment during 5 weeks
89565536|NCT04847375|Experimental|Nebulized Surfactant|The patients in this group will receive exogenous surfactant using nebulizer mask as soon as they are admitted in the hospital (ward or emergency department) with a diagnosis of COVID-19; in addition they will receive standard care based on the national guidelines
89565537|NCT04847375|No Intervention|Standard Care|The patients in this group will receive standard care based on the national guidelines as soon as they are admitted in the hospital (ward or emergency department) with a diagnosis of COVID-19
89565538|NCT03103711|Experimental|Intervention|"The entire intervention is composed by four 30 minutes sessions along 1 week. Its focus is on the promotion of well-being by the use of two virtual environments (Emotional Parks and Walk through Nature). These environments allow participants to involve in different exercises (working with self statements, videos, images, slow breathing, focus on the present exercises) with the purpose of increase positive emotional states."
89565539|NCT03103711|No Intervention|Control|Participants receive the medical treatment deliver by the hospital. They fulfill several questionnaires at two moments (pre and post 1 week after). After this, they have the possibility to receive the psychological intervention.
89565540|NCT03044015|Experimental|Intervention|a defined strategy for the identification of OF. To carry out a primary care based intervention about lifestyle, diet and drug prescription, if needed, with an intensive follow-up
89565541|NCT03044015|Active Comparator|Control|Intervention as usual
89565542|NCT05430607|Experimental|Intervention group|The intervention group will participate in a 9-week running program and will also continue their routine treatment program at the psychiatric ward.
89565543|NCT05430607|No Intervention|Control group|The control group will continue their routine treatment program at the psychiatric ward.
89565544|NCT04847219|Placebo Comparator|Professional flash glucose mornitoring|Professional flash glucose mornitoring will be used in patients once a month for 3 months to monitor glucose level. Patients can learn their blood glucose levels via capillary blood glucose tests, but nor FGM duing FGM, and doctors will adjust their anti-diabetic therapy according to their FGM results after each monitoring.
89565545|NCT04847219|Active Comparator|Personal flash glucose mornitoring|Personal flash glucose mornitoring will be used in patients once a month for 3 months to monitor glucose level. Patients can learn their blood glucose levels via FGM duing FGM, and doctors will adjust their anti-diabetic therapy according to their FGM results after each monitoring.
89565546|NCT03799861||Epoch 1: Care prior to HBB training|A period of demographic and birth outcome data collection for a retrospective cohort of all infants born in the three study hospitals during the 18 months prior to the start of Epoch 2, reflecting care prior to HBB training.
89565547|NCT03799861||Epoch 2: HBB with NeoBeat|Implementation of Helping Babies Breathe training in combination with NeoBeat for detection of HR in non-breathing newborns, after which demographic and birth outcome data will be abstracted from the medical record along with observational data on resuscitation for prospective cohort of all infants born in the three study hospitals for a 9-month period.
89565548|NCT03799861||Epoch 3: HR-guided HBB|Implementation of HR-guided Helping Babies Breathe training with NeoBeat for measurement of HR throughout resuscitation of non-breathing newborns, after which demographic and birth outcome data will be abstracted from the medical record along with observational data on resuscitation for a prospective cohort of all infants born in the three study hospitals for a 9-month period.
89565549|NCT04847297||Preoperative biliary drainage and pancreatoduodenectomy|Patients receiving preoperative biliary drainage before the removal of the tumor.
89565550|NCT04847297||Pancreatoduodenectomy only|Patients undergoing only surgical intervention, without preoperative drainage.
89565551|NCT04737343|Active Comparator|Azathioprine treatment arm|Patients will be treated with Azathioprine 100mg QD for 18 months combined with rednisone. The dosage of prednisone is tapered in the study period but will be maintained at 7.5mg/d to the end of the study period.All included patients will be treated with TMPco 2 tablets everyday during the study period if not contraindicated or intoleran.t
89565552|NCT04737343|Experimental|Leflunomide treatment arm|Patient will be treated with Leflunomide 30mg QD for 18 months combined with prednisone. The dosage of prednisone is tapered in the study period but will be maintained at 7.5mg/d to the end of the study period. All included patients will be treated with TMPco 2 tablets everyday during the study period if not contraindicated or intolerant.
89027703|NCT00485342|No Intervention|standard dose|"the reference strategy : Peg-interferon alpha 2a (180 µg/week) and ribavine (1000 mg/day if weight < 75 kg and 1200 mg/day if weight ≥ 75 kg)"
89027704|NCT00485342|Experimental|adjusted dose|individual dose adjustment of ribavirin dose at D7, based on ribavirin abbreviated AUC-0-4H , estimated itself by two independent methods: multiple linear regression and bayesien estimation based on three ribavirin concentration measurements obtained at 0.5H, 1H, 2H after the first intake of 600 mg at D0.
89027705|NCT00485394|Experimental|1|OT-551 0.3% ophthalmic solution
89027706|NCT00485394|Experimental|2|OT-551 0.45% ophthalmic solution
89565553|NCT04480723|Other|Participants with Low or Intermediate Probability of PH|Participants who underwent a work-up for the suspicion of PH that includes transthoracic echocardiography (TTE) and who were considered to have a low or intermediate probability of PH according to TTE (local interpretation) will be enrolled. Blood samples will be taken and a cardiac magnetic resonance imaging (MRI) will be performed to evaluate the presence of Pulmonary Hypertension (PH). The TTEs that were performed by local standards will be collected and undergo central interpretation using European society of Cardiology / European respiratory society (ESC/ERS) guidelines to confirm the local interpretation.
89565554|NCT04862819|Active Comparator|scaling root planning|patients in this group will have a scaling root planing procedure only
89565555|NCT04862819|Experimental|scaling root planning with new local drug delivery|patients in this group will have a scaling root planing procedure and a drug administered
89027707|NCT00485394|Placebo Comparator|3|vehicle placebo
89565556|NCT03776149|Experimental|Beetroot juice (dietary nitrate)|Over the 7 days preceding each testing session, participants will consume 140 ml per day of beetroot juice (Beet It (HeartBeet Ltd.), Ipswich, UK). During this time participants will be asked to abstain from use of antiseptic mouthwash as this has been shown to temporarily kill the bacteria that facilitate the reduction of nitrate to nitrite. All participants will be asked to refrain from consuming any antioxidant (e.g., Vit E or Fish Oil) supplements during the course of the study as these may impact the study findings.
89565557|NCT03776149|Placebo Comparator|Black currant juice (placebo control)|Over the 7 days preceding each testing session, participants will consume 140 ml per day of a nitrate-depleted placebo. During this time participants will be asked to abstain from use of antiseptic mouthwash as this has been shown to temporarily kill the bacteria that facilitate the reduction of nitrate to nitrite. All participants will be asked to refrain from consuming any antioxidant (e.g., Vit E or Fish Oil) supplements during the course of the study as these may impact the study findings.
89027708|NCT01242995||pancreatobiliary disorders/thin scope|All patients will be evaluated with cholangioscopy and/or pancreatoscopy using the thin scope.
89565558|NCT04854239|Experimental|Machine-driven group|In the machine-driven group, after guided implant bed preparation, implant insertion was performed with contra-angled handpiece.
89565559|NCT04854239|Experimental|Manual group|In the manual group, after guided implant bed preparation, implant insertion was performed with torque-wrench.
89565560|NCT02724631|Experimental|TubeClear® (Phase I)|To determine feasibility and tolerability, 15 subjects will receive the TubeClear® intervention. If the TubeClear® intervention is unable to restore Enteral Access Device patency, further steps to restore patency of the occluded EAD will be determined by the clinical team per usual practice.
89565561|NCT03760783|Other|Effect of microgravity on human sperm|Simulated microgravity flight
89565562|NCT03754231|Experimental|Aingeal|All recruited patients will wear the Aingeal device as a form of heart rate monitoring and respiratory rate monitoring in a paediatric outpatient clinic setting.
89565563|NCT05400213|Active Comparator|Group 1 Vallos|Subjects will be randomized into one of the four groups and receive the corresponding material for ridge preservation following tooth extraction.
89565564|NCT05400213|Active Comparator|Group 2 Vallomix|Subjects will be randomized into one of the four groups and receive the corresponding material for ridge preservation following tooth extraction.
89565565|NCT05400213|Active Comparator|Group 3 Vallos-F|Subjects will be randomized into one of the four groups and receive the corresponding material for ridge preservation following tooth extraction.
89565566|NCT05400213|Active Comparator|Group 4 Vallomix-F|Subjects will be randomized into one of the four groups and receive the corresponding material for ridge preservation following tooth extraction.
89565567|NCT02609399|Experimental|Oseltamivir|Subjects randomized to the oral treatment arm will receive 5 days of oral oseltamivir.
89565568|NCT02609399|Experimental|Peramivir|Subjects randomized to the IV treatment group will receive 1 dose of IV peramivir.
89565569|NCT05430217|Experimental|Buspirone, sustained-release tablets, 15 mg|15 mg/day
89565570|NCT05430217|Placebo Comparator|Placebo|1 placebo tablet/day
89565571|NCT05430061|Experimental|Raw corn starch|Raw corn starch is a slow digesting carbohydrate, corn starch, a commonly consumed food ingredient, considered GRAS (generally recognized as safe) CFR 182.70- 182.90 will be used as the test meal treatment. Participants will receive 21 individual containers of raw corn starch (30 g/container) and 21 cups of 4 oz unsweetened apple sauce. Participants will be asked to consume one starch container mixed in apple sauce at 10 a.m.; each day for 21 days.
89565572|NCT05430061|Sham Comparator|Maltodextrin DE-10|Maltodextrin dextrose equivalent 10 is a fast digesting carbohydrate, is a non-sweet nutritive polymer that consists of D-glucose units linked primarily by [alpha]-1-4 bonds and that has a dextrose equivalent (D.E.) of less than 20. It is regarded as Generally Recognized as Safe (GRAS) by the U.S. Food and Drug Administration for direct use as a food ingredient (GRAS, 21CFR184.1444).DE-1 Maltodextrin is commercially available. Participants will receive 21 individual containers of maltodextrin (30 g/container) and 21 cups of 4 oz unsweetened apple sauce. Participants will be asked to consume one maltodextrin container mixed in apple sauce at 10 a.m.; each day for 21 days.
89565573|NCT04853927|Active Comparator|Proxalutamide + Standard of Care|Proxalutamide + standard of care as determined by the PI
89565574|NCT04853927|Placebo Comparator|Placebo + Standard Care|Placebo + Standard of care as determined by the PI
89565575|NCT03103555|Experimental|Bortezomib and cyclophosphamide|Two cycles of bortezomib administered subcutaneously, followed by 4 months of low dose oral cyclophosphamide.
89565576|NCT04846751|Active Comparator|AEROBIC EXERCISE|50 min of aerobic exercise by pedaling a cycleergometer at 60% of VO2max
89565577|NCT04846751|Placebo Comparator|PLACEBO REST|No exercise, resting during 50 min.
89565578|NCT05417685||Musculoskeletal disorder|
89027709|NCT00489593|Experimental|Olanzapine|Olanzapine 2.5 mg by mouth (PO) Daily x 28 days, increasing about every 3-14 days in increments of 2.5-5 mg until the designated dose for that cohort is reached.
89027710|NCT01241487|Experimental|1|valsartan/amlodipine
89027711|NCT00489632||Questionnaire|Children with leukemia and their families/caregivers.
89027712|NCT00505791|Placebo Comparator|Sugar pill|Lactose, NF (monohydrate)
89565579|NCT04853771|Experimental|experiment|28-29. Between the weeks of gestation, one-time progressive muscle relaxation exercise training prepared by the researcher will be given to the pregnant women. Exercise will be demonstrated in training. Later, pregnant women will be asked to explain and practice the exercise. Women will be repeated until they do the exercise completely correctly (Check-list 1). After the training, pregnant women will be asked to do progressive relaxation exercises at least 3 times a week (every other day). With the progressive muscle relaxation exercise daily follow-up schedule prepared by the researcher, the pregnant women will be followed for 8 weeks and weekly reminders will be made (via whatsapp® or text message). The final test application (36-37 weeks) will be done online at the end of 8 weeks to the pregnant women. In pre-test and post-test applications, RLS Severity Rating Scale form, Johns Hopkins Restless Leg Syndrome Quality of Life Scale and Pittsburg Sleep Quality Index will be used.
89565580|NCT04853771|No Intervention|control|No intervention will be applied to pregnant women, other than the routine training given in the pregnancy school. In the maternity school, training is given on physiological and psychological changes that occur during pregnancy, baby care, postpartum period, family planning. However, pregnant women are not given any information about RLS, coping methods, creating a healthy lifestyle, and progressive muscle relaxation exercises. Final test application to pregnant women; 36-37. It will be held online between weeks. In pre-test and post-test applications, RLS Severity Rating Scale form, Johns Hopkins Restless Leg Syndrome Quality of Life Scale and Pittsburg Sleep Quality Index will be used.
89565581|NCT02720185|Experimental|Dasatinib 100mg|Dasatinib 100mg for 7-10 days until day prior to surgery
89565582|NCT04846673|Experimental|Pregabalin and alpha-lipoic acid combination therapy|Alpha-lipoic acid 480 mg/tablet once daily before breakfast and Pregabalin 150 mg/tablet once daily before bedtime will be administrated for 12 weeks.
89565583|NCT04846673|Experimental|Pregabalin monotherapy|Pregabalin 150 mg/tablet once daily before bedtime will be administrated for 12 weeks.
89565584|NCT04846673|Active Comparator|Alpha-lipoic acid monotherapy|Alpha-lipoic acid 480 mg/tablet once daily before breakfast will be administrated for 12 weeks.
89565585|NCT04846283||Biomarker-group|We considered for the study all patients aged >16 y undergoing elective or emergency colorectal surgery for cancer, diverticular disease, inflammatory bowel-disease or reversal of Hartmann's procedure. Both patients undergoing open and minimally invasive surgery were considered eligible.
89565586|NCT05398497|Experimental|Early stage breast cancer up to 2.5 cm|Patients treated with Cryocare SL followed by traditional surgery, radiotherapy and adjuvant systemic therapy.
89565587|NCT03040739||case|
89565588|NCT03040739||control|
89565589|NCT04498273|Active Comparator|Apixaban 2.5mg|Anticoagulation: prophylactic dose Apixaban 2.5mg po bid
89565590|NCT04498273|Active Comparator|Apixaban 5mg|Anticoagulation: therapeutic dose Apixaban 5.0mg po bid
89565591|NCT04498273|Active Comparator|Aspirin|Antiplatelet agent: low dose aspirin 81mg po qd
89565592|NCT04498273|Placebo Comparator|Placebo|Placebo
89565593|NCT04853615||Group 1|1st group will receive normal saline 10ml/kg over 6 hours before and 6 hours after radiocontrast
89565594|NCT04853615||Group 2|2nd group will receive allopurinol 300 mg and linagliptin 5 mg once daily
89565595|NCT04853615||Group 3|3rd group will receive the SGLT2i empagliflosin 25 mg once daily
89565596|NCT04853615||Group 4|4thwill receive allopurinol and empagliflosin.
89565597|NCT04853537|Experimental|study group|• 126 women will fast 16 consecutive hours per day including sleeping hours. and follow them from 26w till 36w by GTT(glucose tolerance test) and the weight gain and incidence of gestational diabetes
89565598|NCT04853537|No Intervention|control group|• 126 women will not fasting with the same life style and follow the incidence of gestational diabetes
89027713|NCT00505791|Active Comparator|Nesiritide|Natrecor (nesiritide) is a commercially available B-type natriuretic peptide which is indicated for intravenous treatment of patients with acutely decompensated congestive heart failure who have dyspnea at rest or with minimal activity.
89027714|NCT00489671||pre cancerous condition (pancreatitis)|
89565599|NCT02526693|Other|Glaucoma Patients|Glaucoma patients recruited from Wills Eye Hospital Glaucoma Service will be tested with the relative afferent pupillary defect test (RAPDx) Pupillometer. The noninvasive RAPDx measures the pupils response during light stimulation.
89565600|NCT02526693|Other|Healthy Controls|Healthy subjects with no eye diseases recruited from Wills Eye Hospital Glaucoma Service staff, family and friends will be tested with the relative afferent pupillary defect test (RAPDx) Pupillometer. The noninvasive RAPDx measures the pupils response during light stimulation.
89565601|NCT04440475|Experimental|Tap Block|"TAP block at the end of the surgery, in addition to conventional postoperative oral medication as needed~postoperative conventional oral medication as needed: Acetaminophen 650 mg Q 6 hours Ibuprofen 600 mg Q 6 hours Tramadol 50 mg Q 6 hours"
89565602|NCT04440475|No Intervention|Conventional postoperative oral medication|postoperative conventional oral medication as needed: Acetaminophen 650 mg Q 6 hours Ibuprofen 600 mg Q 6 hours Tramadol 50 mg Q 6 hours
89565603|NCT05573607|Placebo Comparator|Placebo|Consists of a maltodextrin tablet
89565604|NCT05573607|Active Comparator|Active|A tablet consisting of a blend of Crominex® 3+, Capros® Amla Extract (Fruit), PrimaVie® Shilajit), and MetaviveTM complex (Salacia Chinensis Extract (Fruit) and a Citrus Bioflavonoids)
89565605|NCT04435483|Experimental|Treatment Sequence 1|Participants will receive Treatment A (100 mg acalabrutinib suspension via NG administration plus 20 mg rabeprazole) in Period 1, Treatment B (100 mg acalabrutinib suspension via NG administration) in Period 2, and Treatment C (100 mg acalabrutinib capsule) in Period 3.
89565606|NCT04435483|Experimental|Treatment Sequence 2|Participants will receive Treatment B (100 mg acalabrutinib suspension via NG administration) in Period 1, Treatment C (100 mg acalabrutinib capsule) in Period 2, and Treatment B (100 mg acalabrutinib suspension via NG administration) in Period 3.
89565607|NCT04861883||76 healthy the Middle and Third Trimester pregnant women in the trial group|The pulse sound waves of three parts and five layers of each of the two hands of 76 pregnant women will be collected by Pulse Detection System of Sound Waves.
89565608|NCT04861883||76 relatively healthy non-pregnant women in the control group|The pulse sound waves of three parts and five layers of each of the two hands of 76 relatively healthy non-pregnant women will be collected by Pulse Detection System of Sound Waves.
89565609|NCT05372445|No Intervention|Reference Group|"People between 30-60 years old, without obesity, prediabetes or type 2 diabetes.~The purpose of this group is to characterize gut microbiota and microbiome to set the reference values of the argentinian local population."
89565610|NCT05372445|Active Comparator|Obesity Group A|People between 30-60 years old, diagnosed with obesity assigned to the non-intensive intervention.
89565611|NCT05372445|Experimental|Obesity Group B|People between 30-60 years old, diagnosed with obesity assigned to the intensive intervention.
89565612|NCT05372445|Active Comparator|Prediabetes Group A|People between 30-60 years old, diagnosed with prediabetes assigned to the non-intensive intervention.
89565613|NCT05372445|Experimental|Prediabetes Group B|People between 30-60 years old, diagnosed with prediabetes assigned to the intensive intervention.
89565614|NCT05372445|Active Comparator|Type 2 Diabetes Group A|People between 30-60 years old, diagnosed with type 2 diabetes assigned to the non-intensive intervention.
88968826|NCT04394130|Experimental|CI group|"Patients will have a preoperative ultrasound-guided interscalene brachial plexus block with 20 ml of lidocaïne 1% and epinephrine 1:100,000, followed by the insertion of a catheter. In the post-operative period, after clinical assessment of motor recovery in the operated limb (flexion of the forearm possible) in order to exclude any neurological damage of surgical origin, ropivacaine 0.5% 20 ml will be injected through the catheter.~Then a continuous infusion of ropivacaine 0.2% at a flow rate of 6 ml.h-1 will be running for 48h after the bolus administration.~During surgery, patients will also receive multimodal analgesia inclusive of iv dexamethasone 8 mg, iv magnesium sulfate 40 mg.kg-1, iv ketorolac 30 mg, and iv acetaminophen 1000 mg, according to the current practice in our institution."
88968827|NCT04394130|No Intervention|SS group|"Patients will have a preoperative ultrasound-guided interscalene brachial plexus block with 20 ml of lidocaïne 1% and epinephrine 1:100,000, followed by the insertion of a catheter. In the post-operative period, after clinical assessment of motor recovery in the operated limb (flexion of the forearm possible) in order to exclude any neurological damage of surgical origin, ropivacaine 0.5% 20 ml will be injected through the catheter.~After the injection, the catheter will be removed.~During surgery, patients will also receive multimodal analgesia inclusive of iv dexamethasone 8 mg, iv magnesium sulfate 40 mg.kg-1, iv ketorolac 30 mg, and iv acetaminophen 1000 mg, according to the current practice in our institution."
88968828|NCT00045916|Experimental|High dosage ECT + nortriptyline|Participants will receive nortriptyline and high dosage ECT. If the ECT is effective participants will receive lithium after ECT treatment.
88968829|NCT00045916|Experimental|High dosage ECT + venlafaxine|Participants will receive venlafaxine and high dosage ECT. If the ECT is effective participants will receive lithium after ECT treatment.
88968830|NCT00045916|Placebo Comparator|High dosage ECT + placebo|Participants will receive placebo and high dosage ECT. If the ECT is effective participants will receive lithium after ECT treatment weeks.
89027715|NCT00485420|Active Comparator|Usual Care|Member with recurrent or chronic depression receives usual specialty mental health care
89565615|NCT05372445|Experimental|Type 2 Diabetes Group B|People between 30-60 years old, diagnosed with type 2 diabetes assigned to the intensive intervention.
89565616|NCT05425849|No Intervention|control group|No attempt was made to reduce pain in the patients in the control group. Standard PIVC insertion procedure was applied.
89565617|NCT05425849|Experimental|rose oil group|After the patients in the rose aromatherapy group were placed in a sitting position, a face mask with 1-2 drops of rose oil was placed on the nose area. Then, the standard PIVC insertion procedure was applied. After the procedure, the patient's rose-scented mask was replaced with a standard mask.
89565618|NCT05425849|Experimental|hand holding group|After the patients in the hand-holding group were placed in a sitting position, the patient's family was asked to hold the patient's hand and not let it go until the procedure was over. Standard PIVC insertion procedure was applied.
89565619|NCT04846205||Patients who underwent a systematic etiological|Patients who underwent a systematic etiological assessment in the context of their cryptogenic ischemic stroke between 2015 and 2020. A collect data in medical record will be realized.
89565620|NCT03103633|Experimental|Individualized Goal-Directed Therapy|The goal of intervention:mean artery pressure declined with less than 20% of baseline, BIS 45-60 before and after CPB; and BIS 40-45 during CPB, Brain oxygen saturation declined with less than 20% of baseline.
89565621|NCT03103633|Sham Comparator|Controlled|no intervention beside the same monitoring with MAP, BIS and brain oxygen saturation and receiving standard measures to achieve a heart rate (HR) in the range of 60-100 beats/min, central venous oxygen saturation (Svco2) higher than 70%, lactate level lower than 3 mmol/L, hematocrit value higher than 28%, and urinary output higher than 0.5 mL/kg/hr.
89565622|NCT04862039|Experimental|Virtual Reality (VR) devices|intervention group (VR).
89565623|NCT04862039|No Intervention|control group|the standard of care (control group, no VR)
89565624|NCT04862117|Active Comparator|Active stimulation QD|
89565625|NCT04862117|Active Comparator|Active stimulation QID|
89565626|NCT03691909|Experimental|Treatment Arm|Single IV administration of autologous adipose-derived mesenchymal stem cells Baseline laboratory data will be collected prior to infusion; follow up data will be compared against baseline at 1, 3, 6 and 12 months. Joint Assessment 68 will be administered at 1, 3, 6 and 12 months.
89565627|NCT04861649|Experimental|Effect and mechanism of fecal microbiota transplantation on patients with COPD malnutrition|"During COPD stable period, nasal and intestinal tubes were placed and fecal bacteria were transplanted from healthy people (three transplants per course of treatment).~200ml of bacterial liquid was transplanted for each course, containing 40g of bacterial volume, transplanted consecutively for 3 times, once a day)"
89565628|NCT03040817|Experimental|G-POEM|Each participant receive gastric peroral endoscopic pyloromyotomy (G-POEM).
89565629|NCT03040817|Active Comparator|Esomeprazole + Mosapride|Each participant receive Esomeprazole+ Mosapride. The dosages are：Nexium 40mg bid， Mosapride Citrate Tablets 5mg tid.
89565630|NCT05416749|Experimental|8MW2311|
89565631|NCT05423431||Radiation with Hydrogel Spacer|Males at least 18 years of age, who underwent radiation therapy with a hydrogel spacer in place.
89565632|NCT04853303|Experimental|Hypnosis VR|The experimental group will receive a 15-minute hypnosis using virtual reality when they are experiencing chemotherapy-induced nausea and vomiting, sleep quality or pain.
89565633|NCT04853303|No Intervention|Control|The control group will receive no intervention.
89565634|NCT05412355||Incomplete ERAS|Incomplete ERAS was defined as ERAS compliance < 70%.
89565635|NCT05412355||Non-ERAS|non-ERAS was defined as not executing any ERAS programs.
89565636|NCT04853069|Active Comparator|Oestrogen Therapy|Patients will receive standard care + transdermal 17ß-estradiol gel (3 mg) for ten days.
89565637|NCT04853069|No Intervention|Control Group|Patients will receive only standard care.
89565638|NCT04259853|Experimental|QFR-guided PCI group|QFR-guided revascularization on non-culprit vessels in patients with STEMI
89565639|NCT04259853|Active Comparator|CAG-guided PCI group|CAG-guided revascularization on non-culprit vessels in patients with STEMI
89565640|NCT05245279|Experimental|Normal placenta-entitle|The 3-DPD indices was measured in the entire placenta volume.
89565641|NCT05245279|Experimental|Normal placenta-sonobyopsy|The 3-DPD indices was measured at cord insertion in placenta by sonobiopsy
89565642|NCT04852913|Experimental|Bowen's Technique|Bowen's Technique The session lasted for 20 minutes, 3 sessions/week 6th week
88968831|NCT00045916|Experimental|Low dosage ECT + nortriptyline|Participants will receive nortriptyline and high dosage ECT. If the ECT is effective participants will receive lithium after ECT treatment.
88968832|NCT00045916|Experimental|Low dosage ECT + venlafaxine|Participants will receive venlafaxine and low dosage ECT. If the ECT is effective participants will receive lithium after ECT treatment.
88968833|NCT00045916|Experimental|Low dosage ECT + placebo|Participants will receive placebo and low dosage ECT. If the ECT is effective participants will receive lithium after ECT treatment weeks.
88968834|NCT04380207|Experimental|QPX7728|antibiotic
88968835|NCT04380207|Placebo Comparator|Placebo|Matched placebo
88968836|NCT04380207|Experimental|QPX2014|antibiotic
89027716|NCT00485420|Experimental|Internet-based disease managment program|Usual care is augmented with internet based education, self monitoring and clinical monitoring
89565643|NCT04852913|Active Comparator|Conventional Physical Therapy|Conventional Physical Therapy with myofascial release The session lasted for 20 minutes, 3 sessions/week 6th week
89565644|NCT04846049||Comprehensive Care|"Veterans with complex medical conditions that may need more help. This intervention will provide extra care coordination after a complete assessment of their health.~Research team will assess veteran's memory, physical function, strength, balance, and from there, find the areas they need the most help with and coordinate services at home. This is in addition to their regular primary care provider."
89565645|NCT04846049||Standard Care|Veterans receiving standard of care
89565646|NCT03685045|Experimental|Campaign Days|All participants have the intervention of the campaign days which include hepatitis C screening, fibroscans and clinical assessments.
89565647|NCT04845971|Experimental|Adult male and female patients who are hospitalized with COVID-19-induced pneumonia.|Eligible patients will be treated with Saisei MAF capsules stronger version, oral administration 2-3 capsules, 3 times per day, 30 minutes before food or in the morning, afternoon and before bed time. The treatment duration will be 21 days. Patients are also provided with nutritional supplementation of Vitamin D3, 10.000 IU per day, monitoring the blood levels of such a vitamin. Efficacy and safety assessments will be performed on Days 0, 7, 14, 21, and 28.
89565648|NCT05245045|Experimental|Shengtaibufen Photodynamic Therapy(STBF-PDT)|The Shengtaibufen photodynamic therapy group underwent narrow-band light-emitting diode (LED) irradiation (630 nm; 150 J/cm2) after applying 0.5mg/ml Shengtaibufen solution for 45min. A repeat treatment was administered once weekly for a maximum of 3 weeks.
89565649|NCT05245045|Placebo Comparator|Red light|The Shengtaibufen photodynamic therapy group underwent narrow-band light-emitting diode (LED) irradiation (630 nm; 150 J/cm2) after applying normal saline solution for 45min. A repeat treatment was administered once weekly for a maximum of 3 weeks.
89565650|NCT03663595|Experimental|PFPS: Model 1 (Hip and Knee)|Females symptomatic for PFPS. This group will be submitted to the rehabilitation program with exercises focusing in proximal (hip) and local (knee) factors.
89565651|NCT03663595|Experimental|PFPS: Model 2 (knee, foot and ankle)|Females symptomatic for PFPS This group will be submitted to the rehabilitation program with exercises focusing in distal (foot and ankle) and local (knee) factors.
89565652|NCT03663595|No Intervention|Healthy group|Healthy females not submitted to intervention
89565653|NCT04846361|Experimental|Hygiene wash plus metronidazole|Hygiene wash once daily at night for two weeks plus oral metronidazole 400mg three times daily for 1 week
89565654|NCT04846361|Placebo Comparator|placebo wash plus metronidazole|Placebo wash once daily at night for two weeks plus oral metronidazole 400mg three times daily for 1 week
89565655|NCT04846361|No Intervention|Healthy control|Asymptomatic healthy women with BV negative test
89565656|NCT04429373|Experimental|Implant installation with PRF|PRF membrane over the buccal aspect of implant site
89565657|NCT04429373|Active Comparator|Implant installation without PRF|Implant installation contralateral to the the experimental implant, without PRF membrane
89565658|NCT05244811|Placebo Comparator|use of placebo in treatment of functional ovarian cyst|trial the effect of placebo in treatment of functional ovarian cyst
89565659|NCT05244811|Active Comparator|use of cocs in treatment of functional ovarian cyst|trial of the effectiveness of cocs in the treatment of functional ovarian cyst
89565660|NCT05244811|Active Comparator|use of progesterone in treatment of functional ovarian cyst|comparison between the effect of progesterone in the treatment of functional ovarian cyst with the effect of cocs
89565661|NCT04845659|Experimental|Intervention|Avatrombopaq administration
89565662|NCT03614611|Experimental|Contiform pessary|Enrolled participants will be part of the intervention arm. They will use of the Contiform Intravaginal pessary for the treatment of stress urinary incontinence, for a period of 3 months.
89565663|NCT04861493||Smokers with stage III,IV periodontitis|patients with stage III,IV periodontitis having CAL>5 mm and PD>5 mm in one or more sites and bleeding on probing >30% and smoking at least 10 cigarettes /day for a minmum of 5 years.
88968837|NCT04369560|Experimental|Magnetic Resonance Imaging|Prior to planned surgical resection, subjects will undergo a single Magnetic Resonance Imaging study: a single breath-hold pre-contrast image followed by sterile placement of a temporary urethral catheter for instillation of a 50mL solution containing Gadobutrol (4 mM) plus ferumoxytol (5 mM) and a second, single breath hold post-contrast image.
88968838|NCT00046111|Experimental|Primary Group|40 subjects on medium doses of Topotecan and tested for bioequivalence for 4 weeks.
88968839|NCT04731493||therapeutic Education Program|"individual and group sessions will be set up with educational workshops specialized by age group (child / adolescent / transition / adult / entourage / parents), socio-administrative workshops, etc.~The objectives will be adapted to each age group and to each patient individually."
88968840|NCT02970487|Experimental|investigational device|Subjects implanted with the Precisight intraocular lens.
88968841|NCT04364880|Experimental|Theta-burst stimulation (TBS)|Theta-burst stimulation (TBS) is a novel repetitive transcranial magnetic stimulation (rTMS)
88968842|NCT04364880|Sham Comparator|Sham controlled intervention|The sham-TBS coil produced a similar sound without a magnetic pulse.
88968843|NCT00397657|Active Comparator|Extended release niacin|
88968844|NCT00397657|Active Comparator|Ezetimibe|
88968845|NCT00397735|Experimental|N-Acetylcysteine|The subjects enrolled in our research protocol must have evidence of infection/inflammation at amniocentesis in order to receive N-acetylcysteine. Women with positive amniocentesis results The dose of N-acetylcysteine is the one recommended to be used in humans to prevent acetaminophen toxicity: 150 mg/kg loading dose (60 min), followed by 50mg/kg IV continuous infusion rate for 4 hours, and followed by 100 mg/kg IV continuous infusion rate for the following 16 hours. Acetadote (Cumberland Pharmaceuticals) is the only FDA-approved intravenous N-acetylcysteine formulation and will be used in our study.
88968846|NCT00397735|Placebo Comparator|Placebo|The subjects enrolled in our research protocol must have infection/inflammation in order to be randomized to receive N-acetylcysteine or placebo. Placebo-assigned patients will receive sodium chloride solution without N-acetylcysteine
88968847|NCT04258410|Placebo Comparator|Placebo|Blinded subjects in this arm will receive 2 placebo (blank) soft chews, twice daily, orally for 20 weeks.
89565664|NCT04861493||Non-smokers with stage III,IV periodontitis|patients with stage III,IV periodontitis having CAL>5 mm and PD>5 mm in one or more sites and bleeding on probing >30% and they are never smoked before.
89565665|NCT04861493||Healthy patients|patients free from periodontitis or any systemic disease and never smoked before.
89565666|NCT05404555||acute myocardia infarction patients with right coronary artery occlusion|
89565667|NCT05404555||acute myocardia infarction patients with non-right coronary artery occlusion|
89565668|NCT03043859|Experimental|Pure Prairie Living Program|Participants in the intervention arm will participate in 5 weekly education sessions ( 2hours / session) on nutrition education and healthy lifestyle.
89565669|NCT03043859|No Intervention|Wait Listed Control|Participants in the control arm will not receive any intervention.
89565670|NCT04852445||Stroke|We will include: 60 patients aged 18 years or older with clinical symptoms of hemispheric ischemic stroke due to occlusion of a large cerebral blood vessel, onset within 48 hours and NIHSS of 1 or more;
88968848|NCT04258410|Experimental|Active Drug|Blinded subjects in this arm will receive 1 g/day of Quercetin delivered in 2 soft chews (250 mg/chew), twice daily, orally, for 20 weeks.
89027717|NCT02955108|Experimental|music first then no music|
89027718|NCT02955108|Experimental|no music first then music|
88968849|NCT04222959|Experimental|Girls Invest Intervention|Girls Invest intervention participants will have been randomized to receive the intervention immediately upon completion of the baseline survey. Intervention participants will also complete the 6 month follow-up survey. (n=50 dyads; 100 total participants)
88968850|NCT04222959|No Intervention|Wait-List Control Condition Participants|Control condition participants will be randomized upon completion of the baseline survey and put on a wait-list to receive Girls Invest behavioral intervention after the 6 month follow-up survey. (n=50 dyads; 100 total participants)
88968851|NCT00046735|Experimental|1|
88968852|NCT00047047|Experimental|Treatment (tanespimycin, gemcitabine hydrochloride, cisplatin)|"Cohort A (closed to accrual as of 3/2/04)*: Patients receive escalating doses of gemcitabine hydrochloride intravenously (IV) over 30 minutes, tanespimycin IV over 1 hour, and cisplatin IV over 2 hours on days 1 and 8. NOTE: *The maximum tolerated dose (MTD) of this 3-drug combination has been determined as of 3/2/04.~Cohort B (closed to accrual as of 3/2/05): Patients receive gemcitabine hydrochloride** IV over 30 minutes, tanespimycin IV over 1 hour, and cisplatin** IV over 2 hours on days 1 and 8.~Cohort C: Patients receive gemcitabine hydrochloride** IV over 30 minutes and tanespimycin IV over 1-2 hours on days 2 and 9.~Cohort D: Patients receive cisplatin** IV over 2 hours and tanespimycin IV over 1-2 hours on days 1 and 8.~Cohort E: Patients receive gemcitabine hydrochloride***, tanespimycin***, and cisplatin*** as in cohort B.~Continued (see detailed description)"
89027719|NCT04697303||Middle and low rectal cancer|
89565671|NCT04852445||Controls|30 healthy controls, age- and sex- matched with stroke study population
89565672|NCT04852445||Carotid arterectomy after stroke|10 patients undergoing carotid endarterectomy within 30 days after stroke
89565673|NCT04852445||Carotid endarterectomy for asymptomatic stenosis|3 patients without stroke undergoing carotid endarterectomy for asymptomatic carotid stenosis.
89565674|NCT02710669|Experimental|(R)-propafenone|Single intravenous dose of (R)-propafenone (2mg/kg) infused over 10 minutes
89565675|NCT02710669|Active Comparator|(S)-Propafenone|Single intravenous dose of (S)-propafenone (2mg/kg) infused over 10 minutes
89565676|NCT02710669|Placebo Comparator|Placebo|Placebo (normal saline) is infused over 10 minutes
89565677|NCT01649661||premenopausal women|Only women already scheduled for a breast MRI will be included in the study, no additional MRIs will be scheduled for study purposes.
89565678|NCT01649661||postmenopausal women|Only women already scheduled for a breast MRI will be included in the study, no additional MRIs will be scheduled for study purposes.
89565679|NCT04844645|Experimental|a mini program trial group|Pharmacists conducted a standardized education session to teach the participants how to operate the mobile phone, use mini program, assess pain. The participants in the trial group were asked to complete initial and final pain assessment questionnaires and Medication compliance on the mobile phones provided to them. Participants were encouraged to use mini program as much as possible to record their pain status.
89565680|NCT04844645|Sham Comparator|a control group|The control group received conventional pharmaceutical care. Initial and final pain and Medication compliance data were collected. Before the patient was discharged from the hospital, the clinical pharmacist conducted detailed medication education (including medication methods, prevention and treatment of adverse reactions, and precautions) and asked the patient to attempt to maintain a paper version of the pain diary.
89565681|NCT02693041|Active Comparator|PROBIOTIC in low-risk women|In low-risk women, probiotic group will be treated with the Active ingredient containing Lactobacillus rhamnosus (LGG) (> 10x8 CFU) during all pregnancy until delivery. Capsules contain maltodextrin, LGG and vegetal magnesium stearate.
89565682|NCT02693041|Placebo Comparator|PLACEBO in low-risk women|In low-risk women, placebo group will be treated with the placebo ingredient during all pregnancy until delivery. The capsules of the placebo Group have similar content but lack the probiotic lactic acid bacteria which has been replaced by maltodextrin to make the mg amount equal.
89565683|NCT02693041|Active Comparator|PROBIOTIC in women with a prior PTB|In women with a prior preterm birth (PTB), probiotic Group will be treated with the Active ingredient containing Lactobacillus rhamnosus (LGG) (> 10x8 CFU) during all pregnancy until delivery. Capsules contain maltodextrin, LGG and vegetal magnesium stearate.
89565684|NCT02693041|Placebo Comparator|PLACEBO in women with a prior PTB|In women with a prior preterm birth (PTB), placebo group will be treated with the placebo ingredient during all pregnancy until delivery. The capsules of the placebo Group have similar content but lack the probiotic lactic acid bacteria which has been replaced by maltodextrin to make the mg amount equal.
89565685|NCT02693041|Active Comparator|PROBIOTIC in women with a prior PE|In women with a prior preeclampsia (PE), probiotic Group will be treated with the Active ingredient containing Lactobacillus rhamnosus (LGG) (> 10x8 CFU) during all pregnancy until delivery. Capsules contain maltodextrin, LGG and vegetal magnesium stearate.
89565686|NCT02693041|Placebo Comparator|PLACEBO in women with a prior PE|In women with a prior preeclampsia (PE), placebo Group will be treated with the placebo ingredient during all pregnancy until delivery. The capsules of the placebo Group have similar content but lack the probiotic lactic acid bacteria which has been replaced by maltodextrin to make the mg amount equal.
89565687|NCT04851743|Experimental|Dry needling Group|Participants will be used as their own controls, with 1 lower extremity randomly receiving intervention. The experimental extremity will received a single treatment session of TrP dry needling as follows: the therapist will located the TrP and will applied manual compression until the participant will reported pain. After that, dry needling technique will be performed on the TrPs for 60 seconds.
89565688|NCT04851743|No Intervention|Control Group|Participants will be used as their own controls, with 1lower extremity randomly receiving intervention. The control extremity did not receive any intervention, and outcomes were assessed 2 minutes apart.
89565689|NCT05392959|Placebo Comparator|Placebo group|The patient will be treated in standard of care for type 2 diabetic mellitus and will receive a placebo (1 tablet) administered orally daily during 24 weeks
89565690|NCT05392959|Experimental|dapagliflozin group|The patient will be treated in standard of care for type 2 diabetic mellitus and will receive Dapagliflozin 10 mg (1 tablet) administered orally daily during 24 weeks
89565691|NCT04851977|Experimental|Cohort 1: low dose|IM injection on Day 0 (12 active, 3 placebo); with follow up at 7 days ± 1 day post vaccination and at Day 30 ± 5 days and a final follow up/end of study (EOS) teleconference assessment at Day 60 ± 5 days.
89565692|NCT04851977|Placebo Comparator|Cohort 2: low dose|IM injection on Day 0 and at Day 30 (12 active, 3 placebo) with follow up at 7 days post vaccination (Day 7 ± 1 day and Day 37 ± 1 day) and Day 60 ± 5 days and a final follow up/ EOS teleconference assessment at Day 90 ± 5 days.
89565693|NCT04851977|Experimental|Cohort 3: high dose|IM injection on Day 0 (12 active, 3 placebo); with follow up at 7 days ± 1 day post vaccination and at Day 30 ± 5 days and a final follow up/end of study (EOS) teleconference assessment at Day 60 ± 5 days.
89565694|NCT04851977|Placebo Comparator|Cohort 4: high dose|IM injection on Day 0 (12 active, 3 placebo); with follow up at 7 days ± 1 day post vaccination and at Day 30 ± 5 days and a final follow up/end of study (EOS) teleconference assessment at Day 60 ± 5 days.
89565695|NCT04851431|Experimental|One-to-One Peer Mentoring|Caregiver will be matched based on characteristics such as age, date of patient injury, level of patient injury, cause of patient injury, marital status, work status before and after patient injury, interests, and leisure activities. After participant is matched with a peer mentor, they will be required to have at least one weekly one-to-one interaction from time of match until 30 days post- discharge.
89565696|NCT04851431|Active Comparator|Usual Care|Participants received the usual discharge planning and family support services offered by the ABI program. These services include nurse instruction in care routines, case management support for discharge, peer support services, referral to family counseling and community services as indicated, and general information resources about brain injury. Participants in both the intervention and usual care groups also had access to the online peer support community created for ABI caregivers (facebook.com/shepherdbi.peers). In addition, usual care participants could request one-to-one visits with peer mentors and, indeed, most usual care participants received at least one peer mentoring visit.
89565697|NCT05370417|Placebo Comparator|Control Group|Participants in this group will receive fluoride toothpaste, simulated laser therapy and sealants.
89565698|NCT05370417|Active Comparator|Photobiomodulation Group|Participants in this group will receive fluoride toothpaste, active laser therapy and sealant simulation.
89565699|NCT03043781|Experimental|Intermittent epidural bolus (IEB)|Bolus of 5 ml every hour + patient controlled extra boluses of 5 ml, maximum 3 / hour. Medicine solution is bupivacaine 1 mg/ml, fentanyl 2 mcg/ml, adrenaline 2 mcg/ml.
89565700|NCT03043781|Active Comparator|Continuous epidural infusion (CEI)|Continuous epidural infusion of 5 ml / hour + patient controlled extra boluses of 5 ml, maximum 3 / hour. Medicine solution is bupivacaine 1 mg/ml, fentanyl 2 mcg/ml, adrenaline 2 mcg/ml.
89565701|NCT03043937||cardiac patients WHO class 1,2|
89565702|NCT03043937||cardiac patients WHO class 3,4|
88968853|NCT00047125|Experimental|Selective irradiation|Irradiation of the ipsilateral level I - V of the neck up to a dose of 60 Gy (30x2Gy in 6 weeks).
88968854|NCT00047125|Active Comparator|Extensive irradiation + ipsilaterals levels|Irradiation on the whole mucosa of the larynx, hypopharynx, oropharynx and nasopharynx, and on both sides of the neck (levels I -V) up to a prophylactic dose of 50 Gy (25 x 2 Gy in 5 week).Irradiation of the ipsilateral level I - V of the neck should continue with an additional 10 Gy boost for a total dose of 60 Gy (30 x 2 Gy in 6 weeks).
88968855|NCT04733781|Active Comparator|Subcutaneous injection of 125ml by a physician and self-injection of 125ml by a volunteer (Arm I):|A volunteer layperson (research subject), at least 16 years of age, will first receive 125ml of TLE injected subcutaneously into the left anterior thigh by a physician. Then the subject will self-inject a second 125ml of TLE into his/her right anterior thigh.
88968856|NCT04733781|Active Comparator|Subcutaneous injection of 125ml by a physician and 125ml by another volunteer (Arm II):|A volunteer layperson (primary research subject), at least 16 years of age, will first receive 125ml of TLE injected subcutaneously into the left anterior thigh by a physician. The primary research subject will then receive a second 125ml of TLE injected into his/her right anterior thigh by a second adult volunteer who is at least 16 years old and not a medical professional.
88968857|NCT04733781|Active Comparator|Subcutaneous injection of 250ml by a physician into a volunteer (Arm III)|A volunteer layperson (research subject), at least 16 years old, will receive 250ml of TLE injected subcutaneously into the one anterior thigh by a physician.
88968858|NCT04198311|Experimental|Cognitive-Behavioral Therapy for Insomnia (CBT-I)|Individual Cognitive Behavioral Therapy for Insomnia (CBT-I) delivered once a week for five (5) weeks
88968859|NCT05641571|Experimental|Exercise group|The 3~6 months home-based extremity exercise program will be intervened between newly diagnosed with breast cancer to the completion of chemotherapy. Participants have to perform a total of 50 minutes of exercise including the Ten Skilled Hand exercise fourth a day, 5 minutes each time and Buerger Allen exercise twice a day, 15 minutes each time.
88968860|NCT05641571|No Intervention|Observational group|The observational group will need to record the extra exercise performed and the exercise prescription will be distributed after the study.
89565703|NCT05369949|Experimental|DEX group|Participants will receive an intraoperative and postoperative DEX infusion. In addition a low dose of sevoflurane will be administered.
89565704|NCT05369949|Active Comparator|Control group|Participants will receive general anesthesia with sevoflurane according to institutinal's practice.
89565705|NCT03043703|Experimental|AirSense 10 AutoSet for Her|Treatment for 1 night with ResMed AirSense 10 AutoSet for Her. Intervention: Administration of PAP Treatment with suboptimal pressure for 1 night.
89565706|NCT03043625|Experimental|Visceral manipulation Group (VMG)|The VMG wil be treated with visceral manipulation to the stomach and liver
89565707|NCT03043625|Placebo Comparator|Control group (CG)|The CG will be received placebo treatment. In the placebo treatment, the therapist should place the hands over the navel region without exerting any local tension for 1 minute.
89565708|NCT04423185|Experimental|Almonertinib-EGFR mutation|Administration: 110 mg oral qd, to disease progression or intolerable adverse effects.
89565709|NCT04423185|Experimental|Dacomitinib-EGFR mutation|Administration: 45 mg oral qd, to disease progression or intolerable adverse effects.
89565710|NCT04423185|Experimental|Alectinib-ALK fusion|Administration: 600 mg oral qd, to disease progression or intolerable adverse effects.
89565711|NCT04423185|Experimental|Crizotinib-ALK fusion|Administration: 250 mg oral bid, to disease progression or intolerable adverse effects.
89565712|NCT04423185|Experimental|Vemurafenib-BRAF mutation|Administration: 960 mg oral bid, to disease progression or intolerable adverse effects.
89565713|NCT04423185|Experimental|Niraparib-BRCA mutation or HRD|Administration: 200/300 mg oral qd, to disease progression or intolerable adverse effects.
89565714|NCT04423185|Experimental|Pyrotinib-HER-2 overexpression/amplification|Administration: 400 mg oral qd, to disease progression or intolerable adverse effects.
89565715|NCT04423185|Experimental|Imatinib-CKIT mutation|Administration: 400 mg oral qd, to disease progression or intolerable adverse effects.
89565716|NCT04423185|Experimental|Palbociclib-CDKN2A mutation|Administration: 125 mg oral qd for 21 days q28d, to disease progression or intolerable adverse effects.
89565717|NCT04423185|Experimental|Crizotinib-ROS-1 fusion|Administration: 250 mg oral bid, to disease progression or intolerable adverse effects.
88968861|NCT00047203|Experimental|Treatment (flavopiridol)|Patients receive flavopiridol IV over 1 hour on days 1-3. Courses repeat every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity. After 12 months, patients achieving at least a partial response may continue treatment in the absence of disease progression or unacceptable toxicity.
88968862|NCT04163874|Experimental|Fiasp-plus-Placebo with Full Carbohydrate Counting|Fiasp insulin and placebo insulin infusion in two insulin pumps with full carbohydrate counting.
88968863|NCT04163874|Placebo Comparator|Fiasp-plus-placebo with Simple Meal Announcement|Fiasp insulin and placebo (saline) insulin infusion in two insulin pumps using the simple meal announcement system.
89565718|NCT04423185|Experimental|Crizotinib-C-MET amplification|Administration: 250 mg oral bid, to disease progression or intolerable adverse effects.
89565719|NCT04423185|Experimental|Crizotinib-C-MET mutation|Administration: 250 mg oral bid, to disease progression or intolerable adverse effects.
89565720|NCT04423185|Experimental|Pyrotinib-HER-2 mutation|Administration: 400 mg oral qd, to disease progression or intolerable adverse effects.
89565721|NCT04423185|Experimental|Sintilimab-PD-1|Administration: 200mg q21d, to disease progression or intolerable adverse effects.
88968864|NCT04163874|Active Comparator|Fiasp-plus-Pramlintide with Simple Meal Announcement|Fiasp insulin and pramlintide insulin infusion in two insulin pumps using the simple meal announcement system.
88968865|NCT00047437|Active Comparator|2|
88968866|NCT00047437|No Intervention|1|
88968867|NCT00047554||TRAVATAN|Travoprost, 0.004% ophthalmic solution, 1 drop to the study eye once daily in the evening for up to 5 years
88968868|NCT00047671|Active Comparator|Citalopram|All subjects receive an FDA approved dose of Citalopram
88968869|NCT00047710|Experimental|Bevacizumab|Radiation, Bevacizumab, and Capecitabine
88968870|NCT00047827|Experimental|1|
89565722|NCT04423185|Experimental|Combination ARM-Niraparib & Sintilimab|Niraparib (200mg oral qd) combined with Sintilimab (200mg iv q21d) after acquired resistance to Niraparib.
89565723|NCT04423185|Experimental|Combination ARM-Vemurafenib & Atezolizumab|Vemurafenib (960 mg oral bid) & Atezolizumab (1200mg iv q21d) after acquired resistance to Vemurafenib.
89565724|NCT04423185|Experimental|Combination ARM-Palbociclib & Atezolizumab|Palbociclib (125 mg oral qd for 21 days q28d) combined with Atezolizumab (1680mg iv q28d) after acquired resistance to Palbociclib.
89565725|NCT04851275|Experimental|Shared decision making for men with lower urinary tract symptoms|Participants used the Visual Analogue Uroflowmetry Score so report their symptoms and were attended by Primary Care Physicians trained in shared decision making
89565726|NCT04851275|Active Comparator|No shared decision making for men with lower urinary tract symptoms|Participants did not use the Visual Analogue Uroflowmetry Score to report their symptoms and received usual care by Primary Care Physicians not trained in shared decision making
89565727|NCT04851041|Experimental|Potato group|The participants in this group consume every day 150g of boiled potatoes for 12 weeks, preferably during dinner. The participants are allowed to eat this portion during lunch as well
88968871|NCT00047983|No Intervention|Control|Controls and will receive no dietary supplements
88968872|NCT00047983|Experimental|Arginine and Canola Oil|Daily nutritional supplements of arginine and canola oil
88968873|NCT00047983|Experimental|Arginine and Coromega|Daily nutritional supplements of arginine and Coromega
88968874|NCT00389480|Experimental|I|Dose escalating
88968875|NCT00291447|Experimental|Cohort 1|Patients received a single infusion of 5 mg/m2 111In-ch806 on Day 0 and followed for 30 days post infusion.
88968876|NCT00291447|Experimental|Cohort 2|Patients received a single infusion of 10 mg/m2 111In-ch806 on Day 0 and followed for 30 days post infusion.
88968877|NCT00291447|Experimental|Cohort 3|Patients received a single infusion of 20 mg/m2 111In-ch806 on Day 0 and followed for 30 days post infusion.
88968878|NCT00291447|Experimental|Cohort 4|Patients received a single infusion of 40 mg/m2 111In-ch806 on Day 0 and followed for 30 days post infusion.
88968879|NCT00048100|Experimental|Apheresis + Transplant|Skin biopsy & either a leukodepletion apheresis or an additional marrow aspiration prior to marrow or stem cell transplantation.
88968880|NCT00048139|Experimental|1|
88968881|NCT03346109|Experimental|MRLN sparing group|Patients in medial group retropharyngeal node（MRLN） sparing group will not routinely receive MRLN irradiation to 56Gy/33Fr
88968882|NCT03346109|No Intervention|MRLN prophylactic irradiation group|Patients in MRLN prophylactic irradiation group will always receive MRLN irradiation to 56Gy/33Fr
89565728|NCT04851041|Active Comparator|Pasta/rice|"The participants in this group consume every day either rice or pasta for 12 weeks, preferably during dinner. The participants are allowed to eat this portion during lunch as well.~The portion of rice and pasta must be as isocaloric as 150g of boiled potatoes."
89565729|NCT04851197|Experimental|control group|"The students in the control group will be filled with the Introductory and Self-Testicular Examination Characteristics Question Form, Testicular Cancer and Self Testicular Examination Knowledge Test and Champion's Health Belief Model Scale, which will be prepared with Microsoft teams forms before the training. Later, the students will be given an average of 20-30 minutes of training from Powerpoint presentation and video presentation. Students' questions will be answered in the last 10 minutes. After two weeks after the training, the students will be asked to fill in the Testicular Cancer and KKTM Knowledge Test and a Visual Analogue Scale that includes their satisfaction with the training method. After 6 weeks, Champion's Health Belief Model Scale will be filled out."
89565730|NCT04851197|Experimental|Intervention|"Before the training, the students in the intervention group will fill the Introductory and Characteristics Question Form on Testicular Cancer and Self Testicular Examination Knowledge Test and Champion's Health Belief Model Scale. Educational materials (lecture presentation, video) will be loaded on the system in accordance with the inverted learning model, and students will be asked to come prepared for the planned lesson. Classical presentations will not be made to the students, and the education will be given in the form of question and answer discussion. After two weeks after the training, the students will be asked to fill in the Testicular Cancer and Self Testicular Examination Knowledge Test and a Visual Analogue Scale that includes their satisfaction with the training method. After 6 weeks, Champion's Health Belief Model Scale will be filled."
89565731|NCT03040271|Experimental|Intervention group- Health-E-PALS|Group of students receiving the school-based intervention: Health-E-PALS, it consists of in class activities and lessons.
89565732|NCT03040271|No Intervention|Control group|Group of students not receiving any intervention
89565733|NCT04423419|Other|A|will undergo Peri -articular nerve group block for hip joint under ultrasound guide as analgesia post operative after hip arthroscopy
89565734|NCT04423419|Other|B|will undergo ultrasound guided fascia iliaca block as postoperative analgesia after hip arthroscopy
89565735|NCT04423419|Other|C|will receive ordinary IV analgesia during operation hip arthroscopy
89565736|NCT04850885|Experimental|Dexamethasone Group ( Group DXN)|Group DXN has received 4 ml Mixture B (2ml Lignocaine 2%+ 2ml dexamethasone 4mg/ml)
89565737|NCT04850885|Active Comparator|Adreanaline Group ( Group ADN)|Group ADN has received 4 ml Mixture A ( 2ml Lignocaine 2%+ 2ml freshly prepared solution of adrenaline 0.01mg/ml in normal saline)
89565738|NCT04851353|Active Comparator|GT+VC|Gentle touch +Verbal comfort
89565739|NCT04851353|Experimental|GT+VC+Smell|Gentle touch +Verbal comfort+ Smell breast milk
89565740|NCT04851353|Experimental|GT+VC+Smell+Taste|Gentle touch +Verbal comfort+ Smell breast milk+ Taste milk
89565741|NCT03043391|Experimental|Polio/Rhinovirus Recombinant (PVSRIPO)|PVSRIPO is an altered form of the live polio vaccine. It was produced by removing a piece of the virus and replacing it with a piece from a common cold virus. This was done to make sure PVSRIPO cannot cause polio even when injected into the brain.
89565742|NCT04844177|Experimental|intervention/treatment|"Total lymphoid irradiation 4 Gy (days -7, -6) in combination with:~Fludarabine 150 mg/m2 (days-6, -5, -4, -3, -2)~Cyclophosphamide 120 mg/kg (days -5, -4, -3)~Thymoglogulin (Genzyme) 5 mg/kg (days -5, -4)~Melphalan 180 mg/m2 (day -2)~Rituximab 100 mg/m2 (day -1)~Hematopoietic stem cell graft infusion after TCRab/CD19 depletion - day 0"
89565743|NCT04844255|Other|Pre and post intervention group|Same individuals are examined before and after taking 2 tablets of salt
89565744|NCT04843865|Experimental|Chinese Herbs|Participants received standardized Chinese Herbs treatment orally twice daily for 1 week.
89565745|NCT02610725|Other|Yoga class|A 30 minute online Hatha yoga video intervention will be administered to participants.Participants will only participate in one yoga class and complete follow-up questionnaires.
89565746|NCT04850417|Experimental|Beta-blockers and Short Antiplatelet Therapy|"Beta-blockers (experimental) and Short Antiplatelet Therapy (experimental). Aspirin alone recommended for Short Antiplatelet Therapy~(The main comparison of this randomized clinical trial (2x2, factorial design) is beta-blockers vs no beta-blockers and short vs long-term antiplatelet therapy)"
89565747|NCT04850417|Experimental|Beta-blockers and Long Antiplatelet Therapy|"Beta-blockers (experimental) and Long Antiplatelet Therapy. Aspirin and Clopidogrel recommended in Long Antiplatelet Therapy~(The main comparison of this randomized clinical trial (2x2, factorial design) is beta-blockers vs no beta-blockers and short vs long-term antiplatelet therapy)"
88968883|NCT05641337|Experimental|group with new combination therapy|The hypoglycemic scheme of the experimental group was that the initial dose of Insulin Degludec and Insulin Aspart was 0.3U/kg multiplied by the patient's weight, plus 5 mg of linagliptin and 0.5 g of metformin three times a day.
88968884|NCT05641337|Active Comparator|group with intensive insulin therapy|group was treated with intensive insulin therapy.The initial total amount of insulin is 0.5U/kg, of which 40% is basal insulin and 20% is aspart insulin before three meals
88968885|NCT04712370|Active Comparator|Conventional caudal block|Patients of this group will receive the conventional method (blind technique without ultrasound) of caudal block
88968886|NCT04712370|Experimental|Ultrasound-guided caudal block|Patients of this group will receive caudal block using ultrasound.
89565748|NCT04850417|Experimental|No Beta-blockers and Short Antiplatelet Therapy|"No Beta-blockers and Short Antiplatelet Therapy (experimental). Aspirin alone recommended in Short Antiplatelet Therapy~(The main comparison of this randomized clinical trial (2x2, factorial design) is beta-blockers vs no beta-blockers and short vs long-term antiplatelet therapy)"
89565749|NCT04850417|Active Comparator|No Beta-blockers and Long Antiplatelet Therapy|"No Beta-blockers and Long Antiplatelet Therapy. Aspirin and Clopidogrel recommended in Long Antiplatelet Therapy~(The main comparison of this randomized clinical trial (2x2, factorial design) is beta-blockers vs no beta-blockers and short vs long-term antiplatelet therapy)"
89565750|NCT04843943|Experimental|Sintilimab+Bevacizumab|
89565751|NCT04850261|Active Comparator|Intervention A: hCG injection|Ovulation induction by subcutaneous injection of 5.000 IU hCG
89565752|NCT04850261|Experimental|Intervention B: nasal application of Nafarelin|Ovulation induction by nasal application of 200 microgram Nafarelin
89565753|NCT04850027||Lower rectal cancer patients with a LLN ≥ 5mm|Patients with lateral lymph node short diameter ≥ 5mm evaluated by MRI were included.
89565754|NCT04850183|Experimental|Intervention group|Patients were interviewed twice, at baseline and at the 3rd month. All forms were applied to the patients in the intervention group at baseline. The patients were assigned to the intervention group at random and participated in a one-to-one training program consisting of a 30-min onset session. The Rheumatoid Arthritis Patient Education Booklet prepared by the researchers was administered to patients in the intervention group during education. In the 3rd month, all forms were applied again to the patients in the intervention group.
89565755|NCT04850183|No Intervention|Control group|Patients were interviewed twice, at baseline and at the 3rd month. All forms were applied to the patients in the control group at baseline. In the 3rd month, the same forms were applied to the untrained patients in the control group.
89565756|NCT04849949|Active Comparator|Control|Participants in this group received a traditional muffin with butter as the predominant source of fat.
89565757|NCT04849949|Experimental|Black walnut|Participants in this group received a muffin in which part of the butter was substituted out for black walnuts.
89565758|NCT04849949|Experimental|English Walnut|Participants in this group received a muffin in which part of the butter was substituted out for English walnuts.
89565759|NCT04843553|Active Comparator|active|Participants receiving oral vitamin B-3
89565760|NCT04843553|Placebo Comparator|placebo|Participants receiving oral inactive pill
89565761|NCT02684461|Active Comparator|Arm A: Sequential Consolidation|Completion of four cycles of Sequential Consolidation of Pembrolizumab 200mg every 21 days and then four cycles Nab-paclitaxel 100 mg/mg2 on day 1 and day 8 every 21 days
89565762|NCT02684461|Active Comparator|Arm B: Sequential Consolidation|Completion of 4 cycles of Sequential Consolidation of Nab-paclitexel 100 mg/m2 on day 1 and day 8 every 21 days and then Pembrolizumab 200 mg every 21
89565763|NCT02684461|Active Comparator|Arm C: Concurrent Consolidation|Concurrent Consolidation of Nab paclitaxel 100 mg/m2 on day 1 and day 8 plus Pembrolizumab 200 m5 on day 1 every 21 days for four cycles
89565764|NCT04843475||MPNs patients who have echocardiographic probability of PH.|
89565765|NCT04843475||MPNs patients who do not have echocardiographic probability of PH|
89565766|NCT03040193|Experimental|Nebulized Lignocaine|4% Lignocaine administered as nebulization for topical anaesthesia during bronchoscopy procedure
89565767|NCT03040193|Placebo Comparator|Nebulized Saline|Normal Saline administered as nebulization for topical anaesthesia during bronchoscopy procedure
89565768|NCT03039101|Experimental|Montelukast|Subjects take 1 montelukast 10mg tablet orally, daily and effect on nasal allergen challenge (based on results of epicutaneous skin testing) induced recruitment of cd49d neutrophils in the peripheral blood and nasal lavage determined at 1 week
89565769|NCT03039101|Placebo Comparator|Placebo|Subjects take 1 placebo oral pill, daily and effect on nasal allergen challenge (based on results of epicutaneous skin testing) induced recruitment of cd49d neutrophils in the peripheral blood and nasal lavage determined at 1 week.
89565770|NCT03604393|Experimental|Practice Facilitation, Cluster 1|Intervention Cluster 1 is the first intervention arm designed to implement and test the effectiveness of a multi-component primary care practice-based intervention on initiation and completion of the HPV vaccine series as well as reduction in rates of missed opportunities to vaccinate.
89565771|NCT03604393|Experimental|Practice Facilitation, Cluster 2|Intervention Cluster 2 is the second intervention arm designed to implement and test the effectiveness of a multi-component primary care practice-based intervention on initiation and completion of the HPV vaccine series as well as reduction in rates of missed opportunities to vaccinate.
89565772|NCT03604393|Experimental|Practice Facilitation, Cluster 3|Intervention Cluster 3 is the third intervention arm designed to implement and test the effectiveness of a multi-component primary care practice-based intervention on initiation and completion of the HPV vaccine series as well as reduction in rates of missed opportunities to vaccinate.
89565773|NCT03604393|Experimental|Practice Facilitation, Cluster 4|Intervention Cluster 4 is the fourth intervention arm designed to implement and test the effectiveness of a multi-component primary care practice-based intervention on initiation and completion of the HPV vaccine series as well as reduction in rates of missed opportunities to vaccinate.
89027720|NCT02274207|Experimental|silver dressing|Frequency and duration : 1 change/1day or according to statue of patient Dosage : 1 ea
89027721|NCT02274207|Active Comparator|non-silver dressing|Frequency and duration : 1 change/1day or according to statue of patient Dosage : 1 ea
89027722|NCT04513431|Experimental|Colorectal cancer|Colorectal cancer treated with T cells modified with Anti-CEA-CAR T.
89565774|NCT03604393|Experimental|Practice Facilitation, Cluster 5|Intervention Cluster 5 is the final intervention arm designed to implement and test the effectiveness of a multi-component primary care practice-based intervention on initiation and completion of the HPV vaccine series as well as reduction in rates of missed opportunities to vaccinate.
89027723|NCT02274246|Experimental|Gadobutrol|Gadobutrol in Healthy volunteers
89027724|NCT04513275||schizophrenia patient group|Schizophrenia patients with first episode and disease duration of 5, 10, 20, and 30 years
89027725|NCT02274194|Active Comparator|Nasal CPAP during titration|Group nasal mask: use of CPAP for one night whit wash out of two weeks
89565775|NCT03043469||Healthy participants|"Day 1: Hospital assessments (~3 hours): Demographic data, Manual Assessment of Respiratory Motion, Slow-breathing task, Six-minute exercise test, Indirect calorimetry, Oxygen saturation monitoring, heart rate variability analysis, continuous measurement of arterial blood pressure, lung function test, the Nijmegen Questionnaire and the Self-Evaluation of Breathing Questionnaire, the Hospital anxiety and depression scale, and the Short-Form Survey Instrument, Breath-hold test, Lung function test, respiratory muscle function assessment.~Days 2-8: Physical Activity Monitoring"
89565776|NCT03043469||Restrictive lung disease group|"Day 1: Hospital assessments (~3 hours): Demographic data, Manual Assessment of Respiratory Motion, Slow-breathing task, Six-minute exercise test, Indirect calorimetry, Oxygen saturation monitoring, heart rate variability analysis, continuous measurement of arterial blood pressure, lung function test, the Nijmegen Questionnaire and the Self-Evaluation of Breathing Questionnaire, the Hospital anxiety and depression scale, and the Short-Form Survey Instrument, Breath-hold test, Lung function test, respiratory muscle function assessment.~Days 2-8: Physical Activity Monitoring"
89565777|NCT03043469||Primary dysfunctional Breathing group|"Day 1: Hospital assessments (~3 hours): Demographic data, Manual Assessment of Respiratory Motion, Slow-breathing task, Six-minute exercise test, Indirect calorimetry, Oxygen saturation monitoring, heart rate variability analysis, continuous measurement of arterial blood pressure, lung function test, the Nijmegen Questionnaire and the Self-Evaluation of Breathing Questionnaire, the Hospital anxiety and depression scale, and the Short-Form Survey Instrument, Breath-hold test, Lung function test, respiratory muscle function assessment.~Days 2-8: Physical Activity Monitoring"
89565778|NCT03043469||Secondary dysfunctional breathing group|"Day 1: Hospital assessments (~3 hours): Demographic data, Manual Assessment of Respiratory Motion, Slow-breathing task, Six-minute exercise test, Indirect calorimetry, Oxygen saturation monitoring, heart rate variability analysis, continuous measurement of arterial blood pressure, lung function test, the Nijmegen Questionnaire and the Self-Evaluation of Breathing Questionnaire, the Hospital anxiety and depression scale, Asthma Control Questionnaire, and the Short-Form Survey Instrument, Breath-hold test, Lung function test, respiratory muscle function assessment.~Days 2-8: Physical Activity Monitoring"
89565779|NCT03103399|Experimental|50 mg nebicapone|At Visit V2, patients received a supply of a placebo to take concomitantly with each levodopa/DDCI dose for the duration of the run-in period (Period 1). At the end of Period 1, patients were randomised to receive 50 mg of the study treatment in addition to their levodopa/DDCI therapy for the duration of the double-blind (Period 2)
89027726|NCT02274194|Experimental|Oronasal CPAP during titration|Group oronasal mask: use of CPAP for one night with wash out of two weeks.
89027727|NCT00505830||1|50 adolescents with AS or high functioning autism (HFS) diagnosed by psychiatrists using established criteria and with an IQ >85.
89027728|NCT00505830||2|50 adolescents with AS or classical autism diagnosed by psychiatrists using established criteria 70<IQ<84.
89027729|NCT00505830||3|50 adolescents with psychiatric disorders but no autism syndrom.
89027730|NCT00505830||4|Sample of 50 healthy adolescents selected randomly from 200.
89027731|NCT02274233|Experimental|1.5 mg/kg|1.5 mg/kg SP-420 once daily for 14 days
89027732|NCT02274233|Experimental|3 mg/kg|3 mg/kg SP-420 once daily for 14 days
89027733|NCT02274233|Experimental|6 mg/kg|6 mg/kg SP-420 once daily for 14 days
89027734|NCT02274233|Experimental|12 mg/kg|12 mg/kg SP-420 once daily for 14 days
89027735|NCT02274233|Experimental|24 mg/kg|24 mg/kg SP-420 once daily for 28 days
89027736|NCT02274233|Experimental|9 mg/kg|9 mg/kg SP-420 twice daily for 28 days
89027737|NCT04697511|Experimental|Midazolam and/or M2951|
89027738|NCT02274272|Placebo Comparator|Placebo Capsules|
89027739|NCT02274272|Experimental|ADR-1|Lactobacillus reuteri GMNL-89
89027740|NCT02274272|Experimental|GMNL-263|Lactobacillus reuteri GMNL-263
89027741|NCT04512963|Experimental|SAD Phase including Food Interaction|Single Ascending Dose (SAD) study with up to 6 cohorts + Food interaction phase on two cohorts
89027742|NCT04512963|Experimental|MAD Phase|Multiple Ascending Dose (MAD) study with up to 2 cohorts
89027743|NCT01302067|Experimental|Fesoterodine 8mg|
89027744|NCT01302067|Experimental|Fesoterodine 4mg|
89027745|NCT01302067|Placebo Comparator|Placebo|
89027746|NCT04697147|Experimental|Intervention Group|Immediately randomized to receive the intervention for 12 weeks.
89027747|NCT04697147|No Intervention|Waitlist Control|Randomized to receive the intervention post-study.
89027748|NCT00485667|Active Comparator|Moxifloxacin tablet|
89027749|NCT00485667|Experimental|Placebo tablet|
89027750|NCT00485667|Experimental|SKY0402 300mg|
89027751|NCT00485667|Experimental|SKY0402 450mg|
89027752|NCT00485667|Placebo Comparator|Placebo injection|
89565780|NCT03103399|Experimental|100 mg nebicapone|At Visit V2, patients received a supply of a placebo to take concomitantly with each levodopa/DDCI dose for the duration of the run-in period (Period 1). At the end of Period 1, patients were randomised to receive 100 mg of the study treatment in addition to their levodopa/DDCI therapy for the duration of the double-blind (Period 2)
89565781|NCT03103399|Experimental|150 mg nebicapone|At Visit V2, patients received a supply of a placebo to take concomitantly with each levodopa/DDCI dose for the duration of the run-in period (Period 1). At the end of Period 1, patients were randomised to receive 150 mg of the study treatment in addition to their levodopa/DDCI therapy for the duration of the double-blind (Period 2)
88968887|NCT04712370|Experimental|Ultrasound guided erector spinae plane Block|Patients of this group will receive ultrasound guided erector spinae plane Block at the level of the transverse process of the second lumbar vertebrae(L2) .
88968888|NCT02970526||colorectal cancer survivors|
88968889|NCT05641220||Biopsy|Newly diagnosed elderly (>70 years of age) glioblastoma patients who undergo biopsy
88968890|NCT05641220||Resection|Newly diagnosed elderly (>70 years of age) glioblastoma patients who undergo resection
88968891|NCT00048646|Placebo Comparator|placebo|placebo
88968892|NCT00048646|Experimental|IV progesterone|IV progesterone
88968893|NCT05641181|Experimental|CRB4101 100mg dose group|Participants will receive a single oral dose of 100mg of CRB4101
88968894|NCT05641181|Experimental|CRB4101 200mg dose group|Participants will receive a single oral dose of 200mg of CRB4101
88968895|NCT05641181|Experimental|CRB4101 400mg dose group|Participants will receive a single oral dose of400mg of CRB4101
88968896|NCT05641181|Experimental|CRB4101 800mg dose group|Participants will receive a single oral dose of 800mg of CRB4101
88968897|NCT05641181|Experimental|CRB4101 1200mg dose group|Participants will receive a single oral dose of 1200mg of CRB4101
88968898|NCT05641181|Experimental|CRB4101 1600mg dose group|Participants will receive a single oral dose of 1600mg of CRB4101
88968899|NCT05641181|Placebo Comparator|placebo group|Subjects will receive a placebo
89565782|NCT03103399|Active Comparator|200 mg entacapone|At Visit V2, patients received a supply of a placebo to take concomitantly with each levodopa/DDCI dose for the duration of the run-in period (Period 1). At the end of Period 1, patients were randomised to receive 200 mg of entacapone (Comtan®) in addition to their levodopa/DDCI therapy for the duration of the double-blind (Period 2)
89565783|NCT03103399|Placebo Comparator|Placebo|At Visit V2, patients received a supply of a placebo to take concomitantly with each levodopa/DDCI dose for the duration of the run-in period (Period 1). At the end of Period 1, patients were randomised to receive study treatment matching placebo tablets in addition to their levodopa/DDCI therapy for the duration of the double-blind (Period 2)
89565784|NCT03043235||African American Females|No intervention
89565785|NCT03043235||African American Males|No intervention
89565786|NCT03043235||Caucasian Females|No intervention
89565787|NCT03043235||Caucasian Males|No intervention
89565788|NCT03038945|Experimental|2/0 barbed suture|Use barbed suture for the closure of the vaginal vault in patients with total Laparoscopic hysterectomy caused by a benign gynecologist pathology
89565789|NCT03038945|Active Comparator|Vicryl suture|Use VICRYL suture for the closure of the vaginal vault in patients with total Laparoscopic hysterectomy caused by a benign gynecologist pathology
89565790|NCT03043157|Other|Dose-finding group|The first patient will receive rocuronium 0,6mg/kg. After that, every patient's dose will depend on the outcome of the previous patient. It will go up 0,1mg/kg if the laparoscopic conditions were not excellent or go down 0,1mg/kg otherwise.
89565791|NCT05339113|Experimental|68Ga-FAPI-46 PET/CT + 18-FDG PET/CT|18FDG PET/CT scan is followed by [68Ga]FAPI-46 PET/CT within 2-3 days.
89565792|NCT04843163|Experimental|Wave A (Immediate NAMI Basics)|Once a participant has completed the questionnaires, that participant will be randomly assigned to either an immediate NAMI Basics class (Wave A), or an 8-week delay (Wave B) condition. Those in the immediate condition will be assigned to take the next available NAMI Basics class. Participants in both groups will be assessed at three time points. Participants in the immediate Basics group (Wave A) condition will be assessed pre-class, post-class, and 6 months after class has ended.
89565793|NCT04843163|No Intervention|Wave B (Waitlist Control)|Participants in the 8-week delay condition will be able to participate in a NAMI Basics class immediately following the 8-week time frame. Participants in the 8-week delay group (Wave B) will be assessed before the 8-week delay, after the 8-week delay (prior to their Basics course), and after the Basics course.
89565794|NCT03103477||Office|"Patients presenting for a routine office visit will be asked to donate at least 50 ml of urine. The urine specimen will be aliquoted in containers, one with and one without a PAF-AH inhibitor and kept at room temperature.~The aliquots (2mL) will be frozen at predetermined intervals of 5, 10, 20, 40 and 60 min from time of collection in liquid nitrogen and then later stored in -80 freezer."
89565795|NCT03103477||Surgery|A separate group of patients undergoing surgery lasting more than 60 min operating time, will be consented as well. These patients have Foley catheters in place during the surgery. Five cc's of urine will be collected from the catheter at pre-determined intervals 5, 10, 20, 40 and 60 minutes, aliquoted (2mL) and frozen in liquid nitrogen and later stored in the -80 freezer.
89565796|NCT04840433|Experimental|MACE|Patients will receive MACE for IDA.
88968900|NCT05576298|Experimental|TR sequence|Experimental:Insulin degludec injection (RD15003)+Tresiba Subjects receive Insulin degludec injection(RD15003) in the first cycle and Tresiba in the second cycle.
88968901|NCT05576298|Experimental|RT sequence|Experimental:Tresiba+Insulin degludec injection (RD15003) Subjects receive Insulin Tresiba in the first cycle and degludec injection(RD15003) in the second cycle.
88968902|NCT00048958||No treatment|Samples as defined per the protocol for previously untreated patients with AML, ALL, MDS or MM will be submitted for analysis and within one month patients are required to register onto a CALGB treatment study.
89565797|NCT03040349|Experimental|TiTAN Intervention|The TiTAN Crete program has adapted the existing curricula and resources originally developed at the University of Ottawa Heart Institute and which are specific to primary practice settings. To facilitate maximum uptake the intervention program was adapted to reflect: language; cultural appropriateness; local patient beliefs and attitudes regarding tobacco-use and cessation; local social and clinical norms; provider perceptions surrounding 5As delivery; and, practice characteristics. The TiTAN multi-component training includes: 1) a 1-day foundational tobacco treatment training program for general practitioners, 2) the dissemination of provider and patient tools, and 3) E-blasts and webinars to supplement skills development and continuing medical education through e-learning.
89565798|NCT05224453|Other|Physical training and high protein diet|Subjects in this group underwent integrated physical training for 8 weeks. In addition to the integrated physical training exercises, group A received a high protein diet in the range of 1.1 - 1.3 g/kg protein/ ideal body weight/day (>1 g/kg aBW/d).
89565799|NCT05224453|Other|Physical training and low protein diet|Subjects in this group underwent integrated physical training for 8 weeks. In addition to the integrated physical training exercises, group B received a low protein diet in the range of 0.7 - 0.9 g/kg protein/ ideal body weight/day (<1 g/kg aBW/d)
89565800|NCT04843397||Single Arm|Patients referred for clinically indicated EGD, without known precancerous condition. Patients will receive endoscopy with standardised biopsy and photodocumentation protocol
89565801|NCT05218837||First vaginal birth|The first vaginal birth in nulliparous women
89565802|NCT05218837||Vaginal birth after cesarean section (VBAC)|The first vaginal birth after one or more prior cesarean sections (VBAC)
89565803|NCT05218837||Second vaginal delivery|The second vaginal delivery
89565804|NCT05211193||eTNM arm|eTNM delivered by URIS I nerve stimulation device, self administered in the subject's home for 30 minutes per day, for a minimum of 34 therapy session between day 1- 42.
89565805|NCT03042923||Treatment|Twenty patients, known to us through care at Women's Surgery Center and the private practice of Dr. R. Scott Furr, will be invited to enroll based on a history of pelvic pain and a plan for surgical evaluation and intervention
89565806|NCT03042923||Control|Ten healthy female patients, without pelvic pain or history of autoimmune disease, will be asked to participate as controls.
89565807|NCT05178355|Experimental|Part A - KVD824 - 10 mg|6 participants were administered10 mg of KVD824 in capsule form (1 x 10 mg capsule) on one occasion on Day 1. 2 participants received matching placebo.
89565808|NCT05178355|Experimental|Part A - KVD824 - 20 mg|6 participants were administered 20mg of KVD824 in capsule form ( 2 x 10 mg capsules) on one occasion on Day 1. 2 participants received matching placebo.
89565809|NCT05178355|Experimental|Part A - KVD824 - 40 mg|6 participants were administered 40mg of KVD824 in capsule form (1 x 40 mg capsule) on one occasion on Day 1. 2 participants received matching placebo.
89565810|NCT05178355|Experimental|Part A - KVD824 - 80 mg|6 participants were administered 80mg of KVD824 in capsule form (2 x 40 mg capsules) on one occasion on Day 1. 2 participants received matching placebo.
88968903|NCT00049114|Experimental|Treatment (doxorubicin, cyclophosphamide, tipifarnib, G-CSF)|"PHASE I (nonregional stage IV disease) (closed to accrual as of 1/19/04): Patients receive doxorubicin IV over 10-15 minutes and cyclophosphamide IV over 30 minutes on day 1, oral tipifarnib twice daily on days 2-7, and G-CSF subcutaneously on days 2-13. Treatment repeats every 2 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.~PHASE II (stage IIB, IIIA, IIIB, or IIIC): Patients receive tipifarnib at the MTD and doxorubicin, cyclophosphamide, and G-CSF as in phase I (phase I closed to accrual as of 1/19/04). After the fourth course, patients may undergo complete resection."
88968904|NCT00049192|Experimental|Treatment (oblimersen sodium, imatinib mesylate)|"Patients receive oblimersen IV continuously on days 1-10 and oral imatinib mesylate once or twice daily. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients without a hematologic response after 2 courses go off study. Patients with complete or partial response after 4 courses may continue to receive oral imatinib mesylate daily.~Patients in cohort 2 receive an escalated dose of oblimersen; if well tolerated, subsequent cohorts receive oblimersen at the higher dose with the original dose of imatinib mesylate. If oblimersen is not well tolerated in cohort 2, subsequent cohorts receive the original dose of oblimersen with an escalated dose of imatinib mesylate. The first 6 patients accrued continue to receive the original dose (dose taken prior to study) of imatinib mesylate throughout the study."
88968905|NCT05576181|Experimental|ThisCART19A cells infusion and HSCT|"In this study, allogeneic anti-CD19 CAR T cell (ThisCART19A) infusion is used to treat patients with refractory or relapsed CD19 positive B cell acute lymphoblastic leukemia.~After patients achieve MRD- remissions through ThisCART19A, they will subsequently receive hematological stem cell transplantations."
88968906|NCT00049309|No Intervention|Control|Usual diet
88968907|NCT00049309|Experimental|Flaxseed diet|30 gram flaxseed dietary modification
88968908|NCT00049309|Experimental|Low fat diet|Low fat dietary modification
88968909|NCT00049309|Experimental|Low fat + Flaxseed diet|Low fat and 30 gram flaxseed dietary modification
88968910|NCT05576142||Case Group|Patients from this group were diagnosed from allergic rhinitis and/or asthma.
89565811|NCT05178355|Experimental|Part A - KVD824 - 160mg|6 participants were administered 160mg of KVD824 in capsule form (1 x 160 mg capsule) on one occasion on Day 1. 2 participants received matching placebo.
89565812|NCT05178355|Experimental|Part A - KVD824 - 320 mg|6 participants were administered 320mg of KVD824 in capsule form (1 x 320 mg capsule) on one occasion on Day 1. 2 participants received matching placebo.
89565813|NCT05178355|Experimental|Part A - KVD824 - 640 mg|6 participants were administered 640 mg of KVD824 in capsule form (2 x 320 mg capsule) on one occasion on Day 1. 2 participants received matching placebo.
89565814|NCT05178355|Experimental|Part A - KVD824 - 1280 mg|6 participants were administered 1280 mg of KVD824 in capsule form (4 x 320 mg capsule) on one occasion on Day 1. 2 participants received matching placebo.
89565815|NCT05178355|Experimental|Part B - KVD824 - 80 mg Multi-Dose|6 participants were administered 80 mg of KVD824 in capsule form (2 x 40 mg capsules) in multiple doses over a period of 5 days (twice a day on Days 1-4 and once in morning of Day 5; the first dose on each day was administered fasted). 2 participants received matching placebo.
89565816|NCT05178355|Experimental|Part B - KVD824 - 160 mg Multi-Dose|6 participants were administered 160mg of KVD824 in capsule form (1 x 160 mg capsule) in multiple doses over a period of 5 days (twice a day on Days 1-4 and once in morning of Day 5; the first dose on each day was administered fasted). 2 participants received matching placebo.
89565817|NCT05178355|Experimental|Part B - KVD824 - 320 mg Multi-Dose|6 participants were administered 320mg of KVD824 in capsule form (1 x 320 mg capsule) in multiple doses over a period of 5 days (twice a day on Days 1-4 and once in morning of Day 5; the first dose on each day was administered fasted). 2 participants received matching placebo.
89565818|NCT05178355|Experimental|Part B - KVD824 - 640 mg Multi-Dose|6 participants were administered 640mg of KVD824 in capsule form (2 x 320 mg capsules) in multiple doses over a period of 5 days (twice a day on Days 1-4 and once in morning of Day 5; the first dose on each day was administered fasted). 2 participants received matching placebo.
89565819|NCT05178355|Experimental|Part C - KVD824 - 320 mg Fasted|12 participants were administered 320 mg of KVD824 in capsule form (1 x 320 mg capsule) on one occasion on Day 1 in a fasted state.
89565820|NCT05178355|Experimental|Part C - KVD824 - 320 mg High fat breakfast|12 participants were administered 320 mg of KVD824 in capsule form (1 x 320 mg capsule) on one occasion on Day 1 following consumption of a high fat breakfast.
89565821|NCT04429295|Experimental|Group A - Intervention regimen|SHAN6™ + routine pediatric vaccines pneumococcal 13-valent conjugate vaccine [PCV] [Prevnar 13®] and oral rotavirus vaccine [ORV-1] [Rotarix™] at age of 2, 4 months; SHAN6™ + Prevnar 13® at age of 6 months; SHAN6™ administered alone as a booster dose at age of 15-18 months
89565822|NCT04429295|Active Comparator|Group B - Control regimen|SHAN5™ + bivalent oral polio vaccine (bOPV), co-administered with Prevnar 13® and Rotarix™ at 2, 4 months of age and with inactivated polio vaccine [IPV] at 4 months of age; SHAN5™ + bOPV, co-administered with Prevnar 13® at 6 months of age SHAN6™ administered alone as a booster dose at 15-18 months of age
89565823|NCT05258851|Experimental|Ceftazidime-avibactam|Ceftazidime-avibactam 2.5 grams intravenous (IV) every 8 hours infused over two hours for a duration of 7-14 days, with dose adjustment for renal impairment according to the FDA prescribing information. Patients who have a positive Xpert Carb-R screening test or culture for CRE with metallo-beta-lactamases will receive aztreonam added to ceftazidime-avibactam.
89565824|NCT05258851|Active Comparator|Colistin|Colistin (9-million-unit loading dose IV followed with 9 million units IV daily divided into 3 doses), for 7 to 14 days. Patients with renal impairment will receive antibiotics with adjusted doses based on their glomerular filtration rate or the use and type of renal replacement therapy according to the 2019 International Consensus Guidelines for the Optimal Use of the Polymyxins.
89565825|NCT04843085||O1|the more aggressive subgroup of oligodendroglioma samples of 30 patients
89565826|NCT04843085||O2|subgroup 2 of oligodendroglioma samples of 30 patients
89565827|NCT04843085||O3|subgroup 3 of oligodendroglioma samples of 30 patients
89565828|NCT04843085||IDH-mutant astrocytomas|patients with IDH-mutant astrocytomas, samples of 15 patients
89565829|NCT04843085||IDH-wildtype glioblastomas|patients with IDH-wildtype glioblastomas, samples of 15 patients
89565830|NCT03103243|Other|Intervention|This is a single arm trial. All participants will be administered two baseline fMRIs and blood analysis prior to participation in a mindfulness group and individual mindfulness intervention sessions. A post intervention fMRI and blood analysis will complete the trial participation.
89565831|NCT03043001|Other|add-on memantine therapy|add-on memantine treatment
88968911|NCT05576142||Control Group|Healthy children.
89565832|NCT04840745|Experimental|CKD-841 A-1(=leuprorelin acetate 3.75mg)|Investigational drug(=CKD-841 A-1) is prescribed single injection dose by subcutaneous to 8 of randomized subjects once.
89565833|NCT04840745|Experimental|CKD-841 A-1(=leuprorelin acetate 1.88mg)|Investigational drug(=CKD-841 A-1) is prescribed single injection dose by subcutaneous to 8 of randomized subjects once.
89565834|NCT04840745|Experimental|CKD-841 D(=leuprorelin acetate 2.92mg)|Investigational drug(=CKD-841 D) is prescribed single injection dose by subcutaneous to 8 of randomized subjects once.
89565835|NCT04840745|Active Comparator|Leuplin Inj.(=leuprorelin acetate 3.75mg)|Investigational drug(=Leuplin Inj.)is prescribed single injection dose by subcutaneous to 8 of randomized subjects once.
89565836|NCT05073757||Orthognatic surgery|Orthognathic surgery patients, adults or minors whose bone maturity is sufficient according to the investigator.
89565837|NCT04840355||Subjects with no irAEs|
89565838|NCT04840355||Subjects with degree 1-2 irAEs|
89565839|NCT04840355||Subjects with degree 3-4 irAEs|
89565840|NCT04435405||Video microanalisys|Video footage analysis of group and individual behavioral processes.
89565841|NCT04842695|Active Comparator|kegel´s exercise (pelvic floor exercise)|A midwife/nurse works with the women according to the following protocol: 1.-identify anal sphincter, and try to raise it from chair (without adding abdominal, thigh, and buttock muscles) with a position of sitting; 2.- identify elevator ani muscle and try to raise vagina from chair (without adding abdominal, thigh, and buttock muscles) with a position of sitting, bent forward, elbows on knees; 3.- contract elevator ani muscle with a position of sitting, lying, and standing; 4.- contract anal sphincter with a position of sitting, lying, and standing. The sessions are conducted by the same midwife/nurse to women in both groups/arms to be performed by the women at home. .
89565842|NCT04842695|Experimental|Electroacupuncture group|"Acupuncture point called bilateral R7 receive acupuncture with 0.25*40 mm needle with a perpendicular puncture 1.5 cun. The electrical stimulator is applied to bilateral R7, with dilatation wave 50 Hz and direct electric current of 1 milliamperes.. Each session lasts 30 minutes per day. Participants are treated 1 time per week for 12 weeks, total 12 sessions for each patient.~Equipment:~Electroacupuncture device.~device made in China"
88968912|NCT00049387|Experimental|Treatment (tipifarnib, temozolomide, radiation therapy)|See Detailed Description
89565843|NCT05073289|Experimental|SAPC|SAPC is a acronmy that defines Sandplay activity in psychiatry clinic
89565844|NCT05073289|Active Comparator|Control Group|
89565845|NCT04840043|Experimental|Osteopathy Group|Stimulation on the sympathetic truncus and prevertebral ganglia
89565846|NCT04840043|Sham Comparator|Control Group|Stimulation on similar areas with lighter touch and shorter duration
89565847|NCT04534933|Experimental|FCV|Artificial ventilation will be performed with individualized flow-controlled ventilation (Evone, Ventinova Medical B.V., Eindhoven, the Netherlands) during thoracic surgery. Individualisation will be established by compliance guided end-expiratory and peak pressure setting during double lung ventilation as well as one lung ventilation, flow setting will be adjusted to secure normocapnia and I:E Ratio set to 1:1.
89565848|NCT04534933|Active Comparator|PCV|Artificial ventilation will be performed with low tidal volume pressure-controlled ventilation (Primus, Dräger, Lübeck, Germany) during thoracic surgery. Peak pressure will be set to achieve a tidal volume of 7ml/kg predicted body weight at a compliance titrated positive end-expiratory pressure in double lung ventilation and 6ml/kg PBW in one lung ventilation. Respiratory rate will be set to maintain normocapnia and I:E ratio set to 1:1.5 except extension of expiration is necessary in order to avoid air trapping.
89565849|NCT04842617|Experimental|Treatment group A|
89565850|NCT04842617|Placebo Comparator|Treatment group B|
89565851|NCT04860557||problematic video game player|
89565852|NCT04860557||control subjects|
89565853|NCT05073211|Experimental|SJW-PDT|Participants were randomized to receive either the SJW extract or IAA on each split-face. The SJW extract (DR-Light complexTM; Genicos Co., Ltd, Cheongju, Korea) consisted of 70% 1, 3-butylene glycol, and 0.1% hypericin as active ingredients. After cleansing the face gently, participants applied 1.5 ml of 0.5% SJW extract on one half of the face and 1.5 ml of 0.015% IAA (AC gel®; Wellskin, Seoul, Korea) on the other half of the face for 10 minutes under occlusion.
89565854|NCT05073211|Active Comparator|IAA-PDT|Participants were randomized to receive either the SJW extract or IAA on each split-face. The SJW extract (DR-Light complexTM; Genicos Co., Ltd, Cheongju, Korea) consisted of 70% 1, 3-butylene glycol, and 0.1% hypericin as active ingredients. After cleansing the face gently, participants applied 1.5 ml of 0.5% SJW extract on one half of the face and 1.5 ml of 0.015% IAA (AC gel®; Wellskin, Seoul, Korea) on the other half of the face for 10 minutes under occlusion.
89565855|NCT04842539|Experimental|FMT Arm|FMT Arm:30 grams stool homogenized with 100 mL normal saline and filtered administered a single time via nasojejunal tube.
89565856|NCT04842539|Other|Standard of care (SOC) Arm|Standard of care treatment with nutritional supplementation and other supportive care
89565857|NCT05072899|Experimental|25 patient with chronic shoulder pain injected with platelet rich plasm|patients with chronic shoulder pain injected with platelet rich plasm ultrasound guided, assessment done on initial visit and follow up after 4weeks and 6month using (VAS, CS, SPADI)
89565858|NCT05072899|Experimental|25 patient with chronic shoulder pain injected with Hyaluronic acid|patients with chronic shoulder pain injected with Hyaluronic acid ultrasound guided, assessment done on initial visit and follow up after 4weeks and 6month using (VAS, CS, SPADI)
89565859|NCT02647645|Active Comparator|Cognitive Training|Cognitive training Sham tDCS
89565860|NCT02647645|Experimental|Cognitive Training with tDCS|Cognitive training Active tDCS
89565861|NCT04842305||G1: Control group|SARS-CoV-2 naïve persons who have neither been vaccinated nor have had COVID-19 (controls)
89565862|NCT04842305||G2: COVID-19 infected|Persons who have had COVID-19
89565863|NCT04842305||G3: COVID-19 vaccinated|Persons who have been vaccinated with Pfizer-BioNTech BNT162b2, Moderna mRNA-1273 or AstraZeneca ChAdOx1-S
89565864|NCT04842305||G4: COVID-19 infected and vaccinated|Individuals who have been infected with COVID-19 and subsequently been vaccinated
89565865|NCT04839653|No Intervention|Control group: standard care|Patients in the standard care group will be prospectively evaluated to determine pre-defined clinical outcomes.
89565866|NCT04839653|Experimental|Selective digestive decontamination group|"Oral paste (0,5 g) containing 10 mg of polymyxin B, 10 mg of gentamycin and 150 mg of amphotericine B q6h~In the NGT 10 ml of suspension containing 100 mg of polymyxin B, 80 mg of gentamycin, 350 mg of amphotericine B and 500 mg of vancomycin q6h~A 3-day course of intravenous cefotaxime 1 g q6h/ceftriaxone 1 qd"
89565867|NCT05072587|Active Comparator|Group A - Standard ADA dietary guidelines (SADA)|Participants in this group will be given prepared meals based on standard ADA dietary guidelines for 12 weeks.
89565868|NCT05072587|Experimental|Group B - Plant Based ADA diet with no oxysterols (PB-ADAØ).|Participants in this group will be given prepared meals based on ADA guidelines but with no dietary cholesterol oxides/oxysterols - Plant-based ADA diet
89565869|NCT03038555||Disease group (subject to strategy)|Choose subjects that have ever got PE before as the diseases group.
89565870|NCT03038555||Control group|Pair the same age, gestational weeks, children's gender and healthy subject as a control group in the ratio of 1:1. The control group should exclude subject that have ever got heart or lung diseases, diabetes, chronic nephrosis, immune disease and other hereditary disease.
89565871|NCT04842149|Active Comparator|Bif195 capsules|The capsule will contain approximately 15*10^9 CFU of Bif195 per day. Excipients: Microcrystalline Cellulose 6 mg per capsule, Magnesium Stearate 1.5 mg per capsule, Maltodextrin 277.8 mg per capsule, and Sodium Ascorbate 14.7 mg per capsule.
89565872|NCT04842149|Placebo Comparator|Placebo capsules|The capsule contain only excipients: Microcrystalline Cellulose 6 mg per capsule, Magnesium Stearate 1.5 mg per capsule, Maltodextrin 277.8 mg per capsule, and Sodium Ascorbate 14.7 mg per capsule.
89565873|NCT04919941|Experimental|Decision aid|The intervention is receipt of a patient decision aid on conservative care, entitled A Guide to Conservative Care. This is 12-page printed handout that provides an overview of conservative care. Participants assigned to the intervention group are mailed a copy of the Guide after their initial baseline visit (T1). Participants keep the Guide throughout the duration of the study.
89565874|NCT04919941|No Intervention|Control|Did not receive the decision aid.
89027753|NCT01301950|Active Comparator|TruMatch® Personalized Solutions|Cruciate Retaining and Posterior Stabilized Fixed-Bearing or Rotating Platform Total Knee Arthroplasty (PFC Sigma System) implanted using TruMatch® Personalized Solutions (Custom Patient Instrumentation)
89027754|NCT01301950|Active Comparator|Conventional Total Knee Replacement|Cruciate Retaining and Posterior Stabilized Fixed-Bearing or Rotating Platform Total Knee Arthroplasty (PFC Sigma System) implanted using conventional instruments
89027755|NCT00485615|Experimental|1|OMEGA 3
89027756|NCT00505869||1|Health & Wellness Intervention + Questionnaire
89027757|NCT00505869||2|Mood Management Intervention + Questionnaire
89027758|NCT00505947|Active Comparator|A|"Infliximab 5 mg/Kg body weight by intravenous infusion on visit 1 (week 0), visit 2 (week 2), visit 3 (week 6)and visit 5 (week 14).~Afterwards, after a washout period of 2 weeks, arm A will receive placebo at visits 6 (week 16), visit 7 (week 18), visit 8 (week 22)and visit 30 (week 30)"
89027759|NCT00505947|Placebo Comparator|B|"Arm B will receive placebo at visit 1 (week 0), visit 2 (week 2), visit 3 (week 6)and visit 5 (week 14).~Afterwards, after a washout period of 2 weeks, group B will receive infliximab 5 mg/Kg body weight by intravenous infusion at visit 6 (week 16), visit 7 (week 18), visit 8 (week 22)and visit 30 (week 30)"
89027760|NCT01241682|Experimental|DC immunotherapy + CTX|Patients with mesothelioma who are fit enough to be treated with chemotherapy and enough tumor material was available are asked for participation in this study. After 4 cycles of Alimta chemotherapy, a leukapheresis is performed of which the monocytes are used for differentiation to DCs using different cytokines. The procedure to grow DCs in vitro and pulse them with tumor lysate is performed according to our earlier performed phase I study that was approved by our local ethics committee. Three doses of properly pulsed autologous DCs (MesoCancerVac) are then re-injected every two weeks. Patients will be treated with a low dose of CTX for seven day in a row the week before the 1st vaccination, the weeks in between the 2nd, and for one week after the 3rd vaccination.
89027761|NCT01241669|Experimental|Arm 1|
89565875|NCT04839263|Active Comparator|"FAST TRACK protocol"|"FAST TRACK protocol Preoperative evaluation and information~Patient general health state optimization proposal prior to hospitalization:~Preoperative strategy:~Hospitalization on surgery day~No prolonged fasting~Perioperative strategy:~Pain control based on limited systemic opioid therapy use~Anti-nausea prophylaxis~Anaesthesia via IV propofol / remifentanyl~Bladder catheter removal postoperative~Postoperative strategy:~Pain control using balanced analgesia~Gum chewing~Early oral refeeding and rapid mobilization~Venflon removal 6 hours post-op"
89027762|NCT01241669|Experimental|Arm 2|
89027763|NCT01241825|Active Comparator|1.|The subject group will chew sugarless chewing gum for a specific amount of time while undergoing capsule endoscopy.
89027764|NCT01241825|Placebo Comparator|2.|The control group will not chew chewing gum while undergoing capsule endoscopy.
89027765|NCT01241721|Experimental|Positron Emission Mammography (PEM)|Positron Emission Mammography (PEM)
89027766|NCT01241942|Experimental|EVLP with STEEN Solution™|The perfusion of the lungs will be performed using STEEN Solution™ and then physiologically assessed. Lungs deemed suitable will be transplanted after Ex-vivo Perfusion w/ STEEN Solution™.
89027767|NCT01241942|Active Comparator|Conventional Lung transplant|No experimental procedures will be carried out. Lungs from conventional brain-dead organ donors will be used for transplant.
89027768|NCT01241799|Experimental|1|Pancreatic biopsy with stylet in then stylet out
89027769|NCT01241799|Experimental|2|Pancreatic biopsy with stylet out then stylet in
89565876|NCT04839263|No Intervention|"Conventional setting protocol"|"Conventional setting protocol~Preoperative strategy:~Hospitalization on surgery day~Fasting as of midnight prior to the day of surgery~Perioperative strategy:~- Balanced anaesthesia via halogens gases~Postoperative strategy:~Same day refeeding and mobilization minimum 6 hours post operation~Bladder catheter and Venflon removal on day 1"
89565877|NCT04353895|Experimental|Robotic group (RG)|Patients in the RG group will be operated using the assistance of the Mazor X Stealth robot
89027770|NCT01241838|Placebo Comparator|Normal left ventricular size|Postoperative patient with normal left ventricular size
89027771|NCT01241838|Active Comparator|Left ventricular hypertrophy|Postoperative patient with left ventricular hypertrophy
89027772|NCT01241877|Experimental|astaxanthin|
89565878|NCT04353895|Active Comparator|O-arm navigation group (NV)|Patients in the NV group will be operated using the guidance of the Stealth navigation
89027773|NCT01241877|Placebo Comparator|placebo|
89565879|NCT04842383|Active Comparator|Half strength Hemp Oil Preparation|The topical preparation contains only 500mg of cannabinoids per ounce. The other ingredients are the same in both arms.
89565880|NCT04842383|Active Comparator|Full strength Hemp Oil Preparation|The topical preparation contains 1000mg of cannabinoids per ounce. The other ingredients are the same in both arms.
89027774|NCT00490295||newborn cardiac surgical study group|
89027775|NCT00490334||Cancer patients|Children with cancer aged 8 to 16 years
89027776|NCT00490334||Control (non-cancer)|Normal children aged 8 to 16 years, age- and gender-matched to the cancer cohort
89027777|NCT00485784|Sham Comparator|control group|control group
89027778|NCT00485784|Experimental|prééclampsies group|prééclampsies group
89027779|NCT00485784|Experimental|RCIU group|RCIU group
89027780|NCT00485784|Experimental|MFIU group|MFIU group
89027781|NCT04512651|Experimental|Intervention Group (IG)|The GI dancers, submitted to tibiotarsal thrust manipulation
89027782|NCT04512651|Sham Comparator|Control Group (CG)|For the CG was performed the simulation of the technique, with the participants and the osteopath positioned in the same way as the IG, however there was no reproduction of joint noise.
89027783|NCT04512417|Experimental|Combined radiotherapy group|
89027784|NCT04512417|Experimental|Immunotherapy alone group|
89027785|NCT00485888|Active Comparator|1|
89027786|NCT00485888|Placebo Comparator|2|
89027787|NCT00490412|Experimental|A: tenofovir/vitamin D|Vitamin D3 (cholecalciferol), 50,000 IU as a single capsule, will be administered orally to subjects in Group A (who are already taking Tenofovir) once every four weeks during study visits.
89027788|NCT00490412|Placebo Comparator|B: tenofovir/placebo|A placebo will be administered orally to subjects in Group B (who are already taking Tenofovir).
89565881|NCT05072353|Experimental|Treatment|DFU Patients are subjected to digital or transmetatarsal amputation. The treatment is provided during the amputation surgical session according to the SEFFI technique. The SEFFICARE® system (SEFFILINE S.r.l., Via delle Lame, 98, 40122 Bologna, Italy) is a disposable commercially available device. The device is provided in a sterile bag without any drugs. The SEFFI is a 5-step technique meaning preparation, anesthesia, harvesting, washing, and fluidification. The resulting tissue (2.5 mL per syringe) is ready for grafting. The stumps are closed by primary intention following adipose tissue injection.
89565882|NCT04884139|Experimental|Dovato arm|DTG/3TC
89027789|NCT00490412|Experimental|C: no tenofovir/vitamin D|Vitamin D3 (cholecalciferol), 50,000 IU as a single capsule, will be administered orally to subjects in Group C (who are not taking Tenofovir) once every four weeks during study visits.
89027790|NCT00490412|Placebo Comparator|D: no tenofovir/placebo|A placebo will be administered orally to subjects in Group D (who are not taking Tenofovir).
89027791|NCT01241955|No Intervention|verbal description of CPR|verbal description of CPR
89565883|NCT04884139|Active Comparator|Biktarvy arm|BIC/FTC/TAF
89565884|NCT04860167|No Intervention|Group A|The intravenous infusion of propofol was administered for ERCP procedure based on clinical judgment and the patient's requirement.
89565885|NCT04860167|Active Comparator|Group B|The intravenous infusion of propofol was administered for ERCP procedure titrated to BIS value 60-80.
89565886|NCT04860167|Active Comparator|Group C|Patients received 75 mg of inj. Diclofenac sodium (diluted in 100 ml of 0.9 % normal saline) intravenously 30 mins before the start of procedure & topical pharyngeal anesthesia with 4 squirts of 10% lidocaine spray ( one squirt each to posterior pharyngeal wall, base of tongue, and bilateral palatoglossal and palatopharyngeal folds ) 5 mins before the start of ERCP procedure. Intravenous infusion of propofol was administered for ERCP procedure titrated to BIS value 60-80.
89565887|NCT04841993|Experimental|Oral formulation: Cannabis decoction|From a standardized preparation cannabis Cannabis FM2 (THC) (~ 6%) and (CBD) (~ 8%) ,cannabis decoction will be prepared at the moment by putting female inflorescences in cold water brought to a boil, boiling for 15 minutes and using 500 mg of medicinal cannabis for 500 ml of water.
89027792|NCT01241955|Experimental|Video decision aid|Video decision aid of CPR
89027793|NCT00485940|Active Comparator|1|Prucalopride 2 mg
89027794|NCT00485940|Placebo Comparator|3|Placebo
89027795|NCT00485940|Active Comparator|2|Prucalopride 4 mg
89027796|NCT00485979|Experimental|Arm A1|Cohort 1: Her2-ve breast cancer
89027797|NCT00485979|Active Comparator|Arm B1|Cohort 1: Her2-ve breast cancer
89027798|NCT00485979|Experimental|Arm A2|Cohort 2: Her2+ve breast cancer
89027799|NCT00485979|Active Comparator|Arm B2|Cohort 2: Her2+ve breast cancer
89027800|NCT04512027|Experimental|Prolectin-M; a (1-6)-alpha-D-Mannopyranose class+Stand of care|Tablet chewed for 5 days along and given alongside standard of care
89027801|NCT04512027|No Intervention|Standard of Care|All patients will receive currently practiced standard of care medicines
89027802|NCT01241981||Digital Breast Tomosynthesis|Digital Breast Tomosynthesis
89027803|NCT04511715|Active Comparator|Intravitreal Bevacizumab IVB group|
89027804|NCT04511715|Sham Comparator|undergo regular follow-up for Diabetic Retinopathy|
89027805|NCT00486135|Experimental|1|Daily dosing for 21 days/7 days off
89027806|NCT00486135|Experimental|2|Continuous daily dosing
89027807|NCT00486135|Experimental|3|Continuous daily dosing
89027808|NCT04511910||Early surgery Group 1|The surgery is performed within the first 3 days
89027809|NCT04511910||Early surgery Group 2|Surgery is performed between the fourth and seventh day
89027810|NCT04511910||Early surgery Group 3|Surgery is performed more than 7 days from the onset of symptoms
89027811|NCT01241994|No Intervention|basal hemodialysis|
89027812|NCT01241994|Active Comparator|AASD|
89027813|NCT01242033|Experimental|one cup red raspberries|treatment meal consists of one cup red raspberries
89027814|NCT01242033|Experimental|two cups red raspberries|treatment meal consists of two cups red raspberries
89027815|NCT01242033|Experimental|four cups red raspberries|treatment meal consists of four cups red raspberries
89027816|NCT01242033|Placebo Comparator|bread|treatment meal consists of two slices white bread
89027817|NCT01242033|Active Comparator|vitamin C|treatment meal consists of two slices white bread and 200 mg vitamin C in the form of supplemental ascorbic acid
89027818|NCT00486174|Active Comparator|1|standard sepsis therapy plus Methylene Blue
89027819|NCT00486174|No Intervention|2|standard sepsis therapy
89027820|NCT04511793|Experimental|Hepatic Artery Infusion (HAI)|The Medtronic Synchromed II pump with the Codman® Catheter will be used to create the investigational device. The Medtronic Synchromed II pump is a surgically implantable device that allows for the delivery of high doses of chemotherapy directly to the liver, in order to treat cancer. The device is surgically implanted into a subcutaneous pocket in the abdominal wall, and the catheter is inserted into the arterial system of the liver, allowing for chemotherapeutic delivery.
89027821|NCT00486213|Active Comparator|Pyridoxine hydrochloride|Pyridoxine (200mg) or placebo once daily orally for 21 days out of each treatment cycle
89027822|NCT00486213|Placebo Comparator|Placebo|Pyridoxine (200mg) or placebo once daily orally for 21 days out of each treatment cycle
89027823|NCT00486395|Active Comparator|1|Mechanical ventilation
89027824|NCT00486395|Experimental|2|CPAP
89027825|NCT00490997|Active Comparator|1|Ketamine only arm
89208589|NCT00615030|Experimental|Indacaterol Morning, Salmeterol, Placebo|In period I, indacaterol 300 μg once a day in the morning delivered via SDDPI with a placebo to salmeterol delivered via DPI. Patients were also instructed to take evening doses of a placebo to indacaterol via SDDPI and placebo to salmeterol via DPI. In period II, salmeterol 50 μg twice daily delivered via DPI. One of the two daily doses of salmeterol was administered in the morning and the second dose in evening along with placebo matching indacaterol delivered by SDDPI. In period III, during morning and evening, placebo matching indacaterol was delivered via SDDPI and placebo matching salmeterol was delivered via DPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
89208590|NCT00615030|Experimental|Indacaterol Evening, Placebo, Salmeterol|In period I, patients were instructed to take morning doses of a placebo to indacaterol delivered via SDDPI and placebo to salmeterol delivered via DPI. Indacaterol 300 μg once a day in the evening delivered via SDDPI with placebo to salmeterol delivered via dry powder inhaler DPI. In period II, during morning and evening, placebo matching indacaterol was delivered via SDDPI and placebo matching salmeterol was delivered via DPI. In period III, salmeterol 50 μg twice daily delivered via DPI. One of the two daily doses of salmeterol was administered in the morning and the second dose in evening along with placebo matching indacaterol delivered by SDDPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
89208591|NCT00615030|Experimental|Salmeterol, Indacaterol Morning, Indacaterol Evening|In period I, salmeterol 50 μg twice daily delivered via DPI. One of the two daily doses of salmeterol was administered in the morning and the second dose in evening along with placebo matching indacaterol delivered by SDDPI. In period II, indacaterol 300 μg once a day in the morning delivered via SDDPI with a placebo to salmeterol delivered via DPI. Patients were also instructed to take evening doses of a placebo to indacaterol via SDDPI and placebo to salmeterol via DPI. In period III, patients were instructed to take morning doses of a placebo to indacaterol delivered via SDDPI and placebo to salmeterol delivered via DPI. Indacaterol 300 μg once a day in the evening delivered via SDDPI with placebo to salmeterol delivered via DPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
89565888|NCT04841993|Experimental|Oral formulation: Cannabis oil|From a standardized preparation cannabis Cannabis FM2 (THC) (~ 6%) and (CBD) (~ 8%), cannabis oil is prepared the day before the experimental session with 500 mg of female inflorescences in 5 ml of olive oil from the European Pharmacopoeia, heating in a water bath (approximately 98 ° C) for 120 minutes and cooling the oil samples. at room temperature.
89565889|NCT04841993|Experimental|Vaporized formulation: Cannabis vaporized|From a standardized preparation cannabis Cannabis FM2 (THC) (~ 6%) and (CBD) (~ 8%), 100 mg of Cannabis inflorescences of FM2 standardized cannabis were administered through Volcano vaporizer .
89565890|NCT05072431|Experimental|Experimental group|The participants in the experimental group received the 3D VR training program.
89565891|NCT05072431|No Intervention|Control group|The control group did not receive any intervention.
88968913|NCT05640791|Experimental|Gemcitabine, cisplatin, nab-paclitaxel, durvalumab|Participants receive nab-paclitaxel over 30 minutes, cisplatin over 60 minutes, and gemcitabine over 30 minutes on days 1 and 8; durvalumab over 60 minutes on days 1. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Participants with stable disease (SD), partial response (PR), or complete response (CR) then undergo standard of care hepatectomy with portal lymphadenectomy.
88968914|NCT00391911|Active Comparator|NAC and CRRT|N-Acetylcysteine and CRRT Patients are assigned to N-Acetylcysteine and CRRT. The N-Acetylcysteine is blinded to everyone except pharmacy. The CRRT is open label,
88968915|NCT00391911|Other|NAC and non CRRT|Patients are assigned to N-Acetylcysteine and CRRT. The N-Acetylcysteine is blinded to everyone except pharmacy. The CRRT is open label as would be impossible to blind
88968916|NCT00391911|Other|Placebo and CRRT|Patients are assigned to placebo treatment and CRRT. The N-Acetylcysteine/placebo is blinded to everyone except pharmacy. The CRRT is open label.
88968917|NCT00391911|Other|Placebo and Non CRRT|Patients are assigned to Placebo and non-CRRT. This is the standard of care arm. The N-Acetylcysteine/placebo is blinded to everyone except pharmacy. The CRRT/non CRRT is open label as would be impossible to blind
88968918|NCT02970409|Active Comparator|heparin|Catheter Lock Therapy with Heparin
88968919|NCT02970409|Experimental|saline|Catheter Lock Therapy with saline
88968920|NCT00049582|Experimental|Treatment (decitabine)|"Patients receive decitabine IV over 3 hours twice daily OR IV over 1 hour once daily on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of decitabine until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity."
89027826|NCT00490997|Active Comparator|2|Ketamine-Propofol arm
89027827|NCT04511949|Other|No arm|No arm
89565892|NCT04839341|Experimental|A Phase I, open-labeled multicenter study|Uproleselan in combination with mitoxantrone, etoposide and cytarabine (MEC)
89565893|NCT05071885|Experimental|Game-based Exercise program|"Each exercise session would last 45 minutes and supervised by study staff at First Step Wellness center you will be shown how to handle and move the joystick and how to play a group of computer games. The game activities will require you to move the joystick at various speeds, movement' amplitudes and in different directions. Each game will be played for 2-3 minutes.~A variety of therapy handles of different shapes and sizes have been produced that Snap-On to joystick handle. These are designed to practice a broad range of manual dexterity skills involving the thumb, fingers, wrist and elbow, o Different games will also be used to vary the movement types and precision levels. To note you will be able to choose the types of movement exercises and games to use."
89565894|NCT05071885|Active Comparator|Range of motion and Strength Exercise program.|"This will involve stretching, range of motion and strength exercises as set out by training staff at the First Step Wellness center.~On completion of the ten week exercise program, you will be invited to take part in a 30-minute interview to discuss the experiences you had on receiving the specific hand exercise program. The whole interview session will be audio taped. Your identity will be protected and your privacy will be maintained. All the information discussed and shared during the interview will be kept confidential and safely protected."
89565895|NCT04841915|Experimental|Micellar Cassein Isolate High-Protein Diet|4weeks eucaloric intake on high-protein diet with micellar cassein as primary protein source followed by 20weeks hypocaloric intake on equivalent protein rich diet.
89565896|NCT04841915|Experimental|Whey Protein High-Protein Diet|4weeks eucaloric intake on high-protein diet with whey protein as primary protein source followed by 20weeks hypocaloric intake on equivalent protein rich diet.
89565897|NCT04841915|Placebo Comparator|Normal Diet|4weeks eucaloric diet with normal protein content (15E%) followed by 20weeks hypocaloric intake on equivalent diet.
89565898|NCT02514031|Experimental|ARQ-761|"A 2 week lead-in monotherapy of ARQ-761 (The amount of ARQ-761 that will be given to the participant will depend on the time at which the participant was enrolled in the study~Afterwards the 28-day cycle of combination treatment of ARQ-761 along with gemcitabine (1000 mg/m2) + nab-paclitaxel (125 mg/m2) will begin."
89565899|NCT04841603|Active Comparator|Treatment as usual|Treatment as usual
89565900|NCT04841603|Experimental|Mindshift CBT|Treatment as usual + Access to Mindshift CBT app
89565901|NCT04823533|Experimental|Probiotic|A probiotic formulation containing two well-documented probiotic strains. The finished product is a lyophilized powder packaged in single-dose sticks sachets Excipients used were as follows: xylitol, maltodextrin, plum flavor, and malic acid.
89565902|NCT04823533|Placebo Comparator|Placebo|Placebo formulation containing only the excipients used were as follows: xylitol, maltodextrin, plum flavor, and malic acid.
89565903|NCT03042845|Active Comparator|Judkins L3.5/R4 cardiac catheters|
89565904|NCT03042845|Experimental|Tiger cardiac catheter|
89565905|NCT02473549|Experimental|Brain Stimulation|Patients will receive, Sham TDCS, Anodal TDCS, Cathodal TDCS, and Magnetic Resonance Imaging (MRI).
89565906|NCT04841681|Experimental|Video-based Psychotherapy|The group received the intervention of video-based psychotherapy.
89027828|NCT00486408|Experimental|1|MRKAd5 HIV-1 gag/pol/nef vaccine administered as 1 ml in either deltoid at study entry and Weeks 4 and 26
89565907|NCT03042533|Active Comparator|Conventional Compression|Nail will be seated using conventional compression technique
89565908|NCT03042533|Active Comparator|Standard Backslapping|Nail will be seated using standard backslapping technique
89565909|NCT03042533|Active Comparator|Dynamic Locking with Backslapping|Nail will be seated using backslapping with dynamic locking
89565910|NCT04751461|Experimental|Product usage order ABECD|Subjects will use each of the 5 products (ABECD) during an evaluation period, followed by a 4 hour Test Session
89565911|NCT04751461|Experimental|Product usage order BCADE|Subjects will use each of the 5 products (BCADE) during an evaluation period, followed by a 4 hour Test Session
89565912|NCT04751461|Experimental|Product usage order CDBEA|Subjects will use each of the 5 products (CDBEA) during an evaluation period, followed by a 4 hour Test Session
89565913|NCT04751461|Experimental|Product usage order DECAB|Subjects will use each of the 5 products (DECAB) during an evaluation period, followed by a 4 hour Test Session
89565914|NCT04751461|Experimental|Product usage order EADBC|Subjects will use each of the 5 products (EADBC) during an evaluation period, followed by a 4 hour Test Session
89565915|NCT04751461|Experimental|Product usage order DCEBA|Subjects will use each of the 5 products (DCEBA) during an evaluation period, followed by a 4 hour Test Session
89565916|NCT04751461|Experimental|Product usage order EDACB|Subjects will use each of the 5 products (EDACB) during an evaluation period, followed by a 4 hour Test Session
89565917|NCT04751461|Experimental|Product usage order AEBDC|Subjects will use each of the 5 products (AEBDC) during an evaluation period, followed by a 4 hour Test Session
89565918|NCT04751461|Experimental|Product usage order BACED|Subjects will use each of the 5 products (BACED) during an evaluation period, followed by a 4 hour Test Session
89565919|NCT04751461|Experimental|Product usage order CBDAE|Subjects will use each of the 5 products (CBDAE) during an evaluation period, followed by a 4 hour Test Session
89565920|NCT03038711|Experimental|Dose Panel 1|BMS-986166 or Placebo matching BMS-986166
89565921|NCT03038711|Experimental|Dose Panel 2|BMS-986166 or Placebo matching BMS-986166
89565922|NCT03038711|Experimental|Dose Panel 3|BMS-986166 or Placebo matching BMS-986166
89565923|NCT03038633|Experimental|Cohort 1|"900 mg novel medical food containing 22.2mg iron~receive 900 mg by mouth (3 capsules, one at each meal) daily; after Day 28 remain on level for additional 2 months if clinically indicated~receive a phone call from coordinator between Day 5-9 to assess side effects and medications~return to General Clinical Research Center, (GCRC) for a blood draw at days 14, 28, 60, and 90 while on novel medical food"
89565924|NCT03038633|Experimental|Cohort 2|"1800 mg novel medical food containing 44.4 mg of iron~receive 1800 mg by mouth (3 capsules, one at each meal) daily; after Day 28 remain on level for additional 2 months if clinically indicated~receive a phone call from coordinator between Day 5-9 to assess side effects and medications~return to GCRC for a blood draw at days 14, 28, 60, and 90 while on novel medical food"
89565925|NCT03038633|Experimental|Cohort 3|"2700 mg novel medical food containing 66.6 mg of iron~receive 2700 mg by mouth (3 capsules, one at each meal) daily; after Day 28 remain on level for additional 2 months if clinically indicated~receive a phone call from coordinator between Day 5-9 to assess side effects and medications~return to GCRC for a blood draw at days 14, 28, 60, and 90 while on novel medical food"
88968921|NCT05640713|Experimental|ThisCART19A cells infusion|In this study, allogeneic anti-CD19 CAR T cell (ThisCART19A) infusion is used to treat patients with refractory or relapsed CD19 positive B cell acute lymphoblastic leukemia.
88968922|NCT05640635|Active Comparator|Ventilator weaning first|
88968923|NCT05640635|Active Comparator|ECMO weaning first|
88968924|NCT00049816|No Intervention|1|Participants will receive no intervention and will act as the control group.
88968925|NCT00049816|Experimental|2|Participants will partake in a walking exercise program.
88968926|NCT00049816|Experimental|3|Participants will partake in a cycling exercise program.
88968927|NCT00389558|Active Comparator|2|Biseptine
88968928|NCT00389558|Active Comparator|1|Amukin
88968929|NCT00389636|Active Comparator|1|TheraGauze alone
88968930|NCT00389636|Active Comparator|2|Theragauze + Regranex
88968931|NCT05640440||children who stutter|assessment executive function and stuttering severity in 30 child with stuttering
88968932|NCT05640440||children who don't stutter|assessment executive function in 30 child with stuttering
88968933|NCT05574660|Experimental|High-Fat/High-Sugar (HF/HS) Diet|Participants randomized to consume an HF/HS yoghurt (40.8 % kcal from fat, 45.6 % kcal from carbohydrates, 13 % kcal from protein of 79.5 total kcal) two times a day for eight weeks in addition to their normal diet.
88968934|NCT05574660|Experimental|Low-Fat/Low-Sugar (LF/LS) Diet|Participants randomized to consume an LF/LS yoghurt (17.1 % kcal from fat, 29.1 % kcal from carbohydrates, 51.9 % kcal from protein of 78 total kcal) two times a day for eight weeks in addition to their normal diet.
88968935|NCT05640362|Placebo Comparator|Benzydamine mouthwash|
88968936|NCT05640362|Experimental|Natural enzymes mouthwash|
88968937|NCT00050440|Experimental|Trabectedin|Trabectedin 1.3 mg/m2 administered intravenously every 21 days. Dexamethasone 4 mg administered orally (by mouth) the day before the trabectedin dose, 30 minutes before the trabectedin dose, and for 2 days following the trabectedin dose.
88968938|NCT05574543|Experimental|0.25 mg AGA111|0.25 mg AGA111 in autologous blood coagulum (ABC) is locally delivered at the intervertebral space.
88968939|NCT05574543|Experimental|0.5 mg AGA111|0.5 mg AGA111 in ABC is locally delivered to the participants at the intervertebral space.
88968940|NCT05574543|Placebo Comparator|Placebo|Placebo in ABC is locally delivered at the intervertebral space.
88968941|NCT00050557|Experimental|1|Participants will receive immediate Multi-Family Psychoeducation Group treatment and ongoing treatment as usual
88968942|NCT00050557|Active Comparator|2|Participants will receive treatment as usual and waitlist Multi-Family Psychoeducation Group treatment
88968943|NCT05574465|Other|Manometry Device|At 10 minutes prior to anticipated removal of the endotracheal tube, pass the routine manometry catheter per naris to 30 cms.
88968944|NCT05640128|Other|Aldosterone in HPLC-MS/MS,|Aldosterone in HPLC-MS/MS measurement
88968945|NCT00397774|Active Comparator|Exercise|Physical exercise twice a week for 8 weeks, and best supportive care
88968946|NCT00397774|Other|No exercise|Best supportive care, no exercise
88968947|NCT00050674|Experimental|Filgrastim-SD/01|6 mg SC, Day 9, 24 hours after the end of the chemotherapy infusion
88968948|NCT00050791|Experimental|VLCD and leptin|Very low calorie diet formula providing 800 calories per day and leptin treatment.
88968949|NCT00050791|Active Comparator|placebo|Very low calorie diet and placebo treatment
88968950|NCT05574348|Experimental|PO2 - Control|"This arm will start with PO2, followed by Control. The PO2 consists of two sessions of 30 minutes each, one week apart, composed of normalizations of joint, muscular, ligament and visceral dysfunctions .~Control is a treatment in 2 sessions that is like PO2 but is not an active osteopathic treatment. A light touch will be made for fictitious normalizations."
89565926|NCT03038633|Experimental|Cohort 4|"3600 mg novel medical food containing 88.8 mg of iron~receive 3600 mg by mouth (3 capsules, one at each meal) daily; after Day 28 remain on level for additional 2 months if clinically indicated~receive a phone call from coordinator between Day 5-9 to assess side effects and medications~return to GCRC for a blood draw at days 14, 28, 60, and 90 while on novel medical food"
89565927|NCT03039803|Active Comparator|single-layer continuous uterotomy suture|Single-layer continuous uterotomy suture
89565928|NCT03039803|Active Comparator|double-layer continuous uterotomy suture|double-layer continuous uterotomy suture
89565929|NCT03038477|Experimental|Durvalumab|Patients in Arm A will be given anti-PD-L1 antibody, durvalumab, every 2 weeks for a maximum of 26 doses if there is no radiographic evidence of disease recurrence. For Arm A, one cycle constitutes two durvalumab treatments on Day 1 and Day 15, respectively, repeated every 28 days.
89565930|NCT03038477|No Intervention|No Durvalumab|Patients in Arm B will be observed.
89565931|NCT04004533||Endoscopic retrograde cholangiopancreatography (ERCP)|At the time of each ERCP procedure, information on procedure indication, technical performance of the duodenoscope and adverse events will be collected using a newly designed duodenoscope assessment tool. The duodenoscope assessment tool was developed to measure the technical performance of the duodenoscopes based on three components: passage and positioning at the papilla, performing requisite technical maneuvers and technical features. Each performance component is graded on a scale ranging from 1 to 5 (1 for easy maneuverability, 5 for most difficult maneuverability). Duodenoscope assessment tool also captures data on procedural indications, cannulation success rates and adverse events.
89565932|NCT03038243|Experimental|Cohort 1|Group 1, 2.25 x 10^11 Sf2aWC cells +10 µg dmLT Group 2, 2.25 x 10^11 Sf2WC cells Group 3, 2.0 grams of NaHCO3 dissolved in 150 mL of sterile water
89565933|NCT03038243|Experimental|Cohort 2|Group 1, 2.25 x 10^11 Sf2aWC cells +10 µg dmLT Group 2, 2.25 x 10^11 Sf2WC cells Group 3, 2.0 grams of NaHCO3 dissolved in 150 mL of sterile water
89565934|NCT03038243|Experimental|Cohort 3|Group 1, 2.25 x 10^11 Sf2aWC cells +10 µg dmLT Group 2, 2.25 x 10^11 Sf2WC cells Group 3, 2.0 grams of NaHCO3 dissolved in 150 mL of sterile water
89565935|NCT03101449|Experimental|Group 1|"20 individuals of Coral UFCSPA without voice problems carry out the exercise with Finnish tube before choir practice once a week for a period of 14 weeks. The exercise will be carried out with blowing set to sound at regular frequency, with frequency variation and with the melody of Happy Birthday; each sequence will be held for 2 minutes with 1 minute interval between them."
89565936|NCT03101449|Experimental|Group 2|"20 individuals of Coral UFCSPA without voice problems carry out the exercise straw phonation before choir practice once a week for a period of 14 weeks. The exercise will be carried out with blowing set to sound at regular frequency, with frequency variation and with the melody of Happy Birthday; each sequence will be held for 2 minutes with 1 minute interval between them."
89565937|NCT03101449|No Intervention|Group 3|10 individuals of Coral UFCSPA without voice problems. Untreated group.
89565938|NCT03038321|Active Comparator|solifenacin|(Sofenacin ''solifenacin 10 m'') [Marcyrl Pharmaceutical Industries - Egypt]
89565939|NCT03038321|Active Comparator|levofloxacin|(Tavanic ''levofloxacin 500 mg'') [Sanofi-Aventis - Egypt]
89565940|NCT03038321|Active Comparator|lornoxicam|(Xefo ''lornoxicam 8 mg'') [Multi-Apex - Egypt, under license of: NYCOMED, Austria]
89565941|NCT02531373|Experimental|Adult: V114 Medium Dose|Adult participants will receive a single 0.5 mL intramuscular injection of medium-dose V114 on Day 1.
89565942|NCT02531373|Experimental|Adult: V114 High Dose|Adult participants will receive a single 0.5 mL intramuscular injection of high-dose V114 on Day 1.
89565943|NCT02531373|Experimental|Adult: V114 Medium Dose with Alternative Carrier Protein|Adult participants will receive a single 0.5 mL intramuscular injection of medium-dose V114 with alternative carrier protein on Day 1.
89565944|NCT02531373|Experimental|Adult: V114 High Dose with Alternative Carrier Protein|Adult participants will receive a single 0.5 mL intramuscular injection of high-dose V114 with alternative carrier protein on Day 1.
88968951|NCT05574348|Experimental|Control - PO2|"This arm will start with Control, followed by PO2. The PO2 consists of two sessions of 30 minutes each, one week apart, composed of normalizations of joint, muscular, ligament and visceral dysfunctions .~Control is a treatment in 2 sessions that is like PO2 but is not an active osteopathic treatment. A light touch will be made for fictitious normalizations."
88968952|NCT05639777|Experimental|Intranasal|That will receive intranasal dexmedetomidine (1.5mcg/kg)
88968953|NCT05639777|Placebo Comparator|control group|That will receive the same volume of 2 ml of intranasal normal saline
89565945|NCT02531373|Experimental|Infant: V114 Medium Dose|Infant participants will receive a 0.5 mL intramuscular injection of medium-dose V114 at 2, 4, 6, and 12 to 15 months of age.
89565946|NCT02531373|Experimental|Infant: V114 High Dose|Infant participants will receive a 0.5 mL intramuscular injection of high-dose V114 at 2, 4, 6, and 12 to 15 months of age.
88968954|NCT00398008|Experimental|1|DC-HIV plus buprenorphine maintenance.
88968955|NCT00398008|Experimental|2|DC-HIV plus naltrexone maintenance
88968956|NCT04731532|Active Comparator|Classical respiratory physiotherapy application|Patient positions, postural drainage application tapping and trifled
88968957|NCT04731532|Active Comparator|classical respiratory physiotherapy with thoracic vibration|Thoracic Vibration: The physiotherapist places his hands open with his / her fingers on the front and side walls of the patient's chest when the elbow is at 5-10 degrees of flexion. The elbow expands the patient's chest with vibrations. Exercise can be repeated 5-10 times a day+Patient positions, postural drainage application tapping and trifled
88968958|NCT05636072|Experimental|Treatment Immediately|Participants will engage in well-being tools immediately for 1-week.
88968959|NCT05636072|No Intervention|Waitlist Control|Participants will wait 1 week to begin the well-being tools.
88968960|NCT04731415|Other|Healthy pregnant women|Optical coherence tomography and Optical coherence tomography angiography using Optovue® were performed in each trimester and at 6 weeks after childbirth.
88968961|NCT05573958|Experimental|Arm A: Rivaroxaban, Clopidogrel, and Aspirin|Rivaroxaban 2.5 mg tablet twice daily orally, Clopidogrel 75 mg tablet once daily orally, and Aspirin 81 mg tablet once daily
88968962|NCT05573958|Active Comparator|Arm B: Clopidogrel and Aspirin|Clopidogrel 75 mg tablet once daily, and Aspirin 81 mg tablet once daily
89565947|NCT02531373|Experimental|Infant: V114 Medium Dose with Alternative Carrier Protein|Infant participants will receive a 0.5 mL intramuscular injection of medium-dose V114 with alternative carrier protein at 2, 4, 6, and 12 to 15 months of age.
89565948|NCT02531373|Experimental|Infant: V114 High Dose with Alternative Carrier Protein|Infant participants will receive a 0.5 mL intramuscular injection of high-dose V114 with alternative carrier protein at 2, 4, 6, and 12 to 15 months of age.
89565949|NCT02531373|Active Comparator|Infant: Prevnar 13™|Infant participants will receive a 0.5 mL intramuscular injection of Prevnar 13™ at 2, 4, 6, and 12 to 15 months of age.
89565950|NCT03101683|Experimental|PCWRT Group|Patients with diagnosis of in situ ductal carcinoma (pTis) or invasive breast carcinoma (pT1 and pT2), submitted to NAC sparing mastectomy with prosthetic-based breast reconstruction who have some additional risk factors will receive a partial chest wall radiotherapy
89565951|NCT03042377|Active Comparator|Single-Visit Retreatment|Root canal retreatment were performed according to the guidelines for single-visit endodontic treatments.
88968963|NCT02971917|Experimental|Clinical study of TRUVIEW ART|Chest x-ray image acquisition Creation of TRUVIEW ART applied image Comparison of TRUVIEW ART image with original image
89565952|NCT03042377|Active Comparator|"Multiple-Visit-Calcium Hydroxide"|Root canal retreatment were performed according to the guidelines for multiple-visit endodontic treatments.
89565953|NCT03042377|Active Comparator|"Multiple-Visit-Corticosteroid Paste"|Root canal retreatment were performed according to the guidelines for multiple-visit endodontic treatments.
89565954|NCT03042377|Active Comparator|"Multiple-Visit-Antibiotic Paste"|Root canal retreatment were performed according to the guidelines for multiple-visit endodontic treatments.
89565955|NCT05071573|Experimental|Intervention arm|"Quality improvement package Identification of a viral load champion whose role will include tracing and recalling patients who need further assessments of their VL or switch to second-line regimen.~QIP to address process and clinic impediments to VLM as well as training in antiretroviral treatment monitoring guidelines Training in the use of enhanced TIER.Net technology developed as part of the trial and how to access reports on the dashboard system.~Augmentation of TIER.Net with a dashboard system VL results will be imported into TIER.Net daily from the National Health Laboratory Service which will be linked to patients in TIER.Net based on multiple exclusive and linked deterministic rules using a combination of variables such as name, surname, sex, date of birth, date of visit, NHLS lab number, facility and folder number. The information contained in TIER.Net will be used to develop a dashboard which summarises viral load data at individual and clinic level."
89565956|NCT05071573|No Intervention|Control arm|Viral load results are manually captured on to the TIER.Net system with filing of the paper results in patients' clinical notes for nurses' review during routine appointments. This is used to produce a monthly enrolment and quarterly cohort reports for the central monitoring of the ART programme.
88815014|NCT02992379|Active Comparator|stabilizing splint|Active Comparator: stabilizing splint A 2-mm-thick, hard, clear sheet of resin will be adapted to the maxillary arch . Small amount of self-curing acrylic will be added to the anterior portion of the appliance as a stop for the lower incisor. The area of this stop is approximately 4 to 6 mm. The patient is instructed to protrude the mandible slightly and to open and close the mouth In this position. Self-curing acrylic will be added to the occluding surface of the appliance. All occluding areas, except the contact on the anterior stop . Excess acrylic surrounding the centric contacts is removed with a hard rubber wheel on a lathe. intervention: pivot splint
88968964|NCT05635136||The DIVAT cohort|"patient > 18 years of age who received renal transplant are registered in the DIVAT cohort (standing for computerized and validated data in transplantation, Données Informatisées VAlidées Transplantation). It comprises more than 300 clinical and biological parameters collected at the time of transplant, at 3 months, 6 months and at each anniversary of the transplant. The DIVAT cohort and network is accredited by the CNIL (standing for Commission Nationale de l'Informatique et des Libertés)"
88968965|NCT05573880|Experimental|generalized joint hypermobility|
88968966|NCT05573880|Experimental|without generalized joint hypermobility|
88968967|NCT00051922|Experimental|1|Participants will receive vaccine and will be followed for 1 year
88968968|NCT05635058|Experimental|Reminisence Therapy|The participants in the intervention group received reminiscence therapy which was implemented by the researcher as one session per week for eight weeks. In the reminiscence sessions, mnemonic materials selected specifically for the determined interview topic were used. In the sessions, topics such as childhood life, work life, religious holidays, national holidays, old songs, military ceremonies, wedding ceremonies, gardening and field work were shared. In the reminiscence sessions, the participants were encouraged to verbally express the feelings and thoughts they remembered about the mnemonics. The interviews were recorded by the researcher and each session lasted 45-60 minutes. At the end of the reminiscence session, the topics addressed in the session were summarized by the researcher.
88968969|NCT05635058|No Intervention|Control Group|"Interviews were conducted with the individuals in the control group on a designated day of the week, at a designated place in the nursing home. The researcher interviewed the individuals in the control group once a week for eight weeks. During these meetings, daily issues and events such as health, sports, and weather were discussed. Each of the mentioned interviews lasted 45-60 minutes. At the end of eight weeks, SMMT and the Multidimensional Observation Scale for Elderly Individuals were implemented again to the participants in the intervention and control groups."
88968970|NCT00052195|Placebo Comparator|B|
88968971|NCT00052195|Experimental|A|
88968972|NCT04731454|Experimental|Healthy Nordic Diet (ND)|A healthy diet meeting and exceeding the Nordic Nutrition Recommendations and with more than 80% foods from the Nordic region.
88968973|NCT04731454|Experimental|Control Diet (CD)|A control diet approximating the average depressed person's diet, i.e. of somewhat lower quality than the average Swedish diet.
89565957|NCT05071417|Experimental|Semaglutide|Patients on semaglutide
89565958|NCT04859777|Experimental|Part A:|Dose-escalation oral MPT-0118 BID
89565959|NCT04859777|Experimental|Part B:|Dose-escalation oral MPT-0118 BID + pembrolizumab (IV)
89565960|NCT04859777|Experimental|Part C:|Dose-expansion oral MPT-0118 BID + pembrolizumab (IV)
89565961|NCT05562609|Experimental|Intramuscular TXA|1g TXA as 2 x 5 ml IM injections (100mg/ml) and slow IV injection of placebo (1 x 10 ml of 0.9% sodium chloride)
89565962|NCT05562609|Active Comparator|Intravenous TXA|1g TXA by slow IV injection and 2 x 5 ml IM injections of placebo
89565963|NCT05562609|Placebo Comparator|Placebo|Placebo by 1 x slow 10ml IV injection and 2 x 5 ml IM injections
89565964|NCT04370873|Experimental|Part 1: MK-5475|Participants receive MK-5475 360 μg once daily (QD) via inhalation from Days 1-7.
89565965|NCT04370873|Placebo Comparator|Part 1: Placebo|Participants receive placebo QD via inhalation from Days 1-7.
89565966|NCT04370873|Experimental|Part 2: MK-5475|Participants receive MK-5475 32 µg, 100 µg, 195 µg or 380 μg QD via inhalation from Days 1-28.
89565967|NCT04370873|Placebo Comparator|Part 2: Placebo|Participants receive placebo QD via inhalation from Days 1-28.
89565968|NCT05388201||FACEFIT|Participants will enter a chamber where they will undergo 3D facial scanning using a dedicated camera system and be trained to don a N95 respirator properly. The fitted filtering efficiency (FFE) of 4 types of face coverings: a N95 respirator, a KN95 respirator (with and without a clip), a surgical mask (with and without a clip), and a KF94 respirator (with and without a clip) will be tested using the OSHA quantitative fit testing protocol for filtering face pieces. Participants will measure their peak expiratory flow pre and post mask fit testing using a disposable peak flow meter.
89565969|NCT03632707|Other|Magnetic resonance imaging of the knee|Patients complain of painful knee with clinical suspicious of medial meniscus posterior root tear of the knee will be examined by all Magnetic Resonance Imaging sequences including sagittal, coronal and axial PD,T2 and PD-SPIR weighted images, and correlate the results with Knee Arthroscopy.while the suspected cases of meniscal extrusion will make MRI using the knee coil for varus stress Overloading simulating weight bearing.
89565970|NCT04429451|Experimental|4SCAR-PSMA Cell Therapy for PSMA positive tumor|Infusion of 4SCAR-PSMA T cells at 10^6 cells/kg body weight via IV
89565971|NCT03101527|Experimental|Supplementation|Subjects received Omega-3 PUFA supplementation
89565972|NCT05367219|Experimental|Air sterilizer|The invesitigators will monitore smoke and try to remove the smoke with an air sterilizer during the endoscopic gastrointestinal surgery in the experimental group.
89565973|NCT05367219|No Intervention|Control|The control group was monitored for smoke during the endoscopic gastrointestinal surgery without any intervention.
89565974|NCT04838873|Active Comparator|Open Radical Cystectomy|Standard open radical cystectomy.
88815015|NCT02992379|Experimental|pivot splint|"Experimental: pivot splint A 2-mm-thick, hard, clear sheet of resin will be adapted to the maxillary arch . Small amount of self-curing acrylic will be added to the anterior portion of the appliance as a stop for the lower incisor. The area of this stop is approximately 4 to 6 mm. The patient should be instructed to close in Centric relation . Self-curing acrylic will be added to the occluding surface of the appliance. All occluding areas, except the contact on the anterior stop . Excess acrylic surrounding the centric contacts is removed with a hard rubber wheel on a lathe. All areas, except labial to the mandibular canines, are flattened to the contact marks.~Other Names: PS"
89027829|NCT04511637|Experimental|Test C: 15 mg ODT with water, then 15 mg film-coated tablet|Participants received one single dose of 15 mg rivaroxaban orally disintegrating tablet (ODT) with water in the fasted state. After a washing period of 5 days, participants received one single oral dose of 15 mg rivaroxaban film-coated tablet in the fasted state
89565975|NCT04838873|Experimental|Laparoscopic-assisted radical cystectomy.|Laparoscopic-assisted radical cystectomy.
89565976|NCT03039959||Pulmonary hypertension cohort|Consecutive adult Pulmonology inpatients with suspected or pre-diagnosed pulmonary hypertension undergoing invasive right heart catheterization.
89565977|NCT03039959||Heart failure cohort|Consecutive adult Cardiology inpatients with a new or pre-existing diagnosis of heart failure who are referred to the consultant nephrologist with a history of diuretic-resistant fluid overload and impaired renal function.
89565978|NCT04544839|Experimental|ADLC attachment in first phase|Each patient will receive 2 implants in the canine region. Three months later, each patient will be randomized and half of the patients will receive first the ADLC (test) device (first phase). In the second phase of the crossover trial (6 months after the start of the first phase), the attachments will be replaced. Patients previously allocated to the ADLC group will receive the LOC attachments.
89565979|NCT04544839|Active Comparator|LOC attachment in first phase|Each patient will receive 2 implants in the canine region. Three months later, each patient will be randomized and half of the patients will receive first the LOC (control) device (first phase). In the second phase of the crossover trial (6 months after the start of the first phase), the attachments will be replaced. Patients previously allocated to the LOC group will receive the ADLC attachments.
89565980|NCT03039335||Adults with an AAT Deficiency|Subjects over the age of 18 that have been recently diagnosed with an Alpha-1 Antitrypsin deficiency will be enrolled into the study to observe the interval between first symptom and initial diagnosis.
89565981|NCT05071339|Experimental|Participants|"Patients treated at the IVF unit at Shamir Medical Center planned for an antagonist cycle will undergo blood test and US exam at day 2-3 of their menstrual cycle. Patients will be recruited if a leading follicle 10-13 is shown in the presence of E2 > 200-350 pmol/L.~Patients will start GnRH antagonist injections [Cetrotide (cetrolix) or Orgalutran (ganirelix) - depending on their primary prescription] for 3-5 days intervention."
89565982|NCT04838483|Experimental|Indirect restorations luted with light-cured composite resin.|"Subjects for the study will be identified from patients who had treated with indirect adhesive restorations onlay or overlay during the period 2016 to 2017 was performed at Istanbul Okan University Faculty of Dentistry by an experienced clinician.~Local anesthesia was applied if necessary. After caries and/or failed restorations were removed, the preparations were performed according to defined principles for adhesive onlays/overlays. At least one cuspal coverage was required for each restoration. All undercuts were eliminated using composite resin. Following the cavity preparation, immediate dentin sealing was applied and polymerized prior to impression taking. Indirect restorations were designed and fabricated with CEREC system. Surface treatments and clinical protocols were performed under manufacturer's instructions. Adhesive cementation with composite resin procedure was carried out with the rubber-dam isolation."
89565983|NCT04521829|Experimental|VR-enhanced treadmill walking|Participants will be tested during 2 sessions of VR-enhanced treadmill walking.
89565984|NCT05386485||Group A (asymptomatic infection)|Absence of clinical manifestation during the acute phase of SARS-CoV-2 infection until discharge.
89565985|NCT05386485||Group B1 (mild symptomatic infection)|Clinical manifestation of the infection without severity signs (respiratory rate < 30/minute; peripheral oxygen saturation (SpO2) >94%) and no radiological evidence of pneumonia
89565986|NCT05386485||Group B2 (moderate symptomatic infection)|Clinical manifestation of the infection without severity signs (respiratory rate < 30/minute; peripheral oxygen saturation (SpO2) >94%) and radiological evidence of pneumonia
89565987|NCT05386485||Group B3 (severe symptomatic infection)|Clinical manifestation of the infection with severity signs (respiratory rate > 30/minute; peripheral oxygen saturation (SpO2) <94%) and radiological evidence of pneumonia
89565988|NCT05386485||Group B4 (critical symptomatic infection)|"Clinical manifestation of the infection with severity signs (respiratory rate > 30/minute; peripheral oxygen saturation (SpO2) <94%) and at least one of the following:~I) Acute Respiratory Distress Syndrome: defined under Berlin Criteria mostly defined by a PaFi<200, II) Shock: Patient diagnosed with sepsis that despite adequate fluid resuscitation, require vasopressors to maintain a mean arterial pressure ≥65 mmHg and lactate values >2 mmol/L (>18 mg/dL) or III) Organ dysfunction that requires ICU admission"
89565989|NCT02606279|Placebo Comparator|Placebo control|20 HIV-infected participants will be randomized into a blinded arm where they will receive 24 weeks of placebo therapy. During this time, they will undergo the same study procedures as the intervention arm.
89565990|NCT02606279|Experimental|Valsartan|20 HIV-infected participants will be randomized into a blinded arm where they receive 24 weeks of valsartan therapy. For those subjects randomized to the valsartan group, they will receive valsartan 40 mg by mouth daily for 2 weeks, then increase to 80 mg by mouth daily for the remaining 22 weeks. During this time, they will undergo the same study procedures as the placebo arm.
88815016|NCT01014728|Active Comparator|Intravenous anesthesia|Intravenous anesthesia with propofol for endoscopic sinus surgery
89565991|NCT03037697|Experimental|TheraTogs Arm|TheraTogs Arm The participating children will wear TheraTogs orthotic undergarment and strapping as preparatory stage without application of any exercise program with gradually increasing the worn time till reaching the 8 hours per day, to allow the children to become acclimated to the system+ Traditional treatment 3 months
89565992|NCT03037697|Active Comparator|Traditional Treatment Arm|"Traditional Treatment Arm~1-Trunk control exercises 2-Core stability training 3-Proximal dynamic stability for the shoulder and pelvic girdles components. 4- Back and abdominal strengthening exercises 5- Standing exercises : - Standing alone gradually increase time. - Stride standing alone. - Step standing alone (other limb supported on wooden step then soft step and finally on small ball). - Standing on balance board~3 months"
89565993|NCT04859855|Experimental|Restrictive strategy (arm A)|Transfusion of RBC if Hb ≤7,0g/dL with the aim of maintaining Hb levels between 7,0-9,0g/dL.
89565994|NCT04859855|Experimental|Liberal strategy (arm B)|Transfusion of RBC if Hb ≤9,0g/dL, with the aim of maintaining Hb levels between 9,0-10,0g/dL.
89565995|NCT04859387|Experimental|group A|set of pragmatic shoulder techniques
89565996|NCT04859387|Active Comparator|group B|traditional physical therapy
89565997|NCT03039491|Experimental|HIV+ 50-65, CD4>200 PCV/PPV|"HIV+ individuals , 50-65 years of age with a nadir cluster of differentiation (CD) 4 count >200 to receive PCV13 vaccine followed 8 weeks later by PPV23~Intervention: 13 valent Pneumococcal conjugate vaccine (PCV13) followed 8 weeks later by 23 valent pneumococcal polysaccharide vaccine"
89565998|NCT03039491|Experimental|HIV+ 50-65, CD4<200 PCV/PPV|"HIV+ individuals , 50-65 years of age with a nadir CD4 count <200 to receive PCV13 vaccine followed 8 weeks later by PPV23~Intervention: 13 valent Pneumococcal conjugate vaccine (PCV13) followed 8 weeks later by 23 valent pneumococcal polysaccharide vaccine"
89565999|NCT03039491|Experimental|HIV+ 50-65, CD4>200 PPV|"HIV+ individuals , 50-65 years of age with a nadir CD4 count >200 to receive PPV23 only~Intervention: 23 valent pneumococcal polysaccharide vaccine only"
89566000|NCT03039491|Experimental|HIV+ 50-65, CD4<200 PCV|"HIV+ individuals , 50-65 years of age with a nadir CD4 count <200 to receive PPV23 only~Intervention: 23 valent pneumococcal polysaccharide vaccine only"
89566001|NCT03039491|Active Comparator|HIV- 50-65, PCV/PPV|"HIV- individuals , 50-65 years of age immunized with PCV13 followed by PPV23~Intervention: 13 valent Pneumococcal conjugate vaccine (PCV13) followed 8 weeks later by 23 valent pneumococcal polysaccharide vaccine"
89566002|NCT03039491|Active Comparator|HIV- 50-65, PPV|"HIV- individuals, 50-65 years of age immunized with PPV23 only.~Intervention: 23 valent pneumococcal polysaccharide vaccine only"
88815017|NCT01014728|Active Comparator|Inhalation anesthesia|Inhalation anesthesia with sevoflurane for endoscopic sinus surgery
89566003|NCT03039491|Active Comparator|HIV+ 21-40, CD4>200 PCV/PPV|"HIV+ individuals , 21-40 years of age with a nadir CD4 count >200 to receive PCV13 vaccine followed 8 weeks later by PPV23~Intervention: 13 valent Pneumococcal conjugate vaccine (PCV13) followed 8 weeks later by 23 valent pneumococcal polysaccharide vaccine"
89566004|NCT03039491|Active Comparator|HIV+ 21-40, CD4<200 PCV/PPV|"HIV+ individuals , 21-40 years of age with a nadir CD4 count <200 to receive PCV13 vaccine followed 8 weeks later by PPV23~Intervention: 13 valent Pneumococcal conjugate vaccine (PCV13) followed 8 weeks later by 23 valent pneumococcal polysaccharide vaccine"
89566005|NCT03037853||Healthy volunteers|Healthy volunteers
89566006|NCT03037775|Other|Investigated group|Subjects underwent procedures: hemodynamic indices will be measured at baseline and during 1/ e-cigarette without nicotine smoking, 2/ e-cigarette with nicotine and during 3/ traditional cigarette smoking in random order
89566007|NCT03039257|Other|Vitamin A|Participants receive single dose vitamin A supplementation prior to HSCT. A 3x3 dose escalation/de-escalation design will be used for this study.
89566008|NCT04838093||Patient cohort:|all patients with vascular disorders consecutively admitted at our tertiary care hospital from March 16 to December 07, 2020
89566009|NCT04838093||Control cohort:|data of two nationwide PCR-based studies conducted in a representative random sample, from April 1-6, and November 12-14, 2020, collected by the Austrian Ministry of Science and the Austrian Red Cross to estimate the spread of SARS-CoV-2 infection among the non-hospitalized Austrian population.
89566010|NCT04838093||HCP cohort:|HCP worker data, including nurses, nurse technicians, physicians, surgical personal, physical therapists, nurse practitioners, environmental service workers, administrative staff, and dietitians, working in close proximity to admitted patients at our tertiary care hospital from March 16 to December 07, 2020.
89566011|NCT04859309|Experimental|ActiveHip Intervention|"The ActiveHip tele-rehabilitation mobile application.~The program consists of a multidisciplinary home-based tele-rehabilitation program delivered through a mobile application. It is comprised by an occupational therapy program and a physical exercise program.~The intervention group have the opportunity to perform three online-based sessions per week (two sessions of physical exercise and one of occupational therapy), each lasting 30-60 min. It is able to realize a fourth session, called bonus session.~In addition, the intervention group will receive the educational program, which has a total of 7 modules. 5 modules are for patients and caregivers, and 2 modules are specific for caregivers."
89566012|NCT04859309|Active Comparator|Standard care|Participants of this group will receive the standard care for hip fracture patients at hospital discharge.
89566013|NCT04859543|Other|Diagnostic group|Tumor and blood samples will be collected from each patient and broad molecular profiling will be performed. The results of the evaluation of the tumor specimens will determine if the patient's tumor has an actionable mutation for which treatment is available.
89566014|NCT04789967|Active Comparator|Guided Imagery (GI)|A 8 minute audio that focuses on evoking mental images in reducing the abdominal bloating sensation in patients
89027830|NCT04511637|Experimental|Test C: 15 mg film-coated tablet, then 15 mg ODT with water|Participants received one single dose of 15 mg rivaroxaban film-coated tablet in the fasted state. After a washing period of 5 days, participants received one single oral dose of 15 mg rivaroxaban orally disintegrating tablet (ODT) with water in the fasted state
89566015|NCT04789967|Active Comparator|Progressive Muscle Relaxation (PMR)|A 8 minute audio that focuses on contracting certain muscle groups and relaxing it progressively in reducing the abdominal bloating sensation in patients
89566016|NCT04789967|Placebo Comparator|Audiobook|A 8 minute audio that focuses on providing educational information regarding functional gastrointestinal disorders and related knowledge.
89566017|NCT04833569|Experimental|Indocyanine green mediated photodynamic therapy (ICG-PDT)|Delivery of ICG solution at a concentration of 1 mg/mL will be used. The photosensitizer will be applied until the bottom of the peri-implant pocket using a 1 ml syringe. An 810 nm diode laser (A.R.C. laser GmbH, Nurnberg, Germany) with a power of 200 mW (continuous mode) and total energy of 4 J will be used to excite the ICG by starting from the papilla for 30 s followed by the insertion inside the peri-implant pocket depth for 10 s from both buccal and lingual side moving to coronal direction.
89566018|NCT04833569|Placebo Comparator|Peri-implant mechanical debridement|Non-surgical peri-implant mechanical debridement (PIMD) through ultrasonic device with a carbon tip.
89566019|NCT04837781|Experimental|Normal vitamin D|Include patients with normal vitamin D level (above 30ng/ml). Vitamin D level will be measured at the beginning of treatment if there is deficiency then the patient refer to specialized physician to be supplied with vitamin D supplement to optimized the level to normal then start orthodontic treatment
89566020|NCT04837781|Experimental|Vitamin D deficiency|Include patients with unknown vitamin D level until time of canine retraction where we measure level if deficiency exist (below 30ng/ml) then the patient will be referred to specialized physician to be supplied with vitamin D supplement.
89566021|NCT04837781|Experimental|Control|includes patients with unknown vitamin D level until the completion of canine retraction where we measure level. If deficiency exists (below 30ng/ml) then we will refer the patient to specialized physician to be supplied with vitamin D supplement
89566022|NCT03038009|Active Comparator|One-month therapy|Pantoprazole, 40mg, tablet, oral, once daily for 1 month.
89566023|NCT03038009|Experimental|Twelve-month therapy|Pantoprazole, 40mg, tablet, oral, once daily for 12 months.
89566024|NCT03466801|Experimental|Group prednisone|Prednisone was taken 1mg/kg/d(maximum 60mg/d)for 8 weeks to start.Then decreased 5mg every 2 weeks; When reduced to 40mg,reduced 5mg every 4 weeks. When reduced to 20mg, reduced 2.5mg every 8 weeks until the end.
89566025|NCT03466801|Active Comparator|Group MP and CTX|The first month,Methylprednisolone(MP) was injected for 3 days(weight >60kg,500mg/d;<60 kg,300mg/d),and 0.4mg/kg/d for 27 day.The second month,Cyclophosphamide(CTX) orally was 100mg/d for 1 month.And this regimen is repeated for six months.
89566026|NCT04833725||COPD combined with OSA|All patients collect sleep monitoring information through wearable devices, together with demographic characteristics, pulmonary function tests, blood routines, biochemistry, electrocardiogram, chest radiograph, COPD assessment scale, modified British Medical Research Association dyspnea index, St. George's Quality of Life Questionnaire, Sleep Apnea Clinical Score, Berlin Questionnaire, Epworth Sleepiness Scale, Etc. This study estimates patient health status from the collected information, then diagnoses sleep apnea and calculates sleep apnea prevalence.
89566027|NCT03101605|Experimental|e-learning|The intervention for this study will be the completion of an original E-learning module on AOM designed by a team of pediatric residents, pediatricians, a pediatric otolaryngologist, a pediatric emergency physician and a pediatric infectious diseases specialist. The module includes interactive sections on anatomy, epidemiology, pathophysiology, microbiology, diagnostic criteria, treatment options and prognosis. A 5 minute video demonstrating appropriate pediatric ear examination techniques is also included in the module. Throughout the module, many examples of ear pathologies captured on video during a previous study. The E-learning module should take 0.5 hr to complete.
89566028|NCT03101605|Other|Standard teaching|"The control group will receive a 2h lecture on AOM, which is the standard teaching method. Given by a pediatrician or a senior pediatric resident, this lecture, using a PowerPoint© presentation support, encompasses clinical cases, notions of anatomy, epidemiology, pathophysiology, diagnostic criteria, treatment options, and prognosis, describes different ear examination techniques, and shows examples of different pathologies."
89566029|NCT05069779|Experimental|Diazepam|Oral
89566030|NCT05069779|Placebo Comparator|Placebo|Oral
89566031|NCT04833491||Senile cataract|
89566032|NCT04833491||Traumatic cataract|
89566033|NCT04833491||Congenital cataract|
89566034|NCT04833491||Lens dislocation group|
89566035|NCT04833491||Complicated cataract|
89566036|NCT04837469|Experimental|Universal Adhesive|universal adhesive
89566037|NCT04837469|Experimental|Etch-And-Rinse Adhesive|Etch-And-Rinse Adhesive
88968974|NCT05634122|Experimental|TAU + Acceptance and Commitment Therapy (ACT)|This therapy is based, as the name implies, on the acceptance (not avoidance) of negative experiences as a coping strategy, and on committing to life values or objectives. ACT has been used for various conditions, including chronic pain. Since avoidance is a strategy frequently used by patients suffering from pain, the application of this therapy seems very appropriate. In fact, it has been proven that patients who accept their pain more are those who score lower in pain intensity, have less negative emotions and enjoy a better quality of life.
89566038|NCT03251911|Experimental|Ivacaftor (VX770)|Ivacaftor (VX-770) for the Treatment of Chronic Bronchitis with CFTR Dysfunction
89566039|NCT04824755|Experimental|Demographics and clinic characteristics of children in different ages|
89566040|NCT04824755|Experimental|PedEyeQ domain scores|
89566041|NCT04824755|Experimental|Boxes represent first, median, and third quartile values.|
89566042|NCT04824755|Experimental|Parent of kids aged 0-4y and 5-11y PedEyeQ domain scores|
89566043|NCT04837391||Urologic oncology surgery in elderly|Elective urologic oncology surgeries such as radical nephrectomy, radical cystectomy, radical prostatectomy in older than 65 years
89566044|NCT02643355|Experimental|Standard of Care - Olanzapine|Drug of interest in the study - Olanzapine
89566045|NCT02643355|Active Comparator|Standard of Care - Clonidine|Standard of care - clonidine
89566046|NCT03036527|Experimental|Activity-based locomotor training|To understand the effects of weight-bearing activity-based locomotor therapy on bladder function and sexual function. Activity-based locomotor training interventions include locomotor step training with a harness and body-weight support, 5 days a week for a total of 80, 1-hour sessions.
88968975|NCT05634122|Active Comparator|Treatment as Usual (TAU)|Standard care. The standard treatment would generally be pharmacological to address chronic pain, adjusted to the symptomatic profile of each patient.
88968976|NCT00052468|Experimental|TCG|Paclitaxel 175 mg/m2 day 1, Carboplatin AUC 5 day 1, Gemcitabine 800 mg/m2 day 1 + 8, q 21 days / 6 - 10 courses
88968977|NCT00052468|Active Comparator|TC|Paclitaxel 175 mg/m2 day 1, Carboplatin AUC 5 day 1, q 21 days / 6 - 10 courses
88968978|NCT05573412||All Particpants|Group contains all participants as this is a systemic review of stem cell cryopreservation techniques
88968979|NCT05633927||Non-immunological responder|Patients who start ART with <350 CD4+ T cells, maintaining undetectable viral load, and increasing <200 CD4+ T cell count after 18 months of follow-up.
89566047|NCT03036527|Experimental|Activity-based stand training|To understand the effects of weight-bearing activity-based stand therapy on bladder and sexual function. Activity-based stand training interventions include stand training with a harness and body-weight support or stand training over ground, 5 days a week for a total of 80, 1-hour sessions.
89566048|NCT03036527|Experimental|Activity-based upper arm ergometry|To understand the effects of non-weight-bearing activity-based stand therapy on bladder and sexual function. Activity-based upper arm ergometry interventions may include arm crank training (upper arm ergometry) in while seated in the wheelchair 5 days a week for a total of 80, 1-hour sessions.
89566049|NCT02604017|Experimental|ABT-493/ABT-530 for 12 weeks|ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 12 weeks.
89566050|NCT02604017|Experimental|ABT-493/ABT-530 for 8 weeks|ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 8 weeks.
89566051|NCT02640547||Paritaprevir/Ritonavir + Ombitasvir ± Dasabuvir ± Ribavirin|"Participants in this observational study received treatment with paritaprevir/ritonavir (r) and ombitasvir with or without dasabuvir ± ribavirin (RBV) for 12 or 24 weeks for the treatment of chronic hepatitis C (CHC), according to hepatitis C virus (HCV) genotype/subtype and stage of liver disease.~The prescription of treatment regimen was at the discretion of the physician in accordance with local clinical practice and label, was made independently from this observational study and preceded the decision to offer the patient the opportunity to participate in this study."
88968980|NCT05633927||Immunological responder|Patients with >350 CD4+ T cells
89566052|NCT03036605|Active Comparator|Group Bupivacaine|4 ml %0.5 bupivacaine and 1 ml %0.9 NaCl infiltration into nasal packing to both sides
89566053|NCT03036605|Active Comparator|Group Bupivacaine+Dexamethasone|4 ml %0.5 bupivacaine and 4mg(1 ml) dexamethasone infiltration into nasal packing to both sides
89566054|NCT03098875|Active Comparator|Sevoflurane|"General anesthesia using sevoflurane as a hypnotic agent, and remifentanil as an analgesic.~Two steady state periods of 10 minutes each, one with a steady bispectral index at 25 +/- 5, the other with a steady bispectral index at 55 +/- 5. Continuous recording of heart rate during the last minute of each steady-state. Off-line spectral analysis of heart rate variability."
89566055|NCT03098875|Active Comparator|Propofol|"General anesthesia using propofol as a hypnotic agent, and remifentanil as an analgesic.~Two steady state periods of 10 minutes each, one with a steady bispectral index at 25 +/- 5, the other with a steady bispectral index at 55 +/- 5. Continuous recording of heart rate during the last minute of each steady-state. Off-line spectral analysis of heart rate variability."
89566056|NCT04837157|Experimental|Intervention Group|9 treatment sessions will be performed with the ATLAS2030 exoskeleton. The rehabilitation sessions last approximately 90 minutes. Two sessions are scheduled per week, for two weeks.
89566057|NCT03099031||Tinzaparin|Patients with objectively confirmed cancer associated venous thromboembolism receiving tinzaparin treatment to prevent recurrence of venous thromboembolism
89566058|NCT03037151|Experimental|HCV mono-infection Treatment naives|HCV treatment-naïve patients will be treated with the combination of grazoprevir plus elbasvir for 12 weeks.
89566059|NCT03037151|Experimental|HCV mono-infection Treatment experienced|HCV treatment-experienced patients, including null responders, partial responders or post-treatment relapsers, will be assigned to treat with the combination plus weight-based RBV for 16 weeks.
89566060|NCT03037151|Experimental|HCV/HIV co-infection Treatment naives|HCV/HIV coinfected, treatment-naïve patients will be treated with the combination of grazoprevir plus elbasvir for 12 weeks.
89566061|NCT03037151|Experimental|HCV/HIV co-infection Treatment experienced|HCV/HIV co-infected treatment-experienced patients, including null responders, partial responders or post-treatment relapsers, will be assigned to treat with the combination plus weight-based RBV for 16 weeks.
89566062|NCT03101059|Experimental|MKS pax|Munier-Kuhn Syndrome patients
89608803|NCT05702775|Experimental|Endoscopic treatment group (EUS-GBD Group)|The procedure will be performed after at least 6 hours of fasting The placement of the drain will be performed using a linear echoendoscope that allows the gallbladder to be punctured from the gastric antrum or the duodenal bulb to generate a cholecystogastrostomy or a cholecystoduodenostomy, respectively. Transmural gallbladder drainage will be performed by placing a metal apposition stent (LAMS) with the 15x15mm Hot AXIOS device (Boston Scientific) in the case of cholecystogastrostomy or 15x10 or 10x10mm in the case of cholecystoduodenostomy.
89608804|NCT05702697|Experimental|F-ESWT|F-EWST with 0.15 mJ/mm2 intensity and 6 Hz frequency for 3 weeks. The shocking head was placed at the muscle positions of the long head of the bicep femoris, semitendinosus, and semimembranosus for 1,000, 500, and 500 shocks, respectively, accounting for 2,000 shocks in total/ session/week.
89608805|NCT05702697|Sham Comparator|Sham-ESWT|sham ESWT by using the focused shockwave device and placing the shocking head in the same muscle positions as performed in the intervention group with 0.01 mJ/mm2 intensity and 6 Hz frequency in 2,000 shocks/session/week for 3 weeks.
88968981|NCT00052585|Experimental|Treatment (irinotecan, gefitinib, leucovorin, fluorouracil)|Patients receive oral gefitinib daily beginning on day 1, irinotecan IV over 90 minutes on days 1 and 15, and leucovorin calcium IV over 2 hours and fluorouracil IV over 3-5 seconds followed by a 22-hour infusion on days 1, 2, 15, and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88968982|NCT00052780|Experimental|Treatment (temozolomide, O6-benzylguanine)|See Detailed Description
88968983|NCT00052897|Experimental|Arm I|"Patients receive SGN-00101 subcutaneously once on weeks 0, 4, and 8. Treatment continues in the absence of disease progression or unacceptable toxicity.~Cohorts of 5-6 patients receive escalating doses of SGN-00101 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which no more than 1 of 6 patients experience dose-limiting toxicity."
88968984|NCT00052936|Experimental|S6|6x CHOP-14
88968985|NCT00052936|Experimental|R6|6x CHOP-14 + 8x Rituximab
88968986|NCT00052936|Experimental|S8|8x CHOP-14
88968987|NCT00052936|Experimental|R8|8x CHOP-14 + 8x Rituximab
88968988|NCT05633849|Placebo Comparator|Placebo group|In placebo group, participants were instructed to take two 500 mg olive oil placebo (placebo group) after breakfast and two after dinner during the first 6 weeks of the study. During the next 6 weeks, participants were instructed to take one softgel after breakfast and one after dinner. Thus, the treatment period was 12 weeks
88968989|NCT05633849|Experimental|Specialized pro-resolving mediators (SMP) group|In SPM group, Participants were instructed to take two 500 mg softgels of LIPINOVA after breakfast and two after dinner during the first 6 weeks of the study. During the next 6 weeks, participants were instructed to take one softgel after breakfast and one after dinner. Thus, the treatment period was 12 weeks
88968990|NCT02970253|Active Comparator|Capsular resection|Capsular resection
88968991|NCT02970253|Active Comparator|Capsular retention|Capsular retention
88968992|NCT05573139|Experimental|muscle strength assessment|
88968993|NCT05633498|Experimental|Self-help book|A self-help book for coping with shift work
88968994|NCT05633498|Active Comparator|Sleep hygiene advice|A sheet of paper with basic and standard sleep hygiene advice
88968995|NCT00053053|Experimental|Juven supplement|Juven nutritional supplement given twice a day for 8 weeks
88968996|NCT00053053|Active Comparator|Non-Juven supplement|Non-Juven nutritional supplement given twice a day for 8 weeks
88968997|NCT03290651|Experimental|Probiotic Natural Health Product - RepHresh Pro-B|One capsule contains 2.5 billion CFU of Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14.
89608806|NCT02947503|Active Comparator|Metformin on top of usual care|"Metformin TEVA 850 mg (1-3 times daily) added to usual care from start of the diagnosis GDM.~Usual care has been defined as intensive counselling for diet and lifestyle plus insulin therapy if needed.~Intervention: metformin TEVA 850 mg (1-3 times daily) on top of usual care."
89608807|NCT02947503|No Intervention|Usual care|"Usual care from start of the diagnosis GDM. Control group without metformin. Usual care has been defined as intensive counselling for diet and lifestyle plus insulin therapy if needed.~Intervention: usual care."
89566063|NCT03037229||STEMI|"Subjects in which a STEMI protocol has been initiated.~An attempt will be made to do the standard 12-lead ECG first, followed immediately after by the Smartphone ECG~If the initial standard 12-lead ECG was already obtained, such as when the patient was first diagnosed with STEMI, a repeat ECG will be performed at the same time as the Smartphone ECG~If possible, the two ECGs will be taken in the Emergency Department, the critical care unit (CCU), or the catheterization laboratory just prior to cardiac catheterization. If not, then the two ECG's will be taken just after the cardiac catheterization is completed (i.e., within one hour of the procedure) while the patient is still in the catheterization laboratory and waiting for transport to the CCU~Both ECGs will be sent to the designated ECG reading station, to be read and evaluated by three independent cardiologists"
89566064|NCT03037229||Chest Pain|"Subjects presenting at the emergency department with chest pain.~An attempt will be made to do the standard 12-lead ECG first, followed immediately after by the Smartphone ECG~If the initial standard 12-lead ECG was already obtained, such as when the patient was first diagnosed with STEMI, a repeat ECG will be performed at the same time as the Smartphone ECG~If possible, the two ECGs will be taken in the Emergency Department, the critical care unit (CCU), or the catheterization laboratory just prior to cardiac catheterization. If not, then the two ECG's will be taken just after the cardiac catheterization is completed (i.e., within one hour of the procedure) while the patient is still in the catheterization laboratory and waiting for transport to the CCU~Both ECGs will be sent to the designated ECG reading station, to be read and evaluated by three independent cardiologists"
89566065|NCT03100981|Experimental|Internet-delivered MBCT|The intervention group will immediately receive 8 weeks of therapist-assisted internet-delivered Mindfulness-Based Cognitive Therapy.
89566066|NCT03100981|Other|Waitlist control|The control group will be on a waiting list to participate in Internet-delivered MBCT after the 6-months follow-up time has passed.
89566067|NCT03036371|Experimental|High Intensity Interval Exercise|home exercise sessions
89566068|NCT03101215|Placebo Comparator|Placebo|glucose drink (100g) with placebo tablets
89566069|NCT03101215|Active Comparator|phosphorus|Glucose drink (100g) with phosphorus tablets (400 mg of phosphorus)
89566070|NCT04824287|Experimental|Experimental|pelvic floor exercise
89566071|NCT04824287|No Intervention|control group|no intervention
89566072|NCT03101137|Active Comparator|Caudal block with dexmedetomedine|Caudal Dexmedetomidine block group (DEXM) (n= 16) will receive caudal block using the bupivacaine 0.25% and Dexmedetomidine 1 μg/kg with the conventional general anesthesia,
89566073|NCT03101137|Active Comparator|Caudal block with dexamethasone|caudal Dexamethasone Block group (DEXA) (n =16) will receive caudal block using the bupivacaine 0.25% and Dexamethasone 0.1 mg/kg with the conventional general anesthesia,
89566074|NCT03101137|Placebo Comparator|Control (caudal block with bupivacaine)|caudal with bubivacaine (CONTROL) group (n = 16) will receive caudal block using the bupivacaine 0.25% and general anesthesia.
89566075|NCT04429139|Experimental|PDT treatment group|All the patients received once PDT with Visudyne® as the initial treatment. Rescue treatment with systemic chemotherapy would be given to patients if tumors were insensitive to PDT treatment, the tumors became larger, or disease relapse.
89566076|NCT04428125||Healthy sporty subjects|Healthy sporty subjects that participate in the following sports: baseball, tennis, swimming, rowing, volleyball, rugby football, weightlifting.
89566077|NCT04428125||Healthy non-sporty subjects|Healthy subjects that do not partecipate in sport activities.
89566078|NCT05069077|Experimental|music group|In the music group, music chosen by the participant will be played through a speaker by the nursing staff during outpatient hysteroscopy. Music will be played through a speaker instead of headphones in order to maintain good communication and interaction between the participant and the doctor.
89027831|NCT04511637|Experimental|Test D: 15 mg ODT without water, then 15 film-coated tablet|Participants received one single dose of 15 mg rivaroxaban orally disintegrating tablet (ODT) without water in the fasted state. After a washing period of 5 days, participants received one single oral dose of 15 mg rivaroxaban film-coated tablet in the fasted state
89027832|NCT04511637|Experimental|Test D: 15 mg film-coated tablet, then 15 mg ODT without water|Participants received one single dose of 15 mg rivaroxaban film-coated tablet in the fasted state. After a washing period of 5 days, participants received one single oral dose of 15 mg rivaroxaban orally disintegrating tablet (ODT) without water in the fasted state
89027833|NCT00491036|Active Comparator|Intraaortic balloon pump|Patients in cardiogenic shock get an intraaortic balloon pump in the cath lab
89027834|NCT00491036|No Intervention|No intraaortic balloon pump|Patients in cardiogenic shock in this group get no intraaortic balloon pump
89027835|NCT00486486|Active Comparator|Bimatoprost/Timolol AM therapy|
89566079|NCT05069077|Other|non-music group|Participants in the non-music group will undergo diagnostic outpatient hysteroscopy in the same setting and standard procedure without listening to any music.
89566080|NCT04833257|Experimental|GP combine with Tislelizumab neoadjuvant therapy+CCRT|Patients receive neoadjuvant therapy with gemcitabine(1000mg per square meter on day 1,8) , cisplatin (80mg per square meter on day 1) and tislelizumab(200mg) every three weeks for three cycles before radiotherapy, then followed by concurrent IMRT and cisplatin (100mg per square meter) concurrent every three weeks during radiotherapy (D1,D22,D43 of RT) .
89566081|NCT03098953|Experimental|Loteprednol Etabonate Ophthalmic Gel|one drop per eye for each eye
89566082|NCT03099889|Experimental|Physical Activity intervention arm|Receive a tailored behavioral interventions for exercise and strength training via multiple channels including frequent mailings, integrated voice response and outreach phone calls, interactive website, and referral to local community exercise resources.
89566083|NCT03099889|No Intervention|Control arm|Receive general health mailings
89608808|NCT03586323|Experimental|L-SLNB|performed a superior laryngeal nerve block with lidocaine
89027836|NCT00486486|Active Comparator|Bimatoprost/Timolol PM therapy|
89027837|NCT04511481||platinum-resistant group|
89027838|NCT04511481||platinum-sensitive group|
89027839|NCT00486668|Active Comparator|Group 1: AC then paclitaxel + trastuzumab|AC followed by paclitaxel plus trastuzumab
89566084|NCT04823507||Concussion patients treated with Photobiomodulation|"Patients between the ages of 15-65 years clinically diagnosed with a mild Traumatic Brain Injury by a health professional and currently not undergoing any treatment during a 1 year period from January 2018 to December 2018.~Documentation of the history of a qualifying mild Traumatic Brain Injury within 3 months of traumatic incident and/or diagnosis with persistent symptomatology after 3 months. For reference, International Classification of Diseases, Tenth Revision (ICD-10) clinical criteria require a history of TBI and the presence of three or more of the following eight symptoms: 1) headache, 2) dizziness, 3) fatigue, 4) irritability, 5) insomnia, 6) concentration or 7) memory difficulty, and 8) intolerance of stress, emotion, or alcohol4."
89566085|NCT03099577|Experimental|radiochemotherapy 1|Patients will be treated with radiation therapy 64.8 Gy
89566086|NCT03099577|Experimental|radiochemotherapy 2|Patients will be treated with radiation therapy 69.6 Gy
89566087|NCT03099577|Experimental|radiochemotherapy 3|Patients will be treated with radiation therapy 74.4 Gy
88968998|NCT03290651|Placebo Comparator|Placebo|Placebo. It is the same composition as the active capsule, without the bacteria.
88968999|NCT05572983|Experimental|Chidamide in Combination With CHOP|Patients with previously untreated peripheral T-cell lymphoma with follicular helper of T cell phenotype will receive chidamide in combination with CHOP for 6 cycles (planned) (21 days per cycle). After 6 cycles of induction therapy, if complete remission (CR) was achieved, maintenance treatment with chidamide will be continued for two years.
88969000|NCT05572905|Experimental|Young lean men and women|25 to 40 y.o. participants with body mass index in range of 18.5 to 25
88969001|NCT05572905|Experimental|Young obese men and women|25 to 40 y.o. participants with body mass index in range of 30 to 45.
88969002|NCT05572905|Experimental|Elderly men and women|65 to 80 y.o. participants with body mass index in range of 18.5 to 30.
88969003|NCT05633069||Patients requiring orotracheal intubation or tracheostomy|"Patients hospitalized in the surgical Intensive Care Unit (ICU) of the University Hospital of Saint-Etienne between September 2015 and August 2016 for medical-surgical pathologies, requiring orotracheal intubation or tracheostomy, and presenting on the day of recording a Riker sedation score of 3 or 4 will be included.~Datas analysed by medical records."
88969004|NCT05572866||2019|No intervention will be carried out. The sum total of surgeries carried out during 2019 will be audited to see how the COVID-19 pandemic has impacted the surgical volume.
88969005|NCT05572866||2020|No intervention will be carried out. The sum total of surgeries carried out during 2020 will be audited to see how the COVID-19 pandemic has impacted the surgical volume.
88969006|NCT05572866||2021|No intervention will be carried out. The sum total of surgeries carried out during 2021 will be audited to see how the COVID-19 pandemic has impacted the surgical volume.
88969007|NCT05572866||2022|No intervention will be carried out. The sum total of surgeries carried out during 2022 will be audited to see how the COVID-19 pandemic has impacted the surgical volume.
88969008|NCT05632055||Pregnancy with GDM|Pregnant women who positive test for 100gm OGTT (abnormal 2 or more blood glucose level according NDDG (National Diabetes Data Group) criteria)
88969009|NCT05632055||Pregnancy without GDM|Pregnant women who negative test for 100gm OGTT
88969010|NCT00053326|Experimental|Treatment (fenretinide)|Patients receive oral fenretinide 3 times daily (or 2 times daily if over 18 years of age) on days 1-7. Treatment repeats every 3 weeks for up to 30 courses in the absence of disease progression or unacceptable toxicity.
88969011|NCT04731220||Study group|Newly diagnosed as bile duct cancer
88969012|NCT04731220||Control group|No history of cancer in previous 5 years
88969013|NCT05631860||DanFunD baseline|The baseline cohort (gathered in the years 2012-2015) is a random sample selected through the National Civil Registration system among people living in 10 municipalities in the western part of greater Copenhagen, Denmark, ages 18 to 76 years. The baseline cohort constitutes data from self-reported questionnaires (n=7,493) and diagnostic interviews data (n=1,590).
88969014|NCT05631860||DanFunD 5-years follow-up investigation|The follow-up cohort (gathered in the years 2018-2020) consists of participants all born in Denmark, between 24 and 84 years of age. The follow-up cohort constitutes data from self-reported questionnaires (n=4,288) and diagnostic interviews data (n=1,094).
88969015|NCT02970058|Active Comparator|Platelet-rich Plasma|30 patients will receive platelet-rich plasma post-spinal anesthesia
88969016|NCT02970058|Placebo Comparator|Control|30 patients will receive sterile saline post-spinal anesthesia
88969017|NCT02970019|Experimental|K0706|K0706 will be administered once a day
88969018|NCT02970019|Experimental|Placebo|Placebo will be administered once a day
88969019|NCT04731259|Experimental|ATR-04|The intervention is an ointment that will be applied topically BID for 28 days. It will be supplied in small aluminum foil packets. Packets of study medication will be labeled with Subject Kit numbers to ensure the double-blind treatment.
88969020|NCT04731259|Placebo Comparator|Placebo|Placebo ointment will be applied topically BID for 28 days. It will be supplied in small aluminum foil packets. Packets of study medication will be labeled with Subject Kit numbers to ensure the double-blind treatment.
88969021|NCT02969941|Active Comparator|Real Stimulation|Participants will receive active transcranial magnetic stimulation (TMS) daily for two weeks
89566088|NCT03099577|Experimental|radiochemotherapy 4|Patients will be treated with radiation therapy 79.2 Gy
89566089|NCT03099577|Experimental|radiochemotherapy 5|Patients will be treated with radiation therapy 84 Gy
89566090|NCT03099577|Experimental|radiochemotherapy 6|Patients will be treated with radiation therapy 88.8 Gy
89566091|NCT03099577|Experimental|radiochemotherapy 7|Patients will be treated with radiation therapy 93.6 Gy
89566092|NCT04833179|Experimental|fecal transplant|Healthy donors will be selected by the fecal transplant unit, in Tel-Aviv medical center. The treatment will be given in the form of fecal capsule. Each capsule will contain a double capsule with 2 layers to ensure that the fecal material will be contained. The treatments will include 30 capsules for the first treatment, that will be taken in two consecutive days, each day 15 capsules. The second, third and fourth treatments will all include 15 fecal capsules. There will be 2 weeks intervals between each treatment.
89566093|NCT04833179|Placebo Comparator|placebo|Placebo capsule that can not be differentiate from the focal transplant capsule will be given in the same interval as the fecal transplant procedure written above.
89566094|NCT03036137|Active Comparator|Active tDCS|Subjects will receive 20 minutes of active tDCS for five consecutive days, current of 2 mA, in the temporoparietal left area, and right prefrontal cortex.
89566095|NCT03036137|Sham Comparator|Sham tDCS|Subjects will receive 20 minutes of Sham tDCS for five consecutive days in the temporoparietal left area, and right prefrontal cortex.
89566096|NCT05069233||UGI+SB|Patients who underwent combined upper digestive tract and small intestine examination under MCE.
89566097|NCT04833101|Experimental|"0-28 days vaccine group"|One dose of recombinant Ad5 vectored COVID-19 vaccine on day 0, the second dose of subunit vaccine (ZF2001) against COVID-19 on day 28, and a third of subunit vaccine (ZF2001) against COVID-19 on month 4.
89566098|NCT04833101|Placebo Comparator|"0-28 days placebo group"|One dose of recombinant Ad5 vectored COVID-19 vaccine on day 0, the second dose of a commercial influenza vaccine on day 28, a third of subunit vaccine (ZF2001) against COVID-19 on month 4.
89566099|NCT04833101|Experimental|"0-56 days vaccine group"|One dose of recombinant Ad5 vectored COVID-19 vaccine on day 0, the second dose of subunit vaccine (ZF2001) against COVID-19 on day 56, a third of subunit vaccine (ZF2001) against COVID-19 on month 4.
89566100|NCT04833101|Placebo Comparator|"0-56 days placebo group"|One dose of recombinant Ad5 vectored COVID-19 vaccine on day 0, the second dose of a commercial influenza vaccine on day 56, a third of subunit vaccine (ZF2001) against COVID-19 on month 4.
89566101|NCT04837313|Experimental|Parkinson's Disease with Constipation|Fecal microbiota transplantation will be performed.
88969022|NCT02969941|Placebo Comparator|Placebo Stimulation|Participants will receive sham transcranial magnetic stimulation (TMS) daily for two weeks
88969023|NCT02970175|Experimental|Bronchoscopy with terlipressin administration|Patients undergoing a bronchoscopy under local anesthesia for biopsy sampling of endobronchial lesions. Bronchoscopy will be done with terlipressin administration
88969024|NCT02970175|Placebo Comparator|Bronchoscopy without terlipressin administration|Patients undergoing a bronchoscopy under local anesthesia for biopsy sampling of endobronchial lesions. Bronchoscopy will be done without terlipressin administration
88969025|NCT00053833|Experimental|irinotecan|irinotecan
88969026|NCT05570682|Active Comparator|Manual induction|General Anesthesia induction: Fentanyl 2 mcg/kg, Propofol 2 mg/kg, Rocuronium 0.6 mg/kg General Anesthesia mainteneance: Propofol 4-6 mg/kg/h to keep an adequate sedation level (BIS between 40-60; entropy between 40-60)
88969027|NCT05570682|Experimental|Target Controlled Induction|"General Anesthesia induction: Fentanyl 2 mcg/kg, Propofol TCI with Schneider site effect model starting from 2 mcg/ml and increasing the dose untile loss of consciousness, Rocuronium 0.6 mg/kg.~General Anesthesia mainteneance: Propofol TCI with Schneider site effect model in order to keep an adequate sedation level (BIS between 40-60; entropy between 40-60)"
88969028|NCT05569902|Experimental|Active tACS|Participants in this group received 20 minutes of active 6 Hz stimulation over the medial prefrontal cortex.
88969029|NCT05569902|Sham Comparator|Sham tACS|Participants in this group received 20 minutes of sham stimulation over the medial prefrontal cortex.
88969030|NCT00053950|Experimental|Cohort I|Groups of 3-6 patients receive escalating doses of PZA at a fixed infusion time until the MTD is determined. In both cohorts the MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Patients receive G-CSF IV or subcutaneously beginning on day 4 and continuing until blood counts recover. Patients also undergo reinfusion of stem cells over 15-30 minutes on day 4 as needed per protocol.
88969031|NCT00053950|Experimental|Cohort II|Groups of 3-6 patients receive PZA at the dose/hour established in cohort I at escalating infusion times until another MTD is determined. In both cohorts the MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Patients receive G-CSF IV or subcutaneously beginning on day 4 and continuing until blood counts recover. Patients also undergo reinfusion of stem cells over 15-30 minutes on day 4 as needed per protocol.
88969032|NCT00054184|Experimental|Study drug|
88969033|NCT00054418|Experimental|calcium carbonate, vitamin D and risedronate|Patients receive calcium carbonate 600 mg daily, vitamin D 400 U daily and risedronate 35 mg weekly.
89566102|NCT05068765|No Intervention|control group|Once enrolled and consent is documented, eligible subject's will participate in the study for approximately six months.
89566103|NCT05068765|Experimental|communication skills psychoeducation|Communication skills focused psychoeducation group will be given a communication skills-focused psychoeducation program for eight weeks, one session per week, for a total of eight sessions. The number of sessions was planned with reference to the study in which the effect of the psychoeducation program on general health and communication skills in caregivers of individuals with schizophrenia was investigated.Session groups will be formed from a single session of 60-90 minutes for each topic.
89566104|NCT05068765|Experimental|general psychoeducation|General psychoeducation group will be given a general psychoeducation program for four weeks, one session per week, in total. Session groups will be formed from a single session of 60-90 minutes for each topic.
89566105|NCT00794599|Experimental|Clarinex followed by Zyrtec|Clarinex 5 mg by mouth daily for 7 days followed by Zyrtec 10 mg by mouth daily for 7 days, with 5-28 days washout between treatments.
89566106|NCT00794599|Experimental|Zyrtec followed by Clarinex|Zyrtec 10 mg by mouth daily for 7 days followed by Clarinex 5 mg by mouth daily for 7 days, with 5-28 days washout between treatments.
89566107|NCT04836611|Other|regular cannabis consumer patients|
89566108|NCT00783133|Experimental|Clarinex followed by Allegra|Clarinex 5 mg by mouth daily for 7 days followed by Allegra 180 mg by mouth daily for 7 days, with 5-28 days washout between treatments.
89566109|NCT00783133|Experimental|Allegra followed by Clarinex|Allegra 180 mg by mouth daily for 7 days followed by Clarinex 5 mg by mouth daily for 7 days, with 5-28 days washout between treatments.
89566110|NCT04823819|Active Comparator|rTMS stimulation|20 sessions of stimulation with increasing intensity, reaching maximum in the 4th session.
89566111|NCT04823819|Active Comparator|tDCS stimulation|The stimulation time will be 20 minutes, the current intensity will be 2mA.
89566112|NCT04823819|Sham Comparator|Sham rTMS stimulation|20 sessions of stimulation, but without current.
89566113|NCT04823819|Sham Comparator|Sham tDCS stimulation|The stimulation time will be 20 minutes, but without current.
89566114|NCT03098719|Experimental|Intervention|
89566115|NCT03098719|No Intervention|Control|
89566116|NCT04823429|Experimental|High intensity-interval training (HIIT)|Subjects performed HIIT (3-min intervals at 40% and 80%VO2peak) on a bicycle ergometer for 30 min/day, 5 days/week for 6 weeks.
89566117|NCT04823429|Experimental|Moderate intensity-continuous (MICT)|Subjects performed MICT (sustained 60%VO 2max) on a bicycle ergometer for 30 min/day, 5 days/week for 6 weeks.
89566118|NCT04823429|No Intervention|Control group|Without any exercise training
89566119|NCT03098407|Other|Buprenorphine Maintenance Treatment|Buprenorphine Maintenance Treatment patients will receive instructions regarding a follow-up, outpatient appointment with the Pregnancy Recovery Center at Magee-Womens Hospital, which specializes in Opioid maintenance treatment for pregnant patients, for the next day following enrollment in the study for induction onto buprenorphine maintenance treatment.
89566120|NCT03098407|Other|Methadone Maintenance Treatment|Methadone Maintenance Treatment patients will be immediately admitted to Magee-Womens Hospital for an inpatient induction onto methadone maintenance treatment.
89566121|NCT05618405||Children who undergo anesthesia because of surgery|Children, aged between 1-11 years, who undergo general anesthesia because of surgery.
89566122|NCT05618405||Children who undergo anesthesia because of an MRI|Children, aged between 1-11 years, who undergo general anesthesia because of an MRI.
89566123|NCT01595555|No Intervention|Wait-list control|Group with no intervention. Only complete questionnaires at baseline, week 8 and 12 and activity logs through the first 8 weeks
89566124|NCT01595555|Experimental|Stress Free Now|Participate in the 8 week online stress management program Stress Free Now. Complete questionnaires at baseline, week 8 and 12 and activity logs through the first 8 weeks
89566125|NCT01595555|Experimental|Stress Free Now + Social Media|Participate in the 8-week Stress Free Now program and a discussion board that provides peer and moderator support. Complete questionnaires at baseline, week 8 and 12 and activity logs through the first 8 weeks
89566126|NCT05068453|Experimental|OH2+HX-008+RT|Patients will get OH2 （once every two weeks）and HX-008 (once every three weeks)and radiotherapy (totally 3 times).
88969034|NCT00054418|Placebo Comparator|calcium carbonate, vitamin D and placebo|Patients receive calcium carbonate 600 mg daily, vitamin D 400 U daily and placebo weekly.
88969035|NCT00054457|Experimental|docetaxel + capecitabine|"Patients receive docetaxel IV over 1 hour on day 1 and oral capecitabine twice daily on days 1-14. Courses repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed at baseline, at each tumor measurement, and at the end of treatment.~Patients are followed every 3 months until disease progression and then every 6 months until 3 years from registration."
88969036|NCT05615519||Eligible participants for smartphone-based strabismus measurement and diagnosis|Facial videos dataset Facial videos were collected using smartphone and following the programmatic cover tests.
88969037|NCT05556993||LGBTQIA+ Persons living with Parkinson's Disease|125 LGBTQIA+ persons living with Parkinson's Disease will be asked to do a 45-minute phone survey.
88969038|NCT05556993||Non- LGBTQIA+ Persons living with Parkinson's Disease|125 Non- LGBTQIA+ persons living with Parkinson's Disease will be asked to do a 45- minute phone survey.
88969039|NCT05556993||LGBTQIA+ caregivers of people living with Parkinson's Disease|125 LGBTQIA+ caregivers of people living with Parkinson's Disease will do a 45-minute phone survey.
88969040|NCT05556993||Non- LGBTQIA+ caregivers of people living with Parkinson's Disease|125 non- LGBTQIA+ caregivers of people living with Parkinson's Disease will do a 45-minute phone survey.
89566127|NCT00751075|Active Comparator|1|MFNS once daily
89566128|NCT00751075|Experimental|2|MFNS twice daily
89566129|NCT00751075|Active Comparator|3|Amoxicillin
89566130|NCT00751075|Placebo Comparator|4|Placebo
89566131|NCT00731185|Experimental|Mometasone Furoate Nasal Spray (MFNS)|MFNS 200 mcg (2 sprays of 50 mcg in each nostril) once daily in the morning
89566132|NCT00731185|Placebo Comparator|Placebo|Placebo nasal spray (2 sprays of 50 mcg in each nostril) once daily in the morning
89566133|NCT04836299|Experimental|Ivermectin|Participants will receive a single 600 µg / kg dose of ivermectin.
89566134|NCT04836299|Placebo Comparator|Placebo Comparator|Participants will receive a single dose of placebo.
89566135|NCT00651391|Experimental|Ezetimibe + Simvastatin|
89566136|NCT00651391|Active Comparator|Simvastatin|
89566137|NCT00651391|Placebo Comparator|Placebo|
89566138|NCT04823351|Other|FFP2 Mask|Universal FFP2-masking for every healthcare worker with patient contact, compared to selective FFP2-masking, which means that FFP2 masks are worn only during aerosol-generating procedures such as tube manipulation;
88969041|NCT05556993||Health care providers of people living with Parkinson's Disease|100 health care providers of people living with Parkinson's Disease will complete a 45-minute online survey.
89027840|NCT00486668|Experimental|Group 2: AC then paclitaxel + lapatinib|AC followed by paclitaxel plus lapatinib
89027841|NCT00486668|Experimental|Group 3: AC then paclitaxel + trastuzumab + lapatinib|AC followed by paclitaxel plus trastuzumab plus lapatinib
89566139|NCT04823351|Other|Surgical Mask|Universal surgical mask IIR type masking for healthcare workers in contact with COVID-19 patients.
89566140|NCT04434859||Patients with tinnitus|Patients (over 18 years old) seen at the medical center due to tinnitus, lasting at least 3 months.
89566141|NCT04823117||Music therapy group|Music therapy lasted 30 minutes every day for a total of 20 days.
89566142|NCT04823117||Control group|No treatment given.
89566143|NCT00650689|Experimental|Ezetimibe + Atorvastatin|
89566144|NCT00650689|Active Comparator|Atorvastatin|
89566145|NCT05067517|Active Comparator|Nintedanib|Nintedanib 150 mg administered PO twice daily
89566146|NCT05067517|Placebo Comparator|Placebo|Placebo administered PO twice daily
89566147|NCT05067361|Experimental|Experimental Group|
89566148|NCT05067361|Active Comparator|Active control Group|
89566149|NCT03100669||Pectus surgery|Single arm study: patient undergoing pectus repair surgery
89566150|NCT03100513|Active Comparator|Lactulose|(20 to 30 g administered orally or by nasogastric tube (3 or more doses within 24 hours) or 200 g by rectal tube if oral intake was not possible or inadequate.
89566151|NCT03100513|Active Comparator|Polyeyhylene Glychol|Polyethylene Glycol 3sachets if patient <75Kg over 3 hours or 4 sachets if patient >75Kg over 4 hours dministered orally or via a nasogastric tube (each sachet 64g/25Kg must be dissolved in one liter of water)
89566152|NCT05059561||Patients group|All patients who applied to the orthopedics and traumatology department between July 2017 and June 2018 for a medical board examination were evaluated by physical and radiological examination. According to the Cobb method, individuals with a Cobb angle greater than 10° were diagnosed with Idiopathic Scoliosis. All participants were evaluated by a senior psychiatrist. Before the interview, all subjects fully informed about the purpose and scope of the study. After their permission was obtained the study and control groups completed a socio-demographic data form consisting of questions about detailed personal and medical history and, the participants were asked to fill in the TCI.
89566153|NCT05059561||Control group|All patients who applied to the orthopedics and traumatology department between July 2017 and June 2018 for a medical board examination were evaluated by physical and radiological examination. Healthy individuals who applied for the same examination and met the inclusion criteria were determined as the control group by random sampling method. All participants were evaluated by a senior psychiatrist. Before the interview, all subjects fully informed about the purpose and scope of the study. After their permission was obtained the control group completed a socio-demographic data form consisting of questions about detailed personal and medical history and, the participants were asked to fill in the TCI.
89566154|NCT02530905|Placebo Comparator|Placebo (double-blind dose titration)|Participants with genotypically confirmed Duchenne muscular dystrophy (DMD) characterized by deletions amenable to exon 45 skipping will receive placebo-matching to casimersen intravenous (IV) infusions, once weekly over approximately 12 weeks in the double-blind period.
89566155|NCT02530905|Experimental|SRP-4045 (double-blind dose titration)|Participants with genotypically confirmed DMD characterized by deletions amenable to exon 45 skipping will receive weekly IV infusions of casimersen at four escalating dose levels, each for at least 2 weeks: 4 milligrams per kilograms (mg/kg) during Week 1 to Week 2, followed by 10 mg/kg during Week 3 to Week 4, followed by 20 mg/kg during Week 5 to Week 6, followed by 30 mg/kg beginning at Week 7 and continue over approximately Week 12 in the double-blind period.
89566156|NCT02530905|Experimental|SRP-4045 (open label extension period)|All participants who completed double blind period will be enrolled to receive casimersen 30 mg/kg once weekly, for up to Week 144 in the open label extension period.
89566157|NCT00552097|Experimental|EZ/Simva|
89566158|NCT00552097|Placebo Comparator|Placebo/Simva|
89566159|NCT05067049|Experimental|Connected EORTC-C30 arm (quality of life questionnaires on pad, phone,...)|The patients in this arm will have connected mobile app at home and they will regularly fill questionnaires. There are two different questionnaires : one with 14 questions about patient's quality of life and about the evolution of his surgical scar. One with 9 questions only about quality of life. They will also have meetings with physicians.
89566160|NCT05067049|Other|No QoL online follow-up arm|The patient haven't any questionnaires to fill at home. This is the normal management of the pathology. They only have different meeting with the specialist,as usual.
89566161|NCT02530671|Active Comparator|Manual toothbrush|ADA reference manual toothbrush
89566162|NCT02530671|Experimental|Power toothbrush|Multi-directional power toothbrush
89566163|NCT02603393|Experimental|QVA149|
89566164|NCT02603393|Active Comparator|Tiotropium + salmeterol/fluticasone|
89566165|NCT04832945||Ivermectin Group|Healthcare personnel receiving Ivermectin weekly PrEP
89566166|NCT04832945||Control Group|Healthcare personnel not receiving Ivermectin
89566167|NCT02642653|Active Comparator|Lovastatin and PILI|Subjects will receive the Parent Implemented Language Intervention (PILI) in combination with study medication Lovastatin.
89566168|NCT02642653|Placebo Comparator|Placebo and PILI|Subjects will receive the Parent Implemented Language Intervention (PILI) in combination with placebo.
89566169|NCT01659567||Chronic Hepatitis C|Participants with chronic hepatitis C, treated with pegylated interferon alfa-2a (Pegasys) and ribavirin (Copegus) according to the current standard of care and in line with current summaries of product characteristics/local labelling, will be observed for up to 96 weeks.
89566170|NCT04832633|Experimental|test bolus(TB) I|We use the TB method with biphasic injection, followed by the saline flush. Initially, we inject the 10 ml of test contrast media with a velocity of 3ml/s and apply the ROI at the bifurcation of PA and descending aorta at the same level. The dynamic curve demonstrates the time to peak enhancement of P second and A second. The first phase of contrast media injection uses a velocity of 2ml/s and the volume of contrast is measured as 2ml/s multiply (A-P) second. The second phase of contrast media injection uses a velocity of 3ml/s and the volume of contrast media is 70ml minus the amount of first phase injection. The total volume of the contrast media is 80ml, including the 10ml for pre-diagnostic test bolus images. We performed the saline flush following the administration of the contrast media with 20 ml normal saline. The start time of the diagnostic scan is at the A second.
89608809|NCT03586323|Placebo Comparator|S-SLNB|performed a superior laryngeal nerve block with saline
89027842|NCT04511598|Experimental|Bellus 3D Face Camera Pro|"Every single patient will be diagnosed using 3D imaging system Bellus 3D Face Camera Pro to be compared to the direct measurements obtained from direct anthropometry."
89027843|NCT04511598|Experimental|Planmeca ProMax 3D Proface|"Every single patient will be diagnosed using 3D imaging systems Planmeca ProMax 3D Proface to be compared to the direct measurements obtained from direct anthropometry."
89027844|NCT00486681||1|period I (warning of the Accu-Check Inform glucose meter on glucose levels not activated)
89027845|NCT00486681||2|period II (warning activated).
89027846|NCT00486707||Patients with ovarian cancer|
89027847|NCT04510935|Experimental|general anesthesia|Patients in this group will have RF ablation for treatment of HCC under general anesthesia.
89027848|NCT04510935|Active Comparator|local anesthesia|In this group, patients will receive radiofrequency ablation under local anesthesia.
89027849|NCT04510974||Cervical SCI|Ages between 21-70 years old Injured between C1-T1 Wheelchair dependent AIS classification of A, B or C Injury occurred more than 1 year ago
89027850|NCT04510974||Thoracic SCI|Ages between 21-70 Injured between T6-T12 Wheelchair dependent AIS classification of A, B or C Injury occurred more than 1 year ago
89027851|NCT04510974||Able-bodied Control|Ages between 21-70
89027852|NCT00486746|Experimental|Lifestyle intervention|
89027853|NCT00486746|Active Comparator|General health counseling|
89027854|NCT04510896|No Intervention|Pre-InheRET|Determine appropriate genetic counseling referral rates (as defined by NCCN guidelines) per patient (across all sites) in the pre-intervention 6-month period. Only referrals to Michigan Medicine (MM) genetics clinics will be included in the statistical analysis. Having access to MM health records, we will be able to assess the appropriateness of the referrals.
89566171|NCT04832633|Experimental|test bolus(TB) II|This group is similar to the TB I. However, we use the lesser contrast media in the second phase of injection. The second phase of contrast media injection is applied with a velocity of 3ml/s and the volume of the contrast media is 60ml minus the amount of first phase injection. The total volume of the contrast media is 70 ml, also including the 10ml for pre-diagnostic test bolus images. The following saline flush uses 30 ml of normal saline. The start time of the diagnostic scan is at the A second as well.
89566172|NCT04832633|Experimental|bolus-tracking(BT) I|Initially, 10ml of test contrast media was administrated but no calculation was performed for these pre-diagnostic test bolus images in this group. Unlike the TB method, we use 10 seconds as the fixed interval of (A-P) in this group. The first phase of contrast media injection uses a velocity of 2ml/s and thus the volume of contrast is 20ml. The second phase of contrast media injection is administered with a velocity of 3ml/s and the volume of the contrast media is 70ml minus 20ml. The total volume of the contrast media is 80 ml. The following saline flush uses 20 ml of normal saline. The tracking scan started after contrast injection was initiated for 15 seconds. The ROI is placed in the descending aorta at the same level of PA bifurcation and the diagnostic CT scan is triggered when the density in the ROI achieves the baseline density plus 150HU.
89566173|NCT04832633|Experimental|bolus-tracking(BT) II|This group is similar to the BT I. The first phase of injection is the same as the BT I group. We use lesser contrast media in the second phase of contrast injection. The second phase of contrast media injection is applied with a velocity of 3ml/s and the volume of the contrast media is 60ml minus 20ml. The total volume of the contrast media is 70 ml, including the 10ml for pre-diagnostic test bolus images. The following saline flush uses 30 ml of normal saline. The protocol for triggering diagnostic CT scan is the same as that in BT I.
89027855|NCT04510896|Experimental|Post-InheRET|Determine appropriate genetic counseling referral rates (as defined by NCCN guidelines) per patient (across all sites) in the post-intervention period. Only referrals to Michigan Medicine genetics clinics will be included in the statistical analysis. Having access to MM health records, we will be able to assess the appropriateness of the referrals.
89027856|NCT01301833|Experimental|teneligliptin|teneligliptin (20 mg once daily, titrated to 40 mg if no adequate efficacy is obtained )
89027857|NCT01301833|Experimental|teneligliptin and glinide|teneligliptin (20 mg once daily, titrated to 40 mg if no adequate efficacy is obtained ) plus glinide
89027858|NCT01301833|Experimental|teneligliptin and biguanide|teneligliptin (20 mg once daily, titrated to 40 mg if no adequate efficacy is obtained ) plus biguanide
89027859|NCT01301833|Experimental|teneligliptin and alpha-glucosidase inhibitor|teneligliptin (20 mg once daily, titrated to 40 mg if no adequate efficacy is obtained ) plus alpha-glucosidase inhibitor
89027860|NCT00486785|Experimental|1|
89027861|NCT04324411|Experimental|treatment group|combined sirolimus(serum concentration to be 4-10ng/ml) and ATRA (20mg bid) for at least 6 months
89027862|NCT04324489|Experimental|DAS181 Treatment|Nebulized DAS181 9mg/day (4.5 mg bid/day) for 10 days
89027863|NCT00486876|Placebo Comparator|1|Placebo
89027864|NCT00486876|Experimental|2|100 mg BID
89027865|NCT00486876|Experimental|3|200 mg BID
89027866|NCT00486876|Experimental|4|300 mg BID
89027867|NCT05643703|Experimental|One-layered Suture|One-layered Suture in transvaginal diverticulum resection
89027868|NCT05643703|Experimental|Two-layered Suture|Two-layered Suture in transvaginal diverticulum resection
89027869|NCT02890420||Female children|Female children in third year of preschool in Thionville (north-eastern France)
89027870|NCT02890420||Male children|Male children in third year of preschool in Thionville (north-eastern France)
89027871|NCT05643586|Experimental|Prasugrel Group|Patient treated with 60 mg prasugrel 12 hours before the procedure
89027872|NCT05643586|Experimental|Ticagrelor|Patient treated with 180 mg ticagrelor 12 hours before the procedure
89027873|NCT01242059|Experimental|Control Tomato Soup|
89027874|NCT01242059|Experimental|10 g of yellow pea fiber|
89027875|NCT01242059|Experimental|20 g of yellow pea fiber|
89027876|NCT01242059|Experimental|10 g of yellow pea protein|
89027877|NCT01242059|Experimental|20 g of yellow pea protein|
89027878|NCT01242072|Experimental|PaCE|Palifosfamide, Carboplatin and Etoposide
89027879|NCT01242098||Fostair switch cohort|Seretide patients who, at an index date, had a step down in therapy (reduction in ICS dose of ≥50%) and switch to Fostair
89027880|NCT01242098||Seretide continuation cohort|Seretide patients who, at an index date, had a step down in therapy (reduction in ICS dose of ≥50%) and continue on Seretide
89027881|NCT01301092|Experimental|Part A: LY2189265 intravenous|Single intravenous (IV) dose, starting at 0.1 milligrams (mg) of LY2189265. Dose may be increased to 0.2 mg or decreased to 0.05 mg for subsequent patients, dependent on safety assessments of the first 3 patients.
89027882|NCT01301092|Experimental|Part B: LY2189265 subcutaneous, intravenous|Patients are randomized to 2 sequences of 2 treatments. Single 1.5 mg subcutaneous (SC) dose of LY2189265 in Period 1; single intravenous (IV) dose of LY2189265 (determined by Part A IV arm data) in Period 2 or vice versa. There is a washout period of at least 4 weeks between dosing periods.
89027883|NCT01301092|Experimental|Part C: LY2189265 subcutaneous, intramuscular|Patients are randomized to 2 sequences of 2 treatments. Single 0.75 mg subcutaneous (SC) dose of LY2189265 in Period 1; single 0.75 mg intramuscular (IM) of LY2189265 in Period 2 or vice versa. There is a washout period of at least 4 weeks between dosing periods.
89027884|NCT01242150|Experimental|NCPAP Helmet|Infants with mild Acute Respiratory Failure who need NCPAP
89027885|NCT01242150|Active Comparator|NCPAP facial mask|Infants with mild Acute Respiratory failure who need NCPAP
89566174|NCT04835909|Experimental|Behavioral: modern board and card games|Participants will play modern board and card games in groups at medical center 2 times per week for at least 1 hour over a period of 16 weeks.
89566175|NCT04835909|Active Comparator|Behavioral: paper and pencil tasks|Participants will do cognitive paper and pencil tasks in groups at medical center 2 times per week for at least 1 hour over a period of 16 weeks.
89566176|NCT04835909|No Intervention|Wait-list|Participants will be in a wait-list over a period of 16 weeks. Then, they received the board and card games' or paper and pencil tasks' intervention.
89566177|NCT05032729|Placebo Comparator|Placebo beverage|"Flavor~Non-nutritive sweetener~Color added to match whey appearance"
89566178|NCT05032729|Experimental|Higher tryptophan beverage|"2.7g high Glycemic Index Carbohydrate~40g whey~0.855g tryptophan~660mg theanine~53mcg 5'AMP~Non-nutritive sweetener~Flavor"
89566179|NCT05032729|Experimental|Lower tryptophan beverage|"2.7g high Glycemic Index Carbohydrate~30g whey~0.641g tryptophan~660mg theanine~53mcg 5'AMP~Non-nutritive sweetener~Flavor"
89566180|NCT04835753|Experimental|study group|received the traditional physical therapy program as muscle stretching and strengthening and neurodevelopmental techniques, proprioceptive training, and balance and gait training plus shock wave on the muscle belly of the planter flexor hypertonic muscles.
89566181|NCT04835753|Other|control group|received the traditional physical therapy program as muscle stretching and strengthening and neurodevelopmental techniques, proprioceptive training, and balance and gait training .these traditional therapy had been approved by previous studies its effectiveness in management cerebral palsy child
89566182|NCT05059171|Active Comparator|Rotary motion using OneShape single file|File size 25 with a taper of 0.06 was mounted to a 6:1 speed-reduction headpiece powered by X Smart Plus endomotor (Dentsply Maillefer, Ballaigues, Switzerland). The speed and torque were set to 400 rpm and 1 N.cm torque, respectively. In a picking motion without pressure, mechanical preparation began with the first RC two-thirds followed by the next 3 mm followed by the full WL.
89566183|NCT05059171|Active Comparator|Reciprocating motion using WaveOne Gold single file|A Primary file size 25 a taper of 0.07 was installed to pre-programmed reciprocation angles and speed for the WaveOne system handpiece of an endomotor (X Smart Plus endomotor (Dentsply Maillefer, Ballaigues, Switzerland). After ensuring a passive fit of the hand file along the predetermined WL, the RC coronal two-thirds was initially instrumented then followed by the full WL.
89566184|NCT04822805|Experimental|Treatment with Anlotinib|Patients with recurrent high-grade gliomas are being enrolled , treated with anlotinib 12mg once daily for 14 days every 3 weeks until disease progression or unacceptable toxicity.The dose can be adjusted to 10mg or 8mg according to the specific conditions of the patient.
89566185|NCT05059249|Experimental|Manual Traction|Moist heat packs & TENS for ten minutes followed by Manual Traction and 3 sets of slow gentle segmental mobilizations (unilateral and posterior-anterior) with at least 10 to 15 repetitions firstly but modified as per the response of the patient.
89027886|NCT05643157||toxic maculopathy|Subjects with a history of 5+ years of Pentosan Polysulfate sodium use and with retinal findings associated with Pentosan polysulfate sodium toxicity on fundus exam
89027887|NCT01242137||Extensive metabolizers|
89027888|NCT01242137||Intermediate mtabolizers|
89027889|NCT01242137||Poor metabolizers|
89027890|NCT04510623||COVID-19 Patients on ARBs|This is an observational cohort study. Those who have COVID-19 in hospital and are on Angiotensin Receptor Blockers will be included in this cohort.
89027891|NCT04510623||COVID-19 Patients on ACE inhibitors|This is an observational cohort study. Those who have COVID-19 in hospital and are on Angiotensin-Converting Enzyme inhibitors will be included in this cohort.
89027892|NCT04510623||COVID-19 Patients on ARBs or ACE inhibitors|This is an observational cohort study. Those who have COVID-19 in hospital and are on ARBs or ACEi's will be included in this cohort.
89027893|NCT04510623||COVID-19 Patients not on ARBs or ACE inhibitors|This is an observational cohort study. Those who have COVID-19 in hospital and are not on ARBs or ACEi's will be included in this cohort.
89027894|NCT05643040|Experimental|femoral nerve block|To evaluate the intraoperative analgesia effectiveness of femoral nerve block in patients who will have knee surgery.
89027895|NCT05643040|Experimental|adductor canal block|To evaluate the intraoperative analgesia effectiveness of adductor canal block in patients who will have knee surgery.
89566186|NCT05059249|Experimental|Mechanical traction|Moist heat packs & TENS for ten minutes followed by Mechanical Traction and 3 sets of slow gentle segmental mobilizations (unilateral and posterior-anterior) with at least 10 to 15 repetitions firstly but modified as per the response of the patient
89566187|NCT04095637|Experimental|Mako medial UKA|Mako medial unicondylar knee arthroplasty
89027896|NCT05643040|Experimental|4in1 block|To evaluate the intraoperative analgesia effectiveness of 4in1 block in patients who will have knee surgery.
89027897|NCT05367622|Experimental|Continuous glucose monitoring group|Self-regulation model of health education will be given for 1-1.5 hrs and telecommunication 10 to 15 minutes for 7 days
89027898|NCT05367622|Placebo Comparator|Self-monitoring of blood glucose group|Usual diabetes health education will be given for 1 hr.
89027899|NCT02274350||radiation therapy|Patients treated with either external beam radiation therapy or brachie therapy for localized prostate cancer
89027900|NCT04510818|Experimental|Experimental|Capecitabine 500mg bid. po. Camrelizumab 200mg ivgtt. d1 q2w
89027901|NCT00623584|Experimental|1|Patients in this arm randomly receive a corneal graft cultured in a serum free culture medium
89027902|NCT00623584|Active Comparator|2|Patients in this arm randomly receive a corneal graft cultured in a serum supplemented culture medium
89027903|NCT01243307|Experimental|CT327 treatment period 1|Subjects in Group 1 will receive CT327 during treatment/testing period 1 and placebo during treatment/testing period 2
89027904|NCT01243307|Experimental|CT327 treatment period 2|Subjects in Group 2 will receive placebo during treatment/testing period 1 and CT327 during treatment/testing period 2
89027905|NCT05642689|Other|1|Comparison of iron absorption from FAP to Ferrous sulfate in milk
89027906|NCT05642689|Other|2|Comparison of iron absorption from ferric pyrophosphate to Ferrous sulfate in milk
89027907|NCT00486915|Active Comparator|Left Atrial Appendage Exclusion|
89027908|NCT00486915|No Intervention|Control|
89027909|NCT01243502|Experimental|0.01% CT327 (or placebo)|Six (of eight) subjects received a single topical dose of 0.01% CT327 followed by a 7 day wash-out period. The subjects then received a single topical dose of CT327 on five consecutive days. Two subjects received placebo.
89027910|NCT01243502|Experimental|0.001% CT327 (or placebo)|Six (of eight) subjects received a single topical dose of 0.001% CT327 followed by a 7 day wash-out period. The subjects then received a single topical dose of CT327 on five consecutive days. Two subjects received placebo.
89027911|NCT01300819|Placebo Comparator|Placebo|
89027912|NCT01300819|Experimental|Rotigotine|
89027913|NCT00486993||asuriesgo|unselected outpatient population
89027914|NCT00487019||1|Neonates aged <72 h and needing antibacterial therapy for early onset neonatal sepsis
89027915|NCT00487019||2|Same as group 1
89027916|NCT01300741|Experimental|Lotrafilcon B|Lotrafilcon B commercially marketed contact lens randomly assigned to one eye, with galyfilcon A commercially marketed contact lens in the fellow eye for contralateral wear. Lenses were worn for approximately 5 days or more per week, at least 10 hours per day, for up to 4 weeks in a daily wear (DW modality).
89027917|NCT01300741|Active Comparator|Galyfilcon A|Galyfilcon A commercially marketed contact lens randomly assigned to one eye, with lotrafilcon B commercially marketed contact lens in the fellow eye for contralateral wear. Lenses were worn for approximately 5 days or more per week, at least 10 hours per day, for up to 4 weeks in a daily wear (DW modality).
89027918|NCT02275962|Experimental|K-877|K-877
89027919|NCT02275962|Experimental|K-877 with Rifampin|K-877 with Rifampin
89027920|NCT00487032|Experimental|1|Prazosin 1mg challenge to block alpha 1 adrenoreceptors
89027921|NCT00487032|Placebo Comparator|2|Placebo to Prazosin
89027922|NCT00491426||<26 weeks|Subjects <26 weeks gestational age
89027923|NCT00491426||26-29 weeks|Subjects 26-29 weeks gestational age
89027924|NCT00491426||30-32 weeks|Subjects 30-32 weeks gestational age
89027925|NCT05642338||cohort 1 dysplastic cohort|208 BE patients referred for work up after diagnosis of LGD, HGD or earlystage cancer in the last 18 months.
89027926|NCT05642338||Cohort 2: non-dysplastic cohort|208 patients under standard BE surveillance without a diagnosis of dysplasia in last 18 months.
89027927|NCT05642299|Experimental|MBCI-SR|BCI based robotic rehabilitation works by detecting the motor intent of the user from Electroencephalogram signals to drive rehabilitation assisted by the soft robotics gloves.
89027928|NCT02274363||Brazilian Participants with Chronic Plaque-type Psoriasis|Brazilian participants with plaque psoriasis followed up at teaching and non-teaching specialized dermatology centers will be included in this study.
89027929|NCT00487097|Experimental|Study Group|Enteral Nutrition with Omega 3 (Eicosapentanoic acid, docosahexaenoic acid)
89027930|NCT00487097|No Intervention|Control Group|Patients in control group will receive nutritional support composed of a standard formula
89027931|NCT01300546|Active Comparator|Sumatriptan/Naproxen Sodium|In Treatment Period, subjects randomized to Sumatriptan/Naproxen Sodium will be provided with 14 tablets of Sumatriptan/Naproxen Sodium to treat migraine within 1 hour of onset on 14 or fewer days per month. Subjects will be provided with 14 tablets of Sumatriptan/Naproxen Sodium per month for rescue of persistent or recurring headache.
89027932|NCT01300546|Active Comparator|Naproxen Sodium|In Treatment Period, subjects randomized to Naproxen Sodium 500mg will be provided with 14 tablets of Naproxen Sodium to treat migraine within 1 hour of onset on 14 or fewer days per month. Subjects will be provided with 14 tablets of Naproxen Sodium per month for rescue of persistent or recurring headache.
89027933|NCT00487071|Experimental|Anal fistula plug|
89027934|NCT05642104||Single group assignment|Patients with invasive breast cancer who need neoadjuvant therapy.
89027935|NCT00487136|Active Comparator|Warfarin|Warfarin fixed dose plus one capsule containing placebo for ABT-335, one placebo tablet to match rosuvastatin 5 mg and one placebo tablet to match rosuvastatin 20 mg, administered for 10 consecutive days.
89027936|NCT00487136|Experimental|Warfarin plus ABT-335 plus Rosuvastatin|Warfarin fixed dose plus one capsule containing ABT-335 mini-tablets equivalent to 135 mg fenofibric acid, one 5 mg tablet of rosuvastatin and one tablet of placebo to match rosuvastatin 20 mg, administered for 10 consecutive days.
89566188|NCT04095637|Active Comparator|Oxford media UKA|Oxford unicompartmental knee arthroplasty with navigation control
89566189|NCT04832555|Experimental|Open: non elective irradiation|Patients within inclusion criteria will be enrolled in the experimental treatment: a radiation therapy addressed to non elective site of disease and with a simultaneous integrated boost
89566190|NCT04832789|No Intervention|Best conventional ventilation|
89566191|NCT04832789|Experimental|Ultra-protective ventilation with ECMO|
89566192|NCT05066893|Active Comparator|standard of care|standard of care will be given as per usual care
89566193|NCT05066893|Experimental|intensive monitoring|intensive monitoring every week will be given to participants
89566194|NCT04832711||the low-risk group for OSA|A Chinese translation of the BQ was used to classify subjects into high risk and low risk for OSA.
89566195|NCT04832711||the high-risk group for OSA|A Chinese translation of the BQ was used to classify subjects into high risk and low risk for OSA.
89566196|NCT04435093||MFM completion|
89566197|NCT03100435|Experimental|Er:YAG Laser|Er:YAG Laser only
89566198|NCT03100435|Active Comparator|Carbon Fiber Curette|Carbon fiber curette only
89566199|NCT03100435|Experimental|Er:YAG Laser + Carbon Fiber Curette|Combination of Er:YAG Laser and carbon fiber curette
89566200|NCT03100435|No Intervention|No Treatment|No treatment (control)
89566201|NCT03036995|Experimental|Apremilast - Group A|Patient will receive narrow UVB treatment and apremilast (2 tablets for day) during 24 weeks. If the patient is responder (response is defined as an increase of at least 30 % in the VASI score at W24 compare to Baseline), he will receive narrow UVB treatment according the and apremilast during 24 weeks.
89566202|NCT03036995|Placebo Comparator|Placebo - Group B|Patient will receive UVB treatment and placebo (2 tablets for day) during 24 weeks. If the patient is responder (response is defined as an increase of at least 30 % in the VASI score at W24 compare to Baseline), he will receive narrow UVB treatment and placebo during 24 weeks.
88969042|NCT05612243|Experimental|Yogurt enriched with probiotics and polyphenols|Participants will consume a meal including 200g of yogurt containing Lacticaseibacillus rhamnosus probiotics (3*10^9 cfu/g) immobilized on oat flakes (1g) and polyphenol-rich lyophilized extract (250mg) of Cistus Albidus (77,3 mg GAE/g), as well as two slices of white bread (80g) with butter (30g)
88969043|NCT05612243|Active Comparator|Yogurt enriched with probiotics|Participants will consume a meal including 200g of yogurt containing Lacticaseibacillus rhamnosus probiotics (3*10^9 cfu/g) immobilized on oat flakes (1g), as well as two slices of white bread (80g) with butter (30g)
88969044|NCT05612243|Placebo Comparator|Plain yogurt with oat flakes|Participants will consume a meal including 200g of plain yogurt containing oat flakes (1g), as well as two slices of white bread (80g) with butter (30g)
88969045|NCT05609591|Experimental|Liquid diet group|From 8:00 on the day before colonoscopy, oral fluids including juice, rice soup, filtered vegetable juice/broth, lotus root powder and milk and egg soup were taken to ensure energy intake and blood glucose stability. The fasting starts at 9:00 AM on the day of colonoscopy.
88969046|NCT05609591|Experimental|Enteral nutrition group|Oral administration of 100% short peptide enteral nutrition preparation from 8:00 on the day before colonoscopy. The fasting starts at 9:00 AM on the day of colonoscopy.
88969047|NCT05609591|Experimental|Low residual diet group|From 8:00 on the day before colonoscopy, the patients were given oral administration of less residue food included gruel with grain only, peeled carrot, white gourd, powdered skin, tofu, vegetable, mud and fruit. The fasting starts at 9:00 AM on the day of colonoscopy.
88969048|NCT00054925|Active Comparator|Personal contact (PC)|The Personal Contact (PC) intervention offers one-on-one guidance and support in maintaining weight loss.
88969049|NCT00054925|Active Comparator|Interactive technology (IT)|Utilizes internet and automated phone technology to enhance the frequency and timeliness of feedback.
88969050|NCT05545878|Experimental|Intervention: Super enhanced single vision lens 01 for spectacles|Participants in the intervention group will wear the newly designed SESL01 lens with anti-reflection coating. Participants will be asked to wear their spectacles for all daily tasks as normal including when looking at digital screens and near tasks.
88969051|NCT05545878|No Intervention|Control: Standard single vision lenses with an anti-reflection coating|Participants in the control group will be corrected with standard single vision lenses with an anti-reflection coating. Participants will be asked to wear their spectacles for all daily tasks as normal including when looking at digital screens and near tasks.
88969052|NCT02970097|Active Comparator|single shot IBP block|Subjects will receive single shot infraclavicular brachial plexus block with 20ml bolus of 0.5% ropivicaine given preoperatively to help with operative and postoperative pain
88969053|NCT02970097|Active Comparator|local infiltration|Subjects will receive local infiltration into portal space and joint space with 10ml of 0.5% ropivicaine given intraoperatively to help with operative and postoperative pain
89566203|NCT03100279|Experimental|CBT for Anxiety or Depression|If a youth meets criteria for a primary diagnosis of clinical or subclinical depressive disorder she or he will be assigned to Primary and Secondary Control Enhancement Therapy (PASCET; Weisz et al., 1987). If a youth meets criteria for a primary diagnosis for a clinical or subclinical anxiety disorder, she or he will be assigned to the Coping Cat (Kendall, 2000). Both CBT treatments include a therapist manual and companion workbooks for the youth. CBT teaches coping skills that help anxious and depressed youth challenge anxious and depressive thinking. It also helps the child habituate to negative physiological feelings and learn skills to cope with emotional distress.
89566204|NCT04835051|Other|Breastfeeding promotion|The breastfeeding promotion intervention included training for health workers, interpersonal communication (in person and digital) between providers and pregnant/breastfeeding women, and mass media.
89566205|NCT04835051|No Intervention|Comparison|
89566206|NCT04001101|Active Comparator|RT and Anti-PD-1|"In the pembrolizumab + RT arm, pembrolizumab will be started on study within 7 days (+/- 7 days) of start of RT.~Pembrolizumab will be given as standard of care in both arms"
89566207|NCT04001101|Placebo Comparator|Anti-PD-1|anti-PD-1 therapy alone Pembrolizumab will be given as standard of care in both arms
89566208|NCT04834895|Active Comparator|mhealth exercise group|home exercise program is given to patients via mobile application
89566209|NCT04834895|Experimental|brochure exercise group|home exercise program is given to patients via brochure
89566210|NCT05066425|Experimental|Soluble Corn Fiber|22g Soluble Corn Fiber/day for 4 weeks
89027937|NCT00487136|Experimental|Warfarin plus ABT-335 mg plus rosuvastatin 20 mg|Warfarin fixed dose plus one capsule containing ABT-335 mini-tablets equivalent to 135 mg fenofibric acid, one tablet of placebo to match rosuvastatin 5 mg and one 20 mg tablet of rosuvastatin, administered for 10 consecutive days.
89566211|NCT05066425|Placebo Comparator|Maltodextrin|22g Maltodextrin/day for 4 weeks
89566212|NCT04832243|Experimental|Experimental: V1: List No. 1|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. The first version of the questionnaire includes 6 sets of 3 true-false statements that are innocuous and contextually applicable (e.g., weather, cultural norms) such that there is a low likelihood that the participant will answer untruthfully. The statements on food and water insecurity that are included in the experimental version are omitted."
89566213|NCT04832243|Experimental|Experimental: V2: List No. 2|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. The second version of the questionnaire includes 6 sets of 4 true-false statements that are innocuous and contextually applicable (e.g., weather, cultural norms) such that there is a low likelihood that the participant will answer untruthfully for 3 of the true-false statements. One statement in each set relates to food and water insecurity and is designed to determine the extent to which social desirability bias may influence responses to food and water insecurity questions."
89566214|NCT04831931|Experimental|Supervised Exercise Group|"Telerehabilitation will be applied in this group, which will last 4 weeks, and include the following processes~Exercises that will be performed every Monday will be taught and applied face-to-face under the supervision of the therapist with online videoconferencing method. Then, videos of weekly exercises that will be prepared by the therapist will be transmitted online to patients.~Patients will be asked to perform these exercises 4 days a week in the same week, on Wednesdays, Fridays and Sundays.~Also, a video call will be made on Fridays to evaluate whether the movements are done effectively and correctly, and questions of patients (if any) will be answered.~Patients will be informed by the physiotherapist that they should send messages on Wednesdays and Sundays to show that they are doing the exercises.~The exercise program of new week will be taught every Monday for 4 weeks, the prepared video will be sent, and the program will be advanced and completed."
89566215|NCT04831931|Active Comparator|Exercise Group|Exercise recommendations will be made to this group. Videos and photographs of weekly exercises prepared by the therapist will be sent online to the patient every Monday for 4 weeks, patients will be advised to repeat these exercises 4 days a week.
89566216|NCT04831931|No Intervention|Control Group|No exercise application will be done in this group.Evaluation tests will be applied for 4 weeks only online.
89566217|NCT05066035|Active Comparator|Neostigmine|"The Group N (Neostigmine) (n=48), patients received standard intravenous neostigmine 0.05 mg/kg and atropine 0.02 mg/kg doses before extubation.~A train-of-four (TOF) count of 2 in TOF Watch monitoring provides information of a shallow neuromuscular block. If at least two twitches are on the TOF watch monitor, the study investigators administer reversal medication for neuromuscular blockade in both groups. At this point, depending on randomization, a reversal agent is administered for each randomized group by an anesthesia resident or nurse who is blinded to the study protocol. The study investigators record the recovery periods between the start of administering the reversal agent to the recovery of TOF ratio < 0.9 to 0.7 and TOF ratio ≥ 0.9 if it occurs. These time periods are in minutes."
89566218|NCT05066035|Active Comparator|Neostigmine and Sugammadex|"In Group N+S (Neostigmine+Sugammadex) (n=50), patients received standard intravenous neostigmine 0.05 mg/kg and atropine 0.02 mg/kg doses before extubation. After a three-minute waiting period, the study investigators administered an intravenous bolus half-dose of 1 mg/kg of sugammadex after the standard reversal dose.~A train-of-four (TOF) count of 2 in TOF Watch monitoring provides information of a shallow neuromuscular block. If at least two twitches are on the TOF watch monitor, the study investigators administer reversal medication for neuromuscular blockade in both groups. At this point, depending on randomization, a reversal agent is administered for each randomized group by an anesthesia resident or nurse who is blinded to the study protocol. The study investigators record the recovery periods between the start of administering the reversal agent to the recovery of TOF ratio < 0.9 to 0.7 and TOF ratio ≥ 0.9 if it occurs. These time periods are in minutes."
89566219|NCT04428593|Experimental|Treamid 5 mg|Cohort 1 - 5 subjects were randomized in a 4:1 ratio to be treated either Treamid 5 mg (4 subjects) or placebo (1 subject, see placebo arm).
89566220|NCT04428593|Experimental|Treamid 15 mg|Cohort 2 - 5 subjects were randomized in a 4:1 ratio to be treated either Treamid 15 mg (4 subjects) or placebo (1 subject, see placebo arm).
89566221|NCT04428593|Experimental|Treamid 50 mg|Cohort 3 - 5 subjects were randomized in a 8:2 ratio to be treated either Treamid 50 mg (8 subjects) or placebo (2 subjects, see placebo arm).
89566222|NCT04428593|Placebo Comparator|Placebo|Placebo comparator arm consists of 4 subjects (1 subject from Сohorts 1 and 2, 2 subjects from Cohort 3).
89566223|NCT03852667|No Intervention|Control|No intervention between the two test sessions
89566224|NCT03852667|Active Comparator|Pain Neuroscience Education|Two sessions (30 min) of Pain Neuroscience Education
89566225|NCT03852667|Experimental|Pain neuroscience education - exercise|2 sessions of PNE and 5 sessions of exercise therapy.
89566226|NCT03753373|Experimental|Acupuncture and Home Exercise|Acupuncture plus the prescribed home exercise program
89566227|NCT03753373|Active Comparator|Home Exercise Only|The prescribed home exercise program alone
89566228|NCT04831853|Experimental|Supervised self-swabbing followed by conventional swabbing|the subjects will first benefit from a 5 minutes explanation on how to perform self-swabbing and will then performed the swabbing under the supervision of a trained healthcare professional
89027938|NCT02276001|Experimental|K-877|K-877
89027939|NCT02276001|Experimental|K-877 with Cyclosporine|K-877 with Cyclosporine
89027940|NCT02276118|Experimental|e.motion PS Pro group|the patients who receives total knee arthroplasty with the e.motion PS pro prosthesis
89566229|NCT04831853|Experimental|Conventional swabbing followed by supervised self-swabbing|the subject will undergo conventional nasopharyngeal swabbing performed by a trained healthcare professional first.
89566230|NCT05058625|Experimental|Needly Group|Once the trigger point has been identified, we will use the Hong tecnique looking for a local spasm response
89208592|NCT00615030|Experimental|Placebo, Indacaterol Evening, Indacaterol Morning|In period, during morning and evening, placebo matching indacaterol was delivered via SDDPI and placebo matching salmeterol was delivered via DPI. In period II, patients were instructed to take morning doses of a placebo to indacaterol delivered via SDDPI and placebo to salmeterol delivered via DPI. Indacaterol 300 μg once a day in the evening delivered via SDDPI with placebo to salmeterol delivered via DPI. In period III, indacaterol 300 μg once a day in the morning delivered via SDDPI with a placebo to salmeterol delivered via DPI. Patients were also instructed to take evening doses of a placebo to indacaterol via SDDPI and placebo to salmeterol via DPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
89566231|NCT05058625|Active Comparator|Control Group|Normal volleyball training
89566232|NCT04831463|Experimental|experimental group|The experimental (N = 49) received a short-term IHAPIM program by one-on-one interview (5 week, 1 hr per week, 10 hr in total).
89566233|NCT04831463|No Intervention|control group|Firstly, Pre-tests were applied to the men in the control group. No intervention was applied to this group. Post-tests were made 3 months after finished intervention which applied to experimental group.
89566234|NCT03099811|Experimental|Intervention: Financial incentives + Smoking cessation program|Caregiver and a social network member will receive financial incentives, in additional to enrollment in a state-sponsored smoking cessation program, based on nicotine biomarker measurements.
89566235|NCT03099811|Other|Intervention: Smoking cessation program|Caregiver and a social network member will be enrolled in a state-sponsored smoking cessation program.
88969054|NCT05539287|Placebo Comparator|Control group|25 patients will receive standard antiepileptic drug plus placebo capsules for 6 months.
88969055|NCT05539287|Experimental|Probiotic Group|25 patients will receive Lactobacillus species 5 billion colony forming unit (CFU) 2 capsules daily together with their standard antiepileptic drug for 6 months.
88969056|NCT00398281|Experimental|Arm I|Patients receive oral dutasteride once daily on days 1-14.
88969057|NCT00398281|Placebo Comparator|Arm II|Patients receive oral placebo once daily on days 1-14.
88969058|NCT00398359|Experimental|1|
88969059|NCT05525325|Active Comparator|General Anesthesia Group|Patients randomized to the GA arm are intubated after anesthetic induction.
88969060|NCT05525325|Experimental|Procedural Sedation Group|After randomization into the PS arm, the need for analgesics or sedatives are evaluated clinically.
88969061|NCT00055315|Active Comparator|STEPPS|Patients with Borderline Personality Disorder. Each subject met DSM-IV criteria for BPD, confirmed through a clinical interview and a review of the patient's case notes
88969062|NCT00055315|Placebo Comparator|Treatment as Usual|"Patients with Borderline Personality Disorder. Each subject met DSM-IV criteria for BPD, confirmed through a clinical interview and a review of the patient's case notes.~TAU for this BPD population includes medical management, group and individual therapy."
88969063|NCT00055393|Active Comparator|Subjects receivng Bupropion|The active arm subjects in this study (n = 18) received flexibly dosed bupropion in this randomized 12-week double-blind trial.
88969064|NCT00055393|Placebo Comparator|Subjects receiving Placebo|The inactive arm subjects in this randomly controlled study (n = 21) received a placebo.
88969065|NCT00055861|Experimental|Treatment (bevacizumab, docetaxel)|Patients receive bevacizumab IV over 30-90 minutes on weeks 1 and 3 and docetaxel IV over 60 minutes on weeks 1, 2, and 3. Treatment repeats every 4 weeks for up to 12 courses in the absence of unacceptable toxicity or disease progression.
88969066|NCT05596292|Experimental|early mobilization protocol and immersive virtual reality|Three days of an early mobilization protocol using immersive virtual reality glasses. The exercises will be progressed every day, starting in the first day with active movements of lower and upper limbs with cycle ergometer; in the second day repeat the first day exercise and do orthostasis training; and in the last day training ambulation. The immersive virtual reality glasses support a smartphone device, allowing videos to be used with 360º rotation and earpods headphones with bluetooth for sound. Video options will be offered to participants according to the exercise performed, ie: a cycling video for activities with a cycle ergometer; video with people walking for ambulation; and videos of the patient's choice, such as forest, beach or city scenarios, for other moments.
88969067|NCT05596292|Active Comparator|early mobilization protocol|Three days of an early mobilization protocol. The exercises will be progressed every day, starting in the first day with active movements of lower and upper limbs with cycle ergometer; in the second day repeat the first day exercise and do orthostasis training; and in the last day training ambulation.
89566236|NCT03722095|Active Comparator|active tDCS + active iTBS|Participants will receive 20 minutes of active tDCS, during the last 7 minutes active iTBS will be applied.
89566237|NCT03722095|Sham Comparator|sham tDCS + active iTBS|Participants will receive 20 minutes of sham tDCS, during the last 7 minutes active iTBS will be applied.
89566238|NCT04822415|Experimental|Mepivacaine|IANB using 3.6 ml of 2% mepivacaine hydrochloride with 1:100,000 epinephrine.
89566239|NCT04822415|Active Comparator|Articaine|IANB using 3.4 ml of 4% articaine hydrochloride with 1:100,000 epinephrine.
89566240|NCT03661333|Experimental|Adolescents with bipolar disorder|40 adolescents aged 13 to 19 with bipolar disorder (type I, type II, not otherwise specified/nos) will be enrolled in the dialectical behavioral therapy intervention.
89566241|NCT05065177|Experimental|Experimental Group|"Single intramuscular injection of the investigational vaccine (0.5 ml) on Day 0;~Intervention: investigational live attenuated mumps vaccine;"
89566242|NCT05065177|Active Comparator|Control Group|"Single intramuscular injection of the control vaccine (0.5 ml) on Day 0;~Intervention: control live attenuated mumps vaccine;"
89566243|NCT04821947|Active Comparator|RIB Group|Drug: Bupivacaine 0.25% patients will receive 20 ml of bupivacaine 0.25% in the rhomboid plane under rhomboid major muscle
89566244|NCT04821947|Active Comparator|LA Group|Drug: Bupivacaine 0.25% patients will receive wound infiltration of VATS incision, single-incision with 10mL 0.25% bupivacaine double-incision with 15 mL (10mL+5mL) 0.25% bupivacaine three-port strategy with 17 mL (10mL+5mL+2mL) 0.25% bupivacaine .
89566245|NCT03037073|Active Comparator|Group D|35 patients will receive duloxetine (Cymbalta; Eli Lilly & Company, Indiana, USA) 30 mg orally with sips of water, 2 h before induction of anesthesia.
89566246|NCT03037073|Active Comparator|Group C|35 patients will receive similar-looking placebo capsules (starch capsules) orally with sips of water, 2 h before induction of anesthesia.
89566247|NCT03099421|Experimental|Prostatic Artery Embolization|Embolization of the prostatic arteries to induce necrosis and a reduction of the prostate volume.
89566248|NCT04834739|Active Comparator|Study group (30 volunteer healthcare workers who had Covid-19|30 volunteer healthcare workers who had Covid-19 and stayed in hospital or at home were included.
89566249|NCT04834739|Active Comparator|Control group (30 volunteer healthcare workers who had not have Covid-19)|In control group, 30 volunteer healthcare workers who were matched for age ande gender with study group were included and these persons had not have Covid-19.
89566250|NCT05058235|Experimental|Active Release Technique|Hot pack, TENS, Quadriceps Isometric strengthening, Active Release Technique
89566251|NCT05058235|Active Comparator|Bent leg raise|Hot pack, TENS, Quadriceps Isometric strengthening, Bent leg raise
89566252|NCT03100201|Active Comparator|Intervention Armeo®Spring|The intervention group will receive conventional occupational- and physiotherapy and an additive robotic-assisted training using the Armeo®Spring robot for three weeks.
89566253|NCT03100201|Active Comparator|Control group|The control group will receive conventional occupational- and physiotherapy.
89566254|NCT03099343|Experimental|Location-based Tailored Messaging|Participants receive location-based tailored messaging via a mobile application throughout the 8-week research study.
89566255|NCT03099343|No Intervention|Control Group|Participants follow their usual eating pattern and will not have access to the application throughout the 8-week research study.
89566256|NCT05005039||Obese postmenopausal women who will undergo RYGB|
88969068|NCT00392106|Active Comparator|Control|Class I or III anti-arrhythmic drug for the treatment of AF
89566257|NCT05005039||Obese postmenopausal women who will undergo SG|
89566258|NCT05058079|Active Comparator|Hand-held group|Patients hand will be held by the anesthesia provider during the procedure. A folded blanket will be over the patient's hand during the procedure and the anesthesia provider will have their hand under the folded blanket holding the patient's hand.
89566259|NCT05058079|No Intervention|No hand holding group|No physical contact for comfort or reassurance during the procedure. A folded blanket will be over the patient's hand during the procedure and the anesthesia provider will be next to the patient's hand.
89566260|NCT03423589|Experimental|VSL#3|Participants will be given the probiotic supplement VSL#3, a commercially available product. VSL#3 is taken by mouth, either once or twice daily, and is dispensed in sachets, each containing 450 billion colony forming units of bacterial strains. Participants will undergo a screening visit. They will be asked to provide a stool sample by the next visit. Within 3 weeks they will return with a stool sample and receive the VSL#3 sachets as well as another stool collection kit. After 6 weeks of taking VSL#3, they will return for their final visit, with their stool sample. Blood will be drawn at the second and third visits.
88969069|NCT00392106|Experimental|Treatment|Pulmonary vein ablation with HIFU
88969070|NCT00055978|Experimental|Arm I|Patients receive oral placebo twice daily for 6 months.
88969071|NCT00055978|Experimental|Arm II|Patients receive oral celecoxib twice daily for 6 months.
88969072|NCT05590754||Experimental Group|8 participants (4 males, 25.5±4.4 years, 63.5±10.6 kg, 163.2±5.6 cm)
88969073|NCT05590754||Observational Group|8 participants (3 males, 27.0±2.0 years, 68.4±11.8 kg, 176.5±10.9 cm
88969074|NCT00056056|Experimental|Bexarotene and PUVA|
88969075|NCT00056056|Active Comparator|PUVA|
88969076|NCT00056095|Experimental|Allograft (compatible family member)|
88969077|NCT00056095|Other|Allograft (compatible non-family member)|
88969078|NCT00056290|Active Comparator|1|VEGF
88969079|NCT00056290|Placebo Comparator|2|Placebo
88969080|NCT05467917||Index Case|a) minor testing positive for SARS-CoV-2; b) symptomatic health workers or any individual with a history of exposure to SARS-CoV-2 confirmed positive patients; c) health workers or any individual who tests positive regardless of symptoms. Index case must be living in a multi-person household that includes at least one child with a history of exposure to SARS-CoV-2 positive patients
88969081|NCT05467917||Household Contact|Anyone residing in the house for at least 24 hours at the time of the index case diagnosis or study enrollment.
88969082|NCT00056329|Experimental|1|vitamin E plus multivitamin
88969083|NCT00056329|Placebo Comparator|2|placebo with multivitamin
88969084|NCT00056446|Experimental|1|Oxaliplatin/5-FU/LV and PTK787/ZK 222584
88969085|NCT00056446|Placebo Comparator|2|Oxaliplatin/5-FU/LV and placebo
88969086|NCT05539469|Experimental|Trial group|Patients from this group will be assisted by Orthodontika application during orthopedic treatment. Reminders will be sent for the activation of Rapid Maxillary Expander and for oral hygiene maneuvers. Written information about orthopedic treatment and oral hygiene tips can be read.
88969087|NCT05539469|Other|Control group|Patients from this group will not have access to Orthodontika application during orthopedic treatment. Patients will receive only verbal instruction about the activation of Rapid Maxillary Expander and for oral hygiene maneuvers.
88969088|NCT05437692|Experimental|zimberelimab plus concurrent radiotherapy and chemotherapy|19 patients will treated with zimberelimab plus concurrent radiotherapy and chemotherapy
88969089|NCT05509283|No Intervention|Passive control|Patients in the passive control arm will receive no additional pro-vaccination intervention beyond the health system's normal efforts. Although some patients are currently targeted for flu vaccination encouragement due to a conventional non-ML assessment that they are at high risk for complications, these patients are not told that they are at high risk or that they have been targeted.
88969090|NCT05509283|Experimental|Active control|Patients in the active control arm will receive messages reminding them to get a flu shot without being advised of their risk status.
89566261|NCT05064475||Recurrent breast cancer patients with elevated tumor markers|PET/CT is the functional imaging tool that can measure increased glucose metabolism in cancer cells by using 18F-FDG. Its ability to identify tumor recurrence before detection of morphologic changes in conventional imaging reflecting its importance in detecting BC recurrence in asymptomatic patients with high tumor markers and negative results of radiological imaging. 18F-FDG PET/CT is frequently used for BC evaluation. However, data on its value in evaluating BC recurrence in patients with elevated tumor markers are limited and unclear
89566262|NCT05057299||Patients with extramedullary leukemia(eAML) with myeloid neoplasms|
89566263|NCT05057455||ICU patients diagnosed with sepsis or septic shock|compare the laboratory and clinical results of cytokine hemadsorption as an immunomodulation therapy in ICU patients diagnosed with sepsis or septic shock.
89566264|NCT05063773|Experimental|Group 1|
89566265|NCT05063773|No Intervention|Group 2|
89566266|NCT05057065||Hyperlipidemia|"HBsAg(+) patients~TC>5.17mmol/L（200mg/dl）and（or）TG>2.3mmol/L（200mg/dl）"
89566267|NCT05057065||diabetes|"HBsAg(+) patients~FPG>126 mg/dL(7.0 mmol/L)Fasting is defined as no caloric intake for at least 8 h."
89566268|NCT05057065||CHB without metabolic disease|"HBsAg(+) patients~without diabetes/ obesity/hyperlipidemia"
89566269|NCT02897479|Experimental|Savolitinib|Pulmonary Sarcomatoid Carcinomas
89566270|NCT05046925||24-hour PACU group|closely monitor in post-anesthetic unit (PACU) and the stay time is less than 24 hours, then patients can be discharged to floor
89566271|NCT05046925||24-hour ICU group|closely monitor in intensive care unit (ICU) and the stay time is less than 24 hours, even patients die within 24 hours in ICU
89566272|NCT04470973||Cefuroxime/Amikacin|20 patients will be included in the cefuroxime cohort and 20 patients in the amikacin cohort.
89566273|NCT05046457|Experimental|3mg BCX supplement|One 3mg BCX capsule + one placebo capsule to be taken once per day for 8 weeks
89566274|NCT05046457|Experimental|6mg BCX supplement|Two 3mg BCX capsules to be taken once per day for 8 weeks
89566275|NCT05046457|Placebo Comparator|0mg BCX supplementation|Two placebo capsules to be taken once per day for 8 weeks
89566276|NCT05063071|Experimental|TAF monotherapy without HBIG|The standard dose of TAF 25mg daily was used. TAF can be used on the first day after orthotopic liver transplantation. No HBIG was used before, during, or after transplantation; and therapeutic vaccination was not routinely used.
89566277|NCT05056285||Down syndrome less than four years Group|
89566278|NCT05045911|Experimental|Endoscopic Barbed-clips Suturing|Patients will be closed the mucosal defect after colorectal ESD using Endoscopic Barbed-clips Suturing.
89566279|NCT05045989|Experimental|Residence-based asymptomatic SARS-CoV-2 testing|The aim of the RB-TPP was to increase and maintain participation of students in regular COVID-19 testing in university residences. The R-TPP was delivered over 4 weeks in April-May 2021 and required asymptomatic students to take a saliva test for COVID-19, twice weekly for four weeks. This was combined with relaxed social restrictions within the residence during the study period (i.e., removing the need for 2 metre distancing between students living in the same residence), surge testing and enhanced support for students who were required to self-isolate (i.e., welfare and financial support).
89566280|NCT05045599|Experimental|Integration of Family planning in Maternal, Newborn and Child Health|Strengthening of capacity of LHWs and Health care provider in providing integrated services Ensure Sustained supplies are available Community Mobilization Infrastructure support to ensure privacy and confidentiality Improvement of data recording, reporting and use
89566281|NCT05045599|Active Comparator|Standard of care|
89566282|NCT05062681|Active Comparator|Dexamethasone group|Patients will receive dexamethasone 8 mg q12hours
89566283|NCT05062681|Experimental|methylprednisolone group|Patients will receive 1mg/kg/day in 2 divided doses over 30 minutes
89566284|NCT05045521|Experimental|plyometric warm up group|set of active exercises used as warm up protocol.
89566285|NCT05045521|Experimental|resistance warm up group|warm up protocol on treadmill wearing weighted jacket
89027941|NCT02276118|Active Comparator|Genesis II group|the patients who receives total knee arthroplasty with the Genesis II prosthesis
89566286|NCT05045521|Active Comparator|control|warm up protocol on treadmill without weights
89566287|NCT05056519|Experimental|Experimental group|Healthy people in experimental group will receive a dose of Live Attenuated Influenza Vaccine
89566288|NCT05056519|Placebo Comparator|Placebo group|Healthy people in placebo group will receive a dose of placebo
89566289|NCT05045287|Experimental|hypofractionated radiation therapy|receive chest wall and nodal irradiation at a dose of 43.5 Gy in 15 fractions over 3 weeks
89566290|NCT05045131|Experimental|PVI+PWI, 6 months reassessment procedure, 3 year continued rhythm monitoring|Single arm experimental, observational study: All participants receive a single-procedure combined PVI + posterior wall isolation (PVI+PWI), loop recorder implantation, esophagoscopy, a mandated interventional reassessment /reablation procedure at six months and continuous rhythm monitoring for three years
89566291|NCT05045053|Experimental|xiidra group|patients are treated with 0.5 % xiidra twice daily and artificial tears for 6 months after corneal collagen cross linking
89566292|NCT05045053|No Intervention|control group|patient are treated with artificial tears for 6 months after corneal collagen cross linking in both groups
89566293|NCT05044741||Perforated group|
89566294|NCT05044741||Controlled group|
89566295|NCT03097627|Experimental|ICG Intervention|The intervention to be administered is intravenous indocyanine green for intra-thoracic lesion localization and use of a near infrared camera to detect the ICG. All study subjects will receive this same intervention; there is only one arm.
89566296|NCT05055739|Experimental|SW|Patients undergoing sternal closure with steel wires
89566297|NCT05055739|Experimental|RP|Patients undergoing sternal closure with a rigid plate
89566298|NCT05055895||early onset deliryum on dementia|It was earlier than The median time of onset of delirium superimposed dementia
89566299|NCT05055895||Delirium on dementia (normal)|It was equal or later than The median time of onset of delirium superimposed dementia
89566300|NCT05055583|Experimental|Toripalimab in Combination With Platinum-based Chemotherapy|Participants receive totally 3-4 cycles of toripalimab combined with platinum-based chemotherapy neoadjuvant treatment during preoperative period. After the last treatment (Day 21 of Cycle 4), surgery will be performed within 4-6 weeks. Postoperatively, a comprehensive evaluation will be conducted by the investigator, and the intention was to receive maintenance therapy within 6-12 weeks of the MDT assessment.
89566301|NCT03097705|Other|IOP and OCT RNFL measurements|all subjects will undergo ophthalmological exams including IOP and RNFL OCT measurements
89566302|NCT05060809|Experimental|Hemodialysis patient with high level of dp uc-MGP|one hundred and twenty hemodialysis patients with high level of dephosphorylated uc-MGP received 5 mg of oral vitamin K1 (phylloquinone) three times /week for 6 months at the end of HD session. We measured the serum dephosphorylated- uncarboxylated matrix Gla protein (dp-ucMGP) 6 months after vitamin K1 supplementation. In addition, plain lateral abdominal x-ray was conducted prior to and after 6 months of vitamin K supplementation to assess lumbar aorta calcification. The extent of aortic calcification score (AAC) was assessed by Kauppila score.In addition, study patients were subjected to an echocardiography at baseline as well as 6 months post vitamin K1 supplementation. Echocardiography was performed by the same operator.
89566303|NCT03097549|Experimental|Tät®II Treatment app|Comprehensive treatment programme with information and exercises. Individual advices.
89566304|NCT03097549|Other|Tät®II Information app|"Information only.~."
89566305|NCT05055349|Active Comparator|corneal collagen cross linking and intrastromal corneal keraring segments.|20 eyes will undergo corneal collagen cross linking (epithelium off) 1 month after Femtosecond laser assisted intrastromal corneal keraring segments
89566306|NCT05055349|Active Comparator|toric phakic posterior IOL implantation and corneal collagen cross linking|20 eyes will undergo toric phakic posterior IOL implantation 1 year after corneal collagen cross linking (epithelium off).
89566307|NCT03098095|Experimental|Experimental group|Device smartphone. Participants will be trained with a supervised physical activity for 3 days a week for 16 weeks with the use of a smartphone application
89566308|NCT03098095|Experimental|Control Group|Participants will train alone with an exercise program for 16 weeks without the use of a smartphone application
89566309|NCT05061043|Active Comparator|Group A|Routine physical therapy treatment
89566310|NCT05061043|Experimental|Group B:|Routine physical therapy along with orofacial therapy
89566311|NCT05054959|Experimental|consolidation chemotherapy|"chemoradiation: intensity-modulated irradiation technique with simultaneous integrated boost to the tumor (IMRT-SIB) or with volumetric modulated arc therapy (VMAT) with simultaneous integrated boost (VMAT-SIB) to the total tumor dose of 46.2 Gy in T1-3 tumors and 48.4 Gy in T4 tumors in 22 fractions with concomitant CT with capecitabine (dosage: 825 mg / m2 / 12 h per os continuously from the first to the last day of irradiation).~6 cycles of CAPOX chemotherapy. One cycle of CAPOX CT lasts 3 weeks and consists of capecitabine 1000 mg / m2 / 12h per os for 1-14 days and oxaliplatin 130 mg / m2 intravenously in a two-hour infusion on day 1."
89566312|NCT05054959|Active Comparator|induction chemotherapy|"4 cycles of induction CAPOX chemotherapy. One cycle of CAPOX CT lasts 3 weeks and consists of capecitabine 1000 mg / m2 / 12h per os for 1-14 days and oxaliplatin 130 mg / m2 intravenously in a two-hour infusion on day 1.~Chemoradiation:intensity-modulated irradiation technique with simultaneous integrated boost to the tumor (IMRT-SIB) or with volumetric modulated arc therapy (VMAT) with simultaneous integrated boost (VMAT-SIB) to the total tumor dose of 46.2 Gy in T1-3 tumors and 48.4 Gy in T4 tumors in 22 fractions with concomitant CT with capecitabine (dosage: 825 mg / m2 / 12 h per os continuously from the first to the last day of irradiation).~2 cycles of consolidation CAPOX chemotherapy."
89566313|NCT03097393||AKI GROUP|measure Procalcitonin among Patient developed Acute kidney injury during ICU stay
89566314|NCT03097393||Non-AKI group|measure Procalcitonin among Patient did not develop Acute kidney injury during ICU stay
89566315|NCT03097237|Experimental|Wholegrain rye|Wholegrain rye products with a high content of dietary fiber
89566316|NCT03097237|Active Comparator|Refined wheat|Refined wheat products with a low content of dietary fiber
89566317|NCT05060419|Experimental|Meropenem-FL058 (180min infusion)|
89566318|NCT05060419|Active Comparator|Piperacillin-Tazobactan (30min infusion)|
89566319|NCT05055193||Preterm infants who received postnatal corticosteroid for bronchopulmonary dysplasia|Corticosteroids used are hydrocortisone (as first-line therapy) and betamethasone (in situations of particular severity)
89566320|NCT05055193||Preterm infants who did not receive postnatal corticosteroid for bronchopulmonary dysplasia|No corticosteroids
89566321|NCT05060185|Other|single arm|the patients will be treated by the trial device
89566322|NCT05060107|Experimental|Experimental group - sEVs|Intra-articular knee injection of exosomes (3-5 x 10e11 particles) derived from allogeneic mesenchymal stromal cells. Single dose.
89566323|NCT05060263|Experimental|Cohort 1|HOT-1030, every 21 days by intravenous administration. HOT-1030 is a recombinant humanized CD137 monoclonal antibody injection.
89566324|NCT05060263|Experimental|Cohort 2|HOT-1030, every 21 days by intravenous administration. HOT-1030 is a recombinant humanized CD137 monoclonal antibody injection.
89566325|NCT05060263|Experimental|Cohort 3|HOT-1030, every 21 days by intravenous administration. HOT-1030 is a recombinant humanized CD137 monoclonal antibody injection.
89566326|NCT05060263|Experimental|Cohort 4|HOT-1030, every 21 days by intravenous administration. HOT-1030 is a recombinant humanized CD137 monoclonal antibody injection.
89566327|NCT05060263|Experimental|Cohort 5|HOT-1030, every 21 days by intravenous administration. HOT-1030 is a recombinant humanized CD137 monoclonal antibody injection.
89566328|NCT05060263|Experimental|Cohort 6|HOT-1030, every 21 days by intravenous administration. HOT-1030 is a recombinant humanized CD137 monoclonal antibody injection.
89566329|NCT05060263|Experimental|Cohort 7|HOT-1030, every 21 days by intravenous administration. HOT-1030 is a recombinant humanized CD137 monoclonal antibody injection.
89566330|NCT05036551||Stage 2 Knee osteoarthritis|The Visual Analogue Scale (VAS) was used to determine the severity of the pain. Tampa Scale for Kinesiophobia (TSK) was used to evaluate kinesiophobia. The functional state was evaluated using The Western Ontario and McMaster Universities Arthritis Index (WOMAC). The Arthritis Self Efficacy Scale was used to determine self efficacy perception.
89566331|NCT05036551||Stage 3 Knee osteoarthritis|The Visual Analogue Scale (VAS) was used to determine the severity of the pain. Tampa Scale for Kinesiophobia (TSK) was used to evaluate kinesiophobia. The functional state was evaluated using The Western Ontario and McMaster Universities Arthritis Index (WOMAC). The Arthritis Self Efficacy Scale was used to determine self efficacy perception.
89566332|NCT03096925|Experimental|Intervention group|The intervention group will receive guided self-help comprising six web-based sessions, comprising information, exposure to physical activity, how worry can excess pain, physical reactions to pain and worry, consequences of avoidance, and specific panic treatment. The first session will be done at the hospital before discharge, the others at home. Between sessions there will be a brief telephone contact with a project worker.
89566333|NCT03096925|No Intervention|Control group|This group will receive treatment as usual, which is no specific treatment. They can however use the general health system as they like.
89566334|NCT03097159||Costoclavicular block|For anesthesia, this group of patients will be received ultrasound guided costoclavicular block
89566335|NCT03097159||Supraclavicular block|For anesthesia, this group of patients will be received ultrasound guided supraclavicular block
89566336|NCT03097003||Use of Apremilast in patient with plaque psoriasis|Psoriasis patients treated with Otezla® (Apremilast) in Belgium
89566337|NCT03098251|Experimental|3D typing|typing the patient with 3D typing system and give treatment according preestablished algorism in our center.
89566338|NCT03098251|Active Comparator|routine typing|typing the patient with routine typing system and give treatment according preestablished algorism in our center.
89566339|NCT05043727|Experimental|Exer gaming treatment plan|Exer gaming treatment plan
89566340|NCT05043727|Active Comparator|conventional treatment plan|conventional treatment plan
89566341|NCT02605967|Experimental|Spartalizumab 400 mg Q4W|anti-PD1 humanized monoclonal antibody. Participants treated with spartalizumab who remained on spartalizumab
89566342|NCT02605967|Active Comparator|Chemotherapy|commonly used chemotherapy as per investigator's choice
89566343|NCT05043571|Experimental|Single arm|Single arm Phase I Clinical Trial
89566344|NCT04473079|Experimental|Experimental group|These participants will receive the standard treatment for H. pylori eradication (proton-pump inhibitor and antibiotics) plus probiotic formulation (commercially-available as Lacidofil) for 12 weeks.
89566345|NCT04473079|Placebo Comparator|Placebo group|These participants will receive the standard treatment for H. pylori eradication (proton-pump inhibitor and antibiotics) plus placebo for 12 weeks.
89566346|NCT05036161||Predicting treatment failure of Nasal High Flow in newborns|newborns with respiratory distress treated with NHF
89566347|NCT05036161||Predicting treatment failure of Continuous Positive Airway Pressure in newborns|newborns with respiratory distress treated with CPAP
88815018|NCT05164211|Experimental|Didgeridoo|The children will have 6 didgeridoo lessons given by a teacher spread over 3 months.They will have a didgeridoo at home to practice with.
88815019|NCT05164211|No Intervention|Absence|The children will have nothing to do.
88815020|NCT02249351|Experimental|Talsaclidine|
88815021|NCT02249351|Placebo Comparator|Placebo|
88815022|NCT01015586|Experimental|Lamotrigine|Add-on lamotrigine plus pre-existing mood stabilizing medication regimen. Active fixed-dose drug titration from 25-200 mg/day over first six weeks, 200 mg/day fixed-dose maintenance for second six weeks
89566348|NCT03036059|Active Comparator|Control group|400 μg/kg Ivermectin + 400 mg Albendazole Tablets given every year for 2 years
89566349|NCT03036059|Experimental|Expanded frequency group|400 μg/kg Ivermectin + 400 mg Albendazole, Tablets given every 6 months for 2 years
89566350|NCT03096769|Other|Study Arm|
89566351|NCT05035849|Active Comparator|Group A|Patients in group A were given sitagliptin and metformin for the first two weeks, and then were treated with acarbose and metformin for the second two weeks. FGM was used to monitor glycemic variations during the whole four weeks.
89566352|NCT05035849|Active Comparator|Group B|Patients in group B were given acarbose and metformin for the first two weeks, and then were treated with sitagliptin and metformin for the second two weeks.FGM was used to monitor glycemic variations during the whole four weeks.
89566353|NCT03095443|Experimental|Personalized Music|Receives personalized playlist twice a day.
89566354|NCT03095443|Active Comparator|Non Personalized Music|Receives standardized low beats per minute playlist twice a day.
89566355|NCT03095443|Active Comparator|Attention Control|Receives audio-book twice a day.
89566356|NCT04821479|Experimental|Repeated MSCs treatment in ALS patients|Four intrathecal (IT) administrations of autologous MSC cells administered every 3 months in ALS patients. the IT treatment will be administered through a regular lumbar puncture at a dose of 1x10^6 MSCs per kg body weight in 3 ml saline.
89566357|NCT05043493|Active Comparator|Injection (study) group|This group will receive platelet rich plasma (PRP) injection
89566358|NCT05043493|Placebo Comparator|Control group|This group will receive normal saline (NS) injection
89566359|NCT05043181|Experimental|Homozygous Familial Hypercholesterolemia|
89566360|NCT03035981|Experimental|White rice, low amylose|Cooked white rice with low amylose content
89566361|NCT03035981|Experimental|White rice, high amylose|Cooked white rice with high amylose content
89566362|NCT03035981|Experimental|White rice, slow|Cooked white rice with slow digesting starch
89566363|NCT03035981|Experimental|White rice, resistant|Cooked white rice with resistant starch
89566364|NCT03035981|Experimental|Brown rice, low amylose|Cooked brown rice with low amylose content
89566365|NCT03035981|Experimental|Brown rice, high amylose|Cooked brown rice with high amylose content
89566366|NCT03035981|Experimental|Fructooligosaccharide (FOS)|Fermentable carbohydrate solution
89566367|NCT05035381|Experimental|Experiment Group|
89566368|NCT03035903|Experimental|Not holding, then holding the MedGem®|Subjects will be seated in an armless chair and have a RMR measurement taken while not holding, then holding a MedGem® Indirect Calorimeter.
89566369|NCT03035903|Active Comparator|Holding, then not holding the MedGem®|Subjects will be seated in an armless chair and have a RMR measurement taken holding, then not holding a MedGem® Indirect Calorimeter.
89566370|NCT05043025|Active Comparator|Neck extension group|The cricothyroid membrane is identified in a neck extended position.
89208593|NCT02596061|No Intervention|Control|These participants are made aware of all smoking cessation services offered by the clinic, for example group counseling or individual counseling, but are not offered any rewards for participating in these activities.
89208594|NCT02596061|Experimental|Intervention-Rewards Only|Patients have access to a website where they can self-report smoking status, add virtual supporters, and submit journal entries. Patients receive incentives for completing these activities and for utilizing counseling services at the clinic. At the 2 mo. mark, these participants come to the clinic for a biochemical verification of their smoking status. Their rewards are contingent on successfully passing this verification test. They are also asked to return to the clinic 6 and 12 mos. after enrollment to complete the smoking tests and are compensated for these 2 visits.
89566371|NCT05043025|Experimental|Modified ramped position group|The cricothyroid membrane is identified in a modified ramped position.
89566372|NCT04152187|Experimental|Inspiratory muscle training (IMT)|Patients will receive IMT for 30 min (15x2), 7 times per week for 8 weeks using inspiratory muscle trainer device (PowerBreathe). During training, patients will be instructed to maintain diaphragmatic breathing. Inspiratory load will be set at 40-60% of maximum inspiratory pressure. Each week, six training sessions will be held at home and a training session will be supervised with physiotherapist.
89566373|NCT04152187|No Intervention|Control|No additional intervention
89566374|NCT04821323|Experimental|Indomethacin Challenge|Participants will receive challenge agent as two single oral doses of Indomethacin, one on Day -1 and one on Day 1. In addition, participants will receive lactulose-mannitol solution on Day -4 (baseline) and on Day 1 (post Indomethacin challenge).
89566375|NCT04821557|Experimental|Microbial Protease Supplement|A microbial protease supplement (31,875 Hemoglobin Unit Tyrosine base (HUT); protease activity) is taken with a 25g pea protein beverage. The test article will be provided in 250mg capsule form. Capsules will be opened and mixed into protein shake 5 minutes before ingestion.
89566376|NCT04821557|Placebo Comparator|Placebo (Maltodextrin)|The placebo (maltodextrin) article will be provided in 250mg capsule form. Capsules will be opened and mixed into 25g pea protein shake 5 minutes before ingestion.
89566377|NCT04434703|Active Comparator|Platelet rich fibrin (PRF)|Platelet rich fibrin is the secoond generation of platelet concentrates which is an autogenous biomaterial that is prepared from the patient's own blood
89566378|NCT04434703|Experimental|Advanced platelet rich fibrin (A-PRF)|Advanced platelet rich fibrin is the last modification of PRF which is expected to contain a relatively greater number of white blood cellsand growth factors
89566379|NCT04434703|Placebo Comparator|blood clot|normal healing of the wound without adding any biomaterial
89566380|NCT03035825|Experimental|Oral Moisturizing Jelly|Daily intake of oral moisturizing jelly 5 times/day for two months
88815023|NCT01015586|Placebo Comparator|Placebo|Add-on placebo plus pre-existing mood stabilization regimen for 12 weeks
89566381|NCT03035825|Active Comparator|Artificial saliva|Daily use of non-edible oral lubricating gel 5 times/day for two months
89566382|NCT04834037|Experimental|Experimental|"Patients in the experimental group were provided with information in addition to routine nursing care and supportive care interventions were made. The information leaflet was explained to the patients in the experimental group face to face by the researchers and the information was repeated according to the patient's needs.~As a pre-test measure, blood gases were taken from the patients in the experimental and control groups, their vital signs were measured, their state of consciousness was evaluated, and DASS-21 (anxiety and stress sub-dimension) and RASS (agitation dimension) were practiced by face-to-face interviews with the patients. As the last test, the same measurements were made 5 days after the first measurement and before the patients were transferred to the normal service. An information pamphlet consisting of textual material about NIV treatment was developed."
89566383|NCT04834037|No Intervention|No intervention|Routine nursing care was practiced to the control group in the intensive care clinic where the patients were located.
89566384|NCT05035069|Experimental|Ciprofol|
89566385|NCT05035069|Active Comparator|Propofol|
89566386|NCT05042557||Sun Yat-sen University Cancer Center|
89566387|NCT05042557||hanghai Chest Hospital|
89566388|NCT05042557||Tianjin Cancer Hospital|
89566389|NCT05042557||Fudan University Shanghai Cancer Center|
89566390|NCT05042557||Anhui Cancer Hospital|
89566391|NCT05042557||Shandong Cancer Hospital|
89566392|NCT05042557||Hunan Cancer Hospital|
89566393|NCT05042557||Yunnan Cancer Hospital|
89566394|NCT05042557||Chinese Academy of Medical Sciences|
89566395|NCT05035147|Experimental|Low dose strength: albumin-bound paclitaxel + gemcitabine|albumin-bound paclitaxel 125mg/m2+ gemcitabine1000mg/m2:day1,8 q3w
89566396|NCT05035147|Active Comparator|High dose strength: albumin-bound paclitaxel + gemcitabine|albumin-bound paclitaxel 125mg/m2+ gemcitabine1000mg/m2:day1,8,15 q4w
89566397|NCT01668173|Experimental|AUY922|This is an open-label phase II trial to assess the efficacy of the HSP90 inhibitor, AUY922, in patients with PMF, post-PV MF, post-ET MF, and with PV/ET who are refractory to hydroxyurea, phlebotomy or anagrelide.
89566398|NCT05042713|Active Comparator|Wave One Gold|The Wave One Gold file will be used with the VDW endodontic motor (VDW) in accordance with the manufacturer's recommendations.
89566399|NCT05042713|Active Comparator|One Flare and Wave One Gold file system|The One Flare file will be used with a rotational speed of 300 rpm and 3 N/cm torque at a working length of 3 mm. After the Wave One Gold file will be used with the VDW endodontic motor (VDW) in accordance with the manufacturer's recommendations.
88969091|NCT05509283|Experimental|High risk only|Patients in this treatment arm will receive messages telling them they have been identified to be at high risk for flu complications, without specifying how or why the health system believes this to be the case.
88969092|NCT05509283|Experimental|Risk based on medical records|Patients in this treatment arm will receive messages telling them they have been identified to be at high risk for flu complications via review of their medical records.
88969093|NCT05509283|Experimental|High risk based on algorithm|Patients in this treatment arm will receive messages telling them they have been identified to be at high risk for flu complications via analysis of their medical records by a computer algorithm.
89566400|NCT05042713|Active Comparator|One Curve|The One Curve file (Size 25) will be used in the VDW endodontic motor (VDW) in continuous rotation at 300 rpm and 2.5 Ncm torque in accordance with the manufacturer's recommendations.
89566401|NCT05042713|Active Comparator|One Curve with One Flare|The One Flare file will be used with a rotational speed of 300 rpm and 3 N/cm torque at a working length of 3 mm. After the One Curve file (Size 25) will be used in the VDW endodontic motor (VDW) in continuous rotation at 300 rpm and 2.5 Ncm torque in accordance with the manufacturer's recommendations.
89566402|NCT03036761|Experimental|AUR+: Auriculotherapy|Patients benefit from 3 sessions of auriculotherapy at one month intervals.
89566403|NCT03036761|No Intervention|AUR-: No auriculotherapy|Patients do not benefit from auriculotherapy.
89566404|NCT04821167|Other|Laparoscopic orchiopexy for intra-canalicular (emergent or peeping) testis|This is a prospective study conducted on male children with intermittent palpable (peeping) UDT to evaluate the safety and efficiency of laparoscopic orchiopexy of intra-canalicular (emergent or peeping) testis.
89566405|NCT05054101|Experimental|VieCovid2020 smartphone application|The VieCovid2020 smartphone application in add-on to usual psychiatric intervention
89566406|NCT05054101|Placebo Comparator|Usual psychiatric intervention|Usual psychiatric intervention alone
89566407|NCT03036449||A|Group A: Phase 1: Observations (Baseline rate of errors); Phase 2: Main Educational program; Phase 3: Observations; Phase 4: Maintenance Educational program; Phase 5: Observations; Phase 6: Maintenance Educational program; Phase 7: Observations; Phase 8: Maintenance Educational program; Phase 9: Observations.
89566408|NCT03036449||B|Group B: Phase 1: Observations (Baseline rate of errors); Phase 2: No intervention; Phase 3: Observations (Baseline rate of errors); Phase 4: Main Educational program; Phase 5: Observations; Phase 6: Maintenance Educational program; Phase 7: Observations; Phase 8: Maintenance Educational program; Phase 9: Observations.
89566409|NCT03036449||C|Group C: Phase 1: Observations (Baseline rate of errors); Phase 2: No intervention; Phase 3: Observations (Baseline rate of errors); Phase 4: No intervention; Phase 5: Observations (Baseline rate of errors); Phase 6: Main educational program; Phase 7: Observations; Phase 8: Maintenance educational program; Phase 9: Observations.
89566410|NCT05034757|Experimental|Hyaluronate|HA injection
89566411|NCT05034757|Experimental|HA + ESWT|HA + ESWT
89566412|NCT04834115|Experimental|Ivermectin|Ivermectin 200mcg/kg single dose, maximum dose 18mg
89566413|NCT04834115|Placebo Comparator|Placebo|Inactive medication tablets indistinguishable from ivermectin tablets
89566414|NCT04820777|Experimental|perturbation based training|External perturbations occur by forces outside the patient' control (e.g., a push or pull from the physiotherapist). Internal perturbations caused when the patient is unable to control the centre of mass and the base of support relationship during voluntary movement; 'agility' tasks, such as kicking a soccer ball,
89566415|NCT04820777|Active Comparator|Conventional' balance training|"Starting from a situated position, expand your left leg until it's corresponding to the floor. Try not to bolt your knee. At that point, gradually bring your foot down to the floor.~Rehash with your correct leg, exchanging to and fro between legs for a sum of 20 repitions (10 on every leg).~Situated Marching Starting with a situated position, lift your effected leg towards your chest, making an honest effort to keep up controlled development."
89566416|NCT04821011||Newborn birth between 28 and 40 Weeks of Gestational Age (wGA)|"Newborn birth between 28 and 40 Weeks of Gestational Age (wGA) will be included. The mother's newborn will be have a record of her heartbeats.~The newborn will be have an acoustic listening of their mother's heartbeat and a record of their own heartbeats."
89566417|NCT01505465|Experimental|Study: Melatonin|
89566418|NCT01505465|Placebo Comparator|Control: Placebo|
89566419|NCT05618015|Experimental|Supervised progressive resistance training|Supervised PRT was conducted face-to-face at the clinic
88969094|NCT05433714||Multiple sclerosis patient|First day, first evaluator will perform all tests, and second day, second evaluator will perform the figure of 8 walk test.
89566420|NCT05618015|Active Comparator|Home-based progressive resistance training|Home-based PRT was conducted at home without supervision
89566421|NCT04833881||The control group|
89566422|NCT04833881||Experimental group|
89566423|NCT04833647|Other|Term|7-10 years old born at 37-42 weeks gestation
89566424|NCT04833647|Other|Late preterms|7-10 years old born at 34.0-36.6 weeks gestation
89566425|NCT04833647|Other|Preterms with BPD|7-10 years old born before 30 weeks gestation with the diagnosis of BPD: the need for oxygen at 36 weeks gestation and/or flow or 3LPM or more, and/or the need for CPAP or invasive ventilation
89566426|NCT04833647|Other|pretermas without BPD|7-10 years old born before 30 weeks gestation without the diagnosis of BPD (without the need for oxygen at 36 weeks gestation and/or flow or 3LPM or more, and/or the need for CPAP or invasive ventilation)
89566427|NCT04830683||ICU Covid-19 patients|Covid-19 patients admitted for refractory respiratory failure despite conventional oxygen therapy requiring Intensive Care Unit (ICU) admission and oxygenation through either High Flow Nasal Cannula (HFNC) therapy or endotracheal intubation with mechanical ventilation
89566428|NCT04830683||non-ICU Covid-19 patients|Covid-19 patients admitted at hospital requiring conventional oxygen or continuous positive airways pressure (cpap)
89566429|NCT04830683||matched control subjects|Healthy subjects matched for similar cardiovascular risk factors than ICU Covid-19 patients
89566430|NCT04830683||ICU septic shock patients|Septic shock patients corresponded to refractory hypotension in response to an infection, in non Covid-19 patients, requiring ICU hospitalisation for vasopressors to maintain mean arterial pressure (MAP) > 65mm Hg despite adequate volume resuscitation according to the Surviving Sepsis Campaign
89566431|NCT05617937|Experimental|Connective tissue massage gruop|In addition, a total of 5 sessions of connective tissue massage were applied to the experimental group as 1 session a day on the postoperative 1st day, 2nd day, 3rd day, 4th day, 5th day. Connective tissue massage was only performed to the patients in the experimental group. A total of 5 sessions of connective tissue massage were applied to the experimental group as 1 session a day on the postoperative 1st day, 2nd day, 3rd day, 4th day, 5th day. Depending on the area of procedure, each session varied between 15 minutes and 20 minutes.
89566432|NCT05617937|No Intervention|Conventional Physiotherapy and Rehabilitation Group|Standard medical treatment, care and pulmonary rehabilitation program were applied to bonventional Physiotherapy and Rehabilitation Group.The patients were mobilized as early as possible. Starting on the postoperative zeroth day, a postoperative rehabilitation program including pulmonary rehabilitation and early mobilization was applied to every patient in the control and experimental groups by a therapist for 1 week as in routine
89566433|NCT04820543|Experimental|Simplified Method|In this method, a uniform BTX-A injection technique with single-site injection of 2 U BTX-A (total, 4 U) at both right and left levator labii superioris alaeque nasi muscles (LLSAN) was administered. The injection points located at the muscle bulge at the uppermost part of the nasolabial fold.
89566434|NCT04820543|Experimental|Individualized Method|In this method, the patients were administered BTX-A after 8 months when the effect of the previous injection vanished. And A dosage and injection sites were individualized according to the degree of severity of anterior GE presented pretreatment. For mild GS (3 to< 5mm), 2 U BTX-A was injected at bilateral LLSAN. For moderate (5 to < 7mm) and severe GS (≥ 7mm), 3 U and 5 U of BTX-A were injected per side (total, 6 U and 10U). And The injection points located at both LLSAN and the Yonsei point, with half doses at each point.
89566435|NCT04816487|Active Comparator|Silver Diamine Flouride|Discoloration of primary carious teeth treated by SDF
89566436|NCT04816487|Experimental|Glutathione|Discoloration rate of primary carious teeth treated by SDF + Glutathione
89566437|NCT04816487|Experimental|Potassium iodide|Discoloration rate of primary carious teeth treated by SDF + KI
89566438|NCT04360577|Experimental|High-dose acupuncture|Acupuncture for 7 times every 3 weeks (one cycle of chemotherapy) for 9 weeks (3 cycles of chemotherapy)
89566439|NCT04360577|Experimental|Low-dose acupuncture|Acupuncture for 3 times every 3 weeks (one cycle of chemotherapy) for 9 weeks (3 cycles of chemotherapy)
89566440|NCT04360577|No Intervention|Usual care|Chemotherapy without acupuncture
89027942|NCT00491582|No Intervention|Athletes, controls, patients|Sedentary controls: age, BMI, Gender and waist matched (to the growth hormone deficient patients) healthy control subjects Endurance trained athletes: minimal >50 mlO2/KG body weight
89027943|NCT00491621|Other|1|surgery or biopsy of the kidney tumor
89027944|NCT04510155|Experimental|Short overnight fast|Overnight fasting duration intervention: Participants will receive their last evening meal at 11 pm and stay overnight fasted afterwards for (9.5h).
89027945|NCT04510155|Experimental|Long overnight fast|Overnight fasting duration intervention: Participants will receive their last evening meal at 4.30 pm and stay overnight fasted afterwards for (16h).
89027946|NCT00487227|Placebo Comparator|Placebo|
89532114|NCT06337838|Experimental|Prophylactic intravenous tranexamic acid and prophylactic intravenous desmopressin.|"Within 20 minutes preceding anticipated skin incision, patients will receive preoperative prophylactic intravenous tranexamic acid at a dose of 1000 mg infused over 10 minutes for patients with estimated glomerular filtration rate (eGFR) <25 ml/min/1.73m2 who do not receive dialysis before surgery and 500 mg infused over 10 minutes for patients who receive dialysis.~Within 20 minutes preceding anticipated skin incision, patients allocated to the desmopressin intervention group will receive intravenous desmopressin at a dose of 20 mcg over 30 minutes."
89027947|NCT00487227|Experimental|2.5mg caffeine|
89027948|NCT00487227|Experimental|5mg caffeine|
89027949|NCT00487227|Experimental|10mg caffeine|
89027950|NCT01300351|Experimental|Fulvestrant 500mg|Fulvestrant 500mg (2 syringes of Fulvestrant 250mg), Fulvestrant 500 mg i.m. every 28 (+/- 3) days plus an additional 500 mg on day 14 (+/-3) of first month only
89027951|NCT01300351|Active Comparator|Fulvestrant 250mg|Fulvestrant 250mg (1 syringe of fulvestrant 250mg + 1 syringe matching placebo), Fulvestrant 250 mg and matching placebo i.m. every 28 (+/- 3) days plus an additional 2 placebo syringes on day 14 (+/-3) of first month only
88969095|NCT05433675|Experimental|Treatment Sequence AB|Participants will receive single oral dose of macitentan formulated as dispersible final market image (FMI) in fasted conditions (test) (Treatment A) in Intervention Period 1 followed by a single oral dose of film-coated opsumit tablet in fasted conditions (reference) (Treatment B) in Intervention Period 2 on Day 1. There will be washout period of at least 10 days between two period.
89566441|NCT04831229|Active Comparator|Active Interactive Media Group|"AIMG children will perform active activities on the interactive tablet media. The games and applications that will be used during this intervention were selected through a search in the online application store compatible with the tablet used during the intervention (Google Play). The search term used was games for children aged 2 to 3 years and they were analyzed for the following criteria: (1) interactivity: critical thinking, active participation, decision making; (2) learning: activities that stimulate cognitive development, fine motor, receptive language, expressive and social-emotional language (see table 1 to view activities); (3) suitability: age, period of development, multiple domains and (4) results: challenging activity, not frustrating, providing feedback"
89566442|NCT04831229|Active Comparator|Passive Interactive Media Group|PIMG children will go to the intervention room where they will use interactive tablet media in passive activities, such as: watching videos and children's stories that they often watch at home. This survey will be possible thanks to the questionnaire on the Use of Interactive Media where parents will list which drawings, stories and videos children use to watch.
89566443|NCT04830371|Experimental|Arm A (Vi-CRM197, Batch #1)|Single dose of Typhoid Conjugate Vaccine (Vi-CRM197) Batch #1 will be intramuscularly administered at Day 0.
89566444|NCT04830371|Experimental|Arm A (Vi-CRM197, Batch #2)|Single dose of Typhoid Conjugate Vaccine (Vi-CRM197) Batch #2 will be intramuscularly administered at Day 0.
89566445|NCT04830371|Experimental|Arm A (Vi-CRM197, Batch #3)|Single dose of Typhoid Conjugate Vaccine (Vi-CRM197) Batch #3 will be intramuscularly administered at Day 0.
88969096|NCT05433675|Experimental|Treatment Sequence BA|Participants will receive Treatment B in Intervention Period 1 followed Treatment A in Intervention Period 2 on Day 1. There will be washout period of at least 10 days between two period.
88969097|NCT00423631|Experimental|Standard Care and Web|Standard care plus a web site based on cognitive behavioral principals.
88969098|NCT00423631|Active Comparator|Standard Care|Subject recieve standard care from their primary care provider.
88969099|NCT05495321|Experimental|low-dose IL-2|"The first stage (double-blind treatment period): One million IU of IL-2 was injected subcutaneously once every other day for 12 weeks.~The second stage (open treatment period): One million IU of IL-2 was injected subcutaneously once every other day for 12 weeks."
88969100|NCT05495321|Placebo Comparator|Placebo|"The first stage (double-blind treatment period): Placebo was injected subcutaneously once every other day for 12 weeks.~The second stage (open treatment period): One million IU of IL-2 was injected subcutaneously once every other day for 12 weeks."
88969101|NCT02969902|Experimental|Buzzy® device|The Buzzy® device is applied just above the selected site of the venipuncture; an ice pack is attached under the device; the device is turned on and after 15 second the venipuncture is made.
88969102|NCT02969902|Active Comparator|Hand-held computer|Using an hand-held computer, children start to play with an age-appropriate videogame three minutes before the procedure. They continue to play during the venipuncture.
88969103|NCT05410197|Experimental|Envofolimab + Lenvatinib + Gemcitabine + Cisplatin|Single-arm trial whereby all consented, enrolled, eligible patients receive Envofolimab, Lenvatinib, Gemcitabine and Cisplatin
88969104|NCT03262454|Experimental|Interventions|Atezolizumab
88969105|NCT00057070|Other|Arm 1|
88969106|NCT00057109||Group 1|
88969107|NCT00057148|Other|Arm 1|
89566446|NCT04830371|Active Comparator|Arm D (Typbar-TCV)|Single dose of Typhoid Conjugate Vaccine (Typbar-TCV) will be intramuscularly administered at Day 0.
88969108|NCT00057187|Other|Arm 1|
88969109|NCT05452811||Open Burch Colposuspension|The retropubic space was entered through a laparotomy Pfannenstiel incision, and two permanent sutures were placed on each side lateral to the urethra, one set at the level of the mid urethra and the other set at the level of the bladder neck.
88969110|NCT05452811||Laparoscopic Burch Colposuspension|After a pneumo peritoneum was established entrance to the retropubic space began with a transverse incision of the anterior peritoneum using sharp dissection and electrocautery. The space was developed using blunt and sharp dissection to identify clearly the retropubic anatomy, including the pubic symphysis, bladder neck, and Cooper's ligaments. The bladder neck was identified and the paraurethral tissue was exposed. A no. 0 permanent suture then was introduced through the 10-mm port and was grasped with a laparoscopic needle driver. With the surgeon's hand in the vagina to elevate the paraurethral tissue, two figure-of-eight sutures incorporating full-thickness vagina excluding epithelium were placed on each side, one set lateral to the mid urethra and the other set lateral to the bladder neck. Each of these sutures then was passed through the ipsilateral Cooper's ligament and was secured with a series of extracorporeal knots using an endoscopic knot pusher.
88969111|NCT04733859|Placebo Comparator|placebo group|subjects drank 50 ml , 1 bottle a day for 8 week
89566447|NCT04820699|Experimental|post isometric relaxation|Group A received Post isometric relaxation technique (MET).The participants performed isometric contractions using 20% of their strength, 5 second holds with 5 seconds rest time in between each contraction
89566448|NCT04820699|Experimental|mulligan bent leg raise|Group B: Mulligan bent leg raise technique. Isometric contraction of hamstring muscle for progressively five greater position of hip flexion; three pain-free repetitions with 5 second hold was performed by participants
88969112|NCT04733859|Experimental|red djulis drinks|subjects drank 50 ml , 1 bottle a day for 8 week
88969113|NCT00057499|Experimental|IBC-VS01 vaccine|IBC-VS01 vaccine is administered twice.
88969114|NCT00057499|Placebo Comparator|Control Group|IBC-VS01 placebo is administered twice
88969115|NCT02969746|Experimental|Charcoal|Patients will receive a single dose (20 gram) of oral activated charcoal
89566449|NCT04816409|Experimental|(Neurodevelopmental therapy)|"Starting Posture Start and evaluate the supreme effective posture to move from(usually straight) Reassemble to mid plane (head/trunk)~•Neutral position of body Identify the Missing Components Detect starting posture and compare to normal.~Neurodevelopmental therapy application :~Tonic postural extensor muscle strengthening:~Push-pull scooter board games contrary to resistive tubing strips.~Developmental movement patterns training:~Obstacle crawl, hold swing's ropes in kneeling anhalf kneeling position, throw balls to aim kneeling and standing position. Manual Cues .Use hands on key points of control to assist normal posture, movement and prevent abnormal posture and movement. Balance and corrective reactions was established by means of ball and tilt board after the development of the skill of sustaining exercise positions in children.4. Ambulation training, suitable to the motor"
89566450|NCT04816409|Active Comparator|Conventional treatment|Range of motion and Resistance training Linear actions are used to regularize extensor muscle tone (Neck extensors, back extensors hip extensors, knee extensors).(49) Postural control exercises Bouncing on gym ball in sitting, kneeling, or standing Linear swinging using a platform and swing, glider, hammock, and barrel; swinging in the kneeling, standing, sitting,
89566451|NCT04816331||Neonatal Encephalopathy (NE)|This study is a follow up of children at 2-3 years of age who were enrolled in the HRB-funded Neonatal Inflammation and Multiorgan dysfunction and Brain injUry reSearch group (NIMBUS) project. These babies had Neonatal Encephalopathy and required Therapeutic Hypothermia and are matched with controls. Detailed antenatal, birth, resuscitation, oxygen requirements throughout inpatient stay and detailed neonatal intensive care management were collected. In addition, details of Therapeutic Hypothermia treatment including initiation, duration and clinical examination, investigations including cranial USS, MRI, EEG and placental histology analysis performed as were recorded.
89566452|NCT04816331||Controls|The controls include age-matched normal children born at term with a normal delivery and postnatal course.
89566453|NCT04830059|Experimental|High intensity intermittent training|HIIT exercise program: 20 minutes HIIT exercise (1min 100% VO2max and 1min 50% VO2max alternately), and warm-up and relaxation before and after exercise for 10 minutes.
89566454|NCT04830059|Experimental|HIIT with pollution reduction|HIIT program: 20 minutes HIIT exercise (1min 100% VO2max and 1min 50% VO2max alternately), and warm-up and relaxation before and after exercise for 10 minutes; Environmental pollution intervention program: air purification system is used order to reduce the PM2.5 and PM10.
89566455|NCT04830059|Experimental|Moderate intensity continuous training|MICT program: 20 minutes of 70-75% VO2max exercise and 10 minutes of warm-up and relaxation before and after exercise.
89566456|NCT04830059|Experimental|MICT with pollution reduction|MICT program: 20 minutes of 70-75% VO2max exercise and 10 minutes of warm-up and relaxation before and after exercise; Environmental pollution intervention program: air purification system is used order to reduce the PM2.5 and PM10.
89566457|NCT04830059|Experimental|Stretch control group|Stretching control group: 30 minutes stretching, posture adjustment and rehabilitation courses is taught by professional therapist.
89566458|NCT04830059|Experimental|Control with pollution reduction|"Stretching control group: 30 minutes stretching, posture adjustment and rehabilitation courses is taught by professional therapist.~Environmental pollution intervention program: air purification system is used order to reduce the PM2.5 and PM10."
89566459|NCT04820621|Experimental|Participants with mild hepatic impairment|All participants will receive a single oral dose in the fasted state on Day 1.
89566460|NCT04820621|Experimental|Participants with moderate hepatic impairment|All participants will receive a single oral dose in the fasted state on Day 1.
89566461|NCT04820621|Experimental|Participants with normal hepatic function|All participants will receive a single oral dose in the fasted state on Day 1.
89566462|NCT04816253|Placebo Comparator|Normal saline|Normal saline irrigation after extraction and No drug placed in tooth socket
89566463|NCT04816253|Active Comparator|Gengigel|Gengigel (Hyaluronic acid) placed after extraction
89566464|NCT04816253|Active Comparator|Methylprednisolone|Methylprednisolone will be given intravenous to a patient half an hour before the surgery
89566465|NCT04816253|Active Comparator|Methylprednisolone and Gengigel|Methylprednisolone will be given intravenous to a patient half an hour before the surgery and Gengigel (Hyaluronic acid) placed after extraction
89566466|NCT04820231|Other|PRP injection group|"Intra-articular PRP injection with ultrasound guidance~Three times PRP injections with an interval of one week"
89566467|NCT04816097|Active Comparator|Steroid Group|Participants will receive 4 doses of dexamethasone 6mg IM 48h before elective CS.
89566468|NCT04816097|No Intervention|No Steroid Group|Participants will receive No treatment before elective CS.
88969116|NCT02969746|No Intervention|control|Standard practice
88969117|NCT05310747|Experimental|Artwork present + social connection high|Individuals participate in an exercise to prime a feeling of high social connection and then explore a virtual museum exhibit with artwork for 10 minutes
88969118|NCT05310747|Experimental|Artwork present + social connection low|Individuals participate in an exercise to prime a feeling of low social connection and then explore a virtual museum exhibit with artwork for 10 minutes
88969119|NCT05310747|Experimental|Artwork absent + social connection high|Individuals participate in an exercise to prime a feeling of high social connection and then explore a virtual museum exhibit with no artwork for 10 minutes
89566469|NCT04815941|Experimental|Soft ball tissue release exercises|
88969120|NCT05310747|Active Comparator|Artwork absent + social connection low|Individuals participate in an exercise to prime a feeling of low social connection and then explore a virtual museum exhibit with no artwork for 10 minutes
89566470|NCT04363619|Placebo Comparator|Controls|
89566471|NCT04363619|Experimental|ICH|
89566472|NCT04363619|Experimental|aSAH|
89566473|NCT04820153|Other|Study Participants|Study participants will participate in both the Physical Activity Monitoring Device intervention and the Lifestyle Redesign Coaching intervention simultaneously. Both interventions are complementary to one another.
89566474|NCT04819529|Experimental|Experimental Group - Early and intensive Occupational Therapy|These sessions will be implemented by occupational therapists trained in ICU, who will conduct 20 sessions of 30 min, distributed depending on the level of sedation, i) SAS (Sedation-Agitation Scale) 1 patients have one session each 48 h, evaluating the change of sedation level each 24 h; ii) SAS 2 patients have one session each 24 h, iii) SAS 3-5 have two sessions every day. The sessions will begin once the patient needs mechanical ventilation for at least 12 h
89566475|NCT04819529|No Intervention|Control group - Standard Analgesia,Sedation, Delirium and Mobilization (ASDM) Protocol|The ASDM protocol will be implemented to mechanically ventilated patients in the ICU, following the aspects recommended by experts and the current evidence. For this, the team of medical, nurses, and physiotherapist will be trained to understand and facilitate the ASDM actions that each one must implement.
89566476|NCT04815863||Elderly|Over 60 years old
89566477|NCT04815863||Non-Elderly|Under 60 years old
89566478|NCT03035591|Experimental|ODM-207|Escalating doses of ODM-207
89566479|NCT04819685|Experimental|test group|Intervention:Anti-radiation spray (liquid dressing)
89566480|NCT04819685|No Intervention|control group|
89566481|NCT04819607||BMFS patients|Patients with BMFS attending Peter MacCallum Cancer Centre haematology clinic.
89566482|NCT02600351|Experimental|LDV/SOF 12 weeks, without cirrhosis|LDV/SOF for 12 weeks
89566483|NCT02600351|Experimental|LDV/SOF + RBV 12 weeks, without cirrhosis|LDV/SOF + RBV for 12 weeks
89566484|NCT02600351|Experimental|LDV/SOF + RBV 12 weeks, with compensated cirrhosis|LDV/SOF + RBV for 12 weeks
89566485|NCT02600351|Experimental|LDV/SOF 24 weeks, with compensated cirrhosis|LDV/SOF for 24 weeks
89566486|NCT02640235|Experimental|CELSTAT|Oxidized cellulose strip (CELSTAT), Single-use treatment, Intraoperative, direct application to target bleeding site
89566487|NCT02640235|Active Comparator|Surgicel Original|Oxidized regenerated cellulose strip (Surgicel Original), Single-use treatment, Intraoperative, direct application to target bleeding site
89566488|NCT05053789|Experimental|Group 1|After enrolment into the study and randomization to the study group (V0) and baseline examinations (V1), patients will receive 1 drop of Lacrimera at the study site and will be instructed to apply one drop of C-NAC into both eyes before bedtime for the following 5 consecutive days and return for a follow-up visit after 7±1 days (V2). Patients will complete a diary describing symptoms during the day, use of Lacrimera and potential side effects until the next visit. If the NEI grading is ≤1 OR the OSDI score <20 at the next visit, treatment with Lacrimera will be discontinued and one further physical follow-up appointment will be arranged, which will take place 28±2 days after the last physical visit.
89566489|NCT05053789|Active Comparator|Group 2|The study days are conducted in the same way as for the study group. Patients of the control group will receive preservative-free, Hyaluronic-acid containing eyedrops (Hylo-Vision® sine) for 4 times a day as control.
88969121|NCT05310747|No Intervention|Hanging control group|Individuals will receive no exposure to any independent variables (i.e. artwork: present or absent; social connection prime: high or low) for 10 minutes before completing their final survey.
88969122|NCT00057850|Experimental|Arm I|"Phase I: Patients receive BMS-247550 IV over 3 hours and cisplatin IV over 30-60 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of BMS-247550 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, up to 10 additional patients receive treatment as above at the recommended phase II dose of BMS-247550.~Phase II: Patients receive treatment as in Phase I at the recommended phase II dose of BMS-247550."
88969123|NCT05436314|Experimental|Manual Lymphatic Drainage Group|Manual Lymphatic Drainage (MLD) in addition to medical treatment is applied to participants in this group.
88969124|NCT05436314|Sham Comparator|Sham Group|Sham Manual Lymphatic Drainage (MLD) in addition to medical treatment is applied to participants in this group.
89566490|NCT04829435|Experimental|ALLN-346 (Engineered Urate Oxidase)|ALLN-346 is novel urate oxidase provided as capsules for oral administration. Two ascending dose cohorts: Cohort A (3 capsules thrice daily (TID) for a total of 9 capsules per day) and Cohort B (5 capsules thrice daily (TID) for a total of 15 capsules per day) will be evaluated for 7 days for each cohort.
88969125|NCT05309304|Experimental|3 g cefazolin|Healthy adult subjects weighing ≥120 kg. (g=grams)
88969126|NCT05309304|Active Comparator|2 g cefazolin|Healthy adult subjects weighing <120 kg. (g=grams)
88969127|NCT00057967|Experimental|Treatment arm|alemtuzumab
88969128|NCT00058084|Experimental|Arm I|Patients receive ixabepilone (BMS-247550) IV over 3 hours on day 1.
89566491|NCT04829435|Placebo Comparator|Placebo|Matching placebo capsules for oral administration. Two ascending dose cohorts: Cohort A (3 capsules thrice daily (TID) for a total of 9 capsules per day) and Cohort B (5 capsules thrice daily (TID) for a total of 15 capsules per day) will be evaluated for 7 days for each cohort.
89566492|NCT05042635|Experimental|Ixekizumab (4 weeks) + Jueyin Granules (12 weeks)|Subjects received Ixekizumab in the first 4 weeks (biologic treatment period); After the cessation of biologic treatment, only Jueyin Granules was used in the 12-week traditional Chinese medicine treatment period.
89566493|NCT05042635|Placebo Comparator|Ixekizumab (4 weeks) + Jueyin placebo Granules(12 weeks)|Subjects received Ixekizumab in the first 4 weeks (biologic treatment period); After the cessation of biologic treatment, only Jueyin placebo Granules was used in the 12-week traditional Chinese medicine treatment period.
89566494|NCT04815395|Experimental|Oral Oxytocin|Oxytocin (24IU) orally
89566495|NCT04815395|Experimental|Intranasal Oxytocin|Oxytocin (24IU) intranasally
89566496|NCT04815395|Placebo Comparator|Oral Placebo|Placebo orally
89566497|NCT04819139|Active Comparator|Thumb exercises +orthosis|"Participants will be instructed to perform daily exercises grouped in 3 sets of 10 repetitions in the absence of pain for 4 weeks. If the patient experienced pain, the number of repetitions dropped sequentially until the exercise was performed pain free. Exercises consisted of active - resistive exercises for the first dorsal interosseous (FDI) muscle, manual distraction of the CMC joint and relaxation of the adductor thumb muscle. Each participant will also engaged in a one month re-education/joint protection program for thumb use during ADL's and completed a weekly record sheet for monitoring purposes.~In addiction, they will received a thumb whale orthosis to wear at night and during ADL's as needed for pain."
89566498|NCT04819139|Experimental|Thumb exercises +orthosis+ proprioceptive program exercises|"Participants will be instructed to perform daily exercises grouped in 3 sets of 10 repetitions in the absence of pain for 4 weeks. If the patient experienced pain, the number of repetitions dropped sequentially until the exercise was performed pain free. Exercises consisted of active - resistive exercises for the first dorsal interosseous (FDI) muscle, manual distraction of the CMC joint and relaxation of the adductor thumb muscle. Each participant will also engaged in a one month re-education/joint protection program for thumb use during ADL's and completed a weekly record sheet for monitoring purposes.~In addiction, they will received a thumb whale orthosis to wear at night and during ADL's as needed for pain. In addiction, patients will received a proprioceptive program exercises using also a online program with a laptop."
89566499|NCT05034679||Vaciinated|First group patients who vaccinated and measure the AMH before and up to 9 months after vaccination.
89566500|NCT05034679||Infected patients by covid-19 and not vacinated|Second group patients who were infected by Covid-19 ant therefor were not vaccinated
89566501|NCT05034679||Not infected nor vacinated|Ptients who who were not infected nor vacinated by Covid-19.
89566502|NCT03096691|Active Comparator|short cervix group|cervical pessary in group with first pregnancy or no preterm labor
89566503|NCT03096691|Active Comparator|group with cervical insufficiency|cervical pessary in group with multiple preterm labor
89566504|NCT03096535|Experimental|Cooling|Individualized cooling protocol.
89566505|NCT03096535|Experimental|Thermoneutral|Thermoneutral condition day.
89566506|NCT05034445||Sputum group|Sputum samples from more than 30 newly diagnosed advanced NSCLC patients with 520 Panel sequencing (sputum 1000X)
89566507|NCT05034445||Tissue group|Clinical data review to obtain corresponding tissue samples from more than 30 newly diagnosed advanced NSCLC patients with 520 Panel sequencing (tissue 1000X)
89566508|NCT05034445||Plasma group|Clinical data review to obtain corresponding plasma samples from more than 30 newly diagnosed advanced NSCLC patients with 520 Panel sequencing (plasma 10000X)
88969129|NCT00058084|Experimental|Arm II|Patients receive mitoxantrone IV over 30 minutes on day 1 and oral prednisone twice daily on days 1-21. In both arms, courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
88969130|NCT05273892|Experimental|Diet + Activity + Sleep|
88969131|NCT05273892|Active Comparator|Diet + Activity|
88969132|NCT02969629|Experimental|apomorphine|1.5 mg apomorphine, administered subcutaneously
89566509|NCT05034211|Active Comparator|Programmed intermittent Bolus Epidural technique|10ml ropivacaine 0,2% and 1,5 mcg/ml fentanyl, will be administered every 60 minutes via an epidural catheter placed for labor analgesia on L2-L3/L3-L4 level
89566510|NCT05034211|Active Comparator|Provider administered bolus epidural technique on patient request|10ml ropivacaine 0,2% and 1,5 mcg/ml fentanyl, will be administered by the provider on patient request
89566511|NCT02599961|Experimental|UX007|UX007 dosing targeted and/or maintained at 35% of total daily caloric intake.
89566512|NCT03096301|Experimental|Low-intensity laser|Twelve laser applications will be applied as initial treatment, with 2 sessions per week. A wave length of 780 nm, with an energy density of 25 J/cm2, a power of 50 mW and power density of 1.25 W/cm2, will be used for a duration of 20 seconds per point, resulting in a total energy of 1J per point. The laser will be applied at each point, using a conventional tip in contact with the skin, thus considering an area of 0.04 cm2, in accordance with the protocol suggested by Venezian et al. (2010) and Carvalho et al. (2010). The laser will be applied to 3 points of the masseter muscle (upper, middle, and lower bundles) and 1 point in the anterior temporalis on each side of the face
89566513|NCT03096301|Active Comparator|Occlusal Plate|"The group undergoing treatment with occlusal plates will be instructed to use the device during sleep, 8 hours per night, for a period of 12 months. The plates will be made following the principles established by Okenson (1998).~Participants will be molded with alginate to obtain models. In the upper model, a 2 mm acetate plate will be made, to be later replaced with acrylic resin (STRINI et al., 2009), and these plates will be adjusted in centric relation, to promote occlusal stability and disocclusion guide.~Weekly follow-up and adjustments will be performed during the evaluation period, until the completion of treatment"
89566514|NCT03096301|Placebo Comparator|Placebo|For the placebo group, all the measures described for the group 1 (LIL) will be adopted, however the laser equipment will remain switched off.
89566515|NCT05033977|Experimental|Center-based Exercise|"patients did exercises with a physical therapist in a clinic 3 days and 45 minute in a week for 6 weeks.~The exercise programe included strenghtening and streching exercises. Strenghtening exercises for lower extremity and streching exercises for hamstrings."
89566516|NCT05033977|Experimental|Home-based exercise|Patients did exercises at home every day and 3 times per day. The exercise programe included strenghtening and streching exercises. Strenghtening exercises for lower extremity and streching exercises for hamstrings.
89566517|NCT04818983||NSCLC cohort|Patients with locally advanced or metastatic non-small cell lung cancer who are planning to provide atezolizumab combination therapy as the most appropriate medical care
89566518|NCT04818983||ED-SCLC cohort|Patients with extensive disease small cell lung cancer who are planning to provide atezolizumab combination therapy as the most appropriate medical care
89566519|NCT05034055|Experimental|atezolizumab / tiragolumab|All patients will receive 1200mg atezolizumab administered by IV infusion on Day 1 of each 21-day cycle after completion of stereotactic body radiotherapy (SBRT) for 21(+5) days. No escalations or reductions in the dose of the investigational product will be allowed.Following the administration of atezolizumab, patients will receive 600mg tiragolumab administered by IV infusion on Day 1 of each 21-day cycle. The tiragolumab dose is fixed and is not dependent on body weight.
89566520|NCT05617703|Experimental|Glass Ionomer with Advanced Glass Hybrid Technology (Equia forte HT fil, GC, Japan)|"Glass Hybrid restorative systems in the clinical point of view are self-cure bulk fill materials laminated with a nano-filled, self-adhesive resin coat.~Nowadays, a new glass hybrid innovation called Advanced Glass Hybrid technology was achieved through introduction of ultra-fine highly reactive glass and high-molecular weight polyacrylic acid powders within conventional glass using prefractive indexes."
89566521|NCT05617703|Active Comparator|Resin Modified Glass Ionomer (Fugi II LC, GC, Japan).|
89566522|NCT03095365|Active Comparator|Dry needling|Received Dry needling in the neck muscles.
89566523|NCT03095365|Active Comparator|Conventional treatment|the participants received the conventional treatment for non-specific neck pain.
89566524|NCT03095365|Experimental|Dry needling and pain neuroscience education|Received the same treatment as dry needling group and pain education.
89566525|NCT03096613|Experimental|Levothyroxine group|The patients allocated to levothyroxine group receive levothyroxine with a starting dose of 12.5ug.
89566526|NCT03096613|No Intervention|Standard therapy group|The patients in this group receive standard therapy in consistent with the local clinical practice.
89566527|NCT04427735||before COVID-19|Patients with myocardial infarction from January 24, 2019 to June 24, 2019
88969133|NCT02969629|Placebo Comparator|Normal saline|saline, administered subcutaneously
89566528|NCT04427735||after COVID-19|Patients with myocardial infarction from January 24, 2020 to June 24, 2020
89566529|NCT05042245|Experimental|ornithine aspartate granule group|Patients in this group will be given aspartate ornithine granules (3 g po tid, after three meals) and silymarin capsule simulant (140 mg po bid, before breakfast and dinner).
88969134|NCT00058201|Active Comparator|Arm I|Patients receive leucovorin calcium IV and fluorouracil IV on days 1-5.
88969135|NCT00058201|Experimental|Arm II|Patients receive gemcitabine IV over 30 minutes on days 1, 8, and 15.
88969136|NCT00058201|No Intervention|Arm III|Patients undergo observation.
88969137|NCT00058318|Experimental|Treatment|Gemcitabine + Capecitabine
88969138|NCT00058357|Active Comparator|Lidocaine patch|Participants will be instructed to apply a patch or patches (up to 3 maximum simultaneously) directly to the affected area. The patch(es) should be applied during awake hours and then left on continuously for approximately 18 hours or until usual bedtime sleep.
88969139|NCT00058357|Placebo Comparator|Placebo patch|Participants will be instructed to apply a patch or patches (up to 3 maximum simultaneously) directly to the affected area. The patch(es) should be applied during awake hours and then left on continuously for approximately 18 hours or until usual bedtime sleep.
89566530|NCT05042245|Active Comparator|silymarin capsule group|Patients in this group will be given silymarin capsule (140 mg po bid, before breakfast and dinner) and aspartate ornithine granules simulant (3 g po tid, after three meals) .
89566531|NCT04427657|Active Comparator|Controls|39 patients with knee osteoarthritis undergoing arthroscopic debridement
89566532|NCT04427657|Experimental|Cases|39 patients with knee osteoarthritis undergoing arthroscopic debridement surgery + intrarticular injection of autologous microfragmented lipoaspirate tissue (Lipogems®).
89566533|NCT03035669|Experimental|Mindfulness group|Mindfulness based stress reduction: 8 week program, including meditation, body-awareness, and yoga practices. Daily assignments and home practices during 50 minutes per day.
89566534|NCT03035669|Active Comparator|Reading group|Reading and sharing group: 8 week program, including readings, interpersonal exchanges, group discussion, listening and role playing exercises. Daily assignments and home practices during 50 minutes per day.
89566535|NCT03095209||Standard of care concurrent chemo-radiation therapy|
89566536|NCT05617547||Pulse Oximetry Observational Cohort|
89566537|NCT05034133|Experimental|Study arm|Patients with limited stage small cell lung cancer receive durvalumab with chemotherapy (Etoposide and Cisplatin) for receive 6 cycles, and then receive thoracic radiotherapy.
89566538|NCT03096379||Magnetic resonance imaging|Patients with new-onset of lower gastrointestinal symptoms and ileocecal mucosal lesions of uncertain diagnosis as evidenced by the presence of inflammation, ulceration, strictures or nodules on colonoscopy.
89566539|NCT03096457|Experimental|Group 1 - Paromomycin cream|40 subjects will be included to receive 15% paromomycin in aquafilm base twice a day during 20 consecutive days. The lesion will be cleaned , then, a generous amount of the study drug (an amount sufficient to cover the area of the ulcer and the lesion border) will be applied to the lesion and rubbed into the ulcer using a gloved finger by a member of the clinical study staff. After application of the study drug, the patient will be observed for 15 minutes for signs of adverse events. If there are no signs of local toxicity, the area of the ulcer will be covered with extra study drug. For Days 2-20, the study drug will be applied and the lesion covered with a sterile gauze and tape dressing as on Day 1.
89566540|NCT03096457|Active Comparator|Group 2. Local Injectable Pentamidine|"20 subjects will be included to receive IL pentamidine [Pentacarinat® Sanofi-Aventis: 30 mg/ml] will administered at a dose of 120 ug (4 ul) per mm2 of lesion area 3 times (on days 1, 3, and 5) as per our previous experience.~A small button of Xylocaine® will be applied by means of a thin needle at the four cardinal points of the lesion and then a small gauge (23g) needle will introduce the drug in each cardinal point. The needle will be moved in all directions to infiltrate of whole lesion and surrounding infiltrated area."
89566541|NCT03096457|Placebo Comparator|Group 3. Vehicle control|10% Urea en parafilm cream will be used in similar ways as paromomycin cream in group 1
89566542|NCT03096223|Experimental|KHK4083|
89566543|NCT03096145|Experimental|Behavioral Intervention|Behavioral: telephone counseling 1 sessions, mobile texting, and health incentive
89566544|NCT04814303|Active Comparator|ITM|spinal anesthesia will be induced with heavy bupivacaine 0.5% 12.5-15 mg (2.5-3 mL) at L3-4 or L4-5 inter-vertebral and Intrathecal morphine 150 μg will be added.
89608810|NCT03586245|Active Comparator|Ferric pyrophosphate|"Study I group was required to consume a total of 3 meals. Each meal contained 4.2 mg added iron compounds.~57FePP (95.8%) 3.49 mg~Aspergillus oryzae (unenriched) 0.025 mg~FePP natural abundance 0.685 mg.~Subjects received iron fortificants in a meal composed of zucchini, cabbage, carrot (42g each), onion (24g), corn oil (6.3 g), jasmine rice (75g dw), and flavored granulated chicken bouillon (6.6g). All meals were consumed in a fasted state with nothing to eat or drink (besides water) for 3 hours following consumption."
88969140|NCT00392145|Active Comparator|1|
88969141|NCT00392145|Experimental|2|
88969142|NCT05413460|Experimental|transcutaneous electrical acupoint stimulation|Electrodes are placed at acupoints and connected to the stimulator. Electrical stimulation is given during surgery.
88969143|NCT05413460|No Intervention|Control|Electrodes are placed at acupoints and connected to the stimulator. But no stimulation is given during surgery.
88969144|NCT00392184|Experimental|APBI|Accelerated Partial Breast Irradiation with interstitial Brachytherapy
88969145|NCT00058474|Active Comparator|Arm 1: 5-FU + RT|Patients receive fluorouracil IV continuously and undergo radiation therapy (RT) once daily 5 days a week for 5-6 weeks.
88969146|NCT00058474|Experimental|Arm 2: 5-FU + RT + Oxaliplatin|Patients receive fluorouracil and undergo RT as in arm 1. Patients also receive oxaliplatin IV over 1 hour once weekly for 5 weeks.
88969147|NCT00058474|Experimental|Arm 3: Capecitabine + RT|Patients receive oral capecitabine twice daily and undergo RT once daily 5 days a week for 5-6 weeks.
88969148|NCT00058474|Experimental|Arm 4: Capecitabine + RT + Oxaliplatin|Patients receive capecitabine and undergo RT as in arm 3. Patients also receive oxaliplatin as in arm 2.
88969149|NCT00058591|Experimental|Treatment|Treatment dose levels 1, 2 and 3
88969150|NCT02969551||Sleep apnea, Manometry and possibly DISE|Sleep apnea Patients recieved manometry measures and those who were not considered for CPAP Therapy recieved Drug induced sleep endoscopy.
88969151|NCT05393141|Experimental|diet group|weight loss diet intervention for 12 weeks
88969152|NCT05393141|Experimental|diet+bety group|weight loss diet intervention for 12 weeks and exercise-based biopsychosocial approach (Cognitive Exercise Therapy Approach-BETY) intervention for 12 weeks
88969153|NCT05393141|No Intervention|control group|no intervention, control
89566545|NCT04814303|Active Comparator|ACB|spinal anesthesia will be induced with heavy bupivacaine 0.5% 12.5-15 mg (2.5-3 mL) at L3-4 or L4-5 inter-vertebral and Intrathecal morphine 150 μg will be added. The block will be performed in the mid adductor canal to block both the saphenous and the nerve to vastus medialis. After skin infiltration with 1 to 2 mL of 2% lidocaine, an 80-mm, 22-gauge, the short-bevel echogenic needle is advanced in-plane with the ultrasound beam in an anterior-to-posterior direction until the tip is located within the adductor canal deep to the vastoadductor membrane. After negative aspiration, 1-2 mL of local anesthetic is injected to confirm the proper injection plane. The study solution will be injected within the canal adjacent to the femoral artery. Patients in this group received 30 mL of 0.25% bupivacaine with 1:400,000 epinephrine and 4 mg dexamethasone.
89566546|NCT04814303|Active Comparator|PAI|spinal anesthesia will be induced with heavy bupivacaine 0.5% 12.5-15 mg (2.5-3 mL) at L3-4 or L4-5 inter-vertebral and Intrathecal morphine 150 μg will be added. PAI intra-operatively will be performed with 150 mL of 0.25% bupivacaine with 1:400,000 epinephrine, 30 mg of ketorolac, and 8 mg dexamethasone.
88969154|NCT02969473|Active Comparator|PF group|This is the active comparator group. All patients in this group will receive concurrent chemoradiotherapy with PF regimen (5-fluorouracil plus cisplatin).
89566547|NCT05053477|Active Comparator|Control Group|Patients will receive median nerve perineural injection of bupivacaine with mehylprednisolone under ultrasound guidance
88969155|NCT02969473|Experimental|DP group|This is the experimental group. All patients in this group will receive concurrent chemoradiotherapy with DP regimen (docetaxel plus cisplatin).
88969156|NCT03254264|Experimental|ESDM-12|an experimental group of 60 children receiving 12 hours a week of Early Start Denver Model (ESDM) intervention delivered by trained therapists during 2 years ESDM is a comprehensive relational, developmental and behavioral intervention.It's described in a manual for Professional and parents.
88969157|NCT03254264|Active Comparator|Control group|a control group of 120 children receiving typical heterogeneous 'as-usual' intervention proposed by professionals and public services over the same period.
88969158|NCT00059254|Experimental|Oleic acid (OA)|
88969159|NCT00059254|Experimental|Palmitic acid (PA)|
88969160|NCT00059371|Active Comparator|Circumcised immediately|
88969161|NCT00059371|Placebo Comparator|Delayed Circumcision|Men who were randomized to delayed circumcision were scheduled to be offered male circumcision 2 years after their randomization.
88969162|NCT01349907|Experimental|Asenapine/Asenapine|Participants treated with asenapine in base trial P06107, were first treated with open-label flavored asenapine 2.5 mg twice per day (BID), then up-titrated to 5 mg BID at day 4, then up-titrated to 10 mg BID at Day 7. After Day 7, flexible dosing of asenapine was continued for up to 50 weeks.
88969163|NCT01349907|Experimental|Placebo/Asenapine|Participants treated with placebo in base trial P06107, were first treated with open-label flavored asenapine 2.5 mg BID, then up-titrated to 5 mg BID at day 4, then up-titrated to 10 mg BID at Day 7. After Day 7, flexible dosing of asenapine was continued for up to 50 weeks.
88969164|NCT02969434|Experimental|Sleep questionnaires assessment tools|Interventions are 3 tools to assess sleep: Verran Snyder Halpern sleep scale, the Pain and Sleep Questionnaire 3 Item Index (PSQ-3) and the Pittsburg Sleep Quality Index (PSQI).
88969165|NCT02969278|Experimental|Vulvar cancer patients cN0 unfit for sentinel node biopsy|"All invasive vulvar cancer patients with cN0 status:~T > 4 cm;~multicentric tumors (mono or bilateral);~primary lesion completely excised during prior diagnostic surgery~patients candidate to bilateral lymphadenectomy because of unilateral groin lymph node involvement, contralateral cN0~previous radiotherapy a/o chemotherapy (sequential or concurrent). These patients are submitted to 18FDG PET/TC and sentinel node biopsy associated with standard preoperative imaging and radical groin lymphadenectomy"
88969166|NCT00059605|Experimental|DOTAP:Chol-fus1|Infusion intravenous once every 3 weeks
88969167|NCT05228262|Other|Cohort follow-up|Exploratory study involving functional explorations in longitudinal follow-up, initiated in parallel with a treatment indicated in the patient's usual care and management.
88969168|NCT00059683|Experimental|Cervical Cerclage Group|Women randomized to receive cerclage should receive cervical cerclage
88969169|NCT00059683|No Intervention|Control Group|Women randomized to not receive cerclage represent the control arm
88969170|NCT05364047|Other|Low-dose group, 18-59 years of age|The subjects were divided into the experimental group and the placebo group according to 3:1. The experimental group was inoculated with a dose of 25μg mRNA vaccine, and the placebo group was inoculated with a dose of placebo.
89566548|NCT05053477|Active Comparator|PRF Group|Patients will receive median nerve pulsed radiofrequency (PRF) and median nerve perineural injection of bupivacaine under ultrasound guidance
88969171|NCT05364047|Other|Middle-dose group, 18-59 years of age|The subjects were divided into the experimental group and the placebo group according to 3:1. The experimental group was inoculated with a dose of 50μg mRNA vaccine, and the placebo group was inoculated with a dose of placebo.
88969172|NCT05364047|Other|High-dose group, 18-59 years of age|The subjects were divided into the experimental group and the placebo group according to 3:1. The experimental group was inoculated with a dose of 100μg mRNA vaccine, and the placebo group was inoculated with a dose of placebo.
88969173|NCT05364047|Other|Low-dose group, over 60 years of age|The subjects were divided into the experimental group and the placebo group according to 3:1. The experimental group was inoculated with a dose of 25μg mRNA vaccine, and the placebo group was inoculated with a dose of placebo.
88969174|NCT05364047|Other|Middle-dose group, over 60 years of age|The subjects were divided into the experimental group and the placebo group according to 3:1. The experimental group was inoculated with a dose of 50μg mRNA vaccine, and the placebo group was inoculated with a dose of placebo.
88969175|NCT05364047|Other|High-dose group, over 60 years of age|The subjects were divided into the experimental group and the placebo group according to 3:1. The experimental group was inoculated with a dose of 100μg mRNA vaccine, and the placebo group was inoculated with a dose of placebo.
88969176|NCT02969239|Experimental|norepinephrine|norepinephrine 5mcg intravenously administered
88969177|NCT02969239|Active Comparator|phenylephrine|phenylephrine 100mcg intravenously administered
89027952|NCT00487253|Active Comparator|Group 1|"Oral administration of Miltefosine, doses: 1,5mg to 2,5mg/kg/day, during 28 days.~presentation: capsulas 10mg and 50mg Miltefosine (Impavido®)"
89566549|NCT05053477|Active Comparator|PRP Group|Patients will receive median nerve perineural injection of platelet-rich plasma (PRP) under ultrasound guidance
89566550|NCT04814459|Experimental|HOP-UP-PT Program|HOP-UP-PT Program group will participate in the 7-month HOP-UP-PT program
89566551|NCT04814459|No Intervention|Normal Level of Activity|Normal Level of Activity group will be instructed to continue their normal level of activity throughout the 7-months after which they will be offered the opportunity to receive the HOP-UP-PT program
89566552|NCT05033587|Experimental|AK105 injection with anlotinib and radiotherapy|"AK105 200mg intravenously (IV) on day 1 of each 21-day cycle until disease progression or treatment intolerance, the dose can not be adjusted.~Anlotinib 12mg capsules given orally on once daily in 21-day cycle until disease progression or treatment intolerance(14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21), the dose can be adjusted to 10mg or 8mg according to the specific conditions of the patient.~The conventional radiotherapy regimen delivered 2.0Gy once a day, five days a week to a total dose of 60Gy."
89566553|NCT05053009|Experimental|Ibuprofen sustained release|Single dose of 800 mg Brufen Retard oral premedication will be administered 1 hour before local anesthesia
89566554|NCT05053009|Placebo Comparator|Placebo|1 capsule of 500 mg of glucose oral premedication will be adminstered 1 hour before local anesthesia
89566555|NCT03095131|Experimental|12-lead ECG|
89566556|NCT05617235|No Intervention|Conventional Physiotherapy and Rehabilitation|A training will be given including information about the postoperative recovery process, the purpose of respiratory physiotherapy and rehabilitation, the importance of physiotherapy and rehabilitation in the postoperative period, attention to speed up recovery and prevention of complications, breathing exercises, coughing training, posture exercises, early mobilization and its importance, and answering patient questions.The program includes progressive ambulation and progressive shoulder and rib cage exercises. These exercises will be performed under the supervision of a physiotherapist from the first postoperative day. The exercises will be advanced every day by increasing the number of repetitions.
89566557|NCT05617235|Experimental|Kinesiology taping|"On the postoperative 0th day, kinesiology taping was applied to the patients in the study group whose hemodynamic status was stable after extubation by an expert physiotherapist. All tapes were applied by the same physiotherapist on clean and shaved skin (if necessary). Investigators applied kinesiology taping as described below:~In order to stimulate the facilitation of the diaphragmatic function, a 5 cm wide kinesiological tape was applied on the skin.~Taping was applied to the latissimus dorsi and serratus anterior muscles, which were cut during the thoracotomy.~In addition, kinesiology taping can be performed on the trigger pain point of the patient (usually above the pectoralis major).~The kinesiology tape can stay for 3-4 days if the patient does not develop any discomfort. After 3-4 days, the tape was renewed. Thus, taping was done twice for each patient. The bands were removed at 1 week postoperatively."
89566558|NCT03095911|Active Comparator|News with Spin|News items reporting results of RCTs with spin
89566559|NCT03095911|Experimental|News without spin|News items reporting results of RCTs without spin
89566560|NCT04813835||suicidal depressed patients|psychiatric history suicidal scale mental state examination screening for sleep disturbance electroencephalography
88969178|NCT02969122|Active Comparator|Chemotherapy-first|Patients will receive hyperthermic intraperitoneal chemotherapy (HIPEC) during laparoscopic staging. Then 3 cycles of preoperative chemotherapy and clinical evaluation of chemotherapy will be performed. If the patient's disease is evaluated as progressed, the patient will receive systemic therapy. If it's stable or remission, a second time laparoscopic staging and peritoneal cytology examination will be performed. If peritoneal implant is observed, the patients will receive systemic therapy. If the peritoneal cytology is still positive, the treatment will be decided according to the suggestion of MDT discussion. If the peritoneal cytology is converted negative, standard gastrectomy with D2 lymphadenectomy and extensive intraperitoneal lavage (EIPL) will be performed. Postoperative chemotherapy will be determined according to the pathological evaluation of preoperative chemotherapy response.
88969179|NCT02969122|Experimental|Surgery-first|Patients in this arm will receive standard gastrectomy with D2 lymphadenectomy after randomization. Hyperthermic intraperitoneal chemotherapy (HIPEC) and extensive intraperitoneal lavage (EIPL) will be applied before abdominal closure. After surgery, 8 cycles of postoperative chemotherapy will be performed.
88969180|NCT00059761|Experimental|Sequence A: Level 1|Irinotecan 40 mg/m2, cisplatin 60 mg/m2, concurrent radiation therapy (RT) at 1.5 Gy BID
88969181|NCT00059761|Experimental|Sequence B: Level 1|Irinotecan 40 mg/m2, cisplatin 60 mg/m2, concurrent RT at 2 Gy once daily
88969182|NCT00059761|Experimental|Sequence A: Level 2|Irinotecan 50 mg/m2, cisplatin 60 mg/m2, concurrent radiation therapy (RT) at 1.5 Gy BID
88969183|NCT00059761|Experimental|Sequence B: Level 2|Irinotecan 50 mg/m2, cisplatin 60 mg/m2, concurrent RT at 2 Gy once daily
88969184|NCT00059761|Experimental|Sequence A: Level 3|Irinotecan 60 mg/m2, cisplatin 60 mg/m2, concurrent radiation therapy (RT) at 1.5 Gy BID
88969185|NCT00059761|Experimental|Sequence B: Level 3|Irinotecan 60 mg/m2, cisplatin 60 mg/m2, concurrent RT at 2 Gy once daily
88969186|NCT03216083|Experimental|Tranexamic Acid|Tranexamic Acid Injectable Solution (1g intravenous) Single dose prior to the start of surgery, after the induction of anesthesia
88969187|NCT03216083|Placebo Comparator|Placebo|67mL intravenous normal saline (0.9% sodium chloride) Single dose prior to the start of surgery, after the induction of anesthesia
88969188|NCT04730752||Right Low Quadrant Pain|AIR and AAS scores will be calculated for the patients with right low quadrant pain in emergency service.
88969189|NCT02969005|Experimental|surgery group|The dissection was continued into the deeper layers until the bone lesion was visualized, and the bone lesion was then thoroughly resected.
88969190|NCT05158257|Active Comparator|Intervention: balloon and Stents|plain balloon and Stents group
89566561|NCT04813835||depressed patients|psychiatric history suicidal scale mental state examination screening for sleep disturbance electroencephalography
88969191|NCT05158257|Experimental|Intervention: debulking and drug coated balloon|debulking and drug coated balloon group
88969192|NCT02968966|Experimental|Therapy regime|Two medical drugs will be administered in a predefined order (1. Phenhydan® (Phenytoin), 2. Lacosamide (Vimpat®) to investigate whether this enables an effective reduction of seizures in early onset epileptic encephalopathies..
88969193|NCT05155020|Experimental|AK120 regimen 1|
89566562|NCT04813835||control|psychiatric history suicidal scale mental state examination screening for sleep disturbance electroencephalography
88969194|NCT05155020|Experimental|AK120 regimen 2|
89566563|NCT03095989|Experimental|Mindfulness|Subjects in the intervention group will participate in an online mindfulness program developed in the first phase of the study, in addition to standard clinical care.
89566564|NCT03095989|No Intervention|Waiting list|Participants from the control group will be placed on a waiting list and will receive the standard care, that they would receive if not in the study. They will be assessed according to the assessment schedule, exactly as subjects in the intervention group. After the last assessment (six months after recruitment), they will receive the option to enter the mindfulness program.
89566565|NCT04813913|Experimental|bevacizumab|bevacizumab in combination with IV fluoropyrimidine chemotherapy.
89566566|NCT03095755|Experimental|Ischemic Conditioning|The investigators will perform ischemic conditioning on the paretic leg by inflating a blood pressure cuff to 225 mmHg to occlude blood flow to the leg for 5 minutes. This will be repeated for 5 cycles, with 5 minutes of rest between each cycle. The intervention will be performed for a maximum of 12 times within a 4 week period.
89566567|NCT03095755|Sham Comparator|Sham|The investigators will perform sham ischemic conditioning on the paretic leg by inflating a blood pressure cuff to only 25 mmHg on the leg for 5 minutes. This will be repeated for 5 cycles, with 5 minutes of rest between each cycle. The intervention will be performed for a maximum of 12 times within a 4 week period.
89566568|NCT04828889|Experimental|research|The subjects in the study group will undergo a series of 4 treatments by 2 certified physiotherapists for pelvic floor treatment that will include instruction in self-use of anal dilators once a week for four weeks. The anal dilation will be performed using Dilatan® anal dilators (Enterprises Sapimed, Alessandria) in varying sizes of 22, 23 and 27 mm. In the first week, a 20 mm dilator will be inserted twice a day for at least 10 minutes. In the second week, a 23 mm extender will be inserted into the anus, twice a day for at least 10 minutes. In the last two weeks, a 27 mm extender will be inserted twice a day for at least 10 minutes. To facilitate the insertion of the extender, patients will use lubricating cream. At the end of each week, patients will meet with a pelvic floor physiotherapist to make sure that the insertion is done properly, that there are no side effects and that it is possible to move on to the next step.
89566569|NCT04828889|No Intervention|waiting|The subjects in the waiting group will be able after a month to choose to undergo surgery or also receive treatment by extenders.
89566570|NCT04828889|Active Comparator|surgery|The subjects in the surgery group will undergo surgical treatment only.
89566571|NCT05033509||ECMO and AKI|
88969195|NCT05155020|Experimental|AK120 regimen 3|
88969196|NCT05155020|Placebo Comparator|Placebo|
88969197|NCT00060112|Experimental|Treatment (oblimersen sodium and gemcitabine hydrochloride)|Patients receive oblimersen IV continuously on days 1-5 and gemcitabine IV over 2-3 hours on day 5. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.
88969198|NCT00060307|Experimental|Treatment (erlotinib hydrochloride)|Patients receive oral erlotinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89566572|NCT04828655|No Intervention|CONTROL GROUP|Recommendations on healthy eating habits based on the Mediterranean diet and moderate physical activity. Specific micronutrient intake focused on improving cardiovascular parameters and body composition.
89566573|NCT04828655|Experimental|EXPERIMENTAL GROUP|Recommendations on healthy eating habits based on the Mediterranean diet and moderate physical activity through an application based on machine learning. Intake of specific micronutrients focused on improving cardiovascular parameters and body composition.
89566574|NCT05033197|Experimental|CBBS intervention group|The CBBS intervention group received the 16-week intervention, including 16 CBBS lessons in basketball unit (two 40-minute lessons/week, 8 weeks) and 16 CBBS lessons in soccer unit (two 40-minute lessons/week, 8 weeks) during the 2018-2019 school year.
89566575|NCT04828499|Experimental|Progressive Cracking Technique|Patients with hard nucleus cataract were treated with Progressive Cracking Technique.
89566576|NCT04828499|Experimental|Conventional Chop Technique|Patients with hard nucleus cataract were treated with Conventional Chop Technique.
89566577|NCT05042089||pathological tumor stage 1-2 (pT1-2)|Stage pT1 and pT2 according to pathology results of patients who underwent partial or radical nephrectomy.
89566578|NCT05042089||pathological tumor stage ≥pT3a|Stage ≥pT3a according to pathology results of patients who underwent partial or radical nephrectomy.
89566579|NCT04819061|Active Comparator|Active group|In the group G1 will be administered: tDCS active + dual-task motor training
88969199|NCT02968927|Active Comparator|2HRbEZ/4HRb|2HRbZE
88969200|NCT02968927|Experimental|Everolimus|Everolimus 0.5 MG
88969201|NCT02968927|Experimental|Auranofin|Auranofin 6 MG
88969202|NCT02968927|Experimental|Vitamin D|Vitamin D3
88969203|NCT02968927|Experimental|CC-11050|CC-11050
88969204|NCT05344040|Experimental|Remotely Delivered and Supported Aerobic Walking Exercise Training|
88969205|NCT05344040|Active Comparator|Remotely Delivered and Supported Stretching and Toning|
88969206|NCT02968888|Placebo Comparator|Milk|Participants performed a bout of strength training and consumed 20g of milk protein
88969207|NCT02968888|Experimental|Whey protein concentrate 80|Participants performed a bout of strength training and consumed 20g of whey protein concentrate 80
88969208|NCT02968888|Experimental|Native whey|Participants performed a bout of strength training and consumed 20g of native whey
88969209|NCT00398515|Experimental|Treatment (antiangiogenesis, chemotherapy, enzyme inhibitor)|Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22 and oral lenalidomide once daily on days 1-21. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.
88969210|NCT05105685|Placebo Comparator|Group A|Subjects were randomly divided into two different groups. Group A began with placebo while group B with rhGH. Randomisation of the treatment order (i.e., starting with rhGH or placebo) was done through a permuted four-block designed by the physician, who was the only one not blinded for treatment allocation.
89027953|NCT00487253|Active Comparator|Group 2|Administration of Parenteral meglumine antimoniate, Glucantime® Amp 5ml (83mg/ml). Dosage:20mg/kg/day, during 20 days.
89566580|NCT04819061|Sham Comparator|Sham group|In the group G2 will be administered: tDCS sham + dual-task motor training
89566581|NCT04814381|Experimental|Ketamine + Magnesium|patients in the experimental group will receive 0.5mg/kg of ketamine over 2 hours, diluted in 50cc of NaCl 0.9% and 3g of magnesium sulfate over 30 minutes diluted in 250cc of NaCl 0.9%.
89566582|NCT04814381|Active Comparator|Control|patients in the control group will receive 25mg of hydroxyzine over 2 hours, diluted in 50cc of NaCl 0.9% and 250cc of NaCl 0.9% over 30 minutes
89566583|NCT05041777||Prospective data collection, retrospective OCT image evaluation|From February 2017-June 2017 patients were included prospectively. OCT images were evaluated retrospectively in conjunction with clinical images. A deep learning algorithm is developed with use of this dataset including 676 OCT images.
89566584|NCT05041777||Prospective data collection and OCT image evaluation|From January 2021-April 2021 patients were included prospectively. OCT images were evaluated prospectively in a clinical setting. The deep learning algorithm will be prospectively validated with use of this dataset including 287 OCT images.
89566585|NCT04819217|Other|Active bamboo charcoal|Based on these previous findings, we will conduct a prospective randomized open blinded end-point (PROBE) study to see if oral uremic toxin absorbent + probiotics prevent CKD progression.
89566586|NCT04819217|Other|Probiotics|Based on these previous findings, we will conduct a prospective randomized open blinded end-point (PROBE) study to see if oral uremic toxin absorbent + probiotics prevent CKD progression.
89566587|NCT05041465|Experimental|French Green Clay Mask|
89566588|NCT05041465|Experimental|Rhassoul Clay Mask|
89566589|NCT05041465|Experimental|Bentonite Clay Mask|
89566590|NCT04818905|Experimental|Helichrysum italicum infusion|1 g of milled plant material (Helichrysum italicun) immersed in hot water (200 mL, 100 °C) for 10 minutes.
89566591|NCT04818905|Placebo Comparator|Hot water|The control beverage contained only hot water (200 mL, 100 ˚C).
89566592|NCT05052619|Experimental|Preventive use of advanced antibiotics group|Treat patients in this group with advanced preventive usage of antibiocs: Sulperazon 3g q8h, in postoperative days 1-5.
89566593|NCT05052619|Other|Routine group|Treat patients in this group with routine preventive usage of antibiocs: Cefmetazole 1g q12h, in postoperative days 1-3.
89566594|NCT04813679||Neutropenic Enterocolite patients assessed with bed side ultrasound sonography|"From March 2007 through the entire study period all patients admitted eighter in our chemotherapy-ward or BMT-ward to receive intensive chemotherapy (chemo) for any hematological malignancies, or chemotherapy (CHT) for both auto transplant (ASTC) and allogeneic transplant (AlloTx), were prospectively enrolled in the study. When the patient received more than one chemo cycle, each ward access was considered a new observational period.~Patients who received CHT and experienced CHT-induced neutropenia (CHTNP) were enrolled in the study. We defined one observational period each admission on the ward to receive CHT, in which CHT and length of stay could vary from the previous admission. One observational period ended with the discharge of the pts form the ward. If a pts experienced a new chemo related NECe during another admission, it was considered as e new NECe."
89566595|NCT04813679||Neutropenic Enterocolite negative patients assessed with bed side ultrasound sonography|NEC negative patients received bed-side ultrasound sonography after three days of neutropenia.
89566596|NCT05052775|Active Comparator|Chlorhexidine Group|These patients were control group given chlorhexidine mouthwash 2 times per day for 15 days
89566597|NCT05052775|Experimental|Morus Alba 20%|Patients were given morus alba 20% concentration 2 times per day for 15 days
89566598|NCT05052775|Experimental|Morus Alba 30%|Patients were given morus alba 30% concentration 2 times per day for 15 days
89566599|NCT04427423|Experimental|Positional Distraction plus Stabilization Exercise group|The treatment group will receive positional distraction with stabilization exercises
89566600|NCT04427423|Active Comparator|Stabilization Exercise group|control group will be treated with stabilization exercises only.
89566601|NCT05052463||sodium (hypo-hyper-normonatremia)|
89566602|NCT05052463||potassium (hypo-hyper-normokalemia)|
89027954|NCT04510233|Experimental|Ivermectin nasal spray|Ivermectin administered as nasal spray (one ml in each nostril two times daily)
89566603|NCT05052463||calcium (hyper-hypo-normocalcemia)|
89566604|NCT05052463||magnesium (hyper-hypo-normocalcemia)|
89566605|NCT05052463||phosphor (hypo-hyper-normophosphatemia)|
89566606|NCT04813367||Twisted fallopian tubes cohort|Description of girls who went through surgery for twisted fallopian tubes
89566607|NCT03094741|Experimental|CancerLife Feasibility Group|Participants will be recruited through advertisements targeted to a specific audience using the keywords cancer and cancer survivors
89566608|NCT04818437|Experimental|Balance training|"Balance training~Trunk, head, and upper limbs rotation from kneeling.~Upper limbs flexion and extension with simultaneous head movement from kneeling.~Pelvic bridging followed by raising one lower limb and extending knee.~Lifting opposite upper and lower limbs from Quadruped position.~6-Heel and toe raises, alternate rising ofthe right and left feet above the floor, and tandem standing. 7-Weight shifting forward. backward, sideward, and diagonally with eyes opened and eyes closed"
89566609|NCT04818437|Active Comparator|Core stability exercise|"Core stability exercises:~Abdominal bracing while lying in supine position.~Abdominal bracing with heel slide while lying in supine position.~Abdominal bracing with Leg lifts while lying in supine position.~Abdominal bracing with bridging while lying in supine position.~Abdominal bracing while Standing 6-Abdominal bracing while walking.~7-Quadra pod arm lifts with bracings while Quadra pod position. 8-Quadra pod alternate arm and leg lifts with bracing while Quadra pod position. 9-Side plank with knee flexion while side lying. 10-Side plank with knee extension while side lying."
89027955|NCT04510233|Experimental|Ivermectin oral|Ivermectin administered orally (one tablet 6 mg three times daily) for 72 hours plus the standard care of COVID-19 cases.
89027956|NCT04510233|Experimental|standard care|COVID-19 cases will receive standard of care [oxygen via masks or ventilators]
89033098|NCT02917863|Experimental|Solid L-Thyroxine|"Patients assume L-Thyroxine (tablet, per os) according to the Summary Product Characteristics for 6 months (then switch to the other formulation).~Dosage in children with hypothyroidism:~0-6 months: 10 mcg/kg body weight/die 6-12 months: 8 mcg/kg body weight/die~1- 5 years: 6 mcg/kg body weight/die 5-10 years: 4 mcg/kg body weight/die~Dosage in adults:~initial dose of 50mcg/die; maintenance dose 100-200 (300) mcg/die (medium dose 2-2,5 mcg/kg body weight/die).~Dosage will be adjusted according to TSH level."
89566610|NCT03095677|Experimental|Apnea Group (GApn)|Program of training with exercises including apneas
89566611|NCT03095677|Other|Control Group (GC)|Program of training with exercises without apnea
89566612|NCT04813757|Experimental|intervention group|Participants in the intervention group will receive 12 treatment sessions over a 6-week period. Three sessions during the first 2 weeks, 2 sessions per week during weeks 3 and 4 , and one session during weeks 5 and 6. Each session will be 30 minutes including 10 minutes of manual therapy and 20 minutes for review and/or modification of the exercise program. The manual therapy will include trigger point manual therapy. The exercise program will include 2 scapular and rotator cuff strengthening exercises emphasizing scapular upward rotation and posterior tilt and one additional flexibility exercise. These exercise will be repeated at home on the days in between the therapy sessions.
89566613|NCT04813757|Active Comparator|control group|Participants in the control group will receive 12 treatment sessions over a 6-week period. Three sessions during the first 2 weeks, 2 sessions per week during weeks 3 and 4 , and one session during weeks 5 and 6. Each session will be 30 minutes including 10 minutes of manual therapy and 20 minutes for review and/or modification of the exercise program. The manual therapy will include trigger point manual therapy, posterior shoulder stretching, and mobilization-with-movement into shoulder elevation. The exercise program will include 2 exercises focusing on scapular and rotator cuff strengthening without a special emphasis on scapular upward rotation as well as one additional flexibility exercise. These exercises will be performed at home on the days on between the therapy sessions.
89566614|NCT03094897|Experimental|18F-Al-NOTA-MATBBN PET/CT|Imaging with 18F-Al-NOTA-MATBBN PET/CT
88969211|NCT05105685|Experimental|Group B|Subjects were randomly divided into two different groups. Group A began with placebo while group B with rhGH. Randomisation of the treatment order (i.e., starting with rhGH or placebo) was done through a permuted four-block designed by the physician, who was the only one not blinded for treatment allocation.
88969212|NCT05325164|Experimental|Methadone|"DESCRIPTION:~Blinded methadone 1mg tablets PO~--~DOSAGE:~A) For patients initially taking 0-30 mg MEDD:~Starting dose: 0.5mg Q4H x 4 doses + 1.0mg QHS + 0.5mg Q2H PRN (max 4 doses)~First increase: 1.0 mg Q4H x 4 doses + 2.0mg QHS + 0.5mg Q2H PRN (max 4 doses)~Second increase: 1.5mg Q4H x 4 doses + 3.0mg QHS + 0.5mg Q2H PRN (max 4 doses)~Third increase: 2.0mg Q4H x 4 doses + 4.0mg QHS + 1.0mg Q2H PRN (max 4 doses)~Fourth increase: 2.5mg Q4H x 4 doses + 5.0mg QHS + 1.0mg Q2H PRN (max 4 doses)~B) For patients initially taking 31-60 mg MEDD:~Starting dose: 1.0mg Q4H x 4 doses + 2.0mg QHS + 0.5mg Q2H PRN (max 4 doses)~First increase: 1.5mg Q4H x 4 doses + 3.0mg QHS + 1.0mg Q2H PRN (max 4 doses)~Second increase: 2.0mg Q4H x 4 doses + 4.0mg QHS + 1.0mg Q2H PRN (max 4 doses)~Third increase: 2.5mg Q4H x 4 doses + 5.0mg QHS + 1.5mg Q2H PRN (max 4 doses)~Fourth increase: 3.0mg Q4H x 4 doses + 6.0mg QHS + 1.5mg Q2H PRN (max 4 doses)"
89027957|NCT05641909|Experimental|Remifentanil|"Remifentanil analgesia combined with propofol sedation. Treatment was started in patients with an CPOT score of 2 or greater after completion of baseline assessments. All patients received an initial infusion of blinded opioid (placebo bolus dose(6ml)~+ 6ug/kg per hour infusion at 6 ml/hour). Optimal analgesia (CPOT score ≤2) was then targeted by titrating the infusion in 1.5 ml/hour increments (placebo bolus dose + 1.5ug/kg per hour rate increase). Only when the opioid infusion rate had reached the 'propofol trigger dose' (12ml/h; 12ug/ kg per hour) was propofol to be administered as an initial bolus dose of up to 0.5 mg/kg and an infusion of 0.5mg/kg per hour, and titrated in 25% increments (0.25mg/kg bolus dose + 0.125mg/kg per hour rate increase to treat agitation."
89566615|NCT04813523|Experimental|Experimental: Pembrolizumab+Cisplatin+5-FU|Participants receive preoperative pembrolizumab 200 mg intravenously (IV) every 3 weeks (Q3W), cisplatin 80 mg/m^2 IV Q3W, and 5-FU 600 mg/m^2/day IV infusion on Days 1 to 5. There are 3 cycels of preoprative therapy and 3 cycles of postoperative therapy.
89566616|NCT05032261||Group 1: surviving Patients|Patients surviving within 5 days of the date of ICU admission for circulatory shock and receiving norepinephrine
89566617|NCT05032261||Group 2: Deceased patients|Patients deceased within 5 days of the date of ICU admission for circulatory shock and receiving norepinephrine
89566618|NCT04812977|Experimental|Group A|A single injection of triamcinolone acetonide (Kenacort-AⓇ). (2mg/0.05ml) and intravitreal bevacizumab (Avastin®) (1.25mg/0.05ml) was given at the start of the treatment whereas intravitreal bevacizumab (1.25mg/0.05ml) was repeated monthly for 3 months.
89566619|NCT04812977|Active Comparator|Group B|Intravitreal bevacizumab (1.25mg/0.05ml) was repeated monthly for 3 months.
89566620|NCT05052073||MD patients|"patients with different forms of muscle dystrophy, for example~facioscapulohumeral dystrophy~dysferlinopathy~caveolinopathy"
89566621|NCT05052073||Controls|- healthy age- and sex-matched controls (10 men, 10 women)
89566622|NCT04813133|Experimental|Synchronized Lifestyle Modification Program|Synchronized Lifestyle Modification Program
88815024|NCT03021902|Experimental|IV amino acid + in-bed cycle ergometry|Beginning within 96 hours of initiation of mechanical ventilation, participants will receive the combined intervention that includes IV amino acids supplementation and in-bed cycle ergometry exercise
88815025|NCT03021902|No Intervention|Usual care|Participants randomized to the usual care arm will receive usual care protein and exercise.
88815026|NCT01676831|Experimental|topical resiquimod 0.06%|Topical resiquimod 0.06% will be applied in dosing frequencies that are periodically adjusted to tolerability. Dosing frequency will be 3 times a week. The dosing frequency may be adjusted (1,2,3,5,or 7times per week) based on the physician assessment of tolerability. Treatment will occur for 8 weeks followed by 4 weeks rest followed by another 8 weeks of treatment with 4 weeks rest. At 24 weeks a final evaluation will be performed. Those with a partial response at week 24 will have the option to continue therapy for up to another 12 weeks.
88969213|NCT05325164|Active Comparator|Morphine|"DESCRIPTION:~Blinded morphine 5mg tablets PO~--~DOSAGE:~A) For patients initially taking 0-30 mg MEDD:~Starting dose: 2.5mg Q4H x 4 doses + 5.0mg QHS + 2.5mg Q2H PRN (max 4 doses)~First increase: 5.0 mg Q4H x 4 doses + 10.0mg QHS + 2.5mg Q2H PRN (max 4 doses)~Second increase: 7.5mg Q4H x 4 doses + 15.0mg QHS + 2.5mg Q2H PRN (max 4 doses)~Third increase: 10.0mg Q4H x 4 doses + 20.0mg QHS + 5.0mg Q2H PRN (max 4 doses)~Fourth increase: 12.5mg Q4H x 4 doses + 25.0mg QHS + 5.0mg Q2H PRN (max 4 doses)~B) For patients initially taking 31-60 mg MEDD:~Starting dose: 5.0mg Q4H x 4 doses + 10.0mg QHS + 2.5mg Q2H PRN (max 4 doses)~First increase: 7.5mg Q4H x 4 doses + 15.0mg QHS + 5.0mg Q2H PRN (max 4 doses)~Second increase: 10.0mg Q4H x 4 doses + 20.0mg QHS + 5.0mg Q2H PRN (max 4 doses)~Third increase: 12.5mg Q4H x 4 doses + 25.0mg QHS + 12.5mg Q2H PRN (max 4 doses)~Fourth increase: 15.0mg Q4H x 4 doses + 30.0mg QHS + 12.5mg Q2H PRN (max 4 doses)"
89566623|NCT04813133|Experimental|Synchronized Lifestyle Modification Program and Physiotherapy|Synchronized Lifestyle Modification Program and Physiotherapy
88969214|NCT02968771||Patients with Physical Cardiac Stress|Patients with Physical Cardiac Stress
89566624|NCT04813133|Experimental|Physiotherapy|Physiotherapy included Aerobics, Resistance exercise, Flexibility exercise, and Balance exercise.
88969215|NCT02968771||Patients with Physical and Pharmacological Cardiac Stress|Patients with Physical and Pharmacological Cardiac Stress with adenosine agonist
88969216|NCT02968771||Patients with Pharmacological Cardiac Stress|Patients with Pharmacological Cardiac Stress with adenosine agonist
89566625|NCT04813133|No Intervention|Control Group|No intervention will be given to this Group
89566626|NCT05032027|Experimental|Probiotic group|Probiotic( recieving Probiotic at the first day of chemoradiotherapy daily)with radiotherapy and Chemotherapy Intervention
89566627|NCT05032027|No Intervention|placebo group|placebo( one times a day)with radiotherapy and Chemotherapy Intervention
89566628|NCT05032027|No Intervention|healthy control group|healthy control group
89566629|NCT04813289||Anaesthesia type|"Inhalational anaesthesia without Remifentanil use~Inhalational anaesthesia with Remifentanil use~Total intravenous anaesthesia"
89566630|NCT04813289||Blood pressure monitoring|"Intraarterial line use~Non-invasive blood pressure monitoring"
89566631|NCT04813211|Experimental|Trial group|20 patients with cervical spondylosis undergoing mobile artificial cervical vertebrae replacement
89566632|NCT04813211|Experimental|Control group|20 patients with cervical spondylosis undergoing anterior cervical corpectomy and fusion
89566633|NCT03098017|Active Comparator|Couscous (dry)|Cooked couscous (50g available carbohydrate, 70g uncooked) eaten with 500 mL of water
89566634|NCT03098017|Experimental|Short pasta (dry)|Cooked penne (50g available carbohydrate, 71g uncooked) eaten with 500 mL of water
89566635|NCT03098017|Experimental|Long pasta (dry)|Cooked spaghetti (50g available carbohydrate, 71g uncooked) eaten with 500 mL of water
89566636|NCT03098017|Active Comparator|Glucose|Glucose monohydrate (55 g) dissolved with 500 mL of water
89566637|NCT05619341|Placebo Comparator|inulin|20g inulin in 500ml water
89566638|NCT05619341|Active Comparator|inulin + psyllium|Inulin 20g + 20g psyllium in 500 ml water
89566639|NCT05619341|Active Comparator|inulin divided doses|2.5 g inulin in 62.5ml water given at 45 minute intervals
89566640|NCT05040919||with an arrythmia|patient suffering from STEMI and presenting an arrythmia
89566641|NCT05040919||without an arrythmia|patient suffering from STEMI and not presenting an arrythmia
89566642|NCT05040607||Primary Ciliary Dyskinesia (PCD)|"The first stage of the study:~Data of 20 PCD patients from the database recorded between 10 July 2015 and 10 January 2017.~The second stage of the study:~Data of 14 PCD patients who had lower inspiratory muscle strength from the same database underwent supervised inspiratory muscle training (IMT) at our research unit and airway clearance techniques (ACT) as a home-based therapy for 6 weeks from the database recorded between 10 July 2015 and 10 January 2017.~Data of 14 PCD patients who had lower inspiratory muscle strength from the same database underwent airway clearance techniques (ACT) as a home-based therapy for 6 weeks from the database recorded between 10 July 2015 and 10 January 2017."
89566643|NCT05040607||Healthy Group|Data of 20 healthy subjects from the database recorded between 10 July 2015 and 10 January 2017.
89566644|NCT04818827||Ketamine group|This cohort includes patients who received ketamine as a sedative analgesic agent during mechanical ventilation
89566645|NCT04818827||Non Ketamine group|This cohort includes patients who received sedatives other than ketamine during mechanical ventilation
89566646|NCT05040529||PLDRH|patients who underwent pure laparoscopic donor right hepatectomy
89566647|NCT05040529||ODRH|patients who underwent conventaional open donor right hepatectomy
89566648|NCT05040139||Malone procedure|The percutaneous caecal access is performed surgically
89027958|NCT05641909|Active Comparator|Fentanyl|"Fentanyl analgesia combined with propofol sedation. Treatment was started in patients with an CPOT score of 2 or greater after completion of baseline assessments. All patients received an initial infusion of blinded opioid (1ug/kg bolus(6ml) + 1ug/kg per hour infusion at 6ml/hour). Optimal analgesia (CPOT score~≤2) was then targeted by titrating the infusion in 1.5 ml/hour increments (1ug/kg bolus dose + 0.25ug/kg per hour rate increase). Only when the opioid infusion rate had reached the 'propofol trigger dose' (12ml/h; 2ug/kg per hour) was propofol to be administered as an initial bolus dose of up to 0.5 mg/kg and an infusion of 0.5mg/kg per hour, and titrated in 25% increments (0.25mg/kg bolus dose + 0.125mg/kg per hour rate increase to treat agitation."
89027959|NCT00487331|Experimental|Acupuncture|Acupuncture sessions 1-3 times per week. 2 pain questionnaires + satisfaction survey completed at beginning and end of treatment.
89027960|NCT05639179|Experimental|Assigned Interventions|Subjects who meet the enrollment conditions will receive intravenous infusion of UCAR-T Cells after lymphodepletion.
89027961|NCT04510077|Experimental|Prevention (SmartQuit)|Patients use the SmartQuit program to learn and practice skill modules as often as they wish over 6 months.
89566649|NCT05040139||Percutaneous Endoscopic Caecostomy|The percutaneous caecal acces is performed endoscopically.
89566650|NCT05031793|Experimental|Collaborative Care of TCM and Western Medicine|
89027962|NCT02274389||Bedaquiline Patient Registry (BPR)|
89027963|NCT05637619||Dentate Patients|Patients with natural dentition - maxilla and mandible
89027964|NCT05637619||Zirconia|Patients that have a full-mouth (maxilla or mandible) dental implant supported rehabilitation restored with monolithic zirconia biomaterial
89566651|NCT05031793|Active Comparator|Western medicine|
89566652|NCT05039905|Experimental|99mTc-MSA-ICG injection|"99mTc-MSA-ICG injection~1mCi of 99mTc~1mg of MSA 0.1mg of ICG Total 1cc injection volume at 2 hours before the surgery"
89566653|NCT05039983|Experimental|EGCG application|We have chosen a dose of 880 umol/L as the lower limit for this phase I study by referring to previous studies. Six dose levels for EGCG were defined as following: 880, 1760, 2640, 3430, and 4400 umol/L per dose. Dose escalation proceeded according to a standard phase I design with three patients initially treated on each tier. If, on any dose tier of EGCG, two of three patients or two of six patients experienced a grade III or IV toxicity due to EGCG, dose escalation of EGCG would cease. The maximally tolerated dose (MTD) was defined as the highest dose with fewer than one-third of patients experiencing a dose-limiting toxicity (DLT) due to EGCG. EGCG solution was given continuously for 8 days before anti-tumor treatment.
89566654|NCT05031403|Experimental|Stroke (Telerehabilitation)|Exercise therapy with telerehabilitation system
89566655|NCT05031403|Other|Stroke (Home Exercise)|Exercise therapy with brochure
89566656|NCT05031403|Experimental|Multiple Sclerosis (Telerehabilitation)|Exercise therapy with telerehabilitation system
89566657|NCT05031403|Other|Multiple Sclerosis (Home Exercise)|Exercise therapy with brochure
89566658|NCT05031403|Experimental|Parkinson Disease (Telerehabilitation)|Exercise therapy with telerehabilitation system
89566659|NCT05031403|Other|Parkinson Disease (Home Exercise)|Exercise therapy with brochure
89566660|NCT05039827|Experimental|MWM GROUP|Mobilization with movement with wrist extension
89566661|NCT05039827|Active Comparator|SOFT TISSUE MOBILIZATION GROUP|Parallel and perpendicular soft tissue massage at common extensor origin
89027965|NCT05637619||Hybrid Acrylic|Patients that have a full-mouth (maxilla or mandible) dental implant supported rehabilitation restored with acrylic material (hybrid acrylic)
89027966|NCT02276196|Experimental|Lixisenatide|Lixisenatide will be administered subcutaneously, once daily for 8 weeks
89027967|NCT02276196|Active Comparator|Insulin glulisine|Insulin glulisine will be administered subcutaneously, once daily for 8 weeks
89027968|NCT00487422|Active Comparator|1|Prucalopride
89027969|NCT00487422|Active Comparator|2|Prucalopride
89027970|NCT00487422|Placebo Comparator|3|Placebo
89027971|NCT05620615||Intensive Drug Therapy|Dual antiplatelet therapy (DAPT) (aspirin 100 mg per day and clopidogrel 75 mg per day were administered for 90 days, followed by aspirin 100 mg per day for long term) and atorvastatin (40 mg per day for 14 days, followed by 20 mg per day long term) after enrollment.
89027972|NCT00506181|Active Comparator|X|receiving probiotics
89027973|NCT00506181|Placebo Comparator|Y|
89027974|NCT00506181|No Intervention|Z|
89027975|NCT00487409|Other|Group A|Standard of Care
89027976|NCT00487409|Other|Group B|Standard of Care
89027977|NCT00623662|Active Comparator|1|Glucose infusion.
89027978|NCT00623662|Placebo Comparator|2|Normal saline infusion.
89566662|NCT05040061|Experimental|SkillJoy Intervention|The savoring treatment consisted of an ecological momentary intervention (EMI) for learning and practicing savoring skills-SkillJoy. SkillJoy prompted participants to attend to positive aspects of the present moment, plan and engage in enjoyable activities, record and reflect on positive experiences, note events that turned out well, and look forward to positive events.
89566663|NCT05040061|Active Comparator|Active Self-Monitoring Control Intervention|The active self-monitoring control EMI consisted of similar activities, but they all omitted savoring practices. These activities included attending to any current thoughts and feelings, planning everyday activities, remembering and recording daily events, and anticipating important events.
89566664|NCT05051839|Experimental|Radiographic bone level|
89566665|NCT05051839|Experimental|Peri implant soft tissue volume|
89566666|NCT05031559|Experimental|Episodic Future Thinking|
89566667|NCT05031559|Experimental|Compassion|
89566668|NCT05031559|Sham Comparator|Control|
89566669|NCT05039749|Experimental|Human Central Lighting (HCL) Room|This inpatient room was outfitted with lights that mimic the day/night cycle, thereby supporting circadian rhythm. Day time lights were automatically on during 0600 to 1900 and in use any time the patients would normally utilize their lights, with a goal of three hours of light exposure per day. The lights automatically transitioned to warmer toned evening lighting at 1900.
89566670|NCT05039749|No Intervention|Standard Hospital Lighting (SL) Room|The lighting in this room was standard florescent hospital lighting. The only changes in the lighting was the on/off settings normally associated with lighting.
89566671|NCT05031013||Dialysis patients|Dialysis patients
88969217|NCT05055921|Experimental|Multi Pulse Therapy as delivered from the Cardialen External Stimulation System|Subjects will have AF induced and the Cardialen External Stimulation System (CESS) device will deliver electrical stimulation to terminate the arrhythmia.
88969218|NCT04730908|Placebo Comparator|G0 - placebo|Dental gel without fluoride in the composition
88969219|NCT04730908|Sham Comparator|G1: Daily Regenerator Dentalclean Neutro (RDCN)|1450 ppm F- of sodium fluoride and tetrasodium pyrophosphate (Refix technology). NEUTRAL pH
88969220|NCT04730908|Active Comparator|G2: Sensodyne Repair & Protect (SRP)|1426 ppm of sodium fluoride and calcium sodium phosphosilicate 5% (NOVAMIN technology).
88969221|NCT04730908|Experimental|G3: Daily Regenerator Dentalclean Acid (RDCA)|1450 ppm F- of sodium fluoride and tetrasodium pyrophosphate (Refix technology). ACIDIC FORMULA
88969222|NCT04730908|Active Comparator|G4: Colgate Total Daily Repair (CTDR)|1450 ppm F- of as sodium fluoride, 0.30% triclosan, arginine, tetrasodium pyrophosphate.
88969223|NCT05319197||SLD Group|
88969224|NCT05319197||Healthy Control Group|
88969225|NCT02968693||combination therapy group|antibiotic-loaded calcium sulfate and antibiotic-loaded polymethyl methacrylate (PMMA) and Vancomycin
88969226|NCT02968693||PMMA group|antibiotic-loaded polymethyl methacrylate and Vancomycin
88969227|NCT05055336|Experimental|Gastroparesis|Participants in this group are children diagnosed with gastroparesis per gastric emptying scintigraphy. Participants will be receiving a gastric emptying breath test three times over the course of 6 months and an ultrasound of the stomach once.
88969228|NCT05055336|Experimental|Dyspepsia|Participants in this group are children diagnosed with functional dyspepsia per gastric emptying scintigraphy. Participants will be receiving a gastric emptying breath test three times over the course of 6 months and an ultrasound of the stomach once.
88969229|NCT05055336|Experimental|Healthy Controls|Participants in this group are children that do not have gastroparesis, functional dyspepsia, or any other gastroenterology condition. Participants will be getting an ultrasound once.
88969230|NCT05312372|Experimental|S095033 in combination with paclitaxel|"Dose escalation - phase 1: S095033 will be administrated at dose of 100 mg,150 mg or 200 mg everyday during a 28-day cycle. The participants will also receive paclitaxel intravenously on D1, D8 and D15 last for 28 days.~Dose expansion - phase 2: Participants with MTAP-deletion and those with MTAP-wild type tumors will be evaluated in separate and independent dose expansion subpopulations.S095033 will be administrated every day during a 28-day cycle at recommended phase 2 dose (RP2D). Paclitaxel given intravenously on D1, D8, and D15 during a 28-day cycle."
88969231|NCT04730713||Admitted to the center ICU due to neurosurgery, brain dysfunction and other neurological reasons|Aneurysmal subarachnoid hemorrhage (aSAH), traumatic brain injury (TBI), acute deficiency Blood stroke (AIS), acute cerebral hemorrhage (ICH), hypoxic ischemic encephalopathy (HIE), Sepsis-associated encephalopathy (SAE), intracranial tumor surgery; older than 18 years old, <85 Years old; patients who need lumbar puncture.
88969232|NCT05038410|Active Comparator|Wobenzym®|Medicinal product Wobenzym® containing Bromelain (67.5-76.5 mg) adjusted to 450 FIP units, Trypsin (32-48mg) adjusted to 24 µkat and Rutoside trihydrate (100mg).
88969233|NCT05038410|Placebo Comparator|PLACEBO|No active ingredients. The active ingredients will be substituted by microcrystalline cellulose.
88969234|NCT00060814|Experimental|Combined Pharmacotherapy and Counseling|300 mg Bupropion/4mg Nicotine Gum/Motivational Interviewing
88969235|NCT00060892|Active Comparator|1|0.4 mg AMG0001 on days 0, 14, and 28
88969236|NCT00060892|Active Comparator|2|4.0 mg AMG0001 on days 0, 14, and 28
88969237|NCT00060892|Active Comparator|3|4.0 mg AMG0001 on days 0 and 28; placebo on day 14
88969238|NCT00060892|Placebo Comparator|4|Placebo (saline) on days 0, 14, and 28
88969239|NCT05300945|No Intervention|Control|
88969240|NCT05300945|Experimental|HIPEC|
88969241|NCT02968615|Experimental|fiber & protein|A single dietary change condition that focuses exclusively on increasing fiber and protein.
88969242|NCT02968498|Active Comparator|Study arm 1|Lactulose crystals 10 g vs lactulose crystals 20 g vs oral glucose 20 g vs still water
88969243|NCT02968498|Active Comparator|Study arm 2|Lactulose liquid 10 g vs lactulose liquid 20 g vs oral glucose 20 g vs still water
88969244|NCT00061087|Active Comparator|METHYLPHENIDATE|Methylphenidate
88969245|NCT00061087|Active Comparator|BUPROPION|Bupropion
88969246|NCT00061087|Placebo Comparator|PLACEBO|Placebo
88969247|NCT02968225|Experimental|Computer Game|"All Computer Game participants will complete:~online screening~Diagnostic and eye-tracking pre-testing~2 month intervention~Eye-tracking post-testing"
88969248|NCT02968225|No Intervention|Waitlist control|"All Treatment as usual control participants will complete:~online screening~Diagnostic and eye-tracking pre-testing~Eye-tracking post-testing"
88969249|NCT02968186|Experimental|Implementation program|Health professionals will receive a training and support implementation program
88969250|NCT02968186|No Intervention|Waiting list|Health professionals will be assigned to a waiting list to receive the implementation program
88969251|NCT00061243|Experimental|1|Participants will receive different doses of the vaccine to determine the optimal dose
88969252|NCT00061243|Experimental|2|Participants will receive different doses of the vaccine to determine the optimal dose
88969253|NCT00061243|Experimental|3|Participants will receive different doses of the vaccine to determine the optimal dose
88969254|NCT00061243|Experimental|4|Participants will receive the vaccine through either intradermal or intramuscular administration
88969255|NCT00061243|Experimental|5|Participants will receive the vaccine through either intradermal or intramuscular administration
88969256|NCT04711564||Provision of olive oil emulsions in PN|Olive oil-based (Oliclinomel: 80% OO, 20% LCT provided in a complete all-in-one PN bag by Baxter) parenteral nutrition
88969257|NCT04711564||Provision of soybean emulsions in PN|Soybean-based (Kabiven: 100% LCT provided in a complete all-in-one PN bag)
88969258|NCT00061321|Active Comparator|1|Mothers: One dose of intrapartum nevirapine by mouth (200mg) at onset of labor Infants: One dose of liquid nevirapine by mouth within 72 hours of birth (2mg/kg) Infants: Liquid multivitamins (1ml/day) week 1 through week 6 post-partum
88969259|NCT00061321|Experimental|2|Mothers: One dose of intrapartum nevirapine by mouth (200mg) at onset of labor Infants: One dose of liquid nevirapine by mouth within 72 hours of birth (2mg/kg) Infants: Liquid multivitamins (1ml/day)by mouth, from week 1 through week 6 post-partum Infants: Liquid nevirapine (5 mg/day) by mouth, from week 1 through week 6 post-partum
89566672|NCT05039437|Experimental|MGF-4|Take two MGF-4 capsules twice a day for 8 weeks. A 250 mg capsule contents 243 mg MGF-4 and other excipients.
89566673|NCT05039437|Experimental|MGF-7|Take two MGF-7 capsules twice a day for 8 weeks. A 250 mg capsule contents 243 mg MGF-7 and other excipients.
89566674|NCT05030779|Experimental|Treatment of SLE|Experimental：Administration of CD19/BCMA CAR T-cells A dose levels of 1-4*10E6/kg are administrated for each subject.
89566675|NCT05031091||Case: patients with confirmed leprosy|diagnosed or followed up in French Guiana between the beginning of 2006 and the end of 2022
89566676|NCT05031091||Control: patient with a dermatological condition not clinically suspicious of leprosy|Any patient, of any age, consulting for a dermatological pathology not clinically suspicious of leprosy during a dermatological consultation by a practitioner of the Cayenne Hospital
89566677|NCT05051683|Active Comparator|group (1)|combined endoscopic & radiologic intervention for management of acute perforated peptic ulcer
89566678|NCT05051683|No Intervention|group (2)|surgical management of acute perforated peptic ulcer
89566679|NCT05031169|Experimental|A-PRF|Surgical treatment A-PRF membrane
89566680|NCT05031169|Active Comparator|SCTG|Surgical treatment with SCTG
89566681|NCT05051137||Infliximab initiators|Rheumatoid arthritis patients initiating infliximab after treatment with methotrexate for a minimum of 30 days.
89566682|NCT05051137||Sulfasalazine + Hydroxychloroquine initiators|Rheumatoid arthritis patients initiating sulfasalazine and hydroxychloroquine after treatment with methotrexate for a minimum of 30 days.
89566683|NCT05039125|Active Comparator|40000HZ ultrasound cavitation|group A (n=15) received 40000HZ ultrasound cavitation, Treatment time was 30 minutes /sessions, 3 times/ week for two months. Both groups (A and B) received a low caloric diet (1200 Kcal/day). All participants had their medical treatment as prescribed by the physician.
89566684|NCT05039125|Active Comparator|2600HZ ultrasound cavitation|group B (n=15) received 2600HZ ultrasound cavitation. Treatment time was 30 minutes /sessions, 3 times/ week for two months. Both groups (A and B) received a low caloric diet (1200 Kcal/day). All participants had their medical treatment as prescribed by the physician.
89566685|NCT05038969|Experimental|A test|Test drug (Stomopral) 1 capsule contains 40 mg Enteric Coated Pellets of Esomeprazole
89566686|NCT05038969|Active Comparator|B reference|Reference drug (Nexium) 1 capsule contains 40 mg Esomeprazole
89566687|NCT04434547|Experimental|PRP group|In the PRP group autologous platelets rich plasma was prepared from the blood using the two step centifuge process .Under ultrasound guidance and complete aseptic procedure , 1 ml of PRP was infused inside the uterus while performing the mock embryo transfer
89566688|NCT04434547|No Intervention|Control group|In the control group mock embryo transfer was performed without injecting anything inside the uterus.
89566689|NCT04434391||QF-PCR for GBS screening|QF-PCR for vaginal-rectal samples in pregnant women
89566690|NCT05030389|Experimental|Adapted Physical Activity (APA)|Participants receive a web-based adapted physical activity (APA) during 12 weeks, on the basis of three at-home sessions a week
89566691|NCT05030389|Experimental|Adapted Physical Activity + Bright Light Exposure (APA + BLE)|Participants receive a web-based APA program during 12 weeks on the basis of three at-home sessions a week, supplemented by a bright light exposure (BLE) during 12 weeks, on the basis of five at-home sessions a week
89566692|NCT05030389|Experimental|Galvanic Vestibular Stimulation (GVS)|Participants receive Galvanic Vestibular Stimulation (GVS) during two weeks, on the basis of five at-home sessions a week
89566693|NCT05030389|Active Comparator|Health Education program (HE)|Participants receive a web-based health education program (HE) during 14 weeks, on the basis of one at-home session a week
89566694|NCT05038579|Experimental|Musiquence|Dementia group was involved in a 14-session customized cognitive stimulation program, using Musiquence.
89566695|NCT05038657|Experimental|Atezolizumab|Treatment will consist of atezolizumab, by IV infusion, at a fixed dose of 1680 mg, every 28 days (day 1 of each cycle, +/- 3 days), for up to one year. Each participant will receive up to 13 doses in total.
89566696|NCT03094585|No Intervention|No information|The nurses in this group are offered no booklet or oral information
89566697|NCT03094585|Experimental|Written and oral information|The nurses in this group are offered written information which consisted of a booklet describing basic aspects of clinical research including aim, background, formalities, ethics, informed consent, randomisation, blinding, placebo, drug development, and financial aspects. Furthermore, they are offered oral information which consisted of group sessions focusing on active feedback
89566698|NCT03094585|Experimental|Written information|The nurses in this group are offered written information which consisted of a booklet describing basic aspects of clinical research including aim, background, formalities, ethics, informed consent, randomisation, blinding, placebo, drug development, and financial aspects.
89566699|NCT05038501||Comorbidities in Oncosurgery patients|Prevalence of comorbidities as Coronary artery disease, Hypertension , Diabetes Mellitus,Hypothyroidism and Corona Virus Infection will be studied in patients undergoing Oncosurgeries.
88969260|NCT00061360|Experimental|ATG+CsA|ATG+CsA for 6 months followed by a slow CsA taper in the subsequent 18 months
88969261|NCT00061360|Experimental|ATG+CsA+RA|ATG+CsA+RAPA for 6 months
88969262|NCT06197958|Experimental|eccentric exercises|Group A: Group A will receive 3 sets of eccentric exercises with 10 RM (repetition maximum) in six sessions.
88969263|NCT06197958|Experimental|concentric exercises|Group B: Group B will receive 3 sets of concentric exercises with 10 RM in six sessions
88969264|NCT06197945|Experimental|Mulligan bent leg raise|The Mulligan Bent Leg Raise technique will be performed with 3 repetition, 3-4 times with 20 sec hold and one minute rest between each repetition.
89566700|NCT03095833|Other|Influence of cognitive biases on food intake|Determine how high-level cognitive control can affect the price to pay for a food and the olfactory and visual perception of these foods in healthy subjects and Prader-Willi patients.
89566701|NCT03095833|Other|Modulation of the floral flavor of a wine|Highlight the brain regions involved in the visual bias related to the intensity of a wine's dress combined with the floral character evaluation of its flavor.
89566702|NCT05038423|Active Comparator|A structured 12-week group walking program|Participants engaged in an evidence-based 12-week walking program.
89566703|NCT05038423|Experimental|A structured 12-week group walking program + 5RS|In addition to the 12-week group walking program, participants engaged in the 5R Shared Leadership Program, which implements a structure of shared leadership and strengthens the identity leadership skills of the appointed peer leaders.
89566704|NCT05038189|Experimental|Ankylosing Spondylitis|Study group
89566705|NCT05038189|Experimental|Non-radiographic Axial Spondyloarthritis|Study group
89566706|NCT05038189|Experimental|Healthy individuals|Control group
89566707|NCT05051215||Control group|40 healthy volunteers were included in the healthy control group
89566708|NCT05051215||NPM group|60 patients of NPM (30 PCM and 30 GM)were included
89566709|NCT04973059|Active Comparator|Summer Conditions with SmartDrive|This arm is with the participant using the SmartDrive during a week in the summer. The SmartDrive is a manual wheelchair accessory that provide power assistance to reduce the necessary level of propulsion force. The goal is to increase participation by reducing propulsion effort.
89566710|NCT04973059|No Intervention|Summer Conditions activity measurement only|This arm is with the participant using their wheelchair during a week in the summer no power assist.
89566711|NCT04973059|No Intervention|Winter Conditions activity measurement only|This arm is with the participant using their wheelchair during a week in the winter no power assist
89566712|NCT04973059|Active Comparator|Winter Conditions with SmartDrive|This arm is with the participant using the SmartDrive during a week in the winter. The SmartDrive is a manual wheelchair accessory that provide power assistance to reduce the necessary level of propulsion force. The goal is to increase participation by reducing propulsion effort.
89566713|NCT05038111||Dex|Dexmedetomidine infusion during the perioperative period
89566714|NCT05038111||Non-Dex|Did not have dexmedetomidine infusion during the perioperative period
89566715|NCT05038033|Experimental|Interpersonal Psychotherapy (IPT)|Interpersonal Psychotherapy program adapted for the prevention of excessive weight gain. Involves one initial 1.5-hour individual session, and 12 weekly 90-minute group sessions.
89566716|NCT05038033|Active Comparator|Cognitive-Behavioral Therapy (CBT)|The CBT program will match the delivery format and dose of the IPT program. There will be one initial 1.5-hour individual session, and 12 weekly 90-minute group sessions.
89566717|NCT05029531|Experimental|intervention/treatment|
89566718|NCT05037643|Experimental|Pre-emptive TIPS in Cystic Fibrosis Related Liver Disease and non-cirrhotic portal hypertension|"Patients with CFLD without cirrhosis were eligible for a pre-emptive TIPS, when early (asymptomatic) signs of portal hypertension. All procedures were performed under general anaesthesia by an experienced interventional radiologist. Depending on the patient's age and physiognomy, TIPS was created following a conventional transjugular technique as for adults or by a dedicated combined percutaneous transhepatic-transjugular (PIPS) approach for small children. Routinely, an expanded polytetrafluoroethylene-covered endoprosthesis was used for shunt creation. If the sheath could not be negotiated into the main portal vein, a self-expandable, non-covered stent was placed. We did not pursue a minimum gradient reduction.~Percutaneous liver biopsy was performed during TIPS procedure to confirm the diagnosis of fibrosis or cirrhosis."
89566719|NCT05050513||interventional group|kidney graft preserved with M101
89566720|NCT05050513||control group|kident graft preserved in standard condition (without M101)
89566721|NCT05029453|Experimental|Experimental Group|apatinib combine with chemotherapy. Apatinib: initial dose: 500mg,oral,once a day, after meal ( try to take the medicine at the same time each day) Recommended chemotherapy: docetaxel(60/75 mg/m2, d1, q3w)、albuminbound paclitaxel(125mg/m2, d1, d8, q3w) or (260mg/m2, d1, q3w)。
89566722|NCT05029453|No Intervention|Control Gtoup|chemotherapy Recommended chemotherapy: docetaxel(60/75 mg/m2, d1, q3w)、albuminbound paclitaxel(125mg/m2, d1, d8, q3w) or (260mg/m2, d1, q3w)。
89566723|NCT04434625|No Intervention|control group|Colonoscopy was performed in the control group directly.
89566724|NCT04434625|Experimental|model-based interference group|Patients with score ≥3 were asked to taking another dose of PEG (1.5L) within 1-2 hours. Colonoscopy was performed in afternoon (about 4h after drinking PEG). Patients with score<3 in IM group colonoscopy directly.
89027979|NCT02274402||adults with glucocorticoids|Adults receiving Prednisone
89566725|NCT05029765|Placebo Comparator|Healthy diet Arm|Healthy diet (WHO recommendations) + placebo
89566726|NCT05029765|Placebo Comparator|Mediterranean diet Arm|Mediterranean diet + placebo
89566727|NCT05029765|Active Comparator|"Mediterranean diet plus Arm"|Mediterranean diet + Biopolis-MIX42 (1 capsule per day containing 10^9 colony forming units of Lactobacillus rhamnosus and Bifidobacterium long).
89566728|NCT02640157|Experimental|Arm A|ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 12 weeks.
89566729|NCT02640157|Active Comparator|Arm B|Sofosbuvir 400 mg once daily (QD) co-administered with daclatasvir 60 mg QD for 12 weeks.
89566730|NCT02640157|Experimental|Arm C|ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 8 weeks.
89566731|NCT04471519|Experimental|BBV152A - Phase I|0.5 mL of Whole Virion Inactivated SARS-CoV-2 Vaccine [BBV152A], is a liquid vaccine administered intramuscularly twice at Day 0 and Day 14
89566732|NCT04471519|Experimental|BBV152B - Phase I|0.5 mL of Whole Virion Inactivated SARS-CoV-2 Vaccine [BBV152B], is a liquid vaccine administered intramuscularly twice at Day 0 and Day 14
89566733|NCT04471519|Experimental|BBV152C - Phase I|0.5 mL of Whole Virion Inactivated SARS-CoV-2 Vaccine [BBV152C], is a liquid vaccine administered intramuscularly twice at Day 0 and Day 14
89027980|NCT04697355|Experimental|Naringenin + Beta carotene|Subject will ingest 300 mg naringenin three times/day and 6 mg beta carotene two times/day
89566734|NCT04471519|Active Comparator|Placebo - Phase I|0.5 mL of Placebo will be administered intramuscularly twice at Day 0 and Day 14.
89566735|NCT04471519|Experimental|BBV152A - Phase II|0.5 mL of Whole Virion Inactivated SARS-CoV-2 Vaccine [BBV152A], is a liquid vaccine administered intramuscularly twice at Day 0 and Day 28.
89566736|NCT04471519|Experimental|BBV152B - Phase II|0.5 mL of Whole Virion Inactivated SARS-CoV-2 Vaccine [BBV152B], is a liquid vaccine administered intramuscularly twice at Day 0 and Day 28
89566737|NCT05037565|Experimental|Treatment group|One group receive PHGG following study protocol (treatment group).
89566738|NCT05037565|No Intervention|Control group|This group will not receive PHGG
89566739|NCT05037721|Experimental|gargling with green tea of stroke patients|Use fresh green tea (package date less than one month) sourced from the local market and serve in the form of soaked tea bags. 0.5% green tea refers to a tea bag soaked in 0.5g green tea, soaked in 100ml warm water for 5 minutes and let cool. Then, put each bottle of 15ml mouthwash into a disposable opaque bottle, and give two bottles of mouthwash required daily at one time. Use 15ml twice a day, 30 minutes after breakfast and 30 minutes after lunch, each time for 30 seconds. Rinse mouth up and down for 30 seconds. Rinse mouth up and down, half sitting and lying down, and shake the head of bed for 30 degrees. After breakfast, the experimental group and the control group were instructed to clean their teeth according to routine procedures, and telephone reminders were provided to inform them to gargle.
89566740|NCT05037721|Active Comparator|gargling with water of stroke patients|Use water 15ml of mouthwash into a disposable opaque bottle, and give two bottles of mouthwash required daily at one time. Use 15ml twice a day, 30 minutes after breakfast and 30 minutes after lunch, each time for 30 seconds. Rinse mouth up and down for 30 seconds. Rinse mouth up and down, half sitting and lying down, and shake the head of bed for 30 degrees. After breakfast, the experimental group and the control group were instructed to clean their teeth according to routine procedures, and telephone reminders were provided to inform them to gargle.
89566741|NCT05037253|Active Comparator|high dose|Vitamin D therapy will initiate at a dosage of 50,000 IU on the first and second week, followed by a switch to a daily intake of 5,000 IU for 3 months.
89566742|NCT05037253|Active Comparator|Low dose:|Vitamin D therapy will prescribe for 3 months at a dosage of 2,000 IU/day.
89566743|NCT05029297|Experimental|CAPSAICIN 0.75 mg/g topical solution applicable in roll-on|CAPSAICIN 0.75 mg / g topical solution applicable in roll-on: 4 applications per day for 8 weeks.
89566744|NCT05029297|Active Comparator|CAPSAICIN 0.075% cream|CAPSAICIN 0.075% cream (ARAFARMADOL® 0.075% cream): 4 applications per day for 8 weeks.
89566745|NCT05028907|Experimental|group one (cases with inflamatory punctal stenosis treated with steroids and antibiotics)|patients with inflammatory punctal stenosis were treated by steroids and antibiotics and evaluated by anterior segment optical coherence tomography before and after treatment
89566746|NCT05028907|Placebo Comparator|control group|patients with inflammatory punctal stenosis received only preservative free tear substitutes
89566747|NCT03094117|Active Comparator|News with Spin|News items reporting results of phase I/II (non-randomized) trials with spin
89566748|NCT03094117|Experimental|News without spin|News items reporting results of phase I/II (non-randomized) trials without spin
88969265|NCT06197945|Experimental|Mulligan bent leg raise with Bowen therapy|The Mulligan Bent Leg Raise technique will be performed with 3 repetition, 3-4 times with 20 sec hold and one minute rest between each repetition. After that Bowen therapy will be applied on hamstring bilateral.
88969266|NCT06197919|Experimental|postural exercises with breathing exercises|"The postural exercise program consisted of two strengthening and stretching exercises. The exercises involved chin tucks in, shoulder retraction , and unilateral and bilateral pectoralis stretches alternating each 2-week period. 36 Participants were instructed to complete 3 sets of 12 repetitions of the strengthening exercises and 3 stretching exercises held for 30 seconds each.~For the breathing exercises in experimental group, breathing program includes respiratory muscle training, relaxation techniques, breathing techniques, e.g., deep breathing, hand controlled abdominal/diaphragmatic breathing, aimed stretching and strengthening exercises are combined with each other. Deep breathing, controlled diaphragmatic breathing, slow relaxed exhalation with pursed lips technique, direct apnoea exercises and segmental breathing techniques. exercise protocol will be continued for 10 weeks with and initial, after 5 weeks and final assessment of pain and CVA."
88969267|NCT06197919|Experimental|postural exercises without breathing exercises|"In this study forward head posture will be defined as CVA<49°, which was diagnosed by photogrammetry method.~The postural exercise program consisted of two strengthening and stretching exercises. The exercises involved~(a) chin tucks in (c) shoulder retraction , and (d) unilateral and bilateral pectoralis stretches alternating each 2-week period. 36 Participants were instructed to complete 3 sets of 12 repetitions of the strengthening exercises and 3 stretching exercises held for 30 seconds each. This program was to be repeated 4 times per week. They also returned for a consultation every 2 weeks to be checked for exercise technique and progression, if appropriate. Progress to the next exercise level was indicated if the participant could complete 12 repetitions, 3 times easily with correct form."
88969268|NCT06197906|Other|DM self-control group|
88969269|NCT06197880|Experimental|Bimaxillary protrusion|En masse retraction
88969270|NCT06197854||Sublay hernioplasty in incisional hernia|Group that will undergo Sublay hernioplasty in management of incisional hernia
89566749|NCT05050201|Experimental|Sleepio Intervention|Participants using the Sleepio application - access for 6 sessions, over 10 weeks
89566750|NCT05028985||early COPD patients|younger than 50 years with 10 or more pack-years smoking history and any of these abnormalities: 1) early airflow limitation (post-bronchodilator forced expiratory volume in the first second(FEV1)/forced vital capacity(FVC) < lower limit of normal), 2) compatible CT abnormalities, 3) rapid decline in FEV1 (≥60 ml/yr).
89566751|NCT05028985||Healthy people|healthy without any disabling, physical, neurological, or mental disease and were excluded living in a nursing home.
89566752|NCT05026411|Other|Orthodontic patients|Magnetic resonance images will be taken from 20 individuals with eating disorders before fixed orthodontic treatment, 12 months of orthodontic treatment and 6 months after orthodontic treatment finished
89566753|NCT03094351|Experimental|Robot assisted esophagectomy|Robot-assisted esophagectomy with gastric conduit formation.
89566754|NCT03094351|Active Comparator|Thoracoscopic esophagectomy|Conventional thoracoscopic esophagectomy with gastric conduit formation.
89566755|NCT05025553|Other|Gut mobilization|Polyethylene Glycol (PEG) at the dose of 6.9 g/d once a day for 6 months.
89566756|NCT05028127|Experimental|Bimekizumab dosage regimen 1|Subjects participating in the study will be receiving assigned bimekizumab dosage regimen 1 during the Treatment Period.
89566757|NCT05028127|Experimental|Bimekizumab dosage regimen 2|Subjects participating in the study will be receiving assigned bimekizumab dosage regimen 2 during the Treatment Period.
89566758|NCT05024695|Experimental|Implant Group|
89566759|NCT05049811|Experimental|a mini program trial group|Pharmacists conducted a standardized education session to teach the participants how to operate the mobile phone, use mini program, assess pain. The participants in the trial group were asked to complete initial and final pain assessment questionnaires and Medication compliance on the mobile phones provided to them. Participants were encouraged to use mini program as much as possible to record their pain status.
89566760|NCT05049811|Sham Comparator|a control group|The control group received conventional pharmaceutical care. Initial and final pain and Medication compliance data were collected. Before the patient was discharged from the hospital, the clinical pharmacist conducted detailed medication education (including medication methods, prevention and treatment of adverse reactions, and precautions) and asked the patient to attempt to maintain a paper version of the pain diary.
89566761|NCT05028049||Sufentanil-analgesia in plain area patients|Sufentanil 0.3 μg/kg is intravenously administrated to maintain intraoperative analgesia in plain area patients.
89566762|NCT05028049||Remifentanil-analgesia in plain area patients|Remifentanil 0.3ug/kg/min is intravenously administrated to maintain intraoperative analgesia in plain area patients.
89566763|NCT05028049||Sufentanil-analgesia in plateau area patients|Sufentanil 0.3 μg/kg is intravenously administrated to maintain intraoperative analgesia in plateau area patients.
89566764|NCT05028049||Remifentanil-analgesia in plateau area patients|Remifentanil 0.3ug/kg/min is intravenously administrated to maintain intraoperative analgesia in plateau area patients.
89566765|NCT04131673||African Americans with MS|African American patients seen in the University of Kentucky's Multiple Sclerosis Clinic between the ages of 18 and 80 who have been diagnosed with MS
89566766|NCT05024461|Experimental|Patient with an indication for a COVID19 test|The persons included will be those who have an indication for a COVID 19 test and who present themselves at the Cayenne hospital and during the screening missions organised by the Red Cross and Médecin du Monde during the COVID 19 epidemic in the territory
89566767|NCT03093649|Experimental|patient reported group|Patients reported adverse events using patient reported outcomes version of common terminology criteria for adverse events (PRO-CTCAE) through Application (APP) during the treatment. The summary report was transferred to their clinician immediately. Oncologists would be alarmed if patients reports exceeding the pre-defined threshold.
89566768|NCT03093649|Active Comparator|non-reported group|Patients in this group received normal care during the treatment without completing patient reported outcomes version of common terminology criteria for adverse events (PRO-CTCAE)
89566769|NCT05024617||trigger finger stage 1-2-3|Volunteer patients between 35-65 years old diagnosed with Stage 1, Stage 2 and Stage 3 trigger finger based on the Froimson Classification were included in the study. Exclusion criteria include paediatric trigger finger, trigger thumb, concomitant de'Quervain tenosynovitis, carpal tunnel syndrome, or Dupuytren's contracture, neurological or rheumatological diseases, chronic pain syndromes, pregnancy and patients with treatment history of related finger/fingers
89566770|NCT05049109|Experimental|Group X|Patients who have had stroke and high blood pressure will participate in 5 telehealth visits, which will take place over 3 months. In addition, remote BP monitoring will be given.
89566771|NCT05049109|Active Comparator|Group Y|Patients who have had stroke and high blood pressure will participate in 3 visits with primary care and stroke practitioner.
88969271|NCT06197854||Onlay Hernioplasty in incisional hernia|Group that will undergo Onlay hernioplasty in management of incisional hernia
89566772|NCT05027659|Experimental|intervention|This study was carried out with two groups. Virtual reality glasses were used for the intervention group.
88969272|NCT06197828||Sepsis-associated acute kidney injury|Between May 2021 and December 2024, patients admitted to the Pediatric Intensive Care Unit (PICU) for a duration exceeding three days were included in the study. Specifically, patients diagnosed with sepsis were selected based on the 2005 international standard for childhood sepsis, the 2012 Surviving Sepsis Campaign guidelines for pediatric sepsis, and the 2015 expert consensus on sepsis criteria for Chinese children with septic shock. The age range of the patients included in the study varied from 1 month to 16 years old.
88969273|NCT06197828||Patients without sepsis In ICU|patients admitted to the Pediatric Intensive Care Unit (PICU) for a duration exceeding three days and those without sepsis were included in the study.
88969274|NCT06197802||Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58) Vaccine(E.Coli) group|Subjects would receive 3 doses of 270μg/0.5ml Recombinant HPV nonavalent (Types 6/11/16/18/31/33/45/52/58) Vaccine(E.Coli)
88969275|NCT06197802||Gardasil®9 group|Subjects would receive 3 doses of 270μg/0.5ml Gardasil®9
88969276|NCT06197789|Experimental|TPX-105|Autologous human dermal fibroblasts
89566773|NCT05027659|No Intervention|control|No application was made to the control group, standard procedure was followed.
89566774|NCT03093571|Experimental|Auricular stimulation|Auricular stimulation using indwelling auricular acupuncture needles
88969277|NCT06197789|Sham Comparator|Placebo|Suspension media
88969278|NCT06197763|Experimental|Fontan participants|Participants will be randomized to be treated with either colesevelam (625 mg tablets - 3 tables twice per day) or placebo (3 tablets twice per day) for 6 weeks, interspersed by 8 week of washout time.
88969279|NCT06197763|Sham Comparator|Healthy control participants|These healthy control participants will be comparators to the randomized Fontan participants. Healthy controls will only undergo the baseline visit and will not receive the investigational drug or placebo.
88969280|NCT06197750|Experimental|Vestibular stimulation|Group A received the vestibular stimulation by swing in different positions supine, prone and with or without support in each position for 10minnts 3 times a week for 10 weeks along with general strengthening exercises of upper and lower limb and
88969281|NCT06197750|Active Comparator|general strengthening exercises|group B will receive general strengthening exercises of whole body for same time period.
88969282|NCT06197737|Experimental|Moderate Intensity Interval Training|These participants will perform moderate intensity interval training. The intervention will be applied thrice a week. Moderate intensity interval training in which they do stair climbing 3 times a week And for every 1 interval I will ask them to take rest for 3 minutes.
89566775|NCT03093571|Experimental|Muscle relaxation|Progressive muscle relaxation according to Jacobsen
89566776|NCT03093571|No Intervention|No intervention|No intervention, just monitoring of outcome parameters
89566777|NCT05023915|Active Comparator|diammonium glycyrrhizinate enteric-coated capsule + high-dose dexamethasone|Diammonium glycyrrhizinate enteric-coated capsule orally at a dose of 150mg tid for 3 months, combining with dexamethasone (given orally at a dose of 40 mg qd for 4 days). Patients who do not respond to the treatment may receive another cycle of high-dose dexamethasone therapy with an interval of 10 days.
89566778|NCT05023915|Active Comparator|High-dose dexamethasone|Dexamethasone orally at a dose of 40 mg qd for 4 days. Patients who do not respond to the treatment may receive another cycle of high-dose dexamethasone therapy with an interval of 10 days.
89566779|NCT05024071|Experimental|Swiss Ball|Swiss ball practice can create an unstable environment, promote the recovery of muscle function and develop joint stability. It can train the muscle groups in chest, abdomen, back, buttocks and legs, which play an important role in maintaining body balance and improving athletes' body.
89566780|NCT05024071|Experimental|Balance Plate|The balance board can exercise athletes' waist explosive force and body balance ability in an unstable state.
88969283|NCT06197737|Experimental|Sprint Interval Training|"These participants will perform sprint interval training and frequency will be 3 days a week.~The participants will perform sprint interval training in which they will do stair climbing 3 times a week with a fast pace."
88969284|NCT06197737|Other|pharmacological treatment|They will be on pharmacological treatment as prescribed by their pulmonologist.
89566781|NCT01673347|Experimental|MENISCAL ALLOGRAFT|The meniscal allograft is taken from the meniscal knee joint and implanted surgically in to the great toe.
89566782|NCT05027191||Sevoflurane|This group will receive sevoflurane as the maintenance inhalational anesthetic.
88969285|NCT06197724||Training and testing cohort|
88969286|NCT06197724||External validation cohort|
88969287|NCT06197711|Experimental|Intervention group|The intervention, PRISMA, addresses the issue of poor mental health of inmates during pretrial detention and after release. PRISMA has been adapted for the context of the model trial from Problem Management Plus (PM+). PRISMA has a total of four sessions provided during the first two weeks after entry such that most inmates can benefit from it before their potential release. The four sessions involve stress management, problem solving, meaningful activities (behavioral activation, and strengthening social support) and relapse prevention (staying well, looking forward). Additionally, participants will receive 2 booster sessions, 4 and 9 weeks after the final session, when most inmates will already have been released from jail.
88969288|NCT06197711|No Intervention|Control group|REGULAR PRETRIAL: participants in this group experience the same pretrial system, conditions, and services that they would have experienced if the RCT did not exist. They will not be offered PRISMA or extended social services, but they can still access social services upon request as well as medical support through the jails' health services.
89566783|NCT05027191||Desflurane|This group will receive desflurane as the maintenance inhalational anesthetic.
89566784|NCT03094507|Experimental|Group One|Tivicay (Dolutegravir 50 mg) for 14 days OD (days 1-14) WASH OUT for 7 days (days 15-21) Tivicay (Dolutegravir 50 mg) OD plus Rezolsta (darunavir/cobicistat 800/150 mg) OD for 14 days (days 22-35) WASH OUT for 7 days (days 36-42) Rezolsta (darunavir/cobicistat 800/150 mg) OD for 14 days (days 43-56)
89566785|NCT03094507|Experimental|Group Two|Rezolsta (darunavir/cobicistat 800/150 mg) OD for 14 days (days 1-14) WASH OUT for 7 days (days 15-21) Tivicay (Dolutegravir 50 mg) OD plus Rezolsta (darunavir/cobicistat 800/150 mg) OD for 14 days (days 22-35) WASH OUT for 7 days (days 36-42) Tivicay (Dolutegravir 50 mg) for 14 days OD (days 43-56)
89566786|NCT02528253|Placebo Comparator|Placebo to Week 16; tanezumab 5 mg SC|
89566787|NCT02528253|Placebo Comparator|Placebo to Week 16, tanezumab 10 mg SC|
89566788|NCT02528253|Experimental|Tanezumab 5 mg SC|
89566789|NCT02528253|Experimental|Tanezumab 10 mg SC|
89566790|NCT02528253|Active Comparator|Tramadol PR oral|
89566791|NCT03093103|Active Comparator|empagliflozin 10mg|Empagliflozin (Jardiance) 10mg is an SGLT-2inhibitor. The drug will be taken qd for 4 weeks.
88969289|NCT06197698|Other|18F-FDG PET is used as an imaging marker of gut microbiota composition evaluation in PD patients|We will investigate the correlation between 18F-FDC PET bowel uptake and dopamine transporter changes in patients with PD.
89566792|NCT03093103|Placebo Comparator|Placebo|Placebo will be taken qd for 4 weeks.
89566793|NCT03092869|Experimental|Experimental Group|Feet and Ankle Mobilization
88969290|NCT06197646|Experimental|Inhaler mask with cartoon characters|Inhalation therapy with cartoon characters inhaler mask and Inhaler therapy training
88969291|NCT06197646|No Intervention|Inhaler mask|Inhalation therapy with the inhaler mask routinely used by the clinic and Inhaler therapy training
88969292|NCT06197581|Other|RT+capecitabine|Patients will receive concurrent radiotherapy and capecitabine.
88969293|NCT06197581|Other|RT+HER2 inhibitors|Patients will receive concurrent radiotherapy and any HER2 inhibitors ( eg. trastuzumab plus pertuzumab or TDM1)
88969294|NCT06197581|Other|RT+ CDK4/6 inhibitors|Patients will receive concurrent radiotherapy and any of the CDK4/6 inhibitors (abemaciclib，palbociclib ,ribociclib or other CDK4/6 inhibitors)
88969295|NCT06197581|Other|RT+PARP inhibitor.|Patients will receive concurrent radiotherapy and PARP inhibitor(Olaparib or other PARP inhibitors)
89566794|NCT03092869|Active Comparator|Control Group|Proprioceptive Training
89566795|NCT03094039|Experimental|Ventilatory support while attached to the cord|Infants will receive active resuscitative care (intubation and ventilation) using a specific designed platform for 120 seconds during delayed cord clamping. Then the cord will be clamped forgoing resuscitation care.
89566796|NCT03094039|Active Comparator|Immediate cord clamping|Infants will receive immediate cord clamping, transferred to the resuscitation table, intubated and mechanical ventilated according to our current Congenital Diaphragm Hernia protocol.
89566797|NCT03093805|Experimental|Calcipotriene|Patients will apply Calcipotriene cream 2 times per day for 7 days.
89566798|NCT03093883|Experimental|Test product|Iron sucrose injection solution 100mg (5 mL single dose vial 20mg/mL elemental iron as iron sucrose for injection).
89566799|NCT03093883|Active Comparator|Reference product|Iron sucrose injection solution 100mg (5 mL single dose ampoule 20mg/mL elemental iron as iron sucrose for injection).
89566800|NCT05047861|Experimental|Study group|patients will receive the implant in the previously preserved socket using Socket shield technique with Alloplastic graft material
89566801|NCT05047861|Active Comparator|Control group|patients will receive the implant in the previously preserved socket shield with Autogenous dentin graft
89566802|NCT03094429|Active Comparator|NaBen® - 2000 mg/day|Two NaBen® ( 500 mg) will be taken twice daily at a total dose of 2000 mg/day during this study.
89566803|NCT03094429|Active Comparator|NaBen® - 1000 mg/day|One NaBen® (500 mg) and one placebo will be taken twice daily at a total dose of 1000 mg/day during this study.
89566804|NCT03094429|Placebo Comparator|Placebo - 0 mg/day|The control treatment is placebo.
89566805|NCT05023447|Experimental|BRIDGE Intervention (+Service as Usual)|The brief, intensive assessment and integrated formulation (BRIDGE) intervention is delivered over 3-6 months and has a three-fold focus: Firstly, an intensive (post-randomisation) assessment, taking up to two sessions, including BPD symptoms, co-presenting difficulties, neurodevelopmental profile, life events history and psychosocial functional impact. Secondly, up to 16 sessions of Cognitive Analytic Therapy (CAT). Thirdly, development of a shared formulation with a multi-agency group; further development of the shared formulation with the young person, using CAT principles (Reformulation, Recognition and Revision) and, where clinically applicable, their family and service-providers.
89566806|NCT05023447|Active Comparator|Service as Usual|For participants randomised to Service-As-Usual (SAU), a routine letter of their participation will be shared with their service provider(s), including the GP. SAU, likely to range from social services, mentalhealth services, forensic services to no intervention will be mapped and described for each participant. Treatment fidelity to SAU will therefore not be assessed, but the nature and intensity of SAU in different contexts will be described in detail through the qualitative process evaluation.
89566807|NCT05026255|Experimental|mechanically ventilated intensive care patients.|Observational data collected for patients in intensive care under mechanical ventilation.
89566808|NCT03090607|Experimental|Aluvra™|Endoscopic injection of bulking agent (Aluvra) to the lower esophageal sphincter
89566809|NCT03090607|Sham Comparator|Saline|Endoscopic injection of saline
89566810|NCT03092557|Experimental|Determination of local pleural strain|Patients will receive four different tidal volumes in random order (6 mL/kg, 8 mL/kg, 10 mL/kg, 12 mL/kg).
88969296|NCT06197581|Other|RT+ICI|Patients will receive concurrent radiotherapy and immune checkpoint inhibitor (Pembrolizumab or other anti-PD1/PDL1 regimens).
89566811|NCT03090529|Experimental|Exercise group|The 12-week exercise-training program will include three sessions of aerobic exercise per week
88969297|NCT06197568|Experimental|Weekly 0.1 μg AZU-101|Weekly 0.1 μg vaginal dose of AZU-101
88969298|NCT06197568|Experimental|Weekly 0.5 μg AZU-101|Weekly 0.5 μg vaginal dose of AZU-101
88969299|NCT06197568|Experimental|Weekly 1 μg AZU-101|Weekly 1 μg vaginal dose of AZU-101
89566812|NCT03090529|No Intervention|Control group|The control group will receive usual medical care
89566813|NCT03092401||hepatic transplant patients with hepatopulmonary syndrome|
89566814|NCT03092401||hepatic transplant patients without hepatopulmonary syndrome|
88969300|NCT06197568|Experimental|Twice-weekly 0.1 μg AZU-101|Twice-weekly 0.1 μg vaginal dose of AZU-101
89566815|NCT03092167|Active Comparator|Case|Patients: this group will be submitted to 12-weeks, twice/week, physical exercises.
89566816|NCT03092167|No Intervention|Control|Patients: this group will not be submitted to 12-weeks, twice/week, physical exercises.
89566817|NCT03092167|No Intervention|Healthy control|Volunteers: this group will not be submitted to 12-weeks, twice/week, physical exercises.
88969301|NCT06197568|Experimental|Twice-weekly 0.5 μg AZU-101|Twice-weekly 0.5 μg vaginal dose of AZU-101
88969302|NCT06197555|Active Comparator|Group A (Sodium Monofluorophosphate)|Dentifrice containing Sodium Monofluorophosphate, daily homecare usage Colgate®, Cavity Protection
88969303|NCT06197555|Active Comparator|Group B (Stannous Fluoride)|Dentifrice containing Stannous Fluoride, daily homecare usage Oral B®, Gum Calm & Sensitivity
88969304|NCT06197555|Active Comparator|Group C (Nano-Hydroxyapatite)|Dentifrice containing Nano-Hydroxyapatite, daily homecare usage ApaCare®
88969305|NCT06197555|Active Comparator|Group D (8% Arginine & Calcium Carbonate)|Dentifrice containing 8% Arginine & Calcium Carbonate, daily homecare usage Colgate®, Sensitive Pro-Relief
88969306|NCT06197542|Experimental|Active Release Technique|Individuals in Group A will be subjected to Heat Therapy over the targeted muscles via hot pack for 5 minutes in every session along with passive stretching for 5 minutes Group A will receive Active release technique on targeted muscles. The participant was comfortably seated and rested the forehead on the forearms .To apply for the release, the active TrP was identified, and sustained and constant pressure was applied. For stretching of the SCM muscle, the patient performed contralateral lateral flexion and ipsilateral rotation of the head to achieve stretching, for trapezius the therapist performed lateral flexion of the neck.The treatment regimen will span over 3 weeks with a follow up frequency of 2 sessions per week.
88969307|NCT06197542|Experimental|Instrument Assisted Soft Tissue Mobilization|Group A will be subjected to Heat Therapy for 5minutes along with Stretching for 5 minutes .Group B will be Subjected to IASTM using M2T blade for approximately 3 minutes per muscle. Lubricant was applied and the tool was cleaned with an alcohol pad.the tool was used to locate soft tissue restrictions in the muscles. Then, the therapist applied IASTM strokes for 20 seconds parallel to muscle fibers, followed by strokes for 20 seconds perpendicular to muscle fibers with the tool held at a 45° to the skin Treatment time was 3 minutes. Cryotherapy was applied for 10 minutes after the session. The treatment regimen will span over 3 weeks with a follow up frequency of 2 sessions per week.
88969308|NCT06197529|Experimental|S1 Homeostatic Plasticity-Pain|"Anodal tDCS CP3 1mA FP2 -1mA~4x4 patch on the dorsum of the hand"
88969309|NCT06197529|Placebo Comparator|S1 Homeostatic Plasticity-NoPain|"Anodal tDCS C3 1mA FP2 -1mA~4x4 patch on the dorsum of the hand"
88969310|NCT06197529|Sham Comparator|S1 Homeostatic Plasticity-Sham|"Sham tDCS C3 FP2~4x4 patch on the dorsum of the hand"
88969311|NCT06197529|Active Comparator|M1 Homeostatic Plasticity|"Anodal tDCS C3 1mA FP2 -1mA~4x4 patch on the dorsum of the hand"
89027981|NCT00491816|Experimental|erlotinib with neoadjuvant chemotherapy|Study drug, erlotinib, is administered along with neoadjuvant chemotherapy. Adjuvant therapy given at discretion of treating physician. Once adjuvant therapy is completed, all patients will receive erlotinib 150 mg daily for 1 year.
89566818|NCT01672957||Renal Transplant Participants|Renal transplant participants who will be subjected to a combined immunosuppressive treatment containing mycophenolate mofetil, will be followed-up until the end of the study (after 12 months), or until the participant's death, withdrawal, or lost contact with the participant, whichever occurs first. The choice of treatment will be made prior to enrolment by the treating physician. The treatment will be administered according to applicable therapeutic protocol and Summary of Product Characteristics (SmPC).
88969312|NCT06197516|Experimental|Integrated Neuromuscular Inhibition Technique|Individuals in Group A, After palpating the trigger point ischemic compression were applied for 20-60 sec while strain counterstain for 60-90 sec and MET is for 7-10 sec. This technique was repeat 3-4 time per session Conventional treatment include Hot Pack for 5mins, AROM exercises ,Home plans include stretching exercise of glutes,hamstring and calf (5-7 reps x 10 sec hold, each).
88969313|NCT06197516|Active Comparator|Neuromuscular Reeducation Technique|Deep pressure were applied along origin and insertion of Piriformis and hamstring muscle combined with active movement of patient for 5 -15 time as per required (depend upon thickness of scar) per session, 10 sec rest b/w pressure. This technique given 5 time per session. Conventional treatment include Hot Pack for 5mins, AROM exercises ,Home plans include stretching exercise of glutes,hamstring and calf (5-7 reps x 10 sec hold, each).
88969314|NCT06197503|Experimental|Conduction system pacing|"Lead placed in the His-Purkinje system (His or left bundle branch) in order to achieve QRS shortening and physiologic pacing.~Crossover from physiological pacing to right ventricular pacing will be allowed in case of failed His bundle pacing or left bundle branch pacing."
88969315|NCT06197503|Active Comparator|Right ventricular pacing|Lead placed in the right ventricle (conventional pacing).
88969316|NCT06197490||Patient with cystic fibrosis, eligible for KAFTRIO therapy|Patient with cystic fibrosis, eligible for KATRIO, over 18 years old.
88969317|NCT06197477|Experimental|Air purification|The intervention will consist of air purification placed in the classrooms.
88969318|NCT06197477|Sham Comparator|Control|Filtration will be turned off in the air purifier placed in the classrooms in the control part of the study.
88969319|NCT06197464|Active Comparator|control|psychoeducation on emotional regulation and distraction strategy + Application
88969320|NCT06197464|Experimental|experimental|psychoeducation on emotional regulation and distraction strategy + Application with the FLOAT app
88969321|NCT06197451||1|Patients who are diagnosed with neurologic disorders The first group consists of 170 diagnosed with neurologic disorders who have at least six months of dysphagia complaints. The participants will given the Turkish version of M.D. Anderson Dysphagia Inventory, consisted of 20 questions, Swallowing Quality-of-Life Questionnaire and Mini Mental Questionnaire. After the two weeks, 50 participants will given the MDADI for sampling.
88969322|NCT06197451||2|Healthy subjects The second group consists of 50 healty participants will given the MDADI consists of 20 questions and Swallowing Quality-of-Life Questionnaire.
88969323|NCT06197438|Experimental|POFI and Tislelizumab|
88969324|NCT06197425|Experimental|Chemotherapy by FOLFIRI|
88969325|NCT06197425|Experimental|Chemotherapy by Trifluridine tipiracil|
88969326|NCT06197425|Active Comparator|Surveillance inside the trial/control arm|
88969327|NCT06197425|No Intervention|Surveillance outside the trial|
88969328|NCT06197412|No Intervention|control group 1|The optimal clinical treatment scheme was used to treat the wound of progressive infection period patients for 2 weeks
88969329|NCT06197412|Experimental|powder group 1|On the basis of the optimal clinical treatment scheme, Yunnan Baiyao powder was used to treat the wound of progressive infection period patients for 2 weeks
88969330|NCT06197412|Experimental|ointment group 1|On the basis of the optimal clinical treatment scheme, Yunnan Baiyao ointment was used to treat the wound of progressive infection period patients for 2 weeks
88969331|NCT06197412|No Intervention|control group 2|The optimal clinical treatment scheme was used to treat the wound of granulation period patients for 2 weeks
88969332|NCT06197412|Experimental|powder group 2|On the basis of the optimal clinical treatment scheme, Yunnan Baiyao powder was used to treat the wound of granulation period patients for 2 weeks
89566819|NCT05018065|Active Comparator|50 women previously diagnosed with mild - medium Covid-19 and had ambulatory care|Women sexual dysfunctions were screened using Female Sexual Functioning Index (FSFI)
89566820|NCT05018065|Active Comparator|51 women having no Covid-19 history|Women sexual dysfunctions were screened using Female Sexual Functioning Index (FSFI)
89566821|NCT05023213|Experimental|Warna-Warni Waktu intervention|Participants in this condition will be asked to view six, approximately five minute videos (each with a number of associated short, interactive reinforcer activities), at a pace of one video per day, for 6 days.
89566822|NCT05023213|No Intervention|Waitlist control condition|These participants will no be contacted during the intervention timeframe.
89566823|NCT05047393||Coccygodynia group|51 patients with a diagnosis of coccygodynia will be included in the study.
89566824|NCT05047081|Experimental|College Workshop Arm|Intervention
89566825|NCT05047081|Placebo Comparator|Placebo|Placebo
89566826|NCT05022745|Experimental|ERAS group|Posterior lumbar interbody fusion Multimodal, multidisciplinary patient care.
89566827|NCT05022745|Active Comparator|Standard group|Posterior lumbar interbody fusion Standard treatment pre-, per-, and post-operative
89566828|NCT04465435||SUN-participants|"University students enrolled in a selected university in Stockholm, studying on a full-time educational program with at least one academic year left before graduation.~There is no intervention. The exposures are repeated measures, 5 times (every three months), using web-based self-report questionnaires during one academic year. Also weekley SMS are used to measure depression, anxiety and pain intensity."
89566829|NCT03090217|Experimental|Pelvic physiotherapy (PP)|Pelvic Physiotherapy include daily pelvic floor muscle training (PFMT). PFMT starts at first session of the brachytherapy and will be conduced during the twelve weeks treatment.
89566830|NCT03090217|Active Comparator|Stander Care (SC)|The stander care (SC) includes a guideline for gynecological cancer patients under radiotherapy/brachytherapy: 1) daily vaginal dilator therapy (10 to 15 minutes); and 2) usual care management. This SC starts at first session of the brachytherapy and will be conduced during the twelve weeks treatment.
89566831|NCT05022277|Experimental|Phone-based intervention Plus SMS messages|
89566832|NCT05022277|Experimental|SMS messages only|
89566833|NCT05022277|No Intervention|Control|
88969333|NCT06197412|Experimental|ointment group 2|On the basis of the optimal clinical treatment scheme, Yunnan Baiyao ointment was used to treat the wound of granulation period patients for 2 weeks
88969334|NCT06197399|Experimental|Detethering Surgery|Participants in this arm will undergo detethering surgery, a traditional surgical intervention that involves releasing the spinal cord from its abnormal attachment. All surgeries will be performed by trained and experienced neurosurgeons following standardized protocols.
88969335|NCT06197399|Experimental|Spinal Column Shortening Surgery|Participants in this arm will undergo spinal column shortening surgery, a surgical technique aimed at reducing tension on the spinal cord by shortening the vertebral column. All surgeries will be conducted by trained and experienced neurosurgeons following standardized protocols. Postoperative care will be similar in both arms to minimize confounding variables.
88969336|NCT06197373||Early laparoscopic cholecystectomy after ERCP|Evaluation of outcomes of early ( within 72 hours) laparoscopic cholecystectomy after ERCP
88969337|NCT06197373||Late laparoscopic cholecystectomy after ERCP|Evaluation of outcomes of late ( form third day up to 2months ) laparoscopic cholecystectomy after ERCP
89566834|NCT05022043|Active Comparator|EOS|
88969338|NCT06197360|Placebo Comparator|General diabetes health education|Patients were provided with regular medication guidance, dietary guidance, exercise guidance and popularization of related diabetes knowledge; regular daily blood glucose testing and recording; and timely answers to patients' clinical problems and psychological support.
88969339|NCT06197360|Experimental|Based on BCW Theory of Health Education|A FOH intervention program based on BCW theory was implemented on top of the control group.
88969340|NCT06197347|Experimental|Web-based nursing intervention|Web-based intervention (8 sessions weekly) which includes the support of a nurse that aims to increase physical activity and quality of life for older people living with heart disease, as well as enhancing knowledge, motivation and self-efficacy.
89566835|NCT05022043|No Intervention|NO-EOS|
89566836|NCT05021887|Experimental|Test Product|Fluticasone Propionate 100 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals
89566837|NCT05021887|Active Comparator|Reference Product|FLOVENT DISKUS® 100 mcg/Blister Oral Inhalation Powder /GSK
89566838|NCT05022199|Experimental|Study Arm: SPY fluorescent angiography|
89566839|NCT05022199|No Intervention|Historic Control Arm: Urinary diversion without the use of SPY|This arm consists of 215 historic controls who have undergone urinary diversion at UVA from 2015-2020 without the use of SPY fluorescent angiography
89566840|NCT05021575||2020|Data on outpatient care, hospitalisation and cardiovascular mortality were collected for the year 2020.
89566841|NCT05021575||2019|Data on outpatient care, hospitalisation and cardiovascular mortality were collected for the year 2019.
89566842|NCT05021419|Active Comparator|Standard Arm|"Active Comparator: Standard Arm~Both the current the European society of cardiology guidelines and National Institute of Health and Care Excellence currently advise that chronic stable heart failure patients with severely impaired left ventricular systolic function should initially be optimized as follows:~Visit 1: ACEi/ARB and Low Betablocker commenced Visit 2: ACEi/ARB up-titrated; (Beta Blocker up-titrated) Visit 3: ACEi/ARB up-titrated; (Beta Blocker up-titrated) Visit 4: Switch ACEi/ARB to Entresto 100mg Visit 5: Modify Entresto dose to 200mg Visit 6: MRA Added Visit 7: MRA up-titrated Visit 8: SGLT2i started"
89566843|NCT05021419|Experimental|Streamlined protocol arm|"Patients are optimized according to the accelerated protocol adapted from and based on the principles proposed by Prof McMurray and Prof Packer (Circulation 2021;143:875-877)~Visit 1: Low Dose Beta Blocker started, SGLT2i started + Entresto 100 mg bd started~Visit 2: MRA Added if renal function and potassium levels permit (Betablocker increased if BP and pulse rate permit)~Visit 3: MRA up-titrated if BP and renal function and potassium levels permit (Betablocker increased if BP and pulse rate permit)~Visit 4+: Betablocker increased if BP and pulse rate permit. Further visits may be required to facilitate a gentle up-titration of betablockers."
89566844|NCT05009953|Experimental|Cohort 1: Irinotecan Liposome Injection + 5-FU/LV|The patients in cohort 1 will receive irinotecan liposome injection combined with 5-Fluorouracil (5-FU) and Leucovorin (LV) intravenously on days 1 of every 14-day cycle until disease progression or unacceptable toxicity, or termination of the study for other reasons.
89566845|NCT05009953|Experimental|Cohort 2: Irinotecan Liposome Injection + SG001 + 5-Fu/LV|The patients in cohort 1 will receive irinotecan liposome injection combined with SG001, 5-Fluorouracil (5-FU) and Leucovorin (LV) intravenously on days 1 of every 14-day cycle until disease progression or unacceptable toxicity, or until 24 months is reached, or the study is terminated for other reasons.
89566846|NCT05009407||HOSTS|patients ongoing corneal transplantation procedure which a full-thickness cornea from the host is replaced by a graft from a donor
89566847|NCT05009407||DONORS|grafts from donors that would be analyzed
89566848|NCT05009641|Experimental|carnitine2|2000 mg L-carnitine per day for 24 weeks
89566849|NCT05009641|Active Comparator|carnitine|1000 mg L-carnitine per day for 24 weeks
89566850|NCT05009641|No Intervention|control|no supplementation
89566851|NCT03079453|Active Comparator|Group 1|The patients in Group 1 (n:15) were injected with dexamethasone (1 ml, 8 mg) through the uvula and soft palate tissue directly at three points (three points on the connection of the uvula, and palatum molle) before tonsillectomy .
89566852|NCT03079453|No Intervention|Group 2|Group 2 (n:15) patients had tonsillectomy without dexamethasone injection.
89608811|NCT03586245|Experimental|Aspiron|"The Aspiron group was required to follow the same protocol as the 57Fe as FePP, with the exception of consuming 58Fe ASP.~ASP-p (8% Fe; natural abundance) 3.516 mg~58ASP-p (5% Fe; 99.5% enrichment) 0.68 mg~4.2 total mg of Fe"
89566853|NCT03090373|Sham Comparator|Control Group|"At catheter replacement subjects will have a sham UroShield device attached to the external portion of the catheter and have it activated for 30 days.~Standard of care for the upkeep and cleanliness of the catheter will be adhered to.~At both the baseline and at the conclusion of 30 days, the distal end of the catheter will be collected as well as a sample of retained urine from the bladder and these samples will be evaluated for bacterial colonization."
89566854|NCT03090373|Active Comparator|Treatment Group|"At catheter replacement subjects will have an active UroShield device attached to the external portion of the catheter and have it activated for 30 days.~Standard of care for the upkeep and cleanliness of the catheter will be adhered to.~At both the baseline and at the conclusion of 30 days, the distal end of the catheter will be collected as well as a sample of retained urine from the bladder and these samples will be evaluated for bacterial colonization."
89566855|NCT03090451|Experimental|Moderate Aerobic Exercise|Subjects will undergo moderate aerobic physical exercise (40-45% of VO2-max) on three separate days at i) low insulin levels, ii) medium insulin levels, and iii) high insulin levels.
88969341|NCT06197334|Experimental|Healthy volunteers|
88969342|NCT06197334|Experimental|Crohn's disease patients with fibrosis|
88969343|NCT06197334|Experimental|Crohn's disease patients without fibrosis|
88969344|NCT06197334|Experimental|Functional gastrointestinal disorders patients|
88969345|NCT06197230|Experimental|Intervention group ; Drawing Intervention|The intervention will be applied every week for 6 weeks. The level of depression, resourcefulness, spiritual resourcefulness, and spiritual health will be tested at the first week before the intervention (T0), the 3rd week (T1), the 6th week right after the interventions (T2), 1 month follow-up after the interventions (T3), and 2 months post-intervention.
88969346|NCT06197230|Other|Control|The control group will receive standard care in nursing home
89566856|NCT03090451|Experimental|Intense Aerobic Exercise|Subjects will undergo intense aerobic physical exercise (60-65% of VO2-max) on three separate days at i) low insulin levels, ii) medium insulin levels, and iii) high insulin levels.
89566857|NCT03090139||All Participants|All participants with diagnosis of UC and CD, who initiated treatment with anti-TNF therapy from 01 March 2010 up to 01 March 2015 will be observed. Retrospective data extraction will be done for eligible participants from March 2017 up to approximately February 2018.
89566858|NCT05610813|Experimental|Test intervention: VER-01|
89566859|NCT05610813|Active Comparator|Comparative intervention: Opioid therapy (with an authorised and marketed opioid, ATC code N02A)|
89566860|NCT03090061|Experimental|Light induced fluorescence intraoral camera|
89566861|NCT03090061|Active Comparator|Visual-tactile assessment method according to FDI criteria|
89566862|NCT05009563|Experimental|Inpatients with RT-PCR proven SARS-CoV-2 infection|Inpatients with real-time reverse-transcriptase polymerase chain reaction (RT-PCR) proven SARS-CoV-2 infection of the Department of Pulmonology of Semmelweis University who will undergo whole-body FDG-PET/CT
88969347|NCT06197204||LCH patients|
88969348|NCT06197204||Control group|"diffuse lung cystic disease~pulmonary emphysema~healthy smokers"
88969349|NCT06197178|Experimental|Chimeric Antigen Receptor T cell LCAR-G08 Cells|Each subject will receive LCAR-G08 Cells
89566863|NCT05009563|Active Comparator|patients undergoing FDG-PET/CT for oncological indication|Age- and gender-matched group of patients undergoing FDG-PET/CT for oncological indication in the same time period
89566864|NCT05021341|Active Comparator|Berberine|500 mg of Berberine
89566865|NCT05021341|Active Comparator|Dihydroberberine 200|200 mg of Dihydroberberine
89566866|NCT05021341|Active Comparator|Dihydroberberine 100|100 mg of Dihydroberberine
89566867|NCT05021341|Placebo Comparator|Placebo|Maltodextrin
89566868|NCT05020561|Experimental|Arm 1 - Group and Individual|Participants in this experimental Arm 1 will receive the 3 group sessions followed by 4 to 5 individual coaching sessions via phone calls that last 60 minutes each.
89566869|NCT05020561|Experimental|Arm 2 - Group only|Arm 2 will receive only the first 3 Life coach sessions (group session).
89566870|NCT05020561|No Intervention|Arm 3 - Routine care|Arm 3 will receive routine care by the Breast clinic team for the entire course of the study.
89566871|NCT05017909|Experimental|Experimental Group 1|3-week web-based education group
89566872|NCT05017909|Experimental|Experimental Group 2|3-week face to face education group
89566873|NCT05017909|Active Comparator|Control Group|Uneducated group
89566874|NCT05020639|Experimental|TQB3820 tablets|TQB3820 tablets are administrated orally on Days 1-28 of each 28-day treatment cycle. Dose escalation of TQB3820 will be based on evaluation of clinical safety and tolerability and guided by accumulating PK data.
89566875|NCT05009017||Biosimilar group|
89566876|NCT05009017||Originator group|
89566877|NCT05008939|Experimental|sevoflurane|Those with 1-hour inhalation of 1% sevoflurane/30% oxygen
88969350|NCT06197165|Experimental|Shiatsu|"Comfort Shiatsu: 39~Targeted Shiatsu: 39"
88969351|NCT06197165|Active Comparator|without Shiatsu|patients with cardiac amyloidosis with severe symptoms
88969352|NCT06197152||100 patients with RSV diagnosis|Patients with acute respiratory infection and positive nasopharyngeal PCR or other respiratory specimen for RSV.
88969353|NCT06197152||33 control patients|Patient admitted for acute respiratory syndrome with no diagnosis of respiratory infection or immunosuppression.
88969354|NCT06197139|Experimental|[177Lu]Lu-XT117 treatment|
88969355|NCT06197126||cervical cancer patients with radiotherapy|Radiotherapy is the main treatment strategy with an overall dose of over 75Gy.
88969356|NCT06197113|Active Comparator|10 Hz rTMS group|To the patients in the high frequency (10 Hz) rTMS (n:9) group, 110% resting motor threshold (rMT), 10 Hz frequency stimulation, 5-second stimulation, and then a total of 30 trains and 1500 pulses at 25-second intervals were applied for 15 minutes while targeting the lower extremity motor area.
89566878|NCT05008939|Placebo Comparator|placebo|Those with 1-hour inhalation of 30% oxygen
89566879|NCT05361525|Active Comparator|Lipoabdominoplasty with anatomic definition|Lipoabdominoplasty with anatomic definition without over dissection on the lateral recti region
89566880|NCT05361525|Sham Comparator|traditional abdominoplasty|abdominoplasty with dissection in v- shaped pattern till coastal margin
88969357|NCT06197113|Active Comparator|iTBS group|To the patients in iTBS group (n:9), three bursts of stimulation at 50 Hz, repeated every 200 milliseconds, were delivered for 2 seconds every 10 seconds, totaling 600 stimuli at MT intensity, applied for a duration of 200 seconds.10 sessions was applied while targeting the lower extremity motor area.
88969358|NCT06197113|Sham Comparator|Sham Group|The patients in the sham group (n:8) were given sham stimulation with a sham coil for 10 sessions.
89566881|NCT03089749||Control|Participants with no history of Traumatic Brain Injury, Traumatic Spinal Cord Injury or Intracranial Neoplasm. A single draw of 5 mL of blood will be obtained as well as demographic information and a brief medical history to act as comparison data to the other groups.
88969359|NCT06197100|Experimental|supportive care training|Training in supportive care will be given to the experimental group (Training group). The mothers will also receive a training booklet from the researchers. The training booklet covers burping newborns, massage, and nourishment for mothers. In addition, mothers will be observed nursing their children, and appropriate breastfeeding instruction will be given if the baby's holding position is a problem. Over the course of a week, the supportive care training intervention will be given in three modules to the experimental group. The interventions will be carried out by the first investigator, a pediatric nursing specialist.
89566882|NCT03089749||Traumatic Brain Injury (TBI)|"Patients with Acute Severe TBI (post-resuscitation GCS of 8 or less). Participants will have blood draws at the time points identified below:~At 24h from the time of CNS insult~At 3, 5, 7, 10, 14, 18, 21, 30 days from the time of CNS insult~At 3, 6, and 12 months from the time of CNS insult~Annually for the next four years Total of up to 16 blood draws.~In all cases, 5 mL of blood will be obtained from the participant. Demographic data will be collected, including:~Age~Sex~History of prior CNS insult~Clinical indicators of severity including baseline, post-resuscitation Glasgow Coma Scale (GCS) scores for brain injury patients~Radiographic indicators of severity including volume of intracranial hemorrhage, effacement of basal cisterns, amount of midline shift as well as Marshall and Rotterdam CT head scores for TBI.~Outcome data including discharge, 3-, 6-, and 12-month extended Glasgow Outcome Scale (GOS) scores"
89566883|NCT03089749||Spinal Cord Injury (SCI)|"Patients with acute spinal cord injury (SCI) (post-resuscitation ASIA score of C, B or A). Participants will have blood draws at the time points identified below:~At 24h from the time of CNS insult~At 3, 5, 7, 10, 14, 18, 21, 30 days from the time of CNS insult~At 3, 6, and 12 months from the time of CNS insult~Annually for the next four years Total of up to 16 blood draws.~In all cases, 5 mL of blood will be obtained. Demographic data will be collected, including:~Age~Sex~History of prior CNS insult~Clinical indicators of severity including baseline post-resuscitation American Spinal Injury Association (ASIA) score and ASIA impairment scale (AIS) grade for patients with spinal cord injury (SCI)~Radiographic indicators of severity including the degree of cord compression, area of cord signal change and the SFGH MRI scale will be employed.~Outcome data including discharge, 3-, 6-, and 12-month ASIA scores for SCI patients"
89566884|NCT03089749||Intracranial Neoplasm|"Patients undergoing resection of intra-axial brain tumors (commonly gliomas such as glioblastoma multiforme, astrocytomas and oligodendrogliomas). All participants will have blood draws at the time points identified below:~At 24h from the time of CNS insult~At 3, 5, 7, 10, 14, 18, 21, 30 days from the time of CNS insult~At 3, 6, and 12 months from the time of CNS insult~Annually for the next four years Total of up to 16 blood draws.~In all cases, 5 mL of blood will be obtained. Demographic data will be collected, including:~Age~Sex~History of prior CNS insult~Clinical indicators of severity including baseline, Karnofsky and Modified Rankin performance status scores for oncology patients.~Radiographic indicators of severity including the pre- and postoperative tumor volumes that will be quantitated.~Outcome data including discharge, 3-, 6-, and 12-month Karnofsky and Modified Rankin scores for oncology patients."
89566885|NCT05361369|Experimental|EVEGYN 600 mg/1000 mg/100 mg Vaginal Ovule|Fixed dose combination of 600 mg fenticonazole nitrate + 1000 mg tinidazole + 100 mg lidocaine vaginal ovule will be administered once as a single dose during a single-period.
89566886|NCT05017519||Nuclear family type|The husband and wife with baby (aged less than 5 months) and with or without children (2-5)
89566887|NCT05017519||Extended family type (three-generation family)|The husband and wife with baby (aged less than 5 months), children (2-5), and grandparents aged > 65 years old
89566888|NCT05020093|Experimental|Injection molding|cavity design, packing technique, bonding technique
89566889|NCT05020093|Active Comparator|Incremental packing|cavity design, packing technique, bonding technique
89566890|NCT05360823|Experimental|Birth Ball Group|In the active and transitional phases, during contractions, performing exercises on the birth ball (fully rotating the hip, moving to the right/left, coming back and forth, and slightly bouncing while sitting on the birth ball) (average 25 minutes). In order to monitor the condition of the fetus, exercises on the birth ball were performed by the pregnant woman during contractions while connected to NST.
89566891|NCT05360823|Experimental|Squatting Group|In the active and transitional phase, squatting position (squatting with feet shoulder-width apart by laying a clean sheet on the floor and getting support from a bed, chair or birth ball) during contractions (average 25 minutes). In order to monitor the condition of the fetus, the squatting position was used by the pregnant woman during contractions while connected to the NST.
89566892|NCT05360823|No Intervention|Control Group|Usual routine care of the service.
89566893|NCT05017285|Other|HoLEP classic|Standard HoLEP prostate resection procedure with enucleation of all three lobes (3-lobe, 2-lobe or monobloc technique).
89566894|NCT05017285|Experimental|HoLEP with median lobe preservation|Enucleation of the lateral lobes and preservation of the medial tissue between the bladder neck and Veru montanum.
89566895|NCT05610501||Patient population|"All consecutive patients (> 18 years) undergoing a tru-cut biopsy at the participating centers during the study periof will be eligible for inclusion in the study.~All biopsies will be performed by trained operators in gynecologic ultrasound and tru-cut biopsies. Tissue samples will be assessed by experienced pathologists, dedicated in gynecologic oncology. Data will be collected by reviewing patients' electronic medical file including data concerning further treatment-strategy and pathology reports. Patients' level of pain and overall experience will be assessed by an independent investigator not present during biopsy. This will be performed from 0-72h after the biopsy using a numeric rating scale (0-100). Safety and complication-rate will be assessed by both using the collected data and via postprocedural assessment and by phone after six weeks. Inclusion and exclusion criteria can be found elsewhere."
89566896|NCT05008861|Experimental|FMT with anti-PD-1/PD-L1 treatment|
89566897|NCT05016739|Experimental|CADISS System|
88969360|NCT06197100|Active Comparator|control groups|An educational pamphlet regarding mother-baby nutrition and how to soothe a crying infant will be distributed to mothers in the control group.
88969361|NCT06197061|Experimental|Robot-assisted modified Soave group|The robotic arms were oriented from the caudal direction. Dissection was begun circumferentially at 1.0 cm above the peritoneal reflection. The rectum was mobilized outside the longitudinal muscle layer, with the anatomical plane farther away from Denonvillier's fascia and the nerve plexus anterior or lateral to the rectum. The mobilization of the rectum reached 4-7 cm into the pelvis. After the robot was unlocked, a circular incision was made 0.5-1 cm from the dentate line, dividing the mucosa upward by 0.5-1.0 cm, breaking through the muscular cuff, and exposing the robotic dissection plane in the pelvis. The diseased colon was then gently pulled out through the anus. The posterior wall of the muscular cuff was completely removed along the left and right sides, accounting for two-thirds of the whole circular muscular cuff to 0.5 cm of the dentate line edge. One third of the anterior wall of the muscular cuff was retained,we then performed Soave's anastomosis.
88969362|NCT06197061|Active Comparator|laparoscopic-assisted modified Soave group|The mesentery of the colon was separated by laparoscopy with the vessel of the pull-through bowel preserved. Under the rectal peritoneal reflex, close to the rectal wall separate with the electric hook, the anterior wall of the rectum was separated to the bladder neck or the posterior wall of the vagina. The posterior wall of the rectum can be separated down to 1cm above the dentate line .a circular incision was made 0.5-1 cm from the dentate line, dividing the mucosa upward by 0.5-1.0 cm, breaking through the muscular cuff, and exposing the robotic dissection plane in the pelvis. The diseased colon was then gently pulled out through the anus. The posterior wall of the muscular cuff was completely removed along the left and right sides, accounting for two-thirds of the whole circular muscular cuff to 0.5 cm of the dentate line edge. One third of the anterior wall of the muscular cuff was retained,we then performed Soave's anastomosis with interrupted 5-0 or 4-0 absorbable sutures.
89566898|NCT04434235||Dynamic cervical stability|"The participant is asked to move the head in 6 directions in a sitting position and 30° leaning backward sitting position; lateral flexion (left / right), flexion, extension, and rotation (left / right). Results are to be taken for each direction and random at each axial load-level (0 kg, 1kg, 2 kg, and 3 kg). In total 24 measurements.~The duration of all measurement will be 60 minutes."
88969363|NCT06197022|Other|Scoring Balloon Angioplasty|Combination of scoring-balloon angioplasty (SBA) plus sirolimus-eluting balloon angioplasty (SEBA) for diffuse (lesion length ≥20 mm), small vessel (diameter 1.5 mm -2.75 mm) coronary disease.
88969364|NCT06197009|Placebo Comparator|Placebo Group /Group1|Induction: Placebo s.c. every 2 weeks. Maintenance: 160mg SCT650C s.c. every 4 weeks
89566899|NCT04434235||Cervical Stiffness|The participant is asked to move the head in 4 directions; flexion, extension, and rotation (left / right). Joint-Position Error measurements will be executed in neutral sitting position. Additionally, stiffness will be measured in neutral sitting position and neutral sitting position with 45° cervical flexion. All measurements will be performed with 0 kg and 3 kg axal loading. In total 18 measurements.The duration of all measurement will be 60 minutes.
89566900|NCT04433923|Active Comparator|GROUP1|Phototherapy with aluminum foil
89566901|NCT04433923|Placebo Comparator|GROUP2|Phototherapy without aluminum foil
89566902|NCT03091933|Experimental|GLIDE|GLIDE single infusion at a target dose of 4x107 viable T-cells/m2
88969365|NCT06197009|Active Comparator|SCT650C low dose Group /Group 2|Induction: 160mg SCT650C s.c. every 2 weeks. Maintenance: 160mg SCT650C s.c. every 4 weeks
88969366|NCT06197009|Active Comparator|SCT650C medium dose Group /Group3|Induction: 320mg SCT650C s.c. every 2 weeks. Maintenance: 320mg SCT650C s.c. every 4 weeks
88969367|NCT06197009|Active Comparator|SCT650C high dose Group /Group 4|Induction: 320mg SCT650C s.c. every 2 weeks. Maintenance: 160mg SCT650C s.c. every 4 weeks
88969368|NCT06196996|Experimental|Allogeneic Regenerative Islet Transplantation for the Treatment of Brittle Type 1 Diabetes Mellitus|
88969369|NCT06196970|Experimental|Baseline warmup along with Pilate exercises|Pilate exercises: Group A perform Pilates exercises for 6 weeks. In the initial stage of training Pilates exercises with lo intensity then we proceeded gradually with high intensity. Pilates was performed for core strengthening and dynamic balance Pelvic curl, The hundred, Side plank with 4-5 rep, 30 sec hold and 3 sets with each exercise.
89566903|NCT05016973|Experimental|RC48-ADC+ Triplizumab|RC48-ADC on days 1 every 21 days plus triplizumab on days 1 every 21 days
89566904|NCT03091855||PLUG Dementia Trial|Patients with atrial fibrillation that undergo a standard of care, clinically approved, left atrial appendage closure will be considered for study. All patients will be followed for 24 months, and will be assessed at the 3-, 6-, 12-, 18- and 24-months post-left atrial appendage closure as well as other visits deemed necessary for clinical care. All subjects will undergo protocol-specified laboratory tests and will complete 6 standard, validated questionnaires at each follow-up visit, except at the 3-month visit when only one questionnaire will be administered.
89566905|NCT03091855||MRI PLUG Dementia Sub-Study|20 of the 60 subjects who are selected for participation in this sub-study will receive a cranial MRI at baseline and at the 2-year (24 months) follow-up visit.
89566906|NCT05359575|Experimental|"Audio recording with instructional flashcard with cervical-collar (audio kit) - 1 month follow-up"|MP3 audio files for each of 6 steps (totaling 1 minute, 19 seconds) and instructional flashcard with seven pictures corresponding to each of the 6 steps of c-collar application, used for c-collar application attempt. Participants repeat the c-collar application with the audio kit at 1 month follow-up.
89566907|NCT05359575|Experimental|Instructional flashcard with cervical-collar - 1 month follow-up|Instructional flashcard with seven pictures corresponding to 6 steps of c-collar application, used for c-collar application attempt. Participants repeat the c-collar application with the instructional flashcard at 1 month follow-up.
88969370|NCT06196970|Experimental|: Baseline physical therapy treatment along with burpees exercises|Burpees Exercises: Group B perform Burpees exercises for 6 weeks. In initial weeks of training Burpees exercises with low intensity then we proceeded gradually with high intensity exercises. Burpees was performed for core strengthening and dynamic balance .10 to 15 repetition ,3 sets with rest interval of 10 sec after each set of exercises
88969371|NCT06196944|Other|Augmentative Alternative Communication|Traditional treatment
89566908|NCT05359575|Experimental|In-person training with cervical-collar - 1 month follow-up|10 minutes of a Lay First Responder (LFR) spinal immobilization course (extracted from the current LFR Level 1 trauma course) are used for instruction for c-collar application attempt. Participants repeat the c-collar application without any POC instruction or re-training at 1 month follow-up.
88969372|NCT06196944|Other|Augmentative Alternative Communication Device|3 sessions per week for 40 minutes
89566909|NCT05359575|No Intervention|Control group with no in-person training and no access to POC instruction - 1 month follow-up|There is no in-person training or point-of-care (POC) instructional interventions for this group for c-collar application attempt. Participants repeat the c-collar application without any in-person training or POC instructional interventions at 1 month follow-up.
89566910|NCT05359575|Experimental|"Audio recording with instructional flashcard with cervical-collar (audio kit) - 2 Months follow-up"|MP3 audio files for each of 6 steps (totaling 1 minute, 19 seconds) and instructional flashcard with seven pictures corresponding to each of the 6 steps of c-collar application, used for c-collar application attempt. Participants repeat the c-collar application with the audio kit at 2 months follow-up.
88969373|NCT06196918|Experimental|Rivaroxaban group|Patients with highly suspected, newly diagnosed, untreated glioma undergo surgical resection. CT scan within 24 hours after surgery is performed to rule out intracranial hemorrhage and/or infarction. Then those patients with postoperative lower extremity dyskinesia are treated with rivaroxaban (10 mg/day) and compression stockings until 1 month after surgery.
89566911|NCT05359575|Experimental|Instructional flashcard with cervical-collar - 2 months follow-up|Instructional flashcard with seven pictures corresponding to 6 steps of c-collar application, used for c-collar application attempt. Participants repeat the c-collar application with the instructional flashcard at 2 months follow-up.
89566912|NCT05359575|Experimental|In-person training with cervical-collar - 2 months follow-up|10 minutes of a Lay First Responder (LFR) spinal immobilization course (extracted from the current LFR Level 1 trauma course) are used for instruction for c-collar application attempt. Participants repeat the c-collar application without any POC instruction or re-training at 2 months follow-up.
89566913|NCT05359575|No Intervention|Control group with no in-person training and no access to POC instruction - 2 months follow-up|There is no in-person training or POC instructional interventions for this group for c-collar application attempt. Participants repeat the c-collar application without any in-person training or POC instructional interventions at 2 months follow-up.
89566914|NCT05359575|Experimental|Audio recording with instructional flashcard (version 1) with cervical-collar - no follow-up|"Prior to randomization to 1 or 2 month follow up, these participants served as an initial cohort of participants who were not assigned to any longitudinal follow-up date so that the POC instructional flashcard could first be piloted to receive feedback for instructional flashcard revision prior to launching the trial after participants expressed concern about ambiguity in the instructional flashcard. Data from these participants is not considered part of the trial for any analytic purposes. Revisions to the instructional flashcard were made."
89566915|NCT05359575|Experimental|Instructional flashcard (version 1) with cervical-collar - no follow-up|"Prior to randomization to 1 or 2 month follow up, these participants served as an initial cohort of participants who were not assigned to any longitudinal follow-up date so that the POC instructional flashcard could first be piloted to receive feedback for instructional flashcard revision prior to launching the trial after participants expressed concern about ambiguity in the instructional flashcard. Data from these participants is not considered part of the trial for any analytic purposes. Revisions to the instructional flashcard were made."
89608812|NCT03586245|Other|Ferrous sulfate|"The FeSO4 study group was required to consume a total of 3 meals. Each meal contained 4.2 mg added iron compounds. .~Aspergillus oryzae (unenriched) 0.027 mg~57FeSO4 (95.4%) 3.18 mg~4.2 total mg of Fe"
88969374|NCT06196918|Active Comparator|Placebo group|Patients with highly suspected, newly diagnosed, untreated glioma undergo surgical resection. CT scan within 24 hours after surgery is performed to rule out intracranial hemorrhage and/or infarction. Then those patients with postoperative lower extremity dyskinesia are treated with placebo and compression stockings until 1 month after surgery.
88969375|NCT06196892|Placebo Comparator|Placebo group|
88969376|NCT06196892|Experimental|Probiotic group|
88969377|NCT06196853|No Intervention|Control|5%DNSS/2 with KCL and MgSO4 IV infusion with rate 125 ml/m2/hr.
88969378|NCT06196853|Experimental|Treatment|5%DNSS/2 with KCL and MgSO4 IV infusion with rate 125 ml/m2/hr. plus aminophylline.
88969379|NCT06196840|Experimental|LX102 Dose 1|LX102 will be administered at the assigned dose level as a single dose subretinal injection on Day 0
88969380|NCT06196840|Experimental|LX102 Dose 2|LX102 will be administered at the assigned dose level as a single dose subretinal injection on Day 0
88969381|NCT06196840|Active Comparator|Control group|Aflibercept at a fixed regimen will be administered.
88969382|NCT06196827|Experimental|LX101 Dose 1|
88969383|NCT06196827|Experimental|LX101 Dose 2|
88969384|NCT06196801||Triple Combination therapy|
88969385|NCT06196775|Experimental|AK104+AK112|
88969386|NCT06196762|Experimental|XKH002|A total of 5 dose cohorts will be enrolled and treated: 0.3, 1.0, 3.0, 10, and 20 mg/kg. The dose-escalation process will utilize both the accelerated titration and the conventional 3+3 methods.
88969387|NCT06196736|Experimental|9MW2821|
88969388|NCT06196736|Active Comparator|Investigator's Choice of Chemotherapy|
88969389|NCT06196697|Experimental|AK104+AK112+SOX/XELOX|Biological: Cadonilimab (AK104) 10mg/kg or 15mg/kg or 6mg/kg Q6W iv D8 (dose choosing depends on the outcome of the dose climb stage) Biological: Ivonescimab (AK112): 20mg/kg Q3W iv D1 Drug:SOX or XELOX SOX: Oxaliplatin (130 mg/m2 intravenous infusion for 2-6 hours on Day 1, Q3W,up to 6 cycles)+ Tegafur (40 mg/m2, p.o., Bid, Q3W, for day 1 to day 14 per cycle) XELOX: Oxaliplatin (130 mg/m2 intravenous infusion for 2-6 hours on Day 1, Q3W,up to 6 cycles)+Capecitabine(1000 mg/m2, p.o., Bid, Q3W, for day 1 to day 14 per cycle)
88969390|NCT06196684||Patients with primary tricuspid valve insufficiency scheduled for tricuspid valve replacement|
89532115|NCT06337838|Experimental|Prophylactic intravenous tranexamic acid and placebo.|"Within 20 minutes preceding anticipated skin incision, patients will receive preoperative prophylactic intravenous tranexamic acid at a dose of 1000 mg infused over 10 minutes for patients with eGFR <25 ml/min/1.73m2 who do not receive dialysis before surgery and 500 mg infused over 10 minutes for patients who receive dialysis.~Within 20 minutes preceding anticipated skin incision, patients allocated to the desmopressin control group will receive an intravenous infusion of 0.9% saline solution, administered over a duration of 30 minutes."
88969392|NCT06196658|Experimental|anti-EX02 CAR T cells|
88969393|NCT06196645|Experimental|Intervention Group-1|Participants in this arm of the experimental group will participate in a school-based intervention program that is based on the theory of planned behavior and includes behavior change techniques. These participants will participate in the intervention plan only in physical education and sports classes at their schools.
88969394|NCT06196645|Experimental|Intervention Group-2|Participants in this arm of the experimental group will participate in a school-based intervention program based on the theory of planned behavior and including behavior change techniques, and at least one of the parents of these participants will also participate in this application. Adolescent female participants will participate in the intervention plan only in physical education and sports classes at their schools. Parents will be invited to physical education and sports classes or participate in the application online, depending on their time availability.
89566916|NCT03091699|Experimental|Moderate intensity exercise|The Exercise intervention will persist of a 20-minute bout of moderate intensity aerobic exercise which by definition is 40-65% of Maximum Heart Rate. Exercise consisted of a 2-minute warm-up, followed by 15 min of walking at a rate, which will allow you to reach 2/3 of your max heart rate, and then a 3-minute cool down on a treadmill equaling 20 minutes. Heart Rate will be examined with Polar Wearlink coded Heart Rate monitors to attain the specific exercise intensity.
89566917|NCT03091699|Active Comparator|Nicotine Inhalation|The nicotine inhalation group will smoke a cigarette to completion of their choice, in the 20 minute time period allocated in the Exercise and Health Psychology Lab psychological assessment room (the room will be equipped with windows that allow for ventilation and an air purifier. During this time the participant will refrain from conversation.
88969395|NCT06196645|No Intervention|Control Group|This group will not be involved in any implementation until the end of the research. Ethically, after the research is completed, the proposal to repeat the most effective intervention arm for this group will be presented to the participants in this group.
89566918|NCT05016115||physiotherapy students|Totally 120 physiotherapy students at a non-governmental university in Istanbul participated in this study.
89566919|NCT03091543|Experimental|Sequence A (25 mg - 50 mg - 100 mg - 200 mg - Placebo)|Concomitantly with the BIA 6-512/Placebo dose, subjects will be administered levodopa/benserazide 100/25 mg. All subjects attended to each 5 treatment periods and received a different dose of BIA 6-512 or placebo in combination with a single-dose of controlled release levodopa/benserazide 100/25 mg in each of these treatment periods. The washout period between periods was 5 days or more.
89566920|NCT03091543|Experimental|Sequence B (Placebo - 25 mg - 50 mg - 100 mg - 200 mg)|Concomitantly with the BIA 6-512/Placebo dose, subjects will be administered levodopa/benserazide 100/25 mg. All subjects attended to each 5 treatment periods and received a different dose of BIA 6-512 or placebo in combination with a single-dose of controlled release levodopa/benserazide 100/25 mg in each of these treatment periods. The washout period between periods was 5 days or more.
89608813|NCT03890991|Experimental|SCOPE-DM only|Participation in SCOPE-DM programme without supply of glucometers and accessories
88969396|NCT06196632||"de novo strategy-HBeAg positive"|HBeAg positive patients treated with simultaneous administration of NA and Peg-IFN
88969397|NCT06196632||"de novo strategy-HBeAg negative"|HBeAg positive patients treated with simultaneous administration of NA and Peg-IFN
88969398|NCT06196632||"add-on strategy-HBeAg positive"|HBeAg positive patients treated with NA followed by addition of Peg-IFN.
88969399|NCT06196632||"add-on strategy-HBeAg negative"|HBeAg negative patients treated with NA followed by addition of Peg-IFN.
88969400|NCT06196619||Stage 1 lipedema patients|It is the stage where normal skin surface, enlarged subcutaneous fat tissue, and many small nodules are present upon palpation.
88969401|NCT06196619||Stage 2 lipedema patients|It is the stage with rough skin surface, large nodules of palpable subcutaneous fat tissue
88969402|NCT06196619||Stage 3 lipedema patients|It is the stage in which lobular deformation of the skin surface occurs with enlarged fatty tissue.
88969403|NCT06196606|Experimental|experimental group|Botulinum toxin type A for injection (Hengli National Drug approval number S10970037) 100U, diluted with 1 ml.9% sodium chloride solution for reserve use.Each patient was injected with 90U
88969404|NCT06196593|Experimental|All eyes|All eyes implanted with AcrySof™ IQ Vivity™ Toric intraocular lens
88969405|NCT06196567|Active Comparator|active control group|will receive the standard prehabilitation a physio-based exercise program designed to increase quadriceps muscle strength for 2 sessions per week for 8 weeks. Sessions will be performed at the same time (i.e., in the morning). The main programme comprised 5 sets of 10 repetitions for each exercise, with 60 rest between sets.
88969406|NCT06196567|Experimental|Pulsed Electromagnetic Field (PEMF)|will receive the active PEMF treatment provided by a PEMF device (Quantum Tx, Singapore). Alternating leg will be exposed to PEMF for 10 minutes per session for 2 sessions per week for 8 weeks.
88969407|NCT06196567|Experimental|standard prehabilitation plus PEMF intervention|This group will have both the standard prehabilitation and PEMF intervention for 2 sessions a week for eight weeks.
88969408|NCT06196541||Individuals with Chronic Venous Insufficiency|Edema, pain, respiratory functions, physical functions and quality of life will be evaluated in individuals with chronic venous insufficiency.
88969409|NCT06196541||Asymptomatic Healthy Individuals|Edema, pain, respiratory functions, physical functions and quality of life will be evaluated in asymptomatic healthy individuals.
88969410|NCT06196515|Experimental|Nano calcium hydroxide in hydrogel form|nano calcium hydroxide in hydrogel form is placed in the dry root canals after complete cleaning and shaping procedure.The intracanal medication will be distributed to fill the canals up to the orifice level.
89608814|NCT03890991|Active Comparator|SCOPE-DM with 3 months' supply of glucometer|Participation in SCOPE-DM programme with 3 months' supply of glucometers and accessories
89208595|NCT02596061|Experimental|Intervention-Pre-Commitment|Patients have access to a website where they can self-report smoking status, add supporters, and submit journal entries. Patients receive incentives for these activities and for using clinic counseling services. At enrollment, patients are offered the chance to set aside some of their future rewards for a deposit contract that lasts for 4 mos. and starts 2 mos. after the rewards contract. If, at the end of 6 mos., the patients pass the second verification test, their rewards are returned to them. At the 2 mo. mark, patients come to the clinic for a biochemical verification of their smoking status. Rewards are contingent on passing this test. They are also asked to return to the clinic 6 and 12 mos. after enrollment to complete the smoking tests and are compensated for these 2 visits.
89208596|NCT02596061|Experimental|Intervention-Commitment|Patients have access to a website where they can self-report smoking status, add virtual supporters, and submit journal entries. Patients receive incentives for these activities and for using clinic counseling services. After 2 mos., this group is offered the chance to set aside some of their rewards towards a deposit contract that lasts for 4 months. If, after the 4 mos., the patients pass the second cessation verification test, their rewards are returned to them. At the 2 mo. mark, these patients come to the clinic for a biochemical verification of their smoking status. Rewards are contingent on passing this test. They are also asked to return to the clinic 6 and 12 mos. after enrollment to complete the smoking tests and are compensated for these 2 visits.
89208597|NCT00789308|Active Comparator|Standard of Care|18 participants randomized to protocol immunosuppression (Daclizumab OR Basiliximab; Tacrolimus OR Cyclosporine; Mycophenolate Mofetil OR Sirolimus; and heparin) without LMW-DS
88969411|NCT06196515|Active Comparator|Nano calcium hydroxide in paste form|nano calcium hydroxide in paste form is placed in the dry root canals after complete cleaning and shaping procedure. The intracanal medication will be distributed to fill the canals up to the orifice level.
88969412|NCT06196515|Active Comparator|Conventional calcium hydroxide in paste form|conventional calcium hydroxide in paste form is placed in the dry root canals after complete cleaning and shaping procedure.The intracanal medication will be distributed to fill the canals up to the orifice level.
88969413|NCT06196502|Experimental|Gentle human touch (GHT)|Experimental: Gentle human touch (GHT) Group 1: Gentle touch is a touch technique that provides a kind of relaxation in premature babies, reduces behavioral stress and motor activities of babies and is effective in their positive behavior.
88969414|NCT06196502|Active Comparator|Kangaroo Care|Experimental: Kangaroo Care Group 2: Kangaroo care is a comforting technique that strengthens and bonds the baby and parent, increases the production of milk by the mother, and lessens the stress and anxiety of both parties. Kangaroo care between parent and baby is a method that regulates vital values, reduces the possibility of hypoglycemia and prevents hypothermia.
88969415|NCT06196502|Active Comparator|Lactation|Breastfeeding will begin 5 minutes before the Hepatitis-B vaccine administration and will continue during and after the procedure. It is planned to last 10 minutes in total.
88969416|NCT06196489|Experimental|telephone|Participants assigned to this group will receive the adapted intervention by telephone.
89208598|NCT00789308|Experimental|LMW-DS|18 participants randomized to protocol immunosuppression (Daclizumab OR Basiliximab; Tacrolimus OR Cyclosporine; Mycophenolate Mofetil OR Sirolimus; and heparin) and LMW-DS
89208599|NCT00518284|No Intervention|No Drug Treatment Control|Following revascularization, participants did not receive any study drug treatment.
89208600|NCT00518284|Experimental|Proximal to Lesion + IV|Participants received an initial intraarterial infusion (proximal to the lesion) of 45 mg/m^2 nanoparticle paclitaxel immediately following revascularization, and a follow-up intravenous injection of 45 mg/m^2 at 7 days.
89208601|NCT00518284|Experimental|During Flow Arrest|Participants received an initial intraarterial infusion (during flow arrest) of 45 mg/m^2 nanoparticle paclitaxel immediately following revascularization.
89208602|NCT00518284|Experimental|During Flow Arrest + IV|Participants received an initial intraarterial infusion (during flow arrest) of 45mg/m^2 nanoparticle paclitaxel immediately following revascularization and a follow-up intravenous injection of 45 mg/m^2 at 7 days.
89208603|NCT02595359|Experimental|moxifloxacin intracameral|moxifloxacin injection given at conclusion of cataract intervention
88969417|NCT06196489|Experimental|Video|Participants assigned to this group will receive the adapted intervention by video telehealth.
88969418|NCT06196476|No Intervention|Control Group|The participants in this group received routine nursing information in which the nurse discussed general knowledge of climate change awareness regarding the management of reducing Climate Anxiety effects to primary health care nurses.
89208604|NCT00871104|Experimental|1|IV fosfomycin and imipenem adjusted to renal function
89208605|NCT00871104|Active Comparator|2|IV Vancomycin twice a day with valley leves higher than 15 mcg/kg
89027982|NCT00487500|Experimental|Ultrabrief, Right Unilateral ECT|Right unilateral ECT administered with an ultrabrief pulse width (0.3 ms), at a dose 6 times the initial seizure threshold
89027983|NCT00487500|Experimental|Ultrabrief, Bilateral ECT (2.5 X ST)|Bilateral (frontotemporal) ECT with an ultrabrief pulse width with dosage 2.5 times the initial seizure threshold
89208606|NCT02595515|Experimental|Chiropractic treatment|Manipulation and/or mobilisation. Intervention: Procedure: Chiropractic treatment.
89208607|NCT02595515|Placebo Comparator|Visit without active treatment|The child is brought in for chiropractic treatment, but no active treatment is delivered. The parents are unaware whether the treatment is delivered or not.
89208608|NCT03868566|Experimental|SNP-612 dose1|dose1 once a day orally for 12 weeks
89208609|NCT03868566|Experimental|SNP-612 dose2|dose2 once a day orally for 12 weeks
89566921|NCT03091543|Experimental|Sequence C (200 mg - Placebo - 25 mg - 50 mg - 100 mg)|Concomitantly with the BIA 6-512/Placebo dose, subjects will be administered levodopa/benserazide 100/25 mg. All subjects attended to each 5 treatment periods and received a different dose of BIA 6-512 or placebo in combination with a single-dose of controlled release levodopa/benserazide 100/25 mg in each of these treatment periods. The washout period between periods was 5 days or more.
89608815|NCT03890991|Active Comparator|SCOPE-DM with 6 months' supply of glucometer|Participation in SCOPE-DM programme with 6 months' supply of glucometers and accessories.
89608816|NCT03890991|No Intervention|Control|Usual care by healthcare provider/ clinics of Tsao Foundation without participation in SCOPE-DM programme
89208610|NCT00796952|Active Comparator|Usual Care|"Patient management by the attending Radiation oncologist as usual."
88969419|NCT06196476|Experimental|Intervention Group|"The participants in this group received an empowerment-based intervention in terms of interactive digital-based educational program regarding the promoting literacy, pro-environmental attitudes, self-efficacy, and reducing climate anxiety.~The Interactive digital-based educational program Sessions:~Session 1: The road start to green planet: Introductory to climate change concept Session 2: Towards Climate Change Literacy Modifications: remove the cover on illiteracy.~Session 3: Green scrubs and green environment: raising climate activities and environment self-efficacy Session 4: Strengthen resilience to overcome climate related anxiety Session 5: Sustaining phase: closing session"
88969420|NCT06196463|Active Comparator|(AG+ESP) Group|In AG+ ESP Group , the ESP block and the General anesthesia will be performed together in the same patient
89566922|NCT03091543|Experimental|Sequence D (100 mg - 200 mg - Placebo - 25 mg - 50 mg)|Concomitantly with the BIA 6-512/Placebo dose, subjects will be administered levodopa/benserazide 100/25 mg. All subjects attended to each 5 treatment periods and received a different dose of BIA 6-512 or placebo in combination with a single-dose of controlled release levodopa/benserazide 100/25 mg in each of these treatment periods. The washout period between periods was 5 days or more.
89566923|NCT03091543|Experimental|Sequence E (50 mg - 100 mg - 200 mg - Placebo - 25 mg)|Concomitantly with the BIA 6-512/Placebo dose, subjects will be administered levodopa/benserazide 100/25 mg. All subjects attended to each 5 treatment periods and received a different dose of BIA 6-512 or placebo in combination with a single-dose of controlled release levodopa/benserazide 100/25 mg in each of these treatment periods. The washout period between periods was 5 days or more.
89566924|NCT04253457|Experimental|Corticosteroid injection|Single injection of 1ml of triamcinolone (40mg/1ml)
88969421|NCT06196463|Sham Comparator|AG Group|In AG Group the ESP block wont' be performed, but only a shamed block, realized through 4 skin puncture
88969422|NCT06196411|Experimental|Study Group|Task-oriented Training Bobath Training
88969423|NCT06196411|Active Comparator|Control Group|Bobath Training
88969424|NCT06196398||Decompensated blood flow reserve|ICAS patients with decompensated cerebral blood flow reserve diagnosed by MR-FFR (FFR baseline≥0.81).
88969425|NCT06196398||Normal blood flow reserve|ICAS patients with normal cerebral blood flow reserve determined by MR-FFR (FFR baseline<0.81).
88969426|NCT06196346|Experimental|Experimental: Main group|The group underwent 16 sessions of supportive-expressive psychotherapy (Luborsky et al., 1995)
89566925|NCT04253457|Active Comparator|Corticosteroid and local anaesthetic injection|Single injection of 1ml of triamcinolone (40mg/1ml) + 1ml 1% Lidocaine
89566926|NCT05380947|Experimental|Treatment sequence 1: R - T1 - T2 - T3|"Treatments:~R: TF1 fasted T1: NF fasted T2: NF fed T3: NF fasted + rabeprazole"
89566927|NCT05380947|Experimental|Treatment sequence 2: T1 - T3 - R - T2|
89566928|NCT05380947|Experimental|Treatment sequence 3: T2 - R - T3 - T1|
89566929|NCT05380947|Experimental|Treatment sequence 4: T3 - T2 - T1 - R|
89566930|NCT05008471|Experimental|Intervention group|The recommended target energy for NPC radiotherapy patients is 25-30kcal/(kg·d), in addition，the intervention group begins with an additional 50% daily energy increase during the peri-radiotherapy.
89566931|NCT05008471|No Intervention|Conventional group|Unlike the intervention group,conventional group should be treated according to the consensus of experts on standardized nutrition management.
89566932|NCT05342727|Active Comparator|tDCS group|The tDCS arm receives two real (or active) stimulation at 2 mA and 3 mA intensities and one placebo electrical stimulation for 20 minutes.
89566933|NCT05342727|Active Comparator|tACS group|The tACS arm receives two real (or active) stimulation at 8 Hz and 40 Hz frequencies and one placebo alternating electrical stimulation for 20 minutes.
89566934|NCT03088969||patient with a chronic back pain|
89566935|NCT02525133|Experimental|XaraColl|3 XaraColl Bupivacaine Implants each containing 100 mg of bupivacaine hydrochloride, for a 300 mg total dose
89566936|NCT02525133|Placebo Comparator|Placebo|3 placebo implants
89566937|NCT03091465||Metastatic Renal Cell Carcinoma patients|This is a nation-wide retrospective observational study with patients treated with first-line pazopanib for mRCC in daily clinical practice since April 2011 (date of approval of pazopanib in Spain), January 2016.
89566938|NCT05356299|Experimental|MagneticTape group|The Magnetic Tape bandage will be placed by the patient's care team and will be placed in the anterior superior part of each hemithorax, matching the large vessels and lymph nodes, in the posterior part of the thorax in the paravertebral area from C3 to T9 and in the subcostal region, following the direct innervation of the thorax and shoulder girdle, as well as the dorsal levels with lateral horns that control the vascularisation of the thorax and shoulder girdle.
89566939|NCT05016427|Experimental|VT301(low dose)|VT301 low dose: 8.5x10^4 cells/kg
89566940|NCT05016427|Experimental|VT301(high dose)|VT301 high dose: 1.7x10^5 cells/kg
89566941|NCT05602311||Group SDB|Children were divided into two groups according to whether they had SDB, group SDB: experimental group (SDB children), group control: control group (typical development children)
89566942|NCT05602311||Group control|Children were divided into two groups according to whether they had SDB, group SDB: experimental group (SDB children), group control: control group (typical development children)
89566943|NCT05016349|Experimental|All trans-retinoic acid, Mifepristone Cannabidiol (Epidiolex) and tamoxifen|Patients will receive oral All trans-retinoic acid and Mifepristone daily for 2 weeks ,after which daily oral Cannabidiol (Epidiolex) is added to the regimen for 2 weeks , after which daily oral tamoxifen is added to the regimen. Patients continue treatment for up to 28 weeks, with tamoxifen continued after the study if medically appropriate.
89566944|NCT05016349|Experimental|Mifepristone, Cannabidiol (Epidiolex) , All trans-retinoic acid and tamoxifen|Patients will receive oral Mifepristone daily for 4 weeks ,after which daily oral All trans-retinoic acid, tamoxifen and Cannabidiol (Epidiolex) is added to the regimen , a. Patients continue treatment for up to 28 weeks, with tamoxifen continued after the study if medically appropriate.
88969427|NCT06196333||Diabetes|Diabetes patients above 40 years
88969428|NCT06196333||Controls|Healthy controlled human beings have no medical histories
89027984|NCT00487500|Active Comparator|Brief Pulse, Right Unilateral ECT|Right unilateral ECT, with a standard brief pulse (1.5 ms), with dosage 6 times the initial seizure threshold
89566945|NCT05016349|Experimental|Mifepristone , All trans-retinoic acid, Cannabidiol (Epidiolex) and tamoxifen|Patients will receive oral Mifepristone, All trans-retinoic acid and Cannabidiol (Epidiolex) daily for 4 weeks ,after which daily oral tamoxifen is added to the regimen , a. Patients continue treatment for up to 28 weeks, with tamoxifen continued after the study if medically appropriate.
89566946|NCT05016349|Experimental|9 cis retinoic acid, Mifepristone Cannabidiol (Epidiolex) and tamoxifen|Patients will receive oral Mifepristone, 9 cis retinoic acid and Cannabidiol (Epidiolex) daily for 4 weeks ,after which daily oral tamoxifen is added to the regimen , a. Patients continue treatment for up to 28 weeks, with tamoxifen continued after the study if medically appropriate.
89566947|NCT05016349|Experimental|Mifepristone, 13 cis retinoic acid , Cannabidiol (Epidiolex) and tamoxifen|Patients will receive oral Mifepristone, 13 cis retinoic acid and Cannabidiol (Epidiolex) daily for 4 weeks ,after which daily oral tamoxifen is added to the regimen , a. Patients continue treatment for up to 28 weeks, with tamoxifen continued after the study if medically appropriate.
89566948|NCT05016349|Experimental|9 cis retinoic acid , Mifepristone Cannabidiol (Epidiolex) and tamoxifen|Patients will receive oral 9 cis retinoic acid and Mifepristone daily for 2 weeks ,after which daily oral Cannabidiol (Epidiolex) is added to the regimen for 2 weeks , after which daily oral tamoxifen is added to the regimen. Patients continue treatment for up to 28 weeks, with tamoxifen continued after the study if medically appropriate.
89566949|NCT05016349|Experimental|13 cis retinoic acid , Mifepristone Cannabidiol (Epidiolex) and tamoxifen|Patients will receive oral Mifepristone, 13 cis retinoic acid and Cannabidiol (Epidiolex) daily for 4 weeks ,after which daily oral tamoxifen is added to the regimen , a. Patients continue treatment for up to 28 weeks, with tamoxifen continued after the study if medically appropriate.
89566950|NCT05016349|Sham Comparator|Standard therapy|Patients will receive the approved standard therapy
89566951|NCT05355675||observational group|Patients with hematologic malignancies following allogeneic hematopoietic stem cell transplantation treatment
89566952|NCT05355675||control group|health control group: healthy volunteers
89566953|NCT05016193|Experimental|Intervention Group|"Participants will attend 3 assessment sessions: one at the beginning of the study, one after about 3 weeks, and one at the end of the study. These sessions will be conducted by a trained physiotherapist.~Participants will be asked to wear the Axem Home prototype headband when doing their daily upper-extremity rehabilitation exercises at home.~Participants will perform a short motor assessment while wearing the Axem Home prototype headband once per week."
89566954|NCT05016193|Active Comparator|Control Group|"Participants will attend 3 assessment sessions: one at the beginning of the study, one after about 3 weeks, and one at the end of the study. These sessions will be conducted by a trained physiotherapist.~Participants will be asked to keep track of how many minutes of rehabilitation they have completed as per standard care.~Participants will perform a short motor assessment while wearing the Axem Home prototype headband once at the beginning of the study and again at the end of the study during the clinical assessment sessions."
89566955|NCT05380635|Experimental|HyBryte (0.25 % Hypericin)|HyBryte (0.25 % hypericin) ointment will be applied to CTCL lesions and treated with visible light 18-24 hours later starting at 5 J/cm^2. Drug application/light session will be done twice a week (at least 2 calendar days apart) for 8 weeks.
89566956|NCT03091309|Experimental|Intervention|Patients randomized to the intervention group will receive a multi-faceted intervention consisting of: (1) Interactive educational video; (2) Initial in-person counseling with an IBD nurse; (3) Motivational interviewing; (4) Telemedicine-based follow-up; (5) Monthly follow-up questionnaires; and (6) Comprehensive questionnaires.
89566957|NCT03091309|Active Comparator|Control|Patients randomized to the control group will complete the comprehensive questionnaires and will continue to receive the standard of care consistent with their condition, at their respective institution.
89566958|NCT05015959||mortality outcomes|mortality classification into preventable, potentially preventable and non-prevenatable
89566959|NCT04254393|Experimental|Early Adolescent Skills for Emotions (EASE) Program|Early Adolescent Skills for Emotions (EASE) is a new, brief, targeted, group psychological intervention program (Dawson et al., 2019) based on cognitive behavioural therapy (CBT) techniques that are empirically supported and formally recommended by the WHO (WHO, 2016).
89566960|NCT04254393|Placebo Comparator|Treatment as Usual (TAU)|Participants in control arm will be able to avail the routine services available in school settings.
89566961|NCT03079609|Experimental|microsurgery urology|20 patients with varicocele (grade II or III) undergoing subinguinal microsurgery varicocelectomy due to infertility and/or pain in the scrotum.
89566962|NCT03079609|Active Comparator|open general surgery|20 patients (without varicocele) undergoing open hernia repair.
89566963|NCT05538819||Glimepiride group|509 patients aged >18 years with T2D and CHF had continuous glimepiride use (1-4 mg/day).
89566964|NCT05538819||Non-glimepiride group|509 patients aged >18 years with T2D and CHF had no glimepiride use.
89566965|NCT05015647|Experimental|LP group|LP group (n=17) was prescribed high calories/low proteins diet (30 Kcal/kg and 0.6-0.7gr/kg respectively) supplemented with commercial protein free products (protein content <2%).
89566966|NCT05015647|Active Comparator|NP group|NP group (n=18) was prescribed high calories/normal proteins diet (30 kcal/kg and 0.8 gr/kg respectively)
89566967|NCT05354583||Acquired Interferon-gamma Autoantibody Syndrome|"Patients infected with M. abscessus at any site, who have acquired interferon-gamma autoantibody syndrome defined as one of the following features:~The M. abscessus infection site is lymph node.~The M. abscessus infection is disseminated (more than 1 organ of infection or blood culture positive for M. abscessus).~The M. abscessus infection is accompanied by one of reactive skin diseases which are Sweet's syndrome, pustular psoriasis, erythema nodosum.~History of opportunistic infection such as salmonellosis, penicillosis, histoplasmosis, cryptococcosis, melioidosis~The patients must not be infected with HIV, in-hospital M. abscessus infection, diagnosed with cancer, or receiving immunosuppressants."
89566968|NCT05354583||Chronic Lung Disease|"Patients with one of chronic lung diseases which are COPD, chronic bronchiectasis, history of pulmonary tuberculosis and diagnosed with Pulmonary M. abscessus infection.~Pulmonary M. abscessus infection diagnosis must be met all of the following criteria:~Symptoms and signs are correlated with the pulmonary M. abscessus infection.~One of the radiological evidences:~2.1) nodular infiltration or cavitary lesion on plain chest radiography~2.2) bronchiectasis and multiple small nodules on chest computerized tomography~Mycobacterial culture from respiratory tract specimen is positive for M. abscessus"
89566969|NCT03079219|Experimental|Experimental|Aprepitant, Ondansetron, Dexamethasone and Olanzapine
89566970|NCT03079219|Other|Standard|Aprepitant, Ondansetron, Dexamethasone
89566971|NCT03078985|Experimental|ablation for typical atrial flutter|This group receives an MR-guide ablation for atrial flutter with the study device ( Vision-MR ablation catheter )
89566972|NCT03078829||Trans female adolescents|All transgender males to females youth in pubertal stage Tanner stage 4-5, starting GnRH agonist and estrogen treatment
89566973|NCT05019469|Experimental|Single arm of study|Single Arm. During each study session the participant undertakes 4 walking/activity circuits. During each circuit the participant receives either continuous cueing, responsive cueing (delivered in response to gait freezing), no cueing and no device. The ordering of the interventions/circuits are systematically alternated for each participant.
89566974|NCT03091153|No Intervention|Control|Standard care. Annual medication review
89566975|NCT03091153|Experimental|Intervention|In depth medication review with a focus on deprescribing
89566976|NCT05015179|No Intervention|Control|Laparoscopic partial nephrectomy is performed with an intraoperative ultrasound (US) control
89566977|NCT05015179|Experimental|Experimental|Underwent Laparoscopic partial nephrectomy with the aid of the mixed reality model
89566978|NCT05019781|Experimental|KT group|Participants were received single session therapeutic tape application for one week.
89566979|NCT05019781|Placebo Comparator|Placebo group|Participants were received single session placebo tape application for one week.
89566980|NCT05019781|No Intervention|Control group|No intervention.
89566981|NCT05019157|Experimental|Telerehabilitation group|Participants will undertake the first three training sessions in the outpatient clinic under the supervision of the specialized staff for familiarization with the intervention. and then the participants will proceed with the telerehabilitation program at their homes. Participants will undergo an exercise - based program 3 times/week, comprised of 10' warm up exercises, 40' aerobic, resistance and balance exercises and 10' cool down, with the use of wearable sensors.
89566982|NCT05019157|Active Comparator|Centre - based rehabilitation group|Participants will attend an exercise - based cardiac rehabilitation program at the outpatient clinic's facilities under the supervision of cardiac rehabilitation specialized staff. The participants will receive an individually tailored training program on a treadmill or a cycle ergometer 3 times/week, comprised of 10' warm up exercises, 40' aerobic, resistance and balance exercises and 10' cool down.
89566983|NCT05019157|No Intervention|Usual care group|Patients will not undertake any exercise based intervention and will only follow their usual medication treatment .The patients will wear the accelerometer for the 12 week study duration and visit the corresponding outpatient cardiac clinic every 4 weeks to upload the recorded data. The patients will also receive educational phone videoconference sessions every week for physical activity, diet/nutritional and smoking cessation counseling.
88969429|NCT06196307||No cardiovascular adverse events (MACE) occurred during the 1-month period|No cardiovascular adverse events (MACE)，which include all-cause death, myocardial infarction, emergency revascularization, cardiogenic shock, cardiac arrest/ventricular fibrillation, stroke, and so on. Follow-up visits are conducted by in-person or telephone and registration is carried out.
88969430|NCT06196307||Group of cardiovascular adverse events (MACE) occurring during 1 month|Cardiovascular adverse events occur, the rest of the same as in the previous group
89208611|NCT00796952|Experimental|Pharyngocise|Standardized high intensity behavioral swallowing therapy (Pharyngocise) comprised a battery of direct isometric / isotonic exercises and appropriate dietary modification, under the direction of the study speech pathologist, twice daily for the duration of the patient's total course of their chemo-radiation treatment (up to a maximum of 6 weeks)
89566984|NCT05008237|Experimental|Cisplatin plus docetaxel|"D1, D8 Docetaxel 35 mg/m2 + D5W 100mL MIV over 1hr D1 Cisplatin 70mg/m2 + NS 150mL MIV over 1hr every 3 weeks~Treatment will be continued until disease progression or unacceptable toxic effects."
89566985|NCT05014711|Experimental|remifentanil group|After enrollment, remifentanil will be used for analgesia. Duration of mechanical ventilation, incidences of adverse events, interval from SBT to extubation, dosages and costs of analgesics and sedatives drugs will be observed.
89566986|NCT05014711|Active Comparator|fentanil group|After enrollment, fentanil will be used for analgesia. Duration of mechanical ventilation, incidences of adverse events, interval from SBT to extubation, dosages and costs of analgesics and sedatives drugs will be observed.
88969431|NCT06196294|Experimental|γδT cell therapy for solid tumor|
88969432|NCT06196294|Experimental|CAR-γδT cell therapy for solid tumor|
88969433|NCT06196281|Experimental|wooble board proprioceptive training|The group A will perform the wobble board proprioceptive training program lasting for four weeks. Both the training programs consisted of one-leg and double-leg static and dynamic balance drills
88969434|NCT06196281|Experimental|multi-station proprioceptive training|The group B will perform the multi-station proprioceptive training program lasting for four weeks. Both the training programs consisted of one-leg and double-leg static and dynamic balance drills basic exercise single length stance walk, Jumper exercise, resistance exercise
88969435|NCT06196255|Experimental|anti FcRL5 CAR-T|anti-FcRL5 autologous CAR T cells will be infused at a dose ranging from 1 - 2 x 10^6/kg CAR+ T cells after receiving lymphodepleting chemotherapy.
88969436|NCT06196242|Experimental|DBS lead localization|Participates will receive a head MRI anc CT scan. The stimulation target and the related neural nuclei will be reconstructed using MRI images. The spatial position of the implanted lead will be identified with MRI and CT. Through comparing with the identified lead position by CT, the accuracy of lead localization by MRI will be evaluated.
89027985|NCT00487500|Active Comparator|Brief Pulse, Bilateral ECT|Bilateral (frontotemporal) ECT with a standard brief pulse (1.5 ms), with dosage 2.5 times the initial seizure threshold
89566987|NCT03087721|Experimental|1x2 HIIT-LV, 3 times a week, 24 min|
89566988|NCT03087721|Active Comparator|CAE, moderate intensity, 3 times a week, 36 min|
89566989|NCT05007457|Experimental|Experimental Group|telerehabilitation
89566990|NCT05007457|Active Comparator|Control group|Standard treatment
89566991|NCT05018923|Experimental|RBMD group|Rabeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid, metronidazole 0.4 g qid and doxycycline 0.1 g bid for 14 days
89566992|NCT05018923|Active Comparator|RAMT group|Rabeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid, metronidazole 0.4 g qid and tetracycline 0.5 g qid for 14 days
89208612|NCT00796952|Sham Comparator|Valchuff|"Standardised sham swallowing therapy comprised a buccal extension maneuver (valchuff) and appropriate dietary modification, under the direction of the study speech pathologist, twice daily each week for the duration of the patient's total course of chemo-radiation treatment."
89566993|NCT03090919|Placebo Comparator|Saline|Subjects randomized to the Saline arm will receive 250cc of physiological saline.
89566994|NCT03090919|Experimental|Platelet transfusion|Subjects randomized to platelet transfusion will receive a unit of platelets (~250cc in volume).
89566995|NCT05019079|Experimental|electroacupuncture group|In the electroacupuncture group, acupoints of Lieque (+), Chize (-), Sanyinjiao (-), Zusanli (+), Tanzhong (+) and Yutang (-) will be selected for electrical stimulation. Density wave will be selected, and the current intensity should be tolerated by the patients. Conventional anesthesia operation could be started after the connection of electroacupuncture, and acupuncture point stimulation was stopped 30min later.
89566996|NCT05019079|No Intervention|control group|The patient underwent routine anesthesia without acupuncture treatment
89566997|NCT03086863|Experimental|verum electroacupuncture|"Electroacupuncture on LI4, LI15, TE14, SI9, SI11, and GB21, unilaterally~Needle insertion by 10-15 mm and de qi sensation~Park sham guide tubes~Low frequency electronic stimulation (30 Hz)~Retention for 20 minutes."
89566998|NCT03086863|Sham Comparator|sham electroacupuncture|"Park sham device on on LI4, LI15, TE14, SI9, SI11, and GB21, unilaterally~Needle installation without penetration~Park sham guide tubes~Low frequency electronic stimulation (30 Hz) for a fake noise without conduction~Retention for 20 minutes."
89566999|NCT05019001|Other|Laminoplasty|A posterior approach surgical method to treat patients with Ossification of the Posterior Longitudinal Ligament
89567000|NCT05019001|Other|Laminectomy With Fusion|Another posterior approach surgical method to treat patients with Ossification of the Posterior Longitudinal Ligament
88969437|NCT06196229|Active Comparator|Action Observation Therapy|"During each training session, participants were asked to observe a specific object-directed daily action presented on a computer screen, and afterward they performed what they have observed, 5 repetitions of each task, time duration was noted.~16 motor tasks related to their daily living that were performed with their own hands which are following~Folding a towel~Cutting a toilet roll~Using scissors~Tightening shoelaces~Opening and closing a square airtight container~Opening a bottle top~Turning a faucet~Using a field of billfold~Drinking water~Setting a seal~Changing batteries~Opening and closing a zipper~Turning over pages of a book~Plugging the outlet~Spraying water with a sprayer~Sorting chopsticks and spoons and putting them in a box • The participants were advised to keep focusing on their affected arm/hand action observational tasks"
89567001|NCT05019313||COVID 19 positive patients|"COVID19 positive patients with hypoxemic acute respiratory failure hospitalized in intensive care unit.~This study evaluates diaphragmatic contractility with ultrasound, blood gas analytical parameters during weaning from invasive mechanical ventilation"
89567002|NCT03086473|Other|Caffeine|Participant will receive caffeine citrate 20mg/kg IV within 2 hours of life and placebo (normal saline IV) at 12 hours of life. Both infusions will be of identical volumes and appearance, and will be administered over 30 minutes.
89567003|NCT03086473|Other|Placebo|Participant will receive placebo (normal saline IV) within 2 hours of life and caffeine citrate 20mg/kg IV at 12 hours of life. Both infusions will be of identical volumes and appearance, and will be administered over 30 minutes.
89567004|NCT03086005|Experimental|Metformin|Metformin 500mg tablet by mouth, every 12 hours, from the first day of oral contraceptive pills taken to the day of oocyte retrieval
88969438|NCT06196229|Experimental|Action Observation Therapy combined with Virtual Reality|"In the VRT group, participants will execute VR-based activities conducted by the same therapist .~16 tasks will be assigned in each session. VR SHINECON 3D Glasses will be used~The virtual environment was set in a 6 m2 physical space~At the beginning of each session, the participant will sit in the center of the set zone and will be assisted to wear the VR glasses~After the participant will confirm that the sight and sound is clear and comfortable, the tasks mentioned in action observation therapy will be done using virtual reality videos~The Extrinsic feedback will be provided, including the time left, number of repetitions, and record number of repetitions"
88969439|NCT06196190||Post Conization HR HPV positive|Women with a Post Conization cervical test positive for HR HPV
88969440|NCT06196190||Post Conization HR HPV negative|Women with a Post Conization cervical test negative for HR HPV
88969441|NCT06196190||No Conization HR HPV positive|Women who did not go through Conization prior to surgery and had a cervical test positive for HR HPV
88969442|NCT06196190||No Conization HR HPV negative|Women who did not go through Conization prior to surgery and had a cervical test negative for HR HPV
88969443|NCT06196177|Experimental|Levosimontane group|name：Levosimendan injection dose：12.5mg；once；24h
88969444|NCT06196177|No Intervention|control group|blank control
88969445|NCT06196164|Experimental|EUS-BD|Endoscopic Ultrasound-guided Biliary Drainage
88969446|NCT06196164|Other|ERCP-BD|Endoscopic Retrograde Cholangiopancreatography
88969447|NCT06196151|Experimental|Experimental|
88969448|NCT06196151|No Intervention|No intervention|
88969449|NCT06196086||HFpEF|Patients who diagnosed with heart failure with preserved ejection fraction based on symptoms, serum biomarker and test according to 2022 AHA/ACC/HFSA Guidelines for Heart Failure Management at the First Affiliated Hospital of Shandong First Medical University from December 20, 2023 to December 20, 2026.
88969450|NCT06196086||Control|Healthy volunteers with no history of heart disease who matched for age, sex, and risk factors with HFpEF group.
89567005|NCT03086005|Placebo Comparator|Placebo|Placebo(identical in appearance to metformin), every 12 hours, from the first day of oral contraceptive pills taken to the day of oocyte retrieval
89608817|NCT05702619||Arm 1|Arm 1 - De novo, treatment-naïve metastatic prostate cancer
89027986|NCT00491855|Experimental|Bevacizumab + Oxaliplatin + Paclitaxel|One cycle of treatment is 21 days. Bevacizumab starting dose level 2.5 mg/kg given intravenously on day 1. Oxaliplatin starting dose level 25 mg/m^2 given intraperitoneally on day 2. Paclitaxel starting dose level 110 mg/m^2 given continuous infusion on day 1 and 30 mg/m^2 given intraperitoneally on day 8.
89027987|NCT04697277|Active Comparator|Group 1|Group 1 (Prophylactic antibiotic 30 minutes before skin incision): Antibiotic diluted in 10 ml syringe 30 minutes before skin incision and after cord clamping, 0.9% NaCl in 10 ml syringe will be administered intravenously within 15 seconds.
89027988|NCT04697277|Active Comparator|Group 2|Group 2 (prophylactic antibiotic after cord clamping): 30 minutes before the skin incision, 0.9% NaCl in a 10 ml injector and after the cord is clamped, the antibiotic diluted in a 10 ml syringe will be administered intravenously within 15 seconds.
89567006|NCT03079141|Active Comparator|Half-dose photodynamic therapy (PDT)|"In the PDT treatment arm, all patients will receive an intravenous drip through which half-dose (3 mg/m2) verteporfin (Visudyne®) is administered, with an infusion time of 10 minutes. At exactly 15 minutes after the start of the infusion, PDT laser treatment is performed with standard 50 J/cm2 fluency, a wavelength of 689 nm, and a treatment duration of 83 seconds.~When patients are randomized to the PDT arm of this study, they will receive this treatment as a first cCSC treatment. Moreover, PDT can be performed in patients in whom SRF is still present on OCT at the Evaluation Visit at 3 months after the start of eplerenone treatment."
89567007|NCT03079141|Active Comparator|Oral eplerenone treatment|"Patients will receive 25 milligrams oral eplerenone once daily for a week, and - when no abnormalities during blood testing for potassium and renal clearance can be detected both before treatment and during the first week of treatment - will receive 50 milligrams oral eplerenone for another 11 weeks thereafter.~When patients are randomized to the eplerenone arm of this study, they will receive this treatment as a first cCSC treatment. Moreover, eplerenone treatment can be initiated in patients in whom SRF is still present on OCT at the Evaluation Visit at 3 months after PDT treatment."
89567008|NCT03085615|Experimental|100%NRG|Patient will receive the enteral nutrition product Jevity 1.5 starting at 20mL per hour and increasing by 20mL every four hours until a goal rate delivering 25-30kcals/kg is achieved. If feeding is interrupted, flow rate will be adjusted to compensate for nutritional loss.
89567009|NCT03085615|Active Comparator|40%NRG|Patient will receive the enteral nutrition product Jevity 1.5 starting at 20mL per hour and increasing by 20mL every four hours until a goal rate delivering 12-14 kcals/kg is achieved. If feeding is interrupted, flow rate will be adjusted to compensate for nutritional loss.
89567010|NCT03090763||Study population|100 Subjects followed in our department for the diagnosis of aortic aneurysm. On admission, the demographic data (see Appendix 1) will be recorded. Furthermore, within the routine clinically indicated laboratory samples, the levels of selected biochemical markers will be recorded (see Appendix 1). Follow up control laboratory will be performed one year, again within the routine samples.
89567011|NCT03090763||Control population|The control population also includes 100 subjects in total. These will be chosen from aged and sex matched individuals seen in our clinic without disease of the aorta. All subjects included in trial must be at least 18 years old and must sign the informed consent to participation in the study. In the control population, also demographic data will be obtained and the levels of selected biochemical markers will be recorded within the routine clinically indicated laboratory samples.
89027989|NCT00506298|Experimental|A|CRx-401 (bezafibrate + diflunisal)
89027990|NCT00506298|Active Comparator|B|bezafibrate + placebo
89027991|NCT01242215|Experimental|ASP group|ASP1941 and sulfonylurea
89027992|NCT01242215|Placebo Comparator|Placebo group|placebo and sulfonylurea
89027993|NCT00487617|Experimental|fruit juice|300 mL of fruit juice
89027994|NCT00487617|Placebo Comparator|placebo|300 mL of fruit juice without polyphenols
89027995|NCT01242228|Experimental|ASP group|Concomitant administration of ASP1941 and DPP-4 inhibitor
89027996|NCT02274428|Other|pneumostem group|single arm, pneumostem treated infants
89027997|NCT01316354|Experimental|Beta-glucan|Bread with purified beta-glucan
89027998|NCT01316354|Experimental|Rye kernels|Rye bread with kernels
89027999|NCT01316354|Experimental|White bread|White bread
89028000|NCT01316354|Experimental|Arabinoxylan|Bread with Purified arabinoxylan
89028001|NCT01242306|Placebo Comparator|BMS arm|bare metal stent arm
89028002|NCT01242306|Active Comparator|SES arm|sirolimus eluting stent arm
89028003|NCT01242345|No Intervention|No Intervention|Standard monitoring.
89028004|NCT01242345|Experimental|Capnography|Arm with capnographic monitoring
89028005|NCT04511364|Experimental|AGN1 treated patients|Patients have been treated with the AGN1 LOEP kit in AgNovos study PST-EU-101.1. An X-ray and DXA scan are performed at 24 and 60 months post AGN1 LOEP treatment.
89028006|NCT00492011|Experimental|Ramelteon 1 mg QD|
89028007|NCT00492011|Experimental|Ramelteon 4 mg QD|
89028008|NCT00492011|Experimental|Ramelteon 8 mg QD|
89028009|NCT00492011|Placebo Comparator|Placebo|
89028010|NCT01242254|Experimental|Group A|Patients will receive an intravitreal injection of KH902 0.5mg/eye/time monthly, after 3-time treatment patients will go on an as needed (PRN) dosing phase till week 52
89028011|NCT01242254|Experimental|Group B|Patients will receive an intravitreal injection of KH902 2.0mg/eye/time monthly, after 3-time treatment patients will go on an as needed (PRN) dosing phase till week 52
89028012|NCT04513353|Experimental|Digital Healthcare System Rehabilitation|
89028013|NCT04513353|Active Comparator|Conventional Rehabilitation|
89028014|NCT00492128|Experimental|Losartan/hydrochlorothiazide|Combination drug with losartan 50mg and hydrochlorothiazide 12.5mg
89028015|NCT00492128|Active Comparator|Losartan/amlodipine|Combination therapy with losartan 50mg and amlodopine 5mg
89028016|NCT00487734|Experimental|1|Subjects in this arm will receive testosterone gel
89028017|NCT00487734|Placebo Comparator|2|
89028018|NCT01242293|Active Comparator|0.9% Saline with glucose 5%|rate of infusion is 125cc/h
89028019|NCT01242293|Active Comparator|Ringer lactate|rate of infusion is 250cc/h
89028020|NCT01242293|Active Comparator|Ringer lactate - Controls|rate of infusion is 125cc/h
89028021|NCT01300234|Experimental|A (TDF tablets)|Tenofovir disoproxil fumarate (TDF) tablets
89567012|NCT03085849|Experimental|Treatment|"Subjects with ES-SCLC, progressive after platinum-based first-line chemotherapy will receive SGI-110 followed by combined durvalumab plus tremelimumab.~Dose escalation phase: 6-12 patients~MTD expansion cohort: 10 patients"
89567013|NCT03090685|Experimental|True auriculotherapy with seeds|Auriculotherapy complementary to the usual drug treatment. At each ear, selected points edible seeds of roasted mustard with a size of approximately 2 mm will be used, since it is natural and non-toxic. The seeds will be stored in ear plate and applied with the use of micropore clamp and tape in 4 to 5 specific points to control for musculoskeletal pain.
89567014|NCT03090685|Placebo Comparator|Placebo Auriculotherapy with seeds|Placebo Auriculotherapy complementary to usual drug treatment. Seeds will be used in 4 auricular points in the lobe of the ear that have no specific relation to the musculoskeletal pain in the lower limbs and with the innervation of the vagus nerve.
89567015|NCT03079063|Experimental|Eptacog alfa biosimilar for PK|Randomized, double-blind, single dose cross-over for PK, with 12 months follow up with eptacog alfa biosimilar provided for treatment of bleeding on demand - or - prophylaxis.
89567016|NCT03079063|Active Comparator|Novoseven|Randomized, double-blind, single dose cross-over for PK, with 12 months follow up with eptacog alfa biosimilar provided for treatment of bleeding on demand - or - prophylaxis.
89567017|NCT03085303|Experimental|Blue light at 415nm|Full body irradiation for 30min (15 min. each body side) with blue light at 415nm peak wavelength with full body blue device.
89567018|NCT03085303|Experimental|Blue light at 450nm|Full body irradiation for 30min (15 min. each body side) with blue light at 450nm peak wavelength with full body blue device.
89567019|NCT03085303|Placebo Comparator|Placebo|Full body irradiation for 30min (15 min. each body side) with blue light at 450nm peak wavelength with a low dose setting (not therapeutically active) of the full body blue device.
89567020|NCT04434079||Included individuals|Adult patients consecutively admitted to the ICU from June to October 2018 are eligible if expected length of stay is superior to 24 hours and no oral nutritional has been offered.
89567021|NCT01659255|Experimental|Tirabrutinib 20 mg Once Daily (CLL)|Participants with relapsed/refractory chronic lymphocytic leukaemia (CLL) received tirabrutinib 20 mg once daily.
89567022|NCT01659255|Experimental|Tirabrutinib 40 mg Once Daily (CLL)|Participants with relapsed/refractory CLL received tirabrutinib 40 mg once daily.
89567023|NCT01659255|Experimental|Tirabrutinib 80 mg Once Daily (CLL)|Participants with relapsed/refractory CLL received tirabrutinib 80 mg once daily.
89567024|NCT01659255|Experimental|Tirabrutinib 160 mg Once Daily (CLL)|Participants with relapsed/refractory CLL received tirabrutinib 160 mg once daily.
89567025|NCT01659255|Experimental|Tirabrutinib 320 mg Once Daily (CLL)|Participants with relapsed/refractory CLL received tirabrutinib 320 mg once daily.
89567026|NCT01659255|Experimental|Tirabrutinib 400 mg Once Daily (CLL)|Participants with relapsed/refractory CLL received tirabrutinib 400 mg once daily.
89567027|NCT01659255|Experimental|Tirabrutinib 500 mg Once Daily (CLL)|Participants with relapsed/refractory CLL received tirabrutinib 500 mg once daily.
89567028|NCT01659255|Experimental|Tirabrutinib 600 mg Once Daily (CLL)|Participants with relapsed/refractory CLL received tirabrutinib 600 mg once daily.
89567029|NCT01659255|Experimental|Tirabrutinib 300 mg Twice Daily (CLL)|Participants with relapsed/refractory CLL received tirabrutinib 300 mg twice daily.
89567030|NCT01659255|Experimental|Tirabrutinib 20 mg Once Daily (NHL)|Participants with relapsed/refractory non-Hodgkin's lymphoma (NHL) received tirabrutinib 20 mg once daily.
89567031|NCT01659255|Experimental|Tirabrutinib 40 mg Once Daily (NHL)|Participants with relapsed/refractory NHL received tirabrutinib 40 mg once daily.
89567032|NCT01659255|Experimental|Tirabrutinib 80 mg Once Daily (NHL)|Participants with relapsed/refractory NHL received tirabrutinib 80 mg once daily.
89567033|NCT01659255|Experimental|Tirabrutinib 160 mg Once Daily (NHL)|Participants with relapsed/refractory NHL received tirabrutinib 160 mg once daily.
89028022|NCT01300234|Active Comparator|B (ADV tablets)|Adefovir dipivoxil (ADV) tablets
89028023|NCT01242332|No Intervention|placebo|po 2 hrs before surgery
89028024|NCT01242332|Experimental|Pregabalin|75 mg po 2 hrs before surgery
89567034|NCT01659255|Experimental|Tirabrutinib 320 mg Once Daily (NHL)|Participants with relapsed/refractory NHL received tirabrutinib 320 mg once daily.
89567035|NCT01659255|Experimental|Tirabrutinib 480 mg Once Daily (NHL)|Participants with relapsed/refractory NHL received tirabrutinib 480 mg once daily.
89567036|NCT01659255|Experimental|Tirabrutinib 600 mg Once Daily (NHL)|Participants with relapsed/refractory NHL received tirabrutinib 600 mg once daily.
89567037|NCT01659255|Experimental|Tirabrutinib 240 mg Twice Daily (NHL)|Participants with relapsed/refractory NHL received tirabrutinib 240 mg twice daily.
89567038|NCT03076567||case|Stomach cancer cases from two previously conducted studies in China
89567039|NCT03076567||control|Controls from two previously conducted studies in China
89567040|NCT05014633|Experimental|EI skills training|Individuals in the intervention group received the pertinent training. The duration of the training for the intervention group was 16 hours (four four-hour sessions). The whole training process lasted for one month. EI training sessions were held and managed by two experienced instructors selected from medical education specialists with sufficient experience in conducting EI training. Both instructors attended the sessions, presented the content, videos, slides, and brochures with the help of each other, and managed related scenarios in each session.
89028025|NCT00487773|Active Comparator|1|budesonide
89028026|NCT00487773|Active Comparator|2|D3 vitamin
89028027|NCT00487773|Active Comparator|3|montelukast sodium
89028028|NCT00487773|Active Comparator|4|salbutamol
89028029|NCT01299961|Experimental|Subcutaneous Abatacept|All subjects will receive an injection of 125 mg of abatacept once a week up to 12 months.
89028030|NCT01299805|Experimental|Vortioxetine|Vortioxetine 20 mg, encapsulated tablet, orally, once daily for up to 14 days.
89028031|NCT01299805|Placebo Comparator|Placebo|Vortioxetine placebo-matching capsules, orally, once daily for up to 14 days.
89028032|NCT00487682|Experimental|1|ASP2151 low dose
88969455|NCT06196047|Active Comparator|ticagrelor arm|the ticagrelor arm will receive (180 mg loading dose during the first 12 hours of stroke onset followed by 90 mg b.i.d from the 2nd to the 90th day) and aspirin at a loading dose of 75 to 300 mg, followed by 75 mg daily for 21 days.
88969456|NCT06196047|Active Comparator|cilostazol arm|The cilostazol arm will receive (a 200mg loading dose during the first 12 hours of stroke onset, followed by 100mg twice daily from the 2nd day to the 90th day) and aspirin at a loading dose of 75 to 300 mg, followed by 75 mg daily for 21 days.
88969457|NCT06196034||Asthma|Subjects with asthma
88969458|NCT06196034||Control|Subjects with no asthma
89532527|NCT06191588|Active Comparator|Conventional Therapy|"Other: Infant BIT Not use of unaffected hand containment. Both hand are use to improve the bimanual coordination~Other: Infant CIMT/BIT Use unaffected hand containment in part of the intervention and then, both hands in bimanual activities without containment.~Other: infant cimt use of unaffected hand containment to improve the use of affected hand with unimanual activities"
89532528|NCT06190093|Experimental|ONS-5010 bevacizumab|
88969461|NCT06195748|Experimental|Group A (Kinesiotape Group)|The technique will follow manufacturer's guidelines, which is described in the Kinesio taping method. According to the manufacturer, the controllable variables in KT application included degree of pre-stretch applied to the tape (75-100%), the location and treatment goals. The subject will be asked to lie supine, with the ankle of the dominant side in neutral position. A Y shaped KT strip will be applied from the heel to lateral and medial femoral condyles. A I shaped KT strip will be applied from medial malleolus to lateral malleolus, passing under the heel. Another I shaped KT strip will be applied from slightly above the medial malleolus to slightly above the lateral malleolus, crossing on the instep at the malleoli level.
88969462|NCT06195748|Placebo Comparator|Group B (Placebo KT Group)|The same tape will be used for the interventional application. Two strips will be used, one from the heel to the proximal third of the leg, the other from the lateral malleolus to the medial malleolus crossing on the instep, both with 0 tension
88969463|NCT06195384|Experimental|Anti-cancer Neoantigen mRNA Vaccine|Anti-cancer neoantigen mRNA vaccine will be produced to treat advanced solid tumors.
88969464|NCT06195293|Experimental|Anti-cancer Neoantigen Polypeptide Vaccine|Anti-cancer neoantigen polypeptide vaccine will be produced to treat advanced solid tumors.
88969465|NCT06195202||AI|Patients with AIs
88969466|NCT06195202||OFS+AI|Patients with OFS+AIs
88969467|NCT06195202||FUL|Patients with FUL
88969468|NCT06194786|Experimental|Group A|Dietary and physical activity
88969469|NCT06194786|Experimental|Group B|Dietary only
88969470|NCT06194786|Experimental|Group C|Physical activity only
88969471|NCT06194695||DEB-TACE-len-anti-PD(L)1|Patients with advanced intrahepatic cholangiocarcinoma who was initially evaluated unsuitable for the radical therapy and received combined DEB-TACE plus lenvatinib (Len) and anti-PD1 or anti-PD-L1 antibodies as conversion therapy for downstaging.
88969472|NCT06194188|Experimental|Low Dose Group|0.06mg/ml/dose, the number of doses administered (no more than 36 doses) will be determined after the area has been assessed by the investigator based on the subject's submental fat accumulation
88969473|NCT06194188|Experimental|High Dose Group|0.08 /ml/dose, the number of doses administered (no more than 36 doses) will be determined after the area has been assessed by the investigator based on the subject's submental fat accumulation
88969474|NCT06194188|Placebo Comparator|Placebo group|0/ml/dose, the number of doses administered (no more than 36 doses) will be determined after the area has been assessed by the investigator based on the subject's submental fat accumulation
88969475|NCT06193954|Experimental|VasoStar guidewire system|The VasoStar guidewire system will be used to cross vascular occlusion lesions.
89532529|NCT06190093|Active Comparator|ranibizumab|
89532530|NCT06181435|Experimental|Amlitelimab dose 1|Subcutaneous injection as per protocol
89532531|NCT06181435|Experimental|Amlitelimab dose 2|Subcutaneous injection as per protocol
89532532|NCT06181435|Placebo Comparator|Placebo|Subcutaneous injection as per protocol
89532533|NCT06179498|Experimental|Intervention|"In addition to standard HCV results disclosure for the comparator arm, intervention participants will have two counseling sessions:~Session 1: Immediately after HCV results disclosure, a staff-facilitated session with the index to (1) Establish HCV Treatment Goals, fostering commitment, and (2) Engage the Injecting Partner, identifying ways to support treatment initiation.~Session 2: One week later, involving both the index and injecting partner, to (1) Enhance Partner Support with specific strategies for HCV treatment initiation and (2) Collaborative Navigation Mapping, using a navigation map tool. By Session 2's end, both will have a completed navigation map, a visual guide for the HCV treatment journey.~Both sessions stress communication and dyadic coordination. The navigation map tool ensures a personalized plan for the index's treatment initiation and the partner's supportive navigator role."
89532534|NCT06179498|No Intervention|Control|Standard of care HCV disclosure. This staff-facilitated session follows the California HIV/HCV test counselor certification protocol with the Index alone.
89532535|NCT06178757|Active Comparator|Group TAPB = Transversus abdominis plane block group|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by a pain nurse blinded to the procedure. 0,5 mg/kg meperidin will be performed for rescue analgesia
89532536|NCT06178757|Active Comparator|Group EOIB = External oblique intercostal plane block group|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by a pain nurse blinded to the procedure. 0,5 mg/kg meperidin will be performed for rescue analgesia
89532537|NCT06177067|Experimental|All Eligible Participants|"All eligible patients receive the following intervention:~Revumenib, Venetoclax, Azacitidine, Intrathecal chemotherapy"
89532538|NCT06169137|Experimental|Premenopausal women (lean and obese)|Ages 18-50 yearsBMI 18.0-24.5 mg/k^2 or BMI > 30 mg/k^2
89532539|NCT06169124|Experimental|Treatment (exemestane, darolutamide, leuprolide acetate)|Patients receive exemestane PO QD and darolutamide PO BID starting on days -14 to -7 prior to C1D1 and then on days 1-28 of each cycle. Patients receive leuprolide acetate IM on day 1 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo chest CT or chest x-ray and CT, MRI, or PET/CT as well as blood sample collection throughout the study. Patients undergo collection of archived tissue during screening.
89567041|NCT05014633|No Intervention|Control|Individuals in the control group did not receive any training
89567042|NCT05308485||Parkinson´s disease individuals|
89567043|NCT05308485||Individuals with recent-onset parkinsonism|
89567044|NCT05308485||Healthy individuals|
89567045|NCT05341089|Experimental|LY3502970 (Formulation 1)|LY3502970 administered orally.
89567046|NCT05341089|Experimental|LY3502970 (Formulation 2)|LY3502970 administered orally.
89567047|NCT05001529|Experimental|Group A|Subject with severe asthma, treated with anti IL5R antibodies
89567048|NCT05001529|No Intervention|Group B|Subject with severe asthma, treated with conventional therapy
89567049|NCT05307159|Experimental|bean protein supplement|The supplement will be consumed daily for 21 days in the athletes' snack, the supplement contains 7 g of bean protein mixed in 60 mL of milk and 60 mL of strawberry drinkable yogurt
89567050|NCT05001061|Active Comparator|Sublingual Misoprostol for termination of first trimester missed abortion|Patients diagnosed as first trimester missed abortion will receive sublingual Misoprostol 800 micrograms every 4 hours up to five doses
89567051|NCT05001061|Active Comparator|Vaginal Misoprostol for termination of first trimester missed abortion|Patients diagnosed as first trimester missed abortion will receive vaginal Misoprostol 800 micrograms every 4 hours up to five doses
89567052|NCT05531955|Experimental|Pirfenidone group|Drug name:Pirfenidone Dosage Form:capsule Dosage:200mg three times a day in 1st week;400mg three times a day in 2ndweek;600mg three times a day in 3rd week~52th week.
89567053|NCT05531955|Placebo Comparator|Placebo group|Drug name:Placebo Dosage Form:capsule Dosage:200mg three times a day in 1st week;400mg three times a day in 2ndweek;600mg three times a day in 3rd week~52th week.
89567054|NCT05006911|Experimental|PBOHB|Pilocarpine, Brimonidine, Oxymetazoline, Hyaluronic Acid, Bromfenac to evaluate safety and efficacy to improve uncorrected near vision in healthy presbyopic patients
89567055|NCT05339295|Experimental|Test Group|Levomerc (Levofloxacin) tablets 500 mg
89567056|NCT05339295|Active Comparator|Reference Group|Tavanic (Levofloxacin) tablets 500 mg
89567057|NCT02637037|Experimental|Treatment A|Under fed conditions, subjects will receive single doses of dapagliflozin/metformin XR test drug (Mount Vernon) 5/500 mg dose
89567058|NCT02637037|Active Comparator|Treatment B|Under fed conditions, subjects will receive single doses of dapagliflozin/metformin XR reference drug (Humacao) 5/500 mg dose
89567059|NCT02637037|Experimental|Treatment C|Under fasted conditions, subjects will receive single doses of dapagliflozin/metformin XR test drug (Mount Vernon) 5/500 mg dose
89567060|NCT02637037|Active Comparator|Treatment D|Under fasted conditions, subjects will receive single doses of dapagliflozin/metformin XR reference drug (Humacao) 5/500 mg dose
89567061|NCT02637037|Experimental|Treatment E|Under fed conditions, subjects will receive single doses of dapagliflozin/metformin XR test drug (Mount Vernon) 10/1000 mg dose
89567062|NCT02637037|Active Comparator|Treatment F|Under fed conditions, subjects will receive single doses of dapagliflozin/metformin XR reference drug (Humacao) 10/1000 mg dose
89567063|NCT02637037|Experimental|Treatment G|Under fasted conditions, subjects will receive single doses of dapagliflozin/metformin XR test drug (Mount Vernon) 10/1000 mg dose
89567064|NCT02637037|Active Comparator|Treatment H|Under fasted conditions, subjects will receive single doses of dapagliflozin/metformin XR reference drug (Humacao) 10/1000 mg dose
89567065|NCT05307081||1|
89567066|NCT05306535|Experimental|occlusal reduction|Performing occlusal reduction on the experimental tooth until absence of occlusal contact is confirmed following completion of the endodontic treatment
88969476|NCT06193941||Case group （bladder cancer）|Urine exosomes were enriched for RT-qPCR within 4 hours after samples were collected.
88969477|NCT06193941||Control group （benigh）|Urine exosomes were enriched for RT-qPCR within 4 hours after samples were collected.
88969478|NCT06193941||Healthy people group|Urine exosomes were enriched for RT-qPCR within 4 hours after samples were collected.
88969479|NCT06193226|Experimental|Cryotherapy|"Cryotherapy can be done in two ways:~Open technique: Using cotton swabs or a cryogun spray, the cryogen is delivered directly to the lesion in this technique.~Closed technique: Cryo-probes are used to apply the cryogen to the lesion in this procedure."
88969480|NCT06193200|Experimental|Dexamethasone sodium phosphate|IV infusion of dexamethasone sodium phosphate (DSP) encapsulated in autologous erythrocytes using the EryDex System (EDS)
88969481|NCT06193200|Placebo Comparator|Placebo|IV infusion of placebo encapsulated in autologous erythrocytes using the EryDex System (EDS)
88969482|NCT06193096|Experimental|Experimental group|Probiotic formula, 1 stick/day
88969483|NCT06193096|Placebo Comparator|Control group|Placebo formula, 1 stick/day
88969484|NCT06193044|Experimental|Amlodipine and Valsartan Tablets USP 10/160 mg, Then Exforge® 10/160 mg|Participants first received Amlodipine and Valsartan Tablet USP 10/160 mg 1 tablet (Test product) in a fasting state.After a washout period of 21 days, they then recieved Exforge® 10/160 mg tablet (Reference product) in a fasting state
88969485|NCT06193044|Active Comparator|Exforge® 10/160 mg, Then Amlodipine and Valsartan Tablets USP 10/160 mg|Participants first received Exforge® 10/160 mg tablet 1 tablet (Reference product) in a fasting state.After a washout period of 21 days, they then recieved Amlodipine and Valsartan Tablets USP 10/160 mg (Test product) in a fasting state.
89567067|NCT05306535|No Intervention|control|No occlusal reduction or modification of the occlusal anatomy will be performed
89567068|NCT04462705|Active Comparator|Usual physiotherapeutic intervention|"the usual physiotherapeutic intervention (respiratory and walking exercices). Each patients will be treated following the ERAS Guideline.~- At D + 1 post-surgical:~- First lift with verticalization.~- A session with the Cliniflo® in a seated position.~- Walk at least 100 m with the help of the physiotherapist.~At- D+2 and D+3 post-surgical Same session as on D+1 with progressive increase in the walking perimeter. Add up and down stairs on D+ 3"
89608818|NCT05702619||Arm 2|Arm 2 - De novo, treatment- naïve localised prostate cancer planned for radical prostatectomy
89608819|NCT03890913||Observation|All childcare centers enrolled to Aim 1 will be observed. The physical activity environment will be examined before and after the implementation of playground stencils.
89608820|NCT01770379|Experimental|Secukinumab 75 mg|Secukinumab 75 mg s.c.
89608821|NCT01770379|Experimental|Secukinumab 150 mg|Secukinumab 150 mg s.c.
88969486|NCT06192784|Experimental|DEB-TACE-len-puco|Patients with advanced intrahepatic cholangiocarcinoma who was initially evaluated unsuitable for the radical therapy and received combined DEB-TACE plus lenvatinib (Len) and pucotenlimab as conversion therapy for downstaging.
88969487|NCT06192667|Experimental|Geanial Injectable Composite Resin|"It contains 31% methacrylate monomer in the resin matrix and 69% silica and barium glass as fillers. A1, A2, A3, A3.5, A4, B1, B2, B3, C3, CV, BW, AO2, AO3, JE, AE colors are available. Due to their high durability, they can be used in places where recyclable composite resins are used. Apart from this, they are used as fissure sealants, sealants, repair of indirect restorations, blocking of undercuts and liner, like flowable composites.~After completing the cavity, the enamel surface was selectively roughened using 37% orthophosphoric acid for 15 seconds. Subsequently, G2 Bond Universal adhesive agent (GC Corp., Tokyo, Japan) was utilized. It was applied in 2mm layers in accordance with the composite manufacturer's instructions. Each layer was polymerized for 20 seconds."
88969488|NCT06192667|Experimental|3M Filtek Z250 Universal Restorative|"It is designed to be used in both anterior and posterior restorations. The filler in the Filtek Z250 restorative is zirconia/silica. The inorganic filler is 60 vol% (without silane treatment) with a particle size of 0.01 to 3.5 μm. Filtek Z250 restorative contains BIS-GMA, UDMA and BIS-EMA monomers. Various restorative color options are available. It is packaged in conventional syringes and single-dose capsules.~After completing the cavity, the enamel surface was selectively roughened using 37% orthophosphoric acid for 15 seconds. Subsequently, G2 Bond Universal adhesive agent (GC Corp., Tokyo, Japan) was utilized. It was applied in 2mm layers in accordance with the composite manufacturer's instructions. Each layer was polymerized for 20 seconds."
89567069|NCT04462705|Experimental|abdominal massage and usual physiotherapeutic intervention|"the usual physiotherapeutic intervention (respiratory and walking exercices). Each patients will be treated following the ERAS Guideline.~- At D + 1post-surgical:~- First lift with verticalization.~- A session with the Cliniflo® in a seated position.~- Walk at least 100 m with the help of the physiotherapist.~At- D + 2 and D + 3 post-surgical Same session as on D + 1 with progressive increase in the walking perimeter. Add up and down stairs on D+ 3~In this experimental arm, a abdominal massage will be performed in addition to the usual physiotherapeutic intervention (respiratory and walking exercices).~The sessions take place on D+1, D+2 and D+3 post-surgical The first session is performed at least 20 hours after surgery (incision begins) Never within an hour of a meal. The session is timed."
89567070|NCT02637895|Placebo Comparator|Placebo|Placebo pill once daily for 12 weeks of active treatment.
89567071|NCT02637895|Active Comparator|Vortioxetine|Vortioxetine pill 10mg once daily up to 4 weeks followed by 20mg once daily if tolerated for the rest of the study. Patients unable to tolerate the 20 mg/day dose may be reduced to 10 mg/day between weeks 4 and 8. The dose of study medication should remain stable for weeks 8-12.
89567072|NCT05013697|Experimental|Experimental group 1|"Initial treatment: Paclitaxel + Cisplatin + TQB2450 injection+ Anlotinib (4-6 cycles).~Maintenance treatment: TQB2450 injection+Anlotinib."
89567073|NCT05013697|Experimental|Experimental group 2|Initial treatment: Paclitaxel + Cisplatin + TQB2450 injection (4-6 cycles). Maintenance treatment: TQB2450 injection.
89567074|NCT05305911|Active Comparator|Treatment Group|Treatment group will receive dapagliflozin in addition to standard heart attack medications for the duration of hospitalization and 6-month duration of the study.
89567075|NCT05305911|Placebo Comparator|Placebo Group|Placebo Group will receive placebo in addition to standard heart attack medications for the duration of hospitalization and 6-month duration of the study.
89567076|NCT05349435|Experimental|Cohort 1 Dose Level 1|Drug: Fezagepras and sodium PBA
89567077|NCT05349435|Experimental|Cohort 2 Dose Level 2|Drug: Fezagepras and sodium PBA
89567078|NCT05007223||1. Experimental: doxycycline|Given doxycycline and assessment of skin
89567079|NCT05007223||2. No Intervention: Healthy Controls|Control subjects to assess if there is baseline difference in the skin microbiome
89567080|NCT05305599|Experimental|ZED1227 (low dose) 10 mg|
89567081|NCT05305599|Experimental|ZED1227 (middle dose) 25 mg|
89567082|NCT05305599|Experimental|ZED1227 (high dose) 50 mg|
89567083|NCT05305599|Placebo Comparator|Placebo|
89567084|NCT03083587|Active Comparator|No intervention|Normal lifestyle. Subjects will undergo a muscle and fat biopsy at the start of the 4 w period and after. An oral glucose test at the start and after completion of the 4 week period. Physical activity and glucose will be monitored during the study period.
89567085|NCT03083587|Experimental|Exercise intervention|Followed by a 1 week normal run in period subjects will undergo a 3 min bout, every half hour between 8 am and 6 pm comprises of simple low-intensity exercise such as moderate walking about or climbing a flight of stairs over a 3-week period. Subjects will undergo a muscle and fat biopsy at the start of the 4 w period and after. An oral glucose test at the start and after completion of the 4 week period. Physical activity and glucose will be monitored during the study period.
89567086|NCT05337891||Patients with suspected or diagnosed myasthenia gravis|Patients with suspected or diagnosed myasthenia gravis (ocular and generalized form), aged 18-80, both sexes, with performed or planned determination of anti-acetylcholine receptor antibodies and muscle-specific tyrosine kinase antibodies
89567087|NCT05000281|Experimental|NSAID|Standard of care pain medication regimen with NSAIDs.
89567088|NCT05000281|No Intervention|No NSAIDs|Standard of care pain medication regiment with no NSAIDs
89567089|NCT05348889|Experimental|Dose Escalation|Open label, single arm trial where 1A46 will be administered
89567090|NCT03081949|Active Comparator|Treatment|Oral Sodium Selenite 200 µg/day for 3 months
89567091|NCT03081949|No Intervention|Control|No treatment
89567092|NCT04999579|Active Comparator|Complete denture|Conventional complete denture without supporting devices
89567093|NCT04999579|Experimental|Ultra suction retained complete denture|Conventional complete denture with ultra suction device
89608822|NCT01770379|Placebo Comparator|Placebo|Placebo patients will be re-randomized 1:1 to secukinumab 75 or 150mg s.c. (non-responders at Week 16 will be re-assigned to new treatment at Week 16; responders at Week 16 will be re-assigned to new treatment at Week 24)
89608823|NCT01986881|Experimental|Ertugliflozin, 15 mg|Ertugliflozin 15 mg administered orally once daily for up to approximately 6 years
89608824|NCT01986881|Experimental|Ertugliflozin, 5 mg|Ertugliflozin 5 mg administered orally once daily for up to approximately 6 years
89567094|NCT04999813|Experimental|Comprehensive intensive intervention|On the basis of routine management, carry out individualized cerebrovascular risk factor assessment and comprehensive intervention in a medical-nursing cooperation model, and require corresponding control indicators to be achieved. A comprehensive intervention team is established by specialized medical staff to monitor blood pressure, heart rate, exercise and other data through smart wearable devices, and automatically upload them to the cloud platform, conduct comprehensive data analysis every week, timely feedback and online reminders, establish health management files, and improve the target population The blood-brain tube risk factor control and self-management ability.
89567095|NCT04999813|No Intervention|Routine management|Only routine management was carried out for the subjects without special intervention.
89567096|NCT05347797|Other|Clinical Performance Study Protocol for therascreen® KRAS RGQ PCR Kit|The KRAS Kit is a real-time qualitative PCR assay used on the Rotor-Gene Q MDx instrument for the detection of somatic G12C mutations in the human KRAS oncogene using DNA extracted from formalin fixed paraffin-embedded (FFPE) Non-small Cell Lung Cancer (NSCLC) tissue. The KRAS Kit is intended to aid in the identification of cancer patients who may be eligible for treatment with AMG 510.
89567097|NCT03076255|Experimental|Supportive care (MID)|Patients undergo Computed Tomography (CT) simulation with thermoplastic mask and maskless immobilization device (MID) for radiation therapy (RT) planning on day 1. Patients undergo standard of care RT using thermoplastic mask only and cone-beam computed tomography (CBCT) imaging with thermoplastic mask and MID on day 8 and 15.
89567098|NCT03076177|Experimental|Kinesio taping group|Participants receiving kinesio taping application
89567099|NCT03076177|Sham Comparator|Non specific taping|Participants receiving non specific taping application
89567100|NCT05006755|Experimental|control group|the group of primary molar teeth that will be treated in furcal perforation with Mineral Trioxide Aggregate
89567101|NCT05006755|Experimental|experimental group|the group of primary molar teeth that will be treated in furcal perforation with Biodentine
89567102|NCT05006287|Experimental|Non-Vitamin K Oral Anticoagulant (NOAC) Group|Anticoagulation with a NOAC (Apixaban, Dabigatran, Edoxaban, Rivaroxaban)
89567103|NCT05006287|Active Comparator|Warfarin Group|Anticoagulation with warfarin to target INR 2.5
89567104|NCT05303415|Experimental|LIFU, heat evoked fMRI signals|fMRI resting and heat evoked signals performed after LIFU application to known brain region of interest or active sham region (within participant all conditions tested).
89567105|NCT05013151|Experimental|Date consumption|Consumption of 6 dates a day until 41 weeks of gestation
89567106|NCT05013151|Experimental|Castor oil consumption|One time consumption of 60 CC of Castor oil
89567107|NCT05013151|No Intervention|Control Group|
89567108|NCT05303337||Patients switching towards a long-aging injectable treatment|
89567109|NCT05303337||Patients maintaining oral ART 2-drug regimens|
88969489|NCT06192498|Experimental|Virtual Reality Glasses Group|Virtual Reality(VR) Glasses were introduced to the children pre-procedure. The children were made to watch a video with VR glasses before starting the application and it continued until the end of the Blood Draw procedure.
88969490|NCT06192498|Experimental|Kaleidoscope Group|Kaleidoscope were introduced to the children pre-procedure. The children were made to watch Kaleidoscope before starting the application and it continued until the end of the Blood Draw procedure.
88969491|NCT06192498|Experimental|Distraction Cards Group|Distraction Cards were introduced to the children pre-procedure. The children were made to apply Distraction Cards before starting the application and it continued until the end of the Blood Draw procedure.
88969492|NCT06192498|No Intervention|Control Group|In this group, children received routine blood draw procedure.
88969493|NCT06192238||Adrenal Venous Sampling|Patients with Primary Aldosteronism (PA) undergoing Adrenal Venous Sampling via antecubital approach or femoral approach to discriminate PA forms with unilateral from bilateral excess aldosterone production.
88969494|NCT06192173||Closure group|Migraine patients with PFO who managed with percutaneous PFO closure.
89208613|NCT02595827|No Intervention|Universal|In this group, caretakers of children will receive the standard advice under current iCCM guidelines in DRC. Specifically, the CHW will advise that the child come back in 2-3 days.
89208614|NCT02595827|Active Comparator|Conditional|In this Conditional Advice group, caretakers will be given advice that is modified from the current iCCM guidelines. Specifically, the CHW will advise that the child come back in 2-3 days if the child's symptoms continue.
89208615|NCT00614874|Experimental|1|Subjects took rosiglitazone 2 mg for 4 weeks, then 4mg for 4 weeks, then 8 mg for 4 weeks
89208616|NCT02553980|Experimental|Physical activity promotion I|"Participants in this group attended the VT3 program (with Automatic HR detection)"
89567110|NCT05303337||Patients maintaining oral ART 3 drug regimens|
89567111|NCT05006365|Experimental|Transcranial Pulse Stimulation|Investigators will use a single-blind randomized controlled trial design with two-armed repeated measures. The trial design complies with the Consolidated Standards of Reporting Trials (CONSORT) statement. The first arm is the Intervention Group (Transcranial Pulse Stimulation) (TPS group)
89567112|NCT05006365|Active Comparator|Waitlist Control Group|Second arm is the waitlist control group.
89567113|NCT05006209|Active Comparator|One visit root canal treatment with CHX|The teeth were treated in one-visit (OV) root canal treatment. Final root canal irrigation was performed with 5% EDTA, followed by 2.5% NaOCl and received an additional final rinse with 2% CHX before obturation.
89567114|NCT05006209|Active Comparator|Two visit root canal treatment with CH|The teeth were treated in two visit (TV) root canal treatment. After completion of root canal instrumentation, calcium hydroxide (CH) paste was placed into the root canal. In second visit, all root canals were irrigated with 5% EDTA followed by 2.5% NaOCl before obturation.
89608825|NCT01986881|Placebo Comparator|Placebo|Matching placebo to ertugliflozin administered orally once daily for up to approximately 6 years
89608826|NCT03156075|Experimental|Intervention group|"This group will receive the nutrition and exercise program intervention. Nutrition education will be about increasing the intake calcium and vitamin D rich foods and exposure to sun will provided for the intervention group.~Education of the patients about exercises that increases the strength of lower limb and hip muscles to increase the mobility of the patients earlier and decrease the mortality in turn.~and the first one will start before discharge. The patients will receive a leaflet to describe the instructions."
89567115|NCT05346003|Experimental|Intervention Group|In the pre-test, all students will be given a BLS information form, followed by blended e-learning with theory and video in a virtual environment. he BLS knowledge post-test will be administered immediately after class.T-shirts and standard pillows (550 g silicon fiber pillow 50x70 cm size) with a simulation of an adult human size (approximately) sternum, rib and heart drawing (printed as picture) will be given to the intervention group only after the pretest. In the study, the BLS will be simulated for adult patients only. To simulate a half-body human CPR mock-up, a pre-made simulation t-shirt will be fitted on a standard pillow to create a CPR mock-up in a home environment, and after blended e-learning, they will be able to perform CPR iteratively on a T-shirt-clad simulation pillow (TCSP) model. In this way, autonomous learning will be supported. All students will practice CPR in a real simulation model two weeks after the blended e-learning.
89567116|NCT05346003|No Intervention|Control Group|In the pretest, all students will be given a BLS knowledge test, followed by e-learning blended with theory and video in a virtual environment. The BLS knowledge post-test will be administered immediately after class. Two weeks after the blended e-learning, all students will practice CPR in a real simulation model. Psychomotor skills will be recorded in the evaluation form.
89567117|NCT03081013|Active Comparator|Private Arm|At the end of each week, participants will be provided with the number of steps logged by the participants in their group. The number of steps will be ranked from highest to the lowest without any identifiable information about the participants.
89567118|NCT03081013|Experimental|Public Arm|At the end of each week, participants will be provided with the number of steps logged by the participants in their group. The number of steps will be ranked from highest to the lowest with the full names of the participants corresponding to the number of steps.
89567119|NCT03078673|Experimental|Motor skill training|training intervention. Poling specific indoor motor skill exercises performed 3 times pr week for 10 weeks in addition to regular training
89567120|NCT03078673|Experimental|Maximal strength training|training intervention. Maximal strength exercises performed 3 times pr week for 10 weeks in addition to regular training
89567121|NCT03078673|Experimental|Control group|Only regular training
89567122|NCT03075787||patients with obstructive sleep apneas|
89567123|NCT03076099|Experimental|Dexmedetomidine|Dexmedetomidine was administered intravenously when tracheal extubation, 1.2μg/kg Dexmedetomidine was mixed with 100 ml normal saline and maintained 4 hours constantly.
89567124|NCT03076099|Placebo Comparator|Control group|Normal Saline was administered intravenously when tracheal extubation,equal volume of normal saline was mixed with 100 ml normal saline and maintained 4 hours constantly.
89567125|NCT05301621||Arthritis patients|It is not planned any intervention. The patients' group will be invited to 4 visits.
89567126|NCT05301621||Healthy controls|No intervention planned. Only one visit will be conducted.
89567127|NCT03075709||Experimental - CPW (Urban)|We are working with Regina Qu'Appelle Health Region (RQHR), a primarily urban health region, to develop and implement a clinical pathway (CPW). The CPW will improve care through the following steps: standardizing diagnostic, coordinating and unifying common components of chronic disease care, coordinating the provision of education and reconditioning programs, and ensuring disease specific care utilizes and delivers evidence-informed practices.
89567128|NCT03075709||Experimental - CPW (Rural)|Following implementation in RQHR a rural health region will be chosen as an intervention site for a second CPW. The CPW will improve care through the following steps: standardizing diagnostic, coordinating and unifying common components of chronic disease care, coordinating the provision of education and reconditioning programs, and ensuring disease specific care utilizes and delivers evidence-informed practices.
89567129|NCT03075709||Control - Standard Care (Urban)|Saskatoon Health Region (SHR) will act as the urban control site. No attempts will made to alter care in SHR and therefore patients will continue to receive the current standard of care.
89208617|NCT02553980|Experimental|Physical activity promotion II|"Participants in this group attended the VT2 program (self PA report)"
88969495|NCT06192173||Drug group|Migraine patients with PFO who treated with medicion.
88969496|NCT06189781|Experimental|Pain Injection|The local anesthetic group will be injected with a combination of ropivacaine, epinephrine, and ketorolac.
88969497|NCT06189781|Active Comparator|Epidural|The control group will receive epidural anesthesia. Lumbar epidural anesthesia will be started intra-operatively.
88969498|NCT06189378|Active Comparator|Conventional blood pressure diary|Blood pressure diaries consisted of tables including columns for date, time as well as systolic and diastolic blood pressure respectively (1 page for 1 week) printed on the right-hand pages of an A5 (ISO 216 format) booklet.
88969499|NCT06189378|Experimental|Blood pressure diary including patient-provided pictures|In the interventional arm pictures chosen by patients were provided over a secure online connection by patients in this group and inserted into the left-hand-pages of the blood pressure diaries.
88969500|NCT06187740|Experimental|Starting Dose, Arm 1|For ES-SCLC patients who completed first-line four-cycle chemo-immunotherapy, and was evaluated to have any response to treatment. Thoracic radiotherapy is administered to treat residual thoracic lesions during immunotherapy maintenance phase. Thoracic radiotherapy should begin within 42 days after the end of the last chemotherapy at an initial dose of 30 Gy in 10 fractions (3 patients).
88969501|NCT06187740|Experimental|Dose escalation 1, Arm 2|"Dose escalation will start after acceptable safety was observed, first at: 35 Gy/10 Fx (3 patients). Radiotherapy was administered between two immunotherapy doses (3 weeks interval) to avoid thoracic radiotherapy on the same day with immunotherapy.~Immunotherapy was maintained until disease progression or the investigator 's judgment there was no further benefit from immunotherapy, patient died, intolerable toxicity developed. Toxicities were assessed periodically during the study. Local radiotherapy is permitted for symptomatic brain/bone metastases."
88969502|NCT06187740|Experimental|Dose escalation 2, Arm 3|"Dose escalation will continue after acceptable safety was observed in the previous dose gourp, at: 40 Gy/10 Fx (22 patients). Radiotherapy was administered between two immunotherapy doses (3 weeks interval) to avoid thoracic radiotherapy on the same day with immunotherapy.~Immunotherapy was maintained until disease progression or the investigator 's judgment there was no further benefit from immunotherapy, patient died, intolerable toxicity developed. Toxicities were assessed periodically during the study. Local radiotherapy is permitted for symptomatic brain/bone metastases."
88969503|NCT06187207||Candidates for AVF intervention|Patients requiring hemodialysis who are intervened for AVF creation.
88969504|NCT06187064|Other|Study cohort|The investigators will enroll 50 female-identifying people who present to the clinical van for care and follow them for 6 months. The investigators will assess uptake of PrEP and buprenorphine; POC STI testing and treatment completion rates; sustained use of PrEP and buprenorphine at months 3 and 6 (n=50). The investigators will conduct surveys to assess and characterize the acceptability and feasibility of venue-based primary and HIV prevention care among women who inject drugs (WWID).
88969505|NCT06185634|Experimental|Group 1|Group starting with the dietary intervention of eating pasta at dinner for 3 months.
88969506|NCT06185634|Experimental|Group 2|Group starting with the dietary intervention of eating pasta at lunch for 3 months.
88969507|NCT06184984|Experimental|Methionine metabolic availability in mung beans|"Participants will be seen initially for pre-study assessment. They will then be studied for up to 7 times.~The participants will be expected to participate in 7 different sets of experiments which will take 2 to 3 months. Each set of experiment consists of a 3 day period. During the first 2 days (Adaptation Days) you will be expected to consume 4 meals per day consisting of a protein liquid drink and protein free-cookies and/or cooked mung bean, which will be provided by the investigators."
89567130|NCT03075709||Control - Standard Care (Rural)|Following implementation in RQHR a rural health region will be chosen to act as the rural control site. No attempts will made to alter care in this health region and therefore patients will continue to receive the current standard of care.
89567131|NCT03075631||Patients with Acute Pancreatitis|Patients with Acute Pancreatitis
89567132|NCT03075865||OmniMax MMF|Patients involved in trauma events will receive intermaxillary fixation with OmniMax MMF system for temporary stabilization of mandibular fracture(s) to maintain proper occlusion during surgery and allow for postoperative fracture healing.
89567133|NCT05554965|Active Comparator|propofol|The control group was sedated with propofol
89567134|NCT05554965|Experimental|Remimazolam besylate|The experimental group was given remazolam besylate for sedation
89567135|NCT03078517|Active Comparator|I-gel group|After the induction of anesthesia, I-gel is inserted into the oropharyngeal space.
88969508|NCT06184412||Control group without periodontal disease|Women without periodontal disease neither PCOS
88969509|NCT06184412||PCOS group with or without periodontal disease|Women with PCOS with or without periodontal disease
88969510|NCT06184347||Screening group|All participants will receive an HBsAg finger blood test and a questionnaire gathering their personal information and medical history concerning viral hepatitis, cirrhosis, and hepatocellular carcinoma. Individuals positive for HBsAg will undergo further clinical detections to distinguish dormant liver diseases and HCC.
88969511|NCT06184347||Control group|All subjects in this arm will be followed by linkage to the Guangdong Provincial Center for Disease Control and Prevention, Cancer Registry, and Population Registry.
88969512|NCT06183814|Experimental|Dose escalation-Cohort 1|Genetic : EXG102-031
88969513|NCT06183814|Experimental|Dose escalation-Cohort 2|Genetic : EXG102-031
88969514|NCT06183814|Experimental|Dose escalation-Cohort 3|Genetic : EXG102-031
88969515|NCT06183814|Experimental|Dose escalation-Cohort 4|Genetic : EXG102-031
88969516|NCT06183814|Experimental|Dose escalation-Cohort 5|Genetic : EXG102-031
88969517|NCT06183437|Experimental|Stop Group|This group will stop their heart failure medication(s) under the supervision of the study team. The investigators expect most participants in the STOP group to only be on beta-blockers and/or angiotensin-converting-enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB). The ACEi or ARB will be stopped first. The ACEi or ARB will be reduced by 50% every 7 days and stopped 7 days after 25% of maximal recommended dose for HF is reached. At this point (or at baseline if only on BB), the BB dose will be reduced by 50% every 7 days then stopped once 25% of the maximal dose is reached.
88969518|NCT06183437|No Intervention|Standard of Care Group|This group with continue with their heart failure medication(s) for at least 1 year.
88969519|NCT06178952|Experimental|Verum TPS|Participants will receive 5 Verum TPS sessions over a period of 10 days, with a singular daily session, each lasting approximately 30 minutes
88969520|NCT06178952|Sham Comparator|Sham TPS|Participants will receive 5 Sham TPS sessions over a period of 10 days, with a singular daily session, each lasting approximately 30 minutes
88969521|NCT06177418|Active Comparator|Standard transumbilical laparoscopic appendectomy|In this group, patients will undergo the standard transumbilical laparoscopic appendectomy procedure through a 15 mm trocar port in the umbilical region. The procedure will involve locating the appendix and removing it via an extracorporeal approach.
88969522|NCT06177418|Experimental|Transumbilical laparoscopic appendectomy + glove finger technique|In addition to the standard transumbilical laparoscopic appendectomy procedure, patients in this group will receive the glove finger technique, aimed at preventing contamination of surrounding tissues by infected tissue.
88969523|NCT06177210||Lifestyle intervention|Participants who achieved type 2 diabetes (T2D) remission through lifestyle interventions.
88969524|NCT06177210||Bariatric surgery|Participants who achieved type 2 diabetes (T2D) remission through bariatric surgery.
89567136|NCT03078517|Experimental|LMA protector group|After the induction of anesthesia, laryngeal mask airway protector is inserted into the oropharyngeal space.
89567137|NCT05300217|Experimental|Intervention Group 1 - Strategies for promoting mental health|Exposure to information about strategies for promoting mental health
89567138|NCT05300217|Experimental|Intervention Group 2 - General information about depression|Exposure to general information about depression
89567139|NCT05335161|Experimental|Home-based leg heat therapy|Patients will be provided with the Aquilo heat therapy device and will be instructed on how to operate the equipment. The device will be used in accordance to the manufacturers recommendations. Patients will be asked to apply the therapy daily in the home setting for 12 week (90 min/day, 7 days/week).
89567140|NCT05268471|Experimental|Positional Device (PD)|Vibrating positional device (Nightbalance, Philips) to treat positional obstructive sleep apnea
89567141|NCT05268471|Active Comparator|Continuos Positive Airway Pressure (CPAP)|Continuos Positive Airway Pressure (standard treatment) to treat obstructive sleep apnea
89567142|NCT05299749|Experimental|stg-rt-fMRI|will receive feedback from the STG
89567143|NCT05299749|Sham Comparator|sham-rt-fMRI|will receive feedback from the motor cortex
89567144|NCT05299047|Active Comparator|Group US-guided|will receive superior hypogastric plexus neurolysis by the US-guided anterior approach
89567145|NCT05299047|Active Comparator|- Group fluoroscopy-guided|will receive superior hypogastric plexus neurolysis by the fluoroscopy-guided anterior approach
89567146|NCT05267769|Experimental|Verum|AP707 single dose oromucosal application
89567147|NCT05267223||Individuals with Paraplegia|After screening the participants according to the inclusion/exclusion criteria, informed consent will be obtained from all the selected participants. Their demographic details will be obtained and asked for their comfortable time for the interview. Data will be collected by in-depth face to face, semi- structured interviews. Audio/video recording of the interview will be taken & it will be written in English and will be transcribed verbatim also manual notes will be prepared for their analysis after the interview is conducted
89567148|NCT04422483||Service Model Level Case Studies|Realist Interviews. MONTHS 9-30 (N=6-8 sites, 12 people per site, 96 interviewees)
89567149|NCT04422483||Individual/family level interviews|Child Interviews. MONTHS 9-30 (N=6-8 sites, 6 people per site, max. 48 interviewees)
89567150|NCT04422483||Individual child/family Level Case Studies:|MONTHS 10-30 (N=6-8 sites, 78 people per model (x4), 312 participants, 156 per NU/SCFT depending on distribution of sites)
89567151|NCT04422483||Focus groups:|MONTHS 9-30 (N=6-8 sites, 6-8 focus groups of up to 8 parents) N= 64
89567152|NCT05297097|Experimental|Trulacta breastmilk supplement|Once daily Trulacta supplement
89567153|NCT05266053|Experimental|Treatment Group|This group will have a PICO negative pressure wound treatment device applied to their surgical wound site.
89567154|NCT05266053|Other|Control Group|Standard Intervention. This group will have a standard wound dressing (gauze, bandage) applied to their surgical wound site.
89567155|NCT04251039||PCI with pre-treatment with P2Y12 inhibitors|"SCAD patients undergoing complex PCI with pre-treatment with P2Y12 inhibitors will undergo:~Assessment of platelet reactivity (Time 0, T0) (VFN)~PCI (start = T1; end= T2)"
89567156|NCT04251039||PCI with treatment with P2Y12 inhibitors only after procedure.|"SCAD patients undergoing complex PCI with treatment with P2Y12 inhibitors only after procedure will undergo:~Administration of Cangrelor (bolus + infusion of at least 2 hours and at least until end of PCI) or decision to not administer (T0)~Assessment of platelet reactivity (Time 0, T0) (VFN)~PCI (start of PCI= T1; end of infusion of Cangrelor= T2)"
89567157|NCT05501379||Cancer Patients|Patients with a verified diagnosis of lymphoma, colorectal or pancreatic cancer requiring surgical, chemo or radio therapy.
88969525|NCT06174246|Active Comparator|Pain self-management|Participants will complete an online pain self-management education program by themselves as it is intended.
88969526|NCT06174246|Experimental|Pain self-management with support from a physiotherapist|Participants will complete an online pain self-management education program, and, during the treatment period, will take part in two sessions with a physiotherapist and one group session led by a peer living with chronic MSKP.
88969527|NCT06172465|Active Comparator|group external oblique intercostal plane block|While patients are still under general anesthesia, external oblique intercostal block (EOIB) will be performed bilaterally according to appropriate asepsis/antisepsis rules at end of the surgery.
88969528|NCT06172465|Active Comparator|group oblique subcostal transversus abdominis plane block|Ultrasound-guided bilateral OSTAP block performed at end of the surgery. Perioperative and postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed
88969529|NCT06171581|Experimental|experimental-stress ball|"The study is planned to consist of two groups as experimental and control.~No intervention will be given to the control group."
88969530|NCT06171581|Experimental|no intervention- none|"The study is planned to consist of two groups as experimental and control.~No intervention will be given to the control group."
88969531|NCT06170346|Experimental|Antioxidant|30 drops of topical antioxidants (Gluconolactone 4%, Hyaluronic acid 0,01%, Allantoin 0,1%, Ferulic acid 3%, Acetyl heptapeptide 0,001%, Silver vine extract 1%, Ectoine 0,01%, Hydroxyectoine 0,01%, and vehicle) will be applied on tested area on each participant for four consecutive days. On the fifth day, the subject will be irradiated on the tested area. After irradiation, erythema intensity and skin biopsy will be taken. Furthermore, skin tissue will be stained to see sunburn cells and assesses the expression of MMP-9, Thymine Dimer, and p-53 by immunohistochemistry.
88969532|NCT06170346|Placebo Comparator|Vehicle|30 drops of topical vehicle (Aqua, Dipropylene glycol, Hydroxypropyl cyclodextrin, Polydextrose, 1,2-hexanediol, Butylene glycol, Propanediol, Caprylhydroxamic acid, Ethylhexylglycerin, Xanthan gum, Benzyl alcohol, Glyceryl caprylate, and Benzoic acid) will be applied on tested area on each participant for four consecutive days. On the fifth day, the subject will be irradiated on the tested area. After irradiation, erythema intensity and skin biopsy will be taken. Furthermore, skin tissue will be stained to see sunburn cells and assesses the expression of MMP-9, Thymine Dimer, and p-53 by immunohistochemistry.
89028033|NCT00487682|Experimental|2|ASP2151 middle dose
89028034|NCT00487682|Experimental|3|ASP2151 high dose
89567158|NCT05262075|Experimental|Mindfulness and Resiliency Program|This is an online mindfulness program that integrates resiliency factors to women
89567159|NCT05261451|Experimental|Head Start Teachers|Participants will engage in three 1- hour workshops and optional consultations with an occupational therapist
89567160|NCT05260359|Active Comparator|6% BEMT HRIPT|During the challenge phase of the HRIPT portion of the study, there will be 6 patches (2 product patches, 2 vehicle controls. 1 saline control and 1 empty patch), leaving out the positive control.
89567161|NCT05260359|Active Comparator|6% BEMT Cumulative Irritation Study|During the Cumulative Irritation portion of the study there will be 7 patches (2 product patches, 2 vehicle controls, 1 positive control, 1 low-irritancy control, and 1 empty patch). The low-irritancy control patch will be a saline patch. The positive control will be a SLS patch. The negative control will be an undosed patch.
89208618|NCT02553980|Placebo Comparator|Control|Participants in this group did not receive any VT treatment, and live as usual.
89208619|NCT00803192|Active Comparator|Test Drug|
89208620|NCT00803192|Active Comparator|Reference Drug|
89208621|NCT00544557||Patients with Ankylosing Spondylitis|
89567162|NCT05330091||Healthy Women|Once Daily Women's Probiotic Placebo
89567163|NCT05295849|Experimental|Habit App|Habit Mobile App
89028035|NCT00487682|Active Comparator|4|Valacyclovir hydrochloride
89028036|NCT00487851|Active Comparator|1|Endoscopic treatment strategy
89028037|NCT00487851|Active Comparator|2|Surgical treatment strategy
89567164|NCT05328063|Experimental|Control Group. Gluteus maximus strengthening specific program|
89567165|NCT05328063|Experimental|Intervention group. Specific manual therapy program for hip joint and Gluteus maximus strengthening|
89567166|NCT05257707|Experimental|intervention|
89567167|NCT05294835|Experimental|Ketamine Infusion|subanesthetic ketamine infusion (0.5mg/kg) over 2-3 weeks
89567168|NCT04422405|Experimental|Patients undergoing OAGB|
89567169|NCT02522481|Experimental|Lumason|Lumason (sulfur hexafluoride lipid-type A microspheres) 2 mL IV injection
89567170|NCT02522403|Active Comparator|Rehabilitation|The investigators will be apply laser acupuncture for the rehabilitation of the wrist and hand of the patients, with the laser device in an off position, plus exercise of wrist flexion, extension, cubital and radial deviation, pronation and supination of the forearm. The investigators will be use ten different acupuncture points for treat this patients.
89567171|NCT02522403|Experimental|Low Lever Laser acupuncture|The investigators will utilize an low level laser therapy device apply into each acupuncture point. Ten acupuncture points will be used. Each acupuncture point will be irradiated for 30 seconds at 8,000 Hz.
89208622|NCT00879840||Females|With endometrial cancer, ovarian cancer, and women undergoing hysterectomy for benign reasons.
89208623|NCT02554214|Experimental|Glafkos device|
89532540|NCT06166732|Experimental|Music-based Mindfulness Group|Participants will receive a music-based mindfulness for 20 minutes.
89532541|NCT06166732|Other|Control Group|Participants will receive a information session for 20 minutes.
89567172|NCT05326581||PATIENTS|patients benefiting from an MRI examination as part of their care
89567173|NCT05326581||VOLUNTEERS|healthy volunteers among staff.
88969533|NCT06170346|No Intervention|Control|Skin without intervention and irradiation. Skin biopsy will be taken as a control. Skin tissue will be stained to see sunburn cells and assesses the expression of MMP-9, Thymine Dimer, and p-53 by immunohistochemistry.
88969534|NCT06169787||Sentinel Lymph Node|Sentinel lymph node biopsy in patients with early stage cervical cancer
88969535|NCT06169787||Lymphadenectomy|Comprehensive lymphadenectomy in patients with early stage cervical cancer
88969536|NCT06158698|Experimental|Colchicine|Patients treated with colchicine 0.5-1 mg (1 mg if tolerated) for 6 months.
88969537|NCT06158698|Placebo Comparator|Placebo|Patients treated with placebo tablets.
89532542|NCT06163508||Cohort 1: 10 microliters of Q cells|10 microliters of Q cells per site
89532543|NCT06163508||Cohort 2: 15 microliters of Q cells|15 microliters of Q cells per site
89532544|NCT06163508||Cohort 3: 20 microliters of Q cells|20 microliters of Q cells per site
89532545|NCT06161558|Experimental|A|Erlotinib with lenvatinib combination
89532546|NCT06161558|Experimental|B|Erlotinib with axitinib combination
89532547|NCT06161545|Experimental|Arm 1|N-803 + pembrolizumab
89532548|NCT06161545|Experimental|Arm 2|N-803 + pembrolizumab + PD-L1 t-haNK cells
89532549|NCT06161532|Experimental|Arm 1|Treatment with sacituzumab govitecan
88969538|NCT06155500||OTQ923|Patients were administered OTQ923 while enrolled on the treatment protocol (CADPT03A12101). Enrolled patients on this study will not be administered any study treatment.
88969539|NCT06148194|Placebo Comparator|Control|The control group receives 0.9% NaCl physiological saline. Caregivers will spray the children twice daily (morning and afternoon), administering 2 sprays in each nostril and 2 sprays in the throat each time (totally 6 sprays each time) for a continuous period of 4 weeks, starting from the time of study participation.
88969540|NCT06148194|Experimental|Probiotic 1|The Probiotic 1 group receives LiveSpo® Navax product which is NaCl 0.9% plus B. subtilis and B. clausii at 1 billion CFU/mL x 30 mL. Caregivers will spray the children twice daily (morning and afternoon), administering 2 sprays in each nostril and 2 sprays in the throat each time (totally 6 sprays each time) for a continuous period of 4 weeks, starting from the time of study participation.
88969541|NCT06148194|Experimental|Probiotic 2|The Probiotic 2 group receives LiveSpo® Navax Kid product which is NaCl 0.9% plus B. subtilis and B. clausii at 0.6 billion CFU/mL x 30 mL. Caregivers will spray the children twice daily (morning and afternoon), administering 2 sprays in the nose and 2 sprays in each nostril, and 2 sprays in the throat each time (totally 6 sprays each time) for a continuous period of 4 weeks, starting from the time of study participation.
88969542|NCT06146894|Experimental|Single cone technique (Bioceramic Sealer)|
88969543|NCT06146894|Experimental|lateral condensation technique (Bioceramic Sealer)|
88969544|NCT06146894|Experimental|Warm Vertical condensation technique (Bioceramic Sealer)|
88969545|NCT06146894|Experimental|lateral condensation technique (AH plus Sealer)|
88969546|NCT06146894|Experimental|Warm Vertical condensation technique (AH plus Sealer)|
88969547|NCT06144242|Experimental|Feedback on RTD metric|An e-mail will be sent to the clinicians in the experimental arm every two months describing their performance on the RTD metric and making a comparison to how their peers have performed. The e-mail will also direct clinicians to visit a dashboard to review their practice in greater depth.
88969548|NCT06144242|No Intervention|No feedback on RTD metric|Any clinician assigned to the control arm will not receive the above-mentioned e-mails.
89532550|NCT06161532|Experimental|Arm 2|Treatment with sacituzumab govitecan and atezolizumab
89532551|NCT06161415|Experimental|Group 1|(3 to 6 participants): Participants will receive a dose of Laquinimod as 2 drops once a day (0.6mg per day) in the study eye for 14 days before the surgery.
89532552|NCT06161415|Experimental|Group 2|(3 to 6 participants): Participants will receive a dose of Laquinimod as 2 drops twice a day (1.2mg per day) in the study eye for 14 days before the surgery
89532553|NCT06161415|Experimental|Group 3|(3 to 6 participants): Participants will receive a dose of Laquinimod as 2 drops three times a day(1.8 mg per day) for 14 days before the surgery.
89532554|NCT06161415|Experimental|Stage 2 Comparison Group A|(3 to 6 participants): Participants will receive a dose of Laquinimod eye drops in the study eye for 14 days before the surgery. Frequency to be decided at the end of stage 1.
89532555|NCT06161415|Experimental|Stage 2 Comparison Group B|(3 to 6 participants): Participants will receive a dose of Laquinimod as 2 drops in the study eye for 14 days before the surgery. Frequency to be decided at the end of stage 1.
88969549|NCT06138288||acupressure group|Women who are in acupressure will apply the application after cesarean section 2nd hour after applying the data collection forms (descriptive features formula, VAS, WHO). For women on acupressure, the application will be applied manually to the SP6, P6 and L14 points in the order indicated by the drawing with the index or middle finger, 1-1.5 cm depth for 5 seconds, pressing for 5 seconds, resting for 2 seconds and continuing for 2 minutes to go. will be with you. VAS will be filled again after the application.
88969550|NCT06138288||control group|
88969551|NCT06138132|Experimental|KYV-101 CAR-T cells with lymphodepletion conditioning|Dosing with KYV-101 CAR T cells
88969552|NCT06135389||blood sampling scheme1|3 strata of 10 children and adolescents - normal weight, overweight and obese Titration of paracetamol (acetaminophen) - scheme 1
88969553|NCT06135389||blood sampling scheme2|3 strata of 10 children and adolescents - normal weight, overweight and obese Titration of paracetamol (acetaminophen) - scheme 2
88969554|NCT06128122|Experimental|Dextrose injection intraarticularly and in subcutaneous tissue with timed dextrose measurements|"Step One: Injection of 30 ml of D12.5% in the knee anteromedially with knee flexed. Placement of IV catheter into the suprapatellar pouch, and secure catheter. Withdraw and analyze samples for dextrose levels at 15-minute intervals. If catheter fails, aspirate directly from suprapatellar pouch.~Step Two: Inject 1-3 ml of D5W into interstitial space about a functioning Dexcom G7 sensor. Measure dextrose levels every 5 minutes on a Dexcom receiver."
88969555|NCT06127706|Active Comparator|Formal lecture and training|exposure to single test of skills
88969556|NCT06127706|Active Comparator|Digital learning only|exposure to single test of skill
88969557|NCT06119568|Experimental|Patients surgically treated with Bitrack System and ESE/ NESE instruments and accessories|
88969558|NCT06117579|Experimental|Inspiratory muscle training group|"Step 1:~During the consultation to diagnose obstructive sleep disorder with the pulmonologist (following polysomnography) to set up continuous positive airway pressure (CPAP):~Introduction of CPAP~Epworth Sleepiness Scale (ESS)~Maximum Inspiratory Pressure (MIP) measurement~Explanation of exercise program and use of POWERBreathe~Step 2:~6-week telephone follow-up with measurement of Epworth Sleepiness Scale (ESS)~Step 3:~Follow-up visit at 12 weeks after introduction of CPAP:~Review of CPAP implementation~Epworth Sleepiness Scale (ESS)~MIP measurement"
88969559|NCT06117579|No Intervention|Control group|"Step 1:~During the consultation to diagnose obstructive sleep disorder with the pulmonologist (following polysomnography) to set up continuous positive airway pressure (CPAP):~Introduction of CPAP~Epworth Sleepiness Scale (ESS)~Maximum Inspiratory Pressure (MIP) measurement~Step 2:~6-week telephone follow-up with measurement of Epworth Sleepiness Scale (ESS)~Step 3:~Follow-up visit at 12 weeks after introduction of CPAP:~Review of CPAP implementation~Epworth Sleepiness Scale (ESS)~MIP measurement"
88969560|NCT06113510||1|50 patients with myocardial infarction and non-obstructive coronary arteries
88969561|NCT06113510||2|10 patients with suspected coronary thromboembolism 10 patients with suspected spontaneous coronary artery dissection 10 patented with iatrogenic spontaneous coronary artery dissection
88969562|NCT06105190|Experimental|IOL implantation experimental|Experimental arm: Premium monofocal intraocular lens LuxSmart
89532556|NCT06153693|Placebo Comparator|Placebo|Placebo once daily (QD) for 12 weeks
89532557|NCT06153693|Experimental|Dose 1|50 mg lorundrostat Dose 1 once daily (QD) for 12 weeks
89532558|NCT06153693|Experimental|Dose 2|50 mg lorundrostat Dose 1 once daily (QD) for 6 weeks then 100 mg lorundrostat Dose 2 once daily (QD) for 6 weeks for subjects who meet prespecified criteria
89532559|NCT06150560|Experimental|Losartan Group|Subjects with Coarctation of Aorta (COA) and high blood pressure will receive Losartan.
89532560|NCT06150560|Active Comparator|Amlodipine Group|Subjects with Coarctation of Aorta (COA) and high blood pressure will receive Amlodipine.
89532561|NCT06150560|Placebo Comparator|Placebo Group|Subjects with Coarctation of Aorta (COA) and high blood pressure will receive Placebo.
89532562|NCT06149481|Experimental|Arm 1|Retifanlimab + TriAdeno Vaccine + N-803
89532563|NCT06149481|Experimental|Arm 2|Retifanlimab + TriAdeno Vaccine + N-803 + SX-682
89532564|NCT06145282|Experimental|Cohort 1|All participants will receive the same dose of the investigational briquilimab antibody and abatacept added to the NIH-established regimen of alemtuzumab-TBI-sirolimus and infusion of filgrastim-mobilized peripheral blood hematopoietic cells from haploidentical related donors. Cohort 1 will receive a single dose of PT-Cy; 50 mg/kg, on day +3 post-HCT
89532565|NCT06145282|Experimental|Cohort 2|All participants will receive the same dose of the investigational briquilimab antibody and abatacept added to the NIH-established regimen of alemtuzumab-TBI-sirolimus and infusion of filgrastim-mobilized peripheral blood hematopoietic cells from haploidentical related donors. Cohort 2 will receive a total of two doses of PT-Cy; 50mg/kg, on days +3 and +4 (total 100 mg/kg) post-HCT
89532566|NCT06141395||Patients with an infection|Patients with high suspicion of infection with at least one sign of the quick Sequential Organ Failure Assessment (qSOFA) score
89532567|NCT06138639|Experimental|Cohort 1: SGT-003|All participants will receive a single IV infusion of SGT-003 on Day 1.
89532568|NCT06138639|Experimental|Cohort 2: SGT-003|All participants will receive a single IV infusion of SGT-003 on Day 1.
89532569|NCT06137248|Experimental|Energy drink intervention|
89532570|NCT06137248|No Intervention|Control arm|Participants on this arm will only consume their normal diet for 4 weeks.
89532571|NCT06130566|Experimental|Amlitelimab dose 1|Subcutaneous injection as per protocol
88969563|NCT06105190|Active Comparator|IOL implantation active comparator|Comparator arm: Monofocal intraocular lens LuxGood
88969564|NCT06104358|Experimental|Active Treatment HU6|Subjects who are randomized to active study drug will receive 450mg of HU6 for 14 day and then 600mg of HU6 for 168 days. N = 24
88969565|NCT06104358|Placebo Comparator|Placebo|Placebo Comparator is non-active study drug. N = 24
88969566|NCT06084364|Experimental|Intraarticular corticosteroid injection (IACS)|A single ultrasound-guided intraarticular injection of 0.50 ml of 40 mg/ml triamcinolone acetonide at baseline. A smaller dosage can be considered if there is increased resistance during injection. The same injection procedure will be repeated after 12 weeks if there is pain (NRS≥3) and inflammation (grey scale synovitis grade 1-3) present in the CMC-1 joint.
88969567|NCT06084364|Placebo Comparator|Saline injection|A single ultrasound-guided intraarticular injection of 0.50 ml of sodium chloride 9 mg/ml at baseline. A smaller dosage can be considered if there is increased resistance during injection. The same injection procedure will be repeated after 12 weeks if there is pain (NRS≥3) and inflammation (grey scale synovitis grade 1-3) present in the CMC-1 joint.
88969568|NCT06084364|Experimental|Occupational Therapy intervention|Patient education, instructions about hand exercises and training in the Happy Hands app. Administration of day and night orthosis. The Happy Hands app involves a 12 week intervention.
89532116|NCT06337838|Experimental|Prophylactic intravenous desmopressin and placebo.|"Within 20 minutes preceding anticipated skin incision, patients will receive intravenous desmopressin at a dose of 20 mcg over 30 minutes. Patients will not receive prophylactic tranexamic acid.~Within 20 minutes preceding anticipated skin incision, patients allocated to the tranexamic acid control group will receive an intravenous infusion of 0.9% saline solution. This saline solution will be administered over a duration of 10 minutes in a volume equivalent to that received by patients in the tranexamic acid intervention group."
89532572|NCT06130566|Experimental|Amlitelimab dose 2|Subcutaneous injection as per protocol
89532573|NCT06130566|Placebo Comparator|Placebo|Subcutaneous injection as per protocol
88969569|NCT06081907|Experimental|IBI363 DL1|IBI363 + IBI325
88969570|NCT06081907|Experimental|IBI363 DL2|IBI363 + IBI325
88969571|NCT06081907|Experimental|IBI363 DL3|IBI363 + Lenvatinib
88969572|NCT06081907|Experimental|IBI363 DL4|IBI363 + Lenvatinib
88969573|NCT06081907|Experimental|IBI363 DL5|Patients with histopathologically confirmed advanced melanoma, who have failed PD-1/PD-L1 treatment and CD73 ≥++ confirmed by IHC.
88969574|NCT06081907|Experimental|IBI363 DL6|Patients with histopathologically confirmed advanced NSCLC, who have failed PD-1/PD-L1 treatment and CD73 ≥++ confirmed by IHC.
89532574|NCT06130501|Experimental|Active tAN|Participants receive active tAN with the Sparrow Ascent device from Spark Biomedical (Dallas, TX).
89532575|NCT06130501|Sham Comparator|Active Sham|Participants receive the active sham version of the Sparrow Ascent device that limits stimulation to trigeminal innervation only and at a charge that is approximately 1000x lower than the active tAN condition.
89532576|NCT06129604|Experimental|pilot window of opportunity trial of TPST-1495|
89532577|NCT06129539|Experimental|Debio 4326|Participants will receive the first injection of Debio 4326, on Day 1 in Part A followed by a second injection 52 weeks later in Part B of the study.
89532578|NCT06126146||Risankizumab|Participants will receive risankizumab on-body injector (OBI) as prescribed by their physician according to local label.
89532579|NCT06124508|Experimental|Lung Cancer Screening Education Group|Participants in this group will receive intensive lung cancer screening and tobacco cessation education for up to two years.
89532580|NCT06124508|Other|Standard of Care Control Group|Participants in this group will receive the standard of care treatment for up to two years.
89532581|NCT06121362|Placebo Comparator|Placebo|The placebo pill is made of inactive cellulose. Participants will be asked to take 2 capsules daily by mouth in the morning 30 minutes before eating for a total of 14 days (Day 1 - Day 14).
89532582|NCT06121362|Experimental|Protocatechuic Acid or PCA|Participants will be asked to take 2 capsules (500 mg each of protocatechuic acid or PCA) daily by mouth in the morning 30 minutes before eating for a total of 14 days (Day 1 - Day 14).
89532583|NCT06118905|Experimental|Denosumab|Denosumab 60mg SQ with placebo zoledronic acid
89532584|NCT06118905|Active Comparator|Zoledronic acid|Zoledronic acid 5mg IV with Denosumab placebo
89532585|NCT06118788|Experimental|BG1805|"Dose escalation: Three dose levels were designed, and if the maximum tolerated dose (MTD) was not found at the highest level, no further dose escalation was to be performed. Approximately 12-18 subjects were planned to be enrolled in the dose-escalation phase to evaluate the safety and tolerability of BG1805 injection and to determine the MTD and/or the recommended phase II dose (RP2D).~Dose Expansion: During or after the dose escalation process, if a certain dose group is determined to have preliminary anti-tumor effects and controllable safety, it can be extended at this dose level to further evaluate the tolerance and safety of BG1805 injection, and to preliminarily evaluate its effectiveness."
89532586|NCT06111755|Active Comparator|SmokefreeTXT|Daily smokers for at least 6 months who report an interest in quitting will be randomized to receive the National Cancer Institute's SmokefreeTXT.
89532587|NCT06111755|Experimental|SmokefreeTXT + smartband|Daily smokers for at least 6 months who report an interest in quitting will be randomized to receive the National Cancer Institute's SmokefreeTXT + smartband.
89532588|NCT06106386|No Intervention|Control Group|Conventional root canal treatment is done and irrigation will be done with 2.5% room temperature sodium hypochlorite
89532589|NCT06106386|Experimental|Cryotherapy Group|Root canal treatment is done and irrigation is done with cooled sodium hypochlorite ( 2- 4°C) through out the visits and final flush with 2- 4°C cold saline will be used for 5 minutes.
89532590|NCT06106386|Active Comparator|Final Flush group|Root canal treatment is done and irrigation is done with sodium hypochlorite at room temperature through out the visits then final flush with 2- 4°C cold saline will be used for 5 minutes.
89532591|NCT06101329|Experimental|Randomized Phase: Lenacapavir (LEN) Group|Participants will receive subcutaneous (SC) lenacapavir (LEN) 927 mg on Day 1 and Week 26 and oral LEN 600 mg on Days 1 and 2.
89532592|NCT06101329|Experimental|Randomized Phase: Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) Group|Participants will receive oral F/TDF (200/300 mg) daily for 52 weeks.
89567174|NCT02522325|Placebo Comparator|Placebo|Subjects will be maintained on oral placebo, administered twice daily for approximately two weeks. Cocaine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.
89567175|NCT02522325|Experimental|Phendimetrazine|Subjects will be maintained on oral phendimetrazine (up to 210 mg/day) administered twice daily for approximately two weeks. Cocaine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.
89567176|NCT04243395|Experimental|Pork|1 ounce lean pork
88969575|NCT06081907|Experimental|IBI363 DL7|Patients with histopathologically confirmed advanced NSCLC, who have failed PD-1/PD-L1 treatment, and whose best response during PD-1/PD-L1 treatment was disease stabilization for less than 6 months or disease progression.
88969576|NCT06081907|Experimental|IBI363 DL8|Patients with histopathologically confirmed advanced NSCLC, who have failed PD-1/PD-L1 treatment, and whose best response during PD-1/PD-L1 treatment was partial response or complete response lasting more than 6 months.
88969577|NCT06081907|Experimental|IBI363 DL9|Patients with histologically confirmed advanced NSCLC, who have undergone NGS testing confirming the presence of an ALK fusion mutation and have previously failed standard treatment.
88969578|NCT06081907|Experimental|IBI363 DL10|Patients with histological or cytological confirmation of advanced NSCLC who harboring EGFR mutation and failed standard treatment.
88969579|NCT06081907|Experimental|IBI363 DL11|Patients with histological or cytological confirmation of advanced NSCLC and failed standard treatment with rare mutations, including but not limited to ROS1, BRAF V600E, METex14 skipping, HER2, NTRK, and RET fusion.
88969580|NCT06077422|Experimental|Exparel|"The experimental medication (Exparel) will be administered per standard of care via ultrasound-guided erector spinae plane (ESP) blocks, bilaterally for sternotomy and unilaterally for mini-thoracotomy. The drug will be administered prior to cardiac surgery. The dosage will be determined by patient body weight.~For this pilot project the investigators anticipate consenting 120 subjects to obtain 96 evaluable subjects; 48 Mini thoractomies (N=24 Exparel, N=24 Marcaine) 48 Open sternotomies (N=24 Exparel, N=24 Marcaine)."
88969581|NCT06077422|Active Comparator|Marcaine|"The active comparator medication (Marcaine) will be administered per standard of care via ultrasound-guided erector spinae plane (ESP) blocks, bilaterally for sternotomy and unilaterally for mini-thoracotomy. The drug will be administered prior to cardiac surgery. The dosage will be determined by patient body weight.~For this pilot project the investigators anticipate consenting 120 subjects to obtain 96 evaluable subjects; 48 Mini thoracotomies (N=24 Exparel, N=24 Marcaine) 48 Open sternotomies (N=24 Exparel, N=24 Marcaine)."
88969582|NCT06075277|Experimental|BI 1810631 (iCF) fed state (Reference, R) then fasting state (Test, T)|
88969583|NCT06075277|Experimental|BI 1810631 (iCF) fasting state (Test, T) then fed state (Reference, R)|
88969584|NCT06074835|Experimental|Test group (Robot-assisted gamete preparation, ICSI, embryo culture and vitrification)|
88969585|NCT06074835|Active Comparator|Control group (routine manual ICSI workflow)|
88969586|NCT06069895|Experimental|NNC0113-6856|Participants will receive NNC0113-6856 oral tablets.
88969587|NCT06069895|Experimental|Placebo|Participants will receive NNC0113-6856 matching placebo oral tablets.
89567177|NCT04243395|Experimental|Egg|1 large whole egg
89208624|NCT00877110|Experimental|chemotherapy, allogeneic NK cells, 3F8|This is a phase I study to assess the safety and feasibility of combining HLA-mismatched (KIR ligand incompatible) NK cells with 3F8 in high-risk NB patients. Following chemotherapy, patients will be treated in sequential groups of 3 patients/dose of NK cells. Four dose levels of NK cells, starting at dose level I, will be evaluated in this treatment protocol. In the unlikely case toxicity is encountered at dose level I, patients will then be treated at the lower dose level 0. Patients can receive up to 3 cycles of treatment on protocol. For subsequent cycles, patients will be treated at either less than or at the same dose level of NK cells as their first cycle.
89567178|NCT04243395|Experimental|Black beans|0.5 cups of cooked black beans
89208625|NCT00727259||Patients with chronic hepatitis C|Adult patients with chronic hepatitis C treated with PegIntron pen/Rebetol.
89208626|NCT00789386|Experimental|Remifentanil|
89208627|NCT00789386|Placebo Comparator|Midazolam|Active Placebo
89567179|NCT04243395|Experimental|Almonds|0.5 ounce of whole almonds
89567180|NCT01672879|Experimental|SIM 200 mg|During the Randomized Double-Blind Phase, participants will receive SIM 200 mg via intravenous infusion every 2 weeks for up to 240 weeks. During the optional Open-Label Phase, participants will receive SIM 700 mg via intravenous infusion every 2 weeks for up to an additional 240 weeks.
89567181|NCT01672879|Experimental|SIM 700 mg|During the Randomized Double-Blind Phase, participants will receive SIM 700 mg via intravenous infusion every 2 weeks for up to 240 weeks. During the optional Open-Label Phase, participants will receive SIM 700 mg via intravenous infusion every 2 weeks for up to an additional 240 weeks.
89567182|NCT01672879|Placebo Comparator|Placebo|During the Randomized Double-Blind Phase, participants will receive placebo to match SIM administered via intravenous infusion every 2 weeks for up to 240 weeks. During the optional Open-Label Phase, participants will receive SIM 700 mg administered via intravenous infusion every 2 weeks for up to an additional 240 weeks.
89567183|NCT02601209|Experimental|Arm I (sapanisertib)|Patients receive sapanisertib as in Phase I. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89567184|NCT02601209|Experimental|Arm II (pazopanib hydrochloride)|Patients receive pazopanib hydrochloride PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients experiencing disease progression may crossover to Arm I.
89567185|NCT05012839||Complicated appendicitis|The development of complicated appendicitis, diagnosed during appendectomy or by pre-operative image study
89567186|NCT05012839||Non-complicated appendicitis|No development of complicated appendicitis, diagnosed during appendectomy or by pre-operative image study
89608827|NCT03156075|No Intervention|Control group|This group will be selected from the previous three months, they didn't receive any intervention and received the usual care postoperative.
89608828|NCT03585855|No Intervention|Historic control|historic cohort of patients with ABMR treated with standard of care therapy
89608829|NCT03585855|Experimental|MSC transplantation|patients with ABMR treated with MSC transplantation
89567187|NCT01659021|Experimental|Idelalisib+ofatumumab|"Randomized Initial Therapy (24 weeks): Idelalisib + ofatumumab for a total of 12 infusions (300 mg on Day 1, followed by 1000 mg weekly for 7 weeks, and then 1000 mg every 4 weeks for 4 doses)~Continuing Therapy/Observation: Idelalisib 150 mg tablets twice daily until the earliest of participant withdrawal from study, definitive progression of CLL, intolerable idelalisib-related toxicity, pregnancy or initiation of breast feeding, substantial noncompliance with study procedures, or study discontinuation.~Long-Term Follow-up: Participants were followed for up to 5 years. Information on medical status, anti-tumor treatments, secondary malignancies, and survival status were collected annually during a routine clinic visit or other contact, such as telephone."
88969591|NCT06068738||Newly diagnosed|Newly diagnosed ovarian carcinoma patients presenting with ascites and/or pleural effusions before start of their initial therapy.
88969592|NCT06068738||Relapsed/refractory|Relapsed/refractory (r/r) ovarian carcinoma patients presenting with ascites before start of their next therapy line (for r/r patients).
88969593|NCT06068543|Experimental|Epigallocatechin-3-Gallate (EGCG)|800mg Epigallocatechin-3-Gallate (EGCG) pills AND 250mg Ascorbic Acid (Vitamin C) once daily
88969594|NCT06068543|Placebo Comparator|Microcrystalline cellulose (MCC)|800mg microcrystalline cellulose (MCC) pills AND 250mg Ascorbic Acid (Vitamin C) once daily
88969595|NCT06067802|Experimental|Triheptanoin|Open label study
88969596|NCT06063356|Active Comparator|Dextrose Prolotherapy|Intra-articular Injection: A total of 5 cc of 25% dextrose solution (4 cc of 30% dextrose + 1 cc of saline) will be administered to the patellofemoral joint space in each patient with the same technique using the supero-lateral technique using a sterile injector with a 20 gauge needle tip.
88969597|NCT06063356|Active Comparator|Saline|Intra-articular Injection: Using a sterile syringe with a 20 gauge needle tip, a total of 5 cc of saline will be administered to the patellofemoral joint space in each patient with the same technique using the supero-lateral technique.
88969598|NCT06060912|Experimental|LAmbre occlusion device|Left atrial occlusion will be performed with the LAmbre occlusion device (Lifetech Scientific, Shenzhen, China)
88969599|NCT06060912|Active Comparator|AMPLATZER Amulet occlusion device|Left atrial occlusion will be performed with AMPLATZER Amulet occlusion device (Abbott Medical, Chicago, ILL, USA)
89567188|NCT01659021|Active Comparator|Ofatumumab|"Randomized Initial Therapy (24 weeks): Ofatumumab for a total of 12 infusions (300 mg on Day 1, followed by 2000 mg weekly for 7 weeks, and then 2000 mg every 4 weeks for 4 doses)~Continuing Therapy/Observation: Observation until the earliest of participant withdrawal from study, definitive progression of CLL, intolerable idelalisib-related toxicity, pregnancy or initiation of breast feeding, substantial noncompliance with study procedures, or study discontinuation.~Long-Term Follow-up: Participants were followed for up to 5 years. Information on medical status, anti-tumor treatments, secondary malignancies, and survival status were collected annually during a routine clinic visit or other contact, such as telephone."
89567189|NCT05012449|Experimental|Arthrography-assisted joystick technology.|Adolescent transitional ankle fracture who were treated with the arthrography-assisted joystick technology.
89567190|NCT05012449|No Intervention|No arthrography-assisted joystick technology.|Adolescent transitional ankle fracture who were treated with open or close reduction .
89567191|NCT05012215|Experimental|Paravertebral|Ultrasound-guided thoracic paravertebral block
89567192|NCT05012215|Active Comparator|Caudal|Caudal block
89567193|NCT05012137|Experimental|SASIS-FICB|All subjects will be enrolled in the experimental group and receive an Ultrasound-guided Supra-anterior Superior Iliac Spine Fascia Iliaca Compartment Block (SASIS-FICB)
89567194|NCT03080467||Suture|Wound repair with suture
88969600|NCT06057701|Experimental|control group|This group consists of 20 postmenopausal women suffering from thoracic hyper kyphosis. They receive daily session of 30minutes even by therapist or at home for 12 weeks. the corrective exercises for the thoracic spine consist of strengthening exercises for back muscles and stretching exercises for pectoral muscles
88969601|NCT06057701|Experimental|interventional group|This group consists of 20 postmenopausal women suffering from thoracic hyper kyphosis, who receive the corrective exercises prescribed above in addition to resisted diaphragmatic breathing exercise. They receive daily session of 30minutes even by therapist or at home for 12 weeks.
88969602|NCT06053658|Experimental|Combination Tivozanib and Nivolumab|Nivolumab by vein over about 60 minutes every 4 weeks (Day 1 of each cycle). Tivozanib tablets by mouth 1 time every day for 21 days (Days 1-21 of each cycle), and then no tablets on Days 22-28 of each cycle.
88969603|NCT06053619|Experimental|GaitTrainer|This group of participants will benefit from 3 consecutive sessions of classic GaitTrainer without VR and then these same participants will benefit from 3 consecutive sessions of GaitTrainer with VR
88969604|NCT06053567|Experimental|High-Intensity Aerobic Exercise|Participants assigned to this arm will be instructed to complete 75 minutes per week of aerobic training at 60-85% of the their heart rate reserve.
88969605|NCT06053567|Active Comparator|Low-Intensity Aerobic Exercise|Participants assigned to this arm will be instructed to complete 75 minutes per week of aerobic training at 20-40% of the their heart rate reserve.
88969606|NCT06052514||Post COVID patient diagnosed with sleep apnea with AHI > 5|Patients with post COVID syndrome diagnosed with sleep apnea starting CPAP
88969607|NCT06045247|Experimental|R-miniCVP+ Epcoritamab|Starting on Day 1 of Cycle 2, you will also receive epcoritamab 1 time each week (Days 1, 8, 15, and 22 of each cycle). Epcoritamab is given as an injection under your skin, after you complete your dose of R-miniCVP. You may receive up to 6 cycles of R-miniCVP (Cycles 1-6) and up to 11 cycles of epcoritamab (Cycles 2-12), depending on how the disease responds to treatment.
88969608|NCT06039358|Experimental|Control - caffeine - placebo.|The order of the assessed sessions will be first the control one, then the caffeine one, and then the placebo one.
88969609|NCT06039358|Experimental|Control - placebo - caffeine.|The order of the assessed sessions will be first the control one, then the placebo one, and then the caffeine one.
89028038|NCT01299766|Experimental|Behavior Activation|BA is a manual-based, behavioral treatment that helps people increase activity levels through goal setting, activity scheduling, graded task assignment, identifying avoidant behaviors, and rating one's sense of accomplishment.
89567195|NCT03080467||Tissue adhesive|Wound repair with tissue adhesive
89567196|NCT05291559|Experimental|Enterade (VS001)|237 mL (8 fluid oz) per os, once daily for 14 days
89567197|NCT05291559|Placebo Comparator|Placebo|237 mL (8 fluid oz) per os, once daily for 14 days
89567198|NCT03075319|Experimental|Received perioperative photograph|Perioperative knee range of motion (ROM) were measured with long arm goniometer immediately after close the wound. Perioperative knee photographs in full flexion and extension positions were taken and gave to experimental group in the day after surgery.
89567199|NCT03075319|Active Comparator|Didn't receive perioperative photograph|Perioperative knee range of motion (ROM) were measured with long arm goniometer immediately after close the wound. Perioperative knee photographs in full flexion and extension positions were taken but participants in this group didn't receive perioperative photographs.
89567200|NCT04999033||Inpatient|This study is a cross-sectional study and no intervention will be involved
89567201|NCT04818203|Experimental|Test Group|Participants receive 1 mL of clusters of autologous dermal fibroblast to three spots around the left eye and three spots around the right eye along the periorbital wrinkles on both sides, perpendicularly to the wrinkles.
89567202|NCT04818203|Placebo Comparator|Placebo|Participants receive 1 mL of placebo solution to three spots around the left eye and three spots around the right eye along the periorbital wrinkles on both sides, perpendicularly to the wrinkles.
89567203|NCT05252793|Experimental|Diabetes Education Program Based on Health Belief Model|"Experimental: Intervention Patients will be given links to training videos once or twice a week depending on the length of the training module for 6 weeks.~At the 6th week, the Diabetes Patients Health Belief Model scale, the Diabetes Self-Efficacy Scale and the Healthy Lifestyle Scale-II will be administered as an interim measure.~Health Belief Model scale in Diabetes Patients, Self-Efficacy Scale in Diabetes and Healthy Lifestyle Scale-II will be applied to the patients at the 12th week as the last measurement."
89567204|NCT05252793|No Intervention|Control|"No intervention will be taken against the patients.~At the 6th week, the Diabetes Patients Health Belief Model scale, the Diabetes Self-Efficacy Scale and the Healthy Lifestyle Scale-II will be administered as an interim measure.~Health Belief Model scale in Diabetes Patients, Self-Efficacy Scale in Diabetes and Healthy Lifestyle Scale-II will be applied to the patients at the 12th week as the last measurement."
89567205|NCT04827797|Experimental|birth ball|The positions and movements for birth ball in the active and latent phases: kneeling on the ground and leaning on the spherical birthing ball, sitting on the ball with front support, sitting positions on the spherical birthing ball, full rotation of hip, moving to the right/left, back and forth. Positions and movements were repeated every 30 minutes. The 30-minute intervals were interrupted in cases where the women were not feeling well.
89567206|NCT04827797|Experimental|peanut ball|The positions and movements for the pregnant women in peanut ball: upright sitting position, forward bending positions, with backward and forward movement and swaying right and left on the peanut ball
89567207|NCT04999189|Experimental|Patients using mobile applications|Patients diagnosed with type 2 diabetes will use a mobile app forDiabetes (Tessera Multimedia, 2020) to manage their disease.
89567208|NCT04999189|No Intervention|Control group|Patients will receive treatment from medical staff (as usual).
89567209|NCT05290779|Active Comparator|ultrasound|selective lumbar nerve root steroid injection under ultrasound guidance.
89567210|NCT05290779|Sham Comparator|fluoroscopy|selective lumbar nerve root steroid injection under fluoroscopy guidance.
89567211|NCT05252481|Active Comparator|Active tDCS|Transcranial current direct stimulation. 8 days.
89567212|NCT05252481|Sham Comparator|Sham tDCS|Sham transcranial current direct stimulation. 8 days.
89567213|NCT04998955|Experimental|MST group|Exercise intervention, 20 supervised MST sessions
89567214|NCT04998955|No Intervention|Control group|IRD patient controls
89567215|NCT05324631|Experimental|Treatment group A|SHR0302
89567216|NCT05324631|Placebo Comparator|Treatment group B|SHR0302 Placebo
89567217|NCT05011747|Active Comparator|single-site VT group|Viscotrabeculotomy is performed through a superonasal triangular scleral flap.
89567218|NCT05011747|Active Comparator|two-site VT group|Viscotrabeculotomy is performed through a superonasal and an inferotemporal triangular scleral flap.
89567219|NCT04422327|Experimental|Probiotic capsule|The participants consume one probiotic capsule a day for 8 weeks
89567220|NCT03075475|Experimental|CETA Treatment|For treatment group participants, they will then have weekly Common Elements Treatment Approach (CETA) counseling sessions with a counselor lasting no more than 1.5 hours per session, and a total of approximately 10-12 sessions. They will then repeat the assessment instrument after their last session, as well as 6 months after finishing treatment, and these meetings will again last no more than 1.5 hours. All total, it is expected that treatment group participants will have 13 meetings with a study team member or counselor over the course of their participation.
89567221|NCT03075475|No Intervention|Waitlist|Waitlist group participants be contacted by a study team member from the local partner organization regularly (weekly) while they are on the wait list. These contacts from the study team will be short and last less than 30 minutes and will be used to briefly assess symptom levels and safety. At the end of their wait period, they will be asked to complete the assessment instrument a second time and this meeting will take no more than 1.5 hours. For participants in the waitlist group, we estimate 13 meetings total during their wait period (2 meetings of no more than 1.5 hours, 10 contacts less than 30 minutes).
89567222|NCT06163456|Experimental|low fitness|
89567223|NCT06163456|Active Comparator|moderate fitness|
88969610|NCT06038955|Experimental|Virtual reality Based Cognitive Remediation|The cognitive remediation program has a duration of four weeks and involves two weekly 1,5-hour virtual reality-based cognitive training sessions with a therapist accompanied by additional between-session virtual reality training at home and homework assignments consisting of cognitively challenging daily life tasks.
88969611|NCT06038955|Sham Comparator|Virtual reality control treatment|The control treatment program also has a duration of four weeks and involves one weekly 2-hour session with a therapist.
89028039|NCT01299766|Placebo Comparator|Supportive Therapy (ST)|ST is a person-centered treatment in which interventionists create a comfortable, non-judgmental environment by demonstrating genuineness, empathy, and acceptance of subjects without imposing any judgments on their decisions.
89567224|NCT06163456|Active Comparator|high fitness|
89567225|NCT06163430|Experimental|Part 1- Dose Level 1 of TERN-701|Dose Level 1 of TERN-701 dosed once daily.
89567226|NCT06163430|Experimental|Part 1- Dose Level 2 of TERN-701|Dose Level 2 of TERN-701 dosed once daily.
89567227|NCT06163430|Experimental|Part 1- Dose Level 3 of TERN-701|Dose Level 3 of TERN-701 dosed once daily.
88969612|NCT06036472|Experimental|Subgingival therapy|Participant will receive standard periodontal treatment consisting of two sessions of supra- and subgingival debridement (steps 1 and 2) under local anesthesia following current guidelines for periodontal therapy in patients with periodontitis (Herrera et al., 2022; Sanz et al., 2020). The use of chlorhexidine (0.12%) and cetylpyridinium chloride (0.05%) mouthwash will be prescribed twice a day for 15 days (Perio-Aid®, Dentaid, Barcelona, Spain). If needed, hopeless teeth might be extracted during this step.
88969613|NCT06036472|Other|Supragingival therapy|Periodontal treatment consisting of two sessions of supragingival debridement with anesthesia (step 1) and administration of a placebo mouthwash (FluorAid®, Dentaid, Barcelona, Spain), twice a day for 15 days.
88969614|NCT06034665|Other|Exercise|All patients will receive an exercise rehabilitation program tailored to their needs.
88969615|NCT06033508|Active Comparator|T2DM with neuropathy + WBV|Patients with type 2 Diabetes mellitus with neuropathy who will be trained by whole body vibration
88969616|NCT06033508|Active Comparator|T2DM without neuropathy + WBV|Patients with type 2 Diabetes mellitus without neuropathy who will be trained by whole body vibration
88969617|NCT06033508|Placebo Comparator|T2DM without neuropathy + land exercise|Patients with type 2 Diabetes mellitus without neuropathy who will be trained on land
88969618|NCT06033378|Experimental|Cerebral blood flow|Change in cerebral blood flow with increased systemic blood pressure
88969619|NCT06024603|Experimental|Drug Sensitivity Testing|The results of the DST and genomic screening will be used to inform treating physician about participant-specific drug sensitivity or resistance guiding best therapy choices. The physician will decide which treatment will be most appropriate for each case. All participants will need to be consented separately for any subsequent investigational treatment if no standard treatment options are available.
89208628|NCT05157282|Active Comparator|Active TESS Group 1|Subjects with SCI and without SCI (controls) will participate in two testing sessions, separated by 2-3 days, using a crossover design. In each session, active transcutaneous electrical spinal stimulation (TESS) will be applied over the cervical spinal cord. Functional and physiological measures will be acquired before and after each session.
89567228|NCT06163430|Experimental|Part 1- Dose Level 4 of TERN-701|Dose Level 4 of TERN-701 dosed once daily.
89567229|NCT06163430|Experimental|Part 2 - Dose 1|Dose 1 will be selected from Part 1 based on the totality of safety, PK, PD and efficacy data from Part 1 will be selected. TERN-701 is planned to be administered once daily.
88969620|NCT06023303|Experimental|Group A- Split face|Group A will receive split face treatments with the Potenza and Morpheus. Randomization will not be used for enrolling subjects to a group but will be used for Group A to determine which side of the face will receive which device.
88969621|NCT06023303|Experimental|Group B- none split face|Group B will receive treatments on the face, abdomen, and/or back with Potenza and/or Morpheus.
88969622|NCT06017089|Experimental|AI Advisor-driven at-home closed loop system initiation and parameter adaptation|In this single-arm intervention trial, all participants will use the study system (t:slim X2 with Control-IQ Technology and Dexcom Continuous Glucose Monitor) in closed-loop mode for 8 weeks at home with periodic parameter adjustment driven by an AI-based Advisor system.
88969623|NCT06016140|Experimental|Intervention group|Medication Plan Prototype
88969624|NCT06016114||HIV-1 positive individuals (non-pregnant)|
89208629|NCT05157282|Sham Comparator|Sham TESS Group 1|Subjects with SCI and without SCI (controls) will participate in two testing sessions, separated by 2-3 days, using a crossover design. In each session, sham transcutaneous electrical spinal stimulation (sham-TESS) will be applied over the cervical spinal cord. Functional and physiological measures will be acquired before and after each session.
88969625|NCT06016114||Pregnant HIV-1 positive/negative individuals|
88969626|NCT06012786||Group 1 (Patients with Stage 0 lymphedema)|It is known that pathophysiological changes develop even if there is no visible lymphedema in patients undergoing surgery and/or radiotherapy for breast cancer. There is a lifetime risk of developing lymphedema, so these patients are considered as Stage 0 (latent). The patients with less than 3 cm difference between the circumference measurements of upper extremities will be included in the 1st group.( Stage 0) (n=55)
89208630|NCT05157282|Active Comparator|Active TESS + Training|Develop methodologies to promote recovery of reaching and grasping movements. To accomplish this goal, the investigators will combine TESS applied in a closed-loop manner with massed practice upper-limb training. Participants will be assigned to one of three groups in a randomized order for a controlled design: [1) Closed-loop TESS applied during grasping + training, 2) Closed-loop TESS applied during reaching + training, and 3) Closed-loop TESS applied during grasping & reaching + training.] TESS for 20-min will be followed by 60 min of massed practice exercise training (total=20 sessions).
89567230|NCT06163430|Experimental|Part 2 - Dose 2|Dose 2 will be selected from Part 1 based on the totality of safety, PK, PD and efficacy data from Part 1 will be selected. TERN-701 is planned to be administered once daily.
89567231|NCT06163417||O group|conventional Kasai portoenterostomy
89567232|NCT06163417||L group|laparoscopic Kasai portoenterostomy
89567233|NCT06163378|Experimental|RUBATO|patients will be asked to listen (using headphones to accommodate patients with hearing aid) to a minimum of 30 minutes per day of music (or a total of 3.5 hours per week), coming up to their scheduled reassessment appointments (every 6 to 12 weeks) using the RL music selection application while wearing an individual smart bracelet aimed to build their optimal music therapy profile;
89567234|NCT06163378|No Intervention|STANDARD OF CARE|patients will continue to receive standard of care.
89608830|NCT03580395|Experimental|apatinib+TP|TP neoadjuvant chemotherapy (paclitaxel 165mg/m2 day 1, cisplatin 40mg, day 1-3) combined with apatinib (received TP concurrently with apatinib 500mg, day1-21).
89608831|NCT03580395|Sham Comparator|TP|TP neoadjuvant chemotherapy alone (paclitaxel 165mg/m2 day 1, cisplatin 40mg, day 1-3).
89608832|NCT03585777||Group 1|Compare serum levels of klotho in patients taking glimepiride in comparison to patients taking metformin
89608833|NCT03585777||Group 2|Compare serum levels of klotho in patients taking glimepiride in comparison to patients taking linagliptin
89608834|NCT03585777||Group 3|Compare serum levels of klotho in patients taking glimepiride in comparison to patients taking impaglifluzin
89608835|NCT01609543|Experimental|Single Arm|
89208631|NCT00789464|Other|ARM A|Probiotics drops plus placebo elixir
89567235|NCT06163365||Cohort 1. Li Fraumeni (TP53 mutations carriers)|Patients with a germline TP53 alteration included in this study will undergo their usual surveillance with their treating team. In addition to their routine scans or examinations, they will provide blood samples at enrollment, during the study (optional) and at the end of their participation (at 12 months). The results of any radiological scan undergone during this period will be collected retrospectively and added to their data collection, which will allow for a correlative analysis between the genetic and epigenetic results and radiological outcomes.
89567236|NCT06163365||Cohort 2. Gastro-intestinal (GI) cohort|"Patients with underlying germline conditions at high risk of developing a GI malignancy (approximately 40-50 patients)~Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM genes)~PTEN~STK11 (Peutz-Jeghers syndrome)~CDH1 and APC gene alterations carriers prior to their risk-reducing surgery if such is performed.~SMAD4~MUTYH* (*biallelic variants)~Carriers of CDH1 and APC pathogenic mutation are invited to give blood and optional urine samples before and after their surgery, if they undergo this intervention, with no need for sequential samples. Samples should be taken when convenient for the patient prior to and post-surgery."
89567237|NCT06163339|Experimental|CFI + Usual Care|About half of participants who are allocated to a person who works with the CFI during the trial.
89567238|NCT06163339|No Intervention|Usual Care|About half of participants who are allocated to a person who do not work with the CFI during the trial (i.e., usual care).
89567239|NCT06163313||Calculosis patients|Patients suffering from kidney stones
89567240|NCT06163248|Experimental|Chrono nutrition|"During the 6-month period, participants will be asked to fast for 12 hours each day. During the fasting period, they may consume non-caloric beverages such as plain water, coffee, or unsweetened tea.~The total daily calorie intake will be calculated using indirect calorimetry, considering the participant's current weight, age, sex, and physical activity level. 500 calories will be subtracted from the total calorie amount.~The dietary plan will have the following macronutrient distribution: 40% carbohydrates (<10% simple carbohydrates), 20% protein, and 40% fats (6-11% polyunsaturated, 15-20% monounsaturated, and <10% saturated).~The plan will consist of 3 meals and breakfast will account for 40% of the total calories.~During dinner, only 10% of the total grams of carbohydrates will be included.~The order of food consumption should be as follows: 1) vegetables, 2) proteins, 3) complex carbohydrates, and 4) simple carbohydrates (fruits)."
89567241|NCT06163248|Active Comparator|Standard|"The total daily calorie intake will be calculated using indirect calorimetry, considering the participant's current weight, age, sex, and physical activity level. 500 calories will be subtracted from the total calorie amount.~The dietary plan will have the following macronutrient distribution: 40% carbohydrates (<10% simple carbohydrates), 20% protein, and 40% fats (6-11% polyunsaturated, 15-20% monounsaturated, and <10% saturated).~The plan will consist of 3 meals with an isocaloric distribution, with each meal containing 33% of the total calories."
89567242|NCT06163235|Experimental|Semi-attendance.|This group will follow a semi-attendance program after bariatric surgery.
88969627|NCT06012786||Group 2 (Patients with Stage 1,2 or 3 lymphedema)|Patients who have more than 3 cm difference between the circumference measurements of upper extremities and those with Stage 1,2 or 3 lymphedema will be included in the second group (n=55)
88969628|NCT06010108|Active Comparator|Heroes for Her|Market outreach intervention- Community entry to engage major stakeholders. Awareness of the project will be made in the community through a public market crier who makes public announcements in the market daily using an audio recording. Lead/Mentor mothers who are mothers from the neighbourhood will be recruited to go door-to-door to reach out to the community. Before the screening and vaccination exercise, the woman will be counselled properly and taught about the HPV self-screening procedure. Mothers are expected to come to the hospital when returning their samples with their daughter so their daughter receive the vaccine
88969629|NCT06010108|Active Comparator|The Reach Initiative|"School based intervention-The Reach Initiative involves the Mother-Daughter Day (MDD) to create awareness and provide screening and vaccination to women and girls. This will adopt the following components. MDD which is a campaign that includes educative activities and participants will be given souvenir packs containing key-cards. On-site vaccination and sample collection kits education to be provided by healthcare providers.~To foster community engagement and promote sustainability, mothers and daughters will be encouraged to volunteer to be on the Mother-Daughter Planning Committee and participate in creating awareness."
88969630|NCT06010108|Active Comparator|W.H.I.T.E Project|"Community based intervention- Community engagement by consulting with stakeholders in the community, and seeking their support for the W.H.I.T.E Project through advocacy visits. Study participants will be recruited through community based outreaches and will be educated on Human Papilloma virus and cervical cancer. This will be carried out through inter-personal communication, and use of Information, Education and Communication (IEC) materials designed for the purpose of this intervention.~Vaccination of girls age 9-14years recruited for the study will be through referral to the service point (health facility) and vaccination at outreach site.~The W.H.I.T.E self-sample kit, will be distributed to women age 30 to 65 years through referral to the service point and distribution at outreach site."
89028040|NCT04512261|Experimental|Tucatinib + Pembrolizumab + Trastuzumab|Patients will receive a combination therapy of tucatinib with pembrolizumab and trastuzumab during the treatment period until progression, treatment intolerance, or patient withdrawal from study. Tucatinib and pembrolizumab are administered as experimental use while trastuzumab is administered per standard use. Patients are expected to be on treatment for at least 12 weeks.
89208632|NCT00789464|Other|ARM B|TMP/SMZ elixir plus placebo drops
89208633|NCT00977067|Experimental|A|
89208634|NCT00797030|Active Comparator|1|Ten HIV-positive-patients with dry eye diagnosis received sodium carboxymethylcellulose 0.5% drops (one drop 4 times per day) and topical cyclosporine 0.05% (one drop twice a day) for six months.
89208635|NCT00797030|Other|2|Ten HIV-positive-patients with dry eye received sodium carboximethylcelullose 0.5% (1 drop 4 times per day) during six months
89208636|NCT00877188|Experimental|exercise|supervised combined aerobic and resistance training for 12 weeks
89208637|NCT00877188|No Intervention|control|waist list control with usual care
89208638|NCT02593955|Active Comparator|PD exercise group|Supervised exercise training, 3x per week for 16 weeks
89208639|NCT02593955|Active Comparator|PD sleep hygeine group|Tips for improved sleep hygiene, reading materials
89208640|NCT02593955|No Intervention|Healthy control|MRI sub-study only
88969631|NCT06010108|Active Comparator|Project Shield|Distribution of branded self-sampling kits for HPV screening and vaccination through community based structures- Participants will be recruited through fliers, posters and community volunteers. The branded kit will include the Evalyn brush, sanitary pad/panty liner, a user manual which will be translated in local languages. Mothers who purchase the self-sampling kit will receive a free vaccination voucher for their daughters. The kits will be sold at a discounted rate. The voucher will enable the daughters to receive the HPV vaccine for free. To create awareness about cervical cancer, banners will be displayed at pharmacies and the community health facilities. The Community Development Association (CDA) will participate in awareness campaigns utilizing local languages and culturally appropriate messages. Community hospitals and pharmacies will serve as points of access for the self-sampling kits and vaccines.
88969632|NCT06010108|Active Comparator|Project SHADE|"Community based intervention using a uniquely designed bag Eno Iban to package and distribute the self collection kit and use of a simple app (d-SHADE) to collect participants data- Community outreaches will be carried out in several areas within the community such as markets to create awareness on cervical cancer prevention and to recruit women and girls. Female healthcare providers will be actively involved in these outreaches. Interested participants will be given uniquely branded kits containing a self-sampling brush from the mothers and a vaccination voucher for daughters. Mothers will be required to collect their samples either at the community facility or at home. When returning the Samples to the community facility, mothers will be expected to come with their daughters who then receive the HPV vaccination. All collected samples will be returned to the reference laboratory for analysis"
89028041|NCT00492362|Active Comparator|A|Ergometer during hemodialysis
89028042|NCT00492362|Active Comparator|B|Pedometer use outside of hemodialysis
89567243|NCT06163235|No Intervention|Control group.|This group will follow the conventional controls after bariatric surgery.
89567244|NCT06163196|Experimental|accupressure|In the study group (n:19), blood pressure, pulse and oxygen saturation were measured, and the acupressure points determined (large intestine meridian 4. Point: LI 4, large intestine meridian 11. Point: LI 11, Heart Meridian 7. Point: HT 7 ) acupressure was applied for only one session by applying light pressure with the thumb of the practitioner's hand, in two directions as the right and left arms, for 2 minutes to each point for a total of 12 minutes. Blood was drawn immediately after the procedure. In order to evaluate the child's pain immediately after the blood collection procedure, the child was asked to mark the most appropriate face on the Wong Baker Faces Pain Rating Scale. In addition, the child's pain was evaluated by the researcher and the parent using the Wong Baker Faces Pain Rating Scale. After the pain assessment, the child's heart rate, oxygen saturation and blood pressure were re-evaluated by the researcher and recorded in the Procedure Record Form.
89567245|NCT06163196|Sham Comparator|control|The point used in our research is the point located in the middle of the third and fourth metacarpal bones on the back of the hand. Children in the placebo control group (n:20) were touched by the researcher for one minute without applying pressure or massage to the determined placebo point immediately after their physiological parameters were evaluated. Immediately after blood collection, the child was asked to mark the most appropriate facial expression on the Wong Baker Faces Pain Rating Scale so that he or she could assess his pain. In addition, the child's pain was evaluated by the researcher and the parent using the Wong Baker Faces Pain Rating Scale.
89567246|NCT06163183||Extubation failure|
89567247|NCT06163183||Extubation success|
89567248|NCT06163170||Participants treated with nivolumab +/- ipilimumab for unresectable/metastatic melanoma|
89567249|NCT06163170||Participants treated with nivolumab as adjuvant therapy for resected stage IIB-IV melanoma|
89567250|NCT06163144||Patients CKD 4, CKD 5 non- HD|chronic kidney disease patients non hemodialysis
89567251|NCT06163144||Patients with ESRD on Regular -HD|end stage renal disease patients on hemodialysis
89567252|NCT06163131||Patients|COPD patients treated with endobronchial valves.
89567253|NCT06163066|Experimental|Web-based Group|The father's phone will be stolen and the father will record the researcher's phone number. After this stage, the researcher will apply a pre-test, make the father a member of the website and show the first video about basic newborn care to the father via his phone. The first access to the website will be made under the guidance of the researcher. For membership, individuals must have an internet connection and know how to use a phone. Even though the fathers made their first viewing before being discharged from the hospital, the web page will be open for 1 month and they will be able to watch the video they want whenever they want. Individuals who visit the page and agree to participate in the study will be given a posttest at the end of the 1st month and at the end of the 6th month.
89567254|NCT06163066|Experimental|Face-to-face Group|The father's phone will be stolen and the father will record the researcher's phone number. Then, before his wife is discharged from the hospital, the father will be interviewed and an appointment will be made to meet at the clinic at a convenient time. During this appointment, the researcher will apply a pre-test and explain information about basic newborn care (hygiene, safety and nutrition) face-to-face and in practice. In addition, brochures about baby care will be provided to fathers that they can use at any time. After this process, the final test will be applied at the end of the 1st month and at the end of the 6th month.
89567255|NCT06163066|No Intervention|Control Group|The father's phone will be stolen and the father will record the researcher's phone number. After this stage, the researcher will perform a pre-test before the mother is discharged and will not have her perform any newborn care procedures. Fathers in the control group will continue to receive routine care. In Turkey, information about the basic care of the newborn is given only verbally by neonatal midwives and nurses before discharge. After these procedures, a final test will be applied to this group at the end of the 1st month and at the end of the 6th month.
89567256|NCT06163053||Participants receiving immunotherapy at home|
89567257|NCT06163040||Treated with Elotuzumab in combination with pomalidomide and dexamethasone|
89567258|NCT06163040||Treated with Elotuzumab in combination with lenalidomide and dexamethasone|
89608836|NCT03585699|Active Comparator|Fluoroscopy Guided Spinal Biopsy Arm|Fluoroscopy guided spinal biopsies were done by spine surgeons in the operation theatre using C-Arm fluoroscopy device (OECFluorostar7900Compact - GE®). C-arm image intensiﬁer was positioned until fluoroscopic beam was collinear with the corresponding vertebral body on AP view prior to insertion of biopsy needle
88969633|NCT06010108|Active Comparator|Operation Reach Her (ORH)|"Faith-based intervention- Reaching women and girls through places of religious worship and religious leaders. Awareness programs would be conducted in the chosen religious centres to educate women and girls about their health, cervical cancer, its prevention. This would be achieved by organizing a  Health Day  for free health check-ups for all members of the congregation. HPV screening and vaccination would be a part of these check-ups. Announcements would be carried out in worship centres to enrol women and girls. HPV vaccination to girls will be provided by health care providers stationed at the religious centres in the area. The self-sampling kit would be distributed to women in mobile tents stationed in churches and mosques. Girls who have been successfully vaccinated would receive a vaccination card and wristband to show that they have been vaccinated. The self-sampling kits would be collected from the women on the same day and transported to the reference laboratory"
89028043|NCT04519515|Experimental|Treatment With Juvederm Vollure Right|Injection of Juvederm Vollure on one half of the face, placebo on the other side
89028044|NCT04519515|Experimental|Treatment Juvederm Vollure Left|Injection of Juvederm Vollure on one half of the face, placebo on the other side
89028045|NCT04516785||Intervention|FIT and urine VOC samples followed by colonoscopy
89567259|NCT06163027|Experimental|Shotblocker|Shotblocker (experimental) group: Patients will undergo standard monitoring. The shotblocker will be sterilized before the procedure. Sterilization of the shotblocker will be controlled by the indicator on the packaging. Necessary sterilization conditions for spinal anesthesia application will be met and the procedure will be performed from the L3 -L4 or L4 -L5 spinal range. During the spinal anesthesia process, the protruding surface of the shot blocker will be placed in the area to be inserted, just before the spinal needle application. The shotblocker will be kept stationary throughout the procedure and pressure will continue to be applied. After entering for the spinal anesthesia procedure, the shot blocker will be removed. During the spinal anesthesia procedure, VAS, patient satisfaction and comfort scale will be applied to the patient in the first 1 minute and at the 24th hour after surgery.
89567260|NCT06163027|Placebo Comparator|Placebo|Placebo group: Patients will undergo standard monitoring (electrocardiogram, noninvasive blood pressure, peripheral oxygen saturation). The shotblocker will be sterilized before the procedure. Sterilization of the shotblocker will be controlled by the indicator on the packaging. Necessary sterilization conditions for spinal anesthesia application will be met and the procedure will be performed from the L3 -L4 or L4 -L5 spinal range. During the spinal anesthesia procedure, the reverse side of the shotblocker (without protrusions) will be placed on the skin surface and gently pressed with the fingertips. The shotblocker will be kept stationary throughout the procedure and pressure will continue to be applied. After entering for the spinal anesthesia procedure, the shot blocker will be removed. During the spinal anesthesia procedure, VAS, patient satisfaction and comfort scale will be applied to the patient in the first 1 minute and at the 24th hour after surgery.
89567261|NCT06163027|No Intervention|Control|Routine treatment and care will be applied to the control group and no intervention will be made. During the spinal anesthesia procedure, VAS, patient satisfaction and comfort scale will be applied to the patient in the first 1 minute and at the 24th hour after surgery. The data obtained will be recorded in the patient diagnosis form. All interventions will be performed by the same anesthesiologist. The data will be filled in by a healthcare professional who is blinded to the study.
89567262|NCT06163001|Experimental|Exercise Group|
89567263|NCT06163001|Active Comparator|Dietary supplementation|
89567264|NCT06162988|Experimental|Patients who underwent 68Ga-NOTA-H006 and 18F-FDG PET/CT|68Ga-NOTA-H006, single dose
89567265|NCT06162962||age groups|The general characteristic of patients and clinical data including age, Enneking stage, surgical methods, type of prosthesis, primary tumor location were recorded.
89567266|NCT06162962||surgical methods|The general characteristic of patients and clinical data including age, Enneking stage, surgical methods, type of prosthesis, primary tumor location were recorded.
88969634|NCT06010108|Active Comparator|Project Care|Use of community pharmacies to promote awareness and serve as service points for self-collection and vaccination-Trained pharmacists and healthcare workers, student pharmacists, and students in other fields of study will serve as ambassadors to recruit, provide education and provide guidance on the use of the self- sample kit when needed. Participants will be recruited through community outreach programs, awareness campaigns in hair saloons, workplaces, social media and collaboration with local healthcare facilities. In addition, pharmacies will display promotional materials and provide information to potential participants. Dedicated areas within the local pharmacies will be set up for screening and vaccinations. The mothers and daughters on participation will be given hair accessories as incentives. The screening and HPV vaccination will also be provided at discounted prices.
89567267|NCT06162962||type of prosthesis|The general characteristic of patients and clinical data including age, Enneking stage, surgical methods, type of prosthesis, primary tumor location were recorded.
89567268|NCT06162962||primary tumor location|The general characteristic of patients and clinical data including age, Enneking stage, surgical methods, type of prosthesis, primary tumor location were recorded.
89567269|NCT06162962||Enneking stage|The general characteristic of patients and clinical data including age, Enneking stage, surgical methods, type of prosthesis, primary tumor location were recorded.
89567270|NCT06162936||Inflammatory bowel disease patients|Pediatric patients (under 18 years of age) diagnosed with IBD
89567271|NCT06162936||Healthy controls|Healthy chidren (no chronic disease)
89567272|NCT06162923|No Intervention|Control group|
89567273|NCT06162923|Experimental|On-site video group|
89567274|NCT06162923|Experimental|Remote video group|
89567275|NCT06162910|Experimental|Clinical swallowing exam|Patients with acute ischemic stroke
89567276|NCT06162897|No Intervention|Treatment as usual|Participants will be offered the current standard of care, Ryan White Non-Medical Case Management. Case management services are need focused and contact is client initiated.
89567277|NCT06162897|Experimental|Intervention|Participants will receive dyadic case management, specifically they will have two case managers assigned to their case. Case management services will be goal focused and will utilize components from Appreciative Inquiry to orient work to future planning, goals, and financial stability.
89567278|NCT06162884||STP >=30%|STP score is 30% or greater than 30% in whole lung at baseline inspirational HRCT scan. STP score is an AL/ML derived score using radiomic patterns of lung parenchyma to identify the spatial location of likely progressed in the short-term follow up.
89567279|NCT06162884||STP < 30%|STP score is less than 30% in whole lung at baseline inspirational HRCT scan.
89567280|NCT06162858|Other|Healthy participants|no shoulder pain no shoulder diagnosis 60 years and older
89567281|NCT06162858|Other|RSA participants|primary reverse shoulder arthroplasty 60 years and older
89567282|NCT06162845|Experimental|Experimental arm recieving free smartohone-based pelvic floor muscle exercise application|Smartphone-based home exercise program for performing pelvic floor muscle exercises
88969635|NCT06006962|Experimental|Intervention|Receiving intervention - AgeWISE-AP
88969636|NCT06006962|No Intervention|Waitlist Control|No intervention; will be invited to participate in intervention after completion of study.
88969637|NCT06006910||Pre-Nudge Deployment into EHR|Rates of SLNB will be recorded for the 12 month period prior to nudge deployment.
88969638|NCT06006910||Post-Nudge Deployment into EHR|Rates of SLNB will be recorded for the 12 month period following nudge deployment into the EHR.
88969639|NCT06004453||Cohort A|Supra-regional HFU Centers and HFU Focus Hospitals
88969640|NCT06004453||Cohort B|Non-HFU Hospitals
88969641|NCT06004453||Cohort C|HFU Residential Cardiologists
89567283|NCT06162845|Active Comparator|Control arm recieving paper-based home exercise program|Paper-based home exercise program for performing pelvic floor muscle exercises.
89567284|NCT06162832|Active Comparator|Allograft|Will be used Demineralized cancellous allograft 250-1000um
89567285|NCT06162832|Sham Comparator|Saline Solution|The saline solution will be used for hydrate the bone graft 20 minutes before the placement at the defect
89567286|NCT06162832|Experimental|rhPDGF-BB (GEM21, Lynch Biologics)|The rhPDGF-BB will be used for hydrate the bone graft 20 minutes before the placement at the defect
89567287|NCT06162793|Experimental|RehaPlus+|Customized motivational text messages twice weekly for six months
89567288|NCT06162793|No Intervention|Usual care|"Standard care (Six-month German outpatient program IRENA)"
88969642|NCT06004453||Cohort D|Non-HFU Residential Cardiologists
89567289|NCT06162741|Experimental|Primary Care Brief Mindfulness Training (PCBMT)|PCBMT is a manualized intervention that is a brief adaptation of MBSR Mindfulness Based Stress Reduction (MBSR). Instruction encompasses sitting meditation, body scan, moving meditation, gentle yoga, and group discussion on topics such as non-judging, patience, trust, non-striving, acceptance, and letting go.
89567290|NCT06162741|Active Comparator|Moving Forward (MF)|"Moving Forward (MF) is a transdiagnostic class that seeks to build resilience and reduce emotional distress by teaching step-by-step problem-solving skills such as stop, slow down, think and act."
89567291|NCT06162702|Experimental|FMT Responder|
89567292|NCT06162702|Experimental|FMT non-Responder|
89567293|NCT06162689||Exposed Group|Women at risk of postpartum psychosis during pregnancy
89567294|NCT06162689||Unexposed Group|Women with no current or past history of psychiatric disorders during pregnancy
89567295|NCT06162676|Experimental|HPV game group|Parent-child dyads receive a HPV game intervention
89567296|NCT06162676|No Intervention|Usual care|Parent-child dyads receive child's usual care
89567297|NCT06162650|Experimental|Experimental arm|The total neoadjuvant therapy with the short-course radiotherapy (5×5 Gy over a maximum of 8 days) followed by chemotherapy with mFOLFOX6 for 9 cycles will be administered.
89567298|NCT06162598|No Intervention|Control Group|Children in the control group will undergo the routine preparation procedure applied in the emergency department. Before and after inhaler treatment, the child, parent, and nurse will be asked to fill out data collection forms to assess the child's anxiety and fear levels.
89567299|NCT06162598|Experimental|Ventriloquist Puppet group|The preparation for the procedure will be accompanied by a puppet before the treatment. The child will be told about the features of the puppet and will be introduced to it. The inhaler treatment application will be explained to the intervention group through the ventriloquist puppet method. By making the puppet talk using the ventriloquism technique, the child will be able to understand the procedure. The application of the inhaler will be shown to the child with the help of a nebulizer mask on the puppet. Before the application and after the inhaler treatment, the child, parent, and nurse will be asked to fill out the children's state anxiety scale and children's fear scale to evaluate the child's anxiety and fear levels.
89567300|NCT06162546||ARREST NEPHROSIS Participants|
88969643|NCT06004453||Cohort E|General practitioners
88969644|NCT06002555|Experimental|Single SC dose of 5 mg from DCS|
88969645|NCT06002555|Experimental|Two concomitant single SC doses of 2.5 mg from DCS|
89567301|NCT06162533||Vaccinated against SARS-CoV-2|"Individuals who received a SARS-CoV-2 vaccine but have no record of a previous SARS-CoV-2 infection.~Subgroups will be formed according to the number and type of vaccines against SARS-CoV-2."
89567302|NCT06162533||Previously SARS-CoV-2 infected|"Individuals who were previously infected with SARS-CoV-2 but have not received a SARS-CoV-2 vaccine.~Subgroups will be formed according to the number and time period of previous SARS-CoV-2 infections."
89567303|NCT06162533||Hybrid Immunity against SARS-CoV-2|"Individuals who received a SARS-CoV-2 vaccine and who were previously infected with SARS-CoV-2.~Subgroups will be formed according to the number and time period of previous SARS-CoV-2 infections, the number and type of vaccines against SARS-CoV-2, and according to whether the vaccination or the infection was the first immune conferring event."
88969646|NCT06002555|Active Comparator|Single SC dose of 5 mg from vial|
88969647|NCT05997875|Experimental|Education|
88969648|NCT05997875|Experimental|Education-Plus|
88969649|NCT05997875|Other|Usual Care|
88969650|NCT05997394|Experimental|Experimental Group|Participants in this group will be given a prayer concert for a month. At the end of one month, the severity of dyspnea, anxiety and spiritual well-being levels experienced by the participants will be re-checked.
88969651|NCT05997394|No Intervention|Control Group|There will be no prayer audience for participants in this group.
88969652|NCT05995704|Experimental|Apraglutide SC injections|
89567304|NCT06162533||No immunity against SARS-CoV-2|Individuals who have not received a SARS-CoV-2 vaccine and were not previously infected with SARS-CoV-2.
89567305|NCT06162520||Congenital biliary dilatation|Patients with congenital biliary dilatation diagnosed according to the Japanese Study Group on Congenital Biliary Dilatation (JSCBD) guideline.
89567306|NCT06162520||Secondary biliary dilatation|Patients with secondary biliary dilatation attributed to choledocholithiasis or malignancies (hilar cholangiocarcinoma, pancreatic carcinoma, and distal cholangiocarcinoma).
89567307|NCT06162507|Experimental|CM310 group A|CM310 injection, subcutaneous injection, once every 3 weeks.
89567308|NCT06162507|Experimental|CM310 group B|CM310 injection, subcutaneous injection, once every 2 weeks.
89567309|NCT06162481||Admitted during office hours|
89567310|NCT06162481||Admitted off hours|
89567311|NCT06162468|Experimental|Single-arm|Gemcitabine 19 mg per 1 ml of estimated cyst fluid + paclitaxel 3 mg per 1 ml of estimated cyst fluid + 0.9% sodium chloride solution, given as a single administration
89567312|NCT06162390|Experimental|Remifentanil for NIM tube intubation|
89567313|NCT06162338|Experimental|A Prospective, single-center, open, single-arm study|The study is single-arm. LY-M001 injection is administered by intravenous infusion at a rate of 1 mL per minute.LY-M001 Injection is Clear and colorless liquid.According to the dose cohort of the subject, the required dosage was accurately calculated by the patient's body weight for infusion.
88969653|NCT05995704|Placebo Comparator|Placebo|
88969654|NCT05993442|Experimental|Intervention group|"The sites randomised in this group will adapt the study intervention consisting of:~Component 1: Skin-to-skin contact for optimised KC, describes the targeted level of early, repeated and sustained skin-to-skin contact (StSC) considered to represent optimised KC in a high-technology neonatal unit environment in which KC is already offered as part of routine care.~Component 2: Implementation Support aims to engage clinical staff in the neonatal unit who are involved in implementing StSC as part of optimised KC."
88969655|NCT05993442|No Intervention|Control group|The sites randomised in this group will follow the standard care, including KC and StSC sessions, treatment of severe infections/sepsis and infection prevention and control measures based on current routine local practice. Standard care in all participating NICUs already includes KC but without specific activities to ensure this is implemented according to international best practice recommendations.
88969656|NCT05991479|Experimental|(Pilates exercises plus traditional physical therapy programme)|"Pilates exercises: The Pilates training protocol will take 60 min per session, including 10 min of warm up prior to initiating the Pilates technique, 40 min for Pilates exercises and 10 min for cool down. The number of repetitions will be 10 times. The patient will perform the following Pilates exercises: (Hundred exercises, spine stretch, single leg stretch , double leg stretch, criss cross, swimming, one leg kick, side kick, clam, one leg circle, shoulder bridge, hip twist, roll up and down and standing footwork).Pilates training (3 sessions/week) for 8 weeks.~traditional physical therapy programme: consisting of a supervised and individualized exercise programme for three sessions per week for eight weeks which will include:~Stretching exercises for calf and hamstring muscles.~Strengthening exercises for hip, knee, ankle, and foot muscles.~Deep friction massage for scar management:"
88969657|NCT05991479|Experimental|(traditional physical therapy programme)|"All patients will receive a traditional physical therapy programme consisting of a supervised and individualized exercise programme for three sessions per week for eight weeks which will include:~Stretching exercises for calf and hamstring muscles.~Strengthening exercises for hip, knee, ankle, and foot muscles.~Deep friction massage for scar management:"
88969658|NCT05989035|Active Comparator|Younger without MetAP2 inhibition|Participants between 18 and 30 years old without MetAP2 inhibition in conditioned media
88969659|NCT05989035|Active Comparator|Older without MetAP2 inhibition|Participants 65 years old and without MetAP2 inhibition in conditioned media
88969660|NCT05989035|Experimental|Younger with MetAP2 inhibition|Participants between 18 and 30 years old with MetAP2 inhibition in conditioned media
88969661|NCT05989035|Experimental|Older with MetAP2 inhibition|Participants 65 years old with MetAP2 inhibition in conditioned media
88969662|NCT05986500|Experimental|Galactose|The participants will receive a galactose infusion
88969663|NCT05986500|Experimental|Saline|The participants will receive a saline infusion
89567314|NCT06162299|Experimental|Low dose 0.5mL|Group A ：The first 4 enrollees in Group A will be sentinel patients and will be allocated at a 1:1 ratio to receive 0.5mL of either YS-HBV-002 or placebo(saline solution), The next 12 enrollees in Group A will be the main patients and will be allocated at 5:1 to receive 0.5mL of either YS-HBV-002 or placebo.
89567315|NCT06162299|Experimental|Mid-dose 1.0mL|Group B ：The first 4 enrollees in Group B will be sentinel patients and will be allocated at a 1:1 ratio to receive 1.0mL of either YS-HBV-002 or placebo(saline solution), The next 12 enrollees in Group A will be the main patients and will be allocated at 5:1 to receive 1.0mL of either YS-HBV-002 or placebo.
89567316|NCT06162299|Experimental|High dose 2.0mL|Group C ：The first 4 enrollees in Group C will be sentinel patients and will be allocated at a 1:1 ratio to receive 2.0mL of either YS-HBV-002 or placebo(saline solution), The next 12 enrollees in Group A will be the main patients and will be allocated at 5:1 to receive 2.0mL of either YS-HBV-002 or placebo.
89567317|NCT06162286|Active Comparator|Moxifloxacin|Moxifloxacin IV/PO
89567318|NCT06162286|Experimental|Omadacycline|Omadacycline IV/PO
89567319|NCT06162273||IBD stent of Shenzhen Xianjian Company and IBE stent of American Gore company|Patients underwent endovascular treatment for reconstruction of internal iliac artery in abdominal aortic aneurysm/iliac aneurysm repair. The lesion will be treated by IBD stent of Shenzhen Xianjian Company and IBE stent of American Gore Company.
89567320|NCT06162260||observation group|(1) Liver transplantation was performed between January 1, 2019 and December 31, 2019; (2) Age < 18 years; (3) The patient was admitted to ICU for the first time due to postoperative monitoring after liver transplantation; (4) Survival on first transfer from ICU.
89567321|NCT06162260||matched group|(1) Liver transplantation was performed between January 1, 2019 and December 31, 2019; (2) Age < 18 years; (3) The patient was admitted to ICU for the first time due to postoperative monitoring after liver transplantation; (4) survive the first transfer from ICU; (5) No ICU re-entry occurred in the same hospitalization period after liver transplantation.
89567322|NCT06162208|No Intervention|Home exercise group with information leaflet|These patients will be asked to do the exercises in the information leaflet themselves at home.
89567323|NCT06162208|Active Comparator|İnformation brochure+standard exercise program group based on telerehabilitation|Patients in this group will be followed up with telerehabilitation method accompanied by a physiotherapist for 30 minutes 3 times a week for 6 weeks after discharge.
89567324|NCT06162208|Active Comparator|İnformation brochure+standard exercise program+action observation therapy group.|Patients in this group will be followed up with telerehabilitation method accompanied by a physiotherapist for 30 minutes 3 times a week for 6 weeks after discharge. In addition, 15 minutes of movement observation therapy will be applied via video conferencing 3 days a week.
89567325|NCT06162195|Experimental|The H1 Implant|Cementless, ceramic-on-ceramic hip resurfacing arthroplasty (HRA) device.
89567326|NCT06162195|Active Comparator|Cementless total hip replacement|Cementless ceramic-on-poly or ceramic-on-ceramic total hip replacement
89567327|NCT06162182|Experimental|Reference test: Radiographic examination|
89567328|NCT06162182|Experimental|Index test: electrical impedance device, Prepometer|
89567329|NCT06162169|Experimental|JAB-21822+Itraconazole|
89567330|NCT06162169|Experimental|JAB-21822+ Rifampicin|
89567331|NCT06162169|Experimental|JAB-21822+ Omeprazole|
89567332|NCT06162169|Experimental|Dazolam , Rosuvastatin calcium and digoxin with JAB-21822|
89567333|NCT06162156|Experimental|back massage group|Volunteer women who meet the inclusion criteria after cesarean delivery will be selected by a random method, and verbal and written consent will be obtained from those included in the intervention group. Pre-test data twelve hours after cesarean delivery: 'Personal Information Form', 'Trait-Trait Anxiety Inventory', 'Postpartum Comfort Scale (PCS)', 'Bristol Breastfeeding Assessment Tool (BBAT)', 'Uterine Involution Evaluation Form ( UIEF)' 'Physiological Parameter Form (PPF)' and 'Visual Analog Scale (VAS)' will be filled in by the participants themselves using face-to-face interview technique in approximately twenty minutes. The intervention group will receive a twenty-minute back massage after the initial data is received. One hour after the massage, 'VAS' and 'PPF data will be filled in again. Post-test data twenty-four hours after the massage; 'Richard Campbell Sleep Scale', 'VAS, 'Trait-Trait Anxiety Inventory', 'PCS', 'BBAT, 'UIEF, 'PPF will be filled in again..
89567334|NCT06162156|No Intervention|control group|Volunteer women who meet the inclusion criteria after cesarean delivery will be selected by random method, and verbal and written consent of those included in the control group will be obtained. Pre-test data twelve hours after cesarean delivery: 'Personal Information Form', 'Trait-Trait Anxiety Inventory', 'Postpartum Comfort Scale (PCS)', 'Bristol Breastfeeding Assessment Tool (BBAT)', 'Uterine Involution Evaluation Form ( UIEF)' 'Physiological Parameter Form (PPF)' and 'Visual Analog Scale (VAS)' will be filled in by the participants themselves using face-to-face interview technique in approximately twenty minutes. The control group will not be massaged anywhere in the study. Thirteen hours after cesarean delivery, 'VAS' and 'PPF data will be filled in again. Posttest data twenty-four hours after cesarean delivery; 'Richard Campbell Sleep Scale', 'VAS, 'Trait-Trait Anxiety Inventory', 'PCS', 'BBAT, 'UIEF, 'PPF will be filled in again.
89567335|NCT06162078||Subgroup 1, Household longitudinal survey of nulligravida cohort|fieldworkers will visit the households in the study area to identify and enroll women meeting the eligibility criteria. After consenting a fingerprick blood sample will be obtained for pregnancy testing and malaria blood smear, and VAR2CSA antibodies measurement. Enrolled women will be visited every trimester to check for pregnancy and malaria infection. The follow up of each participant will end upon a pregnancy test is positive or at month 9 after the enrolment.
89567336|NCT06162078||Subgroup 2, Single timepoint evaluation for primigravidae 1rst, 2nd and 3 rd trimester|Participants will be enrolled by study staff stationed at the antenatal care clinic. Women attending the ANC visit at any gestational age will be screened and those meeting the eligibility criteria will undergo the study procedures which includes collecting demographic data, medical and pregnancy history. They will then be requested to donate a fingerprick blood sample for malaria infection and hemoglobin measurement.
89567337|NCT06162078||Subgroup 3, Single timepoint evaluation at primigravidae delivery|"participants will be recruited during any of the ANC visit as consenting process will not be feasible during the labour at delivery. They will be issued a sticker that will be affixed to the health card so that they could easily be recognized when they come for delivery.~At delivery, samples will be collected from fingerprick, cord blood and placenta for detecting malaria infection by microscopy and histopathology. Additional data will be collected on the neonate for secondary outcomes assessment, adverse birth outcomes ."
89567338|NCT06162065|Active Comparator|Group 1|women with overactive bladder will be treated using oral antimuscarinics for 4 weeks under strict medical indication, with a treatment scheme consisting of 10 mg tablet of oxybutynin once a day.
89567339|NCT06162065|Experimental|Group 2|5 women will receive combined oral treatment. 1 tablet of 10 mg once a day of oral of oxybutynin and they will also be supplemented with powder boldo capsules for 4 weeks under strict medical indication. This group will be supplemented with 1 capsules of 340 mg every 8 hours of boldo (take suggested by the manufacturer), for 5 days in a row and 5 days off.
89567340|NCT06161961|Experimental|prosthetic group|prosthetic group performs the entire protocol with the prosthesis prototype.
89567341|NCT06161909|Experimental|Group A|Postoperative adjuvant sintilimab 200mg fixed dose Q3W, immunotherapy will be administered for a total of 1 year.
89567342|NCT06161909|No Intervention|Group B|Close observation.
89567343|NCT06161883|Experimental|Soffritto group|After a two-week run-in phase, participants (N=20) were randomly assigned to the Soffritto group. For 6 weeks, volunteers received soffritto (100 g/day). After the initial six-week phase, there was a two-week washout period, followed by a second six-week period in which participants were placed in the control group.
89567344|NCT06161883|Experimental|Control group|After a two-week run-in phase, the participants (N=20) were randomly assigned to the control group. For 6 weeks, the volunteers did not receive any product. After the initial six-week run-in phase, there was a two-week washout period, followed by a second six-week period in which participants were switched to the Soffritto group (100g/day).
88969664|NCT05974553|Experimental|Dialectical Behavior Therapy for Justice-Involved Veterans|16 weeks of Dialectical Behavior Therapy for Justice-Involved Veterans
88969665|NCT05974553|Active Comparator|Supportive Group Psychotherapy|16 weeks of supportive group psychotherapy for justice-involved Veterans
88969666|NCT05951491|Experimental|Chronic Stroke|Individuals more than 6 months post-stroke in stable condition with long-term impairment affecting the arm and hand.
88969667|NCT05951036|Experimental|LL-BFRt|30% of repetition maximum and 70% of arterial occlusion pressure
88969668|NCT05951036|Sham Comparator|Sham LL-BFRt|30% of repetition maximum and 10% of arterial occlusion pressure
88969669|NCT05951036|Active Comparator|HL-Et|70% of repetition maximum
89567345|NCT06161870|Experimental|experimental group|The experimental group will be guided by the population pharmacokinetics (PK) model for individual dosing of vancomycin.
89567346|NCT06161870|Other|control group|The control group will be administered empirically (15-20 mg/kg vancomycin infused intermittently every 8-12 hours depending on the actual body weight of participants).
88969670|NCT05950009||Cases _major depression patients|subjects with moderate or severe major depression, without severe suicide ideation, as characterized by the Patient Health Questionnaire (PHQ)-9 index (values of 9 or greater) and by the Structured Clinical Interview for DSM-5 - (SCID) will be selected.
88969671|NCT05950009||Controls|subjects without mental health pathologies identified by SCID, who present an PHQ-9 index of 5 or below will be included as controls.
88969672|NCT05941962||Average Force Production|Average force production of bilateral lower extremities will be collected using the handheld dynamometer, Activbody Activ5.
88969673|NCT05936034|Active Comparator|Patients suffering from chemotherapy-induced ototoxicity|Arm 1: Patients with chemotherapy-induced ototoxicity who continue their usual care.
89567347|NCT06161818|Experimental|TNT FLOT-CROSS|Patients allocated to the TNT FLOT-CROSS arm will be treated with 4 cycles of FLOT chemotherapy followed by a response evaluation consisting of a CT-scan and upper endoscopy with bite-on-bite biopsies of the primary tumor site and of any other suspected lesions in the esophagus. Patients with distant metastases will go off-study. All other patients will proceed to CROSS chemoradiotherapy.
89567348|NCT06161818|Experimental|TNT CROSS-FLOT|Patients allocated to the TNT CROSS-FLOT arm will be treated with CROSS chemoradiotherapy followed by a response evaluation consisting of a CT-scan and upper endoscopy with bite-on-bite biopsies of the primary tumor site and of any other suspected lesions in the esophagus. Patients with distant metastases will go off-study. All other patients will proceed to FLOT chemotherapy.
89567349|NCT06161792|Placebo Comparator|I placebo capsule|"Subjects will be enrolled to about 14-days of placebo-run-in period.~Other Names:~RCN3028 placebo"
89567350|NCT06161792|Experimental|II RCN3028 0.8 mg capsule|"Subjects will be enrolled to about 14-days of placebo-run-in period. Treatment started at 0.4 mg, titrated to 0.8 mg for maintenance phase.~Other Names:~RCN3028 0.8 mg capsule"
89567351|NCT06161779|Experimental|Submental artery flap reconstruction group|
89567352|NCT06161766||Patients with HRS-AKI or HRS-AKI-like syndrome and chronic kidney disease|Patients with clinical suspicion of HRS-AKI or HRS-AKI-like syndrome in case of previously diagnosed chronic kidney disease (CKD) who who receive vasoactive treatment for the management of HRS, as defined by the administration of terlipressin or noradrenalin plus albumin.
89567353|NCT06161740|Active Comparator|Muscle strengthening group MSG|It was based on exercises for strengthening the hip adductor muscles associated with a bridge using a small exercise ball (two sets of 15 repetitions with seven seconds in isometry), strengthening the hamstrings with ankle weights in prone position, bilateral hip flexor strengthening in supine position with ankle weights, bilateral shoulder flexor strengthening with dumbbells, bilateral shoulder extensor strengthening with dumbbells, bilateral shoulder abductor strengthening with dumbbells, and bilateral serratus anterior muscle strengthening with dumbbells (all exercises, except the first, performed in three sets of 10 repetitions). Considering a 15-second interval between repetitions and a one-minute break between sets, totaling 30 minutes. The progression of each patient occurred through load progression.
89567354|NCT06161740|Experimental|Muscle strengthening associated with aerobic training group (MSGA)|It initially consisted of a five-minute warm-up, divided into two minutes of stationary marching and three minutes of jumping jacks. Subsequently, patients were instructed to climb up and down ramps, ascend and descend stairs, walk on a flat surface, and use a cycle ergometer (each task performed for five minutes). For the recovery phase, bilateral stretching of the hamstrings, rectus femoris, triceps brachii, pectoralis major, sternocleidomastoid, and scalene muscles was performed, each lasting 30 seconds per muscle. The proposed protocol was associated with the anaerobic training described in the GF (muscle strengthening group).
89567355|NCT06161727||Men with HPV-positive (HPV+) semen samples|
89567356|NCT06161727||Men with HPV-negative (HPV-) semen samples|
89567357|NCT06161714|Experimental|Right mandibular molar|Articaine 4% with 1:100,000 epinephrine
89567358|NCT06161714|Experimental|Left mandibular molar|Lidocaine 2% with 1:100,000
89567359|NCT06161701||Blood glucose management in patients with kidney disease after using glucocorticoids|Blood glucose monitoring for kidney disease patients after taking glucocorticoids
89567360|NCT06161688|Experimental|Ensitrelvir (S-217622)|Ensitrelvir fumaric acid (S-217622) given orally 375 mg on day 1 followed by 125 mg daily for 4 additional days
88969674|NCT05936034|Experimental|Patients suffring from chemotherapy-induced ototoxicity wearing hearing aids|Arm 2: Experimental group patients with chemotherapy-induced ototoxicity wearing a hearing aid to evaluate quality of life.
88969675|NCT05929404||Patients on antithrombotic medications|Participants undergoing ERCP procedure taking antithrombotic medications (including antiplatelet and/or anticoagulant medications) at baseline.
88969676|NCT05929404||Non-antithrombotic users|Participants undergoing ERCP procedure not taking antithrombotic medications (including antiplatelet and/or anticoagulant medications) at baseline.
88969677|NCT05925803|Experimental|Anifrolumab (subcutaneous weekly injection)|Anifrolumab subcutaneous injection once weekly
88969678|NCT05925803|Placebo Comparator|matched placebo control (subcutaneous weekly injection)|matched placebo control subcutaneous injection once weekly
89567361|NCT06161688|Placebo Comparator|Placebo|Placebo administered orally for 5 days
89567362|NCT06161662|Experimental|Transcutaneous electrical stimulation|At the beginning of anesthesia induction, the electrodes are attached to the skin at the Neiguan point and Shenmen point and connected to the percutaneous acupoint electrical stimulation device (Hwato , Suzhou Medical Equipment Factory). Electrical stimulation is given.
89567363|NCT06161662|Other|Control|At the beginning of anesthesia induction, the electrodes are attached to the skin at the Neiguan point and the Shenmen point without stimulation
89567364|NCT06161623|Experimental|Laughter Yoga Application|The intervention group took eight sessions of laughter yoga, that is, two sessions per week for 4 weeks. The participants in the intervention group were asked to fill in the data collection tools before the laughter yoga sessions, and after the 4th and 8th yoga sessions
89567365|NCT06161623|No Intervention|Control group|The participants in the control group also filled in the data collection tools without undergoing any intervention.
89567366|NCT06161597|Experimental|Informational Support|Parents will be told that they have the option of contacting an informational support specialist any point while completing the program to address questions and discuss the program. Parents will be informed that their questions can be addressed via e-mail or alternatively they can schedule a time to talk with their coach via phone or Zoom. The informational support specialist will not initiate contact with parents in this condition.
89028046|NCT05149248|Other|Group 1: MSM|Arm 1: HPV vaccination in an alternative schedule for MSM of 1 dose (M0). Arm 2: HPV vaccination in an alternative schedule for MSM of 2 doses over a 6-month period (M0,6) Arm 3: a control group will be screened for high-risk HPV and vaccinated at 12 months
89028047|NCT05149248|Other|Group 2: TRANSGENDER WOMEN|Arm 1: Transgender women
89567367|NCT06161597|Experimental|Guidance Coaching|Parents will be informed that they have been assigned a guidance coach who will contact them via email to schedule 1-3 check-in meetings over the phone or via Zoom while they complete the online program. These meetings are structured to help establish parental goals for the program, offer emotional support, and help motivate parents to implement new parenting skills. During these contacts, coaches use motivational interviewing techniques to help promote and support behavioral change. These coaching contacts are designed to be brief and focused, and typically last for less than 30 minutes. Coach contacts are scheduled based on the parents' availability and interest, and additional coaching sessions can be requested by the parent at any point during the program.
89567368|NCT06161480|Other|Weighted Blanket|To prevent and or mitigate delirium in adult ICU patients in urban and rural populations.
89567369|NCT06160492|Experimental|test group|The test group was set to administer a dose of 20 mg/kg body weight, and 3 hours before anesthesia (range 2-4 hours), 5-ALA HCl was dissolved in drinking water and taken orally, after which they underwent fluorescence-guided resection of malignant gliomas
89567370|NCT06160492|No Intervention|control group|The control group was operated by traditional white light microscope tumor resection, and all tumor tissues were removed as far as possible within the safety range. Cranial enhancement MRI was performed within 72h after surgery (60h-72h).
89567371|NCT06159361|Experimental|Balance targeted exercises group|participants in this group will receive the balance targeted exercises for up to 6 weeks
89567372|NCT06155786|Active Comparator|tDCS group|In tDCS, direct electrical currents at the intensity of 2 mA are generated by an electrical stimulator and are noninvasively delivered to the left and right dorsolateral prefrontal cortex through a pair of saline-soaked sponge electrodes (7×5 cm) for 30 minutes.
89567373|NCT06155786|Active Comparator|tRNS group|In tRNS, direct electrical currents at the intensity of 2 mA amplitude (offset at 1 mA) and frequency of 100-640 Hz are generated by an electrical stimulator and are noninvasively delivered to the left and right dorsolateral prefrontal cortex through a pair of saline-soaked sponge electrodes (7×5 cm) for 30 minutes.
89567374|NCT06155786|Sham Comparator|sham group|In sham group, placebo stimulation is generated by an electrical stimulator and is noninvasively delivered to the left and right dorsolateral prefrontal cortex through a pair of saline-soaked sponge electrodes (7×5 cm) for 30 minutes.
89567375|NCT06155773|Experimental|Highly viscous Glass Ionomer|Highly viscous glass ionomer restoration is used to elevate the subgingival cervical margin in deep class II cavities before receiving cad/cam onlay restoration
89567376|NCT06155773|Experimental|Low shrinkage Flowable Composite|Low shrinkage Flowable Composite restoration is used to elevate the subgingival cervical margin in deep class II cavities before receiving cad/cam onlay restoration
89567377|NCT06155773|Experimental|Resin Modified Glass Ionomer|Resin Modified Glass Ionomer restoration is used to elevate the subgingival cervical margin in deep class II cavities before receiving cad/cam onlay restoration
89567378|NCT06155773|Experimental|Bioactive Ionic Resin|Bioactive Ionic Resin restoration is used to elevate the subgingival cervical margin in deep class II cavities before receiving cad/cam onlay restoration
89567379|NCT06155591|No Intervention|Control Group|Usual care of complex and pluripathological chronic patients (CPCP)
89567380|NCT06155591|Experimental|Experimental Group|Usual care of CPCP + Community Nurse Case Manager (CNCM) standardized protocol
89567381|NCT06154811||Extubation Success Group|Extubation success is defined as the successful completion of a Spontaneous Breathing Trial (SBT) and the maintenance of spontaneous breathing without respiratory distress for at least 48 hours, without the need for non-invasive or invasive ventilation.
89567382|NCT06154811||Extubation Failure Group|Extubation failure is defined as successful Spontaneous Breathing Trial (SBT) but an inability to sustain independent breathing for more than 48 hours without non-invasive or invasive ventilation.
89567383|NCT06154720||Study Group|women who received co-amoxiclav 625gm (Megamox® film-coated tablet formed of clavulanic acid 125 mg + amoxicillin 500 mg) tab twice daily for 3 days after delivery
89567384|NCT06154720||Control Group|women who did not receive antibiotics.
89567385|NCT06154434|Experimental|Group A|
89567386|NCT06154434|Experimental|Group B|
89567387|NCT06154213|Experimental|Building Habits Together|The Building Habits Together arm includes the 24-week, Facebook-delivered lifestyle intervention based on the Diabetes Prevention Program and use of the Habit app (temptation tracking, exercise planning, and problem solving features).
89028048|NCT05149248|Other|GROUP 3: WOMEN AND MEN LIVING ON THE STREET|Arm 1: Women and men living on the street
89028049|NCT05149248|Other|GROUP 4: WOMEN AND MEN WHO HAVE SUFFERED RAPE|Women and men who have suffered rape
89028050|NCT05149248|Other|GROUP 5: WOMEN WHO ARE SEX WORKERS|Female sex workers
89028051|NCT01243541|Experimental|Arm I|Patients wear an Elasto-Gel cold glove and sock on their dominant hand and foot every two weeks on days the patient is scheduled for paclitaxel.The glove and sock is worn for 15 minutes prior to paclitaxel infusion, 3 hours during treatment, and for 15 minutes after completion of chemotherapy for a total of 210 minutes.
89567388|NCT06154213|Active Comparator|Getting Healthy Together|The Getting Healthy Together arm includes the 24-week, Facebook-delivered lifestyle intervention based on the Diabetes Prevention Program and use of the MyFitnessPal app (daily calorie tracking, exercise tracking).
89208641|NCT00977145|Experimental|intratumoral IFN-gamma plus MELITAC 12.1,|intratumoral IFN-gamma plus systemic vaccination with MELITAC 12.1, an emulsion of a mixture of 12 class I MHC-restricted melanoma-derived peptides (12-MP) and a class II MHC-restricted tetanus toxoid-derived helper peptide (Peptide-tet).
89208642|NCT05226000|Experimental|Benaglutide Injection|All subjects received multiple doses (tid) of 0.06 mg, 0.1 mg, 0.14 mg, and 0.2 mg in sequence, followed by the next dose after completing the previous multiple dosing. The administration time of each dose was 0.06 mg for 3 days, 0.1 mg for 3 days, 0.14 mg for 5 days, and 0.2 mg for 5 days.
89567389|NCT06154057|Experimental|Dental Implants installed in an grafted area (sinus lifting)|Dental implants produced by additive manufacturing installed in an area grafted with synthetic bone graft (Plenum® Osshp) - sinus lifting.
89567390|NCT06154057|Experimental|Dental Implants installed in an grafted area (ridge augmentation)|Dental implants produced by additive manufacturing installed in an area grafted with synthetic bone graft (Plenum® Osshp) - ridge augmentation.
89567391|NCT06154057|Experimental|Dental Implants installed in an grafted area (extraction sites)|Dental implants produced by additive manufacturing installed in an area grafted with synthetic bone graft (Plenum® Osshp) - extraction sites (socket preservation or dental implant preparation/placement).
89567392|NCT06153836|Active Comparator|ARM I (control)|Patients undergo standard of care NSM on study.
89567393|NCT06153836|Experimental|ARM II (neurotization)|Patients undergo neurotization during standard of care NSM on study.
89567394|NCT06153719|Active Comparator|Exercise group|
89567395|NCT06153719|Placebo Comparator|Control group|
89567396|NCT06153303|Experimental|treatment group|Acceptance and commitment therapy
89567397|NCT06150612|Experimental|Unwinding Anxiety|
89567398|NCT06150456|Experimental|Experimental: Group 1|15 patients who will only have their first teeth or second molars extracted.
89567399|NCT06150456|Experimental|Experimental: Group 2|15 patients who will have only their first or second molars extracted and will receive infrared laser treatment
89567400|NCT06150456|Experimental|Experimental: Group 3|15 patients who will have their first or second molars extracted and will receive a graft with scaffold biomaterial
89567401|NCT06150456|Experimental|Experimental: Group 4|15 patients who will have their first or second molars extracted and will receive a graft with scaffold biomaterial and infrared laser treatment
89567402|NCT06147518|Active Comparator|Metformin with Sitagliptin|Metformin: 1.5g/d CTPA,1g/d CTPB Sitagliptin: Assess HbA1c/HBSG at 8 weeks, increase sitagliptin to 100 mg if HbA1c>7%
89567403|NCT06147518|Experimental|Metformin with Dapagliflozin|"Metformin: 1.5g/d CTPA,1g/d CTPB~Dapagliflozin: Assess HbA1c/HBSG at 8 weeks, increase dapagliflozin to 10 mg if HbA1c>7%"
89028052|NCT01243541|Experimental|Arm II|Patients wear an Elasto-Gel cold glove and sock on their non-dominant hand and foot every two weeks on days the patient is scheduled for paclitaxel. The glove and sock is worn for 15 minutes prior to paclitaxel infusion, 3 hours during treatment, and for 15 minutes after completion of chemotherapy for a total of 210 minutes.
89028053|NCT04518033|Experimental|Face covering use|Participants will be provided various commercially available face coverings
89028054|NCT05149209|Experimental|Fluoride, calcium and phosphate-releasing new bioactive material (Activa™ Presto, Pulpdent®, USA).|ACTIVA Presto is a novel bioactive material with a mineral-enriched hydrophilic resin base and a patented rubberized component that resists abrasion and wear with high release and recharge of not only fluoride but also calcium and phosphate ions. It doesn't contain BIS-GMA, Bisphenol A, or BPA derivatives.
89028055|NCT05149209|Active Comparator|Fluoride-releasing hybrid restorative material (Giomer, Shofu, Japan).|Giomer is a hybrid restorative material that contains a resin base and pre-reacted glass ionomer. S-PRG (surface reaction type) technology provides some properties of GI such as fluoride release and recharge which helps prevent recurrent caries.
89567404|NCT06145698|Experimental|Experimental: theta-gamma tACS|The study is investigating the use of transcranial alternating current stimulation (tACS). For the experimental arm, the stimulation is delivered at 2 milliamperes (mA) with the stimulation electrode over the left prefrontal cortex (F3) and left orbitofrontal cortex (Fp1) using the cross-frequency stimulation waveform theta-gamma.
89567405|NCT06145698|Sham Comparator|Active-sham tACS|For the active sham stimulation, the stimulation is delivered for 12 seconds with the theta-gamma cross-frequency stimulation waveform and then returns to baseline. The stimulus parameter of the sham stimulation is designed to mimic the adaptive sensations experienced by the subject when receiving the real stimulation treatment settings, but no effective brain modulation will be produced, which assists with blinding the participant's assignment.
89567406|NCT06145048|Experimental|0.32 mg/kg VGT-309|0.32 mg/kg VGT-309 given over 15-20 minutes by syringe pump
89567407|NCT06144593|Experimental|Intermittent carbohydrate restriction|Four weeks of intermittent carbohydrate restriction: a dietary regime alternating between two days of restricting carbohydrate intake to 70-90 grams, while energy intake is ad libitum, from fat- and protein-containing foods, and two days of non-restricted diet.
89567408|NCT06144593|No Intervention|Control arm|Four weeks of free-living with no dietary restrictions.
89567409|NCT06143683|Experimental|Early Mobilization|
89567410|NCT06143683|Active Comparator|Usual Care|
89567411|NCT06140108|Experimental|Empagliflozin 10mg|Each participant will receive empagliflozin 10mg daily for 3 months
89567412|NCT06140108|Active Comparator|Metformin 500mg|Each participant will receive metformin 1000mg daily for 3 months
89567413|NCT06134440|Experimental|Arm A (interventional arm)|a low-fiber dietary advice + oral nutritional supplement enriched with immune-nutrients for 5 pre-operative days and 5 post-operative days.
89567414|NCT06134440|No Intervention|Arm B (control arm)|a low fiber dietary advice only
89567415|NCT06134258|Other|Fasting for 24 hours|
89567416|NCT06134258|Other|Fasting for 8 hours|
89567417|NCT06132139|Experimental|VisAR Navigation|Patients randomly assigned to this arm will have their EVD placed using VisAR navigation.
89567418|NCT06132139|No Intervention|Freehand Navigation|Patients randomly assigned to this arm will have their EVD placed using freehand navigation, the typical standard of care.
89567419|NCT06128889|Experimental|STRONG program|
89567420|NCT06114199|Active Comparator|Produce Prescription Program (PPRx) Standard|Participants will receive biweekly deliveries of 20 lbs (~50 servings) of fresh produce (8-10 different kinds of produce) plus standard nutrition education materials consisting of nutrition education infographics inside of the produce prescription boxes as well as online videos, recipes, and nutrition tips accessed via Quick Response (QR) code.
89567421|NCT06114199|Experimental|Produce Prescription Program (PPRx) Standard plus Smartphone App|Participants will receive biweekly deliveries of 20 lbs (~50 servings) of fresh produce (8-10 different kinds of produce) plus the same standard nutrition education materials provided to the control group consisting of nutrition education infographics inside of the produce prescription boxes as well as online videos, recipes, and nutrition tips accessed via Quick Response (QR) code. Additionally, participants will be given access to a smartphone app that allows women to interact with an artificial intelligence (AI) chatbot to obtain real-time cooking suggestions.
89567422|NCT06112015|Experimental|female athletes|21 female athletes from different branches performed 4 different sessions of Bulgarian split squat exercises.
89208643|NCT00803348|Active Comparator|1|Initial Bolus dose of 0.2% ropivicaine followed by 0.2% ropivicaine infusion until day 2 post-op
89208644|NCT00803348|Experimental|2|Initial Bolus dose of 0.2% ropivicaine followed by 0.1% ropivicaine infusion until day 2 post-op
89567423|NCT06108154|Experimental|Educational interventional Arm.|Interventional arm received educational supportive breastfeeding and hand on training session on Latch techniques according to UNICEF guideline.
89567424|NCT06108154|No Intervention|Control routine hospital care Arm.|Control. No interventions receive hospital routine care
89567425|NCT06106009|Experimental|Part A Cohort 1|Single dose administration of PF-07976016 and placebo. Participants will receive up to 4 dose levels of PF-07976016 or matching placebo.
88969679|NCT05923255|Experimental|LISH （Laparoscopic Ileocecal-Sparing Right Hemicolectomy）group|In LISH group, patients suffering from cancer of the hepatic flexure and proximal transverse colon will be undergoing a novel radical right hemicolectomy technique that allows for the preservation of the ileocecal region.
88969680|NCT05923255|Active Comparator|TRH （Traditional Right Hemicolectomy）group|In TRH group, patients suffering from cancer of the hepatic flexure and proximal transverse colon will be undergoing the traditional radical right hemicolectomy.
88969681|NCT05919784|Experimental|Cognitive behavioural therapy|The group therapy program (virtual, synchronous) involves elements based in Cognitive Behavioural Therapy (CBT), Acceptance and Commitment Therapy (ACT), and Dialectical Behaviour Therapy (DBT).
88969682|NCT05909514|Experimental|3 month PelvicSense(R) program|PelvicSense® is a home-based physiotherapy program integrating multiple techniques, including relaxation, breathing, stretching, strengthening and at-home manual therapy. This program also educates participants about the anatomy and physiology of the pelvis and teaches strategies to strengthen the mind-muscle connection to the pelvis.
88969683|NCT05908032|Experimental|CM310 group|Subcutaneous injection， CM310 4ml for first dose and 2ml for following dose
88969684|NCT05908032|Placebo Comparator|Placebo|Subcutaneous injection，matching placebo
89567426|NCT06106009|Experimental|Part A Cohort 2|Single dose administration of PF-07976016 and placebo. Participants will receive up to 4 dose levels of PF-07976016 or matching placebo.
89567427|NCT06106009|Experimental|Part A Optional Cohort 3|Single dose administration of PF-07976016 and placebo. Participants will receive up to 2 dose levels of PF-07976016 or matching placebo.
89567428|NCT06106009|Experimental|Part A Optional Cohort 4|Single dose administration of PF-07976016 and placebo. Participants will receive up to 4 dose levels of PF-07976016 or matching placebo.
89567429|NCT06106009|Experimental|Part B Cohort 5|Multiple dose administration of PF-07976016 or matching placebo.
89567430|NCT06106009|Experimental|Part B Cohort 6|Multiple dose administration of PF-07976016 or matching placebo.
88969685|NCT05905575|Experimental|Intervention|Patient-family member dyads in the family dyad intervention arm will receive 1) 14 sessions (8 weekly and 6 biweekly) over 20 weeks of family-dyad-focused, in-person group sessions on diabetes self-management and family support; 2) family dyad-focused support component in each group session; and 3) individual family feedback telephone sessions.
88969686|NCT05905575|No Intervention|Control|All control participants will receive usual care from their primary healthcare provider. A condensed family dyad diabetes intervention will be delivered to the control participants by the end of the study.
89028056|NCT00495209||Qigong|"Pre-surgical Qigong therapy for women with breast cancer~External Qi Therapy = EQT"
89208645|NCT00803348|Placebo Comparator|3|Initial Bolus dose of 0.375% ropivicaine followed by saline infusion until day 2 post-op
89208646|NCT00918047|Experimental|SPN-804O 150mg/Day|Subjects who weighed 15.0 to 29.9 kg dosed with SPN-804O 150mg/Day
89208647|NCT00918047|Experimental|SPN-8040 300mg/Day|Subjects who weighed 30.0 to 44.9 kg dosed with SPN-8040 300mg/Day
89567431|NCT06106009|Experimental|Part B Cohort 7|Multiple dose administration of PF-07976016 or matching placebo.
89567432|NCT06106009|Experimental|Part B Cohort 8|Multiple dose administration of PF-07976016 or matching placebo.
89567433|NCT06106009|Experimental|Part B Cohort 9|Multiple dose administration of PF-07976016 or matching placebo.
89567434|NCT06106009|Experimental|Part B Optional Cohort 10|Multiple dose administration of PF-07976016 or matching placebo.
89567435|NCT06106009|Experimental|Part C Optional Cohort 11|Single dose midazolam administered alone or in combination with multiple doses of PF-07976016.
88969687|NCT05892276|Experimental|CBD-WR|"300 mg CBD broad-spectrum oil will be administered within the reconsolidation window.~Preclinical studies demonstrate that the disruptive effects of CBD oil on memory reconsolidation depend on the timing of pharmacological administration (within 6 hours of memory reactivation).~Thus, participants will be asked to take a single 300mg oral dose of CBD broad-spectrum oil immediately after the trauma memory reactivation procedure."
89567436|NCT06106009|Experimental|Part C Optional Cohort 12|Single dose midazolam administered alone or in combination with multiple doses of PF-07976016.
89567437|NCT06106009|Experimental|Part D Optional Cohort 13|Multiple dose administration of PF-07976016 or matching placebo.
89567438|NCT06098729|Experimental|Digital Exercise|
89567439|NCT06097312||Participants|Pregnant women who received PREHEVBRIO® vaccine within 28 days prior to conception or at any time during pregnancy.
89567440|NCT06096935||Group 1|patients with type 2 diabetes complicated by active or chronic Charcot neuropathy
89567441|NCT06096935||Group 2|patients living with type 2 diabetes without active or chronic Charcot neuroarthropathy.
89567442|NCT06095401|Experimental|Inelastic adjustable compression garment (INCOM)|"Subjects randomized to the INCOM group will have a CircAid Juxtafit upper leg and knee garment combined with a lower leg garment (Medi USA, Whitsett, NC) applied to their limb at a minimum of 30mm Hg utilizing a standardized garment tensioning tool.~The experimental group will be instructed to wear their garments during all waking hours with a target wear time of >80% of waking hours for the first three weeks after surgery."
89567443|NCT06095401|Active Comparator|Elastic compression garment (CONTROL)|Subjects randomized to the CONTROL group will have a thigh-length elastic compression garment (thromboembolism-deterrent [TED] hose) applied to their limb. The control group will be instructed to wear their garments during all waking hours with a target wear time of >80% waking hours for the first three weeks after surgery.
89567444|NCT06087237|Experimental|Pentoxifylline group|oral Pentoxifylline 400 mg three times per day starting the day before the surgery till 2 weeks after surgery
89567445|NCT06087237|Placebo Comparator|Control group|oral placebo tablets three times per day starting the day before the surgery till 2 weeks after surgery
89567446|NCT06084247|Experimental|KARL STORZ Curved Scope|
88969688|NCT05892276|Placebo Comparator|PBO-WR|"Placebo oil will be administered within the reconsolidation window.~Participants will be asked to take a single dose of an MCT coconut oil placebo solution immediately after the trauma memory reactivation procedure."
88969689|NCT05892276|Active Comparator|CBD-OR|"300mg CBD broad-spectrum oil will be administered outside of the reconsolidation window.~Participants will be asked to take a single 300mg oral dose of CBD broad-spectrum oil approximately 24 hrs after the trauma memory reactivation procedure.~Thus, CBD will be administered well beyond the critical period for memory reconsolidation. The inclusion of this third arm provides a more robust test of the specific reconsolidation theory-based study hypotheses and aids in controlling for any nonspecific possible anxiolytic effects of CBD."
88969690|NCT05887986|Experimental|hand-held fan airflow stimulation|
88969691|NCT05887986|No Intervention|control group|
88969692|NCT05880875|Experimental|Reflective Supervision Enhancement|The Reflective Supervision enhancement is a professional development series for supervisors of state pre-kindergarten programs that is designed to build skills in using Reflective Supervision with teachers. The goal of the Reflective Supervision enhancement is to provide supervisors with foundational knowledge in Reflective Practice and Supervision and increase their use of Reflective Supervision principles and practices within their work. The series consists of a day-long foundational training and nine skills-focused workshops. Supervisors are expected to receive 8 hours of foundational training prior to the start of the academic year, and nine 2-hour monthly small groups over the course of the academic year.
89567447|NCT06084247|Active Comparator|Conventional scopes|
89567448|NCT06074315|Experimental|Nail Genesis DLSO Product|Nail Genesis DLSO Product, poly(urea-urethane) in carrier solvents, applied topically, once daily, to target toenail.
89567449|NCT06074315|Placebo Comparator|Vehicle|poly(urea-urethane) in carrier solvents, applied topically, once daily, to target toenail.
89567450|NCT06072664|Experimental|Caloric Compensation|The researchers will enroll 120 children from the long-term observational study, NCT06039878.
89567451|NCT06072651|Experimental|Relative Reinforcing Value|The researchers will enroll 120 children from the long-term observational study, NCT06039878.
89567452|NCT06072638|Experimental|Eating in the Absence of Hunger (single arm)|The researchers will enroll 120 children from the long-term observational study, NCT06039878.
89567453|NCT06070090|Experimental|Treatment Group|This is the group of participants who will receive group acupuncture after a ketamine experience.
89567454|NCT06067958|Active Comparator|Dexmedetomidine|Intranasal Dexmedetomidine 2 microgram/kilogram, 30 minutes before eye examination
88969693|NCT05880875|No Intervention|Business-As-Usual Waitlist Control|Supervisors in the business-as-usual waitlist control condition will supervise teachers as-per-usual (i.e., using standard administrative supervision), and will be eligible for the typical array of professional development opportunities that may be offered to them. These supervisors will receive the Reflective Supervision enhancement the following academic year.
88969694|NCT05879549|Experimental|Closed Chain Exercise Group|Closed kinetic chain exercises will be given under the supervision of a physiotherapist, 2 sessions a week for 12 weeks.
88969695|NCT05879549|Experimental|Proprioceptive Exercise Group|Proprioceptive exercises will be given under the supervision of a physiotherapist, 2 sessions a week for 12 weeks.
88969696|NCT05879549|No Intervention|Control Group|No intervention will be applied.
88969697|NCT05877105|No Intervention|pre-experimental|assessment of MV patients for VAP incidence and severity ICU staff for will be assessed for Compliance with implementing VAP prevention EBP
89208648|NCT00918047|Experimental|SPN-8040 450mg/Day|Subjects who weighed 45.0 to 59.9 kg dosed with SPN-8040 450mg/Day
89567455|NCT06067958|Placebo Comparator|Placebo|Saline 0.9%, volume will change to match that of dexmedetomidine based on participants' weight. 30 minutes before eye examination
89567456|NCT06062511|Experimental|Verum ESIT12 D|This arm receives 400 mg of ESIT12 and 150 mg of carriers from ESIT12
89567457|NCT06062511|Experimental|Verum ESIT12 4D|This arm receives 1600 mg of ESIT12 and 600 mg of carriers from ESIT12
89567458|NCT06062511|Placebo Comparator|Placebo|This arm receives 550 mg of carriers from ESIT12
89567459|NCT06034236|Experimental|Resistance Training|"In Group A, Task oriented resistance training will be performed, there will be 5 workstations which include 2 task each given in the table below, after warm up exercises of head, neck, trunk and ankle.~Workstation 1: Sitting and reaching in different directions Sit to stand from different chair heights (higher to lower) Workstation 2: Step training (forward, backward, sideways) on blocks Heel lifts-sitting, standing (with and without support) Workstation 3: Reaching with narrow stance (feet in parallel, then in tandem stance) Reciprocal leg flexion and extension Workstation 4: Sit ups Chair stand and walk Workstation 5: Walking race Walking over obstacles This intervention will be given 3 times per week for 4 weeks, every station takes 5-6 minutes and the total intervention will be completed in 50-60 minutes."
89567460|NCT06034236|Experimental|Otago Exercises|"Group B will be given Otago exercises, it has 17 exercises in total. 5 for strength and 12 for balance training.~First component of intervention starts with head movements followed by neck movements, back extension, trunk movements and ankle movements.~Muscle strengthening:~Font knee strengthening exercise Back knee strengthening exercise Side hip strengthening exercise Calf raises (with support and without support) Toe raise (with support and without support).~Balance Training:~Knee bends Backward walking Heel toe standing Heel toe walking One leg stand Heel walking Sideways walk Toe walking Heel toe walking backwards Walk and turn around (figure of 8) Sit to stand Stair walks This intervention will be given 3 times per week for 4 weeks, each session will take 50 minutes to complete. And every exercise is repeated 10 times"
89567461|NCT06034223|Experimental|Conventional Physical Therapy + Proprioceptive Training Using Head Mounted Laser|"Conventional physical therapy along with proprioceptive training, head relocation practice that is relocating the head back to the natural head posture and to pre determined postions in range with eyes open. Tracing figure of eight with eyes open.~3 days per week for 4 weeks, 15 repititions, 1 set."
89567462|NCT06034223|Other|Conventional Physical Therapy only|"Conventional physical therapy, cervical range of motion (flexion, extension, lateral flexion and rotation), isometric exercises of neck muscles, stretching (scalene, trapezius, sternocleidomastoid), TENS, heating pad.~3 days per week for 4 weeks, 15 repitions, 1 set."
89208649|NCT00918047|Experimental|SPN-8040 600mg/Day|Subjects who weighed 60.0 kg and above dosed with SPN-8040 600mg/Day
89567463|NCT06033872|Active Comparator|Intervention|Focused education, medication adjustment and telemonitoring
89567464|NCT06033872|No Intervention|Control|Standard care
89567465|NCT06033157|Active Comparator|Training|A 12 week physiotherapist supervised training program
89567466|NCT06033157|No Intervention|No-training|A short consultation with a designated orthopedic surgeon and a folder with general advice on how to avoid further dislocations and to relieve pain from the shoulder.
89567467|NCT06004752|Experimental|treatment group|"Cyclosporine: 3mg/kg/d 3-5mg/kg bid was administered to maintain the trough concentration at 100-200 μg/ml;~Avatrombopag: The dosage was 40~60mg orally, once a day, and the dosage was adjusted according to the subject's platelet count. The drug was administered for 24 weeks (6 months)."
89567468|NCT06003764|Experimental|Pulsed electromagnetic field group|Pulsed electromagnetic
89567469|NCT06003764|Placebo Comparator|Placebo group|traditional skin care
89567470|NCT06002581|Experimental|the early treatment group|stage1+stage2 real stimulation
89567471|NCT06002581|Other|the control group (delayed treatment group)|stage1 sham stimulation + stage2 real stimulation
89208650|NCT00980733|Active Comparator|Fortified Yoghurt|Yoghurt with fortification of Micronutrients, yoghurt fortified with 1/3rd RDA of iron, zinc, vitamin A and iodine. The salts used for fortification will be iron- Ferric pyrophosphate micronized, zinc - zinc gluconate, Iodine - Potassium Iodide, Vitamin A - Vitamin A acetate.
89208651|NCT00980733|Placebo Comparator|Yoghurt|Plain Yoghurt same as in fortified arm but without fortification
89208652|NCT00980733|No Intervention|Control|Non blinded group given no intervention
89567472|NCT05998239|Experimental|Bootle Boot Camp with movement tracking feedback (virtual Coach Botley present)|Bootle Boot Camp exercise sessions offered with movement tracking feedback through the presence of virtual coach Botley.
89567473|NCT05998239|Experimental|Bootle Boot Camp without movement tracking feedback (virtual Coach Botley absent)|Bootle Boot Camp exercise sessions offered without movement tracking feedback through the absence of virtual coach Botley.
89567474|NCT05996341|Experimental|LBPADIM_BFR group|"Recipient No. 12 lower ribs and upper rechargeable nylon ribs , charge to 160mmHg and do ADIM at the same time and retract the abdominal muscles and let the belly fold inward and upward toward the spine and hold for 10 seconds, once.~The total number of intervention was 20 minutes, once a time, a total of 4 minutes."
89567475|NCT05996341|Placebo Comparator|LBPADIM_shan BFR group|"The recipient has a rechargeable nylon rib under the 12th rib , but it is not filled and does not cause abdominal muscle BFR, which is used as the BFR of abdominal muscle.~At the same time, we also do ADIM authentication,and retract the abdominal muscles and let the belly fold inward and upward toward the spine and hold for 10 seconds, once.~The total number of intervention was 20 minutes, once a time, a total of 4 minutes."
89567476|NCT05996341|Experimental|HealthyADIM_BFR group|"Tested The top rechargeable nylon under the 12th rib , charge to 160mmHg and do ADIM password at the same time, and tand retract the abdominal muscles and let the belly fold inward and upward toward the spine and hold for 10 seconds, once.~The total number of intervention was 20 minutes, once a time, a total of 4 minutes."
89567477|NCT05971602|Experimental|Stage 1: Arm 1: DS-TB Participants receiving DBOS for 4 months (17 Weeks)|
89567478|NCT05971602|Experimental|Stage 1: Arm 2: DS-TB Participants receiving PBOS for 4 months (17 Weeks)|
89567479|NCT05971602|Experimental|Stage 1: Arm 3: DS-TB Participants receiving 2HRZE/4HR for 6 months (26 weeks)|Isoniazid (H), Rifampicin (R), Pyrazinamide (Z), Ethambutol (E) - refers to standard regimen of 8 weeks of HRZE followed by 18 weeks of HR (2HRZE/4HR)
89567480|NCT05971602|Experimental|Stage 2: Arm 1: DS-TB Participants receiving XBOS for 2 months (9 Weeks)|Pretomanid or Delamanid, Bedaquiline, OPC-167832, and Sutezolid (Regimen from Stage 1 that advances to Stage 2 [XBOS])
89567481|NCT05971602|Experimental|Stage 2: Arm 2: DS-TB Participants receiving XBOS for 2.5 months (11 Weeks)|
89567482|NCT05971602|Experimental|Stage 2: Arm 3: DS-TB Participants receiving XBOS for 3 months (13 Weeks)|
89567483|NCT05971602|Experimental|Stage 2: Arm 4: DS-TB Participants receiving XBOS for 3.5 months (15 Weeks)|
89567484|NCT05971602|Experimental|Stage 2: Arm 5: DS-TB Participants receiving XBOS for 4 months (17 Weeks)|
89567485|NCT05971602|Experimental|Stage 2: Arm 6: DS-TB Participants receiving 2HRZE/4HR for 6 months (26 Weeks)|
89567486|NCT05971602|Experimental|Observational cohort: RR/MDR-TB Participants receiving XBOS for 4 months (17 Weeks)|
89567487|NCT05971485||Melatonin group|Preterm neonates will receive melatonin 30 minutes before the venous cannula insertion.
89567488|NCT05971485||Control group|Preterm neonates will undergo venous cannula insertion without giving melatonin before the procedure.
89567489|NCT05957198||ILD patients|Health claims and Electronic Health Records of patients diagnosed with Interstitial Lung Disease (ILD)
89567490|NCT05955183|Active Comparator|AZD5055|Participants will orally receive AZD5055.
89567491|NCT05955183|Placebo Comparator|Placebo|Participants will orally receive placebo.
89028057|NCT05149170|Experimental|Inductive and concurrent anti-PD-1 antibody combined with radiotherapy|All the enrolled patients receive 2 doses of inductive anti-PD-1 antibody (Tislelizumab 200mg) every two weeks, and then Involved-site radiotherapy (50±6-10 Gy) with concurrent anti-PD-1 antibody (Tislelizumab 200mg) every two weeks.
89567492|NCT05946603|Sham Comparator|RARP + IS-002|Subjects will receive IS-002, but during surgery NO fluorescence imaging will be performed.
89028058|NCT02956226|Experimental|Cannabinoids - 99% pure cannabinoids mix|Oral cannabinoids mix [cannabidiol (CBD), Δ9-tetrahydrocannabinol (THC) in a 20:1 ratio] at 1 mg/kg cannabidiol per day, up-titrated until intolerance or to a maximum dose of 10 mg/kg CBD per day, divided to 3 daily doses, for 3 months.
89567493|NCT05946603|Experimental|RARP + IS-002 + intraoperative near-infrared imaging|Subjects will receive IS-002, and during surgery fluorescence imaging will be performed.
89567494|NCT05935514|Experimental|WW Intervention|Participants in the intervention arm will receive a voucher code that provides 12 months of access to the WW program and instructions for redeeming the code by study staff. The program will include access to weekly Virtual Workshops and the WW App. WW is a widely available, commercial behavioral weight management program that encourages healthy habits in the areas of food, activity, mindset, and sleep, with topics tailored specific to T2D. Participants will also be provided with the FreeStyle Libre 2 Flash Glucose Monitoring System to wear for the duration of the trial.
89567495|NCT05935514|Active Comparator|Usual Care|Patients in the Usual Care group will continue to receive routine medical care by their healthcare provider. In addition, within 4 weeks of the baseline visit, participants in the Usual Care group will receive one 50-minute virtual on-line session of nutrition counseling with a registered dietitian with additional materials at the time of their 6- and 12-month follow-up assessments, based on current recommendations of the American Diabetes Association.
89567496|NCT05928039|Active Comparator|TNFα antagonist|"Participants will receive either:~Infliximab 5 mg/kg intravenously [IV] at weeks 0, 2, 6, then 5 mg/kg every 8 weeks; OR~Adalimumab subcutaneously [SC] 160 mg at week 0, 80 mg at week 2, then 40 mg every 2 weeks"
89567497|NCT05928039|Active Comparator|Anti-IL12/23 or anti-IL23|"Participants will receive either:~Ustekinumab ~6 mg/kg IV x1, then 90 mg SC every 8 weeks; OR~Risankizumab 600 mg IV at weeks 0, 4, and 8, then 360 mg SC every 8 weeks"
89567498|NCT05928039|Active Comparator|Anti-integrin|"Participants will receive either:~Vedolizumab 300 mg IV at weeks 0, 2, and 6, then every 8 weeks; OR~Vedolizumab 300 mg IV at weeks 0 and 2, then 108 mg SC every 2 weeks"
89567499|NCT05903040||Episodic migraine|Patients affected by an episodic pattern (< 15 monthly headache days) migraine with or without aura according to ICHD-III criteria.
89567500|NCT05903040||Chronic migraine|Patients affected by chronic migraine according to ICHD-III criteria.
89567501|NCT05903027||Episodic migraine|Patients affected by an episodic pattern migraine(< 15 monthly headache days) with or without aura according to ICHD-III criteria.
89567502|NCT05903027||Chronic migraine|Patients affected by chronic migraine according to ICHD-III criteria.
89567503|NCT05896670|Experimental|licaminlimab (OCS-02)|60 mg/mL licaminlimab ophthalmic suspension
89567504|NCT05896670|Placebo Comparator|Vehicle|Vehicle of licaminlimab (OCS-02) ophthalmic suspension
89567505|NCT05889689|Experimental|Relationship Smarts Plus & Mind Matters|Relationship Smarts Plus (RSP+) is an adolescent pregnancy prevention curriculum that will be combined with lessons from a trauma-coping skills curriculum, Mind Matters (MM).
89567506|NCT05889689|Experimental|Relationship Smarts Plus|Relationship Smarts Plus (RSP+) is an adolescent pregnancy prevention curriculum.
89567507|NCT05889689|Active Comparator|Control Group|Financial literacy curriculum, Preparing Adolescents for Young Adulthood (PAYA)
89567508|NCT05878249|Experimental|wound lavage with normal saline|after removing caries and achieving hemostasis wound lavage of the exposed pulp will be done with 5 ml of Normal saline for 30 seconds
89567509|NCT05878249|Experimental|wound lavage with sodium hypochlorite|after removing caries and achieving hemostasis wound lavage of the exposed pulp will be done with 5 ml of 2.5% sodium hypochlorite (NaOCl) for 30 seconds
89567510|NCT05878249|Experimental|wound lavage with Ethylenediaminetetraacetic acid(EDTA)|after removing caries and achieving hemostasis wound lavage of the exposed pulp will be done with 12%Ethylenediaminetetraacetic acid(EDTA) for 5 minutes
89567511|NCT05878249|Experimental|wound lavage with sodium hypochlorite followed by Ethylenediaminetetraacetic acid|after removing caries and achieving hemostasis wound lavage of the exposed pulp will be done with 5 ml of 2.5%sodium hypochlorite (NaOCl) for 30 seconds followed by 12%Ethylenediaminetetraacetic acid(EDTA) for 5 minutes
89567512|NCT05862870|Experimental|painTRAINER pain management web application|This is a patient-administered pain management training program delivered in 10 sessions over 8 weeks. Each session is composed of different skills useful for managing chronic pain. Each session is also accompanied by recommendations for skills practice to be done between sessions.
88969698|NCT05877105|Experimental|experimental|"The intervention group of patients will receive the proposed VAP prevention EBP which consists of ten items bundle.~also, assessment of MV patients for VAP incidence and severity ICU staff for will be assessed for Compliance with implementing VAP prevention EBP"
89028059|NCT02956226|Placebo Comparator|Placebo|Oral olive oil and flavors that mimic in texture and flavor the cannabinoids' solution.
89567513|NCT05862493|No Intervention|Standard management|Standard preoperative management, no preoperative TTE
89567514|NCT05862493|Experimental|FOCUS optimization|Standard preoperative management AND preoperative FOCUS along with an individualized hemodynamic optimization based on FOCUS findings.
89567515|NCT05842343|Experimental|Acute anorexia nervosa|patient diagnose for a first episode of pure restrictive anorexia nervosa will be included. They will have stool sample and Food intake evaluation.
89567516|NCT05842343|Experimental|Chronic anorexia nervosa|Patient diagnose for anorexia nervosa at least 5 years ago and still maintaining a significant thinness will be included. They will have stool sample and Food intake evaluation.
89567517|NCT05842343|Placebo Comparator|Healthy control|Healthy Patient will be included. They will have stool sample and Food intake evaluation.
89567518|NCT05822492||Group QLB3|Patients who applied the QLB3 block before PCNL surgery were included in this group.
89567519|NCT05822492||Group ESPB|Patients who applied ESP block before PCNL surgery were included in this group.
89567520|NCT05822492||Group Control|Patients who did not use any block before PCNL surgery were included in this group.
88969699|NCT05875168|Experimental|Dose Escalation (Part 1)|Participants with locally advanced, metastatic, or unresectable tumors who will receive an intravenous (IV) infusion of DS-3939a.
88969700|NCT05875168|Experimental|Dose Expansion (Part 2)|Multiple expansion cohorts targeting various advanced solid tumors.
88969701|NCT05869604|Experimental|HEALTHY AYA|Participants randomized to the intervention arm will receive an 8 session intervention providing instruction in cognitive and behavioral symptom coping strategies as well as behavioral strategies to improve diet and decrease sedentary time.
88969702|NCT05869604|Other|Education Control|Participants randomized to the education control arm will receive information about topics of relevance to adolescent and young adult cancer survivors including sleep, cognitive problems, finances, sexual health, and return to work/school.
88969703|NCT05852821|Experimental|remote 5STS through videoconference|
88969704|NCT05850416|Experimental|mGlide-Care|mHealth mediated HTN care model with self-monitoring and medication adjustment
88969705|NCT05850416|Active Comparator|Usual Care Plus|Usual Care including self-monitoring support
88969706|NCT05846009|Experimental|SAR442501|
88969707|NCT05846009|Placebo Comparator|Placebo|
88969708|NCT05843773|Experimental|Low Load Strength Training under Blood Flow Restriction|Low Load Strength Training under blood flow restriction
88969709|NCT05839730|Experimental|Pacemaker with multiple pacing therapies enabled|Device will be programmed for personalized lower rate pacing (PLR) and tachycardiac remodeling pacing (TRT).
88969710|NCT05839730|Active Comparator|Pacemaker with modified pacing therapy on|Device will be programmed for personalized lower rate pacing (PLR).
88969711|NCT05838027|No Intervention|Control|No intervention
88969712|NCT05838027|Experimental|Cash Transfer|Participants will receive $125 every 2 weeks for 8 payments via ClinCard, for a total of $1000.
89567521|NCT05820659|Experimental|stress inducing task|Adolescents will complete an adapted peer rejection task on the computer to elicit the experience of subtle racial discrimination from White peers, as well as an impossible puzzle task to elicit cognitive stress.
89567522|NCT05820256|Experimental|Milk Protein Isolate (MPI)|Study participants in the MPI group will consume 2 smoothies per day for 31 days, where each smoothie provides 300 kcal in total, composed of 45% from carbohydrate (maltodextrin), 20% from protein (milk protein isolate) and 35% from fat (a blend of flaxseed, safflower, and coconut oils). Each smoothie will be mixed with water up to volume of 250mL. Individuals in this group will not consume soy-containing beverages and foods during the 31-day study.
89608837|NCT03585699|Active Comparator|CT guided Spinal Biopsy Arm|CT guided spinal biopsies were done by radiologist under guidance of 128-slice CT scanner (SOMATOM Definition AS+, Siemens Medical Solutions USA, Inc.). Preliminary axial CT scanning was done in bone window (window width, WW:2500; window level, WL:500) at the pre-selected levels decided from previous imaging to plan the needle access. Biopsy was then performed under sequential CT-fluoroscopy scan.
89567523|NCT05820256|Experimental|Soy Protein Isolate (SPI)|Study participants in the SPI group will consume 2 smoothies per day for 31 days, where each smoothie provides 300 kcal in total, composed of 45% from carbohydrate (maltodextrin), 20% from protein (soy protein isolate) and 35% from fat (a blend of flaxseed, safflower, and coconut oils). Each smoothie will be mixed with water up to volume of 250mL. Individuals in this group will not consume dairy-containing beverages and foods during the 31-day study.
89567524|NCT05800405|Experimental|Treatment (leukapheresis, external beam radiation, CAR-T)|Patients undergo leukapheresis per standard of care, undergo external beam radiation therapy, and undergo CAR T-cell infusion per standard of care on study. Patients undergo PET/CT throughout the study and may undergo MRI during screening. Patients also undergo blood sample collection throughout the study.
89567525|NCT05776251|Experimental|PTLD - active taVNS|Participants with Post-treatment Lyme Disease (PTLD) will start with 40 sessions (i.e., 4 weeks of Monday to Friday, twice daily treatments that last 1 hour each session) to receive transcutaneous auricular Vagus Nerve Stimulation (taVNS). If compliance is less than 70% in at least 3 of the first 4 open label treated participants, then the investigators will modify the treatment design accordingly.
89567526|NCT05774977|Experimental|Group 1: A B C D E F|"Subjects will be exposed to six different conditions during a sleep period from 2300-0700. All subjects will experience all six conditions in a randomized and balanced fashion. Conditions #1-6 will be randomly assigned to letters A-F.~After an adaptation night with no interventions on Night 1, subjects will receive the following exposure sequence on Nights 2-7: A B C D E F"
89567527|NCT05774977|Experimental|Group 2: B D A F C E|"Subjects will be exposed to six different conditions during a sleep period from 2300-0700. All subjects will experience all six conditions in a randomized and balanced fashion. Conditions #1-6 will be randomly assigned to letters A-F.~After an adaptation night with no interventions on Night 1, subjects will receive the following exposure sequence on Nights 2-7: B D A F C E"
89567528|NCT05774977|Experimental|Group 3: C A E B F D|"Subjects will be exposed to six different conditions during a sleep period from 2300-0700. All subjects will experience all six conditions in a randomized and balanced fashion. Conditions #1-6 will be randomly assigned to letters A-F.~After an adaptation night with no interventions on Night 1, subjects will receive the following exposure sequence on Nights 2-7: C A E B F D"
89567529|NCT05774977|Experimental|Group 4: D F B E A C|"Subjects will be exposed to six different conditions during a sleep period from 2300-0700. All subjects will experience all six conditions in a randomized and balanced fashion. Conditions #1-6 will be randomly assigned to letters A-F.~After an adaptation night with no interventions on Night 1, subjects will receive the following exposure sequence on Nights 2-7: D F B E A C"
89567530|NCT05774977|Experimental|Group 5: E C F A D B|"Subjects will be exposed to six different conditions during a sleep period from 2300-0700. All subjects will experience all six conditions in a randomized and balanced fashion. Conditions #1-6 will be randomly assigned to letters A-F.~After an adaptation night with no interventions on Night 1, subjects will receive the following exposure sequence on Nights 2-7: E C F A D B"
89567531|NCT05774977|Experimental|Group 6: F E D C B A|"Subjects will be exposed to six different conditions during a sleep period from 2300-0700. All subjects will experience all six conditions in a randomized and balanced fashion. Conditions #1-6 will be randomly assigned to letters A-F.~After an adaptation night with no interventions on Night 1, subjects will receive the following exposure sequence on Nights 2-7: F E D C B A"
89567532|NCT05773261|Active Comparator|MobilLINK TrabecuLINK cup|"The investigational device in this study is the newly developed MobilLINK TrabecuLINK cup. It will in this study be combined with a uncemented LCU stem.~The MobilLINK TrabecuLINK cups are made from Tilastan, a Ti6A4V alloy. The MobileLINK press-fit shells are hemispheric and polar flattened. An equatorial press-fit is built into the shells for primary stability after cementless implantation. All shells have a polar hole, which is used to connect an impactor handle for implantation of the shell. This polar hole can be closed with a polar screw. The MobileLINK TrabecuLINK shells have a 3D printed trabecular surface structure with a pore size of 610 to 820 μm and a porosity of 70 %."
89567533|NCT05773261|Active Comparator|Pinnacle Gription Series 100 cup|"For the control group a Pinnacle Gription cup series 100 with a apex hole eliminator will be used together with a neutral cross-linked polyethylene (XLPE) Marathon liner (DePuy Synthes by Johnson & Johnson, Norderstedt, Germany). The Pinnacle Gription cup is a hemispherical, single-geometry, titanium press-fit cup with a solid body. The outer surface consists of a porous coating with 300 μm sintered titanium beads coated with an extra layer of irregularly shaped pure titanium pieces. In cases where no initial stability can be reached when using the Pinnacle 100 series, the Pinnacle Gription sector cup with additional bone screws will be used. The cross-linked Marathon insert is made of 1050 GUR resin, irradiated with 50 kGy, remelted and plasma sterilized.~The Pinnacle Gription cup will be implanted together with a Corail stem (DePuy Synthes)."
89567534|NCT05742646|Active Comparator|MATADORS app basic information|
89567535|NCT05742646|Experimental|MATADORS app to include basic information and expanded educational features|
89567536|NCT05724030|Active Comparator|integrated pulmonary index hypoxia -capnogarph|integrated pulmonary index montorization apliied
89567537|NCT05724030|Experimental|saturation - apnea|saturation apllied
89567538|NCT05702281|Other|ReLARC 3|"ReLARC® is a GyneFix® device intended to be inserted via hysteroscopy. Hysteroscopic insertion of the device allows direct visualization of the procedure, which makes it extremely safe.~ReLARC® 3 is inserted through a hysteroscope (KARL STORZ HOPKINS® Wide Angle Straight Forward Telescope 6°, art. no. 26208AMA in combination with the irrigation pump Endomat® select)."
89567539|NCT05702281|Other|ReLARC 10|"ReLARC® is a GyneFix® device intended to be inserted via hysteroscopy. Hysteroscopic insertion of the device allows direct visualization of the procedure, which makes it extremely safe.~ReLARC® 10 is inserted through a hysteroscope (KARL STORZ HOPKINS® Wide Angle Straight Forward Telescope 6°, art. no. 26208AMA in combination with the irrigation pump Endomat® select)."
89567540|NCT05698121|Experimental|Intervention|The intervention group will use an eHealth application during the waiting period before cardiac rehabilitation starts.
89567541|NCT05698121|No Intervention|Control|The control group will go through the usual waiting period before the start of cardiac rehabilitation.
89567542|NCT05695417|Active Comparator|OTX-TKI|
89567543|NCT05695417|Sham Comparator|Sham|
89567544|NCT05694676||Mothers|Mothers aged 18 to 40 years, who have singleton pregnancy.
89028060|NCT02956226|Experimental|Cannabinoids - whole plant extract|Oral cannabinoids mix [cannabidiol (CBD), Δ9-tetrahydrocannabinol (THC) in a 20:1 ratio] at 1 mg/kg cannabidiol per day, up-titrated until intolerance or to a maximum dose of 10 mg/kg CBD per day, divided to 3 daily doses, for 3 months
89028061|NCT04516473||Experimental/Body Contouring Intervention|These are participants who have self-selected to undergo an abdominal body contouring procedure within the course of the study.
89028062|NCT04516473||Control/Post Massive Weight Loss Matched Control|"These are participants who have similar characteristics to the body contouring intervention group, but they will not undergo any surgical procedure during the course of the study.~The addition of this matched control group with a similar degree of excess skin but who will not be undergoing body contouring surgery will control for any changes in physical function which may occur without any intervention within the testing sessions. This group will also control for any learning effects between testing sessions."
89028063|NCT00492440|Experimental|CYT107 (r-hIL-7)|
89567545|NCT05694676||Infants|Infants were born at 36-42 weeks of gestation without complication.
89567546|NCT05688748|Experimental|Dengue monitoring system|The participants will be given access to download a dengue self-monitoring application and use the application at home to key in their symptoms, three times a day throughout their outpatient follow up for dengue.
89567547|NCT05688748|No Intervention|Usual care|Patients will be managed as per usual outpatient care for dengue in the clinic.
89567548|NCT05677581||pregnancy and lactation period women|
89567549|NCT05677581||healthy women of childbearing age|
89567550|NCT05675007|Experimental|Colon-delivered multivitamin supplement|Within this arm, study subjects will consume a colon-delivered multivitamin supplement for 6 weeks. Subjects are instructed to consume the capsule daily during breakfast. The capsule must be taken orally with a glass of water.
89567551|NCT05675007|Placebo Comparator|Placebo|Within this arm, study subjects will consume a placebo capsule for 6 weeks. Subjects are instructed to consume the capsule daily during breakfast. The capsule must be taken orally with a glass of water.
89567552|NCT05655507|Experimental|Zuranolone|Participants will be enrolled to receive Zuranolone orally, during the daytime on Day 1 and in the evening on Days 2 to 14. The first 10 enrolled participants will receive 50 mg (participants with a body weight of 54 kg or greater) or 40 mg (participants with a body weight less than 54 kg) once daily. The remaining participants will receive 40 mg once daily with the opportunity to down titrate to 30 mg if 40 mg is not tolerated.
89567553|NCT05622591|Experimental|ELU001|Dose Escalation: Escalating doses of ELU001
89567554|NCT05622110|Experimental|One abdominal side|Arm randomized for adhesive glue closure
89567555|NCT05622110|Experimental|Second abdominal side|Arm randomized for subcuticular suture closure
89567556|NCT05622097|Experimental|Warmed saline|0.9% Saline will be warmed to 37 degrees Celsius
89567557|NCT05622097|Experimental|Room temperature saline|0.9% Saline will be warmed to 24 degrees Celsius
89567558|NCT05610072|Experimental|n-Acetylcysteine|Subjects will receive 0.6 g oral n-acetylcysteine 4 times per day.
89567559|NCT05610072|Placebo Comparator|Placebo|Subjects will receive oral placebo 4 times per day.
89567560|NCT05609123||Brain dead organ donors|Patients with clinically proven bain death were assigned to the paraclinical confirmatory investigation of the brain death and subsequently accepted into the transplantation program.
89567561|NCT05604300|Active Comparator|Vitamin E incorporated oat|Oral vitamin E incorporated oat supplementation
89567562|NCT05604300|Placebo Comparator|Placebo|Oral oat supplementation
89567563|NCT05604300|No Intervention|Control|Control
89567564|NCT05603884|Experimental|treatment arm|2 cycles of VCA regimens followed by 2 cycles of D-MAG regimens, and then repeat the above four courses of treatment once
89567565|NCT05599386||Patients Undergoing VATS|Only one group as primary endpoints are continous
89567566|NCT05597150|Experimental|Experimental Group|
89567567|NCT05596214|Experimental|Curcumin-Berberine (coptis) therapy|Cur-Berberine (Coptis) treatment will consist: 2 capsules of 500 mg Berberine (Coptis) before breakfast (a total of 1.0gr Berberine) and 3 capsules of 500mg curcumin before dinner (a total of 1.5gr curcumin).
89567568|NCT05596214|Placebo Comparator|Placebo|2 capsules of 500 mg placebo before breakfast and 3 capsules of 500mg placebo before dinner.
89567569|NCT05594199|Experimental|Intervention Arm: Virtual Group|The intervention will involve participating in the study's virtual smoking cessation program. This program consists of 2 components: an e-learning module and a tailored email messaging program based on the participant's motivation to quit smoking and their Fagerstrom test for nicotine dependence score.
89567570|NCT05594199|No Intervention|Control Arm: Standard Care|"This arm will receive standard care which may or may not include brief advice to quit smoking from any of the healthcare providers.~Providing smoking cessation intervention is not mandatory in standard care and may not be provided."
89567571|NCT05589233||Patients COVID-19 positive admitted to the hospital|COVID-19-positive patients admitted eighter to the standard ward or intensive care unit who were vaccinated against SARS-Cov-2
89567572|NCT05587049||Venetoclax + Azacitidine Participants|Participants treated with venetoclax in combination with azacitidine in accordance with approved local label.
89567573|NCT05575076|Experimental|Simufilam 100 mg|simufilam 100 mg oral tablet, twice daily
89567574|NCT05565105|Experimental|Regimen A: TBI/Thiotepa/Cyclophosphamide|"Patients in enrolled in Regimen A will receive the following:~Total Body Irradiation (TBI), hyper-fractionated to a dose of 1320 cGy depending on age, stage of disease and requirement of general anesthesia with lung shielding~Thiotepa, 5 mg/kg/day x 2 days via IV infusion over 4 hours daily or 10 mg/kg on one day~Cyclophosphamide, 60 mg/kg/day x 2 days via IV infusion over 2 hours daily (or if cyclophosphamide is contraindicated, fludarabine at 25 mg/m^2 x 5 days may be substituted)"
89567575|NCT05565105|Experimental|Regimen B: Busulfan/Melphalan/Fludarabine|"Patients in enrolled in Regimen B will receive the following:~Busulfan, IV 0.8 mg/kg q6hours x 10 or 12 doses over 3 days, depending on the disease~Melphalan, 70 mg/m^2/day x 2 days via IV infusion over 30 minutes daily~Fludarabine, 25 mg/m^2/day x 5 days via IV infusion over 30 minutes daily"
89567576|NCT05539807|Experimental|Intervention|All participants receive the intervention
89567577|NCT05534971|Active Comparator|Standard technique|The conventional hollow bore needle on a syringe will be used
89567578|NCT05534971|Experimental|Peripheral IV|A peripheral intravenous catheter will be used to obtain initial central venous access
89567579|NCT05530135|Placebo Comparator|Control Group|Takotsubo patients receiving standard care
89567580|NCT05530135|Active Comparator|Exercise Group|Takotsubo patients who will undergo an exercise program in addition to standard care
89567581|NCT05530135|Active Comparator|CBT Group|Takotsubo patients who will receive cognitive behavioural therapy in addition to standard care
89567582|NCT05523674|Experimental|warm-up performed at 30% VO2max|The warm-up exercise will be performed on an ergometric treadmill, through a protocol of 15 minutes duration, with the first 5 minutes of acceleration, until reaching 30% of VO2max, the following 5 minutes of maintenance and the remaining 5 minutes being of slowdown.
89567583|NCT05523674|Experimental|warm-up performed at 80% VO2max|The warm-up exercise will be performed on an ergometric treadmill, through a protocol of 15 minutes duration, with the first 5 minutes of acceleration, until reaching 80% of VO2max, the following 5 minutes of maintenance and the remaining 5 minutes being of slowdown.
89567584|NCT05523674|Experimental|warm-up performed at 30% VO2max with Blood Flow Restriction|The warm-up exercise will be performed on an ergometric treadmill, through a protocol of 15 minutes of duration, with the first 5 minutes of acceleration, until reaching 30% of VO2max, the following 5 minutes of maintenance and the remaining 5 minutes being of slowdown. During the warm-up exercise, a pressure cuff will be used on each leg, with the blood flow restriction technique (80% of arterial occlusion pressure).
89567585|NCT05500001|Experimental|Family Psychoeducation Intervention Arm|These participants will receive the psychoeducation intervention and outcome measures will be taken from them and their young adult service user. The intervention includes psychoeducation on stages of a family's journey, the biopsychosocial basis of psychosis, and skills for coping (Acceptance and Commitment Therapy for Caregivers) and communicating (LEAP).
89567586|NCT05499676|Experimental|Mobile Coached Intervention|Participants randomized to the mobile intervention condition will receive access to the mobile app for 6 consecutive months. Participants will still be able to access other usual care options and will be encouraged to follow the discharge plan provided to them by the eating disorder program from which they were discharged.
89567587|NCT05499676|Experimental|Mobile Coached Intervention Plus Social Networking|Participants randomized to the mobile intervention plus social networking condition will receive access to the mobile app, as well as Facebook social networking component, for 6 consecutive months. Participants will still be able to access other usual care options and will be encouraged to follow the discharge plan provided to them by the eating disorder program from which they were discharged.
89567588|NCT05499676|No Intervention|Treatment as Usual|This group will be encouraged to follow the discharge plan provided to them by the eating disorder program from which they were discharged. Participants will also be encouraged to follow-up with their eating program for additional referral information as needed and/or to reach out to the National Eating Disorders Association (NEDA) and/or Association for Anorexia Nervosa and Associated Disorders (ANAD ) for assistance with finding treatment providers/resources as needed. NEDA and ANAD provide helplines and online treatment provider databases to help individuals find providers.
89567589|NCT05489250||HCC (Hepatocellular cancer)|Hepatocellular cancer patients with NGS based molecular tumor profiling
89567590|NCT05489250||CCA/GBCA (Intra-, extrahepatic cholangiocellular carcinoma or gallbladder cancer)|Intra-, extrahepatic cholangiocellular carcinoma or gallbladder cancer patients with NGS based molecular tumor profiling
89567591|NCT05489250||PanCa (Pancreatic cancer)|Pancreatic cancer patients with NGS based molecular tumor profiling
89567592|NCT05489250||EC/GC (Oesophagogastric cancer)|Oesophagogastric cancer patients with NGS based molecular tumor profiling
88969713|NCT05837455|Experimental|Low-risk group|"Baseline breast MRI and research specimen collection prior to the start of treatment with standard of care anastrozole. All patients will have one 28-day cycle of anastrozole, followed by determination of breast cancer risk category by incorporating results from baseline Ki67, Oncotype DX RS, and molecular intrinsic subtype by PAM50.~An additional blood draw for research purposes at Week 4 (no breast tumor biopsy at this time point) and continue to receive 5 additional 28-day cycles of anastrozole.~After completion of ~6 months of neoadjuvant treatment, will undergo post-treatment breast MRI followed by standard of care surgery."
88969714|NCT05837455|Experimental|High-risk endocrine-sensitive group|"Baseline breast MRI and research specimen collection prior to the start of treatment with standard of care anastrozole. All patients will have one 28-day cycle of anastrozole, followed by determination of breast cancer risk category by incorporating results from baseline Ki67, Oncotype DX RS, and molecular intrinsic subtype by PAM50.~An additional blood draw and breast tumor biopsy at Week 4 to assess Ki67. Patients with Week 4 Ki67 ≤10% (the high-risk endocrine-sensitive group) will continue to receive 5 additional 28-day cycles of anastrozole.~After completion of ~6 months of neoadjuvant treatment, will undergo post-treatment breast MRI followed by standard of care surgery."
89028064|NCT04518501|Experimental|study group|Fuzuloparib Capsules plus table Arsenic Trioxide po
89028065|NCT00495248|Experimental|1|
89028066|NCT00495248|Active Comparator|2|
89028067|NCT05149053|Experimental|Food Supplement|Food supplement packet taken one per day preferably in the morning for 6 months.
89028068|NCT05149053|Placebo Comparator|Control|Placebo packet taken one per day preferably in the morning for 6 months.
89567593|NCT05477979||Cohort 1: advanced NSCLC patients receiving first-line ICIs (STRESS-LUNG-1 study)|For stage IIIB-IV patients with NSCLC who have received immune checkpoint inhibitors as first-line therapy.
89028069|NCT00495287|Active Comparator|A|"Remission induction arm A is with conventional chemotherapy cycle (ICE: idarubicin, standard-dose cytarabine, etoposide)"
89028070|NCT00495287|Experimental|B|Remission induction therapy with high-dose cytarabine sequential regimen (HD-Ara-C, idarubicin)
89028071|NCT00495326|Experimental|1|Nevirapine-based ART
89028072|NCT00495326|Active Comparator|2|Efavirenz-based ART
89567594|NCT05477979||Cohort 2: limited-stage and extensive-stage SCLC patients receiving ICIs (STRESS-LUNG-2 study)|For limited-stage and extensive-stage SCLC patients who have received immune checkpoint inhibitors
89567595|NCT05477979||Cohort 3: NSCLC patients receive neoadjuvant therapy of ICIs（STRESS-LUNG-3 study）|For stage IB-IIIB patients with non-small cell lung cancer who have received neoadjuvant therapy of immune checkpoint inhibitors.
89567596|NCT05477979||Cohort 4: NSCLC patients receive radical resection (STRESS-LUNG-4 study))|For early-stage patients with non-small cell lung cancer who have received radical resection.
89567597|NCT05444335|Other|Intervention arm|Women older than 70 who would wear the Zio patch for 2 weeks
89567598|NCT05443737|Experimental|Multi-component oncofertility care intervention|Eligible cancer patients presenting to oncology clinical visits will receive care through the multi-component oncofertility care intervention.
89567599|NCT05443737|No Intervention|Usual Care|Eligible cancer patients presenting to oncology clinical visits will receive usual care.
89567600|NCT05430334|Experimental|Combination One - 16μg/s protonated nicotine flux|The investigators will test the subjective effects of nicotine flux (16μg/s) coupled with one ratio of nicotine form (100% protonated). Following a one-hour observation period, participants will use Subox Mini C in a 10-puff directed (30sec inter-puff interval) bout. One hour after the first bout, participants will be instructed to puff on the device for 60-min ad libitum. Subjective measures (i.e., nicotine dependence, drug effects, product liking, and craving) will be administered 5 times/session: 5 min before and 5 min after onset of the directed bout and 5 min before, halfway into and 5 min after onset of the ad libitum bout.
89567601|NCT05430334|Experimental|Combination Two - 32μg/s protonated nicotine flux|The investigators will test the subjective effects of nicotine flux (32μg/s) coupled with one ratio of nicotine form (100% protonated). Following a one-hour observation period, participants will use Subox Mini C in a 10-puff directed (30sec inter-puff interval) bout. One hour after the first bout, participants will be instructed to puff on the device for 60-min ad libitum. Subjective measures (i.e., nicotine dependence, drug effects, product liking, and craving) will be administered 5 times/session: 5 min before and 5 min after onset of the directed bout and 5 min before, halfway into and 5 min after onset of the ad libitum bout.
89567602|NCT05430334|Experimental|Combination Three - 16μg/s free base nicotine flux|The investigators will test the subjective effects of nicotine flux (16μg/s) coupled with one ratio of nicotine form (100% free base). Following a one-hour observation period, participants will use Subox Mini C in a 10-puff directed (30sec inter-puff interval) bout. One hour after the first bout, participants will be instructed to puff on the device for 60-min ad libitum. Subjective measures (i.e., nicotine dependence, drug effects, product liking, and craving) will be administered 5 times/session: 5 min before and 5 min after onset of the directed bout and 5 min before, halfway into and 5 min after onset of the ad libitum bout.
89567603|NCT05430334|Experimental|Combination Four - 32μg/s free base nicotine flux|The investigators will test the subjective effects of nicotine flux (32μg/s) coupled with one ratio of nicotine form (100% free base). Following a one-hour observation period, participants will use Subox Mini C in a 10-puff directed (30sec inter-puff interval) bout. One hour after the first bout, participants will be instructed to puff on the device for 60-min ad libitum. Subjective measures (i.e., nicotine dependence, drug effects, product liking, and craving) will be administered 5 times/session: 5 min before and 5 min after onset of the directed bout and 5 min before, halfway into and 5 min after onset of the ad libitum bout.
89567604|NCT05430334|Placebo Comparator|Placebo - Combination Five - 0μg/s nicotine flux|The investigators will test the subjective effects of nicotine flux (0μg/s) placebo. Following a one-hour observation period, participants will use Subox Mini C in a 10-puff directed (30sec inter-puff interval) bout. One hour after the first bout, participants will be instructed to puff on the device for 60-min ad libitum. Subjective measures (i.e., nicotine dependence, drug effects, product liking, and craving) will be administered 5 times/session: 5 min before and 5 min after onset of the directed bout and 5 min before, halfway into and 5 min after onset of the ad libitum bout.
89567605|NCT05426213|Other|Robot-assisted Bronchoscopy|Participants with 8-50 millimeters (mm) diameter size lung lesions identified on computed tomography (CT) scan will be enrolled for robotic assisted bronchoscopy (Monarch Platform) biopsy procedure.
89567606|NCT05418907||Patients with confirmed paraganglioma|10 patients with confirmed PGL who have undergone CT, somatostatin receptor (SSTR) PET/CT and 18F-FDG PET/CT (as standard diagnostic procedures) and are scheduled for surgery.
89567607|NCT05395026|Experimental|Investigational Stimulation Parameters|
89567608|NCT05387434|Experimental|DPP-R|Weekly 60 min. group meetings, lead by trained KSRE staff, (12-15 participants) will be held by Zoom over 6 months followed by monthly 60 min. group meetings for the later 6 months. Approximately 5 min prior to the meeting time (typically early evening) participants will receive call in information to join the group meeting by video conferencing or phone.
89608838|NCT03580239|Experimental|Everolimus & Best Supportive Care|Everolimus will be administered at a dose of 10mg/day orally once a day. One cycle of therapy consists of 28 days.The patients also receive the best supportive care.
88969715|NCT05837455|Experimental|High-risk endocrine-resistant group|"Baseline breast MRI and research specimen collection prior to the start of treatment with standard of care anastrozole. All patients will have one 28-day cycle of anastrozole, followed by determination of breast cancer risk category by incorporating results from baseline Ki67, Oncotype DX RS, and molecular intrinsic subtype by PAM50.~An additional blood draw and breast tumor biopsy at Week 4 to assess Ki67. Patients with Week 4 Ki67 >10% (the high-risk endocrine-resistant group) will receive escalated therapy with ~5-6 additional months of standard of care chemotherapy (combination anthracycline- and/or taxane-based at the discretion of their physician).~After completion of ~6 months of neoadjuvant treatment, will undergo post-treatment breast MRI followed by standard of care surgery."
88969716|NCT05830773|Experimental|App Trial|Use of the smartphone app
88969717|NCT05826743|Experimental|COLO BT™|Patients receive COLO BT™ during colorectal surgery.
88969718|NCT05826743|Active Comparator|Standard of Care|Patients receive the standard of care, a protective stoma, during colorectal surgery.
88969719|NCT05822466|Active Comparator|Virtual tai ji quan|Participants participating are intervened with practice and drills of tai ji quan forms and associated movements. Training focuses on lower-extremity strength, postural control, and mobility, with an emphasis on weight bearing and weight shifting, extending and controlling the body's center of mass over its base of support; self-induced movement perturbation; gait preparation, initiation, locomotion, and termination; and sensory integration. The exercise training also emphasizes connecting tai ji quan forms to transitional movements that are associated with performing daily activities. Each session includes brief movement-based warm-ups and light breathing cool-down exercises.
89567609|NCT05387434|Experimental|DPP-FB|Participants will be asked to join a secret, research team moderated, Facebook® group, which is only accessible by group members. The health educator will post the module, de-identified participant self-monitoring data, and comment on individuals posts weekly. Brief discussion prompts are designed to reinforce the primary objectives of each module and to facilitate inter-participant discussion around these topics. Responses will be monitored and tracked. This is analogous to attendance in the Zoom® group.
89567610|NCT05345132|Active Comparator|A|Nifedipine + Magnesium sulfate
89567611|NCT05345132|Active Comparator|B|Magnesium Sulfate
89028073|NCT04515927|Experimental|subcutaneous injection of JS002, 450mg, Q4W, 3/13 times.|
89028074|NCT05148936|Experimental|At home testing (Aim 1)|High-risk friends and family of contacts exposed to COVID-19 will be provided with COVID-19 testing provided at home by a healthcare worker.
89567612|NCT05343806|Active Comparator|Nifedipine|The initial dose of nifedipine will be 2 × 10 mg nifedipine capsules orally in the first hour, followed by 20 mg slow-release nifedipine every 6 hours for the next 47 hours. In the first hour after starting nifedipine, blood pressure and heart rate will be measured every 15 minutes. If blood pressure remains within the normal limits, treatment will be continued.
89567613|NCT05343806|Active Comparator|Magnesium Sulfate|Women will receive only MgSo4. A loading dose of MgSo4 will be given immediately after enrollment as 4 gm diluted in 200 mL of saline solution administered intravenous over a period of 20 minutes. Afterwards, the maintenance dose of MgSo4 will be administered intravenous in a dose of 1 gm/hour given as 6 gm diluted in 500 mL saline solution titrated with a rate of 100 mL per hour, then this dose is repeated every 6 hours for 48 hours. Respiratory rate and knee jerk will be assessed hourly for women in the MgSo4 group. Serum magnesium level will be measured if clinically indicated.
89567614|NCT05343312|Active Comparator|Artemether-Lumefantrine (AL)|AL (Coartem™) will be administered twice daily for three days (six doses in total) with dosage determined according to body weight: one tablet (20mg artemether and 120mg lumefantrine) for children 5 to <15kg, two tablets per dose for those 15 to <25kg, and three tablets per dose for those 25 to <35kg.
89567615|NCT05343312|Active Comparator|Amodiaquine-Artesunate (AS-AQ)|AQ-AS (Coarsucam™) will be administered once daily according to body weight: one 25mg artesunate and 67.5mg amodiaquine tablet in children <9kg, one 50mg artesunate and 135mg amodiaquine tablet in children 9-17.9kg; and one 100mg artesunate and 270mg amodiaquine tablet in children >18-35kg.
89567616|NCT05343312|Active Comparator|Dihydroartimisin+Piperaquine (DHP)|DHP will be administered once daily according to body weight: tablet (40 mg dihydroartimisin+artesunate) half in children 5 < 10kg, one in children 10 < 20kg and 2 tablets for those children over 20 kg.
89567617|NCT05343312|Active Comparator|Pyronaridine +Artesunate (PA)|PA will be administered once daily according to body weight: granule ( 60 mg pyronaridine + 20 artesunate), one in children 5 < 7kg, two in children 8 < 15kg and three in children 15 < 20kg. Tablets ( 180 mg pyronaridine+ 60 mg artesunate), one in children 20 < 24Kg and two in children 24 < 45Kg.
89567618|NCT05328960||Patients diagnosed before, during or after the pandemic|Patients with rectal cancer
89567619|NCT05326308||Waldenström's Macroglobulinemia|75 patients (excluding screening failures, patients with off-label use or with violation of inclusion/exclusion criteria identified after treatment start) receiving zanubrutinib (Brukinsa®)
89567620|NCT05326308||Chronic Lymphocytic Leukemia|250 patients (excluding screening failures, patients with off-label use or with violation of inclusion/exclusion criteria identified after treatment start) receiving zanubrutinib (Brukinsa®)
89567621|NCT05326308||Marginal Zone Lymphoma|37 patients (excluding screening failures, patients with off-label use or with violation of inclusion/exclusion criteria identified after treatment start) receiving zanubrutinib (Brukinsa®)
89567622|NCT05326308||Follicular Lymphoma|38 patients (excluding screening failures, patients with off-label use or with violation of inclusion/exclusion criteria identified after treatment start) receiving zanubrutinib (Brukinsa®) in combination with obinutuzumab (Gazyvaro®)
89567623|NCT05324254|Experimental|Heavier blanket|A heavier blanket will be worn overnight for 3 months. Blanket weight cannot be disclosed without unblinding participants.
89567624|NCT05324254|Experimental|Lighter blanket|A lighter blanket will be worn overnight for 3 months. Blanket weight cannot be disclosed without unblinding participants.
89567625|NCT05324254|No Intervention|Waitlist control|No blanket will be provided until the end of the study; participants will sleep with their normal bedding.
89567626|NCT05319808|Experimental|Group A|Telehealth using NeckCare equipment
89567627|NCT05319808|Active Comparator|Group B|Exercises without telehealth intervention
89567628|NCT05319808|No Intervention|Group C|No intervention provided by the researchers
89567629|NCT05318300|Experimental|Tested formula LP-2018|infant formula containing fibers
89567630|NCT05318300|Placebo Comparator|Placebo formula CT-2018|infant formula without fibers
89567631|NCT05315700|Experimental|Dose Escalation and Dose Optimization|ORIC-114 dosed orally on a continuous daily dosing regimen in 28-day cycles.
89567632|NCT05315700|Experimental|Combination Dose Escalation|ORIC-114 dosed orally on a continuous dosing regimen in 21-day cycles.
89567633|NCT05313256|Experimental|Experimental group|In this arm patients will receive for epidural extension a Lidocaine epinephrine buffered with sodium bicarbonate.
89567634|NCT05313256|Active Comparator|Comparator group|In this arm patients will receive for epidural extension only Lidocaine epinephrine.
89567635|NCT05305859|Experimental|venetoclax combining chidamide and azacitidine (VCA)|"28 days per cycle × at least 2 cycles；~1) chidamide 30mg biw × 2weeks；2) venetoclax 200mg/d × 2 weeks 3) azacitidine 100mg/d d1-7"
89567636|NCT05302271|Experimental|First Dose Cohort|AAVrh.10hFXN will be administered intravenously.
89567637|NCT05302271|Experimental|Second Dose Cohort|AAVrh.10hFXN will be administered intravenously.
89028075|NCT05148936|Active Comparator|Mobile testing (Aim 1)|High-risk friends and family of contacts exposed to COVID-19 will be referred to study operated mobile testing sites in the community for COVID-19 testing.
89028076|NCT05148936|Other|Mobile testing approach 1 (Aim 2)|Mobile testing utilizing active outreach
89608839|NCT03580239|Placebo Comparator|Placebo & Best Supportive Care|Placebo will be administered at a dose of 10mg/day orally once a day. One cycle of therapy consists of 28 days.The patients also receive the best supportive care.
89567638|NCT05281731|Experimental|Sonobiopsy|"Once enrolled, participants would be prepared for standard of care surgery.~The sonobiopsy involves the standard procedure for a biopsy, but the biopsy needle is replaced with a customized ultrasound probe, a standard ultrasound contrast agent (microbubbles) is injected intravenously, and the probe is turned on for 3 minutes for the sonobiopsy. Then the planned surgery to remove the tumor will occur.~An additional brief MRI scan will be obtained using the intraoperative MRI to define imaging changes (if any) that occur as a result of the sonobiopsy procedure. The imaging protocols will include a 3D T2-weighted (T2w) scan, and 3D contrast T1-weighted (T1w) with dynamic contrast enhancement and if time allows T2* sequence.~Blood will be collected at several time points.~A small skin biopsy or another blood draw will be drawn for comparison against the genetic mutations shown in the tumor.~The blood, tumor, and skin (if applicable) will undergo genetic analysis."
89567639|NCT05275959|Other|Intervention|Intervention measures will be taken against children and adolescents' myopia and obesity at four levels: individual (individual centered activities), environment (supportive family and school settings), and supervision (family, school, program team, and clinical) and feedback (timely feedback from the WeChat applet).
89567640|NCT05275959|No Intervention|Control|health education
89567641|NCT05269381|Experimental|Treatment (cyclophosphamide, vaccine, pembrolizumab)|"Patients receive cyclophosphamide IV on day -3. Patients then receive personalized neoantigen vaccine with sargramostim SC on days 1, 4, 8, and 15 of cycle 1 and day 1 of cycles thereafter. Patients also receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Patients may undergo blood sample collection during screening, cycle 1 days -3, 1, 8, 15, 22, cycles 2, 3, 4, 5, 7, 8 and 9+ day 1 and 30 days after last dose of GM-CSF or pembrolizumab and may undergo tissue biopsy during screening, week 25 or at the time of disease progression. Patients also undergo CT or MRI during screening, week 9 then every 9 weeks, and 30 days after last dose of GM-CSF or pembrolizumab."
89567642|NCT05247827|No Intervention|Control Group|Participants will receive usual and customary post-amputation treatment
89567643|NCT05247827|Experimental|Exercise Group|Participants will be trained for 3 consecutive weeks to perform the targeted exercise of their phantom limb in addition to receiving usual and customary post-amputation treatment.
89567644|NCT05227209|Experimental|SEP-4199 CR|SEP-4199 CR either 200 mg (one 200 mg tablet) or 400 mg (two 200 mg tablets) once daily
89567645|NCT05223582|Experimental|Fluzoparib and abiraterone treatment group|Patients would be treated with 1000mg abiraterone qd. Patients would be treated with 150mg fluzoparib bid. Patients would be treated with 5mg prednisone bid. Patients would get medical castration.
89567646|NCT05206448|Active Comparator|Letrozole|Letrozole 2.5 mg orally for 5 days on cycle days 3-7 in first study treatment cycle. Participants who ovulate and do not become pregnant will repeat the same treatment protocol for their next study cycle. Participants who do not ovulate will repeat the protocol with Letrozole dose increase of 2.5 mg daily in the next treatment cycle, to a maximum dose of 7.5 mg in the 3rd cycle.
89567647|NCT05206448|Experimental|Letrozole + Clomiphene Citrate|Letrozole 2.5 mg orally for 5 days on cycle days 3-7 AND Clomiphene Citrate 50 mg orally for 5 days on cycle days 3-7. Participants who ovulate and do not become pregnant will repeat the same treatment protocol for their next study cycle. Participants who do not ovulate will repeat the protocol with Letrozole dose increase of 2.5mg daily in the next treatment cycle to a maximum dose of 7.5 mg in the 3rd cycle, while maintaining the same dose of Clomiphene Citrate.
89567648|NCT05193604|Experimental|TQB2858 injection|"Cohort 1: TQB2858 injection administered intravenously on day 1 of each 21-day cycle.~Cohort 2: TQB2858 injection administered intravenously on day 1 of each 21-day cycle, gemcitabine and albumin paclitaxel administered intravenously on day 1 and day 7 of each 21-day cycle.~Cohort 3: TQB2858 injection administered intravenously on day 1 of each 21-day cycle，gemcitabine and albumin paclitaxel administered intravenously on day 1 and day 7 of each 21-day cycle，Anlotinib capsules 8 mg given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)."
89567649|NCT05188261|Experimental|Cohort 1: 100 μg IW-3300|Dose 1: within the cohort, 6 participants receive active drug (IW-3300)
89567650|NCT05188261|Placebo Comparator|Cohort 1: Placebo|Within the cohort, 2 participants will receive the matching placebo dose
89567651|NCT05188261|Experimental|Cohort 2: 300 μg IW-3300|Dose 2: within the cohort, 6 participants receive active drug (IW-3300)
89567652|NCT05188261|Placebo Comparator|Cohort 2: Placebo|Within the cohort, 2 participants will receive the matching placebo dose
89567653|NCT05188261|Experimental|Cohort 3: 900 μg IW-3300|Dose 3: within the cohort, 6 participants receive active drug (IW-3300)
89567654|NCT05188261|Placebo Comparator|Cohort 3: Placebo|Within the cohort, 2 participants will receive the matching placebo dose
89567655|NCT05188261|Experimental|Cohort 4: 2500 μg IW-3300|Dose 4: within the cohort, 6 participants receive active drug (IW-3300)
89567656|NCT05188261|Placebo Comparator|Cohort 4: Placebo|Within the cohort, 2 participants will receive the matching placebo dose
88969720|NCT05822466|Active Comparator|Virtual multimodal exercise|Participants participating are intervened with a multicomponent exercise program that involves light walking, strength, postural control, and flexibility exercises. Walking exercises include amble forward and backward walk, long strides, heel-toe walking, narrow- and wide-base walking, and sidestepping. Strength training includes single- and multi-joint exercises such as semi-squats, lunging forward and sideways, and toe stands that involve exercising ankle dorsiflexors, knee extensors, and hip abductors. Balance training involves semi-tandem foot-standing, heel-toe and line walking, single-leg standing, alternation of the base of support, weight transfers, toe and heel movements, and various reaching and stretching movements away from the center of the base of support. Flexibility exercises include a static stretching routine of major upper and lower body muscle groups. Each session includes brief movement-based warm-ups and light breathing cool-down exercises.
89028077|NCT05148936|Other|Mobile testing approach 2 (Aim 2)|Mobile testing utilizing baseline outreach approaches
89028078|NCT00495404|Other|Arm 1|
89028079|NCT00495404|Other|Arm 2|
89567657|NCT05181553|Experimental|Canada's Food Guide principles (CFG diet)|During 28 days, participants will receive de CFG diet. The CFG diet emphasizes low intakes of red and processed meats and high intakes of minimally processed plant foods with water as the drink of choice, as per Canada's Food Guide. The number of portions of protein foods, whole-grains, fruits and vegetables to be served daily reflects the recommended ¼-¼-½ proportions. Regarding protein quality, vegetable proteins are served more often than animal proteins as stated in Canada's Food Guide. Weekly, red meat is served once, two days are meatless, and one day is free of animal products.
89567658|NCT05181553|Experimental|Standard North American diet (NAD diet)|During 28 days, participants will receive de NAD diet. The NAD diet reflects current dietary intakes of the French-Canadian adult population in terms of foods, nutrients, and diet quality, as characterized in recent surveys conducted in an age- and a sex-representative sample of adults from the Province of Quebec. Intakes of minimally processed fruits and vegetables will be low; animal proteins, mostly red and processed meats, will be consumed more often than vegetable proteins; grains will be mostly refined; and ready-to-eat/ready-to-heat foods and sugary beverages will be served daily.
89567659|NCT05159999|Experimental|Home Systolic Blood Pressure <140 mmHg|Participants will take their home blood pressure two times per week (one in the morning and one in the evening) on non-dialysis days, ideally mid-week. Home blood pressures will be reviewed every two weeks and dry weight and medications adjusted accordingly to reach a home systolic blood pressure target of <140 mmHg.
89567660|NCT05159999|Active Comparator|Pre-Dialysis Systolic Blood Pressure <140 mmHg|Participants will have their blood pressure taken by an automated blood pressure device by dialysis unit staff using regular dialysis unit equipment according to usual clinical care. Pre-dialysis blood pressures will be reviewed every two weeks and dry weight and medications adjusted accordingly to reach a pre-dialysis systolic blood pressure target of <140 mmHg.
89567661|NCT05159999|Other|Home Systolic Blood Pressure <130 mmHg|This will be an optional, exploratory 2 month study at the end of the primary 10-month trial. Participants will take their home blood pressure two times per week (one in the morning and one in the evening) on non-dialysis days, ideally mid-week. Home blood pressures will be reviewed every two weeks and dry weight and medications adjusted accordingly to reach a home systolic blood pressure target of <130 mmHg.
89567662|NCT05153876||Participants|Participants filling in the questionnaires
89567663|NCT05146245|Experimental|Therapeutic Drug Monitoring|Physicians receive dosing advice based on measured blood levels of risperidone and 9-OH-risperidone.
89567664|NCT05146245|Active Comparator|Care As Usual|Physician decides on possible dosing changes without receiving advice based on blood levels.
89567665|NCT05145387|Experimental|TEAMSS Intervention in the RCT|Students randomly assigned to the TEAMSS intervention will receive the 5th and 6th grade components.
89567666|NCT05145387|No Intervention|Enhanced Usual Care in the RCT|Enhanced Usual Care (EUC) will serve as the comparison group. EUC will be comprised of written materials (given all at once after randomization by study team) for parents and children that include: 1) a specialty mental health referral list; 2) a list of websites and books on child anxiety; and 3) tip sheets on successful transitions to MS. Families in this condition will not be prohibited from seeking treatment (though this will be monitored) for their children. These students will visit and meet with the 6th grade clinician in the spring of 5th grade.
89567667|NCT05143853|Active Comparator|group with tape augmentation of acromioclavicular (AC) joint|patients randomised in this group will have additional tape fixation around AC joint. Both groups will however have fixation in CC area.
89567668|NCT05143853|Sham Comparator|group without tape augmentation of AC joint|patients randomised in this group will not have additional tape fixation around AC joint. Both groups will however have fixation in CC area.
89567669|NCT05129605||Cohort A|Documented germline known pathogenic or likely pathogenic mutation in a prostate cancer related risk gene
89567670|NCT05129605||Cohort B|Family history suggestive of high genetic risk for prostate cancer with clinical genetic testing negative for known pathogenic or likely pathogenic mutations in prostate cancer-related risk genes
88969721|NCT05820815|Experimental|in-bed self-exercises based on EMG-sensor feedback intervention|Conventional rehabilitation corresponds to general rehabilitation for lower extremity motor function in stroke patients and is mainly performed according to functional mobility with a range of motion. This includes lying down, standing, walking, and balance training. Additional in-bed self-exercises based on EMG-sensor feedback with conventional rehabilitation.
88969722|NCT05820815|No Intervention|Conventional rehabilitation|Conventional rehabilitation corresponds to general rehabilitation for lower extremity motor function in stroke patients and is mainly performed according to functional mobility with a range of motion. This includes lying down, standing, walking, and balance training.
88969723|NCT05820763|Experimental|Consolidation: Selinexor, Lenalidomide, and Dexamethasone|Consolidation will begin between Days 80 and 140 following standard of care autologous hematopoietic stem cell transplant and the treatment will consist of selinexor, lenalidomide, and dexamethasone for 4 28-day cycles.
88969724|NCT05820763|Experimental|Maintenance: Selinexor and Lenalidomide|Maintenance will consist of selinexor and lenalidomide for a maximum of 8 28-day cycles.
88969725|NCT05820490||Dayshift workers|
88969726|NCT05820490||Nightshift workers|
88969727|NCT05812339||Motility Disorder Patients|Adults with history of confirmed motility disorder.
88969728|NCT05812339||Healthy Controls|Adults meeting all inclusion and exclusion criteria with no symptoms or history of motility disorder.
88969729|NCT05809947|Experimental|Growth hormone/somatropin|Somatropin over two weeks (33.3 ug/kg/day in the first week, 50 ug/kg/day in the second week)
88969730|NCT05809947|Placebo Comparator|Placebo|Injections of placebo/saline over two weeks
88969731|NCT05809466|Experimental|Vegan group|
88969732|NCT05809466|Experimental|Vegan group with resistance exercise|
88969733|NCT05809466|Active Comparator|Omnivorous group|
89028080|NCT04510545||Treatment Group|All patients will undergo CAD of any diminutive polyps found in the rectosigmoid on colonoscopy
89028081|NCT00495482||1|Patients receiving palliative care due to incurable illness
89567671|NCT05110924|Other|Treatment arm (T-arm)|"Patients in the T-arm will receive diagnostic investigation(s) as in standard care. This includes clinical and dermoscopic examination and (in most cases) a biopsy to confirm the diagnosis of a BCC. Patients will be asked to fill out a questionnaire (Q) concerning their HrQoL. Important is the possible exclusion of patients (when the biopsy shows the lesion is not a BCC) in this step.~Patients will receive treatment of their BCC in accordance with the standard treatment regimen. The treatment will be performed by an independent dermatologist of the investigator's department who is blinded and not aware of the patient's participation in this study. After the treatment, a new Q will be sent out to capture the HrQoL and possible patient-reported side effects. Afterwards, the patients will be followed every 6 to 12 months for 36 months with a clinical evaluation of the previously treated skin site, evaluation of possible complications and the HrQoL and complications Qs."
89567672|NCT05110924|Other|non-Treatment arm (n-T-arm)|"Patients allocated to the n-T-arm will receive diagnostic investigations by non-invasive imaging techniques to confirm the diagnosis of a BCC. Patients will be asked to fill out a Q concerning their HrQoL. Important to point out is the possible exclusion of certain patients (when the imaging shows the lesion is not a BCC) in this step.~The patients in this arm will be followed every 6 to 12 months for 36 months. Every study visit there will be a clinical evaluation of the tumor. At the follow-up visits of 6, 12, 24 and 36 months a new documentation of the tumor will take place with in vivo imaging. At these time-points, patients will also be asked to fill out the HrQoL Q and complications Q.~Because of ethical reasons, a maximum tolerable diameter of the tumor has been defined in advance: BCCs in the non-treatment arm that reach a diameter of 4cm will be excluded and will receive treatment."
89567673|NCT05094037|Experimental|Treatment group|Patients will be given additional counseling
89567674|NCT05094037|Active Comparator|Control group|Patients will be given standard of care.
89567675|NCT05072808|Active Comparator|Intervention Group|ED Providers randomized to the Intervention Group will be able to view the results of the parent-completed questionnaire, the Pediatric Asthma Control and Communication Instrument for the Emergency Department (PACCI-ED), and outpatient referral recommendations aligned with asthma severity.
89567676|NCT05072808|No Intervention|Control Group|ED providers randomized to the Control Group will neither receive the results of the parent-completed PACCI-ED or specific recommendations for outpatient referrals. Patients randomized to the control group will receive usual care.
89567677|NCT05066776||Patients with Pulmonary Nodule|Patients at high-risk of lung cancer found to have a pulmonary nodule 6-20 mm in size.
89567678|NCT05059652|Experimental|Ischemic Preconditioning (n= 22)|"The IPC protocol will be applied in the proximal region of the thigh of the limb with knee osteoarthritis and if both knees are affected, it will be applied to the knee with the greatest complaint of pain.~Participants will be relaxed and comfortably seated. The same cuff used to determine the total occlusion pressure (TOP) will be used and the protocol will consist of four cycles of total ischemia (according to the TOP value determined individually) of five minutes, followed immediately by four cycles of five minutes of vascular reperfusion (0 mmHg ), totaling 40 minutes."
89567679|NCT05059652|Placebo Comparator|Placebo (n= 22)|The placebo protocol will be performed on the lower limb with knee osteoarthritis and if both knees are affected, it will be applied to the knee with the greatest complaint of pain. Participants will perform a protocol similar to the IPC, but during the four cycles of five minutes of occlusion, the cuffs will only be inflated with 10mmHg so as not to cause arterial or venous occlusion, alternating with four cycles of five minutes of reperfusion (0 mmHg).
89567680|NCT05058469||Tracheotomy without antiplatelet therapy+technique 1|
89567681|NCT05058469||Tracheotomy under antiplatelet therapy+technique 1|
89567682|NCT05058469||Tracheotomy without antiplatelet therapy+technique 2|
89567683|NCT05058469||Tracheotomy under antiplatelet therapy+technique 2|
89567684|NCT05040217|Experimental|Gene transfer of AAV2-BDNF|Up to 12 subjects will receive open-label AAV2-BDNF
89567685|NCT05034042|Experimental|Fezolinetant: low dose (15 mg)|Participants will receive low dose of fezolinetant once daily for 12 weeks.
89567686|NCT05034042|Experimental|Fezolinetant: high dose (30 mg)|Participants will receive high dose of fezolinetant once daily for 12 weeks.
89567687|NCT05034042|Placebo Comparator|Placebo|Participants will receive matching placebo once daily for 12 weeks.
89567688|NCT05025865|Placebo Comparator|HA35 Placebo Group|12 study participants will be given a placebo capsule to take once per day in the morning with breakfast for 3 days.
89567689|NCT05025865|Active Comparator|HA35 Treatment Group|12 study participants will be given an HA35 capsule to take once per day in the morning with breakfast for 3 days.
89567690|NCT05012618|Experimental|Dose escalation part (Part A)|Patients will receive LUNA18 capsule(s) at escalated doses
89567691|NCT05012618|Experimental|Biomarker part (Part B)|Patients will receive LUNA18 capsule(s) at doses where the tolerability is confirmed in Part A
89567692|NCT05012618|Experimental|Cohort expansion part (Part C)|Patients will receive LUNA18 capsule(s) at the recommended dose
89567693|NCT05012618|Experimental|Backfill part (Part AA)|Patients will receive LUNA18 capsule(s) at doses where the tolerability is confirmed in Part A
89567694|NCT05012618|Experimental|Dose finding part (Part D)|Patients will receive LUNA18 capsule(s) in combination with cetuximab at finding doses
89567695|NCT05012618|Experimental|Cohort expansion part (Part E)|Patients will receive LUNA18 capsule(s) in combination with cetuximab at the recommended dose
89028082|NCT00506805|Experimental|Single Arm|
89567696|NCT04996680|Experimental|Blood flow restriction group|patients in this group will undergo a standard strength training program combined with an occlusion cuff. The cuff will reduce the amount of blood flow and therefore increase the metabolic stimulus. The cuff will be used only during one quadriceps exercise, 2 times a week for 12 weeks.
89567697|NCT04996680|Sham Comparator|Sham group|patients in this group will undergo the same standard strength training program as the BFR-group, combined with an occlusion cuff but pressurized so there is no significant effect on the lower limb blood flow. The cuff will be used only during one quadriceps exercise, 2 times a week for 12 weeks.
89567698|NCT04996680|Active Comparator|Control group|patients in this group will undergo the same standard strength training program as the BFR-group and placebo-group, but without a tourniquet.
89567699|NCT04993482||type 2 diabetes mellitus group|124 adults with type 2 diabetes mellitus will be included
89567700|NCT04993482||control group|124 control adults will be included
89567701|NCT04978675|Experimental|Diagnostic (F-18 rhPSMA-7.3, PET/MRI)|Patients receive F-18 rhPSMA-7.3 IV and after approximately 60 minutes of uptake time, will undergo PET/MRI over 60 minutes. Patients with evidence of F-18 rhPSMA-7.3 disease in the first PET/MRI scan undergo a second F-18 rhPSMA-7.3 PET/MRI at 6 months after the second dose of standard hormonal therapy.
88969734|NCT05806463|Experimental|Mother's Time Intervention|Working with local research partners, the research team will train HEWs in the intervention clusters in the Amhara region of Ethiopia to deliver four intervention sessions in a group setting of approximately six to eight women (average: 7). These sessions will take place over a period of approximately one month. Participants in the intervention group will receive four sessions of Mother's Time, delivered by an HEW.
88969735|NCT05806463|No Intervention|Standard of care|Participants in the control group will receive the standard of care that postpartum mothers in Ethiopia receive. Standard of care for postpartum mothers related to family planning and mental health in Ethiopia includes multiple touch points that correspond with postpartum care as well as routine immunization.
88969736|NCT05796583|Active Comparator|Active Pulsed Shortwave Treatment with SofPulse|Application of 8 days of nonthermal, pulsed shortwave (radiofrequency) therapy with Endonovo Therapeutics SofPulse
88969737|NCT05796583|Sham Comparator|Sham Treatment|Application of 8 days of sham device
88969738|NCT05793437|Experimental|permissive hypercapnia|Tidal volume (6-8ml/kg) and respiratory rate is adjusted to achieve the objective values of PaCO2:45～55mmHg
88969739|NCT05793437|Active Comparator|normocapnia|Tidal volume (8-10ml/kg) and respiratory rate is adjusted to achieve the objective values of PaCO2:35～45mmHg
88969740|NCT05786612|Active Comparator|Mepilex Border with Aquacel Extra Hydrofiber|Standard of care (filler, that functions as a primary dressing to manage exudate and the gap/space between the wound bed and the dressing, covered by a secondary dressing on top) defined in this study as Mepilex® Border with AQUACEL® Extra Hydrofiber Dressing
88969741|NCT05786612|Experimental|Biatain® Silicone|The investigational test product is Biatain® Silicone. Biatain® Silicone is intended to be used for moist wound healing and exudate management.
88969742|NCT05783609|Experimental|Epcoritamab + Rituximab|"Participants will undergo study procedures as outlined:~PET/CT scans at baseline and after cycles 2, 5, and 9 of treatment.~Cycle 1:~Days -14, -7, 1, 8 of 6 week cycle: Predetermined dose of Rituximab.~Days 1, 8, 15, 22 of 6 week cycle: Predetermined dose of Epcoritamab. (Day 15 of Epcoritamab dosage will be administered in the hospital.)~Cycles 2 - 3:~--Days 1, 8, 15, 22 of 4 week cycle: Predetermined dose of Epcoritamab.~Cycles 4 - 9:~Day 1 of 4 week cycle: Predetermined dose of Epcoritamab.~Day 15 of 4 week cycle: Predetermined dose of Epcoritamab.~Surveillance imaging (PT/CT scans) at months 13, 18, and 24 after initiation of treatment.~Follow up visits for up to 5 years."
89208653|NCT00877266|Active Comparator|1. Ultrasound|Ultrasound is randomly chosen by use of a computer program. The time for catheter placement will begin with the ultrasound probe touches the patient. Patients will be asked their discomfort on a 0-10 scale (0=no discomfort and 10=worst discomfort imaginable) and will be called the next day by the research staff.
89567702|NCT04976855|Placebo Comparator|Part I: Placebo|Healthy volunteers will receive placebo either once daily or twice daily for 7 days.
89567703|NCT04976855|Experimental|Part I: INDV-2000|Healthy volunteers will receive INDV-2000 once daily or twice daily for 7 days.
89567704|NCT04976855|Placebo Comparator|Part II: Placebo|Healthy volunteers will receive placebo twice daily for 28 days.
89567705|NCT04976855|Experimental|Part II: INDV-2000|Healthy volunteers will receive INDV-2000 twice daily for 28 days.
89567706|NCT04976855|Experimental|Part III: INDV-2000 + SUBOXONE|Participants with opioid use disorder will receive SUBOXONE sublingual (SL) film for 6 days during the run-in period. Participants will then receive SUBOXONE SL film alone for 2 days, then SUBOXONE SL film and INDV-2000 for 7 days followed by INDV-2000 dosing alone for 4 days.
89567707|NCT04904692||COVID-19 positive|"Peripheral blood draw:~Day 1 of admission: blood draw.~Day 7-10 of hospitalization: blood draw.~Follow-up consultation: blood draw (selected patients).~Bronchoscopic sampling:~Material from bronchoscopic sampling (lavage fluid) will be collected only in those subjects in whom there is a diagnostic or therapeutic need for this procedure.~Swabs for SARS-CoV-2 PCR:~Day 1 of admission: Extra oropharyngeal, nasal and nasopharyngeal (NP) swabs will be collected after the result of the initial diagnostic swab is known. In case of shortage of swabs, sputum samples will be collected as an alternative.~Day 7-14 of hospitalization: NP swab or clinically available alternative will be executed on day 7 repeated weekly."
89567708|NCT04904692||COVID-19 negative|"Peripheral blood draw:~Day 1 of admission: blood draw.~Follow-up consultation: blood draw (selected patients).~Bronchoscopic sampling:~Material from bronchoscopic sampling (lavage fluid) will be collected only in those subjects in whom there is a diagnostic or therapeutic need for this procedure.~Swabs for SARS-CoV-2 PCR:~o Day 1 of admission: Extra oropharyngeal, nasal and nasopharyngeal (NP) swabs will be collected after the result of the initial diagnostic swab is known. In case of shortage of swabs, sputum samples will be collected as an alternative."
89567709|NCT04865978|Experimental|Apixaban|LVAD patients randomized to the experimental arm will be prescribed apixaban 5 mg twice daily.
89567710|NCT04865978|Active Comparator|Warfarin|LVAD patients randomized to the control arm will be prescribed warfarin which will be dosed to achieve an INR goal of 2-2.5
89208654|NCT00877266|Active Comparator|2. Electrical Stimulation|Nerve Stimulation (electrical stimulation) is randomly chosen using a computer program. Time of placement begins when the catheter-placement first touches the patient. After catheter placement patient is asked their discomfort on a 0-10 scale (0=no discomfort and 10=worst discomfort imaginable) and called the day after surgery by the research staff.
89208655|NCT02553824|Experimental|Phentermine/Topiramate-First + Placebo|Patients randomly assigned to this condition will receive the study medication first, have a 2 week washout, and then crossover to receive the control medication/placebo
89567711|NCT04861558|Active Comparator|Standard HIPEC|Injection of oxaliplatin 460 mg/m2 and an intraoperational IV of 5-fluorouracil 400 mg/m2, and calcium folinate 60 mg/m2.
89567712|NCT04861558|Experimental|Intensified HIPEC+EPIC|"Injection of irinotecan 360 mg/m2 and 5-fluorouracil 24-hr EPIC 250-850 mg/m2 in combination with Oxaliplatin 360 mg/m2 and an intraoperational IV of 5-fluorouracil bolus 400 mg/m2 with calcium folinate 60mg/m2.~The EPIC treatment is given after the abdomen is completely sutured in the operating theater. The dose will be divided equally into 2 injections á 200ml each through two abdominal drains."
89567713|NCT04858061|Experimental|Treatment-as-usual supplemented with virtual reality cue-exposure therapy|Treatment-as-usual supplemented with virtual reality cue-exposure therapy (TAU + VR-CET).
89567714|NCT04858061|Active Comparator|Treatment-as-usual|Only treatment-as-usual (TAU)
89567715|NCT04851587|Experimental|In-Person (or Remote) Intervention Visits|Participants will initially complete a baseline assessment assessing study eligibility. The intervention includes 8 core in-person group sessions and 8 optional in-person group sessions (1.5 hours each) targeting standard weight loss and pain treatment content and eight individual phone calls (30 minutes each) focusing primarily on increasing environmental reward and positive affect. Intervention sessions may be delivered online through protected health information (PHI) Zoom. Group sessions will be delivered every-other week and phone calls will occur every-other week (during weeks with no group). Sessions will be administered by a study interventionist with bachelors- or masters-level training and certification in health education or a related field (e.g., Certified Health Education Specialist), and materials will be developed to be appropriate for delivery by this level of training, given the potential for greater availability of these types of health professionals.
89567716|NCT04851366|Experimental|PROCARE+ (with add-on modules)|In addition to core UP-A preventive intervention, PROCARE will apply an innovative personalized medicine approach by adding specific modules according to the risk factor evidenced by adolescents. Different modules will be suited for the stratified groups in a more personalized format. Add-on young-focused modules would include, but not limited to social, parental, stress-related (including CoVid19 impact) risk factors, and health. Dosage (number of modules) will be included as covariate in all subsequent analyses.
89567717|NCT04851366|Experimental|PROCARE (UP-A for selective purposes)|To ensure cost-effectiveness, PROCARE core intervention will be designed as a brief 8-session child-focused programme which aims to build resilience for adolescents by adapting the core modules from UP-A, along with one individual session with adolescent and parents. Sessions will be delivered in reduced groups, using a typical selective preventive intervention format focused on cost-effectiveness.
89567718|NCT04851366|Active Comparator|Active control condition.|"The active control condition will be based on the U talk programme developed by Prf. Jill Ehrenreich-May at University of Miami and colleagues. It follows a similar structure as the UP-A original programme and allows for two alternative compare conditions to PROCARE. The U Talk programme support-based group condition will be used as active control condition."
89567719|NCT04848896|Experimental|CORI|Subjects in need for total knee arthroplasty (TKA) as decided by their doctor and treated with CORI Robotics System.
89567720|NCT04848896|Active Comparator|Conventional Procedure|Subjects in need for total knee arthroplasty (TKA) as decided by their doctor and treated with conventional approach with conventional manual instrumentation.
89567721|NCT04803214|Other|Treatment (ReActiv8)|Market-approved ReActiv8 device
88969748|NCT05778188|Experimental|RLS-0071|Doses of RLS-0071 to be administered every 8 hours (q8h), for a total of 10 doses over 72 hours.
88969749|NCT05778188|Placebo Comparator|Placebo|Doses of sterile saline (sodium chloride, 0.9%) to be administered every 8 hours (q8h), for a total of 10 doses over 72 hours.
88969750|NCT05771649|Experimental|Mindfulness-based intervention (MBI)|A 4-week mindfulness-based intervention comprised of focused attention meditations. From 15 to 30 minutes of practice per session, four times/week through audio guides.
88969751|NCT05771649|Active Comparator|Physical exercise (PE)|A 4-week physical exercise intervention comprised of running with mental association strategies. From 15 to 30 minutes of practice per session, three times/week through workout audio guides.
88969752|NCT05771649|No Intervention|Treatment as Usual (TAU)|The participants will continue their daily activity and obligations in the academy as usual.
88969753|NCT05769530|Experimental|DEX and Nalbuphine group|In group B, DEX 0.5μg/kg was injected intravenously 30min before the end of the operation, 30min after the pump, and Nalbuphine 0.20 mg/kg (5 mL) was injected intravenously 30min before the end of the operation.
88969754|NCT05769530|Placebo Comparator|placebo group|Group A was continuously injected with normal saline during the operation, and 5 mL of normal saline was injected intravenously 30min before the end of the operation
88969755|NCT05769530|Experimental|nalbuphine group|Group C was continuously injected with normal saline 30 minutes before the end of the operation, and intravenous injection of nalbuphine 0.20 mg/kg (5 mL) 30 minutes before the end of the operation.
88969756|NCT05762640|Experimental|Ruxolitinib|
88969757|NCT05754892|Other|Patients with ACC|These patients will be followed up and proposed a search for targetable molecular alterations
88969758|NCT05754892|Other|Patients with MPP|These patients will be followed up and proposed a search for targetable molecular alterations
88969759|NCT05729945|Experimental|Home Visiting Group|The home visiting group receives the program interventions which comprises home visits.
88969760|NCT05729945|No Intervention|Business as Usual Group|The control group is business as usual and does not receive the program intervention.
89028083|NCT00506376||Surgical Treatment Preferences|Assessment of patient's feelings toward risks associated with surgical treatment of cervical cancer.
89567722|NCT04803214|No Intervention|Control (OMM)|Standard of Care
89567723|NCT04800484|Experimental|Arm 1:|Testing Order: Clinical AFO, Tall Soft, Tall Firm, Short Soft, Short Firm, NoAFO
89567724|NCT04800484|Experimental|Arm 2:|Testing Order: Clinical AFO, Tall Soft, Tall Firm, Short Firm, Short Soft, NoAFO
89567725|NCT04800484|Experimental|Arm 3:|Testing Order: Clinical AFO, Tall Soft, Short Soft, Tall Firm, Short Firm, NoAFO
88969761|NCT05729516|Experimental|Immediate Treatment Group (ITG)|"ITG participants receive access to the Hope App, a newly designed immersive learning and telehealth application designed to deliver engaging diabetes care and self-management education and support for older adults with diabetes.~ITG participants also complete data collection (surveys and HbA1c measurements) at baseline, 3 months after baseline, and 6 months after baseline."
88969762|NCT05729516|No Intervention|Wait List Control (WLC)|"WLC participants receive care as usual for 6 months. They will complete data collection (surveys and HbA1c measurements) at baseline, 3 months after baseline, and 6 months after baseline.~After 6 months, WLC participants will gain access to the Hope App and receive diabetes programming and health coaching for the remaining 6 months."
88969763|NCT05724589|Experimental|Epidermal Growth Factor Serum Application|Participants received Epidermal growth factor serum application on the face daily for two months compared to pre and post-results of skin quality.
88969764|NCT05723523|Experimental|CI-CDS|In clinics randomized to the CI-CDS, the providers will be given the option to use the CI-CDS tool during eligible patient encounters.
88969765|NCT05723523|No Intervention|Usual Care (UC)|In clinics randomized to UC, patients will receive usual care at their primary care visits over the accrual period (no intervention will be given).
88969766|NCT05723133|Active Comparator|Active Comparator: Control group: Manual Toothbrush|Patients will receive oral hygiene instructions and a new manual toothbrush
88969767|NCT05723133|Experimental|Test group: Electric Toothbrush without visual feedback|Patients will receive the same oral hygiene instructions and an electric toothbrush without daily personal feedback using the brushing application.
89567726|NCT04800484|Experimental|Arm 4:|Testing Order: Clinical AFO, Tall Soft, Short Soft, Short Firm, Tall Firm, NoAFO
89567727|NCT04800484|Experimental|Arm 5:|Testing Order: Clinical AFO, Tall Soft, Short Firm, Tall Firm, Short Soft, NoAFO
89567728|NCT04800484|Experimental|Arm 6:|Testing Order: Clinical AFO, Tall Soft, Short Firm, Short Soft, Tall Firm, NoAFO
89567729|NCT04800484|Experimental|Arm 7:|Testing Order: Clinical AFO, Tall Firm, Tall Soft, Short Soft, Short Firm, NoAFO
89567730|NCT04800484|Experimental|Arm 8:|Testing Order: Clinical AFO, Tall Firm, Tall Soft, Short Firm, Short Soft, NoAFO
89567731|NCT04800484|Experimental|Arm 9:|Testing Order: Clinical AFO, Tall Firm, Short Soft, Tall Soft, Short Firm, NoAFO
89567732|NCT04800484|Experimental|Arm 10:|Testing Order: Clinical AFO, Tall Firm, Short Soft, Short Firm, Tall Soft, NoAFO
89567733|NCT04800484|Experimental|Arm 11:|Testing Order: Clinical AFO, Tall Firm, Short Firm, Tall Soft, Short Soft, NoAFO
89567734|NCT04800484|Experimental|Arm 12:|Testing Order: Clinical AFO, Tall Firm, Short Firm, Short Soft, Tall Soft, NoAFO
89567735|NCT04800484|Experimental|Arm 13:|Testing Order: Clinical AFO, Short Soft, Tall Soft, Short Firm, Tall Firm, NoAFO
89567736|NCT04800484|Experimental|Arm 14:|Testing Order: Clinical AFO, Short Soft, Tall Soft, Tall Firm, Short Firm, NoAFO
89567737|NCT04800484|Experimental|Arm 15:|Testing Order: Clinical AFO, Short Soft, Tall Firm, Short Firm, Tall Soft, NoAFO
89567738|NCT04800484|Experimental|Arm 16:|Testing Order: Clinical AFO, Short Soft, Tall Firm, Tall Soft, Short Firm, NoAFO
89567739|NCT04800484|Experimental|Arm 17:|Testing Order: Clinical AFO, Short Soft, Short Firm, Tall Soft, Tall Firm, NoAFO
88969768|NCT05723133|Experimental|Test group: Electric Toothbrush with visual feedback|Patients will receive the same oral hygiene instructions and an electric toothbrush with daily personal feedback using the brushing app (Oral-B app).
88969769|NCT05720494|Experimental|JZP441|Healthy participants who will be randomized to receive an oral dose of JZP441.
89567740|NCT04800484|Experimental|Arm 18:|Testing Order: Clinical AFO, Short Soft, Short Firm, Tall Firm, Tall Soft, NoAFO
89567741|NCT04800484|Experimental|Arm 19:|Testing Order: Clinical AFO, Short Firm, Tall Soft, Tall Firm, Short Soft, NoAFO
89567742|NCT04800484|Experimental|Arm 20:|Testing Order: Clinical AFO, Short Firm, Tall Soft, Short Soft, Tall Firm, NoAFO
89567743|NCT04800484|Experimental|Arm 21:|Testing Order: Clinical AFO, Short Firm, Tall Firm, Short Soft, Tall Soft, NoAFO
89567744|NCT04800484|Experimental|Arm 22:|Testing Order: Clinical AFO, Short Firm, Tall Firm, Tall Soft, Short Soft, NoAFO
89567745|NCT04800484|Experimental|Arm 23:|Testing Order: Clinical AFO, Short Firm, Short Soft, Tall Firm, Tall Soft, NoAFO
89567746|NCT04800484|Experimental|Arm 24:|Testing Order: Clinical AFO, Short Firm, Short Soft, Tall Soft, Tall Firm, NoAFO
89567747|NCT04792892||Patients with a new diagnosis of anal cancer|All patients identified at our national tumour board will be offered to participate
89567748|NCT04792008|Experimental|YQ23 Single dose|Two-third of randomized patients will receive YQ23 as active treatment
89567749|NCT04792008|Placebo Comparator|Placebo Single dose|One-third of randomized patients will receive matching placebo
89567750|NCT04786379|Experimental|Patients with confirmed septic arthritis of the native knee|
89567751|NCT04776083|Experimental|radiotherapy arm|after first line systemic therapy, patients will receive radiotherapy to the primary lesion, hypo-fractionated regimen 45gy will be given over 15 fractions
89567752|NCT04776083|Active Comparator|no intervention arm|after first line systemic therapy, patients will be kept under follow up
89567753|NCT04772521|Experimental|Intervention|Personalized chat-based support and nicotine replacement therapy sampling (NRT-S) for continued smokers at 6 months for intervention group
89567754|NCT04772521|Placebo Comparator|Control|Regular text-based support and nicotine replacement therapy sampling (NRT-S) for continued smokers at 6 months for control group
89567755|NCT04768257||Patients with COVID-19, treated in intensive care|
89567756|NCT04768257||Patients with COVID-19, treated in hospital ward|
89567757|NCT04768257||Patients with COVID-19, treated at home|
89567758|NCT04764357|Experimental|Cooling Cap Therapy|Participants receiving cooling cap therapy
89608840|NCT03156153|Experimental|Bumetanide group|Double-blind phase: in the first 3 months, patients will receive the experimental treatment - bumetanide, oral intake, 0.5mg/time, twice a day; Open-label phase: after 3 month double-blined treatment, all the patients will receive 3-month bumetanide treatment - oral intake, 0.5mg/time, twice a day.
89567759|NCT04763174|Experimental|mHealth Coping Skills Training for Symptom Management (mCOPE)|mHealth Coping Skills Training for Symptom Management (mCOPE) protocol tests the efficacy of a theory-based symptom management intervention designed to target multiple interrelated symptoms (pain, fatigue, psychological distress) with content uniquely relevant for young and middle-aged colorectal cancer patients. Addressing the co-morbid consequences of cancer while providing support in the context of age-related challenges (e.g., caring for children and parents, career) has the potential to significantly improve overall quality of life in young and middle-aged patients with cancer.
89028084|NCT04515693|Experimental|Maximal Assist group|Subjects with acute stroke who ambulate with Maximal assistance of 1.
89028085|NCT04515693|Experimental|Moderate Assist group|Subjects with acute stroke who ambulate with Moderate assistance of 1.
89028086|NCT04515693|Experimental|Minimal Assist group|Subjects with acute stroke who ambulate with Minimal assistance of 1.
89028087|NCT04515693|Experimental|Supervision/Modified Independence/Independence|Subjects who walk without physical assistance of a helper.
89028088|NCT00495833|No Intervention|1|
89028089|NCT00495833|Experimental|2|photo and blood pressure personalization
89028090|NCT00495833|Experimental|3|photo personalization only
89028091|NCT00495833|Experimental|4|blood pressure personalization only
89028092|NCT00495833|Experimental|5|no personalization
89028093|NCT00495833|Experimental|A|receives gift card in blood pressure (BP) kit
89028094|NCT00495833|Experimental|B|does not receive gift card in BP kit
89028095|NCT00506961|Active Comparator|1|10 mg rosuvastatin for 4 weeks followed by 20 m rosuvastatin for another 8 weeks
89028096|NCT00506961|Active Comparator|2|20 mg simvastatin for 4 weeks followed by 40 mg simvastatin for another 8 weeks
89028097|NCT00492635|Experimental|Arm 1|
89028098|NCT00492635|Experimental|Arm 2|
89028099|NCT00492635|Placebo Comparator|Arm 3|
89028100|NCT00507000|Active Comparator|A, Cholecalciferol|A Cholecalciferol Drug: Cholecalciferol 60,000 IU sachet and calcium carbonate Oral cholecalciferol (vitamin D)60,000 IU weekly along with daily oral dose of 1 gm calcium carbonate for first two months followed by 1 gm of elemental calcium in form of calcium carbonate daily cholecalciferol (vitamin D)60,000 IU per month for the next four months
89028101|NCT00507000|Placebo Comparator|Vitamin D and Tuberculosis|B, Lactose
89028102|NCT00495872|Experimental|VN|Valproic Acid + Sorafenib
89028103|NCT00495872|Experimental|VS|Valproic Acid + Sunitinib
89028104|NCT00495872|Experimental|VD|Valproic Acid + Dasatinib
89028105|NCT00495872|Experimental|VT|Valproic Acid + Erlotinib
89028106|NCT00495872|Experimental|VL|Valproic Acid + Lapatinib
89028107|NCT00495872|Experimental|VR|Valproic Acid + Lenalidomide
89028108|NCT00507039||grass allergy, bronchial challenge|subjects with known allergy against grass-pollen undergo bronchial challenges
89028109|NCT00492713|Active Comparator|1|Dark chocolate
89028110|NCT00492713|Active Comparator|2|Milk chocolate 1
89028111|NCT00492713|Active Comparator|3|Milk chocolate 2
89028112|NCT00507117|Active Comparator|PSG|
89028113|NCT00492791||Endoscopic Capsule|Patient enrolled for performing an endoscopic capsule
89028114|NCT01299727|Experimental|rhHNS-10 mg|Once per month via an Intrathecal Drug Delivery Device (IDDD) for a maximum of 8 years
89028115|NCT01299727|Experimental|rhHNS-45 mg|Once per month via an Intrathecal Drug Delivery Device (IDDD) for a maximum of 8 years
89028116|NCT01299727|Experimental|rhHNS-90 mg|Once per month via an Intrathecal Drug Delivery Device (IDDD) for a maximum of 8 years
89028117|NCT00492908|Active Comparator|Titanium Nitride Oxide Coated Stent|Stent
89028118|NCT00492908|Active Comparator|Zotarohlimus Eluting Stent|Stent
89028119|NCT01299571||Dutasteride|Patients administrated dutasteride at the site
89028120|NCT01243736|No Intervention|Standard prep|One group will receive the standard bowel preparation, which consists of eating no solid foods after 7 p.m. the evening prior to the capsule endoscopy test and being able to consume clear liquids up to 4 hours prior to the capsule endoscopy test
89028121|NCT01243736|Active Comparator|Combination Prep|"The other group will receive the combination bowel preparation, which consists of taking the standard bowel preparation plus:~drinking 2-liters (8 cups) of polyethylene glycol starting at 7 p.m. the night prior to the capsule endoscopy test;~drinking a teaspoon of simethicone 20 minutes prior to the capsule endoscopy test;~drinking a teaspoon of metoclopramide 20 minutes prior to the capsule endoscopy test;~lying on your right side for 30 minutes following the swallowing of the capsule endoscope."
89028122|NCT02274467|Active Comparator|Uniport catheter|19 gauge uniport epidural catheter
89028123|NCT02274467|Active Comparator|Multiport catheter|19 gauge multiorifice epidural catheter
89028124|NCT01299376|Experimental|L50/H12.5/A5→L50/H12.5/A5|One combination tablet containing L50 mg, H12.5 mg, and A5 mg, orally, once daily, for up to 8 weeks (double-blind treatment period). Participants continue with once daily L50/H12.5/A5 for 44 weeks during open label extension.
89028125|NCT01299376|Active Comparator|L50/H12.5→L50/H12.5/A5|One combination tablet containing L50 mg and H12.5 mg, orally, once daily, for up to 8 weeks during double-blind treatment period. Participants then receive once daily L50/H12.5/A5 for 44 weeks during open-label extension
89028126|NCT04324450|Experimental|Patients radiotherapy +|Patients cured of a brain tumour and who have received radiotherapy in childhood
89028127|NCT04324450|Experimental|Patients radiotherapy -|Patients cured of a brain tumour and who have received surgery and/or chemotherapy but were not irradiated
89028128|NCT04324450|Experimental|Healthy volunteers|"Healthy volunteers (control group) matched in age, manual laterality, gender and parental education to Patients radiotherapy +"
89028129|NCT02890537|Experimental|Core decompression/PREOB® implantation|Core decompression/autologous osteoblastic cells (PREOB®) implantation
89028130|NCT02890537|Active Comparator|Core decompression/BMC implantation|Core decompression/bone marrow concentrate (BMC) implantation
89028131|NCT02890225|Other|3|Patients in 3 days
89028132|NCT02890225|Other|10|Patients in10ys
89028133|NCT02890225|Experimental|30|Patients in10ys
89028134|NCT01299025|No Intervention|Control|Participants allocated as controls receive no treatment. They may be physically active as usual.
89567760|NCT04763174|No Intervention|Standard Care|Standard Care group will complete assessment questionnaires at the same time points as mCOPE, but will not receive mCOPE protocol.
89567761|NCT04755322|Other|hydroxychloroquine group|hydroxychloroquine 400 mg+ Folic Acid 5 mg+ Low-dose aspirin 75 mg
89567762|NCT04755322|Other|control group|Folic Acid 5 mg+ Low-dose aspirin 75 mg
89028135|NCT01299025|Experimental|Training with Nintendo Wii Fit|Training 6 weeks with Nintendo Wii Fit, 30 minutes 2 times per week
89028136|NCT00492986|Experimental|Arm 1|
89028137|NCT04324528|Experimental|vv-ECMO + cytokine adsorption|after indication of treatment with vv-ECMO in acute respiratory failure in COVID-19-disease, patients will additionally receive cytokine adsorption using a Cytosorb adsorber
89028138|NCT04324528|Other|control-arm: vv-ECMO (no cytokine adsorption)|treatment with vv-ECMO in acute respiratory failure in COVID-19-disease (standard treatment without additional cytokine adsorption)
89028139|NCT04327258||All patients|Patients undergoing elective surgery with anesthesia
89028140|NCT01298596|Experimental|Cryotherapy|Cryotherapy procedure involves using a cryoprobe and carbon dioxide or nitrous oxide gas to freeze the diseased part of the cervix
89028141|NCT01298596|Experimental|Loop Electrosurgical Excision Procedure|Loop Electrosurgical Excision Procedure (LEEP) uses a low-voltage electrified wire loop to cut out diseased part of cervix
89028142|NCT02890108|Experimental|Sugar sweetened beverages|Subjects will receive, in 3 different ocassions, 350cc (1 can) of a sugar sweetened beverage, that contain 38,7 grams of carbs and 154 kcal, separated by at least 1 week each one
89028143|NCT02890108|Experimental|Artificially sweetened beverage|Subjects will receive, in 3 different ocassions, 350cc (1 can) of a artificially sweetened beverage, that contain 84 mg of Aspartame, 56 mg of Acesulfame K and 0,7 kcal, separated by at least 1 week each one
89028144|NCT04324138|Experimental|Experimental group|Jianpi Qinghua granules, 3 times a day and 1 hour after a meal
89028145|NCT04324138|Sham Comparator|Control group|Jianpi Qinghua placebo granules(inclued 5% of experimental drug),3 times a day and 1 hour after a meal
89028146|NCT00493337|No Intervention|Control group|
89028147|NCT00493337|Experimental|Advanced counseling|
89028148|NCT00493337|Active Comparator|Compliance Card only|
89028149|NCT01243814|Active Comparator|supartz|active intervention arm
89028150|NCT01243814|Placebo Comparator|saline injection|placebo intervention arm
89028151|NCT01243853|Active Comparator|Alpha-galactosidase|
89028152|NCT01243853|Placebo Comparator|Placebo|
89028153|NCT01298518|Experimental|PF-04620110|
89028154|NCT01298518|Placebo Comparator|placebo|
89028155|NCT01243970|Active Comparator|phenylephrine infusion|
89028156|NCT01243970|Active Comparator|Ephedrine infusion|
89028157|NCT04515576|Experimental|LY3493269|LY3493269 administered Subcutaneous (SC).
89028158|NCT04515576|Active Comparator|Dulaglutide|Dulaglutide administered SC.
89567763|NCT04738409|Experimental|Ov/Ob group|PCOS subjects (Overweight/Obesity)
89028159|NCT04515576|Placebo Comparator|Placebo|Placebo administered SC.
89028160|NCT01298362||AIs as first line therapy|Patients in postmenopausal status, with ER-positive early breast cancer, treated with an AI as first line therapy for 12 months.
89028161|NCT01298362||AIs after chemotherapy|Patients in postmenopausal status, with ER-positive early breast cancer, treated with an AI as maintenance therapy for 12 months after initial treatment with anthracycline- and/or taxane-based chemotherapy (chemotherapy treatment duration: 1-6 months).
89028162|NCT00493415|Experimental|1|nitroglycerine iv
89028163|NCT00493415|Placebo Comparator|2|nacl 0.9% 4 ml/h iv in the first 30 minutes, 2 ml/h iv in the next 23 hours and 30 minutes
89028164|NCT05148741||Group 1|implanted with the C-loop haptic intraocular lens
89028165|NCT05148741||Group 2|implanted with the plate haptic intraocular lens
89028166|NCT01244009|Experimental|MK-4827|All Participants
89028167|NCT04511832|Experimental|Acupuncture to NSAIDs|
89028168|NCT04511832|Experimental|NSAIDs to Acupuncture|
89028169|NCT04511832|Experimental|Combined both acupuncture and NSAIDs|
89028170|NCT00495950||Questionnaire|
89028171|NCT05148273||intervention|After the selection process with 1 to 1 randomization method, a personal information form and Beck anxiety scale will be applied to the women selected for the case group on the day of the initiation of treatment with assisted reproductive techniques interview. Then, within an average of 10 days, there is a treatment procedure including planned drug use, messages containing drug doses, drug use, drug administration, follicle count, reminder of the times of operations such as OPU, IUI, ET, and motivational issues. Medication use, time, date, dose, application form and motivational sentences will be sent every day through the WhatsApp application. The Beck anxiety scale will be repeated on the day of IUI and ET procedures, and the effect of telehealth practices on the anxiety levels of women undergoing infertility treatment will be evaluated. During the study, the participants will be able to reach the researcher from their mobile phones whenever they want.
89567764|NCT04738409|Experimental|N group|PCOS subjects (Normal weight)
89567765|NCT04738409|No Intervention|H group|Healthy control subjects
89567766|NCT04728165||control group|Age (+/-5 yrs) and BMI (+/- 5 kg/m2) matched control male subjects for inclusion in the control group
89567767|NCT04728165||psoriasis group|Males between the ages of 18 and 70 with mild to moderate active psoriasis by PASI score for inclusion in psoriasis group
89567768|NCT04721795|Experimental|Atorvastatin with standard anti tuberculosis drugs|Participants will receive oral 30/40mg of atorvastatin daily for 2 months together with oral doses of standard antituberculosis drugs consisting of Rifampicin, INH, Ethambuthol and pyrazinamide for 2months. At the end of 2months, participants will continue with only standard anti tuberculosis drugs, Rifampicin and INH for 4months.Doseage of antituberculosis drugs are dependent on weight
89567769|NCT04721795|Active Comparator|Anti tuberculosis drugs only|Participants will receive oral doses of standard antituberculosis drugs only consisting of Rifampicin, INH, Ethambuthol and pyrazinamide for 2months. At the end of 2months, participants will continue with only standard anti tuberculosis drugs, Rifampicin and INH for 4months.Doseage of antituberculosis drugs are dependent on weight
89567770|NCT04707066|Experimental|1|Subject assigned to CAMS for Phase 1. Subject is a Phase 1 CAMS Responder, thus placed into ongoing Maintenance/Monitoring.
89567771|NCT04707066|Experimental|2|Subject assigned to CAMS for Phase 1. Subject is a Phase 1 CAMS Insufficient Responder, then assigned to Phase 2 CAMS.
89567772|NCT04707066|Experimental|3|Subject assigned to CAMS for Phase 1. Subject is a Phase 1 CAMS Insufficient Responder, then assigned to Phase 2 DBT.
89567773|NCT04707066|Experimental|4|Subject assigned to TAU for Phase 1. Subject is a Phase 1 TAU Responder, thus placed into ongoing Maintenance/Monitoring.
89567774|NCT04707066|Experimental|5|Subject assigned to TAU for Phase 1. Subject is a Phase 1 TAU Insufficient Responder, then assigned to Phase 2 CAMS.
89567775|NCT04707066|Experimental|6|Subject assigned to TAU for Phase 1. Subject is a Phase 1 TAU Insufficient Responder, then assigned to Phase 2 DBT.
89028172|NCT05148273||control|In the first interview at the beginning of the treatment protocol with assisted reproductive techniques, a personal information questionnaire and beck anxiety scale will be applied to the control group selected by the 1-to-1 randomization method. Afterwards, the Beck anxiety scale will be applied again at the end of the treatment without any intervention.
89567776|NCT04705415|Experimental|ANA001|"For the single ascending dose (SAD) portion of the study, subjects will receive their assigned treatment as a single oral dose (1000 mg, 2000 mg, or 3000 mg of ANA001) with a standardized light meal. Each capsule is 250 mg.~For the multiple ascending dose (MAD) portion of the study, subjects will receive their assigned treatment twice daily (BID) or thrice daily (TID) (total daily dose is to be determined following the completion of the SAD portion of the study and will not exceed 2000 mg ANA001) with a standardized light meal for 7 consecutive days. Each capsule is 250 mg."
89567777|NCT04705415|Placebo Comparator|Matching Placebo|"For the single ascending dose (SAD) portion of the study, subjects will receive their assigned matching placebo (hydroxypropylmethylcellulose (HPMC) as a single dose (4, 8, or 12 capsules) with a standardized light meal.~For the multiple ascending dose (MAD) portion of the study, subjects will receive their assigned matching placebo (hydroxypropylmethylcellulose (HPMC) dose twice daily (BID) or thrice daily (TID) with a standardized light meal."
89567778|NCT04693494|Experimental|Intervention group|"Four training sessions (before the baby is 1 month old, at 3 months, at 6 and at 9 months old) teaching the main motor milestones to get in the next 3 months and how to help infants with the correct stimuli, positions or plays; triptychs containing the main points explained at the session and links to short videos about the given advices.~Two evaluations of motor milestones at the age of 9 and 12 months old"
89567779|NCT04693494|No Intervention|Control group|Two evaluations of motor milestones at the age of 9 and 12 months old
89028173|NCT01244204|Experimental|Vitamin D|
89028174|NCT01244204|Placebo Comparator|Placebo|
89028175|NCT00496028|Experimental|1|AZD0530 + Paclitaxel
89028176|NCT00496028|Experimental|2|AZD0530 + Carboplatin
89028177|NCT00496028|Experimental|3|AZD0530 + Carboplatin + Paclitaxel
89028178|NCT01297504||Palivizumab|Infants at risk for respiratory syncytial virus infection received palivizumab prescribed in accordance with the terms of the local marketing authorization.
89028179|NCT00496067|Experimental|1|DUAO Device
89028180|NCT04516278|Experimental|Biological: bevacizumab|ONS-5010
89028181|NCT04516200|Experimental|Transcranial direct current stimulation|Transcranial direct current stimulation will be applied to study group only . Anodal transcranial stimulation will be applied on left somatosensory cortex while the cathodal one will be applied on right supra-orbital area with frequency of 2m.A for 20 minutes.Stimulation will be applied three times per week for two months.
89028182|NCT04516200|Placebo Comparator|traditional physical therapy program|traditional physical therapy program will be applied to both the control group and study group. It will be consist of sensory re-education training and balance training.Exercises will be applied three times per week for two months
89028183|NCT01297465|Active Comparator|Gonal-f® Plus Pergoveris®|
89028184|NCT01297465|Experimental|Pergoveris®|
89028185|NCT02276508|Experimental|Probiotic|Participants will take the E. coli Nissle 1917 as an orally administered medication first while in clinic to be observed for 30 minutes for any hypersensitivity reaction. The dose of Nissle 1917 will be 100mg capsule (2.5-25x109 organism) once daily for a total of 4 days. Participants will then increase the dose to 2 capsules (200mg) once daily for the remaining 26 days of the study period.
89028186|NCT00496106|Experimental|Control Arm|6 telephone counseling sessions
89028187|NCT00496106|Active Comparator|Usual Care Arm|6 telephone counseling sessions
89028188|NCT04511286|Experimental|Internet-delivered exposure-based treatment|Eight weeks of therapist-guided exposure-based treatment delivered via the Internet.
89028189|NCT00493571|Experimental|Gimatecan|Gimatecan Starting dose: 0.6 mg capsules administered orally once daily.
89028190|NCT02276586|Active Comparator|Group 1|Horizontal Tooth preparation
89028191|NCT02276586|Experimental|Group 2|Vertical tooth preparation
89028192|NCT00496145|Experimental|treatment|Spanish Diabetes Self-Management Program
89028193|NCT00496145|No Intervention|control|usual-care control group
89028194|NCT01297309|Experimental|NPSP558|titration of 25, 50, 75 or 100 μg
89028195|NCT04518462|Experimental|EXPAREL arm|Subjects randomized to this treatment arm will receive 20 mL (266 mg)EXPAREL mixed with 20 mL saline
89567780|NCT04662164|Placebo Comparator|placebo|control
89567781|NCT04662164|Active Comparator|4.2mg hepalatide|low dose
89567782|NCT04662164|Active Comparator|6.3mg hepalatide|middle dose
89567783|NCT04662164|Active Comparator|8.4mg hepalatide|high dose
89567784|NCT04647162|Active Comparator|medical group|Patients receive only medical treatment including active life support, nutritional support, homeostasis maintenance of the internal environment, and other symptomatic treatment.
89567785|NCT04647162|Experimental|surgical group|Patients receive intervention such as the evacuation of hematoma under craniotomy or by stereotactic puncture or neuroendoscopy.
89567786|NCT04644016|Experimental|Participants with non-malignant and malignant hematologic disorders|Participants with life threatening non-malignant and malignant hematologic disorders who do not have a matched related donor for allogeneic transplantation.
89567787|NCT04626921|Experimental|Active treatment with 30 mg of CNM-Au8|Highly pure elemental Au nanocrystals are suspended in deionized water buffered with 0.546 mg/mL (6.5 mM) sodium bicarbonate (NaHCO3) concentrated up to 0.5 mg/mL (500 ppm) Au.
89567788|NCT04622176||Patients with rectal cancer|Patients with rectal cancer will be included and asked to participate in the study where a MMUS will be used after resection to test diagnostic accuracy.
89567789|NCT04615910|Experimental|Verapamil|Patients treated with Verapamil within the Ver-A-T1D trial
89567790|NCT04615910|Placebo Comparator|Placebo|Patients treated with placebo within the Ver-A-T1D trial
89567791|NCT04603924|Experimental|ANA001|Subjects in the ANA001 treatment arm will receive 1,000 mg (4 capsules; 250 mg each) by mouth twice per day for 7 consecutive days with a meal. If the participant requires mechanical ventilation over the course of the study, ANA001 may be administered via nasogastric (NG), percutaneous endoscopic gastrostomy (PEG) or orogastric (OG) tube and, if possible, should be administered with a scheduled nasogastric (NG) or orogastric (OG) feeding.
89567792|NCT04603924|Placebo Comparator|Matching Placebo|Subjects in the comparator arm will receive matching placebo (hydroxypropylmethylcellulose (HPMC)) (4 capsules, by mouth twice a day) for the 7-day treatment duration.
89028196|NCT04518462|Experimental|EXPAREL admix arm|subjects randomized to this treatment arm will receive 20 mL (266 mg)EXPAREL admixed with 20 mL (50 mg) 0.25% bupivacaine HCl.
89028197|NCT04518462|Active Comparator|Bupivacaine HCl Arm|subjects randomized to this treatment arm will receive 40 mL (100 mg)0.25% bupivacaine HCl.
89028198|NCT00493610|Other|1|
89028199|NCT02274506|Experimental|T-Cell Administration|"Cyclophosphamide 60 mg/kg by vein for 2 consecutive days, followed by Fludarabine at 25 mg/m2/day by vein for 5 consecutive days. Fludarabine dose calculated per adjusted ideal body weight.~T-cell product divided into 2 portions. Up to 25% of the genetically modified cells given on first day, with plan to infuse up to 75% of the remaining T-cell dose no sooner than 24 hours after completion of first portion. Second portion should not be given later than 72 hours after first portion. First group of 3 participants receive lowest dose of T-cells. Each new group receive a higher dose of T-cells than the group before it, if no intolerable side effects were seen. Up to 6 dose levels of T-cells will be tested."
89567793|NCT04596657|Experimental|Intervention|
89567794|NCT04596657|No Intervention|Control|
89028200|NCT04519632||Parents|Qualitative interviews
89028201|NCT04519632||Healthcare Professionals|Qualitative interviews
89028202|NCT04519632||Children|Children and young people aged 6-18 years, Qualitative interviews
89028203|NCT00496223|Experimental|1|
89208656|NCT02553824|Placebo Comparator|Placebo-First + Phentermine/Topiramate|Patients randomly assigned to this condition will receive the control medication (placebo) first followed by a 2 week washout, and then receive the study medication.
89208657|NCT00980889|Active Comparator|steel|Insertion of Metalic Steel Stent, Wallstent® in malignant distal bile duct obstruction
89208658|NCT00980889|Active Comparator|Nitinol|Insertion of Metalic nitinol Stent, Wallflex® in malignant distal bile duct obstruction
89208659|NCT04039854|Active Comparator|Volatile anaesthetics arm|Patients randomised to receive volatile anaesthetics will receive either isoflurane, sevoflurane or desflurane during the surgical procedure.
89567795|NCT04569058|Experimental|Transcranial Photobiomodulation|Transcranial Photobiomodulation--a noninvasive intervention in which near-infrared light (850 nanometer) is applied to forebrain.
89567796|NCT04562766|Experimental|Rilzabrutinib|Patients receive rilzabrutinib 400mg orally twice daily for up to 24 weeks followed by 28 weeks of open label period
89567797|NCT04562766|Placebo Comparator|Placebo|Patients receive matching placebo 400mg orally twice daily for up to 24 weeks
89567798|NCT04553757||Observational (survey)|Patients complete a seizure assessment survey over 5 minutes at each clinic visit.
89567799|NCT04528082|Experimental|Apremilast|Participants will receive apremilast orally in the double-blind 12 week treatment phase. Then the participants will continue to receive apremilast in the active 40 weeks treatment phase.
89567800|NCT04528082|Placebo Comparator|Placebo to Apremilast|Participants will receive the matching placebo orally in the double-blind 12 week treatment phase. Then the participants will receive apremilast in the active 40 weeks treatment phase.
89567801|NCT04519827|Experimental|New Rice-based hydrolysate|The TEST formula is a new Rice-based hydrolysate with new ingredient.
89567802|NCT04519827|Placebo Comparator|Amino-acid based formula|The PLACEBO is an Amino-acid based formula.
89567803|NCT04518085|Experimental|Hypnosis + iACT|Single 20 minute medical hypnosis session delivered pre-surgery plus internet-based acceptance and commitment therapy delivered post-surgery
89567804|NCT04518085|Active Comparator|Mindfulness + treatment as usual (TAU)|Single 20 minute mindfulness session delivered pre-surgery plus treatment as usual post-surgery
89567805|NCT04513067|Experimental|Stage 1: Single agent|Intravenous weekly dose of YQ23 for 6 weeks with an ascending dose levels of 20, 30, 60, 90 and 120 mg/kg will be evaluated.
89567806|NCT04513067|Experimental|Stage 2: Combination Therapy|Intravenous weekly dose of YQ23 for 6 weeks with an ascending dose levels from 20 mg/kg to the MTD obtained from Stage 1 in combination of a fixed dose of 200 mg intravenous pembrolizumab given on the same day following YQ23 administration and every 3 weeks thereafter.
89567807|NCT04513054|Other|Takotsubo Case Arm|A patient that has been diagnosed with Takotsubo Cardiomyopathy from 2010 onwards.
89567808|NCT04505410|Experimental|Tofacitinib plus FMD group|Participants in this group with UC consuming a standard, regular low-fiber diet will be provided Tofacitinib for eight consecutive weeks with the addition of two, five-day cycles of Fast Mimicking Diet (FMD) daily meals on weeks 2 and 6.
89567809|NCT04505410|Active Comparator|Tofacitinib only group|Participants in this group with UC consuming a standard, regular low-fiber diet will be provided Tofacitinib for eight consecutive weeks.
89567810|NCT04505410|Experimental|Infliximab plus FMD group|Participants in this group with UC consuming a standard, regular low-fiber diet and will have initiated second line biologic therapy with infliximab with the addition of two, five-day cycles of Fast Mimicking Diet (FMD) daily meals on weeks 2 and 6.
89567811|NCT04505410|Active Comparator|Infliximab only|Participants in this group with UC consuming a standard, regular low-fiber diet for 8 consecutive weeks and will have initiated second line biologic therapy with infliximab
89567812|NCT04505410|Experimental|Ustekinumab plus FMD group|Participants in this group with UC consuming a standard, regular low-fiber diet and will have initiated second line biologic therapy with ustekinumab with the addition of two, five-day cycles of Fast Mimicking Diet (FMD) daily meals on weeks 2 and 6.
89567813|NCT04505410|Active Comparator|Ustekinumab only|Participants in this group with UC consuming a standard, regular low-fiber diet for 8 consecutive weeks and will have initiated second line biologic therapy with ustekinumab
89567814|NCT04488289|Other|Parallel measurement of blood pressure|Office blood pressure, self-directed and ambulatory blood pressure measurement.
89567815|NCT04479696|Experimental|Arm I (NIRS)|Patients receive standard of care verbal and written education materials. Patients also receive a customized video which includes a description of each of their tumor, functional areas of the brain affected, and possible symptoms from the tumor and radiation treatment based on the neuro-imaging features. Patients and their caregivers watch the video together or separately over 1.5-3 minutes before the end of the first week of radiation treatment. Within 2 weeks after watching the NIRS video, patients complete an optional survey over 5-10 minutes.
89567816|NCT04479696|Active Comparator|Arm II (standard of care)|Patients receive standard of care verbal and written education materials.
89567817|NCT04478266|Active Comparator|Letrozole + Palbociclib|Participants received letrozole 2.5 milligrams (mg) capsule along with amcenestrant-matching placebo once daily, continuously and palbociclib 125 mg orally (PO), once daily (QD) from Day 1 to Day 21 of each 28-day treatment cycle until disease progression, death or study cut-off date, whichever comes first (maximum exposure: 112 weeks). Goserelin once every 4 weeks in pre/peri menopausal women and men.
89567818|NCT04478266|Experimental|Amcenestrant + Palbociclib|Participants received amcenestrant 200 mg tablet along with letrozole-matching placebo once daily, continuously and palbociclib 125 mg PO, QD from Day 1 to Day 21 of each 28-day treatment cycle until disease progression, death, or study cut-off date, whichever comes first (maximum exposure: 109 weeks). Goserelin once every 4 weeks in pre/peri menopausal women and men.
89567819|NCT04457778|Experimental|Part 1A: M6223 Monotherapy|
89567820|NCT04457778|Experimental|Part1B: M6223 + Bintrafusp alfa|
89567821|NCT04456504|Experimental|Healthcare worker|Healthcare worker who has previously received at least 5 doses of hepatitis B vaccine with aluminum adjuvant (Recombivax B or Engerix B) and has an antibody to the hepatitis B surface antigen (antiHBs) that is less than 10 mIU/ml.
89567822|NCT04450693|Experimental|TTAX01|TTAX01 plus standard of care
89567823|NCT04450693|Other|Control|Standard care alone
89567824|NCT04435288|Active Comparator|TNFi-induction group|"The patients in the TNFi-induction group will receive golimumab at a standard dose of 50 mg subcutaneously (SC) every 4 weeks (with matching methotrexate (MTX)-placebo). In case of potential intolerance or toxicity to MTX-placebo, the dose will be gradually tapered to a minimum of 7.5 mg per week. When there are no tolerability/toxicity issues, the weekly dose of MTX-placebo will be increased to 20 mg at week 4. At week 12, a Patient Acceptable Signs & Symptoms Improvement ('PASSI') will be assessed by asking the question Taking into account both efficacy and side effects, did you experience over the past 12 weeks enough improvement in signs and symptoms of your' arthritis-enthesitis-dactylitis to consider continuation of the same treatment schedule for the next 12 weeks?. If yes, all study medication will be kept stable until week 24; if no, oral sulphasalazine at a dose of 2 g per day will be started (escape medication)."
89208660|NCT04039854|Active Comparator|Propofol anaesthetics arm|Patients randomised to receive propofol will not receive any volatile anaesthetics during the surgical procedure.
89567825|NCT04435288|Active Comparator|csDMARD-Step-up group|"The patients in the csDMARD-Step-up group will start with oral methotrexate (MTX) at a weekly dose of 15 mg for 4 weeks (with matching TNFi-placebo injections). In case of potential intolerance or toxicity to MTX , the dose will be gradually tapered to a minimum of 7.5 mg per week. When there are no tolerability/toxicity issues, the weekly dose of MTX will be increased to 20 mg at week 4. At week 12, a Patient Acceptable Signs & Symptoms Improvement ('PASSI') will be assessed by asking the question Taking into account both efficacy and side effects, did you experience over the past 12 weeks enough improvement in signs and symptoms of your' arthritis-enthesitis-dactylitis to consider continuation of the same treatment schedule for the next 12 weeks?. If yes, all study medication will be kept stable until week 24; if no, oral sulphasalazine at a dose of 2 g per day will be started (escape medication)."
88969770|NCT05720494|Placebo Comparator|Placebo|Healthy participants who will be randomized to receive placebo.
88969771|NCT05714891|Experimental|Neoadjuvant therapy (JDQ443) followed by surgery.|"If *MPR/cPR* - standard of care adjuvant treatment may be followed by experimental adjuvant therapy (JDQ443)~*Major Pathological Response (MPR)/ Complete Pathological Response (cPR)"
88969772|NCT05701059||Semi-Constrained Nuvasive Simplify|This group will be undergoing cervical arthroplasty with the Nuvasive Simplify artificial disc implant. The Nuvasive Simplify implements a three-piece design with two endplates and a semi-constrained mobile core.
88969773|NCT05701059||Unconstrained Biomet Zimmer Mobi-C|This group will be undergoing cervical arthroplasty with the Biomet Zimmer Mobi-C artificial disc implant. The Biomet Zimmer Mobi-C implements an unconstrained three piece design.
88969774|NCT05691738|Experimental|Exercise Group|Information will be given about diabetes and its complications.Modified Otago Exercise will be applied by the physiotherapist.Participants will be given a home program
88969775|NCT05691738|Other|Control Group|Information will be given about diabetes and its complications.Participants will be given a home program
88969776|NCT05687682|Experimental|Level -1|0.1 mg/kg
89567826|NCT04426968|Experimental|Hepalatide 2.1mg+Pegylated Interferon|"Hepalatide 2.1mg s.c., q.d., treatment continued for 24 weeks, follow up 4 weeks.~PEG-IFNalpha, s.c., q.w.,treatment continued for 48 weeks"
89567827|NCT04426968|Experimental|Hepalatide 4.2mg+Pegylated Interferon|"Hepalatide 4.2mg s.c., q.d., treatment continued for 24 weeks, follow up 4 weeks.~PEG-IFNalpha, s.c., q.w.,treatment continued for 48 weeks"
89567828|NCT04426968|Experimental|Hepalatide 6.3mg+Pegylated Interferon|"Hepalatide 6.3mg s.c., q.d., treatment continued for 24 weeks, follow up 4 weeks.~PEG-IFNalpha, s.c., q.w.,treatment continued for 48 weeks"
89567829|NCT04426968|Active Comparator|placebo+Pegylated Interferon|"Hepalatide placebo s.c., q.d., treatment continued for 24 weeks, follow up 4 weeks.~PEG-IFNalpha, s.c., q.w.,treatment continued for 48 weeks"
89567830|NCT04413877||Descriptive cohort study|"Prospective cohort study of community-dwelling adults ≥65-year-old living at home, with no other exclusion criteria than the inability to use the ICOPE Apps or communicate by telephone/video-call for any reason (cognitive or limited access to technologies like telephone/video-call).~Cohort study, designed to determine the incidence of frailty in community-dwelling older people during 1-year follow-up, starting the recruitment at a certain point of the COVID-19 pandemic and beyond."
89567831|NCT04406974||Patients with local recurrence|
89567832|NCT04406974||Patients with advanced colorectal cancer|
89567833|NCT04379505|Experimental|Quad shot radiation|-Radiotherapy will consist of Quad shot radiation delivered on the Ethos ring gantry kV-CBCT combined with linear accelerator system to a dose of 14 Gy in four, twice-daily fractions of 3.5 Gy delivered at least 6 hours apart over two days for a possible total of 3 cycles delivered in 3 to 4 intervals for a cumulative dose of of 42 Gy in 12 fractions. Cycle 2 and 3 of treatment is not mandated per protocol but may be given at the discretion of the treating physician.
89567834|NCT04333524||Group A|Staging
89567835|NCT04333524||Group B|Criteria for response assessment
89567836|NCT04286295|Experimental|Cytisine|Cravv™ (Zpharm, Waterloo) is a natural health product licensed by Health Canada to assist with smoking cessation; each oral capsule contains 1.5mg of cytisine. The dosing is as follows: 6 capsules daily for the first 3 days; 5 capsules daily for days 4-12; 4 capsules daily for days 13-16; 3 capsules daily for days 17-20; and 1-2 capsules daily for days 21-25.
89567837|NCT04286295|Active Comparator|NRT+|The Nicoderm® patch plus Nicorette® Lozenge will be provided to participants in the combination NRT group. Participants smoking less than 15 cigarettes per day will be provided with 14 mg patches while those smoking 15 or more cigarettes per day will receive 21 mg patches. Participants will be told to apply a new patch each morning. Participants will be instructed to use the lozenges as needed (up to 15 per day) to overcome nicotine cravings. Lozenges are available in both 2mg and 4mg strengths. For those who are smoking less than 15 cigarettes per day, they will be given the 2mg strength. For those who are smoking 15 or more cigarettes per day, they will receive the 4mg strength.
89567838|NCT04286269|Experimental|Intervention|Participants in this group will be randomized to receive the intervention.
88969777|NCT05687682|Experimental|Level 1|0.3 mg/kg (Starting Dose)
88969778|NCT05687682|Experimental|Level 2|1 mg/kg
88969779|NCT05687682|Experimental|Level 3|3 mg/kg
88969780|NCT05687682|Experimental|Level 4|6 mg/kg
88969781|NCT05687682|Experimental|Level 5|10 mg/kg
88969782|NCT05687682|Experimental|Level 6|15 mg/kg
88969783|NCT05686512|Experimental|Step-by-Step treatment|Stepped care cognitive behavioral therapy
88969784|NCT05686512|Experimental|Cool Kids treatment|Cognitive behavioral therapy
88969785|NCT05685498|Other|Peer-led HIV self-testing among male fisherfolk in Uganda|Men aged 15 years or older, who self-report a HIV-negative or unknown HIV status at enrolment and last tested for HIV three or more months are enrolled into the study. Enrolled men receive two HIV self-test kits from a trained community-based distributor (or peer-leader). Peer-leaders are selected from existing social networks and are trained in HIV self-testing procedures prior to distributing HIV self-test kits. The goal of the study is to assess if distribution of HIV self-test kits to men through trained local peer-leaders is feasible and acceptable in a fishing community context, and whether this approach can help to improve access to HIV testing services and, by implication, improve HIV testing uptake and subsequent linkage to appropriate HIV prevention, care and treatment services. Men are interviewed at baseline will be followed up at 1, 6 and 12 months post-baseline to determine HIV testing uptake, linkage to and retention in HIV care.
88969786|NCT05678686|Active Comparator|Routine Exercise Group|Conventional swallowing therapy exercises will be given to the routine exercise group.
88969787|NCT05678686|Experimental|PNF Exercise|Head-neck PNF (Proprioceptive Neuromuscular Facilitation) movement patterns will be applied to the participants with the combined isometric contraction technique.
88969788|NCT05678686|Experimental|CTAR Exercise|CTAR (Chin Tuck Against Resistance) exercises will be applied to the participants.
88969789|NCT05673226|Experimental|Surface disinfection with organosilane|Organosilane will be sprayed on the surfaces, using an atomizer. When the environment has been completely covered (i.e., when all surfaces and equipment have a slightly damp film), we will proceed with the second phase of the disinfection of all heavily touched surfaces. surfaces of the bed, with a microfiber cloth with organosilane.
89567839|NCT04286269|Sham Comparator|Placebo|Participants in this group will be randomized to receive a sham treatment.
89567840|NCT04286087|Experimental|Investigational Arm|
89567841|NCT04286087|Active Comparator|Control Group|
89608841|NCT03156153|Placebo Comparator|Control group|Double-blind phase: in the first 3 months, patients will receive the placebo - oral intake, 0.5mg/time, twice a day; Open-label phase: after 3 month double-blined treatment, patients in this group will receive 3-month bumetanide treatment - oral intake, 0.5mg/time, twice a day.
89608842|NCT03155919|Experimental|TAUchoc|Treatment composed by taurine powder and chocolate milk
89608843|NCT03155919|Placebo Comparator|PLAchoc|Treatment composed by placebo (starch powder) and chocolate milk
89608844|NCT02003183||Suspected CTE|A total of 22 participants with suspected CTE were studied. Each received clinical and neuropsychological assessments, [F-18]FDDNP-PET scans, and magnetic resonance imaging (MRI) scans, or computed tomography scans if they could not tolerate MRI (to assist in PET region of interest identification).
89608845|NCT03156231|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m
89567842|NCT04267744|Other|Remote patient monitoring|"After consenting to the study, the Myia in-home suite of devices, and mobile phone application if the patient owns a smart phone, will be provided to all recruited patients. The data flowing from the Myia platform will be available to clinicians and patients for the duration of the pilot and utilized to complete study activities.~Patients enrolled will transmit daily vital sign data to the Myia Health remote patient monitoring platforms for clinical review.~Enrolled patients will complete medication change/compliance survey monthly to assess for medication changes.~Enrolled patients will complete symptomatic assessments (KCCQ-12) at 0, 3, and 6 months.~Enrolled patients will complete a Check-In survey to assess utility and usability of the intervention at the 2, 4, and 6 month timepoints"
89567843|NCT04241068|Experimental|Aducanumab|Participants will be administered aducanumab 10 milligrams per kilogram (mg/kg) by intravenous (IV) infusions every four weeks (Q4W) for a duration of 100 weeks during the Core Treatment Period. Eligible participants will continue to receive aducanumab 10 mg/kg IV infusion, Q4W, for 52 weeks during the Long-Term Extension (LTE) Treatment Period.
89567844|NCT04233216|Experimental|ISL + ART|HTE participants with HIV-1 infection take ISL 0.75 mg once daily (QD) in combination with failing ART from Day 1 to Day 7; followed by open-label 100 mg DOR/0.75 mg ISL fixed dose combination (FDC) QD + OBT from Day 8 to Week 97.
89567845|NCT04233216|Experimental|DOR + ART|HTE participants with HIV-1 infection take DOR 100 mg QD in combination with failing ART from Day 1 to Day 7; followed by open-label 100 mg DOR/0.75 mg ISL FDC QD + OBT from Day 8 to Week 97.
89567846|NCT04233216|Experimental|DOR/ISL + ART|HTE participants with HIV-1 infection take 100 mg DOR/0.75 mg ISL FDC QD in combination with failing ART from Day 1 to Day 7; followed by open-label 100 mg DOR/0.75 mg ISL FDC QD + OBT from Day 8 to Week 97.
89567847|NCT04233216|Placebo Comparator|Placebo + ART|HTE participants with HIV-1 infection take placebo QD in combination with failing ART from Day 1 to Day 7; followed by open-label 100 mg DOR/0.75 mg ISL FDC QD + OBT from Day 8 to Week 97.
89567848|NCT04218409|Active Comparator|oxycodone (5mg) + intranasal oxytocin (48 IU)|Combined effects of oxycodone and oxytocin
89567849|NCT04218409|Active Comparator|Oral oxycodone (5mg) + intranasal placebo|Separate effects of oxycodone. As is standard methodology in abuse liability and pain assessments a placebo condition will be included for each drug in order to compare the abuse liability and pain assessments change from placebo
89567850|NCT04218409|Active Comparator|oxytocin+placebo|Separate effects of oxytocin. As is standard methodology in abuse liability and pain assessments a placebo condition will be included for each drug in order to compare the abuse liability and pain assessments change from placebo
89567851|NCT04218409|Sham Comparator|placebo+placebo|Serves as the control
89567852|NCT04218409|Active Comparator|Oral oxycodone (2.5mg) + intranasal oxytocin (48 IU)|Combined effects of oxycodone and oxytocin
89567853|NCT04218409|Active Comparator|Oral oxycodone (2.5mg) + intranasal placebo|Separate effects of oxycodone. As is standard methodology in abuse liability and pain assessments a placebo condition will be included for each drug in order to compare the abuse liability and pain assessments change from placebo
88969790|NCT05673226|No Intervention|Usual surface disinfection|The control group will perform standard cleaning and disinfection of the beds and the environment according to their previous protocols, using the usual products.
88969791|NCT05672667|Experimental|Oxytocin Intravenous|Oxytocin 14 micrograms infusion over 30 minutes
88969792|NCT05672667|Experimental|Oxytocin intranasal|Oxytocin 102 micrograms self administered into nasal passages
88969793|NCT05671406|Experimental|Sensor-controlled digital game|The intervention group will receive a sensor-controlled digital game (SCDG) app and physical activity tracker.
88969794|NCT05671406|Active Comparator|Sensor-only|The control group will receive only the physical activity tracker.
88969795|NCT05671159|Experimental|bacterial infection|
88969796|NCT05671159|Other|viral infection|
88969797|NCT05669417|Active Comparator|Magnesium Sulfate|Magnesium sulfate is the active compound and will be administered to achieve plasma serum level of magnesium between 1.5 and 2.0 mmol/L according to the study protocol.
88969798|NCT05669417|Placebo Comparator|Ringers Lactate|Ringers Lactate is the comparator/placebo and will be administered according to the study protocol.
88969799|NCT05668754|Experimental|Experimental: SDX|SDX capsules at the optimized daily dose, once in the evening daily (qd pm) or twice per day (bid), for 2 weeks (DBWP)
88969800|NCT05668754|Placebo Comparator|Active Comparator|Placebo capsules once in the evening daily (qd pm) or twice per day (bid), for 2 weeks (DBWP)
88969801|NCT05668104|Experimental|Jing Si Herbal Tea Liquid Packet|Participants received Jing Si Herbal Tea Liquid Packet 15 mg tablet orally twice daily for 28 days.
88969802|NCT05668104|Placebo Comparator|Jing Si Herbal Tea Liquid Packet Placebo|Participants received Jing Si Herbal Tea Liquid Packet Placebo 15 mg tablet orally twice daily for 28 days.
88969803|NCT05664217|Experimental|Stage 1 NKTR-255 at 1.5 µg/kg|"In this arm of Stage 1 (Phase 2 of the study), NKTR-255 will be dosed at 1.5 µg/kg. NKTR-255 will be administered intravenously approximately 14 days after CD19-directed CAR-T cell infusion.~Patients will be dosed every 3 weeks for up to 7 cycles or 5 months, whichever is earlier, in the absence of disease progression or unacceptable toxicity.~The dose regimen for Stage 2 (Phase 3 of the study) will be selected based on the results of Stage 1 as reviewed by the Data Monitoring Committee (DMC) and the study team."
89567854|NCT04217408|Experimental|ON stimulation followed by OFF stimulation|All patients complete the same 52 week open-label phase with active stimulation. After this, they enter a blinded randomized crossover phase of 2 weeks of ON (active) stimulation, followed by 2 weeks of OFF (sham) stimulation
89567855|NCT04217408|Experimental|OFF stimulation followed by ON stimulation|All patients complete the same 52 week open-label phase with active stimulation. After this, they enter a blinded randomized crossover phase of 2 weeks of OFF (sham) stimulation, followed by 2 weeks of ON (active) stimulation
89608846|NCT03156231|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m.
89608847|NCT03585387||Main|Each subject in this group will be its own control for the two navigation methods.
89608848|NCT05702151|Active Comparator|Morphine infusion|IV morphine 50mcg/kg/h infusion with Patient Controlled Analgesia extra bolus on demand of 1mg (lockout interval 20 minutes), and paracetamol 1g every 8 hours.
89567856|NCT04198857|No Intervention|Standard Care + Telemonitoring: Control|Standard care for GDM will be modifying diet& exercise and/or medication use. Participants will have consultations with a dietitian and a physical therapist to develop a diet and physical activity plan based on pre-pregnancy weight and disease severity. In addition to verbal information about managing GDM with diet and physical activity, patients will be provided with leaflets and brochures. As per the standard care protocol, GDM patients will be asked to visit the OPD for glucose testing every two weeks, and after each testing, blood glucose levels will be recorded in paper booklets assigned to each patient. In addition, the women will be provided with a glucometer and a blood pressure monitor machine. Participants will be taught to use these devices for self-monitoring and will be provided guidelines to follow at home. The OB/GYN physicians will monitor the blood glucose levels across testing, and will prescribe oral hypoglycemic medications or insulin to the patient if needed.
89567857|NCT04198857|Experimental|Standard Care + GDM-DH app + Telemonitoring|In addition to standard care and telemonitoring, this group will use the GDM-DH app. This group will be provided with the same devices as the control group and in addition, the GDM-DH app will be set up in their cellular device. The app will be on their smart phone and will support self-management by: i) providing health education, ii) helping patients identify and set target health goals (for diet, physical activity, and glucose levels), iii) enhancing their self-efficacy to meet target goals, and iv) facilitating desired support from family members. The core component of the GDM-DH app will be to allow GDM patients to record and self-monitor their carbohydrate intake, physical activity and blood glucose levels. Patients will be able to manually enter their weekly blood glucose levels and blood pressure readings on to the app
89567858|NCT04187976||Patients with moderate to severe uncontrolled asthma|Patients with moderate to severe uncontrolled asthma defined on clinical assessment and spirometric criteria. Non controlled asthma is considered when ACQ score ≥ 1.5 or in case of acute exacerbation
89567859|NCT04187976||Patients with recalcitrant CRSwNP requiring sinus surgery|The medical failure in CRSwNP is defined as persistent disease in spite of 3 courses of oral corticosteroid and double dose of local corticoid over 12 months
89567860|NCT04187976||Patients with concomitant CRSwNP and uncontrolled asthma|Patients with concomitant CRSwNP and moderate to severe uncontrolled asthma
89567861|NCT04187976||Healthy subjects|Patients without any airway inflammatory disease or atopy
89567862|NCT04173507|Experimental|Treatment (talazoparib, avelumab)|Patients receive talazoparib PO daily and avelumab IV over 60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89567863|NCT04165798||Prospective NSCLC Participants|Male and female participants with histologically-confirmed diagnosis of squamous or nonsquamous NSCLC will be screened for participation in 1 of 3 pembrolizumab substudies.
89567864|NCT04124393|Active Comparator|Water Exchange (WE) Colonoscopy|In the WE group, the air pump will be turned off before starting the procedure. During the insertion phase, the colon will be irrigated with warm water (32C-35C). WE entails the infusion of water to open the lumen and simultaneous suction if the endoscope has two channels, and sequentially if the endoscope has only one channel. When the cecum is reached and after most of the water is suctioned to collapse the cecal lumen, CO2 will be opened. The colonoscope will be withdrawn to the hepatic flexure. All polyps identified will be resected (colon polypectomy). The colonoscope will then be reinserted into the cecum by the first endoscopist. A tandem inspection of the right colon will be performed by a blinded endoscopist. All polyps found herein will be counted as the missed polyps. After the second withdrawal to the distal hepatic flexure, the remainder of the colon will be examined in a standard manner by the first endoscopist.
89567865|NCT04124393|Active Comparator|CO2 Insufflation Colonoscopy|In the CO2 group, colonoscopy is performed in the usual fashion, with minimal insufflation required to aid insertion. Cleaning in the CO2 group will be performed entirely during withdrawal. Upon arriving at the cecum, CO2 insufflation will be used and the colonoscope will be withdrawn from the cecum to the hepatic flexure. All polyps identified will be resected (colon polypectomy). Then, the colonoscope will be reinserted into the cecum by the first endoscopist. A tandem inspection of the right colon will be performed by a blinded endoscopist. All polyps found herein will be counted as the missed polyps. After the second withdrawal to the distal hepatic flexure, the remainder of the colon will be examined in a standard manner by the first endoscopist.
89567866|NCT04121260|Experimental|Daratumumab|Participants will receive daratumumab dose 1 subcutaneously (SC) with recombinant human hyaluronidase [rHuPH20] 30,000 units [U] that is 2,000 U/milliliter (U/mL) SC injection once weekly for the first 8 weeks Cycles 1 and 2 (Days 1, 8, 15, and 22 of each week), every 2 weeks Cycles 3 to 6 (Days 1 and 15) or the following 16 weeks and then every 4 weeks from Cycle 7 [Day 1] in subsequent cycles, until disease progression, unacceptable toxicity, or any other reason for discontinuation. Each cycle is 28 days in duration.
89567867|NCT04118660||Thoracic Disease|Thoracic Diseases (which includes but not limited to the following: thoracic neoplasms (masses/nodules) malignant or benign, interstitial lung diseases (ILD), chronic obstructive pulmonary disease (COPD), thoracic infections, thoracic malignancies metastatic to other organs, other cancers metastatic to the thoracic cavity.
89608849|NCT05702151|Experimental|ESP Block analgesia|"After induction of anesthesia in the operating room, the patient is positioned in lateral decubitus. Under strict aseptic conditions, and guided by ultrasound, an Erector Spinae Plane block is performed injecting ropivacaine 0.2% 20ml, and a catheter is placed.~An infusion of ropivacaine 0.16% at 10ml/h is started in the operating room. Patient Controlled Analgesia pump will be connected with 1mg IV morphine bolus on demand, and paracetamol 1g every 8 hours, is also delivered."
88969804|NCT05664217|Experimental|Stage 1 NKTR-255 at 3.0 μg/kg|"In this arm of Stage 1 (Phase 2 of the study), NKTR-255 will be dosed at 3.0 μg/kg. NKTR-255 will be administered intravenously approximately 14 days after CD19-directed CAR-T cell infusion.~Patients will be dosed every 3 weeks for up to 7 cycles or 5 months, whichever is earlier, in the absence of disease progression or unacceptable toxicity.~The dose regimen for Stage 2 (Phase 3 of the study) will be selected based on the results of Stage 1 as reviewed by the Data Monitoring Committee (DMC) and the study team."
89028204|NCT02593422|Experimental|Expressive Writing|Writing about ovarian cancer: Participants will be asked to write about their deepest thoughts and emotions about their experience with ovarian cancer
89028205|NCT02593422|Active Comparator|Fact Writing (Control)|Writing about ovarian cancer: Participants will be asked to write about the facts of their experience with ovarian cancer
89028206|NCT00493688||Cardiopulmonary Exercise Testing (CPET)|
89028207|NCT02597985|Active Comparator|Prehabilitation|Will receive 4 weeks of supervised exercised prescription before they undergo TAVR and will monitor and record, improvement if any, in the short-term physical performance battery score
89608850|NCT01986647|Experimental|On the Move Exercise - exercise leader|On the Move group exercise - 2 times per week for 12 weeks. Each session lasts approximately 1 hour. Timing and coordination exercises to improve walking. Led by exercise leader
89028208|NCT02597985|Placebo Comparator|Usual care|Will receive usual care
89028209|NCT00496418|Experimental|Prophylactic stoma mesh|Mesh
89028210|NCT00496418|Active Comparator|No mesh prophylaxis|No mesh
89028211|NCT05141838|Experimental|Group 1 - Vitamin D|Patients receiving vitamin D supplements in therapy
89028212|NCT05141838|Experimental|Group 2 - Oral nutritional supplement|Patients receiving oral nutritional supplement
89028213|NCT05141838|Experimental|Group 3 - Vitamin D+Oral nutritional supplement|Patients receiving vitamin D supplements and oral nutritional supplement in therapy
89028214|NCT05141838|No Intervention|Group 4 - No intervention|Patients with dystrophic form of congenital epidermolysis bullosa who have not taken vitamin D supplements and/or oral nutritional supplement
89028215|NCT00493727|Other|1|
89028216|NCT05143788|Experimental|New surgical plan group|The investigators use monopolar stimulators to determine and retain the tumor margin within 5mm from the posterior limb of the inner capsule in type III motor area glioma patients.
89028217|NCT05143788|Active Comparator|Traditional surgical plan group|The investigators use bipolar stimulator according to the current standard surgery plan. After the positive points are identified by stimulator, the positive points are retained in order to preserve the motor function while all the non-positive points of the tumor are resected.
89028218|NCT00493766|Experimental|oral LBH589 alone|
89028219|NCT00493766|Experimental|oral LBH589 + IV docetaxel + oral prednisone|
89028220|NCT05140005|Other|15 subjects testing themselves|15 subjects will use the Glow Test Kit to test themselves for Covid 19.
89028221|NCT05140005|Other|15 subjects testing someone else|15 subjects will use the Glow Test Kit to test someone else (a child) for Covid 19.
89028222|NCT00496457|Experimental|1|TRO19622
89028223|NCT00496457|Placebo Comparator|2|
89028224|NCT02598648|Other|ALI( acute lung injury)|Diagnostic criteria: 1.Acute onset；2.FiO2/ PaO2< 40.0 kPa (300mmHg, ALI); 3.Chest X-ray showed that the double lung texture increased, the increase of crude, fuzzy, visible diffuse patchy infiltration shadow with compensatory emphysema, for the most early performance; B. double lung field large sheet, asymmetric, edge fuzzy infiltration shadow, the most dense in the lung；4. Echocardiography, left atrial hypertension; 5.The gestational age >35 week, have maternal age cholestasis (severe), sepsis or meconium aspiration syndrome (MAS) understanding of history, and with the exception of the primary pulmonary surfactant (PS) lack of. FXR and RIPK3 were measured in neonate with ALI.
89028225|NCT02598648|Other|ARDS(respiratory distress syndrome)|"ARDS :Diagnostic criteria: 1.Acute onset；2.FiO2/ PaO2< 26.7 kPa (200mmHg, ARDS); 3.Chest X-ray showed that the double lung transparent brightness is generally lower, the glass sample, with bronchial inflatable sign, and even double lung field common density increased, the heart shadow is not clear, a white lung, as the most important performance；4. Echocardiography, left atrial hypertension; 5.The gestational age >35 week, have maternal age cholestasis (severe), sepsis or meconium aspiration syndrome (MAS) understanding of history, and with the exception of the primary pulmonary surfactant (PS) lack of；6.Need to use a ventilator.~FXR and RIPK3 were measured in neonate with ALI.were measured in another group neonate with ARDS"
89028226|NCT02598648|Other|control|Control group: Patients with mechanical ventilation due to external causes of the lung, no ALI-ARDS performance,FiO2/ PaO2< 40.0 kPa (300 mmHg), such as premature apnea or HIE. FXR and RIPK3 were measured in neonate with HIE
89028227|NCT00493844|Experimental|1|Discharge if clinical risk score <3 points + Nt-proBNP <110 ng/L
89028228|NCT00493844|Active Comparator|2|Discharge if negative exercise testing
89028229|NCT05146479||Fluoride varnish (FA group)|Application of 5% NaF varnish onto first permanent molars
89028230|NCT05146479||Fluoride varnish + dental sealant (FA+S group)|Application of 5% NaF varnish plus pit and fissure sealant onto first permanent molars
89028231|NCT01297270|Active Comparator|PegIFN/RBV|48 weeks
89028232|NCT01297270|Experimental|BI 201335 for 24 weeks|BI 201 335 QD dosing in combination with IFN/RBV
89028233|NCT01297270|Experimental|BI201335 for 12 weeks|BI 201335 QD doing in combination with PEFG IFN/RBV
89028234|NCT01297270|Placebo Comparator|Placebo|
89028235|NCT02593578||Biomarker group|Advanced cancer undergoing genomic profiling
89028236|NCT05145621|Active Comparator|Test|Fingolimod 0.5 mg capsules - (administered as 3 x Fingolimod 0.5 mg capsules)
89028237|NCT05145621|Active Comparator|Reference|Fingolimod 0.5 mg capsules -(administered as 3 x Fingolimod 0.5 mg capsules)
89028238|NCT00493883|Other|TheraSphere|"Y-90 is incorporated into very tiny glass beads, it can be injected into the liver through the blood vessels supplying the liver~--------------------------------------------------------------------------------"
89028239|NCT01296568|Experimental|LY2603618|"Single 250 milligram (mg) intravenous dose of LY2603618 containing carbon-14-labeled LY2603618 ([^14C]LY2603618).~After the completion of a minimum 7-day washout period, participants may receive additional doses of LY2603618 in combination as follows:~Gemcitabine 1000 milligrams per square meter (mg/m^2) on Days 1, 8, and 15 with 230 mg LY2603618 being administered on Days 2, 9 and 16 of a 28-day cycle OR~Pemetrexed 500 mg/m^2 on Day 1 and 275 mg LY2603618 on Day 2 of a 21-day cycle~Participants will be allowed to continue to receive the combination therapy until fulfilling one of the criteria for discontinuation, such as unacceptable toxicity or disease progression."
89028240|NCT05140668|Active Comparator|Supraclavicular central venous catheterization approach group|supraclavicular central venous catheterization group catheter is inserted in supraclavicular fossa (an indentation immediately above the clavicle) with a long-axis in plane approach
89028241|NCT05140668|Active Comparator|Infraclavicular central venous catheterization approach group|infraclavicular central venous catheterization group catheter is inserted in infraclavicular fossa (an indentation, immediately below the clavicle, above the third rib and between the deltoid muscle laterally and medioclavicular line medially) with a short-axis out-of-plane approach
89028242|NCT00496574|Active Comparator|1|
89028243|NCT00496574|No Intervention|2|no intevention
89028244|NCT02598999|Experimental|Part I, SAD|Single administration of OSCN- or bLF or Placebo in healthy male volunteers
89028245|NCT02598999|Experimental|Part II, SAD and MAD|Single and multiple administrations of ALX-009 or Placebo in healthy male volunteers
89028246|NCT02598999|Experimental|Part III, MAD|Multiple administrations of OSCN- or bLF or Placebo in CF patients in healthy volunteers
89567868|NCT04084249|Experimental|ctDNA guided surveillance|ctDNA analysis will be performed every 4 months postoperatively (4, 8, 12, 16, 20 and 24). At time of first positive ctDNA, patients undergo a whole-body FDG-PET/CT-scan for radiological assessment and a colonoscopy. If the initial assessment is without evidence of recurrence, patients will be offered high-intensive radiological surveillance with FDG-PET/CT-scans every 3 months, until recurrence detection or 21 months has passed. At baseline and months 12, 18, 24 and 36 patients complete the QoL questionnaires including EORTC QLQ-C30, fear of cancer recurrence inventory (FCRI), and impact of events scale for cancer (IES-C). At every FDG-PET/CT-scans the patients also complete the questionnaire.
89567869|NCT04084249|No Intervention|Standard Danish follow-up program|Patients will undergo surveillance according to current Danish Guidelines with CT-scans at months 12 and 36 postoperative and colonoscopy every 5 year until age 75. Longitudinal blood samples will be collected at same time-points as in the experimental group but not analyzed until end of trial. At baseline and months 12, 18, 24 and 36 patients complete the QoL questionnaires including EORTC QLQ-C30, fear of cancer recurrence inventory (FCRI), and impact of events scale for cancer (IES-C).
89567870|NCT04082689|Active Comparator|Assisted Infant Toilet Training-Group A|"Parents to Children randomized to group A will be instructed in how infant toilet training is performed by the investigators. They receive a book in Swedish concerning infant toilet training and a brief summary of the book made by the investigators. The parents are encouraged to begin infant toilet training as early as possible, 0-2 months of age~The definition of adherence to the intervention is to perform at least one attempt a day of infant toilet training (without the requirement of a successful outcome) on at least 5 out of 7 days per week."
89567871|NCT04082689|Active Comparator|Assisted Infant Toilet Training- Group B|"Parents to Children randomized to group B will be instructed in how infant toilet training is performed by the co-workers doing the ultrasound measure of rectal diameter at 9 months. They receive a book in Swedish concerning infant toilet training and a brief summary of it made by the investigators. They start infant toilet training at the age of 10-11 months.~The definition of adherence to the intervention is to perform at least one attempt a day of infant toilet training (without the requirement of a successful outcome) on at least 5 out of 7 days per week."
89567872|NCT04077411||Children with severe TBI|Children with severe Traumatic Brain Injury
89567873|NCT04075864|Experimental|behavioral intervention to improve physical activity|"The proposed study is prospective single-arm feasibility clinical trial that will enroll 12 hospitalized patients with CF in accordance with consensus criteria.~Standard care for an acute CF exacerbation includes i.v. antibiotics and airway clearance therapies for 10-14 days. Routine care following hospitalization is an outpatient CF clinic visit 2-4 weeks after discharge, and then regular follow up every 2-3 months.~In addition, to standard care in the hospital, study participants will receive a 1) tailored exercise prescription, 2) daily, individual, supervised, aerobic and strength/power training, as well as 3) daily behavioral counseling focused on topics related to long-term adherence to exercise (details below)."
89567874|NCT04074330|Experimental|Phase 1: TAK-981 10mg QW|Participants with indolent or aggressive non-Hodgkin lymphoma (NHL) received TAK-981 10 mg, infusion, intravenously (IV), once weekly (QW) on Days 1 and 8 every 21 days in each 21-day treatment cycle in combination with rituximab 375 milligram per square meter (mg/m^2), infusion, IV, once on Days 1, 8, and 15 of Cycle 1 and then on Day 1 of each 21-day treatment cycle from Cycle 2 for up to 12 months or disease progression (PD) or unacceptable toxicity.
89567875|NCT04074330|Experimental|Phase 1: TAK-981 40mg QW|Participants with indolent or aggressive NHL received TAK-981 40 mg, infusion, IV, QW on Days 1 and 8 every 21 days in each 21-day treatment cycle in combination with rituximab 375 mg/m^2, infusion, IV, once on Days 1, 8, and 15 of Cycle 1 and then on Day 1 of each 21-day treatment cycle from Cycle 2 for up to 12 months or PD or unacceptable toxicity.
89567876|NCT04074330|Experimental|Phase 1: TAK-981 60mg QW|Participants with indolent or aggressive NHL received TAK-981 60 mg, infusion, IV, QW on Days 1 and 8 every 21 days in each 21-day treatment cycle in combination with rituximab 375 mg/m^2, infusion, IV, once on Days 1, 8, and 15 of Cycle 1 and then on Day 1 of each 21-day treatment cycle from Cycle 2 for up to 12 months or PD or unacceptable toxicity.
89567877|NCT04074330|Experimental|Phase 1: TAK-981 90mg QW|Participants with indolent or aggressive NHL received TAK-981 90 mg, infusion, IV, QW on Days 1 and 8 every 21 days in each 21-day treatment cycle in combination with rituximab 375 mg/m^2, infusion, IV, once on Days 1, 8, and 15 of Cycle 1 and then on Day 1 of each 21-day treatment cycle from Cycle 2 for up to 12 months or PD or unacceptable toxicity.
89567878|NCT04074330|Experimental|Phase 1: TAK-981 90mg BIW|Participants with indolent or aggressive NHL received TAK-981 90 mg, infusion, IV, BIW on Days 1, 4, 8, and 11 every 21 days in each 21-day treatment cycle in combination with rituximab 375 mg/m^2, infusion, IV, once on Days 1, 8, and 15 of Cycle 1 and then on Day 1 of each 21-day treatment cycle from Cycle 2 for up to 12 months or PD or unacceptable toxicity.
89567879|NCT04074330|Experimental|Phase 1: TAK-981 120mg QW|Participants with indolent or aggressive NHL received TAK-981 120 mg, infusion, IV, QW on Days 1 and 8 every 21 days in each 21-day treatment cycle in combination with rituximab 375 mg/m^2, infusion, IV, once on Days 1, 8, and 15 of Cycle 1 and then on Day 1 of each 21-day treatment cycle from Cycle 2 for up to 12 months or PD or unacceptable toxicity.
89608851|NCT01986647|Active Comparator|Standard program - exercise leader|Standard impairment based seated group exercise program. 2 times per week for 12 weeks, approximately 1 hour class. Led by exercise leader
89028247|NCT02598999|Experimental|Part IV, MAD|Multiple administrations of ALX-009 or Placebo in healthy volunteers and in patients (CF and NCFBE)
89028248|NCT00493922|Active Comparator|2|Microscopy for diagnosis of malaria
89208661|NCT04045730|Experimental|Patients with metastatic pancreatic ductal adenocarcinoma|Patients must have histologically or cytologically confirmed pancreatic ductal adenocarcinoma, and all patients must have at least 15 unstained slides of formalin fixed paraffin embedded (FFPE) tumor tissue available or a pre-treatment core needle biopsy will be required as outlined in section 7.1.2.7. All patients will receive treatment with gemcitabine, nab-paclitaxel, PVHA, and pembrolizumab in 4-week cycles.
89028249|NCT00493922|Active Comparator|3|Clinical diagnosis for malaria
89028250|NCT00493922|Experimental|1|Rapid Diagnostic Test for Malaria
89567880|NCT04074330|Experimental|Phase 1: Japan Lead-in: TAK-981 60mg QW|Japanese participants with indolent or aggressive NHL received TAK-981 60 mg, infusion, IV, QW on Days 1 and 8 every 21 days in each 21-day treatment cycle in combination with rituximab 375 mg/m^2, infusion, IV, once on Days 1, 8, and 15 of Cycle 1 and then on Day 1 of each 21-day treatment cycle from Cycle 2 for up to 12 months or PD or unacceptable toxicity.
89208662|NCT00977223|Experimental|Aprepitant|7 days treatment with study drug, order of periods (active treatment or placebo) being sorted out.
89208663|NCT00977223|Placebo Comparator|placebo|7 days treatment with study drug, order of periods (active treatment or placebo) being sorted out.
89208664|NCT00803426|Active Comparator|1|Local anesthetic will be injected above the division of the sciatic nerve.
89567881|NCT04074330|Experimental|Phase 1: Japan Lead-in: TAK-981 60mg BIW|Japanese participants with indolent or aggressive NHL received TAK-981 60 mg, infusion, IV, BIW on Days 1, 4, 8, and 11 every 21 days in each 21-day treatment cycle for up to 12 months or PD or unacceptable toxicity.
89567882|NCT04074330|Experimental|Phase 2 (A): TAK-981 120 mg|Participants with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL) received TAK-981 120 mg, infusion, IV, QW on Days 1 and 8 every 21 days in each 21-day treatment cycle in combination with rituximab infusion, intravenously, once on Days 1, 8, and 15 of Cycle 1 and then on Day 1 of each 21-day treatment cycle from Cycle 2 for up to 12 months or PD or unacceptable toxicity.
89567883|NCT04074330|Experimental|Phase 2 (C): TAK-981 120 mg|Participants with follicular lymphoma (FL) received TAK-981 120 mg, infusion, IV, QW on Days 1 and 8 every 21 days in each 21-day treatment cycle in combination with rituximab infusion, intravenously, once on Days 1, 8, and 15 of Cycle 1 and then on Day 1 of each 21-day treatment cycle from Cycle 2 for up to 12 months or PD or unacceptable toxicity.
89567884|NCT04035226||Relapsed/refractory Multiple Myeloma|Patients with relapsed/refractory multiple myeloma who received at least 3 prior lines of therapy including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody treatment will be observed.
89567885|NCT04007874|Experimental|Ethinylestradiol/levonorgestrel|Ethinylestradiol/levonorgestrel 30/150 µg oral tablets once daily without a stopweek for 3 months
89567886|NCT04007874|Active Comparator|Vitamin E|Vitamin E 400 IU oral capsules once daily for 3 months
89567887|NCT04001946|Other|G-button Securement Device|Subjects will be provided instructions and a 12-week supply of test devices, sufficient to change the gauze dressing at least once per day.
89567888|NCT04001946|No Intervention|Standard Dressing|Subjects will be provided instructions and a 12-week supply of tape and gauze (current standard of care), sufficient to change the gauze dressing at least once per day.
89567889|NCT03978624|Experimental|A: Pembrolizumab alone|Subjects will be administered pembrolizumab alone 200 mg IV on day 1 and day 22
89567890|NCT03978624|Experimental|B: Pembrolizumab plus Entinostat|Subjects will be administered pembrolizumab on day 1 and day 22 and entinostat 5 mg given orally on day 1, day 8 and day 15
89567891|NCT03971474|Active Comparator|Arm A (docetaxel, gemcitabine, ramucirumab, pemetrexed)|Patients receive docetaxel IV over 10-30 minutes on day 1 and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 or ramucirumab IV over 60 minutes and docetaxel IV over 10-30 minutes on day 1. Patients with non-squamous NSCLC receiving docetaxel and gemcitabine hydrochloride, also receive pemetrexed IV over 10 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89567892|NCT03971474|Experimental|Arm B (ramucirumab, pembrolizumab)|Patients receive ramucirumab IV over 60 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 35 cycles in the absence of disease progression or unacceptable toxicity.
89567893|NCT03954314|Active Comparator|Topical Tranexamic Acid/Placebo|Topical Tranexamic Acid 5g to 10g (50 to 100mL) or placebo. The topical will be poured into the pericardial and mediastinal cavities after protamine administration.
89567894|NCT03954314|Active Comparator|Intravenous Tranexamic Acid/Placebo|Intravenous Tranexamic Acid 1 to 10g (10 to 100mL) or placebo administered intravenously at the induction of anesthesia as a bolus-infusion.
89567895|NCT03930992|Experimental|1 Arm: Experimental|Experimental: 4 mg zoledronic acid plus colaren ® This arm include: 20 man with HIV infection plus osteoporosis
89567896|NCT03930992|Active Comparator|2 Arm: Active comparator|Active comparator: 4mg zoledronic acid + standard treatment (or conventional treatment) This arm include: 20 man with HIV infection plus osteoporosis
89567897|NCT03930992|Experimental|3 Arm: Experimental|Experimental: 4 mg zoledronic acid plus colaren ® This arm include: 20 man without HIV infection plus osteoporosis
89567898|NCT03930992|Active Comparator|4 Arm: Active comparator|Active comparator: 4mg zoledronic acid + standard treatment (or conventional treatment) This arm include: 20 man without HIV infection plus osteoporosis
89567899|NCT03927027|Active Comparator|Group I (ALND)|Patients receive isosulfan blue SC and undergo ALND.
89567900|NCT03927027|Experimental|Group II (ARM, ALND)|Patients undergo ARM. Patients then receive isosulfan blue and undergo ALND as in Group I.
89567901|NCT03926130|Experimental|Mirikizumab|"Mirikizumab given intravenously (IV) and subcutaneously (SC).~Participants in the open-label adolescent addendum will be given mirikizumab IV and SC."
89567902|NCT03926130|Active Comparator|Ustekinumab|Ustekinumab given IV and SC.
89208665|NCT00803426|Experimental|2|Local anesthetic will be injected below the division of the sciatic nerve, around the common peroneal and tibial nerves.
89028251|NCT01296412|Experimental|Sitagliptin +/- glimepiride|Sitagliptin 100 mg tablet orally once daily for 26 weeks. Participants continued their stable dose of metformin >=1500 mg orally daily. Participants may have received glimepiride orally for glycemic control.
89028252|NCT01296412|Active Comparator|Liraglutide|Liraglutide subcutaneous injection once daily for 26 weeks (starting dose 0.6 mg daily up-titrated to 1.2 mg daily on Day 8). Participants continued their stable dose of metformin >=1500 mg orally daily. Participants may have had their liraglutide dose uptitrated to 1.8 mg daily for glycemic control.
89208666|NCT00977301|Experimental|fosamprenavir/ritonavir/olanzapine|single dose of 15 mg olanzapine after 13 days of fosamprenavir/ritonavir 700mg/100mg BID
89208667|NCT00977301|Active Comparator|single dose olanzapine|Single dose of 10 mg olanzapine
89567903|NCT03926130|Placebo Comparator|Placebo|Placebo given IV and SC.
88969805|NCT05664217|Experimental|Stage 1 NKTR-255 at 3.0/6.0 μg/kg|"In this arm of Stage 1 (Phase 2 of the study), patients will be dosed with 3.0 μg/kg NKTR-255 in Cycle 1 (C1) and continue in Cycle 2 and subsequent cycles (C+) with 6.0 μg/kg NKTR-255 (hereinafter referred to as 3.0/6.0 µg/kg NKTR-255).~NKTR-255 will be administered intravenously approximately 14 days after CD19-directed CAR-T cell infusion.~Patients will be dosed every 3 weeks for up to 7 cycles or 5 months, whichever is earlier, in the absence of disease progression or unacceptable toxicity.~The dose regimen for Stage 2 (Phase 3 of the study) will be selected based on the results of Stage 1 as reviewed by the Data Monitoring Committee (DMC) and the study team."
88969806|NCT05664217|Placebo Comparator|Placebo|Placebo is commercially available 0.9% Sodium Chloride Solution for Injection (USP). Placebo will be administered intravenously approximately 14 days after CD19-directed CAR-T cell infusion. Placebo will be infused every 3 weeks for up to 7 cycles or 5 months, whichever is earlier.
88969807|NCT05657652|Experimental|CAV regimen|
88969808|NCT05655013|Active Comparator|First part (year 1): groups 1+2|Zoledronate will be administered as an infusion six months after the last injection of denosumab followed by zoledronate infusions 3 and 6 months thereafter
88969809|NCT05655013|Active Comparator|First part (year 1): groups 3+4|Zoledronate will be administered as an infusion six months after the last injection of denosumab followed by zoledronate infusions when bone turnover is increased (s-carboxy-terminal collagen crosslinks (p-CTX) > 0.4 ug/l which corresponds to the upper 50 % of the normal range for premenopausal women).
88969810|NCT05655013|Active Comparator|Second part (year 2-3): groups 1+3|Patients will receive yearly infusions of zoledronate 5 mg
88969811|NCT05655013|Placebo Comparator|Second part (year 2-3): groups 2+4|Patients will receive yearly infusions of placebo.
88969812|NCT05653557|Experimental|Shen Que Moxibustion group|
88969813|NCT05653557|No Intervention|Control group|
88969814|NCT05649189||Participants testing positive for Food Addiction (FA)|these participants have tested positive for Food Addiction (FA) at a severe level using the YaleFAS-2 Food Addiction Scale.
88969815|NCT05649189||Participants testing negative for Food Addiction (FA)|these participants have tested negative for Addiction (FA) using the YaleFAS-2 Food Addiction Scale.
88969816|NCT05644821|Experimental|Intervention group|Patients who are not fully continent 6-weeks post-surgery (i.e., do not use pads in 24 hours) are randomized into the intervention or control group. In the intervention group, when the respective questionnaire thresholds are exceeded in the ePROM survey, an alarm is triggered at the treating prostate cancer center and contact is made by the center, as well as subsequent actions, if necessary.
89208668|NCT00735371|Active Comparator|Lisdexamfetamine Dimesylate (LDX) 30 mg|
89208669|NCT00735371|Active Comparator|LDX 50 mg|
89208670|NCT00735371|Active Comparator|LDX 70 mg|
89567904|NCT03919526|Experimental|anti-CD19/CD22 CAR-T cells|Administration with anti-CD19/ CD22 CAR-T cells in the MRD-positive ALL patients.
89567905|NCT03905798||Lorazepam|Patients administered Lorazepam in accordance with the indication (for Status Epilepticus, SE) and have no history of using this drug
89567906|NCT03901079||CTO BridgePoint system|"BridgePoint CTO System:~CrossBoss Catheter~Stingray LP Catheter~Stingray Guidewire and Extension Wire"
89567907|NCT03881696|Experimental|Stage 1:Omalizumab as Monotherapy|"Eligible participants are randomized to receive omalizumab by subcutaneous injection either every 2 weeks or every 4 weeks for 16 to 20 weeks. The dose administered and the dosing interval are determined by serum total IgE level and body weight (measured before the start of treatment) per the study drug dosing table.~After 16 weeks of treatment, each participant will complete double-blind placebo-controlled food challenge (DBPCFCs) to each of their three specific foods to a cumulative dose of 6044 mg protein of each food.~Throughout Stage 1, each participant will be instructed to strictly avoid all foods to which they are allergic.~The first 60 participants who complete all four DBPCFCs at the end of Stage 1 will participate in the Stage 1 Open Label Extension (OLE).All other participants who complete all four DBPCFCs will move Stage 2 of the study."
89567908|NCT03881696|Experimental|Stage 1: Omalizumab OLE|"OLE: Open Label Extension, Long-Term Treatment with Omalizumab. Participants will receive 24 weeks of open label omalizumab in accordance with the omalizumab dosing table defined in the study protocol. Omalizumab is administered by subcutaneous injection either every 2 weeks or every 4 weeks for 24 weeks. The dose administered and the dosing interval are determined by serum total IgE level and body weight (measured before the start of treatment) per the study drug dosing table.~After 24 weeks of treatment, each participant will complete DBPCFCs to each of their three specific foods to a cumulative dose of 8044 mg protein of each food. Each participant who completes all four DBPCFCs at the end of the Stage 1 OLE will move on to Stage 3 of the study.~Throughout Stage 1 OLE, each participant will be instructed to strictly avoid all foods to which they are allergic."
89567909|NCT03881696|Placebo Comparator|Stage 1: Placebo for Omalizumab as Monotherapy|"Eligible participants are randomized to receive placebo for omalizumab by subcutaneous injection either every 2 weeks or every 4 weeks for 16 to 20 weeks. The dose administered and the dosing interval are determined by serum total IgE level and body weight (measured before the start of treatment) per the study drug dosing table.~After 16 weeks of treatment, each participant will complete DBPCFCs to each of their three specific foods to a cumulative dose of 6044 mg protein of each food.~Throughout Stage 1, each participant will be instructed to strictly avoid all foods to which they are allergic.~The first 60 participants who complete all four DBPCFCs at the end of Stage 1 will participate in the Stage 1 OLE. All other participants who complete all four DBPCFCs will move Stage 2 of the study."
89608852|NCT01986647|Active Comparator|On the Move - staff activity personnel|On the Move group exercise - 2 times per week for 12 weeks. Each session lasts approximately 1 hour. Timing and coordination exercises to improve walking. Led by activity personnel.
89608853|NCT01986647|Active Comparator|Standard - staff activity personnel|Standard impairment based seated group exercise program. 2 times per week for 12 weeks, approximately 1 hour class. Led by staff activity personnel
89608854|NCT03585309|Experimental|Laparascopy comper with coagulation and without coagulation|
89208671|NCT00735371|Placebo Comparator|Placebo|
89208672|NCT00518206|Experimental|Cohort 1|NY-ESO-1 ISCOM vaccine (100 μg of the NY-ESO-1 protein formulated with 120 μg of ISCOM adjuvant) administered as an intramuscular injection every 4 weeks for 3 doses in every cycle.
88969817|NCT05644821|No Intervention|Control group|Patients who are not fully continent 6-weeks post-surgery (i.e., do not use pads in 24 hours) are randomized into the intervention or control group. In the control group, ePROMs will be collected 24 and 52 weeks after radical prostatectomy, but without triggering an alarm with subsequent measures - the control group will therefore receive treatment according to the current clinical routine.
89567910|NCT03881696|Experimental|Stage 2: Omalizumab|"Participants will receive eight weeks of treatment with open label omalizumab in accordance with the omalizumab dosing table specified in the study protocol, administered by subcutaneous injection. The dose administered and the dosing interval are determined by serum total IgE level and body weight (measured before the start of treatment) per the study drug dosing table.~After completion of eight weeks of open label omalizumab, participants will be randomized 1:1 to either:~Omalizumab-facilitated oral immunotherapy (OIT): Open label omalizumab + Multi-allergen OIT for eight weeks, followed by placebo for omalizumab + Multi-allergen OIT for 44 weeks OR~Omalizumab + placebo OIT: Open label omalizumab + placebo for Multi-allergen OIT for eight weeks, followed by omalizumab + placebo for Multi-allergen OIT for 44 weeks.~Throughout Stage 2, each participant will be instructed to strictly avoid all foods to which they are allergic."
88969818|NCT05644821|Other|Comparison group|In patients who are fully continent 6-weeks post-surgery (i.e., do not use pads in 24 hours), ePROMs are collected at 24 and 52 weeks, but no alarms or further actions are derived from them. Thus, treatment is provided according to routine clinical practice. Patients are not randomized.
89567911|NCT03881696|Experimental|Stage 2: Omalizumab-Facilitated OIT|"OIT: oral immunotherapy-Omalizumab as Adjunct Therapy to Multi-Allergen Oral Immunotherapy~Participants randomized to open label omalizumab + Multi-allergen OIT for eight weeks, followed by placebo for omalizumab + Multi-allergen OIT for 44 weeks.~Throughout Stage 2, each participant will be instructed to strictly avoid all foods to which they are allergic."
89567912|NCT03881696|Experimental|Stage 2: Omalizumab + Placebo OIT|"OIT: oral immunotherapy Participants randomized to open label omalizumab + placebo for Multi-allergen OIT for eight weeks, followed by omalizumab + placebo for Multi-allergen OIT for 44 weeks.~Throughout Stage 2, each participant will be instructed to strictly avoid all foods to which they are allergic."
89567913|NCT03881696|Other|Stage 3: DBPCFC Based Treatment|"DBPCFC Based Treatment-Long-term Follow-up Treatment Plan for Peanut and Each of the Two Other Participant-Specific Foods.~Upon completion of the DBPCFCs at the end of Stage 1 OLE or Stage 2, each participant will receive a separate treatment plan for peanut and each of the two other participant-specific foods based on the results of the DBPCFCs. A treatment plan will include instructions for one of the following:~Long-term follow-up with dietary consumption of a food;~Long-term follow-up with avoidance of a food; or~Rescue OIT for a food.~The treatment plan for each food may change throughout Stage 3 depending on a participant's response to treatment. Once a participant enters Stage 3, the participant will have a minimum of 12 months follow-up until at least December 2022.~Note: Participants will be instructed to strictly avoid a food if they receive rescue OIT for the food during Stage 3."
89567914|NCT03845296|Experimental|Treatment (rucaparib)|Patients receive rucaparib PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89567915|NCT03841448|Experimental|Double-Blind Treatment (DBT) Period: Cemdisiran|Participants received cemdisiran, 600 milligrams (mg), subcutaneous (SC) injection, once every 4 weeks (Q4W) in combination with standard of care treatment up to a maximum of 38 weeks in the DBT period.
89567916|NCT03841448|Placebo Comparator|DBT Period: Placebo|Participants received cemdisiran matching placebo, SC injection, Q4W in combination with standard of care treatment up to a maximum of 38 weeks in the DBT period.
89567917|NCT03841448|Experimental|DBT Period: Cemdisiran to Open-Label Extension (OLE) Period: Cemdisiran|Participants who were randomized to receive cemdisiran in the DBT period continued receiving cemdisiran, 600 mg, SC injection, Q4W in combination with standard of care treatment up to a maximum of 88 weeks in the OLE treatment period.
89567918|NCT03841448|Placebo Comparator|DBT Period: Placebo to OLE Period: Cemdisiran|Participants who were randomized to receive cemdisiran matching placebo in the DBT period started receiving cemdisiran, 600 mg, SC injection, Q4W in combination with standard of care treatment up to a maximum of 88 weeks in the OLE treatment period.
89567919|NCT03819296|Experimental|Supportive Care (standard of care, sample collection, FMT)|"PROJECT 1: Patients receive standard of care and undergo collection of stool and blood samples.~PROJECT 2: Patients receive prednisone, infliximab, or vedolizumab per standard of care and undergo standard of care endoscopy 2 months after treatment. Patients also undergo collection of stool, blood, and tissue samples.~PROJECT 3: Patients undergo FMT."
89567920|NCT03814850|Experimental|Treatment group: standard blood pressure cuff|A standard blood pressure cuff inflated on the participants arm for 4 cycles; each cycle will include 5 minutes of inflation followed by 5 minutes of deflection. RIPC will be applied via a standard blood pressure cuff. The ischemic cycle will involve cuff inflating to 30mmHg above resting systolic blood pressure and demonstration of loss of radial pulse.
89567921|NCT03814850|Sham Comparator|Sham group: standard blood pressure cuff|The blood pressure cuff will be inflated to 30mmHg during the first 5 minutes of each cycle and deflated for the following 5 minutes, with re-demonstration of radial pulse. This will be repeated for 4 cycles.
89567922|NCT03809520|Experimental|Experimental: pedCAT|Subjects in this group will undergo weight-bearing CT (pedCAT) imaging at 6 months, 12 months, and 18 months post-ankle injury.
89567923|NCT03805581|Experimental|Interventional|Defibrotide 6.25 mg/kg IV q6h
89567924|NCT03769766|Active Comparator|Curcumin|"Other names for the supplement: BCM-95 CG (Biocurcumax),Tumeric~Manufacture- DolCas Biotech, LLC.~Classification - type of agent: Supplement~Protocol dose: 500 mg twice"
89567925|NCT03769766|Placebo Comparator|Placebo|"Drug: placebo~placebo orally twice a day Other Names: •sugar pill"
89567926|NCT03755167|Experimental|IPL344|IV IPL344 administered once a day
89567927|NCT03746873|Experimental|COPD Web|Participants randomised to experimental group will be introduced to the COPD Web by a letter containing written information. All participants will receive a pedometer and written information about the importance of physical activity.
88969819|NCT05642026|Experimental|continuous intercostal nerve block (CINB)|patients admitted to the adult trauma service with rib fractures who are receiving CINB
88969820|NCT05642026|Active Comparator|standard medical care|patients admitted to the adult trauma service with rib fractures who are receiving standard medical care
89208673|NCT00518206|Experimental|Cohort 2|Cyclophosphamide (300 mg/m^2) administered as an intravenous injection 1 day prior to each vaccination with NY-ESO-1 ISCOM (100 μg of the NY-ESO-1 protein formulated with 120 μg of ISCOM adjuvant), which was administered as an intramuscular injection every 4 weeks for 3 doses in every cycle.
89567928|NCT03746873|No Intervention|Control|Other than receiving a pedometer and written information about the importance of physical activity the patients in the control group will not receive any intervention.
89567929|NCT03737318|Experimental|Group 1|Traditional articulation treatment
89567930|NCT03737318|Experimental|Group 2|Biofeedback--visual-acoustic
89567931|NCT03737318|Experimental|Group 3|Biofeedback-ultrasound
89567932|NCT03728088||Surgical Candidates|"Under- and postgraduate candidates applying for surgical training in general surgery, orthopedics, urology or plastic surgery at Ghent University Hospital.~All candidates will complete the rating scales concerning non-technical attributes in the period prior to the surgical selections."
89567933|NCT03728088||Surgical trainees|"Surgical trainees active in general surgery, orthopaedics, urology or plastic surgery, at Ghent University Hospital or an affiliated non-academic training hospital.~All trainees will be invited to participate in the study. Trainees who agree to participate will complete the rating scales concerning non-technical attributes."
89567934|NCT03728088||Surgical staff|"Surgical staff members active in general surgery, orthopaedics, urology or plastic surgery, at Ghent University Hospital.~All surgical staff members will be invited to participate in the study. Surgical staff members who agree to participate will complete the rating scales concerning non-technical attributes."
89567935|NCT03725956|Experimental|endoscopic sinus surgery|Single group of patients with nasal polyposis eligible for endoscopic sinus surgery
89567936|NCT03713580|Experimental|Venetoclax+BEAM x 1 cycle prior to ASCT|"Venetoclax dose escalation cohorts + BEAM (Carmustine, Etoposide, Cytarabine, Melphalan) begin with dose level 1 (800mg on Day -7 and Day -6). The dosing cohorts are escalated in a 3 + 3 design but with increasing duration instead of increasing dosage.~Carmustine 300 mg/m2 by IV over 2 hours on Day -7.~Etoposide 100 mg/m2 by IV over 6 hours daily for 4 consecutive days, Day-6 through Day-3.~Cytarabine 200 mg/m2 by IV over 2 hours every 12 hours for 3 consecutive days, Day-6 through Day-4.~Melphalan 140 mg/m2 by IV over 30 minutes or IV push once on Day -2.~Following V+BEAM therapy, participants will receive Autologous Stem Cell Transplant (ASCT): infusion of previously collected autologous stem cells and supportive care per institutional guidelines"
89567937|NCT03712657|Experimental|ERAS group|interventions: 1.preoperative pain control; 2.avoiding application of ureter; 3.avoiding application of gastric tube; 4.avoiding application of irrigation; 5.avoiding application of drainage; 6.early exercising postoperatively; 7.early oral feeding postoperatively; 8.early discharging.
89567938|NCT03712657|No Intervention|control group|normal treatment
89567939|NCT03703856|Active Comparator|Memantine|
89567940|NCT03703856|Placebo Comparator|Placebo|
89567941|NCT03699540|Experimental|Active Marijuana Dose|Participants will receive experimental/non-therapeutic dose(s) of active marijuana, under double-blind conditions
89567942|NCT03699540|Placebo Comparator|Inactive Marijuana Dose|Participants will receive experimental/non-therapeutic dose(s) of inactive marijuana, under double-blind conditions
89567943|NCT03699540|Active Comparator|Active Alcohol Dose|Participants will receive experimental/non-therapeutic dose(s) of active alcohol, under double-blind conditions
89567944|NCT03699540|Placebo Comparator|Inactive Alcohol Dose|Participants will receive experimental/non-therapeutic dose(s) of inactive alcohol, under double-blind conditions
89567945|NCT03691714|Experimental|Durvalumab and Cetuximab|Durvalumab 500mg as a 120-minute intravenous infusion every two weeks. Cetuximab 400mg/m2 IV loading dose followed by weekly Cetuximab 250mg/m2 IV Treatment with Durvalumab continues until progression and Cetuximab may continue as maintenance
89567946|NCT03682757||Severe Injury/Shock|Severely injured trauma patients presenting with shock, as defined by an Injury Severity Score (ISS)>=25, and base deficit (BD)>=6.
89567947|NCT03682757||Without Severe Injury/Shock|Not severely injured trauma patients presenting without shock, as defined by an Injury Severity Score (ISS)<25, and base deficit (BD) <6.
89567948|NCT03682757||Healthy Controls|Uninjured healthy volunteers
89567949|NCT03673657|Experimental|The study group|"Patients in the study group received early nutritional intervention, including individualized nutrition counseling and oral nutritional supplements from the initiation of CCRT to 2 weeks after its completion. Energy goal: daily total nutritional intake of about 30 kcal/kg.~Definitive thoracic radiotherapy with total radiation doses of 60-68 Gy; Weekly DP chemotherapy concurrent with thoracic radiotherapy."
89567950|NCT03656718|Experimental|Part A, Group 1: nivolumab (dose 1) + rHuPH20|
89567951|NCT03656718|Experimental|Part B, Group 3: nivolumab (dose 2) + rHuPH20|
89567952|NCT03656718|Experimental|Part B, Group 2: nivolumab (dose 1)|
89208674|NCT00984945|Active Comparator|H5 VLP vaccine 5 µg|
89567953|NCT03656718|Experimental|Part B, Group 4: nivolumab (dose 2)|
89567954|NCT03656718|Experimental|Part C: nivolumab (dose 3) + rHuPH20|
89567955|NCT03656718|Experimental|Part D, Group 5: nivolumab (dose 3) + rHuPH20|
89567956|NCT03656718|Experimental|Part E, Group 6: nivolumab (dose 4) coformulated with rHuPH20|
89208675|NCT00984945|Active Comparator|H5 VLP vaccine 10 µg|
89208676|NCT00984945|Active Comparator|H5 VLP vaccine 20 µg|
89567957|NCT03652805|Experimental|IPL344|IPL344 will be administered Intravenously on a daily basis. The dose range of IPL344 is 1.7-3.2 mg/kg
89567958|NCT03645928|Experimental|Cohort 1A|LN-144 therapy in combination with pembrolizumab in patients with Stage IIIC to IV unresectable or metastatic melanoma with ≤ 3 prior lines of systemic therapy, excluding checkpoint inhibitors (CPI).
89567959|NCT03645928|Experimental|Cohort 1B|LN-145-S1 therapy as a single agent in patients with Stage IIIC or Stage IV unresectable or metastatic melanoma, who have previously received systemic therapy with a PD-1 blocking antibody. If the tumor is proto-oncogene B-Raf (BRAF) V600 mutation positive, patients must have received a BRAF inhibitor with or without a mitogen-activated extracellular signal-related kinase (MEK) inhibitor.
89567960|NCT03645928|Experimental|Cohort 1C|LN-144 Generation 3 (Gen 3) therapy as a single agent in patients with Stage IIIC or Stage IV unresectable or metastatic melanoma, who have previously received systemic therapy with a PD-1 blocking antibody. If the tumor is BRAF V600 mutation positive, patients must have received BRAF inhibitor with or without a MEK inhibitor.
89567961|NCT03645928|Experimental|Cohort 2A|LN-145 therapy in combination with pembrolizumab in patients with advanced, recurrent, or metastatic HNSCC, with ≤ 3 prior lines of systemic therapy, excluding CPIs.
89567962|NCT03645928|Experimental|Cohort 3A|LN-145 therapy in combination with pembrolizumab in patients with locally advanced or metastatic (Stage III or Stage IV) non-small-cell lung cancer (NSCLC) with ≤ 3 prior lines of systemic therapy, excluding CPIs, or ≤ 4 lines if 2 or more of the lines are TKI therapy for those with tumors that harbored actionable mutations (eg, EGFR, ALK, ROS).
89567963|NCT03645928|Experimental|Cohort 3B|LN-145 therapy as a single agent in patients with Stage III or Stage IV NSCLC, who have previously received 1-3 lines of prior systemic therapy. Patients with known oncogene drivers (eg, EGFR, ALK, ROS) who have mutations that are sensitive to targeted therapies are not required to have received prior systemic therapy with CPIs.
89567964|NCT03645928|Experimental|Cohort 3C|LN-145 therapy in combination with ipilimumab and nivolumab in patients with Stage III or Stage IV NSCLC who have previously received 1 line of CPI monotherapy. No other systemic therapy for metastatic disease is allowed. Prior chemoradiation and/or chemotherapy in the adjuvant and/or neo-adjuvant settings are allowed.
89567965|NCT03577431|Experimental|arTreg-CSB|"arTreg CSB: alloantigen-reactive T regulatory cells costimulatory blockade per protocol.~The investigational product is donor alloantigen-specific T regulatory cells (arTreg-CSB). Supportive regimen for receipt of arTregs-CSB includes everolimus, leukapheresis, cyclophosphamide, and mesna.~Participants will receive a single dose of Treg product (arTreg-CSB). The target dose is 2.5 to 125 x 10^6 total cells. arTreg-CSB will be administered as a single peripheral intravenous (IV) infusion over approximately 15 to 30 minutes.~Note: Participants who receive at least the minimum Treg product (arTreg-CSB) dose of 1 to < 2.5 x 10^6 cells will be included in intent-to-treat analysis."
89567966|NCT03528642|Experimental|Treatment (telaglenastat, temozolomide, RT)|Patients receive telaglenastat PO BID 7 days a week, temozolomide PO QD 7 days a week, and undergo RT 5 days a week for up to 5.5 weeks (diffuse astrocytoma) or 6.5 weeks (anaplastic astrocytoma) in the absence of disease progression or unacceptable toxicity.
89567967|NCT03474731|Experimental|Diabetes Self Management Program only|group education classes of the Diabetes Self-Management Program, (DSMP)
89567968|NCT03474731|Experimental|Tailored Patient Navigation (PN) only|assisting patients in navigation to physician offices, allowing for standard of care to follow.
89567969|NCT03474731|Experimental|DSMP AND Tailored Patient Navigation|Both group education classes and patient navigation
89567970|NCT03409185|Experimental|Alcon lens group|Alcon 1 piece SA60AT lens
89567971|NCT03409185|Active Comparator|AMO lens group|AMO 1 piece Sensar AABOO lens
89567972|NCT03407144|Experimental|Pembrolizumab + AVD (Group 1)|After receiving two 4-week cycles of ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine) induction therapy, SER participants in Group 1 will receive pembrolizumab 2 mg/kg up to a maximum of 200 mg (3 to 17 years of age) or 200 mg (18 to 25 years of age) on Day 1 of each 3-week cycle (Q3W) in combination with two cycles of AVD chemotherapy (doxorubicin 25 mg/m^2, vinblastine 6 mg/m^2 and dacarbazine 375 mg/m^2 on Days 1 and 15; cycle frequency every 4 weeks [Q4W]). All SERs in Group 1 will receive radiotherapy (RT) after completing AVD chemotherapy.
89208677|NCT00984945|Placebo Comparator|Placebo (Formulation buffer)|
89208678|NCT00871650||Combat Veterans with PTSD|Male Veterans of Operation Iraqi Freedom (OIF) and/or Operation Enduring Freedom (OEF), ages 18-50, with Combat Exposure Scale score > 17, who are not on medication and do not have trauma history before age 18.
89567973|NCT03407144|Experimental|Pembrolizumab + COPDAC-28 (Group 2)|After receiving two 4-week cycles of OEPA (vincristine, etoposide/etopophos, prednisone/prednisolone and doxorubicin) induction therapy, SER participants in Group 2 will receive pembrolizumab 2 mg/kg up to a maximum of 200 mg (3 to 17 years of age) or 200 mg (18 to 25 years of age) Q3W, in combination with 4 cycles of COPDAC-28 chemotherapy (cyclophosphamide 500 mg/m^2 on Days 1 and 8, vincristine 1.5 mg/m^2 with maximum single dose 2 mg on Days 1 and 8, prednisone/prednisolone 40 mg/m^2/day divided in 3 doses on Days 1 to 15, dacarbazine 250 mg/m^2 on Days 1 to 3; cycle frequency Q4W). SERs in Group 2 will receive RT if they have a positive Positron Emission Tomography (PET) response after completing COPDAC-28 chemotherapy.
89567974|NCT03396276|Experimental|Suboxone induction into MAT in the ED|Suboxone induction into medication-assisted treatment (MAT) in the emergency department (ED)
89567975|NCT03382782|Active Comparator|Behavioral Weight Loss Intervention|"Participants will enroll in the BWLI program for 12 months. BWLI consists of a 8-month initial intervention phase followed by 4-month maintenance phase. The initial intervention phase comprises four types of contact:~1-hour to 1-hour, 30 minute group weight-management class led by facilitator (once per week; 26 classes followed by a one week break and an additional 8 weight management review classes)~45 minute, physical activity led by facilitator (one-two times per week);~20 minute, monthly individual visit with facilitator to address barriers to goals and appropriate skills; and~weigh-in during weight management group and individual visits (once each week)."
89567976|NCT03382782|Experimental|BWLI & Peer Navigator|"Participants randomly assigned to this condition will begin simultaneously with BWLI and run concurrently across the eight months of the intervention. Peer navigators will meet individually and face-to-face with research participants in time and places convenient to the person as needed. Specific practices are determined by the research participant with the peer navigator and may include:~partnering with participant on BWLI homework;~meeting with participant and BWLI facilitator individually;~attending all other health care appointments; and~partnering on tasks that arise out of those appointments."
89608855|NCT03585231|Experimental|Experimental|This is the experimental arm of the study. This includes receiving immediate access to the novel/experimental smoking cessation messaging program. Therapy description withheld to protect the integrity of the study.
89208679|NCT00871650||Combat Veterans without PTSD|Male Veterans of Operation Iraqi Freedom (OIF) and/or Operation Enduring Freedom (OEF), ages 18-50, with combat experience, who are not suffering from PTSD, and who are not on medication.
89208680|NCT04046588|Other|COPD group|This group will include 40 patients with chronic obstructive pulmonary disease (COPD).
89208681|NCT04046588|Other|Healthy control group|This group will include 40 healthy volunteers.
89567977|NCT03382782|Active Comparator|Integrated Care (Treatment as Usual)|Participants in this arm will receive integrated care from their usual provider, which is treatment as usual. Integrated care is mental health specialty and general medical care providers working together to address the physical and behavioral health care needs of patients. One-third of research participants will be randomized to integrated care alone.
88969821|NCT05630417|Experimental|Geriatric Massage Group|The fragility of the elderly, the sensitivity of skin, muscle and bone tissue necessitate modification of massage techniques according to the individual characteristics of the elderly. Geriatric massage is a form of massage applied according to the characteristics of the elderly individual and can be applied to all body parts according to the needs of the elderly. However, since diabetic neuropathy, which is a long-term complication that is common in individuals with Type 2 diabetes and can affect all body parts, shows more symptoms in the feet, foot massage as a geriatric massage may be effective in reducing diabetes symptoms and improving blood parameters. Because of its more systemic effects, back massage was preferred.
89567978|NCT03382652||Patients who received the Continuum Metal on Metal System|Patients requiring total hip arthroplasty, who meet the inclusion/exclusion criteria and received the Continuum Metal on Metal System
89567979|NCT03377062||EEG monitoring|Patients arriving to the emergency room with decreased consciousness, severe headaches or dizziness
89567980|NCT03362970|Active Comparator|Standard of Care|For children randomized to the standard of care arm, the treating physician will be informed to proceed as per their usual practice and treatment patterns. If stool is unavailable a rectal swab will be collected and sent to Calgary Laboratory Services (CLS) for routine culture. A routine stool specimen for back-up culture will still be requested as per standard of care. Home stool collection will be performed for those unable to provide a sample at enrolment and will be achieved by providing families with collection kits.
89567981|NCT03362970|Experimental|BioFire Gastrointestinal Panel FilmArray|For children randomized to the BioFire FilmArray arm, stool, if available, will be sent STAT to Calgary Laboratory Services (CLS) for the performance of the BioFire FilmArray test and routine culture. If stool is unavailable, a rectal swab will be performed and sent to CLS for the performance of the BioFire FilmArray test and routine culture. A routine stool specimen for back-up culture will still be requested as per standard of care once it is available. Treatment decisions will be at the sole discretion of the ED treating physician who receives the result.
88969822|NCT05630417|No Intervention|Control Group|No attempt will be made by the researcher on the elderly with Type 2 diabetes in the control group. The elderly in this group will benefit from the standard care practices offered by the institution.
89208682|NCT04046588|Experimental|Healthy intervention group|This study will include 40 healthy adults. Two sessions of moxibustion intervention will be performed in the Heart meridian and Lung meridian successively.
89208683|NCT04981431|Experimental|Elinzanetant single dose step 1|Each participant will receive a single oral dose of elinzanetant or placebo.
89567982|NCT03360916|Placebo Comparator|Placebo & Exercise Group|Participants randomized to this group will undergo placebo treatment and an aerobic exercise program.
89567983|NCT03360916|Experimental|Low Statin & Exercise Group|Participants randomized to this group will undergo low statin treatment (Lipitor 20Mg Tablet) and an aerobic exercise program.
89567984|NCT03360916|Experimental|High Statin & Exercise Group|Participants randomized to this group will undergo high statin treatment (Lipitor 80Mg Tablet) and an aerobic exercise program.
89208684|NCT04981431|Experimental|Elinzanetant single dose step 2|Each participant will receive a single oral dose of elinzanetant or placebo.
89567985|NCT03351998|Placebo Comparator|Placebo|Participants receiving matching placebo oral tablet.
89567986|NCT03351998|Active Comparator|Low dose statin|Participants will receive Lipitor 20Mg Tablet to take daily.
89567987|NCT03351998|Active Comparator|High dose statin|Participants will receive Lipitor 80Mg Tablet to take daily.
89567988|NCT03299569||Takotsubo cardiomyopathy|All patients diagnosed with Takotsubo cardiomyopathy in Scotland since 2010.
89567989|NCT03299569||Myocardial Infarction|An equal number of myocardial infarction patients in NHS Grampian since 2010.
89567990|NCT03211741|Other|open label|
89567991|NCT03203525|Experimental|Arm A (FOLFOX6, bevacizumab, NovoTTF-100L[P])|Participants receive oxaliplatin, leucovorin, and fluorouracil via pump over 46 hours on beginning on day 1, bevacizumab IV over 30-90 minutes on days 1 and 15, and use NovoTTF-100L(P) system over 18 hours daily. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89567992|NCT03203525|Experimental|Arm B(bevacizumab,liposomal doxorubicin, DAT, NovoTTF-100L[P])|Participants receive bevacizumab IV over 90 minutes on days 1 and 15, pegylated liposomal doxorubicin hydrochloride IV over 30 minutes-3 hours on days 1 and 15, and temsirolimus IV over 60-90 minutes on days 1, 8, 15, and 22. Participants also use NovoTTF-100L(P) system over 18 hours daily. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89567993|NCT03195140|Experimental|Intervention Arm|"The intervention arm (use of PLGS feature) will utilize Tandem Diabetes Care's ambulatory insulin infusion pump with integrated Dexcom G5 CGM and predictive low glucose suspend function. This pump is called the t:slim X2 with Basal-IQ Technology and is referred to in the protocol as the Tandem PLGS pump."
89567994|NCT03195140|No Intervention|Control Arm|The control arm (SAP only) will utilize an identical pump in functionality as the Tandem PLGS pump except for the lack of the PLGS feature and the associated user interface. This pump is called the t:slim X2 Dexcom G5 Mobile CGM Enabled pump, and is referred to in the protocol as the Tandem SAP pump.
89567995|NCT03184454|Experimental|Medtronic Percept Deep Brain Stimulation|"Single open label arm.~Patients with severe, treatment-refractory obsessive-compulsive disorder (OCD) will receive stimulation in two separate, but related, brain regions, the dorsolateral prefrontal cortex (dlPFC) and the ventral anterior limb of the internal capsule and adjacent ventral striatum (VC/VS) with a novel Medtronic Percept deep brain stimulation (DBS) system."
89567996|NCT03182192|Experimental|Hypoglycemia|Patients with hypoglycemia after gastric bypass
89567997|NCT03182192|Active Comparator|Control|Patients without hypoglycemia after gastric bypass
89567998|NCT03173924|Experimental|1/Experimental intervention|18F-DCFPyL is administered to cohorts
89608856|NCT03585231|Active Comparator|Control|This is the control arm of the study. This includes receiving receiving immediate access to the standard of care smoking cessation messaging program. Therapy description withheld to protect the integrity of the study.
89208685|NCT04981431|Experimental|Elinzanetant single dose step 3|Each participant will receive a single oral dose of elinzanetant or placebo.
89567999|NCT03137771|Active Comparator|Arm 1 (maintenance chemotherapy)|Patients may receive docetaxel IV over 60 minutes on day 1, erlotinib hydrochloride PO QD, or gemcitabine IV over 30 minutes on days 1 and 8. Patients with non-squamous non-small cell lung cancer may receive pemetrexed disodium IV over 10 minutes on day 1 alone or in combination with pembrolizumab IV over 30 minutes. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89568000|NCT03137771|Experimental|Arm 2 (SBRT + maintenance chemotherapy)|Patients undergo LCT over 2-4 weeks. If LCT cannot be used to treat primary disease sites, patients also undergo IMRT or 3DCRT over 3-5 weeks. Within 2 weeks after completion of radiation therapy, patients receive chemotherapy as in Arm 1. Patients may possibly undergo surgery.
89568001|NCT03134755||Study cohort (all children with asthma)|300 children with asthma will receive the same inhaled corticosteroid (ICS) for six weeks, in order to assess response to ICS.Bronchodilator response will be measured before and after ICS therapy. Stress levels (the exposure of interest) will be assessed with a validated questionnaire, before ICS administration (thus, it is an observational study of whether stress is related to treatment response)
89568002|NCT03096262|Experimental|Stroke Patients|
89568003|NCT03096262|Active Comparator|Healthy Controls|
89568004|NCT03083184|Experimental|Intervention group|Enrolled patients will be randomly assigned in a 1:1 ratio either to the intervention group (Ethenox) or to the control group (reference solution: UFH 5000 U/mL or citrate 4% w/v depending on which solution is generally used).
89568005|NCT03083184|Other|control group|Enrolled patients will be randomly assigned in a 1:1 ratio either to the intervention group (Ethenox) or to the control group (reference solution: UFH 5000 U/mL or citrate 4% w/v depending on which solution is generally used).
89568006|NCT03023631|Experimental|Prevention (Gardasil 9 vaccine)|Patients undergo standard of care allogeneic stem cell transplant. 6-12 months following transplant, patients receive recombinant human papillomavirus nonavalent vaccine IM on day 0 and at 2 and 6 months in the absence of disease progression or unacceptable toxicity.
89568007|NCT02987049||ICR (Intensive Cardiac Rehab)|The Intensive Cardiac Rehabilitation (ICR) group will follow their physician-prescribed series of supervised exercise sessions and educational sessions in a cardiac rehab facility. The education component includes a series of Pritikin videos, nutrition workshops and cooking classes led by a registered dietitian, one-on-one dietary consultation with a registered dietitian, and a Pritikin notebook. The intervention for this study is comprised of 24 exercise sessions plus 24 educational sessions in 24 visits.
89568008|NCT02987049||CR (conventional Cardiac Rehab)|The conventional Cardiac Rehabilitation (CR) group will follow their physician-prescribed series of supervised exercise sessions in the same cardiac rehab facility as the ICR group. The intervention for this study is comprised of 24 exercise sessions during 24 visits.
89568009|NCT02965716|Experimental|Treatment (talimogene laherparepvec, pembrolizumab)|Patients receive talimogene laherparepvec IL and pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 36 cycles in the absence of disease progression or unacceptable toxicity.
89568010|NCT02946528|Experimental|urgent-start peritoneal dialysis|All patients in urgent-start peritoneal dialysis arm initiate peritoneal dialysis as urgent-start dialysis modality.
89568011|NCT02946528|Active Comparator|urgent-start hemodialysis|All patients in urgent-start hemodialysis arm initiate hemodialysis as urgent-start dialysis modality.
89568012|NCT02916108||Concussion|"Study group include up to 30 children with history of concussion in the last 24 hours before admitting to emergency department.~Reading EEG."
89568013|NCT02916108||Isolated limb injury|"Cohort group include up to 30 children with history of isolated limb injury in the last 24 hours before admitting to emergency department.~Reading EEG."
89568014|NCT02877693|Experimental|Thoracic MRI Scan with 1.5 Tesla MRI|Subjects will be enrolled at least 60 days post successful St. Jude Medical™ MR Conditional ICD System implant. Enrolled subjects will undergo an elective 1.5T MRI scan within 30 days post enrollment. Post MRI visit all subjects will be followed up at 1-Month post MRI visit.
89568015|NCT02877693|Experimental|Thoracic MRI Scan with 3 Tesla MRI|Subjects will be enrolled at least 60 days post successful St. Jude Medical™ MR Conditional ICD System implant. Enrolled subjects will undergo an elective 3T MRI scan within 30 days post enrollment. Post MRI visit all subjects will be followed up at 1-Month post MRI visit.
89568016|NCT02876328|Experimental|Ad26.ZEBOV (rHAd26) vaccine + MVA-BN-Filo (MVA) boost|Participants will receive the Ad26.ZEBOV (rHAd26) vaccine at Day 0 followed by an MVA-BN-Filo (MVA) boost at Day 56.
89568017|NCT02876328|Placebo Comparator|Placebo (0.5 mL)|Participants will receive placebo at Day 0 followed by a placebo boost at Day 56.
89568018|NCT02876328|Experimental|rVSVΔG-ZEBOV-GP (rVSV) vaccine + placebo boost|Participants will receive the rVSVΔG-ZEBOV-GP (rVSV) vaccine at Day 0 followed by a placebo boost at Day 56.
89568019|NCT02876328|Experimental|rVSVΔG-ZEBOV-GP (rVSV) vaccine + rVSV boost|Participants will receive the rVSVΔG-ZEBOV-GP (rVSV) vaccine at Day 0 followed by an rVSV boost at Day 56.
89568020|NCT02876328|Placebo Comparator|Placebo (1 mL)|Participants will receive placebo at Day 0 followed by a placebo boost at Day 56.
88969823|NCT05623670||Patients after minimally invasive cardiac surgery using a VJI cannula.|
88969824|NCT05622578|Other|scleroderma with pain|systemic sclerosis (SSc) with chronic pain
88969825|NCT05622578|Other|scleroderma without pain|systemic sclerosis patients without chronic pain
88969826|NCT05621850|Experimental|cerebral AVM embolization|
88969827|NCT05621850|Other|cerebral aneurism embolization|
88969828|NCT05606315|Experimental|Remimazolam besylate|Remimazolam besylate is a new ultra-short-acting benzodiazepine drug, which is a benzodiazepine central nervous system inhibitor. It can bind to central GABAA receptors and produce sedative effects in animal experiments. Currently, it is used in painless diagnosis and treatment sedation, colonoscopy sedation, general anesthesia, ICU sedation and local anesthesia sedation.
88969829|NCT05606315|Active Comparator|propofol|Propofol, known chemically as 2, 6-diisopropyl phenol, is an organic compound with the chemical formula C12H18O and is a short-acting intravenous anesthetic used for the induction and maintenance of general anesthesia. It is often used in conjunction with epidural or spinal anesthesia, as well as with analgesics, muscle relaxants, and inhalation anesthetics.
89208686|NCT04981431|Experimental|Elinzanetant single dose step 4|Each participant will receive a single oral dose of elinzanetant or placebo.
89208687|NCT04981431|Experimental|Elinzanetant single dose step 6|Each participant will receive a single oral dose of elinzanetant or placebo.
89208688|NCT04981431|Experimental|Elinzanetant multiple dose step 5|Each participant will receive multiple doses of elinzanetant or placebo administered once a day for 7 consecutive days.
89568021|NCT02875223|Experimental|CC-90011 and Rifampicin|
89568022|NCT02875223|Experimental|CC-90011 and Itraconazole|
89568023|NCT02870920|Active Comparator|Best Supportive Care|Best supportive care available
89568024|NCT02870920|Experimental|Durvalumab plus Tremelimumab and Best Supportive Care|Tremelimumab 75mg IV 60 minutes Day 1, cycles 1-4 Durvalumab 1500mg IV 60 minutes Day 1 every 28 days. Plus best supportive care
89568025|NCT02869217|Experimental|Cohort B (retreatment)|"Cyclophosphamide will be given intravenously (by vein) at a fixed dose of 750mg/m^2/d for 2 days.~Fludarabine will be given intravenously at a fixed dose of 30mg/m^2/d for 2 days.~TBI-1301 cells will be infused on Day 0 at a dose of 5x10^9 cells.~*Patients will only enter into this cohort if they have already been enrolled in another cohort prior"
89568026|NCT02869217|Experimental|Cohort C (double infusion)|"Cyclophosphamide will be given intravenously (by vein) at a fixed dose of 750mg/m^2/d for 2 days.~Fludarabine will be given intravenously at a fixed dose of 30mg/m^2/d for 2 days.~TBI-1301 cells will be infused on Day 0 and Day 14 at a dose of 5x10^9 cells."
89568027|NCT02863523|Experimental|Integrated Behavioral Intervention|Patients receive intensive behavioral counseling that may include elements of cognitive behavioral therapy, problem solving therapy, and small changes lifestyle counseling in addition to medical care.
89568028|NCT02863523|No Intervention|Usual Care|Patients receive usual care
89568029|NCT02804061|Active Comparator|Full NELIP|This group will receive the full Nutrition and Exercise Lifestyle Intervention Program (two behavior changes) from enrollment until birth and serves as the comparator control (Group A).
89568030|NCT02804061|Experimental|Nutrition followed by Exercise (N+E)|Intervention - Nutrition component only (one behaviour) until 24 week assessment, then the addition of the second behavior change (Exercise component) at 25 weeks, with both behaviours followed until birth (Group B).
89568031|NCT02804061|Experimental|Exercise followed by Nutrition (E+N)|Intervention - Exercise component only (one behaviour) until 24 week assessment, after which there will be the addition of the second behaviour change (Nutrition component), with both behaviours followed until birth (Group C).
89568032|NCT02697630|Experimental|Pembrolizumab and Entinostat|
89568033|NCT02691338||patients undergoing thrombectomy|150 anesthetized patients undergoing intra-arterial catheterization for thrombectomy after CVA. The patients will be recruited at the Rambam Health Center, Haifa, Israel. The patients will undergo EEG recording during the procedure, without changing patient's standard treatment care. The EEG recording will continue after the procedure for four hours approximately, while the patients are admitted to intensive care unit (ICU).
89568034|NCT02691338||Control - healthy individuals|20 health individuals under general anesthesia or sedation for other surgery or procedures. They will undergo EEG recording during the surgery/ procedure, to validate the sensitivity of the EEG to the effect of the anaesthetic medications.
89568035|NCT02639806||Prospective - General Anesthetic|The prospective treatment group will have an anesthetic induction according to the anesthetic provider's preference that will include propofol and fentanyl as IV induction agents and rocuronium as a muscle paralytic. Maintenance of anesthesia for the treatment group will include sevoflurane with a target end tidal concentration of 1-1.5%, rocuronium as a paralytic as needed, opioids and any other standard medication deemed necessary by the provider.
89568036|NCT02639806||Retrospective - Local Anesthetic with Sedation|The retrospective group will have received local anesthetic from the surgeon using lidocaine injected subcutaneously and received sedation using fentanyl and midazolam as needed to achieve the desired level of sedation.
89568037|NCT02633553|Experimental|radiotherapy group|complete resection and adjuvant radiotherapy
89568038|NCT02633553|No Intervention|observation group|complete resection
89568039|NCT02577354|Experimental|Treatment|
89208689|NCT00879918|Experimental|Nicotine pharmacokinetics|circadian smoking protocol and IV pharmacokinetic protocol
89208690|NCT00803582|Experimental|Experimental|Traditional acupuncture
89208691|NCT00803582|Sham Comparator|Placebo|Placebo acupuncture
89208692|NCT00803582|No Intervention|No-treatment|no treatment
89568040|NCT02577354|Experimental|Control|
89568041|NCT02546973||Patients with anal cancer|All patients with anal cancer during 2011-2013 will be asked to participate
89568042|NCT02542059||Responders|Patients with resolved type 2 diabetes after bariatric surgery, will undergo 68Ga-exendin PET/CT
89568043|NCT02542059||Non-responders|Patients with unresolved type 2 diabetes after bariatric surgery, will undergo 68Ga-exendin PET/CT
89568044|NCT02468232|Experimental|LCZ696|Before randomization, all patients received 2 week LCZ696 50 mg twice daily (b.i.d) as single blind run-in active treatment epoch. In double blind epoch, randomized patients in this arm started with 100 mg twice daily (b.i.d.) for 4 weeks. Patients were then up-titrated to 200 mg b.i.d. at week 4 if they were tolerant to 100 mg b.i.d. Total duration of treatment was up to approximately 40 months.
89568045|NCT02468232|Active Comparator|Enalapril|Before randomization, all patients received 2 week LCZ696 50 mg twice daily (b.i.d) as single blind run-in active treatment epoch. In double blind period, all randomized patients in this arm received enalapril 5mg twice daily (b.i.d.) for 4 weeks. Patients were then up-titrated to 10 mg b.i.d. at week 4 if they were tolerant to 5 mg b.i.d. Total duration of treatment was up to approximately 40 months.
89568046|NCT02363595||Papillary Microcarcinoma|This clinical trial protocol describes implementation of a prospective observation protocol to standardize data collection and obtain permission to collect samples of PMC tumors in a cohort of PMC patients being followed with active surveillance. This will allow PMC tumors to be accurately classified as either stable or progressive over time and used for comprehensive molecular profiling if surgical removal is required during follow-up
89568047|NCT02262780|Experimental|Single low dose Telmisartan with HCTZ|
89568048|NCT02262780|Experimental|Single high dose Telmisartan with HCTZ|
89568049|NCT02262780|Experimental|Multiple high dose Telmisartan with HCTZ|
89568050|NCT02241265||Past Bronchial Thermoplasty data|Data will be collected from records of patients who, in the past, have undergone bronchial thermoplasty.
89568051|NCT02221778|Experimental|SBRT|SBRT according to the intervention description
89568052|NCT02210117|Experimental|Arm A (nivolumab, surgery)|"Patients receive nivolumab IV over 60 minutes on day 1 every 2 weeks for 6 weeks. Approximately 4 weeks later, patients undergo nephrectomy, metastasectomy or biopsy.~Beginning 4-6 weeks after surgery, patients in all arms who have clinical response, stable disease, or even slight progression of disease to therapy preoperatively, receive maintenance nivolumab IV over 60 minutes on day 1. Cycles repeat every 4 weeks for 2 years in the absence of disease progression or unacceptable toxicity."
89568053|NCT02210117|Experimental|Arm B (nivolumab, bevacizumab, surgery)|"Patients receive nivolumab IV over 60 minutes and bevacizumab IV over 90 minutes on day 1 every 2 weeks for 6 weeks. Patients also undergo nephrectomy, metastasectomy or biopsy as in Arm A.~Beginning 4-6 weeks after surgery, patients in all arms who have clinical response, stable disease, or even slight progression of disease to therapy preoperatively, receive maintenance nivolumab IV over 60 minutes on day 1. Cycles repeat every 4 weeks for 2 years in the absence of disease progression or unacceptable toxicity."
89568054|NCT02210117|Experimental|Arm C (nivolumab, ipilimumab, surgery)|"Patients receive nivolumab IV over 60 minutes and ipilimumab IV over 90 minutes on day 1 every 3 weeks for 6 weeks. Patients also undergo nephrectomy, metastasectomy or biopsy as in Arm A.~Beginning 4-6 weeks after surgery, patients in all arms who have clinical response, stable disease, or even slight progression of disease to therapy preoperatively, receive maintenance nivolumab IV over 60 minutes on day 1. Cycles repeat every 4 weeks for 2 years in the absence of disease progression or unacceptable toxicity."
89568055|NCT02199600|Other|GMK Sphere Knee Replacement|Patients who comply with the protocol and received GMK Sphere component.
89568056|NCT02185443|Experimental|SBRT|
89028253|NCT05605561|Experimental|Intervention Group (Digital Story)|The web-based digital story preparation process will be completed as a 3-5 minute short film by using pictures, videos, voiceovers and various video editing techniques by the researcher trained in storytelling. The digital story will be prepared in an appropriate format, taking into account the cognitive development and period characteristics of school children (7-12 years old).
89028254|NCT05605561|No Intervention|Standard Maintenance Group|It is the standard of care given according to the hospital's policies and procedures.
89028255|NCT05146128|Experimental|Analytic group|The participants had to perform analytic exercices for shoulder rotators and scapular stabilizing muscles
89028256|NCT05146128|Experimental|Functional group|The participants had to perform functional exercices for shoulder rotators and scapular stabilizing muscles
89028257|NCT05146128|Experimental|Mixed group|The participants had to perform both analytic and functional exercices for shoulder rotators and scapular stabilizing muscles
89028258|NCT00496652|Active Comparator|1|Radiotherapy (+cisplatin to stage 3+4)
89028259|NCT00496652|Experimental|2|Radiotherapy 66-68 Gy, 2Gy/fx, 6 fx/week (+ weekly cisplatin 40 mg/m2 during radiotherapy to stage 3+4) + Zalutumumab 8 mg/kg every week during radiotherapy + the week before start of radiotherapy (as loading dose)
89028260|NCT01295905|Experimental|delefilcon A|Investigational contact lenses worn in both eyes on a daily wear, daily disposable basis for 3 months.
89028261|NCT01295905|Active Comparator|narafilcon B|Commercially marketed contact lenses worn in both eyes on a daily wear, daily disposable basis for 3 months.
89028262|NCT02956148|Experimental|Radioligand [18F]MNI-659|"All subjects will receive a single intravenous dose of the radioligand [18F]MNI-659 (investigational medicinal product [IMP]) and undergo PET imaging.~The radioligand [18F]MNI-659 will be administered at a dose of less than 5 micrograms, i.e. within the micro dosing concept, and no pharmacological effects are expected.~The injected radioactivity of [18F]MNI-659 will be 185 MBq/70 kg of body weight ± 10%."
89028263|NCT02597634|Experimental|SST-0225|Subjects will be treated with IP for 48 hours. While on-site, subjects will apply the first dose of IP at 0 hours, the second dose at 2 hours, and all subsequent doses every 5 (±1) hours, up to a maximum of 6 doses in 24 hours. After subjects complete their 24 hour post first dose NRS pain/soreness on movement assessment, they will be released from the clinic and will continue outpatient treatment for the remaining 24 hours. While off-site subjects will dose every 5 (±1) hours, not to exceed 6 doses in 24 hours.
89028264|NCT02597634|Placebo Comparator|Placebo|Subjects will be treated with IP for 48 hours. While on-site, subjects will apply the first dose of IP at 0 hours, the second dose at 2 hours, and all subsequent doses every 5 (±1) hours, up to a maximum of 6 doses in 24 hours. After subjects complete their 24 hour post first dose NRS pain/soreness on movement assessment, they will be released from the clinic and will continue outpatient treatment for the remaining 24 hours. While off-site subjects will dose every 5 (±1) hours, not to exceed 6 doses in 24 hours.
89028265|NCT05148429||Fetuses with abnormal positionning of mesenteric vessels|All pregnant women with abnormal positionning of mesenteric vessels during second trimester scan
89028266|NCT00496691|Experimental|1|Parent-child
89028267|NCT00496691|Active Comparator|2|Adolescent only intervention focusing on condom use skills and assertiveness training around sexual discussions
89028268|NCT00496691|Placebo Comparator|3|Health promotion intervention including general health promotion topics such as smoking, diet, exercise, etc.
89028269|NCT05145972|Active Comparator|• Group P|Ultrasound guided SHPN will be done by injecting 10 ml of Phenol 10 %.
89028270|NCT05145972|Active Comparator|• Group LP|Ultrasound guided SHPN will be done by injecting 10 ml Phenol 10 % then injecting 3 ml Lidocaine 10%.
89028271|NCT00496847|Experimental|Drug Group|PERIOGEN
89208693|NCT01565590|Active Comparator|Propofol|
89028272|NCT00496847|Active Comparator|Control group|Beta TCP alone
89028273|NCT02591199|Experimental|URG101|A single 15 mL dose of URG101,a mix of buffered Lidocaine (200 mg) and Heparin (50,000 IU), delivered to the bladder via catheter.
89028274|NCT02591199|Placebo Comparator|Placebo|A single 15 mL dose of placebo delivered to the bladder via catheter.
89028275|NCT02591199|Experimental|Lidocaine|A single 15 mL dose of buffered Lidocaine (200 mg) delivered to the bladder via catheter.
89028276|NCT02591199|Experimental|Heparin|A single 15 mL dose of buffered Heparin (50,000 IU) delivered to the bladder.
89028277|NCT00494078|Active Comparator|1|Patients randomised to this arm are treated with intensive insulin therapy guided by the continuous glucose monitoring system.
89028278|NCT00494078|Active Comparator|2|intensive insulin therapy guided by an algorithm
89028279|NCT02596035|Experimental|Nivolumab|Nivolumab dose as specified
89208694|NCT01565590|Experimental|Dexmedetomidine|
89568057|NCT02161380|Experimental|1 Chronic Bilateral Severe Vision Loss|injection of scAAV2-P1ND4v2
89028280|NCT05147883|Experimental|Exercise|Patients will be given an aerobic exercise program for 1 hour, 3 days a week for 12 weeks.
89028281|NCT05147883|No Intervention|Control|No intervention will be applied to the patients
89028282|NCT02595489|Experimental|Vitamin D3|Single-arm, dose-escalation starting at 1,000 IU or 2,000 IU of vitamin D3 daily for a 6 month period, followed by a conditional titration up to 4,000 IU daily for at least 6 months thereafter. No placebo.
89568058|NCT02161380|Experimental|2 Acute Bilateral Severe Vision Loss|injection of scAAV2-P1ND4v2
89568059|NCT02161380|Experimental|3 Acute Unilateral Severe Vision Loss|injection of scAAV2-P1ND4v2
89568060|NCT02092155||Indwelling tunneled pleural catheter|
89568061|NCT01994239|Active Comparator|Radiation|"Pelvic radiotherapy~46 Gy in 23 fractions of 2 Gy.~prostate only-boost up to 66 Gy"
89568062|NCT01994239|Experimental|Radiation and Degarelix|"Radiotherapy:~46 Gy in 23 fractions of 2 Gy.~prostate only-boost up to 66 Gy~Associated with hormonal therapy by degarelix:~beginning in parallel to radiotherapy for 6 months~First dose of 240 mg~Maintenance dose of 80 mg"
89208695|NCT00877422|No Intervention|Group A|Group A is identified as serum vitamin D level more than 16 ng/dl.
89568063|NCT01985230|Experimental|ReActiv8 Implant|
89568064|NCT01895933|Active Comparator|Active / control|One side has been treated with SurgiShield
89568065|NCT01895933|No Intervention|No intervention|One side has no intervention
89568066|NCT01804816|Experimental|Acupuncture|10 standardized verum acupuncture (VA) sessions twice a week, over 5 weeks. The 5 weeks of acupuncture were scheduled after the period of no acupuncture for each subject.
89568067|NCT01804816|Placebo Comparator|No Acupuncture|"No acupuncture treatment or other study intervention over 5 weeks. All subjects had a 5 week period of no acupuncture prior to the 5 weeks of acupuncture sessions."
89568068|NCT01803555|Experimental|BF Spiromax|2 inhalations of BF Spiromax at a dosage of 160/4.5 mcg and 2 inhalations of SYMBICORT placebo administered twice daily (AM and PM) during the 12-week treatment period.
89568069|NCT01803555|Active Comparator|Symbicort Turbohaler|2 inhalations of SYMBICORT TURBOHALER at a dosage of 200/6 mcg and 2 inhalations of placebo SPIROMAX administered twice daily (AM and PM) during the 12-week treatment period.
89568070|NCT01499628|No Intervention|Group 1-Control|No extra training will be given.
89028283|NCT00494195|Experimental|1|The first cohort will receive a total of 1.5 ml volume of study agent in two to six separate injections into the selected muscle (extensor digitorum brevis) or other muscle if more appropriate upon considering the individual patient. The dose will be 3.25 X 10 to the 11 vg in 1.5 ml. The anatomical midline point of the muscle will be identified on the skin and two to six vector injections will be distributed in the direction of an X. In each cohort, only one extremity will receive vector with transgene while the opposite extremity will be injected with placebo.
89028284|NCT00494195|Experimental|2|The second cohort will receive the same dose of 3.25 X 10 to the 11 vg in 1.5 ml delivered to muscle according to the same paradigm. In each cohort, only one extremity will receive vector with transgene while the opposite extremity will be injected with placebo.
89568071|NCT01499628|Active Comparator|Group 2-Control plus supervised reading|The same amount of contact time as Groups 3 and 4 - three 45 minute sessions completed over three weeks.
89568072|NCT01499628|Experimental|Group 3-EVT at the PRL|Eccentric viewing training at the Preferred Retinal Locus (PRL), using reading/target cards. Three 45 minute sessions completed over three weeks.
89568073|NCT01499628|Experimental|Group 4-EVT at the TRL|Eccentric viewing training at the Trained Retinal Locus (TRL), using reading/target cards and microperimeter. Three 45 minute sessions completed over three weeks.
89568074|NCT01477229||Abdominoperineal resection|Patients with low rectal cancers
89568075|NCT01477229||Anterior resection|Patients where it is possible to perform an anterior resection
89568076|NCT01477229||Preoperative chemo-radiation treatment|Patients with locally advanced rectal cancer
89028285|NCT00494312|Experimental|Pioglitazone QD|
89028286|NCT00494312|Active Comparator|Glyburide QD|
89028287|NCT05145348||Down syndrome, adults|Adults and adolescents with Down syndrome >16 years old.
89028288|NCT05145348||Healthy control, adults|Healthy adults and adolescents without Down syndrome > 16 years old. Without any significant comorbidities.
89028289|NCT05145348||Down syndrome, children|Children with Down syndrome < 16 years old.
89028290|NCT05145348||Healthy control, children|Healthy children without Down syndrome < 16 years old. Without any significant comorbidities.
89568077|NCT01477229||Palliative treatment|Patients with systemic disease
89568078|NCT01464177|Active Comparator|Stereotactic hypofractionated RT 5x5Gy|"Stereotactic hypofractionated radiation therapy delivered as follows:~Gross tumor volume (GTV) equals enhancement area in T1 contrast enhanced MRI.~Planning tumor volume (PTV) equals GTV plus 3mm margin.~the dose of radiation will be 25Gy delivered in 5 fractions.1 fraction per day, non consecutive days in a maximum period of 10 working days.~RT to begin in a maximum of 2 weeks after randomization."
89568079|NCT01464177|Experimental|Stereotactic hypofractionated RT 5x7Gy|"Stereotactic hypofractionated radiation therapy delivered as follows:~Gross tumor volume (GTV) equals enhancement area in T1 contrast enhanced MRI.~Planning tumor volume (PTV) equals GTV plus 3mm margin.~the dose of radiation will be 35Gy delivered in 5 fractions.1 fraction per day, non consecutive days in a maximum period of 10 working days.~RT to begin in a maximum of 2 weeks after randomization."
89608857|NCT03585231|Active Comparator|Delayed Control|This is the second control arm of the study. This includes receiving the novel/experimental smoking cessation messaging program after completing the 3-month follow-up survey. Therapy description withheld to protect the integrity of the study.
89608858|NCT02002091||Complications,no specific treatment|After screening for complications, a non specific multi interventional treatment is applied to patients. After one year of follow up, we will compare two groups: with and without chronic kidney disease, on the advent of cardiovascular events. An adjustment is done for age and major risk factors.
89608859|NCT02926521|No Intervention|Dressing A|Dressing A: a nerve block catheter affixed with Pajunk anchor and covered with Tegaderm.
89608860|NCT02926521|Active Comparator|Dressing B|Dressing B: a nerve block catheter affixed with Pajunk anchor, skin treated with gum mastic liquid adhesive (Mastisol), all covered with Tegaderm
89568080|NCT01297764|Experimental|carfilzomib for MML|Vorinostat, Lenalidomide, Carfilzomib, Dexamethasone - This study will be conducted as an open-label Phase I/II, single-center study in which subjects will receive carfilzomib, lenalidomide, vorinostat and dexamethasone, for relapsed and/or refractory multiple myeloma. Study treatment will be administered in sequential cohorts, with 3-6 subjects in each cohort. Treatment will be administered in 28-day cycles, with the fourth week as a rest week, for 12 cycles or until disease progression or unacceptable toxicity develops.
89568081|NCT01245179|Experimental|Panobinostat|All patients will receive Panobinostat at specified dose levels and dosing schedules.
89568082|NCT01112306|Experimental|1|ACT-293987, twice daily
89568083|NCT00967863|Experimental|Arm I|Patients undergo 80 Gy of conformal or intensity-modulated radiotherapy 5 times a week for 7-8 weeks.
89568084|NCT00967863|Experimental|Arm II|Patients undergo 70 Gy of conformal or intensity-modulated radiotherapy 5 times a week for 7-8 weeks.
89568085|NCT00633633|Other|Group 1|Usual Care
89568086|NCT00633633|Experimental|Group 2|Exercise Training + Dietary Counseling
89568087|NCT00607828|Experimental|Hypofractionated stereotactic radiotherapy (SRT)|All patients who have had successful implantation of a liver marker will undergo a 4D CT scan for planning SRT. Following transfer to the treatment planning system, the CT scan may be correlated by imaging fusion with MRI for contouring integrated tumor volume (ITV). The planning target volume (PTV) will be defined as ITV plus individualized margins which are determined by a 4D CT scan. Novalis with 6MV photons will be used for imaging guided SRT. Cohorts of 3-6 patients will receive SRT at daily doses of 8, 10, 12, 14 Gy within 2 weeks. The starting daily dose level will be 10 Gy. The marker will be localized by orthogonal X-ray to ensure reproducibility. A continuous respiratory gating will be accomplished with ExacTrac Adaptive Gating system if the required planning target margin is larger than 1 cm based on the 4D CT data.
89568088|NCT00574886|Experimental|1 High dose BEAM chemotherapy, transplant & idiotype vaccine therapy|This is a compassionate use protocol for participants who failed induction chemotherapy + Vaccine on previous trials. These participants then went on to high dose BEAM chemotherapy and transplant, then received idiotype vaccine therapy at 3 months post transplant. Vaccine was given monthly x 4 series, with a fifth series given 12 weeks after the fourth. Participants were then followed annually until progression or death with standard staging.
89568089|NCT00542438|Active Comparator|Physical Activity Recall|Hand-held computers will be used to record information for 7 days about physical activity. Assessments will be completed either 3 times a day or once a day.
89568090|NCT00542438|Active Comparator|Environmental Assessment|Environmental assessments on a palm pilot either 3 times a day or once a day. Hand-held computer programs will be used to collect information about the community. Some factors will be assessed only once (e.g., availability of facilities) while other information will be collected over the course of 7 days (e.g., perceptions of neighborhood safety).
89568091|NCT04827329||Patients with a sleep disorder|Patients with a sleep disorder recording performed in the Sleep Unit in Montpellier University Hospital.
89568092|NCT04827329||Patients with a narcolepsy|Patients with a narcolepsy (type 1 or type 2) / a idiopathic hypersomnia or a restless legs syndrome.
88969830|NCT05606315|Active Comparator|midazolam|Midazolam, an organic compound with the chemical formula C18H13ClFN3, is used clinically to treat insomnia and can also be used to induce sleep during surgery or diagnostic tests.
88969831|NCT05605548|Experimental|MitoQ|Participants will take 1 pill each day for 6 weeks
88969832|NCT05605548|Placebo Comparator|Placebo|Participants will take 1 pill each day for 6 weeks
88969833|NCT05590195|Experimental|PreforPro|Preforpro Dosage form - capsule Dosage - participants will consume one capsule per day for 2 months treatment period
88969834|NCT05590195|Placebo Comparator|Placebo|placebo will come in a capsule, which has to be consumed one capsule per day for 2 months treatment period
88969835|NCT05575336|Experimental|Intervention group|Use of the ADLIFE system
88969836|NCT05575336|No Intervention|Control group|Patients will receive the Standard of Care
88969837|NCT05574036|Active Comparator|Group 1 Febuxostat group|35 non alcoholic steatohepatitis hyperuricemic patients receiving Febuxostat 80 mg once daily for 6 months duration
88969838|NCT05574036|Active Comparator|Group 2 vitamin E group|35 non alcoholic steatohepatitis Hyperuricemic patients receiving vitamin E 400 mg twice daily for 6 months duration
88969839|NCT05573204|Active Comparator|Group 1 obeticholic acid group|28 non alcoholic steatohepatitis patients receiving obeticholic acid 10 mg once daily for 6 months duration
88969840|NCT05573204|Active Comparator|Group 2 vitamin E group|31 non alcoholic steatohepatitis patients receiving vitamin E 400 mg twice daily for 6 months duration
88969841|NCT05561478||Test device (Synthesis Plus Toric)|Requiring bilateral cataract surgery with pre-existing astigmatism
88969842|NCT05561478||Control device (Synthesis Plus)|Requiring bilateral cataract surgery
88969843|NCT05559684|No Intervention|Control|"Patients in this group will receive fentanyl infusion at a dose of (0.5 μg/kg/h) all through the whole operation; in addition to~1μg/kg during skin incision, sternotomy, aortic cannulation and increase in MBP or HR more than 20% of the baseline readings."
88969844|NCT05559684|Active Comparator|Erector Spinae Plane Block|This group will receive fentanyl infusion at a dose of (0.5 μg/kg / h) all through the whole operation plus Ultrasound guided bilateral ESPB which will be done by injecting 0.4 ml/kg (1:1 solution of bupivacaine 0.25% and lidocaine 1%) at each side
88969845|NCT05559684|Experimental|Transversus Thoracis Plane Block|This group will receive fentanyl infusion at a dose of (0.5 μg/kg / h) all through the whole operation plus ultrasound guided bilateral TTPB which will be done by injecting 0.4 ml/kg (1:1 solution of bupivacaine 0.25% and lidocaine 1%) at each side
88969846|NCT05539300|Experimental|PSMA response evaluation arm|PSMA-PET/CT response evaluation, 2 months after starting hormonal therapy, 2 months after starting upfront enzalutamide therapy
88969847|NCT05530798|Experimental|Contrast Enhanced Ultrasound Arm|
88969848|NCT05529914|Experimental|Myofascial release + Neuromuscular exercises + Cold pack|
88969849|NCT05529914|Active Comparator|Neuromuscular exercises + Cold pack|
89028291|NCT02595372|Experimental|High dose omeprazole treatment|Patients will be treated with omeprazole 80 mg orally BID beginning 4-7 days prior to chemotherapy and continuing until surgery.
89208696|NCT00877422|Active Comparator|Group B|Group B is identified as serum vitamin D level less than 16 ng/dl and is supplemented with vitamin D3.
89208697|NCT00877422|No Intervention|Group C|Group C is identified as serum vitamin D less than 16 ng/dl and is not supplemented with vitamin D3.
89568093|NCT05251467||People with CF age 12 years and over|Participants will be identified through one of the 6 participating UK CF centres as well as recruiting via social media. Participants outside the 6 listed CF centres as well as outside the UK are also eligible.
89568094|NCT04812587|Experimental|Experimental group|The healthy elderly will be were recruited to participate in this study. All the subjects were independent in basic daily living activities, but at least one or more given assistance in the instrumental IADL assessment (ability to use telephone, shopping, food preparing, housekeeping, laundry, mode of transportation, responsibility for own medications, ability to handle finances). Their age should be ranged between 65 - 81 years.
89568095|NCT04812587|No Intervention|Comparison group|The healthy elderly will be were recruited to participate in this study. All the subjects were independent in basic daily living activities, but at least one or more given assistance in the instrumental IADL assessment (ability to use telephone, shopping, food preparing, housekeeping, laundry, mode of transportation, responsibility for own medications, ability to handle finances). Their age should be ranged between 65 - 81 years.
89568096|NCT04998565|Experimental|Routine care|Routine care for early postpartum breast engorgement, including reverse pressure technique over areola, along with hand expression of breastmilk.
89568097|NCT04998565|Experimental|Routine care plus EA|"Routine care for early postpartum breast engorgement, including reverse pressure technique over areola, along with hand expression of breastmilk.~plus: Electrical acupuncture on body acupoints"
89568098|NCT04998565|Experimental|Routine care plus TENS|"Routine care for early postpartum breast engorgement, including reverse pressure technique over areola, along with hand expression of breastmilk.~plus: Transcutaneous electrical nerve stimulation on breasts"
89568099|NCT04427267||Health workers|
89568100|NCT04812431|Experimental|PSA-NCAM(+) NPC|Cells are administered through intrathecal injection. Injection is administered to a total of five areas.
89568101|NCT05011669|Experimental|Latuda® 40mg/d|
89568102|NCT05011669|Experimental|Latuda® 80mg/d|
89568103|NCT02524665|Experimental|MAXCLARITY II|MAXCLARITY II Foam Cleanser (2.5% BPO) plus Foam Treatment (2.5% BPO) and (0.5% Salicylic Acid) Toner Foam. Available over the counter. Each subject applies both arms (MAXCLARITY II and MURAD) simultaneously for the entire duration of the study (8 weeks), each arm to be applied to one side of the face only (split-face study) according to randomization.
89568104|NCT02524665|Active Comparator|MURAD|MURADClarifying Cleanser (1.5% SA) plus Exfoliating Acne Treatment Gel (1% SA) and Skin Perfecting Lotion. Available over the counter. Each subject applies both arms (MAXCLARITY II and MURAD) simultaneously for the entire duration of the study (8 weeks), each arm to be applied to one side of the face only (split-face study) according to randomization.
89568105|NCT04812353|Other|Foot and ankle arthrodesis or osteotomy|Patients who underwent a foot- or ankle reconstruction surgery using the Io-Fix system
89568106|NCT03079843|Experimental|facemask first then no face mask|wearing of mask each day for the two hours of exposure for the first week of exposure then not wearing the mask each day for the two hours of exposure for the second week of exposure
89568107|NCT03079843|Experimental|no face mask followed by wearing face mask|not wearing the mask each day for the two hours of exposure for the first week of exposure then wearing the mask each day for the two hours of exposure for the second week of exposure
89208698|NCT04088201|Experimental|Measuring glucose|Measuring glucose from interstitial fluid
89568108|NCT04433689||Pregnant women|Pregnant woman, age 18 to 38 yo, with uncomplicated singleton pregnancy and no ocular diseases.
89568109|NCT04817423||Model training and test group|Data set will be split into training group and test group, where training group will be used for model building, and test group for subsequent evaluation and verification.
89028292|NCT05142969|No Intervention|Control arm|Patients were daily bathed with soap and water only.
89208699|NCT04007133||Diabetic patients|Patients with non-insulin-dependent diabetes, taking statins for at least 1 month
89208700|NCT00797186|Other|Intensive therapy|There is one arm in this trial. All patients receive the same therapy. The goal is to compare a noninvasive and invasive imaging technique in the same population.
89208701|NCT00586313|Experimental|a1: Tru-Cut biopsy for liver|Tru-Cut Biospy.
89208702|NCT00871806|Active Comparator|Eletriptan commercial tablet with water|Eletriptan commercial tablet given with water
89208703|NCT00871806|Experimental|Eletriptan oral disintegrating tablet (ODT) #1 without water|Oral disintegrating tablet formulation #1 without water
89208704|NCT00871806|Experimental|Oral disintegrating tablet formulation (ODT) #2 without water|Oral disintegrating tablet formulation #2 without water
89208705|NCT00871806|Experimental|Oral disintegrating tablet formulation (ODT) #1 with water|Oral disintegrating tablet formulation (ODT) #1 with water
89568110|NCT03079765|Experimental|Baseline|Participants will be given a written protocol for conducting the relevant assessment procedure (e.g., open-ended interview).
89568111|NCT03079765|Active Comparator|Telehealth Treatment|Participants will receive feedback and error correction on their implementation of the relevant assessment procedure to improve their performance.
89568112|NCT04998175|Experimental|iNPH cohort|The patients diagnosed of iNPH.
89568113|NCT04427969||EPP|patients who applied early awake prone position for treatment with conventional oxygen supply
89568114|NCT04427969||non-EPP|patient who only get conventional oxygen therapy as respiratory supply
89608861|NCT02926521|Active Comparator|Dressing C|Dressing C: a nerve block catheter sealed with 2-octyl cyanoacrylate liquid adhesive (Dermabond), trailing catheter affixed with Pajunk anchor, all covered with Tegaderm
89608862|NCT02926521|Active Comparator|Dressing D|Dressing D: a nerve block catheter sealed with 2-octyl cyanoacrylate (Dermabond), trailing catheter affixed with Pajunk anchor, skin treated with gum mastic liquid adhesive (Mastisol), all covered with Tegaderm
89608863|NCT03584997|Experimental|PRF , ABB & Autogenous Particulate|Platelets rich fibrin + anorganic bovine bone + autogenous particulate graft
89608864|NCT03584997|Active Comparator|ABB And Autogenous Particulate|anorganic bovine bone +autogenous particulate graft
89568115|NCT04998253|Experimental|Group 1: Sevofruorane (Svofast)|"Experimental group: will receive sedation with sevoflurane with an infusion rate to maintain MAC of 0.7 and fentanyl 1mcg /kg/hour.~Inhalation sedation The AnaConda device (Sedana Medical, Ireland) is placed between the endotracheal tube and the ventilator circuit. The anesthetic infusion line is attached to a syringe, from where the anesthetic (sevoflurane) will be delivered to said device. The sample line will be taken to the anesthetic gas analyzer whit the Carescape B450 multiparametric monitors (General Electric, Finland) for MAC control. The anesthetic gas outlet port will be attached to the absorbent material container."
89568116|NCT04998253|Active Comparator|Group 2: Propofol (Diprivant)|"Control group: will receive sedation with Propofol (Diprivant) at doses of 20-50mcg/kg/min and fentanyl (Fentanest) at doses of 1 to 2mcg/kg /hour.~For both groups, the doses will be titrated to maintain a RASS score between -3 to -4 in both groups.~Both groups will receive cisatracurium (Nimbex) as a continuous infusion of 3 to 5mcg / kg/min for 48 hours. We will maintain sedation for both groups with the same scheme for 48 hours, after which the drugs used for sedation will be modified at the discretion of the intensive care physicians."
89568117|NCT05289999|Experimental|Using the virtual reality headset for the first injection|Performing the first ultrasound-guided epidural injection through the sacrococcygeal hiatus using the virtual reality headset, then the second injection following the usual conditions of care without the device
89568118|NCT05289999|Experimental|Using the virtual reality headset for the second injection|Performing the first ultrasound-guided epidural injection through the sacrococcygeal hiatus following the usual conditions of care, then the second injection using the virtual reality headset
89568119|NCT05324475|Placebo Comparator|Standard treatment (SC)|nutritional counselling (SC) + Placebo: These patients will receive Oral Nutrient Supplementation (ONS) and maltodextrin 4 g
89568120|NCT05324475|Experimental|Branch-chained aminoacids|In addition to the ONS these patients will receive 4 gram per day of BCAAs mixture. Ratio between the BCAAs will be Leucine/Isoleucine/Valine=2:1:1.
89568121|NCT05324475|Experimental|Micronutrients|In addition to the ONS the patients will receive a combination of micronutrients
89568122|NCT03078283|Experimental|Participants|Consumption of a given type of high-fiber snack food, with each individual functioning as her own control
89568123|NCT03075007||Group A|All participants will undergo an amyloid PET scan with Florbetaben F 18 contrast as well as a transcranial Doppler ultrasound.
89568124|NCT03078205|No Intervention|The control group|No Intervention
89568125|NCT03078205|Experimental|The dual therapy group|TCM prescriptionⅡof cultivated emotion and assisted reproduction +auricular acupoint therapy.
89568126|NCT03078205|Experimental|The triple therapy group|TCM prescriptionⅡof cultivated emotion and assisted reproduction + auricular acupoint therapy+ retention enema of TCM.
89568127|NCT02638129|Other|Lead-In: Naltrexone/Bupropion + Placebo|Naltrexone hydrochloride (HCl) 8 mg/bupropion HCl 90 mg extended release (ER) combination tablets, orally, once daily for 1 week, followed by naltrexone/bupropion placebo-matching tablets, orally, once daily for 1 week. Participants who tolerate the naltrexone/bupropion treatment and comply with taking the study medication during the Lead-In Period will be randomized to the Double-Blind Treatment Period.
89568128|NCT02638129|Other|Lead-In: Placebo + Naltrexone/Bupropion|Naltrexone/bupropion placebo-matching tablets, orally, once daily, for 1 week, followed by naltrexone HCl 8 mg/bupropion HCl 90 mg ER combination tablets, orally, once daily, for 1 week. Participants who tolerate the naltrexone/bupropion treatment and comply with taking the study medication during the Lead-In Period will be randomized to the Double-Blind Treatment Period.
89568129|NCT02638129|Active Comparator|Naltrexone/Bupropion|Naltrexone HCl 8 mg/bupropion HCl 90 mg ER combination tablets, orally, one tablet, in the morning (AM), daily, for 1 week, followed by naltrexone HCl 8 mg/bupropion HCl 90 mg ER combination tablets, orally, one tablet in the AM and one in the evening (PM), daily, for 1 week, followed by naltrexone HCl 8 mg/bupropion HCl 90 mg ER combination tablets, orally, two tablets in the AM and one in the PM, daily, for 1 week, followed by naltrexone HCl 8 mg/bupropion HCl 90 mg ER combination tablets, orally, two tablets in the AM and two in the PM, daily, for up to 6 years.
89568130|NCT02638129|Placebo Comparator|Placebo|Naltrexone/bupropion placebo-matching tablets, orally, one tablet in the AM, daily, for 1 week, followed by naltrexone/bupropion placebo-matching tablets, orally, one tablet in the AM and one in the PM, daily, for 1 week, followed by naltrexone/bupropion placebo-matching tablets, orally, two tablets in the AM and one in the PM, daily, for 1 week, followed by naltrexone/bupropion placebo-matching tablets, orally, two tablets in the AM and two in the PM, daily, for up to 6 years.
89568131|NCT03078049||Dapagliflozin|Patients taking dapagliflozin
89568132|NCT03078049||Sitagliptin|Patients take sitagliptin
89568133|NCT04997551|Active Comparator|Colchicine|EC Experimental group: colchicine for 2 weeks orally added to standard treatment.
89568134|NCT04997551|Placebo Comparator|Placebo|Control group: placebo for 2 weeks added to standard treatment.
89568135|NCT04997707|Active Comparator|P group|75-100 µg/kg/min propofol
89568136|NCT04997707|Active Comparator|BA group|25ug/kg/min propofol and 0.2% below corrected-to-age- half MAC of sevoflurane
89568137|NCT04997863|Experimental|Sericin hydrogel sheet impregnated with EBN extract|Apply sericin hydrogel sheet impregnated with EBN extract on one-half of the donor site once daily for 8-12 hours per day for 6 months.
89568138|NCT04997863|Placebo Comparator|Placebo hydrogel sheet|Apply placebo hydrogel sheet on another half of the donor site once daily for 8-12 hours per day for 6 months.
89568139|NCT05010889||Achalasia patients|Patients schedule to undergo POEM for treatment of symptomatic achalasia. The diagnosis of achalasia was based on high resolution manometry, barium esophagram, and upper endoscopy.
89568140|NCT05010499|Active Comparator|Femoral nerve block|Patients will receive femoral nerve block (20 ml levobupivacaine 0.25%) after general anesthesia for hip arthroscpe
88969850|NCT05526417|Experimental|Arm I (prehabilitation physical therapy)|Patients perform personalized prehabilitation physical therapy exercises BID 5 days per week for 8 weeks while receiving standard of care radiotherapy and prior to standard of care surgery, attend telemedicine visits with a physical therapist once a week for 9 weeks, and receive educational materials. Patients undergo MRI and CT at week 9.
89028293|NCT05142969|Experimental|Intervention arm|Patients were daily bathed with soap and water and then receive 2% Chlorhexidine bathing (Petel Skin care wipes, Likang LtD, shanghai, China).
89568141|NCT05010499|Active Comparator|Fascia iliaca block|Patients will receive fascia iliaca block (40 ml levobupivacaine 0.25%) after general anesthesia for hip arthroscpe
89568142|NCT05010187|Experimental|Behavioral: Motivational Interview (MI)|Participants will complete a brief motivational interview focusing on determinants of women's alcohol use, including a focus on normative perceptions as well as motives for drinking.
89568143|NCT05010187|Active Comparator|Behavioral: Health Coaching (HC)|Participants will complete a brief health coaching interview and session focusing on educational modules.
89568144|NCT03075241|Experimental|Zolpidem|Study group will receive zolpidem 10mg capsules, 10pm (before bedtime) for 14 nights
89568145|NCT03075241|Experimental|Zoplicone|Study group will receive zoplicone 7.5mg capsules, 10pm (before bedtime) for 14 nights
89568146|NCT03075241|Placebo Comparator|Placebo|Study group will receive inactive or inert capsules, which will be used as a comparator, 10pm (before bedtime) for 14 nights
88969851|NCT05526417|Active Comparator|Arm II (educational materials)|Patients receive educational materials and attend a telemedicine visit with a research assistant once a week for 8 weeks while receiving standard of care radiotherapy and prior to standard of care surgery. Patients undergo MRI and CT at week 9.
88969852|NCT05524311|Experimental|Baricitinib|
89208706|NCT00871806|Experimental|Oral disintegrating tablet formulation (ODT) #2 with water|Oral disintegrating tablet formulation (ODT) #2 with water
89208707|NCT02553668|Experimental|Hyperoxia|Participants receive 100% oxygen
88969853|NCT05523297|Experimental|Octaplex|Each participant to receive up to 2 Octaplex infusion intravenously within first 24 hours. Exceeding 24 hours frozen plasma will be administered
88969854|NCT05523297|Active Comparator|Frozen plasma|Each participant will be administered FP according to the local standard
88969855|NCT05518656|Experimental|Online emotion regulation training version 1|
88969856|NCT05518656|Active Comparator|Online emotion regulation training version 2|
89208708|NCT00877578|Experimental|1|Nutri-Energie ®, a cake of high caloric density and palatability, twice a day for 4 weeks, in addition to an enriched diet.
89208709|NCT00877578|Active Comparator|2|Clinutren 1.5 ® standard isocaloric commercially available supplement, twice a day for 4 weeks, in addition to an enriched diet.
89208710|NCT04007913|Experimental|teleCBIT|Patient receive eight sessions of individual teleCBIT, in accordance with Woods et al's (2008) protocol, from a licensed psychologist.
89208711|NCT04046432|Experimental|Vigiis 101-LAB|The Vigiis 101-LAB mixed lactose, crystalline cellulose, and excipient were made into capsules (Vigiis 101-LAB capsule I) containing 5 billion bacteria per capsule for the gut flora clinical trial 1. The Vigiis 101-LAB mixed lactose, crystalline cellulose, and excipient were also mixed into capsules (Vigiis 101-LAB capsule II) containing 10 billion bacteria per capsule for clinical trial 2.
89208712|NCT04046432|Placebo Comparator|placebo|Maltodextrin was used as a placebo.
89208713|NCT02593799||Patients with esophageal varices|"Esophageal varices were confirmed by endoscopy. They were divided into any grade and high-risk varices."
89208714|NCT02593799||Patients without esophageal varices|"Patients without esophageal varices were divided into patients without any grade or high-risk varices."
89208715|NCT04039698|Experimental|Telemedicine|Sofosbuvir 400mg and velpatasvir 100mg qd for 12 weeks Telemedicine support
89208716|NCT04006821|Experimental|PD-1 antibody + Apatinib mesylate|Every patient will receive PD-1 antibody 200mg iv every 2 weeks and apatinib 250mg or 500mg (according to the patient's tolerance) orally every day. PD-1 antibody will be administered until disease progression or lasts for two years. Apatinib mesylate will be administered until disease progression.
89208717|NCT00871884|Active Comparator|Treatment As Usual|
89568147|NCT03074929|Experimental|Novel risk communication|Intervention parents will receive a novel risk communication message via a tablet app. Parents will also receive height, weight, and BMI percentile information typically provided by a provider during well-child visits as usual.
89568148|NCT03074929|No Intervention|Usual Care|Parents will receive height, weight, and BMI percentile information typically provided by a provider during well-child visits as usual.
89568149|NCT04997083|Experimental|cleft lip and palate patients|Cleft patients with transverse maxillary constriction and anteroposterior deficiency
89568150|NCT04994119|Experimental|BIA 5-1058|Treatment Period 1: Subjects were admitted to the clinical unit on Day 1. Subjects received a single oral dose of BIA 5-1058 400 mg (4 x 100 mg tablets) on Day 1 after an overnight fast of at least 8 hours. Subjects were discharged from the clinical unit on Day 4 (approximately 72 hours after dosing) barring any medical reasons for an extended clinical stay.
89568151|NCT04994119|Experimental|Warfarin|Treatment Period 2: Subjects were admitted to the clinical unit on Day 1. Subjects received a single dose of racemic warfarin (Coumadin® 5 x 5 mg tablets) on Day 1 after an overnight fast of at least 8 hours. Subjects were discharged from the clinical unit on Day 4 (approximately 72 hours after dosing) barring any medical reasons for an extended clinical stay. Subjects were required to return for out patient visits.
89568152|NCT04994119|Experimental|BIA 5-1058 and Warfarin|Treatment Period 3: Subjects were admitted to the clinical unit on Day 1. Subjects received a single concomitant dose of BIA 5-1058 400 mg (4 x 100 mg tablets) and racemic warfarin (Coumadin® 5 x 5 mg tablets) on Day 1 after an overnight fast of at least 8 hours. Subjects were discharged from the clinical unit on Day 4 (approximately 72 hours after dosing) barring any medical reasons for an extended clinical stay. Subjects were required to return for out patient visits.
89568153|NCT03074851|Experimental|Salt Substitute|To seek the relationship between blood pressure and low sodium salt.
89568154|NCT03074851|Other|informational intervention|to give 1 month informational intervention
89568155|NCT01658943|Experimental|Arm I (mFOLFOX regimen)|Patients receive oxaliplatin IV over 2 hours on days 1 and 15 and fluorouracil IV over 46-48 hours on days 1-2 and 15-16.
89568156|NCT01658943|Experimental|Arm II (Akt inhibitor MK2206 and selumetinib)|Patients receive Akt inhibitor MK2206 PO on days 1, 8, 15, and 22, and selumetinib PO daily on days 1-28.
89608865|NCT01985321|Experimental|Merlin - ethanol/glycolic acid solution|36 applications over a 96 hour period
89608866|NCT01985321|Placebo Comparator|Placebo/Ethanol|36 applications over a 96 hour period
89028294|NCT01244867|Experimental|20 microgram H5 VLP vaccine + Alhydrogel|
89028295|NCT01244867|Experimental|30 micrograms H5 VLP vaccine + Alhydrogel|
89568157|NCT02600819|Experimental|E/C/F/TAF|Participants will switch their current antiretroviral regimen to E/C/F/TAF and receive treatment for 96 weeks. After Week 96, participants in the United States (US) who wish to participate in the open-label (OL) rollover extension will continue to take E/C/F/TAF FDC until the End of E/C/F/TAF Visit.
89568158|NCT02600819|Experimental|Open-Label Rollover Extension B/F/TAF|At Week 96 or the End of E/C/F/TAF Visit (whichever occurs last), participants will be given the option to receive open-label bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) for at least 48 weeks.
89568159|NCT03077971|Experimental|ACT Self-Help|Participants in this arm will receive a self-help book based on Acceptance and Commitment Therapy (ACT). Participants will receive chapters each week, either electronically or by post, for 8 weeks.
89568160|NCT03077971|Experimental|ACT Self-Help with Telephone Support|Participants in this arm will receive a self-help book based on Acceptance and Commitment Therapy (ACT). Participants will receive chapters each week, either electronically or by post, for 8 weeks. In addition to this, participants will have weekly telephone calls to support the use of the book.
89568161|NCT03077971|No Intervention|Treatment As Usual|Participants in this arm will have no intervention as part of the trial.
89568162|NCT04433533|Active Comparator|Rosuvastatin 20mg (Group 1)|
89568163|NCT04433533|Experimental|Rosuvamibe 10/10mg (Group 2)|
89568164|NCT04996459||Tislelizumab group|
89568165|NCT04993105|Experimental|B (exercise + graston):|"In graston + exercises treatment will be same but after exercises added with proper application of graston which included application of a cream to the posterior calf and plantar foot from the knee to the toes to reduce friction on the skin.The Graston tools will be then used to mobilize the tissues of the triceps surf and plantar foot. In areas of increased tissue restriction, more aggressive pressure with graston was applied using increased force and shorter strokes over the areas of restriction was offered as needed for pain management after each session. This will be continued for three sessions. NPRS score, score on FADI and dorsiflexors range will be assessed after treatment of two weeks. Along with conventional treatment.~."
89568166|NCT04993105|Active Comparator|A (exercise only)|Exercises only. Patients will be given gastrocnemius stretching, plantar fascia stretching, myofascial release and then graston will be given as sham treatment for 10 minutes after applying cream (applying graston on skin but not giving enough pressure).
89568167|NCT03074773|Active Comparator|paravertebral block with bupivacaine|this group will receive 0.5mg/kg bupivacaine 0.25% diluted with isotonic saline (total volume 15ml) paravertebral block ultrasound guided pre-emptively
89568168|NCT03074773|Active Comparator|paravertebral block with bupivacaine and dexamethasone|this group will receive 0.5mg/kg bupivacaine 0.25% mixed to 0.1 mg/kg dexamethasone diluted with isotonic saline (total volume 15ml) paravertebral block ultrasound guided pre-emptively
89568169|NCT03077581|Active Comparator|Transevrsus abdominus plane block group|
89568170|NCT03077581|Active Comparator|Rectus sheath block group|
89568171|NCT03077581|Active Comparator|local infiltration group|
89568172|NCT04993573||Caregivers|Caregivers who work with older patients will be included. They will have a questionnaire
89568173|NCT04993573||Older|Older 65 people who live alone in their house will be included. They will have Individual interviews.
89568174|NCT03073447|Other|women under 50 years with acute MI|this clinical study is to systematically pool clinical, morphological and biological data of young women (< 50 years) presenting an Acute MI and to assess their short-term (in-hospital) and mid-term (12 months) prognosis. The usual blood tests will be performed at the patient's admission and then repeated at least 24 hours after coronary angiography, including repeated sampling assays for troponin, in order to measure the peak, following the routine of the department The specific assays, corresponding to the tests carried out as part of the WAMIF study will be sampled before discharge.
88969857|NCT05512949|Experimental|Arm 1|0.1 mL of 2 x 10^7 (50% Tissue Culture Infectious Dose (TCID50) JYNNEOS (Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN)) administered intradermally on Days 1 and 29. N=70
88969858|NCT05512949|Experimental|Arm 2|0.05 mL of 1 x 10^7 (50% Tissue Culture Infectious Dose (TCID50) JYNNEOS (Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN)) administered intradermally on Days 1 and 29. N=70
88969859|NCT05512949|Active Comparator|Arm 3|0.5 mL of 1 x 10^8 (50% Tissue Culture Infectious Dose (TCID50) JYNNEOS (Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN)) administered subcutaneously on Days 1 and 29. N=70
88969860|NCT05509790|Experimental|LY3484356 Dose Level 1|Administered orally.
88969861|NCT05509790|Experimental|LY3484356 Dose Level 2|Administered orally.
88969862|NCT05507437|Experimental|TIN816|Administered as an intravenous dose
89568175|NCT03074461|Experimental|Side-to-End|Side-to-End Anastomosis as neorectal reconstruction technique in low anterior resection (LAR)
89568176|NCT03074461|Active Comparator|Transverse Coloplasty|Transverse Coloplasty pouch as neorectal reconstruction technique in low anterior resection (LAR)
89568177|NCT05287737||Referred for Total pancreatectomy with islet autotransplantation|Followed up for up for 15 years after TPIAT.
89568178|NCT04996537|Experimental|Micro-video with pressure injury(PI) education|"The experimental group's flipped education and training courses adopt a digital learning method and provide a digital learning platform. Log in according to personal account and password, and learn the curriculum units planned by the researcher in order: Prevention and management of stressful injury care as the main axis, enter the digital platform The provided video audio-visual digital teaching materials, combined with clinical situational learning, are equipped with basic knowledge learning, in-class test questions, and unit review, and can open courses for self-study anytime and anywhere, regardless of time and space constraints."
89568179|NCT04996537|Active Comparator|NIS with PI education|At the login interface of the Nursing Information System (NIS) used by the nursing staff daily, a link to the lecture notes (PDF file) of the course on prevention of stress injury is attached, and the nursing staff can view or download them according to their needs. Learn. At the same time, it provides a digital learning platform to download the self-study course handouts (PDF files) and complete the basic demography, pre-test, and post-test data on the platform.
89568180|NCT04996303|Other|Routine|Routine steroid administration group
89568181|NCT04996303|Other|Pulse|Steroid pulse therapy group
89608867|NCT03584919|Active Comparator|EM doxycycline|patients with EM who received doxycycline
89608868|NCT03584919|Active Comparator|EM cefuroxime axetil|patients with EM who received cefuroxime axetil
89028296|NCT01244867|Experimental|45 micrograms H5 VLP vaccine + Alhydrogel|
89208718|NCT00871884|Experimental|Experimental|
89028297|NCT01244867|Experimental|45 micrograms H5 VLP vaccine|
89532593|NCT06101329|Experimental|PK Tail Phase: F/TDF|After the completion of the Randomized Phase, participants in LEN group will be transitioned to receive F/TDF and participants in F/TDF group will continue to receive F/TDF in the PK Tail Phase. All participants will receive F/TDF, once daily for 78 weeks beginning 26 weeks after the last LEN injection.
89028298|NCT01244867|Placebo Comparator|Placebo|
89532594|NCT06098742|Experimental|TR-sequence (T-test drug, R-reference drug)|Group 1 (25 volunteers, TR sequence) will take 2 sachets of Antareit 800 mg/10 ml oral suspension 2 h prior to food intake in Period 1 and 2 tablets of Riopan 800 mg chewable tablets 2 h prior to food intake in Period 2
89532595|NCT06098742|Experimental|RT-sequence|Group 2 (25 volunteers, RT sequence) will take 2 tablets of Riopan 800 mg chewable tablets 2 h prior to food intake in Period 1 and 2 sachets of Antareit 800 mg/10 ml oral suspension 2 h prior to food intake in Period 2
89532596|NCT06097234|Active Comparator|Pelex Upp Device|Subjects will receive treatment with the Pelex Upp device, the device under study. The subjects will use the device for treatment four times a week, ten minutes a day, for four weeks.
89532597|NCT06097234|Active Comparator|Pelex Upp Device + Pelvic Floor Physical Therapy|"Subjects will receive treatment with the Pelex Upp device, the device under study. The subjects will use the device for treatment four times a week, ten minutes a day, for four weeks.~In addition, subjects will have four weekly virtual visits with a pelvic floor physical therapist, who will provide further care instructions and pelvic floor training."
89532598|NCT06097234|Active Comparator|Pelvic Floor Physical Therapy|Subjects will have four weekly virtual visits with a pelvic floor physical therapist, who will provide care instructions and pelvic floor training, as well as provide a weekly treatment schedule for Kegel exercises.
89532599|NCT06096870|Experimental|Arm 1|Enzalutamide
89532600|NCT06096870|Experimental|Arm 2|Enzalutamide+M9241
89532601|NCT06096857|Active Comparator|Active|Roseomonas and Cardamom seeds
89532602|NCT06096857|Placebo Comparator|Placebo|Sucrose
89532603|NCT06096844|Active Comparator|Arm A (pembrolizumab)|"INDUCTION: Patients receive pembrolizumab IV over 30 minutes on day 1 of each cycle. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive pembrolizumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 21 or 42 days for 2 years in the absence of disease progression or unacceptable toxicity.~Patients undergo MRI at baseline and CT and/or PET on the trial at baseline and throughout the trial. Patients may also undergo stool sample collection at baseline and on the trial."
89532604|NCT06096844|Experimental|Arm B (pembrolizumab, chemotherapy)|See Detailed Description
89532605|NCT06096571|Other|Experimental: RT-sequence|Group 1 (18 volunteers, RT sequence) will take 1 tablet of Aterixen,100 mg as a single dose in the fasting state in Period 1 and 1 tablet of Aterixen,100 mg film-coated tablet as a single dose in the fasting conditions in Period 2
89532606|NCT06096571|Other|Experimental: TR-sequence|Group 2 (18 volunteers, TR sequence) will take 1 tablet of Aterixen,100 mg film-coated tablet as a single dose in the fasting state in Period 1 and 1 tablet of Aterixen,100 mg as a single dose in the fasting conditions in Period 2
89532607|NCT06095245||35 patients with advanced PD treated with subthalamic deep brain stimulation|35 patients with advanced PD treated with subthalamic deep brain stimulation. The decision of DBS treatment had been performed on the clinical decision by the treating neurologist and the patients. Patients are between 18 and 80 years old.
89532608|NCT06094634|No Intervention|Assessment-only control|Participants receive study assessment visits and standard of care from providers at the PrEP clinic.
89532609|NCT06094634|Experimental|The Brief Alcohol Intervention (BAI)|Participants receive the Brief Alcohol Intervention (2 in-person sessions and 2 phone sessions), study assessment visits, and standard of care from providers at the PrEP clinic.
89532610|NCT06093906|Experimental|Positive Processes and Transition to Health (PATH)|PATH includes six 60-90 min, weekly sessions, with two booster sessions for partial responders. Session 1 provides the PATH rationale and a review of life events (PATH of life: negative and positive). A rationale for an explicit focus on positive events/emotions will be provided. Sessions 2-4 focus on a verbal narrative of the destabilizing life event, reminiscence and processing of a major positive life event, and real-life practice to enact what was taught. Sessions 5 focuses on constructive processing and provides opportunity for integration and consolidation of learning. Session 6 focuses on future negative and positive events to promote application of new learning and resilience. Booster sessions focus on positive and negative life events since the last session and adaptive processes (constructive processing, approach, and reward). All sessions will include cultivation and elaboration of positive emotions to promote engagement and to build on the benefits of positive emotions.
89532611|NCT06093906|Active Comparator|Progressive Muscle Relaxation (PMR)|PMR will be adapted from Berstein, Borkoveck, and Hazlett- Stevens (2000). PMR will be conducted in six, 60-90 min individual weekly sessions with a study therapist. Muscle groups are tightened and then relaxed with the attention of the patient focused on the contrast between tension and relaxation. Through regular practice, the person becomes more aware of tension in the body and can induce relaxation as needed (Field, 2009). During the six sessions of training, patients will be encouraged to practice PMR and learn how to deliberately induce physical relaxation to reduce stress and mental tension. Sessions will move from relaxation of 16-muscle groups to 7 muscle groups, 4 muscle groups, and finally to relaxation by recall. Patients will be instructed to practice daily, if possible, but at least two or three times a week, and to integrate the practice into their daily life. They will be provided with audio recordings and homework reporting forms to assist their home PMR exercises.
89532612|NCT06093867||allogeneic HSCT|Up to 30 men or women, 18 - 70 years of age, who are being treated with allogeneic HSCT for a hematologic malignancy, blood, or immune system disorder at the NIH Clinical CenterUp to 10 children 5 - 17 years of age who are being treated with allogeneic HSCT for a hematologic malignancies, blood, or immune system disorder at the NIH Clinical CenterNIH Clinical Center
89532613|NCT06092333|Other|Single arm, open label|open label
89532614|NCT06088264|Experimental|Administration of BMS-986322|
89532615|NCT06086886|Experimental|BMS-986454|
89568182|NCT03077503|Experimental|Dexmedetomidine (Group A)|In induction period, group A received dexmedetomidine 1 µg/kg diluted to 20 ml with 0.9% normal saline 10 minute through a syringe pump. Three minutes before application of skull pins, group A received infusion of 2 ml of 0.9% normal saline.
89568183|NCT03077503|Active Comparator|Fentanyl (group B)|In induction period, group B received 20ml of 0.9% normal saline.Three minutes before application of skull pins, group B received infusion of fentanyl 1 µg/kg diluted to 2 ml with 0.9% normal saline
89532616|NCT06086886|Placebo Comparator|Placebo|
89532617|NCT06086704|Experimental|Group 1: Metabolite Analysis|participants will undergo venous blood sampling during the PET/MRI scan
89532618|NCT06086704|Experimental|Group 2: Pre-surgical Treatment|participants will undergo PET/MRI scans before and after 2 weeks treatment with anastrozole
89532619|NCT06086704|Experimental|Group 3: Test-Retest|participants will undergo baseline and repeat PET/MRI scans without intervening treatment to determine repeatability
89532620|NCT06084481|Experimental|Cohort 1: Hepatocellular Carcinoma (HCC)|Participants with HCC will receive ABBV-400 for up to 2 years during and up to the treatment period with an additional safety follow-up period of up to 2 years.
89532621|NCT06084481|Experimental|Cohort 2: Pancreatic Ductal Adenocarcinoma (PDAC)|Participants with PDAC will receive ABBV-400 for up to 2 years during and up to the treatment period with an additional safety follow-up period of up to 2 years.
89532622|NCT06084481|Experimental|Cohort 3: Biliary Tract Cancers (BTC)|Participants with BTC will receive ABBV-400 for up to 2 years during and up to the treatment period with an additional safety follow-up period of up to 2 years.
89532623|NCT06084481|Experimental|Cohort 4: Esophageal Squamous Cell Carcinoma, (ESCC)|Participants with ESCC will receive ABBV-400 for up to 2 years during and up to the treatment period with an additional safety follow-up period of up to 2 years.
88969863|NCT05507437|Placebo Comparator|Placebo|0.9% sterile sodium chloride solution administered as an intravenous dose
89532624|NCT06084481|Experimental|Cohort 5: Triple Negative Breast Cancer (TNBC)|Participants with TNBC will receive ABBV-400 for up to 2 years during and up to the treatment period with an additional safety follow-up period of up to 2 years.
89532625|NCT06084481|Experimental|Cohort 6: Hormone Receptor+/HER2-breast Cancer (HR+/HER2-BC)|Participants with HR+/HER2-BC will receive ABBV-400 for up to 2 years during and up to the treatment period with an additional safety follow-up period of up to 2 years.
88969864|NCT05503862|Experimental|Arm A|At home semen testing via the YoSperm device
88969865|NCT05503862|No Intervention|Arm B|Standard of Care
88969866|NCT05503199|Experimental|Combined suture- and plug-based VCD strategy|1 ProGlide or ProStyle + 1 Angio-Seal
88969867|NCT05503199|Experimental|Pure suture-based VCD strategy|2 ProGlides or ProStyles
88969868|NCT05501899|Experimental|Treatment Arm (single arm)|
88969869|NCT05500755||Patients DS Prime Taper|Patients who receive al least one DS Prime Taper on his dental implant treatment.
88969870|NCT05499858|Other|Vegetables|Vegetables will be provided to volunteers as part of a heat and serve meal kit.
88969871|NCT05498818|Experimental|Synaquell Male Group|Male youth hockey players will receive the dietary supplement Synaquell, twice-daily during the hockey season. Due to difference in game rules and playing styles, males and females will be treated as two separate arms of the research protocol.
88969872|NCT05498818|Placebo Comparator|Placebo Male Group|Male youth hockey players will receive the placebo twice-daily, during the hockey season. Due to difference in game rules and playing styles, males and females will be treated as two separate arms of the research protocol.
88969873|NCT05498818|Experimental|Synaquell Female Group|Female youth hockey players will receive the dietary supplement Synaquell, twice-daily during the hockey season. Due to difference in game rules and playing styles, males and females will be treated as two separate arms of the research protocol.
88969874|NCT05498818|Placebo Comparator|Placebo Female Group|Female youth hockey players will receive the placebo twice-daily, during the hockey season. Due to difference in game rules and playing styles, males and females will be treated as two separate arms of the research protocol.
89532626|NCT06084481|Experimental|Cohort 7: Head and Neck Squamous-cell-carcinoma (HNSCC)|Participants with HNSCC will receive ABBV-400 for up to 2 years during and up to the treatment period with an additional safety follow-up period of up to 2 years.
89532627|NCT06084234|Active Comparator|Arm A: Semi-annual surveillance using liver ultrasound +/- alpha-fetoprotein|Participants in this arm will undergo current standard of care surveillance procedures i.e. liver ultrasound with or without alpha fetoprotein (AFP) measurement.
89532628|NCT06084234|Experimental|Arm B: Semi-annual surveillance using GALAD|For participants in this arm, study team will order GALAD measurement every 6 months +/- 3 months.
89532629|NCT06083883|Experimental|Dose escalation - Inpatient and Outpatient|Participants will be assigned to receive a dose level of NK cells based on when the participants joins the study. Up to 6 participants will be enrolled at each dose level. If no intolerable side effects are seen after the first 3-6, the next group of participants will get at higher dose. Up to 4 dose levels of NK cells will be tested. If the first dosing group shows intolerable side effects, a lower dose will be tested.
89532630|NCT06083376|Experimental|exercise group|
89532631|NCT06083376|Active Comparator|control group|
89532632|NCT06082037|Experimental|Belumosudil + Azithromycin|Participants will receive 200 mg belumosudil orally once daily
89532633|NCT06082037|Placebo Comparator|Placebo + Azithromycin|Participants will receive placebo orally once daily
89532634|NCT06081894|Experimental|Aficamten|Participants in this arm will receive a single daily oral dose of 5 mg, 10 mg, 15 mg, or 20 mg of aficamten with dose levels guided by echocardiography assessments, for up to 72 weeks.
89532635|NCT06081894|Placebo Comparator|Placebo|Participants in this arm will receive placebo, for up to 72 weeks.
89532636|NCT06080048|Experimental|Part 3 SOR102 QD|SOR102 once a day for 6 weeks SOR102 oral capsules
89532637|NCT06080048|Experimental|Part 3 SOR102 BID|SOR102 twice a day for 6 weeks SOR102 oral capsules
89532638|NCT06080048|Placebo Comparator|Part 3 Placebo|Placebo for twice a day for 6 weeks Placebo oral capsules
89532639|NCT06079736|Experimental|PGN-EDO51 at Dose Level 1 every 4 weeks|
89532640|NCT06079736|Experimental|PGN-EDO51 at Dose Level 2 every 4 weeks|
89532641|NCT06079736|Experimental|PGN-EDO51 at Dose Level 3 every 4 weeks|
89568184|NCT04993417|Experimental|Mime Therapy along with EMS|MT Group: Mime Therapy along with EMS
89568185|NCT04993417|Experimental|Motor imagery technique along with EMS|MIT Group: Motor imagery technique along with EMS
89568186|NCT03074383|Experimental|Workshop|Self-Care Multidisciplinary Workshop for Diabetes consist in individual meetings with a multidisciplinary team (nurse, pharmacist, nutritionist, physical educator, physiotherapist and social worker) in which education and self-care topics will be approached. The workshop will be offered in 3 different modules with 2-4 weeks difference between them.
89568187|NCT03074383|Active Comparator|Usual Care|Usual care at outpatient Diabetes clinic AND 3 brief meetings with research team to receive printed educational material.
89568188|NCT05518695|Experimental|A1/100mg|Drug:BAT2022 for Intravenous fluids 100mg
89568189|NCT05518695|Experimental|A2/300mg|Drug:BAT2022 for Intravenous fluids 300mg
89568190|NCT05518695|Experimental|A3/1000mg|Drug:BAT2022 for Intravenous fluids 1000mg
89568191|NCT05518695|Experimental|A4/1500mg|Drug:BAT2022 for Intravenous fluids 1500mg
89208719|NCT02554994|Active Comparator|Intervention|"ASPRA (Aging Study of PyeongChang Rural Area) cohort is a population-based, prospective cohort study of older adults living in PyeongChang County of South Korea. This cohort study is supported by public health center, named PyeongChang Health Center and Country Hospital managed by government, to improve the quality of aged public health services.~All participants will be recruited from ASPRA cohort. After 6 months of usual care period, eligible participants are screened by characteristics of ASPRA database, and are assigned to a multifactorial intervention arm."
89568192|NCT05285475|Experimental|Group A|"The exercise protocol for this group will be abdominals, pelvic stretching and kegels exercises (PFM) for three days/week lasting about 30 minutes with approximately 1600-1800ml (8-10 glasses) intake of water for 8 weeks (two consecutive menstrual cycles)~Exercises include:~Piriformis stretching (5 repetitions×20 seconds) Adductor stretching (5 repetitions×20 seconds) Sit-ups (10 repetitions×3 sets) Bridging (10 repetitions×3 sets) Kegels exercises (10 repetions×3 sets) Pelvic elevation (10 repetitions×3 sets) Pelvic rotation (10 repetitions×3 sets) Cobra pose (5 repetitions×20 seconds)"
89568193|NCT05285475|No Intervention|Group B|The participants in this group will be asked neither to do any exercise nor to change their daily basis routine.
89568194|NCT05285319|Experimental|Prostate Only (Arm A)|Hypofractionated Intensity modulated radiotherapy (IMRT) to the prostate only to a dose of 60Gy/20fractions (3 Gy per fraction)
89568195|NCT05285319|Experimental|Prostate and Pelvic Lymph Nodes (Arm B)|Hypofractionated Intensity modulated radiotherapy (IMRT) with elective pelvic nodes irradiation up to 44Gy/20 fractions (2.2 Gy per fraction) with a Simultaneous Integrated Boost (SIB) to the prostate to a dose of 60Gy/20fractions (3 Gy per fraction)
89568196|NCT04136067|Experimental|NNC0268-0965|Participants will receive NNC0268-0965
89568197|NCT04136067|Active Comparator|Insulin glargine|Participants will receive insulin glargine
89568198|NCT03073291|Experimental|Responsible Marijuana Vendor Training|The TrainToTend online responsible marijuana vendor training teaches responsible sales practices in five modules: Module 1, The Laws; Module 2, ID Checking; Module 3, Health Effects; Module 4, Customer Service, and Module 5, Rules of the Trade. The training content will be conveyed using online educational activities providing application and feedback such as in tabs with appropriate graphics and interactive simulations where users apply the skill and receive informative/corrective feedback.
89568199|NCT03073291|No Intervention|Usual and Customary Sales Practices Training|Usual and customary training in retail sales practices delivered to employees at retail recreational marijuana stores by store managers. Some retail stores in Colorado may receive responsible marijuana vendor training of some type from another state-approved training provider. Thus, we consider the outlets in the control group to have usual and customer sales training but not to be entirely untrained.
89568200|NCT05244291|Experimental|Intervention Group 1|Therapeutic Touch will be applied to infants for 3 consecutive days, once a day, 10 minutes at any time during the day. There will be a four-day break. The Therapeutic Touch will be done a total of 3 times in 1 weeks.
89208720|NCT02554994|Active Comparator|usual care|The other participants enrolled to ASPRA cohort are acted as a control arm. The usual care according to ASPRA protocol will be maintained.
89208721|NCT04007679|Experimental|Pain education group|Pain education was conducted in physical conditions similar to the university classrooms where the study was performed for all participants.
89568201|NCT05244291|Experimental|Intervention Group 2|Therapeutic Touch will be applied to infants for 3 consecutive days, once a day, 10 minutes at any time during the day. There will be a four-day break. The Therapeutic Touch will be done a total of 6 times in 2 weeks.
89568202|NCT05244291|No Intervention|Control Group|The therapeutic touch will not be applied to the control group infants. However, the routine follow-up and behavior of the weekly baby will be evaluated to ensure that parents are blind.
89568203|NCT03073135|Experimental|Psychodrama Group Therapy (PGT)|The PGT is a 15-session weekly program. Sessions last one and a half hours, conducted by two psychologists with more than ten years of experience. The process will be divided into three stages: the first (5 sessions) will be focused on the management of the individual's relationship challenges. The second stage (5 sessions) will focus on the association between the subject's management of their relationships and the excoriation disorder (ED) symptoms. The third (5 sessions) will focus on the development of new skills for the management of ED. Psychodramatic methods will be used throughout the process.
89568204|NCT03073135|Active Comparator|Supportive Group Therapy (SGT)|The SGT is a 15-session weekly program. Sessions last one and a half hours, conducted by two psychologists with more than ten years of experience.
89568205|NCT05284383|Experimental|Open-label counterconditioning|Closed-label conditioning followed by open-label counterconditioning, using moderately painful stimuli (during conditioning) and non-painful stimuli (during counterconditioning), combined with closed-label nocebo suggestions and open-label nocebo reduction suggestions
89568206|NCT05284383|Experimental|Closed-label counterconditioning|Closed-label conditioning followed by closed-label counterconditioning, using moderately painful stimuli (during conditioning) and non-painful stimuli (during counterconditioning), combined with closed-label nocebo suggestions and closed-label nocebo reduction suggestions
89608869|NCT03584919|Placebo Comparator|controls|control subjects without history of Lyme disease
89608870|NCT03584841|Experimental|Patients with mucoviscidosis|For patients with cystic fibrosis: clinically stable, all genotypes included.
89568207|NCT05284383|Active Comparator|Closed-label extinction|Closed-label conditioning followed by closed-label extinction, using moderately painful stimuli (during conditioning) and slightly-painful stimuli (during extinction), combined with closed-label nocebo suggestions during conditioning and no/neutral suggestions during extinction
89568208|NCT04995991|Experimental|RRT rhythm only|10 RRT rhythm only sessions of 60 minutes, twice a week under the supervision of a trainer
89568209|NCT04995991|Experimental|RRT rhythm + visual cue|10 RRT rhythm + visual cue sessions of 60 minutes, twice a week under the supervision of a trainer
89568210|NCT04995991|No Intervention|No intervention|5 weeks no intervention period
89568211|NCT03077113|Other|Ventilation Images for Comparison|"Standard of Care: 4-D CT scan will be used to make a radiation treatment plan.~SPECT-CT Scan: This second scan will be done on another day to make a treatment plan for comparison to the first plan."
89568212|NCT03072901||EndoBarrier Gastrointestinal Liner|244 subjects; The registry will be open to subjects who meet the EndoBarrier's Indications for Use and none of the Contraindications in the device's Instructions For Use document. Subjects who successfully receive the device implant at a participating registry center will be included in the registry.
89568213|NCT03073057|Experimental|Charcoal and Budesonide/formoterol Easyhaler A|160/4.5microg/inhalation Charcoal
89568214|NCT03073057|Experimental|Charcoal and Budesonide/formoterol Easyhaler B|160/4.5microg/inhalation Charcoal
89568215|NCT03073057|Experimental|Charcoal and Budesonide/formoterol Easyhaler C|160/4.5microg/inhalation Charcoal
89568216|NCT03073057|Active Comparator|Charcoal and Symbicort Turbuhaler|160/4.5microg/inhalation Charcoal
89568217|NCT03073369|Active Comparator|Oral Ergocalciferol|Oral Ergocalciferol 50000 IU once daily for 6 weeks
89568218|NCT03073369|Placebo Comparator|Placebo|
89568219|NCT04995757|Experimental|MicroPort NeuroTech Stentretriever|
89568220|NCT04995757|Active Comparator|Solitaire FR|
89568221|NCT03072823|Active Comparator|n-3 polyunsaturated fatty acids|n-3 polyunsaturated fatty acids dosage of 2 g of Eicosapentaenoic acid(EPA) and 1 g of Docosahexaenoic acid (DHA).
89568222|NCT03072823|Placebo Comparator|placebo|olive oil ethyl esters
88969875|NCT05497804|Experimental|Treatment (combination chemotherapy)|"INDUCTION: Patients receive carfilzomib IV on days 2, 8, and 15 of cycle 1 and days 1, 8, and 15 of cycles 2-12, lenalidomide PO days 1-21 of each cycle, daratumumab SC days 1, 8, 15, and 22 of cycles 1 and 2, days 1 and 15 of cycles 3-6, and day 1 of subsequent cycles, and dexamethasone PO or IV on days 1, 8, 15, and 22 of each cycle. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Patients receive carfilzomib IV on days 1, 8, and 15, lenalidomide PO days 1-21, daratumumab SC day 1 of each cycle. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive carfilzomib IV on day 1, lenalidomide PO days 1-21, daratumumab day 1 of each cycle. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspirate and biopsy, MRI and, CT/PET."
88969876|NCT05490355|Active Comparator|Perineural Steroid Injections Alone|"Participants assigned to this study arm will receive only Perineural Steroid Injections per clinical standards.~Participant will also complete a joint function questionnaire at 4 time points, pre-procedure, 2 weeks post procedure, 3 months post procedure, and 6 months post procedure."
88969877|NCT05490355|Experimental|Perineural Steroid Injections Plus Radiofrequency Ablation|"Participants assigned to this study arm will receive Perineural Steroid Injections plus Radiofrequency Ablation per clinical standards.~Participant will also complete a joint function questionnaire at 4 time points, pre-procedure, 2 weeks post procedure, 3 months post procedure, and 6 months post procedure."
88969878|NCT05485623|Experimental|clinician guided scan comparing the device output to the in clinic scan (ground truth)|"Naïve subjects who haven't use the FC device will be allocated to use the CG-mode~The patient will perform a CG scan, guided by a professional sonographer on a Pulsenmore telehealth platform, who will instruct the patient during the exam. At visit 1: the procedure will be performed in a private room in the clinic, while the clinician will be in a different room than the patient. At visit 2 and all other visits, until the last visit, FC scans will be done from home. The clinician will guide the patient using a standardized language which was practiced and used during the clinician training. By the end of the scan, the patient will transmit the videos to the cloud. Then the clinician will review the video scans for visualization of ovaries and uterus, identifying the number and size of ovarian follicles, endometrial thickness and additional parameters"
88969879|NCT05485623|Experimental|App guided scan comparing the device output to the in clinic scan (ground truth)|"Experienced patients who already used the FC device will be offered to use the AG node for a second cycle.~The patient will perform self - administered vaginal sonography using the study device and assisted by videos on Pulsenmore app. The procedure will be performed at home, in the morning before the patient come to the clinic for the conventional US and tests. All scans are automatically uploaded to the Pulsenmore web-viewer. A qualified reviewer will review the videos for visualization of ovaries and uterus, identify the number and size of ovarian follicles, and measure endometrial thickness. Other parameters might be evaluated as well. The App guided scan is limited to 4 minutes and the session will be deactivated by the end of the scanning time."
89568223|NCT04995679|Other|Patient whit osteoarthritis of the knee|Patients with osteoarthritis of the knee undergoing total knee replacement surgery with metaphyseal sleeves
89568224|NCT03076957|Experimental|Treat Regimen|CKD-516(investigational Drug) Irinotecan
89568225|NCT03077035|Experimental|glass ionomer sealant|
89568226|NCT03077035|Active Comparator|resin-based sealant|
89568227|NCT04992325||Patients with type 2 diabetes mellitus|The patients with previous diagnosis of type 2 diabetes mellitus, without signs of diabetic retinopathy
89568228|NCT04992325||Healthy subjects|Healthy subjects without actual and previous ocular diseases
89568229|NCT03074071|Active Comparator|Breast Cancer patient|Patients with Stage IV breast cancer will be taught to build hope by defining attainable goals for themselves in a Hope Enhancement Workshop.
89568230|NCT03074071|Active Comparator|Oncologists|Oncologists will will be taught to build hope by defining attainable goals for themselves and for their patients in a Hope Enhancement Workshop.
89568231|NCT01652911|Experimental|Cell Pouch|Participants with Type-1 diabetes will receive the Sernova Cell Pouch™ implanted in the subcutaneous site, two to approximately twelve weeks prior to transplantation of islets into the Cell Pouch™.
89568232|NCT03073993|Active Comparator|Nasogastric|Feeding tube insertion in nasogastric group
89568233|NCT03073993|Active Comparator|Orogastric|Feeding tube insertion in orogastric group
89568234|NCT04433611|Experimental|'lidocaine flushing' group|intrauterine infusion of 2% lidocaine (Rafa laboratories, Israel) just prior to HyFoSy
89568235|NCT04433611|Placebo Comparator|Placebo group|intrauterine infusion of 0.9 % normal saline (placebo group) just prior to HyFoSy.
89568236|NCT04992559|Experimental|Toripalimab Arm|Toripalimab consolidation therapy
89568237|NCT04992481|Experimental|1. professional mechanical tooth cleaning (PMTC)+fluoride varnish|This arm constituted of randomly selected 30 participants. In this group professional mechanical tooth cleaning (PMTC)+fluoride varnish were performed.
89568238|NCT04992481|Experimental|2. PMTC+fluoride varnish+gaseous ozone therapy|This arm constituted of randomly selected 30 participants. In this group PMTC+fluoride varnish+gaseous ozone therapy were performed.
89568239|NCT04992481|Experimental|3. PMTC+fluoride varnish+domestic octenidin mouth rinse|This arm contituted of randomly selected 30 participants. In this group PMTC+fluoride varnish+domestic octenidin mouth rinse were applied.
89568240|NCT04992481|Experimental|4. PMTC+fluoride varnish+domestic octenidin mouth rinse+ gaseous ozone therapy|This arm constituted of randomly selected 30 participants. In this group PMTC+fluoride varnish+domestic octenidin mouth rinse+ gaseous ozone therapy were performed.
89568241|NCT04992481|No Intervention|Control group|Control group not subjected to any prophylactic program constituted of randomly selected 30 participants.
89568242|NCT04992091|Experimental|CONSTRUCTIVE DEBRIEFING|interventional group
89568243|NCT04992091|No Intervention|traditional debriefing|noninterventional group
89568244|NCT02597933|Experimental|Nintedanib|patient receives capsules containing nintedanib twice a day
89568245|NCT02597933|Placebo Comparator|Placebo|patient receives capsules identical to those containing active drug
89568246|NCT04995367|Experimental|Implementation of a BCI system integrated to the T-FLEX lower-limb exoskeleton in post-stroke|The participants will carry out tests for the evaluation of the functionality of the BCI system integrated to the T-FLEX device. The test consists of 1 session that includes four conditional experiments. Real Movement, Continuous Stationary Therapy, Motor Imagery Detection with Visual Stimulation, and Motor Imagery Detection with Tactile Stimulation.
89208722|NCT02592785|Experimental|BAY1163877|Cohort 1: Safety, tolerability and PK of 600 mg dose given twice daily. Escalation to cohort 2 in case no safety relevant adverse event has been observed within 21 days after start of study treatment Cohort 2: Safety, tolerability and PK of 800 mg dose given twice daily
89568247|NCT05004415|Experimental|AT-527 550 mg (R07496998)|
89568248|NCT04912843|Experimental|NR082 injection|0.5E9 viral genomes (vg), 0.05 mL eye/dose ,single-dose,only one eye per subject; 1.5E9 viral genomes (vg), 0.05 mL eye/dose single-dose,only one eye per subject; 4.5E9 viral genomes (vg) , 0.05 mL eye/dose single-dose,only one eye per subject Part 1: Dose-Finding；The recommended dose (safe and effective dose) of the Part 2 study will be determined jointly by the SRC, IDMC, sponsor and the drug regulatory authority after the interim analysis in Part 1 is completed.
89208723|NCT00871962||1|COPD patients on necessity of long-term oxygen therapy
89208724|NCT00803816|Other|Addition of everolimus to standard care|refractive to cyclosporine A (CsA) received additional everolimus.
89208725|NCT00981123||1|
89208726|NCT00872040||Nuliparous women and their husbands|Women in their first pregnancy with their husbands
89568249|NCT04912843|Sham Comparator|sham-injection|Part2.Second Stage: randomized, double-blind, sham-injection control study One eye of each participant will undergo sham injection. Sham intravitreal injection will be performed by applying pressure to the eye at the location of a typical intravitreal injection procedure using the blunt end of a syringe without a needle.
89568250|NCT04995133|Experimental|Colistin Arm|Intravenous administration of 6.75 x 106 Units Colistin for 30 minutes
89028299|NCT02596503|Experimental|Eribulin + Irinotecan|"Eribulin will be administered intravenously on days 1 and 8 of a 21-day cycle, while irinotecan will be administered orally on days 1-5. The oral antibiotic cefixime will be used to reduce irinotecan-associated diarrhea.~Eribulin dose will be assigned at time of enrollment using a 3+ 3 Phase 1 design (ranging from 0.8 - 1.4 mg/m2/dos). The dose of irinotecan will be fixed at 90 mg/m2/day x 5 days."
89568251|NCT04827173|Experimental|Healthy volunteers|
89568252|NCT04994821|Experimental|Active tDCS|Active Transcranial Direct Current Stimulation (tDCS), (Soterix Medical mini-CT tDCS stimulator)
89568253|NCT04994821|Sham Comparator|Sham tDCS|Sham (Placebo) Transcranial Direct Current Stimulation (tDCS), Soterix Medical mini-CT tDCS stimulator
89568254|NCT04994821|Experimental|Active tDCS with Cognitive Reappraisal (CR)|Active Transcranial Direct Current Stimulation (tDCS) (Soterix Medical mini-CT tDCS stimulator), and Cognitive Reappraisal (CR)
89568255|NCT04361669||Intervention|Patients that receive pharmacist-delivered services in the pilot program
89568256|NCT04361669||Control|Patients that do not receive pharmacist-delivered services in the pilot program
89568257|NCT04361591||COVID-19|Liver Transplant recipients
89568258|NCT04991623|Experimental|Kinesiology taping|Apply a kinesiology taping on the abdominal muscles plus conventional physiotherapy
89568259|NCT04991623|Active Comparator|Physiotherapy Group|Apply a conventional physiotherapy
89568260|NCT04360889|Experimental|Tocopherol|patients with lower limb lymphedema who will receive conservative therapy with elastic compression and an antioxidant (Tocopherol-400 IU/day) - 90 days
89568261|NCT04360889|Experimental|Micronised purified flavonoid fraction|patients with lower limb lymphedema who will receive conservative therapy with Micronised purified flavonoid fraction (diosmin+flavonoids expressed as hesperidin)-1000mg/day) in addition to elastic compression - 90 days
89568262|NCT04360889|Other|Elastic compression|patients with lower limb lymphedema who will be treated with elastic compression - 90 days
89568263|NCT04360889|No Intervention|Healthy volunteers|healthy volunteers with no history or clinical signs of venous or lymphatic disease - 90 days
89568264|NCT03072589|Experimental|Regadenoson infusion|Dose escalation of Regadenoson infusion
89028300|NCT02597790||Group A (HIV/HCV coinfected)|
89028301|NCT02597790||Group B (HIV monoinfected)|
89568265|NCT04994743|Experimental|Cohort 1: CORT113176 150 mg|Participants will receive CORT113176 150 mg lipid capsule formulation by mouth once daily under fed conditions for 14 days.
89568266|NCT04994743|Placebo Comparator|Cohort 1: Placebo matching CORT113176|Participants will receive placebo matching CORT113176 capsule by mouth once daily under fed conditions for 14 days.
89568267|NCT04994743|Experimental|Cohort 2: CORT113176 300 mg|Participants will receive CORT113176 300 mg lipid capsule formulation by mouth once daily under fed conditions for 14 days. Progression from Cohort 1 to 2 will be done based on safety and tolerability outcome from Cohort 1 and only after Cohort 1 has received study drug for ≥7 days.
89028302|NCT00494429|Experimental|1|Gestational Age< 29 weeks will be administered a loading dose of 0.05 mg/kg I.V. morphine over 30-minutes, followed by a continuous infusion of 0.005 mg/kg/hr.
89028303|NCT00494429|Experimental|2|Gestational Age>= 29 weeks will be administered a loading dose of 0.1 mg/kg I.V. morphine over 30-minutes, followed by a continuous infusion of 0.01 mg/kg/h.
89028304|NCT01245023|Active Comparator|laparoscopy|laparoscopic adhesiolysis and application of Sprayshield spray to prevent further adhesions
89028305|NCT01245023|Placebo Comparator|placebo-control|anaethesia and skin incisions without laparoscopy or related procedures
89028306|NCT02276352|Experimental|Meloxicam low dose - one tablet|
89028307|NCT02276352|Experimental|Meloxicam high dose - two tablets|
89028308|NCT02276352|Active Comparator|Meloxicam high dose - one tablet|
89028309|NCT00497237|Experimental|1|Foster
89028310|NCT00497237|Active Comparator|2|Seretide
89028311|NCT05144061|Experimental|Single Arm|HRS2398 Tablets
89028312|NCT01244282|Experimental|All Participants|fMRI studies with sensory stimulation in the presence of 0 mg, 250 mg, 350 mg, and 510 mg cumulative doses of ferumoxytol
89028313|NCT00497276|Experimental|I|Ultrasound guided placement of popliteal catheter
89028314|NCT00497276|Experimental|II|Nerve stimulation guided placement of popliteal catheter
89028315|NCT05144178||Mild and moderated COVID -19 patient treated out side the hospital sitting|Reviewing files of such group that had been received Sotrovimab
89028316|NCT00497315|Experimental|A|pemetrexed + cisplatin (3 cycles) followed by thoracic irradiation + pemetrexed
89028317|NCT00497315|Experimental|B|thoracic irradiation + pemetrexed followed by pemetrexed + cisplatin
89028318|NCT05142072|Experimental|vitamin D film|Prepared intranasal films containing vitamin D3 by the investigators and administered to the right nostril with the aid of an ENT surgeon
89028319|NCT05142072|Other|control group|No devices will be added
89028320|NCT00497393|No Intervention|Control|regular use of the 2-bed areas in the Emergency department
89028321|NCT05140785|Experimental|Brain tumour patients|Patients will be those undergoing routine care of primary brain tumours. Study group patients will undergo additional MRI sequences and biopsies in addition to the standard of care.
89028322|NCT00507156|Experimental|Mek postcon|Re-opening of the infarcted coronary artery by several balloon inflations separated by reperfusion of the vessel.
89028323|NCT00507156|Active Comparator|Standard treatment|Standard treatment (primary PCI)
89028324|NCT00494663|Experimental|1|150mg DIO-902 + 10mg atorvastatin
89028325|NCT00494663|Experimental|2|300mg DIO-902 + 10mg atorvastatin
89028326|NCT00494663|Experimental|3|450mg DIO-902 + 10mg atorvastatin
89028327|NCT00494663|Placebo Comparator|4|DIO-902 Placebo + 10mg atorvastatin
89028328|NCT00494663|Experimental|5|150mg DIO-902 + atorvastatin placebo
89568268|NCT04994743|Placebo Comparator|Cohort 2: Placebo matching CORT113176|Participants will receive placebo matching CORT113176 capsule by mouth once daily under fed conditions for 14 days.
89568269|NCT04994743|Experimental|Cohort 3: CORT113176 ≥300 mg|Participants will receive CORT113176 ≥300 mg not to exceed 450 mg lipid capsule formulation by mouth once daily under fed conditions for 14 days. Cohort 3 is optional, and progression from Cohort 2 to 3 be done based on safety and tolerability outcome from Cohort 2 and only after Cohort 2 has received study drug for ≥7 days.
88969880|NCT05474872||BIS monitoring|Patients in this group will be subjected to Bispectral index-guided general anesthesia.
88969881|NCT05474872||PRST score monitoring|Patients in this group will be subjected PRST score-guided general anesthesia.
88969882|NCT05472779|Active Comparator|Intravaginal Estrogen Application|Intravaginal application of 1 gram estradiol cream at bedtime twice a week for 6 months
88969883|NCT05472779|Experimental|Periurethral Estrogen Application|Periurethral application of 0.5 gram estradiol cream at bedtime twice a week for 6 months
89568270|NCT04994743|Placebo Comparator|Cohort 3: Placebo matching CORT113176|Participants will receive placebo matching CORT113176 capsule by mouth once daily under fed conditions for 14 days.
89568271|NCT04812041||Intensive care unit delirium|Covid-19 patients in ICU are screened for delirium and rated the severity with CAM-ICU 7 scores.
89568272|NCT03076879|Experimental|Intervention group|The selected ASM was associated with risk factors related to direct cervical cancer in Turkey (using age 5 or older oral contraceptives, having three or more children, initiating sexual intercourse 16 years or older, at least one parenthesized smear test between 40-55 years) And randomly assigned to the experimental group to promoting participation in cervical cancer screening
89568273|NCT03076879|No Intervention|Control Group|The selected ASM is the most common and associated with direct cervical cancer-related risk factors in Turkey (using oral contraceptives for longer than five years, having three or more children, starting sexual intercourse at the age of 16 and before, Women who are randomly assigned to the control group of women who have at least one pap smear test between the ages of 40 and 55 and who have at least one pap smear test in the family (especially a mother and a sister)
89568274|NCT04811885||child with ASD of school going age|Questionnaire complete by parent with children with ASD semi structure interview complete by parent with children
89568275|NCT03072355|Active Comparator|Elastic Band|Perform the maximum of the possible repetition with a load of 50% of the 1RM (performing 1½ seconds in the concentric phase and 1½ seconds in the eccentric phase).
89568276|NCT03072355|Active Comparator|Isokinetic dynamometer|Realization of the maximum of the possible repetition to 50% of the MIVM in the speed of 60º / s for abduction and 500º / s in the return of the movement.
89028329|NCT00494663|Experimental|6|300mg DIO-902 + atorvastatin placebo
89028330|NCT00494663|Experimental|7|450mg DIO-902 + atorvastatin placebo
89568277|NCT04426877|Experimental|Experimental group|The experimental group will receive access to the web-based lifestyle intervention (exercise and nutritional education), supported by audiovisual instructions given by their hypertension specialist doctor.
89028331|NCT00494663|Placebo Comparator|8|DIO-902 placebo + atorvastatin placebo
89033099|NCT02917863|Active Comparator|Liquid L-Thyroxine|"Patients assume L-Thyroxine (oral drops, solution) according to the Summary Product Characteristics for 6 months (then switch to the other formulation).~Dosage in children with acquired hypothyroidism:~initial dose: 12,5-50 mcg/die maintenance dose: 100-150 mcg/m2 body surface area~Dosage in adults:~initial dose: 50 mcg/die; maintenance dose: 100-200 (300) mcg/die (medium dose 2-2,5 mcg/kg body weight/die).~Dosage will be adjusted according to TSH level."
89033100|NCT02917824|Experimental|High-intensity IMT|Participants enrolled in this arm received high-intensity IMT
89033101|NCT02917824|Active Comparator|Low-intensity IMT|Participants enrolled in this arm received low-intensity IMT
89033102|NCT00530738|Experimental|1|treatment with Lipoplus & Nutriflex plus (commercially available and marketed 2 Chamber Bag)
89033103|NCT00530738|Active Comparator|2|treatment with Lipofundin MCT & Nutriflex plus (commercially available and marketed 2 Chamber Bag)
89033104|NCT02921685|Experimental|Monalizumab|Monalizumab treatment will be initiated 75 to 100 days after hematopoietic stem cells transplantation. Patients will receive a single dose of monalizumab by intravenous route over 1 hour.
89568278|NCT04426877|Experimental|Control Group|The control group will receive the same web-based lifestyle intervention (exercise and nutritional education), but in this case supported by audiovisual instructions given by a doctor outside the patient.
89568279|NCT03076801|Experimental|Choral Singing Intervention|In addition to usual medical care, participants in the intervention group will participate in choral singing.
89568280|NCT03076801|No Intervention|Control|The control group will receive usual medical care only. If control group participants join an external singing group during the study period they will not be excluded, but this data will be collected and considered.
89568281|NCT04426799|No Intervention|Control group|no application
89568282|NCT04426799|Experimental|Experimental group|application is done
89568283|NCT04994353|Experimental|Supplementation|"Three days before the intervention, every subject was informed to maintain their normal diet, physical activities, and enough sleep (6-8 hours/day). All subjects fasted 10-12 hours before the intervention. An intravenous cannula was inserted into the cubital vein to provide access to repeated glucose measurement. Peripheral vein whole blood samples were taken for analysis of glucose concentration using a commercially available FreeStyle Optium glucose monitoring system (Abbot Laboratories, Chicago, Illinois, USA) .For the first week, we measured blood glucose to a meal without any intervention and use those data as a baseline. After that, blood glucose was measured at 0, 30, 60, 90, and 120 minutes after intervention and meal. After intervention, the subjects maintain daily predefined ready-meal (470 kcal). The supplementation formulas are food grade, purchased from PT. Lautan Natural Krimerindo (Mojokerto, Jawa Timur, Indonesia)."
89568284|NCT04826783|Experimental|Diode laser|
89568285|NCT04826783|Experimental|Er,Cr:YSGG laser|
89568286|NCT04826783|Experimental|Er:YAG LAser|
89568287|NCT03072745|Experimental|Neuropsychological assessment|Assessment with a neuropsychological test battery and self-report measures.
89568288|NCT04807829|Experimental|Nabilone|Patients in the treatment group will be administered oral Nabilone 2 mg once daily for 3 days in addition to treatment as usual according to current clinical guidelines and standard of care.
89568289|NCT04807829|Placebo Comparator|Placebo Comparator|Patients in the Placebo Comparator group will receive placebo once daily for 3 days plus treatment as usual.
89568290|NCT04994275||Patients admitted to undergo a major elective surgery|
89568291|NCT05619029||Positive|chest radiographs with the specific target radiologic findings (Atelectasis, Calcification, Cardiomegaly, Consolidation, Fibrosis, Mediastinal Widening, Nodule/Mass, Pleural Effusion, Pneumoperitoneum, Pneumothorax)
89208727|NCT04087499|Sham Comparator|regular medication treatment|regular medication treatment
89208728|NCT04087499|Experimental|acupuncture and regular medication treatment|acupuncture and regular medication treatment
89568292|NCT05619029||Negative|chest radiographs with no target radiologic findings
89568293|NCT03076645|Experimental|Experimental|The Experimental Group will be placed in a group using the matching algorithm. Facilitator support and education intervention
88969891|NCT05464329|Experimental|Arm A: Mosunetuzumab + DHAX|"3 cycles (cycle=21 days) of mosunetuzumab with DHAX salvage chemotherapy (selected at the discretion of the treating physician).~The first 3 patients in each arm will receive Dose Level 1 along with standard dosing of DHAX. The rate of dose-limiting toxicities will determine whether the subsequent 3 patients in each arm are enrolled at Dose Level 1, or alternatively at Dose Level -1.~For patients tolerating Cycle 1 of treatment, Cycles 2 and 3 will consist of mosunetuzumab administered as a single dose on Day 1 along with DHAX. Patients will undergo PET-CT restaging prior to Cycle 3, and those achieving a CR (or PR, at their physician's discretion) will receive the Cycle 3 dose of mosunetuzumab and DHAX, followed by standard of care stem cell mobilization and autoSCT. Patients with SD or PD after restaging will discontinue study treatment."
89208729|NCT00797264|Experimental|A|Ketamine pre and per operative, and morphine postoperative
89208730|NCT00797264|Active Comparator|B|NaCl pre and per operative, and morphine postoperative
89568294|NCT03072511|Experimental|Spotlight on Smoke-Free Living|Treatment will include a 1.5-hour intervention session combined with daily text-messaging for up to 1 week pre-quit and 4 weeks post-quit. The intervention includes: mindful breathing, visualization, and identification and thinking about goals and priorities inconsistent with smoking. During the text-messaging phase, elements of the intervention discussed during the in-person session will be reinforced. Participants will be provided transdermal nicotine patches (TNP). TNP are a safe and effective approach to nicotine replacement when an individual attempts to stop smoking and are safe for use without prescription. Participants will begin the regimen on the scheduled quit date with an initial dose of 21 mg (4 weeks), followed by 14 mg (2 weeks), and 7 mg (2 weeks). Alterations to dosing will be allowed when appropriate and consistent with manufacturer's recommendations. While TNP will be offered to all participants, they can decline or discontinue use of TNP at any time.
89568295|NCT03072511|Active Comparator|Standard Informational Treatment|Standard informational treatment is based on conventional, information-based smoking cessation approaches commonly found in public health settings. This will include the following information: prevalence/incidence of cigarette smoking and negative health outcomes associated with cigarette smoking (e.g., cancer, respiratory disease, complications), other health consequences resulting from diseases associated with cigarette smoking, personal/financial/social consequences of cigarette smoking. During the text-messaging phase, information about the consequences of smoking discussed during the in-person session will be reiterated. As with the experimental condition, participants will be provided with 8-weeks TNP.
89568296|NCT05616611|Active Comparator|Control group|control group received medication and traditional physiotherapy programs for stroke patients (strengthening, stretching, and balance exercise)
89568297|NCT05616611|Experimental|high-intensity laser group|The high-intensity laser (HIL) group received the same intervention as the control group in addition to high-intensity laser therapy.
89568298|NCT05616611|Experimental|shock wave group|shock wave (SW) group received the same intervention as the control group in addition to shock wave therapy.
89568299|NCT04991545|No Intervention|Group A: control group (intubation without IRD/IRRIS device)|Group A = control group (intubation without IRD/IRRIS device) (15 subjects) The first operator experienced with video-laryngoscopy intubation will do the endotracheal intubation after induction of anesthesia.
89608871|NCT03584841|Experimental|Parents of patients with confirmed diagnosis of mucoviscidosis|The parents are heterozygous subjects
89608872|NCT03584841|Active Comparator|Healthy volunteers|
89608873|NCT02000921|Experimental|CN + combusted & non-combusted products|Subjects will be asked to smoke the assigned conventional nicotine content (CN) cigarettes, instead of their normal brand, for 8 weeks and will also be given access to use other combusted and non-combusted tobacco and medicinal nicotine products during that time.
89608874|NCT02000921|Experimental|VLNC + combusted & non-combusted products|Subjects will be asked to smoke the assigned very low nicotine content (VLNC) cigarettes, instead of their normal brand, for 8 weeks and will also be given access to use other combusted and non-combusted tobacco and medicinal nicotine products during that time.
89208731|NCT00797264|Experimental|C|Ketamine and morphine postoperative
89208732|NCT00981201|Experimental|Celecoxib + Placebo|
89208733|NCT00981201|Experimental|Celecoxib + Celecoxib|
89208734|NCT00981201|Active Comparator|Placebo + Celecoxib|
89208735|NCT00981201|Placebo Comparator|Placebo + Placebo|
89208736|NCT04842708|No Intervention|Healthy Volunteers that are not to be vaccinated against COVID19|Healthy Volunteers that are not eligible to be vaccinated against COVID19
88969892|NCT05464329|Experimental|Arm B: Mosunetuzumab + ICE|"3 cycles (cycle=21 days) of mosunetuzumab with ICE salvage chemotherapy (selected at the discretion of the treating physician).~The first 3 patients in each arm will receive Dose Level 1 along with standard dosing of ICE. The rate of dose-limiting toxicities will determine whether the subsequent 3 patients in each arm are enrolled at Dose Level 1, or alternatively at Dose Level -1.~For patients tolerating Cycle 1 of treatment, Cycles 2 and 3 will consist of mosunetuzumab administered as a single dose on Day 1 along with ICE. Patients will undergo PET-CT restaging prior to Cycle 3, and those achieving a CR (or PR, at their physician's discretion) will receive the Cycle 3 dose of mosunetuzumab and ICE, followed by standard of care stem cell mobilization and autoSCT. Patients with SD or PD after restaging will discontinue study treatment."
89568300|NCT04991545|Experimental|Intervention group using Infrared (Active IRD/ IRRIS) device|Group B = intervention group using Infrared active IRD/IRRIS device (15 subjects) Before inducing anesthesia, the second operator will open the randomization envelope and adhere IRRIS/IRD device to the anterior skin of the neck above the sternal notch according to the group of patients. After confirming lack of discomfort during application of the IRRIS/IRD device, anesthesia will be induced
89208737|NCT04842708|Experimental|Healthy Volunteers that are assigned to be vaccinated against COVID19|Healthy Volunteers that are eligible to be vaccinated against COVID19
89208738|NCT00797342|Other|first of three dosing cohorts|
88969893|NCT05455424|Experimental|Niraparib + ASC|"Patients will receive 200/300 mg of niraparib daily for study period of up to 24 weeks. Patients will be treated until disease progression, withdrawal, death or development of significant treatment limiting toxicity. Niraparib will be supplied in oral formulation as 100 mg capsules. The starting dose of Niraparib will be based upon the patient's baseline body weight and/or platelet count:~Participants with a baseline body weight ≥77 kg and baseline platelet count ≥150 x 109/L will be administered niraparib 300 mg daily.~Participants with a baseline body weight <77 kg or baseline platelet count <150 x 109/L will be administered niraparib 200 mg daily.~The dose of Niraparib can be reduced in 100 mg increments, to a minimum of 100 mg, per protocol. Dose escalations are not permitted."
88969894|NCT05455424|Active Comparator|Active Symptom Control|Patients in this arm will be managed symptomatically and will be treated as per the standard of care at each participating site. ASC could involve regular specialist follow up; structured assessment of physical, psychological, and social problems; and appropriate treatment, including palliative radiotherapy and steroids.
88969895|NCT05453565||Vasopressors|A haemodynamic resuscitation strategy based upon the restriction of IV fluids (by either volume or rate of infusion) with initiation or change of rate of vasopressors if required to meet perfusion targets
88969896|NCT05453565||Fluids|A strategy of resuscitation with intravenous fluids as the primary intervention to achieve perfusion targets with subsequent initiation or change of rate of vasopressors if required.
88969897|NCT05448339||PVHA|Patients undergo tumor feeding vessels deprivation
89208739|NCT00797342|Other|second of three dosing cohorts|
89208740|NCT00797342|Other|third of three dosing cohorts|
89568301|NCT03073681||Historical controls|This group of historical controls makes up patients who have previously undergone cataract surgery with a 3.0 add ReSTOR lens in each eye. This group has already completed a satisfaction questionnaire identical to what will be posed in the 2.5/3.0 add lens group.
89568302|NCT03073681||2.5 and 3.0 add lenses|This group will have undergone cataract surgery at least 2 months before conducting a questionnaire. Patients enrolled in this group had cataract surgery with a 2.5 add ReSTOR lens in one eye and a 3.0 add lens in the other.
89568303|NCT04807751|Experimental|Delgocitinib cream 20 mg/g|topical occlusive administration
89568304|NCT04807751|Placebo Comparator|Delgocitinib cream vehicle|topical occlusive administration
89568305|NCT04807751|No Intervention|Untreated skin|topical occlusive administration
89568306|NCT03072277|Active Comparator|Docosa Hexaenoic Acid (DHA)|Omega 3 Fatty Acid
89568307|NCT03072277|Placebo Comparator|Placebo|Corn/Soy Oil
89568308|NCT03073837|Other|Rhinovirus Challenge|Challenge with HRV-16
89568309|NCT03072121|Experimental|Shexiang baoxin pill|Shexiang baoxin 22.5mg pill by mouth,2 pills three times daily for 6 months & Conventional western medicine (including Aspirin Enteric-coated Tablets, Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet, Atorvastatin Calcium, Isosorbide Mononitrate Tab 20 MG, Metoprolol Tartrate Tab 25 MG, Trimetazidine Dihydrochloride Tablets)
89568310|NCT03072121|Placebo Comparator|SBP placebo|Placebo shexiang baoxin 22.5mg pill by mouth,2 pills three times daily for 6 months & Conventional western medicine (including Aspirin Enteric-coated Tablets, Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet, Atorvastatin Calcium, Isosorbide Mononitrate Tab 20 MG, Metoprolol Tartrate Tab 25 MG, Trimetazidine Dihydrochloride Tablets)
89568311|NCT05618873|Experimental|flutter device therapy|The flutter was used as follows. Sitting with a straight back and the elbows supported on the table, the patient held the flutter horizontally. The patient inhaled deeply, held their breath for 2 or 3 s and then took the mouthpiece into the mouth and exhaled quietly yet quickly enough to activate the flutter. The patient had to keep their cheeks as stiff as possible. This procedure was repeated 15 times, following which the patient huffed three times and evacuated sputum by a voluntary cough. This sequence was repeated five times. The patient obtained the maximal vibration sensation by tilting the flutter upwards or downwards by a few degrees.
88969898|NCT05448339||TACE|Patients undergo TACE therapy
88969899|NCT05433519||Pregnant Women|Pregnant women with gestational age established at less than 14 weeks of gestation
88969900|NCT05433168|Experimental|SHIATSU GROUP|The patients will benefit from shiatsu treatments by a professional according to the shiatsu protocol developed by the Syndicate's evaluation commission Shiatsu Professionals (SPS).
89033105|NCT02944175|Experimental|Sugammadex|Patients will receive Sugammadex to antagonise the residual effects of neuromuscular blocking drugs
89033106|NCT02944175|Active Comparator|Neostigmine|Patients will receive Neostigmine to antagonise the residual effects of neuromuscular blocking drugs
89033107|NCT02917746|Experimental|Imiquimod treatment arm|Treatment by vaginal imiquimod cream during 16 weeks.
89033108|NCT02917746|Active Comparator|Standard treatment arm|Treatment by large loop excision of the transformation zone.
89208741|NCT00872118|Experimental|1|Brief Intervention for Socially Anxious Drinkers
89208742|NCT00872118|Active Comparator|2|Enhanced Alcohol Skills and Education Program
89208743|NCT05279391|Active Comparator|SOC|Patients included in this arm treated with the standard of care (SOC), including dexamethasone plus heparin, with or without the addition of antibiotics and remdesivir
89208744|NCT05279391|Active Comparator|TOCI|Patients included in this arm treated with the SOC plus Tocilizumab (single IV dose: 8mg/kg)
89568312|NCT05618873|Experimental|Positive Expiratory Pressure Mask|"The PEP-mask was used as follows. Sitting with a straight back and the elbows supported on the table, the patient pressed the mask against the face with both hands. After a quiet inhalation, a slow active exhalation followed. The exhalation was restricted by a resistance selected to cause a positive expiratory pressure of 8-12 cmH2O. The patient exhaled 15 times through the mask.~Thereafter, the patient huffed three times and evacuated sputum by a voluntary cough. This sequence was repeated five times."
89568313|NCT04993963|Experimental|Cycle Ergometery Training (Prehabilitation)|Hospital-based ergometer cycling for 20 minutes (Including warm-up and cooldown) Interval training on cycle ergometer: between 40% and 60% Vo2max, perceived exertion <13 on Borg scale
89568314|NCT04993963|Active Comparator|Control Standard Group|Breathing exercise 15 Reps and Walk (10-15 minutes)
89568315|NCT05618795|Other|aggresive gap arthoplasty|control group- aggressive gap arthroplasty(15 to 20 mm) for management of TMJ ankyosis
89568316|NCT05618795|Active Comparator|minimal gap arthoplasty|experimental group-minimal gap arthroplasty(5 to 8mm) for management of TMJ ankylosis
89568317|NCT04994041|Experimental|Pelvic floor muscle plus adductor strengthening|pelvic floor muscle plus adductor strengthening
89568318|NCT04994041|Active Comparator|Pelvic floor muscle exercises|pelvic floor muscle exercises
89568319|NCT02597855||Type 1 polypoidal choroidal vasculopathy|Monthly intravitreal aflibercept injection for 3 months and 1 additional injection after 2 months. Indocyanine green angiography was used to classify the type of PCV and evaluate the polyp closure rate.
89568320|NCT02597855||Type 2 polypoidal choroidal vasculopathy|Monthly intravitreal aflibercept injection for 3 months and 1 additional injection after 2 months. Indocyanine green angiography was used to classify the type of PCV and evaluate the polyp closure rate.
89568321|NCT04987567|Active Comparator|Antioxidant docosahexaenoic acid (DHA)|"Antioxidant docosahexaenoic acid (Tridocosahexaenoin-AOX ® 70%) 50mg/kg/day:~50mg/kg/day so:~> = 13-17kg: 2 pearls (700mg DHA) every day, once or twice daily (od or bd)~> = 18-24kg: 3 pearls (1050mg DHA) every day, od or bd~> = 25-30kg: 4 pearls (1400mg DHA) every day, bd (2-0-2)~> = 31-36kg: 5 pearls (1750mg DHA) every day, bd (2-0-3)~> = 37-43kg: 6 pearls (2100mg DHA) every day, bd (3-0-3)~> = 44-49kg: 7 pearls (2450mg DHA) every day, three times a day (td) (3-1-3)~> = 50kg: 8 prearls (2800mg DHA) every day, td (3-2-3)."
89568322|NCT04987567|Placebo Comparator|Placebo|"Olive oil 50mg/kg/day so:~> = 13-17kg: 2 pearls every day, once or twice daily (od or bd)~> = 18-24kg: 3 pearls every day, od or bd~> = 25-30kg: 4 pearls every day, bd (2-0-2)~> = 31-36kg: 5 pearls every day, bd (2-0-3)~> = 37-43kg: 6 pearls every day, bd (3-0-3)~> = 44-49kg: 7 pearls every day, three times a day (td) (3-1-3)~> = 50kg: 8 prearls every day, td (3-2-3)."
89208745|NCT05279391|Active Comparator|ANA|Patients included in this arm treated with the SOC plus Anakinra (200mg twice daily IV for 3-6 days, then 100 mg/twice daily, for up to 10 days in total)
89208746|NCT05279391|Active Comparator|COMBI|Patients included in this arm treated with the SOC plus the combination of Tocilizumab, Baricitinib and inhaled DNase (COMBI) as a rescue treatment.
89568323|NCT04811495|Experimental|patient with temporomandibular joint disorders|
89568324|NCT05004103|Experimental|Skin microbiome evaluation|Female healthy volunteers applied cosmetic products (cleanser and moisturizer cream), the diversity of skin microbiome will be examined before and after using the products
89568325|NCT05003869|Experimental|Intraoperative resection of intrauterine scar tissue by TCRA|Study group: patients took the bladder lithotomy position, routinely disinfected vulva and vagina, and laid sterile towel and sheet.pliers Clamp the front lip of the cervix, explore the depth of the uterine cavity, dilate the cervical canal one by one, place the endoscopy, and examine the uterine cavity.After the scar tissue contracted on one side, the scar tissue was disintegrated at the boundary between the intima and scar tissue. The scar tissue was removed with the annular electrode, and a balloon was placed after surgery to prevent re-adhesion.Complete adhesion release is defined as a return to normal shape of the uterine cavity with bilateral uterine angles exposed.
89568326|NCT05003869|No Intervention|No scar tissue resection group|During the operation, the scar tissue covering the anterior, posterior and lateral walls of the uterine cavity was ploughed longitudinally into several narrow strips with needle-like electrodes, and scar tissue was not excised.
89568327|NCT03072199|Experimental|Rituximab|
89568328|NCT04811105|Active Comparator|steam ablation|The fistula tract which treated with steam ablation
89568329|NCT04811105|Active Comparator|control group|The fistula tract which do not take any treatment
88969901|NCT05433168|Experimental|DUMMY SHIATSU GROUP|Exercising a fake shiatsu is a real problem as opinions differ. The consensus of the different schools and styles of the technique is that shiatsu pressure is weight transfer. We are therefore going to remove this aspect from the SFASPA shiatsu protocol. The professional will run the same sequence of points, without any weight transfer, being only in contact with the receiver.
88969902|NCT05431452|No Intervention|Group 1 (Control Group)|"There is no non-pharmacological method applied during routine heel blood collection in the clinic where the research will be conducted. No intervention will be applied to this group within the scope of the research. In order to minimize the risk of aspiration during the procedure, the head of the bed in the incubator will be elevated at a 45-degree angle. The 1st minute before the procedure, the 1st minute and the 2nd minute during and after the procedure will be recorded with a video camera and the data on the monitor will be recorded in the Physiological Parameters Measurement Form."
89208747|NCT00789542|Experimental|Intermittent Pneumatic Compression|SCD Express device applied with thigh length sleeves for up to 30 days
89208748|NCT00789542|Other|Routine care|Routine care which might include: early mobilisation, adequate hydration, aspirin if ischaemic stroke and graduated compression stockings according to local protocols.
89568330|NCT04990999|Experimental|Vestibular Root Extraction|
89568331|NCT04990999|Active Comparator|Atraumatic extractions using periotomes followed by conventional forceps|
88969903|NCT05431452|Experimental|Group 2 (Breast milk)|"2 minutes before the procedure, the bedside of the baby will be raised at an angle of 45 degrees and 2 ml of breast milk will be given by the research clinic nurse with the help of a sterile injector, provided that each baby will be their own breast milk. Heel blood collection will be performed 2 minutes after breast milk is given. The 1st minute before the procedure, the 1st and 2nd minutes during and after the procedure will be recorded with a video camera and the data on the monitor will be recorded in the Physiological Parameters Measurement Form."
88969904|NCT05431452|Experimental|Group 3 (Supine Fetal Position)|"This method is a lower form of the method of taking the baby into the nest and is defined as the process of keeping the baby's upper and lower extremities flexed by hand, and taking the body into a closed position close to the midline. While applying this method, the baby can be placed in a lateral, supine or prone position (Neto et al., 2020).~In our research, according to the literature, the baby will be placed in the fetal position 3 minutes before the procedure, and the baby will be kept in the fetal position for 3 minutes after the procedure. The 1st minute before the procedure, the 1st and 2nd minutes during and after the procedure will be recorded with a video camera and the data on the monitor will be recorded in the Physiological Parameters Measurement Form."
88969905|NCT05431452|Experimental|Group 4 (Kangaroo maternal care)|"10 minutes before the procedure, the mother will be placed on the mother's chest at an angle of 60 degrees, with only the diaper left under the baby in the baby adjustment room, in a way that it will contact the mother's chest directly from skin to skin. In order not to lower the newborn's body temperature, a thin blanket will be covered on his back and the mother will be asked to gently soothe the baby's movements by wrapping her hands around the newborn's back. The mother will be instructed not to make additional movements such as stroking, talking, feeding and shaking her baby. After 10 minutes of kangaroo mother care, heel blood collection will be performed and after the procedure, kangaroo mother care will continue for 2 more minutes. The 1st minute before the procedure, the 1st and 2nd minutes during and after the procedure will be recorded with a video camera and the data on the monitor will be recorded in the Physiological Parameters Measurement Form."
88969906|NCT05431452|Experimental|Group 5 (Supine Fetal position + Breast milk)|"The head of the baby's bed is elevated to a 45-degree angle and before the procedure, 2 ml of breast milk will be given with the help of a sterile injector by the research clinical nurse, on the condition that each baby has its own breast milk, and then the baby will be placed in the fetal position (Shah et al., 2012; Shukla et al. , 2018). After the baby is held in the fetal position for 3 minutes, heel blood sampling will be performed. The 1st minute before the procedure, the 1st and 2nd minutes during and after the procedure will be recorded with a video camera and the data on the monitor will be recorded in the Physiological Parameters Measurement Form. In line with the literature recommendations, the baby will be supported in the fetal position for 3 minutes after the procedure (Axelin et al. 2006; Cignacco et al. 2010; Obeidat et al. 2009; Çağlayan and Balci, 2014)."
89028332|NCT05146674|Active Comparator|Tadalafil group|"Our prospective, randomized, study will consist of a 1-week baseline period and 12-week double-blind treatment period During the baseline period, patients' characteristics, including medical and sexual history, physical examination results, vital signs, HPMDQ score, IPSS, International Index of Erectile Function (IIEF) score, PMD volume, and uroflowmetry results; and laboratory results, including urine analysis results, will be recorded.~After the baseline period, patients will be randomly assigned, 1:1, to the treatment or control groups using a computer-generated system. Both study groups will be advised to do bulbar urethral massage in addition to pelvic floor muscle exercise (explained later) during the study period, treatment group will be given tadalafil 5 mg (treatment group) daily or no medication (control group)."
89208749|NCT04087733|Experimental|GROUP / TREATED EYE|OZODROP® (ozonized oil 0.5% in liposomes) ophthalmic solution, 2 drops 4 times a day. OZODROP® will be instilled in the eye that will have to undergo cataract surgery.
89568332|NCT04811183||Experimental group|Adult patients hospitalized with diabetes and polymedicated. Selected to benefit from a pharmaceutical consultation before their return home.
89568333|NCT04901533|Experimental|cervical manipulation|The objective of this technique is to restore joint mobility between the joints of the occipital, first (atlas) and second cervical vertebra (axis). It is a technique performed in rotation on a vertical axis that passes through the odontoid process of the axis, without placing flexion or extension, and with very slight sidebending; it is done bilaterally.
89568334|NCT04901533|Active Comparator|Cranial Listening|Cranial palpation maneuver
89568335|NCT04825925|Experimental|DEB-BACE|
89568336|NCT05003479|Experimental|candidate vaccine|
89568337|NCT05003479|Placebo Comparator|Placebo|
89568338|NCT04806659|Experimental|SH1573 Capsules|SH1573 capsules administered orally. Multiple doses will be administered by effiacy and safety to determine the RP2D.
89568339|NCT04806581|Experimental|Allogeneic Hepatocyte Cohort 1|"Participants will each be administered L dose for one time. With 28days follow-up after the cells infusion.~Allogeneic hepatocyte cell numbers: L"
89568340|NCT04806581|Experimental|Allogeneic Hepatocyte Cohort 2|"Participants will each be administered M dose for one time. With 28days follow-up after the cells infusion.~Allogeneic hepatocyte cell numbers: M"
89568341|NCT04806581|Experimental|Allogeneic Hepatocyte Cohort 3|"Participants will each be administered H dose for one time. With 28days follow-up after the cells infusion.~Allogeneic hepatocyte cell numbers: H"
89568342|NCT04806737|Active Comparator|IMP|Teriflunomide 14 mg tablets, first 7 days 5 tablets once pr day, thereafter 1 pr day for another 6 days.
89568343|NCT04806737|Placebo Comparator|Placebo|Sham tablets
89568344|NCT03070249||Emergency Department Healthcare Providers|This study will assess compassion fatigue among healthcare providers in a single emergency department (ED) using the Professional Quality of Life (ProQoL) scale.
88969907|NCT05431452|Experimental|Group 6 (Kangaroo care + Breast milk)|"The head of the baby's bed will be raised at an angle of 45 degrees and before the procedure, 2 ml of breast milk will be given by the research clinical nurse with the help of a sterile injector, provided that each baby is breast milk, and then the mother will be in direct skin-to-skin contact with the mother's breast, with only the diaper under the baby in the baby adaptation room. It will be placed on the mother's chest at an angle of 60 degrees. The mother will be instructed not to make additional movements such as stroking, talking, feeding and shaking her baby. After 10 minutes of kangaroo mother care, heel blood collection will be performed and after the procedure, kangaroo mother care will continue for 2 more minutes. The 1st minute before the procedure, the 1st and 2nd minutes during and after the procedure will be recorded with a video camera and the data on the monitor will be recorded in the Physiological Parameters Measurement Form."
88969908|NCT05426096|No Intervention|Control|
88969909|NCT05426096|Experimental|BPA Intervention|"The BPA intervention will test the delivery of the insulin calculator (BPA) which automates the standard insulin dosing protocol guidelines. When a patient meets the study criteria, the BPA will provide an automated notification through the electronic health record system. These automated notifications will pop up intraoperatively after the glucose check reminder in cases where the patient meets the study criteria. The provider is not forced to follow the recommendations of the insulin dosing calculator, rather it just serves as a reminder of best practices as defined by our department.~The intervention will be assessed using a sequential and repeated cross-over design at the institutional level with periods of time for wash in, wash out, control and study intervention."
88969910|NCT05423379||XIENCE Skypoint Large Vessel Everolimus Eluting Coronary Stent System|Subjects who were implanted with XIENCE Skypoint Large Vessel Everolimus Eluting Coronary Stent System will be included.
88969911|NCT05415410|Experimental|Apraglutide Low Dose|Apraglutide SC injections, once weekly, for subjects with body weight of more than 50.0 kg.
88969912|NCT05415410|Experimental|Apraglutide High Dose|Apraglutide SC injections, once weekly, for subjects with body weight of more than 50.0 kg.
88969913|NCT05415410|Experimental|Apraglutide Standard Dose|Apraglutide SC injections, once weekly, for subjects with body weight between 40.0 kg to 49.9 kg.
88969914|NCT05414682|Experimental|MIND+SOUL Diet|The MIND+SOUL diet is an adapted brain-healthy soul food diet. Participants follow the diet for 12 weeks.
88969915|NCT05413980||Moxifloxacin hydrochloride ophthalmic solution|patients prescribed with 0.5% Moxifloxacin hydrochloride ophthalmic solution during the perioperative (preoperative and postoperative) period of ophthalmic surgery.
88969916|NCT05412160|Experimental|ARM A - BioArginine receivers|Patients will be randomized to receive BioArginine C™ twice daily on top of usual chronic inhaled therapy
88969917|NCT05412160|Placebo Comparator|ARM B - placebo receivers|Patients will be randomized to receive placebo twice daily on top of usual chronic inhaled therapy
88969918|NCT05409573|Experimental|monitoring of the expired oxygen fraction|"A double monitoring of EtO2 will be performed during the procedure of intubation (from the beginning of the preoxygenation to the success of intubation):~In the pharynx (via a nasopharyngeal catheter) for the needs of the study~On the facemask (as the practice in the OR)"
88969919|NCT05404867|Other|ALS patients|Patients with ALS
89568345|NCT04825691||cases diagnosed as prostatic acinar adenocarcinoma|
89568346|NCT04991233|Experimental|Endoscopic surgery|Endoscopic surgery group
89568347|NCT04991233|Active Comparator|Suboccipital craniotomy surgery|Suboccipital craniotomy surgery group
89568348|NCT04810637|Experimental|GX-I7|Patients randomised on experimental arm will receive GX-I7 drug
89568349|NCT04810637|Placebo Comparator|GX-I7 vehicle|Patients randomised on comparator arm will receive placebo
89568350|NCT04987411||Hemorrhagic group|Patients with bleeding confirmed with eFAST or CT.
89568351|NCT04991155|Experimental|PART 1 (400 mg BIA 5-1058)|Each subject was orally administered a single oral dose of BIA 5-1058 on D1 (dosing day) on three different occasions (Period 1, Period 2 and Period 3): Part 1: 400 mg BIA 5-1058 as four (4) 100 mg tablets in Period 1, 400 mg BIA 5-1058 as four (4) 100 mg tablets in Period 2, and 400 mg BIA 5-1058 as four (4) 100 mg tablets in Period 3.
89568352|NCT04991155|Experimental|PART 2 (800 mg BIA 5-1058)|"Each subject was orally administered a single oral dose of BIA 5-1058 on D1 (dosing day) on three different occasions (Period 1, Period 2 and Period 3):~Part 2: 800 mg BIA 5-1058 as eight (8) 100 mg tablets in Period 1, 800 mg BIA 5-1058 as eight (8) 100 mg tablets in Period 2, and 800 mg BIA 5-1058 as eight (8) 100 mg tablets in Period 3."
89568353|NCT04991155|Experimental|PART 3 (1200 mg BIA 5-1058)|"Each subject was orally administered a single oral dose of BIA 5-1058 on D1 (dosing day) on three different occasions (Period 1, Period 2 and Period 3):~Part 3: 1200 mg BIA 5-1058 as twelve (12) 100 mg tablets in Period 1, 1200 mg BIA 5-1058 as twelve (12) 100 mg tablets in Period 2, and 1200 mg BIA 5-1058 as twelve (12) 100 mg tablets in Period 3."
89568354|NCT04825457|Active Comparator|Anchoring-tip EMR|AEMR, the snare tip was projected from the sheath by 1-2 mm length. Consequently, a small mucosal incision was made at proximal side of lesion. Then the snare was deployed progressively and adjusted around the lesion trying to obtain free margins.
89568355|NCT04825457|Active Comparator|Conventional EMR|After injection of normal saline solution mix, snaring was tried for CEMR.
89568356|NCT03070015|Experimental|Nutrisystem|All subjects received Nutrisystem pre-packaged, portion-controlled foods and followed the Nutrisystem program for a total of 12 weeks (4 weeks for Part A, and an additional 8 weeks for Part B)
89568357|NCT03070015|Active Comparator|Self-Directed DASH|All subjects provided publically available information on the DASH diet and a sample meal plan. Subjects were instructed to follow a reduced calorie DASH diet meal plan on their own for 4 weeks (Part A only).
89568358|NCT03071653|Active Comparator|Left Cardiac Sympathetic Denervation (LCSD)|Left Cardiac Sympathetic Denervation (LCSD) in addition to Optimal Medical Therapy (OMT)
89568359|NCT03071653|Other|OMT only|Optimal Medical Therapy (OMT) only
89568360|NCT02604407|Experimental|SHP465 12.5 mg|Subjects will receive SHP465 12.5 mg
88969920|NCT05404867|Other|Healthy controls|Age-matched healthy controls
89208750|NCT04087733|No Intervention|GROUP / CONTROL EYE|Saline solution 2 drops 4 times a day. As a check it will be used the contralateral eye that will not have to undergo cataract surgery.
89208751|NCT00880152|Experimental|MBSR|An 8-week course in mindfulness-based stress reduction (MBSR)
89568361|NCT02604407|Experimental|SHP465 37.5 mg|Subjects will receive SHP465 titrated up to 37.5 mg
89028333|NCT05146674|No Intervention|Control group|"Our prospective, randomized, study will consist of a 1-week baseline period and 12-week double-blind treatment period During the baseline period, patients' characteristics, including medical and sexual history, physical examination results, vital signs, HPMDQ score, IPSS, International Index of Erectile Function (IIEF) score, PMD volume, and uroflowmetry results; and laboratory results, including urine analysis results, will be recorded.~After the baseline period, patients will be randomly assigned, 1:1, to the treatment or control groups using a computer-generated system. Both study groups will be advised to do bulbar urethral massage in addition to pelvic floor muscle exercise (explained later) during the study period, treatment group will be given tadalafil 5 mg (treatment group) daily or no medication (control group)."
89568362|NCT02604407|Placebo Comparator|Placebo|Subjects will receive matching placebo
89568363|NCT04462315||Everolimus Arm|Everolimus Eluting Coronary Stent System
89568364|NCT04462315||Non-drug eluting stent Arm|Cobalt chromium balloon-expandable stent
89568365|NCT04825535|Experimental|Standard psychiatry and cognitive behavioural online intervention|The online group CBT-M program combines software-based workbooks with phone-based Navigator-Coaching that coordinates software interactions (e.g., secure text messaging, Fitbit tracked walking, food monitoring via photography). Navigation coaching is supplied by students who were pursuing graduate degrees (MSc, MA, PhD) in kinesiology and health science, education, and psychology.
89568366|NCT04825535|Active Comparator|Standard psychiatry and cognitive behavioural in-person intervention|The on-site, usual-care CBT group follows the structure of the Mind Over Mood workbook in reviewing CBT concepts and procedures. A series of work sheets assist participants in differentiating moods, and in differentiating moods from thoughts and situational influences, leading to modifications of thinking, behaviour, emotion and mood. Group leaders are standard leaders in the CAMH group-CBT program who have Masters-level degrees in psychology, social work and occupational therapists.
89028334|NCT00494702|Experimental|LOX|Low saturation group of premature infants that will be kept within preset limits of 85-89%
89028335|NCT00494702|Active Comparator|HOX|HOX group of premature infants will be kept within preset saturation limits of 90-93%
89208752|NCT00880152|No Intervention|2|Treatment as usual
89568367|NCT04461067|Experimental|Gastric antrum measurement|
89568368|NCT04806425|Active Comparator|IL group|receive 1.5 ml /kg intralipid 20% through Central venous line after sternotomy over 1 hour
89568369|NCT04806425|Placebo Comparator|NS group|recieve 1.5 ml /kg normal saline 0.9% through central venous line after sternotomy over 1 hour
89568370|NCT04460677|Experimental|Emotional Support Plan (ESP) + Weekly Monitoring|This will involve weekly assessments without prompting to use the plan.
89568371|NCT04460677|Experimental|Emotional Support Plan (ESP) + 4x Daily Monitoring|Participants in this arm will be prompted on their phones 4x/day randomly, to report on activities, mood, suicidal ideation, distress level and ESP use since the last prompt
89568372|NCT03071731|Experimental|Bronchodilators|Nebulization of ipratropium bromide/salbutamol sulfate (500 µg/2.5 mg) before the administration of the Glittre ADL-test
89568373|NCT03071731|Placebo Comparator|Placebo|Nebulization of a placebo before the administration of the Glittre ADL-test
89568374|NCT04809779|Experimental|Sintilimab|
89568375|NCT04809935|Active Comparator|EUS-CPB|Chemical ablation of the coeliac plexus
89568376|NCT04809935|Active Comparator|EUS-CPA|Radiofrequency ablation of the coeliac plexus
89028336|NCT05146635|Active Comparator|Intravesical immunotherapy (BCG) group|
89028337|NCT05146635|Active Comparator|Intravesical chemotherapy (Epirubicin) group|
89028338|NCT00494741|Experimental|mycophenolate mofetil|
89028339|NCT00494741|Experimental|azathioprine|
89208753|NCT00922220|Active Comparator|stationary bike|Participants rode a stationary bike for five minutes
89568377|NCT04255927|Experimental|Coated Polyglactin 910 with Triclosan|Coated Polyglactin 910 with Triclosan
89568378|NCT04255927|Active Comparator|Coated Polyglactin 910 without Triclosan|Coated Polyglactin 910 without Triclosan
89568379|NCT04809857|Experimental|Plyometric Exercise Group|Plyometric exercise training 3 days a week for 6 weeks
89568380|NCT04809857|Active Comparator|Isokinetic Exercise Group|Isokinetic exercise training 3 days a week for 6 weeks
89568381|NCT04809857|No Intervention|Control Group|no exercise intervention
89568382|NCT03069781|Experimental|17β-estradiol|1mg/day for 3-days and 3mg/day for 7-days of 17β-estradiol (Estrace, Acerus Pharmaceuticals Corporation, Mississauga, ON, Canada). 7 Day Breg Knee Brace unilateral immobilization.
89568383|NCT03069781|Placebo Comparator|Placebo|400 mg/day for 10-days of Polycose (Abbott Laboratories, St. Laurent, QC, Canada).7 Day Breg Knee Brace unilateral immobilization.
89568384|NCT04427111||Mild-moderate OSA patients for MAD treatment|Patients are classified as mild Obstructive Sleep Apnea (OSA) if they have between 5-15 Apnea-Hypopnea Index, moderate if they have between 15-30, and severe if they have >30, as measured by Polysomnography (Epstein LJ, Kristo D, Strollo PJ, et al. 2009). The principal treatment methodology for OSA patients is positive airway pressure. In patients with mild to moderate OSA, oral appliances such as mandibular advancement devices (MAD) is alternately indicated (Ramar K, Dort LC, Katz SG, et al. 2015) The American Academy of Dental Sleep Medicine (Ramar K, Dort LC, Katz SG, et al. 2015) recommended titratable-customized MADs for patient comfort and the ability to permit modifications in the amount of mandibular protrusion for treatment efficacy. However, Aarab et al (Aarab G, Lobbezoo F, Hamburger HL, Naeije M. 2010) demonstrated similar therapeutic efficiency of non-titratable-customized MADs in the treatment of OSA
89568385|NCT03069625|Experimental|Sit-to-stand test|Children and adolescents will perform 2 STS tests. First one is used to eliminate learning effect. Number of repetitions will be noted at the end of the second test.
89568386|NCT03069625|Active Comparator|6-Minute Walk Test|Children and adolescents will perform 2 6MWT tests. First one is used to eliminate learning effect. Number of repetitions will be noted at the end of the second test.
89568387|NCT04809389|Experimental|Test Product|DelNS1-nCoV-RBD LAIV at 1×107 EID50 and 1×107.7 EID50, 2 doses 4 weeks apart, intranasal administration
89568388|NCT04809389|Placebo Comparator|Reference Product|Matching placebo, 2 doses 4 weeks apart, intranasal administration
89568389|NCT03069391|Active Comparator|physical, cognitive, then interactive|physical exercise alone (PES) first, then iPACES
89568390|NCT03069391|Active Comparator|cognitive, physical, then interactive|cognitive exercise alone (iCE) first, then iPACES
89568391|NCT04805723|Experimental|Patients with pulmonary nodule scheduled VATS|"Patients with pulmonary nodule scheduled VATS were included in this study. Inclusion and exclusion criteria were considered.~Pulmonary function (spirometry), functional exercise capacity (6-minute walk test (6-MWT); 6-minute stepper test (6-MST)), physical activity level (metabolic holter), respiratory (maximal inspiratory and expiratory pressures (MIP-MEP); mouth pressure device) and peripheral muscle strength (dynamometer), inspiratory muscle endurance (incremental loading test), quality of life (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTCQOL)), fatigue (Fatigue Severity Scale), dyspnea perception (Modified Medical Research Council dyspnea scale (MMRC)) and pain severity (Visual Analog Scale) were assessed before VATS and average two weeks after surgery."
89568392|NCT04805723|Experimental|Patients with pulmonary nodule scheduled thoracotomy|"Patients with pulmonary nodule scheduled thoracotomy were included in this study. Inclusion and exclusion criteria were considered.~Pulmonary function (spirometry), functional exercise capacity (6-minute walk test (6-MWT); 6-minute stepper test (6-MST)), physical activity level (metabolic holter), respiratory (maximal inspiratory and expiratory pressures (MIP-MEP); mouth pressure device) and peripheral muscle strength (dynamometer), inspiratory muscle endurance (incremental loading test), quality of life (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTCQOL)), fatigue (Fatigue Severity Scale), dyspnea perception (Modified Medical Research Council dyspnea scale (MMRC)) and pain severity (Visual Analog Scale) were assessed before VATS and average two weeks after surgery."
89568393|NCT03071575|Active Comparator|Group A:|Group A will receive a measles-rubella vaccine dose at 6 and 9 months
89568394|NCT03071575|Active Comparator|Group B:|Group B will receive a measles-rubella dose at 9 months only
89568395|NCT04798391|Experimental|Dexamethasone with lignocaine|
88969921|NCT05404386|Experimental|Study group|"Study group intervention consists of a mobile application called My Fight with Incontinence structured according to the health belief model, and a 3-month follow-up."
89568396|NCT03071497||Study Group|Detecting iron deficiency using various methods. All patients that fit the inclusion criteria and are willing to participate in the study will be included in this group.
89568397|NCT05616455|Experimental|Propionibacterium extract gel|"The Propionibacterium extract gel is a topical product that protect the skin and mucous membranes from external agents. Its film forming property on the epidermis helps reduce inflammation, itching and pain, while the adjunct of antioxidant ingredients helps promote the healing process.~Patients were instructed to squeeze out from the aluminium tubes containing the Propionibacterium extract gel, 3 grams of gel (3 cm), applying it twice a day for 40 days in the distal anal canal and perianal area."
89608875|NCT02000921|Experimental|VLNC with non-combusted products|Subjects will be asked to smoke very low nicotine content (VLNC) cigarettes instead of their usual cigarettes for an 8 week period and will be given the opportunity to use non-combusted types of tobacco and medicinal tobacco products.
89608876|NCT03584685|Experimental|With Mask|Use of the surgical mask in one routine wound treatment appointment.
88969922|NCT05404386|Other|Control group|"In addition to routine care, control group intervention consists of the training booklet My Fight with Incontinence which includes healthy lifestyle behaviors, bladder training, and Kegel exercises related to urinary incontinence, and a 3-month follow-up."
88969923|NCT05399043|Experimental|Technology-based Rehabilitation Group|Patients will undergo conventional treatment and, additionally, robot-assisted therapy or virtual reality-based rehabilitation.
88969924|NCT05399043|Active Comparator|Conventional Rehabilitation Group|Patients will undergo conventional treatment exclusively.
88969925|NCT05396053|Active Comparator|Control|A traditional physical therapy program
88969926|NCT05396053|Experimental|Study 1|Mirror therapy plus traditional physical therapy program
88969927|NCT05396053|Experimental|Study 2|Constraint-induced movement therapy plus traditional
88969928|NCT05393921|No Intervention|Patients receiving HoLEP surgery only|50 patients diagnosed with benign prostatic hyperplasia and overactive bladder and referred for HoLEP to treat their urinary symptoms. No Botox injections will be given.
89568398|NCT05616455|Active Comparator|0.4% glyceryl trinitrate ointment|"0.4% glyceryl trinitrate ointment is a well-known nitric oxide donor which promotes fissure healing by decreasing resting anal pressure and increasing anoderm blood flow, via the stimulation of the intracellular cyclic GMP resulting in a consequent reduction in cytosolic calcium. The success rate is variable, with 28% of patients experiencing transient headache often leading to drug discontinuation and poor compliance to treatment.~Patients were instructed to squeeze out from the aluminium tubes containing 0.4% glyceryl trinitrate ointment approximately 1.5 mg of the ointment applying it to the distal anal canal and perianal area with a gloved finger, every 12 hours for 40 days."
89568399|NCT04986319||Adequately sun-exposed healthy population|Healthy coastal fishermen of Cox's Bazar district of Bangladesh
89568400|NCT04986319||Inadequately sun-exposed healthy population|Healthcare workers of the selected hospitals of Dhaka, Bangladesh
89568401|NCT02593097|Experimental|Metformin first, then matching placebo|Subjects will be randomized into the Metformin group, treated for 12 weeks with a 4 week washout period in between treatments, then treated with matching placebo for 12 weeks.
89568402|NCT02593097|Experimental|Matching placebo first, then Metformin|Subjects will be randomized into the matching placebo group, treated for 12 weeks with a 4 week washout period in between treatments, then treated with Metformin for 12 weeks.
89568403|NCT05002855||Enhanced Recovery After Surgery (ERAS)|
89568404|NCT05002855||Conventional Recovery Strategy (pre-ERAS)|
89568405|NCT04805801||Hemophilia A with FVIII inhibitors|Hemophilia A patients with FVIII inhibitors will administer Emicizumab at a loading dose of 3 mg/kg/week SC for the first 4 weeks of treatment followed by 1.5 mg/kg QW SC or 3mg/kg Q2W or 6mg/kg Q4W
89568406|NCT04805801||Hemophilia A without FVIII inhibitors|Hemophilia A patients without FVIII inhibitors will administer Emicizumab at a loading dose of 3 mg/kg/week SC for the first 4 weeks of treatment followed by 1.5 mg/kg QW SC or 3mg/kg Q2W or 6mg/kg Q4W
89568407|NCT03071809||Early stage neoplasm|Patients with stage I-III early stage non-hematologic neoplasm
89568408|NCT03071809||Healthy Control|Patients undergoing surgery for a non-malignant condition with no prior history of malignancy.
89568409|NCT04990765|Experimental|Virtual Reality Cognitive Behavioral Therapy (VRCBT)|The VR exposure is performed to induce alcohol craving during the therapy session, in order to trigger a lifelike response to alcohol, while the therapist is present and able to train the participant in applying CBT-based coping strategies to deal with the alcohol cravings.
89568410|NCT04990765|Active Comparator|Cognitive Behavioral Therapy (CBT)|CBT is made up of the following elements: i) recognition (ii) avoiding and (iii) overcoming drinking cravings in high-risk situations with the aim of preventing relapse.
89568411|NCT04797923|Experimental|Intraperitoneal paclitaxel with systemic chemotherapy|
89568412|NCT04798157|Experimental|Children with Hemoglobinopathies|children from 2-18 years old , diagnosed to have hemoglobinopathy disease
88969929|NCT05393921|Experimental|Patients receiving HoLEP surgery + Intravesical Botox Injections|50 patients diagnosed with benign prostatic hyperplasia and overactive bladder and referred for HoLEP to treat their urinary symptoms. Botox injections will be given during the surgery.
88969930|NCT05388006|Experimental|Treatment (acalabrutinib, durvalumab, venetoclax)|"Patients receive acalabrutinib PO BID on days 1-28, durvalumab IV over 1 hour on day 1, and venetoclax PO QD on days 1-28. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive acalabrutinib PO BID and venetoclax PO QD on days 1-90. Treatment repeats every 90 days for 4 cycles in the absence of disease progression or unacceptable toxicity."
88969931|NCT05387564|Active Comparator|"All-in"|"In the all-in arm, pediatric primary care physicians receive all toolkit components at once."
88969932|NCT05387564|Active Comparator|"Add-in"|"In the add-in arm, pediatric primary care physicians will have sequential addition of toolkit components in 6 week increments"
88969933|NCT05381597|Experimental|Combination cream of 5-fluorouracil and calcipotriene|Participants randomized to this group will receive treatment with the combination cream consisting of 5-fluorouracil and calcipotriene twice a day for 7 days and the treatment can be extended to 14 days based on evaluation at 7 days.
88969934|NCT05381597|Active Comparator|5-fluorouracil cream|Participants randomized to this group will receive treatment with 5-fluorouracil cream twice a day for 28 days.
88969935|NCT05372094|Experimental|Experimental|Participants will be fit with a commercially available hearing aid and tested using various strengths of the noise reduction feature.
88969936|NCT05371184|Experimental|cases|• 30 patients will receive glutamine in a dose of 0.3 gm /kg/dose twice daily orally (up to a maximum of 15 g/dose) for 24 weeks as an add on to the SOC
88969937|NCT05371184|Active Comparator|control|30 patients will be assigned as a control group to receive standard of care therapy without glutamine intake.
88969938|NCT05350527|Experimental|Arm A: Web platform and video information support|After usual preoperative information delivered by surgeon, patients allocated to Arm will be able to access to video information support and web platform.
88969939|NCT05350527|No Intervention|Arm B: Standard Preoperative information|Patients randomized in Arm B will only receive usual preoperative information delivered by the surgeon.
88969940|NCT05336409|Experimental|Dose Escalation: Schedule A|Lymphodepleting chemotherapy (LDC) will be followed by single dose administration of CNTY-101, alone or with supplemental human recombinant interleukin 2 (IL-2).
88969941|NCT05336409|Experimental|Dose Escalation: Schedule B|LDC will be followed by administration of CNTY-101, 3 times over 3 weeks, alone or with supplemental IL-2.
88969942|NCT05333445|Experimental|Nursing intervention|The NI will be performed at 3 times: face to face between 21 and 7 days before admission, between 7 and 15 days after the date of ablation, and 6 months after the ablation procedure.
89568413|NCT04990453|Other|RPD frameworks fabricated from PEEK material|14 patients received extracoronal precision attachment RPD frameworks fabricated from PEEK material using milling machine (CAD/CAM technology)
89568414|NCT04990453|Other|RPD frameworks fabricated from Co-Cr|14 patients received extracoronal precision attachment RPD frameworks fabricated from Co-Cr material using casting machine
89568415|NCT03071419|Experimental|Nutrition and Parenting Intervention|Participants (n=30, father/child dyads in groups of 10) will receive an 8 session (2 hours/session) community-based intervention including nutrition and parent education with between-session technology enhancements.
89568416|NCT03071419|Active Comparator|Wait-list Control|Participants (n=30, father/child dyads in groups of 10) will serve as a wait-list control group and receive the same Nutrition and Parenting Intervention after completing pre and post assessments several weeks apart.
89568417|NCT04805567||Patients with polyps and adenomas|The inclusion criteria are: (i) CRC screening; (ii) post-polypectomy surveillance; (iii) diagnostic assessment (anemia, lower gastrointestinal bleeding, abdominal pain, recent change in bowel habits); and (iv) age over 50 years.
89568418|NCT04985617|Experimental|Warmed Fluids|When patients recovered from the effect of anesthesia, awakened and were able to switch to normal spontaneous breathing, they were taken from the sober unit to the service or intensive care unit, and subsequent follow-ups were carried out by the researcher in these units. The IV fluid given to the patients in the intervention group was heated to 36ºC using the medical heating device.
89568419|NCT04985617|No Intervention|Room Temperature Fluids|When patients recovered from the effect of anesthesia, awakened and were able to switch to normal spontaneous breathing, they were taken from the sober unit to the service or intensive care unit, and subsequent follow-ups were carried out by the researcher in these units. The IV fluid given to the patients in the control group was given at room temperature without heating and without intervention
89568420|NCT03071029|Experimental|Intervention (receive data updates)|Intervention clinics will receive a monthly poster that centres will receive which informs service providers of the PAFP LARC uptake rate at their centre. This is a step-wedged randomised controlled trial where all the clinics will eventually receive an intervention by the end of the study.
89568421|NCT03071029|No Intervention|Control (no data updates)|Service providers at these clinics will not receive monthly information on PAFP LARC rates.
89568422|NCT03071107|Active Comparator|Multi-disciplinary intervention arm|Multi-disciplinary intervention on frailty parameters including input from dietitian, physiotherapist and medical team
89568423|NCT03071107|No Intervention|Control arm|Standard of care
89568424|NCT04990063|Experimental|adoptive TKC transfer combined with chemotherapy|NK cells and γδT cells are isolated from the patients' PBMCs obtained before standard chemotherapy and then co-cultured ex-vivo. Patients will receive multiple TKC treatments under administration, 3 weeks/cycle. The first infusion will be conducted in 7-10 days after chemotherapy and is assessed by the investigators. TKC cells are transfused to patients in a dosage escalated manner. Dose escalation starts at 1×10^8 cells/kg (based on the whole body weight). After the safety assurance of the initial administration, the next course, up to 8 courses, is resumed and the dose maybe increased subsequently at the discretion of the investigators, or reduced for safety reason.
89568425|NCT04985149|Other|Grup 1; participants with fibromyalgia|Participants with fibromyalgia
89568426|NCT04985149|Other|Grup 2: patients without fibromyalgia|Patients without fibromyalgia
89568427|NCT05001997|Active Comparator|Diet A - Lactose free probiotic yogurt|Plain flavoured lactose free probiotic yogurt (contains Lactobacillus acidophilus and Bifidobacterium lactis)
89568428|NCT05001997|Placebo Comparator|Diet B - Lactose free yogurt (non-probiotic)|Plain flavoured lactose free yogurt (contains only starter cultures)
89568429|NCT01657461|Experimental|IV t-PA with Solitaire™ revascularization device|Dual IV tPA therapy and adjunctive treatment with the Solitaire revascularization device
89568430|NCT01657461|Active Comparator|IV t-PA|Infusion of intravenous tissue plasminogen activator (IV t-PA)
89568431|NCT05001919|Placebo Comparator|collagen membrane|10 sites treated with surgery and bone graft and collagen membrane as GTR
89568432|NCT05001919|Experimental|Concentrated growth factor membrane|10 sites treated by surgery +bone graft and concentrated growth factor membrane as GTR
89568433|NCT05001763|Placebo Comparator|Placebo|Glucose, 2mg, tablet.
89568434|NCT05001763|Experimental|Prucalopride|Prucalopride, 2mg, tablet. First given 2 days before surgery beginning on POD 1, until defecation or for a maximum of 7 days of postoperative treatment.
89568435|NCT04989985|Active Comparator|Active Comparator|"SOX: Oxaliplatin+S-1~Oxaliplatin: 130mg/m2, iv drip for 2h, d1, q3w;~S-1:40~60mg Bid, d1~14, q3w;~Neoadjuvant chemotherapy for 2-4 cycles, adjuvant chemotherapy for 4-6 cycles."
89568436|NCT04989985|Experimental|Experimental|"Sinitlimab + SOX； SOX: Oxaliplatin+S-1~Sinitlimab: 200mg, ivdrip, d1, q3w;~Oxaliplatin: 130mg/m2, iv drip for 2h, d1, q3w;~S-1:40~60mg Bid, d1~14, q3w;~Neoadjuvant chemotherapy for 2-4 cycles, adjuvant chemotherapy for 4-6 cycles."
89568437|NCT05242653|Experimental|cotton swab|
89568438|NCT05242653|Active Comparator|balanced salt solution (BSS)|
89568439|NCT05239845|Active Comparator|Investigational Supplement 1 (INV-1)|The total daily supplement to be consumed by participants is 33.0 g. This will be administered as 2 separate doses mixed with water, a 16.5 g dose (two 8.25 g sachets) to be consumed in the morning (AM dose) and a 16.5 g dose (two 8.25 g sachets) to be consumed in the evening (PM dose). Supplementation will last 56 days.
89568440|NCT05239845|Active Comparator|Investigational Supplement 1 (INV-2)|The total daily supplement to be consumed by participants is 33.0 g. This will be administered as 2 separate doses mixed with water, a 16.5 g dose (two 8.25 g sachets) to be consumed in the morning (AM dose) and a 16.5 g dose (two 8.25 g sachets) to be consumed in the evening (PM dose). Supplementation will last 56 days.
89568441|NCT05239845|Active Comparator|Investigational Supplement 1 (INV-3)|The total daily supplement to be consumed by participants is 33.0 g. This will be administered as 2 separate doses mixed with water, a 16.5 g dose (two 8.25 g sachets) to be consumed in the morning (AM dose) and a 16.5 g dose (two 8.25 g sachets) to be consumed in the evening (PM dose). Supplementation will last 56 days.
89608877|NCT03584685|Active Comparator|Without Mask|Routine wound treatment appointment without nurses wearing the surgical mask.
89208754|NCT00922220|Active Comparator|lumbar extension exercises|Participants performed four sets of fifteen lumbar extension exercises over five minutes
89608878|NCT03587337||Prophylaxis|
89028340|NCT01244321||CoSeal Group|Subjects with indication for LVAD implantation, meeting the requirements for LVAD implantation. Patients for whom LVAD removal is anticipated not earlier than 6 weeks after LVAD implantation.
89028341|NCT01244321||CoSeal Control Group|Subjects who had a LVAD for more than 6 weeks.
89028342|NCT00507273||GIST|Patients diagnosed with a gastrointestinal stromal tumor (GIST)
89568442|NCT05239845|Placebo Comparator|Control|The total daily supplement to be consumed by participants is 33.0 g. This will be administered as 2 separate doses mixed with water, a 16.5 g dose (two 8.25 g sachets) to be consumed in the morning (AM dose) and a 16.5 g dose (two 8.25 g sachets) to be consumed in the evening (PM dose). Supplementation will last 56 days.
89568443|NCT05001607|Other|Study trial|All participants will perform pulmonary blockade on an intubating manikin using 4 different methods: Endobronchial intubation with an endotracheal tube; Bronchial blocker attached to the outside of an endotracheal tube; Double lumen endotracheal tube; and Intraluminal placement of bronchial blocker.
89568444|NCT05321355||Patient with narcolepsy treated with vagus nerve stimulation|Patient with narcolepsy treated with vagus nerve stimulation
89568445|NCT05321355||Patient without narcolepsy treated with vagus nerve stimulation|Patient without narcolepsy treated with vagus nerve stimulation
89568446|NCT04989673||Exposed group (GE)|Pregnant women with symptomatic dengue fever, confirmed biologically between the presumed date of conception and the date of delivery.
89568447|NCT04989673||Unexposed group with fever (GNEF)|Pregnant women presenting a febrile syndrome not due to the dengue virus between the presumed date of conception and the date of delivery, excluding malaria, rubella, toxoplasmosis, chickenpox, listeriosis, CMV infection and primary HIV infection.
89568448|NCT04989673||Unexposed group without fever or dengue (GNES)|Pregnant women exhibiting neither febrile syndrome nor asymptomatic dengue fever between the presumed date of conception and the date of delivery.
89568449|NCT02592551|Experimental|MEDI4736|8 patients will receive an infusion of MEDI4736 (15 mg/kg intravenously, once), one to six weeks prior to surgical resection.
89568450|NCT02592551|Active Comparator|MEDI4736 + Tremelimumab|8 patients will receive an infusion of MEDI4736 (1500 mg intravenously, once) + tremelimumab (75mg intravenously, once), one to six weeks prior to surgical resection.
89568451|NCT02592551|Placebo Comparator|Untreated arm (control)|4 patients will not receive MEDI4736 or Tremelimumab.
89568452|NCT05281887||ischemic stroke|According to diagnostic criteria
89568453|NCT05281887||healthy control|without any retinal diseases
89568454|NCT03070873|Experimental|group A|accepted Perigee and Apogee mesh(PA)
89568455|NCT03070873|Experimental|group B|accepted Gynecare prolift mesh
89568456|NCT03070873|Placebo Comparator|group C|Traditional surgery without any mesh
89568457|NCT05320185||Control group|CCTA images will be visually evaluated by physicians.
89568458|NCT05320185||Experiment group|CCTA images will be evaluated by physicians using RuiXin-CoronaryAI.
89028343|NCT00507312|Active Comparator|1|Healthy subjects (with no evidence of cardiovascular disease).
89568459|NCT05320185||Reference group|CCTA images will be visually evaluated by cardiologists with at least 10 years experiences, and the conclusions they offer will be used as golden standard.
89568460|NCT05238753|Experimental|Intervention, stimulated|Electromagnetic stimulation of the phrenic nerve in critically ill patients.
89028344|NCT00507312|Experimental|2|Patients with risk factors for heart failure
89028345|NCT00507312|Experimental|3|Patients with heart failure
89028346|NCT00497549|Active Comparator|1|A proper site on the anterior wall of stomach away from the stapled line approximately 2 cm below the highest point of the gastric conduit will be anastamosed to esophagus Posterior interrupted seromuscular sutures will be taken with 3-0 silk. The stomach will then be opened transversely (2.5 to 3 cm long). Interrupted stitches with full thickness of the stomach and esophagus will be placed to achieve mucosa to mucosa approximation. A 16F nasogastric tube will then be placed across the anastomosis into the intrathoracic stomach. The anterior wall of the anastomosis will be completed in a manner similar to posterior wall.
89028347|NCT00497549|Active Comparator|2|5 cm of the mobilized stomach will be placed in the neck. Three interrupted sutures will be taken between the posterior wall of esophagus and anterior wall of stomach. A 1.5 cm gastrotomy will be made. Two stay sutures will then be taken, one at the anterior corner of esophagus and another between posterior corner of esophagus and the middle of the gastrotomy. The stapler device (Endopath, EZ45) will be introduced.The staple cartridge will then be rotated so that the posterior wall of the esophagus and the anterior wall of the stomach will align in a parallel manner and fire the stapler. A 16F nasogastric tube will be placed across the anastomosis and the anterior edges of the gastrotomy and open esophagus will be approximated with interrupted 3-0 silk.
89028348|NCT05148546|Experimental|A: Neoadjuvant nivolumab|Neoadjuvant 2 cycles of nivolumab 360mg every 3 weeks
89568461|NCT05238753|No Intervention|Control, not stimulated|Control group, no stimulation of the phrenic nerve.
89568462|NCT04984135||Enrolled patients|Patients fulfilling the study criteria were included.
89568463|NCT04797377|Experimental|Ovarian Reserve|Patients with diminished ovarian reserve or premature ovarian insufficiency
89568464|NCT04989205||HAP - group|The target group was individuals who engaged in regular or daily cannabis use, and who were motivated to quit cannabis. The formal inclusion criteria was a Severity of Dependence Scale (SDS) score ≥4 and being ≥16 years old. Exclusion criteria was polydrug use where cannabis was not the predominating substance of use and psychiatric comorbidity that was perceived as too severe to handle at the community-based centers .
89568465|NCT01356251|Experimental|Surgical group with mesothelioma|The study proposed here has two parts: part 1 surveys mesothelioma patients' psychological and physical symptom burden and quality of life through a set of questionnaires that covers topics including coping, interpersonal support, mood, anxiety, and overall quality of life. In part 2, patients are invited to participate in an Internet-based discussion group.
89568466|NCT01356251|Experimental|Non Surgical group with mesothelioma|The study proposed here has two parts: part 1 surveys mesothelioma patients' psychological and physical symptom burden and quality of life through a set of questionnaires that covers topics including coping, interpersonal support, mood, anxiety, and overall quality of life. In part 2, patients are invited to participate in an Internet-based discussion group
89568467|NCT04982809|Active Comparator|Betamethasone group|
89568468|NCT04982809|Active Comparator|Dexamethasone group|
89028349|NCT05148546|Experimental|B: Neoadjuvant nivolumab + ipilimumab|Neoadjuvant 2 cycles of nivolumab 3 mg/kg + ipilimumab 1 mg/kg every 3 weeks
89028350|NCT05148546|Experimental|C: Neoadjuvant nivolumab + relatlimab|Neoadjuvant 2 cycles of nivolumab 360mg + relatlimab 360mg every 3 weeks
89028351|NCT00507351||Cancer Pain Management|Patients receiving chemotherapy for breast, colon, lung, or prostate cancer.
89028352|NCT00497588|Active Comparator|radiotherapy|patients receive radiotherapy
89568469|NCT04982809|Active Comparator|Prednisolone group|
89568470|NCT04808765|Experimental|VAC group|A randomized group of patients receiving negative pressure wound therapy dressing (Avelle-ConvaTec) on closed incision
89028353|NCT00497588|Experimental|surgery|Patients undergo surgery
89568471|NCT04808765|Active Comparator|ST group|A randomized group of patients receiving standard dressing (sterile gauze and medical tape) on closed incision
89028354|NCT00494858|Active Comparator|CBT-EF|Participants will receive cognitive behavioral therapy - focused
89568472|NCT03068533|Active Comparator|Strontium acetate toothpaste|All eligible patients will receive mechanical debridement in 1 or 2 sessions within 1 week before final evaluation.
89568473|NCT03068533|Experimental|Arginine/calcium carbonate toothpaste|All eligible patients will receive mechanical debridement in 1 or 2 sessions within 1 week before final evaluation.
89568474|NCT04804865||population|"The population includes adult patients.~Patients died from refractory or relapsed diffuse large-cell lymphoma.~Patients <65 years of age eligible for an autologous transplant should have relapsed after the autologous transplant.~Patients >65 years of age or not eligible after an autologous transplant must have received at least one RCHOP-type treatment line (2 cycles)."
89568475|NCT05281341|Experimental|Poseidon Group 4A & 3A|80 eligible infertile women fulfilling the criteria of Poseidon Group 4 (35 years or more and AMH <1.2ng/ml) will be randomized into Group 4A will receive controlled ovarian stimulation (COS) and growth hormone (GH) and Group 4B will receive COS only. Similarly, 80 eligible infertile women fulfilling the criteria of Poseidon Group 3 (less than 35 years and AMH <1.2ng/ml) will be randomized into Group 3A will receive COS and GH and Group 3B will receive COS only.
89568476|NCT05281341|No Intervention|poseidon Group 4B & 3B|80 eligible infertile women fulfilling the criteria of Poseidon Group 4 (35 years or more and AMH <1.2ng/ml) will be randomized into Group 4A will receive controlled ovarian stimulation (COS) and growth hormone (GH) and Group 4B will receive COS only. Similarly, 80 eligible infertile women fulfilling the criteria of Poseidon Group 3 (less than 35 years and AMH <1.2ng/ml) will be randomized into Group 3A will receive COS and GH and Group 3B will receive COS only.
89568477|NCT03068377|Placebo Comparator|Placebo|Soft gel capsules without test material
89568478|NCT03068377|Experimental|Experimental|Soft gel capsules containing a mixture of tomato extract, lutein, zeaxanthin as well as other phytonutrients and vitamins
89568479|NCT04809155|Experimental|Girl2Girl|Girls receive text messages that address the information, motivation, and behavioral skills components need to prevent unwanted pregnancy.
88811037|NCT04674254|Active Comparator|Standard pan-retinal photocoagulation|"Standard pan-retinal photocoagulation will be performed at baseline and then every 3 months thereafter if needed, for a minimum follow-up period of 12 months.~PRP will be performed at two consecutive sessions with adherence to the guidelines of the Early Treatment Diabetic Retinopathy Study Group. Following topical anesthesia, 1000 to 1200 laser spots will be applied to the retina at each session with a 532 nm frequency doubled Nd-YAG laser (VISULAS, Carl Zeiss, Germany) using a spot size of 300-500 μm. PRP will be applied in all 4 retina quadrants.~The Mainster lens will be used. Retreatment will be done according to the Diabetic Retinopathy Clinical Research network protocol S classification for patients with stable, worsening, or with failure of regression of neovascularization."
89028355|NCT00494858|Experimental|CBT-EB|Participants will receive cognitive behavioral therapy - broad
89028356|NCT05143983|Active Comparator|depressed subjects, positive valence music listening at first|patients with major depressive disorder will be recruited and will complete 3 cognitive tasks after listening to positive musical excepts (3 minutes)
89028357|NCT05143983|Other|depressed subjects, neutral valence music listening|patients with major depressive disorder will be recruited and will complete 3 cognitive tasks after listening to neutral valence musical excepts (3 minutes)
89028358|NCT05143983|Other|healthy controls, positive valence music listening|healthy individuals will be recruited and will complete 3 cognitive task after listening to positive valence musical excepts (3 minutes)
89028359|NCT05143983|Other|healthy controls, neutral valence music listening|healthy individuals will be recruited and will complete 3 cognitive task after listening to neutral valence musical excepts (3 minutes)
89028360|NCT05149560|Experimental|Ticagrelor|Ticagrelor 90 mg twice daily for 12 months
89028361|NCT05148624|Experimental|Immediate ambulation|Sub-infertile women will immediately ambulate and empty her bladder after embryo transfer.
89028362|NCT05148624|Active Comparator|short time bed rest|Sub-infertile women will stay in the bed (same bed where embryo transfer was performed) after embryo transfer for a period of 5 minutes without emptying her bladder.
89028363|NCT05144919|No Intervention|Control|The control group will continue to receive routine health check and nutrition education from health staff at commune health facilities. Access to agriculture extension services as offered by provincial staff will also continue as normal.
89208755|NCT00922220|Experimental|spinal manipulative therapy|Participants received spinal manipulative therapy to the low back
89568480|NCT04809155|No Intervention|Control - Healthy lifestyle|Girls receive text messages about a 'healthy lifestyle', including healthy social media use and self-esteem.
89568481|NCT05280249|Experimental|Both aerobic and resistance exercises in the green exercise concept|Green exercise is a type of exercise done outdoors. It is an advantageous type of exercise in benefiting from sunlight and reducing anxiety. Participants in this group will be given aerobic and resistance exercises in the open air. For 20 participants who met the inclusion criteria, first 10 minutes of warm-up exercises, then 20 minutes of moderate-intensity (65% of heart rate) walking, followed by 15 minutes of low-intensity (50% of the maximum repetitions) resistance exercises will be trained in the presence of a physiotherapist. resistance exercises will be performed for shoulder flexors and abductors, elbow flexors and extensors, hip flexors and extensors, knee flexors and extensors, hip abductor muscle groups. At the end of each session, 5 minutes of stretching exercises will also be trained.
89608879|NCT03587337||Antibiotic tp|
89568482|NCT05280249|No Intervention|Control group|The exercise program will not be implemented. Evaluations will be made at the beginning and end of the study.
89532117|NCT06337838|Placebo Comparator|Placebo and placebo.|"Within 20 minutes preceding anticipated skin incision, patients allocated to the tranexamic acid control group will receive an intravenous infusion of 0.9% saline solution. This saline solution will be administered over a duration of 10 minutes in a volume equivalent to that received by patients in the tranexamic acid intervention group.~Within 20 minutes preceding anticipated skin incision, patients allocated to the desmopressin control group will receive an intravenous infusion of 0.9% saline solution, administered over a duration of 30 minutes."
89532118|NCT06337825||40 patients with primary hyperparathyroidism|patients undergoing parathyroidectomy for primary hyperparathyroidism
88811038|NCT04665843|Experimental|Atezolizumab + Tiragolumab|Participants will receive atezolizumab followed by tiragolumab every three weeks (Q3W) on Day 1 of each 21-day cycle.
88811039|NCT04665843|Placebo Comparator|Atezolizumab + Placebo|Participants will receive atezolizumab followed by placebo Q3W on Day 1 of each 21-day cycle.
88811040|NCT04660500|Experimental|PD Drivers Using AV Technologies On-road|Each driver will drive on-road, everybody will be exposed to two drives (Drive 1, Drive 2) one drive with and the other without in-vehicle technology. The order of technology (with vs. without IVIS or ADAS) and the order of the routes (Drive 1 vs. Drive 2) will be randomly allocated to control for order effects.
88811041|NCT04657302|Experimental|R/R DLBCL|Participants will receive a fixed dose of obinutuzumab pre-treatment followed by glofitamab on Cycle 1 Days 8 and 15, then every 3 weeks (Q3W) from Cycles 2-12 (cycle length = 21 days).
88969943|NCT05333445|Active Comparator|control group|"After hospital discharge, all patients will be referred to their primary care physician or cardiologist for follow-up.~Patients will receive standard follow-up checks by the medical team will not receive structured education from the nurse."
89532119|NCT06337825||40 patients with multinodular goiters|patients undergoing thyroidectomy for multinodular goiter
89532120|NCT06337812|Experimental|Potato starch supplement|Participants will take the supplement for approximately 4 weeks.
89532121|NCT06337799|Experimental|Research Pharmacist Monitoring|The research pharmacist will help the mother find a primary care physician if she doesn't have one and discuss strategies to lower blood pressure, if needed. The pharmacist interactions will occur 7 days after enrollment and then approximately every 2 weeks to 2 months during 12 months of follow up, depending on blood pressure control. They may recommend medications to the participant's physician. The pharmacist will have access to the participant's electronic medical record to obtain any blood pressure-related medications that the mother is prescribed as well as throughout the follow up to ensure any health-related conditions can be discussed.
89532122|NCT06337786|Experimental|Intervention arm|Patients diagnosed with rheumatoid arthritis receiving standard routine care and the digital app RB4.0.
89532123|NCT06337786|Active Comparator|Control arm|Matched controls from the DANBIO register receiving standard routine care. Up to 3 patients will be matched based on sex, age (+/-5 years), time at enrolment (< 2 years prior to index date is allowed) and DAS28 scores (+/- 0.4).
89532124|NCT06337773|Experimental|Treatment group|The survivors receiving 8 weeks (90 mins per weeks) on-line percious nursing education intervention
89532125|NCT06337773|No Intervention|Control group|As usual
89532126|NCT06337760||neuroendocrine neoplasm young patient|Patients aged at diagnosis from18 to 39 years of age with neuroendocrine neoplasm NEN from Gastroenteropancreatic (GEP) or lung/thymus origin
88811042|NCT04616781|Active Comparator|Ketone ester with alcohol consumption|Drink a single dose of ketone ester 1.9 kcal/kg, complete 1 hour MRI scan, drink an alcohol priming dose to produce a 0.03 g/dl breath alcohol concentration (BrAC) followed by a choice paradigm in which subjects receive 2 trays of 4 min-drinks each beverages Each min-drink would achieve 0.015 g/ld BrAC over a 1 hour period to achieve a max 0.1 g/dl BrAC.
88811043|NCT04616781|Placebo Comparator|Isocaloric dextrose placebo drink with alcohol consumption|Drink a single dose of Isocaloric dextrose placebo drink, complete 1 hour MRI scan, drink an alcohol priming dose to produce a 0.03 g/dl breath alcohol concentration (BrAC) followed by a choice paradigm in which subjects receive 2 trays of 4 min-drinks each beverages Each min-drink would achieve 0.015 g/ld BrAC over a 1 hour period to achieve a max 0.1 g/dl BrAC.
88811044|NCT04611893||Ischemic stroke patient|Ischemic stroke patients who are on dabigatran, apixaban and rivaroxaban based on the above inclusion and exclusion criteria will be recruited from the Prince of Wales Hospital, either in-patient or out-patient clinic
88811045|NCT04610788||SSc-PAH Group|Scleroderma patients referred for a clinically indicated right heart catheterization (RHC).
88811046|NCT04610788||IPAH Group|Presumed/known IPAH patients referred for a clinically indicated right heart catheterization (RHC).
89532127|NCT06337760||adenocarcinoma young patient|Patients aged at diagnosis from18 to 39 years of age with carcinoma (without limitations for histologic subtypes) from any primary sites: esophagus, stomach, pancreas, biliary tract, liver, small bowel, colon, rectum, anus and cancer of unknown origin.
89532128|NCT06337747|Active Comparator|Traditional technique|
89532129|NCT06337747|Experimental|Extended technique|
89532130|NCT06337734|Experimental|AI-Driven Lifestyle Coaching Group|
89532131|NCT06337721|Experimental|SPEAR|This arm will consist of the SPEAR (Strategies for Pacific Empowerment and Alcohol Reduction) behavioral group intervention to reduce AUDs and alcohol-related harms in Pacific Islander young adults.
89532132|NCT06337721|No Intervention|Control|This control group arm will be compared to the SPEAR intervention.
89532133|NCT06337708|Experimental|Smart Walk|Participants will receive a culturally tailored smartphone-delivered physical activity intervention.
89532134|NCT06337708|Active Comparator|Fitbit|Participants will receive a Fitbit Inspire 3 activity monitor.
89532135|NCT06337695|Experimental|Vedolizumab|Participants receive 300 mg vedolizumab IV at weeks 0, 3, 6, 14, and 22.
89532136|NCT06337695|Placebo Comparator|Placebo|Participants receive 300 mg placebo IV at weeks 0, 3, 6, 14, and 22.
89532137|NCT06337682||Care home cohort|Individuals aged 65 or over registered to a GP practice which is part of the Connected Bradford Database who have been admitted to a CH between January 2016 and January 2020, with a recorded length of stay more than 6 weeks, will be included in the study.
89532138|NCT06337656|Experimental|Galileo Intervention|
89532139|NCT06337656|No Intervention|Galileo Control|
89568483|NCT05635981|Active Comparator|Clearfil S3 Bond Plus|"After selective etching is applied to the enamel surface, Clearfil S3 Bond Plus is applied according to the manufacturer's instructions, restorations are completed with Clearfil Majesty ES-2.~Clearfil S3 Bond Plus: one-step self-etch adhesive with HEMA"
89568484|NCT05635981|Experimental|Clearfil S3 Bond Plus with Additional Hydrophobic Adhesive Layer Application|"After selective etching is applied to the enamel surface, Clearfil S3 Bond Plus is applied according to the manufacturer's instructions. Heliobond is applied as an additional hydrophobic adhesive layer and restorations are completed with Clearfil Majesty ES-2.~Clearfil S3 Bond Plus: one-step self-etch adhesive with HEMA Heliobond: hydrophobic adhesive with Bis-GMA and TEGDMA"
89568485|NCT05635981|Active Comparator|G-Premio Bond|"After selective etching is applied to the enamel surface, G-Premio Bond is applied according to the manufacturer's instructions, restorations are completed with Clearfil Majesty ES-2.~G-Premio Bond: universal adhesive without HEMA"
89568486|NCT05635981|Experimental|G-Premio Bond with Additional Hydrophobic Adhesive Layer Application|"After selective etching is applied to the enamel surface, G-Premio Bond is applied according to the manufacturer's instructions. Heliobond is applied as an additional hydrophobic adhesive layer and restorations are completed with Clearfil Majesty ES-2.~G-Premio Bond: universal adhesive without HEMA Heliobond: hydrophobic adhesive with Bis-GMA and TEGDMA"
89568487|NCT04797689|Experimental|Trauma Informed Yoga|Participants will receive 12 x 60 min group-based yoga sessions, delivered synchronously over Zoom.
89568488|NCT04797689|Experimental|Trauma Informed Psychotherapy|Participants will receive 12 x 120 min group-based psychotherapy sessions, delivered synchronously over Zoom.
89568489|NCT04797689|No Intervention|Control|These participants will not receive an intervention.
89568490|NCT04988581|Experimental|Intensively Integrated Care of Microvascular Risk Factors|intensively integrated care of microvascular risk factors (glycated hemoglobin [HbA1C], urinary albumin-to-creatinine ratio [ACR], blood pressure [BP], estimated glomerular filtration rate [eGFR], uric acid [UA] and low-density lipoprotein cholesterol [LDL])
89568491|NCT04988581|No Intervention|Usual Care of Microvascular Risk Factors|Usual care among patients with diabetes
89568492|NCT05516511||cases|systemic lupus erythematosus patients
89568493|NCT05516511||control|healthy individuals
89568494|NCT04796987||cervical myelopathy|MR images of patients with cervical myelopathy
89568495|NCT04796987||normal|normal section of the MRI of patients with cervical myelopathy
89568496|NCT05237895|Other|Patients with Gestational Diabetes|pregnant women who are at 24-26 weeks of gestational age with positive oral glucose tolerance screening test.
89568497|NCT05237895|Other|Healty Pregnants|pregnant women who are at 24-26 weeks of gestational age with normal oral glucose tolerance screening test.
89568498|NCT04796753||Youth basketball players who belonged to basketball developmental teams (U12, U14,U16,U17).|All participants completed the same ten-minute neuromuscular warm-up consisting of the following exercises: joint mobility exercises, dynamic stretching exercises, jumps, multidirectional displacements and changes of direction. Following, subjects were allowed three practice trials for each test. Consistent feedback was provided throughout to ensure proper technique. The performance of each test was recorded using two cameras (Iphone XS, Apple). To allow visible tracking of the different joints, participants were required to wear shorts with the hem at approximately mid-thigh. When scoring performance, each test was viewed in both planes (sagittal and frontal views).
89568499|NCT05237271|No Intervention|Control Group|Control group treats their simulated patients using standard practice and have no introduction to the new SomaLogic test.
89568500|NCT05237271|Experimental|Intervention Group 1|Intervention group 1 will receive educational materials on the single cardiovascular disease in type 2 diabetes risk score. They will then be forced to used the risk score for their simulated patients, which will allow us to assess how the risk score may improve clinical practice and reduce variation.
89568501|NCT05237271|Experimental|Intervention Group 2|Intervention group 2 will receive educational materials on the cardiovascular disease in type 2 diabetes (CVD-T2D) risk score as well as the panel of metabolic scores. They will then be forced to used the CVD-T2D score and the metabolic panel scores for their simulated patients, which will allow us to assess how the risk score may improve clinical practice and reduce variation.
88969944|NCT05326516|Experimental|SNDX-5613 and Chemotherapy Regimen 1|Participants with acute lymphoblastic leukemia/mixed phenotype acute leukemia (ALL/MPAL) will receive SNDX-5613 every 12 hours in combination with 2 treatment cycles of Chemotherapy Regimen 1.
88969945|NCT05326516|Experimental|SNDX-5613 and Chemotherapy Regimen 2|Participants with ALL/MPAL or acute myeloid leukemia (AML) will receive SNDX-5613 every 12 hours in combination with 2 treatment cycles of Chemotherapy Regimen 2.
88969946|NCT05326464|Experimental|Tofacitinib 10 mg|Participants will take the 10mg Tofacitinib twice daily until evidence of progression, intolerance of treatment, withdrawal of consent, or death.
88969947|NCT05315817|Experimental|multiPlus dialysate|Treatment of acute kidney injury patients either with continuous veno-venous haemodialysis (CVVHD) or continuous veno-venous haemodiafiltration (CVVHDF) using the multiPlus dialysate.
88969948|NCT05315583|Other|Group with collection of biological samples|All participants will have at each of the visits: a venipuncture sample of 2 dry tubes of 7 mL to make up 3 aliquots and a nasopharyngeal swab (optional). The aliquots of serum / plasma and the nasopharyngeal swab will be stored at -80°C until sent to the Pasteur Institute.
88969949|NCT05311527|Experimental|All Study participants|Study participants will undergo Urolift System followed by SABR
88969950|NCT05303350||e_FLS|Patients detected by an automated patient detection tool with a web-based platform
88969951|NCT05303350||FLS|Control group / Conventional group : Patients followed in a conventional fracture liaison department
88969952|NCT05303129|Other|Blood tests|"Realization of 4 blood tests for Lymphocyte typing (Neutrophil/Lymphocyte ratio (NLR), CD4+ and CD8+ lymphocyte counts ), during CDK4/6 treatment :~before initiation of CDK4/6 treatment~At 3 mois after initiation of CDK4/6 treatment~At 6 mois after initiation of CDK4/6 treatment~At 12 mois after initiation of CDK4/6 treatment or at early end of study"
88969953|NCT05296733|Experimental|Part A: BI 456906: Cohort 1|Healthy subjects
88969954|NCT05296733|Experimental|Part A: BI 456906: Cohort 2|Patients with cirrhosis + Child-Turcotte-Pugh (CTP) Class A
89517456|NCT02296918|Experimental|Cohort 1: Acalabrutinib+Obinutuzumab (R/R)|Dose-escalation and dose-expansion phases will be conducted for relapsed/refractory (R/R) participants with CLL. In dose-escalation phase, participants will receive oral acalabrutinib Dose 1 once daily (QD), later the dose was switched to Dose 2 twice daily (BID) per Amendment 02. In dose- expansion phase, participants will receive oral acalabrutinib Dose 2 BID in 28-day continuous cycles; and will receive intravenous (IV) infusion of obinutuzumab for total 6 cycles (from Cycles 2 to 7) as on Cycle 2 Day 1 participants will receive Dose 1, on Cycle 2 Day 2 participants will receive Dose 2, on Cycle 2 Days 8 and 15 participants will receive Dose 3, and on Day 1 of Cycles 3 to 7 participants will receive Dose 3. Participants will continue to receive acalabrutinib Dose 2 BID until disease progression, an unacceptable drug-related toxicity, or per the investigator the study treatment is intolerable or no longer in participant's best interest, whichever occurs first.
89568502|NCT03068299|Experimental|Dance|n=29 participants randomized. Cognition performance, frailty and burden will be measured at baseline and after of interventions (6 months after baseline). Instruments of measurement described in Time Frame.
89568503|NCT03068299|Experimental|Health care guidance|n=29 participants randomized. Cognition performance, frailty and burden will be measured at baseline and after of interventions (6 months after baseline). Instruments of measurement described in Time Frame.
89568504|NCT05280015|Active Comparator|Microbiotherapy in addition of venlafaxin|Subjects suffering of MDD and treated by venlafaxine in a second-line assigned to start the microbiotherapy during 12 weeks. The microbiotherapy is GynMDD devlopped by Gynov and which is composed by a probiotic associated to polyphenol and an amino acid.
89568505|NCT05280015|Placebo Comparator|calibration arm|Subjects suffering of MDD and treated by venlafaxine in a second-line assigned to start the placebo therapy during 12 weeks.
89568506|NCT03070795|Experimental|early feeding|patients undergoing elective cesarean section will be allowed to feed (sips) four hours after cesarean section.
89568507|NCT03070795|Active Comparator|delayed feeding|patients undergoing elective cesarean section will be allowed to feed on post operation day 1 (12 hours post op).
89568508|NCT04808687|Experimental|nab-paclitaxel and S-1|neoadjuvant chemotherapy with Nab-paclitaxel and S-1, repeat every 21 days for 2-4 cycles
89568509|NCT05635825||Healthy Asian|Healthy Asian, non-vegetarian that is aged between 21 to 99, literate and numerate.
89568510|NCT04804397|Experimental|Sucrose|Sucrose: 1l sucrose sweetened soft drink per day for 8 weeks (1650 KJ, 97g carbohydrate per day) as 4 25cl drinks
89568511|NCT04804397|Placebo Comparator|Aspartame|Aspartame: 1l aspartame sweetened soft drink per day for 8 weeks as 4 25cl drinks
89568512|NCT05279703|Active Comparator|0.03 mcg group|epinephrine infusion will be started after subarachnoid block until 5 minutes after delivery of the baby
89568513|NCT05279703|Active Comparator|0.02 mcg group|epinephrine infusion will be started after subarachnoid block until 5 minutes after delivery of the baby
89568514|NCT05279703|Active Comparator|0.01 mcg group|epinephrine infusion will be started after subarachnoid block until 5 minutes after delivery of the baby
89568515|NCT05635747||Patients who have completed the Relizorb Trial and consented into the 90 day extension trial|Patients aged 2-18 who have completed the 90 day open label phase 3 Relizorb trial who consent to the 90 day observational Relizorb extension trial
89568516|NCT04808219||Driver|Ambulance driver who was involved in a traffic collision - video analysis of the collision records and in-depth interview aiming to find the cause of the collision.
89568517|NCT04796519|Experimental|Unilateral TKA|Unilateral total knee arthroplasty group (UTKA) consisted of patients who did not undergo a second TKA within 3 months of the first TKA
89568518|NCT04796519|Experimental|Bilateral TKA|bilateral total knee arthroplasty group (BTKA) were those who had a second TKA within 12 months after initial TKA
89568519|NCT03070639|No Intervention|Standard Care Study Condition|The Standard of Care control group will not receive any additional services at the newborn visit.
89568520|NCT03070639|Active Comparator|Attention-Matched Control Condition|The Attention-Matched Control Condition will include the Scald Prevention Intervention.
89568521|NCT03070639|Experimental|Safe Sleep Intervention Condition|The Intervention Condition will include the Safe Sleep Intervention.
89568522|NCT04804475|Active Comparator|Training Group|Throughout 3 weeks SSE training was administered 4 days a week for a length of 45 minutes in each session. All the analyses were conducted at the start and at the end of 3-week long training.
89568523|NCT04804475|No Intervention|Control Group|This group has no intervention. Evaluations were only made at the start and at the end of 3-week long.
89608880|NCT03586947|Experimental|Vitamin D3 Drops group|Patients in this group would take Vitamin D3 400 UNT Oral Capsule.
88969955|NCT05296733|Experimental|Part A: BI 456906: Cohort 3|Patients with cirrhosis + CTP Class B
88969956|NCT05296733|Experimental|Part A: BI 456906: Cohort 4|Patients with cirrhosis + CTP Class C
88969957|NCT05296733|Experimental|Part B: BI456906: Cohort 1|Patients with overweight/obesity without cirrhosis/hepatic impairment
88969958|NCT05296733|Experimental|Part B: BI456906: Cohort 2|Patients with overweight/obesity with cirrhosis + CTP Class A
88969959|NCT05296733|Experimental|Part B: BI456906: Cohort 3|Patients with overweight/obesity with cirrhosis + CTP Class B
88969960|NCT05285618|Experimental|Predicting the perceptual experience of retinal prosthesis patients|This intervention will assess the effect of different stimulation strategies on the perceptual experience of retinal prosthesis patients. We will produce visual percepts in patients either by directly stimulating electrodes (using FDA-approved pulse trains) or by asking them to view a computer or projector screen and using standard FDA-approved stimulation protocols (as is standardly used for their devices) to convert the computer or projector screen image into pulse trains on their electrodes. Existing blind users of the Argus II will be recruited for this study. Performance of Argus II users will be compared to performance of sighted subjects viewing a prosthetic vision simulation in virtual reality.
88969963|NCT05270109|Experimental|BiZact|
88969964|NCT05270109|Active Comparator|Cold Steel|
88969966|NCT05262023|Experimental|DNL593 (Healthy Participant)|
88969967|NCT05262023|Placebo Comparator|Placebo (Healthy Participant)|
88969968|NCT05262023|Experimental|DNL593 (Participants with FTD)|
88969969|NCT05262023|Placebo Comparator|Placebo (Participants with FTD)|
88969970|NCT05260008|Experimental|ATX-101 Dose A|ATX-101 Dose A
89568524|NCT04808063|Experimental|Algorithm use for prphylactic mesh after emergency laparotomy|Patients with emergency surgery in whom algorithm for prophylactic mesh is use to help decide abdominal wall mesh reinforcement or not.
89568525|NCT03070561|Experimental|Sublingual film with peanut extract|
89568526|NCT05514951|Experimental|Blood sampling|Blood sampling
89568527|NCT04796441|Experimental|CAR--γδT|Patients will be treated with CAR--γδT cells
89568528|NCT05318781||Patients undergoing bariatric surgery|Adult patients (≥ 30y yrs.) scheduled to undergo a first bariatric surgery recruited from the bariatric surgery clinic at the CIUSSS du Nord-de-l'Île-de-Montréal [N=120]
89568529|NCT05318781||Patients on the bariatric surgery waitlist|Age-, sex-, and BMI-matched waitlist control group [awaiting for bariatric surgery] recruited from the bariatric surgery clinic at the CIUSSS du Nord-de-l'Île-de-Montréal [N=60]
89208756|NCT00977847|Experimental|Interactive Voice Response Practice|"The introductory letter to patients will allow them an opportunity to opt-out of the study using a toll-free number. If they do not opt-out within 2 weeks of receiving the letter, the IVR system will make up to 15 call attempts over a 2 week period to reach the patient. The system will make outbound calls during preset hours. The system continuously checks the call list for the next scheduled call. Once contact is made, the spoken script greets the patient by name, authenticates identify, and will ask the patient the programmed questions. The IVR server will send completed family history assessments to the patients EHR as an HL7 compliant summary note as well as transmitting the separate coded responses for each condition/ family member to coded family history fields in the EHR."
89568530|NCT05318781||Non-bariatric eligible individuals|"Age-and sex-matched individuals who are not eligible for bariatric surgery, as an additional non-bariatric comparison group [N=60]~*The 60 age-and sex-matched non-bariatric participants will have data captured just once [at baseline] on a limited number of key assessments"
89568531|NCT04988737|Experimental|CDS Group|Clinicians complete tasks using the CDS prototype. Briefly, the clinician scans the barcode on the syringe label immediately prior to medication administration. The scan triggers the CDS to display a dosing window with pertinent patient-specific information and/or alert(s) when necessary to prevent a medication error (ME) prior to the medication being administered. Medication data are then sent from the CDS application to the patient's anesthesia record for automatic documentation in real-time, eliminating the need to manually document the medication in the Anesthesia Information Management System (AIMS). When necessary, the CDS application generates alerts to prevent medication errors. Upon receiving an alert, the anesthesia clinician may accept the alert and revise the action that generated the alert, or override the alert and continue with the planned action.
89568532|NCT04988737|No Intervention|Control Group|Clinicians complete tasks using the conventional medication administration and documentation workflow in anesthesia.
89568533|NCT05278845|Experimental|Treatment Sequence 1|SLC-391 10 mg capsules (manufactured by China Gateway Pharmaceutical Development Co. (Shanghai, P.R. China)) administered as 5 x 10 mg capsules under fasted conditions.
89568534|NCT05278845|Experimental|Treatment Sequence 2|SLC SLC-391 10 mg capsules (manufactured by China Gateway Pharmaceutical Development Co. (Shanghai, P.R. China)) administered as 5 x 10 mg capsules under fed conditions.
89608881|NCT03586947|No Intervention|Non-Vitamin D3 Drops group|Patients in this group would take nothing.
88969971|NCT05260008|Experimental|ATX-101 Dose B|ATX-101 Dose B
88969972|NCT05260008|Active Comparator|bupivacaine hydrochloride|bupivacaine hydrochloride without epinephrine via local infiltration and/or nerve block
88969973|NCT05257525|Other|Univentricular physiology|Neonates with univentricular physiology
88969974|NCT05257525|Other|Biventricular physiology|Neonates with biventricular physiology
88969975|NCT05253131|Experimental|Phase 1 and 2 Study of Selumentinib, BI and Durvalumab|"Part A will be a phase 1 dose escalation study of the combination with selumetinib and BI, and,~Part B will be phase 1 study combining the determined dose of selumetinib and BI from Part A with durvalumab.~Part C will be a phase 2 study combining selumetinib, BI with durvalumab in MPNST patients at the recommended doses from part B. A Simon's two-stage design will be used in the phase 2 trial to determine the clinical benefit in patients with unresectable or metastatic NF associated MPNST."
88969976|NCT05248022|Experimental|Combination Treatment Group|Drug-eluting Beads Bronchial Arterial Chemoembolization combined with Programmed Cell Death Protein 1 Inhibitor was used for treatment.
88969977|NCT05248022|Active Comparator|Single Treatment Group|Only receive drug-eluting beads bronchial arterial chemoembolization treatment.
88969978|NCT05246345||Cohort of refractory and/or relapsed chronic lymphocytic leukemia during or after venetoclax|Cohort of refractory and/or relapsed chronic lymphocytic leukemia during or after venetoclax
88969979|NCT05237245||1|Adult T-cell leukemia / lymphoma (ATL) patients
89608882|NCT04765215||Breast or lung cancer patients receiving active chemotherapy and 2 doses of CoronaVac vaccine|
88969980|NCT05237245||2|HTLV-1 chronically infected patients without ATL
88969981|NCT05236712|Experimental|Mobile health|Participants will receive access to a mobile app installed on their device and will be asked to use the app at least once a week
88969982|NCT05236712|No Intervention|Usual care|Participants will receive information on public online resources
88969983|NCT05228691||Long COVID|"Participants will self-complete some questionnaires, while the rest of the variables will be evaluated by the evaluating physiotherapist.~After the consultation, the evaluator himself will provide the participants with some recommendations that he should make. As support, a diptych has been made with different general activities to be developed by the participant. With the purpose of track this activity, they will be informed that they will be contacted once 6 months have passed since the evaluation (via phone call or SMS)."
89608883|NCT04765215||Healthy volunteers who received two doses of coronavac vaccine|
88969984|NCT05213572||subjects w sickle cell disease|to evaluate heart, lung, liver, kidney, brain, and neurocognitive function post-hematopoietic stem cell transplant (HSCT) in subjects with sickle cell disease (SCD) who undergo curative therapies
88969985|NCT05211206||Aggressive hydration|Patients with greater than or equal to 2 L of intravenous crystalloid fluids administered within the immediate pre-, peri- and post-procedural period
88969986|NCT05211206||Conservative hydration|Patients with less than 1 L of intravenous crystalloid fluids administered within the immediate pre-, peri- and post-procedural period
89568535|NCT05392933|Experimental|Piriformis syndrome with lumbar radiculopathy (PSWLR)|All patients (n=40) will be evaluated with detailed physical examination and special clinical tests for both lumbar radiculopathy and piriformis syndrome. If patients have lumbar magnetic resonance imaging or electromyography results, they will be recorded to confirm the diagnosis of lumbar radiculopathy. The patients who have the final diagnosis of lumbar radiculopathy and prediagnosis of piriformis syndrome will be evaluated for the pain scores (pain at resting, sitting, standing, lying, at night and during activity) using numeric rating scale. Then, an ultrasound guided piriformis muscle injection will be performed. The patients will be kept under observation for 30 minutes afterwards and the percentage of their pain relief will be recorded. The patients whose pain resolves at least 50% from the baseline after the injection will be diagnosed as piriformis syndrome and will be reevaluated one week and one month after the injection and the changes in the pain scores will be recorded.
89568536|NCT04796675|Experimental|Fludarabine + Cyclophosphamide + CAR-NK-CD19 Cells|Patients will received lymphodepletion with fludarabine (30 mg/kg) and cyclophosphamide (300 mg/kg) on day -5, -4, and -3, followed by one infusion of CAR-NK-CD19 cells on day 0. The study will be divided into three groups: Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, and Non Hodgkin's Lymphoma. Doses of 0.01×10^7, 0.1×10^7, 1.0×10^7 CAR+ T cells (with an allowance of ±20%) will be tested in each group in the 3+3 dose-escalation study. Each dose group has 3 patients. If no dose-limited toxicity (DLT) emerges in the group, then the subsequent higher dose will be used in the next group. If DLT emerges in a single subject in any dose level, 3 more subjects will be enrolled to the same dose level. The maximum dose could be extended.
89568537|NCT04954677|Experimental|Participates being subjected to capsule endoscopy (AI-box assistant)|In this group ,Participates will be subjected to magnet controlled capsule endoscopy with AI-box assistant.
88969987|NCT05186259|Active Comparator|Patients with chronic tinnitus|Patients with chronic subjective tinnitus (> 3 months)
88969988|NCT05186259|Active Comparator|Patients with chronic idiopathic neck pain|Patients with chronic idiopathic neck pain (> 3 months)
88969989|NCT05186259|Active Comparator|Patients with chronic tinnitus and chronic musculoskeletal pain|Patients with chronic tinnitus and chronic musculoskeletal pain (> 3 months)
88969990|NCT05186259|Active Comparator|Healthy controls|Healthy controls without tinnitus or pain complaints
88969991|NCT05184257||Study Drugs|The study drug is Zoladex® 10.8 mg. The maximum observation time window for effectiveness analysis is 28 (24+4) weeks.
88969992|NCT05184257||Comparison Drugs|The comparison drug is Zoladex® 3.6 mg. The maximum observation time window for effectiveness analysis is 28 (24+4) weeks.
88969993|NCT05177328|Experimental|ShA9 dominant and placebo non-dominant|The ShA9 product and placebo will be provided in single dose dispensers. Dispensers will be stored at -80°Celsius (= -112 degrees Fahrenheit) and thawed to 4°Celsius (=39.2 degrees Fahrenheit) prior to administration. Participants will have a single application of ShA9 applied by clinic staff to their dominant arm (i.e. right arm for a right handed participant) and a single application of placebo applied to their contralateral arm (i.e. left arm for a right handed participant).
88969994|NCT05177328|Experimental|ShA9 non-dominant and placebo dominant|The ShA9 product and placebo will be provided in single dose dispensers. Dispensers will be stored at -80°Celsius (= -112 degrees Fahrenheit) and thawed to 4°Celsius (=39.2 degrees Fahrenheit) prior to administration. Participants will have a single application of placebo applied by clinic staff to their dominant arm (i.e. right arm for a right handed participant) and a single application of ShA9 applied to their contralateral arm (i.e. left arm for a right handed participant).
88969995|NCT05174182|Experimental|A novel treatment approach|"The experimental intervention were first comprised and tested in a large cohort of 10-14-year-old adolescents with a similar condition (patellofemoral pain) and was associated with a successful outcome after 12 weeks.~Afterwards, the intervention was changed slightly to target adolescents with Osgood Schlatter and then pilot-tested in a cohort of 51 participants. In this cohort, most participants needed more time to progress through exercises and sport, and the investigators have therefore piloted extending the intervention further in the clinic, with more success on these aspects.~The experimental intervention will contain an active approach with self-management of load and progressive exercise therapy throughout the treatment course, delivered through 4 one-on-one visits lasting approximately 20 minutes (at months 0, 1, 2, 3) with a physiotherapist and an accompanying leaflet with written and illustrated exercise description, and advice and information."
88969996|NCT05174182|Active Comparator|Usual care|The investigators have performed a step-wise mixed-methods sub-study to investigate current standard of care in the most common settings in Denmark (Sports Physiotherapists mainly from private primary practice, and Orthopedic Surgeons caring for these patients, invited from all public secondary care orthopedic departments in Denmark). Results were then combined with reports from patients seen in the clinic (n=34) who were questioned in detail on what modalities and advice they had previously received. The results were mostly compatible with the recent international survey of clinicians treating Osgood-Schlatter. With the findings from this process the investigators have developed a patient-aimed leaflet, which will contain vignettes and elaborations of the multimodal approaches included in the standardized usual care package, which will be implemented through four visits (at months 0, 1, 2, 3) with a physiotherapist (mirroring the plan of care of the experimental group).
88969997|NCT05168930|Experimental|Cohort A: BTKi and BCL2i naive|Participants who have never received a BTK inhibitor or a BCL-2 inhibitor
88969998|NCT05168930|Experimental|Cohort B: BTKi or BCL2i exposed without disease progression|Participants who have received prior treatment with a BTK or BCL-2 inhibitor and discontinued treatment for any reason other than disease progression
88969999|NCT05168930|Experimental|Cohort C: BTKi exposed and with disease progression|Participants who experienced disease progression on a prior BTK inhibitor. Participants with BTK C481X mutation at enrollment will be excluded.
88970000|NCT05161728|Experimental|PSMA response evaluation arm|PSMA-PET/CT response evaluation, 2 months after starting hormonal therapy, 2 months after starting upfront therapy
88970001|NCT05155254|Experimental|IO102-IO103 + pembrolizumab|"IO102-IO103 subcutaneous injections (85µg) every 3 weeks for a maximum 35 cycles (up to 2 years treatment). Additional dose given during the induction period on Day 8 of cycles 1 and 2. Each patient can be treated for a maximum of 37 administrations in total (up to 2 years treatment).~Pembrolizumab 200 mg intravenously every 3 weeks for a maximum of 35 cycles."
89568538|NCT04954677|No Intervention|Participates being subjected to capsule endoscopy|In this group ,Participates will be subjected to magnet controlled capsule endoscopy without AI-box assistant.
89568539|NCT05233839|Experimental|Telerehabilitation (TR)|The TR group will be followed up through the application within the 8-week home exercise program.
89568540|NCT05233839|Active Comparator|Paper Based Rehabilitation (PBR)|The PBR group will be followed up through the paper instruction within the 8-week home exercise program.
89568541|NCT05233761|Experimental|Defined CBD|Defined CBD will be administered as two small capsules that will be taken orally with a glass of water one hour before bedtime that contain a total of 300 mg CBD and 8 mg terpenes. Participants will take the treatment on a minimum of four nights per week, over a total of four-weeks.
89568542|NCT05233761|Placebo Comparator|Placebo|The placebo control will be administered as two small capsules that will be taken orally with a glass of water one hour before bedtime that do not contain any CBD or terpenes. Participants will take the treatment on a minimum of four nights per week, over a total of four-weeks. The Placebo capsules will look and smell identical to the Defined CBD capsules.
89568543|NCT04803929|Experimental|Anti-ILT3 CAR-T cells|All subjects were intravenous administrated with anti-ILT3 CAR-T cells
89568544|NCT04796207|Experimental|Fish Oil Capsules|Participants in the treatment arm will receive 3 grams of DHA and EPA (2:1 weight ratio) 3 times a week for 25-weeks during regular football season.
89568545|NCT04796207|Placebo Comparator|Safflower Oil Capsules|Participants in the treatment arm will receive 3 grams of high-oleic safflower oil) in a 1:1 allocation ratio for 25-weeks during regular football season.
89568546|NCT05317923|Experimental|airway management and ventilation in patients with unusual placement of tracheal stenosis|Flow-controlled ventilation (FCV) in patients with unusual placement of tracheal stenosis
89568547|NCT04786925|Placebo Comparator|Control diet|A conventional diet based on the current Spanish Mediterranean dietary guidelines: Spanish Society of Community Nutrition (SENC).
89568548|NCT04786925|Experimental|Nutriprecision diet|A Mediterranean, balanced diet based on the inclusion of precision foods designed and developed within the framework of Nutriprecision project. A mobile application to empower and support the management of the dietary prescription. A digital tool for cognitive stimulation.
89568549|NCT05230875||Patients participating in the therapeutic education program|Patients participating in an educational program on Inflammatory Bowel Disease (IBD) including a specific discussion on intimacy and sexuality .
89568550|NCT05230875||Patients control (not participating in the therapeutic education program)|A control group (at the rate of two controls for one case) will be made up of IBD patients routinely followed in the gastroenterology department.Those patients will not participate in the therapeutic education program.
89568551|NCT05276037||Study group|Milan-out, up-to-7-in, PET negative (≤1.15) HCC patients
89568552|NCT05276037||Control group|Milan-in HCC patients
89568553|NCT04803617||Patient's group|geriatric patients with interstitial lung disease
89568554|NCT04803617||Control group|healthy volunteers selected from the geriatric population
89568555|NCT05229939||Development cohort|kidney transplant recipients in 3 centres in France: Necker, Saint-Louis and Toulouse hospitals
89568556|NCT05229939||Validation cohort 1|kidney transplant recipients from Montpellier Hospital, France
89568557|NCT05229939||Validation cohort 2|kidney transplant recipients from Lyon Hospital, France
89568558|NCT05229939||Validation cohort 3|kidney transplant recipients from Tenon Hospital, France
89568559|NCT05229939||Validation cohort 4|kidney transplant recipients from Saint-Etienne Hospital, France
89568560|NCT05229939||Validation cohort 5|kidney transplant recipients from Mayo Clinic Hospital, USA
89568561|NCT05229939||Validation cohort 6|kidney transplant recipients from Bergamo hospital, Italy
88970002|NCT05155254|Active Comparator|pembrolizumab|Pembrolizumab 200 mg intravenously every 3 weeks for a maximum of 35 cycles (up to 2 years treatment).
89532140|NCT06337643|Experimental|MVX01 Vaccine - Cohort 1|MVX01 Vaccine: liquid formulation, 0.5 mL intramuscular injection, 10 μg Frequency: 2 doses administered approximately 1 month apart Age: 18-50 years,
89568562|NCT05229939||Validation cohort 7|kidney transplant recipients from Zagreb hospital, Croatia
89568563|NCT05275413|Experimental|family-based mHealth intervention|The expectant mothers and their family members (fathers and grandparents) in this group will receive health education and support and family support via a smartphone app.
89568564|NCT05275413|Experimental|mother-only mHealth intervention|The expectant mothers in this group will receive health education and support via a smartphone app.
89568565|NCT05275413|Active Comparator|Health education|The expectant mothers in the control group will receive health education via a smartphone app.
89568566|NCT04795349|Experimental|NAC Patients.|Breast cancer patients after NAC completion, prior to surgery
89568567|NCT04786535|Active Comparator|Hemodiafiltration|
89532141|NCT06337643|Experimental|MVX01 Vaccine or Placebo - Cohort 2|MVX01 Vaccine: liquid formulation, 0.5 mL intramuscular injection, 30 μg, or Placebo: liquid formulation, 0.5 mL intramuscular injection Frequency: 2 doses administered approximately 1 month apart Age: 18-50 years
89568568|NCT04786535|Experimental|Expanded hemodialysis|
89568569|NCT04786535|Experimental|Conventional high-flux hemodialysis|
89568570|NCT05272917|Experimental|head and neck cancer patients with radiotherapy AND chemotherapy|patients included for a head and neck cancer and treated by radiotherapy (+/- surgery) + chemotherapy
89568571|NCT05272917|Experimental|head and neck cancer patients with radiotherapy only|patients included for a head and neck cancer and treated by radiotherapy (+/- surgery) without chemotherapy
89568572|NCT05272917|Active Comparator|healthy volunteers|healthy volunteers paired with experimental patients on age (+/- 5 years), gender, tobacco status
89568573|NCT05316987|Other|Active vitiligo patients|NBUVB
89568574|NCT04925895|Experimental|Dynamic soft tissue mobilization|Dynamic soft tissue mobilization (DSTM) is a soft tissue mobilization technique use to treat tight spasm using progressive muscle activation.
89568575|NCT04925895|Active Comparator|Proprioceptive neuromuscular facilitation stretching|PNF stretching technique, a type of flexibility training that is effective in improving muscle flexibility and restore functional ranges using a wide array of techniques.
89568576|NCT05616377||target therapy + local therapy group vs target therapy alone group|
89568577|NCT05616377||local therapy before target therapy group vs local therapy after target therapy group|
89568578|NCT04785755|Active Comparator|Group I|The control group (n=15) received oral standard diuretic therapy (furosemide 40 mg tablet plus spironolactone 100 mg tablet with a dose increase in 40 mg:100 mg ratio) given once daily in the morning for 38 days (from the first day of the study to the end of the study).
89568579|NCT04785755|Experimental|Group II|The hypertonic saline solution (HSS) group (n=25) received oral standard diuretic therapy (furosemide 40 mg tablet plus spironolactone 100 mg tablet with a dose increase in 40 mg:100 mg ratio) given once daily in the morning for 38 days (from the start of the study to the end of the study) with hypertonic saline solution (150ml, 1.4% - 4.6%) infused slowly over one hour peripherally once daily from the first day of the study for eight days.
89568580|NCT04785755|Experimental|Group III|The etilefrine group (n=25) received oral standard diuretic therapy (furosemide 40 mg tablet plus spironolactone 100 mg tablet with a dose increase in 40 mg:100 mg ratio) given once daily in the morning for 38 days (from the first day of the study to the end of the study), and etilefrine 5 mg tablet given by mouth three times daily for 38 days (from the first day of the study to the end of the study).
89568581|NCT04785755|Experimental|Group IV|The hypertonic saline solution (HSS) + Etilefrine group (n=25) received oral standard diuretic therapy (furosemide 40 mg tablet plus spironolactone 100 mg tablet with a dose increase in 40 mg100mg ratio) given once daily in the morning for 38 days (from the first day of the study to the end of the study), with hypertonic saline solution (150ml, 1.4% - 4.6%) infused slowly over one hour peripherally once daily from the first day of the study for eight days, and etilefrine 5 mg tablet given by mouth three times daily for 38 days (from the first day of the study to the end of the study).
89568582|NCT04244253|Experimental|OPC-64005 20 mg|
89568583|NCT04244253|Experimental|OPC-64005 10 mg|
89568584|NCT04244253|Placebo Comparator|Placebo|
89568585|NCT04785833|Experimental|T cell injection targeting CD7 chimeric antigen receptor|
89568586|NCT04240899|Experimental|Tele-yoga|This is a single group study, therefore all subjects will be included in this single arm and will undergo the same telerehabilitation yoga intervention delivered through videoconferencing.
89568587|NCT04795193|Experimental|MICS-CABG|Patients undergoing MICS-CABG.
89568588|NCT04795193|Active Comparator|OPCABG|Patients undergoing thoracotomy OPCABG.
89568589|NCT05615441|Active Comparator|ANI-guided|Patients receiving remimazolam-based total intravenous general anesthesia with nociception monitoring with the ANI monitor
89028364|NCT05144919|Experimental|Intervention|The intervention group will receive capacity building sessions on both Agriculture and Nutrition, in addition to access to routine health and nutrition checks, and agriculture extension as offered by commune and provincial staff as normal.
89028365|NCT00494936||HIV/HCV|HIV and HCV coinfected
89028366|NCT00494936||HIV infected|HIV monoinfected
89568590|NCT05615441|Experimental|Standard|Patients receiving remimazolam-based total intravenous general anesthesia based on hemodynamic variables and without ANI nociception monitoring
89568591|NCT05218941|Experimental|Passive robotic group|Implant surgery without flap assisted by passive robotics
89568592|NCT05218941|Active Comparator|Control group|Implant surgery with flap
89568593|NCT04785599|Experimental|Group EC1: Exercices, informative talk|Group EC1 carried out the conventional prevention program consisting of an informative talk and an exercise program
89568594|NCT04785599|Experimental|Group ECCP2: Exercices, informative talk, compression garment|Group ECCP2 carried out the same program but with the addition of a prophylactic compression garment
89568595|NCT05314101|Experimental|TAS-102 combined with bevacizumab and tislelizumab|TAS-102 combined with bevacizumab and tislelizumab third-line or above in the treatment of liver metastasis in colorectal cancer
89568596|NCT02595749|Experimental|Placebo then Intranasal Oxytocin (40 IU)|Participants received a single placebo nasal spray (consisting of 4ml sterile saline [Ocean Nasal Spray Solution]) during the first experimental session, which occurred on a single day. After a 72 hour washout period, they then received a single 40 IU dose of Pitocin (oxytocin, USP; concentration = 10 IU/1 mL; PAR Pharmaceuticals, NY, USA) during the second experimental session, which occurred on a single day. All nasal spray solutions were transferred into two, 2 ml intranasal atomizers and administered in four sprays to each nostril over the course of 10 minutes.
89568597|NCT02595749|Experimental|Intranasal Oxytocin (40 IU) then Placebo|Participants received a single 40 IU dose of Pitocin (oxytocin, USP; concentration = 10 IU/1 mL; PAR Pharmaceuticals, NY, USA) during the first experimental session, which occurred on a single day. After a 72 hour washout period, they then received a single placebo nasal spray (consisting of 4ml sterile saline [Ocean Nasal Spray Solution]) during the second experimental session, which occurred on a single day. All nasal spray solutions were transferred into two, 2 ml intranasal atomizers and administered in four sprays to each nostril over the course of 10 minutes.
89568598|NCT01657305|Experimental|Oleogel-S10, non-adhesive wound dressing|A split-thickness skin graft (STSG) donor site wound >15cm2 in size was divided in 2 halves. One half was randomized to Oleogel-S10 treatment and non-adhesive wound dressing (intra-individual comparison). Oleogel-S10 was administered (1 cm or 100 mg per cm2 wound area corresponding to thickness of about 1 mm or 0.04 inch) every 3 to 4 days until 95% epithelialization of the wound or end of treatment at Day 28.
89568599|NCT01657305|Other|Non-adhesive wound dressing only|A STSG donor site wound >15cm2 in size was divided in 2 halves. One half was randomized to treatment with non-adhesive wound dressing only (intra-individual comparison). Non-adhesive wound dressings are standard of care (SOC) in the treatment of STSG donor sites. Wound dressings were changed every 3 to 4 days until 95% epithelialization of the wound or end of treatment at Day 28.
89028367|NCT00494936||HIV/HCV nonviremnic|HIV and HCV coinfected with HCV RNA less than 600 copies
89028368|NCT00494936||HCV infected|HCV monoinfected with HCV viremia
89028369|NCT05144568|Experimental|experimental group|Nutrition education will be given to participants with PMS in the experimental group.
89028370|NCT05144568|No Intervention|Control group|
89028371|NCT05144217|Placebo Comparator|Placebo|1 capsule twice per day
89028372|NCT05144217|Active Comparator|oral administration of 2x 140 mg per day|1 capsule twice per day
89028373|NCT05144217|Active Comparator|oral administration of 3x 280 mg per day|2 capsules three times a day
89568600|NCT04785209||No complication|Thrombolysis in myocardial infarction flow grade III flow after PPCI, mean platelet volume, lymphocyte ratio, detailed echo within 24 hrs of admission, clinical STEMI risk scores
89568601|NCT04785209||No reflow|No reflow phenomenon after pci on STEMI patients, mean platelet volume, lymphocyte ratio, detailed echo within 24 hrs of admission, clinical STEMI risk scores
89568602|NCT04794881|Experimental|24 hours|Newborn infants in this group will undergo repeat lumbar puncture at 24 hours after a traumatic lumbar puncture
89568603|NCT04794881|Active Comparator|48 hours|Newborn infants in this group will undergo repeat lumbar puncture at 48 hours after a traumatic lumbar puncture
89568604|NCT04426721|Experimental|Ozone|Participant will receive an intraarticular injection of oxygen-ozone, once a week for three weeks. During procedure a clear ultrasound image is to be taken to document needle placement in the synovial space. The injector may choose the position of the knee (e.g., extended or bent) and the approach for the injection (e.g., medial or lateral).
89568605|NCT04426721|Active Comparator|Hyaluronic acid|Participant will receive an intraarticular injection of hyaluronic acid, once a week for three weeks. During procedure a clear ultrasound image is to be taken to document needle placement in the synovial space. The injector may choose the position of the knee (e.g., extended or bent) and the approach for the injection (e.g., medial or lateral).
89568606|NCT05221359|Experimental|test arm|All patients will be enrolled in same arm which contains the two interventions (device + drug) and follow mandatory phases of trial: screening, implantation, treatment with ExOlin, explantation.
89568607|NCT04803071|Experimental|Adjuvant therapy trial group|N-3pufas improved cognitive formula adjuvant therapy intervention group
89568608|NCT04803071|Active Comparator|Adjuvant treatment control group|General fish oil formula product adjuvant treatment control group
89568609|NCT04803071|Placebo Comparator|Placebo assisted treatment control group|
89568610|NCT04803071|No Intervention|Healthy group|
88970003|NCT05153447|Experimental|M-Tech|M-Tech involves the use of a mobile app delivery platform to several interventions. The components of M-Tech include: 1) Hybrid in-person and telehealth visits with oncology providers; 2) Disease-specific education videos; 3) Activity level monitoring via a wearable device with promotion of physical activity; 4) Symptom monitoring with provision of self-management strategies, and 5) Medication management.
88970004|NCT05153447|Active Comparator|Usual Care|Participants randomized to the usual care arm will receive standard of care.
88970005|NCT05144841|Experimental|Arm A|Participants will receive treatment with zilovertamab vedotin 2.5 mg/kg via intravenous (IV) infusion on Day 1 of each 21-day cycle (every 3 weeks (Q3W)) until documented disease progression or any other discontinuation criterion is met.
88970006|NCT05144841|Experimental|Arm B|Participants will receive treatment with zilovertamab vedotin 2.25 mg/kg via intravenous (IV) infusion on Day 1 of each 21-day cycle (every 3 weeks (Q3W)) until documented disease progression or any other discontinuation criterion is met.
88970007|NCT05131789|Experimental|Information System Group|The dementia case managers in the experiment group use information system to perform case management.
88970008|NCT05130801|Experimental|MRI and pHLIP® ICG|All study participants in Phase I will receive pre-operative MRI and mpMRI scans, a pre-operative injection of pHLIP ICG, and NIRF imaging during surgery (intra-operatively). During phase IIa of the study, if pHLIP® ICG NIRF imaging indicates tumor in areas outside of the planned resection area, biopsy samples will be taken from these areas and submitted for pathological analysis.
89208757|NCT00977847|Experimental|Wireless Tablet PC Practice|Patients will receive an info letter in advance of their visit explaining the project with description of what information they will be asked to provide. Study staff will train the practice staff to hand out and collect the tablets for the patient. Staff will be trained to verify a patient's identity to ensure that the family history is sent to the correct EHR record. The initial screen of the tablet PC portal will include a paragraph of informed consent, and patients in this practice will be given the opportunity to decline participation. For patients who participate, the completed family history data will be transmitted to the patient's EHR as an HL7 compliant note and transmitting separate coded responses for each condition/ family member to coded family history fields.
89568611|NCT04794413|Experimental|Pimavanserin|All participants will receive pimavanserin 17mg once daily for 1 week and, if the tics are deemed to be inadequately controlled then increase to 34 mg once daily, taken orally as two 17 mg tablets once daily.
89568612|NCT04802993||All patients with pancreatic ductal adenocarcinoma aged 70 years and older|All patients in the registry aged 70 years and older with right-sided pancreatic ductal adenocarcinoma
89568613|NCT04802993||All patients with pancreatic ductal adenocarcinoma aged 70-79 years|All patients in the registry aged 70-79 years with right-sided pancreatic ductal adenocarcinoma
89568614|NCT04802993||All patients with pancreatic ductal adenocarcinoma aged 80 years and older|All patients in the registry aged 80 years and older with right-sided pancreatic ductal adenocarcinoma
89568615|NCT04802993||All patients resected with pancreaticoduodenectomy, all ages|All patients in the registry resected with pancreaticoduodenectomy during the study period
89568616|NCT04802993||All patients resected with pancreaticoduodenectomy, aged 70-79 years|All patients in the registry resected with pancreaticoduodenectomy during the study period, aged 70-79 years
89568617|NCT04802993||All patients resected with pancreaticoduodenectomy, aged 80 years and older|All patients in the registry resected with pancreaticoduodenectomy during the study period, aged 80 years and older
89568618|NCT02634307|Experimental|ALKS 8700|Oral capsules taken twice daily.
89568619|NCT01365273|No Intervention|Bridal Veil together with staples|Standard of care. Bridal Veil is fixed over the graft with staples.
89568620|NCT01365273|Active Comparator|Mepitel One|Device, dressing
89568621|NCT04793945|Active Comparator|light therapy twice weekly|15 or half of the patients with three patches of Alopecia Areata on the scalp the first patch will be treated by 308nm Excimer light twice weekly and topical steroid twice daily the second patch will be treated by topical steroid twice daily. the third patch will be left as a control.
89568622|NCT04793945|Active Comparator|light therapy once weekly|"15 or half of the patients with three patches of Alopecia Areata on the scalp the first patch will be treated by 308nm Excimer light once weekly and topical steroid twice daily.~the second patch will be treated by topical steroid twice daily. the third patch will be left as a control."
89568623|NCT04794257|Active Comparator|i-IONM|In operations with i-IONM mode the IONM stimulator will be used to test vagal response at the beginning of surgery, map out and trace the RLNs during surgery by repetitive stimulations, and in case of loss of signal (LOS) it will be used to identify the type and site of neural injury (Type I vs. Type II). Final prognostication of postoperative neral function will be based on vagal stimulation at the end of each lobectomy.
89568624|NCT04794257|Experimental|NerveTrend|In operations with NerveTrend the IONM stimulator will be used in the same manner as in the i-IONM arm, but the EMG trending including amplitude and latency changes from initial vagal baseline will be evaluated using the NerveTrend mode at 3 - 5min intervals to assure almost real time EMG tracing and allow for modification of surgical maneuvers in case of occurrence of severe combined events (yellow zone) in order not to end up with the LOS (red zone).
89568625|NCT04794179|Other|Naida Link CROS device|Individuals 65+ who already have Advanced Bionics CII/90K/Ultra cochlear implants will be given Naida Link CROS device to assess the effect the device has on speech understanding in challenging listening situations and on the quality of life in unilateral cochlear implant recipients and their frequent communication partners.
89568626|NCT05311449|Experimental|Acupressure Group (experimental)|The experimental group will be given acupressure.
88970009|NCT05127148||Adolescents and young adults Ph-negative ALL patients in first-line|Adolescents and young adults patients (18-40 years old) with recent diagnosis of Ph-negative acute lymphoblastic leukemia who receive argentinian pediatric-like treatment depending on risk category.
88970010|NCT05122793|Experimental|Prevention Group|In addition to the usual treatment (SoC), the prevention group receives an innovative prevention offer tailored to the severity of the heart failure (telemedical connection via health app as well as additional therapy recommendations).
88970011|NCT05122793|No Intervention|Control Group|The control group receives the current standard treatment according to the valid guidelines (Standard of Care = SoC).
89568627|NCT05311449|Placebo Comparator|Placebo Acupressure Group (control)|The placebo group will be given placebo acupressure.
89568628|NCT04784741|Other|Control group|The control group was given the static hamstring muscle stretches, five sessions on alternative days according to the set protocols.
89568629|NCT04784741|Experimental|Experimental Group|Given five sessions of low amplitude whole body vibration therapy for duration of 10 minutes, on alternative days, along with static stretching of hamstring muscles.
89568630|NCT05635279||HCC patients who received ICIs combined with TKIs|HCC patients who received ICIs combined with TKIs regularly and periodically.
89568631|NCT05635279||HCC patients treated with TACE|HCC patients who underwent TACE as initial treatment.
89568632|NCT04802915|Other|epiretinal membrane group|Patient with epiretinal fibrosis confirmed by OCT with BCVA< 0,6 and complaints of metamorphopsies
89568633|NCT04988191|Experimental|Toripalimab combined with bevacizumab and chemotherapy|
89568634|NCT05310201|Experimental|Be Well Care Well|
89568635|NCT05310201|No Intervention|Control|
89568636|NCT02595437|Experimental|Triferic via IV and Hemodialysate|On study Day 1, patients will receive IV Triferic iron 0.07 mg/kg diluted in an appropriate amount of D5W administered as a 100 mL infusion into the venous return port of the blood lines during the time the patient is receiving dialysis.The rate of administration will be calculated as such that the entire amount will be administered over the course of the dialysis treatment. On study Day 3, Triferic will be mixed with the liquid bicarbonate concentrate used in the preparation of the hemodialysate solution. This will result in a final Triferic iron concentration in the dialysate of 2 µM (110 µg/L). The patients will receive Triferic via the hemodialysate over the course of the dialysis treatment.
89568637|NCT04784975||Preclinical Type 1 Diabetes|"Adolescents and young adults with preclinical diabetes (having at least 2 positive diabetes autoantibodies but who do not meet criteria for clinical diagnosis of type 1 diabetes).~There is no intervention. Each group will complete a bone health assessment, a microbiome assessment and a glycemic assessment with the goal of better understanding the association between these different variables and bone health."
89568638|NCT04784975||New Onset Type 1 Diabetes|Adolescents and young adults with a diagnosis of clinical type 1 diabetes. There is no intervention. Each group will complete a bone health assessment, a microbiome assessment and a glycemic assessment with the goal of better understanding the association between these different variables and bone health.
89568639|NCT04784975||Long standing Type 1 Diabetes|Adolescents and young adults with type 1 diabetes for at least 2 years. There is no intervention. Each group will complete a bone health assessment, a microbiome assessment and a glycemic assessment with the goal of better understanding the association between these different variables and bone health.
88970012|NCT05103657|Experimental|BI 1358894|
89568640|NCT04784975||Control|Adolescents and young adults without any evidence of diabetes or hyperglycemia. There is no intervention. Each group will complete a bone health assessment, a microbiome assessment and a glycemic assessment with the goal of better understanding the association between these different variables and bone health.
89568641|NCT03069001|Active Comparator|Sofosbuvir-Simeprevir|"Sofosbuvir 400 mg orally once-daily.~Simeprevir 150 mg orally once-daily.~Group A included 50 patients who received sofosbuvir 400 mg orally once-daily plus simeprevir 150 mg orally once-daily for 12 weeks."
89568642|NCT03069001|Active Comparator|Sofosbuvir-Ribavirin|"Sofosbuvir 400 mg orally once-daily.~Ribavirin orally twice-daily (according to body weight: 1000 mg daily in patients with a body weight of <75 kg and 1200 mg daily in patients with a body weight of ≥75 kg).~Group B included 40 patients who received sofosbuvir 400 mg orally once-daily plus ribavirin orally twice-daily for 24 weeks."
89568643|NCT04784195||Profesional acrobatics|Profesional Acrobatic Skyedivers as the cort group
88970013|NCT05103657|Placebo Comparator|Placebo|
89028374|NCT05144217|Active Comparator|oral administration of 1x 1120 mg per day|8 capsules once per day
89568644|NCT04784195||General active participations|Adults with meched caracteristics with the profesional acrobatics
89568645|NCT03070717||All patients|Patients with diagnosis of high myopia secondary to an anterior-posterior elongation of the bulbus confirmed by ocular examination in either eye using specific criteria.
89568646|NCT04784351||Training|A subset of patients that are used to train the machine learning algorithm.
89568647|NCT04784351||Validation|"A subset of patients that are held back and used to validate the algorithm's accuracy."
89568648|NCT04239651|Active Comparator|Enrolment in rTMS sessions alone|All patients will be scheduled to receive 30 sessions of rTMS treatments over a six-week period as pre-determined by Alberta Health Services' Strategic Clinical Network for Addiction and Mental Health.
89568649|NCT04239651|Active Comparator|Enrolment in iCBT Plus rTMS|Patients in the rTMS plus iCBT arm of the study, would be assisted to register on the iCBT program (Moodgym) to receive unique login information. They would be assisted to participate in 12 one-hour sessions of iCBT at the clinic prior to receiving rTMS treatments. These in-clinic iCBT sessions would be scheduled in about three days intervals (ideally Tuesdays and Thursdays) so that patients receive two iCBT sessions each week. Patients would also be encouraged to continue with iCBT treatments on their own at home outside the sessions delivered in the clinic.
89568650|NCT04784273||All study patients|Device - DynaNail - Utilization of a novel dynamic compression pseudoelastic intramedullary nail
89568651|NCT05163171||patient consulting or hospitalized in addiction structure|patient consulting or hospitalized in addiction structure
89568652|NCT04426643|Experimental|mesenchymal stem cells|Patients with Urinary incontinence receiving standard treatment plus adipose-derived mesenchymal stem cells
89568653|NCT04426643|Active Comparator|control|Patients with Urinary incontinence receiving standard treatment
89568654|NCT03070405|Active Comparator|Tenofovir|Tenofovir disoproxil fumarate 300mg single dose administration
89568655|NCT03070405|Experimental|Tenofovir + PAS|Tenofovir disoproxil fumarate 300mg single dose, Para-aminosalicylic acid Ca Granule 5.28 g BID seven dose administration
89568656|NCT03068065|Active Comparator|Liraglutide|the dosage of liraglutide was 0.6 mg/day during the first week, 1.2 mg/day during the second week, and 1.8 mg/day from the third week to the conclusion of the study
89568657|NCT03068065|Active Comparator|Metformin|the dosage of merformin was 250 mg thrice a day during the first week, 500 mg thrice a day during the second week, and 1000 mg twice a day from the third week to the conclusion of the study
89568658|NCT03068065|Active Comparator|Gliclazide|the initial dosage of gliclazide was 30 mg before breakfast, which was gradually titrated to a maximum of 120 mg/day to achieve a fasting capillary plasma glucose of <7.0 mmol/L
89568659|NCT04988347|Experimental|Spirulina|Active treatment with Spirulina platensis in capsules containing 530 mg, 1 capsule orally each 8 hours, for 60 days
88970014|NCT05102617|Experimental|Group A: Split-Face Device Only Treatment|Subjects will receive a split face treatment with the PicoSure Pro and/or PicoSure devices using different device settings on each half of the face.
88970015|NCT05102617|Experimental|Group B: Split-Face Treatment with Cosmeceuticals|Subjects will receive a full face treatment with the PicoSure Pro or PicoSure device and will use topical cosmeceuticals on only half of their face.
88970016|NCT05102617|Experimental|Group C: Device Only Treatment|Subjects will receive treatments with the PicoSure Pro or PicoSure device on multiple areas of the body such as the face, décolletage, back, legs, arms, and hands.
88970017|NCT05096741||OCS Liver|
88970018|NCT05096741||Control|
88970019|NCT05092126|Active Comparator|6MST VO2|Completion of 6MST exercise protocol
88970020|NCT05092126|Active Comparator|DASI VO2|Completion of DASI fitness activity questionnaire
88970021|NCT05090280|Experimental|PF614 solution|"Cohort 1 and 6 will consist of 6 evaluable subjects. Subjects will receive the PF614 solution alone and concomitantly with nafamostat as an IR solution and/or ER prototype capsules. Subjects will receive naltrexone prior to and following each regimen.~Cohorts 2 to 5 and Cohorts 7 to 10 will consist of 5 evaluable subjects in each cohort.~Only 2 sentinel subjects will be dosed (one male and one female) in Period 2, Cohort 1. After review of the PK data and safety data, the safety advisory committee will decide the nafamostat dose level.~After Cohorts 3 and 8 only: The fed vs fasted regimen will be determined for Cohorts 4 and 9."
88970022|NCT05090280|Experimental|PF614 solution concomitantly with nafamostat|"Cohort 1 and 6 will consist of 6 evaluable subjects. Subjects will receive the PF614 solution alone and concomitantly with nafamostat as an IR solution and/or ER prototype capsules. Subjects will receive naltrexone prior to and following each regimen.~Cohorts 2 to 5 and Cohorts 7 to 10 will consist of 5 evaluable subjects in each cohort.~Only 2 sentinel subjects will be dosed (one male and one female) in Period 2, Cohort 1. After review of the PK data and safety data, the safety advisory committee will decide the nafamostat dose level.~After Cohorts 3 and 8 only: The fed vs fasted regimen will be determined for Cohorts 4 and 9."
88970023|NCT05079477|Active Comparator|Calorie label|"Calorie label (control) will display a calories per package label on all beverages, not just sugary drinks. This is modeled after the American Beverage Association's current Clear on Calories labels. Additionally, all snack items will have a calories per serving label."
88970024|NCT05079477|Experimental|Sugar graphic warning label|"All products in this arm will also have calorie labels. Beverages with added sugar will also have sugar graphic warning labels with the text: WARNING: drinking beverages with added sugars contributes to obesity, diabetes, and tooth decay along with graphics depicting the amount of sugar in the beverage."
88970025|NCT05078840||Patients with DLBCL limited stages and without risk factors|Patients with DLBCL in limited stages and without risk factors that will receive standard chemoimmunotherapy and their treatment will be adapted according to PET response after 3 cycles.
89568660|NCT04988347|Placebo Comparator|Placebo|Placebo in capsules, 1 capsule orally each 8 hours, for 60 days
89568661|NCT05473169||Patients|Patients with Vocal fold immobility
89568662|NCT05473169||Control|Normal volunteer don't have dysphagia , neurological diseases , heart burn and acid regurgitation
89568663|NCT04452097|Experimental|Phase 1 Low-dose Group|Eligible subjects will receive a single infusion of hUC-MCS product at the dose of 0.5 million cells/kg in addition to standard of care treatment.
89568664|NCT04452097|Experimental|Phase 1 Middle-dose Group|Eligible subjects will receive a single infusion of hUC-MCS product at the dose of 1 million cells/kg in addition to standard of care treatment.
89568665|NCT04452097|Experimental|Phase 1 High-dose Group|Eligible subjects will receive a single infusion of hUC-MCS product at the dose of 1.5 million cells/kg in addition to standard of care treatment.
89568666|NCT04452097|Experimental|Phase 2a Treatment Group|Eligible subjects will receive a single infusion of hUC-MCS product at the selected dose from phase 1 in addition to standard of care treatment.
89568667|NCT04452097|Placebo Comparator|Phase 2a Control Group|Eligible subjects will receive a single infusion of placebo control and standard of care treatment.
89568668|NCT05213091|Experimental|Otago Exercise Group|Otago Exercise program wil be applied to the elderly.
89568669|NCT05213091|No Intervention|Control Group|The elderly wil be expected to continue their daily life.
89568670|NCT04802369|Active Comparator|Identyfication of prognostic factors in VO2max<17 ml/kg/min|Selected prognostic factors will be analyzed in patients with VO2max<17 ml/kg/min
89568671|NCT04802369|Sham Comparator|Identyfication of prognostic factors in VO2max>17 ml/kg/min|Selected prognostic factors will be analyzed in patients with VO2max>17 ml/kg/min
89568672|NCT04988269||Patients (Cases)|"Adult consecutive patients that visited the Emergency Department of LAIKO General Hospital of Athens, Greece from May to July 2021 due to confirmed COVID-19 and related symptomatology.~Blood sampling on the day of admission (one time point) and saliva sampling at 4 different time points (0.800, 12.00, 18.00,22.00) the next day (all sampling in one day)."
89568673|NCT04988269||Healthy Controls|Age and gender matched healthy individuals without COVID-19. Blood sampling (at day 1) and saliva sampling at different time points (0.800, 12.00, 18.00,22.00) the next day (all sampling in one day-day 2).
89568674|NCT05109039|Experimental|Creatine Supplementation|
89568675|NCT05109039|Placebo Comparator|Placebo Supplementation|
89568676|NCT05211921|Other|Multi-Gyn ActiGel Plus|vaginal gel
89568677|NCT05161611|Experimental|Zinc sulfate|Patients will receive 10mg/day zinc sulfate along with phototherapy after being diagnosed to have hyperbilirubinemia
89568678|NCT05161611|Placebo Comparator|Placebo|Patients will receive placebo in addition to phototherapy
89568679|NCT05634655||invasive PAs|
89568680|NCT05634655||non-invasive PAs|
89568681|NCT04802525|Experimental|Moderate-intensity aerobic exercise training without dietary control group|
89568682|NCT04802525|Experimental|Low-fat diet program without exercise intervention group|
89568683|NCT04802525|Experimental|Moderate-intensity aerobic exercise training plus a low-fat diet program group|
89568684|NCT03660475|Experimental|Naltrexone|Naltrexone Ophthalmic Solution 0.002%
89568685|NCT03660475|Placebo Comparator|Placebo|Placebo Ophthalmic Solution
89568686|NCT04802213|Active Comparator|Rehabilitation exercise|1.perform rehabilitation exercise for patients with frozen shoulders (10 repetitions of each exercise, three times a day, 3 days a week for 8 weeks)
89568687|NCT04802213|Experimental|Rehabilitation exercise + joint mobilization device treatment|"perform rehabilitation exercise for patients with frozen shoulders (10 repetitions of each exercise, three times a day, 3 days a week for 8 weeks)~perform joint mobilization device treatment for patients with frozen shoulders (The treatment time was total of 30 minutes. Three times a week for 8 continuous weeks.)"
89568688|NCT04802213|Experimental|Rehabilitation exercise +joint mobilization device treatment + laser acupuncture device treatment|"perform rehabilitation exercise for patients with frozen shoulders (10 repetitions of each exercise, three times a day, 3 days a week for 8 weeks)~perform joint mobilization device treatment for patients with frozen shoulders (The treatment time was total of 30 minutes. Three times a week for 8 continuous weeks.)~perform laser acupuncture device treatment for patients with frozen shoulders ( three sessions per week for 8 consecutive weeks. patients in each treatment session received laser at a dosage of 4 joules/cm2 for the eight chosen position. )"
89568689|NCT05211609|Experimental|Plasmatic 3-O-Methyldopa Level|Prevalence of High Plasmatic 3-O-Methyldopa Level in a Specific Population of Patients With a Symptomatology Compatible With AADC Deficiency (Aromatic L-Amino Acid Decarboxylase)
89568690|NCT05615987|Active Comparator|Classic injection|200iu/2ml OnabotulinumtoxinA in total to 2-4 points proximal to the gastrocnemius muscle
89568691|NCT05615987|Experimental|İnjection along the length of the muscle|A total of 200iu/2ml of onabotulinumtoxinA by spreading along the length of the gastrocnemius muscle
89568692|NCT05478135|Experimental|NAVIFY Oncology Hub|We will first conduct a small number of simulation sessions (3-5) to validate study methods and data collection procedures. Study methods may then be refined before conducting simulation sessions with a larger number of participants (approx. 25). In this phase, each participant will participate in a 90-minute simulation session in which they will use NAVIFY Oncology Hub to review synthetic patient cases. Participants will be tasked with reviewing the cases as if they were preparing to see a patient in a real clinical setting.
89568693|NCT03069157|No Intervention|Without lung recruitment maneuver|patient ventilation will be maintained After induction of anesthesia all patients will be ventilated using pressure controlled mode targeting tidal volume 6-8 ml/kg with inspiratory to expiratory ( I: E) ratio 1:1.5 without recruitment but with PEEP 5cm H2O.
89568694|NCT03069157|Active Comparator|recruitment group|lung recruitment manoeuvre will be performed in patients using continuous positive airway pressure( CPAP) (30) cm H2O for (40) seconds after induction of anesthesia then patient will be converted to pressure controlled mode again with PEEP 5 cm H2O.
88970026|NCT05072730|Experimental|Super high-pressure balloon (OPN NC)|Patients will be treated with a Super High Pressure percutaneous transluminal coronary angioplasty (PTCA) Balloon (OPN NC).
88970027|NCT05072730|Experimental|Intravascular lithotripsy (IVL)|Patients will be treated with intravascular lithotripsy (IVL).
88970028|NCT05065736|Experimental|18F-Clofarabine|18F-Clofarabine as PET imaging agent for measuring the activity of deoxycytidine kinase (DCK) in various normal and abnormal tissues in cancer participants before and after therapy
88970029|NCT05062356|Experimental|Suprainguinal fascia iliaca compartment block (FICB)|Suprainguinal fascia iliaca compartment block (FICB) is a technique that involves injection of local anesthetics underneath the fascia of the iliacus muscle to block the femoral nerve, the lateral femoral cutaneous nerve and, possibly, the obturator nerve.
89028375|NCT05143944||Nice clinical guidelines for intrapartum care for healthy women and babies|define gold standards in intrapartum care for healthy women and babies
89568695|NCT05107557|Experimental|Experimental Group|The experimental group is also called the combined immunization group.260 participants will receive the first dose of COVID-19 vaccine and EV71 vaccine on day 0 and the second dose of COVID-19 vaccine and EV71 vaccine on day 28.
89568696|NCT05107557|Active Comparator|Control Group|The control group is also called the Non-combined immunization group.260 participants will receive the first dose of COVID-19 vaccine on day 0,the first dose of EV71 vaccine on day 14,the second dose of COVID-19 vaccine on day 28 and the second dose of EV71 vaccine on day 42.
89568697|NCT02594735|Other|Open Label (One Arm)|A patient's participation in this study will last approximately 24 weeks ( screening visit and 5 intervention visits) with possible extension to 48 weeks. At screening, participants will have a physical exam, muscle strength assessment, blood and urine collection, and chest x-ray; they will also be asked to complete several questionnaires. All participants will receive each week subcutaneous injection of Abatacept. During intervention phase of the trial, muscle strength testing, physical exam, disease activity measurements, blood and urine collection, and muscle MRI will be performed. Participants will also be asked to complete several questionnaires. Participants will be also monitored closely for for serious drug related side effects.
89568698|NCT03645499|Experimental|Topical TA-102 A|A thin layer of the study medication will be applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily
89568699|NCT03645499|Experimental|Topical TA-102 B|A thin layer of the study medication will be applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily
89568700|NCT03645499|Experimental|Topical TA-102 C|A thin layer of the study medication will be applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily
89568701|NCT03645499|Experimental|Topical TA-102 D|A thin layer of the study medication will be applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily
89568702|NCT03645499|Experimental|Topical TA-102 E|A thin layer of the study medication will be applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily
89568703|NCT04793243|Experimental|Intervention group|Formed by 22 patients that received oral supplementation of 10,000 IU daily for fourteen days of vitamin D3
89568704|NCT04793243|No Intervention|Control group|Formed by 20 patients that did not receive supplementation
89568705|NCT05158569|Experimental|Slow breathing exercise group|Slow breathing 5-6 breaths/minute, 3 sets of 5 minutes 2 times/day for 4 weeks.
89568706|NCT05158569|Experimental|Diaphragmatic breathing exercise group|Diaphragmatic breathing, 3 sets of 5 minutes 2 times/day for 4 weeks.
89568707|NCT05472467|Experimental|Immunotherapy combined with Stereotactic Body Radiation Therapy|"Camrelizumab： 200mg IV Q3W~Chemotherapy：Squamous carcinoma: docetaxel 60 mg/m2, d1 + cisplatin 25 mg/m2, d1-3 or carboplatin AUC=4-6 d1, 21 days for one cycle, up to 4 cycles.~Non-squamous carcinoma: pemetrexed 500 mg/m2, d1 + cisplatin 25 mg/m2, d1-3 or carboplatin AUC=4-6, d1,21 days for one cycle, up to 4 cycles.~Stereotactic Body Radiation Therapy(SBRT) for Oligometastatic the total dose 35Gy/5f(7.0Gy/f,5f per week)。"
89568708|NCT04760639||Test group|Participants who have a positive Covid-19 Test or negative Covid-19 test who provide a breath sample.
89568709|NCT04793165|Experimental|Non-hybrid closed-loop system|"To compare two types of treatments:~During the first 3 days: Previous or conventional, with CSII plus CGM in open loop.~During the second 3 day period: AP with CSII plus CGM in a closed-loop system, through the ARG algorithm."
89568710|NCT05634265|Experimental|Pilot|Participants will be offered the Vijana-SMART WhatsApp group intervention
89568711|NCT05157711|Experimental|Anusol ointment|Anusol ointment (Zinc oxide [10.75g], Bismuth subgallate [2.25 g], Balsam peru [1.875 g], Bismuth oxide [0.875 g] in each 100g of ointment).
89568712|NCT05157711|Active Comparator|Benchmark|RELIEF® rectal ointment (phenylephrine hydrochloride 2.5mg/g), marketed
89568713|NCT05157711|Placebo Comparator|Placebo|Anusol ointment after the removal of the active ingredients
89568714|NCT04793321|Other|healty nulliparous females|"each participant did three conditions:~holding nothing (unloaded).~holding an infant mannequin in arms(arms).~holding an infant mannequin in the baby carrier(carriers)."
89568715|NCT05105997|Active Comparator|Dexamethasone/ Erector Spinae Plane Block|Patients will receive bilateral Ultrasound-guided Erector Spinae Plane Block with bupivacaine and dexamethasone 15 minutes before skin incision.
89568716|NCT05105997|Placebo Comparator|Erector Spinae Plane Block|Patients will receive bilateral Ultrasound-guided Erector Spinae Plane Block with bupivacaine and one ml of normal saline 15 minutes before skin incision.
89568717|NCT04801433|Experimental|Boleda Supramolecular Active Zinc|Boleda Supramolecular Active Zinc (Shanghai Ruizhi Pharmaceutical Technology Co., Ltd.): 30ml/bottle. Once a day for 4 weeks, apply topically to the scalp psoriasis area, gently massage for 15 minutes then rinse off with warm water.
88970030|NCT05062356|Active Comparator|Pericapsular nerve group block (PENG)|The pericapsular nerve group block (PENG) is a technique that involves injection of local anesthetic in the musculofascial plane between the psoas muscle and the superior pubic ramus.
88970031|NCT05062356|Sham Comparator|Local analgesia infiltration (LAI)|local anesthetic infiltration (LAI) into the anterior pericapsular tissues
88970032|NCT05062356|Sham Comparator|No adjunct: spinal anaesthesia (control)|Standard spinal anesthesia technique
88970033|NCT05058430|Experimental|Subjects with xerostomia|"The primary objective of this research is to assess the human factors in relabeling the SaliPen from a prescription-based device to an OTC.~Primary performance endpoints:~The user can select the device properly.~The user can use the device as instructed in the IFU."
88970034|NCT05058430|Active Comparator|Subjects without xerostomia|"The primary objective of this research is to assess the human factors in relabeling the SaliPen from a prescription-based device to an OTC.~Primary performance endpoints:~• The user can select the device properly."
88970035|NCT05056727|Experimental|Sodium Zirconium Cyclosilicate (SZC)|SZC 5 g every other day to 15 g once daily + Lisinopril/Valsartan
88970036|NCT05056727|Placebo Comparator|Placebo|Placebo + Lisinopril/Valsartan
88970037|NCT05046353|Experimental|D-serine|Subjects will receive 16 sessions of auditory remediation paired with either D-serine or Placebo in a 1:1 D-serine 120 mg/kg:placebo ratio.
88970038|NCT05046353|Placebo Comparator|placebo|Subjects will receive 16 sessions of auditory remediation paired with either D-serine or Placebo in a 1:1 D-serine 120 mg/kg:placebo ratio.
88970039|NCT05028569|Experimental|BOTOX Dose A|Participants will receive BOTOX Dose A on Week 0 and Week 12. Eligible participants will receive BOTOX Dose A on Week 24 and Week 36.
88970040|NCT05028569|Experimental|BOTOX Dose B|Participants will receive BOTOX Dose B on Week 0 and Week 12. Eligible participants will receive BOTOX Dose A on Week 24 and Week 36.
88970041|NCT05028569|Placebo Comparator|Placebo|Participants will receive placebo on Week 0 and Week 12. Eligible participants will receive BOTOX Dose A on Week 24 and Week 36.
89568718|NCT04801433|Active Comparator|Capotetriol scalp solution|30ml/bottle. Two times a day for 4 weeks, topically applied to scalp psoriasis.
88970042|NCT05025774||Case|Adolescent or young adult acute lymphoblastic leukemia survivor, OR living with chronic lung disease of prematurity, OR living with heart transplant
88970043|NCT05025774||Control|14-25 years old healthy individuals who are ambulatory without assistance. We may enroll younger subjects but we wish to subjects to match our patient population
88970044|NCT05018286|Experimental|Apraglutide subcutaneous (SC) injections, once weekly|Peptide analogue of Glucagon-like Peptide 2 (GLP-2)
88970045|NCT05015855|Placebo Comparator|OBGYN-PrEP|OBGYN-PrEP has 4 parts: (1) prioritize PrEP; (2) train providers in PrEP and intervention; (3) identify PrEP-appropriate women through a risk screen; and (4) monitor progress and fidelity to protocol.
88970046|NCT05015855|Experimental|NP-PC PrEP|NP-PC PrEP incorporates the standard of care and practices in OBGYN-PrEP but enhances access to additional skilled providers, as the PrEP provider burden is shifted to a Nurse Practitioner (NP) who will use a sex-positive approach to deliver PrEP services via telemedicine
88970047|NCT05011864|Experimental|Tele-Behavioral Activation and Fall Prevention|Each subject will participate in five 1-hour, weekly Tele-BA sessions followed by four 1-1.5 hour, weekly in-home FP sessions with the same provider
88970048|NCT05011864|Experimental|Tele-Behavioral Activation|Each subject in this arm will participate in five 1-hour, weekly Tele-BA sessions followed by four weekly check-in (booster) calls of up to 30 minutes each.
88970049|NCT05011864|Experimental|Fall Prevention|Each subject will participate in four 1-1.5 hour, weekly in-home (or tele, if COVID continues) FP sessions followed by four weekly check-in (booster) calls of up to 30 minutes each.
89532142|NCT06337643|Experimental|MVX01 Vaccine or Placebo - Cohort 3|MVX01 Vaccine: liquid formulation, 0.5 mL intramuscular injection, 60 μg, or Placebo: liquid formulation, 0.5 mL intramuscular injection Frequency: 2 doses administered approximately 1 month apart Age: 18-50 years
88970050|NCT05011864|Active Comparator|Attention Control (Telephone Support Call)|AC participants in this study will receive five weekly telephone calls of up to 45 minutes each and four weekly check-in calls of up to 30 minutes each from a research assistant (RA) who will employ genuine regard and attentive listening and provide nonspecific support.
89532143|NCT06337643|Experimental|MVX01 Vaccine or Placebo - Cohort 4|MVX01 Vaccine: liquid formulation, 0.5 mL intramuscular injection, 90 μg, or Placebo: liquid formulation, 0.5 mL intramuscular injection Frequency: 2 doses administered approximately 1 month apart Age: 18-50 years
89532144|NCT06337643|Experimental|MVX01 Vaccine or Placebo - Cohort 5|MVX01 Vaccine: liquid formulation, 0.5 mL intramuscular injection, 90 μg, or Placebo: liquid formulation, 0.5 mL intramuscular injection Frequency: 2 doses administered approximately 1 month apart Age: 60-75 years
89532145|NCT06337630|Experimental|Single arm: treatment with PLX038 and Tuvusertib|"Dose escalation step Dose escalation will be conducted on the grid defined by the 4 doses of PLX038 (800 mg/m², 1000 mg/m², 1300 mg/m² and 1700 mg/m² IV every 21 days D1=D22) and 3 doses of Tuvusertib (90 mg, 130 mg and 180 mg QD for 10 days from D3, D3-12). Premedication with anti-emetic agents is not required prior to the initial infusion, but may be used for an individual patient, as needed.~Expansion cohorts Two expansion cohorts are planned, investigating the efficacy and safety in pre-specified populations of interest.~Patients will be treated at the RP2D; 25 evaluable patients are needed in each cohort, to account for possible non evaluable patients, up to 28 patients will be enrolled in each cohort.~Patients enrolled in the phase I part at the RP2D and fulfilling the eligibility criteria of one of the expansion cohorts will be counted in those 25 evaluable patients."
89532146|NCT06337617||Cohort A (mucosal melanoma patients)|
89532147|NCT06337617||Cohort B (non-mucosal melanoma patients)|
89532148|NCT06337604|Experimental|Study Group|Rabeprazole Sodium Enteric-coated Tablets 20 mg + TNP-2092 Capsules 300 mg (n = 10)
89532149|NCT06337604|Placebo Comparator|Control Group|Rabeprazole Sodium Enteric-coated Tablets 20 mg + TNP-2092 capsules placebo (n = 10)
89532150|NCT06337591||patients with suspected primary bladder tumour (TV) at cystoscopy|
89532151|NCT06337578||Patients with amyotrophic lateral sclerosis (ALS)|Individuals having been received a clinical diagnosis of amyotrophic lateral sclerosis according to current diagnostic criteria
89532152|NCT06337578||Patients with Alzheimer's disease (AD)|Individuals having been received a neurochemical and/or aclinical diagnosis of Alzheimer's according to current diagnostic criteria
89532153|NCT06337578||Patients with Lewy body dementia (LBD)|Individuals having been received a clinical diagnosis of Lewy body dementia according to current diagnostic criteria
89532154|NCT06337578||Patients with frontotemporal dementia (FTD)|Individuals having been received a clinical diagnosis of frontotemporal dementia (i.e., behavioural variant-frontotemporal dementia; semantic dementia; progressive non-fluent aphasia) according to current diagnostic criteria
89532155|NCT06337578||Patients with chronic cerebrovascular disorders (CVD)|Individuals with mild cognitive impairment/dementia and neuroradiological evidence of chronic cerebrovascular diseases
89532156|NCT06337578||Normotypical individuals (NI)|Individuals without brain disorders
89532157|NCT06337552|Experimental|FEED-FF|"Participants will be asked to pick up the fermented foods at the Research Kitchen at Moffitt. Participants will be asked to eat 3-6 servings of FFs per day, from 1 week prior to treatment start through 12 weeks after treatment start/until the restaging scope is completed.~At baseline, the end of week 6.5 and again at week 12.5, participants will be asked to provide biospecimens including a stool sample collected at home and a blood specimen collected in clinic.~Participants will be asked to complete a food frequency questionnaire, a quality-of-life survey, two symptom related surveys, and a stool collection questionnaire at these same timepoints.~After the dietary intervention, participants will be asked to complete an exit survey to provide feedback on the study and intervention."
89532158|NCT06337552|Active Comparator|Standard of Care (SUC)|"Participants will receive general healthy eating handouts similar to current usual care documents provided in clinic.~These handouts will detail typical healthy foods and the suggested level of intake, or servings per day.~At baseline, the end of week 6.5 and again at week 12.5, participants will be asked to provide biospecimens including a stool sample collected at home and a blood specimen collected in clinic. Participants will be asked to complete a food frequency questionnaire, a quality-of-life survey, two symptom related surveys, and a stool collection questionnaire at these same timepoints."
89568719|NCT04801433|Placebo Comparator|Supramolecular Hydrogel|30ml/bottle. Once a day for 4 weeks, apply topically to the scalp psoriasis area, gently massage for 15 minutes then rinse off with warm water.
89568720|NCT05105607|Experimental|Cohort 1: 0.25 mg/kg D-4517.2|Participants will be administered a single dose of 0.25 mg/kg D-4517.2. A sentinel participant will be enrolled for each cohort. After the sentinel participant completes Day 3, the safety review committee (SRC) will determine if it is safe to continue with the enrollment of the remaining 3 participants in the cohort. The SRC will also determine the dose escalation to the next cohort.
89568721|NCT05105607|Experimental|Cohort 2: 0.5 mg/kg D-4517.2|Participants will be administered a single dose of 0.5 mg/kg D-4517.2. A sentinel participant will be enrolled for each cohort. After the sentinel participant completes Day 3, the SRC will determine if it is safe to continue with the enrollment of the remaining 3 participants in the cohort. The SRC will also determine the dose escalation to the next cohort.
89568722|NCT05105607|Experimental|Cohort 3: 1.0 mg/kg D-4517.2|Participants will be administered a single dose of 1.0 mg/kg D-4517.2. A sentinel participant will be enrolled for each cohort. After the sentinel participant completes Day 3, the SRC will determine if it is safe to continue with the enrollment of the remaining 3 participants in the cohort. The SRC will also determine the dose escalation to the next cohort.
89568723|NCT05105607|Experimental|Cohort 4: 2.0 mg/kg D-4517.2|Participants will be administered a single dose of 2.0 mg/kg D-4517.2. A sentinel participant will be enrolled for each cohort. After the sentinel participant completes Day 3, the SRC will determine if it is safe to continue with the enrollment of the remaining 3 participants in the cohort.
89568724|NCT05206383|Experimental|Positive message|Group A - 30 subjects who will be told that positive message.
89568725|NCT05206383|Experimental|Negative message|Group B - 30 subjects who will be told negative message.
89568726|NCT05206383|Experimental|Neutral message|Group C - 30 people who will be told neutral message.
89568727|NCT04421781||Salvage HIFU for local recurrence after prostatectomy and EBRT|Between July 2005 and November 2018, at Edouard Herriot Hospital (Lyon, France), 22 consecutive patients were treated with S-HIFU for a local recurrence after RP and salvage or adjuvant EBRT. The oncological outcomes (treatment failure-free survival, progression-free survival), the adverse events and urinary incontinence were retrospectively reviewed.
89568728|NCT04801511|Experimental|Experimental|"Preoperative concurrent chemoradiotherapy and high-dose intravenous vitamin C :~The eligible subjects will be treated with concurrent chemoradiotherapy and high-dose intravenous vitamin C preoperatively. IMRT will be delivered to PTV-CTV (plan target volume-clinical target volume) with a dose of 45Gy/25fraction/5weeks. If necessary. During IMRT, 2-3 cycles of concurrent chemotherapy (mFOLFOX6) will be delivered. High-dose intravenous vitamin C ( 24g/d，QD ) will be delivered on the day of radiotherapy from the beginning to the end of IMRT.~preoperative consolidation chemotherapy: Three additional cycles of neoadjuvant chemotherapy (mFOLFOX6) will be given after the end of IMRT.~TME （total mesorectal excision）or sphincter preserving surgery will be performed approximately the 10th-12th weeks after the end of IMRT. Whether or not to select watch and wait needs to refer to the tumor location, tumor regression, surgeon's opinion and patient's will."
89568729|NCT05471765|Experimental|Moderate Obstructive Sleep Apnea|Patients whom have an apnea/hypopnea index above fifteen are classified to have moderate obstructive sleep apnea
89568730|NCT05471765|Experimental|Severe Obstructive Sleep Apnea|Patients whom have an apnea/hypopnea index with a result higher than thirty are considered to have severe obstructive sleep apnea
89568731|NCT05156229|Experimental|CDK-003|CDK-003 administered subcutaneously every 2 weeks.
89028376|NCT05143944||performance in the care provided to patients in periods of audit|measure performance in the care provided to the patients in the period of audit
89568732|NCT03069235|Active Comparator|Standard of Care|group/individual counselling.
89568733|NCT03069235|Experimental|Family member / peer support|Structured family member / peer support.
89568734|NCT03069235|Experimental|Special infant feeding counselor support|Enhanced intervention with counselor support
89568735|NCT04793009||mesh group|patients undergoing abdominoperineal resection with end colostomy and implantation of a prophylactic, funnel-shaped, intraperitoneal mesh
89568736|NCT04793009||no-mesh group|patients undergoing abdominoperineal resection with end colostomy without implantation of a prophylactic, funnel-shaped, intraperitoneal mesh
89568737|NCT05615909||Online MR-guided radiotherapy|Prostate cancer patients treated with online MR-guided radiotherapy in the Unity MR-linac.
89568738|NCT05615909||CT-guided radiotherapy|Prostate cancer patients treated with CT-guided radiotherapy (VMAT) in linear accerelators.
89568739|NCT05471687|Experimental|Patients with CAC ≥ 300 three years ago|Patients with CAC ≥ 300 three years ago with the need for repeat screening. Adult asymptomatic diabetic patients whose risk of ischemic complications is considered major in primary prevention due to a calcium score >300 AU and requiring iterative screening for IMS recommended every 3 at 5 years.
89568740|NCT05471687|Experimental|Patients with CAC between 200-299 three years ago|"Patients with CAC between 200 and 299 three years ago, with the need for a reassessment of their cardiovascular risk.~Adult asymptomatic diabetic patients whose risk of ischemic complications is considered major in primary prevention due to a calcium score that has become pathological > 300 AU during the reassessment of their cardiovascular risk."
88811047|NCT04609410|Experimental|Deep neuromuscular blockade|"During surgery, deep neuromuscular blockade will be achieved with the use of train of four (TOF) monitoring, aiming for a Post-Tetanic Count (PTC) = 0 or PTC = 1 and Train of Four Count (TOFC) = 0. TOF and PTC measurements will be performed every 15 minutes. Boluses of 0,1 mg/kg Rocuronium will be administered if monitored PTC is > 1.~Complete neuromuscular blockade reversal at the end of surgery will be achieved with an i.v. bolus of Sugammadex (variable dose according to depth of residual blockade) if TOF ratio is ≤ 0.9. If TOF ratio is > 0.9, pharmacological neuromuscular blockade reversal can be avoided."
89028377|NCT00495053|Experimental|hMaxi-K 5000 µg/mL|5000 micrograms (µg)/90 milliliter (mL) intravesical instillation
89028378|NCT00495053|Experimental|hMaxi-K 10000 µg/mL|10000 µg/90 mL intravesical instillation
89028379|NCT00495053|Placebo Comparator|Placebo|Matching placebo (PBS-20% sucrose)
89028380|NCT05143515|Experimental|PACE Label group|This group used the PACE label plus calorie label to help participants to know about the number of minutes of walking or running required to burn off the calories in food and drinks.
89208758|NCT00977847|Experimental|Internet Portal Practice|Patients in this practice will receive the informational letter either by email or mail one month before their scheduled visit. It will have directions to access the MFHP website and how to transfer data through the hospitals secure internet portal (Patient Gateway). About 1/3 of patients are signed up to use this service. Those who do not have a Patient Gateway account will be provided with directions on how to establish this service. Patients will be required to have a Gateway account to ensure that the MFHP data file is sent securely to the correct EHR record. Patients in this arm will receive an initial email or letter with a single follow-up reminder sent 2 weeks later. For patients who participate, the completed family history data will be transmitted to the patient's EHR.
89568741|NCT05471687|Experimental|Patients with a recent positive scintigraphy (< three months)|Patients with a recent positive scintigraphy (< three months) requiring coronary angiography Stable symptomatic diabetic adult patients, suspected of coronary insufficiency in whom the assessment included a positive scintigraphy with indication of coronary angiography in the perspective of revascularization.
89208759|NCT00977847|Active Comparator|Usual Care Physician Assesment Practice|Usual standard family history assessments will be conducted by physicians during the patient visit. This arm will allow us to account for any temporal trends in family history assessment.
89208760|NCT02595203|Experimental|Part A: Cohort 1|Participants receive a single intravenous (IV) dose of 240 mg/3.7 megabecquerel (MBq) of [14C-pos 1]-Debio 1450 BES solution.
89028381|NCT05143515|No Intervention|Calorie Label group|This group used only calorie labels to show the number of calories in food and drinks.
89028382|NCT00495092|Experimental|1|This study arm will receive caffeine+placebo
89568742|NCT04230369|Experimental|Internet-CBT|The internet-CBT will comprise 8 weekly modules with therapist-support, encouraging exposure for fear of asthma symptoms while ensuring a stable asthma medication through a written medical plan on medical adherence Participants work independently from home with the treatment and receive weekly support from their psychologist through written messages online.
89568743|NCT04230369|Other|Treatment as usual|Patients randomized to treatment as usual will receive the same medical information that participants in the Internet-CBT get, with physiological information about asthma and the importance of medical adherence to achieve well controlled asthma, but without the exposure-based treatment and no therapist support. All participants in both conditions can use any other available treatment, but psychological, from pre-assessments to 2 months after treatment completion. Participants in this arm will be crossed over to Internet-CBT after the primary endpoint at to 2 months follow up.
89568744|NCT03068845|Experimental|Drug-eluting Balloon Angioplasty (DEBA)|After predilatation of the target lesion with conventional balloon angioplasty, a drug-eluting balloon will be inflated to an appropriate inflation pressure, but not exceeding the rated burst pressure of the balloon, for at least a minute.
89568745|NCT03068845|Active Comparator|Conventional Balloon Angioplasty (CBA)|The target lesion will be dilated with a conventional angioplasty balloon to an appropriate inflation pressure, but not exceeding the rated burst pressure of the balloon, for at least a minute.
89568746|NCT05370729|Experimental|N-acetyl cysteine (NAC)|Conservative management + ILE infusion 10 ml/hr + N-acetyl cysteine (NAC) infusion 150 mg/kg body weight in 200 ml of 5% dextrose over 1 h, followed by 50 mg/kg body weight in 500 ml of 5% dextrose over 4 h, and then 100 mg/kg body weight in 1000 ml of 5% dextrose over 16 h.
89568747|NCT05370729|No Intervention|Intra lipid emulsion (ILE)|Conservative management + ILE infusion 10 ml/hr + normal saline infusion
89568748|NCT05471531|Experimental|Combined immunization group|160 subjects received one dose of quadrivalent influenza vaccine and one dose of 23-valent pneumococcal polysaccharide vaccine on day 0.
89568749|NCT05471531|Experimental|Non combined immunization group|There were two subgroups in non combined immunization group,and 160 subjects in each subgroup.The non combined immunization subgroup 1 received one dose of quadrivalent influenza vaccine on day 0 and one dose of 23-valent pneumococcal polysaccharide vaccine on day 28.The non combined immunization subgroup 2 received one dose of 23-valent pneumococcal polysaccharide vaccine on day 0 and one dose of quadrivalent influenza vaccine on day 28.
89568750|NCT05471531|Experimental|Safety group|2520 subjects were enrolled and received one dose of quadrivalent influenza vaccine and one dose of 23-valent pneumococcal polysaccharide vaccine on day 0.
89568751|NCT04426331|No Intervention|No Voucher|"Individuals being referred from screening events randomized to no intervention received the standard approach to offering free follow-up examinations (patient education, standard counseling, appointment information packet, reminder phone calls)."
89568752|NCT04426331|Experimental|Voucher Without Value Information|"In addition to receiving the standard approach above, individuals being referred from screening events randomized to Voucher Without Value Information received a personal voucher."
89568753|NCT04426331|Experimental|Voucher With Value Information|"In addition to receiving the standard approach above, individuals being referred from screening events randomized to Voucher With Value Information received a personal voucher, which differed from the voucher in the second arm since it included a statement of value."
89568754|NCT05104671|Active Comparator|Scapular stabilization exercises|Group I (control group) will receive scapular stabilization exercises.
89568755|NCT05104671|Experimental|Thoracic manipulation.|Group II will receive scapular stabilization exercises and thoracic manipulation.
89568756|NCT05104671|Experimental|Myofascial release|Group III will receive scapular stabilization exercises and myofascial release by instrument assisted soft tissue mobilization techniques.
89568757|NCT04792619|Experimental|Control|
89568758|NCT04792619|Active Comparator|Study|
89568759|NCT04801199|Experimental|CPL-2009-0031 140 mg|Single dose, Oral tablet containing 140 mg of CPL-2009-0031, Once daily for 36-weeks
89568760|NCT04801199|Active Comparator|Sitagliptin 100 mg|Single dose, Oral tablet containing 100 mg of Sitagliptin, Once daily for 36-weeks
89568761|NCT05102877|Experimental|Sensory level stimulation|ten, 45-minute anterior neck sensory level electrical stimulation sessions in addition to traditional dysphagia therapy.
89568762|NCT05102877|Experimental|Motor level stimulation|ten, 45-minute anterior neck sensory level electrical stimulation sessions in addition to traditional dysphagia therapy.
89208761|NCT02595203|Experimental|Part A: Cohort 2|Participants receive a single oral dose of 240 mg/3.7 MBq of [14C-pos 1]-Debio 1450 BES solution.
89208762|NCT02595203|Experimental|Part B: Cohort 3|Participants receive a single oral dose of 240 mg Debio 1450/37 kilobecquerel (kBq) of [14C-pos 25]-Debio 1450 BES solution.
89208763|NCT04828746|No Intervention|Control|Patients who will undergo lumbar puncture without pre-procedural ultrasound-guided skin marking
89208764|NCT04828746|Experimental|Experimental|Patients who will undergo lumbar puncture after pre-procedural ultrasound-guided skin marking
89208765|NCT00789620|Active Comparator|1|Lidocaine 1% administrated as a bolus of 1.5 mg/kg, then intraoperative 2mg/kg/h and postoperative 1.3mg/kg/h during 24 h
89208766|NCT00789620|Placebo Comparator|2|NaCl 0.9% as a bolus 1.5mg/kg, then intraoperative 2mg/kg/h and postoperative 1.3mg/kg/h during 24h
89208767|NCT00981279||HIV seroposite patients|Seroposite HIV patients that take their treatment at the Clinical Hospital of The Federal University of Goias, and have their records in the hospital.
89208768|NCT00803894|Active Comparator|A|MK0752 1000 mg
89208769|NCT00803894|Active Comparator|B|MK0752 350 mg
89028383|NCT00495092|Experimental|2|this study arm will receive Caffeine+Biperiden
89568763|NCT05154357|Experimental|Group 1|Half an hour before the first feeding hour, the infant's heart rate and oxygen saturation will be recorded. Then, he/she will be placed in the elastic sac, positioned and will be allowed to take a rest until the feeding hour for 30 minutes. His/her physiological parameters will be recorded ten minutes before the feeding time, during feeding and ten minutes after feeding. When the feeding time begins, the chronometer will be started and it will be stopped when feeding is completed. At the second feeding time, the infant's heart rate and oxygen saturation will be recorded half an hour before the feeding hour. Then, he/she will be positioned without performing any different application and will be allowed to take a rest until the feeding time. His/her physiological parameters will be recorded ten minutes before the feeding time, during feeding and ten minutes after feeding. When feeding begins, the chronometer will be started and when it is over, the chronometer will be stopped.
89568764|NCT05154357|Experimental|Group 2|Half an hour before the first feeding time of the infant, his/her heart rate and oxygen saturation will be recorded. Then, he/she will be positioned without performing any different application and will be allowed to take a rest until the feeding time. His/her physiological parameters will be recorded ten minutes before the feeding hour, during feeding and ten minutes after feeding. When feeding begins, the chronometer will be started and when it is over, the chronometer will be stopped. At the second feeding hour, the infant's heart rate and oxygen saturation will be recorded half an hour before the feeding hour. Then, he/she will be placed in the elastic sac, positioned, and allowed to take a rest until the feeding hour. His/her physiological parameters will be recorded ten minutes before the feeding hour, during feeding and ten minutes after feeding. When feeding begins, the chronometer will be started and when it is over, the chronometer will be stopped.
89568765|NCT05153421|Experimental|All'InCath CBC 035M Balloon Dilatation Catheter|Peripheral Vasculature Percutaneous Transluminal Angioplasty and Control Angiography with single balloon dilatation catheter.
89568766|NCT05203575|No Intervention|Control|Control condition
89568767|NCT05203575|Experimental|Weekly nudge in Cycle 2|Weekly nudge intervention in Cycle 2
89568768|NCT05203575|Experimental|Fast-forwarding|Fast-forwarding interventions in both Cycles
89568769|NCT05203575|Experimental|Fast-forwarding with weekly nudge in Cycle 2|Fast-forwarding interventions in both Cycles, plus weekly nudge intervention in Cycle 2
89568770|NCT05203575|Experimental|Weekly nudge in Cycle 1|Weekly nudge intervention in Cycle 1
89568771|NCT05203575|Experimental|Weekly nudge|Weekly nudge interventions in both Cycles
89568772|NCT05203575|Experimental|Fast-forwarding with weekly nudge in Cycle 1|Fast-forwarding interventions in both Cycles, plus weekly nudge intervention in Cycle 1
89568773|NCT05203575|Experimental|Full intervention|All interventions applied in all Cycles
89568774|NCT05203575|Experimental|Fast-forwarding in Cycle 1|Fast-forwarding intervention in Cycle 1
89568775|NCT05203575|Experimental|Full in Cycle 1|Fast-forwarding and weekly nudge interventions in Cycle 1
89028384|NCT00495092|Placebo Comparator|3|this study arm will receive placebo+placebo
89028385|NCT05143359|Experimental|Wharfe and Pederson difficulty index|Assessment of Difficulty in third molar extraction using Wharfe and Pederson difficulty index
89208770|NCT00803894|Placebo Comparator|C|Placebo
89208771|NCT05371925|Active Comparator|Sulodexide group|the participant will receive one Sulodexide capsule of 250LRU twice a day for 8 weeks
89208772|NCT05371925|Placebo Comparator|control group|the participant will receive on placebo capsule twice a day for 8 weeks of same appearance as IMP
89208773|NCT00985023|Active Comparator|Steel screw fixation|
89208774|NCT00985023|Experimental|Bioabsorbable screw fixation|
89208775|NCT00797420|Other|Loading Dose|Loading Dose
89208776|NCT00797420|Other|Loading & high dose|Loading dose & high dose Fluconazole
89208777|NCT00981513|Active Comparator|Influenza vaccination|Live attenuated influenza vaccine (seasonal and pandemic strains) by nasal spray
89208778|NCT00981513|Placebo Comparator|Saline placebo|Saline nasal spray
89208779|NCT00872274|Experimental|1|sumatriptan succinate tablets 100 mg (containing sumatriptan succinate equivalent to 100 mg of sumatriptan) manufactured by OHM Laboratories In
89208780|NCT00872274|Active Comparator|2|IMITREX® 100 mg tablets (containing sumatriptan succinate equivalent to 100 mg of sumatriptan)
89208781|NCT00734747|Experimental|Medigus SRS Endoscopic Stapling System|Endoluminal fundoplication for the treatment of GERD
89208782|NCT00805688||Symptom Study|Questionnaires + Blood Draw + Pedometer used to learn about symptoms related to chemotherapy and the disease, in patients with advanced pancreatic cancer.
89208783|NCT00985101||diabetes no complications|
89208784|NCT00985101||diabetes with complications|
89208785|NCT00880308|Experimental|LDE225|
89208786|NCT00797498||Xerostomia Questionnaire|All of the tests, procedures and treatments may be considered standard of care for someone with this type of cancer, except for the Xerostomia Questionnaire.
89208787|NCT04006899||subj 1|Three commercially available BIA devices vs SBIS device
89208788|NCT02595047|Experimental|tissue/ organ prefabrication|in vivo generation of autologous tissue for joint replacement
89568776|NCT05445791|Placebo Comparator|Placebo|Patients randomized to this study arm will be treated with tyrosine kinase inhibitors (Gefitinib 250 mg/day; afatinib 30-40 mg/day; erlotinib 150 mg/day) plus placebo 500 mg twice daily until disease progression.
89568777|NCT05445791|Experimental|Metformin|Patients randomized to this study arm will be treated with tyrosine kinase inhibitors (Gefitinib 250 mg/day; afatinib 30-40 mg/day; erlotinib 150 mg/day) plus metformin 500 mg twice daily until disease progression.
89568778|NCT04801277|Active Comparator|Acupuncture on PC6 and LI4|Acupuncture on bilateral acupoints, that are PC6 and LI4. The pericardium meridian PC6 point (Neiguan) is defined as follows. The patient's four fingerbreadths will be placed on the medial aspect of their forearm with the edge of the 4th finger on the wrist crease. This is then subtracted from the width of the interphalangeal joint of her thumb. The point between the tendons of extensor carpi radialis and palmaris longus was the pericardium meridian PC6 point (Neiguan). The large intestine LI4 point (Hegu) located on the dorsum of the hand, between the first and second metacarpal bones, at the midpoint of the second metacarpal bone and close to its radial border.
89568779|NCT04801277|Sham Comparator|Acupuncture on Sham acupoints|Acupuncture on bilateral non acupoints. In sham/placebo group, patient will have the acupuncture needles inserted at non-acupoint 2cm radial to PC6 and between 2nd and 3rd metacarpal bone bilaterally, superficial skin piercing (adequate depth to let patient feels needle is inserted)
89568780|NCT05150457|Experimental|Dose Escalation Phase, Dose Level 1|"Starting dose level of BNA035 administered as an IV infusion once weekly in 28 day cycles.~Drug: BNA035 Administered once weekly as an IV infusion at the assigned dose level in 28 day cycles"
89568781|NCT05150457|Experimental|Dose Escalation Phase, Dose Level 2|3 times the starting dose level of BNA035 administered as an IV infusion once weekly in 28 day cycles Drug: BNA035 Administered once weekly as an IV infusion at the assigned dose level in 28 day cycles
89568782|NCT05150457|Experimental|Dose Escalation Phase, Dose Level 3|10 times the starting dose level of BNA035 administered as an IV infusion once weekly in 28 day cycles Drug: BNA035 Administered once weekly as an IV infusion at the assigned dose level in 28 day cycles
89568783|NCT05150457|Experimental|Dose Escalation Phase, Dose Level 4|30 times the starting dose level of BNA035 administered as an IV infusion once weekly in 28 day cycles Drug: BNA035 Administered once weekly as an IV infusion at the assigned dose level in 28 day cycles
89568784|NCT05150457|Experimental|Dose Escalation Phase, Dose Level 5|100 times the starting dose level of BNA035 administered as an IV infusion once weekly in 28 day cycles Drug: BNA035 Administered once weekly as an IV infusion at the assigned dose level in 28 day cycles
89568785|NCT05150457|Experimental|Dose Escalation Phase, Dose Level 6|200 times the starting dose level of BNA035 administered as an IV infusion once weekly in 28 day cycles Drug: BNA035 Administered once weekly as an IV infusion at the assigned dose level in 28 day cycles
89568786|NCT04792229|Experimental|Experimental Group|"Standing on WBV device (frequency of 40 Hz); 3 Minute vibration with 3 minute rest.~Three times repetition . Total 18-minute vibrational therapy protocol. 3 days session per week"
89568787|NCT04792229|Active Comparator|Control Group|"Stretching exercise (hip adductors ,plantar flexors, external rotators of hip & knee flexors).~Active and passive ROMS to lower extremities. Strengthening exercises (hip and knee extensors, ankle dorsiflexes) 3 Repetitions into 3 day session per week"
89568788|NCT05102175||African American adults with poor sleep|Individuals with self-identified poor sleep quality and/or quantity
89568789|NCT04800653|Experimental|Stellate ganglion block|Before the operation, the left stellate ganglion block was performed, and 0.375% ropivacaine 5ml was injected into the stellate ganglion.
89568790|NCT04800653|No Intervention|Control|Do nothing
89208789|NCT00985179|Experimental|Intervention Group (IG)|Employees in the IG will receive an interactive, computerized expert system which tailors treatment components to the individual needs of them
89568791|NCT05203263|Experimental|Condition 1 : Prototype (810A-v1) and Frequency of application 1|Application of the prototype (810A-v1) at Day 0, Day 1, Day 2, Day 3, Day 4 and Day 5.
89568792|NCT05203263|Experimental|Condition 2 :Prototype (810B-v1) and Frequency of application 1|Application of the prototype (810B-v1) at Day 0, Day 1, Day 2, Day 3, Day 4 and Day 5.
89568793|NCT05203263|Experimental|Condition 3 : Prototype (810A-v1) and Frequency of application 2|Application of the prototype (810A-v1) at Day 0, Day 7, Day 14, Day 21, Day 28 and Day 35.
89568794|NCT05203263|Experimental|Condition 4 : Prototype (810C-v1) and Frequency of application 2|Application of the prototype (810C-v1) at Day 0, Day 7, Day 14, Day 21, Day 28 and Day 35.
89568795|NCT05203263|Active Comparator|Condition 5 : Prototype (810C-v1) and Frequency of application 3|Application of the prototype (810C-v1) at Day 0, Day 14, Day 28, Day 42, Day 56 and Day 70.
89568796|NCT04792307|Other|Neuromuscular electrical stimulation (NMES) to one leg|"NMES left leg, no high protein ice cream supplementation~NMES right leg, no high protein ice cream supplementation"
89208790|NCT00985179|No Intervention|Waiting control group (WCG)|
89028386|NCT05143359|Active Comparator|Winters difficulty index|Assessment of Difficulty in third molar extraction using Winters difficulty index
89028387|NCT05143320||Covid+|
89028388|NCT05143320||Covid-|
89568797|NCT04792307|Other|High protein ice cream supplementation|"NMES left leg, high protein ice cream supplementation~NMES right leg, high protein ice cream supplementation"
89568798|NCT05101473|Experimental|Exercise therapy|Exercises will be performed with minimal weight bearing on foot soles, as recommended in the literature for people with diabetic peripheral neuropathy.
89568799|NCT04800419|Experimental|Acceptance and Commitment Therapy (ACT)|ACT will be conducted in a group of 10 for each session. The ACT modules covered over 8 sessions, 1 hour in each session. The sessions will be held every week according to the patient's appointment date for chemotherapy treatment.
89208791|NCT00797576||1/Cases|Subjects whom had cardioversion aborted due to LAA thrombus or suspicion of LAA thrombus on TEE.
89208792|NCT00797576||2/Controls|Subjects with underlying atrial fibrillation undergoing elective TEE as clinically indicated for any reason.
89208793|NCT00872586|Experimental|1|Olmesartan medoxomil and hydrochlorothiazide
89208794|NCT00872586|Active Comparator|2|olmesartan medoxomil
89208795|NCT00726557||PegIntron + Rebetol|There will be a distinction between the patients depending on the type of substitution drug used (secondary parameters).
89568800|NCT04800419|Experimental|Mindfulness-based Stress Reduction (MBSR)|MBSR will be conducted in a group of 10 for each session. The MBSR modules covered over 8 sessions, 1 hour in each session. The sessions will be held every week according to the patient's appointment date for chemotherapy treatment.
89568801|NCT04800419|No Intervention|Control|The subjects in the control group will be assigned in the wait-list where either ACT or MBSR will be provided after the study has been completed.
89568802|NCT05100537|Experimental|Mindfulness Based Stress Reduction|The Mindfulness Based Stress Reduction program is a manualized course that includes meditation, relaxing movement, and breathing. A certified MBSR instructor will teach the courses in a group-based format for 120 minute sessions, once per week for eight weeks.
89568803|NCT05100537|Active Comparator|CONTROL GROUP|no intervention
89568804|NCT04800575|Experimental|Semi-permeable film dressing|Experiment group use semi-permeable film as dressing in exit-site of CVC and dressings will be changed per hemodialysis session, or whenever the dressing is soiled, bloody, or fell off.
89568805|NCT04800575|Other|sterile gauze and tape dressing|Control group use sterile gauze and tape as dressing in exit-site of CVC and dressings will be changed per hemodialysis session, or or whenever the dressing is soiled, bloody, or fell off.
89568806|NCT05203029|Experimental|Aerobic exercises|The warm-up for 5 minutes; stretching exercises include stretching the neck to the sides, stretching the muscles of the shoulder girdle, back, and legs for 10 minutes; resistance exercises for 15 minutes, which will initially be applied in a light and weight-bearing manner, and in each session, according to the patient's progress, using free lightweights; light aerobic exercise for 10 minutes standing, sitting and lying down by controlling patients' heartbeat; cool down for 5 minutes.
89568807|NCT05203029|Experimental|Laughter yoga|Breathing techniques for 20 minutes including deep breathing, diaphragmatic breathing, tap on immune-boosting centers like thymus; laughter concert for 20 minutes such as laughter for no reason, childish movements, release the inner child; and laughter meditation for 5 minutes.
89568808|NCT05203029|Active Comparator|Yoga|Meditation and deep breathing for 10 minutes; physical posture for 15 minutes; 15 minutes relaxation exercises; and 5 minutes mindfulness practices.
89568809|NCT04349111|Other|Experimental: Intra-operative Radiation Therapy - IORT|Intra-operative Radiation Therapy
89568810|NCT02634151|Placebo Comparator|Placebo|Participants on stable statin therapy received matching placebo orally, once daily for 12 weeks.
89568811|NCT02634151|Experimental|Gemcabene 600 mg|Participants on stable statin therapy received 600 milligrams (mg) of Gemcabene orally, once daily for 12 weeks.
89568812|NCT04799951||Breast Surgeon|surgeons having experience in and regularly conducting breast conservation surgery and mastectomy surgeries
89568813|NCT05202639||Continuation of pregnancy|The parents who have chosen to continue pregnancy will be asked to complete a questionnaire.
89568814|NCT05202639||Medical termination of pregnancy|The parents who have chosen to terminate pregnancy will be asked to complete a questionnaire.
89568815|NCT05147337|Experimental|Cohort 1: E2511 10 mg or Placebo|Non-Japanese adult (greater than or equal to [>=] 18 years and less than [<] 55 years old) participants will receive 10 milligram (mg) E2511 or E2511 matched placebo, tablets, orally, once daily from Day 1 to Day 14.
89568816|NCT05147337|Experimental|Cohort 2: E2511 20 mg or Placebo|Non-Japanese adult participants will receive 20 mg E2511 or E2511 matched placebo, tablets, orally, once daily from Day 1 to Day 14.
89208796|NCT00977925|Experimental|Fibrin Pad|
89208797|NCT00977925|Active Comparator|Standard of Care|
89208798|NCT00803972|Experimental|Stage 1: 3 U insulin plus rHuPH20|Participants will receive 3 Units (U) of regular insulin (100 U/milliliter [mL]), coadministered with sequential concentrations of 0, 1.25, 5, 10, 20, and 80 micrograms (μg)/mL recombinant human hyaluronidase (rHuPH20).
89568817|NCT05147337|Experimental|Cohort 3: E2511 40 mg or Placebo|Non-Japanese adult participants will receive 40 mg E2511 or E2511 matched placebo, tablets, orally, once daily from Day 1 to Day 14.
89568818|NCT05147337|Experimental|Cohort 4: E2511 80 mg or Placebo|Non-Japanese adult participants will receive 80 mg E2511 or E2511 matched placebo, tablets, orally, once daily from Day 1 to Day 14.
89568819|NCT05147337|Experimental|Cohort 5: E2511 20 mg or Placebo|Japanese adult (>=20 years and <55 years old) participants will receive 20 mg E2511 or E2511 matched placebo, tablets, orally, once daily from Day 1 to Day 14.
89568820|NCT05147337|Experimental|Cohort 6: E2511 40 mg or Placebo|Japanese adult participants will receive 40 mg E2511 or E2511 matched placebo, tablets, orally, once daily from Day 1 to Day 14.
89568821|NCT05147337|Experimental|Cohort 7: E2511 80 mg or Placebo|Japanese adult participants will receive 80 mg E2511 or E2511 matched placebo, tablets, orally, once daily from Day 1 to Day 14.
89568822|NCT05147337|Experimental|Cohort 8: E2511 40 mg or Placebo|Non-Japanese older (>=55 years and less than or equal to [<=] 85 years old) participants will receive 40 mg E2511 or E2511 matched placebo, tablets, orally, once daily from Day 1 to Day 14.
89568823|NCT04791605|Experimental|Gait analysis of cemented total hip|Gait analysis of acute collum femoris fracture patient randomized to cemented stem
89568824|NCT04791605|Experimental|Gait analysis of non-cemented total hip|Gait analysis of acute collum femoris fracture patient randomized to non-cemented stem
89568825|NCT04791683|No Intervention|Control|Infertile couples in the control group were selected by randomization, routine protocols in the clinic were applied
89208799|NCT00803972|Experimental|Stage 1: 12 U insulin plus rHuPH20|Participants will receive 12 U of regular insulin (100 U/mL), coadministered with sequential concentrations of 0, 1.25, 5, 10, 20, and 80 μg/mL rHuPH20.
89208800|NCT00803972|Experimental|Stage 2: insulin plus rHuPH20|Participants will receive 6, 12, and 24 U regular insulin (100 U/mL) in a randomly assigned order, with each insulin dose administered once with and once without 5 μg/mL rHuPH20.
89028389|NCT01244360|Placebo Comparator|Sugar Pill|Subject will take placebo for daily for 4 weeks, with optional additional 4 week treatment period.
89028390|NCT01244360|Active Comparator|Dietary Supplement: resveratrol|Subject will take resveratrol supplement for 4 weeks, with optional additional 4 week treatment period.
89568826|NCT04791683|Experimental|Experimental|"st interview: Application of data collection tools~nd meeting: Sexual counseling (1 week after the first interview)~rd interview: Sexual counseling (1 week after the first session)~th meeting: Sexual counseling (1 week after the second session)~th interview: Telephone interview (2 months after the first assessment)~th interview: re-application of data collection tools, including the final evaluation"
89568827|NCT05145699|Experimental|Right hemispheric stroke with hemineglect|
89568828|NCT05145699|Active Comparator|Right hemispheric stroke without hemineglect|
89568829|NCT05145699|Other|Normal people|
89568830|NCT04799561|Experimental|Teleprehabilitation cohort|Patients in this single-arm study will receive multimodal teleprehabilitation.
89568831|NCT05199519|Other|IBI345|Single arm
89568832|NCT04799639|Experimental|paclitaxel + cisplantin + Sindilimab|standard dose paclitaxel + cisplantin + Sindilimab every 3 weeks for 3 cycles paclitaxel 150mg/m2，ivdrip,>3 hours cisplantin 70mg/m2，ivdrip，>1 hours Sindilimab 200mg，ivdrip, >0.5 hours
89568833|NCT05614973|Active Comparator|Conventional|Percutaneous liver biopsy is carried out through multiple punctures of liver capsule.
89568834|NCT05614973|Experimental|Coaxial/plugging|Percutaneous liver biopsy is carried out through single puncture of liver capsule using coaxial needle and subsequent needle tract plugging.
89208801|NCT00803972|Experimental|Stage 3: 1.5 U insulin lispro plus rHuPH20|Participants will receive 1.5 U of insulin lispro (50 U/mL), coadministered with sequential concentrations of 0, 0.0625, 0.3125, 1.25, 5, and 20 μg/mL rHuPH20.
89208802|NCT00803972|Experimental|Stage 3: 6 U insulin lispro plus rHuPH20|Participants will receive 6 U of insulin lispro (50 U/mL), coadministered with sequential concentrations of 0, 0.0625, 0.3125, 1.25, 5, and 20 μg/mL rHuPH20.
89208803|NCT00803972|Experimental|Stage 4: 95 U/mL insulin lispro plus 5 μg/mL rHuPH20|Participants will receive 95 U/mL insulin lispro, administered once with and once without 5 μg/mL rHuPH20. At each insulin lispro concentration, participants will receive 2, 6, and 20 U lispro.
89208804|NCT00803972|Experimental|Stage 4: 50 U/mL insulin lispro plus 5 μg/mL rHuPH20|Participants will receive 50 U/mL insulin lispro, administered once with and once without 5 μg/mL rHuPH20. At each insulin lispro concentration, participants will receive 2, 6, and 20 U lispro.
89208805|NCT00803972|Experimental|Stage 4: 25 U/mL insulin lispro plus 5 μg/mL rHuPH20|Participants will receive 25 U/mL insulin lispro, administered once with and once without 5 μg/mL rHuPH20. At each insulin lispro concentration, participants will receive 2, 6, and 20 U lispro.
89208806|NCT00880386|Experimental|Losartan Group|50 mg Losartan tablet taken daily for 24 weeks
89208807|NCT00978081|Experimental|Arm I|Patients receive oral aminolevulinic acid and then undergo continuous photodynamic therapy 4-6 hours later.
89208808|NCT00978081|Experimental|Arm II|Patients receive aminolevulinic acid as in arm I and then undergo fractionated photodynamic therapy 4-6 hours later.
89208809|NCT00804050|Experimental|Infusion A: rEPO|rEPO for 4 mounths consequently
89208810|NCT00804050|Experimental|Infusion B combined r-EPO|rEPO in association with acid 13-cis-retinoic acid and Dihydroxyvitamin D3 for 4 mounths consequently
89028391|NCT00497900|Experimental|1|Calcium and vitamin D
89028392|NCT00497900|Placebo Comparator|2|Calcium and placebo (cellulose)
89028393|NCT05143125|Experimental|Treatment group|Decitabine combined with NK cell infusion as post-remission therapy
89028394|NCT01244555|Experimental|Massage treatment|
89208811|NCT00877734|Experimental|1|Baclofen
89028395|NCT01244555|Experimental|Ultrasound|
89028396|NCT01244555|No Intervention|Wait-list|
89208812|NCT00877734|Placebo Comparator|2|Placebo
89208813|NCT00981591|Experimental|Inhaled Iloprost|
89208814|NCT00981591|Placebo Comparator|Inhaled Placebo|
89208815|NCT00805844||1|Spine surgery with Motor Evoked Potential monitoring without SedLine monitoring visible.
89208816|NCT00805844||2|Spine surgery with Motor Evoked Potential Monitoring with SedLine monitoring visible.
89208817|NCT04545216||UT4M 40|athletes participating to the 40 km mountain race.
89208818|NCT04545216||UT4M 160|athletes participating to the 160 km mountain race.
89208819|NCT04545216||UTV 55|athletes participating to the 55 km mountain race.
89208820|NCT00978159|Active Comparator|esomeprazole|esomeprazole 20 mg
89208821|NCT00978159|Active Comparator|Famotidine|famotidine 40 mg
89208822|NCT00804206|Experimental|Group A|Bevacizumab before panretinal photocoagulation.
89208823|NCT00804206|Experimental|Group B|Bevacizumab after panretinal photocoagulation
89208824|NCT00877812|Experimental|Arm 1 glycine and leucine infusion|Determine in healthy, adequately pyridoxine nourished humans using a protocol based on amino acid glycine tracer methods: (a) the postprandial rates of in vivo glycine turnover, glycine-based generation of one-carbon units, thymidylate and purine synthesis, and the impact of vitamin B6 deficiency on the rates of these processes and (b) the effect of vitamin B6 deficiency on the postprandial rate of glutathione synthesis. 14 subjects will be chosen after screening is complete and will begin a B6 deficient diet for 30 days. At the beginning and end of the 30 days they will receive an infusion of leucine and glycine then they will begin the four week diet. At the end of four weeks the infusion will be repeated.
89568835|NCT04799093||Cannabis users|
89568836|NCT04799093||Normals|
89568837|NCT04790981|Active Comparator|selected physical therapy program group|The Control group received the selected physical therapy program for one hour, three times weekly for three successive months including facilitation of balance and protective reactions from standing position, standing on one leg, weight shifting from standing, squat to standing, strengthening exercises for trunk muscles and for upper and lower extremities musculatures, gait training activities for correction of gait pattern
89568838|NCT04790981|Active Comparator|motor imaginary training and selected physical therapy program group|"The study group received the selected physical therapy program for one hour, three times weekly for three successive months in addition to motor imagery program for 30 minutes as the following.~Each child shown a video of 5 minutes of illustrating normal movements while the child resting in semi-reclined sitting in quiet room in front the screen. Children then asked to close their eyes and imagine practicing the task like the illustrative video. Repetition of the exercises depend on the children ranging from 5 to 10 repetitions per exercise"
89568839|NCT03068689|Experimental|Intervention (RIPC)|RIPC treatment prior to partial nephrectomy.
89208825|NCT00877812|Experimental|Arm 2 Intervention of Serine and methionine infusion|This arm will allow investigation of total Hcy remethylation and remethylation from serine-derived 1C units, kinetics of serine and the methionine cycle and kinetics of transsulfuration reactions. 14 healthy subjects will be selected and screened. Prior to starting a B6 deficient diet for four weeks an infusion of serine and methionine will commence. Following the first infusion the diet will begin and after four weeks another infusion will be done.
89208826|NCT00981903|Experimental|VTE Treatment Group|
89208827|NCT00981903|No Intervention|Control|
89208828|NCT00738881|Experimental|Arm I (erlotinib hydrochloride)|Patients receive erlotinib hydrochloride PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89208829|NCT00738881|Experimental|Arm II (pemetrexed disodium)|Patients receive pemetrexed disodium IV over 10 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89208830|NCT00797654|Experimental|1|Participants will receive pre and post HIV-test counseling and an information-motivation-behavior skills training combined with cognitive processing therapy
89568840|NCT03068689|Placebo Comparator|Placebo Control|Placebo prior to partial nephrectomy.
89568841|NCT04798937|Experimental|Intervention group|Youth in this group received usual care, consisting of medical consultations, in combination with a health education program based on motivational interviewing provided by a nurse
89568842|NCT04798937|No Intervention|Control group|Youth in this group received usual care only consisting of medical consultations
89568843|NCT05629897|Experimental|Intervention|They will perform an initial test of processing speed, attentional span and executive control. After this test, they will start the training programme. It consists of 40 sessions of cognitive stimulation, distributed over 8 weeks of treatment with a frequency of five sessions per week. In the last session, a final test will be performed, the same as the initial one.
89568844|NCT05629897|No Intervention|Waiting list|"They will perform an initial test of processing speed, attentional span and executive control. In the last session, 8 weeks after the initial test, a final test will be performed, the same as the initial one.~They will have the opportunity to perform the same training as the experimental group after performing the final test. At 8 weeks, patients on the waiting list will be taught, if the wish, how to use the platform to perform the stimulation. They will be offered cognitive training with COPERIA-COG under the same conditions, periodicity, automatic reminders and calls from the psychologist as in the intervention group."
89568845|NCT05154539|Experimental|Test Group 1 (TG1)|"TG1 participants are testing the new digital assessment routine in a private setting.~Audiology assistants in private hearing clinics located in the Region of Northern Jutland in Denmark are performing the standardized examination packages. The private hearing clinics also conduct hearing aid treatment for TG1 participants with simple hearing loss.~TG21 participants with complicated hearing loss or ear-related diseases are referred to the Department of Audiology at Aalborg University Hospital for further examination prior to treatment initiation."
89208831|NCT00797654|Active Comparator|2|Participants will receive pre and post HIV-test counseling
89568846|NCT05154539|Experimental|Test Group 2 (TG2)|"TG2 participants are testing the new digital assessment routine in a public setting.~Audiology assistants in public hearing clinics located in the Region of Northern Jutland in Denmark are performing the standardized examination packages. The public hearing clinics also conduct hearing aid treatment for TG2 participants with simple hearing loss.~TG2 participants with complicated hearing loss or ear-related diseases are referred to the Department of Audiology at Aalborg University Hospital for further examination prior to treatment initiation."
89208832|NCT00877968|Placebo Comparator|Whole wheat banana bread|Banana bread made with whole wheat flour
89208833|NCT00877968|Active Comparator|Whole pea flour banana bread|Banana bread made with whole pea flour
89208834|NCT00877968|Placebo Comparator|Whole wheat biscotti|Biscotti made with whole wheat flour
89208835|NCT00877968|Active Comparator|Whole pea biscotti|Biscotti made with whole pea flour
89208836|NCT00877968|Placebo Comparator|Whole wheat pasta|Pasta made with whole wheat durum
89208837|NCT00877968|Active Comparator|Whole pea flour|Pasta made with 30% whole pea flour and 70% white wheat durum
89208838|NCT00877968|Placebo Comparator|White bread|
89208839|NCT00877968|Placebo Comparator|Boiled yellow peas|
89208840|NCT00878046|Experimental|DePuy Silent™ Hip femoral prosthesis|A short cementless, femoral component for use in total hip arthroplasty
89208841|NCT00657020|Experimental|Nicotine lozenge|Nicotine lozenge containing 4 mg of nicotine to be placed in mouth and suck to dissolution.
89208842|NCT00657020|Placebo Comparator|Placebo lozenge|Placebo lozenge to be placed in mouth and suck to dissolution.
89208843|NCT04773288|Experimental|Live feedback provided on display during handwashing|
89208844|NCT04773288|No Intervention|No live feedback provided during handwashing|
89208845|NCT03921723|Experimental|Subject receiving Dolutegravir 10 mg|Subject will receive a prototype equivalent to DTG 10 mg liquid formulation in period 1, a prototype equivalent to DTG 10 mg liquid formulation in period 2, a DTG 10 mg dispersible tablet in Period 3, each period will be separated by washout period of >= 7 days, if required a prototype equivalent to DTG 10 mg liquid formulation in period 4, a prototype equivalent to DTG 10 mg liquid formulation in period 5, and a prototype equivalent to DTG 10 mg liquid formulation in period 6 will be evaluated.
89208846|NCT00872664|Active Comparator|formula with added carotenoids|Both arms are double-blinded. Infant will be assigned to receive preterm formula with added carotenoids. If infant is receiving human milk then the study formula will only be used as a supplement.
89208847|NCT00872664|Active Comparator|formula without added carotenoids|Both arms are double-blinded. This arm will use preterm formula as it is currently available, which is without any carotenoids. If the infant is receiving human milk, then the formula will be used as a supplement as needed.
89208848|NCT00872742|Experimental|1|Participants will receive acceptance enhanced behavior therapy (AEBT) for trichotillomania (TTM).
89208849|NCT00872742|Active Comparator|2|Participants will receive psychoeducation and supportive therapy (PST) for TTM.
89568847|NCT05154539|Active Comparator|Control Group 3 (CG3)|"CG3 participants will be assessed conventionally by a private practicing ENT specialist in the Region of Northern Jutland in Denmark at physical consultation in accordance with current Danish practice. CG3 participants with simple hearing loss can choose whether hearing aid treatment should be conducted in either a private or a public hearing clinic.~CG3 participants with complicated hearing loss or ear-related diseases are referred to the Department of Audiology at Aalborg University Hospital for further examination prior to treatment initiation."
89568848|NCT04798703|Experimental|ONCOFID-P-B™ (PACLITAXEL-HYALURONIC ACID)|
89568849|NCT04798313|Experimental|MW031|MW031 injection (60mg) by subcutaneous injection once on the first day of treatment.
89568850|NCT04798313|Active Comparator|Prolia®|Prolia® injection (60mg) by subcutaneous injection once on the first day of treatment.
89568851|NCT01655823|Placebo Comparator|Placebo (twice daily)|Placebo for injection (1 ml volume), twice a day for four consecutive days.
89568852|NCT01655823|Experimental|Low dose Tetrodotoxin (twice daily)|Low dose Tetrodotoxin injectable (1 ml volume), twice a day for four consecutive days.
89568853|NCT01655823|Experimental|Mid-range dose of Tetrodotoxin (twice daily)|Mid-range dose Tetrodotoxin injectable (1 ml volume), twice a day for four consecutive days.
89568854|NCT01655823|Experimental|Max dose Tetrodotoxin (once daily)|Max dose Tetrodotoxin injectable (1 ml volume), once a day in the morning for four consecutive days and Placebo for injection (1 ml volume), once a day in the afternoon for four consecutive days. Total of 4 treatment days.
89568855|NCT01655823|Experimental|Max dose Tetrodotoxin (twice daily)|Max dose Tetrodotoxin injectable (1 ml volume), twice a day for four consecutive days.
89568856|NCT01360645|Experimental|Phase B|"Drug: OPC-34712 + ADT~Drug: Placebo + ADT"
89568857|NCT01360645|Placebo Comparator|Phase A|Intervention: Drug: Placebo + ADT
89568858|NCT05132855|Experimental|Booster group 1 (BNT162b2 30ug)|The participants in this group will receive BNT162b2 30ug as the booster dose.
89568859|NCT05132855|Experimental|Booster group 2 (mRNA-1273 50ug)|The participants in this group will receive mRNA-1273 50ug as the booster dose.
89568860|NCT05132855|Experimental|Booster group 3 (mRNA-1273 100ug)|The participants in this group will receive mRNA-1273 100ug as the booster dose.
89568861|NCT05132855|Experimental|Booster group 4 (MVC-COV1901 15ug)|The participants in this group will receive MCV COVID-19 vaccine 15ug as the booster dose.
89568862|NCT05141799|Active Comparator|high-intensity laser therapy (HILT)|"we will apply the HILT device to the most painful area of the wrist in two phases. In both phase I and phase II, the laser will be applied using continuous circular movements.~The first three sessions (phase I) will be used to provide analgesic effects at an intermittent phase, applying a 75 sec, 8 W, 6 J/cm2 treatment for a total of 150 J of energy. The subsequent six sessions (phase II) will provide a biostimulatory effect at a continuous phase, applying a 30 sec, 6 W, 120 to 150 J/cm2 treatment. The HILT will be applied for a total of nine treatment sessions over a period of three consecutive weeks."
89208850|NCT05056155|Experimental|Systane Complete|First dose of Systane Complete in both eyes on Day 0, followed by Systane Complete self-administered 4 times daily for 28 days
89208851|NCT00878124|Experimental|CoQ10|Coenzyme Q10 co-treatment
89208852|NCT00878124|Placebo Comparator|Placebo control|Placebo Co-treatment
89208853|NCT00978237|Active Comparator|EFV and Fixed combinations of analogues|EFV + Fixed combinations of analogue tenofovir + emtricitabine, or abacavir + lamivudine
89208854|NCT00978237|Experimental|LPV/r and combination of analogues.|
89208855|NCT00872820|Active Comparator|1|Participants will receive standard cognitive behavioral therapy.
89208856|NCT00872820|Experimental|2|Participants will receive acceptance- and commitment-based behavioral therapy.
89208857|NCT00872820|No Intervention|3|Participants will be placed on a waitlist for 3 months before being offered treatment.
89208858|NCT00978315|Active Comparator|Vigantol oil|Vigantol oil will be administered in 2-monthly oral bolus doses over a period of one year
89568863|NCT05141799|Sham Comparator|sham HILT|We will apply the HILT device to the most painful area of the wrist by using continuous circular movements, but the laser instrument will switched off during applications. The sham HILT will be applied for a total of nine treatment sessions over a period of three consecutive weeks.
89568864|NCT05105711|Experimental|Primary care providers|Providers who treat 11-12 year old adolescent patients in participating Kaiser Permanente Washington pediatric and family medicine practices.
89208859|NCT00978315|Placebo Comparator|Miglyol oil|Miglyol oil will be administered in 2-monthly oral bolus doses over a period of one year
89208860|NCT00878202|No Intervention|Control|Optimal medical treatment of Heart failure and therapeutic education
89208861|NCT00878202|Experimental|Telemedicine|Optimal medical treatment of heart failure disease and therapeutic education
89208862|NCT00978393|Experimental|A|
89208863|NCT00978393|Experimental|B|
89208864|NCT00978393|Experimental|C|
89208865|NCT00978393|Experimental|D|
89208866|NCT00978393|Experimental|E|
89208867|NCT00978393|Experimental|F|
89208868|NCT04040010|Experimental|Postmenopausal women colostrum supplement|
89208869|NCT04040010|Experimental|Osteoporosis patients colostrum supplement|
89208870|NCT04040010|Experimental|Osteopenia patients colostrum supplement|
89208871|NCT04040010|Placebo Comparator|Postmenopausal women placebo|
89208872|NCT04040010|Placebo Comparator|Osteoporosis patients placebo|
89208873|NCT04040010|Placebo Comparator|Osteopenia patients placebo|
89208874|NCT00878280||1|1:control(healthy subjects)
89208875|NCT00878280||2|2:case(dementia patients)
89208876|NCT00872976|Experimental|Cohort #1|
89208877|NCT00872976|Experimental|Cohort #2|
89208878|NCT00544167|Experimental|Intervention|All patients received doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 (AC) both administered intravenously day 1 every 3 weeks for four cycles, followed by paclitaxel 175 mg/m2 intravenously day 1 every 3 weeks for four cycles or 80 mg/m2 for twelve weeks (physician discretion), combined with sorafenib 400 mg orally twice daily. Sorafenib was held during radiation therapy where indicated and resumed once completed. Sorafenib was continued for a total of 12 months and in combination with adjuvant hormonal therapy where indicated.
89208879|NCT00659438|Experimental|1|Bicalutamide 150mg + ZD6474 300mg
89568865|NCT04345289|Active Comparator|Convalescent plasma|Will receive active treatment with convalescent anti-SARS-CoV-2 plasma (600 ml) as a single dose iv infusion in addition to standard care.
89568866|NCT04345289|Placebo Comparator|Infusion placebo|Will receive placebo treatment with saline 0.9% (2 x 300 ml) as an iv single dose infusion in addition to standard care.
89568867|NCT05195463|Experimental|First group|Core stabilization exercises
89568868|NCT05195463|Experimental|Second group|Combination of core stabilization and abdominal corset
89568869|NCT05195463|Experimental|Third group|Only abdominal corset
89568870|NCT04343105|Sham Comparator|sham group|will receive sham bilateral ultrasounded guided single shot pecto-intercostal plane block between 3rd and 4th rib 2 cm lateral to sternal border for each side after induction of anaesthesia in supine position
89568871|NCT04343105|Experimental|real group|will receive real bilateral ultrasounded guided single shot pecto-intercostal plane block between 3rd and 4th rib 2 cm lateral to sternal border for each side after induction of anaesthesia in supine position with 10 ml bupivacaine 0.5% + 10 ml lidocaine 2% in total volume 20 ml for each side.
89568872|NCT04342793|Placebo Comparator|Placebo|Placebo
89568873|NCT04342793|Experimental|ALS-L1023 1,200mg|ALS-L1023 600mg twice a day
89568874|NCT04342793|Experimental|ALS-L1023 1,800mg|ALS-L1023 900mg twice a day
89568875|NCT05095389|Experimental|Standard Care plus ARDCs|"All patients will undergo small volume liposuction, and adipose tissue harvested will be processed to ADRCs during same procedure.~All patients will receive standard care for their Diabetic Foot Ulcer.~Additionally, patients randomized to the ADRC arm will receive ADRCs"
89568876|NCT05095389|Active Comparator|Standard Care plus Placebo|"All patients will undergo small volume liposuction, and adipose tissue harvested will be processed to ADRCs during same procedure.~All patients will receive standard care for their Diabetic Foot Ulcer.~Additionally, patients randomized to the Control arm will receive Placebo"
89568877|NCT04790747|Experimental|radiotherapy and CAR-T therapy|sequential radiotherapy and CAR-T cell therapy
89568878|NCT03068221|Active Comparator|Poly Cystic Ovary Syndrome|anaerobic exercise in overweight patients with PCOS
89568879|NCT03068221|Active Comparator|non Poly Cystic Ovary Syndrome|anaerobic exercise in overweight patients without PCOS
89568880|NCT05181085|Active Comparator|NST 6179|double blind, single ascending and multiple ascending dose, sequential group design
89568881|NCT05181085|Placebo Comparator|Placebo|matched placebo arm
89568882|NCT05195385|Other|Procedure|Baseline low dose Ct acquisition, then at 1 year and 2 years to depict suspicious lung nodules
89208880|NCT00659438|Placebo Comparator|2|Bicalutamide 150mg + placebo
89568883|NCT05056103|Other|TrachFlush|
89568884|NCT04336163|Experimental|Prospective Study Group|For the experimental group, the laser surgeon will be exposed to the OCT measurements and will select laser settings and determine treatment parameters based on the measurements.
89568885|NCT04336163|Other|Prospective Control Group|For the control group, the laser surgeon will not be exposed to the OCT measurements and will select laser settings and determine treatment parameters based on standard of care, intuition, and experience.
89568886|NCT05139381||Treated with Mepolizumab|
89568887|NCT05614505|Active Comparator|RUTF standard|PlumpyNut
89568888|NCT05614505|Experimental|RUTF local_1|Soybean RUTF
89568889|NCT05614505|Experimental|RUTF local_2|Mungbean-thick RUTF
89568890|NCT05614505|Experimental|RUTF local_3|Mungbean-thin RUTF
89568891|NCT05614505|Experimental|RUTF local_4|Wafer RUTF
89568892|NCT04790591|Active Comparator|Age <80 yrs. and ASA class <3|To follow a same-day surgery protocol when undergoing a partial knee replacement procedure.
89568893|NCT04790591|Active Comparator|Age ≥80 yrs. and/or ASA class ≥3|To follow a same-day surgery protocol when undergoing a partial knee replacement procedure.
89568894|NCT02633527|Placebo Comparator|Placebo|Placebo, qd, oral capsule
89568895|NCT02633527|Experimental|100mg SPN-812|100mg SPN-812, qd, oral capsule
89568896|NCT02633527|Experimental|200mg SPN-812|200mg SPN-812, qd, oral capsule
89568897|NCT02633527|Experimental|300mg SPN-812|300mg SPN-812, qd, oral capsule
89568898|NCT02633527|Experimental|400mg SPN-812|400mg SPN-812, qd, oral capsule
89568899|NCT04790669|Experimental|Daily adjustable progressive resistance exercises (DAPRE)|DAPRE technique, hot pack, stretching exercises.
89568900|NCT04790669|Experimental|Close kinetic chain exercises (CKC).|CKC exercises, hot pack, stretching exercises
89568901|NCT05092971|Other|Clinic|Tasks to be completed in OP4 clinic
89568902|NCT05092971|Other|fMRI|Tasks to be completed in fMRI
89568903|NCT05092893||Children with Developmental Coordination Disorder|"INCLUSION:~Confirmed diagnosis of DCD~Comorbidities are allowed (f.e. ASD, ADHD, ADD,…)~EXCLUSION:~o Any other neurodevelopmental disorder which might affect motor development (f.e. CP)."
89568904|NCT01667549|Experimental|1M0.5|"Mothers will receive the intervention for 1 month beginning when their infant is 0.5 months old.~Intervention: Timing of Diet and Flavor Experience"
89568905|NCT01667549|Experimental|1M1.5|"Mothers will receive the intervention for 1 month beginning when their infant is 1.5 months old.~Intervention: Timing of Diet and Flavor Experience"
89568906|NCT01667549|Experimental|3M0.5|"Mothers will receive the intervention for 3 months beginning when their infant is 0.5 months old.~Intervention: Timing of Diet and Flavor Experience"
89568907|NCT01667549|No Intervention|Control|Mothers will not receive the intervention.
89568908|NCT05092581|Experimental|casirivimab+imdevimab|
89568909|NCT04790357|Other|Reference strategy|correspond to the reference techniques according to the current guidelines in the etiological work up of ischemic strokes and TIA
89568910|NCT04790357|Other|Evaluated strategy|correspond to perform the cci-MR: cardiac MRI with late-enhancement, angio-MRI of the cervical and intracranial arteries
89208881|NCT00878358|Active Comparator|Physiotherapy|
89208882|NCT00878358|Experimental|Hydrotherapy|
89568911|NCT05614427|Active Comparator|Anterior nasal swab|Lateral flow tests performed on anterior nasal swabs compared to routinely taken nose and throat swabs with RT-PCR
89568912|NCT05614427|Active Comparator|Buccal swab|Lateral flow tests performed on buccal swabs compared to routinely taken nose and throat swabs with RT-PCR
89208883|NCT00873054||1 ESWL|In this procedure,scope will be placed inside bladder and a plastic tube (stent) will be left to drain the kidney on the affected side in a routine manner. Next the patient will be transferred to a separate room and sound waves will be aimed at the center of the stone until the stone is broken into pieces.
89208884|NCT00873054||2 PCNL|In this procedure,scope will be placed inside bladder and a plastic tube (stent) will be left to drain the kidney on the affected side in a routine manner. Next, a small (1cm) cut will be made in the back and a tube will be placed into the kidney. Through this tube a small camera will be placed inside the kidney and break the stone into many pieces and remove them through the same tube. All fragments that can be seen will be removed. A different plastic tube (drain) will be placed through the cut and into the kidney and left in place for 5-7 days.
89208885|NCT02553200|Active Comparator|BreatheMAX (OPEP)|for 10 breathes/set, 10 sets/day and rest 1 minute between set
89568913|NCT04089371||Arm A Total Shoulder Arthroplasty / Hemiarthroplasty|Total Shoulder Arthroplasty (TSA) Humeral & Glenoid components as a Hemiarthroplasty or Total Shoulder Replacement.
89208886|NCT02553200|Experimental|BreatheMAX (OIS and OPEP)|for 10 breathes/set, 10 sets/day and rest 1 minute between set
89208887|NCT02553200|Sham Comparator|BreatheMAX (unload and non-oscillated)|inspiratory and expiratory breathing exercise for 10 breathes/set, 10 sets/day and rest 1 minute between set
89208888|NCT05225844|Experimental|Camrelizumab Plus Apatinib mesylate|for advanced gastric cancer with previous standard treatment failure
89208889|NCT05225844|Experimental|Camrelizumab and Apatinib mesylate|for advanced colorectal cancer with previous standard treatment failure
89208890|NCT00878514|Experimental|Alprazolam|Alprazolam 1 mg tablet
88970094|NCT04971252||Co existance of diabetes mellitus and chronic kidney disease|Study basic coagulation profile and platelet indices among those patients with combined diabetes mellitus and chronic kidney disease
88970095|NCT04971252||Diabetes mellitus without chronic kidney disease|Study basic coagulation profile and platelet indices among those patients with diabetes mellitus only
88970096|NCT04971252||Chronic kidney disease without diabetes mellitus|Study basic coagulation profile and platelet indices among those patients with chronic kidney disease without diabetes mellitus
88970097|NCT04968314||ChiPP Groups|Parents enroll in Chicago Parent Program groups offered at their child's school
89208891|NCT00878514|Active Comparator|Xanax|Xanax 1 mg tablet
89208892|NCT00804284||Pentacel Group|Infants initiated on PENTACEL® vaccine
89208893|NCT00804284||Other DTap vaccines Group|Infants initiated on other DTaP vaccines
89208894|NCT00804440|Active Comparator|Test Product|
89208895|NCT00804440|Active Comparator|Reference Product|
89208896|NCT00880854|Experimental|1|BCG 81 mg intravesical weekly x 6 beginning on week 1, and weekly x 3 beginning at week 15 in combination with CP-675,206 I.V. week 3, week 1
89208897|NCT03871868||study group|In Woman With Myoma Uteri
89208898|NCT03871868||control group|In Woman Without Myoma Uteri
89208899|NCT00873132||Data Collection|Collect data both retrospectively and prospectively on subjects seen at the Preston Robert Tisch Brain Tumor Center
89208900|NCT00804518|Experimental|Exercise intervention|
89208901|NCT00880932|Experimental|customized electronic alert|"This intervention was not targeted to patients with a disease but to the providers. The intervention was not a drug but a customized electronic alert, requesting the prescriber to specify a reason for override whenever the combination drugs of warfarin and NSAID were ordered together."
89568914|NCT04089371||Arm B Reverse Shoulder Arthroplasty|Reverse Shoulder Arthroplasty (RSA) Humeral & Glenoid Components as a primary, fracture or revision total shoulder replacement
89208902|NCT00880932|No Intervention|Standard practice|The control group was not patients but the providers. Providers in the control group continued with the standard practice of receiving passive alerts in the form of message boxes warning the provider not to prescribe the combination drugs warfarin and NSAID.
89208903|NCT00543855|Experimental|3 mg Donepezil hydrochloride|
89208904|NCT00543855|Experimental|5 mg Donepezil hydrochloride|
89208905|NCT00543855|Experimental|10 mg Donepezil hydrochloride|
89208906|NCT00543855|Placebo Comparator|Placebo|
89208907|NCT00797810|Experimental|therapy|
89208908|NCT03831048|Experimental|DCD Heart Possible|
89208909|NCT03831048|Active Comparator|Standard of Care Heart Only|
89208910|NCT00881010||Telephone Intervention|
89208911|NCT00881010||Usual Care|
89208912|NCT04921605|Experimental|Tricuspid regurgitation|Subjects received the Dragonfly system for the treatment of tricuspid regurgitation.
89208913|NCT00656474|Experimental|1|GLYC-101 Active Retro-auricular Site (1 per participant)
89208914|NCT00656474|Placebo Comparator|2 Comparator|"Placebo Retro-auricular Site (1 per participant)~This arm undergoes laser ablation with subsequent Placebo gel administration"
88970098|NCT04967196|Experimental|Cohort A (ipilimumab DC and IV, nivolumab) CLOSED|Patients receive ipilimumab intra-lymphatically via DoseConnect™ on day 1 of cycle 1 and IV over 30 minutes on day 1 of cycles 2-4. Patients also receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo lymphatic imaging with ICG prior to treatment start and blood sample collection throughout the study. (CLOSED TO ENROLLMENT)
88970099|NCT04967196|Experimental|Cohort B (Ipilimumab DC and nivolumab IV)|Patients receive ipilimumab intra-lymphatically via DoseConnect™ and nivolumab IV over 30 minutes on day 1 of each cycle. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection throughout the study and may optionally undergo lymphatic imaging with ICG prior to treatment start.
88970100|NCT04962737|Experimental|Non-invasive Neuromodulation|Non-invasive Neuromodulation Intervention with microcurrents: application of 6 electrodes per extremity and an adhesive electrode at C7 level.
88970101|NCT04960735|Experimental|Patients with cancer (patients with breast cancer and patients with lung cancer)|"Health-related Quality of Life evidence was collected from patients with cancer (patients with breast cancer and patients with lung cancer) for six months. The evidence was collected by means of health related and patient reported questionnaires (ICHOM standard sets for breast cancer and lung cancer).~Patients were monitored for six months. Intervention outcomes were monitored at different times: for patients with breast cancer, at the start (on recruitment which coincided with diagnosis) and at six months; for patients with lung cancer, at the start (on recruitment which coincided with diagnosis), at three and at six months."
88970102|NCT04958668|Active Comparator|Volatile procedere|Intensive care treatment with demand-adapted sedation with volatile anaesthetics
88970103|NCT04958668|No Intervention|Conventional procedere|Conventional Intensive care treatment with demand-adapted sedation with intravenous sedatives
88970104|NCT04957095||Parkinson's disease patients|This group consists of Parkinson's disease patients who are undergoing deep brain stimulation surgery for treatment of their movement disorder. Participants will complete behavioral assessments while receiving subcortical DBS stimulation and / or inhaled levodopa medication, Inbrija. Stimulation will be applied at the previously determined therapeutic frequency. Two capsules (84 mg) of Inbrija will be administered.
88970105|NCT04957095||Essential Tremor patients|This group consists of essential tremor patients who are undergoing deep brain stimulation for treatment of their movement disorder. Participants will complete behavioral assessments while receiving subcortical DBS stimulation. Stimulation will be applied at the previously determined therapeutic frequency.
88970106|NCT04952909|Experimental|ShortCut™|
89568915|NCT04010981|Experimental|study grup-Virtual reality- Nintendo Wii Fit exercise group|in this group patients will complete 12 sessions of virtual reality exercise - Nintendo Wii Fit Plus, 30-minute training sessions with strengthening exercises for the lower extremities and upper extremities, aerobic and balance exercises, two days a week. They will do 5 minute warm-up exercises before stretching, stretching exercises and 5 minute cooling exercises at the end of the session, as well as breathing exercises and will attend a total of 50 minutes of treatment.
89568916|NCT04010981|Active Comparator|control group-home based video exercise group|Patients will be join home based exercises two days a week during 12 sessions .we will prepare for the lower and upper extremity features similar to Nintendo Wii Fit exercises 30 minutes of video game exercise practices, 5 minutes warm-up exercises, 5 minutes cooling exercises and complete the 50-minute training session with the breathing exercises we will teach them. In addition to exercise sessions, patients will record their activities (walking, cycling, swimming ına) in daily life schedules with their pedometers. Thus, changes in physical activity levels will be monitored.
89568917|NCT05191017|Experimental|Phase 1b Dose Escalation|"NUV-422 will be administered orally at escalating dose levels in combination with enzalutamide until the recommended Phase 2 combination dose (RP2cD) is determined.~160 mg enzalutamide will be administered orally daily throughout the 28-day cycles of NUV-422."
89568918|NCT05191017|Experimental|Phase 2|"NUV-422 will be administered orally at the RP2cD in combination with enzalutamide.~160 mg enzalutamide will be administered orally daily throughout the 28-day cycles of NUV-422."
88970107|NCT04940546|Experimental|Sintilimab + XELOX + Bevacizumab|"Patients receive Sintilimab + XELOX regimen every 3 weeks for 4 cycles and Bevacizumab every 3 weeks for 2 cycles.~Details are as follows:~Sintilimab: 200mg intravenously, d1 Oxaliplatin: 135mg/m2 intravenously, d1 Capecitabine: 2g/m2 orally, d1-14 for Bevacizumab: 7.5mg/kg intravenously, d1~After neoadjuvant treatment, if there are no new lesions upon radiological and Multidisciplinary Team (MDT) assessment, radical surgery is performed within 6 weeks. If there are new lesions the surgical team will assess the optimal time for surgery.~After surgery 4 cycles of XELOX regimen is advised for adjuvant therapy."
88970108|NCT04925544|Experimental|VK-2019_arm|1800 mg VK 2019 once daily, cycles will be defined as 28 days of treatment, subjects will receive VK 2019 until progression or dose limiting toxicity, for up to 12 cycles.
88970109|NCT04925349||affected subjects|"adult patients with adrenomyeloneuropathy/adrenoleukodystrophy~children with adrenoleukodystrophy~children with metachromatic leukodystrophy"
88970110|NCT04925349||control subjects|-healthy children
88970111|NCT04923646|Experimental|Active|Primer
88970112|NCT04923646|No Intervention|Control|No Primer
89208915|NCT00873210||Patients treated with Sutent|125 consecutive patients in outpatient care with advanced or metastatic renal cell carcinoma, that are indicated for 1st or 2nd line anticancer therapy
89208916|NCT00978471|Experimental|experimental arm thiotepa|4 courses of conventional chemotherapy followed by high-dose Thiotepa with peripheral stem cell rescue. Surgical resection of all tumor masses will be performed as soon as possible.
89208917|NCT00978471|Other|Reference arm|4 courses of conventional chemotherapy. Surgical resection of all tumor masses will be performed as soon as possible.
89568919|NCT05190159||Monster Screw System|
89568920|NCT03973385|Experimental|cryotherapy group|cryotherapy by vapocoolant spray is applied on skin for 4 to 10 seconds ( or up to skin whitening) to 15 centimeters distance with sweeping action before ABG
89568921|NCT03973385|Placebo Comparator|control group|water spray is applied on skin for 4 to 10 seconds to centimeters distance with sweeping action before ABG
89568922|NCT05137431||High Flow Nasal Oxygenation-HFNO|The current will be adjusted from 50-70 liters. The patient's SpO2 value will be maintained at at least 92%. Arterial blood gas will be checked at the 1st hour
89028397|NCT05143008|Experimental|SMART Intervention|Counseling sessions will be completed with a toolbox approach so that clinicians can work on topics that are of interest and relevant to each participant. SMART will focus on weight, physical activity, eating and psychosocial issues. Intervention goals will emphasize adherence to healthy behaviors rather than absolute weight goals. Specifically, women will receive consultation about nutritional balance, dietary guidelines for pregnant women and advice to maintain an optimal rate of weight gain according to prepregnancy BMI. Women will use self-monitoring forms to identify and modify cues for unhealthy behaviors. Beliefs about body weight and eating during pregnancy will be addressed and effects of physical activity on body weight, health, and mood will be included.
89028398|NCT05142930|Active Comparator|Intermittent ultrasound|Patients with coccydynia will receive 10 sessions of physical therapy, 5 days a week for 2 weeks. Intermittent ultrasound will be used as a physical therapy agent. Intermittent ultrasound treatment will be applied to the muscles of the bilateral coccyx region at a dose of 1.0W/cm², at a frequency of 1 Megahertz, for 3+3 minutes.
89028399|NCT05142930|Active Comparator|Continuous ultrasound|Patients with coccydynia will receive 10 sessions of physical therapy, 5 days a week for 2 weeks. Continuous ultrasound will be used as a physical therapy agent. Continuous ultrasound treatment will be applied to the muscles of the bilateral coccyx region at a dose of 1.0W/cm², at a frequency of 1 Megahertz, for 3+3 minutes.
89028400|NCT01244594|Experimental|High cadence, low resistance|Subjects in this arm will cycle with functional electrical stimulation at a higher cadence (speed) and a lower resistance.
89028401|NCT01244594|Experimental|Low cadence, high resistance|Subjects in this arm will cycle with functional electrical stimulation at a lower cadence (speed) and a higher resistance.
89028402|NCT00497978|Active Comparator|1|taurine will be given per capsule
89028403|NCT00497978|Placebo Comparator|2|placebo capsules containing microcrystalline cellulose will be given
89028404|NCT01244672|Active Comparator|Trans-anal dearterialization|24 patients were assigned to the Transanal hemorrhoidal dearterialization with mucopexy arm, which is a Doppler guided procedure for suture ligation of hemorrhidal arteries rather than excisional
89028405|NCT01244672|Active Comparator|Ferguson|17 patients were randomized to Ferguson method, which is the operative gold standard for hemorrhoids. This is an excisional surgery.
89028406|NCT05142852|Experimental|Extracorporeal shock wave therapy|The participants in the experiment group received 5 consecutive sessions of ESWT for 5 minutes. Treatment parameters for the shock wave therapy group were set similar to a previous study (Devrimsel et al., 2013) 2000 shock waves with 1.6 bar intensity and 16 Hz frequency were applied for five sessions using the Swiss DolorClast Master (EMS, Nyon, Switzerland). All participants used 10-cm lateral epicondyle bandages in the treatment period, while none of them received analgesic or anti-inflammatory drugs and received exercise programs.
89028407|NCT05142852|Active Comparator|Conventional physiotherapy|The participants in the control group received 5 sessions of conventional physical therapy intervention for 5 minutes. The control group intervention consists of a 1-minute friction massage over the common extensor tendon of the elbow, followed by 3 minutes therapeutic ultrasound with a frequency of 1.5 Hz, and a 1-minute ice massage over the common extensor tendon of the elbow. All participants used 10-cm lateral epicondyle bandages in the treatment period, while none of them received analgesic or anti-inflammatory drugs and received exercise programs.
89028408|NCT00498056|Experimental|1|Participants will receive a total of three injections of the DNA vaccine VRC-HIVDNA016-00-VP followed by one injection of the adenovirus vaccine VRC-HIVADV014-00-VP. Injections will occur at study entry and Weeks 4, 8, and 24.
89028409|NCT00498056|Placebo Comparator|2|Participants will receive a total of three injections of the DNA vaccine VRC-HIVDNA016-00-VP placebo followed by one injection of the adenovirus vaccine VRC-HIVADV014-00-VP placebo. Injections will occur at study entry and Weeks 4, 8, and 24.
89568923|NCT05137431||Non-Invasive Ventilation-NIV|Tidal volume will be adjusted to be 6-8 ml/kg. The respiratory rate will be <30. The patient's SpO2 value will be maintained at at least 92%. The PEEP value will be 5 cmH2O. At the 1st hour, arterial blood gas will be checked.
89568924|NCT05135871|Experimental|Cohort 1: Mavacamten 15 mg|Cohort 1: 15 mg capsules × 1 on Day 1
89568925|NCT05135871|Experimental|Cohort 2: Mavacamten 25 mg|Cohort 2: 10 mg capsules x 1 and 15 mg capsules x 1 on Day 1
89568926|NCT05135871|Experimental|Cohort 3: Mavacamten 15 mg|Cohort 3: 15 mg capsules × 1 on Day 1
89568927|NCT05135871|Experimental|Cohort 4: Mavacamten 15 mg|Cohort 4: 15 mg capsules × 1 on Day 1
89568928|NCT04338659|Experimental|Dose Escalation of IBI322|Participants will receive escalating dose levels of IBI322 to determine maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of IBI322
89568929|NCT05190003|Experimental|Study group I: The first time of patients attending single-level lumbar microdiscectomy|"Study group I:~On the basis of neurosurgical examination and MRI imaging, 40 patients aged 20-65 years with pains in the lumbar spine will be referred for the first-time single-level microdiscectomy procedure. Microdiscectomy patients will begin a rehabilitation program that will be includes exercises to reduce pain and strengthen the stabilizing muscles of the lumbar spine. From week to week, exercises will be difficult, among others due to the change of initial positions, the number of repetitions of exercises, or a longer duration of isometric exercises."
89568930|NCT05190003|No Intervention|Study group II: Control healthy people|"Study group II:~40 people aged 20-65 years. Including criteria: healthy persons without lumbar spine pain for at least 6 months and without lumbar spine surgery."
89568931|NCT03744611|Experimental|Cortex Eucommiae(CE)|CE capsule administered orally twice daily for 12 weeks.
89568932|NCT03744611|Placebo Comparator|Placebo|Placebo capsule administered orally twice daily for 12 weeks.
89568933|NCT04755179||Complex appendicitis without abscess or mass formation|All children (<18 years old) that present with a suspicion of complex appendicitis without clinical or radiological signs of abscess or mass formation. Preoperative suspicion of complex appendicitis is based upon a previously developed clinical scoring system.
89568934|NCT04755179||Complex appendicitis with abscess or mass formation|All children (<18 years old) that present with a suspicion of complex appendicitis with clinical or radiological signs of abscess or mass formation. Preoperative suspicion of complex appendicitis is based upon a previously developed clinical scoring system.
89568935|NCT05133999||Preterm infants|infants born at <31 week's post-menstrual age (PMA) or ≤1250g of birth weight
89028410|NCT05141331|Experimental|Piezoelectric split-crest technique in treatment of Maxillary Narrow Ridges|Piezoelectric split-crest technique in treatment of Maxillary Narrow Ridges
89028411|NCT05141331|Active Comparator|Hand Driven Ridge Expanders in treatment of Maxillary Narrow Ridges|Hand Driven Ridge Expanders in treatment of Maxillary Narrow Ridges
89028412|NCT05146557||Group Obese adolescents|BMI above the 97th percentile + 2.17 to+2.18 SDS
89028413|NCT05146557||Group Normal weight adolescents|BMI between the 10th and 90th percentile -1.64 to +1.64 SDS
89028414|NCT00502580||1|Patients with lesions of the oral cavity mucosa.
89028415|NCT05146518|Experimental|Single-arm, pre-post|Maternity staff of health public health facilities will exposed to the intervention package (capacity building and systemic changes in the health facilities).
89028416|NCT05146401||Gestational diabetes mellitus|"Gestational diabetes mellitus (GDM) was diagnosed according to the American Diabetes Association criteria, which is based on the one-step approach recommended by the International Association of Diabetes and Pregnancy Study Groups. All women underwent a 75g OGTT in the morning after an overnight fast, with plasma glucose measurement fasting and at 1 and 2 hours. The criteria for GDM diagnosis was to have at least one abnormal value: Fasting glucose ≥ 5.1 mmol/L (92 mg/dL), 1 h glucose ≥ 10.0 mmol/L (180 mg/dL), 2 h glucose ≥ 8.5 mmol/L (153 mg/dL)."
89028417|NCT05146401||Healthy pregnant women|Pregnant women with fasting glucose < 5.1 mmol/L (92 mg/dL), 1 h glucose < 10.0 mmol/L (180 mg/dL) and 2 h glucose < 8.5 mmol/L (153 mg/dL) were considered as healthy controls. Controls were randomly selected and individually matched to cases by age (± 2 years), gestational age (± 2 weeks) and parity.
89028418|NCT00502619|Experimental|Acupuncture plus Treadmill Exercise|Acupuncture plus Treadmill Exercise
89028419|NCT00498290|Experimental|A|received enhanced recovery after surgery (ERAS) protocol in colorectal surgery
89028420|NCT00498290|No Intervention|B|normal recovery protocol in colorectal surgery
89028421|NCT00502736|Experimental|1|
89028422|NCT05146089|Experimental|Hypoxia Exposure|Men and women will be exposed to acute intermittent hypoxic episodes.
89028423|NCT02955030|Experimental|NSV0001(Cohort1)|15 µg of hemagglutinin [HA] antigen per strain with 150 µg of ND002 adjuvant, administration by sublingual route
89568936|NCT05133219|Experimental|Research Group|"Participants will be received Intensified sensory therapy.~Other: Occupational Therapy Activities of Daily Living Training~Intervention: Other: Occupational therapy intervention"
89568937|NCT05133219|Experimental|Control Group|"Participants will be received Occupational Therapy.~Other: Activities of Daily Living Training"
89568938|NCT05090553|Active Comparator|surgical treatment|Lumbar Spinal Fusion Surgery
89568939|NCT05090553|Experimental|Bacterial culture|"Cutibacterium acnes culture in two different atmosphere:~Carbon dioxide (CO2) from 5% up to 10%~CO2 10%, H2 10% and N2 80%"
89568940|NCT05090553|Experimental|Phenotypic and genotypic characterization|Mass spectrometry and (Polimerase Chain Reaction) PCR
89568941|NCT05090553|Experimental|Multiomics analysis|"Genome sequencing~Proteomics~Metabolomics"
89568942|NCT04789811|Experimental|Exercise Group|It describes the exercise protocol that the patients will do.
89568943|NCT04789811|Experimental|Exercise plus Dry Needling Group|It describes the exercise protocol to be performed by the patients and the methodology of dry needling to be applied.
89568944|NCT05089461|Experimental|Mitoxantrone Hydrochloride Liposome Injection|Patients with advanced malignant tumor will receive 20 mg/m^2 Mitoxantrone Hydrochloride Liposome by an intravenous infusion (IV) on day 1 of each treatment cycle.
89568945|NCT04789343|Experimental|hand files with lateral condensation technique|Previously done root canal filling removed by hand files (Hedstrom file,VDW, Munich,Germany ) and shaped with the same files and after instrumentation, all canals were filled by AH Plus sealer (Dentsply De Tray, Costanz, Germany) and lateral condensation technique of gutta-percha.
89568946|NCT04789343|Experimental|Reciproc instrument with lateral condensation technique|Previous root canal filling removed by Reciproc instrument (VDW ,Munich, Germany )using Endomotor (VDW, Munich, Germany). After removal, root canal instrumented with the same instrument and obturated using AHPlus sealer with lateral condensation technique of gutta-percha.
89568947|NCT04789343|Experimental|Reciporoc instrument with continuous warmed condensation technique|Previous root canal removed by Reciproc instrument using Endomotor, shaped and obturated by AhPlus sealer with continuous gutta-percha technique (Diadent Dia-Duo (Diadent, Chongju, Korea).
89568948|NCT05730439|Experimental|Arm I (usual SLT, ZYN NP, Rogue NP)|Participants receive their usual brand of smokeless tobacco at study visit 1, ZYN brand nicotine patch at study visit 2, and Rogue brand nicotine patch at study visit 3. Participants also undergo IV line insertion and collection of blood on study.
89568949|NCT05730439|Experimental|Arm II (usual SLT, Rogue NP, ZYN NP)|Participants receive their usual brand of smokeless tobacco at study visit 1, Rogue brand nicotine patch at study visit 2, and ZYN brand nicotine patch at study visit 3. Participants also undergo IV line insertion and collection of blood on study.
89568950|NCT05730439|Experimental|Arm III (ZYN NP, usual SLT, Rogue NP)|Participants receive ZYN brand nicotine patch at study visit 1, their usual brand of smokeless tobacco at study visit 2, and Rogue brand nicotine patch at study visit 3. Participants also undergo IV line insertion and collection of blood on study.
89568951|NCT05730439|Experimental|Arm IV (ZYN NP, Rogue NP, usual SLT)|Participants receive ZYN brand nicotine patch at study visit 1, Rogue brand nicotine patch at study visit 2, and their usual brand of smokeless tobacco at study visit 3. Participants also undergo IV line insertion and collection of blood on study.
89568952|NCT05730439|Experimental|Arm V (Rogue NP, usual SLT, ZYN NP)|Participants receive Rogue brand nicotine patch at study visit 1, their usual brand of smokeless tobacco at study visit 2, and ZYN brand nicotine patch at study visit 3. Participants also undergo IV line insertion and collection of blood on study.
89568953|NCT05730439|Experimental|Arm VI (Rogue NP, ZYN NP, usual SLT)|Participants receive Rogue brand nicotine patch at study visit 1, ZYN brand nicotine patch at study visit 2, and their usual brand of smokeless tobacco at study visit 3. Participants also undergo IV line insertion and collection of blood on study
89568954|NCT03683147|Experimental|Control (online sessions, content manual, CD after 6 weeks)|Participants randomized to the wait-list control condition complete the online intervention as in the intervention arm after the initial 6-week period has ended.
89568955|NCT03683147|Experimental|Intervention (online sessions, content manual, relaxation CD)|Participants receive online group sessions over 60 minutes for 6 weeks, including 15 minutes of practice on that session's topic and daily meditation or yoga for 45 minutes. At the conclusion of the study period participants participate in mindfulness meditation over 3 hours. Participants also receive a content manual and relaxation CD.
89028424|NCT02955030|Experimental|NSV0001(Cohort2)|30 µg of hemagglutinin[HA] antigen per strain with 300 µg of ND002 adjuvant, administration by sublingual route
89028425|NCT02955030|Experimental|NSV0001(Cohort3)|60 µg of hemagglutinin[HA] antigen per strain with 600 µg of ND002 adjuvant, administration by sublingual route
89568956|NCT05730361|Experimental|ScTIL injection|This trial is designed single arm. All the subjects enrolled will receive the experimental intervention: ScTIL210 injection alone or with B lymphocytes adjuvant.
89568957|NCT04789187|Active Comparator|Arm A: Exercise intervention arm|
89568958|NCT04789187|Placebo Comparator|Arm B: Control arm|
89568959|NCT05550493|Experimental|Digital Therapeutics|The DTx group was asked to download and install a smartphone application (WonderLab Harbor) that incorporated Internet-based Cognitive Behavioral Therapy (ICBT), Approach Bias Modification (ApBM), cognitive function training, and Contingency Management (CM). During the 8-week treatment program, the participants in the DTx group were instructed to complete ICBT, cognitive trainings, and ApBM trainings. Reward points (which can be redeemed for cellphone plan credit) were rewarded following completing each task as part of the positive reinforcement following CM principles.
89568960|NCT05550493|Active Comparator|Treatment as Usual|Upon enrollment, TAU participants were informed that they would receive weekly counseling sessions from a social worker for eight weeks. The counseling covered topics including work, family, stress management, and drug craving suppression.
89568961|NCT03671291|Experimental|Recently infected with HIV|Men and women recently infected with HIV and have been eligible for PrEP based on the recommendation of french national regulatory agency regarding the prescription of Truvada® in prophylaxis to HIV exposure. The potential reasons behind these missed opportunity of Pre-exposure prophylaxis will be studied through a self-administrated questionnaire.
89568962|NCT05730283|Experimental|High Dose ORC-13661|This arm is a daily treatment regimen of study drug (ORC-13661) with a loading dose of 150mg followed by a daily dose of 30mg. Treatment regimen will run concurrently with treatment with IV amikacin. Study drug treatment will continue until treatment with IV amikacin ends or 90 days, whichever is earlier.
89568963|NCT05730283|Experimental|Low Dose ORC-13661|This arm is a daily treatment regimen of study drug (ORC-13661) with a loading dose of 60mg capsules followed by a daily dose of 12mg capsules. Treatment regimen will run concurrently with treatment with IV amikacin. Study drug treatment will continue until treatment with IV amikacin ends or 90 days, whichever is earlier.
89568964|NCT05730283|Placebo Comparator|Placebo|This arm is a daily treatment regimen of a placebo with a loading dose and a daily dose of placebo capsules to match the treatment arms. Placebo regimen will run concurrently with treatment with IV amikacin. Placebo regimen will continue until treatment with IV amikacin ends or 90 days, whichever is earlier.
89568965|NCT05087667|Experimental|Polymer Cerclage System OrthoLoop|Patients receives Ortholoop Cerclage System
89568966|NCT05087667|Active Comparator|cerclages used in standard care|"Patients receives cerclages used in standard care"
89568967|NCT05613959||Veress +|The Veress+ system was used
89568968|NCT05613959||Veress conventional|The Conventional Veress needle was used
89568969|NCT05730049|Experimental|Active taVNS|Stimulation will target the auricular branch of the vagus nerve by applying stimulation to the cymba conchae region of the ear using the NEMOS® taVNS device (taVNS Technologies, Erlangen, Germany). To achieve adequate stimulation while avoiding unpleasant or painful sensations, the stimulation intensity will be gradually increased in increments of 0.1mA until the subjective pain threshold is reached, and then reduced to a stimulus intensity just below the individuals pain threshold (expected range based on prior studies 1 - 3.2mA. Pulse width will be set at 100μs and frequency will be set at 25Hz as performed in a previous protocol in stroke patients. Stimulation will be applied for a duration of 1 hour.
89568970|NCT05730049|Sham Comparator|Sham taVNS|The control group will receive the same stimulation parameters but will have the earpiece placed in the sham position such that stimulation is applied to the earlobe and does not activate the vagus nerve.
89568971|NCT04517279|Experimental|Peer Approaches to Substances in Early Psychosis Programs|The Peer Approaches to Substances in Early Psychosis Programs arm is an intervention focused on enhancing the recovery capital of individuals in early psychosis care. The intervention is provided by a peer provider, operating on the coordinated specialty care team
89568972|NCT04517279|Active Comparator|Usual Care|The peer providers operating under the Usual Care condition will continue to provide peer support services to individuals within the coordinated specialty care team.
89568973|NCT04789031|Experimental|Intervention group|Patients received oral nutritional supplementation and standard nutritional counseling for 6 months.
89568974|NCT04789031|No Intervention|Control group|Patients received standard nutritional counseling for 6 months.
89028426|NCT02955030|Placebo Comparator|Placebo|0 µg of hemagglutinin[HA] antigen per strain with 0 µg of ND002 adjuvant, administration by sublingual route
89028427|NCT02955030|Active Comparator|"Influenza HA vaccine Biken HA"|Seasonal quadrivalent influenza vaccine, administration by subcutaneous injection route
89028428|NCT02954913|Experimental|Simultaneous Resection|Patients will undergo resection of the colon or rectum and liver in the same anesthetic setting. The type of colorectal and liver resection will be decided by the treating physician. The type of liver resection will be described according to the Couinaud classification and the Brisbane terminology of liver anatomy.
89028429|NCT00498524||1|Sib who has received an ICD
89568975|NCT05126745||Patients who had an epidural placed for labour|Patients who had an epidural placed for labour may take part. Study procedures will take place after delivery and prior to removal of the epidural catheter.
89568976|NCT04789421|Active Comparator|Arm 1 (interventional)|Patients with equivocal skin lesions suspicious for melanoma, randomised to adjunctive RCM evaluation, following clinical and dermoscopy evaluation.
89568977|NCT04789421|Placebo Comparator|Arm 2 (control)|Patients with equivocal skin lesions suspicious for melanoma, randomised to clinical and dermoscopy evaluation only; adjunctive RCM evaluation refused.
89568978|NCT05126199|Experimental|Time restricted eating|"Time-restricted eating using 18:6 protocol (12 weeks)~Washout Period (4 weeks)~Crossover to Normal ad libitum diet (12 weeks)"
89568979|NCT05126199|Active Comparator|Normal ad libitum diet|"Normal ad libitum dietary patterns without defined eating window, fasting or restrictions on types of food or drink consumed (12 weeks)~Washout Period (4 weeks)~Crossover to time-restricted eating using 18:6 protocol (12 weeks)"
89568980|NCT04789265|Experimental|Combined Therapy (Instrumented Soft Tissue Mobilization)|
89568981|NCT04789265|No Intervention|Control Group (Exercise Therapy)|
89568982|NCT05493787|No Intervention|Passive control|No message
89568983|NCT05493787|Active Comparator|Active control message|A message that simply states that patients can get a flu shot at Geisinger
89568984|NCT05493787|Experimental|Ease message|A message emphasizing the ease of scheduling a flu shot at Geisinger
89568985|NCT05493787|Experimental|Waiting for you message|"A message that states the patient's flu shot is waiting for them at Geisinger"
89568986|NCT05493787|Experimental|Protect yourself - rare message|A message that emphasizes the rare, dangerous outcomes of getting the flu (e.g., hospitalization, pneumonia), and states that a flu shot can offer protection from those outcomes
89568987|NCT05493787|Experimental|Protect yourself - frequent message|A message that emphasizes the outcomes that frequently occur in people with the flu (e.g., fever, chills, missing important events), and states that a flu shot can offer protection from those outcomes
89028430|NCT00498524||2|Sib who has not received an ICD
89568988|NCT05613569||A group who administered KLS-2031 in the KS-GIG-001-01 Study|
89568989|NCT04830163|Experimental|PCMS during brain states reflecting strong corticospinal transmission|
89568990|NCT04830163|Active Comparator|PCMS during random brain states|
89568991|NCT04788719|Experimental|Preoperative|Gait analysis kinematics and kinetics
89568992|NCT04788719|Experimental|Postoperative|Gait analysis kinematics and kinetics
89568993|NCT05125263|Experimental|group 1|This group receives KinesioTaping along with conventional treatment
89568994|NCT05125263|Experimental|group 2|This group receives mulligan taping along with conventional treatment
89568995|NCT04805515|Experimental|Nicotine Corrective Messages|Participants in the nicotine corrective messages condition will receive 8 brief nicotine corrective public education messages delivered online during 4 waves of the 12 week study. The messages will communicate misperceptions about nicotine's role in health harms as well as misperceptions that reduced nicotine content cigarettes are less harmful than tobacco cigarettes and that e-cigarettes contain less nicotine than tobacco cigarettes.
89568996|NCT04805515|No Intervention|Delayed Message Control|Participants in the control condition will be exposed to the nicotine corrective messages after the completion of the final assessment at the end of the 12 week study.
89568997|NCT05729971||with NGT|In these patients, the nasogastric tube remains after surgery. It was removed after x-ray test.
89568998|NCT05729971||noNGT|In these patients, NGT was removed at the end of surgery.
89568999|NCT05123859||age groups|"A total of 30 participants in the 25- to 34-year age group~A total of 45 participants in the 35- to 44-year age group~A total of 50 participants in the 45- to 54-year age group~A total of 50 participants in the 55- to 64-year age group~A total of 45 participants in the 65- to 74-year age group~A total of 30 participants in the 75- to 85-year age group"
89569000|NCT05170919|Experimental|Olanzapine|
89569001|NCT05170919|Experimental|Mirtazapine|
89569002|NCT05729893|Active Comparator|resin group|obturated with resin sealer
89028431|NCT02954757|Experimental|Treatment arm|HIFU treatment
89028432|NCT00502814||1|Patients with Breast Cancer.
89569003|NCT05729893|Active Comparator|bio ceramic group|obturated with bioceramic sealer
89569004|NCT05602285||Usual care group|Usual IV securement
89569005|NCT05602285||Dislodgement device group|Usual IV securement plus dislodgement device
89569006|NCT05729737||Pancreatic ductal adenocarcinoma|"Patients who planned to receive first-line chemotherapy for pathologically diagnosed PDAC were recruited.~Intervention:Diagnostic test:Contrast-enhanced ultrasound"
89569007|NCT05179629|Active Comparator|Group M = M-TAPA group|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by a pain nurse blinded to the procedure. 100 mg tramadol will be performed for rescue analgesia.
89569008|NCT05179629|No Intervention|Group C = Control group|"Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by a pain nurse blinded to the procedure.~Wound local anesthetic infiltration will be applied to the patients in the control group. 100 mg tramadol will be performed for rescue analgesia."
89028433|NCT02954640|Other|Patient with PID|"For patient with clinical diagnosis of PID, an additional blood sampling will be taken.~The genetic diagnosis will be done via the method of gene-panel in the frame of the study.~A genetic confirmation will, in any case, be done via the reference method (Sanger), in order to establish a final diagnosis for these patients."
89028434|NCT02954796|Experimental|(Dose Escalation) Cohort -1 - 6|SGN-CD352A will be given intravenously (into a vein; IV) every 28 days at increasing doses.
89569009|NCT05613491|Experimental|Intranasal insulin group|Before anesthesia induction, give the first insulin nasal spray, once per hour, 20 IU each time, until the end of the operation
89569010|NCT05613491|Placebo Comparator|Saline group|Before anesthesia induction, give the equal volumes'saline nasal spray, once per hour, 20 IU each time, until the end of the operation
89569011|NCT05082207|Experimental|Remote Ischaemic preconditioning (RIPC)|The group underwent Remote Ischemic Preconditioning.
89569012|NCT05082207|Sham Comparator|Sham Group|Sham control group without remote ischemic preconditioning
89028435|NCT00502892|Experimental|Topotecan + Ifosfamide + Carboplatin|
89028436|NCT02954835|Active Comparator|Prevena|Subjects randomized to the Prevena dressing will have the dressing in place for 5 to 7 days postoperatively and removed before discharge, or at the first outpatient visit.
89028437|NCT02954835|Active Comparator|Traditional Dressing|Subjects randomized to the traditional dressing will undergo dressing changes as per the standard protocol with the first dressing change at postoperative day 2 or 3, or at the discretion of the attending surgeon.
89569013|NCT05157425|Experimental|Experimental|Probiotic multi-strain formulation comprising L. plantarum CECT30292, CECT7484, CECT7585 and P. acidilactici and maltodextrin (E1400, qs) as excipient in hydroxymethylpropyl-cellulose (HPMC) capsules. Probiotic strains have Qualified Presumption of Safety (QPS) status by European Food Safety Authority
89028438|NCT00502970|Experimental|1|16 weeks Interferon Tiw with Ribavirin
89028439|NCT00502970|Active Comparator|2|24 weeks Interferon Tiw with Ribavirin
89028440|NCT00503048||1|foster care children
89569014|NCT05157425|Placebo Comparator|Placebo|Maltodextrin (E1400, qs) in HPMC capsules
89569015|NCT05179317|Experimental|QL1706+chemotherapy±Bevacizumab|On Day 1 of each 21-day cycle, participants receive an intravenous (IV) infusion of QL1706 5mg/kg plus Investigator choice of chemotherapy (paclitaxel 175 mg/m^2 plus cisplatin 70 mg/m^2 or paclitaxel 175 mg/m^2 plus carboplatin Area Under the Curve (AUC) 6 withor without bevacizumab 15 mg/kg)
89569016|NCT03276065|Experimental|Laser plus Standard of Care Depilation|Laser depilation to the natal cleft (pilonidal region) every 4-6 weeks for 5 treatments with either an 810nm or Nd:YAG laser dependent on Fitzpatrick skin type and tolerability. Patients and families in the intervention group will also be taught hair removal techniques and asked to perform either chemical or mechanical depilation as needed to keep the area hair-free between clinic treatments.
89569017|NCT03276065|Active Comparator|Standard of Care Depilation|Patients and families in the standard of care group will be taught hair removal techniques and asked to perform either chemical or mechanical depilation as needed to keep the area hair-free. Patients will be given supplies for six months of hair removal.
89569018|NCT05177757|Experimental|Yoga Intervention|The yoga exercise program will be conducted at the Marquette campus and will consist of one session per week for 12 weeks. The duration of each session will be approximately one hour. The program the investigators will use is the Mindful Resilience for Trauma Recovery Program (https://www.veteransyogaproject.org/), an evidence-informed practice adapted for veterans with PTSD based on clinical and neuroscientific knowledge. This program is a 12-week protocol developed by a licensed clinical psychologist and is publicly available. All yoga sessions will be standardized based on the resilience program guidelines.
89569019|NCT04410679|Experimental|injectabl PRF for treatment of internal root resorption|
89569020|NCT04788407|Experimental|Nitazoxanide|Subjects will receive nitazoxanide 500 mg TID.
89028441|NCT00503048||2|reference children (living with families)
89028442|NCT05140980||"women aged 18 to 25 group"|"women aged 18 to 25 group: women aged 18 to 25 with or without sexual activity"
89569021|NCT04788407|Placebo Comparator|Placebo|Subjects will receive placebo TID.
89569022|NCT03066427|Experimental|Sunitinib|Sunitinib 50 mg/day, 4 weeks on/2weeks off
89569023|NCT04788485|Active Comparator|Neonates before adding smectite|neonates will receive diosmectite for treating of gastroesophageal reflux in neonates after MII-ph
89028443|NCT00498680|Active Comparator|Viagra 100mg|
89028444|NCT00498680|Active Comparator|Levitra 20mg|
89028445|NCT00498680|Active Comparator|Viagra 50mg+ Levitra 10mg|
89028446|NCT05146011||Single stage pathway|
89028447|NCT05146011||Two stage pathway|
89028448|NCT00498719||CTP Group|One-on-one cognitive training
89028449|NCT00498719||Control Group|Standard educational support.
89028450|NCT00507390|Active Comparator|A1|n-3 PUFAs
89028451|NCT00507390|Placebo Comparator|A2|olive oil capsules
89028452|NCT05145894||Asthma|Asthma patients aged 3 years and older with confirmed asthma diagnosis treated by a monotherapy ICS or ICS plus LABA or other controllers and presenting with moderate or severe disease exacerbation
89028453|NCT05145894||COPD|COPD patients aged 40 years and older with confirmed COPD diagnosis treated by a monotherapy long-acting muscarinic antagonist (LAMA), or LAMA plus long acting beta2-agonist (LABA), or inhaled corticosteroid (ICS) plus LABA, or LAMA plus LABA plus ICS and presenting with moderate or severe disease exacerbation
89028454|NCT05145543|Placebo Comparator|Group C|0.9 NaCl % (Saline) (5 ml)
89028455|NCT05145543|Active Comparator|Group L|0.25 % levobupivacaine (5 ml) will be applied.
89569024|NCT04788485|Active Comparator|neonates after adding smectite|neonates after they received diosmectite for treating of gastroesophageal reflux in neonates after MII-ph
89569025|NCT05118087|Active Comparator|Coaptation Splint|
89569026|NCT05118087|Active Comparator|Sarmiento Brace|
89569027|NCT03067909||Patients undergoing CIED surgery|Patients with standard indications to CIED implantations/replacements receiving concomitant antithrombotic therapy (either or both antiplatelet agents and/or anticoagulants).
89569028|NCT05177133|Experimental|Capecitabine, oxaliplatin and retifanlimab|IV and PO Capecitabine 1000 mg/m2, oxaliplatin 130 mg/m2, every three weeks (up to 2 cycles) IV retifanlimab 500mg, every four weeks
89569029|NCT03065803|Active Comparator|Buccal plate expansion technique in dental socket preservation|"An internal osteotomy of the socket buccal plate will be performed with a piezotome (SurgyStar).~Two vertical osteotomies and one horizontal osteotomy will be made to push the buccal plate outward from the socket. Two small cervical releasing incisions will be made in the mesiobuccal and distobuccal aspects of the socket to permit the displacement of the osteotomies in the area of keratinized tissue. The socket will be loaded with natural bovine bone mineral (cerabone). The biomaterial will be pressed to push the released buccal plate outward. A collagen bio absorbable membrane will be utilized to cover the socket. The collagen membrane plug will be stabilized on the top of the socket with a cross suture (silk 4/0)."
89569030|NCT03065803|Other|Guided Bone regeneration technique for socket preservation|On buccal side, two vertical incisions will be made at mesial and distal papilla of the adjoining teeth. These incisions will be stretched out past mucogingival junction. After full-thickness flap reflection on buccal and lingual sides, atraumatic tooth extraction utilizing periotome will be performed. The periosteum of buccal flap will be incised; this would permit coronal advancement of facial flap and a tension-free primary closure. Extraction sockets will be grafted with natural bovine bone mineral (cerabone). Collagen membrane will be trimmed and placed on the grafted socket and alveolar bone. Buccal and lingual/palatal flaps will be approximated utilizing interrupted simple loop and vertical mattress sutures (4/0) (Sadeghi et al., 2016).
89569031|NCT02994563|Experimental|Open arm|Thrombectomy device to be used to retrieve clot and restore blood flow.
89569032|NCT03066505|Active Comparator|Active MeRT Treatment|Active treatment will consist of 6 seconds a minute for 30 minutes a day, 5 days a week for 4 weeks.
89569033|NCT03066505|Sham Comparator|Sham MeRT Treatment|Sham treatment will consist of 6 seconds a minute for 30 minutes a day, 5 days a week for 4 weeks. Sham treatment mimicks same noise and sensation of active treatment but provides no treatment.
89569034|NCT02866643|Experimental|Delivery Room Insertion|Participants who randomize to this arm will receive the contraceptive implant in the Labor and Delivery room (0-2 hours following delivery).
89028456|NCT05145543|Experimental|Group LF|fentanyl plus 0.25 % levobupivacaine (5 ml) will be applied.
89569035|NCT02866643|Active Comparator|Postpartum Insertion|Participants who randomize to this arm will receive the contraceptive implant in the postpartum ward room before discharge (24-48 hours following delivery).
89028457|NCT05145543|Experimental|Group LD|dexamethasone plus levobupivacaine (5 ml) will be applied.
89028458|NCT00503204|Experimental|1|Lomustine + Cediranib (AZD2171)
89028459|NCT05145504||20 obese patients, with BMI ≥ 30|
89028460|NCT05145504||20 normal weight patients with BMI between 18.5 - 24.9 inclusive|
89028461|NCT05145465|Experimental|Telerehabilitation group|"Participants will undertake the first training session in the University of Thessaly under the supervision of a specialized physiotherapist in order to precept the exercises. All the other sessions will proceed via telerehabilitation program at their home. Participants will undergo an exercise home based program 3 times/week.~The program will start with 10 minutes warm up exercise , 20 minutes continuous aerobic exercise ( 60-80% of target heart rate), 20 minutes resistance training exercise ( 30-50% 1RM), 5 minutes cool down and breathing exercises. For their safety patients will monitor glucose, blood pressure, pulse-oxygen and heart rate via, blood pressure monitor, pulse oximeter and smart-watch devices. They will be assessed at the beginning of the study and after the intervention ( at 6 weeks)"
89028462|NCT05145465|No Intervention|control group|The participants in this group will just receive the education session and they will continue their current medical therapies.They will be assessed at the beginning of the study and after the intervention ( at 6 weeks).
89028463|NCT04696107|Experimental|Intervention Group|Standard pharmacological treatment aimed at controlling mCNCP with four-week face to face psychoeducational intervention.
89028464|NCT04696107|No Intervention|Control Group|Standard pharmacological treatment aimed at controlling mCNCP without psychoeducational intervention.
89028465|NCT02276391|Experimental|Telmisartan/HCTZ fixed-dose combination|
89028466|NCT02276391|Active Comparator|Telmisartan|
89028467|NCT05145270|Active Comparator|Escitalopram|The dose of Escitalopram based on treatment guidelines for major depressive disorder and drug prescription manual is 10-20mg/day, once per day.
89569036|NCT05729581|No Intervention|Control group|This group of pregnant women (24-32 SG) will not be provided educational programme and information on sustainlably and healthy diet and sustainable breastfeeding. It is a control group.
89569037|NCT05729581|Experimental|Experimental group|This group of pregnant women (24-32 SG) will be provided educational programme and information on sustainlably and healthy diet and sustainable breastfeeding
89569038|NCT05176821|Experimental|High-dose dual therapy group|esomeprazole 20mg qid plus amoxicillin 750mg qid were used in the high-dose dual therapy group
89569039|NCT05176821|Active Comparator|Furazolidone-based quadruple therapy|furazolidone 100mg bid + amoxicillin 1000mg bid + esomeprazole 20mg bid + bismuth potassium citrate 1000mg(220mg of bismuth) bid were used in the Furazolidone-based quadruple therapy
89028468|NCT05145270|Experimental|Escitalopram plus Sulforaphane|"The dose of Escitalopram based on treatment guidelines for major depressive disorder and drug prescription manual is 10-20mg/day, once per day.~The oral dose of SFN is based on weight. The usage and dosage are as follows: 40-70kg, 4 tablets/day (containing 274μmol of glucosinolates); 70-90kg, 6 tablets/day (containing 411μmol of glucosinolates). Take it once in the morning and evening."
89028469|NCT05145270|Experimental|Escitalopram plus rTMS|"The dose of Escitalopram based on treatment guidelines for major depressive disorder and drug prescription manual is 10-20mg/day, once per day.~rTMS is delivered to the left dorsolateral prefrontal lobe position. Stimulation parameters are set to be 80 stimulation strings of 10Hz with an interval of 12 seconds. Each stimulation string includes 30 stimulations lasting for 3 seconds. One session includes 2400 stimulation strings lasting for 19 minutes and 40 seconds. The course of rTMS treatment includes 20 sessions, once a day or twice a day."
89569040|NCT05555641|Experimental|Nafamostat Mesylate|VV-ECMO patients were given continuous anticoagulation with nafamostat mesylate, coagulation function was monitored every 6 hours, and APTT was maintained at 1-1.75 times the upper limit of normal detection until reaching the study endpoints, including 14 days after enrollment, 24 hours after withdrawal from ECMO, or any switch to ECMO mode during ECMO treatment.
89569041|NCT05555641|Active Comparator|Unfractionated Heparin|VV-ECMO patients were given continuous anticoagulation with unfractionated heparin, coagulation function was monitored every 6 hours, and APTT was maintained at 1-1.75 times the upper limit of normal detection until reaching the study endpoints, including 14 days after enrollment, 24 hours after withdrawal from ECMO, or any switch to ECMO mode during ECMO treatment.
89569042|NCT05116527|Experimental|High Dose THC|Participants will receive high dose THC.
89569043|NCT05116527|Experimental|Placebo THC|Participants will receive placebo THC.
89569044|NCT03067831|Experimental|Stem Cells|Transplantation of purified autologous bone marrow-derived stem cells.
89569045|NCT05175729||Pregnant Group|First trimester pregnant group would be included and will be followed up in second, third trimesters and after pregnancy
89569046|NCT05175729||Control group|Age-, sex-matched healthy volunteers
89569047|NCT01672801|Placebo Comparator|Placebo|All subjects in both arms will receive Clomid 100 mg tablets by mouth for 5 days prior to receiving either placebo comparator or active comparator. Placebo comparator subjects will receive 8 total doses of liquid placebo orally 4 times a day for 8 total doses in pre-filled liquid placebo containing syringes
89569048|NCT01672801|Active Comparator|Nimodipine|All subjects in both arms will receive Clomid 100 mg tablets by mouth for 5 days prior to receiving either placebo comparator or active comparator. Active comparator subjects will receive Nimodipine 30mg liquid orally 4 times a day for 8 total doses in pre-filled syringes
89569049|NCT04939259|Experimental|New Music Program|The new hearing aid contains the new music program will be worn by all participants at the same time. The participants must switch between the two programs during use to make the comparison.
89569050|NCT04939259|Active Comparator|Standard Listening Program|The new hearing aid also contains the standard listening program worn by all participants at the same time. The participants must switch between the two programs during use to make the comparison.
89569051|NCT05729269||Chronic liver disease|non-alcohol liver disease, alcohol liver disease, liver cirrhosis
89569052|NCT04787861|Active Comparator|Control group|Control group treatment is identical to treatment of the study group but without a motorized movement device.Childen in this group received chest physical therapy program including positioning, breathing exercises, and postural drainage in addition to incentive spirometer training for 20 minutes, 3 times/week for 12 weeks.
89569053|NCT04787861|Experimental|study group|This group received the same program given to the control group in addition to an aerobic training regimen for 25 minutes 3 times/week for 12 weeks using a motorized movement device.
89569054|NCT05612087||gastrointestinal post acute COVID-19 syndrome|newly developped functional dyspepsia or irritable bowel syndrome after COVID-19 infection
89028470|NCT02276625|Experimental|A - ID|Intradermal administration. 20% dose in a single visit.
89028471|NCT02276625|Experimental|B - ID|Intradermal administration. 40% dose in a single visit.
89028472|NCT02276625|Experimental|C - ID|Intradermal administration. 60% dose in a single visit.
89028473|NCT02276625|Active Comparator|D - IM|1x IM
89028474|NCT01245257||Alcoholic Hepatitis|Patients with alcoholic hepatitis
89028475|NCT02276664|No Intervention|Study 1 - Focus Groups|Using focus group methodology, investigators will identify and explore new content topics for inclusion in smoking cessation booklets and gather feedback about the existing Stop Smoking for Good booklets regarding tone and message design. Results will be used to modify and adapt the existing cessation intervention.
89569055|NCT05729113|Experimental|Distraction technique|
89569056|NCT05729113|No Intervention|Pain monitor|
89569057|NCT05613335|Experimental|fibrin glue group|Maxillary sinus augmentation using autologous fibrin glue with simultaneous implant placement
89569058|NCT05613335|Experimental|sticky bone group|Maxillary sinus augmentation using mixture of autologous fibrin glue with bone graft with simultaneous implant placement
89569059|NCT05508997|Experimental|Positive End Expiatory Pressure + Reverse Trendelenburg Position|Group A received the procedures of the physiotherapy part by applying proper positioning for better oxygenation and ventilation (Reverse Trendelenburg Position), which is the patient laid supine with the head up 30 degrees higher than the feet & received the recruitment maneuver (RM) by Positive End Expiratory Pressure (PEEP) titration
89028476|NCT02276664|Experimental|Study 2 - Self-Help Intervention (SHI)|The SHI arm will receive the intervention developed in Study I.
89028477|NCT02276664|Active Comparator|Study 2 - Usual Care (UC)|The UC arm will receive the existing Clearing the Air smoking-cessation manual.
89028478|NCT01245296|Other|Early cord clamping (ECC)|Early cord clamping consisted of early (< 10 s) clamping of the umbilical cord and obtaining blood gas samples after clamping.
89028479|NCT01245296|Other|Delayed cord clamping (DCC)|Delayed cord clamping consisted of delayed (> 180 s) clamping of the umbilical cord and obtaining blood gas samples before clamping (within 30 seconds).
89028480|NCT04695990|Experimental|Experimental group|On the basis of basic western medicine treatment (secondary prevention of coronary heart disease + anti-heart failure treatment), Patients in this group will be given Wenyang Huoxue Decoction, one dose per day, administered in two doses, 150-200 mL each time, for 12 weeks.
89028481|NCT04695990|Placebo Comparator|Control group|On the basis of basic western medicine treatment (secondary prevention of coronary heart disease + anti-heart failure treatment), Patients in this group will be given placebo, one dose per day, administered in two doses, 150-200 mL each time, for 12 weeks.
89028482|NCT00503321|Experimental|Arm B|S-1 plus PSK group
89028483|NCT00503321|Active Comparator|Arm A|S-1 alone
89028484|NCT05144295|Experimental|Investigational Arm|"Patients will receive lubiprostone capsules (Amiprostone 8 and 24 mcg, or Lubicont 8 mcg)~Patients weighing <50 kg will be given lubiprostone at doses of 8 mcg/8 hours.~Patients weighing ≥ 50 kg will be given lubiprostone at doses of 24 mcg BID.~Patients and their parents/legal guardians will be instructed to administer the doses at least 5 hours apart with meals and a large volume of fluid."
89028485|NCT05144295|Active Comparator|Control Arm|"Subjects will receive the conventional therapy (one or a combination of the following):~Lactulose  Lactulose, or Duphalac syrup at a dose of 1 ml/kg once or twice daily (maximum 60 mL/day),~Bisacodyl tablets  Bisacodyl 5 mg/tablet in a dose of 2 tab/day for < 12 years or 3 tab/day for > 12 years, or~Sodium Picosulfate 0.75% drops (Picolax drops) in a daily dose of 2.5-20 mg/day."
89028486|NCT01245452|Experimental|Tocilizumab|Tocilizumab (8 mg/kg monthly from week 0 to 20)
89028487|NCT01245452|Active Comparator|Methotrexate|MTX at a dose ranging from 10 mg/week at baseline to 20 mg/week at week 8
89028488|NCT00503516|Experimental|1|Megestrol acetate 160 mg b.i.d. during 24 weeks
89028489|NCT00503516|Placebo Comparator|2|1 sachet of powder of placebo b.i.d. during 24 weeks
89028490|NCT04696991|Experimental|Experimental Group|The mothers in the experimental group (70) were given the postpartum discharge education with PechaKucha Method.
89028491|NCT04696991|No Intervention|Control Group|The mothers in the control group (70) were given the routine postpartum discharge education.
89028492|NCT05146869|Experimental|50 mg DBPR108 tablets|10 patients will be randomized to receive 50 mg DBPR108 tablets.
89028493|NCT05146869|Experimental|100 mg DBPR108 tablets|10 patients will be randomized to receive 100 mg DBPR108 tablets.
89028494|NCT05146869|Experimental|200 mg DBPR108 tablets|10 patients will be randomized to receive 200 mg DBPR108 tablets.
89028495|NCT05143827|Experimental|Senatore Cappelli pasta|
89028496|NCT05143827|Experimental|Korasan pasta|
89028497|NCT05143827|Active Comparator|Claudio pasta|
89028498|NCT00499187||Fanconi Cases|This cohort enrolled participants with evidence of protocol-defined Fanconi syndrome (confirmed creatinine clearance decline and evidence of proximal tubulopathy).
89028499|NCT00499187||Control Cases|This cohort enrolled participants with no evidence of protocol-defined Fanconi syndrome.
89028500|NCT01246544||Data collection group: physicians|Online survey for physicians/members of the innovation alliance Berlin-Brandenburg (INABBRA)
89028501|NCT05147259|Experimental|Cohort one: Low dose|Subjects will be randomized to a treatment sequence consisting of two treatment periods: received two formulation HR011408 injections successively
89028502|NCT05147259|Experimental|Cohort two: Medium dose|Subjects will be randomized to a treatment sequence consisting of two treatment periods: received two formulation HR011408 injections successively
89028503|NCT05147259|Experimental|Cohort three: high dose|Subjects will be randomized to a treatment sequence consisting of two treatment periods: received two formulation HR011408 injections successively
89028504|NCT00499265|Active Comparator|Gemcitabine|
89028505|NCT00499265|Experimental|Gemcitabine plus 200 mg WX-671|
89028506|NCT00499265|Experimental|Gemcitabine plus 400 mg WX-671|
89028507|NCT05147064|Experimental|group A|randomly allocated
89028508|NCT05147064|Experimental|group B|randomly allocated
89028509|NCT01246622|Experimental|Treatment (biological therapy)|Patients receive lenalidomide PO on days 6-26 and cytarabine IV over 3 hours on days 1-5. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
89028510|NCT01245530|Active Comparator|Aricept|Intervention: Drug: Aricept
89028511|NCT01245530|Experimental|INM-176|Intervention: Drug: INM-176
89028512|NCT00499382||PET/CT scan + NM cardiac scan|
89028513|NCT05148312|Experimental|AQ001S 0.125 mg/2mL single-dose|AQ001S 0.125 mg/2 ml (budesonide 0.125 mg/2 ml inhalation solution) single-dose administered by nebulization.
89028514|NCT05148312|Experimental|AQ001S 0.250 mg/2mL single-dose|AQ001S 0.250 mg/2 ml (budesonide 0.250 mg/2 ml inhalation solution) single-dose administered by nebulization.
89028515|NCT05148312|Experimental|AQ001S 0.500 mg/2mL single-dose|AQ001S 0.500 mg/2 ml (budesonide 0.500 mg/2 ml inhalation solution) single-dose administered by nebulization.
89028516|NCT05148312|Active Comparator|Budesonide inhalation suspension 1.0 mg/2 ml single-dose|Pulmicort Respules® 1.0 mg/2 ml is a budesonide inhalation suspension administered by nebulization.
89028517|NCT01246700|Experimental|Group A|Participants received 12 weeks of Sensory Attention Focused Exercise, then received 12 weeks of no exercise.
89028518|NCT01246700|Experimental|Group B|Participants received no treatment for 12 weeks, then received Sensory Attention Focused Exercise for 12 weeks.
89028519|NCT05142306|Experimental|COVID-HIG Intramuscular|COVID-HIG single dose administered IM
89028520|NCT05142306|Experimental|COVID-HIG Subcutaneous|COVID-HIG single dose administered SC
89028521|NCT05142306|Experimental|COVID-HIG Intravenous|COVID-HIG single dose administered IV
89028522|NCT01246778||With/without sunitinib|Two trabeculas will be isolated and one will be exposed to sunitinib and the other to normal buffer solution. Both will be stimulated to contraction during 200 minutes.
89569060|NCT05508997|Active Comparator|Reverse Trendelenburg Position|"Group B received only the procedures of the physiotherapy part at the 3rd phase of operation by applying proper positioning for better oxygenation and ventilation (Reverse Trendelenburg Position), in which the patient laid supine with the head at 15-30 degrees higher than the feet to unload the weight of intra-abdominal contents from the diaphragm, this position:~Increase pulmonary compliance, functional residual capacity (FRC), and oxygenation.~Allows easier ventilation.~This position called safe apnea time allows time to secure the airway before desaturation for a 20-minute positioning time."
89569061|NCT05612009||1. Signal Expert Protection|After scoring clinically and with dental plaque imaging methods, Signal Expert Protection toothpaste was given to 10 volunteers.
89569062|NCT05612009||2. Colgate Hemp Seed Oil|After scoring clinically and with dental plaque imaging methods, Colgate Hemp Seed Oil toothpaste was given to 10 volunteers.
89569063|NCT05612009||3. Gumgumix|After scoring clinically and with dental plaque imaging methods, Gumgumix toothpaste was given to 10 volunteers.
89569064|NCT01655901|Experimental|Active video gaming|Playing Kinect
89569065|NCT01655901|Experimental|Passive video gaming|Playing Xbox 360
89569066|NCT01655901|Experimental|Resting|Stay seated on a comfortable chair
89569067|NCT05504551|Active Comparator|group B|Superficial cervical plexus block (SCP) block is given using high frequency linear ultrasound probe connected to an ultrasound machine to visualize superficial cervical plexus (SCP) posterior to the midpoint of sterno cleido mastoid (SCM) muscle. Once SCP is identified, a combination of 5 ml bupivacaine (0.5%) and 5 ml lidocaine (2%) is injected after negative aspiration followed by injection of 1 ml to confirm the area, using a 22 gauge B-bevel Echogenic Needle.
89569068|NCT05504551|Placebo Comparator|group S|SCP block is given using high frequency linear ultrasound probe connected to an ultrasound machine to visualize SCP posterior to the midpoint of SCM muscle. Once SCP is identified, 10 ml of normal saline is injected after negative aspiration followed by injection of 1 ml to confirm the area, using a 22 gauge B-bevel Echogenic Needle.
89569069|NCT05173779|Experimental|Left atrial isolation arm|All the enrolled subjects will receive left atrial isolation through catheter ablation.
89569070|NCT05475353|Active Comparator|Asyncronized Exercise Group|- Ergonomics awareness education and exercise suggestions
89569071|NCT05475353|Experimental|Syncronized Exercise Group|- Ergonomics awareness education and than 6 weeks online supervised exercise training
89569072|NCT05113797|Active Comparator|Control Group|Subjects will perform YBT-LQ practice tests using standardized set of verbal instructions provided in the YBT-LQ online manual prior to the testing condition.
89569073|NCT05113797|Experimental|OPTIMAL Motor Learning Group|Subjects will perform the YBT-LQ with the practice period altered to implement aspects of the three pillars of the OPTIMAL motor learning theory (promotion of autonomy support (AS), presence of an external focus (EF) of attention, and implementation of enhanced expectancies (EE) placed upon a task).
89569074|NCT04787081|Experimental|Sleep Care Positioning Training Program GRP1|A sleep care positioning lesson created by a University's postural-care scholars using Camtasia® video creation software with modules on evidence for night-time postural care, risk factor monitoring, sleep system types and set up, positioning methods, and outcome measures. This lesson consisted of interactive videos embedded with learning checkpoints. All videos included narration and closed captioning. The following link contains the videos which were modified post-study to reflect some of the participant's feedback: https://stkatentpc.weebly.com/
89569075|NCT04787081|Active Comparator|Sleep Care Positioning Training Program GRP2|A sleep care positioning lesson created by a research assistant along with the principal investigator with modules on evidence for night-time postural care, risk factor monitoring, sleep system types and set up, positioning methods, and outcome measures. This lesson consisted of primarily written summary statements and links to freely available web-based information. Most of this lesson's modules included written information that the participant would need to read with the exception of the positioning methods modules. For the positioning module, participants were provided with links to manufacturers' websites which contained video clips on how to place postural supports.
89569076|NCT05172375|Experimental|The Shared Care model - intervention group|The patients are referred to outpatient clinics based on their home address. The two outpatient clinics should be comparable in terms of patients' diagnoses and staffing. The Shared Care model consists of the following key elements: Shared care is a collaboration between general practice and mental health services and enables a 'best of both worlds' scenario with the opportunity to provide holistic care of high quality to support the recovery process of people with mental health difficulties. The final version of the intervention can only be determined based on the results of the research steps 1+2.
89569077|NCT05172375|No Intervention|Treatment as usual - Control group|The patients are referred to outpatient clinics based on their home address. The two outpatient clinics should be comparable in terms of patients' diagnoses and staffing. In the control group the patients will receive treatment as usual.
89569078|NCT04911803|Experimental|Anxiety Group|Participants will download the anxiety application to their own handphones, and will complete the programme subsequently in their own time over the course of 2 weeks. The expected duration participants will spend on the anxiety application daily is estimated to be around 5 to 10 minutes, amounting to a total of around 140 minutes (2 hours and 10 minutes) during the 2 weeks intervention. Participants in the anxiety group are asked to complete daily brief exercises. For example, they will practice noticing worry thoughts and journal them down.
89208918|NCT04017416||Standard Care|Audiologists in the standard care group were instructed to manage the patients in the same way as they would do in their routine clinics which were in accordance with national practice guidelines and were typical of National Healthcare Services (NHS) audiology departments across the UK.
89208919|NCT04017416||I-PLAN|Audiologists were instructed to deliver the I-PLAN in addition to standard care at the hearing aid fitting consultation.
89569079|NCT04911803|Active Comparator|Procrastination Group|Participants will download the procrastination application to their own handphones, and will complete the programme subsequently in their own time over the course of 2 weeks. The expected duration participants will spend on the procrastination application daily is estimated to be around 5 to 10 minutes, amounting to a total of around 140 minutes (2 hours and 10 minutes) during the 2 weeks intervention. Participants in the procrastination group are asked to complete daily brief exercises. For example, they will practice to reduce procrastination-related thoughts.
89569080|NCT04838405|Experimental|CT-388|SC dose of CT-388
89569081|NCT04838405|Placebo Comparator|Placebo|SC dose of placebo matching CT-388 dose
89569082|NCT04801121||Pregestational diabetic pregnant|Cases: Women with type 1 or type 2 diabetes before start of pregnancy
89569083|NCT04801121||Non-diabetic pregnant|Controls: Women without metabolic disease before start of pregnancy
89569084|NCT05111301|Experimental|Basal Insulin Only (Group A)|"2 to 4 week CGM run-in~2 to 4 week pump run-in~6 weeks Control-IQ technology use"
89569085|NCT05111301|Experimental|Multiple Daily Injections (Group B)|"2 to 4 week CGM run-in~2 to 4 week pump run-in~6 weeks Control-IQ technology use"
89569086|NCT05475275|Experimental|Experimental group|"The experimental group underwent intraoperative measurements (A: short distance from the center of the pancreatic duct to the edge of the pancreas) and (B: pancreatic thickness). When the ratio of the thickness of the short distance from the center of the pancreatic duct to the edge of the pancreas at the pancreatic section was ≥0.401, it was divided into the N1 group (central pancreatic duct). If the ratio was <0.401, it was divided into the N2 group (eccentric pancreatic duct). The central pancreatic duct group was given 1+1 mode pancreaticojejunostomy; the eccentric pancreatic duct group was given 1+1² mode pancreaticojejunostomy."
89569087|NCT05475275|Active Comparator|Control group|"The patients in the control group were given traditional pancreaticojejunostomy"
89569088|NCT05078463|Experimental|Intervention A: Microneedle with 1 Finger Tip Unit (FTU) EMLA for 30 minutes|A Maltose Microneedle array patch (size: 1 cm x 1 cm) containing 36 microneedles (the height, base width and tip radius of each microneedle are 400 μm, 100 μm and 3 μm, respectively) with 1 mm needle gap in between will be firmly applied for 5 seconds against the pre-specified 1 cm x 1 cm grid (which will be the ideal site for intravenous cannulation for blood transfusion) on the dorsal surface of the hand. 1 Finger Tip Unit (FTU) of EMLA cream (containing an equal amount (25 mg) of lidocaine 2.5% and prilocaine 2.5%) (approximately 0.68g/cm2) will then be topically applied for 30 minutes on the same site of microneedle application. Intravenous cannulation will subsequently be carried out.
89569089|NCT05078463|Experimental|Intervention B: Microneedle with 0.5 Finger Tip Unit (FTU) EMLA for 30 minutes|A Maltose Microneedle array patch (size: 1 cm x 1 cm) containing 36 microneedles (the height, base width and tip radius of each microneedle are 400 μm, 100 μm and 3 μm, respectively) with 1 mm needle gap in between will be firmly applied for 5 seconds against the pre-specified 1 cm x 1 cm grid (which will be the ideal site for intravenous cannulation for blood transfusion) on the dorsal surface of the hand. 0.5 Finger Tip Unit (FTU) of EMLA cream containing an equal amount (25 mg) of lidocaine 2.5% and prilocaine 2.5% (dose: approximately 0.369 g/cm2) will then be topically applied for 30 minutes on the same site of microneedle application. Intravenous cannulation will subsequently be carried out.
89028523|NCT01246778||With/without sunitinib IP|Two trabeculas will be isolated and one will be exposed to sunitinib and the other to normal buffer solution. Both will be stimulated to contraction and ischemia/reperfusion
89028524|NCT05143437|Experimental|Writing Intervention|Couples will take part in three 7-minute online writing sessions over the course of four weeks.
89028525|NCT00499499|Experimental|1|
89028526|NCT05148663||blood drawing and hemorrhagic events in CCM patients|planned for three blood drawing before surgery
89028527|NCT05148663||blood drawing for age/gender/ethnicity matched controls|Blood draw from Control patients with no inflammation
89028528|NCT04696341|Experimental|Matrix Rhythm Therapy|Group I (15 subjects) received 10 sessions as 5 sessions a week. Hot pack to cervical and upper thoracic regions, conventional TENS, therapeutic ultrasound, conventional massage and Matrix Rhythm Therapy were applied. Home-based exercise program and recommendations were also given to patients.
89208920|NCT00804674|Active Comparator|1 bupivacain|
89208921|NCT00804674|Placebo Comparator|2 placebo|
89208922|NCT00881088|No Intervention|1|Patients randomized to the no intervention group
89569090|NCT05078463|Experimental|Intervention C: Microneedle with 1 Finger Tip Units (FTUs) EMLA for 15 minutes|A Maltose Microneedle array patch (size: 1 cm x 1 cm) containing 36 microneedles (the height, base width and tip radius of each microneedle are 400 μm, 100 μm and 3 μm, respectively) with1 mm needle gap in between will be firmly applied for 5 seconds against the pre-specified 1 cm x 1 cm grid (which will be the ideal site for intravenous cannulation for blood transfusion) on the dorsal surface of the hand. One (1) Finger Tip Unit (FTU) of EMLA cream (containing an equal amount (25 mg) of lidocaine 2.5% and prilocaine 2.5%) (approximately 0.68g/cm2) will then be topically applied for 15 minutes on the same site of microneedle application. Intravenous cannulation will subsequently be carried out.
89569091|NCT05078463|Sham Comparator|Intervention D: 1 Finger Tip Unit (FTUs) EMLA only and PVA-containing PET Sham Patch|A Polyvinyl Alcohol (PVA)-containing Polyethylene Terephthalate (PET) Sham Patch of 1 cm x 1cm size will be applied for 5 seconds against the pre-specified 1 cm x 1 cm grid (which will be the ideal site for intravenous cannulation for blood transfusion) on the dorsal surface of the hand. One (1) Finger Tip Unit (FTU) of EMLA cream (containing an equal amount (25 mg) of lidocaine 2.5% and prilocaine 2.5%) (approximately 0.68g/cm2) will then be topically applied for 30 minutes on the same site of microneedle application. Intravenous cannulation will subsequently be carried out.
89569092|NCT05077137|Experimental|Td Vaccine|The first 15 subjects enrolled will receive the Td (tetanus diphtheria) vaccine at cycle 4 of IO therapy. The Td vaccine is administered as 0.5 mL intramuscular injection in the extremity (thigh or upper arm) in closest proximity to the largest tumor.
89569093|NCT05077137|Experimental|IPOL Vaccine|Subjects 16 through 25 will receive the IPOL (polio booster) vaccine at cycle 4 of IO therapy. The IPOL vaccine is administered as 0.5 mL intramuscular or subcutaneous injection in the extremity (thigh or upper arm) in closest proximity to the largest tumor
89569094|NCT04786769|Experimental|Iron supplementation|"Intravenous ferric carboxymaltose will be administered according to weight and hemoglobin values at randomization as follows:~2-4 weeks before valve intervention On the day of admission to valve intervention (if determined by dose calculation, otherwise placebo) 12 weeks after valve intervention (if iron deficiency persists, otherwise placebo)"
89569095|NCT04786769|Placebo Comparator|Placebo|"Intravenous 0.9% NaCl (placebo) will be administered as follows:~2-4 weeks before valve intervention On the day of admission to valve intervention 12 weeks after valve intervention"
89569096|NCT05611541|Experimental|İntervention group|"Progressive Muscle Relaxation Training Program; The training was carried out in a single session for 2 hours and a break of 10-15 minutes was given.~Pregnant women were instructed to perform PMR at least 1 hour after dinner 5 days a week."
89569097|NCT05611541|Active Comparator|Control group|"The Progressive Muscle Relaxation Training Program and the Progressive Muscle Relaxation were not applied.~The pregnant women were asked to continue their normal daily activities for 8 weeks."
89569098|NCT05170113|Active Comparator|Alpinia galanga formulation|Alpinia galanga formulation capsule: Take one (1) capsule once daily at noon with 8 oz. (240 ml) of water for a 14-day dosing period
89569099|NCT05170113|Active Comparator|Theacrine formulation|Theacrine formulation capsule: Take one (1) capsule once daily at noon with 8 oz. (240 ml) of water for a 14-day dosing period
89569100|NCT05170113|Active Comparator|Caffeine formulation.|Caffeine formulation capsule: Take one (1) capsules once daily at noon with 8 oz.(240 ml) of water for a 14-day dosing period
89569101|NCT05170113|Placebo Comparator|Placebo|Placebo capsule: Take one (1) capsule once daily at noon with 8 oz. (240 ml) of water for a 14-day dosing period
89569102|NCT05475119|Experimental|Participants diagnosed with Obstructive Sleep Apnea|The participants will sleep three nights at the sleep lab and undergo in their first night, Polysomnography (PSG). Then at random, some of them will do CPAP titration in the second night followed by HFNC titration in the third night. While others will do HFNC titration in the second night followed by CPAP titration in the third night
89028529|NCT04696341|Experimental|Control|Group II (15 subjects) received 10 sessions as 5 sessions a week. Hot pack to cervical and upper thoracic regions, conventional TENS, therapeutic ultrasound and conventional massage were applied. Home-based exercise program and recommendations were also given to patients.
89028530|NCT05147025|Experimental|Revasularization|Revascularization of failed previously revascularized younge permenant inciors
89028531|NCT01245803|Experimental|rosuvastatin,one month,lipid lowering|additional rosuvastatin(10mg) is given at 18hr and 4-6hr before PCI
89028532|NCT01245803|Placebo Comparator|sugar pill, one month|sugar pill is given 18-24hr and 4-6hr before PCI as control
89028533|NCT05148975||Mild ARDS due to Covid- 19 pneumonia|Adults with SARS-CoV-2 PCR positivity in the last 21 days on mechanical ventilation for Covid-19 pneumonia, fulfilling criteria for mild acute respiratory distress syndrome (ARDS) definition.
89028534|NCT01246934|No Intervention|COMPLICATION|
89028535|NCT01247012|Active Comparator|Lipid minimization|
89569103|NCT05110521|Experimental|Intervention (PROMPTS and MENTORS offered)|Health facilities randomized into the Intervention Arm will be offered the MENTORS program, which trains in-facility nurse-mentors to provide health workers with training and mentorship on aspects of basic and emergency obstetric and newborn care. At health facilities in the intervention arm, patients attending antenatal care clinics will be offered the PROMPTS program, which is a digital health platform that connects mothers with information, advice and referrals to care.
89569104|NCT05110521|No Intervention|Control (Routine Care/No PROMPTS or MENTORS OFFERED)|In the control arm, neither the PROMPTS program nor the MENTORS program will be offered during the study period.
89569105|NCT01295723|Experimental|Intraoperative Electron Radiation Therapy|A single dose of electron irradiation given at the surgical site during the operation to remove the cancerous tumor will replace the usual 5-8 days of localized radiation. Hypofractionated Whole Breast Radiation Therapy must start within 14-56 days post operatively.
89028536|NCT01247012|Experimental|Omegaven|
89028537|NCT03454191|Experimental|Erector spinae plane block|
89028538|NCT03454191|Placebo Comparator|Placebo|
89208923|NCT00881088|Experimental|Nadroparin|Subjects randomized to group receiving nadroparin 0,3 cc daily during immobilization
89569106|NCT05611463|Experimental|Camrelizumab Plus Docetaxel and Cisplatin|Participants receive Camrelizumab 200 mg intravenously (IV) on Day 1 of each 3-week cycle for up to 24 months;plus cisplatin 75 mg/m^2 IV or carboplatin at a target area under the curve of 5 (AUC 5) IV, per Investigator's choice, on Day 1 of each 3-week cycle (6 cycle maximum); plus docetaxel 75 mg/m^2 IV on Day 1 of each 3-week cycle (6 cycle maximum).
89569107|NCT05110365|Experimental|proprioceptive neuromuscular facilitation|proprioceptive neuromuscular facilitation techniques
89569108|NCT05110365|No Intervention|control|no intervention
89569109|NCT05110131|Active Comparator|Needle-centered|Participants affiliated to this arm will undergo ENB-guided biopsy with needle aspiration first, followed by forceps biopsy
89569110|NCT05110131|Active Comparator|Forceps-centered|Participants affiliated to this arm will undergo ENB-guided biopsy with forceps first, followed by needle aspiration.
89569111|NCT05611385||Positive for Amphetamine|Patients admitted to the burn unit that are positive for amphetamine
89569112|NCT05611385||Negative for Amphetamine|Patients admitted to the burn unit that are negative for amphetamine
89569113|NCT05475041||Minor liver resection|Minor liver resection (<3 contiguous segments) in the anterolateral segments
89569114|NCT05475041||Technically major liver resection|Minor liver resection (<3 contiguous segments) in the posterosuperior segments (Segment 1,4a,7,8)
89569115|NCT05475041||Major liver resection|Major liver resection (3 or more contiguous segments)
89569116|NCT01656759|No Intervention|Control Group|Control group. Will not receive the fibrin spray.
89569117|NCT01656759|Active Comparator|Treatment Group--Evicel Fibrin Spray|"Patient will receive the fibrin spray after implantation of device but before the wound is closed.~Patients will be randomized to receive spray or not and postop parameters measured."
89569118|NCT04234737|Experimental|Hypnotherapy|
89028539|NCT00499577|Experimental|Group 1 (HLA-A2 positive)|Patients receive the following peptides emulsified in incomplete Freund's adjuvant VG: I) hTERT I540 peptide; ii) hTERT R572Y peptide; iii) hTERT D988Y peptide; iv) survivin Sur1M2 peptide ; and v) CMV control peptide N495 subcutaneously (SC). Patients also receive sargramostim (GM-CSF) SC and pneumococcal conjugate vaccine intramuscularly.
89569119|NCT04234737|No Intervention|Control|
89569120|NCT04998747|Experimental|AMG 701: dose exploration|Cohorts of 3 to 6 participants each will be administered AMG 701 at different doses to determine the RP2D based on occurence of dose-limiting toxicities (DLTs) and on emerging safety, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy data.
89569121|NCT04998747|Experimental|AMG 701: dose expansion|Participants will be administered AMG 701 at the RP2D determined from dose exploration stage to further assess the safety, PK, PD, and efficacy of the selected dose.
89569122|NCT02631577|Experimental|Atezolizumab-G-lena 15mg|Participants were administered obinutuzumab, Atezolizumab, and 15 mg of Lenalidomide.
89569123|NCT02631577|Experimental|Atezolizumab-G-lena 20mg|Participants were administered obinutuzumab, Atezolizumab, and 20 mg of Lenalidomide.
89569124|NCT01667081||Grazoprevir|Participants who previously received grazoprevir as study treatment on a prior study.
89569125|NCT04998045|Experimental|Intervention arm|Youth aged 15-24 years Intervention: screening and brief intervention for substance use
89569126|NCT05558111||Patients with orthotopic neobladder|Patients with orthotopic neobladder who met the inclusion criteria will be enrolled.Inclusion criteria :(1) being right-handed;(2) 3 months or more after operation;(3) No contraindications to fMIR examination;(4)Does not meet the relevant exclusion criteria.
89569127|NCT05052411|Experimental|Expanded beta testing of the JomPrEP app|App usage assessments and analytics over a 1-month period.
89569128|NCT04545619|Experimental|Paroxysmal and Early Persistent AFIB|
89569129|NCT05474885|Experimental|BCMA-CD19 cCAR T cells|Dose escalation phase: patient's T cells will be transduced with a lentiviral vector to express a BCMA-CD19 cCAR. with an escalation approach.
89569130|NCT05728879|Experimental|CTCL participants|Visits will include screening, pre-treatment (week 0), weeks 4 and 8.
89569131|NCT04421469|Experimental|Comprehensive treatment|Patients with multiple metastatic NPC were given Triprilimab(JS001) and chemotherapy combined with local treatment.
89569132|NCT03067753|Active Comparator|Pulsed steroid|Pulse steroid, methylprednisolone, was administered by intravenous infusion over 3 consecutive days. Three grams of methylprednisolone was given in each cycle. Administration of 1 g was infused over 1 h daily for 3 days on an in-patient basis, which then tailed off in 10 days with administration of oral prednisolone.
89569133|NCT03067753|Experimental|Monosialoganglioside ganglioside|Monosialoganglioside ganglioside was given at 100 mg/time, once a day for 2 months.
89569134|NCT05073861|Experimental|App-based STEM online learning group|Participants in the experimental group will receive a 2.5-month intervention with the blended STEM learning app.
89569135|NCT05073861|Active Comparator|E-book learning group|The control group receive e-book chapters about STEM for learning for the same period of 2.5-month as the experimental group.
89028540|NCT00499577|Experimental|Group 2|Patients receive pneumococcal conjugate vaccine intramuscularly and GM-CSF subcutaneously.
89569136|NCT05613179|Experimental|Group1 (lever positioning manipulation)|Patients with lumbar disc herniation treated by lever positioning manipulation
89569137|NCT05613179|Active Comparator|Group2 (placebo group)|Patients with lumbar disc herniation treated by sham lever positioning manipulation
89569138|NCT05613179|No Intervention|Group3 (healthy controls)|Healthy control group without any intervention.
89569139|NCT04997031||Latinx Adults 18 - 65 y|
89569140|NCT05073393|Experimental|Probiotic|In this group participants will receive probiotic supplements twice a day (morning and evening) for at period of 28 days (14 days with sugar stress followed by 14 days without sugar stress).
89569141|NCT05073393|Placebo Comparator|Placebo|In this group participants will receive placebo twice a day (morning and evening) for at period of 28 days (14 days with sugar stress followed by 14 days without sugar stress).
89569142|NCT04212351||Patients with NF1 and active LGGs|Patients with Neurofibromatosis Type 1 with clinical or radiographic evidence of low grade glioma but no clinical or radiographic evidence of plexiform neurofibroma.
89569143|NCT04212351||Patients with NF1 and active PNs|Patients with Neurofibromatosis Type 1 with clinical or radiographic evidence of plexiform neurofibroma but no clinical or radiographic evidence of low grade glioma.
89569144|NCT04212351||Patients with NF1 with no active LGGs or PNs|Patients with Neurofibromatosis Type 1 with no clinical or radiographic evidence of both active plexiform neurofibroma and active low grade glioma.
89569145|NCT05050149|Experimental|Experimental: PTX-022|PTX-022 QTORIN
89569146|NCT05557799|Active Comparator|Photobiomodulation group|Participants in this group will receive photobiomodulation with a vaginal diode laser and its introit.
89569147|NCT05557799|Placebo Comparator|Placebo group|Participants in this group will receive simulated photobiomodulation, with the laser device turned off.
89569148|NCT05613101|Active Comparator|Erector Spinae Plane Block|Erector Spina Plane Block was performed to the patients after coplition of total knee arthroplasty operation for postopetaive pain.
89569149|NCT05613101|Active Comparator|Adductor Canal Block|Adductor Canal Block was performed to the patients after coplition of total knee arthroplasty operation for postopetaive pain.
89569150|NCT05613023|Active Comparator|P-SBRT|Participants allocated P-SBRT will receive 36.25Gy in 5 fractions to the prostate and seminal vesicles on alternate days (40Gy to prostate CTV).
89569151|NCT05613023|Experimental|PPN-SBRT|Participants allocated PPN-SBRT will receive 36.25Gy in 5 fractions to the prostate and seminal vesicles on alternate days (40Gy to prostate clinical target volume (CTV)) and 25Gy in 5 fractions to pelvic nodes on alternate days.
89569152|NCT03067597|Experimental|Dinoprostone vaginal insert (DVI)|
89569153|NCT02518971|Experimental|tamsulosin|0.4 mg daily for five days pre-op through post-op day one (seven total)
89569154|NCT02518971|Placebo Comparator|placebo|One capsule daily for five days pre-op through post-op day one (seven total)
89569155|NCT03067519|Experimental|Fast track surgery|Intervention: Fast track surgery patients underwent early feeding and mobilization after surgery
89569156|NCT03067519|Active Comparator|Conventional management|usual postoperative care per surgeon
89569157|NCT04733963|Experimental|Arm A|Maintenance therapy with Fruquintinib Plus Capecitabine
89569158|NCT04733963|Active Comparator|Arm B|Maintenance therapy with Bevacizumab Plus Capecitabine
89569159|NCT03066115|Experimental|NOS, COX, and ROS Inhibition|Subjects will receive L-NMMA, ketorolac, then ascorbic acid via intravenous catheter. L-NMMA will have a 3 mg kg-1 loading dose over 5-minutes (36 mg kg-1 hr-1), followed by a maintenance dose of 1 mg kg-1 hr-1. Ketorolac will have a 0.3 mg kg-1 loading dose over 5 minutes (3.6 mg kg-1 hr-1) with a minimum loading dose of 15 mg. This will be followed by a maintenance dose of 0.03 mg kg-1 hr-1. Ascorbic acid will have a loading dose of 0.035 g kg fat-free mass-1 over 5-minutes (0.42 g kg fat-free mass-1 hr-1), followed by a maintenance dose of 0.060 g kg fat-free mass-1 hr-1. Cerebral blood flow velocity will be measured throughout the drug infusions via transcranial Doppler ultrasound.
89569160|NCT03066115|Experimental|COX, NOS, and ROS Inhibition|"Subjects will receive ketorolac, L-NMMA, then ascorbic acid via intravenous catheter.~Ketorolac will have a 0.3 mg kg-1 loading dose over 5 minutes (3.6 mg kg-1 hr-1) with a minimum loading dose of 15 mg. This will be followed by a maintenance dose of 0.03 mg kg-1 hr-1. L-NMMA will have a 3 mg kg-1 loading dose over 5-minutes (36 mg kg-1 hr-1), followed by a maintenance dose of 1 mg kg-1 hr-1. Ascorbic acid will have a loading dose of 0.035 g kg fat-free mass-1 over 5-minutes (0.42 g kg fat-free mass-1 hr-1), followed by a maintenance dose of 0.060 g kg fat-free mass-1 hr-1. Cerebral blood flow velocity will be measured throughout the drug infusions via transcranial Doppler ultrasound."
89569161|NCT04212039|Active Comparator|ultrasound guided pericapsular nerve group block|Ultrasound guided 0.5 ml/kg % 0.250 bupivacaine injection between to iliopubic eminentia and psoas tendon
89569162|NCT04212039|Sham Comparator|ultrasound guided sham block|Ultrasound guided 0.5 ml/kg saline injection injection between to iliopubic eminentia and psoas tendon
89028541|NCT00499577|Experimental|Second group 1|On days 14, 42, and 90 post-transplant, patients receive peptides and GM-CSF subcutaneously and pneumococcal conjugate vaccine intramuscularly.
89028542|NCT00499577|Experimental|Second group 2|On day 14, 42, 90 post-transplant, patients receive pneumococcal conjugate vaccine intramuscularly and GM-CSF subcutaneously.
89569163|NCT04433377|Experimental|Suprascapular nerve block group|"Suprascapular nerve block will be performed with a MyLab60 model a high resolution 7-12-MHz linear probe ultrasonography device. After the suprascapular fossa will be observed by ultrasonography, a betamethasone dipropionate plus betamethasone sodium phosphate solution (6.43 mg / mL + 2.63 mg / mL; 1 mL), 0.5 % bupivacaine (2 mL) and physiological serum (2 mL) will be injected with an in-plane technique using a 22 gauge 90-mm injector.~Home exercise: The exercise program consists of passive and active-assistive ROM exercises (3 sets daily, 20 times in each set)."
89569164|NCT04433377|Experimental|Subacromial injection group|"Subacromial injection will be performed with a MyLab60 model a high resolution 7-12-MHz linear probe ultrasonography device. After the subacromial bursa will be observed by ultrasonography, a betamethasone dipropionate plus betamethasone sodium phosphate solution (6.43 mg/mL + 2.63 mg/mL; 1 mL), 2% lidocaine (2 mL) and physiological serum (2 mL) will be injected with an in-plane technique using a 21 gauge 38-mm injector.~Home exercise: The exercise program consists of passive and active-assistive ROM exercises (3 sets daily, 20 times in each set)."
89569165|NCT05048589|Active Comparator|Standard-Dose Quadrivalent Influenza Vaccine|QIV-SD single injection at Day 0
89569166|NCT05048589|Experimental|High-Dose Quadrivalent Influenza Vaccine|QIV-HD single injection at Day 0
89569167|NCT05728567||Health control group|The participants without type 2 diabetes (T2DM) and mild cognitive impairment (MCI)
89569168|NCT05728567||T2DM group|The T2DM patients without MCI
89569169|NCT05728567||DCI group|The T2DM patients with MCI
89569170|NCT03067285|Active Comparator|Arm 1|Patients who postpone switching from DTG/3TC/ABC to ELV/COBI/FTC/TAF four weeks:
89569171|NCT03067285|Experimental|Arm 2|Patients who switch from DTG/3TC/ABC to ELV/COBI/FTC/TAF during the baseline visit
89569172|NCT01365039|Experimental|Test lens|Test contact lens will be worn on a daily disposable wear basis.
89569173|NCT01365039|Active Comparator|SofLens lens|The currently marketed Bausch + Lomb SofLens daily disposable contact lens. Worn on a daily disposable wear basis.
89028543|NCT03450096|Active Comparator|Treatment group|A bolus injection for LPB of 0.5 ml/kg ropivacaine 3.75 mg/ml (max 40 ml will be performed and the catheter will be placed before surgical interventions. A continuous perineural infusion of 0.2 ml/kg/h ropivacaine 0.2%, starting immediately after initial bolus injection will be then administered
89569174|NCT03067207|Experimental|Experimental|The experimental arm will consist of four groups with a target of 15 participants each: one early intervention group, one wait-list in-person group, one early e-Health group and one wait-list e-health group. All participants will receive the mindfulness intervention, MARS-A, either in-person or via e-health by the end of the 6-month study period. Participants in the in-person groups will meet at in hospital at a designated teen-friendly room containing chairs and yoga mats. Participants in the e-health groups will be encouraged to find a quiet room in their home and will be required to have access to the Internet, a desktop/laptop computer equipped with a webcam or a tablet/smartphone with webcam function.
89569175|NCT03067207|Other|Feasibility|The feasibility arm, which will only take place if the targeted number of study participants (60) is not reached for the experimental arm, will be offered to participants who are not able to commit to the in-person mode of delivery. It will consist of two groups, one early e-health group and one wait-list e-Health group. The intervention delivered, MARS-A, will be identical as the intervention delivered to e-health groups in the experimental arm.
89569176|NCT03065881|Active Comparator|Dilated versus Natural pupil|
89569177|NCT03065881|Active Comparator|Normal retina versus abnormal retina|
89569178|NCT05047575|Experimental|REASSURE Cohort 1|Survivors who are enrolled at time of a follow-up visit and who will be offered the REASSURE intervention at the next 6 month visit (including the opportunity to replace a visit with feedback communication).
89569179|NCT05047575|Experimental|REASSURE Cohort 2|Survivors who are enrolled prior to a follow-up visit and who will be offered the REASSURE PRO assessment and feedback communication (but not provided the opportunity to replace a visit with feedback communication).
89569180|NCT03065959|Experimental|CK-2127107, then Placebo|Participants will first receive CK-2127107 tablets (twice daily) for 14 days. After a 14 day wash out period participants will then receive matching placebo.
89569181|NCT03065959|Experimental|Placebo, then CK-2127107|Participants will first receive Placebo tablets (twice daily) for 14 days. After a 14 day wash out period participants will then receive matching CK-2127107.
89569182|NCT04993365|Experimental|Experimental Group|The experimental group is also called the combined immunization group .260 participants will receive the first dose of COVID-19 vaccine and EV71 vaccine on day 0 and the second dose of COVID-19 vaccine and EV71 vaccine on day 28.
89569183|NCT04993365|Active Comparator|Control Group|The control group is also called the Non-combined immunization group.260 participants will receive the first dose of COVID-19 vaccine on day 0,the first dose of EV71 vaccine on day 14,the second dose of COVID-19 vaccine on day 28 and the second dose of EV71 vaccine on day 42.
89569184|NCT03067363|Experimental|Part 1, MOR107 Dose level 1|MOR107, single subcutaneous injection
89569185|NCT03067363|Experimental|Part 1, MOR107 Dose level 2|MOR107, single subcutaneous injection
89569186|NCT03067363|Experimental|Part 1, MOR107 Dose level 3|MOR107, single subcutaneous injection
89569187|NCT03067363|Experimental|Part 1, MOR107 Dose level 4|MOR107, single subcutaneous injection
89569188|NCT03067363|Experimental|Part 1, MOR107 Dose level 5|MOR107, single subcutaneous injection
89569189|NCT03067363|Experimental|Part 1, MOR107 Dose level 6|MOR107, single subcutaneous injection
89569190|NCT03067363|Placebo Comparator|Part 1, Placebo|Placebo, single subcutaneous injection
89569191|NCT03067363|Experimental|Part 2: MOR107 low dose|MOR107 low dose single subcutaneous injection and low sodium diet for 6 days before dosing and 2 days after dosing
89569192|NCT03067363|Experimental|Part 2: MOR107 medium dose|MOR107 medium dose single subcutaneous injection and low sodium diet for 6 days before dosing and 2 days after dosing
89569193|NCT03067363|Experimental|Part 2: MOR107 high dose|MOR107 high dose single subcutaneous injection and low sodium diet for 6 days before dosing and 2 days after dosing
89569194|NCT03067363|Placebo Comparator|Part 2: Placebo|Placebo single subcutaneous injection and low sodium diet for 6 days before dosing and 2 days after dosing
89569195|NCT05428813|Experimental|Experimental|The group to which art therapy techniques will be applied.
89569196|NCT05428813|No Intervention|Control|The group that will continue their routine coping habits related to premenstrual syndrome.
89569197|NCT05046561|Active Comparator|STRI Formula|STRI Formula 3 capsules by mouth twice daily for 10 days
89028544|NCT03450096|No Intervention|Control group|Patients in the control group (and in the active treatment group) will receive an opioid-based analgesia with a hydromorphone-patient controlled analgesia (PCA) depending on their analgesic demand
89569198|NCT05046561|Placebo Comparator|Placebo|Placebo 3 capsules by mouth twice daily for 10 days
89569199|NCT05419219|Active Comparator|The Multi-domain Tai Chi Digital Therapy Group|participants will be provided via a tablet or smart phone the traditional Tai Chi exercise with background music and respiratory control exercise with 18 BPM metronome, and 40 Hz sound stimulation for 4-week therapeutic session.
89569200|NCT05419219|Placebo Comparator|The regular Tai Chi Exercise Group|participants will be provided by the same way to deliver traditional Tai Chi exercise with plain music background, but without respiratory control exercise or 40 Hz sound stimulation. All participants will receive any other routine care or treatment as usual (TAU).
89569201|NCT05416801||Volleyball Group|Female Volleyball players who are currently playing in a university team and who are meeting the inclusion criteria.
89569202|NCT05416801||Control Group|Female university students who are meeting the inclusion criteria.
89569203|NCT04447651||Patients with SF3B1, U2AF1 or SRSF2 mutation|Metastatic solid tumor patients that have a SF3B1, U2AF1 or SRSF2 mutation
89569204|NCT05370703||Standard of Care (SOC) group|This group will continue their current lipid-lowering therapy and will not need to download any mobile application.
89569205|NCT05370703||SOC + My A:Care group:|This group will continue their current lipid-lowering therapy along with access to the mobile application My A:Care that supports medication adherence through motivational messages and challenges, health insights, and medication reminders.
89028545|NCT02274740|Experimental|lixisenatide|"Lixisenatide injection should be performed in the morning, within 1 hour (ie, 0-60 minutes), prior to breakfast (or standardized meal).~Lixisenatide is to be started with once daily injections of 10 μg per day for 2 weeks then to be continued by the maintenance dose (8 weeks) of 20 μg/d up to the end of the treatment period."
89208924|NCT00881088|Experimental|Fondaparinux|Subjects randomized to fondaparinux 2,5 mg daily group during immobilization
89569206|NCT05370703||SOC + Smart Coach group:|"This group will continue their current lipid-lowering therapy along with access to the mobile application Smart Coach that supports medication adherence through personalized motivational messages and challenges, health insights, and medication reminders. Personalization of the messages and challenges will be based on a behavioral profiling Social, Psychological, Usage, Rational (SPUR™) questionnaire that is completed at randomization to the Smart Coach application.~Study site will guide the subjects on how to use these mobile applications. Eligibility assessment will be based on information collected at screening/baseline visit (Visit 1) and assessment of Part 1 of MARS 5VA questionnaire. Adherence at baseline (Visit 1) and after 12 weeks of observation (Visit 2), will be evaluated by the complete MARS 5VA (Part 1 and 2) questionnaire. Each subject will be followed up for approximately 12 weeks from randomization at Visit 1."
89569207|NCT01364727|Experimental|Amrubicin|Amrubicin 35mg/m2 IV days 1-3 every 3 weeks
89569208|NCT02633215|Experimental|Active stimulation with motor training|2 hours of active peripheral nerve stimulation (intervention) paired with 4 hours of intensive task-oriented upper extremity training. Peripheral nerve stimulation of Erb's point, radial and median nerves paired with task-oriented therapy. Peripheral nerve stimulation will be delivered using a S88 Dual Output Stimulator by Grass Technologies.
89569209|NCT02633215|Active Comparator|Sham stimulation with motor training|2 hours of sham peripheral nerve stimulation (intervention) paired with 4 hours of intensive task-oriented upper extremity training. Peripheral nerve stimulation of Erb's point, radial and median nerves paired with task-oriented therapy. Peripheral nerve stimulation will be delivered using a S88 Dual Output Stimulator by Grass Technologies.
89208925|NCT00981981|Placebo Comparator|Control|Wheat bran cereal
89208926|NCT00981981|Active Comparator|3g high MW|Cereal containing 3g high molecular weight oat beta glucan
89569210|NCT05728177|Experimental|STUDY GROUP|"Patients' medical charts in the outpatient clinic were reviewed to identify those who meet the inclusion criteria. Patients who meet the predetermined inclusion criteria were recruited in the study using simple randomization technique using computer-generated sequence technique to pick up these patients. After simple sampling and dividing patients into two groups of study and control. Patients from the study and control groups were interviewed individually by the researcher to apply the study tools~The program of intervention took four-weeks for each patient (total eight sessions- four outpatient sessions and four home-based sessions- two sessions per week- one outpatient and one home session/week). The outpatient sessions were done once per week during the patient visit to the outpatient clinic, as the patients visited the clinic 4 times/ month."
89569211|NCT05728177|Active Comparator|Control group|Patients in this control group will be left without any intervention to undergo the usual outpatient routine care.
89569212|NCT05725993||TBI Patient|
89569213|NCT05725993||Healthy Control|
89569214|NCT01364649|Experimental|Vortioxetine|Vortioxetine 10 mg, tablets, orally, once daily for 1 week, then dose adjustment to a maximum 20 mg, tablets, orally, once daily for up to 7 weeks. At week 8, vortioxetine placebo-matching capsules, orally, once daily for 1 week only.
88970113|NCT04913857|Experimental|24-week SUDOKU Training Programme|"The SUDOKU training program include a 12-week face-to-face training session and a 12-week facilitated self-practice. The 12-week (60-minute sessions) training program will be evenly divided into 3 modules of increasing difficulty for the suboptimal cognitive function of the participants with MCI. As the use of T-code in solving the SUDOKU allows communicating the way a number is assigned to a box, participants are grouped into a small team of 3, so that they will work together during the tutorial practice.~Facilitated self-practice will last for another 12 weeks immediately after the group training session. The instructor will give them a workbook with 12 SUDOKU puzzles of increasing level of difficulty for completion. The instructor will encourage and facilitate their accomplishment by giving them guidance on the taught method through regular phone call. Solutions of the assigned puzzle and the T-code will be provided in the following week."
88970114|NCT04913857|Active Comparator|wait-list|wait-list comparison group will receive the same program upon completion of the 6-month posttest evaluation on study outcomes
88970115|NCT04910399|Experimental|Blue fish hydrolysate|The test product is a food supplement named BrainBooster in our project. It is presented as a capsule containing a blue fish hydrolysate, containing peptides and n-3 polyunsaturated fatty acids.
89208927|NCT00981981|Active Comparator|4g medium MW|Cereal containing 4g oat beta glucan with medium molecular weight
89208928|NCT00981981|Active Comparator|3g medium MW|Cereal containing 3g oat beta glucan with medium molecular weight
89208929|NCT00981981|Active Comparator|4g low MW|Cereal containing 4g oat beta glucan with low molecular weight
88970116|NCT04910399|Placebo Comparator|Placebo|The placebo is a capsule with same appearance and organoleptic properties as the active product, containing no active component.
88970117|NCT04908930|No Intervention|Unexposed practice group- Aim 1|Data from an unexposed sample (football players practicing as they would otherwise).
88970118|NCT04908930|Experimental|On-field activity group - Aim 3|Athletes of two new teams at the middle school level to pilot the practice structure intervention and continuously monitor on-field activity with head impact sensors to evaluate the feasibility, acceptability, and sustainability of the practice structure
88970119|NCT04899141||Coronary Artery Disease|
88970120|NCT04897490||Adult APL in first line|Patients >/= 18 years old with recent diagnosis of acute promyelocytic leukemia who receive treatment with ATO/ATRA according to our local guidelines. HR patients will receive 2-3 additional doses of idarubicin.
88970121|NCT04883645|Experimental|Experimental: Topical Aldara|"All patients receive the same treatment (there is no placebo arm). Treatment will be self-administered by the patients on an outpatient basis. All patients with untreated and biopsy confirmed oral squamous cell carcinoma (OSCC) who meet the inclusion criteria."
88970122|NCT04873583|Experimental|Steroids + Standard of care|Standard of care (including aspirin) and intravenous steroids, followed by oral tapering.
88970123|NCT04873583|No Intervention|Standard of care|Standard of care (including aspirin)
89208930|NCT00878592|No Intervention|Control group|The first group (Group 1) will include the control subjects. They will receive one session of dietary and behavioral education.
89028546|NCT02274740|No Intervention|metformin|Greater than or equal than 1.5 g/day as background therapy for 10 weeks
89569215|NCT01364649|Active Comparator|Escitalopram|Escitalopram 10 mg, tablets, orally, once daily for 1 week, then escitalopram dose adjustment to a maximum 20 mg, capsules, orally, once daily for up to 7 weeks. At week 8, escitalopram 10 mg, capsules, capsules, orally, once daily for 1 week only.
89569216|NCT03065569|Active Comparator|Standard Epidural Technique|Epidural will be performed Initial dose of 16 mL of 0.125% bupivacaine will be given Upon patient request, rescue bolus based on protocol will be administered.
89569217|NCT03065569|Experimental|Combined Spinal Epidural Technique|CSE will be performed Initial dose of 16 mL of 0.125% bupivacaine will be given Upon patient request, rescue bolus based on protocol will be administered.
89569218|NCT03065491|Active Comparator|Active treatment|Combined nutraceutical
89569219|NCT03065491|Placebo Comparator|Placebo|Placebo
89569220|NCT02588261|Experimental|ASP8273|Participants received 300 mg of ASP8273 orally once daily in 28-day cycles until one of the discontinuation criteria was met (developed radiological progressive disease, required to receive local or systemic anti-cancer treatment, developed unacceptable toxicity, participant pregnancy, investigator decision, required to receive significant surgical procedure, participant protocol deviation or noncompliance, participant decline of further treatment and participant lost to follow-up).
89569221|NCT02588261|Active Comparator|erlotinib or gefitinib|Participants received 150 mg of erlotinib or 250 mg of gefitinib orally once daily in 28-day cycles until one of the discontinuation criteria was met (developed radiological progressive disease, required to receive local or systemic anti-cancer treatment, developed unacceptable toxicity, participant pregnancy, investigator decision, required to receive significant surgical procedure, participant protocol deviation or noncompliance, participant decline of further treatment and participant lost to follow-up).
89569222|NCT03065257||Endoscopic Resection|Patients undergoing Endoscopic Resection
89569223|NCT05040633|Experimental|Low Level Laser Therapy + standard exercise therapy|This group of participants will first receive the standard therapy of strengthening and stretching exercises followed by the Low Lever Laser Therapy.
89569224|NCT05040633|Sham Comparator|Sham Low Level Laser Therapy + standard exercise therapy|This group of participants will first receive the standard therapy of strengthening and stretching exercises followed by a sham Low Level Laser Therapy (LLLT). The laser equipment will be deactivated and not switched on.
89569225|NCT05040633|Active Comparator|Standard Exercise Therapy|Trial participants in this group will only receive the standard exercise therapy. The exercise therapy will consist of strengthening and stretching exercises.
89569226|NCT05711407||Peri-implantitis|Group Case
89569227|NCT05711407||Healthy|Group Control
89569228|NCT05286229|Experimental|Cohort 1 (ABBV-383 Dose A)|Participants with relapsed or refractory (R/R) multiple myeloma (MM) who meet the criteria outline in the protocol will receive ABBV-383 dose A in 21-day cycles.
89569229|NCT05286229|Experimental|Cohort 2 (ABBV-383 Dose B)|Participants with R/R MM who meet the criteria outline in the protocol will receive ABBV-383 dose B in 21-day cycles.
89569230|NCT04426487|Placebo Comparator|Control|Receiving conventional management for traumatic subarachinoid hemorrhage
89569231|NCT04426487|Active Comparator|progesterone group|Intramusculer progesterone therapy before and after craniotomy
89569232|NCT03797937|Experimental|Multiple sclerosis (MS) patients|Patients will undergo magnetic resonance imaging (MRI). Stool and blood samples will be collected.
89569233|NCT03797937|No Intervention|Healthy controls|Healthy controls will not undergo magnetic resonance imaging (MRI). Stool and blood samples will be collected.
89569234|NCT03797937|No Intervention|Multiple sclerosis (MS) patients undergoing a relapse|Multiple sclerosis (MS) patients undergoing a relapse will not undergo magnetic resonance imaging (MRI). Stool and blood samples will be collected.
89569235|NCT03797937|No Intervention|Multiple sclerosis (MS) patients from multiplex MS families|Multiple sclerosis (MS) patients from multiplex MS families will not undergo magnetic resonance imaging (MRI). Stool and blood samples will be collected.
89569236|NCT04989465|Experimental|Experimental Group|450 Participants (including 150 subjects aged 2~17 years, 150 subjects aged18~60 years and 150 subjects aged 61years and older ) received one dose of 23-valent pneumococcal polysaccharide vaccine manufactured by Sinovac Biotech Co., Ltd will be collected venous blood about 3.0~3.5 ml.
89569237|NCT04989465|Placebo Comparator|Control Group|150 Participants (including 50 subjects aged 2~17 years, 50 subjects aged18~60 years and 50 subjects aged 61years and older ) received one dose of 23-valent pneumococcal polysaccharide vaccine manufactured by Chengdu Institute of Biological Products will be collected venous blood about 3.0~3.5 ml.
89569238|NCT05557565|Experimental|QL1706 injection|The dosage of QL1706 is 5.0 mg/kg, and QL1706 is administered every 3 weeks (Q3W) by intravenous infusion
89569239|NCT03066895|Experimental|Experimental|BabyGentleStick
89569240|NCT03066895|Active Comparator|Standard of Care|HMC Standard Lancing Device
89028547|NCT00499733|Experimental|Intervention|Participant will receive one time intravenous infusion of cyclophosphamide three days after scheduled cryoablation surgery.
89028548|NCT03452202|Experimental|Active Stimulation|crossover design such that each participant receives behavioral treatment twice - once with active stimulation and once with sham stimulation - in order to evaluate differences in improvement based on treatment condition.
89028549|NCT03452202|Sham Comparator|Sham Stimulation|crossover design such that each participant receives behavioral treatment twice - once with active stimulation and once with sham stimulation - in order to evaluate differences in improvement based on treatment condition.
89569241|NCT05040243|Experimental|Treatment Group|"On the basis of conventional acupuncture treatment combined with acupoint application of Yanqing Zhitong Ointment.~Acupuncture point:Weizhong,Shenshu,Dachangshu,Jaji,Ashi Acupoint application:Pain in the lumbar spine, Mingmen, Yaoyangguan, Shenshu (double), Ashi (6 points in total); Within 3 inches beside the spine on both sides of the waist, Shenshu (double), Dachangshu (double), Ashi (6 points in total); 3 inches away from the sides of the spine on both sides of the waist, Shenshu (double), Zhishi (double), Ashi (6 points in total).~Stick to each point for about 4 hours. If there is a burning sensation or obvious itching or other discomfort on the part after application, it can be removed in advance.~Three times a week( Monday, Wednesday, and Friday). Course of treatment: each course lasts for 2 weeks, a total of 2 courses of continuous treatment."
89569242|NCT05040243|Sham Comparator|Control Group|"The control group was combined with placebo acupoint application on the basis of conventional acupuncture treatment.~Placebo patch: colored and drug-free patch (composition: petrolatum, food coloring) Acupuncture, application of acupuncture points and treatment course were the same as those in the treatment group."
89569243|NCT05697133|Experimental|SEMSTOP|It is the group to which the initiatives will be applied.
89569244|NCT05697133|Active Comparator|Control|It is the group to be compared to which the interventions will not be applied.
89569245|NCT04988217|Experimental|Part 1a: Interferon alpha 2b 2.5 MIU|Nebulized interferon alpha 2b 2.5 MIU every 12 hours during 10 days (20 doses total)
89569246|NCT04988217|Experimental|Part 1b: Interferon alpha 2b 5 MIU|Nebulized interferon alpha 2b 5 MIU every 12 hours during 10 days (20 doses total)
89569247|NCT04988217|Placebo Comparator|Part 1: Placebo|Nebulized placebo every 12 hours during 10 days (20 doses total)
89569248|NCT04988217|Experimental|Part 2: Interferon alpha 2b 5 MIU (or maximum tolerated dose from part 1)|Nebulized interferon alpha 2b 5 MIU (or maximum tolerated dose from part 1) every 12 hours during 10 days (20 doses total)
89569249|NCT04988217|Placebo Comparator|Part 2: Placebo|Nebulized placebo every 12 hours during 10 days (20 doses total)
89569250|NCT01359449|Experimental|Menactra® Vaccine Group|Meningococcal vaccine naive participants will receive Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate vaccine (Menactra®) at 12 months of age and at 18 months of age concomitantly with routine vaccines administered as per provincial schedule
89569251|NCT01359449|Active Comparator|Menjugate® Vaccine Group|Meningococcal vaccine naive participants will receive MenC vaccine (Menjugate) given concomitantly at 12 months of age with routine vaccines administered as per provincial schedule.
89569252|NCT01672723|Experimental|Naltrexone|"Participants will take 4 doses of naltrexone over 4 days (25mg/day for days 1 and 2, 50mg/day for days 3 and 4) as well as 4 matched placebo pills for a total of 8 days. Capsules will be packaged into blister packs.~Participants will be asked to take the first drug, either naltrexone or placebo, once a day for three days prior to the first experimental session and when they arrive at the lab for the experimental procedure . After the first session, participants will take the second study drug for three days prior to the second experimental session and when they arrive for the second experimental procedure."
89569253|NCT01672723|Placebo Comparator|Placebi|"Participants will take 4 doses of naltrexone over 4 days (25mg/day for days 1 and 2, 50mg/day for days 3 and 4) as well as 4 matched placebo pills for a total of 8 days. Capsules will be packaged into blister packs.~Participants will be asked to take the first drug, either naltrexone or placebo, once a day for three days prior to the first experimental session and when they arrive at the lab for the experimental procedure . After the first session, participants will take the second study drug for three days prior to the second experimental session and when they arrive for the second experimental procedure."
89569254|NCT05038371||Patients with neovascular age-related macular degeneration|This will include 10 subjects with a diagnosis of age-related macular degeneration.
89569255|NCT05038371||Controls|This group will comprise 10 participants who plan to undergo vitrectomy for macular hole, macular pucker, or vitreomacular traction, vitreous floaters or another condition unrelated to scarring.
89569256|NCT04443673|Experimental|Glycine|Along with habitual treatment for their severe condition, participants will receive 0.5 g/kg/day glycine by nasogastric tube, divided in four equal doses in a day, since their enrollment and until they are weaned from mechanical ventilator or die.
89569257|NCT04443673|No Intervention|Control|Participants will receive the habitual treatment for their severe condition.
89569258|NCT05037903|Experimental|Cognitive-behavioral therapy|Cognitive-behavioral therapy, including behavioral exercises and homework assignments.
89569259|NCT05033145|Experimental|AZVUDINE|"Experimental:~AZVUDINE 1mg tablet~Interventions:~AZVUDINE 1mg tablet, 5 tablets QD + standard treatment, for up to 14 days"
89569260|NCT05033145|Placebo Comparator|AZVUDINE placebo|"Control:~AZVUDINE placebo~Intervention:~AZVUDINE placebo tablet, 5 tablets QD + standard treatment, for up to 14 days"
89569261|NCT05031975|Experimental|TEMIRI|"Irinotecan intravenous infusion (IV) given every 14 days in combination with oral (PO) temozolomide over days 1-5 every 28 days.~The treatment will consist of six 28-days cycles of TEMIRI."
89569262|NCT02632747|Experimental|Sequence A|Empagliflozin followed by a wash-out followed by empagliflozin matching placebo on a background of open label ramipril.
89569263|NCT02632747|Experimental|Sequence B|Empagliflozin matching placebo followed a wash-out followed by empagliflozin on a background of open label ramipril.
89569264|NCT04217811||Late neutropenia|Neutrophil count < 1500
89569265|NCT04217811||No late neutropenia|Neutrophil count > 1500
89569266|NCT04217343||non-complement mediated pAMR(H+)|
89569267|NCT04217343||complement mediated pAMR(I+)|
89569268|NCT04216797|Active Comparator|Oral Administration|10 mg diazepam tablets to be taken orally once daily for 4 weeks.
89569269|NCT04216797|Active Comparator|Rectal Administration|10 mg diazepam tablets to be taken rectally once daily for 4 weeks.
89569270|NCT05029401|Experimental|Single dose IMP (DMX-1002)|"Stage 1 (single blind, placebo controlled): initial dose of placebo, followed by treatment at one of 4 ascending dose levels of IMP (3, 6, 9 or 12 mg/kg)~Stage 2 (blinded): MTD/TTD established in Stage 1 vs placebo (proof of concept)"
89569271|NCT05029401|Placebo Comparator|Matching Placebo|Placebo using capsules identical to the IMP (DMX-1002)
89569272|NCT05029011||Patients of the Sleep Disorders Laboratory|Monitoring vital signs
89569273|NCT05025813|Experimental|Arm A|"Neoadjuvant Pembrolizumab 4 cycles, 200mg IV Q3W followed by interval restaging:~If restaging imaging positive will have Radical Neck Resection followed by Pembrolizumab 17 cycles, 200mg IV Q3W +/- External Beam Radiotherapy (if >10% viable tumour cells at resection) If restaging imaging negative will have Mapping biopsy. If biopsy positive will proceed to Radical Neck dissection followed by Pembrolizumab 17 cycles 200mg IV, Q3W If biopsy negative will proceed to Pembrolizumab 17 cycles 200mg IV, Q3W"
89569274|NCT05064501||Asthma and COVID19 infection|Asthma and COVID19 infection
89569275|NCT05064501||Asthma without COVID19 infection|Asthma and COVID19 infection
89569276|NCT05627089||Patients with Rheumatoid Arthritis and/or Myositis|"All patients 18 years or older who have been diagnosed with Rheumatoid Arthritis according to the 2010 ACR/EULAR Classification Criteria.~All patients 18 years or older who have been diagnosed with Myositis according to the 2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies Classification Criteria."
89569277|NCT05064345|Active Comparator|HB0034 dose group 1|HB0034 single dose
89569278|NCT05064345|Active Comparator|HB0034 dose group 2|HB0034 single dose
89569279|NCT05064345|Active Comparator|HB0034 dose group 3|HB0034 single dose
89569280|NCT05064345|Active Comparator|HB0034 dose group 4|HB0034 single dose
89569281|NCT05064345|Active Comparator|HB0034 dose group 5|HB0034 single dose
89569282|NCT05064345|Active Comparator|HB0034 dose group 6|HB0034 single dose
89569283|NCT05064345|Active Comparator|HB0034 dose group 7|HB0034 single dose
89569284|NCT05064345|Placebo Comparator|Matching placebo for each dose group|placebo, single dose
89569285|NCT05623735|Experimental|Instrument Assisted Soft Tissue Mobilization (IASTM) Group While Lying Prone|"The application will take a total of 6 sessions, with two sessions per week for 3 weeks.~While individuals are lying in the prone position, the IASTM protocol will be applied bilaterally on the erector spinae and then on the hamstrings. The application will take approximately 17 minutes."
89569286|NCT05623735|Experimental|Instrument Assisted Soft Tissue Mobilization Group Combined with Functional Movement|"While standing in the extended child pose (utthita balasana) stance, the IASTM protocol will be applied bilaterally on the lumbar erector spines, with the hands on them and moving back to the old position. Then, the IASTM protocol will be applied bilaterally on the hamstrings by making consecutive knee flexion-extension up to 90 degrees while the individuals are lying prone.~The application will take approximately 17 minutes."
89569287|NCT04421547|Experimental|Letrozole|Letrozole 1 tablet (2,5 mg) orally once a day
89569288|NCT04421547|Active Comparator|Standard Chemotherapy|Either Paclitaxel 80 mg/m2 as a 1-h infusion, on days 1,8,15,22 every 28 days or Pegylated Liposomal Doxorubicin (PLD) 40 mg/m2 given every 4 weeks or Topotecan 4mg/m2 IV on days 1,8,15 every 4 weeks or Gemcitabine 1000 mg/m2 IV over 30 min on days 1,8,15 every 28 days.
89569289|NCT05061069|Experimental|Infants with permanent hearing loss|Each infant with permanent hearing loss in Flanders will be offered a vestibular screening by means of the cVEMP (cervical vestibular evoked myogenic potentials) test to screen for vestibular deficits.
89569290|NCT03885583|Active Comparator|thoracic epidural group|patients in this group will receive ultrasound guided thoracic epidural block preoperatively for pain management, continuous infusion of 0.5% bupivacaine through epidural catheter during operation and early post-operative period
89569291|NCT03885583|Active Comparator|paravertebral group|patients in this group will receive ultrasound guided pararvertebral block preoperatively for pain management, continuous infusion of paravertebral bupivacaine 0.5% through paravetebral catheter during operation and early post-operative period
89569292|NCT03066817|Placebo Comparator|Vitamin D control|The control cohort will receive 50cc of propylene glycol as placebo via oral, nasogastric tube, or gastrostomy route on hospital admission.
89569293|NCT03066817|Experimental|Vitamin D intervention cohort|The intervention cohort will receive a one-time 400,000 IU liquid ergocalciferol (50cc of Ergocalciferol 8000 IU/ML Oral Liquid [DRISDOL]) via oral, nasogastric tube, or gastrostomy route on hospital admission.
89569294|NCT05060913|Experimental|5% EMLA Cream|EMLA cream will be applied over buccal mucosa of one side for 1.5 minutes of Maxillary of Mandibular anterior teeth.
89569295|NCT05060913|Active Comparator|20% Benzocaine gel|Benzocaine gel will be applied over buccal mucosa on another side for 1.5 minutes of Maxillary of Mandibular anterior teeth.
89569296|NCT05060367|Experimental|Liposomal multivitamin/mineral condition|Ingestion of novel, liposomal multivitamin/mineral.
89569297|NCT05060367|Active Comparator|Standard multivitamin/mineral condition|Ingestion of standard multivitamin/mineral.
89569298|NCT05059821|Experimental|Experimental Personalized Cancer Vaccine|Patients with recurrent HCC after surgical resection and refractory to available line of treatment will receive Personalized peptide based vaccine with autologous heat shock protein 70 and autologous activated monocytes
89569299|NCT05165251|Experimental|Amlodipine/atorvastatin|amlodipine/atorvastatin (5mg/10mg QD)
89569300|NCT05165251|Active Comparator|Amlodipine|amlodipine (5mg QD)
89569301|NCT05165251|Other|Lifestyle intervention|
89569302|NCT04209075|Experimental|Placebo then Prebiotic|Participant will take Placebo during Period 1 and Prebiotic during Period 2
89569303|NCT04209075|Experimental|Prebiotic then Placebo|Participant will take Prebiotic during Period 1 and Placebo during Period 2
89569304|NCT05151601|Experimental|HMOs + Probiotics|"Dosing: A total daily dose of 2 x sachets (6g/day)~Product Comprised of:~2.5g of a proprietary blend of human milk oligosaccharides combined with~20 billion CFUs of a mixture of Lactobacillus rhamnosus, Lactobacillus plantarum, Bifidobacterium animalis spp. lactis, and Bifidobacterium longum.~Mode of administration: oral."
89569305|NCT05151601|Placebo Comparator|Placebo|Dosing: A total daily dose of 2 x sachets (6g/day)u (8 weeks of phase 1A). Product: powdered maltodextrin. Mode of administration: oral.
89569306|NCT04433221|Experimental|Multiple sarcoma-specific CAR-T cells|Patients who have confirmed surface antigens including GD2, PSMA, Her2, CD276 or other markers
89569307|NCT05125939||Screening indication|Screening indication includes asymptomatic patients aged ≥50 years with no prior colonoscopy and at average risk of CRC. Screening indication also includes asymptomatic patients with negative prior colonoscopy.
89569308|NCT05125939||Surveillance indication|Surveillance indication includes patients with prior colon neoplasms, including conventional adenomas and clinically significant serrated polyps.
89569309|NCT05125939||Diagnostic indication|Diagnostic indication includes patients who report symptoms (e.g., abdominal pain, a change in bowel habits, or rectal bleeding) before their first screening examination and undergo evaluation of an abnormality on other image study, unexplained anemia and/or unexplained weight loss.
89569310|NCT05125939||Positive fecal immunochemical test|FIT+ indication includes patients who undergo colonoscopy for positive FIT results in screen-eligible individuals. FIT+ indication also applies to those with a positive FIT result and a recent colonoscopy.
89569311|NCT03065101|Other|Trigen Intertan|"Unique integrated interlocking screw and trapezoidal nail shape~Resistance to femoral head rotation and cut-out~Active compression through linear motion without rotation~Single subtrochanteric lag screw option for stable fractures below lesser trochanter~Preloaded cannulated set screw converts construct to fixed angle device~Small proximal diameter of the nail promotes preservation of the lateral wall of the greater trochanter and gluteus medius tendon~Clothespin tip for stress modulation in femoral shaft~Potential for improved patient mobility and recovery~Manufactured by Smith & Nephew Inc., 1450 Brooks Road, Memphis, TN 38116, U.S.A.~Interventions:~Randomisation to either Trigen Intertan or Sliding Hip Screw, Post-Surgery Follow Up"
89569312|NCT03065101|Other|Sliding Hip Screw|"SHS is a generic term for a group of devices used for internal fixation of trochanteric hip fractures. Also known as Compression Hip Screw or Dynamic Hip Screw. All devices feature a lag screw inserted into the femoral neck and a side plate held in place by cortical screws inserted into the proximal femoral shaft.~Therapeutic effect is achieved by guided collapse, where the lag screw can slide in the barrel of the side plate which compresses the fracture as the patient begins to weight-bear.~Participating sites may use whichever brand of SHS is currently in use.~Interventions:~Randomisation to either Trigen Intertan or Sliding Hip Screw, Post-Surgery Follow Up"
89569313|NCT05023473|Active Comparator|PENG block+ morhine|the participants will receive PENG block before being attached to morphine PCA
89569314|NCT05023473|Active Comparator|MORPHINE|The participants will be given morphine PCA without PENG block
89569315|NCT05105503||Adults with AVFs currently in the process of maturing|Adults with ESRD who currently have a maturing AVF that has not yet been cannulated
89569316|NCT03775629|Experimental|Polmacoxib and Tramadol combination|Tramadol + Polmacoxib capsule
89569317|NCT03775629|Active Comparator|Polmacoxib|Polmacoxib
89028550|NCT06155825|Placebo Comparator|Group 4 (placebo)|this group will be A control group receive no intervention.
89028551|NCT06155825|Experimental|group 1 (interventional group)|Intervention groups which will receive nonnutritive suckling.
89028552|NCT06155825|Experimental|group 2 (interventional group )|Group 2 will receive oral glucose 25%
89028553|NCT06155825|Experimental|Group 3 (interventional group)|Group 3 will undergo facilitated tuckling
89028554|NCT06155812|Active Comparator|STEPWISE VASOPRESSOR SEPTIC SHOCK MANAGEMENT|Regimen: Norepinephrine increases of 0.05-0.1 mcg/kg/min up to 0.5 mcg/kg/min, followed by vasopressin (administered at a fixed dose of 0.03 IE/min). If MAP remains < 65 mmHg, norepinephrine will be titrated above dose of 0.5 mcg/kg/min until MAP ≥ 65 mmHg. Maximum norepinephrine dose as per clinical team decision. Initiation of additional vasoactive drugs (epinephrine, methylene blue, angiotensin II, dobutamine, or dopamine) as per clinical team decision.
89028555|NCT06155812|Experimental|BALANCED MULTIMODAL VASOPRESSOR SEPTIC SHOCK MANAGEMENT|Regimen: Simultaneous administration of norepinephrine, angiotensin II and vasopressin at equivalent starting doses (equivalent to approximately 0.05 mcg/kg/min of norepinephrine). Increments of 0.05 mcg/kg/min of equivalent doses of all three vasopressors every 3-5 min until MAP ≥ 65 mmHg is reached (vasopressin will be administered at a maximum dose of 0.03 IE/min).
89028556|NCT06155799|Experimental|Navigation group|Zygomatic implant placement by dynamic computer assisted surgery system.
89028557|NCT06155799|Active Comparator|Freehand group|Zygomatic implant placement by Freehand, without any guidance.
89028558|NCT06155760|Experimental|Extended Steroid Therapy|10mg of prednisolone plus standard medical therapy for 60 days. SMT- IV Albumin, Diuretics, Multi vitamins as per clinicians decision
89028559|NCT06155760|Active Comparator|Placebo group|"Standard treatment plus placebo that the patient would receive included in the trial.~SMT- IV Albumin, Diuretics, Multi vitamins as per clinicians decision"
89028560|NCT06155734||Retrospective intervention cohort|
89569318|NCT03775629|Active Comparator|Tramadol|Tramadol hydrochloride (HCl)
89569319|NCT04976205|Experimental|TMI/TMLI|"The standard planning optimization for TMI/TMLI preview a two-free-breathing-CT scan without contrast will be performed for simulation at day -15(-10) to the BMT. The same day a WB-MRI will be acquired for lymph-nodes delineation. WB-MRI scans will be performed using a 1.5T MR scanner. The two CT will be co-registered to the WB-MRI.~CTV will be manually defined as the bones excluding mandible and hands (CTVBones), the spleen (CTVSpleen), and lymph nodes (CTVLN) using both MRI and CT images. The day -3 (4) to the BMT, further two-CT series will be acquired and co-registered to the first CTs for dose verification. Pre-treatment quality assurance (QA) will be performed the day before the treatment using the standard internal procedure.~The treatment will be performed the day before the BMT."
89569320|NCT01671319|Experimental|dose dense TC + pegfilgrastim|Docetaxel + Cyclophosphamide chemotherapy given every 2 weeks x 4 cycles plus pegfilgrastim given 24-48 hours post day 1 of each cycle
89033109|NCT04688892|Active Comparator|Intervention Group|The type of cupping therapy will be dry-cupping with moving-cupping (dynamic cupping therapy). The participants will remain in the supine position on a massage table (Posturarte® Olympic), without inclination. Cupping therapy will be performed with a plastic suction cup (5.08 cm in diameter) (K.S. Choi Corp®) and with a pistol for dosing pumps (K.S. Choi Corp®). Prior to the cupping therapy, a small amount of massage cream (ATL®) will be applied throughout the median nerve pathway in order to facilitate the sliding of the suction cup. The cupping therapy will performed with the suction cup sliding with a slow rhythm, insufflation of the suction cup with two pumps for 5 minutes along the median nerve path.
89033110|NCT04688892|No Intervention|Control Group|The participants will remain at rest in a supine position on a massage table (Posturarte® Olympic) without inclination for 5 minutes.
89532159|NCT06337539||SSRI treatment|"The subjects who will participate in this study will be outpatients seen in the Psychiatry Outpatient Clinics of the Germans Trias i Pujol University Hospital (Badalona, Spain) clinically diagnosed with major depression and eligible to receive antidepressant treatment with SSRIs.~The control group will be made up of healthy subjects, using the same inclusion and exclusion criteria except for the psychiatric diagnosis."
89532160|NCT06337526||Children & Adolescents with Active CRPS|"Subjects between the ages of 10 and 18 years, who have CRPS diagnosed in a pediatric pain center or clinic and whose CRPS is presently active (i.e. unresolved), of either gender, and any ethnicity or racial group.~For 6 months subjects will wear an Apple Watch, transmitting physiologic and movement data to the investigators, will photograph their meals for AI analysis of content, and log their pain scores and episodes of pain flares, and independently the investigators will collect weather and environmental data in the subject's location. These data will be analyzed by AI to identify chronologic triggers of pain flares."
89532161|NCT06337513|Experimental|Intervention group|The intervention consists of a physiotherapist-coordinated (PT) interdisciplinary outpatient rehabilitation for 6-months.
89532162|NCT06337513|Active Comparator|Usual care (control group)|Both groups are offered standard care.
89532163|NCT06337500|Experimental|Iowa Gambling Task - ecologic|The participant performs the card selection task in its ecological version (with real cards).
89532164|NCT06337500|Active Comparator|Iowa Gambling Task - virtual|The participant performs the card selection task in its virtual version (computer task).
89532165|NCT06337500|Experimental|Iowa Gambling Task - hybrid|"The participant performs the card selection task thanks to our homemade interface LAB-Life."
89532166|NCT06337500|Experimental|Game of Dice Task - ecologic|The participant performs the dice-rolling task in its ecological version (with real dices).
89532167|NCT06337500|Active Comparator|Game of Dice Task - virtual|The participant performs the dice-rolling task in its virtual version (computer task)
89532168|NCT06337500|Experimental|Game of Dice Task - hybrid|"The participant performs the dice-rolling task thanks to our homemade interface LAB-Life."
89532169|NCT06337487|Experimental|Patients|Quality of life and satisfaction assessment
89532170|NCT06337487|Other|Nurses|Assess the value of nurses using the Quality of Life (QoL) scores from the EORTC QLQ-C30 questionnaire to help identify SOS needs at the start of care.
89532171|NCT06337487|Other|Health professionals and professionals assimilated to the health|ORIC questionnaire
89532172|NCT06337474|Experimental|anti-CD19 CAR NK cells|
89532173|NCT06337448|Experimental|Light-emitting diode|The LED application protocol will be carried out with external use equipment model Antares, from the company IBRAMED (Amparo, São Paulo, Brazil), with a cluster G2 applicator. The power will be 450mW/cm2 and dose 5J/cm2 for 2 minutes and 13 seconds (automatic programming) in 450nm waves (blue wavelength). The treatment consists of eight sessions, carried out daily, except on weekends. The patient will remain naked, in a closed room, in the lithotomy position on a gynecological table, in the presence of only a physiotherapist specializing in women's health, who will apply the light.
89532174|NCT06337422|Experimental|Generic celecoxib 200 mg capsule|Generic celecoxib 200 mg capsule. The test product will be formulated using the same active ingredient with the same strength as the reference product, CELEBREX™. The test product to be used in this bioequivalence study is prepared in accordance with GMP regulations.
89532175|NCT06337422|Active Comparator|Celecoxib 200 mg capsule|Celecoxib 200 mg capsule, CELEBREX™, has been registered with Food and Drug Administration, Thailand (TFDA).
89532176|NCT06337409|Experimental|Empagliflozin 25 mg film-coated tablets|The test product, generic empagliflozin 25 mg film-coated tablets, will be formulated using the same active ingredient with the same strength as the reference product, JARDIANCE®. The test product to be used in this bioequivalence study is prepared in accordance with GMP regulations.
89532177|NCT06337409|Active Comparator|Empagliflozin 25 mg film-coated tablets, JARDIANCE|Empagliflozin 25 mg film-coated tablets, JARDIANCE®, has been registered with Food and Drug Administration, Thailand (TFDA).
89532178|NCT06337396|Experimental|Whole Genome Sequencing (WGS) and transcriptome analysis|"to investigate by WGS analysis the genome of selected patients with a detailed clinical characterization. WGS will be also performed on the DNA of the parent from which originated the CNV to look for any potential genomic signatures predisposing to the rearrangement detected in his/her son/daughter.~to investigate the expression profiles of structural variants by transcriptome analysis"
89532179|NCT06337370|Experimental|CDSMP Group|Participants will receive the chronic disease selfmanagement program for 6 weeks.
89532180|NCT06337370|Active Comparator|Conventional Care Group|Participants will receive conventional care.
89532181|NCT06337357|Experimental|Intervention group|"The intervention group receives supervised resistance training instructions and baseline treatment for sarcopenia and diabetes:~Resistance training with elastic bands aims to increase muscle strength and muscle mass of the upper and lower limbs. Training duration 12 weeks, frequency 2 times/week, intensity gradually increases.~Baseline treatment for diabetes and sarcopenia: Recommendations according to American Diabetes Association guidelines which include instructions to follow the diet and exercises as recommended for older type 2 diabetic patients and baseline treatment for sarcopenia (education about sarcopenia and treatment measures such as diet and exercise) and provide basic information on resistance training."
89569321|NCT05055609|Experimental|Open Label|In the dose escalation portion, it is estimated that approximately 12-24 subjects will be enrolled in four dose cohorts. The dose expansion portion will enroll 6-12 subjects.
89569322|NCT05019105|Placebo Comparator|Placebo|Placebo administered orally
89569323|NCT05019105|Active Comparator|ALKS 1140|Up to 8 single ascending doses of ALKS 1140 and 4 multiple ascending doses administered orally
89569324|NCT04933747|Experimental|Group 1: Participants with severe Renal Impairment (RI)|Severe Renal Impairment (RI), as defined by an eGFR < 30 mL/min/1.73 m2 and not requiring dialysis, at screening
89569325|NCT04933747|Experimental|Group 2: Participants with kidney failure who are on intermittent hemodialysis (IHD)|Kidney failure participants on intermittent hemodialysis (IHD)
89569326|NCT04933747|Experimental|Group 3: Participants with normal renal function|Normal renal function, as defined by a creatinine clearance (Clcr) > 90 mL/min estimated using the Cockcroft-Gault (C-G) equation, at screening.
89208931|NCT00878592|Experimental|Dietary and Lifestyle counseling|This group will receive a weight management and life style modification program. It consists of up to 6 weekly sessions of nutritional and physical exercise education. These initial sessions will concentrate on lifestyle modifications program including healthy food selections, emphasizing reduced fat consumption (<=30% of daily calories) and restriction of proteins to create a daily negative energy balance of ~500 kcal/day. Participants will be encouraged to start with 10 minutes of outdoor or at home physical activity such as walking or cycling then gradually increase the activity duration up to 30 minutes daily.
89569327|NCT05018325|Active Comparator|Arm 1: Colonoscopy 6 minute withdrawal time|-Undergo colonoscopy with the standard 6-minute withdrawal time followed by a tandem colonoscopy of at least another 6-minute withdrawal time.
89569328|NCT05018325|Experimental|Arm 2: Colonoscopy 9 minute withdrawal time|-Undergo a 9-minute withdrawal time followed by a tandem colonoscopy with at least the standard 6-minute withdrawal time.
89569329|NCT05018325|Experimental|Arm 3: Colonoscopy 12 minute withdrawal time|-Undergo colonoscopy with a 12-minute withdrawal time followed by a tandem colonoscopy with at least the standard 6-minute withdrawal time
89569330|NCT03064945|Sham Comparator|Shame device|
89569331|NCT03064945|Experimental|Livia® Transcutaneous Electrical Nerve Stimulation (TENS)|
89569332|NCT03763305|Experimental|Total intravenous anesthesia (TIVA)|Study participants are anesthetized by total intravenous anesthesia (TIVA) using propofol continuous infusion and remifentanil continuous infusion. During induction of general anesthesia, participants receive 3~5mcg/mL Propofol Fresenius and 3~5ng/mL and Remifentanil [Ultiva] as initial effect site concentrations. The effect site concentration is controlled with target-controlled infusion to maintain bispectral index (BIS) values between 40 and 60.
89569333|NCT03763305|Experimental|Sevoflurane|Study participants receive fentanyl 1mcg/kg and propofol bolus injection 1.5~2mg/kg for induction of general anesthesia. For maintenance of anesthesia, sevoflurane inhalant solution [Sojourn] is used to maintain 1 age-related minimum alveolar concentration (MAC).
89569334|NCT03763305|Experimental|Desflurane|Study participants receive fentanyl 1mcg/kg and propofol bolus injection 1.5~2mg/kg for induction of general anesthesia. For maintenance of anesthesia, desflurane [Suprane] is used to maintain 1 age-related minimum alveolar concentration (MAC).
89569335|NCT05054361||recent onset patients|patients with recently diagnosed type 1 diabetes
89569336|NCT05054361||at risk patients|patients with a high genetic risk type 1 diabetes
89569337|NCT05054361||control subjects|control patients (no risk of type 1 diabetes and no diagnosed type 1 diabetes)
89569338|NCT05054361||control subjects for endoscopy|patients without type 1 diabetes requiring UGI endoscopy for any medical reason
89569339|NCT03066973|Experimental|Intervention group|The trial compares nulliparous pregnant in the second stage of labor instructed regarding breathing exercise with a control group that received standard care service.
89569340|NCT03066973|No Intervention|Control group|control group that received standard care service.
89569341|NCT05015283|Experimental|Laparoscopic One-anastomosis gastric bypass|In this group, the bariatric procedure is laparoscopic one-anastomosis gastric bypass, all operations follow the same standard operating procedure.
89208932|NCT00873444|Active Comparator|1) Ceramic-on-Metal Bearing|A cementless acetabular cup with ceramic liner for use in total hip replacement
89569342|NCT05015283|Active Comparator|Laparoscopic Roux-en-Y gastric bypass|In this group, the bariatric procedure is laparoscopic Roux-en-Y gastric bypass, all operations follow the same standard operating procedure.
89569343|NCT03066583|Placebo Comparator|trephination with placebo|meniscal repair with trephination and placebo
89569344|NCT03066583|Experimental|trephination with platelet rich plasma|meniscal repair with trephination and platelet rich plasma
89569345|NCT04972305|Experimental|Exercise group|12 weeks exercise programme, 3 days a week Bicycle ergonomics will be applied.
89569346|NCT04972305|Experimental|Ergonomics group|Bicycle ergonomics will be applied.
89569347|NCT04972305|No Intervention|Control group|No Intervention
89569348|NCT03064555||Participants with end stage renal disease|"Cardiopulmonary exercise test~Cardiopulmonary exercise testing will be conducted on an electronically braked cycle ergometer using a ramped protocol with participants being required to pedal until exhaustion.~Constant load exercise test~Constant load exercise will be performed for 30 min on an electronically braked cycle ergometer whilst seated in a dialysis chair. Blood sampling and echocardiogram will be measured throughout."
89569349|NCT03064555||Healthy participants|"Cardiopulmonary exercise test~Cardiopulmonary exercise testing will be conducted on an electronically braked cycle ergometer using a ramped protocol with participants being required to pedal until exhaustion.~Constant load exercise test~Constant load exercise will be performed for 30 min on an electronically braked cycle ergometer whilst seated in a dialysis chair. Blood sampling and echocardiogram will be measured throughout."
89569350|NCT03064477|Experimental|Unified Protocol (UP)|"Investigators in the present study have adapted the UP to implement it in group format in a Public Mental Health setting in Spain. This adaptation is composed of 12 treatment sessions of two hours of duration each, at a rate of one per week.~Participants in the UP will receive UP treatment in group format instead of the usual Cognitive Behavioral Therapy in individual format. Patients in the UP condition will receive pharmacological treatment (i.e., antidepressants and / or anxiolytics) as usual."
89033111|NCT02944370|Experimental|PlayFit, Modified exercise games|Subjects will participate in three 60 minute game sessions each week for 12 weeks. During each game session, subjects will be divided randomly into two teams to play a modified game. Research staff will review the instructions of the game and if needed, modify the game rules during play to enhance the experience (ie. keep it fun, keep it to moderate intensity level). The length of play session between breaks increases each week.
89569351|NCT03064477|Active Comparator|Treatment As Usual (TAU)|Cognitive Behavioral Therapy in individual format is the treatment of choice (TAU) by psychologists and psychiatrists at the collaborating Public Mental Health Centers and Primary Care Centers, together with pharmacological treatment (i.e., antidepressants and / or anxiolytics).
89569352|NCT01670539|Experimental|Telemonitor|"In addition to routine care, the HomMed Telemonitor wireless telemonitoring system (intervention)will be used in the patient's home for 14 days to alert the clinical research nurse to changes in patients conditions in order to contact them to teach self-management. The Honeywell HomMed Genesis™ DM Remote Patient Care Monitor will be used to measure temperature, pulse, oxygen level,weight and blood pressure. The telemonitor will also ask for a YES or NO response to questions on symptoms such as difficulty breathing. Research nurses review the data daily and call the participant for 2 weeks, and continue to monitor outcomes for 2 months."
89569353|NCT01670539|No Intervention|Routine care for patients with lungCa|Traditional physician ordered post-hospital care for patients with lung CA in rural WV requires patients to make an outpatient office/ clinic visit two to three weeks after discharge;a few patients receive homecare service referrals. No attempt to change care - just monitor what is used and collect study data at Discharge, 2 weeks, one month and two months.
89569354|NCT03064789||Women with candidiases infection|Women that are prescribed treatment with clotrimazole: 500 mg. and probiotics (routine clinical practice)
89569355|NCT04431895|Experimental|tofacitinib 5mg twice a day|
89569356|NCT02516163|Other|Shapematch Cutting Guides|"The ShapeMatch® Cutting Guides are intended to be used as patient-specific surgical instrumentation to assist in the positioning of knee arthroplasty components intra-operatively and in guiding the marking of bone before cutting.~They are intended for single use only."
89569357|NCT03064633|Active Comparator|Dexamethasone arm (group A)|The local anesthetic solution mixture consists of dexamethasone 8 mg in Bupivacaine 0.25% Injectable Solution to a total volume of 40 ml (19 ml bupivacaine 0.5 % + 19 ml normal saline + 2 ml dexamethasone = 40ml). 20 ml of the local anesthetic solution mixture will be injected on each side.The Transversus abdominis Plane (TAP) block will be performed once after induction of anesthesia.
89569358|NCT03064633|Active Comparator|Dexmedetomidine arm (group B)|The local anesthetic solution mixture consists of dexmedetomidine 80 µg in Bupivacaine 0.25% Injectable Solution to a total volume of 40 ml (19 ml bupivacaine 0.5 % + 19 ml normal saline + 80 µg dexmedetomidine in 2 ml = 40ml). 20 ml of the local anesthetic solution mixture will be injected on each side.The Transversus abdominis Plane (TAP) block will be performed once after induction of anesthesia.
89569359|NCT02589665|Experimental|50 mg Mirikizumab IV Q4W (Induction)|50 mg mirikizumab administered every 4 weeks (Q4W) intravenously (IV) during the induction period. Participants who do not have a clinical response may choose to participate in the unblinded study extension period.
89569360|NCT02589665|Experimental|200 mg Mirikizumab IV Q4W (induction)|"200 mg mirikizumab administered every 4 weeks (Q4W) intravenously (IV) during the induction period.~Participants who do not have a clinical response may choose to participate in the unblinded study extension period."
89569361|NCT02589665|Experimental|600 mg Mirikizumab IV Q4W (Induction)|"600 mg mirikizumab administered every 4 weeks (Q4W) intravenously (IV) during the induction period.~Participants who do not have a clinical response may choose to participate in the unblinded study extension period."
89569362|NCT02589665|Placebo Comparator|Placebo IV Q4W (Induction)|Placebo administered every 4 weeks (Q4W) intravenously (IV) during the induction period.
89569363|NCT02589665|Experimental|200 mg Mirikizumab SC Q4W (Maintenance)|Induction mirikizumab responders were re-randomized: 200 mg mirikizumab administered subcutaneously (SC) Q4W during the maintenance period.
89569364|NCT02589665|Experimental|200 mg Mirikizumab SC Q12W (Maintenance)|Induction mirikizumab responders were re-randomized: 200 mg mirikizumab administered subcutaneously (SC) once every 12 weeks (Q12W) during the maintenance period.
89569365|NCT02589665|Placebo Comparator|Placebo SC Q4W (Maintenance)|Induction placebo responders: Placebo administered subcutaneously (SC) Q4W during the maintenance period.
89569366|NCT02589665|Experimental|600mg Mirikizumab IV Q4W Extension Open-Label|Induction non-responders: 600 mg mirikizumab administered intravenously (IV) once every 4 weeks (Q4W) during the Extension Open-Label.
89569367|NCT02589665|Experimental|1000mg Mirikizumab IV Q4W Extension Open-Label|Induction non-responders: 1000 mg mirikizumab administered intravenously (IV) once every 4 weeks (Q4W) during the Extension Open-Label.
89569368|NCT02589665|Experimental|200mg Mirikizumab SC Q4W Extension Open-Label|Extension Induction responders: 200 mg mirikizumab administered subcutaneously (SC) once every 4 weeks (Q4W) during the Extension Open-Label
89033112|NCT00531557|Other|1|Darunavir 600mg BID with ritonavir 100mg BID administered orally.
89033113|NCT02921568|Other|All patients|All patients will be imaged on the P200TE and Spectral OCT/SLO devices.
89033114|NCT02944097|Experimental|Vineatrol30 native powder|500 mg Vineatrol30 containing 30 mg trans-resveratrol and 75.2 mg trans-epsilon-viniferin
89028563|NCT06155630|Experimental|3D printed mandibular implant overdenture|First appointment: The first visit will consist of scanning the patients' existing upper complete denture and lower mandibular implant overdenture by using a desktop scanner. In the lab, the .stl files will be 3D printed using a DLP 3D printer. Second clinical appointment: the interim printed dentures will be adjusted with wax for the desired lip support and VD. Secondary impressions will be taken to refine fit. Maxillary and mandibular interim printed dentures will be scanned separately and together with an intraoral scanner. Patient's face will also be scanned by a face scanner. 2nd lab session: .stl files will be superimposed for the digital pathway. Teeth and denture bases will be designed virtually. Dentures bases will be manufactured by a DLP 3D printer with Dentca Resin. Dentures will receive Dentsply Portrait 3D teeth. Dentures will be finished and polished, and sandblasted in the attachment sockets. 4th appointment: denture delivery.
89028564|NCT06155630|Active Comparator|traditional mandibular implant overdenture|"The first visit will be the same. For the conventional pathway, the 2nd lab session will consist of pouring the impressions (type 4 stone), mounting the casts in arcon semi-adjustable articulator, removing the printed teeth, and replacing it with wax rim and acrylic tooth setup (Dentsply Portrait - same shape, size and shade used for 3D printed dentures).~A 3rd appointment will be used for wax try-in for the conventional pathway. For the digital pathway, participants will have a chance to appraise their smile on a computer screen (virtual try-in, done remotely) and request modifications.~Denture bases will be manufactured with conventional heat-polymerized resins, and participants will return for a 4th appointment for delivery, including chairside pick-up of attachments (GC Reline resin). Two short-term adjustments will be scheduled 24-72 h and 7 days after delivery, and then weekly until the dentures are comfortable."
89028565|NCT06155617|Other|Single Arm Clinical Trial|Participants with various upper extremity disorders are provided treatment/interventions and evaluated at baseline, 3-6 weeks, and at discharge using the PRESS to Function Approach
89569369|NCT01905397|Active Comparator|Negative Pressure Wound Therapy|The Prevena Incision Management System is a 510K cleared device that covers and protects the incision from external infectious sources, while negative pressure removes fluid and infectious material from the surgical incision. The ActiVAC pump (also 510K cleared) may be used in some cases with the Prevena dressings as to achieve the negative pressure
89569370|NCT01905397|Active Comparator|Conventional wound therapy|Traditional wound therapy (sterile bandages and dressing)
89569371|NCT05010603||Families with a history of Alzheimer's Disease|Families with two or more family members affected with Alzheimer's Disease
89569372|NCT05010603||Un-related, non-demented controls|Un-related, non-demented healthy controls over age 55
89569373|NCT05010603||Individuals with Dementia (Alzheimer's Disease)|Individuals with dementia over the age of 65
89569374|NCT04613843|Active Comparator|Water stirring|
89569375|NCT04613843|Experimental|No water stirring|
89569376|NCT04457453|Active Comparator|control group|intubation with direct laryngoscope in sniffing position
89569377|NCT04457453|Experimental|direct laryngoscope in Trendelenburg and Sellick position|intubation with direct laryngoscope in Trendelenburg and Sellick position
89569378|NCT04457453|Experimental|video laryngoscope in Trendelenburg and Sellick position|intubation with video laryngoscope in Trendelenburg and Sellick position
89569379|NCT04426409|No Intervention|control group|
89028566|NCT06155604|Experimental|Treatment group|standard maintenance therapy plus dapagliflozin 10 mg daily
89028567|NCT06155604|Other|Control group|standard maintenance therapy only
89028568|NCT06155578|Active Comparator|Sodium metabisulfite cream|Sodium metabisulfite prepared in pediatric cold cream (water in oil emulsion) at a concentration of 25% to be applied on calcinosis topically twice daily.
89028569|NCT06155578|Placebo Comparator|Placebo cream|Pediatric cold cream (water in oil emulsion) to be applied on calcinosis topically twice daily.
89028570|NCT06155539||Pre-diabetes|Fasting blood glucose level of 5.6-6.9 mmol/L (impaired fasting blood glucose) or 2-hour postprandial blood glucose of 7.8-11.0 mmol/L (impaired glucose tolerance) or haemoglobin A1c (HBA1c) of 5.7-6.4%.
89208933|NCT00873444|Active Comparator|2) Metal-on-Metal Bearing|A cementless acetabular cup with metal liner for use in total hip replacement
89569380|NCT04426409|Experimental|ointment group|Ointment group should apply a nasal ointment to both noses using a cotton swab the night before surgery and the morning of surgery.
89569381|NCT04966923||Breast Cancer and documented pathogenic variant TP53|Documented pathogenic or likely pathogenic variants of TP53 were identified using blood DNA colection and localized breast cancer diagnosis by histological confirmation. All patients met Revised Chompret criteria or Li Fraumeni like syndrome or family member of carrier TP53
89028571|NCT06155539||Diabetes in the early stages|Fasting blood glucose is higher than 7.0mmol/L, 2 hours postprandial blood glucose is higher than 11.1mmol/L, random blood glucose is higher than 11.1mmol/L with classic symptoms of hyperglycemia, and the HbA1C is higher than 6.5%, but there is no obvious complication of heart, kidney and eyes.
89569382|NCT04966923||Breast Cancer and no documented pathogenic variants in genetic test|Control group with localized breast cancer and no pathogenic variants documented in a genetic test
89569383|NCT04421157|Experimental|Schroth group|The Schroth group received Schroth exercises in addition to traditional rehabilitation.
89569384|NCT04421157|Experimental|Stabilization group|The stabilization group received core stabilization in addition to traditional rehabilitation.
89569385|NCT04432753|Experimental|Decision aid with incidental findings information|Participants in this arm will view a video decision aid that include information on incidental findings in lung cancer screening.
89569386|NCT04432753|Active Comparator|Decision aid without incidental findings information|Participants in this arm will view a video decision aid that does not include information on incidental findings in lung cancer screening.
89028572|NCT06155539||Diabetes in the middle and late stages|Includes diabetics with various degrees of complications. Among the minor complications are microalbuminuria and mild diabetic retinopathy (e.g. microaneurysms, mild haemorrhages). Mild to moderate complications included diabetic nephropathy without renal failure and diabetic retinopathy without proliferative diabetic retinopathy. Severe complications include hyperglycaemic crises such as diabetic ketoacidosis and hyperosmolar hyperglycaemic state, microvascular complications such as retinopathy (neovascularisation and vitreous or preretinal haemorrhage preretinal haemorrhage), nephropathy, cardiomyopathy, neuropathy (sensory lesions such as podiatry, autonomic neuropathies such as sexual dysfunction and gastroparesis), and macrovascular complications (coronary heart disease, cerebrovascular disease, proliferative diabetic retinopathy, peripheral arterial disease, amputations and foot ulcers).
89569387|NCT05473793|Experimental|Highest fiber dose|This arm receives the highest dose of the intervention product, which is 15g dried vegetable per day divided into two portions of each 7.5g, which are consumed during the course of the day in the food of choice.
89569388|NCT05473793|Experimental|Medium fiber dose|This arm receives the highest dose of the intervention product, which is 10g dried vegetable per day divided into two portions of each 5.0g, which are consumed during the course of the day in the food of choice.
89569389|NCT05473793|Experimental|Lowest fiber dose|This arm receives the highest dose of the intervention product, which is 5g dried vegetable per day divided into two portions of each 2.5g, which are consumed during the course of the day in the food of choice.
89569390|NCT05473793|Placebo Comparator|Control|This arm is the control arm receiving as placebo rice puff particles each day, whose amount corresponds iso-calorically to the medium fiber dosage (~ 21 kcal/day).
89569391|NCT01362595|Other|Leucine|No alternative treatment arm
89569392|NCT04421391|Experimental|Treatment Arm|Patients will receive 2 pills of QuadraMune(TM) daily for 12 weeks
89569393|NCT05556941|Experimental|Metacognitive Group Intervention|Meta cognitive intervention protocol based on the dynamic interactional model of cognition (Toglia, 2005), and specifically tailored to individuals with schizophrenia.
89569394|NCT05556941|Active Comparator|Occupational therapy standard care|Standard care of occupational therapy in mental health, focused on work occupations.
89569395|NCT03064399|Experimental|lateral ligament repairment|
89569396|NCT03064399|Experimental|without lateral ligament repairment|
89569397|NCT04948983|Active Comparator|Intervention group|"The intervention group will access a web page, answer a set of questionnaires at baseline, and then the DA (developed according to the IPDAS recommendations). The intervention group will complete the same questionnaires two weeks later. Six months later we will confirm if the screening was undertaken by checking medical records.~The online DA for breast cancer screening is a web-based education material to inform women about the benefits and risks associated with the screening. The contents of the DA are: 1) Assessing breast cancer; 2) What is breast cancer screening?; 3) What will happen if I diagnosed with breast cancer?; 4) What is overdiagnosis?; 5) What is false positive?; 6) the statistics of breast cancer screening; 7) Now is my turn, do I want to take it?"
89569398|NCT04948983|Placebo Comparator|Control group|"The Control group will access a webpage, answer a set of questionnaires at baseline, and then receive standardised information given by the healthcare system.~The control group will complete the same questionnaires two weeks later, afterwards they will access the DA. Six months later we will confirm if the screening was undertaken by checking medical records."
89569399|NCT04426097|Experimental|Cervical Vagal Blockade|
89569400|NCT04426097|Placebo Comparator|Without Blockade|
89569401|NCT05556551|Other|Hybrid resin ceramic restoration|Dental restoration
89569402|NCT05556551|Other|Full ceramic restoration|Dental restoration
89028573|NCT06155526||active rest|patients taking an active rest after swimming sets
89028574|NCT06155526||passive rest|patients taking a passive rest after swimming sets
89028575|NCT06155487|Experimental|(Part A) Single dose group 1|Oral dose of AJH-2947/placebo 100 mg, Korean Only*
89028576|NCT06155487|Experimental|(Part A) Single dose group 2|Oral dose of AJH-2947/placebo 200 mg, Korean and Caucasian
89028577|NCT06155487|Experimental|(Part A) Single dose group 3|Oral dose of AJH-2947/placebo 300 mg, Korean and Caucasian
89028578|NCT06155487|Experimental|(Part A) Single dose group 4|Oral dose of AJH-2947/placebo 400 mg, Korean and Caucasian
89028579|NCT06155487|Experimental|(Part A) Single dose group 5|Oral dose of AJH-2947/placebo 600 mg, Korean and Caucasian
89028580|NCT06155487|Experimental|(Part A) Single dose group 6|Oral dose of AJH-2947/placebo 800 mg, Korean and Caucasian
89028581|NCT06155487|Experimental|(Part B) Multiple dose group 1|Oral dose of AJH-2947/placebo 200 mg, Korean and Caucasian
89028582|NCT06155487|Experimental|(Part B) Multiple dose group 2|Oral dose of AJH-2947/placebo 400 mg, Korean and Caucasian
89028583|NCT06155487|Experimental|(Part B) Multiple dose group 3|Oral dose of AJH-2947/placebo 600 mg, Korean and Caucasian
89569403|NCT04411173|Active Comparator|Rice Protein|Rice Protein - 24 grams, chocolate, powder
89569404|NCT04411173|Active Comparator|Whey Protein|Whey Protein - 24 grams, chocolate, powder
89569405|NCT05556317|Experimental|Group A|Receive advices to reduce insomnia
89569406|NCT05556317|Active Comparator|Group B|Receive advices and resistive exercise
89569407|NCT04411407|Other|Group WT|PROM registration via the DANBIO WebApp and thereafter the outpatient touchscreen
89028584|NCT06155474|Placebo Comparator|Healthy/Control (Starch)|The Healthy Controls will be given starch packed in the same way as the active prebiotics
89028585|NCT06155474|Experimental|Malnutrition (RUTF + Starch)|The Malnutrition group with RUTF and Starch only. The RUTF will be given as per the WHO guidelines
89028586|NCT06155474|Active Comparator|Malnutrition (RUTF + prebiotics)|The Malnutrition group with RUTF and Prebiotic only. The RUTF will be given as per the WHO guidelines
89033115|NCT02944097|Experimental|Vineatrol30 micelles|500 mg Vineatrol30 micelles containing 30 mg trans-resveratrol and 75.2 mg trans-epsilon-viniferin
89033116|NCT02917902|Experimental|Immediate intervention|Intervention: Food boxes. Monthly boxes of food for 6 months, along with brief educational information from food pantry staff regarding eating healthy on a budget, starting immediately after randomization. Patients will continue to receive routine medical care at the Free Clinic.
89569408|NCT04411407|Other|Group TW|PROM registration via the outpatient touchscreen and thereafter the DANBIO WebApp
89208934|NCT00656084|Experimental|Experimental arm|Patients will be treated a maximum of 8 cycles or until the patient has evidence of a response, progressive disease, or until intolerable toxicity develops. Patients with a complete response will receive an additional 2 cycles of treatment (not to exceed 8 cycles). Drug order is gemcitabine, mitoxantrone, and rituximab.
89569409|NCT05556083|Active Comparator|sofenacine recievers group A|Group (A) will receive sildenafil 50mg tablet form as additive therapy to dapoxetine 30 mg tablet form on demand for 8 weeks.
89569410|NCT05556083|Placebo Comparator|palcebo recievers group B|Group (B) will continue on dapoxetine 30mg tablet form with placebo tablet form of the same shap and colour of sildinafile on demand for 8 weeks.
89569411|NCT05556005|Experimental|Group 1|Patients will receive 35 mg of Trimetazidine modified release tablet twice daily in addition to their standard treatment for three months.
89569412|NCT05556005|Placebo Comparator|Group 2|Patients will receive Placebo tablet twice daily in addition to their standard treatment for three months.
89569413|NCT04373603|Experimental|Intervention: HA plus TXA|HA will be diluted with TXA using a Leur-Lok hub in a ratio of 1.0 mL HA filler to 0.2 mL TXA (100mg/mL)
89569414|NCT04373603|Placebo Comparator|Control: HA plus Saline|HA will be diluted with saline in a ratio of 1.0 mL HA filler to 0.2 mL saline
89569415|NCT02519595|Experimental|ketamine IV 1 mg/kg|Intervention: A blinded dose of 1mg/kg IV ketamine is administered to patients
89569416|NCT02519595|Experimental|Ketamine IV 1.5 mg/kg|Intervention: A blinded dose of 1.5mg/kg IV ketamine is administered to patients
89569417|NCT02519595|Experimental|Ketamine IV 2 mg/kg|Intervention: A blinded dose of 2 mg/kg IV ketamine is administered to patients
89569418|NCT05610917|Experimental|case group,|Patients in case group will be treated with CBRM program
89569419|NCT05610917|Other|control group|the control group patients will be treated routinely as usual.
89569420|NCT04278755|Experimental|Continuous OC|Continuous daily oral drospirenone + ethinyl estradiol for 84 days (i.e., 12-weeks).
89028587|NCT06155448|Experimental|PMC intervention|The PMC intervention is designed to deliver a core regimen of six paediatric doses of sulphadoxine pyrimethamine linked to the EPI delivery platform in children 10 weeks to 15 months of age through trained health facility staff, plus additional 'pragmatic' monthly doses offered outside of the EPI schedule to children up to 18 months of age. Additional social mobilisation and social behaviour change (SBC) activities will be conducted throughout the implementation period to increase demand and uptake of vaccination and PMC services in the study population. at EPI scheduled touchpoints, plus additional monthly doses at non-scheduled monthly intervals up to age 18 months. The primary source of delivery will be government-run primary care health facilities in intervention arm wards. Coordination of implementation of the study within intervention and control arm wards will take place at the LGA level (unit of implementation).
89028588|NCT06155448|No Intervention|Control|The control sites will have normal immunization as business as usual. However, the same sentinel site surveillance happening in the intervention arm will also be carried out in this arm. Pharmacovigilance will be passive in the control arm.
89028589|NCT06155422||Cadonilimab-treated Recurrent or Metastatic Cervical Cancer|
89028590|NCT06155370||cohort of cervical cancer organoids|organoids derived from cervical cancer
89028591|NCT06155370||cohort of endometrial cancer organoids|organoids derived from endometrial cancer
89028592|NCT06155370||cohort of ovarian cancer organoids|organoids derived from ovarian cancer
89028593|NCT06155370||cohort of vulva cancer organoids|organoids derived from vulva cancer
89569421|NCT04277975|Active Comparator|A: liberal post-discharge opioid prescribing|Standardized postoperative instructions on non-opioid pain control + liberal opioid prescription provided prior to surgery (standard prescription for opioid prescribed prior to surgery)
89569422|NCT04277975|Experimental|B: restricted post-discharge opioid prescribing|Standardized postoperative instructions on non-opioid pain control + opioid prescribed only 'as needed' after discharge
89569423|NCT04093349|Experimental|SPK-3006|All participants who meet the eligibility criteria will receive a single intravenous (i.v.) administration of SPK-3006.
89569424|NCT04062695|Active Comparator|Tofacitinib|5 mg oral BID
89569425|NCT04062695|Placebo Comparator|Placebo|matching Placebo BID
89569426|NCT05555927|Experimental|active tDCS|tDCS devices (Neuroelectrics, Starstim 8, USA) are used. The anode and cathode electrodes are inserted in saline-soaked sponges with diameter of 3.2cm and then positioned over the left and right dorsolateral prefrontal cortex (DLPFC) using specific headgear. Each session uses a 2mA current and lasts 60 minutes. Ten sessions are daily performed.
89569427|NCT05555927|Sham Comparator|sham tDCS|The anode and cathode electrodes are inserted in saline-soaked sponges with diameter of 3.2cm and then positioned over the left and right dorsolateral prefrontal cortex (DLPFC) using specific headgear. Each session uses a 2mA current and lasts 60 minutes. Ten sessions are daily performed. For sham, the current rapidly ramp up to 2mA over the first 30s and rapidly ramped down to 0mA over the next 30s automatically to allow participants to feel typical initial sensations of active tDCS.
89569428|NCT04330235||Intervention Group|Children 2-10 years of age dining at fast-food restaurants in New York City and Philadelphia, where a healthy default beverage policy will be enacted.
89569429|NCT04330235||Control Group|Children 2-10 years of age dining at fast-food restaurants in northern New Jersey, where a healthy default beverage policy will not be enacted.
89028594|NCT06155370||cohort of vaginal cancer organoids|organoids derived from vaginal cancer
89028595|NCT06155370||cohort of gestational trophoblastic tumor organoids|organoids derived from gestational trophoblastic tumor
89028596|NCT06155279|Experimental|Single arm|"Single arm Carboplatin/Cisplatin - Pemetrexed - Pembrolizumab~The neoadjuvant systemic treatment will be based on three cycles of pembrolizumab 200 mg flat dose in combination with standard doses of cisplatin (75 mg/sm) or carboplatin (AUC 5) and pemetrexed (500 mg/sm) administered intra-venous every 3 weeks.~The surgical intervention of pleurectomy/decortication will be planned to occur within 6 weeks after the completion of neoadjuvant treatment.~The adjuvant systemic treatment will be based on 14 cycles of pembrolizumab 200 mg flat dose administered intra-venous every 3 weeks. Patients should be able to start pembrolizumab following surgery as soon as clinically feasible and within 10 weeks from surgery."
89028597|NCT06155253|Active Comparator|Single-level ESP group (1ESP)|Subjects in 1ESP group will receive a single-shot single-level erector spinae plane block at L1 level under ultrasound guidance immediately before surgery.
89569430|NCT04330079|Experimental|Dapagliflozin|
89028598|NCT06155253|Active Comparator|Bi-level ESP group (2ESP)|Subjects in this group will receive a single-shot single-level erector spinae plane block at T12 and L1 levels under ultrasound guidance immediately before surgery.
89028599|NCT06155240|Experimental|Yoga participant|Providing once weekly class for 8 weeks, participants will take part in performing yoga poses and yoga breathing and meditation for stress management
89028600|NCT06155214||autism spectrum disorder children|100 children with autism spectrum disorder who met the inclusion criteria and signed informed consent forms were included. Among them, there are 30 cases of children with regressive autism spectrum disorder.
89569431|NCT04330079|Other|Lifestyle modification|
89569432|NCT05555693||Patients in the control group were followed up without POCD postoperatively.|If the MOCA or MMSE assessment all show a negative resluts at all time point.
89569433|NCT05555693||Patients in the case group were followed up with POCD postoperatively.|If the MOCA assessment is positive at any time point after surgery, and there is a positive MMSE at any time point after surgery(no need for both MOCA and MMSE to be positive at the same time
89569434|NCT00660673|Experimental|Levodopa-Carbidopa Intestinal Gel|"Initial dosing is based on the dosing regimen that the participant received during the previous LCIG study. Dosing is individually optimized and can be adjusted at any time during the study as clinically indicated. The total dose/day of LCIG is composed of 3 individually adjusted doses. The morning dose is administered as a bolus infusion, usually 5 to 10 mL (100 to 200 mg levodopa). The maintenance dose is adjustable in steps of 2 mg/hour (0.1 mL/hour), within a range of 1 to 10 mL/hour (20 to 200 mg levodopa/hour) and is usually 2 to 6 mL/hour (40 to 120 mg levodopa/hour). Participants will be allowed to self-administer extra doses of LCIG to address immediate medical needs, normally 0.5 to 2.0 mL.~Participants will receive LCIG until it is commercially available."
89569435|NCT05612867||PO Vitamin C|Patients who got PO vitamin C
89569436|NCT05612867||IV Vitamin C|Patients who got IV vitamin C
89569437|NCT05473559|Active Comparator|Adductor canal block with Ipack block|
89569438|NCT05473559|Active Comparator|Adductor canal block with selective tibial nerve block|
89569439|NCT05555459|Experimental|CompressOn group|125 participant patients undergoing bone fixation surgical operation specified in the study description. All bone fixation surgeries are performed using Inion CompressOn screws.
89569440|NCT03816137|Active Comparator|ConM SOSIP and Mosaic SOSIPs|"ConM SOSIP 100g Intramuscular injections into the left or right arm Administered at 0, 3 and 6 months~Mosaic SOSIPs 100ug (3x33ug) Intramuscular injections into the left or right arm Administered at 12 months only"
89569441|NCT03816137|Active Comparator|EDC ConM SOSIP and Mosaic SOSIPs|"EDC ConM SOSIP 100G Intramuscular injections into the left or right arm Administered at 0, 3 and 6 months~Mosaic SOSIPs 100ug (3x33ug) Intramuscular injections into the left or right arm Administered at 12 months only"
89028601|NCT06155214||global developmental delay children|100 children with global developmental delay who met the inclusion criteria and signed informed consent forms were included. Among them, there are 30 cases of children with regressive global developmental delay.
89028602|NCT06155214||normally developing children|Included 100 children with normal development.
89028603|NCT06155201|Experimental|depression disorder|The depressive disorder group must complete four years of follow-up and intervention. Collect blood samples from more than 5,000 patients with depressive disorders.
89028604|NCT06155201|Experimental|anxiety disorder|The anxiety disorder group must complete four years of follow-up and intervention. Collect blood samples from more than 5,000 patients with depressive disorders.
89028605|NCT06155201|Experimental|autism spectrum disorder|The autism spectrum disorder group must complete four years of follow-up and intervention. Collect blood samples from more than 1,000 patients with depressive disorders.
89569442|NCT03816137|Active Comparator|ConS UFO and Mosaic SOSIPs|"ConS UFO 100g Intramuscular injections into the left or right arm Administered at 0, 3 and 6 months~Mosaic SOSIPs 100ug (3x33ug) Intramuscular injections into the left or right arm Administered at 12 months only"
89569443|NCT03816137|Active Comparator|EDC ConS UFO and Mosaic SOSIPs|"EDC ConS UFO 100g Intramuscular injections into the left or right arm Administered at 0, 3 and 6 months~Mosaic SOSIPs 100ug (3x33ug) Intramuscular injections into the left or right arm Administered at 12 months only"
89569444|NCT03816137|Active Comparator|ConS UFO and ConM SOSIPs and Mosaic SOSIPs|"ConS UFO 100g Intramuscular injections into the left or right arm Administered at 0 and 3 months~ConM SOSIP Administered at 12 months~Mosaic SOSIPs 100ug (3x33ug) Intramuscular injections into the left or right arm Administered at 12 months only"
89028606|NCT06155201|Experimental|attention deficit hyperactivity disorder|The attention deficit hyperactivity disorder group must complete four years of follow-up and intervention. Collect blood samples from more than 1,000 patients with depressive disorders.
89028607|NCT06155188|Experimental|PT/FLU+CY|The group consisted of fludarabine (40mg/m2, day-5 to day-3 and day+3, day+4), busulfan (100mg/m2, day-6 to day-3), haplo-PBSC (day0), cyclophosphamide (50mg/kg, day+3, day+4) , and UCB (day+6)
89028608|NCT06155162|Experimental|Original HuggyPuppy doll|The original puppy doll used in Sadeh et al., 2006 is a sad dog with Velcro on its paws will be provided to children allocated to this treatment arm.
89028609|NCT06155162|Experimental|Monkey with velcro on paws, neutral expression|A monkey doll with a neutral expression and with Velcro on its paws will be provided to children allocated to this treatment arm.
89028610|NCT06155162|Experimental|Dog without velcro on paws, neutral expression|A puppy doll with a neutral expression and without Velcro on its paws will be provided to children allocated to this treatment arm.
89569445|NCT03644381|No Intervention|Control|Following randomization, this arm will receive no intervention. After twelve months, participants in this group will undergo a singe-blind, placebo-controlled oral food challenge
89028611|NCT06155162|Experimental|Bear, smiling|A smiling bear doll with a neutral expression and without Velcro on its paws will be provided to children allocated to this treatment arm.
89028612|NCT06155162|Experimental|Rabbit, neutral expression|A bunny-rabbit doll with a neutral expression and without Velcro on its paws will be provided to children allocated to this treatment arm.
89028613|NCT06155110|Experimental|Cardiomyopeptidin group|The Cardiomyopeptidin group received intravenous infusion 3 mg/(kg·d) of cardiomyopeptidin during the PCI until 3 days after operation
89569446|NCT03644381|Experimental|Treatment|Following randomization, participants in this group will receive escalating doses milk, up to a daily dose of 200 ml. Once they attain that dose, they will maintain it for one month. At the end of this period, they will undergo a open challenge to 300 ml of milk. They will then enter a year-long follow-up period
89028614|NCT06155110|No Intervention|The control group|
89028615|NCT06155058|Experimental|Robotic Mirror Therapy|Serial training with the help of exoskeletal robot therapy
89569447|NCT05612711|Experimental|Dronabinol First|Participants will take Dronabinol 2.5 mg capsules twice daily for 1 week, followed by dronabinol 5 mg twice daily for 6 weeks, followed by dronabinol 2.5 mg twice daily for 1 week. They will then undergo a 3-week washout period, followed by placebo capsules twice daily for 8 weeks.
89569448|NCT05612711|Experimental|Placebo First|Participants will take matching placebo capsules twice daily for 8 weeks, followed by a three week washout period. They will then begin taking dronabinol 2.5 mg capsules twice daily for 1 week, followed by dronabinol 5 mg twice daily for 6 weeks, followed by dronabinol 2.5 mg twice daily for 1 week.
89569449|NCT04807309|Placebo Comparator|Placebo|Placebo comparison
89569450|NCT04807309|Active Comparator|Danazol Pill|Danazol 200mg orally twice a day
89569451|NCT04744649|Active Comparator|Control group|"The patients with combined positive score (CPS) of PD-L1 protein expression≥5 were randomised to control group(N=40), will receive the neoadjuvant regime of XELOX or SOX.~XELOX: Oxaliplatin+Capecitabine; SOX: Oxaliplatin+S-1. Oxaliplatin: 130mg/m2, iv drip for 2h, d1, q3w; S-1:40~60mg Bid, d1~14, q3w; Capecitabine: 1000mg/m2 Bid, d1-14, q3w; Neoadjuvant chemotherapy for 4 cycles, adjuvant chemotherapy for 4 cycles."
89569452|NCT04744649|Experimental|Experimental group|"The patients with combined positive score (CPS) of PD-L1 protein expression≥5 were randomised to experimental group(N=40), will receive the neoadjuvant regime of JS001+XELOX or SOX.~XELOX: Oxaliplatin+Capecitabine; SOX: Oxaliplatin+S-1. JS001: 240mg, ivdrip, d1, q3w; S-1:40~60mg Bid, d1~14, q3w; Capecitabine: 1000mg/m2 Bid, d1-14, q3w; Neoadjuvant chemotherapy for 4 cycles, adjuvant chemotherapy for 4 cycles."
89569453|NCT04744649|Other|Exploratory group|"All the patients of Epstein-Barr virus-positive (EBV(+)) [N=15]or mismatch repair-deficient (dMMR)/ microsatellite instability-high (MSI-H)[N=15] , will be assigned to exploratory group, and will receive the neoadjuvant regime of JS001+XELOX or SOX.~XELOX: Oxaliplatin+Capecitabine; SOX: Oxaliplatin+S-1. JS001: 240mg, ivdrip, d1, q3w; S-1:40~60mg Bid, d1~14, q3w; Capecitabine: 1000mg/m2 Bid, d1-14, q3w; Neoadjuvant chemotherapy for 4 cycles, adjuvant chemotherapy for 4 cycles."
89569454|NCT04801225|Experimental|VItalFlow Stimulation Treatment|"Enrolled subjects shall receive a VitalFlow stimulation after other standard-of-care treatments are initiated. VitalFlow treatment is initiated by powering on the System and positioning the two (Left and Right) VItalFlow coils on each side of the head (by the ear).~The operator controls the VItalFlow Stimulation through the accompanying console with simple button operation. Once treatment is initiated, the VitalFlow provides continuous, biphasic pulses at a preset power cycle with the total treatment time under 5 min (fixed time). After treatment is completed, the coils are removed and replaced on the VitalFlow System."
88815027|NCT01676831|Experimental|topical resiquimod 0.03%|Topical resiquimod 0.03% will be applied in dosing frequencies that are periodically adjusted to tolerability. Dosing frequency will begin 5 times a week. The dosing frequency may be adjusted (1,2,3,5,or 7times per week) based on the physician assessment of tolerability. Treatment will occur for 8 weeks followed by 4 weeks rest followed by another 8 weeks of treatment with 4 weeks rest. At 24 weeks a final evaluation will be performed. Those with a partial response at week 24 will have the option to continue therapy for up to another 12 weeks.
89028616|NCT06155058|Active Comparator|Conventional Mirror Therapy|Serial training with the help of physical therapist
89028617|NCT06155006||Adults with risk factors for hepatitis C virus|All persons over 18 years of age who are treated in the included health care institutions (IPS) and who are users of hospitalization, emergency, outpatient, and any other hospital care services.
89028618|NCT06154993|Experimental|static opener with slider + Conventional PT|"Patient supine Maintaining neck flexion + contralateral flexion and rotation and applying median nerve slider mobilization while maintaining the neck static in mentioned position.~Conventional PT includes hot pack for 10 mins and cervical isometrics."
89208935|NCT00985335|Experimental|External Application of Neem-based Cream|Non Controlled, non-randomized, single group pilot study.
89208936|NCT00873522||Community acquired pneumonia|
89208937|NCT00873522||Health-Care-Associated pneumonia|
89208938|NCT00982059||All|All patients enrolled in the study will be undergoing the same procedures.
89208939|NCT04016948|Experimental|Probe-based confocal laser endomicroscopy(pCLE)|Confocal laser endomicroscopy optical biopsy will be performed in surgery for patients assigned to this group
89208940|NCT04016948|Active Comparator|Intra-operative frozen section(IFS)|Intra-operative frozen section will be performed for patients assigned to this group
89028619|NCT06154993|Experimental|dynamic opener with slider + Conventional PT|"Patient supine Neck flexion + contralateral flexion and rotation. And sliding the median nerve along with neck movement from contralateral flexion+rotation to neutal position in repetitive manner, by releasing tension from median nerve when bringing neck in neutral to ease tension from affected side.~Conventional PT includes hot pack for 10 mins and cervical isometrics."
89569455|NCT05612633|Other|Oral zelavespib 100 mg|Oral zelavespib 100 mg will be administered once daily
89569456|NCT05458583|Other|Direct bonding with conventional adhesive|The fixed retainer was applied with direct bonding technique using two-step (conventional) adhesive
89569457|NCT05458583|Other|Direct bonding with one-step adhesive|The fixed retainer was applied with direct bonding technique using one-step adhesive
89569458|NCT05458583|Other|Indirect bonding with conventional adhesive|The fixed retainer was applied with indirect bonding technique using two-step (conventional) adhesive
89028620|NCT06154967|Experimental|ICIs regimen: tislelizumab 200mg every 3 weeks, the first dose was given 7 days after the last SBRT|
89028621|NCT06154941|Experimental|Giomer based Varnish|
89569459|NCT05458583|Other|Indirect bonding with one-step adhesive|The fixed retainer was applied with indirect bonding technique using one-step adhesive
89028622|NCT06154941|Active Comparator|CPP-ACP based varnish|
89028623|NCT06154928|No Intervention|Control Groups|Routine treatment and care of patients in the CG was continued. The onset of bowel sounds and flatus requires the initiation of oral fluid and nutrient intake. Patients in the CG were evaluated at T0, T1, T2, and T3, and data were recorded on a data collection form.
89028624|NCT06154928|Experimental|Wather Groups|Patients in the WG were provided warm water at the 2nd postoperative hour on the day of surgery. Patients in the WG were evaluated at T0, T1, T2, and T3 and data were recorded on a data collection form. The onset of bowel sounds and flatus requires the initiation of oral fluid and nutrient intake. No other water or food was provided to patients who had no bowel sounds or flatus other than warm water.
89028625|NCT06154915||Healing Ulcer|"The patients will be recruited from the doctors and the nurses of the foot clinic of Department of Endocrinology. A complete medical history and physical parameters will be collected, moreover a peripheral circulation status will assess at the time of the enrolment. During the first visit blood samples and a biopsy from the site of foot ulcers will be taken together with a picture of the ulcer. All patients will follow the medical treatments, as recommended by the multidisciplinary clinical team (for example revascularization or ulcer debriding). Intervals between visits will range between 4 to 8 weeks according to the usual medical routine. During visits 1, 2 and 3 the ulcers status will be documented by pictures, physical parameter collected, biopsies, ulcer fluid and blood samples will be taken for further analysis.~At visit 3 the ulcers will be classified as healing if completely resolved or dramatically reduced (more than 50%), otherwise will be classified as non-healing."
89028626|NCT06154915||Non-Healing Ulcer|"The patients will be recruited from the doctors and the nurses of the foot clinic of Department of Endocrinology. A complete medical history and physical parameters will be collected, moreover a peripheral circulation status will assess at the time of the enrolment. During the first visit blood samples and a biopsy from the site of foot ulcers will be taken together with a picture of the ulcer. All patients will follow the medical treatments, as recommended by the multidisciplinary clinical team (for example revascularization or ulcer debriding). Intervals between visits will range between 4 to 8 weeks according to the usual medical routine. During visits 1, 2 and 3 the ulcers status will be documented by pictures, physical parameter collected, biopsies, ulcer fluid and blood samples will be taken for further analysis.~At visit 3 the ulcers will be classified as non-healing if not resolved or not dramatically reduced (more than 50%)."
89028627|NCT06154902||Treated with idecabtagene vicleucel|
89569460|NCT03998605|Experimental|Abuse Prevention Program Condition|"The abuse prevention program will address: (1) BEFORE -- (a) Learning about problem of abuse and what abuse is; (b) Knowing about types of abuse, who the abusers are and where abuse happens; (c) Planning ahead and identifying safe people; (2) DURING -- (a) Rejecting abuse by saying no; (b) Getting away if possible/staying safe and paying attention, (c) Staying calm and getting home; and (3) AFTER -- (a) Telling your safe person, (b) Knowing what to do and what not to do, and (c) Reporting the abuse and getting help to cope with the event."
89569461|NCT03998605|Active Comparator|Control condition|During the study the control group will receive 12 activity sheets from the ESCAPE-NOW curriculum. Six activity sheets will be given at the initial meeting and half way through the study the remaining activity sheets will be mailed to the dyads. We chose these activity sheets because they provide abuse information that was designed for individuals with ID.
89569462|NCT04983277||Diabetes|patients with diagnosed Diabetes Mellitus
89569463|NCT03201575|Experimental|Remote ischemic conditioning|A brachial cuff is positioned around the arm of the patient. The remote ischemic conditioning consists in alternative inflations and deflations of the brachial cuff.
89028628|NCT06154902||Eligible for idecabtagene vicleucel|Eligible for idecabtagene vicleucel treatment but not treated
89208941|NCT04007211|Experimental|ABT13107|
89208942|NCT04007211|Active Comparator|Hyalobarrier|
89208943|NCT00881166|Experimental|1|oral MP-470 + paclitaxel/carboplatin
88811048|NCT04609410|Active Comparator|Moderate neuromuscular blockade|"During surgery, a moderate neuromuscular blockade will be achieved with the use of train of four (TOF) monitoring. TOF and Post-Tetanic Count (PTC) measurements will be performed every 15 minutes. Boluses of 0,1 mg/kg Rocuronium will be administered if monitored TOF count is ≥ 1 and/or PTC > 5.~Complete neuromuscular blockade reversal at the end of surgery will be achieved with an i.v. bolus of Sugammadex (variable dose according to depth of residual blockade) if TOF ratio is ≤ 0.9. If TOF ratio is > 0.9, pharmacological neuromuscular blockade reversal can be avoided."
89569464|NCT03201575|Other|Control group|A brachial cuff is positioned around the arm of the patient. No inflation or deflation is made.
89569465|NCT04426955|Experimental|Arm A|Camrelizumb + Paclitaxel + Cisplatin + Radiotherapy.
89569466|NCT04426955|Placebo Comparator|Arm B|Placebo + Paclitaxel + Cisplatin + Radiotherapy.
89569467|NCT02630563|Experimental|Mycophenolate Mofetil+Corticosteroids+Cyclosporine|Part 1: Participants will receive mycophenolate mofetil. Part 2: Participants will receive mycophenolate mofetil along with cyclosporine and corticosteroids.
89569468|NCT04982341||HFNC/prone|awake patients with COVID-19 and severe acute respiratory failure receiving HFNC in prone position
89028629|NCT06154876|Experimental|Cough assist device and designed chest physical therapy|Cough assist device involved 3-5 cycles with insufflation/exsufflation pressure beginning with +15 cm H2O to -15 cm H2O and maximum pressure of +40 cm H2O to -40 cm H2O for 4-5 sets for pediatric patients .and percussion, vibration, end expiratory pressure and bed mobility exercise.
89028630|NCT06154876|Active Comparator|Designed chest physical therapy|Percussion, vibration, end expiratory pressure and bed mobility exercise.
89569469|NCT04432987|Experimental|Newly Diagnosed Patient Group (n=30)|"I. Dornase Alpha treated group (n=15)~ii. Control group (n=15)"
89569470|NCT04432987|Experimental|Patient Group Monitored by Mechanical Ventilation (n=30)|"I. Dornase Alpha treated group (n=15)~ii. Control group (n=15)"
89028633|NCT06154837|Experimental|Part A: Single ascending dose (SAD) of GSK3862995B|Healthy participants will receive GSK3862995B.
89028634|NCT06154837|Experimental|Part B: Repeat doses GSK3862995B|Participants with COPD will receive repeat doses of GSK3862995B.
89028635|NCT06154837|Experimental|Part B: Placebo|Participants with COPD will receive repeat doses of Placebo.
89028636|NCT06154798|Active Comparator|World Digital Detox Women's Health Program|The intervention is a 6-week World Digital Detox Program designed to help participants reduce their dependence on digital devices and foster a healthier balance between technology use and overall well-being.
89028637|NCT06154798|No Intervention|Control Group|Participants assigned to the control group will continue with their regular, unrestricted digital device usage throughout the 6-week study period.
89569471|NCT05412329|Experimental|GC012F treatment|R/R multiple myeloma patients be treated with a single dose of GC012F cells.
89569472|NCT05555381|Experimental|Intervention group (pilot study)|"needs detection by means of survey and interviews (mixed-methods)~6 week program (1 hour) on a weekly basis including cognitive behavioural therapy, sleep/stress hygiene education, heart coherence exercises, mindfulness and relaxation exercises"
89569473|NCT05397743|Experimental|Questionnaires|Questionnaires for global, psychological and visual Quality of Life (QoL)
89569474|NCT05555225||Patients with amelia|Patients with severe hypoplasia or agenesia of at least two limbs who gave their consent for the research and for whom a DNA sample is available in our laboratory
89569475|NCT05555225||Patients with Femur-Fibula-Ulna Syndrome|Patients with anomaly of at least one femur, one fibula and with oligodactyly who gave their consent for the research and for whom a DNA sample is available in our laboratory.
89569476|NCT05555225||Healthy subjects|Healthy subjects used as controls, who gave their consent for the research and for whom a DNA sample is available in our laboratory.
89569477|NCT05555147|Experimental|Nerve Block Group|Thirty minutes prior to surgery the patients received bilateral infraorbital and infratrochlear nerve block. Infraorbital nerve block was performed while using an extraoral approach. A 25 gauge needle was inserted laterally to the ipsilateral nostril after palpating the infraorbital ridge to locate the infraorbital foramen. The index finger of the non-dominant hand was positioned above the infraorbital foramen, and the needle was advanced until it was felt beneath the finger. 2 mL of the 0.5% ropivacaine slowly injected after negative aspiration of blood was confirmed. Inserting the needle 1 cm above the inner canthus, targeting the junction of the orbit and the nasal bone, performed Infratrochlear nerve block. After negative aspiration of blood, 1 mL of the 0.5% ropivacaine was injected. Contralateral nerve block was performed in the same manner.
89569478|NCT05555147|Sham Comparator|Control Group|Patients receiving general anesthesia without Infraorbital and Infratrochlear nerve block.
89569479|NCT02587247|Experimental|TF2 antibody/68Ga-IMP-288|TF2 antibody/68Ga-IMP-288
89569480|NCT02555111|Experimental|Xarelto|15mg/day oral administration during 2 to 4 years (based on the recruitment date).
89569481|NCT02555111|No Intervention|untreated|the patient won't receive any treatment during his study participation.
88811049|NCT04607850|Experimental|Lead-in Group A ChAdOx1-HPV low dose and MVA-HPV low dose|Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10^8 vp) and MVA-HPV (1 x 10^7 pfu)
89028638|NCT06154759|Experimental|experimental caregiver group|33 of whom were in the experimental group and 33 in the control group, were included in the study. In the study, quantitative data were collected using Descriptive Characteristics Form, Beck Hopelessness Scale, Templer Death Anxiety Scale and Caregiver Strain Index, while qualitative data were collected using Structured Interview Form-1 and Structured Interview Form-2. Quantitative data collection tools were applied to the relatives of the patients in the experimental and control groups after the randomization group assignment within the scope of the pre-test. Psychoeducation was given to the relatives of the patients in the experimental group for 45-60 minutes once a week for eight weeks. Qualitative data were collected in sessions (sessions 2,3,5,7,8) and for this purpose, Structured Interview Form-1, Structured Interview Form-2, and audio recording were used. The same data collection tools were applied to the Experiment group for the post-test measurements after eight weeks.
89208944|NCT00881166|Experimental|2|oral MP-470 + carboplatin/etoposide
88811050|NCT04607850|Experimental|Lead-in Group B ChAdOx1-HPV mid dose and MVA-HPV low dose|Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10^9 vp) and MVA-HPV (1 x 10^7 pfu)
88811051|NCT04607850|Experimental|Lead-in Group C ChAdOx1-HPV high dose and MVA-HPV high dose|Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10^10) vp and MVA-HPV (1 x 10^8 pfu)
89028639|NCT06154759|No Intervention|control caregiver group|In the study, quantitative data were collected using Descriptive Characteristics Form, Beck Hopelessness Scale, Templer Death Anxiety Scale and Caregiver Strain Index in control group. The control group received no intervention for eight weeks. The same data collection tools were applied to the Control group for the post-test measurements after eight weeks.
89028640|NCT06154733|Experimental|Photobiomodulation with low level laser therapy|This group will be subjected to photo biomodulation by low level laser therapy. Diode laser will be used (SIROLaser Blue®, Sirona, Germany) at a wavelength of 660 nm and a power of 100 mW for 10 sec, corresponding to an energy dose of 1 J. Irradiation will be performed at the hypomineralized area: two irradiations scanning the surface in the mesiodistal direction and two in the occlusogingival direction (perpendicular to the tooth surface) precisely over the lesion, in a uniform scanning motion with relative isolation. Treatment will be performed in 3 sessions with a 72-hour interval between sessions. During the laser treatments, both the volunteer and operator will use protective eyewear and all rules of safety will be obeyed.
89569482|NCT02521415|Experimental|ketamine|ketamine (1mg/kg)
89569483|NCT02521415|Active Comparator|fentanyl|fentanyl (1.5 micrograms/kg)
89208945|NCT00881166|Experimental|3|oral MP-470 + topotecan
89569484|NCT02461511||Therapeutic Education + Documentation|diabetic patient hospitalized patient particpating in therapeutic education program
89569485|NCT02461511||No Therapeutic Education No Documents|diabetic patient hospitalized patient without therapeutic education program no documentation submitted
89569486|NCT02461511||Documentation, No Therapeutic Education|diabetic patient hospitalized patient without therapeutic education program documentation submitted
89569487|NCT02078141|Experimental|18F-deoxyglucose (FDG)|18F-deoxyglucose (FDG)
88970124|NCT04869449|Experimental|Ketoconazole|Participants will be taking 400 mg of the study drug (two 200 mg tablets) by mouth twice a day until the day of biopsy or surgery. On the day of biopsy or surgery, participants will take their medication the morning of their biopsy or surgery (before the operation) and in the evening after their biopsy or surgery (after the operation). Participants will then take the last dose of the medication in the morning of the day after their biopsy or surgery. Participants will be given 12 days' worth of the study drug (pills) and verbally instructed how and when to take them.
88970125|NCT04851457|Experimental|Intervention group|The participants in the experimental group will receive intravenous tirofiban combined with a standard MT protocol recommended by the current guidelines for the management of AIS
88970126|NCT04851457|No Intervention|Control group|Patients are treated with MT therapy with no antiplatelet drugs (intravenous or intra-arterial) are administered. Besides, they will receive a standard pharmacological treatment as per current clinical guidelines.
88970127|NCT04840693|Experimental|Excess of endogenous glucoglucocorticoids (group 1)|v
88970128|NCT04840693|Experimental|Exogenous hypercortisolisms (group 2)|a disease justifying the up-coming start of a glucocorticoid therapy
88970129|NCT04840693|Experimental|Adrenal insufficiency (group 3)|chronic adrenal insufficiency
88970130|NCT04840693|Other|Control (group 4)|without glucocorticoid excess
88970131|NCT04836455|Experimental|The Real Cost vaping prevention ads - Health effects theme|
88970132|NCT04836455|Experimental|The Real Cost vaping prevention ads - Addiction theme|
88970133|NCT04836455|Other|Neutral vaping ads|
88970134|NCT04825275|Experimental|Posaconazole|Participants will be taking 300 mg of the study drug (three 100 mg tablets) by mouth twice a day the first day and then 300 mg once a day until the day of biopsy or surgery. On the day of biopsy or surgery, participants will take their medication the morning of their biopsy or surgery (before the operation). Participants will then take the last dose of the medication in the morning of the day after their biopsy or surgery. Participants will be given 12 days' worth of the study drug (pills) and verbally instructed how and when to take them.
88970135|NCT04825275|No Intervention|Control|Participants will not undergo any intervention.
88970136|NCT04822220|Experimental|Experimental|Fatigue Self-management Programme
88970137|NCT04822220|No Intervention|Controlled|The control group received routine treatment and nursing care
88970138|NCT04803110|Experimental|Immediate Implant with SST (SST)|Patients who will receive immediate implant placement using the Socket-Shield Technique.
88970139|NCT04803110|Active Comparator|Immediate Implant with biomaterial (GAP)|Patients who will receive immediate implant placement using bone biomaterials to fill the gap after complete extraction of the tooth.
88970140|NCT04795843|Experimental|Exercise and patient education|6-months
88970141|NCT04795843|Active Comparator|Usual Care|6-months
89208946|NCT00881166|Experimental|4|oral MP-470 + docetaxel
89569488|NCT02588339|Experimental|Panobinostat (PANO) Therapy|Participants will be treated with standard of care chemotherapy agents prior to their allogeneic hematopoietic cell transplant. For Graft Versus Host Disease (GVHD) prevention, participants will receive PANO, Sirolimus and Tacrolimus.
89569489|NCT05554913|Experimental|QL0911|The study in a 2:1 randomization ratio(40 subjects to QL0911). Qilu investigational product (QL0911 or placebo) will be administered in the clinic by a qualified healthcare provider as a subcutaneous injection.
89569490|NCT05554913|Placebo Comparator|Placebo|The study in a 2:1 randomization ratio(20 subjects to Placebo ). Qilu investigational product (QL0911 or placebo) will be administered in the clinic by a qualified healthcare provider as a subcutaneous injection.
89569491|NCT05554757|Experimental|conventional rubber dam system|in the first 30 patients, the conventional rubber dam was used prior to the OptraDam For the first 30 patients, on the day of the first appointment, the stopwatch was set for recording the time taken for the application of the conventional rubber dam . Following this, the required dental treatment was carried out. Radiographs were taken as & when necessary . At the end of the appointment, the questionnaires were filled by the patient as well as the operator regarding their experience of the conventional rubber dam
88970142|NCT04794491|Experimental|Open-Label Conversion and Treatment Optimization|Conversion from Xyrem to XYWAV, maintaining the dose and regimen of any concomitant anticataplectics or stimulants unchanged throughout study.
88970143|NCT04791748|Experimental|Patients with chronic vestibular deficits|Patients aged 7 to 17 years with chronic vestibular deficits
88970144|NCT04791748|Active Comparator|Controls|Patients aged 7 to 17 years without chronic vestibular deficits
89208947|NCT00881166|Experimental|5|oral MP-470 + Erlotinib
89208948|NCT00804752|Experimental|Vitamin D|An addition of Vitamin D to the standard treatment
89208949|NCT05225766|Active Comparator|Group ESPB|Erector spinae plane block
89208950|NCT05225766|Active Comparator|Group RSB|Rectus sheath block
89208951|NCT00804830|Experimental|chemotherapy|Treatment with Avastin 15 mg/kg q3w and doxorubicin 20 mg q1w for 6 months.
89208952|NCT00873678||1|Children or adult patients affected with JS/CORS
89569492|NCT05554757|Active Comparator|OPTRADAM|In second appoinment the optradam was applied. The stopwatch was set for the recording the time of application of the OptraDam. The required dental treatment was carried out. Radiographs were taken. At the end of the appointment, the questionnaires were again filled by the patient as well as the operator regarding their experience of the OptraDam.
89569493|NCT05612321|Active Comparator|Traditional supine position|Participants enrolled in the Control Group undergo vacuum-assisted delivery in traditional supine position (supine with 90 degrees bended legs on footrests)
89569494|NCT05612321|Experimental|All-fours position|Participants enrolled in Experimental Group experience vacuum application in all-fours position.
89569495|NCT05317247||Discovery Cohort|An anticipated number of 473 participants will be recruited in Cape Town, South Africa. Data (cough audio) will be collected and used to train a machine learning algorithm. The cough audio signal specific for TB will be refined. During the discovery phase, the ground truth obtained through biological testing of sputum specimens will be used to inform the machine learning.
89569496|NCT05317247||Validation Cohort|In the validation phase, the cough audio signature will have its sensitivity and specificity measured in new patients in Cape Town, South Africa (n=511) and Kampala, Uganda (n=767). The data will be used to evaluate the performance of the algorithm.
89569497|NCT05554523||Vitiligo|
89569498|NCT05554523||Fitzpatrick Type 1|
89569499|NCT05554523||Fitzpatrick Type 2|
89569500|NCT05554523||Fitzpatrick Type 3|
89569501|NCT05554523||Fitzpatrick Type 4|
89569502|NCT05554523||Fitzpatrick Type 5|
89569503|NCT05554523||Fitzpatrick Type 6|
89569504|NCT04426565|Other|the motivational enhancement interview|The motivational enhancement interview is a counseling approach developed in part by clinical psychologists William R. Miller and Stephen Rollnick. It is a directive, client-centered counseling style for eliciting behavior change by helping clients to explore and resolve ambivalence.
89569505|NCT04426565|Other|the individual psychotherapy|The individual psychotherapy is the use of psychological methods, particularly when based on regular personal interaction with adults, to help a person change behavior and overcome problems in desired ways. Psychotherapy aims to improve an individual's well-being and mental health, to resolve or mitigate troublesome behaviors, beliefs, compulsions, thoughts, or emotions, and to improve relationships and social skills.
89569506|NCT04426565|Other|the group psychotherapy|The group psychotherapy is a form of psychotherapy in which one or more therapists treat a small group of clients together as a group. The term can legitimately refer to any form of psychotherapy when delivered in a group format, including Art therapy, cognitive behavioural therapy or interpersonal therapy, but it is usually applied to psychodynamic group therapy where the group context and group process is explicitly utilised as a mechanism of change by developing, exploring and examining interpersonal relationships within the group.
89569507|NCT04426565|Other|the family therapy|The family therapy is is a branch of psychotherapy that works with families and couples in intimate relationships to nurture change and development. It tends to view change in terms of the systems of interaction between family members.
89569508|NCT04328831|Other|IBI322|Single arm
89569509|NCT05700851|Other|Immuno-nutrition|"Participants will be advised to take daily one sachet (74 g) of the immuno-nutrition supplement (Oral Impact®, Nestle) dissolved in 125 ml of water and will be followed-up for 6 weeks.~Participants will receive individualised (to patient needs and food preferences) dietetic advice formulated and delivered by an experienced renal dietitian under an honorary NHS research contract, who is a member of the research team and will be supervised by an NHS renal dietitian, aiming to achieve estimated nutritional requirements for people on haemodialysis (i.e., energy: 30-35 kcal/kg/day, and protein intake: 1.0-1.2 g/kg/day). Each dietetic advice provided to participants will also be reviewed by the NHS clinical renal dietitians who are members of the participants' usual clinical care team."
89569510|NCT05612165|Experimental|tDCS group|
89569511|NCT05612165|Sham Comparator|Control group|
89569512|NCT05558345|Experimental|Contingency Management for Methamphetamine Reduction|8 weeks of contingency management, twice weekly visits, with escalating rewards from $10 to $40 for negative urine tests
89569513|NCT05558345|No Intervention|Non-substance-using Control|Observational visits (no intervention) at baseline, Week 4, Week 8, and Week 12 for those who do not use methamphetamine.
89569514|NCT05543291||healthy controls|
89569515|NCT05543291||mild CKD|
89569516|NCT05543291||Moderate CKD|
89569517|NCT05543291||ESRD|
89569518|NCT05553899|Experimental|Diagnostic (PET-MRI)|Patients will undergo PET-MRI
89569519|NCT05553821|Active Comparator|Manual pressure group|A sand bag weighing 3.5-4 kg is applied to the CAG area of this group of patients.
88811052|NCT04607850|Experimental|Group 1 ChAdOx1-HPV mid dose and MVA-HPV low dose|Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10^9 vp) and MVA-HPV (1 x 10^7 pfu)
88811053|NCT04607850|Experimental|Group 2 ChAdOx1-HPV high dose and MVA-HPV low dose|Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10^10 vp) and MVA-HPV (1 x 10^7 pfu)
88811054|NCT04607850|Experimental|Group 3 ChAdOx1-HPV low dose and MVA-HPV high dose|Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10^8 vp) and MVA-HPV (1 x 10^8 pfu)
89569520|NCT05553821|Experimental|Cold pressure group|A cold sand bag weighing 3.5-4 kg is applied to the CAG area of this group of patients.
89569521|NCT05543135||cases|patients with asymmetrical hearing loss
89569522|NCT05549375|Experimental|Neurorehabilitation of the Hand|
89569523|NCT05700617|Active Comparator|1:1 Randomization to Milrinone or Dobutamine|Patients will be randomized 1:1 to either Milrinone or Dobutamine. Milrinone will be given as a bolus at a dose of 5 mcg/kg/min over 15 minutes, for a total of 75 mcg/kg. For patients randomized to the arm for maintenance milrinone, they will be maintained at 0.125-0.375 mcg/kg/min. Patients may be randomized to dobutamine will be infused at 10-40 mcg/kg/min during the infusion phase and for those randomized to dobutamine for maintenance, they will be kept at 5-10 mcg/kg/min.
89569524|NCT05700617|Active Comparator|1:1 Randomization to Dobutamine or Milrinone|Patients will be randomized 1:1 to either Milrinone or Dobutamine. Dobutamine will be infused at 10-40 mcg/kg/min during the infusion phase, and for those randomized to dobutamine for maintenance, they will be kept at 5-10 mcg/kg/min. Milrinone will be given as a bolus at a dose of 5 mcg/kg/min over 15 minutes, for a total of 75 mcg/kg. For patients randomized to the arm for maintenance milrinone, they will be maintained at 0.125-0.375 mcg/kg/min.
89569525|NCT05542979|Experimental|HH-003 Group|
89569526|NCT05542979|Placebo Comparator|Placebo Group|
89569527|NCT05542745|Active Comparator|palatal retractor|palatal retraction
89569528|NCT05542745|Active Comparator|buccal retractor|buccal retraction
89569529|NCT05553587|Experimental|Amara Drops|Phytopharmaceutical / therapeutic intervention
89569530|NCT04322747||Participants scheduled to undergo skull-based surgery|Participants scheduled to undergo skull-based or mastoid surgery as part of their standard care will receive Audiometry for extended high frequencies, DPOAE, ECochG before and after the procedure in the non operated ear.
89569531|NCT02629159|Placebo Comparator|Placebo followed by ABT-494|"Participants were to receive placebo to upadacitinib orally once daily (QD) and placebo to adalimumab by subcutaneous injection once every two weeks (eow) for up to 26 weeks. Participants who did not achieve a ≥ 20% improvement in tender joint count (TJC) and swollen joint count (SJC) at Weeks 14, 18, or 22 compared to Baseline were to be switched to 15 mg upadacitinib orally QD. At Week 26, all remaining participants were to be switched to 15 mg upadacitinib QD until Week 48 (end of Period 1).~Participants who complete Period 1 will continue to receive 15 mg upadacitinib orally QD for up to 5 years in Period 2."
89569532|NCT02629159|Active Comparator|Adalimumab|"Participants were to receive placebo to upadacitinib orally QD and 40 mg adalimumab by subcutaneous injection eow for up to 48 weeks in Period 1. Participants who did not achieve a ≥ 20% improvement in TJC and SJC at Weeks 14, 18, or 22 compared to Baseline were to be switched to 15 mg upadacitinib orally QD. At Week 26 remaining participants who did not achieve low disease activity (defined as Clinical Disease Activity Index [CDAI] ≤ 10) were to be switched to 15 mg upadacitinib orally QD until Week 48.~Participants who complete Period 1 will continue to receive the same treatment assigned at the end of Period 1 (15 mg upadacitinib QD or 40 mg adalimumab eow) for up to 5 years in Period 2."
88970145|NCT04783519|Experimental|BASICS + SLEEP|The BASICS + SLEEP intervention will integrate BASICS feedback and the Motivational Interviewing (MI) process described in the BASICS arm with Brief Behavioral Therapy for Insomnia (BBTI) content and materials. The BASICS + SLEEP intervention will be implemented in 2 sessions of 45-75 minutes and 2 telephone booster sessions. We will follow BBTI procedures, including provision of a physiological rationale for insomnia and the importance of behavioral strategies to regulate sleep; introduction of sleep hygiene; discussion of factors that can impede duration and quality of sleep; introduction of sleep restriction and stimulus control strategies and negotiation of an initial sleep restriction schedule; and follow-up evaluation of success and continued refinement to achieve sleep efficiency goals. Booster contacts serve as opportunities to adjust the sleep restriction schedule, problem-solve challenges, and further build motivation.
88970146|NCT04783519|Active Comparator|BASICS|The BASICS condition will meet for 2 sessions of 45-75 minutes. Content depends on the degree to which participants discuss the feedback, have questions, and/or explore behavior change options. Therapists review feedback components with participants, eliciting personally relevant reasons to change as domains are explored. When the participant is ambivalent about change, therapists work with them to explore and resolve that ambivalence. The method is non-confrontational and utilizes exploration of personalized graphic feedback (i.e., frequency, quantity, and peak use alongside perceived and actual norms for alcohol/MJ use) to increase motivation for change by highlighting ways alcohol and/or marijuana use could be incongruent with goals or values. Beliefs, expectations, and motives for use are discussed as are strategies to minimize risks and consequences. Booster sessions address questions and problem-solve challenges that have arisen since the session.
88970147|NCT04783519|No Intervention|Assessment Only Control|Participants in Assessment Only Control (AOC) condition will complete all assessments (including survey, daily, actigraphy) at the same time as participants in the 2 active interventions. AOC will also attend an in-person meeting to verify identity, provide rationale for daily monitoring, control for time/attention, and participants in all conditions including AOC will receive referrals for community services to address alcohol and MJ use, sleep, and other mental health concerns. No participants will be deprived of services; use of outside services will be tracked to assist with interpretation of outcomes. AOC condition will be offered BASICS + SLEEP after 3-month follow-up.
88970148|NCT04777851|Experimental|Regorafenib + Pembrolizumab|Investigational arm: regorafenib at a dose of 90 mg orally once per day (on days 1 to 21 of a 28-day cycle), in combination with pembrolizumab 400 mg using a 30-minute intravenous infusion, on day 1 of a 6-week cycle.
88970149|NCT04777851|Active Comparator|Loco-regional therapy|"Control arm: Patients will be treated with TACE or TARE on-demand according to site's standard of practice."
88970150|NCT04776577|Other|Study arm|"Group 1 and group 2 will be recruited and assessed in parallel at the discretion of the treating physician, based on the characteristics of the patient. Group 3 will be recruited from suitable patients in group 1 and 2.~Simultaneous measurements study (group 1) Regular study group (group 2) Echocardiography-CFR group (group 3)"
88970151|NCT04776265||RR HL Who Receive Salvage Chemotherapy and ASCT|Patients With Relapsed/Refractory Classical Hodgkin Lymphoma Who Receive Salvage Chemotherapy and Autologous Stem Cell Transplant
88970152|NCT04770272|Experimental|Arm A|2 weeks Atezolizumab monotherapy before biopsy, followed by a 12-week therapy with Paclitaxel + Carboplatin+ Atezolizumab every 3 weeks for 4 cycles. This will be followed by Epirubicin + Cyclophosphamide + Atezolizumab every 3 weeks for 4 cycles.
88970153|NCT04770272|Active Comparator|Arm B|12-week therapy with Paclitaxel + Carboplatin + Atezolizumab every 3 weeks for 4 cycles. This will be followed by Epirubicin + Cyclophosphamide + Atezolizumab every 3 weeks for 4 cycles.
88970154|NCT04754581|Other|All Participants|
88970155|NCT04745793||Thyroids|The aim is to identify and preserve the parathyroid glands during the total or partial removal of the thyroid. Repeating of the procedure for each lobe
88970156|NCT04745793||Parathyroids|The aim is to selectively remove the pathological parathyroid gland(s). Repeating of the procedure for each removed gland
89208953|NCT00985569||Lubiprostone|Subjects switching from current bowel medicines to lubiprostone
89569533|NCT02629159|Experimental|Upadacitinib|"Participants were to receive 15 mg upadacitinib orally QD and placebo to adalimumab by subcutaneous injection eow for up to 48 weeks in Period 1. Participants who did not achieve a ≥ 20% improvement in TJC and SJC at Weeks 14, 18, or 22 compared to Baseline were to be switched to 40 mg adalimumab eow. At Week 26 remaining participants who did not achieve low disease activity (defined as CDAI ≤ 10) were to be switched to 40 mg adalimumab eow until Week 48.~Participants who complete Period 1 will continue to receive the same treatment assigned at the end of Period 1 (15 mg upadacitinib QD or 40 mg adalimumab eow) for up to 5 years in Period 2."
89569534|NCT05548829||Non-hospitalised Covid-19 patients (mild infection)|COVRES1, retrospective recuitment from public advertisment, attended CTRIC or home visits. Obtained saliva and whole blood samples for DNA and RNA extraction.
89569535|NCT05548829||Hospitalised Covid-19 patients (severe infection)|COVRES1, retrospective recuitment from secondary care, attended wards. Obtained saliva and whole blood samples for DNA and RNA extraction.
89569536|NCT05548829||Non-hospitalised Covid-19 patients (mild infection) 3 month follow up|COVRES2, prospective recuitment, attended CTRIC or home visits. Obtained saliva and whole blood samples for DNA and RNA extraction.
89569537|NCT05548829||Hospitalised Covid-19 patients (severe infection) 3 month follow up|COVRES2, prospective recuitment, attended CTRIC or home visits. Obtained saliva and whole blood samples for DNA and RNA extraction.
89569538|NCT05548829||Non-hospitalised Covid-19 patients (mild infection) 6 month follow up|COVRES2, prospective recuitment, attended CTRIC or home visits. Obtained saliva and whole blood samples for DNA and RNA extraction.
89569539|NCT05548829||Hospitalised Covid-19 patients (severe infection) 6 month follow up|COVRES2, prospective recuitment, attended CTRIC or home visits. Obtained saliva and whole blood samples for DNA and RNA extraction.
89569540|NCT05553431|Experimental|No EP system Group|Patients were performed left bundle branch pacing without EP system.
89569541|NCT05552885||Stroke patients|General cognitive level will be evaluated with the Standardized Mini Mental Test to determine the eligibility of the participants for the study. The American National Institutes of Health Stroke Scale will be applied to determine the stroke severity and functional status of the participants. The reliability and validity of the eight-shape gait test and the double-task octagonal gait test will be examined. The reliability of the tests will be evaluated by calculating the test-retest method, standard error measurement and minimum detectable change values. The initial test and retest will be evaluated two days apart. The concurrent validity of the tests will be evaluated by the correlation between the timed get-and-go test, the 10-meter walk test, and the modified four-square step test.
89569542|NCT04982263||Mild cases|Patients with confirmed COVID-19 and with mild disease
89569543|NCT04982263||Severe cases|Patients with confirmed COVID-19 and with severe disease
89569544|NCT05548673|Experimental|Experimental Group|Stress management training was applied to the experimental group for eight weeks in sessions of 60-90 minutes once a week.
89569545|NCT05548673|No Intervention|Control group.|No action was taken on the students in the control group.
89569546|NCT05548595|Experimental|Investigational|"Active ingredients (per tablet):~• NeumentixTM Phenolic~Complex K110-42:~450 mg Spearmint extract (Mentha spicata)~100 mg Alpha-Glyceryl Phosphoryl Choline~50 mg Phosphatidylserine (Sharp PS®)~10 mg Pyrroloquinoline quinone~Inactive ingredients (per tablet):~Microcrystalline cellulose~Maltodextrin~Hardened rapeseed fat~Magnesium salts from fatty acids (palm oil free)~Silicon dioxide~Glycerin~Hydroxypropyl methylcellulose"
89569547|NCT05548595|Placebo Comparator|Placebo|"Active ingredients (per tablet):~N/A~Inactive ingredients (per tablet):~Lactose monohydrate~Magnesium stearate~Microcrystalline cellulose"
89208954|NCT00798044|Experimental|Feedback to counselors|substance abuse counselors received feedback reports on their average performance and on the average performance of the clinic as a whole. Feedback reports contained information on average alliance, treatment satisfaction, and drug/alcohol use.
89208955|NCT00798044|No Intervention|Treatment as Usual|No feedback reports were provided in this arm.
89569548|NCT04982185||Deep block|Deep neuromuscular block before initial (V1) vagal stimulation.
89569549|NCT04982185||Moderate block|Moderate neuromuscular block before initial (V1) vagal stimulation.
89569550|NCT02628769|Experimental|Solithromycin|28 day treatment of 400 mg Solithromycin taken once a day.
89569551|NCT02628769|Placebo Comparator|Placebo|28 day treatment with placebo taken once per day.
89569552|NCT05552807|Experimental|Cohort 1 SCT200+SCT-I10A|SCT200+SCT-I10A was given to patients who had failed previous platinum-based therapy. Among them, SCT200 was administered as 6 mg/kg/QW for 12 weeks and 8 mg/kg/Q2W maintenance by intravenous infusion; SCT-I10A was 200 mg/Q3W by intravenous infusion for no more than 2 years. Every 6 weeks is a treatment cycle. After the first dose, tumor assessment was performed every 6 weeks until the occurrence of PD, initiation of new antitumor therapy, withdrawal of informed consent, death, or loss of visit
89569553|NCT05552807|Experimental|Cohort 2-1 SCT200+SCT-I10A|SCT200+SCT-I10A was given to patients who had failed previous platinum-based and immune checkpoint inhibitor therapy. Among them, SCT200 was administered as 6 mg/kg/QW for 12 weeks and 8 mg/kg/Q2W maintenance by intravenous infusion; SCT-I10A was 200 mg/Q3W by intravenous infusion for no more than 2 years. Every 6 weeks is a treatment cycle. After the first dose, tumor assessment was performed every 6 weeks until the occurrence of PD, initiation of new antitumor therapy, withdrawal of informed
89208956|NCT00805922||A|
89208957|NCT00978783|Active Comparator|speaking valve|
89208958|NCT00978783|Active Comparator|Positive end expiratory pressure|
89208959|NCT00806000||Athletes|
89208960|NCT00982293|Active Comparator|Active fields|
89208961|NCT00982293|Sham Comparator|Inactive device|"Placebo treated group, will receive the 3 times weekly for 13 weeks (39) sessions, however, the device will not be on."
89569554|NCT05552807|Experimental|Cohort 2-2 SCT200+paclitaxel/docetaxel|SCT200+paclitaxel/docetaxel was given to patients who had failed previous platinum-based and immune checkpoint inhibitor therapy. Among them, SCT200 was administered as 6 mg/kg/QW for 12 weeks and 8 mg/kg/Q2W maintenance by intravenous infusion; paclitaxel was 80mg/m^2/QW by intravenous infusion; docetaxel was 75mg/m^2/Q3W. Every 6 weeks is a treatment cycle. After the first dose, tumor assessment was performed every 6 weeks until the occurrence of PD, initiation of new antitumor therapy, withdrawal of informed
89569555|NCT05552807|Experimental|Cohort 3 SCT200+SCT-I10A|SCT200+SCT-I10A was given to patients who have not received prior systemic chemotherapy. Among them, SCT200 was administered as 6 mg/kg/QW for 12 weeks and 8 mg/kg/Q2W maintenance by intravenous infusion; SCT-I10A was 200 mg/Q3W by intravenous infusion for no more than 2 years. Every 6 weeks is a treatment cycle. After the first dose, tumor assessment was performed every 6 weeks until the occurrence of PD, initiation of new antitumor therapy, withdrawal of informed
89028641|NCT06154733|Active Comparator|light cured resin-based sealant|This group will receive light cured resin-based sealant (Fissured Novo Plus). Cotton rolls and a four-handed technique will be applied for isolation. Scotchbond Universal will be rubbed in the cleaned surface for 20 seconds and air dried for 5 seconds. Afterwards, Fissured Novo Plus will be applied with a syringe. Before light-curing, the presence of air bubbles will be checked and teased out. Light curing for 40 seconds will be done. Occlusion will be checked using articulating paper and necessary adjustments will be done using finishing burs.
89569556|NCT04432909||Urothelial carcinoma group|Pre-surgery patients with urothelial carcinoma will be the experimental group to determine the sensitivity and specificity of UroCAD analysis, the result will be compared with cytology and FISH test.
89569557|NCT04432909||Non-cancer participants|Patients being treated for other diseases but without any tumor will provide a negative control to provide data for determining the sensitivity and specificity of UroCAD analysis.
89569558|NCT05552729|Active Comparator|High dose group|A 2000IU vitamin D3 supplement was started the next day after surgery.
89569559|NCT05552729|Active Comparator|Low dose group|A 400IU vitamin D3 supplement was started the next day after surgery.
89569560|NCT05552729|No Intervention|The control group.|No vitamin D3 supplement was started the next day after surgery.
89569561|NCT05548049|Experimental|Piezosurgery Group|In the experimental group, a piezosurgical device was used to harvest the bone block from the ramus area.
89028642|NCT06154733|Active Comparator|glass ionomer sealant|This group will receive glass ionomer sealant. Fuji triage will be applied after activating and mixing the capsule. Light cure for 20 seconds. Occlusion will be checked using articulating paper and necessary adjustments will be done using finishing burs.
89028643|NCT06154694||Shoulder osteoarthritis patients|Patients with glenohumeral osteoarthritis
89028644|NCT06154694||Healthy control|Healthy adult volunteers with no history of shoulder pain or trauma
89028645|NCT06154681|Experimental|World Digital Detox Family Program|The 4-week Self-Help World Digital Detox Family and Society Program is a comprehensive program, with variety of self-guided activities, discussions, and reflection exercises. The intervention encompasses both individual and collective components.
89569562|NCT05548049|Active Comparator|Conventional Group|In the experimental group, a conventional burr was used to harvest the bone block from the ramus area.
89569563|NCT05547971||Radiation Encephalopathy Group|Patients with radioactive encephalopathy during follow-up
89569564|NCT05547971||No Radiation Encephalopathy Group|Patients without radioactive encephalopathy during follow-up
89028646|NCT06154681|No Intervention|Wait-list Control|Wait-list control group underwent the standard assessment and screening process but not engaged in the intervention during the 4-week period.
89028647|NCT06154655|Experimental|Intervention Group|participants will receive health education on climate change included in their routine antenatal care and also have access to the e-magazine accessible through mobile phones
89028648|NCT06154655|No Intervention|Control Group|participants will receive health education on climate change included in their routine antenatal care
89569565|NCT03062527|Experimental|Low Glycemic Index Diet|"Group consuming low glycemic index diet. Calculated glycemic index of daily diet was lower than 40. Carbohydrate- containing foods included whole rye bread, pumpernickel bread, whole oats, wheat brans, brown rice, buckwheat, vegetables (besides corn, cooked carrots, potatoes and pumpkin) and fruit such as apples, pears, grapefruits, tangerines, prunes, dried apricots and unripe bananas.~Interventions:~The experimental procedure for each participant included a 3-week low glycemic index diet. Between the 3-week low and moderate glycemic index diets or a moderate and low glycemic index treatment, a 14-day washout period was introduced."
89028649|NCT06154603||Oesophageal perforation|Adult patients (at least 18 years of age) with an oesophageal perforation, treated for it at a Swedish hospital between 2005-2023.
89028650|NCT06154603||Gastric perforation|Adult patients (at least 18 years of age) with a gastric perforation, treated for it at a Swedish hospital between 2005-2023.
89569566|NCT03062527|Experimental|Moderate Glycemic Index Diet|"Group consuming moderate glycemic index diet. Calculated glycemic index of diet was higher than 60. Carbohydrate- containing foods included wheat bread, wheat rolls, potatoes, instant oats, cornflakes, white rice, millet, boiled carrots and fruit (ripe bananas, grapes, raisins, dates, cranberry, honey and high sugar jams)~Interventions:~The experimental procedure for each participant included a 3-week moderate glycemic index diet. Between the 3-week low and moderate glycemic index diets or a moderate and low glycemic index treatment, a 14-day washout period was introduced."
89569567|NCT05547893|No Intervention|control group|workshop discussing the clinical ethical case scenario
89569568|NCT05547893|Experimental|Intervention group|a simulated clinical ethical situation with simulation patients
89569569|NCT04981561|Experimental|100 microgram GATE-251|GATE-251, 100 microgram tablet, PO, Single Dose with 28 day follow up
89569570|NCT04981561|Experimental|1 mg GATE-251|GATE-251, 1 mg tablet, PO, Single Dose with 28 day follow up
89569571|NCT04981561|Experimental|3 mg GATE-251|GATE-251, 3 mg tablet, PO, Single Dose with 28 day follow up
89569572|NCT04981561|Experimental|10 mg GATE-251|GATE-251, 10 mg tablet, PO, Single Dose with 28 day follow up
89569573|NCT04981561|Experimental|25 mg GATE-251|GATE-251, 25 mg tablet, PO, Single Dose with 28 day follow up
89569574|NCT04981561|Experimental|50 mg GATE-251|GATE-251, 50 mg tablet, PO, Single Dose with 28 day follow up
89569575|NCT04981561|Experimental|100 mg GATE-251|GATE-251, 100 mg tablet, PO, Single Dose with 28 day follow up
89569576|NCT04981561|Experimental|1 mg GATE-251 with CSF collection|GATE-251, 1 mg tablet, PO, Single Dose with 28 day follow up, with CSF collection
89569577|NCT04981561|Experimental|10 mg GATE-251 with CSF collection|GATE-251, 10 mg tablet, PO, Single Dose with 28 day follow up, with CSF collection
89028651|NCT06154603||Small intestinal perforation|Adult patients (at least 18 years of age) with a small intestinal perforation, treated for it at a Swedish hospital between 2005-2023.
89028652|NCT06154590||Method(s)1/PIF Used to Evaluate|"Competency Areas- Surgical care to patients with complex or recurrent neoplasms, including diagnosis and management of rare or unusual tumors.~Determining disease stage/treatment options for individual cancer patients at time of diagnosis and throughout the disease course.~Provide surgical care to patients with complex or recurrent neoplasms, including selecting for surgical therapy in combination with other forms of cancer treatment.~Performing palliative surgical.~Intervention(s): Use Attribution, assign category code of attribution Codes: 1-5, Descriptor, Unrelated, Unlikely, Possible, Probable, Definite.~Definitions: Use list of Adverse Events.~Dose Units -1 mg, anastrozole. 20 mgs NOLVADEX administer to patient. Tamoxifen citrate was added to melphalan (Lphenylalanine mustard (P) and fluorouracil (F))."
89028653|NCT06154590||Method(s)2/PIF Used to Evaluate|"Competency Areas- Biologic, pharmacologic, and physiologic rationale for each form of therapy, indications, risks, and benefits of regional and systemic therapy in adjuvant and advanced disease settings.~Nonsurgical cancer treatment modalities, including radiotherapy, chemotherapy, immunotherapy, and endocrine therapy.~Nonsurgical palliative treatments.~Rehabilitative services, including reconstructive surgery and physical rehabilitation.~Tumor biology, carcinogenesis, epidemiology, tumor markers, and tumor pathology.~Intervention(s): Attribution defines the relationship between the adverse event and the investigational agent(s)/intervention. Assign category code of attribution Codes: 1-5, Descriptor, Unrelated, Unlikely, Possible, Probable, Definite.~Definitions: Use list of Adverse Events.~Dose Units- adjuvant cytotoxic chemotherapy, added to lequo, low-dose cyclophosphamide methotrexate and fluoruracil"
89028654|NCT06154577||Obstructive sleep apnea patients|39 obstructive sleep apnea patients with hypoglossal nerve stimulation
89028655|NCT06154577||Healthy controls|15 healthy control participants
89569578|NCT04981561|Placebo Comparator|Placebo|Placebo tablet, PO, Single Dose with 28 day follow up
89569579|NCT02626819|Experimental|Arm 1: Receiving MOVE! Toward Your Goals|Receiving MOVE! Toward Your Goals intervention (MTG tool, health coaching at baseline, follow-up health coaching calls, potential support of goals from primary care provider)
89569580|NCT02626819|Active Comparator|Arm 2: Receiving Enhanced Usual Care|Receiving Enhanced Usual Care (standard VA Health Living Messages handouts, potential support of weight management efforts from primary care provider)
89569581|NCT05552651|Experimental|Envafolimab plus chemotherapy|
89569582|NCT05542199|Active Comparator|+MCNS+WL|This group receives the multicomponent nutrition supplement and the behavioral weight loss intervention.
89569583|NCT05542199|Placebo Comparator|-MCNS+WL|This group receives the placebo nutrition supplement and the behavioral weight loss intervention.
89028656|NCT06154551||Group A|fifteen patients with OPMLs (lichen planus, leukoplakia)
89028657|NCT06154551||Group B|fifteen patients with OSCC
89028658|NCT06154551||Group C|fifteen systemically healthy control subjects
89028659|NCT06154538|Experimental|Cadonilimab+FOLFOX group|Patients in this group will receive cetuximab combined with FOLFOX regimen, specifically: Cetuximab 6 mg/kg, intravenous infusion, D1; Oxaliplatin (85mg/m2), intravenous infusion, D1; Calcium folinate (400mg/m2), intravenous infusion, D1; 5-FU (400mg/m2), intravenous infusion, D1, then continuous intravenous infusion of 1200mg/(m2·d)×2d (total amount of 2400mg/m2, infusion for 46-48h) every two weeks; in the control group, qualified subjects will receive Oxaliplatin (85mg/m2), intravenous infusion, D1; Calcium folinate (400mg/m2), intravenous infusion, D1; 5-FU (400mg/m2), intravenous infusion, D1, then continuous intravenous infusion of 1200mg/(m2·d)×2d (total amount of 2400mg/m2, infusion for 46-48h) every two weeks. Imaging evaluation will be performed after 3 cycles of preoperative treatment. If the disease is resectable, surgery will be performed. If R0 resection is achieved, the preoperative regimen will continue for up to 9 cycles.
89569584|NCT05542199|Active Comparator|+MCNS-WL|This group receives the multicomponent nutrition supplement and is in the control group for the behavioral weight loss intervention (no behavioral intervention during the trial, but participant is wait-listed to receive one after the trial finishes).
89569585|NCT05542199|No Intervention|-MCNS-WL|This group receives the placebo nutrition supplement and is in the control group for the behavioral weight loss intervention (no behavioral intervention during the trial, but participant is wait-listed to receive one after the trial finishes)
89569586|NCT04981327|Experimental|Experimental|After a conventional course of 7 days of Apixaban 10mg BID, Apixaban 2.5mg BID during 3 months.
89569587|NCT04981327|Active Comparator|Standard|After a conventional course of 7 days of Apixaban 10 mg BID, Apixaban 5 mg BID during 3 months.
89569588|NCT05699837|Experimental|hBET 1|Rhythmic stimulation (2 weeks) followed by non-rhythmic stimulation (2 weeks)
89569589|NCT05699837|Experimental|hBET 2|Non-rhythmic stimulation (2 weeks) followed by rhythmic stimulation (2 weeks)
89569590|NCT05547815|Experimental|experimental arm|5 doses of rabies vaccine
89569591|NCT05541965|Experimental|Median score distributions of the reflexology groups, ICIQ-SF, IQOL and ISI|
89569592|NCT05541965|Active Comparator|Median score distributions of the kegel groups, ICIQ-SF, IQOL and ISI|
89569593|NCT05541965|Active Comparator|Median score distributions of the control groups, ICIQ-SF, IQOL and ISI|
89569594|NCT05547659|Active Comparator|multimodal|pregabalin/ acetaminophen/ celecoxib
89569595|NCT05547659|Active Comparator|unimodal|Pregabalin
89569596|NCT05547659|No Intervention|control|
89569597|NCT05552417|No Intervention|control group|Conventional control group(C) (n=--) where --- children will not receive any intervention.
89569598|NCT05552417|Active Comparator|Pectointercostal|Pectointercostal facial group (PI) (n=--) where --children will have bilateral Pectointercostal Block.
89569599|NCT04426175|Experimental|2D LASIK|With the 2D method, the flap resection is created in a planar mode (xy-plane), without vertical cut, at the requested depth.
89569600|NCT04426175|Experimental|3D LASIK|With the 3D method, the flap resection is done in a three-dimensional mode, at the requested depth, with the requested diameter and the desired border (side cut) angle
89028660|NCT06154538|Active Comparator|FOLFOX group|Patients in this group will undergo FOLFOX chemotherapy regimen, specifically: Oxaliplatin 85 mg/m2 dissolved in 500 ml of 5% glucose solution, intravenous drip, on Day 1, in combination with calcium folinate (400mg/m2), intravenous infusion, on Day 1, and 5-FU (400mg/m2), intravenous infusion, on Day 1, followed by continuous intravenous infusion of 1200mg/(m2·d) for 2 days (total dose of 2400mg/m2, infusion for 46-48 hours), once every 2 weeks. After 3 cycles of preoperative treatment, imaging evaluation will be performed. If the disease is resectable, surgery will be performed. If R0 resection is achieved, the preoperative treatment regimen will be continued after surgery, for a maximum of 9 cycles.
89028661|NCT06154499||Patients referred to the Urology Department who need to undergo radical prostatectomy surgery|
89028662|NCT06154486||semaglutide group|patients without risk factors for gastroparesis, fasting for at least 8 hours, BMI less than 30 and currently using semaglutide
89569601|NCT05552105|Other|Cohort|
89569602|NCT05541575|Experimental|Intervention|Experimental: offered 3 films of VR course of BPSD for 30 mins to each participants.
89569603|NCT05541575|No Intervention|No intervention|NO films of VR course of BPSD to any participants.
89569604|NCT05541419|Experimental|Maximum clinical treatment + Budesonide diluted|"The maximum clinical treatment consists of intramuscular injection of Dispropan® in intramuscular injectable suspension and busonid in nasal spray, two sprays of 50mcg in each nostril.~In this study, the investigator wishes to add to the maximum clinical treatment a daily wash with high volume diluted budesonide."
89569605|NCT05541419|Placebo Comparator|Maximum clinical treatment + Placebo|To compare the efficacy of adding diluted budesonide lavage to maximal clinical treatment, the placebo group is used. The placebo formula is composed of 1% glycerin diluted in water.
89569606|NCT05551637|No Intervention|control group|(n=300): Children eat usual dietary (not using Oral Nutritional Supplementation) for 3 months. After that, they will use the product in 3 months
89569607|NCT05551637|Experimental|specific intervention group|"(n=300): Children eat usual dietary and using 2 glasses (49,2 gr powdered milk x 180 ml boil water/time x 2 times/day) of the Oral Nutritional Supplementation as the side meals. The product provides GOS, Calcium, Probiotics, HMO, DHA, and Taurine within 3 months of use.~The product will be provided for subjects at school in 5 days per week (From Monday to Friday) and at home on weekend."
89569608|NCT02630251|Experimental|GSK2820151 arm|An accelerated dose escalation phase will be utilized in order to minimize sub-optimal drug exposures, followed by a conventional 3+3 dose escalation phase to achieve MTD. Initially, one subject per dose cohort will be recruited (accelerated dose escalation phase) until the first instance of a >=Grade 2 drug related toxicity or dose-limiting toxicity (DLT). Further cohorts will be recruited in blocks of three subjects (3+3 dose escalation phase). Projected dose levels are 3 mg, 6 mg, 12 mg, 20 mg, 40 mg, 60 mg, 100 mg, 150 mg, 200 mg, and 300 mg. Additional subjects may be enrolled at previously cleared dose levels in order to obtain further data for PK and/or PD analysis. Once MTD is determined, additional subjects (18 subjects total at MTD) may be enrolled to collect additional safety data.
89569609|NCT04321109|Experimental|Collagen cone|Collagen matrix
89569610|NCT04321109|Active Comparator|Allograft|mineralized corticocancellous allograft
89569611|NCT05551559|Experimental|Bariatric surgery|
89569612|NCT05541263|Experimental|MBSR group|The MBSR group participants will receive an Mindfulness Based Stress Reduction training programme over 2 months.
89569613|NCT05541263|No Intervention|Wait-list group|The wait-list control group participants will wait while the experimental group is participating in the Mindfulness Based Stress Reduction training. This group will follow the training at the end of the study (7 months after baseline), after all relevant measurements are concluded.
89569614|NCT04980937||Patients with perineal nerve damage after ski injury|Retrospectively aquired patients from insight in medical records. All patients with perineal nerve damage after ski injury in the time period of question were enrolled. Inclusion required operative management of the injury interns of microsurgical reconstruction of peroneal nerve.
89569615|NCT03063229|Active Comparator|Islet Transplant Patients|Patients with Type 1 Diabetes who are on the waiting list to undergo an islet transplant.
89569616|NCT03063229|Active Comparator|Insulin Pump Therapy Patients|Patients with Type 1 Diabetes waiting to start on an Insulin Pump.
89569617|NCT03063229|Other|Healthy Volunteers|Participants with no Diabetes.
89569618|NCT05541185|Experimental|Nigella sativa oil group|1 ml of nigella sativa oil was applied to both knee areas of the nigella sativa oil group by massaging for 2 minutes three times a day for 21 days.
89569619|NCT05541185|Experimental|Naproxen and lidocaine gel group|1 ml of naproxen and lidocaine gel was applied to both knee areas of the naproxen and lidocaine gel group by massaging for 2 minutes three times a day for 21 days.
89028663|NCT06154486||control group|patients without risk factors for gastroparesis, fasting for at least 8 hours, BMI less than 30 and who have never used semaglutide or another GLP-1 analogue
89028664|NCT06154473||Open heart surgery|Cohort of patient undergoing an open heart surgery. Open heart surgery is defined as a surgical procedure that involves making an incision in the chest to opening the chest wall to access and operate on the heart. The study will include patients who undergo valve repair, valve replacement, or coronary artery bypass grafting. In addition, combined surgery, define as valve surgery in combination with coronary artery bypass grafting, will also be included. Heart transplant will not be included.
89569620|NCT05541185|Placebo Comparator|Massage group|1 ml of vaseline was applied to both knee areas of the massage group by massaging for 2 minutes three times a day for 21 days.
89569621|NCT02518113|Experimental|LY3039478 + Dexamethasone (Adult)|"Part A: 50 mg LY3039478 administered orally three times per week (TIW) and 24 mg dexamethasone administered orally on days 1-5 every other week during 28 day cycles. Participants receiving benefit may continue until disease progression.~75 mg LY3039478 administered orally three times per week (TIW) and 24 mg dexamethasone administered orally on days 1-5 every other week during 28 day cycles. Participants receiving benefit may continue until disease progression.~100 mg LY3039478 administered orally three times per week (TIW) and 24 mg dexamethasone administered orally on days 1-5 every other week during 28 day cycles. Participants receiving benefit may continue until disease progression.~125 mg LY3039478 administered orally three times per week (TIW) and 24 mg dexamethasone administered orally on days 1-5 every other week during 28 day cycles. Participants receiving benefit may continue until disease progression."
89569622|NCT02518113|Experimental|LY3039478 + Dexamethasone (Pediatric)|"Part B: LY3039478 administered orally TIW at escalating doses and dexamethasone administered orally twice a day (BID) on days 1-5 every other week during 28 day cycles. Participants receiving benefit may continue until disease progression.~There were no participants enrolled to Part B of the study."
89569623|NCT02518113|Experimental|Phase 2: LY3039478 + Dexamethasone|"LY3039478 administered orally TIW and dexamethasone administered orally BID on days 1-5 every other week during 28 day cycles. Participants receiving benefit may continue until disease progression.~There were no participants enrolled to Phase 2 of the study."
89569624|NCT02518113|Placebo Comparator|Phase 2: Placebo + Dexamethasone|"Placebo administered orally TIW and dexamethasone administered orally BID on days 1-5 every other week during 28 day cycles. Participants receiving benefit may continue until disease progression.~There were no participants enrolled to Phase 2 of the study."
89569625|NCT05541107|Experimental|MAT2203 Induction / MAT2203 Consolidation|2 days IV Amphotericin B (AMB) + flucytosine (5FC) followed by oral MAT2203 + 5FC for 12 days of induction therapy followed by MAT2203 +fluconazole for 4 weeks of consolidation therapy
89569626|NCT05541107|Experimental|MAT2203 Induction / SOC Consolidation|2 days IV AMB + 5FC followed by oral MAT2203 + 5FC for 12 days of induction therapy followed by 4 weeks of standard of care consolidation therapy
89569627|NCT05541107|Active Comparator|SOC Induction / SOC Consolidation|Standard of care induction therapy (IV AMB + 5FC) followed by 4 weeks of standard of care consolidation therapy (fluconazole)
89569628|NCT03062839|Experimental|Melatonin|Melatonin 5 mg taken 30 minutes before bed time
89569629|NCT03062839|Placebo Comparator|Placebo|Placebo identical to melatonin capsule taken 30 min before bed time
89569630|NCT05540951|Experimental|VIC|VIC Regimen (Vemurafenib/Irinotecan/Cetuximab)
89569631|NCT05540951|Active Comparator|BEV|Bevacizumab Plus Chemotherapy
89569632|NCT03062293|Experimental|Functional Re-adaptive Exercise Device|Single arm for within subject repeated measures design.
89532182|NCT06337357|No Intervention|Control group|"The control group receives the baseline treatment for diabetes and sarcopenia:~- Recommendations according to American Diabetes Association guidelines which include instructions to follow the diet and exercises as recommended for older type 2 diabetic patients and baseline treatment for sarcopenia (education about sarcopenia and treatment measures such as diet and exercise) and provide basic information on resistance training."
89532183|NCT06337344|Experimental|Baduanjin Qigong(BDJ)|
89532184|NCT06337344|Active Comparator|Aerobic exercise|
89532185|NCT06337344|Sham Comparator|Video viewing|
89532186|NCT06337331|Experimental|High-dose Chemotherapy + Mismatched Allogeneic Stem Cell Transplant|
89532187|NCT06337318|Experimental|Arm I (Rituximab, rituximab and hyaluronidase)|Patients receive rituximab IV on day 1 of cycle 1 and receive rituximab and hyaluronidase SC on days 8, 15 and 22 of cycle 1 and SC on day 1 of subsequent cycles. Cycles repeat every 56 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan and/or PET/CT and blood sample collection on study and during follow up.
89532188|NCT06337318|Experimental|Arm II (Mosunetuzumab)|Patients receive mosunetuzumab SC on days 1, 8 and 15 of cycle 1 and on day 1 of subsequent cycles. Cycles repeat every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan and/or PET/CT and blood sample collection on study and during follow up.
89532189|NCT06337305||Bladder cancer patients undergoing radical cystectomy.|This is a prospective cross-sectional survey of bladder cancer patients undergoing radical cystectomy.
89532190|NCT06337292|No Intervention|Standard of Care Wound Care|Patients randomized to the control group will receive standard wound care.
89532191|NCT06337292|Experimental|Incisional Negative Pressure Wound Therapy (NPWT)|Patients randomized to the treatment group will receive wound care which includes the application of an incisional negative pressure wound vacuum.
89532192|NCT06337266||Observational|Cohort
89532193|NCT06337253|Experimental|Intervention|"The intervention in this study is the administration of one cycle of SPAQ medicines. SPAQ medicines procured by Malaria Consortium are from Tridem Pharma, one of the three manufacturers with WHO prequalification, with whom Malaria Consortium has framework agreements.~Each monthly SMC cycle consists of one dispersible tablet of SP and three daily dispersible tablets of AQ. There are two doses of SPAQ: a lower dose for children aged 3-12 months, and a higher dose for children aged 12 to 59 months. For children aged 12 to 59 months, the dosage comprises a single dose of a full tablet of SP 500/25mg and three daily doses of a full tablet of AQ 153mg. Those aged 3-12 months are administered half the dose given to those aged 12 to 59 months, given as full dispersible tablets."
89532194|NCT06337240||Pelvic floor exercises on COPD patients|30 COPD female patients with urinary incontinence will receive pelvic floor exercises.
89532195|NCT06337227||atherosclerosis and calcific aortic stenosis with diabetes patients|
89532196|NCT06337227||atherosclerosis and calcific aortic stenosis without diabetes patients|
89532197|NCT06337227||Patients without atherosclerosis undergoing surgical procedure for endocarditis|
89532198|NCT06337214|Experimental|Traditional Chinese Medicine Therapy Program for Reinforcing Vital Energy|"This study aims to evaluate whether the participation in Traditional Chinese Medicine (TCM) supportive therapy courses, specifically the Traditional Chinese Medicine Therapy Program for Reinforcing Vital Energy , can enhance the quality of life of breast cancer patients undergoing treatment, increase their understanding and satisfaction with TCM adjunctive treatments, and bolster their confidence in cancer recovery. Evaluations will be conducted using pre- and post-tests spaced 4 to 6 weeks apart, during which participants will be administered three questionnaires."
89532199|NCT06337201||Healthcare professionals working in daycare center and residential care.|
89532200|NCT06337188|Experimental|Experimental and Generic Communication Interfaces for AAC|Each participant receives both Experimental and Generic AAC systems to communicate - in that order.
89532201|NCT06337175|Active Comparator|Hemorragic transformation group|One hundred fifty-two acute ischemic stroke (AIS) patients who had hemorrhagic transformation of brain infarction after 24-36 hours of receiving alteplase.
89532202|NCT06337175|Active Comparator|non-hemorragic transformation group|Four hundred sixty-four acute ischemic stroke (AIS) patients did not have a hemorrhagic transformation of brain infarction after 24-36 hours of receiving alteplase.
89532203|NCT06337162|Experimental|INCB099280|Study participants will receive the recommended phase II dose (400mg/kg) of INCB099280 orally on days 1 through 28 of each 28-day cycle until liver transplant.
89532204|NCT06337123||Physica Porous KR femoral component|"Devices: Physica TT Tibial Plate and Physica Porous KR femoral component~Total knee arthroplasty with Physica TT Tibial Plate and Physica Porous KR femoral component"
89532205|NCT06337123||Physica Porous PS femoral component|"Devices: Physica TT Tibial Plate and Physica Porous PS femoral component~Total knee arthroplasty with Physica TT Tibial Plate and physica Porous PS femoral component"
89532206|NCT06337110|Experimental|Lu AF28996|Participants will receive a single oral dose of Lu AF28996.
89532207|NCT06337097|Experimental|Troponin Surveillance|Participants in Group 1, will have blood tests performed every 2 weeks for 12 weeks.
89532208|NCT06337097|Experimental|Standard of Care|Participants in Group 2, will have standard of care testing for any heart-related side effects of immune checkpoint inhibitors.
89532209|NCT06337084|Experimental|MNPR-101-DFO*-89Zr|Participants receive a single injection of MNPR-101-DFO*-89Zr on Day 1 with injected activity between 37-74 MBq (±10%).
89532210|NCT06337071|Experimental|Experimental Group 2~15 years|2~15 years old participants who vaccinated by experimental vaccine
89532211|NCT06337071|Active Comparator|Control Group 2~15 years|2~15 years old participants who vaccinated by control vaccine 2
89532212|NCT06337071|Experimental|Experimental Group 6~23 months(0,1)|6~23 months old participants who vaccinated by experimental vaccine at month 0 and 1
89532213|NCT06337071|Active Comparator|Control Group 6~23 months(0,1)|6~23 months old participants who vaccinated by control vaccine 1 at month 0 and 1
89532214|NCT06337071|Experimental|Experimental Group 6~23 months(0,3)|6~23 months old participants who vaccinated by experimental vaccine at month 0 and 3
89532215|NCT06337071|Active Comparator|Control Group 6~23 months(0,3)|6~23 months old participants who vaccinated by control vaccine 1 at month 0 and 3
89532216|NCT06337071|Experimental|Experimental Group 3~5 months|3~5 months old participants who vaccinated by experimental vaccine at month 0, 1, 2 for primary vaccination, and vaccinated by experimental vaccine at 12-month old for booster vaccination
89532217|NCT06337071|Active Comparator|Control Group 3~5 months|3~5 months old participants who vaccinated by control vaccine 1 at month 0, 1, 2 for primary vaccination, and vaccinated by control vaccine at 12-month old for booster vaccination
89532218|NCT06337058|Experimental|experimental group|intervention group
89532219|NCT06337058|No Intervention|control group|control group
89532220|NCT06337045|Experimental|Complex prevention and rehabilitation intervention (single arm)|It was a single-arm study.
89532221|NCT06337032|Experimental|Rollover from Parent Study: GS-US-311-1269: Parent Study Drug (F/TAF) or B/F/TAF|"Participants will continue to take the study drug they were taking in the parent study, emtricitabine/tenofovir alafenamide (F/TAF) along with a 3rd antiretroviral (ARV) agent. The dose of F/TAF will be based on the weight of the participant, ranging between 120/15 mg to 200/25 mg. The dose of F/TAF will be different when given with the boosted and the unboosted 3rd ARV agent: F/TAF (High Dose Tablet) for unboosted 3rd ARV agent; F/TAF (Low Dose Tablet) for the boosted 3rd ARV agent.~Participants may switch to B/F/TAF, at a dose based on participant's weight."
89532222|NCT06337032|Experimental|Rollover from Parent Study: GS-US-292-0106: Parent Study Drug (E/C/F/TAF) or B/F/TAF|"Participants will continue to take the study drug they were taking in the parent study, elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF). The dose of E/C/F/TAF will be based on the weight of the participant, ranging between 90/90/120/6 mg to 150/150/200/10 mg.~Participants may switch to B/F/TAF at a dose based on participant's weight."
89532223|NCT06337032|Experimental|Rollover Parent Study GS-US-216-0128: Parent Study Drug (Combination Drugs) or B/F/TAF|"Participants will continue to take the following study drugs they were taking in the parent study:~Cobicistat (COBI) + DRV + NRTI backbone~COBI + ATV + NRTI backbone~F/TAF + DRV+ COBI~F/TAF + ATV+ COBI~F/TAF + LPV/r~F/TAF + 3rd unboosted agent~The dose of F/TAF will be based on the weight of the participant, ranging between 15/1.88 mg and 200/25 mg, once daily. Additionally, the dose of COBI will be based on the weight of the participant, ranging between 30 mg and 150 mg, once or twice daily.~Participants may switch to B/F/TAF at a dose based on participant's weight."
89532224|NCT06337032|Experimental|Rollover from Parent Studies: GS-US-380-1474 and CO-US-380-5578: Parent Study Drug (B/F/TAF)|Participants will continue to take the study drug they were taking in the parent study, B/F/TAF. Participants who are diagnosed with HIV-1 infection in parent study CO-US-380-5578 and complete the study drug will continue to take the study drug they were taking in the parent study, B/F/TAF. The dose of B/F/TAF will be based on the weight of the participant.
89532225|NCT06337019||Cohort observational|Overall study cohort
89532226|NCT06337006||Group S|The LMA was successfully placed after the first attempt.
89532227|NCT06337006||Group non-S|The LMA was not placed successfully after the first attempt.
89532228|NCT06336993|Experimental|herbal compound|
89532229|NCT06336993|Active Comparator|celecoxib|
89532230|NCT06336980|Experimental|Behavior intervention to increase inclusionary practices|Each congregation will participate in the intervention for 11-12 months
89532231|NCT06336967|Experimental|GUIDE with incentives|Immediate access to the GUIDE App smartphone application for 4 weeks with the opportunity to earn additional compensation, up to $100 in total, based on app engagement.
89532232|NCT06336967|Experimental|GUIDE without incentives|Immediate access to the GUIDE App for 4 weeks without the opportunity to earn additional compensation.
89532233|NCT06336967|No Intervention|Waitlist|Waitlisted with delayed access to the GUIDE App without the opportunity to earn additional compensation.
89532234|NCT06336954|Experimental|experimental group|Adibelimab (1200mg, IV, every 3 weeks) combined with Famitinib (20mg, daily, orally) and Albumin-bound Paclitaxel (260mg/m2, Day 1, every 3 weeks).
89532235|NCT06336941|Experimental|Ultrasound group|The patients with a clinical diagnosis of oral squamous cell carcinoma will undergo intraoral ultrasonographic scan with a 70 MHz frequency probe to evaluate tumor depth of invasion and thickness
89532236|NCT06336928||Observational|Patients undergo blood sample collection and have their medical records reviewed on study.
89532237|NCT06336902|Experimental|Treatment (botensilimab, balstilimab, FMD, vitamin C)|Patients receive botensilimab IV over 30 minutes on day 1 of each cycle for up to 4 cycles. Patients receive balstilimab IV over 30 minutes and vitamin C IV over 30 minutes on days 1, 15 and 29 of each cycle. Patients undergo a FMD on days -4 to -1 of each cycle. Cycles repeat every 42 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection, CT scans and MRI throughout the study.
89532238|NCT06336876|Experimental|Survey Participant|The sample will be a convenience sample of hospital-registered nurses and para-professional nursing services staff (e.g., patient care technicians and specialty area technicians) who agree to participate in an online survey launched via the Survey Monkey® portal.
89532239|NCT06336863|Experimental|Immunosuppression Taper|Patients included in this arm are kidney transplant recipients with stable kidney function currently on a Belatacept based immunosuppression regimen. Eligible patients who are deemed immune quiescent will undergo sequential withdrawal of immunosuppression medications over a 12-month period from a multi-drug regimen to a Belatacept only immunosuppression regimen. During this period, patients will be monitored with monthly clinic visits and blood draws, which is inclusive of routine monitoring with dd-cfDNA testing (AlloSure) and gene expression profiling (TruGraf).
89532240|NCT06336863|Other|Multi-Drug Regimen|Patients included in this arm are kidney transplant recipients on a Belatacept based regimen who are not deemed immune quiescent. These patients will continue on a multi-drug regimen and will be monitored with monthly clinic visits and blood draws, which is inclusive of routine monitoring with dd-cfDNA testing (AlloSure) and gene expression profiling (TruGraf).
89532241|NCT06336850|Experimental|Treatment|Patients undergoing Endoscopic-Ultrasound Guided liver biopsies and Endoscopic Ultrasound-Guided Portal Pressure Gradient Measurements
89532242|NCT06336837||No arm used.|
89532243|NCT06336824|Experimental|Group 1|Intervention arm (Early Oral Switch therapy)
89532244|NCT06336824|Active Comparator|Group 2|Comparator arm (Standard IV therapy)
89569633|NCT05540639|Experimental|Intervention with modified Mindfetalness|The pregnant woman will be informed about the possibility of practicing Mindfetalness verbally, by a video, in a leaflet and at a website. The practice is described as spending 15 minutes every day from gestational week 28+0 to get to know the fetal movement pattern. The fetus must be awake when practicing Mindfetalness and the woman is suggested to lay on her left side when she observes fetal movements. In the leaflet the woman can write down something about the nature, frequency or strength of the fetal movements. If the woman experiences decreased frequency of fetal movements or weaker movements she is instructed to seek healthcare without unnecessary delay.
89569634|NCT05540639|No Intervention|Routine care|Historical comparison of the maternal clinics before the intervention. No activities have been taken place.
89569635|NCT04981093|Experimental|Group Dexamethasone|"Group dexamethasone patients received intravenous injection after anesthesia induction~Injection 0.15mg/kg dexamethasone (2ml）"
89569636|NCT04981093|Placebo Comparator|Group Saline|Group Control patients were also given 2ml of normal saline intravenously after induction of anesthesia
89569637|NCT05699681||Study cohort|Children aged below 12 years undergoing elective cardiac surgery for congenital heart disease with left to right shunt with prior evidence of pulmonary arterial hypertension on preoperative echocardiography
89569638|NCT05004831|Experimental|fruquintinib plus TAS-102|fruquintinib plus TAS-102, orally given, Q4W
89569639|NCT05546489|Experimental|Lymfit intervention|Participants will receive a Fitbit wearable tracker, expert guidance, and a personalized exercise prescription to optimize physical activities among lymphoma survivors. The intervention is 12 weeks long, participants are meeting with a kinesiologist every 2 weeks.
89569640|NCT04981015||Women with lower urinary tract symptoms|Women with lower urinary tract symptoms without cystocele were included.
89569641|NCT05551247|Experimental|Envafolimab plus recombinant human endostatin (endostatin)|Envafolimab:300mg,sc,d3,Q3W; endostatin:210mg,civ,d1-3,Q3W.
89569642|NCT05540561||Subjects consuming nitrous oxide with clinical outcomes|Subjects who consume nitrous oxide and who have been hospitalized in this context and who present clinical signs determined during a neurological evaluation according to the PND (Peripheral Neuropathy Disability) score or who have had a thrombotic accident related to the consumption of nitrous oxide.
89569643|NCT05540561||Subjects consuming nitrous oxide without clinical outcomes|Subjects who consume nitrous oxide who do not present clinical signs related to this consumption and recruited during a routine medical consultation.
89569644|NCT05540483|Experimental|Experimental arm|Disitamab Vedotin combined with Zimberelizumab
89569645|NCT05002257|Experimental|Experimental Arm|
89028665|NCT06154473||Percutaneous cardiovascular surgery|Cohort of patient undergoing a percutaneous cardiovascular surgery. Percutaneous cardiovascular surgery is defined as a surgical procedure that involves making an incision in the skin to use a catheter-based approach to access and operate on the heart. The study will include patients who undergo transcatheter aortic valve implantation, valve in valve transcatheter aortic valve implantation and transcatheter mitral-valve repair or replacement.
89028666|NCT06154460||Laterjet Surgery Group|This group will consist of individuals who underwent laterjet surgery.
89028667|NCT06154460||Reimplissage Surgery Group|This group will consist of individuals who underwent reimplissage surgery.
89028668|NCT06154460||Capsular Reconstruction Surgery Group|This group will consist of individuals who underwent capsular reconstruction surgery.
89028669|NCT06154395|Experimental|OCT-guided group|
89028670|NCT06154395|Experimental|60 MHz HD-IVUS-guided group|
89028671|NCT06154395|Active Comparator|Angiography-guided group|
89028672|NCT06154369|Experimental|JoyPop|Participants will receive access to the Joypop app for 8 weeks.
89569646|NCT05002257|Active Comparator|Control arm|
89569647|NCT05546255|Experimental|Eribulin Combined With Lobaplatin|Eribulin 1.4mg/m2 d1 Lobaplatin 25g/m2 d1 / q14d
89028673|NCT06154369|No Intervention|No Intervention|No intervention will be offered. After 8 weeks in the control condition, participants will be offered access to the JoyPop app.
89028674|NCT06154343|Experimental|Dose Escalation|"GQ1005 will be administered intravenously every 21 days. Dose Escalation will be guided by Bayesian Optimal Interval (BOIN) Design.~Multiple dose grouping"
89028675|NCT06154343|Experimental|Dose Expansion|GQ1005 at the recommended phase II dose (RP2D) will be administered intravenously every 21 days. Dose expansion will further evaluate the MTD or RP2D in different types of malignant solid tumor in four cohorts.
89028676|NCT06154304|Placebo Comparator|Placebo Product|One actuation each from four different placebo inhalation aerosols.
89028677|NCT06154304|Experimental|Test Product|One actuation from the test inhalation aerosol and one actuation each from three different placebo inhalation aerosols
89028678|NCT06154304|Active Comparator|Reference 90mcg Product|One actuation from the reference inhalation aerosol and one actuation each from three different placebo inhalation aerosols.
89028679|NCT06154304|Active Comparator|Reference 180mcg Product|One actuation each from two different reference inhalation aerosols and one actuation each from two different placebo inhalation aerosols
89028680|NCT06154200|Placebo Comparator|Vehicle Gel|Vehicle gel applied to eyelids twice per day
89028681|NCT06154200|Active Comparator|Testosterone gel 4.5%|Testosterone gel 4.5% applied to eyelids twice per day
89028682|NCT06154187|Experimental|test 1|PBK_L2201
89028683|NCT06154187|Placebo Comparator|placebo|placebo
89028684|NCT06149299|Placebo Comparator|interfascial plane group|injection into inferfascial plane
89028685|NCT06149299|Experimental|intramuscular group|injection into obliqus capitis inferior muscle
89028686|NCT06149234|No Intervention|Control Group|Normal panoramic positioning
89028687|NCT06149234|Experimental|Fruit leather on the tongue|The patient holding a stripe of fruit leather on the tongue while acquiring a panoramic image
89028688|NCT06149234|Experimental|Chewing gum strip|The patient holding a stripe of chewing gum on the tongue while acquiring a panoramic image
89028689|NCT06149234|Experimental|Celluloid matrix group|The patient holding a stripe of celluloid matrix group on the tongue while acquiring a panoramic image
89028690|NCT06149182|Experimental|Life stress interview/therapeutic interview|"Revised Life stress interview according to protocol from emotional awareness and expression therapy"
89569648|NCT05546177|Experimental|instrumented assisted soft tissue mobilization|the patients will receive instrumented assisted soft tissue mobilization three times a week for eight weeks
89569649|NCT05546177|Active Comparator|traditional therapy|the patients will receive traditional therapy three times a week for eight weeks
89569650|NCT05551091|Experimental|GMP 25 mg BID|Investigators will conduct a pilot cross-over study in which 13 obese participants undergo measures of study outcomes: satiety hormones, glucose, amino acid and cytokine levels and changes in the fecal microbiota at baseline and after 7 days of consuming the supplement. On day one participants will consume a liquid soy breakfast, undergo study measures and then initiate GMP supplements twice a day (BID) x 7 days, with repeat study measures on day 7 of consuming the GMP supplement.
89569651|NCT05551091|Experimental|GMP 25 mg TID|After a washout period, the same 13 participants will undergo repeated measures of study outcomes (satiety hormones, glucose, amino acid and cytokine levels and changes in the fecal microbiota). On day one subjects will consume a liquid soy breakfast, undergo study measures and then initiate GMP supplements thrice a day (TID) x 7 days, with repeat study measures on day 7 of consuming the GMP supplement.
89569652|NCT02629861|Placebo Comparator|Placebo|Matching Placebo
89569653|NCT02629861|Experimental|Fremanezumab 675 mg/placebo/placebo|Participants randomized to receive fremanezumab 675 mg/placebo/placebo received 675 mg of fremanezumab as 3 injections (225 mg/1.5 mL) on Day 0, and placebo as a single 1.5-mL injection on Days 28 and 56.
89569654|NCT02629861|Experimental|Fremanezumab 225/225/225 mg|Participants randomized to receive fremanezumab 225/225/225 mg received 1 active injection (225 mg/1.5 mL) on Days 0, 28 and 56.
89569655|NCT05540249|Experimental|Group CHO|Patients in Group CHO will orally consume CHO 355ml containing 50 g of carbohydrates 8-12 hours before operation (20:00 -24:00 the evening before operation).
89569656|NCT05540249|No Intervention|Group CTRL|Patients in Group CTRL will consume no food or drink 12 hours before operation (20:00 the evening before operation).
89569657|NCT05461287|Experimental|QLS31904|Qls31904 is a bi-specific recombinant protein construct containing 2 humanized antibody derived binding domains.
89569658|NCT05546021|Active Comparator|NOL monitor|Patients will receive opioids as per the guidance of a nociception level monitor (NOL)
89569659|NCT05546021|No Intervention|Standard care|Patients will be treated as per the department´s standard protocol.
89569660|NCT04958733|Active Comparator|Autologous Bone Grafting|Excess bone obtained from graft preparation and the coring reamer will be used to fill the patellar and tibial donor sites.
89569661|NCT04958733|Placebo Comparator|Control|The control group will have their patellar and tibial defects remain unfilled.
89569662|NCT05540015|Active Comparator|Group with impacted third molar, extracted by cutting and rotary tools|The study group will include 28 patients with indications (impacted third molars that exerts pressure on the adjacent tooth and cause inflammation process in the surrounding tissue; absence of antagonist; pericorinitis; periodontitis; periodontal pockets) for the impacted third molar extraction. Patients will be comparable by gender and age, the patients age will be between 18 and 70 years. Patients should be with therapeutic and surgical oral hygiene and without co-morbidities.
89028691|NCT06149182|Active Comparator|Psychiatric interview|"Psychiatric interview (M.I.N.I. etc) according to Region stockholm - basutredning"
89028692|NCT06148636|Experimental|-1 Dose Level|"This dose level is used if the starting dose level is deemed to have unacceptable toxicity.~Participants are prescribed [212Pb] VMT-α-NET with the total radiation dose to kidneys not to exceed 200 cGy."
89028693|NCT06148636|Experimental|Cohort 1|This is the starting dose level for participants. Participants are prescribed [212Pb] VMT-α-NET with the total radiation dose to kidneys not to exceed 350 cGy.
89028694|NCT06148636|Experimental|Cohort 2|If the participants from Cohort 1 tolerate therapy, new participants are enrolled and are prescribed [212Pb] VMT-α-NET with the total radiation dose to kidneys not to exceed 600 cGy.
89028695|NCT06148636|Experimental|Cohort 3|If the participants from Cohort 2 tolerate therapy, new participants are enrolled and are prescribed [212Pb] VMT-α-NET with the total radiation dose to kidneys not to exceed 810 cGy.
89028696|NCT06148636|Experimental|Cohort 4|If the participants from Cohort 3 tolerate therapy, new participants are enrolled and are prescribed [212Pb] VMT-α-NET with the total radiation dose to kidneys not to exceed 1050 cGy.
89028697|NCT06145360|Experimental|Empagliflozin 10mg|Group A: Empagliflozin 10 mg once daily with antidiabetic drugs
89028698|NCT06145360|Active Comparator|regimen of Insulin+Metformin+DPP4 inhibitor (DPP4I)|Group B: usual care group [Insulin+Metformin+DPP4 inhibitor (DPP4I)] but without Empagliflozin with adjustment of therapy as the standard of care.
89028699|NCT06143644||Cohort|Patients with stage I to IV colorectal cancer
89028700|NCT06126419|Experimental|Group 1: Effect of high-dose insulin therapy on pre-operative liver function|Group 1 will consist of participants scheduled for liver resection and will undergo high-dose insulin pre-operatively to determine if baseline liver function can be optimized/improved, as measured by 99mTc-Mebrofenin HBS.
89569663|NCT05540015|Active Comparator|Group with impacted third molar, extracted by erbium laser 2.94 nm|The study group will include 28 patients with indications (impacted third molars that exerts pressure on the adjacent tooth and cause inflammation process in the surrounding tissue; absence of antagonist; pericorinitis; periodontitis; periodontal pockets) for the impacted third molar extraction.Patients will be comparable by gender and age, the patients age will be between 18 and 70 years. Patients should be with therapeutic and surgical oral hygiene and without co-morbidities.
88811055|NCT04607850|Experimental|Group 4 ChAdOx1-HPV mid dose and MVA-HPV high dose|Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10^9 vp) and MVA-HPV (1 x 10^8 pfu)
88811056|NCT04607850|Experimental|Group 5 ChAdOx1-HPV high dose and MVA-HPV high dose|Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10^10 vp) and MVA-HPV (1 x 10^8 pfu)
89028701|NCT06126419|Experimental|Group 2: Effect of high-dose insulin therapy on pre-operative liver function after LVD|Group 2 will consist of participants scheduled for liver resection that require LVD. The participants in the experimental arm will receive high-dose insulin therapy after LVD.
89569664|NCT05545709||remote group|Based on the 5G network, the orthopedic robotic remote surgery platform is built at Beijing Jishuitan Hospital, providing primary hospitals with a platform for preoperative consultation, intraoperative communication and surgical robot teleoperation, and postoperative follow-up. With the support of the 5G network, equipment and surgical robots are integrated into the remote surgery service platform, building a high-speed transmission channel between Beijing Jishuitan Hospital and other hospitals.
89569665|NCT05545709||local group|Local orthopedic robot-assisted spine surgeries were performed according to the guidelines for thoracolumbar pedicle screw placement assisted by orthopedic surgical robots.
89569666|NCT05545631||Conception positive|serum human chorionic gonadotropin ≥10 mIU/mL
89569667|NCT05545631||Conception negative|serum human chorionic gonadotropin <10 mIU/mL
89569668|NCT02482935|Experimental|Abemaciclib High Fat Meal|Abemaciclib capsules administered once orally in the fed state.
89569669|NCT02482935|Experimental|Abemaciclib Fasted|Abemaciclib capsules administered once orally in the fasted state.
89569670|NCT02513823|Experimental|Intervention|2,000 IU of vitamin D given to African American women for 10 weeks
89569671|NCT04980859|Experimental|Zebutinib Combined With CIT arm|Zebutinib Combined With FCR( under 60 years of age) or BR (over 60 years of age )
89569672|NCT04432519|Experimental|Group CA|Customized healing abutment inserted in immediate implant placement.
89569673|NCT04432519|Active Comparator|Group CM|Resorbable Collagen Membrane for socket closure in immediate implant placement.
89569674|NCT05545475||Anticoagulation group|1 mg/kg of nadroparin calcium or enoxaparin every 12 h, 5000 IU of low molecular weight heparin (LMWH) every 12 h, 20 mg of rivaroxaban once daily, or warfarin adjusted by an increase or decrease of 0.75 mg until the target international normalized ratio (INR) of 2-3 was reached.
89569675|NCT05545475||Control group|No anticoagulation group.
89569676|NCT05539703|Experimental|Intervention groups: Invitation to get 2nd booster|Participants in the intervention group will receive an invitation to get a 2nd COVID-19 booster dose. Those who accept the invitation to be vaccinated will receive the vaccine through their municipality's vaccination service.
89569677|NCT05539703|No Intervention|Control group: No invitation to get 2nd booster|The control group will receive no intervention.
89569678|NCT02513745|Active Comparator|Conventional|Surgeon's standard of care prior to getting VERION. Spherical power will be selected using the surgeon's preferred formula (Haigis, Holladay 2, Holladay, or other) and biometry method (IOL Master, Lenstar). Astigmatism correction will be planned using the surgeon's preferred keratometry method and calculator/nomogram to determine toric power and corneal incisions (i.e. Alcon toric calculator, Holladay toric calculator, Abbott Medical Optics (AMO) LRI calculator, etc). At time of surgery, axis of placement will be marked using blue ink marks. Corneal incisions will be made manually.
89569679|NCT02513745|Active Comparator|Refractive Cataract Suite (Verion + ORA)|Digital Surgical Planning and Positioning Tools + ORA System with VerifEye or VerifEye +. Spherical power of the IOL will be selected using the Verion Planner with the surgeon's preferred formula with an optimized A-constant (Haigis, Holladay 2, Holladay, or other). Both toric lenses and corneal incisions will be calculated with the Verion Planner using the Verion Reference Unit keratometry and white to white measurements, and Lenstar biometry. The VERION Digital Markers L and M will be used for axis of placement and confirmed using ORA System with VerifEye or VerifEye +.
89569680|NCT05545397||The propofol group|Patients undergoing painless gastroenteroscopy under general anesthesia
89569681|NCT04952727|Experimental|heterologous boost arm with Ad5 vectored vaccine|Subjects who have been primed with two doses of inactive SARS-CoV-2 vaccine will receive a booster of recombinant SARS-CoV-2 Ad5 vectored vaccine after 3~6 months.
89569682|NCT04952727|Active Comparator|homogeneous boost arm with inactive vaccine|Subjects who have been primed with two doses of inactive SARS-CoV-2 vaccine will receive a booster dose of inactive SARS-CoV-2 vaccine after 3~6 months.
89569683|NCT04952727|Experimental|heterologous regimen with Ad5 vectored vaccine|Subjects who have been primed with one dose of inactive SARS-CoV-2 vaccine will receive one dose of recombinant SARS-CoV-2 Ad5 vectored vaccine after 1~3 months
89569684|NCT04952727|Active Comparator|homogeneous regimen arm with inactive vaccine|Subjects who have been primed with one dose of inactive SARS-CoV-2 vaccine will receive one dose of inactive SARS-CoV-2 vaccine after 1~3 months.
88811057|NCT04607850|Placebo Comparator|Group 6 Placebo Saline|Sodium Chloride (0.9%)
89569685|NCT05539625|Active Comparator|MitoQ|Once daily dosing of two capsules for 40mg/d (or one capsule for 20mg/d if weight <30kgs)
89569686|NCT05539625|Placebo Comparator|Placebo|Participants will take an oral matched placebo daily
89569687|NCT05539547|Sham Comparator|Control Group|Patients shall receive the usual physiotherapy care, including chest and mobility physiotherapy on quadriceps strength and endurance during hospital admission on patients with severe acute exacerbation COPD.
89569688|NCT05539547|Experimental|Experimental Group|Patients shall receive the investigated modality, NMES on quadriceps strength and endurance as an adjunct to usual physiotherapy care (chest physiotherapy and mobility) during hospital admission in patients with severe acute exacerbation COPD.
89569689|NCT05545241|Experimental|Neurofeedback and BART-EEG assessment|Healthy subjects realized 10 sessions of emotional neurofeedback. Before (Baseline, Day 0), and after (at the study completion (after 10 neurofeedback sessions, Week 5)) neurofeedback sessions, the BART, assessing risk-taking behavior, coupled with an EEG record is realized by the subjects.
89569690|NCT05545241|Sham Comparator|BART-EEG assessment without neurofeedback|At the same times (Baseline, Day 0), and at the study completion (after 10 neurofeedback sessions, Week 5), healthy subjects realized the BART, assessing risk-taking behavior, coupled with an EEG record.
89569691|NCT05539235|Experimental|2 week group|Drug injection adjustment interval is 2 weeks
89569692|NCT05539235|Experimental|4 week group|Drug injection adjustment interval is 4 weeks
89569693|NCT04940403|Active Comparator|Unimanual robot-assisted upper-limb rehabilitation|Participants randomized to this arm of the study will undergo 18 one-hour sessions of robot-assisted upper-limb rehabilitation. During the sessions, study participants will only train their hemiparetic arm (unimanual tasks only).
89028702|NCT06126419|No Intervention|Group 3: Effect of high-dose insulin therapy on pre-operative liver function after LVD|Group 3 will consist of participants scheduled for liver resection that require LVD. The participants in the no intervention arm will not undergo intervention with high-dose insulin therapy after LVD.
89028703|NCT06117761|Experimental|COMBAT-ICU|The COMBAT-ICU group will receive an intervention which will last for 8 weeks, with 3 sessions per week. A blended training platform with supervised in-person home visits and a real-time supervised online and unsupervised selfpractice approach will be used to deliver the intervention, with the platform gradually shifted from home visits to unsupervised self-practice according to participants' physical functioning level. Family caregivers will be involved in the intervention, so that they can facilitate home-based training. Each intervention session will last for 80 minutes and comprise 45 minutes of exercise training, a 5-minute break and 30 minutes of cognitive training. Moreover, all participants in the COMBAT-ICU group will be invited to complete a satisfaction survey and semi-structured qualitative interview, which will focus on exploring the acceptability and perceived effects from participants' perspective.
89028704|NCT06117761|Experimental|Exercise Group|The exercise group will receive an 8-week, home-based, exercise intervention which is the same as that of the exercise component of the COMBAT-ICU intervention, 3 sessions per week, and 45 minutes per session, but will not receive any structured cognitive training.
89028705|NCT06117761|Placebo Comparator|Attention Placebo Group|The attention placebo group will receive a telephone call every 2 weeks, with the conversation focused on information provision and brief counselling relating to their health conditions, in order to reduce the potential bias from greater attention for the COMBAT-ICU and exercise groups. They will also receive the routine care provided by the healthcare system, including medical follow-ups with the clinical team, without structured out-patient rehabilitation services.
89569694|NCT04940403|Experimental|Bimanual robot-assisted upper-limb rehabilitation|Participants randomized to this arm of the study will undergo 18 one-hour sessions of robot-assisted upper-limb rehabilitation. During the sessions, study participants will train their hemiparetic arm as well as interacting with the contralateral arm for bimanual tasks (unimanual + bimanual tasks).
89569695|NCT05545163|No Intervention|I-gel with standard insertion technique|in this arm, trainees performed the standard I-gel insertion technique
89569696|NCT05545163|Experimental|Modified jaw thrust I-gel insertion technique|in this arm, trainees performed modified jaw thrust insertion technique
89569697|NCT04433143|Experimental|oral medication|just oral minocycline hydrochloride capsules (100mg/ time, once per day),
89569698|NCT04433143|Experimental|Intense Pulsed Light single filter|Intense pulsed Acne filter
89569699|NCT04433143|Experimental|Intense Pulsed Light two filters|Intense pulsed light Acne filter and another filter (560nm, 590nm or 640nm filter)
89569700|NCT02477553|Experimental|Quantitative|"Subjects view:~A computer-based presentation regarding colorectal cancer (CRC) and screening for CRC with colonoscopy and stool testing. Includes excerpts from a video from the American Cancer Society.~Computer-based presentation providing quantitative information regarding (a) the lifetime average probability of getting and dying from CRC, (b) the reduction in morbidity and mortality provided by colonoscopy and stool tests, (c) the sensitivity of colonoscopy and stool tests for finding cancer, (d) the false negative values of colonoscopy and stool tests for finding cancer, (e) the risk of heavy bleeding or colon injury from colonoscopy, and (f) the chance of having a positive stool test."
89569701|NCT02477553|Active Comparator|Verbal|"Subjects view:~A computer-based presentation regarding colorectal cancer (CRC) and screening for CRC with colonoscopy and stool testing. Includes excerpts from a video from the American Cancer Society.~Computer-based presentation providing verbal information regarding (a) the lifetime average probability of getting and dying from CRC, (b) the reduction in morbidity and mortality provided by colonoscopy and stool tests, (c) the sensitivity of colonoscopy and stool tests for finding cancer, (d) the false negative values of colonoscopy and stool tests for finding cancer, (e) the risk of heavy bleeding or colon injury from colonoscopy, and (f) the chance of having a positive stool test."
89569702|NCT01665911|Other|Arm 1|non-fluoridated milk, 200 ml 1.5 mg sodium fluoride in 100 ml milk, 1.5 mg sodium fluoride in 200 ml milk, 3 mg sodium fluoride in 100 ml milk, 3 mg sodium fluoride in 200 ml milk
89569703|NCT01665911|Other|Arm 2|non-fluoridated milk, 200 ml 1.5 mg sodium fluoride in 100 ml milk, 1.5 mg sodium fluoride in 200 ml milk, 3 mg sodium fluoride in 100 ml milk, 3 mg sodium fluoride in 200 ml milk
89569704|NCT01665911|Other|Arm 3|non-fluoridated milk, 200 ml 1.5 mg sodium fluoride in 100 ml milk, 1.5 mg sodium fluoride in 200 ml milk, 3 mg sodium fluoride in 100 ml milk, 3 mg sodium fluoride in 200 ml milk
89569705|NCT01665911|Other|Arm 4|non-fluoridated milk, 200 ml 1.5 mg sodium fluoride in 100 ml milk, 1.5 mg sodium fluoride in 200 ml milk, 3 mg sodium fluoride in 100 ml milk, 3 mg sodium fluoride in 200 ml milk
89569706|NCT01665911|Active Comparator|Arm 5|non-fluoridated milk, 200 ml 1.5 mg sodium fluoride in 100 ml milk, 1.5 mg sodium fluoride in 200 ml milk, 3 mg sodium fluoride in 100 ml milk, 3 mg sodium fluoride in 200 ml milk
89028706|NCT06107335|Active Comparator|Fluid restriction using crystalloid|Fluid restriction will be achieved with the crystalloid lactated ringer's injection administered at at a keep-the-vein-open (KVO) rate of 75 milliliters per hour (mL/hr).
89569707|NCT03063073|Placebo Comparator|Group I (Bupivacaine group)|ultrasound guided modified Pec's block with 30 mL of 0.25% bupivacaine divided into 10 ml injected between the pectoralis muscles and 20 ml between the Pectoralis minor muscle and the serratus muscle
89569708|NCT03063073|Active Comparator|Dexmedetomidine Injection [Precedex]|ultrasound guided modified Pecs block with 30 mL of 0.25% bupivacaine plus Dexmedetomidine Injection [Precedex] (1 µg/kg) divided into 20 ml injected between the pectoralis muscles and 10 ml injected between the Pectoralis minor muscle and the serratus muscle.
89569709|NCT02452359|Experimental|Treatment Group|Group receiving treatment with Venus Versa IPL energy
89569710|NCT04620733|Experimental|Seladelpar 10 mg|
89569711|NCT04620733|Placebo Comparator|Placebo|
89569712|NCT04620733|Experimental|Seladelpar 5 mg|
89569713|NCT05538923||Patients with IBD|Patients with inflammatory bowel disease on remission period
89569714|NCT05538923||Control|Age- and gender- matched healthy population
89569715|NCT05544851|Experimental|Educated Reproductive Women|"Inclusion Criteria / Patient~Women of reproductive age (range 18-49 years) No history of STD, literate, Ability to understand and answer questions Those who have not received training on STDs before,~Exclusion Criteria from Research~Getting training on STDs before Absence from education for at least two sessions, Women with a history of STD (HIV, HPV, etc.) disease will be excluded from the study."
89569716|NCT05544851|Experimental|Non-Educated Reproductive Women|"Inclusion Criteria / Patient~Women of reproductive age (range 18-49 years) No history of STD, literate, Ability to understand and answer questions Those who have not received training on STDs before,~Exclusion Criteria from Research~Getting training on STDs before Absence from education for at least two sessions, Women with a history of STD (HIV, HPV, etc.) disease will be excluded from the study."
89569717|NCT05550155|Sham Comparator|sham rTMS|"The sham treatment, following the group assignment, will be maintained during the two successive phases of the evaluated protocol. One initial sham rTMS phase will consist of four sham stimulation sessions (20 Hz sham) within two consecutive days. One sham rTMS maintenance phase will consist of two sham stimulation sessions on one day every week for one month and then every two weeks for three months.~Clinical data will be assessed by an investigator blind to group assignment until the end of the study. Patients will also be blind to stimulation. A questionnaire will assess the investigator physician and patient beliefs about what group the patient was involved in (placebo group or active group) at the end of the treatment initial phase and at the end of the treatment maintenance phase"
89569718|NCT05550155|Experimental|active rTMS|The active treatment, following the group assignment, will be maintained during the two successive phases of the evaluated protocol. One initial active rTMS phase will consist of four stimulation sessions (20 Hz) within two consecutive days. One active rTMS maintenance phase will consist of two active stimulation sessions on one day every week for one month and then every two weeks for three months.
89569719|NCT04429009|Experimental|Active Study Group|"Participants in this group will be prescribed to use the ZEPHYRx RT device for incentive spectrometer once every hour during waking hours to perform a series of 10 deep breaths. The novel ZEPHYRx RT system consists three components:~The Spirobank Smart Spirometer, which is a non-significant risk, FDA-cleared diagnostic spirometer made by Medical International Research (MIR) that connects via bluetooth to an Android tablet.~A Samsung 10-inch tablet provided by Pad-in-Motion Inc. that will be connected to the hospital GuestWiFi network.~The ZEPHYRx Respiratory Therapy video game application installed on the tablet. This application consists of seven games that have been created to combine traditional IS techniques with playing a breath controlled video game. The application will record data while playing the video games including date/time of use, game played, inhalation duration, and inhalation volume."
88970157|NCT04743401|Experimental|Tele-exergame arm|COVID-19 patients or PUI (persons under investigation) or other inpatients admitted to the MEDVAMC (n=60), with an anticipated length of stay of at least 3 days will be recruited. Participants will be randomized (n=1:1) to either intervention (IG) or control (CG) groups. Both groups will receive standard of care. IG will additionally receive Tele-Exergame MP therapy. Tele-Exergame sessions will range from 3-10 minutes based on patient ability and completed twice daily. They will complete assessments at baseline and at one-month post-hospital discharge.
89569720|NCT04429009|Active Comparator|Control Group|Participants in this group will be prescribed to routine respiratory care, Routine respiratory care involves the use of a standard incentive spirometer that is not a digital device and does not include any built-in reminder. As per routine care, the nurse or respiratory therapist will remind the subjects to perform a series of at least 10 deep breaths every hour.
89569721|NCT02476617|Experimental|Ombitasvir/paritaprevir/ritonavir + dasabuvir + RBV|Ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily [QD]) + dasabuvir (250 mg twice daily [BID]) + weight based Ribavirin (RBV; dosed 1,000 or 1,200 mg daily divided BID)
89569722|NCT05550077||Optical Coherence Tomography (OCT)|OCT and other classical imaging evaluation such as Transcranial Color Doppler (TCCD) and High resolution-MRI will be performed. The tailored treatment (such as anti-thrombotic management, post-dilation, et al) will be considered when specific plaque characteristics (including but not limited to in situ thrombus formation, macrocacilfication, et al), were observed under OCT.
89569723|NCT05550077||Non-Optical Coherence Tomography (N-OCT)|Classical imaging evaluation such as TCCD and High resolution-MRI will be performed, followed by standard percutaneous transluminal angioplasty and stenting.
89569724|NCT05538845||Screw|Screw fixation
89569725|NCT05538845||Suture button|Suture button
88970158|NCT04743401|No Intervention|Convention care or control group|Standard of care only
88970159|NCT04739176|Experimental|One-on-one rehabilitation program|
88970160|NCT04727411|Experimental|Gel Stent implantation|XEN gel stent: a clear cornea incision in the inferotemporal quadrant was performed, injecting the XEN 45 device into the superonasal quadrant using an ab interno approach. Approximately 15 min before inserting the implant, 0.1 ml of a MMC solution (0.01%) was injected into the superior conjunctiva. Both stand-alone and combined phaco-glaucoma procedures were used.
88970161|NCT04727411|Experimental|Trabeculectomy|Trabeculectomy: the surgical technique is as follows: retro/peribulbar o subtenon's anesthesia, superior corneal traction suture, phacoemulsification through 2.2 with in-the-bag IOL implantation, a fornix-based conjunctival flap, sufficient but not excessive cauterization, application MMC 0,2 mg/ml for 2 minutes under the conjunctiva, then MMC was washed out with 100 ml of saline solution, then a scleral flap (4x3 mm in the trabeculectomy) is dissected. A sclerectomy with punch and peripheral iridectomy were performed, and suture nylon 10/00 sutures was used to place 3 or 4 stiches in the scleral flap
88970162|NCT04713098|Experimental|Peripheral Nerve Stimulation|ACTIVE percutaneous peripheral nerve stimulation with an ultrasound-guided percutaneous lead (SPR Therapeutics, Cleveland, Ohio) and wearable stimulator (SPR Therapeutics, Cleveland, Ohio) that generates electrical current
89569726|NCT05535725|Experimental|expose|A group of patients receiving 1g of powdered vancomycin in the operative wound before its closure, and another group not receiving it
89569727|NCT05535725|No Intervention|non expose|A group of patients not receiving 1g of powdered vancomycin in the operative wound before its closure
89569728|NCT05698355|Experimental|Telerehabilitation group|"Multimodal self-treatment-based telerehabilitation will be implemented with a video conference method. For telerehabilitation, at each session, manual therapy techniques, (i.e., stretching, myofascial release, and tissue desensitization), sex education, and pelvic floor muscle relaxation massages with a pelvic wand (i.e., relaxation, stretching) using small intra-vaginal wand were used. Women were also asked to perform home exercises resembling those performed under supervision five times per week as well as auto-insertion exercises with a pelvic wand in addition to desensitization techniques three times per week.~Sessions consist of 60 minutes. Telerehabilitation will take place 2 days a week for 12 weeks."
89569729|NCT05698355|No Intervention|Education group|60 minutes of video recording training will be given about pelvic pain relaxation exercises.
89569730|NCT05535647|Experimental|Regorafenib and HAIC|Regorafenib HAIC with FOLFOX
89569731|NCT05535647|Active Comparator|FOLFOX|FOLFOX
89569732|NCT03064321|Experimental|Insomnia Intervention|Insomnia intervention delivered via web using Cognitive Behavior Treatment
89569733|NCT03064321|Other|Information Control|General health information website
89569734|NCT05535569|Experimental|Experimental|
89569735|NCT04980079|Active Comparator|group A -undergo primary ureteroscopy URS|Thirty children with calicular anuria will undergo primary ureteroscopy URS
89569736|NCT04980079|Active Comparator|the group B(30 patients) will undergo deferred ureteroscopy URS|group B (30) patients will be admitted to do urinary drainage through the insertion of a double-J stent or percutaneous nephrostomy (PCN) at first , then a deferred ureteroscopy URS will be done
89569737|NCT05538455|Experimental|Experimental group, use of PC4L solutions|Participants who will use the PC4L solutions for the estabilished period of time, in the selected scenario (home, neurorehabilitation and daycare centers), and will receive recommendations in the PC4L app
89569738|NCT05538455|No Intervention|Control group, no use of PC4L solutions|Participants who will be monitored for the estabilished period of time, in the selected scenario (home, neurorehabilitation and daycare centers), and will only receive written recommendations
89569739|NCT04980313|Experimental|Xenogenic collagen matrix|Volumetrically stable xenogenic collagen matrix
89569740|NCT04980313|Active Comparator|Autogenous connective tissue graft|Autogenous connective tissue graft obtained from the tuberosity area
89569741|NCT05544539|Experimental|drug arm|In the study group the (0.5 ml) of Ozone oil (perio3®, Hoffmann, German) was placed inside the socket of the extracted tooth filling it completely following suturing of the flap
89569742|NCT05544539|Placebo Comparator|placebo arm|the ozone oil syringe was placed inside the patient mouth without applying the oil.
89569743|NCT04979689|Experimental|Intensive physical therapy|Intensive session
89569744|NCT04979689|Other|Non intensive physical therapy|Non intensive session
89569745|NCT05538377|Experimental|Focal Vibration|
89569746|NCT05538377|Active Comparator|Control Group|
89569747|NCT05544383|Experimental|Intervention group|Interdisciplinary Pain Education Program and conventional physical therapy treatment
89569748|NCT05544383|Active Comparator|Comparison group|Conventional physical therapy treatment
89569749|NCT04425551|Active Comparator|Treated|"The lower eyelid margin of the clinically worse eye was selected for treatment. A slit lamp based 532 nm optically pumped dual diode solid state SP-Mode (subthreshold) laser system was used. After cleaning eyelids with a cosmetic face wash, a drop of proparacaine hydrochloride 0.5% was then administered onto the conjunctival sac. No eye or cornea shield was used, since laser light was directly aimed at telangiectasias.~The treatment parameters were set with 50 μm spot size and 200 ms duration with 30% duty cycle. The power ranged from 1500 to 1700 mW with monospot micropulse model and a just visible destruction of the telangiectatic vessels served as the threshold burn.~After the procedure, the patient received corticosteroid ointment for 5 days on both eyes and was advised to continue applying her pre-treatment medication on both eyes."
89569750|NCT04425551|No Intervention|Untreated|The lateral eye was observed as control.
89569751|NCT03064165|Experimental|Obturator nerve block|Postoperative obturator nerve block with 15 mL bupivacain 5 mg/mL and epinephrine 5 µg/mL.
89569752|NCT03064165|Placebo Comparator|Sham block|Postoperative sham-block with normal saline.
89569753|NCT05544149|Experimental|TRT|Patients with es-SCLC after first line treatment with immune checkpoint inhibitors will be treated with thoracic radiotherapy.
89569754|NCT05535491|Experimental|GROUP 1|BREATHING EXERCISE GROUP
89569755|NCT05535491|No Intervention|GROUP 2|CONTROL GROUP
89569756|NCT05535413|Experimental|UDT1 combined with capecitabine|
89569757|NCT03813199|Experimental|ABX464 50mg + methotrexate|"Participants will receive one capsule of 50mg ABX464 plus one capsule of matching placebo once daily for 12 weeks~+ methotrexate"
89569758|NCT03813199|Experimental|ABX464 100mg + methotrexate|"Participants will receive two capsules of 50mg ABX464 once daily for 12 weeks~+ methotrexate"
89569759|NCT03813199|Placebo Comparator|Placebo + methotrexate|"Participants will receive two capsules of matching placebo once daily for 12 weeks~+ methotrexate"
89569760|NCT05537909|Experimental|Patients|adult patients with aseptic abscess syndrome
89569761|NCT05537909|Experimental|control|control An adult person living in the same environment as the case.
89569762|NCT03064009||Open Fractures|Patients with Open fractures between the distal radius and the distal tibia
89569763|NCT05699135||Canadian Patients with Advanced Urothelial Carcinoma|Patients with LA/mUC who following 4-6 cycles of platinum chemotherapy and have not progressed, received avelumab, recommended dose of 10mg/kg body weight intravenously administered over 60 minutes every 2 weeks
89569764|NCT03791593|Experimental|Experimental group|The patient will receive evolocumab 420 mg/month on top of guideline-driven medical treatment
89569765|NCT03791593|No Intervention|Control group|The patient will continue guideline-driven medical treatment
89569766|NCT04732715|Experimental|CaRE Course|Black American caregivers of PLWD will participate in the CaRE Course.
89569767|NCT03064243|Experimental|apatinib group|apatinib 500mg po qd
89569768|NCT05537831|Active Comparator|Study Intervention Group (Ultrasound)|The ultrasound probe will be used for real-time needle and hematoma localization using the linear probe. The hematoma block will then be performed with aseptic technique. The skin will be prepped with chlorhexidine. A 20-gauge needle will be inserted in-plane into the hematoma site. A small amount of blood will be aspirated to confirm placement and 5-10 mL of 1% lidocaine will be infiltrated.
89569769|NCT05537831|No Intervention|Study Control Group (Landmark)|The ultrasound probe will be in place on the patient's arm to maintain single blinding of the study. The ultrasound machine will not be used for needle and hematoma localization. The hematoma block will then be performed with aseptic technique. The skin will be prepped with chlorhexidine. A 20-gauge needle will be inserted in-plane into the hematoma site. A small amount of blood will be aspirated to confirm placement and 5-10 mL of 1% lidocaine will be infiltrated.
89569770|NCT05543993||COVID-19 booster in pregnancy|Pregnant singletons who have received COVID-19 booster in pregnancy
89569771|NCT05543993||COVID-19 booster in breastfeeding|Breastfeeding individuals who have received COVID-19 booster while breastfeeding
89569772|NCT05698043|Experimental|Sequence 1|"Period 1: D013, D326, D337- A single oral dose of 3 tablets under fasting condition~Period 2: CKD-386(5)- A single oral dose of 1 tablet under fasting condition~Period 3: D013, D326, D337- A single oral dose of 3tablets under fasting condition~Period 4: CKD-386(5)- A single oral dose of 1 tablet under fasting condition"
89569773|NCT05698043|Experimental|Sequence 2|"Period 1: CKD-386(5)- A single oral dose of 1 tablet under fasting condition~Period 2: D013, D326, D337- A single oral dose of 3 tablets under fasting condition~Period 3: CKD-386(5)- A single oral dose of 1 tablet under fasting condition~Period 4: D013, D326, D337- A single oral dose of 3 tablets under fasting condition"
89569774|NCT04979845|Experimental|Telerehabilitation|
88970163|NCT04713098|Sham Comparator|Sham|SHAM percutaneous peripheral nerve stimulation with an ultrasound-guided percutaneous lead (SPR Therapeutics, Cleveland, Ohio) and wearable stimulator (SPR Therapeutics, Cleveland, Ohio) that does NOT generate electrical current
88970164|NCT04690374||Desmoplastic small round cell tumor (DSRCT)|Collect historical/longitudinal clinical, radiographic and molecular features of DSRCT patients as documented in medical records to improve knowledge about DSRCT
88970165|NCT04689386|Experimental|"Group I Stimulation of reflex rolling from the Vojta method"|
88970166|NCT04689386|Experimental|Group II Expiratory flow increase technique|
88970167|NCT04689386|No Intervention|Control Group|Routine intervention in the NICU with mechanical ventilation.
89569775|NCT04979845|Active Comparator|Video exercise|
89569776|NCT03062215|Experimental|Space from depression|SilverCloud Health is a leading provider of online therapeutic solutions to support and promote positive behavior change and mental wellness. SilverCloud delivers interventions depression. The treatment includes self-monitoring, behavioural activation, cognitive restructuring, and challenging core beliefs. All modules have the same structure and format, which consist of quizzes, videos, educational content, activities with homework suggestions and a module review page. Also, users have a supporter, who will give feedback asynchronously (D Richards et al., 2015). Research on the SilverCloud interventions has yielded significant clinical outcomes (D Richards et al., 2015).
88970170|NCT04672330|Experimental|Neoadjuvant arm|Patients will receive 2-4 cycles of Tislelizumab (200mg per cycle) prior to surgery（radical nephroureterectomy, segmental ureteral resection, endoscopic ablation） Drug: Tislelizumab 200 mg per cycle, IV on day 1 of every 3-week cycle, for 2-4 cycles prior to surgery
88970171|NCT04658147|Experimental|Arm A - Nivolumab|Participants receive Nivolumab only.
88970172|NCT04658147|Experimental|Arm B - Nivolumab and Relatlimab|Participants receive Nivolumab and Relatlimab.
88970173|NCT04645173||CanGaroo Envelope|Participants who received a CanGaroo envelope during CIED implantation
88970174|NCT04645173||TYRX Envelope|Participants who received a TYRX envelope during CIED implantation
88970175|NCT04645173||No Envelope|Participants who did not receive an envelope during CIED implantation
88970176|NCT04589884||Parathyroid disease|
88970177|NCT04589884||Thyroid disease|
88970178|NCT04589884||Liver tumors and metastases|
88970179|NCT04589884||Digestive tumors|
88970180|NCT04589884||Digestive perfusion|
88970181|NCT04589741|Experimental|toripalimab combined with CAV/IE regimen|toripalimab combined with CAV/IE regimen in patients with advanced or unresectable bone and soft tissue sarcomas who failed standard treatment
88970182|NCT04589741|Placebo Comparator|CAV/IE chemotherapy alone|CAV/IE chemotherapy alone in patients with advanced or unresectable bone and soft tissue sarcomas who failed standard treatment
88970183|NCT04582539|Experimental|INCB000928|INCB000928 will be administered in participants with MDS or MM who are transfusion-dependent or present with symptomatic anemia.
89569777|NCT03062215|No Intervention|Control Group|Waiting list
88970184|NCT04547595|No Intervention|CONTROL|Standard care
88970185|NCT04547595|Active Comparator|Hypnosis|Standard care + intervention
88970186|NCT04530149|Active Comparator|serratus anterior plane block group|The injection of bupivicaine into the chest muscle is performed with an ultrasound machine which can see the needle as it enters the muscle. The skin is cleaned with a sterile solution and the needle is guided right next to the chest muscle where either the bupivicaine injected. After the injection, the needle is taken out.
89569778|NCT05543603|Experimental|Chlorhexidine 0,12%|15 ml 0,12% Chlorhexidine, one minute rinse.
89569779|NCT05543603|Experimental|Chlorhexidine 0,20%|15 ml 0,20% Chlorhexidine, one minute rinse.
89569780|NCT05543603|Experimental|Gingilacer Encias Delicadas|15 ml 0,10% cymenol + 0,10% zinc chloride, one minute rinse.
89569781|NCT05543603|Placebo Comparator|Distilled Water|15 ml Distilled Water, one minute rinse.
89532245|NCT06336811|No Intervention|Control|"No additional intervention will be performed on the patient in the control group, and until the intervention begins, How old are you? Which grade are you in? What is the name of your favorite friend? Which sport do you enjoy doing more? His attention was distracted by asking questions such as."
89532246|NCT06336811|Experimental|active Virtual reality|The remote control of the virtual glasses will be given to the hand that will not be interfered with, and the child will start, slow down or stop the application herself. Samsung Gear Oculus Guest 2 headset allows watching virtual reality applications.
88811058|NCT04601831|Experimental|Radiation Therapy to all residual FDG-avid sites*|"All patients enrolled in the trial will receive focal radiation therapy (RT) to all* residual FDG-avid sites per Lugano criteria (Lugano 4-5) as noted on day 30 post-CAR-T PET/CT scan.~*If >5 distinct sites, physician discretion will be allowed as to how many sites are treated, with recommendation that at least all symptomatic and bulky (>=7.5 cm in largest dimension) sites be treated."
89532247|NCT06336811|Experimental|passive virtual reality|It was said that he could watch videos by wearing virtual headset glasses during the procedure. A virtual reality application that will attract the attention of children was determined by the researchers.
89532248|NCT06336798|Experimental|Pioglitazone, Then Placebo|Participants will first receive a 30 mg tablet of Pioglitazone once daily for 28 days. After a washout period of 14 days, they will then receive a Placebo tablet (matching Pioglitazone 30 mg tablet) once daily for 28 days.
89532249|NCT06336798|Experimental|Placebo, Then Pioglitazone|Participants will first receive a Placebo for 28 days. After a washout period of 14 days, they will then receive a 30 mg Pioglitazone tablet once daily for 28 days.
89532250|NCT06336785|Experimental|Restylane Filler Line and Dysport Neuromodulator|"This study will consist of an open-label, prospective, cohort trial design. Twenty-four subjects will be recruited.~Subjects will be recruited based on their primary deficit, 8 subjects will have a primary deficit in lip volume, 8 subjects will have a primary deficit in lip framing and 8 subjects will have a primary deficit in expression. All subjects will receive active treatment with hyaluronic acid at Baseline, with an optional touch at week two. There will be no placebo or no-treatment control groups. Subjects will be followed for five months."
89532251|NCT06336772|Experimental|Restylane Shaype|"Restylane Shaype is approved and commercially available for use in Canada and is manufactured by Q-Med AB, part of the Galderma Group.~It is an injectable, sterile, transparent, biodegradable gel of non-animal crosslinked sodium hyaluronate with the addition of lidocaine hydrochloride. It is supplied in a glass syringe. The contents of the syringe are sterilized using moist heat. Disposable TSK 27G Ultra Thin Wall (UTW) x ¾ (19 mm) needles sterilized using gamma irradiation are provided.~The participant will be treated at the Baseline visit and will be eligible for retreatment 2 weeks later if a touch up is deemed necessary by the Treating Investigator. Volumes used for each participant will be determined by the aesthetic judgement of the Treating Investigator."
89532252|NCT06336772|Active Comparator|Juvederm Volux|"Juvéderm Volux is approved and commercially available for use in Canada and is manufactured by Allergan Aesthetics, an Abbvie company.~It is a smooth, clear, sterile, colourless, biodegadable gel which contains hyaluronic acid produced by Streptococcus species of bacteria crosslinked with BDDE to help retain natural moisture and softness in the skin and lidocaine (local anaesthetic) which helps improve comfort to the patient during injection. The product is supplied in a box of two, 1ml syringes containing four single use 27G1/2 sterile needles.~The participant will be treated at the Baseline visit and will be eligible for retreatment 2 weeks later if a touch up is deemed necessary by the Treating Investigator. Volumes used for each participant will be determined by the aesthetic judgement of the Treating Investigator."
89532253|NCT06336759|Active Comparator|Retylane Defyne|"Restylane Defyne is manufactured by Q-Med AB, part of the Galderma Group.~The sterilized gel contain 20 mg/mL stabilized HA and 3 mg/mL lidocaine hydrochloride in a physiological buffer (phosphate buffered saline pH 7). Each syringe contains 1 mL gel. The study products are for single use only.~The product is considered to have a moderate rheological property.~The participant will be treated at the Baseline visit and will be eligible for retreatment 2 weeks later if a touch up is deemed necessary by the Treating Investigator. Volumes used for each subject will be determined by the aesthetic judgement of the Treating Investigator."
89532254|NCT06336759|Active Comparator|Retylane Lyft|"Restylane Defyne is manufactured by Q-Med AB, part of the Galderma Group.~The sterilized gel contain 20 mg/mL stabilized HA and 3 mg/mL lidocaine hydrochloride in a physiological buffer (phosphate buffered saline pH 7). Each syringe contains 1 mL gel. The study products are for single use only.~The product is considered to have a firm rheological property.~The participant will be treated at the Baseline visit and will be eligible for retreatment 2 weeks later if a touch up is deemed necessary by the Treating Investigator. Volumes used for each subject will be determined by the aesthetic judgement of the Treating Investigator."
89532255|NCT06336746||Patients with Preoperative EF: 50% or higher|Patients included will be examined with Transthoracic Echocardiography preoperatively and Ejection Fraction (EF) measured.
89532256|NCT06336746||Patients with Preoperative EF: 45% or lower|Patients included will be examined with Transthoracic Echocardiography preoperatively and Ejection Fraction (EF) measured.
89532257|NCT06336746||Patients without intrathecal bupivacain and morphine.|The routine is that all patient receive an intrathecal injection of morphine and bupivacain before start of anesthesia. Patients who have contraindications for spinal anesthesia will be collected in this group.
89569782|NCT04979923|Experimental|Lidocaine group|
89569783|NCT04979923|Placebo Comparator|Salbutamol group|
89208962|NCT02553278|Experimental|Treatment with VelaShape device|"One treatment will be performed by the VelaShape device on one randomized abdominal subarea, while the other abdominal subarea will not be treated and will serve as a control. Biopsies will be harvested during abdominoplasty and cultured. Two histology samples, for each subject, will be obtained during the abdominoplasty surgery, The arm is divided to 6 sub-groups, where each Sub-group contains up to 2 subjects as follows:~Sub-group 1: Surgery immediately after treatment Sub-group 2: Surgery 5 days after treatment Sub-group 3: Surgery 10 days after treatment Sub-group 4: Surgery 20 days after treatment Sub-group 5: Surgery 30 days after treatment Sub-group 6: Surgery 60 days after treatment Sub-group 7: Surgery 90 days after treatment"
89532258|NCT06336733|Experimental|ANAKINRA on Demand|On demand Anakinra 100 mg/j from the prodromal phase of the attack until 24 hours of remission (during 7 days maximum) + colchicine + on demand analgesics
89532259|NCT06336733|No Intervention|Standard of Care|Usual analgesics + colchicine
89532260|NCT06336720|Other|Single Arm|open label administration of translingual neurostimulation.
89532261|NCT06336707|Experimental|HS-20089 and Adebrelimab|
89532262|NCT06336707|Experimental|HS-20089, Adebrelimab and cisplatin / carboplatin|
89532263|NCT06336707|Experimental|HS-20089 and Bevacizumab|
89532264|NCT06336707|Experimental|HS-20089, Bevacizumab and cisplatin / carboplatin|
89532265|NCT06336694||peritoneal metastases|No intervention had been adminstered during treatment of patients.
89532266|NCT06336694||without peritoneal metastases|No intervention had been adminstered during treatment of patients.
89532267|NCT06336681|Experimental|Inspiratory Muscle Training (IMT) group|The test protocol requires participants to inhale maximally (maximum inspiratory pressure, MIP) against 2mm diameter leak and sustain inhalation (sustained maximal inspiratory pressure, SMIP) until task failure. Participants will complete 3 SMIP maneuvers with each training session and use the best of the three for that day's training template (corresponding to about 80% SMIP for the IMT group) via the PrO2Fit software. Participants must match or exceed the SMIP template with each increasing level of the work-rest ratio. Work at each level consists of 6 breaths, 36 breaths total. If six breaths are completed, the next level starts. Rest intervals will progressively shorten as training continues from 40-seconds to 5-seconds. The session will be terminated if participants are unable to match at least 90% of the training template for two consecutive breaths or have completed all 36 breaths. Training will be done 3 times a week, and over 8-weeks.
89532268|NCT06336681|Sham Comparator|Sham Inspiratory Muscle Training (Sham-IMT) group|Similar to the IMT group protocol, participants will be required to complete 3 SMIP maneuvers with each training session. Participants will use the best of the three for that day's training template (corresponding to about 30% SMIP for the Sham-IMT group) via the PrO2Fit software. Participants must match or exceed the SMIP template with each increasing level of the work-rest ratio. Work at each level consists of 6 breaths, 36 breaths total. If six breaths are completed, the next level starts. Rest intervals will progressively shorten as training continues from 40-seconds to 30-, 20-, 15-, 10-, and 5-seconds. The training session will be terminated if participants are unable to match at least 90% of the training template for two consecutive breaths or have completed all 36 breaths. Training will be done 3 times a week, and over 8-weeks.
89532269|NCT06336668|Active Comparator|Bovine based-HMF|The infant will fed human milk fortified with bovine-based HMF.
89532270|NCT06336668|Experimental|Human milk-based HMF|The infant will be fed human milk fortified with human milk-based HMF.
89532271|NCT06336655|Experimental|With LV Unloading|Patients on VA ECMO who randomize to receive LV unloading
89532272|NCT06336655|No Intervention|Without LV Unloading|Patients on VA ECMO who randomize to receive no LV unloading
89569784|NCT04979923|Active Comparator|Beclomethasone plus salbutamol|
89569785|NCT05543525||Male Athletes|Athletes who underwent a pre-participation medical evaluation in the Nancy University Hospital between January 1st, 2013, and January 1st, 2020.
89569786|NCT05543525||Control Group|A subgroup of 161 participants in a population-based cohort (STANISLAS Cohort) restricted by age and sex to create a control group in the current analysis.
89569787|NCT04979767||Sepsis|I. ≥ 50 years with ≥ 2 chronic comorbidities II. Highly suspected bacterial infection based on clinical or radiologic evidence III. ≥ 2 systemic inflammatory response syndrome (SIRS) criteria IV. Actual/anticipated admission to intensive care unit (ICU) V. Anticipated length of hospital stay ≥ 5 days
88970187|NCT04530149|Placebo Comparator|Placeoo injection group|The injection of normal saline into the chest muscle is performed with an ultrasound machine which can see the needle as it enters the muscle. The skin is cleaned with a sterile solution and the needle is guided right next to the chest muscle where saline is injected. After the injection, the needle is taken out.
88970188|NCT04518943|Experimental|F1M1P1R1|Financial Reward, mixed lottery, pre-commitment postcard reminders, request physical activity advice
88970189|NCT04518943|Experimental|N1M1P1R1|Non-financial reward, mixed lottery, pre-commitment postcard reminders, request physical activity advice
88970190|NCT04518943|Experimental|N1M1P1R0|Non-financial reward, mixed lottery, pre-commitment postcard reminders, no request physical activity advice
88970191|NCT04518943|Experimental|N1M1P0R0|Non-financial reward, mixed lottery, no pre-commitment postcard reminders, no request physical activity advice
88970192|NCT04518943|Experimental|N1M1P0R1|Non-financial reward, mixed lottery, no pre-commitment postcard reminders, request physical activity advice
88970193|NCT04518943|Experimental|N1L1P1R1|Non-financial reward, loss incentive, pre-commitment postcard reminders, request physical activity advice
88970194|NCT04518943|Experimental|N1L1P1R0|Non-financial reward, loss incentive, pre-commitment postcard reminders, no request physical activity advice
88970195|NCT04518943|Experimental|N1L1P0R0|Non-financial reward, loss incentive, no pre-commitment postcard reminders, no request physical activity advice
88970196|NCT04518943|Experimental|N1L1P0R1|Non-financial reward, loss incentive, no pre-commitment postcard reminders, request physical activity advice
88970197|NCT04518943|Experimental|F1M1P1R0|Financial Reward, mixed lottery, pre-commitment postcard reminders, no request physical activity advice
88970198|NCT04518943|Experimental|F1M1P0R0|Financial Reward, mixed lottery, no pre-commitment postcard reminders, no request physical activity advice
88970199|NCT04518943|Experimental|F1M1P0R1|Financial Reward, mixed lottery, no pre-commitment postcard reminders, request physical activity advice
88970200|NCT04518943|Experimental|F1L1P1R1|Financial Reward, loss incentive, pre-commitment postcard reminders, request physical activity advice
88970201|NCT04518943|Experimental|F1L1P1R0|Financial Reward, loss incentive, pre-commitment postcard reminders, no request physical activity advice
88970202|NCT04518943|Experimental|F1L1P0R0|Financial Reward, loss incentive, no pre-commitment postcard reminders, no request physical activity advice
88970203|NCT04518943|Experimental|F1L1P0R1|Financial Reward, loss incentive, no pre-commitment postcard reminders, request physical activity advice
88970204|NCT04508400|Experimental|a single dose of fosaprepitant|Participants received a single dose of fosaprepitant (age-based adjustment) administered intravenously (IV) on Day 1 prior to chemotherapy plus ondansetron (weight based) IV with dexamethasone (weight based) iv/po prior to chemotherapy and up to 72 hours after chemotherapy.
88970205|NCT04508400|Placebo Comparator|a single dose of matched placebo|Participants received a single dose of matched placebo for fosaprepitant administered intravenously (IV) on Day 1 prior to chemotherapy plus ondansetron (weight based) IV with dexamethasone (weight based) iv/po prior to chemotherapy and up to 72 hours after chemotherapy.
89569788|NCT04979767||Control|I. ≥ 50 years with ≥ 2 chronic comorbidities II. No suspected bacterial infection III. Actual/anticipated admission to intensive care unit (ICU) IV. Anticipated length of hospital stay ≥ 5 days
89569789|NCT04519411|Experimental|Intubated pediatric patients with COVID-19 respiratory failure|
89569790|NCT03714997|Experimental|High Intensity Locomotor Training|High Intensity Locomotor Training will consist of 30 sessions of walking related activities in variable contexts (i..e, on a treadmill, overground, and on stairs), with a primary goal to achieve 40 minutes of walking within 1 hour sessions while achieving heart rates close to 80% of heart rate reserve.
88970206|NCT04502550||Parkinson's Disease patients with DBS, no stimulation|"This cohort will serve as as the observed group, displaying basal ganglia pathology.~A syringe pump controlled by Stanpump implementing the Eleveld Pharmacokinetics-Pharmacodynamics (PK-PD) model for propofol will be used as a targeted controlled infusion (TCI) system to achieve plasma target propofol concentrations. Target effect-site concentration of propofol will be started at 1.4 μg/mL and will be increased by 0.3 μg/mL with reassessment until endpoints are achieved.~Experiments will be completed with DBS off."
88970207|NCT04502550||Essential Tremor patients with DBS|"This cohort will serve as a control group (no basal ganglia pathology). A syringe pump controlled by Stanpump implementing the Eleveld Pharmacokinetics-Pharmacodynamics (PK-PD) model for propofol will be used as a TCI system to achieve plasma target propofol concentrations. Target effect-site concentration of propofol will be started at 1.4 μg/mL and will be increased by 0.3 μg/mL with reassessment until endpoints are achieved.~Experiments will be completed with DBS off."
88970208|NCT04502550||Parkinson's Disease patients with DBS, Gpi stimulation|"This cohort will serve as as the observed group, displaying basal ganglia pathology.~A syringe pump controlled by Stanpump implementing the Eleveld Pharmacokinetics-Pharmacodynamics (PK-PD) model for propofol will be used as a targeted controlled infusion (TCI) system to achieve plasma target propofol concentrations. Target effect-site concentration of propofol will be started at 1.4 μg/mL and will be increased by 0.3 μg/mL with reassessment until endpoints are achieved.~Participants will be stimulated at the Gpi via DBS leads during propofol induced loss of consciousness."
89569791|NCT03714997|Active Comparator|Low Intensity Locomotor Training|High Intensity Locomotor Training will consist of 30 sessions of walking related activities in variable contexts (i..e, on a treadmill, overground, and on stairs), with a primary goal to achieve 40 minutes of walking within 1 hour sessions while achieving heart rates from 30% to 40% of heart rate reserve.
89569792|NCT03706885|Placebo Comparator|Placebo|Treatment with placebo - 1 pill per day for 20 weeks
89569793|NCT03706885|Active Comparator|Sustiva 50mg|Treatment with Sustiva 50mg - 1 pill per day for 20 weeks
89569794|NCT03706885|Active Comparator|Sustiva 200mg|Treatment with Sustiva 200mg - 1 pill per day for 20 weeks
89569795|NCT01665599|Experimental|Testosterone gel (FE 999303)|"Subjects received a starting dose of 46 mg (two actuations) of testosterone gel (2%) daily in the morning. The dose was further titrated (increased or decreased - three actuations [69 mg] or single actuation [23 mg], respectively) based on serum testosterone concentrations.~Testosterone gel was applied using an applicator, to the shoulder/upper arm in a contralateral fashion."
89569796|NCT04979221|Experimental|Cyproheptadine and usual care|"Patients allocated to the intervention group will receive cyproheptadine within 6 hours after randomization, at a dose of 8mg every 8 hours for 10 days.~Usual care (diagnostic testing, antibiotic administration, fluid resuscitation, hemodynamic management, and ventilatory support) will be applied in accordance with the clinical practice of each institution."
89569797|NCT04979221|No Intervention|Usual care|Usual care (diagnostic testing, antibiotic administration, fluid resuscitation, hemodynamic management, and ventilatory support) will be applied in accordance with the clinical practice of each institution.
89569798|NCT04503109|Other|Nalu SCS System|All eligible subjects will receive the Nalu Neurostimulation System
89569799|NCT05697887|Experimental|The feasibility of the ketogenic diet|The purpose of this study was to verify the feasibility of the ketogenic diet in children with refractory epilepsies followed at a pediatric center in South Vietnam. The patient was considered feasible if he (or she) did not have the contra-indication for the ketogenic diet
89569800|NCT05697887|Experimental|the tolerability of the ketogenic diet|The purpose of this study was to verify the tolerability of the ketogenic diet in children with refractory epilepsies followed at a pediatric center in South Vietnam. The patient was considered tolerant if he (or she) did not have any side effects caused by the ketogenic diet
89569801|NCT05697887|Experimental|the efficacy of the ketogenic diet|The purpose of this study was to verify the efficacy of the ketogenic diet in children with refractory epilepsies followed at a pediatric center in South Vietnam. Patients were considered responders when a 50% seizure frequency was reached.
89569802|NCT01671085|Experimental|1.0 milligrams per kilogram (mg/kg) of LY3015014|1.0 mg/kg of LY3015014 given subcutaneously (SQ) on 2 dosing occasions occurring 4 weeks apart (Q4W) (Days 1 and 29).
89569803|NCT01671085|Placebo Comparator|Placebo|0.9% sodium chloride injection given SQ (to match LY3015014) on 2 dosing occasions Q4W (Days 1 and 29).
89569804|NCT05537363|No Intervention|Healthy adults|Year 1: To assess levels of agility and agility performance in relation to the motor and cognitive abilities of healthy young adults, healthy elderly, and elderly with MCI.
89569805|NCT05537363|No Intervention|Healthy elderly and mild cognitive impairment elderly|Year 1: To assess levels of agility and agility performance in relation to the motor and cognitive abilities of healthy young adults, healthy elderly, and elderly with MCI.
89569806|NCT05537363|Active Comparator|Mild cognitive impairment elderly with health education|Year 2: To determine the short and long-term effects of a multicomponent training protocol and an agility training protocol on agility, motor, and cognitive function in elderly with MCI.
89569807|NCT05537363|Experimental|Mild cognitive impairment elderly with multicomponent training|Year 2: To determine the short and long-term effects of a multicomponent training protocol and an agility training protocol on agility, motor, and cognitive function in elderly with MCI.
88970209|NCT04502550||Parkinson's Disease patients with DBS, Gpe stimulation|"This cohort will serve as as the observed group, displaying basal ganglia pathology.~A syringe pump controlled by Stanpump implementing the Eleveld Pharmacokinetics-Pharmacodynamics (PK-PD) model for propofol will be used as a targeted controlled infusion (TCI) system to achieve plasma target propofol concentrations. Target effect-site concentration of propofol will be started at 1.4 μg/mL and will be increased by 0.3 μg/mL with reassessment until endpoints are achieved.~Participants will be stimulated at the Gpe via DBS leads during propofol induced loss of consciousness."
89569808|NCT05537363|Experimental|Mild cognitive impairment elderly with agility training|Year 2: To determine the short and long-term effects of a multicomponent training protocol and an agility training protocol on agility, motor, and cognitive function in elderly with MCI.
89569809|NCT05537363|Active Comparator|Healthy elderly with health education|Year 3: To determine the short and long-term effects of a multicomponent training protocol and an agility training protocol on agility ability, motor, and cognitive function in healthy elderly adults.
89569810|NCT05537363|Experimental|Healthy elderly with multicomponent training|Year 3: To determine the short and long-term effects of a multicomponent training protocol and an agility training protocol on agility ability, motor, and cognitive function in healthy elderly adults.
89569811|NCT05537363|Experimental|Healthy elderly with agility training|Year 3: To determine the short and long-term effects of a multicomponent training protocol and an agility training protocol on agility ability, motor, and cognitive function in healthy elderly adults.
89569812|NCT03063931|Experimental|magnesium|
88970210|NCT04502550||Parkinson's Disease patients undergoing DBS surgery, Gpe stimulation|"A syringe pump controlled by Stanpump implementing the Eleveld Pharmacokinetics-Pharmacodynamics (PK-PD) model for propofol will be used as a targeted controlled infusion (TCI) system to achieve plasma target propofol concentrations. Target effect-site concentration of propofol will be started at 1.4 μg/mL and will be increased by 0.3 μg/mL with reassessment until endpoints are achieved.~Participants will be stimulated at the Gpe via DBS leads, and cortical activity will be recorded via ECoG during propofol induced loss of consciousness."
89569813|NCT03063931|Placebo Comparator|placebo|
89569814|NCT03621631|Experimental|optimized Tai Chi intervention|optimized Tai Chi intervention
89569815|NCT03621631|Active Comparator|traditional Tai Chi intervention|traditional Tai Chi intervention
89569816|NCT03063775|Active Comparator|1. Mucograft® Seal + Bio-Oss®|
89569817|NCT03063775|Active Comparator|2. FGG + Bio-Oss®|
89569818|NCT03063775|Active Comparator|3. FGG + Gelatine sponge (Spongostan®)|
89569819|NCT03063775|Active Comparator|4. Spongostan®+ Mucograft® Seal|
88970211|NCT04502550||Parkinson's Disease patients undergoing DBS surgery, Gpi stimulation|"A syringe pump controlled by Stanpump implementing the Eleveld Pharmacokinetics-Pharmacodynamics (PK-PD) model for propofol will be used as a targeted controlled infusion (TCI) system to achieve plasma target propofol concentrations. Target effect-site concentration of propofol will be started at 1.4 μg/mL and will be increased by 0.3 μg/mL with reassessment until endpoints are achieved.~Participants will be stimulated at the Gpi via DBS leads, and cortical activity will be recorded via ECoG during propofol induced loss of consciousness."
89569820|NCT03063775|No Intervention|5. Spongostan®|
89569821|NCT03063541|Experimental|Acetylsalicylic acid, BP-target 120|100 mg ASA plus intensified blood pressure management. Recommended systolic blood pressure 120 mm/Hg
89569822|NCT03063541|No Intervention|standard care|blood pressure management according to guidelines
89569823|NCT04978753|Experimental|treatment|Anlotinib (12mg/time (BSA≥1.6 m2) or 10mg/time (BSA<1.6 m2), once a day orally, taking two weeks and stopping for one week) combine with Almonertinib (110mg, orally once a day)
89569824|NCT03545737||Measurement|The distances between the midpoint of the thyroid cartilage to suprasternal notch base on body surface measurement add the distance between suprasternal notch to carina of trachea according to chest CT.
89569825|NCT03545737||Formula|"The formula base on patient's height as a guide for the intubation of a Left-sided Double-lumen tube.~The depth of intubation = 0.1977* height-4.2423"
89569826|NCT03063853|Other|POD4|REMOVAL OF SURGICAL STAPLES AT POSTOPERATIVE DAY 4
89569827|NCT03063853|Other|POD8|REMOVAL OF SURGICAL STAPLES AT POSTOPERATIVE DAY 8
89569828|NCT03062761|Experimental|Active product: partially hydrolysed proteins|Partially hydrolysed whey protein based infant formula containing prebiotics.
89569829|NCT03062761|Active Comparator|Control product: standard formula (intact protein)|Intact cow's milk protein based infant formula containing prebiotics.
89569830|NCT03063151|Experimental|Study Group|The Maximum isometric Voluntary Contraction (MVC) was measured by standard muscle testing. Then the subject sat in front of a table with his forearm resting in a comfortable position. The Hand Reaching Spatial Device (HRSD) was located at the maximal hand-reaching range of motion. Participants were requested to point on each target 5 times according to voice prompting that was activated by the EMG software every 10 seconds, for 45 pointing movements. The order of pointing targets was constant for all the participants.
89569831|NCT03063151|Experimental|Control Group|The Maximum isometric Voluntary Contraction (MVC) was measured by standard muscle testing. Then the subject sat in front of a table with his forearm resting in a comfortable position. The Hand Reaching Spatial Device (HRSD) was located at the maximal hand-reaching range of motion. Participants were requested to point on each target 5 times according to voice prompting that was activated by the EMG software every 10 seconds, for 45 pointing movements. The order of pointing targets was constant for all the participants.
88970212|NCT04502550||Parkinson's Disease patients undergoing DBS surgery, no stimulation|"A syringe pump controlled by Stanpump implementing the Eleveld Pharmacokinetics-Pharmacodynamics (PK-PD) model for propofol will be used as a targeted controlled infusion (TCI) system to achieve plasma target propofol concentrations. Target effect-site concentration of propofol will be started at 1.4 μg/mL and will be increased by 0.3 μg/mL with reassessment until endpoints are achieved.~Participants will not receive any stimulation via DBS leads, and cortical activity will be recorded via ECoG during propofol induced loss of consciousness."
88970216|NCT04492319|Active Comparator|control group|
88970217|NCT04492319|Active Comparator|neostigmine group|
88970218|NCT04485013|Experimental|Phase 1a, Monotherapy Dose Escalation|
89569832|NCT04978597|Experimental|Opicapone|OPC will be taken orally once daily in the evening at least 1 hour after the last daily dose of L-DOPA/DDCI (considered the bedtime dose).
89569833|NCT04978597|Placebo Comparator|Matching placebo|Matching placebo will be taken orally once daily in the evening at least 1 hour after the last daily dose of L-DOPA/DDCI (considered the bedtime dose).
89569834|NCT04978441||Type 1 diabetes mellitus (T1DM)|"Males or females above 18 years old~Patients with a prior medical history diagnosis of T1DM~Patients who are using a continuous glucose monitor (CGM or FGM)"
89569835|NCT04977973|Experimental|Intervention group: Body Image|Participants will complete a 9-day self-guided programme on body image delivered via a mobile phone application with daily exercises informed by cognitive-behavioural and self-compassion principles.
89569836|NCT04977973|Active Comparator|Control group|Participants will complete a 9-day self-guided programme on cooperation delivered via a mobile phone application with daily exercises that differ to the intervention group in terms of content but are comparable in terms of duration.
89569837|NCT04977661|Active Comparator|Group1|Group I (n = 34) received 400 IU Vitamin E (Vitamin E 400 IU®, MEPACO Pharmaceutical Company, Sharqia, Egypt) twice daily for 3 month
89569838|NCT04977661|Active Comparator|Group2|Group II (n =34) received 250 mg Ursodeoxycholic acid (Ursofalk 250 mg®, MINAPHARM Pharmaceutical Company, Cairo, Egypt) twice daily for 3 months
89569839|NCT04977661|Active Comparator|Group3|Group III (n = 34) received 400 mg sustained release (SR) Film-Coated Tablets of pentoxifylline (Trental 400 mg®, SANOFI Pharmaceutical Company, Cairo, Egypt) twice daily for 3 months
89569840|NCT04977427|Active Comparator|Prednisolone Arm|Standard post-cataract surgery therapy arm; acts as control in each patient.
89569841|NCT04977427|Active Comparator|Dextenza Arm|Investigational arm to compare the effectiveness of the Dextenza insert to standard therapy.
89569842|NCT03063697||patients who check the safety data after taking Dilatrend SR|
89569843|NCT04977505||Pushlock|Patients with recurrent shoulder dislocation received surgery fixed by pushlock
89569844|NCT04977505||Gryphon|Patients with recurrent shoulder dislocation received surgery fixed by Gryphon
89569845|NCT03267043|Active Comparator|Standard Care|Participants enrolled in Phase 1 will be receiving the current standard of care in the NICU at The Valley Hospital.
89569846|NCT03267043|Experimental|Family Nurture Intervention (FNI)|Participants enrolled in Phase 2 will be receiving family nurture intervention (FNI) that focuses on supporting the parents and facilitating emotional connection between mother and infant during the infant's NICU stay.
89569847|NCT03267043|Active Comparator|Standard Care - Case Studies|Participants enrolled as case studies in Phase 1 will be receiving the current standard of care in the NICU at The Valley Hospital. These participants will be those who fall outside the inclusion criteria.
89569848|NCT03267043|Experimental|FNI - Case Studies|Participants enrolled in Phase 2 will be receiving family nurture intervention (FNI) that focuses on supporting the parents and facilitating emotional connection between mother and infant during the infant's NICU stay. These fall outside the inclusion criteria but act as a comparator to the case studies of Phase 1.
89569849|NCT04235257|Experimental|Bivalent HPV vaccine|One-fifth fractional dose (0.1 ml) of bivalent HPV vaccine administered subcutaneously
89569850|NCT04235257|Experimental|Nonavalent HPV vaccine|One-fifth fractional dose (0.1 ml) of nonavalent HPV vaccine administered subcutaneously
89569851|NCT04977193|Experimental|Treatment group|
89569852|NCT04977115|Experimental|Intraocular caliper-assisted capsulotomy group|In intraocular caliper-assisted capsulotomy group, a modified intraocular caliper with standard calibration on the rinse needle was used to measure and locate the position of capsulorhexis with 5.3 mm diameter and the principle of pupillary margin in concentric circles. The surgeon could gently use the blunt needle in the front of the intraocular caliper to further make corresponding markers on the lens anterior capsule, and then carry out capsulotomy according to the marks.
89569853|NCT04977115|Active Comparator|Verion navigation system-assisted capsulotomy group|In the Verion-assisted capsulotomy group, Verion navigation system was applied to project a 5.3 mm capsulorhexis centered on the corneal vertex. According to the projected capsulorhexis, capsulotomy was performed.
89569854|NCT04224415|Other|C225+CPT-11|"Patients will receive Systemic C225+CPT-11 every 14 days:~C225 500 mg/m2 IV over 90 minutes on Day 1; Irinotecan 180 mg/m2 IV on Day 1"
89569855|NCT03217045||Before Protocol|72 premature infants born between 26 and 32 weeks gestation, over 6 months period, and involved before the introduction of a strict nutrition protocol
89569856|NCT03217045||After Protocol|86 premature infants born between 26 and 32 weeks gestation, over 6 months period, and involved after the introduction of a strict nutrition protocol and a washout period of 6 months
89569857|NCT03061981|Active Comparator|DA-1241:8 subjects in each cohort(Cohort 1-6)|Subjects will participate in 1 of 6 cohorts consisting of 10 subjects per cohort. Within cohorts, subjects will be randomized to a ratio of 8:2 (DA-1241 to matching placebo).
89569858|NCT03061981|Placebo Comparator|Placebo: 2 subjects in each cohort(Cohort 1-6)|Subjects will participate in 1 of 6 cohorts consisting of 10 subjects per cohort. Within cohorts, subjects will be randomized to a ratio of 8:2 (DA-1241 to matching placebo).
89569859|NCT03061981|Other|DA-1241 in IE Cohort: 8 subjects in choosen cohort|One of the cohorts will be selected,based on a review of the data from cohort 1-6, to assess the IE of metformin on the PK of DA-1241.
89569860|NCT03061981|Other|Placebo in IE Cohort: 2 subjects in choosen cohort|One of the cohorts will be selected,based on a review of the data from cohort 1-6, to assess the IE of metformin on the PK of DA-1241.
89569861|NCT02510001|Experimental|Dose Escalation Phase Cohort 1 Dose level 1|Crizotinib 250mg OD Days 1-28 continuously PD-0325901 2mg BD Run in Day -7 to Cycle 1 Day1, then Day 1-21 every 28 day cycle
89569862|NCT02510001|Experimental|Dose Escalation Phase Cohort 2 Dose level 2|Crizotinib 200mg BD Days 1-28 continuously PD-0325901 2mg BD Run in Day -7 to Cycle 1 Day1, then Day 1-21 every 28 day cycle
89569863|NCT02510001|Experimental|Dose Escalation Phase Cohort 3 Dose level 3|Crizotinib 200mg BD Days 1-28 continuously PD-0325901 4mg BD Run in Day -7 to Cycle 1 Day 1, then Day 1-21 every 28 day cycle
89569864|NCT02510001|Experimental|Dose Escalation Phase Cohort 4 Dose level 4|Crizotinib 200mg BD Days 1-28 continuously PD-0325901 8mg BD Run in Day -7 to Cycle 1 Day1, then Day 1-21 every 28 day cycle
89569865|NCT02510001|Experimental|Dose Escalation Phase Cohort 7 Dose level 5|Binimetinib 30mg BD continuous administration or Days 1-21 every 28 days. PF-02341066 200mg BD continuous administration
89569866|NCT02510001|Experimental|Dose Escalation Phase Cohort 13 Dose level 5a|Binimetinib 30mg BD interval dose administration Days 1-21 every 28 days. PF-02341066 250mg OD continuous administration
89569867|NCT02510001|Experimental|Dose Expansion Phase|Binimetinib 30mg BD interval dose administration Days 1-21 every 28 days PF-02341066 (Crizotinib) 250mg OD Days 1-28 continuously Dosage determined following the recommended Phase II dose identification in the dose escalation phase.
89569868|NCT02510001|Experimental|Dose Escalation Phase Cohort 12 Dose level 5 (Interval dosing)|Binimetinib 30mg BD interval dose administration days 1-21 every 28 days. PF-02341066 200mg BD continuous administration
88811059|NCT04594070|Active Comparator|Daily iron supplementation|Oral ferrous sulfate, 325 mg, take once daily
88811060|NCT04594070|Experimental|Alternate day iron supplementation|Oral ferrous sulfated, 650mg, taken once daily every other day
89569869|NCT02452047|Experimental|Group 1: Imipenem+Cilastatin/Relebactam|Participants will be stratified by infection type (HABP/VABP, cIAI, and cUTI) and randomized to receive imipenem+cilastatin/relebactam intravenous (IV) infusion once every 6 hours and placebo for colistimethate sodium IV infusion once every 12 hours for 5 to 21 days for cIAI and cUTI or for 7 to 21 days for HABP or VABP. Treatment durations >21 days may be approved by the Sponsor for participants requiring longer treatment duration.
89569870|NCT02452047|Active Comparator|Group 2: Colistimethate sodium + Imipenem+Cilastatin|Participants will be stratified by infection type (HABP/VABP, cIAI, and cUTI) and randomized to receive colistimethate sodium IV infusion once every 12 hours and imipenem+cilastatin IV infusion once every 6 hours for 5 to 21 days for cIAI and cUTI or for 7 to 21 days for HABP or VABP. Treatment durations >21 days may be approved by the Sponsor for participants requiring longer treatment duration.
89569871|NCT02452047|Experimental|Group 3: Imipenem+Cilastatin/Relebactam|Participants with documented imipenem-resistant and colistin-resistant bacterial infections may be eligible to receive open-label imipenem+cilastatin/relebactam IV infusion once every 6 hours for 5 to 21 days for cIAI and cUTI or for 7 to 21 days for HABP or VABP. Treatment durations >21 days may be approved by the Sponsor for participants requiring longer treatment duration.
89569872|NCT02475369|Other|PES, Then Placebo|Participants first received Pancreatic Enzyme Supplementation (PES) for 10 days. PES taken 6 times daily with gluten free meals and snacks. To facilitate duodenal digestion Omeprazole (20 mg/QD) was co-administered. After a washout period of 1 week, they then received placebo tablets (matching PES treatment) 6 times daily for 10 days.
89569873|NCT02475369|Other|Placebo, Then PES|Participants first received placebo tablets (matching PES) for 10 days. Placebo was taken 6 times daily with gluten-free meals and snacks. To facilitate duodenal digestion Omeprazole (20 mg/QD) was co-administered. After a washout period of 1 week, they then received PES tablets six times daily for 10 days.
89569874|NCT02474589|Active Comparator|Active|600 mg tecovirimat capsules BID to assess safety and tolerability and pharmacokinetics of the anit-orthopoxvirus compound Tecovirimat when administered orally in healthy subjects
89569875|NCT02474589|Placebo Comparator|Placebo|matching placebo capsules BID to assess safety and tolerability and pharmacokinetics of the anit-orthopoxvirus compound Tecovirimat when administered orally in healthy subjects
89569876|NCT02586233|Experimental|DS-1040b|Participants who will be randomized to receive intravenous (IV) infusion of DS-1040b ranging from 0.6 mg to 9.6 mg.
89569877|NCT02586233|Placebo Comparator|Placebo|Participants who will be randomized to receive intravenous (IV) infusion of placebo.
89569878|NCT03936101||Prenatally Sequenced Group|750 trios with fetal structural anomalies who receive prenatal sequencing from the study
89569879|NCT03936101||No Prenatal Sequencing (Unsequenced) Group|350 trios with fetal structural anomalies who do not have prenatal sequencing
89569880|NCT05592431|Experimental|High Frequency Oscillatory Ventilation with Volume Guarantee (HFOV-VG )|After documenting parental consent, preterm neonates with respiratory insufficiency randomly ventilated on (HFOV-VG ) will be assessed by doppler cerebral blood flow velocity measurements
89569881|NCT05592431|Active Comparator|High Frequency Oscillatory Ventilation (HFOV)|After documenting parental consent, preterm neonates with respiratory insufficiency randomly ventilated on (HFOV) will be assessed by doppler cerebral blood flow velocity measurements
89569882|NCT05537207|Experimental|study group|low level laser therapy (LLLT) on the acupuncture points.in addition to non-steroidal anti-inflammatory drugs
89569883|NCT05537207|Experimental|control group|All women will receive non-steroidal anti-inflammatory drugs in the form of Brufen (Ibuprofen), 400 mg, 3 times per day after meals, for 6 weeks, as will be described by their gynecologist.
89569884|NCT05537129|Experimental|Laparoscopic Total Gastrectomy|
89569885|NCT05537129|Active Comparator|Open Total Gastrectomy|
89569886|NCT02474355|Experimental|AZD9291|Single arm of AZD9291, starting dose of 80mg
89569887|NCT02474199|Experimental|darTregs|Donor Alloantigen Reactive Tregs (darTregs). Participants will receive a target dose of 400X10^6 darTregs (range 300-500 x10^6) infused intravenously (IV) over an approximate 20-30 minute interval
89569888|NCT02450487|Experimental|Interventional group|100 patients will be treated with Piroxicam (20 mg once daily for 4 days) for pain control after lower third molar surgery
89569889|NCT02473965|Experimental|IGIV-C|An IGIV-C loading dose of 2 g/kg and maintenance dose of 1 g/kg will be administered in CS dependent subjects with MG.
89569890|NCT02473965|Placebo Comparator|Placebo|0.9% sodium chloride injection, USP or equivalent
89569891|NCT04939311|Experimental|VB-201|One dose of VB-201 80 mg (1 tablet) will be administered orally once daily for 52 weeks.
89569892|NCT04939311|Placebo Comparator|Placebo|One dose of placebo 80 mg (1 tablet) will be administered orally once daily for 52 weeks.
89569893|NCT02472795|Experimental|Cenerimod 0.5 mg (Part A)|Participants will receive cenerimod 0.5 mg capsules orally once daily for 12 weeks.
89569894|NCT02472795|Experimental|Cenerimod 1 mg (Part A)|Participants will receive cenerimod 1 mg capsules orally once daily for 12 weeks.
89569895|NCT02472795|Experimental|Cenerimod 2 mg (Part A)|Participants will receive cenerimod 2 mg capsules orally once daily for 12 weeks.
89569896|NCT02472795|Experimental|Cenerimod 4 mg (Part B)|Participants will received cenerimod 4 mg capsules orally once daily for 12 weeks. This treatment arm will start after all patients in Part A have completed 4 weeks of placebo, 0.5 mg, 1 mg and 2 mg cenerimod treatment.
89569897|NCT02472795|Placebo Comparator|Matching placebo (Part A and B)|Capsules of matching placebo taken orally once daily for 12 weeks.
89569898|NCT02507349|Active Comparator|Person-Centered Care|Decision support center staffed by peers. Patient uses the CommonGround program prior to medication visit to prepare a personal report, with support from peer(s). The CommonGround report expresses goals for medication, how other strategies help with functioning, current problems, and medication side effects. Patient brings report into the medication visit. Prescriber and patient discuss medication options, and prescriber enters the shared decision into CommonGround during the visit.
89569899|NCT02507349|Active Comparator|Measurement-Based Care|Clinic staff asks each patient to use a tablet computer to complete a brief assessment of symptoms and problems prior to medication visit. Prescriber views assessment results on office computer and discusses next steps in medication management with the patient.
89569900|NCT02506881|Experimental|BCD-066 → Aranesp - subcutaneous|Volunteers in this group initially will receive a single sc injection of the study drug BCD-066 (darbepoetin alfa) at a dose of 1 µg/kg (on Day 1) and then, after at least 25 days, a single sc injection of the reference drug Aranesp® (darbepoetin alfa) at a dose of 1 µg/kg.
89569901|NCT02506881|Experimental|Aranesp → BCD-066 - subcutaneous|Volunteers in this group initially will receive a single sc injection of the reference drug Aranesp® (darbepoetin alfa) at a dose of 1 µg/kg (on Day 1) and then, after at least 25 days, a single sc injection of the study drug BCD-066 (darbepoetin alfa) at a dose of 1 µg/kg.
89569902|NCT02506881|Experimental|BCD-066 → Aranesp - intravenous|Volunteers in this group initially will receive a single iv injection of the study drug BCD-066 (darbepoetin alfa) at a dose of 1 µg/kg (on Day 1) and then, after at least 25 days, a single iv injection of the reference drug Aranesp® (darbepoetin alfa) at a dose of 1 µg/kg.
88970219|NCT04485013|Experimental|Phase 1b, Dose Expansion: TTX-080 in combination with pembrolizumab (HNSCC)|Arm 1 will enroll subjects with advanced/metastatic, prior checkpoint inhibitor treated Head and Neck Squamous Cell Carcinoma (HNSCC)
88970220|NCT04485013|Experimental|Phase 1b, Dose Expansion: TTX-080 in combination with cetuximab (HNSCC)|Arm 2 will enroll subjects with advanced/metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
88970221|NCT04485013|Experimental|Phase 1b, Dose Expansion: TTX-080 monotherapy (CRC)|Arm 3 will enroll subjects with advanced/metastatic colorectal cancer (CRC)
88970222|NCT04485013|Experimental|Phase 1b, Dose Expansion: TTX-080 in combination with cetuximab (CRC), prior anti-EGFR therapy|Arm 4 will enroll subjects with advanced/metastatic MSI-L/MSS, KRAS wild-type colorectal cancer (CRC) who have progressed on a prior anti-EGFR therapy
88970223|NCT04485013|Experimental|Phase 1b, Dose Expansion: TTX-080 in combination with cetuximab (CRC), no prior anti-EGFR therapy|Arm 5 will enroll subjects with advanced/metastatic MSI-L/MSS, KRAS wild type colorectal cancer (CRC) who have not received a prior anti-EGFR therapy
88970224|NCT04485013|Experimental|Phase 1b, Dose Expansion: TTX-080 monotherapy (NSCLC)|Arm 6 will enroll subjects with advanced/metastatic non-small cell lung cancer (NSCLC)
88970225|NCT04485013|Experimental|Phase 1b, Dose Expansion: TTX-080 in combination with pembrolizumab (NSCLC)|Arm 7 will enroll subjects with advanced/metastatic prior checkpoint inhibitor treated non-small cell lung cancer (NSCLC)
88970226|NCT04485013|Experimental|Phase 1b, Dose Expansion: TTX-080 as monotherapy OR in combination with pembrolizumab|"Arm 8: TTX-080 monotherapy:~Advanced/metastatic, prior checkpoint inhibitor treated renal cell carcinoma with predominance of clear cell component~Advanced/metastatic acral melanoma~Arm 8: TTX-080 in combination with pembrolizumab:~• Advanced/metastatic triple-negative breast cancer (estrogen and progesterone receptor negative and HER2 negative) who has received a prior checkpoint inhibitor"
88970227|NCT04480736|Placebo Comparator|Placebo|Participants will receive matching placebo of JNJ-64281802 orally.
89569903|NCT02506881|Experimental|Aranesp → BCD-066 - intravenous|Volunteers in this group initially will receive a single iv injection of the reference drug Aranesp® (darbepoetin alfa) at a dose of 1 µg/kg (on Day 1) and then, after at least 25 days, a single iv injection of the study drug BCD-066 (darbepoetin alfa) at a dose of 1 µg/kg.
89569904|NCT02506257|Experimental|0.04% PHMB|0.04% PHMB eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
89569905|NCT02506257|Experimental|0.06% PHMB|0.06% PHMB eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
89569906|NCT02506257|Experimental|0.08% PHMB|0.08% PHMB eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
89569907|NCT02506257|Placebo Comparator|PHMB Vehicle|PHMB vehicle eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
89569908|NCT02506101|Experimental|narrow-band ultraviolet B phototherapy|We will use the 3 Series PC & SP Phototherapy Cabinet for treatment of vitiligo.
89569909|NCT02506101|No Intervention|no intervention|untreated
89569910|NCT02505945|Active Comparator|Control Arm|Double-dose PPI [Omeprazole 20 mg BID (twice a day)]
89569911|NCT02505945|Active Comparator|Treatment Arm|LINX Reflux Management System
89569912|NCT02505867|Experimental|Device - ASV Therapy|Participants are provided with Adaptive Servo Ventilation (ASV) device during inpatient hospitalization or shortly after discharge.
89569913|NCT02505867|No Intervention|Control|No device provided
89569914|NCT02472639|Experimental|Ostom-i Alert Sensor|Patients will wear Ostom-i sensor
89569915|NCT02472639|Other|No Ostom-i Alert Sensor|Patient will not wear Ostom-i sensor
89569916|NCT02472405|Active Comparator|595nm PDL|One third of the scar will be treated with 595nm PDL solely for 3 weeks (1 treatment session per week). A blinded observer will evaluate each third of the scar 4 weeks after the last treatment session using the POSAS system.
89569917|NCT02472405|Active Comparator|595/1064nm Multiplex Laser|One third of the scar will be treated with 595/1064nm Multiplex laser for 3 weeks (1 treatment session per week). A blinded observer will evaluate each third of the scar 4 weeks after the last treatment session using the POSAS system.
89569918|NCT02472405|No Intervention|Control|One third of the scar will be left untreated for the duration of the study. A blinded observer will evaluate each third of the scar 4 weeks after the last treatment session using the POSAS system.
89028707|NCT06107335|Experimental|Fluid replacement using colloid as guided by stroke volume variation (SVV)|Fluid replacement will be achieved with the colloid 5% albumin infusion. Use of colloid will be guided by stroke volume variation (SVV) as assessed by the Edwards HemoSphere monitor with ClearSight-Acumen finger cuff device.
89028708|NCT06101290|Experimental|Ablative local therapy|Stereotactic ablative radiotherapy (SABR) or interventional radiology (IR) ablation therapy
89028709|NCT06100549||16 Healthy people|The volunteers will be healthy men and women aged 18 to 65 with a BMI between 18.5 and 30 kg/m2. Volunteers will provide a single stool sample to compare 16S rRNA gene sequencing results for gut microbiota between faeces processed from standard stool sample and those collected by the collection device (EXTEL HEMO AUTO MC Collection Picker) used in the Scottish Bowel Screening Programme.
89028710|NCT06100549||100 anonymised qFIT samples|To determine whether our carefully controlled conditions are replicated in the NHS setting, one hundred anonymised qFIT samples will be obtained from Chemical Pathology Aberdeen Royal Infirmary under NHS Grampian Biorepository ethical approval. Extracted DNA will be quantified by Qubit and run on an agarose gel to determine the intact nature of the DNA.
89569919|NCT02448771|Experimental|Palbociclib in Combination with Bazedoxifene|"Palbociclib 125 mg Oral on days 1-21 per cycle Bazedoxifene 40 mg Oral on days 1-28 per cycle~One cycle is 28 days."
89028712|NCT06097156||Healthy donors|Participants who are in good health and without history of cancer disease
89569920|NCT02504541|Experimental|Testosterone enanthate auto-injector|Testosterone enanthate 50 mg / 75 mg / 100 mg administered subcutaneously once each week with possible titration to a higher or lower dose at scheduled intervals during study.
89569921|NCT04924257|Experimental|Intranasal Esketamine|
89569922|NCT04924257|Active Comparator|ECT|
89569923|NCT04924179|Experimental|Tislelizumab plus Fruquintinib and SBRT|
89569924|NCT04975945|Experimental|Local|Participants will receive single-time intra-operative intra-dermal ceftriaxone (15-20mg/kg diluted in 10 ml normal saline)
89569925|NCT04975945|Active Comparator|Parenteral|Participants will receive parenteral ceftriaxone (15-20mg/kg) for prolonged duration as per local protocol
89569926|NCT03053479|Experimental|Laparoscopic sacrocolpopexy|Laparoscopic sacrocolpopexy will be performed in the following way: Identification of the promontory, dissection of the peritoneum above the promontory and preparation of the ligamentum longitudinale anterior, peritoneum dissection, dissection of the vesicovaginal septum up to the bladder neck, dissection of the rectovaginal septum towards the perineum, application of Y mesh, fixation to the vaginal apex using non-absorbable sutures, and for anterior and posterior vaginal wall absorbable sutures. Fixation of the upper mesh arm to the ligamentum longitudinale anterior using non-absorbable suture, following with complete peritoneum closure above the mesh. The procedure could include salpingo-oophorectomy, supracervical hysterectomy or total hysterectomy (concomitant procedures are not exclusion criteria).
89569927|NCT03053479|Experimental|Transvaginal mesh procedure|Hydrodissection of the anterior vaginal wall, midline anterior colporrhaphy, preparation beyond the endopelvic fascia, mesh kit with bilateral fixation to sacrospinous ligaments should be used. The procedure could include salpingo-oophorectomy, total hysterectomy and posterior vaginal wall repair (concomitant procedures are not exclusion criteria).
89569928|NCT03053479|Experimental|Amreich-Richter procedure:|At least unilateral fixation with non-absorbable suture to sacrospinous ligament (fixation could be performed from the anterior approach). At the time of anterior vaginal wall repair or traditional posterior approach, it is possible to use a device for stich fixation (for example Capio, I- stitch etc). The procedure could include salpingo-oophorectomy, total hysterectomy and posterior vaginal wall repair (concomitant procedures are not exclusion criteria).
89569929|NCT03034603|Experimental|Nutri-jelly with PEITC|Continuous intake of 200 g Nutri-jelly with 20 mg PEITC per day, five days per week for 3 months.
89028713|NCT06097156||Metastatic Breast Cancer patients|Metastatic breast cancer category is based on the definition of the European Society of Medical Oncology and is defined as disease spread to other parts of the body, such as bones, liver or lungs (also called stage IV). Tumours at distant sites are called metastases.
89028714|NCT06095687|Active Comparator|Mindfulness Meditation|"Condition 1, Mindfulness Meditation (MM): The MM recording will be adapted from Day (2017). It will first instruct the listener to anchor attention on the breath while being mindfully aware of any physical sensations that arise throughout the body. The listener is then encouraged to explore sensations with non-judgmental attentiveness, without attempts to change the sensation in any way. This will implicitly provide training in mindful acceptance. Finally, the listener is instructed to simply label any thinking that arises as thinking, before returning to the object of the meditation."
89208963|NCT02553278|Experimental|Treatment with Contour I V3 device|"One treatment will be performed by Contour I V3 device on one randomized abdominal subarea, while the other abdominal subarea will not be treated and will serve as a control. Biopsies from treated and untreated subareas will be harvested during abdominoplasty and cultured. Two histology samples, for each subject, will be obtained during the abdominoplasty surgery. The arm is divided to 6 sub-groups, where each Sub-group contains up to 2 subjects as follows:~Sub-group 1: Surgery immediately after treatment Sub-group 2: Surgery 10 days after treatment Sub-group 3: Surgery 20 days after treatment Sub-group 4: Surgery 30 days after treatment Sub-group 5: Surgery 60 days after treatment Sub-group 6: Surgery 90 days after treatment"
89208964|NCT00613938|Placebo Comparator|004|placebo 1 capsule q4-6 hrs for 3 days
89208965|NCT00613938|Active Comparator|003|oxycodone 10mg capsule q4-6 hrs for 3 days
89208966|NCT00613938|Experimental|001|Tapentadol (CG5503) 50mg capsule q4-6 hrs for 3 days
89569930|NCT03034603|Placebo Comparator|Nutri-jelly|Continuous intake of 200 g Nutri-jelly per day, five days per week for 3 months.
89208967|NCT00613938|Experimental|002|Tapentadol (CG5503) 75mg capsule q4-6 hrs for 3 days
89208968|NCT00978861|Experimental|whitening|30% Hydrogen peroxide
89569931|NCT03063307|Active Comparator|Atraumatic Restorative Treatment|
89569932|NCT03063307|Experimental|Silver Diamine Fluoride|
89569933|NCT02970565|Experimental|Nutrition and Play Intervention|Mother-child dyads who are enrolled into the study will be randomly assigned to the Nutrition and Play Intervention group.
89569934|NCT02970565|Experimental|Family Nurture Intervention|Mother-child dyads who are enrolled into the study will be randomly assigned to the Family Nurture Intervention group.
89569935|NCT04434313|Experimental|Delivery of iStride™ device gait treatment using telemedicine|"Treatment with the gait device will be adapted to remote delivery using the telemedicine platform. Participants and caregivers will be guided through an adapted treatment protocol remotely by physical therapists. Training will include platform navigation, device instruction, treatment guidelines, safety precautions, and assessment performance. Understanding will be verified through a caregiver quiz.~Gait patterns will be monitored before, during, and after treatment using gait sensors and outcome measures. Assessments include the 10-Meter Walk Test, Six Minute Walk Test, Timed Up and Go Test, Geriatric Depression Scale, Activities-Specific Balance Confidence Scale, and Stroke Impact Scale-16. Treatment will consist of 12 sessions of walking on the device for a goal of 30 minutes per session. Assessments will be repeated one-week, one-month, three-months, six-months, and 12-months after treatment. Feasibility and safety of the delivery method will be measured throughout the trial."
89569936|NCT04874935|Active Comparator|Lansoprazole arm|33 patients who will receive neoadjuvant chemotherapy and lansoprazole 60 mg twice daily four days before starting chemotherapy regimen and then the same dose will be used during chemotherapy cycles
89569937|NCT04874935|Placebo Comparator|Placebo arm|33 patients who will receive neoadjuvant chemotherapy and placebo capsules.
89569938|NCT04975477||Training cohort|A cohort was used to develop the novel score for predicting liver decompensation
89569939|NCT04975477||Validation cohort|A cohort was used to validate the performance of novel score for predicting liver decompensation
89569940|NCT04975477||Exploratory cohort|A cohort was used to study the diagnostic value of novel score for clinically significant portal hypertension
89569941|NCT03061591|Active Comparator|Wholistic Turmeric capsules|"Oral capsules of wholistic Turmeric capsules (Pukka herbs) (each capsule 100 mg curcumin) divided twice daily, or an identical placebo in 2 divided doses daily all taken before meals.~Pukka's Wholistic Turmeric"
89569942|NCT03061591|Placebo Comparator|Placebo|Identical placebo capsules
89569943|NCT02961361|Experimental|Group Control|40 ml 0.375% ropivacaine was injected after Locating brachial plexus.
89569944|NCT02961361|Experimental|Group Dexmedetomidine|40 ml 0.375% ropivacaine mixed with dexmedetomidine was injected after Locating brachial plexus.
89569945|NCT04974229||acute non-specific low back pain|patients with acute low back pain of (< 6 weeks) were consecutively included with or without radiating pain, aged 18 to 60 years with a pain-free episode for at least 3 months before the onset of their current back pain. They were also required to be able to read and understand the Dutch language.
89569946|NCT04974931|Active Comparator|Patients applied with PREVENA system|This arm relates to the group of participants applied with PREVANA system post reversal of colostomy/ileostomy.
89208969|NCT00805064|Active Comparator|ischemic CRVO|treatment was applied to this entity
89208970|NCT00805064|Active Comparator|non ischemic CRVO|treatment was applied to this entity
89208971|NCT00805064|Active Comparator|BRVO|treatment was applied to this entity
89208972|NCT04007445|Active Comparator|Formally Directed Group (Exercise Group)|A group performing a 12 - week guided exercise program at an accessible Community Health and Wellness Center
89208973|NCT04007445|Placebo Comparator|Self-Directed Group (Control Group)|A group receiving educational information about physical activity and exercise at home and then self-directing a 12 - week exercise program on their own.
89208974|NCT00881244|Experimental|1|AS1411
89208975|NCT00655928|Experimental|N-acetylcysteine|Participant received N-acetylcysteine 240mg/kg in 1 litre 0.9% saline intravenous over 12 hours pre-operatively
89208976|NCT00655928|Placebo Comparator|Placebo|Participant received 0.9% saline 1 litre intravenous over 12 hours pre-operatively
89208977|NCT04038762|Active Comparator|Conventional nasal intubation|Passage of an endotracheal tube via the nare followed by video laryngoscopy-assisted passage through the glottis, with or without the aid of Magill forceps
89208978|NCT04038762|Experimental|Nasotracheal Intubation with cuff inflation-deflation method|Nasotracheal intubation placed with video laryngoscopy assistance, via the tracheal tube cuff inflation-deflation method with or without the aid of Magill forceps
89208979|NCT00805220|Active Comparator|1|Regular overground walking without poles
89208980|NCT00805220|Experimental|2|Nordic Walking
89208981|NCT00798200|Other|Exercise|All participants will take part in a supervised, structured, exercise program
89208982|NCT00873756|Experimental|A|
89208983|NCT00798278|Experimental|Urokinase|urokinase infusion for 3 days
89208984|NCT00798278|Active Comparator|Thoracoscopic|Video-Assisted Thoracoscopic
89569947|NCT04974931|No Intervention|Patients applied with conventional dressings|This arm relates to the group of participants applied with conventional dressings post reversal of colostomy/ileostomy
88811061|NCT04583501|Experimental|Omalizumab|Ex vivo exposure of excised human surgical polyp tissue to omalizumab.
88811062|NCT04580771|Experimental|Treatment (radiation therapy, cisplatin, PDS0101)|Patients undergo radiation therapy over 1 hour 5 days per week (Monday-Friday) for 5-7 weeks and receive cisplatin IV over 4 hours QW during the 5 weeks of radiation therapy in the absence of disease progression and unacceptable toxicity. Patients also receive PDS0101 SC on days -10, 7, 28, 49, and 170 in the absence of disease progression or unacceptable toxicity.
88811063|NCT04578834|Experimental|LNP023 200mg b.i.d|
88811064|NCT04578834|Placebo Comparator|Placebo to LNP023 200mg b.i.d|
88811065|NCT04577599|Other|Single Arm|Mobile Low-dose Computed Tomography (LDCT) Screening
88811066|NCT04568486|Other|Rural-dwelling older adults (seed) and Key players (alter|Rural-dwelling older adults will be interviewed to map their social network structure, determine the types of social support provided by members of their social network, and identify key players within these networks. This group will be paired with their key players (identified during interviews) to receive the diabetes education. The pair complete the intervention as a dyad.
88811067|NCT04548180||TBI BIAFAC|100 TBI subjects with BIAFAC will be enrolled. No intervention
89569948|NCT04975165|Experimental|Staged total knee arthroplasty|Staged replacement of both knees in two separate surgeries.
89569949|NCT04975165|Experimental|Simultaneous total knee arthroplasty|Simultaneous replacement of both knees in a single surgery.
89569950|NCT04974073|No Intervention|control group|with traditional western medicine treatment based on underlined disease
89569951|NCT04974073|Experimental|PHY606|PHY606 7.5gm BID for 3 months
89569952|NCT04974073|Other|Healthy group|PHY606 7.5gm BID for 2 days
89569953|NCT04975087||Patients group|Individuals with primary Sjögren's syndrome
89569954|NCT04973995||Patients with shoulder pain who received ER lag sign|
88811068|NCT04544046|Active Comparator|Usual Care|Participants assigned to the standard care arm will receive standard oncology care and attend regular clinic visits. Participants on the standard care arm will complete questionnaires from baseline up to 6 months following enrollment.
89569955|NCT04973995||Patients with shoulder pain who received External rotation resistence strength test|
89569956|NCT04973995||Patients with shoulder pain who received Patte's test|
89569957|NCT04973995||Patients with shoulder pain who received Errsair test|
89569958|NCT04973995||Patients with shoulder pain who received speed test|
89569959|NCT04973995||Patients with shoulder pain who received Yergason test|
89569960|NCT04973995||Patients with shoulder pain who received backward traction test|
89569961|NCT04973995||Patients with shoulder pain who received Cui's test|
89569962|NCT04974853|Experimental|Ayurveda Formulation|Patients with hypercholesterolemia treated with Ayurveda formulation, Cardio-Complement
89569963|NCT04973839|Experimental|Video optimizing expectations before PMR (unguided)|watching a video aiming to optimize participants' expectations before undergoing a single PMR session without personal support of the experimenter (unguided)
89569964|NCT04973839|Experimental|Video optimizing expectations before PMR (guided)|watching a video aiming to optimize participants' expectations before undergoing a single PMR session with the personal support of the experimenter (guided)
89569965|NCT04973839|Active Comparator|Neutral video before PMR (unguided)|watching a neutral video (not aiming to optimize participants' expectations) before undergoing a single PMR session without personal support of the experimenter (unguided),
89569966|NCT04973839|Active Comparator|Neutral video before PMR (guided)|watching a neutral video (not aiming to optimize participants' expectations) before undergoing a single PMR session with the personal support of the experimenter (guided)
89569967|NCT02426281|Experimental|nab-paclitaxel in combination with gemcitabine|nab-paclitaxel in combination with gemcitabine nab- paclitaxel 125mg/m2 in combination with gemcitabine 1000mg/m2 D1, 8 15 every 4 weeks.
89569968|NCT02448537|Experimental|PM01183 and Doxorubicin|"Anthracycline-naïve patients will receive combination of PM01183 and Doxorubicin per cycle.~PM01183 predetermined dose daily via IV per cycle~Doxorubicin predetermined dose daily via IV per cycle"
89569969|NCT02448537|Experimental|PM01183 and Gemcitabine|"Prior anthracycline exposure and without prior gemcitabine exposure~PM01183 predetermined dose given twice via IV per cycle~Gemcitabine predetermined dose given twice via IV per cycle"
89569970|NCT02448537|Experimental|Single Agent PM01183|"Patients who have received at least both prior anthracycline and prior gemcitabine~-PM01183 predetermined dose once via IV per cycle"
88811069|NCT04544046|Experimental|Supportive Oncology Care at Home|"The research study procedures include:~Remote monitoring of symptoms, vitals, and body weight~Questionnaires asking about demographic information (e.g. gender, ethnicity, income) and experience with cancer (e.g. quality of life, symptoms)~Data collection from medical record"
88811070|NCT04542330|Active Comparator|BCG-Denmark|"Participants that are randomized to the active comparator arm will receive an adult 0.1 ml dose of BCG vaccine (BCG-Denmark, AJ Vaccines) in the skin covering the left upper deltoid muscle.~Each 0.1 ml dose of vaccine contains between 200,000 to 800,000 colony forming units of the live attenuated strain of Mycobacterium bovis (BCG), Danish strain 1331."
88811071|NCT04542330|Placebo Comparator|Control|Participants randomized to the control group will receive one 0.1 ml dose sterile 0.9 % NaCl by intradermal injection in the left deltoid region.
88811072|NCT04527991|Experimental|Sacituzumab Govitecan-hziy|Participants will receive 10 mg/kg of sacituzumab govitecan-hziy intravenously on Day 1 and Day 8 of 21-day cycles.
88811073|NCT04527991|Active Comparator|Treatment of Physician's Choice|Participants will have the choice of receiving paclitaxel, docetaxel, or vinflunine at standard of care (SOC) doses of 175, 75, and 320 mg/m^2 respectively, every 3 weeks on Day 1 of 21-day cycles.
88811074|NCT04522076||COVID-19 with pneumonia|patients with positive COVID 19 by PCR and pneumonia by CT
88811075|NCT04522076||COVID-19 without pneumonia|patients with positive COVID 19 by PCR and absent of pneumonia by CT
88811076|NCT04522076||Patients with pneumonia and without COVID 19|patients with negative COVID 19 by PCR and with pneumonia by CT
88811077|NCT04522076||Patients without pneumonia and COVID 19|Patients with suspected COVID-19 and/or pneumonia at the pre-hospital stage that were not confirmed in hospital
88811078|NCT04496063|Experimental|Group 1 Ustekinumab|Intravenous induction (6mg/kg) followed by Ustekinumab subcutaneous 90mg every 8 weeks
88811079|NCT04496063|Placebo Comparator|Group 2 Placebo|Placebo intravenous followed by Placebo subcutaneous every 8 weeks
88811080|NCT04493060|Experimental|Treatment (niraparib, dostarlimab)|Patients receive niraparib PO QD on days 1-21. Patients also receive dostarlimab IV over 30 minutes on day 1 Q3W for cycles 1-4 and Q6W for subsequent cycles. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
88811081|NCT04489238||Young onset Colorectal Cancer Participants|(Stool collection on newly diagnosed patients in this cohort) Participants will include patients under the age of 50 who are diagnosed with colorectal adenocarcinoma.
88811082|NCT04489238||Average onset Colorectal Cancer Participants|"(Stool collection cohort only) 166 colorectal cancer patients 50 year-old or older will serve as controls.~Stool collection cohort only."
88811083|NCT04445805|Active Comparator|CBTI Treatment Group|Telemedicine Cognitive Behavioral Therapy for Insomnia (CBTI)
89569971|NCT03062371|Experimental|Playgroup Intervention|The approach of the playgroup is to promote healthy family play routines with an emphasis on child and family well-being. The intervention types for playgroup sessions included the occupation of play, activities to promote play and participation, educating caregivers through modeling and coaching, advocating for the child and family, and the use of group sessions. Specific playgroup strategies included a predictable routine, following the child's lead, imitating the child, modeling of new behaviors, and scaffolding play - within both the social and physical environment. When developing activities, play objects that families have at home and are easily obtained were used and positioned intentionally with respect to the child-caregiver dyad and the group as a whole.
89569972|NCT03062683||Non-convulsive syncope patients|Patients with a non-convulsive syncope triggered by a tilting table examination and whose serum lactate, prolactin and creatine kinase conc. in blood samples had been measured after the event.
89569973|NCT03062683||Convulsive syncope patients|Patients with a convulsive syncope triggered by a tilting table examination and whose serum lactate, prolactin and creatine kinase conc. in blood samples had been measured after the event.
89569974|NCT03060265|Active Comparator|Paracetamol|Paracetamol Braun Germany 1 gram in 100ml normal saline, one dose IV
89569975|NCT03060265|Placebo Comparator|Placebo|100ml normal saline, one dose IV
89569976|NCT02504151|Experimental|Cannabidiol, then Placebo|The subject will receive treatment with cannabidiol (CBD)(800mg/day) for four weeks, followed by a two week washout period, followed by four weeks of placebo.
89569977|NCT02504151|Experimental|Placebo, then Cannabidiol|The subject will receive placebo for four weeks, followed by a two week washout period, followed by four weeks of treatment with cannabidiol (CBD)(800mg/day).
89569978|NCT03060109||Suspected traumatic brain injury|
89569979|NCT02448381|Active Comparator|SGX301|"Three treatment cycles, each six (6) weeks followed by a two (2) week rest period. Treatment uses 0.25% SGX301 in USP Hydrophilic Ointment (or placebo) applied twice per week followed by fluorescent light therapy.~Cycle 1: Patients randomized 2:1 to active/placebo will have three (3) index lesions treated and evaluated.~Cycle 2: All patients will have three (3) index lesions treated and evaluated with active SGX301 ointment.~Cycle 3: All patients will be given the opportunity to enter an open-label cycle of active SGX301 ointment treatment for all lesions (index and non-index)."
89569980|NCT02448381|Placebo Comparator|Placebo|Placebo ointment is indistinguishable from ointment containing active SGX301 and is only used in Cycle 1. Treatment paradigm (ointment application and fluorescent light therapy) is identical.
89569981|NCT02448225|Experimental|Diagnostic (18F-FDG PET/CT, 18F-FSPG PET/CT)|Patients undergo 18F-FDG PET/CT scan per standard of care. Within 15 working days, patients also undergo 18F-FSPG PET scan over 60 minutes followed by an 18F-FSPG PET/CT scan over 30 minutes.
89569982|NCT02503215|Experimental|Compression Stockings|Patients will wear graduated lower limb compression stockings for a week. The investigators will evaluate if such procedure will cause better sleep performance
89569983|NCT02447991|Placebo Comparator|Placebo|During the Treatment Phase, three placebo capsules will be administered to each subject. One capsule will be taken during one acute episode, until three episodes are treated with the study drug.
89569984|NCT02447991|Experimental|Rizatriptan|During the Treatment Phase, three Rizatriptan capsules will be administered to each subject. One capsule will be taken during one acute episode, until three episodes are treated with the study drug.
89569985|NCT02586155|Experimental|High-Intensity statin therapy+RVX000222|Daily dose 100 mg capsule b.i.d. with high-intensity statin therapy (atorvastatin or rosuvastatin)
89569986|NCT02586155|Active Comparator|High-Intensity statin therapy+Placebo|Placebo (for RVX000222 100 mg capsule) b.i.d. with high-intensity statin therapy (atorvastatin or rosuvastatin)
89569987|NCT05697731||obese|Vidiac score Mallampati score upper lip bite test Thyromental distance Mandible ramus length Mouth opening distance
89569988|NCT05697731||non-obese|Vidiac score Mallampati score upper lip bite test Thyromental distance Mandible ramus length Mouth opening distance
89569989|NCT02446743|Experimental|Group 3B|Subjects who received a third dose booster of rMenB+OMV NZ at 4 to 7.5 years after the last dose received during studies V72P10 (NCT00661713) or V72_41(NCT0142384), and had blood collected at baseline and at 3, 7 and 30 days after the third dose booster.
88811084|NCT04445805|Experimental|Perinatal-enhanced behavioral therapy for insomnia|Telemedicine Mindfulness Based Therapy for Insomnia (MBTI)
88811085|NCT04445805|Placebo Comparator|Attention Control Treatment Group|Minimal intervention control
88811086|NCT04440566|Experimental|Systemic lupus erythematosus (SLE)|
88811087|NCT04436640|Experimental|Bimekizumab|Subjects will receive bimekizumab throughout the Treatment Period.
88811088|NCT04434066|Experimental|Abdominal Morcellation|Abdominal morcellation will occur following completion of the hysterectomy. Route of incision will be either suprapubic or umbilical incision - based on surgeon preferences. All steps and instruments have been standardized for abdominal morcellation.
89569990|NCT02446743|Active Comparator|Group B_0_1|Subjects who received two doses of rMenB+OMV NZ at a 0 and 1 month schedule and had blood collected at baseline, 30 days after the first dose and 3 or 7, and 30 days after the second dose.
89569991|NCT02586077|Experimental|Exparel|Patients will receive a single shot popliteal block (standard of care) and then undergo their standardized procedure. Patients will then receive 20cc Exparel and 10cc of normal saline at the conclusion of the case.
88811089|NCT04434066|Experimental|Vaginal Morcellation|Vaginal morcellation will occur following completion of the hysterectomy. All steps and instruments have been standardized for vaginal morcellation.
88811090|NCT04432376|Active Comparator|Active treatment arm|Treatment with miconazole 2% oil, 5 drops into each ear twice daily for 14 consecutive days
88811091|NCT04432376|Placebo Comparator|Placebo treatment arm|Treatment with the vehicle oil, placebo, 5 drops into each ear twice daily for 14 consecutive days
89569992|NCT05536661|Experimental|Study group|Preservative free Hyaluronic acid 0.15% artificial tear instilled in both eyes 4 times daily for 3 days
89569993|NCT05536661|No Intervention|Control group|No artificial tear instilation
89569994|NCT03241121|Experimental|Time restricted feeding|For those in the intervention phase (Part 2)
89569995|NCT03241121|Active Comparator|Regular dietary advices|For those in the intervention phase (Part 2)
89569996|NCT05536583|Experimental|PCOS group|Obese Patients with PCOS underwent LSG
89569997|NCT05536583|Active Comparator|Control group|Sample obese patients without PCOS underwent LSG
89569998|NCT05536505|Experimental|MRD Positivity Post Operation|If MRD confirmed Positivity at either of the two timepoints (Time point 1: blood draw from the 3rd day to 7th day post operation. Time point 2: blood draw on the 28th day post operation), patients would receive icotinib until MRD turned Negativity. During MRD monitoring, icotinib would rechallenge
89569999|NCT05536505|No Intervention|MRD Negativity Post Operation|If MRD confirmed negativity at both of the two timepoints (Time point 1: blood draw from the 3rd day to 7th day post operation. Time point 2: blood draw on the 28th day post operation), patients would receive ctDNA MRD monitoring.
89570000|NCT05536271|Experimental|Acute coronary syndrome patients|Acute coronary syndrome patients prescribed with bisoprolol
89570001|NCT05536193|Experimental|Topical Metformin Emulgel and salicylic acid|
89570002|NCT05535881|Experimental|Experimental Group|
89570003|NCT05535881|No Intervention|Waitlist Control Group|
89570004|NCT04425707|Experimental|A ivermectin alone|ivermectin will be administarted alone to COVID 19 patients
89570005|NCT04425707|Experimental|B standard care alone|standard care will be administarted alone
89570006|NCT04425707|Active Comparator|C ivermectin added to standard of care|ivermectin will be administarted in adition to standard care
89570007|NCT05697185|Experimental|the evolocumab plus statin therapy|Patients with AIS are treated with atorvastatin (40mg) daily and evolocumab (420 mg) every months throughout the study period
89570008|NCT05697185|No Intervention|the statin alone therapy|Patients with AIS are treated with atorvastatin (40mg) daily throughout the study period.
89570009|NCT02583425|Experimental|DFN-11|DFN-11 Injection upon occurrence of migraine
89570010|NCT05535803|Experimental|Patients with tracheal/laryngeal stenosis receiving standard treatment and stem cells|Patients with tracheal/laryngeal stenosis receiving standard surgical treatment and mesenchymal stem cells
89570011|NCT05535803|Active Comparator|Patients with tracheal/laryngeal stenosis receiving standard treatment|Patients with tracheal/laryngeal stenosis receiving standard surgical treatment
89570012|NCT05511233|No Intervention|CONTROL GROUP|Control Group: Electronic health records of the newborns who do not receive breast milk in the first 48 hours of the postoperative period will be in the control group.
89570013|NCT05511233|Experimental|ERAS GROUP|ERAS Group: Electronic health records of the newborns who had breastmilk within the first 48 hours in the postoperative period will be in the ERAS group.
89570014|NCT02581163||Participants with HCV genotype 1 or 4|Ombitasvir/paritaprevir/ritonavir (two 12.5 mg/75 mg/50 mg co-formulated tablets once daily); ± dasabuvir (tablet; 250 mg twice daily); ± weight-based ribavirin (tablet; 1000 or 1200 mg divided twice a day) up to 24 weeks
89570015|NCT05535179|Experimental|treatment group|
88970228|NCT04480736|Experimental|JNJ-64281802 High dose|Participants will receive high dose of JNJ-64281802 orally.
88970229|NCT04480736|Experimental|JNJ-64281802 Medium dose|Participants will receive medium dose of JNJ-64281802 orally.
88970230|NCT04480736|Experimental|JNJ-64281802 Low dose|Participants will receive low dose of JNJ-64281802 orally.
88970231|NCT04480736|Experimental|JNJ-64281802 Dosing Regimen X|Participants will receive dosing regimen X of JNJ-64281802 orally.
89570016|NCT05535179|No Intervention|control group|
89570017|NCT05462405|Experimental|Experimental group|All subjects enrolled will be in the same experimental group.
89570018|NCT05679089||Cancer Arm|Participants with newly diagnosed intracranial malignant tumors, from whom blood samples will be collected.
89570019|NCT05679089||Benign Arm|Participants with newly diagnosed benign central nervous system disorders, from whom blood samples will be collected.
89570020|NCT05679089||Healthy arm|Participants without known presence of malignancies or certain benign diseases, from whom blood samples will be collected.
89570021|NCT05591261|Experimental|ePREP condition|The ePREP program is the online version of the Prevention and Relationship Enhancement Program. It consists of 6 self-directed online sessions and accompanying homework and brief coach calls.
89570022|NCT05589545|Experimental|Intervention|Prosthetic full-arch rehabilitation using a PEEK-acrylic resin prosthesis
89570023|NCT01938547|Experimental|clevidipine|"An initial clevidipine IV infusion dose for the adolescent cohort has been specified per protocol. The initial dose for each of the subsequent age cohorts will be modified if necessary, based on the recommendation of the Data and Safety Monitoring Board (DSMB).~Following the initial dose, clevidipine will be up-titrated every 1.5 minutes, according to participant need, to achieve a systolic blood pressure (SBP) within the pre-specified SBP target range. Doses may be increased by less than doubling, and the time between dose adjustments may be lengthened, as the target blood pressure is approached. The infusion rate may be maintained for up to 96 hours, once the participant's SBP is within the target range, and titrated as necessary to maintain blood pressure within the range."
88970232|NCT04480736|Experimental|JNJ-64281802 Dosing Regimen Y|Participants will receive dosing regimen Y of JNJ-64281802 orally.
88970233|NCT04480736|Experimental|JNJ-64281802 Dosing Regimen Z|Participants will receive dosing regimen Z of JNJ-64281802 orally.
88970234|NCT04479761|Experimental|Virtual Reality|Participants will be wearing a virtual reality headset and observing 2 types of scenes: abstract (a display of stars) or contextual (a subway station).
88970235|NCT04474678|Other|All Patients|Since this is a single-group study, all patients are within the same arm
88970236|NCT04459065|Experimental|Low dose intermediate time|Participants will receive an i.v. infusion of 50 mg IRDye800CW-nimotuzumab. Participants will undergo lung cancer resection surgery 4-6 days after infusion. Vitals, blood sample and urine sample will be collected before infusion for a baseline. Blood and vitals will be taken post infusion. Blood and urine samples will be collected on the day of surgery. Participants will be followed up for any adverse event until day 30 post administration
89570024|NCT05685485||Standard Implantation|Standard Implantation
89570025|NCT05685485||Tied off Tube|Tied off Tube
89570026|NCT05695625|Active Comparator|Group ESPB|Spinal anesthesia + bilateral ESPB (total of 40 ml, %0.5 bupivacaine)
89570027|NCT05695625|Active Comparator|Group SA|Only spinal anesthesia
89570028|NCT05695547|No Intervention|Standard education|Patients will be educated about the procedure in a standard way by a doctor and a nurse
89570029|NCT05695547|Experimental|VR Education|Patients will be educated with the use of virtual reality
89570030|NCT05586737|Experimental|rituximab|Controlled ovarian hyperstimulation will be performed before and four months after two infusions of 1-gram rituximab (Mabthera®).
89570031|NCT05678933|Experimental|AC-CHOP|Azacitidine administered IV at day 1-5 and Chidamide admistered twice a week for two weeks in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP)
89208985|NCT00873834|Experimental|Fluoxetine arm|"Treatment with fluoxetine in an oral solution will be given at 0.25mg/kg day during 2 weeks and at 0.4mg/kg day during 16 weeks.~A progressive decreased of dosage on a period of 4 weeks to 0.25mg/kg/day (2 weeks) and 0.10mg/kg/day(2 weeks) will be realized"
89208986|NCT00873834|Placebo Comparator|placebo arm|Placebo comparator. The packaging of study drug and placebo will be performed according to applicable regulatory requirements in the same packaging. An oral solution will be administrated.
89570032|NCT05678933|Active Comparator|CHOP|CHOP administered every 3 weeks for 6 cycles.
89570033|NCT05678855|No Intervention|control group|Control Group: The topics of the course were prepared by the researcher using PowerPoint. Before starting the courses, it is ensured that all students attended the course using the Microsoft Teams program. The contents prepared were presented to the students in the control group with the traditional education method on a weekly basis.
88970237|NCT04459065|Experimental|High dose intermediate time|Participants will receive an i.v. infusion of 100 mg IRDye800CW-nimotuzumab. Participants will undergo lung cancer resection surgery 4-6 days after infusion. Vitals, blood sample and urine sample will be collected before infusion for a baseline. Blood and vitals will be taken post infusion. Blood and urine samples will be collected on the day of surgery. Participants will be followed up for any adverse event until day 30 post administration
88970238|NCT04459065|Experimental|Optimal dose early time|Participants will receive an i.v. infusion of 50 or 100 mg IRDye800CW-nimotuzumab (depending on results from cohorts 1 and 2). Participants will undergo lung cancer resection surgery 1-3 days after infusion. Vitals, blood sample and urine sample will be collected before infusion for a baseline. Blood and vitals will be taken post infusion. Blood and urine samples will be collected on the day of surgery. Participants will be followed up for any adverse event until day 30 post administration
88970239|NCT04459065|Experimental|Optimal dose late time|Participants will receive an i.v. infusion of 50 or 100 mg IRDye800CW-nimotuzumab (depending on cohorts 1 and 2). Participants will undergo lung cancer resection surgery 7+ days after infusion. Vitals, blood sample and urine sample will be collected before infusion for a baseline. Blood and vitals will be taken post infusion. Blood and urine samples will be collected on the day of surgery. Participants will be followed up for any adverse event until day 30 post administration
88970240|NCT04452305|Experimental|Spermatogonial Stem Cell Transplant & Testicular Tissue Graft|Stem cell transplantation Testicular tissue grafting
88970241|NCT04441060|Experimental|distress intervention subject group|Distress intervention program will be developed, and applied to the subject group, and they will be assessed before and after the intervention program with several tools.
88970242|NCT04441060|No Intervention|distress intervention control group|No intervention will be applied to the control group. They will be assessed before and after the intervention program with same tools with subject group.
88970243|NCT04436289|No Intervention|PLWH care-as-usual (CAU) study arm|Participants living with HIV will receive standard discharge care as provided at Tshepong Hospital during the study. This currently includes discharge counseling from a trained discharge counselor and will be provided with a follow-up return date (usually two weeks post-hospital). Discharge counseling will include a review of discharge medications and instructions regarding follow-up care visits.
88970244|NCT04436289|Experimental|PLWH Home Link study arm|"The Home Link intervention will be delivered by a home visit team including a primary care nurse and counselor trained in patient-centered counseling. A rotating hospital-based doctor will be available for pre-home visit clinical file review and post-visit discussion, via cell phone, for decision making and input on patient care during a household visit. We have termed this individual a discharge officer. The discharge officer will be a Tshepong clinician who is working in the hospital. Supporting Home Link is expected to take <30 minutes of the physician's time during the day. For study-specific concerns, the team will consult with a GCP-trained, PHRU research doctor based at Tshepong Hospital."
88970245|NCT04436289|No Intervention|PLWOH care-as-usual (CAU) study arm|Participants living without HIV will receive standard discharge care as provided at Tshepong Hospital during the study. This currently includes discharge counseling from a trained discharge counselor and will be provided with a follow-up return date (usually two weeks post-hospital). Discharge counseling will include a review of discharge medications and instructions regarding follow-up care visits.
89570034|NCT05678855|Experimental|experimental group|a) Experimental Group: First, the topics of the course were prepared by the researcher using multimedia tools. Before starting the courses, it is ensured that all students attended the course using the Microsoft Teams program. The contents prepared were presented to the students in the experimental group in an interactive way on a weekly basis.
89570035|NCT05357495|Experimental|frustration and control fMRI tasks|all subjects complete one scanning session with frustration induction and one scanning session with the control task.
89570036|NCT05678621|Experimental|ARM A: Stop immunoglobulin (Ig) and commence prophylactic oral antibiotics|"Once daily trimethoprim-sulfamethoxazole (co-trimoxazole) 160mg/800mg. Nb: Doxycycline 100mg daily as an alternative for participants with hypersensitivity to co-trimoxazole.~Duration: 12 months. Route: PO"
89570037|NCT05678621|Experimental|ARM B: Stop immunoglobulin (without prophylactic antibiotics)|"Participants will be prescribed amoxycillin/clavulanic acid 1750-2000mg/250mg and ciprofloxacin 750 mg, to keep at home for initial use if symptoms of infection develop, with immediate review by their treating clinical team, or nearest emergency department or medical practitioner with phone contact to treating team if most practical.~Nb: clindamycin 600 mg is permitted as an alternative to amoxycillin/clavulanic acid for participants with hypersensitivity to penicillin.~Duration: 12 months. Route: PO"
89570038|NCT05678621|Active Comparator|ARM C: Continue immunoglobulin|"Participants will continue treatment with their current Ig replacement schedule. Participants will receive either Intravenous Ig (IVIg) or Subcutaneous Ig (SCIg)~IVIg: Participants will be treated in accordance with the Criteria for Clinical Use of Immunoglobulin in Australia. Monthly (every 4 weeks ± 1 week) dose of 0.4g/kg, modified to achieve an Immunoglobulin G (IgG) trough level of at least lower limit of age-specific serum IgG reference range. In the first month of therapy, if IgG <4g/L then an additional (loading) dose of 0.4g/kg may be given at the clinician's discretion.~SCIg: Subcutaneous immunoglobulin weekly may be used in patients who meet local criteria for home based self-administration in centres with established SCIg programs. A loading IVIg dose may be given in the first month if required. Thereafter, dosing at 100mg/kg/week, modified to achieve an IgG steady state level of at least the lower limit of the serum reference range.~Duration: 12 months."
89570039|NCT05338073||Cancer patients|Patients who have primary solid cancer that is being surgically resected, biopsied, or drained (via malignant pleural effusion) and are 18 years of age or older.
89570040|NCT05334953|Experimental|Experimental: ESWT(Extracorporeal Shock Wave Therapy)|Group 1 (n = 17) will be given two times a week, total 5 sessions of ESWT + home exercise program
89570041|NCT05334953|Experimental|Phonophoresis|Group 2 ( n=17) will be given five times a week, total 10 sessions of diclofenac phonophoresis + home exercise program
89570042|NCT05334953|Experimental|Ultrasound therapy|Group 2 (n=17) will be given five times a week, total 10 sessions of ultrasound therapy+ home exercise program
89570043|NCT05334953|Other|Control goup|Group 4 ( n=17) will be given home exercise program
89570044|NCT05240729|Active Comparator|Retroclavicular|Retroclavicular approach to the infraclavicular region, the probe will be placed below and perpendicular to the clavicle, in a paramedian sagittal plane, medial to the coracoid process, to obtain a short-axis view of the cords of the brachial plexus and the axillary vessels. The needle will then be inserted in the supraclavicular fossa, approximately 1 cm posteriorly to the clavicle, and advanced in plane and strictly parallel to the ultrasound transducer. After passing the initial blind zone of about 2 cm caused by the acoustic shadow of the clavicle, the needle tip will be constantly seen, until it will be positioned posterior to the axillary artery.
88811092|NCT04432376|Other|Open-label treatment arm|Application of miconazole 2% oil, 5 drops into each ear twice daily for 14 consecutive days
88811093|NCT04430426|Experimental|Controlled Dietary Study|Participants will consume the controlled diet for five days and be administered an intravenous (IV) load of glycolate. Participants will provide urine and blood samples both before the glycolate load to establish baseline levels and after the glycolate load to measure oxalate levels afterwards.
88811094|NCT04412096|Experimental|Timolol 0.5%|To compare the variation in response to timolol between individuals
88811095|NCT04412096|Experimental|Latanoprost 0.005%|To compare the variation in response to latanoprost between individuals
88811096|NCT04409834|Experimental|Full-dose anticoagulation (FDAC)|"Unfractionated heparin (UFH) administered intravenously with a nomogram targeting an activated partial thromboplastin time (aPTT) of 1.5-2.5 times the control as per institutional therapeutic target for treatment of venous thrombotic events (VTE)~Enoxaparin 1 mg/kg administered subcutaneously (SC) every 12 hours~With or without anti-platelet therapy: Clopidogrel 300 mg administered once orally on the day of randomization, followed by 75 mg administered once daily on subsequent days"
88811097|NCT04409834|Active Comparator|Standard-dose prophylactic anticoagulation (SDPAC)|"Enoxaparin 40 mg administered subcutaneously (SC) once daily (reduce to 30 mg if creatinine clearance CrCl <30 ml/min)~Heparin 5,000 units administered subcutaneous three times daily~With or without anti-platelet therapy: Clopidogrel 300 mg administered once orally on the day of randomization, followed by 75 mg administered once daily on subsequent days"
88811098|NCT04369677||First-Episode Psychosis|Twenty individuals with FEP will complete a 24-hour continuous assessment of core body temperature using a CorTemp ingestible sensor (HQInc., Palmetto, FL).
88811099|NCT04369677||Healthy|Twenty age-matched individuals with no psychotic disorder will complete a 24-hour continuous assessment of core body temperature using a CorTemp ingestible sensor (HQInc., Palmetto, FL).
88811100|NCT04365023||1|Well-differentiated grade 3 gastrointestinal neuroendocrine tumors patients who receive first line platinum based chemotherapy
88811101|NCT04365023||2|Well-differentiated grade 3 gastrointestinal neuroendocrine tumors patients who receive receiving first line non-platinum chemotherapy
88811102|NCT04340076|Experimental|Dose reduction|Dose reduction by interval prolongation in 2 steps to a maximum decrease of 50% of the original dose when disease activity (PASI) and quality of life index (DLQI) remain low.
88811103|NCT04340076|Active Comparator|Normal dose|Patients will continue treatment with the normal/maintenance dose of the biologicals.
88811104|NCT04332211|Experimental|Pseudoephedrine Group|Patients randomized to pseudoephedrine prior to hyperbaric therapy
88811105|NCT04332211|Placebo Comparator|Placebo Group|Patients randomized to placebo prior to hyperbaric therapy
88811106|NCT04330716|Active Comparator|Group A: Standard genetic counseling|Will receive standard genetic counseling prior to genetic testing.
88811107|NCT04330716|Experimental|Group B: Educational video|Will watch a brief educational video that is approximately 8 minutes in length about the genetic testing process and what to expect prior to genetic testing.
88811108|NCT04320849||Patients with protocol identified RV Leads|Medtronic model 6935M (Quattro Secure Single Coil Defibrillation Lead) Abbott model LDA 210Q (Optisure Single Coil Defibrillation Lead) Abbott model LDA 220Q (Optisure Dual Coil Defibrillation Lead) Boston Scientific model 4470/4471 (FINELINE II/FINELINE II Sterox); Positive Fixation Biotronik model Solia S (Active Fixation Leads)
88811109|NCT04318665|Experimental|CT Perfusion|Severe TBI patients will be undergoing CT perfusion test
88811110|NCT04316611|Experimental|Potassium chloride|Potassium chloride
89570045|NCT05240729|Active Comparator|Costoclavicular|A new approach to the infraclavicular block The ultrasound transducer will be placed parallel and inferior to the clavicle and angled cephalad to optimize the ultrasound view. The block needle will be inserted in-plane from a lateral to medial direction into the costoclavicular space and the entire drug will be deposited in this location
89570046|NCT05240729|Active Comparator|Classic|Infraclavicular brachial plexus block (ICPB) ultrasound probe will be placed near the lower edge of the clavicle, and a transverse view of the subclavian artery and vein will be visualized. Using a needle guide, the needle will be advanced under real-time ultrasound guidance, and local anaesthetic will be injected near the subclavian artery, 15 mm medially and 15 mm laterally to the artery. The extent of sensory and motor block will be evaluated at 30 minutes after the injection
89570047|NCT05530577|Experimental|Semaglutide|Participants will receive semaglutide via subcutaneous injections at escalating doses (0.25mg to 1.0mg) over 9 weeks.
89570048|NCT05530577|Sham Comparator|Sham/Placebo|Participants will receive sham subcutaneous injections over 9 weeks.
89570049|NCT04718909|Experimental|Regorafenib + sintilimab|Regorafenib combined with sintilimab.
89570050|NCT04718909|Active Comparator|Regorafenib|Regorafenib alone.
89570051|NCT05216549|Experimental|Water-based exercise|The water-based exercise group will be held twice a week, 45 min per session for 8 weeks. Supervised exercise will be led by the experienced physiotherapist and water-based exercise by physiotherapist with aquatic exercise expertise.Each session will consist of warm up (10 min), main part (30 min) and cool-down (5 min). During warm up children will perform lower and upper limbs aerobics and breathing exercises. The main part will consist of endurance exercises of upper and lower limbs with focus on breathing pattern. During cool-down focus will be on upper limb and thoracic cage stretches and breathing control.
89570052|NCT05216549|Experimental|Land-based exercise|The land-based exercise group will be held twice a week, 45 min per session for 8 weeks. Supervised exercise will be led by the experienced physiotherapist and water-based exercise by physiotherapist with aquatic exercise expertise.Each session will consist of warm up (10 min), main part (30 min) and cool-down (5 min). During warm up children will perform lower and upper limbs aerobics and breathing exercises. The main part will consist of endurance exercises of upper and lower limbs with focus on breathing pattern. During cool-down focus will be on upper limb and thoracic cage stretches and breathing control.
89570053|NCT05216549|No Intervention|Control|The control group will be asked not to change their physical activity for 8 weeks. After that period and post-test the control group will receive the exercise.
89570054|NCT05379881|No Intervention|Waiting list control (WLC)|Participants who are assigned to the control condition will complete the baseline questionnaires and assessments at weeks 2, 4, and 8. After the last assessment, they will be given access to COMET.
89570055|NCT05379881|Experimental|Common Elements Toolbox (COMET)|"COMET consists of the following modules: cognitive restructuring (labeled flexible thinking), behavioral activation (labeled positive activities), gratitude, and self-compassion. Participants complete these COMET modules by themselves. The format is reading psychoeducational along with completing specific activities."
89570056|NCT04315337|Experimental|Virtual Training Arm|This is a within-participant study with two arms. All participants receive the Virtual Training with one target task and they are tested (after one day and one month) on the target task (arm 1) and as well as on a control task(arm 2). Assignment to the specific task that is trained is randomized across participants.
89570057|NCT04315337|No Intervention|Control Arm|This is a within-participant study with two arms. All participants receive the Virtual Training with one target task and they are tested (after one day and one month) on the target task (arm 1) and as well as on a control task(arm 2). Assignment to the specific task that is trained is randomized across participants.
89570058|NCT05160155|Active Comparator|Serratus Anterior Plane Block|Following the visualization of the anatomical structures, the nerve block needle will be advanced via the in-plane technique above the serratus anterior muscles until the interfascial space was reached. After hydrodissection with 2 ml normal saline, 20 ml 0.25% bupivacaine will be injected into the area. The block will be terminated.
89570059|NCT05160155|Active Comparator|Intercostal Block|The USG probe will be placed at the level of the posterior axillary line and the broken ribs. The ribs, external intercostal muscle, and internal intercostal muscle structures will be imaged. 3 ml of 0.25% bupivacaine will be injected into the subcostal area. This 3 ml 0.25% bupivacaine injection will be administered for each broken rib. The block will be terminated.
89570060|NCT02627677|Experimental|Cohort A: Ponatinib 30 mg|Ponatinib 30 mg, tablets, orally, once daily (QD) until achievement of major molecular response (MMR) up to 12 months. Once MMR was achieved, participants received reduced dose of ponatinib 15 mg orally once daily up to 42 months.
89570061|NCT02627677|Experimental|Cohort B: Ponatinib 15 mg|Ponatinib 15 mg, tablets, orally, QD until achievement of MMR up to 12 months. Once MMR was achieved, participants received reduced dose of ponatinib 15 mg orally once daily up to 45 months.
89570062|NCT02627677|Active Comparator|Cohort C: Nilotinib 400 mg|Nilotinib 400 mg, tablets, orally, twice daily up to approximately 42 months.
89570063|NCT05660603|Placebo Comparator|control group|patients will be operated on under general anesthesia
89570064|NCT05660603|Active Comparator|LSP group (lumbar and sacral plexus block)|patients will receive ultrasound-guided combined lumbar and sacral plexus blocks with 40 ml of 0.25% of bupivacaine.
89570065|NCT05660603|Active Comparator|CP group (circum-psoas block)|patients will receive ultrasound-guided circum-psoas blocks with 40 ml of 0.25% of bupivacaine.
89570066|NCT03059875|Other|Strategy A|Comprehensive Geriatric Assessment before the surgery of breast
89570067|NCT03059875|Other|Strategy B|Comprehensive Geriatric Assessment after the surgery of breast
88811111|NCT04314089|Experimental|GT103|Participants will receive GT103 every 3 weeks. GT103 will be escalated from .3mg/kg up 10 to mg/kg or until MTD is found
88811112|NCT04305834|Experimental|Treatment (abemaciclib)|Patients receive abemaciclib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88811113|NCT04297280|Experimental|TACE in combination with sintilimab|One-session TACE treatment starts at day 0. Sintilimab will be initiated on day 14 after TACE. Sintilimab will be administered every three weeks (200mg fixed dose IV) until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
89570068|NCT05677685|Active Comparator|Investigational Device|
89570069|NCT05677685|Placebo Comparator|Placebo|
89570070|NCT04964479|Experimental|TQB2450 injection + Anlotinib Hydrochloride capsules|"TQB2450 injection: once every 3 weeks, 1200mg each time, intravenous infusion. Until the disease progression or unbearable adverse events occur.~Anlotinib Hydrochloride capsules: once a day,12mg each time, oral administration before breakfast. Continuous administration for 2 weeks, withdrawal for 1 week, i.e. 3 weeks (21 days) as a course of treatment. Until the disease progression or unbearable adverse events occur."
89570071|NCT04964479|Active Comparator|Pembrolizuma injection + placebo of Anlotinib hydrochloride capsules|"Pembrolizumab injection: once every 3 weeks, 200mg each time, intravenous infusion. Until the disease progression or unbearable adverse events occur.~Placebo of Anlotinib hydrochloride capsules:once a day, 0mg each time, oral administration before breakfast. Continuous administration for 2 weeks, withdrawal for 1 week, i.e. 3 weeks (21 days) as a course of treatment. Until the disease progression or unbearable adverse events occur."
89570072|NCT05261867||Diabetic patients treated with SGLT2-I|Diabetic patients treated with SGLT2-I alone or in combination with other oral anti-diabetic (OAD) agents. Patients were considered in the SGLT2-I group if it was started at least 1 month prior to index hospitalization.
89570073|NCT05261867||Diabetic patients treated with other oral anti-diabetic (OAD) agents|Diabetic patients treated with other oral anti-diabetic agents alone.
89570074|NCT04964401|Active Comparator|Thoracic Paravertebral Block|After the linear ultrasound (US) probe will be placed 2-3 cm lateral to the thoracic 5 spinous process, the US-compatible needle will be advanced to the paravertebral area with in-plane technique, and 20 ml of 0.25% bupivacaine hydrochloride will be injected into this area.
89570075|NCT04964401|Active Comparator|Erector spinae plane block|After the linear ultrasound (US) probe will be placed 2-3 cm lateral to the T5 spinous process, 20 ml of 0.25% bupivacaine hydrochloride will be injected into the interfacial space below the erector spinae muscle, above the transverse process.
89570076|NCT04964245|Experimental|Respiration monitoring group|The respiration is simultaneously measured by accelerometer, thermographic camera, Impedance Tomography, and mattress sensor.
89570077|NCT03059797|Experimental|Anlotinib|Anlotinib Day 1 to day 14 followed by 7 days off treatment in a 21-day cycle
89570078|NCT03059797|Placebo Comparator|Placebo|Placebo Day 1 to day 14 followed by 7 days off treatment in a 21-day cycle
89570079|NCT02501811|Experimental|Mesenchymal Stem Cells (MSC)|Target dose of 150 million MSCs
89570080|NCT02501811|Experimental|c-kit+ cells|Target dose of 5 million c-kit+ cells
89570081|NCT02501811|Experimental|Combination Cells (MSC and c-kit+ cells)|Target dose of 150 million MSCs and 5 million c-kit+ cells
89570082|NCT02501811|Placebo Comparator|Placebo (Plasmalyte A)|Plasmalyte A
89570083|NCT04964011|Experimental|Board game group|The Board game group was led by an occupational therapist who has been working for six years. The intervention comprised 1 week of board game instruction and 11 weeks of board game tasks (combined with daily tasks), for a total of 12 weeks, once a week for 2 hours, for a total of 24 hours of intervention.
89570084|NCT04964011|Active Comparator|Health promotion group|MCI seniors in the health promotion group received general health promotion and were led by instructors from the long-term care facility for 12 weeks, including 4 weeks of physical activities, 4 weeks of singing activities, and 4 weeks of art activities, once a week for 2 hours, for a total of 24 hours.
89570085|NCT02585999|Other|Xulane|All participants using the Xulane contraceptive patch for 12 continuous weeks
89570086|NCT04963621|Experimental|Intervention|Child-Adolescent Emotion and Stress Intervention Program
89570087|NCT04963621|Active Comparator|waiting|treat as usual
89570088|NCT05696951|Active Comparator|The effectiveness of Tranexamic acid use of sleeve gastrectomy|In this study, it was determined which treatment package would be received by opening the closed envelopes of patients who had at least one point or more bleeding during the operation and had hemostasis with clips. In the intervention group, at the end of the surgery, intravenous TXA (Transamine) 1000 mg dissolved in 100 mL 0.9% sodium chloride was administered intravenously within 10 minutes as a loading dose within the first 30 minutes. After the end of the loading dose, a maintenance dose of 120mg/hour TXA was infused in 500ml (60ml/hour) saline.
89570089|NCT05696951|Placebo Comparator|Plasebo grup|The placebo group was given 100ml of saline in the first 30 minutes, followed by a maintenance dose of 60ml/hour of saline for 8 hours.
89570090|NCT05696951|Active Comparator|Sham grup|Patients with no bleeding to be treated were not enveloped and were excluded from the intervention or placebo group.
89570091|NCT01444495|Active Comparator|Short time interval|Patients operated on 7-10 days after completing preoperative radiotherapy 5x5Gy.
89570092|NCT01444495|Experimental|Long time interval|Patients operated on 4-5 weeks after completing preoperative radiotherapy 5x5Gy.
89570093|NCT01439269|No Intervention|Phase 1: Standard Care|Mothers are given infant care instruction as part of standard care
89570094|NCT01439269|Experimental|Phase 1: Facilitated infant care|Family Nurture Intervention (FNI)
89570095|NCT01439269|Active Comparator|Phase 2: Effectiveness|All participants receiving FNI
89570096|NCT02582255|Experimental|Sabin mOPV2 1 dose|IPV-vaccinated children to receive 1 dose of SABIN mOPV2 (Group 1)
89570097|NCT02582255|Experimental|SABIN mOPV2 2 doses|IPV-vaccinated children to receive 2 doses of SABIN mOPV2 (Group 2)
89570098|NCT04973761|Other|Strip composite crowns|
89570099|NCT04973761|Experimental|Zirconium crowns|
89570100|NCT04973371|Experimental|Home-based GeneXpert TB test|Screening household contacts + home-based GeneXpert® MTB/RIF TB testing for those with TB symptoms + immediate referral for clinic-based treatment initiation.
89570101|NCT04973371|No Intervention|Standard home-based TB symptom screening with immediate referral|Screening household contacts + immediate referral for clinic-based TB testing
89570102|NCT03061435|Other|Screening anal Pap Smear - Negative (75%)|All patients will receive an anal Pap test. 75% of patients with a negative anal Pap will complete study with no further intervention.
89570103|NCT03061435|Other|Screening anal Pap Smear - Negative (25%)|All patients will receive an anal Pap test. Remaining 25% of patients will proceed to high-resolution anoscopy (HRA) clinic to assess the negative predictive rate of HRA.
89570104|NCT03061435|Other|Screening anal Pap Smear - Positive|All patients will receive an anal Pap test. Any patient with abnormal cytology on their Pap test will be referred to HRA clinic for management. This includes potential biopsy and treatment.
89570105|NCT04432363|Active Comparator|M1 stimulation|A 20 minutes 1mA direct current stimulation over left M1.
89570106|NCT04432363|Active Comparator|M1+DLPFC stimulation|A 20 minutes 1mA direct current stimulation over left M1 and 1mA direct current stimulation over left DLPFC.
89570107|NCT04432363|Sham Comparator|Sham stimulation|A 20 minutes sham stimulation where the device only is working first 30s and last 30s of the intervention and have a 10 seconds fade out in intensity at each ramp.
89570108|NCT02500719|Experimental|Healthy Participants|A group of healthy participants will be enrolled first in the pilot phase of the study. This phase allows for the refinement (prior to the implementing in our PTSD participant group) the application of our support vector machine based real-time functional magnetic resonance imaging (rt-fMRI) algorithm, which evaluates brain networks thought to mediate emotional arousal and presents them (in real time) to subjects to aide in volitional manipulation of arousal.
89570109|NCT02500719|Experimental|PTSD Participants|A group of participants with symptoms of PTSD will be enrolled in the implementation phase of the study. This phase allows for the evaluation of rt-fMRI guidance of brain networks thought to mediate emotional arousal, specifically whether participants can learn volitional control of these networks.
89570110|NCT04963855|Active Comparator|CT300|GT300 capsule given once daily
89570111|NCT04963855|Placebo Comparator|Placebo|Microcrystalline cellulose capsule given once daily
89570112|NCT03061357|Experimental|Activity tracker group|Participants in intervention arm were provided with a small and lightweight activity tracker, Misfit Flash (Misfit Wearables Co., Burlingame, CA), that can be worn with a clasp or watch band. A handout detailing the step-by-step instructions for utilizing the activity tracker with Misfit App on their smartphone was provided. There was no intervention component mandated in the curriculum of intervention PAIP courses; rather, participants were continuously encouraged by the instructors to track their activity levels and use all the features in Misfit App on a daily basis as they learned health benefits of PA and as to how to develop individualized, life-long PA plan during the course of semester.
88970246|NCT04436289|Experimental|PLWOH Home Link study arm|"The Home Link intervention will be delivered by a home visit team including a primary care nurse and counselor trained in patient-centered counseling. A rotating hospital-based doctor will be available for pre-home visit clinical file review and post-visit discussion, via cell phone, for decision making and input on patient care during a household visit. We have termed this individual a discharge officer. The discharge officer will be a Tshepong clinician who is working in the hospital. Supporting Home Link is expected to take <30 minutes of the physician's time during the day. For study-specific concerns, the team will consult with a GCP-trained, PHRU research doctor based at Tshepong Hospital."
88970247|NCT04432532||Neuroendocrine Tumor|
88970248|NCT04432532||Adrenal Tumor|
88970249|NCT04396795|Experimental|PRP group|Participants in this group will receive 2 sessions of autologous PRP penile injection, each administered 1 month apart ± 7 days
88970250|NCT04396795|Placebo Comparator|Placebo group|Participants in this group will receive 2 sessions of placebo injection, each administered 1 month apart ± 7 days.
88970251|NCT04379115|Active Comparator|Active (tDCS) + Active TUS|Subjects in the experimental group will undergo 20 minutes of active transcranial direct current stimulation (tDCS) and active transcranial ultrasound (TUS)
89570113|NCT03061357|No Intervention|Control group|Participants in control arm did not receive any additional instructions other than the scheduled class activities based on the standardized core-curriculum of PAIP
89570114|NCT05695235||Traditional call|In the traditional overnight on-call system, each resident is on call for 4-6 nights per month (7 am - 5 pm, followed by overnight call until 8 am the next morning)
89570115|NCT05695235||Float call|In the night float system, residents work from 8 pm to 8 am for 5 - 7 consecutive nights once every month
89570116|NCT04954729||Experimental Group|The experimental group underwent neuropsychological testing, 18F-FDG PET/CT, 3T resting state fMRI examinations.
89570117|NCT04954729||MRI Control Group|The MRI control group underwent neuropsychological testing and 3T resting state fMRI examinations
89570118|NCT04954729||PET Control Group|The PET control group underwent 18F-FDG PET/CT examination
89570119|NCT04973215||work package 1|all participants in Norwegian introduction program and their family relations
89570120|NCT04973215||work package 2|strategic sample of refugees with health problems currently participating in the introduction program
89570121|NCT04973215||work package 3|3-6 families from which one or more participate in the introduction program and one or more have health problems
89028715|NCT06095687|Active Comparator|Clinical Hypnosis|Condition 2, Clinical Hypnosis (HYP): The HYP recording will be adapted from Jensen (2011). It will take the listener through a standardised self-hypnosis practice that includes an induction, followed by tailored suggestions. Specifically, the HYP session aims to take the listener through four basic ideas: 1) an induction to get the individual into a state of readiness to accept new ideas; 2) instructions to go to a favourite place to deepen the induction and provide a context for feeling heat while being relaxed; 3) linking suggestions for reducing automatic behavioural inhibition system and behavioural activation system (BIS-BAS) activation in response to stressors and enhancing awareness of when to activate each system; 4) suggestions that target enhancing self-confidence in pain management, well-being and the rehabilitation process; and 5) alerting.
89028716|NCT06091969|Experimental|Active multi-ingredient supplement (Fertility Enhancer; FE)|Volunteers will be randomized in a double-blinded fashion into the experimental treatment group, which entails daily supplementation of an active multi-ingredient supplement designed to enhance fertility (Fertility Enhancer; FE) for 3 months.
89028717|NCT06091969|Placebo Comparator|Inactive placebo (Placebo; PLA)|Volunteers will be randomized in a double-blinded fashion into a placebo group, which entails daily supplementation of a calorie-matched, inactive placebo (Placebo; PLA) identical in flavor to the active supplement for 3 months.
89570122|NCT04963309||OR-EX|the group with endotracheal tube extubation in the operating room in patients who underwent living-donor liver transplantation for end-stage liver failure
89570123|NCT04963309||NOR-EX|the group without endotracheal tube extubation in the operating room in patients who underwent living-donor liver transplantation for end-stage liver failure
89570124|NCT05019209|Experimental|Exposure to saline-dissolved house dust mite allergen and allergen-free air|Subjects are blinded to the sequence of interventions in the allergen challenge chamber (ACC). Overall, subjects will be in the ACC 4 times during the study. Of those, exposure to allergen-free air and HDM is allocated in a 2:2 ratio.
89570125|NCT04963387|Experimental|Whole body vibration|Balance and muscle strengthening exercises with whole-body vibration, strengthening exercise included straight leg raise with weights, and balance training including walking heel to toe for 20 steps vibration exposure was given in 1-minute bouts, with rest period of one to two minutes between bouts, with the exposure whole body vibration for about four minutes on every session. The duration of vibration exposure was preset with the automatic set time intervals in the vibration machine Prior to each vibration bout. When the predefined time was reached the machine automatically turned off . Based on previous researches the total exposure of four minutes per session interval was selected. In this study frequency of 30Hz (4 weeks), with 0.9 mm vertical displacement was used.
89570126|NCT04963387|Active Comparator|Balance and Strengthening exercise|Balance and strengthening exercises includes straight leg raise with weights 10 reps. and tandem walk 20 steps 3 days in week for 4 weeks
89570127|NCT05694299|Experimental|Nasal bridle|Nasal bridle fixation after nasoenteral feeding tube placement.
89570128|NCT05694299|Active Comparator|Nasal patch|Nasal patch fixation after nasoenteral feeding tube placement.
89570129|NCT04962763||Heart Failure|
89570130|NCT04962763||Control|
89570131|NCT05674253|Active Comparator|Dexmedetomidine + Hydrocortisone group|Patients will receive dexmedetomidine 0.7 ɥg/kg/hr IV infusion before aortic cross-clamping, and will be continued intra-operatively and in ICU till weaning from mechanical ventilation Patients also will also receive Hydrocortisone 100 mg intravenous (IV) before aortic cross-clamping then 100 mg every 8 hours after surgery which will be continued for 48 hours .
89570132|NCT05674253|No Intervention|Standard group|Patients will not receive dexmedetomidine nor Hydrocortisone and will receive the standard management
89570133|NCT04954417||MSCT image|Scanning of the vertebral body using MSCT
89570134|NCT04954417||micro-CT image|Scanning of the vertebral body using micro-CT
89570135|NCT02500641|Experimental|Febuxostat 80/120 mg/day|"Febuxostat 80/120 mg film coated tablets.The initial daily dose is 80 mg given orally. In case a patient has serum urate level 6 mg/dl after 2 weeks of treatment the dose will be escalated to 120 mg and if tolerated will be maintained during the study treatment period.~To prevent flares in the initial stages of treatment, patients will be treated for at least 6 months with colchicine 0.5 - 1 mg quaque die (QD ) or in case of colchicine intolerance, Naproxen 550 mg bis in die (BID) with Omeprazole (20-40 mg once daily), if indicated to be used."
89570136|NCT02500641|Active Comparator|Allopurinol 100 up to 600 mg/day|"Allopurinol 100/300 mg tablets.The initial daily allopurinol dose is 100 mg given orally, to be escalated of 100 mg every 2 weeks in patients with serum urate concentration >6 mg/dl.~The maximum dose of allopurinol achievable in the study will depend on kidney function and tolerability, but will not exceed 600 mg daily.To prevent flares in the initial stages of treatment, patients will be treated for at least 6 months with colchicine 0.5 - 1 mg QD or in case of colchicine intolerance, Naproxen 550 mg BID with Omeprazole (20-40 mg once daily), if indicated to be used."
89570137|NCT05662553|Experimental|Ablation|After randomization, the enrolled patients in this arm should be performed path simulation under ENB with preoperative CT. On the operation day, single-cavity intubation will be carried out first, and the secondary lesion will be reached through the planned path. After that，the biopsy tissue of the lesion will be sent to ROSE for detection. If malignant，the ablation will be performed，and the location, energy and ablation time will be adjusted according to intraoperative CT. After ablation, radical surgery will be performed on the primary lesion.
89570138|NCT05662553|Active Comparator|Surgery|The control group will undergo VATS treatment on the primary lesion on the day of operation, and will be re-admitted to the hospital after discharge and recovery (3-4 months) for contralateral secondary lesion surgery.
89028722|NCT06049199|Experimental|Hearing impaired group|The hearing impaired group will compare the reference condition (SpeechEnhancer on) with the intervention condition (SpeechEnhancer off).
89028723|NCT06039566|Placebo Comparator|IV Placebo|Patients will receive: Placebo 0 mg/kg (placebo: 0.45% NaCl or D5W) through an IV that will run for 60 minutes at the start of the procedure.
88970252|NCT04379115|Sham Comparator|Sham (tDCS) + Sham TUS|Subjects in the sham group will undergo 20 minutes of sham transcranial direct current stimulation (tDCS) and sham transcranial ultrasound (TUS).
89570139|NCT04973293|Experimental|Neoadjuvant treatment|"Participants will receive 4 doses of sintilimab (200 mg, IV) and bevacizumab (15 mg/kg, IV) every 3 weeks (Q3W). Participants will also receive 4 doses of carboplatin (AUC=5, IV) and pemetrexed (500 mg/m2, IV) Q3W.~Surgery will be performed within 4 to 6 weeks after completion of preoperative therapy.~After the second dose of sintilimab, bevacizumab and chemotherapy, contrast-enhanced chest CT will be performed. Patients with progression disease will receive surgery without the last 2 doses of treatment."
88970253|NCT04370730|Other|prospective cohort|prospective monitoring of children and adolescents with schizophrenia and related psychotic disorders
88970254|NCT04330378||Hospital-at-home|All patients who are enrolled into the NUHS@Home Programme will be recruited into this arm. Patients will be sent home via ambulance, where they will be reviewed by a NUHS@Home nurse. Intravenous therapies, pillboxes for medication, remote monitoring software, and telecommunication tools will be set up as indicated. NUHS@Home doctors will visit at least once daily, and nurses at least twice daily as required. Therapists will conduct home visits as necessary. The NUHS@Home team is available 24/7. When conventional discharge criteria are met, the patient will be discharged. The NUHS@Home clinical team will be under clinical governance of Division of Advanced Internal Medicine at NUH and patients will be considered 'inpatients' throughout the treatment period.
88970255|NCT04330378||Usual in-hospital care|Patients who would otherwise be eligible for NUHS@Home but are not able to be enrolled due to capacity will be recruited into this arm. They will receive usual care in the wards that they are already in until they are discharged.
88970256|NCT04330378||Rejected cohort|Patients who were offered but declined enrolments inot the NUHS@Home programme will be approached for consent to be in the rejected cohort. There will be no change to the patient's clinical management.
88970257|NCT04328233|Experimental|Time-Restricted Eating|
89570140|NCT05657249|Experimental|US & MRI|All participants undergo biannual US (as a part of standard-of-care) and annual non-contrast focused MRI.
89570141|NCT04972903||Group 1.HIV+/SAM+|Group 1. HIV-infected with SAM (WHZ<-3SD or edematous malnutrition or MUAC <115) (HIV+/SAM+)
89570142|NCT04972903||Group 2. HIV+/SAM-|Group 2. HIV-infected without SAM (none of the 3 criteria above) (HIV+/SAM-)
89570143|NCT04972903||Group 3. HIV-/SAM+|Group 3. HIV-negative with SAM (WHZ<-3SD or edematous malnutrition or MUAC <115) (HIV-/SAM+)
89570144|NCT04972903||Group 4. HIV-/SAM-|Group 4. HIV-negative without SAM (none of the 3 criteria above) (HIV-/SAM-)
89570145|NCT04972669|Sham Comparator|control group|sham electroaupuncture
89570146|NCT04972669|Experimental|experimental group|Electroaupuncture
89570147|NCT05061173|Experimental|Aerobic exercise training Group|
89570148|NCT05061173|Experimental|Resistance Exercise Training Group|
89570149|NCT05061173|Experimental|Combined Exercise Training Group|
89570150|NCT04962451|Experimental|Intervention group|
89570151|NCT04962451|Placebo Comparator|Placebo group|
89570152|NCT05059925|Experimental|Structured gym activities|Planned and structured activities such as Strength training for 4 weeks
89570153|NCT05059925|Active Comparator|Traditional aerobic activities|Activities performed such as Treadmill , Cycle ergometer , Elliptical exercises for 4 weeks
89570154|NCT04962295||Cerebral Small Vessel Diseases group|CSVD patients
89570155|NCT05010083|Experimental|diet and lifestyle program|
89570156|NCT04972591||CHB Group|Patients with CHB
89570157|NCT04972591||Compared Group|Healthy people
88970258|NCT04325386|Experimental|Education sessions|Project ECHO (Extension for Community Healthcare Outcomes) based intervention sessions for improving the use of clozapine in people with treatment-resistant schizophrenia. The sessions will include: 1) active dissemination of knowledge and information by an expert followed by 2) clozapine case presentations and vignettes.
88970259|NCT04325386|Placebo Comparator|No education sessions|
89570158|NCT04953793|Experimental|TAY SUCCESS intervention|This intervention group received the TAY SUCCESS intervention over the course of 1 school year approximately 30 sessions.
89570159|NCT04953793|Active Comparator|Usual Care|This usual care group received typical High school or transition program curriculum over the course of 1 school year.
89570160|NCT04953871|Experimental|Spondyloarthritis|Spondyloarthritis patients who was initiated TNF alfa blocker
89570161|NCT03059719|Experimental|PB-119 injection|PB119 injection 25ug or 50ug once each week, for three months
89570162|NCT03059719|Active Comparator|Exenatide Injection (Byetta)|Byetta 5ug or 10ug twice each day, for three months
89570163|NCT04980599|Active Comparator|K56 very high dose -E1|Probiotic drink (lactobacillus paracasei K56 10^11CFU) 350ml/d , for 60days
89570164|NCT04980599|Placebo Comparator|control -E2|maltodextrin , for 60days
89570165|NCT04980599|Active Comparator|K56 high dose-E3|Probiotic powder 1.5g/sachet , 3.0g/d (lactobacillus paracasei K56 10^10cfu) , for 60days
89570166|NCT04980599|Active Comparator|K56 middle dose-E5|Probiotic powder 8.0g/sachet , 8g/d ( Lactobacillus paracasei K56 10^9cfu) , for 60days
89570167|NCT04980599|Active Comparator|K56 low dose -E7|probiotic k56 capsule, 2capsules/d ( Lactobacillus paracasei K56 10^7cfu) , for 60days
89570168|NCT04980599|Active Comparator|K56 middle dose-E9|probiotic K56 capsule, 2capsules/d (Lactobacillus paracasei K56 10^9cfu) ,for 60days
89570169|NCT04980599|Active Comparator|K56 high dose-E1K|probiotic K56 capsule, 2capsules/d (Lactobacillus paracasei K56 10^10cfu), for 60days
89570170|NCT04980599|Active Comparator|K56 very high dose-E11|probiotic K56 capsule, 4capsules/d (Lactobacillus paracasei K56 10^11cfu) ,for 60days
89570171|NCT04972435|Experimental|Multifocal intraocular lens group|Cataract patients with PAC or PACG who underwent phacoemulsification with multifocal intraocular lens implantation.
89570172|NCT04972435|Sham Comparator|Monofocal intraocular lens group|Cataract patients with PAC or PACG who underwent phacoemulsification with monofocal intraocular lens implantation which are the standard IOL.
89570173|NCT04972357||Standard RYGB|
89570174|NCT04972357||Banded RYGB|
89570175|NCT04972357||Extended pouch RYGB|
89028724|NCT06039566|Active Comparator|IV N-acetylcysteine|Patients will receive: N-acetylcysteine (NAC) 150 mg/kg (Max dose 15,000 mg) through an IV that will run for 60 minutes at the start of the procedure.
89028725|NCT06030622|Experimental|C3 (Combination Digoxin, Simvastatin, and Metformin)|Study participants will receive metformin (850 mg twice a day), digoxin (0.25 mg once a day), and simvastatin (20 mg once a day) combination (C3) and Gemcitabine for up to 2 years.
89570176|NCT03060031|Experimental|Oxytocin|Each participant will undergo pain tasks after self-administration of oxytocin
89570177|NCT03060031|Placebo Comparator|Placebo|Each participant will undergo pain tasks after self-administration of placebo
89570178|NCT02499783|Experimental|Placebo Induction Regimen|"Double-blind period (Weeks 0-8): Placebo at Weeks 0 and 2, followed by adalimumab 160 mg at Week 4, 80 mg at Week 6.~Open label period: adalimumab 40 mg every other week (eow) from Week 8 through last dose at Week 24."
89570179|NCT02499783|Experimental|Adalimumab Induction Regimen|"Double-blind period (Weeks 0-8): adalimumab 160 mg at Weeks 0 and 80 mg at Week 2, followed by adalimumab 40 mg at Week 4 and Week 6.~Open label period: adalimumab 40 mg eow from Week 8 through last dose at Week 24."
89570180|NCT04972045|Experimental|CuminUP60®,then Curcumin capsules|Participants first received CuminUP60® 1600mg on the first day in a fasting state.After a washout period of 7days,they then received curcumin capsules 1600mg on the eighth day in a fasting state.
89570181|NCT04972045|Experimental|Curcumin capsules,then CuminUP60®|Participants first received curcumin capsules 1600mg on the first day in a fasting state.After a washout period of 7days,they then received CuminUP60® 1600mg on the eighth day in a fasting state.
89570182|NCT04953481||Amyotrophic lateral sclerosis group|Patients with amyotrophic lateral sclerosis undergoing home care.
89570183|NCT04953481||Caregiver group|Caregivers
89570184|NCT03059017|Experimental|Niosomal salbutamol sulphate inhalers|Niosomes
89570185|NCT03059017|Placebo Comparator|salbutamol sulphate inhalers|control testing
89570186|NCT04971421||Benign ovarian tumors|All histological proven benign ovarian tumors
89570187|NCT04971421||Malignant ovarian tumors|All histological proven malignant ovarian tumors
89570188|NCT04971421||Borderline ovarian tumors|All histological proven borderline ovarian tumors
89570189|NCT05691335|Other|Standard CXL|Patients treated according to Dresden Protocol with epithelium-off CXL.
89570190|NCT05691335|Experimental|Accelerated CXL|Patients treated according to accelerated Protocol with epithelium-off CXL.
89570191|NCT05691335|Experimental|Transepithelial CXL|Patients treated according to transepithelial Protocol with epithelium-on CXL.
89570192|NCT04772885|Experimental|Single ascending dose cohorts in healthy subjects|Healthy volunteer subject cohorts randomized 6:2 receiving a single dose of KT-474 or placebo. The first cohort will receive 25 mg of KT-474 or placebo. Dose escalation will occur if KT-474 or placebo is tolerated.
89570193|NCT04772885|Experimental|Multiple ascending dose cohorts in healthy subjects|Healthy volunteer subject cohorts randomized 9:3 to receive KT-474 or placebo for 14 days continuous dosing. The first cohort will receive a dose of KT-474 or placebo determined to be safe based on data generated in the SAD portion.
89570194|NCT04772885|Experimental|Food Effect Cohort in healthy subjects|Healthy Volunteer SAD subject cohorts (up to 5) will receive a single dose of KT-474 in the fed state.
89570195|NCT04772885|Experimental|Multiple dose cohort in HS and AD patients|A single cohort of up to 30 patients with AD or HS to receive a dose of KT-474 determined to be safe based on data generated in the healthy volunteer MAD portion, dosed daily X 28 days.
89570196|NCT04772885|Experimental|Multiple dose cohorts in healthy subjects|Healthy volunteer subject cohorts randomized 9:3 to receive KT-474 or placebo every other day over 14 days, and/or twice weekly over 15 days. The first cohort will receive a dose of KT-474 or placebo determined to be safe based on data generated in the SAD and MAD portion.
89028726|NCT06029010||Long-term responders of regorafenib ≥5 months|Defined as treatment duration ≥5 months after treatment initiation.
89028727|NCT06029010||Long-term responders of regorafenib ≥4 months|Defined as treatment duration ≥4 months after treatment initiation.
89028728|NCT06025253|Experimental|Negative Pressure Wound Therapy.|Application of a negative wound pressure therapy dressing to the wound post major lower extremity amputation
89028729|NCT06025253|Active Comparator|Standard Wound dressing|Application of sterile standard gauze dressing to the wound post major lower extremity amputation
89028730|NCT06023433|Active Comparator|Canines to be distalized|The canines need distalization after orthodontic upper first premolar asymmetrical extractions.
89028731|NCT06023433|No Intervention|Controlateral canines|The controlateral canines don't need distalization since the adjacent first premolars are not extracted.
89028732|NCT05989763|Experimental|Transcutaneous Electrical Acustimulation (TEA)|
89028733|NCT05989763|Sham Comparator|Sham-TEA|
89208987|NCT00873990|Active Comparator|1|application of total etch bonding agent ( 5th generation) for placement of resing based pit and fissure sealants.
89570197|NCT04755413|Experimental|Optimization Group|Participants with CAD and a BRS greater than 0 who are randomized to the Optimization Group have treatment goals that include achieving LDL-C<70 mg/dL, hemoglobin A1c <7%, blood pressure <130/80 mmHg, smoking cessation, at least 30 minutes of moderate-intensity aerobic activity 5 days a week and weight loss to body mass index <30 kg/m2. To achieve these goals, both pharmacological and lifestyle interventions will be considered and individualized for each patient.
89570198|NCT04755413|Active Comparator|Usual Care Group|Participants with CAD and a BRS greater than 0 who are randomized to the usual care group will receive standard of care therapy prescribed by their primary care physician and/or cardiologist. Patients and their physicians will be informed that their BRS is ≥1 and they have been randomized to the usual care group.
89570199|NCT04755413|Other|Registry Group|Participants with BRS of 0 at baseline and after 3 months will undergo follow-up including measurements of BRS at the time-points specified for the randomized subjects and also for adverse events. Laboratory results and questionnaire data will be obtained on the phone.
89570200|NCT04961983|Experimental|Intervention group|Tour guides who will receive a comprehensive travel health education model.
89570201|NCT04961983|No Intervention|Control group|Tour guides who will receive no intervention.
89570202|NCT04961749|Experimental|Vibration group|This group will receive vibration stimulation while standing on a side-alternating vibration platform. Vibration sessions will occur three times per week over four-weeks. Each session will include three-minutes of vibration followed by three-minutes rest, completing this sequence three times per session
89570203|NCT04961749|No Intervention|Control group|This group will not receive vibration, but will rather hear a recording of the vibration, while still standing on the vibration platform. Still, this group will receive this training three times per week over four-weeks with a similar three-minute rotation as the vibration group.
89570204|NCT04953247||Methylprednisolone|"As there was no consensus on the use of steroids in the early stage of the COVID-19 pandemic, all steroid therapies were initiated at the time of admission at the discretion of attending physicians on the basis of clinical symptoms and CT images. According to our previous experience, intravenous methylprednisolone at a dose of 1.0-1.5 mg/kg every 12 h was initiated for 5 days or until oxygen saturation improved, followed by gradual tapering by 0.5 mg/kg every 3-5 days.~Standard care such as the use of antibiotics, ventilation, laboratory testing, and hemodynamic management were performed following the sixth edition of the Guidelines on the Diagnosis and Treatment of COVID-19 published by the National Health Commission of China."
89208988|NCT00873990|Experimental|2|Self etch bonding agent (7th generation) application for placement of resin based pit and fissure sealant
89570205|NCT04953247||Standard care|Standard care were performed following the sixth edition of the Guidelines on the Diagnosis and Treatment of COVID-19 published by the National Health Commission of China.
89570206|NCT04953013||sodium bicarbonate group|Sodium bicarbonate was initiated within 48 hours after ICU admission.
89570207|NCT04953013||non-sodium bicarbonate group|Patients were not infused with sodium bicarbonate.
89570208|NCT04953169|Other|Video|The video is information regarding biobanking
89570209|NCT04953169|Other|Non-Video|The non-video group will receive a written informed consent
89570210|NCT04425655|Experimental|Fludarabine and CPX351|"Induction 1:~Fludarabine 30 mg/m2/day IV on days 1-5 for 5 doses Daunorubicin and cytarabine liposome (CPX-351) daunorubicin 44 mg/m2/day and cytarabine 100 mg/m2/day IV on days 1, 3, 5 (given 4 hours after fludarabine infusion) for 3 doses~Induction 2 (residual leukemia after Induction 1):~Fludarabine 30 mg/m2/day IV on days 1-3 for 3 doses~Daunorubicin and cytarabine liposome (CPX-351) daunorubicin 44 mg/m2/day and cytarabine 100 mg/m2/day IV on days 1, 3 (given 4 hours after fludarabine infusion) for 2 doses~Optional consolidation, up to 2 cycles:~Daunorubicin and cytarabine liposome (CPX-351) daunorubicin 29 mg/m2/day and cytarabine 65 mg/m2/day IV on days 1, 3 for 2 doses"
89570211|NCT04970719|Experimental|Remdesivir plus Baricitinib|200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 5-day total course; 4 mg of baricitinib administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course
89570212|NCT04970719|Active Comparator|Remdesivir plus Dexamethasone|200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 5 -day total course; and 6 mg of dexamethasone administered as an intravenous injection daily while hospitalized for up to a 10-day total course.
89570213|NCT02468193|Experimental|Osilodrostat|Patients in this arm took the study drug, osilodrostat.
89570214|NCT04970797||Conventional treatment group|Western medicine treatment
89570215|NCT04970797||Combination treatment group|Xinglouchengqi decoction combined with western medicine treatment
89570216|NCT04431817||Left transtibial|Left below knee amputation- 25
89208989|NCT00655850|Experimental|Paclitaxel and Gemcitabine + Avastin|Patients will be treated with metronomic chemotherapy with paclitaxel and gemcitabine weekly for 3 out of 4 weeks which constitutes one cycle (4 weeks). Avastin will be administered every 2 weeks. Treatment with metronomic chemotherapy and Avastin will continue for a total of 6 cycles unless there is evidence of disease progression, intolerable toxicity, or withdrawal of consent. Maintenance therapy with Avastin will continue until disease progression, intolerable toxicity, or withdrawal of consent.
89208990|NCT00881322|Experimental|BC-130|Active Arm
89570217|NCT04431817||Right transtibial|Right below knee amputation- 25
89570218|NCT04431817||Left transfemoral|Left above knee amputation- 25
89570219|NCT04431817||Right transfemoral|Right above knee amputation- 25
89570220|NCT04431817||Provider|Provider- 15
88811114|NCT04281771|Experimental|Patients who undergo cardiac MRI|"Patients undergo cardiac MRI within 30 days after TAVI to assess the amount of paravalvular leakage~Patients with anemia pre-TAVI are asked to undergo videocapsule endoscopy before and 6 months after the TAVI procedure."
88811115|NCT04265144|Experimental|subjects SSc diagnosed|Patient with systemic scleroderma according to the American College of Rheumatology (ACR) / EULAR 2013 criteria
88811116|NCT04264026|Experimental|Open Label|Participants will receive an initial dose of 80 mg of 3,4-methylenedioxymethamphetamine (MDMA) and an optional supplemental dose of 40 mg MDMA during the first Experimental Session. In the second and third Experimental Sessions, the participant will receive an initial dose of 120 mg MDMA and an optional supplemental dose of 40 mg MDMA.
88811117|NCT04254107|Experimental|SEA-TGT Monotherapy (Parts A and B)|SEA-TGT
88811118|NCT04254107|Experimental|SEA-TGT + sasanlimab Combination Therapy (Part C)|SEA-TGT + sasanlimab
88811119|NCT04254107|Experimental|SEA-TGT + brentuximab vedotin Combination Therapy (Part D)|SEA-TGT + brentuximab vedotin
88811120|NCT04224480|Experimental|Treatment|Neoadjuvant treatment will consist of one dose of IV pembrolizumab. Tumor resection will be performed approximately 4 weeks after neoadjuvant pembrolizumab. Adjuvant treatment with pembrolizumab will be administered 4 weeks after the surgery.
89570221|NCT02466555|Experimental|Music Therapy Group|Music therapy is the clinical and evidence-based use of music interventions to accomplish individualized goals within a therapeutic relationship by a credentialed professional who has completed an approved music therapy program. Music therapy is an established health profession in which music is used within a therapeutic relationship to address physical, emotional, cognitive, and social needs of individuals (American Music Therapy Association [AMTA], 2013, para 1 and 2).
88970260|NCT04313335|Experimental|Duloxetine|Apart from the standard treatment, participants in the Duloxetine Arm will be administered with oral duloxetine (up to 60 mg per day) in the acute herpes zoster period.
89208991|NCT00881322|Placebo Comparator|Sugar Pill|Placebo
89570222|NCT04960969|Experimental|Time-restricted Feeding Group|Participants will apply time-restricted feeding (8 hours/day) for 28 days.
89570223|NCT04960969|No Intervention|Control Group|No intervention will be applied.
89570224|NCT04972201||Cancer Arm|Participants with new diagnosis of cancer, from whom blood samples will be collected.
89570225|NCT04972201||Healthy Arm|Participants without known presence of malignancies or benign diseases, from whom blood samples will be collected.
89570226|NCT02466399|Experimental|POLAT-001|Latanoprost liposome ophthalmic injection
89570227|NCT02466399|Active Comparator|Latanoprost ophthalmic solution|latanoprost ophthalmic solution 0.005%
89570228|NCT03059251||Obinutuzumab|All participants with chronic lymphocytic leukemia (CLL) who have received the indication for treatment with Obinutuzumab, as per routine clinical practice in Argentina.
89570229|NCT04936191|Experimental|DynamX Bioadaptor|Patients were randomized during the percutaneous coronary intervention before stent implantation and assigned to the study arm using an electronic spreadsheet indicating the group assignment by random numbers. The patients will be 1:1 randomized to 2 groups: DynamX Bioadaptor and DESyne DES groups.
89570230|NCT04936191|Active Comparator|DESyne Drug-eluting Stent|Patients were randomized during the percutaneous coronary intervention before stent implantation and assigned to the study arm using an electronic spreadsheet indicating the group assignment by random numbers. The patients will be 1:1 randomized to 2 groups: DynamX Bioadaptor and DESyne DES groups.
89570231|NCT02465931|Other|Comparison Condition|Paper and pencil informed consent
88811121|NCT04218591|Active Comparator|PRP|Intra-articular injection PRP
88811122|NCT04218591|Placebo Comparator|Saline|Intra-articular injection Saline
88811123|NCT04218084|Experimental|Voxelotor|Voxelotor 1500mg or equivalent daily as a tablet, dispersible tablet, or as powder for oral suspension.
88811124|NCT04218084|Placebo Comparator|Placebo|Matching placebo.
89208992|NCT02553434|Experimental|Pigtail catheter (case)|Inserting 14 French pigtail catheter
89208993|NCT02553434|No Intervention|Chest tube|inserting 32-36 French chest tube
89208994|NCT02553122|Other|Control Group|This group of patients will receive standard protocol to control intra-operative blood loss.
88811128|NCT04201457|Experimental|Phase 1 Stratum 1 BRAF V600E LGG or HGG|LGG or HGG with BRAF V600E/D/K mutation will receive Dabrafenib, Trametinib and Hydroxychloroquine. All medications are administered orally with Dabrafenib and HCQ given twice a day and Trametinib given once per day at the assigned dose for a 28 day course. Courses may repeat until the patient meets an off treatment criteria.
89208995|NCT02553122|Active Comparator|Treatment Group|This group of patients will receive TXA, Evicel and standard protocol to control intra-operative blood loss.
89208996|NCT00874068|Active Comparator|Standard vegetable oil formula|
89208997|NCT00874068|Active Comparator|InFat|
89208998|NCT00874068|No Intervention|Breast-fed|
89208999|NCT00805298|Active Comparator|methylprednisolone|
89209000|NCT00805298|Placebo Comparator|placebo|
89209001|NCT00805298|Active Comparator|lidocaine|
89209002|NCT00805298|Active Comparator|bupivacaine|
89570232|NCT02465931|Experimental|Intervention condition|Digital informed consent tool
89570233|NCT04961125||colorectal polyposis|
89570234|NCT04970329|Experimental|Systane|Instill one drop three times a day for one month.
89570235|NCT04970329|Experimental|Tears Naturale 2|Instill one drop three times a day for one month.
89570236|NCT04970329|Placebo Comparator|Placebo|Instill one drop three times a day for one month.
89570237|NCT02465463|Experimental|FMT arm|Patients in the experimental arm with undergo a fecal microbiota transplant (FMT) after finishing a course of antibiotics.
89570238|NCT02465463|No Intervention|Control|Patients in the non-interventional group will not receive a FMT but will be followed over the course of 6 months to assess for recurrence of C.difficile.
89570239|NCT04970095|Experimental|cleft lip and palate patient|Clefts patient with transverse maxillary constriction and anteroposterior deficiency
89570240|NCT04960657|Active Comparator|PACAP38 and glibenclamide|Participants will receive glibenclamide after PACAP38 infusion
89570241|NCT04960657|Active Comparator|PACAP38 and placebo|Participants will receive placebo after PACAP38 infusion
89570242|NCT02464059|Experimental|Vitamin D3|Oral supplementation with 50,000 IU vitamin D3 weekly for eight weeks
89570243|NCT04960501||New tension band system|
89570244|NCT04960501||Patella reduction band system|
89570245|NCT02463357|Experimental|Quercetin|Quercetin: 500mg pill, twice daily for 5 days
89570246|NCT02463357|Experimental|Nifedipine+Methazolamide|Nifedipine extended release: 30mg pill, twice daily for 5 days; Methazolamide: 125mg pill, twice daily for 5 days
89570247|NCT02463357|Experimental|Metformin|Metformin: 500mg pill, once daily for 2 days, then 500mg twice daily at altitude (3 days)
89570248|NCT02463357|Placebo Comparator|Placebo|Sugar pill manufactured to look like all other investigational products
89570249|NCT02463357|Experimental|Nitrite|Nitrite: 20mg pill, three times daily for 5 days
89570250|NCT04960345||The traditional group|The traditional group underwent prosthesis placement using traditional intramedullary positioning method.
89570251|NCT04960345||The navigation group|The navigation group performed surgery using the Brainlab Knee 3 navigation system.Informed consent was signed after grouping.
89570252|NCT02579759|Active Comparator|PXT3003 dose 1|Oral solution, 5 ml b.i.d. (taken morning and evening with food) during 15 months
89570253|NCT02579759|Active Comparator|PXT3003 dose 2|Oral solution, 5 ml b.i.d. (taken morning and evening with food) during 15 months
89570254|NCT02579759|Placebo Comparator|placebo|Oral solution, 5 ml b.i.d. (taken morning and evening with food) during 15 months
89570255|NCT04960189|Experimental|Acupuncture|GB34 acupuncture will be applied every day. Patients will receive standard medical treatment
89570256|NCT04960189|No Intervention|Controls|Patients will only receive standard medical treatment
89570257|NCT04935255||Single Arm|The participating patients are treated according to local standard treatment (consisting of etoposide 100mg/m2 and cisplatin 20 mg/m2 during 5 consecutive days). Anti-emetic treatment with aprepitant will be given during days 3 to 7.
89570258|NCT04960267|Experimental|Use of pre-peritoneal drainage after rTAPP|"Use of pre-peritoneal drainage after rTAPP~Outcomes will be compared with retrospective cohort from our previous experiments"
89570259|NCT04960033||Osteoporosis fracture|The 10-year MOF probability and the 10-year HF probability were calculated using the FRAXs of different regions (mainland China, Hong Kong, Taiwan, and Asia-America). Subjects were deemed as high-risk for osteoporotic fracture if the 10-year probability of MOF was ≥20% or the 10-year probability of HF was ≥3%.
89570260|NCT04960033||women without osteoporosis fracture|The 10-year MOF probability and the 10-year HF probability were calculated using the FRAXs of different regions (mainland China, Hong Kong, Taiwan, and Asia-America). Subjects were deemed as high-risk for osteoporotic fracture if the 10-year probability of MOF was <20% or the 10-year probability of HF was <3%.
89570261|NCT04952935|Experimental|True Acupuncture|
89570262|NCT04952935|Sham Comparator|Sham Acupuncture|
89570263|NCT05600465|Experimental|BA+OT intervention|Following baseline assessment, the PI, a BA-trained, licensed occupational therapist will deliver a 10-session manualized program in the participants' homes to ensure optimal uptake of the active ingredients and integration into daily life routines. This intervention occurs over 10 weeks. The intervention manual will include educational materials for the 4-step approach, and worksheets for goal setting and developing daily routines. In the 1st BA-OT session, the PI will collect baseline assessments and use Canadian Occupational Performance Measure (COPM) data to facilitate goal setting. The top 5 participant-selected goals chosen will be the subject of the 4-step process in sessions 2 - 10. At least one goal must be related to improving physical activity routines; each participant will receive a Fitbit Charge 5 to self-monitor fitness progress. The unbiased evaluator will carry out follow-up assessments at 10 weeks and 22 weeks with participants in both conditions.
89570264|NCT05600465|Placebo Comparator|Enhanced Usual Care|The enhanced usual care control group will receive the same assessment battery, a Fitbit Charge 5 with 1 hour training, and a handout about living with chronic conditions.
89570265|NCT04969393|Experimental|Group A (High Intensity Laser therapy + Conventional Physical Therapy)|Patients in group (A) received conventional physical therapy program along with HILT. Patients received pulsed Nd: YAG laser treatment, produced by EXAND MY 1064 nm Laser system, Mectronic Medicale, Italy. The apparatus provided pulsed emission (1064 nm), very high peak power (3 kW), a high level of fluency (energy density; 360-1780 mJ/cm2).
89570266|NCT04969393|Active Comparator|Group B (Conventional Physical Therapy)|Patients in this group received the conventional physical therapy program in the form of splinting, tendon and neural gliding exercises. Patients were instructed to wear a neutral custom volar splint at night and while performing strenuous activities during the day for 5 weeks.Also, the patients performed nerve-and tendon-gliding exercise under direct supervision of the therapist during the treatment sessions. Each exercise was repeated 10 times at each session and patients were encouraged to apply exercise 3-5 times per day for 5 weeks.
89570267|NCT04960111|Experimental|knee arthroplasty with radiostereometry tecnique|patient underwent total knee arthroplasty with insertion of microsphere in tantallium for radiostereometry tecnique.
89570268|NCT04968691|Experimental|Telerehabilitation group|The group to which a structured exercise program supported by telerehabilitation will be treated.
89570269|NCT04968691|Active Comparator|Control group|The group to which the home exercise program will be treated.
89570270|NCT04959955||AECOPD group|
89570271|NCT04959955||CAP group|
89570272|NCT04951843|Experimental|Black soybean koji product|Oral supplement 2 servings of black soybean koji product per day, for 10 weeks.
89209003|NCT00726323|Experimental|5/9 dosing|240 mg of foretinib on a 5 day on / 9 day off regimen every 14 days.
89570273|NCT04968769|Experimental|ischemic compression and exercise|"Individuals were positioned in a comfortable position in a chair with back support. By palpating the UT muscle, first the taut band and then the active TP on the muscle were determined. Before starting the treatment, , a statement was made to the individual that you will soon feel a high level of pain with pressure, and at the same time, you may feel pain, tingling, pricking in additional areas (head-neck-shoulder-arm), after a while the pain will decrease and disappear. In this process, try to stay as steady as possible and breathe regularly and calmly.'' The highest level of pressure that the patient could tolerate was applied to the determined TP with the thumb. Pressure time will be in the range of at least 10-20 seconds and at most 60 seconds; It was terminated after the therapist felt complete relaxation in the tissue under his thumb or after the patient received the return of pain completely disappeared"
88970261|NCT04313335|No Intervention|Control|Participants will be given the standard treatment during the acute herpes zoster period.
88970262|NCT04302740|Active Comparator|LEAP|Housing First plus LEAP
88970263|NCT04302740|No Intervention|Service-As-Usual|Housing First
88970264|NCT04297618|Experimental|Xiidra treatment|Each participant will use the same study drops, Xiidra, over the course of the 12-week study.
88970265|NCT04282109|Experimental|Arm 1|NIVOTAX (nivolumab + paclitaxel, follow by maintenance with nivolumab)
88970266|NCT04282109|Active Comparator|Arm 2|ERBITAX (cetuximab + paclitaxel, follow by maintenance with cetuximab)
88970267|NCT04266704|Experimental|Intervention|Along with providing education on a low sodium diet (Dietary Approaches to Stop Hypertension or DASH), exercise, and medication adherence, the intervention arm is designed to promote information sharing and stimulate broad cortical neural networks, the default mode (DMN), which focuses on emotion-management and self-awareness.
89570274|NCT04968769|Experimental|kinesio taping and exercise|While performing KT, the individual was seated in a comfortable and upright position in a chair with back support. The subject was asked to bring his hand to his back in internal rotation of the shoulder of the taped side and to bring his head to the contralateral lateral flexion and contralateral rotation so that the UT muscle was in a tense position. KT was applied using 'muscle inhibition technique' to ensure correct contraction of the muscle with muscle length/tension optimization, to target the reduction of excessive muscle tension, and to increase circulation with the effects of the tape on the skin. In this technique, to inhibit the muscle, the tape direction is from the muscle insertion to the origin. KT was performed 5 cm below the acromion to the protuberantia occipitalis with 10% tension
89570275|NCT04968769|Active Comparator|exercise|In order for all the exercises to be done correctly and not to cause any pain, the individuals were asked to perform the movements in front of the mirror. Posture exercises given the individuals for scapular retraction. During the posture exercises individual was positioned in a chair without back support. By counting 5 it was requested to do 10 repetitions of each exercise. For the UT muscle stretching, individuals were asked to hold their right ear with their left hand over their head while sitting on a back-supported chair with their hips and back fully resting on the chair, and to bring their left ear closer to their left shoulder with the help of their hand and count to 20 from the outside.
89570276|NCT04952155|Experimental|IL-2|The administration period was divided into 6 courses. 6 cycles of IL-2 were administered subcutaneously at a dose of 1 million IU every other day for 2 weeks, followed by a 2-week break in treatment.
89570277|NCT04959721|Experimental|Injection group|Patients in the injection group will be injected 10 mg (0.25 mL) of triamcinolone acetonide, mixed with 0.25 mL of 0.125% bupivacaine and 0.5 mL of normal saline.
89570278|NCT04717739||GBM with indication for TTFields|newly diagnosed GBM with clinical indication for TTFields
89570279|NCT04968613|Experimental|Madopar monotherapy group|Patients in this group received Madopar monotherapy
89570280|NCT04968613|Active Comparator|senfrol monotherapy group|Patients in this group were treated with senfrol (D2 receptor agonist) alone
89570281|NCT04968613|Placebo Comparator|placebo group|Patients in this group were treated with selegiline alone
89570282|NCT04968535|Experimental|Therapy|Patients receiving suprathreshold electrotherapy in weekly intervals for a Duration of 30 min each. Device calibration with determination of the individual threshold was performed prior to the application of electrical current.
89570283|NCT04968535|Sham Comparator|Control|Patients receiving device calibration without consequent electrotherapy.
89570284|NCT04968535|No Intervention|Control of control|Patients lay on the mat without receiving device calibration nor electrotherapy.
89570285|NCT03058549|Experimental|Intervention: Family Expectations|Family Expectations includes 36 hours of relationship education and parenting content, coaching sessions for couples, and group case management/referral information about local resources. Each couple will also complete an initial case management assessment, followed by referrals to any needed services, such as employment, substance abuse, mental health, housing, etc. Based on need, couples will have the option of additional case management/coaching services during their involvement in Family Expectations.
89570286|NCT03058549|No Intervention|Control Group|The control group will not receive the intervention though they are able to seek and obtain any services they wish in the community (Treatment as Usual).
89570287|NCT04676555||Ocrelizumab|Ocrelizumab is administered intravenously (IV) under the guidance of a specialized physician and followed by one-hour observation after the infusion. It requires a corticosteroid pre-medication and some antipyretics may also be administered.
89570288|NCT04676555||Ofatumumab|Ofatumumab is administered through a subcutaneous injection and allows self-administration after training.
89570289|NCT02445963|Active Comparator|10 μg S. flexneri 2a Invaplex|10 subjects vaccinated on days 0, 14, 28
89570290|NCT02445963|Active Comparator|50 μg S. flexneri 2a Invaplex|10 subjects vaccinated on days 0, 14, 28
89570291|NCT02445963|Active Comparator|250 μg S. flexneri 2a Invaplex|10 subjects vaccinated on days 0, 14, 28
89570292|NCT02445963|Active Comparator|500 μg S. flexneri 2a Invaplex|10 subjects vaccinated on days 0, 14, 28
89570293|NCT04314167|Experimental|LDL lowering therapy|Patients will receive the PCSK9-inhibitor Evolocumab as part of routine clinical management within the indication of this drug.
89570294|NCT04968301||hip developmental dysplasia group|patients with developmental dysplasia of hip
89570295|NCT04968301||femoroacetabular impingement group|patients with femoroacetabular impingement
89570296|NCT04968301||control group|healthy volunteers
89570297|NCT05575427|Experimental|Combination therapy with minocycline|"Minocycline oral 50 mg per capsule~4 capsules oral stat then 2 capsules oral every 12 hours~duration 7-28 days"
89209004|NCT00726323|Experimental|daily dosing|80 mg foretinib on a daily dosing regimen
89209005|NCT00881400|Experimental|1|Cefprozil 250 mg/5 ml Oral Suspension (Sandoz, Austria)
89209006|NCT00881400|Active Comparator|2|Cefzil (Cefprozil) 250 mg/5 ml Oral Suspension (Bristol-Myers Squibb, USA)
89209007|NCT00805376|Experimental|Group A: DNX-2401|Surgical procedure precisely injects DNX-2401 through a catheter (small tube) into brain tumor.
89209008|NCT00805376|Experimental|Group B: DNX-2401 + Surgery|DNX-2401 injection + Tumor removal
89570298|NCT05575427|Active Comparator|Monotherapy plus placebo|Patients were treated Stenotrophomonas maltophilia infection with standard monotherapy either levofloxacin or Trimethoprim/sulfamethoxazole plus placebo
89570299|NCT03059095|Experimental|Yoga and Meditation|Yoga and Meditation online sessions 2x's a week.
89570300|NCT04959253|Experimental|Psilocybin 25mg PO|
89570301|NCT04959253|Placebo Comparator|Placebo PO|
89570302|NCT02499159|Experimental|Exparel|Liposomal Bupivicaine (Exparel) - 266 mg, 20 mL total, diluted at surgeon's discretion, Two doses of 10 mL each, into two separate incisions, delivered via 22 gauge needle.
89570303|NCT02499159|Active Comparator|0.25% standard bupivicaine|Bupivicaine - 0.25%, 20 mL total. Two doses of 10 mL each, into two separate incisions, delivered via 22 gauge needle.
89570304|NCT01664039|Experimental|TRAVATAN|Travoprost 0.004% ophthalmic solution with Polyquad®, 1 drop to the study eye(s), once a day in the evening, for 6 months
89209009|NCT00246571|Experimental|A|
89209010|NCT00246571|Active Comparator|B|
89209011|NCT02553356|Experimental|Fasted|PT2385 taken after fasting.
89570305|NCT01664039|Active Comparator|LUMIGAN|Bimatoprost 0.01% ophthalmic solution with BAK, 1 drop to the study eye(s), once a day in the evening, for 6 months
89570306|NCT04968145|No Intervention|Control Group|Participants in the control group receive routine follow up care which consists of (i) written instructions regarding potential complications and the contact information of their treating surgeon, (ii) a follow up telephone call 4 weeks following discharge by a member of the health care team and (iii) an in-person follow up visit in clinic with the treating surgeon 4-6 weeks following discharge.
89570307|NCT04968145|Experimental|Intervention Group|The participants in the intrevention group receive the same routine care as the control group in addition to post discharge monitoring with the Home to Stay app
89570308|NCT02445573|Active Comparator|EA group|
89570309|NCT02445573|Placebo Comparator|Sham EA group|
89570310|NCT05645705|Experimental|Arm 1: Brush/ LISTERINE Cool Mint Antiseptic Mouthwash|At Day 0, participants will use their products at the site and saliva samples will be taken at pre-determined timepoints. At home, participants will use their products twice a day for approximately 14 days.
89570311|NCT05645705|Experimental|Arm 2: Brush / Listerine Advanced Gum Alcohol|At Day 0, participants will use their products at the site and saliva samples will be taken at pre-determined timepoints. At home, participants will use their products twice a day for approximately 14 days.
89570312|NCT05645705|Experimental|Arm 3: Brush / Listerine Advanced Gum Zero|At Day 0, participants will use their products at the site and saliva samples will be taken at pre-determined timepoints. At home, participants will use their products twice a day for approximately 14 days.
89570313|NCT05645705|Experimental|Arm 4: Brush / LISTERINE ULTRACLEAN Tartar Control Antiseptic Mouthwash Cool Mint|At Day 0, participants will use their products at the site and saliva samples will be taken at pre-determined timepoints. At home, participants will use their products twice a day for approximately 14 days.
89570314|NCT05645705|Other|Arm 5: Brush Only|At Day 0, participants will use their products at the site and saliva samples will be taken at pre-determined timepoints. At home, participants will use their products twice a day for approximately 14 days.
89570315|NCT04968067|Experimental|App group|In addition to the usual care, the participant will receive a health talk , a CHD app and a briefing from a trained research nurse (A). The app provides features such as structured e-educational contents and supportive features such as knowledge platform and member area.
89570316|NCT04968067|Active Comparator|Nursing telephone advice (NTA) group|In addition to the above usual care, the participant will receive a health talk , three monthly 20-minute telephone follow-ups supplemented by take home leaflet will be provided by a trained research nurse for up to 3 months. Patients can ask about their related health problems, if any. The team has set up a telephone advice guide to support the research nurse in giving phone advice and text messages.
89570317|NCT05644613|Active Comparator|GROUP A|will consist of (20) adolescent girls age ranged from 14-17 suffering from PMS without any pathological cause they will receive an aerobic exercise on land in form of walking on the treadmill for 20 min 3 times per week for 3 months.
89570318|NCT05644613|Active Comparator|GROUP B|will consist of (20) adolescent girls age ranged from 14-17 suffering from PMS without any pathological cause they will receive an aerobic exercises in water in form of walking on the treadmill for 20 min 3 times per week for 3 months
88970268|NCT04266704|Active Comparator|Control|education on a low sodium diet (Dietary Approaches to Stop Hypertension or DASH), exercise, and medication adherence
88970269|NCT04253080|No Intervention|patients with primary thin melanoma < or = 1mm|patients with primary thin melanoma (Breslow thickness less than or equal 1 mm)
88970270|NCT04253080|No Intervention|patients with primary thick melanoma > or = 3 mm|patients with primary thick melanoma (Breslow greater than or equal 3 mm)
88970271|NCT04253080|Other|patient with melanoma who received treatment|patient with melanoma (stages III or IV inoperable) and who received first line treatment with immunotherapy and / or targeted therapies
88970272|NCT04240054|Experimental|Safety Lead-in Cohort A|"Six transplant-eligible multiple myeloma patients with renal impairment will be enrolled.~Bortezomib (1.5 mg/m^2) subcutaneous on days 1,8 and 15 Isatuximab (10 mg/kg) IV on days 1, 8, 15 and 22 Cyclophosphamide (250 mg/m^2) IV on days 1, 8 and 15 Dexamethasone 20 mg PO or IV (10 mg if >75 years) on days 1, 2, 8, 9,15,16, 22 and 23"
89570319|NCT02445339|Active Comparator|Intervention Arm: XR-NTX+CM|XR-NTX+CM (Extended Release Naltrexone + Care Management)
89570320|NCT02445339|No Intervention|Standard Care Arm|Standard Care/Alcohol-Medical Management (MM) Only
89570321|NCT04951531|Experimental|BPTB double-bundle allograft group|The patient underwent arthroscopic double-bundle anterior cruciate ligament (ACL) reconstruction with bone-patellar tendon-bone (BPTB) allograft．
89570322|NCT04951531|Active Comparator|BPTB single-bundle allograft group|The patient underwent arthroscopic single-bundle anterior cruciate ligament (ACL) reconstruction with bone-patellar tendon-bone (BPTB) allograft．
89570323|NCT04951531|Active Comparator|BPTB single-bundle autograft group|The patient underwent arthroscopic single-bundle anterior cruciate ligament (ACL) reconstruction with bone-patellar tendon-bone (BPTB) autograft．
89570324|NCT04934787|Experimental|ENMS-BSF assisted gait training|The participants will receive the full assistance of the ENMS-BSF during a 20-session gait rehabilitation.
89570325|NCT04934787|Active Comparator|Partial ENMS-BSF assisted gait training|The participants will receive a partial assistance of the ENMS-BSF during a 20-session gait rehabilitation.
89570326|NCT04934787|Sham Comparator|Sham ENMS-BSF assisted gait training|The participants will only wear the device without assistance during a 20-session gait rehabilitation.
89570327|NCT04951765|Experimental|Arm A|Cycle1 Day 1：fasting；Cycle2 Day 1：high-fat meal；Cycle3 Day 1：low-fat meal
89570328|NCT04951765|Experimental|Arm B|Cycle1 Day 1：high-fat meal；Cycle2 Day 1：low-fat meal；Cycle3 Day 1：fasting
89570329|NCT04951765|Experimental|Arm C|Cycle1 Day 1：low-fat meal；Cycle2 Day 1：fasting；Cycle3 Day 1：high-fat meal
89570330|NCT04951765|Experimental|Arm D|Cycle1 Day 1：fasting；Cycle2 Day 1：low-fat meal；Cycle3 Day 1：high-fat meal
89570331|NCT04951765|Experimental|Arm E|Cycle1 Day 1：high-fat meal；Cycle2 Day 1：fasting；Cycle3 Day 1：low-fat meal
89570332|NCT04951765|Experimental|Arm F|Cycle1 Day 1：low-fat meal；Cycle2 Day 1：high-fat meal；Cycle3 Day 1：fasting
89570333|NCT03674931|Experimental|musical practice|Intensive weekly musical keyboard training over 12 months
89570334|NCT03674931|Active Comparator|music education|Recreative weekly musical courses without practice over 12 months
89570335|NCT04959409||Exposed Cohort|Children receiving topical analgesia
89570336|NCT04959409||Control / Unexposed Cohort|Children who do not receive topical analgesia
89570337|NCT03058939|Experimental|Paclitaxel|Investigators plan to treat patients with paclitaxel weekly for a total of approximately 16 weeks (8 weeks before ultrasonography for response assessment and 8 weeks before surgery in good responders). Paclitaxel 80mg/m2 will be given on days 1, 8, 15 and so on for a total of 8 doses.
89570338|NCT03058939|Other|Carboplatin|After first 8 weeks of paclitaxel, those with progressive disease (based on breast US assessment) or partial response but inoperable will have carboplatin added to their regimen. Patients will receive 8 cycles of weekly paclitaxel and carboplatin (PC).
89570339|NCT03058939|Other|Fluorouracil Epirubicin Hydrochloride Cyclophonsphamide (FEC)|Patients with poor response to 8 courses of paclitaxel followed by 8 courses of PC based on ultrasound assessment will be regarded as failing to respond to treatment. These patients will receive 4 cycles of 3-weekly FEC and will be followed up.
89570340|NCT03058939|Other|LHRH (luteinizing hormone-releasing hormone)|All Premenopausal patients will receive LHRH agonist for two years for contraception and fertility preservation.
89570341|NCT03058939|Other|Tamoxifen or letrozole|Hormone-receptor positive patients will receive hormonal therapy with tamoxifen or letrozole after surgery, radiotherapy and LHRH agonist according to the expression of hormone receptors and according to the state of primary menopause at the onset of the study.
89570342|NCT03058939|Other|Herceptin SC and Perjeta|Patients with HER2-positive disease (see glossary and section 10.3) will receive 5 three-weekly courses of trastuzumab (Herceptin SC) with pertuzumab (Perjeta). After that pts will continue receiving trastuzumab to complete total of 18 doses within 1 year of treatment.
89570343|NCT03061045|Experimental|Contrast Enhanced Brain Ultrasound|Neonates with post-hemorrhagic hydrocephalus recruited for this study will all undergo contrast enhanced ultrasound examination of the head, a diagnostic intervention for the study.
89570344|NCT03058471|Active Comparator|methotrexate|mehotrexate 10 mg weekly, to be increased by 5 mg in each visit to a maximum of 25 mg
89570345|NCT03058471|Active Comparator|non steroidal anti inflammatory drugs|NSAID in full dose with Pantoprazole. If remission not achieved at 2 months, will be given methotrexate as in methotrexate arm
89570346|NCT03060967|Experimental|Depressed patients|Computer-based tasks evaluating size and time discrimination capacities of food and control images
89570347|NCT03060967|Experimental|Normal Healthy Volunteers|Computer-based tasks evaluating size and time discrimination capacities of food and control images
89570348|NCT02579603|Experimental|Nintedanib|Nintedanib 150 mg bid
89570349|NCT02579603|Experimental|Nintedanib and Pirfenidone|Nintedanib 150 mg bid combined with pirfenidone up to 801 mg tid
89570350|NCT04958629||non-FH Group|
89570351|NCT04958629||FH Group|
89570352|NCT04958863|No Intervention|No Mask|Runners do not use mask while running
89028734|NCT05986370|Experimental|lumbar spinal manipulative therapy|Participants will receive spinal manipulative therapy (SMT) exclusively at dysfunctional lumbar segments. Participants will receive 36 SMT sessions over 12 weeks, 3 times per week, each session lasting ≈15 min. Spinal manipulation will be performed using the diversified technique. For each treatment, the SMT provider will perform two spinal manipulations, one on each side of the most painful lumbar vertebra. During spinal manipulations, participants will lay on their side and they will be instructed to inhale and exhale fully before each thrust.
89028735|NCT05986370|Experimental|full spine spinal manipulative therapy|Participants will receive spinal manipulative therapy (SMT) at dysfunctional spinal segments in the lumbar AND other spine regions. Participants will receive 36 spinal manipulative therapy (SMT) sessions over 12 weeks, 3 times per week, each session lasting ≈15 min. Spinal manipulation will be performed using the diversified technique. For each treatment, the SMT provider will perform a minimum of two spinal manipulations, one on each side of the most painful lumbar vertebra. Spinal manipulation will also be delivered at other dysfunctional spinal segments, based on clinical examination. During spinal manipulations, participants will lay prone, supine or on their side and they will be instructed to inhale and exhale fully before each thrust.
89033117|NCT02917902|Other|Delayed intervention|Intervention: Food boxes. Monthly boxes of food for 6 months, along with brief educational information from food pantry staff regarding eating healthy on a budget, starting 3 months after randomization. Patients will continue to receive routine medical care at the Free Clinic. Participants will be given referrals to local food pantries in their neighborhoods that provide food free of charge as well as referrals for CalFresh (formerly known as food stamps) during the 3 month time frame when patients are waiting to receive food distributions on site at the clinics.
89033118|NCT00531596|Active Comparator|A|EMSAM 6mg/24hr
89033119|NCT00531596|Active Comparator|B|EMSAM 9mg/24Hr
89033120|NCT00531596|Active Comparator|C|EMSAM 12mg/24Hr
89570353|NCT04958863|Experimental|Surgical Mask|Runners use surgical mask while running
89570354|NCT04958863|Experimental|Polyester Reusable Mask|Runners use polyester reusable mask while running
89570355|NCT04416841|Experimental|Tai Chi Chuan Group|In addition to conventional medical treatment, participants will receive 3 sessions of 1-hour Tai Chi Chuan training per week for 24 weeks and standard diabetic care education.
89570356|NCT04416841|Active Comparator|Fitness Walking Group|In addition to conventional medical treatment, participants will receive 3 sessions of 1-hour fitness walking training per week for 24 weeks and standard diabetic care education
89570357|NCT04416841|Other|Control group|In addition to conventional medical treatment, participants will receive standard diabetic care education 0.5hour/session, 2 sessions/month for 6 months.
89570358|NCT05696639||Undeveloped venous group|patients with undeveloped cerebral venous
89570359|NCT05696639||Well Developed venous group|patients with well-developed cerebral venous
89570360|NCT04967911|Experimental|Rhythmic stabilization exercises|baseline physical therapy conventional treatment along Rhythmic stabilization exercises
89570361|NCT04967911|Other|Conventional treatment|Baseline physical therapy conventional treatment
89570362|NCT04951141|Experimental|anti-GPC3 CAR-T|
89570363|NCT03060889|Active Comparator|Cases|Tranexamic acid 10 mg/ kg body weight will be given by intravenous infusion with induction of anesthesia in elective cesarean section for non complicated cases of placenta previa
89570364|NCT03060889|No Intervention|Controls|Control group will not receive Tranexamic acid
89570365|NCT04950829|Active Comparator|Conventional brackets|Patients will receive an orthodontic treatment using conventional brackets until achieving appropriate alignment of the upper anterior teeth.
89570366|NCT04950829|Experimental|Self-ligating brackets|Patients will receive an orthodontic treatment using self-ligating brackets until achieving appropriate alignment of the upper anterior teeth.
89570367|NCT04950829|Experimental|3- Self-Ligating brackets with fapless corticotomy|Patients will receive an orthodontic treatment using self-ligating brackets with corticotomy until achieving appropriate alignment of the upper anterior teeth.
89570368|NCT05564195||Patients undergoing elective surgery with a duration of > 60 minutes|Participants included will be patients undergoing planned non-cardiac surgery with general anesthesia that are >60 years of age, have a Mini-mental state examination score of >24, are able to speak Swedish and does not suffer from uncorrected severe visual or auditory disorder, disease of the central nervous system, psychiatric diseases including alcoholism or drug dependence, current motor impairment in dominant hand, or colour-blindness.
89570369|NCT04373993||Nordlandssykehuset HF|
89570370|NCT04373993||Akershus universitetsssykehus|
89028736|NCT05986370|Sham Comparator|sham spinal manipulative therapy|"Participants will receive 36 sham SMT sessions (3x/week for 12 weeks, each session ≈15 min). This will target dysfunctional segments in the lumbar and other spine regions. Three maneuvers will be used:~Ventral decubitus: 1 to 5 light and brief manual contacts (≈ 20 N and 5 s) will be applied and quickly released over the spinous process of dysfunctional vertebrae identified during clinical examination.~Dorsal decubitus: sections of the treatment table will be slightly raised or lowered (≈ 5 cm) and their lower limbs' position changed once or twice e.g., knees bent, hips internally or externally rotated. Each position maintained during ≈ 30 s.~Lateral decubitus: 1 to 5 impulses at the lowest setting of the Activator V instrument (Activator Methods Int. Ltd., Phoenix, Arizona, USA) will be applied on their gluteus and quadratus lumborum muscles. The position of the instrument will change after each impulse."
89028737|NCT05986370|No Intervention|no intervention|This fourth arm will comprise healthy volunteers (age/sex-matched to the participants in the test intervention - lumbar group) who will not receive any intervention. The main purpose of this fourth group is to provide reference values to interpret some results obtained in participants with chronic primary low back pain.
89028738|NCT05985668||Suspected|Suspected Platelet Function Disorder during bleeding investigation
89028739|NCT05985668||Confirmed|Confirmed Platelet Function Disorder by Functional or Genetic Assay, or confirmed negative by gold standard assay
89028740|NCT05980065|Experimental|Dose level 1|C1K 150mg
89028741|NCT05980065|Experimental|Dose level 2|C1K 300mg or placebo
89028742|NCT05980065|Experimental|Dose level 3|C1K 600mg or placebo
89028743|NCT05980065|Experimental|Dose level 4|C1K 900mg or placebo
89028744|NCT05980065|Experimental|Dose level 5|C1K 1200mg or placebo
89028745|NCT05974488|Experimental|Distal Pharyngeal Airway|Participants in this group will use the McMurray enhanced airway to have oxygen delivered throughout a TEE procedure for up to 60 minutes.
89570371|NCT04373993||Helgelandssykehuset|
89570372|NCT04373993||Basel University Hospital|
89570373|NCT04967755|Experimental|Jing-Si-Herbal-Tea(JSHT)|Eligible patients were randomized to receive routine treatment alone based on the Novel Coronavirus Interim Guidelines for Clinical Management of SARS-CoV-2 Infection (Eleventh edition 2021) (control group) or the combination of routine treatment and JSHT (1 drink thrice daily for 7 days) (JSHT group) at the discretion of the attending clinicians.
89570374|NCT04950907|Experimental|treatment|Uniportal VATS biopsy
89570375|NCT04950907|Active Comparator|control|CT-guided fine needle biopsy
89570376|NCT04950595|Experimental|Beef mince group|The test meal provided at lunch will be made up of 45% beef mince, with all remaining ingredients the same as the other arm.
88811129|NCT04201457|Experimental|Phase 1 Stratum 2 BRAF aberration or LGG with NF1|LGG with BRAF duplication or fusion with any partner or LGG with NF1 will received Trametinib and Hydroxychloroquine. All medications are administered orally with Trametinib given once per day and HCQ give twice per day at the assigned dose for a 28 day course. Courses may repeat until the patient meets an off treatment criteria.
89028746|NCT05974488|Active Comparator|Nasal cannula group|Participant in this group will receive oxygen through a nasal cannula during the TEE procedure for up to 60 minutes.
89028747|NCT05973435||General Anesthesia|
89028748|NCT05973435||Spinal anesthesia|
89028749|NCT05970094|Experimental|Low PRAL diet|Crossover design: 1 arm consisting of three consecutive periods of two weeks (control, intervention and follow up).
89028750|NCT05968963|Experimental|Mindfulness-based Music Therapy (MBMT)|Participants will be in the MBMT group for 5 months.
89028751|NCT05968963|Experimental|Mindfulness Meditation (MM)|Participants will be in the MM group for 5 months.
89028752|NCT05967663|Experimental|Intervention group|Immediate complete revascularisation
89028753|NCT05967663|Active Comparator|Control group|Staged complete revascularisation
89209012|NCT02553356|Experimental|Non-Fasting|PT2385 taken after eating a high calorie meal.
89570377|NCT04950595|Experimental|Plant-based mince group|The test meal provided at lunch will be made up of 45% plant-based mince, with all remaining ingredients the same as the other arm.
89570378|NCT04421365|Active Comparator|Active neurofeedback BCI|Patients are presented with symptomatic speech and asymptomatic whisper and, using active EEG-based neurofeedback, are trained to correct their speech by matching their brain patterns to those of whisper. This training is expected to be effective for symptom improvement.
89570379|NCT04421365|Sham Comparator|Sham neurofeedback BCI|Patients are presented with symptomatic speech and asymptomatic whisper and, using sham EEG-based neurofeedback, are trained to correct their speech by matching their brain patterns to those of whisper. This training is expected not to be effective for symptom improvement.
89570380|NCT04411589|Experimental|Magnifying endoscopy with optical enhancement system group|Patients in this group go through gastroscopy under the magnifying endoscopy with optical enhancement system.
89570381|NCT04411589|Active Comparator|white light endoscopy group|Patients in this group go through gastroscopy under white light endoscopy.
89570382|NCT04958395||Myocardial bridge|Measure FFR and d-FFR
89570383|NCT04311827||Serratus anterior plane block and traditional analgesia|Serratus anterior plane block (Bupivacaine 75mg injected into facial plane once) Acetaminophen 1000mg IV every 6 hours as needed Toradol 15mg IV every 6 hours as needed Morphine 4mg every 2 hours as needed Hydromorphone 0.5mg IV every 2 hours as needed
89570384|NCT04311827||Traditional analgesia|Serratus anterior plane block (Bupivacaine 75mg injected into facial plane once) Acetaminophen 1000mg IV every 6 hours as needed Toradol 15mg IV every 6 hours as needed Morphine 4mg every 2 hours as needed Hydromorphone 0.5mg IV every 2 hours as needed
89570385|NCT04958317|Placebo Comparator|Early exercise|Participants will exercise for 30 minutes prior to an evening meal
89570386|NCT04958317|Experimental|Late exercise|Participants will exercise for 30 minutes after an evening meal
89570387|NCT04950751|Experimental|SCB-2020S Standard Dose|Day 1 and 22: standard dose SCB-2020S with CpG 1018/alum adjuvant
89570388|NCT04950751|Experimental|SCB-2020S Low Antigen Dose|Day 1 and 22: low dose SCB-2020S with CpG 1018/alum adjuvant
89570389|NCT04950751|Experimental|SCB-2020S Low Adjuvant Dose|Day 1 and 22: standard dose SCB-2020S with low dose CpG 1018/alum adjuvant
89570390|NCT04950751|Experimental|SCB-2020S Mixed Series|Day 1 (Dose 1) standard dose SCB-2020S with CpG 1018/alum adjuvant and Day 22 Dose 2) standard dose SCB-2020S with alum adjuvant
89570391|NCT04950751|Active Comparator|SCB-2019|Day 1 and 22: standard dose SCB-2019 with CpG 1018/alum adjuvant
89570392|NCT04950517||Wave 1 participants|The study consists of three work packages. Wave 1 participants will be included in all work packages.
89570393|NCT04950517||Wave 2 participants|The study consists of three work packages. Wave 2 participants will only be recruited for work package 2.
89570394|NCT04967131||PNF group|Proprioceptive Neuromuscular Fascilitation exercises were given this group
89570395|NCT05546957|Experimental|Arm 1: Aspirin QD|Randomized 1:1:1
89570396|NCT05546957|Experimental|Arm 2: Aspirin QD + rivaroxaban BID|Randomized 1:1:1
89570397|NCT05546957|Experimental|Arm 3: Aspirin QD + rivaroxaban QD|Randomized 1:1:1
89570398|NCT04950205|Experimental|Sevoflurane post conditioning group（S1）|propofol：0.05～0.1mg/(kg.min) maintain throughout the whole surgery ,1% sevoflurane plus after open Carotid artery until the end of surgery
89570399|NCT04950205|No Intervention|The control group（P）|propofol：0.05～0.1mg/(kg.min) maintain throughout the whole surgery without sevoflurane
89570400|NCT05544461|Experimental|Intervention group|Those in the intervention group will receive eNutri PN advice after completing the eNutri FFQ at baseline only. At weeks 1 and 3 of the study, participants will also receive coaching emails which includes reminders of their PN advice, questions asking them to reflect on their goal progress (if any), and tips and recipes to help them follow the PN advice.
89570401|NCT05544461|No Intervention|Control group|Those in the control group will not receive any PN advice from eNutri and hence, will not receive any coaching emails. They will only record their diet using the eNutri FFQ.
89570402|NCT04415047|Experimental|Transcatheter Aortic Valve Replacement (TAVR)|TAVR with JenaValve Trilogy Heart Valve System Intervention Device: JenaValve Trilogy Heart Valve System
89570403|NCT05540093|Experimental|high power pain threshold ultrasound|the patients will receive high power pain threshold ultrasound and traditional therapy twice a week for four weeks
89570404|NCT05540093|Active Comparator|traditional therapy|the patients will receive traditional therapy twice a week for four weeks
89570405|NCT05592041|Experimental|Treatment group (Group I)|
89570406|NCT05592041|No Intervention|Control group (Group II)|
89570407|NCT02625259|Experimental|Part 1: TAK-117 9*100 mg + TAK-117 3*300 mg|TAK-117900 milligram (mg), capsules, orally, once on Day 1, followed by 2 weeks of washout, followed by TAK-117 900 mg, tablets, orally, once on Day 15.
89570408|NCT02625259|Experimental|Part 1: TAK-117 3*300 mg + TAK-117 9*100 mg|TAK-117 900 mg tablets, orally, once on Day 1, followed by 2 weeks of washout, followed by TAK-117 900 mg, capsules, orally, once on Day 15.
89570409|NCT02625259|Experimental|Part 2: TAK-117 Fasted + TAK-117 Fed|TAK-117 at the dose determined in Part 1, tablets, in fasted condition, orally, once on Day 1, followed by 2 weeks of washout, followed by TAK-117 at the dose determined in Part 1, tablets, with a standard high-fat meal, orally, once on Day 15.
89570410|NCT02625259|Experimental|Part 2: TAK-117 Fed + TAK-117 Fasted|TAK-117 at the dose determined in Part 1, tablets, with a standard high-fat meal, orally, once on Day 1, followed by 2 weeks of washout, followed by TAK-117 at the dose determined in Part 1, tablets, in fasted condition, orally, once on Day 15.
89570411|NCT02625259|Experimental|Part 3: TAK-117 + Lansoprazole|TAK-117 at the dose determined in Part 1, tablets, orally, once on Day 1, followed by lansoprazole 30 mg, tablets or capsules, once daily from Day 10 to Day 15, followed by TAK-117 at the dose determined in Part 1, tablets, orally, once on Day 15.
89570412|NCT04958083|Experimental|aortopathy patient|Patients who have proximal aortic conditions and are referred to the aortic team in Royal Brompton and Harefield Hospitals will be screened for eligibility. For this pilot study and in view of the volume of aortic surgery in the Trust (approx. 100 cases per year), 30 patients will be recruited in the first year of this project to be followed for at least one year for clinical outcomes.
89570413|NCT02577107|Experimental|Ranibizumab 0.5 mg|Three monthly injections of 0.5mg Ranibizumab
89570414|NCT02577107|Active Comparator|Conbercept 0.5 mg|Three monthly injections of 0.5mg Conbercept
89570415|NCT04958473|Experimental|Patients with advanced RCC|Patients with a diagnosis of kidney cancer (renal cell carcinoma, advanced or metastatic, previously treated or untreated)
89570416|NCT04957927|Experimental|Intranasal Fluticasone Propionate Group|Intranasal Fluticasone Propionate 50mcg/actuation in each nostril 24 hourly
89028754|NCT05966896|Experimental|Epidural stimulation with Physical Therapy|"Stimulation parameters will be optimized for each lower extremity and joint movement. During physical therapy sessions, electrode configurations may be adjusted as needed to optimize stimulation frequencies, and voltage intensity ranges to best enable voluntary control of lower extremity (ankle, knee, and hip) flexion and extension, as well as standing.~Intensive physical therapy will consist of 3 visits per week over the course of 6 months directed by a licensed physical therapist with over a decade of experience working with individuals with spinal cord injury, and the epidural stimulator will be ON continuously during these sessions. Physical therapy will involve neurorehabilitation to facilitate voluntary lower extremity movement in the presence of stimulation, with the research participants in the supine, seated, and standing positions."
89570417|NCT04957927|Experimental|Montelukast Group|Montelukast 4mg oral granule formulation 24 hourly
89570418|NCT04957849|Active Comparator|Trans-frontal keyhole approach|After general anesthesia, the patient was placed in supine position with head frame fixed. A straight or arc incision was made in the hairline of the affected side. The incision was 3cm beside the midline. The length of the incision was about 4cm and the diameter of the bone window was about 2.5cm. According to the preoperative thin-layer CT scan, the dura mater and part of the cerebral cortex were cut, and the endoport and other hard channels were inserted. The incision reached 2 / 3 of the length of the hematoma along the direction parallel to the long axis of the hematoma, During the operation, mini aneurysms were clipped to close the responsible vessels, and hemostatic gauze was applied on the surface of the hematoma cavity. Silica gel external drainage tube was placed in the hematoma cavity. The external drainage tube led out the skin through the subcutaneous tunnel, and the dura was sutured.
89570419|NCT04957849|Active Comparator|Trans-occipital keyhole approach|After general anesthesia, the patient was placed in prone position with head frame fixed. According to the preoperative thin-layer CT scan, the long axis of hematoma was perpendicular to the ground, and the occipital puncture point was found along the extension line of the long axis of hematoma. Taking the puncture point as the center, a straight or arc incision parallel to the sagittal sinus was taken. The length of the incision was about 4cm, and the diameter of the bone window was about 2.5cm, Endoport and other hard channels were inserted to reach 2 / 3 of the long diameter of the hematoma along the direction parallel to the long axis of the hematoma. Under the neuroendoscope, the hematoma was aspirated or resected in blocks. During the operation, mini aneurysm clamp was used to clamp the responsible vessels, and hemostatic gauze was applied on the surface of the hematoma cavity. Silica gel external drainage tube was placed in the hematoma cavity.
89570420|NCT04688801|Active Comparator|Chemotherapy± Radiotherapy Group|Chemotherapy± Radiotherapy is used as adjuvant therapy for high risk patients after surgery with or without neoadjuvant therapy.
89570421|NCT04688801|Experimental|Chemotherapy + Immunotherapy ± Radiotherapy Group|Chemotherapy + Immunotherapy ± Radiotherapy is used as adjuvant therapy for high risk patients after surgery with or without neoadjuvant therapy.
89570422|NCT04957771|Experimental|Regular exercise group|
89570423|NCT04957771|No Intervention|non-regurlar exercise group|
89570424|NCT04966975||Histologically confirmed bladder cancer treated with NAC|
89570425|NCT04950049|Active Comparator|2 ml dexamethasone (5 mg/ml)|50 patients receive 2 ml dexamethasone (5 mg/ml) , the injection time of dexamethasone was less than 2s.
89570426|NCT04950049|Experimental|5 ml dexamethasone (2mg/ml)|50 patients receive 5 ml dexamethasone (2mg/ml) diluted with 5% glucose, the injection time of dexamethasone was 30s.
89570427|NCT04950049|Experimental|10 ml dexamethasone (1mg/ml)|50 patients receive 10 ml dexamethasone (1mg/ml) diluted with 5% glucose, the injection time of dexamethasone was 30s.
89570428|NCT04950049|Experimental|20 ml dexamethasone (0.5mg/ml)|50 patients receive 20 ml dexamethasone (0.5mg/ml) diluted with 5% glucose, the injection time of dexamethasone was 30s.
89570429|NCT04966897|Experimental|GBNS + PERT placebo|GBNS + PERT placebo (drink volume sufficient to supply 0.5 g of MAG per kg of body weight plus PERT placebo capsules according to patient body weight.
89570430|NCT04966897|Active Comparator|Standard Nutritional Supplement + PERT|Standard nutritional supplement + PERT (drink volume sufficient to supply 0.5 g of TAG per kg of body weight plus PERT capsules according to body weight).
89570431|NCT03737045|Other|Decision Aid Testing|Participants will have the opportunity to test the different decision aid prototypes while selecting new treatment/therapy.
89570432|NCT05587673|Experimental|Methylprednisolone|Participants who have failed first line therapy and are still experiencing flare symptoms.
89570433|NCT02444793|Experimental|PF-05082566 + KW-0761|During Parts 1 & 2 Mogamulizumab and PF-05082566 will be administered at appropriate intervals. Part 1: PF-05082566 dose escalation; increased doses of PF-05082566 IV are administered with mogamulizumab IV. Part 2: patients will be treated with the maximum tolerated dose established in Phase 1 for the combination.
89570434|NCT04957381||low to moderate CRF with low MF|According to the senior fitness test norms in Taiwan, participants with low to moderate cardiorespiratory fitness (CRF) and low muscular fitness (MF).
89570435|NCT04957381||low to moderate CRF with moderate MF|According to the senior fitness test norms in Taiwan, participants with low to moderate cardiorespiratory fitness (CRF) and moderate muscular fitness (MF).
89570436|NCT04957381||low to moderate CRF with high MF|According to the senior fitness test norms in Taiwan, participants with low to moderate cardiorespiratory fitness (CRF) and high muscular fitness (MF).
89570437|NCT04957381||high CRF with low to moderate MF|According to the senior fitness test norms in Taiwan, participants with high cardiorespiratory fitness (CRF) and low to moderate muscular fitness (MF).
89570438|NCT04957381||high CRF and high MF|According to the senior fitness test norms in Taiwan, participants with high cardiorespiratory fitness (CRF) and high muscular fitness (MF).
89570439|NCT04957069||Avulsion fracture|avulsion fracture of the Achilles tendon
89570440|NCT04957069||Rupture|Achilles tendon rupture
89570441|NCT04966429|Active Comparator|Maraviroc 150 mg per day|
89570442|NCT04966429|Active Comparator|Maraviroc 600 mg per day|
89570443|NCT04966429|Placebo Comparator|Placebo|
89570444|NCT04956913||Mac Grath|Patients of this group were intubated using Mac Gath videolaryngoscope
89570445|NCT04956913||Machintosh|Patients of this group were intubated using the classic Macintosh laryngscoscope
89570446|NCT04956991||CDAI≤220|According to the Crohn's disease activity index (CDAI) scores, all the patients included in the study were divided into group A (CDAI≤220)
89570447|NCT04956991||CDAI>220|According to the Crohn's disease activity index (CDAI) scores, all the patients included in the study were divided into group B (CDAI>220)
89570448|NCT04949659|Experimental|Low pressure pneumoperitoneum|Use of low pressure pneumoperitoneum during laparoscopic appendectomy
89028755|NCT05949047|Experimental|Distancing|Participants will receive structured cognitive emotion regulation training from an experimenter during an approximately 10-minute interaction via videoconference in which detailed instructions for implementation of the distancing strategy is explained (i.e. appraising an emotional stimulus as an objective, impartial observer).
89028756|NCT05949047|Active Comparator|Reinterpretation|Participants will receive structured cognitive emotion regulation training from an experimenter during an approximately 10-minute interaction via videoconference in which detailed instructions for implementation of the reinterpretation strategy is explained (i.e. imagining a better outcome than what initially seemed apparent).
89028757|NCT05949047|No Intervention|"No regulation Look Only"|"The No Regulation Look Only Control group will serve as a habituation and natural history control; they will see the same emotional images, but they will only be cued to look and respond naturally for all trials."
89028758|NCT05940584|Experimental|Intervention Group Tele-reha (1)|Tele-reha group
89028759|NCT05940584|Active Comparator|Control Group Paper-based exercises (1)|Paper-based exercises with option to do tele-reha afterwards
89028760|NCT05940584|Active Comparator|Control Group Paper-based exercises (2)|Only paper-based exercises
89028761|NCT05939492|No Intervention|Standard of Care Control|Participants in this arm will receive the standard of care. For patients with idiopathic chest pain, the standard of care is typically just reassurance of the benign nature of their pain.
89028762|NCT05939492|Experimental|Mindfulness-Based Intervention|Participants in this arm will partake in a 30 day mindfulness-based intervention on the mobile app Headspace.
89028763|NCT05932589||RTT Females|Females with Rett Syndrome
89028764|NCT05932589||Controls|Females with typical development
89028765|NCT05929664|Experimental|Treatment (cemiplimab)|Patients receive cemiplimab IV on study. Patients undergo CT scans and collection of blood samples throughout the trial.
89028766|NCT05927519|Active Comparator|morbidly obese|Class 2 (bmı >35) weight kg/height m2 and class 3 (bmı>40) obese men
89028767|NCT05927519|Placebo Comparator|nonobese|bmı<30 weight kg/ height m2 men
89570449|NCT04949659|Experimental|Medium pressure pneumoperitoneum|Use of medium pressure pneumoperitoneum during laparoscopic appendectomy
89570450|NCT04949581|Experimental|bioelectric therapy|patients will receive micro-current electrical stimulation three times/week for four weeks
89570451|NCT04949581|Active Comparator|cardiac rehabilitation programe|patients will receive a cardiac rehabilitation program three times/week for four weeks
89570452|NCT04949971||High volume group|The tidal volume of the exposed group was 10ml/kg ideal body weight.
89570453|NCT04949971||Low volume group|The tidal volume of the non-exposed group was 6ml/kg ideal body weight
89570454|NCT04966195|Other|radiotherapy|stereotactic body radiotherapy of hepatocellular carcinoma patients with portal vein tumor thrombosis
89570455|NCT04965883|Experimental|Early Excision and Grafting|"The early excision will be done surgically within 4-10 days post burn by whatson knife by tangential excision of burned tissue until capillary bleeding appears to make a good bed to be covered with grafts split thickness grafts STG at the same time.~The first dressing will be in the fifth day post operative."
89570456|NCT04965883|Experimental|Dressing and Delayed Grafting|• Dressing will be done for the second group every other day until spontanous eschar seperation or after surgiacl debridrment of adherent eschar then for delayed grafting more than 10 days post burn.
89570457|NCT04949347||Glycerin-preserved, human-donor, cornescleral patch grafts|Consecutive glaucoma patients who had undergone glaucoma drainage device implantation using glycerin-preserved, human-donor, cornescleral patch grafts
89570458|NCT04956367|Experimental|CO2 laser with PRP|After anesthetizing the area and undergo one pass of ablative fractional CO2 laser (Smaxel, iDS, Korea) using the following settings: energy = 50 mJ; pulse duration = 2 ms; and density level = 15, PRP will be injected through nappage technique at 1 cm intervals for three treatment sessions at four-week intervals.
89570459|NCT04956367|Placebo Comparator|CO2 laser with placebo|After anesthetizing the area and undergo one pass of ablative fractional CO2 laser (Smaxel, iDS, Korea) using the following settings: energy = 50 mJ; pulse duration = 2 ms; and density level = 15, pNSS will be injected through nappage technique at 1 cm intervals for three treatment sessions at four-week intervals.
89570460|NCT04956601|Experimental|VBT|CT image guided high-dose-rate vaginal brachytherapy, 30Gy/6f, 2f/w.
89028768|NCT05918757|Experimental|Protein dose 1.5 g/kg/day|Administration of 1.5 g of protein/kg/day in critically ill patients receiving invasive mechanical ventilation
89028769|NCT05918757|Active Comparator|Protein dose 1.0 g/kg/day|Administration of 1.0 g of protein/kg/day in critically ill patients receiving invasive mechanical ventilation
89028770|NCT05915104|Experimental|Budesonide MMX®|Participant received 9 mg delayed and extended-release tablet, once daily, oral administration, for 8 weeks
89028771|NCT05915104|Active Comparator|Budesonide controlled ileal release (CR) capsules|Participant received three 3 mg capsules, daily oral administration, for 8 weeks
89028772|NCT05897684||Treated with avacopan for active AAV|The study will enrol approximately 250 adult patients diagnosed with AAV (MPA or GPA) treated with avacopan for active severe AAV.
89033121|NCT02921646|Other|energetic expenditure measure|To a standard treatment by chemotherapy, energetic expenditure will be measured 5 times during the study.
89028773|NCT05897684||Treated with a cyclophosphamide or rituximab-based induction regimen without avacopan for active AAV|The study will enrol approximately 250 adult patients diagnosed with AAV (MPA or GPA) treated with a cyclophosphamide or rituximab-based induction regimen without avacopan for active severe AAV.
89570461|NCT04956601|Active Comparator|EBRT|Pelvic external beam radiotherapy，IMRT/VAMT，IGRT suggested，DT 45Gy/25f.
89570462|NCT04966039||monochorionic twin pregnancies with demise of one fetus|Twin pregnancy was diagnosed and one fetus died in utero, 20 pregnant women
89570463|NCT04966039||Twin control group|Twin pregnancy with one abnormal fetus, 20 pregnant women
89570464|NCT04966039||Singleton control group|Singleton pregnancy with abnormalities outside the fetal brain, 20 pregnant women
89570465|NCT04956055|Experimental|Experiment group|Experimental group to be applied hand reflexology
89570466|NCT04956055|No Intervention|Control group|experimental group for which hand reflexology will not be applied
89570467|NCT04955977|Experimental|G1: People with a diagnosis of COPD stratified in GOLD 1-2.|"Adult person, over 40 years of age, both sexes, resident in medium altitudes or 2,600 meters above sea level in the last 2 years.~People with a diagnosis of COPD categorized in GOLD 1-2, with no record of respiratory crises in the last 3 months.~People with a diagnosis of COPD categorized by lung function in GOLD 1,2,3 and 4 and by severity of symptoms in A, B and C, without the need for supplemental oxygen.~People with a diagnosis of COPD settled and domiciled for a minimum time of 14 months at moderate altitudes or 2600 m.a.s.l.~People who have read and signed informed consent and who have membership in a mandatory health plan."
89570468|NCT04955977|Experimental|G2: People with a diagnosis of COPD stratified in GOLD 3-4.|"Adult person, over 40 years of age, both sexes, resident in medium altitudes or 2,600 meters above sea level in the last 2 years.~People with a diagnosis of COPD categorized in GOLD 1,2,3 and 4, with no record of respiratory crises in the last 3 months.~People with a diagnosis of COPD categorized by lung function in GOLD 3-4 and by severity of symptoms in A, B and C, without the need for supplemental oxygen.~People with a diagnosis of COPD settled and domiciled for a minimum time of 14 months at moderate altitudes or 2600 m.a.s.l.~People who have read and signed informed consent and who have membership in a mandatory health plan."
89570469|NCT04955977|Active Comparator|G3: Control - People without a COPD diagnosis.|Healthy people, over 40 years old. No history of cigarette smoking or exposure to wood smoke. Who do not present diagnoses of musculoskeletal injuries and who are residents at 2600 meters above sea level for more than 14 months. With affiliation to a mandatory health plan and signature of informed consent.
89570470|NCT04956211|Experimental|Non-surgical periodontal therapy|Oral hygiene instructions will be given to all individuals. Any hopeless tooth or categorised as irrational to treat at baseline visit will be extracted at the treatment visit(s). Patients will receive a standard regimen of scaling and root planing of the root surfaces under local analgesia (depending on the severity in one or two sessions within 2 days) with curettes and ultrasonic instruments .
89570471|NCT04956211|Active Comparator|Conventional periodontal therapy|Oral hygiene instructions will be given to all individuals. Any hopeless tooth or categorised as irrational to treat at baseline visit will be extracted at the treatment visit(s). Supragingival cleaning and polishing of all dentition will be delivered to individuals in this group.
89570472|NCT04949035||COVID-19 survivors|
89570473|NCT04948879||Vascular reconstruction|Patients who have undergone resection with or without reconstruction of a major blood vessel in the context of surgery for a locally advanced pelvic malignancy. This will mostly refer to patients who have had resection/reconstruction of their internal iliac vessels, or less likely common iliacs.
89570474|NCT04948957||esmolol (Group E)|
89570475|NCT04948957||nitroglycerin (Group N)|
89570476|NCT04948801||genotype 3a HCV|genotype 3a hepatitis C
89570477|NCT04948801||genotype 6 HCV|genotype 6 hepatitis C
89570478|NCT04948801||genotype 3b HCV|genotype 3b hepatitis C
89570479|NCT04948255||Healthcare Workers at the Gill Medical Centre|Clinical and non-clinical staff at the Gill Medical Centre will complete a validated stress questionnaire during the Covid-19 pandemic. A baseline was established in May, 2019.
89570480|NCT04965415|Active Comparator|Lagged|Businesses in the lagged arm participated in Health Links for one year from their baseline assessment to their first follow-up assessment one year later. They were eligible to participate in the Leadership Training after both assessments were completed.
89570481|NCT04965415|Experimental|Early|Businesses in this arm participated in Health Links + Leadership Training for one year from their baseline assessment to their first follow-up assessment one year later.
89570482|NCT04948567|Experimental|split-dose of Magnesium Sulfate solution|Those assigned to MSS group were instructed to take 30ml of 50% magnesium sulfate solution and then drink 600ml water on the evening before colonoscopy. 70ml of 50% MMS and then 1500ml water was taken at least 4 hours before procedure on the colonoscopy day.
89570483|NCT04948567|Placebo Comparator|split-dose of PEG|Patients in PEG group were instructed to take first dose of 1.5L PEG on the evening before colonoscopy and take the second dose of 1.5L PEG at least 4 hours before the colonoscopy procedure on the morning.
89033122|NCT02943707|Experimental|treatment group: ABMSCi & drugs|ABMSCi: Autologous bone marrow stem cells infusion drugs such as Ursodeoxycholic Acid tablets(UDCA), each time 150 mg, three times a day orally
89570484|NCT04955665||Bone block procedure|patients with recurrent peroneal tendon dislocation underwent the bone block procedure
89033123|NCT02943707|Active Comparator|control group: drugs|drugs such as Ursodeoxycholic Acid tablets(UDCA), each time 150 mg, three times a day orally
89570485|NCT04955665||Reattachment of the superior peroneal retinaculum|patients with recurrent peroneal tendon dislocation underwent reattachment of the superior peroneal retinaculum
89570486|NCT04965571||WD-seizures|Chinese WD patients with generalized epilepsy
89570487|NCT04955509||Training|random splitting based on random sequences generated by engineers to train and optimize a machine learning model
89570488|NCT04955509||Testing|random splitting based on random sequences generated by engineers to evaluate the performance of the model
89570489|NCT04948177||Group A|Group A: Individuals who had normal pyloric orifice structure;
89570490|NCT04948177||Group B|Group B: Individuals who have abnormal pyloric orifice structure
89570491|NCT03060655|Placebo Comparator|PLGA-Mg material|The fixation of fragments of study group was accomplished with PLGA-Mg material.
89033124|NCT02917551|Active Comparator|Shorter duration (7 days)|Patients in 7 day arm will receive adequate antibiotics until the end of day 7 only
89033125|NCT02917551|Active Comparator|Longer duration (14 days)|Patients in 14 day arm will receive adequate antibiotics until the end of day 14 only
89570492|NCT03060655|Placebo Comparator|titanium alloy|The fixation of fragments of control group was accomplished with titanium alloy material.
89570493|NCT03060187||KU Score|Participants asked to answer questions for the KU Score exam
89570494|NCT04955353|Experimental|AVC-H2|Participants received Avicenna Hydrolyzed Chicken Collagen Type II (AVC-H2), 2.5g daily, for 8 weeks.
89570495|NCT04955353|Placebo Comparator|Placebo|Participants received placebo of matching amount to that of AVC-H2 daily for 8 weeks.
89570496|NCT03060343|Experimental|Zeushield Cytotoxic T Lymphocytes|Enrolled patients will receive Zeushield Cytotoxic T Lymphocytes by infusion
89570497|NCT04955119|Experimental|Fusion imaging contrast-enhanced ultrasound LI-RADS|"Fusion imaging contrast-enhanced ultrasound will be performed in patients with invisible lesion at conventional ultrasound.~Drug: SonoVue"
89570498|NCT04965103|Active Comparator|Bridging|Tendon repair with graft interposition
89570499|NCT04965103|Experimental|SCR|Superior Capsule reconstruction
89570500|NCT04954963||conventional examination|patients undergo conventional examination
88811130|NCT04201457|Experimental|Phase 2 Stratum 3 LGG with BRAF V600 mutation|LGG with BRAF V600E/D/K mutation will receive Dabrafenib, Trametinib and Hydroxychloroquine. All medications are administered orally with Dabrafenib and HCQ given twice a day and Trametinib given once per day at the recommended Phase 2 dose for a 28 day course. Courses may repeat until the patient meets an off treatment criteria.
88970273|NCT04240054|Experimental|Expansion Cohort A|"15 transplant-eligible multiple myeloma patients with renal impairment will be enrolled.~Bortezomib (1.5 mg/m^2)subcutaneous on days 1, 8 and 15 Isatuximab (10 mg/kg) IV on days 1, 8, 15 and 22 Cyclophosphamide (250 mg/m^2) IV on days 1, 8 and 15 Dexamethasone 20 mg PO or IV (10 mg if >75 years) on days 1, 2, 8, 9,15,16, 22 and 23"
88970274|NCT04240054|Experimental|Expansion Cohort B|"20 transplant-eligible non-renal impairment multiple myeloma patients will be enrolled.~Bortezomib (1.5 mg/m^2) subcutaneous on days 1, 8 and 15 Isatuximab (10 mg/kg) IV on days 1, 8, 15 and 22 Cyclophosphamide (250 mg/m^2) IV on days 1, 8 and 15 Dexamethasone 20 mg PO or IV (10 mg if >75 years) on days 1, 2, 8, 9,15,16, 22 and 23"
89033126|NCT00531674|Experimental|1|Nutritional supplementation for pregnant and lactating women
89033127|NCT00531674|Experimental|2|Nutritional supplementation for children
89570501|NCT04954963||Reduce metal artifacts examination|patients undergo reduce metal artifacts examination
89570502|NCT03060421||Aquamid Reconstruction|Patients that have been treated with at least one intra-articular injection of aquamid as a treatment of osteoarthritis of the knee
89570503|NCT04955041||mild CSM|preoperative modified Japanese Orthopedic Association (mJOA) score ≥15
89570504|NCT04955041||moderate CSM|preoperative mJOA score 13~14
89570505|NCT04955041||severe CSM|preoperative mJOA score ≤12
89570506|NCT04954885||Ancillary-correlative (biospecimen, questionnaire, testing)|Patients receive treatment by their treating physician as described in the INSIGNA protocol based on their designated treatment arm. Patients then undergo stool sample collection, complete questionnaires and functional status assessments, such as short physical performance battery over 10 minutes and 6 minute walk test, at baseline, days 40 (cycle 3), day 80 (cycle 5), day 180 (cycle 10) and end of treatment (up to 2 years).
88970275|NCT04235114|Experimental|Establish Imaging Time|Participants will receive an i.v. injection of 50 mg 2 mCi 89Zr-DFO-nimotuzumab. Participants will undergo imaging at four different time points till day 7 after infusion. Vitals, blood sample and urine sample will be collected every time before imaging. Participants will be followed up for any adverse event until day 30 post administration
88970276|NCT04235114|Experimental|Diagnostic Quality|Participants will receive an i.v. injection of 50 mg 2 mCi 89Zr-DFO-nimotuzumab. Participants will undergo imaging once at the best time calculated from arm 1 participants. Vitals, blood sample and urine sample will be collected before imaging. Participants will be followed up for any adverse event until day 30 post administration
88970277|NCT04235114|Experimental|Establish Cold Dose|Participants will receive an i.v. injection of 1 mg 2 mCi 89Zr-DFO-nimotuzumab. Participants will undergo imaging at four different time points till day 7 after infusion. Vitals, blood sample and urine sample will be collected every time before imaging. Participants will be followed up for any adverse event until day 30 post administration
88970278|NCT04222764||Real-time three-dimensional echocardiography|
88970279|NCT04222504|Experimental|Intervention Salons|Intervention: Behavioral: Provision of sexual health preventative services in the salon setting
88970280|NCT04222504|No Intervention|Control Salons|No Intervention
88970281|NCT04218851|Experimental|Posaconazole|On Day 1 participants receive 2 administrations of posaconazole (POS) 6 mg/kg body weight by intravenous (IV) infusion. On Days 2 through 7, participants receive POS 6 mg/kg body weight once daily by IV infusion. Beginning at Day 8 up to Day 84, participants may transition to receiving an oral formulation, or they may remain on the IV formulation.
89570507|NCT04965805|Experimental|Cold plasma jet|The treatment scheme of the cold plasma jet will be applied in the following manner, quantity and frequency: Cold plasma is always applicated for 30 seconds/ cm^2 wound size. Wounds will be treated three times in the first week, twice in the second week and once per week in the following observation period. In case of locally infected ulcers, treatment will be performed 1x per day during the first week and afterwards in the same manner as in non-infected ulcers. After application of cold plasma, the wound will be covered with Adaptic perforated gauze and a non-active dressing.
89028774|NCT05897021|Experimental|Expressive Writing on Minority Stressors|The EWMS protocol will consist of 3 sessions delivered by a therapist (either in-person or remotely via telehealth platform) to sexual minority Veterans. The intervention will begin with an overview of the intervention, brief psychoeducation about expressive writing, and a review of the potential benefits of expressive writing. The initial session will also consist of psychoeducation on sexual minority stressors and common reactions to these stressors (i.e., universal stress reactions and minority-identity specific reactions) and how this relates to psychological outcomes, such as depression and anxiety, and high-risk behaviors, such as substance use and suicidal ideation. The initial session will be 60 minutes (introduction, psychoeducation, and first writing exercise) and the following two sessions (feedback, writing exercises, and check-ins) will take approximately 40 minutes.
89028775|NCT05897021|Placebo Comparator|Neutral Writing|To be comparable to EWMS, the control intervention will also be a 3-session individual intervention involving engaging in a writing exercise per session. For the control writing exercises, participants will be asked to write for 30 minutes about their daily activities since waking up that day based on Pennebaker's standard writing paradigm (Pennebaker & Beall, 1987). Individuals in the control condition will also be given information about the purpose of the writing exercises to be comparable to the psychoeducation information provided in EWMS. Similar to EWMS, the clinician will check in with the participant about the writing session, such as asking how the session went and how it felt to do the writing, following the 30 minutes of writing.
89028776|NCT05893225|Active Comparator|Treatment group|The treatment group will receive Metformin Hydrochloride oral tablets 850mg tid or bid, during a maximum of 96 weeks.
89028777|NCT05893225|Placebo Comparator|Control group|The control group will receive a matching placebo, during a maximum of 96 weeks.
89028778|NCT05887141|Other|Control Condition (no perspective change)|The intervention (two role-plays), however without using a perspective change afterwards.
89570508|NCT04965805|Active Comparator|Best Practice wound dressings|Immediately after dressing removal, the wound will be cleaned with a physiological saline solution soaked swab. In case of locally infected wounds, an antiseptic will be used instead of the physiological saline solution. Subsequently, a wound phase-adapted primary dressing will be applied according to the experience of the practitioner and, if necessary, the wound will be covered with a secondary dressing according to the experience of the practitioner as well. In case of locally infected wounds, silver dressings can be applied. The dressing will be changed at least every 2nd day and on weekends every 3rd day; in case of locally infected wounds, dressings will be changed daily. Dressing changes beyond visits can also be performed by the general practitioner, a nursing service, or by the participant him- or herself.
89570509|NCT02624713|Other|Retrospective Random Controlled Research|"In the controlled retrospective follow up, (not random) 44 families participated with their 81 children and siblings. The intervention group included 18 families who participated in the Maccabi Active program (obesity treatment) in the years 2012-2013 in the northern district, with their 24 children (18 overweight children and 6 siblings). The control group included 26 families with their 57 children (27 children who had been overweight or obese in the years 2012-2013 when they were 8-14 years old and their 30 siblings). These families did not take part in a family based treatment for their overweight child. The parameters were measured at one set point time. All participants from both the control and research groups were evaluated at the follow-up and the data collected at follow-up is being reported collectively for the Retrospective Controlled Research branch."
89570510|NCT02624713|Other|The Prospective study|The Prospective study had only an intervention group (obesity treatment). Forty-two families took part in this study, with 78 children: 48 overweight children and 30 siblings . The parameters were measured in three different times. Before the program (time 1), at the end of the program (after 6 months - time 2) and 8 months after completing the program (time 3).
89570511|NCT03058081|Experimental|High Flow Nasal Test|Patients will perform one Constant Work-Rate Exercise Test at 80% of maximum workload with High Flow Nasal at 60L/min (with or without additional oxygen)
89570512|NCT03058081|No Intervention|Control Test|Patient will perform one Constant Work-Rate Exercise Test at 80% of maximum workload on room air or with oxygen supplementation
89570513|NCT03058315||Low back pain patients|Cohort of 800 consecutive low back pain patients, 18 years +, who have been referred from general practice to the secondary sector for further examination and MR scan.
89570514|NCT04430179|Active Comparator|Active drug|Dupilumab 300 mg every other week for 24 weeks
89570515|NCT04430179|Placebo Comparator|Placebo|Placebo
89570516|NCT04946929|Experimental|Ticagrelor, 2-3mg/kg, 12h|2-3mg/kg, q12h, p.o. for 2w
89570517|NCT04946929|Active Comparator|low molecular weight heparin|half amount low molecular weight heparin
89570518|NCT04933045||Syndesmotic Fixation Group|Cohort of patients treated with anatomic ATFL reconstruction for syndesmotic ankle injury.
89570519|NCT03058159|Other|Subjects with a high dream recall frequency|
89570520|NCT03058159|Other|Subjects with a law dream recall frequency|
89570521|NCT02624791|Experimental|Lens sequence 1|"No contact lenses; 1-DAY ACUVUE® MOIST contact lenses;~1-DAY ACUVUE® MOIST for ASTIGMATISM contact lenses"
89570522|NCT02624791|Experimental|Lens sequence 2|"No contact lenses; 1-DAY ACUVUE® MOIST for ASTIGMATISM contact lenses;~1-DAY ACUVUE® MOIST contact lenses"
89570523|NCT02624791|Experimental|Lens sequence 3|"1-DAY ACUVUE® MOIST contact lenses; No contact lenses;~1-DAY ACUVUE® MOIST for ASTIGMATISM contact lenses"
89570524|NCT02624791|Experimental|Lens sequence 4|"1-DAY ACUVUE® MOIST contact lenses;~1-DAY ACUVUE® MOIST for ASTIGMATISM contact lenses; No contact lenses"
89570525|NCT02624791|Experimental|Lens sequence 5|"1-DAY ACUVUE® MOIST for ASTIGMATISM contact lenses;~1-DAY ACUVUE® MOIST contact lenses; No contact lenses"
89570526|NCT02624791|Experimental|Lens sequence 6|"1-DAY ACUVUE® MOIST for ASTIGMATISM contact lenses; No contact lenses;~1-DAY ACUVUE® MOIST contact lenses"
89570527|NCT03058237|Experimental|Part 1: Regimen A|"One low dose Arbaclofen Placarbil MR Prototype A tablet taken under fasting conditions.~Part 1 participants receive Regimens A, B, C, D and E in a sequential manner."
89570528|NCT03058237|Experimental|Part 1: Regimen B|"One low dose Arbaclofen Placarbil MR Prototype B tablet taken under fasting conditions.~Part 1 participants receive Regimens A, B, C, D and E in a sequential manner."
89570529|NCT03058237|Active Comparator|Part 1: Regimen C|"One low dose Arbaclofen Placarbil SR tablet taken under fasting conditions as the reference product.~Part 1 participants receive Regimens A, B, C, D and E in a sequential manner."
89570530|NCT03058237|Experimental|Part 1: Regimen D|"One low dose tablet of the selected Arbaclofen Placarbil MR Prototype administered with 0.6 g/kg of beverage in orange juice.~Part 1 participants receive Regimens A, B, C, D and E in a sequential manner."
89570531|NCT03058237|Experimental|Part 1: Regimen E|"An optional regimen of one low dose tablet of the selected Arbaclofen Placarbil MR Prototype administered with 0.6 g/kg of beverage in orange juice.~Part 1 participants receive Regimens A, B, C, D and E in a sequential manner."
89570532|NCT03058237|Experimental|Part 2: Regimen F|"One low dose Arbaclofen Placarbil MR prototype tablet (selected based on review of the data in Part 1) taken under fasting conditions.~Part 2 participants receive Regimens F, G, H, I and J in a sequential manner."
89570533|NCT03058237|Active Comparator|Part 2: Regimen G|"One low dose Arbaclofen Placarbil IR capsule taken under fasting conditions as the reference product.~Part 2 participants receive Regimens F, G, H, I and J in a sequential manner."
89570534|NCT03058237|Experimental|Part 2: Regimen H|"One low dose Arbaclofen Placarbil MR prototype tablet (selected based on review of the data in Part 1) taken under fasting conditions.~Part 2 participants receive Regimens F, G, H, I and J in a sequential manner."
89570535|NCT03058237|Experimental|Part 2: Regimen I|"One low dose Arbaclofen Placarbil MR prototype tablet (selected based on review of the data in Part 1) taken under fasting conditions.~Part 2 participants receive Regimens F, G, H, I and J in a sequential manner."
89570536|NCT03058237|Experimental|Part 2: Regimen J|One low dose Arbaclofen Placarbil MR prototype tablet (selected based on review of the data in Part 1) taken under fasting conditions, or a previously dosed MR prototype in the fed state. Part 2 participants receive Regimens F, G, H, I and J in a sequential manner.
89570537|NCT03058237|Experimental|Part 3: Regimen K|"One low dose selected Arbaclofen Placarbil MR prototype tablet (selected based on review of the data in Part 2) taken under fasting conditions.~Part 3 participants receive Regimens K and L in a randomised crossover manner as the first two treatments, followed by Regimens M and N in a sequential manner."
89570538|NCT03058237|Experimental|Part 3: Regimen L|"One low dose selected Arbaclofen Placarbil MR prototype tablet administered with 0.6 g/kg of beverage in orange juice or in the fed state, or one mid-low dose of the selected Arbaclofen Placarbil MR prototype tablet.~Part 3 participants receive Regimens K and L in a randomised crossover manner as the first two treatments, followed by Regimens M and N in a sequential manner."
89570539|NCT03058237|Experimental|Part 3: Regimen M|"An optional regimen of one mid-low dose of the selected Arbaclofen Placarbil MR prototype tablet (if not previously dosed in Regimen L) or one mid-high dose of the selected Arbaclofen Placarbil MR prototype tablet taken under fasting conditions.~Part 3 participants receive Regimens K and L in a randomised crossover manner as the first two treatments, followed by Regimens M and N in a sequential manner."
89570540|NCT03058237|Experimental|Part 3: Regimen N|"An optional regimen of one mid-high dose of the selected Arbaclofen Placarbil MR prototype tablet (if not previously dosed in Regimen M) or two mid-low dose of the selected Arbaclofen Placarbil MR prototype tablets.~Part 3 participants receive Regimens K and L in a randomised crossover manner as the first two treatments, followed by Regimens M and N in a sequential manner."
89028779|NCT05887141|Experimental|Perspective change condition|The intervention (two role-plays) with a perspective change after each role-play.
89028780|NCT05881252||Traditional clinical blood pressure threshold of SBP >= 160 mmHg for acute treatment of hypertension|
89028781|NCT05881252||Updated clinical blood pressure threshold of SBP >= 180 mmHg for acute treatment of hypertension|
89570541|NCT04947241|Experimental|Neoadjuvant therapy|Patients included are going to receive neoadjuvant therapy, surgery and adjuvamt therapy post surgery. Before surgery, patients will receive therapy as follows: PD-1 inhibitor: 240mg (day1) , intravenous, Q3W, 2cycles; cisplatin: 80 mg/m2(day1), intravenous , intravenous, Q3W, 2cycles Gemcitabine: 1000mg/m2(day1and day8), intravenous, Q3W, 2cycles
89570542|NCT04946539||Spondyloarthritis|
89570543|NCT03058393|Experimental|Teach-Back Group|A teach-back lesson will be provided to physician participants (Teach-Back Group), who are participating in challenging clinical discussions with patients
89570544|NCT04944511|Experimental|PD-1 antibody for mixed chimerism|PD-1 antibody (Toripalimab Injection) used for mixed chimerism in HLH patients after allo-HCT
89570545|NCT03057925|Experimental|Group A|MWA Percutaneous Microwave Ablation intervention procedure: Ultrasound-guided Percutaneous Microwave Ablation
89570546|NCT03057925|No Intervention|Group B|untreated no treatment; regular ultrasonic image follow-up
89570547|NCT04933279|Experimental|Potassium iodide group|administrated the subjects with 150 ml - 200 ml iodine-containing spareribs soup delivering ≈ 600 µg or 1200 µg iodine
89028782|NCT05880160|Experimental|Treatment Withdrawal|Participants will undergo phased withdrawal of heart failure/ cardioprotective treatments according to a pre-specified algorithm based on the 'Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy' (TRED-HF) study protocol (Halliday et al 2019). Medications will be down titrated in a phased process every 2 weeks over 16 weeks maximum. Drug doses will be reduced by 50% every 2 weeks, until the patient is taking 25% or less of the maximum recommended dose at which point they will be stopped. Monitoring with fortnightly virtual consultations will confirm dose reduction and provide support. Participants will undergo clinical assessment at 6, 14 and 24 weeks and 6, 9 and 12 months with weight, blood pressure, and biomarker measurement. At baseline, 6- and 12-month visits detailed cardiovascular phenotyping using cardiovascular magnetic resonance scans and symptom and disutility questionnaires will be undertaken.
89033128|NCT02921529|Experimental|TEAS|Patients were given 30min of TEAS(transcutaneous electrical acupoint stimulation) before anesthesia and 1,2,3 day after surgery
89033129|NCT02921529|Sham Comparator|false stimulation|Attach electrodes without electric current
89570548|NCT04933279|Experimental|Natural kelp group|administrated the subjects with a bowl of 45 g or 80 g natural kelp delivering ≈ 600 µg or 1200 µg iodine (intrinsic iodine in natural kelp).
89570549|NCT04943809||POD 26P AY FT|26 patients with corneal astigmatism higher than 1.0D in both eyes and lower than 2.5D and will be implanted with the POD 26P AY FT
89570550|NCT04943809||POD 26P AY F|26 patients with corneal astigmatism lower than 1.0D in both eyes will be implanted with the POD 26P AY F
89570551|NCT04946695|Experimental|Telefisio India|Feasibility and efficacy of the use of Telephysiotherapy for improving functional independence and quality of life in children and young people with lower limb fracture in a low resource setting in Anantapur (India).
89570552|NCT03058003||Patients|subjects suffering from chronic pain undergoing Posturography Evaluation and Central Sensitization Inventory
89570553|NCT03058003||Healthy|subjects self assessed to be in good health undergoing Posturography Evaluation and Central Sensitization Inventory
89570554|NCT02577029|Experimental|Cohort 1|"Treatment-naïve, hepatitis B e antigen (HBeAg)-positive participants with chronic hepatitis B (CHB) of any genotype administered ARC-520 (2 mg/kg intravenous [IV]) every 4 weeks for 48 weeks (13 doses)."
89570555|NCT02577029|Experimental|Cohort 2|Treatment-naïve, HBeAg-positive, Genotype B participants with CHB administered ARC-520 (2 mg/kg increasing to 4 mg/kg or 4 mg/kg IV) every 4 weeks for 48 weeks (13 doses) concomitantly with daily orally administered ETV or TDF for approximately 60 weeks starting Day 1 and weekly subcutaneously administered peginterferon (PEG IFN) alpha 2a for 48 weeks starting Day 87.
89570556|NCT02577029|Experimental|Cohort 3|Treatment-naïve, HBeAg-negative, Genotype B participants with CHB administered ARC-520 (2 mg/kg increasing to 4 mg/kg or 4 mg/kg IV) every 4 weeks for 48 weeks (13 doses) concomitantly with daily orally administered ETV or TDF for approximately 60 weeks starting Day 1 and weekly subcutaneously administered PEG IFN alpha 2a for 48 weeks starting Day 87.
89570557|NCT02577029|Experimental|Cohort 4|Treatment-naïve, HBeAg-positive, Genotype C participants with CHB administered ARC-520 (2 mg/kg increasing to 4 mg/kg or 4 mg/kg IV) every 4 weeks for 48 weeks (13 doses) concomitantly with daily orally administered ETV or TDF for approximately 60 weeks starting Day 1 and weekly subcutaneously administered PEG IFN alpha 2a for 48 weeks starting Day 87.
89570558|NCT02577029|Experimental|Cohort 5|Treatment-naïve, HBeAg-negative, Genotype C participants with CHB administered ARC-520 (2 mg/kg increasing to 4 mg/kg or 4 mg/kg IV) every 4 weeks for 48 weeks (13 doses) concomitantly with daily orally administered ETV or TDF for approximately 60 weeks starting Day 1 and weekly subcutaneously administered PEG IFN alpha 2a for 48 weeks starting Day 87.
89570559|NCT02577029|Experimental|Cohort 6|Treatment-naïve, HBeAg-negative, Genotype D participants with CHB administered ARC-520 (2 mg/kg increasing to 4 mg/kg or 4 mg/kg IV) every 4 weeks for 48 weeks (13 doses) concomitantly with daily orally administered ETV or TDF for approximately 60 weeks starting Day 1 and weekly subcutaneously administered PEG IFN alpha 2a for 48 weeks starting Day 87.
89570560|NCT02577029|Experimental|Cohort 7|Treatment-naïve, HBeAg-negative or HBeAg-positive participants with hepatitis delta virus (HDV) administered ARC-520 (2 mg/kg increasing to 4 mg/kg or 4 mg/kg IV) every 4 weeks for 48 weeks (13 doses) and weekly subcutaneously administered PEG IFN alpha 2a for 48 weeks starting Day 15.
89570561|NCT02577029|Experimental|Cohort 8|Treatment-naïve, HBeAg-positive participants with CHB of any genotype administered ARC-520 (4 mg/kg IV) every 4 weeks for 48 weeks (13 doses).
89570562|NCT04946773||Malignancy Cohort|Patients with hepatic or hepatobiliary malignancy at enrolment
89570563|NCT04946773||Control Cohort|Patients with chronic liver disease but no hepatic or hepatobiliary malignancy at enrolment
89570564|NCT04932889||Change|the patients whose musculoskeletal symptoms initiated or aggravated with Covid-19 (n=240)
89570565|NCT04932889||No change|the patients whose musculoskeletal symptoms did not change with Covid-19 (n=40)
89570566|NCT04946617||H group|healthy periodontium, BOP at \20 % of the sites and no sites with probing depth (PD) [3 mm and clinical attachment level (CAL) [2 mm or alveolar bone loss (N = 20, 12 males, 8 females, mean age: 33.38
89570567|NCT04946617||G group|gingivitis, BOP at ≥20 % of the sites and no sites with PD and CAL [3 mm or bone loss (N = 20, 6 males, 14 females, mean age: 32.35);
89570568|NCT04946617||CP group|chronic periodontitis, ≥4 teeth in each jaw with PD of ≥5 mm, CAL of C4 mm, BOP at [≥80 % of the proximal sites and radiographic evidence of interproximal bone loss
89570569|NCT04946383|Experimental|Quercetin and Dasatinib supplements|500mg Quercetin and 50mg Dasatinib oral capsules on Monday, Tuesday, Wednesday (3 days in a row) per month for the duration of 6 months.
89028783|NCT05880160|No Intervention|Treatment Continuation|Participants will continue their current heart failure/ cardioprotective treatments. Participants will undergo clinical assessment at 6, 14 and 24 weeks and 6, 9 and 12 months with weight, blood pressure, and biomarker measurement. At baseline, 6- and 12-month visits detailed cardiovascular phenotyping using cardiovascular magnetic resonance scans and symptom and disutility questionnaires will be undertaken.
89028784|NCT05870982|Experimental|Early time restricted eating|Participants will asked to follow early time restricted eating
89028785|NCT05870982|Experimental|Late time restricted eating|Participants will be asked to follow late time restricted eating
89028786|NCT05870982|Active Comparator|Daily caloric restriction|Participants will be instructed to follow daily caloric restriction
89209013|NCT00805610|Experimental|Hepatocyte Transplantation|Hepatocyte Transplantation through single donor will be transplanted into the liver via intraportal or intrasplenic routes.
89209014|NCT00798356|Other|1|Yoga training
89209015|NCT00734591||Previously treated with Exubera|
89028787|NCT05863520|Active Comparator|Facing Your Fears - School Based|Facing Your Fears-School Based (FYF-SB) is a 12 week school based group program comprised of psychoeducation (somatic management, development of positive self-statements and strategies for managing emotions), and graded exposure (facing fears a little at a time).
89028788|NCT05863520|Active Comparator|Zones of Regulation|"Zones of Regulation (ZOR) focuses on four different emotional states called zones. Each zone is represented by different colors that represent different levels of emotions or arousal. ZOR includes psychoeducation about emotions and emotional states (e.g., reading facial expressions, identifying triggers for emotion dysregulations, using emotion regulation tools) and problem-solving strategies. In ZOR, students are also taught emotion regulation strategies (e.g., calming, cognitive and sensory strategies) to stay in a specific zone and/or to move from one zone to another."
89028789|NCT05861076|Experimental|Moringa Powder - Medium Dose|Group A
89570570|NCT04943653|Experimental|Intraperitoneal paclitaxel + XELOX|"Intraperitoneal paclitaxel Day1, Day8 + *XELOX~*XELOX ; Capecitabine 2000mg/m2/day(Day1-14) Oxaliplatin 100mg/m2 IV Day1 q 3 weeks"
89570571|NCT04942951||Pregnant women with the diagnosis of urinary incontinence (Study group)|The pregnant women who were diagnosed with the urinary incontinence (n=80) with category 0 or category 1 Pelvic Organ Prolapse Quantification (POP-Q) score in physical examination.
89570572|NCT04942951||Healthy pregnant women (Control group)|Control group consisted of healthy women with uncomplicated pregnancies (n=80). They had no complaint of urinary incontinence and their gynecological examination did not reveal any finding of pelvic organ prolapse.
89570573|NCT04943029|Experimental|PD-1+Chemo+surgery+PD-1|Participants will receive neoadjuvant Carrelizumab plus double platinum based chemotherapy for 3 cycles, followed by surgical resection and adjuvant Carrelizumab for 16 cycles.
89570574|NCT05236283||Bern ICU|
89570575|NCT05236283||Lausanne ICU|
89570576|NCT04932499|Active Comparator|Control group|Standard of care
89570577|NCT04932499|Experimental|Mindfulness Meditation|Mindfulness meditation in addition to standard of care
89570578|NCT05535101|Experimental|theta burst stimulation|Those participants to receive 1-3 sessions in a single day at an interval of 15 minutes(at least), and 5 high-frequency iTBS sessions per week in total four weeks. Each session: 600-900 pulses with 120-100% resting motor threshold.
89570579|NCT05535101|Sham Comparator|Sham arm|Sham stimulation was delivered using the same protocol as active stimulation, but with the TMS coil rotated by 90 degrees with the edge of the coil touching the scalp.
89570580|NCT04943107||healthy control|adults without glaucoma history or hypertension history
89570581|NCT04943107||glaucoma patients|adults with primary glaucoma history; without glaucoma-related operation history; without hypertension history
89570582|NCT04943107||hypertension patients|adults with primary hypertension history; without glaucoma history
89570583|NCT04943107||glaucoma+hypertension|adults with primary glaucoma history and primary hypertension history; without glaucoma-related operation history
89570584|NCT03660059|Experimental|ASP015K 100 mg|Participants will receive 100 milligrams (mg) of ASP015K once daily after breakfast for 52 weeks.
89570585|NCT03660059|Experimental|ASP015K 150 mg|Participants will receive 150 mg of ASP015K once daily after breakfast for 52 weeks.
88811131|NCT04201457|Experimental|Phase 2 Stratum 4 HGG with BRAF V600 mutation|HGG with BRAF V600E/D/K mutation will receive Dabrafenib, Trametinib and Hydroxychloroquine. All medications are administered orally with Dabrafenib and HCQ given twice a day and Trametinib given once per day at the recommended Phase 2 dose for a 28 day course. Courses may repeat until the patient meets an off treatment criteria
89028790|NCT05861076|Experimental|Moringa Powder - High Dose|Group B
89028791|NCT05861076|Experimental|Moringa Powder - Low Dose|Group C
89028792|NCT05851508|Active Comparator|Methylprednisolon|Intratympanal injection with Methylprednisolon 62.5 mg/ ml
89028793|NCT05851508|Placebo Comparator|Placebo|Intratympanal injection with saline, natriumchloride 0.9%
89028794|NCT05838196|No Intervention|Control|Participant will follow standard of care
89028795|NCT05838196|Experimental|Point-of-care Ultrasound|Participant will receive point-of-care ultrasound at time of clinic appointment and clinician will use result to inform treatment decision
89028796|NCT05830643|Experimental|Social skills group psychotherapy|Originally designed to meet the needs of patients with ASD or ASPD, this group is now popular with patients who want to work on issues involving their relationships with their probation or parole officers or in establishing health romantic relationships.
89028797|NCT05830643|Active Comparator|Adult interest group psychotherapy|The adult interest group has dual aims to (1) stop illegal sex acts and (2) enhance noncriminal sexual interests. The group focuses on respect for informed, voluntary, revocable, consent by examining various cognitive distortions that group members may endorse.
89028798|NCT05823220|Experimental|Homeless diversion (HD) group|
89028799|NCT05823220|Active Comparator|Treatment-as-usual (TAU) group|
89028800|NCT05822297|Experimental|All participants|Each participant will undergo the same procedures and intervention, consisting of a baseline phase, intervention phase and follow-up phase. The length of the baseline phase will be randomized 3, 4, 5 or 6 weeks.
89028801|NCT05816369|Experimental|Taste preferences of five ONS flavors|Taste session with corresponding questionnaires
89028802|NCT05809011|Experimental|Corticosteroid therapy plus standard-of-care|Patients randomized to this arm will receive a single-bolus intravenous injection of dexamethasone 20 mg at day 1 (as soon as possible after randomization), followed by oral prednisone 1 mg/kg daily (maximum 60 mg daily) from day 2 to day 7 after randomization. Patients randomized to this arm will also receive standard-of-care therapy for acute heart failure.
89028803|NCT05809011|No Intervention|Standard-of-care|Patients randomized to this arm will receive standard-of-care therapy for acute heart failure.
89028804|NCT05801419|Experimental|Baseline, post e-cigarette without nicotine and post e-cigarette with nicotine|Pattern visual event-related potential (ERP) and pattern electroretinogram (pERG) on right eye (non-dilated pupil), followed by eye fundus tissue oximetry on left eye (dilated pupil), followed by optical coherence tomography angiography (OCT-A) on left eye (dilated pupil).
89028805|NCT05789069|Experimental|Dose Escalation - HFB200603 monotherapy|Participants will be administered HFB200603 at dose levels 1-4 as an intravenous infusion to determine the Recommended Dose for Expansion (RDE).
89033130|NCT02943824|Experimental|Machine Learning Planning|Patients will be pre-operatively planned using a machine-learning computer program. An expert radiation oncologist will evaluate the plan prior to implantation. The prescription dose is 145 Gy for monotherapy LDR brachytherapy.
89570586|NCT03660059|Placebo Comparator|Placebo/ASP015K|Participants will receive placebo for 24 weeks, then either 100 mg or 150 mg of ASP015K for 28 weeks as determined randomly at Week 0 in advance.
89570587|NCT04943263|Experimental|Tracheal Temperature|Intubation done with a temperature sensor located on the cuff surface of the endotracheal tube
89570588|NCT05519969||6-4-2 group|- Cases from centres implementing the rule of a minimum of 6 hours of fasting for solids, 4 hours for breast milk and 2 hours for clear fluids before anesthesia.
89570589|NCT05519969||6-4-1 group|- Cases from centres implementing the 1 hour fasting rule for clear fluids recommended by ESAIC and specified in the guideline Preoperative fasting in children
89570590|NCT05519969||6-4-0 group|"- Cases from centres implementing the zero hour clear fasting rule, which means that children are allowed intake of clear fluids until they are called to the operating room"
89570591|NCT04943185|Other|Ab interno technique|Ab Interno is traditional method of stent XEN implantation, where the device will injected through a small corneal incision that closes with the preloaded XEN injector.
89209016|NCT00734591||Previously treated with comparator|Subjects who had been treated with a comparator (other diabetes treatment such as injected insulin) in a prior Exubera controlled trial.
89570592|NCT04943185|Other|Ab externo technique|The ab externo approach does this without any incision, less invasive, and the implant is directly injected through the conjunctiva into the anterior chamber of the eye. Both methods create a new way out through the subconjunctival space, which is the traditional target of trabeculectomy.
89570593|NCT04942873||dabigatran group|NVAF patients who taking dabigatran capsule 110mg，bid during 2016.2-2021.1，the duration of continuous medication was more than 3 months.PDC value and MMAS-8 scale were used to evaluate the compliance of patients with dabigatran.
89570594|NCT04942873||Rivaroxaban group|NVAF patients who taking rivaroxaban tablet 15mg，bid during 2016.2-2021.1，the duration of continuous medication was more than 3 months.PDC value and mmas-8 scale were used to evaluate the compliance of patients with dabigatran. PDC value and mmas-8 scale were used to evaluate the compliance of patients with rivaroxaban.
89570595|NCT04942873||wafarin group|NVAF patients who taking wafarin tablet during 2016.2-2021.1，the duration of continuous medication was more than 3 months， the dosage is adjusted according to INR. MMAS-8 scale was used to evaluate the compliance of patients with rivaroxaban.evaluate the compliance of patients with wafarin.
89570596|NCT04946227|Experimental|Single Arm|Pembrolizumab is a potent humanized immunoglobulin G4 (IgG4) monoclonal antibody (mAb) with high specificity of binding to the programmed cell death 1 (PD-1) receptor.
89570597|NCT04945525|Experimental|Care Continuity Program + Education|Participating clinics (and their prescribers and patients) will be randomly selected to implement the Care Continuity Program (CCP) intervention, at which time prescribers will view an Accreditation Council for Continuing Medical Education (ACCME) accredited educational video about the safe initiation, continuation, and discontinuation of opioid therapy, as well as the data elements required by law and regulation to be included in the medical records of patients prescribed opioids. Then patients will receive welcome letters and be required to complete CCP self-assessments before each appointment. Prescribers will begin using the generated CCP summary page at each appointment to help make decisions about initiating or maintaining an opioid prescription for an individual patient.
89570598|NCT04945525|No Intervention|Education Alone|Participating clinics (and their prescribers and patients) will be randomly selected to the control group, at which time prescribers will view an Accreditation Council for Continuing Medical Education (ACCME) accredited educational video about the safe initiation, continuation, and discontinuation of opioid therapy, as well as the data elements required by law and regulation to be included in the medical records of patients prescribed opioids. Then patients and prescribers will continue treatment as usual in their clinic.
89570599|NCT04932187|Experimental|Experimental|Capecitabine 500mg bid. po. Camrelizumab 200mg ivgtt. d1 q2w
89570600|NCT04931719|Active Comparator|the PRP+Artz group|The patients in the PRP+Artz group received one intraarticular Artz injection (2.5 ml) followed consecutively by one intraarticular injection of PRP (3ml).
89570601|NCT04931719|Experimental|the PRP+HYAJOINT Plus group|The patients in the PRP+HYAJOINT Plus group received one intraarticular HYAJOINT Plus injection (3ml) followed by one intraarticular injection of PRP (3ml).
89570602|NCT04945681|Experimental|Mass vaccination|Mass vaccination of children aged 6 weeks to 14 years old with pneumococcal conjugate vaccine. Children 6 weeks to 11 months old receive two doses, spaced 4 weeks apart. All other children receive a single dose. Vaccination is simultaneous, as per a campaign delivery strategy.
89570603|NCT04945291|Experimental|research built JA Method mobile application + Counting method using the hands|The participant will watch a video that explains a new counting method using the hands and use the research built mobile application to log and track the calories
89570604|NCT04945291|Active Comparator|FitnessPal mobile application (or Arabic alternative) + Counting method using the hands|the participants will watch a video that explains a new counting method using the hands and they will be asked to use a commercial mobile app to log and track the calories
89570605|NCT04945291|Active Comparator|Fitness Pal Mobile Application (or Arabi alternative)|The participants will watch a generic video about the mobile app and they will be asked to use a commercial mobile app to log and track the calories
89570606|NCT04942795||Mechanical thrombectomy|Patients who underwent mechanical thrombectomy for large vessel occlusion of the anterior circulation
89570607|NCT04942561|No Intervention|Standard of Care (No VR) Randomization|In the standard of care treatment condition, participants will receive the standard CHLA treatment protocol for PIVC placement (i.e., a topical numbing spray and Buzzy® Bee, a vibrating device placed near the PIVC site for pain distraction).
88811132|NCT04201457|Experimental|Phase 2 Stratum 5 LGG with BRAF aberration|LGG with BRAF duplication or fusion with any partner will receive Trametinib and Hydroxychloroquine. All medications are administered orally with Trametinib given once per day and HCQ give twice per day at the recommended Phase 2 dose for a 28 day course. Courses may repeat until the patient meets an off treatment criteria.
89028806|NCT05789069|Experimental|Dose Escalation - HFB200603 in combination with tislelizumab|Participants will be administered HFB200603 at dose levels 1-3 in combination with one dose level of tislelizumab as an intravenous infusion to determine the combination Recommended Doses for Expansion (RDEs).
89209017|NCT02554058|Experimental|Cycling and Mechanical stimulation|Cycling and Mechanical stimulation : 30 minute cycling training, 3 times a week for 8 weeks.
89209018|NCT00798512|Experimental|1|Single arm Study in which 120 patients fulfilling eligibility criteria will be screened and undergo carotid stenting with the Cristallo ideale™ carotid stent after placement of the Mo.Ma device as cerebral protection system. The technique of diffusion-weighted magnetic resonance imaging (DW-MRI) will be used to identify new ischemic lesions.
89028807|NCT05789069|Experimental|Dose Expansion - HFB200603 monotherapy (optional)|Participants will be administered HFB200603 at monotherapy RDE as an intravenous infusion.
89570608|NCT04942561|Experimental|VR Randomization|Children in the VR condition will undergo the invasive procedure while distracted by interaction with an immersive virtual environment (VE) presented via a head mounted display (HMD). The intervention group will receive standard CHLA treatment with VR distraction. Patients began gameplay <5 minutes before their PIVC placement and concluded after successful vascular access.
89570609|NCT04942171|Experimental|Atrial fibrillation catheter ablation group|catheter ablation
89028808|NCT05789069|Experimental|Dose Expansion - HFB200603 in combination with tislelizumab|Participants will be administered HFB200603 in combination with tislelizumab at combination RDEs as an intravenous infusion. Based on the cancer type, participants will be randomized to combination HFB200603 RDE 1 or RDE 2.
89028809|NCT05775978|Experimental|UGRComp group|This arm will instruct the students on the Más Presente program. This is a socio-emotional competence-based program which has been designed following the European LifeComp framework. This program is a combination of theory and practice aimed at developing the core elements of personal, social and learning to learn key competences for lifelong learning.
89033131|NCT02943824|Active Comparator|Radiation Therapist Planning|Patients will be pre-operatively planned manually by an expert radiation therapist (> 60 cases planned). An expert radiation oncologist will evaluate the plan prior to implantation.The prescription dose is 145 Gy for monotherapy LDR brachytherapy.
89570610|NCT04942171|Active Comparator|Medical therapy group|standard treatment include anti-arrhythmic drug
89570611|NCT04945135||liver donors|
89570612|NCT04944823||Patients with COVID 19 infection who develop bacterial coinfection.|Follow-up for 24 months
89570613|NCT04944823||Patients with COVID 19 infection who do not develop bacterial coinfection.|Follow-up for 24 months
89570614|NCT04930939|Experimental|Heart rate variability-guided training group|Patients allocated to heart rate variability-guided training group trained 3 days a week for 6 weeks. These patients carried out moderate continuous traininig sessions or high intensity interval training sessions based on their daily heart rate variability assessments follwing a decision schema.
89570615|NCT04930939|Active Comparator|Predefined training group|Patients allocated to predefined training group also trained 3 days a week for 6 weeks. Nonetheless, these patients performed a predefined training program regarless of their parasympathetic modulation status.
89570616|NCT03597347|Experimental|Group 1|Participants with chronic pulmonary MAC or MABSC infection who have not consistently achieved negative NTM sputum cultures while currently on a multidrug NTM guideline-based antimycobacterial regimen, which has been ongoing for at least 9 months prior to the Baseline visit.
89570617|NCT03597347|Experimental|Group 2|Participants with chronic pulmonary MAC or MABSC infection who remain sputum culture positive but have stopped a multidrug NTM guideline-based antimycobacterial regimen at least 28 days prior to Screening due to lack of response or intolerance.
89570618|NCT03597347|Experimental|Group 3|Participants with chronic pulmonary MAC or MABSC infection not meeting recommendations for treatment with a multidrug NTM guideline-based antimycobacterial regimen based on failure to meet American Thoracic Society/Infectious Diseases Society of America (ATS/IDSA) criteria for NTM pulmonary disease (i.e. absence of radiologic findings and clinical symptoms beyond what is expected from underlying CF).
89570619|NCT04942015|Experimental|Honghuaruyi Wan|Honghuaruyi Wan will be used in this arm. Patients should start taking medicine with warm water on the first day of menstruation. For patients with VAS score < 7 points, 1g / time, twice a day; for patients with VAS score ≥ 7 points and pain is hard to bear, 2g / time, twice a day. According to the above usage and dosage, take 3 menstrual cycles continuously, and observe 3 menstrual cycles after stopping the drug.
89570620|NCT04942015|Placebo Comparator|Placebo|Placebo of Honghuaruyi Wan will be used in this arm. Patients should start taking medicine with warm water on the first day of menstruation. For patients with VAS score < 7 points, 1g / time, twice a day; for patients with VAS score ≥ 7 points and pain is hard to bear, 2g / time, twice a day. According to the above usage and dosage, take 3 menstrual cycles continuously, and observe 3 menstrual cycles after stopping the drug.
89570621|NCT04941859|Experimental|experimental group|Patients in the experimental group were treated with acupoint application combined with acupoint massage on the basis of standard treatment for acute poisoning. When the patient began to launder the stomach, the acupoint was applied to Shenque (umbilical). After the end of the gastric launder, Shenque acupoint and Zusanli diarrhea method (referring to counterclockwise and strong stimulation) were massaged for 15 minutes, and the massage frequency was Q8H.
89570622|NCT04941859|No Intervention|control group|The treatment plan of control group was carried out according to the diagnosis and treatment standard of acute poisoning.
89570623|NCT04942249||Symptomatic|167 symptomatic Swiss army recruits who tested positive for SARS-CoV-2 in 2020
89570624|NCT04942249||Asymptomatic|167 asymptomatic Swiss army recruits who tested positive for SARS-CoV-2 in 2020
89570625|NCT04942249||No evidence of infection|167 Swiss army recruits with no evidence of infection (who also were tested for SARS-CoV-2 in 2020)
89570626|NCT04431427|Active Comparator|Partially Covered Metal Stent Arm|The patients who had extra-hepatic malignant biliary obstruction will be enrolled in our study. Enrolled patient will be randomized to two group (uncovered metallic stent vs. partially covered metallic stent). After metallic biliary stent insertion, enrolled patients will be followed until bilirubin values will be under 2 mg/dl.
89570627|NCT04431427|Active Comparator|Uncovered Metal Stent Arm|The patients who had extra-hepatic malignant biliary obstruction will be enrolled in our study. Enrolled patient will be randomized to two group (uncovered metallic stent vs. partially covered metallic stent). After metallic biliary stent insertion, enrolled patients will be followed until bilirubin values will be under 2 mg/dl.
89570628|NCT04930627|Experimental|oral administration of Empagliflozin|
89570629|NCT03057769|Experimental|PES group|All patients in this group receive 20 ml of 0.02% epinephrine sprayed on the duodenal papilla, over a period of 10-15 seconds using sphincterotome, at the end of procedure, just before the withdrawal of endoscope.
89570630|NCT03057769|Placebo Comparator|Control group|All patients in this group receive 20 ml of saline sprayed on the duodenal papilla, over a period of 10-15 seconds using sphincterotome, at the end of procedure, just before the withdrawal of endoscope.
89570631|NCT05508269||Control subjects|control cases who were diagonosed as healthy subjects after diagnostic catheterization
89570632|NCT05508269||Stable coronary artery disease|patients with stable coronary artery disease undergoing elective PCI who were diagnozed with coronary lesion/s and underwent stent implantation without previous history of myocardial infarction
89570633|NCT05508269||Myocardial infarction patients|patients with history of myocardial infarction or with acute myocardial infarction undergoing primary PCI
89570634|NCT05508269||Ischaemic cardiomyopathy patients|patients with ischaemic cardiomyopathy diagnosed by ejection fraction less than 35% with history of coronary artery disease or myocardial infarction or those with acute myocardial infarction with reduced ejection fraction.
89570635|NCT05531045||Cohort|FDG PET/CT assessed after 2 cycles of chemotherapy
89570636|NCT04633577|Experimental|Group Lidocaine|20 eligible patients are received 1.5mg/kg 1%lidocaine intravenously over 30-60s. Then, 4mg/kg/h lidocaine infused intravenously until end of procedure.
89570637|NCT04633577|Placebo Comparator|Group Control|2020 eligible patients are received equal 0.9% normal saline.
89570638|NCT04941625||non-AKI|patients do not have post-HIPEC AKI
89570639|NCT04941625||AKI|patients have post-HIPEC AKI
89570640|NCT04944589|Experimental|single visit root canal treatment(RCT)|RCT(ROOT CANAL TREATMENT) of this group was performed in single visit including access cavity, chemo-mechanical preparation and obturation, all were done in one visit
89570641|NCT04944589|Experimental|Multiple visit root canal treatment(RCT)|RCT(ROOT CANAL TREATMENT) of this group was performed in multiple visit including access cavity, chemo-mechanical preparation and obturation, all were done in two or three visits
89570642|NCT04922125|Experimental|Pulse flour|Puree produced from pulse flours and with added oil and herbs/spices. To standardize test products on textural aspects, different levels of thickener will be added. All test products will be produced in the Future Consumer Lab at the Department of Food Science at the University of Copenhagen prior to the appetite test days. Pulse flour will be produced in the food-grade laboratory environment at the Department of Food Design and Consumer behavior and dried prior to use.
89570643|NCT04922125|Experimental|Pre-processed pulse flour|Puree produced from pre-processed pulse flour with different structural aspects and with added oil and herbs/spices. To standardize test products on textural aspects, different levels of thickener will be added. All test products will be produced in the Future Consumer Lab at the Department of Food Science at the University of Copenhagen prior to the appetite test days. Pulse flour will be produced in the food-grade laboratory environment at the Department of Food Design and Consumer behavior and dried prior to use.
89570644|NCT04922203|No Intervention|Control group|Anesthesiology residents do not receive any in situ simulation sessions during the observation period
89570645|NCT04922203|Experimental|Simulation group|Anesthesiology residents receive in situ simulations sessions during the observation period
89570646|NCT04922047|Experimental|Experimental: Intravenous tislelizumab / Intravesical BCG|"Drug: tislelizumab / BCG~Tislelizumab 200 mg administered by intravenous infusion every 3 weeks in first year and continue to second year based on physician choose. BCG 120 mg induction therapy administered via intravesical instillation (once weekly for 6 weeks). BCG induction therapy is followed by maintenance therapy (once weekly for 3 weeks at months 3, 6, 12, 18, 24m).~Other Name: BGB-A317"
89570647|NCT03057535|Experimental|Sodium Bicarbonate|Ingestion of sodium bicarbonate (0.3 g/kg of body mass)
89028810|NCT05775978|Experimental|MBSR group|This arm will instruct the students on the Mindfulness-Based Stress Reduction (MBSR) program. The MBSR is a secular, evidence-based practice originally developed for chronic pain, but which has reported positive results among an array of clinical and nonclinical populations. This program aims to cultivate non-judgmental attention to and awareness of present moment experience while promoting stress reduction.
89028811|NCT05775978|Active Comparator|Neuro-muscular stimulation group|"The students in this arm will receive training on physical wellbeing and neuro-muscular stimulation.~Non-specific factors such as number and duration of sessions, or instructor training and qualifications will match the other 2 experimental groups. Active ingredients such as mindfulness or socio-emotional training are not contained in the program."
89570648|NCT03057535|Placebo Comparator|Sodium Chloride|Ingestion of sodium chloride (4 g)
89570649|NCT04407013|Experimental|A|Experimental group with application of the standardized care pathways and symptom management education
89570650|NCT04407013|Other|B|Control group with usual care (symptom monitoring only)
89570651|NCT04941235|Active Comparator|NU group|Bth nerve stimulator and ultrasound guided interscalene brachial plexus block
89570652|NCT04941235|Active Comparator|U group|Ultrasound guided interscalene brachial plexus block
89570653|NCT04941235|Active Comparator|N group|Nerve stimulator guided interscalene brachial plexus block
89570654|NCT04941235|No Intervention|C group|No block only IV analgesics
89570655|NCT04921891|Active Comparator|Blocked arm|The investigators performed an infraclavicular nerve block to the operated arm group to provide anesthesia.
89570656|NCT04921891|Active Comparator|Unblocked arm|The upper extremity without block was assigned as the control group, and a comparison was made between the two upper extremities.
89570657|NCT04941079||Immune-related Myopathy Patient (myasthenia gravis and inflammatory myopathy)|
89570658|NCT04941079||Health Control|
89570659|NCT03057457||Kidney Injury|
89570660|NCT04921579|Experimental|En masse retraction|six anterior teeth are retracted by en masse technique using a crimpable hook distal to upper lateral incisor and a power chain.
89570661|NCT04921579|Experimental|two step retraction|six anterior teeth are retracted by two step technique by canine retraction followed by four anterior teeth retraction using a crimpable hook distal to upper lateral incisor and a power chain.
89570662|NCT04921657||Patients treated with statin.|Patients with hypercholesterolemia treated with rosuvastatin 10 mg daily or simvastatin 40 mg daily.
89570663|NCT04930471||Metformin (all participants)|Patients with a new indication for Metformin (standard dosage as assigned by the treating physician) therapy. Samples will be collected before and after 12 weeks of Metformin treatment.
89570664|NCT04921813|Experimental|Schroth method + brace|3-dimensional scoliosis exercise program according to Schroth method + brace.
89570665|NCT04921813|Experimental|Schroth + balance-coordination exercises + brace.|3-dimensional scoliosis exercise program according to Schroth + balance-coordination exercises + brace.
89570666|NCT04921813|Experimental|Brace|Only brace treatment.
89570667|NCT04921813|No Intervention|healthy individuals|Age-matched control group
89570668|NCT03057223|Experimental|3D Jaw Plate|3D Jaw Plate will be used in internal fixation.
89570669|NCT04940923||Patients|Patients within 4 weeks of a whiplash injury.
89570670|NCT04940923||Healthy controls|Age and gender matched healthy controls
89570671|NCT02576951|Experimental|Galcanezumab Solution Formulation-Part A|Galcanezumab solution formulation in a prefilled syringe given SC once.
89570672|NCT02576951|Placebo Comparator|Placebo-Part A|Placebo in a prefilled syringe given SC once.
89570673|NCT02576951|Experimental|Galcanezumab Lyophilized Formulation-Part B|Galcanezumab lyophilized (freeze dried) formulation given SC once.
89570674|NCT02576951|Experimental|Galcanezumab Solution Formulation-Part B|Galcanezumab solution formulation in a prefilled syringe given SC once.
89570675|NCT04921501|Experimental|Proven or suspected arrhythmias group|
89570676|NCT04921267|Experimental|trained group|group receives training with sounds that correspond to simulated hearing protection
89570677|NCT04921267|No Intervention|Control|group receives no training
89570678|NCT05530811|Active Comparator|with dexamethasone|bilateral suprazygomatic maxillary nerve block will be performed with 1 mL of 0.5% bupivacaine was added to 0.1 mg.kg-1 dexamethasone and diluted to 2 mL with 0.9% saline.
89570679|NCT05530811|Placebo Comparator|without dexamethasone|bilateral suprazygomatic maxillary nerve block will be performed with 1 mL of 0.5% bupivacaine alone and diluted to 2 mL with 0.9% saline.
89570680|NCT04940845|Experimental|HS-20090-2|
89570681|NCT04940845|Active Comparator|Prolia®|
89570682|NCT05507567|Experimental|Neumifil multiple dose prophylactic treatment|Neumifil intranasal spray administered as 3 single daily doses prior to viral challenge
89570683|NCT05507567|Experimental|Neumifil single dose prophylactic treatment|Neumifil intranasal spray administered as a single dose and blinded by placebo administered as two single daily doses. All administrations completed prior to viral challenge
89570684|NCT05507567|Placebo Comparator|Placebo|Intranasal spray administered as 3 single daily doses prior to viral challenge
89570685|NCT04921111|Experimental|Healthy Women Aged 18 to 26 Years|120 healthy women aged18 to 26 years are in this arm. The first group was 40 subjects to be inoculated with low dose vaccine; After the first low dose group was completed, the safety observation was conducted 7 days after the first dose was completed. If there was no need to suspend / terminate the study, 40 subjects in the group were continued to receive the medium dose vaccine; After the first dose group was completed, the safety observation was 7 days after the first dose was completed. If there was no need to suspend / terminate the test, 40 subjects in the group were inoculated with high dose group. In each dose group SCT1000 : Gardasil®9 : placebo =3:1:1.
89570686|NCT04921111|Experimental|Healthy Women Aged 27 to 45 Years|120 healthy women aged 27 to 45 years are in this arm. The first group was 40 subjects to be inoculated with low dose vaccine; After the first low dose group was completed, the safety observation was conducted 7 days after the first dose was completed. If there was no need to suspend / terminate the study, 40 subjects in the group were continued to receive the medium dose vaccine; After the first dose group was completed, the safety observation was 7 days after the first dose was completed. If there was no need to suspend / terminate the test, 40 subjects in the group were inoculated with high dose group. In each dose group SCT1000 : Gardasil® : placebo =3:1:1.
88811133|NCT04201457|Experimental|Phase 2 Stratum 6 LGG with NF Type 1|LGG with Neurofibromatosis Type 1 will receive Trametinib and Hydroxychloroquine. All medications are administered orally with Trametinib given once per day and HCQ give twice per day at the recommended Phase 2 dose for a 28 day course. Courses may repeat until the patient meets an off treatment criteria.
89028812|NCT05763810|Other|Erector Spinae Plane Block group|Erector Spinae Plane Block
89570687|NCT05530733|Other|Pacifier only|Participants in the pacifier-only group will get a pacifier five minutes prior to tube feeding. During feedings, a pacifier will be employed. Five minutes following the end of tube feeding, the pacifier application will be discontinued. The vital signs will be monitored prior to, during, and following feeding. Two hours after the feeding has finished, the volume of gastric residue will be controlled.
89570688|NCT05530733|Other|Pacifier with breast milk|Five minutes prior to tube feeding, participants in the pacifier with breast milk group will get their own breast milk dripping pacifier. During feedings, a pacifier will be employed. Five minutes following the end of tube feeding, the pacifier application will be discontinued. The vital signs will be monitored prior to, during, and following feeding. Two hours after the feeding has finished, the amount of gastric residue will be controlled.
89570689|NCT05530733|No Intervention|standard care (no pacifier)|The premature babies in the standard care (no pacifier) will get standard care while being fed through an orogastric tube. The vital signs will be monitored prior to, during, and following feeding. Two hours after the feeding has finished, the amount of gastric residue will be controlled.
89028813|NCT05763810|Other|Superficial Parasternal Intercostal Plane Block and Rectus Sheath Block group|Superficial Parasternal Intercostal Plane Block and Rectus Sheath Block
89209019|NCT00806312||1 PAH|Patients who are ≥ 18 years of age, not pregnant, and undergoing right heart catheterization for PAH diagnosis as part of their clinical care will be approached for consent and participation in this study.
89570690|NCT03057145|Experimental|Prexasertib Combine with Olaparib|"Olaparib will be administered orally on an intermittent schedule during each 28-day cycle. Exact administration schedule will depend on assigned dose level.~Prexasertib will be administered intravenously on Days 1 and 15 of a cycle"
89570691|NCT04921423|Experimental|situational simulation teaching|Clinical case role play and empathy skill practice
89570692|NCT04921423|No Intervention|Clinical Case (Problem Based Learning)|Clinical Case discuss (Problem Based Learning)
89570693|NCT04425005|No Intervention|Control group|
89570694|NCT04425005|Experimental|Exercise training group|
89570695|NCT03056989|Experimental|SPX-101 Low Dose|Inhalation Solution twice daily for 7 days.
89570696|NCT03056989|Experimental|SPX-101 Mid Dose|Inhalation Solution twice daily for 7 days.
89028814|NCT05763693|Active Comparator|Azithro-Azithro|A single oral dose of azithromycin (20 mg/kg) at baseline and a single oral dose of azithromycin (20 mg/kg) at the day 21 follow-up
89570697|NCT03056989|Experimental|SPX-101 High Dose|Inhalation Solution twice daily for 7 days.
89028815|NCT05763693|Active Comparator|Azithro-Placebo|A single oral dose of azithromycin (20 mg/kg) at baseline and a single oral dose of matching placebo at the day 21 follow-up
89028816|NCT05763693|Active Comparator|Placebo-Azithro|A single oral dose of placebo at baseline and a single oral dose of azithromycin (20 mg/kg) at the day 21 follow-up
89028817|NCT05763693|Placebo Comparator|Placebo-Placebo|A single oral dose of placebo at baseline and a single oral dose of matching placebo at the day 21 follow-up
89570698|NCT04940455|Experimental|Educational digital platforms|"Nursing students from the Experimental Group (GE), will participate in educational activities made available on digital platforms on nursing care for patients with signs and symptoms of sepsis"
89570699|NCT04940455|Active Comparator|High-Fidelity Simulation|Nursing students in the Control Group (GC) will be exposed to high-fidelity simulation in the intensive care setting, where they must solve situations and procedures related to the nurse's performance in recognizing the signs and symptoms of sepsis.
89570700|NCT04920877|Experimental|Central catheter-related bloodstream infection rates in intensive care units|
89570701|NCT04940143|Experimental|Botulinum toxin-A|Botulinum toxin-A (Onabotulinum toxin type-A) injection with electrical stimulation guidance will be administered to spastic ankle plantar flexor muscles. After the injection, the patients will be included in the comprehensive physiotherapy program.
89570702|NCT03057067|Experimental|pelvic vein embolization|female patients referred for assessment of chronic pelvic pain at the gynecological outpatient clinic or the Multidisciplinary Pain Clinic at St. Olavs Hospital, Trondheim, Norway
89570703|NCT03056911||ozone|Chemonucleolysis by ozone therapy Patients visiting the pain clinic of the hospital who had cervical discogenic or radicular pain that did not resolve after the use of conventional therapy. Written informed consent was obtained from all participants.
89570704|NCT04929613|Experimental|Mindfulness-Based Resilience Training|Designed to train participants in a number of experiential exercises evoking qualities of mindfulness: mental focus, sustained attention and personal and situational awareness. These exercises include versions of the body scan (body awareness exercise), sitting meditation, mindful movement, walking meditation, eating meditation, mindful martial arts exercises and other elements of mindfulness.
89570705|NCT04920409|Experimental|FAWGT Diet|Composed of fruit, avocado, whole grains and trout
89570706|NCT04920409|Active Comparator|Usual diet (UD)|Based on the food which the participants usually consumed prior to the study in their normal lifestyle.
89570707|NCT04920721||Allergic|suspected of immediate hypersensitivity reaction to platinum salts with positiv skin tests
89570708|NCT04920721||Non allergic|suspected of immediate hypersensitivity reaction to platinum salts with negativ skin tests
89570709|NCT04939675|Experimental|Anti-seizure medication|The intervention group will receive anti-epileptic drug treatment according to the guideline of American Epilepsy Society 15 for 12 weeks. The recommended regimens include zonisamide, lamotrigine, or levetiracetam at the minimal therapeutic doses (zonisamide 100mg twice daily, levetiracetam 500mg twice daily, lamotrigine 50mg twice daily), and the choices depend on tolerability of the participants and contraindications (allergy to any drugs, or allergy to sulphonamides in zonisamide users). The participants will be followed every 4 weeks.
89570710|NCT04939675|No Intervention|Observation|The participants will be followed every 4 weeks without anti-seizure medication.
89570711|NCT04939285|Experimental|PEEP=5cmH2O|In PSV mode,PS = 8 cmH2O,PEEP= 5 cmH2O, and FiO2 level was consistent with that before SBT
89570712|NCT04939285|Experimental|PEEP=0cmH2O|In PSV mode,PS = 8 cmH2O,PEEP=0 cmH2O, and FiO2 level was consistent with that before SBT
89570713|NCT04929691|Experimental|CPAP- Helmet Users|Patients admitted to a study site with suspected or confirmed COVID-19 and who consented to using the CPAP helmet
89570714|NCT04929691|Active Comparator|Non-CPAP helmet users|Patients admitted to a study site with suspected or confirmed COVID-19 but who did not use a CPAP helmet
89570715|NCT04938739|Experimental|Cognitive Behavioral therapy|to modify any erroneous beliefs about pain and disability and to promote coping strategies and self-efficacy through a graded activity.
89570716|NCT04938739|Active Comparator|Home program exercises|Patients in both groups carried out exercise therapy for six weeks. There will be an educational session for each patient to make sure the exercises will be done successfully and supervision once per week.
89570717|NCT04929145||MICROMS|No intervention will be administered. Stool, hair, and blood samples will be collected at baseline and three months post baseline. Clinical follow-up will occur at year 1, 2, and 4.5 (neurological consultation) and in-between visits (regular follow-up).
89570718|NCT03055975||Primary treatments|Patients undergoing primary root canal treatments. Only teeth which have not previously been accessed are included in this cohort.The source population are adults aged 18-65, referred by their general dental practitioner into specialist endodontic clinics of Guy's Hospital
89570719|NCT03055975||Re-treatments|Patients undergoing re-treatments. Only teeth which had a previous root canal treatment which failed are included in this cohort.The source population are adults aged 18-65, referred by their general dental practitioner into specialist endodontic clinics of Guy's Hospital
89570720|NCT04929301|Experimental|AME Hand-Expression|Participants in the antenatal milk expression (AME) group will learn hand-expression from a certified lactation consultant beginning at 37 weeks of pregnancy. At the same visit, the PI or RA will also provide oral and written instructions for AME at home, specifically instructing participants to do AME 1-2 times per day for no longer than 10 minutes.
89570721|NCT04929301|Active Comparator|Education|Participants in the education group will receive a weekly educational hand-out on varying breastfeeding topics (e.g., latch).
89570722|NCT03055663|Experimental|Virtual reality sedation|Patients watches virtual reality sedation program that shows underwater world with comfortable music and narrations during surgery.
89570723|NCT03055663|Active Comparator|Sedation with intravenous sedatives|Patients receives intravenous sedative of midazolam (initial bolus 1-2 mg with maintenance dose of 1 mg every 10 - 30 min).
89570724|NCT04928443||Scar dressing group|Patients planning to treat surgical scar with scar dressing
89570725|NCT04928443||Regular care group|Patients treated with adhesive tapes or strips or did not take care of surgical scar.
89570726|NCT02621047|Experimental|Alectinib: Moderate Hepatic Impairment|Participants with moderate hepatic impairment (based on Child-Pugh score) will receive alectinib at a single oral dose of 300 milligrams (mg) on Day 1.
89028818|NCT05758857|Experimental|Guidelines-based physical activity|150 weekly minutes of moderate-intensity aerobic activity and twice weekly whole-body muscle strengthening
89028819|NCT05758857|Experimental|Guidelines-based physical activity and healthy eating|150 weekly minutes of moderate-intensity aerobic activity and twice weekly whole-body muscle strengthening + counselling to follow Canada's Food Guide
89028820|NCT05758857|Placebo Comparator|Stretching exercise|Whole-body stretching
89570727|NCT02621047|Experimental|Alectinib: Severe Hepatic Impairment|Participants with severe hepatic impairment (based on Child-Pugh score) will receive alectinib at a single oral dose of 300 mg on Day 1.
89028821|NCT05750264|Active Comparator|ibuprofen group|intravenous ibuprofen 800mg in 200 ml normal saline+IV paracetamol 1000mg+Transversus abdominis plane block
89028822|NCT05750264|No Intervention|Control group|200 ml normal saline+IV paracetamol1000mg+Transversus abdominis plane block
89028823|NCT05746754|Experimental|Craniospinal proton radiotherapy|30 Gy in 10 fractions to CNS
89570728|NCT02621047|Experimental|Alectinib: Normal Hepatic Function|Participants with normal hepatic function will receive alectinib at a single oral dose of 300 mg on Day 1.
89028824|NCT05742685|Experimental|Reinforcement Learning Intervention Arm|Up to daily, tailored text messages.
89028825|NCT05742685|No Intervention|Control Arm|Up to daily, untailored text messages.
89028826|NCT05736679|Experimental|In2Care EaveTube|EaveTube installation with deltamethrin treated netting; in addition to standard of care (standard pyrethroid-only bednets)
89028827|NCT05736679|No Intervention|Control|Standard of care (standard pyrethroid-only bednets)
89028828|NCT05730335|Experimental|Rapid Acoustic Pulse (RAP)|Participants will receive 2 separate RAP cellulite treatments sessions.
89028829|NCT05726123|Placebo Comparator|Control group (G1)|Control group (G1): in which the suit shall be switched on, but with the current of all electrodes at 0 mA.
89028830|NCT05726123|Experimental|Suit group (G2)|Suit group (G2): will only receive treatment with the neuromodulation suit at the intensity preset by the manufacturer and according to the assessment criteria. The duration of the treatment will be 1 hour. Exopulse Molly Suit with all 58 electrodes active with an intensity of 2 milliamperes (mA) and pulse width of 30 milliseconds (ms)
89028831|NCT05726123|Experimental|Suit + VR group (G3):|Suit + VR group (G3): the intervention on this group was carried out in the same way as the suit group. However, the session was different as the participant wore VR glasses besides wearing the suit for an hour. The patient sees the same room he is in and a person performing a series of exercises he must follow as indicated by the video by video and voice commands. As exercise are performed in a laying position the patient must stay in this position for the whole session.
89028832|NCT05726123|Experimental|Exercise group (G4):|Exercise group: The procedure carried out is the same as in the suit group, but the session performed was a 1-hour session of strength exercise carried out by a certified professional.
89028833|NCT05712538|Experimental|ARCT-032, Healthy Adults|Ascending single doses of ARCT-032 administered to healthy adults via nebulizer
89028834|NCT05712538|Placebo Comparator|Placebo, Healthy Adults|Single doses of 0.9% Saline administered to healthy adults via nebulizer
89028835|NCT05712538|Experimental|ARCT-032,. Adults with Cystic Fibrosis|Two doses of ARCT-032 administered to adults with Cystic Fibrosis via nebulizer
89028836|NCT05707871|Active Comparator|Usual Brand of Cigarettes|Participants will smoke 2-3 cigarettes of their usual brand
89028837|NCT05707871|Experimental|Research Cigarettes (SPECTRUM)|Participants will smoke 1-2 SPECTRUM cigarettes
89028838|NCT05703152|Experimental|Combined Exercise|Therapeutic exercise program
89028839|NCT05701072||All participants|
89028840|NCT05685927||Non-obese participants with dysregulated type 1 diabetes|
89028841|NCT05685927||Non-obese participants with dysregulated type 2 diabetes|
89028842|NCT05685927||Obese participants with type 2 diabetes|
89028843|NCT05685927||Obese participants without type 2 diabetes|
89570729|NCT03057691||No depression/anxiety|patients suffered from ACS who have undergone PCI without depression or anxiety
89570730|NCT03057691||Depression|patients suffered from post-ACS depression who have undergone PCI
89570731|NCT03057691||Anxiety|patients suffered from post-ACS anxiety who have undergone PCI
89570732|NCT03057691||Depression with anxiety|patients suffered from post-ACS depression with anxiety who have undergone PCI
89570733|NCT03057379|No Intervention|Control arm|Usual source of care
89570734|NCT03057379|Experimental|1 R/R per Dose|Sending up to one recall notice per dose of HPV vaccine needed
89570735|NCT03057379|Experimental|2 R/R per dose|Sending up to two recall notice per dose of HPV vaccine needed
89570736|NCT03057379|Experimental|3 R/R per dose|Sending up to three recall notice per dose of HPV vaccine needed
89570737|NCT04928365|Other|Advanced melanoma patients|
89570738|NCT04928365|Other|Stage III and IV melanoma patients after radical surgery|
89570739|NCT04938037|Experimental|SSNB through the spinoglenoid notch|US guided 1ml methylprednisolone acetate (1ml / 40mg) and 5ml 0.5% bupivacaine Intervention: Medication: corticosteroids and local anesthetics
89570740|NCT04938037|Active Comparator|SSNB through the suprascapular notch|US guided 1ml methylprednisolone acetate (1ml / 40mg) and 5ml 0.5% bupivacaine Intervention: Medication: corticosteroids and local anesthetics
89570741|NCT04431271||Robot-assisted laparoscopy|Patients who underwent robot-assisted groin hernia repair
89570742|NCT04431271||Conventional laparoscopy|Patients who underwent conventional laparoscopic groin hernia repair
89570743|NCT04919785|Experimental|Deep brain stimulation|Deep brain stimulation in the bed nucleus of stria terminalis
89570744|NCT04928833|Experimental|Pilates Group|Pilates training was carried out as group exercises for about 1 hour, 3 days a week for 8 weeks.
89570745|NCT04928833|Active Comparator|Control Group|Breathing exercises, active range of motion exercises and relaxation exercises were given to the control group as a home program. They were asked to do the exercises 3 days a week for 8 weeks.
89570746|NCT04928833|No Intervention|Evaluation of 'Core' Stability|"Core stability was evaluated with two important dimensions, core strength and endurance tests."
89570747|NCT04928833|No Intervention|Ultrasound Examination of M. Transversus Abdominus and M. Multifidus|M. transversus abdominus (TrA) and m. multifidus (MF) muscles were visualized by ultrasonography and the evaluations were performed by an experienced radiologist who was blind to the case groups.
89570748|NCT04928833|No Intervention|Evaluation of Lower Extremity Functional Strength|Lower extremity functional strength was evaluated with the 5-Times Sit-and-Stand Test.
89570749|NCT04928833|No Intervention|Evaluation of Balance|Balance was evaluated using the Berg Balance Scale (BBS).
89570750|NCT04928833|No Intervention|Evaluation of Functional Mobility|Functional mobility was evaluated using the Timed Up and Go Test (TUG).
89028844|NCT05685927||Healthy control participants|
89570751|NCT04928833|No Intervention|Evaluation of Functional Exercise Capacity|Functional exercise capacity was evaluated using the 6 Minute Walking Test (6-MWT).
89028845|NCT05681858||CT coronary angiography and [12N] NH3 PET-MR|All patients will undergo CT coronary angiography and stress [12N] NH3 PET-MR
89028846|NCT05673993|Experimental|Telitacicept 80 mg|Subjects will be given subcutaneous Telitacicept 80 mg once a week for 48 weeks.
89570752|NCT04928833|No Intervention|Activities of Daily Living and Evaluation of Motor Impairment|Activities of daily living and motor impairment were evaluated with activities of daily living (II) and motor impairment (III) sub-dimensions of the Unified Parkinson's Disease Rating Scale (UPDRS).
89570753|NCT04928833|No Intervention|Evaluation of Freezing|The Freezing of Gait Questionnaire (FOGQ) was used to identify and evaluate the subjective perception of Parkinson's patients regarding the severity and effect of freezing on gait performance.
89028847|NCT05673993|Experimental|Telitacicept 160 mg|Subjects will be given subcutaneous Telitacicept 160 mg once a week for 48 weeks.
89028848|NCT05673993|Placebo Comparator|Placebo|Subjects will be given subcutaneous placebo once a week for 24-48 weeks. Subjects who are randomized to the placebo group are allowed to be transferred to either Telitacicept 80 mg or Telitacicept 160 mg after Week 24 by the investigator. Subjects and investigators are blinded throughout the study.
89028849|NCT05673148|Experimental|Arm 1 (TAT, SOC chemotherapy|Patients undergo TAT on study, consisting of SABR with or without surgical resection and/or microwave ablation. Patients also receive SOC chemotherapy on study. Patients also undergo CT or MRI or PET/CT scans throughout the trial.
89028850|NCT05673148|Active Comparator|Arm 2 (SOC chemotherapy)|Patients receive SOC chemotherapy on study. Patients also undergo Patients also undergo CT or MRI or PET/CT scans throughout the trial.
89570754|NCT04928833|No Intervention|Evaluation of Fatigue|Fatigue, one of the non-motor findings associated with Parkinson's, was evaluated with the Parkinson's Fatigue Scale-16 (PFS-16).
89028851|NCT05646459|Placebo Comparator|Control - Floss|Subjects will use only floss at study site
89028852|NCT05646459|Sham Comparator|Proxabrush - Control|Subjects will use only proxabrush at study site.
89028853|NCT05646459|Experimental|Proxabrush - CBD|Subject will use CBD + proxabrush on study site.
89028854|NCT05638633|Active Comparator|1st arm (prednisolone and placebo)|Day 1-5: prednisolone 20mg 1x1 and placebo 1x1 Day 6-28: prednisolone 5mg 1x1 and placebo 1x1
89028855|NCT05638633|Active Comparator|2nd arm (placebo and Vitamin B compound)|Day 1-5: Placebo 1x1 and Vitamin B compound (100 mg B1, 50 mg B6, 500µ B12) 1x1 Day 6-28: placebo 1x1 and Vitamin B compound (100 mg B1, 50 mg B6, 500 µg B12) 1x1
89028856|NCT05638633|Active Comparator|3rd arm (prednisolone and Vitamin B compound)|Day 1-5: prednisolone 20mg 1x1 and Vitamin B compound (100 mg B1, 50 mg B6, 500µg B12) 1x1 Day 6-28: prednisolone 5mg 1x1 and Vitamin B compound (100 mg B1, 50mg B6, 500µg B12) 1x1
89028857|NCT05638633|Placebo Comparator|4rd arm (placebo and placebo)|Day 1-5: Placebo 1x1 and placebo 1x1 Day 6-28: placebo 1x1 and placebo 1x1
89028858|NCT05635604|Active Comparator|Eptinezumab and PACAP-38|The participants will receive an intravenous infusion of eptinezumab (300 mg) over 30 minutes followed (2 hours later) by an intravenous infusion of PACAP-38 (10 pmol/kg/min) over 20 minutes.
89028859|NCT05635604|Placebo Comparator|Placebo and PACAP-38|The participants will receive an intravenous infusion of placebo (saline) over 30 minutes followed (2 hours later) by an intravenous infusion of PACAP-38 (10 pmol/kg/min) over 20 minutes.
89028860|NCT05630378|Experimental|Treatment group|"The treatment group has 11 visits in the outpatient clinic of integrative medicine and naturopathy. Additional they fill in a diary and wear a pedometer during the day. Diary and pedometer continue to week 15. In week 12 a video conference with the treatment-group takes place. During week 14+15 a qualitative telephone interview is set.~Patients fill in questionnaires before the start of the outpatient clinic and directly afterwards (week 11)."
89028861|NCT05630378|Other|Waiting group|Parallel to the treatment group the waiting group receives no intervention, but fills in a diary and wear a pedometer during the day. Their diary and pedometer continue only to week 11. No additional interventions (refresher; video conference; interview) take place. Patients fill in questionnaires before the start of the waiting phase, parallel to the start of the outpatient clinic and directly after its end (week 11).
89209020|NCT00806312||2. Control|Patients who present with symptoms of PAH and whose clinical right heart catheterization doesn't support this diagnosis will be enrolled as control subjects.
89570755|NCT04928833|No Intervention|Evaluation of Quality of Life|Quality of Life was evaluated with Parkinson's Disease Questionnaire-39 (PDQ-39).
89570756|NCT04919473|Experimental|vMCO-I High dose|Participants received 3.5E11vg/eye of vMCO-I
89570757|NCT04919473|Experimental|vMCO-I Low Dose|Participants received 1.75E11vg/eye of vMCO-I
89570758|NCT04937569|Active Comparator|Group 1: Ivermectin + standard treatment|Patients will receive 4-days course of Ivermectin 400 microgram/kg body weight maximum 4 tablets (6mg / tablet) once daily dose before breakfast plus standard treatment (Azithromycin 500mg once daily for 5 days, Paracetamol 500mg every 8 hours, vitamin C 1gm once daily, Zinc 50 mg once daily, Lactoferrin 100mg sachets twice daily and prophylactic or therapeutic anticoagulation if D-dimer is elevated.
89570759|NCT04937569|Other|Group-2: Standard treatment only|This group will receive the standard treatment protocol as outlined above according to the Egyptian Ministry of Health protocol of treating cases with mild COVID-19.
89570760|NCT04937257|Active Comparator|Virtual Reality|"Participants randomized to the immersive virtual reality study arm, considered the intervention group received training on donning and doffing PPE using a program developed by Axon Park Inc. (California, USA)"
89570761|NCT04937257|Placebo Comparator|E-module|"Participants randomized to the e-module study arm, considered the control group received training on donning and doffing PPE using an e-module containing a video and slide show."
89570762|NCT04937335||Non-hemorrhage group|Patients recognized as craniopharyngioma pathologically without tumoral hemorrhage observed during the operation
89570763|NCT04937335||Hemorrhage group|Patients recognized as craniopharyngioma pathologically with tumoral hemorrhage observed during the operation
89209021|NCT00798668|Experimental|1|participants continue current exercise and take liquid supplement
89028862|NCT05625490|Experimental|Rest/ Stress imaging day 1|Participants will receive two [68Ga]Galmydar intravenous administrations, 4 mCi during rest and 8 mCi during stress for the PET MPI performed on Imaging Day-1.
89028863|NCT05625490|Experimental|rest/ stress imaging day 2|On Imaging Day-2, participants will receive two single administrations each of 10 mCi of 13N-Ammonia during the rest and stress PET MPI.
89028864|NCT05625425|Experimental|LabyrinthVR Scoot|Multi-session cognitive intervention with VIVE high-resolution head-mounted display virtual reality computer game that presents an adaptive spatial wayfinding challenge. Game movement via handheld controllers.
89570764|NCT04919005|Experimental|Healthy elderly people|Twelve healthy elderly people. Each participant underwent a pre-test, the intervention with a Virtual Environment, and a post-test.
89570765|NCT04919005|Experimental|Elderly people with Alzheimer's in the initial phase|Seven elderly people with Alzheimer's in the initial phase. Each participant underwent a pre-test, the intervention with a Virtual Environment, and a post-test.
89570766|NCT04919005|Experimental|Healthy young people|Fifteen healthy young people. Each participant underwent a pre-test, the intervention with a Virtual Environment, and a post-test.
89570767|NCT04927507|No Intervention|Control group|The control group was given routine nursing.
89570768|NCT04927507|Experimental|Observation group|The observation group was given the Internet plus nursing home rehabilitation mode.
89570769|NCT04918849||Community Sample|We plan to recruit a community sample of 1000 from the Indian Population.
89570770|NCT04937101|Experimental|Antihistamine treatment group|Chlorpheniramine, the concentration is 10mg/ml per unit point, the highest dose is 1ml
89570771|NCT04937101|No Intervention|Control group|
89570772|NCT04937023|Experimental|UDCA gel will be injected using a syringe with blunt cannula into the defect site|In the test group, the prepared UDCA gel will be injected using a syringe with blunt cannula into the two or three wall intra-bony defects with probing pocket depth ≥3mm after performing SRP.
89570773|NCT04937023|Placebo Comparator|placebo gel will be injected in to the defect site using a syringe with blunt cannula.|In patients allocated to control group, placebo gel will be injected in to the defect site using a syringe with blunt cannula after scaling and root planing.
89028865|NCT05625425|Placebo Comparator|Placebo Controls|Multi-session cognitive intervention with handheld tablet or wireless virtual reality headset presentation of commercially available, narrative computer games.
89028866|NCT05625425|Experimental|Labyrinth Tablet|Multi-session cognitive intervention with tablet computer, displaying 2.5D version of Labyrinth game in an adaptive spatial wayfinding challenge. Game movement via on-screen control buttons.
89028867|NCT05625425|Experimental|Labyrinth VR wireless|Multi-session cognitive intervention with QUEST head-mounted display virtual reality computer game using wireless technology to present an adaptive spatial wayfinding challenge. Game movement via handheld controllers.
89028868|NCT05621772|Experimental|Experimental group (Meridian Activation Remedy System for Parkinson's Disease)|Meridian Activation Remedy System for Parkinson's Disease (MARS-PD) treatment (16 times/8 weeks total, 2 times/week)
89028869|NCT05621772|No Intervention|Control group (Usual Care)|Usual care (all participants will be allowed to continue their prescribed medication and treatment (except Korean Medicine therapy), and they will not receive any additional treatment or therapy in the research institute), and lifestyle advice (all participants will receive a smart band and application-based guidance about their lifestyle)
89028870|NCT05619302|Experimental|[68Ga]CBP8 PET/MRI Amyloid Subjects|Individuals with documented cardiac amyloidosis will undergo [68Ga]CBP8 PET/MRI.
89028871|NCT05619302|Active Comparator|[68Ga]CBP8 PET/MRI Recent Myocardial Infarction Subjects|Individuals with recent myocardial infarction will undergo [68Ga]CBP8 PET/MRI.
89028872|NCT05619302|Placebo Comparator|[68Ga]CBP8 PET/MRI Healthy Controls|Individuals without documented cardiovascular disease will undergo [68Ga]CBP8 PET/MRI.
89028873|NCT05619302|Active Comparator|[68Ga]CBP8 PET/MRI Hypertrophic Cardiomyopathy Subjects|Individuals with hypertrophic cardiomyopathy will undergo [68Ga]CBP8 PET/MRI.
89028874|NCT05618782|Active Comparator|0.3 mg/kg dose intravenous infusion of LEVI-04|LEVI- 04 is a proprietary p75 neurotrophin receptor fusion protein (p75NTR-Fc).It modulates the nerve growth factor (NGF) pathway, clinically proven to provide effective analgesia.
89570774|NCT04937179|Sham Comparator|Ischemic Conditioning Low|Blood flow restriction with low compression
89570775|NCT04937179|Active Comparator|Ischemic Conditioning High|Blood flow restriction with high compression
89570776|NCT04936711|Experimental|Back Massager Device + Standard Pain Treatment|"Resteck Shiatsu Neck and Back Massager (brand name), with recommended use for at least every 2 hours for at least 15 minutes on the first post-operative day and then every 4 hours for 2 days and then as needed.~Standard pain treatment:~Local anesthetic agent at the incision sites include: 0.5% Marcaine (10 cc) + 0.5% lidocaine and epinephrine (10 cc) (total volume: 20 cc)~Morphine 2 mg: Intravenous administration every 2 hours or as needed, if unable to take pills by mouth~Oxycodone 5 - 10 mg elixir: oral administration every 6 hours or as needed~Tylenol 650 mg Tab: oral administration every 6 hours"
89028875|NCT05618782|Active Comparator|1.0 mg/kg dose intravenous infusion of LEVI-04|LEVI- 04 is a proprietary p75 neurotrophin receptor fusion protein (p75NTR-Fc).It modulates the nerve growth factor (NGF) pathway, clinically proven to provide effective analgesia.
89209022|NCT00798668|Experimental|2|Participants continue current exercise and take solid supplement
89028876|NCT05618782|Active Comparator|2.0 mg/kg dose intravenous infusion of LEVI-04|LEVI- 04 is a proprietary p75 neurotrophin receptor fusion protein (p75NTR-Fc).It modulates the nerve growth factor (NGF) pathway, clinically proven to provide effective analgesia.
89028877|NCT05618782|Placebo Comparator|Placebo dose intravenous infusion|
89028878|NCT05613803|Active Comparator|Fish oil|6g of Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA) in a 1.3:1 ratio; respectively, as six Omacor capsules, taken once daily, or in divided doses, with food.
89028879|NCT05613803|Placebo Comparator|Placebo|Matched capsules (six) containing palm olein IV 56 taken once daily, or in divided doses, with food.
89028880|NCT05612295|Experimental|MBPP group|The Mindfulness-based Peak Performance (MBPP) program consists of eight 60-min training sessions, once weekly for 8 weeks, which aim to enhance human performance.
89028881|NCT05612295|Active Comparator|Self-talk group|The self-talk intervention serving as the active control group will be included in the current trial. In line with the MBPP intervention, the self-talk intervention is also designed to enhance athletic performance, and will consist of eight 60-min meaningful sessions, once per week for eight weeks.
89028882|NCT05612295|No Intervention|Waiting-list control|The participants in waiting-list control group are advised to maintain their everyday lifestyles and regular training. Once the participants in WC finish the experiment, they will be invited to participate in one of the 8-week interventions (i.e., MBPP or ST) based upon their preference.
89028883|NCT05601583|Experimental|CP-CGMH|"CP-CGMH: Care Partner-Assisted Intervention through linking continuous glucose monitoring and Mobile Health.~Participants will receive a CGM device and asked to share CGM data with their care partners for daily decision-making for diabetes self-management for two weeks. The LibreLinkup mHealth app will be used to share data."
89028884|NCT05566873|Active Comparator|PA Education plus human and planetary health information|"Participants will continue to receive the remote light touch physical activity education program that they have been receiving for the past several years along with additional remote health education information to control for nonspecific factors (staff attention, participant time)."
89028885|NCT05566873|Experimental|PA Education plus Our Voice citizen science|"Participants will receive the remote light touch physical activity education program in combination with the remote Our Voice citizen science program aimed at identifying and addressing physical and social environmental barriers to and enablers of regular physical activity."
89028886|NCT05555732|Experimental|Dato-DXd + Pembrolizumab + Platinum Chemotherapy|Participants will be randomized to receive 6.0mg/kg Dato-DXd plus 200 mg pembrolizumab plus platinum chemotherapy (cisplatin 75 mg/m^2 or carboplatin area under the curve [AUC) 5]).
89028887|NCT05555732|Experimental|Dato-DXd + Pembrolizumab|Participants will be randomized to receive 6.0mg/kg Dato-DXd plus 200 mg pembrolizumab.
89209023|NCT00798668|Experimental|3|Participants continue current sedentary behavior and take liquid supplements
89570777|NCT04936711|Active Comparator|Marcaine spray + Standard Pain Treatment|"30cc of 0.25% Marcaine spray on the diaphragm at the end of surgery.~Standard pain treatment:~Local anesthetic agent at the incision sites include: 0.5% Marcaine (10 cc) + 0.5% lidocaine and epinephrine (10 cc) (total volume: 20 cc)~Morphine 2 mg: Intravenous administration every 2 hours or as needed, if unable to take pills by mouth~Oxycodone 5 - 10 mg elixir: oral administration every 6 hours or as needed~Tylenol 650 mg Tab: oral administration every 6 hours"
89570778|NCT04936711|No Intervention|Standard Pain Treatment|"will receive standard pain treatment include local anesthetic agent at the incision sites + oral Tylenol and oral or IV opioid as breakthrough pain treatment postoperatively as needed.~Standard pain treatment:~Local anesthetic agent at the incision sites include: 0.5% Marcaine (10 cc) + 0.5% lidocaine and epinephrine (10 cc) (total volume: 20 cc)~Morphine 2 mg: Intravenous administration every 2 hours or as needed, if unable to take pills by mouth~Oxycodone 5 - 10 mg elixir: oral administration every 6 hours or as needed~Tylenol 650 mg Tab: oral administration every 6 hours"
89570779|NCT04927117||high myopic group (group1:AL≥26.0 mm)|axial length≥26.0 mm)
89570780|NCT04927117||age-matched control group|axial length<26.0mm
89570781|NCT04936945|Active Comparator|arthroscopy plus platelet rich plasma.|Group A: will be treated with operative arthroscopy plus intra-articular injection of platelet rich plasma
89570782|NCT04936945|Active Comparator|arthroscopy plus hyaluronic acid.|Group B: will be treated with operative arthroscopy plus intra-articular injection of hyaluronic acid
89570783|NCT04936789|Experimental|Single arm|Single arm. All subjects will receive the intervention. Comparator device will be subjects' own prosthesis at baseline.
89570784|NCT04936555|Experimental|Self-Acupressure|Each application to the acupressure points (H17, L14, ST36, SP6) will be done in 2 minutes and right and left)
89570785|NCT04936555|No Intervention|No Intervention|Control group Routine maintenance will be applied
89570786|NCT03056521|Experimental|Info|"In this arm the patients are counseled preoperatively about post operative pain.~Specific information about post operative pain which includes both pharmacologic and non-pharmacologic treatments, complications of pain and benefits of good pain management. This is in addition to the routine care provided"
89570787|NCT03056521|No Intervention|No info|These patients are in the control group. They are left to receive only the routine preoperative care as made available to them while on ward.
89570788|NCT04431349||ticagrelor|The patient with acute myocardial infarction received loading dose of ticagrelor for coronary angiography within 2 days prior to OPCAB or CABG.
89570789|NCT04431349||clopidogrel|The patient with acute myocardial infarction received loading dose of clopidogrel for coronary angiography within 2 days prior to OPCAB or CABG.
89570790|NCT03056677|Experimental|Control|No Whey Protein
89570791|NCT03056677|Experimental|Normal Whey protein|Whey protein (50grams) drink will be given prior to a mixed carbohydrate meal
89570792|NCT03056677|Experimental|Modified Whey|Modified whey protein will be given
89570793|NCT04431583||2008-2012 Participants|Participants who underwent bariatric surgery between 2008 and 2012 (inclusive).
89570794|NCT04431583||2013-2016 Participants|Participants who underwent bariatric surgery between 2013 and 2016 (inclusive).
89570795|NCT04431583||2017- 2018 Participants|Participants who underwent bariatric surgery between 2017 and 2018 (inclusive).
89028888|NCT05555732|Active Comparator|Pembrolizumab + Pemetrexed + Platinum Chemotherapy|Participants will be randomized to receive 200 mg pembrolizumab plus 500 mg/m^2 pemetrexed plus platinum chemotherapy (cisplatin 75 mg/m^2 or carboplatin area under the curve [AUC) 5]).
89028889|NCT05555264|Experimental|Self-Guided Alcohol Change Course Enhanced|"Clients who select or are assigned the self-guided condition will receive access to 6 ICBT core lessons, 6 associated worksheets to enhance skill acquisition, and 8 additional resources addressing potential co-morbid concerns (e.g., Addressing Anger, Improving Assertiveness and Communication, Changing Cannabis Use, Developing Cognitive Coping, Coping with Grief, Understanding PTSD, Improving Sleep Quality, and Managing Worry). The 6 lessons and 6 associated worksheets are released at a rate of 1 per week over 7 weeks, with no new content being released to participants in Week 4. The 8 additional resources are available at any time during the course.~Clients will not receive therapist support/guidance during the 8-week intervention."
89570796|NCT04431115||Stakeholders|"Academic experts, Politicians and officials of state ministries of health and education and teachers.~Interviews will be conducted for academic experts, politicians and officials of state ministries of health and education.~Headteachers and physical education teachers will be administered questionnaires."
89033132|NCT02921607||Observational|One group - all participants will be completing questionnaires and will be followed up with three months post discharge.
89570797|NCT04431115||Parents|Parents of the primary school children to be recruited for the study. Focus group discussion in a group of 3 of ten in each group.
89570798|NCT04431115||Primary school children aged 6-12 yrs.|"A cross sectional survey of the biographical data, socio economic status, physical activity level through appropriate questionnaires will be done.~A pedometer will be attached to the waist of each of the participants for a consecutive 7 days to objectively determine the level of their physical activity."
89570799|NCT03055741|Experimental|Group 1|"donepezil: 5mg or 10mg is orally administrated once a day for 24 weeks~DHP1401: Total 500mg is orally administrated in two divided doses a day for 24 weeks"
89570800|NCT03055741|Experimental|Group 2|"donepezil: 5mg or 10mg is orally administrated once a day for 24 weeks~DHP1401: Total 1,000mg is orally administrated in two divided doses a day for 24 weeks"
89570801|NCT03055741|Placebo Comparator|Group 3|"donepezil: 5mg or 10mg is orally administrated once a day for 24 weeks~DHP1401: Placebo is orally administrated in two divided doses a day for 24 weeks"
89570802|NCT04926883|Active Comparator|Sonic fill|
89570803|NCT04926883|Active Comparator|X-tra fill|
89570804|NCT04936087|Other|WHO 8-steps|Single group intervention and described in the Intervention section.
89570805|NCT04936165|Experimental|Healthy experimental participants|"The participants sat in a a quiet and darkened room with the upper arm at heart level and the forearm in an upward angle of 30°, 15-20 min prior to the experiment.~The experiments consists of 5-min rest, 90s inflated wrist cuff (240 mmHg) with 30s VO(one minute later), 3-min rest, 10-min intervention, the same 4.5-min process of the wrist cuff, VO and rest.~Device: Optical monitor for hemodynamic parameter. Near infrared spectroscopy probes of tow wavelengths were attached on the participants' forearm and brain to detect the changes of hemodynamic parameters."
89570806|NCT04936165|No Intervention|Healthy controlled participants|"The participants sat in a a quiet and darkened room with the upper arm at heart level and the forearm in an upward angle of 30°, 15-20 min prior to the experiment.~The experiments consists of 5-min rest, 90s inflated wrist cuff (240 mmHg) with 30s VO(one minute later), 3-min rest, 10-min rest, the same 4.5-min process of the wrist cuff, VO and rest.~Device: Optical monitor for hemodynamic parameter. Near infrared spectroscopy probes of tow wavelengths were attached on the participants' forearm and brain to detect the changes of hemodynamic parameters."
89570807|NCT04926727||Pregnant women|"600 Pregnant women between the 18th and 22nd week.~200 from Northern Italy;~200 from Central Italy;~200 from Southern Italy and the Islands."
89570808|NCT04927039|Placebo Comparator|Control group|
89570809|NCT04927039|Experimental|Iloprost group|
89570810|NCT04926493||BIOPAVIR Cohort|Critically ill patient > 18 years of age with mechanical ventilation for >2 calendar days, at increased risk for the development of Ventilator-Associated Pneumonia in the Intensive Care Unit during COVID-19 pandemic.
89570811|NCT04918303|Experimental|SKNA group|
89570812|NCT03055585|Experimental|Intervention arm|Deployment of Wolbachia-infected Aedes aegypti mosquitoes
89570813|NCT03055585|Other|Comparison arm|Standard practice dengue control activities
89033133|NCT00530933|Sham Comparator|1|Sham tibial nerve stimulation
89570814|NCT04926649|Sham Comparator|Conventional ventilation group|Conventional SLV and complementary with DLV when necessary. When SLV was initiated, the patient was ventilated with left lung. FiO2 of 1.0, tidal volume of 6ml/kg, respiratory rate of 16-24 bpm, PEEP of 5-10 cmH2O. The right lung was totally collapsed. If the SpO2 decreased lower than 90%, DLV was started and the operation was paused until the SpO2 increased to 100%. Then the operation was restarted.
89570815|NCT04926649|Active Comparator|CPAP group|"SLV of left lung and CPAP of right lung, and complementary with DLV when necessary.~When SLV was initiated, the patient was ventilated with left lung. FiO2 of 1.0, tidal volume of 6ml/kg, respiratory rate of 16-24 bpm, PEEP of 5-10 cmH2O. After the right lung was totally collapsed, CPAP was started with the pressure less than 8 cmH2O. If SpO2 decreased lower than 90%, DLV was started and the operation was paused until the SpO2 increased to 100%. Then the operation was restarted."
89570816|NCT04926649|Experimental|HFLVV group|"SLV of left lung and HFLVV of right lung, and complementary with DLV when necessary.~When SLV was initiated, the patient was ventilated with left lung. FiO2 of 1.0, tidal volume of 6ml/kg, respiratory rate of 16-24 bpm, PEEP of 5-10 cmH2O. After the right lung was totally collapsed, HFLVV was started with tidal volume of 2ml/kg, respiratory rate of 60 bpm. If SpO2 decreased lower than 90%, DLV was started and the operation was paused until the SpO2 increased to 100%. Then the operation was restarted."
89570817|NCT03055351|No Intervention|Control group|Participants will complete the outcome measures but will not receive any intervention.
89570818|NCT03055351|Experimental|Stop&Go Intervention|Participants in this group will participate in an intervention aimed at promoting a healthy and physically active lifestyle. The intervention will be based on Self-determination theory postulates and will have two axes: training and motivation.
89570819|NCT02443155|Experimental|NNC0114-0006 + Liraglutide|
89570820|NCT02443155|Experimental|NNC0114-0006 + Placebo|
89570821|NCT02443155|Active Comparator|Liraglutide + Placebo|
89570822|NCT02443155|Placebo Comparator|Placebo|
89570823|NCT03055117|Experimental|Group-based exercise rehabilitation|Group-based rehabilitation: Group-based sessions (4-8 patients per group) with physiotherapist and home training for 8 weeks (maximum of 12 training sessions).
89570824|NCT03055117|Active Comparator|Individual exercise rehabilitation|Individual rehabilitation: One-on-one sessions with physiotherapist and home training for 8 weeks (maximum of 12 training sessions).
89570825|NCT03055117|Active Comparator|Home exercise|Home exercise: Instruction in home exercise by physiotherapist, with maximum of 4 follow-up consultations over a period of 8 weeks.
89570826|NCT04935541|Active Comparator|Dexmedetomidine infusion|Dexmedetomidine (Precedex, Meditera, USA) was administered at a loading dose of 1 µg/kg for 10 minutes before local anesthesia to be applied to the eye by the surgeon. During the surgical procedure, it was administered at a dose of 0.4 µg/kg/h-1 infusion.
89570827|NCT04935541|Active Comparator|Remifentanil infusion|Remifentanil (Ultiva, Glaxo SmithKline, Turkey) infusion was started at a dose of 0.05 µg/kg/min-1, 10 minutes before the start of the surgery as baseline infusion and continued at the same infusion dose throughout the surgical procedure.
89570828|NCT04935151|Active Comparator|holmium laser enucleation of the prostate|holmium laser enucleation of the prostate (HoLEP)
89570829|NCT04935151|Active Comparator|bipolar resection of the prostate|bipolar resection of the prostate (BPEP)
89570830|NCT04935073|Experimental|Traditional Chinese Medicine herbs treatment group|the treatment group will receive treatment with the Chinese herbal formula on the 5th day of the menstrual cycle and lasts to 14 days after IVF-ET.
89570831|NCT04935073|Active Comparator|Western medicine group|The control group will be treated with conventional Western medicine
89570832|NCT04934761|Experimental|capacity shock|2ml/kg succinylateol gelatin
89570833|NCT04934761|Other|routine management|conventional strategy
89570834|NCT04934059|Experimental|Yuxuebi tablet|take 5 tablets once, 3 times a day, for 42（±3）days.
89570835|NCT04934059|Placebo Comparator|Placebo tablet|take 5 tablets once, 3 times a day, for 42（±3）days.
88970282|NCT04213560|Experimental|Weighted waist-hooping|Participants weighted waist-hooping on their own for ten minutes a day, four days a week, for six weeks resulting in a total of 40 minutes of weighted waist-hooping each week. Participants weighted waist-hooped with a three-pound weighted hula hoop at the waist for ten minutes. Half time hooping to the left and the other half hooping to the right. If discomfort while hooping occurred participants were instructed to take breaks, change directions more frequently, or where thicker clothing to lessen the impact of the hoop around their waists. The investigators would check in on the participants weekly to provide feedback on technique and answer all questions throughout the six-week intervention.
88970283|NCT04213560|No Intervention|Control|No Intervention
88970284|NCT04211766|Experimental|Cross-over Randomization 1: Fiber plus Fish Oil followed by Comparator|Participants first received a fiber supplement and a fish oil supplement PO daily for 30 days (Period 1). Participants entered a washout period for at least 60 days. For period 2 they received similarly packaged comparator (maltodextrin and corn oil)
88970285|NCT04211766|Experimental|Cross-over Randomization 2: Comparator followed by Fiber plus Fish Oil|Participants first received the comparator (maltodextrin and corn oil) supplement PO daily for 30 days (Period 1). Participants enter a washout period for at least 60 days. For period 2 they received the fiber supplement and a fish oil supplement
88970286|NCT04198662|Active Comparator|Cryoneurolysis|Active cryoneurolysis: 3 mL of normal SALINE will be injected into the muscle superficial to the nerve followed by an ACTIVE cryoneurolysis procedure using 2 cycles of 2-minute gas activation separated by 1-minute defrost periods.
88970287|NCT04198662|Sham Comparator|Sham|Sham cryoneurolysis: 3 mL of ropivacaine 0.5% (with epinephrine) will be injected perineurally to provide the intercostal nerve block followed by a SHAM cryoneurolysis procedure with a probe that vents the nitrous oxide prior to reaching the probe tip using 2 cycles of 2-minute gas activation separated by 1-minute defrost periods.
88970288|NCT04197310|Experimental|Nivolumab and Cabozantinib|"The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits.~Cabozantinib will be administered at a dose of 40mg orally, once daily~Nivolumab will be given at a dose of 240mg every 14 days, intravenously~Retreat Phase (Optional)~Participants may elect to stop nivolumab and cabozantinib with confirmed CR after at least 24 weeks of treatment.~Participants who elect to stop and then the condition progresses after stopping study treatment may be eligible to resume nivolumab and cabozantinib therapy.~This resumption will be termed as a retreatment second course phase and is available only while the study remains open and the subject meets specified criteria."
89033134|NCT00530933|Experimental|2|Percutaneous tibial nerve stimulation
89033135|NCT00530933|Experimental|3|Transcutaneous tibial nerve stimulation
89033136|NCT02917668|Active Comparator|Group A|15 patients who will receive usual care for 30 minutes and then switch to FreeO2 for another 30 minutes
89033137|NCT02917668|Active Comparator|Group B|15 patients who will be oxygenated by FreeO2 for 30 minutes and then switch to usual care for another 30 minutes
89033138|NCT00531713|No Intervention|1|Usual T4 dose is given
89570836|NCT04917835|Experimental|treatment with argon- and nitrogen-NTAPP|PLADUO (argon- and nitrogen- non-thermal, atmospheric-pressure plasma) treatment
89570837|NCT04917991|Experimental|Extra Virgin Olive Oil Group|Subjects will consume 100 grams of Extra Virgin Olive Oil-enriched chocolate spread for 14 days.
89570838|NCT04917991|Active Comparator|Palm oil Group|Subjects will consume 100 grams of palm oil enriched chocolate spread for 14 days.
89570839|NCT04917289|Experimental|Treatment Arm|Patients in this arm will receive treatment or change current adjuvant therapy immediately after detecting CTC.
89570840|NCT04917289|No Intervention|Control Arm|Patients in this arm will keep follow-up after detecting CTC until radiology evidence of recurrence appear.
89570841|NCT04917913|Experimental|Intervention|Subjects will be administered 3 daily doses (one per meal) of digestive enzymes (50mg), in a capsule, for 30 days
89570842|NCT04917913|Placebo Comparator|Placebo|Subjects will be administered 3 daily doses (one per meal) of digestive enzymes (50mg), in a capsule, for 30 days
89570843|NCT04925869||The hospitals of Besançon|Adult patients with MRI-confirmed CVA admitted to the hospitals of Besançon
89570844|NCT04925869||the hospitals of Cayenne|Adult patients with MRI-confirmed CVA admitted to the hospitals of Cayenne.
89570845|NCT04925869||the hospitals of Tours|Adult patients with MRI-confirmed CVA admitted to the hospitals of Tours.
89570846|NCT04925635||experimental group|The arteriovenous fistula care mobile health application will be installed and promoted on the smart phones of the patients in the experimental group.
89570847|NCT04925635||control group|Patients in the control group will receive arteriovenous fistula care training and a training booklet will be given.
89570848|NCT03055273|Experimental|SOCIABLE IMMEDIATE|Receive services now
89570849|NCT03055273|Active Comparator|SOCIABLE wait list|Receive services four months post-enrollment
89570850|NCT04916899||Group A: Rifampicin/ Isoniazid/ Pyrazinamide/ Ethambutol|Pharmaceutical Form: Tablets Dosage: 150 mg / 75 mg / 400 mg / 300 mg Administration way: oral
89570851|NCT04933981||interventional nursing home (INH).|regular, twice to three times weekly, and voluntary, i.e. non-mandatory, on-site testing for SARS-CoV-2 of HCW and visitors (INH)
89570852|NCT04933981||control nursing home (CNH)|routine setting without frequent regular testing for SARS-CoV-2 (control nursing homes; CNH). Testing only performed by local health authorities upon medical indication, i.e. non-surveillance testing
89570853|NCT04925245|Experimental|Clinical Reminder|
89570854|NCT04925245|No Intervention|No Reminder|
89570855|NCT04933357|Experimental|Dose escalation|
89570856|NCT04933357|Active Comparator|Standard dose|
89570857|NCT04916821|Experimental|water extract of propolis|Patients given 2 ml of aqueous propolis extract (50mg / ml) orally 3 times a day for 1 week
89570858|NCT04916821|Experimental|olive oil extract of propolis including perga|Patients given 1 ml oily propolis extract (64 mg / ml) + 1 ml oily perga extract (120 mg / ml) orally 3 times a day for 1 week
88970289|NCT04196738|Experimental|Dual Mode first|Four consecutive steps (45 min per step) in the following order: APRV (A), Dual Mode (B) , APRV (A) and VAC (C). (ABAC)
89570859|NCT04916821|No Intervention|control|control group (patients not given any investigational product)
89570860|NCT04933201|Experimental|Music group|Perioperative music intervention
89570861|NCT04933201|Active Comparator|Control group|No perioperative music
89570862|NCT04925323|Experimental|a plastic or repair surgery indication generating surgical waste|
89570863|NCT02460159|Experimental|EZ 10 mg/Atorva 10 mg FDC|one EZ 10 mg/Atorva 10 mg fixed-dose combination (FDC) tablet orally with food once daily for 52 weeks.
89570864|NCT02460159|Experimental|EZ 10 mg/Atorva 20 mg FDC|one EZ 10 mg/Atorva 20 mg fixed -dose combination (FDC) tablet orally with food once daily for 52 weeks.
89570865|NCT04925011|Other|Roxadustat|Starting doses of 20, 50, 70 or 100 mg/30,70,90,or 120mg based on weight and dialysis or not.
89570866|NCT04913155|Other|Reporting group (coronary calcium score and emphysema score)|Coronary calcium score and emphysema score are reported to subjects
89570867|NCT04913155|Other|Reporting group (coronary calcium score only)|Only coronary calcium score is reported to subjects
89570868|NCT04913155|Other|Reporting group (emphysema score only)|Only emphysema score is reported to subjects
89570869|NCT04913155|Other|Non-reporting group|Coronary calcium score and emphysema score are not reported to subjects
89570870|NCT04913155|No Intervention|Low-risk group|No CT screening, collection of health data only
88970290|NCT04196738|Experimental|VAC fist|Four consecutive steps (45 min per step) in the following order: APRV (A), VAC (C) , APRV (A) and Dual Mode (B). (ACAB)
89570871|NCT02498067|Experimental|Intervention|Participants will complete a 10-15 minute questionnaire . After completing the questionnaire, a research assistant (RA) will provide a brief orientation to the rPlan app and use the rPlan app for up to 15 minutes. After viewing rPlan, participants will be asked a series of questions regarding the app's usability, helpfulness, and content appropriateness (10 min). The participant will also be given an STI test.
89570872|NCT04916353|Experimental|20% hypertonic dextrose water injection group|echo guide 20% dextrose water 3ml was injection in lesion site
89570873|NCT04916353|Active Comparator|Steroid injection group|Triamcinolone Acetonide 40mg/ml, 1ml, and Lidocaine 2ml as the active comparator group
89570874|NCT02497755|Experimental|Mobile app|Participants will install an app on their smartphone to add to their treatment for depression and/or anxiety.
89570875|NCT03056599|Experimental|Multiple drug microinjection|Patients who are scheduled for surgical biopsy or tumor resection surgery will be injected 4 to 72 hours prior to surgery using the CIVO device. Minute volumes (up to 8.3 microliters) of saline (negative control) or microdoses of anti-cancer agents will be percutaneously injected in a columnar fashion through each of 8 needles into a single enlarged solid tumor.
89570876|NCT04924465||Anti-Jo1|Patients with anti-Jo1 antibodies
89570877|NCT04924465||Anti-PL7|Patients with anti-PL7 antibodies
89570878|NCT04924465||Anti-PL12|Patients with anti-PL12 antibodies
89570879|NCT04924465||Anti-EJ|Patients with anti-EJ antibodies
89570880|NCT04924465||Anti-OJ|Patients with anti-OJ antibodies
89570881|NCT04916275||Staff working in a nursing home in Occitanie|
89570882|NCT02619175|Experimental|Perturbation-based balance training|"perturbation-based balance training while standing and walking on the BalanceTutor (MediTouch).~10-12 training sessions, 4-5 per week for 3 weeks. Each session will last 30 minutes."
89570883|NCT02619175|Active Comparator|Weight shifting and gait training|"Balance and gait training without external perturbations. Voluntary weight shifting while standing on a computerized posturography (NeuroCom) and walking on a treadmill.~10-12 training sessions, 4-5 per week for 3 weeks. Each session will last 30 minutes."
89570884|NCT03056443|Experimental|Continuous Positive Airway Pressure-CPAP|CPAP education and discharge with auto-adjusting Continuous Positive Airway Pressure (CPAP) in addition to usual standards of clinical care for heart failure.
89570885|NCT03056443|No Intervention|Standard of Care|CPAP initiation per standard of care based on approval by insurance company and DME company with management as per usual standards of clinical care for heart failure.
89570886|NCT04915885|Other|Control arm|routine contraceptive counseling and care and a range of family planning methods that are routinely available at field level
89570887|NCT04915885|Experimental|Intervention package|contraceptive counseling package but still with a range of family planning methods that are routinely available at field level
89033139|NCT00531713|Active Comparator|2|20 microgram of T3 is given and 50 microgram of T4 is withdrawn
89033140|NCT02921334|Experimental|Intervention group|Patients in this group are received ventilator weaning by switching between invasive and noninvasive ventilation.
89033141|NCT02921334|No Intervention|Control group|Patients in this group are weaned from ventilator as conventional methods.
89033142|NCT00530972|Experimental|Peginterferon alfa-2a plus ribavirin|
89033143|NCT02943863|Active Comparator|HFNC first|"Patients in HFNC first receive oxygen therapy using HFNC in ahead of conventional nasal cannula oxygen therapy. After 20 minutes of HFNC therapy, patients receive conventional nasal cannula oxygen therapy."
89209024|NCT00798668|Experimental|4|Participants continue current sedentary behavior and take solid supplements
89570888|NCT04915885|Experimental|Intervention package & expanded methods|contraceptive counseling package but with an expanded range of family planning methods that are recommended by national guidance
89570889|NCT04915963|Experimental|vitamin D group|170 patients receiving a single dose of 400,000 IU of VD3 (2 vials of 200,000 IU VD3; B.O.N., BOUCHARA RECORDATI) orally or through a nasogastric tube
89570890|NCT04915963|Sham Comparator|Placebo group|170 patients receiving distilled water (2 vials of 1 ml distilled water) orally or through a nasogastric tube
89570891|NCT04915807||Prospective population|The target group for the purpose of prospectively collecting the clinical data (RWD) of patients using ramucirumab/paclitaxel as 2nd-line chemotherapy in patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma
89570892|NCT04915807||Historical retrospective population|The target group for the purpose of retrospectively collecting the clinical data (RWD) of patients who have failed platinum-based palliative first-line therapy, and who started the following second-line therapy: taxane, irinotecan , or fluoropyrimidine-based single or combined chemotherapy, before May 1, 2018, when health insurance coverage for the ramucirumab/paclitaxel combination therapy started in South Korea.
89570893|NCT04915651|Experimental|Gallbladder Cryoablation|High-risk patients who undergo gallbladder cryoablation
89570894|NCT01360021|Active Comparator|1 Symbicort/inhaler|Symbicort BA MDI 2x160/4.5 μg twice daily
89570895|NCT01360021|Active Comparator|Symbicort/inhaler|Symbicort AC pDMI 2x160/4.5 μg twice daily
89570896|NCT01360021|Active Comparator|Budesonide/inhaler|Budesonide AC pMDI 2x160 μg twice daily
89570897|NCT04924309||Patients undergoing assisted reproductive technology with donor sperm|
89570898|NCT04924309||Patients undergoing assisted reproductive technology with husband's semen due to male factor|
89570899|NCT04915573||patients with Cirrhosis|Patient with clinical evidence of liver disease, portal hypertension, ultrasound or computed tomography results, laboratory data will be used to confirm liver disease
89570900|NCT04912219|Experimental|Treatment|
89570901|NCT04912219|No Intervention|Control|
89570902|NCT04915339|Experimental|Group 1: physical activity then cognitive training|Using an online-computerized application, physical activities will be prescribed for one month. After a 15 days break, cognitive training activities will be prescribed the same way. A feedback by the patient will be asked fallowing each activity to control the observance.
89570903|NCT04915339|Experimental|Group 2: Cognitive training then physical activity|Contrary to the first group, the second one starts with cognitive training intervention then engages in physical activity in same way as the first group. A feedback by the patient will also be asked fallowing each activity to control the observance
89570904|NCT04915339|Experimental|Group 3 : resonance frequency breathing then combined physical activity and cognitive training|The third group takes part in a 1 month breathing exercise program. After a 15 days break (as the groups 1 and 2), a combined physical activity and cognitive training program is administrated for 1 month. As the others arms, a feedback by the patient will be asked fallowing each activity to control the observance
89570905|NCT04923373|Experimental|telerehabilitation|physiotherapeutic programme brochure exercises 7/week controlled by phone every week (5x in total)
89570906|NCT04923373|Active Comparator|standard physiotherapy|"Supervised physical therapy 3/ week,~+ physiotherapeutic programme brochure 4/week"
89570907|NCT04915417|Experimental|Resectable Pancreatic Ductal Adenocarcinoma (PDAC)|10 Resectable PDAC patients will receive a hybrid PET/MRI before SABR and DCE-CT before SABR, 6 hours after the first SABR fraction, and 4 weeks after the last fraction of SABR (before surgery)
89570908|NCT04915417|Experimental|Borderline Resectable Pancreatic Ductal Adenocarcinoma (PDAC)|20 Borderline Resectable PDAC patients will receive a DCE-CT scan prior to neoadjuvant chemotherapy, a PET/MRI and DCE-CT after neoadjuvant chemotherapy and before SABR, DCE-CT at 6 hours after the first SABR fraction, and 4 weeks after the last fraction of SABR (before surgery)
89570909|NCT04912297||PCV10 2+1 schedule|Ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10; GlaxoSmithKline) administered with a 2+1 schedule (two vaccinations with minimum 8-week intervals followed by a booster dose at least 4 months after the last primary dose).
89570910|NCT04912297||PCV10 3+1 schedule|Ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10; GlaxoSmithKline) administered with a 3+1 schedule (three vaccinations with minimum 4-week intervals, followed by a booster dose at least 4 months after the last primary dose).
89028890|NCT05555264|Experimental|Therapist-Guided Alcohol Change Course Enhanced|"Clients who select the therapist-guided condition will receive access to 6 ICBT core lessons, 6 associated worksheets to enhance skill acquisition, and 8 additional resources addressing potential co-morbid concerns (e.g., sleep quality, cannabis use). The 6 lessons and 6 associated worksheets are released at a rate of 1 per week over 7 weeks, with no new content being released to participants in Week 4. The 8 additional resources are available at any time during the course.~Clients will receive therapist support/guidance during the 8-week intervention."
89028891|NCT05547191|Experimental|Investigational device|ChloraSolv
89033144|NCT02943863|Active Comparator|LFS first|"Patients in LFS first receive oxygen therapy using conventional nasal cannula in ahead of HFNC therapy. After 20 minutes of conventional nasal cannula oxygen therapy, patients receive HFNC oxygen therapy."
89033145|NCT02943278|Placebo Comparator|Sleep Hygiene Group|Participants assigned to the sleep hygiene group you have 1 session with a clinician to learn about different things they can do to improve their sleep.
89209025|NCT02553044|Experimental|50 000IU Vitamin D3|50 000IU oral vitamin D3 (cholecalciferol) administered at baseline only.
89209026|NCT02553044|Experimental|150 000IU Vitamin D3|150 000IU oral vitamin D3 (cholecalciferol) administered at baseline only.
89570911|NCT02497287|Experimental|Intranasal Esketamine plus oral antidepressant|Open-Label Induction Phase: Participants will self-administer esketamine intranasally twice per week for 4 weeks as a flexible dose regimen (56 mg or 84 mg). Participants greater than or equal to (>=) 65 will start at a dose of 28 mg on Day 1. Direct-entry participants will initiate a new, open-label oral antidepressant (duloxetine, escitalopram, sertraline, or venlafaxine extended release [XR]) on Day 1; transferred-entry participants will continue the same oral antidepressant from ESKETINTRD3005. Optimization/Maintenance Phase: Participants will self-administer esketamine (56mg or 84mg for those < 65 years; 28 mg, 56 mg or 84 mg for those >= 65 years) intranasally once per week for 4 weeks; transferred entry responder subjects from ESKETINTRD3005 will start at a dose of 28 mg in the first week. All participants will continue their same oral antidepressant during this phase.
89570912|NCT04923607|Experimental|TQC2731 injection(sc.) in healthy subjects|"For the single ascending dose (SAD) portion of the study, healthy subjects received subcutaneous(sc.) injection of TQC2731(12mg、105mg、210mg、420mg、630mg) once.~For the multiple ascending dose (MAD) portion of the study, healthy subjects received subcutaneous(sc.) injection of 420mg TQC2731 ."
89570913|NCT04923607|Placebo Comparator|Matching Placebo(sc.) in healthy subjects|"For the single ascending dose (SAD) portion of the study, healthy subjects received subcutaneous(sc.) injection of matching placebo(12mg、105mg、210mg、420mg、630mg) once.~For the multiple ascending dose (MAD) portion of the study, healthy subjects received subcutaneous(sc.) injection of 420mg matching placebo(12mg、105mg、210mg、420mg、630mg)."
89570914|NCT04923607|Experimental|TQC2731 injection(SAD,iv.)|Healthy subjects received 210mg TQC2731 intravenously (iv.) once.
89570915|NCT04923607|Placebo Comparator|Matching Placebo(SAD,iv.)|Healthy subjects received 210mg matching placebo intravenously (iv.) once.
89570916|NCT04923607|Experimental|TQC2731 injection(sc.) in asthma subjects|For the multiple ascending dose (MAD) portion of the study, asthma subjects received subcutaneous(sc.) injection of TQC2731(70mg、210mg、280mg) .
89570917|NCT04923607|Placebo Comparator|Matching Placebo(sc.) in asthma subjects|For the multiple ascending dose (MAD) portion of the study, asthma subjects received subcutaneous(sc.) injection of matching placebo(70mg、210mg、280mg) .
89570918|NCT04911985||ICU Patients with PAC|All patients admitted to the Medical ICU of the University Hospital Zürich, complying with the inclusion criteria and monitored by a pilmonary artery catheter
89570919|NCT04912141|Placebo Comparator|Conestat alfa 50 U/kg - Placebo|50 U/kg conestat alfa pre-angiography and placebo 3 hours after the first dose
89570920|NCT04912141|Active Comparator|Conestat alfa 50 U/kg - Conestat alfa 50 U/kg|50 U/kg conestat alfa pre-angiography and 3 hours after the first dose
89570921|NCT04912141|Active Comparator|Conestat alfa 100 U/kg - Conestat alfa 50 U/kg|100 U/kg conestat alfa pre-angiography and 50 U/kg conestat alfa 3 hours after the first dose
89570922|NCT04912141|Placebo Comparator|Placebo - Placebo|Placebo pre-angiography and 3 hours after the first dose
89570923|NCT04915105|Experimental|Prescreen on psoriasis and psoriatic arthritis treatment|Prescreen markers from individual PBMCs and choose proper biologics before starting treatment on psoriasis and psoriatic arthritis patients.
89570924|NCT04923451|Active Comparator|Patient with sexual addiction - active stimulation|25 patients with sexual addiction will be stimulated by active tDCS during 5 consecutive days
89570925|NCT04923451|Sham Comparator|Patient with sexual addiction - sham stimulation (placebo)|25 patients with sexual addiction will be stimulated by sham tDCS stimulation (placebo) during 5 consecutive days
89570926|NCT04922385|Experimental|CBT|Individual 4-week CBT protocol
89570927|NCT04923061|Experimental|Acupressure group|The experimental group will apply acupressure to themselves three times a week for a total of 12 sessions for four weeks.
89570928|NCT04923061|Sham Comparator|Sham acupressure group|The sham group will apply acupressure to themselves three times a week for a total of 12 sessions for four weeks.
89570929|NCT03056287|Experimental|Aerobic Exercise|Treadmill aerobic exercise
89570930|NCT03056287|Experimental|rTMS|repetitive transcranial magnetic stimulation
89570931|NCT03056287|Experimental|AET+rTMS|Combined aerobic exercise and rTMS
89570932|NCT03056287|Sham Comparator|Sham|Sham rTMS
89570933|NCT04911829|Active Comparator|Inpatient treatment|High intensity high dosage inpatient short-term psychodynamic psychotherapy
89570934|NCT04911829|Experimental|Outpatient treatment|Low dosage outpatient short-term psychodynamic psychotherapy
88970291|NCT04182061|Experimental|The AMTE Protocol|"Will receive the AMTE (Aprende a Manejar tus Emociones) Protocol; this is a modified UP-A adapted as an internet-based program of T-CBT, consisting in 10 modules delivered over 12 weeks."
88970292|NCT04182061|No Intervention|Waiting List Control Group|Participants in a 12-week waiting list control condition. They will be offered the possibility of receiving the online treatment protocol after the waiting list period.
89209027|NCT02553044|Experimental|500 000IU Vitamin D3|500 000IU oral vitamin D3 (cholecalciferol) administered at baseline only.
89570935|NCT02458287|Experimental|Bococizumab 150mg|Bococizumab 150mg autoinjector (pre-filled pen)
89570936|NCT02458287|Experimental|Bococizumab 75mg|Bococizumab 75mg autoinjector (pre-filled pen)
89570937|NCT02458287|Placebo Comparator|Bococizumab 150mg placebo|Bococizumab 150mg placebo autoinjector (pre-filled pen)
89570938|NCT02458287|Placebo Comparator|Bococizumab 75mg placebo|Bococizumab 75mg autoinjector (pre-filled pen)
89570939|NCT04914715|Experimental|Non-invasive High Frequency Oscillatory Ventilation|"Preterm babies (26-28 weeks) born with respiratory distress will be initially started on nCPAP with setting of flow 6-8 liter, PEEP 5-6, FiO2 21-40%. If fio2 requirefment more than 40%, surfactant will be given in first 2 hours of birth. If baby fails on CPAP then will be switched to nHFOV with below mentioned settings.~Preterm born babies 28-34 weeks gestation with RDS, respiratory support will be started on Heated Humidified High Flow Oxygen therapy or nCPAP, if that fails then baby will be switched to NHFOV with frequency of 5-20 (300-1200 breathe/min), Amplitude of 1-10, flow1-17.5 liter/min, fiO2 21-100% and integrated pressure triggered sensitivity option."
89570940|NCT04914715|Active Comparator|Conventional Invasive Ventilation|"Preterm babies (26-28 weeks) born with respiratory distress will be initially started on nCPAP with setting of flow 6-8 liter, PEEP 5-6, FiO2 21-40%. If fio2 requirement more than 40%, surfactant will be given in first 2 hours of birth. If baby fails on CPAP then will be switched to nHFOV with below mentioned settings.~Preterm born babies 28-34 weeks gestation with RDS, respiratory support will be started on Heated Humidified High Flow Oxygen therapy or nCPAP, if that fails then baby will be switched to invasive ventilation through endotracheal tube, mode will be selected as Synchronized Intermittent Mandatory ventilation (SIMV) with rate of 25-60 breath/min, flow of 8 liter, positive inspiratory pressure (PIP) of 14-25, Positive end expiratory pressure (PEEP) 4-5, fio2 of 21-40."
89570941|NCT04914871|Experimental|The experimental protocol UN Lifeguard Kids in the Tunja version|Group to which the experimental protocol will be offered.
89570942|NCT04914871|Placebo Comparator|Educational session, accident prevention and wound management.|The control group will be offered the Educational session.
89570943|NCT02441517|Experimental|Enzalutamide|Participants received 160 mg enzalutamide orally once daily until radiographic or clinical progression, or unacceptable toxicity.
88970293|NCT04177940|Active Comparator|Denosumab (DMAB) to Alendronate (ALN)|Switch from Denosumab 60 mg administered subcutaneously (SC) to weekly oral alendronate (70 mg; started 6 months after last denosumab dose)
88970294|NCT04177940|Active Comparator|"DMAB to Early Zoledronic Acid (ZA)"|"Switch from Denosumab 60 mg administered subcutaneously (SC) to one early zoledronic acid infusion (5 mg; 6 months after last denosumab dose)"
88970295|NCT04177940|Active Comparator|"DMAB to Late ZA"|"Switch from Denosumab 60 mg administered subcutaneously (SC) to one late zoledronic acid infusion (5 mg; 9 months after last denosumab dose)"
88970296|NCT04176588|Experimental|Experimental: Etrasimod 2mg|2mg/tablet, administratered orally, once daily
88970297|NCT04176588|Placebo Comparator|Placebo Comparator: Placebo|matching tablet, administratered orally, once daily
88970298|NCT04176588|Experimental|Etrasimod 2mg (optional open-label extension period)|2mg/tablet, administratered orally, once daily
88970299|NCT04173260|Experimental|Intervention arm - Oral Deutetrabenazine|This is the only arm for this trial. All subjects will receive oral Deutetrabanazine.
89570944|NCT04914481||Classical Low-Flow, Low-Gradient Aortic Stenosis|Classical Low-Flow, Low-Gradient Aortic Stenosis is defined as valve area <1 cm2, mean gradient <40 mmHg, ejection fraction <50% and stroke volume index (SVi) ≤35 mL/m2 by resting transthoracic echocardiography. Dobutamine stress echocardiography is not mandatory for the definition of classical LFLG AS. All patients in this subgroup underwent TAVI and have available data on aortic valve calcification.
89570945|NCT04914481||Paradoxical Low-Flow, Low-Gradient Aortic Stenosis|Paradoxical Low-Flow, Low-Gradient Aortic Stenosis is defined as valve area <1 cm2, mean gradient <40 mmHg, ejection fraction ≥50% and SVi ≤35 mL/m2 by resting transthoracic echocardiography. All patients in this subgroup underwent TAVI and have available data on aortic valve calcification.
89570946|NCT04914481||High-Gradient Aortic Stenosis (Control group)|High-Gradient Aortic Stenosis is defined as valve area <1 cm2 and mean gradient >40 mmHg by resting transthoracic echocardiography. All patients in this subgroup underwent TAVI. Data on aortic valve calcification is not mandatory for this control group.
89570947|NCT04914481||Conservative treatment (Control group)|The subgroup includes all patients with (severe or non-severe) aortic stenosis, who underwent conservative treatment. Data on aortic valve calcification is not mandatory for this control group.
89570948|NCT03056131|Experimental|Diacutaneous Fibrolysis Treatment|
89570949|NCT03056131|No Intervention|Control Group|
89570950|NCT03056209|Experimental|KL1333 25mg|Group 1
89570951|NCT03056209|Experimental|KL1333 50mg|Group 2
89570952|NCT03056209|Experimental|KL1333 100mg|Group 3
89570953|NCT03056209|Experimental|KL1333 200mg|Group 4
89570954|NCT03056209|Experimental|KL1333 400mg|Group 5
89570955|NCT03056209|Experimental|KL1333 600mg|Group 6
89570956|NCT03056209|Experimental|KL1333 800mg|Group 7
89570957|NCT02457819|Experimental|Dasotraline|Dasotraline 2, 4, 6 mg
89570958|NCT03056053|Other|Zolpidem|Commercially available zolpidem (5 or 10 mg) will be administered orally once daily during the treatment period (Day 1 to Day 14) following prescribing information from each country participating in this study
89570959|NCT04922905|Other|NEURO +|"Patients neuro + are those with a CASE score ≥ 2, Neuro + patients will benefit from additional evaluations using paraclinical examinations"
89028892|NCT05530642|Experimental|Emotional Resilience Skills Training (ERST)|The Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (UP) is an evidence-based cognitive-behavioral intervention designed to cultivate constructive approach-oriented emotional engagement. The 13-week Emotional Resilience Training (ERST) is an adaptation of the UP designed for use as a proactive training course. The ERST frames emotional experiences as natural responses to threat, rather than pathological occurrences to avoid; as such, the ERST is well-suited for mitigating health challenges and the skills may also help PSP to support persons in distress, including other PSP and the community members they all serve. The ERST training materials include an instructor guide, didactic PowerPoints, and a trainee workbook.
89570960|NCT04922905|Other|NEURO -|"Patients neuro - are those with a CASE score < 2"
89570961|NCT04914559|Active Comparator|Oral Nutrition Supplement Control|The control study intervention is an oral drink that contain protein, carbohydrate and fat and are intended for use as supplemental nutrition.
89570962|NCT04914559|Active Comparator|Oral Nutrition Supplement Test|The test study intervention is an oral drink that contain protein, carbohydrate and fat and are intended for use as supplemental nutrition for people living with diabetes.
89570963|NCT02496039|Other|NUEDEXTA®|NUEDEXTA capsules (20 mg dextromethorphan hydrobromide and 10 mg quinidine sulfate) administered orally, once a day from Days 1 to 7 and twice a day from Days 8 to 180
89570964|NCT04911205|Experimental|Intervention Group|Patients who were randomly allocated to intervention group (N=44) completed a 6-week preoperative training program, 5 days per week prior to surgery
89570965|NCT04911205|No Intervention|Control Group|Patients who were randomly allocated to control group (N=44), they continued to live as usual, prior to surgery
89570966|NCT04910971||Group 1: Recipients of BNT162b2 mRNA Covid-19 Vaccine|
89570967|NCT04910971||Group 2: Recipients of mRNA-1273 SARS-CoV-2 Vaccine|
89570968|NCT04911283||MCs type 1 patients (study group; n=37)|
89570969|NCT04911283||MCs type 2 patients (comparator group; n=44)|
89570970|NCT04911283||healthy controls (n=37)|
89570971|NCT02441283|No Intervention|HCV-infected Participants|Hepatitis C virus (HCV)-infected participants who received ABT-493 and/or ABT-530 in prior Phase 2 or 3 clinical studies with these agents for the treatment of chronic HCV and were not retreated prior to entering this study. No AbbVie study drug was administered in this study.
89570972|NCT04922359|Experimental|Experimental: Lidocaine group|
89570973|NCT04922359|Placebo Comparator|Placebo Comparator: comparator group|
89570974|NCT02495883|Other|Essential Tremor Group|Patients will be randomized to start in one of two treatment arms: 1) 50ml of 40% ethanol or 2) Propranolol SR 60-120mg. In patients who receive ethanol first, they will return for a second visit when they will receive Propranolol, and vice versa. Ethanol will be administered to participants diagnosed with Essential Tremor during the study visit, whereas patients receiving Propranolol SR will be administered daily over an estimated period of two weeks prior to the fMRI visit.
89570975|NCT02495883|No Intervention|Health Volunteer Group|Healthy Volunteers will receive no interventions.
89570976|NCT04910893|Experimental|Cytokine Adsorption Arm|Intervention with CytoSorb
89570977|NCT04910893|Other|Historical Comparison|Patients extracted from a septic shock population treated at the same institution between 2010 and 2018 and matched to the intervention group.
89028893|NCT05530330||Infants with concern regarding late onset sepsis|Infants who are being investigated for late onset sepsis will be included. These infants may ultimately be classified in a number of ways, including culture positive late onset sepsis, culture negative late onset sepsis, necrotising enterocolitis or non infectious etiologies suspected (i.e prematurity)
89028894|NCT05529693|Experimental|Bif-038 arm, high dose|Active trial product with minimum 10 billion CFU daily dose
89570978|NCT02495025|Experimental|Telephone-based screening|Families randomized to the intervention arm will be connected with 211 Los Angeles for completion of developmental screening over the phone. Screening will consist of three structured, validated, parent-report tools: the Parental Evaluation of Developmental Status (PEDS), the PEDS Developmental Milestones (PEDS:DM), and the Modified Checklist for Autism in Toddlers (M-CHAT). If any developmental or behavioral concerns are present, the care coordinator at 211 Los Angeles will make appropriate referrals for developmental evaluation and intervention services. A copy of the care plan generated from 211 will be sent to the child's primary care provider and included in the medical record.
89570979|NCT02495025|No Intervention|Usual care|Children randomized to the control group will report for their well-child care visits as scheduled, and will receive clinic-based developmental screening and care coordination. Any developmental or behavioral concerns will be directed to the child's pediatrician, as is the current clinical recommendation.
89570980|NCT04910659|Active Comparator|acupuncture|Group1, laser acupuncture was applied to each of the previously described P6, LI4 and LI 11 points on both arms with laser acupuncture device (Sedatelec Premio 32) for 30 seconds
89570981|NCT04910659|Sham Comparator|false acupuncture|P6, LI4 and LI 11 points on both arms with laser acupuncture device (Sedatelec Premio 32) for 30 seconds while laser acupuncture closed
89570982|NCT04910347|Experimental|Single Arm|Nivolumab
89570983|NCT04914169||Indoor cycling training|8 subjects were asked to complete indoor cycling training, 3 times a week for 4 weeks. Each session of training consisted of 30-minute stationary biking (5 minutes of warm-up, 20 minutes of training and 5 minutes of cooldown).
89570984|NCT02439957|Active Comparator|Treatment 1|100 mg brincidofovir (BCV; one 100 mg tablet) twice weekly plus valganciclovir (vGCV) placebo (2 tablets) once daily.
89570985|NCT02439957|Active Comparator|Treatment 2|900 mg valanciclovir (vGCV; two 450 tablets) once daily plus brincidofovir (BCV) placebo (1 tablet) twice weekly.
89570986|NCT02494401|Active Comparator|Internet-based self-management program|Internet-based self-management program Patients randomized to active treatment intervention will be assigned to the Internet program. The site will be accessed via secured website. The modules will be presented 1-2 per week and will be moderated by a researcher with expertise in moderating Discussion Boards.
89570987|NCT02494401|Other|Education book group|Educational book group. Participants in the control group will receive a copy of The Scleroderma Book: A Guide for Patients and Families, by Dr. Maureen Mayes.
89570988|NCT03054415|Other|Healthy Subjects|
89570989|NCT04922437||Enterocystoplasty (EC)|Patients who had an implantation of the catheterizable continent channel by seromuscular plicature on the anterior wall of the bladder augmentation.
89570990|NCT04922437||Detrusor (D)|Patients who had an implantation of the catheterizable continent channel in the detruosr of their native bladder (Lich-Gregoir or Cohen).
89570991|NCT04913545||normal group|participants with out any systemic medical problemes or oral lesions. we will only take saliva sample.
89570992|NCT04913545||potientially malignant group|participants with suspicious oral lesions without any medical diseases. we will take saliva sample and take a biopsy sample .
89570993|NCT04913545||malignant group|participants with already diagnosed oral malignant lesions without receiving any treatment yett
89570994|NCT04913935||TMC OA|women who were diagnosed with TMC OA
89570995|NCT04913935||Control|healty volunteer women
89570996|NCT04910191|Experimental|Open Label|"Up to 200 patients will participate in this open study. Before each examination with the study device, data from each patient (Current medical condition, medical history and demographic data) will be inserted to a computer and added to the database of the study for further processing in conjunction with the study device results.~The study device electronic stethoscope membrane will be put on the patient's chest area in predefined anterior and posterior points. At the end of each examination the data will be transferred to a computer and stored in the patient's file. Each patient will be requested to attend the examination once."
89028895|NCT05529693|Experimental|Bif-038 arm, low dose|Active trial product with minimum 1 billion CFU daily dose
89028896|NCT05529693|Placebo Comparator|Placebo arm|Similar trial product, but without Bif-038 probiotic bacteria
89028897|NCT05521958|Other|Acute tibial shaft or tibial plateau fractures without compartment syndrome|Patients with acute lower leg fractures who do not have clinical compartment syndrome.
89570997|NCT02457195|Experimental|Admnistration of granisetron|Preoperative administration of granisetron transdemal patch
89570998|NCT04913779|Active Comparator|Anti-SARS-CoV-2|Administration of 10 ml of a concentrated equine hyperimmune serum solution with neutralizing activity of SARS-CoV-2 not less than1/5120, administered in slow intravenous infusion (10 ml diluted in100 ml of physiological solution, administered over 50 to 60 minutes in slow drip), produced by ANLIS-Malbrán, administered twice (time 0 when incorporated into the study -initial dose- and at 48 hours -second dose-).
89570999|NCT04913779|Placebo Comparator|Placebo|Administration of 10 ml of a control-solution with no-neutralizing activity of SARS-CoV-2, administered in slow intravenous infusion (10ml diluted in 100 ml of physiological solution, administered over 50 to60 minutes in slow drip), produced by ANLIS-Malbrán, administered twice (time 0when incorporated into the study -initial dose- and at 48 hours -second dose-).
89571000|NCT04904497|Experimental|Early Occupational Therapy|These sessions will be implemented by occupational therapists trained in ICU, who will conduct 20 sessions of 30 min, distributed depending on the level of sedation, i) SAS (Sedation-Agitation Scale) 1 patients have one session each 48 h, evaluating the change of sedation level each 24 h; ii) SAS 2 patients have one session each 24 h, iii) SAS 3-5 have two sessions every day. The sessions will begin once the patient needs mechanical ventilation for at least 12 h
89571001|NCT04904497|No Intervention|Standard|"The ASDM protocol will be implemented to mechanically ventilated patients in the ICU, following the aspects recommended by experts and the current evidence. For this, the team of medical, nurses, and physiotherapist will be trained to understand and facilitate the ASDM actions that each one must implement.~Occupational Therapy interventions for control group will be allowed for this group only before 1 week after the first day on light sedation"
89571002|NCT04913623||Correlation of intramedullary pressure and systemic inflammatory parameters in cemented THA|
89571003|NCT04913623||Correlation of intramedullary pressure and systemic inflammatory parameters in non cemented THA|
89571004|NCT03054259|Experimental|Intervention|2 x 1000mg Rituximab and 100mg methylprednisolone
89571005|NCT03054259|Placebo Comparator|Control|2 x 100mg methylprednisolone plus placebo
89571006|NCT02456727|Active Comparator|Individual Acupuncture|Participants will be treated weekly with individual acupuncture treatment sessions for 12 consecutive weeks. Quality of life assessments will be taken at intervals during treatment and post-treatment.
89571007|NCT02456727|Active Comparator|Group/Community Acupuncture|Participants will be treated weekly with group acupuncture treatments sessions for 12 consecutive weeks. Quality of life assessments will be taken at intervals during treatment and post-treatment.
89571008|NCT03054025|Experimental|Supportive care (smart phone application)|Participants download the physical activity readiness smart phone application onto their personal smartphone and receive training on how to use the app which includes animated video clips, tailored email reminders, and feedback on progress for 3 weeks.
89571009|NCT04910035|Active Comparator|Training Group|Throughout 3 weeks SSE training was administered 4 days a week for a length of 45 minutes in each session. All the analyses were conducted at the start and at the end of 3-week long training.
89571010|NCT04910035|No Intervention|Control Group|This group has no intervention. Evaluations were only made at the start and at the end of 3-week long.
89571011|NCT03052387|Placebo Comparator|control|"Crestal pyramidal flap will be done with 2 releasing incisions for adequate exposure.~Buccal& palatal full reflection for adequate exposure and to avoid the interference between the onlay graft and the residual bone.~Decortication of the bone bed to increase the blood supply to the onlay graft.~The block graft harvested from the chin is placed crestal to the residual ridge and stabilized in place using dental implant immediately.~Periosteal incisions are usually needed to allow tension free sutures.~Vicryl 3/0 sutures for closer.~augmentin 1g twice daily for 5 days.~catflam 50g twice daily for 3 days"
89571012|NCT03052387|Active Comparator|Comparator|"Crestal incision with labial flap reflected leaving the palatal tissues without elevation.~Marking of the 3 bony cuts ( 2 vertical cuts & 1 horizontal cut ) using fine fissure bur in the form of perforations along the cuts position.~Drilling of pilot drill and first drill only.~3 full thickness cuts will be performed (2 vertical stop cuts will be made by using the tungsten carbide disc at the distal ends of the horizontal bony cut on the facial surface of alveolar ridge.~splitting osteotomes are used and mallet to complete the splitting of the bony segment.~After bony separation the rectangular bony segment (transport segment) will be mobilized occlusally and pedicled on the palatal mucoperiosteum.~The autogenous block graft harvested from the chin area is placed in the space gained under the mobile bony segment.~Drilling through the bony segment and the block graft.~Immediate implant placement~chin graft block dental implants"
89571013|NCT04909879|Experimental|COVI-MSC|Subjects will receive intravenous infusions of COVI-MSC (two vials or a total of ≈ 30 million cells) on Day 0, Day 2, and Day 4
89571014|NCT04909879|Placebo Comparator|Placebo|Subjects will receive intravenous infusions of placebo (two vials) on Day 0, Day 2, and Day 4
89028898|NCT05521958|Other|Acute tibial shaft or tibial plateau fractures with compartment syndrome.|Patients with acute lower leg fractures with acute compartment syndrome.
89571015|NCT04894513|Experimental|study group|the study group received the conventional selected program in addition to Kabat motor control re-education
89028899|NCT05521958|Other|Exertional compartment syndrome|Patients with a diagnosis of exertional compartment syndrome who are planning to undergo surgical procedure to release the compartment fascia will be recruited to participate prior to surgical intervention.
89028900|NCT05504707|Experimental|Dendritic Cell Vaccine dose Escalation|Dose escalation to determine the maximum tolerated dose (MTD) of HER2- and HER3- primed DC1 study vaccines. Participants will be treated in cohorts of size three to six and the dosage will be escalated if the clinical toxicity is acceptable. A total of 3 dose levels will be used.
89028901|NCT05491538|Experimental|Social Cognition and Interaction Training-Work Edition|Social Cognition and Interaction Training-Work Edition is a group-based, skills training group that will be offered to participants after they enroll in supported employment.
89028902|NCT05483296|Experimental|Crossover sequence 1: Dim, Moderate, High|All participants will go through all three light conditions in the three experiment sessions: They will receive white fluorescent overhead light (given in melanopic EDI at eye level) as the 3h afternoon light intervention. In the first experimental session, they receive an intensity of <10 lx. In the second experimental session, they receive an intensity of ~100 lx, and in the third experimental session, they receive an intensity of >1000 lx.
89028903|NCT05483296|Experimental|Crossover sequence 2: Dim, High, Moderate|All participants will go through all three light conditions in the three experiment sessions: They will receive white fluorescent overhead light (given in melanopic EDI at eye level) as the 3h afternoon light intervention. In the first experimental session, they receive an intensity of <10 lx. In the second experimental session, they receive an intensity of >1000 lx, and in the third experimental session, they receive an intensity of ~100 lx.
89028904|NCT05483296|Experimental|Crossover sequence 3: Moderate, Dim, High|All participants will go through all three light conditions in the three experiment sessions: They will receive white fluorescent overhead light (given in melanopic EDI at eye level) as the 3h afternoon light intervention. In the first experimental session, they receive an intensity of ~100 lx. In the second experimental session, they receive an intensity of <10 lx, and in the third experimental session, they receive an intensity of >1000 lx.
89028905|NCT05483296|Experimental|Crossover sequence 4: Moderate, High, Dim|All participants will go through all three light conditions in the three experiment sessions: They will receive white fluorescent overhead light (given in melanopic EDI at eye level) as the 3h afternoon light intervention. In the first experimental session, they receive an intensity of ~100 lx. In the second experimental session, they receive an intensity of >1000 lx, and in the third experimental session, they receive an intensity of <10 lx.
89028906|NCT05483296|Experimental|Crossover sequence 5: High, Moderate, Dim|All participants will go through all three light conditions in the three experiment sessions: They will receive white fluorescent overhead light (given in melanopic EDI at eye level) as the 3h afternoon light intervention. In the first experimental session, they receive an intensity of >1000 lx. In the second experimental session, they receive an intensity of ~100 lx, and in the third experimental session, they receive an intensity of <10 lx.
89028907|NCT05483296|Experimental|Crossover sequence 5: High, Dim, Moderate|All participants will go through all three light conditions in the three experiment sessions: They will receive white fluorescent overhead light (given in melanopic EDI at eye level) as the 3h afternoon light intervention. In the first experimental session, they receive an intensity of >1000 lx. In the second experimental session, they receive an intensity of <10 lx, and in the third experimental session, they receive an intensity of ~100 lx.
89028908|NCT05480111|Experimental|QL Block|
89028909|NCT05480111|Active Comparator|Local Anesthesia at incision site|
89028910|NCT05439005|Experimental|OFA group|OFA (Opioid Free Anaesthesia) group:
89028911|NCT05439005|No Intervention|CGA control group|CGA (Conventional General Anaesthesia) control group:
89028912|NCT05436613|Experimental|Device: transcranial direct current stimulation|6-week course of active tDCS treatment, consisting of 5 sessions per week for the first 3 weeks followed by 2 sessions per week for 3 weeks, for a total of 21 tDCS sessions. The duration of each session is 30 minutes.
89028913|NCT05434442|Other|1-simulation model training|"Tracheal aspiration training of caregivers assigned to the simulation training group will be given to the same standard by researcher. It will be shown in practice on the tracheostomy care simulator. They will also receive clinical routine training"
89028914|NCT05434442|Other|2-mobile app training|"An animation-based mobile application will be installed on the phones of the caregivers assigned to the mobile application group and will be introduced and made available to their use by the researcher. They will also receive clinical routine training"
89028915|NCT05434442|Other|3-control group|Clinical routine training will be given to caregivers in this group.
89028916|NCT05432024||Radiofrequency ablation, High power, short duration|Radiofrequency ablation is an ablation modality that uses radiofrequency energy to create ablation lesions through heat. Patients that are scheduled for pulmonary vein isolation using radiofrequency ablation will be consented for study participation.
89028917|NCT05432024||Ultra-low temperature cryo ablation|Ultra-low temperature cryo ablation is an ablation modality that uses nitrogen near its liquid-vapor critical point to create ablation lesions through ultra-low temperatures. Patients that are scheduled for pulmonary vein isolation using ultra-low temperature cryo ablation will be consented for study participation.
89028918|NCT05432024||Pulsed field ablation|Pulsed field ablation is an ablation modality that uses short lived electrical fields to create ablation lesions through irreversible electroporation. Patients that are scheduled for pulmonary vein isolation using pulsed field ablation will be consented for study participation.
89571016|NCT04894513|Experimental|control group|the control group received the conventional selected program
89571017|NCT04921137|Experimental|Omission of endocrine therapy|Omission of endocrine therapy
89571018|NCT04921137|Active Comparator|Administration of endocrine therapy for at least 5 years|Administration of endocrine therapy for at least 5 years
89571019|NCT04894201||All patients with relevant dental findings|
88970300|NCT04169828|Experimental|Ondansetron premedication|Methotrexate and folic/folinic acid as prescribed by physician. Ondansetron: 2 mg if <15Kg, 4 mg if 15-30Kg, 8 mg if >30Kg to be taken by mouth one hour before each weekly methotrexate dose, followed by two additional doses every 6-8 hours if awake. To be started from the very first dose of methotrexate.
88970301|NCT04169828|Active Comparator|Ondansetron as needed|Methotrexate and folic/folinic acid as prescribed by physician. ONLY children who report nausea/vomiting during regular care will be prescribed ondansetron at the same dose as in experimental group (2 mg if <15Kg, 4 mg if 15-30Kg, 8 mg if >30Kg to be taken by mouth one hour before each weekly methotrexate dose, followed by two additional doses every 6-8 hours if awake), as per the attending rheumatologist's discretion
88970302|NCT04167033|Experimental|Premature ovarian insufficiency|60 patients with POI followed in the endocrinology department
89571020|NCT03052465|Experimental|Feeding|Test soup meal feeding intervention
89571021|NCT04893889|Experimental|Fabry disease patients|Patients diagnosed with Fabry disease. Interventions will be as follows: Shear wave myocardial elastography to assess myocardial stiffness by non-invasively quantifying diastolic myocardial elasticity (EMD) in Fabry disease (DF) and cardiac amyloidosis (AC) in the ATTRh form and correlating with other complementary imaging tests and laboratory tests (electrocardiogram, 2D echocardiogram, troponin and BNP) and with a 6-minute walk test and quality of life questionnaires.
89571022|NCT04893889|Active Comparator|Amyloidosis transthyretin with cardiac commitment|Patients diagnosed with amyloidosis who present cardiac commitment. Interventions will be as follows: Shear wave myocardial elastography to assess myocardial stiffness by non-invasively quantifying diastolic myocardial elasticity (EMD) in Fabry disease (DF) and cardiac amyloidosis (AC) in the ATTRh form and correlating with other complementary imaging tests and laboratory tests (electrocardiogram, 2D echocardiogram, troponin and BNP) and with a 6-minute walk test and quality of life questionnaires.
89571023|NCT04893889|Placebo Comparator|Healthy subjects|Healthy patients. Interventions will be as follows: Shear wave myocardial elastography to assess myocardial stiffness by non-invasively quantifying diastolic myocardial elasticity (EMD) in Fabry disease (DF) and cardiac amyloidosis (AC) in the ATTRh form and correlating with other complementary imaging tests and laboratory tests (electrocardiogram, 2D echocardiogram, troponin and BNP) and with a 6-minute walk test.
89571024|NCT02456103|Experimental|Ataluren|Participants will be administered ataluren orally at a dose of 10 milligrams/grams (mg/kg) in the morning, 10 mg/kg at midday, and 20 mg/kg in the evening for up to 96 weeks.
89571025|NCT01653327|Active Comparator|Ketamine|Twenty milligrams of ketamine will be dissolved in 4 mL of pharmaceutical cherry syrup and 1 ml of normal saline.
89571026|NCT01653327|Placebo Comparator|Placebo|The placebo will consist of 4 ml of cherry syrup and 1 ml of normal saline.
89571027|NCT03053869|Experimental|Benzodiazepine - Limited use strategy|"No routine use of any intraoperative benzodiazepines.~Accepted benzodiazepine use in the case of seizure, alcohol withdrawal, or known benzodiazepine dependence.~Accepted benzodiazepine use in patients who are hemodynamically unstable and/or have cardiac anatomy that puts them at high risk of developing ischemia on induction of anesthesia."
89571028|NCT03053869|Active Comparator|Benzodiazepine - Ad libitum strategy|"Administration of some benzodiazepine to most patients undergoing cardiac surgery.~Accepted lack of benzodiazepine use in patients who have contraindications to the administration of these medications (e.g. documented allergy)."
89571029|NCT03053947|Other|Ketamine IN|All participants will receive intranasal Ketamine between 3mg/kg up to 9 mg/kg, once.
89571030|NCT04893733|Experimental|Vitamin B complex|Randomized patients with AKI to this arm will received during 5 consecutive days IV Vitamin B complex each 12 hours. They will also received the Institution standard of care for AKI.
89571031|NCT04893733|Placebo Comparator|Placebo|Randomized patients with AKI to this arm will received during 5 consecutive days IV placebo each 12 hours. They will also received the Institution standard of care for AKI.
89571032|NCT04903405||Sepsis|
89571033|NCT04903639||obese COPD|COPD patient with BMI more than 30
89571034|NCT04903639||non obese COPD|COPD patient with BMI less than 30
89571035|NCT03051139|Experimental|ICU A and ICU B|This is the intervention group.
88970303|NCT04167033|Other|healthy volunteers|60 healthy volunteers matched with POI's patients
88970304|NCT04166396|Experimental|A: Cystic fibrosis|Patients with CF will be randomly assigned to resveratrol or placebo.
88970305|NCT04166396|Experimental|A: Healthy Controls|Healthy controls will be randomly assigned to resveratrol or placebo
89571036|NCT03051139|No Intervention|ICU C and ICU D|This is the usual care group.
89571037|NCT03053323|Experimental|Lifestyle Intervention|
89571038|NCT03053557|Experimental|Social Skills Coach|The Social Skills Coach arm of the study will be provided access, instruction, and support for using the newly developed multi-platform device to address social impairments among individuals with schizophrenia, based on the evidence-based Social Skills Training (SST) intervention.
89571039|NCT03053557|No Intervention|Social Skills Training course|Social Skills Training classes are widely available and regularly used in the study setting. As such, this group will serve as a treatment as usual control group.
89571040|NCT04903171|No Intervention|GROUP ONE|The participants do not receive incentive to visit any gardens
89571041|NCT04903171|Placebo Comparator|GROUP TWO|The participants receive incentives by carers to visit regularly a conventional sensory garden
89571042|NCT04903171|Experimental|GROUP THREE|The participants receive incentives by carers to visit regularly an enriched garden
89571043|NCT03053635|Experimental|0.35 mg/cm^2 TLD1433 Bladder Dose|"TLD1433 infusion and photodynamic therapy treatment (PDT):~TLD1433 is infused for 1 hour and photodynamic therapy treatment is performed after TLD1433 has been rinsed from the bladder. If treatment with the maximum recommended starting dose of 0.35mg/cm^2 does not raise significant safety concerns as determined by the safety monitoring committee, the therapeutic dose of TLD1433 (0.70mg/cm^2) will be used."
89571044|NCT03053011|Experimental|Vibrating bracelet|A bracelet with vibrations triggered randomly overnight
89571045|NCT04909489||PDR group|Phlegm-Dampness Retention syndrome group
89571046|NCT04909489||SKYD group|Spleen and Kidney Yang Deficiency syndrome group
89571047|NCT04909489||NC group|Normal Control group
89571048|NCT04893031||Tocilizumab treatment group|Symptoms of hypoxia and systemic inflammation (SpO2 <90% on room air with accompanying elevation of any two of the systemic inflammatory markers such as CRP, LDH and Ferritin) and / or acute bilateral infiltrations on chest radiography or rapid progression of existing infiltrations, but who did not need mechanical ventilation at admission and were given tocilizumab treatment.
89571049|NCT04893031||Standard treatment group|Patients who did not require mechanical ventilation in intensive care admission and did not receive tocilizumab treatment during any period of hospitalization.
89571050|NCT02493855|Experimental|Arm A: Ribavirin Full Dose for Last 10 Weeks|Participants received ombitasvir/ABT-450/ritonavir 25 mg/150 mg/100 mg once daily (QD) + dasabuvir 250 mg twice daily (BID) for 12 weeks and weight-based ribavirin (1000 mg or 1200 mg split BID) for the last 10 weeks.
89571051|NCT02493855|Experimental|Arm B: Ribavirin Full Dose for 12 Weeks|Participants received ombitasvir/ABT-450/ritonavir 25 mg/150 mg/100 mg once daily (QD) + dasabuvir 250 mg twice daily (BID) and weight-based ribavirin (1000 mg or 1200 mg split BID) for 12 weeks.
89571052|NCT02493855|Experimental|Arm C: Ribavirin Low-dose for 12 Weeks|Participants received ombitasvir/ABT-450/ritonavir 25 mg/150 mg/100 mg once daily (QD) + dasabuvir 250 mg twice daily (BID) and 600 mg ribavirin once daily for 12 weeks.
89571053|NCT04892485||CF patients|
89571054|NCT04892485||Controls|
89571055|NCT04892563|Experimental|ESPB Block|Patients with rib fracture randomized to block group
89571056|NCT04892563|Active Comparator|Standard Care|Patients with rib fracture receiving IV analgesia/standard care
89571057|NCT04909255|Active Comparator|Antimuscarinic|oxybutynin, tolterodine, solifenacin
89571058|NCT04909255|Experimental|B3-agonist|mirabegron
89571059|NCT03052231|Active Comparator|Interactive Mobile Health Information|Receives Interactive Mobile Health Information via caremessage. EAI staff focus group content will include qualitative descriptions of their experiences with training and actual use of the Caremessages.org service, as well as to elicit comments about contributing features and other mitigating or enhancing factors of the intervention's implementation, outreach and promotion, and integration into workflow practices.
89571060|NCT03052231|No Intervention|Usual care|Usual care - clinic education, medication refills without reminders, appointments without reminders
89571061|NCT04891939|Experimental|The intervention Arm|This arm will receive the novel intervention package for a period of three months to prevent smoking initiation and increase quit rate. The intervention will consist of 4 lessons which will be taught for about one hour each day. This will be segmented into two broad areas as knowledge and skill development. Under the knowledge-based program, participants will be taught, the global challenge of tobacco and tobacco products, correcting the erroneous impression about tobacco, the media and advertisement, and the harmful effects of smoking. The skill development program teaches about refusal skills (self-esteem, interpersonal relationship skills, and problem-solving skills). The participants will understand the tobacco advertising and marketing strategies; peer influence, and skills for resisting influences to smoke.
89571062|NCT04891939|Active Comparator|The Control Arm|The control arm will not receive novel intervention program but will continue with the usual School Health and Education program (SHEP) however, at the end of the intervention, all the materials will be sent to the control arm to also benefit from the lessons.
89571063|NCT04892095||Study participants|Adult subjects (men and women) aged 18 years or more, living in 12 European countries
89209028|NCT02553044|No Intervention|Concurrent Control|Control group to receive no intervention.
89209029|NCT00569270|Active Comparator|Tiotropium 18 µg capsule, bronchodilator|tiotropium 18 µg capsule for 1 month versus placebo. To study bronchodilation and effect following metronome paced hyperventilation and induced dynamic hyperinflation of active tiotropium versus placebo
89209030|NCT00569270|Placebo Comparator|2|placebo 18ug tiotropium for 1 month
89571064|NCT04891861|Active Comparator|1 week restart|restart DOAC at 1 week post injury at label dose and frequency
89571065|NCT04891861|Active Comparator|4 week restart|restart DOAC at 4 weeks post injury at label dose and frequency
89571066|NCT04902313|Experimental|Cancer patients|Youths (10-18 y) with newly diagnosed cancer, as well as their family members.
89571067|NCT04902313|Active Comparator|Pediatric patients|Youths (10-18 y) with a chronic somatic disease receiving care at a pediatric outpatient facility.
89571068|NCT04891783||50 patients diagnosed as AS|50 patients diagnosed as AS according to 1984 modified New York criteria of AS .including radiographic and non-radiographic AS according to ASAS criteria these patients will undergo carotid ultrasound examination
89571069|NCT04891783||30 patients with psoriatic arthritis|30 patients with psoriatic arthritis who will be diagnosed according to the Classification Criteria of Psoriatic Arthritis (CASPAR) study these patients will undergo carotid ultrasound examination
89571070|NCT04891783||40 healthy controls|healthy controls will undergo carotid ultrasound examination
89571071|NCT03053167|Experimental|Irinotecan & Raltitrexed|"advanced colorectal cancer patients treated with irinotecan plus raltitrexed as second-line treatment.~Irinotecan:180mg/㎡+NS250ml, ivgtt, 90min, d1~Raltitrexed: 3mg/㎡+NS100ml，ivgtt，15min, d1 Every 3 weeks"
89571072|NCT03052543||BISblind|The BISblind group will have the BIS monitor and data physically hidden from the anesthesiologist. The patient will receive an anesthetic as per the anesthesiologist's particular care plan, unaltered by the study.
89571073|NCT03052543||BISvisible|BISvisible group will have the BIS monitor and data available for the anesthesiologist to view. The patient will receive an anesthetic as per the anesthesiologist's particular care plan, unaltered by the study.
88970306|NCT04166396|Experimental|B: Cystic Fibrosis|Patients with CF will be randomly assigned to NR or placebo.
88970307|NCT04166396|Experimental|B: Healthy Controls|Healthy controls will be randomly assigned to NR or placebo
88970308|NCT04160455||Cohort A, group A1|40 patients on suppressive antiretroviral therapy (HIV RNA <50 copies / ml for at least 4 years) initiated during the chronic phase : CD4 count less than 500 cells / ml at the time of inclusion in the study
88970309|NCT04160455||Cohort A, group A2|40 patients on suppressive antiretroviral therapy (HIV RNA <50 copies / ml for at least 4 years) initiated during the chronic phase: CD4 count above 500 cells / ml at the time of inclusion in the study
88970310|NCT04160455||Cohort B|20 patients on suppressive antiretroviral therapy (HIV RNA <50 copies / ml for at least 4 years) initiated since the primary-infection (within 4 months after acute infection)
88970311|NCT04160455||Cohort C, group C1|20 patients with detectable HIV RNA, naïve of antiretroviral, but who have an indication to start antiretroviral therapy: HIV diagnosis made during primary infection (within 4 months of infection)
88970312|NCT04160455||Cohort C, group C2|20 patients with detectable HIV RNA, naïve of antiretroviral, but who have an indication to start antiretroviral therapy: HIV diagnosis made during the chronic phase (more than 1 year after contamination), with CD4 count above 200 cells/ml at the time of inclusion in the study
89209031|NCT00545103|Experimental|SPD476 (1.2 g)|
89209032|NCT00545103|Experimental|SPD476 (2.4 g)|
89209033|NCT00545103|Experimental|SPD476 (4.8 g)|
89571074|NCT04901923|Experimental|Part 1 Cohort 1|Participants will receive ACP-196 2.5 mg capsule orally BID on Day 1.
89571075|NCT04901923|Experimental|Part 1 Cohort 2|Participants will receive ACP-196 5 mg (2 x 2.5 mg capsules) orally BID on Day 1.
89571076|NCT04901923|Experimental|Part 1 Cohort 3|Participants will receive ACP-196 25 mg capsule orally BID on Day 1.
89571077|NCT04901923|Experimental|Part 1 Cohort 4|Participants will receive ACP-196 50 mg (2 x 25 mg capsules) orally BID on Day 1.
89571078|NCT04901923|Experimental|Part 1 Cohort 5|Participants will receive ACP-196 100 mg (4 x 25 mg capsules) orally QD on Day 1.
89571079|NCT04901923|Experimental|Part 2 Cohort 6|Participants will receive ACP-196 75 mg (3 x 25 mg capsules) orally QD on Day 1 and Day 8.
89571080|NCT04901923|Experimental|Part 3 Cohort 7|Participants will receive ACP-196 50 mg (2 x 25 mg capsules) orally QD on Day 1, itraconazole 200 mg capsules BID from Days 4 to 8 with meals and then ACP-196 50 mg (2 x 25 mg capsules) along with itraconazole 200 mg capsule QD on Day 9 under fasting state.
89571081|NCT04901845||Patients applying to Primary Healthcare Consultation|Consequent patients applying to the Primary healthcare to consult for any reason during 2 week period
89571082|NCT04901845||Patients applying to Specialized Healthcare Consultation|Consequent patients applying to the Specialized healthcare to consult for any reason during 2 week period
89571083|NCT04908007||Professional qualitative group|Qualitative analysis of crisis management by interviewing professionals most involved during the crisis in each university hospital.
89571084|NCT04908007||Professional quantitative group|Quantitative analysis of crisis management using the WHO grid adapted sent to the target persons identified within the establishments
89571085|NCT04908007||Patient quantitative group|Quantitative analysis of crisis management using a questionnaire sent to patients hospitalized in the first wave asking them about their perception of crisis and post-crisis management.
89571086|NCT04908007||Tools development|Development of tools to prepare for situations of uncertainty
89571087|NCT03050905|Experimental|Treatment|The study will include 1 group. Patients will be treated according to label recommendation as for GT1b (with and without cirrhosis) for 12 weeks. All subjects will receive Ombitasvir+Paritaprevir+Ritonavir (VEKIRAX) and Dasabuvir (EXVIERA).
89571088|NCT03050827|Active Comparator|3% oxybutynin|Subjects with IENF loss of between 20-75% of normative values11 and thus amenable to therapy-induced recovery, will be randomized into the active drug arm (N=30) and instructed in how to apply 84 mg Gelnique 3%TM or hydrogel placebo to cover a 2 in2 region of skin adjacent to the initial biopsy site,
89571089|NCT03050827|Placebo Comparator|Placebo|Subjects with IENF loss of between 20-75% of normative values11 and thus amenable to therapy-induced recovery, will be randomized into the placebo group arm (N=30) and instructed in how to apply 84 mg Gelnique 3%TM or hydrogel placebo to cover a 2 in2 region of skin adjacent to the initial biopsy site,
89571090|NCT04891159||Shared decision making|During the first consultation (V1), the doctor will present the patient on the therapeutic treatment information related to diabetes according to the shared decision making (options, benefits, risks) with the assistance of decision support tools. The decision-making visit will take place after a reflection period of 8 to 15 days after V1. A discussion based on the feedback from this period of reflection will take place between the two actors and either there is a common agreement on the decision taken (shared decision-making), or the decision is taken by the patient, or the decision is made by the physician at the request of the patient. A social sciences and humanities methodologist will attend each consultation, onsite or in videoconferencing. After the consultation, he realized a semi-structured interview with the patient. During this interview, the patient filled the self-administered questionnaires: SDM-Q-9, SURE, CollaboRATE, Spielberger test and the research team questionnaire
89571091|NCT04891159||Control group|"Decision-making for insulin therapy is based on the usual practice defined in each Cystic Fibrosis Centers Competences with decision-making procedures specific to each center and doctor. The decision-making process is generally carried out in two consultations.~A social sciences and humanities methodologist will attend each consultation, onsite or in videoconferencing.~After the consultation, he realized a semi-structured interview with the patient. During this interview, the patient filled the self-administered questionnaires (SDM-Q-9, SURE, CollaboRATE, Spielberger test and the research team questionnaire)."
89571092|NCT04900909||Aortic valve replacement with mechanical valves|
89571093|NCT04900909||Aortic valve replacement with bioprostheses|
89571094|NCT04891003||Patients Diagnosed with Endometriosis (or endometrioma alone)|Nulliparous patients who had diagnosed with endometriosis, no additional gynecological patology such as myoma uteri, polype, a history of pelvic inflammatuar disease, a history of cervical or uterine surgery, uterine anomalies
89571095|NCT04891003||Patients With No Gynecological Pathology|Nulliparous patients who had not diagnosed with endometriosis, no additional gynecological patology such as myoma uteri, polype, a history of pelvic inflammatuar disease, a history of cervical or uterine surgery, uterine anomalies
89571096|NCT04907617|Experimental|G1|After the induction of anaesthesia, the first group will be heated with only forced-air warming device.
89571097|NCT04907617|Experimental|G2|After the induction of anaesthesia, the second group will receive only warmed IV and irrigation fluids.
89571098|NCT04907617|Experimental|G3|After the induction of anaesthesia, forced-air warming as well as warmed IV and irrigation fluids will be applied to the third group
89571099|NCT04907617|Experimental|G4|After the induction of anaesthesia, the fourth group will be the control group without any intervention.
89571100|NCT02438787|Placebo Comparator|Group 1 (placebo)|Placebo subcutaneous (SC) injection at Weeks 0, 4, and 16. At Week 24 all participants (with the exception of participants who qualified for early escape [EE]) will be re-randomized to receive either ustekinumab 45 or 90 milligram (mg) SC injection at Weeks 24 and 28 followed by every 12 weeks (q12w) dosing, with the last administration of study agent at Week 52. Participants who meet EE criteria (less than [<] 10 percent [%] improvement from baseline in both total back pain and morning stiffness measures at both Week 12 and Week 16) will be administered open-label golimumab 50 mg SC administrations at Week 16 and every 4 weeks (q4w) thereafter through Week 52.
89571101|NCT02438787|Experimental|Group 2 (ustekinumab 45 mg)|Ustekinumab 45 mg SC injection at Weeks 0 and 4, followed by q12w dosing, with the last administration of study agent at Week 52. At Week 24, participants will receive placebo SC injection to maintain the blind. Participants who meet EE criteria (<10% improvement from baseline in both total back pain and morning stiffness measures at both Week 12 and Week 16) will be administered open-label golimumab 50 mg SC administrations at Week 16 and q4w thereafter through Week 52.
89209034|NCT00545103|Placebo Comparator|Placebo|
89209035|NCT00586157|Active Comparator|Methylphenidate Transdermal System (MTS)|
89209036|NCT00586157|Placebo Comparator|Placebo|
89571102|NCT02438787|Experimental|Group 3 (ustekinumab 90 mg)|Ustekinumab 90 mg SC injection at Weeks 0 and 4, followed by q12w dosing, with the last administration of study agent at Week 52. At Week 24, participants will receive placebo SC injection to maintain the blind. Participants who meet EE criteria (<10% improvement from baseline in both total back pain and morning stiffness measures at both Week 12 and Week 16) will be administered open-label golimumab 50 mg SC administrations at Week 16 and q4w thereafter through Week 52.
89571103|NCT04901065|Experimental|Xylocaine|The study intervention was the administration of 10 mg of intranasal lidocaine in one nostril using 1 spray of 0.1mL of a 10% lidocaine solution 5 minutes before NPS. This was done using the standard long nozzle.
89571104|NCT04901065|Sham Comparator|Control|The control group received the placebo with the same application technique using an empty bottle of lidocaine 10% with the same long nozzle for delivery.
89571105|NCT04430803|Experimental|Hydrogen-rich water|"Hydrogen-rich water (Rejuvenation, HRW Natural Health Products Inc.)~8 ppm of hydrogen~Administered one dose two times per day on an empty stomach in the morning and at the evening"
89571106|NCT04430803|Placebo Comparator|Control water|"Tap water~0 ppm of hydrogen~Administered one dose two times per day on an empty stomach in the morning and at the evening"
89571107|NCT04891081||Patients with cyanotic Congenital Heart Disease|
89571108|NCT04891081||Patients with acyanotic Congenital Heart Disease|
89571109|NCT04412005||Manhiça|Pregnant women attending the Manhiça District Hospital
89571110|NCT04412005||Ilha Josina|Pregnant women attending the Ilha Josina Health Center
89571111|NCT04412005||Magude|Pregnant women attending the Magude Health Center
89571112|NCT04890847||human-machine collaboration group|healthcare professionals and machine collaboration for annotation and AI model development
89571113|NCT04890847||pure mannual group|healthcare professionals for pure manual annotation and AI model development
89571114|NCT02493777|Experimental|HLD200 (methylphenidate)|The investigational drug for this study is HLD200 MPH MR capsules comprised of the active pharmaceutical ingredient (MPH) in a dual-coated drug-layered core. Following open-label treatment optimization, subjects will be randomized (1:1) to double-blind HLD200 to be taken once daily during the evening for a period of 1-week prior to testing.
89571115|NCT02493777|Placebo Comparator|Placebo|Placebo capsules will be composed of microcrystalline cellulose beads in place of MPH containing beads found in the HLD200 capsules. Following open-label treatment optimization, subjects will be randomized (1:1) to double-blind placebo to be taken once daily during the evening for a period of 1-week prior to testing.
89571116|NCT04890691|Experimental|BLT-1|Light therapy (wavelengths between 470nm and 525nm), 30 minutes/day for 4 weeks.
89571117|NCT04890691|Placebo Comparator|BLT-2|Placebo light (wavelength between 620nm and 750 nm), 30 minutes/day for 4 weeks.
89571118|NCT04890457|Experimental|Tragus then earlobe stimulation|
89571119|NCT04890457|Experimental|Earlobe then tragus stimulation|
89571120|NCT03052699||vaginal Cesarean Section|patients operated to vaginal Cesarean Section
89571121|NCT04907149|Experimental|Absolute Bioavailability - Period 1|Participants will receive GLPG3970 under fasted conditions followed by an intravenous (i.v.) microtracer microdose of [14C]GLPG3970 on Day 1.
89571122|NCT04907149|Experimental|Mass Balance - Period 2|Participants will receive [14C]GLPG397 under fasted conditions on Day 1.
88970313|NCT04160455||Cohort C, group C3|20 patients with detectable HIV RNA, naïve of antiretroviral, but who have an indication to start antiretroviral therapy: HIV diagnosis made during the chronic phase (more than 1 year after contamination), with CD4 count less than 200 cells/ml at the time of inclusion in the study
88970314|NCT04160455||Cohort D|20 patients who have undetectable plasma HIV RNA (HIV RNA <50 copies / ml ) without antiretroviral therapy, either spontaneously (HIV controllers or elite controllers) or after treatment interruption (post-treatment controllers).
88970315|NCT04145180|Experimental|Manual Therapy|Manual Therapy-based intervention
89571123|NCT04431037|Experimental|Early oral feeding group(A)|Patients admitted in the HDU postoperatively.NG tube and foley's catheter removed within 12 hours and patients allowed oral sips on day 1 with gradual shift to liquid diet after 12 hrs and semisolid food started after 24 hours later.Patients were given i/v antibiotics,painkillers and i/v PPIs and shifted to oral pain killers on 2nd POD.
89571124|NCT04431037|No Intervention|Traditional postoperative care group(B)|Patients in this group were managed traditionally
89571125|NCT03052621||Curative group|Locally advance breast cancer and locally recurrent breast cancer without metastasis underwent omental transposition
89571126|NCT03052621||Palliative group|Locally advance breast cancer and locally recurrent breast cancer with metastasis underwent omental transposition
89571127|NCT04906681|Experimental|Arthroplasty, hip or knee|Minimum 5x/week (of which minimal 3x/week with therapists and 2x/week during weekend), 30-60 minutes training, for 4 weeks, with i-ACT system. i-ACT provides individualised exercises based on patients own goalsetting.
89571128|NCT04906681|Experimental|Neurology: stroke or Parkinson disease|Minimum 5x/week (of which minimal 3x/week with therapists and 2x/week during weekend), 30-60 minutes training, for 4 weeks, with i-ACT system. i-ACT provides individualised exercises based on patients own goalsetting.
89571129|NCT04906915|Experimental|Ketamine|The experimental group was continuously pumped with remifentanil + ketamine for analgesia, and the control group was continuously pumped with remifentanil + placebo (normal saline) for analgesia. RASS and CPOT scores were performed to evaluate the pain degree of the patients.
89571130|NCT04900285|Other|Dental Device Arm|Subjects in this single arm study serve as their own control by recording snoring on the SnoreLab device for five days and completing the Snore Outcomes survey. After five nights with now device, the lower dental device is used for five nights and snoring is recorded in the SnoreLab app. At the end of the five nights the subjects complete the Comfort and Difficulties Form and the bed partner completes the Snore Outcomes Survey. If the lower device was tolerated well, the process is repeated with the upper dental device used with the lower device.
89571131|NCT03052777|Experimental|Telephone Counselling|Participants will be asked to increase their exercise by at least 60 minutes per week and will receive a copy of Canada's Physical Activity Guideline plus 12 weekly telephone counseling sessions aimed at helping survivors follow-through on their exercise intention.
89571132|NCT03052777|No Intervention|Control|Participants will be asked to increase their exercise by at least 60 minutes per week and will be self-directed, only receiving a copy of Canada's Physical Activity Guideline as standard of care.
89571133|NCT04906291|Experimental|H.A.F. toothpaste (1000 ppm F-)|The children were instructed to brush their teeth for at least two minutes after each main meal (three times/day).
89571134|NCT04906291|Active Comparator|Fluoridated toothpaste (1000 ppm F-)|The subjects were instructed to brush their teeth for at least two minutes after each main meal (three times/day).
88970316|NCT04145180|No Intervention|Control|Patients waiting list
88970317|NCT04134819||Vaginally Delivered Babies- No antibiotic treatment|Adult healthy pregnant females (in total 400) as well as their infants will be recruited. It is expected 67% of babies will be vaginally delivered and that 60% will not have antibiotic treatment during pregnancy. This will be up to 161 mother/infant dyads.
88970318|NCT04134819||Vaginally Delivered Babies- antibiotic treatment|It is expected based from previous hospital statistics that 67% of babies will be vaginally delivered and 40% of these women will be treated with antibiotics during pregnancy. This could be up to 107 mother/infant dyads.
88970319|NCT04134819||C-section Delivered Babies- No antibiotic treatment|It is expected based from previous hospital statistics that 33% of babies will be delivered by C section and that 60% will not have antibiotic treatment during pregnancy. This will be up to 80 mother/infant dyads All C Section women (including emergency C Section) will be treated with IV Cefazolin at the time of incision, in theatre, to prevent internal wound infection.
88970320|NCT04134819||C-section Delivered Babies- antibiotic treatment|It is expected based from previous hospital statistics that 33% of babies will be delivered by c section and 40% of these women will be treated with antibiotics during pregnancy. This could be up to 52 mother/infant dyads .All C Section women (including emergency C Section) will be treated with IV Cefazolin at the time of incision, in theatre, to prevent internal wound infection.
88970321|NCT04134390|Experimental|Cabozantinib|Cabozantinib 40 mg p.o. once daily in 28-day cycles.
89571135|NCT04906291|Experimental|H.A.F. toothpaste (1450 ppm F-)|The subjects were instructed to brush their teeth for at least two minutes after each main meal (three times/day).
89571136|NCT04906291|Active Comparator|Fluoridated toothpaste (1450 ppm F-)|The subjects were instructed to brush their teeth for at least two minutes after each main meal (three times/day).
89571137|NCT04900129|Experimental|Study Group|This group inhaled vapor containing Menthol 0.02%, Methyl salicylate 0.05%, N- Acetyl cysteine 1.2 gm%, and Diclofenac sodium 1gm% twice daily in addition to conventional treatment. That is, 100 gram of emulsion contain diclofenac sodium 1 gram, N-acetyl cysteine 1.2 gm, menthol 20 mg, and methyl salicylic acid 50 mg. These drugs have no systemic and local side effects in these small doses, though it may cause slight eye irritation.
89571138|NCT04900129|No Intervention|Control Group|This group inhaled plain aquatic vapor in addition to conventional treatment.
89571139|NCT02616601|Experimental|Generic Fluorouracil Cream|Participants are to apply up to 1 gram of generic fluorouracil 0.5% topical cream once daily for 2 weeks as a thin film to the skin of the treatment area and rub until the cream is no longer visible. Participants will be instructed to apply the study drug 10 minutes after thoroughly washing, rinsing, and drying the entire treatment area and 1 to 2 hours before bedtime. Study drug should be left on the skin for approximately 8 hours and then removed by washing the area with mild soap and water. Treatment should be continued for the full treatment course even if the actinic keratoses lesions appear to be gone.
89571140|NCT02616601|Active Comparator|Carac® (Fluorouracil) Cream|Participants are to apply up to 1 gram of Carac (fluorouracil) 0.5% topical cream once daily for 2 weeks as a thin film to the skin of the treatment area and rub until the cream is no longer visible. Participants will be instructed to apply the study drug 10 minutes after thoroughly washing, rinsing, and drying the entire treatment area and 1 to 2 hours before bedtime. Study drug should be left on the skin for approximately 8 hours and then removed by washing the area with mild soap and water. Treatment should be continued for the full treatment course even if the actinic keratoses lesions appear to be gone.
89571141|NCT02616601|Placebo Comparator|Vehicle Cream|Participants are to apply up to 1 gram of vehicle topical cream once daily for 2 weeks as a thin film to the skin of the treatment area and rub until the cream is no longer visible. Participants will be instructed to apply the study drug 10 minutes after thoroughly washing, rinsing, and drying the entire treatment area and 1 to 2 hours before bedtime. Study drug should be left on the skin for approximately 8 hours and then removed by washing the area with mild soap and water. Treatment should be continued for the full treatment course even if the actinic keratoses lesions appear to be gone.
89571142|NCT04927845|Experimental|Immediate Intervention Condition|Participants in this condition will receive 7-8 weeks of online intervention modules. Specific modules will be selected based on a campus-wide needs assessment conducted in May 2021.
89571143|NCT04927845|No Intervention|Waitlist Condition|Participants in this condition will wait to receive StriveWeekly until after the Immediate Intervention condition is complete and participants from both conditions have completed the posttest survey.
89571144|NCT02492997|Experimental|Treatment Group|Group treated with the active Venus Versa octipolar applicator and the glycerine gel.
89571145|NCT02492997|Sham Comparator|Control Group|Group treated with the inactive Venus Versa octipolar applicator and the glycerine gel.
89571146|NCT04920279||The patients with diabetes mellitus|When patients with diabetes mellitus admitted to our outpatient clinic if they have inclusion criteria, we have used the ABC questionnaire. And we have done perform Time Up And Go Test twice respectively.
89571147|NCT03052075||Parathyroidectomy Data Review|The research plan is for a retrospective review to be performed of a prospectively maintained parathyroid database within the Department of Surgical Oncology at the University of Texas MD Anderson Cancer Center.
89571148|NCT04906603|Experimental|TBS Headache|
89571149|NCT02437305|Experimental|ABCDEs of Melanoma Skin Cancer|"A modified melanoma educational intervention that uses the ABCDEs of Melanoma pamphlet from the Skin Cancer Foundation but also incorporates the nomenclature melanoma skin cancer; indicates that melanoma is relevant for everyone regardless of race and ethnicity; includes images of melanoma on ethnic skin; informs people of the likelihood of melanoma developing in acral, subungual and mucosal surfaces; and provides guidance on self-skin examinations."
88970322|NCT04126408|Sham Comparator|Sham arm|gammaCore sham device which will not provide stimulation of the vagus nerve
88970323|NCT04126408|Active Comparator|Treatment group|Active gammaCore device that supplies non-invasive stimulation of the cervical branch of the Vagus nerve
89209037|NCT00809432|Experimental|Visit 1|2 hour city centre kerbside walk in Beijing China
89571150|NCT02437305|Active Comparator|ABCDEs of Melanoma|"A conventional melanoma educational intervention using the ABCDEs of Melanoma pamphlet from the Skin Cancer Foundation."
89571151|NCT03051919||no reinforcement|Group I: 25 patients; no reinforcement (NoR) Observation : Patients would be followed up for any signs of leaks. If any, treatment would be offered appropriataly but the results of treatment are not affiliated as a part in the study.
89571152|NCT03051919||fibrin glue|Group II: 26 patients; fibrin glue (FG) Observation : Patients would be followed up for any signs of leaks. If any, treatment would be offered appropriataly but the results of treatment are not affiliated as a part in the study.
89571153|NCT03051919||suture reinforcement|Group III: 44 patients; suture reinforcement with 2-0 polypropylene suture (S) Observation : Patients would be followed up for any signs of leaks. If any, treatment would be offered appropriataly but the results of treatment are not affiliated as a part in the study.
89571154|NCT03051919||biological buttressing materaia|Group IV: 14 patients; biological buttressing material Observation : Patients would be followed up for any signs of leaks. If any, treatment would be offered appropriataly but the results of treatment are not affiliated as a part in the study.
89571155|NCT04393207|Active Comparator|Control group (Bupivacaine)|Patient will receive intrathecal morphine and TAP block with plain bupivacaine.
89571156|NCT04393207|Experimental|Liposomal Bupivacaine|Patient will receive intrathecal morphine + TAP block with Liposomal bupivacaine and bupivacaine 0.25%
89571157|NCT04393207|Active Comparator|Bupivacaine + dexamethasone and methylprednisolone|Patient will receive intrathecal morphine + TAP block with only bupivacaine.
89571158|NCT02492841|Experimental|Mineral trioxide aggregate (MTA)|Mineral trioxide aggregate Root canal repair material
89571159|NCT02492841|Active Comparator|Calcium hydroxide|-material for pulp capping
89571160|NCT02492841|Experimental|Biodentine|Is a calcium-silicate based materia root perforations, apexification, resorptive lesions, and retrograde filling material in endodontic surgery, pulp capping
89571161|NCT04817917|Experimental|3JEV-I (Group 1)|"Retrospective: 3 doses of JE vaccines. 2 doses of Inactivated JE Vaccine (JEV-I, 7-10 days apart) at 8 months of age and 1 dose of JEV-I at 2 years old.~Prospective: 1 booster dose of JEV-I at 6 years old."
89571162|NCT04817917|Experimental|JEV-L+JEV-I (Group 2)|"Retrospective: 2 doses of JE vaccines.~1 dose of JE attenuated live vaccine (JEV-L) at 8 months of age and 1 dose of JEV-I at 2 years old.~Prospective: 1 booster dose of JEV-I at 6 years old."
89571163|NCT04817917|Experimental|JEV-L+2JEV-I (Group 3)|"Retrospective: 3 doses of JE vaccines.~1 dose of JEV-L at 8 months of age and 2 dose (7-10 days apart) of JEV-I at 2 years old."
89571164|NCT04817917|Experimental|2JEV-I+JEV-L (Group 4)|Retrospective: 3 doses of JE vaccines. 2 doses of JEV-I (7-10 days apart) at 8 months of age and 1 dose of JEV-L at 2 years old.
89571165|NCT04817917|Experimental|2JEV-L (Group 5)|Retrospective: 2 doses of JE vaccines. 2 doses of JEV-L respectively administered at 8 months of age and 2 years old.
89571166|NCT04412161||Extra-Malatya|Liver transplant patients with MTD>6 cm of HCC
89571167|NCT02436915|Experimental|Real tDCS|"The real tDCS intervention will consist of 10 daily 20-minute sessions of transcranial direct current stimulation (tDCS) targeting left prefrontal cortex at a target current intensity of 1.5 mA."
89571168|NCT02436915|Sham Comparator|Sham tDCS|"The sham tDCS intervention will consist of 10 daily 20-minute sessions of transcranial direct current stimulation with same montage as the real tDCS, except current will only be applied for the first 60 seconds of each session."
89571169|NCT04815499|Experimental|Food supplement|One tablet a day, during 12 months
89571170|NCT04815499|Placebo Comparator|Placebo|One tablet a day, during 12 months
89571171|NCT04398901||Colombia ZIKV-exposed|Seventy children in Colombia were previously enrolled as part of a fetal-neonatal neuroimaging study in 2016-2017 and were from Department of Atlantico, Colombia on the Caribbean coast. Eligible children had prior normal fetal MRI and fetal US, normal birth head circumference, normal clinical exam, no more than mild non-specific postnatal imaging findings, and are thus without findings of CZS.
89571172|NCT04398901||Colombia Non-ZIKV exposed control|The investigators will enroll 70 non-ZIKV exposed children, age 4 to 5 years, in Department of Atlántico, Colombia with birth dates prior to March 31, 2016. Based on the arrival of ZIKV to Colombia in November 2015, this date would ensure a control cohort without congenital ZIKV exposure in the first half of gestation and unlikely during any of the pregnancy.
89571173|NCT04398901||United States ZIKV-exposed|The US cohort either presented during pregnancy or after birth and sought clinical care with the Children's National Congenital Zika Program in Washington, DC and were ZIKV-exposed.
89571174|NCT04398901||United States Non-ZIKV exposed control|The investigators will enroll 32 non-ZIKV exposed children, age 4 years, in Washington, DC.
89571175|NCT02492763|Experimental|MK-8521 300 μg|Participants receive double-blind MK-8521 300 μg daily (QD), subcutaneously, over 12 weeks.
89571176|NCT02492763|Experimental|MK-8521 180 μg|Participants receive double-blind MK-8521 180 μg QD, subcutaneously, over 12 weeks.
89571177|NCT02492763|Placebo Comparator|Placebo|Participants receive matching double-blind placebo, QD over 12 weeks.
89571178|NCT02492763|Active Comparator|Liraglutide 1.8 mg|Participants receive open-label 1.8 mg of liraglutide, QD, subcutaneously, over 12 weeks.
89571179|NCT04899817|Active Comparator|Group G|will receive granisteron 1mg after induction of general anesthesia
89571180|NCT04899817|Placebo Comparator|Group C|Will receive metoclopramide 10 mg after induction of general anesthesia
89571181|NCT04905667|Experimental|GB221 group|6 mg/kg, single dose, intravenous infusion, 90-100 min
89571182|NCT04905667|Active Comparator|Herceptin group|6 mg/kg, single dose, intravenous infusion, 90-100 min
89571183|NCT03050749|Other|Princess® VOLUME|
89571184|NCT02491671|Experimental|Experimental group|Experimental group: At the end of lung resection, lung sutures and 1.5 cm of lung parenchyma on each side will be covered by Hemopatch. No additional measures for preventing air leak will be indicated. In the case of massive air leak in spite of the use of Hemopatch, each surgeon will decide on the indication of additional sutures of tissue plasties. These cases will be accounted for failures on an intention to treat basis.
89571185|NCT02491671|Other|Control group|Control group: The standard preventive measures will be followed in each center, including reinforcement of sutures, pleural tents, suturing pericardial or subcutaneous fat
89571186|NCT04889677|Experimental|Group 1: 200 mg|All participants (fasted) received either 200 mg of danicopan as a single oral dose or dose-matched placebo.
89571187|NCT04889677|Experimental|Group 2: 600 mg|All participants (fasted) received either 600 mg of danicopan as a single oral dose or dose-matched placebo.
89571188|NCT04889677|Experimental|Group 3: 1200 mg|All participants (fasted) received either 1200 mg of danicopan as a single oral dose or dose-matched placebo.
89571189|NCT04889677|Experimental|Group 4: 2400 mg|All participants (fasted) received either 2400 mg of danicopan administered as 2 single doses of 1200 mg each, 12 hours apart, or dose-matched placebo.
89571190|NCT04889677|Experimental|Group 5: 1200 mg|All participants (fed) received either 1200 mg of danicopan as a single oral dose or dose-matched placebo.
89571191|NCT04397107|Experimental|Recombinant Human Interleukin-2|Induced remission period,recombinant human IL-2(500,000 unit per square meter) infusions five days;Maintenance treatment period,recombinant human IL-2 infusions five days then once every two weeks for 6 months.
89571192|NCT04397107|No Intervention|Traditional therapy|Patients were treated with glucocorticoid and/or immunosuppressor.
89571193|NCT02453841|Active Comparator|FESS|Patients undergoing functional endoscopic sinus surgery and receiving oxymetazoline as part of their surgery.
89571194|NCT02453841|Active Comparator|Turbinates|Patients undergoing turbinate reduction surgery and receiving oxymetazoline as part of their surgery.
89571195|NCT02453841|Active Comparator|Adenoidectomy|Patients undergoing an adenoidectomy and receiving oxymetazoline as part of their surgery.
89571196|NCT04430647|Experimental|phaco-UCP|Under peribulbar anesthesia, UCP was performed first, followed by phacoemulsification. UCP was performed using the same technique described before [18]. For all treatments, 2nd generation probe was used (EyeOP1, Eye Tech care; France) with the same parameters; Operating frequency was 21 MHz. Number of sectors activated was 6. Acoustic power was 2.45 W; duration of each shot was 8s; and the time between shots was 20s. The probe diameter (11, 12 or 13 mm) was determined according to the eye's biometric readings. The coupling cone was centered on the eye and kept in place with low vacuum suction, followed by introduction of the treatment probe inside the cone, then activation of the transducers by constantly pressing the foot switch. Once UCP treatment was finished, phacoemulsification was commenced
89571197|NCT04430647|Active Comparator|Phaco alone|A standard phacoemulsification was performed with 2.2 mm clear corneal incision, continuous curvilinear capsulorhexis, phacoemulsification and intrabagal implantation of foldable acrylic intraocular lens (AcrySof® IQ SN60WF monofocal; Alcon Laboratories Inc, Fort Worth, TX, USA) for all patients. Irrigation-aspiration was performed for at least 30 seconds to remove any viscoelastic from the anterior chamber. Reformation of the anterior chamber was done with balanced saline solution (BSS), followed by hydration of the corneal wound and side port.
89571198|NCT04889365||COVID-19 positive, asymptomatic|COVID-19 positive, asymptomatic (i.e. no current symptoms of COVID-19, confirmed PCR positive for COVID-19)
89571199|NCT04889365||COVID-19 positive, symptomatic|COVID-19 positive, symptomatic (i.e. current symptoms of COVID-19, confirmed PCR positive for COVID-19)
89571200|NCT04889365||COVID-19 negative|COVID-19 negative (i.e. no current or previous symptoms of COVID-19, confirmed PCR negative for COVID-19)
89571201|NCT04889131|Experimental|Yoga Program|12-week yoga program begins immediately
89209038|NCT00809432|Experimental|Visit 2|2 hour city centre kerbside walk in Beijing China
89571202|NCT04889131|Active Comparator|Wait-list Control|Wait-listed to take the Yoga Program in 12-weeks time
89571203|NCT04889053||D2M, Vascular calcification-free|Meet the inclusion criteria, there is no calcification detected by low dose prospectively triggered sequential dual-source CT coronary angiography
89571204|NCT04889053||D2M with vascular calcification|Meet the inclusion criteria, and have coronary artery calcification ( be confirmed by low dose prospectively triggered sequential dual-source CT coronary angiography)
89571205|NCT04888663|Experimental|Study treatment|(Phase Ib part) Trastuzumab 4 mg/kg (loading dose) followed by 2 mg/kg IV, ramucirumab 8 mg/kg IV, and paclitaxel 80 or 70 mg/m2 IV (according to dose level) (Phase II part) Trastuzumab 4 mg/kg (loading dose) followed by 2 mg/kg IV, ramucirumab 8 mg/kg IV, and paclitaxel at RP2D (80 or 70 mg/m2 IV)
89571206|NCT04899427|Experimental|orelabrutinib combined with PD-1 inhibitor|"The experimental arm will be treated orelabrutinib plus PD-1(programmed death）inhibitor every 21 days as one cycle. The responses will be evaluated every 2 cycles during the first 6 cycles and every 3 months until progression.~The investigators can choose Sintilimab Injection or Tislelizumab Injection at the beginning of treatment，but they can't exchange to another during the whole treatment."
89571207|NCT02453685|Experimental|BIAsp|
89571208|NCT02453685|Active Comparator|IGlar + IAsp|
89571209|NCT04888975|Experimental|Patients with Breast-cancer related lymphedema (BCRL) after lymphatic surgery|Patients with Breast-cancer related lymphedema (BCRL) after lymphatic surgery
89571210|NCT04918797|Experimental|Study vaccine|SARS-COV2 vaccine
89571211|NCT05530187|No Intervention|Control|
89571212|NCT05530187|Experimental|Intervention|
89571213|NCT04905355|Active Comparator|Virtual Reality (VR)|Patient with VR experience during the ambulatory orthopedic surgery
89571214|NCT04905355|No Intervention|NO VR|Patient without any VR experience during the ambulatory orthopedic surgery
89571215|NCT03051841|Experimental|Treat Regimen|CKD-581(investigational Drug) Bortezomib Dexamethasone
89028919|NCT05429580|Other|postpartum bleeding risks as low-risk|The patients were divided into two groups according to their postpartum bleeding risks as low-risk (240 patients) and high-risk (240 patients), and then the patients in each group were randomly divided into two groups, and some of these pregnant women were given intravenous tranexamic acid and some were given placebo.
89028920|NCT05429580|Other|postpartum bleeding risks as high-risk|The patients were divided into two groups according to their postpartum bleeding risks as low-risk (240 patients) and high-risk (240 patients), and then the patients in each group were randomly divided into two groups, and some of these pregnant women were given intravenous tranexamic acid and some were given placebo.
89209039|NCT02595125|Sham Comparator|Conventional technique|Intrauterine device (IUD) insertion by the conventional technique
89209040|NCT02595125|Experimental|Direct technique|Intrauterine device (IUD) insertion by the direct technique
89209041|NCT02552654|Experimental|Hydrocortisone and Stress Film|Administration of 10mg hydrocortisone before the trauma film.
89209042|NCT02552654|Experimental|Placebo and Stress Film|Administration of placebo before the trauma film.
89209043|NCT04045574|Experimental|DAMP1 :|Single arm trial comparing a conventional technique with an experimental one, within the same patient.
89209044|NCT00918359||HI|Subjects who experienced heat exhaustion or heat stroke in their past and will be identified by heat tolerance test (HTT) as Heat Intolerance .
89209045|NCT00918359||HT|Subjects who experienced heat exhaustion or heat stroke in their past and will be identified by heat tolerance test (HTT) as Heat Tolerance .
89209046|NCT00982371||Controls|female; >65 years old; BMI >25kg/m2; postmenopausal >5 yrs; NO clinical diagnosis of type 2 diabetes for >5 years (according to Canadian Diabetes Association criteria)
89571216|NCT04905043|Experimental|SmartPill® + Acalabrutinib|Participants will receive 1 SmartPill® capsule followed immediately by a single oral dose of acalabrutinib 100 mg capsule on Day 1 (Period 1) and Day 4 (Period 2). There will be 72 hours of washout between acalabrutinib dosing of each period.
89571217|NCT03050983||Phase I|Prospective observation of alarmed events on the general care floor with continuous capnography and pulse oximetry monitoring prior to enabling IPI.
89571218|NCT03050983||Phase II|Enable the Integrated Pulmonary Index (IPI) and IPI alarm for the prospective observation of alarmed events on the general care floor with continuous capnography and pulse oximetry monitoring.
89571219|NCT02436759|Experimental|RVL-1201|RVL-1201 Ophthalmic Solution 0.1% 1 drop per eye QD for 6 weeks
89571220|NCT02436759|Placebo Comparator|RVL-1201 Vehicle Placebo|RVL-1201 Ophthalmic Solution vehicle (placebo) 1 drop per eye QD for 6 weeks
89571221|NCT04888819|Experimental|fed state group|just after a meal
89571222|NCT04888819|Experimental|fasted state group|before a meal
89571223|NCT02436681|Other|MIROMESH|Single-arm study. MIROMESH will be used in the surgical repair of hiatal hernias.
89571224|NCT03052153||Lung Transplant Surgery|Subjects included in the study will have undergone a single or bilateral lung transplant surgery at The Ohio State University Wexner Medical Center between 01 JAN 2014 and 18 NOV 2016. No investigational intervention performed for this study.
89571225|NCT03051685|Experimental|DFN-15 Dose 1|
89571226|NCT03051685|Experimental|DFN-15 Dose 2|
89571227|NCT03051685|Experimental|DFN-15 Dose 3|
89571228|NCT03051685|Active Comparator|Active Comparator|
89571229|NCT04888351||Mastectomies with IBR|Every women>18 years who underwent mastectomies followed by IBR (prothesis, latissimus dorsi flap, lipofeeling, isolated or combined) for breast cancer in Hôpital de la Croix-Rousse between January 2016 and January 2020
89571230|NCT04888351||Mastectomies without IBR|Every women>18 years who underwent mastectomies for breast cancer followed by delayed reconstructions (prothesis, latissimus dorsi flap, lipofeeling, isolated or combined) or no reconstructions between January 2016 and January 2020 in Hôpital de la Croix-Rousse
89571231|NCT04904887|Other|Assessment of intermediate vision, defocus curve|"Standardized logarithm of the minimum angle of resolution (logMAR) charts were used for visual acuity measurement at 4 m, 80 cm, and 40 cm.~he binocular defocus curve: The binocular defocus curve was done to evaluate the functional range of vision. The curve was obtained while the patient wearing his distance correction to provide the best distance visual acuity in both eyes. The test was performed under photopic conditions (85 candelas/m2) using ETDRS charts at a distance of 4m with the introduction of defocusing lenses from +1.00 D to -4.00 D in 0.50 D steps."
89571232|NCT04078243||CardioMEMS HF System|Eligible patients will be recruited and will attend for the implantation in line with standard of care procedures. The patient's details will be uploaded to the CardioMEMS HF system, enabling remote monitoring of their heart failure device. The patient will also be given a Fitbit activity monitor and set up with an account that is accessible to patient and physician to allowing activity to be monitored. The research team will be able to continuously monitor data remotely from the CardioMEMS HF system and Fitbit platform.
89571233|NCT04898881|Active Comparator|Breast Milk|2 ml of Breast milk given one time, two minutes prior to the heel lance
89571234|NCT04898881|Other|24 %Sucrose|0.5 ml sucrose to be given once, two minutes prior to the heel lance
89571235|NCT04904185|Other|Part A|Six patients will be included in Part A. After inclusion 300 mL blood will be drawn from the patients for the production of the MASE-T cell product. Four days prior to MASE-T infusion the patient will receive lymphodepleting chemotherapy (cyclophosphamide 500 mg/m2/day i.v. on day -4, -3, -2 and fludarabine 30 mg/m2/day i.v. on day -4, -3) followed by i.v. infusion of the MASE-T product on day 0.
89571236|NCT04904185|Other|Part B|Six patients will be includede in Part B. After inclusion 300 mL blood will be drawn from the patients for the production of the MASE-T cell product. Four days prior to MASE-T infusion the patient will receive lymphodepleting chemotherapy (cyclophosphamide 500 mg/m2/day i.v. on day -4, -3, -2 and fludarabine 30 mg/m2/day i.v on day -4, -3) followed by i.v infusion of the MASE-T product on day 0. Pembrolizumab 2 mg/kg will be administered on day -1 and day +21.
89571237|NCT04887961|Experimental|Single Arm|PLD 30 mg/mq 1 h iv + Trabectedin 1.1 mg/mq 3 h iv d1q21 up to 6 cycles or PD.
89571238|NCT04887883||Males|10 young healthy biological males aged 18 - 30 y
89571239|NCT04887883||Females|10 young healthy biological females aged 18 - 30 y
89571240|NCT04887649|Placebo Comparator|Placebo|Patients en treatment whit placebo, salIne solution in peridural cateter
89571241|NCT04887649|Active Comparator|Morphine|Epidural Catheter morphine 2mg
89571242|NCT04887649|Active Comparator|morphine|Epidurla cateter morphine 3 mg
89571243|NCT03050437|Experimental|Pem/Cis|Pem/Cis IV every 3 weeks
89571244|NCT03050437|Active Comparator|Pem alone|Pem IV alone every 3 weeks
89571245|NCT03050593||HFpEF group|clinical or radiographic evidence of heart failure and left ventricular ejection fraction > 50% on transthoracic echocardiography
89571246|NCT03050593||HFrEF group|Clinical or radiographic evidence of heart failure and left ventricular ejection fraction < 40% on transthoracic echocardiography
89571247|NCT03050593||Healthy control group|Asymptomatic controls (age and sex-matched) without known heart disease
89571248|NCT02436135|Experimental|Cohort A, Idelalisib + Ruxolitinib|Idelalisib 50 mg once daily in participants receiving ruxolitinib.
89571249|NCT02436135|Experimental|Cohort B, Idelalisib + Ruxolitinib|Idelalisib 50 mg twice daily in participants receiving ruxolitinib.
89571250|NCT02436135|Experimental|Cohort C, Idelalisib + Ruxolitinib|Idelalisib 150 mg once daily in participants receiving ruxolitinib.
89571251|NCT02436135|Experimental|Cohort D, Idelalisib + Ruxolitinib|Idelalisib 150 mg twice daily in participants receiving ruxolitinib.
89571252|NCT04898569|Experimental|Ferinject®|
89571253|NCT04898569|Placebo Comparator|Normal saline|
89571254|NCT03050515|Experimental|Fecal Transplant|"Enrolled and screened patients will receive a donor directed fecal transplant via retention enema. This procedure will take place at the University of California Irvine Women's Health Center on the day of the participant's choosing.~The day prior to the procedure, the participant will undergo a bowel prep and stop all prophylactic antibiotics. On the day of procedure, the patient will present to the clinic and undergo a simple, retention enema. This procedure takes about 30-40 minutes to complete and does not require any anesthesia or sedation."
89571255|NCT02489799|Active Comparator|Intervention|Advance care planning video
89571256|NCT02489799|Placebo Comparator|Control|Control video - no advance care planning content
89571257|NCT04391257|Other|Main|gekoTM neuromuscular electrostimulation device (NMES) briefly used on patients with cardiac pacemakers to check if pacemakers detect the gekoTM electrical pulses as interference.
89571258|NCT04884841||Patients with postoperative complications|Patients with postoperative complications
89571259|NCT04884841||Patients without postoperative complications|Patients without postoperative complications
89571260|NCT04884529|Experimental|Chair Yoga Treatment Group|The chair-yoga session will occur for 8-weeks (60 minutes/week) on Zoom. The chair-yoga intervention will include gentle seated postures, relaxation using breathing techniques, and a mindfulness component.
89571261|NCT04884529|No Intervention|Waitlist Control Group|These participants will be on a waitlist to receive the chair yoga program after data collection has been completed (e.g., after 8-weeks).
89571262|NCT04884217|Active Comparator|Pro-ocular™|Pro-ocular™ Topical Gel
89571263|NCT04884217|Placebo Comparator|Placebo|Placebo Topical Gel
89571264|NCT03050281|Experimental|Simulation/Cadaver Workshop|2-day workshop using the Simulation/Cadaver Lab
89571265|NCT03050281|Placebo Comparator|Didactic Workshop|Lectures
89571266|NCT02435277|Experimental|Low Metformin|3 capsules BID with each capsule containing 366.7 mg L-Leucine and 41.7 mg of metformin
89571267|NCT02435277|Experimental|Mid Metformin|3 capsules BID with each capsule containing 366.7 mg L-Leucine and 83.3 mg of metformin
89571268|NCT02435277|Experimental|High Metformin|3 capsules BID with each capsule containing 366.7 mg L-Leucine and 166.7 mg of metformin
89209047|NCT00982371||Type 2 Diabetes|female; >65 years old; BMI >25kg/m2; postmenopausal >5 yrs; clinical diagnosis of type 2 diabetes for >5 years (according to Canadian Diabetes Association criteria)
89571269|NCT02435277|Active Comparator|Metformin Monotherapy|3 Capsules BID each containing 283.3 mg of metformin BID (1,700 mg/Day) at Day 14.
89571270|NCT04898335||Tendyne|all patients treated with a Tendyne Mitral Valve System
89571271|NCT02420223|Experimental|Propranolol|Patient's randomized to the Propranolol arm will be starting 7 days prior to transplant and continuing through 28 days post-transplant. Propranolol will start at 20mg twice daily and will be titrated to 40mg twice daily as tolerated. Both groups will come back to the hospital weekly in order to assess items such as patient's level of anxiety, depression, your adherence, and also to monitor for side effects. The patient's will complete questionnaires during your visit. These will take approximately 15 minutes to complete. This will continue for up to 7 total weeks for patient's on the Propranolol arm.
89571272|NCT02420223|No Intervention|Control Arm|Both groups will come back to the hospital weekly in order to assess items such as patient's level of anxiety, depression, your adherence, and also to monitor for side effects. The patient's will complete questionnaires during your visit. These will take approximately 15 minutes to complete. This will continue for 6 total weeks for patient's on the control arm.
89571273|NCT02433483|Experimental|Myeloid Malignancies|"Includes participants with AML and MDS. Participants receive chemotherapy based on diagnosis followed by infusion of donor HPC-A.~Participants with CNS disease receive weekly age-adjusted intrathecal triples therapy until the cerebrospinal fluid becomes free of leukemia (minimum of 4 doses).~Interventions:~Cycle 1: cytarabine, HPC-A donor infusion~Cycle 2: Participants who have at least a partial response to Cycle 1 are eligible to receive Cycle 2: cytarabine, HPC-A infusion"
89571274|NCT02419755|Experimental|Stratum 1: Myeloid Malignancies|Participants receive cytarabine, bortezomib, vorinostat, methotrexate, hydrocortisone, mitoxantrone as described in the Detailed Study Description.
89571275|NCT02419755|Experimental|Stratum 2: ALL and MLM|Participants in Stratum 2 [Acute Lymphoid Leukemia (ALL) and Mixed Lineage Malignancies (MLM)] receive mitoxantrone, PEG-L-Asparaginase (or Erwinia L-asparaginase), dexamethasone, bortezomib, vorinostat, cytarabine, methotrexate, hydrocortisone, mercaptopurine, and doxorubicin as described in the Detailed Study Description.
89571276|NCT04913025|Active Comparator|Standard interval|Standard of care regimen Nivolumab administered as an approximate 60-minute IV infusion, as a flat dose of 480mg once every 4 weeks OR Pembrolizumab administered as an approximate 60-minute IV infusion, as a flat dose of 400mg once every 6 weeks
89571277|NCT04913025|Experimental|Extended interval|Nivolumab administered as an approximate 60-minute IV infusion, as a flat dose of 480mg once every 8 weeks OR Pembrolizumab administered as an approximate 60-minute IV infusion, as a flat dose of 400mg once every 12 weeks
89571278|NCT02488551|Experimental|CALM Tools for Living - computer|This intervention includes the delivery of CALM via computer
89571279|NCT02488551|Active Comparator|CALM Tools for Living - manual|This intervention includes the delivery of CALM delivered manual
89571280|NCT02488239||CRT-P indicated patients|Planned to be implanted with a 3-lead CRT-P system and connected to the remote data collection through the Latitude® system
89571281|NCT02488005|Experimental|Small Bowel Ultrasound|Subjects will receive a small bowel ultrasound to measure bowel wall thickness at Week 0 and Week 14
89571282|NCT02487771|Placebo Comparator|Placebo Capsule|
89571283|NCT02487771|Experimental|DHA Capsule|
89571284|NCT01359943|Experimental|secukinumab 10 mg/kg i.v. loading|secukinumab 10mg/kg i.v. loading at Weeks 0, 2 and 4, and placebo s.c. at weeks 0, 1, 2, 3 and 4, followed by secukinumab 150mg s.c. every 4 weeks starting at Week 8
89571285|NCT01359943|Experimental|secukinumab 150 mg s.c. loading|secukinumab 150mg s.c. loading at Weeks 0, 1, 2, 3 and 4, and placebo i.v. at weeks 0, 2 and 4, followed by secukinumab 150mg s.c. every 4 weeks starting at Week 8
89571286|NCT01359943|Placebo Comparator|placebo|placebo at Weeks 0, 1, 2, 3, 4, 8 & 12, followed by secukinumab 150mg s.c. every 4 weeks starting at Week 16
89571287|NCT04898101|Experimental|Cohort 1|Participants will receive a single 100 mg oral capsule dose of acalabrutinib and at 58 minutes postdose, participants will receive a single microtracer (<10 μg; <=1 μCi) [14C]ACP-196 as a 5 mL IV push over 2 minutes.
89571288|NCT04898101|Experimental|Cohort 2|Participants will receive a single 100 mL oral solution of acalabrutinib, 1 mg/mL oral solution containing a microtracer dose (<10 μg; <=1 μCi) of [14C]ACP-196.
89571289|NCT04884451|Experimental|Intervention|Participants will receive nutritional counselling from the researcher based on Stage-Based, Nutrition Education Package for Childhood Obesity (ST-NEPCO). Nutritional advice and educational tools will be provided according to participants' stages of change.
89571290|NCT04884451|No Intervention|Control|Participants will receive counseling from dietitians based on the routine care for the management of childhood obesity.
89571291|NCT02432703|Experimental|JNJ-42165279|Participants will receive 25 milligram (mg) JNJ-42165279 orally once-daily from Day 1 up to 12 weeks.
89571292|NCT02432703|Placebo Comparator|Placebo|Participants will receive a matching placebo orally once-daily from Day 1 up to 12 weeks.
88970324|NCT04063631||1/Birth cohort|Prospective, longitudinal cohort of 1000 healthy infants. Recruited at birth and followed for 3 years. Samples to be collected at 5-10 days old, 1 and 3 years old. 100 participants with additional samples collected at 3 and 6 months of age. Approximately 300 participants to have samples collected at time of active wheezing and during convalescence.
88970325|NCT04063631||2/mild wheezers and controls|Children under 5 years old undergoing elective general surgical procedure. Some will have mild-to-moderate wheeze while others will be non-wheezing controls
88970326|NCT04063631||3/pre-school aged severe wheezers|50 children aged 1-6 years undergoing clinically indicated bronchoscopy due to recurrent wheezing.
88970327|NCT04063631||4/school aged severe asthmatics|50 kids aged 6-16 undergoing clinically indicated bronchoscopy due to asthma.
88970328|NCT04063020||Reconstructive plastic surgery procedure|Minors with ear aplasia and initiating a reconstructive plastic surgery procedure
88970329|NCT04059237|Experimental|Online Decision Aid|web-based psychosocial assessment questionnaires will be administered at baseline (T1; pre-intervention) and at one-month (T2) and three-month (T3) follow-up time points.
88970330|NCT04039204|Experimental|Elagolix|Elagolix will be dosed at the higher dose used in pelvic pain trials, 200 mg twice a day for 2 months.
88970331|NCT04039204|Active Comparator|Oral contraceptives (Ortho Cyclen)|Elagolix will be compared to a less potent standard commonly used prior to IVF or embryo transfer, namely estrogen containing birth control pills.
88970332|NCT04034706||PCOS females|Females diagnosed with PCOS with a BMI between 23 and 40 kg/m2.
88970333|NCT04034706||Non-PCOS control females|Females without PCOS with a BMI between 23 and 40 kg/m2 split into 2 groups- apple shaped and pear shaped.
88970334|NCT04014296|Experimental|High Protein Diet|Enrollment in State of Slim (SOS) weight loss program with a high protein diet.
88970335|NCT04014296|Experimental|Resistance Training|Enrollment in State of Slim (SOS) weight loss program with resistance training counseling sessions.
88970336|NCT03964792|Experimental|DREPAGLOBE drug product|The DREPAGLOBE is a genetically modified cell therapy product that consists of autologous human CD34+ hematopoietic stem and progenitor cells (HSPCs) that are enriched in CD34+ cells which have been transduced ex vivo with the lentiviral vector, GLOBE1, expressing an anti-sickling β-globin protein (AS3) containing three amino acid substitutions in the wild-type β-globin gene.
89209048|NCT00809666|No Intervention|Mercury|All subsequent blood pressure recording done using mercury sphygmomanometry
89209049|NCT00978939|Experimental|Aggressive Drainage Arm|Patients will drain up to 1 liter of pleural fluid everyday
89571293|NCT04887727|Experimental|Healthy, recreationally-active adult males - Muscle Trial|Subjects receive 0.25g/kg crystalline amino acids modelled after egg protein, enriched with L-[1-13C]leucine and L-ring-[2H5]phenylalanine with a primed-constant infusion of L-[555-2H3]leucine to assess myofibrillar protein synthesis rates
89571294|NCT04887727|Experimental|Healthy, recreationally-active adult males - Whole Body Trial|Subjects receive 0.25g/kg crystalline amino acids modelled after egg protein, enriched with L-[1-13C]leucine with a primed-constant infusion of L-[555-2H3]leucine to whole-body protein turnover, amino acid oxidation, and net protein balance
89571295|NCT04887493|Experimental|Sublingual misoprostol|Sublingual misoprostol group will receive misoprostol 25µg by sublingual routes; the dose will be given repeatedly every 4 hours by sublingual route till there is labour pain or contraction or to a maximum of 6 dosages.
89571296|NCT04887493|Experimental|Vaginal misoprostol|Vaginal misoprostol group will receive misoprostol 25µg by per vaginal routes; the dose will be given repeatedly every 4 hours by per vaginal route till there is labour pain or contraction or to a maximum of 6 dosages.
89571297|NCT04898257|Other|Lactibiane Tolerance®|30 consecutive patients with IBS-D and an increased intestinal permeability assessed by 51Cr-EDTA or 99mTc-DTPA will receive the multistrain probiotic Lactibiane Tolerance® 10 billion CFU 1 capsule twice a day (30 minutes before breakfast and 30 minutes before dinner) for 30 days treatment. At the end of treatment, patients will repeat intestinal permeability assessment by 51Cr-EDTA or 99mTc-DTPA.
89571298|NCT02486757|Experimental|Interventional|estradiol 50 mcg transdermal patch x 7 days oral micronized progesterone 0.5 mg/kg/dose TID x 7 days
89571299|NCT04887103|Experimental|hot water application|Pregnant women will apply hot water to their legs before going to sleep for a week.
89571300|NCT04887103|No Intervention|Control group|There will be no intervention other than routine follow-up and maintenance.
89571301|NCT04887181|Active Comparator|Teethmate Desensitizer|Tetracalcium phosphate and dicalcium phosphate containing desensitizer
89571302|NCT04887181|Active Comparator|Gluma Desensitizer|%35 hydroxyethyl methacrylate and %5 glutaraldehyde containing desensitizer
89571303|NCT04887181|Active Comparator|Hybrid Bond|Self-etch adhesive resin
89571304|NCT04883515|Experimental|Oral glutamine supplementation|patient will receive Oral glutamine supplementation 10 g Ter In Die during 8 weeks
89571305|NCT04883515|Active Comparator|Oral protein powder supplementation|patient will receive Oral protein powder supplementation10 g Ter In Die during 8 weeks
89571306|NCT04883593|Experimental|TA103|The assigned Investigational Product will be applied to the skin between, under, all over the toes, sole and sides of the entire foot. Both feet are to be treated in the same way, even if the skin looks healthy and lesions are present on one foot only.
89571307|NCT04883593|Placebo Comparator|Placebo Control|The assigned Investigational Product will be applied to the skin between, under, all over the toes, sole and sides of the entire foot. Both feet are to be treated in the same way, even if the skin looks healthy and lesions are present on one foot only.
89571308|NCT04883203|Active Comparator|VITD|A single vial of Cholecalciferol (1 ml) (200,000 IU / 1 m), Oral form,
89571309|NCT04883203|Placebo Comparator|Placebo|A single vial of physiological salin Oral form
89571310|NCT04897789||children/pregnant women|children/pregnant women (2,310)
89571311|NCT04897789||parents|parents (2,310)
89571312|NCT04897789||classrooms/teachers|classrooms/teachers (840)
89571313|NCT04897789||home visitors|home visitors (630)
89571314|NCT04897789||center directors|center directors (493)
89571315|NCT04897789||program directors|program directors (140)
89571316|NCT04883047|Experimental|experiment|"Women in the experimental group will be given care at the first stage of labor (will start in the latent phase) using Integrated Birth Support Strategies created in line with the Algorithm for Coping with Birth Pain.~Among the interventions made into a checklist, the interventions applied to the woman will be marked by the midwives and nurses working in the delivery room. The Scale for Coping with Birth Pain (DABS), which will be applied once in each phase (latent phase, active phase and transition phase), will guide the delivery of care; Care practices will differ depending on the woman's ability to cope with labor pain.At least 3 of each sub-heading of the physical comfort parameter, at least 1 of each sub-heading of the parameter of providing emotional comfort, at least 2 of each sub-heading of informative support and advocacy sub-parameters will be applied to pregnant women by midwives / nurses working in the delivery room."
89571317|NCT04883047|No Intervention|control|Pregnant women assigned to the control group will be followed up with the routine care applied in the delivery room.
89571318|NCT04897555|Experimental|LLLT Active Treatment|LLLT Therapy will be administered to the treatment site.
89571319|NCT04897555|No Intervention|No LLLT Comparator|No LLLT Therapy will be administered to the comparator site.
89571320|NCT04882969|Experimental|Fractionated Thulium Laser and KeraFactor|All participating subjects will serve as their own baseline control and will receive treatment of their androgenetic alopecia with LaseMD, a 1927nm Fractionated Thulium laser and post-treatment topically applied KeraFactor every 2 weeks for 12 week period.
89571321|NCT03051529||combined spinal epidural|24 patients with dilated cardiomyopathy undergoing vascular surgery in the lower half of the body under combined spinal epidural anesthesia will be enrolled in the study
89571322|NCT02418819|Experimental|PF-06412562 3mg|PF-06412562 3mg BID
89571323|NCT02418819|Experimental|PF-06412562 9mg|PF-06412562 9mg BID
89571324|NCT02418819|Experimental|PF-06412562 45mg|PF-06412562 45mg BID
89571325|NCT02418819|Placebo Comparator|Placebo|Placebo BID
89571326|NCT04886869|Experimental|Coffee|Oral consumption of 3 cups of coffee containing 240 mg caffeine
89571327|NCT04886869|Experimental|Energy drink|Oral consumption of 750 mL of a commercial energy drink containing 240 mg caffeine
89571328|NCT04886869|Placebo Comparator|Placebo|Oral consumption of 750 mL water
89571329|NCT04886947|Experimental|stem cell intervention|"Arm A patients who will have surgery with stem cell added.~Arm B only surgery with no stem cell added."
89571330|NCT04897477|Experimental|combination of Azacytidine, Bendamustine and Piamprizumab|combination of Azacytidine, Bendamustine and Piamprizumab in Refractory/Relapsed B-cell Non-Hodgkin's Lymphoma, every 28 days
89571331|NCT04886713||Obese HFpEF|Left ventricular-EF ≥ 50%, N-terminal-pro-brain natriuretic peptide (NT-proBNP) ≥ 125ng/l, evidence of structural heart diseases (diastolic dysfunction, Left ventricular-hypertrophy or Left atrial-dilatation) BMI ≥30 kg/m²
89571332|NCT04886713||Obese controls|No history of heart failure, Left ventricular-EF > 50% and NT-pro-BNP <125ng/l, BMI ≥ 30kg/m²
89571333|NCT04886713||Lean control|No history of heart failure, Left ventricular-EF > 50% and NT-pro-BNP <125ng/l, BMI < 30kg/m²
89571334|NCT04886557||DDS fixation|Adult patients with degenerative spondylolisthesis over L4-L5 received DDS with a minimum of 2-year follow-up were reviewed. Surgical indications were patients who failed to respond to conservative treatment for at least 6 months. The exclusion criteria were: (1) presence of degenerative scoliosis or spinal deformity, (2) prior spine surgery, (3) lost to follow-up, or (4) failure to complete the questionnaires or radiographic examinations.
89571335|NCT03049891||Children down-referred from DNH|This group includes children who were transferred from DNH to a study facility. The investigators will first abstract data from the electronic data system 'Tier.net' for these children, which will tell us where they were down-referred. For children who were labeled as down-referred from DNH in Tier.net, data abstraction of the child's clinical data will be conducted at the down-referral site and from the National Health Laboratory Service (NHLS) data.
89571336|NCT03049891||Children LTF from DNH|This group includes children who began ART at DNH and were subsequently LTF. The investigators will first abstract data from the electronic data system 'Tier.net', which will classify them as LTF followed by examination of the the NHLS laboratory data to determine whether these children had received care at another facility since they were LTF.
89571337|NCT03049891||Caregivers of LTF|This group includes the caregivers of a subset of children in the 'LTF from DNH' and 'down-referred from DNH' groups. Among those children down-referred and LTF from DNH, the investigators will use their clinical and laboratory data to determine whether they are still receiving care or not. For children identified as LTF based on their abstracted data will be traced in order to contact their caregivers. If located, caregivers will be interviewed to ascertain if and why these children are no longer in care through a 'Tracing questionnaire'.
89571338|NCT03049891||DNH only|This group includes children who are still in care at DNH, died while in care at DNH, or were transferred to facilities from tier.net will not have any additional information collected other than what is recorded in the Tier.net database.
89571339|NCT02576639|Placebo Comparator|Placebo|Matching placebo to CNP520 was taken once daily (qd) orally for 13 weeks.
89571340|NCT02576639|Experimental|CNP520 2 mg|CNP520 2 mg was taken qd orally for 13 weeks.
89571341|NCT02576639|Experimental|CNP520 10 mg|CNP520 10 mg was taken qd orally for 13 weeks.
89571342|NCT02576639|Experimental|CNP520 35 mg|CNP520 35 mg was taken qd orally for 13 weeks.
89571343|NCT02576639|Experimental|CNP520 85 mg|CNP520 85 mg was taken qd orally for 13 weeks.
89571344|NCT03049579|Experimental|Weiquan Yogurt with probiotics|Weiquan Yogurt with probiotics contained Lactobacillus paracasei (108 colony forming units (CFU)/ml), Lactobacillus casei 431® (108 CFU/ml) and Lactobacillus fermentum PCC® (106 CFU/ml)
89571345|NCT03049579|Placebo Comparator|Weiquan Yogurt without probiotics|Weiquan Yogurt devoid of probiotics, but otherwise similar to the experimental product.
89571346|NCT02418585|Experimental|Intranasal Esketamine plus oral antidepressant|Participants will self-administer esketamine intranasally twice per week for 4 weeks as a flexible dose regimen in the Double-Blind Induction Phase. All participants will start at a dose of 56 mg on Day 1. On Day 4, the dose may be increased to 84 mg or remain at 56 mg per investigator's discretion. On Days 8 and 11 the dose may be increased to 84 mg (from 56 mg), remain same, or be reduced to 56 mg (from 84 mg) per investigator's discretion. On Day 15, a dose reduction from 84 mg to 56 mg is permitted, if required for tolerability; no dose increase permitted. After Day 15, dose must remain stable (unchanged). In addition participants will simultaneously initiate a new, open-label oral antidepressant (duloxetine, escitalopram, sertraline, or venlafaxine extended release [XR]) on Day 1 that will be continued for the duration of Double-Blind Induction Phase.
89571347|NCT02418585|Active Comparator|Placebo plus oral antidepressant|Participants will self-administer matching placebo, intranasally, twice per week for 4 weeks as a flexible dose regimen in Double-Blind Induction Phase. In addition participants will simultaneously initiate a new, open-label oral antidepressant (ie, duloxetine, escitalopram, sertraline, or venlafaxine extended release [XR]) on Day 1 that will be continued for the duration of Double-Blind Induction Phase.
89571348|NCT04896853|Experimental|Treatment|Wharton's Jelly (WJ)-Umbilical Cord (UC) Mesenchymal Stromal Cells (ProTrans®).Study patients 1-3 will receive a single dose of 25 million cells, patients 4-6 will receive 100 million cells and patients 7-9 will receive 200 million cells.
89571349|NCT05530031|Experimental|pediatric glaucoma patients either primary or secondary|All Cases with pediatric glaucoma prepared for trabeculotomy including Primary congenital glaucoma and secondary glaucoma as : glaucoma following cataract surgery and traumatic glaucoma
89571350|NCT04897165|Experimental|Resilience training with mobile HRV-BfB based on an e-learning approach (with digital lectures)|
89571351|NCT04897165|Experimental|Resilience training with mobile HRV-BfB based on a blended learning approach (with live lectures)|
89571352|NCT04897165|No Intervention|Waitlist controls|
89571353|NCT05529875|Active Comparator|Group PRO|"Anesthesia was induced by sufentanil citrate 0.2ug/kg and propofol in TCI effect compartment concentration 4-6ug/kg.~Anesthesia was maintained with propofol in TCI effect compartment concentration 3-4ug/kg."
89571354|NCT05529875|Active Comparator|Group SEVO|"Anesthesia was induced by sufentanil citrate 0.2ug/kg and sevoflurane in the method of vital capacity with inspired-limb drug concentration measured upon 6%.~Anesthesia was then maintained with sevoflurane in vaporizer concentration 1.5-2%."
89571355|NCT03051451|Active Comparator|combination metformin hydrochloride/ fluoxetine 500/20 mg|"Dosage: The dose will depend on the period of treatment in which the patient is:~Single dose treatment (from visit 2 (from day 0 to day 30 ± 7), the patient will take 1 metformin hydrochloride tablet 500 mg / fluoxetine 20 mg and 1 placebo tablet , every 24 hours in the morning for 30 days).~Treatment at double dose (from visit 3 and until visit 8), the patient will take 2 tablets of metformin hydrochloride 500 mg / fluoxetine 20 mg and 2 tablets of Placebo, every 24 hours in the morning for 150 days)."
89571356|NCT03051451|Active Comparator|combination metformin hydrochloride/ fluoxetine 1000/20mg|"Dosage: The dose will depend on the period of treatment in which the patient is:~Single dose treatment (from visit 2 (from day 0 to day 30 ± 7), the patient will take 1 metformin hydrochloride tablet 850 mg / fluoxetine 20 mg and 1 placebo tablet , every 24 hours in the morning for 30 days).~Treatment at double dose (from visit 3 and until visit 8), the patient will take 2 tablets of metformin hydrochloride 850 mg / fluoxetine 20 mg and 2 tablets of Placebo, every 24 hours in the morning for 150 days)."
89571357|NCT03051451|Placebo Comparator|Placebo Oral Tablet|Placebo
89571358|NCT02417961|Experimental|Benralizumab 30 mg|Benralizumab administered subcutaneously every 4 weeks
89571359|NCT03049657|Active Comparator|ANGIOLITE|Compare the efficacy of Angiolite Stent versus a second-generation drug-eluting stent such as Xience stent.
89571360|NCT03049657|Active Comparator|Xience|Compare the efficacy of Angiolite Stent versus a second-generation drug-eluting stent such as Xience stent.
89571361|NCT05529719|Other|Control group|Patients assigned to the control group were given theoretical training and a brochure containing MBA information. The control group patients participating in the evaluation session were recommended to be included in the same clinical Pilates training conducted by the intervention group after the study was completed.
89571362|NCT03050047|Experimental|BCD-100 0.3 mg/kg|Patients who receive BCD-100 in a dose of 0.3 mg/kg
89571363|NCT03050047|Experimental|BCD-100 1 mg/kg|Patients who receive BCD-100 in a dose of 1 mg/kg
89209050|NCT00978939|Active Comparator|Standard Drainage Arm|Patients will drain up to 1 liter of pleural fluid every other day
89209051|NCT00809822|Active Comparator|1|Intravenous immunoglobulin
89571364|NCT03050047|Experimental|BCD-100 3 mg/kg|Patients who receive BCD-100 in a dose of 3 mg/kg
89571365|NCT03050047|Experimental|BCD-100 10 mg/kg|Patients who receive BCD-100 in a dose of 10 mg/kg
89571366|NCT04885933||COPD exacerbation|
89571367|NCT04883125|Active Comparator|Interventional no|Patients treated with both drugs ( imatinib and pioglitazone)
89571368|NCT04883125|No Intervention|Control|Historical control (treated with imatinib only)
89571369|NCT04882423|Experimental|Test meal 1 - grilled hamburger (7 oz) with no vegetables|Randomly assigned participants are given grilled hamburger (7 oz) with no vegetables
89571370|NCT04882423|Experimental|Test meal 2 - grilled hamburger with steamed broccoli and Brussels sprouts|Randomly assigned participants are given grilled hamburger with steamed broccoli and Brussels sprouts (3g/kg body weight combined)
89571371|NCT04882423|Experimental|Test meal 3 - grilled hamburger with steamed parsnips, fresh parsley, and celery sticks|Randomly assigned participants are given grilled hamburger (7 oz) with steamed parsnips, fresh parsley, and celery sticks (3g/kg body weight combined)
89571372|NCT04882423|Experimental|Test meal 4- grilled hamburger with broccoli, Brussels sprouts, parsnips, parsley and celery sticks|Randomly assigned participants are given grilled hamburger (7 oz) with steamed broccoli, Brussels sprouts, and parsnips plus fresh parsley and celery sticks (6g/kg body weight combined).
89571373|NCT05529563||obesity without AN (OB group) and obesity with AN (AN group)|LSG
88970337|NCT03909412|Experimental|Carfilzomib Mobilization - Dose Level 0|"Carfilzomib at 20mg/m2 over 10 minutes will be administered concomitantly with Cyclophosphamide 2 gm/m2, Dexamethasone 40mg and G-CSF.~For patients who are naïve to carfilzomib based therapy a priming dose of Carfilzomib (20mg/m2) will be administered 1 week prior to the cohort dosing."
88970338|NCT03909412|Experimental|Carfilzomib Mobilization - Dose Level 1|"Carfilzomib at 27mg/m2 over 10 minutes will be administered concomitantly with Cyclophosphamide 2 gm/m2, Dexamethasone 40mg and G-CSF.~For patients who are naïve to carfilzomib based therapy a priming dose of Carfilzomib (20mg/m2) will be administered 1 week prior to the cohort dosing."
88970339|NCT03909412|Experimental|Carfilzomib Mobilization - Dose Level 2|"Carfilzomib at 36mg/m2 over 30 minutes will be administered concomitantly with Cyclophosphamide 2 gm/m2, Dexamethasone 40mg and G-CSF.~For patients who are naïve to carfilzomib based therapy a priming dose of Carfilzomib (20mg/m2) will be administered 1 week prior to the cohort dosing."
88970340|NCT03909412|Experimental|Carfilzomib Mobilization - Dose Level 3|"Carfilzomib at 45mg/m2 over 30 minutes will be administered concomitantly with Cyclophosphamide 2 gm/m2, Dexamethasone 40mg and G-CSF.~For patients who are naïve to carfilzomib based therapy a priming dose of Carfilzomib (20mg/m2) will be administered 1 week prior to the cohort dosing."
89209052|NCT00809822|Placebo Comparator|2|Physiological saline
89209053|NCT04006587|Experimental|IS intervention|patients were instructed how to use the IS in a seated or semi-seated position, and to maintain sustained maximal inspiration for 3-5 seconds before exhalation, ten times per hour, and for at least eight hours a day.
89571374|NCT04882267|No Intervention|Determination of attitudes and perceived barriers to exercise|Adults with CF will take part in a quantitative modified Exercise Benefits/Barriers Scale (EB/BS) survey to identify universal and unique benefits and barriers to regular exercise activity. Subjects will be surveyed on potential ways to engage in exercise, including perceptions and prior use of smart device exercise technology. Qualitative input will be incorporated to better understand potential solutions to barriers, and develop more personalized plans for exercise engagement.
89028921|NCT05426993||Patients diagnosed with lymphedema with metabolic syndrome|"Demographic information of the patients (age, height, weight, occupation, history), comorbid diseases (hypertension, diabetes, cardiac problems, circulatory problems, thyroid dysfunction), operation date, operation type, affected extremity, type of lymphedema will be recorded. In addition to these, mental status, edema and quality of life assessments will also be made.~As a treatment, extremity volume and quality of life evaluations will be made before and after the first phase of CDT (manual lymphatic drainage, skin care, compression therapy and exercises) for 3 weeks."
89028922|NCT05426993||Patients diagnosed with lymphedema without metabolic syndrome|"Demographic information of the patients (age, height, weight, occupation, history), comorbid diseases (hypertension, diabetes, cardiac problems, circulatory problems, thyroid dysfunction), operation date, operation type, affected extremity, type of lymphedema will be recorded. In addition to these, mental status, edema and quality of life assessments will also be made.~As a treatment, extremity volume and quality of life evaluations will be made before and after the first phase of CDT (manual lymphatic drainage, skin care, compression therapy and exercises) for 3 weeks."
89028923|NCT05401565|Experimental|Balovaptan|
89028924|NCT05401565|Placebo Comparator|Placebo|
89571375|NCT04882267|No Intervention|Determination of baseline exercise activity (Baseline Period)|Adults with CF who identify as 'willing to use technology' and own compatible smart phones/tablets will undergo the Short General Health Questionnaires (GHQ 12) to establish baseline levels of general and mental health. Subjects will be fitted with wrist actigraphy and monitored for four weeks to establish baseline levels of exercise activity at home. Anticipated outcomes: Access to actigraphy will encourage personal accountability, and physical activity will increase during the first two weeks before reaching a plateau.
89028925|NCT05397106||CODMAN CERTAS Programmable Valves|CODMAN CERTAS Plus Programmable Valve, CODMAN CERTAS Plus Small Inline Programmable Valve, and CODMAN CERTAS Plus Right Angle Programmable Valve.
89028926|NCT05389670|Experimental|Continuous Theta-burst stimulation (cTBS)|Theta-burst stimulation (TBS), a form of repetitive transcranial magnetic stimulation (rTMS), affects brain areas stimulated directly underneath the scalp and brain areas that are functionally connected. Continuous TBS (cTBS) which is thought to temporarily dampen brain activity in that specific area.
89571376|NCT04882267|Experimental|Engagement in home self-directed exercise incorporating Team and Technology (Intervention Period)|"Subjects will take part in a live demonstration of three subscription-based AI-learning home exercise apps, and one self-directed exercise website designed by a CF patient partner. Subjects will be surveyed on willingness to use technology, and provide feedback on exercise options. They will be given free full access to the apps and website (Technology), and receive a phone call once a week from their CF specialty team offering encouragement and positive reinforcement (Team). App and website usage, actigraphy, EB/BS and GHQ 12 scores will be measured at the end of four weeks. Anticipated outcomes: Activity will increase significantly during the Team and Technology intervention period, barriers on the EB/BS score will decrease, and GHQ 12 scores will increase."
89571377|NCT04882267|Active Comparator|Determination of sustainability (Sustainability Period)|Phone calls will cease, but subjects will maintain access to apps, websites, and actigraphy. After four weeks, EB/BS and GHQ 12 scores, physical activity, app and website use will be reassessed. Anticipated outcomes: Activity will decrease during the sustainability period, but will remain significantly greater than the pre-intervention period. Overall GHQ 12 and EB/BS scores will improve.
89571378|NCT04430413|No Intervention|Group A|50 Participants who underwent a total excision of the pilonidal sinus and the wound remained open for secondary healing.
89571379|NCT04430413|Active Comparator|Group B|50 Participants who underwent the same operation with secondary healing intention but on postoperative days 4 and 12 the platelet rich plasma was injected to the surgical wound.
89571380|NCT04882345|Experimental|Almonertinib group|Patients meeting the criteria for inclusion and exclusion were included in the Almonertinib treatment group and received 110 mg of Almonertinib orally once a day.
89209054|NCT04006587|No Intervention|control|standard care without IS intervention
89209055|NCT00246337|Placebo Comparator|Placebo|Placebo to match assigned treatment arm; one orally-administered dose, plus an optional second dose of active drug, per assigned treatment arm, to treat a single moderate-to-severe migraine headache.
89028927|NCT05389670|Sham Comparator|Sham Theta-burst stimulation|
89028928|NCT05382598|Active Comparator|Early renal replacement therapy (RRT) group|"In this group of patients, RRT will be initiated if the patient either presents with or develops AKI, while mechanically ventilated, provided that he is in stage 2 according to KDIGO classification.~RRT will not be delayed till the presence of an urgent indication for the procedure.~A trial of furosemide stress test will be applied before proceeding towards early RRT after volume optimization."
89209056|NCT00246337|Experimental|MK0974 25 mg|MK0974 25 mg; one orally-administered dose, plus an optional second dose (placebo) to treat a single moderate-to-severe migraine headache.
89571381|NCT04882033|Experimental|Concurrent chemoradiotherapy plus anlotinib|Concurrent chemoradiotherapy plus anlotinib for 4-6 cycles This study will include a sequential evaluation of 3 subjects per dose group. Low-dose groups: anlotinib 8mg per day with concurrent chemoradiotherapy. Middle-dose groups: anlotinib 10mg per day with concurrent chemoradiotherapy. High-dose groups: anlotinib 12mg per day with concurrent chemoradiotherapy.
89571382|NCT05474183|Active Comparator|Group (K)|Group (K): (n=30) will receive ketamine infusion 1-2 μg/kg/min (0.12 mg/kg/h) titrated to desired level of sedation.
89571383|NCT05474183|Active Comparator|Group (D)|Group (D): (n=30) will receive Dexmedetomidine infusion 0.1- 0.2 μg/kg/hour titrated to desired level of sedation.
89571384|NCT05474183|Placebo Comparator|Group (C)|Group (C): (n=30) will receive fentanyl only.
89571385|NCT04885777|Active Comparator|Lidocaine group|One ml of a solution containing 20 mg/ml of lidocaine was applied to each nostril of the participants in the Lidocaine group. Thus, a total of 40 mg of lidocaine, 20 mg for each nostril, was given to the individuals of the Lidocaine group.
89571386|NCT04885777|Placebo Comparator|Placebo group|The Placebo group received only a total of 2 ml of 0.9% NaCl (one ml for each nostril).
89571387|NCT05529407|Experimental|Simple Vaginal Tampon|Dilation exercises will be performed with tampon
89571388|NCT05529407|Experimental|Glass Vaginal Dilator|Dilation exercises will be performed with vaginal dilator
89571389|NCT04885855|Experimental|8-week|Patient will be receiving treatment of tablet Sofosbuvir 400mg and tablet Ravidasvir 200mg combination once daily for the duration of 8 weeks.
89571390|NCT04885855|Active Comparator|12-week|Patient will be receiving treatment of tablet Sofosbuvir 400mg and tablet Ravidasvir 200mg combination once daily for the duration of 12 weeks.
89571391|NCT05196659|No Intervention|CONTROL Group|"Regular current system of care~Treating physicians provided current cardiovascular disease management guidelines~Patients provided a leaflet (printed information) on healthy lifestyle"
89571392|NCT05196659|Active Comparator|INTERVENTION Group|"Electronic Health Record-Decision Support Software (EHR-DSS):~Electronic patient health record storage~Management prompts to the clinical team (following algorithms)~Structured follow-up schedule with automatic reminders to patients, clinical team, and non-physician health worker~Non-physician health worker-led continuity of care:~- individually tailored follow-up and guidance regarding treatment adherence as well as help in resolving issues related to access, convenience, cost of care, and equity~Text-message based reminders for a healthy lifestyle~Patient diary containing visual assessment tool for adherence to medication (VITA) and reinforcement tool for lifestyle modification~Quarterly audit and feedback to the clinical team"
89571393|NCT04895683|Active Comparator|Arm 1 - Control SMS|Control (current practice) text message invitation
89028929|NCT05382598|Active Comparator|Late renal replacement therapy (RRT) group|"This group of patients will receive RRT if they develop any of the following indications:~Severe hyperkalemia (> 6.5 mEq/L).~Oliguria with failed response to diuretics in the presence of life-threatening pulmonary edema requiring high ventilatory settings i.e. PEEP >10 in addition to FiO2 > 50%.~Severe metabolic acidosis (PH <7.15).~Uremic pericarditis, encephalopathy or coagulopathy."
89571394|NCT04895683|Experimental|Arm 2 - Behavioural Science informed SMS content|Experimental text message invitation
89571395|NCT04895683|Experimental|Arm 3 - Pre-alert and behavioural science informed SMS content|Two text messages, including a pre-alert SMS and the text message intervention in trial arm 2.
89571396|NCT05534555|Other|Febridx|Undergo FebriDx testing
89571397|NCT05534399|Experimental|Sparing antibiotic strategy|No antibiotic therapy will be administered during the peri-operative period
89571398|NCT05534399|Sham Comparator|Peri-operative antibiotic strategy|"Recommendations - An antibiotic therapy will be administered during the peri-operative period.~The antibiotic will be selected according to the type of bacteria isolated and the antibiotic susceptibility testing, and started two days before and pursued until two days following intra-vesical BoNTA injections"
89571399|NCT03051295|Active Comparator|Diagnostic percentages.|Dentist receives diagnostic test results presented in conditional probabilities.
89571400|NCT03051295|Experimental|Diagnostic frequencies|Dentist receives diagnostic test results presented in natural frequencies.
89571401|NCT03051295|Active Comparator|Treatment percentages.|Dentist receives treatment efficacy presented in percentages.
89571402|NCT03051295|Experimental|Treatment frequencies.|Dentist receives treatment efficacy presented in natural frequencies.
89571403|NCT05529095|Experimental|Sublingual Apomorphine (Kynmobi)|Sublingual apomorphine to be titrated after initial dose of 10 mg. Titration is dependent on subjects response.
89571404|NCT05529095|Placebo Comparator|Placebo|At week 4, subjects will be given randomization packet including 2 drug doses and 2 placebos.
89571405|NCT01596127|Experimental|Intrathecal Rituximab|"Phase I Starting Dose: Rituximab administered via lumbar puncture at dose of 10 - 25 mg twice weekly according to the dose escalation.~Phase II Rituximab Starting Dose: Maximum tolerated dose from Phase I."
89571406|NCT03051373|Experimental|nab-paclitaxel plus S-1|Nanoparticle albumin-bound paclitaxel is given at 120mg/m2 intravenously over 30 minutes on day 1 and 8, in combination with S-1 which is orally administered (40-60 mg according to the body surface, Bid) on day 1-14 of each 21-days cycle. Number of cycle: 6 cycles.
89571407|NCT03051373|Active Comparator|Gemcitabine plus cisplatin|Gemcitabine is given at 1000mg/m2 combination with cisplatin 75mg/m2 intravenously on day 1 and 8 of each 21-days cycle. Number of cycle: 6 cycles.
89571408|NCT05529017||non/injured players|rink hockey players participating in senior leagues
89571409|NCT04895059|Experimental|Group A: Rosuvastatin / Ezetimibe fixed dose|In fixed dose Pharmaceutical Form: Tablets Dosage: 20 mg / 10 mg Administration way: oral
89571410|NCT04895059|Active Comparator|Group B: Rosuvastatin (Crestor®)|Pharmaceutical Form: Tablets Dosage: 20 mg Adminstration wat: Oral
89571411|NCT04895059|Active Comparator|Group C: Ezetimibe (Ezetrol®)|Pharmaceutical Form: Tablets Dosage: 10 mg Adminstration wat: Oral
89571412|NCT04391413|Experimental|OCT group|"OCT will be performed after initial coronary angiography and at the end of the procedure. Several OCT runs can be performed. The operator may change procedural strategy, and use additional interventions. The operator must evaluate the following parameters, based on OCT data:~Before angioplasty: reference diameter and reference area of distal main vessel; lesion length; presence and extent of thrombus or calcification.~Stent implantation: Stent should be sized according to distal reference diameter, and should allow for expansion to the reference diameter of the proximal main vessel.~After stent implantation: minimal and reference lumen diameter, minimal and reference lumen area, minimal stent area, presence of thrombus, presence of edge dissection, tissue protrusion, optimal lesion coverage, malapposition, suboptimal stent deployment."
89571413|NCT04391413|No Intervention|Control group|Angioplasty will be guided by traditional fluoroscopy alone, performed before and after stent implantation. The recommendation for angioplasty of left main stenosis is to use main vessel (MV) stenting with a proximal optimisation technique (POT) and provisional side branch (SB) stenting as a preferred approach. Predilatation of the side branch (SB) may be considered, but is recommended in the following circumstances: extensive ostial SB involvement, heavy calcification, etc. even with a provisional SB stenting approach.
89571414|NCT05467475|Experimental|esomeprazole + BI 1819479 (Test (T))/ BI 1819479 (Reference (R))|
89571415|NCT05467475|Experimental|BI 1819479 (R)/ esomeprazole + BI 1819479 (T)|
89571416|NCT05528705|Experimental|LAENNEC|4ml once a week for 3 weeks of Subacromial spatial administration + conservative treatment
89571417|NCT05528705|Active Comparator|0.9% Normal saline|4ml once a week for 3 weeks of Subacromial spatial administration + conservative treatment
89571418|NCT04430491||Training dataset|No interventions
89571419|NCT04430491||Validation dataset|No interventions
89571420|NCT05534165|Experimental|Tecovirimat|Tecovirimat (TPOXX®) Capsules, 200 mg (as tecovirimat monohydrate) administered as 600 mg (three 200 mg capsules) taken twice daily orally, every 12 hours, within 30 minutes after a full meal of moderate or high fat (approximately 25 g of fat) for 14 days
89571421|NCT05534165|Placebo Comparator|Placebo|Identical placebo supplied by SIGA Technologies Inc.
89571422|NCT04885387|Other|Standard protocol using chest CT|
89571423|NCT04885387|Experimental|Magnetic Resonance Imaging and a low-cost portable three-dimensional scanning device|
89028930|NCT05365672|Experimental|MIC with low immunosuppression|"Patients in MIC Arm A receive the investigational medicinal product MIC plus immunosuppression consisting of tacrolimus, mycophenolic acid derivative and corticosteroids (without IL-2 receptor antibody induction therapy).~Tacrolimus dose will be gradually reduced to 4-8 μg/L at Day 183 and the corticosteroid treatment will be stopped at Day 92 after gradual dose reduction."
89028931|NCT05365672|Experimental|MIC with minimal immunosuppression|"Patients in MIC Arm B receive the investigational medicinal product MIC plus immunosuppression consisting of tacrolimus, mycophenolic acid derivative and corticosteroids (without IL-2 receptor antibody induction therapy).~Tacrolimus dose will be gradually reduced to 4-8 μg/L at Day 183 and the corticosteroid treatment will be stopped at Day 92 after gradual dose reduction.~The mycophenolic acid derivative will be stopped between Days 141 and 182."
89209057|NCT00246337|Experimental|MK0974 50 mg|MK0974 50 mg; one orally-administered dose, plus an optional second dose (placebo) to treat a single moderate-to-severe migraine headache.
89571424|NCT04885309|Active Comparator|Obturator Nerve Block + Spinal Anaesthesia|Patients who underwent obturator nerve block with spinal anesthesia prior to TURBT
89571425|NCT04885309|Sham Comparator|Spinal Anaesthesia|Patients who underwent spinal anesthesia prior to TURBT
89571426|NCT04880941|Experimental|Progressive Relaxation Exercise|The Progressive Relaxation Exercise will be held 7 days for 4 weeks, a total of twenty eight sessions. Each session is set as fifty minutes
89571427|NCT04880941|No Intervention|Control group|Routine maintenance will be applied
89571428|NCT04880551||COPD patients with a recent Spirometry|Patients that have a diagnosis of COPD and have completed a recent Pulmonary Function Test - Spirometry.
89571429|NCT05528627|Other|Pectoral Nerve (PECS) block|Pectoral Nerve (PECs) block was performed at the surgical side 30 min before the procedure
89571430|NCT04880005|Experimental|The intervention group|The three core elements of the intervention are: 1) individualized data-driven recommendations to GPs on how to treat each individual T2D patient, as well as 2) individualized digital coaching of T2D patients, and 3) on-line presentation of patient registered outcomes (PRO) to GPs.
89571431|NCT04880005|No Intervention|Control group|Usual care
89571432|NCT05377697|Experimental|Dry lavender flower scent|Participants in the experimental group will be informed about the effects of lavender scent on sleep and lavender sachets will be given. They will be informed that they should put these lavender sachets in their pillows every day and sleep with a lavender sachet for the next month, and that they should not make any changes in their rooms or beds other than the lavender sachet.
89571433|NCT05377697|No Intervention|Control group|Participants in the control group will not receive any intervention.
89571434|NCT05528393||GDM and Non-GDM|
89571435|NCT05528393||Pregnant group and non-pregnant group|
89571436|NCT01595581|Experimental|Testosterone|Weekly injection of testosterone enanthate 200mg
89571437|NCT01595581|Placebo Comparator|Placebo|Weekly injection of saline as the placebo
89571438|NCT05534009||Heath care workers (HCW)|Adult (>18 years) HCW with mandatory information on their SARS-CoV-2 infection and vaccination status. For those with a history of SARS-CoV-2 infection, diagnosis obtained by detection of SARS-CoV-2 RNA
89571439|NCT03050125|Experimental|Hypo-osmolar drop 1|Subject will receive regular instillations of hypo-osmolar sterile saline drops with the lowest osmolarity of the two hypo-osmolar drops.
89571440|NCT03050125|Experimental|Hypo-osmolar drop 2|Subject will receive regular instillations of hypo-osmolar sterile saline drops with the highest osmolarity of the two hypo-osmolar drops.
89571441|NCT03050125|Experimental|Iso-osmolar drop|Subject will receive regular instillations of sterile iso-osmolar saline drops.
89571442|NCT03048955|Active Comparator|Indirect Decompression System|Superion® IDS surgical procedure
89571443|NCT03048955|Active Comparator|Direct decompression Surgery|Open, direct decompression surgical procedure
89571444|NCT04885153|Experimental|Intervention Group|Subjects who were given simvastatin 10 mg and fenofibrate 200 mg.
89571445|NCT04885153|Placebo Comparator|Control Group|Subjects who were given simvastatin 10 mg and placebo (lactic acid) 200 mg.
89571446|NCT03048643|No Intervention|Standard of Care|Subjects will receive medication-assisted treatment for opioid use disorder and will complete IV antibiotic therapy for infective endocarditis according to usual care.
89571447|NCT03048643|Experimental|Outpatient Parenteral Antibiotic Therapy|Subjects will receive medication-assisted treatment for opioid use disorder and will complete IV antibiotic therapy via outpatient parenteral antibiotic therapy (OPAT).
89571448|NCT04884997|Active Comparator|Arm A|toripalimab 3mg/kg, Q2w;
89571449|NCT04884997|Experimental|Arm B|toripalimab 3mg/kg, Q2w; Temozolomide 150mg/m2,d1-5,Q4w
88970341|NCT03909412|Experimental|Carfilzomib Mobilization - Dose Level 4|"Carfilzomib at 56mg/m2 over 30 minutes will be administered concomitantly with Cyclophosphamide 2 gm/m2, Dexamethasone 40mg and G-CSF.~For patients who are naïve to carfilzomib based therapy a priming dose of Carfilzomib (20mg/m2) will be administered 1 week prior to the cohort dosing."
88970342|NCT03909412|Experimental|Carfilzomib Mobilization - Dose Level 5|"Carfilzomib at 70mg/m2 over 30 minutes will be administered concomitantly with Cyclophosphamide 2 gm/m2, Dexamethasone 40mg and G-CSF.~For patients who are naïve to carfilzomib based therapy a priming dose of Carfilzomib (20mg/m2) will be administered 1 week prior to the cohort dosing."
88970343|NCT03905434||Control|A total of 15 healthy controls will be enrolled and miRNA samples will be collected
88970344|NCT03905434||Stroke|A total of 30 acute stroke patients with large vessel occlusions will be enrolled.
89571450|NCT01774643||Pancreatic cancer with liver metastases|Tumor tissue biopsy, blood samples
89571451|NCT03048721|Experimental|Psoriasis|Participants with psoriasis will undergo both skin tape stripping and punch biopsy.
89571452|NCT03048721|Experimental|Control|Participants without psoriasis will undergo both skin tape stripping and punch biopsy.
89571453|NCT04879771||Morning GIE|
89571454|NCT04879771||Afternoon GIE|
89571455|NCT03048565|No Intervention|Usual care|No intervention
89571456|NCT03048565|Experimental|Mindfulness based Stress Reduction|This is an active intervention The MBSR programme is delivered online with weekly telephone and email contact from a trained mindfulness teacher. Participants are encouraged to practice mindfulness exercises and homework between sessions. The online programme was developed be a trained mindfulness teacher.
89571457|NCT04879693|Experimental|Hospitalized Patients|To assess performance of CGM compared to comparator measurement.
89571458|NCT04885075|Other|Intravenous Diazepam|Intravenous diazepam (0.2mg/kg/dose) single dose stat
89571459|NCT04885075|Other|Intranasal Midazolam|Intranasal midazolam (0.2mg/kg/dose) single dose stat
89571460|NCT01610687|Experimental|GW-1000-02|Active treatment
89571461|NCT04884919|Placebo Comparator|Regular Gauze Treatment|Participants who undergo a cesarean section are first dissected in about 5 cm length and 2 cm width and receive a regular gauze made of traditional cotton yarn. The regular gauze is applied on the half side of the wound.
89571462|NCT04884919|Experimental|Chitosan Dressing Treatment|Participants who undergo a cesarean section are first dissected in about 5 cm length and 2 cm width and receive a chitosan dressing made of chitosan material. The chitosan dressing is applied on another half side of the wound.
89571463|NCT04879303|Experimental|Robot-assisted social skill intervention|Social robotics will be used by the instructor to conduct the social skill training activities.
89571464|NCT04879303|Active Comparator|Human-only instruction program on social skill training|The children will receive only the human-delivered social skill training.
89571465|NCT04879303|No Intervention|Control|There will be no intervention conducted during the tested period
89571466|NCT05533931|Experimental|Resistive Breathing Training group|The patients performed two sessions each of 15 minutes session of resistive breathing for four days a week for six weeks using an inspiratory resistive device. Ask patient to take long slow inspirations while breathing through the resistive device
89571467|NCT05533931|Active Comparator|inspiratory hold technique|With the patient in a comfortable position such as side lying or reclined, the therapist may assist the patient by placing both hands on abdominal area to provide proprioceptive feedback. Then in a relaxed tone of voice therapist instructs the patient to sniff quickly through the nose three times with slow, relaxed exhalations
88970345|NCT03889834|Experimental|Autotransfusion: blood stored at 4 ° C|Intervention: Autologous Blood Transfusion of packed red blood cells (200 ml) stored at 4 ° C for 31 days
88970346|NCT03889834|Experimental|Autotransfusion: blood stored at -80°C|Intervention: Autologous Blood Transfusion of packed red blood cells (200 ml) stored at -80°C for 31 days
88970347|NCT03889834|Other|Controls not transfused|no transfusion
89571468|NCT04879381||Cystic Fibrosis patients|Sputum samples
89571469|NCT05528237|Experimental|HPV self-sampling|Participants will be offered self-collection kits for HPV-based cervical cancer screening.
89571470|NCT05533853|Active Comparator|Traditional exercise|The exercise group will receive a posture corrective exercise program in the form of two strengthening(deep cervical flexors and shoulder retractors)and two stretching (cervical extensors and pectoral muscles) exercises. The exercise program will be done according to Harman et al.'s protocol and based on Kendall et al.'s approach.
89571471|NCT05533853|Experimental|Denneroll extension traction|Denneroll extension traction. Participants in the intervention group will receive the Denneroll cervical orthotic . In the current study, Denneroll cervical traction will be used to restore the normal cervical alignment. . We will follow previously published protocols and procedures for application of this orthotic. The Denneroll orthotic will be performed in the physiotherapy clinic setting. The participants will be instructed to lie supine on the floor, in a straightened position, with their arms gently folded across their stomach.
89571472|NCT03048409||Enteral tube fed adults|Enteral formula
88970348|NCT03876054||Spinal cord stimulation (SCS)|Subjects using Abbott SCS systems
88970349|NCT03876054||Dorsal root ganglion stimulation (DRG)|Subjects using Abbott DRG system
88970350|NCT03875287|Experimental|Decitabine and Cedazuridine|Treatment will be administered on an outpatient basis. Cycle length is 28 days. The dose of cedazuridine is fixed at 100mg and the dose and duration of decitabine will vary depending on when a patient enters the study.
88970351|NCT03870529|Experimental|Vitamin A compound|Participants receive vitamin A compound PO for 7 consecutive days in the absence of disease progression or unacceptable toxicity. Within 21 days of completing treatment, participants then undergo surgical resection.
88970352|NCT03870529|Active Comparator|Therapeutic Conventional Surgery|Description Participants undergo surgical resection.
88970353|NCT03867981|Experimental|Internet weight loss + possibility of brief phone coaching|Participants randomized to this group will receive a 4-month, Internet-delivered weight loss program followed by an 8-month, Internet-delivered weight loss maintenance program. All individuals will be taught behavioral strategies for changing diet and physical activity behaviors via video lessons. Some participants in this group will also be selected to receive a brief period (i.e., once/week for 3 weeks) of phone coaching starting at week 5. The first coaching call will be approximately 45 minutes in duration and remaining calls with be 10-15 minutes. Coaches will problem solve with participants and help them develop an individualized meal plan.
88970354|NCT03867981|Experimental|Internet weight loss + possibility of extended phone coaching|Participants randomized to this group will receive a 4-month, Internet-delivered weight loss program followed by an 8-month, Internet-delivered weight loss maintenance program. All individuals will be taught behavioral strategies for changing diet and physical activity behaviors via video lessons. Some participants in this group will also be selected to receive an extended period (i.e., once/week for 12 weeks) of phone coaching starting at week 5. The first coaching call will be approximately 45 minutes in duration and remaining calls with be 10-15 minutes. Coaches will problem solve with participants and help them develop an individualized meal plan.
88970355|NCT03867981|Active Comparator|Internet weight loss only|Participants randomized to this group will receive a 4-month, Internet-delivered weight loss program followed by an 8-month, Internet-delivered weight loss maintenance program. All individuals will be taught behavioral strategies for changing diet and physical activity behaviors via video lessons. No participants in this group will receive any phone coaching.
88970356|NCT03865212|Experimental|Group A (VSV-IFNbetaTYRP1)|Patients receive recombinant vesicular stomatitis virus-expressing interferon-beta and tyrosinase related protein 1 IT and IV over 30-60 minutes 2-4 hours later on day 1.
88970357|NCT03865212|Experimental|Group B (VSV-IFNbetaTYRP1)|Patients receive recombinant vesicular stomatitis virus-expressing interferon-beta and tyrosinase related protein 1 IT and IV over 30-60 minutes 2-4 hours later on day 1. Cycle 1 continues for 28 days, with subsequent cycles repeating every 21 days in the absence of disease progression or unacceptable toxicity.
88970358|NCT03858569|Active Comparator|Oxytocin|10 units of oxytocin will be given intramuscularly immediately after delivery of the fetus
88970359|NCT03858569|Active Comparator|Oxytocin plus uterine massage|10 units of oxytocin will be given intramuscularly immediately after delivery of the fetus and transabdominal uterine massage will be performed.
88970360|NCT03856710|Active Comparator|Group 1 (Self-gripping Mesh),|The initial laparoscopic approach will be the same for both groups until the process of selection and placement of the mesh , which would be decided by randomization by sealed envelope. This group will receive self-gripping mesh
88970361|NCT03856710|Active Comparator|Group 2 (Stapled Mesh)|The initial laparoscopic approach will be the same for both groups until the process of selection and placement of the mesh , which would be decided by randomization by sealed envelope. This group will receive stapled mesh
88970362|NCT03854318||Family|Direct family members of enrolled patients will be asked to enroll in the study to provide specimens for genetic testing, next-generation sequencing, and other related studies.
89571473|NCT05528081||Persons with migraine disease|Persons diagnosed with migraine based on the third edition of the International Classification of Headache Disorders (ICHD-3) and underwent baseline 3-tesla MRI
89571474|NCT05528081||Persons with medication-overuse headache|Persons diagnosed with MOH based on the ICHD-3 and underwent baseline 3-tesla MRI
89571475|NCT05528081||Healthy controls|Healthy individuals with no history of primary or secondary headache based on the ICHD-3 and underwent baseline 3-tesla MRI
89571476|NCT04879147||Syncope|Subjects admitted immediately after syncopation.
89571477|NCT04879147||Seizre|Subject admitted immediately after cerebarl seizure
89571478|NCT04879069||Intermediate-high risk PE|Confirmed PE causing right ventricle dysfunction confirmed by computed tomography pulmonary angiography or transthoracic echocardiography and elevated troponin level
89571479|NCT04879069||High-risk PE|"Confirmed PE causing hemodynamic instability:~Cardiac arrest (need for cardiopulmonary resuscitation) or,~Obstructive shock (systolic blood pressure < 90 mmHg or vasopressors required to achieve a systolic blood pressure ≥90 mmHg despite adequate filling status and end-organ hypoperfusion), or~Persistent hypotension (systolic blood pressure < 90 mmHg for at least 15 minutes)"
89571480|NCT04878835|No Intervention|Control group|No intervention was given. No intralesional ranibizumab (Lucentis; Genentech, Inc, San Francisco, California, USA 0.5mg/ 0.05mL) was given at 2 weeks prior to pterygium excision surgery
89571481|NCT04878835|Experimental|Intervention group|The interventional group was given intralesional ranibizumab (Lucentis; Genentech, Inc, San Francisco, California, USA 0.5mg/ 0.05mL) 2 weeks prior to pterygium excision surgery
88970363|NCT03854318||RUNX1|Patients enrolled in this protocol will have been referred with a known or suspected RUNX1 mutation.
88970364|NCT03835416|Experimental|WL-Control|0.8 g protein per kg body weight. Seven servings of whey protein powder (15 g/serving) per week will be provided to participants to support diet affordability.
88970365|NCT03835416|Experimental|WL-Protein|>30 g of high quality protein per meal, 1.2 g protein/kg body weight/day. Fourteen servings of high quality (30 g/serving) protein (lean meats, low fat dairy products) provided to participants each week to increase compliance.
88970366|NCT03820843|Experimental|Art therapy|Art therapy and standard orthophonic rehabilitation
88970367|NCT03820843|No Intervention|Control group|Only standard orthophonic rehabilitation
88970368|NCT03816644|Experimental|5-Cog|The 5-Cog coupled with a decision tree is a simple, 5-minute procedure that will identify older persons with cognitive impairment in primary care settings, and flag them for further evaluation. The 5-Cog includes the Picture Memory Impairment Screen (PMIS), Motoric Cognitive Risk syndrome (MCR), and the Symbol Match test. The 5-Cog will be given after randomization and before the patients sees the physician. The 5-Cog will sort patients with 'cognitive impairment' from those with 'no cognitive impairment'. After completing the 5-Cog, the non-physician tester will send a message through the Electronic medical record (EMR) system to provide the physician with the 5-Cog results and guide the them through the follow-up based on the results.
88970369|NCT03816644|Active Comparator|Health Literacy & Grip Assessment|The 5 minute assessment includes the Short Assessment of Health Literacy (SAHL) and a grip assessment measured using a handgrip dynamometer. After completing the SAHL and grip assessment, the non-physician tester will send a message through the EMR to provide the physician with the results from the assessments and guide the them through the follow-up based on the results.
88970370|NCT03815344|Active Comparator|Standard|Use of laparoscopic injection of diluted vasopressin (20units in 100mL 0.9NS) prior to incision throughout the myomectomy.
88970371|NCT03815344|Experimental|Standard-Vaginal Misoprostol|Use of laparoscopic injection of diluted vasopressin (20units in 100mL 0.9NS) prior to incision throughout the myomectomy. 400mcg of misoprostol placed in the vagina at HUMI/foley placement .
88970372|NCT03812614|Experimental|FAM-ACT|"Patient and Support Person (dyad) will be included together as much as possible. The dyad will:~Take part in a one-hour introductory session and review of the patient's Diabetes Complications Risk Assessment profile.~Be invited to 4-6 Support Person-focused, group diabetes self-management education (DSME) sessions lasting 1-2 ½ hours each.~Receive case management contacts with a Community Health Worker (CHW) once every 2-4 weeks, subject to participant availability. Successful contacts will last approximately 20 minutes."
88970373|NCT03812614|Active Comparator|I-DSMES|"This arm will focus on the patient only. The Support Person assigned to this arm will not be invited to the introduction sessions, care management contacts, or diabetes self-management education sessions. Patients assigned to this arm will:~Take part in a one-hour introductory session and review of patient's diabetes management risk assessment.~Be invited to 4-6 group diabetes self-management education (DSME) sessions lasting 45 min to 2 hours each.~Receive case management contacts with a Community Health Worker (CHW) once every 2-4 weeks, subject to participant availability. Successful contacts will last approximately 20 minutes."
88970374|NCT03803969|Other|ConfirmRx (Insertable Cardiac Monitor)|This is a single arm study where in patients with an approved indication for a cardiac monitor will receive a ConfirmRx Device.
88970375|NCT03773562|Other|Erenumab|All participants receive erenumab 140mg by subcutaneous injection at baseline and again 4 weeks later.
88970376|NCT03769714|Active Comparator|Saline Solution for Injection|Group A (control, n=26) to receive 20ml of saline while prepping. The syringe will covered as to disguise the contents of the syringe.
89571482|NCT05528003||Handmade single-access port device|The homemade single-access device was composed of a wound protector, sterile surgical glove, and three trocars inserted into and secured over three digits of the glove
89571483|NCT05528003||Commercialized single-access port devices|Commercialized single-access port devices including GelPOINT® (Applied Medical, Rancho Santa Margarita, CA, USA) and LAGIPORT® (LAGIS, Taichung, Taiwan)
89571484|NCT03049423||the trial group|30 patients with ankle ligament and tendon injury were selected in accordance with the diagnostic criteria of ankle ligament and tendon injury in the trial group. Each participant was required to undergo MRI scans in normal position and during complete plantar flexion and complete dorsiflexion.
89571485|NCT03049423||the control group|30 patients with normal ankle joint were selected in accordance with the diagnostic criteria of ankle ligament and tendon injury in the control group. Each participant was required to undergo MRI scans and general physical examination in normal position and during complete plantar flexion and complete dorsiflexion.
89571486|NCT04878523|Placebo Comparator|Placebo drink|
89571487|NCT04878523|Experimental|multi berries juice|
89571488|NCT05527925||Congenital cataracts children (0~3 years)|Children with congenital cataracts between the ages of 0 and 3 years
89571489|NCT05527925||Normal children (0~3 years)|Children without congenital cataracts between the ages of 0 and 3 years
89571490|NCT05527925||Congenital cataracts children (6~18 years)|Children with congenital cataracts between the ages of 6 and 18 years
89571491|NCT05527925||Normal children (6~18 years)|Children without congenital cataracts between the ages of 6 and 18 years
89571492|NCT04872283|Active Comparator|Ketorolac administration|Participants who have surgery for great toe (1st metatarsophalangeal joint) fusion will receive 30 mg of IV ketorolac during surgery as well as 20 mg ketorolac pills to take after surgery for pain
89571493|NCT04872283|Active Comparator|No Ketorolac administration|Participants who have surgery for great toe (1st metatarsophalangeal joint) fusion will receive the standard treatment of 30 tablets of oxycodone-acetaminophen to take as needed for pain
89571494|NCT05182385|Experimental|hematological relapse|"Diagnosis of Ph-negative, CD19-positive B-precursor acute lymphoblastic leukemia according to WHO classification:~Refractory BCP-ALL to primary induction therapy, including at least three cycles of standard chemotherapy~Untreated first relapse of BCP-ALL with first remission duration < 12 months or~Second or greater relapse of BCP-ALL or refractory relapse or~Relapse of BCP-ALL any time after allogeneic HSCT"
89571495|NCT05182385|Experimental|molecular relapse|"Diagnosis of Ph-negative, CD19-positive B-precursor acute lymphoblastic leukemia according to WHO classification:~-Positivity of MRD marker of immunoglobulin/T-cell receptor gene rearrangements of greater than 0.01% if in first or second remission of BCP-ALL"
89571496|NCT04871581|Active Comparator|Device|Subjects receiving the FDA-cleared device
89571497|NCT04871581|Placebo Comparator|Placebo|Subjects receiving the sham device
89571498|NCT04871347|Experimental|Dose Escalation Cohort|Three dose levels of TWP-101 will be tested by a conventional 3 + 3 study design.
89571499|NCT04871347|Experimental|Dose Expansion Cohort|Once the effective dose has been determined, an expansion cohort will be opened to evaluate the efficacy and safety of the selected dose.
89571500|NCT04589533||EDUCATIONAL PROGRAM GROUP|This group will receive an educational program based . This group, as the other group, during phase 1 and phase 3, will review the medical records of the last 40 patients (for each phase) with known T2DM and hospitalized for any cause.
89571501|NCT04589533||CONTROL GROUP|Control group will not receive educational program. This group, as the other group, during phase 1 and phase 3, will review the medical records of the last 40 patients (for each phase) with known T2DM and hospitalized for any cause.
88970377|NCT03769714|Experimental|Exparel|Group B (study, n=26) to receive 20ml of liposomal bupivacaine (EXPAREL) into the stroma of the cervix at the 4 and 8 o'clock positions (innervation insertion points of the cervix).
89209058|NCT00246337|Experimental|MK0974 100 mg|MK0974 100 mg; one orally-administered dose, plus an optional second dose (placebo) to treat a single moderate-to-severe migraine headache.
89571502|NCT05524805|Experimental|BTL-785-7 Treatment|Treatment with the BTL-785-7 applicator to the BTL-785F system.
88970378|NCT03759847|Experimental|Vanguard|Participants in this arm will use the fluid intake app and take a survey to test the fluid intake monitoring app for both safety and design issues.
88970379|NCT03754218|Experimental|Amnion membrane product treatment area|The prepared amnion membrane powder will be directly applied to the prepared donor wound site (Site A). The wound will then be covered with the SOC dressing.
88970380|NCT03754218|Active Comparator|SOC Wound Covering treatment area|The donor wound site (Site B) will be covered per SOC (Standard of care).
88970381|NCT03750331|Active Comparator|traditional patient follow-up|a group of renal transplant outpatients consulting their Transplant Centre following a traditional schedule (every other week up to 6 months post-transplant, once a month up to year 1, every three months up to year 2 and every 6 months thereafter)
89571503|NCT04466761|Experimental|Experimental: Cohort 1-4|60% of subjects per cohort will consume 30-90 grams of dietary supplement daily for 4 weeks, with each successive cohort dosage increasing according to a Fibonacci dose escalation.
89571504|NCT04466761|Placebo Comparator|Placebo: Cohort 1-4|40% of subjects per cohort will consume 30-90 grams of daily placebo for 4 weeks with each successive cohort dosage increasing in parallel to the experimental arm.
89571505|NCT04425083||Polycystic Ovary Syndrome|Polycystic Ovary Syndrome women
89571506|NCT04425083||control|non- Polycystic Ovary Syndrome women
89571507|NCT05527613|Experimental|Conventional bracket bonding with instructions by WhatsApp|will receive the WhatsApp application, through which oral hygiene reminders will be sent through images and videos with the necessary information, and at the same time they will receive verbal oral hygiene instructions
89571508|NCT05527613|Active Comparator|Conventional bracket bonding without instructions by whatsapp|receive verbal instructions on oral hygiene
89571509|NCT04878133|Experimental|Exsperimental Arm|
89571510|NCT04878133|No Intervention|Control Arm|
89571511|NCT05527535||AI screening group|Diabetes mellitus patients undergo diabetic retinopathy screening by AI
89571512|NCT05527535||Manual screening group|Diabetes mellitus patients undergo diabetic retinopathy screening by health care personnel
89571513|NCT05533385|Experimental|Extract J. oxycedrus + extract C. arizonica + positive control + negative control|"There is only one treatment arm. In each subject, one drop of each of the 3 concentrations of each allergenic extract (2 extracts) will be applied in addition to the positive control (histamine 10 mg/mL) and the negative control, with prick test.~Juniperus oxycedrus: 300, 60 and 12 µg/mL Cupressus arizonica: 100, 20 and 4 µg/mL"
89571514|NCT04389073|Experimental|Arm 1 (PD-1+NVB)|"The treatments received are:~Vinorelbine (40 mg/day, tiw, per os)~Toripalimab (240 mg every 3 weeks, intravenously [IV])."
89571515|NCT04389073|Experimental|Arm 2 (PD-1+NVB+Bev)|"The treatments received are:~Vinorelbine (40 mg/day, tiw, per os)~Toripalimab (240 mg every 3 weeks, intravenously [IV])~Bevacizumab (5 mg/kg every 3 weeks, intravenously [IV])."
89571516|NCT04389073|Experimental|Arm 3 (PD-1+NVB+DDP)|"Vinorelbine (40 mg/day, tiw, per os)~Toripalimab (240 mg every 3 weeks, intravenously [IV])~Cisplatin (50mg/m2 every 3 weeks, intravenously [IV])."
89571517|NCT04389073|Experimental|Arm 4 (PD-1+VEX)|"Vinorelbine (40 mg/day, tiw, per os)~Toripalimab (240 mg every 3 weeks, intravenously [IV])~Cyclophosphamide (50 mg/day, qd, per os)~Capecitabine (500 mg, tid, per os)"
89571518|NCT04389073|Active Comparator|Arm 5 (NVB)|• Vinorelbine (40 mg/day, tiw, per os)
89571519|NCT05175443|Experimental|Exercise Intervention|"Wall Angels:Stretching tight anterior shoulder musculature Participants will assume this position and slide their arms up and down the wall for 2 minutes.~Cervical Spine Mobility: will be accomplished by having the participant stabilize their shoulders and side bend their head in various positions to stretch each side of their next for 2 minutes with 10-15 second holds in each position.~Posterior shoulder strengthening: will be performed with shoulder externally rotating and squeezing the scapular with 5 second holds for 2 minutes.~Thoracic Spinal mobility: to improve thoracic extension participants will use a strap or tennis ball and perform thoracic extension with 10 second holds for 2 minutes."
89571520|NCT04371445|Experimental|Intracanalicular dexamethasone insert group|This arm will receive the DEXTENZA® insert within minutes after the completion of the surgery.
89571521|NCT04371445|Active Comparator|Topical steroid drop group|This arm will receive the prescription for daily prednisolone acetate 1% eye drops 4 times a day for the first week following the procedure, starting on the day of surgery.
89571522|NCT05524337|Experimental|White noise group|"In the white noise group, it will be explained to the mother of the baby that the white noise sound to be used in the research will be used for pain relief. Dr. Harvery Karp's song The Happiest Baby, consisting of intrauterine sounds only, will be used for white noise. The sound will be set to 45 db. The loudspeaker will be placed on the tip of the foot, approximately 30 cm from the newborns ear, five minutes before the procedure, and will be played to the baby during the procedure. 5 minutes without taking heel blood. Before, during the procedure and 5 minutes after the end of the procedure, this sound will be played to the baby and the data will be recorded by the observer."
89571523|NCT05524337|Experimental|therapeutic touch group|"Therapeutic touch steps:~Before the application, explaining the study and the intervention to be applied to the mother, obtaining the consent of the mother to participate in the study, and filling the introductory information form will be done at this stage.~Immobile touching: Hands will be washed and warmed so that they do not disturb the baby. The researcher will support the babys back and hips with one hand, while holding the baby's chest and abdomen with the other hand. In the meantime, the nurse who will take the heel blood will start the process and continue to touch.~Compassionate touch: While the practitioners hands are in the same position; He would caress for 1 minute, rest his hands for 30 seconds, then caress again for 1 minute, rest his hands for 30 seconds, and finally continued to caress for 2 minutes. The caressing process was completed by touching it with circular movements of 1 cm diameter in a clockwise direction every 10 seconds."
89571524|NCT05524337|Experimental|therapeutic touch and white noise group|the group where therapeutic touch and white noise will be applied together, after the family is informed about the procedure, white noise will be listened to 5 minutes before, during and 5 minutes after the heel blood collection, and therapeutic touch steps will be applied during this time. Meanwhile, the data will be recorded on the form by the observer.
89571525|NCT05524337|No Intervention|Control group|Non-pharmacological intervention will not be made for the baby in the control group,
89571526|NCT04230577|Active Comparator|Real LED Intervention|Participants receive 15 Real (active) LED treatments with the Vielight Neuro Alpha head frame device (with intranasal). Parameters: NIR, 810nm, pulsed at 10 Hz, 50% duty cycle, synchronized for a 20-minute treatment time. Total Energy Dose per head set plus intranasal: 225 J/cm2+ 15 J/cm2 = 240 J/cm2 per 20 min LED treatment. Total Energy Dose delivered (3x/Week, 5 Weeks) = 3600 J/cm2. The light from these LEDs is not visible to the eye. There is no potential for eye damage because the LEDs are not laser light. The head frame device falls within the FDA category General Wellness, low-risk devices, and no medical claims are made. It is approved for use by the VA Boston Healthcare System Safety Committee and Institutional Review Board.
89571527|NCT04230577|Sham Comparator|Sham LED Intervention|Participants receive a series of 15 Sham (control) LED treatments with the Vielight Neuro Alpha head frame device (with intranasal) containing Sham LEDs, synchronized for a 20-minute treatment time (3x/Week, 5 Weeks). Sham and Real devices are identical in look and feel, except no photons are emitted from the Sham devices.
89571528|NCT05533307||nulliparous women with normal birth (not needed mediolateral episitomy)/1|group without mediolateral episiotomy
89571529|NCT05533307||nulliparous women with normal birth (with mediaolateral episiotomy)/2|group with mediolateral episiotomy
89571530|NCT03049267|Experimental|Apremilast|N=15
89571531|NCT03049267|Placebo Comparator|Placebo Oral Tablet|N=5
89571532|NCT02615509|Other|Imaging on experimental tomo device|"Women will have a bilateral two-view mammogram (a total of four images) with the Philips MicroDose Tomosynthesis system and a bilateral two-view mammogram (a total of four images) with an FFDM system. The order of this will be randomised.~After collecting the cases together with ground truth a readers study will be performed."
89571533|NCT05524259|Active Comparator|Myo-inositol and routinely recommended folic acid|Myo-inositol is a naturally occurring substance, with a structure quite similar to glucose, which forms an essential component of the cell membrane and is known to support several cellular processes in all living organisms. It is present in nature in high abundance and can be found in many food products. Myo-inositol was historically considered part of the vitamin-B complex and can safely be used as a dietary supplement. In humans, it is synthesized de novo from glucose-6-phosphate in many tissues, mainly in the kidney. Under normal circumstances, the kidneys produce large quantities of myo-inositol, estimated at about 4 grams of endogenous production per day. Myo-inositol has been shown to have a physiological role in supporting the effects of insulin in all living beings. It fulfils a second messenger role in the insulin signalling pathway by enhancing the translocation of GLUT-4 receptors on the plasma membrane and thereby facilitates the intra-cellular uptake of glucose.
89571534|NCT05524259|Placebo Comparator|Routinely recommended folic acid|Folic acid supplements are part of routine pregnancy care and frequently used as background supplements in previous trials on myo-inositol supplementation in pregnancy.
89571535|NCT03047317|Experimental|MABp1|
89571536|NCT05533151|Experimental|Bronchial asthma|This group envolves parients suffering from bronchial asthma.
89571537|NCT05533151|Experimental|Interstitial lung diseases|This group envolves parients suffering from interstitial lung disease.
89571538|NCT05533151|Experimental|Lung transplantation|This group envolves parients after lung transplantation done for a pulmonary disease.
89571539|NCT04112095|Experimental|Use Phase Norgestrel 0.075 mg|Norgestrel 0.075 mg tablets to be taken orally, one tablet daily at the same time every day for up to 24 weeks
89571540|NCT05257993|Experimental|Arm A (mFOLFIRINOX)|JPI-547 and Combination Chemotherapy(mFOLFIRINOX) The study is conducted in a 3+3 dose escalation method.
89571541|NCT05257993|Experimental|Arm B (GemAbraxane)|JPI-547 and Combination Chemotherapy (Gemcitabine-nab-paclitaxel) The study is conducted in a 3+3 dose escalation method.
89571542|NCT05533073|Experimental|Group A: Etoricoxib/Tramadol FDC|Pharmaceutical Form: Sachet with granules to dilute in 100 mL of water Formula: Each sachet contains Etoricoxib 90 mg / Tramadol 50 mg Dosage: 100 mL Administration way: oral
89571543|NCT05533073|Active Comparator|Group B: Etoricoxib|Pharmaceutical Form: Tablet Formula: Tablet containing Etoricoxib 90 mg Dosage: 1 tablet of 90 mg Administration way: oral
89571544|NCT05533073|Active Comparator|Group C: Tramadol|Pharmaceutical Form: Capsule Formula: Each capsule contains 50mg of Tramadol Dosage:1 capsule of 50 mg Administration way: oral
89571545|NCT04050553|Experimental|Tirzepatide|Tirzepatide administered subcutaneously (SC) in one of two study periods.
89571546|NCT04050553|Placebo Comparator|Placebo|Placebo administered SC in one of two study periods.
89571547|NCT03946891|Experimental|Arm A|
89571548|NCT03946891|Experimental|Arm B|
89571549|NCT05524103|Experimental|ALMB-0166|Two-thirds of patients will be randomized to receive a single dose of ALMB-0166 within 72 hours after spinal cord injury.
89571550|NCT05524103|Placebo Comparator|Placebo|One-third of patients will be randomized to receive a single dose of placebo within 72 hours after spinal cord injury.
89571551|NCT05257915||Perampanel|Epilepsy patients who had failed clinical treatment with 1-3 anti-epileptic drugs (AEDs) with the optimal dose and course of treatment and needed perampanel additional treatment.
89571552|NCT05257837|Experimental|Gun safety vid x Movie clip - guns present|Participants in this condition will view a gun safety video featuring The Ohio State University Chief of Police about a week before coming into the lab. In the lab, they will watch a ~20 minute clip of either The Rocketeer or National Treasure featuring guns.
88970382|NCT03750331|Experimental|medically-tailored follow-up with Ap'Telecare|a group of patients assisted by Ap'Telecare and consulting their Transplant Centre following a less stringent schedule of consultations (every month up to 6 months, every other month up to year 1, every six months up to year 2 and once a year thereafter).
89571553|NCT05257837|Active Comparator|Gun safety vid x Movie clip - guns absent|Participants in this condition will view a gun safety video featuring The Ohio State University Chief of Police about a week before coming into the lab. In the lab, they will watch a ~20 minute clip of either The Rocketeer or National Treasure with the guns edited out.
89571554|NCT05257837|Active Comparator|Seatbelt safety video x Movie clip - guns present|Participants in this condition will view a seatbelt safety video about a week before coming into the lab. In the lab, they will watch a ~20 minute clip of either The Rocketeer or National Treasure featuring guns.
89571555|NCT05257837|Active Comparator|Seatbelt safety video x Movie clip - guns absent|Participants in this condition will view a seatbelt safety video about a week before coming into the lab. In the lab, they will watch a ~20 minute clip of either The Rocketeer or National Treasure featuring guns.
89571556|NCT04870723|Experimental|Immediate|Behavioral: Motivational interviewing (MI)-based peer counseling: MI-based peer counseling will comprise of 3 weekly 1-hour sessions administered online addressing 1) Covid-19 knowledge; 2) Assessing risk for infection and understanding and practicing public health-recommended protective behaviors (masking, physical distancing, handwashing); and 3) Understanding psychosocial issues and maintaining mental wellness.
88970383|NCT03706456|Experimental|Darvadstrocel 24 mL|Darvadstrocel (Cx601) 24 mL suspension of 120 million cells of expanded allogeneic adipose-derived stem cells (eASC) as an intralesional injection, once on Day 1.
88970384|NCT03701048|Active Comparator|reappoximation of rectus muscle|During Cesarean Section rectus muscle will be reapproximated with interrupted sutures.
88970385|NCT03701048|Active Comparator|no reappoximation of rectus muscle|During Cesarean Section rectus muscle will not be closed.
88970386|NCT03698162|Experimental|Cohort I (STAR DCE-MRI)|Participants with recurrent high-grade glioma undergo STAR DCE-MRI every 2 months, and just prior to and 4-6 weeks after starting bevacizumab treatment. Participants may undergo more frequent MRI if there is concern for tumor progression.
89209059|NCT00246337|Experimental|MK0974 200 mg|MK0974 200 mg; one orally-administered dose, plus an optional second dose (placebo) to treat a single moderate-to-severe migraine headache.
89571557|NCT04870723|Other|Waitlist|"Behavioral: Motivational interviewing (MI)-based peer counseling: After the immediate group completes the intervention, the waitlist group will receive the intervention.~MI-based peer counseling will comprise of 3 weekly 1-hour sessions administered online addressing 1) Covid-19 knowledge; 2) Assessing risk for infection and understanding and practicing public health-recommended protective behaviors (masking, physical distancing, handwashing); and 3) Understanding psychosocial issues and maintaining mental wellness."
89571558|NCT04870879|Experimental|Study arm|Liver transplant
89571559|NCT04870879|Other|Parallel arm|Chemotherapy
89571560|NCT03849625||NSAID sensitivity|Patients diagnosed with an immediate reaction to aspirin/NSAIDs/or paracetamol
89571561|NCT03046693|Experimental|Group A|Subjects in group A get citicoline 1000 mg per day for 60 days
89571562|NCT03046693|Placebo Comparator|Group B|Subjects in group B get placebo for 60 days.
89571563|NCT05257369|Experimental|1.Blue-Green LED wide band phototherapy|"For experimental group was used Malysh phototherapeutic device (Luzar ltd, Belarus); it includes of eighteen blue- green super bright LEDs (12 blue (λmax 476 ) and 6 green (505 nm)."
89571564|NCT05257369|Active Comparator|2.Blue LED narrow band phototherapy|For control group was used blue LED BILI-THERAPY (Atom Medical Inc., Tokyo, Japan) in high-mode which have a 20 μW/cm2 with peak wavelength between (λmax 480 nm).
89571565|NCT04632329|Experimental|Negative Pressure|
89571566|NCT04632329|No Intervention|Control Eye|
89571567|NCT03327493|Other|Refractory cardiogenic shock under ECLS|
89571568|NCT05523791|Experimental|WPS|Patients continued their standard therapy, received a standard protein redistribution dietary regimen plus a whey protein-based oral formula twice a day
89571569|NCT05523791|Active Comparator|Mg|Patients continued their standard therapy, received a standard protein redistribution dietary regimen plus 2.250g of magnesium pidolate twice a day
89571570|NCT03049345|Experimental|Sentinel Node Sampling Arm|The day before surgery, 2mL of endoscopically-placed technetium 99m sulfur colloid solution will be injected submucosally at 4 points around the tumour. At the time of surgery, 2cc of 1% isosulfan blue dye will be similarly injected. Laparoscopically, the gastrocolic ligament will be opened to expose all gastric lymph node drainage basins. Using visual inspection and a laparoscopic gamma probe, blue nodes and those emitting 10x greater than background activity will be considered sentinel nodes and extracted. Patients will then under regular gastric cancer resection with D2 lymphadenectomy as per routine in our institution.
89571571|NCT02575079|Experimental|Parafilm|Pediatric patients undergoing hematopoietic stem cell transplant (HCT) with central venous catheters (CVCs) will have pre-cut, single-use sections of parafilm applied over the CVC hub (if not connected) or around the CVC hub connection (if connected). Parafilm will be maintained on the CVC and routine CVC care will be continued, per institutional standard of practice, until the CVC is removed.
89571572|NCT02575079|No Intervention|Historical Cohort|Pediatric patients receiving hematopoietic cell transplantation in the 16 months preceding the study intervention. Data were obtained retrospectively through medical records for the purpose of comparing CLABSI rates among recipients of parafilm to a control group.
89571573|NCT05526911|Active Comparator|Group 1|The pharmacokinetics of midazolam, a CYP3A4 substrate, and digoxin, a P-gp substrate, will be studied before and after dosing with TBAJ-876.
89571574|NCT05526911|Active Comparator|Group 2|The pharmacokinetics of antiretroviral regimen TLD will be studied before and after dosing with TBAJ-876.
89571575|NCT03046771|Experimental|Transport PLUS group|EMTs randomized to the Transport Plus group will view a 60-minute training video and then complete a 60-minute simulation training exercise on how to conduct the home fall hazard assessment (FHA) and the discharge comprehension assessment (DCA) and how to complete the FHA and DCA checklists. The FHA involves performing a visual assessment of the home environment and noting certain fall hazards. The DCA involves engaging the patient or caregiver in a conversation to assess their level of understanding of the elements of the discharge instructions. The Transport Plus EMTs will offer to perform the FHA and DCA for all transports of patients aged 65 or older, who are being transported from The Mount Sinai Hospital to a private residence
89571576|NCT03046771|No Intervention|Routine Care|Providers randomized to routine care will not be trained on the FHA or DCA or the completion of the checklists. All EMTs in both groups (Transport Plus and standard education), will be asked to answer some demographic questions and will be trained to collect responses to 3questions commonly used to assess a patient's risk of falling and to collect best contact information for phone follow up from patients or their caregivers and to obtain permission for a follow-up phone call from research personnel.
89571577|NCT03048175|Experimental|Cases: wisdom tooth pathology|Subjects affected by bilateral wisdom tooth pathology, undergoing surgical removal
89571578|NCT03048175|No Intervention|Controls: no wisdom tooth pathology|Subjects showing agenesia/previous extraction/no symptoms of the lower third molars.
89571579|NCT04870489|Active Comparator|Isotretinoin + Co2 ablative laser|Isotretinoin treatment while being treated with CO2 laser
89571580|NCT04870489|Active Comparator|Co2 ablative laser|6 months to 1 year without isotretinoin treatments to start second side of face with CO2 ablative laser only
89571581|NCT05526677||dynamic navigation group or static guide group|"Every patient has 2 missing in one jaw The missing tooth will be restored with one-visit single implant immediate loading.~One implant placed is assisted with dynamic navigation system, and the other one is assisted with static surgical guide."
89571582|NCT05523245||complete response|Patients receiving neoadjuvant therapy achieved pathological complete response before LARC.
89571583|NCT05523245||non complete response|Patients receiving neoadjuvant therapy did not achieve pathological complete response before LARC.
89571584|NCT05532761||diffuse lare B cells lymphoma|Diffuse large B cells lymphoma patients eligibles for CAR-T cells therapy
89571585|NCT04301453|Experimental|Maternal Scent Group|Infants in this group will be exposed to a breast pad worn by their mothers to extract maternal scent. This exposure will last 24 hours.
89571586|NCT04301453|No Intervention|Control Group|Infants in this group will receive standard of care.
89571587|NCT02614183|Experimental|Galcanezumab 120mg|Galcanezumab given by subcutaneous (SC) injection at 120mg dose once a month for 6 months. Participants received a loading dose of 240mg (2 injections of 120mg each) was administered at visit 3 only.
89571588|NCT02614183|Experimental|Galcanezumab 240mg|Galcanezumab 240mg given by SC injection once a month for 6 months.
89571589|NCT02614183|Placebo Comparator|Placebo|Placebo given by SC injection once a month for 6 months.
88970387|NCT03698162|Experimental|Cohort II (STAR DCE-MRI)|Participants with melanoma brain metastases undergo STAR DCE-MRI at baseline and 4-6 weeks after therapy. Participants may undergo more frequent MRI if there is concern for tumor progression.
88970388|NCT03667014|Experimental|Dupilumab treatment|30 subjects will receive dupilumab for a treatment period of 52 weeks. All patients quality of life measures will be assessed with Psychological General Well-Being scale (PGWB), Work Productivity and Activity Impairment scale (WPAI), and Dermatology Life Quality Index (DLQI). Symptom and satisfaction will be assessed with Treatment Satisfaction Questionnaire for Medication (TSQM), Itch Numerical Rating Scale, Pain Numerical Rating Scale, and Pittsburgh Sleep Quality Assessment (PSQI).
88970389|NCT03659448|Active Comparator|Treatment|"Patients will receive a single dose of the study drug, SGM-101, and subsequently undergo surgical resections under both standard white light conditions and then NIR."
88970390|NCT03659448|No Intervention|No Treatment|"Patients will not be administered the study drug, SGM-101, and will undergo surgical resections under standard :white light conditions only."
88970391|NCT03657641|Experimental|Treatment (pembrolizumab, regorafenib)|Participants receive pembrolizumab IV over 30 minutes on day 1 and regorafenib PO QD on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
88970392|NCT03651518|Experimental|Kineret|
88970393|NCT03651518|Experimental|Humira|
88970394|NCT03651518|Experimental|Stelara|
89571590|NCT05523011|Experimental|Exosome Ointment|The subjects will apply exosome ointment along with Vesiderm liposome cream (TID per day, 20 days). Each day (from Day 1 to 20), the study product will be applied with a gap of 4 hours between three doses to a healthy area (one hand area) on the forearm using 1 fingertip unit (FTU). The Vesiderm liposome cream is meant to keep the application site moisturized.
89571591|NCT05522933|Experimental|Musculoskeletal Health|The intervention group will receive the 4 weekly workshops
89571592|NCT05526209||1 with using longitudinal relaxing incision|using longitudinal relaxing incision as a technique for recurrence prevention in ventral hernia
89571593|NCT05526209||2 without using longitudinal relaxing incision|without using longitudinal relaxing incision as a technique for recurrence prevention in ventral hernia
89571594|NCT04870567|Active Comparator|High dose rate brachytherapy|After spinal anesthesia steel or plastic needle placement performed under TRUS guidance. Pre- and post-insertion ultrasound based planning is obligatory in all cases. Two fractions of 13Gy are delivered with 2 separate implantations and 2-3 weeks interval. The CTV was defined as the prostate capsule with 1mm (low-risk) - 3 mm (intermediate risk) expansion plus proximal 1/3 of seminal vesicles. The PTV was equal to CTV. The rectum, bladder and urethra are contoured as organs at risk. The dosimetry plan objectives are the following: prostate D90 - above 104% and V100% - above 92%; urethra D10 < 110% , rectum D2cc<75% (below 75Gy EQD2).
89571595|NCT04870567|Experimental|Stereotactic ablative radiotherapy|"Before SBRT three fiducial markers are obligatory inserted into the prostate.Planning MRI on diagnostic table with subsequent fusing with simulation CT is obligatory. CTV to planning target volume (PTV) expansion was 3-5 mm in all direction except posteriorly (in the direction of the rectum) where it is 1-3 mm. Dose must be delivered as 5 fraction of 7.25Gy. V100% for PTV ≥ 95%. Main dose constraints are as follows: D 2cm³ ≤ 36Gy for rectum (below 75Gy EQD2)., V 37.5 Gy <5 cm³ for bladder, V 20 Gy <10 cm³ for femoral heads. Androgen deprivation therapy is not permitted.~All treatments must be performed on conventional linear accelerators with cone beam CT guidance before each fraction, intrafractional motion monitoring is optional."
89571596|NCT05526131|Active Comparator|Patients with type 2 Diabetes Mellitus and depression|This arm includes patients with type 2 diabetes mellitus that were diagnosed with depression using structured clinical interview for DSM-IV Axis disorder (SCID-I) and Hamilton Depression Rating Scale (HAM-D) for diagnosing depression and exclusion of other psychiatric disorders.
89571597|NCT05526131|Active Comparator|Patients with type 2 Diabetes Mellitus and no depression|This arm includes patients with type 2 diabetes mellitus where depression was ruled out using structured clinical interview for DSM-IV Axis disorder (SCID-I) and Hamilton Depression Rating Scale (HAM-D) for diagnosing depression and exclusion of other psychiatric disorders.
89571598|NCT05256433|Experimental|IASTM|
89571599|NCT05256433|Active Comparator|Transverse friction massage|
89571600|NCT05522621|Experimental|TJAOA102|Once enrolled, participants will be administrated TJAOA102 and followed by a 3-month medication cycle. The usage of this herbal compound is to take orally twice a day(two sacks per). Add it to about 200ml warm water and take it half an hour before breakfast in the morning and half an hour before bedtime in the evening except menstrual period.
89571601|NCT05256043||Target Population|Adult patients age ≥ 18 admitted to the Stamford Hospital ICU between 9/14/11 and 11/30/19 with HbA1c available on admission and at least 4 blood glucose (BG) tests during ICU stay. Two groups were created; patients with previously undiagnosed diabetes (NDDM) compared to those with known diabetes (KDM) at the time of admission to the intensive care unit (ICU).
89571602|NCT05532527|Experimental|Study group|Microwave ablation combined with Camrelizumab and chemotherapy
89571603|NCT05231941|Experimental|Lidocaine Group|After induction of anaesthesia, a bolus of 2mg/kg intravenous lidocaine will be given followed by Lidocaine infusion at the rate of 1.5 mg/kg/hour which will be stopped at the end of surgery.
89571604|NCT05231941|Experimental|TAP group|After completion of procedure and before extubation, bilateral ultrasound guided subcoastal transversus abdominis plane (TAP) block will be performed by the primary anaesthetist. After taking aseptic measures, with patient in supine position a high frequency (6-13 MHz) linear ultrasound probe will be placed obliquely just inferior to the costal margin over the anterior abdominal wall. With the help of a 21G or 22G, 100 mm needle, 20 ml of 0.375% Ropivacaine will be injected between rectus sheath and fascia of transversus abdominis muscle, bilaterally.
89571605|NCT05231941|No Intervention|Control group|No additional intervention will be given to this group
89209060|NCT00246337|Experimental|MK0974 300 mg|MK0974 300 mg; one orally-administered dose, plus an optional second dose (placebo) to treat a single moderate-to-severe migraine headache.
89209061|NCT00246337|Experimental|MK0974 400 mg|MK0974 400 mg; one orally-administered dose plus an optional second dose (placebo) to treat a single moderate-to-severe migraine headache.
89571606|NCT05217745|Experimental|Treatment|MLCT oil (provided through ready to eat meals and snacks)
89571607|NCT05217745|Placebo Comparator|Control|Corn oil (provided through ready to eat meals and snacks)
89571608|NCT05216575||Almitrine treated patients|Administration of Almitrine in spontaneoulsy breathing COVID-19 patients with moderate to severe ARDS treated by high-flow nasal canula oxygen therapy as first-line ventilatory support with persitent severe hypoxemia after awake prone positioning.
89571609|NCT05522543|Experimental|Conventional treatment with manual segmental lumber traction|"Patient education (Postural correction, lifting, sitting and sleeping positions) • Hot Pack 10 mins~• Manual lumbar Traction (L1-L5) for 15-20 sec x5 sets • Lumbar facet gapping (LFG) in side lying (10 sec 3 sets) and Lumbar rotational facet gapping (LRFG) in side lying (10 sec 3 sets) • .Core stability exercises (Knee to chest, bridges, prone press ups, cat and camel stretches) • Home plan"
89571610|NCT05522543|Active Comparator|Conventional treatment with passive translatoric intervertebral glides|"Patient education (Postural correction, lifting, sitting and sleeping positions) • Hot Pack 10 mins~• PA Glides (Central and Transverse mobilizations) (10 sec each) x5 sets • Core stabilization exercise (Knee to chest, bridges, prone press ups, cat and camel stretches) • Home plan (bridges, knee to chest, cat and camel stretch and prone press ups"
89571611|NCT05522387|Experimental|Experimental: 1.0 mg/kg XPro1595|Patients will receive XPro1595.
89571612|NCT05532449|No Intervention|control|
89571613|NCT05532449|Experimental|Dezocine|intravenous dezocine (0.03mg/kg diluted to 5 ml)
89571614|NCT05532371|Experimental|Aerobic exercise training combined with lower limb strengthening group (AG)|Aerobic exercise training combined with lower limb strengthening.
89571615|NCT05532371|Experimental|Dual-task training combined with lower limb strengthening group (DG)|Dual-task training combined with lower limb strengthening.
89571616|NCT05532371|Experimental|Aerobic exercise training combined with dual-task training and lower limb strengthening group (ADG)|Aerobic exercise training combined with dual-task training and lower limb strengthening.
89571617|NCT05532371|Active Comparator|Only lower limb strengthening group (CG)|Only lower limb strengthening.
89571618|NCT02352103|Active Comparator|Control arm|Vattikuti Urology Institute radical prostatectomy da Vinci Surgical System
89571619|NCT02352103|Experimental|Treatment arm|Retzius sparing radical prostatectomy da Vinci Surgical System
89571620|NCT05146037|Active Comparator|Saline flushing|TAVI valves will be prepared according to instruction for use(IFU) with saline flushing only.
89571621|NCT05146037|Experimental|CO2 and saline flushing|TAVI valves will be flushed with CO2 and then saline as per IFU
89571622|NCT04870021|Experimental|Intervention Arm|"After birth, one cc of intravenous blood was drawn from the peripheral veins of healthy newborn. The blood was immediately centrifuged, and serum was put in a plastic container, labeled with a unique identification number. The serum containers were frozen and then sent using a cold chain container, to Pakistan Medical Research Council laboratory at Jinnah Postgraduate Medical Center Karachi. The serum was tested for anti-hepatitis B surface antigen antibody on Enzyme Immunoassay (EIA) kit DS-EIA-Anti-HBsAg, manufactured by DSI S.r.I (Italy).~After obtaining a blood sample, infants born to mothers in the intervention group were administered GSK's ® recombinant hepatitis B vaccine ENGERIX 10 micrograms (µ gm), intramuscular in the anterolateral part of either of thighs. This birth dose of hepatitis B was followed by zero dose oral polio vaccine as per hospital policy. Infants born to mother in the control group were given oral polio vaccine as per the hospital policy."
89571623|NCT04870021|Other|Control Arm|"In this arm of the study, after birth, one cc of intravenous blood was drawn from the peripheral veins of healthy newborn. The blood was immediately centrifuged, and serum was put in a plastic container, labeled with a unique identification number. The serum containers were frozen and then sent using a cold chain container, to Pakistan Medical Research Council laboratory at Jinnah Postgraduate Medical Center Karachi. The serum was tested for anti-hepatitis B surface antigen antibody on Enzyme Immunoassay (EIA) kit DS-EIA-Anti-HBsAg, manufactured by DSI S.r.I (Italy).~After obtaining a blood sample, infants born to mothers in the control group were given oral polio vaccine as per the hospital policy. Subsequent vaccinations were administered as per the expanded program on immunization schedule in Pakistan."
89571624|NCT04144387|Experimental|Test group|Each patient included in the study will be followed for 5 years
89571625|NCT05525897|Experimental|Life skills course|Participants will take part in the psychoeducational course
89571626|NCT05525897|No Intervention|Waitlist|
89571627|NCT04877509||Over 50 year's COVID-19 patients hospitalized at HCL from 1st March to 29th May 2020.|
89571628|NCT05525819|Experimental|Control group|Cases will be subjected to spinal anesthesia with hyperbaric bupivacaine 10 mg.
89571629|NCT05525819|Experimental|Intrathecal group|Cases will be subjected to the same anesthetic mixture as controls with adding dexmedetomidine 5 μg.
89571630|NCT05525819|Experimental|Intravenous group|Cases will receive hyperbaric bupivacaine (10 mg), in addition to IV dexmedetomidine (1 μg/kg loading dose, followed by 0.4 μg/kg/h maintenance dose).
89571631|NCT03044743|Experimental|PD-1 knockout EBV-CTL|"Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) gene will be knocked out by CRISP-Cas9 system and EBV-CTL will be generated in the laboratory (PD-1 Knockout EBV-CTL).~Fludarabine at 30mg/m2 and Cyclophosphamide at 300mg/m2 single dose will be administered 3 days i.v. before cell infusion.~A total of 2 x 10^7/kg PD-1 Knockout CTL will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third.~Interleukin-2 (IL-2) will be given daily( iv) since the first day of the cell infusion for 5 consecutive days, 4000,000 international unit（IU）/day . Patients will receive a total of four cycles of treatment."
89571632|NCT05532293|Experimental|MSP008-22|"MSP008-22 is a New Chemical Entity (NCE) that has demonstrated positive outcomes during in vitro and in vivo studies for COVID19.~Formulated as tablets intended for oral dosing to trial participants."
89571633|NCT05532293|Placebo Comparator|Placebo|placebo will be identical in smell, taste, and appearance to the tablets of MSP008-22
89571634|NCT03044665|Active Comparator|High-intensity statin monotherapy|Statin monotherapy
88970395|NCT03651518|Experimental|Cosentyx|
88970396|NCT03651518|Experimental|Roactemra|
88970397|NCT03651518|Experimental|Rituximab|
88970398|NCT03650725||Mandatory Split bowel preparation|Patients will be advised to take 4 liters of polyethylene glycol (PEG), split into two 2 liter doses. The first 2 liters are to be taken starting at 1800 hours the day before the colonoscopy, and the second dose is to be taken starting 4-5 hours prior to the scheduled time for the colonoscopy. Each dose will be taken within a 2-hour time span.
89571635|NCT03044665|Experimental|Statin plus ezetimibe combination therapy|Statin plus ezetimibe combination therapy
89571636|NCT03046537|Active Comparator|ovulatory|Comparison in metabolic state between ovulatory and PCOS women by collecting breath test from participant.
89571637|NCT03046537|Active Comparator|PCOS|Comparison in metabolic state between ovulatory and PCOS women by collecting breath test from participant
89571638|NCT03046615||EEG Electrode Patch|The additional electrodes are modified EEG electrodes (used in clinical practice on the head already) placed in a silicone molding. These are placed lateral to the eye with the patient asleep. These are then wired to the same recording apparatus that is commonly used for recording.
88970399|NCT03650725||Optional Split bowel preparation|Patients will be advised on split-dose bowel preparation (as per option 1), but will also receive instructions on day before bowel preparation. The instructions will indicate that split-dose bowel preparation is the optimal preparation for cleansing the bowel and for visualizing polyps, but they may choose day before bowel preparation if the split dose preparation is too difficult for them.
88970400|NCT03636243|Other|Group of obese patients with type-2 diabetes|
88970401|NCT03636243|Other|Group of non-diabetic obese patients|
89209062|NCT00246337|Experimental|MK0974 600 mg|MK0974 600 mg; one orally-administered dose plus an optional second dose (placebo) to treat a single moderate-to-severe migraine headache.
89571639|NCT03046615||Standard Needles|The current solution to monitor eye movement during surgery is to place standard needles in the muscles surrounding the eye.
89571640|NCT04877353|Experimental|Group N|50 patients.NIV applied for approximately 30 to 45 min at 2- to 4-h intervals for 48 h following surgery
89571641|NCT04877353|No Intervention|group C|50 patients recieved conventional oxygen therpy.
89571642|NCT05521841|Experimental|Erector Spinae Plane Block|Bilateral Ultrasound Guided Erector Spinae Plane Block
89571643|NCT05521841|Active Comparator|Transversus abdominis plane block|Bilateral Ultrasound-guided bilateral Transversus abdominis plane block
89571644|NCT05525351||NI-VATS (Non-intubated video-assisted thoracoscopic surgery)|"This is a purely observational study of the routine anesthetic practice involving the simultaneous use of three drugs. Types of surgery (non-intubated video-assisted thoracoscopic surgery or video-assisted thoracoscopic surgery) are discussed and decided totally by patients and surgeons independently.~NI-VATS: induction and maintenance are achieved by propofol, alfentanil and dexmedetomidine. Patients are monitored with standard monitors (electrocardiography, Non-invasive blood pressure, and pulse oximetry), arterial blood pressure (ABP) and bispectral index (BIS) or Patient State Index (PSI) monitor. Patients are observed in the recovery unit with designate nursing staff until full conscious recovery before discharge."
89571645|NCT05525351||VATS (video-assisted thoracoscopic surgery)|"This is a purely observational study of the routine anesthetic practice involving the simultaneous use of three drugs. Types of surgery (non-intubated video-assisted thoracoscopic surgery or video-assisted thoracoscopic surgery) are discussed and decided totally by patients and surgeons independently.~NI-VATS: induction and maintenance are achieved by propofol, alfentanil and dexmedetomidine. Patients are monitored with standard monitors (electrocardiography, Non-invasive blood pressure, and pulse oximetry), arterial blood pressure (ABP) and bispectral index (BIS) or Patient State Index (PSI) monitor. Patients are observed in the recovery unit with designate nursing staff until full conscious recovery before discharge."
89571646|NCT04869865|Experimental|Intervention|Detoxification cleanse
89571647|NCT04869475|Experimental|Experimental|arsenic trioxide 7mg/m2 ivgtt d1-14, q3w
89571648|NCT05521763|Experimental|Intervention package with the availability of vaccine supply only|"The investigators will work with the supplier to make that vaccine available at the hospital premises. Then a vaccination booth will be set up at the hospital premises and will administer the vaccine at the MRP.~All HCWs will be notified about only vaccine availability information by the hospital director and respective heads.~A list of all staff working in the study hospitals will be prepared, and they will be provided with an influenza vaccination record card with a unique identification number. The study staff will ensure receipt of vaccination cards for all participants.~A short message (SMS) will be delivered over the mobile phone number to all participants, e.g. vaccination program duration, venue, time, vaccine price, to cascade vaccination information to participants.~Posters with only vaccine delivery information (i.e. vaccination duration, vaccination venue, vaccine price) will be displayed at key hospital locations."
89571649|NCT05521763|Experimental|Intervention package with vaccinationation awareness only|"The hospital director and respective heads will notify all HCWs about participating in the vaccination awareness program facilitated by the study team.~The investigators will arrange separate seminars for each group of HCWs in the hospital to sensitize participants about the significance of receiving the influenza vaccine and the risk and benefits of influenza vaccination.~Posters containing messages on the importance of influenza vaccination will be displayed at key hospital locations, e.g., the main entrance of the hospital, nursing station, vaccine delivery point/place, doctors' room, nurses' room, intern doctors' room, common room canteen etc."
89571650|NCT05521763|Experimental|Intervention package with a combination of vaccine availability and awareness|"The investigators will work with the study hospital authority, Influenza vaccine manufacturer, and supplier company to set up a vaccination booth at the hospital premises to administer the vaccine at the market-rated price (MRP) by hospital nurses.~The hospital director and respective department heads will notify all HCWs to receive the offered influenza vaccine.~A list of all staff working in the study hospitals will be prepared, and they will be provided with an influenza vaccination record card with a unique identification number.~The investigators will arrange separate seminars for each group of HCWs in the hospital to sensitize participants about the significance of receiving the influenza vaccine and the risk and benefits of influenza vaccination.~A short message (SMS) will be delivered over the mobile phone number to all participants.~Posters with key messages will be displayed at key hospital locations,"
88970402|NCT03618641|Experimental|Nivolumab and CMP-001 Combination|"Prime Phase -Nivolumab 240mg, IV Infusion, every two weeks starting with Cycle 2 ( Cycles 2, 4, 6) for 6 weeks in combination with CMP-001, 5mg, Injection, at Week 1 and the remaining injections, 10 mg will be administered Weeks 2 -7.~Boost Phase -Nivolumab 240mg, IV Infusion, every two weeks, over a 46 week period in combination with CMP-001, 5mg, administered every 4 weeks for 1 year."
88970403|NCT03600831|Experimental|concurrent chemoradiotherapy group|All patients in this group will receive concurrent chemoradiotherapy with DP regimen (docetaxel plus cisplatin).
88970404|NCT03600831|Active Comparator|radiotherapy group|All patients in this group will receive radiotherapy alone 50Gy (2.0 Gy/fraction, 5 days a week).
88970405|NCT03599141|Active Comparator|Depression Management|8 weekly group sessions
88970406|NCT03599141|Experimental|Trust-building Self-management Together|8 weekly group sessions
88970407|NCT03580928|Experimental|Acalabrutinib/Venetoclax/Obinutuzumab|"Acalabrutinib will be administered orally twice daily at 100 mg bid~Venetoclax will be administered orally once daily, with dose ramp-up from 20 mg up to a final dose of 400 mg~Obinutuzumab will be administered as per standard of care for 6 months with dosing at 100 mg on cycle 1 day 1, 900 mg on cycle 1 day 2, and then 1,000 mg on cycle 1 days 8, 15, and day 1 of cycles 2-6"
88970408|NCT03567096|Active Comparator|BiV+MPP|"Patients randomized to the BiV pacing with MPP and SyncAV study arm will have CRT programming to biventricular pacing with MPP activated. RV-LV pacing delay set to 5 ms, LV1 & LV2 pacing cathodes selected as the maximal spaced electrodes (D1+P4, D2+M3, M2+P4) with pacing delay set to 5 ms and SyncAV offset programmed providing the optimum electrical resynchronization (shortest QRS duration)."
89028932|NCT05365672|Other|Standard of care immunosuppression for transplantation|Patients of the Control Arm receive standard of care immunosuppression for kidney transplantations according to the Efficacy Limiting Toxicity Elimination (ELITE) symphony scheme (interleukin [IL]-2 receptor antibody induction therapy, tacrolimus, mycophenolic acid derivative and corticosteroids) without the investigational medicinal product MIC.
89028933|NCT05362318|Active Comparator|Group 1: Usual Care|Participants will receive brief advice to quit, an offer of enrollment to the Florida Tobacco Quitline, and a 12 week supply of nicotine replacement therapy (nicotine patches and lozenges).
89028934|NCT05362318|Experimental|Group 2: Usual Care + Motivation and Problem Solving + Relapse Prevention|Participants will receive brief advice to quit, an offer of enrollment to the Florida Tobacco Quitline, and a 12 week supply of nicotine replacement therapy (nicotine patches and lozenges), 6 telephone counseling sessions over 6 months, and access to a web based video.
89028935|NCT05359250||Patients with evidence of myocardial injury related to vaccination with a SARS-CoV-2 mRNA vaccine|Patients who present with new symptoms of chest pain within 2-10 days following SARS-CoV-2 mRNA vaccination will be recruited up to 180 days following diagnosis. Patients will be screened using multiple methods and then provided informed consent. If patients are unable to consent, health care decision makers of patients who meet initial inclusion criteria will be approached for consent. Following informed consent, a cardiac MRI will be performed (if not performed prior) to assess myocardial function and potential damage. Patients will qualify on the basis of the presence of late-gadolinium enhancement and/or abnormal T1 mapping on MRI. The patient will then be taken to the cardiac catheterization lab where he/she will undergo endomyocardial biopsy and right heart catheterization (RHC) for candidate gene analysis. A blood sample will be collected to analyze circulating biomarkers associated with myocardial injury.
89028936|NCT05350046|Experimental|Physically active adults|A cohort of physically-active adults will use ear-worn prototype devices and established gold standard and comparator devices during rest periods, physical activity, and various activities of daily living.
89571651|NCT05521763|No Intervention|No intervention|In the control facility, we will not intervene in the existing knowledge and practice about influenza vaccination of the HCWs.
89571652|NCT03044821|Experimental|Open-Uterus Fetal Repair|Single arm study. All patients will receive the open-uterus fetal repair.
89571653|NCT02612155|Experimental|Intervention cell recipients|Experimental: infusions: infants with moderate to severe hypoxic ischemic encephalopathy, begin cooling, and have autologous nucleated cord blood cells available for infusion will receive up to two infusions. Outcomes will be measured at 22-26 months by neurodevelopment assessment
89571654|NCT02612155|Placebo Comparator|Placebo recipients|Control: infants with moderate to severe hypoxic ischemic encephalopathy, begin cooling, and have cord blood available for infusion will receive placebo (a mix of autologous cord blood red blood cells and plasma) infusions. Outcomes will be measured at 22-26 months by neurodevelopment assessment
89209063|NCT00246337|Active Comparator|Rizatriptan 10 mg|Rizatriptan 10 mg; one orally-administered dose plus an optional second dose (placebo) to treat a single moderate-to-severe migraine headache.
89209064|NCT02552576|Experimental|Voncento|The frequency and dose of Voncento administration will be determined by the investigator using the information included in the Voncento Summary of product characteristics (SmPC)
89209065|NCT00809900||Dietary Supplement|Cranberry Juice Consumption
89571655|NCT05100251|Experimental|WBC100|WBC100
89571656|NCT04865575||controlled asthmatics|moderate-to-severe asthmatic children with good asthma control
89571657|NCT04865575||uncontrolled asthmatics|moderate-to-severe asthmatic children with poor asthma control / recurrent exacerbations
89571658|NCT04876885|Other|General public|The individuals recruited to the study will include those who are age 16 and older. Due to recruitment feasibility we will focus efforts on individuals living in Ontario. We intend to recruit individuals from COVID-19 assessment centres that are partnering in our study as well as through social media posts (Facebook, Twitter, LinkedIn).
89571659|NCT04876885|Other|Healthcare professionals and public health professionals|The individuals recruited to the study will include healthcare professionals and public health professionals impacted by infectious disease outbreaks. Social media will be used to disseminate surveys to physicians, nurses, nurse practitioners, pharmacists, and healthcare workers. Public health units will disseminate surveys to their workforce.
89571660|NCT04865185|Active Comparator|Xylocaine spray 100mg/ml|Topical application
89571661|NCT04865185|Placebo Comparator|Ethanol|Topical application
89571662|NCT04865107|Experimental|MSCs Arm|3 daily doses of up to 90-million cells/unit dose (cumulative dose of up to 270 million UC-MSCs)
89571663|NCT04865107|Placebo Comparator|Placebo Arm|3 daily doses of up to 90-million cells/unit dose (cumulative dose of up to 270 million UC-MSCs)
89571664|NCT05531903|Experimental|Patients with atrioventricular node reentrant tachycardia|Patient with documented AVNRT and fragmented/slow conduction zones observed in a 3D high density mapping
89571665|NCT03046459|Experimental|BNZ132-1-40|a range of IV doses
89571666|NCT03046381|Other|Tocilizumab|Tocilizumab 162mg 1x weekly as subcutaneous syringe
89571667|NCT05521373|Active Comparator|ultrasound cervical selective nerve root block|"A (7-12) MHz linear transducer will be applied to the symptomatic side of the neck in the transverse plane. The targeted nerve root of each patient will be identified by moving the transducer cranially from the C7 transverse process as a reference point.~After the targeted nerve root identified, a needle will be gently introduced toward the dorsal aspect of the nerve root under real-time US guidance with an in-plane approach. The needle tip will be placed between the nerve root and posterior tubercle outside of the intervertebral foramen and the vessels will be around the nerve root with color Doppler. On confirmation of the absence of abnormal findings and careful aspiration, 3 cc of the treatment drug composed of dexamethasone (10 mg) and 0.2% lidocaine, will be injected under real-time US guidance"
89571668|NCT05521373|Active Comparator|ultrasound and fluoroscopy-guided cervical selective nerve root block|The targeted transverse process was identified by slowly moving the probe in all directions with the 7th cervical spine transverse process as the reference point. a spinal needle 22 G was inserted. First, 1 ml of the contrast media was injected. The antero-posterior images were obtained to confirm the distribution or spread pattern of the injected contrast media with C-arm fluoroscopy. The following steps were initiated after confirming for proper shadowed contrast of the nerve root and absence of intravascular injection of the contrast media. Three cc of the treatment drug, composed of dexamethasone (10 mg) and 0.5 % lidocaine will be injected after confirming the absence of abnormal findings.
89571669|NCT05521295||Conception positive|serum human chorionic gonadotropin ≥10 mIU/mL
89571670|NCT05521295||Conception negative|serum human chorionic gonadotropin <10 mIU/mL
89571671|NCT04876807|Experimental|Part 1 (Acidic formulation)|In Part 1 of the study, the participants will receive Dose 1 of ACP-196 (reference or acidic formulation as applicable) with 240 mL water in 4 treatment schedules on Day 1, Day 3, Day 8 (with omeprazole), and Day 10 (with omeprazole).
89571672|NCT04876807|Experimental|Part 2 (Orange drink)|In Part 2 of the study, the participants will receive Dose 1 of ACP-196 (reference formulation) with 240 mL water or acidic beverage as applicable in 4 treatment schedules on Day 1, Day 3, Day 8 (with omeprazole), and Day 10 (with omeprazole).
89571673|NCT04876807|Experimental|Part 3 (Grapefruit juice)|In Part 3 of the study, the participants will receive Dose 1 of ACP-196 (reference formulation) with 240 mL water or grapefruit as applicable in 4 treatment schedules on Day 1, Day 3, Day 8 (with omeprazole), and Day 10 (with omeprazole).
89571674|NCT05518409|Experimental|AD group|20 subjects who met the diagnostic criteria and exclusion criteria of AD were included in the discovery cohort.
89571675|NCT05518409|Experimental|DLB group|Of the 30 subjects who met the DLB diagnostic criteria and exclusion criteria, 20 were included in the discovery cohort and 10 in the validation cohort.
89571676|NCT05518409|Experimental|Healthy control group|Among the 30 subjects who met the diagnostic and exclusion criteria of the healthy control group, 20 were included in the discovery cohort and 10 in the validation cohort.
89571677|NCT02614729|Experimental|Energy Balance Comparison|"Participants will randomly consume 4 eucaloric diets for 7 consecutive days/treatment. Energy levels for all diets are established according to needs for energy balance.~Interventions:~Standard Protein-Plant, Even Distribution (SP-PLANT-EVEN); Standard Protein-Beef, Even Distribution (SP-BEEF-EVEN); High Protein-Beef, Even Distribution (HP-BEEF-EVEN); High Protein-Beef, Uneven Distribution (HP-BEEF-UNEVEN)"
89571678|NCT02614729|Experimental|Energy Restriction Comparison|"Participants will randomly consume 3 energy restriction diets (1250 kcal/day) for 7 consecutive days/treatment. Energy levels for all diets are established according to needs for energy restriction.~Interventions:~Standard Protein-Plant, Even Distribution (SP-PLANT-EVEN); Standard Protein-Beef, Even Distribution (SP-BEEF-EVEN); High Protein-Beef, Even Distribution (HP-BEEF-EVEN)"
89571679|NCT05531825||Normal control group|Patients with no disease in the main organs, with well-developed body shape, and with good physiological functions, physical activity abilities and labor abilities.
89571680|NCT05531825||Newly established arteriovenous fistula group|Chronic kidney disease stage 5 (CKD5) non-dialysis patients planning to undergo internal arteriovenous fistula surgery.
89571681|NCT05531825||reconstructed arteriovenous fistula group|Patients with maintenance hemodialysis who need to reconstruct the internal arteriovenous fistula on account of dissatisfaction with blood flow.
89571682|NCT05531825||Long-term maintenance hemodialysis group|Patients undergoing hemodialysis with long-term fixed internal arteriovenous fistula.
89571683|NCT05518331|Experimental|Avatrombopag in RAA|"After the patients met the above-mentioned inclusion conditions and signed informed consent, they began to be included in this program.~The main research objectives are to take avatrombopag conversion therapy for at least 3 months, to monitor hematological indicators, biochemical indicators and bone marrow related tests, to determine hematological responses, and to evaluate the safety of the drug.~In the 6th and 12th months after treatment, comprehensive review of bone marrow and peripheral blood was performed to evaluate the recovery of hematopoiesis, determine the curative effect, evaluate adverse events, and whether there was clonal transformation.~After the patients completed the main study observation, they were followed up for at least 3 months, that is, from the time the patients were enrolled, for a total of at least 6 months of follow-up."
89571684|NCT04876573|Experimental|Cyproheptadine|
89571685|NCT05521139||CRKP-PLA|Klebsiella pneumoniae were isolated from pyogenic liver abscess patients' blood or pus and the antibiotic drug sensitivity results shows it is carbapenem-resistant Klebsiella pneumoniae.
89571686|NCT05521139||CSKP-PLA|Klebsiella pneumoniae were isolated from pyogenic liver abscess patients' blood or pus and the antibiotic drug sensitivity results shows it is carbapenem-sensitive Klebsiella pneumoniae.
89028937|NCT05336370|Experimental|Hypnosis|A brief hypnosis session will be provided to participants in this arm prior to immersion in the cold water.
89028938|NCT05336370|Experimental|Active tVNS|Participants in the active tVNS condition will receive electronic stimulation of the vagus nerve prior to immersion in the cold water.
89028939|NCT05336370|Sham Comparator|Sham tVNS|Participants in the sham tVNS will receive the electrode similar to the active treatment, but no stimulation will be performed.
89571687|NCT03046147||RYGB patients with preoperative type diabetes|Recruited from a previously investigated cohort (NCT 01202526)
89571688|NCT03046147||RYGB patients with preoperative normal glucose tolerance|Recruited from a previously investigated cohort (NCT 01202526)
89571689|NCT03046069||Subjects included in telephone interviews|Approximately 10 subjects with COPD per country will be included in qualitative concept elicitation telephone interviews.
89571690|NCT03046069||Subjects included in in-person focus groups|1 in-person focus-group per country including up to 5 subjects with COPD will be included in the qualitative analysis.
89571691|NCT03046069||Subjects included in DCE surveys- cognitive interviews|Up to six subjects with COPD in each of the UK, US and Germany will be asked to complete and provide feedback on the surveys.
89571692|NCT03046069||Subjects included in modified DCEs|Up to 20 subjects with COPD in each country will be included in pilot testing of the modified DCEs.
89571693|NCT03046069||Subjects included in Final DCE|150 subjects with COPD in each of the UK, US and Germany will be included in the final online market specific DCE survey.
89571694|NCT04864873|Active Comparator|Standard diagnostic pathway|Part of each patient sample will be tested using current standard microbiological techniques.
89571695|NCT04864873|Experimental|mNGS pathway|Part of each sample will be testing using mNGS methodology, which will be compared to the standard diagnostic pathway.
89571696|NCT04864717|Active Comparator|Doxycycline|Doxycycline 100mg po once daily x 6 months
89571697|NCT04864717|Active Comparator|Isotretinoin|Isotretinoin 40mg po once daily x 6 months
89571698|NCT04876495|Active Comparator|Whey protein|Whey protein isolate (45.5g total protein content)
89571699|NCT04876495|Active Comparator|Potato protein|Potato protein isolate (45.3g total protein content)
89571700|NCT04876495|Active Comparator|Rice protein|Rice protein isolate (45.5g total protein content)
89571701|NCT04876261|Active Comparator|Group A|Group A will receive Oliphenolia® bitter on intervention visit 1 followed by Oliphenolia® on intervention visit 2 and followed by La Vialla Extra Virgin Olive Oil with 5 mg hydroxytyrosol on the third and final intervention visit
89571702|NCT04876261|Active Comparator|Group B|Group B will receive Oliphenolia® on intervention visit 1 followed by La Vialla Extra Virgin Olive Oil with 5 mg hydroxytyrosol on intervention visit 2 and followed by Oliphenolia® bitter on the third and final intervention visit
89571703|NCT04876261|Active Comparator|Group C|Group C will receive La Vialla Extra Virgin Olive Oil with 5 mg hydroxytyrosol on intervention visit 1 followed by Oliphenolia® bitter on intervention visit 2 and followed by Oliphenolia® on the third and final intervention visit
89571704|NCT05518097||Conventional Physical Therapy Program|Patients with knee osteoarthritis underwent a conventional physical therapy program including hotpack, US, TENS and exercise.
89571705|NCT05518019|Experimental|"Prima CBD The Daily Supplement"|Participants are provided with the dietary supplement (1 capsule per day). Participants are to take the supplement at the same time every day Participants will take a weekly well-being survey Participants are to complete the well-being questionnaire after the 4th week
88970409|NCT03567096|Experimental|LV-only + MPP|"Patients randomized to the  LV only pacing with MPP and SyncAV study arm will have CRT programming to left ventricular only pacing with MPP activated. LV1 & LV2 pacing cathodes selected as the maximal spaced electrodes (D1+P4, D2+M3, M2+P4) with pacing delay set to 5 ms and SyncAV offset programmed providing the optimum electrical resynchronization (shortest QRS duration)"
88970410|NCT03552627|Active Comparator|80% Oxygen|Patients will receive 80% oxygen throughout anaesthesia in accordance with current World Health Organisation Recommendations
89571706|NCT02613871|Experimental|LDV/SOF|LDV/SOF FDC for 12 weeks
89571707|NCT05531747|Experimental|Physiopathologic exploration|A non randomised study with one arm, addind experimental acts to standard of care (skin biopsy and biological sample ) in order to explore Hidradenitis Suppurativa physiopathology
89571708|NCT04425161||VO2 ≥15 %|This group is classified based on increased oxygen consumption (VO2) ≥15 % by volume expansion in fluid responders
88970411|NCT03552627|Active Comparator|55% Oxygen|Patients will receive 55% oxygen throughout anaesthesia in accordance with current UK clinical practice
88970412|NCT03552627|Experimental|30% Oxygen|Patients will receive 30% oxygen throughout anaesthesia in accordance with this research's hypothesis that lowering intraoperative oxygen concentrations may benefit patients
89571709|NCT04425161||VO2 <15 %|This group is classified based on increased oxygen consumption (VO2) < 15 % by volume expansion in fluid responders
89571710|NCT04875949|Experimental|Anti-AChRs Abs positive patients|Immunoabsorption
88970413|NCT03525678|Experimental|Participants receiving frozen 2.5 mg/kg belantamab mafodotin|Participants will receive 2.5 mg/kg frozen liquid belantamab mafodotin. Participants will be administered with frozen liquid belantamab mafodotin via infusion pump every 3 weeks.
88970414|NCT03525678|Experimental|Participants receiving frozen 3.4 mg/kg belantamab mafodotin|Participants will receive 3.4 mg/kg frozen liquid belantamab mafodotin. Participants will be administered with frozen liquid belantamab mafodotin via infusion pump every 3 weeks.
89571711|NCT05520671|Experimental|TESLA-G|Participants will be randomised into the two arms with a 1:1 allocation ratio stratified by year of study. There will be 25 participants in this arm.
89571712|NCT05520671|Active Comparator|Control|Participants will be randomised into the two arms with a 1:1 allocation ratio stratified by year of study. There will be 25 participants in this arm.
89571713|NCT04869709|Active Comparator|Late Preterm Steroids 2 Days|
89571714|NCT04869709|Active Comparator|Late Preterm Steroids 7 Days|
89571715|NCT05021081|Experimental|TEST/CONTROL|For Phase 2, eligible subjects that are enrolled will be randomized to the Test/Control contralateral sequence.
89571716|NCT05021081|Experimental|CONTROL/TEST|For Phase 2, eligible subjects that are enrolled will be randomized to the Control/Test contralateral sequence.
89571717|NCT04864327|No Intervention|control|Usual care
88970415|NCT03525678|Experimental|Participants receiving lyophilized belantamab mafodotin|Participants in lyophilized arm will receive lyophilized belantamab mafodotin once lyophilized configuration becomes available and enrollment has been completed for frozen liquid arms.
88970416|NCT03506360|Experimental|Treatment (ixazomib citrate, pembrolizumab, dexamethasone)|Patients receive ixazomib citrate PO on days 1, 8, 15, 29, 36, 43, 57, 64, and 71 and pembrolizumab IV over 30 minutes on days 1, 22, 43, 64. Patients also receive dexamethasone PO on days 1, 8, 15, 29, 36, 43, 57, 64, and 71. Cycles with dexamethasone repeat every 84 days for up to 1 year and cycles with ixazomib citrate and pembrolizumab repeat every 84 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
88970417|NCT03492801||Ancillary-Correlative (biospecimen collection)|Patients undergo collection of blood samples at baseline and every 12 weeks for up to 6 times.
88970418|NCT03488628|Active Comparator|Noninvasive ventilation|Noninvasive ventilation delivered through a face mask, in alternance with standard nasal oxygen therapy
88970419|NCT03488628|Experimental|High-Flow Nasal Oxygen therapy|High-Flow Nasal Oxygen therapy delivered continuously over the first 24 hours by the AIRVO2® device (Fisher & Paykel Healthcare,New Zealand) through nasal canula.
89033146|NCT02943278|Active Comparator|Intensive Sleep Retraining Group|Participants assigned to this group will spend just over 1 day at our sleep lab, starting around your usual bedtime and ending the following day. Over a 20 hour period participants will complete a sleep retraining session, which involves an opportunity to fall asleep every 30 minutes; we will wake the participant up after a few minutes if they fall asleep.
89571718|NCT04864327|Other|intervention|5 minutes brief smoking cessation advise
89571719|NCT05520437|Experimental|Physically active males|Half of the study population will consist of long-distance runners with 2-5 years of experience in running and similar times in covering the half-marathon distance.
89571720|NCT05520437|Experimental|Physically inactive males|The other half of the study population will consist of age-matched individuals involved in no regular physical activity.
89571721|NCT02612077||Observational Chemotherapy/Bevacizumab|Observed patients receiving chemotherapy with concomitant bevacizumab
89571722|NCT04622735|Experimental|FDC nefopam hydrochloride 30 mg / paracetamol 500 mg (X2)|Each dose: 2 tablets (included in masking capsule)
89571723|NCT04622735|Active Comparator|Paracetamol 500 mg (X2)|Each dose: 2 tablets (included in masking capsule)
89571724|NCT04622735|Active Comparator|Nefopam hydrochloride 30 mg (X2)|Each dose: 2 tablets (included in masking capsule)
89571725|NCT03045991|Experimental|sequential training group (SEQ)|"The sequential training group (SEQ) will first receive 30-minutes aerobic exercise training followed by 30-minutes computerized cognitive training. All participants will receive a training session for 60 minutes per day, three days per week for 12 weeks, a total of 36 training sessions.~Before and after the treatment, a total of 2 evaluations were conducted, including clinical assessments and blood test (each 18c.c.). A saliva sample (2 mL) will only be collected once from each subject. A follow-up assessment of clinical outcomes will be conducted at six month after the end of the course of treatment."
89571726|NCT03045991|Active Comparator|control intervention group (CI)|"The control intervention group (CI) will receive a control training session for 60 minutes per day, three days per week for 12 weeks, a total of 36 training sessions.~Before and after the treatment, a total of 2 evaluations were conducted, including clinical assessments and blood test (each 18c.c.). A saliva sample (2 mL) will only be collected once from each subject. A follow-up assessment of clinical outcomes will be conducted at six month after the end of the course of treatment."
89571727|NCT04615559|Experimental|contrast enhanced ultrasound|CEUS will be performed at one month post-op, six months post-op and at one year.
89571728|NCT03047785||Hospital population|All patients who have had a biochemistry blood tests requested at the trust will have a troponin blood level determined.
89571729|NCT05517629||All the time|Students who wore face masks all the time when outside
89571730|NCT05517629||Most of the time|Students who wore face masks most of the time when outside
89571731|NCT05517629||Only when told to|Students who wore face masks only when they were told to when outside
89571732|NCT05517629||Not At All|Students who did not wear face masks at all when outside
89571733|NCT03046303|Experimental|ERAS group|Patients were admitted 1-3 days prior to their respective dates of operation. A ERAS protocol was used in the ERAS group.
89571734|NCT03046303|No Intervention|conventional pathway group|The conventional pathway group received conventional care.
89571735|NCT04875637|Other|MEMR Diagnostic Evaluation|Middle Ear Muscle Reflex using wideband acoustic reflectance to assess hearing status.
89571736|NCT05531669|Experimental|Study group|the study group will receive 12 months of Play Project + Parental Education intervention
89571737|NCT05531669|Active Comparator|control group|the control group will receive Parental Education intervention in the first 6 months, and then receive Play Project + Parental Education intervention in the next 6 months
89571738|NCT02613481|Other|Poly-L-Lactic Acid (Sculptra) injection|Poly-L-Lactic Acid (Sculptra) injection for all enrolled subjects
89571739|NCT04864015|Placebo Comparator|Conventional mouthpiece|Patients undergoing standard EGD using a conventional mouthpiece
89571740|NCT04864015|Active Comparator|Droplet reduction mouthpiece|Patients undergoing standard EGD using a new droplet reduction mouthpiece
89571741|NCT05298917|Other|extended contact lens wear|subjects wear silicone hydrogel contact lenses continuously for 7+/- 1 days - corneal sensitivity will be measured and compared at baseline versus after extended contact lens wear
89571742|NCT04385251||SARS-CoV-2 infection/COVID-19|Adults who present for SARS-CoV-2 testing will be consented for this study. Participants who are enrolled will be informed that if they have SARS-CoV-2 infection/COVID-19, they will be followed for 28 days in an observational cohort study, and that if they do not have SARS-CoV-2 infection, there will be no further follow-up.
89571743|NCT04384705||caregivers|caregivers
89571744|NCT05517551||normal flow anesthesia|A fresh gas flow of 3 L/min will be applied continuously
89571745|NCT05517551||low flow anesthesia|A fresh gas flow of 3 L/min will be applied for the first 20 minutes after intubation , and then it will be reduced to 1 L/min.
89571746|NCT05520125|Experimental|Patients with bone defects receiving standard treatment and MSC enriched with extracellular vesicles|Patients with bone defects receiving standard treatment and MSC enriched with extracellular vesicles
89571747|NCT05520125|Active Comparator|Patients with bone defects receiving standard treatment|Patients with bone defects receiving standard surgical treatment
89571748|NCT04297319|Experimental|1 - Laser intervention|Laser diiodo treatment, 3 procedures of 5-10 minutes at intervals of 4 weeks
89571749|NCT04297319|Placebo Comparator|2 - Laser placebo|Only the laser speculum is placed in the vagina but the laser is not activated. 3 procedures of 5-10 minutes at intervals of 4 weeks
89571750|NCT05517395|Experimental|health nutrition education|The participants in intervention group will receive health nutrition education based on a health belief model including nutrition health education (booklet), and telephone call support.
89571751|NCT05517395|Active Comparator|usual care|Control group will only receive usual care. Usual care is routine measurement of children including height, length, weight, head circumference, monitoring children's activities, and monitoring the immunization status of children.
89571752|NCT05048615|Experimental|Low-dose Ventoclax and oral itraconazol plus subcutaneous Azacitdine|Patients will recieve Low-dose Venetoclax at a dose of 100mg/day por 21 days, oral itraconazol 100mg every 12 hours, and subcutaneous Azacitidine 75mg/m2 (maximun dose 100mg) daily for seven days. Each cycle duration is 21 days and patients will recieve a maximun of two cycles.
89571753|NCT05531435|Experimental|SleeperOne|SleeperOne S4 (Revello S.p.A., Verona, Italy) appliance will be used for the administration of local anesthetic.
89571754|NCT05531435|Active Comparator|Traditional anesthesia|Local anesthesia will be performed with a traditional syringe (0480-1, ASA Dental, Massarosa, LU, Italy).
89571755|NCT05517317|Experimental|Autologous BMMC infusion|One administration of autologous bone marrow mononuclear cells via the hepatic artery
89571756|NCT05517239|Experimental|Gemcitabine, Oxaliplatin|Gemcitabine 1,000 mg/m2 infusion for 30minutes and followed by oxaliplatin 100mg/m2 infusion for 2hours on day1. All drugs were administered intravenously until progression, intolerance, patient withdrawal, or death.
89571757|NCT05519813|Experimental|Use Metformin for 3 months to treat PCOS|Active Comparator: Metformin (BMI<24) Subjects: PCOS patients whoseBMI<24 Drug: Glucophage Generic name: Metformin Dosage form: 500mg Dosage: 1500-2000mg/day Frequency: 500mg three times a day/1000mg twice a day Duration: 3 months
89571758|NCT05519813|Experimental|Use Pioglitazone Hydrochloride And Metformin Hydrochloride Tablets for 3 months to treat PCOS|Active Comparator: Pioglitazone Hydrochloride And Metformin Hydrochloride Tablets (BMI<24) Subjects: PCOS patients whoseBMI<24 Drug: Pioglitazone Hydrochloride And Metformin Hydrochloride Tablets Generic name: Pioglitazone Hydrochloride And Metformin Hydrochloride Tablets Dosage form: 15mg/500mg Dosage: 2 tablets/day Frequency: one tablet twice a day Duration: 3 months
89571759|NCT05517005|Experimental|Hype Bites Supplement|Participants will take the 2 chocolates each day, complete surveys at baseline, midpoint, and study conclusion, and take blood biomarker samples at baseline and conclusion
89571760|NCT05519657||postoperative pulmonary complications group|Postoperative pulmonary complications group no intervention
89571761|NCT05519657||non-postoperative pulmonary complications group|Non-postoperative pulmonary complications group no intervention
89028940|NCT05333627|Experimental|Fast-Track Course|Clients who select the Fast-Track Course option will receive access to a single ICBT core lesson and Do-It-Yourself guide, followed by three additional Do-It-Yourself guides that they can access in any order. The content includes examples that are tailored to students' experiences. Clients have access to diverse additional resources (e.g., managing panic, assertive communication) throughout the course. Clients will receive up to five weeks of optional therapist support.
89571762|NCT05082311||Patients with Pheochromocytoma/Paraganglioma (secretory, extra adrenal pheochromocytoma)|"Patients included in this cohort (n=50) are those who are diagnosed of Pheochromocytoma / Paraganglioma, willing to consent for the study and not on α-blockade at the time of recruitment into study, while can be on any other anti hypertensives~Patients in this group, besides the usual evaluation of Pheochromocytoma / Paraganglioma, will also undergo detailed cardiac and vascular evaluation, which will be done at diagnosis, at 7- 10 days of α-blockade, and 7 days, 3 and 6 months post adrenalectomy/ Paraganglioma excision The cardiovascular evaluation includes 2D-echocardiography, speckle tracking Echo (for measuring global longitudinal strain), serum NT-proBNP estimation and flow mediated vasodilatory studies by Doppler Ultrasonography of the brachial artery to assess the endothelial dependent and smooth muscle dependent vasodilatory responses"
89571763|NCT05082311||Essential Hypertensive Groups|This is a contemporary age- and gender-matched control group This group includes 10 newly detected (within 3 months) Essential Hypertensive patients, who will undergo treatment with standard anti- HT medications Cardiac evaluation will be done at baseline and after 3 months of anti hypertensive medications
89571764|NCT05082311||Healthy Individuals|This is a contemporary age- and gender-matched control group This group includes 10 Healthy individuals (normal in physical examination, ECG , Echo), that include hospital staff nurses, technicians, doctors whom would be requested to volunteer Cardiac evaluation will be done at the start of study and after 6 months
89571765|NCT05519501|Experimental|SyntrFuge System|Adipose tissue microsized via the SyntrFuge System
89571766|NCT05519501|Other|Standard of Care|Offloading
89571767|NCT02613403|Experimental|[Part A, Arm 1] Prior SOF/LDV Failure: MK-3682B + RBV|C or NC HCV GT1 participants previously failing a DAA regimen of SOF/LDV receive MK-3682B, an FDC of GZR (MK-5172 [50 mg]) + UPR (MK-3682 [225 mg]) + RZR (MK-8408 [30 mg]), administered as 2 tablets once daily in combination with RBV twice daily for 16 weeks.
89571768|NCT02613403|Experimental|[Part A, Arm 2] Prior SOF/LDV Failure: MK-3682B|C or NC HCV GT1 participants previously failing a DAA regimen of SOF/LDV receive MK-3682B, an FDC of GZR (MK-5172 [50 mg]) + UPR (MK-3682 [225 mg]) + RZR (MK-8408 [30 mg]), administered as 2 tablets once daily for 24 weeks.
89571769|NCT02613403|Experimental|[Part A, Arm 3] Prior GZR/EBR Failure: MK-3682B + RBV|C or NC HCV GT1 participants previously failing a DAA regimen of GZR/EBR (MK-5172/MK-8742) receive MK-3682B, an FDC of GZR (MK-5172 [50 mg]) + UPR (MK-3682 [225 mg]) + RZR (MK-8408 [30 mg]), administered as 2 tablets once daily in combination with RBV twice daily for 16 weeks.
89028941|NCT05333627|Experimental|5-Week Course|Clients who select the 5-week course will receive access to an ICBT course which consists of four lessons spread across the span of five weeks. The content includes examples that are tailored to students' experiences. Clients have access to diverse additional resources (e.g., managing panic, assertive communication) throughout the course. Clients will receive five weeks of optional therapist support.
89571770|NCT02613403|Experimental|[Part A, Arm 4] Prior GZR/EBR Failure: MK-3682B|C or NC HCV GT1 participants previously failing a DAA regimen of GZR/EBR (MK-5172/MK-8742) receive MK-3682B, an FDC of GZR (MK-5172 [50 mg]) + UPR (MK-3682 [225 mg]) + RZR (MK-8408 [30 mg]), administered as 2 tablets once daily for 24 weeks.
89571771|NCT02613403|Experimental|[Part B] Prior DAA (GT1-6) or SOF/PR (GT3) Failure: MK-3682B|C or NC HCV participants previously failing any all-oral DAA regimen (GT1-6) or SOF/PR regimen (GT 3 only) receive MK-3682B, an FDC of GZR (MK-5172 [50 mg]) + UPR (MK-3682 [225 mg]) + RZR (MK-8408 [30 mg]), administered as 2 tablets once daily for 16 weeks.
89571772|NCT05531279|Experimental|PEG-rhG-CSF group A|PEG-rhG-CSF group A(q7d):6mg d1,8,subcutaneously injected,after monitoring ANC>0.5×109/L,the drug was stopped,and then ANC<0.5×109/L was temporarily supplemented with one dose of the same drug.
89571773|NCT05531279|Experimental|PEG-rhG-CSF group B|PEG-rhG-CSF group B(q10d):6mg d1,11,subcutaneously injected,after monitoring ANC>0.5×109/L,the drug was stopped,and then ANC<0.5×109/L was temporarily supplemented with one dose of the same drug.
89571774|NCT05531279|Experimental|rhG-CSF group(short-acting )|rhG-CSF group(short-acting ): 480ug d1-14(daily for 14days),subcutaneously injected.After monitoring ANC>0.5×109/L,the drug was stopped,and then ANC<0.5×109/L was temporarily supplemented with one dose of the same drug.
89028942|NCT05333627|Experimental|8-Week Course|Clients who select the 8-week course will receive access to an ICBT course which consists of five lessons spread across the span of eight weeks. The content in this course is not student-specific. Clients have access to diverse additional resources (e.g., managing panic, assertive communication) throughout the course. Clients will receive eight weeks of optional therapist support.
89028943|NCT05321784|Experimental|Self-skin exam (SSE), digital dermoscopy image (DDI), Sklip System, full body skin exam (FBSE).|This is a single-arm prospective trial. Participants perform self-skin exams using naked-eye criteria and will take smartphone clinical images (SCI) of each PSL of concern (PSLC). Participants will also take digital dermoscopy images (DDIs) and apply the Sklip System (integrating the Sklip Mole Scan Algorithm (SMSA) to each PSLC of concern in up to 14 days. Within up to 28 days of completing the at-home exams, participants will undergo an in-office visit full body skin exam (FBSE).
89028944|NCT05312801|Experimental|LMY-920 dose escalation|Open label, dose escalation study with up to four dose levels of LMY-920. The maximum tolerated dose (MTD) of LMY-920 will be determined using dose-escalation 3+3 design.
89571775|NCT04875403|Experimental|Respiratory muscle training group|Inspiratory muscle training with linear load device, associated with the resisted training. The initial training load for each participant will be adjusted to 25% of MIP. Each week, the researcher determines the new values for load (1 to week 25%, 2 to week 35%;. 3 to week 40%;. 4 to week 45%;. 5 to week 50%.).The resistance training protocol will consist of the exercises of the front pull, the extension chair and the vertical bench press, covering large muscle groups in the dorsal region of the quadriceps and chest, respectively. Each year consist of three sets of 10 repetitions with a load equivalent to 60% of a test Repetition Maximum (1RM), which will be changed every week (1 to week 60%, 2 to week 65%;. 3 the . week 70%, 4 to week. 75%, 5 to week 80%).
89571776|NCT04875403|Active Comparator|Aerobic exercise group|Exercise bike for 30 minutes, which will be divided into 10 minutes for the foot heating and 20 minutes for the workout aerobic exercise that will have to maintain a target training heart rate, training has to be equivalent to 40% to 60%% target intensity.
89571777|NCT05519267|Experimental|MBSWSC programme|The Experimental group will take part in the Mindfulness Based Social Work and Self Care (MBSWSC) programme (6 sessions). MBSWSC will be facilitated by two accredited mindfulness practitioners, who are also qualified social workers. Sessions will be supplemented by brief homework activities.
89571778|NCT05519267|Active Comparator|MBSC Programme|The Active comparator group will take part in the Mindfulness and Self-compassion (MBSC) programme (3 sessions). MBSC will be facilitated by two accredited mindfulness practitioners, who are also qualified social workers. Sessions will be supplemented by brief homework activities.
89571779|NCT03044119|Active Comparator|Dental Implant with PRFM|Intervention in the form of Dental Implants placement in the adjacent edentulous bone with the placement of platelet rich fibrin matrix a biological material procured from patient's peripheral blood
89571780|NCT03044119|Experimental|Dental Implant with PRFM and PBMSCs|Intervention in the form of Dental Implant placement in the adjacent edentulous bone with the placement of platelet rich fibrin matrix and peripheral blood mesenchymal stem cells which are the biological materials procured from patient's peripheral blood
89571781|NCT04863937|Experimental|Randomized Comparison of Knee Sleeve, Distal Thigh Compression Garment and No Device|Randomized Comparison of Knee Sleeve, Distal Thigh Compression Garment and No Device
89571782|NCT03044275|Experimental|Cohort 8|"This is a sub-study testing the effect of real output on the skin applied under two adhesive strips.~New adhesive strip Standard adhesive strip"
89571783|NCT04874701|Experimental|Capsimax|
89571784|NCT04874701|Placebo Comparator|Placebo|Placebo, 2 capsules per day, for 12 weeks
89571785|NCT03045835|Experimental|BASKA mask|Selection of size : size 3 (30-50kg), size 4 (50-70kg), size 5 (70-100kg)
89571786|NCT03045835|Active Comparator|Endotracheal intubation|Selection of size : ID 7.0-7.5mm (women), ID 7.5-8.0mm (men)
89571787|NCT05516693|Experimental|Intervention group (MOG)|Patients in the experimental group (MOG) will undergo a myofunctional training protocol.
89571788|NCT05516693|No Intervention|Control group (COG)|Patients in the control group (COG) will not undergo any intervention, being only evaluated at the beginning and at the end of the protocol.
89571789|NCT04874779||Acute kidney injury (AKI) group|Acute kidney injury (AKI) group met the guidelines of Kidney Disease, Improving Global Outcomes (KDIGO)
89571790|NCT04874779||NON-Acute kidney injury (non-AKI) group|NON-Acute kidney injury (non-AKI) group not met the guidelines of Kidney Disease Improving Global Outcomes (KDIGO)
89571791|NCT05002127|Experimental|Phase 2 - Arm A|Evorpacept (ALX148) 30 mg/kg Q2W IV, trastuzumab (initial dose of 6 mg/kg followed by 4 mg/kg) Q2W IV, ramucirumab 8 mg/kg Q2W IV, and paclitaxel 80 mg/m2 IV Days 1, 8, and 15 of a 28-day cycle.
89571792|NCT05002127|Active Comparator|Phase 2 - Arm B|Trastuzumab (initial dose of 6 mg/kg followed by 4 mg/kg) Q2W IV, ramucirumab 8 mg/kg Q2W IV, and paclitaxel 80 mg/m2 IV Days 1, 8, and 15 of a 28-day cycle.
89571793|NCT05002127|Experimental|Phase 3 - Arm A|Evorpacept (ALX148) 30 mg/kg Q2W IV, trastuzumab (initial dose of 6 mg/kg followed by 4 mg/kg) Q2W IV, ramucirumab 8 mg/kg Q2W IV, and paclitaxel 80 mg/m2 IV Days 1, 8, and 15 of a 28-day cycle.
89571794|NCT05002127|Active Comparator|Phase 3 - Arm B|Ramucirumab 8 mg/kg Q2W IV and paclitaxel 80 mg/m2 IV Days 1, 8, and 15 of a 28-day cycle.
89571795|NCT04863547||Exposed|Patients hospitalized for COVID-19 with SARS-CoV-2 variant 20I / 501Y.V1
89571796|NCT04863547||Non exposed|Patients hospitalized for COVID-19 to SARS-CoV-2 corresponding to wild type 20A variants. EU1 or 20A. EU2
89571797|NCT04874389||Recreationally active males and females|"Subjects to be considered recreationally must regularly engage in >150 min/wk of physical activity (e.g., resistance training, sport or activity specific exercise, group exercise, or aerobic exercise). Healthy participants, defined as not currently injured, or recovering from an injury within the past 12 months, or undergone surgery within the last 12 months, or with any known history of moderate to severe traumatic brain injury resulting in impaired judgment or inability to make sound decisions or mild traumatic brain injury (mTBI, also commonly named concussion) within the last 12 months."
89571798|NCT04874389||Athletes or performing artists with reported history of concussion|Participants will be considered if they are recreationally active or considered an athletic performer (i.e.,history of participation in athletics at the university, amateur, elite or professional levels, or a military veteran), or a performing artist (i.e., stunt actors, circus artists, dancers or acrobats) with reported history of concussion incident(s), with most recent incident occurring >1 month and less than five years from the study testing dates.
89571799|NCT04873921|Experimental|Group 1: Sterile Kinesio tape application|Sterile Kinesio Taping application will be applied with Sterile Web Cut Kinesio Tape (Sterile Kinesio Tex Tape, Alberquerque, USA) without tension.
89571800|NCT04873921|No Intervention|Group 2: Control group|Group 2 will not receive any taping
89571801|NCT04869241|Experimental|Experimental group|Group measuring shoulder muscle activities by surface EMG with carrying backpacks forward
89571802|NCT04429867|Experimental|Hydroxychloroquine|
89571803|NCT04429867|Placebo Comparator|Placebo|
89571804|NCT03044041|Experimental|Low dose|single dose of intra-articular Tranexamic acid 500 miligrams
89571805|NCT03044041|Active Comparator|High dose|Single dose of intra-articular Tranexamic acid 3 grams
89571806|NCT03047941||All patients|All patients included in the present study
89571807|NCT04863391||early/none vs.|For identification of early/none (i.e., non-referral level) Age Related Macular Degeneration (ARMD)
89571808|NCT04863391||intermediate/late AMD|intermediate/late (i.e., referral level) Age Related Macular Degeneration (ARMD)
89571809|NCT04869007||Patients with a history of cesarean section and a hysterosonographically diagnosed isthmocoele|"For patients who agreed to participate in the study, a specific measurement is made during the hysterosonography examination in order to determine the presence or absence of an isthmocele. Inclusion in the study is validated after a successful hysterosonography examination that confirms the presence or absence of an isthmocele. The patients are then attributed either to the: isthmocele + group or isthmocele - group."
89571810|NCT04869007||Patients with a history of cesarean section without isthmocoele hysterosonographically diagnosed|"For patients who agreed to participate in the study, a specific measurement is made during the hysterosonography examination in order to determine the presence or absence of an isthmocele. Inclusion in the study is validated after a successful hysterosonography examination that confirms the presence or absence of an isthmocele. The patients are then attributed either to the: isthmocele + group or isthmocele - group."
89571811|NCT05029427|Experimental|Study period 1: β-glucan Oat ; Study period 2: Wheat|For the first period, the participant will receive food products made from oats containing a total of 4 grams per day HMW oat β-glucan. For the second period, the participant will receive food products made from wheat.
89571812|NCT05029427|Experimental|Study period 1: Wheat ; Study period 2: β-glucan Oat|For the first period, the participant will receive food products made from wheat. For the second period, the participant will receive food products made from oats containing a total of 4 grams per day HMW oat β-glucan.
89571813|NCT04429789|Experimental|Active-Alert Hypnosis|
89571814|NCT04429789|Experimental|Traditional Hypnosis|
89571815|NCT04429789|No Intervention|Wait-List Control|Participants in this arm will continue their usual care for fatigue. The therapist will notify participants assigned to Usual Care via the participant's preferred mode of communication (phone, U.S. mail, or email). People assigned to usual care will be encouraged to continue using the health care services available to them to address their fatigue. The study therapist will emphasize the importance of completing the outcome assessments. Following the completion of their final assessment (3 month follow-up); these individuals will be offered their choice of the two hypnosis treatments.
89571816|NCT05518955|Experimental|Virtual reality combine with sleep promotion routine|Participants will receive virtual reality for 30 minutes before bedtime then will be placed on an eye mask and combine with the sleep promotion routine. The intervention duration need continues for two days or until discharge from ICU.
89571817|NCT05518955|No Intervention|control group|Participants will receive eye masks during their sleep for consecutive two days or until discharge from ICU.
89571818|NCT04863235|Active Comparator|Control Group|Session 1: Participants will meet individually with a research assistant to discuss their type 2 risk, discuss benefits of engaging in 150 minutes of moderate-to-vigorous physical activity per week, and set a physical activity goal. Ideal Care will involve: Session 2: Introductions and Goal setting/planning. Session 3: Monitoring Physical Activity Session 4: Action and Coping Planning. Session 5: Self-Efficacy (master and vicarious experiences). Session 6: Self-Efficacy (modeling experiences, verbal persuasion). Session 7: Physical Activity Enjoyment and Barriers. Session 8: Making long-term Change. The last 30 minutes of sessions 2-6, control participants will receive 30-minutes of non-self-compassion or physical activity related health education (i.e., sleep, screen time, blood pressure, cholesterol, benefits of water, benefits of vitamin D, the Infodemic).
88970420|NCT03477500|Experimental|HSCT (Cyclophosphamide and ATG)|"Day 1: Cyclophosphamide 2.0 g/m2 body surface area Days 5-10: Granulocyte colony stimulating factor (filgrastim) 5 mcg/kg body weight/day sc.~Day 11 and until apheresis is discontinued: Granulocyte colony stimulating factor (filgrastim) 5 mcg/kg body weight x 2 sc/day.~HSCT days -5 to -2: Cyclophosphamide 50 mg/kg/day. HSCT days -5 to -1: Anti-thymocyte globulin (ATG-rabbit, Thymoglobuline®) 0.5 mg/kg body weight iv on day -5, 1.0 mg ATG-rabbit/kg will be given iv on day -4, and 1.5 mg ATG-rabbit /kg will be given iv on days -3,-2 and -1 over 10 hours.~HSCT day 0: Reinfusion of a minimum of 3,0 x 106 CD 34+ cells/kg body weight."
88970421|NCT03477500|Active Comparator|Alemtuzumab, Cladribine or Ocrelizumab|Alemtuzumab, Cladribine or Ocrelizumab administered after the label of the study drug.
88970422|NCT03467698|Experimental|Active tDCS|active HD-tDCS will be administered
88970423|NCT03467698|Sham Comparator|Sham tDCS|sham HD-tDCS will be administered
88970424|NCT03439514|Experimental|Part 1 Double-blind Treatment|ARRY-371797 (PF-07265803) tablet orally OR matching placebo tablet orally
88970425|NCT03439514|Experimental|Part 2 Open-label Treatment|ARRY-371797 (PF-07265803) tablet orally
88970426|NCT03421834|Experimental|Prophylactic VT ablation prior to ICD implantation|
88970427|NCT03421834|Active Comparator|ICD implantation and optimal medical treatment|ICD implantation and optimal medical care until at least 2 appropriate ICD shock occurs or an arrhythmic storm and catheter ablation thereafter.
89571819|NCT04863235|Experimental|Intervention Group|Session 1: Participants will meet individually with a research assistant to discuss their type 2 risk, discuss benefits of engaging in 150 minutes of moderate-to-vigorous physical activity per week and set a physical activity goal. First 30 minutes of each subsequent session will be ideal care (as described above in the control group). Last 30 minutes of sessions 2-6, self-compassion condition participants will learn to apply self-compassion to their prediabetes experience and physical activity. Session 2: Introduction to self-compassion. Session 3: Yin and Yang of self-compassion. Session 4: Mindfulness. Session 5: Mindfulness and Resistance. Session 6: Meeting Difficult Emotions. Session 7: Embracing the Good. Session 8: Applying Self-compassion to Physical Activity and Moving Forward.
89571820|NCT03048097|Experimental|All Participants|Subjects with high-likelihood of cardiac sarcoidosis.
89571821|NCT05516303||Case|MS patients treated with fingolimod who experienced liver enzymes elevation
89571822|NCT05516303||Control|MS patients treated with fingolimod not experiencing elevated liver enzymes
89571823|NCT04863079|Experimental|Pembrolizumab for Postoperative Adjuvant Treatment of ESCC|Participants receive pembrolizumab 200 mg IV, Q3W, up to one year or disease progression or intolerance as postoperative adjuvant treatment of ESCC with pN+.
89571824|NCT05512325||Gene evolution of glioma in vivo|Group A: gene evolution with relapsed. From the first day after the operation, the ctDNA was extracted from TISF before concurrent chemoradiotherapy as the baseline, and then the ctDNA was detected again after concurrent chemoradiotherapy. For the third time, ctDNA was detected in intensive chemotherapy with temozolomide. The image showed that the tumor progress was detected for the fourth time, and the ctDNA was detected for the fifth time when the tumor recurred. Patients with glioma were routinely treated with temozolomide chemotherapy from the 4th week after operation, for 5 days continuously, once every 4 weeks, with a single dose as follows: Single dose = BSA (body surface area) * 150mg/m2/day BSA(Body Surface Area)=[weight (kg)* height (cm)/3600]2,
89571825|NCT05512325||Gene evolution and molecular response under Bevacizumab treatment|After the recurrence, temozolomide combined with bevacizumab was used for chemotherapy, After bevacizumab was applied after six week , ctDNA is tested every six weeks. temozolomide combined with bevacizumab (600mg) in the course of tumor progression once a month.
89571826|NCT04868383|Experimental|Single pilot arm|In this single arm pilot study, all participants will receive access to a novel smartphone app designed to support PrEP uptake and adherence for a 6 month period.
89571827|NCT03047863|Experimental|Repair Control EGF®|EGF cream was applied. Half of face was treated with emollient containing EGF.
89571828|NCT03047863|Placebo Comparator|Cream without rhEGF|Placebo cream without EGF was applied. The other half of face was treated with only emollient which was not containing EGF.
89571829|NCT04868227|Experimental|INTERVENTION STUDY|TREATED WITH 3200IU FULTIUM VITAMIN D3
89571830|NCT04873531|Experimental|Neostigmine|"For the Neostigmine (N) group, neostigmine (0.03 mcg / kg) and glycopyrrolate with a 5:1 ratio will be administered just after tracheal intubation.~Investigators evaluate the quality of signal of IONM during the surgery."
89571831|NCT04873531|Placebo Comparator|Normal saline|"For the Normal saline (NS) group, normal saline with a same volume of the N group will be administered just after tracheal intubation.~Investigators evaluate the quality of signal of IONM during the surgery."
89571832|NCT03045601|Experimental|CT-FFR|Analyse With New CT-FFR Method
89571833|NCT03045601|Active Comparator|Stress echocardiography|Analyse With invasive FFR and stress echocardiography
89571834|NCT02572817|Experimental|High-titer anti-influenza plasma|Participants received two intravenous infusions of high-titer anti-influenza plasma on Study Day 0.
89571835|NCT02572817|Active Comparator|Low-titer anti-influenza plasma|Participants received two intravenous infusions of low-titer anti-influenza plasma on Study Day 0.
89571836|NCT04862845|Active Comparator|Patients in group I (PD group)|
89571837|NCT04862845|Active Comparator|patients in group II (P group)|
89571838|NCT04862845|Sham Comparator|patients in group III (C groups)|
89571839|NCT04873609|No Intervention|No primary care provider (PCP) appointment, No patient outreach|400 patients that did not have an upcoming PCP appointment in 6 months were randomly assigned to control group and did not receive a patient portal message with order for HCV antibody screening
88970428|NCT03420521|Other|Nivolumab plus Ipilimumab|Nivolumab 240 mg IV over 60 minutes every 2 weeks (Q2W) Ipilimumab 1mg/kg IV over 30 minutes every 6 weeks (Q6W)
88970429|NCT03412045|Experimental|treatment|this preliminary study will be a convenience sample of patients admitted to hospital for vaso-occlusive sickle cell crisis to be treated with hyperbaric oxygen in an effort to ameliorate pain and shorten the length of stay. In this sense, hyperbaric oxygen will be used as a treatment drug. Results will be compared with historical controls
89571840|NCT04873609|Active Comparator|No PCP appointment, Patient outreach|400 patients that did not have an upcoming PCP appointment in 6 months were randomly assigned to receive a patient portal message with order for HCV antibody screening
89571841|NCT04873609|No Intervention|PCP appointment, No patient outreach|400 patients that had an upcoming PCP appointment in 6 months were randomly assigned to control group and did not receive a patient portal message with order for HCV antibody screening
89571842|NCT04873609|Active Comparator|PCP appointment, Patient outreach|400 patients that had an upcoming PCP appointment in 6 months were randomly assigned to receive a patient portal message with order for HCV antibody screening
88970430|NCT03411096|Experimental|Quadratus lumborum block|Quadratus lumborum block with 0.75% ropivacaine
88970431|NCT03411096|Placebo Comparator|Placebo|Quadratus lumborum block with normal saline
88970432|NCT03394976||Study population|Participants will be enrolled passively at health centres. Passive enrolment will include patients referred to or presenting directly at the health facilities.
88970433|NCT03334305|Experimental|Group A|Dose-intensified TMZ with TTRNA-DC vaccines with GM-CSF and TTRNA-xALT plus Td vaccine without Autologous Hematopoietic Stem cells (HSCs)
88970434|NCT03334305|Experimental|Group B|Dose-intensified TMZ with TTRNA-DC vaccines with GM-CSF and TTRNA-xALT plus Td vaccine with Autologous Hematopoietic Stem cells (HSCs)
89571843|NCT04873141||Case Group|All the patients suffering from severe covid pneumonia and laboratory parameter suggestive of cytokine release syndrome.
89571844|NCT04862377|Active Comparator|Standard treatment group|"Infants randomised to the standard treatment arm will receive intratracheal surfactant as per usual clinical indications of respiratory distress syndrome in these preterm infants.~In that sense, and based in those clinical indications, we have developed a risk calculator for surfactant administration in preterm infants ≤32 weeks GA. We will use it to decide what patients will receive surfactant (calculator available on: https://1drv.ms/x/s!Arjkl83HIXSngP8TWh8O6oi6Ztdw3w?e=gNCMxP)."
89571845|NCT04862377|Experimental|Interventional treatment group|"Infants randomised to the interventional treatment arm will receive intratracheal surfactant mixed with budesonide. Indication of surfactant, as equal as for the standard treatment arm, will be decided using the calculator."
89571846|NCT04862377|No Intervention|Control group|Infants ≤32 weeks with no indications for surfactant administration. Their clinical management will be the usual in our neonatal unit.
89571847|NCT05516225|Experimental|PBCLN-003, 1.8 g daily in 3 divided oral doses for 7 days|
89571848|NCT05516225|Experimental|PBCLN-003, 3.6 g daily in 3 divided oral doses for 7 days|
89571849|NCT05516225|Experimental|PBCLN-003, 9 g daily in 3 divided oral doses for 7 days|
89571850|NCT05516225|Experimental|PBCLN-003, 18 g daily in 3 divided oral doses for 7 days|
89571851|NCT04867993|Active Comparator|asphyxiated neonates treated with amikacin and hypothermia|Amikacin (Likacin®; 500 mg/2mL vial; Lisapharma S.p.A., Erba, Italy) is given to the neonate, as an IV infusion via umbilical vein over 20 min by use of a syringe-pump (Braun; B. Braun Medical Inc., Bethlehem, PA USA). Infusion is followed by slow 0.5 mL Sodium chloride 0.9% flush.
89571852|NCT04867993|Placebo Comparator|asphyxiated neonates treated with amikacin|Amikacin (Likacin®; 500m g/2mL vial; Lisapharma S.p.A., Erba, Italy) is given to the neonate, as an IV infusion via umbilical vein over 20 min by use of a syringe-pump (Braun; B. Braun Medical Inc., Bethlehem, PA USA). Infusion is followed by slow 0.5 mL Sodium chloride 0.9% flush.
89571853|NCT04873219|Active Comparator|CAD/CAM milled complete denture|the dentures were milled out of a block of pre-polymerized PMMA resin (Avadent, Global dental Science, Netherlands)
89571854|NCT04873219|Experimental|CAD/CAM rapid prototyped complete denture|the dentures will be 3D-printed from a liquid PMMA, including the teeth (NexDent, Netherlands)
89571855|NCT04872985|Experimental|Arm 1: Pyrotinib+ AC/EC followed by T|400 mg Pyrotinib orally once per day with four cycles of epirubicin (100 mg/m2) (or doxorubicin hydrochloride liposome injection 30mg/m2) and cyclophosphamide (600 mg/m2) intravenously, once every 3 weeks, followed by four cycles of docetaxel (100 mg/m2) intravenously, once every 3 weeks (or 12 cycles of weekly nab-paclitaxel 120mg/m2 intravenously) .
89571856|NCT04872985|Placebo Comparator|Arm 2: Placebo+ AC/EC followed by T|400 mg placebo orally once per day with four cycles of epirubicin (100 mg/m2) (or doxorubicin hydrochloride liposome injection 30mg/m2) and cyclophosphamide (600 mg/m2) intravenously, once every 3 weeks, followed by four cycles of docetaxel (100 mg/m2) intravenously, once every 3 weeks (or 12 cycles of weekly nab-paclitaxel 120mg/m2 intravenously) .
89571857|NCT04872907|Experimental|adhesive system + flowable composite|Side of the mouth randomlly assigned to this arm will receive self etch adhesive system and flowable composite combination on temporary molars and self etch adhesive system on anterior temporary teeth at baseline, M6, M12, M18
89571858|NCT04872907|Active Comparator|Fluoride varnish|Side of the mouth randomly assigned to this arm will receive the fluride varnish at baseline, M6, M12, M18 on the temporary teeth
89571859|NCT02566109|Other|Fast MRI|All patients who agree to participate in this study will have a 10 minute fast MRI scan and Baseline and 6 month time periods. The fast MRI will be used to determine if cardiovascular injury can be detected early while patients are receiving chemotherapy treatment.
88970435|NCT03330821|Experimental|Treatment (idarubicin, cytarabine, pevonedistat)|"INDUCTION: Patients receive idarubicin IV over 10-15 minutes on days 1-3, cytarabine IV over 1-3 hours on days 1-7, and pevonedistat IV over 60 minutes on days 1, 3, and 5. Patients with gross residual disease on day 14 bone marrow may receive a second course of induction chemotherapy.~CONSOLIDATION: Patients who achieve CR and will not undergo bone marrow transplant receive cytarabine IV over 3 hours every 12 hours on days 1, 3, and 5. Treatment repeats every 28-35 days for 4 courses in the absence of disease progression or unaccepted toxicity."
88970436|NCT03309475|Experimental|SocialMIND|The experimental arm will receive treatment as usual (both psychotropic treatment and psychosocial treatment) and mindfulness-based social cognition group training (SocialMind), specifically designed for patients with first episode psychosis by the research team. There will be a first phase (intensive intervention) consisting of 8 weekly sessions and a second phase (follow-up sessions) consisting of 4 fortnightly sessions and 5 monthly sessions.
88970437|NCT03309475|Active Comparator|Psychoeducational Multicomponent Intervention|The active comparator arm will receive treatment as usual (both psychotropic treatment and psychosocial treatment) and a psychoeducational multicomponent intervention for psychosis.There will be a first phase (intensive intervention) consisting of 8 weekly sessions and a second phase (follow-up sessions) consisting of 4 fortnightly sessions and 7 monthly sessions.
89571860|NCT04868071|Experimental|High-Speed Resistance Training|Participants performed exercises 8 times (sets) with 3-5 repetitions at 70%-75% of the maximal strength.
89571861|NCT04868071|Experimental|Low-Speed Resistance Training|Participants performed exercises 4 times (sets) with 8-10 repetitions at 70%-75% of the maximal strength.
89571862|NCT04868071|No Intervention|Control Group|No activities
89571863|NCT04861909||AT LISA tri 839MP|Patients implanted with AT LISA tri 839MP
89571864|NCT03047707|Experimental|S-Shearwave and TE|
89571865|NCT02566031|Experimental|Indacaterol and glycopyrronium (QVA149)|QVA149 110/50 μg capsules for inhalation delivered once daily via single-dose dry powder inhaler (SDPPI) for 12 weeks
89571866|NCT02566031|Active Comparator|Tiotropium|Tiotropium 18 μg capsules for inhalation delivered once daily via HandiHaler® device for 12 weeks
89571867|NCT04861753||Reiki|"The modern-day Reiki (pronounced ray-kee) practiced in the United States originated in Japan with Mikao Usui in the early 1900s. Reiki is a complementary and adjuvant therapeutic technique. Reiki, which is classified as an energy healing therapy, is a technique of channeling universal energy in order to reduce stress, promote relaxation, and enhance well-being."
89571868|NCT04861753||Back massage|Massage therapy involves the manipulation of the soft tissues of the body by touch. It consists of gentle movements such as effleurage, petrissage and percussion.
89571869|NCT04861753||Control|Routine postoperative care was given to the control group without any intervention
89571870|NCT04861675||Prospective follow up cohort study|Assessment of Changes in Oral Health-related Quality of Life , Oral Hygiene status and Body Growth in Egyptian Children with Special Health Care Needs following Dental Treatment under General Anaesthesia
89571871|NCT04769765|Experimental|All patients on the basic diabetic program, eligible for an individualized care pathway.|This research aims to demonstrate the feasibility of telemedicine through collaborative tele-expertise for the collegial definition of an individualized care pathway, in the context of diabetic patients with unscheduled hospitalizations repeated throughout the year (≥ 2/year). The feasibility will be assessed by the number of patients who have had at least 3 of the 4 planned follow-up visits, that is to say, who are eligible for the individualized care pathway.
89571872|NCT03045523|Experimental|GLPG2222 Dose 1|
89028945|NCT05292313|Other|Single distal femur implant|Single implant constructs will be either a retrograde intramedullary nail with interlocking screws or a single plate and screw construct.
89571873|NCT03045523|Experimental|GLPG2222 Dose 2|
89571874|NCT03045523|Placebo Comparator|Placebo|
89571875|NCT04984967|Experimental|Insertion of peripheral venous catheter with micro-guide|
89571876|NCT04984967|Other|Classic insertion of peripheral venous catheter, without micro-guide|
89571877|NCT04872829||multifocal IOL group|patients with unilateral and bilateral multifocal IOL
89571878|NCT04872829||monofocal IOL group|patients with unilateral and bilateral monofocal IOL
89571879|NCT03045211|Experimental|In-Home Standing Table|"Participants in this arm will receive a dynamic standing table to be used in their home for at least two hours per day for at least five days per week for a 16-week period. Specific activities will be tracked with a logbook. PD subjects will be coached by a physical therapist on proper body positioning at the table, use of anti-fatigue mat, and optimal monitor height. The physical therapist will adhere to the neutral body positioning guidelines as provided by the OSHA. The physical therapist will also perform an in-home safety assessment of the office or room in which the table will be placed to ensure safety not only for the users but also for family members or children. The physical therapist will monitor each participant throughout the study by making biweekly compliance phone calls.~In addition, this group will received standard of care, which is weekly group exercise sessions during the 16-week period of table use."
89571880|NCT03045211|No Intervention|Standard of Care|this group will received standard of care only, which is weekly group exercise sessions during a 16-week period. Instructions, coaching, and compliance phone calls will also be provided to the participants of this arm such that both arms have the same amount of contact time with the physical therapist.
89571881|NCT04872361|Placebo Comparator|Low PEEP|Low positive end-expiratory pressure (PEEP) and no recruitment maneuver (RM)
89571882|NCT04872361|Active Comparator|High PEEP|High positive end-expiratory pressure (PEEP)
89571883|NCT04872361|Active Comparator|High PEEP/RM|High positive end-expiratory pressure (PEEP) and recruitment maneuver (RM)
89571884|NCT03045367||Outpatients|Phacoemulsification, intraocular lens implant, vitrectomy.
88970438|NCT03272828|Active Comparator|Parallel sided implant Group|A Parallel sided titanium dental implant will be placed in the edentulous mandible.
88970439|NCT03272828|Active Comparator|Tapered shaped implant Group|A tapered shaped titanium dental implant will be placed in the edentulous mandible.
88970440|NCT03270501|Experimental|Arm 1: Golimumab|
88970441|NCT03270241|Experimental|Phototherapy (NB-UVB)|Phototherapy (NB-UVB) will be administered for all enrolled subjects. The starting dosage will be 250 mJ/cm2. The dose will be increased by 10% with each treatment, as long as there are no side effects with treatment.
88970442|NCT03258567|Experimental|Nivolumab (A)|Nivolumab, 3mg/kg IV every 2 weeks for up to 2 years in subjects with responding disease with clinical benefit if they are tolerating treatment (closed effective with activation of Amendment C)
88970443|NCT03258567|Experimental|Nivolumab (B)|Nivolumab, 480 mg IV every 4 weeks for up to 2 years in subjects with responding disease with clinical benefit if they are tolerating treatment
88970444|NCT03257761|Experimental|Treatment (guadecitabine, durvalumab)|Patients receive guadecitabine SC QD on days 1-5 and durvalumab IV over 60 minutes on day 8. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88970445|NCT03250273|Experimental|Arm A - Cholangiocarcinoma|
88970446|NCT03250273|Experimental|ARM B - Pancreatic Cancer|
88970447|NCT03214263||Cross-sectional samples:|Any patient followed in the DANBIO registry may be invited to participate when they meet for a scheduled routine clinical visit. These patients provide one cross-sectional blood sample.
88970448|NCT03214263||Longitudinal samples:|Any patient followed in the DANBIO registry will be invited to participate when they start treatment with a new DMARD. Switching from csDMARD to bDMARD, or from one bDMARD to another bDMARD indicates a new baseline.
88970449|NCT03214263||Samples of other biological material:|Patients followed in the DANBIO registry may be invited to participate if scheduled for one of the following procedures: joint puncture with extraction of synovial fluid, surgery or tissue sampling involving synovia, cartilage, bone, bone-marrow or other tissues. Representative samples from the synovial fluid or relevant tissue are collected after routine diagnostic or therapeutic analyses have been done
88970450|NCT03189381|Experimental|Cohort A|Standard PCI dose
88970451|NCT03189381|Experimental|Cohort B|Low PCI dose
88970452|NCT03128359|Experimental|Regimen A (fludarabine, melphalan, PBSC HCT, GVHD prophylaxis)|"Patients receive fludarabine phosphate IV over 60 minutes on days -7 to -3 and melphalan hydrochloride IV over 20 minutes on day -2.~Patients undergo PBSC HCT on day 0.~Patients receive cyclophosphamide IV over 1-2 hours on days 3-4, mycophenolate mofetil IV or PO TID beginning on days 5 and stopping on day 35 if no severe GVHD is present-35, and tacrolimus IV continuously on days 5-180 with a taper beginning on day 90 in the absence of disease progression or unacceptable toxicity."
88970453|NCT03128359|Experimental|Regimen B (fludarabine, busulfan, PBSC HCT, GVHD prophylaxis)|"Patients receive fludarabine phosphate IV over 1-3 hours and busulfan IV over 3 hour on days -5 to -2.~Patients undergo PBSC HCT on day 0.~Patients receive cyclophosphamide IV over 1-2 hours on days 3-4, mycophenolate mofetil IV or PO TID beginning on days 5 and stopping on day 35 if no severe GVHD is present-35, and tacrolimus IV continuously on days 5-180 with a taper beginning on day 90 in the absence of disease progression or unacceptable toxicity."
89571885|NCT04763681|Experimental|Immediate Couple HOPES|Immediately assigned to receive seven modules of an Internet-delivered self-help intervention with paraprofessional coaching for PTSD completed at the participant's own pace within 8 weeks.
89571886|NCT04763681|No Intervention|Delayed Intervention|Participants will not receive Couple HOPES for the first 8 weeks, and complete assessments at the beginning, middle, and end of this period. After this 8-week delay, participants will then receive seven modules of an Internet-delivered self-help intervention with paraprofessional coaching for PTSD completed at the participant's own pace within 8 weeks.
89571887|NCT04861129|Experimental|Bowen therapy group|The experimental group will receive Bowen therapy according to ISBT Bowen Therapy® (Black & Murray, 2005). It may include sequences 1, 4, 2, hamstrings (movements 1-6) and sacrum sequences in the prone position, and hamstrings sequence (7-18 movements) and 3 in the supine position,. The sequences may also include Bowen movements in the scalenes, trapezius, all erector spinae, sacro-iliac joint ligaments, gluteus maximus and medius, tensor fasciae latae, and gastrocnemius. The application of Bowen sequences is varied between sessions and participants depending on the presenting functional deficit and treatment response.
89571888|NCT04861129|Sham Comparator|Sham Bowen Therapy group|The control group will receive a sham Bowen therapy with the same number of treatment session, treatment time and rest time, that received in the experimental group. However, it consists of gently placing the hands over the areas just enough to maintain contact for the desired time as required by Bowen Therapy, without applying Bowen movement, which is considered the active principle of this technique.
89571889|NCT05507489|Experimental|treatment group|Jinzhen oral liquid(for 3 years old, 10 ml once, twice a day; for 4 to 7 years old, 10 ml a time, 3 times a day; for 8 to 18 years old, 15 ml a time, 3 times a day)
89571890|NCT05507489|Active Comparator|control group|The usage and dosage of Jinhua Qinggan granules were determined by the researcher according to the patient's condition and recorded truthfully
89571891|NCT04761341|Experimental|AMD|
89571892|NCT04761341|Active Comparator|healthy control|
89571893|NCT05507411|Other|CCR-Watch and Wait|
89571894|NCT05507411|Other|CCR-Surgery|
89571895|NCT05507411|Other|Non-CCR|
89571896|NCT05515913||ASD ( autistic spectrum disorder)|Children already diagnosed with autistic spectrum disorder
89571897|NCT05515913||TDC (typically developing children)|Children within the typically development
89571898|NCT02569853|Experimental|DFN-11|DFN-11 active injection upon occurrence of migraine
89571899|NCT02569853|Placebo Comparator|Placebo|Placebo injection upon occurrence of migraine
89571900|NCT04894643|Other|Preoperative, proton- radiotherapy combined with chemotherapy|Patients treated with three cycles of chemotherapy with Nab-PACLitaxel (Abraxane®) (125 mg/m² on day 1, 8, 15; powder for making a infusion solution) and Gemcitabine (1000 mg/m² on day 1, 8, 15; powder for making a infusion solution), followed by concomitant chemotherapy with capecitabine (1.660ml/m² on 5 days per week during the radiation therapy) and proton-therapy (with simultaneous integrated boost (SIB) 50.4 Gy Relative Biological Effectiveness (RBE) and 60.2 Gy (RBE) in 28 fractions of 1.8 Gy (RBE) and 2.15 Gy (RBE) 5 days per week), followed by re-evaluation and surgery
89571901|NCT05511857|Experimental|The effect of a self-distanced view on pain perception.|The participant will exert self-distanced, third-person self-talk following a cue-card while induced with experimental pain.
89571902|NCT05511857|Experimental|The effect of a self-immersed view on pain perception.|The participant will exert self-immersed, first-person self-talk following a cue-card while induced with experimental pain.
88970454|NCT03128359|Experimental|Regimen C (fludarabine, TBI, PBSC HCT, GVHD prophylaxis)|"Patients receive fludarabine phosphate IV over 60 minutes on days -7 to -5 and TBI BID on days -4 to -1.~Patients undergo PBSC HCT on day 0.~Patients receive cyclophosphamide IV over 1-2 hours on days 3-4, mycophenolate mofetil IV or PO TID beginning on days 5 and stopping on day 35 if no severe GVHD is present-35, and tacrolimus IV continuously on days 5-180 with a taper beginning on day 90 in the absence of disease progression or unacceptable toxicity."
88970455|NCT03122886|Experimental|Group I (fat emulsion)|Patients receive fat emulsion IV immediately before each dose of either carboplatin or oxaliplatin. Treatment continues for up to 2 years in the absence of disease progression or unacceptable toxicity.
88970456|NCT03122886|Placebo Comparator|Group II (placebo)|Patients receive placebo IV immediately before each dose of either carboplatin or oxaliplatin. Treatment continues for up to 2 years in the absence of disease progression or unacceptable toxicity.
88970457|NCT03113422|Experimental|Induction Venetoclax|Cycle 1-6: Obinutuzumab intravenously (IV) and bendamustine IV. Cycle 2-6: Venetoclax (oral)
88970458|NCT03113422|Experimental|Maintenance Venetoclax|Patients with stable or improved disease will receive venetoclax by mouth daily for 24 cycles (1 cycle=1 month) and obinutuzumab IV every 2 months for 12 cycles. Patients with no evidence of disease will receive obinutuzumab IV every 2 months for 12 cycles.
88970459|NCT03069924|Active Comparator|No NRT - Unframed Messaging|Unframed smoking cessation materials, but no NRT and no gain-framed messaging.
88970460|NCT03069924|Experimental|NRT plus Gain-framed Messaging|Gain-framed messaging plus NRT.
89571903|NCT05511857|Experimental|The effect of non-view, self-talk on pain perception.|The participant will exert self-talk following a cue-card while induced with experimental pain.
89571904|NCT05511857|No Intervention|Pain perception in induced, experimental pain.|Control group. This group will be induced with experimental pain, but will receive no specific task to exert.
89571905|NCT05511545|Experimental|Patient Education Booklet|"One day before surgery:~The patients in the training group were informed about the study one day before the operation and their verbal and written consents were obtained. Afterwards, the Descriptive Information Form, the State-Trait Anxiety Inventory, and the Surgery-Specific Anxiety Inventory were administered. A training booklet was prepared by the researchers in line with the recommendations of the European Association of Urology and the relevant literature. The training took an average of 25-30 minutes. Afterwards, the questions of the patients were answered and the training booklet was given to the patient.The scales were reapplied on the morning of the surgery.~Before discharge, the State Anxiety Scale and the Readiness to Discharge Scale-Patient Self-Assessment Form were administered. Then, the Adult Patient Discharge Readiness Scale-Nurse Evaluation Short Form was filled by the clinical nurse caring for the patient."
89571906|NCT05506865|Experimental|Indacaterol|Indacaterol 150 mcgr, one inhaled capsule, dose once daily, with dry powder inhaler device.
89571907|NCT05506865|Active Comparator|Tiotropium|Tiotropium 18 mcgr, 1 inhaled capsule, dose once daily, with dry powder inhaler device
89571908|NCT05506709|Experimental|Test|Subjects receive only the test product (medical device/nasal pump containing moderately hypertonic solution produced based on 100% natural sea water rich of marine trace elements with added manganese and calcium)
89571909|NCT05506553|Active Comparator|Control arm|Bilateral insertion of Alcon IQ Toric IOL in micro-monovision
89571910|NCT05506553|Experimental|Intervention arm|Bilateral insertion of Eyhance Toric II IOL
89571911|NCT05506397|Experimental|Acupressure (intervention group)|Acupressure was applied to individuals in the acupressure group every day for 12 days.
89571912|NCT05506397|Placebo Comparator|control group|Placebo acupressure was applied to the individuals in the placebo acupressure group in accordance with the same protocol.
89571913|NCT04140773|Experimental|D-serine group|Oral administration of 2g D-serine per day, for 6 weeks.
89571914|NCT04140773|Placebo Comparator|Placebo group|Oral administration of 2g Placebo (Mannitol) per day, for 6 weeks.
89571915|NCT05506319|Experimental|norepinephrine group|Initial suspension of norepinephrine.
89571916|NCT05506319|Experimental|vasopressin group|Initial suspension of vasopressin.
88970461|NCT03056794||PDC Deficiency|Pyruvate Dehydrogenase Complex Deficiency Disease
88970462|NCT03040596|Experimental|inhaled steroid + voice therapy|fluticasone inhaler, 88mcg (2 puffs), twice a day for 4 weeks + standard voice therapy
88970463|NCT03040596|Other|voice therapy only|standard voice therapy
88970464|NCT03023696|Experimental|Foraminotomy Group|Prophylactic bilateral cervical keyhole foraminotomy will be done in addition to their decompression surgery
88970465|NCT03023696|Active Comparator|Control Group|Cervical decompression will be done without prophylactic bilateral foraminotomy
89571917|NCT05506007|Experimental|[Part A] DA-5216|
89571918|NCT05506007|Experimental|[Part A] DA-5216-R|
89571919|NCT05506007|Experimental|[Part B] DA-5216(Fasting)|
89571920|NCT05506007|Experimental|[Part B] DA-5216(Fed)|
89571921|NCT05515757|Other|Mobile app-based contingency management|All participants will be enrolled into an 8-week mobile app-based contingency management intervention starting during a prolonged hospitalization.
88970466|NCT03003533|Experimental|SPK-8011|All participants who meet the eligibility criteria will receive an outpatient single intravenous (i.v.) administration of SPK-8011.
88970467|NCT02986984||Confirmed Diabetic Nephropathy|Patients undergoing a clinically indicated kidney biopsy with a history of diabetes who satisfy pre-specified criteria for diabetic nephropathy.
88970468|NCT02986984||Confirmed Non-diabetic Nephropathy|Patients undergoing a clinically indicated kidney biopsy with a history of diabetes who fail pre-specified criteria for diabetic nephropathy.
88970469|NCT02977442|Experimental|exercise|12 week exercise program, 5 days/week, 60 min/day
88970470|NCT02977442|No Intervention|standard of care|12 week standard of care recommendations
88970471|NCT02910401|Active Comparator|Asthmatic|Asthmatic subjects will be infected with Rhinovirus (GMP RV16 human (H)RV-16)
88970472|NCT02910401|Active Comparator|Allergic rhinitis|Allergic rhinitis subjects will be infected with Rhinovirus (GMP RV16 HRV-16)
88970473|NCT02910401|Active Comparator|Healthy control|Healthy controls will be infected with Rhinovirus (GMP RV16 HRV-16)
88970474|NCT02863068|Placebo Comparator|control|patients will receive placebo and standard of care
88970475|NCT02863068|Experimental|topical sodium nitrite|patients will receive 2% topical sodium nitrite cream and standard of care
89571922|NCT04591067||Hip Dysplasia group|Subjects who have undergone a periacetabular osteotomy (PAO) for hip dysplasia within the last 1-5 years.
89571923|NCT05515133||Observation group of newly diagnosed glioblastoma patients with high-level psychological stress|The patients had high threshold levels of perceived stress, psychological distress, fear, anxiety, and depression as assessed by psychologists
89571924|NCT05515133||Observation group of newly diagnosed glioblastoma patients with low-level psychological stress|The patients had lower than threshold levels of perceived stress, psychological distress, fear, anxiety, and depression as assessed by psychologists
89571925|NCT04969445||Vaccine group|Participants in this arm have received 3 doses of HPV 16/18 bivalent vaccine that contains 40μg HPV 16 virus-like particle antigen and 20μg HPV 18 virus-like particle antigen adsorbed in alum-adjuvant.
89571926|NCT04969445||Control group|Participants in this arm have received 3 doses of HEV vaccine that contains 30μg HEV virus-like particle antigen adsorbed in alum-adjuvant.
89571927|NCT05505695|Experimental|"Brace&Exercise Group"|The patients who were the rigid brace and performed the SSE therapy in the specified constituted the Brace & Exercise. Experimental group patients wore full-time rigid brace and Schroth exercises for 60 minutes 5 days a week by the physician.
89571928|NCT05505695|Active Comparator|"Brace Group"|The patients who wore full-time rigid braces but did not perform exercise constituted the Brace group. Comparator group patients wore full-time brace only, did not perform Schroth exercises.
89571929|NCT04945187|No Intervention|Standard care|No intervention. This arm will continue standard clinical practice consisting of clinical assessment regarding side effects and management before each cycle of chemotherapy conducted by physicians.
89571930|NCT04945187|Experimental|Intervention group|Intervention: This arm will be assigned to the intervention which will be nurse-led consultations based on electronic patient-reported outcomes. The patients will report ePRO weekly during chemotherapy and the answers will be used proactively in the nurse-led consultations. Nurses will conduct the clinical assessment regarding side effects and management before each cycle of chemotherapy.
89571931|NCT05505539|Experimental|5-fluorouracil|Participants will receive up to 3 intralesional 5-fluorouracil injections (0.25 mL of a 50mg/mL solution) once every 2 weeks into an oral leukoplakia lesion.
89571932|NCT04588103|No Intervention|Control|Participants will be asked to maintain their regular physical activity habits for the duration of the 8-week intervention period.
89571933|NCT04588103|Experimental|Heat therapy|Participants will be asked to undergo 45 minutes of lower limb hot water immersion (42 degrees C) 3 times per week for 8 weeks.
88970476|NCT02840240|Experimental|Gabapentin enacarbil|Patients going through elective hip or knee replacement surgery with spinal anesthesia will receive Gabapentin enacarbil for 5 days
88970477|NCT02840240|Placebo Comparator|Placebo|Patients going through elective hip or knee replacement surgery with spinal anesthesia will receive placebo for 5 days
88970478|NCT02824471||Minor SCD Group, Ages 12-17|No Intervention. Use of discarded blood/tissue only
88970479|NCT02824471||Adult SCD. Ages 18+|No Intervention. Use of discarded blood/tissue only
88970480|NCT02816697|Active Comparator|Cease-Aim 1|"Cease Implementation~100 Patients after CEASE Implementation~Exit Interview and Tobacco Use Survey"
88970481|NCT02816697|Active Comparator|Pre Cease Implementation Aim 2|"50 Current or former smokers (3 months +/-2 month) patients in usual care (before CEASE implementation)~Tobacco Use Survey (Baseline,1- 6 Months)~Biochemical verification"
88970482|NCT02816697|Experimental|After Cease Implementation Aim 2|"50 Current or former smokers (3 months +/-2 month)~Tobacco Use Survey (Baseline,1- 6 Months)~Biochemical verification"
88970483|NCT02816697|Active Comparator|Usual Care-Aim 1|"Usual Care Tobacco Treatment Services~100 patients in usual care~Exit Interview and Tobacco Use Survey"
88970484|NCT02816697|No Intervention|Clinician and Staff Survey|- Interview clinicians and support staff (40)
88970485|NCT02718820|Experimental|Docetaxel plus pembrolizumab|Docetaxel 75mg/m2 plus pembrolizumab 200mg will be administered every 3 weeks intravenously for 6 cycles. Thereafter pembrolizumab 200mg every 3 weeks will be given as maintenance therapy until progression.
88970486|NCT02657954|Experimental|Compensatory Cognitive Training (CCT)|Compensatory Cognitive Training
88970487|NCT02657954|Active Comparator|Holistic Cognitive Education (HCE)|Holistic Cognitive Education
88970488|NCT02609503|Experimental|Open label|Pembrolizumab
88970489|NCT02609503|Other|Radiation|Intensity Modulated Radiation Therapy (IMRT)
88970490|NCT02539537|Active Comparator|Arm A: Gemcitabine|Gemcitabine 1000 mg/m² IV infusion over 30 minutes on D1 of each week for the 4 weeks of the first cycle (1 cycle = 4 weeks). For the following five cycles, gemcitabine infusion on D1, D8, and D15 of each cycle, followed by 1 week without injection (i.e. in total 4 cycles over 24 weeks; with 19 administrations of Gemcitabine).
88970491|NCT02539537|Experimental|Arm B: Folfirinox|"Administered once every 14 days for 24 weeks (12 cycles). A cycle equals 14 days with injection on D1 of each cycle. Treatment starts with oxaliplatin (85 mg/m²) administration; IV infusion over 2 hours, followed by the simultaneous administration (using a Y-tubing) of folinic acid 400 mg/m² (racemic) (or 200 mg/m² if L-folinic acid) IV infusion over 2 hours and irinotecan 180 mg/m² IV infusion over 90 minutes. The irinotecan will begin 30 minutes after the start of the folinic acid infusion.~5-Fluoro-uracil (5-FU) IV 2,400 mg/m²/h will be administered over 46 hours after the end of the folinic acid infusion, i.e. 1200 mg/m²/day for the duration of 2 days.~Treatment will be continued for 24 weeks (12 cycles)."
88970492|NCT02537613|Experimental|Arm A- obinutuzumab -> ibrutinib|Participants enrolled in Arm A will receive obinutuzumab weekly starting cycle 1, and will receive obinutuzumab monthly during cycles 2-6. Participants will begin to take ibrutinib daily starting cycle 2 and will continue with daily ibrutinib until the end of treatment.
88970493|NCT02537613|Experimental|Arm B- ibrutinib -> obinutuzumab|Participants enrolled in Arm B will begin to take ibrutinib daily starting cycle 1 and will continue with daily ibrutinib until the end of treatment. Participants will begin to receive obinutuzumab weekly starting cycle 2, and will receive obinutuzumab monthly during cycles 3-7
89571934|NCT04588103|Experimental|Exercise training|Participants will be asked to undergo 45 minutes of moderate-intensity cycling exercise (~40-59% VO2 reserve) 3 times per week for 8 weeks.
89571935|NCT04588103|Experimental|Combined training|Participants will be asked to undergo 90 minutes of moderate-intensity cycling exercise and lower limb hot water immersion sequentially 3 times per week for 8 weeks.
88970494|NCT02537613|Experimental|Arm C- obinutuzumab/ibrutinib|Participants enrolled in Arm C will begin to take ibrutinib daily starting cycle 1 and will continue with daily ibrutinib until the end of treatment. At the same time, participants will begin to receive obinutuzumab weekly starting cycle 1, and will receive obinutuzumab monthly during cycles 2-6.
88970495|NCT02479451|Experimental|Nasal theophylline|20 μg intranasal theophylline (theophylline methylpropyl paraben in a 0.4-mL saline solution) once daily (in the morning) into each naris for a total of 6 weeks
88970496|NCT02466776|Active Comparator|Stainless steel staples|Patients in this arm will receive stainless steel staples for skin closure at time of cesarean delivery (CD).
88970497|NCT02466776|Active Comparator|Absorbable subcuticular Suture|Patients will receive absorbable subcuticular suture for skin closure at time of cesarean delivery (CD).
89209066|NCT01581853|Other|Lopinavir/ritonavir 800 mg / 200mg|Kaletra 200/50 mg comprimidos recubiertos con película Lopinavir/ritonavir 800 mg / 200mg will be changed from its approved posology (2 times daily)to once daily in patients with undetectable viral load and in stable treatment with Lopinavir/ritonavir 800 mg / 200mg in monotherapy for at least 6 months
89209067|NCT02594969|Active Comparator|Healthy Group|These subjects do not have atopic dermatitis and are considered healthy. They will participate in the bleach bath and the moisturizer application.
89571936|NCT04943315|Experimental|Monolithic zirconia|To assess the clinical performance and survival of posterior monolithic zirconia crowns
89571937|NCT04943315|Active Comparator|Metal-ceramic|To assess the clinical performance and survival of posterior metal-ceramic crowns
89571938|NCT05514977|Active Comparator|L group|Patients are given 20 ml of 2 % lidocaine for ESPB
89571939|NCT05514977|Active Comparator|H group|Patients are given 40 ml of 1 % lidocaine for ESPB
89571940|NCT04140539|Experimental|Gene Therapy|Infusion OTL-101
89571941|NCT05505461|Experimental|Neoadjuvant therpy|Neoadjuvant chemoradiation plus SOX and PD-1 antibody
89571942|NCT05505383|Experimental|Backward walking training group|This group will participate in a backward walking training program (8-week, 3 times weekly, and 30-min each time) and conventional gait training program (8-week, 3 times weekly, and 45-min each time).
89571943|NCT05505383|Active Comparator|Conventional gait training|This group will participate in a conventional gait training program (8-week, 3 times weekly, and 45-min each time).
89571944|NCT05514743|Active Comparator|Heart rate|"Heart rate monitors can assess a person's heart rate and reveal whether it is high or low. Heart rate Trusted Source is a clinical indicator of overall cardiac health, and it can also help a person determine their performance during a workout."
89571945|NCT05514743|Active Comparator|Blood pressure|It will be carried out before and after interventions to determine the patients functional capacity (in the 7th.day &in the 21st.day.) It will be used as a training tool as well as an assessment tool.
89571946|NCT05511311|Active Comparator|Control|12-week of Standard Therapy using elastic-band
89571947|NCT05511311|Experimental|Intervention|12-week of Resistance Training developed by RSCM using sand-bag
89571948|NCT05514275|Experimental|Endostatin and Capecitabine|Patients received radiotherapy Combined With Endostatin and Capecitabine
89209068|NCT02594969|Experimental|Atopic Dermatitis Group|These subjects have atopic dermatitis and are considered healthy. They will participate in the bleach bath and the moisturizer application.
88970501|NCT02437110|Experimental|ALS|20 participants with ALS and a level of HERV-K:RPP30 greater than or equal to 13
88970502|NCT02314611||PROFEMUR® Gladiator HA Coated Stem|Single study group previously implanted with a primary PROFEMUR® Gladiator HA Coated Modular Femoral Stem (HA = Hydroxyapatite)
88970503|NCT02290834|Active Comparator|ARM 1|"Breast cancer patients treated with chemotherapy~Cognitive, functional and subjective assessments (Pre and Post Treatment)~Imaging (Pre and Post Treatment)~Magnetic Resonance Imaging (MRI) Scan~Magnetic Resonance Imaging (MRI) Scan / Positron Emission Tomography (PET) Scan"
88970504|NCT02290834|Active Comparator|ARM 2|"Non-treated breast cancer patient control~Cognitive, functional and subjective assessments (Post enrollment and 6-14 months later~Imaging (Post Enrollment and at 8-14 months later)~Magnetic Resonance Imaging (MRI) Scan~Magnetic Resonance Imaging (MRI) Scan / Positron Emission Tomography (PET) Scan"
88970505|NCT02290834|Active Comparator|ARM 3|"Healthy control subjects~Cognitive, functional and subjective assessments (Post enrollment and 6-14 months later~Imaging (Post Enrollment and at 8-14 months later)~Magnetic Resonance Imaging (MRI) Scan~Magnetic Resonance Imaging (MRI) Scan / Positron Emission Tomography (PET) Scan"
89571949|NCT05510999|Placebo Comparator|Placebo|Participants will be instructed to take one (1) capsule twice daily before breakfast and dinner with a glass of water for 24 weeks beginning on the Day 1, the day after their baseline visit. If a dose is missed participants are instructed to take the missed dose with the next scheduled dose. Participants will be advised not to exceed 3 capsules daily.
89571950|NCT05510999|Experimental|Water soluble pollen extract fraction|The experimental product contains 180mg (360mg/day) of water soluble pollen extract fraction. Participants will be instructed to take one (1) capsule twice daily before breakfast and dinner with a glass of water for 24 weeks beginning on the Day 1, the day after their baseline visit. If a dose is missed participants are instructed to take the missed dose with the next scheduled dose. Participants will be advised not to exceed 3 capsules daily.
89571951|NCT05510999|Experimental|Lipid soluble pollen extract fraction + water soluble pollen extract fraction|The experimental product is a combination of 9 mg lipid soluble pollen extract fraction (18mg/day) and 180 mg water soluble pollen extract fraction (360mg/day). Participants will be instructed to take one (1) capsule twice daily before breakfast and dinner with a glass of water for 24 weeks beginning on the Day 1, the day after their baseline visit. If a dose is missed participants are instructed to take the missed dose with the next scheduled dose. Participants will be advised not to exceed 3 capsules daily.
89571952|NCT05510999|Experimental|Lipid soluble pollen extract fraction|The experimental product contains 9mg (18mg/day) of lipid soluble pollen extract fraction. Participants will be instructed to take one (1) capsule twice daily before breakfast and dinner with a glass of water for 24 weeks beginning on the Day 1, the day after their baseline visit. If a dose is missed participants are instructed to take the missed dose with the next scheduled dose. Participants will be advised not to exceed 3 capsules daily.
88970506|NCT02268851|Experimental|CLL|"Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.~Each Cycle = 28 days~TGR-1202 (oral): Starting on Day 1 administered daily.~Ibrutinib (oral): Starting on Day 1 administered daily."
88970507|NCT02268851|Experimental|MCL|"Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.~Each Cycle = 28 days~TGR-1202 (oral): Starting on Day 1 administered daily.~Ibrutinib (oral): Starting on Day 1 administered daily."
88970508|NCT02245230|Active Comparator|Intact Study Day|Subjects will receive saline infusion for 60 minutes followed by five ascending doses of Angiotensin (1-7) ranging from 0.5 to 20 ng/kg/min. Each dose will be maintained for 10 minutes with hemodynamic measurements and blood samples collected at the end of each dosing period.
88970509|NCT02245230|Experimental|Autonomic Blockade Study Day|Autonomic blockade will be induced by continuous intravenous infusion of trimethaphan starting at 0.5-1.0 mg/min and increasing by 1.0 mg/min every 2 to 6 minutes up to an infusion rate of 5 mg/min. Blood pressure will be restored to pre-trimethaphan levels with intravenous phenylephrine infusion at individually titrated doses, starting with 0.1 ug/kg/min. Angiotensin (1-7) will then be infused in five ascending doses ranging from 0.5 to 20 ng/kg/min. Each dose will be maintained for 10 minutes with hemodynamic measurements and blood samples collected at the end of each dosing period.
88970510|NCT02230839|Experimental|Exercise training protocol|
89209069|NCT00798746||Pyloric Drainage Procedure|Esophagectomy with pyloric drainage procedure
89209070|NCT00798746||No Pyloric Drainage Procedure|Esophagectomy without pyloric drainage procedure
89571953|NCT05510999|Experimental|Water soluble pollen extract fraction + cranberry powder|The experimental product is a combination of 42 mg water soluble pollen extract fraction (84 mg/day) and 125 mg cranberry powder (250 mg/day). Participants will be instructed to take one (1) capsule twice daily before breakfast and dinner with a glass of water for 24 weeks beginning on the Day 1, the day after their baseline visit. If a dose is missed participants are instructed to take the missed dose with the next scheduled dose. Participants will be advised not to exceed 3 capsules daily.
89571954|NCT05505149|Active Comparator|0 to 6 years old spastic cerebral palsy|Children were individually included in the physiotherapy and rehabilitation program for 2 years, with 45 minutes each session, two days a week. All children's treatment program included targeted, personalized functional exercises according to neurodevelopmental treatment principles, and they were applied by the physiotherapists of the children in the rehabilitation centers.
89571955|NCT05505149|Active Comparator|7 to 12 years old spastic cerebral palsy|Children were individually included in the physiotherapy and rehabilitation program for 2 years, with 45 minutes each session, two days a week. All children's treatment program included targeted, personalized functional exercises according to neurodevelopmental treatment principles, and they were applied by the physiotherapists of the children in the rehabilitation centers.
89571956|NCT05505149|Active Comparator|13 to 18 years old spastic cerebral palsy|Children were individually included in the physiotherapy and rehabilitation program for 2 years, with 45 minutes each session, two days a week. All children's treatment program included targeted, personalized functional exercises according to neurodevelopmental treatment principles, and they were applied by the physiotherapists of the children in the rehabilitation centers.
89571957|NCT05505071|Experimental|DANTE SPACE MRI Sequence|Participants will receive an additional DANTE SPACE sequence with their clinical MRI
89571958|NCT05504993||High comorbidity group|CCI equal or higher than 2 COTE equal or higher than 4 COMCOLD equal or higher than 4
89571959|NCT05504993||Low comorbidity group|CCI lower than 2 COTE lower than 4 COMCOLD lower than 4
89571960|NCT05514041|Experimental|OC-01 (varenicline solution) nasal spray 0.03 mg|Subjects will be randomized 1:1 to be treated with the agent delivered as a 0.05 mL intranasal spray in each nostril at the following formulations
89571961|NCT05514041|Placebo Comparator|Placebo nasal spray (OC-01 Vehicle Nasal Spray)|Subjects will be randomized 1:1 to be treated with the agent delivered as a 0.05 mL intranasal spray in each nostril at the following formulations
89571962|NCT04691531|Experimental|group C|After induction of general anesthesia, patients will undergo caudal block by classical Gauge 22 needle under ultrasound guidance using a linear probe 5.5-12 MHz, and Bupivacaine 1 ml/kg of 0.25% will be injected.
89571963|NCT04691531|Experimental|Group S|After induction of general anesthesia, patients will undergo caudal block by Gauge 27 needle under ultrasound guidance using a linear probe 5.5-12 MHz, and Bupivacaine 1 ml/kg of 0.25% will be injected.
89571964|NCT05513963|Experimental|Treatment|Participants will complete a Clairity session between their regular therapy visits. The Clairity interview is between 4-11 minutes where a clinical research coordinator will ask participants questions about hope, secrets, anger, fear, and emotional pain.
89571965|NCT05513963|No Intervention|Control|Participants will submit demographics and medical records and will only complete standard of care.
89571966|NCT05510765|Experimental|Study arm|Low resource, high risk individuals with limited transportation options as a social determinant of health.
88970511|NCT02230839|Experimental|Energy restriction-induced weight loss|
88970512|NCT02230839|No Intervention|Health Education|
88970513|NCT01846663|Experimental|Rifaximin|Rifaximin, oral, 550 mg BID, 6 months of treatment
88970514|NCT01846663|Placebo Comparator|Placebo|Placebo, oral, 0 mg BID, 6 months of treatment
89571967|NCT05504759|Experimental|Group 1|2 weeks rest protocol + standardized exercise program
89571968|NCT05504759|Experimental|Group 2|local steroid injection + 2 weeks rest protocol + standardized exercise program
88970515|NCT01738204||Females with endometriosis|Females with a surgical diagnosis of endometriosis or who undergoing surgery for suspected endometriosis. At this time, we are only recruiting patients of Boston Children's Hospital and Brigham and Women's Hospital for this group.
88970516|NCT01738204||Females without surgical diagnosis of endometriosis|Females do not need to be patients of Boston Children's Hospital or Brigham and Women's Hospital.
88970517|NCT01659151|Experimental|Combination Therapy|Combination Chemotherapy and Immunotherapy. The combination of vemurafenib followed by lymphodepletion with chemotherapy, Adoptive Cell Therapy (ACT) with Tumor Infiltrating Lymphocytes (TIL) infusion, and High Dose Interleukin-2 (IL-2).
88970518|NCT01597388|Experimental|AZD2014 with Fulvestrant|AZD2014 with Fulvestrant
88970519|NCT01491789|Experimental|Virtual Sailing|you will be doing 60 minutes of Virtual Sailing training, 1 time a week for 12 weeks
88970520|NCT01394640||Healthy Volunteers|Healthy people without any serious comorbidity (no immunosuppressive treatment, no autoimmune disease, no cancer) receiving the same vaccine
88970521|NCT01394640||Onco-hematologic patients|Patients with lymphoma or myeloproliferative diseases or multiple myeloma either receiving chemotherapy or in follow-up or treated with allogeneic hematopoietic stem cell transplant.
88970522|NCT01364480|Experimental|Brain-Machine Interface Users|All participants enrolled in the study will undergo Implantation of NeuroPort Arrays in the motor cortex. There is no control group.
89028946|NCT05292313|Other|Dual distal femur implants|Dual implant constructs will either be an intramedullary nail with an additional plate and screw construct or dual (two plates in any orientation) plate and screw construct.
89028947|NCT05275166|Other|Patients|Patients hospitalized for rehab. HRE following induction of alcohol craving and questionnaires
89028948|NCT05275166|Other|Healthy Volunteers|Healthy Volunteers with non alcohol dependance. HRE following induction of alcohol craving and questionnaires
89209071|NCT01070641|Active Comparator|Carvedilol|Each patient will receive Carvedilol 12.5mg QD
89209072|NCT01070641|Active Comparator|Esophageal Variceal Band Ligation|Each patient will undergo for serial esophageal variceal band ligations after 3 weeks of last session till the eradication of varices
89571969|NCT05504759|Experimental|Group 3|dry needling of forearm extensor muscles + 2 weeks rest protocol + standardized exercise program
89571970|NCT02570711|Experimental|Regimen 1|ACP-196 and nab-paclitaxel and gemcitabine
89571971|NCT02570711|Experimental|Regimen 2|Nab-paclitaxel and gemcitabine
89571972|NCT05513729||Canagliflozin treatment group|40 patients with T2DM combined with NAFLD will be assigned to receive canagliflozin on top of metformin monotherapy according to clinical guideline of type 2 diabetes as experimental group.
89571973|NCT05513729||Pioglitazone treatment group|40 patients with T2DM combined with NAFLD will be assigned to receive pioglitazone on top of metformin monotherapy according to clinical guideline of type 2 diabetes as experimental group. as placebo comparator group.
89571974|NCT05504603|Experimental|zanubrutinib(80mg), rituximab(100mg), ASCT|"Phase I(Combined Immunotherapy Phase):~Part A(Induction Immunotherapy Phase): Patients receive zanubrutinib on days 1-28 and rituximab on day 1,8,15,22.~Part B(Consolidation Immunotherapy Phase): Patients receive zanubrutinib on days 1-28 and rituximab on day 1. Treatment cycles repeat every 28 days for 4 cycles.~Phase II(ASCT): BEAM pretreatment. Patients receive semustine on day1, etoposide on days 2-5, cytarabine on days 2-5 and melphalan on day 6.~Phase III(maintenance): Zanubrutinib"
89571975|NCT05510609|Other|Thyroidectomy|Patients set for total thyroidectomy incl. functional total thyroidectomies.
89571976|NCT04863131|Experimental|EXG-5003|
89571977|NCT04863131|Placebo Comparator|Placebo|
89571978|NCT05504369|Active Comparator|Magnetic tape arm|Tape application bilaterally in the lumbar spine
89571979|NCT05504369|Sham Comparator|Placebo tape arm|Tape application bilaterally in the lumbar spine
89571980|NCT05513495|Active Comparator|Drip Group|Each infant received the same amount of feed via continuous administration for 3 hours, and subsequent feeding resumed 1 hour after the end of continuous feeding. All of the infants were fed through an orogastric tube that was attached to a syringe infusion pump for continuous feeding. Once a full enteral feed of 120 mL/kg/day was achieved, the drip feeding was stopped.
89571981|NCT05513495|Active Comparator|Intermittent Group|Every 3 hours (×8/day), each infant received a 10-minute gravity bolus of milk/preterm formula via orogastric tube.
89571982|NCT05513417||Intervention|These programs will cover participants with pelvic floor conditions which significantly impact their quality of life, to the extent they seek specialised care in direct relation to these conditions.
89571983|NCT04662047||Adults and children living in the 11 principal cities of Cataluña, Spain.|Adults and children living in the 11 principal cities of Cataluña, Spain: Barcelona, Hospitalet de Llobregat, Tarrasa, Badalona, Sabadell, Lérida, Tarragona, Mataró, Santa Coloma de Gramanet, Reus, Girona.
89571984|NCT05504213|Experimental|Cohort 1: Endocrine therapy-resistant (Stage 1)|Participants who are endocrine therapy pre-treated will be administrated at escalating doses orally of HS-10352 in combination with fulvestrant (500 mg, intramuscular).
89571985|NCT05504213|Experimental|Cohort 2: Endocrine therapy-resistant (Stage 2)|Participants who are endocrine therapy-resistant will be treated with HS-10352 orally at the MTD/MAD identified in Stage 1 or/and lower dose in combination with fulvestrant (500 mg, intramuscular)
89571986|NCT05504213|Experimental|Cohort 3: Endocrine therapy-sensitive or endocrine-naïve (Stage 2)|Participants who are endocrine therapy-sensitive or naïve will be treated with HS-10352 orally at MTD/MAD or/and lower dose identified in Stage 1 in combination with fulvestrant (500 mg, intramuscular)
88970523|NCT01228331|Active Comparator|Arm I intensification (cytarabine)|"LR-S patients receive HD cytarabine IV 4 x 3 g over 12 hours daily on days 29-31 and pegaspargase IV over 2 hours on days 31, 52, and 80.~LR-I and precursor B-cell ALL HR-S and HR-I patients receive HD cytarabine IV 2.500 over 3 hours twice daily on days 29-31 and 106-108 and pegaspargase IV over 2 hours on days 31, 53, 67, and 108.~Followed by standard consolidation therapy regarding to stratification containing:~methotrexate, cyclophosphamide, thioguanin, mercaptopurine, etoposide phosphate, amsacrine, cytarabine, methylprednisolone, dexamethasone, vincristine sulfate; whole-brain radiation therapy only if indicated in patients with cns involvement or T-cell ALL"
88970524|NCT01228331|Active Comparator|Arm II intensification (clofarabine)|"LR-S patients receive clofarabine* IV 5 x 40 mg over 2 hours every day on days 29-33 and pegaspargase IV over 2 hours on days 33, 52, and 80.~LR-I and precursor B-cell ALL HR-S and HR-I patients receive clofarabine* IV over 2 hours on days 29-33 and pegaspargase IV over 2 hours on days 33, 53, 67, and 108.~Followed by standard consolidation therapy regarding to stratification containing:~methotrexate, cyclophosphamide, thioguanin, mercaptopurine, etoposide phosphate, amsacrine, cytarabine, methylprednisolone, dexamethasone, vincristine sulfate; whole-brain radiation therapy only if indicated in patients with cns involvement or T-cell ALL"
89028949|NCT05258305|Other|Augmentation|Subjects undergoing an aesthetic fat grafting procedure to the breast with or without a breast implant.
89209073|NCT00982449|Active Comparator|4 mCi of I-FIAU|GROUP B 1-3 days after any chemotherapy that may activate viral TK, 4 mCi of I-FIAU are administered, followed 2 - 4 hours later by FIAU-PET-CT-4.
89571987|NCT04424771||Health workers|They include doctors, nurses, techinicians, biologists and other non technical inhospital workers
89571988|NCT02570165|Experimental|Batefenterol 37.5 mcg|Each subject will receive batefenterol 37.5 mcg (1 actuation) once daily via DPI in the morning for 42 days of treatment period.
89571989|NCT02570165|Experimental|Batefenterol 75 mcg|Each subject will receive batefenterol 75 mcg (1 actuation) once daily via DPI in the morning for 42 days of treatment period.
89571990|NCT02570165|Experimental|Batefenterol 150 mcg|Each subject will receive batefenterol 150 mcg (1 actuation) once daily via DPI in the morning for 42 days of treatment period.
89571991|NCT02570165|Experimental|Batefenterol 300 mcg|Each subject will receive batefenterol 300 mcg (1 actuation) once daily via DPI in the morning for 42 days of treatment period.
89571992|NCT02570165|Experimental|Batefenterol 600 mcg|Each subject will receive batefenterol 600 mcg (1 actuation) once daily via DPI in the morning for 42 days of treatment period.
89571993|NCT02570165|Experimental|UMEC/VI 62.5/25 mcg|Each subject will receive UMEC/VI 62.5/25 mcg (1 actuation) once daily via DPI in the morning for 42 days of treatment period.
89571994|NCT02570165|Experimental|Placebo|Each subject will receive placebo (1 actuation) once daily via DPI in the morning for 42 days of treatment period.
89571995|NCT04661813|Experimental|EXTRA-CVD Virtual Care|"An adapted version of a Nurse-led intervention to EXtend the HIV TReatment CascAde for CardioVascular Disease prevention (EXTRA-CVD)."
89571996|NCT05513339||Cardiology Fellows|Cardiology fellows at Thomas Jefferson University Hospital (PGY4-PGY6)
89571997|NCT05510453|Experimental|Intervention|
89571998|NCT05510453|Other|Wait-list control|
89028950|NCT05258305|Other|Reconstruction|Subjects undergoing reconstructive fat grafting procedure to the breast with or without a breast implant.
89028951|NCT05246527|Experimental|Exercise|"30 min of cycling on a stationary ergometer, guided by a video of a professional cycling instructor.~Half of the patients (n=30) and their respective matched healthy controls (n=30) will perform moderate-intensity exercise: continuous cycling at 64-76% of the individual HRmax).~The other half will perform a high-intensity interval training (HIIT) protocol: 5 min warm-up phase, followed by bursts of high-intensity cycling interspersed with varied recovery times (21 min in total), 4 min cool-down. Excluding warm-up and cool-down, intensities will remain >77% of individual HRmax during the whole routine.~Heart rate will be continuously recorded using a chest strap heart rate monitor and monitored by the patients themselves and the experimenter."
89028952|NCT05246527|Active Comparator|Control condition|30 min of watching a documentary about the benefits of physical activity on health. Heart rate will be recorded also during the control condition.
89028953|NCT05242822|Experimental|Part A - dose escalation|Dose escalation of KIN-3248 in patients with solid tumors
89028954|NCT05242822|Experimental|Part B - dose expansion|Dose expansion evaluating the recommended dose and schedule of KIN-3248 identified from Part A
89571999|NCT05510375|Active Comparator|Cocoa extract + multivitamin|Two capsules/day for 600 mg/day of cocoa flavanols One tablet/day of multivitamin
89028955|NCT05235958|Experimental|Training intervention|8 weeks of non-linear periodized aerobic exercise; 3 sessions per week; 1 hour per session; standardized warm-up; individual training intensity according to cardiorespiratory fitness level
89028956|NCT05235958|Sham Comparator|Control Intervention|Recommendation to continue with current lifestyle (especially physical activity habits) during the following 8 weeks. At the final assessment after 8 weeks, individualized exercise recommendations according to established standard procedures in exercise medicine and offer to attend the standard medical follow-up in our outpatient clinics subsequent to study termination
89572000|NCT05510375|Active Comparator|Cocoa extract + multivitamin placebo|Two capsules/day for 600 mg/day of cocoa flavanols Multivitamin placebo
89028957|NCT05229042|Active Comparator|Active arm|Subjects received ricolinostat
89028958|NCT05229042|Placebo Comparator|Placebo arm|Subjects received placebo
89028959|NCT05220566|Experimental|'Reserved Therapeutic Space'|Participants will receive 'Reserved Therapeutic Space' Nursing Intervention
89028960|NCT05220566|No Intervention|Control|Participants will receive usual care
89028961|NCT05207345|Experimental|Experimental Group|"90-minute session divided into:~45 minutes of core stability treatment~45 minutes of general rehabilitation (active / active, assisted / passive mobilization, stretching, posture maintenance, postural and autonomy training, cycle ergometer, exercise bike and ambulatory training)."
89028962|NCT05207345|Active Comparator|General Group|90 minutes of general rehabilitation (active / active assisted / passive mobilization, stretching, posture maintenance, postural and autonomy training, cycle ergometer, exercise bike and ambulatory training).
89028963|NCT05200325|No Intervention|Control Group|The control group does not receive educational materials about the TissueCypher diagnostic test and will treat their simulated patients with the current standard of care tools.
89028964|NCT05200325|Experimental|Intervention Group 1|Intervention group 1 receives educational materials about the TissueCypher diagnostic test. These materials detail what the test does, how it is used, the validity and specifications of the test, and how to read its test report. This intervention group is then forced to use the test results in treating their simulated patients.
89028965|NCT05200325|Experimental|Intervention Group 2|Intervention group 2 receives educational materials about the TissueCypher diagnostic test. These materials detail what the test does, how it is used, the validity and specifications of the test, and how to read its test report. This intervention group then gets to decide whether or not they want to use the TissueCypher test results for their simulated patients.
89028966|NCT05197608|Experimental|Intervention - System Navigator|"The intervention group will be connected to a system navigator who is a trained staff member embedded within the primary health clinic team with a focus to address participant's biological, psychological and social needs.~Working with the System Navigator will mean:~Discussing patients' current health status and concerns~Receiving support on management of chronic diseases and mental health including connection to local resources e.g. counseling, harm reduction, crisis support services~Receiving information about benefits that they may be entitled to and learning about free services~Receiving help from the System Navigator on forms or letters that are required to access resources"
89028967|NCT05197608|Active Comparator|Tailored list of community resources|Control group will be provided a tailored list of community resources.
89028968|NCT05196620||EAUS|Patients with EAUS pre and postpartum
89209074|NCT00982449|Active Comparator|2 mCi of I-FIAU|GROUP A 1-3 days after any chemotherapy that may activate viral TK, 2 mCi of I-FIAU are administered, followed 2 - 4 hours later by FIAU-PET-CT-2.
89572001|NCT05510375|Active Comparator|Cocoa extract placebo + multivitamin|Cocoa extract placebo One tablet/day of multivitamin
89572002|NCT05510375|Placebo Comparator|Cocoa extract placebo + multivitamin placebo|Cocoa extract placebo Multivitamin placebo
89572003|NCT05512715|Active Comparator|Lithium|Tablet Lithium Carbonate 300mg daily for 2 months
89572004|NCT05512715|Active Comparator|Carbimazole|Tablet Carbimazole 10mg daily for 2 months
89572005|NCT05510219|Experimental|Intravenous rapid infusion of obinutuzumab|Patients with B-cell non-Hodgkin's lymphoma were treated with the standard infusion regimen of obinutuzumab in cycle 1, and for patients who did not develop severe infusion-related reactions in cycle 1, a rapid 90-min obinutuzumab infusion regimen was used from cycle 2 onward while recording any occurrence of infusion reactions in different treatment cycles.
89572006|NCT05503745|Active Comparator|CBT-E|Participants in the CBT-E condition will receive a total of 20 CBT-E sessions over 20 weeks. CBT-E treatment will consist of four stages. In particular, CBT aims to inform patients about the importance of self-control, the dangers of some restrictive behaviors such as self-induced vomiting. Moreover, CBT provides strategies to patients in order to monitor their usually dysfunctional behaviors and so increasing their awareness (i.e. food diary method) while reducing the availability of food and encourages activities that are incompatible with overeating. Patients will be trained in problem solving in order to change these feelings, as well as in increasing their self-awareness in order to recognize irrational thoughts about their body weight and shape. Additionally, they will be gradually exposed to foods that they had been avoiding.
89572007|NCT05503745|Experimental|CBT-F+MIT|"Participants in the CBT-F+MIT condition will receive a total of 20 sessions over 20 weeks. Specifically, 2 sessions will be based on CBT-F as usual only. During these sessions participants will receive psychoeducational training on eating behaviors and an introduction to the protocol tools, namely the monitoring form, weight chart, transdiagnostic formulation and Eating Problem Check List (EPCL).~These elements will be used at the beginning of the remaining 18 sessions, in order to monitor the regulations of eating behaviors as well eliciting narrative episodes. These materials will form the basis for the MIT-part of the session, in which therapists will seek to form with the patient a shared understanding of the psychological reasons underlying their ED symptoms and their maladaptive interpersonal functioning. MIT sessions will be integrated within the CBT-F protocol which will provide psycho-educational, nutritional re-education and management for ED."
89572008|NCT02564471|Experimental|Chloroquine|Chloroquine Phosphate tablet for oral administration 500 mg chloroquine phosphate (equivalent to 300 mg base)
89572009|NCT02564471|Experimental|Atovaquone and Proguanil (Malarone)|"Malarone tablet for oral administration 250 mg atovaquone and 100 mg proguanil hydrochloride.~RabAvert rabies vaccine, at least 2.5 IU of rabies antigen."
89572010|NCT02564471|Experimental|Doxycycline|"Doxycycline hyclate tablet for oral administration, contains specially coated pellets of doxycycline hyclate equivalent to 100 mg of doxycycline.~RabAvert rabies vaccine, at least 2.5 IU of rabies antigen."
89572011|NCT02564471|Active Comparator|Rabies|RabAvert rabies vaccine, at least 2.5 IU of rabies antigen.
89572012|NCT05503667|Experimental|Furmonertinib Plus Bevacizumab|Furmonertinib Plus Bevacizumab
89572013|NCT05503667|Active Comparator|Furmonertinib|Furmonertinib monotherapy
89572014|NCT04411979|No Intervention|treatment-as-usual|
88970525|NCT01228331|Active Comparator|Arm III reinduct.(doxorubicin hydrochl.)|"LR-S patients receive doxorubicin hydrochloride IV 30 mg/m2 over 24 hours on days 1 and 8.~LR-I, HR-S and HR-I Patients receive doxorubicin hydrochloride IV 30 mg/m2 over 24 hours on days 1, 8, 22, and 29.~Followed by standard reinduction and maintenance therapy containing:~cyclophophamide, cytarabine, thioguanine, mercaptopurine, methotrexate and pegaspargase, dexamethasone, vincristine sulfate"
88970526|NCT01228331|Active Comparator|Arm IV reinduct.(daunorubicin hydrochl.)|"LR-S patients receive daunorubicin hydrochloride IV 36 mg/m2 over 24 hours on days 1 and 8.~LR-I, HR-S and HR-I Patients receive daunorubicin hydrochloride IV 36 mg/m2 over 24 hours on days 1, 8, 22, and 29.~Followed by standard reinduction and maintenance therapy containing:~cyclophophamide, cytarabine, thioguanine, mercaptopurine, methotrexate and pegaspargase, dexamethasone, vincristine sulfate"
88970527|NCT00957086|Active Comparator|Nimotuzumab|Comprising Adjuvant Cisplatin, Concurrent RT and Nimotuzumab
88970528|NCT00957086|Placebo Comparator|Placebo|Comprising Adjuvant Cisplatin, Concurrent RT and Placebo
88970529|NCT00936364|Experimental|Group I (Stage I of study)|Patients fast for 24 hours on day -1
88970530|NCT00936364|Experimental|Group II (Stage I of study)|Patients fast for 48 hours on days -2 and -1
88970531|NCT00936364|Experimental|Group III (Stage I of study)|Patients fast for 72 hours on days -3, -2, and -1
88970532|NCT00936364|Experimental|Group IV (Stage I of study)|Patients undergo a modified 48-hour fast with minimal caloric intake on day -2 and -1
88970533|NCT00745030|Experimental|1|Ramelteon (TAK-375) 8mg tablets
88970534|NCT00745030|Placebo Comparator|2|Placebo 8 mg tablets
88970535|NCT00585234||1|We intend to photograph male and female subjects from age 1 through skeletal maturity. Healthy children will be photographed to determine the normative characteristics of thoracic function using this technique. We will also enroll patients with thoracic pathology to determine how digital imaging can document thoracic dysfunction. There are no specific disease related exclusion criteria. Participation is voluntary.
89028969|NCT05195710|Experimental|Yttrium-90|Help to control the tumor(s) on the right side of the liver while the remaining left side of the liver, which is clear of cancer, grows.
89028970|NCT05194488|Experimental|Low level laser therapy|
89028971|NCT05194488|Experimental|Botulinum toxin type A|
89028972|NCT05194488|Active Comparator|Anterior repositioning appliance|
89028973|NCT05187182|Experimental|Dose Escalation (CA4948 + FOLFOX + Nivolumab)|"CA4948 (dose will depend on dose level assigned) twice daily by mouth. Standard of care mFOLFOX7 every 14 days. Nivolumab every 14 days.~Each cycle is 14 days."
89572015|NCT04411979|Experimental|treatment-as-usual plus aerobic walking|
89572016|NCT05512637||neurodevelopmental disorders|"Step 1 - Screening: the targeted sample is the siblings of the autistic children, these siblings being at risk of neurodevelopmental disorders.~Step 2 - Clinical interview: All the children with a positive screening."
89572017|NCT05503589||student group|have taken the professional practice/internship lecture and be practicing in the hospital
89572018|NCT05503589||control group|who routinely work during the pandemic
89572019|NCT02563067|Experimental|QAW039 150 mg|QAW039 150 mg once daily
89572020|NCT02563067|Experimental|QAW039 450 mg|QAW039 450 mg once daily
89572021|NCT02563067|Placebo Comparator|Placebo|Placebo once daily
89572022|NCT02568683|Experimental|Dose Escalation: ENTO|Participants will be enrolled sequentially in a 3 + 3 dose escalation design to receive escalating dose of ENTO+VCR at dose levels 1 to 4 with the objective of defining the maximum tolerated dose (MTD) or recommended dose for the dose expansion stage. Following the determination of the MTD of the dose levels 1 to 4 (or concurrently with the opening of dose level 4), the safety of administering ENTO with VCR when administered as a 4-day prolonged continuous infusion may be evaluated in the continuous infusion dose escalation level (dose level C1) with the objective of investigating the schedule of dosing ENTO when administered with VCR as a continuous infusion.
89572023|NCT02568683|Experimental|Dose Expansion: VCR+ENTO (Cohort A)|Based on the tolerability, safety, and efficacy data from the dose escalation phase, participants with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) may receive VCR+ENTO.
89572024|NCT02568683|Experimental|Dose Expansion: VCR+ENTO (Cohort B)|Based on the tolerability, safety, and efficacy data from the dose escalation phase, participants with relapsed or refractory B-cell NHL (non-DLBCL) may receive VCR+ENTO.
89572025|NCT05502731|Experimental|Add-on filgotinib|Treatment with a combination therapy of MTX (7.5 - 15 mg once weekly) and filgotinib p.o. (200 mg once daily) for 24 weeks
88970536|NCT00055224|Experimental|Healthy Participants|Substudy 1/ Neutral, Predictable, and Unpredictable Responses (NPU): physiological responses to different threat of shock conditions - no shock, unpredictable shock, and predictable-cued shock. Substudy 2/ Working Memory Task: Subjects performed a working memory task under threat of shock and in safety. Substudy 5 /Face Stroop Task: Stimuli were pictures of faces exhibiting anger, disgust, fear, happiness, sadness, and surprise intermixed with pleasant, unpleasant, and neutral pictures. Substudy 7/ Active Avoidance Signal Task (AAST) and Sustained Attention Response Task (SART): In AAST, participants performed paradigms which tested whether threats impact the initiation and the inhibition of behavioral responses. In SART, participants were presented with stimuli and either initiated a go or nogo response. Pilot Tasks: Participants completed one/more tasks: nerve stimulation, short speech, air burst, saliva samples, squeezer task, virtual reality task, or computer-based task.
88970537|NCT00055224|Experimental|Anxiety subjects|Substudy 1/ Neutral, Predictable, and Unpredictable Responses (NPU): physiological responses to different threat of shock conditions - no shock, unpredictable shock, and predictable-cued shock. Substudy 2/ Working Memory Task: Subjects performed a working memory task under threat of shock and in safety. Substudy 5 /Face Stroop Task: Stimuli were pictures of faces exhibiting anger, disgust, fear, happiness, sadness, and surprise intermixed with pleasant, unpleasant, and neutral pictures. Substudy 7/ Active Avoidance Signal Task (AAST) and Sustained Attention Response Task (SART): In AAST, participants performed paradigms which tested whether threats impact the initiation and the inhibition of behavioral responses. In SART, participants were presented with stimuli and either initiated a go or nogo response. Pilot Tasks: Participants completed one/more tasks: nerve stimulation, short speech, air burst, saliva samples, squeezer task, virtual reality task, or computer-based task.
89028974|NCT05187182|Experimental|Dose Expansion Cohort A (CA4948 + FOLFOX + Nivolumab)|"CA4948 (dose will be the recommended phase II dose found in the dose escalation portion of study) twice daily by mouth. Standard of care mFOLFOX7 every 14 days. Nivolumab every 14 days.~Each cycle is 14 days."
89028975|NCT05187182|Experimental|Dose Expansion Cohort B (CA4948 + FOLFOX + Pembrolizumab + Trastuzumab)|"CA4948 (dose will be the recommended dose found in the dose escalation portion of study) twice daily by mouth Standard of care mFOLFOX7 every 14 days. Pembrolizumab on day 1 of every 3 cycles. Trastuzumab every 14 days.~Each cycle is 14 days."
89033147|NCT02943434|Other|Processed Food|Changes in resting energy expenditure will be measured via indirect calorimetry after consumption of a processed foods meal to determine changes in diet-induced thermogenesis.
89572026|NCT05502731|Active Comparator|Add-on adalimumab|Treatment with a combination therapy of MTX (7.5 - 15 mg once weekly) and adalimumab s.c. (40 mg biweekly) for 24 weeks
89572027|NCT05502497|Other|Control Group|Which leg of the individuals will be treated will be determined by tossing a coin. After the toss, the right leg will be applied when the tail comes, and the left leg will be applied when it comes to the heads. The leg to be treated, the treatment group of the individuals; the other leg (the untreated leg) will form the control group of the individuals.
89572028|NCT05502497|Experimental|IASTM Treatment Group|Which leg of the individuals will be treated will be determined by tossing a coin. After the toss, the right leg will be applied when the tail comes, and the left leg will be applied when it comes to the heads. The leg to be treated, the treatment group of the individuals; the other leg (the untreated leg) will form the control group of the individuals.
89572029|NCT05503277|Active Comparator|Superglottic airway device LTSD|measuring seal pressure
89572030|NCT05503277|Active Comparator|Superglottic airway device i-gel|measuring seal pressure
89572031|NCT05502419|Active Comparator|conventional physical therapy|
89572032|NCT05502419|Experimental|conventional physical therapy with slump stretching|
89572033|NCT05502263||moderate/high risk|FEV and/or DLCO <80% And VO2peak <20ml/kg.min or <75% predicted value
89572034|NCT05502263||Control|FEV and DLCO >80% and VO2peak > 20ml/kg.min or >75% predicted value
89572035|NCT05503121||Study Group|"The volunteer group planned to be included in the study will consist of individuals diagnosed with Nonspecific Low Back Pain who applied to Istinye University Physiotherapy and Rehabilitation Application and Research Center (Isu Fizyotem).~21 volunteers with low back pain will be included in the study."
89572036|NCT05503121||Contol Group|The control group will consist of healthy individuals. 21 healty volunteers will be included in the study.
89572037|NCT05503043|Experimental|Lidocaine|Intravenous bolus of 1.5 mg/kg of lidocaine followed by a continuous infusion of 3.0 mg/kg for the first hour, 1.5 mg/kg for the second hour, 0.7 mg/kg until the end of the surgery.
89572038|NCT05503043|Placebo Comparator|Normal saline|Normal saline administered as a bolus and an infusion with identical volume and rate changes as the treatment group.
89572039|NCT05502185||healthy volunteers|no intervention
89572040|NCT05502185||Atopic Dermatitis patients|no intervention
89572041|NCT04579211||Adults with a diagnosis of CF with history of negative NTM sputum cultures|Male or female participants age 18 or greater at time of enrollment with diagnosis of CF consistent with the 2017 CFF Guidelines and NTM culture status of negative, as defined by a review of at least 3 year or more years of culture data and at least 3 NTM negative cultures with one of those negative cultures being within the last 3 years and no known history of previous positive cultures for pathogenic NTM by chart review.
89517457|NCT02296918|Experimental|Cohort 2: Acalabrutinib+Obinutuzumab (Treatment-naive)|Dose-escalation and dose-expansion phases will be conducted for treatment-naïve participants with CLL/ small lymphocytic lymphoma (SLL). In dose-escalation phase, participants will receive oral acalabrutinib Dose 2 BID in first cycle (28-day cycle). In dose- expansion phase, participants will receive oral acalabrutinib Dose 2 BID in 28-day continuous cycles; and will receive IV infusion of obinutuzumab for total 6 cycles (from Cycles 2 to 7) as on Cycle 2 Day 1 participants will receive Dose 1, on Cycle 2 Day 2 participants will receive Dose 2, on Cycle 2 Days 8 and 15 participants will receive Dose 3, and on Day 1 of Cycles 3 to 7 participants will receive Dose 3. Participants will continue to receive acalabrutinib Dose 2 BID until disease progression, an unacceptable drug-related toxicity, or per the investigator the study treatment is intolerable or no longer in participant's best interest, whichever occurs first.
89517458|NCT02296918|Experimental|Cohort 3: Acalabrutinib+Rituximab+Venetoclax (R/R)|The R/R participants with CLL will receive oral acalabrutinib, IV infusion of rituximab, and oral venetoclax. Participants will receive acalabrutinib Dose 2 BID in 28-day continuous cycles until disease progression, an unacceptable drug-related toxicity, or per the investigator the study treatment is intolerable or no longer in participant's best interest, whichever occurs first. Participants will receive rituximab for total 6 cycles (from Cycles 2 to 7) as Dose 1 on Cycle 2 Day 1, followed by Dose 1 every 3 weeks (Q3W) for 3 doses, then every 4 weeks (Q4W) for 5 doses (total 9 infusions through the end of Cycle 7). Participants will receive venetoclax weekly ramp-up schedule over 5 weeks from Cycles 3 to 15, Dose 1 QD for 1 week on Cycle 3 Day 1, Dose 2 QD for 1 week on Cycle 3 Day 8, Dose 3 QD for 1 week on Cycle 3 Day 15, Dose 4 QD for 1 week on Cycle 3 Day 22, and Dose 5 QD from Cycle 4 Day 1 until completion of Cycle 15.
89517459|NCT02296918|Experimental|Cohort 4: Acalabrutinib+Obinutuzumab+Venetoclax (Treatment-naive)|The treatment-naïve participants with CLL will receive oral acalabrutinib, IV infusion of obinutuzumab, and oral venetoclax. Participants will receive acalabrutinib Dose 2 BID in 28-day continuous cycles until disease progression, an unacceptable drug-related toxicity, or per the investigator the study treatment is intolerable or no longer in participant's best interest, whichever occurs first. Participants will receive obinutuzumab for total 6 cycles (from Cycles 2 to 7) as Dose 1 on Cycle 2 Day 1, Dose 2 on Cycle 2 Day 2, Dose 3 on Cycle 2 Days 8 and 15, and Dose 3 on Day 1 of Cycles 3 to 7. Participants will receive venetoclax weekly ramp-up schedule over 5 weeks from Cycles 3 to 15 as Dose 1 QD for 1 week on Cycle 3 Day 1, Dose 2 QD for 1 week on Cycle 3 Day 8, Dose 3 QD for 1 week on Cycle 3 Day 15, Dose 4 QD for 1 week on Cycle 3 Day 22, and from Cycle 4 Day 1 participants will receive Dose 5 QD until completion of Cycle 15.
89517460|NCT02281097|Active Comparator|Vagal Stimulation First|"Vagal stimulation to improve upright heart rate modulation and symptoms is given on first tilt study day.~Placebo stimulation with ineffective low amplitude and frequency (sham intervention) is given on second tilt study."
89028976|NCT05174559|Active Comparator|Active LNAA|Active LNAA tablets are given to each participant in 3 multiple crossovers for a total exposure to the Active Comparator 3 times. The allocation is randomized within each cycle of two treatments (active/inactive). There are 3 total cycles for each participant. The intervention is PreKUnil® tablets.
89028977|NCT05174559|Placebo Comparator|Inactive LNAA|Inactive LNAA tablets (placebos) are given to each participant in 3 multiple crossovers for a total exposure to the Inactive Comparator 3 times. The allocation is randomized within each cycle of two treatments (inactive/active). There are 3 total cycles for each participant. The placebo intervention is PreKUnil® placebo tablets.
89517461|NCT02281097|Placebo Comparator|Placebo First|"Placebo stimulation with ineffective low amplitude and frequency (sham intervention) is given on first tilt study day.~Vagal stimulation to improve upright heart rate modulation and symptoms is given on second tilt study day."
89517462|NCT02117791||Group 1|Riociguat treatment group
89517463|NCT02032823|Experimental|Olaparib|Olaparib tablets 300mg b.i.d. p.o.
89517464|NCT02032823|Placebo Comparator|Placebo|Placebo tablets b.i.d. p.o.
89517465|NCT01847326|Experimental|Treatment (induction therapy and AFHX or AXX)|See Detailed Description
89517466|NCT01526096|Active Comparator|Standard ASCT (Grp 1)|Standard autologous stem cell transplantation (ASCT)
89517467|NCT01526096|Experimental|Depletion of T-cells after ASCT (Grp 2)|Standard ASCT followed by treatment with basiliximab to remove certain immune cells (called regulatory T-cells or Tregs) from the blood
89517468|NCT01526096|Experimental|Depletion of T-cells before ASCT(Grp 3)|Blood collected for an ASCT will be processed using a special cell sorting machine (CliniMACS device) to remove Treg cells before the stem cells are infused back into the body during stem cell transplant.
89517469|NCT01280825||Adult Patients|Adults receiving health care at the University of Chicago Medical Center.
89517470|NCT01267955|Experimental|Treatment (vismodegib)|Patients receive vismodegib PO on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89517471|NCT00961792|Experimental|Beverage with Heavy Alcohol Dose|Beverage containing 0.8 g/kg alcohol
89517472|NCT00961792|Experimental|Beverage with Low Alcohol Dose|Beverage containing 0.4 g/kg alcohol
89517473|NCT00961792|Placebo Comparator|Beverage with No alcohol (Placebo)|Beverage containing 0.0 g/kg alcohol to act as placebo
89517474|NCT00961792|Experimental|Beverage with Diphenhydramine|Beverage containing 1.5 standard dose of Diphenhydramine (Benadryl)
89517475|NCT00961792|Experimental|Beverage with Caffeine|Beverage containing the equivalent of 1.5 times participant's average caffeine consumption
89517476|NCT00961792|No Intervention|Beverage in Natural Environment|Participant consumes alcohol containing beverages or non-alcohol beverages in natural environment
89517477|NCT00890045|Active Comparator|Control graft|Conventional ePTFE hemodialysis graft
89517478|NCT00890045|Experimental|HeRO Vascular Access Device|HeRO Vascular Access Device
89517479|NCT00861042|Experimental|1|
89517480|NCT00819208|Active Comparator|Physical Activity Program + General Health Education Materials|Intervention Arm
89517481|NCT00819208|Active Comparator|General Health Education Materials|Control Arm
89517482|NCT00630565|Experimental|Bone Marrow Transplant (2-70 Years old)|Patients over the age of two will receive a cytoreductive regimen of total-body irradiation and cyclophosphamide (TBI/CY) as well as sargramostim, dexamethasone, etoposide, transplantation (bone marrow transplantation/hematopoietic stem cell transplantation/peripheral blood stem cell transplantation).
89572042|NCT02563925|Experimental|Radiation and Tremelimumab|Subjects will get either whole brain radiation treatment (WBRT) or stereotactic radiosurgery (SRS), as per standard of care, with tremelimumab administered every 28 days. Patients, for whom concurrent HER2 directed therapy trastuzumab is indicated, as determined by the treating investigator, will be enrolled in a parallel HER2 directed therapy trastuzumab safety cohort. Protocol Expansion: Dose 1 of tremelimumab & durvalumab (75 mg & 1500 mg, respectively) will ideally be administered 2 days prior to initiation of brain radiotherapy (or between 5 days prior & 3 days after initiation of radiotherapy). Subjects will get either WBRT or SRS, depending on the number & size of their brain metastases. Following the 1st dose, tremelimumab & duvralumab will be administered q28 days from the date of 1st tremelimumab & durvalumab administration, plus or minus 1 week, for 4 cycles. After the 4th cycle, durvalumab will be administered alone until progression of disease or unacceptable toxicity.
89572043|NCT01663727|Experimental|A|Paclitaxel + Bevacizumab [Avastin]
89572044|NCT01663727|Experimental|B|Paclitaxel + Placebo
89572045|NCT02614261|Placebo Comparator|Placebo|"Double-blind treatment phase: Participants received placebo once a month by subcutaneous (SC) injection for 3 months.~Open-label extension phase: After completion of double-blind phase, participants had an option to enter open-label extension phase where they receive 240 milligram (mg) galcanezumab SC at first month, 120mg at second month followed by 120mg or 240mg once a month (at the discretion of the investigator) for the remaining 7 months.~Follow-up phase: After completion or discontinuation from double-blind or open-label extension phases, participants entered follow-up phase where they were observed for 4 months. No treatments administered."
89572046|NCT02614261|Experimental|Galcanezumab 120 mg|"Double-blind treatment phase: Participants received loading dose of 240 mg of galcanezumab at first dosing visit followed 120 mg galcanezumab once a month by SC injection for 2 months.~Open-label extension phase: After completion of double-blind phase, participants had an option to enter open-label extension phase where they received 240mg galcanezumab SC at first month, 120mg at second month followed by 120mg or 240mg once a month (at the discretion of the investigator) for the remaining 7 months.~Follow-up phase: After completion or discontinuation from double-blind or open-label extension phases, participants entered follow-up phase where they were observed for 4 months. No treatments administered."
89572047|NCT02614261|Experimental|Galcanezumab 240 mg|"Double-blind treatment phase: Participants received 240 mg of galcanezumab once a month by subcutaneous injection for 3 months.~Open-label extension phase: After completion of double-blind phase, participants had an option to enter open-label extension phase where they received 240mg galcanezumab SC at first month, 120mg at second month followed by 120mg or 240mg once a month (at the discretion of the investigator) for the remaining 7 months.~Follow-up phase: After completion or discontinuation from double-blind or open-label extension phases, participants entered follow-up phase where they were observed for 4 months. No treatments administered."
89572048|NCT02614261|Experimental|Israel Addendum|Eligible participants from main study were enrolled in Israel addendum. Participants received 120mg or 240mg galcanezumab SC once a month, at the discretion of the investigator, for up to 3 years or until Israel's Ministry of Health's conditions for continued access cease to be met, whichever occurs first.
89572049|NCT04859023|Experimental|mass screening SARS-COV-19|"20 0000 participant will be included during mass screening SARS-COV-19 of the population of the city of Saint-Etienne.~They will have two strategies both based on self-samples: (i) a saliva sample combined to an anterior nare self-swabbing tested by antigenic test versus (ii) a saliva sample tested by RT-PCR."
89572050|NCT03043261|Experimental|Psycho-Behavioral Intervention|"Williams LifeSkills modules which cover 10 core skills designed to improve coping skills, stress management and interpersonal relationships: 1) being aware of negative thoughts and feelings, 2) making a decision, 3) deflection skills, 4) problem solving or action skills, 5) assertion, 6) saying no, in addition to the following preventive skills: 7) speaking up, 8) listening, 9) empathy and 10) increasing positives"
89572051|NCT03043417|Experimental|CHC's given the intervention|Three CHC sites where all staff receive all components of the intervention. Training, Media, Art workshops, and a Policy analysis as well as survey completion.
89572052|NCT03043417|No Intervention|CHC's with NO intervention|Three CHC sites where all staff and a selection of clients complete surveys but receive no intervention.
89572053|NCT03042325|Experimental|Alogliptin|Alogliptin 25 mg, tablets, orally, once, daily for 26 weeks in addition to standard care for the management of Type 2 Diabetes Mellitus (T2DM). Dose will be adjusted as per creatinine clearance [CrCl].
89572054|NCT03045445|Experimental|Double Low-Dose protocol CT|Low radiation dose + low amount of iodine contrast media at spectral CT (Philips Healthcare)
89572055|NCT03045445|Active Comparator|Standard protocol CT|Standard protocol quadriphasic liver CT according to current liver CT protocol in our institution, at spectral CT (Philips Healthcare)
89572056|NCT01594411||All subjects|Subjects are enrolled at multiple participating primary care practices. The main inclusion criterion for enrollment is the occurrence of chest pain (or anginal equivalent) in a patient without known significant coronary artery disease (CAD) or a history of prior myocardial infarction.
89028978|NCT05167669|Other|Prospective, interventional, single-center, feasibility pilot study.|10 patients with radiologically confirmed bone metastases and eligible for a course of palliative EBRT. Eligible patients will be mainly discussed and recruited in a dedicated tumor-board for bone metastases performed in a weekly basis at HUG.
89572057|NCT01594333|Experimental|Methotrexate|Methotrexate: Tablet, Oral, Target dose 15-20mg weekly plus 1.0 mg folic acid 6 days/week
89572058|NCT01594333|Placebo Comparator|Placebo|Placebo: Tablet, Oral weekly plus 1.0mg folic acid 6 days/week
89572059|NCT04860895|Other|Nasopharyngeal swabs|Nasopharyngeal swabs samples of volunteers who is referred with suspicion of Covid19.
89572060|NCT03042247||Hodgkin lymphoma patients|Hodgkin lymphoma patients with confirmed histological diagnosis
89572061|NCT03042247||DLBC non Hodgkin lymphoma patients|DLBC non Hodgkin lymphoma patients with confirmed histological diagnosis
89033148|NCT02943434|Other|Whole Food|Changes in resting energy expenditure will be measured via indirect calorimetry after consumption of a whole foods meal to determine changes in diet-induced thermogenesis.
89033149|NCT02917707||normal colorectal tissues (PN)|normal colorectal tissues
89033150|NCT02917707||primary colorectal carcinoma tissues|primary colorectal carcinoma tissues
88970538|NCT00026559|Experimental|Healthy volunteers|"Sub-study A: Working memory task / Participant performed a working memory task in two conditions, under threat of shock and in safety and asked to remember verbal and nonverbal stimuli from the current stimulus on the screen (N-back task) Sub-study C: Sustained attention to response task (SART) / participant was presented with stimuli and either initiated a response (i.e. go) or inhibited their response (i.e. stop) based on what stimuli were presented Sub-study D: Stroop task/ In the classic Stroop test, the name of a color is printed in a color that conflicts or does not conflict with the word. In the emotional Stroop, the words emotional words. The participant's task was to name the color of the word Pilot studies / (1) Shocks were delivered via electrodes located on the forearm or fingers while participant performed a working memory or vigilance task or (2) Subject performed cognitive tasks during alternating safe and threat periods"
88970539|NCT02968342|Experimental|Vaginal progesterone 8%|Vaginal progesterone application 8%
88970540|NCT02968342|Placebo Comparator|Placebo|Oral multivitamin supplement
88970541|NCT05243732|Experimental|Mindful Music Listening|"Participants in the mindful music listening group, will receive personalised music playlists based on music tracks or albums or genres suggested by the participant in the pre-intervention survey. The playlist will be created on the streaming platform they are subscribed to.~In addition to listening to their preferred music daily, they will be emailed a brief mindful music exercise to complete prior to listening to their preferred music playlist (weeks 1-4). The mindful music exercise will have spoken instructions, and focus on key element of mindfulness of paying attention to the present moment. For example, If participants were to notice any thoughts or sensations arising either during the brief exercise or during subsequent music listening, they are to allow them to pass and to gently bring their attention back to the exercise/music."
89572062|NCT03042403||Breath stacking|During initial rest period, the volunteer remained seated for 10' in spontaneous breathing. During carrying out of the breath stacking technic, the volunteer remained seated, being requested to hold the mask on his/her face not allowing air scape, The volunteer was oriented to inhale normally and exhale all the air during expiration for 20 seconds. During the 20 seconds of applying of technic, in the three series the maximum inspiratory and expiratory pressures reached during the carrying out of technic. In the final rest period, right after technic end, the volunteers remained seated for 10 minutes in spontaneous breathing and again the same variables of control at the 10th minute were assessed.
89572063|NCT04858633|Active Comparator|PEP group|Tablet HCQ 400 mg q 12 hourly on day one followed by 400 mg once weekly for 3 weeks (total 5 tablets, cumulative dose of 2000 mg)
89572064|NCT04858633|Placebo Comparator|Control group|Placebo one tablet 12 hourly on day one followed by one tablet once weekly for 3 weeks (total 5 tablets)
89572065|NCT04867291|Experimental|Pizza|Consumption of a portion of Eat Balanced pizza equivalent to 200 µg of iodine (half a pizza) consumed with 450 mL water. Collection of urine for 36 hours following pizza ingestion. Collection of one fecal sample up to 24 hours following pizza ingestion.
89572066|NCT04867291|Experimental|Seaweed Sheets|Consumption of a portion of Itsu Crispy Seaweed Thins equivalent to 200 µg of iodine (10g) consumed with 450 mL water. Collection of urine for 36 hours following ingestion. Collection of one fecal sample up to 24 hours following ingestion.
89572067|NCT04867291|Experimental|Seaweed Powder|Consumption of a portion of seaweed powder in a capsule equivalent to 200 µg of iodine (0.25g) consumed with 450 mL water. Collection of urine for 36 hours following ingestion. Collection of one fecal sample up to 24 hours following ingestion.
89572068|NCT04867291|Experimental|Potassium Iodide Supplement|Consumption of a portion of Piping Rock Potassium Iodide supplements equivalent to 200 µg of iodine (1.3 tablets) consumed with 450 mL water. Collection of urine for 36 hours following ingestion. Collection of one fecal sample up to 24 hours following ingestion.
89572069|NCT03043495|Active Comparator|Group A|N-12 Ultrasound guided supraclavicular brachial plexus block will be preformed using a total volume solution of 20ml: 18ml Bupivacaine 0.5%, 0.5ml (2mg) Dexamethasone, 1.5ml Normal saline.
89572070|NCT03043495|Active Comparator|Group B|N-12 Ultrasound guided supraclavicular brachial plexus block will be preformed using a total volume solution of 20ml: 18ml Bupivacaine 0.5%, 1ml (4mg) Dexamethasone, 1ml Normal saline.
89572071|NCT03043495|Active Comparator|Group C|N-12 Ultrasound guided supraclavicular brachial plexus block will be preformed using a total volume solution of 20ml: 18ml Bupivacaine 0.5%, 2ml (8mg) Dexamethasone.
89572072|NCT03043495|Active Comparator|Group Control|N-12 Ultrasound guided supraclavicular brachial plexus block will be preformed using a total volume solution of 20ml: 18ml Bupivacaine 0.5%, 2ml Normal saline.
89572073|NCT03043183|Experimental|Preoperational nutrition support group|Scored patient-generated subjective global assessment(PG-SGA) ≥2，<9 Oral enteral nutrition support（25 kcal/kg or 1.5 g protein/kg） for 3 days before operation
89572074|NCT03043183|No Intervention|Conventional group|PG-SGA ≥2，<9
89572075|NCT03042949|Experimental|Blood pressure measurement|Patients requiring blood pressure measurement will have their blood pressure measured in the standard manner by plethysmography, and then with the Elfor -1 device , the new optical sensor, in order to determine the performance of the new sensor.
89572076|NCT03043027|Experimental|Liposomal bupivicaine|
89572077|NCT03043027|Active Comparator|bupivicaine|
89572078|NCT03043027|Placebo Comparator|saline|
89572079|NCT04861207|Experimental|Cladribine|
89572080|NCT04858165|No Intervention|CONTROL|without MY GERYFS
89572081|NCT04858165|Other|INTERVENTION|with MY GERYFS
89572082|NCT04858321|Experimental|Passive heating|8-12 x1 h water immersion (to the clavicle, @40 °C, rectal temperature ~38.5 °C and <39 °C) sessions over a period of 14 days.
88970542|NCT05243732|Active Comparator|Music Listening|Participants in the music listening group will receive personalised playlists based on music tracks or albums or genres suggested by the participant in the pre-intervention survey. The playlist will be created on the streaming platform they are subscribed to. In contrast to the mindful-music condition, no specific listening instructions will be given to the music listening only condition.
88970543|NCT02968303|Experimental|Induction treatment|Induction vemurafenib and cobimetinib (6 weeks) directly followed by ipilimumab and nivolumab
88970544|NCT02968303|No Intervention|No induction treatment|Upfront ipilimumab and nivolumab without induction by vemurafenib and cobimetinib
89572083|NCT04858087||All students|All participating students were screened for Pf infection using malaria rapid diagnostic tests (mRDTs) and treated if positive. All were followed 1, 2, and 6 weeks after screening-and-treatment.
89572084|NCT03041935|Active Comparator|Caudal-epidural nerve block|All patients will receive acetaminophen (15mg/kg) within one hour of induction of anesthesia. Inhalation induction of anesthesia will be performed with sevoflurane in 100% O2. A single dose of up to 2-4 mg/kg of propofol and Remifentanil 0.5-1mcg/kg will be given prior insertion of a laryngeal mask airway or endotracheal tube. Anesthesia will be maintained with Propofol and Remifentanil (2.5mcg/ml) which will be started at 300 mcg/kg/min and titrated to effect. If necessary additional boluses of Propofol (1mg/kg) and/or Remifentanil (0.5-1mcg/kg) and/or Morphine 0.05mg/kg boluses IV will be administered. Ondansetron (0.1mg/kg) and Dexamethasone (0.15mg/kg) will be given as antiemetic prophylaxis for all patients. Ketorolac 0.3mg/kg will be given to each patient. The CE group will receive an US-confirmed CE nerve block with 0.8 mL/kg of 0.2% ropivacaine (maximum 15 mL). An additional 0.2 mL/kg of ropivacaine 0.2% (max 4mL) will be used for scrotal skin infiltration.
89572085|NCT03041935|Experimental|Ilioinguinal/iliohypogastric nerve block|All patients will receive acetaminophen (15mg/kg) within one hour of induction of anesthesia. Inhalation induction of anesthesia will be performed with sevoflurane in 100% O2. A single dose of up to 2-4 mg/kg of propofol and Remifentanil 0.5-1mcg/kg will be given prior insertion of a laryngeal mask airway or endotracheal tube. Anesthesia will be maintained with Propofol and Remifentanil (2.5mcg/ml) which will be started at 300 mcg/kg/min and titrated to effect. If necessary additional boluses of Propofol (1mg/kg) and/or Remifentanil (0.5-1mcg/kg) and/or Morphine 0.05mg/kg boluses IV will be administered. Ondansetron (0.1mg/kg) and Dexamethasone (0.15mg/kg) will be given as antiemetic prophylaxis for all patients. Ketorolac 0.3mg/kg will be given to each patient. The IIG/IHG group will receive a unilateral US guided IIG/IHG with 0.4mL/kg of ropivacaine 0.2% (max 12 mL). An additional 0.2 mL/kg of ropivacaine 0.2% (max 4mL) will be used for scrotal skin infiltration.
89572086|NCT03042013|Experimental|ASP8273|Subjects will receive a once or twice daily oral dose of ASP8273 (3 dose strengths)
89572087|NCT04857853|Experimental|Exercise Without Rest Breaks|Exercise Without Rest Breaks
89572088|NCT04857853|Experimental|Exercise With Rest Break|Exercise With Rest Break
89572089|NCT04857853|Experimental|Rest Break|Rest Break
89572090|NCT03042793|Experimental|Vaccination|Vaccine: PD-L1 peptide.
89572091|NCT03042871|Active Comparator|Group A|Group A included 30 patients treated with one 0.5mg intravitreal ranibizumab injection. All patients were followed monthly for 12 months with additional injections performed as needed.
89572092|NCT03042871|Active Comparator|Group B|Group B included 30 patients treated with three monthly 0.5mg intravitreal ranibizumab injections. All patients were followed monthly for 12 months with additional injections performed as needed.
89572093|NCT03042637||Acthar Gel and Tacrolimus|Combination therapy with Acthar Gel and Tacrolimus
89572094|NCT03045133|Active Comparator|MT group|Immediately after the induction of anesthesia, patients will receive intravenously methadone 0.1 mg/kg
89572095|NCT03045133|Active Comparator|MF group|Immediately after the induction of anesthesia, patients will receive intravenously morphine 0.1 mg/kg
89572096|NCT04866667||antidiabetic drugs including GLP-1 RAs|Apply Type 2 Diabetes mellitus patients with high risk of ASCVD with antidiabetic drugs including GLP-1 RAs
89572097|NCT04866667||antidiabetic drugs not including GLP-1 RAs|Apply Type 2 Diabetes mellitus patients with high risk of ASCVD with antidiabetic drugs not including GLP-1 RAs，such as metformin，insulin
89572098|NCT04866745|Experimental|Magnetotherapy plus exercise|"The patients will receive a total of 12 sessions, 3 sessions per week of magnetotherapy. The duration of treatment will be 20 minutes with a magnetic field frequency of 50Hz and a power of 100 Gauss.~After the magnetotherapy treatment, the patient will have to perform 12 sessions, 3 sessions per week of a program of therapeutic exercise with a duration of 25 minutes. This exercise program will be the same in the microwave and sham groups."
89572099|NCT04866745|Placebo Comparator|Sham Magnetotherapy plus exercise|The patients will receive a total of 12 sessions, 3 sessions per week of sham magnetotherapy. For the simulated/sham magnetotherapy group, it will be applied in the same way as the real MT group, but the equipment will be programmed to apply 0 Gauss. The physiotherapist performing the application will not have access to the magnetotherapy parameters on the display of the device, but will only have to enter the code. After the application of sham magnetotherapy, the patient will have to perform a program of therapeutic exercise.
89572100|NCT04866745|Active Comparator|Microwave plus exercise|The patients will receive a total of 12 sessions, 3 sessions per week of microwave therapy. The duration of the session will be 20 minutes, 10 minutes on the anterior side and 10 minutes on the posterior side of the joint in case of unilateral knee osteoarthritis. In the case of bilateral knee osteoarthritis, the MW will be applied 20 minutes over the anterosuperior side of both knees. After the microwave session, the patient will have to perform a program of therapeutic exercise.
88970545|NCT00061516|Experimental|Brinzolamide suspension, 1%|Dosed twice daily for 12 weeks
88970546|NCT00061516|Experimental|Levobetaxolol suspension, 0.5%|Dosed twice daily for 12 weeks
88970547|NCT02968147|Experimental|Conventional ventilation|Catheter ablation for persistent atrial fibrillation with general anesthesia and conventional ventilation
88970548|NCT02968147|Experimental|Jet ventilation|Catheter ablation for persistent atrial fibrillation with general anesthesia and high frequency jet ventilation
88970549|NCT00389792|No Intervention|ATI-2042 200 mg|
88970550|NCT00389792|No Intervention|ATI-2042 400 mg|
88970551|NCT00389792|No Intervention|ATI-2042 600 mg|
88970552|NCT00389792|No Intervention|ATI-2042 Placebo|
88970553|NCT02968069|Experimental|Suspected gastric cancerous lesions|Magnifying endoscopy with NBI would be conducted for every patient included in our study
88970554|NCT00061750|Experimental|ICL670|
88970555|NCT00061750|Active Comparator|Deferoxamine|
88970556|NCT02968030|Experimental|Muscle strength|Evaluate the effects of a eight weeks program of strengthening exercise on balance and functional mobility in irregular active elderly women
89033151|NCT02917707||liver metastasis tissues|liver metastasis tissues
89033152|NCT02921451|Other|Restorelle Smartmesh|Surgical procedure for treatment of uterine prolapse will use the device, Restorelle Smartmesh.
89033153|NCT02943317|Experimental|Part A: VS-6063|Part A - Oral VS-6063 (defactinib) twice-daily (BID) continuously starting on Day 1 of Cycle 1.
89572101|NCT04867213||SARS-CoV-2 Positive|Clinically tested for SARS-CoV-2 (as completed by standard laboratory testing e.g. RT-PCR) and with a positive result and clinical features in keeping with COVID-19 illness. The investigators aim to collect breath samples within 7 days of symptom onset in 50% of Covid positive patients, with the remaining patients breath samples collected after 7 days of symptoms onset.
89572102|NCT04867213||SARS-CoV-2 Negative|Patients with a negative RT-PCR COVID-19 test and without any clinical features to suggest COVID-19 illness.
89572103|NCT04860115|Experimental|Block group|Patients in a Block group will be anesthetized and receive PECS II+PIFB with dexmetomidine prior to their surgery.
89572104|NCT04860115|No Intervention|Control group|Patients in a Control group will receive a standard general anesthesia the same way as patients in the interventional group but without regional anesthesia.
89572105|NCT02609659|Experimental|3-DAA + RBV 600 mg|3-DAA (ombitasvir/paritaprevir/ritonavir [25 mg/150 mg/100 mg once daily] and dasabuvir [250 mg twice daily]) plus RBV (ribavirin [600 mg once daily]) for 12 weeks.
89572106|NCT04856995||working in the operating|operating room workers exposed to surgical smoke
89572107|NCT04856995||working in internal units|Internal unit workers not exposed to surgical smoke
89572108|NCT04859881||Barotrauma/cases|Cases were defined as patients with barotrauma consulted with the Surgery Department
89572109|NCT04859881||No braotruma/Controls|Controls were selected from a random sample of the COVID-19-ARDS cohort.
89572110|NCT04429711|Placebo Comparator|IVERMECTIN|
89572111|NCT04429711|Active Comparator|PLACEBO|
89572112|NCT04429633|Active Comparator|Conventional Cardiac intervention|Starting candesartan in patients with left ventricular ejection fraction (LVEF) between 45% and 50% by echocardiogram.
89572113|NCT04429633|Active Comparator|Early Cardiac intervention|Starting candesartan in patients with decreased myocardial strain below 18% regardless of LVEF by echocardiogram.
89572114|NCT04856839||syringomyelia group|
89572115|NCT04856839||Other neurodegenerative diseases|such as hydrocephalus
89572116|NCT04856839||Normal group|
89572117|NCT03042091|Active Comparator|Arm I (mechanical bowel prep, oral antibiotics)|Patients receive polyethylene glycol orally (PO), neomycin PO, and metronidazole hydrochloride PO on day -1. Patients undergo colorectal resection on day 0.
89572118|NCT03042091|Experimental|Arm II (oral antibiotics)|Patients receive neomycin PO and metronidazole hydrochloride PO on day -1. Patients undergo colorectal resection on day 0.
89572119|NCT04859569|Experimental|LY01011|Subcutaneous injection of LY01011 120 mg (1.7ml) every 4 weeks for a maximum of 13 consecutive doses up to week 49.
89572120|NCT04859569|Active Comparator|Xgeva®+LY01011|After subcutaneous injection of Xgeva® 120 mg (1.7ml) every 4 weeks 3 times, patients of Xgeva® group continue to receive LY01011 120 mg (1.7ml) every 4 weeks for ten doses consecutively.
88970557|NCT04939584|Experimental|Intervention|"The study will be conducted using the venous cannulations that are standard of care for the indicated procedure. Additional access points may be necessary if access to coronary sinus is difficult from existing femoral venous cannulations. Sterile study leads or EP catheters will be temporarily placed into the RA, CS, and RV (for R-wave sensing using intracardiac electrograms - optional) which will be connected to the investigational device (CESS).~Up to two MPTs will be delivered and subject responses following each MPT regarding perception and acceptability of MPT to treat AF will be obtained. MPT voltages will not exceed 100V."
88970558|NCT05221346|Experimental|Plant food supplement|"Dietary supplements in capsule form~1 capsule per day at breakfast"
88970559|NCT05221346|Placebo Comparator|Maltodextrin|"Dietary supplements in capsule form~1 capsule per day at breakfast"
88970560|NCT02967913|Experimental|Bladder flap performed as per routine|Bladder flap surgical step performed at time of non-urgent primary cesarean delivery as per routine
88970561|NCT02967913|No Intervention|Bladder flap is omitted|No bladder flap performed at time of non-urgent primary cesarean delivery
88970562|NCT02967835|Experimental|Telepsychiatry Consult|One time tele-psychiatry consultation to provide treatment recommendations for patients primary care physician.
88970563|NCT00398554|Experimental|VECOPA|dose and time intensified consoloditation chemotherapy cycle
88970564|NCT04917900|Experimental|Pyrotinib combined with albumin-bound paclitaxel and trastuzumab|Pyrotinib: 400mg, po,qd,with warm water within 30 minutes after breakfast, q3weeks, 6 cycles in total. Albumin-bound paclitaxel: 260mg/m2, iv, Day1, q3weeks, 6 cycles in total. Trastuzumab: The first cycle dose is 8mg/kg, and each subsequent cycle is 6mg/kg, iv, Day 1, q3weeks, a total of 6 cycles.
88970565|NCT04730323|Experimental|Tocilizumab Group|Tocilizumab administration protocol: Patients received an initial dose calculated as per the body weight (8mg/kg) maximum 800mg/dose) over 1 hour, followed by up to three additional doses if required as per the response after the first dose with 8 hours intervals. Predefined Parameters of disease severity were assessed 12 to 24 hourly. Injection Paracetamol 1g was administered before infusion.
88970566|NCT04730323|Active Comparator|Methylprednisolone (corticosteroid) group|Corticosteroid administration protocol: Patients received methylprednisolone 80mg/day in two divided doses as per national/local guidelines and predefined parameters of disease severity were assessed on each day.
88970567|NCT02967796||Supplemented group|6 capsule of Proteochoc during 4 day, from day 0 (day of delivery) to day 4
88970568|NCT02967796||Control group|no supplementation, just the same follow-up as supplemented group
89033154|NCT02943317|Experimental|Part A: Avelumab|Part A - avelumab IV treatment in 28-day cycles (10 mg/kg over approximately 1 hour on Days 1 and 15).
89033155|NCT02917590|Experimental|Dual-task obstacle crossing training|The four obstacles in the sizes of 4cm wide, 8cm wide, 4cm high, and 8cm high are randomly placed along a 10-meter walkway in 2-meter intervals. Subjects are instructed to walk continuously over obstacles at their comfortable speed, as good as they can without contact the obstacles by their leg or device. During walk over obstacles, subjects asked to perform simultaneously with a color word stroop task which requires subjects to see and answer the color of the name of a color words in the monitor (ignore the meaning) as quickly as possible, and loudly.
89033156|NCT02917590|Sham Comparator|Single-task obstacle crossing training|The four obstacles in the sizes of 4cm wide, 8cm wide, 4cm high, and 8cm high are randomly placed along a 10-meter walkway in 2-meter intervals. Subjects are asked to walk continuously over obstacles at their comfortable speed, as good as they can without contact the obstacles by their leg or device.
89033157|NCT02943356|Experimental|Tadalafil|Patients will be treated with Tadalafil for 8 weeks.
89572121|NCT04859413||the young group|healthy participants age between 20 and 40
89572122|NCT04859413||the elder group|healthy participants age over 60
89572123|NCT04859959|Experimental|68Ga-Pentixafor PET/CT scan|Intravenous Inject 68Ga-Pentixafor and perform PET/CT scan 1h later.
89572124|NCT04856371|Experimental|CYH33 + fulvestrant|Participants will receive CYH33 in combination with a standard fixed dose of fulvestrant 500 mg.
89572125|NCT04856371|Experimental|CYH33 + fulvestrant + palbociclib|Participants will receive CYH33 in combination with standard fixed dose of fulvestrant (500 mg) and palbociclib (125 mg).
89572126|NCT04856371|Experimental|CYH33 + letrozole + palbociclib|Participants will receive CYH33 in combination with standard fixed dose of letrozole (2.5 mg) and palbociclib (125 mg)
89572127|NCT04866277|Experimental|Intervention|"Women who present at least one of the four risk factors - smoking, risk alcohol consumption, risk of depression, physical violence - will be eligible to receive the intervention. The intervention will be the activation of fast-track referral for specialized units and care programs for the four psychosocial and behavioural risk factors under study. All pregnant women referred by the STOP LBW project would have access to consultations or other health activities, such as counselling and group meetings, within a maximum of seven days, in reference services available in each metropolitan area. The activation of the fast-track referral will be the responsibility of the doctor/nurse who applies the questionnaires to identify the risk factors. The intervention ends with childbirth, abortion or if the participant decides to abandon the study."
89572128|NCT04866277|No Intervention|Standard of care|Women who present at least one of the risk factors - smoking, risk alcohol consumption, risk of depression, physical violence - will receive the standard of care currently existing in each PHCU. The standard of care varies across the various PHCU and may include several approaches: routine screening with care by the antenatal care provider; routine screening with referral to other health professional in the same health unit; and routine screening with referral to other health services, with the time elapsed for consultation depending on the health resources available in each area. In each PHCU, different standards of care may exist for each of the four risk factors.
89572129|NCT03041779|Active Comparator|Paracetamol|Paracetamol 500Mg Suppository
89572130|NCT03041779|Active Comparator|Voltaren|Diclofenac Sodium 50Mg Suppository
89572131|NCT02612779|Experimental|Elotuzumab + Pomalidamide + Low Dose Dexamethasone (EPd)|patients will receive treatment with elotuzumab in combination with pomalidomide and low-dose dexamethasone. Patients are eligible to receive Nivolumab at progression.
89572132|NCT02612779|Experimental|Elotuzumab + Nivolumab (EN)|Patients will receive treatment with a combination of elotuzumab and nivolumab
89572133|NCT02612623|Experimental|Gefapixant 15 mg twice daily|Two 7.5 mg gefapixant tablets administered by mouth twice daily for 8 weeks
89572134|NCT02612623|Experimental|Gefapixant 30 mg twice daily|Four 7.5 mg gefapixant tablets administered by mouth twice daily for 8 weeks
89572135|NCT02612623|Experimental|Gefapixant 50 mg twice daily|One 50 mg gefapixant tablet administered by mouth twice daily for 8 weeks
89572136|NCT02612623|Experimental|Placebo to match gefapixant|Matching placebo tablets administered by mouth twice daily for 8 weeks
89572137|NCT03041857||GMK Sphere|Subjects with a unilateral Medacta GMK Sphere TKA
89572138|NCT03041857||GMK PS|Subjects with a unilateral Medacta GMK Primary PS Fixed Bearing TKA
89572139|NCT03041857||GMK UC|Subjects with a unilateral Medacta GMK Primary UC Fixed Bearing TKA
89572140|NCT04808011|Experimental|Treatment|Each subjects will be treated with his prescribed dialysis device for 14 days, followed by a treatment period of 30 days with the investigational IDA system, and concluding with additional 14 days of treatment with the prescribed dialysis device.
89572141|NCT04866355|Experimental|Lumbar spine manipulation|Application of lumbar spine manipulation by a physical therapist.
89572142|NCT04866355|Active Comparator|Lumbar spine manipulation plus pharmacological therapy|Application of lumbar spine manipulation by a physical therapist along with pharmacological therapy.
89572143|NCT04866355|Active Comparator|Pharmacological therapy|Application of pharmacological therapy
89572144|NCT04866121|No Intervention|Standard Treatment|Following 8 hours fasting, standard anesthesia protocol, 3 mg kg-1 Propofol, 0.6 mg kg-1 rocuronium and 2 µg kg-1 fentanyl will be administered. Laparoscopic cholecystectomy will be performed. Twenty minutes prior to the completion of the operation tramadol 100mg will be administered for analgesia.
89572145|NCT04866121|Active Comparator|Single point (P6) Acupuncture|"Prior to the anesthesia induction, the same certified medical doctor will perform a standard acupuncture protocol to the P6 point bilaterally. For P6 acupuncture stimulation 0,25x25mm steel needles will be immersed for 2cm. For stimulation, the needles will be turned clock-wise 3 times. This stimulation will be repeated for 3 times with 10 seconds intervals. The needles will be held in place for 20 minutes and will be removed afterwards.~Following 8 hours fasting, standard anesthesia protocol, 3 mg kg-1 Propofol, 0.6 mg kg-1 rocuronium and 2 µg kg-1 fentanyl will be administered. Laparoscopic cholecystectomy will be performed. Twenty minutes prior to the completion of the operation tramadol 100mg will be administered for analgesia."
89033158|NCT02921373|Experimental|Prostate Cancer Patients|"Up to 6 Male prostate cancer patients with metastatic, castration resistant prostate cancer will be enrolled.~19F Cell Sense-labeled PBMC (3 million cells) will be injected intradermally into the upper thigh of each participant above the inguinal lymph node. MRI will be used to image the administration site."
89033159|NCT02921373|Experimental|Healthy Volunteers|"Up to 6 male or female healthy volunteers will be enrolled.~19F Cell Sense-labeled PBMC (3 million cells) will be injected intradermally into the upper thigh of each participant above the inguinal lymph node. MRI will be used to image the administration site."
89033160|NCT02943239|Experimental|Panel A|REGN1033 + REGN2477 (Regimen 1) or placebo
89033161|NCT02943239|Experimental|Panel B|Panel B - REGN1033 + REGN2477 (Regimen 2) or Placebo
89572146|NCT04866121|Experimental|Double point (P6+ST36) Acupuncture|Prior to the anesthesia induction, the same certified medical doctor will perform a standard acupuncture protocol both to the P6 and ST36 points bilaterally. For P6 acupuncture stimulation 0,25x25mm steel needles will be immersed for 2cm. For ST6 acupuncture stimulation 0,25x50mm steel needles will be immersed for 5cm. For stimulation, the needles will be turned clock-wise 3 times. This stimulation will be repeated for 3 times with 10 seconds intervals. The needles will be held in place for 20 minutes and will be removed afterwards. Following 8 hours fasting, standard anesthesia protocol, 3 mg kg-1 Propofol, 0.6 mg kg-1 rocuronium and 2 µg kg-1 fentanyl will be administered. Laparoscopic cholecystectomy will be performed. Twenty minutes prior to the completion of the operation tramadol 100mg will be administered for analgesia.
89572147|NCT04849819||never receive systemic medications|
89572148|NCT04849819||ever user of systemic medications|
89572149|NCT04849819||current user of systemic medications|
89572150|NCT02607865|Experimental|Semaglutide 3 mg|
89572151|NCT02607865|Experimental|Semaglutide 7 mg|
89572152|NCT02607865|Experimental|Semaglutide 14 mg|
89572153|NCT02607865|Active Comparator|Sitagliptin 100 mg|
89572154|NCT04856137|Experimental|single arm|ruxolitinib, paclitaxel, and rituximab
89572155|NCT03041545||Fitbit|All participants will be asked to wear the Fitbit as much as possible and to sync it at least once a week, from one week prior to start of chemotherapy treatment to six months after ending chemotherapy.
89572156|NCT04849195||Model training and test group|Data set will be split into training group and test group, where training group will be used for model building, and test group for subsequent evaluation and verification.
89572157|NCT04849351|Experimental|Relapsed/Refractory MZL and FL|Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma
89572158|NCT04849039||Mechanicaly ventilated adult patients for non-pulmonary conditions|
89572159|NCT03044899||Adult surgical patients|All surgeries in adult patients
89572160|NCT03045055|Experimental|RIC group|RIC (remote ischemic conditioning) paired with endovascular treatment.
89572161|NCT03045055|Sham Comparator|Sham group|Sham RIC (remote ischemic conditioning) paired with endovascular treatment.
89572162|NCT04849117||Systemic analgesia|Patients received only systemic analgesia : Acetaminophen, Ketoprofen, and Nefopam were administered systematically. Morphine was administered if necessary, according to our institutional pain management protocol.
89033162|NCT02943239|Experimental|Panel C|Panel C - Patients will receive either REGN1033 + REGN2477 (Regimen 3) or Placebo
89033163|NCT02943239|Experimental|Panel D|Panel D - Patients will receive either REGN1033 + REGN2477 (Regimen 4), REGN1033, REGN2477 (high dose) or Placebo
89033164|NCT02943239|Experimental|Panel E|REGN2477 (Regimen 5) or placebo
89572163|NCT04849117||Bilateral TTMP block + systemic analgesia|Patients received the same protocol of systemic analgesia associated with a bilateral TTMP block performed during the first four hours after ICU admission, before tracheal tube removal.
89572164|NCT04848493||HEMATOLOGICAL MALIGNANCIES|"1a. Newly diagnosed patients with ANY haematological malignancy requiring treatment (No.=100).~1b. Patients with ongoing treatments or with treatments completed within 6 months (chemotherapy and target therapies) other than antibodies. More specifically: patients with ongoing or completed chemotherapy (No.=50) or patients with ongoing or completed Ibrutinib (No.=50) or patients with ongoing or completed ruxolitinib (No.=50)~1c. Patients treated with anti-CD19 or CD20 or CD22 or CD30 or anti-PD1 antibodies with or without chemotherapy OR patients receiving CAR-T cells: patients treated anti-B-cell (No.=50) or patients treated anti-CD30 (No.=50) or patients treated anti-PD1 (No.=50).~1d. Patients at three months after autologous or allogeneic transplantation without active immune suppressive therapy: after autologous transplantation (No.=50) or after allogenic transplantation (No.=50)."
89572165|NCT04848493||SOLID TUMORS|"2a. Chemotherapy in adjuvant therapy. All patients with a diagnosis of solid tumors apart resected basal-cell or squamous-cell carcinoma of the skin, melanoma in situ, carcinoma in situ of the cervix, and carcinoma in situ of the Breast. Under curative surgery (stage II-III) for the solid tumor or hemotherapy alone or in combination with target therapies or radiotherapy (No.=100).~2b. Chemotherapy in metastatic Disease. All patients with a diagnosis of solid tumors with Metastatic disease (stage IV), undergoing chemotherapy alone or in combination with immunotherapy or target therapy (No.=100).~2c. Immunotherapy in metastatic Disease. All patients with a diagnosis of solid tumors with Metastatic disease (stage IV), undergoing immunotherapy alone (No.=100).~2d. Target therapies in metastatic Disease. All patients with a diagnosis of solid tumors with Metastatic disease (stage IV), Undergoing target therapy alone (No.=100)"
89033165|NCT02943239|Experimental|Panel F|REGN2477 + REGN1033 (Regimen 6) or placebo
89572166|NCT04848493||IMMUNORHEUMATOLOGICAL DISEASES|3a. Patients with ANCA-associated vasculitis classified according to Chapel Hill Consensus Conference nomenclature, treated with immunodepressants agents with/without glucocorticoids (No.=50) or treated with RTX with/without glucocorticoids (No.=50) 3b. Interstitial Lung Disease in Autoimmune Conditions. Patients with a diagnosis of a specific CTD, myositis or rheumatoid arthritis based on validated classification criteria, and clinically significant ILD defined as disease treated with traditional immunodepressants or rituximab and fibrotic and/or inflammatory changes on chest CT not attributable to infection, and no evidence of obstructive lung disease. Patients treated with traditional immunodepressive agents with/without glucocorticoidspatients (No.=50) or patients treated with rituximab with/without glucocorticoids (No.=50)
89572167|NCT04848493||NEUROLOGICAL DISEASES|"4a. Patients with a diagnosis of multiple sclerosis, age < 60 years with relapsing-remitting MS on Ocrelizumab (anti-CD20 monoclonal antibody) (No.=50) or with secondary/primary progressive MS on Ocrelizumab (anti-CD20 monoclonal antibody) (No.=50).~4b. Generalized Myasthenia Gravis, on immunosuppressive polytherapies or on B-cell targeted biological treatments, with lymphocytes count < 1 cell/microliter, or with thymoma (No.=100)"
89572168|NCT04855591|Experimental|SHR-1703 Dose Level 1|Dose level 1 SHR-1703
89572169|NCT04855591|Experimental|SHR-1703 Dose Level 2|Dose level 2 SHR-1703
89572170|NCT04855591|Experimental|SHR-1703 Dose Level 3|Dose level 3 SHR-1703
89572171|NCT04855591|Experimental|SHR-1703 Dose Level 4 (optional)|Dose level 4 SHR-1703 Additional dose escalations, as determined by the SMC depend on PK and safety data review
89572172|NCT04848649|Experimental|Arm 1|
89572173|NCT04855279|Placebo Comparator|Control|
89572174|NCT04855279|Active Comparator|Topical neutral sodium fluoride|
89572175|NCT04855279|Active Comparator|ACP-CCP gel|
89572176|NCT04855279|Active Comparator|nano-hydroxyapatite solution|
89572177|NCT04848259|Placebo Comparator|Control|No drug given before surgery
89572178|NCT04848259|Active Comparator|Dexamethason|Dexamethason will be given IV before surgery
89572179|NCT04848259|Active Comparator|Natural honey|Honey will be placed locally after impaction removal
89572180|NCT04848259|Active Comparator|Dexamethason and natural honey|Dexamethason will be given IV before surgery and Honey will be placed locally after impaction removal
89572181|NCT03040609||Group 1|The duration of follow-up of group 1 in the study is 1 day.
89572182|NCT03040609||Group 2|The duration of follow-up of group 2 in the study is 2 weeks.
89572183|NCT03040609||Group 3|The duration of follow-up of group 3 in the study is 6 months.
89572184|NCT04848571|Placebo Comparator|control group|Pregnant women who received IVF and not taken Chinesene fetal protection medicine until sampling
89572185|NCT04848571|Experimental|medicine group|Pregnant women who received IVF and have taken Chinesene fetal protection medicine from the fourth week during early pregnancy
89572186|NCT04840537|Active Comparator|cytological brushing followed by cholangioscopy in case of failure|
89572187|NCT04840537|Experimental|cholangioscopy from the start|
89572188|NCT03038971|Other|Concentration 1: Short and Tall Ragweed Mix|
89033166|NCT02943239|Experimental|Panel G|REGN2477 (Regimen 7) or placebo
89033167|NCT02917512|Experimental|HU00701|"HU00701(Cyclosporine 0.01% + 3% trehalose)~1 drop b.i.d at 12 hour interval for 12 weeks"
89572189|NCT03038971|Other|Concentration 2: Short and Tall Ragweed Mix|
89572190|NCT03038971|Other|Placebo: Saline with 0.4% Phenol|
88811134|NCT04199117|Experimental|Incentive,Tailored,Care Manage,Intensive Treatment|Participants randomly assigned to this condition will have access to incentives for completing a first smoking cessation counseling call up to 4 times over 2 years, will receive 5 tailored letters promoting use of smoking cessation treatment over 2 years, will receive 5 Tobacco Care Management support and motivational encouragement calls over 2 years, and will have access to 3 smoking cessation quit counseling calls and 12-weeks of either combination nicotine replacement or varenicline up to 4 times over 2 years.
89033168|NCT02917512|Experimental|HU007|"HU007(Cyclosporine 0.02% + 3% trehalose)~1 drop b.i.d at 12 hour interval for 12 weeks"
89033169|NCT02917512|Active Comparator|Restasis|"Restasis(Cyclosporine 0.05%)~1 drop b.i.d at 12 hour interval for 12 weeks"
89572191|NCT03039127|Experimental|imILT|Immunostimulating Interstitial Laser Thermotherapy (imILT)
89572192|NCT03039049|Experimental|GnRH agonist|"Drug: Triptorelin 0.1mg Triptorelin 0.1 mg administered subcutaneously 6 days after ovum pick-up (OPU) in IVF/ICSI cycles triggered by triptorelin 0.2 mg.~Other Names:~• Decapeptyl 0.1 mg"
89572193|NCT03039049|No Intervention|Control|No intervention
89572194|NCT03038893|Experimental|POCUS + EDUS|Patients were first submitted to Point Of Care Ultrasound (POCUS) and then to Echo Doppler Ultrasound (EDUS) for the diagnosis of DVT.
89572195|NCT03038893|Active Comparator|Echo Doppler Ultrasound (EDUS)|Patients were submitted only to Echo Doppler Ultrasound (EDUS) for the diagnosis of DVT.
89572196|NCT03040453|Other|Microwave ablation|20 patients will be treated with microwave ablation
89572197|NCT03040453|Other|Irreversible electroporation|20 patients will be treated with irreversible electroporation
89572198|NCT04848181|Active Comparator|cyproterone acetate|20 patients received cyproterone acetate 50 mg twice per day for two weeks before TURP
89572199|NCT04848181|Active Comparator|finasteride group|20 patients received finasteride 5 mg once per day for two weeks before TURP
89572200|NCT04848181|Placebo Comparator|control group|20 patients received no treatment before TURP
89572201|NCT04847791|Experimental|Group A|Standard Anti-Covid-19 Therapy + Oral Administration of Bovine Lactoferrin 400mg (two capsules of Mosiac 200 product) every 12 h (i.e., fixed dose 800 mg / day) for 30 days and still away from meals
89572202|NCT04847791|Placebo Comparator|Group B|Standard anti-Covid-19 therapy + Placebo administration (capsule identical with the same amount as an inert compound, starch of corn powder), according to the same pattern of use.
89572203|NCT04848103|Experimental|Radial extracorporeal shockwave therapy|
89572204|NCT04847869|Experimental|NIR laser treatment 200mW/cm2 dose|"Each NIR light treatment will consist of a 90 second exposure of the macula of the study eye to the Ellex Integre NIR laser with the patient fixating on the central aiming beam. The laser light beam is 4.5mm in diameter with a central masked area of 1.0 mm diameter containing the central fixation target. In this way the central macula will be spared in the event of an adverse effect of the laser, which we do not anticipate.~The patient will be seated at the slit lamp laser delivery system and after the eye has been dilated and anesthetised with topical eye drops a standard fundus contact lens will be placed on the eye through which the post area pole will be visualised while the treatment is delivered. There will be 12 treatments administered over a 5 week period."
89572205|NCT03041389|Experimental|CCBT-I Group|The patients who will be randomized to CCBT-I group will get Cleveland Clinic CCBT-I program through the internet (Cleveland Clinic Wellness Go! To Sleep six-week online program). The program involves a 6-week effective sleep therapy, an online sleep log and daily sleep score, six specially crafted relaxation practices, daily sleep improvement recommendations, activities to help the patient get the sleep needed, daily e-mails from the patient's program coach, daily articles to help the patient get the most out of the program and a mobile application for easy sleep tracking.
89572206|NCT03041389|Active Comparator|Control Group|"The patients who will be randomized control group will be given a reading material only including recommendations about sleep hygiene, stimulus control and sleep restriction. The control group will have access to the CCBT-I program through the internet (Cleveland Clinic Wellness Go! To Sleep six-week online program), if proven effective, after the study is completed.~To identify PD-specific barriers to Internet usage and CCBT-I, all patients at the end of the study or at the time of drop out will have a questionnaire on the barriers to CCBT-I."
89572207|NCT04847713||Fabry's disease|children and adults male or female between 6 and 70 years old, patients with diagnosis of FD, treated and non-treated
89572208|NCT04847713||Healthy controls|age and sex-matched group of healthy subjects with a negative family history for lysosomal storage disorders and no clinical signs of FD.
89572209|NCT03041155|Experimental|treatment|Muscle respiratory training
89572210|NCT03041155|No Intervention|control|No intervention
89572211|NCT04375813|Active Comparator|Active Study Drug Group|Patients will be given 0.5mg eRapa (encapuslated rapamycin) orally each weekday (Monday-Friday) for one year.
89572212|NCT04375813|Placebo Comparator|Placebo Group|Patients will be given a placebo (visually identical to the eRapa (encapsulated rapamycin)) orally each weekday (Monday-Friday) for one year.
89572213|NCT03041077|Experimental|Instaflex Advanced|Dietary supplement: Joint function
89572214|NCT03041077|Placebo Comparator|Placebo|Dietary supplement: Placebo
89572215|NCT04847245|Active Comparator|Pregabalin group|Pregabalin capsules were administered orally (75 mg, tid), combined administration of duloxetine.
89572216|NCT04847245|Experimental|0.125 mg/kg esketamine group|Intravenous administration of esketamine 0.125 mg/kg，and duloxetine is co- administered orally.
89572217|NCT04847245|Experimental|0.25 mg/kg esketamine group|Intravenous administration of esketamine 0.25mg/kg，and duloxetine is co- administered orally.
88970569|NCT04900272|Experimental|VIPA device and companion booklet|For Aim 2, we will recruit a total of 20-40 older adult homebound patients who are likely to be socially isolated, through the Geriatric and General Internal Medicine clinics at Northwestern (over 2,300 homebound older adults) to use the VIPA and accompanying instructional booklet focused on social-isolation. Either the study PI or Research Study Coordinator (RSC) will visit the participant's home, or assist the patient virtually, once consented, to set up the Google Home or Amazon Alexa device for them and review the companion VIPA booklet with them.
88970570|NCT00062023|Active Comparator|Arm I Sulindac|Oral sulindac twice daily.
88970571|NCT00062023|Active Comparator|Arm II Aspirin|Oral aspirin once daily.
88970572|NCT00062023|Active Comparator|Arm III Ursodiol|Oral ursodiol three times daily.
88970573|NCT00062023|Placebo Comparator|Arm IV: Sulindac Placebo|Oral sulindac placebo twice daily.
89572218|NCT04847245|Experimental|0.50 mg/kg esketamine group|Intravenous administration of esketamine 0.50 mg/kg，and duloxetine is co- administered orally.
89572219|NCT04854733||Referees|There will be no interventions. Motor and cognitive assessments will be conducted.
89572220|NCT04854733||Athletes|There will be no interventions. Motor and cognitive assessments will be conducted.
89572221|NCT04840225||Endocarditis|100 patients diagnosed with infectious endocarditis according to DUKE criteria. Detailed characterization of inflammation, anemia and markers of iron hemostatis will be made at diagnosis and followed undtill 6 months after discharge.
89572222|NCT04840225||TAVI/TEVAR patietns|30 patients undergoing elektive TAVI/TEVAR procedures. Detailed characterization of inflammation, anemia and markers of iron hemostatis will be made at directly prior to procedure and followed undtill 3 months after discharge.
88970574|NCT00062062|Experimental|gefitinib|"Patients receive oral gefitinib on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed at baseline and after the completion of course 2.~Patients are followed every 3 months for 5 years."
88970575|NCT00062062|Experimental|paclitaxel + carboplatin + gefitinib|"Patients receive paclitaxel IV over 1 hour and carboplatin IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. After completion of chemotherapy and in the absence of disease progression, patients receive oral gefitinib as in group I.~Quality of life is assessed at baseline and after the completion of course 2.~Patients are followed every 3 months for 5 years."
88970576|NCT05195684|Other|single arm|entirely within-subject outcome variables
89572223|NCT04840225||Patients with bacterial infections without endocarditis|30 patients diagnosed with with bacterial infections, without endocarditis. Detailed characterization of inflammation, anemia and markers of iron hemostatis will be made at diagnosis and followed undtill 3 months after discharge.
89572224|NCT04840225||Healthy blood donors|Detailed characterization of inflammation, anemia and markers of iron hemostatis will be made at directly prior to blood donation and approximately 1 week after blood donations
89572225|NCT04839835|No Intervention|standard waiting room|standard chemoterapy waiting room
89572226|NCT04839835|Experimental|waiting room enriched with art objects|waiting room enriched with music, paintings and artificial plants
89572227|NCT04847401||Group 1|patients with Irritable Bowel Syndrome
89572228|NCT04847401||Group 2|normal
89572229|NCT04846699||group 1|bulls eye localization
89572230|NCT04846699||group 2|stone targeted technique renal access
89572231|NCT04846699||group 3|triangulation renal access technique
89572232|NCT04847089|Experimental|Motor Imagery BCI training|Complete intervention with motor imagery BCI training. Patients recruited by physiotherapists who underwent baseline evaluations with clinical tests, fMRI and EEG measurements. Patients will after intervention perform clinical tests, fMRI, and EEG measurements to evaluate outcomes of intervention.
89572233|NCT04846621|Other|group Nicorandil|women will receive oral Nicorandil 20 mg initially followed by 10 mg at 8 hourly intervals for 48 hours
89572234|NCT04846621|Other|group Nifedipine|Women will receive oral Nifedipine loading dose 20 mg orally followed by 10 mg every 8 hours for 48 hours
89572235|NCT04846777|Experimental|Mindfulness ecological momentary intervention|The SMP condition was developed to parallel the treatment while eliminating its theorized active therapeutic elements - open monitoring, acceptance, attending to small moments, breathing retraining, continual practice of mindfulness. Therefore, it did not mention anything about mindfulness at all. Instead, SMP participants were instructed to notice their cognitions and emotions and how distress they might be. No instruction on accepting their thoughts and feelings as they are were given.
89572236|NCT04846777|Placebo Comparator|Self-monitoring placebo|The SMP condition was developed to parallel the treatment while eliminating its theorized active therapeutic elements - open monitoring, acceptance, attending to small moments, breathing retraining, continual practice of mindfulness. Therefore, it did not mention anything about mindfulness at all. Instead, SMP participants were instructed to notice their cognitions and emotions and how distress they might be. No instruction on accepting their thoughts and feelings as they are were given.
89572237|NCT04846543|Other|MRI scan 1st and 2nd year|Additionally to routinely follow up, there will be an MRI scan of enrolled patients after one and two years in some of the study sites
89572238|NCT04854655|Active Comparator|Control|Conventional resin composite
89572239|NCT04854655|Experimental|Intervention 1|Activa Presto
89572240|NCT04854655|Experimental|Intervention 2|Giomer
89572241|NCT03038737|Active Comparator|group 1|patients will receive partial denture constructed from breflex material
89572242|NCT03038737|Experimental|group 2|patients will receive partial denture constructed from PEEK material
89572243|NCT04854421||healthy adults|Community dwelling and have no life-threatening conditions or diseases that would alter body composition from what is typical for their age, sex, ethnicity, and BMI.
89572244|NCT04846153|Other|Human-based Quantification|No intervention. No support tool will be used for quantifying airway stenosis from the bronchoscopic images collected previously.
89572245|NCT04846153|Active Comparator|Computer-based Quantifiction|Computer based support tool will quantifying airway stenosis from the bronchoscopic images collected previously.
89572246|NCT04854577|Experimental|"Intervention group: Opioid Free Anesthesia with a pecto-intercostal fascial plane block"|Patients to whom a standardized opioid free anesthesia consisting of esketamine, lidocaine and dexmedetomidine will be administered with a pre-incisional pecto-intercostal fascial plane block.
89572247|NCT04854577|Active Comparator|"Control group: Traditional Opioid-based Anesthetic Regimen"|Patients who will receive a traditional opioid based anesthetic regimen. The administered dose of opioids is at the discretion of the attending anesthesiologist.
89572248|NCT04846465||male|normal Sohag healthy male (≥18 & ≤ 60 years)
89572249|NCT04846465||female|normal Sohag healthy female (≥18 & ≤ 60 years)
89572250|NCT04846075||Ramadan Group|Diurnal fasting and spiritual practices. Operationally assessed by the level of compliance to Sawm, Salat, and Zakat.
89572251|NCT03038581||Self-inflicted wrist injury|Wrist injury by self-infliction
89572252|NCT03038581||Traumatic wrist injury|Wrist injury by not self-inflicted trauma
89572253|NCT04860427|Active Comparator|Trapezoidal condylar plate|Trapezoidal condylar plate open reduction and internal fixation of subcondylar fractures
89572254|NCT04860427|Active Comparator|two miniplates|two miniplates open reduction and internal fixation of subcondylar fractures
89572255|NCT04839445|Active Comparator|General anesthesia + TAP block|Induction: remifentanil in total intravenous anesthesia (TIVA), Propofol 2 mg/kg/h and Rocuronium 0.6 mg/kg. Transversus abdominis plane (TAP) block: 20 minutes before surgery. Ropivacaine 0.37% 20ml + dexamethasone 2mg per side. Maintenance: TIVA with Propofol, the infusion rate will be adjusted according to the bispectral index system (BIS) values (30 <BIS <50). Patients will receive additional remifentanil by infusion at 0.02 mcg/kg/min per time if blood pressure and heart rate values exceed 20% pre-operative baseline values. Additional rocuronium 0.1 mg/kg based on clinical needs and train of four (TOF) monitoring. Analgesic starter bolus: 30 minutes before the end of the surgery, paracetamol 1 gr ev and ketorolac 30 mg ev. Postoperative pain: paracetamol 1 gr ev every 8 hours for 36 hours; ketorolac 30 mg ev if NRS >4 / morphine 2 mg ev if NRS >4 30 min after ketorolac administration. In case of nausea and vomiting ondansetron 4 mg ev.
89572256|NCT04839445|Active Comparator|General anesthesia + ESP block|"Erector spinae plane (ESP) block: 20 minutes before surgery. T8 level bilaterally, ropivacaine 0.37% 20ml + dexamethasone 2mg per side.~Induction: Remifentanil in TIVA, Propofol 2 mg/kg/h and Rocuronium 0.6 mg/kg. Maintenance: TIVA with Propofol, the infusion rate will be adjusted according to the BIS values (30 <BIS <50). Patients will receive additional remifentanil by infusion at 0.02 mcg/kg/min per time if blood pressure and heart rate values exceed 20% pre-operative baseline values. Additional rocuronium 0.1 mg/kg based on clinical needs and TOF monitoring.~Analgesic starter bolus: 30 minutes before the end of the surgery, paracetamol 1 gr ev and ketorolac 30 mg ev.~Postoperative pain: paracetamol 1 gr ev every 8 hours for 36 hours; ketorolac 30 mg ev if NRS >4 / morphine 2 mg ev if NRS >4 30 min after ketorolac administration. In case of nausea and vomiting ondansetron 4 mg ev."
89209075|NCT02593721|Experimental|Median Nerve Neural Mobilization|15 minute Median Nerve Neural Mobilization sessions 5 times a week (monday to Friday) during 6 continuous weeks The maximum degree of elbow extension applied in the Median Nerve neural mobilization procedure was determined through the use of a Universal Goniometer Device.
89572257|NCT04845607|Experimental|Prophylactic amiodarone|
89572258|NCT04845607|No Intervention|Conventional management|
89572259|NCT04845763||Intervention|Each patient complete the french version of the QoR-15 score (FQoR-15) at 3 times (before surgery, on Day 1, on Day 2).
89572260|NCT04845529|Experimental|1 tDCS Parietal|Anodal tDCS applied to the right inferior parietal cortex
89572261|NCT04845529|Experimental|2 tDCS Frontal|Anodal tDCS applied to the medial frontal cortex
89572262|NCT04845529|Sham Comparator|3 Sham|Sham tDCS (control, no stimulation delivered). Following a standard sham protocol, in this condition the tDCS will be active the first 30seconds and the last 30seconds of the session, but silent during the other 19minutes
89572263|NCT04845295|Experimental|Fast Tempo|Performed training intervention with a tempo of 1 second for eccentric and 1 second for concentric phase
89572264|NCT04845295|Experimental|Slow Tempo|Performed training intervention with a tempo of 4 seconds for eccentric and 1 second for concentric phase
89572265|NCT04845373|Experimental|Mediterrenean diet|Mediterranean diet:Target macronutrient energy contributions were 40% from carbohydrate, 35%-40% from fat (with <10% of energy as saturated fat), and 20% of energy as protein.Participant in this group were trained to consume fish, legumes at least 2-3 times a week, walnuts and olive oil every day in accordance with the Mediterranean diet model.
89572266|NCT04845373|Active Comparator|Low fat diet|Low fat diet:Target macronutrient energy contributions for the low fat diet diet were 50-60% from carbohydrate, <30% from fat (with <10% of energy as saturated fat), and 20% from protein.Participants in this group were especially recommended to consume low-fat foods.
89572267|NCT03040531|Experimental|Genistein|"Each tablet will contain 27 mg of 98% pure genistein + 500mg Calcium + 200 IU Vit. D3. Subjects will receive 2 tablets per day 6 days/week for all the duration of the study.~Once a week subjects will receive a tablet containing only 500mg Calcium + 200 IU Vit. D3."
89572268|NCT03040531|Active Comparator|Alendronate|"Each tablet will contain 500mg Calcium + 200 IU Vit. D3. Subjects will receive 2 tablets per day 6 days/week for all the duration of the study.~Once a week subjects will take one tablet containing 70mg alendronate."
89572269|NCT03040375|Experimental|Peer counselling|There were two types of intervention: one providing breast-feeding and complementary feeding counselling + psychosocial stimulation interventions.
89572270|NCT03040375|No Intervention|Non peer counselling|Usual health messages
89572271|NCT04839055|Experimental|Experimental: Coenzyme A 200U|Coenzyme A 200U per day
89572272|NCT04839055|Placebo Comparator|Placebo Comparator: Placebo|Abiraterone without coenzyme A
88970577|NCT00062101|Experimental|Group I (erlotinib hydrochloride, celecoxib)|Patients receive oral erlotinib once daily and oral celecoxib twice daily.
88970578|NCT00062101|Experimental|Group II (erlotinib hydrochloride)|Patients receive erlotinib as in group 1.
88970579|NCT04870476|Experimental|"Internet-delivered treatment: One step at the time"|"Internet-delivered treatment: One step at the time. All participants receive the internet-delivered therapist-assisted 11-modules treatment program One step at the time."
88970580|NCT00062179|Experimental|paclitaxel/carboplatin/celecoxib|Paclitaxel: 225 mg/m2 by 3-hour intravenous infusion Carboplatin: dosed at an AUC of 6 by the Calvert Formula Celecoxib: 400 mg po BID 3 cycles of paclitaxel and carboplatin 21 days apart celecoxib 3-7 days before first dose of chemotherapy
88970581|NCT00062179|Placebo Comparator|paclitaxel/Carboplatin/Placebo|Paclitaxel: 225 mg/m2 by 3-hour intravenous infusion Carboplatin: dosed at an AUC of 6 by the Calvert Formula Placebo 3 cycles of paclitaxel and carboplatin 21 days apart Placebo 3-7 days before first dose of chemotherapy
88970582|NCT04865874|Experimental|PPV-GDT|Intra-operative fluid-therapy based (lactated Ringer) on continous PPV monitoring (target ≤5.8%)
88970583|NCT04865874|Active Comparator|Zero balance|Intra-operative fluid-therapy (lactated Ringer) based on 1:1 compensation of urinary output
88970584|NCT02967874|Experimental|Intra-articular auto-SVFs injection|"The participants will undergo a standard liposuction to harvest adipose tissue. The adipose tissue will then be processed to obtain the SVFs.~This group of subjects (n=16) will receive a single injection of auto-SVFs into affected knees (3.0 mL cell suspension/joint)."
88970585|NCT02967874|Active Comparator|Intra-articular Hyaluronic Acid|This group of subjects (n=11) will receive a single injection of Synocrom Forte 2% into affected knees (1.0 mL/joint).
88970586|NCT02967952|Active Comparator|supraglottic airway (SGA)|Adult patients with non-trauma causes of OHCA who are resuscitated by emergency medical technician paramedic (EMTP) in the prehospital setting and received airway management of supraglottic airway (SGA).
88970587|NCT02967952|Active Comparator|endotracheal intubation (ETI)|Adult patients with non-trauma causes of OHCA who are resuscitated by emergency medical technician paramedic (EMTP) in the prehospital setting and received airway management of endotracheal intubation (ETI).
88970588|NCT00062452||A-1,2,3|The cohort (A) comprised of high risk infants. There were 3 sub groups studied within this cohort: (1) premature infants, (2) Infants with congenital gut anomalies, and (3) perinatal asphyxia.
88970589|NCT00062491|Experimental|1|Karenitecin (BNP1350)
89572273|NCT04838821|Experimental|Anti SARS-CoV-2 equine hyperimmune serum|All participants in the treatment groups will receive a single intravenous infusion on day 1 containing the specified dose according to their assigned group 12mg/kg, 30 mg/kg or 56mg/kg. Total volume of the infusion is 180ml, to be administered during a time period of at least 1 hour. Study participants will be followed during their hospitalization until they are discharged and on Study Day 28.
89572274|NCT04838821|Experimental|Placebo|All participants in the placebo group will receive a single intravenous infusion on day 1 containing a specified volume of a saline IV solution preparation. Total volume of the infusion is 180ml, to be administered during a time period of at least 1 hour. Study participants will be followed during their hospitalization until they are discharged and on Study Day 28.
89572275|NCT04838665|Active Comparator|Multiple Alternate Instillation of 0.5% cyclopentolate and 2.5% phenylephrine (MAI)|20 infants were enrolled in Multiple Alternate Instillation of 0.5% cyclopentolate and 2.5% phenylephrine (MAI)
89572276|NCT04838665|Experimental|Single instillation of 0.5% tropicamide + 0.5% phenylephrine (SI)|Single instillation of 0.5% tropicamide + 0.5% phenylephrine (SI)
89572277|NCT04838665|Experimental|1 instillation of 0.5% tropicamide +0.5% phenylephrine w/a cotton wick placed in the inferior fornix|Single instillation of 0.5% tropicamide + 0.5% phenylephrine with a cotton wick placed in the inferior fornix (SIW)
89572278|NCT03038659||Penile Duplex|Measuring intima media thickness
89572279|NCT04845061|Placebo Comparator|nebivolol then placebo|Comprises15 copd patients, after recruitment in study and written informed consent, patient's administered nebivolol (1.25 mg for one week then2.5mg fore another one week and 5 mg at 8am for 10 weeks)and washout period4 weeks then shifted to placebo for 12 weeks
89572280|NCT04845061|Active Comparator|placebo then nebivolol|Contain 15 copd patient's after recruitment and Written informed consent administered placebo for 12 weeks and washout period for 4 weeks then shifted to nebivolol for 12 weeks
89572281|NCT03040765|Active Comparator|Denosumab|"Denosumab 60 MG/ML Prefilled Syringe~Denosumab Dose: 60 milligrams, subcutaneous injection, every 6 months (twice a year)"
89572282|NCT03040765|Active Comparator|Zoledronic Acid|"Zoledronic Acid 5Mg/Bag 100Ml Inj~Zoledronic acid will be 5 milligrams, Intravenous injection, once a year"
89572283|NCT04853953||COVID-19 ARDS patients requiring veno-venous ECMO support|Critically ill COVID-19 patients with ARDS requiring ECMO support will be analyzed in this group. Patients from all three study sites will be assessed for participation.
89572284|NCT04853953||Non-COVID-19 ARDS patients requiring veno-venous ECMO support|Critically ill Non-COVID-19 patients with ARDS requiring ECMO support will be analyzed in this group. Patients from all three study sites will be assessed for participation.
89572285|NCT01668667|Active Comparator|GSK1838262 600 mg|Once-daily dose with food in the evening at approximately 5 PM
89572286|NCT01668667|Active Comparator|GSK1838262 450 mg|Once-daily dose with food in the evening at approximately 5 PM
89572287|NCT01668667|Active Comparator|GSK1838262 300 mg|Once-daily dose with food in the evening at approximately 5 PM
89572288|NCT01668667|Placebo Comparator|GSK1838262 placebo match|Once-daily dose with food in the evening at approximately 5 PM
89572289|NCT04852939|Experimental|Bowen's Technique|Bowen's Technique
89572290|NCT04852939|Active Comparator|Conventional Physical Therapy|Conventional Physical Therapy including stretching and strengthening exercises
89572291|NCT03040219|Active Comparator|Treatment group|
89572292|NCT03040219|Placebo Comparator|Control|
89572293|NCT03038503|No Intervention|A|standard care septic shock according sepsis bundles
89572294|NCT03038503|Experimental|B|after defined refractory shock (adequate fluid resuscitation + add NE>0.5 mcg/kg/min) add Methylene blue 1 mg/kg iv drip then 2 hr later drip 0.5 mg/kg/hr*4 hr (intervention add on to standard care)
89572295|NCT03038503|Experimental|C|after defined refractory shock (adequate fluid resuscitation + add NE>0.5 mcg/kg/min) add terlipressin 1 mg IV then repeated dose 20 min later if unstable BP (intervention add on to standard care)
89572296|NCT02608879|Experimental|OMDP Group|Subjects randomized to this group will attend weekly visits and receive a full dental cleaning, as well as have their gums/tongue cleaned by a dental professional. Subjects will also receive standard of care oral hygiene instructions.
89572297|NCT02608879|Other|Control Group|Subjects assigned to the control group will receive standard of care oral health instructions and will come for bi-weekly treatment visits where they will have their teeth cleaned (brushed) by a dental professional.
89572298|NCT04852549|No Intervention|No intervention group|The control group continued with routine training after evaluations.
89572299|NCT04852549|Experimental|Oculomotor exercise group|After the evaluation, the intervention group performed oculo-motor exercises for 4 weeks, 6 days a week, morning and evening, twice a day for 10 minutes, in addition to normal ball training. While doing the exercises, individuals were taught to focus on the purpose they held in their hands, move their head, and aim fast enough to see the image clearly. Two repetitions each week were added to the exercise numbers. Ten seconds rest between two sets and five seconds rest between movements.
89572300|NCT04852705|Experimental|candidate vaccine|
89572301|NCT04852705|Placebo Comparator|Placebo|
89572302|NCT03040297|Active Comparator|TGI 6 L/min|Tracheal gas insufflation 6 L/min
89572303|NCT03040297|Active Comparator|TGI 11 L/min|Tracheal gas insufflation 11 L/min
89572304|NCT03040297|Active Comparator|TGI 0 L/min|Tracheal gas insufflation catheter, without gas flow
89572305|NCT04852315|Experimental|Caffeine supplementation|Acute caffeine supplementation
89572306|NCT04852315|Placebo Comparator|Placebo supplementation|Acute placebo supplementation
89572307|NCT03038425|Placebo Comparator|Saline infusion|Participants in this group will receive normal saline infusion (5ml/hr, patient controlled bolus 5ml, lockout 30min) in the adductor canal, starting in PACU on post-operative day 0 and continuing for 96 hours
89572308|NCT03038425|Active Comparator|Ropivacaine infusion|Participants in this group will receive ropivacaine 0.2% infusion (5ml/hr, patient controlled bolus 5ml, lockout 30min) in the adductor canal, starting in PACU on post-operative day 0 and continuing for 96 hours
89572309|NCT04852237||Pregnancies from ICSI-TESE cycles for obstructive azoospermia.|Pregnancies occurred between January 2010 and December 2019 at Humanitas Fertility Center after ICSI-TESE cycles for obstructive azoospermia.
89572310|NCT04852237||Pregnancies from ICSI cycles with ejaculated sperm.|Pregnancies occurred between January 2010 and December 2019 at Humanitas Fertility Center after ICSI cycles with ejaculated sperm.
89572311|NCT04844047|Active Comparator|FAST|Twice per week exercise program, 45 minutes duration for 12 weeks conducted in the community. Participants attended a 30-minute fall prevention education session once per week. FAST followed the same principles as Standard, with the addition of the following goals: 1) Increase UE strength (shoulder girdle/arm) utilizing both concentric and eccentric contractions, 2) Improve trunk and neck postural control during slow and fast body motions, 3) Optimize forward descent strategies via practice of quick response reaching, landing and controlled descent with hands on the wall or on the floor as able. Training progression for strength and body control included increasing the distance standing from the wall, progressing to one arm descents, increasing reps and speed and moving to greater gravity and body weight resistance such as hands and knees position on the floor as able. Quick movement practice targeted unexpected reaching activities, balloon and ball toss
89572312|NCT04844047|Placebo Comparator|Standard|Twice per week exercise program, 45 minutes duration for 12 weeks conducted in a community site (assisted living residence). Participants also attended a 3o minute fall prevention education session once per week. The Standard intervention consisted of a fall prevention exercise program designed for community-dwelling older adults. Exercises focussed on balance, leg strength, walking and mobility exercises designed to decrease fall risk.
89572313|NCT04843969|Experimental|Stress task and smoking cue|Exposure to a psychosocial stress task followed by smoking video cues
88970590|NCT00062530|Experimental|1|All participants will receive oral vaccine at study entry, although dosage will vary
88970591|NCT04733625|Active Comparator|Intervention(Vitamin D therapy|40 patients with diabetes and vitamin D deficinecy that are Covid-19 positive. a single dose of Cholecaciferol will be administered
88970592|NCT04733625|Placebo Comparator|Placebo|16 diabetic patients with vitamin D deficiancy and COVID-19 POSITIVE
88970593|NCT02967718||Control group|the healthy patients
88970594|NCT02967718||Metabolic syndrome group|Include patients who are accordance with diagnostic criteria of metabolic syndrome
88970595|NCT02967718||CHD stable stage group|Include patients who are accordance with diagnostic criteria of asymptomatic angina, stable angina or stable (more than 1 month) acute coronary syndrome
88970596|NCT02967718||Acute coronary syndrome group|Include patients who are accordance with diagnostic criteria of unstable angina or non-ST-segment elevated myocardial infarction
88970597|NCT02967718||PCI or CABG group|Include the patients who will undergo percutaneous coronary intervention of coronary artery bypass grafting
88970598|NCT02967718||CHD heart failure group|Include the patients who suffered heart failure cause by CHD
88970599|NCT05181293|Experimental|Experimental|A mobile gaming app (BabyThrive) will be disseminated to teenage mothers to help them learn about exclusive breastfeeding, introduction to solid/semi-solid foods, meal frequency and dietary diversity. BabyThrive will also demonstrate how to prepare 30 nutritious recipes for complementary feeding; create a calendar and set reminders to prompt mothers to access child health services; and plot growth patterns of the baby to facilitate growth monitoring.
88970600|NCT05181293|No Intervention|No Intervention|In addition to routine health services, teenage mothers will receive the BabyThrive app after the intervention is completed. Participants will learn about exclusive breastfeeding, introduction to solid/semi-solid foods, meal frequency and dietary diversity. BabyThrive also will demonstrate how to prepare 30 nutritious recipes for complementary feeding; create a calendar and set reminders to prompt mothers to access child health services; and plot growth patterns of baby to facilitate growth monitoring.
88970601|NCT00062569|Experimental|1|
88970602|NCT00062569|Experimental|2|
88970603|NCT05178914|Experimental|The interventional group|"Patients are defined by the disclosure of the IMR value. The initial IMR is used to guide therapy.~For patients with initial IMR ≥ 25 will benefit from intensified coronary artery disease treatment to manage the microcirculatory damage according to the recommendations and consensus of European experts.~For patients with a initial IMR < 25 will benefit from de-escalade therapeutic adaptation."
88970604|NCT05178914|Sham Comparator|The control group|The control group is defined as follows: the initial IMR has been performed but its result is not undisclosed (sham procedure) ; patients will receive standard medical treatment according to the physician's preference.
89572314|NCT04843969|Experimental|Stress task and neutral cue|Exposure to a psychosocial stress task followed by neutral video cues
89572315|NCT04843969|Active Comparator|Control task and smoking cue|Exposure to a control task followed by smoking video cues
89572316|NCT04843969|Active Comparator|Control task and neutral cue|Exposure to a control task followed by neutral video cues
89572317|NCT04851769|Experimental|alirocumab plus statin|Patients in the alirocumab arm will receive alirocumab 75 mg Q2W added to statin therapy (atorvastatin 20 mg/day or rosuvastatin 10mg/day).
89572318|NCT04851769|Active Comparator|standard statin therapy|Patients in the standard statin arm will continue to receive atorvastatin 20 mg/day or rosuvastatin 10 mg/day. Statin dose escalation or adding concomitant non-statin lipid-lowering therapy could be considered by their responsible physician to achieve an LDL-C target <100 mg/dL.
89572319|NCT04843813|Experimental|Lutein|
89572320|NCT04843813|Placebo Comparator|Safflower Oil|
89572321|NCT04843189||Da Vinci Robotic Surgery Group|Da Vinci Robotic Surgery Group
89572322|NCT04843189||Laparoscopy-assisted surgery group|Laparoscopy-assisted surgery group
89572323|NCT04838899|Experimental|Treatment Arm|All metastases that fulfill the definition of oligoprogression seen on conventional imaging will be treated with standard SABR dose fractionation schemes routinely used at Sunnybrook Odette Cancer Centre. The prostate (if present and not previously treated) will be treated to a dose of 35 Gy in 5 fractions. Non-spine bone metastases will be treated to a dose of 30-40 Gy in 5 fractions. Spine metastases will be treated to a dose of 24 Gy in 2-3 fractions or 30-40 Gy in 5 fractions. Involved lymphadenopathy will be treated to a dose of 30-40 Gy in 5 fractions. Similarly, brain, lung, liver, and adrenal metastases will be treated with standard Sunnybrook SABR doses. Patients will remain on abiraterone during and after SABR treatments.
89572324|NCT03037957||Group A Strep Assay|
89572325|NCT04852081||patients with HR+, HER2- advanced or metastatic breast cancer|patients with HR+, HER2- advanced or metastatic breast cancer
89572326|NCT04851067|Active Comparator|Dry Needling and Therapeutic Exercises (DNTEx)|"Dry Needling - A fine needle, of 5-10 mm, will be used to penetrate the skin, subcutaneous tissues, and muscle with the intent to stimulate Myofascial Trigger Point (MTrP) or mechanically disrupt tissue without the use of an anesthetic.~Therapeutic Exercises - Are exercises will be performed to achieve a specific physical benefit, including increasing and maintaining range of motion, strengthening weak muscles, increasing joint flexibility, or improving cardiovascular and respiratory function."
89572327|NCT04851067|Active Comparator|Manual Therapy and Therapeutic Exercises (MTTEx)|"Joint Mobilization - A manual therapy technique comprising of a continuum of skilled passive movements to the joint complex will be applied at varying speeds and amplitudes. It will include a low-grades/velocity (grades I and II), high grades (grades III and IV), and small- or large-amplitude passive movement techniques within the patient's physiological range of motion and within the patient's control with the intent to restore optimal motion, function, and/ or to reduce pain.~Joint Manipulation - A passive, high velocity, low amplitude thrust will be applied to a localized joint segment/s within its anatomical limit with the intent to restore optimal motion, function, and/ or to reduce pain."
89572328|NCT04838509||Patients with elevated creatine kinase|
89572329|NCT04843033|Experimental|Daily oral administration of SH3809 tablet|
89572330|NCT02608099|Active Comparator|Interrupted apixaban|Apixaban dose is administered on the evening prior to the procedure; apixaban dose is held on the morning of the procedure; apixaban dose is administered on the evening after the procedure if there were no peri-procedural complications that necessitated withholding anticoagulation for longer duration.
89572331|NCT02608099|Experimental|Uninterrupted apixaban|Apixaban dose is administered on the evening prior to the procedure; apixaban dose is administered on the morning of the procedure; apixaban dose is administered on the evening after the procedure if there were no peri-procedural complications that necessitated withholding anticoagulation for longer duration.
89572332|NCT04842565|Experimental|TACE+Sintilimab|
89572333|NCT04850755|Experimental|patients with advanced solid malignancies|Patients will be dosed with selinexor once a week continuously in a 6 week cycle. Nivolumab will be administered on biweekly of each cycle . Ipilimumab will be dosed only on D1 of each cycle . Ipilimumab will continue for a maximum of 4 cycles. Nivolumab and selinexor will continue for up to 24 months or until discontinuation criteria is met.
89572334|NCT03038035|Active Comparator|MLC901|"NeuroAid II MLC901 is a derivative product of NeuroAid MLC601. It is a simplified formula based on the 9 Herbal ingredients that are present in NeuroAid MLC 601. Neuroaid II has been approved for sale as a Chinese Proprietary Medicine in Singapore by the HSA since March 2010. 24 weeks intervention. Dosage: 2 capsules 3 times a a day~Upon completion of 24 weeks, subject will be given an option to continue an open-label extension for another 24 weeks."
89572335|NCT03038035|Placebo Comparator|Placebo|"24 weeks intervention with orally placebo. 2 capsules 3 times a day.~Upon completion of 24 weeks, subject will be given an option to continue an open-label extension for another 24 weeks."
89572336|NCT03037801|No Intervention|Control|
89572337|NCT03037801|Experimental|Intrapulmonary Percussive Ventilation|15 minutes of IPV physiotherapy
89572338|NCT04850131|Active Comparator|Desarda|Forty-one patients who were randomly assigned to the Desarda group underwent the Desarda repair for their problem. Patients were followed for various data point values during operation, immediately after the operation, and for a period of one year post-operatively.
89572339|NCT04850131|Active Comparator|Lichtenstein|Forty-one patients randomly assigned to the Lichtenstein group underwent the standard mesh repair and were followed for the same data point values and variables for the same specified period of time.
89572340|NCT04842487|Experimental|Treatment arm|"Lenalidomide：25mg po QN,D1-10~Rituximab: 375mg/m2, ivdrip, D1~CTX: 750mg/m2, iv or ivdrip, D1~THP: 50mg/m2, iv or ivdrip, D1~VCR： 1.4 mg/m2 , iv（max：2mg）, D1~Pred: 60mg/m2, po, D1-5"
89572341|NCT04833751||Anesthesia for cardio/neurovascular surgery or procedure|Patients undergoing anesthesia in an operating room or hybrid room for cardio/neurovascular surgery or procedure.
89572342|NCT03040063|Experimental|Combined endovascular approach|Combined endovascular approach using covered stent and flexible stent in the popliteal artery
89572343|NCT03040063|Experimental|Standard optimal therapy (OPT)|standard therapy of popliteal artery aneurysm using thrombolysis and surgery
89572344|NCT04841941|Experimental|single arm|G4 Multifocal soft contact lens with a 54% water content for presbyopia
89572345|NCT04841863|Active Comparator|Drug Code Active Patient o DCAP|"Inclusion in the active group involves the use of MyPlan digital health tool that aims to improve clinical-patient communication, enahnce patient empowerment, improve early detection of side effects and allows professionals to individualize interventions.~Patients will receive follow-up by videoconference 48 hours after discharge and in the phase II, at 6 and 12 months after discharge."
89572346|NCT04841863|Placebo Comparator|Standard care|"Inclusion in the control group do not involves the use of MyPlan digital health tool. Patients will receive the standard of care.~Patients will receive follow-up by videoconference 48 hours after discharge and in the phase II, at 6 and 12 months after discharge."
89572347|NCT04838119||Patients with a preoperative asymptomatic COVID screening test|
89572348|NCT04833673|Experimental|PMR|"The PMR intervention involving tensing and relaxing the body muscles accompanied with deep breathing. The researchers told each~participant to sit in a soundless and breathable room and in a comfortable position before each session at their home. The participants performed tensing and relaxing for each body part in order, starting with the facial muscles and head, followed by neck, shoulders, chest, abdomen, legs, and feet; all muscle tension and relaxation procedures were performed with deep breathing. The participants were instructed to tense a specified group of muscles for 5 s and relax it for 10 s while breathing out. Moreover, throughout this exercise, the participants imagined a wave of relaxation flowing over their body."
89572349|NCT04833673|Experimental|BRT|Within the scope of this technique, first of all, the participants were asked to focus on a word that relieves them such as love, health or well-being. And so, the participants were asked to be in comfortable position in a silent and breathable room with the closed eyes, relax their muscles from the sole of their feet and progressing up to their face gradually, keep them relaxed, accompanied with deep breathing, be aware of their breathing, exhale gently. They continue these practices for 20 minutes and try to relax their muscles. After finishing the duration, they sit quietly for several minutes with eyes closed and later with eye opened.
89572350|NCT04833673|No Intervention|CG|"Regarding CG, the participants were invited to the same room and received only a single time attention-matched education on Living with MS; including definition of MS, dietary advices for MS patients. The attention-matched education was performed face to face and lasted for 10 min. All participants in the three study groups also received usual treatment and care."
89572351|NCT04837885|Experimental|68Ga-DOTA-peptides PET/CT|68Ga-DOTA-peptides injections for targeted liver metastases in Positron emission tomography-computed tomography (PET/CT)
89572352|NCT04837885|Experimental|LUTATHERA® by intra-arterial hepatic injection (IAH)|One treatment dose of LUTATHERA® by intra-arterial hepatic injection after conventional treatment by 4 intravenous administrations
89572353|NCT03039829|Experimental|Creatine nitrate, low dose|Creatine nitrate at 3.0 grams (2.0 grams creatine; 1.0 gram nitrate, 3.0 grams dextrose)
89572354|NCT03039829|Active Comparator|Creatine nitrate, high dose|Creatine nitrate at 6.0 grams (4.0 grams creatine; 2.0 grams nitrate)
89572355|NCT03039829|Placebo Comparator|Placebo|Placebo at 6.0 grams dextrose
89572356|NCT04833595|Experimental|Mindfulness Arm|"A recommendation on healthy food intake will be sent to participants. At the end of each week, participants will be required 1) to submit THREE photos of the meals that they are most satisfied with in terms of healthiness and 2) using the photos to answer a questionnaire about their diet. The photos and completed questionnaire must be submitted to the research investigator each week for a total of 8 weeks. After 8 weeks, participants will be required to get tested for your fasting total cholesterol and blood glucose level in the appointed pharmacy for the second time. It is estimated to require 15-30 minutes of their time weekly.~The questionnaire used for experimental group contains reflective questions as part of the mindfulness intervention."
89572357|NCT04833595|Active Comparator|Non-mindfulness Arm|Everything is similar to the experimental arm. However, the questionnaire used for control group does not contain reflective questions to serve as control group.
89572358|NCT04833205|Experimental|Leptomeningeal metastases received EGFR-TKI and Nimotuzumab|The patients received Nimotuzumab 200 mg,which was diluted in 250mL 0.9% sodium chloride injection, intravenously dripping.And the duration of administration was controlled over 60 min), and the drug was used continuously for 8 weeks.One the other hand,the patient received the third generation of EGFR-TKI
89572359|NCT03037645|Experimental|Dose escalating cohorts of SNS-062|Sequential groups, 25, 50, 100, 200, 300, 400 and 500 mg twice daily to determine maximum tolerated dose and recommended dose (RD) in the treatment of various hematological cancers followed by expansion of the recommended dose cohort in Phase 2 of the study treating hematological cancers.
89572360|NCT03036631||Conscious Sedation/Monitored Anesthesia Care|
89572361|NCT03036631||General Anesthesia|
89572362|NCT04370665|Experimental|Open label single arm|Using Exablate Model 4000 Type-2 to temporarily disrupt the blood brain barrier to deliver Cerezyme in patients with Parkinson's Disease.
88970605|NCT00062842|Experimental|Irinotecan weekly|Irinotecan was administered over 90 min weekly 4x, every 6 weeks.
88970606|NCT02967445|Experimental|Cervical pessary|Arabin Pessary
88970607|NCT02967445|Active Comparator|Cervical cerclage|McDonald Cerclage
88970608|NCT00389909|Active Comparator|1|Treatment based on patient weight;
88970609|NCT00389909|Active Comparator|2|Treatment based on a chart taking into account weight, age and gender
88970610|NCT00063076|Experimental|Targretin®|Targretin® (bexarotene) Gel 1%, treat half head
88970611|NCT00063076|No Intervention|Control|Half head untreated as control
89572363|NCT04312243|Experimental|Treatment Group|Inhaled NO (160 ppm) before and after the work shift. Daily monitoring of body temperature and symptoms. SARS-CoV-2 RT-PCR test if fever or COVID-19 symptoms.
89572364|NCT04312243|No Intervention|Control Group|Daily monitoring of body temperature and symptoms. SARS-CoV-2 RT-PCR test if fever or COVID-19 symptoms.
89572365|NCT04841551|Other|Kybella Flanks|10 subjects will be treated with Kybella in the flanks
89572366|NCT03037567|Experimental|Modified Weight Watchers plan|Modified Weight Watchers Plan which includes a food plan, activity plan, group support and cognitive behavior modification. Weekly study-specific group meetings; electronic tools through iPhone app for 24 weeks.
89572367|NCT04833049|Experimental|TAK-994 Dose 1 + [14C]TAK-994 Dose 2 + [14C]TAK-994 Dose 3|TAK-994 Dose 1, tablet, orally, on Day 1, followed by [14C]TAK-994 Dose 2, infusion, intravenously, on Day 1 of Part A, followed by a washout period of at least 8 days, further followed by [14C]TAK-994 Dose 3, suspension, orally, on Day 1 of Part B.
89572368|NCT03037177||CHL like GZL|Classical Hodgkin Lymphoma like Grey Zone Lymphoma (morphology of CHL and phenotype of PMBCL)
89572369|NCT03037177||PMBCL like GZL|Primary Mediastinal B Cell Lymphoma like Grey Zone Lymphoma(morphology of PMBCL and phenotype of CHL)
89572370|NCT03037177||Composite|with a morphology of CHL on the one side and of PMBCL on the other side of the same diagnosis biopsy
89572371|NCT04841161|Other|Healthy subjects|The healthy adults who have not any neurological, musculoskeletal or rhematogical disease, a history of orthopedic surgery on spine or lower extremity. Their age should be ranged between 20 - 75 years.
89572372|NCT04841161|Experimental|Stroke subjects|Stroke patients were included if they were: (1) diagnosed with unilateral ischemic or hemorrhagic stroke; (2) a minimum of six months post stroke ; (2) able to stand without support for 1 minutes; (3) able to understand and follow verbal instructions. and (4) medically stable with physician release.
89572373|NCT04841239|Experimental|Herbal topical formulation|
89572374|NCT04841239|No Intervention|Control|
89572375|NCT04841395||PE|Premature ejaculation group
88970612|NCT02967484|Experimental|Treatment Group|"Participants will recieve the therapy as follows: Huo Xue San Feng acupuncture method+Routine care for ischemic stroke+One type of antihypertensive medication.~Intervention:Acupuncture(choosing the bilatral acupoint: Renying(ST9),Hegu(L14), Taichong(LR3),Quchi(LI11),Zusanli(ST36))+Drugs(one type of antihypertensive medicine)"
88970613|NCT02967484|No Intervention|Control Group|"Participants recieve the therapy as follows:Routine care for ischemic stroke +One type of antihypertensive medication.~Intervention:Acupuncture(choosing the acupoint: Neiguan(PC6),Renzhong(10), Sanyinjiao(SP6),Jiquan(HT1),Chize(LU5),Weizhong(BL40).)+Drugs(one type of antihypertensive medicine)"
88970614|NCT05167019|Active Comparator|Usual care|Usual care
88970615|NCT05167019|Experimental|The CODE intervention|The CODE intervention consists of 4 items, of which individual coaching sessions of 1 hour. In total each doctor taking care of hospitalized patients will be able to receive maximum 16 individual coaching sessions during the 4 months intervention period (one weekly). Every doctor will be invited to participate to at least 8 coaching sessions, to be extended on request, during the intervention period.
88970616|NCT02967406|Experimental|Lifestyle modification|4 x 4 lifestyle modification intervention, addressing four health behaviors including physical activity, diet, smoking and alcohol drinking, at four different levels, i.e. individual, household, group/ knowledge management, and community levels
88970617|NCT02967406|No Intervention|Control|No special intervention will be given. Prevention and treatment in normal practice is allowed
88970618|NCT02967601||Elective Cesarean Section|
88970619|NCT00063388|Experimental|1|Cetuximab 400 mg/m2 intravenously (IV) (over 120 minutes) on Day 1 of Cycle 1. followed by weekly doses of 250 mg/m2 (over 60 minutes).
88970620|NCT00063583|Placebo Comparator|Placebo|Placebo
88970621|NCT00063583|Experimental|Pirfenidone 1200 mg/day|Pirfenidone will be administered at a dose of 1200 mg/day
88970622|NCT00063583|Experimental|Pirfenidone 2400 mg/day|Pirfenidone will be administered at 2400 mg/day
89572376|NCT04841395||CG|Control group (Healthy subjects)
89572377|NCT03036241|Experimental|Drug-eluting balloon|
89572378|NCT03036241|Active Comparator|Conventional angioplasty|
89572379|NCT03037333|Other|fluoroscopy|
89572380|NCT03037333|Other|ECG/ECHO|
89572381|NCT03039517|Experimental|ACTitouch - ACT-Adaptive Compression Therapy|a dual treatment pneumatic compression device offering two operational modes: sustained compression mode and intermittent compression mode. The device is applied to the lower leg (calf, ankle, and foot) and consists of an under-sock worn against the skin, a compression sleeve containing 4 inflatable chambers and a controller unit. The controller provides the airflow to inflate the chambers and monitors and adjusts the chamber pressure to maintain the intended treatment pressures.
88970623|NCT05157191||mRNA COVID-19 vaccine|Children and adolescents (ages ≥ 5 to < 16) who receive mRNA COVID-19 vaccine per standard of care
88970624|NCT00063778|Experimental|1 x 10^4 IU dose|Vaccine dose of 1 x 10^4 IU per injection
88970625|NCT00063778|Experimental|1 x 10^5 IU dose|Vaccine dose of 1 x 10^5 IU per injection
88970626|NCT00063778|Placebo Comparator|Placebo|
88970627|NCT04655118|Experimental|Cohort 1a, Relapsed/Refractory Myelofibrosis|150 mg of TL-895 will be administered orally, twice daily (BID) continuously starting on Day 1 in a 28-day cycle.
88970628|NCT04655118|Experimental|Cohort 1b, Relapsed/Refractory Myelofibrosis|300 mg of TL-895 will be administered orally, once daily (QD) continuously starting on Day 1 in a 28-day cycle.
88970629|NCT04655118|Experimental|Cohort 1c, Relapsed/Refractory Myelofibrosis|300 mg of TL-895 will be administered orally, twice daily (BID) continuously starting on Day 1 in a 28-day cycle.
88970630|NCT04655118|Experimental|Cohort 1d, Relapsed/Refractory Myelofibrosis|450 mg of TL-895 will be administered orally, twice daily (BID) continuously starting on Day 1 in a 28-day cycle.
89572382|NCT03039517|Experimental|Standard Compression Stocking|The control group will receive care using elastic compression stocking.
89572383|NCT04366219||2019|Data collection on patients with Lung cancer diagnosed between March 13, 2019 and August 28, 2019.
89572384|NCT04366219||2020|Data collection on patients with Lung cancer diagnosed between March 13, 2020 and August 28, 2020.
89572385|NCT03039361|Experimental|Equine Assisted Psychotherapy|6 week Equine Assisted Psychotherapy program
89572386|NCT03039361|No Intervention|Control|Standard of Care, Existing PTSD therapy
89572387|NCT04837651||Ocrelizumab Treated Multiple Sclerosis Patients|
89572388|NCT04837651||Natalizumab Treated Multiple Sclerosis Patients|
89572389|NCT04832581|Experimental|Experimental Group|The experimental group was informed that they participated in a study. After the data collection forms were introduced, written and verbal consents were obtained. Information has been received. The experimental group was included in the program based on the Orem Self Care Model. The program includes anatomical, physiological and hormonal changes during pregnancy, urinary system infections and preventive measures. A phone call was scheduled 2 weeks later. Second evaluation forms were applied. Both groups were informed that the study was concluded.
89572390|NCT04832581|No Intervention|Control Group|The control group was informed that they participated in a study. After the data collection forms were introduced, written and verbal consents were obtained. Information has been received. A phone call was scheduled 2 weeks later. Second evaluation forms were applied. After the research was completed, information was given in order to avoid bias and the brochure was delivered. Both groups were informed that the study was concluded.
89572391|NCT03039205|Active Comparator|Chronic kidney dysfunction Clopidogrel|Patients with creatinine clearance <60ml/min/m2 (estimated by MDRD formula) randomized to clopidogrel group
89572392|NCT03039205|Active Comparator|Chronic kidney dysfunction Ticagrelor|Patients with creatinine clearance <60ml/min/m2 (estimated by MDRD formula) randomized to ticagrelor group
89572393|NCT03039205|Active Comparator|Normal kidney function Clopidogrel|Patients with creatinine clearance ≥60ml/min/m2 (estimated by MDRD formula) randomized to clopidogrel group
89572394|NCT03039205|Active Comparator|Normal kidney function Ticagrelor|Patients with creatinine clearance ≥60ml/min/m2 (estimated by MDRD formula) randomized to ticagrelor group
89572395|NCT04832035|Experimental|"Standard psychotherapeutic care + coordinated and peer supported mental health care"|"Participants receive standard psychotherapeutic care in the public healthcare system. For participants and therapists in this group standard care and additional organisational support is available which is labeled coordinated and peer supported mental health care. This includes several additional organisational assistance components that are currently not part of the services of the public mental health care system, i.e. a coordination center, trained peers to support treatment utilisation, a support and training center for therapists, and an interpreter pool.This is Treatment as Usual plus coordination and peer support."
89572396|NCT04832035|Other|"Standard psychotherapeutic care"|Participants receive standard psychotherapeutic care in the public healthcare system. For participants in this group no additional organisational support is available. This is Treatment as Usual.
89572397|NCT04792177|Experimental|Intervention group|Emotion regulation skills training group
89572398|NCT04792177|No Intervention|waitlist control group|The control group will not receive any intervention during the trial but will be offered the same treatment at the end of the six-months follow-up assessment.
89572399|NCT04832347|Experimental|Exercise group|Exercise group will be given stabilization exercises for a total of 24 sessions, 3 times a week for 8 weeks, each session for 45 minutes.
89572400|NCT04832347|Experimental|Vagus group|Vagus therapy will be applied to Group 2 for 8 weeks, 3 times a week for a total of 24 sessions, each session for 30 minutes.
88970631|NCT04655118|Experimental|Cohort 2a, JAKi Intolerant Myelofibrosis|150 mg of TL-895 will be administered orally, twice daily (BID) continuously starting on Day 1 in a 28-day cycle.
88970632|NCT04655118|Experimental|Cohort 2b, JAKi Intolerant Myelofibrosis|300 mg of TL-895 will be administered orally, once daily (QD) continuously starting on Day 1 in a 28-day cycle.
88970633|NCT04655118|Experimental|Cohort 3a, JAKi Ineligible Myelofibrosis|150 mg of TL-895 will be administered orally, twice daily (BID) continuously starting on Day 1 in a 28-day cycle.
88970634|NCT04655118|Experimental|Cohort 3b, JAKi Ineligible Myelofibrosis|300 mg of TL-895 will be administered orally, once daily (QD) continuously starting on Day 1 in a 28-day cycle.
88970635|NCT04655118|Experimental|Cohort 1 Expansion, Relapsed/Refractory Myelofibrosis|TL-895 administered orally at RP2D and schedule
89572401|NCT04832347|No Intervention|Control group|Control group will be followed as a control group and no application will be made.
89572402|NCT04428697|Experimental|Sungurtekin Technique|Sungurtekin technique was performed through the base of the posterior fissure; thus, no additional incision was necessary in the lithotomy position. The mucosa was dissected along the submucosal plane, starting at the hypertrophic papilla, and extended for 1.5 cm. After identifying both the internal and external sphincters completely, under direct vision, a 0.5-cm section of the bottom part of the internal anal sphincter was measured and marked with a ruler. This section was preserved during the operation in a standard fashion for all patients . Next, the internal sphincter bundle was measured with a sterile scale and a mark was placed at 1 cm towards the proximal end. The internal sphincter bundle was elevated with a right angle clamp, then cut with cautery . The operation was completed with meticulous hemostasis and additional suturing (3/0 absorbable suture) of the proximally dissected mucosal flap underlying the muscularis layer
89572403|NCT04428697|Active Comparator|Closed Lateral Internal Sphincterotomy|The sphincterotomy was performed through a new incision, guided by the surgeon's finger, as described by Boulos et al Boulos PB, Araujo JG. Adequate internal sphincterotomy for chronic anal fissure: subcutaneous or open technique? The British journal of surgery 1984;71:360-2.
88970636|NCT04655118|Experimental|Cohort 3 Expansion, JAKi Ineligible Myelofibrosis|TL-895 administered orally at RP2D and schedule
89033170|NCT02917512|Placebo Comparator|Placebo(without main component)|"Placebo~1 drop b.i.d at 12 hour interval for 12 weeks"
89033171|NCT02943902|Experimental|Group 1a (1+1, 6 weeks)|PCV10 (Synflorix 0.5ml injection) will be administered at 6 weeks and 9 months of age
89033172|NCT02943902|Experimental|Group 1b (1+1, 6 weeks)|PCV13 (Prevenar 13, 0.5ml injection) will be administered at 6 weeks and 9 months of age
89572404|NCT04831489||deep sedation|Anesthesia will be induced using titrated doses of propofol (0.5-1.5 mg/kg) and fentanyl (25-50 μg) initially to carefully maintain spontaneous breathing yet maintaining airway patency. Once adequate jaw relaxation is achieved, the endoscopy probe will be inserted. Maintenance of sedation will be carried out using propofol infusion between 80-120 mcg/kg/min. Additional dose 25-50 mg propofol will be given to the patient if spontaneous movement occurs
89572405|NCT04831489||Genral anesthesia|"After mask pre-oxygenation, anesthesia will be induced with (2 mg/kg) propofol and (1 μg /kg) fentanyl. The neuromuscular blockade will be achieved with (0.5 mg/kg) atracurium followed by tracheal intubation. Anesthesia will be maintained to keep the end-tidal anesthetic concentrations within 1 MAC for sevoflurane.~The neuromuscular blockade will be maintained with intermittent doses of atracurium (0.1mg/kg). Mechanical ventilation is adjusted with fresh gas flow oxygen in air 30-40% at a rate of 2 L/min to maintain end-tidal carbon dioxide of 35-40 mm Hg. Reversal of neuromuscular blockade will be achieved by intravenous administration of neostigmine 0.05 mg/kg and atropine 0.02 mg/kg."
89572406|NCT04831879|Experimental|Group A AMPS - sham|Treatment phase 1: AMPS Treatment phase 2: sham
89572407|NCT04831879|Experimental|Group B sham - AMPS|Treatment phase 1: sham Treatment phase 2: AMPS
89572408|NCT04824937|Experimental|Telaglenastat + Talazoparib|"During 28 day study cycles, participants will receive:~Telaglenastat 2x daily at a predetermined dose~Talazoparib 1x daily at a predetermined dose"
89572409|NCT04824937|Experimental|Telaglenastat + Talazoparib Staggered|If a beneficial response is seen with the Arm 1 Telaglenastat + Talazoparib combination, participants will receive telaglenastat alone 2x daily at a predetermined dose with the addition of talazoparib at 1x daily at a predetermined dose if the disease gets worse.
89572410|NCT03037099|Experimental|Enhanced GI Concept Education|This group will receive enhanced GI concept nutrition education including GI values of foods, low GI recipes, menus, and application through websites with chat rooms, online videos and print materials. These will be reinforced through email, text messaging/phone calls, and postal mail.
89572411|NCT03037099|No Intervention|Usual Care|Usual care group will receive only standard printed copies of Canada Food Guide and Canadian Diabetes Association GI resources.
89572412|NCT04836949|Experimental|Shear Wave Elastography Group|
89572413|NCT04836949|Active Comparator|Conventional ultrasonography Group|
89572414|NCT04836793||Patients with cancer|"Patients with active treatment in adjuvant/induction setting,~Patients with active treatment in metastatic/relapse setting,~Patients without active treatment (last treatment above 6 months)."
89572415|NCT04836793||Patients without cancer but aged above 70 years|
89572416|NCT04836793||Healthy person|
89572417|NCT04428073|Experimental|Low dose group|Subjects will receive 1.0 mL of low dose vaccine at week 0 and 2.
89572418|NCT04428073|Experimental|High dose group|Subjects will receive 1.0 mL of high dose vaccine at week 0 and 2.
89572419|NCT04824313||COVID-CAVA PE|Patients with RT-PCR proven COVID-19 disease and CTA proven pulmonary embolism
89572420|NCT04824313||COVID-CAVA non-PE|Patients with RT-PCR proven COVID-19 disease and no evidence of pulmonary embolism on CT
89572421|NCT04824001||STEMI|ST-segment elevation myocardial infarction (STEMI) is defined by symptoms of myocardial ischemia accompanied by a persistent elevation of the ST segment on the electrocardiogram (ECG) and the subsequent release of biomarkers of myocardial necrosis.
89572422|NCT04824001||NSTEMI|If there is elevation of the blood markers suggesting heart damage, but no ST elevation seen on the EKG tracing, this is known as a non ST-elevation myocardial infarction (NSTEMI).
89572423|NCT03036085|Active Comparator|Bupivacaine|Under thoracoscopic guidance, a posterior intercostal nerve block will be performed with 0.5% bupivacaine with 1% epinephrine. In the bupivacaine group 20 ml of 0.5% bupivacaine with 1% epinephrine will be diluted to a total volume of 40 ml using 20 ml normal saline. From those 40 ml, 30 ml will be used for the posterior intercostal nerve block and 10 ml will be injected locally into the surgical wounds.
89572424|NCT03036085|Experimental|Liposomal bupivacaine|Under thoracoscopic guidance, a posterior intercostal nerve block will be performed with liposomal bupivacaine (13.3 mg/ml). In the liposomal bupivacaine group, a total dose of 266 mg of liposomal bupivacaine (one 20 ml vial of 13.3 mg/ml) per patient will be diluted to a total volume of 40 ml using 20 ml normal saline.
89572425|NCT04823767|Experimental|Single anastomosis sleeve jejunal bypass with hiatal repair|Single anastomosis sleeve jejunal bypass with hiatal repair
89572426|NCT04836715||Parkinson's Disease|Individuals with idiopathic Parkinson's Disease and no other neurological disease
89572427|NCT04836715||Other Neurological Disorders|Individuals with one neurological disorder other than Parkinson's Disease (e.g. Multiple Sclerosis, Amyotrophic Lateral Sclerosis, Traumatic Brain Injury, Parkinsonism)
89572428|NCT04836715||Healthy|Individuals without any neurological disorder
89572429|NCT04836481||LEV8|Levetiracetam 1000 mg every 8 hours
89572430|NCT04836481||LEV12|Levetiracetam 1000 mg every 12 hours
89572431|NCT04831333||Active CMVR|The UWF images of cytomegalovirus retinitis (CMVR) included various patterns: hemorrhagic necrotizing lesion, granular lesion, frosted branch angiitis, and optic neuropathy lesion. Active CMVR lesion was defined as obvious opacity (mild, moderate, severe, very severe)
89033173|NCT02943902|Experimental|Group 2a (1+1, 14 weeks)|PCV10 (Synflorix 0.5ml injection) will be administered at 14 weeks and 9 months of age
89033174|NCT02943902|Experimental|Group 2b (1+1, 14 weeks)|PCV13 (Prevenar 13, 0.5ml injection) will be administered at 14 weeks and 9 months of age
89572432|NCT04831333||Inactive CMVR|Inactive CMVR lesion was defined as a lack of opacity or questionable/equivocal activity.
89572433|NCT04831333||Non-CMVR|The non-CMVR images included normal retina and other retinopathies such as HIV-related microvascular retinopathy, diabetic retinopathy, retinal detachment, vitreous hemorrhage.
89572434|NCT04831255|Experimental|ZILRETTA|Single injection of triamcinolone acetonide extended-release injectable suspension, injected in the glenohumeral joint under ultrasound guidance.
89572435|NCT04831177|Active Comparator|Patients planned to undergo Femtosecond laser FS assisted LASIK|In FS group, Allegretto WaveLight FS-200 femtosecond laser was used to create flaps with flap thickness planned to be 100 um.
89572436|NCT04831177|Active Comparator|Patients planned to undergo Microkeratome MK assisted LASIK|In MK group, Moria 2 Microkeratome was used to create flaps with flap thickness planned to be 100 um.
89572437|NCT02432235|Experimental|3 μg/kg|Participants received an intravenous (IV) infusion of camidanlumab tesirine (3 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 2 cycles.
89572438|NCT02432235|Experimental|5 μg/kg|Participants received an intravenous (IV) infusion of camidanlumab tesirine (5 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 4 cycles.
89572439|NCT02432235|Experimental|8 μg/kg|Participants received an intravenous (IV) infusion of camidanlumab tesirine (8 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 3 cycles.
89572440|NCT02432235|Experimental|13 μg/kg|Participants received an intravenous (IV) infusion of camidanlumab tesirine (13 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 15 cycles.
89572441|NCT02432235|Experimental|20 μg/kg|Participants received an intravenous (IV) infusion of camidanlumab tesirine (20 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 3 cycles.
89572442|NCT02432235|Experimental|30 μg/kg|Participants received an intravenous (IV) infusion of camidanlumab tesirine (30 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 10 cycles.
89572443|NCT02432235|Experimental|45 μg/kg|Participants received an intravenous (IV) infusion of camidanlumab tesirine (45 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 10 cycles.
89572444|NCT02432235|Experimental|60 μg/kg|Participants received an intravenous (IV) infusion of camidanlumab tesirine (60 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 8 cycles.
89572445|NCT02432235|Experimental|80 μg/kg|Participants received an intravenous (IV) infusion of camidanlumab tesirine (80 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 7 cycles.
89572446|NCT02432235|Experimental|100 μg/kg|Participants received an intravenous (IV) infusion of camidanlumab tesirine (100 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 5 cycles.
89572447|NCT02432235|Experimental|150 μg/kg|Participants received an intravenous (IV) infusion of camidanlumab tesirine (150 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 2 cycles.
89572448|NCT02432235|Experimental|300 μg/kg|A single participant received by error an intravenous (IV) infusion of camidanlumab tesirine (300 μg/kg) on Day 1 of Cycle 1 (planned dose was 30 μg/kg). Dosing in the subsequent cycles was 30 μg/kg (for 2 more cycles).
89572449|NCT02431533|Experimental|Probiotic PX0612|PX0612 is a probiotic contained in a veggie capsule.
89572450|NCT02431533|Placebo Comparator|Di-Calcium Phosphate|Patients in the 'placebo' group will receive the placebo capsules. The main ingredient in the placebo capsule is Di-Calcium Phosphate
89572451|NCT02416791|Active Comparator|Active tDCS + robotic therapy + physical therapy|"Active tDCS (transcranial direct current stimulation) will be applied prior to the robotic training. After robot training, the patient will receive physical therapy for 40 minutes.~Number of treatment sessions: 18 (3 times a week, for 6 weeks)."
89572452|NCT02416791|Active Comparator|sham tDCS + robotic therapy + physical therapy|"Sham tDCS (transcranial direct current stimulation) will be applied prior to robotic training. After robot training, the patient will receive physical therapy for 40 minutes.~Number of treatment sessions: 18 (3 times a week, for 6 weeks)."
89572453|NCT02416791|Experimental|sham tDCS + physical therapy + occupational therapy|Sham tDCS (transcranial direct current stimulation) will be applied prior to conventional therapy (40 minutes of physical therapy and 40 minutes of occupational therapy) Number of treatment sessions: 18 (3 times a week, for 6 weeks).
89572454|NCT02414841|Active Comparator|Vonapanitase|Vonapanitase administered at the time of radiocephalic fistula creation
89572455|NCT02414841|Placebo Comparator|Placebo|Placebo administered at the time of radiocephalic fistula creation
89572456|NCT02413593|Experimental|LDV/SOF+RBV|LDV/SOF FDC plus RBV for 12 weeks
89572457|NCT04942275|Experimental|Intervention : Lung perfusion PET/CT using Ga68-MAA and SBRT planification|"All patients included for treatment with stereotactic radiotherapy for non-small cell lung cancer or lung metastasis will benefit from a pre-therapeutic functional assessment including:~The standard functional assessment recommended before performing an SBRT.~A perfusion PET/CT scan~The treatment planning will be carried out in 2 stages:~First, an anatomical planning will be carried out, blinded to the PET results.~Then, a functional planning, respecting the standard constraints applied during anatomical planning, but also incorporating a new functional lung volume constraint defined by pulmonary PET, will then be carried out.~A follow-up will be carried out for 12 months, including repeated perfusion PET/CT imaging at 3 and 12 months"
89572458|NCT01652703|Placebo Comparator|Placebo Q2W|Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.
89572459|NCT01652703|Placebo Comparator|Placebo Q4W|Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for 12 weeks.
89572460|NCT01652703|Experimental|Evolocumab 70 mg Q2W|Participants received 70 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
89572461|NCT01652703|Experimental|Evolocumab 140 mg Q2W|Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
89572462|NCT01652703|Experimental|Evolocumab 280 mg Q4W|Participants received 280 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
89572463|NCT01652703|Experimental|Evolocumab 420 mg Q4W|Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
89572464|NCT01652469|Experimental|A: Erlotinib|Erlotinib in standard dose. Until progression (clinical or radiological) or unacceptable toxicity.
89033175|NCT02943902|Active Comparator|Group 3a (2+1)|PCV10 (Synflorix 0.5ml injection) will be administered at 6 weeks, 14 weeks and 9 months of age, as per EPI schedule in South Africa
89572465|NCT01652469|Experimental|B: Docetaxel|Docetaxel in standard dose. Until progression (clinical or radiological) or unacceptable toxicity.
89572466|NCT02429427|Experimental|Celecoxib|Patients in this arm will receive 400mg of celecoxib once daily. In addition, Hormone Receptor (+) patients will receive endocrine treatment according to local practice.
89572467|NCT02429427|Placebo Comparator|Placebo|Patients in this arm will receive 2 tablets once daily. In addition Hormone Receptor (+) patients will receive endocrine treatment according to local practice.
89572468|NCT05370573||Patients with central nervous system infections admitted to intensive care|
89572469|NCT02412735|Experimental|Rexlemestrocel-L|Participants received rexlemestrocel-L 2.0 mL injection of approximately 6 million rexlemestrocel-L cells in freeze media mixed in a 1:1 by-volume ratio with saline on Day 0 (Visit 2).
89572470|NCT02412735|Experimental|Rexlemestrocel-L + HA|Participants received rexlemestrocel-L 2.0 mL injection of approximately 6 million rexlemestrocel-L cells in freeze media mixed in a 1:1 by-volume ratio with hyaluronic acid (HA) solution on Day 0 (Visit 2).
89572471|NCT02412735|Placebo Comparator|Placebo|Participants received saline solution as matching-placebo on Day 0 (Visit 2).
89572472|NCT02412657|Experimental|Dexamethasone 10 mg intravenous|Dexamethasone 10 mg diluted with Normal Saline 17,5 mL i.v. (20 mL total) injected slowly during 30 seconds immediately after performing interscalene brachial plexus block
89572473|NCT02412657|Experimental|Dexamethasone 4 mg intravenous|Dexamethasone 4 mg diluted with Normal Saline 19 mL i.v. (20 mL total) injected slowly during 30 seconds, immediately after performing interscalene brachial plexus block
89572474|NCT02412657|Placebo Comparator|Normal Saline 20 mL intravenous|Normal saline 20 mL injected slowly during 30 seconds, immediately after performing interscalene brachial plexus block
89572475|NCT02428413|Active Comparator|Standard oxygen mask|Standard face mask to provide supplemental oxygen
89572476|NCT02428413|Active Comparator|ISO-Gard Mask|Face mask to scavenge waste anesthetic gases from patient during recovery from general anesthesia and to provide supplemental oxygen.
89572477|NCT02412111|Experimental|Ivacaftor (Run-in Period)|Ivacaftor 150 milligram (mg) tablet orally every 12 hours for 4 weeks.
89572478|NCT02412111|Experimental|VX-661 + Ivacaftor (Active comparator period)|VX-661 100 mg and ivacaftor 150 mg fixed-dose combination tablet orally once daily in the morning and ivacaftor 150 mg tablet orally once daily in the evening for 8 weeks.
89572479|NCT02412111|Active Comparator|Ivacaftor monotherapy (Active comparator period)|Ivacaftor 150 mg tablet orally every 12 hours as monotherapy for 8 weeks.
89572480|NCT02427477|Experimental|senofilcon A/ delefilcon A/ senofilcon A|Subjects were randomized to one two lens wear sequences. Subjects randomized to this sequence first wore the senofilcon A contact lens, then wore the delefilcon A contact lens second and then wore the senofilcon A contact lens third.
89572481|NCT02427477|Active Comparator|delefilcon A/senofilcon A/ delfilcon A|Subjects were randomized to one two lens wear sequences. Subjects randomized to this sequence first wore the delefilcon A contact lens then wore the senofilcon A contact lens second and then wore the Control lens delefilcon A contact lens third.
89572482|NCT02427399|No Intervention|Usual care / opportunistic screening|This group will not be contacted by the study team in any way and will receive the general standard of care at Fenway. Patient charts are reviewed by the provider and medical team shortly before a scheduled visit to determine if the patient is due for a Pap, and if so, the patient is offered a Pap during the visit or the chance to schedule one for another date. Any proactive outreach occurs infrequently and at an ad-hoc basis, but should any proactive outreach occur, the study team will not interfere.
89572483|NCT02427399|Experimental|Letter and informational sheet|The patients in this group will be mailed a letter at time 0. The letter will inform the patient that she is overdue for a Pap and will also contain an informational sheet about cervical cancer and Pap tests. If the patient does not contact Fenway within 1 month to schedule an appointment, an additional letter will be sent at 1 month, and similarly again at 2 months. These letters will be the same, except that letters two and three will mention that previous attempts have been made at contact. Based on best practices in the literature, the letters will be signed by the patient's primary care provider.
89572484|NCT02427399|Experimental|Email|The same text shared in the letter will be sent as an email to the patients in this intervention group, again at time 0, 1, and 2 months, as necessary for nonresponders. The email will be sent from the provider's email account. The email will have an informational sheet attached or included in the body of the email. The emails will be sent through MyFenway, the secure, Health Insurance Portability and Accountability Act (HIPAA)-compliant patient contact system at Fenway.
89572485|NCT02427399|Experimental|Phone|The patient will be telephoned and informed that they are due for a Pap, and given the opportunity to schedule an appointment over the phone immediately. As per HIPAA regulations, if the patient does not answer, a voicemail will be left saying that a Fenway representative has called and request that the patient calls back, but a reason will not be given. Some, but not all of the information contained in the info sheet will be provided during the call (see phone script). The script used is consistent with the scripts used currently for patient outreach. A voicemail will still count as one outreach attempt out of three. Patients will be contacted at time 0, 1, and 2 months as necessary for nonresponders.
89572486|NCT02427399|Experimental|Multimodal|The patient will be sent a letter/informational sheet at time 0. If she does not respond within one month, she will be sent an email. If she does not respond by 2 months after the start of the intervention period, she will be called. If a patient randomly selected for this group does not have an email listed, she will receive one letter and two phone calls.
89572487|NCT02426541|Experimental|Dapagliflozin|Dapagliflozin Once Daily 10 mg
89572488|NCT02426541|Placebo Comparator|Placebo|Matching placebo for Dapagliflozin Once Daily 10 mg
89572489|NCT02484651|No Intervention|Standard Group|Standard Clinical Practice Group - standard neuromuscular block, with a standard rocuronium dose for intubation (0.6 mg/kg). If required, the reversal of neuromuscular block is performed with neostigmine.
89572490|NCT02484651|Experimental|Deep NMB group|Deep Neuromuscular Block group - with a standard rocuronium dose for intubation (0.6 mg/kg), followed by a constant infusion of rocuronium (10-15 ug/kg/min) to guarantee a PTC less or equal to 2 on the TOF monitor (PTC is evaluated every 5 minutes). The reversal of neuromuscular block is performed with Sugammadex (4 mg/kg).
89033176|NCT02943902|Active Comparator|Group 3b (2+1)|PCV13 (Prevenar 13, 0.5ml injection) will be administered at 6 weeks, 14 weeks and 9 months of age, as per EPI schedule in South Africa
89572491|NCT02410551|Experimental|Pacritinib + Allogeneic Stem Cell Transplantation|Participants start Pacritinib 200 mg by mouth twice a day. Participants proceed to transplant after 60 days of Pacritinib but not more than 180 days. Pacritinib stopped 21 days prior to starting preparative regimen for standard of care stem cell transplantation (SOC Allo TP). SOC transplant conditioning with Fludarabine and Busulfan AUC of 4000 microMol-min per day providing that pharmacokinetic can be done, otherwise Busulfan dose given as a fixed dose of 100 mg/m2 daily for four days. Questionnaires about symptoms and quality of life completed at baseline, 1, 3, 6, and 12 months after transplant. Phone calls made by study staff to participant on second and third week of each month.
89572492|NCT02424591|Active Comparator|Ketamine|ketamine group will be infused after intubation and terminated at the start of skin closure
89572493|NCT02424591|Placebo Comparator|Placebo|placebo group will have standard of care rather than ketamine infusion
89572494|NCT02408523|Experimental|Lacosamide|"Lacosamide 50 mg tablets: starting with 100 mg/day at Week 1. Weekly increase in steps of 50 mg or 100 mg/day are allowed. Maximal dose 400 mg/day for adult subjects and pediatric subjects >= 50 kg.~Lacosamide oral solution 10 mg/ml: starting with 2 mg/kg/day, titrations steps (1 mg/kg/day to 2 mg/kg/day; maximal dose 12 mg/kg/day for pediatric subjects < 30 kg.)~Lasosamide oral solution 10 mg/ml: starting with 2 mg/kg/day, titrations steps (1 mg/kg/day to 2 mg/kg/day; maximal dose 8 mg/kg/day for pediatric subjects 30 kg to < 50 kg.)"
89572495|NCT02408523|Placebo Comparator|Placebo|"Placebo 50 mg tablets: starting with 100 mg/day at Week 1. Weekly increase in steps of 50 mg or 100 mg/day are allowed. Maximal dose 400mg/day for adult subjects and pediatric subjects >= 50kg.~Placebo oral solution 10 mg/ml: starting with 2 mg/kg/day, titrations steps (1 mg/kg/day to 2 mg/kg/day; maximal dose 12 mg/kg/day for pediatric subjects < 30kg.)~Placebo oral solution 10 mg/ml: starting with 2 mg/kg/day, titrations steps (1 mg/kg/day to 2 mg/kg/day; maximal dose 8 mg/kg/day for pediatric subjects 30kg to < 50kg.)"
89572496|NCT04830319|Experimental|Test-control group (TCG)|The test-control group (TCG) will initiate the protocol with exercises of the Pilates method, which includes exercises in soil, that associate the correct respiratory movement with muscular strengthening and control, stretching from the eccentric movement, selective upper and lower trunk movements. There will be used accessories described by the method for their realization. Participants will perform the first week of awareness and body alignment exercises for 10 minutes, 10 minute breath perception, 10 minute proximal muscle accuracy and control, and 10 minute stretches; from the second week will be included selective trunk movements, with muscle strengthening of lower limbs. Rest intervals will be performed between exercises.After 20 sessions, the patients will be reassessed and will remain for a period of one month without any intervention, and at the end of this period will be reevaluated again. The TCG group will then conduct 20 task-oriented training sessions
89572497|NCT04830319|Active Comparator|Control-test group (CTG)|The control-test group (CTG) will initiate the task-oriented training protocol. The task-oriented training protocol will include functional exercise drills, such as sit-up and workout, obstacle course workout, speed-and-direction workout, balance workout, work-up and downhill workout, each tasks performed for eight minutes, with two minutes of rest between them. The difficulty in carrying out the tasks will be progressively adjusted. At all times, individuals will be instructed to contract the pelvic floor musculature. After 20 sessions, the patients will be reassessed and will remain for a period of one month without any intervention, and at the end of this period will be reevaluated again. Next, the CTG group will perform 20 sessions of Pilates exercises.
89572498|NCT04836403||Rhinosinusitis without treatment group|children aged 2 and 12 years with rhinosinusitis not receiving treatment
89572499|NCT04836403||Rhinosinusitis with treatment group|children aged 2 and 12 years with rhinosinusitis receiving treatment
89572500|NCT04836403||healthy volunteers|children aged 2 and 12 years without rhinosinusitis
89572501|NCT04836091|Experimental|Immediate intervention|From baseline to 2-month post-test, participants in the intervention arm will have access to the OurPlan program app.
89572502|NCT04836091|Experimental|Waitlist-delayed intervention|Participants in this study arm will not have access to the OurPlan program in the app from baseline to day 30 (month 1) of the trial. From day 31 to day 60, participants in this study arm will be given access to the OurPlan program in the app.
89572503|NCT04836169|Experimental|InCaveo EOA System|InCaveo EOA System (including integrated CBT but without tapering) group
89028979|NCT05146739|Experimental|Treatment (uproleselan, fludarabine, cytarabine)|Patients receive uproleselan IV QD over 20 minutes on day 1 and IV over 20 minutes BID on days 2-8, fludarabine IV QD over 30 minutes on days 2-6, and high dose cytarabine IV QD over 1-3 hours on days 2-6. Patients also receive cytarabine IT on day 0 then weekly starting on day 7-28 or ITT on day 0 then weekly starting on day 7-28. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients (with down syndrome only) receive leuvoorine PO or IV BID on days 1, 8, 15, 22, and 29.
89033177|NCT00531908|Experimental|A|To compare natriuretic effect of a single dose administration of amiloride (20 mg) in patients with acromegaly
89033178|NCT03403569|Experimental|Triptolide Wilfordii Group|150 patients will be enrolled and be administrated with Triptolide Wilfordii 20mg three times a day(TID) per os combined with appropriate ART for 12 months.
89033179|NCT03403569|Placebo Comparator|Placebo Oral Tablet Group|150 patients will be enrolled and be administrated with placebo per os combined with appropriate ART for 12 months.
89033180|NCT00531791|Active Comparator|1|
89033181|NCT00531791|Experimental|2|
89033182|NCT00531830||1|Preschool children with PDD
89033183|NCT00531830||2|Preschool children without PDD
89572504|NCT04836169|No Intervention|Control Group-usual care with pill bottles|UCPB group-usual care with pill bottles
89572505|NCT04836013|Experimental|Probiotic group|Lactobacillus reuteri LMG P-27481 and Lactobacillus rhamnosus GG (ATCC 53103), sucralose and isomalt as an oral stick formulation of 1,6 g with a concentration of probiotic of 2x100bilion colony forming unit (CFU) per stick.
89572506|NCT04836013|Placebo Comparator|Placebo group|The placebo will contain 1.6 g per stick of sucralose and isomalt
89572507|NCT04822909|Experimental|Apremilast group|"The study patients will be treated with oral apremilast, administered initially a dose of 10 mg once daily, gradually increasing to reach the maximal therapeutic dosage of 30 mg twice daily before end of 1st week of starting the therapy.~The treatment will be continued till 6 months and we will taper the steroids by 10mg/ 2 weeks till 20mg and then 5 mg/ 2 weeks till discontinuation of steroids."
89572508|NCT04831099|Experimental|Testosterone|Testosterone gel (20 mg/day) for 8 weeks per period.
89572509|NCT04831099|Placebo Comparator|Placebo|Placebo gel (20 mg/day) for 8 weeks per period.
89572510|NCT04830085|Experimental|Patients with adenomyosis|Hysterectomy (abdominal or vaginal or laparoscopic) Histopathological assessment Adenomyosis was diagnosed with histopathological assessment.
89572511|NCT04830085|Active Comparator|Patients without adenomyosis|Hysterectomy (abdominal or vaginal or laparoscopic) Histopathological assessment Adenomyosis was excluded with histopathological assessment.
89572512|NCT04822831|Experimental|Long-term Ventilator-dependent Patients with intervention|45 Degree Semi-recumbent Position With Upper Limb Exercise Training on Long-term Ventilator-dependent Patients
89572513|NCT04822831|Experimental|Long-term Ventilator-dependent Patients without intervention|There is no intervention on Long-term Ventilator-dependent Patients ,and just keep routine treatment.
89572514|NCT04302337|Active Comparator|Conventional Curettage Adenoidectomy|Adenoidectomy with Beckmann Adenoid Curette
89572515|NCT04302337|Experimental|Curettage Adenoidectomy With Transoral Endoscopic Ablation|Transoral endoscopic adenoidectomy with Coblator 2 system
89572516|NCT03036943|Experimental|Fluciclovine (18F) PET/CT|
89572517|NCT03036865|Experimental|Cohort 1: 1 mg, IV BOS161721|Each participant will receive a single intravenous (IV) dose of BOS161721 1 milligram (mg).
89572518|NCT03036865|Placebo Comparator|Cohort 1: matching placebo|Each participant will receive matching IV placebo.
89572519|NCT03036865|Experimental|Cohort 2: 3 mg, SC BOS161721|Each participant will receive a single subcutaneous (SC) dose of BOS161721 3 mg.
89572520|NCT03036865|Placebo Comparator|Cohort 2: matching placebo|Each participant will receive matching SC placebo.
89572521|NCT03036865|Experimental|Cohort 3: 10 mg, SC BOS161721|Each participant will receive a single SC dose of BOS161721 10 mg.
89572522|NCT03036865|Placebo Comparator|Cohort 3: matching placebo|Each participant will receive matching SC placebo.
89572523|NCT03036865|Experimental|Cohort 4: 30 mg, SC BOS161721|Each participant will receive a single SC dose of BOS161721 30 mg.
89572524|NCT03036865|Placebo Comparator|Cohort 4: matching placebo|Each participant will receive matching SC placebo.
89572525|NCT03036865|Experimental|Cohort 5: 60 mg, SC BOS161721|Each participant will receive a single SC dose of BOS161721 60 mg.
89572526|NCT03036865|Placebo Comparator|Cohort 5: matching placebo|Each participant will receive matching SC placebo.
89572527|NCT03036865|Experimental|Cohort 6: 22 mg, IV BOS161721|Each participant will receive a single IV dose of BOS161721 22 mg.
89572528|NCT03036865|Experimental|Cohort 7: 120 mg, SC BOS161721|Each participant will receive a single SC dose of BOS161721 120 mg.
89572529|NCT03036865|Placebo Comparator|Cohort 7: matching placebo|Each participant will receive matching SC placebo.
89572530|NCT03036865|Experimental|Cohort 8: 240 mg, SC BOS161721|Each participant will receive a single SC dose of BOS161721 240 mg.
89572531|NCT03036865|Placebo Comparator|Cohort 8: matching placebo|Each participant will receive matching SC placebo.
89572532|NCT04835389|Experimental|AlloGen Liquid|A single-dose, intra-articular (IA) injection of 2.0 mL of AlloGen Liquid administered to the affected knee.
88970637|NCT00063817|Experimental|Conditioning Regimen|"Cyclophosphamide intravenously (IV) on days -5 and -4 with respect to transplantation; MEDI-507 on days -1, 0, and 1 (after a test dose of 0.1 mg per kg on day -2); and cyclosporine A IV and thymic irradiation on day -1. Hemodialysis was performed before and 14 hours after each dose of cyclophosphamide.Kidney transplantation was followed by IV infusion of donor bone marrow. Oral cyclosporine A was administered daily postoperatively, with target trough blood levels of 250 to 350 ng per milliliter; the dose was tapered and discontinued over a period of several months.~Amendment applicable to the 4th and 5th participant: rituximab on days -7 and -2; and prednisone, 2 mg per kg per day starting on the day of transplantation with tapering over the next 10 days."
88970638|NCT00063895|Experimental|Treatment (erlotinib hydrochloride)|Patients receive oral erlotinib on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89572533|NCT04835389|Placebo Comparator|Saline|A single-dose, intra-articular (IA) injection of 2.0 mL of saline administered to the affected knee.
89572534|NCT04832893|Active Comparator|Use of FFP2 respirator|Using of FFP2 respirator during the 30 minutes test
89572535|NCT04832893|Active Comparator|Use of surgical mask|Using of surgical mask during the 30 minutes test
89572536|NCT04832893|Sham Comparator|no mask|The 30 minutes test will be carried out without mask
89572537|NCT02603419|Experimental|Lead-in phase-Cohort A|X1 mg IV every 2 weeks
89572538|NCT02603419|Experimental|Lead-in phase-Cohort B|X2 mg IV every 2 weeks
89572539|NCT02603419|Experimental|Lead-in phase-Cohort C|X3 mg IV every 3 weeks
89572540|NCT02603419|Experimental|Lead-in phase-Cohort D|X4 mg IV every 2 weeks
89572541|NCT02603419|Experimental|Lead-in phase-Cohort E|X5 mg IV every 2 weeks
89572542|NCT02603419|Experimental|Expansion phase|X1 mg IV every 2 weeks followed by X1 or X4 mg every 2 weeks
89572543|NCT04367935|Active Comparator|Intervention|Pentoxifylline tablets 400mg three times daily for 2 months
89572544|NCT04367935|No Intervention|Control|Control Group receiving placebo tablets three times daily for 2 months
89572545|NCT04829773|Experimental|PK Cohort 1|"Subjects received three single oral doses of palovarotene on Days 1, 6, and 11, separated by 5-day washout periods.~Sequence A-B-C: Subjects received a single oral dose of palovarotene whole capsule under fasting conditions (at least a 10-hour overnight fast); followed by a single oral dose of palovarotene whole capsule 30 minutes after the start of a standardized high-fat, high-caloric breakfast; and then followed by a single oral dose of palovarotene sprinkled on 1 teaspoon of apple sauce, administered 30 minutes after the start of a standardized high-fat, high-caloric breakfast."
89572546|NCT04829773|Experimental|PK Cohort 2|"Subjects received three single oral doses of palovarotene on Days 1, 6, and 11, separated by 5-day washout periods.~Sequence B-C-A: Subjects received a single oral dose of palovarotene whole capsule 30 minutes after the start of a standardized high-fat, high-caloric breakfast; followed by a single oral dose of palovarotene sprinkled on 1 teaspoon of apple sauce, administered 30 minutes after the start of a standardized high-fat, high-caloric breakfast; and then followed by a single oral dose of palovarotene whole capsule under fasting conditions (at least a 10-hour overnight fast)."
89572547|NCT04829773|Experimental|PK Cohort 3|"Subjects received three single oral doses of palovarotene on Days 1, 6, and 11, separated by 5-day washout periods.~Sequence C-A-B: Subjects received a single oral dose of palovarotene sprinkled on 1 teaspoon of apple sauce, administered 30 minutes after the start of a standardized high-fat, high-caloric breakfast; followed by a single oral dose of palovarotene whole capsule under fasting conditions (at least a 10-hour overnight fast); and then followed by a single oral dose of palovarotene whole capsule 30 minutes after the start of a standardized high-fat, high-caloric breakfast."
89572548|NCT04829773|Experimental|Drug-Drug interaction (DDI) Cohort|On the morning of Day 1, subjects received a single dose of midazolam 30 minutes after the start of a standardized breakfast. On Day 2 (after the 24-hour midazolam blood draw) through Day 15, subjects received a daily, single dose of palovarotene in the morning 30 minutes after the start of a standardized breakfast. A second dose of midazolam was administered on Day 15 in the morning (immediately following the palovarotene dose) 30 minutes after the start of a standardized breakfast.
89572549|NCT04822285|Experimental|Psychological Triaging Intervention|The PTI intervention followed the path of RAPID Psychological First Aid model of John Hopkins University (Everly& Lating 2012). The content of the PTI represents a simple structure that is revolved around five core phases including (R: establishing rapport and reflective listening, A: assessment, P: prioritization, I: intervention and D: disposition& follow up).
89572550|NCT04822285|Active Comparator|Routine Psychological support|For the comparison group, the researchers provided them with routine psychological support that mainly revolved around enhancing their self-compassion, practicing mindfulness exercises, keeping them socially connected with their family and peers. Moreover, adopt a healthy lifestyle such as; engage in physical activity, eating a well-balanced diet, and sleeping well.
88970639|NCT00063973|Experimental|Treatment (cilengitide)|"Patients receive cilengitide (EMD 121974) IV over 1 hour twice weekly. Treatment repeats every 4 weeks for 13 courses in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of cilengitide until the MTD is determined. The MTD is defined as the dose at which 25% of patients are expected to experience dose-limiting toxicity. Once the MTD is determined, 6 additional patients are accrued and treated at that dose level for a total of 12 patients at the MTD."
88970640|NCT04648683|Experimental|Individual telehealth mindfulness|Telehealth mindfulness sessions delivered one-on-one with mindfulness therapist
88970641|NCT04648683|Experimental|Group Telehealth Mindfulness|Telehealth mindfulness sessions delivered in a small-group format with mindfulness therapist
88970642|NCT00064012|Active Comparator|Velcade Alone|Velcade
88970643|NCT00064012|Experimental|Velcade plus Docetaxel|Velcade plus Docetaxel
88970644|NCT02967328||RP% Measurement by FCM as a Diagnostic Test for ITP|The investigators are undertaking a multi-center, prospective blind trial of 500 adults with thrombocytopenic disorders with a platelet count less than 60000/uL from 4 medical centers in China. In brief, 15 ul aliquots of anti-coagulated whole blood were incubated for 70 min with 5 ul of phycoerythrin-conjugated anti-CD42b monoclonal antibody (BD Pharmingen, Tokyo, Japan) and 1 ml of thiazole orange (Retic-COUNT; Becton-Dickinson, San Jose, CA, USA) diluted 10 times by phosphate-buffered saline. RP% was analyzed on a flow cytometer (FACScan, Becton-Dickinson) by measuring 10,000 events in the CD42b-positive fraction.
88970645|NCT00064129|Experimental|Treatment (monoclonal antibody, colony-stimulating factors)|Patients receive ipilimumab IV over 90 minutes on day 1 and sargramostim (GM-CSF) SC on days 1-14. Treatment repeats every 28 days for 4-6 courses. GM-CSF continues beyond 4 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of ipilimumab until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Some patients undergo blood sample collection periodically for laboratory and pharmacokinetic studies. Samples are analyzed for human anti-human antibodies, IgG antibodies to ipilimumab semi-quantitative ELISA assay, and plasma concentrations of ipilimumab via quantitative ELISA assay.
88970646|NCT00064246|Experimental|Treatment (rituximab, yttrium Y 90 ibritumomab tiuxetan)|"Phase I: Patients receive rituximab IV and indium In 111 ibritumomab tiuxetan IV over 10 minutes on day 1. Patients undergo 2 (or 3 if needed) imaging scans between days 1-6. In the absence of altered biodistribution, patients receive rituximab IV followed within 4 hours by IDEC-Y2B8 IV over 10 minutes on day 8.~Phase II: Patients receive treatment as in phase I at the MTD of IDEC-Y2B8. Patients are followed monthly for 3 months, every 3 months for 2 years, and then every 6 months for 2 years."
89572551|NCT04829695|Experimental|Artesunate-amodiaquine (Arm A)|Artesunate-amodiaquine is co-packaged as artesunate 50 mg and amodiaquine hydrochloride USP equivalent to amodiaquine base of 153.1 mg. Each child shall be given one, two or three tablets depending on the weight.
89572552|NCT04829695|Active Comparator|Artemether-lumefantrine (Arm B)|Artemether-lumefantrine is formulated as tablets and will be provided in blister packs. Each tablet contains 20 mg artemether and 120 mg lumefantrine. Every pack has a picture showing how the drug should be given and contains two blisters for each day with one, two or three tablets depending on the weight of the child.
89572553|NCT03035539|Active Comparator|Standard treatment|Standard treatment after randomization
89572554|NCT03035539|Experimental|Cardiac Rehabilitation|The rehabilitation programme includes education, physical exercise, optimisation of the medical treatment, and discussion of implications for the daily life of each participant.
89572555|NCT04821973|Active Comparator|Control Respiratory Monitoring Group|
89572556|NCT04821973|Experimental|Experimental Respiratory Monitoring Group|
89572557|NCT04822207|Experimental|Acupuncture group|In the acupuncture group, those patients undergo acupuncture at the beginning of embryo transfer cycle three times a week until 14 days after embryo transfer. These patients should be checked including endometrial receptivity index and fill in SAS anxiety scale form.
89572558|NCT04822207|No Intervention|Control group|In the control group, these patients do not receive any treatments during embryo transfer cycle. These patients should be checked including endometrial receptivity index and fill in SAS anxiety scale form.
89572559|NCT03035695|Experimental|Axiostat® Size|"Device: Axiostat® Size: 8 x 5 cm Axiostat® is a sterile, non-absorbable haemostatic dressing intended to control profuse bleeding within minutes of application by providing an active mechanical barrier to the wound site.~Mechanism of action is such that Axiostat® is an extremely positive dressing that becomes very sticky in the presence of negatively charged blood and thus seals the wound area."
89572560|NCT03035695|Active Comparator|Cotton Gauze|Cotton Gauze Size: 8 x 5 cm
89572561|NCT04822051|Experimental|Psychoeducation Group|"Uncertainty Management Psychoeducation Program was given."
89572562|NCT04822051|No Intervention|Control Group|No attempt was made by the researcher during the study. Only data collection was carried out.
89572563|NCT04821427|Experimental|Brief mHealth Intervention + mobile messaging|The intervention is a brief, motivational video-conferencing intervention followed by four weeks of app-based, interactive mobile messages
89572564|NCT04821427|No Intervention|Assessment Only|This is an assessment only condition. No intervention following completion of baseline surveys will be administered.
89572565|NCT04821583|Experimental|Hydrocortisone|Hydrocortisone (20 mg/day) in a 10-5-5 schedule: 10 mg at 0700h, 5 mg at 1200h, and 5 mg at 1700h. The hydrocortisone periods last 10 weeks per period. In total, there are two hydrocortisone periods.
89572566|NCT04821583|Placebo Comparator|Placebo|Placebo (20 mg/day) in a 10-5-5 schedule: 10 mg at 0700h, 5 mg at 1200h, and 5 mg at 1700h. The placebo periods last 10 weeks per period. In total, there are two placebo periods.
89572567|NCT04834921|Experimental|MCO-CVVHD|CVVHD with MCO filter for 24 hours
89572568|NCT04834921|Active Comparator|HFF-CVVHDF|CVVHDF with high flux filter for 24 hours
89572569|NCT04829149||Statin therapy group (No interventional)|Observational. Statin therapy group: Once daily administered per the locally approved product information of rosuvastatin, simvastatin, atorvastatin, pitavastatin etc,. (except Rosuzet Tab.)
89572570|NCT04829149||Rosuzet tablet group (No interventional)|Observational. Rosuzet Tab.(ezetimibe/rosuvastatin) group: once daily administered per the locally approved product information of Rosuzet Tab. 10/5mg, 10/10mg, 10/20mg
89572571|NCT01668355|Experimental|SMI-PACT|Patient Aligned Care Team (PACT) medical home model to address the physical healthcare needs of individuals with serious mental illness
89572572|NCT01668355|No Intervention|Usual Care|Usual Primary Care
88970647|NCT00064324|Experimental|Arm I|Patients receive a loading dose of oral perifosine every 6 hours for a total of 4 doses on day 1 and once daily on days 2-28 of course 1 only. For all subsequent courses, patients receive oral perifosine once daily on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
88970648|NCT00064402|Experimental|1|Arformoterol 50 mcg QD and placebo MDI
88970649|NCT00064402|Experimental|2|Arformoterol 25 mcg BID and Placebo MDI
89572573|NCT01667731|Experimental|SOF+RBV 12 Weeks (GT 2/3, TN)|Treatment-naive (TN) participants coinfected with HIV-1 and genotype (GT) 2 or genotype 3 HCV infection will receive SOF+RBV for 12 weeks.
89572574|NCT01667731|Experimental|SOF+RBV 24 Weeks (GT 2/3, TE)|Treatment-experienced (TE) participants coinfected with HIV-1 and genotype 2 or genotype 3 HCV infection will receive SOF+RBV for 24 weeks.
89572575|NCT01667731|Experimental|SOF+RBV 24 Weeks (GT 1, TN)|Treatment-naive (TN) participants coinfected with HIV-1 and genotype 1 HCV infection will receive SOF+RBV for 24 weeks.
89572576|NCT05618119|Active Comparator|Male|5 male participants will undergo a [18F]MC225 PET scan
89572577|NCT05618119|Active Comparator|Female|5 female participants will undergo a [18F]MC225 PET scan
89572578|NCT04828759|Experimental|VR-treatment, then Treatment as usual|Participants will receive 8 weeks of VR-treatment. Participants are allowed to practice as much as they wish during the VR-intervention. However, they are given a recommendation of the amount of practice (5 h / week). Before the VR-intervention, the participants will receive a guidance for using the VR-devices (i.e. orientation period) by the SLT. Participants will be able to contact the SLT freely during the 8 weeks VR-intervention period. After the orientation period, the participants will be practicing at their homes independently. However, they will receive remote guidance by the SLT. The guidance includes weekly remote guidance sessions by SLT (8 x 45 min) to ensure that training is fluent and unproblematic. Additionally, the content of exercises can be modified during these sessions. The SLT is also able to monitor the training of participants with the system. Devices: VR headset and controller, Tablet computer.
89572579|NCT04828759|Experimental|Treatment as usual, then VR-treatment|Wait list control group: During the waitlist period the participants will receive the traditional speech and language therapy rehabilitation offered by (if offered) the general health care system in their own home municipality. The amount of rehabilitation is not controlled during the wait list period. However, the amount of received traditional speech and language rehabilitation in waitlist period will be documented. The waitlist control group will receive the same VR intervention period after the 8 weeks waitlist period.
89572580|NCT04828525|Experimental|Experimental|participants will be given corticosteroids in addition to conventional treatment
89572581|NCT04828525|Placebo Comparator|Placebo|participants will be given normal saline in addition to conventional treatment
89572582|NCT04821505|Experimental|Meditation|The Transcendental Meditation program is described as a simple natural technique practiced for 20 minutes twice daily for deep rest and relaxation. Previous studies have shown its feasibility, validity, and reliability in Blacks at risk for CVD.
89572583|NCT04821505|Active Comparator|Health Education|Health education program matched to the experimental intervention for time, attention, and other non-specific factors.
89572584|NCT04835155|Experimental|experimental group|The researcher applied Premature Infant Oral Motor Intervention to the experimental group for 5 minutes per day for 14 consecutive days, 15-20 minutes before a sheduled feeding at either the 09:00 or 12:00 feeding. On the first day, the baseline sucking capacity of babies in experimental group was measured before any intervention. On the following 8th, 11th and 14th days, the measures of sucking capacity were repeated and followed by oral feeding trials. Growth measures were collected on the 1st and 14th days and the day of disharge.
89572585|NCT04835155|No Intervention|control grup|The researcher did not apply any intervention. On the first day, the baseline sucking capacity of babies in control group was measured before any intervention. On the following 8th, 11th and 14th days, the measures of sucking capacity were repeated and followed by oral feeding trials.
89572586|NCT04828915||Training cohort|Randomly selection of 80% of the study population. The machine learning algorithm is trained on this dataset
89572587|NCT04828915||Validation cohort|Randomly selection of 20% of the study population. The machine learning algorithm which was trained on the basis of the training data cohort is validated on the validation cohort.
89572588|NCT04427683|Experimental|Brief mindful parenting program|The program will consist of a four-session and last for eight hours integrating mindfulness skills and psychoeducation in managing stress under social unrest and promoting strategies for emotion regulation, conflict management, and self-care.
89572589|NCT04427683|Other|Wait-list control group|A four-minute educational video will be distributed to the participants who accept the randomisation. It includes brief information on mental health. After the participants from experimental group complete the intervention, those in wait-list control group will receive the same intervention.
89572590|NCT04828213|Experimental|Tooth-borne RME appliance (Hyrax)|"In the Tooth-borne RME expander group, bands were placed to the maxillary right and left upper 1st premolar and 1st molar teeth. The impression of the upper jaw was obtained with the bands in mouth by using alginate impression material. In the laboratory process, a hyrax (Forestadent, Pforzheim, Germany; Forestadent USA, St Louis, Missouri, USA) expansion appliance with an expansion screw in the middle was prepared on the models by the same technician under standard conditions.~RME activation was performed twice a day for the first week and then once per day. When it was decided that the expansion was sufficient (until the palatal tubercles of the upper molars came into contact with the buccal tubercles of the lower molars), the screw was fixed with the 0.012-inch ligature wire (American Orthodontics) and the appliance was kept in the mouth without being activated for 3 months."
89572591|NCT04828213|Experimental|Hybrid hyrax RME appliance|"Rapid Maxillary Expansion Treatment. In the Hybrid hyrax RME appliance group, mini-screws of 2 mm diameter and 9 mm length (Benefit mini-implants; PSM Medical Solutions; Tuttlingen, Germany) were placed 3 mm posterior and 1 to 5 mm paramedian to the incisive foramina.~RME activation was performed twice a day for the first week and then once per day. When it was decided that the expansion was sufficient (until the palatal tubercles of the upper molars came into contact with the buccal tubercles of the lower molars), the screw was fixed with the 0.012-inch ligature wire (American Orthodontics) and the appliance was kept in the mouth without being activated for 3 months."
89572592|NCT04821193|Experimental|Experimental Group 1|Cleansing the skin with an antiseptic solution before intravenous catheterization Skin antisepsis with 5% NaHCO3 water solution group Grup number: 20
89572593|NCT04821193|Experimental|Experimental Group 2|Cleansing the skin with an antiseptic solution before intravenous catheterization Skin antisepsis with 2% Chlorhexidine Gluconate solution group Grup number: 21
88970650|NCT00064402|Experimental|3|Arformoterol 15 mcg BID and placebo MDI
88970651|NCT00064402|Active Comparator|4|Salmeterol MDI 42 mcg BID and placebo inhalation solution
88970652|NCT00064402|Placebo Comparator|5|Placebo MDI and placebo inhalation solution
88970653|NCT04604847|Other|Total knee arthroplasty|patient operated for a total knee arthroplasty
88970654|NCT05125211|Experimental|Single dose-escalation of GB001 recombinant peptide spray|Each subject will receive one single administration of GB001 recombinant peptide. The dosage of each group is 0.054mg, 0.108mg, 0.216mg, 0.432mg and 0.864mg, respectively.
88970655|NCT05125211|Experimental|Oral retention time test for a single dose|Each subject will receive one single administration of GB001 recombinant peptide. The dosage of the group is 0.108mg.
89572594|NCT04821193|No Intervention|Control Group|Cleansing the skin with an antiseptic solution before intravenous catheterization Skin antisepsis with 70% Alcohol solution group Grup number: 21
89572595|NCT04821037|Experimental|ACT|"A digitally-based ACT program will be conducted in two half-day workshops via meeting software (e.g. Zoom) consisting of:~mindfulness exercises, for stress reduction and to guide nurses to observe their painful thoughts and feelings that they are attempting to avoid;~ACT-metaphors, to let nurses realize the cost of struggling with psychological distress often create more distress;~experiential exercises, to guide nurses to notice their own experiences in providing nursing care throughout their nursing career and explore any special qualities;~explore the nurses' values with respect to different areas in their lives."
89572596|NCT04820725|Experimental|Study group|Patients whose BASMI score is 2 will be included in the study
89572597|NCT04820725|Experimental|Control group|Patients whose BASMI score is 0 and 1 will be included in the study
89572598|NCT04828291|Experimental|Online Mindfulness Intervention (OMI)|Before beginning the daily practices, this group will be introduced to the OMI via an online platform and answer any questions about the practice. Then, each day, this group will be guided through a series of mindfulness practices offered online (www.bemindfulonline.com) delivered on their smartphones or laptops.
89572599|NCT04828291|Experimental|OMI paired with peer support (OMI+)|Before beginning the daily OMI, in addition to being briefed, this group will be paired with a peer to be in touch with and guide and support each other in this process. Then they will start the OMI program and will follow parallel instructions as the OMI group. The peer support will include five brief (30-minute) weekly meetings to support and encourage each other to continue practicing mindfulness and to complete the online intervention. Each week we will provide prompts and topics for participants to discuss and at the end of each meeting, participants will then complete a short, 5-10 minute post-meeting survey to assess the well-being and attitudes of their partner (see additional materials for meeting prompts and post-meeting survey questions). The first of these meetings will occur on Day 8, and subsequent weekly meetings during the intervention period will be scheduled based on the shared availability of both participants in each pair.
89572600|NCT04828291|Active Comparator|Active control receiving cognitive exercises|Instead of the OMI, this group will be receiving cognitive exercises in the intervention period.
89572601|NCT04820803|Experimental|Cetylpyridinium Chloride (CPC) 0,07%|patients who rinse with cetylpyiridinium chloride 0,07% mouthwash for 60 seconds
89572602|NCT04820803|Placebo Comparator|Placebo: Distilled water with the same flavor and coloring as the product to be evaluated|patients who rinse with distilled water mouthwash for 60 seconds
89572603|NCT03036787||moderate-early preterm infants|infant who births in 32 weeks to 37 weeks with family based intervention
88970656|NCT05125211|Experimental|Multiple Ascending Dose of GB001 recombinant peptide spray|Each subject will be dosed with oral spray of GB001 recombinant peptide ten times per day for four days. GB001 recombinant peptide will be administrated, and the dosage of each group is 0.108mg, 0.216mg and 0.432mg, respectively.
88970657|NCT04578873|Experimental|QPX7831 SAD Cohorts|oral, single ascending dose (or placebo)
88970658|NCT04578873|Experimental|QPX7831 MAD Cohorts|oral, multiple ascending dose (or placebo)
88970659|NCT00064519||Families with MI|"In conjunction with collaborators in Germany, we have established one of the largest collections of families with MI, comprising 1,406 individuals in 513 Western-European families. Based on this collection, our total genome scan and linkage analysis has identified a region on chromosome 14 with a significant linkage signal for myocardial infarction (LOD = 3.9, pointwise P = 0.00015, genome-wide P < 0.05)5. Preliminary results from an association study in a subset of these families has identified a small set of single nucleotide polymorphisms (SNPs) within candidate genes in this region as being suggestively associated with MI.~No drugs are to be administre"
88970660|NCT02967211|Experimental|Toujeo|Toujeo will be administered once daily in addition to non-insulin antidiabetic agents
88970661|NCT02967211|Active Comparator|"Standard of care commercially available basal insulin"|Lantus, Humulin Neutral Protamine Hagedorn (NPH), Levemir, and Tresiba or other basal insulin, including biosimilar insulin will be administered once or twice daily according to label in addition to non-insulin antidiabetic agents
88970662|NCT04573452||Normal pregnancy group|
88970663|NCT04573452||Placenta accreta at 24-32 weeks group|
88970664|NCT05113394|Experimental|Experimental arm|HDM sublingual Immunotherapy (HDM-SLIT) with Odactra® for 3 years to high-risk infants aged between 6 to 12 months at enrollment in preventing the development of asthma, assessed 1.5 years after discontinuation of treatment.
88970665|NCT05113394|Placebo Comparator|Placebo arm|Placebo administered sublingually for 3 years to high-risk infants aged between 6 to 12 months with outcome of asthma development assessed 1.5 years after discontinuation of treatment.
89572604|NCT03036787||extremely-very preterm infants|infant who births in 27 weeks to 32 weeks with family based intervention
89572605|NCT04827511||cohort group|80 children with disabilities like autism, ADHD, Down syndrome, deafness, phocomelia, dyslexia, different motor problems
89572606|NCT04827511||control group|81 healthy children, not known or diagnosed with a chronic disease of any kind
89572607|NCT04827667||Patients with lung cancer|In lung cancer patients with indication for bronchoscopy, bronchoalveolar lavage is performed to assess PD1-lymphocytes.
89572608|NCT04827667||Patients wiht interstitial lung disease|In patients with interstitial lung disease with indication for bronchoscopy, bronchoalveolar lavage is performed to assess PD1-lymphocytes.
89572609|NCT04827667||Patients with asthma|In patients with asthma with indication for bronchoscopy, bronchoalveolar lavage is performed to assess PD1-lymphocytes.
89572610|NCT04834609|Experimental|Injection with adipose tissue|Injection of freshly collected autologous adipose tissue
89572611|NCT04834531|Experimental|Zhuli capsule|Base on the standard medical treatment, the patients in this group will be used Zhuli capsule, 2 capsules (1.2 g) once, three time a day for 7 days.
89572612|NCT04834531|Placebo Comparator|Placebo|Base on the standard medical treatment, the patients in this group will be used placebo capsule, 2 capsules (1.2 g) once, three time a day for 7 days.
89572613|NCT04360135|Experimental|Preemptive acetominophen|Acetaminophen 975mg BID the day before surgery and again 30-60 minutes preoperatively
89572614|NCT04360135|Placebo Comparator|Standard of care|Placebo the day before surgery and acetaminophen 30-60 minutes preoperatively
89572615|NCT04827823||Group 1- Amalgam restorations|Multi-surface amalgam restorations performed by dental students and are in function for about 5 years.
89572616|NCT04827823||Group 2- Composite restorations|Multi-surface composite restorations performed by dental students and are in function for about 5 years.
89572617|NCT04827589|Experimental|Tirabrutinib|Participant will receive tirabrutinib twice daily in addition to their standard-of-care therapy for up to 8 weeks.
89572618|NCT04827589|Placebo Comparator|Placebo|Participants will receive placebo twice daily in addition to their standard-of-care therapy for up to 8 weeks.
89572619|NCT04827589|Experimental|Tirabrutinib, Open Label Extension|At Week 8, participants who have not discontinued the study drug will receive tirabrutinib twice daily in addition to their standard-of-care therapy for up to 16 weeks.
89572620|NCT04834687|Experimental|Rope-skipping group|Participants would be required to take part in an exercise plan, under the instruction and guidance of professional sports teachers.
89572621|NCT04834687|Experimental|Diet intervention group|Participants would be required to take part in a diet plan , including a high-fiber diet and time-restricted eating.
88970666|NCT04527861|Experimental|Single-incision Laparoscopic Surgery|Patients with colorectal cancer undergo single-incision laparoscopic surgery.
89572622|NCT04834687|Experimental|Combined intervention group|Participants will receive both rope-skipping and diet interventions at the same time.
89572623|NCT04834687|No Intervention|Control group|Participants would be required to maintain existing diet patterns and physical activity levels.
88970667|NCT04527861|Active Comparator|Conventional Laparoscopic Surgery|Patients with colorectal cancer undergo conventional laparoscopic surgery（3~5 ports）.
88970668|NCT00398749||Epoetin alfa|Epoetin alfa 40 000 IU once weekly variable treatment length
89572624|NCT04827277|Active Comparator|Reverse total shoulder replacement|Participants will receive a reverse total shoulder arthroplasty
89572625|NCT04827277|Active Comparator|Anatomic total shoulder replacement|Participants will receive an anatomic total shoulder arthroplasty
89572626|NCT02605837|Experimental|Oral Budesonide Suspension (OBS)|Participants will receive Oral Budesonide Suspension (OBS) 10 milliliter (ml) of 0.2 milligram per milliliter (mg/ml) twice daily up to 16 weeks.
89572627|NCT02605837|Placebo Comparator|Placebo|Participants will receive oral dose of 10 ml of placebo matched with the experimental drug twice daily up to 16 weeks.
89572628|NCT05619133|No Intervention|placebo|No PBM will be emitted from the device; dose: 0 J.cm-2
89572629|NCT05619133|Experimental|PBM High standard|A PBM high standard dose of 6.5 J.cm-2 with a wavelength of 850 nm, a pulse of 15 Hz and 8 ms and duty factor of 12%
89572630|NCT05619133|Experimental|PBM High wavelength|A PBM high dose of 6.5 J.cm-2 with a wavelength of 940 nm, a pulse of 15 Hz and 8 ms and duty factor of 12%
89572631|NCT05619133|Experimental|PBM High pulse|A PBM high dose of 6.5 J.cm-2 with a wavelength of 850 nm, a pulse of 100 Hz and 1.2 ms and duty factor of 12%
89572632|NCT05619133|Experimental|PBM High skin only|A PBM high standard dose of 6.5 J.cm-2 with a wavelength of 850 nm, a pulse of 15 Hz and 8 ms and duty factor of 12%, but in this case the participants will wear filtering googles which will not allow PBM from entering the eyes
89572633|NCT04819789|Experimental|Fermotein™ dry|Fermotein™ powder presented in the form of a porridge.
89572634|NCT04819789|Experimental|Fermotein™ wet|Fermotein™ wet presented in the form of a porridge.
89572635|NCT04819789|Experimental|Fermotein™ modified wet|Fermotein™ modified wet presented in the form of a porridge.
89572636|NCT04819789|Active Comparator|Mycoprotein|This mycoprotein product presented in the form of a porridge.
89572637|NCT04833985|Experimental|transesophageal echocardiography guidance|
89572638|NCT04833985|Experimental|intracardiac echocardiography guidance|
89572639|NCT04833985|Experimental|fluoroscopy only guidance|
89572640|NCT04827121|Active Comparator|Fascial iliac compartment block group|Patients in this group will recieve supra-inguinal fascial iliac compartment block after anesthesia induction.
89209076|NCT02593721|Active Comparator|Ibuprofen|A single daily 400 mg dose of oral Ibuprofen that can be increased depending on patient tolerance to a maximum dose of 1200 mg/day equally divided in 3 oral intakes of the drug every 8 hours during 6 continuous weeks.
89209077|NCT00798824|Active Comparator|Indwelling nasogastric tube placement|
89572641|NCT04827121|Active Comparator|Quadratus lumborum block group|Patients in this group will recieve quadratus lumborum block after anesthesia induction.
89572642|NCT04820101|Experimental|Every preterm newborns 26+0 -36+6 wGA with RDS needing surfactant therapy|Every preterm newborns 26+0-36+6 wGA who undergoes LISA procedure will receive sedation with dexmedetomidine in order to evaluate its efficacy in achieving pain control and comfort.
89572643|NCT04826887||Solep Arm|Use of SOLTIVE Thulium Laser for HoLEP (Holmium Laser Enucleation of the Prostate) procedure
89572644|NCT04826887||Control Arm|Use of Holmium Laser for HoLEP (Holmium Laser Enucleation of the Prostate) procedure
89572645|NCT04328311|Experimental|Active|Watermelon juice
89572646|NCT04328311|Other|Control|Low nitrate water.
89572647|NCT04428463|Active Comparator|tympanoplasty using fascia and cartilage|tympanoplasty under general anesthesia using fascia and cartilage witch is the gold standard for treating tympanic membrane perforations.
89572648|NCT04428463|Experimental|Tachosil|repair of tympanic perforations under local anesthesia using Tachosil patch.
89572649|NCT04819633||Study Group|30 patients within the reproductive ages (18-45 years) who were diagnosed with leiomyomas using transvaginal ultrasonography without any additional chronic, systemic or autoimmune disease, are not currently using any medical, hormonal, antiinflammatory treatments are included in this group.
89572650|NCT04819633||Control Group|30 healthy subjects within the reproductive ages (18-45 years) who visited the outpatient gynecological clinic for routine examination who do not have any additional chronic, systemic or autoimmune disease, who are not currently using any medical, hormonal, antiinflammatory treatments are included in this group.
89572651|NCT04819867|Experimental|propolis|propolis will be applied to the affected teeth
89572652|NCT04819867|Active Comparator|gluma desensitizer|Gluma desensitizer will be applied to the affected teeth
89572653|NCT04827043|Experimental|Quadratus lumborum block|QLB group: will receive 0.3ml/Kg bupivacaine 0.25% ( keeping in mind not to exceed the maximum recommended toxic dose of plain bupivacaine which is 2.5 mg/Kg & 3mg/Kg with epinephrine), single injection sonar guided.
89572654|NCT04827043|Experimental|Thoracic paravertebral block|PVB group: will receive 0.25ml/Kg/side of 0.375% bupivacaine with epinephrine 5ug/ml, yielding the same dose of bupivacaine of 1.875mg/ml at the level of T10 as a single injection sonar guided.
89572655|NCT02423343|Experimental|Galunisertib + Nivolumab (Cohort 1) Phase 1b|50 milligrams (mg) Galunisertib administered orally once daily (QD) on Day 1 through Day 14 of each 4-week cycle in combination with 3 milligrams per kilogram (3 mg/kg) nivolumab given intravenously (IV), every 2 weeks (Q2W), (Day 1 and Day 15). Participants may continue to receive study drug until discontinuation criteria are met.
89572656|NCT02423343|Experimental|Galunisertib + Nivolumab (Cohort 2) Phase 1b|50 mg Galunisertib administered orally twice daily (BID) on Day 1 through Day 14 of each 4-week cycle in combination with 3 mg/kg nivolumab given IV, Q2W,(Day 1 and Day 15). Participants may continue to receive study drug until discontinuation criteria are met.
89572657|NCT02423343|Experimental|Galunisertib + Nivolumab (Cohort 3) Phase 1b|80 mg Galunisertib administered orally BID on Day 1 through Day 14 of each 4-week cycle in combination with 3 mg/kg nivolumab given IV, Q2W, (Day 1 and Day 15). Participants may continue to receive study drug until discontinuation criteria are met.
89572658|NCT02423343|Experimental|Galunisertib + Nivolumab (Cohort 4) Phase 1b|150 mg Galunisertib administered orally BID on Day 1 through Day 14 of each 4-week cycle in combination with 3 mg/kg nivolumab given IV, Q2W,(Day 1 and Day 15). Participants may continue to receive study drug until discontinuation criteria are met.
88970669|NCT00398827|Experimental|Dexmedetomidine 0.5 mcg/kg load|
88970670|NCT00398827|Experimental|Dexmedetomidine 1 mcg/kg load|
88970671|NCT00398827|Placebo Comparator|Placebo|
89209078|NCT00798824|Active Comparator|Intermittent orogastric tube placement|
89209079|NCT00979095||Multiple hernia|Patients with more than 3 primary hernias
89572659|NCT02423343|Experimental|Galunisertib + Nivolumab - Non-small Cell Lung Cancer (NSCLC) Phase 2|150 mg Galunisertib administered orally BID for the first 14 days of each 4-week cycle in combination with 3 mg/kg nivolumab given IV, Q2W, (Day 1 and Day 15) of each 4-week cycle. Participants may continue to receive study drug until discontinuation criteria are met.
89572660|NCT02423343|Experimental|Galunisertib + Nivolumab - Hepatocellular Carcinoma (HCC) Phase 2|150 mg Galunisertib administered orally BID for the first 14 days of each 4-week cycle in combination with 3 mg/kg nivolumab given IV, Q2W, (Day 1 and Day 15) of each 4-week cycle. Participants may continue to receive study drug until discontinuation criteria are met.
89572661|NCT04909515|Experimental|naxitamab + GM-CSF + isotretinoin|8 cycles. Cycles 1+2 naxitamab + GM-CSF, cycles 3-5 naxitamab + GM-CSF + isotretinoin, cycles 6-8 isotretinoin
88970672|NCT02966977|Active Comparator|Conventional microbiological diagnostics|Conventional microbiological identification by culture plate (overnight cultures with subsequent bacterial/fungal identification).
88970673|NCT02966977|Experimental|Conventional plus mass spectrometry|Conventional microbiological identification by culture plate plus Direct mass spectrometry identification from urine sample. This additional diagnostic procedure is supplied additionally to conventional diagnostics.
88970674|NCT04518111||Unicompartmental Knee Arthroplasty (UKA)|Patients who underwent primary UKA with Oxford Partial Knee with the Microplasty® instrumentation for AMOA.
88970675|NCT04518111||High Tibial Osteotomy (HTO)|Patients who underwent Open Wedge HTO for AMOA.
88970676|NCT00065845|No Intervention|Abdominal Sacral Colpopexy with no Burch colposuspension|Abdominal sacral colpopexy is performed through a laparotomy approach.
88970677|NCT00065845|Experimental|Abdominal Sacral Colpopexy with Burch Colposuspension|The Burch colposuspension procedure entails the retropubic placement of at least two stitches in the vaginal tissue lateral to each side of the urethra, and suspension of these stitches from Cooper's ligament (the iliopectineal line at the superior aspect of the posterior pubic bone).
88970678|NCT04438044|Experimental|ICP-022|150mg,QD
89028980|NCT05137327|Experimental|Classroom Behavior Support (CBS) Condition|"Consultants follow the problem-solving process used in the comparison condition and attempt to address barriers to integrity using the knowledge, skills, beliefs, or stress components in the CBS manual. Consultants conduct a Values Interview, so teacher values can be used in the individual goal setting and decision making process. Consultants are trained to (a) incorporate the teacher's values into the problem-solving process, (b) elicit change talk from teachers using techniques borrowed from Motivational Interviewing, and (c) engage in Socratic questioning and cognitive restructuring for beliefs that may be barriers to integrity (e.g., should statements). Enhanced performance feedback involves highlighting connections between teacher integrity and child outcomes and using this as a catalyst for a knowledge, skills, beliefs, or stress component. Consultants use change rulers to elicit motivation to achieve the stated goals."
89572662|NCT02605447|Experimental|SYNERGY stent + 3 month DAPT|Subject with implantation of at least one SYNERGY stent within the preceding 3 calendar days that takes the required dual antiplatelet therapy (3 months of P2Y12 inhibitor, 15 months of aspirin)
89033184|NCT02943551|Other|Providers|"Physicians, pediatric nurse practitioners and physician assistants (referred to as providers from here forward) will be recruited from 20 practices, with a maximum of four providers participating from a single practice, for a maximum of 80 providers.~Providers will receive an online tutorials, interactive group webinars, simulated booster sessions as well as feedback reports."
89209080|NCT00979095||Control group|Patients without hernias
89209081|NCT00798902|Active Comparator|Control|Iliac Crest Autograft
89209082|NCT00798902|Experimental|Prefix 150|Prefix (AMPLEX) B2A Peptide Enhanced Ceramic Granules
89572663|NCT05617729|Placebo Comparator|Saline|this treatment consists of sterile saline that is applied to the nares using a swab
89572664|NCT05617729|Active Comparator|Povidone-iodine based gel|this treatment consists of a Povidone-Iodine based gel that is applied to the nares using a swab
89572665|NCT02485899|Experimental|BMN190 recombinant human tripeptidyl peptidase-1 (rhTPP1)|All 190-202 study subjects administered BMN 190 300 mg by continuous Intracerebroventricular (ICV) infusion at a rate of 2.5 mL/hour for approximately 4 hours) every 14 days.
89572666|NCT04362553||Adults|Adults scheduled to receive a TTE (Trans-esophogeal echocardiogram)
89572667|NCT05619055||neonate with necrotizing enterocolitis|premature infants diagnosed as necrotizing enterocolitis
89572668|NCT05619055||neonate without necrotizing enterocolitis|premature infants without necrotizing enterocolitis
89572669|NCT04818931|Experimental|Antibiotics|Cefazolin 2 g or clindamycin 900 mg in case of penicillin allergy
89572670|NCT04818931|No Intervention|No antibiotics|
89572671|NCT02423109|Experimental|fanfilcon A|Each subject randomized to wear either the test or control as a matched pair and cross over to the second matched pair.
89572672|NCT02423109|Active Comparator|enfilcon A|Each subject randomized to wear either the test or control as a matched pair and cross over to the second matched pair.
89572673|NCT02420691|Experimental|Treatment (ribociclib)|Patients receive ribociclib PO QD on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89572674|NCT02406651|Experimental|F-652 and systemic coritcosteroids|Subjects will be dosed once a week for four weeks with Recombinant Human Interleukin-22 IgG2-Fc (F-652). Dosing will be concurrent with systemic corticosteroids.
89572675|NCT02406261|Experimental|Cohort A|"500 microgram (mcg) midazolam, single oral dose on Days 1, 17, and 35;~20 mg simvastatin, single oral dose on Days 2 and 36;~250 microgram (mcg) midazolam, intravenous (IV) on Days 3 and 37;~50 mg lanabecestat, single oral dose on Day 4;~50 mg lanabecestat, single oral dose, Days 10 to 37"
89572676|NCT02406261|Experimental|Cohort B|"5 mg donepezil, single oral dose on Day 1, Period 1;~50 mg lanabecestat, single oral dose Days 1 to 43, Period 2;~5 mg donepezil, single oral dose on Day 28, Period 2"
89572677|NCT04421001|Experimental|I-Port™*(Medtronic) use Arm|Patients will administer insulin via iport system. I-Port™* (Medtronic), infusion set, dedicated for insulin deliery for 72 hours.
89572678|NCT04421001|Active Comparator|Insulin Pen Injections|Patients will administer insulin via injections as usual
89572679|NCT04420767|Experimental|tDCS and Go-No Go task|"Certain randomly assigned participants will receive tDCS to the DLPFC for 8 daily 20-minute sessions, with a TDCS amplitude of 2 mAmps.~During the tDCS session, individuals will perform a 10-min computerized Go-No Go task"
89572680|NCT04420767|Sham Comparator|Sham brain stimulation and Go-No Go task|"Certain randomly assigned participants will receive Sham Stimulation to the DLPFC for 8 daily 20-min sessions. The Sham stimulation is an inactive form of stimulation.~During the sham brain stimulation session, individuals will perform a 10-min computerized Go-No Go task"
89572681|NCT02405091|Experimental|Dose Group 1|Fixed dose of NBI-98854 administered once daily for 48 weeks
89572682|NCT02405091|Experimental|Dose Group 2|Fixed dose of NBI-98854 administered once daily up to 48 weeks
89572683|NCT02485353|Other|Vosaroxin and Cytarabine|
89572684|NCT02603107|Experimental|B/F/TAF|"Randomized Phase: Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) for at least 48 weeks, without regard to food.~Extension Phase: After Week 48, participants in countries where B/F/TAF is not available will be given the option to receive B/F/TAF for up to 96 additional weeks or until the product becomes accessible to participants through an access program, or until Gilead Sciences elects to discontinue the study in that country, whichever occurs first."
89572685|NCT02603107|Experimental|Stay on Baseline Regimen (SBR)|"Randomized Phase: Participants remained on current antiretroviral (ARV) regimen consisting of ritonavir (RTV)-boosted or cobicistat (COBI)-boosted atazanavir (ATV) or darunavir (DRV), plus either emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) or abacavir/lamivudine (ABC/3TC) for at least 48 weeks with food.~Extension Phase: After Week 48, participants in countries where B/F/TAF is not available will be given the option to receive B/F/TAF for up to 96 additional weeks or until the product becomes accessible to participants through an access program, or until Gilead Sciences elects to discontinue the study in that country, whichever occurs first."
89572686|NCT04826263|Experimental|ESWT Group|The patients in the ESWT group will receive ESWT treatment and a home exercise program.
89572687|NCT04826263|Experimental|LLLT Group|The patients in the LLLT Group will receive LLLT treatment and a home exercise program.
89572688|NCT02484729|Experimental|AZD9977 oral suspension, single doses|In Part A up to 10 cohorts with single ascending doses with AZD9977 as oral suspension. In Part B AZD9977 as oral suspension in IntelliCap® capsule
89572689|NCT02484729|Placebo Comparator|Placebo, oral suspension, single doses|In Part A up to 10 cohorts with single doses with matching placebo to AZD9977
89572690|NCT02484729|Experimental|AZD9977, oral solution, single dose|In Part B, of oral solution of AZD9977 will be used as reference
89572691|NCT02601625|Experimental|Anifrolumab 300 mg SC injections|300 mg single dose anifrolumab delivered as 2 separate 1 mL SC injections administered serially
89572692|NCT02601625|Experimental|Anifrolumab 300 mg IV infusion|300 mg single dose anifrolumab delivered as an IV infusion over 30 minutes
89572693|NCT02601625|Experimental|Anifrolumab 600 mg SC infusion|600 mg single dose anifrolumab or placebo delivered as 4 mL SC by infusion pump
89572694|NCT02601625|Placebo Comparator|Placebo 300 mg SC injections|300 mg single dose placebo delivered as 2 separate 1 mL SC injections administered serially
89572695|NCT02601625|Placebo Comparator|Placebo 300 mg IV infusion|300 mg single dose placebo delivered as an IV infusion over 30 minutes
89572696|NCT02601625|Placebo Comparator|Placebo 600mg SC infusion|600 mg single dose placebo delivered as 4 mL SC by infusion pump
89572697|NCT04819087|Experimental|Patients|Patients with Pelvic Floor Dysfunction Related Temporamandibular Joint Problems and Tinnitus
89572698|NCT04819165||COVID-19 patients|Patients with invasive mechanical ventilation admitted to the Intensive Care Unit (UCI) of the Anchorena San Martín Clinic, San Martín, Buenos Aires with confirmed COVID-19 diagnosis (positive polymerase chain reaction in nasopharyngeal swab).
89572699|NCT04819165||non COVID-19 patients|Patients with invasive mechanical ventilation admitted to the Intensive Care Unit (UCI) of the Anchorena San Martín Clinic, San Martín, Buenos Aires with negative COVID-19 diagnosis (positive polymerase chain reaction in nasopharyngeal swab).
89572700|NCT04819321|Experimental|CoolSculpting® System|A treatment is comprised of timed segments of cooling and heating; a vacuum treatment may include an optional massage
89572701|NCT03036553||Chronic musculoskeletal pain|"(i) men / women over the age of 18 (ii) participants with musculoskeletal pain (pain intensity of 3 or more on a numerical scale of pain 0-10) will be included in this study, among all of the following conditions: pain around the axial skeleton (neck, lower back And / or pelvis) or peripheral joints (shoulder, elbow, wrist, knee and / or ankle). We included people with clinical diagnoses of chronic pain (shoulder pain, neck pain, whiplash disorder, temporomandibular joint disorders, pelvic pain syndrome, ankle pain and epicondylalgia), non-specific low back pain, fibromyalgia, chronic fatigue syndrome and those with a radiological diagnosis of osteoarthritis.~(iii) duration of symptoms: more than 3 months."
89572702|NCT04834141||Kyphotic Group|"Participants with kyphosis angle ≥ 40 degrees joined the kyphosis group. FlexiCurve ruler method was used, which is a reliable tool for measuring kyphosis height and kyphosis index. In addition, it is non-invasive, inexpensive, and easy to use in a clinical setting.~Static balance Assessment:~Objective evaluation of the static balance evaluated by the NeuroCom Balance Manager System ® static posturography device (45 × 45 cm NeuroCom® System Version 8.1 Balance Manager International, Clackamas, Oregon, USA)"
89572703|NCT04834141||Control Group|"Participants with kyphosis angle < 40 degrees for the control group. FlexiCurve ruler method was used, which is a reliable tool for measuring kyphosis height and kyphosis index. In addition, it is non-invasive, inexpensive, and easy to use in a clinical setting.~Static balance Assessment:~Objective evaluation of the static balance evaluated by the NeuroCom Balance Manager System ® static posturography device (45 × 45 cm NeuroCom® System Version 8.1 Balance Manager International, Clackamas, Oregon, USA)"
89572704|NCT04826497|Experimental|Nicorandil|Patients who received intracoronary and intravenous nicorandil before and after reperfusion with primary percutaneous coronary intervention
89572705|NCT04826497|Placebo Comparator|Placebo （normal saline）|Patients who received intracoronary and intravenous placebo before and after reperfusion with primary percutaneous coronary intervention
89572706|NCT04834219||On-pump CABG|Patients with an on-pump indication by the cardiovascular surgery department will be included in the study.
89209083|NCT00979173|Experimental|AC480|Patients who are not on enzyme inducing anti-epileptic drugs (EIAEDs) and are scheduled to undergo salvage surgical resection treated with preoperative AC480 at 300 mg BID followed by post-surgical AC480 at 300 mg BID.
89572707|NCT04834219||Off-pump CABG|Patients with an off-pump indication by the cardiovascular surgery department will be included in the study.
89572708|NCT04819243|Experimental|Atezolizumab+Talazoparib|"st line treatment~Palbociclib 125mg po D1-21~AI : Prescribed as per local guideline~GnRH agonist: Prescribed as per local guideline~nd line treatment~Talazoparib 1mg po~Atezolizumab 1200mg IV (3week)"
89572709|NCT04819243|Experimental|Talazoparib|"st line treatment~Palbociclib 125mg po D1-21~AI : Prescribed as per local guideline~GnRH agonist: Prescribed as per local guideline~nd line treatment - Talazoparib 1mg po"
89572710|NCT05618821|Experimental|ICG|Laparoscopic gastrectomy Group with the use of near-infrared imaging (ICG group)
89572711|NCT05618821|Active Comparator|Non-ICG|Laparoscopic gastrectomy Group without the use of near-infrared imaging (Non-ICG group)
89572712|NCT04818619||chronic myeloid leukemia patients|
89572713|NCT04818619||Healthy individuals|
89572714|NCT04818697||Patients with heart rhythm disorders|Having been diagnosed with heart rhythm disorders such as atrial fibrillation, atrial tachycardia, ventricular tachycardia, and ventricular extrasystole
89572715|NCT04818697||Healthy individuals|Healthy individuals without chronic disease
89572716|NCT02601469|Experimental|DSXS1503|administered twice daily for 28 days in patients with moderate to severe plaque psoriasis.
88970679|NCT00066001|Placebo Comparator|1, 2, 3, 4|The 4 arms of the study are based on the treatment groups: 1. scaling and root planing alone (SRP); 2. SRP plus repeated professional supragingival plaque removal; 3. SRP + systemically administered metronidazole; 4. SRP + repeated professional supragingival plaque removal + systemically administered metronidazole.
88970680|NCT04432779||Women tested positive to SARS-CoV-2 during pregnancy|"All women who had a positive nasal swab or a positive serology during pregnancy or at delivery are included.~Follow up end at 1 month post delivery."
88970681|NCT04432779||Women tested negative to SARS-CoV-2 during pregnancy|"All women who had a positive nasal swab or a positive serology during pregnancy or at delivery are included.~No follow up after delivery."
88970682|NCT04432779||Newborns from women tested positive|"Newborns born to mothers who had a positive nasal swab or a positive serology during pregnancy or at delivery and who consented the follow up study.~Follow up end at 3 years of age."
89028981|NCT05137327|Active Comparator|Standard Problem Solving Comparison Condition|Consultation in the comparison condition follows a 5-step problem solving approach and provide brief performance feedback procedures that mirror (in duration, content, and process) best practice procedures (Gilbertson et al., 2007; Noell et al., 1997). The guiding principles for this condition are that the performance feedback portion of the session should be limited to 5 to 10 minutes and unless the teacher initiates discussion of other content, the problem solving should remain student-focused, rather than teacher-focused. Discussion on teacher values and beliefs, and attempts to facilitate change talk, are contra-indicated. If the teacher initiates discussion of knowledge, beliefs, or skills, the consultant may answer questions, but may not use strategies associated with Motivational Interview or Cognitive-Behavioral Therapy (CBT) or strategies in CBS condition. We have separate scripts and checklists for each condition.
89028982|NCT05135715|Experimental|RC48-ADC|Participants will receive RC48-ADC every 2 weeks (Q2W) until investigator assessed loss of clinical benefit, unacceptable toxicity, investigator or participant decision to withdraw from therapy, or death (whichever occurs first).
89572717|NCT05618743|No Intervention|Control Group|Periodontally and systemically healthy participants (Control group)
89028983|NCT05122325|Experimental|Intervention group 1: Transcutaneous tibial nerve stimulation (TTNS)|"Transcutaneous application of low frequency electrical current over the tibial nerve TENS® EMS NMS60 for a 30 minutes session, twice a week.~Placing a small electrode 3 fingers up to the internal malleolus and 1 cm posterior (adjusting its placement with a point finder or testing with low frequencies of 2-3 Hz). A large electrode placed in the calcaneus."
89572718|NCT05618743|Experimental|Periodontitis without Cardiovascular disease|Periodontitis participants without cardiovascular disease
89572719|NCT05618743|Experimental|Periodontitis with cardiovascular disease|Periodontitis participants with cardiovascular disease
89572720|NCT04826107|Experimental|Part 1: Dose-finding stage|Patients with HER2-positive advanced or metastatic gastric cancer after receiving 1st-line treatment will be treated with DP303c injection at 2.0 mg/kg，2.5 mg/kg or 3.0 mg/kg every 3 weeks to determine the recommended dose.
89572721|NCT04826107|Experimental|Part 2: Cohort A|Patients with HER2-positive advanced or metastatic gastric cancer after receiving 1st-line treatment will be treated with DP303c injection at the recommended dose.
89572722|NCT04826107|Experimental|Part 2: Cohort B|Patients with HER2-positive advanced or metastatic gastric cancer after receiving ≥ 2nd-line treatment will be treated with DP303c injection at the recommended dose.
89572723|NCT04826107|Experimental|Part 2: Cohort C|Patients with advanced or metastatic gastric cancer with HER2 low expression after receiving ≥1st-line treatment will be treated with DP303c injection at the recommended dose.
89572724|NCT04826107|Experimental|Part 2: Cohort D|Patients with advanced or metastatic gastric cancer with HER2 low expression or HER2-positive expression after receiving ≥1st-line treatment will be treated with DP303c injection combined with PD-1/PD-L1 treatment.
89572725|NCT05617417|Other|The women with stress urinary incontinence administered injectable platelet-rich fibrin|Injectable platelet-rich fibrin was prepared by centrifuging venous blood samples from women with stress urinary incontinence. The obtained autologous material was injected into the anterior vaginal wall, approximately 1.5 cm below the urethral meatus, without applying a local anesthetic. The procedure was repeated for the same patient three times with an interval of one month. The severity of urinary incontinence was evaluated by filling out questionnaires before and after the procedure.
89572726|NCT02604589|Placebo Comparator|PCA only|Procedure: Standard of care - Intravenous Patient Controlled Anesthesia (PCA) 0.1 mg hydromorphone hydrochloride, every 6 minutes. Boluses of 0.1 mg IV hydromorphone for uncontrolled pain up to a maximum of 2.5 mg/hr.
89572727|NCT02604589|Experimental|Bupivicaine 0.25% (LOW DOSE)|"Standard PCA infusion 0.1 mg hydromorphone hydrochloride, every 6 minutes. Bolus 0.1 mg hydromorphone for uncontrolled pain up to a maximum of 2.5 mg/hr.~Infusion catheter placement. Bupivacaine 0.25% 4 ml/hr total for dual chamber catheter."
89572728|NCT02604589|Experimental|Bupivicaine 0.5% (HIGH DOSE)|"Standard PCA infusion 0.1 mg hydromorphone hydrochloride, every 6 minutes. Bolus 0.1 mg hydromorphone for uncontrolled pain up to a maximum of 2.5 mg/hr.~Infusion catheter placement. Bupivacaine 0.5% 4 ml/hr total for dual chamber catheter."
89572729|NCT04825249|Experimental|The traditional suture bridge technique group|For the TSB group, if the tear type is confirmed to be medium-sized during the operation, TSB technique will be performed
89572730|NCT04825249|Experimental|The modified suture bridge technique group|For the MSB group, if the tear type is confirmed to be medium-sized during the operation, TSB technique will be performed
89572731|NCT04818307|Experimental|Macquarie Injury Management group|
89572732|NCT04818307|Active Comparator|Mulligan Mobilization with Movement|
89572733|NCT02601001|Placebo Comparator|Placebo|Participants received placebo tablets twice a day (BID) in dosing period 1 (days 1 to 8) and in dosing period 2 (days 20 to 27).
89572734|NCT02601001|Experimental|Omecamtiv mecarbil 25 mg / 37.5 mg|Participants received omecamtiv mecarbil 25 mg BID in dosing period 1 (days 1 to 8) and 25 mg or 37.5 mg BID in dosing period 2 (days 20 to 27) based on their day 8 predose omecamtiv mecarbil plasma concentration (Cpredose): If day 8 Cpredose was < 200 ng/mL, participants received 37.5 mg BID; if day 8 Cpredose was ≥ 200 ng/mL or a day 8 PK value was not available participants continued to receive 25 mg BID.
89572735|NCT02601001|Experimental|Omecamtiv mecarbil 25 mg / 50 mg|Participants received omecamtiv mecarbil 25 mg BID in dosing period 1 (days 1 to 8) and 25 mg or 50 mg BID in dosing period 2 (days 20 to 27) based on their day 8 predose omecamtiv mecarbil plasma concentration (Cpredose): If day 8 Cpredose was < 200 ng/mL, participants received 50 mg BID; if day 8 Cpredose was ≥ 200 ng/mL or a day 8 PK value was not available participants continued to receive 25 mg BID.
89572736|NCT04825405|Active Comparator|The use of the active Tip Stim device to achieve coordinated of the hand.|Influence of the tested position and the use of the active TipStim Glove device on the improvement of motor coordination and grip force in patients after a stroke.
89572737|NCT04825405|Placebo Comparator|The use of the passive Tip Stim device to achieve coordinated of the hand.|Influence of the tested position and the use of the passive TipStim Glove device on the improvement of motor coordination and grip force in patients after a stroke.
89572738|NCT05618665|Experimental|Intervention Group - Children and parents|Asthma education which consisted of asthma disease, its symptoms, diagnosis, treatment, risk factors, use of medication, use of medication apparatus, vaccination treatment, follow-up of the asthmatic child, precautions to be taken in prevention, what to do during an attack, what to do for adaptation to the disease and things to do in school life was prepared and presented in 40 minutes. The booklets about education would be given at the end of the education.
89572739|NCT05618665|Experimental|Intervention Group - Children|Asthma education which consisted of asthma disease, its symptoms, diagnosis, treatment, risk factors, use of medication, use of medication apparatus, vaccination treatment, follow-up of the asthmatic child, precautions to be taken in prevention, what to do during an attack, what to do for adaptation to the disease and things to do in school life was prepared and presented in 40 minutes. The booklets about education would be given at the end of the education.
89572740|NCT05618665|No Intervention|Control group|No intervention was applied to the control group.
89572741|NCT04818151||ESRD patients with VTE treated with warfarin|Warfarin as primary treatment of VTE
89572742|NCT04818151||ESRD patients with VTE treated with apixaban|Apixaban as primary treatment of VTE
89572743|NCT04817527|Experimental|Edaravone Dexborneol|
89572744|NCT04817527|No Intervention|conventional therapy|conventional therapy of acute ischemic stroke after Endovascular Therapy based on Chinese guidelines for endovascular therapy
89572745|NCT01616329||Cases and Controls|Cases: alloantibody formers Controls: non-alloantibody formers
89572746|NCT05617339|Experimental|"Personalised internet-based treatment I am."|Need-based internet-based treatment
89572747|NCT05617339|No Intervention|Treatment As Usual|Control group, Treatment in primary care which is medical treatment
89572748|NCT04816279||First Audit cycle|
89572749|NCT04816279||Second Audit cycle|
89572750|NCT02604199|Placebo Comparator|PBO Low Dose|0.9% normal saline, once every 4 weeks for 4 doses plus daily oral entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg) throughout the study period
89572751|NCT02604199|Placebo Comparator|PBO High Dose|0.9% normal saline, once every 4 weeks for 4 doses plus daily oral entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg) throughout the study period
89572752|NCT02604199|Experimental|ARC-520 Injection 1 mg/kg|Intravenous ARC-520 at 1.0 mg/kg, once every 4 weeks for 4 doses plus daily oral entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg) throughout the study period
89572753|NCT02604199|Experimental|ARC-520 Injection 2 mg/kg|Intravenous ARC-520 at 2.0 mg/kg, once every 4 weeks for 4 doses plus daily oral entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg) throughout the study period
89572754|NCT04807699||Total participants|3500 participants that will have their medical forms checked
89572755|NCT04817215|Experimental|Patients who are Drug naïve or diet controlled|
89572756|NCT04817215|Experimental|Patients on Metformin only|
89572757|NCT04817215|Experimental|Patients on two or three oral glucose-lowering agents|
89572758|NCT04817059|Experimental|Head mold on|
89572759|NCT04817059|No Intervention|Head mold off|
89572760|NCT04816903|Experimental|Symptomatic vaginitis patients|All participants will be enrolled according to their complaints, All will be tested by the Gyni system, Only in the second group the physician will be unblinded to the Gyni results.
89572761|NCT04816045|Active Comparator|Intervention|Electrochemotherapy with bleomycin
89572762|NCT04816045|Active Comparator|Control|Electroporation with saline
89572763|NCT04816123|Experimental|[14C]Donafenib|
89572764|NCT04807465|Other|G-Premio universal adhesive used in smoker participants|Participants who smoke at least 10 cigarettes per day
89572765|NCT04807465|Other|G-Premio universal adhesive used in non-smoker participants|participants who non-smoke have never smoked before
89572766|NCT04807621|Active Comparator|Platelets|Patients recieve, in the presence of significant bleeding and pathological results of ROTEM analysis, a platelet transfusion.
89572767|NCT04807621|Experimental|Fibrinogen|Patients recieve, in the presence of significant bleeding and pathological results of ROTEM analysis, fibrinogen concentrate.
89572768|NCT04807543|Active Comparator|study group|17-hydroxyprogesterone caproate (17P) (250 mg in castor oil, 1 mL total volume)intramuscular injection
89572769|NCT04807543|Placebo Comparator|control group|castor oil, 1 mL total volume intramuscular injection
89572770|NCT05616559||Patient cohort (n=800)|All participants included will contribute with basic clinical, cognitive, psychometric, genetic and biochemical data.
89572771|NCT05616559||Subcohort I (n=600)|Patients in Subcohort I undergo MRI and EEG in addition to expanded clinical, cognitive, psychometric, and biological data.
89572772|NCT05616559||Subcohort II - drug naive PET subgroup (n=60)|A subgroup of Subcohort I, including only patients who at inclusion do not receive any pharmacological treatment for their depression, undergo in addition Positron Emission Tomography imaging with [11C]-UCB-J for measurement of cerebral synaptic density.
89572773|NCT04815811|Experimental|Children suffering from acute inflammatory processes.|"The study population will consist of male and female children, aged from 6 months to 7 years old, admitted to the hospital for one of the three following types of acute inflammatory processes:~Urinary tract infection caused by Escherichia coli~Pneumonia with pleural effusion caused by Streptococcus pneumoniae~Sepsis"
89572774|NCT04815811|Other|Control group|Male and female children, aged from 6 months to 7 years old, admitted to the hospital for a scheduled operation for a non-inflammatory pathology.
89572775|NCT02600845|Experimental|ACCU-CHEK|All participants will utilize ACCU-CHEK Connect Diabetes Management System containing three primary components: ACCU-CHEK Aviva Connect Blood Glucose Monitoring System intended to be used for the quantitative measurement of glucose, ACCU-CHEK Connect Diabetes Management App indicated as an aid in the treatment of diabetes, and ACCU-CHEK Connect Online Diabetes Management System indicated for use by persons with diabetes or by healthcare professionals in the home or in healthcare facilities.
89572776|NCT04427995||Oen Angle Glaucoma|• Patients aged 30-95 with primary or pigmentary / pseudoexfolliative / juvenile / normal pressure open angle glaucoma or combined mechanism glaucoma with IOP of 10-40 mmHg on maximum tolerated medical therapy who are either progressing, above IOP target, or poorly adherent or tolerant to medical therapy. Phakic or pseudophakic eyes and previous laser trabeculoplasty will be included.
89572777|NCT04798105|Sham Comparator|tDCS sham|Transcranial direct current stimulation (tDCS) of the dorsolateral prefrontal cortex (dlPFC) in sham mode.
89028984|NCT05122325|Experimental|Intervention group 2: Genital vibration|Women will be instructed in the use of the Ferticare 2.0® vibrator with a frequency of 70 Hz, amplitude of 1.5 mm. It will be recommended to gradually increase its use over time, with a limit of 30 minutes a day.
89028985|NCT05122325|Sham Comparator|Control group|A sham of TTNS intervention with the device turned off, twice a week.
89572778|NCT04798105|Active Comparator|tDCS anodal|Transcranial direct current stimulation (tDCS) of the dorsolateral prefrontal cortex (dlPFC) in anodal/excitatory mode.
89572779|NCT04798183||Healthy participants|
89572780|NCT04798183||Amyotrophic Lateral Sclerosis with bulbar involvement patients|
89572781|NCT04806763|Experimental|Menicon Z Night|The experimental group is allocated to wear Menicon Z Night orthokeratology contact lenses for two years
89572782|NCT04806763|Active Comparator|Glasses|The active comparator includes a group that was allocated to wear distance, single-vision glasses for two years
89572783|NCT04797949|Active Comparator|Randomized to USPSTF Criteria|Women randomized to knowing their risk of preeclampsia and therefore, candidates for low dose aspirin.
89572784|NCT04797949|Active Comparator|Randomized to Universal aspirin receipt|Women randomized to receiving low dose aspirin without knowing their risk status.
89572785|NCT04797793|Experimental|Adapalene gel 0.1%|The study medication will be self-applied topically, on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
89572786|NCT04797793|Active Comparator|Differin® Gel (Adapalene 0.1%, Galderma)|The study medication will be self-applied topically, on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
89572787|NCT04797793|Placebo Comparator|Placebo Control|The study medication will be self-applied topically, on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
89572788|NCT04806529|Experimental|Adjuvanted SARS-CoV-2 Subunit vaccine (aCoV2)|The experimental group will receive a 2-dose series of 0.5 mL of the study vaccine, administered intramuscularly (IM) into the deltoid muscle, preferably in the non-dominant arm, Day 1 and Day 29 (e.g. 28 days apart)
89572789|NCT04806529|Placebo Comparator|The Comparator Group - Placebo|The comparator group will receive a 2-dose series of 0.5 mL of the study vaccine, administered intramuscularly (IM) into the deltoid muscle, preferably in the non-dominant arm, Day 1 and Day 29 (e.g. 28 days apart)
89572790|NCT04796857|Experimental|Tislelizumab in Combination With Lenalidomide|On the day of tislelizumab infusion, lenalidomide should be taken 30 minutes after the end of tislelizumab infusion
89572791|NCT04796623|Experimental|TQB3616 capsules combined with fulvestrant injection|TQB3616 capsules 180 mg given orally, once daily in 28-day cycle. Fulvestrant injection was given at a fixed dose of 500mg on day 1, day 15 of the first cycle and day 1 of each subsequent cycle, and each cycle is 28 days.
89572792|NCT04815421|Experimental|the paste group|Patients in the paste group were treated with Nanxing paste on the affected region include shoulder, neck or back and no more than 3 pieces. The therapy duration was 6 days.
88811135|NCT04199117|Experimental|Incentive,Tailored,Care Manage,Standard Treatment|Participants randomly assigned to this condition will have access to incentives for completing a first smoking cessation counseling call up to 4 times over 2 years, will receive 5 tailored letters promoting use of smoking cessation treatment over 2 years, will receive 5 Tobacco Care Management support and motivational encouragement calls over 2 years, and will have access to standard smoking cessation treatment (referral to the state tobacco quitline and/or their primary care provider) over 2 years.
89028986|NCT05111002|Experimental|Lefamulin alone|Lefamulin 600mg tablet orally twice daily for 7 days
89572793|NCT04815421|Experimental|the meridian group|Patients in the meridian group were treated with dredging the same side Hand yang meridian techniques
89572794|NCT04815265|Experimental|Experimental group|Participants in the experimental group received remimazolam for sedation
89572795|NCT04815265|Active Comparator|Control group|participants in the control group received dexmedetomidine for sedation
89572796|NCT04796389|Experimental|Recorded music|Recorded music intervention
89572797|NCT04796389|No Intervention|Control|Standard of care
89028987|NCT05111002|Experimental|Doxycycline followed by lefamulin|Doxycycline 100mg tablet orally twice daily for 7 days followed by lefamulin 600mg tablet orally twice daily for 7 days
89572798|NCT04806841|Experimental|Intervention group|Participants will have access to 4 weekly supervised training sessions for 3 months. The intervention group will also take part in 3 group meetings (behavioral intervention) and will receive follow-up phone calls from month 4 to 6.
89572799|NCT04806841|Experimental|Control group|Participants will have access to 4 weekly supervised training sessions for 3 months without any behavioral intervention.
89572800|NCT05616481|Active Comparator|Laparoscopic Burch|The original procedure will be performed
89572801|NCT05616481|Active Comparator|Laparoscopic modefied Burch procedur (TOT-like)|Sutures on the pubocervical fascia are placed at the level of the attachment of the arcus tendinous fascia pelvis and the pubourethral ligament.
89572802|NCT02599129|Experimental|Secukinumab|300 mg subcutaneous injections
89572803|NCT02599129|Placebo Comparator|Placebo|matching placebo subcutaneous injections
89572804|NCT04796077|Experimental|Pop-Up Book|Patients read an interactive pop-up book about general anesthesia induction in addition to standard consultation with an anesthesia provider.
89572805|NCT04796077|No Intervention|Standard Care|Patients received standard consultation with an anesthesia provider (standard care).
89572806|NCT04806061|Experimental|sodium bicarbonate|iv sodium bicarbonate 8.4%
89572807|NCT04806061|Experimental|control|standard care
89033185|NCT02943551|Other|Parents|"The number of parents who participate will depend on the number of providers who agree to participate at each of the 20 practices. The total could range from a minimum of 1800 parents to a maximum of 7200 parents.~Throughout the study, parents at participating practice sites will be offered the opportunity to complete a DART Parent Survey after their child's visit."
89033186|NCT03279276|Experimental|Primoris|Total hip arthroplasty surgery using a Primoris® femur component, Exceed ® acetabular cup + E-poly liner ®.
89033187|NCT03279276|Active Comparator|Echo|Total hip arthroplasty surgery using a standard uncemented Echo® femur component, Exceed ® acetabular cup + E-poly liner ®.
89572808|NCT04805749|Experimental|Osteopathic manipulation|Spinal Mobilisation / Cranial Osteopathy therapy / Circulatory Techniques / Visceral osteopathic therapy
89572809|NCT04814797||"CF children with gas trapping"|"CF children with gas trapping will be defined by a ratio between the difference of functional residual capacity (FRC) obtained by plethysmography (FRCpleth) and FRC obtained by helium dilution method (FRCHe) divided by the FRCpleth of >10%"
89572810|NCT04814797||"CF children without gas trapping"|"CF children without gas trapping will be defined by a ratio between the difference of the functional residual capacity (FRC) obtained by plethysmography (FRCpleth) and FRC obtained by helium dilution method (FRCHe) divided by the FRCpleth of ≤10%"
89572811|NCT04814641||Infants with hypophosphatemia|Infant less than 3 months with severe bronchiolitis admitted in a pediatric intensive care unit, with hypophosphatemia in the first 5th days
89572812|NCT04814641||Infants without hypophosphatemia|Infant less than 3 months with severe bronchiolitis admitted in a pediatric intensive care unit, without hypophosphatemia
89572813|NCT04814719|Experimental|Pentosan Polysulfate Sodium|Pentosan Polysulfate Sodium (PPS) at Dose and frequency selected in Stage 1 of Parent Study for 6 weeks
89572814|NCT04814719|Placebo Comparator|Placebo|Placebo for 6 weeks
89572815|NCT04795609|Active Comparator|Interventional group|Early mobilization postoperative programme based on supervised aerobic exercise, resistance and flexibility training or to standard rehabilitation care
89572816|NCT04795609|No Intervention|Control group|Bed restriction strategy for 5 days
89572817|NCT04805905||Skin graft|
89572818|NCT04805905||Local flap|
89572819|NCT04805827|Experimental|Gabapentin|1 tablet contains 600 mg Gabapentin
89572820|NCT04805827|Active Comparator|Neurontin|2 capsule contains 2*300 = 600 mg Gabapentin
89572821|NCT04795687||Ischemic stroke patients|
89572822|NCT04795687||Control|
89572823|NCT04805359|Experimental|Normoxic exercise (NE)|The subjects were trained on a bicycle ergometer at 60% of maximal work-rate (60%Wmax) under 21%O2 in air (NE) for 30 minutes per day, 5 days per week for 6 weeks
89572824|NCT04805359|Experimental|Hypoxic exercise (HE)|The subjects were trained on a bicycle ergometer at 60% of maximal work-rate (60%Wmax) under 15%O2 in air (HE) for 30 minutes per day, 5 days per week for 6 weeks
89572825|NCT04805359|No Intervention|Normoxic control|Without any exercise training
89572826|NCT02596711|Experimental|Health Education (HE) Group|Participants receive general health education and handouts. Participants attend 3 counseling sessions during the study. Each of these counseling sessions are audio recorded. Counselor discusses a health topic (such as sleep, nutrition, and exercise) and how it relates to participant and their smoking. Participants receive 12 weeks of Nicotine Replacement Therapy (NRT).
89572827|NCT02596711|Experimental|Culturally Tailored Smoking Cessation (CTSC) Group|Participants given reading materials that highlight how aspects of their culture relate to health, smoking and quitting. Participants attend 3 counseling sessions during the study. Each of these counseling sessions are audio recorded. Participant and counselor discuss how smoking and their culture may relate to each other. Participants receive 12 weeks of Nicotine Replacement Therapy (NRT).
89572828|NCT02596711|Experimental|Culturally Tailored Smoking + Adherence Enhancement (AE) Group|Participants given reading materials that highlight how aspects of their culture relate to health, smoking and quitting. Participants attend 3 counseling sessions during the study. Each of these counseling sessions are audio recorded. Participants receive additional talks related to smoking cessation tailored to their culture. Participants receive 12 weeks of Nicotine Replacement Therapy (NRT).
88970683|NCT04432779||Newborns from women tested negative|"Newborns born to mothers who had no COVID-19 infection during pregnancy or at delivery and who consented the follow up study. These control children will be matched with children from the other group for gestational age and ethnicity.~Follow up end at 3 years of age."
88970684|NCT00066157|Experimental|1|estradiol patch and medroxyprogesterone
89572829|NCT04805281|Active Comparator|Lithium Disilicate IPS e.max crowns in posterior teeth|
89572830|NCT04805281|Experimental|Monolithic Zirconia (5Y-TZP/3-YTZP) crowns in posterior teeth|
89572831|NCT05616403||Textbook outcome group|Achieving textbook outcome after laparoscopic pancreaticoduodenectomy
89572832|NCT05616403||Non-Textbook outcome group|Not achieving textbook outcome after laparoscopic pancreaticoduodenectomy
89572833|NCT04814485|Experimental|SHR-1020 combined with albumin-bound paclitaxel|SHR-1020 combined with albumin-bound paclitaxel
89572834|NCT04288141||Group 1: Early HER2 positive breast cancer|Study participants in Group 1 will include patients prescribed neoadjuvant systemic therapy (including trastuzumab and pertuzumab) by their treating oncologist for a diagnosis of HER2 positive early breast cancer.
89572835|NCT04288141||Group 2: Metastatic HER2 positive breast cancer|Study participants in Group 2 will include patients prescribed systemic therapy (including trastuzumab and pertuzumab) by their treating oncologist for a diagnosis of HER2 positive metastatic breast cancer.
89572836|NCT04280887|Experimental|Intervention|Participants will wear the device for the specified test period (3 months)
89572837|NCT04262401|Active Comparator|Standard health coaching|Standard health coaching to increase health behaviors
89572838|NCT04262401|Experimental|Habit-focused health coaching|Health coaching enhanced with a focus on habit formation using a mobile application called Habit Design
89572839|NCT04795063|Experimental|Total Robotic Distal Gastrectomy|After exploration and randomization, patients received total robotic distal gastrectomy
89572840|NCT04795063|Active Comparator|Robotic-Assisted Distal Gastrectomy|After exploration and randomization, patients received robotic-assisted distal gastrectomy.
89572841|NCT04804501|Experimental|Blue Light Glasses (experimental)|These subjects will wear the device (glasses) while performing a reading task.
89572842|NCT04804501|Other|No Glasses (control)|These subjects will not wear the device (glasses) while performing a reading task.
89572843|NCT04795297||recurrent BCC|recurrent BCC
88970685|NCT00066157|Active Comparator|2|estradiol patch and placebo pill
89572844|NCT04795297||resected BCC|resected BCC
89572845|NCT04814017|Experimental|Radial shock-wave group|Group I (15 subjects) received radial shock-wave application one times a week for six weeks and home based stretching exercises.
89572846|NCT04814017|Experimental|Control|Group II (15 subjects) received home based stretching exercises for six weeks.
89572847|NCT04804657|Active Comparator|Sage extract|Two hours before the endurance test, participants were asked to absorb two capsules of sage extracts (600mg each - cognivia™)
89572848|NCT04804657|Placebo Comparator|placebo|Two hours before the endurance test, participants were asked to absorb two capsules of placebo (similar appearance than active comparator).
89572849|NCT04804423|Active Comparator|Fluoride varnish (Duraphat®)|Fluoride varnish application is recommended by the German National Health System for managing hypersensitivity and dental caries. Sodium fluoride varnish (Duraphat®) will be applied on hypersensitive active carious lesions (ICDAS 5).
89572850|NCT04804423|Experimental|Silver fluoride and potassium iodide (Riva Star®)|Silver fluoride and potassium iodide (Riva Star®) is primarily indicated for relieving hypersensitivity will be applied on hypersensitive active carious lesions (ICDAS 5) following isolation of the affected teeth and according to manufacturer's instructions.
89572851|NCT04804111|Placebo Comparator|Placebo|maintain the initial dose, without increasing the dose.
89572852|NCT04804111|Active Comparator|URC102 3mg|Administer 3 mg of URC102 for 12 weeks
89572853|NCT04804111|Active Comparator|URC102 6mg|Administer 3 mg of URC102 for 1 week and 6 mg of URC102 for 11 Weeks.
89572854|NCT04804111|Active Comparator|URC102 9mg|Administer 3 mg of URC102 for 1 week and 6 mg of URC102 for 1 Weeks, maintain 9 mg of URC102 dose
89572855|NCT04804111|Other|Febuxostat 80 mg|maintain the initial dose, without increasing the dose.
89572856|NCT04794673||Left damage|Have the brain damage and the location of the damage in the left brain
89572857|NCT04794673||Right damage|Have the brain damage and the location of the damage in the right brain
89572858|NCT04794673||Nomal control|Not have the brain damage
89572859|NCT04794049|Experimental|Experiment cohort|4-6 hours before colonoscopy, patients in experiment cohort began to drink the first 150ml lactulose and half hour later, drink other 150ml lactulose dissolved in 1.5 L of water at a rate of 250ml every 15 minutes.
89572860|NCT04794049|Active Comparator|Control cohort|The participants in control cohort began to drink the first 2 L of PEG at 7:00-9 PM on the day before colonoscopy at a rate of 250 mL every 15 minutes. On the day of the procedure, patients took the remaining 2 L 4-6 hours before colonoscopy.
89572861|NCT04804267|Experimental|Experimental|Linaclotide Manufactured by Jiangsu Hansoh Pharmaceutical Co., Ltd. Drug: Linaclotide 145μg orally once daily
89572862|NCT04804267|Active Comparator|Active Comparator|LINZESS® Manufactured by Almac Pharma Services Limited Drug: Linaclotide 145μg orally once daily
89572863|NCT04804267|Placebo Comparator|Placebo Comparator|Placebo Drug: Placebo orally once daily
89572864|NCT04427059|Experimental|Arm A - laparoscopic assisted TAP block|Patients will undergo the planned bariatric intervention according to the standard of treatment. A solution of 20 ml of the local anesthetic Ropivacaine (0.25%) is then injected for postoperative pain control according to the allocated procedure (TPA).
89572865|NCT04427059|Active Comparator|Arm B - PSI|Patients will undergo the planned bariatric intervention according to the standard of treatment. A solution of 20 ml of the local anesthetic Ropivacaine (0.25%) is then injected for postoperative pain control according to the allocated procedure (PSI).
89572866|NCT04793971||postoperative cases|patients that underwent percutaneous release of the paratenon for chronic midportion Achilles tendinopathy
89572867|NCT04794439|Active Comparator|Toothpaste 1 with Stannous Fluoride|Toothpaste with Stannous Fluoride
89572868|NCT04794439|Active Comparator|Toothpaste 1 with Sodium Fluoride and sodium bicarbonate|Toothpaste with Sodium Fluoride and sodium bicarbonate
89572869|NCT04794439|Active Comparator|Toothpaste 2 with Stannous Fluoride|Toothpaste with Stannous Fluoride
89572870|NCT04794439|Active Comparator|Toothpaste 2 with sodium Fluoride and sodium bicarbonate|Toothpaste with sodium Fluoride and sodium bicarbonate
89572871|NCT02596009|Experimental|Breezhaler®|Each patient was required to inhale via Breezhaler® in a randomized cross-over sequence. The randomization numbers were generated using 6 sequences: BEH, EHB, HBE, BHE, EBH, HEB (B: Breezhaler, E: Ellipta, H: Handihaler).
89572872|NCT02596009|Other|Ellipta®|Each patient were required to inhale via Ellipta® in a randomized cross-over sequence. The randomization numbers were generated using 6 sequences: BEH, EHB, HBE, BHE, EBH, HEB (B: Breezhaler, E: Ellipta, H: Handihaler).
89572873|NCT02596009|Other|Handihaler®|Each patient were required to inhale via Handihaler® in a randomized cross-over sequence. The randomization numbers were generated using 6 sequences: BEH, EHB, HBE, BHE, EBH, HEB (B: Breezhaler, E: Ellipta, H: Handihaler).
89572874|NCT02590939|Experimental|Active device|60 minutes of active external trigeminal nerve stimulation with a CEFALY Active device
89572875|NCT02590939|Sham Comparator|Sham device|60 minutes of placebo external trigeminal nerve stimulation with a CEFALY Placebo device
89572876|NCT04793503|Active Comparator|conventional complete denture|the patients receive conventional complete denture constructed from heat cure acrylic resin
89572877|NCT04793503|Active Comparator|CADCAM 3D printed denture|the patients receiveCADCAM 3D printed denture constructed by using printing machine
89572878|NCT04793503|Active Comparator|CAD/CAM milled denture|the patients receiveCADCAM 3D printed denture constructed by using milling machine
89572879|NCT04793113|Experimental|Intervention|Low carbohydrate, high protein meals
88970686|NCT00066157|Active Comparator|3|placebo patch and medroxyprogesterone
88970687|NCT00066157|Placebo Comparator|4|placebo patch and placebo pill
88970688|NCT00066196|Other|2|Integrin + Dacarbazine
88970689|NCT00066196|Active Comparator|1|MEDI-522
88970690|NCT04401150|Experimental|Vitamin C|Vitamin C: 50 mg/kg of weight administered intravenously every 6 hours for 96 hours (16 doses).
88970691|NCT04401150|Placebo Comparator|Control|Normal saline (0.9% NaCl) or dextrose 5% in water (D5W) in a volume to match the vitamin C.
88970692|NCT05077280|Experimental|one arm|see below
88970693|NCT04388475|Experimental|All patients|All patients enrolled in this study
88970694|NCT00066430|Experimental|Infrared coagulator|
89572880|NCT04813471|Experimental|Endothelial Dysfunction Protocol|"Experimental: Endothelial Dysfunction Protocol~Our study will evaluate the impact of the endothelial treatment protocol (atorvastatin(or home statin), nicorandil, l-arginine, folic acid and vitamin B complex) in critically Ill patients already on optimal medical therapy for the treatment of COVID-19 virus. Protocol will be given for a total of 14 days or until discharge from the hospital~Patients already on home statin will continue their medication or if the are eligible for statins they will recieve 40 mg tablet to be given PO once daily.~Nicorandil Nicorandil 10 mg PO BID for the first 7 days and then if no contraindications escalated to 20 mg PO BID for the remaining 7 days~Folic Acid Folic Acid 5 mg po once daily~L-Arginine L-Arginine 1 g po TID~Vitamin B complex (Becozyme) 1 ampoule IV daily"
89572881|NCT04813471|No Intervention|Standard of care|Standard of Care
89572882|NCT04813393||Compliance of Parents of Children with Cerebral Palsy to Home Program Assesment Questionnaire Group|The CPHP-Q was administered as a caregiver-report questionnaire. It aims to measure home program adherence of parents of children with CP. Parents applied this instrument in the study.
89572883|NCT04803175||Sacubitril/valsartan|Patients undergoing continued treatment with sacubitril/valsartan after improvement of LVEF >40% with > 3 months of sacubitril/valsartan treatment. Dose and titration schedule will be individualized by discretion of the attending physician.
89572884|NCT04803175||Valsartan|Patients undergoing continued treatment with valsartan after improvement of LVEF >40% with > 3 months of sacubitril/valsartan treatment. Dose and titration schedule will be individualized by discretion of the attending physician.
89572885|NCT04793347|Experimental|shock waves|group of patients with anal fissure will be treated with shock waves
89572886|NCT04793425|No Intervention|Standard care|Patients randomized to standard care arm will take part in the rehabilitation program according to regular schedule. Additionally every patient will have 2 cardiological visits: 1 and 6 months after the hospitalization due to MI.
89572887|NCT04793425|Experimental|Mobile app care|Patients randomized to standard care arm will take part in the rehabilitation program according to regular schedule. Additionally every patient will have 2 cardiological visits: 1 and 6 months after the hospitalization due to MI. On top of that every patient will be given an access to mobile application, which will support rehab process. The application stands as a educational and coordination tool.
89572888|NCT04351087|Active Comparator|Platelet Rich Plasma|157cc of whole blood will be harvested via standard venipuncture from the antecubital fossa and mixed with 24cc ACD-A (manufacturer recommends 8cc ACD-A per 52cc of whole blood). 156ml of whole blood will be processed in the FDA Cleared Angel cPRP system at 2% hematocrit. 1ml of whole blood and the resultant PRP will be analyzed in the Sysmex XN-350 for complete analysis (platelet, leukocyte, red blood cell counts). The remaining PRP will be injected under sterile technique using ultrasound-guidance through a superolateral approach. For patient comfort, 2cc of 1% lidocaine can be administered using a 26-gauge needle (into soft tissues only). PRP will then be injected using a 25-guage needle. A maximum of 6ml of PRP will be injected. Injection site will be cleaned and bandaged and patient will be dismissed with post-injection precautions and 1 month follow-up scheduled.
89572889|NCT04351087|Active Comparator|Microfragmented adipose tissue|Adipose is aspirated from the subcutaneous tissue of the buttock or abdomen. Aspiration site is injected with 10ml 1% lidocaine with epinephrine. A small poke incision is made with an 11-blade scalpel. Then 120ml of Klein solution is injected into the adipose tissue. Solution sits for 15 minutes to allow for adequate anesthesia. Aspiration cannula is inserted and moved in a back and forth motion for 2 minutes to allow for adipose aspiration. 30ml fat will be aspirated. Aspiration site is cleaned and bandaged. The aspirated fat is processed using the Lipogems system. 30ml of adipose is transferred to the device, saline is run through the device to remove oils and then approximately 5-7ml of adipose tissue is removed and ready for injection. The Microfragmented adipose tissue are then injected in identical fashion to the PRP above.
89572890|NCT04803253|Experimental|Participants using the ORTHOPUS set of prosthetic solution|
89572891|NCT04792723|Experimental|Healthy volunteer|Sublingual or oral aspirin 80mg tablet, single dose, two-treatment, two-period, two-sequence, randomized, crossover design, with washout 1-2 weeks
89572892|NCT04813081|Active Comparator|Free gingival graft around dental implant patients|Test Group (TG) consists of patients have free gingival graft around dental implant patients
89572893|NCT04813081|Active Comparator|Free gingival graft around the teeth|Control Group (CG) consists of patients have free gingival graft around the teeth.
89572894|NCT04427215|Experimental|A - Music Therapy|Two section a week of music therapy
89572895|NCT04427215|Experimental|B - Art Therapy|Two section a week of Art therapy
89572896|NCT04427215|Experimental|C - Dance-Movement Therapy|Two section a week of Dance-Movement Therapy
89572897|NCT04427215|Experimental|D - Bibliotherapy|Two section a week of Bibliotherapy
89572898|NCT04427215|Experimental|E - Physical Activity|Two section a week of systematized physical activity
89572899|NCT04427449|Experimental|Experimental: Single arm 4SCAR-CD44v6 T cells to treat cancer|
89572900|NCT04803487|Experimental|the Micro Hand S robot group|41 patients were randomly allocated in the Micro Hand S robot group and cholecystectomy was performed using the Micro Hand S robot.
89572901|NCT04803487|Other|the da Vinci robot group|41 patients were randomly allocated in the da Vinci robot group and cholecystectomy was performed using the da Vinci robot.
88970695|NCT00066586|Active Comparator|Exemestane|
88970696|NCT00066586|Placebo Comparator|Placebo|
88970697|NCT00066625|Experimental|Treatment (oxaliplatin, bortezomib)|"Patients receive oxaliplatin IV over 2 hours on days 1 and 15 and bortezomib IV over 3-5 seconds on days 1, 4, 15, and 18. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of oxaliplatin and bortezomib until the MTDs are determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
88970698|NCT00066859|Active Comparator|Arm 1: Sertraline (Zoloft) 50 mg|Zoloft 50 mg by mouth daily for 1 week if tolerated dose may be increased to 100 mg daily for 4 months
88970699|NCT00066859|Active Comparator|Arm 2 - St. John's Wort 600mg|St. John's wort 600 mg daily for 1 week. If tolerated dose may be increased to 900 mg daily for four months.
89572902|NCT04803097||pediatric cataract group|Children who underwent cataract surgery and primary IOL implantation at the Eye Hospital of Wenzhou Medical University (Hangzhou, China) between 2016 and 2019 were included in the study. Every surgery included posterior capsulorhexis or capsulotomy and anterior vitrectomy. Patients accept slit-lamp-adapted anterior segmental photography at 1 week, 2 weeks, 1 month, 3 months, and 6 months postoperatively.
89572903|NCT04812769|Experimental|Intervention|Two nursing homes will receive the eCARE-ID intervention
89572904|NCT04812769|Placebo Comparator|Control|One control nursing home will receive infectious disease consultations and antibiotic stewardship services per routine practice.
89572905|NCT04792333|Experimental|Treatment|500 mg (2 capsules of 250 mg)
89572906|NCT04803019|Active Comparator|DEB-TACE or chemoembolization with microspheres|The chemotherapy used in this arm is the Doxorubicin that will be carried into the tumor by Embozene TANDEM® (Boston Scientific) microspheres. TANDEM® embozene microspheres are made of non-resorbable, biocompatible, hydrogel microspheres, subjected to precision calibration and coated with an inorganic perfluorate polymer (Polyzene®-F)
89572907|NCT04803019|Active Comparator|TAE or embolization with microspheres|The TAE will be performed with Embozene microspheres (Boston Scientific). Embozene microspheres are spherical particles of hydrogel, precisely calibrated, biocompatible, non-absorbable and coated with a perfluorinated inorganic polymer (Polyzene®-F)
89572908|NCT04802785|Experimental|The study Group|"Before the flight in the conditions of the clinic's medical treatment room: Citicoline 500 mg(Vitaae®) and Cytochrome10 mg (Cytochrome C®) per os.~30 minutes before the flight: dilute 1 sachet of ORS® (Sodium Chloride 2.6 g+Potassium Chloride 1.5 g+Sodium Citrate 2.90 g+Dextrose 13.5 g) in 1 liter of water. Drink half of the solution (0.5 l) 30 minutes before the flight (at the airport). Also, 0.5 L of the solution will be provided on the plane during landing. If the flight lasts more than 1.5 hours, then dilute the second sachet of ORS® with 0.5-1 liters of water.~30 minutes before the flight (per os): Domperidone (Motilium ®) (1 tablet), Simethicone (Gas-X®) (3-4 capsules), Acetylsalicylic acid 150 mg and magnesium hydroxide 30,39 mg (Cardiomagnyl®)(1 tablet), probiotic (Bactistatin®) (1 capsule) per os."
89572909|NCT04802785|Active Comparator|Control group|Melatonin® 5 mg per os 2 hours before bedtime on the day of arrival for 3-4 days.
89572910|NCT04802785|No Intervention|Explanatory group:|12 participants without any intervention.
89572911|NCT04802941|Experimental|Neoadjuvant Chemotherapy by CDSS|
89572912|NCT04802941|Active Comparator|Neoadjuvant Chemotherapy in General practice|
88970700|NCT04235673|Experimental|melatonin|melatonin oral drops; 3 mg/kg/day for 15 days
88970701|NCT04235673|Placebo Comparator|placebo|oral drops manufactured to mimic melatonin
88970702|NCT00067015|Experimental|IMRT alone to 86.4 Gy|External radiotherapy is given for 10 weeks, Monday through Friday for a total of 48 sessions. The total dose of radiotherapy delivered during these 10 weeks is 86.4 Gy. The radiation treatments are delivered with a high precision technique called intensity modulated radiotherapy or IMRT. For this treatment, no hormonal therapy is required.
88970703|NCT00067015|Experimental|IMRT TO 75.6 Gy plus Adjuvant Androgen Deprivation|Prior to a planned course of radiotherapy, which will last for eight and a half weeks, 10 weeks of hormonal therapy are given. The hormonal therapy will start with a daily pill called Casodex. Three to seven days after starting this pill, a Zoladex injection will be administered in addition to the Casodex pill. Zoladex hormonal therapy is given in the form of a monthly injection. After 10 weeks from the initiation of hormone therapy, you will begin external radiotherapy. For these treatments only 42 treatment sessions are given. The total dose of radiotherapy delivered during these 8.5 weeks is 75.6 Gy. The hormone injections continue during the radiation treatments and for 2 years after the radiation treatments. The pills are only taken for the 10 weeks before and also during the radiation treatments, however afterwards the pills are discontinued.
88970704|NCT04220307|Experimental|AK104 6 mg/kg|AK104 IV every 2 weeks (q2w)
88970705|NCT04220307|Experimental|AK104 15 mg/kg|AK104 IV every 3 weeks (q3w)
88970706|NCT00398905|Experimental|Arm 1|
88970707|NCT00398905|Experimental|Arm 2|
88970708|NCT00398905|Experimental|Arm 3|
88970709|NCT00398905|Experimental|Arm 4|
88970710|NCT00398905|Experimental|Arm 5|
88970711|NCT00398905|Active Comparator|Arm 6|
88970712|NCT04172571|Experimental|AK105 and anlotinib|
88970713|NCT02966938||Nut allergic patients|Allergic patient and their family with allergy to peanut or other tree nuts that are in elimination diet.
88970714|NCT00067366|Experimental|Coping Skills Training|manualized coping skills training delivered along with conservative care
88970715|NCT00067366|Active Comparator|Standard Care|Attention and life counseling added to Standard conservative care
88970716|NCT02967094|Experimental|A - mucolytic solution|Mucolytic solution consisting of 100 ml of water, 100 mg of simethicon and 400 mg of N-acetylcystein administered 30 minutes prior to upper endoscopy.
88970717|NCT02967094|No Intervention|B - no intervention|Upper endoscopy without neither mucolytic solution nor water prior to upper endoscopy.
88970718|NCT02967094|Placebo Comparator|C - water|100 ml of water given 30 minutes prior to upper endoscopy.
88970719|NCT04096833|Experimental|Intervention Group|Participants use as a distracting measure Virtual Reality glasses during the vaccination.
88970720|NCT04096833|No Intervention|Control Group|Participants use usual non-virtual distracting measures during the vaccination.
88970721|NCT00067639|Experimental|Pegfilgrastim + Apheresis|12 mg Pegfilgrastim as subcutaneous injection on day 1 + Apheresis daily till target stem cell dose reached.
88970722|NCT00067717|Experimental|Distant Healing|This group received distant healing but was blinded to the condition.
89033188|NCT02921217|Experimental|ActivBPL1|Active Probiotic Bifidobacterium animalis subsp. lactis BPL1 (CECT 8145)
89572913|NCT02598193|Experimental|Pirfenidone+Nintedanib|Participants with IPF will receive pirfenidone at 1602-2403 milligrams per day (mg/day) dose and nintedanib at the 200-300 mg/day dose up to 24 weeks.
89572914|NCT04791397|Experimental|Group trial|Included 30 patients, with metabolic syndrome, aged 24-71 year old.
89572915|NCT04791397|Experimental|Group control|Included 30 patients, with metabolic syndrome, aged 24-71 year old.
89572916|NCT04802239|Active Comparator|calm waking group|calm waking state group
89572917|NCT04802239|Experimental|hypnosis session|hypnosis session group
89572918|NCT04802551|Experimental|Intervention group|
89572919|NCT04802551|No Intervention|Control group|
89572920|NCT02595073|Experimental|DSXS topical product|DSXS Active treatment
89572921|NCT02595073|Placebo Comparator|Placebo topical product|Placebo treatment
89572922|NCT04791007|Experimental|Single dose administration (Part 1)|the dose of the drug (4g OB-002H (8.0 mg/g)) administrated once vaginally or rectally
89572923|NCT04791007|Experimental|Multidose administration (Part 2)|the dose of the drug (4g OB-002H (8.0 mg/g)) or placebo administered vaginally through five consecutive days
89572924|NCT04791085||general surgeons|General surgeons who work at general or private hospitals in Greece
89572925|NCT04790929|Experimental|Regular Muse Meditation System - No Coaching|Participants will join a 1.5-hour virtual onboarding session where they will complete their first Muse session. Participants will then be asked to use the Muse Meditation system for a minimum of 5 minutes a day (in one or multiple sessions), a minimum of 5 days a week, for 6 weeks. If they wish to use the system more frequently within the 6 weeks, they will be encouraged to do so and will be able to choose between all the styles of meditation available in the Muse Meditation System (Mind, Heart, Breath, Body, Guided or Sleep Journeys). For any challenges that arise, participants will have unlimited access to Muse Customer Care via phone, email, and video where appropriate during normal business hours.
89572926|NCT04790929|Experimental|Regular Muse Meditation System - Additional Coaching|The procedure will be identical to Group 1 above, but in addition, all participants will be asked to join regular online coaching sessions. Participants will be divided into 8 cohorts of 10 people per cohort. Each cohort will be offered group coaching once per week. Coaches will be versed in Mindfulness and how to use Muse. Coaching will take place virtually using Interaxon's Zoom account. Throughout the coaching, all participants will be referred to via their first names or their anonymized login names. In addition, for any challenges that arise, participants will have unlimited access to Muse Customer Care via phone, email, and video where appropriate during normal business hours.
89572927|NCT04790929|No Intervention|Controls|The participants in the control group will receive a Muse Device, which they will be free to keep at the end of the study. They will be asked not to open and/or use the Muse device until the entire study is complete. On day 1 of the Study, they will complete the Cambridge Brain Sciences online cognitive assessment battery, plus a longer questionnaire about stress levels, workplace wellness, quality of life, mindfulness, anxiety and depression and sleep quality. At the completion of the study controls will be offered optional, free group coaching sessions if they complete the study requirements.
89608884|NCT03155529||radical hysterectomy group|"Using dynamic MRI and 3D reconstruction to assess the effect of RH on pelvic floor muscles and pelvic organs (location and mobility of bladder neck and urethral).~Inclusion Criteria： ①Patients diagnosed as FIGO stage IA2、IB1、IIA1 cervical cancer ; ②Patients diagnosed as FIGO stage IB2、IIA2 cervical cancer, eligible for RH after neoadjuvant chemotherapy; ③Patients diagnosed as FIGO stage IIA endometrial carcinoma; ④Patients didn't have pelvic organ prolapse and urinary incontinence; ⑤Ability to hold Valsalva for dynamic MRI; ⑥Patients aged 20-70 years; ⑦Patients undergone RH surgery; ⑧Informed consent was signed.~Exclusion Criteria：~①With MRI or urodynamic examination contraindication; ②Previously undergone POP or SUI surgery; ③BMI>30 ④With serious postoperative complications."
89028988|NCT05105373|Experimental|Intervention-Parenting for Respectability|Randomisation in the cRCT will be conducted at the cluster level. PfR is a 16-session manualised programme starting with nine single sex sessions followed by seven mixed sex sessions, delivered once a week by two local facilitators who receive one week's training. Activities were developed specifically for PfR or adapted from other parenting programs, including Project H, Stepping Stones, Mema kwa Jamii, The International Child Development Programme and Parenting for Lifelong Health. The programme addresses four familial processes associated with GBV and VAC: poor parental bonding and child attachment; harsh parenting; inequitable socialisation by gender and parental conflict. A particular goal is to involve fathers, whom most parenting programmes find hard to recruit, and the first nine sessions are delivered in single-sex groups.
89028989|NCT05105373|Active Comparator|Control-Parenting for Respectability in a nutshell|Randomisation in the cRCT will be conducted at the cluster level immediately after baseline data collection. Parents allocated to the control arm will receive a two-hour structured lecture called Parenting in a Nutshell on parenting and partner relationships. Three topics will be covered: 1) child development; 2) positive parenting; and 3) resolving partner conflicts. Facilitators delivering this lecture will have same/similar expertise with the facilitators engaged in PfR. .
89028990|NCT05091346|Experimental|Phase 1b and 2: E7386 + Pembrolizumab|Participants will receive E7386 twice daily (BID) along with pembrolizumab 200 mg intravenous (IV) infusion once every 3 weeks (Q3W) in 21-day treatment cycle until RP2D is determined in Phase 1b. The recommended dose for Phase 2 part of the study will be based on Phase 1b result. Participants will continue to receive study treatment in Phase 2 part until disease progression, development of unacceptable toxicity, withdrawal of consent, or termination of the study.
89028991|NCT05091346|Experimental|Phase 2: E7386 + Pembrolizumab + Lenvatinib|Participants will be randomized to receive E7386 Dose 1 (Cohort 1) or Dose 2 (Cohort 2) tablet, BID, orally in combination with pembrolizumab 200 mg Q3W IV infusion plus lenvatinib 8 mg capsule, orally, once daily (QD) continuously in 21-days treatment cycles until disease progression, development of unacceptable toxicity, withdrawal of consent, or termination of the study. The dose of treatment depends on tolerability data of both Cohorts.
89028992|NCT05088655|Experimental|Treatment group A: T - R- R|
89028993|NCT05088655|Experimental|Treatment group B: R -T - R|
89028994|NCT05088655|Experimental|Treatment group C: R- R-T|
89028995|NCT05054790|Experimental|"Autologous Neo-Bladder Construct"|All subjects enrolled will have non-neurogenic, fibrotic contracted bladder that is refractory to medical treatment and require augmentation cystoplasty for preventing long-term sequelae (i.e., kidney failure) that result from persistently high intravesical pressure.
89028996|NCT05039216||patients initiating a biotherapy or a target treatment|Blood sampling
89028997|NCT05039216||patients with chronic inflammatory rheumatism, weakening osteopathy or mechanical pathology|Blood sampling
89028998|NCT05037812|Placebo Comparator|Saline injection|Saline
89033189|NCT02921217|Experimental|InactivBPL1|Inactivated probiotic Bifidobacterium animalis subsp. lactis BPL1 (CECT 8145)
89033190|NCT02921217|Placebo Comparator|Control|Control
89033191|NCT00531986|Experimental|Monotherapy|Ritonavir-boosted lopinavir (Kaletra®) will be used as monotherapy
89033192|NCT00531986|Active Comparator|Continued ART|Continuation Therapy, conventional triple HAART
89028999|NCT05037812|Experimental|Multimodal injections|"Superficial multimodal analgesia composition includes 5mg morphine, 500 micrograms epinephrine, and 4ml normal saline.~Deep medial multimodal analgesia composition includes 2.5mg morphine, 40 micrograms clonidine, 15mg ketorolac, and 4ml normal saline."
89572928|NCT04802005|Experimental|Aerobic interval|Aerobic interval will consist of a supervised aerobic interval training sessions 3 times/week. Duration will range between 45-50 min/session depending on the exercise energy expenditure (target expenditure ~450-500kcal/session). Each interval will have a total duration of 5 min, and it will be divided into 2 periods. The first period will consist of 3 minutes of high-intensity activity at 70-85% of predicted HRmax, and for the second period the intensity will be reduced to 60-65% of predicted HRmax for 2 minutes. The training sessions will be carried out outdoors at the trails located on campus. The activity will consist of walking and/or light jogging. The speed/incline will be changed depending on the participants' heart rate and perception using the Borg's rating of perceived exertion (RPE) as needed. The RPE for the first period range will be 13-17 (15-17 at the end of the period) and 10-12 for the second period.
89572929|NCT04802005|No Intervention|Control group|Participants in the control group will not participate in the training programs.
89572930|NCT04790383|Experimental|Advanced Self-Adhesive resin composite hybrid restorations|(Surefil one (Dentsply Sirona)).
89572931|NCT04790383|Active Comparator|Conventional resin composite restoration.|Sphere Tec, (Dentsply Sirona)
89572932|NCT04790539|Experimental|SHR-1210+Paclitaxel-albumin+Carboplatin|SHR-1210 was given in the first day of each cycle, Carboplatin was given in the first day of each cycle, Paclitaxel-albumin was given in the first day of each cycle, with intravenous drip.
89572933|NCT04790149|Sham Comparator|Conventional Group|Conventional usual Rehabilitation is administered to a group of patients without any effect on their recovery
89572934|NCT04790149|Experimental|NEUROM|participants received the new protocol of a method called NEUROM consisting of 3 phases of treatment : Motor Imagery training, active rehabilitation and functional rehabilitation
89572935|NCT04790149|Experimental|NEUROM combined with tDCS|same as the second arm of NEUROM combined with transcranial direct stimulation
89572936|NCT04812301||Group 1|Egg-white sandwich is added with 1 mCi Tc-99m sodium phytate, then Abbott Vital® added with 1 mCi Tc-99m sodium phytate
89572937|NCT04812301||Group 2|Abbott Vital® is added with 1 mCi Tc-99m sodium phytate, then egg-white sandwich added with 1 mCi Tc-99m sodium phytate
89572938|NCT04427371||survivors|Improve or under treatment
89572939|NCT04427371||nonsurvivors|all-cause 28-day mortality
89572940|NCT04801069|Experimental|Auto-Adaptative Servo-Ventilation|
89572941|NCT04801069|No Intervention|Control|
89572942|NCT04426903|Experimental|LLM Care|LLM Care training Participants use the webFitForAll exergaming computer platform as the physical training component (PT); Participants use the language adapted version of the BrainHQ Program as the cognitive training component (CT)
89572943|NCT04426903|Experimental|Physical Training (PT)|Physical training only. Participants use the webFitForAll exergaming computer platform as the physical training component (PT).
89572944|NCT04426903|Experimental|Cognitive Training (CT)|Cognitive training only. Participants use the language adapted Version of the BrainHQ Program as the cognitive training component (CT).
89572945|NCT04812223|Active Comparator|Delayed Clamping|In this group, the umbilical cord will be clamped 60 seconds after the baby is born.
89572946|NCT04812223|Active Comparator|Early Clamping|In this group, the umbilical cord will be clamped 15 seconds after the baby is born.
89572947|NCT04812223|Active Comparator|Milking Clamping|In this group in which the umbilical cord will be milked, the cord will be milked 5 times with 2 seconds milking, then letting 2 seconds for spontaneous blood flow.
89572948|NCT04789759|Experimental|Socket Preservation Alloplastic Material|"10 Consecutive Patients with hopeless teeth and 1/3 or more buccal bone resorption will be placed in a therapy go bone regeneration called socket preservation technique.~The surgery will include placement of 2/3 biphasic calcium sulfate cement matrix's with hydroxyapatite (HA granules) to fill the alveolar defects, and place a resorbable membrane sutured to adjacent tissue, to avoid material leakage.~No flap retraction. 3 Month later an implant will be placed, and a bone biopsy of the healed socket harvested. 2 Month later a final Zirconia ceramic crown screw retained to the osseointegrated implant.~Primary (T0) and Secondary (T1) stability measured with ISQ values.~Intraoral Scanner and an STL File will be taken at T0 , T1 and T2 for volumetric alteration evaluation."
89572949|NCT04789759|Active Comparator|Extraction Socket Spontaneous Healing|10 Consecutive patients with a tooth extraction without the aim of placing a future implant and without Biomaterial filler placed in the socket. Spontaneous healing
89572950|NCT04789525|Experimental|Group A (high-intensity aerobic training with high protein diet )|
89572951|NCT04789525|Experimental|Group B(regular physical activities and taken regular diet)|
89572952|NCT04801147|Experimental|Immunotherapy|Autologous DC loaded with a autologous tumor lysate, in order to stimulate the immune response of the patient.
89572953|NCT02388165|Active Comparator|SA4Ag|Staphylococcus aureus 4-antigen Vaccine
89572954|NCT02388165|Placebo Comparator|Placebo|Diluent (sterile water) for Placebo
89572955|NCT04789447||COVID-19 patients in hospital|All patients aged 18 years and over, positive for SARS-CoV-2 PCR test and / or Covid-19 treatment with signs of Covid-19 disease on CT
89572956|NCT04811599||deep learning algorithm group|Before patients going through colonoscopy or gastroscopy ,taking them tongue images and collecting basic information by mobile phone with Anymed.After examination,endoscopic report and histology analysis is collected .Categorizing the images by gastrointestinal diseases，developing and validating a deep learning algorithm for the diagnosis of digestive tract diseases depending on tongue images.Extracting tougue coating,gastric mucosa and stool DNA by high-throughput sequencing,and analyzing their composation,adundance and diversity.
89572957|NCT04800679|Active Comparator|intravitreal bevacizumab injections and then rescue|
89572958|NCT04800679|Active Comparator|PRP group|
89572959|NCT04800679|Active Comparator|IVB injections and a modified laser|
89033193|NCT02917434|Active Comparator|Patients with PsA and obesity|Very Low Energy Diet (VLED)
89033194|NCT02917434|Other|Patients with obesity|Very Low Energy Diet (VLED)
89033195|NCT02920827|Experimental|Dapivirine Vaginal Ring|Vaginal ring containing 25 mg dapivirine
89033196|NCT02920827|Placebo Comparator|Placebo Vaginal Ring|Placebo vaginal ring
89572960|NCT04811911|Active Comparator|Narrowband ultraviolet B|Patients will receive 8 sessions of NB-UVB per month for 3 successive months
89572961|NCT04811911|Active Comparator|Methotrexate group|Patients will receive 25 mg/1ml of methotrexate vial per week for 3 successive months
89572962|NCT04811911|No Intervention|healthy individuals as control group|
89572963|NCT04789603|Active Comparator|Without Mask Group|Patients who will perform the 6-min walk test without mask
89572964|NCT04789603|Active Comparator|Surgical Mask|Patients who will perform the 6-min walk test with surgical mask
89572965|NCT04789603|Experimental|Fpp2 Mask|Patients who will perform the 6-min walk test with Fpp2 mask
89572966|NCT04789135|Experimental|Ozone Therapy|Administration of intravesical ozone gas in patients with Interstitial cystitis/bladder pain sydrome
89572967|NCT04348669|Experimental|Tele-yoga|This is a single group study with all subjects included in this single arm. All subjects will undergo the same telerehabilitation yoga intervention delivered through videoconferencing.
88811136|NCT04199117|Experimental|Incentive,Tailored,No Care Manage,Intensive Treatment|Participants randomly assigned to this condition will have access to incentives for completing a first smoking cessation counseling call up to 4 times over 2 years, will receive 5 tailored letters promoting use of smoking cessation treatment over 2 years, will not receive Tobacco Care Management support and motivational encouragement calls, and will have access to 3 smoking cessation quit counseling calls and 12-weeks of either combination nicotine replacement or varenicline up to 4 times over 2 years.
89029000|NCT05019638|Active Comparator|Regional anesthesia group|Standard single-shot anesthesia consists of bupivacaine 0.25% with epinephrine 1:400,000.
89029001|NCT05019638|Experimental|Local multimodal analgesia group|Local multimodal analgesia composition will include 5mg of morphine, 500 mg of epinephrine, 15mg of ketorolac, and 20mg of bupivacaine.
89029002|NCT05019430|Placebo Comparator|Placebo|Subjects will be maintained on oral placebo. Cocaine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.
89572968|NCT04800445||Case group of fullterm neonates with neonatal sepsis|
89572969|NCT04800445||Healthy fullterm neonates|
89572970|NCT02404545|No Intervention|Group 1 - Ideal Conduit No Mesh|No mesh will be placed at the time of radical cystectomy and ileal conduit.
89572971|NCT02404545|Active Comparator|Group 2 - Ileal Conduit with Mesh|Ethicon Physiomesh will be placed at the time of radical cystectomy and ileal conduit.
89572972|NCT04811209||single group, open labelled observational study with no blinding.|All study patients will be managed per routine clinical practice and institutional standard for the performed surgery.
89572973|NCT04800211|No Intervention|Control|Continue smoking under ad libitum use of subjects' own brand of conventional lit-end cigarettes, without use of any other type of tobacco/nicotine containing product, for the entire duration of study participation.
88970723|NCT00067717|Placebo Comparator|Non-blinded Distant Healing|This group received the distant healing intervention and was called every day they were receiving to be told they were receiving it, therefore enhancing expectancy.
89572974|NCT04800211|Experimental|Test 1|"Exclusive ad libitum use of test e-Vapor Product NuMark LLC, MarkTen® XL Bold CLASSIC* without use of any other type of tobacco/nicotine containing product, for the entire duration of study participation.~*Product no longer sold commercially"
89572975|NCT04800211|Experimental|Test 2|"Exclusive ad libitum use of test e-Vapor Product Nu Mark LLC, MarkTen® XL Bold MENTHOL* without use of any other type of tobacco/nicotine containing product, for the entire duration of study participation.~*Product no longer sold commercially"
88970724|NCT00067717|No Intervention|Blinded Control|This group was blinded to the intervention condition and did not receive any distant healing.
88970725|NCT05010707|Active Comparator|Transdermal estradiol plus spironolactone|"Starting dose will be 100 mcg/24hrs Plan to increase by 100 mcg/24hrs every month to a max dose of 400 mcg/24hrs Goal is to achieve a serum estradiol level between 100-200 pg/mL and to suppress testosterone to cisgender female levels~All patients will also receive spironolactone. Spironolactone will be started at 50 mg daily and will increase to standard dose."
88970726|NCT05010707|Active Comparator|Daily sublingual estradiol plus spironolactone|"Starting dose will be 2 mg daily Plan to increase every month by 2 mg daily Goal is to achieve serum estradiol level between 100-200 pg/mL mL and to suppress testosterone to cisgender female levels.~All patients will also receive spironolactone. Spironolactone will be started at 50 mg daily and will increase to standard dose.~Spironolactone will be started at 50 mg daily and will increase to standard dose."
88970727|NCT05010707|Active Comparator|Twice daily sublingual estradiol plus spironolactone|"Starting dose will be 1 mg twice daily Plan to increase every month by 2 mg daily divided BID Goal is to achieve serum estradiol level between 100-200 pg/mL mL and to suppress testosterone to cisgender female levels~All patients will also receive spironolactone. Spironolactone will be started at 50 mg daily and will increase to standard dose.~Spironolactone will be started at 50 mg daily and will increase to standard dose."
88970728|NCT00067756|Experimental|4-PBA|The study will involve a 4-PBA dose escalation and pharmacokinetics component The study group will be comprised of a total of at least 10 AAT-deficient,(phenotype ZZ referred to as PiZZ) patients. These patients will be divided into two groups: with and without clinical evidence of mild to moderate hepatocellular injury.
88970729|NCT04091880|Experimental|experimental group|378 subjects from the experimental group will be simultaneously administrated with one dose of EV71 vaccine (0.5 ml) and one dose of influenza vaccine (0.25 ml). One month later, they are going to receive a second dose of EV71 vaccine and influenza vaccine, simultaneously.
88970730|NCT04091880|Active Comparator|control group A|378 subjects from the control group A will be only administrated with two doses of EV71 vaccine (0.5 ml) (1 month apart).
88970731|NCT04091880|Active Comparator|control group B|378 subjects from the control group B will be only administrated with two doses of influenza vaccine (0.25 ml) (1 month apart).
88970732|NCT00067873|Active Comparator|Diet only|
88970733|NCT00067873|Experimental|Diet plus aerobic exercise|
88970734|NCT00067873|Experimental|Diet plus resistance exercise|
88970735|NCT02966860|Experimental|Oxycodone and acetaminophen (OC/APAP)|Single 15 mL dose of oral solution of OC/APAP (total dose 15 mg oxycodone/975 mg acetaminophen)
88970736|NCT02958475|Experimental|Attention Control|Participants in control arm will receive normal standard messages about infant injury prevention.
89572976|NCT04811443||Patients with solid tumors who have received myelosupressive therapy|
89572977|NCT04810897||Parkinson's disease|The neurologists will inform the individuals with PD that we are doing this research and we will attach the research advertisement at Movement Disorder Clinic, Division of Neurology, Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand. Only individuals with PD who meet the inclusion and exclusion criteria will be invited to participate in the study. The researcher will inform participants about the purpose, procedure, and advantage of the study prior to participation in the study. Individuals with PD will be asked to sign an informed consent if they agree to participate in the study.
89572978|NCT04788355|Active Comparator|Control Group standard treatment|Patients will be treated only with standard hospital treatment
89572979|NCT04788355|Experimental|Group Hydroxychloroquine|Patients will be treated with Hydroxychloroquine associated with standard hospital treatment
89572980|NCT04788355|Experimental|Group Hydroxychloroquine e Apixaban|Patients will be treated with Hydroxychloroquine associated with apixaban and standard hospital treatment
89572981|NCT04788355|Experimental|Group Apixabana|Patients will be treated with apixaban associated with standard hospital treatment
89572982|NCT02420379|Experimental|Open-Label|Approximately 20 patients will receive weekly infusions of eteplirsen 30 mg/kg .
89572983|NCT02420379|No Intervention|Control Group|Approximately 20 patients with DMD not amenable to exon 51 skipping will be observed for 96 weeks.
89572984|NCT04799977||COVID19 infection with olfaction disorder|Patients, ≥18 ans, who suffered from an olfaction disorder while going through a COVID19 infection
89572985|NCT04799977||COVID19 infection without olfaction disorder|Patients, ≥18 ans, who suffered from a COVID19 infection without any olfaction disorders
89572986|NCT04799743|Experimental|Resveratrol group|Resveratrol group (treatment group) will be instructed to consume with capsules (1.0 g, orally once a day) for six months.
89572987|NCT04799743|Placebo Comparator|Placebo group|Placebo group (control group) will be instructed to orally take placebo (edible paraffin, 1.0) once a day.
89572988|NCT04788199||Non-closure group|Group in which mesenteric defects were not closed after laparoscopic Roux-en-Y gastric bypass.
89572989|NCT04788199||Closure group|Group in which mesenteric defects were closed using cyano-acrylate glue after laparoscopic Roux-en-Y gastric bypass.
89572990|NCT04788121|Active Comparator|Treatment/Tranexamic Acid Group|The treatment group will receive Injection TXA 1gm intravenous (IV) over 15 minutes infusion dissolved in 100 ml normal saline (NS- 0.9% NaCl), followed by injection TXA 2 g IV over 12 hours infusion dissolved in a 500 ml NS.
89572991|NCT04788121|Placebo Comparator|Control Group|The control group will receive injection 100 ml NS over 15 minutes infusion, followed by injection 500 ml NS over 12 hours infusion.
89572992|NCT04811053|Experimental|Treatment group A|
89572993|NCT04811053|Placebo Comparator|Treatment group B|
89029003|NCT05019430|Experimental|Zolmitriptan Dose 1|Subjects will be maintained on oral zolmitriptan dose 1. Cocaine will be administered acutely during zolmitriptan dose 1 maintenance. Placebo will be administered acutely during zolmitriptan dose 1 maintenance.
89029004|NCT05019430|Experimental|Zolmitriptan Dose 2|Subjects will be maintained on oral zolmitriptan dose 2. Cocaine will be administered acutely during zolmitriptan dose 2 maintenance. Placebo will be administered acutely during zolmitriptan dose 2 maintenance.
89029005|NCT05019430|Experimental|Zolmitriptan Dose 3|Subjects will be maintained on oral zolmitriptan dose 3. Cocaine will be administered acutely during zolmitriptan dose 3 maintenance. Placebo will be administered acutely during zolmitriptan dose 3 maintenance.
89572994|NCT04810819|Experimental|Experimental group|
89572995|NCT04810819|Placebo Comparator|control group|
89572996|NCT04810507|Experimental|Anagliptin arm|Anagliptin 100 mg twice a day
89572997|NCT04810507|Active Comparator|Sitagliptin 100mg|Sitagliptin 100mg once a day
89572998|NCT04810585|Experimental|Treatment|
89572999|NCT04787887|Active Comparator|Abcertin|Abcertin 60IU/kg
89573000|NCT04787887|Active Comparator|Cerezyme|EU-sourced Cerezyme
89029006|NCT05013749|Active Comparator|Hysterectomy|Hysterectomy: An incision will be made above the level of the placenta, delivering the newborn. Uterotonics will be administered, and spontaneous delivery of the placenta will be awaited using gentle traction. The absence of spontaneous separation of the placenta will confirm the diagnosis of PAS, the patient will undergo to hysterectomy. The complete removal of the uterus will be attempted, including the cervix, the duration of the intervention and intraoperative blood loss will be recorded, as well as the damage to organs neighboring the uterus. In this arm of the study, to hysterectomy will be performed in 100% of patients
89573001|NCT04799041|Active Comparator|GTX 2/3|Dose level administered of GTX 2/3 was 80 mcg. Dose was administered as IM paravertebral injections, 1 mL per site. Total of 2 mL of GTX 2/3 was injected. The IMP was supplied in glass vials containing 1.2 mL solution at a total GTX 2 and GTX 3 concentration of 40 mcg/mL (at a relative epimer ratio of 62% GTX 2:38% GTX 3).
89573002|NCT04799041|Placebo Comparator|Placebo|Placebo was of identical appearance to the IMP, and was administered as IM paravertebral injections, 1 mL per site. Total of 2 mL of placebo was injected.
89573003|NCT02347761|Experimental|SUN-101 50 mcg BID eFlow (CS) nebulizer|SUN-101 50 mcg twice daily (BID) eFlow (R) Closed System (CR) nebulizer
89573004|NCT02347761|Experimental|SUN-101 25 mcg BID eFlow (CS) nebulizer|SUN-101 25 mcg twice daily (BID) eFlow (R) Closed System (CR) nebulizer
89573005|NCT02347761|Placebo Comparator|Placebo BID eFlow (CS) nebulizer|Placebo twice daily (BID) eFlow (R) Closed System (CR) nebulizer
89573006|NCT04798807||Hospitalized non-critical services patients|"Patients, who were hospitalized in the clinics (hematology, neurology, gastroenterology, nephrology, endocrine, pulmonary disease and cardiology) of Malatya Training and Research Hospital, were screened both Nutritional Risk Screening 2002 (NRS-2002) and Subjective Global Assessment (SGA) tools within the first days of admission to the patients.~The nutritional status of patients categorized according the screening tools.~Nutritional Risk Screening 2002 (NRS-2002) : The patients were classified as being nutritionally risk (NRS+): total score ≥ 3 or nutritionally risk-free (NRS-): total score < 3 according to NRS 2002 results.~Subjective Global Assessment (SGA) The SGA screening provides three alternative categories for nutritional classification: well nourished (A); mild-to-moderately malnourished (B); or severely malnourished (C)."
89573007|NCT04798963|Other|On-clamp partial nephrectomy|Patients who are assigned to on-clamp partial nephrectomy.
89573008|NCT04798963|Other|Off-clamp partial nephrectomy|Patients who are assigned to off-clamp partial nephrectomy.
89573009|NCT04787263|Experimental|CD19-CAR_Lenti|Following lymphodepletion with chemotherapy (fludarabine + cyclophosphamide), patients will be treated with 1.0 to 3.0 x 10^6/kg CD19-Chimeric Antigen Receptor (CAR)_Lenti positive cells as a single dose. The product will be infused fresh, at the end of manufacturing.
88970737|NCT02958475|Active Comparator|Breastfeeding Messages plus Social Support|Participant will receive between 5-7 text messages weekly through push notifications to their phone. The text messages are targeted at specific theoretical constructs such as outcome expectations/attitudes, barrier self-efficacy, reinforcing a message using peripheral (expert) opinion, eliciting a sense of social currency or providing a cue-to-action. In addition they will be able to download the MMM app, which will store text messages received. Additionally, participants in this arm will be able to link within the app to a private Facebook page. Participants can access this page through their app or directly via Facebook where they can view, comment, and share in response to posts. The MMM app has three main elements: text messages via push notification are stored and searchable on the app, access to a breastfeeding social support group on Facebook, and access to videos and written material to facilitate knowledge acquisition and skills building.
89573010|NCT04810039||doctor working in neuro-intensive unite care|doctor predicting the outcome of the Glasgow Outcome Scale (GOS) score at 6 months compared to the actual outcome, in 20 anonymized records.
89573011|NCT04809727|Experimental|Biopsy|four quadrant biopsy
89573012|NCT04798417|Experimental|Probiotic|
89573013|NCT04798417|Experimental|Prebiotic|
89573014|NCT04798417|Placebo Comparator|Maltodextrin|
89573015|NCT04809649|Experimental|SUBA-itraconazole|Drug: SUBA-itraconazole Dosage Form: 65 mg capsules Dosage: 260 mg/day Frequency: 130 mg twice daily (BID) Duration: Up to 180 days
89573016|NCT04354831|Experimental|ICU Cohort|Patients who are in the ICU at the time of enrollment. Patients will receive anti-SARS-CoV-2 convalescent plasma.
89573017|NCT04354831|Experimental|Non-ICU Cohort|Patients who are NOT in the ICU at the time of enrollment. Patients will receive anti-SARS-CoV-2 convalescent plasma.
89573018|NCT04786795|Experimental|Compound Azintamide Enteric-coated Tablets|If dyspeptic symptoms occur after laparoscopic cholecystectomy and are randomized, the experimental group takes Compound Azintamide Enteric-coated Tablets. They were registered before medication and on days 14 and 28 after medication, and gastrointestinal symptoms were assessed at each follow-up visit.
89573019|NCT04786795|Placebo Comparator|Oryz-aspergillus Enzyme|If dyspeptic symptoms occur after laparoscopic cholecystectomy and are randomized, the control group takes Oryz-aspergillus Enzyme both Pancreatin Tablet and Ursodeoxycholic Acid Tablets. They were registered before medication and on days 14 and 28 after medication, and gastrointestinal symptoms were assessed at each follow-up visit.
89573020|NCT04375189|No Intervention|Standard Care|
89573021|NCT04375189|Experimental|Complex Clinic Arm|
89573022|NCT04809337|Experimental|Stabilization Exercise Group|
89573023|NCT04809337|Experimental|Therapeutic Exercise Group|
89573024|NCT04808635||general surgery residents|
89573025|NCT04808635||orthopedic surgery residents|
89573026|NCT04808635||urology residents|
89573027|NCT04808635||OBGYN residents|
89573028|NCT05614219|Experimental|Biochemistry interpretive comment on LDL-C levels|"The general practitioners and hospital wards will be allocated in cluster according to their providing lab, and stepwise implement the comment on LDL-C > 4 mmol/L in persons under the age of 40 and over 5 mmol/L in persons over the age of 40 years. Raising awareness on familial hypercholesterolemia an encouraging to referral.~Cluster 1. Will from the 01.12.2022 implement comment on LDL-C Cluster 2. Will from the 01.03.2023 implement comment on LDL-C Cluster 3. Will from the 01.06.2023 implement comment on LDL-C Cluster 4.Will from the 01.09.2023 implement comment on LDL-C"
89573029|NCT05614219|No Intervention|Control|"The clusters will act as their own controls, due to the stepwise implementation of the comment.~Cluster 2: Will not implement the comment before the 01.03.2023 Cluster 3: Will not implement the comment before the 01.06.2023 Cluster 4: Will not implement the comment before the 01.09.2023"
89573030|NCT04241575|Experimental|Intervention group|"For patients in the intervention group, we will calculate the fibrosis scores. For patients with increased fibrosis scores, we will type the following pop-up message in our electronic clinical management system:~This patient has high Fibrosis-4 index (and/or AST-to-platelet ratio index) of xxx suggestive of significant liver fibrosis. Please consider referring the patient to the hepatology clinic or arranging further test such as FibroScan.~The reminder message will pop up when physicians see the patient at the clinic and use the electronic clinical management system. The message will remain active for one year. Although the message is entered manually at this stage, the arrangement mimics an automated computer system. If the study results are positive, the next step is to modify the system to automate the process."
89573031|NCT04241575|No Intervention|Control group|Patients in the control group will undergo the same assessments as patients in the intervention group. Although physicians will have access to the raw liver biochemistry results and platelet count, the fibrosis score results will not be specifically shown, and there will be no electronic reminder messages regardless of the fibrosis scores. This is to mimic usual care when there is no dedicated care model for case identification.
89573032|NCT04767685||All patients|Consenting patients undergoing non-emergency surgery with anesthesia
89573033|NCT02596945||Peritoneal Dialysis participants|Participants who are on peritoneal dialysis and have been prescribed with methoxy polyethylene glycol were observed for a period of 9 months.
89573034|NCT04761523|Active Comparator|Reduced fat arm|Daily calorie intake will be composed of 15% fat, 65% carbohydrates, 20% proteins
89573035|NCT04761523|Active Comparator|Standard healthy diet arm|Daily calorie intake will be composed of 30% fat, 50% carbohydrates and 20% proteins.
89573036|NCT04786483|Experimental|Laughter Therapy group|All students enrolled in the laughter therapy group will receive a total of 10 sessions of laughter therapy, 60 minutes, 2 days a week.
89573037|NCT04786483|No Intervention|Control|No attempt will be made to students in this group.
89573038|NCT04786327|Placebo Comparator|treated by using Minimally invasive flap only.|7 sites treated with Minimally invasive flap only
89573039|NCT04786327|Experimental|Minimally invasive flap with root conditioning (EDTA) and platelet rich fibrin .|7 sites treated with Minimally invasive flap plus EDTA root conditioning and application of platelet rich fibrin graft
89573040|NCT04786327|Experimental|MIST with root conditioning (EDTA) and GEM 21S .|7 sites treated with Minimally invasive flap plus EDTA root conditioning and application of growth factor enhanced matrix GEM21S
89573041|NCT05614141||Study Group|
89573042|NCT05614141||Control Group|
89573043|NCT04153435|Experimental|Calcium|The intervention will consist of 5 mmol (10 mL ampoule) of calcium chloride (CaCl2) administered intravenously or intraosseously immediately after the first dose of adrenaline and again after the second dose of adrenaline.
89573044|NCT04153435|Placebo Comparator|Placebo|"The placebo will consist of 10 mL of 9 mg/mL sodium chloride (NaCl, normal saline) administered intravenously or intraosseously immediately after the first dose of adrenaline and again after the second dose of adrenaline."
89573045|NCT04121845|Active Comparator|Treatment group|Coronary sinus reducer implantation through right internal jugular vein.
89573046|NCT04121845|Sham Comparator|Sham group|Puncture of the right internal jugular vein and simulation of the CSR implantation procedure.
89573047|NCT02404389|Experimental|LFX453 0.1% NMC|LFX453 0.1% nanomedicinal cream (NMC) Twice daily applications
89573048|NCT02404389|Experimental|LFX453 0.15% LCC|LFX453 0.15% liquid crystal cream (LCC) Twice daily applications
89573049|NCT02404389|Placebo Comparator|Vehicle to NMC|Vehicle to nanomedicinal cream (NMC) Twice daily applications
89573050|NCT02404389|Placebo Comparator|Vehicle to LCC|Vehicle to liquid crystal cream (LCC) Twice daily applications
89573051|NCT02404389|Active Comparator|Aldara|Aldara cream 3 applications per week
89573052|NCT01667419|Experimental|Cohort 1 Vemurafenib|Participants with completely resected Stage IIC, IIIA, or IIIB cutaneous melanoma) received vemurafenib, 960 milligrams (mg) twice daily, in 28-day cycles, for up to 52 weeks
89573053|NCT01667419|Placebo Comparator|Cohort 1 Placebo|Participants with completely resected Stage IIC, IIIA, or IIIB cutaneous melanoma) received vemurafenib-matching placebo twice daily, in 28-day cycles, for up to 52 weeks
89573054|NCT01667419|Experimental|Cohort 2 Vemurafenib|Participants with Stage IIIC cutaneous melanoma received vemurafenib, 960 mg twice daily, in 28-day cycles, for up to 52 weeks
89573055|NCT01667419|Placebo Comparator|Cohort 2 Placebo|Participants with Stage IIIC cutaneous melanoma received vemurafenib-matching placebo twice daily, in 28-day cycles, for up to 52 weeks
89573056|NCT04089709|Experimental|Study arm|Patients randomized to this group will be provided exercises to perform with the uninjured arm once daily for 3 months.
89573057|NCT04089709|No Intervention|Control arm|"Patients randomized to this group will not be provided exercises for the well-arm and will be managed according to the current standard of care."
89573058|NCT04808791|Experimental|Single Arm iTTO treatment|"Patients will receive the combination of irinotecan, TAS-102, and Oxaliplatin on a 28 day cycle with the following doses;~Irinotecan 160mg/m2 IV infusion over 60-90 mins on day 1~Oxaliplatin 100mg/m2 IV infusion over 2 hours on day 1~TAS-102 (Trifluridine/Tipiracil) 25mg/m2 twice a day, on days 1-5 and 8-12 every 28days."
89573059|NCT04808557|Active Comparator|Trial Group|Volunteers from this group will have bonded buttons on vestibular surfaces of elements 1.4, 1.5 and 1.6. Then they will use Biorepair Total Protection for home oral care for 30 days. In this time period, the buttons will be respectively debonded at 7 (1.4), 15 (1.5) and 30 (1.6) days after the bonding procedures, in order to be evaluated at SEM.
89573060|NCT04808557|Active Comparator|Control Group|Volunteers from this group will have bonded buttons on vestibular surfaces of elements 1.4, 1.5 and 1.6. Then they will use Sensodyne Repair & Protect for home oral care for 30 days. In this time period, the buttons will be respectively debonded at 7 (1.4), 15 (1.5) and 30 (1.6) days after the bonding procedures, in order to be evaluated at SEM.
89573061|NCT04808089|Experimental|Health Lung App. +ezOxygen|"Health Lung App. (AstraZeneca Pharmaceuticals LP) is the application for mobile phone to help asthma care and is available freely in Google Play. Health Lung can be connected to the mobile spirometry, ezOxygen (Genius Holding Co.,Ltd Taiwan Branch).~The functions of Health Lung App. include asthma control monitor, lung function monitor, controller and reliver inhaler reminder and recording, asthma educational topics in brief and information of air quality~Subjects can get reminder to use inhaler on schedule, input ACT score to evaluate the asthma control, get education materials about asthma and operate spirometer to access lung function outside of hospital.~he physicians in charge will get the information about control status score by ACT, adherence of controller and usage of reliver of patients between each clinical visit, if patients following the instruction of Health Lung."
89573062|NCT04808089|Active Comparator|Usual care|The research assistant assess/ teach inhaler technique, offering the asthma education as the regular clinical service.
89573063|NCT04785937|Experimental|Imaging and Biopsy|All patients undergo both liver biopsy and liver imaging (US and MR) to assess the diagnostic performance of imaging compared to histopathological examination in the diagnosis of NASH and fibrosis.
89573064|NCT04785703||oral lichen planus group|patients with chronic bollus erosive lichen planus
89573065|NCT04785313||Retrievable Inferior Vena Cava Filters (IVCF)|The population study includes patients with a Retrievable Inferior Vena Cava Filters (IVCF) placed because of temporary contraindication to curative anticoagulation and that was been removed by the radiology department at the University Hospital of Saint-Etienne, between January 1, 2010 and December 31, 2014. All the Inferior Vena Cava Filters (IVCF) were been sent for histological examination.
89573066|NCT04785235||ACS|Group ACS: Acute Coronary Syndrome
89573067|NCT04785235||Periodontitis|Group P :Periodontitis
89573068|NCT04807855|Experimental|the experimental arm|All subjects, the ptosis group and the normal group receive the same intervention.
89573069|NCT03843853|Experimental|Pemetrexed + S-1 + Bevacizumab|Pemetrexed 500 mg/m2 d1+ S-1 (20mg、25mg), capsule, 40~60mg, Bid,p.o, d1~14 + Bevacizumab 7.5 mg/kg d1; Repeated every 3 weeks
89573070|NCT04784923||Instrumentation patients|Instrumentation patients
89573071|NCT04784767|Experimental|1A: 25 µg of SpFN + ALFQ on Days 1, 29 and 181.|Up to 20 participants will receive 25 µg of SpFN_1B-06-PL vaccine with 0.5 mL ALFQ adjuvant in a total 1.0 mL injection volume.
89573072|NCT04784767|Placebo Comparator|1B: Placebo (Sodium chloride, USP, for injection (0.9% NaCl) on Days 1, 29 and 181.|4 participants will receive 1.0mL of normal saline as Placebo on Study Days 1, 29, and 181.
89573073|NCT04784767|Experimental|2A: 50 µg of SpFN + ALFQ on Days 1, 29, and 181.|Up to 20 participants will receive 3 intramuscular injections of: 50 ug of SpFN_1B-06-PL with 0.5 mL ALFQ adjuvant.
88970738|NCT02958475|Active Comparator|Breastfeeding Messages only|Participant will receive between 5-7 text messages weekly through push notifications to their phone. The text messages are targeted at specific theoretical constructs such as outcome expectations/attitudes, barrier self-efficacy, reinforcing a message using peripheral (expert) opinion, eliciting a sense of social currency or providing a cue-to-action.
88970739|NCT00392535|Active Comparator|Control arm|conventional radiotherapy (74 Gy delivered in 37 fractions over 7·4 weeks)
88970740|NCT00392535|Experimental|Hypofractionated arm 1|Hypofractionated radiotherapy (60 Gy in 20 fractions over 4 weeks)
89573074|NCT04784767|Placebo Comparator|2B: Placebo (Sodium chloride, USP, for injection (0.9% NaCl) on Days 1, 29, and 181.|4 participants will receive 1.0mL of normal saline as Placebo on Study Days 1, 29, and 181.
89573075|NCT04784767|Experimental|3A: 50 µg of SpFN + ALFQ on Days 1 and 181.|Up to 20 participants will receive 2 intramuscular injections of: 50 ug of SpFN_1B-06-PL with 0.5 mL ALFQ adjuvant.
89573076|NCT04784767|Placebo Comparator|3B: Placebo (Sodium chloride, USP, for injection (0.9% NaCl) on Days 1 and 181.|4 participants will receive 1.0mL of normal saline as Placebo on Study Days 1 and 181.
89573077|NCT04784611|Experimental|Group 1 - OP-ENS Intervention|Participants will be matched with a peer health navigator. As part of this complex behavioral intervention, participants and peer health navigators will engage in a systematic process of barrier and strength identification, goal setting and action planning related to issues of healthcare access and quality. Participants and peers will meet at least monthly over the course of the 12-month study period (but frequency is determined by participant need). Given the nature of the disability and healthcare experience, we anticipate the needs and therefore frequency will fluctuate over the duration of the study period. Beginning in month 10, participants and peers will engage in a period of transition planning to ensure that participants have the strategies and supports in place to assume the role of their own health navigator.
89573078|NCT04784611|No Intervention|Group 2 - Usual Care|Participants randomized to the usual care group will continue with their usual health and healthcare routines. Participants in the usual care group will receive a monthly newsletter with general interest information relevant to the disability community.
89573079|NCT05054179|Experimental|Intervention Group|The participants of this group will receive 20 mL of 0.2% Ropivacaine via parasternal multi-orifice catheters on each side of the sternum, followed by infusion of 3 mL/h for 48 hours.
89573080|NCT05054179|Placebo Comparator|Placebo group|The participants of this group will receive 20 mL of 0.2% Ropivacaine via parasternal multi-orifice catheters on each side of the sternum, followed by infusion of 3 mL/h of normal saline for 48 hours.
89573081|NCT03688945|Experimental|Arm I (art sessions)|Participants attend at least 1 session of viewing art pieces over 15 minutes every day for 2 years.
89573082|NCT03688945|Active Comparator|Arm II (standard of care)|Participants receive standard of care for 2 years.
89573083|NCT05612113|Active Comparator|Baseline - Session Goal Formulation|"In the baseline phase, the therapist will formulate two session goals, see under descriptions of primary outcome measure.~In this SCED-study, the baseline phase will be of randomized length (5-9 sessions) for each therapist.~The reason for defining this as an active comparator is that we the behavior of formulating two session goals before each session should be considered an intervention, stimulating the therapist to reflect on the upcoming session goals, on defining concrete behaviors to reach the session goal, and to reflect upon his/her session behaviors afterwards. Thus, regarding the baselinephase as a no intervention would be misleading."
88970741|NCT00392535|Experimental|Hypofractionated arm 2|Hypofractionated radiotherapy (57 Gy in 19 fractions over 3·8 weeks)
88970742|NCT00068224||Ciliopathy|Children and adults who carry a clinical diagnosis of a known ciliopathy and those patients who have typical features suggestive of a cliopathy but not fulfilling the diagnostic criteria.
89573084|NCT05612113|Experimental|Live Supervision with Bug-in-the-Ear (BITEar) as method|"LS with the Bug-in-the-Ear (BITEar) is a video based supervision format where the supervisor watches the therapy session live through a webcam in the therapy room. During the therapy session, the supervisor provide verbal feedback and guidance to the therapist who wears wireless in-ear headphones.~In this SCED-study, the intervention phase consist of 5 to 9 BITEar supervision sessions (number of supervision sessions is randomized between therapists)~The BITEar supervision will consist of three phases:~Pre-supervision (15 minutes): Discussion of the therapists session goals, how the therapist wants the supervisor's help and agreement on prompts and cues from supervisor~Live supervision during the therapy session (≈ 45-60 minutes): Supervisor gives real time feedback and guidance focusing on helping the therapist achieve session goals~Post-supervision (15 minutes): Reflection about the session, session goals and the supervision."
88970743|NCT04975295|Experimental|LY3361237|LY3361237 administered subcutaneously (SC).
88970744|NCT04975295|Placebo Comparator|Placebo|Placebo administered SC.
88970745|NCT00068302|Experimental|Sirolimus|This is a dose escalation study including 4-dose levels. Subjects will receive a one-time loading dose of sirolimus on day 0, time 0. Subsequent dosing at the assigned dose level will start 24 hours following the initial loading dose
88970746|NCT00068458|Active Comparator|Arm 1: calcium diet|Calcium-Rich Diet (dietary counseling + materials promoting an intake of 1,200 - 2,500 mg/day).
88970747|NCT00068458|Active Comparator|Arm 2: Exercise + Calcium-Rich Diet|Exercise + Calcium Rich Diet (dietary counseling + materials promoting strength training and aerobic activity + a calcium intake of 1,200 - 2,500 mg/day).
88970748|NCT00068458|Active Comparator|Exercise + Fruit & Vegetable, Low Fat + Calcium Diet|Dietary counseling + materials promoting strength training and aerobic activity + a diet that has < 20% of energy coming from fat and intakes of fruits and vegetables of > 5 servings/day + a calcium intake of 1,200 - 2,500 mg/day. 6 month intervention.
88970749|NCT02966821|Experimental|Surufatinib|Surufatinib 300mg once-daily
88970750|NCT00068497|Experimental|Treatment (gefitinib)|Patients receive oral gefitinib on day 1 and then daily beginning on day 8. Treatment continues in the absence of disease progression or unacceptable toxicity.
88970751|NCT00068653|Experimental|Celecoxib & ZD1839|"Celecoxib: 400mg orally two times a day, taken with meals.~ZD1839: 250 mg po every day, taken with or without food."
89033197|NCT05319743||Medicaid expansion states|Eight Medicaid expansion states: (experimental group): Arizona, California, Illinois, Massachusetts, New Jersey, Ohio, Washington
89029007|NCT05013749|Active Comparator|Partial myometrial resection|Partial myometrial resection: The technique described by Palacios-Jaraquemada et al5. will be followed. Briefly, the uterus will be dissected to free it from the posterior wall of the bladder to the cervix. The vesicouterine vessels will be ligated and the parametrial space will be visualized. The hysterotomy will be performed in the upper segment, immediately above the area of invasion of the myometrium. The entire invaded myometrium and the entire placenta will be removed. The uterus will repair itself in one or two layers. Intrauterine balloon tamponade will be used if indicated.
89573085|NCT05014477||Patients experiencing device embolization after left atrial appendage occlusion|Device embolization following either surgical or interventional left atrial appendage occlusion
89573086|NCT03679585|Experimental|Supportive Care (social media intervention)|Participants undergo Talking Pictures social media intervention for 10 weeks, receiving weekly assignments via email with requirements to use the Pixstori app to take and upload photographs with verbal narratives attached to a website. Participants can then share their pixstories to a group page and view and respond to others' pixstories.
89573087|NCT04972825|Experimental|UNITED|UNITED is premised on the idea that successful implementation in organizations like schools and early intervention systems requires a team-based approach, in which the team is thoughtfully assembled, develops a plan for implementation, assigns roles and responsibilities, and carefully tracks and supports implementation and sustainment in all its stages within a few meetings and ongoing coaching from the research staff.
89573088|NCT04972825|Active Comparator|Implementation as Usual (IAU)|The organizations will implement Mind the Gap as usual. The research team will be available to provide support on the Mind the Gap intervention as needed.
89573089|NCT03588637||Study population|Patient who receive at least one dose of daptomycin
89573090|NCT05472805||CIMT ≥1mm|The measurement of CIMT will be carried by a cardiologist in the cardiovascular department using B mode ultrasound. The cardiologist will measure both of the carotid artery, and higher measurement of CIMT will be recorded. This group includes individual with CIMT ≥1mm
89573091|NCT05472805||CIMT <1mm|The measurement of CIMT will be carried by a cardiologist in the cardiovascular department using B mode ultrasound. The cardiologist will measure both of the carotid artery, and higher measurement of CIMT will be recorded. This group includes individual with CIMT <1mm
89573092|NCT05472727||Case group (mild cognitive impairment)|geriatric population with mild cognitive impairment
89573093|NCT05472727||Control Group (healthy elderly)|healthy older adults without cognitive impairment
89573094|NCT05472571|Experimental|Forest bathing|
89573095|NCT03529669|Experimental|Cytosponge™|All participants will receive the Cytosponge™ device.
89573096|NCT05472493|Experimental|CETO|The consented participants will receive the [18-F] CETO through the IV and a PET/CT scan afterwards.
89573097|NCT02588833|Experimental|Cohort 1|180 mg pegcetacoplan/day
89573098|NCT02588833|Experimental|Cohort 2|270 mg pegcetacoplan/day
89573099|NCT05472415|Experimental|experimental group|cognicise training with insole intervention
89029008|NCT05008965|Experimental|FB825|"FB825 will be administered at 8 mg/kg for the first dose and 4 mg/kg for the other five doses.~FB825 will be administered as 1-hour IV- infusions every 4 weeks."
89573100|NCT05472415|Active Comparator|control group|cognicise training
89573101|NCT04884373||Fasted adult patients for elective surgery|"Age ≥ 18 years~Fasted according to national guidelines~Elective surgery~ASA physical status I-II~Ability to assume both supine and right lateral decubitus position.~Able to understand and to sign informed consent"
89573102|NCT05472103|Experimental|treatment|administration of Surgical ergonomics workshop
89029009|NCT05008965|Placebo Comparator|Placebo|"Placebo will be administered at 8 mg/kg for the first dose and 4 mg/kg for the other five doses.~Placebo will be administered as 1-hour IV- infusions every 4 weeks."
89029010|NCT05005078|Placebo Comparator|Placebo|WST-057 Matching placebo
89029011|NCT05005078|Experimental|WST-057|WST-057 topical solution
89029012|NCT04994327|Experimental|Beta-glucan bread|Frozen bread is administered to the participants for home storage. Bread is thawed at home before consumption. Dosage: At least 3 slices of bread 6 days per week for 16 weeks
89029013|NCT04994327|Placebo Comparator|Control bread|Frozen bread is administered to the participants for home storage. Bread is thawed at home before consumption. Dosage: At least 3 slices of bread 6 days per week for 16 weeks
89029014|NCT04978454|Experimental|Cohort 1A|10^4 TCID50of recombinant H3N2 (A/Texas/71/2017, clade 3C3a) 1.0 mL (0.5mL per nostril) influenza virus (n=12) and Sham Sucrose phosphate glutamate (SPG) inoculum 1.0 mL (0.5mL per nostril) (n=1) administered intranasally on Day 1. If 80% or more subjects in Cohort 1A meet the case definition for influenza, proceed to Cohort 1B. If fewer than 80% of subjects meet the case definition for influenza in Cohort 1A, the dose will escalate to include Cohort 2A. N = 13
89033198|NCT05319743||Non-Medicaid expansion states|Five states that did not expand Medicaid (control group): Florida, Georgia, North Carolina, Texas, Virginia
89033199|NCT02921100|Other|Conventional cytology|Patients in this arm will undergo an operation of EUS-FNA . The acquired cytological samples from EUS-FNA will undergo a conventional cytology.
89573103|NCT05472103|No Intervention|control|no intervention
89573104|NCT05613595|Active Comparator|Positive Psychotherapy Group|In this phase of the study, the caregivers of CP having moderate to high scores on mental health issues on three scales (Depression, Burnout & Caregiver burden) will receive positive Psychotherapy sessions for a period of four months, divided over different weekly sessions. For Psychotherapy treatment group participants will be given both counseling as well as Positive psychotherapy based interventions. . Each session will be based upon individual session and duration of the session will be 40 minutes. Before starting every session feedback will be taken about the previous session and home based assignments will also be discussed
89573105|NCT05613595|Active Comparator|Counseling Group|10 participants will be included in in control group (N=10), for control group caregivers will be given regular counseling as a part of treatment of their child (psychoeducation). Each session will be based upon individual session and duration of the session will be 40 minutes.
89573106|NCT05613439||Day-surgery group|Patients having hip or knee replacement as day-surgery with successful discharge to own home on day of surgery
89029015|NCT04978454|Experimental|Cohort 1B|10^4 TCID50 of recombinant H3N2 (A/Texas/71/2017, clade 3C3a) 1.0 mL (0.5 mL per nostril) influenza virus (n=12) and Sham Sucrose phosphate glutamate (SPG) inoculum 1.0 mL (0.5 mL per nostril) (n=1) administered intranasally on Day 1. If 80% or more subjects in Cohort 1A and 1B meet the case definition for influenza, proceed to Cohort 1C. Cumulatively, if fewer than 80% of subjects in Cohorts 1A and 1B meet the case definition for influenza, the dose will escalate to include Cohort 2A. N = 13
89029016|NCT04978454|Experimental|Cohort 1C|10^4 TCID50 of recombinant H3N2 (A/Texas/71/2017, clade 3C3a) 1.0 mL (0.5 mL per nostril) influenza virus (n=12) and sham sucrose phosphate glutamate (SPG) inoculum 1.0 mL (0.5 mL per nostril) (n=1) administered intranasally on Day 1. If 80% or more of the subjects in Cohorts 1A, 1B, and 1C combined meet the case definition for influenza then the optimal dose of 104 TCID50 will be selected. Cumulatively, if fewer than 80% of subjects in Cohorts 1A, 1B, and 1C meet the case definition for influenza the dose will escalate to include Cohort 2A. N = 13
89573107|NCT05613439||High-risk patients|Patients evaluated to be at increased risk of postoperative complications. These patients will receive relevant additional attention based on type of comorbidity. I.e. preoperative evaluation of iron status and i.v. iron treatment in case of preoperative anaemia, increased focus on avoidance of NSAIDs and adequate fluid therapy in patients with renal disease etc.
89573108|NCT05613439||Main group|"Patients who are not scheduled for day-surgery and without comorbidities qualifying as high-risk. These patients go through a standard fast-track procedure with discharge to own home when fulfilling functional discharge criteria."
89573109|NCT05471713||PD with AutD|Parkinson's disease with autonomic dysfunction
89573110|NCT05471713||PD without AutD|Parkinson's disease without autonomic dysfunction
89573111|NCT04789057|Experimental|Statins|Atorvastatin 40 mg treatment, p.o., QD
89573112|NCT04789057|Placebo Comparator|Placebo|Placebo tablet, p.o., QD
89573113|NCT05611723||Healthy older Adults|Healthy older Adults: older adults without disability indicators
89573114|NCT05611723||Disability Older Adults|Disability Older Adults: older adults with disability indicators
89573115|NCT05611645|Experimental|HSRT+Low-dose Bevacizumab|HSRT with low-dose bevacizumab every 2 weeks
89573116|NCT05611645|Active Comparator|Bevacizumab|Bevacizumab every 2 weeks
89573117|NCT05611567|Experimental|POSE2.0|This is the arm that got the POSE2.0 procedure. The POSE 2.0 involves full-thickness plications by suture anchor pairs that shorten and tabularize the stomach along its greater curvature. The POSE 2.0 procedure was carried out using the Incisionless Operating Platform (USGI Medical, San Clemente, CA). This device is registered and commercially available in the United Arab Emirates for the management of obesity.
89573118|NCT05611567|Active Comparator|Life style and behavioral intervention|This is the comparator arm that received lifestyle modification alone for weight loss and NAFLD management (representing the comparative control group). This group underwent the same lifestyle program and clinical follow-up as the POSE2.0, but under a parallel standard clinical care pathway, which is the standard clinical pathway in the hospital this study was conducted in.
89573119|NCT05611489|Other|Open appendectomy|Appendectomy will be done through Mcberney incision.
89029017|NCT04978454|Experimental|Cohort 2A|10^5 TCID50 of recombinant H3N2 (A/Texas/71/2017, clade 3C3a) 1.0 mL (0.5 mL per nostril) influenza virus (n=12) and Sham Sucrose phosphate glutamate (SPG) inoculum 1.0 mL (0.5 mL per nostril) (n=1) administered intranasally on Day 1. If 70% or more subjects in Cohort 2A meet the case definition for influenza, proceed to Cohort 1B. If fewer than 70% of subjects meet the case definition for influenza in Cohort 2A, the dose will escalate to include Cohort 3A. N = 13
89029018|NCT04978454|Experimental|Cohort 2B|10^5 TCID50 of recombinant H3N2 (A/Texas/71/2017, clade 3C3a) 1.0 mL (0.5 mL per nostril) influenza virus (n=12) and Sham Sucrose phosphate glutamate (SPG) inoculum 1.0 mL (0.5 mL per nostril) (n=1) administered intranasally on Day 1.If 70% or more subjects in Cohort 2A and 2B meet the case definition for influenza, proceed to Cohort 2C. Cumulatively, if fewer than 70% of subjects in Cohorts 2A and 2B meet the case definition for influenza, the dose will escalate to include Cohort 3A N = 13
89033200|NCT02921100|Other|DNA ploidy test|Patients in this arm will undergo an operation of EUS-FNA . The acquired cytological samples from EUS-FNA will undergo DNA ploidy test.
89573120|NCT05611489|Other|Conventional lap appendectomy|Three ports will be inserted as follows: One 10/12 umbilical port, one 5mm suprapubic (or right suprapubic)port, one 5mm or 10/12mm port in left iliac fossa (or left suprapubic).
89573121|NCT04426513|Active Comparator|Only kinesiotherapy|Patients have only kinesiotherapy of hand without steroid anti-inflammatory drugs and magnetotherapy.
89033201|NCT02943005|Active Comparator|Rotator cuff repair with sling|Patients wear a sling during 4 weeks, they also move passively during this period. Then progressive active mobilization is done.
89573122|NCT04426513|Experimental|Kinesiotherapy with bipolar magnetic field|Patients have kinesiotherapy of hand and bipolar magnetic field. All patients without steroid anti-inflammatory drugs.
89573123|NCT04426513|Experimental|Kinesiotherapy with unipolar magnetic field|Patients have kinesiotherapy of hand and unipolar magnetic field. All patients without steroid anti-inflammatory drugs.
89573124|NCT02977195|Experimental|Dose escalation part, biological cohort and expansion Parts|Dose Escalation and Biological Cohort: NP137 was administrated in patients with locally advanced or metastatic solid tumors Expansion Parts: NP137 was administrated in patients with locally advanced or metastatic solid tumors (Expansion part 1) and in patients with RH+ endometrial cancers (Expansion part 2)
89573125|NCT04340167|Experimental|Autologous humanized anti-CD22 CAR-T treatment|
89573126|NCT02907697|Experimental|LifeSteps-Drug Use|The investigators expect the LifeSteps-Drug Use adaptation will be modeled after the Life Steps adherence intervention with the addition of a Drug Use module based on motivational interviewing and the FRAMES approach. The LifeSteps-Drug Use intervention is expected to include two in-person sessions and two telephone booster sessions. While anticipated preliminary adaptations have been based on the extant literature, changes to the protocol will be based on data obtained during the qualitative phase which will be sufficiently broad and open to assess for factors that we have not anticipated.
89573127|NCT02907697|Active Comparator|Health Education|The health education condition is a time-matched, active control arm. It will consist of two in-person sessions and two telephone sessions. Each session will cover a general health education topic.
89573128|NCT02906215|Experimental|Care Coordination Intervention|The care coordination intervention will consist of a mobile application designed for treatment providers, an interagency communication protocol, and a series of cross-training in HIV and addiction issues.
89573129|NCT02835079|Other|open label study|one arm open label study
89573130|NCT02474095|Experimental|Arm I (ALTENS QIW)|Patients undergo ALTENS delivered via the Codetron machine QIW for 6 weeks in the absence of disease progression or unacceptable toxicity.
89573131|NCT02474095|Active Comparator|Arm II (ALTENS BIW)|Patients undergo ALTENS delivered via the Codetron machine BIW for 12 weeks in the absence of disease progression or unacceptable toxicity.
89573132|NCT05455567||patients with pre perimetric open angle glaucoma|
89573133|NCT05455567||patients with perimetric open angle glaucoma|
89573134|NCT05455567||healthy patients|
89573135|NCT05446285||Treated|Patients initiating disease modifying treatment within the first year of diagnosis
89573136|NCT05446285||Untreated|Patients who do not initiate disease modifying treatment within the first year of diagnosis
89573137|NCT05436145|Experimental|Within-participant micro-randomization|"Each day in the study, with probability .5 for each, a participant is randomized to receive a notification that day or no notification that day.~If a participant is assigned to receive a notification that day, 1 message set will be randomly selected from a pool of 60 message sets. There are 2 types of message sets: 1) Support and 2) Consequences.~If a participant is assigned to receive a Support message set, they will be randomized to receive either the Emotional or Practical Support version. If a participant is assigned to receive a Consequences message set, they will be randomized to receive either the Gain Framed or Loss Framed version."
89573138|NCT01667107|Experimental|Posaconazole - CF Participants|Posaconazole 400 mg oral solution twice daily administered with Calogen® to optimize absorption for a total of 6 weeks starting within 12 hours of leaving surgery, thereafter administered in the hospital or as an outpatient; the dose could be changed to posaconazole 200 mg 4 times per day if the participant is unable to meet the conditions for optimal absorption of posaconazole.
89573139|NCT01667107|Experimental|Posaconazole - Non-CF Participants|Posaconazole 400 mg oral solution twice daily administered with Calogen® to optimize absorption for a total of 6 weeks starting within 12 hours of leaving surgery, thereafter administered in the hospital or as an outpatient; the dose could be changed to posaconazole 200 mg 4 times per day if the participant is unable to meet the conditions for optimal absorption of posaconazole.
88970752|NCT00068731|Experimental|lycopene|"Patients receive oral lycopene twice daily on days 1-28. Courses repeat every 28 days for at least 4 months in the absence of disease progression or unacceptable toxicity.~Patients are followed every 3 months until disease progression and then every 6 months for up to 5 years."
89573140|NCT04412239|Experimental|Telephone Consultation in TB Patients|The COVID-19 pandemic might be an opportunity to review and refine our practices in TB care. For the follow-up of selected patients, telephone consultations may be efficient and cost-effective.
89573141|NCT02410213|Experimental|Ferric Carboxymaltose (FCM)|FCM at 7.5 mg/kg or 15 mg/kg to a maximum single dose of 750 mg iron, whichever is smaller
89573142|NCT04411615|Experimental|Omega|Omega-3 re-esterified triglyceride form
89573143|NCT01802203||truFreeze spray cryotherapy|truFreeze Spray Cryotherapy administered as routine clinical care
88970753|NCT00068809|Experimental|Short-cycle therapy (SCT)|At entry, subjects will switch from continuous HAART to SCT. All subjects will then be followed to assess viral load breakthrough over 48 weeks on SCT.
88970754|NCT00399061|Active Comparator|1|Systane
88970755|NCT00399061|Active Comparator|2|Optive
88970756|NCT00399061|Placebo Comparator|3|Restasis
88970757|NCT00069082|Active Comparator|Civamide|Nasal Solution 0.01%
88970758|NCT00069082|Placebo Comparator|Placebo|Placebo nasal solution with sodium chloride 10%
88970759|NCT04002219|Experimental|Active arm|Subjects will receive treatment with active beverage containing the active ingredient
88970760|NCT04002219|Placebo Comparator|Placebo arm|Subjects will receive treatment with placebo beverage not containing the active ingredient
88970761|NCT02966587|Experimental|Treatment (durvalumab)|Patients receive durvalumab IV over 60 minutes on day 1. Courses repeat every 4 weeks for up to 12 months in the absence of disease progression or unacceptable toxicity.
88970762|NCT04958720||Cohort 1|Resectable non-advanced cancer
88970763|NCT04958720||Cohort 2|Unresectable advanced cancer
88970764|NCT00069706|Experimental|AL-12182 0.003%|One drop in the study eye(s) once daily at approximately 8 a.m. for 14 days
88970765|NCT00069706|Placebo Comparator|AL-12182 Solution Vehicle|One drop in the study eye(s) once daily at approximately 8 a.m. for 14 days
88970766|NCT00069706|Active Comparator|Latanoprost|One drop in the study eye(s) once daily at approximately 8 a.m. for 14 days
88970767|NCT00069706|Experimental|AL-12182 0.01%|One drop in the study eye(s) once daily at approximately 8 a.m. for 14 days
88970768|NCT00069706|Experimental|AL-12182 0.03%|One drop in the study eye(s) once daily at approximately 8 a.m. for 14 days
88970769|NCT03960099|Active Comparator|Pictograph in Banner and Verification Alert|Patient Pictograph displayed in the banner (at the top of the screen) AND Pictograph displayed in a verification alert when placing electronic orders.
88970770|NCT03960099|No Intervention|No Pictograph|No patient Pictographs displayed in the electronic health record.
88970771|NCT03960060|Experimental|CCT301-59|The safety and preliminary therapeutic efficacy of CCT301-59 will be evaluated for subjects with ROR2 positive biopsy in a standard 3+3 dose escalation rule. Three dose levels of CAR T will be administered in this study: 1x10^6, 3x10^6, 1x10^7 CCT301-59 CAR positive T cells/kg weight, intravenous infusion.
88970772|NCT00070057|Experimental|Arm I (celecoxib)|Patients receive oral celecoxib twice daily for 1-3 weeks (according to the duration between biopsy and surgery) in the absence of unacceptable toxicity.
88970773|NCT00070057|Experimental|Arm II (high-dose celecoxib)|Patients receive a higher dose of oral celecoxib as in arm I.
88970774|NCT00070057|Active Comparator|Arm III (surgery)|Patients do not receive treatment. All patients undergo surgery.
88970775|NCT00070213|Active Comparator|MdG (modified de Gramont)|2 weekly 5FU/FA schedule
88970776|NCT00070213|Experimental|OxMdG (80%) for 12 weeks|MdG + oxaliplatin
89573144|NCT04685551|Experimental|Survivorship Management among African American and Latinx Cancer Dyads|"This arm will implement a one group pre-test and posttest design to improve health outcomes of African American and Latinx cancer survivors and caregivers in collaboration with health professional students trained as Cancer Survivorship and Caregiver Leaders Aimed for Minority Populations (CSC LAMPs)."
89573145|NCT04638673|Experimental|Active-Active Stimulation Group|This group will be randomized into the active stimulation group for weeks 1&2 of stimulation and active stimulation during weeks 3&4 of stimulation of study participation.
89573146|NCT04638673|Sham Comparator|Sham-Active Stimulation Group|This group will be randomized into the sham stimulation group for weeks 1&2 of stimulation and active stimulation for weeks 3&4 of stimulation of study participation.
89573147|NCT05240131|Experimental|Part A - GB1211 200 mg and 400 mg BID in combination with atezolizumab.|Part A of the study, open-label sentinel dosing will be undertaken to assess safety and tolerability of GB1211 at 200 mg and 400 mg BID in combination with atezolizumab.
89573148|NCT05240131|Experimental|Part B - GB1211 (200 or 400 mg BID) or Placebo in addition to atezolizumab|Part B of the study, GB1211 (200 or 400 mg BID to be selected from part A) in addition to atezolizumab, for 12 weeks
89573149|NCT05240131|Experimental|Part C - Extension of GB1211 (200 or 400 mg BID) or Placebo in addition to atezolizumab|"Extension of GB1211 in addition to atezolizumab until part B has been unblinded.~Extension of placebo in addition to atezolizumab until part B has been unblinded"
89573150|NCT05220943|Other|Video|All participants are invited to complete a pre survey, watch a five minute video, and then complete a post survey.
89573151|NCT05475145|Experimental|Child|Each patient receives treatment of dental caries in two primary molars using two diffferent methods - Resin based sealing [RBS] or Glassionomer cement [GIC].
89573152|NCT05614999|Active Comparator|Training group|Participants in this group will do the pre-training test, practicing eight-sessions (each session is approximately 15minutes) and then do the post-training test.
89573153|NCT05614999|No Intervention|Non-training group|Participants in this group will do the pre-training test, and then do the post-training test after the pre-test 4-6weeks.
89573154|NCT05188339|Experimental|4% sodium citrate group|Dose of 4% sodium citrate is also according to catheter lumen (LVR) instilled into each lumen of catheter after HD session, eg. 1.6 cc/lumen for LV R 1.6, 1.8 cc/lumen for LVR 1.8.
89573155|NCT05188339|Active Comparator|heparin group|Heparin dosage is based on volume ratio in catheter lumen (LVR) after each HD session, eg. 8000u/lumen in 1.6 LVR, 9000u/lumen in LVR 1.8.
89573156|NCT04393909|Active Comparator|Control group|Patients do not have access to the Patient Dx Questionnaire.
89573157|NCT04393909|Active Comparator|Patient Dx Questionnaire User group|Patient enrollees will be randomized to receive the Patient Dx Questionnaire administered by the research staff at the bedside.
89573158|NCT05474911|Active Comparator|Conventional care|
89573159|NCT05474911|Experimental|Negative pressure therapy|
89573160|NCT05614765||Treatment group|statin+ezetimibe compound
88970777|NCT00070213|Experimental|Capcitabine|
88970778|NCT00070213|Experimental|OxCap|
88970779|NCT04949204||Migraine patients|Wearable wrist sensor + headache application on smartphone
88970780|NCT04949204||Cluster Headache Patients|Wearable wrist sensor + headache application on smartphone
89573161|NCT05613127|Experimental|Test group|Inactivated Hepatitis A vaccine
89573162|NCT05613127|Active Comparator|Control group|Inactivated Hepatitis A vaccine
89573163|NCT05610865|Active Comparator|Control; Standard-of-care management|Saline dressing will be done as a routine care management.
89573164|NCT05610865|Experimental|Only PRP injection|Only PRP will be injected at the wound site.
89573165|NCT05610865|Experimental|PRP + SVF injection|SVF pellet mixed with PRP will be injected at the wound site after adjusting number of cells.
88970781|NCT00070252|Experimental|Treatment (tipifarnib, capecitabine, docetaxel)|"Phase Ib: Patients receive oral tipifarnib twice daily and oral capecitabine twice daily on days 1-14 and docetaxel IV over 30-60 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Phase II: Patients receive oral tipifarnib twice daily for 6 days. Beginning at least 48 hours after completion of the initial dose of tipifarnib, patients receive treatment as in phase Ib for up to 6 courses at the MTD of capecitabine."
88970782|NCT03959865||Long-acting GLP-1RA|Patients who have been treated with weekly GLP-1RA (exenatide once weekly or dulaglutide)
88970783|NCT03959865||Short-acting GLP-1RA|Patients who have been treated with daily GLP-1RA (exenatide bid or liraglutide or lixisenatide)
89573166|NCT05610865|Experimental|PRP + ASCs injection|Cultured ASCs mixed with PRP will be injected at the wound site after adjusting number of cells.
89573167|NCT05134051|Experimental|Single arm|single arm intervention with IVL in calcified de novo coronary stenoses with indication of plaque modification technique during PCI
89573168|NCT02590003|Experimental|Platinum-based doublet chemotherapy|"Carboplatin AUC 5 30 minute infusion IV on day 1~Nab-paclitaxel 100mg/mg2 30 minute infusion IV on days 1, 8 of a 21 day cycle"
89573169|NCT02590003|Active Comparator|Single agent chemotherapy|-Nab-paclitaxel 100mg/mg2 30 minute infusion IV on days 1, 8 of a 21 day cycle
89573170|NCT05474521|Experimental|Participant 1|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
88970784|NCT03959865||Human GLP-1 based GLP-1RA|Patients who have been treated with GLP-1RA based on human GLP-1 (dulaglutide or liraglutide)
89209084|NCT00985647|Active Comparator|3TC 300mg/150mg|Group 1: Participants will be administered 3TC 300 mg once daily orally for 10 days. A 10 day wash-out period will follow (days 11-20). From day 21, participants will be administered 3TC 150 mg once daily for 10 days
89573171|NCT05474521|Experimental|Participant 2|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
88970785|NCT03959865||Exendin-based GLP-1RA|Patients who have been treated with weekly GLP-1RA (exenatide or lixisenatide)
88970786|NCT03959865||Fixed ratio combination of BI/GLP-1RA|Patients who have been treated with a fixed ratio combination of GLP-1RA and basal insulin (BI), such as IdegLira (insulin degludec / liraglutide) or IglarLixi (insulin glargine / lixisenatide)
89573172|NCT05474521|Experimental|Participant 3|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
89573173|NCT05474521|Experimental|Participant 4|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
89573174|NCT05474521|Experimental|Participant 5|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
89573175|NCT05474521|Experimental|Participant 6|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
89573176|NCT05474521|Experimental|Participant 7|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
89573177|NCT05474521|Experimental|Participant 8|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
89573178|NCT05474521|Experimental|Participant 9|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
89573179|NCT05474521|Experimental|Participant 10|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
89573180|NCT05474521|Experimental|Participant 11|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
89573181|NCT05474521|Experimental|Participant 12|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
89573182|NCT05474521|Experimental|Participant 13|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
89573183|NCT05474521|Experimental|Participant 14|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
89573184|NCT05474521|Experimental|Participant 15|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
89573185|NCT05474521|Experimental|Participant 16|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
89573186|NCT05474521|Experimental|Participant 17|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
89573187|NCT05474521|Experimental|Participant 18|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
89573188|NCT05474521|Experimental|Participant 19|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
89573189|NCT05474521|Experimental|Participant 20|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
89573190|NCT05474521|Experimental|Participant 21|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
89573191|NCT05474521|Experimental|Participant 22|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
89573192|NCT05474521|Experimental|Participant 23|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
89573193|NCT05474521|Experimental|Participant 24|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
89573194|NCT05474521|Experimental|Participant 25|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
89573195|NCT05474521|Experimental|Participant 26|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
89573196|NCT05474521|Experimental|Participant 27|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
89573197|NCT05474521|Experimental|Participant 28|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
89573198|NCT05474521|Experimental|Participant 29|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
89573199|NCT05474521|Experimental|Participant 30|The participant applied the Illinois test twice to determine the validity, reliability, and usefulness of the data collection tools.
89573200|NCT05614531|Experimental|Dose escalation- Cohort 1|dose 1 of EXG001-307 delivered one-time through a venous catheter inserted into a peripheral vein (n=3~6)
89573201|NCT05614531|Experimental|Dose escalation-Cohort 2|dose 2 of EXG001-307 delivered one-time through a venous catheter inserted into a peripheral vein (n=6~12)
89573202|NCT05614531|Experimental|Dose escalation-Cohort 3|dose 3 of EXG001-307 delivered one-time through a venous catheter inserted into a peripheral vein (n=3~6)
89573203|NCT04131439||"cochlear implantation group"|"cochlear implantation group: patients undergoing cochlear implantation between December 2019 and December 2021in the ENT department of Assiut university hospital."
89573204|NCT05474443|Experimental|Myofascial gun with Conventional therapy|• Myofascial gun was applied over the Upper Trapezius muscle for 5 minutes. In the first two sessions frequency was set to 1-2 then increased to next two sessions 3-4 and so on.
89573205|NCT05474443|Active Comparator|Instrument Assisted Soft Tissue Mobilization with Conventional therapy|Graston's tool moved over the skin on upper trapezius muscle from its origin to insertion at 45 degree. conventional therapy applied with Thermotherapy, upper trapezius, levator scapulae and pectoralis major stretching and cryotherapy at the end
89573206|NCT04116697|Experimental|Acupuncture with Anti-Emetics|
89573207|NCT04116697|Experimental|Aromatherapy with Anti-Emetics|
89573208|NCT04116697|No Intervention|Control Group|
89573209|NCT05474365|Experimental|Medical students|
89573210|NCT05474365|Experimental|Surgical trainees|
89573211|NCT05474365|No Intervention|Attending Surgeons|
89573212|NCT05474209|Active Comparator|exercise patients with multiple sclerosis|"a group that undergoes a tai-chi intervention - a special program for patients with multiple sclerosis - once a week with a Tai Chi instructor lasting 90 minutes. At V0, each patient will receive an accurate instructional video for a separate home exercise tai-chi at an intensity of twice a week."
89573213|NCT05474209|No Intervention|non-exercising patients with multiple sclerosis|the group will be a control group, patients with multiple sclerosis undergo a whole battery of examinations and scales, they will not undergo exercise.
89573214|NCT05474053|Experimental|Brilique group|volunteers in the Brilique group received a loading dose of 180 mg brand Brilique® (AstraZeneca , Sweden) then 90 mg twice daily regimen for 4 days
89573215|NCT05474053|Experimental|Ticaloguard group|volunteers in the Ticaloguard group received the Egyptian made generic ticalogaurd in a loading dose of 180 mg then 90 mg twice daily regimen for 4 day
89573216|NCT04027465|No Intervention|Control|Following randomization, this arm will receive no intervention. After twelve months, participants in this group will undergo a singe-blind, placebo-controlled oral food challenge
89573217|NCT04027465|Experimental|Treatment|Following randomization, participants in this group will receive escalating doses of egg protein, up to a dose of 300 mg. Once they attain that dose, they will maintain it for six months. At the end of this maintenance period, they will undergo a singe-blind, placebo-controlled oral food challenge
89573218|NCT05473819|Experimental|Buffered Anaesthetic solution|8.4% sodium bicarbonate will be added to the 4% articaine HCL with 1:1000000 epinephrine carpule in ratio 19:1 the Articaine to the Sodium bicarbonate
89573219|NCT05473819|Active Comparator|Conventional Anaesthetic solution|4% Articaine HCL with 1:1000000 epinephrine Anaesthetic carpule
89573220|NCT04842721|Active Comparator|Hypertonic Saturated Saline Mouth Rinse Active Arm|The Active Rinse is a 25 ml of Hypertonic Saturated Saline solution made by mixing 10 grams of Sodium Chloride (Table Salt) in 25 ml of Tap water with some salt crystals deposited.
88811137|NCT04199117|Experimental|Incentive,Tailored,No Care Manage,Standard Treatment|Participants randomly assigned to this condition will have access to incentives for completing a first smoking cessation counseling call up to 4 times over 2 years, will receive 5 tailored letters promoting use of smoking cessation treatment over 2 years, will not receive Tobacco Care Management support and motivational encouragement calls, and will have access to standard smoking cessation treatment (referral to the state tobacco quitline and/or their primary care provider) over 2 years.
89029019|NCT04978454|Experimental|Cohort 2C|10^5 TCID50 of recombinant H3N2 (A/Texas/71/2017, clade 3C3a) 1.0 mL (0.5 mL per nostril) influenza virus (n=12) and Sham Sucrose phosphate glutamate (SPG) inoculum 1.0 mL (0.5 mL per nostril) (n=1) administered intranasally on Day 1. If 70% or more of the subjects in Cohorts 2A, 2B, and 2C combined meet the case definition for influenza then the optimal dose of 10^4 TCID50 will be selected. Cumulatively, if fewer than 70% of subjects in Cohorts 2A, 2B, and 2C meet the case definition for influenza the dose will escalate to include Cohort 3A. N = 13
89029020|NCT04978454|Experimental|Cohort 3A|10^6 TCID50 of recombinant H3N2 (A/Texas/71/2017, clade 3C3a) 1.0 mL (0.5 mL per nostril) influenza virus (n=17) and Sham Sucrose phosphate glutamate (SPG) inoculum 1.0 mL (0.5 mL per nostril) (n=1) administered intranasally on Day 1. If no safety threshold is met (halting conditions) proceed to Cohort 3B. N = 18
89029021|NCT04978454|Experimental|Cohort 3B|10^6 TCID50 of recombinant H3N2 (A/Texas/71/2017, clade 3C3a) 1.0 mL (0.5 mL per nostril) influenza virus (n=17) and Sham Sucrose phosphate glutamate (SPG) inoculum 1.0 mL (0.5 mL per nostril) (n=1) administered intranasally on Day 1. N = 18
89029022|NCT04973956|Active Comparator|Relaxation group|This group will perform the APMR
89029023|NCT04973956|Active Comparator|Control group|This group will perform the control intervention
89029024|NCT04951219|Experimental|Double-blind 80 mg Daily|For patients assigned to double-blind treatment and who completed Week 52 and 56 of MAESTRO-NAFLD-1, double-blind resmetirom 80 mg for first 12 weeks followed by open-label resmetirom 100 mg for weeks 12-52
89029025|NCT04951219|Experimental|Double-blind 100 mg Daily|For patients assigned to double-blind treatment and who completed Week 52 and 56 of MAESTRO-NAFLD-1, double-blind resmetirom 100 mg for first 12 weeks followed by open-label resmetirom 100 mg for weeks 12-52
89029026|NCT04951219|Experimental|Open-label|For patients assigned to open-label treatment and who completed Week 52 and 56 of MAESTRO-NAFLD-1, open-label resmetirom at same dose as MGL-3196-14 for an additional 52 weeks. NASH cirrhosis patients may receive open-label resmetirom for an additional 52 weeks (ie, 52 weeks in MGL-3196-14 and 104 weeks in MGL-3196-18).
89029027|NCT04951219|Experimental|Open-Label 80 mg|For patients with NASH cirrhosis who were screen failures from MGL-3196-11, open-label resmetirom 80 mg for 104 weeks
89029028|NCT04951219|Experimental|Open Label 100 mg|For patients without NASH cirrhosis who were screen failures from MGL-3196-11, open-label resmetirom 100 mg for 52 weeks
89029029|NCT04951219|Experimental|Open-Label 40 mg|For NASH cirrhosis patients who enter MGL-3196-18 directly or were screen failures from MGL-3196-19, open-label resmetirom 40 mg for 104 weeks
89029030|NCT04949399|Experimental|BOTOX|BOTOX will be injected into the platysma muscle on Day 1
89573221|NCT04842721|Placebo Comparator|Plain Water Control Arm|The Control Rinse is a 25 ml of Plain Tap Water.
89573222|NCT05614375||soft tissue sarcoma with endoscopic surgery|patients with soft tissue sarcoma accept endoscopic surgery
89573223|NCT05612893||Influenza upper respiratory infection|This cohort aims to descirbe the nasal mucosal immune response in influenza patients. We will collect nasal mucosal cells from influenza patients using Nasal Cytology Curettes. Blood samples will also be obtained from the patient. All samples will be used for single cell sequencing.
89573224|NCT05612893||Viral Sepsis and Viral pneumonia|The purpose of this cohort is to characterize the immune pattern of patients with viral sepsis and find specific target for the treatment of viral sepsis. Blood samples will be obtained from the viral sepsis/pneumonia patients.All samples will be used for transcriptome sequencing.
89573225|NCT05612893||Bacterial Sepsis and Bacterial pneumonia|This cohort served as a control for the viral sepsis/pneumonia cohort.Blood samples will be obtained from the bacterial sepsis/pneumonia patients.All samples will be used for transcriptome sequencing.
89573226|NCT03882307|No Intervention|group1 (naive)|Assess serum level of interleukin-6 and transforming growth factor beta before the course of treatment
89573227|NCT03882307|Active Comparator|group2 (sustained responder)|Assess serum level of interleukin-6 and transforming growth factor beta after three months from the end of treatment Sofosbuvir (SOF) (400 mg once per day) and daclatasvir (DCV)(60mg once per day) or simeprevir (SIM) (150 mg once per day) for 3 months treatment regimens
89573228|NCT03858517||ReUnion TSA System|"Subject with one or more of the following diagnoses will be treated with the ReUnion TSA System:~Aseptic necrosis of the humeral head~Painful, disabling joint disease of the shoulder resulting from degenerative arthritis, rheumatoid arthritis or post-traumatic arthritis~Failed previous total shoulder replacement, resurfacing or other procedure"
89573229|NCT04803799|Experimental|Experimental Arm|Training programme using Exergame as a support over a 12 week period
89573230|NCT04800601|Experimental|Experimental group|
89573231|NCT04800601|Active Comparator|Control group|
89573232|NCT04762771|Active Comparator|Active|Hospitalized covid-19 patients treated with colchicine plus current care per institution treating physicians.
89573233|NCT04762771|No Intervention|Control|Hospitalized covid-19 patients treated with current standard of care (per institution treating physicians) alone.
89573234|NCT04339465|Experimental|CARE-FAM|The face-to-face intervention CARE-FAM is a family-based intervention for the diagnostic, early detection and early treatment of mental health issues of children affected by rare diseases, their siblings and their parents. CARE-FAM is a brief low-frequency intervention comprising six to eight sessions per family over a period of six months. Following a preliminary talk, 2 sessions with the parents, 1 session with each affected child and each sibling and 3 sessions with the whole family will take place. This low-frequency approach (sessions every 2 to 3 weeks) allows families to integrate the intervention into their daily life. Upon request, the sessions will take place at the family's home (home-treatment).
89573235|NCT04339465|Experimental|WEP-CARE|The online intervention WEP-CARE addresses parents of children and adolescents affected by rare diseases. The program is based on principles of cognitive-behavioral writing therapy. Supported by trained professionals, the participants perform 12 standardized writing tasks on a secured internet platform. The 12 writing tasks will be conducted with a weekly frequency and participants will receive personalized feedback. WEP-CARE aims at enhancing mental health problems and the coping strategies of the family.
89573236|NCT04339465|Experimental|CARE-FAM + WEP-CARE|The families will receive both the face-to-face intervention CARE-FAM and the online intervention WEP-CARE.
89573237|NCT04339465|No Intervention|Treatment as usual|The treatment as usual implies that families of the control group receive the treatment that is customary in regular care. Thus, these families normally don't receive any post-treatment. If, however, a member of a control group family appears to have an urgent need for treatment (every family receives a comprehensive diagnostic investigation at the beginning of the study), the respective family will be placed in the ambulatory care system.
89573238|NCT05614297||Patients with ACL injuries|Patients who have sustained an ACL injury, surgically or non-surgically treated.
89573239|NCT04754737|Other|Prophylactic antibiotic|These patients will receive the current standard of care, which is to receive a single dose of prophylactic antibiotics just prior to receiving intravesical injection of Onabotulinumtoxin A via cystoscopy. The specific prophylactic antibiotics will vary depending on patient's prior urine culture sensitivities and patient medication allergies/sensitivities and medical comorbidities.
89573240|NCT04754737|Experimental|No antibiotics|These patients will receive no prophylactic antibiotics prior to receiving intravesical injection of Onabotulinumtoxin A via cystoscopy.
89573241|NCT04705363|Experimental|Interaction with a VHA with voice|A virtual health assistant computer-generated doctor who will have a conversation with you.
89573242|NCT04705363|Active Comparator|Interaction with a VHA without voice|A virtual health assistant that will consist of photos of the computer-generated doctor with text that will guide you through the interaction. No voice will accompany the photos or text.
89573243|NCT05612737|Experimental|"Sticky bone and tenting screw"|
89573244|NCT04608721||Postpartum Anxiety|Postpartum anxiety will be assessed at 1-3 days (T1), 1(T2), 3 (T3), 6 (T4) and 12 months (T5) postpartum by using the State-Trait Anxiety Inventory (STAI).
89573245|NCT04426357|Experimental|Group 1 (Participants with Renal impairment): JNJ-64417184|Participants with varying degrees of impaired renal impairment function (moderate renal impairment [optional], severe renal impairment, and end stage renal disease [ESRD] not requiring hemodialysis) will be enrolled and will receive a single oral dose of JNJ-64417184 as film coated tablet on Day 1.
89573246|NCT04426357|Active Comparator|Group 2 (Healthy Participants): Control Group|Participants with normal renal function will be enrolled in controlled group and will receive a single oral dose of JNJ-64417184 as film coated tablet on Day 1.
89573247|NCT04603417|Other|Patients|Patients with CRPS diagnosis
89573248|NCT04603417|Other|Controls|Healthy controls with known Neurological Disorders
88970787|NCT03959865||Flexible combination of BI/GLP-1RA|Patients who have been treated with any GLP-1RA in combination with any basal insulin (BI)
88970788|NCT00070486|Experimental|Gem + Carboplatin + Zileuton|
88970789|NCT00070486|Experimental|Gem + Carboplatin + celecoxib|
88970790|NCT00070486|Experimental|Gem + carboplatin + zilueton + celecoxib|
88970791|NCT00070525|Experimental|Arm I|Patients receive oral tipifarnib twice daily on days 1-21. Courses repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
88970792|NCT00070642|Experimental|CPG 7909 Injection plus chemotherapy|CPG 7909 Injection plus DTIC
88970793|NCT00070642|Active Comparator|Chemotherapy alone|dacarbazine
88970794|NCT00070642|Experimental|CPG 7909 Injection 10 mg|
88970795|NCT00070642|Experimental|CPG 7909 Injection 40 mg|
88970796|NCT00070954|Placebo Comparator|2|look-alike placebo
88970797|NCT00070954|Active Comparator|Ginkgo Biloba|Compared to placebo
88970798|NCT02966431|Experimental|Counseling|Receive counseling for 8-wks
88970799|NCT02966431|Placebo Comparator|Control|Does not receive counseling for 8-wks
88970800|NCT04730440||AD-TAR|AD subjects who take part to Facial Emotion Recognition rehabilitation (TAR)
88970801|NCT04730440||AD-Cognitive Stimulation|AD subjects who take part to cognitive stimulation session (12 sessions during 4 weeks)
89573249|NCT05421481|Experimental|intervention group|"In the first interview, the mobile phone contact information of the elderly will be obtained and planning will be made for the first home visit when appropriate. Physical activity education and health promotion during home visit brochure will be provided. A brochure containing healthy lifestyle habits, health responsibility, exercise, nutrition, oral hygiene and social support behaviors will be provided for general health promotion awareness. The Google Fit application, which is a mobile application, will be downloaded to the phones of the people and installed together, how to use the application will be explained and the application will be made. The group walk to be done. A reminder message will be sent by phone. Message content For your health, you should exercise at least 30 minutes a week for a total of 150 minutes. will be. Groups of five will be formed for the group walking, and it will be completed within seven days."
89573250|NCT05421481|No Intervention|control group|There is no health-related practice in the pensioners' club. No intervention will be made in the control group. After the experimental group's attempts are completed, a home visit is planned for the control group, and it is planned to make physical activity training, brochure, google fit application installation attempts.
89573251|NCT04580563|Experimental|Experimental group|"The experimental group will receive 12 ml/kg of OctaplasLG® at day 1, within the 2 hours after randomization (i.e. within the 8 hours after coagulopathy diagnosis). A new identical dose will be infused at day 2 according to coagulation parameters.~OctaplasLG® is a donor plasma product, with unique features compared to standard fresh frozen plasma: standardized concentrations of natural pro-/anti-coagulation factors; a standardized volume; pathogen free. OctaplasLG® should reduce the inflammatory hit on the endothelium, including the glycocalyx, by having standardized levels of coagulation proteins, which can give more sustainable support to the endothelial regeneration as compared to standard fresh frozen plasma."
89573252|NCT04580563|Placebo Comparator|Control group|The control group will receive 12 ml/kg of placebo (0.9% NaCl) at day 1, within the 2 hours after randomization (i.e. within the 8 hours after coagulopathy diagnosis). A new identical dose will be infused at day 2 according to coagulation parameters.
89573253|NCT02404311|Active Comparator|Part A, Group 1: Vaccine|ALVAC-HIV at months 0 and 1, and ALVAC-HIV + bivalent subtype C gp120/MF59 at months 3, 6, and 12
89573254|NCT02404311|Placebo Comparator|Part A, Group 2: Placebo|Placebo for ALVAC-HIV at months 0 and 1, and placebo for ALVAC-HIV + placebo for bivalent subtype C gp120/MF59 at months 3, 6, and 12
89573255|NCT02404311|Active Comparator|Part B, Group 1a: Vaccine|Participants originally in Part A Group 1 (Vaccine) receive ALVAC-HIV + bivalent subtype C gp120/MF59 at month 30
89573256|NCT02404311|Active Comparator|Part B, Group 1b: Vaccine + Placebo|Participants originally in Part A Group 1 (Vaccine) receive placebo for ALVAC-HIV + bivalent subtype C gp120/MF59 at month 30
89573257|NCT02404311|Placebo Comparator|Part B, Group 2: Placebo|Participants originally in Part A Group 2 (Placebo) receive placebo for ALVAC-HIV + placebo for bivalent subtype C gp120/MF59 at month 30
89573258|NCT03032107|Experimental|Pembrolizumab Combine With Trastuzumab Emtansine|"Pembrolizumab will be administered intravenousely in clinic on day 1 of each 3-week cycle~Pembrolizumab will be administered prior to T-DM1 administration~Pembrolizumab will be given at a predetermine dose~T-DM1 will be administered intravenousely in clinic on day 1 of each 3-week cycle~T-DM1 will be given at a predetermine dose"
89573259|NCT02841163||Lumbar/cervical disc herniation group|Lumbar and cervical intervertebral disc herniation patients are administered integrative Korean medicine treatment consisting of herbal medicine, acupuncture, pharmacopuncture, bee venom pharmacopuncture, and Chuna manipulation.
89573260|NCT05388175|Experimental|Less invasive surfactant administration (LISA) with a rigid catheter|Participants will simulate the procedure of surfactant administration by using a rigid catheter
89573261|NCT05388175|Active Comparator|Less invasive surfactant administration (LISA) with a soft catheter|Participants will simulate the procedure of surfactant administration by using a soft catheter
89573262|NCT05700955|Experimental|temozolomide|Participants will take Temozolomide pills at home at a dose determined by body weight. They will take the pills for five days every 3 weeks. It will be dispensed by the pharmacy and must be stored in a closed container at room temperature, away from heat, moisture, and direct light and kept from freezing. It will be kept out of the reach of children. Outdated medicine or medicine no longer needed will be returned to the Brown Cancer Center pharmacy for disposal.
89573263|NCT05700955|Experimental|Pembrolizumab|Pembrolizumab will be administered at a dose of 200 mg as an IV infusion through a freely flowing IV. The diluted solution will be administered intravenously over 30 minutes through an intravenous line containing a sterile, non-pyrogenic, low-protein binding 0.2 micron to 5 micron in-line or add-on filter. Other drugs will not be co-administered through the same infusion line. Pembrolizumab doses will be repeated every three weeks.
89573264|NCT01650519|Active Comparator|IV ibuprofen|Intravenous ibuprofen (800 mg) administered intravenously over 10 minutes at study hour 0 and again at study hour 4 (Ibuprofen arm) and a corresponding volume of normal saline (ketorolac arm) will be administered intravenously over no less than 15 seconds at the end of the arthroscopic procedure
89573265|NCT01650519|Active Comparator|IV ketorolac|A corresponding volume of normal saline (Ibuprofen arm) administered intravenously over 10 minutes at study hour 0 and again at study hour 4 and 30 mg ketorolac for patients < 65 years of age (15 mg ketorolac for patients > 65 years of age) (ketorolac arm) will be administered intravenously over no less than 15 seconds at the end of the arthroscopic procedure
89573266|NCT01650285|Experimental|Cabazitaxel and radiation|Radiation therapy (RT) will be delivered to 64.8 Gy, using IMRT treatment Cabazitaxel will be administered IV every 21 days for 3 doses at the assigned dose level.
89573267|NCT05612503|Sham Comparator|Traditional physical therapy program|For 15 minutes, each child in both groups perform the following specific respiratory exercises: resistance-based diaphragm strengthening exercises, breathing exercises.
89573268|NCT05612503|Experimental|Virtual reality-based exercises|Following a session of traditional physical therapy, the children in study group toke 30 minutes rest then they joined in a 30-minute VR exercise session using Nintendo Wii systems.
89573269|NCT02347527|Experimental|Active Implicit Priming (MRI sample)|Participants will complete active implicit priming, in which food images are implicitly primed (i.e., below conscious awareness) with images of positive or negative affect. In addition to measures of food image ratings, this group completed a visual food cues scan during fMRI to assess change in neuronal response to food cues. They also completed a measure of food intake post-intervention.
89573270|NCT02347527|Placebo Comparator|Control Implicit Priming (MRI sample)|Participants will complete a control implicit priming intervention, which matches the active intervention, but with neutral stimuli as primes. In addition to measures of food image ratings, this group completed a visual food cues scan during fMRI to assess change in neuronal response to food cues. They also completed a measure of food intake post-intervention.
89573271|NCT02347527|Experimental|Active Implicit Priming (Behavioral-only sample)|Participants will complete active implicit priming, in which food images are implicitly primed (i.e., below conscious awareness) with images of positive or negative affect.
89573272|NCT02347527|Placebo Comparator|Control Implicit Priming (Behavioral-only sample)|Participants will complete a control implicit priming intervention, which matches the active intervention, but with neutral stimuli as primes.
89573273|NCT02197039||The High risk group|"Each enrolled patient receives an 80 mg loading dose of intravenous esomeprazole or pantoprazole immediately after successful endoscopic hemostasis. Patients then receive a 3-day continuous high dose (8 mg per hour) of esomeprazole or pantoprazole infusion.~Patients are defined in the high risk group if they still have major stigmata of recent hemorrhage at the second-look endoscopy or have early recurrent bleeding before the schedule time for follow-up.~Recurrent bleeding is defined as: 1) continuous melena, hematochezia, or the presence of recurrent bloody aspirates through a nasogastric tube and 2) relapse of hemodynamic instability, including systolic blood pressure <90 mmHg, heart rate >120 beats per minute, or a drop in hemoglobin concentration by more than 2 g/dL."
89573274|NCT02197039||The control group|"Each enrolled patient receives an 80 mg loading dose of intravenous esomeprazole or pantoprazole immediately after successful endoscopic hemostasis. Patients then receive a 3-day continuous high dose (8 mg per hour) of esomeprazole or pantoprazole infusion.~Patients are defined in the control group if they does not have recurrent bleeding before the schedule time for follow-up, and have only minor stigmata of hemorrhage or clean ulcer base at the second-look endoscopy.~Recurrent bleeding is defined as: 1) continuous melena, hematochezia, or the presence of recurrent bloody aspirates through a nasogastric tube and 2) relapse of hemodynamic instability, including systolic blood pressure <90 mmHg, heart rate >120 beats per minute, or a drop in hemoglobin concentration by more than 2 g/dL."
89573275|NCT05557903|Experimental|Treatment Group of anti-CD52 monoclonal antibody|safety and tolerability, pharmacokinetic characteristics and preliminary efficacy in the treatment of relapsed and refractory nhl (including cll/sll, pll, ptcl, diffuse large b-cell lymphoma, follicular cell lymphoma, mantle cell lymphoma, and marginal zone lymphoma) and initially treated t-pll of recombinant humanized anti-cd52 monoclonal antibody injection
89573276|NCT04335097|Active Comparator|Control|Follow general recommendations fram doctor and health authorities what to do and pay attention to before new contact with health service.
89573277|NCT04335097|Active Comparator|Intervention|Follow general recommendations fram doctor and health authorities what to do and pay attention to before new contact with health service. I addition active reporting of clinical status and continuous vital sign monitoring based on electronic sensors (Welfare technology).
88970802|NCT03959787|Experimental|Educational pamphlet and standard care|patients randomized to the educational pamphlet arm will receive the educational pamphlet
88970803|NCT03959787|No Intervention|control group - standard care|Patients randomized to control arm, will receive the standard care.
88970804|NCT03959748||PAH adults|Patients with pulmonary arterial hypertension who are at least 18 years old at study entry
88970805|NCT03959748||PAH children|Patients with pulmonary arterial hypertension who are at least 3 months old and are less than 18 years old at study entry
88970806|NCT03959748||CTEPH|Patients with chronic thromboembolic pulmonary hypertension who are at least 18 years old at study entry
88970807|NCT00071422|Placebo Comparator|placebo|1.5 mL SC injection, once daily for 90 days
88970808|NCT00071422|Experimental|300 mg INGAP Peptide|1.5 mL SC injection, once daily for 90 days
88970809|NCT00071422|Experimental|600 mg INGAP Peptide|1.5 mL SC injection, once daily for 90 days
88970810|NCT00071500|Experimental|1|Participants will use MedSignals with all of its features
89573278|NCT02386839|Experimental|Antecedent Standard of Care|Participants who were treated with standard neonatal care in study ROPP-2008-01 (NCT01096784) were enrolled in this group for assessment of rhIGF-1/rhIGFBP-3 long-term efficacy and safety outcomes.
89573279|NCT02386839|Experimental|Antecedent rhIGF-1/rhIGFBP-3|Participants who were treated with rhIGF-1/rhIGFBP-3 in study ROPP-2008-01 (NCT01096784) were enrolled in this group for assessment of rhIGF-1/rhIGFBP-3 long-term efficacy and safety outcomes.
89573280|NCT01718041|Experimental|VRS-317|Active treatment arm
89573281|NCT01676077||Patients with a genetically confirmed dysferlinopathy|
89573282|NCT05557669|Experimental|Investigation Group|Patients undergoing laparoscopic cholecystectomy for cholelithiasis
89573283|NCT05557669|No Intervention|Control group|Patients with gallstone disease who are not planned for laparoscopic cholecystectomy in upcoming 3 months
89573284|NCT05347459||New Antidiabetic|Type 2 diabetic patients receiving SGLT2 inhibitors and/or DPP-4 inhibitors with metformin
89573285|NCT05347459||Traditional Antidiabetic|Type 2 diabetic patients treated with metformin
89573286|NCT05347459||Control|Healthy non-diabetic patients
89573287|NCT05346445|Active Comparator|Fluoxetine group|Participants received fluoxetine, 20 mg tablets, once a day for six months.
89573288|NCT05346445|Experimental|Citalopram group|Participants received citalopram, 20 mg tablets, once a day for six months.
89573289|NCT05334121|Experimental|Product - Beta Alanine|The product will be consumed every day for 4 weeks. Four intakes of 3g each, separated by three hours each, will be carried out.
89573290|NCT05334121|Placebo Comparator|Control group - Placebo|The product will be consumed every day for 4 weeks. Four intakes of 3g each, separated by three hours each, will be carried out.
88970811|NCT00071500|Experimental|2|Participants will use MedSignals with only alarm features
88970812|NCT00071500|No Intervention|3|Participants will not use any device
89573291|NCT05557201||Miscarriage|Patients with at least 3 recurrent early miscarriages (before 14 weeks of gestation)
89573292|NCT05557123|Experimental|MEDI-app|conventional treatment with MEDI-app feedback
89573293|NCT05557123|Active Comparator|conventional treatment|conventional treatment
89573294|NCT01649271|Experimental|Phase Ia, group 1|afatinib escalating dose with 3-weekly trastuzumab
88970813|NCT02966743|Experimental|midazolam|administration of midazolam during spinal anesthesia for target bispectral index 75-80
88970814|NCT02966743|Active Comparator|dexmedetomidine|administration of dexmedeomidine during spinal anesthesia for target bispectral index 75-80
88970815|NCT00071539|Experimental|TP38 50 ng/mL|
88970816|NCT00071539|Experimental|TP38 100 ng/mL|
88970817|NCT03959709|Experimental|Prepectoral implant placement|Immediate acellular dermal matrix-assisted implant-based breast reconstruction with prepectoral implant placement.
88970818|NCT03959709|Active Comparator|Subpectoral implant placement|Immediate acellular dermal matrix-assisted implant-based breast reconstruction with subpectoral implant placement.
88970819|NCT00071578|Experimental|1|Group therapy Negative Emotion Focus
88970820|NCT00071578|Placebo Comparator|2|Group Psychotherapy- Self Esteem Focus
88970821|NCT00071617|Experimental|Youth-Nominated Support Team|Adolescents nominate up to 4 caring adults from family, school, community settings. These adults participate in psychoeducation sessions regarding adolescent's treatment plan and support needs. They maintain regular, supportive contact with the adolescent for 3 months -- with ongoing consultation and support check-ins from study clinical staff.
88970822|NCT00071617|No Intervention|Enhanced Treatment as Usual|Adolescents in this condition receive study assessments and risk management services (at time of assessments) only
88970823|NCT00071773|Active Comparator|Modified Early Treatment Diabetic Retinopathy Study (ETDRS)|modified-ETDRS
88970824|NCT00071773|Active Comparator|Mild Macular Grid (MMG)|MMG technique
89573295|NCT01649271|Experimental|Phase Ia, group 2|afatinib at MTD dose with weekly trastuzumab
89573296|NCT01649271|Experimental|Phase Ib|afatinib at MTD level with 3-weekly trastuzumab
89573297|NCT05700877|Experimental|CAC-based treatment|"Patients randomized to CAC-based treatment, will be stratified into low- or high-risk patients (defined by CAC score=0 or ≥ 100), and hence, allocated to two parallel l clinical studies.~High-risk patients (CAC≥ 100) in the CAC-based treatment group will be included in a study in which they will receive information on CAC-score, mandatory treatment with dapagliflozin and semaglutide (both study drugs), and advise on further multifactorial treatment of blood lipid levels, blood pressure and antithrombotic therapy.~Low-risk patients (CAC=0) will be included in a study in which they will receive information on CAC-score and advise on how multifactorial treatment may be de-intensified."
89573298|NCT05700877|Other|Standard treatment|Patients randomized to standard treatment and their primary physician are not informed about the screening findings. Patients are encouraged to follow contemporary diabetes guidelines at the time of inclusion. This information will be given in a written letter within a week of randomization.
89573299|NCT05558917|Active Comparator|PECS BLOCK 2|PECS 2 (or modified PECS) is a block that involves the administration of local anesthetic under ultrasound guidance between the great pectoral and small pectoral and between the small pectoral and serratus anterior.
89573300|NCT05558917|Experimental|ESP BLOCK|ESP block is a block that involves injection of local anesthetic below the elevator muscles of the spine.
89573301|NCT05558839|Experimental|exercise training|Physiotherapists prescribed and delivered interventions in the exercise arm. Each exercise session began with a 5-minute warm up and stretching, followed by 15-minute Aerobic exercises, 15-minute of resistance training, 10-minute of agility and balance training, and 5-minute of cooling down.
89573302|NCT05558839|Experimental|cognitive training|"Board game teachers who have more than 5 years of community teaching experience prescribed and delivered interventions in the cognitive arm.~Each cognitive session uses different board games to strengthen training for different cognitive aspects."
89573303|NCT04334239||Intervention|Cancer patients who have undergone substantial parts of inpatient treatment in a certified cancer centre.
89573304|NCT04334239||Control|Cancer patients who have not undergone inpatient treatment in a certified cancer centre.
89573305|NCT02385669|Experimental|6MHP and ipilimumab|"The vaccine drug product, 6MHP, consists of 6 class II MHC-restricted peptides derived from melanoma proteins. Each vaccine consists of 200 mcg of each of the six peptides. An aqueous solution of vaccine is mixed 1/1 with Montanide ISA-51 to form water-in-oil emulsions. Vaccines are administered days 1, 8, 15, 43, 64, and 85. All peptide vaccines are administered intradermally and subcutaneously.~Ipilimumab will be administered in accord with the official prescribing information: 3 mg/kg intravenously once every 3 weeks, for 4 doses. Ipilimumab will be administered on days 1, 22, 43, and 64."
89573306|NCT05558683|Active Comparator|Vojta Reflex Locomotion Therapy|The Vojta Method or Vojta Reflex Locomotion Therapy (TLRV) is a rehabilitative method for neuromusculoskeletal pathologies widely used in Europe. Its development is based on the concept of motor ontogenesis and tries to trigger innate motor reactions (reflex locomotion patterns) in the trunk and limbs from defined tactile and proprioceptive stimuli, starting from certain postures. This therapy presents differential elements with respect to other existing therapies, both for neurophysiological principles and for methodological principles. It is an active therapy, in which great concentration is required on the part of the patient, that is, both therapist and patient are the central axes of the treatment.
89573307|NCT05558683|Active Comparator|Bobath Method|Within physiotherapy, the Bobath concept is a valid and recognized option in the treatment of patients with neurological disorders, and therefore, of those diagnosed with MS. It was developed by Karel and Berta Bobath. The Bobath concept is defined as a problem-solving approach in the assessment and treatment of people with impaired neuromotor function, becoming a valid tool as part of the comprehensive treatment of people with MS
89573308|NCT02402907|Experimental|CHG cloth|2% chlorhexidine gluconate (CHG) cloth
89573309|NCT02402907|Placebo Comparator|Placebo cloth|A fragrance free cleansing cloth
89573310|NCT05254093|No Intervention|group A|
89573311|NCT05254093|Active Comparator|group B|
89573312|NCT05254093|Active Comparator|group C|
89573313|NCT02345889|Active Comparator|FUSE® Colonoscopy|A FUSE® system with 3 HD (high-definition) monitors will be used to perform the colonoscopy
89573314|NCT02345889|Active Comparator|Colonoscopy with EndoCuff™|An EndoCuff™ distal attachment will be placed at the distal end of a standard colonoscope
89573315|NCT02345889|Active Comparator|Colonoscopy with EndoRings™|An EndoRings™ distal attachment will be placed at the distal end of a standard colonoscope
89573316|NCT02345889|Active Comparator|Standard Colonoscopy|A standard colonoscope will be used to complete the procedure
89573317|NCT05556421||case group|dislocated intrauterine device
89573318|NCT05556421||control group|normal intrauterine device position
89573319|NCT04328623|Active Comparator|Infiltration|Ultrasound-guided hand infiltration
89573320|NCT04328623|Experimental|Hypnosis|Hypnosis before Ultrasound-guided hand infiltration
89573321|NCT02345811|Experimental|Sapphire|Participants were randomized to wear the Sapphire lens pair for two weeks during the cross over study.
89573322|NCT02345811|Active Comparator|senofilcon A|Participants were randomized to wear the senofilcon A lens pair for two weeks during the cross over study.
89573323|NCT05549869|Active Comparator|group A|obese with vitligo
89573324|NCT05549869|Active Comparator|group b|obese without vitligo
89573325|NCT05549869|Active Comparator|group C|non obese with vitiligo
89573326|NCT05549869|Active Comparator|group D|non obese without vitiligo
89573327|NCT05556109||Epileptic seizure|patients diagnosed as epileptic seizure are aged >12 years
89573328|NCT05556109||Psychogenic non-epileptic seizure|patients diagnosed as psychogenic non-epileptic seizure are aged >12 years
89573329|NCT05556109||Normal healthy control|Heathy control are aged >12 years with no history of lifetime seizures or suspected seizures or febrile seizure and no treatment with an antiepileptic drug (AED) prior to blood draw
89573330|NCT02586493|Experimental|Placebo ELLIPTA inhaler|Subjects will be provided the ELLIPTA inhaler, which is a molded plastic two-sided inhaler that holds two individual blister strips containing either lactose or a blend of lactose and magnesium stearate. Subjects will continue to use regular COPD medications throughout the study as per protocol.
89573331|NCT05543395||The group accepting to report|
89573332|NCT05543395||The group refusing to report|
89573333|NCT02400333|Experimental|Treatments A-D-B-C sequence|Treatment A in Period 1, Treatment D in Period 2, Treatment B in Period 3 and Treatment C in Period 4
89573334|NCT02400333|Experimental|Treatments B-A-C-D sequence|Treatment B in Period 1, Treatment A in Period 2, Treatment C in Period 3 and Treatment D in Period 4
89573335|NCT02400333|Experimental|Treatments C-B-D-A sequence|Treatment C in Period 1, Treatment B in Period 2, Treatment D in Period 3 and Treatment A in Period 4
89573336|NCT02400333|Experimental|Treatments D-C-A-B sequence|Treatment D in Period 1, Treatment C in Period 2, Treatment A in Period 3 and Treatment B in Period 4
89573337|NCT02399475|Experimental|Levothyroxine First|Participants will start on the thyroid hormone Levothyroxine prior to crossing over to Liothyronine
89573338|NCT02399475|Experimental|Liothyronine First|Participants will start on the thyroid hormone Liothyronine prior to crossing over to Levothyroxine
89573339|NCT04420377|Placebo Comparator|Placebo Group|Participants will engage in a 5-week, whole-body, resistance training program 2 days per week will consuming a visually identical placebo (25mg hydroxypropyl methylcellulose) 30 minutes prior to exercise on training days or with the first meal of the day on non-training days. For week 5 of the study, participants will come in for 1 intense exercise training day.
89573340|NCT04420377|Experimental|Experimental Group|Participants will engage in a 5-week, whole-body, resistance training program 2 days per week will consuming a treatment condition (Carnipure™) 30 minutes prior to exercise on training days or with the first meal of the day on non-training days. For week 5 of the study, participants will come in for 1 intense exercise training day.
89573341|NCT02399163|Experimental|Placebo dentifrice/Fluoride rinse|Twice daily brushing with a non-fluoride (placebo) toothpaste followed by once daily rinsing (post night time brushing) with a fluoride mouthwash containing 220 ppm of fluoride as sodium fluoride
89573342|NCT02399163|Placebo Comparator|Placebo dentifrice/No rinse|Twice daily brushing with a non-fluoride (placebo) toothpaste
89573343|NCT02399163|Active Comparator|Fluoride dentifrice/No rinse|Twice daily brushing with a fluoride toothpaste containing 1150 ppm of fluoride as sodium fluoride
89573344|NCT02399163|Experimental|Fluoride dentifrice/Fluoride rinse|Twice daily brushing with a fluoride toothpaste containing 1150 ppm of fluoride as sodium fluoride, followed by once daily rinsing (post night time brushing) with a fluoride mouthwash containing 220 ppm of fluoride as sodium fluoride.
88970825|NCT03959670||extensive TAAA|including Crawford extent I and II TAAA
89573345|NCT02398227|Experimental|HOPE|Cognitive Behavioral Treatment Program for PTSD
89573346|NCT02398227|Active Comparator|PCT|Present Centered Therapy for PTSD
89573347|NCT02397915|Experimental|Fluticasone Furoate|Subjects will receive a single dose of intranasal FF (total dose of 110 mcg) as 2 sprays per nostril / 4 sprays in total.
89573348|NCT02397915|Experimental|Mometasone Furoate|Subjects will receive a single dose of intranasal MF (total dose of 200 mcg) nasal spray as 2 sprays per nostril / 4 sprays in total.
88970826|NCT03959670||Crawford extent III TAAA|
89573349|NCT02397837|Experimental|Pramipexole|Pramipexole, by mouth. Dosing will be initiated at 0.25 mg on night one, followed by 0.25 mg twice-a-day day two onward, and increased every week to a target of 4.5 mg/day for the 12-week duration of the study.
89573350|NCT02397837|Placebo Comparator|Placebo|Placebo, by mouth. Dosing will be initiated at 0.25 mg on night one, followed by 0.25 mg twice-a-day day two onward, and increased every week to a target of 4.5 mg/day for the 12-week duration of the study.
89573351|NCT02586415|Active Comparator|endovascular thrombectomy therapy|"Treatment with one or more thrombectomy devices (only the devices listed in this protocol are approved for use in DEFUSE 3) plus standard medical therapy for patients who have evidence of an ICA or MCA M1 occlusion and a Target Mismatch Profile.~Devices approved for use in DEFUSE 3:~Trevo Retriever~Solitaire™ FR Revascularization Device~Penumbra thrombectomy system~Covidien MindFrame Capture Revascularization Device"
89573352|NCT02586415|No Intervention|Medical Management|standard medical therapy alone
89573353|NCT02383017|Experimental|Shroom Tech Sport|Shroom Tech Sport is a multi-ingredient performance supplement taken, in pill form, prior to work outs to enhance workout performance.
89573354|NCT02383017|Placebo Comparator|Placebo|The placebo is a calorie matched sugar pill that will be taken in the same fashion as the STS pill.
88970827|NCT03959670||supra-renal aortic aneurysms|Crawford extent IV TAAA and para-renal abdominal aortic aneurysms.
88970828|NCT00390065|Experimental|Study group|Hypoxemic Respiratory Failure treated by Nitric Oxide;
88970829|NCT00390065|Placebo Comparator|Control|Hypoxemic Respiratory Failure control (Placebo);
88970830|NCT00390065|No Intervention|Reference|Reference (Non hypoxemic respiratory failure)
88970831|NCT02966392|Experimental|Continuous Pressure Control (CPC)|Continuous endotracheal cuff pressure control using Tracoe cuff pressure controller during their intubated stay on ICU.
88970832|NCT02966392|No Intervention|Standard Care|Intermittent cuff pressure control through manual measurement performed 3 times per day (standard care)
88970833|NCT00072046|Experimental|Interferon|Treatment with interferon alfa 2b
88970834|NCT00072046|Experimental|Interferon + bevacizumab|Addition of bevacizumab to interferon alfa 2b treatment
88970835|NCT03959553|Placebo Comparator|Placebo|Placebo SC injection administered once weekly for 4 weeks then every 2 weeks through Week 24
88970836|NCT03959553|Experimental|GV1001 0.56 mg|GV1001 0.56 mg SC injection administered once weekly for 4 weeks then every 2 weeks through Week 24
88970837|NCT03959553|Experimental|GV1001 1.12 mg|GV1001 1.12 mg SC injection administered once weekly for 4 weeks then every 2 weeks through Week 24
88970838|NCT04847141|Experimental|C19-IG 20% 1 g|Participants will receive 1 gram (g) of C19-IG 20% subcutaneous (SC) infusion containing one syringe of 5 milliliters (mL) C19-IG 20% plus one syringe of 5 mL sterile 0.9% sodium chloride (NaCl) on Day 1.
89573355|NCT05556031||REDUCE|Standard care
89573356|NCT05549791||General anesthesia cohort|
89573357|NCT05549791||Bronchoscopy sedation cohort|
89573358|NCT02382939|Experimental|somapacitan|
89573359|NCT02382939|Active Comparator|hGH (somatropin)|
89573360|NCT05549557|Experimental|IMM40H|IMM40H is a monoclonal antibody with target CD70.
88970839|NCT04847141|Experimental|C19-IG 20% 2 g|Participants will receive 2 g of C19-IG 20% SC infusion containing two syringes 5 mL each of C19-IG 20% on Day 1.
88970840|NCT04847141|Placebo Comparator|Placebo|Participants will receive C19-IG 20% matching placebo as SC infusion containing two syringes of 5 mL each sterile 0.9% NaCl injection on Day 1.
88970841|NCT03959514|Experimental|AT247|Single subcutaneous injection 0.3 U/Kg
88970842|NCT03959514|Active Comparator|NovoRapid|Single subcutaneous injection 0.3 U/Kg
88970843|NCT03959514|Active Comparator|Fiasp|Single subcutaneous injection 0.3 U/Kg
88970844|NCT03959475||Saint-Etienne Hospital|All people aged 75 years and over hospitalized in short-stay geriatric care via a hotline in this hospital
88970845|NCT03959475||Firminy hospital|All people aged 75 years and over hospitalized in short-stay geriatric care via a hotline in this hospital
88970846|NCT03959475||South Lyon hospital|All people aged 75 years and over hospitalized in short-stay geriatric care via a hotline in this hospital
89573361|NCT05543005|Experimental|experimental group|maternal voice
89573362|NCT05543005|No Intervention|control group|no maternal voice
89573363|NCT05542927||Critically ill Acute kidney injury patients|"AKI is defined as any of the following: Increase in SCr by ≥0.3 mg/dl (≥ 26.5 μmol/l) within 48 hours; OR increase in SCr to≥1.5 times baseline, which is known or presumed to have occurred within prior 7 days; OR Urine volume <0.5 ml/kg/h for 6 hour)~Serum chloride, urinary chloride & serum creatinine will be requested on the first day of admission in ICU~Serum chloride & urinary chloride will be requested every 48 hours in ICU with correlation between urinary chloride concentrations, AKI & mortality.~Serum creatinine will be requested every 24 hours in ICU.~Monitoring of Urinary Output every 24 hours.~Daily SOFA score."
89573364|NCT04425889||exposed Healthcare workers|Healthcare workers working for 8 weeks in a COVID-19 area
89573365|NCT05555563|No Intervention|Control|Root canal instrumentation was performed using the Reciproc Blue (VDW, Munich) #50/0.5 file. During instrumentation of the root canals, irrigation was applied with 10 mL 2.5% NaOCl using side-vented needles. The final irrigation in Control group was applied with 5 ml of 17% EDTA solution and 5 ml of distilled water. The root canals were dried with sterile paper points and were filled with cold lateral condensation technique using AH Plus root canal sealer and gutta percha. Then the cavity entry was restored with composite (Solarex, GC Corparation, Tokyo, Japan) and radiography was taken. The pre-treatment and 24-month follow-up radiographs of teeth, were prepared as a Power Point presentation and the change in periapical radiolucency was assessed according to PAI scores Teeth with a PAI≤ 2 score and clinically asymptomatic were considered 'healthy' in the radiographic evaluation, while teeth with a PAI≥ 3 and/or clinically symptomatic were considered 'failure'.
89573366|NCT05555563|Experimental|MTAD irrigation|Root canal instrumentation was performed using the Reciproc Blue (VDW, Munich) #50/0.5 file. During instrumentation of the root canals, irrigation was applied with 10 mL 2.5% NaOCl using side-vented needles. The final irrigation in MTAD group was applied 5 ml MTAD (n=50) and 5 ml of distilled water. The root canals were dried with sterile paper points and were filled with cold lateral condensation technique using AH Plus root canal sealer and gutta percha. Then the cavity entry was restored with composite (Solarex, GC Corparation, Tokyo, Japan) and radiography was taken. The pre-treatment and 24-month follow-up radiographs of teeth, were prepared as a Power Point presentation and the change in periapical radiolucency was assessed according to PAI scores Teeth with a PAI≤ 2 score and clinically asymptomatic were considered 'healthy' in the radiographic evaluation, while teeth with a PAI≥ 3 and/or clinically symptomatic were considered 'failure'.
89573367|NCT04426435|Experimental|Intervention|Group A: patients receiving HB syrup, 10 cc three times daily
89573368|NCT04426435|Placebo Comparator|Placebo|Group B: patients receiving placebo, 10 cc three times daily
89573369|NCT05549245|Experimental|High-flow Nasal Cannula Oxygen Therapy group|
89573370|NCT05549245|Other|Continues Positive Airway Pressure group|
88970847|NCT03959475||Bordeaux hospital|All people aged 75 years and over hospitalized in short-stay geriatric care via a hotline in this hospital
88970848|NCT03959475||Saint-Chamond hospital|All people aged 75 years and over hospitalized in short-stay geriatric care via a hotline in this hospital
88970849|NCT03959475||Angers hospital|All people aged 75 years and over hospitalized in short-stay geriatric care via a hotline in this hospital
88970850|NCT03959475||Clermont Ferrand hospital|All people aged 75 years and over hospitalized in short-stay geriatric care via a hotline in this hospital
88970851|NCT04730596|Placebo Comparator|Group I (Control group)|- The patients in this group will receive normal saline in a labeled syringe which will be prepared by an assistant nurse not participating in the study.
88970852|NCT04730596|Experimental|Group II (Ketamine group)|- The patients in this group will receive ketamine at a dose of 0.3 mg/kg dissolved in normal saline in a labeled syringe which will be prepared by an assistant nurse not participating in the study.
88970853|NCT04730596|Experimental|Group III (Dexmedetomidine group)|- The patients in this group will receive Dexmedetomidine in a dose of 0.5 ug/kg dissolved in normal saline in a labeled syringe which will be prepared by an assistant nurse not participating in the study.
88970854|NCT04846088|Experimental|Product usage order ABICHDGEF|Subjects will use each of the 9 products (ABICHDGEF) during a familiarization period, followed by a 3 hour Test Session
89573371|NCT05699005|Experimental|Individulised transfusion strategy group|Patients will recieve red blood cells transfusion in case of a drop of ScVO2 <65% after an assessment for the optimisation of SaO2 normalisation (SaO2>94%), volume optimisation, ECMO output increase, Fever (body temperature 38°3 C°), Anxiety and Pain
89573372|NCT05699005|Active Comparator|Conventionnal transfusion strategy group|Transfusion will be performed in case of a hemoglobin drop <9 g/dL
89573373|NCT05549167|Experimental|intervention/treatment|
89573374|NCT05542693|Experimental|RNA MCTI CIMATEC HDT 5µg|Intramuscular injections of novel Lipid-Inorganic Nanoparticle (LION) formulated replicating RNA-based vaccine (VACCINE RNA MCTI CIMATEC HDT) at a dose of 5 µg of single-dose administration on day 1.
89573375|NCT05542693|Experimental|RNA MCTI CIMATEC HDT 10µg|Intramuscular injections of novel Lipid-Inorganic Nanoparticle (LION) formulated replicating RNA-based vaccine (VACCINE RNA MCTI CIMATEC HDT) at a dose of 10 µg of single-dose administration on day 1.
88970855|NCT04846088|Experimental|Product usage order BCADIEHFG|Subjects will use each of the 9 products (BCADIEHFG) during a familiarization period, followed by a 3 hour Test Session
88970856|NCT04846088|Experimental|Product usage order CDBEAFIGH|Subjects will use each of the 9 products (CDBEAFIGH) during a familiarization period, followed by a 3 hour Test Session
88970857|NCT04846088|Experimental|Product usage order DECFBGAHI|Subjects will use each of the 9 products (DECFBGAHI) during a familiarization period, followed by a 3 hour Test Session
88970858|NCT04846088|Experimental|Product usage order EFDGCHBIA|Subjects will use each of the 9 products (EFDGCHBIA) during a familiarization period, followed by a 3 hour Test Session
88970859|NCT04846088|Experimental|Product usage order FGEHDICAB|Subjects will use each of the 9 products (FGEHDICAB) during a familiarization period, followed by a 3 hour Test Session
88970860|NCT04846088|Experimental|Product usage order GHFIEADBC|Subjects will use each of the 9 products (GHFIEADBC) during a familiarization period, followed by a 3 hour Test Session
89029031|NCT04949399|Placebo Comparator|Placebo|Placebo will be injected into the platysma muscle on Day 1
89029032|NCT04942626|Other|Chemoradiotherapy with Anakinra followed by either TME surgery or Watch and Wait|Capecitabine 500 mg/m2 bid or Capecitabine 650 mg/m2 bid or Capecitabine 825 mg/m2 bid combined with Radiotherapy and Kineret
89573376|NCT05542693|Active Comparator|Covishield® - AstraZeneca|Intramuscular injections of vaccine Covishield® - AstraZeneca at a usual dose of single-dose administration on day 1.
89573377|NCT05542693|Active Comparator|Comirnaty® - Pfizer|Intramuscular injections of vaccine Comirnaty® - Pfizer at a usual dose of single-dose administration on day 1.
89573378|NCT05549089|Experimental|CAD/CAM Insignia™ brackets|The result from this group (10 patients) considered as a gold standard for other two groups through assessing the treatment outcomes using American Board of Orthodontics (ABO) scoring.
89573379|NCT05549089|Experimental|Software-driven indirect bonding tray|The first comparison group (10 patients): digital setup, virtual bracket placement and creation of 3D printing indirect bounding tray by using Maestro® 3D Ortho Studio software.
89573380|NCT05549089|Experimental|Manual-driven indirect bonding tray|the second comparison group (10 patients): digital setup by using Maestro® 3D Ortho Studio software, but the bracket positioning done manually by using Ray Set® device. in this group using double-layer vacuum-formed thermoplastic indirect bonding tray.
89573381|NCT04323553||ESBL E.coli strains from 24 contact-index patients|48 ESBL-E. coli strains from 24 contact-index patients
89573382|NCT05542537|Experimental|BB Produce Distribution + BB Nutrition Education + CHF Weekly Wellness Groups + CHF Web-Based Module|BB is Brighter Bites. CHF is Create Healthy Futures.
89573383|NCT05542537|Active Comparator|CHF Web-Based Module|CHF is Create Healthy Futures.
89573384|NCT04320667||Active ANCA glomerulonephritis|Patients with ANCA related disease (Microscopic Polyangiitis, Granulomatosis with Polyangiitis or Churg-Strauss Syndrome) and active renal involvement
89573385|NCT04320667||Control|Patients with ANCA related disease (MPA, GPA, CSS) without renal involvement or complete remission
89573386|NCT05548933||HP|Chronic periodontitis (stage III/IV) patients with hyperlipidemia
89573387|NCT05548933||CP|Chronic periodontitis(stage III/IV) patients without hyperlipidemia
89573388|NCT05542459||Non-IBD control group|A control group in which patients are not diagnosed as inflammatory bowel disease.
89573389|NCT05542459||CD group|A group in which patients are diagnosed as crohn's disease
89573390|NCT05542459||UC group|A group in which patients are diagnosed as ulcerative colitis
88970861|NCT04846088|Experimental|Product usage order HIGAFBECD|Subjects will use each of the 9 products (HIGAFBECD) during a familiarization period, followed by a 3 hour Test Session
88970862|NCT04846088|Experimental|Product usage order IAHBGCFDE|Subjects will use each of the 9 products (IAHBGCFDE) during a familiarization period, followed by a 3 hour Test Session
89573391|NCT05698849|Placebo Comparator|Commercially Available Sports Drink A|A commercially available flavored electrolyte solution, The Coca-Cola Company
88970863|NCT04846088|Experimental|Product usage order FEGDHCIBA|Subjects will use each of the 9 products (FEGDHCIBA) during a familiarization period, followed by a 3 hour Test Session
88970864|NCT04846088|Experimental|Product usage order GFHEIDACB|Subjects will use each of the 9 products (GFHEIDACB) during a familiarization period, followed by a 3 hour Test Session
88970865|NCT04846088|Experimental|Product usage order HGIFAEBDC|Subjects will use each of the 9 products (HGIFAEBDC) during a familiarization period, followed by a 3 hour Test Session
89573392|NCT05698849|Experimental|Commercially Available Sports Drink B|A commercially available flavored carbohydrate-electrolyte solution, PepsiCo
89573393|NCT05698849|Experimental|Commercially Available Sports Drink A with added Amino Acids|The same as sports drink A above (a commercially available flavored electrolyte solution, The Coca-Cola Company), but with the addition of a small amount of amino acids.
89573394|NCT05542225|Experimental|conventional physical therapy with strength training|TENS with a frequency of 2-125Hz for about 30mins in prone position. FITT guidelines for strength training: frequency: 2-3 times perweek, time: 3o mins for the whole session, intensity: 8-15 repetitions and type : major muscles( shoulder flexors and extensors, hip and knee flexors, hip abductors and adductors, foot plantar flexors and dorsiflexors using resistance bands)
89573395|NCT05542225|Active Comparator|conventional physical therapy with flexibility training|TENS with a frequency of 2-125 Hz for 30 minutes. FITT guidelines for flexibility; frequency: 5 times per week, intensity: stop before it becomes painful, time: 10-15 minutes,hold for 15 secs and type: major muscle groups( latissmus dorsi, trapezius, gluteus maximus, gluteus medius, gatrocnemius, soleus, hamstringsand paraspinals( errector spinae and multifidus through static stretching technique.
88970866|NCT04846088|Experimental|Product usage order IHAGBFCED|Subjects will use each of the 9 products (IHAGBFCED) during a familiarization period, followed by a 3 hour Test Session
88970867|NCT04846088|Experimental|Product usage order AIBHCGDFE|Subjects will use each of the 9 products (AIBHCGDFE) during a familiarization period, followed by a 3 hour Test Session
88970868|NCT04846088|Experimental|Product usage order BACIDHEGF|Subjects will use each of the 9 products (BACIDHEGF) during a familiarization period, followed by a 3 hour Test Session
88970869|NCT04846088|Experimental|Product usage order CBDAEIFHG|Subjects will use each of the 9 products (CBDAEIFHG) during a familiarization period, followed by a 3 hour Test Session
88970870|NCT04846088|Experimental|Product usage order DCEBFAGIH|Subjects will use each of the 9 products (DCEBFAGIH) during a familiarization period, followed by a 3 hour Test Session
89573396|NCT02587819|Experimental|Treatment with BSCT|21 patients with BCC were treated with BSCT (anti-nf-P2X7) 10% Ointment topically applied twice daily for 28 consecutive days.
88970871|NCT04846088|Experimental|Product usage order EDFCGBHAI|Subjects will use each of the 9 products (EDFCGBHAI) during a familiarization period, followed by a 3 hour Test Session
88970872|NCT04730674|Experimental|post-mastectomty seroma group|female patients with established diagnosis of post-mastectomy seroma following modified radical mastectomy, were treated by local injection of tetracycline after the seroma fluid was aspirated, then a crepe bandage was applied over the mastectomy area. Then after 5 days the patient were examined again for seroma re-collection or the presence of complications. The amount of seroma aspirated in each session.
88970873|NCT00072163|Experimental|Treatment (temozolomide, thalidomide)|Patients receive oral temozolomide once daily on days 1-42 and oral thalidomide once daily on days 1-56. Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity. Patients achieving CR receive 2 additional courses of therapy beyond CR.
88970874|NCT03959397|Experimental|nab-paclitaxel|nab-paclitaxel monotherapy or combination therapeutic regimen
89573397|NCT04426045|Experimental|Pericapsular nerve group block|Participants receiving pericapsular nerve group block
89573398|NCT04426045|Active Comparator|Supra-inguinal fascia iliaca compartment block|Participants receiving supra-inguinal fascia iliaca compartment block
89573399|NCT05548465|Experimental|Long-term-opioid-free anesthesia group.|
89029033|NCT04915079|Experimental|PRISM|Patients in this arm will be recipients of the PRISM intervention
89029034|NCT04915079|No Intervention|Usual Care|Patients in this arm will not receive the PRISM intervention, but will continue to receive usual care the discretion of their treating clinicians.
89029035|NCT04914403|Experimental|UMC119-06-05|Human Umbilical Cord Derived-Mesenchymal Stem Cells, Single treatment by intravenous infusion.
89029036|NCT04893174|Experimental|UMC119-06-05|Human Umbilical Cord Derived-Mesenchymal Stem Cells. Subjects will receive a single-dose intra-articular (IA) injection of UMC119-06-05 followed by an IA injection of hyaluronic acid.
89029037|NCT04858503|Experimental|internet-based cardiac rehabilitation enhancement intervention|internet-based cardiac rehabilitation enhancement intervention
89029038|NCT04858503|No Intervention|conventional cares as arranged by hospital or community centers|Participants will receive conventional cares as arranged by hospital or community centers
89029039|NCT04835467|Experimental|Intracoronary imaging|Intracoronary imaging during PCI
89029040|NCT04829916|Experimental|RMC-035|Participants will receive RMC-035 intravenously
89029041|NCT04829916|Placebo Comparator|Placebo|Participants will receive matching placebo solution intravenously
89029042|NCT04816812|Other|Exercise|In the intervention arm, a 12-week aerobic exercise program tailored to the individual patients by physiotherapists using the principles of Frequency, Intensity, Time, and, Type (FITT) aiming to increase or maintain the physical activity level to a weekly moderate activity level.
89029043|NCT04816812|Other|Comparison|Comparison
89029044|NCT04786405|Experimental|Mindfulness Meditation|Participants in this arm will complete five, 20-minute mindfulness meditation sessions delivered over consecutive days.
89029045|NCT04786405|Active Comparator|Clinical Hypnosis|Participants in this arm will complete five, 20-minute clinical hypnosis sessions delivered over consecutive days.
89573400|NCT05548465|Active Comparator|Long-term-opioid anesthesia group.|
89573401|NCT04882735|Experimental|Acoramidis HCI 800 mg (two 400mg tablets)|TTR stabilizer administered orally twice daily (BID)
89573402|NCT05548309|Active Comparator|High flow nasal cannula|High flow nasal cannula (HFNC) was inserted through nasal prongs (Fisher & Paykel Healthcare, Auckland, New Zealand) . FiO2 was continuously measured by a dedicated system (AIRVO™ 2; Fisher & Paykel Healthcare, Auckland, New Zealand) .
89573403|NCT05548309|Active Comparator|oxygen face mask|Simple oxygen face mask was applied to patients starting with flow rate 6L/min .
89573404|NCT05554471|Experimental|Mynx Control Venous Closure|204 (2:1 randomized - 136 VCD:68 manual compression)
89573405|NCT05554471|Active Comparator|Manual Compression|204 (2:1 randomized - 136 VCD:68 manual compression)
89573406|NCT05541991|Experimental|Single dose product|A single dose coated tablet with standardised rhubarb extract is administrated daily in the evening during 30days
89573407|NCT05541991|Experimental|Double dose product|A double dose coated tablet with standardised rhubarb extract is administrated daily in the evening during 30days
89573408|NCT05541991|Placebo Comparator|placebo product|A placebo coated tablet without active is administrated daily in the evening during 30days
89573409|NCT05700097|Experimental|Low Dose Arm|Dengzhanxixin injection 40ml/day, placebo 40ml/day. Dengzhanxixin injection 40ml, diluted with 250ml of 0.9% sodium chloride injection and then slowly intravenously infused once a day; placebo injection 40ml, diluted with 250ml of 0.9% sodium chloride injection and then slowly intravenously infused once a day.
89573410|NCT05700097|Experimental|High Dose Arm|Dengzhanxixin injection 80ml/day. Dengzhanxixin injection 40ml, diluted with 250ml of 0.9% sodium chloride injection, and then slowly intravenously infused twice a day.
89029046|NCT04779424||Primary Health Care Providers (PHCPs)|Any Belgian general practitioner (GP) (including those in professional training) currently working in primary care and any other primary health care providers (PHCPs) from the same GP practice who physically manage (examine, test, treat) patients/clients (frontline PHCP).
89029047|NCT04779294||Fetus in labour at risk of acedimia|The Group of patients studied are fetuses in labour at risk of hypoxia with internal fetal monitoring and scalp lactate bloodsamples ( standard monitoring).
89029048|NCT04779294||Fetus in labour at risk of acedemia with STAN analysis|Same group of fetuses in labour at risk of hypoxia with internal fetal monitoring and STAN analysis(ST waveform analysis of the fetal electrocardiogram, opened after study inclusion finished)
89029049|NCT04772040|Experimental|Young loading dose group|Participants (18-35) will receive a loading dose of fish oil supplementation during the first 4 weeks of the intervention period of the study. In the last 8 weeks participants will receive a maintenance dose of fish oil supplementation. The total amount of EPA/DHA received throughout the supplementation period will be the same as the old group.
89033202|NCT02943005|Experimental|Rotator cuff repair without sling|Patients don't wear any sling, they move passively in all axes during 4 weeks. Then progressive active mobilization is done.
89573411|NCT05700097|Placebo Comparator|Placebo Arm|Placebo injection 80ml/day. Placebo injection 40ml, diluted with 250ml of 0.9% sodium chloride injection, and then slowly intravenously infused twice a day.
89573412|NCT05554081|Placebo Comparator|Clean catch BMI < 30|Standard of care urine collection
89573413|NCT05554081|Placebo Comparator|Clean catch BMI > 30|Standard of care urine collection
89573414|NCT05554081|Experimental|PEEZy collection BMI < 30|PEEZY device for urine collection
89573415|NCT05554081|Experimental|PEEZY collection BMI > 30|PEEZY device for urine collection
89573416|NCT05554003|Experimental|Metronomic Temozolomide|Metronomic Temozolomide in unfit patients with advanced neuroendocrine neoplasms (NENs) Dosage and schedule: 60 mg/die continuosly
89573417|NCT05541757||control group|five healthy adults
89573418|NCT05541757||Study group|Twenty-five patients using the direct oral factor Xa inhibitor rivaroxaban
89573419|NCT05541601||Pearl Cohort|All 3000 patients recruited to the Pearl study
89573420|NCT05547997|Experimental|two way traction|The study group will receive 3-point bending cervical extension traction following the protocol of Harrison et al. The duration of each session will starte at approximately three minutes and increased one minute per session until reaching the goal of 20 minutes per session
89573421|NCT05547997|Active Comparator|traditional treatment|Stretching exercises: Patients will perform the stretching program 3 times a week; with a single session taking about 10 minutes to perform.
89573422|NCT05541523|Experimental|cognitive behavioural therapy|
89573423|NCT05541523|Experimental|mindfulness-based therapy|
89573424|NCT05541445|Experimental|Experimental arm|Immunotherapy combined with chemotherapy and radiotherapy
89573425|NCT05547763|Experimental|resorbable plates, test group|after a surgical procedure under general anesthesia , resorbable plates will be placed on the fracture site of the mandibule in 20 patients out of 40 total sample size and will be compared with the titanium plates in the control group
89573426|NCT05547763|Experimental|titatnium plates, control group|after a surgical procedure under general anesthesia , titanium plates will be placed on the fracturte site in the mandible in 20 patients out of 40 total sample size and will be compared to the test group containing resorbable plates
89573427|NCT05540977|Experimental|Donepezil|Patients were randomly divided into experimental group and control group. The experimental group received routine postoperative treatment and took donepezil 5mg orally before going to bed every night from the first day after surgery.
89573428|NCT05540977|Other|Usual care|Usual care
89573429|NCT05553535||cases|cases of rotator cuff calcific tendinosis on imaging studies
89573430|NCT05553535||witnesses|differential diagnosis or normal cases
89573431|NCT05547685|Experimental|Methylene blue intradermal injection|Methylene blue intradermal injection
89573432|NCT05553379||Children 7 to 17|Children with asthma
89573433|NCT05553379||Adults 18 to 80|Adults with asthma
89573434|NCT05540821||conventional transvaginal ultrasound group|
89573435|NCT05540821||double contrast-enhanced ultrasound group|perfromed hysterosalpingo-contrast sonography and sonoPODography examination
89029050|NCT04772040|Experimental|Old loading dose group|Participants (60y+) will receive a loading dose of fish oil supplementation during the first 4 weeks of the intervention period of the study. In the last 8 weeks participants will receive a maintenance dose of fish oil supplementation. The total amount of EPA/DHA received throughout the supplementation period will be the same as the young group.
89209085|NCT00985647|Active Comparator|3TC 150mg/300mg|Group 2: Participants will be administered 3TC 150 mg once daily orally for 10 days. A 10 day wash-out period will follow (days 11-20). From day 21, participants will be administered 3TC 300 mg once daily for 10 days
89573436|NCT05540587|Experimental|Edoxaban|"Patients in the Edoxaban group take Edoxaban 60mg once daily. If any of the following conditions are present, take 30mg once daily.~CrCl 15-50mL/min~Body weight ≤ 60kg~Concomitant use of P-glycoprotein inhibitor (Dronearone, Ciclosporine, Erythromycin or Ketoconazole)"
89573437|NCT05540587|Active Comparator|Warfarin|Patients in the Warfarin group take Warfarin 2-10mg once daily, dose adjusted with the target INR 2-3. In the elderly or frail patients, a lower dose administration is allowed at the discretion of the investigator.
89573438|NCT05540509|Experimental|Community-based intervention|This program consisted of 12 group exercise sessions over a three-month period that were offered in Spanish and English. Each two-hour session consisted of 90 minutes of flexibility, cardiovascular, and strength exercises to meet physical activity recommendations and 30 minutes of group discussions that focused on topics related to the adoption and maintenance of physical activity.
89573439|NCT05540509|Active Comparator|Home-based intervention|Mothers randomized to the HBI group participated in a three-month program where they were given print-based materials (offered in Spanish or English) at each monthly assessment time point. The print-based materials provided information on multiple cardiovascular, strength training, and flexibility exercises that they could do at home.
89573440|NCT05540431|Other|Activated charcoal|"1st group~Oral activated charcoal~20 to 25 patient with CKD will receive standard care plus Activated charcoal capsule (charconut) three times dialy for six weeks."
89573441|NCT05540431|Other|Probiotic|"2nd group~Oral probiotic~20 to 25 patient with CKD will receive standard care plus Probiotic tablet twice dialy for six weeks."
89573442|NCT05540431|Other|Control group|"3rd group~Control group~20 to 25 patient with CKD will receive standard care only for six weeks."
89573443|NCT05700409|Experimental|Telemedicine|The telemedicine arm will include 30, mostly video, consultations for each participant: 3 physician appointments, 7 exercise consultations by our exercise physiologist, 10 dietary consultations by our pediatric dietitian, and 10 psychologist consultations to assist with goal setting and overall well-being. Three visits will be conducted in-office, for physician assessment, smartphone technical assistance and physical measurements (baseline, at 3 months and at the end of the 6-month period). Participants randomized to the telemedicine arm will have a step-counting rewarding app installed on their smartphone by our staff.
89573444|NCT05700409|Active Comparator|On-site|The on-site arm will have 6 monthly visits during the study period, with two consultations performed in each visit - one by the physician or exercise physiologist, and one by our pediatric dietitian.
89573445|NCT04319809|Experimental|Device feasibility|To investigate the utility of a device adaptation allowing Argus II users to detect the presence and location of desired objects. Performance of the unaided Argus II system will be compared with performance using the system augmented with object recognition.
89573446|NCT05547139|No Intervention|Usual care group|Infants randomized to this group will receive the present standard of care for weaning respiratory support. This means the attending provider will decide when each infant is ready to be changed from CPAP to nasal cannula and the nasal cannula will be weaned according to an existing unit protocol.
89573447|NCT05547139|Active Comparator|Protocol care group|Infants randomized to this group will remain on CPAP until they are at least 32 weeks corrected gestational age or 1250g. At that point, if they meet a set of criteria, they will be transitioned to either 2L nasal cannula if they require supplemental oxygen or room air.
89573448|NCT04318249|Experimental|Assisted Relaxation Therapy|This group will be receiving an assisted relaxation therapy intervention
89573449|NCT04318249|Experimental|Modified Assisted Relaxation Therapy|This group will be receiving a modified version of an assisted relaxation therapy intervention
89573450|NCT05540197||Autologous islet transplantation|Arginine stimulation test: 5 grams of arginine hydrochloride intravenously. Performed at baseline after mixed meal tolerance test (MMTT), performed separately at day -1 or 0, day 1, day 3, day 7 and 3 months, and also at 3 months after MMTT.
89573451|NCT05540197||Allogeneic islet transplantation|Arginine stimulation test: 5 grams of arginine hydrochloride intravenously. Performed at day -1 or 0, day 1, day 3, day 7, 3 months and at 3 months after MMTT.
89573452|NCT05540119||SWEGASS|Gastric cancer patients.
89573453|NCT05540119||SESS|Oesophageal cancer patients.
89573454|NCT05552677|No Intervention|Control Group (CG)|Patients will recieve no intervention for the period of 12 weeks
89573455|NCT05552677|Experimental|Exercise Group (EG)|Patients will undergo a 12 week multicomponent training program
89573456|NCT05539885|Active Comparator|Pre-incisional PIFB|Group P (ultrasound guided parasternal; PIFP block): patients will be injected with 0.4 mL/kg 0.25 bupivacaine in the fascial plane between the pectoralis major and internal intercostal muscles on each side of the sternum after induction of anesthesia and before skin incision under ultrasound guidance.
89573457|NCT05539885|Active Comparator|Post-incisional PIFB|"Group S: After sternal closure, the surgeon will inject bupivacaine (0.5- to 2-mL aliquots depending on the weight) in the fascial plane under direct vision between the 5 anterior (2nd-6th) intercostal spaces on each side 1 to 1.5 cm lateral to the sternal edge using 25-gauge, 50 mm needle. The surgeon will inject the same dose and concentration of bupivacaine used in the ultrasound technique. This technique was prescribed before by Chaudhary et al (23).~In both techniques, the maximum dose of bupivacaine will never be exceeded (2 mg/kg). In addition, all patients were administered 2 mL of 0.25% bupivacaine at the site of the mediastinal drain location."
89573458|NCT05552599|Experimental|woolen blanket|Preoperative pressure sore risk was assessed with the Braden Risk Assessment Scale. The patient's room temperature was recorded on the day of surgery before the patient was admitted for the operation. Body temperature was measured before the patient wore surgical gown. Before leaving the room, patient's body was covered with a woolen blanket. The temperature of the operating room was recorded. Body temperature was stabilized under normothermic conditions with a woolen blanket until the operation began. Body temperature was measured before anesthesia was given. Body temperature was measured in the 1st, 2nd and 3rd hour after anesthesia was given. The patient was evaluated with the Braden Risk Assessment Scale on the first, second and third postoperative days.
89573459|NCT05552599|No Intervention|standard of care|Preoperative pressure sore risk was assessed with the Braden Risk Assessment Scale. The patient's room temperature was recorded on the day of surgery before the patient was taken to the operation. Body temperature was measured before the patient wore surgical clothes. The temperature of the operating room was recorded. Body temperature was measured before anesthesia was givenBody temperature was measured at the 1st, 2nd and 3rd hour after anesthesia was given. The patient was evaluated with the Braden Risk Assessment Scale on the first, second and third postoperative days.
89573460|NCT04426123|Active Comparator|Botulinum toxin|Botulinum toxin type A
89573461|NCT04426123|Placebo Comparator|Saline solution|NaCl
89573462|NCT05539651|Experimental|RBD5044 SAD experimental group|Subjects in SAD experimental groups will receive a single subcutaneous injection of RBD5044 on Day 1.
89573463|NCT05539651|Experimental|RBD5044 MAD experimental group|Subjects in MAD experimental groups will receive one subcutaneous injection of RBD5044 on Day 1 and another subcutaneous injection of RBD5044 on Day 29.
89573464|NCT05539651|Placebo Comparator|Placebo SAD group|Subjects in SAD placebo groups will receive a single subcutaneous injection of placebo on Day 1.
89573465|NCT05539651|Placebo Comparator|Placebo MAD group|Subjects in MAD placebo groups will receive one subcutaneous injection of placebo on Day 1 and another subcutaneous injection of placebo on Day 29.
89573466|NCT04425811|No Intervention|No tape applied|Walking parameters were evaluated without any intervention.
89573467|NCT04425811|Experimental|Kinesiological Tape|Walking parameters were evaluated after kinesiological taping on the tibialis anterior muscle
89573468|NCT04425811|Sham Comparator|Sham taping|Walking parameters were evaluated after sham taping on the tibialis anterior muscle
89573469|NCT01666951|Experimental|LCP-Tacro|LCP-Tacro Tablets, once daily (Veloxis Pharmaceuticals A/S, Horsholm, DK)
89573470|NCT01666951|Active Comparator|Prograf|Prograf Capsules, twice daily (Astellas Pharma US, Deerfield, IL)
88811138|NCT04199117|Experimental|Incentive,Untailored,Care Manage,Intensive Treatment|Participants randomly assigned to this condition will have access to incentives for completing a first smoking cessation counseling call up to 4 times over 2 years, will receive 5 untailored letters promoting use of smoking cessation treatment over 2 years, will receive 5 Tobacco Care Management support and motivational encouragement calls over 2 years, and will have access to 3 smoking cessation quit counseling calls and 12-weeks of either combination nicotine replacement or varenicline up to 4 times over 2 years.
89573471|NCT05699395||Aortic Dissection|
89573472|NCT05699395||Non Aortic Dissection|
89573473|NCT05539339|Experimental|Arm 1|This arm includes patients with ctDNA-level-relapse glioblastoma before imaging recurrence.
89573474|NCT05539261||HVD|Heart Valve Disease
89573475|NCT05539261||HC|Healthy controls
89573476|NCT05539183|Experimental|Solid cancer patients with malignant pleural effusion|Solid cancer patients that have to undergo pleural evacuation because of diagnosed malignant pleural effusion mediated discomfort.
89573477|NCT05539105||Double tract reconstruction|Double tract reconstruction would be applied after proximal gastrectomy
89573478|NCT05539105||Gastric conduit reconstruction|Gastric conduit reconstruction would be applied after proximal gastrectomy
89573479|NCT05539105||Other reconstructions|Other reconstructions except for double tract and gastric conduit reconstructions would be applied after proximal gastrectomy
89573480|NCT05546203|Experimental|Ischemic compression (IC) group|Ischemic compression group received ischemic compression and standardized exercise program twice a week for 6 weeks. Each session takes 50 minutes.
89573481|NCT05546203|Experimental|Low-level laser therapy (LLLT) group|Low-level laser therapy group received Low-level laser therapy and standardized exercise program twice a week for 6 weeks. Each session takes 50 minutes.
89573482|NCT05551507|Experimental|IN10018 in combination with PLD|IN10018 in combination with PLD in platinum-resistant recurrent epithelial ovarian cancer, fallopian tube cancer or primary peritoneum cancer with the subtype limited to high-grade serous carcinoma subjects.
89573483|NCT05538559|Experimental|Test|
89573484|NCT05538559|Active Comparator|Control|
89573485|NCT05698303|Experimental|CT103A in patients with RRMM|After lymphodepletion, CT103A will be administered as a single infusion.
89573486|NCT05551351||Coronary CT|The single cohort consists of all patients enrolled in the study. All participants performs cardiac CT and coronary angiography as part of routine care.
89573487|NCT02586805|Experimental|DX-2930 300 mg every 2 weeks|300 mg DX-2930 administered every 2 weeks by subcutaneous injection.
89573488|NCT02586805|Experimental|DX-2930 300 mg every 4 weeks|300 mg DX-2930 administered every 4 weeks by subcutaneous injection
89573489|NCT02586805|Experimental|DX-2930 150 mg every 4 weeks|150 mg DX-2930 administered every 4 weeks by subcutaneous injection
89573490|NCT02586805|Placebo Comparator|Placebo|Placebo administered every 2 weeks by subcutaneous injection.
89573491|NCT05545423|Experimental|instrumented assisted soft tissue mobilization|patients will receive IASTM three times a week for eight weeks
89573492|NCT05545423|Active Comparator|traditional therapy|patients will receive traditional therapy three times a week for eight weeks
89573493|NCT05545345|Active Comparator|TT|Participants only receive tympanostomy tube placement.
89573494|NCT05545345|Experimental|Ad+TT|Participants will receive tympanostomy tube placement and concurrent adenoidectomy.
89573495|NCT05550883|Experimental|Group A (aerobic exercise group)|aerobic exercise training for 45 minutes, three sessions per week for 6 weeks.
89573496|NCT05550883|Active Comparator|Group B (Medications group)|The patients in this group did not receive treatment program. just received their medical treatment tricyclic antidepressants (low evening doses), and mostly when needed, low doses of: analgesics, muscle relaxants, hypnotics, and tranquilizers over the period of 6 weeks.
89573497|NCT05545189||colonoscopy group1|Polypectomy, histological examination, NICE classification and AIPHP analyzis will be performed 200 patients.
89209086|NCT00806468|Experimental|Desmopressin|Desmopressin 0,2 mg once daily and Desmopressin 0,2 mg bid for one week each.
89573498|NCT05545189||colonoscopy group 2|Polypectomy, histological examination, NICE classification and AIPHP analyzis will be performed 200 patients
89573499|NCT05545189||colonoscopy group 3|Polypectomy, histological examination, NICE classification and AIPHP analyzis will be performed 200 patients
89573500|NCT05545189||colonoscopy group 4|Polypectomy, histological examination, NICE classification and AIPHP analyzis will be performed 200 patients
89573501|NCT05545189||colonoscopy group 5|Polypectomy, histological examination, NICE classification and AIPHP analyzis will be performed 200 patients
89573502|NCT05545189||colonoscopy group 6|Polypectomy, histological examination, NICE classification and AIPHP analyzis will be performed 200 patients
89573503|NCT05698225|Experimental|Inoculation with Streptococcus pneumoniae serotype 6B|Participants will be inoculation with a controlled concentration of full sequenced, fully antibiotic sensitive Streptococcus pneumonia serotype 6B
89573504|NCT04736017|Experimental|Verum|The device records EEG and other biosignals throughout the night and scans these signals for slow waves associated with deep Non-Rapid Eye Movement (NREM) sleep. Upon recognition of such slow waves and fulfilment of other criteria, a tone is played via the headphones to stimulate and enhance slow waves without waking up the patient.
89573505|NCT04736017|Sham Comparator|Sham|Playing no tones during NREM sleep but wearing the device and recording the biosignals over a period of 2 weeks, every night.
89573506|NCT05545033|Experimental|Virtual reality intervention|Comparison of pain and anxiety levels before and after VR intervention within the same patient.
89573507|NCT05550649|Experimental|Prophylic Embolization|Prophylactic arterial embolization is performed for the artery in the diseased blood supply area. The embolization material: gelatin sponge particles are recommended, and micro-steel ring can be used as an auxiliary if necessary; after operation, symptomatic and supportive treatment such as acid suppression, hemostasis, blood transfusion, and fluid replacement are given according to the condition.
89573508|NCT05550649|Sham Comparator|Sham Embolization|After the angiography was completed, no embolization was performed, the catheter was withdrawn, the vascular sheath was removed, and symptomatic and supportive treatments such as acid suppression, hemostasis, blood transfusion, and fluid replacement were given.
89573509|NCT05544955|Experimental|Protein ingestion immediately prior to and immediately after resistance training|This arm involved protein ingestion immediately prior to and immediately after resistance training for 12 weeks. Participants will consume 40 g of isolate whey protein at their recommended timing.
89573510|NCT05544955|Experimental|Protein ingestion 3 hours prior to and 3 hours after resistance training|This arm involved protein ingestion 3 hours prior to and 3 hours after resistance training for 12 weeks. Participants will consume 40 g of isolate whey protein at their recommended timing.
89209087|NCT00982527|Placebo Comparator|Placebo|Saline blinded infusion
89209088|NCT00982527|Active Comparator|Fenoldopam|Drug infusion
89209089|NCT00798980||Arm 1|
89209090|NCT00243919|Active Comparator|Early Locomotor Training Program|body weight supported training program with treadmill
89209091|NCT00243919|Active Comparator|Late Locomotor Training Program|body weight supported training program with treadmill
89209092|NCT00243919|Active Comparator|Early Home Exercise Program|a non-specific low intensity exercise program
89573511|NCT05544877|Experimental|Brain2Business (B2B)|"The Brain2Business (B2B) technique aims to improve creative thinking. It is a game-based conceptual combination method that is performed by the participant with support of one trained B2B administrator in a laboratory session and without support in 5 at-home sessions. In this technique, thirty-six different images are randomly selected on a board by throwing two dices. Inspired by these images, participants are asked to create new ideas regarding three questions for a total of at least 39 minutes over a period of 5 days. One question is from a standardized creativity test and two questions are part of psychotherapeutic techniques (idea generation for pleasurable activities within behavioral activation (PA-BA) and for a gratefulness exercise (GE)). The B2B technique is based on the principles of solo brainstorming (SBS). A trained B2B administrator is documenting the answers of the participant, and mentioning the principles of SBS (see SBS group)."
89029051|NCT04772040|Experimental|Young constant dose group|Participants (18-35y) will receive a constant dose of fish oil supplementation throughout the intervention period of the study. Total amount of EPA/DHA received throughout the 12 weeks supplementation period will be the same as the loading groups.
89029052|NCT04772040|Experimental|Old constant dose group|Participants (60y+) will receive a constant dose of fish oil supplementation throughout the intervention period of the study. Total amount of EPA/DHA received throughout the 12 weeks supplementation period will be the same as the loading groups.
89573512|NCT05544877|Active Comparator|Solo Brainstorming (SBS)|Solo brain storming (SBS) is the active control condition. The technique aims to improve creative thinking through the principles of SBS. SBS principles include i) idea quantity goes before quality, ii) no criticism and evaluation of ideas during idea generation, iii) original ideas are encouraged. The principles are provided to participants in the same way, with the same questions to be answered, and over the same time period as in the B2B group. A trained SBS administrator is documenting the answers of the participant, and mentioning the principles of SBS.
89573513|NCT05550415|Experimental|Simvastatin|The group received standard treatment with simvastatin 40mg in capsule by oral route, once a day, for 21 days (every cycle of the chemotherapy regiment)
89573514|NCT05550415|Placebo Comparator|Placebo|The group received standard treatment with placebo 40mg in capsule by oral route, once a day, for 21 days (every cycle of the chemotherapy regiment)
89573515|NCT05699161|Experimental|Single group assignment.|"Bilateral treatment.~Subdermal plane injection of SVF cells into the submuscular aponeurotic fascia of the face."
89573516|NCT05537155|Experimental|Buccal acupuncture|Buccal acupuncture will be performed in addition to routine care.
89573517|NCT05537155|Active Comparator|Routine care|Routine care will be provided.
89573518|NCT05550259|No Intervention|control period|the control period corresponds to usual care of centers
89573519|NCT05550259|Experimental|protocolized period|the protocolized period corresponds to a protocolized use of HFNO or NIV after extubation
89573520|NCT05537077|Active Comparator|Group 1|%5 Dextrose prolotherapy, hotpack therapy and home based exercise program was applied to group 1.
89573521|NCT05537077|Active Comparator|Group 2|%10 Dextrose prolotherapy, hotpack therapy and home based exercise program was applied to group 2.
89573522|NCT05537077|Active Comparator|Group 3|%20 Dextrose prolotherapy, hotpack therapy and home based exercise program was applied to group 3.
89573523|NCT05537077|Active Comparator|Group 4|Hotpack therapy and home based exercise program was applied to group 4.
89573524|NCT05544643|Experimental|A - M30IS vs. EM30IS. First phase Mio 30, second phase Extended Mio 30.|"Subjects will be randomized to a group who will be using the Mio 30 infusion set (M30IS) for the Phase 1. All patients will be retrained on the use of the M30IS by site staff and will be asked to demonstrate proficiency. All subjects will be instructed to change sets every 3 days or at set failure (replace with another M30IS).~At day 12 or after using 4 sets (set used defined as a set that was used for more than 6 hours), the patients will return to a visit, return all the extracted catheters sets and will switch to the Extended Mio 30 infusion set (EM30IS), entering Phase 2. All patients will be trained at this visit on the use of the EM30IS by site staff and demonstrate proficiency in the use of the EM30IS. All subjects will be instructed to change sets every 7 days or at set failure (replace with another EM30IS). After 28 days or after using 4 sets, the patients will return all the extracted catheters sets."
89573525|NCT05544643|Experimental|B - EM30IS vs. M30IS. First phase Extended Mio 30, second phase Mio 30|"Subjects will be randomized to a group who will be using the EM30IS for the initial Phase. All patients will be trained on the use of the EM30IS by site staff and will be asked to demonstrate proficiency. All subjects will be instructed to change sets every 7 days or at set failure (replace with another EM30IS).~At day 28 or after using 4 sets (set used defined as a set that was used for more than 6 hours), the patients will return to a visit, return all the extracted catheters sets and will switch to the M30IS, entering Phase 2. All patients will then be retrained on the use of the M30IS by site staff and demonstrate proficiency. All subjects will be instructed to change sets every 3 days or at set failure (replace with another M30IS). After 12 days or after using 4 sets, the patients will all the extracted catheters sets."
89029053|NCT04768881|Experimental|Arm A: Primary resistance to Initial CPI Therapy|Participants will receive a dose of 80 milligrams (mg) selinexor orally once weekly (QW) and a dose of pembrolizumab 400 mg intravenously (IV) once in every six weeks (Q6W), both on Day 1 of a 6-week cycle until progressive disease (PD), intolerable toxicity or withdrawal from the study, whichever occurs first.
89029054|NCT04768881|Experimental|Arm B: Acquired Resistance to Initial CPI Therapy|Participants will receive a dose of 80 mg selinexor orally once weekly (QW) and a dose of pembrolizumab 400 mg IV Q6W, both on Day 1 of a 6-week cycle until PD, intolerable toxicity or withdrawal from the study, whichever occurs first.
89029055|NCT04768790|Experimental|Multidisciplinary Group|Description of the interventions of the multidisciplinary program: multimodal exercises to improve, through gradual exposure, cervical mobility, postural control and strengthening of the cervical muscles; stabilization techniques for the deep neck muscles; task-oriented exercises maintaining the activation of the deep spinal muscle. Under the supervision of a psychologist, the subjects will also be involved in cognitive-behavioral therapy aimed at modifying the fear of movement (kinesiophobia) and the maladaptive behavior of the disease. Ergonomic consultancy.
89029056|NCT04768790|Active Comparator|General Group|Description of the interventions of the general program: exercises for muscle strengthening, regional stretching and spinal mobilization. Ergonomic consultancy.
89573526|NCT05550025|Experimental|TACE combined with Apatinib and Camrelizumab|TACE（transcatheter arterial chemoembolization） combined with Apatinib and Camrelizumab
89573527|NCT05544409|Experimental|MAKv1|The MAKv1 group will receive 1 hour of MAKv1 rehabilitation, thrice per week during 1 month
89573528|NCT05700253|Experimental|Cooled Radiofrequency Ablation|Relieves pain by blocking pain signals via the deactivation of nerve structures using radiofrequency energy.
89573529|NCT05700253|Active Comparator|Hyaluronic Acid Injection|Injection of hyaluronic acid into the affected knee provides lubrication and shock absorption.
89573530|NCT05536765||Patients with impacted tooth|
89573531|NCT05536687|Other|Healthy|
89573532|NCT05544331|Experimental|Written exercise group|The exercise program will consist of core stabilization exercises, which target various trunk muscles to optimize segmental control, spinal stability, spinal stiffness, orientation and the interoperability of these features. The exercise program will be in writing form, which is a common home exercise program type.
89573533|NCT05544331|Experimental|Video based exercise group|The exercise program will consist of core stabilization exercises, which provide segmental control optimization, spinal stabilization, spinal stiffness, orientation and the interoperability of these features. The exercise program will be given patients as video records, which provide visual and auditory feedbacks.
89573534|NCT05544331|No Intervention|Control group|The patients, who are referred and will wait for the exercise program in their routine daily life. Measurements will be performed at the same time frame in experimental group. After the 12 weeks of follow up period, they will join the exercise program.
89573535|NCT05535673|Experimental|ThisCART19A cell injection|In this study, allogeneic anti-CD19 CART cell (This CART19A) injection is used to treat patients with refractory or relapsed CD19 positive B cell Lymphoma.
89573536|NCT05544253|Experimental|HIPEC group|
89573537|NCT05544253|No Intervention|non-HIPEC group|
89573538|NCT05535517||Group 1|"KP Scoring Day Participants~Participants who attend the one-day scoring session in August 2022."
89573539|NCT05535517||Group 2|"KP Follow-up Scoring (September)~Participants who attended the scoring day in August will be invited to attend a follow-up scoring session in September - October 2022. The purpose of this scoring session is to see how stable their condition is and take baseline photographs of their skin to monitor their condition.~Four assessors will score the participants in 5-minute intervals with the proposed scoring system KPAI and the KP-IGA. Participants will be offered free samples of Cerave Salicylic Acid Smoothing Cleanser and Cream to try."
89573540|NCT05535517||Group 3|"KP Follow-up Scoring (November)~Participants who attend the September scoring session will be invited to return for another rescoring in November - December 2022 to see if there is any improvement in their KP and if the score is responsive to change.~Participants will be given free samples of Propaira 30% Urea exfoliating emollient and Propaira 20% Lactic acid exfoliating lotion to try."
89573541|NCT05535517||Group 4|"KP Follow-up Scoring (December)~Participants who attend the November scoring session will be invited to return for another rescoring in December 2022 to monitor their progress, and see if there is any improvement in their KP and if the score is responsive to change."
89573542|NCT05698069||Patients with chronic pain|Patients with non-cancer pain of more than 3 months duration.
89573543|NCT05536531|Experimental|NMES group|NMES will be implemented simultaneously on quadriceps femoris muscles of both lower limbs using an electrical stimulator (TRAINFES 6 ADVANCED, Biomedical devices Spa, Santiago, Chile). Four rubber surface electrodes will be placed over motor points. However, since the electrodes will cover big proportion of muscle surface, anatomical distribution of the belly muscle plus visible contraction of it will be considered for correct setting. The stimulation will be delivered by biphasic current, symmetric (compensated) impulses of 45-50 Hz frequency, 400 μsec pulse duration. With a stimulus duration of 25 minutes, and an on-off programming of 5 seconds on (including 0.8 second rise time, 3.4 seconds of plateau and 0.8 second of fall time) and 5 seconds off, at current intensities able to cause maximal visible contractions. The session duration will be 30 minutes and will be applied twice a day.
89573544|NCT05536531|No Intervention|Control|Sham NMES will not be provided. Standard care won´t be altered and passive mobilization will be performed according to routine ICU procedures.
89573545|NCT05536063|Experimental|group A|bilateral ESPB with 0.5 ml/kg of 0.25% bupivacaine (limited to a maximum dose of 20 ml) for each side
88970875|NCT00072436|Experimental|Treatment|"Some patients receive an initial dose of alvocidib IV over 1-7 hours on day 1 (course 0). Beginning 1 week later and for all subsequent courses, all patients receive gemcitabine hydrochloride IV over 60-150 minutes on days 1 and 15 and alvocidib IV over 1-7 hours on days 2 and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of gemcitabine hydrochloride and alvocidib until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, up to 10 additional patients receive treatment at that dose."
89029057|NCT04761822|Experimental|Moderna COVID-19 Vaccine|The Moderna COVID-19 Vaccine (0.5 mL) will be administered intramuscularly in the deltoid, as a series of two doses (0.5 mL each) administered 1 month (28 days) apart.
89029058|NCT04761822|Experimental|Pfizer-BioNTech COVID-19 Vaccine|The Pfizer-BioNTech COVID-19 Vaccine (0.3 mL) will be administered intramuscularly in the deltoid, as a series of two doses (0.3 mL each) administered 3 weeks (21 days) apart.
89573546|NCT05536063|Experimental|Group B|bilateral ESPB with 0.5 ml/kg of 0.25% bupivacaine (limited to a maximum dose of 20 ml) + dexamethasone 0.1 mg/kg for each side
89573547|NCT05536063|No Intervention|Group C|control group will receive the standard analgesic regimen only
89573548|NCT05535985|Experimental|acupuncture group|In the acupuncture group, acupoints of Baihui, Shenting, Sishencong will be selected for acupuncture stimulation be anesthesia. The needle will be kept for 30 minutes, during which the needle will be performed once every 10 minutes for 10 seconds each time, 4 times in total. The therapist will give the subject verbal cues before and during the needle manipulation.
89573549|NCT05535985|Placebo Comparator|placebo acupuncture group|The patients will be treated with consolation needle. Choose treatment of points that near but without going through the acupoints(upper arm deltoid muscle). Use the Park needle (blunt needle, tip obtuse, when acupuncture the feeling is similar to acupuncture needles into the skin, but it retracts instead of piercing the skin) to conduct acupuncture treatment. The retention time and number of needles will be the same as those in the acupuncture group. The therapist will give the subjects verbal cues before and during the acupuncture manipulation, which further reduces the subjects' doubts about the authenticity of acupuncture in the this group. To ensure the implementation of the blinding method, all patients will be treated independently and avoid contacting with each other.
89573550|NCT05535985|No Intervention|control group|The patients will undergoing routine anesthesia without acupuncture treatment.
89573551|NCT05592535||FFR below 0.80|Patients with significant coronary hyperemic gradient
89573552|NCT05592535||FFR above 0.80|Patients without significant coronary hyperemic gradient
89573553|NCT05699083|Other|Patients with BMI between 30-34.5 kg/m2|Patients with BMI between 30-34.5 kg/m2 will be administered a body image/self-esteem questionnaire pre-operatively and at 1 month, 3 months, 6 months and 12 months post-operatively.
89573554|NCT05697913|Experimental|MRDI-driven treatment|Patients continue treatment until complete remission with negative MRD and Image is achieved, changing the therapeutic line if this is not achieved with the prescribed treatment. In this group of patients, treatment is suspended only when this degree of profound response is reached, in any phase of treatment.
89573555|NCT05697913|No Intervention|Conventional treatment|The patients of the conventional treatment group (control group) received six cycles of the induction traetment, bone marrow auto-transplantation, and consolidation treatment after transplantation if complete remission had not been achieved.
89573556|NCT05543941|Experimental|XPERIENCE Advanced Surgical Irrigation|Patients will receive the XPERIENCE Advanced Surgical Irrigation prior to wound closure.
89573557|NCT05543941|Active Comparator|Dilute Betadine|Patients will receive Dilute Betadine solution prior to wound closure.
88970876|NCT02966158|Experimental|AIT Group|"The AIT Group will perform usual care CR exercise for the 1st month of the program. This includes performing aerobic exercise 5 times/week and resistance training twice/week (offered 2 weeks after program start). In month two, this group will begin to perform AIT three days/week, along with two MICE and two RT sessions.~The AIT exercise protocol includes the following components:~Warm Up Period: 5-10 minutes of walking performed at an intensity that will feel fairly light. Heart rate monitors and watches will be used to gauge their effort.~Intervals: Between two to four 4-minute intervals of walking/jogging performed at an intensity that is close to participants' maximal effort, based on the exercise tests that were performed at the beginning of the program. These hard intervals will be separated by 3-minutes of active recovery performed at a very light intensity.~Cool Down Period: 5 minutes of walking performed at a fairly light intensity."
89029059|NCT04761822|Experimental|Placebo +Moderna COVID-19 Vaccine|"Participants will receive placebo as a first dose followed by two doses of their assigned active vaccine at subsequent visits. 0.5 mL of placebo will be administered intramuscularly in the deltoid.~The placebo dose will be followed by two doses of Moderna COVID-19 Vaccine, with the first dose administered 1 month later. The Moderna COVID-19 Vaccine (0.5 mL) will be administered intramuscularly in the deltoid, as a series of two doses (0.5 mL each) administered 1 month (28 days) apart."
89573558|NCT04425733|Experimental|Panel A MK-5475 180 µg|Participants receive 180 µg of MK-5475 once daily (QD) via inhalation from Days 1-7.
89573559|NCT04425733|Placebo Comparator|Panel A Placebo|Participants receive MK-5475-matching placebo QD via inhalation from Days 1-7.
88811139|NCT04199117|Experimental|Incentive,Untailored,Care Manage,Standard Treatment|Participants randomly assigned to this condition will have access to incentives for completing a first smoking cessation counseling call up to 4 times over 2 years, will receive 5 untailored letters promoting use of smoking cessation treatment over 2 years, will receive 5 Tobacco Care Management support and motivational encouragement calls over 2 years, and will have access to standard smoking cessation treatment (referral to the state tobacco quitline and/or their primary care provider) over 2 years.
89573560|NCT04425733|Experimental|Panel B MK-5475 360 µg|Participants receive 360 µg of MK-5475 QD via inhalation from Days 1-7.
89573561|NCT04425733|Placebo Comparator|Panel B Placebo|Participants receive MK-5475-matching placebo QD via inhalation from Days 1-7.
89573562|NCT04425733|Experimental|Panel C MK-5475 ≤360 µg|Participants receive ≤360 µg of MK-5475 QD via inhalation from Days 1-7.
89573563|NCT04425733|Placebo Comparator|Panel C Placebo|Participants receive MK-5475-matching placebo QD via inhalation from Days 1-7.
89573564|NCT05543473|Experimental|patients|patients with brain radiological findings that affect balance functions
89573565|NCT05696041|Experimental|The exercise group (WSE)|"Initial static strength training program for the wrist, which could progress to a higher weight in kilos alternatively to a dynamic strength training program~Information about HSD/hEDS~Daily exercise~Training schedule~3-4 return visits to the OT"
89573566|NCT05696041|No Intervention|Conventional intervention (HO)|"Prescribed the wrist´s with plastic or metal orthoses~Information about HSD/hEDS~Use the orthosis in specific activities; carrying, vacuuming, doing laundry, driving, bicycling~Training schedule~3-4 return visits to the OT"
89573567|NCT05498701|Experimental|Test tablet (fasted) followed by Reference capsule (fasted) followed by Test tablet (fed)|On Day 1 of each period, participants will receive a single dose of one of the tafamidis formulations under fasted or fed conditions. Each period is separated by a washout of at least 16 days between administration of study drug.
89573568|NCT05498701|Experimental|Reference capsule (fasted) followed by Test tablet (fasted) followed by Test tablet (fed)|On Day 1 of each period, participants will receive a single dose of one of the tafamidis formulations under fasted or fed conditions. Each period is separated by a washout of at least 16 days between administration of study drug.
88811140|NCT04199117|Experimental|Incentive,Untailored,No Care Manage,Intensive Treatment|Participants randomly assigned to this condition will have access to incentives for completing a first smoking cessation counseling call up to 4 times over 2 years, will receive 5 untailored letters promoting use of smoking cessation treatment over 2 years, will not receive Tobacco Care Management support and motivational encouragement calls, and will have access to 3 smoking cessation quit counseling calls and 12-weeks of either combination nicotine replacement or varenicline up to 4 times over 2 years.
89573569|NCT05695807|Experimental|Carboxytherapy|Device
89573570|NCT05695807|Active Comparator|Fractional CO2 laser|Device
89573571|NCT05695807|Active Comparator|Platelet rich plasma|platelet rich plasma
89573572|NCT02580877|Experimental|67.5 mg oral insulin crystals daily|67.5 mg oral insulin crystals in capsules (by mouth or sprinkled on food) given daily for six months
89573573|NCT02580877|Experimental|500mg oral insulin crystals every other week|500 mg oral insulin crystals in capsules (by mouth or sprinkled on food) given every other week for six months
89573574|NCT05688163|Active Comparator|traditional cognitive stimulation|The control group will carry out the programme based on traditional cognitive stimulation. Individual cognitive skills such as attention, memory, executive functions, orientation, praxis, calculation, visual perception and reasoning will be trained. The materials and media used will be a cognitive stimulation notebook created for the study which includes cards in printed paper format to be completed by the participants.
89573575|NCT05688163|Experimental|programme based on everyday cognition|The experimental group, on the other hand, will carry out a programme based on everyday cognition, i.e. the use of cognitive functions to solve real everyday problems that occur in our daily lives and that allow us to be autonomous in our homes, such as preparing food, taking care of the house, using transport, shopping, using the telephone, medication, financial management and access to information and current affairs. As material for use as for the traditional cognitive stimulation sessions, a training booklet on everyday cognition has been created which includes all the sessions mentioned above.
89573576|NCT04316923||Children with cardiomyopathies|Children aged 0-18 years that have been diagnosed with DCM, HCM or LVNC on the basis of a two-dimensional echocardiography with color Doppler.
89573577|NCT04316923||Healthy children|The control group will be composed of healthy children, in whom heart disease will be excluded using echocardiography.
89573578|NCT05697523||Patient group|people with mild RRMS
89573579|NCT05697523||Healthy group|healthy people
89573580|NCT04425499|Placebo Comparator|Control group|On GEN (Gamified Educational Network), each student will view individually eight videos of an expert performing a running subcuticular suture correctly. The OSATS (Objective Structured Assessment of Technical Skills) Global Rating Scale (GRS) and Subcuticular Suture Checklist will be available beside each video and students will be required to fill them out for each video. For three days, students will have access to a distinct set of videos on GEN to learn running subcuticular sutures. Three days later, students will view the same eight videos of an expert performing a running subcuticular suture, however, the videos will be shuffled in a different order. The order of the videos will be the same for all students.
89573581|NCT04425499|Experimental|Self-learning|Each student will view eight videos individually and complete the GRS and Subcuticular Suture Checklist for each video. Six videos will contain errors and two videos will not. The errors will be technical mistakes in the execution of a running subcuticular suture. For three days, students will have access to a distinct set of videos on GEN to learn running subcuticular sutures. Three days later, all students will repeat this activity. However, the same videos will be shuffled in a different order. The order of the videos will be the same for all students.
89573582|NCT04425499|Experimental|Peer-learning|Each student will view eight videos and complete the GRS and Subcuticular Suture Checklist for each video. Six videos will contain errors and two videos will not. After this initial test, students will interact with other medical students in their group on the GEN platform anonymously for three days. We will display distinct videos on GEN. Comments will be allowed in an interactive way to encourage exchanges. Students will be required to participate in the discussion of at least two videos. Students will not be able to modify their answers on the initial test. On the third day, students in this group will perform a post-test individually with the same eight initial videos but shuffled. The order of the videos will be the same for all students.
89573583|NCT04425499|Experimental|Peer-learning with expert feedback|"Same as group 3, the only difference is that an expert will actively participate in the discussion by commenting on each video on GEN, enhancing students' educational experience. Although anonymous, students will be able to identify the expert as the name expert will be used. The expert will answer any question and comment on the discussion in order to guide the students."
89573584|NCT01905631|No Intervention|Untreated Control Group|Subjects will apply nothing for the entire three days of the trial. Subjects will also fill out a study diary assessing adverse events or other events they experience during the trial.
89573585|NCT01905631|Active Comparator|Treatment Group (Aurstat)|Subjects will apply Aurstat Anti-Itch Hydrogel 2 times daily or as needed for up to three days to reduce itching. Subjects will also fill out a study diary assessing adverse events or other events they experience during the trial.
89573586|NCT05679115|Experimental|Lifestyle intervention|Participants get access to the tool and use it regularly
89573587|NCT05679115|No Intervention|Controls on standard care|Participants who get randomized to control cannot access the tool.
88970877|NCT02966158|No Intervention|MICE Group|"This group will perform usual care CR for 6 months, which includes both resistance and aerobic exercise (MICE) training. Aerobic exercise is prescribed in the first exercise class and performed 5 times/week, the resistance training program is offered after 2 weeks in the program and performed 2 times/week. Participants will be asked to keep a record of the exercise that they do.~Resistance/Strength Training: Patients will be performing 1-2 sets of 5 to 10 resistance training exercises using a combination of hand-held dumbbells, elastic bands of varying thicknesses, as well as their own body weight for resistance.~Aerobic Training: Patients will have their aerobic exercise prescription set at an intensity and duration that will be comfortable for them, based on the tests conducted at the beginning of the program to ensure their safety."
88970878|NCT02966470||General surgery patient|General surgery patient admitted to the Section of General Surgery, Trauma, and Surgical Critical Care who are over 60.
88970879|NCT04733586|Active Comparator|fascia iliaca group|
88970880|NCT04733586|Active Comparator|quadratus lumborum|
88970881|NCT00072631|Experimental|1 erlotinib|
88970882|NCT00072670|Experimental|Trabectedin 0.58 milligram per square meter (mg/m^2)|Trabectedin will be administered as 3-hour intravenous infusion at dose of 0.58 mg/m^2 weekly on Day 1, 8 and 15 in 28-day cycle and will be continued until disease progression or unacceptable toxicity.
88970883|NCT00072670|Experimental|Trabectedin 1.5 mg/m^2|Trabectedin will be administered at dose of 1.5 mg/m^2 as 24-hour infusion every three weeks, and will be continued until disease progression or unacceptable toxicity.
89573588|NCT05591443||Heart failure patients|Patients with CHF will be considered for inclusion in the study based on their verified medical record, indicating that they are diagnosed with CHF and are using guideline-directed medical therapy (GDMT). Diagnostic criteria, as laid out in the latest 2021 European Society of Cardiology (ESC) guidelines for the diagnosis and management of chronic and acute heart failure, will be followed.
89573589|NCT05535205|Active Comparator|Face-to-face preoperative assessment group|The face-to-face screening consist of two 20-minute consecutive consultations with a nurse and subsequently an anesthesiologist or PA. The nurse obtains basic patient health information, provides information on the upcoming hospital admission, and gives advice in lifestyle procedures around the surgery. The physician assesses the patient's health status based on co-morbidities, medication use, previous surgery, and lifestyle habits to predict preoperative risks and determine the optimal anesthetic technique. Additional diagnostics, such as blood tests or electrocardiogram, can be ordered and optional anesthetic techniques will subsequently be presented and discussed with the patient, after which informed consent will be obtained.
89573590|NCT05535205|Active Comparator|Digital preoperative assessment group|Patients in the digital preoperative assessment group are asked to complete an electronic screening questionnaire through the digital patient portal of the hospital. The questionnaire was designed by the anesthetic department physicians and consisted of 50 health related questions. Through the same digital patient portal, patients have access to animated instructional videos that provides information on anesthetic techniques, preoperative lifestyle advises and procedures around the upcoming surgery. The videos can be reviewed at any desired moment in time. A telephone appointment is scheduled solemnly to decide on the anesthesia technique and obtain informed consent since this process was technically not available in the electronic portal. Physicians were thoroughly instructed not to provide more information or answer questions. Patients are instructed to complete the electronic screening questionnaire and assess the animated videos before the scheduled appointment with the physician.
89573591|NCT05679037|Placebo Comparator|Placebo group who received insulin only plus placebo tablets|(Placebo group; n=22) which will receive insulin plus placebo tablets once daily for 6 months.
89573592|NCT05679037|Active Comparator|ALA group who received Alpha lipoic acid plus insulin|(alpha-lipoic acid group; n=22) which will receive insulin plus ALA 600mg once daily for 6 months.
89573593|NCT05587465|Experimental|Treatment|Lobster device implantation
89573594|NCT05678881|Experimental|High dose RLS103|8 mg CBD inhaled dry powder
89573595|NCT05678881|Placebo Comparator|Placebo|placebo inhaled dry powder
89573596|NCT05678881|Experimental|Low dose RLS103|4 mg CBD inhaled dry powder (open label)
89573597|NCT05678725|Active Comparator|Transcranial Alternating Current Stimulation|the alternating current stimulation lasted 20 mins and was delivered at 2mA (peak to peak) at 20Hz during the Simple Reaction Task(SRT), targeting the primary motor cortex. EEG should be acquired before and after the stimulation session.
89573598|NCT05678725|Active Comparator|Transcranial Direct Current Stimulation|the direct current stimulation lasted 20 minutes and was delivered at 2mA during the SRT, targeting at the primary motor cortex. EEG should be acquired before and after the stimulation session.
89573599|NCT05678725|Sham Comparator|Sham Group with No Actual Stimulation|the procedure of this protocol lasted 20 minutes and was delivered at 0mA during the SRT. EEG should be acquired before and after the stimulation session.
89573600|NCT05678569||High Risk Group|Group identified by machine learning model as being at high risk of developing osteoporosis.
89573601|NCT02582983|Experimental|Enfuvirtide|Participants received Enfuvirtide 90 mg subcutaneously (SC) twice daily (BID).
89573602|NCT02582749|Active Comparator|Control Arm A|All subjects will receive LHRH agonist/antagonist per dosage and route of administration specified by the treating physician. Bicalutamide, 50mg, PO will be administered daily. Cycles will be 28 days.
89573603|NCT02582749|Experimental|Experimental Arm B|All subjects will receive LHRH agonist/antagonist per dosage and route of administration specified by the treating physician. Bicalutamide, 50mg, PO will be administered daily. Cycles will be 28 days. Radium-223 dichloride, 50 kBq/kg body weight, will be administered as a bolus intravenous (IV) injection at intervals of every 28 days for up to 6 cycles.
89573604|NCT05461261|Experimental|Docetaxel plus platinum|Docetaxel combined with platinum-based drugs will be applied every 3 weeks for 6 cycles.
89573605|NCT05461261|Active Comparator|Docetaxel alone|Docetaxel alone will be applied every 3 weeks for 6 cycles.
89573606|NCT05383729|Experimental|new training|"In this new learning-curve-based training modality, after participants complete 16 procedures on a high-fidelity simulator, an individual learning curve will be generated using the previously validated equation:~ln⁡(γ)=γ_0 e^(-kn)+γ_∞ where γ is procedure time, n is previous experiences.[2] Other parameters and their 95% Confidence Interval (CI) can be obtained after curve fitting. And e^(γ_∞ ) is the asymptote of this curve. Then the trainees will continue the training. If the following procedure time falls into the 95% CI of the asymptote for three consecutive times,[6] the individual training goal is considered achieved.[2]"
89573607|NCT05383729|Active Comparator|reference training|In this reference fixed-training-time training modality, participants will receive training with a high-fidelity simulator for 1h.
89573608|NCT05339815||36 mm CoCrMo glenospheres|
89573609|NCT05339815||40 mm cross-linked UHMWPE glenospheres|
89573610|NCT05204875||Functional lung imaging|Assess the applicability of XV ventilation distribution and heterogeneity for BLVR candidate screening compared to conventional tools of quantitative HRCT and ventilation perfusion scanning.
89573611|NCT05678413|Active Comparator|DVIU with paclitaxel|Cystourethroscopy will be performed using a 22 Fr rigid cystoscope to allow for ureteric catheter 3F/a wire to be passed through the stricture and into the urinary bladder. DVIU will be performed by cold-knife incisions at the 12-, 3-, and 9 o'clock positions through the full thickness of the fibrosis to healthier appearing tissue. A 23 Fr Wolf (Vernon Hills, IL) injection scope and a standard injection needle was used to inject 30 mg/5mL of paclitaxel vial, 1.5 mL will be injected along the length of each incision into healthier appearing tissue for a total of 5 mL.
89573612|NCT05678413|Active Comparator|DVIU|Cystourethroscopy will be performed using a 22 Fr rigid cystoscope to allow for ureteric catheter 3F/a wire to be passed through the stricture and into the urinary bladder. DVIU will be performed by cold-knife incisions at the 12-, 3-, and 9 o'clock positions through the full thickness of the fibrosis to healthier appearing tissue.
89573613|NCT05678335|Placebo Comparator|Hydroxychloroquine monotherapy|Oral hydroxychloroquine 200mg twice daily for 12 weeks.
89573614|NCT05678335|Experimental|Tacrolimus monotherapy|Oral tacrolimus 1-2mg twice daily for 12 weeks.
89573615|NCT02582671||Participants with HCV genotype 1|Ombitasvir/paritaprevir/ritonavir (two 12.5 mg/75 mg/50 mg co-formulated tablets once daily); ± dasabuvir (tablet; 250 mg twice daily); ± weight-based ribavirin (tablet; 1000 or 1200 mg divided twice a day) up to 24 weeks
89573616|NCT04714567||Patients with severe asthma|Patients of all ages with severe asthma included in the RAG.
89573617|NCT05696899|Experimental|Aromatherapy|Patients will be given STILL QuickTAB Medipack blended scent aromatherapy in addition to standard supportive measures, which include numbing cream, Child Life support, distraction, caregiver hold, or any combination of these, based on patient preference.
89573618|NCT05696899|No Intervention|Control Group|Participants will be offered standard supportive measures, which include numbing cream, Child Life support, distraction, caregiver hold, or any combination of these, based on patient preference.
89573619|NCT05154721|Experimental|EXPE Group|The experimental group (EXPE Group) will receive the Mila-Learn game.
89573620|NCT05154721|Placebo Comparator|CONT Group|The control group (CONT Group) will receive the Mila-Placebo game.
89573621|NCT02585713|Experimental|Arm I (apixaban)|Patients receive apixaban 10 mg PO BID on days 1-7 and lower-dose apixaban 5 mg PO BID on days 8-180.
89573622|NCT02585713|Experimental|Arm II (dalteparin)|Patients receive dalteparin 200 IU/kg/day SC QD on days 1-30 and lower-dose dalteparin 150 IU/kg/day SC QD on days 31-180.
89573623|NCT05032495||Heart patients who experienced a cardiac arrhythmia while in hospital|Heart patients who experienced a cardiac arrhythmia while in hospital
89573624|NCT05032495||Heart patients who did not experience a cardiac arrhythmia while in hospital|Heart patients who did not experience a cardiac arrhythmia while in hospital
89573625|NCT05032495||Heart patients with an upcoming procedure that have not had a cardiac arrhythmia|Heart patients with an upcoming procedure that have not had a cardiac arrhythmia
89573626|NCT05032495||Members of the general public|Members of the general public
89573627|NCT05078671|Active Comparator|Standard olaparib|Olaparib 300mg twice daily
89573628|NCT05078671|Experimental|Boosted olaparib|Olaparib 100mg twice daily + cobicistat 150mg twice daily
89573629|NCT02579863|Experimental|Pembrolizumab + Lenalidomide + Dexamethasone|Participants received pembrolizumab 200 mg intravenously (IV) on Day 1 of each 21-day cycle PLUS lenalidomide 25 mg orally (PO) on Days 1 to 21 of each 21-day treatment cycle, and dexamethasone 40 mg PO on Days 1, 8, 15 and 22 of each 28-day cycle for up to 18 cycles.
89573630|NCT02579863|Active Comparator|Lenalidomide + Dexamethasone|Participants received lenalidomide 25 mg PO on Days 1 to 21 of each 21-day treatment cycle, and dexamethasone 40 mg PO on Days 1, 8, 15 and 22 of each 28-day cycle for up to 18 cycles.
88970884|NCT00072670|Experimental|Trabectedin 1.2 mg/m^2|Trabectedin will be administered at dose of 1.2 mg/m^2 as 24-hour infusion every three weeks, and will be continued until disease progression or unacceptable toxicity.
88970885|NCT02966704|Experimental|meal 1|mixed meal with high level of intrinsically labeled milk protein
88970886|NCT02966704|Experimental|meal 2|mixed meal with low level of intrinsically labeled milk protein
88970887|NCT04839848||Permanent suture|Mesh fixation with permanent suture
88970888|NCT04839848||Long-term absorbable|Mesh fixation with long-term absorbable suture
88970889|NCT04839848||Short-term absorbable|Mesh fixation with short-term absorbable suture
88970890|NCT04839848||Fibrin glue|Biologic glue/sealant produced from human donor blood
88970891|NCT04839848||Progrip|Pre-fabricated absorbable fixation hooks, integrated in mesh. Progrip is a registered trademark owned by Medtronic
89573631|NCT05677945|Experimental|(Group I Experimental Group):Simvastatin mixed with modified triple antibiotic (3Mixtatin)|"Patients will then be allocated into either one of the groups alternatively after access cavity preparation depending on the mix to be used as follows:~for this group:~2mg of pure Simvastatin powder will be added to the 1:1:1 3Mix powder and will be stored together in an air tight porcelain container to avoid the exposure to moisture and light.~Upon clinical application the 3Mixtatin powder will be mixed with normal saline to form a paste and is then applied in the same manner as the Modified 3Mix-MP paste."
89573632|NCT05677945|Active Comparator|Group II Control group Modified triple antibiotic mix in propylene glycol (3Mix)|"Removal of enteric coating/capsule of the three antibiotic tablets using a surgical blade.~500 mg Metronidazole tab~500 mg Ciprofloxacin tab~200 mg Cefixime caps~Pulverization of each of the drug, will be done using a pestle & mortar, stored in an air tight porcelain container to avoid the exposure to moisture & light.~Pulverized powders will be stored at a temperature of 16°C.Powder should be allowed to be cooled to the room temperature before initiating the preparation of 3Mix-MP paste.~Powders will be mixed in the proportion of: 1:1:1 by volume (Hoshino et al., 1988).~Vehicle that will be used is Systane eye drops (Kharadly et al., 2022) it contains the two main components propylene Glycol (Macrogol) & polyethylene glycol.~The prepared antibiotic powder is mixed with the prepared vehicle in the ratio of 7:1 by volume. The two steps above are done after access cavity preparation to obtain a fresh mix."
89573633|NCT05650177|Experimental|Receiving intervention.|Patients with persistent depression who are receiving the intervention.
89573634|NCT05677789||Participants The patient's CORMB score is 0 to 2|Participants The patient's CORMB score is 0 to 2
88970892|NCT03959280|Experimental|Tailored intervention|"In this group, participants will receive a comprehensive lifestyle program in addition to CPAP therapy which will include a supervised exercise program, diet interventions and behavioural counselling during 12 weeks.~Then, participants will follow a real-world maintenance program from weeks 12 to 24. It will include one telephone-based contact per month with the study coordinator. Participants will be encouraged to maintain their lifestyle modification during this phase."
88970893|NCT03959280|Active Comparator|Control|Participant in this group will benefit from routine CPAP therapy management from week 0 to 24.
88970894|NCT00072904|Placebo Comparator|III|Placebo take half tab with meals tid
88970895|NCT02966197|Experimental|Balloon group|Prophylactic Internal Iliac Artery Balloon Catheterization
88970896|NCT02966197|No Intervention|Control group|no intervention
88970897|NCT00072982|Active Comparator|1|Fish Oil
88970898|NCT00072982|Active Comparator|2|Borage Oil
88970899|NCT00072982|Active Comparator|3|Fish Oil and Borage Oil
88970900|NCT03959124|Experimental|AD with DBS|Alzheimer's disease subjects with optimal medication therapy and with DBS treatment
89573635|NCT05677789||Participants The patient's CORMB score is 3 to 4|Participants The patient's CORMB score is 3 to 4
89573636|NCT05677789||Participants The patient's CORMB score is 5 or above|Participants The patient's CORMB score is 5 or above
89573637|NCT02582515|Experimental|D-cycloserine + Habit Reversal Training|Participants randomly assigned to the D-cycloserine (DCS) condition will receive a single dose of DCS immediately prior to a single session of habit reversal training.
89573638|NCT02582515|Placebo Comparator|Placebo + Habit Reversal Training|Participants randomly assigned to the placebo condition will receive a single dose of placebo immediately prior to a single session of habit reversal training.
89573639|NCT02579629|Active Comparator|Ropivacaine 0.1%|Subjects undergoing their first,second or third cesarean sections will receive a bolus dose of 8ml of 0.1% ropivacaine followed by an infusion of 8ml/hr of 0.1% ropivacaine using the On-Q® elastomeric pump for 3 days after the cesarean section.
89573640|NCT02579629|Experimental|Ropivacaine 0.2%|Subjects undergoing their first,second or third cesarean sections will receive a bolus dose of 8ml of 0.2% ropivacaine followed by an infusion of 8ml/hr of 0.2% ropivacaine using the On-Q® elastomeric pump for 3 days after the cesarean section.
89573641|NCT02579629|Active Comparator|Normal Saline|Subjects undergoing their first, second or third cesarean sections will receive a bolus dose of 8ml normal saline followed by an infusion of 8ml/hr of normal saline using the On-Q® elastomeric pump for 3 days after the cesarean section.
89573642|NCT05677555|Experimental|colchicine group|Treatment with colchicine 0.5 mg
89573643|NCT05677555|Placebo Comparator|placebo group|Treatment with matched placebo
89209093|NCT00725621||Remicade|Patients with severe RA (indication according to Austrian labeling) will receive Remicade induction therapy consisting of three Remicade infusions in weeks 0, 2, and 6 given in specialized centers. Maintenance therapy will consist of another maximal 6 infusions. Remicade induction and maintenance therapy doses and intervals will be at the discretion of the physicians.
89573644|NCT04874857|Experimental|Intervention group (Aromatherapy group)|With a mixture of Lavandula angustifolia, Rosmarinus officinalis L. and Origanum majorana L. essential oils, the foot and lower leg will be massaged for three sessions a week for 30 minutes in each session for four weeks.
89573645|NCT04874857|Experimental|Placebo group|The foot and lower leg will be massaged with baby oil for four weeks, three sessions a week, 30 minutes in each session.
89573646|NCT04874857|No Intervention|Control group|No application will be made in addition to standard HD treatment.
89573647|NCT05677477|Experimental|Intervention/Treatment|In the implementation process of the research, knowledge tests will be applied as pre-test and post-test, and training will be given to the mother who has a baby with physiological jaundice. In the study, the scenario of the mother with a baby with jaundice will be implemented only with the intervention group
89573648|NCT05677477|No Intervention|Control|During the application process of the research, knowledge tests will be applied as pre-test and post-test.
89573649|NCT05677399|Experimental|Treatment Group|Treatment group received 30 minutes of aquatic exercise by a physiotherapist in a warmed up to 33° C tap water and 30 minutes of mud pack treatment at 42°C on both knees 5 weekdays for 2 consecutive weeks (totally 10 sessions).
89573650|NCT05677399|No Intervention|Control Group|Control group continued to use their usual medical treatment.
89573651|NCT02343939|Experimental|Entospletinib + daunorubicin + cytarabine (Group A)|"Dose Escalation: Entospletinib up to 400 mg for 14 days and then entospletinib up to 400 mg in combination with daunorubicin and cytarabine for up to two 14-day cycles.~Dose Expansion: Entospletinib 400 mg for 14 days and then entospletinib 400 mg in combination with daunorubicin and cytarabine for up to two 14-day cycles. Some participants will have the option to receive post-induction therapy with entospletinib 400 mg in combination with cytarabine/cytosine arabinoside (ARA-C). Participants may receive maintenance therapy with 28-day cycles of entospletinib 400 mg for up to twelve 28-day cycles, if the participant is not eligible for stem cell transplant."
89573652|NCT02343939|Experimental|Entospletinib + decitabine (Group B)|"Dose Escalation: Entospletinib 400 mg for 14 days and then entospletinib 400 mg in combination with decitabine for 10 days beginning on Day 1 of every 28-day cycle (at least 2 cycles of induction therapy but no more than 4 cycles). Participants who are intolerant of decitabine may switch to entospletinib monotherapy maintenance at any time after completing the first 2 cycles.~Dose Expansion: Entospletinib 400 mg for 14 days for the safety run-in participants or Entospletinib 400 mg for 5 days for the randomization participants. Then entospletinib 400 mg in combination with decitabine or azacitidine (at least 2 cycles of induction therapy but no more than 4 cycles). Some participants will have the option to receive maintenance therapy with entospletinib in combination with decitabine or azacitidine. Participants who are intolerant of decitabine or azacitidine may switch to entospletinib monotherapy maintenance at any time after completing the first 2 cycles."
89209094|NCT00613626|Placebo Comparator|Arm A: ZD6474 Matched Placebo|Subjects will receive cisplatin 60 mg/m2 IV day 1 plus etoposide 120 mg/m2 IV days 1, 2, and 3 every 21 days for a total of 4 cycles plus ZD6474 matched placebo oral daily to be continued for the duration of the study. Prophylactic antiemetics will be given at the discretion of the treating investigator.
89209095|NCT00613626|Active Comparator|Arm B: ZD6474|Subjects will receive cisplatin 60 mg/m2 IV day 1 plus etoposide 120 mg/m2 IV days 1, 2, and 3 every 21 days for a total of 4 cycles plus ZD6474 100mg oral daily to be continued for the duration of the study. Prophylactic antiemetics will be given at the discretion of the treating investigator.
89573653|NCT02343939|Experimental|Entospletinib (Group C)|"Dose Escalation: Entospletinib up to 800 mg for 28-day cycles until the participant meets criteria for study treatment discontinuation per the study protocol.~Dose Expansion: Entospletinib 400 mg for 28-day cycles until the participant meets criteria for study treatment discontinuation per the protocol."
89573654|NCT02397447|Experimental|Momordica charantia|Two 500 mg capsules of Momordica Charantia twice daily before breakfast and dinner for 90 days
89573655|NCT02397447|Placebo Comparator|Placebo|Two 500 mg capsules of calcined magnesia twice daily before breakfast and dinner for 90 days
89573656|NCT02397057|Active Comparator|Injectafer|Two doses of Injectafer 750 mg undiluted dose at 100 mg/minute given 5 days apart for a total of 1500 mgs.
89573657|NCT02397057|Placebo Comparator|Normal Saline|IV Placebo (15ml of Normal Saline) IV push at 2ml/minute
89573658|NCT02343549|Experimental|Planned RT + TMZ + BEV + NovoTTF100A Device|Best standard of care radiation therapy (RT, 2 Gy given daily 5 days per week), temozolomide (TMZ, 75 mg/m2 administered daily), and bevacizumab (BEV, 10 mg/kg administered every 2 weeks as an IV infusion) for 6 weeks. After completion of chemoradiation, NovoTTF100A system was initiated, to be worn on average 18 hours or more a day for up to 12 months. The patients also continued with maintenance TMZ/BEV.
89573659|NCT02343159|Experimental|Arm 1: Standard MEMS Cap|A standard MEMS cap that records the time and date when the bottle is opened without a visual LCD reader. Standard-of-care commercial supply of DMF (BID oral capsule) will be used in this study.
89573660|NCT02343159|Experimental|Arm 2: Smart MEMS Cap|A smart MEMS cap with feedback (an LCD reader that allows the participant to monitor DMF bottle openings). Standard-of-care commercial supply of DMF (BID oral capsule) will be used in this study.
89573661|NCT02343159|Experimental|Arm 3: Smart MEMS Cap + Counseling|A smart MEMS cap with feedback (an LCD reader that allows the participant to monitor DMF bottle openings) and an adherence counseling intervention. Standard-of-care commercial supply of DMF (BID oral capsule) will be used in this study.
89573662|NCT02395653|Experimental|SSEC Fentanyl|SSEC fentanyl iontophoretic transdermal system, 40 mcg fentanyl per activation.
89573663|NCT01664923|Experimental|Enzalutamide|Enzalutamide 160 mg/day orally
89573664|NCT01664923|Active Comparator|Bicalutamide|50 mg/day orally
89573665|NCT04743583||Endosonography group|Patients with known or suspected lung cancer or intrathoracic malignancy with indication to endosonography for diagnosis or staging of intrathoracic lymph nodes according to currently accepted international guidelines
89573666|NCT05696665|Active Comparator|Group A|conventional therapy only
89573667|NCT05696665|Experimental|Group B|conventional therapy +500 mg chamomile 15 mg saffron twice daily
89573668|NCT05696665|Experimental|Group C|conventional therapy +500mgApigenin +30mg Crocin once daily
89573669|NCT04465201|Experimental|Subjects receiving the Impella/Impella® Hemodynamics platform|
89573670|NCT04403347|Experimental|Innovative Dietary Formulation|In addition to regular diets and usual care of hypertension, additional innovative dietary formulation will be orally taken 3 times per day.
89573671|NCT04403347|Active Comparator|Antihypertensive Medication|In addition to regular diets and usual care of hypertension, antihypertensive medication will be orally taken (Losartan 50mg per day).
89573672|NCT04403347|No Intervention|Usual Care|Usual Care (Guideline-based patient education and lifestyle recommendations)
89573673|NCT05677009|Other|BUFEO vs Standard Condition|In the BUFEO vs Standard Condition arm, the patient will receive both treatments. The order in which the subject receives the treatment will be randomized.
89573674|NCT05675761||Combined bacterial and fungal infection|Combined bacterial and fungal infection
89573675|NCT05675761||No bacterial and fungal infection|No bacterial and fungal infection
89573676|NCT01664533||Erlotinib|Selection of the dose of erlotinib most suitable for each participant was left to the discretion of the physician, guided by the recommendation in the Summary of Product Characteristics. The recommended daily oral dose of erlotinib is 150 mg.
89573677|NCT05673655|Active Comparator|transcutaneous injection|
89573678|NCT05673655|Active Comparator|intraoral injection|
89573679|NCT05692297|Experimental|Denosumab group|Fifty-one patients were randomly assigned to the denosumab group, which received subcutaneous injection of denosumab 60mg once every 6 months. Serum calcium, phosphorus, alkaline phosphatase, iPTH, tPINP, 25(OH)VitD, DXA and qCT were measured before medication. Serum calcium, phosphorus and iPTH were examined at day 1, 7 and 14, alkaline phosphatase, tPINP and 25(OH)VitD at day 7 and 14, and electrocardiogram at day 1 and 7 after treatment. Intravenous calcium supplementation was required if muscle spasms and QT prolongation occurred. Six months after medication, subcutaneous injections of denosumab 60mg were repeated. The protocol was repeated every 6 months, totally 24 months. Bone mineral density, clinical parameters and adverse events were evaluated at 24 months.
89573680|NCT05692297|Active Comparator|Non-denosumab group|The other 51 patients did not use denosumab and used other medications, such as diphosphonates, active vitamin D and/or active vitamin D analogue, calcimimetics, calcitonin, estrogen receptor agonists, etc. At the same time, calcium and vitamin D were supplemented. The baseline serum calcium, phosphorus, alkaline phosphatase, iPTH, tPINP, 25(OH)VitD, DXA, and qCT were measured. The above parameters were rechecked every 6 months, and the medications was recorded, totally 24 months.
88970901|NCT03959124|Active Comparator|AD without DBS|Alzheimer's disease subjects with optimal medication therapy and without DBS treatment
88970902|NCT03959124|No Intervention|Normal control|Matched aged and demographics subjects
89573681|NCT05696587|Experimental|CRPS|Participants meeting inclusion and exclusion criteria undergoing 4-week multimodal rehabilitation, undergoing assessment at baseline and at 4 weeks.
89573682|NCT05696587|No Intervention|Healthy Control|Participants matched according to sex, age and education to experimental arm, undergoing psychological assessment at baseline and at 4 weeks.
89573683|NCT05696509|Other|Propofol|Anesthetic
89573684|NCT05696509|Other|Isofluran|Anesthetic
89573685|NCT05696509|Other|Sevofluran|Anesthetic
88970903|NCT02966236|Experimental|Tranexamic Acid Group|Tranexamic acid 1g IV during anesthesiology induction, single dose
88970904|NCT02966236|Placebo Comparator|Placebo group|normal saline 1g IV during anesthesiology induction, single dose
89573686|NCT02584855|Experimental|Ixekizumab Open Label|Open-Label Treatment Period: Starting dose of 160 milligrams (mg) ixekizumab given as two subcutaneous (SC) injections at baseline (week 0) followed by 80 mg given as one SC injection every two weeks (Q2W) from week 2 to randomization (week 36 to 64).
89573687|NCT02584855|Experimental|Ixekizumab|"Participants completed open label and met criteria for randomization to the double-blind Withdrawal Period.~Double-Blind Withdrawal Period: 80 mg ixekizumab given as one SC injection Q2W from randomization to week 104 (or, early termination or relapse)."
89573688|NCT02584855|Placebo Comparator|Placebo|"Participants completed open label and met criteria for randomization to the double-blind Withdrawal Period.~Double-Blind Withdrawal Period: Placebo given as one SC injection Q2W any time from randomization to week 104 (or, early termination or relapse)"
89573689|NCT02584855|Experimental|IXE80Q2W Non-randomized|"Participants completed open label but did not meet criteria for randomization to the double-blind Withdrawal Period.~Participants continued to receive 80 mg given as one SC injection every two weeks during the double-blind withdrawal period."
89573690|NCT05654935||Cohort A|Includes 26 healthy volunteers >18 years of age without history of stroke or transient ischemic attack, coronary artery disease (prior myocardial infarction, typical angina, prior percutaneous coronary revascularization, and prior coronary bypass graft surgery), and peripheral arterial disease (claudication, peripheral arterial revascularization stenting of bypass surgery). Subjects will be recruited using advertisement flyers and emails.
89573691|NCT05654935||Cohort B|Includes 100 subjects ≥ 60 years of age without known carotid artery disease. These subjects will be recruited from patients scheduled to receive a clinically indicated cardiac stress test or echocardiogram in the noninvasive cardiac testing area at Rush University Medical Center (Chicago, IL).
89573692|NCT04523857|Experimental|A (Abema)|Abemaciclib (150 mg BID)
89573693|NCT04523857|Experimental|B (Abema + HCQ)|"Abemaciclib (100 mg or 150 mg BID*) + Hydroxychloroquine (600 mg BID)~*Abemaciclib dose will be determined by safety cohort"
89573694|NCT02581345|Experimental|M923|Participants assigned to receive M923
89573695|NCT02581345|Active Comparator|Humira|Participants assigned to receive Humira
89573696|NCT02581345|Other|M923 and Humira|Participants assigned to receive M923 and Humira
89573697|NCT05579509|Experimental|High Pain Catastrophizing|Based on the Pain Catastrophizing Scale (PCS)
89573698|NCT05579509|Experimental|Low Pain Catastrophizing|Based on the Pain Catastrophizing Scale (PCS)
89573699|NCT04314661|Experimental|Arthroscopy + Booster|After arthroscopy intervention, patient will be given 10 million UC-MSCs and 2 cc Secretome twice with 2 weeks interval via intra-articular injection.
89573700|NCT04314661|Experimental|Arthroscopy + Pre-Conditioning|After arthroscopy intervention, patient will be given 2 cc Secretome, 10 million UC-MSCs, and 2 cc Secretome with 2 weeks interval via intra-articular injection.
89573701|NCT04314661|Experimental|Non Arthroscopy + Booster|Without arthroscopy intervention, patient will be given 10 million UC-MSCs and 2 cc Secretome twice with 2 weeks interval via intra-articular injection.
89573702|NCT04314661|Experimental|Non Arthroscopy + Pre-Conditioning|Without arthroscopy intervention, patient will be given 2 cc Secretome, 10 million UC-MSCs, and 2 cc Secretome with 2 weeks interval via intra-articular injection.
89573703|NCT05696431|Placebo Comparator|Universal adhesive|After preparation of three posterior cavities in each patient. The cavities will be randomly divided into three groups according to the type of the adhesive used. This group will receive a universal adhesive as control group.
89573704|NCT05696431|Active Comparator|Fluoride-releasing universal adhesive|After preparation of three posterior cavities in each patient. The cavities will be randomly divided into three groups according to the type of the adhesive used. This group will receive a Fluoride-releasing universal adhesive.
89573705|NCT05696431|Active Comparator|Universal adhesive with bioactive properties|After preparation of three posterior cavities in each patient. The cavities will be randomly divided into three groups according to the type of the adhesive used.This group will receive a universal adhesive with bioactive properties.
89573706|NCT05696275|Experimental|exercise|combine walking and elastic band exercise
89573707|NCT05696275|No Intervention|usual care|as usual care
89573708|NCT05575453|Active Comparator|Kvatchii Portal|The intervention group will be given access to the Kvatchii portal and home blood pressure monitor
89573709|NCT05575453|No Intervention|Usual Care|The control group will not have access to the portal but will be provided with home blood pressure monitor
89573710|NCT05568745|Experimental|Balloon+oxytocin|Mecanical cervical ripening will be done by transcervical balloon (Teleflex French Dufour catheter CH20 reference 174000). Oxytocin will be started 6 hours after balloon insertion. At H12 balloon will be removed and induction continued by oxytocin alone.
89573711|NCT05568745|Active Comparator|Oral misoprostol|Patients will receive misoprostol 25 micrograms given orally (oral prostaglandin E1). The same dose will be given every 2 hours until beginning of labor with a maximum of 8 administrations. (Oxytocin can be started at least 4 hours after the last misoprostol administration if patient remains not in labour.)
89573712|NCT04302493|Experimental|Mindfulness Based Stress Reduction (MBSR)|Participants randomized to the MBSR arm will undergo a standard 8 week course.
89573713|NCT04302493|Active Comparator|Stroke Support Group (SSG)|As a control group, participants will participate in 8 weeks of weekly Stroke Support Group.
89573714|NCT02581189||Participants with HCV genotype 1 or 4|Ombitasvir/paritaprevir/ritonavir (two 12.5 mg/75 mg/50 mg co-formulated tablets once daily); ± dasabuvir (tablet; 250 mg twice daily); ± weight-based ribavirin (tablet; 1000 or 1200 mg divided twice a day) up to 24 weeks
89573715|NCT05535127|Active Comparator|"Palpation with  laryngeal handshake technique "|"With the non-dominant hand, the larynx is stabilized, the hyoid bone is identified with the thumb and index finger by palpation of the greater horns with a horizontal movement from side to side, move thumb and fingers inferiorly to locate thyroid cartilage,Once identified, its location is maintained with the middle finger and thumb, and the index finger travels towards the midline.~The index finger, already in the midline, makes a longitudinal movement downwards to determine the small depression between the cricoid and thyroid cartilage that corresponds to the cricothyroid membrane."
89573716|NCT05535127|Experimental|Palpation strategy plus sequential ultrasound|Palpation is performed with the previously described laryngeal handshake technique If the participant is unable to identify the location of the cricothyroid membrane with certainty, the mixed ultrasound protocol is continued. as decribed in Identification of the cricothyroid membrane with ultrasound
89573717|NCT05535127|Active Comparator|Identification of the cricothyroid membrane with routine ultrasound|"With the patient on a supine stretcher position, neck extended, with a linear transducer and ultrasound gel, a cross-sectional evaluation of the airway is performed, identifying the cartilaginous referents of the airway. In this case, the midline referent will be the union of the laminae of the thyroid cartilage. The midpoint of the hyperechoic image is located between both referents (MCT).~Next, tracheal rings are identified, the transducer is moved laterally and a 90° turn is performed for axial evaluation of the MCT. The aim is to preserve the same anatomical landmarks already identified in the transverse plane, the cephalocaudal distance between the thyroid cartilage and the cricoid is evaluated, locating the midpoint with the help of the acoustic shadow generated by a yelco without a needle. Based on these 2 measurements, the topographical location of the MCT will be marked with a visible ink marker under UV light, which will serve as a benchmark for comparison."
89573718|NCT05595655|No Intervention|control group|The dyads will receive traditional educational treatment only and will complete the questionnaires after 3, 6, 9 and 12 months follow-up post-intervention. Enrolled dyads will be monitored by the research team responsible for recruitment and follow-up.
89573719|NCT05595655|Other|First interventional arm|MI intervention will be administered to patients only and caregivers will receive standard education. The intervention will last approximately 30 minutes. Thereafter, the nurse who performed the MI will contact the patients over the phone 3 times during the first 2 months after MI, to strengthen the intervention. Then, the intervention will be employed again after 3, 6, 9 and 12 months from enrolment. After each MI session, both patients and caregivers will be asked to complete the questionnaires of follow-up post-intervention
89573720|NCT05595655|Experimental|Second interventional arm|MI intervention will be administered both to patients and caregivers. The intervention will be administered to the dyad in one session and patients and their caregivers will receive the reinforcing educational treatment calibrated on the specific lacking areas of patients' self-care behaviours. After each MI session, both patients and caregivers will be asked to complete the questionnaires of follow-up post-intervention.
89573721|NCT04425265|Experimental|Plasma radiofrequency ablation arm|Plasma radiofrequency ablation at low temperature for localized recurrent nasopharyngeal carcinoma
89573722|NCT04425265|Active Comparator|Electrocautery block resection arm|Electrocautery block resection at high frequency for localized recurrent nasopharyngeal carcinoma
89573723|NCT05594641|Experimental|T (Treatment)|Remote ischaemic preconditioning (RIPC) will be performed before the start of liver resection and the associated Pringle maneuver
89573724|NCT05594641|Other|C (Control)|RIPC will be not performed
89573725|NCT04686253||PFO patients with CS or/and TIA|PFO patients with CS or/and TIA (transcatheter closure of PFO was performed).
89573726|NCT04686253||PFO patients with migraine|PFO patients with migraine (transcatheter closure of PFO was performed).
89573727|NCT04686253||PFO patients without symptom|PFO patients without symptom (5-year follow-up).
89573728|NCT05551039||Physicians treating patients with mCRC|Physicians provide case histories of mCRC patients
89573729|NCT04685941|Other|Drug-mediated hyperemia|Patients presenting with slow flow after PPCI undergo to at least 200 mcg of intracoronary nitroprussiate or 500 mcg of intracoronary adenosine during 2 minutes
89573730|NCT04685941|Experimental|Flow-mediated hyperemia|Patients presenting with slow flow after PPCI undergo to controlled saline intracoronary infusion by a dedicated microcatheter (RayFlow) at 20 ml/min during 2 minutes
89573731|NCT02576977|Experimental|Pembrolizumab+Pomalidomide+Dexamethasone|Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 every 3 weeks (Q3W) PLUS pomalidomide 4 mg orally (PO) on Days 1 to 21 of each 28-day cycle PLUS dexamethasone 40 mg PO on Days 1, 8, 15 and 22 of each 28-day cycle.
89573732|NCT02576977|Active Comparator|Pomalidomide+Dexamethasone|Participants receive pomalidomide 4 mg PO on Days 1 to 21 of each 28-day cycle PLUS dexamethasone 40 mg PO on Days 1, 8, 15 and 22 of each 28-day cycle.
89573733|NCT04421755|Experimental|Produce Only|Receives weekly home delivery of fresh fruits and vegetables
89573734|NCT04421755|Experimental|Produce + Cooking Classes|Receives weekly home delivery of fresh fruits and vegetables plus invitation to participate in a series of three small group culinary medicine cooking classes
89573735|NCT04421755|No Intervention|Control|Control group with no cooking classes or groceries
89573736|NCT05213845|Other|Patients with chronic low back pain|
89573737|NCT05867290|No Intervention|Baseline Phase|Randomly allocated baseline phase (no intervention) of 7, 11 or 15 days.
89209096|NCT00613626|Experimental|Safety Lead-In|Subjects will receive cisplatin 60 mg/m2 IV day 1 plus etoposide 120 mg/m2 IV days 1, 2, and 3 every 21 days for a total of 4 cycles plus ZD6474 100mg oral daily to be continued for the duration of the study. Prophylactic antiemetics will be given at the discretion of the treating investigator. The safety lead-in will be conducted to determine the safety of the combination of ZD6474 and cisplation + etopiside. If this combination is found to be unsafe, no patients will be randomized in the Phase II portion of the trial. If the combination is deemed safe according to the protocol, participants from the safety lead-in cohort will not be included in the efficacy analysis.
89573738|NCT05867290|Experimental|Intervention Phase|5 week mindful-music listening intervention including sleep hygiene
89573739|NCT05867277|Experimental|music|"Support was received from the Turkish Music Research and Promotion Group (TÜMATA) in choosing the music. To increase attention before and during the PIVC catheter placement skill practice in the intervention group, Acemaşiran music was played, which increases the sense of concentration and creativity. To reduce anxiety, Pentatonic melodies were played, which gave self-confidence and determination. The music was played from a computer in the vocational skills laboratory using a loudspeaker. During the entire skill practice, the students continued to listen to the music in a light tone."
89573740|NCT05867277|No Intervention|control|The students in the control group were given standard skills laboratory training without any intervention
89209097|NCT00985803|No Intervention|Group Control|
89209098|NCT00985803|Experimental|Endurance|
89209099|NCT00985803|Experimental|Cardiovascular|
89573741|NCT05867264|Placebo Comparator|EOF 1 group：Early drinking water group|After passing the evaluation by the anesthesiologist team in PACU, the EOF1 group drank 200ml of water.
89573742|NCT05867264|Experimental|EOF 2 group: Early oral carbohydrate group|After passing the evaluation by the anesthesiologist team in PACU, the EOF2 group had a drinking capacity of 200ml of 12.5% carbohydrates (100ml containing 12.5g of maltodextrin, fructose, and glucose).
89573743|NCT05867264|Placebo Comparator|Control group: Late feeding group|After observing the vital signs for 30 minutes after surgery, patients in Group C were sent back to the ward to continue fasting and drinking for at least 6 hours. After the anus exhausts, they began to gradually drink and eat
89573744|NCT05867199|Experimental|MI+AOT|Subjects assigned to this group will be asked to perform Motor Imagery and Action Observation Training during immobilisation period after surgery. The training will be performed once a day, for three weeks. The duration of the training will last about 15 minutes.
89573745|NCT05867199|No Intervention|Control|Subjects assigned will be asked to follow standard care pathway during immobilisation period.
89573746|NCT05867160||Adult patients with focal-onset seizures starting a treatment with ASM as adjunctive therapy|"Adult patients having focal-onset seizures not adequately controlled despite a history of treatment with at least 2 ASM.~The patients should be eligible to start a treatment with ASM as adjunctive therapy.The patients will be prospectively observed up to 12 months after having completed the related titration."
89573747|NCT05867134|Experimental|Activity as tolerated|"Instruction will be a treatment group return to activity as tolerated/comfortable and stop activity if pain present."
89573748|NCT05867134|No Intervention|Standard Lifting Restrictions|"Instructions will be no lifting greater than 20lbs for 6 weeks for open surgery, 2 weeks for minimally invasive surgery."
89573749|NCT05867095|Experimental|Navigation|Patients will get the standard of care in the Netherlands with the addition of surgical navigation
89573750|NCT05867095|Other|Conventional|Patients will get the standard of care in the Netherlands
89573751|NCT05867082|Experimental|Neural Mobilization Group|Each participant underwent 15 treatment sessions (5 days per week for 3 weeks). Further, in the NM group, in addition to conventional treatment, 10 sessions of neural mobilization were performed.
89573752|NCT05867082|Experimental|Control Group|Each participant underwent 15 treatment sessions (5 days per week for 3 weeks).
89573753|NCT05867069||Ipsilateral knee pain group|Those FAI patients presenting with preoperative ipsilateral knee pain.
89209100|NCT00810056|Active Comparator|Assessment only|Cognitive, academic achievement and mental health screening assessment and report.
89573754|NCT05867069||No ipsilateral knee pain group|Those FAI patients presenting without preoperative ipsilateral knee pain.
89573755|NCT05867043||Experience gastrointestinal dysfunction|"Gastrointestinal dysfunction is defined as acute gastrointestinal injury (AGI) score >= 2 based on ESICM criteria, monitored within 72 hours according to early postoperative gastrointestinal dysfunction.~Experience gastrointestinal dysfunction = AGI score >=2"
89573756|NCT05867043||Did not experience gastrointestinal dysfunction|Did not experience gastrointestinal dysfunction = AGI score <2
89573757|NCT05866978|Other|An integrated workplace intervention|Intervention: A group of employees at each workplace will develop and implement their own project activities at meetings four times during the intervention. Activities are implemented at workplaces for all employees. Employees will participate in one screening questionnaire prior to the intervention followed by five health checks and interview based questionnaires.
89573758|NCT05866978|No Intervention|Reference|Reference: No intervention activities.
89573759|NCT05866965|Active Comparator|control|standard third molar surgery following surgical protocol of Department of Oral Surgery, University of Medicine and Pharmacy
89573760|NCT05866965|Experimental|PRF|PRF was applied in third molar socket after removal following surgical protocol of Department of Oral Surgery, University of Medicine and Pharmacy
89573761|NCT05866861|Experimental|CUG252|CUG252 or placebo will be administered to participants in a 3:1 ratio.
89573762|NCT05866861|Placebo Comparator|Placebo|CUG252 or placebo will be administered to participants in a 3:1 ratio.
89573763|NCT05866848|Placebo Comparator|No caffeine|The control group took flour capsules.
89573764|NCT05866848|Experimental|Low caffeine|Group with relatively small amount of caffeine (45 mg) administered.
89573765|NCT05866848|Experimental|High caffeine|Group with greater amount of caffeine (120 mg) administered.
89573766|NCT05866822|Active Comparator|APA (adapted physical activity)|24 APA sessions will take place, there will be 2 sessions a week for 12 weeks which will include global exercises for the upper and lower limb. One session will be 1 hour long and supervised by professionals. It will be divided in 4 cycles which will be differentiated by the intensity of its components: aerobic, strength, speed, balance, coordination and flexibility. The intensity of the sessions will be measured by RPE and heart rate monitor,
89573767|NCT05866822|Experimental|APA (adapted physical activity) + physical activity education (PAE)|"24 APA sessions will take place, there will be 2 sessions a week for 12 weeks which will include global exercises for the upper and lower limb. One session will be 1 hour long and supervised by professionals. It will be divided in 4 cycles which will be differentiated by the intensity of its components: aerobic, strength, speed, balance, coordination and flexibility. The intensity of the sessions will be measured by RPE and heart rate monitor,~+ 8 individuals sessions of PAE (one per week, half an hour long) that will consist of advising and setting weekly goals related to improving PA level and sedentary behavior"
89573768|NCT05866796||No graft loss|Patients receiving liver transplantation that do NOT experience graft loss within 3-months or 12-months after liver transplantation.
89209101|NCT00810056|Experimental|Assessment + FHF|Cognitive, academic achievement and mental health screening assessment and report. Fostering Healthy Futures program (FHF) including weekly therapeutic skill groups and mentoring over a 9-month period.
89209102|NCT00979329||mRCC or GIST treated with sunitinib/sorafenib|
89209103|NCT00810134|Other|Thrupass|Endovascular treatment (Thrupass) is performed as a femoropopliteal above knee endovascular recanalisation and Viabahn introduction with 6-7 mm Viabahn endo-prosthesis.
89209104|NCT00810134|Other|Bypass|Surgical procedure is performed as a femoropopliteal above knee by-pass with 6 mm non-coated PTFE-graft
89573769|NCT05866796||Graft loss|"Patients receiving liver transplantation that experience graft loss within 3-months or 12-months after liver transplantation.~Graft loss is defined as either death of the liver transplant recipient (all-cause), or need for retransplantation of the liver."
89573770|NCT05866783||No HCC recurrence|Patients receiving a liver transplantation that do NOT develop HCC recurrence after liver transplantation.
89573771|NCT05866783||HCC recurrence|Patients receiving a liver transplantation that develop HCC recurrence after liver transplantation.
89573772|NCT05866744|Experimental|Early Time-Restricted Feeding Plus Hypocaloric Mediterranean Diet|Early 14:10 time-restricted feeding plus hypocaloric Mediterranean diet
89573773|NCT05866744|Experimental|Late Time-Restricted Feeding Plus Hypocaloric Mediterranean Diet|Late 14:10 time-restricted feeding plus hypocaloric Mediterranean diet
89573774|NCT05866744|Active Comparator|Hypocaloric Mediterranean Diet Without Time Restriction In Feeding|Hypocaloric Mediterranean diet without time restriction in feeding
89573775|NCT05866731||Identical twins|60 identical twins (30 sets) will be enrolled. Participants will answer 15-20 minutes of questionnaires on demographics, lifestyle, medical history, and family history over Zoom or the phone with a study coordinator. Participants will then be mailed an iRhythm Zio XT heart rhythm monitor, or EKG, to apply and wear for a maximum of 2 weeks, as well as a DNA Genotek saliva collection kit to collect a small saliva sample. Participants will return the monitor and saliva sample to the study team, and will be reimbursed upon return. The study team is also requesting photo validation to verify twin status.
89573776|NCT05866731||Same-sex fraternal twins|60 same-sex fraternal twins (30 sets) will be enrolled. Participants will answer 15-20 minutes of questionnaires on demographics, lifestyle, medical history, and family history over Zoom or the phone with a study coordinator. Participants will then be mailed an iRhythm Zio XT heart rhythm monitor, or EKG, to apply and wear for a maximum of 2 weeks, as well as a DNA Genotek saliva collection kit to collect a small saliva sample. Participants will return the monitor and saliva sample to the study team, and will be reimbursed upon return. The study team is also requesting photo validation to verify twin status.
89573777|NCT05866614||CT-P13 SC for RA patients|Patient will be treated as per the SmPC. The enrolled patient with RA will be administered Remsima® SC on the enrolment date and Remsima® SC injections will be continued according to the local standard of care. Study assessment will be done at least every 3 months through outpatient visit or telephone follow-up as part of routine care practice. Each outpatient visit is recommended to be done at least every 6 months and telephone follow-up will be done every 3 months after each outpatient visit to assess the patient.
89573778|NCT05866614||CT-P13 SC for As, PsA and Ps patients|Patient will be treated as per the SmPC. The enrolled patient with AS, PsA, and Ps will be administered Remsima® SC on the enrolment date and Remsima® SC injections will be continued according to the local standard of care. Study assessment will be done at least every 3 months through outpatient visit or telephone follow-up as part of routine care practice. Each outpatient visit is recommended to be done at least every 6 months and telephone follow-up will be done every 3 months after each outpatient visit to assess the patient.
89573779|NCT05866614||CT-P13 IV for As, PsA and Ps patients|Patient will be treated as per the SmPC. The enrolled patient with AS, PsA, and Ps will be administered Remsima® IV on the enrolment date and Remsima® IV infusions will be continued according to the local standard of care. Study assessment will be done at least every 3 months through outpatient visit or telephone follow-up as part of routine care practice. Each outpatient visit is recommended to be done at least every 6 months and telephone follow-up will be done every 3 months after each outpatient visit to assess the patient.
89573780|NCT05866588|Experimental|experimental group|Participants in the experimental group will receive training and counseling consisting of a total of 8 modules from the 28th week of pregnancy to the fourth month of the postpartum period.
89573781|NCT05866588|No Intervention|Control group|No educational counseling will be applied to the women in the control group. These participants will receive routine antenatal, natal and postnatal care
89573782|NCT05866575|Other|escitalopram strategy|The strategy will not be modified for a period of 4 weeks. Dosage adjustment and co-prescriptions will be at the discretion of the refeering psychiatrist.
89573783|NCT05866575|Other|vortioxetine strategy|The strategy will not be modified for a period of 4 weeks. Dosage adjustment and co-prescriptions will be at the discretion of the refeering psychiatrist.
88970905|NCT04711291|No Intervention|Remain on IR-Tac prescribed doses every 12 hours|Patient will remain in Tacrolimus IR-Tac Arm and will complete medication adherence questionnaire monthly. They will not receive any notifications from TransMedAx application. Research staff and PI will collect their Tacrolimus Trough levels and change in tacrolimus dose levels during their routine follow up.
88970906|NCT04711291|Active Comparator|Convert to Envarsus XR once daily|Subjects randomized to this arm will switch from IR-Tac to Envarsus XR and will complete medication adherence questionnaire. However, patients in this group will not receive any notifications from TransMedAx application. Research staff and PI will collect their Tacrolimus trough levels and change in tacrolimus dose during their follow up.
88970907|NCT04711291|Experimental|Convert to Envarsus XR once daily combined with TransMedAx app use|Subjects randomized to this arm will switch from IR-Tac to Envarsus XR, will receive notification by scanning a QR code through TransMedAx application and will complete medication adherence questionnaire. Research staff and PI will collect their Tacrolimus trough levels and change in tacrolimus dose during their follow up.
88970908|NCT00073645|Experimental|1|Family/Parents CBT (FCBT) for 14 to 16 weekly sessions
88970909|NCT00073645|Active Comparator|2|Peer/Group CBT (GCBT) for 14 to 16 weekly sessions
88970910|NCT00073684|Experimental|1|Participants will receive 8 sessions of TF-CBT with narrative.
88970911|NCT00073684|Experimental|2|Participants will receive 8 sessions of TF-CBT without narrative.
88970912|NCT00073684|Experimental|3|Participants will receive 16 sessions of TF-CBT with narrative.
88970913|NCT00073684|Experimental|4|Participants will receive 16 sessions of TF-CBT without narrative.
88970914|NCT02966041|Experimental|Ondansetron|Ondansetron 4mg IV at time of discontinuation of Propofol Infusion
88970915|NCT02966041|Placebo Comparator|Saline|2 mL IV Normal Saline at time of discontinuation of Propofol Infusion
88970916|NCT00073840|Active Comparator|I|Levalbuterol 90 ųg QID (manufacturing site A or B)
88970917|NCT00073840|Active Comparator|II|Racemic Albuterol 180 ųg QID
88970918|NCT00073840|Placebo Comparator|III|Placebo QID
89029060|NCT04761822|Experimental|Placebo+Pfizer-BioNTech COVID-19 Vaccine|"Participants will receive placebo as a first dose followed by two doses of their assigned active vaccine at subsequent visits. 0.3 mL of placebo will be administered intramuscularly in the deltoid.~The placebo dose will be followed by two doses of Pfizer-BioNTech COVID-19 Vaccine, with the first dose administered 1 month later. The Pfizer-BioNTech COVID-19 Vaccine (0.3 mL) will be administered intramuscularly in the deltoid, as a series of two doses (0.3 mL each) administered 3 weeks (21 days) apart."
89029061|NCT04729543|Experimental|Adoptive therapy with autologous MC2 TCR T cells|"Accelerated titration phase I design and a subsequent single arm phase II study~Prior to T cell transfer (day 0), patients will be treated with valproic acid (dose 50 mg/kg/d, 7d; days -9 to day -3) and 5' azacytidine (dose 75mg/m2/d, 7d; days -9 to day -3)~Phase I: patients will be treated with one single intravenous administration of MC2 TCR T cells at 5 different escalated doses of 5x10E7, 5x10E8, 5x10E9,1.0x10E10, and the total number of cultured TCR T cells (i.e., usually 1.0-5.0 x10E10 TCR T cells). MC2 TCR T cell infusions will be supported by low dose of IL-2 administrations (s.c. 5x10E5 IU/m2 2qd for 5 days)~T cells will be processed using IL-15 and IL-21 to generate young T cells"
89029062|NCT04709692|Other|Arm 1 A (cohort 1)|Combination of 600 mg SJ733 with 150 mg Cobicistat administered orally once every day for three consecutive days for patients with P.vivax
89573784|NCT05866562|Experimental|Dupilumab|every other week 200 mg or 300 mg (weight-based) SC injections
89573785|NCT05866562|Placebo Comparator|Placebo|Tablets without active ingredients
89573786|NCT05866510|Experimental|Utidelone and Anlotinib|The treatment group will be treated with Utidelone and Anlotinib until the presence of progressive disease or unacceptable toxicity.
89573787|NCT05866497||diabetes and periodontitis group (group 1)|"35 subjects with type 2 diabetes and severe periodontitis were recruited in group 1.~The clinical periodontal parameters taken are as follows:~plaque index (PI), gingival index (GI), bleeding on brobing (BOP), probing depth (PD) and clinical attachment level (CAL).~The present number of teeth in participants was recorded. Cardio-ankle vascular index (CAVI) was measured"
89029063|NCT04709692|Other|Arm 1 B (cohort 1)|Combination of 600 mg SJ733 with 150 mg Cobicistat administered orally once every day for three consecutive days for patients with P.falciparum
89029064|NCT04709692|Other|Arm 2 A (cohort 2)|600 mg SJ733 administered orally once every day for three consecutive days for patients with P.vivax
89029065|NCT04709692|Other|Arm 2 B (cohort 2)|600 mg SJ733 administered orally once every day for three consecutive days for patients with P.falciparum
89029066|NCT04709692|Other|Arm 3 A (cohort 3)|Combination of 300 mg SJ733 with 150 mg Cobicistat administered orally once every day for three consecutive days for patients with P.vivax
89029067|NCT04709692|Other|Arm 3 B (cohort 3)|Combination of 300 mg SJ733 with 150 mg Cobicistat administered orally once every day for three consecutive days for patients with P.falciparum
89029068|NCT04706962|Experimental|TH1902|TH1902 peptide-drug conjugate
89029069|NCT04692285|Active Comparator|Patients with focal dystonia treatment first placebo second|Zolpidem 5 mg single dose
89029070|NCT04692285|Placebo Comparator|Patients with focal dystonia placebo first treatment second|Placebo 5 mg single dose
89029071|NCT04690855|Experimental|Study Treatment Arm|"All patients will be treated with induction talazoparib of 1mg PO daily starting Day 1. Patients will then receive 8 Gy x 3 fractions to 1-4 metastatic lesions beginning Day 12,13, or 14 and given QOD. 840 mg of atezolizumab will be given intravenously (IV) on Day 15 of the 1st cycle and then on Day 1 and Day 15 of the remaining cycles. The sequence of administration is not specified on the days in which talazoparib and atezolizumab are given on the same day. Each cycle equals 28 days. Treatment will continue until progression or severe toxicity.~A safety lead in of up to 6 patients will be performed. Immune-related and non-immune related adverse events will be tracked up to 12 weeks post initiation of atezolizumab, as the majority of treatment-related toxicities from talazoparib, radiation, and atezolizumab occur within this time period."
89029072|NCT04665258||COVID-19 vaccine group|Participants scheduled to receive the COVID-19 vaccine will be evaluated on its effect on semen parameters for up to 6 months post vaccination.
89029073|NCT04663100|Experimental|Pharmacist Coordinated care Oncology Model|The Pharmacist Coordinated care Oncology Model includes patient self-reported symptoms and medication adherence, comprehensive medication review(s) and intentional communication between oncology and community pharmacists.
89029074|NCT04643015||Study Participants|Patients of any age, including males and females, who are being treated in the Department of Pediatrics and are already scheduled to undergo MRI
89033203|NCT02943161|Experimental|L-Citrulline|In this pilot study subjects with asthma that have an increased body mass index compatible with being obese, will be invited to participate in a short open-label treatment with 15g/day of L-citrulline for two weeks. Study participants will be asked to do lung function testing and donate blood before and after taking the supplement. L-citrulline is safe and well tolerated and has been used at much higher doses without significant side effects.
89033204|NCT02921139|Experimental|Arm I|Stereotactic ablative radiotherapy (SABR)
89573788|NCT05866497||diabetes and periodontally healthy (group 2)|"34 subjects with type 2 diabetes and periodontally healthy were recruited in group 2.~The clinical periodontal parameters taken are as follows:~plaque index (PI), gingival index (GI), bleeding on brobing (BOP), probing depth (PD) and clinical attachment level (CAL).~The present number of teeth in participants was recorded. Cardio-ankle vascular index (CAVI) was measured"
89573789|NCT05866497||systemically healthy and periodontitis (group 3)|"32 systemically healthy subjects with severe periodontitis were recruited in group 3.~The clinical periodontal parameters taken are as follows:~plaque index (PI), gingival index (GI), bleeding on brobing (BOP), probing depth (PD) and clinical attachment level (CAL).~The present number of teeth in participants was recorded. Cardio-ankle vascular index (CAVI) was measured"
89033205|NCT02921139|Active Comparator|Arm II|Re-transcatheter arterial chemoembolization (re-TACE)
89033206|NCT05319704|Active Comparator|Test of effort, sub-maximal, progressive, carried out in eccentric mode|The exercise will start at 10% of VO2max. However, every six minutes, the level of VO2max will be increased by 10%, up to 50%.
89573790|NCT05866497||systemically healthy and periodontally healthy (group 4)|"35 systemically and periodontally healthy subjects were recruited in group 4.~The clinical periodontal parameters taken are as follows:~plaque index (PI), gingival index (GI), bleeding on brobing (BOP), probing depth (PD) and clinical attachment level (CAL).~The present number of teeth in participants was recorded. Cardio-ankle vascular index (CAVI) was measured"
89573791|NCT05866393|No Intervention|Usual Care|Based on the literature reviewed and previous studies, the enrollment and the control group (Group 1- Usual Care) will begin within 24 hours of participants' admission to medical surgical units (4A, 4B, 5A, 5B- Cleveland VA and 9B, 9C, 11C, 7A MetroHealth). Data collection times are: the day of admission (Baseline, Day 0-1) and Day 3-4 between 2pm and 5pm. Participants will be consented for the research study staff to collect swabs for their nares on Day 0-1 and Day 3-4 and their hands at admission Day 0-1 and Day 3-4. No education or hand hygiene products will be provided. It is established that at both institutions a lemon towelette packet is provided with each meal.
89573792|NCT05866393|Experimental|Clean Hands Accessible and Manageable for Patients|"CHAMPs participants will receive a patient hand-sanitation system attached via an R-shape clip to the bed rail. After it is placed on the bed rail, the personalized verbal electronic audio reminder with the RA's voice to insert the participants' name,  ____ it is (breakfast, lunch, dinner) time, please clean your hands. The times will be within an hour window of 7 a.m., noon, and 5 p.m. The CHAMPs system will be labeled For Patient Use Only. The times were chosen around meal times because these times also are similar to around the time when medications are being administered. The hands can be a vector for germs to the face and mouth as shown in the literature. On Day 3 or 4 whichever comes later without anticipated discharge, the Interventionist will provide the evaluation of intervention questionnaires, clean the system turn it in to the project manager to retrieve SD card which contains the month, day, time, and number of system usages."
89573793|NCT05866289||Includes 681 patients who were placed in prone position|
89573794|NCT05866289||Includes 388 patients who were placed in supine position|
89573795|NCT05866263|Experimental|green walking and intelligence game group|The randomized controlled study to examine the effects of green walking and intelligence games on the cognitive skills of individuals aged 50-70 years who had COVID-19 on an outpatient basis were completed with 40 individuals, 20 of which were in the green walking and intelligence game group
89573796|NCT05866263|Active Comparator|control group|The randomized controlled study to examine the effects of green walking and intelligence games on the cognitive skills of individuals aged 50-70 years who had COVID-19 on an outpatient basis were completed with 40 individuals, 20 of which were in the 20 were in the control group
89573797|NCT05866224|Experimental|Supervised home telerehabilitation program|COVID-19 patients will perform a total of 15 weeks of a telerehabilitation program combined with aerobic and strength exercises using the circuit training methodology. COVID-19 patients will carry out 3 weekly sessions on non-consecutive days to avoid unnecessary overload and maximize the adaptations, completing a total of 45 sessions
89573798|NCT05866224|No Intervention|non-supervised control group|COVID-19 patients that will not perform the telerehabilitation program
89573799|NCT05866211||Case|Individuals with impaired lung function, according to spirometry results (FVC ≤ LLN and FEV1/FVC ≥ LLN).
89573800|NCT05866211||Control|Individuals with normal lung function
89573801|NCT05866172|Experimental|HAIC with zoledronic Acid|
89573802|NCT05866172|Active Comparator|HAIC without zoledronic Acid|
89573803|NCT05866146|Experimental|Interprofessional rehabilitation program|Participants of the intervention group will receive an interprofessional rehabilitation program, which involve a combination of physical, psychological, behavioral, and/or vocational components, for four weeks.
89573804|NCT05866146|Active Comparator|Usual standard care|The control group participants will receive the usual standard care according to the current practices at the University of Gondar specialized hospital over the same four weeks.
89573805|NCT05866133||Young people with addiction|Both behavioural and drug addiction will be assessed. Participants with scores consistent with an addiction will be included in this group.
89573806|NCT05866133||Young people without addiction|Both behavioural and drug addiction will be assessed. Participants with scores not consistent with an addiction will be included in this group.
89573807|NCT05866120|Active Comparator|Individuals with Parkinson's Disease to perform physiotherapy on the ground.|The protocols will last for 12 weeks, with a frequency of 2 times a week.
89573808|NCT05866120|Active Comparator|Individuals with Parkinson's Disease to undergo aquatic physiotherapy|The protocols will last for 12 weeks, with a frequency of 2 times a week.
89573809|NCT05866120|Active Comparator|Individuals with Parkinson's Disease to perform physiotherapy on the ground with power training.|The protocols will last for 12 weeks, with a frequency of 2 times a week.
89573810|NCT05866042|Experimental|Active tDCS|Administration of active tDCS, not followed by MCT session, but by a usual visit psychiatric follow-up
89573811|NCT05866042|No Intervention|sham tDCS and MCT|Administration of sham tDCS, followed by MCT session
89573812|NCT05866042|Experimental|active tDCS and MCT|Administration of active tDCS, followed by MCT session
89573813|NCT05865938||PASCAL-Group|M-TEER using MitraClip
89573814|NCT05865938||MitraClip-Group|M-TEER using PASCAL
89573815|NCT05865925|Experimental|LY010616(30 mg/m2)|30 mg/m2 measured by Irinotecan hydrochloride, IV infusion was 90min (±5min), with an interval of 3 weeks between the first administration and the second administration, and once every 2 weeks thereafter)
89573816|NCT05865925|Experimental|LY010616(60 mg/m2)|60 mg/m2 measured by Irinotecan hydrochloride, IV infusion was 90min (±5min), with an interval of 3 weeks between the first administration and the second administration, and once every 2 weeks thereafter)
89573817|NCT05865925|Experimental|LY010616(90 mg/m2)|90 mg/m2 measured by Irinotecan hydrochloride, IV infusion was 90min (±5min), with an interval of 3 weeks between the first administration and the second administration, and once every 2 weeks thereafter)
89573818|NCT05865925|Experimental|LY010616(120 mg/m2)|120 mg/m2 measured by Irinotecan hydrochloride, IV infusion was 90min (±5min), with an interval of 3 weeks between the first administration and the second administration, and once every 2 weeks thereafter)
89573819|NCT05865925|Experimental|LY010616(150 mg/m2)|150 mg/m2 measured by Irinotecan hydrochloride, IV infusion was 90min (±5min), with an interval of 3 weeks between the first administration and the second administration, and once every 2 weeks thereafter)
89573820|NCT05865925|Experimental|LY010616(180 mg/m2)|180 mg/m2 measured by Irinotecan hydrochloride, IV infusion was 90min (±5min), with an interval of 3 weeks between the first administration and the second administration, and once every 2 weeks thereafter)
89573821|NCT05865912|Experimental|[Mindfulness training + real tDCS]|
89573822|NCT05865912|Placebo Comparator|[Mindfulness training + sham tDCS]|
89573823|NCT05865912|No Intervention|[Waiting list control group].|
89573824|NCT05865899|Experimental|surgical|patients who undergo high tibial osteotomy procedure
89573825|NCT05865899|No Intervention|conservative|patients who undergo conservative treatment
89573826|NCT05865873|Experimental|Interventional group|Intervention group: will receive routine plus pre-recorded audio-based HEI package for six months until date of delivery.
89573827|NCT05865873|Active Comparator|Comparator group|Comparator group: will receive the routine health education package for six months until the date of delivery as per the Ethiopian guidelines.
89573828|NCT05865860||ophthalmologists with microsurgical training|Participants underwent training by digital and microscope, and we observed the changes of functions before and immediately after the training
89573829|NCT05865847||Lowest income groups|Deciles of equivalized net household income. The method compares the whole socioeconomic distribution.
89573830|NCT05865834|Experimental|intervention arm|"One public and one private school will be randomly placed into intervention arm. Students from grade 6th - grade 10th will be recruited on their willingness to participant.~A smartphone application will be installed on the personal gadgets of the students in the interventional arm at baseline. For assessing the effectiveness of this app, the first follow-up will be done at one month after the intervention and the second follow up after 3 months to evaluate whether the application had an impact on their depressive and anxiety symptom using PHQ-A, GAD-7 and WHO-5 scales."
89573831|NCT05865834|Active Comparator|control arm|"one public and one private school will be randomly allocated to control arm. Students from grade 6th - grade 10th will be recruited on their willingness to participant.~the control group will receive self-reading educational leaflets. the first follow-up will be done at one month after the intervention and the second follow up after 3 months to evaluated whether the application had an impact on their depressive and anxiety symptom using PHQ-A, GAD-7 and WHO-5 scales."
89573832|NCT05865821|Active Comparator|Negative pressure drainage|Negative pressure drainage is a drainage catheter which is placed in subcutaneous surgical wound for draining fluid such as hematoma, seroma, and pus. In this study the drainage the catheter will be placed in the wound for 5 days and/or removed if fluid content is less than 20 ml per day. Jackson-Pratt or Redivac catheter is used in this study because it is cheap and widespread in all hospitals. The drainage catheter is placed after completion of surgery and before skin closure.
89573833|NCT05865821|Other|No pressure drain|no drainage catheter in subcutaneous surgical wound
89573834|NCT05865782|Experimental|Schoolyard reconstruction|Schools undertaking schoolyard reconstruction will act as both control and intervention schools. Each year, a cross-sectional sample of 2nd and 5th grade children will be measured in all participating schools.
89573835|NCT05865769||Normal children|Have FEV1 higher than median on their class
89573836|NCT05865769||subclinical pulmonary impairment|Have FEV1 lower than median on their class
89573837|NCT05865730|Experimental|Phase 2 - NSCLC|Oncobax-AK (1 capsule) will be administered daily until PD< excessive toxicity or withdrawal of consent
89573838|NCT05865730|Experimental|Phase 2 -RCC|Oncobax-AK (1 capsule) will be administered daily until PD< excessive toxicity or withdrawal of consent
88970919|NCT03958851||patients with lupus nephritis|Lupus nephritis is diagnosed by either the presence of proteinuria (>0.5 g/day), active urinary sediment (with red blood cell, granular, tubular and/or mixed casts), or an unexplained rise in serum creatinine in patients with systemic lupus.
88970920|NCT03958851||systemic lupus patients without lupus nephritis|The diagnosis of SLE will be according to the 1997 American college of Romatology revised criteria (Hochberg 1997).these group will be taken as a control group
88970921|NCT03958851||healthy individuals|a group of age and sex matched healthy individuals will be taken as a control group.
88970922|NCT00392652|Experimental|Arm I (low-dose oral diindolylmethane)|Participants receive low-dose oral diindolylmethane (BR-DIM) twice daily for 4 weeks.
88970923|NCT00392652|Experimental|Arm II (high-dose oral diinolylmethane)|Participants receive high-dose oral BR-DIM twice daily for 4 weeks.
88970924|NCT02965885|Experimental|TAS-116|
88970925|NCT00392691|Experimental|Zevalin, Rituximab, Melphalan|
88970926|NCT02966080|Other|Adjusted-dose heparin|Patients in this arm of the study will receive intravenous unfractionated heparin at a dose adjusted to achieve an activated clotting time of 180-200 seconds.
88970927|NCT02966080|Other|Fixed low-dose heparin|Patients in this arm of the study will receive intravenous unfractionated heparin at 500 units/hour without activated clotting time monitoring.
88970928|NCT04767776|Experimental|Arm A|"Period  rivaroxaban and 6 milligram of activated charcoal ~Washout period (6 days)~Period  rivaroxaban and 12 milligram of activated charcoal ~Washout period (6 days)~Period  rivaroxaban and 50 milligram of activated charcoal ~Washout period (6 days)"
88970929|NCT04767776|Experimental|Arm B|"Period  rivaroxaban and 12 milligram of activated charcoal ~Washout period (6 days)~Period  rivaroxaban and 6 milligram of activated charcoal ~Washout period (6 days)~Period  rivaroxaban and 24 milligram of activated charcoal ~Washout period (6 days)"
88970930|NCT04767776|Experimental|Arm C|"Period  rivaroxaban and 50 milligram of activated charcoal ~Washout period (6 days)~Period  rivaroxaban and 24 milligram of activated charcoal ~Washout period (6 days)~Period  rivaroxaban and 6 milligram of activated charcoal ~Washout period (6 days)"
88970931|NCT04767776|Experimental|Arm D|"Period  rivaroxaban and 24 milligram of activated charcoal ~Washout period (6 days)~Period  rivaroxaban and 50 milligram of activated charcoal ~Washout period (6 days)~Period  rivaroxaban and 12 milligram of activated charcoal ~Washout period (6 days)"
88970932|NCT04730284|Experimental|Health supplements|One arm only
88970933|NCT03958812||Gastric cancer|patients with definitive diagnosis of gastric cancer by pathology
88970934|NCT03958812||Breast cancer|patients with definitive diagnosis of breast cancer by pathology
88970935|NCT03958812||Benign gastric diseases|Gastritis or gastric ulcer
88970936|NCT03958812||Benign breast diseases|Hyperplasia of mammary glands or mastitis
88970937|NCT03958812||Normal|healthy volunteers
88970938|NCT04730245|Experimental|Microbiota modification|
88970939|NCT03958773|Experimental|Cardiovalve treatment|Patients that implanted with the Cardiovalve device
88970940|NCT02965807|Experimental|Bronchial Thermoplasty|Moderate bronchial asthma patients under the Bronchial Thermoplasty.
89573839|NCT05865717||Teachers|A professional whose teaching at an academic institution from the past 3 years. e.g College or university
89573840|NCT05865717||Bankers|A professional who has a desk job of at least 8-10 hours per day working in the corporate sector.
89573841|NCT05865717||IT experts|A person who uses computers for work or communication, having a desk job of at least 8-10 hours per day
89573842|NCT05865717||Doctors|Physicians having a desk job in their outpatient clinic for at least 8-10 hours per day
89573843|NCT05865717||Administrative job personal|Personals working in the human resource department or administration department whose job involves desk work 10 hours per day.
89573844|NCT05865691||controls without liver disease|blood collection on the day of inclusion
89573845|NCT05865691||patients with chronic liver disease without cirrhosis|blood collection on the day of inclusion
89573846|NCT05865691||patients with chronic liver disease with compensated cirrhosis|blood collection on the day of inclusion
89573847|NCT05865691||patients with chronic liver disease with stable decompensated cirrhosis|blood collection on the day of inclusion
89573848|NCT05865691||patients with chronic liver disease with decompensated cirrhosis in the acute phase|blood collection on the day of inclusion
89573849|NCT05865691||patients with chronic liver disease with decompensated cirrhosis and organ failure|blood collection on the day of inclusion
89573850|NCT05865665||Patients hospitalized for acute heart failure|Patients admitted for acute heart failure for at least 72 hours who are not treated with optimal doses of oral medications for HF including renin-angiotensin system inhibitors (RASI), beta-blockers (BB), and mineralocorticoid receptor antagonists (MRA) meeting all eligibility criteria including elevated NT-proBNP.
89573851|NCT05865639|Experimental|Aerobic Exercise|Aerobic exercise for eight weeks. Three weekly, supervised training sessions.
89573852|NCT05865639|Experimental|Time Restricted Fasting|Time restricted fasting for eight weeks. Maximal daily eating window of 8 hours.
88970941|NCT02972333|Experimental|AZD9291 80mg oral each day±RT|AZD9291(80mg, QD, p.o.) was provided to patients with confirmed EGFR T790M positive NSCLC who have received prior therapy with an EGFR-TKI and concurrent with brain metastasis. Radiation therapy will be implemented according to investigator's clinical practice(A 7-10 days washout period before radiotherapy and 1 week period after completion of brain radiothearpy before re-starting AZD9291.).
88970942|NCT00074737|Active Comparator|cenersen, idarubicin|cenersen, idarubicin, no cytarabine
88970943|NCT00074737|Active Comparator|cenersen, idarubicin, cytarabine|cenersen, idarubicin, standard dose cytarabine
88970944|NCT00074737|Active Comparator|cenersen, idarubicin, HDAC|cenersen, idarubicin, HDAC (high dose cytarabine)
88970945|NCT03958734|Other|Low physical activity/fitness|Participants will be classified as into low-physical fitness based on self-reported physical activity and cardiorespiratory fitness testing.
88970946|NCT03958734|Other|High physical activity/fitness|Participants will be classified as into high-physical fitness based on self-reported physical activity and cardiorespiratory fitness testing.
88970947|NCT00074776|Experimental|1 Lithium|
88970948|NCT00074776|Experimental|2 Lamotrigine|
88970949|NCT00074932|Other|1|
88970950|NCT00075010|Experimental|Decitabine + Valproic acid|Decitabine 15 mg/m^2 by vein over 1 hour times 10 days
88970951|NCT04729595|Active Comparator|Active Treatment|Tempol (MMB-02) 800 mg per Day (n=124)
88970952|NCT04729595|Placebo Comparator|Placebo|Placebo (n=124)
88970953|NCT01349829|Experimental|HAVpur|
88970954|NCT01349829|Active Comparator|Havrix|
88970955|NCT02965495|Experimental|YYD302 2ml|YYD302 2ml
88970956|NCT02965495|Experimental|YYD302 3ml|YYD302 3ml
88970957|NCT02965495|Placebo Comparator|Placebo 3ml|Phosphate buffered saline 3ml
88970958|NCT04716101|Experimental|Patients with nonspecific low back pain|Patients will be randomized to receive either a massage technique or a sham massage technique.
88970959|NCT04716101|Active Comparator|Asymptomatic volunteers|Similarly, the volunteers will be randomized to receive either a massage technique or a sham massage technique.
88970960|NCT03958617|Active Comparator|On condition|Ongoing thalamic deep brain stimulation
88970961|NCT03958617|Sham Comparator|Off condition|Switched off thalamic deep brain stimulation, sham stimulation
88970962|NCT00075439|Experimental|Arm I|Patients receive oral gefitinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88970963|NCT02965417|Experimental|Sym004|All patients will receive a loading dose of Sym004, followed by weekly (q1w) infusions
88970964|NCT03958539|Active Comparator|Intervention arm|6 sites out of a total of 12 will act as the intervention sites. 450 Patients with high risk of primary DFUs defined by peripheral sensory neuropathy and callus formation or critical limb ischaemia or on renal replacement therapy will be cluster randomised to be provided with bespoke 3-D printed insoles.
88970965|NCT03958539|No Intervention|Control|6 sites out of a total of 12 will act as the control sites providing standard care. 450 Patients with high risk of primary DFUs defined by peripheral sensory neuropathy and callus formation or critical limb ischaemia or on renal replacement therapy will be cluster randomised to standard care
88970966|NCT00075634|Experimental|Arm I|"PART A (solid tumor patients): Patients receive decitabine IV over 1 hour on days 0-6 and doxorubicin IV over 15 minutes and cyclophosphamide IV over 1 hour on day 7. Patients then receive filgrastim (G-CSF) subcutaneously (SC) beginning on day 8 and continuing until blood counts recover OR pegfilgrastim SC once on day 8 or 9*. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.~PART B (neuroblastoma patients): Once the MTD is determined for part A, patients are treated as in part A at the MTD."
88970967|NCT04703855|Experimental|HeartMate 3™ left ventricular assist system (HM3 LVAS)|Patients will be implanted with the HM3 LVAS
89573853|NCT05865639|Experimental|Aerobic exercise & Time Restricted Fasting|
89573854|NCT05865639|No Intervention|Control|Will be given information about the recommended level of physical activity for health benefits and a healthy diet.
89573855|NCT05865626|Experimental|VOT without cash incentive at the begining|Participants in this group start VOT without financial motivation. In the second part of their follow-up, VOT is combined with financial motivation.
89573856|NCT05865626|Experimental|VOT with cash incentive at the begining|The participants in this group start the VOT with the financial motivation. In the second part of their follow-up, VOT is no longer associated with financial motivation
89573857|NCT05865626|No Intervention|Standard care|The participants in this group self-administer the anti-tuberculosis treatment as is done routinely.
89573858|NCT05865613|Experimental|Magnetic group|Participants were randomized into either the PEMF group or sham treatment group by a computer-generated random number. The participants were treated using PEMF (20 G,7H for 10min). treatment was delivered for one month.
89573859|NCT05865613|Sham Comparator|Sham magnetic group|Participants were randomized into either the PEMF group or sham treatment group by a computer-generated random number. The participants were treated using PEMF without adjusting the output. treatment was delivered for one month.
89573860|NCT05865600|Other|Cohort study|All patients with symptomatic chronic coronary syndrome undergoing clinically referred [15O]H2O cardiac PET/CT will be included in a prospective cohort with repeated symptom questionnaires and outcomes registered in national registries. A total of 570 patients are expected to be included in order to have 200 randomized patients reaching the 3-month assessment
89573861|NCT05865600|Experimental|Immediate referral to invasive coronary angiography|Patients with abnormal perfusion on [15O]H2O cardiac PET/CT and clinical indication for invasive coronary angiography randomized to immediate referral for invasive coronary angiography with concomitant optimization of guideline-directed medical therapy. Enrollment will continue until a total of 200 randomized patients reach the 3-month assessment.
89573862|NCT05865600|Experimental|Delayed referral to invasive coronary angiography|Patients with abnormal perfusion on [15O]H2O cardiac PET/CT and clinical indication for invasive coronary angiography randomized to 3-months delayed referral for invasive coronary angiography with concomitant optimization of guideline-directed medical therapy. Enrollment will continue until a total of 200 randomized patients reach the 3-month assessment.
89573863|NCT05865574|Experimental|BAT1706（New Process）|"Drug: BAT1706~1 mg/kg, the corresponding volume of bulk solution should be drawn according to the actual body weight of the subject, diluted to 100 mL with 0.9% sodium chloride solution, and administered by intravenous drip"
89573864|NCT05865574|Active Comparator|BAT1706（Old Process）|"Drug: BAT1706~1 mg/kg, the corresponding volume of bulk solution should be drawn according to the actual body weight of the subject, diluted to 100 mL with 0.9% sodium chloride solution, and administered by intravenous drip"
89573865|NCT05865548|Experimental|Interventional arm|Aspirin 150mg PO daily along with standard of care
89573866|NCT05865548|Active Comparator|Standard of care|Standard of care as per the stage of disease and guidelines i.e. Surgery, Surgery with radiation or palliative chemotherapy as per investigators choice
89573867|NCT05865509|Experimental|Escape room|This group received training on stress response using the escape room method.
89573868|NCT05865509|Experimental|Storytelling|This group received training on stress response using the storytelling method.
89573869|NCT05864079||Control|22 healthy age-matched normal-weight male subjects (BMI is from 18.5 to < 25)
89573870|NCT05864079||Overweight|22 healthy overweight male subjects (BMI is from 25 to < 30). Patients with cardiovascular diseases, any malignancy, hepatic or renal failure, diabetic, hyperthyroid patients, patients with a previous history of thromboembolic diseases, or with a history of major surgery within 60 days will be excluded.
89573871|NCT05864079||Obesity|22 healthy obese male subjects (BMI is ≥ 30). Patients with cardiovascular diseases, any malignancy, hepatic or renal failure, diabetic, hyperthyroid patients, patients with a previous history of thromboembolic diseases, or with a history of major surgery within 60 days will be excluded.
89573872|NCT05863247||pseudophakic patients with post-operative dysphotpsias|Patients who report dyshoptsias after bilateral in-the-bag implantation of a trifocal intra-ocular lens (AT LISA 839mp)
89573873|NCT05863247||pseudophakic patients without post-operative dysphotpsias|Patients who don't report dyshoptsias after bilateral in-the-bag implantation of a trifocal intra-ocular lens (AT LISA 839mp)
89573874|NCT05862363|Active Comparator|Normal BMI women|A total of 30 women with functional dyspepsia will be recruited as a control arm of AIM 1A. The women will be recruited from the outpatient department who will present with GI symptoms. A total of 100 women will undergo EGD, out of which 30 women will be enrolled based on their diagnosis of functional dyspepsia and willingness to participate in the study.
89573875|NCT05862363|Active Comparator|Low- BMI women|A total of 60 women from low-socioeconomic status (SES) and with low BMI will be included in the intervention arm of aim A1. They will be recruited based on their willingness to participate and through meeting the inclusion criteria. They will under EGD, including collection of duodenal aspirates and 6-8 biopsy samples.
89573876|NCT05862363|Active Comparator|Low-BMI pregnant women|We will recruit 30 pregnant women with low-BMI before 14 weeks of gestation. One group of women will be provided with RUSF. They will be followed to note changes in weight gain, BMI, changes in EED biomarkers, gut microbial community repair, and pregnancy related outcomes.
89573877|NCT05862363|Active Comparator|Normal BMI pregnant women|We will recruit 30 pregnant women with low-BMI before 14 weeks of gestation. One group of women will be provided with MDCF-2. They will be followed to note changes in weight gain, BMI, changes in EED biomarkers, gut microbial community repair, and pregnancy related outcomes.
89573878|NCT05862012|Experimental|Part 1: Dose Escalation|Participants with R/R MM will be administered ISB 2001 weekly on Days 1, 8, 15, and 22 of each 28-day cycle, with an additional step-up dose in Cycle 1 on Day 4. Treatment cycle duration is 28 days. Participants will receive ISB 2001 until disease progression, unacceptable toxicity occurs, any criterion for stopping the study treatment or participant withdrawal from the study
89573879|NCT05862012|Experimental|Part 2: Dose Expansion|Dose expansion cohorts will be initiated to further confirm safety and optimal biologically active dose at each putative recommended Phase 2 dose(s). Participants will receive ISB 2001 until disease progression, unacceptable toxicity occurs, any criterion for stopping the study treatment or participant withdrawal from the study.
89573880|NCT05861440|Experimental|Adjunct corticosteroid and standard anti-tuberculosis agent|Prednisolone dosing and duration per study protocol
89573881|NCT05861440|Active Comparator|Standard of care with standard anti-tuberculosis agent|standard anti-tuberculosis agent
89573882|NCT05858814|Experimental|RC1012 injection (allo-DNT Cells)|The trial is divided into two parts: Part A is a dose escalation trial with two dose groups (1.0×10^8 cells/kg, 1.5×10^8 cells/kg at day 0, day 28 and day 56), with 6-12 patients planned to be enrolled. Part B is a dose-expansion randomized controlled trial in which 40-60 patients will receive RC1012 infusions at RP2D dose levels.
89573883|NCT05858125|No Intervention|Routine counseling|Patients randomized to routine counseling will receive usual counseling in the standard fashion of their provider.
89573884|NCT05858125|Experimental|Routine counseling + Social Media Navigation Aid Kit|Patients randomized to the intervention will receive routine counseling in the usual manner as well as receive access to the Social Media Navigation Aid Kit in the format of their choice (hardcopy via trifold, email, text, or QR code)
89573885|NCT05854654|Experimental|Air Leaks|Lungs from patients undergoing lung transplantation after their removal from the recipient patient with previous informed consent signed before transplantation will be obtained. The organs will be placed in an acrylic box and will be kept at a temperature of 37 Celsius degrees. In order to reproduce intraoperative air leaks, various manipulations, including stapling and creating lacerations of different depts and lengths on the parenchyma, will be performed on deflated lungs. Following the introduction of a leak, condensed gas will be pushed through the airway to precisely localize the defect. The sealant prepared at room temperature will then be applied in a thin layer to cover the defect and will be left to dry for 5 minutes. The seal will be tested using the condensed gas with the lung still deflated as well as with the water immersion technique after inflating the lung.
89573886|NCT05853094|Experimental|Ileostomy|Protective ileostomy as a defunction mean after low anterior resection
89573887|NCT05853094|Experimental|Transverse colostomy|Protective transverse colostomy as a defunction mean after low anterior resection
89573888|NCT05834491|Experimental|Minimal Footwear (Vivobarefoot)|The experimental intervention involves the combination of foot strengthening/stretching and minimal footwear to promote the foot strengthening beyond the exercise program to mitigate weakening from chronic support.
89573889|NCT05834491|Active Comparator|Supportive Footwear|The control intervention is considered the standard of care and involves combination of foot stretching and the addition of supportive shoes and foot orthoses.
89573890|NCT05828992||Person at risk|Survey personalised for people living at risk of developing Huntington's Disease, meaning they have a parent diagnosed with HD but the person themselves have not undertaken a genetic test.
89573891|NCT05828992||Person HD gene positive asymptomatic|Survey personalised for people that tested positive in their predictive genetic test but have not been yet diagnosed with clinical HD (manifest HD).
89573892|NCT05828992||Person HD gene positive symptomatic|Survey personalised for people that tested positive in their predictive genetic test and have been diagnosed with clinical HD (manifest HD).
89573893|NCT05828992||Informal caregiver|Survey personalised for people caring for another person diagnosed with HD.
89573894|NCT05828992||Former informal caregiver|Survey personalised for people that have cared for another person diagnosed with HD in the last 3 years.
89573895|NCT05820295|Experimental|Intervention|The intervention group will assign care coordinators to individuals based on perceived need for assistance with care coordination. Perceived need will be measured through a proxy's responses to a previously validated telephone survey on perceptions of care coordination.
89573896|NCT05820295|Active Comparator|Control|Usual care assigns patients to care coordinators in response to a discharge from a hospital or a direct referral from a physician.
89573897|NCT05819502|Experimental|Treatment|
89573898|NCT05816304|Active Comparator|Intervention arm|Digital CBTi will be offered using the SleepioTM website and supporting Sleepio™ app (Big Health Ltd., London, UK) via 6 sessions training program (spanning 6 to 12 weeks), lasting an average of 20 minutes each, unlocked weekly. The participant will receive the Sleepio intervention as soon as they become assigned.
89573899|NCT05816304|No Intervention|Attention Control arm|Participants in the control group will have access to online the sleep diary and sleep education material for 12 weeks, without the CBTi intervention by the Sleepio™ app (Big Health Ltd., London, UK). They will start the digital cognitive behavioral therapy for insomnia (dCBTi) intervention 12 weeks after the initial enrollment.
89573900|NCT05805345|Other|DT1fA/T30fA/AOHGfA/P1fA|DT1fA worn first, followed by T30fA, as randomized, during the first wear period, with AOHGfA worn first, followed by P1fA during the second wear period. Each lens type will be worn in both eyes for approximately 30 minutes. The wear periods will be separated by 1 to 9 days.
89573901|NCT05805345|Other|T30fA/AOHGfA/P1fA/DT1fA|T30fA worn first, followed by AOHGfA, as randomized, during the first wear period, with P1fA worn first, followed by DT1fA during the second wear period. Each lens type will be worn in both eyes for approximately 30 minutes. The wear periods will be separated by 1 to 9 days.
89573902|NCT05805345|Other|AOHGfA/P1fA/DT1fA/T30fA|AOHGfA worn first, followed by P1fA, as randomized, during the first wear period, with DT1fA worn first, followed by T30fA during the second wear period. Each lens type will be worn in both eyes for approximately 30 minutes. The wear periods will be separated by 1 to 9 days.
89573903|NCT05805345|Other|P1fA/DT1fA/T30fA/AOHGfA|P1fA worn first, followed by DT1fA, as randomized, during the first wear period, with T30fA worn first, followed by AOHGfA during the second wear period. Each lens type will be worn in both eyes for approximately 30 minutes. The wear periods will be separated by 1 to 9 days.
89573904|NCT05782062|Experimental|Rotational Thrombectomy|Use of the Cleaner XT
89573905|NCT05782062|Active Comparator|Balloon Assisted maceration|Use of angioplasty balloons for balloon maceration
89573906|NCT05771025|Experimental|Hepatectomy group|Patients in the hepatectomy group receive hepatectomy, which could be combined with radiotherapy and chemotherapy for the primary tumor during the perioperative period.
89573907|NCT05866029|Active Comparator|60mg of Denosumab treatment|
89573908|NCT05866029|Experimental|Teriparatide was sequentially treated with Denosumab|
89573909|NCT05764278|Experimental|effectiveness of earlier rehabilitation intervention after IA thrombectomy(experimental)|The effectiveness of early rehabilitation interventions within 24 hours compared with the control group
89573910|NCT05764278|Active Comparator|effectiveness of earlier rehabilitation intervention after IA thrombectomy(control)|The effectiveness of early rehabilitation interventions compared with the experimental group
89573911|NCT05762705|Experimental|Multilevel Gaming Adherence|Participants in the intervention arm will receive Multilevel Gaming Adherence Intervention. Participants receive Viral Combat on their mobile phones, and, for 24 weeks, game-related text messages guided by self-reported medication adherence.
89573912|NCT05762705|Active Comparator|Treatment as Usual +|TAU+ participants will receive the Treatment As Usual + intervention, which includes receiving a non-HIV related mobile game.
89573913|NCT05751473|Experimental|Prolonged Exposure for Primary Care|
89573914|NCT05751473|Active Comparator|EAP Treatment as Usual (TAU)|Employee Assistance Programs standard treatment.
89573915|NCT05747105|Experimental|Sleep Extension Intervention|All participants will receive the 16-week sleep extension intervention aimed to lengthen nighttime sleep duration by at least 30-60 minutes per night. No prescription for daily calorie/dietary intake or physical activity will be provided in this study, except behaviors consistent with sleep hygiene recommendations.
89573916|NCT05740618|Experimental|Inhaled Mannitol|All study participants will receive the same study treatment. Study treatment will be dry powder mannitol 400 mg twice a day by oral inhalation (the contents of 10 capsules administered individually) for 14 days +/- 2 days.
89573917|NCT05736718|Experimental|Champion AAT|Staff in clinics randomized to this arm will receive an intervention called Announcement Approach Training (AAT). This training is designed to improve communication about HPV vaccination. The training will be organized and delivered by vaccine champions from participating healthcare systems.
89573918|NCT05736718|Experimental|Traditional AAT|Staff in clinics randomized to this arm will also receive Announcement Approach Training (AAT). The training will be organized and delivered by outside experts.
89573919|NCT05698290||Health Department of Northwest Michigan|School providers (school nurses, mental health specialists) from the Health Department of Northwest Michigan.
89573920|NCT05698290||Michigan Association of School Nurses|School providers (nurses) from the Michigan Association of School Nurses.
89573921|NCT05691387|Experimental|Thera PEP|"Sitting comfortably, patients receiving Thera PEP will be told to place dental cotton swabs between their cheek and gum, and then under their tongue, to absorb saliva and prevent contamination of the collected sputum by the patient's own saliva. The diameter of the opening will be modified to achieve a ventilation rate of 1:4. The patient will be taught to take in a larger than normal breath but not fill the lungs to capacity in order to maintain a tight seal during exhalation. After completing ten PEP breaths, the patient will have the mouthpiece removed and be instructed to do two or three puff coughs. When secretions need to be brought up, a good cough will do the trick. During the duration of the treatment, which will last around thirty minutes, the patient will be asked to complete three cycles of ten breaths each."
89573922|NCT05691387|Active Comparator|ACBT and PLB|On the day of the ACBT, the patient will be taught to place dental cotton swabs between the cheek and gum, as well as beneath the tongue, to absorb saliva and prevent contamination of the collected sputum by saliva. Throughout the treatment, the patient will be urged to maintain a comfortable sitting position. The patient will then be instructed to perform PLB at a normal tidal volume (for approximately 6 breaths), followed by 3-4 deep inspirations with relaxed exhalation (thoracic expansion exercise), and finally, another period of breathing control, i.e. PLB, followed by FET, i.e. a deep breath in and a huff cough, followed by a medium breath in and a huff cough again. Approximately thirty minutes will pass over the course of this session.
89573923|NCT05684198|Experimental|subcutaneous NPWT|The peritoneum and fascia will be closed as in the PC arm. Subsequently, patients will be treated with commercially available vacuum-assisted closure systems (provided by Smith&Nephew or Hartmann) according to the manufacturer's instructions. Following fascia closure, the NPWT foam will be adjusted to the wound size to fill the wound cavity without causing excessive wound dehiscence. Subsequently, the foam will be placed in the subcutaneous tissue. The foam will not be fixated on the skin with sutures. The wound will be sealed with adhesive film. In case of air leak in problematic areas such as the navel or ostomy, ostomy paste will be used to create a tighter seal. Continuous pressure of 120 mmHg will be applied. On the 3rd day postop, the dressing will be removed and closure by secondary intention will be performed.
89573924|NCT05684198|No Intervention|primary closure|The peritoneum will be closed as a separate layer with a 2-0 multifilament absorbable suture. Subsequently, the fascia will be closed with a continuous suture using absorbable monofilament 0 sutures. Subcutaneous tissue will be rinsed twice with hypochlorite solution following peritoneal closure and fascial closure. Interrupted subcutaneous closure will be performed with absorbable multifilament 2-0 sutures. Following skin disinfection with an alcohol solution, the skin will be closed with non-absorbable monofilament 2-0 or 3-0 sutures using the interrupted mattress technique. Conventional Cosmopor® sterile gauze dressings will be applied. Unless the dressing material will be saturated, the dressing will remain unchanged until 3rd day post-op.
89573925|NCT05684146|Experimental|Emboliner Embolic Protection Device|Emboliner embolic protection device to be used during TAVR procedures for stroke prevention
89573926|NCT05684146|Active Comparator|Sentinel Cerebral Protection System|Sentinel Cerebral Protection System to be used during TAVR procedures for stroke prevention
89573927|NCT05682846|Experimental|Intervention group|"Optimization of serum phosphorus to ≥ 3.5 and ≤ 4.5 mg/dL (Average 4mg/dL) using Sodium glycerophosphate pentahydrate solution.~Sodium glycerophosphate pentahydrate 20ml solution (20 mmol glycerophosphate) dose will be given once daily till the target serum phosphorus level is achieved."
89573928|NCT05682846|No Intervention|Control group|Maintaining serum phosphorus level at ≥ 2.5 and < 3.5 mg/dL.
88970968|NCT03958500|Experimental|Comprehensive anastomotic testing|"All patients undergo:~Indocyanine green fluorescent angiography intraluminally and intraperitoneally~Air leak test~Methylene blue test"
89573929|NCT05682222|Other|Cohort 1|EDP1815 or placebo in capsule A, dosed for 60 days. Randomization is 2:1 active:placebo.
89573930|NCT05682222|Other|Cohort 2|EDP1815 or placebo in capsule B, dosed for 60 days. Randomization is 2:1 active:placebo.
89573931|NCT05682222|Other|Cohort 3|EDP2939 lower dose or placebo in capsule B, dosed for 60 days. Randomization is 2:1 active:placebo.
89573932|NCT05682222|Other|Cohort 4|EDP2939 higher dose or placebo in capsule B, dosed for 60 days. Randomization is 2:1 active:placebo.
89573933|NCT05677295|Experimental|Duloxetine|
89573934|NCT05677295|Active Comparator|Imipramine|
89573935|NCT05669690||Fresh breast milk|Fresh breast milk obtained from volunteer mothers will be divided into four parts. Fresh breast milk will be studied for microbiota composition immediately within 3 hours.
89573936|NCT05669690||Breast milk stored at +4'C for 3 days|One part of previously obtained fresh breast milk will be stored at +4'C at refrigerator for 3 days long, then microbiota composition will be studied.
89573937|NCT05669690||Breast milk stored at -20'C for 3 months|Last part of the same breast milk specimen will be freezed at -20'C for 3 months and microbiota composition of the 3 months frozen milk will be studied.
89573938|NCT05654025||Non-surgical group: Refractive change, ocular parameter changes, and prognosis without surgery|To evaluate the long-term changes in refractive state, ocular parameter, ocular development and visual prognosis in patients without congenital ectopia lentis surgery.
89573939|NCT05654025||Surgical group: Safety and efficacy of different congenital ectopia lentis surgeries|To compare the safety and efficacy of different congenital ectopia lentis surgeries, including phacoemulsification， phacoemulsification + Intraocular lens (IOL) implantation， phacoemulsification + IOL implantation + Capsular Tension Ring implantation or phacoemulsification + IOL implantation + transscleral fixation.
89573940|NCT05623514|Experimental|Candidates for vaginal natural orifice trans-luminal surgery approach|Candidates for benign gynecological surgery in the vaginal natural orifice trans-luminal surgery approach
89573941|NCT05608304|Experimental|Formal mindfulness induction|
89573942|NCT05608304|Experimental|Informal mindfulness induction|
89573943|NCT05608304|Active Comparator|Active control task|
89573944|NCT05580640|Experimental|6 months + post knee surgery|: For study participation subjects need a history of unilateral knee arthroscopy or arthroplasty performed > 6 months ago with completion of post-operative rehabilitation. Subjects will be between the ages of 21 and 90 years old and the ability to walk for 5-10 minutes on level ground.
89573945|NCT05569122|Experimental|Aim 1: Primary Mitochondrial Disease Patients|"The participant has the interventions/study visits occur in a random order:~CPET pGz administration through pGz Bed pGz administration through Gentle Jogger"
89573946|NCT05569122|Experimental|Aim 1: Healthy Controls|"The participant has the interventions/study visits occur in a random order:~pGz administration through Gentle Jogger CPET pGz administration through pGz Bed"
89573947|NCT05569122|Experimental|Aim 2: PICU Patients|All participants in Aim 2 will have the interventions/study visits occur in the same order: Exercise Pedal and Gentle Jogger
89573948|NCT05499741|Experimental|Forehead Temperature-Regulating Therapy|Forehead Temperature-Regulating Therapy
89573949|NCT05476991|Experimental|Colchicine + Ticagrelor|
89573950|NCT05476991|Experimental|Colchine + Aspirine|
89573951|NCT05476991|Experimental|SOC + Ticagrelor|
89573952|NCT05476991|Active Comparator|SOC + Aspirine|
89573953|NCT05471323|Experimental|RC1012 injection (allo-DNT Cells)|Experimental: RC1012 injection (allo-DNT Cells) The trial is divided into two parts: Part A1 is a single- dose escalation trial with three dose groups (5×10^7 cells/kg, 1.5×10^8 cells/kg, 4.5×10^8 cells/kg), with 9-18 patients planned to be enrolled. Part A2 is a multiple-dose escalation trial consisting of 2 dose groups (1.5×10^8 cells/kg and 4.5×10^8 cells/ kg at day 0, day 7 and day 14), with 9-12 patients planned to be enrolled. Part B is a multiple-dose extension trial in which the Safety Review Committee evaluates whether to extend an additional 3-6 patients to receive the multiple cell infusions based on available PK and safety data.
89573954|NCT05465226|Experimental|Oliceridine Arm|Initially, patients will receive oliceridine 1-3 mg IVP every 1-3 hours as needed for moderate or severe pain (NRS ≥ 4) with 1-3 mg every 1-3 hours for breakthrough pain. NRS will be assessed every 3-4 hours routinely. Rescue doses will be allowed per clinical discretion as oliceridine 1-3 mg every hour. Doses will be titrated according to patient response and clinical discretion. In settings where rapid analgesia is needed, such as the operating room, post-anesthesia care unit, emergency room, or hydrotherapy, oliceridine will be administered in 0.5-2 mg doses every 5 minutes as needed for moderate or severe pain, according to anesthesiologist or treating physician's discretion. For the purposes of the study oliceridine will not exceed 7 days of administration and patients will be transitioned from intravenous opioids to oral therapy and de-escalated from opioids, as soon as the team deems appropriate.
89573955|NCT05465226|Active Comparator|Historical control|Retrospective, observational, historical control arm matched by age, TBSA, number of surgeries, and opioid and illicit drug use histories
89573956|NCT05461599|Other|SparkRx Mobile App|The 5-week SparkRx app is divided into 5 levels intended to be completed weekly. A character called 'Limbot' is used as a guide. Limbot encourages the user in completing the behavioral activation program and provides personal examples of how they have undertaken behavioral activation therapy. Participants are instructed to complete a weekly Patient Health Questionnaire (PHQ)-8 assessment and Participant Symptom Check (PSC) questionnaire in the mobile app. Tasks in the mobile app progress in a linear fashion-- i.e., each task must be completed to progress to the next task. Certain on-demand resources can be accessed in the app at any time, including crisis resources. Text entries that match a database of concerning words/phrases will trigger an automated pop-up suggesting participants visit the in-app crisis resources if they need additional support.
88970969|NCT00075751|Experimental|Treatment (gemcitabine hydrochloride, carboplatin, bortezomib)|Patients receive gemcitabine IV over 30 minutes on days 1 and 8, carboplatin IV over 15-30 minutes on day 1, and bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with stable or responding disease may continue to receive bortezomib alone on the above schedule for up to 1 year at the discretion of the treating physician.
89573957|NCT05455710|Experimental|VigiApp|"the intervention group, which will use the mobile application to detect SSI. The Vigi-App application will be installed on the Smartphone of the selected patients, who will receive training on how to use the application; should access it on days seven, 14, 21 and 30 after the surgical procedure, they will additionally be evaluated in person in an outpatient consultation, according to the hospital routine.~The patients in the intervention group will receive notices the day before, through reminders issued by the application, reminding them that they must access and complete the requested information. If the patient presents signs and symptoms of infection on dates other than filling out the application, he can access the application and send his data normally as an extra access."
89573958|NCT05455710|Sham Comparator|telephone call|the called control, consisting of the standard infection surgical site post-discharge surveillance the developed infection of the surgical site procedure, by means of a telephone call. You will receive guidance on phone calls; will follow the standard SSI post-discharge surveillance procedure, by means of a telephone call on days seven, 14, 21 and 30 after the date of surgery, being asked about the presence of signs and symptoms of infection according to the instrument previously validated in previous investigation and will be evaluated in person in an outpatient consultation, according to the hospital routine.
89573959|NCT05451693||Outreach-ER|Outreach-ER is a psychosocial intervention designed by dementia experts in the field of care partner interventions. The care plan will be personalized to the needs of the care partner/PLWD.
89573960|NCT05450003|Other|xp endo finisher file|
89573961|NCT05450003|Other|new sonic EDDY system|
89573962|NCT05450003|Other|syringe needle irrigation|
89573963|NCT05443321|No Intervention|Baseline|The baseline arm will include all included patient transfers from the 3 participating transfer hospitals to the 1 accepting hospital during the 1-year pre-intervention phase. They will not receive any intervention, but rather usual care
89573964|NCT05443321|Experimental|Intervention|The intervention arm will include all included patient transfers from the 3 participating transfer hospitals to the 1 accepting hospital during the 1-year intervention phase. They will receive the intervention, which will include utilization of the developed health information exchange platform to transfer clinical information between transferring and accepting hospital. The intervention will not interact directly with the patient, but rather their clinical data.
89573965|NCT05437380|Experimental|CEUS|
89573966|NCT05402436||Women attending Breast Cancer Screening in England with an atypia diagnosis|Women attending Breast Cancer Screening in England with an atypia diagnosis between 1st January 2003 and 30th June 2018
89573967|NCT05382806|Placebo Comparator|group Control|participants are administered 2mL of 0.9% placebo at the end of procedure.
89573968|NCT05382806|Active Comparator|group Flumazenil|participants are administered 0.2mg (2mL) of flumazenil at the end of procedure.
89573969|NCT05379972|Experimental|HR deficient cohort|Pre-identified presence of somatic or germline deleterious mutation, as determined by NGS only, in at least one gene critical to DNA repair through homologous recombination, including but not limited to: ARID1A, ATM, ATRX, MRE11A, NBN, PTEN, RAD50/51/51B, BARD1, BLM, BRCA1, BRCA2, BRIP1, FANCA/C/D2/E/F/G/L, PALB2, WRN, CHEK2, CHEK1, BAP1, FAM175A, SLX4, MLL2 or XRCC.
89573970|NCT05379972|Experimental|HR proficient cohort|No identifiable somatic or germline deleterious mutation in DNA Response and Repair pathway
89573971|NCT05369494|Experimental|Experimental Product|Infant formula product consumed ad libitum as instructed for approximately 28 days; Powder formula mixed to 20 kcal/fl. oz.
89573972|NCT05366400||Group I (CAT) ≥ 10|CAT is an eight-item questionnaire with a six-item Likert scale ranging from 0 to 5. The score ranges from zero (completely asymptomatic) to 40 (extremely symptomatic). A CAT score ≥10 is associated with a significantly impaired health status.
89573973|NCT05366400||Group II (CAT) < 10|CAT is an eight-item questionnaire with a six-item Likert scale ranging from 0 to 5. The score ranges from zero (completely asymptomatic) to 40 (extremely symptomatic). A CAT score < 10 is associated with a significantly preserved health status.
89029075|NCT04634539|Experimental|Gemcitabine + Nab-paclitaxel + L-glutamine|For the dose-finding portion of this study, all subjects will receive a combination of L-glutamine, gemcitabine, and nab-paclitaxel which will be preceded by a 1-week (+/- 1 day) administration of L-glutamine. This 1-week administration of L-glutamine will facilitate measurement of baseline and post-glutamine monotherapy plasma metabolite levels prior to addition of gemcitabine and nab-paclitaxel. The combination therapy will be administered over 28-day cycles during the treatment period until disease progression, treatment intolerance, or withdrawal from the study. Patients are expected to be on treatment for 12 cycles.
89029076|NCT04619264|Experimental|Papacarie-Duo|
89029077|NCT04619264|Active Comparator|Atraumatic Restorative Treatment|
89573974|NCT05362435|Experimental|Participation in Makoyoh'sokoi (the Wolf Trail Program)|"This is a self-control, non-randomised intervention study. 7 locations will run a total of 10 programs (4 urban, off-reserve; 6 rural, on reserve).~Makoyoh'sokoi (The Wolf Trail Program) is a holistic health and wellness program that consists of a 12-week live phase where participants engage weekly in approximately 45 minutes of physical activity, 20 minutes of a health education module, and 20 minutes of a sharing circle. The live phase is followed by a 12-week follow-up phase where participants meet bi-weekly for approximately 30 minutes of a health education module and 30 minutes of a sharing circle."
89029078|NCT04615819|Experimental|Arm 1|KTFT
89029079|NCT04615819|Experimental|Arm 2|PN
89573975|NCT05358366|Experimental|Infeccion de Amor (Love Infection)|"33 Latinas will view four IA intervention episodes, one per week immediately after the baseline survey and orientation.~Participants will receive an email to their preferred email address with a password to access to the episode on the IA's website: https://www.infecciondeamor.com. Each 10-minute episode can be watched more than once during the week and presents a situation with notable HIV risk and ways the characters avoided risk (e.g., condom use) or confronted consequences of poor practices (e.g., HIV infection). The one-week time frame for each episode is needed to provide time to review and reflect about IA's content and modify HIV prevention behaviors. It will also allow Latinas to obtain information and support from the team and referral if needed. This time frame was effective to improve behaviors in previous studies."
89573976|NCT05358366|Other|Wait-listed|"A wait-listed control group of 33 Latinas will receive IA in the same manner as the intervention group.~Latinas will start watching the telenovela episodes 4 months after their baseline survey (after T3 survey).~Latinas will be informed at recruitment of this group condition and the study randomization. During the waiting time, participants will be called on a monthly basis to encourage participation and refer to services if needed."
89573977|NCT05342155||Focus Group|For the focus group, the participant will be asked to review the potential platform the investigators are developing to better describe risks of health are developing to better describe risks of health issues in childhood cancer survivors. The focus group session will last approximately 2 hours.
89573978|NCT05342155||Campus and Home Assessments|"For the campus and home assessments, the participant will be engaged in the research activities over 108 weeks (approximately 2 years).~DatStat Connect app-Throughout participation in this research study, the participant will use a personal compatible device, such as smartphone or tablet, to report information about their health and respond to questionnaires using a website app called DatStat Connect.~The wrist monitor (Actigraph) and heart monitor (CorSense) will also transmit information to DatStat Connect. The wrist monitor and heart monitor will connect to a compatible personal device via Bluetooth.~The wrist monitor and heart CorSense device and St Jude Life study visit St Jude LIFE study visit: the participant will be asked to complete a St Jude LIFE research study assessment on the St Jude campus at three timepoints: initial visit (Week 0),approximately end of Year 1 (Week 60), and approximately end of Year 2 (Week 108)."
89573979|NCT05336188|Experimental|Smartphone|Participants randomized into the Smartphone app arm would use the smartphone app OptiMAT in conjunction with treatment as usual (TAU). Participants would use OptiMAT to complete daily self-assessments of opiate misuse, opiate craving, opiate withdrawal, and mood. The app will personalized feedback for maintaining abstinence goals. The app would also use geographic ecological momentary assessment (GEMA) to intervene via push notification when participants enter areas previously identified as high-risk for opiate use.
89573980|NCT05336188|No Intervention|Monitoring Only|Participants randomized into the Monitoring Only arm would undergo treatment as usual (TAU) but without the smartphone app.
89573981|NCT05335187|Experimental|micro-macro electrode|In this single-arm, open-label study, all patients receive one or a handful of micro-macro electrode (MME) in place of conventional intracranial EEG electrodes.
89573982|NCT05334420|Experimental|Healthy Dads Healthy Kids|A group-based lifestyle behavioral program for Hispanic fathers and children
89573983|NCT05334420|Other|Standard of care control|National guidelines and recommendations for healthy eating, physical activity and weight loss.
89573984|NCT05321407||X-linked agammaglobulinemia (XLA)|This study is a non-randomized observational cohort study of participants with XLA who have either received, as standard care, the Pfizer BioNTech BNT162b2 mRNA vaccine or the Moderna mRNA-1273 vaccine. In this protocol, vaccination is entirely voluntary and vaccines are not provided by the study.
89573985|NCT05312008|Experimental|Clamp|Clamped alcohol exposure, repeated tests of subjective and cognitive effects of alcohol, 2 sessions (intranasal oxytocin or placebo), double blind
89573986|NCT05312008|Experimental|Progressive work for alcohol|Progressive work alcohol exposure, 2 sessions (intranasal oxytocin or placebo), double blind
89573987|NCT05307900|Experimental|All patients requiring intubations|All intubated patients with feeding tube
89573988|NCT05296252|Experimental|Mind Wandering Intervention|75% of participants will receive proactive and reactive mind-wandering information and redirection.
89573989|NCT05296252|Active Comparator|Mind Wandering Comparison|25% of participants will receive only mind-wandering redirection, but only at random times.
89573990|NCT05281874|Placebo Comparator|Control|A healthy lifestyles attention control will be used as the control condition. We will match the control and intervention conditions on content (text, pictures, number of pages); type (interactive vs. psychoeducation); and average completion time.
89573991|NCT05281874|Experimental|Positive Change (+Change)|This is an integrated social norms-based personalized feedback intervention for college students targeting alcohol misuse and sexual assault. It targets alcohol, sexual assault victimization risk, sexual assault perpetration, and bystander intervention. It is tailored by gender and sexual orientation.
89573992|NCT05281874|Experimental|Positive Change (+Change) Plus Booster|This is an integrated social norms-based personalized feedback intervention for college students targeting alcohol misuse and sexual assault. It targets alcohol, sexual assault victimization risk, sexual assault perpetration, and bystander intervention. It is tailored by gender and sexual orientation. It is provided at baseline and a booster at 6 months.
89573993|NCT05280639|Experimental|Simplified block protocol|subjects in this group will perform a simplified post operative rehabilitation program using a simplified wooden block protocol
89573994|NCT05280639|Active Comparator|Usual care|Subjects in this group will perform formal physical therapy or a home exercise program consistent with AAOS standards.
89573995|NCT05268276|Experimental|study group|"the study group will recelve adesigned protocol of care that entails three interventions as the following1) Application of ice gel pad on perineal trauma for the first 24 hours post partum 2) Performance of pelvic floor exercises (Kegel exercises) from six hours till one week postpartum 3) Application of warm compresses after 48 hours and through the first week postpartum.~The investigator will perform demonstration and then redemonstration by the women on each intervention will be done. A designed booklet (developed previously) that explains each intervention will be given to each woman."
89573996|NCT05268276|No Intervention|control group|The control group will receive the routine hospital care only
89573997|NCT05242432|Experimental|Cohort (C)1 Group (G)1: Adults, 60 years and older (Ad26/protein preF RSV Vaccine)|Participants will receive a single intramuscular (IM) injection of Adenovirus Serotype 26.Respiratory Syncytial Virus.Pre-Fusion F (Ad26/protein preF RSV) vaccine on Day 1.
89573998|NCT05242432|Placebo Comparator|C1 G2: Adults, 60 years and older (Placebo)|Participants will receive a single IM injection of matching placebo on Day 1.
89573999|NCT05242432|Experimental|C2 G3: Adults Aged 20 to 59 years at High-risk of Severe RSV Disease (Ad26/protein preF RSV Vaccine)|Participants will receive a single IM injection of Ad26/protein preF RSV vaccine on Day 1.
89574000|NCT05242432|Placebo Comparator|C2 G4: Adults Aged 20 to 59 years at High-risk of Severe RSV Disease (Placebo)|Participants will receive a single IM injection of matching placebo on Day 1.
89574001|NCT05220982|Experimental|Conversation Training Therapy|
89574002|NCT05220982|Experimental|Global Voice Prevention and Therapy Model|
89574003|NCT05220982|Experimental|Modified Conversation Training Therapy|
89574004|NCT05220982|Experimental|Modified Global Voice Prevention and Therapy Model|
89574005|NCT05213923|No Intervention|Pre-intervention|Patients presenting to the Emergency Department meeting severe sepsis criteria prior to implementation of an ED Sepsis Tracking Sheet
89574006|NCT05213923|Experimental|Post-intervention|Patients presenting to the Emergency Department meeting severe sepsis criteria following implementation of an ED Sepsis Tracking Sheet
89574007|NCT05209243|Experimental|Interventional arm|STANDARD OF CARE + SBRT (all metastatic lesions). ADT+ RT to the primary tumor (previously not treated) + Second generation hormonal treatment
89574008|NCT05209243|Active Comparator|Control arm|STANDARD OF CARE. ADT+ RT to the primary tumor (previously not treated) + Second generation hormonal treatment
89574009|NCT05203237|Placebo Comparator|Placebo (Part A)|Placebo administered SC once in healthy participants
89574010|NCT05203237|Experimental|VK2735 (Part A)|Escalating doses of VK2735 administered subcutaneously (SC) once in healthy participants.
89574011|NCT05203237|Placebo Comparator|Placebo (Part B)|Placebo administered SC once weekly for four weeks in healthy participants
89574012|NCT05203237|Experimental|VK2735 (Part B)|Escalating doses of VK2735 administered subcutaneously (SC) once weekly in healthy participants.
89574013|NCT05203237|Placebo Comparator|VK2735 (Part C )|Placebo administered orally daily for 28 days in healthy participants
89574014|NCT05203237|Experimental|VK2735 (Part C)|Escalating doses of VK2735 administered daily (PO) in healthy participants.
89574015|NCT05195931||Preload and Afterload|10 participants with heart failure who are supported by LVADs will undergo hemodynamic monitoring and observation while undergoing changes in preload (head-up tilt and saline infusion), and afterload (nitroprusside and phenylephrine infusion).
89209105|NCT04008303||Patients with migraines|"Patients seen in clinic and assessed with Migraine Headache Diagnostic Criteria to ensure diagnosis.~Patients track the characteristics of migraine headaches for one month before surgery.~After this month, patients receive surgery in the operating room for migraine.~After surgery, patients track the characteristics of migraine headaches for 3 months.~Patients will then be asked to track the characteristics migraine headaches again at 1 year and 2 years and 5 years after surgery. For these time periods, patients only have to keep track of the characteristics for 1 month intervals."
89574016|NCT05195931||Contractility|10 participants with heart failure who are supported by LVADs will undergo hemodynamic monitoring and observation while undergoing changes in contractility with adjustments in heart rate (by adjusting pacemaker), dobutamine infusion, and during exercise.
89574017|NCT05163496|Experimental|Psilocybin arm|psychedelic assisted psychotherapy + 25mg psilocybin
89574018|NCT05163496|Active Comparator|Placebo|Psychedelic assisted psychotherapy + 250mg niacin
89574019|NCT05150964|Experimental|Experimental|One group will be fit with commercially available hearing aids that will have different program settings
89209106|NCT00806780|No Intervention|1|routine surgery with cholangiography
89209107|NCT00806780|Experimental|2|routine cholangiography
89574020|NCT05135533|Experimental|Portable Neuromodulation Stimulator|
89574021|NCT05135533|Sham Comparator|Sham|
89574022|NCT05114668|Experimental|Stage 1|- Stage 1 (Dose Escalation Cohorts): Stage 1 is a multiple ascending dose escalation of EVT801 in patients with advanced solid tumours to evaluate the safety and tolerability of EVT801 and to determine MTD / RP2D for further investigation.
89574023|NCT05114668|Experimental|Stage 2|- Stage 2 (Biomarker Expansion cohorts): A biomarker expansion cohort, in which all subjects will receive EVT801 at the MTD / RP2D, will be recruited to explore pharmacodynamic outcomes and further elucidate tolerability, activity, and pharmacokinetics.
89574024|NCT05112432|Active Comparator|Treatment as Usual|Participants will be treated as usual and will not complete cognitive training or use the Personalized Real-Time Motivational Enhancement App. Participants may choose to complete study activities in person at their coordinated specialty care program or may choose to complete study activities remotely.
89574025|NCT05112432|Experimental|Cognitive Training plus Personalized Real-Time Intervention for Motivational Enhancement App (PRIME)|The Mobile Intervention. 20 hours of training consisting of 10 hours of cognitive training exercises plus 10 hours of social cognitive training exercises will be delivered over the course of 12 weeks in addition to PRIME. Participants may choose to complete study activities in person at their coordinated specialty care program or may choose to complete study activities remotely.
89574026|NCT05107960||Azilsartan|Azilsartan tablets or granules formulation, orally once daily. For children aged 6 years or older, the usual initial oral dosage of azilsartan is 2.5 mg and 5 mg once daily for those weighing <50 kg and >=50 kg, respectively.
89574027|NCT05091255|Experimental|Patients|
89574028|NCT05085756|Active Comparator|Guided treatment|8-week transdiagnostic CBT with written guidance from M.Sc-level students under supervision.
89574029|NCT05085756|Active Comparator|Unguided treatment|8-week transdiagnostic CBT without guidance.
89574030|NCT05085756|Other|Waitlist|8-week transdiagnostic CBT without guidance, made available 6 months after recruitment.
89574031|NCT05013190||Participants With Multiple Myeloma (MM)|Participants diagnosed with MM (Newly Diagnosed Multiple Myeloma [NDMM]) using IMWG criteria and received a bortezomib-based triple-drug regimens for more than 2 cycles as initial therapy will be treated with ixazomib based regimens strictly following NINLARO® label will be observed prospectively for 24 months.
89574032|NCT04968210||Pulmonary arterial hypertension (PAH)|Patients that have been clinically diagnosed with pulmonary arterial hypertension and fall under the category of WHO group 1 PAH.
89574033|NCT04952402|Experimental|Cohort: ACTIV-2/A5401|Participants of the ACTIV-2/A5401 randomized trial who received a select investigational (active) therapy (AZD7442 IM or IV, BRII-196 + BRII 198 IV, SAB 185 (3,840 or 10,240 units/kg) IV, BMS 096414+BMS 986413 subcutaneous, Camostat Oral) or its corresponding comparator (Placebo).
89574034|NCT04952402|Experimental|Cohort: COVID-19 Naïve|Participants without known history of prior SARS-CoV-2 infection defined as no known history of any SARS-CoV-2 positive test (non-ACTIV-2/A5401 participants).
89574035|NCT04941144||COVID-19 Vaccine Intramuscular Injection 0.5 milliliters (mL)|COVID-19 vaccine intramuscular injection, 2 doses of 0.5 mL per dose administered intramuscularly at an interval of 4 weeks.
89574036|NCT04938895|Experimental|Black Woman Investigator|Survey respondents are exposed to a Black woman investigator.
89574037|NCT04938895|Experimental|Black Man Investigator|Survey respondents are exposed to a Black man investigator.
89574038|NCT04938895|Experimental|White Woman Investigator|Survey respondents are exposed to a white woman investigator.
89574039|NCT04938895|Experimental|White Man Investigator|Survey respondents are exposed to a white man investigator.
89574040|NCT04930055||Group 1|Patients with solid tumors receiving courses of cytotoxic therapy.
89574041|NCT04930055||Group 2|Patients with hematological cancers receiving courses of cytotoxic chemotherapy.
89574042|NCT04930055||Group 3|Patients with solid tumors receiving TKIs or other targeted therapies, but not cytotoxic regimens within 3 months
89574043|NCT04930055||Group 4|Patients with hematologic cancers receiving TKIs or other targeted therapies, but not cytotoxic regimens within 3 months
89574044|NCT04930055||Group 5|Patients receiving immune checkpoint inhibitors.
89574045|NCT04930055||Group 6|Patients who underwent allogeneic stem cell transplant within 12 months.
89574046|NCT04930055||Group 7|Patients who underwent cellular therapy, including CAR-T cells or T cells with engineered TCRs within 12 months.
89574047|NCT04930055||Group 8|Patients in remission who have received cellular therapy more than 12 months in the past, including allogeneic, autologous or engineered cellular approaches
89574048|NCT04930055||Group 9|Patients with cancer in remission for at least 2 years not receiving active cytotoxic cancer chemotherapy (hormonal therapy is permitted).
89574049|NCT04930055||Group 10|Patients who have undergone allogenic bone marrow transplant and are currently receiving immunosuppressants
89574050|NCT04930055||Group 11|Patients who have undergone allogenic bone marrow transplant who are not currently receiving immunosuppressants
89029080|NCT04611854|Active Comparator|ICBT for alcohol misuse: Guidance|In this arm, participants will receive the 8-week internet-delivered cognitive behaviour therapy (ICBT) course for alcohol misuse with guidance from a health educator through regular weekly online messages. Participants may also be contacted through emails and phone calls. The team of guides consists of registered social workers, psychologists, and graduate students, with experience delivering ICBT.
89029081|NCT04611854|Experimental|ICBT for alcohol misuse: Self-Guidance|Participants who select this arm will receive the 8-week internet-delivered cognitive behaviour therapy (ICBT) course for alcohol misuse. Participants are able to contact the Online Therapy Unit regarding any technical issues with logging onto the site. However, no guidance from a health educator will be provided. Clients will be monitored by providing brief measures on alcohol each week and measures of depression and anxiety administered at the beginning of week 5. However, clients will only be contacted if there is a significant clinical issue requiring attention (e.g., sudden increase in symptoms of depression and suicidal ideation).
89574051|NCT04930055||Group 12|Patients who have a cancer diagnosis but do not fall into group 1-11
89574052|NCT04890535|Active Comparator|Single Ascending Dose 25 - 800 mg|single dose of TBAJ-587
89574053|NCT04890535|Placebo Comparator|Single Ascending Dose 25 - 800 mg placebo|single dose of placebo
89574054|NCT04890535|Active Comparator|Multiple Ascending Dose 50 - 200 mg|28 days dose of TBAJ-587
89574055|NCT04890535|Placebo Comparator|Multiple Ascending Dose 50 - 200 mg Placebo|28 days dose of placebo
89574056|NCT04849000|Experimental|SHR-1209|
89574057|NCT04849000|Placebo Comparator|SHR-1209 Placebo|
89574058|NCT04843319|Experimental|VERU-100 at various doses|2 ml, 2.5 ml, 3 ml, 3.5 ml of VERU-100
89574059|NCT04842045|Experimental|Single Arm|Medically and psychiatrically healthy adults ages 21 to 65 years will receive a single 25 mg dose of psilocybin combined with repeated boluses of midazolam administered in a clinically supportive setting.
89574060|NCT04839302||Patients with possible nectrotizing fascitis|Patients with clinical suspicion of necrotizing fasciitis would receive a weight-appropriate IV dose of indocyanine green (ICG, FDA-approved) with immediate fluorescence imaging of the affected body part and simultaneous imaging of an unaffected region
89574061|NCT04810650|Experimental|PREP/PEP at Outpatient Clinics Dynamic Prevention Intervention|
89574062|NCT04810650|Active Comparator|PREP/PEP at Outpatient Clinics Control|
89574063|NCT04810650|Experimental|PREP/PEP at Antenatal Clinics Dynamic Prevention Intervention|
89574064|NCT04810650|Active Comparator|PREP/PEP at Antenatal Clinics Control|
89574065|NCT04810650|Experimental|PREP/PEP at Community Households Dynamic Prevention Intervention|
89574066|NCT04810650|Active Comparator|PREP/PEP at Community Households Control|
89574067|NCT04810650|Experimental|Mobility Dynamic Treatment Intervention|
89574068|NCT04810650|Active Comparator|Mobility Control|
89574069|NCT04810650|Experimental|Healthy Living for Heavy Alcohol Users Intervention|
89574070|NCT04810650|Active Comparator|Heavy Alcohol Users Control|
89574071|NCT04810650|Experimental|Hypertension Linkage Intervention|
89574072|NCT04810650|Active Comparator|Hypertension Linkage Control|
89574073|NCT04810650|Experimental|Hypertension Community Intervention|
89574074|NCT04810650|Active Comparator|Hypertension Community Control|
89574075|NCT04795895|Experimental|ultrasonography (US)|
89574076|NCT04795895|Active Comparator|Standard routine (SR)|
89574077|NCT04780815|Experimental|myBluTM Formulation 1 Oral cavity and lungs|This group was used for measuring oral cavity and lungs endpoints after administration of Formulation 1
89574078|NCT04780815|Experimental|myBluTM Formulation 2 Oral cavity and lungs|This group was used for measuring oral cavity and lungs endpoints after administration of Formulation 2
89574079|NCT04780815|Experimental|myBluTM Formulation 1 Brain|This group was used for measuring brain endpoints after administration of Formulation 1
89574080|NCT04780815|Experimental|myBluTM Formulation 2 Brain|This group was used for measuring brain endpoints after administration of Formulation 2
89574081|NCT04754945|Experimental|Treatment (isatuximab, chemotherapy)|"All patients will receive Isatuximab plus dexamethasone 4 mg PO/IV days weekly. Based on tolerance, patients will add to their treatment subcutaneous Velcade (earliest time to add Velcade is cycle 1 day 15) and intravenous cyclophosphamide (earliest time to add cyclophosphamide is cycle 4 day 1)~Patients then receive dexamethasone and isatuximab as maintenance treatment twice per month for 12 months in the absence of disease progression or unacceptable toxicity."
89574082|NCT04754776|Experimental|Low dose|5 x 10^9 vp ChAdOx1 RVF delivered intramuscularly
89574083|NCT04754776|Experimental|Medium dose|2.5 x 10^10 vp ChAdOx1 RVF delivered intramuscularly
89574084|NCT04754776|Experimental|High dose|5 x 10^10 vp ChAdOx1 RVF delivered intramuscularly
89574085|NCT04728841|Experimental|Treatment group|Arm of GS001
89574086|NCT04723667|Experimental|Intervention|13-week multimodal intervention
89574087|NCT04723667|Active Comparator|Active control|5-week health education programme
89574088|NCT04702178|Experimental|Group A-2|COVAC-2 25 µg: 8 healthy adults 18 to 54 years of age receive the vaccine on Day 0, followed by a second dose on Day 28.
89574089|NCT04702178|Placebo Comparator|Group B-2|Placebo Control: 4 healthy adults 18 to 54 years of age receive a dose of normal saline (placebo) on Day 0, followed by a dose of normal saline (placebo) on Day 28.
89574090|NCT04702178|Experimental|Group C-2|COVAC-2 50 µg: 8 healthy adults 18 to 54 years of age receive the vaccine on Day 0, followed by a second dose on Day 28.
89574091|NCT04702178|Placebo Comparator|Group D-2|Placebo Control: 4 healthy adults 18 to 54 years of age receive a dose of normal saline (placebo) on Day 0, followed by a dose of saline placebo on Day 28.
89029082|NCT04602611|No Intervention|Standard of Care|Standard of Care
89029083|NCT04602611|Experimental|Oncology Nurse Navigation|Standard of Care + Oncology Nurse Navigation
89029084|NCT04596267|Experimental|Pitolisant|Subjects will take an 8.9 mg dose (two 4.45 mg pills) of pitolisant once per day on day 1 through 4. On day 5, 8.9 mg will be taken in front of staff prior to an alcohol self administration trial.
89029085|NCT04596267|Placebo Comparator|Placebo|Subjects will take an placebo once per day on day 1 through 4. On day 5, a placebo will be taken in front of staff prior to an alcohol self administration trial.
89029086|NCT04557878|Experimental|Hypertonic Dextrose Solution|
89029087|NCT04557878|Active Comparator|Liquid Phase Concentrated Growth Factor (LPCGFs)|
89029088|NCT04517266|Experimental|experimental group|whole breast/chest wall irradiation + SVC irradiation
89029089|NCT04517266|Active Comparator|controlled group|whole breast/chest wall irradiation + IMI+SVC irradiation
89029090|NCT04513912|Experimental|Seltorexant|Adult participants will receive seltorexant once daily from Day 1-7 and together with matching placebo from Day 8 till Day 182. Elderly participants will receive seltorexant once daily from Day 1-3 and together with matching placebo from Day 4 till Day 182.
89033207|NCT05319704|Placebo Comparator|Test of effort, sub-maximal, progressive, carried out in concentric mode|The exercise will start at 10% of VO2max. However, every six minutes, the level of VO2max will be increased by 10%, up to 50%.
89209108|NCT02592239|Experimental|Patients|Functional dyspepsia patients will be studied using functional brain MRI before and after receiving a test meal. Cognitive and hedonic response will be evaluated using 10 score scales.
89574092|NCT04702178|Experimental|Group E-2|COVAC-2 100 µg: 8 healthy adults 18 to 54 years of age receive the vaccine on Day 0, followed by a second dose on Day 28.
89574093|NCT04702178|Placebo Comparator|Group F-2|Placebo Control: 4 healthy adults 18 to 54 years of age receive a dose of normal saline (placebo) on Day 0, followed by a dose of saline placebo on Day 28.
89574094|NCT04702178|Experimental|Group G-2|COVAC-2 25 µg: 8 or 9 healthy adults ≥ 55 years of age receive the vaccine on Day 0, followed by a second dose on Day 28.
89574095|NCT04702178|Placebo Comparator|Group H-2|Placebo Control: 4 or 5 healthy adults ≥ 55 years of age receive a dose of normal saline (placebo) on Day 0, followed by a dose of normal saline (placebo) on Day 28.
89574096|NCT04702178|Experimental|Group I-2|COVAC-2 50 µg: 8 healthy adults ≥ 55 years of age receive the vaccine on Day 0, followed by a second dose on Day 28.
89574097|NCT04702178|Placebo Comparator|Group J-2|Placebo Control: 4 healthy adults ≥ 55 years of age receive a dose of normal saline (placebo) on Day 0, followed by a dose of saline placebo on Day 28.
89574098|NCT04698967|Experimental|CCD-V Group|Veterans in this arm will receive treatment as usual, which is transitional work experience intervention, as well as the CCD-V intervention
89574099|NCT04698967|Active Comparator|Treatment as Usual|Veterans in this arm will receive treatment as usual, which is transitional work experience intervention.
89574100|NCT04588740|Active Comparator|Dietary nitrate|The active treatment, beetroot juice (BEET IT, James White Drinks, Ipswich, UK), contains 6.2mmol of inorganic nitrate. Participants will continue supplementation until they complete all testing visits.
89574101|NCT04588740|Placebo Comparator|Placebo|The placebo beet root juice is made by the same company (BEET IT, James White Drinks, Ipswich, UK) and contains no inorganic nitrate.
89574102|NCT04580498|Experimental|Treatment group A|SHR-1701+Paclitaxel+carboplatin
89574103|NCT04580498|Experimental|Treatment group B|SHR-1701
89574104|NCT04574843|Experimental|Embolization arm|Intervention: Embolization of middle meningeal artery Device: Onyx, squid, Phil
89574105|NCT04560075|Experimental|Text2Connect|Participants receiving Text2Connect (T2C) personalized messages will receive a monthly check-in text prompt. Based on their response, the participants then receive either general psychoeducational videos and prompts to continue to monitor mental health or are then prompted to endorse stressors and symptoms they are experiencing to prompt awareness of treatment targets in daily life.
89574106|NCT04560075|Active Comparator|Psychoeducational Videos (PE) Only|Participants will receive a web link to a library of 4 PE videos. These brief 2-minute videos include general information about self-care during college.
89574107|NCT04544462||Infertile patients|Patients attending an IVF center for infertility treatment
89574108|NCT04523337|Experimental|MISSION-CJ|Maintaining Independence and Sobriety through Systems Integration Outreach and Networking- Criminal Justice version (MISSION-CJ) programming targets co-occurring substance use and mental health disorders and other related health outcomes faced by justice-involved homeless Veterans through assertive outreach, psychoeducation, and linkages to community-based services.
89574109|NCT04523337|Experimental|Enhanced Usual Care|Usual care provided by the mental health residential rehabilitation treatment programs, with patients in both groups are enrolled in, in addition to peer support and community outreach case management. Patients receive 2 Peer Support Curriculum sessions per week (24 sessions total). Patients will receive unstructured community outreach and linkage support while enrolled in the mental health residential rehabilitation program. After discharge, patients will continue to receive 1 hour of weekly linkage support per week.
89574110|NCT04483414|Experimental|Patients with suspected BCR or metastatic prostate cancer|Patients with suspected BCR or metastatic prostate cancer
89574111|NCT04469569|Other|Delayed Intervention|Sites randomized to the Delayed Intervention Arm (Sites A, B, C) will be assigned to the control condition in Years 1 and 2, to the HPV-PROTECT intervention in Year 3, and to the sustainability condition in Year 4
89574112|NCT04469569|Other|Early Intervention|Sites randomized to the Early Intervention Arm (Sites D, E, F) will be assigned to the control condition in Year 1, to the HPV-PROTECT intervention in Year 2, and to the sustainability condition in Years 3 and 4
89574113|NCT04428385|No Intervention|Arm 1 (control)|RDTs available at study-recommended price, providers trained on mobile reporting app
89574114|NCT04428385|Experimental|Arm 2 (consumer-directed and provider-directed intervention)|providers receive a small payment for each RDT that they perform and consumers with a positive test are eligible for a subsidy on a quality-assured ACT, RDTs are available at study recommended price
89574115|NCT04378010|Experimental|EDP-305 1.5 mg|Once a day orally for 72 weeks
89574116|NCT04378010|Experimental|EDP-305 2 mg|Once a day orally for 72 weeks
89574117|NCT04378010|Placebo Comparator|Placebo|Once a day orally for 72 weeks
89574118|NCT04365114||Single reading|Only one clinician examined the woman's mammograms for signs of cancer and recommended whether to recall her for further tests or not.
89574119|NCT04365114||Double reading|Two clinicians examined the woman's mammograms for signs of cancer and recommended whether to recall her for further tests or not.
89574120|NCT04361006|Active Comparator|Radiofrequency (RF)|Twenty patients will be allocated to this group, which will be treated using radiofrequency (RF) ablation technique.
89574121|NCT04361006|Active Comparator|Cryotherapy (CRYO)|Twenty patients will be allocated to this group, which will be treated using Cryotherapy (CRYO) ablation technique.
89574122|NCT04349072|Experimental|Drug: Mavacamten|"Mavacamten Capsules~Other names:~MYK-461"
89574123|NCT04349072|Placebo Comparator|Drug: Placebo|Matching Placebo Capsules
89574124|NCT04319354|Experimental|pCR|
89574125|NCT04319354|Experimental|Partial responders|
89574126|NCT04319354|Active Comparator|Non-responders|
89574127|NCT04313868|Experimental|Phase 1A.1: Peripheral IV|GEN2 is administered in repeating three week cycles. On week one, GEN2 is given intravenously on three consecutive days and the presence of the HSV-TK-m2 expression is monitored by [18F]FHBG PET scanning after 3 to 8 days. Valganciclovir dosing is initiated on day 7 to 9 for 5 days. An approximately one week drug holiday follows.
89574128|NCT04313868|Experimental|Phase IA.2: Hepatic Artery Infusion|GEN2 is administered in repeating three week cycles. On week one, GEN2 is given as a single hepatic artery infusion (HAI) on two successive days and the presence of the HSV-TK-m2 expression is monitored by [18F]FHBG PET scanning after 3 to 8 days. Valganciclovir dosing is initiated on day 7 to 9 for 5 days. An approximately one week drug holiday follows.
89574129|NCT04313868|Experimental|Phase IA.3: Intratumoral Injection|GEN2 is administered in repeating three week cycles. On week one, GEN2 is given via injection directly into the tumor lesions on one day and the presence of the HSV-TK-m2 expression is monitored by [18F]FHBG PET scanning after 3 to 8 days. Valganciclovir dosing is initiated on day 7 to 9 for 5 days. An approximately one week drug holiday follows.
89574130|NCT04312191|No Intervention|Control Group|The Control Group participants (Group A) will be initiating radiation therapy and receiving only standard of care therapy per their Radiation Oncologist.
89574131|NCT04312191|Experimental|Test Group|The Test Group participants (Group B) will be initiating radiation therapy and receiving standard of care therapy per their Radiation Oncologist. This group will also be taught mantra-based meditation to use during each radiation treatment session and encouraged to practice MM ad libitum outside of the treatment setting.
89574132|NCT04304729||Diabetics|Girls and boys aged 14-18 years old, living with Type 1 Diabetes.
89574133|NCT04304729||Control|Age and sex matched adolescents without any type of diabetes
89574134|NCT04277559|Active Comparator|Patient preferential music|The preference of the patients will be listened to preoperatively through the headphones.
89574135|NCT04277559|Active Comparator|Classical music|Classical music (Four Seasons from Vivaldi) will be listened to preoperatively through the headphones.
89574136|NCT04277559|Placebo Comparator|No music|the patients will not listen.
89574137|NCT04275700|Experimental|A-PRP|The cortex of each ovary will be injected with autologous platelet rich plasma.
89574138|NCT04242277||WF-OCT imaging of excised breast lumpectomy tissue|Excised lumpectomy tissue from all consented patients will be imaged on an investigational OCT-based device. No clinical decisions will be made based on the images acquired.
89574139|NCT04240886|Experimental|Cohort A: fosmanogepix (APX001)|
89574140|NCT04240886|Experimental|Cohort B: fosmanogepix (APX001)|
89574141|NCT04240665|Experimental|DMN Intervention|Subjects will attend 2-hour weekly sessions for 6- weeks. Participants will continue to use the DMN application for 4-weeks after the intervention is complete.
89574142|NCT04223154|Experimental|Real TBS to the dlPFC|One session of real intermittent Theta Burst Stimulation (TBS) will be delivered to the left dorsolateral prefrontal cortex (dlPFC)
89574143|NCT04223154|Sham Comparator|Sham TBS to the dlPFC|One session of sham Theta Burst Stimulation (TBS) will be delivered to the left dorsolateral prefrontal cortex (dlPFC)
89574144|NCT04173065|Placebo Comparator|Placebo|
89574145|NCT04173065|Experimental|1.0 mg|
89574146|NCT04173065|Experimental|2.5mg|
89574147|NCT04173065|Experimental|5.0 mg|
88970970|NCT02965612|Experimental|ITS with Injex|For Each patient, at each monthly vaccination session and randomly in alternate mode, will be administered two vaccine doses of 0.25 ml each at 20 minutes from one another in the two arms, in an alternating manner via Injex and via subcutaneous.
88970971|NCT02965612|Active Comparator|SCIT: ITS via subcutaneous|For Each patient, at each monthly vaccination session and randomly in alternate mode, will be administered two vaccine doses of 0.25 ml each at 20 minutes from one another in the two arms, in an alternating manner via Injex and via subcutaneous.
88970972|NCT00392730||1|Preterm infants in NICU and age-matched controls
88970973|NCT00392730||2|Term infants in NICU and age-matched controls
88970974|NCT00392730||3|Children on home PN (to age 6) and age-matched controls
88970975|NCT00075868|Experimental|Sandostatin LAR® Depot|Sandostatin LAR® Depot Pre-RT (between day -7 and day -4 of RT) and Day 22 (± 3 days)
88970976|NCT00075868|Placebo Comparator|Placebo|Placebo Pre-RT (between day -7 and day -4 of RT) and Day 22 (± 3 days)
88970977|NCT03958422|Experimental|Myocardin test group|Patients in cardiomyopeptidin group are given the injection of cardiomyopeptidinl before primary percutaneous coronary intervention (PCI) and intravenous infusion of cardiomyopeptidin was performed 3 days after primary PCI.
88970978|NCT03958422|No Intervention|Blank test group|Patients in blank test group aren't given the injection of cardiomyopeptidinl before primary percutaneous coronary intervention (PCI) .
88970979|NCT00076063|Experimental|A|Participants in Groups A will receive four injections over 6 months of either LIPO-5 or a placebo.
88970980|NCT00076063|Experimental|B|Participants in Group B will receive four injections over 6 months of either the ALVAC-HIV (vCP1452) or a placebo.
88970981|NCT00076063|Experimental|C|Participants in Groups C will receive six injections over 6 months. Participants in this group will receive either ALVAC-HIV (vCP1452) and LIPO-5 or a placebo. Participants who receive the vaccine combination will receive four injections of the same dose of ALVAC-HIV (vCP1452) and two injections of LIPO-5. The dose of LIPO-5 will be different for participants in Groups C, D, and E.
88970982|NCT00076063|Experimental|D|Participants in Group D will receive six injections over 6 months. Participants in this group will receive either ALVAC-HIV (vCP1452) and LIPO-5 or a placebo. Participants who receive the vaccine combination will receive four injections of the same dose of ALVAC-HIV (vCP1452) and two injections of LIPO-5. The dose of LIPO-5 will be different for participants in Groups C, D, and E.
88970983|NCT00076063|Experimental|E|Participants in Group E will receive six injections over 6 months. Participants in this group will receive either ALVAC-HIV (vCP1452) and LIPO-5 or a placebo. Participants who receive the vaccine combination will receive four injections of the same dose of ALVAC-HIV (vCP1452) and two injections of LIPO-5. The dose of LIPO-5 will be different for participants in Groups C, D, and E.
88970984|NCT00076141||Older, Racially Diverse Males|Racially Divers Males over 50, expected to live more than 5 years
88970985|NCT00076180|Experimental|1|One dose of Hu-MiK Beta-1
89209109|NCT02592239|Experimental|Controls|Healthy subjects recruited by public advertisement will be studied using functional brain MRI before and after receiving a test meal. Cognitive and hedonic response will be evaluated using 10 score scales.
89209110|NCT00874146||1|HER2-positive advanced breast cancer
89209111|NCT00982605||non small cell lung cancer|cancer patients
89574148|NCT04173065|Experimental|10 mg|
89574149|NCT04173026|Active Comparator|Provider intervention|A web-based application called ProviderMinder has been developed and will be used to alert providers when a patient who has been lost-to-follow-up or has missed their Sickle Stroke Screen (TCD). This will allow providers to follow up with such patients and improve screening rates.
89574150|NCT04173026|Active Comparator|Provider and Patient level intervention|A web-based application called ProviderMinder has been developed and will be used to alert providers when a patient who has been lost-to-follow-up or has missed their Sickle Stroke Screen (TCD). This will allow providers to follow up with such patients and improve screening rates. Additionally, sites will have a patient intervention of a single Sickle Stroke Screen coordinator who will interact directly with patients to schedule, reschedule, remind, and follow-up on stroke screening. This person will also act as a point of contact for any educational needs the patient may have. The second patient intervention will include the caregivers own mobile device. When Sickle Stroke Screens are scheduled the coordinator will ensure these appointments are directly put into the caregiver's mobile device calendar acting as an additional reminder for stroke screening.
89574151|NCT04099511|Active Comparator|Usual Care Occupational Therapy-Outpatient|
89574152|NCT04099511|Experimental|Cognitive Orientation to daily Occupational Performance|
89574153|NCT04092660|Experimental|Intervention Care Group|"The Intervention care group will receive the Mandibular Advancement Appliance (MAA) or the anti-snoring mouthguard. Additionally, they will also receive special support in the form of behaviour change interventions. The behavior change interventions consist of motivational interviewing, will be shown a video highlighting the negative consequences of sleep apnoea.~Booster calls at week 3,6, 18 and 12 for verbal encouragement and to resolve any technical problems with the device.~Participants will be asked to complete questionnaires regarding their personality, socio-economic status, social support and quality of sleep and life."
89574154|NCT04092660|Active Comparator|Standardized Care Group|"The standardized care group will only receive the Mandibular Advancement Appliance (MAA) or the anti-snoring mouthguard along with routine care and will be called for follow up at 3rd and 6th month of treatment to assess their use and to resolve any technical problems with the device.~Participants will be asked to complete questionnaires regarding their personality, socio-economic status, social support and quality of sleep and life at the initial visit and subsequent follow-up."
89574155|NCT04074161|Experimental|Semaglutide|Semaglutide administered s.c. (subcutaneously, under the skin) adjunct to a reduced-calorie diet and increased physical activity
89574156|NCT04074161|Placebo Comparator|Placebo (semaglutide)|Placebo (semaglutide) administered s.c. adjunct to a reduced-calorie diet and increased physical activity
89574157|NCT04074161|Active Comparator|Liraglutide|Liraglutide administered s.c. adjunct to a reduced-calorie diet and increased physical activity
89574158|NCT04074161|Placebo Comparator|Placebo (liraglutide)|Placebo (liraglutide) administered s.c. adjunct to a reduced-calorie diet and increased physical activity
89574159|NCT04066075|Experimental|Telerehabilitation with low vision provider|
89574160|NCT04066075|Experimental|Telerehabilitation w/ low vision provider plus tele-extender|
89574161|NCT04066075|Active Comparator|Usual Care (active control)|
89574162|NCT04062981|Experimental|Cohort I|"Subjects ≥ 18 years of age~These subjects will reach maximum stable dose and continue onto YKP509C002."
89574163|NCT04062981|Experimental|Cohort II|"Subjects 12 to <18 years of age~These subjects will reach maximum stable dose and continue onto YKP509C002."
89574164|NCT04062981|Experimental|Cohort III|"Subjects 6 to <12 years of age~These subjects will reach maximum stable dose and continue onto YKP509C002."
89574165|NCT04062981|Experimental|Cohort IV|"Subjects 2 to <6 years of age~These subjects will reach maximum stable dose and continue onto YKP509C002."
89574166|NCT04045652||Kenyan women|Kenyan women, some HIV-infected and some HIV-uninfected, VIA negative at enrollment.
89574167|NCT04044456|Experimental|GMT plus attention|GMT consists of 2-hour, 10 weekly sessions using an interactive Power Point presentations. Attention training consists of 2-hour computerized attention training using Attention Process Training III and Brain HQ.
89574168|NCT04044456|Placebo Comparator|BHW plus movies|Brain Health Workshop consists of 2-hour, 10 weekly sessions using Power Point presentations and national geographic movies (2-hour, 10 weekly sessions).
89574169|NCT04006652|Experimental|Recipient|"Will undergo institutionally standard myeloablative or reduced intensity chemotherapy or chemoradiotherapy which will be administered at the discretion of the treating physician~Recipients will undergo a single fresh ApoGraft transplant as per standard clinical site guidelines"
89574170|NCT04006652|No Intervention|Donor|-Donors will undergo apheresis from peripheral blood after daily G-CSF administration (for up to 5 days prior to Day -1)
89574171|NCT03997903|Experimental|Imatinib Intervention|
89574172|NCT03982212|Experimental|Intratumoral Copaxone|Eligible subjects receive at least 1 and up to 3 doses of Copaxone® 40 milligrams (mg) intratumorally prior to standard of care surgery. The doses will be administered at least 48 hours apart. The last dose will be given within 96 hours of standard of care surgery.
89574173|NCT03966157|Experimental|Nasal Bridle|Patients randomized to have nasal bridle.
89574174|NCT03966157|No Intervention|Standard|Patients randomized with adhesive tape.
89574175|NCT03888898|Active Comparator|N95 Filtering Facepiece Respirator|control fit testing
88970986|NCT03958383|Experimental|Experimental Groups|"PHASE IA: As described above. Participants receive hu14.18-IL2 fusion protein intratumorally (IT).~PHASE IB: As described above. Participants undergo palliative RT and hu14.18-IL2 fusion protein IT as in phase IA.~PHASE IC: As described above. Participants undergo palliative RT, receive nivolumab, and hu14.18-IL2 fusion protein IT as in phase IA.~PHASE ID: As described above. Participants undergo palliative RT, receive nivolumab in combination with ipilimumab, and hu14.18-IL2 fusion protein IT as in phase IA."
88970987|NCT04608188|Experimental|Summer Program|Children in the intervention will attend a summer day camp operated at their school.
89574176|NCT03888898|Experimental|Elastomeric Respirator|experimental rapid conversion fit testing and competency evaluations
89574177|NCT03843528|Experimental|Combined therapy|"Patients will be enrolled in blocks of 3, with vorinostat dose-escalation according to 3+3 study design.~Low-dose azacitidine will be administered in a fixed dose to all patients, for days 1-5 of each 28 day cycle."
89574178|NCT03837691|Experimental|g-Cath EZ|Placement of Snowshoe suture anchors from g-Cath EZ Delivery Catheters, in a defined pattern in the mid and distal portions of the stomach, along with a moderate intensity diet & exercise program, to treat primary obesity.
89574179|NCT03837691|No Intervention|Diet and Exercise|A moderate intensity diet & exercise program to treat primary obesity
89574180|NCT03827824|Experimental|Hysteroscopy & Virtual reality glasses|Hysteroscopy with use of virtual reality glasses
89574181|NCT03827824|Active Comparator|Hysteroscopy|Hysteroscopy without use of virtual reality glasses
89574182|NCT03827460|Experimental|Free access alcohol self-administration|During the 2.5-hour free-access self-administration sessions, the participant may choose to complete a task for an alcohol or water reward. Interventions include Abstinence from Alcohol and Usual Drinking
88970988|NCT04608188|No Intervention|No Program|The control children will not receive an intervention of any kind and will be asked to go about their summer as they typically would.
88970989|NCT03958305||LAPAROTOMY|Radical hysterectomy by laparotomy
89574183|NCT03827460|Experimental|Clamped alcohol exposure|A battery of behavioral tasks will be administered to participants before, and at the beginning and end of a 3 hour clamped exposure to alcohol (fixed at 80 mg/dL). EEG will be recorded throughout to assess event related potentials associated with task performance. Interventions include Abstinence from Alcohol and Usual Drinking.
89574184|NCT03827460|Experimental|2 year followup|Participants from both Arm 1 and Arm 2 will be surveyed every 2 months for alcohol consumption for 2 years following the Experimental phase. Interventions include Abstinence from Alcohol and Usual Drinking.
89574185|NCT03779789|Experimental|vortioxetine|
89574186|NCT03779789|Active Comparator|SSRIs|
89574187|NCT03737539||Colorectal cancer|Patients diagnosed with resectable colorectal cancer
89574188|NCT03733210|Experimental|Tumor-negative Lymph Nodes (by 18F-FDG scan)|Participants whose lymph nodes are negative for cancer
89574189|NCT03733210|Experimental|Tumor-positive Lymph Nodes (by 18F-FDG scan)|Participants whose lymph nodes are positive for cancer.
89574190|NCT03667820|Experimental|Osimertinib|Osimertinib in combination with Stereotactic Ablative Radiation (SABR)
89574191|NCT03628846||Traumatically Injured Adolescent|
89574192|NCT03628846||Not Traumatically Injured Adolescent|
89574193|NCT03627468|Experimental|Gel, 5%|Sofpironium Bromide Gel, 5%, applied topically to each axilla once daily for 48 weeks
89574194|NCT03627468|Experimental|Gel, 15%|Sofpironium Bromide Gel, 15%, applied topically to each axilla once daily for 48 weeks
89574195|NCT03595176|Experimental|Coronary Lithotripsy System|All subjects will receive lithotripsy treatment from the Shockwave Medical Coronary IVL System
89029091|NCT04513912|Active Comparator|Quetiapine Extended-Release (XR)|Adult participants will receive quetiapine XR once daily from Day 1-2, followed by an increase in dose from Day 3-7, and from Day 8-14 together with matching placebo. After Day 14, quetiapine XR twice daily from Day 14 till Day 182. Elderly participants will receive quetiapine XR once daily from Day 1-3 and twice from Day 4-7, followed by an increase in dose once daily from Day 8-14 together with matching placebo. After Day 14 till Day 182, quetiapine XR will be adjusted by investigator based on the participant's clinical response and tolerability.
89029092|NCT04510311|Experimental|PET/CT scan with radiotracer [18F]3F-PHPG|Novel radiotracer [18F]3F-PHPG prior to whole-body PET/CT scan.
89029093|NCT04510311|Active Comparator|Planar scintigraphy/SPECT scans with radiotracer [123I]MIBG|FDA approved radiotracer [123I]MIBG prior to whole-body planar scintigraphy and SPECT/CT scan (standard clinical imaging procedures).
89209112|NCT00874224|Active Comparator|1|patients undergoing open left lateral hepatic sectionectomy
89209113|NCT00874224|Active Comparator|2|patients undergoing a laparoscopic left lateral hepatic sectionectomy
89209114|NCT00874224|Active Comparator|3|Prospective registry of patients that cannot be randomized (both open and laparoscopic left lateral hepatic sectionectomy)
89574196|NCT03588039|Experimental|Dose escalation-Arm 1|During the dose escalation period Oraxol will be administered once daily for 2 days per week for 2 weeks followed by 1 week off treatment (2 weeks on and 1 week off). Pembrolizumab will be administered on Day 1 of each 3-week cycle.
89574197|NCT03588039|Experimental|Dose escalation-Arm 2|During the dose escalation period Oraxol will be administered once daily for 3 days per week for 2 weeks followed by 1 week off treatment (2 weeks on and 1 week off). Pembrolizumab will be administered on Day 1 of each 3-week cycle.
89574198|NCT03588039|Experimental|Dose escalation-Arm 3|During the dose escalation period Oraxol will be administered once daily for 4 days per week for 2 weeks followed by 1 week off treatment (2 weeks on and 1 week off). Pembrolizumab will be administered on Day 1 of each 3-week cycle.
89574199|NCT03588039|Experimental|Dose escalation-Arm 4|During the dose escalation period Oraxol will be administered once daily for 5 days per week for 2 weeks followed by 1 week off treatment (2 weeks on and 1 week off). Pembrolizumab will be administered on Day 1 of each 3-week cycle.
89574200|NCT03588039|Experimental|Dose escalation-Arm 5|During the dose escalation period Oraxol will be administered once daily for 5 days per week for 2 weeks followed by 1 week off treatment (2 weeks on and 1 week off). Pembrolizumab will be administered on Day 1 of each 3-week cycle.
89574201|NCT03588039|Experimental|Dose escalation-Arm 6|During the dose escalation period Oraxol will be administered once daily for 5 days per week for 2 weeks followed by 1 week off treatment (2 weeks on and 1 week off). Pembrolizumab will be administered on Day 1 of each 3-week cycle.
89574202|NCT03588039|Experimental|Dose expansion-Gastric/GE|The dose expansion period will enroll subjects with gastric/gastro-esophageal cancer to further evaluate the activity and safety of the study treatment. Oraxol will be administered at the dose determined from part 1 for 2 out of 3 weeks. Pembrolizumab will be administered on Day 1 of each 3-week cycle.
89574203|NCT03588039|Experimental|Dose expansion-NSCLC cancer|The dose expansion period will enroll subjects with NSCLC to further evaluate the activity and safety of the study treatment. Oraxol will be administered at the dose determined from part 1 for 2 out of 3 weeks. Pembrolizumab will be administered on Day 1 of each 3-week cycle.
89574204|NCT03570021|Active Comparator|Group 1|total thyroidectomy with bilateral prophylactic central compartment (level VI) neck dissection as defined by the American Thyroid Association [American Thyroid Association Surgery Working Group, Thyroid 2009]. This is a standard treatment recognized by the French Society of Otolaryngology Head and Neck Surgery [French Society of Otolaryngology Head and Neck Sugery].
89574205|NCT03570021|Experimental|Group 2|total thyroidectomy alone without neck dissection. This is recognized as a standard treatment by the Francophone Association of Endocrine Surgery
89574206|NCT03553004|Experimental|Niraparib Treatment|"Niraparib 300 milligrams (mg) by mouth daily for 28 days (1 cycle = 28 days)~(Dose reduced to 200mg dose for participants whose baseline weight is less than 77 kilograms (kg) [169.756 pounds (lbs)] or baseline platelet count is less than 150,000 microliters (µL))."
88970990|NCT03958305||MINIMALLY INVASIVE SURGERY|Radical hysterectomy by minimally invasive surgery (Laparoscopy or Robotics)
88970991|NCT00399334||001|
88970992|NCT00399373||Quality Improvement Initiative|The initial step in the quality improvement initiative was a letter sent from JHHC Care Management Department to the quality improvement initiative group, inviting them to take advantage of the case management services that are part of their current benefits in the Priority Partners MCO. It is similar to the standard letter sent to PPMCO members who are appropriate for a JHHC disease or case management program. A substance abuse outreach staff initiated telephonic contact with the members in the intervention group. The staff member then refered to substance abuse treatment when possible and appropriate and refered to medical case management.
88970993|NCT00399373||Control group|No additional improvement modalities
89574207|NCT03488667|Experimental|mFOLFOX6 (Leucovorin-Fluorouracil-Oxaliplatin) + Pembrolizumab|"Drug: Pembrolizumab Dose: 200 mg Dose Frequency: Every three weeks (Q3W) Route: Intravenous (IV) infusion~Drug: Oxaliplatin Dose: 85 milligrams per meter squared (mg/m2) Dose Frequency: Every 2 weeks (Q2W) Route: IV infusion~Drug: Leucovorin Dose: 400 mg/m2 Dose Frequency: Q2W Route: IV infusion~Drug: Fluorouracil Dose: 400 mg/m2 Dose Frequency: Q2W Route: IV bolus~Drug: Fluorouracil Dose: 2,400 mg/m2 Dose Frequency: Q2W Route: IV continuous 46-hour infusion~Pembrolizumab will be administered at a fixed dose of 200 mg IV over 30 minutes every 3 weeks. Participants will receive 3 doses of the drug on Days 1, 22, 43 during the neoadjuvant phase of the study, and 12 doses of the drug on Days 1, 22, 43 during the adjuvant phase of the study (total 15 doses). Participants will receive 4 doses of mFOLFOX6 regimen on Days 1, 15, 29, 43 during the neoadjuvant phase of the study, and 4 doses during the adjuvant phase of the study (total 8 doses)."
89574208|NCT03399175|Other|Treatment group|Early high-dose corticosteroid and immunosuppressive therapy
89574209|NCT03317535|Other|Local anesthesia/conscious sedation|Patients will be injected by propofol (adjusted by bispectral index scale ≥70 ) and /or remifentanil（0.01-0.06μg/kg/min）. Patients will maintain spontaneous breathing.
89574210|NCT03317535|Other|General anesthesia|Patients will be induced with remifentanil (0.2-0.8 μg/kg), propofol (1-2mg/kg) and rocuronium (0.6 mg/kg). Anesthesia will then be maintained keep the BIS between 40 and 60 with propofol and remifentanil. After tracheal intubation, patients will be kept with controlled ventilation.
89574211|NCT03313206|Experimental|Cohort A|The cohort A (Pembrolizumab only) will be opened in a first study step. Anti-PD1 antibody will be used (pembrolizumab, Merck®) intravenously at a dose of 200 mg every 3 weeks (4 injections maximum over 12 weeks), monotherapy
89574212|NCT03313206|Experimental|Cohort B|Up to 26 evaluable patients will be treated in the cohort B (Pembrolizumab with Lenvatinib) if they do not have any contraindication for receiving lenvatinib treatment, otherwise they will be treated in the cohort A if slots are available. In the cohort B, the neo-adjuvant anti-PD1 immunotherapy will be combined with orally lenvatinib at a daily dose of 20 mg for 6 weeks started on the day of the first anti-PD1 dose.
89574213|NCT03250377|Experimental|Brivaracetam|Subjects randomized to this arm will receive open-label Brivaracetam
89574214|NCT03107520|Experimental|DDH Surgical Reduction Patients|Infants treated for DDH who failed conservative measures and are undergoing intraoperative open or closed hip reduction. Intraoperative contrast-enhanced ultrasound using Lumason contrast agent will be administered to improve visualization of the epiphyseal vascularity after hip reduction and during placement of the spica cast.
89574215|NCT03052816|Experimental|ICE T|"ICE PACKS applied to the perineum every hour for 20 minutes ATC until discharge.~6 hours from the time of first dose of surgery patients will receive 30mg of IV toradol ATC until discharge.~Once out of the PACU will receive 1 gram of Tylenol every 6 hours for a total of 4 grams daily ATC until discharge~Patients will receive dilaudid 0.2mg IV Q3 hr PRN for breakthrough pain.~Patients will be discharged home with PO Tylenol and PO toradol PRN."
89574216|NCT03052816|Active Comparator|Standard|"Motrin 600mg PO Q4h PRN pain 1-3~Percocet 1 tab PO Q4-6 hours PRN 4-6 pain~Percocet 2 tabs PO Q 7-10 hours PRN 7-10 pain~Patients will receive dilaudid 0.2mg IV Q3 hr PRN for breakthrough pain.~Patients will be discharged home with Motrin and Percocet for pain PRN."
89574217|NCT03029156|Active Comparator|Small volume jet nebulizer|Administration of bronchodilator through small volume jet nebulizer. The nebulized solution contains ipratropium / albuterol.
89574218|NCT03029156|Experimental|Aeroneb nebulizer|Administration of bronchodilator via Aeroneb nebulizer. The nebulized solution contains ipratropium / albuterol.
89574219|NCT02955940|Experimental|Ruxolitinib|Study treatment for participants should be the same as the dosage from the parent study at the time the roll over protocol is initiated. Dose modifications are permitted.
89574220|NCT02955940|Experimental|Ruxolitinib plus background cancer therapy|Study treatment for participants should be the same as the dosage from the parent study at the time the roll over protocol is initiated. Dose modifications are permitted.
89574221|NCT02955940|Experimental|Background cancer therapy alone|Capecitabine and Regorafenib at the same dose provided in the parent study at the time of the rollover.
89574222|NCT02742922|Experimental|Culturally adapted therapy (C-MAP)|Culturally adapted manual assisted (C-MAP) brief problem solving therapy
89574223|NCT02742922|No Intervention|Treatment as usual|This arm will receive no intervention only TAٓU.
88970994|NCT00076453|Experimental|1|Participants will wear lateral wedge orthotic inserts.
88970995|NCT00076453|Active Comparator|2|Participants will wear standard orthotic inserts.
88970996|NCT04607993|Experimental|Prone position ventilation technique|Prone position ventilation for children with congenital heart disease after surgery
88970997|NCT04607993|No Intervention|Control group|conventional postoperative position, no prone position ventilation
88970998|NCT03958227|Experimental|''Manuel Therapy group''|This treatment group will be received Manuel Therapy techniques and exercise interventions.
88970999|NCT03958227|Experimental|''Exercise group''|This treatment group will be received only exercise interventions.
88971000|NCT03958188||Patients|"Patients who have undergone pre-operated computerized tomography (CT) imaging for a subsequently operated Neuro-endocrine tumor (NET).~Clinical data collected for each patients:~Age~Sex~Symptomatology (abdominal pain, diarrhea, carcinoid flush, digestive bleeding, weight loss, occlusive syndrome)~Blood Chromogranine A and urinary 5-hydroxyindoleacetic acid (5-HIAA)~Carcinoid valvulopathy"
88971001|NCT04576949|Placebo Comparator|Placebo + Behavioral Support|one placebo tablet orally (PO) three times daily (TID) plus behavioral support for 12 weeks
88971002|NCT04576949|Experimental|Cytisinicline + Placebo + Behavioral Support|one cytisinicline tablet PO TID plus behavioral support for 6 weeks followed by one placebo tablet PO TID plus behavioral support for 6 weeks
89574224|NCT02702596|Experimental|MBIC + DEF|Measurement-Based Integrated Care with Depression Education Fotonovela
89574225|NCT02702596|Experimental|MBIC + SE|Measurement-Based Integrated Care + Standard Education
89574226|NCT02682238|Experimental|BBI-4000, 15%|15% BBI-4000 (sofpironium bromide) topical gel
89574227|NCT02682238|Placebo Comparator|Vehicle|Vehicle (placebo) gel
89574228|NCT02674711|Experimental|Educational Video|Evidence-based video: Best Advice for People Taking Opioid Medication
89574229|NCT02674711|No Intervention|Usual Care|Usual care education provided at time of pre-operative appointment.
89574230|NCT02606201|Experimental|IPSMA|Injection Peri Sphincter Myofibers Autologous
89574231|NCT02577978|Other|Medacta Sphere|Ball-and-socket
89574232|NCT02577978|Other|Medacta PS|Cam-and-post
89574233|NCT02564705||anterior cohort|Anterior Lumbar Interbody Fusion (ALIF)
89574234|NCT02564705||posterior cohort|"Posterolateral Fusion (PLF)~Posterior Lumbar Interbody Fusion (PLIF)~Transforaminal Lumbar Interbody Fusion (TLIF)"
89574235|NCT02539771|Other|Nocturnal VOC|
89574236|NCT02539771|Other|Diurnal VOC|
89574237|NCT02539771|Other|Slightly symptomatic|
89574238|NCT02393625|Experimental|Dose Escalation|
89574239|NCT02393625|Experimental|Dose Expansion|
89574240|NCT02294032||Kidney Transplant|Patients who are about to undergo a kidney transplant and are on immunosuppressive agents.
89574241|NCT02168829|Active Comparator|Rivaroxaban|Rivaroxaban 15 mg daily
89574242|NCT02168829|Active Comparator|Acetylsalicylic acid (ASA)|ASA 75-160 mg daily (if intolerant to ASA, no antiplatelet therapy will be prescribed)
89574243|NCT01732120|Experimental|Off-clamp partial nephrectomy|Partial nephrectomy will be performed without clamping of the renal blood vessels.
89574244|NCT01732120|No Intervention|Traditional partial nephrectomy|Partial nephrectomy will be performed with clamping of the renal blood vessels.
89574245|NCT01719562|Experimental|ADDENDUM: Physical Activity Intervention|Participants will be offered one to two training sessions per week at onsite rehab facilities and 1-2 sessions per week at home consisting of slow 15 minute aerobic warm-up followed by 20 minutes of strength training, 15 minutes of progressive intensity aerobic exercise and 10 minute cool down.
88971003|NCT04576949|Experimental|Cytisinicline + Behavioral Support|one cytisinicline tablet PO TID plus behavioral support for 12 weeks
88971004|NCT02958436|Experimental|Cohort 1|Dose regimen 1 of REGN3500 (IV) versus placebo
88971005|NCT02958436|Experimental|Cohort 2|Dose regimen 2 of REGN3500 (IV) versus placebo
88971006|NCT02958436|Experimental|Cohort 3|Dose regimen 3 of REGN3500 (IV) versus placebo
88971007|NCT02958436|Experimental|Cohort 4|Dose regimen 4 of REGN3500 (SC) versus placebo
88971008|NCT02958436|Experimental|Cohort 5|Dose regimen 5 of REGN3500 (IV) versus placebo
88971009|NCT04572074|Active Comparator|Arm 1 (Guided imagery)|10 minutes of guided imagery experience
88971010|NCT04572074|Experimental|Arm 2 (Virtual reality)|10 minutes of virtual reality experience
88971011|NCT03951207|Experimental|Rosuampin 10/5mg|Rosuvastatin 10mg/Amlodipine 5mg qd for 8 weeks
88971012|NCT03951207|Experimental|Rosuampin 20/5mg|Rosuvastatin 20mg/Amlodipine 5mg qd for 8 weeks
89574246|NCT01719562|Experimental|ADDENDUM: Healthy Living Instruction Group (Control Arm)|Organized various health workshops lasting for 60 minutes to match the number of visits to the rehab centers for participants in Arm 1 with 2 sessions offered per month onsite and remaining sessions offered over the phone for 6 months. .
89574247|NCT01719562|Experimental|MRI (Diagnostic)|Patients undergo MRI scans for LV function, T1 myocardial signal, and aortic PWV at baseline, 3 months, and 24 months.
89574248|NCT01700439|Experimental|EDWARDS INTUITY valve|All subjects enrolled into the study are implanted with the EDWARDS INTUITY Valve System.
89574249|NCT01647698|Experimental|Early training group|The early training group will consist of 10 randomly assigned participants who will begin the adaptive working memory training task immediately after baseline assessment. They will continue training on the adaptive working memory training task for 5 weeks, after which they will continue for 5 weeks using a non-adaptive working memory task (active control task).
89574250|NCT01647698|Experimental|Late training group|The late training group will consist of 10 randomly assigned participants who will engage in a non-adaptive working memory training task (i.e. an active control task) immediately after baseline assessment for 5 weeks. After the initial 5 weeks of the active control task they will then switch to the adaptive working memory task (the intervention) for 5 weeks. This is a randomized controlled cross-over design.
89574251|NCT01647698|Placebo Comparator|No training group|The no training group will engage in no training over the course of the pilot study, but will still participate in baseline, 5 week, 10 . This will allow us to determine if changes in the outcome and assessment variables are due to the working memory training or progression in the disease itself.
89574252|NCT01433289|Experimental|Polyphenon E 1600 mg/day|Drug: Polyphenon E Polyphenon E capsules containing 200 mg of epigallocatechin-gallate. Four capsules twice a day.
89574253|NCT01433289|Experimental|Polyphenon E 2400 mg/day|Drug: Polyphenon E Polyphenon E capsules containing 200 mg of epigallocatechin-gallate. Six capsules twice a day.
89574254|NCT01433289|Experimental|Polyphenon E 3200 mg/day|Drug: Polyphenon E Polyphenon E capsules containing 200 mg of epigallocatechin-gallate. Eight capsules twice a day.
89574255|NCT01433289|Placebo Comparator|Placebo|
89574256|NCT01381029||HIV positive|HIV positive, receiving Influenza vaccine as standard of care.
89574257|NCT01345552|Other|SBRT|
89574258|NCT00995475|Experimental|Inhaled corticosteroid, Then placebo|FP 250μg per actuation pMDI one puff twice daily (total daily dose 500μg) for two weeks then FP 250μg per actuation pMDI four puffs twice daily (total daily dose 2000μg) for two weeks. After a washout period of 2 weeks, they then received FP matched placebo pMDI one puff twice daily for two weeks then FP four puffs twice daily for two weeks.
89574259|NCT00995475|Placebo Comparator|Placebo control, Then inhaled corticosteroid|FP matched placebo pMDI one puff twice daily for two weeks then FP four puffs twice daily for two weeks. After a washout period of 2 weeks, they then received FP 250μg per actuation pMDI one puff twice daily (total daily dose 500μg) for two weeks then FP 250μg per actuation pMDI four puffs twice daily (total daily dose 2000μg) for two weeks.
89574260|NCT00945529|No Intervention|No Intervention/ historical control group|historical controls group of patients who did not receive iNO.
89574261|NCT00945529|Experimental|Intervention|Prospective group who received iNO.
89574262|NCT00921115|Experimental|Arimidex + Faslodex|"Patients will have an Oncotype Dx performed and if the RS is <25, they will receive Anastrazole and Fulvestrant for 16 weeks.~On day 28, subjects will be evaluated for side effects and a needle core biopsy (optional) will be obtained. Response evaluation will occur every 28 days. All treatment will continue for 4 months followed by breast surgery. After surgery, patients will be off study and will receive additional breast cancer therapy per their treating physician. Patients who develop progressive disease on protocol will be removed from the study and treated by their treating physician. The protocol will be closed after the last accrued patient has had surgery."
89574263|NCT00891085||Open Lung Ventilation|within 24 hours of arrival trauma patients with ISS >25 will be randomized to BiVent (APRV)
89574264|NCT00891085||SIMV|within 24 hours of arrival trauma patients with ISS >25 will be randomized to either SIMV or BiVent
89574265|NCT00642213||ischemic stroke sample with DNA|We prospectively collected 450(1999), 502(2005), and 512(2010) ischemic stroke patients who agreed to participate and also most provided a sample for DNA. The cohort data consists of a baseline interview, medical record abstraction and various timeframes of followup interviews from 3 months to 3 years. See website (www.gcnkss.com for data forms)
89574266|NCT00642213||stroke data from medical record review|The second part of the study is a retrospective medical record review of all potential ischemic strokes, TIAs, and Hemorrhagic strokes in our 5 county region that occurred in all study years.
89574267|NCT04130893|Experimental|A stimulation of G13 then G15|The first session is similar between the two arms: Cold water hand immersion only At the Second session: Cold water hand immersion + G13 auricular stimulation At the Third session: Cold water hand immersion + G15 auricular stimulation
89574268|NCT04130893|Experimental|B: stimulation of G15 then G13|The first session is similar between the two arms: Cold water hand immersion only At the Second session: Cold water hand immersion + G15 auricular stimulation At the Third session: Cold water hand immersion + G13 auricular stimulation
89574269|NCT03906565|Experimental|utidelone|Utidelone Injection: 40 mg/m2/day, IV transfusing over 90 min. on day 1-day 5 of each 21 day cycle, administered to enrolled patients with advanced or metastatic CRC
89574270|NCT05534659||Programmable valve(PV) group|Adult patients with hydrocephalus who received programmable ventricular CSF shunts operation.
89574271|NCT05534659||Non-programmable valve(NPV) group|Adult patients with hydrocephalus who received non-programmable ventricular CSF shunts operation.
89574272|NCT05530681|Experimental|Participants|
89574273|NCT05530525||Test-retest reliability and responsiveness group (All of the data was collected from medical record)|All the participants received conventional rehabilitation (e.g., occupational therapy, physical therapy, or speech therapy) or other interventions (e.g., acupuncture).
89574274|NCT04425187|Active Comparator|gefitinib|
89574275|NCT04425187|Experimental|gefitinib&bevacizumab|
89574276|NCT04425109|Experimental|tempeh steak|The subjects were received the tempeh steak meal with isocal diet containing energy 307.4Kcal
89574277|NCT04425109|Experimental|soybean steak|The subjects were received the soybean steak meal with isocal diet containing energy 307.4Kcal
89574278|NCT03730207|Experimental|Xpede™ Bone Cement|The subjects in this group will be injected the Xpede™ Bone Cement into vertebral body via percutaneous Vertebroplasty or Kyphoplasty to stabilize the fractured vertebral body.
89574279|NCT03730207|Active Comparator|Mendec Spine Bone Cement|The subjects in this group will be injected the Mendec Spine Bone Cement into vertebral body via percutaneous Vertebroplasty or Kyphoplasty to stabilize the fractured vertebral body.
89574280|NCT03693547|Experimental|utidelone|Utidelone Injection: 30 mg/m2/day, IV on day 1-day 5 of each 21 day cycle, administered to enrolled patients with advanced NSCLC
89574281|NCT05534113|Experimental|sequential Envafolimab therapy after Almonertinib treatment|Sequential Envafolimab therapy after patients with ctDNA EGFR mutation clearance and achieve stable radiographically deep response after treatment with Almonertinib
89574282|NCT05534035|Experimental|PTX-COVID19-B|
89574283|NCT05534035|Active Comparator|Vaxzevria®|
89029094|NCT04508764|No Intervention|Usual Care|"For approximately the first 6 months of the study, or until 75 patient with cancer who is initially approached in clinic (probands) are enrolled, the investigators will be enrolling probands into the Usual Care group. During this time, the investigators will clarify usual care regarding cascade genetic testing for each participating clinic and proband participant. The investigators will do this by proband participant surveys, as well as initial provider semi-structured interviews.~Proband: Complete Cascade Genetic Testing survey. The survey will also contain questions regarding willingness or not to invite each eligible 1st degree family member to participate in the family study. At 6 months, there will be a follow-up survey~Family Member: Complete survey at study entry and at 6 month follow-up"
89029095|NCT04508764|Experimental|FACT Toolkit (FACTT)|"Proband: Introduced to FACTT and will complete Cascade Genetic Testing survey. The survey will contain questions regarding willingness or not to invite each eligible 1st degree family member to participate in the family study. The probands will also fill out assessments of each FACTT component. At 6 months, there will be a follow-up survey.~Family Member: Introduced to FACTT and will complete surveys at study entry and 6 month follow-up. They will also fill out assessments of each FACTT component"
89029096|NCT04504253|Experimental|Creatine monohydrate|"Week 1: Creatine monohydrate 5g PO QID~Week 2 up to Week 6: Creatine monohydrate 5g PO qday"
89029097|NCT04504253|Placebo Comparator|Placebo|"Week 1: Placebo 5g PO QID~Week 2 up to Week 6: Placebo 5g PO qday"
89029098|NCT04484337|Experimental|Part 1:Cohort 1: CAB 400 mg/mL IM gluteal|
89029099|NCT04484337|Active Comparator|Part 1:Cohort 1: CAB 200 mg/mL IM gluteal|
89029100|NCT04484337|Experimental|Part 1:Cohort 2: CAB 400 mg/mL SC abdominal|
89029101|NCT04484337|Active Comparator|Part 1:Cohort 2: CAB 200 mg/mL SC abdominal|
89029102|NCT04484337|Experimental|Part 1:Cohort 3: CAB 400 mg/mL IM (lateral thigh)|
89029103|NCT04484337|Active Comparator|Part 1:Cohort 3: CAB 200 mg/mL IM (lateral thigh)|
89574284|NCT05530057|Experimental|Eribulin + SB3|- Patients will receive eribulin mesylate 1.4 mg/m2 administered I.V. with infusion over 2 to 5 minutes on days 1 and 8 of each 21-day cycle and SB3 8 mg/kg I.V. over 90 minutes on day 1 of cycle 1 . Thereafter, SB3 6 mg/kg will be infused over 30 minutes on day 1 of each subsequent 21-day cycle until progression or unacceptable toxicity.
89574285|NCT05530057|Active Comparator|Eribulin monotherapy|- Patients will receive eribulin mesylate 1.4 mg/m2 administered I.V. with infusion over 2 to 5 minutes on days 1 and 8 of each 21-day cycle until progression or unacceptable toxicity.
89574286|NCT05533957|Experimental|Oxygen therapy administration|Three different dosages of oxygen therapy will be administered to Chronic Obstructive Pulmonary Disease (COPD) with Chronic Respiratory Failure (CRF) and Long Oxygen Therapy (LTOT)
89574287|NCT04310917|Other|Lipoprotein a level|blood lipoprotein (a) test
89574288|NCT02576587|Other|Case (diagnosed with PAF)|"Cases. Patients with Paroxysmal Atrial Fibrillation who present to Electrophysiology Clinic at UHCMC and the Cleveland Clinic Foundation will be approached for recruitment in the study.~Cases found to have an apnea hypopnea index >=15 will be asked to continue in the study for 3 months wearing a Continuous Positive Airway Pressure (CPAP) machine."
89574289|NCT02576587|No Intervention|Controls|Controls. Patients without AF will be recruited from General Cardiology and Internal Medicine clinics (geographically similar to controls). Selection bias will be minimized as there are a broad range of reasons for patients to present to these clinics.
89574290|NCT05519839|Experimental|Group A (Part 1)|CIC Vaccine Formulation 1 doses of Formulation 1. 1 dose on Days 0.
89574291|NCT05519839|Experimental|Group B (Part 1)|CIC Vaccine Formulation 1 doses of Formulation 2. 1 dose on Days 0.
89574292|NCT05519839|Experimental|Group C (Part 1)|CIC Vaccine Formulation 1 doses of Formulation 3. 1 dose on Days 0.
89574293|NCT05519839|Experimental|Group D (Part 1)|CIC Vaccine Formulation1 doses of Formulation 4. 1 dose on Days 0.
89574294|NCT05519839|Experimental|Group E (Part 1)|CIC Vaccine Formulation 1 doses of Formulation 5. 1 dose on Days 0.
89574295|NCT05519839|Experimental|Group F (Part 1)|CIC Vaccine Formulation 1 doses of Formulation 6. 1 dose on Days 0.
89574296|NCT05519839|Experimental|Group G (Part 1)|CIC Vaccine Formulation 1 doses of Formulation 7. 1 dose on Days 0.
89574297|NCT05519839|Experimental|Group H (Part 1)|CIC Vaccine Formulation 1 doses of Formulation 8. 1 dose on Days 0.
89574298|NCT05519839|Experimental|Group I (Part 1)|CIC Vaccine Formulation 1 doses of Formulation 9. 1 dose on Days 0.
89574299|NCT05519839|Experimental|Group J (Part 1)|CIC Vaccine Formulation 1 doses of Formulation 10. 1 dose on Days 0.
89574300|NCT05519839|Experimental|Group K (Part 1)|CIC Vaccine Formulation 1 doses of Formulation 11. 1 dose on Days 0.
89574301|NCT05519839|Experimental|Group L (Part 1)|qNIV Vaccine Formulation 1 doses of Formulation 12. 1 dose on Days 0.
89574302|NCT05519839|Experimental|Group M (Part 1)|qNIV Vaccine Formulation 1 doses of Formulation 13. 1 dose on Days 0.
89574303|NCT05519839|Experimental|Group N (Part 1)|CIC Vaccine Formulation 1 doses of Formulation 14. 1 dose on Days 0.
89574304|NCT05519839|Experimental|Group O (Part 1)|SARS-CoV-2 rS Vaccine Formulation 1 doses of Formulation 15. 1 dose on Days 0.
88971013|NCT03951207|Active Comparator|Amlodipine/Atorvastatin 5/20mg|Atorvastatin 20mg/Amlodipine 5mg qd for 8 weeks
89574305|NCT05519839|Experimental|Group P (Part 1)|Reference Vaccine Formulation 1 doses of Formulation 16. 1 dose on Days 0.
88971014|NCT00077155|Experimental|Treatment (cilengitide)|Patients receive cilengitide (EMD 121974) IV continuously on weeks 1-4. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of EMD 121974 until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
88971015|NCT00077194|Experimental|Arm I|Patients receive FR901228 (depsipeptide) IV over 4 hours on days 1, 8, and 15. Treatment repeats every 28 days for at least 6 courses in the absence of disease progression or unacceptable toxicity.
88971016|NCT00077233|Active Comparator|Arm A: FOLFIRI|Patients receive irinotecan 180 mg/m^2 over 90 minutes on day 1, then leucovorin 400 mg/m^2 over 2 hours followed by 5FU 400 mg/m^2 IV bolus injection then 5FU 2400 mg/m^2 continuous IV infusion over 46-48 hours repeated every 2 weeks. One cycle of therapy is 8 weeks.
89029104|NCT04484337|Experimental|Part 1: Cohort 4: CAB 400 mg/mL (IM or SC)|
89029105|NCT04484337|Active Comparator|Part 1: Cohort 4: CAB 200 mg/mL (IM or SC)|
89029106|NCT04484337|Experimental|Part 2: Cohort 5: CAB 400 mg/mL IM (gluteus medius)|
89029107|NCT04484337|Active Comparator|Part 2: Cohort 5: CAB 200 mg/mL IM (gluteus medius)|
89029108|NCT04484337|Experimental|Part 2: Cohort 6: CAB 400 mg/mL IM (gluteus medius)|
89574306|NCT05519839|Experimental|Group Q (Part 1)|Reference Vaccine Formulation 1 doses of Formulation 17. 1 dose on Days 0.
89574307|NCT05519839|Experimental|Group R (Part 1)|Reference Vaccine Formulation 1 doses of Formulation 18. 1 dose on Days 0.
89574308|NCT05519839|Experimental|Group S (Part 1)|Comparator Influenza Vaccine Formulation 1 doses of Formulation 19. 1 dose on Days 0.
89574309|NCT05519839|Experimental|Group T (Part 1)|Comparator Influenza Vaccine Formulation 1 doses of Formulation 20. 1 dose on Days 0.
89574310|NCT05519839|Experimental|Group U (Part 2)|CIC Vaccine Formulation 1 doses of Formulation 1. 1 dose on Days 0.
89574311|NCT05519839|Experimental|Group V (Part 2)|CIC Vaccine Formulation 1 doses of Formulation 2. 1 dose on Days 0.
89574312|NCT03648073|Experimental|Patients with Radiographic Evidence of HCC on CT or MRI|[68Ga]DOTATATE-PET/MRI in Hepatocellular Carcinoma
89574313|NCT03622411|Experimental|aphasia therapy + speech app|3 hours per week of conventional aphasia therapy during 3 weeks + 5 hours per week during 3 weeks independent practice via the speech app
89574314|NCT03622411|Active Comparator|aphasia therapy + brain games|3 hours per week of conventional aphasia therapy during 3 weeks + 5 hours per week during 3 weeks of recreational tables use (brain games)
89574315|NCT03622411|Active Comparator|aphasia therapy|3 hours per week of conventional aphasia therapy during 3 weeks
89574316|NCT05533879|Experimental|Yoga group|Women with having received a minimum of 17 points from the kinesiophobia questionnaire, have chronic low back pain and aged between 25-65
89574317|NCT05529745|Experimental|Treatment in cerebellar lesioned patient|Group of patients with a lesion of the cerebellum gaining a neurorehabilitation intervention
89574318|NCT05529745|Active Comparator|Treatment in supratentorial lesioned patient|Group of patients with a lesion of the supratentorial area gaining a neurorehabilitation intervention
89574319|NCT05533723||Percutaneous epidural neuroplasty (PEN) group|Patients over 20 years of age with radiating pain in the lower back and legs who received PEN in patients who did not respond to medication and epidural nerve block treatment.
89209115|NCT00725543||Remicade|Subjects with AS with severe axial symptoms and elevated serological markers of inflammatory activity will receive Remicade induction therapy consisting of 3 Remicade infusions in weeks 0, 2, and 6 given in specialized centers. Maintenance therapy will consist of another maximal 6 infusions given in doses and intervals due to discretion of physicians. Whole observation period cannot exceed 102 weeks per subject if the maximal therapy interval of 16 weeks as defined in Summary of Product Characteristics (SPC) is taken into consideration.
89209116|NCT00881478|Active Comparator|Nutrition counselling alone|Nutrition counseling session with registered dietician
89574320|NCT05533723||Endoscopic epidural neuroplasty (EEN) group|Patients over 20 years of age with radiating pain in the lower back and legs who received EEN in patients who did not respond to medication and epidural nerve block treatment.
89574321|NCT05529667|Experimental|Experimental|"phase>~INCB054828 begins with oral administration of 13.5 mg once a day.~Paclitaxel is administered intravenously every week at 80mg / m2. (Days 1, 8 and 15) It is one cycle of 4 weeks and it is administered until the time of disease progression.~phase>~INCB54828 is dosed at the dose specified in phase 1.~Paclitaxel is administered intravenously every week at 80mg / m2. (Days 1, 8 and 15) It is one cycle of 4 weeks and it is administered until the time of disease progression"
89574322|NCT05533645|Experimental|Experimental group|patients with high blood pressure or chronic kidney diseases stages 4-5
89574323|NCT03571633|Experimental|Paclitaxel+Trastuzumab+Pegfilgrastim|"NEOADJUVANT TREATMENT PERIOD (up to 12 weeks) :Paclitaxel (80 mg/m2, weekly (D1, D8, D15), IV) + Trastuzumab (a loading dose 8 mg/kg at C1D1 followed by 6 mg/kg Q3W, IV OR 600mg, Q3W SC) + Pegfilgrastim (6 mg, Q3W, subcutaneously, the day after the trastuzumab + paclitaxel infusion (i.e. Day 2 of each cycle)).~ADJUVANT TREATMENT PERIOD (up to 12 months) : Trastuzumab (a loading dose 8 mg/kg at C1D1 followed by 6 mg/kg Q3W, (IV) OR 600mg, Q3W SC)"
89574324|NCT03571633|Active Comparator|Paclitaxel+Trastuzumab|"NEOADJUVANT TREATMENT PERIOD (up to 12 weeks) :Paclitaxel (80 mg/m2, weekly (D1, D8, D15), IV) + Trastuzumab (a loading dose 8 mg/kg at C1D1 followed by 6 mg/kg Q3W, IV OR 600mg, Q3W SC).~ADJUVANT TREATMENT PERIOD (up to 12 months) : Trastuzumab (a loading dose 8 mg/kg at C1D1 followed by 6 mg/kg Q3W, (IV) OR 600mg, Q3W SC)"
89574325|NCT05197387||Cases|Women with intrahepatic cholestasis of pregnancy
89574326|NCT05197387||Controls|Women without intrahepatic cholestasis of pregnancy
89574327|NCT03535597|No Intervention|Arm 1|Standard of Care (TR Band)
89574328|NCT03535597|Experimental|Arm 2|Quikclot Radial pad with Coban Bandage to hold the pad in place
89574329|NCT03535597|Experimental|Arm 3|Quikclot Radial Pad with Tegaderm dressing to hold the pad in place
89574330|NCT03473353|Other|Pediatric Clinicians|Survey data will be gathered from pediatric clinicians and also parents of pediatric patients at two time periods. At baseline, no Medical Scribes will be working with the clinicians, and then several months later, data will be gathered when Medical scribes ARE working with clinicians.
89574331|NCT05529433|Active Comparator|Atraumatic Restorative Treatment (ART)|Atraumatic Restorative Treatment is a simple technique based on preservation of sound tooth structure and minimal patient's discomfort.
89574332|NCT05529433|Experimental|Smart Burs|Smart Burs are minimally invasive technique which selectively removes the infected carious dentin leaving the affected intact dentin.
89574333|NCT05529433|Experimental|Chemo-Mechanical Caries Removal (CMCR)|A chemical agent which selectively removes the carious dentin by breaking the denatured collagen fibers making them soft and preserving the healthy dentin without drilling.
89029109|NCT04484337|Active Comparator|Part 2: Cohort 6: CAB 200 mg/mL IM (gluteus medius)|
89209117|NCT00881478|Experimental|Nutrition counselling + portion control|Nutrition counseling with registered dietician in addition to teaching about use of a portion control tool
89209118|NCT00985881|Experimental|Arm 1: stochastic resonance|Mechanical stochastic resonance
89209119|NCT00985881|Other|Arm 2: current clinical practice|Current clinical practice
89209120|NCT00917813|Experimental|KD-247|
89209121|NCT00917813|Placebo Comparator|Placebo|
89209122|NCT00239005|Active Comparator|Mycophenolate Mofetil (MMF)|250 mg capsules or 500 mg tablets of mycophenolate mofetil. Daily dose decided by physician, was taken morning and evening.
89209123|NCT00239005|Experimental|Enteric-Coated Mycophenolate Sodium (EC-MPS )|Oral film-coated gastroresistant tablets containing 360mg or 180mg of mycophenolate sodium. Daily dose decided by the physician, was taken morning and evening.
89209124|NCT02594891|Experimental|endoscopic retrograde biliary drainage|Patients will undergo endoscopic retrograde biliary drainage (ERBD) with 8.5 F plastic stent with proximal flap when bile duct stones were removed clearly with ERCP. The stent will be taken out with endoscopy three months later if not discharge self-driven.
89574334|NCT05533255|Experimental|Preheated Resin Composites|Preheated resin composite is placed on the noncarious cervical lesion of a canine/ first premolar/ second premolar/ first molar on either one quadrant of the maxillary arch.
89574335|NCT05533255|Active Comparator|Conventional Resin Composites|Conventional resin composite is placed on the noncarious cervical lesion of a canine/ first premolar/ second premolar/ first molar on the other quadrant of the maxillary arch.
89574336|NCT05533177||Schizophrenia, schizotypal and delusional disorders|Patients in Shanghai Mental Health Center and Qingdao Mental Health Center; meet ICD-10 diagnosis of F20-F29 Schizophrenia、schizotypal and delusional disorders criteria and its subtype (mental examination was conducted by three levels of doctors including at least one attending physician and one chief physician in psychiatric); available relevant HIS system biochemical data; have been treated with physical therapy; age and gender is not limited.
89574337|NCT05533177||Mood disorders|Patients in Shanghai Mental Health Center and Qingdao Mental Health Center; meet ICD-10 diagnosis of F30-F39 Mood disorders criteria and its subtype (mental examination was conducted by three levels of doctors including at least one attending physician and one chief physician in psychiatric); available relevant HIS system biochemical data; have been treated with physical therapy; age and gender is not limited.
89574338|NCT05533177||Neurotic, stress-related and somatoform disorders|Patients in Shanghai Mental Health Center and Qingdao Mental Health Center; meet ICD-10 diagnosis of F40-F48 Neurotic、stress-related and somatoform disorders criteria and its subtype (mental examination was conducted by three levels of doctors including at least one attending physician and one chief physician in psychiatric); available relevant HIS system biochemical data; have been treated with physical therapy; age and gender is not limited.
89574339|NCT05529355|Experimental|Envafolimab plus Endostar and S-1|Envafolimab (300 mg subcutaneously each time, using 4-6 cycles), Recombinant Human Endostartin Injection (210 mg, d1-7 pumps, repeat every 3 weeks, using 4-6 cycles), Tegafur,Gimeracil and Oteracil Porassium Capsules (40 mg Bid, take 2 weeks stop for 1 week, use 4-6 cycles)
89574340|NCT05529355|Active Comparator|Envafolimab plus Endostar|Envafolimab (300 mg subcutaneously each time, using 4-6 cycles), Recombinant Human Endostartin Injection (210 mg, d1-7 pumps, repeat every 3 weeks, using 4-6 cycles),
89574341|NCT05529355|Active Comparator|Envafolimab plus S-1|Envafolimab (300 mg subcutaneously each time, using 4-6 cycles), Tegafur,Gimeracil and Oteracil Porassium Capsules (40 mg Bid, take 2 weeks stop for 1 week, use 4-6 cycles)
89574342|NCT05533021|Experimental|intervention group|Training and consultancy
89574343|NCT05533021|No Intervention|control group|Standard postpartum care
89574344|NCT03244033|Experimental|Contextual Survey + Contextual CDS|Contextual factors obtained from patients in the Contextual Survey along with contextual red flags already stored in the EHR will produce a variety of Contextual Clinical Decision Support, both passive and interruptive alerts.
89574345|NCT03244033|Active Comparator|Contextual Survey Only|Contextual factors obtained from patients in the Contextual Survey along with contextual red flags already stored in the EHR will not be used for CDS or to produce alerts.
89574346|NCT05528887|Experimental|Autologous CAR-T cells|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by investigational treatment, CAR-T cells. CAR-T cells targeted CD19/BCMA/CD123/CD7 are autologous genetically modified T cells.
89574347|NCT05532787||Chest pain|Patients >18 years of age presenting to ED with chief complaint of chest pain or cardiac symptoms suggestive of acute coronary syndrome with at least one troponin ordered, without evidence of ST-segment elevation myocardial infarction on ECG
89574348|NCT03009019|Experimental|DFN-15 Active|DFN-15 Active
89574349|NCT03009019|Placebo Comparator|DFN-15 Placebo|DFN-15 Placebo
89574350|NCT04425343|Experimental|Periodontitis, Adult|Plaque samples were taken from subgingival pocket and send to the lab for metagenomic analysis
89574351|NCT04425343|Experimental|Metgenomic analysis|Analysis for whole bacterial count
89574352|NCT05340751||Anesthesia|hemoglobin
89574353|NCT02575807|Experimental|Phase 1: CRS-207|"CRS-207 administered in 3-week cycles.~* CRS-207 (1 x 10e9 colony forming units [CFU]) administered by intravenous (IV) infusion. For Cycle 1 through Cycle 6, CRS-207 will be administered on Day 1 of each cycle. After 6 cycles, CRS-207 will be administered on Day 1 once every 6 weeks (every other cycle)."
88971017|NCT00077233|Experimental|Arm B: FOLFIRI + C225|Patients receive irinotecan 180 mg/m^2 over 90 minutes, then leucovorin 400 mg/m^2 IV over 2 hours followed by 5FU 400 mg/m^2 IV bolus injection then 5FU 2400 mg/m^2 continuous IV infusion over 46-48 hours repeated every 2 weeks. Patients also receive cetuximab 400 mg/m^2 IV over 120 minutes day 1, then 250 mg/m^2 IV over 60 minutes weekly. All patients must be premedicated with diphenhydramine hydrochloride 50 mg (or a similar agent) IV prior to the first dose of cetuximab in an effort to prevent a hypersensitivity reaction. Premedication is recommended prior to subsequent doses, but at the Investigator's discretion the dose of diphenhydramine (or a similar agent) may be reduced.
89574354|NCT02575807|Experimental|Phase 1: CRS-207/IDO 100 mg|"CRS-207 administered in 3-week cycles, IDO administered twice daily (BID).~CRS-207 (1 x 10e9 CFU) administered by IV infusion. For Cycle 1 through Cycle 6, CRS-207 administered on Day 1 of each cycle. After 6 cycles, CRS-207 administered on Day 1 once every 6 weeks (every other cycle).~IDO (100 milligrams [mg]) administered by mouth (PO) BID, starting on Day 2 of the first CRS-207 treatment cycle."
89574355|NCT02575807|Experimental|Phase 1: CRS-207/IDO 300 mg|"CRS-207 administered in 3-week cycles, IDO administered BID.~CRS-207 (1 x 10e9 CFU) administered by IV infusion. For Cycle 1 through Cycle 6, CRS-207 administered on Day 1 of each cycle. After 6 cycles, CRS-207 administered on Day 1 once every 6 weeks (every other cycle).~IDO (300 mg) administered PO BID, starting on Day 2 of the first CRS-207 treatment cycle."
89574356|NCT02575807|Experimental|Phase 2: CRS-207/Pembro/IDO|"CRS-207 and pembrolizumab (pembro) administered in 3-week cycles, IDO administered BID.~CRS-207 (1 x 10e9 CFU) administered by IV infusion. For Cycle 1 through Cycle 6, CRS-207 administered on Day 2 of each cycle. After 6 cycles, CRS-207 administered on Day 2 once every 6 weeks (every other cycle).~Pembro (200 mg) administered by IV infusion on Day 1 in 3-week cycles.~IDO (300 mg) administered PO BID, starting on Day 3 of the first CRS-207 treatment cycle."
89574357|NCT02575807|Experimental|Phase 2: CRS-207/Pembro|"CRS-207 and pembro administered in 3-week cycles.~CRS-207 (1 x 10e9 CFU) administered by IV infusion. For Cycle 1 through Cycle 6, CRS-207 administered on Day 2 of each cycle. After 6 cycles, CRS-207 administered on Day 2 once every 6 weeks (every other cycle).~Pembro (200 mg) administered by IV infusion on Day 1 in 3-week cycles."
88971018|NCT00077233|Active Comparator|Arm C: FOLFOX|Patients receive oxaliplatin 85 mg/m^2 IV infused over 120 minutes, then leucovorin 400 mg/m^2 IV over 2 hours followed by 5 FU 400 mg/m^2 IV bolus injection then 5 FU 2400 mg/m^2 continuous IV infusion over 46-48 hours every 2 weeks.
89029110|NCT04484337|Experimental|Part 1: Cohort 4b: CAB 400 mg/mL (SC)|
89029111|NCT04484337|Experimental|Part 1: Cohort 4h: CAB 400 mg/mL (SC)|
89029112|NCT04484337|Active Comparator|Part 1: Cohort 4h: CAB 200 mg/mL (SC)|
89209125|NCT02594891|Placebo Comparator|endoscopic nasobiliary drainage|Patients will undergo endoscopic nasobiliary drainage (ENBD) when bile duct stones were removed clearly with ERCP. The nose bile duct will be pulled out 3-5 days later if no cholangitis occurrence.
89574358|NCT05334589|Experimental|Experimental: Intervention group|Patients in the intervention group will be prewarming with a hot air blowing system for 30 minutes before the operation. The patients will continue to be warmed with a carbon fiber heating bed, which is a resistive system, during the surgery.
89574359|NCT05334589|No Intervention|Control group|The patients will continue to be warmed with a carbon fiber heating bed, which is a resistive system, during the surgery.
89574360|NCT05532553||Group 1|Patient with T2DM and fatty liver.
89574361|NCT05532553||Group 2|patients with fatty liver only ( control group).
89574362|NCT02813785|Experimental|Atezolizumab|Participants will receive atezolizumab until loss of clinical benefit and will thereafter enter survival follow-up until death, loss to follow-up, withdrawal, or study end.
89574363|NCT02813785|Active Comparator|Docetaxel|Participants will receive docetaxel until disease progression per standard RECIST v1.1 criteria or unacceptable toxicity and will thereafter enter survival follow-up until death, loss to follow-up, withdrawal, or study end.
89574364|NCT04302181|Experimental|Stellate Ganglion Block|One time administration of a stellate ganglion block
89574365|NCT05528185|Experimental|Intervention|The intervention consists of family participation in morning interdisciplinary team rounds in the cardiac ICU. Family participation will consist of orientation, engagement, summary, questions, and communication follow-up by the care team.
89574366|NCT05528185|No Intervention|Usual care|Usual care consists of interdisciplinary team rounds that occur outside the patient's room each morning without a family member present.
89574367|NCT05532475||cases|patient with retinal vein occlusion
89574368|NCT05532475||control|cataract patient undergoing cataract surgery
89574369|NCT05527951|Experimental|Enhanced MBC Implementation(eMBC)|The eMBC implementation arm use our WeChat Easy to Recover from Depression Mini-Program, which consists of mood tracking and lay-coached self-management.
89574370|NCT05527951|Active Comparator|Standard MBC Implementation|The standard MBC implementation arm use paper and pencil questionnaires.
89029113|NCT04473053|Experimental|Nafamostat|It is intended that the licensed dose (0.2mg/kg/hr) in Japan will be used. Patients randomised to Nafamostat will receive a continuous intravenous infusion at 0.2 mg/kg/hr for 7 days. If a participant is discharged from hospital or can no longer receive this treatment, the treatment will be stopped.
89029114|NCT04473053|Experimental|TD139|"Patients will inhale 5mg x 2 (10 mg) twice daily for the first 48 hrs and then subsequently 5mg x 2 (10 mg) once daily for the remaining 12 days. Unless a participant is discharged from hospital or can no longer use an inhaler - in which case treatment will be stopped at such time.~CE marked inhalers will be provided by the Manufacturer. All patients will receive guidance on how to use the inhaler by an appropriately trained member of the research team. Two individual inhalers will be used by each patient over the course of the 14 day study period (each inhaler will be used by one patient for 7 days) and will be thoroughly cleaned with an antiseptic wipe before and after each use."
89029115|NCT04473053|Active Comparator|Standard of Care|Nafamostat and TD139 will be compared to the Standard of Care arm.
89029116|NCT04473053|Experimental|Allogeneic SARS-CoV-2 VSTs|This is an early dose escalation safety trial phase Ib/IIa interventional clinical trial with SARS-CoV-2 VSTs. This is a standalone arm of the Define study and will not be compared to any other trial appendices. A dose escalation strategy from 2x104 cells/kg to 2x106 cells/kg (based on standard 75kg weight) will be administered to patients with COVID-19 infection, and patients will be followed up to ensure their safety.
89029117|NCT04469452||Healthy Adults (19-99yrs)|Healthy adults already enrolled in separate studies using indirect calorimetry to measure RMR within our lab will be recruited for this study. Fifty participants (25 male, 25 female) will be heterogeneous in age, body composition, and physical activity based on the inclusion and exclusion of their respective studies. To test reliability, 25 of the 50 participants will repeat RMR measurements within 1 week of initial measurements.
89574371|NCT05527795||Non-mutated|Non mutated (BRAF or NRAS) stage II, III or IV (resected) melanoma patients treated with first line adjuvant immunotherapy (anti-PD-1 with either pembrolizumab or nivolumab)
89574372|NCT05527795||BRAF-mutated|BRAF-mutated stage II, III or IV (resected) melanoma patients treated with first line adjuvant immunotherapy (anti-PD-1 with either pembrolizumab or nivolumab)
89574373|NCT05527795||NRAS-mutated|NRAS-mutated (BRAF or NRAS) stage II, III or IV (resected) melanoma patients treated with first line adjuvant immunotherapy (anti-PD-1 with either pembrolizumab or nivolumab)
89574374|NCT04128553|Experimental|Intervention motivational interview group|"Face-to-face motivational interviews lasted for an average of 30 minutes. After the MI, the exercise information guideline prepared by the researcher and the TTM-based MI guideline according to the stages were given to the older adults. During the MI, a form prepared by the researcher was used to note the content of the interview. At the end of MI, the next appointment was planned. In addition, the older adults were given a chart prepared by the researcher to note their walk.~On the other hand, the phone-based motivation interviews lasted an average of five to seven minutes. Before the telephone interview, it was determined which stage of change the older adult was in. Then a motivational interview was held according to the stage."
89574375|NCT04128553|No Intervention|Control|The Control Group (CG) was only followed up at the beginning and end of the study, no intervention was made. The CG received standard care. Although the family health staff do not give routine and standard training about the benefits of exercising in the FHC to the elderly, they give information when necessary.
89574376|NCT05527561|Experimental|Latin Dance-Rumba|Rumba dance training was shown for the 1-6 weeks.
89029118|NCT04466228|Experimental|Stim1 high dose|This group will receive high dose non-invasive transcranial electrical stimulation
89029119|NCT04466228|Experimental|Stim2 low dose|This group will receive low dose non-invasive transcranial electrical stimulation
89029120|NCT04466228|Sham Comparator|Sham control|This group will receive sham control non-invasive transcranial electrical stimulation
89209126|NCT00616434|Experimental|Interferon beta-1a|Interferon beta-1a 30 µg intramuscular (IM) injection twice weekly for 12 weeks
89574377|NCT05527561|Experimental|Latin Dance-Cha Cha Cha|Cha Cha Cha dance training for the 7-12 weeks.
89574378|NCT05527249|Experimental|Dietary supplement group|20g of protein powder + 1 tablet of pomegranate extracts / day for 21 days of the dietary supplement, to be taken every day before lunch time.
89574379|NCT05527249|Placebo Comparator|Placebo group|20g of protein powder + 1 tablet of maltodextrin / day for 21 days of the dietary supplement, to be taken every day before lunch time.
89574380|NCT05532085||Group: Medical abortion without analgesic protocol|All women over the age of 15, benefiting from a medical abortion between June and October 2020, including oral French.
89574381|NCT05532085||Group: Medical abortion with analgesic protocol|All women over the age of 15, benefiting from a medical abortion between October 2020 and February 2021, including spoken French.
89574382|NCT05532085||Group: Abortion by aspiration under local anesthesia without analgesic protocol|All women over the age of 15, benefiting from an abortion by aspiration under local anesthesia between June and October 2020, including oral French.
89574383|NCT05532085||Group: Abortion by aspiration under local anesthesia with analgesic protocol|All women over the age of 15, benefiting from an abortion by aspiration under local anesthesia between October 2020 and February 2021, including oral French.
89574384|NCT02303119|Active Comparator|Am A : Rituximab IV|4 infusions of intravenous rituximab (375mg/m²) at Day 1, Day 8, Day 15 and D22
89574385|NCT02303119|Experimental|Arm B: Rituximab SC|1 infusion of intravenous rituximab (375mg/m²) at Day 1, and 7 administrations of sub-cutaneous rituximab (1400mg) at Day 8, Day15, Day 22, Month 3, Month 5, Month 7 and Month 9.
89574386|NCT02303119|Experimental|Arm C : Rituximab SC first cycle|8 administrations of sub-cutaneous rituximab (1400mg) at Day 8, Day15, Day 22, Month 3, Month 5, Month 7 and Month 9.
89574387|NCT02006251|Active Comparator|Standard Total Hip Arthroplasty|Each surgeon will use their standard methods of pre-operative planning using pre-operative x-rays, and complete the procedure using standard surgical instruments for total hip arthroplasty.
89574388|NCT02006251|Experimental|Real-time Instrumentation|Pre-operative planning through 3D software with design of real-time instrument intraoperatively using bone cement and surrogate bone model for placement of a guide pin to be used to aid in bone preparation for insertion of an acetabular cup in total hip arthroplasty
89574389|NCT02575339|Experimental|Phase I MLN0128 Dose Escalation Study|"Subjects will receive MLN0128 orally on days 1, 8, 15 and 22 in successive cohorts.~Cohort 1 MLN0128 15mg each week (QW); Cohort 2 MLN0128 20mg QW; Cohort 3 MLN0128 30mg QW"
89574390|NCT02575339|Experimental|Phase II Arm A: MLN0128|Subjects randomized to experimental arm will receive MLN0128 orally at the recommended phase II dose (RP2D) once weekly.
89574391|NCT02575339|Active Comparator|Phase II Arm B: Sorafenib|Subjects randomized to control arm will receive sorafenib 400mg by mouth (PO) twice a day (BID) daily.
89574392|NCT01712659|Experimental|Original Phase II Standard Ruxolitinib dose cohort|Ruxolitinib 20 mg orally twice daily for 28 days. Subjects may continue to receive treatment until progressive disease (PD) or unacceptable toxicity.
89574393|NCT01712659|Experimental|2- Phase 1 Dose Escalation cohorts|"Dose level 1: Ruxolitinib 30 mg orally twice daily for 28 days to determine the maximum tolerated dose (MTD). Subjects may continue to receive treatment until progressive disease (PD) or dose limiting toxicity (DLT) or unacceptable toxicity.~Dose level 2: Ruxolitinib: Ruxolitinib 40 mg orally twice daily for 28 days to determine the maximum tolerated dose (MTD). Subjects may continue to receive treatment until progressive disease (PD) or dose limiting toxicity (DLT) or unacceptable toxicity.~Dose level 3: Ruxolitinib: Ruxolitinib 50 mg orally twice daily for 28 days to determine the maximum tolerated dose (MTD). Subjects may continue to receive treatment until progressive disease (PD) or dose limiting toxicity (DLT) or unacceptable toxicity."
89029121|NCT04461080|Experimental|Integrated care promoter|Patients who are randomized to the intervention group will be connected with a trained Community Health Worker (CHW). The CHW is a peer with lived-experience of system navigation that could have a background in social work, health promotion or community work. All CHWs will receive 2 weeks of training to assist participants with social needs.
89029122|NCT04461080|Active Comparator|Information on community resources|Patients randomized to the control group will receive a list of tailored written information.
89029123|NCT04455750|Experimental|Arm I (enzalutamide, rucaparib)|Patients receive enzalutamide PO QD and rucaparib PO BID. Patients who did not undergo bilateral orchiectomy also receive ADT consisting of leuprolide acetate IM, goserelin acetate SC every 12 weeks or degarelix SC. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89029124|NCT04455750|Active Comparator|Arm II (enzalutamide, placebo)|Patients receive enzalutamide PO QD and placebo PO BID. Patients who did not undergo bilateral orchiectomy also receive ADT consisting of leuprolide acetate IM, goserelin acetate SC every 12 weeks or degarelix SC. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89029125|NCT04439903|Experimental|Web-based Simulation Tool (WST)|
89029126|NCT04410107||Severe Pneumonia|"Presence of fever or suspected lower respiratory infection, plus one of the following criteria:~1) respiratory rate> 30 movements / min; 2) severe respiratory distress 3) Pulse oximetry (SpO2) ≤93% in room air; and/or 3) Pulmonary infiltrates> 50% on chest imaging within 24-48hrs of symptom onset."
89209127|NCT00616434|Placebo Comparator|Placebo|Placebo IM injection twice weekly for 12 weeks
89209128|NCT01581697|Experimental|Oat bran|
89209129|NCT00652340|Experimental|A|
89574394|NCT01712659|Experimental|3- Phase 1 Dose Expansion Cohort|Ruxolitinib at the maximum tolerated dose (MTD) or the maximum administered dose (MAD) defined in the phase 1 dose escalation cohorts. Subjects may continue to receive treatment until progressive disease (PD) or unacceptable toxicity.
89574395|NCT01640587|Experimental|DP|2.4 mg/kg dihydroartemisinin AND 20 mg/kg piperaquine once daily on Days 0, 1 and 2
89574396|NCT01640587|Active Comparator|MAS3|4mg/kg artesunate AND 8 mg/kg mefloquine once daily on Days 0, 1 and 2
89574397|NCT05531851|Experimental|Experiment group.|İnstrument-assisted soft tissue mobilization will be applied after the delayed onset muscle soreness induction protocol
89574398|NCT05531851|No Intervention|Control Group|Delayed onset muscle soreness generation protocol will be applied
89574399|NCT01610713|Experimental|GW-1000-02|Active treatment.
89574400|NCT01606189|Experimental|GW-1000-02|Active treatment.
89574401|NCT01606189|Experimental|GW-2000-02|Active treatment.
89574402|NCT01606189|Placebo Comparator|Placebo|Placebo control.
89574403|NCT05526859|Experimental|Group 1|Hyperactive muscle correction for wrist extensors: Kinesiotape was applied to facilitate wrist extensor muscles from proximal to distal with 15-35% tension in therapeutic zone and no tension at anchor and end.
89574404|NCT05526859|Experimental|Group 2|Hypoactive muscle correction for wrist flexors: Wrist flexors muscles were inhibited by applying tape from distal to proximal with 15-25% tension in therapeutic zone and no tension at anchor and end.
89574405|NCT01663987|Active Comparator|18 mcg tiotropium|Patient to receive one tiotropium bromide inhalation powder capsule daily (in the morning) via HandiHaler
89574406|NCT01663987|Placebo Comparator|Placebo|Patient to receive one placebo capsule daily (in the morning) identical to those containing tiotropium bromide inhalation powder via HandiHaler
89574407|NCT05531773||COVID-19 patients|patients recovered from an acute COVID-19 episode
89574408|NCT05305651|Other|Cohort receiving Sotrovimab|Immunocompromised non-hospitalized participants will receive sotrovimab as standard of clinical care for COVID-19 in sentinel sites
89574409|NCT05524831|Experimental|groupA(Kinesiotape)|kinesio tape on orbicularis oris muscle for 45 minute /3times per week for 2 successive months
89574410|NCT05524831|Experimental|group B(oromotor training)|oromotor training for 45 minute/ 3 times per week for 2 successive months
89574411|NCT05531695|Experimental|Aerobic Exercise|Graduated supervised moderate intensity aerobic exercise
89574412|NCT05531695|Active Comparator|Flexibility Exercise|Home based self-supervised flexibility exercises
89574413|NCT05531617|Active Comparator|M group|Group Intubated with Macintosh laryngoscope is labelled as M group
89574414|NCT05531617|Active Comparator|V group|Group Intubated with C-Mac video laryngoscope is labelled as V group
89574415|NCT05524441||Airline 1|2 conditions; 18 participants per condition (n = 36)
89574416|NCT05524441||Airline 2|2 conditions; 18 participants per condition (n = 36)
89574417|NCT05524441||Airline 3|2 conditions; 18 participants per condition (n = 36)
89574418|NCT05524441||Airline 4|2 conditions; 18 participants per condition (n = 36)
89574419|NCT02380677|Experimental|Schedule 1 Cohort 1|CRLX301 7.5 mg/m2 IV given every 3 weeks
89574420|NCT02380677|Experimental|Schedule 1 Cohort 2|CRLX301 15 mg/m2 IV given every 3 weeks
89574421|NCT02380677|Experimental|Schedule 1 Cohort 3|CRLX301 30 mg/m2 IV given every 3 weeks
89574422|NCT02380677|Experimental|Schedule 1 Cohort 4|CRLX301 60 mg/m2 IV given every 3 weeks
89209130|NCT00652340|Placebo Comparator|B|
89574423|NCT02380677|Experimental|Schedule 1 Cohort 5|CRLX301 75 mg/m2 IV given every 3 weeks
89574424|NCT02380677|Experimental|Schedule 1 Cohort 6|CRLX301 90 mg/m2 IV given every 3 weeks
89574425|NCT02380677|Experimental|Schedule 2 Cohort 1|CRLX301 25 mg/m2 IV given weekly
89574426|NCT02380677|Experimental|Schedule 2 Cohort 2|CRLX301 35 mg/m2 IV given weekly
89574427|NCT02380677|Experimental|Schedule 2 Cohort 3|CRLX301 45 mg/m2 IV given weekly
89574428|NCT02380677|Experimental|Schedule 2 Cohort 4|CRLX301 54 mg/m2 IV given weekly
89574429|NCT02380677|Experimental|Schedule 2 Cohort 5|CRLX301 54 mg/m2 given weekly for 3 weeks with 1 week off
89574430|NCT02380677|Experimental|Phase 2a expansion cohort|CRLX301 75mg/m2 IV given every 3 weeks
89574431|NCT02380287|Experimental|Cohort no.1|This cohort includes just one subject who will receive the maximum safe starting dose of BCD-085 (0.05 mg/kg) subcutaneously. If the dose limitating toxicity occurs within the first seven days after injection the study will be stopped. If there is no DLT within mentioned above period then Cohort no.2 is included.
89574432|NCT02380287|Experimental|Cohort no.2|"This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-085 at a dose of 0.05 mg/kg.~If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 subjects are observed to have DLT, the dose level is escalated one step for the next cohort no. 3 of 3 subjects, and the process continues as above. If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level. If none of these additional 3 patients show DLT, the dose level is escalated for the next Cohort no. 3."
89574433|NCT02380287|Experimental|Cohort no.3|"This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-085 at a dose of 0.25 mg/kg.~If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 subjects are observed to have DLT, the dose level is escalated one step for the next cohort no. 4 of 3 subjects, and the process continues as above. If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level. If none of these additional 3 patients show DLT, the dose level is escalated for the next Cohort no. 4."
89574434|NCT02380287|Experimental|Cohort no.4|"This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-085 at a dose of 0.825 mg/kg.~If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 subjects are observed to have DLT, the dose level is escalated one step for the next cohort no. 5 of 3 subjects, and the process continues as above. If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level. If none of these additional 3 patients show DLT, the dose level is escalated for the next Cohort no. 5."
89209131|NCT00257725|Experimental|ADHD Treatment Group|Single-arm, open-label, once-daily-dosing of long-duration beaded MPH (B-MPH) at 10-30 mg (flexible titration) in 4-to-5 year old children with ADHD.
89209132|NCT00544869|Experimental|1|
89574435|NCT02380287|Experimental|Cohort no.5|"This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-085 at a dose of 1.25 mg/kg.~If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 subjects are observed to have DLT, the dose level is escalated one step for the next cohort no. 6 of 3 subjects, and the process continues as above. If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level. If none of these additional 3 patients show DLT, the dose level is escalated for the next Cohort no. 6."
89574436|NCT02380287|Experimental|Cohort no.6|"This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-085 at a dose of 1.75 mg/kg.~If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 subjects are observed to have DLT, the dose level is escalated one step for the next cohort no. 7 of 3 subjects, and the process continues as above. If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level. If none of these additional 3 patients show DLT, the dose level is escalated for the next Cohort no. 7."
89574437|NCT02380287|Experimental|Cohort no.7|"This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-085 at a dose of 2.25 mg/kg.~If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 subjects are observed to have DLT, the dose level is escalated one step for the next cohort no. 8 of 3 subjects, and the process continues as above. If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level. If none of these additional 3 patients show DLT, the dose level is escalated for the next Cohort no. 8."
89029127|NCT04410107||Acute respiratory distress syndrome (ARDS)|"Onset: acute, i.e. within 1 week of known clinical insult or new or worsening respiratory symptoms; and~Chest imaging (e.g. X-ray or CT scan): bilateral opacities, not fully explained by effusions, lobar/lung collapse or nodules; and~Origin of pulmonary edema: respiratory failure not fully explained by cardiac failure or fluid overload; and~Degree of hypoxemia: arterial oxygen partial pressure to fractional inspired oxygen (PaO2/FiO2) ≤ 300 mm Hg with positive end-expiratory pressure ≥ 5 cm H2O."
89574438|NCT02380287|Experimental|Cohort no.8|"This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-085 at a dose of 3.0 mg/kg.~If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level."
89574439|NCT02343003|Experimental|Cooled radiofrequency|Cooled radiofrequency energy will be delivered to study subjects' knees to ablate culprit sensory nerves and reduce knee pain
89574440|NCT02343003|Active Comparator|Corticosteroid injection|Corticosteroid injections will be administered to study subjects' knees to reduce knee pain
89574441|NCT04900701|Experimental|Hypocaloric|Participants placed in energy restriction.
89574442|NCT04900701|Experimental|Energy Balance|Participants placed in energy balance.
89574443|NCT04900701|Experimental|Hypercaloric|Participants placed in energy surplus.
89574444|NCT02394561|Experimental|Cw6-positive AIN457 300 mg|Stratified to Cw6 positive cohort. Investigators and patients were blinded to Cw6 results. All patients were treated according to an induction regimen of two injections of secukinumab 150 mg a week for five weeks starting at baseline (week 0), followed by a maintenance period of two injections per month. At week 16, patients achieving PASI 50 response were eligible to continue on secukinumab for an additional 8 weeks in CORE. Eligible patients with at least a PASI 75 response were included in the extension phase, up to 72 weeks
89574445|NCT02394561|Experimental|Cw6-negative AIN457 300 mg|Stratified to Cw6 negative cohort. Investigators and patients were blinded to Cw6 results. All patients were treated according to an induction regimen of two injections of secukinumab 150 mg a week for five weeks starting at baseline (week 0), followed by a maintenance period of two injections per month. At week 16, patients achieving PASI 50 response were eligible to continue on secukinumab for an additional 8 weeks in CORE. Eligible patients with at least a PASI 75 response were included in the extension phase, up to 72 weeks
89574446|NCT04904913|Experimental|IBI362 high dose|high dose IBI362 administered subcutaneously (SC) once a week.
89574447|NCT04904913|Experimental|IBI362 low dose|Low dose IBI362 administered subcutaneously (SC) once a week.
89574448|NCT04904913|Placebo Comparator|placebo|placebo administered subcutaneously (SC) once a week.
89574449|NCT04904913|Experimental|IBI362 moderate dose|moderate dose IBI362 administered subcutaneously (SC) once a week.
89574450|NCT04904913|Experimental|IBI362 extra high dose|extra high dose IBI362 administered subcutaneously (SC) once a week.
89574451|NCT02342223|Experimental|Voluma|"Subjects will be screened for severity on their HIV facial lipoatrophy according to the Carruthers Lipoatrophy Severity Scale (CLSS), and will receive subcutaneous injections of Voluma in the affected facial areas with the 'smile and fill' technique (Jagdeo 2014) based on Carruthers scoring scale.~Subjects with Carruthers Score level 2 will receive total of 2-6 syringes of Voluma.~Subjects with Carruthers Score level 3 will receive total of 4-8 syringes of Voluma.~Subjects with Carruthers Score level 4 will receive total of 6-12 syringes of Voluma.~All subjects will receive one Voluma treatment at initial time = 0 and may be eligible for touchup treatment, if necessary, at 2 weeks post-initial treatment."
89029128|NCT04387201|Placebo Comparator|Cyanocobalamin|Placebo comparator
89029129|NCT04387201|Experimental|Dulaglutide|Experimental arm
89029130|NCT04369066|Other|Subjects who are not showing active SARS-Cov2 infection|
89029131|NCT04349839||ACRODAT study arm|No intervention
89029132|NCT04349839||Standard Practice Arm|No intervention
89029133|NCT04347967|Experimental|UMC119-06|Human Umbilical Cord Derived-Mesenchymal Stem Cells, Single treatment by intravenous infusion.
89209133|NCT00725075|Experimental|MK-8435 (Org 25935) 8-16 mg per day|Participants will be maintained on a stable dose of Second Generation Antipsychotic (SGA) and receive 4-8 mg MK-8435 (Org 25935) BID, in the morning and the evening, as add-on treatment for up to 87 days. The dose of MK-8435 (Org 25935) can be titrated upward or downward within the specified dose range, as needed, up to Day 42 of the study. The dose must remain stable after Day 42 for the remainder of the study.
89574452|NCT02393547|Experimental|Varenicline + Lorcaserin|Open label all subjects receive both Varenicline and Lorcaserin
89574453|NCT02574637|Placebo Comparator|Placebo|Placebo-matching brazikumab intravenous (IV) infusion and subcutaneous (SC) injection at Weeks 0 and 4 followed by placebo-matching brazikumab SC injection at Weeks 8 and 12 in the induction phase and at Weeks 16, 20 and 24 in the maintenance phase. Participants received brazikumab 210 mg, SC injection every 4 weeks up to Week 48 in the open-label period.
89574454|NCT02574637|Experimental|Brazikumab High Dose|Brazikumab 700 mg, IV infusion and placebo-matching brazikumab, SC injection at Weeks 0 and 4 followed by brazikumab 210 mg, SC injection at Weeks 8 and 12 in the induction phase. Participants received brazikumab 210 mg, SC injection every 4 weeks in the maintenance phase and open-label period up to Week 48.
89574455|NCT02574637|Experimental|Brazikumab High-Medium Dose|Brazikumab 280 mg, IV infusion and placebo-matching brazikumab, SC injection at Week 0 followed by brazikumab 210 mg, SC injection and placebo-matching brazikumab, IV infusion at Week 4, followed by brazikumab 210 mg, SC injection at Weeks 8 and 12 in the induction phase. Participants received brazikumab 210 mg, SC injection every 4 weeks in the maintenance phase and open-label period up to Week 48.
89574456|NCT02574637|Experimental|Brazikumab Low-Medium Dose|Brazikumab 210 mg, SC injection and placebo-matching brazikumab, IV infusion at Week 0 followed by brazikumab 105 mg, SC injection and placebo-matching brazikumab, IV infusion at Week 4, followed by brazikumab 105 mg, SC injection at Weeks 8 and 12 in the induction phase. Participants received brazikumab 105 mg, SC injection every 4 weeks up to Week 24 in the maintenance phase. Participants received brazikumab 210 mg, SC injection, every 4 weeks up to Week 48 in the open-label period.
89574457|NCT02574637|Experimental|Brazikumab Low Dose|Brazikumab 70 mg, SC injection and placebo-matching brazikumab, IV infusion at Week 0 followed by brazikumab 35 mg, SC injection and placebo-matching brazikumab, IV infusion at Week 4, followed by brazikumab 35 mg, SC injection at Weeks 8 and 12 in the induction phase. Participants received brazikumab 35 mg, SC injection every 4 weeks up to Week 24 in the maintenance phase. Participants received brazikumab 210 mg, SC injection, every 4 weeks up to Week 48 in the open-label period.
89574458|NCT05531539|Experimental|Outpatient Respiratory patients|They were examined with spirometry, manual auscultation of the thorax and where necessary, with chest X-ray or CT scan. They wore the WELMO sensors vest for a period of 15-20 minutes during which they performed tidal and deep breathing, cough and spirometry maneuvers and changes of posture. At the end of the study, they were requested to fill in a questionnaire about comfort and usability of the vest.
89574459|NCT05531539|Experimental|Hospitalized Respiratory patients|They were examined with spirometry, manual auscultation of the thorax and where necessary, with chest X-ray or CT scan. They wore the WELMO sensors vest for a period of 15-20 minutes during which they performed tidal and deep breathing, cough and spirometry maneuvers and changes of posture. At the end of the study, they were requested to fill in a questionnaire about comfort and usability of the vest.
89574460|NCT05531539|Experimental|Critically ill Respiratory patients|They were examined with manual auscultation of the thorax and where necessary, with chest X-ray or CT scan. They wore the WELMO sensors vest for a period of 15-20 minutes during which the vest recorded the breathing provided by the mechanical ventilator.
89209134|NCT00725075|Experimental|MK-8435 (Org 25935) 24-32 mg per day|Participants will be maintained on a stable dose of SGA and receive 12-16 mg MK-8435 (Org 25935) BID, in the morning and the evening, as add-on treatment for up to 87 days. The dose of MK-8435 (Org 25935) can be titrated upward or downward within the specified dose range, as needed, up to Day 42 of the study. The dose must remain stable after Day 42 for the remainder of the study.
89209135|NCT00725075|Placebo Comparator|Placebo|Participants will be maintained on a stable dose of SGA and receive matching placebo for MK-8435 (Org 25935) BID, in the morning and the evening, as add-on treatment for up to 87 days.
89209136|NCT00874302|Experimental|25 mg|25 mg Proellex
89209137|NCT00874302|Experimental|50 mg|50 mg Proellex
89209138|NCT02593643|Experimental|ketamine+TAU - MDD|Ketamine + treatment as usual (TAU) in MDD inpatients with SI
89209139|NCT02593643|Active Comparator|midazolam + TAU - MDD|Midazolam + treatment as usual (TAU) in MDD inpatients with SI
89209140|NCT02593643|Experimental|ketamine + TAU - BD|Ketamine + treatment as usual (TAU) in BD inpatients with SI
89209141|NCT02593643|Active Comparator|midazolam + TAU - BD|Midazolam + treatment as usual (TAU) in BD inpatients with SI
89209142|NCT05261087||Factory worker|Workers working in the TPI blade factory will be included in the study. Those working in the wind vane production at the factory are divided into departments. The 65.5 main mold workers, which will require the most attention, will be included in our work.
89574461|NCT05526235|Experimental|Stepped-care program (Step 1: DWM; Step 2: PM+)|"The treatment group will first receive Psychological First Aid (PFA). PFA consists of a 15-min call that assess the immediate concerns and needs of an individual in order to connect individuals to help and resources.~Afterwards participants will receive the stepped-care program consisting of Doing What Matters (DWM) (step 1) and Problem Management Plus (PM+) (step 2). Step 2 will only be provided if the participant still has elevated levels of psychological distress (i.e. during the second quantitative assessment at 2 weeks after DWM).~Participants will also be allowed to continue with their mental health interventions (CAU), as long as they meet eligibility criteria.~Interventions:~Behavioral: Doing What Matters (DWM) Behavioral: Problem Management Plus (PM+) Behavioral: Psychological First Aid (PFA)"
89574462|NCT05526235|Active Comparator|Psychological First Aid (PFA)|"Participants allocated to the control arm will also receive PFA. Participants will also be allowed to continue with their mental health interventions (CAU), as long as they meet eligibility criteria.~Intervention: Behavioral: Psychological First Aid (PFA)"
89574463|NCT05531383|No Intervention|Control group (group 1)|Patients in the control group (group 1) No memantine administration
89574464|NCT05531383|Active Comparator|Treatment group (group 2)|in addition to the standard treatment, they will receive memantine (30 mg) twice daily, either orally or through a nasogastric tube for 7 days, starting on the first day of admission to the hospital. The memantine dose administered in our study was based on the maximum dose of 60 mg/day reported in prior human studies
89574465|NCT05524207||Vulnerable plaque group|Patients with preoperative contrast-enhanced intra-plaque contrast agent were classified as vulnerable plaque group
89574466|NCT05524207||Stable plaque group|The patients with no contrast agent enhancement in the plaque showed preoperative contrast-enhanced ultrasound were classified as stable plaque group
89574467|NCT02392611|Experimental|Monotherapy: Alobresib 0.6 mg|Participants with advanced solid tumors and lymphomas who have failed or are intolerant to standard therapy or for whom no standard therapy exists, will receive alobresib at a dose of 0.6 mg to determine the MTD.
89574468|NCT02392611|Experimental|Monotherapy: Alobresib 1.4 mg|Participants with advanced solid tumors and lymphomas who have failed or are intolerant to standard therapy or for whom no standard therapy exists, will receive alobresib at a dose of 1.4 mg to determine the MTD.
89574469|NCT02392611|Experimental|Monotherapy: Alobresib 2 mg|Participants with advanced solid tumors and lymphomas who have failed or are intolerant to standard therapy or for whom no standard therapy exists, will receive alobresib at a dose of 2 mg to determine the MTD.
89574470|NCT02392611|Experimental|Monotherapy: Alobresib 3 mg|Participants with advanced solid tumors and lymphomas who have failed or are intolerant to standard therapy or for whom no standard therapy exists, will receive alobresib at a dose of 3 mg to determine the MTD.
89029134|NCT04331288|Experimental|PT150 with alcohol consumption|Study drug to be administered as a single, fixed dose over a 5-day period. An alcohol challenge will be completed on day 1 (pre-treatment) followed by blood draws over a 24-hour period. PT150 dosing will begin on study day 2 and continue until steady state is reached on day 6, at which point blood draws will occur over a 24-hour period. On day 7, after PT150 steady state has been achieved, an alcohol challenge will be completed followed by blood draws over a 40-hour period.
89029135|NCT04329156|Experimental|Digitally Flip Technique|
89029136|NCT04329156|Active Comparator|Stock Healing Abutment|
89029137|NCT04317820|Experimental|DBR Condition|Involves 8 weekly sessions of DBR treatment.
89029138|NCT04317820|No Intervention|Wait-list Condition|No intervention for approximately 8 weeks.
89029139|NCT04303715|Experimental|No SLNB group|The study arm - BCS without SLNB
89029140|NCT04303715|Other|SLNB group|The Control Arm - BCS with SLNB(+/-ALND)
89574471|NCT02392611|Experimental|Monotherapy: Alobresib 4 mg|Participants with advanced solid tumors and lymphomas who have failed or are intolerant to standard therapy or for whom no standard therapy exists, will receive alobresib at a dose of 4 mg to determine the MTD.
89574472|NCT02392611|Experimental|Monotherapy: Alobresib 6 mg|Participants with advanced solid tumors and lymphomas who have failed or are intolerant to standard therapy or for whom no standard therapy exists, will receive alobresib at a dose of 6 mg to determine the MTD.
89574473|NCT02392611|Experimental|Combination Therapy: Alobresib 2 mg + Exemestane|Participants with advanced stage estrogen receptor positive breast cancer for whom no standard curative therapy exists, will receive alobresib at a dose of 2 mg in combination with exemestane 25 mg.
89574474|NCT02392611|Experimental|Combination Therapy: Alobresib 2 mg + Fulvestrant|Participants with advanced stage estrogen receptor positive breast cancer for whom no standard curative therapy exists, will receive alobresib at a dose of 2 mg in combination with fulvestrant 500 mg.
89029141|NCT04298970|Active Comparator|Intervention|Consuming a product containing 35-40 gram of freeze dried kale a day.
89029142|NCT04298970|Placebo Comparator|Placebo|Consuming a placebo product.
89029143|NCT04293055|Experimental|Maintenance program+possibility of phone coaching|All participants are provided with a monthly newsletter which contains useful strategies for maintaining weight loss long-term. Participants are also encouraged to weigh themselves daily using a smart scale, which electronically transmits weight data to the research staff. Some participants randomized to this condition will also receive 4 consecutive weeks of phone coaching at some point over the 1-year intervention period (this is determined by a weight-based algorithm).
89574475|NCT02392611|Experimental|Combination Therapy: Alobresib 3 mg + Fulvestrant|Participants with advanced stage estrogen receptor positive breast cancer for whom no standard curative therapy exists, will receive alobresib at a dose of 3 mg in combination with fulvestrant 500 mg.
89574476|NCT02378961|Experimental|VOX+SOF/VEL 6 wk, TN, without cirrhosis|VOX + SOF/VEL for 6 weeks (treatment naive (TN), without cirrhosis)
89574477|NCT02378961|Experimental|GS-9857+SOF/VEL 6 wk, TN, with cirrhosis|GS-9857 + SOF/VEL for 6 weeks (treatment naive, with cirrhosis)
89574478|NCT02378961|Experimental|VOX+SOF/VEL 8 wk, TN, with cirrhosis|GS-9857 + SOF/VEL for 8 weeks (treatment naive, with cirrhosis)
89574479|NCT02378961|Experimental|VOX+SOF/VEL 8 wk,TE, without cirrhosis|GS-9857 + SOF/VEL for 8 weeks (treatment experienced (TE), without cirrhosis)
89574480|NCT02378961|Experimental|VOX+SOF/VEL 12 wk, TE, without cirrhosis|VOX + SOF/VEL for 12 weeks (treatment experienced, without cirrhosis)
89574481|NCT02378961|Experimental|GS-9857+SOF/VEL 8 wk, TE, with cirrhosis|GS-9857 + SOF/VEL for 8 weeks (treatment experienced, with cirrhosis)
89574482|NCT02378961|Experimental|VOX+SOF/VEL 12 wk, TE, with cirrhosis|VOX + SOF/VEL for 12 weeks (treatment experienced, without cirrhosis)
89574483|NCT02378883|Other|AVM treatment|Apollo™ Onyx™ Delivery Micro Catheter
89574484|NCT05145829|Experimental|Melanoma patients|All patients will undergo lymphatic mapping with SPIO, 99mTc and PB.
89574485|NCT05531071|Active Comparator|Biofeedback electrical stimulation|Use the PHENIX USB4 Pelvic Floor Rehabilitation Therapy Apparatus to enter the Stress Urinary Incontinence Treatment Module. The frequency of electrical stimulation was 50Hz, the pulse width was 250μs, and the current intensity increased from 0mA, generally not exceeding 50mA. For the 1st to 3rd treatments, intermittent bioelectrical stimulation mode was given.For the 4th to 10th treatments, the biofeedback mode with intermittent bioelectrical stimulation was given, and for the 11th to 15th treatments, the simple biofeedback mode was given. 3 times a week, 30 minutes each time, a total of 15 treatments. Instruct the patient to go home to perform pelvic floor muscle training, focusing on anal contractions. Each anal contraction takes 3-5s and relaxes for 5-10s. so repeatedly. 20 minutes each time, 3 times a day in the morning, noon and evening, 5 days a week, until the end of the treatment.
89574486|NCT05531071|Active Comparator|Acupuncture|A single-use sterile needle of Changchun Aikang brand was selected, with a size of 0.30 mm × 40 mm. Ding points: Guanyuan point, Qihai point, Zhongji point, Zusanli point, Sanyinjiao point, Yinlingquan point. Routine disinfection of the patient's skin is performed, and Guanyuan, Qihai, and Zhongji points are punctured obliquely downward, and the needle is inserted 1-1.2 cun; evenly lift, insert and twist to get qi. At the same time, the moxa column was ignited and placed in the moxibustion box, and the moxibustion box was placed above the three points of Guanyuan, Qihai, and Zhongji in the patient's abdomen, and the moxibustion was performed until the skin was red and the deep tissue was heated. 1 time a day, every Monday to Friday, 30 minutes each time, 10 times as a course of treatment. The patients were instructed to go home for pelvic floor muscle training, and the method was the same as that of group Biofeedback electrical stimulation.
89574487|NCT05531071|Experimental|Acupuncture combined with biofeedback electrical stimulation|Biofeedback electrical stimulation therapy combined with acupuncture and moxibustion were given to the patients. After 10 sessions of acupuncture, continue the unfinished biofeedback electrical stimulation treatment. The patients were instructed to go home for pelvic floor muscle training, and the method was the same as that of group Biofeedback electrical stimulation.
89574488|NCT05518591|Experimental|CFT & BPR|6-week, virtual, psychological therapy group involving compassion focused therapy and breathing pattern retraining. This group involves exercises in practicing self-compassion, emotional regulation, and breathing retraining.
89574489|NCT05518591|No Intervention|Treatment As Usual|Those in the treatment as usual arm are not being asked to engage in anything additional to their regular treatment plan. They will, however, be given the option to participate in the psychological intervention after the study has ended, if they elect to do so.
89574490|NCT05518513|Experimental|Continuous infusion|adductor canal block with continuous infusion of 0.25% bupivacaine 3.5 ml per hour for 2 days postoperatively
89574491|NCT05518513|Active Comparator|12hrs intermittent bolus|adductor canal block with intermittent bolus of 0.25% bupivacaine 21 ml every 12 hours for 2 days postoperatively
89574492|NCT05518513|Experimental|6hrs intermittent bolus|adductor canal block with intermittent bolus of 0.25% bupivacaine 21 ml every 6 hours for 2 days postoperatively
89574493|NCT05518279|Active Comparator|Tranexamic Acid Treatment Group|The intervention for the treatment group is as follows: participants in this treatment arm will given 1950mg of oral tranexamic acid pills (3 tablets, 650mg each) in the emergency department following diagnosis of hip fracture.
89574494|NCT05518279|Placebo Comparator|Oral Placebo Control Group|The intervention for the control group is as follows: participants in this treatment arm will given 3 tablets of oral placebo pills in the emergency department following diagnosis of hip fracture.
89574495|NCT04424953|Active Comparator|McGrath videolaryngoscope|Anesthetists randomized to this group will intubate patients using the McGrath videolaryngoscope
89574496|NCT04424953|Active Comparator|Direct laryngoscope|Anesthetists randomized to this group will intubate patients using the direct laryngoscope
89574497|NCT05523193||Treatment group|"Treatment group (Formal treatment model group): Patients who agree and accept the surgical treatment recommendation (including medical and surgical treatment) enter the formal treatment model group.~Those who have received any of the following treatments (including but not limited to) as recommended by the standardized treatment process are considered to have received the standardized treatment, otherwise, they have not.~Surgical procedures: valve repair or replacement, left auricular ligation, left auricular clip.~Internal surgery: transcatheter valve replacement, radiofrequency ablation of atrial fibrillation, and left heart ear occlusion."
89209143|NCT00881556|Experimental|RIC Group|"Reduced Intensity Transplant Conditioning (RIC):~Palifermin (Kepivance®) 60 mcg/kg/day for 6 days Fludarabine 30 mg/m2 IV x 1 for 6 days Busulfan 4 mg/kg/day IV divided BID for 4 days Lorazepam 0.02-0.05 mg/kg for 5 days Alemtuzumab 20 mg/m2 IV for 5 days Tacrolimus 0.03mg/kg/24 hours as continuous infusion for 4 days"
89209144|NCT00874380||1|First describe the diet of a cohort of dialysis patients with focus on fiber content.
89209145|NCT00881634|Experimental|1|Cetirizine HCl/Pseudoephedrine HCl 5 mg/120 mg Tablets (Sandoz, USA)
89209146|NCT00881634|Active Comparator|2|Zyrtec-D 12 Hour 5 mg/120 mg Extended Release Tablets (Pfizer, USA)
89209147|NCT00874458|Experimental|MRI|
89209148|NCT00874536|Experimental|ALA|This group will receive the ALA supplement
89209149|NCT00874536|Placebo Comparator|Placebo|This group will receive the placebo supplement
89209150|NCT00733499|Other|LCS Complete Duofix|102 patients
89209151|NCT00733499|Active Comparator|LCS Complete Porocoat|104 patients
89209152|NCT00878748|Experimental|A|Effexor XR
89209153|NCT00878748|Other|B|Effexor XR discontinue
89517483|NCT00630565|Experimental|Bone Marrow Transplant (less and 2 years old)|Patients under the age of two, and patients who cannot receive total body irradiation (TBI), will receive a cytoreductive regimen of Busulfan and cyclophosphamide (BU/CY) as per the Johns Hopkins University Hospital regimen as well as sargramostim, dexamethasone, etoposide, transplantation (bone marrow transplantation/hematopoietic stem cell transplantation/peripheral blood stem cell transplantation).
89517484|NCT00598481|Experimental|Gene Therapy|Infusion of autologous CD34+ cells transduced with retroviral vector encoding ADA after non-myeloablative conditioning with busulfan
89517485|NCT00442195||1|Healthy Volunteers
89517486|NCT04437693|Experimental|Hydroxychloroquine|400mg twice a day on day 1 followed by 400 mg weekly for 7 weeks.
89517487|NCT04437693|Placebo Comparator|Placebo|2 tablets (Placebo White tablets) twice daily on day 1 followed by 2 tablets weekly for 7 weeks
89517488|NCT02317679|Experimental|Bosentan and laser|Patients with PWS resistant to PDL treatment will be included. A test area of the PWS will be treated by pulsed dye laser (PDL) (λ= 595 nm, 7 mm spot diameter, τp= 1.5 ms, same energy density used at the last session for each subject). The treatment by Bosentan (twice daily :2 mg/kg and maximum 62,5 mg) will be given 1 day before the PDL irradiation (maximum area treated 100 cm2) and continued for 14 days. The clinical improvement of the lesions will be evaluated by comparing standardized pictures, 14 days after the end of the treatment by Bosentan which corresponds to 1 month after the laser PDL irradiation. The evaluation will be realized by 2 independent physicians blinded to the area treated or not. Hemoglobin and SGOT/SGPT will be controlled before and after the treatment by Bosentan.
89517489|NCT05009667||IMR first group|In this group, IMR based on pressure wire and arterial physiological detector will be measured first, and then caIMR base on angiography images and pressure sensor will be measured secondly.
89517490|NCT05009667||caIMR first group|In this group, caIMR based on angiography images and pressure sensor will be measured first, and then IMR based on pressure wire and arterial physiological detector will be measured secondly.
89517491|NCT02315807|Experimental|dlPFC|Participants in the chronic post-stroke stage will receive active transcranial direct current stimulation in dorsolateral prefrontal cortex
89517492|NCT02315807|Experimental|CON|Participants in the chronic post-stroke stage will receive active transcranial direct current stimulation in cingulo-opercular network
89517493|NCT02315807|Active Comparator|M1|Participants in the chronic post-stroke stage will receive active transcranial direct current stimulation in motor primary cortex
89517494|NCT03475381||Orkambi treated patients|All patients with CF who started ivacaftor+lumacaftor outside of a clinical trial between January 22nd 2016 and January 22nd 2017.
89517495|NCT02315963|No Intervention|No intervention group|Patients in stroke rehabilitation receiving standard therapy
89517496|NCT02315963|Active Comparator|Intervention group|Patients in stroke rehabilitation receiving standard therapy plus performance feedback
89517497|NCT05389891|Experimental|Group 1|Experimental Group (n=54) The implementation phase was achieved through sessions within Feb-April2017 second semester of the academic year 2016/2017.Each session started by the objectives of the new session and summary of previous one. Motivation and reinforcement during session were used to enhance participation and sharing in this study. The researcher did the explanation of the questionnaire sheet to the pediatric student nurses to assess their awareness and attitude toward hemoglobinopathies. The researcher observed the pediatric student nurses 'practice during applying blood transfusion, subcutaneous medication administration, and oral medication administration using the observational checklist at faculty laboratory.
89517498|NCT05389891|No Intervention|Group 2|Control Group (n=54) The researcher did the explanation of the questionnaire sheet to the pediatric student nurses to assess their awareness and attitude toward hemoglobinopathies. The researcher observed the pediatric student nurses 'practice during applying blood transfusion, subcutaneous medication administration, and oral medication administration using the observational checklist at faculty laboratory.
89517499|NCT03855111|Experimental|Standard (fixed) protocol Acu/Moxa - Active|"Standard (Fixed) Acupuncture / Moxibustion Active Protocol~Subjects receive active standard Acu/Moxa protocol aimed at reducing neuropathic pain/discomfort."
89517500|NCT03855111|Experimental|Individualized (tailored) protocol Acu/Moxa - Active|"Individualized (Tailored) Active Acupuncture / Moxibustion Protocol~Subjects receive active individualized Acu/Moxa protocol based on traditional Chinese medicine assessment aimed reducing neuropathic pain/discomfort."
89517501|NCT03855111|No Intervention|Sham Acu/Placebo Moxa (Control)|"Sham Acu/Placebo Moxa (Control)~Note. All subjects randomized to the Control will be offered 12 active protocol acupuncture/ moxibustion treatments, at no cost, at the end of their study participation."
89209154|NCT04088045|Experimental|Receiving PRP injections or PRP plus neural prolotherapy|"This experiment compares the effect of injecting PRP alone into the knee joint and pes anserinus complex with when dextrose solution is also injected to the genicular nerves.~The injection of dextrose solution is to decrease the inflammation of the genicular nerves, hoping to further effectively alleviate the knee pain condition. Therefore, upon the conclusion of this study, we can see whether the inclusion of dextrose injection in addition to PRP treatment can really be effective in treating patients with more severe degrees of knee OA."
89574498|NCT05523193||Control group|Control group（Conventional treatment model group）:Patients who do not agree to enter the Formal treatment model group will automatically enter the Conventional treatment model group.
89574499|NCT05523037||Group S|"Anesthesia induction was achieved by continuous infusion of 6 mg/kg/h of remimazolam, and the maintenance of anesthesia was maintained at a BIS between 40 and 60.~For the maintenance of anesthesia, the end-tidal concentration of 1 minimum alveolar concentration (MAC) sevoflurane was administered"
89574500|NCT05523037||Group R|"Anesthesia induction was achieved by continuous infusion of 6 mg/kg/h of remimazolam, and the maintenance of anesthesia was maintained at a BIS between 40 and 60.~For the maintenance of anesthesia, 1-2 mg/kg/h of remimazolam was continuously infused."
89574501|NCT04625647|Experimental|Treatment (AMG 510)|Patients receive AMG 510 PO QD on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89574502|NCT05122741||Acute Myocardial Infarction|40 patients with clinical presentation of acute myocardial infarction undergoing primary percutaneous coronary intervention and eligible for dual antiplatelet therapy (DAPT) with either prasugrel or ticagrelor on top of aspirin.
89574503|NCT05122741||Chronic Coronary Syndrome|10 patients with stable coronary artery disease with an indication, according to current guidelines, to percutaneous coronary intervention and subsequent DAPT with aspirin and clopidogrel.
89574504|NCT05525767|Experimental|Assigned Interventions|Bevacizumab 10mg/Kg d1, 1/21d
89574505|NCT05522725|Experimental|Intervention phase|Single-use wipes installed at the bedside
89574506|NCT05522725|No Intervention|Non-intervention phase|Standard practice according to Israeli ministry of health (MOH)
89574507|NCT05025085|Experimental|Monotherapy with AGEN1777|3+3 Dose escalation of AGEN1777 will be administered by Intravenous (IV) infusion every 3 weeks (each cycle is 21 days [3 weeks]).
89574508|NCT05025085|Experimental|AGEN1777 in combination with a PD-1 inhibitor|3+3 Dose escalation of AGEN1777 in combination with a PD-1 inhibitor will be administered by IV infusion with specified dose on specified days.
89574509|NCT05522491|Experimental|Olapalib|Olaparib Oral 300mg 2/day; 4 weeks (28 days) as a treatment cycle.
89574510|NCT02340975|Experimental|Phase 1b-M20 mg/kg (Q4W) + T 1 mg/kg (Q4W) Fw M10 mg/kg (Q2W)|Participants in second-line therapy with gastric or gastroesophageal junction (GEJ) adenocarcinoma will receive intravenous (IV) infusion of 20 mg/kg MEDI4736 every 4 weeks (Q4W) for 4 months (up to 4 doses) in combination with IV 1 mg/kg tremelimumab Q4W for 4 months (up to 4 doses in total). Thereafter, participants will receive MEDI4736 monotherapy (10 mg/kg) every 2 weeks (Q2W) to complete a total of 12 months of therapy (up to 18 additional doses).
89574511|NCT02340975|Experimental|Phase 2 Arm A-(M20 mg/kg (Q4W) + T1 mg/kg Fw M10 mg/kg (Q2W)|Participants in second-line therapy with metastatic or recurrent gastric or GEJ adenocarcinoma will receive IV infusion of 20 mg/kg MEDI4736 Q4W for 4 months (up to 4 doses) in combination with IV 1 mg/kg tremelimumab Q4W for 4 months (up to 4 doses in total). Thereafter, participants will receive MEDI4736 monotherapy (10 mg/kg) every 2 weeks (Q2W) to complete a total of 12 months of therapy (up to 18 additional doses).
89574512|NCT02340975|Experimental|Phase 2 Arm B-M10 mg/kg (Q2W)|Participants in second-line therapy with metastatic or recurrent gastric or GEJ adenocarcinoma will receive IV infusion of 10 mg/kg MEDI4736 Q2W for 12 months (up to 26 doses).
89574513|NCT02340975|Experimental|Phase 2 Arm C-T10 mg/kg (Q4W)|Participants in second-line therapy with metastatic or recurrent gastric or GEJ adenocarcinoma will receive IV infusion of 10 mg/kg tremelimumab Q4W for 7 doses and then Q12W for 2 doses for 12 months (for a total of up to 9 doses).
89574514|NCT02340975|Experimental|Phase 2 Arm D-M20 mg/kg (Q4W) + T1 mg/kg Fw M10 mg/kg (Q2W)|Participants in third-line therapy with metastatic or recurrent gastric or GEJ adenocarcinoma will receive IV infusion of 20 mg/kg MEDI4736 Q4W for 4 months (up to 4 doses) in combination with IV 1 mg/kg tremelimumab Q4W for 4 months (up to 4 doses in total). Thereafter, participants will receive MEDI4736 monotherapy (10 mg/kg) every 2 weeks (Q2W) to complete a total of 12 months of therapy (up to 18 additional doses).
89574515|NCT02340975|Experimental|Phase 2 Arm E-M20 mg/kg (Q4W) + T1 mg/kg Fw M10 mg/kg (Q2W)|Participants in second and third-line therapy with metastatic or recurrent gastric or GEJ adenocarcinoma and a positive IFN-γ gene expression signature will receive IV infusion of 20 mg/kg MEDI4736 Q4W for 4 months (up to 4 doses) in combination with IV 1 mg/kg tremelimumab Q4W for 4 months (up to 4 doses in total). Thereafter, participants will receive MEDI4736 monotherapy (10 mg/kg) every 2 weeks (Q2W) to complete a total of 12 months of therapy (up to 18 additional doses).
89574516|NCT02392377|Experimental|Arm I (paclitaxel, carboplatin, radiation therapy, surgery)|"INDUCTION: Patients receive chemotherapy with carboplatin and paclitaxel. Patients receive carboplatin (AUC=2) and paclitaxel (90 mg/m2) intravenously on days 1 and 8 of a 21 day treatment cycle for two cycles (total of 6 weeks).~CHEMORADIATION THERAPY: Patients receive carboplatin (AUC=2) and paclitaxel (50 mg/m2) intravenously once weekly for five weeks throughout the duration of their radiation which is daily (Monday through Friday).~SURGERY: Approximately 4-10 weeks after completion of chemoradiation therapy, patients undergo esophagectomy at the discretion of the treating team."
89574517|NCT02392377|Experimental|Arm II (combination chemotherapy, radiation therapy, surgery)|"INDUCTION: Patients receive mFOLFOX6 where they get oxaliplatin 85 mg/m2 intravenously on day 1, leucovorin 400 mg/m2 IV on day 1, 5-FU 400 mg/m2 IV on day 1 and then 5FU at 2400 mg/m2 IV to be administered over a 46 hour period. This is repeated every 2 weeks for 3 cycles (total of 6 weeks).~CHEMORADIATION THERAPY: Patients receive oxaliplatin 85 mg/m2 IV on day 1 every 2 weeks for a total of 3 cycles (6 weeks) as well as 5FU 300 mg/m2/day over 96 hours via continuous infusion each week of radiation for a total of 6 weeks.~SURGERY: Approximately 4-10 weeks after completion of chemoradiation therapy, patients undergo esophagectomy at the discretion of the treating team."
89574518|NCT02340819|Experimental|Arm 1|0.05 mg/kg/day administered by subcutaneous injection over a 24-week period.
89574519|NCT04904289||Sepsis with MODS|Patients with sepsis occurred MODS.
89574520|NCT04904289||Sepsis without MODS|Patients with sepsis did not occur MODS.
89574521|NCT02340663|Experimental|SOVA bite splint|SOVA Bite splint: Over-the-counter, heat-and-mold bite splint. Investigators evaluate subject self-fabrication, and evaluate fit. Subjects wear splint nightly for one week. Polysomnographic data obtained from one night during the week. Subjects continue to wear splint for 3 months, dairy kept of nightly wear. Polysomnographic data obtained from one night at the end of three months.
89574522|NCT02340663|Active Comparator|Michigan Bite Splint|Michigan bite splint: Gold standard, custom acrylic bite splint made for subjects. Investigators evaluate fit. Subjects wear splint nightly for one week. Polysomnographic data obtained from one night during the week. Subjects continue to wear splint for 3 months, dairy kept of nightly wear. Polysomnographic data obtained from one night at the end of three months.
89574523|NCT02573467|Experimental|BYM338/bimagrumab 10 mg/kg|Participants received BYM338 10 mg/kg administered via intravenous infusion every 4 weeks for up to a maximum of 8 months after which they entered a 6-month, treatment-free follow-up period.
89574524|NCT02573467|Experimental|BYM338/bimagrumab 3 mg/kg|Participants received BYM338 3 mg/kg administered via intravenous infusion every 4 weeks for up to a maximum of 8 months after which they entered a 6-month, treatment-free follow-up period.
89574525|NCT02573467|Experimental|BYM338/bimagrumab 1 mg/kg|Participants received BYM338 1 mg/kg administered via intravenous infusion every 4 weeks for up to a maximum of 8 months after which they entered a 6-month, treatment-free follow-up period.
89574526|NCT02573467|Placebo Comparator|Placebo|Participants received placebo administered via intravenous infusion every 4 weeks for up to a maximum of 8 months after which they entered a 6-month, treatment-free follow-up period.
89574527|NCT05517733|Experimental|Platelet Rich Fibrin (PRF)|
89574528|NCT05517733|Experimental|Diode laser|
89574529|NCT05522413||Health Status|normal examination in recent six months and not fit inclusion criteria of suboptimal health status.
89574530|NCT05522413||Suboptimal health Status|(A) Sub-Health Questionnaire (SHSQ-25) ≧35 points (B) Resting blood pressure 120-139/80-89 mmHg measured more than 3 times a week (C) The PSQI score of the sleep questionnaire on the first test is greater than 5 points (D) Body mass index (BMI): 24~29 Kg/m2
89574531|NCT02337387|Experimental|Blosozumab Formulation A|Part A. Blosozumab administered as 2 subcutaneous (SC) injections in week 1 followed by once weekly (QW) injections SC in weeks 2 to 6, followed by six week follow-up period.
89574532|NCT02337387|Experimental|Blosozumab Formulation B|Part A. Blosozumab administered as 2 SC injections in week 1 followed by QW injections SC in weeks 2 to 6, followed by six week follow-up period.
89574533|NCT02337387|Placebo Comparator|Placebo|Part A. Placebo administered as 2 SC injections in week 1 followed by QW injections SC in weeks 2 to 6, followed by six week follow-up period.
89574534|NCT02337387|Experimental|Blosozumab (Part B)|Part B. Blosozumab formulation determined by Part A administered as 2 SC injections in week 1 followed by QW injections SC in weeks 2 to 6, followed by six week follow-up period.
89574535|NCT04903665||Cancer Arm|Participants with new diagnosis of gynecologic cancers, from whom blood samples will be collected.
89574536|NCT04903665||Benign Arm|Participants with new diagnosis of benign gynecologic diseases, from whom blood samples will be collected.
89574537|NCT02574247|Experimental|Training|Participants in the Training arm will undergo 15 hours of computerized auditory training across 10 laboratory visits. Medial olivocochlear reflex function and speech perception abilities will be measured before, during, and after the training visits to examine the changes in the measurements across time.
88971019|NCT00077233|Experimental|Arm D: FOLFOX + C225|Patients receive oxaliplatin 85 mg/m^2 IV infused over 120 minutes, then leucovorin 400 mg/m^2 over 2 hours followed by 5 FU 400 mg/m^2 IV bolus injection then 5 FU 2400 mg/m^2 continuous IV infusion over 46-48 hours every 2 weeks. Patients also receive cetuximab 400 mg/m^2 IV over 120 minutes day 1, then 250 mg/m^2 IV over 60 minutes weekly. All patients must be premedicated with diphenhydramine hydrochloride 50 mg (or a similar agent) IV prior to the first dose of cetuximab in an effort to prevent a hypersensitivity reaction. Premedication is recommended prior to subsequent doses, but at the Investigator's discretion the dose of diphenhydramine (or a similar agent) may be reduced.
88971020|NCT04566848||Gastrointestinal cancers|Patients with advanced stage colorectal cancer, gastric cancer and pancreatic cancer who develop malignant ascites
88971021|NCT04566848||Control|Patients with intraabdominal ascites with benign reasons (liver cirrhosis, Congestive heart failure, etc.) .
88971022|NCT03939429|Experimental|QPX2015|QPX2015, antibiotic
88971023|NCT03939429|Placebo Comparator|Placebo|Matched placebo
88971024|NCT02958631|Experimental|Fimasartan|Fimasartan 60mg, QD
88971025|NCT02958631|Active Comparator|Losartan|Losartan 50mg, QD
88971026|NCT04729894|Experimental|Safe Medication Storage Device + Education|
88971027|NCT04729894|Active Comparator|Education|
88971028|NCT00077311|Experimental|Chemotherapy without BNP7787|Chemotherapy with dose-dense docetaxel and cisplatin with pegfilgrastim and darbepoetin for pts with NSCLC
88971029|NCT00077311|Experimental|Chemotherapy + BNP7787|Chemotherapy with dose-dense docetaxel and cisplastin with pegfilgrastim and darbepoetin with the addition of BNP7787
88971030|NCT04561388|Other|Cochlear implant candidates with measurable residual hearing|"Electrocochleography responses to acoustic will be recorded during the cochlear implantation and the 6 first months of use of the cochlear implant.~A pure tone audiometry will be done prior and after the implantation. Speech audiometry will be done twice after the cochlear implantation."
89574538|NCT02574247|No Intervention|Control|Participants in the Control arm will undergo the same number of visits as the Training arm, but will not participate in computerized auditory training. Medial olivocochlear reflex function and speech perception abilities will be measured at each visit to establish the test-retest reliability of these measurements in the absence of any training.
89574539|NCT02574247|No Intervention|Speech Group|Participants in the Speech Group will undergo 1 visit. Medial olivocochlear reflex function and speech perception abilities will be measured at this visit to establish the correlation between these measures in the absence of any training.
89574540|NCT02391363|Experimental|Calmer Life|Cognitive behavior treatment for anxiety
89574541|NCT02391363|Active Comparator|Enhanced Community Care|Enhanced information and referral services for mental health and basic needs
89574542|NCT05522335|Active Comparator|BBV154 Lot-1|Safety Group : In this group, 1000 participants will be recruited, receive BBV154 vaccine (0.5 mL each dose) on day 0 and day 28 via intranasal route and assess for the safety.
89574543|NCT05522335|Active Comparator|BBV154 Lot-2|Safety Group : In this group, 1000 participants will be recruited, receive BBV154 vaccine (0.5 mL each dose) on day 0 and day 28 via intranasal route and assess for the safety.
89574544|NCT05522335|Active Comparator|BBV154 Lot-3|Safety Group : In this group, 1000 participants will be recruited, receive BBV154 vaccine (0.5 mL each dose) on day 0 and day 28 via intranasal route and assess for the safety.
89574545|NCT05522335|Active Comparator|COVAXIN®|Immunogenicity Group :In this group, 160 participants will be recruited, receive Covaxin vaccine (0.5 mL each dose) on day 0 and day 28 via intramuscular route and assess for the Immunogenicity.
89574546|NCT05512429||Stage-IV non small cell lung cancer (NSCLC)|Eighty-three patients with stage-IV NSCLC who received at least one cycle of platinum based chemotherapy (PBCT) or tyrosine kinase inhibitor (TKI) therapy and who underwent pre treatment fluorodeoxyglucose (FDG)-positron emission tomography (PET) /computed tomography (FDG PET/CT) from June 2012 to February 2019
89574547|NCT05522257|Other|Advanced soft tissue sarcoma (n=60) and advanced urothelial cell carcinoma (n=60)|The study population comprises sixty adult patients with diagnosis of advanced (locally irresectable or metastasized) soft tissue sarcoma (cohort 1) and sixty adult patients with diagnosis of advanced (muscle invasive or metastasized) urothelial cell carcinoma (cohort 2).
89574548|NCT04903509|Experimental|BI 1820237|Part 1 and part 2 of the trial.
89574549|NCT04903509|Placebo Comparator|Placebo|Part 1 and part 2 of the trial.
89574550|NCT04903509|Experimental|BI 1820237 + liraglutide|Part 3 of the trial.
89574551|NCT04903509|Placebo Comparator|Placebo + liraglutide|Part 3 of the trial.
89574552|NCT05517499|Experimental|Group A (Dexamethasone Group),|Group A (Case Group) was given dexamethasone i.e., 0.2 mg per kg per day every 12 hours for 7 days intravenously. All treatment strategies were same in both groups but steroid was given to group A
89574553|NCT05517499|No Intervention|Group B (Control Group)|Group B (Control group), received routine treatment.No dexamethasone
89574554|NCT05450211|Active Comparator|Group SFI (Suprainguinal fascia iliaca block)|"In the patient lying in the supine position, a high-frequency linear probe is inserted under sterile conditions, using an in-plane technique, 1 cm cephalad of the inguinal ligament with an 85 mm needle. Using hydro-dissection, the fascia iliaca is separated from the iliac muscle and a space is created where the needle can be advanced cranially, and the procedure will be completed by injecting local anesthetic into this space.~When the patient whose block procedure is successful, is taken to the recovery room, controlled analgesia will be applied to the patient and he will be transferred to the ward. Tramadol HCL will be used for postoperative pain control for PCA."
89574555|NCT05450211|Active Comparator|Group PCA (patient controlled analgesia)|No block attempt will be made to the patients in this group, and when the patient is taken to the recovery room after surgery, controlled analgesia will be administered and transferred to the ward. Tramadol HCL will be used for postoperative pain control for PCA.
89574556|NCT05512351|Experimental|Cohort 1|Subjects with ctDNA-level-relapse Oligodendroglioma before clinical relapse, determined according to the dynamics of TISF ctDNA.
89574557|NCT05512351|Experimental|Cohort 2|Subjects with clinical-relapse Oligodendroglioma, determined according to the response assessment in neuro-oncology (RANO) criteria for gliomas.
88971031|NCT00077350|Experimental|Treatment (triapine and gemcitabine hydrochloride)|Patients receive 3-AP (Triapine^®) IV over 2 hours and gemcitabine IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
89209155|NCT00652028|Other|Group 1|Dose level 1
89574558|NCT05512351|No Intervention|Cohort 3|Subjects without ctDNA-level-relapse and clinical-relapse Oligodendroglioma.
89574559|NCT04898985||500 patients in the LLS COVID-19 Registry with no/limited antibody response|Five hundred (500) patients participating in the LLS COVID-19 Registry, who have shown either no antibody or limited antibody response by way of the Spike Antibody test to one of the vaccinations authorized for emergency use (EUA) by FDA will participate in this Research Study.
89574560|NCT04898985||500 patients also participating in the LLS COVID-19 Registry with antibody response|500 patients with similar blood cancer diagnosis, also participating in the LLS COVID-19 Registry, who have shown full Spike antibody response to one of the vaccinations authorized for emergency use (EUA) by FDA will also be enrolled in this Research Study for comparison (as a control arm) and will also be followed for at least 10 years (in the COVID-19 Registry).
89209156|NCT00652028|Other|Group 2|Dose level 2
89209157|NCT00652028|Other|Group 3|Dose level 3
89209158|NCT00652028|Other|Group 4|Dose level 4
89574561|NCT05517343|No Intervention|Ordinary care (OC)|The participants of this arm received the endoscopic optical diagnosis, histological diagnosis of the resected colon polyps and the recommended surveillance colonoscopy schedule at next scheduled clinic visit (around 1 to 2 weeks later).
89574562|NCT05517343|Experimental|Real-time notification (RTN)|The participants of this arm received the endoscopic optical diagnosis of the resected colon polyps and the recommended surveillance colonoscopy schedule right after the sedated colonoscopy. Histological diagnosis will be informed at next scheduled clinic visit (around 1 to 2 weeks later).
89574563|NCT05517187|Placebo Comparator|Blood Clot BC (Control arm)|Regenerative endodontic treatment with induced Blood Clot in root canal space as a secondary treatment for failed root canal treated incisors
89574564|NCT05517187|Experimental|Platelets Rich Fibrin PRF (Intervention)|Regenerative endodontic treatment with Platelet- rich fibrin in root canal space as a secondary treatment for failed root canal treated incisors
89574565|NCT05512273|Experimental|Study|
89574566|NCT05512273|Active Comparator|Control|
89574567|NCT05521711|Experimental|Active low dose oral immunotherapy and Placebo sublingual immunotherapy|
89574568|NCT05521711|Experimental|Placebo low dose oral immunotherapy and Active sublingual immunotherapy|
89574569|NCT05521711|Experimental|Placebo low dose oral immunotherapy and Placebo sublingual immunotherapy|
89574570|NCT05516875|Experimental|High dose|JM-010 fixed combination drug (Group A) will be administered orally.
89574571|NCT05516875|Experimental|Low dose|JM-010 fixed combination drug (Group B) will be administered orally.
89574572|NCT02569957|Active Comparator|Arm I (topotecan hydrochloride)|Patients receive topotecan hydrochloride IV over 30 minutes on days 1, 8, and 15 (+/- 1 day window for each treatment day). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89574573|NCT02569957|Experimental|Arm II (topotecan hydrochloride, acetylcysteine)|Patients receive topotecan hydrochloride as in Arm I. Patients also receive acetylcysteine IV over 60 minutes on days 1, 8, 15, and 22 (+/- 1 day window for each treatment day) and acetylcysteine PO BID on days 2-7, 9-14, 16-21, and 23-28, unless administration window was utilized. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89574574|NCT01649427|Experimental|Prograf|Control therapy: one capsule containing 0.5 mg, 1mg or 5mg Prograf®, one tablet containing 180mg or 360mg Myfortic®, corticosteroids and one vial containing 20mg lyophilisate Simulect®
89574575|NCT01649427|Experimental|Tacroliums Hexal|Investigational therapy: one capsule containing 0.5mg, 1mg or 5mg Tacrolimus Hexal®, one tablet containing 180mg or 360mg Myfortic®, corticosteroids and one vial containing 20mg lyophilisate Simulect®
89574576|NCT05521633|Active Comparator|Metformin Group|Group-A; every participant took 500 mg of metformin daily
89574577|NCT05521633|Active Comparator|Pioglitazone Group|Group-B; every participant took 30 mg of pioglitazone daily
89574578|NCT05512195|Experimental|New delineation approach （NDA）group|use a new method for clinical target volume delineation by referencing the nerve fiber bundles
89574579|NCT05512117|Experimental|Midline Catheter|Midline catheter insertion
89574580|NCT05512117|No Intervention|Peripheral intravenous cannulation (PIVC)|Peripheral intravenous cannulation (PIVC)
89574581|NCT02375373||Observational Chickpea Diet|Observed long-term to study legume intake and GI health (Observational Chickpea Diet)
89574582|NCT05521555||total knee arthroplasty under 55|Patient who had total knee arthroplasty before 55 between January 2010 and December 2019
89574583|NCT02336607|Experimental|Felodipine tablet (Plendil)|
88971032|NCT00077428|Experimental|Treatment (bortezomib, doxorubicin hydrochloride)|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression continue to receive bortezomib as above and doxorubicin IV over 2-5 minutes on days 1 and 8. Treatment repeats every 21 days for up to 14 courses in the absence of further disease progression or unacceptable toxicity.
88971033|NCT00077467|Experimental|Arm I|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
88971034|NCT02965651|Experimental|ECA System|Access to website and virtual patient advocate
88971035|NCT02965651|No Intervention|Standard of Care|Patient information sheets and meditation CD
89574584|NCT02336607|Active Comparator|Felodipine tablet (Plendil)+Metoprolol tablet (Betaloc ZOK)|
89574585|NCT02336607|Active Comparator|Felodipine tablets (Plendil)+Lisinopril (Zestril)|
89574586|NCT02336607|Active Comparator|Felodipine tablet (Plendil)+Hydrochlorothiazide|
89574587|NCT02374671|Experimental|Implantation-Non-Randomized|Subjects are not participants in the randomized sub-study. VisAbility micro inserts surgically implanted in the eye(s) after enrollment and meeting inclusion/exclusion criteria.
89574588|NCT02374671|Experimental|Implantation-Randomized|Subjects are participants in the randomized sub-study. Subjects were randomized to the Immediate Treatment group. VisAbility micro inserts surgically implanted in the eyes. Subjects are participants in the randomized sub-study after enrollment and meeting inclusion/exclusion criteria.
89574589|NCT02374671|No Intervention|Deferred Implantation-Randomized|Subjects are participants in the randomized sub-study after enrollment and meeting inclusion/exclusion criteria. Subjects were randomized to the Deferred Treatment group are observed for 6 months. Upon completion of the observation follow-up, subjects can opt to have VisAbility micro inserts surgically implanted in the eye(s) and become part of the overall study experimental group.
89574590|NCT02569801|Active Comparator|Fulvestrant|Participants will receive 500 milligrams (mg) of fulvestrant as two intramuscular injections (250 mg each) on Day 1 and Day 15 of Cycle 1, and on Day 1 of each subsequent 28-day cycle until disease progression, unmanageable toxicity, withdrawal of consent, exhaustion of GDC-0810 drug supply, or termination of study by the Sponsor.
89574591|NCT02569801|Experimental|GDC-0810|Participants will receive three 200 mg tablets (total dose = 600 mg) of GDC-0810 orally once daily until disease progression, unmanageable toxicity, withdrawal of consent, exhaustion of GDC-0810 drug supply, or termination of study by the Sponsor.
89574592|NCT05521477|Experimental|participant procedure|"each participant will go through 3 phases of identical protocol. In each phases blood and stools will be collected at specific days, as well as cardiometabolic measures, transit time, cognitive tests and food consumption.~Each phase last 2 weeks with a washout period of 1 month in between. In the first phase, no treatment will be provided, in the second phase a low dose of probiotic (once a day for five days) will be given and in the third phase high dose of probiotic (twice a day for five days) will be administered."
89574593|NCT05516641|Experimental|Prebiotic|Soluble Corn Fiber
89574594|NCT05516641|Placebo Comparator|Control|Maltodextrin
89574595|NCT05521165|Experimental|group A|The patients in group (A) (n=29) will receive an American physical therapy association (APTA) guided program consisting of stretching exercises for global trunk, back muscles, and hamstring muscles, strengthening exercises for abdominal and back muscles, and stabilizing exercises for trunk and pelvic muscles.
89574596|NCT05521165|Experimental|group B|The patients in group (B) (n=29) will receive treatment as in group (A) in addition to selected G Med strengthening exercises.
89574597|NCT05511727|Active Comparator|single Foley's catheter group|
89574598|NCT05511727|Active Comparator|Double Foley's catheter group|
89574599|NCT05516407|Experimental|FEN164|"Full-Spectrum Medicinal Cannabis Plant Extract with less than 0.08% THC (FEN164)~Stage 1: 5mg/kg, 10mg/kg, 15mg/kg, 20mg/kg (1 week each) Stage 2: 20mg/kg (8 weeks), 15mg/kg, 10mg/kg, 5mg/kg (1 week each)"
89574600|NCT05511571|Experimental|TENS group|Transcutaneous electrical neural stimulation (TENS)
89574601|NCT05511571|Experimental|PRE group|Progressive relaxation exercises (PRE)
89574602|NCT05511571|Experimental|TENS+PRE group|Transcutaneous electrical neural stimulation (TENS) and Progressive relaxation exercises (PRE)
89574603|NCT05511571|No Intervention|Control group|
89574604|NCT02573311|Experimental|men|
89574605|NCT05520853|Experimental|SBRT combined with PD-1 inhibitors and thoracic hyperthermia|At least one lesion (primary or metastatic) was selected for SBRT treatment, and the radiotherapy dose of each lesion was 32Gy/4Fx. SBRT was combined with thoracic hyperthermia from the first fraction, and hyperthermia was performed 6 times, twice a week. PD-1 inhibitor was used on the second day after the completion of SBRT. The PD-1 inhibitor was administered at a dose of 200mg every time, every 3 weeks for 2 years (35 times total), or until the investigators deem that the patient need to discontinue the drug because of treatment-related toxicity or disease progression.
89574606|NCT05511493|Experimental|fractional(Er: YAG) laser with platelet-rich plasma|"Subjected to fractional erbium: yttrium-aluminum-garnet (Er: YAG) laser (FotonaXs~Dynamis, Slovenia) with the energy of 1400 mJ in short pulse mode (SP) with spot size of 7 mm diameter, frequency of 3 Hz, and pixel 1. PRP is applied over the treated areas.This procedure will be repeated every two weeks for six months"
89574607|NCT05511493|Experimental|Microneedling with platelet-rich plasma|"Subjected to microneedling using electronic dermapen device (Dr Pen Derma Pen Ultima A6®) which has a disposable head that personalized for each patient and sterilized after each session. The derma pen will penetrate the skin with variable depths ranging from 0.25 to 0.5 mm (not more than the depth of the epidermis). It will pass vertically over the vitiligo area in a circular pattern from the perilesional areas toward the depigmented center until pinpoint bleeding appears then the PRP is applied over the treated areas.~- This procedure will be repeated every two weeks for six months."
89574608|NCT05516251|Active Comparator|Topiramate|
89574609|NCT05516251|Experimental|Transcutaneous Supraorbital Nerve Stimulator|
88971036|NCT00077545|Experimental|Treatment (triapine and cisplatin)|Patients receive 3-AP (Triapine) IV over 2 hours on days 1-4. Patients also receive cisplatin IV over 60 minutes on days 2 and 3 before 3-AP infusion. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
88971037|NCT00077584|Experimental|Bosentan|The patients received bosentan 62.5 mg twice daily (b.i.d.) for 4 weeks and then 125 mg b.i.d. for 20 weeks
88971038|NCT00077584|Placebo Comparator|Placebo|The patients received the matching placebo for 24 weeks
88971039|NCT03780972|Active Comparator|Cohort 1 Dose A|Intravitreal injection of 50 μl of ONL1204 liquid formulation to deliver dose 1
89209159|NCT02592473|Experimental|Embozene Microspheres|Embozene Microspheres are spherical particles consisting of a hydrogel core and a poly nanocoat that will be used during study procedure, Prostatic Artery Embolization (PAE) to reduce or eliminate bloodflow to the prostate.
89574610|NCT05520697|Active Comparator|Control|Nutritional treatment with caloric restriction and mental exercise
89574611|NCT05520697|Experimental|Intervention|Nutritional treatment with caloric restriction, mental exercise, and physical training program.
89574612|NCT04886791|Experimental|VANH hysterectomy|Access to the peritoneal cavity will be performed similar to vaginal surgery by a circular incision around the cervix, anterior and posterior colpotomy and transsecting the sacro-uterine ligaments. The vNOTES port will be placed to get access to the abdominal cavity and a pneumoperitoneum will be created. After positioning in 20o degree Trendelenburg laparoscopic instruments will be introduced. The peritoneal cavity and ureters are inspected. The hysterectomy is performed by dissecting from caudally to cranially. The fallopian tubes will be removed elective after counselling in the outpatient clinic and the ovaries will be removed on indication only. Haemostasis is checked and the vNOTES port and the uterus are removed trans-vaginally and the pneumoperitoneum is deflated. The vaginal cuff will be closed using a running Vicryl-1 suture. The urinary bladder catheter will be removed directly postoperative.
89574613|NCT04886791|Active Comparator|Vaginal hysterectomy|A circumferential incision is made around the cervix. Access to the peritoneal cavity will be performed through anterior and posterior colpotomy. The sacro-uterine ligaments, ligamenta cardinalia uterine arteries will be clamped and dissected. Finally, the ovarian ligament, round ligament and fallopian tubes will be dissected and tied. The uterus will be removed and the vagina will be closed. The urinary bladder catheter will be removed directly postoperative.
88971040|NCT03780972|Active Comparator|Cohort 2 Dose B|Intravitreal injection of 100 μl of ONL1204 liquid formulation to deliver dose 2
88971041|NCT03780972|Active Comparator|Cohort 3 Dose C|Intravitreal injection of 50 μl of ONL1204 liquid formulation to deliver dose 3
88971042|NCT03780972|Active Comparator|Cohort 4 Dose D|Intravitreal injection of 100 μl of ONL1204 liquid formulation to deliver dose 4
88971043|NCT00399412||LQTS|Long QT syndrome
88971044|NCT00399412||HF|Heart Failure
88971045|NCT00399412||CRT|Cardiac Resynchronization Therapy
88971046|NCT00399412||Wide QRS|QRS > 120 milliseconds
88971047|NCT00399607||Aim 1|Participants previously randomized for the parent study will be eligible for a portion of the adjunct biomarker study.
88971048|NCT00399607||All aims|Participants entering the parent study will be eligible for all sample collections of the adjunct biomarker study.
89517502|NCT03855111|No Intervention|WaitList (Control)|"WaitList (Control) No treatment. Subjects receive all aspects of study participation with the exception of exposure to Acupuncture / Moxibustion.~Note. All subjects randomized to the Control will then be offered 12 active protocol acupuncture/ moxibustion treatments, at no cost, at the end of their study participation."
89029144|NCT04293055|Active Comparator|Maintenance program only|All participants are provided with a monthly newsletter which contains useful strategies for maintaining weight loss long-term. Participants are also encouraged to weigh themselves daily using a smart scale, which electronically transmits weight data to the research staff. No participants in this condition will receive phone coaching.
89517503|NCT02316041|Experimental|Small incision lenticule extraction|Small incision lenticule extraction (SMILE) is a form of corneal laser refractive surgery performed using a femtosecond laser
89517504|NCT03419221|Active Comparator|A: Patients with PET/CT performs at day 14 after the drawing|Arm A: Patients with PET/CT performs at day 14 after the drawing of the first blood culture
89517505|NCT03419221|Placebo Comparator|B : Patients' routine care with performance of explorations|Arm B : Patients' routine care with performance of explorations based on anamnesis and clinical symptoms
89517506|NCT02316119||Control group|Post-ACS patients without history of IS/TIA previously to the acute coronary and taking aspirin
89517507|NCT02316119||Case group|Post ACS patients with history of IS/TIA previously to the acute coronary event and taking aspirin
89517508|NCT04454983|Experimental|Lipiflow - All Subjects|Both Lipiflow and iLux procedures were performed bilaterally on all subjects on the same day. Subjects were randomized to which procedure they received first. There was a 1-hour wait between procedures.
89517509|NCT04454983|Experimental|iLux - All Subjects|Both Lipiflow and iLux procedures were performed bilaterally on all subjects on the same day. Subjects were randomized to which procedure they received first. There was a 1-hour wait between procedures.
89517510|NCT04462757|Active Comparator|Subcutaneous Arm|100mg anakinra SC will be administered subcutaneously at consistent times that are convenient and practical for the patients and research/nursing staff providing there is a minimum 8 hours and maximum 16 hours between administrations.
89517511|NCT04462757|Active Comparator|Intravenous Arm|100mg anakinra in 100mL 0.9% NaCl will be administered intravenously four times a day every 6 hours.
89517512|NCT04535505||pertussis test population|People with clinical diagnosis of suspected pertussis in outpatient and ward in the Children's Hospital of Fudan University will be collected as study subjects. Their nasopharyngeal swabs will be collected. Bordetella isolation culture and identification method is the gold standard, and the new CPA platform based on CRISPR technology is the method to be tested. Diagnostic values of this research platform would be detected.
89517513|NCT04462679|Experimental|Pilot arm|Mixed methods, acceptability and feasibility pilot of the COMMIT mHealth application
89517514|NCT02522689|Active Comparator|Ultra-mini PCNL|Endoscopic kidney stone surgery: Patients will undergo ultra-mini percutaneous nephrolithotripsy.
89517515|NCT02522689|Active Comparator|Micro PCNL|Endoscopic kidney stone surgery: Patients will undergo micro percutaneous nephrolithotripsy.
89517516|NCT04534101||Inpatient Subjects|Inpatients will be presented with an informed consent. If they sign the consent, they will then be given a VR headset pre- programmed with content that they may use for the duration of their stay. GI patients headsets will be collected when they are discharged. There are pain and anxiety analog scales at the end of each program. This data will be downloaded to Stanford. Patient's will not be entering their PHI. we will know who has headsets, as they will be numbered. Patient who are hospitalized for chronic pain will be allowed to take the VR headset home for month and be asked to return it at their followup outpatient visit.
89517517|NCT04534101||Outpatient Subjects|Outpatient: Patient's who are about to undergo gastrointestinal disease testing or be seen for an outpatient GI appointment will be presented with an informed consent. If they sign the consent, they will be given the VR headset to use prior to their procedure. There are pain and anxiety analog scales at the end of each program. This data will be downloaded to Stanford Medicine Box.Patient's will not be entering their PHI. we will know who has headsets, as they will be numbered.
89517518|NCT02320799|Active Comparator|treatment as usual|Usual Clinic psychosocial treatment
89517519|NCT02320799|Experimental|interpersonal psychotherapy|Interpersonal Psychotherapy is an evidence-based structured, brief psychotherapy which focuses on improving relationships in order to improve mood and reduce anxiety.
89517520|NCT04934943||Intervention _mini_FC|"The fluid challenge consists of 4 ml*Kg of Crystalloids' solution infused over 10 minutes, administered via either a central or a peripheral line.~The patient is already connected to the PICCO monitoring for clinical purpose of hemodynamic monitoring (before study enrollment)~The MOSTCARE system is connected to the MONITOR of the patient (and not to the patient itself) by means of a cable inserted into the connections system.~The echocardiography will be performed by a senior intensivist/cardiologist. The stroke volume is calculated by measuring VTI and diameter at the same point. This is best performed by measuring the diameter of the LVOT in the parasternal long axis (PLAX) view"
89517521|NCT03498599|Experimental|Novelty facilitated extinction|Behavioral intervention. After Pavlovian fear conditioning, the shock is omitted and replaced by a novel, surprising, and neutral auditory tone.
89517522|NCT03498599|Other|Standard extinction|The shock is omitted during standard extinction
89517523|NCT03130543|No Intervention|Standard Formula|This is the group of subjects randomized to receive their standard formula
89517524|NCT03130543|Experimental|Standard Formula with Rice Cereal|This is the group of subjects randomized to receive their standard formula with rice cereal added
89517525|NCT03130543|Experimental|Enfamil AR|This is the group of subjects randomized to receive Enfamil AR
89517526|NCT03500783|Experimental|Nitric Oxide|Patients of this group receive treatment with exogenous gaseous nitric oxide supplied directly to the oxygenator in the cardiopulmonary bypass circuit during coronary artery bypass grafting for coronary artery disease.
89574614|NCT05516173||Ambulatory patients|"Patient with a high blood pressure during regular visit will undertake an ambulatory blood pressure monitoring. Before wearing the device , they will be asked to answer to the questionnaire and the investigators will gather their demographic,clinical characteristics and dietary habits data.~Ethical considerations will be undertaken and respected."
89574615|NCT02571049|Experimental|Sumatriptan 3 mg then 6 mg|DFN-11 (sumatriptan, 3 mg) and placebo first then two DFN-11 injections
89574616|NCT02571049|Experimental|Sumatriptan 6 mg then 3 mg|Two DFN-11 (sumatriptan, 3 mg) injections first then DFN-11 injection and placebo
89574617|NCT04597801|Experimental|Fluorescein sodium|A single dose of fluorescein sodium is applied before brain tumor resection. 20-40 minutes prior to the planned tumor resection, a bolus of 5 mg per kg body weight is administered intravenously, staining tumor tissue with fluorescent dye to visualize tumor cells.
89574618|NCT05516095|Active Comparator|Active iTBS|iTBS will be delivered with 120% of resting motor threshold, triplet 50 Hz bursts repeated at 5 Hz; 2 seconds on and 8 s off, 600 pulses per session with a total duration of 3 min 9 s. Treatment will be provided for 10 days for two consecutive weeks (except Saturdays and Sundays). Each patient will start treatment at the same time between 9 am and 3 pm during the 10-day treatment period.
89574619|NCT05516095|Placebo Comparator|Sham iTBS|The sham system has an identical look, weight and sound compared to the true coil, and delivers electrical stimulation that can be felt at the skin but without penetrating the skull and thus not inducing any treatment effect. The sham stimulation will be given with the same procedure as the active stimulation; 2 seconds on and 8 s off, 600 pulses per session with a total duration of 3 min 9 s.
89574620|NCT04296955|Experimental|Health communication intervention|Motivational interview as a new health communication intervention (one arm)
89574621|NCT04296955|No Intervention|Standard care|Standard care
89574622|NCT04979533|Experimental|Oxygen Insufflation|Oxygen insufflation via oxygen tubing at 15 L/min
89574623|NCT05511259|Experimental|Intervention|Square stepping exercise
89574624|NCT05511259|No Intervention|Control|Passive control group
89574625|NCT05520151|Experimental|ORAL impact group|This group of patients will receive a 7-day course of IMPACT ORAL 10 days before the operation.
89574626|NCT05520151|Other|control|a retrospective cohort of patients operated on between 2016 and 2019 by nephrectomy cystectomy and laparotomy who did not receive oral impact
89574627|NCT05519995||Sensate II Users|Users will be adults (18+ years of age) who have been using the Sensate II device for stress management for a minimum of 30-days or 1-month
89574628|NCT04297423|Experimental|Plenvu|Plenvu split dose
89574629|NCT04297423|Active Comparator|Citrafleet|citrafleet in split dose
89574630|NCT05515861|Experimental|EUS group|The EUS group uses endoscopic ultrasound to observe the diameter and blood flow of residual variceal veins after endoscopic cyanoacrylate injection for gastric varices to evaluate the embolization effect.
89574631|NCT05515861|No Intervention|Control group|The control group doesn't perform endoscopic ultrasound after endoscopic cyanoacrylate injection for gastric varices.
89574632|NCT04295941||Trazodone once-a-day treated patients|Major Depressive Disorder outpatients who, following an initial positive response to the acute treatment with Trazodone once-a-day monotherapy, will be eligible to enter the continuation therapy and will be observed up to 24 weeks.
88971049|NCT04711447|Other|no-tape, experimental KT, sham KT|Participants were asked to perform a repeated arm elevation task during three different taping conditions: no KT, experimental KT and sham KT. Each taping condition performed the repeated arm elevation task during two loading conditions: no load and loaded with 2.3 kilograms. All six conditions were tested during one visit with the no load condition preceding the loaded condition for each taping condition. This trial consisted of a baseline trial (no KT; N-KT) that was performed first, followed by both an experimental-KT (E-KT) and sham-KT (S-KT) condition.
88971050|NCT04711447|Other|no-tape, sham KT, experimental KT|Participants were asked to perform a repeated arm elevation task during three different taping conditions: no KT, experimental KT and sham KT. Each taping condition performed the repeated arm elevation task during two loading conditions: no load and loaded with 2.3 kilograms. All six conditions were tested during one visit with the no load condition preceding the loaded condition for each taping condition. This trial consisted of a baseline trial (no KT; N-KT) that was performed first, followed by both a sham-KT (S-KT) condition and experimental-KT (E-KT).
88971051|NCT04711213|Active Comparator|Dexamethasone Dose 1|
88971052|NCT04711213|Active Comparator|Dexamethasone Dose 2|
89574633|NCT05510869|Experimental|B-MICS 1.4 mm|bimanual 1.4 mm cataract surgery (B-MICS)
89574634|NCT05510869|Active Comparator|C-MICS 1.8 mm|coaxial 1.8 mm cataract surgery (C-MICS)
89574635|NCT05510869|Active Comparator|C-SICS 2.4 mm|coaxial 2.4 mm small incision cataract surgery (C-SICS)
89574636|NCT05515549||Venous thrombosis group|"The venous blood of the patients under fasting state was collected, and the level of thrombus molecular markers was detected. Color Doppler ultrasound was used as the gold standard to determine whether VTE occurred."
89574637|NCT05515549||Group without venous thrombosis|"The venous blood of the patients under fasting state was collected, and the level of thrombus molecular markers was detected. Color Doppler ultrasound was used as the gold standard to determine whether VTE occurred."
88971053|NCT04711213|Placebo Comparator|Placebo Dose 1|
88971054|NCT04711213|Placebo Comparator|Placebo Dose 2|
88971055|NCT03697707|Experimental|Cohort 1: Low dose|patients receiving 4 bi-weekly vaccinations with 25E6 cells/vaccination of DCP-001, and 2 booster vaccinations with 10E6 cells/vaccination
88971056|NCT03697707|Experimental|Cohort 2: High dose|patients receiving 4 bi-weekly vaccinations with 50E6 cells/vaccination of DCP-001, and 2 booster vaccinations with 10E6 cells/vaccination
88971057|NCT00078247|Experimental|1|Participants will receive 6 months of ARV therapy and treatment for TB
88971058|NCT00078247|Experimental|2|Participants will not receive ARV therapy until CD4 counts drop below 250 cells/mm3. All participants will receive treatment for TB.
88971059|NCT04534751|Experimental|Intervention Group- Clotting Factor Concentrates|"Fibryga + Octaplex (Fibrinogen + PCC)~Fibrinogen Concentrate 4g (Fibryga) + Prothrombin Complex Concentrate 2000 IU (Octaplex) in the first and second massive hemorrhage protocol (MHP) packs."
88971060|NCT04534751|Active Comparator|Control Group: Standard FP transfusion|Frozen Plasma (FP)
88971061|NCT00078442|Experimental|1|Participants will receive weekly injections of 180 mcg PEG-IFN alfa-2a at the clinic for 12 weeks. After Week 12, participants will be followed off-treatment until Week 18.
88971062|NCT03696810|Other|• Laboratory tests|• Laboratory tests (HbA1C levels and lipids)
88971063|NCT04510454|Experimental|RT-PCR and ddPCR sampling analyses|Nasopharyngeal and throat/oropharyngeal swabs analyzed by both RT-PCR and ddPCR
88971064|NCT00078520|Experimental|Dose Level 1|Patients may be treated with a minimum of 3-6 injections of their IL-2-secreting and CD40L-expressing autologous B-CLL cells, separated by one to two weeks in an immunological treatment window. Any patient whose disease regresses after the administration of 6 injections may be offered further injections (i.e. more than 6 injections) of tumor vaccine at the dose level previously administered, if enough vaccines are available. Patients will receive a fixed dose of IL-2 secreting B-CLL cells throughout the entire treatment protocol while an escalating number of CD40L-expressing B-CLL cells will be given at each dose-level.
88971065|NCT00078520|Experimental|Dose Level 2|Patients may be treated with a minimum of 3-6 injections of their IL-2-secreting and CD40L-expressing autologous B-CLL cells, separated by one to two weeks in an immunological treatment window. Any patient whose disease regresses after the administration of 6 injections may be offered further injections (i.e. more than 6 injections) of tumor vaccine at the dose level previously administered, if enough vaccines are available. Patients will receive a fixed dose of IL-2 secreting B-CLL cells throughout the entire treatment protocol while an escalating number of CD40L-expressing B-CLL cells will be given at each dose-level.
89517527|NCT03500783|Placebo Comparator|Standard CPB|Patients of this group receive sham-treatment without supplying nitric oxide to the cardiopulmonary bypass circuit during coronary artery bypass grafting for coronary artery disease. Considering dilution of nitric oxide at a high ratio of 1 to 25,000 in the gas mixture of the cardiopulmonary bypass circuit (CPB), no addition of any inert gas to the CPB circuit is required in sham-treatment group.
88971066|NCT00078520|Experimental|Dose Level- Fixed Dose|Patients may be treated with a minimum of 3-6 injections of their IL-2-secreting and CD40L-expressing autologous B-CLL cells, separated by one to two weeks in an immunological treatment window. Any patient whose disease regresses after the administration of 6 injections may be offered further injections (i.e. more than 6 injections) of tumor vaccine at the dose level previously administered, if enough vaccines are available. Patients will receive a fixed dose of IL-2 secreting B-CLL cells throughout the entire treatment protocol while an escalating number of CD40L-expressing B-CLL cells will be given at each dose-level.
88971067|NCT00078793||Methotrexate group|Includes subjects being treated with methotrexate alone or in combination with other DMARDs with the exception of etanercept.
88971068|NCT00078832|Experimental|anastrozole|anastrozole 1mg
89517528|NCT03353233|Experimental|iPACK Block Group|A nerve block technique using a numbing medication called ropivacaine.
89517529|NCT03353233|Placebo Comparator|Sham Group|The same nerve block technique as above, however using an inactive solution of salt water.
89517530|NCT02320877|Experimental|Mandibular Advancement Device|Mandibular advancement Devices are worn intra-orally at night in order to advance the mandible and to reduce the collapsibility of the upper airway.
89517531|NCT03323281||Diabetic Type 1 or Type 2 with foot wound|Type 1 or type 2 diabetic patients with hospitalization for foot wounds having an interview with a neuropsychologist or a physician trained in neuropsychological assessments
89517532|NCT03323281||Diabetic Type 1 or Type 2 without a foot wound or antecedent|Type 1 or Type 2 diabetic patients with no foot wounds or history of foot wounds having an interview with a neuropsychologist or a physician trained in neuropsychological assessments
89517533|NCT03500705|Experimental|Mirror Therapy + Cross-Education.|Patients performed 4 sets of 5 maximal isometric elbow extensions with their less-affected upper limb (Cross-Education of Strengthening) while observing the reflection of the exercising limb in the mirror (Mirror Therapy) which was placed in the patient's mid-sagittal plane. Training sessions took place 3 days per week for four weeks in the participant's own home under the supervision of 2 exercise professionals.
89517534|NCT03500705|Active Comparator|Cross-Education of Strengthening.|Patients trained without a mirror entirely. They performed 4 sets of 5 maximal isometric elbow extensions with their less-affected upper limb (Cross-Education of Strengthening). Training sessions took place 3 days per week for four weeks in the participant's own home under the supervision of 2 exercise professionals.
89517535|NCT04455607|Experimental|experimental group|Random perturbation training
89517536|NCT04455607|Active Comparator|control group|Block perturbation training
89517537|NCT02317757||cancer patients receiving chemotherapy|Patients who are older than 70 years old receiving chemotherapy
89517538|NCT03052855|Other|Participants|All the participants of the 3 groups (depressed patients with suicide attempt, depressed patients without suicide attempt, healthy volunteers) will have to realize a MRI and biological samples.
89517539|NCT02317835|Other|Study in healthy volunteers|Skin foot temperature measurement by DFUPS device
89517540|NCT03498365|Experimental|Online MCDA|
89517541|NCT03498365|Active Comparator|Online Delphi|
89517542|NCT05234593|Other|Lightning Stick|Feasibility and acceptability
89517543|NCT02318069|Active Comparator|TBE vaccine at 0+30 days|This group of 50 participants will follow the standard recommendation and will be given TBE vaccine 0.5 ml FSME immune at 0 + 30 days during the first year and an additional dose one year later
89517544|NCT02318069|Active Comparator|TBE vaccine at 0+7+21 days|This group of 50 participants will will be given TBE vaccine 0.5 ml FSME immune at 0 + 7 +21 days during the first year and an additional dose one year later
89517545|NCT02318069|Active Comparator|TBE vaccine at 0+30+90 days|This group of 50 participants will will be given TBE vaccine 0.5 ml FSME immune at 0 + 30 + 90 days during the first year and an additional dose one year later
89574638|NCT02573155|Experimental|Sequence 1, Part 1|Period 1: Dose 1 Period 2: Dose 3 Period 3: Dose 5
89574639|NCT02573155|Experimental|Sequence 2, Part 1|Period 1: Placebo Period 2: Dose 3 Period 3: Dose 5
89574640|NCT02573155|Experimental|Sequence 3, Part 1|Period 1: Dose 1 Period 2: Placebo Period 3: Dose 5
89574641|NCT02573155|Experimental|Sequence 4, Part 1|Period 1: Dose 1 Period 2: Dose 3 Period 3: Placebo
89574642|NCT02573155|Experimental|Sequence 5, Part 1|Period 1: Dose 2 Period 2: Dose 4 Period 3: Dose 6
89574643|NCT02573155|Experimental|Sequence 6, Part 1|Period 1: Placebo Period 2: Dose 4 Period 3: Dose 6
89574644|NCT02573155|Experimental|Sequence 7, Part 1|Period 1: Dose 2 Period 2: Placebo Period 3: Dose 6
89574645|NCT02573155|Experimental|Sequence 8, Part 1|Period 1: Dose 2 Period 2: Dose 4 Period 3: Placebo
89574646|NCT02573155|Experimental|Sequence 1, Part 2|Period 1: Treatment A Period 2: Treatment B Period 3: Treatment E Period 4: Treatment C Period 5: Treatment D
89574647|NCT02573155|Experimental|Sequence 2, Part 2|Period 1: Treatment B Period 2: Treatment C Period 3: Treatment A Period 4: Treatment D Period 5: Treatment E
89574648|NCT02573155|Experimental|Sequence 3, Part 2|Period 1: Treatment C Period 2: Treatment D Period 3: Treatment B Period 4: Treatment E Period 5: Treatment A
88971069|NCT00078832|Placebo Comparator|placebo|anastrozole 1mg PLACEBO
88971070|NCT01350128|Experimental|PT001 MDI (Dose 1)|PT001 MDI
89574649|NCT02573155|Experimental|Sequence 4, Part 2|Period 1: Treatment D Period 2: Treatment E Period 3: Treatment C Period 4: Treatment A Period 5: Treatment B
89574650|NCT02573155|Experimental|Sequence 5, Part 2|Period 1: Treatment E Period 2: Treatment A Period 3: Treatment D Period 4: Treatment B Period 5: Treatment C
89574651|NCT02573155|Experimental|Sequence 6, Part 2|Period 1: Treatment D Period 2: Treatment C Period 3: Treatment E Period 4: Treatment B Period 5: Treatment A
89574652|NCT02573155|Experimental|Sequence 7, Part 2|Period 1: Treatment E Period 2: Treatment D Period 3: Treatment A Period 4: Treatment C Period 5: Treatment B
88971071|NCT01350128|Experimental|PT001 MDI (Dose 2)|PT001 MDI
88971072|NCT01350128|Experimental|PT001 MDI (Dose 3)|PT001 MDI
88971073|NCT01350128|Experimental|PT001 MDI (Dose 4)|PT001 MDI
88971074|NCT01350128|Active Comparator|Ipratropium Bromide HFA Inhalation Aerosol|Ipratropium Bromide HFA Inhalation Aerosol
88971075|NCT01350128|Placebo Comparator|Placebo MDI|PT001 Placebo MDI
88971076|NCT00078988|Experimental|Arm I (high-dose chemotherapy and ASCR)|Patients receive high-dose chemotherapy comprising carboplatin IV over 4 hours on days -8 to -6; thiotepa IV over 3 hours and etoposide IV over 3 hours on days -5 to -3; and filgrastim (G-CSF) IV or SC once daily beginning on day 1 and continuing until blood counts recover. Autologous PBSC or bone marrow are reinfused on day 0.
88971077|NCT00078988|Experimental|Arm II (intermediate-dose chemotherapy and ASCR)|Patients receive intermediate-dose chemotherapy comprising carboplatin IV over 4 hours and thiotepa IV over 3 hours on days 1-2 and G-CSF IV or SC once daily beginning on day 4 and continuing until blood counts recover. Autologous PBSC or bone marrow are reinfused on day 3. Treatment repeats every 28 days for a total of 3 courses.
88971078|NCT00078988|Experimental|Arm III (isotretinoin)|Patients receive oral isotretinoin twice daily on days 1-14. Treatment repeats every 28 days for a total of 6 courses.
88971079|NCT00078988|No Intervention|Arm IV (no isotretinoin)|Patients do not receive maintenance therapy.
88971080|NCT00079105|Active Comparator|Treatment|Treatment with VEPEMB - Vinblastine sulfate, Cyclophosphamide, Procarbazine hydrochloride, Prednisolone, Etoposide, Mitoxantrone hydrochloride, and Bleomycin sulfate
88971081|NCT00079105|No Intervention|Registration|Registration, without treatment
89574653|NCT02573155|Experimental|Sequence 8, Part 2|Period 1: Treatment A Period 2: Treatment E Period 3: Treatment B Period 4: Treatment D Period 5: Treatment C
89574654|NCT02573155|Experimental|Sequence 9, Part 2|Period 1: Treatment B Period 2: Treatment A Period 3: Treatment C Period 4: Treatment E Period 5: Treatment D
88971082|NCT03647124||Lenalidomide treated Relapsed or refractory mantle cell lymphoma (R/R-MCL) participants in Europe|
88971083|NCT00423787|Experimental|Ragweed MATA MPL|modified Ragweed pollen allergen absorbed to Tyrosine and containing MPL adjuvant
88971084|NCT00423787|Placebo Comparator|Placebo|4 injections of placebo 0.5 ml (2% tyrosine)
88971085|NCT04467827||Group A1 male|back shape neutral - a vertical line applied to the back of the body meets at the level of the thoracic segment and buttocks
89574655|NCT02573155|Experimental|Sequence 10, Part 2|Period 1: Treatment C Period 2: Treatment B Period 3: Treatment D Period 4: Treatment A Period 5: Treatment E
89574656|NCT05045755||Vaccine group|Participants in this arm have received 3 doses of HPV 16/18 bivalent vaccine that contains 40μg HPV 16 virus-like particle antigen and 20μg HPV 18 virus-like particle antigen adsorbed in alum-adjuvant.
88971086|NCT04467827||Group A2 female|back shape neutral - a vertical line applied to the back of the body meets at the level of the thoracic segment and buttocks
88971087|NCT04467827||Group B1 male|round back shape - a vertical line applied to the back of the body contacts only at the level of the thoracic segment
88971088|NCT04467827||Group B2 female|round back shape - a vertical line applied to the back of the body contacts only at the level of the thoracic segment
88971089|NCT04467827||Group C1 male|round back shape - a vertical line applied to the back of the body only touches the level of the buttock section
88971090|NCT04467827||Group C2 female|round back shape - a vertical line applied to the back of the body only touches the level of the buttock section
89574657|NCT05045755||Control group|Participants in this arm have received 3 doses of HEV vaccine that contains 30μg HEV virus-like particle antigen adsorbed in alum-adjuvant.
89574658|NCT05510791|Experimental|Nuun Sport|Citric Acid, Dextrose, Sodium Carbonate, Potassium Bicarbonate, Sodium Bicarbonate, Natural Flavors, Potassium Chloride, Magnesium Oxide, Calcium Carbonate, Stevia Leaf Extract, Avocado Oil, Riboflavin (for color).
89574659|NCT05510791|Sham Comparator|Control|Water
89574660|NCT05515471|Experimental|Treatment group A: SHR8058 eye drops|
89574661|NCT05515471|Placebo Comparator|Treatment group B: saline eye drops|
89574662|NCT05510713|No Intervention|the treatment-as-usual group|we used the single-cannula in femoral venous blood purification therapy in the following patients with vena cava disconnection or severe obstruction
88971091|NCT00079378|Experimental|Treatment (decitabine, valproic acid)|"Patients receive decitabine IV over 1 hour on days 1-5 or 1-10. Treatment repeats every 28 days.~Cohorts of 6 patients receive escalating doses of decitabine until the MEPD is determined. The MEPD is defined as the dose at which at least 5 of 6 patients meet gene methylation criteria and no more than 1 of 6 patients experiences DLT.~Once the MEPD is determined, patients receive decitabine at that dose level administered as above and oral valproic acid three times daily on days 5-21. Treatment repeats every 28 days.~Cohorts of 3-6 patients receive escalating doses of valproic acid until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience DLT. The MEPD of valproic acid is then determined using established gene methylation and toxicity criteria. Treatment continues for up to 24 months in the absence of disease progression or unacceptable toxicity."
88971092|NCT00079456|Experimental|Treatment (temsirolimus)|Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88971093|NCT04467086|No Intervention|Control Arm - Usual Care|"Participants in the control group will receive usual intravenous sedation according to practices already in place at each participating site. The choice of agent, route of delivery, method of monitoring, and target levels of sedation will be determined by the treating team; however, we will recommend best practice clinical guidelines be followed. Current guidelines recommend analgesia first sedation titrated to relief of pain and dyspnea and sedative infusions if need for anxiety or agitation titrated to a prescribed level of sedation using a validated sedation scale. Patients may receive adjunct sedative/analgesic medications (e.g., enteral benzodiazepines) but propranolol use in the control group will be considered a protocol violation."
88971094|NCT04467086|Experimental|Intervention Arm - Propranolol hydrochloride|"Participants in the control arm will received sedation as described for the control arm, but with the addition of propranolol hydrochloride (titrated up as described under Intervention Description) and a corresponding reduction in sedatives as appropriate and described under Intervention Description."
89517546|NCT02318069|Active Comparator|younger participants|This group of 50 participants in the age group 18-49 years will be given TBE vaccine 0.5 ml FSME immune at 0 +30 days during the first year and an additional dose one year later
89517547|NCT02318069|Active Comparator|double dose of vaccine|This group of 50 participants will be given two doses of TBE vaccine 0.5 ml FSME immune at the first day of the study and an additional dose at day 30 as well as one year later
88971095|NCT03528681|Experimental|Sodium Zirconium Cyclosilicate 10g|Suspension administered 10g orally once daily for 28 days after the open label initial phase.
88971096|NCT03528681|Experimental|Sodium Zirconium Cyclosilicate 5g|Suspension administered 5g orally once daily for 28 days after the open label initial phase.
88971097|NCT03528681|Placebo Comparator|Matching Placebo|Suspension administered orally placebo once daily for 28 days after the open label initial phase.
88971098|NCT00079612|Experimental|Arm 1|
88971099|NCT00079612|Placebo Comparator|Arm 2|
88971100|NCT03526107|Active Comparator|CF Control|CF Control: 587 mg of cocoa flavanols (101 mg epicatechin), <1 mg caffeine and <1 mg theobromine
88971101|NCT03526107|Experimental|CF-Theobromine|CF-Theobromine: 575 mg of cocoa flavanols (102 mg epicatechin), 11 mg caffeine and 93 mg theobromine
89517548|NCT02321033|Experimental|low glycemic index|palatinose in soft drinks
89517549|NCT02321033|Experimental|high glycemic index|sucrose plus maltodextrin in soft drinks
89517550|NCT01322971|Active Comparator|Metronidazole|Patients randomized to the metronidazole arm will receive metronidazole 500mg orally twice daily for seven days.
89517551|NCT01322971|Placebo Comparator|Placebo|Patients randomized to the placebo arm will receive placebo orally twice daily for seven days(control arm
89517552|NCT02318147|Experimental|Fecal Microbiota Transplantation|FMT by retention enema with fresh bacteria from healthy donor，At the same time give patients the traditional treatment of SAP
89517553|NCT02318147|Other|The traditional treatment|The traditional treatment of SAP according to the associated guidelines
89517554|NCT04454281|Experimental|Naloxone HCl Low dose: 0.02 mg|This arm will receive 0.02 mg naloxone hcl on the experimental visit and balance salt solution on the control visit.
89517555|NCT04454281|Experimental|Naloxone HCl High dose: 0.08 mg|This arm will receive 0.08 mg naloxone hcl on the experimental visit and balance salt solution on the control visit.
89517556|NCT03498053|Other|Cigarette brands smoked by participant|"The 3 experimental days per participant are exactly the same, except the cigarette brand they smoke.~The content of an experimental day is described in the study design."
89517557|NCT05389579|No Intervention|Control Group|After the patients were taken to their own beds after surgery, the researcher covered them with a wool blanket from the top of clavicle to the bottom of their feet, put the sphygmomanometer on the arm without an IV line, positioned the sphygmomanometer so that the instrument panel was on the blanket and measured blood pressure. the SPO2 probe was put on the patients' fingers after blood pressure measurements and counted respiratory rates for one minute while waiting for the SPO2 measurements. After this measurement, the researcher evaluated shivering by observation, and recorded these data on the DCIF. the temperature and humidity in the room on a thermohygrometer were read and recorded on the evaluation form. Body temperature, pulse rate, respiration rate, arterial blood pressure, pulse pressure, oxygen saturation, feeling cold and shivering were examined both experimental and control group before their surgeries, every 15 minutes after surgeries until being 36 0C.
89517558|NCT05389579|Experimental|Intervention Group|"After the patients were taken to their own beds after surgery, the researcher covered them with a wool blanket from the top of clavicle to the bottom of their feet, put the sphygmomanometer on the arm without an IV line, positioned the sphygmomanometer so that the instrument panel was on the blanket and measured the patients' blood pressure. Then, the electric blanket was operated at the warm level for the experimental group, and it was turned off and unplugged when their body temperature reached 36.0 °C."
89574663|NCT05510713|Experimental|intervention group|we used the dual-cannula in jugular-femoral venous blood purification therapy in the following patients with vena cava disconnection or severe obstruction
88971102|NCT03526107|Experimental|CF-Caffeine|CF-Caffeine: 587 mg of cocoa flavanols (101 mg epicatechin), 112 mg caffeine and <1 mg theobromine(Experimental)
88971103|NCT04451720|Experimental|Risankizumab|In Period A, participants will receive risankizumab dose A at Weeks 0 and 4. In Period B, participants will receive risankizumab dose A at Weeks 16, 28, 40 and 52, and also placebo at Weeks 20, 32, 44 and 56.
88971104|NCT04451720|Experimental|Placebo|In Period A, participants will receive placebo at Weeks 0 and 4. In period B, participants will receive risankizumab dose A at Weeks 16, 20,32,44 and 56. and also placebo at Weeks 28,40 and 52.
88971105|NCT00392847|Active Comparator|2|The first group will receive routine follow-up as currently provided by national community health and social services.
88971106|NCT00392847|Experimental|1|will receive home visits by community workers. These visits will start during pregnancy and will continue up to the child's second birthday.
88971107|NCT00079963|Experimental|X|Vitamin C
88971108|NCT00079963|Experimental|Y|Vitamin E
88971109|NCT00079963|Placebo Comparator|Z|Placebo
88971110|NCT04450901|Experimental|Cohort A1 group|YBL-006 will be administered once every 2 weeks (Q2W). Dose: 0.5 mg/kg
88971111|NCT04450901|Experimental|Cohort A2 group|YBL-006 will be administered once every 2 weeks (Q2W). Dose: 2 mg/kg
88971112|NCT04450901|Experimental|Cohort A3 group|YBL-006 will be administered once every 2 weeks (Q2W). Dose: 5 mg/kg
88971113|NCT04450901|Experimental|Cohort A4 group|YBL-006 will be administered once every 2 weeks (Q2W). Dose: 10 mg/kg
88971114|NCT04450901|Experimental|Cohort B1|"Tumor type: Advanced Solid tumor (unresectable, locally advanced, or metastatic and have progressed following all standard treatments or are not suitable for standard treatments).~YBL-006 will be administered once every 2 weeks (Q2W). Dose: 200 mg"
88971115|NCT04450901|Experimental|Cohort B2|"Tumor type: Advanced Solid tumor (unresectable, locally advanced, or metastatic and have progressed following all standard treatments or are not suitable for standard treatments).~YBL-006 will be administered once every 3 weeks (Q3W). Dose: 300 mg"
89517559|NCT02318225|Active Comparator|Misoprostol|Misoprostol (400µg) is administered vaginally 12 hours before office hysteroscopy
89517560|NCT02318225|Placebo Comparator|Placebo|Placebo is administered vaginally 12 hours before office hysteroscopy
89517561|NCT03500627|Experimental|Cohort 1|20 mg/kg OP-101 administered intravenously for over 1 hour.
89517562|NCT03500627|Experimental|Cohort 2|40 mg/kg OP-101 administered intravenously for over 1 hour.
89517563|NCT03500627|Experimental|Cohort 3 (optional)|80 mg/kg OP-101 administered intravenously for over 1 hour.
89517564|NCT03497819|Experimental|CARTmeso/19 treatment arm|Patients with pancreatic cancer receiving CARTmeso and CART19 autologous cells via artery infusion or i.v. with cyclophosphamide precondition
89517565|NCT02318381|No Intervention|Control|Patients with suprascapular neuropathy and rotator cuff tear treated arthroscopically without release of the superior transverse scapular ligament.
89517566|NCT02318381|Other|Ligament Release|"Patients with suprascapular neuropathy and rotator cuff tear treated arthroscopically with release of the suprascapular nerve.~Arthroscopic dissection of the superior transverse scapular ligament"
89517567|NCT01378429|Experimental|ciclesonide nasal aerosol|ciclesonide nasal aerosol (74 mcg)
89517568|NCT01378429|Placebo Comparator|Placebo|
89517569|NCT03500393|Active Comparator|Unsupervised Exercise (UNSUP)|The control condition represents a minimalist intervention that could occur in any setting: (1) enthusiastic provision on an exercise prescription and (2) provision of a fitness device (i.e., the Garmin VivioActive) that can help participants track their exercise engagement. Participants are instructed in how to use the device to track their adherence to the exercise prescription.
89517570|NCT03500393|Experimental|Remotely Supervised Exercise (REM)|The REM program is designed to function as an Acceptance-based health coaching intervention and will utilize theory-based behavior change techniques (i.e., goal setting/action planning, self-monitoring, receiving feedback, and reviewing relevant goals in the light of feedback) to promote adoption and adherence to the exercise prescription.
89517571|NCT01599754|Experimental|Axitinib|
89517572|NCT01599754|Placebo Comparator|Placebo|
89517573|NCT05400343|Active Comparator|Standard care (control group)|fluid therapy will be guided by conventional ICU policies to maintain an adequate intravascular volume and good urine output
89517574|NCT05400343|Experimental|US-guided ﬂuid management (active group)|Fluid therapy will be guided by measurements of lung and IVC sonography
89517575|NCT02321189|Placebo Comparator|LONGEVINEX|The Effect of LONGEVINEX on Choroidal Thickness
89517576|NCT02321189|Placebo Comparator|placebo|The Effect of placebo on Choroidal Thickness
89517577|NCT05400187|Experimental|Body composition assessment and smart-phone based counselling group|"In this study, we consider body composition measurement together with an immediate brief counselling after the measurement as part of the intervention. The body composition measurement will allow the participants to get familiar with their own anthropometric data and serve as cues to actions of healthy diet adoption and weight management and control. Based on the measured body fat and anthropometric data, a trained research assistant will give brief individualized dietary and weight management counselling to the participants.~The Whatsapp-based counselling and communication will heighten the awareness through reinforcing the need and benefits of body composition and weight control, the importance of energy balance, as well as providing professional and tailor-made advice on healthy eating and weight management. Qualitative dietary counselling will be offered every two weeks through the Whatsapp."
89517578|NCT05400187|No Intervention|Control group|Participants in the control group will receive the simple body composition measurement only, without an immediate counselling after the measurement. Whey will be informed the values of anthropometric data and body composition parameters, no detailed interpretation of the values will be delivered to them. They will also not receive the professional consultant of the healthy diet and weight management from the diatetitian during the intervention period.
89517579|NCT02321267|Other|Macular disease with adequate treatments|Macular diseases can be treated with most appropriate treatment, including pegaptanib, ranibizumab, afibercept, visudyne, or vitrectomy.
89574664|NCT05519371|Experimental|remimazolam group|For induction of anesthesia, rimazolam benzoate was pumped at a rate of 12 mg/kg/h; for maintenance of anesthesia, 1.0-2.0 mg/kg/h rimazolam was given as a continuous pump.
89574665|NCT05519371|Active Comparator|propoful group|For induction of anesthesia, propofol medium-length chain fatty milk injection 2 mg/kg was given by intravenous push; for maintenance of anesthesia, 6-8 mg/kg/h propofol medium-length chain fatty milk injection was given by continuous pumping.
89574666|NCT04948645|Active Comparator|ABBV-CLS-7262 LOW DOSE|
89574667|NCT04948645|Active Comparator|ABBV-CLS-7262 MEDIUM DOSE|
89574668|NCT04948645|Active Comparator|ABBV-CLS-7262 HIGH DOSE|
89574669|NCT04948645|Placebo Comparator|PLACEBO|
89574670|NCT05515003|Experimental|Education group|Individualized patient education
89574671|NCT05515003|No Intervention|Control group|No training will be provided
89574672|NCT04847947|Experimental|Interventional group|Oral capsule Cholecalciferol 4000 IU once daily and Calcium Lactate 500 mg once daily for 12 weeks.
89574673|NCT04847947|Placebo Comparator|Control Group|Oral capsule Placebo once daily and Calcium Lactate 500 mg once daily for 12 weeks.
89574674|NCT05519137|Active Comparator|Active lighting intervention then Control lighting condition|Each lighting condition will be 8 weeks in length. After a 4 week washout, each participant will crossover to the opposite condition.
89574675|NCT05519137|Active Comparator|Control lighting condition then Active light intervention|Each lighting condition will be 8 weeks in length. After a 4 week washout, each participant will crossover to the opposite condition.
89574676|NCT05510479||OdySight vs Standardized methods|All patients perform Visual Acuity testing through OdySight and according to standard practice
89574677|NCT05514925|Active Comparator|Preoperative Anti-VEGF Intravitreal Injection|Three to five days before vitrectomy, each participant received one intravitreal Bevacizumab injection (1.25 mg,0.05 ml).
89574678|NCT05514925|Experimental|Peripheral Retinal Cryoapplication|Four to six weeks before vitrectomy, each participant underwent peripheral retinal cryoapplication.
89574679|NCT05514847|No Intervention|1 Control Group|Control Group (Group 1): These patients will be screened negative for both the ACOG screening test and the FMF preeclampsia screen. These women will receive no aspirin.
89574680|NCT05514847|Active Comparator|2 Randomized Group 1|Group 2: These patients will be screened negative for the ACOG screening test but positive for the FMF preeclampsia screen. These women will be randomized to either 81mg or 162 mg aspirin.
89574681|NCT05514847|Other|3 Standard of Care Group|Group 3: These patients will be screened positive for the ACOG screening test but negative for the FMF preeclampsia screen. These women will be offered 81 mg aspirin, which is the standard of care.
89574682|NCT05514847|Active Comparator|Group 4 Randomized Group 2|Group 4: These patients will be screened negative for the ACOG screening test and positive for the FMF preeclampsia screen. These women will be randomized to either 81mg or 162 mg aspirin.
88971116|NCT04450901|Experimental|Cohort B2 reserve|"Tumor type: Advanced Solid tumor (unresectable, locally advanced, or metastatic and have progressed following all standard treatments or are not suitable for standard treatments).~YBL-006 will be administered once every 2 weeks (Q2W). Dose: 300 mg"
88971117|NCT04450901|Experimental|Cohort B3|"Tumor type: Metastatic NSCLC (Non-small-cell lung carcinoma), unresectable or metastatic, MSI-H (microsatellite instability-high) or dMMR (Deficient MisMatch Repair), recurrent or metastatic HNSCC (Head and neck squamous cell carcinoma), non-clear cell RCC (renal cell carcinoma), aSCC (anal squamous cell carcinoma), uterine cervical cancer, cSCC (cutaneous squamous cell carcinoma of the skin), uterine endometrial carcinoma, TMB-H (high tumor mutation burden) tumors, epithelial tumor of the penis (squamous cell carcinoma or adenocarcinoma), neuroendocrine tumor (any origin, pancreatic or non-pancreatic), and nasopharyngeal cancer.~YBL-006 will be administered once every 2 weeks (Q2W). Dose: 200 mg"
88971118|NCT00392886|Experimental|Regimen C|Patients receive induction therapy of vincristine IV on days 1, 8, and 15 of courses 1-3, oral temozolomide once daily on days 1-5, and carboplatin IV over 4 hours on days 1 and 2. Patients also receive G-CSF SC beginning on day 6 and continuing until blood counts recover. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients receive consolidation therapy of carboplatin IV over 4 hours on days -8 to -6 and thiotepa IV over 3 hours on days -5 to -3, undergo reinfusion of bone marrow or peripheral blood stem cells on day 0, and receive G-CSF SC beginning on day 1 and continuing until blood counts recover. Beginning within 6 weeks after transplantation, some patients undergo radiotherapy once daily 5 days a week for 4-6 weeks in the absence of disease progression or unacceptable toxicity and some patients undergo radiotherapy if there is evidence of tumor remaining after completion of induction chemotherapy.
89029145|NCT04292496|Experimental|Intraperative leak testing group|i) the integrity of the anastomosis can be directly observed under gastroscopy. ii) the distal of Roux limb was temporarily blocked, then the bowel of anastomosis was inflated by air, following 60 milliliter methylene blue.
89029146|NCT04292496|No Intervention|Non-intraoperative leak testing group|Non intraoperative leak testing was performed intraoperatively.
89574683|NCT05510401|Other|SECURIDRAP® SELFIA®|Use of a SECURIDRAP® SELFIA® restraint system Monitoring with passage of an independent assessor
89574684|NCT05510323|Active Comparator|CS|low-dose corticosteroids monotherapy
89574685|NCT05510323|Active Comparator|CS+CTX|low-dose corticosteroids combined with cyclophosphamide
89574686|NCT05514691|Active Comparator|Anterior nasal swab sample tested on iStatis Covid-19 Antigen Testing diagnostic device|An anterior nasal swab was collected using the swab provided with the iStatis test kit and will be used for the iStatis Covid-19 Antigen Testing at the site.
89574687|NCT05514691|Active Comparator|Anterior nasal swab sample tested with RT-PCR|Another anterior nasal swab sample was collected to be tested with RT-PCR at the central research laboratory.
89574688|NCT05514613||Group G|Group G is a tracheostomy group opened using the anatomical sign technique (Griggs technique).
89574689|NCT05514613||Group U|Group U; Ultrasound-guided is used during tracheostomy technique.
89574690|NCT05510167|Active Comparator|Study|Complete abstinence or ≤2 drinks/week in group 1 during the study period
89574691|NCT05510167|Active Comparator|Control|Allowed to continue their pre-ablation drinking habit
89574692|NCT05514379|Experimental|Group cognitive training|The experimental group will undergo 60 minutes long cognitive training group sessions twice a week for 12 weeks focused on executive function, attention and working memory.
89574693|NCT05514379|Active Comparator|Home-based cognitive training|The control group will perform executive function, attention and working memory training similar to the experimental group but at home as instructed by their therapist using specialized software for cognitive training (Rehacom). This training will be dose matched to the experimental group, i.e. it will be performed four times a week for 30 minutes for 12 weeks. In this group, therapists will only provide coaching once a month.
89574694|NCT04128397|Experimental|traditional stimulation site continuous theta burst stimulation (cTBS)|arm: experimental: performing cTBS to tic patients for continuous 5 days ,3 times for a day (0 minute ,15 minute ,60 minute). The stimulation site include left supplementary motor area, right supplementary motor area, left primary motor area, right primary motor area , left superior parietal lobule, right superior parietal lobule. Determination of stimulation target is a common method of determination in previous studies. For example the vertex (Cz) was measured for each patient and the SMA defined at 15% of the distance between inion and nasion anterior to Cz on the sagittal midline.
89574695|NCT04128397|Experimental|precise stimulation site cTBS|arm: experimental: performing cTBS to tic patients for 5 days ,3 times for a day (0 minute ,15 minute ,60 minute). The stimulation site include left supplementary motor area, right supplementary motor area, left primary motor area, right primary motor area , left superior parietal lobule, right superior parietal lobule. The stimulation target is determined by the resting-state functional connectivity, which is robust functional connectivity with the GPi or Thalamus.
89574696|NCT02568475|Experimental|Decision aid|"Provision of Go to the Hospital or Stay Here?"
89574697|NCT02568475|No Intervention|No decision aid|Does not receive the decision aid.
89574698|NCT05507671|Active Comparator|BCG vaccine|BCG (Bacillus Calmette-Guérin) vaccine - 0,1ml intradermal
89574699|NCT05507671|Placebo Comparator|Placebo|Solvent of BCG vaccine - 0,1ml intradermal
89574700|NCT02568397|Experimental|Dabigatran Etexilate|Single dose of dabigatran etexilate administered orally.
89574701|NCT02568397|Experimental|Lanabecestat and Dabigatran Etexilate|Single dose of lanabecestat administered orally once daily on Days 3 to 21. Single doses of dabigatran etexilate administered orally on Days 16 and 20 during the lanabecestat dosing.
89574702|NCT02566525|Experimental|CytoSorb Device|Standard of care plus treatment with CytSorb device installed on the CPB machine
88971119|NCT00392886|Experimental|Regimen D2|In courses 1, 3, and 5, patients receive cisplatin IV over 6 hours on day 1, cyclophosphamide IV over 1 hour and etoposide IV over 2 hours on days 2 and 3, high-dose methotrexate IV over 4 hours on day 4, vincristine IV on days 1, 8, and 15 (in courses1 and 3), and filgrastim (G-CSF) subcutaneously (SC) beginning on day 5 and continuing until blood counts recover. In courses 2 and 4, patients receive oral temozolomide once daily on days 1-5, oral etoposide once daily on days 1-10, cyclophosphamide IV over 1 hour on days 11 and 12, vincristine IV on days 1, 8, and 15 (in course 2), and G-CSF SC beginning on day 13 and continuing until blood counts recover. Patients receive consolidation therapy as in regimen C in combination with etoposide IV over 3 hours on days -5 to -3 and undergo autologous bone marrow or peripheral blood stem cell transplantation, receive G-CSF, and undergo radiotherapy as in regimen C.
88971120|NCT00080236|Placebo Comparator|Donor organ placebo and Recipient placebo|
88971121|NCT00080236|Active Comparator|Donor organ: IDN-6556 (15μg/ml), Recipient: Placebo|
88971122|NCT00080236|Active Comparator|Donor organ: IDN-6556 (5 μg/ml), Recipient: IDN-6556 0.5 mg/kg|
88971123|NCT00080236|Active Comparator|Donor organ: IDN-6556(15 μg/ml), Recipient: IDN-6556 0.5 mg/kg|
88971124|NCT04436666|Experimental|Ice Application|Music-funded, park, nature and seaside walks, submarine, museum, with virtual reality glasses (Bobo VR Z4 Binocular Glasses and 5.7 inch 1440x2560 pixel display resolution, China) for 10 minutes to diabetic patients before blood glucose measurement and insulin injection The videos that the patient wants to watch will be watched from videos such as his trip Studies have indicated that these videos are relaxing environments, and motion videos should not be watched to reduce nausea and vomiting.
88971125|NCT04436666|Experimental|Virtual Reality|Before the blood glucose measurement and insulin injection, patients with diabetes will be given ice for 5 minutes. It is planned to apply ice cubes in liquid-proof ice bags.
88971126|NCT04436666|No Intervention|control|No Intervention
88971127|NCT00080314|Active Comparator|A1|
88971128|NCT00080314|Placebo Comparator|A2|
88971129|NCT03506373|Experimental|Treatment (ixazomib citrate, ibrutinib)|Patients receive ixazomib citrate PO on days 1, 8, and 15 and ibrutinib PO daily on days 1-28. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
88971130|NCT02972411|Experimental|Intervention|Voluntary increase in respiration
88971131|NCT02972411|Active Comparator|Acetazolamide|Administration of Acetazolamide 125mg. since 24 hours before ascent and until 48 hours post altitude exposure, and absence of altitude sickness symptoms
89574703|NCT02566525|No Intervention|Control|Standard of care
89574704|NCT05514145|Active Comparator|Nance space maintainer|Conventional space maintainer for the maxillary arch as control
88971132|NCT00080626|Experimental|Docetaxel|Neoadjuvant therapy with docetaxel (IV, 100 mg/m2, every 14 days with growth factor support with pegfilgrastim) for a total of 4 cycles prior to conventional surgery for breast cancer.
88971133|NCT00080665|Experimental|Imatinib mesylate and docetaxel|Imatinib mesylate (400-600 mg, oral, once daily) and docetaxel (15-30 mg/m2, IV, weekly on days 1, 8, and 15) each 28 day cycle
88971134|NCT00080743|Active Comparator|Tamoxifen|Tamoxifen 20 mg po once daily
88971135|NCT00080743|Placebo Comparator|Placebo|Placebo comparator one tablet po once daily
89574705|NCT05514145|Experimental|Nance/Transpalatal arch space maintainer|New design of a space maintainer for the maxillary arch
89574706|NCT05513989|Active Comparator|modified Magill forceps group|One hundred and ten patients for whom modified pediatric Magill forceps was used to assist nasotracheal intubation
89574707|NCT05513989|Active Comparator|Magill forceps group|One hundred and ten patients for whom Magill forceps was used to assist nasotracheal intubation.
89574708|NCT05513911|Experimental|Acute intermittent Hypoxia Therapy|This group will receive the acute intermittent hypoxia therapy (9% O2) for 30 minutes. Before and after the intervention the participant will perform flexion of the elbow at various levels of intensity
89574709|NCT05513755|Experimental|Cardioneuroablation|
89574710|NCT05513755|No Intervention|Conventional treatment (counter-pressurre maneuver, drugs or pacemaker)|
89574711|NCT05513677|Active Comparator|Standard of Care|Standard of Care
89574712|NCT05513677|Experimental|M4D coated catheter|Experimental
89574713|NCT05507593|Experimental|Group A|Patients of group A will be received 1x10^7 DLL3-CAR-NK cells infusion treatment.
89574714|NCT05507593|Experimental|Group B|Patients of group B will be received 1x10^8 DLL3-CAR-NK cells infusion treatment.
89574715|NCT05507593|Experimental|Group C|Patients of group C will be received 1x10^9 DLL3-CAR-NK cells infusion treatment.
89574716|NCT05507281|Sham Comparator|Control group|Patients received general anesthesia alone.
89574717|NCT05507281|Experimental|Ultrasound-guided Erector Spinae Plane Block|A 22-gauge needle is inserted at a puncture site lateral to the target spinous process using ultrasound imaging and advanced until contact is made with the transverse process. The local anesthetic agent will be injected between the transverse process and the erector spinae muscle using 20 ml (19ml bupivacaine 0.25% plus 1ml dexamethasone 4mg).
89574718|NCT05507281|Experimental|Retrolaminar Block|A 22-gauge needle is inserted at a puncture site lateral to the target spinous process using ultrasound imaging and advanced caudally or cranially until it contacts the lamina. The local anesthetic agent will be injected on the lamina using 20 ml (19ml bupivacaine 0.25% plus 1ml dexamethasone 4mg).
89574719|NCT05507047|Experimental|Transcrestal Sinus Lifting with Emdogain|Osteotome sinus floor elevation with enamel matrix derivated
89574720|NCT05507047|Active Comparator|Transcrestal Sinus Lifting|Osteotome sinus floor elevation
89574721|NCT04757857|Active Comparator|Rivaroxaban 10 mg|Participants will receive, from the 1st to the 14th day, a dose of 10 mg of rivaroxaban - OA (Oral Administration).
89574722|NCT04757857|No Intervention|Best locally standardized care|According to the study protocol, participating investigators are advised to follow the best available local practice in each participating site. There is no formal recommendation for any particular COVID-19 treatment, except symptomatic therapies.
89574723|NCT04754191|Experimental|Treatment: all patients|Enfortumab will be administered in monotherapy on days 1, 8, and 15 as part of a 28-day cycle at 1.25 mg/kg up to 125 mg.
89574724|NCT05513287||Spinal anethesia|group number one which recive spinal anethesia in cesarean section in 2020 and 2021
89574725|NCT05513287||General anesthesia|Group number 2 which recive general anathesia in cesarean section in 2020 snd 2021
89574726|NCT05513131|Experimental|Venetoclax combined with Azacitidine and Harringtonine|Venetoclax 100mg d1，200mg d2，400mg d3~d14； Azacitidine 75mg/m2/d，d1~d7； Homoharringtonine 2mg/d d1~d7
88971136|NCT00080782|Experimental|Arm I: Celecoxib|Doxorubicin IV over 30 minutes on days 1, 8, 15, and 22 + Strontium chloride Sr 89 IV on day 1, and oral celecoxib twice daily in absence of disease progression.
88971137|NCT00080782|Experimental|Arm II: No Celecoxib|Doxorubicin IV over 30 minutes on days 1, 8, 15, and 22 + Strontium chloride Sr 89 IV on day 1.
88971138|NCT03437148|Experimental|patients with Atrial septal defect type Ostium Secundum|patients with Atrial septal defect type Ostium Secundum, eligible for an interventional closure
89574727|NCT05509465|Experimental|Ergonomic chinrest used with low shoulder rest (EC+)|Participants will play the violin using the ergonomic chinrest with a low Kun Super shoulder rest (EC+) for a two-week period to test its usability and acceptability. Each day participants have to use half of their playing time with EC+.
89574728|NCT05509465|Experimental|Ergonomic chinrest used without shoulder rest (EC-)|Participants will play the violin using the ergonomic chinrest without a shoulder rest for a two-week period to test its usability and acceptability. Each day participants have to use half of their playing time with EC-.
89574729|NCT05506657|Other|State Counselor-Coordinated Services|In this program, services are coordinated by a counselor employed by the New Jersey State Division of Vocational Rehabilitation Services (NJDVRS), a state-based agency that assists people with disabilities who are interested in pursuing employment. While the participant is in inpatient rehabilitation or soon after their discharge, a member of the research team will assist them in completing the necessary documentation to apply for services from this agency. Services for which they are eligible will be provided directly through NJDVRS.
89574730|NCT05506657|Other|Center Facilitator-Coordinated Services|In this program, services are coordinated by a facilitator who is employed by Kessler Institute for Rehabilitation and works cooperatively with NJDVRS. The facilitator will begin working with the participant during inpatient rehabilitation, or soon after discharge, depending on when they enroll in the study. Some services for which they are eligible will be provided through NJDVRS and others will be provided to them by the facilitator.
89574731|NCT05512975|Experimental|Control Porridge arm|Control/ regular protein porridge recipe, not containing any additional protein fortification.
89574732|NCT05512975|Experimental|Dairy Protein Porridge arm|Porridge containing regular protein ingredients with dairy protein fortification (delical- a whey protein powder)
88971139|NCT00081094|Other|PET scan (FDG-PET & 11C-acetate-PET)|Patients will undergo routine clinical FDG-PET and research 11C-acetate-PET prior to planned surgical resection of the lesion(s) or explantation of the liver.
88971140|NCT04343027|No Intervention|Standard of care group|Participants who did not have their physicians review their patient-reported outcome measurements with them during the office visit.
88971141|NCT04343027|Experimental|Consultation group|Participants who had their physicians review their patient-reported outcome measurements reviewed with them during the office visit.
88971142|NCT00081211|Experimental|Treatment (PV701)|Patients receive intratumoral PV701 once weekly for 3 weeks. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of PV701 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, at least 6 evaluable patients are treated at that dose.
88971143|NCT00081250|Experimental|Arm I|Patients receive oral creatine daily.
89574733|NCT05512975|Experimental|Plant Protein Porridge arm|Porridge containing regular protein ingredients with plant protein fortification (extruded soy and soya milk)
89574734|NCT05512897|No Intervention|standard care|standard analgesic treatment
89574735|NCT05512897|Experimental|standard care + ESP block|intraoperativeESP block + standard analgesic treatment
89574736|NCT05509387|Experimental|4mA Stimulation|
89574737|NCT05509387|Active Comparator|2mA Stimulation|
89532273|NCT06336642|Experimental|Group 1: SPOT-ON|Participants will work with the healthcare team to find the best ways to reduce your shortness of breath by finding what combination of treatments work for participant. Participants will receive education about shortness of breath by the research staff in addition to information about standard treatments or medications for your shortness of breath that would be offered by your medical team.
89574738|NCT05509387|Sham Comparator|SHAM|
89574739|NCT05506501|Active Comparator|Unilateral epidural anesthesia group|Forty patients with low ejection fraction (30-40%) will do elective insertion of nail tibia for fixation of fracture shaft tibia using unilateral epidural anesthesia.
89574740|NCT05506501|Active Comparator|Ultrasound guided femoro/ sciatic nerve block group|Forty patients with low ejection fraction (30-40%) will do elective insertion of nail tibia for fixation of fracture shaft tibia by femoral/sciatic nerve block using ultrasound guidance.
89574741|NCT05512663|Experimental|Irreversible Electroporation (IRE) treatment|Focal Irreversible Electroporation (IRE) delivered by NanoKnife System is composed of the NanoKnife Generator and NanoKnife Single Electrode Probes.With the NanoKnife System, electrical current is delivered between pairs of probes in a series of pulses. The waveform of the current is adjustable as determined by clinician chosen parameters. Up to six probes may be placed in an array within the tissue. The probes of the array are matched as pairs by the system. When probes are activated via a foot pedal, the scheduled current is delivered to tissue between subsequent pairs of probes. Soft tissue between the probes is ablated.
89574742|NCT05509153|Experimental|NAC|1g N-Acetylcysteine capsules, taken orally twice a day.
89574743|NCT05509153|Placebo Comparator|Placebo|Coated Placebo capsules, taken orally twice a day
89574744|NCT05506189||Breast cancer survivors with over-weight or obesity|Breast cancer survivors with 25 and more than 25 of BMI will be supported with 6 months life style modification program using mobile application including human coach for reducing BMI.
89574745|NCT05506033|No Intervention|Standard GCs taper group|After a complete response (PLT ≥100x10^9/L) was confirmed, the dose of prednisone (or equivalent dose of glucocorticoids) would be reduced by 2 tablets every two weeks. When it reaches 6 tablets /d, the dose would be reduced by 1 tablet every 2 weeks, and when it reaches 15mg/d, the dose would be reduced by half tablet every 2 weeks.
89574746|NCT05506033|Experimental|rapid GCs taper group|After a complete response (PLT ≥100x10^9/L) was confirmed, the dose of prednisone (or equivalent dose of glucocorticoids) would be cut in half (25mg/d for weight less than 50kg, 30mg/d for weight 50-75kg , 40mg/d for weight more than 75kg ). After that, the dose would be reduced by 2 tablets every two weeks. When it reaches 6 tablets /d, the dose would be reduced by 1 tablet every 2 weeks, and when it reaches 15mg/d, the dose would be reduced by half tablet every 2 weeks.
89574747|NCT04594837|Experimental|PTR (Physical Therapy while wearing Robot group) (Phase II)|Subjects receive 18 one-hour PT training sessions over 9 weeks while wearing the robot initially parameterized to individual deficit severity. Subjects perform over-ground mobility tasks of increasing challenge with robotic assist, as needed. Training is generally divided into 3 phases based on individual ability to address gait deficits, postural transitions, physical demand and environmental terrain.
89574748|NCT04594837|Active Comparator|PT (Physical Therapy Only) (Phase II)|Subjects receive 18 one-hour PT training sessions over 9 weeks. Subjects perform over-ground mobility tasks of increasing challenge with therapist assist, as needed. Training is generally divided into 3 phases based on individual ability to address gait deficits, postural transitions, physical demand and environmental terrain.
89574749|NCT04594837|Experimental|X-PTR, Cross over group for Physical Therapy n Sub-Acute group.|Participants enrolled in the physical therapy only group will be given the option to re-enroll as a cross over participant to receive 18 one-hour PT training sessions over 9 weeks while wearing the robot initially parameterized to individual deficit severity. Subjects perform over-ground mobility tasks of increasing challenge with robotic assist, as needed. Training is generally divided into 3 phases based on individual ability to address gait deficits, postural transitions, physical demand and environmental terrain.
89574750|NCT04594837|Experimental|C-PTR, Chronic Stroke Subjects to receive robotic gait training therapy.|Chronic stroke subjects receive 18 one-hour PT training sessions over 9 weeks while wearing the robot initially parameterized to individual deficit severity. Subjects perform over-ground mobility tasks of increasing challenge with robotic assist, as needed. Training is generally divided into 3 phases based on individual ability to address gait deficits, postural transitions, physical demand and environmental terrain.
88971144|NCT00081250|Placebo Comparator|Arm II|Patients receive oral placebo daily.
88971145|NCT00081367|Experimental|Cognitive behavioral therapy (CBT) + standard care|Participants will receive ten weekly sessions of treatment plus standard care for suicide prevention.
88971146|NCT00081367|Active Comparator|Standard care alone|Participants will receive standard care for suicide prevention.
88971147|NCT03152292||Group 1: Parkinson Disease Psychosis (PDP) patients|PDP patients not treated with an antipsychotic at the time of enrollment
88971148|NCT03152292||Group 2: Parkinson Disease Psychosis (PDP) patients|PDP patients treated with an antipsychotic (other than NUPLAZID®) at the time of enrollment
88971149|NCT03152292||Group 3: Parkinson Disease Psychosis (PDP) patients|PDP patients treated with NUPLAZID® at the time of enrollment
88971150|NCT00081484|Experimental|1|
88971151|NCT00081484|Active Comparator|2|
88971152|NCT03152253|Experimental|Text Message for Smoking Cessation|smoking cessation promotion messages and medication reminders sent via text messages for up to 30 days before quit day and 8 weeks following quit day, along with access to a social support chat room
88971153|NCT03152253|Placebo Comparator|Non-Interventional Text Messages|General motivational text messages sent on the same schedule at TMQ arm of the study with access to a social support chat room.
88971154|NCT03152214|Experimental|Team RWB + Vigorous Intensity Aerobic Exercise|"Participants assigned to the integrated arm will be prescribed the following for the course of 8 weeks:~1 session of exercise counseling~3 weekly 25-minute sessions of vigorous intensity aerobic exercise~1 weekly Team RWB event~4 biweekly assessments~Participants will also complete an online assessment at week 9 to provide follow-up data."
89574751|NCT05509075||nutraceuticals and neurological disorders|evaluation of nutraceuticals in subjects with memory disorders
89574752|NCT05509075||nutraceuticals and skin disorders|evaluation of nutraceuticals in clinical conditions requiring topical treatment for skin diseases
89574753|NCT05509075||nutraceuticals and gastrointestinal diseases|evaluation of nutraceuticals in clinical conditions requiring systemic treatment for gastrointestinal diseases
89574754|NCT05509075||nutraceuticals and urological diseases|evaluation of nutraceuticals in the management of patients with prostate diseases or with lower tract infectious diseases requiring systemic or local treatment
89574755|NCT05509075||nutraceuticals and immunomediate diseases|evaluation of nutraceuticals in the management of patients with immunomediate disorders
89574756|NCT05509075||nutraceuticals and pain|evaluation of nutraceuticals in the management of patients with acute or chronic pain
89574757|NCT05508919|Experimental|Biofeedback Group|"The training consists of a total of 8 sessions for every individual with 2 sessions per week over the duration of 4 weeks. Each session will be approximately of 1 to 1.30 hour.~Subjects will be given clear instructions to not to use chocolate, coffee, tea and cocoa drinks at least 3 hours before the training session.~Since it is suggested that Anxiety tends to change with time so we might consider a one-month pretreatment measure as well as a just before treatment measure. That way we can be sure if our baseline is stable or not.~Baseline session: Subject will be asked to sit quietly for 15 minutes and their breathing rate, skin temperature and muscle tension using EMG will be measure without giving any intervention.~Subjects will then be given biofeedback training gradually to control their breathing rate, relaxed their muscle activity and temperature through RESP biofeedback, assisted EMG biofeedback and TEMP biofeedback, from the 1st session till their 8th Session."
89574758|NCT05508919|Active Comparator|Active Control Group|Active Control: Writing Sessions The subjects will be asked to take three 20-minute writing sessions and write about the given control topic about their daily events of the past week. For example, in Session 1, we may ask the Subjects to write about how they will use their time. Similarly, we will ask the subject to give more detail and write briefly about the given control condition in session 2 and session 3. At the end of three writing session, we will measure their EMG, RESP and TEMP to compare with the Biofeedback training group.
89574759|NCT04735393|Experimental|Reproxalap Ophthalmic Solution (0.25%) QID for four weeks followed by BID for two weeks.|
89574760|NCT04735393|Placebo Comparator|Vehicle Ophthalmic Solution QID for four weeks followed by BID for two weeks.|
89574761|NCT04735393|Experimental|Reproxalap Ophthalmic Solution (0.25%) QID for four weeks followed by BID for 11 months.|
89574762|NCT04735393|Placebo Comparator|Vehicle Ophthalmic Solution QID for four weeks followed by BID for 11 months.|
89574763|NCT05508841|Experimental|4mA Stimulation|
89574764|NCT05508841|Active Comparator|2mA Stimulation|
89574765|NCT05508841|Sham Comparator|SHAM|
89574766|NCT05502445|No Intervention|Control Group|"This group will follow the hospital's standard nutritional assessment and monitoring flow:~24-hour recall: patients will be interviewed to report about one day of their usual diet.~Application of a questionnaire: to assess the knowledge about the importance of protein intake in the prevention of sarcopenia and functionality, and whether the participant regularly performs physical activity.~Energy and protein needs: estimated according to the clinical status and patient associated pathologies. The protocol of the Clinical Nutrition Service will be followed.~Calculation of the Body Mass Index (BMI)~Nutritional risk was determined using the Mini Nutritional Assessment-Short Form~Screening for sarcopenia: SARC-F ,Calf Circumference and Hand Grip Strength"
88971155|NCT03152214|Active Comparator|Team RWB|"Participants assigned to the Team RWB arm will be prescribed the following for the course of 8 weeks:~1 weekly Team RWB event~4 biweekly assessments~Participants will also complete an online assessment at week 9 to provide follow-up data."
88971156|NCT03152214|No Intervention|Waitlist|"Participants assigned to the waitlist arm will be prescribed the following for the course of 8 weeks:~• 4 biweekly assessments~Participants will also complete an online assessment at week 9 to provide follow-up data."
88971157|NCT00390338|Experimental|peptide-pulsed type-1-polarized dendritic cells|intralymphatic vaccination with peptide-pulsed type-1-polarized dendritic cells (aDC1)
88971158|NCT00390338|Experimental|peptide-pulsed mature non-polarized dendritic cells (cDCs)|intralymphatic vaccination with peptide-pulsed mature non-polarized dendritic cells (cDCs)
88971159|NCT03152175|Experimental|Propranolol Hydrochloride|1mg / kg of propranolol hydrochloride administered as a capsule 60 minutes prior to memory reactivation
88971160|NCT03152175|Placebo Comparator|Placebo|Placebo manufactured as a capsule to mimic 1mg/kg of propranolol hydrochloride administered 60 minutes prior to memory reactivation
88971161|NCT00399685|Active Comparator|A|
88971162|NCT00399685|Active Comparator|B|
88971163|NCT00399685|Active Comparator|C|
88971164|NCT00399685|Active Comparator|D|
88971165|NCT03152136|Experimental|TAPS|Subjects will receive a Cala ONE device that delivers TAPS, transcutaneous afferent patterned stimulation.
88971166|NCT03152136|Sham Comparator|Sham|Subjects will receive a Cala ONE device that delivers sham stimulation.
88971167|NCT03152136|No Intervention|No Intervention|Subjects will not receive a Cala ONE device, and will stay on their current treatment regimen for their essential tremor.
88971168|NCT03152097|Placebo Comparator|Placebo|This crossover design will include 4 weeks of diindolylmethane and 4 weeks of matching placebo assignment.
88971169|NCT03152097|Experimental|Commercially available Diindolylmethane|This crossover design will include 4 weeks of diindolylmethane and 4 weeks of matching placebo assignment.
88971170|NCT00082147|Experimental|Biopsy|Biopsy
88971171|NCT00082186|Experimental|1|Oral bosentan tablets
88971172|NCT00082225|Experimental|EBV specific T cells|"Patients receiving CTLs as therapy for relapsed Lymphoma or who are at high risk for relapse or patients receiving CTLs as adjunctive therapy following autologous or syngeneic transplant.~A fixed dose of CD45 MAb (400ug/kg over 4 hours daily times 4 given over 2 daily IV infusions) will be used."
88971173|NCT00082498|Placebo Comparator|1|Group 1 will receive placebo
88971174|NCT00082498|Experimental|2|Group 2 will receive 5 mg vicriviroc daily
88971175|NCT00082498|Experimental|3|Group 3 will receive 10 mg vicriviroc daily
89574767|NCT05502445|Active Comparator|Intervention Group|"In this group, the steps below are added:~On the first day, the delivery of the leaflet on the importance of nutrition in the hospital environment will be added in addition to verbal guidance.~On the second day, an educational institutional video with duration of two minutes, will be shown with the title Food Intake and Oral Supplement in Nutritional Rehabilitation via tablet or mobile phone.~When the 24-hour recall will be collected, an assessment of food intake will be performed, mainly of foods that are sources of protein and, when they were less than 75%, strategies must be designed to increase the acceptance or indication of oral nutritional supplements (ONS)."
89574768|NCT05505877|Experimental|BR790+Tislelizumab dose escalation|Dose escalation part
89574769|NCT05505877|Experimental|BR790+Tislelizumab dose expansion|Dose expansion part
89574770|NCT05508685|Experimental|HIIT and Cognitive Reassessment|The experimental group will receive high-intensity interval training associated with cognitive reassessment
89574771|NCT05508685|Active Comparator|HIIT Group|The HITT group will receive only the exercise without cognitive reassessment
89574772|NCT05508685|Active Comparator|Emotional regulation strategy group|This group will receive only cognitive reassessment strategy
89574773|NCT05508685|Placebo Comparator|Group No exercise and cognitive reassessment|This group will only be evaluated in pre and post, without intervention.
89574774|NCT02336451|Experimental|Arm 1 (PrALKi=Y, PrBRad=Y)|Participants with metastases in the brain without evidence of leptomeningeal carcinomatosis (LC), previously treated with radiation to the brain and with prior exposure to an Anaplastic lymphoma kinase inhibitor (ALK-I). Previous treatment with ALK-I other than crizotinib was not allowed in this arm as of protocol amendment 3 and had to present with active brain lesion defined as a lesion free of any local treatment (like stereotactic radiosurgery or whole brain radiation).
89574775|NCT02336451|Experimental|Arm 2 (PrALKi=Y, PrBRad=N)|Participants with metastases in the brain without evidence of LC, previously untreated with radiation to the brain but with prior exposure to an ALK-I. Previous treatment with ALK-I other than crizotinib was not allowed in this arm 2 as of protocol amendment 3 and had to present with active brain lesion defined as a lesion free of any local treatment (like stereotactic radiosurgery or whole brain radiation).
89574776|NCT02336451|Experimental|Arm 3 (PrALKi=N, PrBRad=Y)|Participants with metastases in the brain without evidence of LC, previously treated with radiation to the brain but with no prior exposure to an ALK-I. Participants in this arm had to present with active brain lesion defined as a lesion free of any local treatment (like stereotactic radiosurgery or whole brain radiation).
89574777|NCT02336451|Experimental|Arm 4 (PrALKi=N, PrBRad=N)|Participants with metastases in the brain without evidence of LC, previously untreated with radiation to the brain and with no prior exposure to an ALK-I. Participants in this arm had to present with active brain lesion defined as a lesion free of any local treatment (like stereotactic radiosurgery or whole brain radiation).
89574778|NCT02336451|Experimental|Arm 5 (LepDis)|Participants had LC with or without evidence of active lesion at the baseline Gadolinium-enhanced brain magnetic resonance imaging (MRI). Previous treatment with ALK-I other than crizotinib was not allowed in this arm as of protocol amendment 3.
89574779|NCT02374593|Experimental|Targeted dosing|Patients in this arm will receive targeted levothyroxine dosing based on thyroid anatomy on ultrasound as follows: 10 mcg/kg for normal gland, 12 mcg/kg for ectopic gland, 15 mcg/kg for athyreosis.
89574780|NCT01648101|Experimental|Retigabine 900mg|900mg total daily dose
89574781|NCT01648101|Experimental|Retigabine 600mg|600mg total daily dose
89574782|NCT01648101|Placebo Comparator|Placebo|Placebo
89574783|NCT02336373|Experimental|Hydroxurea|Initiate hydroxyurea at 10 mg/kg daily and escalate hydroxyurea dose by 5 mg/kg/day every 8 weeks up to a maximum dose of 35 mg/kg/day if blood counts meet escalation criteria on at least 2 blood tests over eight weeks prior to dose increase.
89574784|NCT02372799|Experimental|Vilazodone|Vilazodone tablets, 5mg, 10mg and 20mg. Oral administration, once per day.
89574785|NCT02372799|Placebo Comparator|Placebo|Dose-matched placebo tablets or capsules, oral administration, once per day.
89574786|NCT02372799|Active Comparator|Fluoxetine|Fluoxetine capsules, 10mg and 20 mg. Oral administration, once per day.
89574787|NCT02566993|Experimental|Experimental Arm|Lurbinectedin (PM01183) / Doxorubicin
88971176|NCT00082498|Experimental|4|Group 4 will receive 15 mg vicriviroc daily
88971177|NCT03151980|Active Comparator|Hamam treated skin and sun exposure|
88971178|NCT03151980|Other|Untreated skin and sun exposure|
88971179|NCT00082732|Experimental|Arm I: Dietary Intervention|Nutritional counseling on a low-fat, high-fiber, soy supplemented diet and behavior-based activities, such as goal-setting, contracting, and stimulus control, once weekly for 6 weeks, every 3 weeks for 33 weeks, and then at weeks 44, 48, and 52.
88971180|NCT00082732|No Intervention|Arm II: Observation|Observation every 6 weeks for 36 weeks and then every 8 weeks for 18 weeks.
88971181|NCT00082966|Experimental|Arm I|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Treatment repeats every 21 days for up to 8 courses in the absence of rapid disease progression or unacceptable toxicity.
88971182|NCT04245956|Experimental|Transcatheter Mitral Valve Repair arm|Patients with severe Mitral Insufficiency with concomitant intermediate coronary artery stenosis undergoing Transcatheter Mitral Valve Repair using the percutaneous edge-to-edge MitraClip system
89574788|NCT02566993|Active Comparator|Control Arm 1|CAV (Cyclophosphamide (CTX), Doxorubicin (DOX) and Vincristine (VCR))
88971183|NCT03151863|Active Comparator|Opioids, placebo|One single dose of subcutaneous opioids and intranasal placebo (NaCl0.9%).
89574789|NCT02566993|Active Comparator|Control Arm 2|Topotecan
89574790|NCT05508607||Pre-Implementation|
89574791|NCT05508607||Post-Implementation|
88971184|NCT03151863|Experimental|Placebo, Dexmedetomidine|One single dose of subcutaneous placebo (NaCl0.9%) and intranasal Dexmedetomidine 1.25ug/Kg
88971185|NCT00083161|Experimental|Oral cyclophosphamide plus standard cisplatin with etoposide|"Etoposide 120 mg/m2 IV Days 1-3 or Etoposide 120 mg/ m2 IV Day1 followed by Etoposide 120 mg/ m2 PO BID Days 2-3~Cisplatin 60 mg/m2 IV Day 1 Every 21 days x 4 cycles~Cyclophosphamide 25 mg PO BID Days 8-19 of each cycle"
88971186|NCT03151785|Active Comparator|Face-to-face BLS training|Pupils will receive CPR training by standardised face-to-face BLS training only
88971187|NCT03151785|Active Comparator|Lifesaver training|Pupils will receive CPR training by Lifesaver programme only
89574792|NCT05508529|Active Comparator|Chaga Mushroom|Chaga mushroom extract (1 capsule daily) Active ingredients: 480mg chaga mushroom extract Inactive ingredients: none
88971188|NCT03151785|Active Comparator|Lifesaver and Face-to-Face BLS training|Pupils will receive CPR training by Lifesaver and standardised face-to-face BLS training
88971189|NCT04729699|Experimental|Intervention group|Intervention group (n=10) received 12 physiotherapy sessions and exercises for TMJ 30-45 minutes 2 days per week.
88971190|NCT04729699|Active Comparator|Control group|Control group (n=9) was introduced with physiotherapy program in order to perform it independently at home.
89532274|NCT06336642|Experimental|Group 2: SPOT-ON Waitlist|Participants will work with the healthcare team to find the best ways to reduce your shortness of breath by finding what combination of treatments work for participant. Participants will receive education about shortness of breath by the research staff in addition to information about standard treatments or medications for your shortness of breath that would be offered by your medical team.
88971191|NCT03151746|Placebo Comparator|Placebo|Placebo pill administered 1 hour before planned surgical procedure
88971192|NCT03151746|Experimental|Gabapentin|Gabapentin pill (1200mg) administered orally 1 hour prior to planned surgical procedure
88971193|NCT05568589||Preoperative Interpectoral - Pectoserratus Plane Block|The block will be done by the Anesthesiologist.
88971194|NCT05568589||Intraoperative Interpectoral - Pectoserratus Plane Block|The block will be made by the surgeon.
88971195|NCT05568589||Non Block|will not be blocked.
89532275|NCT06336629|Experimental|Winlevi (clascoterone) 1% & Duac gel|
89532276|NCT06336616|Experimental|Intervention group|All participants will receive an online behavioral intervention for 10 weeks, followed by monthly maintenance sessions for 3 months.
89532277|NCT06336603|Experimental|Winlevi (clascoterone) 1% & Adapalene 0.3% gel|Combined use of Winlevi twice daily and Adapalene once daily
89532278|NCT06336590|No Intervention|Normal Exercise|This arm has no intervention. Participants will continue to exercise at their normal evening time (6pm-11pm).
89532279|NCT06336590|Experimental|Morning Exercise|Participants will change their exercise times to the morning (6am-11am).
89532280|NCT06336551|Experimental|Acceptance and Commitment Therapy for insomnia (ACT-I)|In this condition, participants receive five individual face-to-face 60-minute sessions of ACT-I psychotherapy within a 7-week treatment period.
89532281|NCT06336551|No Intervention|Waitlist control|In this condition, participants fill out assessments only during a 7-week waiting period. After completing the post-assessment, participants in the control condition receive ACT-I treatment as well.
89532282|NCT06336538|Experimental|Mindfulness-Based Cognitive Therapy|MBCT-Brief includes 8 weekly 1-hour group sessions delivered either via telephone or video teleconferencing. The decision to deliver the intervention either via phone or teleconferencing will be made based on participant preference obtained during the formative focus groups. Telephone delivery of MBCT-Brief only requires a landline, while teleconferencing requires either a smartphone, tablet, or computer with audio and video functionality. During the MBCT-Brief intervention the instructor will lead in-session practice of medication and cognitive therapy exercises, guided inquiry, and assign and review at-home practice exercises. All sessions will be audio-recorded. Participants will be encouraged to practice daily meditation in between group sessions for 20 minutes, 6 days per week. Participants will complete practice logs to document daily meditation practice.
89532283|NCT06336499||Malignant orbital tumors|Patients with malignant orbital tumors (lymphoma, melanoma, ...) diagnosed by pathological confirmation.
89532284|NCT06336499||Benign orbital tumors|Patients with benign orbital tumors (cavernous hemangioma, inflammatory pseudotumor, ...) diagnosed by pathological confirmation.
89532285|NCT06336486|Active Comparator|intermittent pneumatic compression +pregabalin|Patients were given an intermittent pneumatic compression program at a pressure of 35 mmhg for 30 min to the lower extremity for 10 days of extreme alternation in our clinic and pregabalin treatment was continued.
89532286|NCT06336486|Other|pregabalin|only pregabalin treatment was continued.
89532287|NCT06336122|Other|Peer Participant Group A|Participants will self-select their peer coach and will receive contact once a week.
89532288|NCT06336122|Other|Peer Participant Group B|Participants will self-selected their peer coach and will receive contact every 2 weeks
89532289|NCT06336122|Other|Peer Participant Group C|Participants will be matched with a peer coach and will receive contact once a week
89532290|NCT06336122|Other|Peer Participant Group D|Participants will be matched with a peer coach and will receive contact every 2 weeks.
89532291|NCT06335901||2|
89532292|NCT06335173|Experimental|Double-blind Treatment (DBT) Period: ACU193 35 mg/kg|Participants will receive ACU193, 35 milligrams per kilogram (mg/kg), Q4W as intravenous (IV) infusion during the DBT period.
89532293|NCT06335173|Experimental|DBT Period: ACU193 50 mg/kg|Participants will receive ACU193, 35 mg/kg, for the first two doses, followed by AUC193, 50 mg/kg, Q4W as an IV infusion during the DBT period.
89532294|NCT06335173|Placebo Comparator|DBT Period: Placebo|Participants will receive AUC193 matching placebo, Q4W as an IV infusion during the DBT period.
89532295|NCT06335173|Experimental|Open-Label Extension (OLE) Period: ACU193 35 mg/kg|Participants will receive ACU193, 35 mg/kg, Q4W as an IV infusion during the OLE period.
89532296|NCT06334302|Experimental|Omega Galil O'Sweet hazelnut cocoa spread|Omega Galil O'Sweet hazelnut cocoa spread is composed of 8% sucrose, 26% MCT oil, 6% cocoa butter, 6% cocoa powder, 10% Hazelnut paste, 24% fibers, 13% rice flour. It contains a total of 27.3 gram carbohydrates/ 100gram, 520 kcals/100 grams, and very low estimated GL according to healthy adults
89532297|NCT06334302|Active Comparator|Nutella hazelnut cocoa spread|Nutella hazelnut cocoa spread is composed of 56% sugar, 30% vegetable fat, 13% Hazelnut paste, milk powder (8.7%), and cocoa powder (7.4%), containing a total of 57.5 grams carbohydrates /100grams, 532 kcals/100 grams, and an estimated GL of 4
89532298|NCT06334211|Experimental|FP-020|100 mg capsule
89532299|NCT06334211|Placebo Comparator|placebo|placebo capsule
89532300|NCT06333548||Appropriate for gestational age|Appropriate for gestational age
89532301|NCT06333548||small for gestational age|small for gestational age
89532302|NCT06333548||large for gestational age|large for gestational age
89532303|NCT06333548||Baby of mother diagnosed with GDM|Baby of mother diagnosed with gestational diabetes mellitus
89574793|NCT05508529|Active Comparator|Algae Extract|Algae Concentrate (2 tablets daily) Active ingredients: 8mg algae concentrate Inactive ingredients: none
89574794|NCT05508529|Active Comparator|Black Cumin Seed Oil|Black cumin seed oil (1 softgel daily) Active ingredients: 500mg black cumin seed oil Inactive ingredients: medium chain triglyceride (MCT) oil
89574795|NCT05508529|Active Comparator|Black Cumin Seed Oil + Astaxanthin|Black Cumin Seed Oil + Astaxanthin (3 softgels daily) Active ingredients: 500mg black cumin seed oil + 8mg astaxanthin oleoresin Inactive ingredients: medium chain triglyceride (MCT) oil
89574796|NCT05508529|Active Comparator|Black Cumin Seed Oil + Omega 3|Black Cumin Seed Oil + Omega 3 (3 softgels daily) Active ingredients: 500mg black cumin seed oil + 1200mg omega3 from 1500mg fish oil Inactive ingredients: none
89574797|NCT05508529|Placebo Comparator|Placebo|Placebo (1 capsule daily) Inactive ingredients: 500 mg Cornstarch/Maltodextrin
89574798|NCT05505487|No Intervention|control group|Implement routine nursing such as: routine oral nursing, tracheostomy, dressing change, sputum suction nursing, oral education, etc.
89574799|NCT05505487|Experimental|intervention group|Implement comprehensive nursing models such as: admission risk assessment, personalized oral care based on beck oral score, aspiration prevention, airway care, diversified health education
89574800|NCT05508451|Active Comparator|paracetamol|
89574801|NCT05508451|Active Comparator|tenoxicam|
89574802|NCT05508451|Active Comparator|tenoxicam+paracetamol|
89574803|NCT05508451|Placebo Comparator|placebo|
89574804|NCT05508373|Experimental|Dose Escalation: dose level：0.3mg/kg|Dose Escalation: 0.3mg/kg, IV infusion, every 3 weeks (q3w).
89574805|NCT05508373|Experimental|Dose Escalation: dose level：1 mg/kg|Dose Escalation: 1 mg/kg IV infusion, every 3 weeks (q3w).
89574806|NCT05508373|Experimental|Dose Escalation: dose level：3 mg/kg|Dose Escalation: 3 mg/kg IV infusion, every 3 weeks (q3w).
89574807|NCT05508373|Experimental|Dose Escalation: dose level：10 mg/kg|Dose Escalation: 10 mg/kg IV infusion, every 3 weeks (q3w).
89574808|NCT02311881|Experimental|Paracetamol 2000 mg twice daily (BID)|Participants will be instructed to take two active paracetamol 1000 mg SR tablets twice daily (with 10-12 hours between adjacent doses) and two placebo to match paracetamol 665 mg SR tablets thrice daily (with 6-8 hours between adjacent doses) orally with approximately 8 ounces (~ 240 mL) of water/dose for 12 weeks.
88971196|NCT05568238|Other|Vacuum Assisted Wound Closure and Permanent On-lay Mesh-mediated fascial traction|Incisional hernia incidence for patients treated with Vacuum Assisted Wound Closure and Permanent On-lay Mesh mediated fascial traction
88971197|NCT03151668|Experimental|Dexmedetomidin|
88971198|NCT03151668|No Intervention|Midazolam|
88971199|NCT05568082|Experimental|AMG 510 + Itraconazole|
88971200|NCT05567965|Experimental|Intensified home care intervention + Training|Users will receive an intensification in their home care intervention for dependence, receiving an intervention of a minimum of 1 hour per day and a maximum of 3.5 hours, to support their activities of daily living. The intensification will be personalised according to the specific needs of the user that the professionals consider necessary to attend. The weekly distribution of the intervention will be flexible in terms of timetables, as agreed between professional and informal caregivers. In addition, each informal caregiver will receive multimodal online training with the aim of providing knowledge, skills and attitudes that empower them to face the challenge of caring, guaranteeing quality care, preventing situations that may negatively affect both the person and the family dynamics and enabling an optimal evolution in caregiving.
88971201|NCT05567965|Active Comparator|Conventional home care intervention|Participants will continue with their conventional home care intervention for dependence, comprising activities that are mainly carried out at the users' home and are oriented towards supporting their activities of daily living. This intervention is of personalised attention and its average intensity is about 20 minutes per day.
89574809|NCT02311881|Active Comparator|Paracetamol 1330 mg thrice daily (TID)|Participants will be instructed to take two active paracetamol 665 mg SR tablets orally thrice daily (with 6-8 hours between adjacent doses) and two placebo to match paracetamol 1000 mg SR tablets orally twice daily (with 10-12 hours between adjacent doses) orally with approximately 8 ounces (~ 240 mL) of water/dose for 12 weeks.
89574810|NCT02311881|Placebo Comparator|Placebo|Participants will be instructed to take two placebo to match paracetamol 1000 mg SR tablets twice daily (with 10-12 hours between adjacent doses) and two placebo to match paracetamol 665 mg SR tablets thrice daily (with 6-8 hours between adjacent doses) orally with approximately 8 ounces (~ 240 mL) of water/dose for 12 weeks.
88971202|NCT02965066|Experimental|First Coloplast Test catheter; then Speedicath catheter|The subjects allocated to this arm first test Coloplast Test catheter and after cross over test the comparator speedicath catheter
88971203|NCT02965066|Experimental|First Speedicath catheter; then Coloplast Test catheter|The subjects allocated to this arm first test Speedicath catheter and after cross over test the Coloplast test catheter
89574811|NCT02565511|Experimental|Cohort I (CAD106)|CAD106 (450 µg) + Alum (450 µg) intra-muscular injection at Weeks 1, 7, 13 and every 13 weeks thereafter
89574812|NCT02565511|Placebo Comparator|Cohort I (CAD106 Placebo)|Placebo to CAD106 + Alum (450 µg) intra-muscular injection at Weeks 1, 7, 13 and every 13 weeks thereafter
89574813|NCT02565511|Experimental|Cohort II (CNP520)|CNP520 (50 mg) capsules taken orally once daily
89574814|NCT02565511|Placebo Comparator|Cohort II (CNP520 Placebo)|Matching Placebo to CNP520 capsules taken orally once daily
88971204|NCT05567653|Experimental|Probiotic treatment group|ca. 30 participants
88971205|NCT05567653|Placebo Comparator|Placebo group|ca. 30 participants
88971206|NCT05567614||75|patients with chronic hepatitis B infection will be collected and underwill liver fibroscan then corelate between platelets indicies and predict degree of liver fibrosis
88971207|NCT04172714|Experimental|Second mapping with low-dose Y90|Patients will undergo standard of care mapping study with 99TC-MAA to plan for Y90 radioembolization therapy. Additionally,non-standard of care, intervention will be to do a second mapping study using SIR-spheres microspheres with low-dose Y90 (15 mCi) before the therapeutic Y90 radioembolization.
89574815|NCT02561455|Experimental|Gilteritinib 40 mg|Participants received gilteritinib 40 milligrams (mg) dose (one tablet of 40 mg) orally once a day in continuous 28-day cycles at least 2 hours after or 1 hour before food. Gilteritinib treatment continued until participants no longer received clinical benefit from therapy, or unacceptable toxicity occured, or met one of the treatment discontinuation criteria.
89574816|NCT02561455|Experimental|Gilteritinib 80 mg|Participants received gilteritinib 80 mg dose (two tablets of 40 mg) orally once a day in continuous 28-day cycles at least 2 hours after or 1 hour before food. Gilteritinib treatment continued until participants no longer received clinical benefit from therapy, or unacceptable toxicity occured, or met one of the treatment discontinuation criteria.
89574817|NCT02561455|Experimental|Gilteritinib 120 mg|Participants received gilteritinib 120 mg dose (three tablets of 40 mg) orally once a day in continuous 28-day cycles at least 2 hours after or 1 hour before food. Gilteritinib treatment continued until participants no longer received clinical benefit from therapy, or unacceptable toxicity occured, or met one of the treatment discontinuation criteria.
89574818|NCT02561455|Experimental|Gilteritinib 200 mg|Participants received gilteritinib 200 mg dose (five tablets of 40 mg) orally once a day in continuous 28-day cycles at least 2 hours after or 1 hour before food. Gilteritinib treatment continued until participants no longer received clinical benefit from therapy, or unacceptable toxicity occured, or met one of the treatment discontinuation criteria.
89574819|NCT02561299|Experimental|OA with adjunctive DCB angioplasty|Lesion preparation with Peripheral Orbital Atherectomy System followed by drug-coated balloon angioplasty
89574820|NCT02561299|Active Comparator|DCB angioplasty|014 Drug Coated Balloon angioplasty
88971208|NCT05567575|Experimental|TechCare|"Participants in this arm will receive a mobile app based cognitive behavior therapy informed TechCare intervention for a period of 12 weeks."
88971209|NCT05567575|Active Comparator|Wait-List control group:|Participants in this arm will be offered the intervention once the intervention arm have completed their 3rd month outcome assessment.
89574821|NCT04549051|Experimental|Tenex plus local anesthetic|Use of the TENEX device for sectioning of the CHL
89574822|NCT04549051|Other|Local Anesthetic|Only Local anesthetic will be injected into the CHL. This arm will have the option to cross over into Tenex arm at 1 month
89574823|NCT04547413|No Intervention|Control Arm|"Control Arm will will complete a total of three visits:~Visit 1 (Day 1): Recruitment/Baseline Biological Testing, if needed; completion of baseline study surveys including Knowledge Assessment~Monthly: Prevention Maintenance Intervention Messages from months 2-11~Visit 3 (Day 180): 6 Month Follow-up biological testing and study survey~Visit 4 (Day 365): 12 Month Follow-up biological testing and study surveys"
89574824|NCT04547413|Active Comparator|Intervention Arm|"Intervention Arm will will complete a total of four visits:~Visit 1 (Day 1): Recruitment/Baseline Biological Testing, if needed; completion of baseline study surveys including Knowledge Assessment~Visit 2 (Day 2-30): Group Intervention Session, Feedback form, and post-intervention knowledge assessment (for intervention arm only)~Monthly: Prevention Maintenance Intervention Messages from months 2-11~Visit 3 (Day 180): 6 Month Follow-up biological testing and study survey~Visit 4 (Day 365): 12 Month Follow-up biological testing and study surveys"
89574825|NCT05505253|Active Comparator|Alfacalcidol|Alfacalcidol 0.5 mcg orally given for 3 months
89574826|NCT05505253|Placebo Comparator|Control|Placebo given orally for 3 months
89574827|NCT05501977||patients with chronic pain after thoracotomy|patients with chronic pain after thoracotomy
89574828|NCT05501977||patients without chronic pain after thoracotomy|patients without chronic pain after thoracotomy
89574829|NCT04784377|Experimental|High laser group|
89574830|NCT04784377|Experimental|low laser group|
89574831|NCT04784377|Other|control group|
89574832|NCT04541095|Experimental|EX_IMF group|Infants will receive infants formula with large amounts of beta-palmitate (EX_IMF).
89574833|NCT04541095|Active Comparator|ST_IMF group|Infants will receive infants formula with low amounts of beta-palmitate (ST_IMF).
88971210|NCT04733508|Experimental|111In-exendin-DTPA|Injection of 111In-exendin-DTPA for subsequent localization of the tracer in excised tissue using autoradiography
88971211|NCT04733508|Experimental|exendin-IRDye800CW|Injection of exendin-4-IRDye800CW for subsequent localization of the tracer in excised tissue using fluorescence microscopy
88971212|NCT05567536||Clopidogrel group|This group are those who received clopidogrel 75mg qd as a single antiplatelet agent therapy after PCI.
88971213|NCT05567536||Aspirin group|This group are those who received aspirin 100mg qd as a single antiplatelet agent therapy after PCI.
89574834|NCT04541095|No Intervention|HM group|Infants will receive human milk (HM).
89574835|NCT02566759|Experimental|Part 1, Cohort 1: TAK-831 100 mg|TAK-831 100 milligram (mg), suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1.
89574836|NCT02566759|Experimental|Part 1, Cohort 2: TAK-831 250 mg|TAK-831 250 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1.
89574837|NCT02566759|Experimental|Part 1, Cohort 3: TAK-831 500 mg|TAK-831 500 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1.
89574838|NCT02566759|Experimental|Part 1, Cohort 4: TAK-831 30 mg|TAK-831 30 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1.
89574839|NCT02566759|Experimental|Part 1, Cohort 5: TAK-831 750 mg|TAK-831 750 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1.
88971214|NCT05567341|Experimental|RIC|On the right upper extremity a blood pressure cuff is inflated to 200mmHg for 4x5min at the beginning of the surgery
88971215|NCT05567341|Sham Comparator|Control|On the right upper extremity a blood pressure cuff is inflated to 0mmHg for 4x5min at the beginning of the surgery
88971216|NCT05567146|Experimental|Experimental group|"Adolescents going to high school, Gamification technique is applied to the Intervention group for seven weeks.~Intervention:gamification technique with tele-nursing"
88971217|NCT05567146|No Intervention|Control group|Adolescents going to high school
88971218|NCT04114370|Experimental|Participants with Glioma|[F18]fluciclovine will be utilized to assess tumor viability compared with F-18 FDG PET or diagnostic MRI.
88971219|NCT00135304|Experimental|Cinacalcet and low-dose Vitamin D|Cinacalcet and low-dose IV Vitamin D
88971220|NCT00135304|Active Comparator|Vitamin D alone|Escalating doses of IV Vitamin D alone
88971221|NCT04103606|Experimental|immediate-use App group (iApp group)|Participants in the iApp group start using the app immediately (Time 0; T0) for 16 consecutive days (until Time 1; T1).
89574840|NCT02566759|Experimental|Part 1, Cohort 6: TAK-831 10 mg|TAK-831 10 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1.
89574841|NCT02566759|Experimental|Part 2, Cohort 1: TAK-831 30 mg|TAK-831 30 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1 and once daily from Days 4 to 16.
89574842|NCT02566759|Experimental|Part 2, Cohort 2: TAK-831 100 mg|TAK-831 100 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1 and once daily from Days 4 to 16.
89574843|NCT02566759|Experimental|Part 2, Cohort 3: TAK-831 200 mg|TAK-831 200 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1 and once daily from Days 4 to 16.
89574844|NCT02566759|Experimental|Part 2, Cohort 4: TAK-831 400 mg|TAK-831 400 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1 and once daily from Days 4 to 16.
89574845|NCT02566759|Experimental|Part 3, Cohort 1: TAK-831 400 mg|TAK-831 400 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once daily from Days 1 to 14.
89532304|NCT06333314|Experimental|Dostarlimab|Patient will receive dostarlimab intravenously 500 mg every 3 weeks for 4 cycles followed by 1000 mg every 6 weeks for all cycles thereafter until disease progression, unacceptable toxicity, death, investigator's decision, patient's decision or for a maximum of 24 months.
89532305|NCT06333314|Active Comparator|Standard of care|Patients will receive the standard of care chemotherapy
89532306|NCT06333223|Experimental|Mixture of (Poly)phenols and a probiotic supplement|This is a Mixture of (Poly)phenols and a probiotic supplement
89532307|NCT06333223|Placebo Comparator|(Poly)phenols and maltodextrin|This is a mixture of (Poly)phenols and maltodextrin (placebo comparator)
89532308|NCT06332209|Active Comparator|Tele-TF-CBT|Trauma-Focused Cognitive Behavioral Therapy delivered via telehealth
89532309|NCT06332209|Active Comparator|Clinic-TF-CBT|Trauma-Focused Cognitive Behavioral Therapy delivered in clinic (in-person)
89532310|NCT06331533|Experimental|Botulinum toxin A|30 points were marked on a randomly selected face half at 0.5 cm intervals. 0.5 U BoNT-A was injected into each point, making a total of 15 U BoNT-A.
89532311|NCT06331533|Placebo Comparator|Placebo|30 points were marked on a randomly selected face half at 0.5 cm intervals. 1.5 ml isotonic NaCl was injected intradermally into 30 points.
89532312|NCT06331143|Experimental|Mid-Transverse Process block (MTP) group|Patients will receive mid-transverse process to pleura (MTP) block after induction of anesthesia.
89532313|NCT06331143|Experimental|Intrathecal morphine (IM) group|Patients will receive intrathecal morphine in a dose of 12 μg/kg (max 1000 μg) immediately after induction of anesthesia.
89532314|NCT06331078|Experimental|Square Stepping Exercise Group|The experimental group will have Square Stepping Exercise training twice a week for 4 weeks. Each session will start with a 15-minute warm-up, followed by a 40-minute Square Stepping Exercise workout and ending with a 15-minute cool-down. The Square Stepping Exercise part will start with the Elementary 2 level, which has 30 different patterns. Participants will start with the first pattern at this level. If they can complete it without mistakes within 15 seconds, they'll move on to the next pattern. If not, they'll repeat the pattern until they get it right within the time limit. Each session will have four participants, with two participants working on each of the two mats, which are divided into 40 squares and measure 100cm by 250 cm.
89532315|NCT06331078|Active Comparator|Aerobic Exercise Group|Individuals in the aerobic control cohort will partake in a 40-minute treadmill walking session, maintaining their heart rate at 60% of their individual heart rate reserve as calculated using the Karvonen formula. Before and after the aerobic exercise, a 5-minute warm-up session incorporating stretching and calisthenics, as well as a 5-minute cool-down session, will be conducted.
89532316|NCT06330311|Experimental|Whole-Body Vibration Group|Allocated participants will receive an intervention with Whole-Body vibration (12 - 18 minutes, 12 - 20 hz, 1 - 2 mm progression) added to a physical therapy treatment based on learning and motor control through activities with a defined goal and therapeutic exercises (56 minutes per session) 4 sessions per week for 4 weeks.
89532317|NCT06330311|Active Comparator|Control Group|"Physical therapy treatment based on learning and motor control through activities with a defined goal and therapeutic exercises (56 minutes per session) 4 sessions per week for 4 weeks.~In the control group, the same measurements will be made at the same time as the subjects in the experimental group."
89532318|NCT06329427|Active Comparator|Intervention - Dragon Ambient eXperience (DAX)|Clinicians interacted with DAX Copilot
89532319|NCT06329427|No Intervention|No Intervention - Control group|Clinicians with standard care
89532320|NCT06328777|Experimental|CABA-201|"Severe Skin Cohort: Infusion of CABA-201 with preconditioning in subjects with SSc with severe skin involvement~Organ Cohort: Infusion of CABA-201 with preconditioning in subjects with SSc with organ involvement"
89532321|NCT06328699|Experimental|Arm I (Chaplain delivered compassion meditation)|Patients receive chaplain led compassionate centered spiritual health sessions over 30 minutes, twice per week for up to 2 weeks.
89532322|NCT06328699|Active Comparator|Arm II (Traditional chaplain consultation)|Patients receive a traditional chaplain consultation and care upon request, per standard of care.
89532323|NCT06325722|Experimental|low-carbohydrate diet then low-fat diet|A low-carbohydrate followed by low-fat diet, each lasting for 4 weeks in adults with overweight or obesity
89532324|NCT06325722|Experimental|low-fat diet then low-carbohydrate diet|A low-fat followed by low-carbohydrate diet, each lasting for 4 weeks in adults with overweight or obesity
89532325|NCT06325709|Experimental|Single Arm Study|
89532326|NCT06325696|Experimental|Treatment|Adults, male and female with a diagnosis of interstitial lung disease, take 2 doses of 400 mg H01, morning and evening
89532327|NCT06323161|Active Comparator|CagriSema Dose 1|Participants will receive once-weekly subcutaneous (s.c) injections of CagriSema (cagrilintide and semaglutide) at escalating doses every week in 8-week dose escalation period until target dose (dose 1) of CagriSema (cagrilintide and semaglutide) is achieved and maintained up to 32 weeks.
89532328|NCT06323161|Active Comparator|CagriSema Dose 2|Participants will receive once-weekly s.c injections of CagriSema (cagrilintide and semaglutide) at escalating doses every week in 16-week dose escalation period until target dose (dose 2) of CagriSema(cagrilintide and semaglutide) is achieved and maintained up to 24 weeks.
89532329|NCT06323161|Placebo Comparator|Placebo Dose 1|Participants will receive once-weekly s.c injection of placebo matched to cagrisema dose 1 (cagrilintide and semaglutide) for 40 weeks.
89532330|NCT06323161|Placebo Comparator|Placebo Dose 2|Participants will receive once-weekly s.c injection of placebo matched to cagrisema dose 2 (cagrilintide and semaglutide) for 40 weeks
89532331|NCT06321263|Experimental|Peripheral Muscle Training Group|Older individuals in this group will participate in group exercise training, including aerobic and resistance training, twice a week for ten weeks, each session supervised by a researcher physiotherapist and lasting one hour.
89574846|NCT02566759|Experimental|Part 4:TAK-831(Tablet Fasted+ Tablet Fed + Suspension Fasted)|TAK-831 100 mg, tablet, orally, once after an overnight fast of at least 10 hours on Day 1 of Period 1, followed by a washout interval of 5 days, further followed by TAK-831 100 mg, tablet, orally, once 30 minutes after starting a high fat meal on Day 1 of Period 2, followed by a washout interval of 5 days, further followed by TAK-831 100 mg, suspension, orally, once after an overnight fast of at least 10 hours on Day 1 of Period 3.
89574847|NCT02566759|Experimental|Part 4:TAK-831(Tablet Fed + Tablet Fasted + Suspension Fasted)|TAK-831 100 mg, tablet, orally, once 30 minutes after starting a high fat meal on Day 1 of Period 1, followed by a washout interval of 5 days, further followed by TAK-831 100 mg, tablet, orally, once after an overnight fast of at least 10 hours on Day 1 of Period 2, followed by a washout interval of 5 days, further followed by TAK-831 100 mg, suspension, orally, once after an overnight fast of at least 10 hours on Day 1 of Period 3.
89574848|NCT02566759|Experimental|Part 4:TAK-831(Suspension Fasted+ Tablet Fed + Tablet Fasted)|TAK-831 100 mg, suspension, orally, once after an overnight fast of at least 10 hours on Day 1 of Period 1, followed by a washout interval of 5 days, further followed by TAK-831 100 mg, tablet, orally, once 30 minutes after starting a high fat meal on Day 1 of Period 2, followed by a washout interval of 5 days, further followed by TAK-831 100 mg, tablet, orally, once after an overnight fast of at least 10 hours on Day 1 of Period 3.
89574849|NCT04782349|Experimental|high intensity laser group|
89574850|NCT04782349|Experimental|low intensity laser group|
89574851|NCT04782349|Other|control group|
89574852|NCT05501587||Participants with CF|
89574853|NCT05501587||Participants with other Respiratory Disease|
89574854|NCT05501587||Healthy Participants|
89574855|NCT05501509|Active Comparator|Restoring Vertical and horizontal stability of the acromioclavicular joint|
89574856|NCT05501509|Experimental|Restoring Vertical stability of the acromioclavicular joint|
89574857|NCT05501431||Progressive Supranuclear Palsy (PSP)|Participants with possible or probable PSP, wearing the Verily Study Watch for 1 year.
89574858|NCT05501431||Healthy Controls (HC)|Participants without a neurological condition, age and gender matched to the PSP cohort, , wearing the Verily Study Watch for 1 year.
89574859|NCT05504785|Active Comparator|Control Group|Twenty type 2 diabetic patients in the Control Group will be managed according to standard-of-care methods at TJUH using finger-stick blood glucose measurements in an attempt to maintain the patient's blood glucose levels in the desired target range (80 to 180 mg/dL). Three blinded CGM will be used to record the patient's glucose trend data (for 20 days maximum) for future download to a computer and analysis.
89574860|NCT05504785|Active Comparator|Investigational Group|Forty type 2 diabetic patients in the Investigational Group will be managed by the orthopedic floor nurses using the real-time DexCom G6 CGM trend data to determine the appropriate therapy to maintain the patient's glucose levels in the desired target range (80 to 180 mg/dL). In addition, three blinded CGM will be used to record the patient's glucose trend data (for 20 days maximum) for future download to a computer and analysis.
89574861|NCT05504629|Experimental|Endurance Training (ET) plus Resistance Training (RT)|Concurrent training of Endurance Training plus Resistance Training order.
89029147|NCT04280783|Experimental|PATH Treatment Group|The PATH group will be granted password protected access to one of the 3 PATH levels based on their baseline fitness status. The intervention is designed to help participants increase their baseline PA via health coaching, self-monitoring and pragmatic workout videos that provide convenient options for overcoming socio-environmental barriers to PA.
89574862|NCT05504629|Active Comparator|Resistance Training (RT) plus Endurance Training (ET)|Concurrent training of Resistance Training plus Endurance Training order.
89574863|NCT05501197|Active Comparator|Synchronous Telerehabilitation Group|Synchronous Telerehabilitation Group will receive exercise therapy via video conference.
89574864|NCT05501197|Experimental|Asynchronous Telerehabilitation Group|Asynchronous Telerehabilitation Group will receive exercise therapy via mobile application.
89574865|NCT05504473|Experimental|Patients with facial nerve palsy and lagophthalmus|There is only one arm in this study. The investigators examine if the medical device can achieve a painless blinking in patients with facial nerve palsy and lagophthalmus.
89574866|NCT05504317|Experimental|AK111 regimen|
89574867|NCT05504317|Placebo Comparator|Placebo|
89574868|NCT05504239|Experimental|Teneligliptin 20 mg|Once daily for 24 weeks
89029148|NCT04280783|Other|Wait-list control group|Participants in this group will not have access to the PATH intervention until after 12 weeks when they cross over. After randomization, the control group will be provided with a copy of the Be Active Your Way booklet, developed by the Centers for Disease Control (CDC) to help individuals integrate PA in their daily lives.
89029149|NCT04272268||Nasal High flow Oxygen|Following consent, the participant will undergo Oesophagectomy as per routine care. During surgery, prior to trial participation and as per standard of care at the site, a nasogastric tube will be placed into the gastric conduit and secured to the nose. This tube will be left on free drainage and aspirated every 4 hours to check for inadvertent insufflation.
89029150|NCT04262128||Type 2 Diabetes Mellitus|women age 60-75 years with uncomplicated type 2 diabetes mellitus
89574869|NCT05504239|Placebo Comparator|Teneligliptin placebo|Once daily for 24 weeks
89574870|NCT04587661|Active Comparator|off-the-shelf digital CBT|standard implementation strategy that has no content or references to SCD, chronic pain, or the unique challenges facing minority groups
89574871|NCT04587661|Experimental|adapted digital CBT|has content or references to SCD, chronic pain, and the unique challenges facing minority groups
89574872|NCT05504161||Endometrial cancer group|Patients pathologically diagnosed with endometrial cancer
89029151|NCT04262128||Healthy Controls|healthy women age 60-75 years
89029152|NCT04237467||Older transgender men|This cohort will consist of transgender men aged 50-75 years old who have taken testosterone for at least one year.
89029153|NCT04237467||Younger transgender men|This cohort will consist of transgender men aged 18-40 years old who have taken testosterone for at least one year.
89029154|NCT04230759|Active Comparator|5FU+Mitomycin C|Radiochemotherapy for anal cancer
89029155|NCT04230759|Experimental|5FU+Mitomycin C+Durvalumab|Radiochemotherapy with Durvalumab for anal cancer
89574873|NCT05504161||Control group|Patients with benign endometrial pathology and interepithelial neoplasia
89029156|NCT04222790|Experimental|monosialic ganglioside|On the days -1, 1, and 2 of albumin paclitaxel application, 80 mg of monosialic ganglioside were applied (monosialic ganglioside was a single infusion)
89029157|NCT04222790|Placebo Comparator|Placebo|The control group received placebo on days -1, 1, and 2 of albumin paclitaxel (placebo as a single infusion)
89029158|NCT04219917|Experimental|Hip|Gluteus medius facilitation tape
89029159|NCT04219917|Experimental|Knee|Patellar sling tape
89574874|NCT04651699|Experimental|Active Transcranial Direct Current Stimulation|Active Transcranial Direct Current Stimulation (a-tDCS) will be applied over the Primary Motor Cortex during 10 sessions of 20 minutes at 2 milli amps.
89574875|NCT04651699|Sham Comparator|Sham Transcranial Direct Current Stimulation|Sham Transcranial Direct Current (s-tDCS) will be applied over the Primary Motor Cortex during 10 sessions of 20 minutes.
89574876|NCT02335983|Experimental|RRMM Dose-evaluation: Carfilzomib 56 mg/m²|"Participants with relapsed or refractory multiple myeloma (RRMM) received treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) for up to eighteen 28-day cycles, or until disease progression, patient withdrawal, stem cell transplant, or death.~Participants received carfilzomib on days 1, 8, and 15 of each cycle. The dose was 20 mg/m² on cycle 1, day 1, and 56 mg/m² thereafter. Participants also received lenalidomide 25 mg once daily on days 1-21 and dexamethasone 40 mg (oral or IV) on days 1, 8, and 15 of each cycle, and on day 22 of cycles 1 to 8."
89574877|NCT02335983|Experimental|RRMM Dose-evaluation: Carfilzomib 70 mg/m²|"Participants with RRMM received treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) for up to eighteen 28-day cycles, or until disease progression, patient withdrawal, stem cell transplant, or death.~Participants received carfilzomib on days 1, 8, and 15 of each cycle. The dose was 20 mg/m² on cycle 1, day 1, and 70 mg/m² thereafter. Participants also received lenalidomide 25 mg once daily on days 1-21 and dexamethasone 40 mg (oral or IV) on days 1, 8, and 15 of each cycle, and on day 22 of cycles 1 to 8."
89029160|NCT04219917|Experimental|Hip and Knee|Gluteus medius facilitation and patellar sling tape
89029161|NCT04219826|Experimental|CK-3773274 - Cohort 1 (Obstructive HCM)|Subjects will receive doses of 5 - 15 mg of CK-3773274 with dose levels guided by echocardiography assessments for up to 10 weeks
89029162|NCT04219826|Placebo Comparator|Placebo - Cohort 1 (Obstructive HCM)|Subjects will receive placebo for up to 10 weeks
89029163|NCT04219826|Experimental|CK-3773274 - Cohort 2 (Obstructive HCM)|Subjects will receive doses 10 - 30 mg of CK-3773274 with dose levels guided by echocardiography assessments for up to 10 weeks
89029164|NCT04219826|Placebo Comparator|Placebo - Cohort 2 (Obstructive HCM)|Subjects will receive placebo for up to 10 weeks
89029165|NCT04219826|Experimental|CK-3773274 & disopyramide - Cohort 3 (Obstructive HCM)|Subjects will receive doses 5 - 15 mg of CK-3773274 with dose levels guided by echocardiography assessments for up to 10 weeks while taking disopyramide
89029166|NCT04219826|Experimental|CK-3773274 - Cohort 4 (non-obstructive HCM)|Subjects will receive doses of 5 - 15 mg of CK-3773274 with dose levels guided by echocardiography assessments for up to 10 weeks
89029167|NCT04216342|Experimental|1|subjects entered into the trial may go thru a 0-4 weeks screening (Screening Phase). On the Intervention phase, subjects will be followed for 7 days which includes: entry criteria assessments and settling at the inpatient unit on Day 0, a single-dose I.V. infusion with data collection on Day 1 followed by 24 hours monitoring (Day 2), a 7-day and 28-day outpatient follow-up visit (Follow-Up Phase).
89029168|NCT04214041|Experimental|Autologous fat grafting|
89029169|NCT04214041|Active Comparator|Sub-epithelial connective tissue graft|
89029170|NCT04206007|Experimental|UMC119-06|Human Umbilical Cord Derived-Mesenchymal Stem Cells, Single treatment by intravenous infusion.
89029171|NCT04200365|Experimental|Itacitinib|
89029172|NCT04186260|Experimental|NAFLD-specific weight loss intervention|Participants will attend 12 weekly 30-45-minute individual counseling sessions and receive tailored lesson materials focused on behavioral strategies for adopting and maintaining healthy eating and physical activity (PA) behaviors. Participants will self-monitor their body weight, eating, and PA behaviors in a weekly journal. Dietary recommendations will follow nutritional guidelines for the treatment of NAFLD. To facilitate the adoption of the dietary recommendation, participants will be provided culturally-tailored meal plans and grocery lists that allow them to make small, practical dietary changes of ~100 calories. Participants will be prescribed weekly exercise goals with the duration increasing from 15-45 minutes, 5 days/week, over the 12-month program. After the completion of 12 weekly individual counseling sessions, participants will complete a 12-week follow-up including bi-weekly phone calls, followed by a 6-month follow-up period in which no intervention contact is made.
89029173|NCT04186260|Other|Wait-list control|The wait-list control group will receive the same intervention strategies described for the NAFLD-specific weight loss intervention after study comparisons have been made.
89029174|NCT04177095|Experimental|Belatacept treated patients|Renal transplant recipients treated with a combination of belatacept and any of the following: mycophenolate, sirolimus, everolimus and prednisone
89029175|NCT04158050||anti-IL5/IL5R-therapy group|Asthma patients, asthma and rhinitis, asthma and nasal polyps and anti-IL5/IL5R
89029176|NCT04158050||anti-IgE-therapy group|Asthma patients, asthma and rhinitis, asthma and nasal polyps and anti-IgE-therapy
89029177|NCT04150731|Experimental|Breast cancer and FES|Only one arm: All included are patients with disseminated breast cancer and all have an experimental FES-PET/CT done
89029178|NCT04142996|Active Comparator|Unilateral TBS|Intermittent Theta Burst Stimulation (iTBS) will be applied to the left DLPFC. Realistic sham continuous TBS (cTBS-sham) will be applied to the right DLPFC. Participants will receive daily sessions (Mon-Fri) for 4 to 6 weeks (stop at 4 weeks if remission is achieved).
89029179|NCT04142996|Active Comparator|Bilateral TBS|Intermittent Theta Burst Stimulation (iTBS) will be applied to the left DLPFC and continuous TBS (cTBS) will be applied to the right DLPFC. Participants will receive daily sessions (Mon-Fri) for 4 to 6 weeks (stop at 4 weeks if remission is achieved).
89574878|NCT02335983|Experimental|RRMM Dose-expansion: Carfilzomib 70 mg/m²|"Participants with RRMM received treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) for up to eighteen 28-day cycles, or until disease progression, patient withdrawal, stem cell transplant, or death.~Participants received carfilzomib on days 1, 8, and 15 of each cycle. The dose was 20 mg/m² on cycle 1, day 1, and 70 mg/m² thereafter. Participants also received lenalidomide 25 mg once daily on days 1-21 and dexamethasone 40 mg (oral or IV) on days 1, 8, and 15 of each cycle, and on day 22 of cycles 1 to 8."
89574879|NCT02335983|Experimental|NDMM Dose-evaluation: Carfilzomib 56/70 mg/m²|"Participants with newly diagnosed multiple myeloma (NDMM) received treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) for up to eighteen 28-day cycles, or until disease progression, patient withdrawal, stem cell transplant, or death.~Participants received carfilzomib on days 1, 8, and 15 of each cycle. The dose was 20 mg/m² on cycle 1 day 1, 56 mg/m² on cycle 1 days 8 and 15, and then 70 mg/m² thereafter. Participants also received lenalidomide 25 mg once daily on days 1-21 and dexamethasone 40 mg (oral or IV) on days 1, 8, and 15 of each cycle, and on day 22 of cycles 1 to 8."
89574880|NCT02335983|Experimental|NDMM Dose-expansion: Carfilzomib 70 mg/m²|"Participants with NDMM received treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) for up to eighteen 28-day cycles, or until disease progression, patient withdrawal, stem cell transplant, or death.~Participants received carfilzomib on days 1, 8, and 15 of each cycle. The dose was 20 mg/m² on cycle 1, day 1, and 70 mg/m² thereafter. Participants also received lenalidomide 25 mg once daily on days 1-21 and dexamethasone 40 mg (oral or IV) on days 1, 8, and 15 of each cycle, and on day 22 of cycles 1 to 8."
89574881|NCT02335983|Experimental|NDMM Dose-expansion: Carfilzomib 56 mg/m²|"Participants with NDMM received treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) for up to eighteen 28-day cycles, or until disease progression, patient withdrawal, stem cell transplant, or death.~Participants received carfilzomib on days 1, 8, and 15 of each cycle. The dose was 20 mg/m² on cycle 1, day 1, and 56 mg/m² thereafter. Participants also received lenalidomide 25 mg once daily on days 1-21 and dexamethasone 40 mg (oral or IV) on days 1, 8, and 15 of each cycle, and on day 22 of cycles 1 to 8."
89574882|NCT04640311|Experimental|Part A: Daprodustat Dissolution 1/Dissolution 2/Reference|
89574883|NCT04640311|Experimental|Part A: Daprodustat Dissolution 2/Reference/Dissolution 1|
89574884|NCT04640311|Experimental|Part A: Daprodustat Reference/Dissolution 1/Dissolution 2|
89574885|NCT04640311|Experimental|Part B: Daprodustat Process 1/ Process 2|
89574886|NCT04640311|Experimental|Part B: Daprodustat Process 2/ Process 1|
89574887|NCT04578691|Experimental|"Anatase Spine Surgery Navigation System"|"Using Anatase Spine Surgery Navigation System in pedicle screw placement in spine surgery"
89574888|NCT04578691|Active Comparator|Medtronic Stealthstation S7 Treatment Guidance System|Using Medtronic Stealthstation S7 Treatment Guidance System in pedicle screw placement in spine surgery
89574889|NCT02334423|Experimental|Botulinum toxin, Type A|Botulinum toxin, Type A
89574890|NCT02334423|Placebo Comparator|Placebo|0.9 % sterile, unpreserved saline
89574891|NCT02310789|Experimental|Ivacaftor|Participants will receive ivacaftor orally for 3 days, followed by 35 days off drug. Participants will repeat this cycle then receive ivacaftor for 3 additional days. For sweat testing, participants will receive β-adrenergic cocktail to stimulated sweating, at both 1% stimulation strength and full stimulation strength. Each participant will also receive pilocarpine nitrate 5% administered by Macroduct sweat stimulator device. Sweat stimulation testing will be done on- and off-ivacaftor.
89574892|NCT02372253|Experimental|Verapamil|13-26 subjects with Type 1 Diabetes meeting the inclusion criteria will be randomly assigned to receive daily oral verapamil for 12 months. The initial dose of verapamil will be 120 mg daily, and this will be advanced if tolerated to a maximum dose of 360 mg daily. The verapamil tablets will be encapsulated to match the placebo capsules
89574893|NCT02372253|Placebo Comparator|Placebo|13-26 subjects with Type 1 Diabetes meeting the inclusion criteria will be randomly assigned to receive daily oral placebo for 12 months. The initial dose of placebo will be 120 mg daily, and this will be advanced if tolerated to a maximum dose of 360 mg daily. The placebo tablets will be encapsulated to match the verapamil capsules
88971222|NCT04103606|Active Comparator|delayed-use App group (dApp)|Participants in the dApp group start using the app at Time 1 (T1; 16 days after the iApp group) and use the app for the following 16 days (Time 2; T2).
88971223|NCT00135499|Experimental|R-ACVBP|Rituximab, Doxorubicin, Cyclophosphamide, Vindesine, Bleomycin, Prednisone
88971224|NCT00135499|Active Comparator|R-CHOP|Rituximab, Doxorubicin, Cyclophosphamide, Vincristine, Prednisone
88971225|NCT03151434|Active Comparator|Group #1|US Guided Single Shot Paravertebral Block
88971226|NCT03151434|Active Comparator|Group #2|US Guided Paravertebral Catheter
88971227|NCT03151434|Active Comparator|Group #3|Thoracic Epidural
89029180|NCT04142996|Active Comparator|Maintenance Phase: Flexible|The flexible maintenance protocol will be based on symptom emergence. Participants will receive a fixed TBS (2x/week) schedule for the first month. For the following months (2-6), they will come in for an assessment (HRSD-17) to determine how many TBS sessions (0, 1, or 2) they receive on a flexible basis.
89029181|NCT04119271|Other|Breathe Easy at Home Kit Products|"Families will be provided with a Breathe Easy at Home Kit. These kits will include:~a HEPA filtered upright vacuum cleaner, a HEPA-filtered Air Purifier, a Hypoallergenic latex free mattress cover, box spring cover, and two pillow covers, Healthier alternative to most household cleaners, Non- toxic glue type pest control devices for rodent control, and a combination of safe products to locate and kill roaches."
89029182|NCT04118062|Other|Metastatic Uveal Melanoma|Questionnaires and semi-structured individual interviews with patients with Metastatic Uveal Melanoma
89029183|NCT04118062|Other|Triple Negative Breast Cancer|Questionnaires and semi-structured individual interviews with patients with Triple Negative Breast Cancer
88971228|NCT00135577|Experimental|Alvimopan 0.5 mg Twice Daily (BID)|0.5 milligrams (mg) of alvimopan was administered orally once in the morning and once in the evening.
88971229|NCT00135577|Experimental|Alvimopan 1 mg Once Daily (QD)|"Participants who did not have an interruption in blinded investigational product between the original study and the extension study received Alvimopan 1 mg in the morning and received placebo in the evening.~Participants who had an interruption in blinded investigational product between studies received 0.5 mg of alvimopan in the morning and placebo in the evening for 3 days, then 1 mg of alvimopan in the morning and placebo in the evening for the remaining 3 weeks."
89574894|NCT02559895|Experimental|ALD403 Dose Level 1|ALD403 Dose Level 1 (IV)
89574895|NCT02559895|Experimental|ALD403 Dose Level 2|ALD403 Dose Level 2 (IV)
89574896|NCT02559895|Experimental|ALD403 Dose Level 3|ALD403 Dose Level 3 (IV)
89574897|NCT02559895|Placebo Comparator|Placebo|Placebo (IV)
89574898|NCT02371629|Experimental|NVA237 Twice daily|Patients randomized to this arm received an NVA237 22 μg capsule in the morning and evening for 26 weeks. All participants received salbutamol as rescue medicine.
89574899|NCT02371629|Experimental|NVA237 Once daily|Patients randomized to this arm received an NVA237 44 μg capsule in the morning and a placebo capsule in the evening for 26 weeks. All participants received salbutamol as rescue medicine.
89574900|NCT02559817|Experimental|Linaclotide Dose A|"Taken once daily each morning at least 30 minutes before breakfast, with the exception of the first Treatment Period dose which will be taken at the study center, after at least a 2-hour fast.~Dose A: 18 micrograms liquid oral solution or solid oral capsule in children 7-11 years of age with weight 18 to <35 kg~Dose A: 36 micrograms liquid oral solution or solid oral capsule in children 7-11 years of age with weight ≥ 35 kg~Dose A: 36 micrograms solid oral capsule in children 12-17 years of age"
89574901|NCT02559817|Experimental|Linaclotide Dose B|"Taken once daily each morning at least 30 minutes before breakfast, with the exception of the first Treatment Period dose which will be taken at the study center, after at least a 2-hour fast.~Dose B: 36 micrograms liquid oral solution or solid oral capsule in children 7-11 years of age with weight 18 to <35 kg~Dose B: 72 micrograms liquid oral solution or solid oral capsule in children 7-11 years of age with weight ≥ 35 kg~Dose B: 72 micrograms solid oral capsule in children 12-17 years of age"
89574902|NCT02559817|Experimental|Linaclotide Dose C|"Taken once daily each morning at least 30 minutes before breakfast, with the exception of the first Treatment Period dose which will be taken at the study center, after at least a 2-hour fast.~Dose C: 72 micrograms liquid oral solution or solid oral capsule in children 7-11 years of age with weight 18 to <35 kg~Dose C: 145 micrograms liquid oral solution or solid oral capsule in children 7-11 years of age with weight ≥ 35 kg~Dose C: 145 micrograms solid oral capsule in children 12-17 years of age"
89574903|NCT02559817|Experimental|Linaclotide Approved Adult Dose|"Taken once daily each morning at least 30 minutes before breakfast, with the exception of the first Treatment Period dose which will be taken at the study center, after at least a 2-hour fast.~Approved Adult Dose: 290 micrograms solid oral capsule in children 12-17 years of age"
89574904|NCT02559817|Placebo Comparator|Matching Placebo|"Taken once daily each morning at least 30 minutes before breakfast, with the exception of the first Treatment Period dose which will be taken at the study center, after at least a 2-hour fast~Placebo liquid oral solution or placebo solid oral capsule in children 7-11 years of age~Placebo solid oral capsule in children 12-17 years of age"
89574905|NCT05504005|Experimental|Clinical Validation of mμSORS for Noninvasive Blood Glucose Detection|Enrolled subjects will perform oral glucose tolerance test. A measurement session of blood glucose consists of plasma sample and a measurement by mμSORS will be conducted synchronously.
89574906|NCT02564887|Other|Traditional Therapy Only|"Standard of care therapy for qualifying population (with opportunity to crossover and be assigned to the IOPI device if so desired after initial 8 week standard of care therapy completion."
89574907|NCT02564887|Experimental|Traditional Therapy with IOPI|Standard of care therapy plus the addition of the IOPI instrument
89574908|NCT04517929|No Intervention|control group|Patients in this group will receive recommendations regarding lifestyle change, exercise, and nutrition related to fibromyalgia.
89574909|NCT04517929|Experimental|intervention group|Patients in this group will receive recommendations regarding lifestyle change, exercise, and nutrition related to fibromyalgia and group psychotherapy.
89574910|NCT04577443|Active Comparator|Adenosine|
89574911|NCT04577443|Placebo Comparator|Saline|
89574912|NCT02333487|Experimental|Lu AF35700 (Group D1)|Up to 3 PET scans, besides baseline scan, using [11C]-NNC 112 tracer to detect D1 dopamine receptor occupancy before and after multiple oral dosing of Lu AF35700
89574913|NCT02333487|Experimental|Lu AF35700 (Group D2)|Up to 3 PET scans, besides baseline scan, using [11C]-Raclopride to detect D2 dopamine receptor occupancy before and after multiple oral dosing of Lu AF35700
89574914|NCT02333487|Experimental|Lu AF35700 (Group 5-HT6)|Up to 3 PET scans, besides baseline scan, using [11C]- Lu AE60157 tracer to detect 5-HT6 (5-hydroxytryptamine-6) receptor occupancy before and after multiple oral dosing of Lu AF35700
89574915|NCT05500729||Female CrossFitters|Crossfit practitioners born as female
89574916|NCT05500729||Male CrossFitters|Crossfit practitioners born as male
89209160|NCT00738101|Experimental|Fish Oil Emulsion Arm|"In infants who meet the eligibility criteria for Fish Oil Emulsion arm will receive Fish Oil Emulsion after enrollment under the study.~Therapy with Fish Oil Emulsion (Omegaven) will be provided at a dose of 1 gm/kg/day (by continuous infusion) and will be infused intravenously through either a central or peripheral catheter in conjunction with parenteral nutrition. If previously on Intralipid, it will be stopped prior to initiation of Fish Oil Emulsion.Fish oil emulsion will be provided as a continuous intravenous emulsion over 24 hours."
89574917|NCT04411537|Experimental|Treatment Arm|A total of 50 MSS LARC patients will receive 2 cycles of PD-1 antibody, followed by capecitabine plus irinotecan radiosensitized neoadjuvant chemoradiotherapy, and another 3 cycles of PD-1 antibody, finally received the total mesorectal excision (TME) and 6 cycles of adjuvant chemotherapy of XELOX.
89574918|NCT05500495||prolonged mechanical ventilation group|patients had 96 hours or more (PMV group).
89574919|NCT05500495||control group|patients had less than 96 hours of mechanical ventilation (control group)
89574920|NCT05503615|Other|Control Group|Which leg of the individuals will be applied will be determined by the coin toss. After the money shot, the right leg will be applied when the writing comes, and the left leg will be applied when the tour comes. The leg to be applied includes the treatment group of the individuals; the other leg (the leg without application) will form the control group of individuals.
89209161|NCT00810212|Active Comparator|1|Autograft
89574921|NCT05503615|Experimental|IASTM Treatment Group|Which leg of the individuals will be applied will be determined by the coin toss. After the money shot, the right leg will be applied when the writing comes, and the left leg will be applied when the tour comes. The leg to be applied includes the treatment group of the individuals; the other leg (the leg without application) will form the control group of individuals.
89574922|NCT05503537|Active Comparator|Basic Cardiac Rehabilitation protocol|ankle pumps and leg slides, 2 sets of 10 repetitions of each exercise. Walk for 10 minutes.
89574923|NCT05503537|Experimental|post-isometric relaxation technique with basic cardiac protocol|ankle pumps and leg slides, 2 sets of 10 repetitions of each exercise. Walk for 10 minutes. Post-isometric relaxation technique: contraction time 10 second using 20% of strength with 15 second rest period in between contractions + 4 repetitions.
89574924|NCT05503537|Experimental|static stretching with basic cardiac protocol|Ankle pumps and leg slides, 2 sets of 10 repetitions of each exercise. Walk for 10 minutes. Static stretching: 5 repetitions with 15 sec hold time of stretch.
89574925|NCT04636723||HNC Patients w/ CSS|HNC survivor patients presenting high chronic systemic symptoms
89574926|NCT04636723||Healthy Controls|Non-clinical controls
89574927|NCT04636723||HNC Patients wo/ CSS|Patient Control - HNC survivor patients presenting no/low chronic systemic symptoms
89574928|NCT05503459|Experimental|Bicycle learning|The protocol for this intervention group was a 2-week bicycle training program consisting of 10 sessions (five sessions per week, 60 mins per session) in a hall/gymnasium of each participating school and the Education University of Hong Kong. Each intervention session was conducted by a professional cycling instructor assisted by student helpers. The staff-to-participant ratio was 1:1.
89574929|NCT05503459|Experimental|Stationary cycling group|Participants were asked to ride on a stationary bicycle in the same format as that in the learning to bicycle group.
89574930|NCT05503459|No Intervention|Active control group|Participants were asked to walk with their major caregivers for 20 minutes every day during the study period. After the study, they were taught how to ride a bicycle to recognize their contribution as controls.
89574931|NCT05500027||Pancreatic cancer|All TNM stages of pancreatic cancer, before/after surgery, before/after chemotherapy, before/after bile drainage
89574932|NCT05500027||Low malignant grade of pancreatic neoplasms|IPMN, MCN, PNEN, and SPN
89574933|NCT05500027||Pancreatitis|acute, chronic, and auto-immune pancreatitis
89574934|NCT05500027||Auto-immune diseases|SLE, RA, et al
89574935|NCT05500027||Pancreatic-biliary infections|cholecystitis, cholangitis, et al
89574936|NCT05503381|Experimental|Natural Orifice Specimen Extraction Surgery Group|The patient underwent laparoscopic lower rectal cancer surgery with transanal specimen collection
89574937|NCT05503381|No Intervention|Traditional laparoscopic surgery|The patient underwent conventional laparoscopic lower rectal cancer surgery
89574938|NCT05503147|Experimental|Sativex first (blinded) (3 dose of spray)|Trial day 1: Sativex (3 dose of spray x 2) Trial day 2: Placebo (3 dose of spray x 2) Trial day 3: Voluntary
89574939|NCT05503147|Experimental|Placebo first (blinded) (3 dose of spray)|Trial day 1: Placebo (3 dose of spray x 2) Trial day 2: Sativex (3 dose of spray x 2) Trial day 3: Voluntary
89574940|NCT04619095|Experimental|Psyllium|For participants aged 8-11 and weighing > 24 kgs, the dosage is daily 3 grams for 2 weeks followed by daily 6 grams for 10 weeks. For children aged 12-16 and weighing > 40 kgs, the dosage is daily 5 grams for 2 weeks followed by daily 10 grams for 10 weeks.
89574941|NCT04619095|Placebo Comparator|Placebo|For participants aged 8-11 and weighing > 24 kgs, the dosage is daily 3 grams for 2 weeks followed by daily 6 grams for 10 weeks. For children aged 12-16 and weighing > 40 kgs, the dosage is daily 5 grams for 2 weeks followed by daily 10 grams for 10 weeks.
89574942|NCT05499949||FONS group|Patients with morbid obesity enrolled for bariatric surgery in the Franciscus Gasthuis, Rotterdam, the Netherland
89574943|NCT04490005||Acute brain injury|"Intensive care unit (ICU) admission after ABI, including traumatic brain injury (TBI), aneurysmal subarachnoid haemorrhage (SAH) and intracerebral haemorrhage (ICH)~• Age 18 years old."
89029184|NCT04118062|Other|Luminal B Breast Cancer|Questionnaires and semi-structured individual interviews with patients with Luminal B Breast Cancer
89029185|NCT04118062|Other|Pediatric Cancer|Questionnaires and semi-structured individual interviews with parents of children with cancer.
89574944|NCT05499793|Experimental|Treatment group (Ginger)|"All the participants were given Zingiber Officinale powder (500 mg) capsules twice daily for twelve weeks.~Zingiber Officinale capsules were purchased from Pure Mountain Botanicals, 1712 Pioneer Ave # 1139 Cheyenne Wyoming 82001 (USA)"
89574945|NCT05499793|Placebo Comparator|Control group (Placebo)|All the participants were given starch powder (50 mg) capsules twice daily for twelve weeks.
89574946|NCT05499715|Experimental|ScTIL injection|In the dose escalation of the study, starting with the dose of injection of 5x10^9. If there is no DLT, followed by the second dose of 1.0x10^10 until the third dose of 2.0x10^10.
89574947|NCT04557553|Experimental|Lagenbone|Lagenbone 500mg capsules, 8 capsules by mouth every day for 12 months.
89574948|NCT05502991|Experimental|Cohort 1|Subjects with ctDNA-level-relapse glioblastoma before clinical relapse, determined according to the dynamics of TISF ctDNA.
89574949|NCT05502991|Experimental|Cohort 2|Subjects with clinical-relapse glioblastoma, determined according to the response assessment in neuro-oncology (RANO) criteria for gliomas.
89574950|NCT02333331|Experimental|BYM338 70 mg|BYM338 70 mg intravenous infusion
89574951|NCT02333331|Experimental|BYM338 210 mg|BYM338 210 mg intravenous infusion
89574952|NCT02333331|Experimental|BYM338 700 mg|BYM338 700 mg intravenous infusion
89574953|NCT02333331|Placebo Comparator|Placebo|Placebo intravenous infusion
89574954|NCT02563561|Experimental|1 Dose Apaziquone|Participants were randomized to receive first dose of 4 mg of apaziquone by intravesical administration into the bladder at 60 ± 30 minutes post transurethral resection of bladder tumor (TURBT) on Day 1 via an indwelling 100% Silicone Foley catheter. Followed by second dose of placebo by intravesical administration via an indwelling catheter on Day 15 (±5 days).
89029186|NCT04118062|Other|Expert Patients|Focus groups (or group interviews) and DELPHI consensus method with expert patients
89574955|NCT02563561|Experimental|2 Dose Apaziquone|Participants were randomized to receive first dose of 4 mg of apaziquone by intravesical administration into the bladder at 60 ± 30 minutes post TURBT on Day 1 via an indwelling 100% Silicone Foley catheter. Followed by second dose of 4 mg of apaziquone by intravesical administration via an indwelling catheter on Day 15 (±5 days).
89574956|NCT02563561|Placebo Comparator|Placebo|Participants were randomized to receive first dose of matching placebo by intravesical administration into the bladder at 60 ± 30 minutes post TURBT on Day 1 via an indwelling 100% Silicone Foley catheter. Followed by second dose of matching placebo by intravesical administration via an indwelling catheter on Day 15 (±5 days).
89574957|NCT05499481|Active Comparator|Long Antibiotic Arm|"Without implant material in place:~6 weeks of systemic post-surgical antibiotic therapy~With mateial in place 12 weeks of systemic post-surgical antibiotic therapy"
89574958|NCT05499481|Experimental|Short Antibiotic Arm|"Without implant material in place:~3 weeks of systemic post-surgical antibiotic therapy~With mateial in place 6 weeks of systemic post-surgical antibiotic therapy"
89574959|NCT05564533|Experimental|Heart-Smile Training Intensive Introductory Program (HST-IIP) Group|The HST-IIP group will complete the Heart-Smile Training Intensive Introductory Program during weeks 1 through 4 of the study.
89574960|NCT05564533|No Intervention|Waitlist Control Group|The waitlist arm will not complete any intervention during their time in the study. They will continue their treatment as usual without any change in their therapy session or medication. After their post study visits are complete, they will have the opportunity to participate in Mindfulness-Based Intervention courses through the Cambridge Health Alliance Center for Mindfulness and Compassion.
89574961|NCT05498077|Experimental|10 minute body scan meditation|Participants will be taken through a 10 minute body scan meditation by a physical therapist
89574962|NCT04140955|Experimental|Tapering plan and telephone counselling|Patients receive an individually customized tapering plan at discharge and telephone counselling 5-7 days after discharge.
89574963|NCT04140955|No Intervention|Control group|Patients receive standard care and treatment, i.e. no tapering plan or telephone counselling.
89574964|NCT05564143|Active Comparator|EUS-guided gastroenterostomy (EUS-GE)|All EUS-GE procedures were performed under general anesthesia with endotracheal intubation. A forward-viewing gastroscope or side-viewing duodenoscope is first inserted into the site of the obstruction and a 0.025- or 0.035-inch stiff GW is placed down-stream of the jejunum beyond the obstruction as far as possible. Then, oral enteral tube is placed where the jejunum intended for stent placement under fluoroscopic guidance. After exchanging to EUS endoscope, the target jejunum is visualized by EUS after continuously injection of mixed saline and contrast medium. Finally, the gastrojejunostomy stent is directly advanced from the gastric wall into the target jejunum by AXIOS-EC delivery system.
89574965|NCT05564143|Active Comparator|Laparoscopic gastroenterostomy (LGE)|All LGE were performed in the operation room with patients under general anesthesia. After CO2 insufflation, 4 to 5 trocars were introduced. Next, the Treitz ligament was identified. An anterior, dorsal laterolateral, or side- to-side isoperistaltic gastroenteric anastomosis was constructed. The exact location of the gastroenteric anastomosis, with regard to the Treitz ligament, varied from 30 to 60 cm.
89574966|NCT05564065|Active Comparator|Radiofrequency thermocoagulation of sensory branches of hip joint|There are two main nerves that carry the pain sensation of the hip joint. These nerves are the femoral and obturator nerves. The sensory branches of these nerves going to the hip joint will be detected with a radiofrequency device under fluoroscopy and percutaneous ablation will be performed.
89574967|NCT05564065|Active Comparator|Intraarticular steroid injection of hip joint|Fluoroscopy guided percutaneous intra articular steroid injection of hip joint will be performed
89574968|NCT04047511|Experimental|Virtual Reality|"Twice a week, for a 4 consecutive weeks:~8 sessions of VRTierOne therapy ( 20 minutes each)~8 sessions of general fitness training (40 minutes each)"
89574969|NCT04047511|Active Comparator|Control|"Twice a week, for a 4 consecutive weeks:~8 sessions of group psychoeducation and relaxation (20 minutes each)~8 sessions of general fitness training (40 minutes each)"
89574970|NCT04424875|Experimental|study arm|patients will undergo surgery to remove impacted lower third molar and receive Melatonin (3 mg melatonin into 2 ml hydroxyethyl cellulose gel 2%) in the socket following removal of the impacted third molar
89574971|NCT04424875|Placebo Comparator|controlled arm|patients will undergo surgery to remove impacted lower third molar and patients will receive no melatonin (2 ml of hydroxyethyl cellulose gel 2 %).
89574972|NCT03961555|Experimental|SYN023+Rabies vaccine|"SYN023:~Interventions: are administered by direct injection into the wound or by subcutaneous or intramuscular injection when this is not possible~SYN023 is an equal mass mixture of CTB011 and CTB012, two monoclonal antibodies that exhibit a wide spectrum of activity against various wild-type rabies strains in vitro.~Dosage form: 6mg/2mL, liquid,~Dosage: 0.3 mg/kg of SYN023~Frequency/duration: at Day 1~Rabies vaccine (RabAvert/Rabipur):~Interventions: should be administered in deltoid muscle~Dosage form: >=2.5 IU, freeze-dried vaccine, reconstitute into 1mL before use~Dosage: 1 mL after reconstitution~Frequency/duration: at Day 1, 4, 8, 15, 29"
89574973|NCT03961555|Active Comparator|HRIG+Rabies vaccine|"HRIG:~Interventions: are administered by direct injection into the wound or by subcutaneous or intramuscular injection when this is not possible~Dosage form: 150 IU/mL or 300 IU/mL, liquid,~Dosage: 20 IU/kg of HyperRab (HRIG)~Frequency/duration: at Day 1~Rabies vaccine (RabAvert/Rabipur):~Interventions: should be administered in deltoid muscle~Dosage form: >=2.5 IU, freeze-dried vaccine, reconstitute into 1mL before use~Dosage: 1 mL after reconstitution~Frequency/duration: at Day 1, 4, 8, 15, 29"
89574974|NCT04277845|Experimental|Group 1|"Group 1: 1 cycle will be repeated every 4 weeks~Bortezomib 1.3mg/m2 SC D1, 8, 15 - Dose adjustment for more than 85 : 1.0mg/m2 SC D1, 8, 15~Lenalidomide 25mg/d D1-21~- Dose adjustment for more than 75 : 15mg/d D1-21~Dexamethasone 40mg D1, 8, 15, 22 - Dose adjustment for more than 75 years old: 20mg If it is difficult to maintain bortezomib due to unacceptable toxicity, it can early discontinue from Group 1.~<for patients with old age or frail>~Bortezomib 1.0mg/m2 SC D1, 8, 15~: Dose adjustment for more than 85 : 1.0mg/m2 SC D1,8,15 Lenalidomide 15mg/d D1-21 Dexamethasone 20mg D1, 8, 15, 22"
89029187|NCT04118062|Other|Researchers and Clinicians|Focus groups (or group interviews) and DELPHI consensus method with Researchers and Clinicians
89574975|NCT04277845|Active Comparator|Group 2|"Group 2: 1 cycle will be repeated every 4 weeks~Lenalidomide 25mg/d D1-21~Dose adjustment for more than 75: 15mg Dexamethasone 40mg D1, 8, 15, 22~Dose adjustment for more than 75: 20mg~<for patients with old age or frail>~Lenalidomide 15mg/d D1-21~Dexamethasone 20mg D1, 8, 15, 22"
89574976|NCT03874117|Other|Twice weekly hemodialysis|Participants will undergo hemodialysis twice per week.
89574977|NCT03874117|Other|Thrice weekly hemodialysis|Participants will undergo hemodialysis three times per week.
89574978|NCT05497141|Experimental|tricuspid valve edge-to edge Repair group|Subjects who received Neoblazar® Transcatheter Tricuspid Valve Edge-to Edge Repair System will be included in this arm
89574979|NCT02559505|Experimental|6-12 months Seasonal IIV|Children 6 - 12 months of age vaccinated with seasonal IIV
89574980|NCT02559505|Experimental|3-12 months natural infection|Children 3-12 months of age presenting with natural influenza infection
89574981|NCT02559505|Experimental|13-35 months Seasonal IIV|Children 13-35 months of age vaccinated with seasonal IIV
89574982|NCT02559505|Experimental|13-35 months natural infection|Children 13-35 months of age presenting with natural influenza infection
89574983|NCT02559505|Experimental|3-5 years Seasonal IIV|Children 3-5 years of age vaccinated with seasonal IIV
89574984|NCT02559505|Experimental|3-5 years natural infection|Children 3-5 years of age presenting with natural influenza infection
89574985|NCT02559505|Experimental|6-8 years Seasonal IIV|Children 6-8 years of age vaccinated with seasonal IIV
89574986|NCT02559505|Experimental|6-8 years natural infection|Children 6-8 years of age presenting with natural influenza infection
89574987|NCT04470349||LITOS|Patients who received a LITOS dynamic distraction system after 31.12.2017
89574988|NCT04470349||Ligamentotaxor|Patients who received a Ligamentotaxor dynamic distraction system after 31.12.2017
89574989|NCT05563207|Experimental|control group|Both groups of patients were given routine treatment, and were intervened by the same batch of nursing staff. Among them, patients in the control group were given intervention for TCM health education standard path. During chemotherapy, the patient's condition was closely observed, patiently listened to the patient's chief complaint, answered their questions, and instructed the patient to follow the doctor's instructions to prevent complications such as infection and bleeding.
89574990|NCT05563207|Active Comparator|observation group|The patients in the observation group were given TCM health education standard path intervention. The contents of the health intervention mainly included: ① Graphic and text education;②Language education;③ Psychological education; ④Dietary education; ⑤ Complication education
89574991|NCT05562661||M89PF/standard skin care|use of M89PF on one side of the face standard skin care products on the other side of the face
89574992|NCT05497063|Experimental|Sulfadoxine/Pyrimethamine dispersible tablets, 250 mg sulfadoxine / 12.5 mg pyrimethamine|Two dispersible tablets of Sulfadoxine/Pyrimethamine (250 mg sulfadoxine / 12.5 mg pyrimethamine to be given as single dose once under fasting condition
89574993|NCT05497063|Active Comparator|G-COSPE® tablets, 500 mg sulfadoxine / 25 mg pyrimethamine|One tablet of G-COSPE® tablets, 500 mg sulfadoxine / 25 mg pyrimethamine to be given as single dose once under fasting condition
89574994|NCT05496985|Experimental|Patients in coma|Patients in coma were assessed by the SECONDs and CRS-R for five days.
89574995|NCT05496985|Experimental|Patients in unresponsive wakefulness syndrome|Patients in unresponsive wakefulness syndrome were assessed by the SECONDs and CRS-R for five days.
89574996|NCT05496985|Experimental|Patients in minimally conscious state|Patients in minimally conscious state were assessed by the SECONDs and CRS-R for five days.
89574997|NCT05496985|Experimental|Patients in emerge from the minimally conscious state|Patients in emerge from the minimally conscious state were assessed by the SECONDs and CRS-R for five days.
89029188|NCT04110379|Experimental|Virtual Reality (VR)|Child behavior management will be done using virtual reality glasses distraction (Remax Fantasy Land virtual reality glasses (Schenzen Remax Co.,Ltd))
89574998|NCT04277611|Active Comparator|QLB|The patient is in the prone position, an ultrasound probe is placed in a transverse, oblique, and paramedian orientation approximately lateral to the posterior axillary line. The needle is then inserted in-plane from the medial side of the transducer and advanced laterally to enter the interfascial plane between the Quadratus Lumborum muscle and the kidney. We confirmed that the local anesthetic appeared to press down the kidney in the ultrasound image
89574999|NCT04277611|Active Comparator|ESPB|Using aseptic technique, an ultrasound probe is placed at the T9 vertebral level. After identifying the ribs and sliding towards the midline in a longitudinal parasagittal orientation, the overlying Erector Spinae is identified by visualization of the transition between the rib and transverse apophysis a block needle is inserted in plane with ultrasound beam and is advanced in a cephalo-caudal direction until the tip contacted the transverse process.
89209162|NCT00810212|Experimental|2|Low Dose MPCs
89575000|NCT05561413|Experimental|Mindfulness and exercise|This group will undertake exercise and mindfulness for 8 weeks. The home based walking and strengthening intervention is individually tailored for each participant. All exercise demonstrations, information, reporting of activity and setting of goals will take place in the app that participants will download. Additionally this group will receive a hard copy of the goal setting diary. All mindfulness information and practices are available in the app. New content will be released each week as the participants progress through the program. Participants will be phoned weekly over the 8 weeks to monitor progress.
89575001|NCT05561413|Active Comparator|Mindfulness|This group will undertake mindfulness only over 8 weeks. The mindfulness program is based on mindfulness-based stress reduction (MBSR). All information, practices and logging of the mindfulness practice will be done via the app that participants will download. Participants will be phoned weekly over the 8 weeks to monitor progress. New content will be released each week as participants progress through the program.
89575002|NCT05560945|Active Comparator|0.32% Sodium Fluoride Dentifrice Toothpaste|Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
89575003|NCT05560945|Experimental|1.5% Arginine Dentifrice Toothpaste|Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
89575004|NCT05560945|Experimental|8.0% Arginine Dentifrice Toothpaste|Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
89575005|NCT05559463|Experimental|ITIS diet|anti-inflammatory (ITIS) diet for 28 days
89575006|NCT05559385|Experimental|Robotic Rehabilitation Group|"The standardized ITR program was applied to both groups for 60 minutes a day, five days a week, for six weeks. The ITR program included exercises of abdominal strengthening, controlled pelvic movements, bridging, trunk lateral flexion and rotation, reaching forward, and push-ups with a Swiss Ball. This group received a robotic rehabilitation program for the upper extremity with a Houston Bionics ExoRehab X brand/model device. This device has no motor force of repulsion or attraction. Patients initiate and maintain their movements during the exercise. The device supports the patient's active movement and allows extensive movement repetition.~Before starting robotic rehabilitation, the patient was seated upright on the platform. The games were projected onto a 43-inch television screen. The exercise program was planned to include upper extremity movements in all directions."
89575007|NCT05559385|Active Comparator|Conventional Rehabilitation Group|"The standardized ITR program was applied to both groups for 60 minutes a day, five days a week, for six weeks. During this period, lower extremity rehabilitation was added if needed in addition to trunk rehabilitation. Exercises for the lower extremities were applied according to the patient's individual needs. The ITR program included exercises of abdominal strengthening, controlled pelvic movements, bridging, trunk lateral flexion and rotation, reaching forward and sideways, and push-ups with a Swiss Ball.~CR applied after the ITR program consisted of an individualized rehabilitation program for the upper extremities. These rehabilitation programs generally included activities for functional purposes (dressing, object manipulation, reaching, cup holding, range of motion, strengthening, weight-bearing, etc.). The treatment program was applied five days a week for six weeks, with the session duration limited to 60 minutes."
89575008|NCT04047277|Experimental|Treatment Right-Away|Cognitive Behavioral Therapy using exposure, relaxztion, and rescripting - Child utilizes behavioral and cognitive therapy techniques of exposure therapy and cognitive restructuring.
89575009|NCT04047277|No Intervention|Waitlist Control|Waitlist control group will complete pre and post assessments at beginning and end of wait period.
89575010|NCT04224961|Experimental|Minimal to No Respiratory Weakness|MIP ≥ 70% predicted Complete home-based RMT program and participate in weekly web-based RMT therapy sessions.
89575011|NCT04224961|Experimental|Mild to Moderate Inspiratory Weakness|MIP 40-70% predicted Complete home-based RMT program and participate in weekly web-based RMT therapy sessions.
89575012|NCT04424563||Group A|Patients of group A include 40 patients, received aminocaproic acid at dose of 4 gram slowly intravenous infusion over 1 hour and continues slowly intravenous infusion 1 gram/ hour for 8 hours.
89575013|NCT04424563||Group B|While patients of group B include 40 patients, received aFVII according to the following protocol, First dose 200 microgram/kg. If patient still oozing, vital data not stable and/or could not achieve and keep the target Hb (>10 gm%) another 2 doses of aFVII received each dose 100microgram /kg 1 hour and 3 hours apart from the initial dose if needed.
89575014|NCT04038151|Experimental|Condition A: Hybrid Leg|Subject will be trained on use of the experimental device, the Hybrid Leg.
89575015|NCT04038151|Other|Condition B: Passive Leg|Subject will use their currently prescribed home passive prosthesis
88971230|NCT00135577|Experimental|Alvimopan 1 mg Twice Daily (BID)|"Participants who did not have an interruption in blinded investigational product between the original study and the extension study received Alvimopan 1 mg once in the morning and once in the evening.~Participants who had an interruption in blinded investigational product between studies received 0.5 mg of alvimopan once in the morning and once in the evening for 3 days, then 1 mg of alvimopan once in the morning and once in the evening."
89209163|NCT00810212|Experimental|3|Medium Dose MPCs
89209164|NCT00810212|Experimental|4|High Dose MPCs
89209165|NCT00799136|Other|One|Rituxan with EPOCH and Antiretrovirals
89209166|NCT02592395|Experimental|Electrochemotherapy with FOLFIRINOX|During the first cycle of chemotherapy, patients will receive electroporation of the primary pancreatic tumor prior to administration of chemotherapy with FOLFIRINOX . The schedule of administration of FOLFIRINOX will be administered as per standard of care.
89209167|NCT00799214|Placebo Comparator|1|1 gram emollient cream to be inserted intravaginally qhs (once before bed) for 10 days or less if intolerable side effects occur.
89575016|NCT05496361|Experimental|Tianyi Revascularization Device|
89575017|NCT05496361|Active Comparator|Solitaire FR Revascularization Device|
89575018|NCT05496127|Experimental|Sensorimotor Exercise Group|Sensorimotor exercise group; oculomotor exercise to provide information from the visual system, laser target exercise to provide information from the proprioception system, and postural stability exercise to provide information from the vestibular system. Within the scope of oculomotor exercise, gaze stability exercise and head-body coordination exercise will be given to the participants. Laser target exercise will be given with the laser target fixed on the participant's head and 90 cm away from the target. Postural stability exercise will be given in the form of tandem exercise and standing on one leg.
89209168|NCT00799214|Experimental|2|Boric acid = 600 mg boric acid compounded in emollient cream (1 gram total) to be inserted intravaginally qhs (once before bed) for 10 days or less if intolerable side effects occur.
89575019|NCT05496127|Experimental|Yoga Exercise Group|Yoga group will be given yoga exercises including 14 poses. These exercises are: bridge pose, corpse pose, bharadvaja's twist, downward facing dog, downward facing hero, extended side angle, extended triangle, mountain pose, prosperous pose, reclining big toe, standing half forward bend, thunderbolt pose, upward hand pose, warrior pose II.
89575020|NCT05496049|Experimental|Triburter|The intervention group will receive a triburter device for training, the patients will have to repeat 50 ventilations (start with 20 repetitions in the first week, 30 in the second, 40 in the four week, and 50 in the last week) five days per day.
89575021|NCT05496049|Active Comparator|Incentive spirometry|For the control group (incentive spirometry) they will repeat 10 ventilations per 5 five times a day. Both interventions will be performed for 4 weeks.
89575022|NCT05495893|Experimental|Cyclophosphamide|Cyclophosphamide for injection, 750mg/m2 each time, 1g at most, once a month for 6 consecutive months. Steroids : intravenous methylprednisolone, 15~30mg/kg · day, maximum 1000mg/day, 3 consecutive days a week for 2 weeks; during the interval of methylprednisolone pulse therapy and after:prednisone tablets 2mg/kg · day with a maximum dose 60mg / day
89575023|NCT05495893|Experimental|Mycophenolate mofetil|Mycophenolate mofetil, tablets, 30-40mg/ (kg · day), BID, the maximum amount is no more than 2g/d. Steroids : intravenous methylprednisolone, 15~30mg/kg · day, maximum 1000mg/day, 3 consecutive days a week for 2 weeks; during the interval of methylprednisolone pulse therapy and after:prednisone tablets 2mg/kg · day with a maximum dose 60mg / day
89575024|NCT03542461|Experimental|A_Nivolumab|Nivolumab 240 mg IV every 2 weeks until disease progression, unacceptable toxicity, patient refusal or Investigator's decision
89575025|NCT03542461|Other|B_Best Supportive Care|Best Supportive Care until disease progression followed by Nivolumab at a dose of 240 mg IV until further disease progression, unacceptable toxicity, patient refusal or Investigator's decision.
89575026|NCT04201639|Experimental|Refit|Refit and dispense patient with Verofilcon A contact lenses and evaluate lens performance.
89575027|NCT04201015|No Intervention|Standard rate-response settings|Patients allocated to standard rate-response settings.
89575028|NCT04201015|Active Comparator|Rate-response settings off|Patients allocated to deactivated rate-response settings.
89575029|NCT04201015|Experimental|Optimized rate-response settings|Patients allocated to optimised rate-response settings.
89575030|NCT04191967|Experimental|Thermocoagulation|Thermal ablation of cervix for treatment of CIN2/3 among HIV-positive participants will be performed by a trained, non-physician clinician. Thermocoagulation will last approximately 20 seconds and will be performed using the Liger Thermocoagulator device
89575031|NCT05491291|Other|Patients with chronic wound of the lower limbs|Passing of the scale when the patient will come at the hospital for his routine health care visit in M@diCICAT center
89575032|NCT02556307||Peginterferon alfa-2a + Ribavirin|
89575033|NCT02861521|Experimental|Corrective shoe lift|Participants will be given an external shoe lift to correct post-operative leg length discrepancy (LLD).
89575034|NCT02861521|Sham Comparator|Sham shoe intervention|Participants will be given a sham shoe intervention that does not correct post-operative leg length discrepancy.
89575035|NCT05495347||Registry of patients|
89575036|NCT05491135|Experimental|HMB002|All patients will receive HMB002 infusion into the peritoneal cavity.
89575037|NCT02232997|Active Comparator|Standard Hydration|Standard long-term hydration, i.e. hydrated with normal saline 12 hours before and 12 hours after coronary intervention at a rate of 1 ml/kg/h
89575038|NCT02232997|Active Comparator|Simplified Hydration|Rapid short-term hydration, i.e. hydrated with normal saline from 1 hour before to 4 hours after coronary intervention at a rate of 3 ml/kg/h
89575039|NCT05491057||Neratinib extended ajuvant treatmeng for 1 year|
89575040|NCT05490901||Patients with Unexplained Dyspnea|Patients with dyspnea on exertion
89575041|NCT05495191||Grouped as the favorable outcome|<3 mRS of discharge or 7th day in the patients with the lenticulostriate artery infarction
89575042|NCT05495191||Grouped as the unfavorable outcome|≥3 mRS of discharge or 7th day in the patients with the lenticulostriate artery infarction
89575043|NCT05495113|Sham Comparator|Sham Stimulation|Sham Stimulation
88971231|NCT00135577|Placebo Comparator|Placebo|Placebo was administered orally once in the morning and once in evening.
88971232|NCT03151356||Patients|Patients addressed for prostate biopsies because of clinical and/or biological suspicion of prostate cancer.
88971233|NCT00135733|Active Comparator|A|Amevive
88971234|NCT00135733|Placebo Comparator|B|Placebo
88971235|NCT03151317||With therapeutic education|Patients assigned to this group will have participated in a therapeutic education program.
88971236|NCT03151317||Without therapeutic education (control)|Patients assigned to this (control) group have not had any kind of therapeutic education.
88971237|NCT00135811|Active Comparator|1|Cyclosporin
88971238|NCT00135811|Active Comparator|2|MMF and Dexamethasone
88971239|NCT04059380||Patients with Hypoparathyroidism|Patients with Post-Surgical or Autoimmune Chronic Hypoparathyroidism requiring daily calcium and calcitriol therapy
88971240|NCT04059380||Healthy Controls|Age-, sex- and BMI- matched patients referring to our center for diagnostic procedures not affected by hypoparathyroidism
88971241|NCT00136201|Experimental|1|armDesc1
88971242|NCT03151239|Placebo Comparator|Placebo|
88971243|NCT03151239|Experimental|NMN supplementation|
88971244|NCT00136279|Experimental|School plus parent|Adolescents receive school-based curriculum (either Project TNT or Making a Difference) and mothers receive the Linking Lives curriculum
88971245|NCT00136279|Active Comparator|School-only|Adolescents receive school-based curriculum and parents received a control curriculum on helping their child choose a high school
88971246|NCT00136279|Experimental|Parent-Only|In the sex risk reduction portion of the study only, a second experimental group consisted of parents receiving the Linking Lives intervention and adolescents receiving no in-school intervention
88971247|NCT00136474|Active Comparator|Group 1|Amifostine plus radiation therapy
88971248|NCT00136474|Active Comparator|Group 2|Radiation therapy alone
89575044|NCT05495113|Experimental|Real Stimulation (Active)|transcranial Direct Current Stimulation (tDCS) application 5 ~7 days a week for 26 weeks
89575045|NCT04364737|Active Comparator|Convalescent donor plasma|
89575046|NCT04364737|Placebo Comparator|Lactated ringer's solution or sterile saline solution|
89575047|NCT02559115|Experimental|PET/CT imaging with 68Ga-RM2|The intervention is the administration of a single dose of 150-200 MBq 68Ga-RM2 (mass <= 30 μg) for imaging purposes. This will be followed by a 30-40 min PET/CT study after a waiting period of 60 min (+/- 10 min). Prior clinical experience suggests that imaging can be performed within 1 hour post injection (27, 28). MR imaging and prostatectomy will be performed as standard of care at MSKCC.
89575048|NCT05494957|Experimental|New treatment regimen including bedaquiline|Treatment regimens that include bedaquiline, linezolid, clofazimine, and other optional drugs.
89575049|NCT05494879|Experimental|microkinesitherapy treatment|"The study group received a single therapy session of microkinesitherapy. The entire procedure lasted about 10 minutes. Microkinesitherapy is based on locating information in the patient's body about previous traumas/traumas that have been experienced physically and emotionally, which the body could not eliminate. This information is interpreted on the body by sensitive tensions and called body scars and does not necessarily remain in the brain."
89575050|NCT05490823|Experimental|Eligible patients for app-based anemia screening|Device: A smartphone app for anemia screening This app can achieve automatic detection of anemia based on patient-sourced images of fingernails and conjunctivae.
89575051|NCT04424485|Active Comparator|Thyroid carcinoma patients (biopsy-proven)-Total thyroidectomy|"Control group-Total thyroidectomy (TT) with central lymph node dissection (CLND) procedure for patients with papillary thyroid carcinoma (PTC)~Standard TT+CLND procedure only"
89575052|NCT04424485|Experimental|Thyroid carcinoma patients (biopsy-proven)-Sentinel lymph node|"Experimental group- Sentinel lymph node dissection (SLND) after intratumoral indocyanine green (ICG) injection and visualization of all 4 parathyroid glands with infra-red (NIR) fluorescence after intravenous (iv) ICG injection, during total thyroidectomy and central lymph node dissection (CLND).~TT+CLND with NIR fluorescence ICG"
89575053|NCT05490745|Experimental|Immediate Intervention Group (IIG)|Participants receive initially one session for psychological assessment. At the end of the session, the second session is scheduled for the following week, where feedback about the assessment will be provided. If in the second session participants agree to proceed with the psychological intervention, then the remaining 4-6 sessions of Skills4Parenting+ are conducted.
89575054|NCT05490745|Other|Delayed Intervention Group (DIG)|Waiting-list Comparator (nocebo): Participants initially receive one session for psychological assessment. At the end of the session, participants are informed that they will be contacted to schedule the second session, where feedback about the assessment will be provided. Participants are contacted during the same week, to schedule the second session 8 weeks after the first session. If in the second session participants agree to proceed with the psychological intervention, then the remaining 4-6 sessions of Skills4Parenting+ are conducted.
89575055|NCT05494645|Active Comparator|Peripheral Nerve Block Without Exparel|Lower extremity peripheral nerve block without Exparel: 0.25-0.5% bupivacaine
89575056|NCT05494645|Experimental|Peripheral Nerve Block with Exparel|Liposomal bupivicaine administered for peripheral nerve block: mixed with 0.25-0.5% bupivacaine
89575057|NCT05494645|Experimental|Local Infiltration of Exparel|Liposomal bupivicaine administered by surgeon intra-operatively in field block, mix with 0.25% bupivacaine
89575058|NCT05494567|Active Comparator|Tadalafil / solifenacin combination therapy|Patients will be treated by combination of Tadalafil 5 mg + solifenacin 10 mg once daily for 12 weeks
89575059|NCT05494567|Active Comparator|Tamsulosin / solifenacin combination therapy|Patients will be treated by combination of Tamsulosin 0.4 mg + solifenacin 10 mg once daily for 12 weeks
88971249|NCT00136591|Active Comparator|A|Arm A: a 21-day cycle of 1.5 mg/m2 Velcade™ twice weekly for 2 weeks. Days 1, 4, 8, and 11 of a 21-day cycle. Subjects in this treatment arm will receive a total of 8 cycles of treatment,
88971250|NCT00136591|Experimental|B|
88971251|NCT03151161|Experimental|Experimental Group|"Chemotherapy regime: Pemetrexed (500mg/m2) + Carboplatin (AUC=5), 1 cycle every 3 weeks, maximum 4 cycles;~Intermittent regime: Icotinib 125mg, three times a day, d2-15 in each cycle; maintenance regime: icotinib 125mg, three times a day, since the last cycle until disease progression."
88971252|NCT03151161|Active Comparator|Control Group|Single drug: Icotinib 125mg, three times a day, continous until disease progression
89575060|NCT04331587||Bronchoscopy|The bronchoscopy procedure and use of both the thin and ultrathin bronchoscopes are considered standard of care and will be performed under moderate sedation in an outpatient bronchoscopy suite as part of each patient's clinical care.
89575061|NCT00609115|Experimental|Test-Phase 1|The Test Group receives 18 half-hour AMES (Assisted Movement with Enhanced Sensation) treatments with the AMES device (Test) in which the hand or wrist is moved, and the subject assists the motion while vibration (60 pulses/sec) is applied to the lengthening muscle. Sessions to be scheduled preferably 2 to 3 times per week, with the 18 sessions to be completed within the 6 month anniversary date of the subject's stroke.
89575062|NCT00609115|Sham Comparator|Control-Phase 1|Eighteen treatment sessions for each qualifying subject limb using the AMES device (sham) programed to provide placebo therapy. Each treatment session consisting of 30 minutes of sham therapy. Sessions to be scheduled preferably 2 to 3 times per week, with the 18 sessions to be completed within the 6 month anniversary date of the subject's stroke.
88971253|NCT02964520|Experimental|A/T Neurofeedback training|10 sessions of uptraining alpha (8-11 Hz) and theta (5-7.5 Hz) frequency bands, inhibiting beta (15-30 Hz) and delta (2-4 Hz)
88971254|NCT02964520|Sham Comparator|Sham neurofeedback training|"5 sessions of (sessions 1,3,5,7,9) up-training lobeta (13-16 Hz) and hibeta (16-22 Hz), inhibiting alpha (8-11 Hz), theta (5-7.5 Hz) and hibeta (23-30 Hz).~5 sessions of (sessions 2,4,6,8,10) down-training beta (13-16 Hz) and hibeta (16-22 Hz), inhibiting alpha (8-11 Hz), theta (5-7.5 Hz) and hibeta (23-30 Hz)"
88971255|NCT00136708|Experimental|NRP Training (Intervention)|Training in AAP neonatal resuscitation training program
88971256|NCT00136708|Other|Control|
88971257|NCT03991130|Experimental|High Dose IL-2 and Nivolumab|
88971258|NCT00136747|Experimental|BUPROPION|Participants receive 20 mg bid of memantine, placebo, or bupropion in a double-blind crossover design and are maintained on active or placebo medication for 5 or 10 days before the inpatient testing
89575063|NCT00609115|Active Comparator|Crossover-Phase 2|Original Control Group receives 18 half-hour crossover treatments with the AMES device (Crossover) in which the hand or wrist is moved, and the subject assists the motion while vibration (60 pulses/sec) is applied to the lengthening muscle. Sessions to be scheduled preferably 2 to 3 times per week with each session one-half hour in length.
89575064|NCT05494333||2|NO INTERVENTION
89575065|NCT04265209|Other|SPECT and PET|[123I]-FP-CIT SPECT imaging procedure first, then [18F] LBT-999 PET Imaging procedure
89575066|NCT04265209|Other|PET and SPECT|[18F] LBT-999 PET imaging procedure first, then [123I]-FP-CIT SPECT imaging procedure
89575067|NCT04077619|Experimental|Modern pain neuroscience approach|Behavioral: Modern pain neuroscience approach
89575068|NCT04077619|Active Comparator|Usual care evidence-based physiotherapy|Behavioral: Usual care evidence-based physiotherapy
89575069|NCT04251169|Experimental|Pembrolizumab + Paclitaxel|Pembrolizumab 200 mg every 3 weeks (on D1 of each 21-day cycle, beginning in Cycle 1) in combination with paclitaxel 80 mg/m2 administered at days 1, 8, 15 of each 21-day cycle beginning at cycle 2.
89575070|NCT04073329||Plain x ray|measurement the accuracy of post operative reduction by Matta method
89575071|NCT04073329||CT|measure the accuracy of reduction by Verbeek method
89575072|NCT04279951|Experimental|Omega 3|"Intake of 1 gram omega-3 (capsules) per day for 20 weeks~+ high-load and low-load resistance exercise two times per week for 10 weeks, preceded by 3 weeks of familiarization to training (high-load training)"
89575073|NCT04279951|Placebo Comparator|Placebo|"Intake of 1 gram sunflower oleic oil (capsules) per day for 20 weeks~+ high-load and low-load resistance exercise two times per week for 10 weeks, preceded by 3 weeks of familiarization to training (high-load training)"
89209169|NCT00799214|Active Comparator|3|Metronidazole = 10 % intravaginal cream (Sanofi-Aventis Canada Inc Product DIN 01926861) (for a total of 37.5 mg metronidazole) inserted intravaginally qhs (once before bed) for 10 days or less if intolerable side effects occur.
89575074|NCT04279951|No Intervention|Control|No intervention
89575075|NCT05494099||Group A (1st 25 patients)|The middle meatal mega-antrostomy approach.
89575076|NCT05494099||Group B (2nd 25 patients)|The endoscopic modified medial maxillectomy approach.
89209170|NCT00733421|Experimental|1|"Active study drug:~Etoricoxib 90 mg once daily"
89575077|NCT05494099||Group C (3rd 25 patients)|The endoscopic prelacrimal recess approach.
89575078|NCT04165837|Experimental|Active|
89575079|NCT04165837|Placebo Comparator|Placebo|
89575080|NCT04163341|Experimental|CETA protocol|
89575081|NCT04163341|No Intervention|Enhanced Usual Care|
89575082|NCT04279561|Experimental|Diagnostic (68GA-PSMA-11 PET/CT)|Patients receive 68Ga-PSMA-11 IV. After 50-100 minutes, patients undergo PET/CT over 20-50 minutes. Patients undergo 68Ga-PSMA-11 PET/CT at baseline, at 1 week and 3 months after initiation of ARSI, and at time of biochemical progression (within 1 year if applicable).
88971259|NCT00136747|Experimental|placebo|Participants receive 20 mg bid of memantine, placebo, or bupropion in a double-blind crossover design and are maintained on active or placebo medication for 5 or 10 days before the inpatient testing
88971260|NCT00136747|Experimental|memantine|Participants receive 20 mg bid of memantine, placebo, or bupropion in a double-blind crossover design and are maintained on active or placebo medication for 5 or 10 days before the inpatient testing
88971261|NCT00136786|Placebo Comparator|Intervention 1|"Each participant receives three consecutive interventions.~Placebo~Bupropion~Memantine"
88971262|NCT00136786|Placebo Comparator|Intervention 2|"Bupropion~Memantine~Placebo"
88971263|NCT00136786|Placebo Comparator|Intervention 3|"Memantine~Placebo~Bupropion"
88971264|NCT00136825|Placebo Comparator|2|Identical appearing placebo pill containing lactose powder, packaged to have similar odor as N-Acetylcysteine in capsule form
88971265|NCT00136825|Experimental|1|N-Acetylcysteine
88971266|NCT00393198|Experimental|Arm 1|
88971267|NCT00393198|Placebo Comparator|Arm 2|
88971268|NCT00393198|Active Comparator|Arm 3|
88971269|NCT00136864|Experimental|1|PET Imaging
88971270|NCT00136864|No Intervention|2|Standard Imaging
88971271|NCT03947606|Experimental|Basic social support + communication + Ottawa guide|3 in-person/telephone weekly sessions on providing decision social support, tips for good communication, and decision support tools
88971272|NCT03947606|Experimental|Basic social support + communication|2 in-person/telephone weekly sessions on providing decision social support and tips for good communication
88971273|NCT03947606|Experimental|Basic social support + Ottawa guide|2 in-person/telephone weekly sessions on providing decision social support and decision support tools
88971274|NCT03947606|Experimental|Basic social support only|1 in-person/telephone weekly session on providing decision social support
88971275|NCT03947606|Experimental|Advanced social support + communication + Ottawa guide|5 in-person/telephone weekly sessions on providing decision social support, tips for good communication, and decision support tools
88971276|NCT03947606|Experimental|Advanced social support + communication|4 in-person/telephone weekly sessions on providing decision social support and tips for good communication
89575083|NCT01662895|Active Comparator|Deferoxamine|Deferoxamine mesylate supplied in vials containing 2 gm of sterile, lyophilized, powdered deferoxamine mesylate. The drug will be reconstituted for injection, by dissolving in 20 ml of sterile water. The reconstituted drug will be further diluted in normal saline to achieve a final concentration of 7.5 mg per ml.
89575084|NCT01662895|Placebo Comparator|Normal Saline|0.9% sodium chloride
89575085|NCT05499169||16 patients with CAA-related ICH|16 patient above the age of 55 that fit the inclusion criteria. CAA-related ICH is defined as an ICH that meets the criteria for definite or probable CAA according to the Modified Boston Criteria.
89575086|NCT05499169||16 patients with HA-related ICH|16 patient above the age of 55 that fit the inclusion criteria. HA-related ICH is defined as ICH located in the basal ganglia, thalamus, or the deep white matter and the presence of hypertension defined as: on treatment for hypertension, or known with high blood pressure (two measurements systolic blood pressure (SBP) >140 or diastolic blood pressure (DBP) >90 mmHg) but not treated for hypertension.
89575087|NCT05494021|Experimental|Whole-process management strategy|"High-risk individuls are provided with whole-process management strategy, including lung cancer education, decision-making, assisting in making and attending LCS LDCT appointments, arranging follow-up when needed, tobacco cessation support for smokers, treatment assistance if diagnosed as lung cancer.~LDCT was performed at baseline + 2 biennial repeated LDCT rounds."
89575088|NCT05494021|Active Comparator|Rountine screening strategy|LDCT was performed at baseline + 2 biennial repeated LDCT rounds.
89575089|NCT05493943|Active Comparator|PEMF low power|PEMF therapy using a device with low pulse intensity.
89575090|NCT05493943|Active Comparator|PEMF medium power|PEMF therapy using a medium pulse intensity.
89575091|NCT05493943|Sham Comparator|PEMF Sham control|Control arm using a sham PEMF device.
89575092|NCT05493865|Experimental|The Parent-Child Single-Session-intervention of Mindset Intelligence, Failure and Emotion (PC-SMILE)|The PC-SMILE integrates the growth mindsets of intelligence, failure and negative emotions. The interventions for both students and parents consist of five components: (a) an introduction to brain functions regarding the potential of neuroplasticity and the possibility of changes in intelligence and emotions; (b) stories and testimonials from high-school-aged youths who describe their beliefs-in-change; (c) short videos with stories of improving intelligence and emotions and of failure-is-enhancing; (d) common questions and misconceptions about growth mindset; and (e) self-persuasion writing exercises in which the participants write notes to young students/others about the growth mindsets. The interventions for parents and students are different in terms of narrative and content. A total of 10 weekly booster messages with core intervention content will be sent to the intervention group between the two-week post-test and the three-month follow-up survey.
89575093|NCT05493865|No Intervention|Waitlist control group|The waitlist control group will continue with normal education activities and do the pre- and post- intervention surveys at the same timeframe as the intervention group. Participants in waitlist group will be invited to complete the PC-SMILE after the three-month post-intervention survey.
89575094|NCT04318171||Carotid arteries.|No intervention is required. Routine Doppler assessment + 3D scan immediately afterwards.
89575095|NCT04318171||Peripheral arteries.|No intervention is required. Routine Doppler assessment + 3D scan immediately afterwards.
89575096|NCT04318171||AVF.|No intervention is required. Routine Doppler assessment + 3D scan immediately afterwards.
89575097|NCT04318171||Vein mapping|No intervention is required. Routine Doppler assessment + 3D scan immediately afterwards.
89575098|NCT05489809|Experimental|Endotracheal extubation with suctioning|Suctioning is applied to the endotracheal tube while removing it.
89575099|NCT05489809|Experimental|Endotracheal extubation with positive pressure|Positive pressure is applied to the endotracheal tube while removing it.
89575100|NCT05493631|Active Comparator|Cohort 1 (2.0 mg/kg, once weekly)|"Anti-tissue factor pathway inhibitor (TFPI) recombinant antibody~Each vial contains 1mL of study drug~The subjects will be treated with 2.0 mg/kg once weekly in cohort 1."
89575101|NCT05493631|Active Comparator|Cohort 2 (A mg/kg, once weekly)|"Anti-tissue factor pathway inhibitor (TFPI) recombinant antibody~Each vial contains 1mL of study drug~The subjects will be treated with A mg/kg once weekly in cohort 2.~The Dose A mg/kg will be determined based on the safety, PK, and PD data obtained from previous dose level (cohort 1)."
89575102|NCT05493631|Active Comparator|Cohort 3 (B mg/kg, once weekly)|"Anti-tissue factor pathway inhibitor (TFPI) recombinant antibody~Each vial contains 1mL of study drug~The subjects will be treated with B mg/kg once weekly in cohort 3.~The Dose B mg/kg will be determined based on the safety, PK, and PD data obtained from previous dose level (cohort 2)."
89575103|NCT05498857|Active Comparator|Ephedrine group|Patients will receive intramuscular ephedrine 0,5 mg/kg before spinal anesthesia
88971277|NCT03947606|Experimental|Advanced social support + Ottawa guide|4 in-person/telephone weekly sessions on providing decision social support and decision support tools
89575104|NCT05498857|Placebo Comparator|Placebo group|Patients will receive intramuscular saline before spinal anesthesia
89575105|NCT04424329|Experimental|Nutrition intervention|Ingestion of fibers and probiotics daily for 22 days
89575106|NCT04424329|No Intervention|No intervention|No intervention
89575107|NCT05498545|Experimental|LUCAR-B68 cells product|Each subject will receive LUCAR-B68 cells
89575108|NCT05489419|Experimental|Prehabilitation|Patients undergo prehabilitation during 3-4 weeks before undergoing pancreatic surgery.
89575109|NCT05493319|Experimental|Hypopresive, strength and resistance exercises|Participants will perform 3 types of hypopresive exercises in the end of strength and resistance exercises intervention.
89575110|NCT05493319|Active Comparator|Strength and resistance exercises|Participants will perform strength and resistance exercises intervention.
89575111|NCT05498467|Active Comparator|Anakinra|
89575112|NCT05498467|Placebo Comparator|Placebo|
89575113|NCT05498311|Experimental|Intraoperative Radiotherapy (IORT)|Patients with diagnosis of invasive breast cancer (IBC) will be treated with conservative surgery (with or without oncoplastic surgery) and 20 Gy IORT followed by hypofractionated radiotherapy.
89575114|NCT05489263||AKI|AKI is defined by KDIGO criterion based on peri-operative serum creatinine variation.
88971278|NCT03947606|Experimental|Advanced social support only|3 in-person/telephone weekly sessions on providing decision social support
88971279|NCT03151122|Experimental|continuous care group|continuous care group (CCG): This is the experimental group where continuous care supported would be offered by the nurse coordinated integrative health care team. which is, parents in this group receive support during infant hospitalization. The support covers both hospitalization phase and after-discharge phase. In-hospital support include educational support and promoting mother-infant attachment. Nurses will be responsible for home visits after infant discharge.
88971280|NCT03151122|Active Comparator|routine care group|Routine Care Group (RCG): This is the comparison group of preterm infants. the routine care interventions generally include telephone reminding about follow-up care of the infants and hotline for parents to call when needed.
88971281|NCT03940157|Experimental|Oh Happy Day Class - Still I Rise|The Oh Happy Day Class-Still I Rise (OHDC-SIR) is a one-time, 4-hour class focused on awareness of depression and healthy self-management strategies ( a workbook is created with the class content). The class is offered in non clinical setting, but will be delivered in a classroom setting at the University. The class will be taught by the PI Dr. Ward, who is an associate professor and licensed psychologist, and Dr. Ward's research program manager, Lucretia Sullivan-Wade.
89575115|NCT05489263||No-AKI|No-AKI is defined by KDIGO criterion based on peri-operative serum creatinine variation.
89575116|NCT05486221||Cryptogenic stroke patients|Patients with an acute ischemic stroke of cryptogenic origin with a previous negative work-up that includes: blood analysis, brain CT / MRI, angio-TC / angio-MRI, brain vessel ultrasound, ECG, 24h ECG-holter, echocardiography).
89575117|NCT05492929|Experimental|The deep breathing group|The deep breathing group was administered the nightly state and trait anxiety scale and SAAQ before the operation, and then they were informed about the deep breathing exercise. Between the 1st and 6th hours of the postoperative period, deep breathing exercise was performed, with 10 breaths per hour. At the end of the 6th hour, the state anxiety scale and SSWS were administered.
89575118|NCT05492929|Experimental|4-7-8 breathing technique Group|The nightly state and trait anxiety scale and the PSSQ were applied to the 4-7-8 breathing group before the operation, and then they were given information about the 4-7-8 breathing technique. Between the 1st and 6th hours postoperatively, the 4-7-8 breathing technique was applied for 1 set (4 breaths) every hour. At the end of the 6th hour, the state anxiety scale and SSWS were administered.
89575119|NCT05492929|No Intervention|control group|In the control group, the nightly state and trait anxiety scale and PSSQ were applied before the operation. At the end of the 6th hour postoperatively, without any application, the state anxiety scale and PSSQ were applied.
88971282|NCT00137176|Experimental|Rebif + Lipitor|
88971283|NCT00137215|Active Comparator|A|
88971284|NCT00137254|Active Comparator|A|
88971285|NCT03151044|Experimental|EPI-90|"Participants in this arm shall be given high-dose Epirubicin Combined with CVP ± Rituximab for six 21-day cycles:~High-dose Epirubicin 90mg/m2, i.v., Day 1; Cyclophosphamide 750mg/m2, i.v., Day 1; Vincristine 1.4mg/m2, i.v., Day 1; Prednisolone 100mg/m2, p.o., Day 1-5;~Plus/not plus:~Rituximab 375mg/m2, i.v., Day 0"
89575120|NCT02557399|Experimental|Duac® fixed dose combination gel|Subjects will use Duac® fixed dose combination gel (clindamycin phosphate 1.2% and benzoyl peroxide 3%) with quantity sufficient to cover entire face (including the forehead, nose, cheeks and chin) once daily in the evening (at bedtime) for 12 weeks.
89575121|NCT02557399|Active Comparator|Combination therapy: ADA 0.1% gel + CLDM 1% gel|Subjects will use combination therapy of ADA 0.1% gel with quantity sufficient to cover entire face (including the forehead, nose, cheeks and chin) once daily in the evening (at bedtime) and subjects will also apply CLDM 1% gel twice daily, once in the morning and once in the evening (at bedtime) for 12 weeks. The CLDM 1% gel should apply subsequent to the application of ADA 0.1% gel in the evening. The CLDM 1% gel should be applied to ILs only.
89575122|NCT05485909|Experimental|Regorafenib and Toripalimab Combined with RFA|
89575123|NCT04139395|Experimental|Diagnostic 68Ga-Citrate PET/MRI Imaging|Participants will receive separate scans, first a SPECT scan following administration of the 67Ga Citrate tracer (standard of care), then a PET/MRI scan following administration of the 68Ga-Citrate tracer (investigational); some participants will also receive IV gadolinium-based contrast injection. Scans will be performed 45-60 minutes following injection of the tracer.
89575124|NCT02555371|Experimental|Arm Mepolizumab 100 mg|There will be 4 parts during the study. Part A will be Variable Open-Label Run-in (maximum up to 132 weeks). Part B- Fixed Open-Label Run-In (4 Weeks to 8 weeks). Part C will be randomized double-blind treatment period (Up to 52 weeks) and in case of clinically significant asthma exacerbation, optional open label switch Part D (Up to 52 weeks post randomization). Subjects will receive mepolizumab (100 mg SC) every 4 weeks throughout study
89575125|NCT02555371|Placebo Comparator|Arm Placebo|There will be 4 parts during the study. Part A will be Variable Open-Label Run-in (maximum up to 132 weeks). Part B- Fixed Open-Label Run-In (4 Weeks to 8 weeks). Part C will be randomized double-blind treatment period (Up to 52 weeks) and in case of clinically significant asthma exacerbation, optional open label switch Part D (Up to 52 weeks post randomization). During Part A, B and D, subjects will receive open label mepolizumab (100 mg SC) every 4 weeks and during Part C, subjects will receive placebo SC every 4 weeks.
89575126|NCT05489029||retrospective analysis|A retrospective analysis of disease histories for the period from 2014 to 2021 was carried out. Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury.
88971286|NCT03151044|Active Comparator|EPI-75|"Participants in this arm shall be given standard-dose Epirubicin, Combined with CVP ± Rituximab for six 21-day cycles:~Standard-dose Epirubicin 75mg/m2, i.v., Day 1; Cyclophosphamide 750mg/m2, i.v., Day 1; Vincristine 1.4mg/m2, i.v., Day 1; Prednisolone 100mg/m2, p.o., Day 1-5;~Plus/not plus:~Rituximab 375mg/m2, i.v., Day 0"
89575127|NCT05489029||prospective study|Recruitment of patients for the prospective study was carried out in the period from 02.24.2022 to 05.24.2022
89575128|NCT04122235|Experimental|Intervention arm|New follow-up model
89575129|NCT04122235|No Intervention|Control arm|Usual care
89575130|NCT02555215|Experimental|dimethyl fumarate|Participants will receive 120 mg capsule(s) taken orally.
89575131|NCT05485597|Experimental|Study Group: Neurological inpatients with Gait disorders|The group participates in the study intervention (they will undergo the Myosuit-based gait training)
89575132|NCT02555683|Experimental|QAW039 150 mg|QAW039 150 mg once daily
89575133|NCT02555683|Experimental|QAW039 450 mg|QAW039 450 mg once daily
89575134|NCT02555683|Placebo Comparator|Placebo|Placebo once daily
88971287|NCT00137566|Experimental|1 Paracetamol|Paracetamol as per protocol
88971288|NCT00137566|Placebo Comparator|2 Placebo|Inactive placebo as per protocol.
88971289|NCT00137605|Experimental|Pneumovax/immediate|
88971290|NCT00137605|Experimental|Pneumovax/delayed|
88971291|NCT00137605|Experimental|Prevnar/immediate|
88971292|NCT00137605|Experimental|Prevnar/delayed|
88971293|NCT03150966|Experimental|Patients who received nanocurcumin|Patients who received nanocurcumin
88971294|NCT03150966|Placebo Comparator|Patients who received placebo|Patients who received placebo
88971295|NCT00137800|Experimental|Tarceva|Chemotherapy Single Agent Systemic
88971296|NCT03150927|Experimental|Probiotic Microbial Composite|Probiotic Microbial Composite is a safe, 100% natural material containing all Generally Recognized as Safe (GRAS) Probiotics, combined with FDA approved food grade excipient materials. The probiotics contained within are also all 100% natural and non-Genetically Modified Organisms (non-GMO).
89575135|NCT04424095||Pediatric patients|Recruited pediatric patients will undergo an in-office vascular visit and an echo duplex scan of lower limbs, in order to detect any symptoms or signs related to chronic venous disease.
89575136|NCT02554981|Experimental|RESTASIS®|1 drop of RESTASIS® ophthalmic emulsion instilled in each eye twice a day for 6 months.
88971297|NCT03150927|Placebo Comparator|Placebo|Placebo is a mixture of inactive ingredients found in Probiotic Microbial Composite. These ingredients are FDA approved food grade materials, 100% natural and palatable.
89575137|NCT02556775||Alternative Product Arm|Participant stops HYQVIA treatment (if the participant is still treated) and a licensed human normal immunoglobulin other than HYQVIA for intravenous (IV) or subcutaneous (SC) infusion or an alternative treatment will be administered, as determined by the physician.
89575138|NCT02556775||HYQVIA Arm|Participant continues to receive HYQVIA (Immune Globulin (Human) 10% with recombinant human hyaluronidase (rHuPH20)), according to her treatment regimen.
89209171|NCT00733421|Active Comparator|2|Tramadol 100 mg slow release twice daily
89209172|NCT00613080|Other|IMRT + Chemotherapy , Resection, Postoperative Chemotherapy|Radiation therapy (intensity modulated radiation therapy [IMRT] + three dimensional conformal radiation therapy [3D-CRT]) + neoadjuvant chemotherapy (capecitabine and oxaliplatin) followed by resection and postoperative chemotherapy (FOLFOX)
89575139|NCT01662505|Experimental|Volasertib|Patient to receive escalating dose of volasertib
88971298|NCT00137995|Experimental|R-ICE|R-ICE + R-BEAM /ASCT Rituximab, Etoposide, Carboplatine, Ifosfamide + Mesna BCNU, Etoposide, Cytarabine, Melphalan Autologous Stem Cell Transplantation
88971299|NCT00137995|Experimental|R-DHAP|R-DHAP + R-BEAM /ASCT Rituximab, Cisplatine, Cytosine Arabinoside, Dexamethasone BCNU, Etoposide, Cytarabine, Melphalan Autologous Stem Cell Transplantation
88971300|NCT03150888||Hospital based hypertension cohort|
88971301|NCT03150888||Community based hypertension cohort|
88971302|NCT03150849||patient group|patient with chronic lymphocytic leukemia
88971303|NCT03150849||control group|healthy control group
88971304|NCT00138463||West Nile Virus (WNV) Neuroinvasive Disease Cohort|Fever (temperature > 38 C) documented by a health care provider AND: at least one of the following, as documented by a health care provider and in the absence of a more likely clinical explanation: acutely altered mental status; other acute signs of central or peripheral neurologic dysfunction; or cerebrospinal fluid (CSF) pleocytosis associated with illness clinically compatible with meningitis.
88971305|NCT00138463||West Nile Virus Fever Cohort|Temperature > 38 C as documented by a health care provider.
89209173|NCT00806858||A|
89209174|NCT00917891|Placebo Comparator|vehicle placebo gel|
89209175|NCT00917891|Experimental|dapivirine gel|
89209176|NCT02554136|Experimental|Sequence 1|HGP0918 -> HGP0816 -> HGP0918 + HGP0816
89209177|NCT02554136|Experimental|Sequence 2|HGP0816 -> HGP0918 + HGP0816 -> HGP0918
89209178|NCT02554136|Experimental|Sequence 3|HGP0918 + HGP0816 -> HGP0918 -> HGP0816
89209179|NCT02554136|Experimental|Sequence 4|HGP0918 -> HGP0918 + HGP0816 -> HGP0816
89575140|NCT05485363|Experimental|optic nerve sheath diameter by using ocular sonography|
89575141|NCT05491993|Experimental|SARS-CoV-2 Antigen Rapid Test|The same group of patients participated in two arms of the study. One arm was for obtaining data on the Rapid Antigen Test for Covid-19. The comparator arm was to obtain data from the RT-PCR.
89575142|NCT03986749|Experimental|ARCR-BursaSeries|Tendon healing in the reconstruction of the rotator cuff, taking advantage of augmentation potential of the subacromial bursa.
89575143|NCT04074733||Patients with fractures|
88971306|NCT03150771|Experimental|Cohort 1|Aripiprazole; single; gluteal
88971307|NCT03150771|Experimental|Cohort 2|Aripiprazole; single; gluteal
88971308|NCT03893825|Experimental|TV-46000 q1m|Participants will receive a subcutaneous (SC) injection of TV-46000 at baseline and every 4 weeks (q4w) thereafter for up to 56 weeks. The maximal dose administered to adult participants is comparable to an oral risperidone dose of 5 mg/day, and the maximal dose administered to adolescents is comparable to 4 mg/day.
88971309|NCT03893825|Experimental|TV-46000 q2m|Participants will receive an SC injection of TV-46000 at baseline and every 8 weeks (q8w) thereafter, and a placebo SC injection 4 weeks after baseline and q8w thereafter for up to 56 weeks. The maximal dose administered to adult participants is comparable to an oral risperidone dose of 5 mg/day, and the maximal dose administered to adolescents is comparable to 4 mg/day.
89029189|NCT04110379|Active Comparator|Conventional Behavior Management|Child behavior management will be done using conventional behavior management techniques
89209180|NCT02554136|Experimental|Sequence 5|HGP0816 -> HGP0918 -> HGP0918 + HGP0816
89209181|NCT02554136|Experimental|Sequence 6|HGP0918 + HGP0816 -> HGP0816 -> HGP0918
89209182|NCT00732875|Experimental|Open Label Infliximab + Methotrexate|Open label Infliximab infusions at weeks 0, 2, and 6 and every 8 weeks + methotrexate (MTX)
89209183|NCT00799370|Experimental|1|Early weight bearing: immediate in postoperative
89209184|NCT00799370|Experimental|2|Delayed weight bearing: 2 months after surgery
89209185|NCT00874692|Experimental|BMS and sterilisation|BMS and sterilisation programme will be delivered
89209186|NCT00874692|No Intervention|BMS standard water heating|
89209187|NCT00881790||Fluoride application|
89209188|NCT05097456|Active Comparator|Laser treatment|carbon dioxide treatment
89209189|NCT05097456|Sham Comparator|Sham treatment|sham treatment
89209190|NCT00810446||rifabutin|Patients administered Rifabutin.
89209191|NCT00810524|Experimental|A|120 subjects (have family history of hepatic carcinoma or liver cirrhosis). Antiviral treatment are started when ALT is lower than 80u/L (early antiviral treatment).
89209192|NCT00810524|Active Comparator|B|120 subjects (have family history of hepatic carcinoma or liver cirrhosis). Antiviral treatment are started when ALT is higher than 80u/L (regular antiviral treatment).
89575144|NCT05488717|Experimental|Application|"Patients who are routinely scheduled for bone marrow transplantation are admitted to the unit one week before the transplant and treatment is started and transplantation is performed a week later. All patients in the intervention and control group will be filled out forms upon hospitalization after receiving their informed consent at the beginning of the study. Subsequently, patients in the intervention group will be given art-based mandala painting, which is sampled below, for 30 minutes for a week, accompanied by instrumental music featuring natural sounds in a room with light-heat control. Mandala painting templates and crayons will be provided by the researcher. The researcher will not intervene in any way other than time management during the preparation and painting of the environment. The researcher participated in training on art-based mandala and made preliminary preparations.~No intervention will be made to the control group except for routine clinical applications."
89575145|NCT05485207|Experimental|Transvaginal Botulinum Toxin A (BTA) injection|Botulinum toxin A (Botox® 100 units) will be injected into the detrusor muscle of the bladder by inserting a needle through the anterior vaginal wall.
89029190|NCT04097652|Experimental|UMC119-06|Human Umbilical Cord Derived-Mesenchymal Stem Cells, Single treatment by intravenous infusion.
89029191|NCT04083183|Experimental|Treatment (astatine 211,fludarabine,cyclophosphamide,TBI,HCT)|Patients receive astatine At 211 anti-CD45 monoclonal antibody BC8-B10 IV on any day between days -10 and -7, fludarabine IV on days -6 to -2, cyclophosphamide IV over 1 hour on days -6 to -5 and 3 to 4, and thymoglobulin IV over 4-6 hours on days -4 to -2. Patients undergo TBI on day -1 and hematopoietic cell transplant on day 0. Beginning day 5, patients also receive mycophenolate mofetil PO or IV thrice daily every 8 hours up to day 35 if no GVHD present and sirolimus PO daily until day 365.
89575146|NCT03897907|Experimental|Psychologically Informed Education|This arm will provide an education intervention which will attempt to address maladaptive psychological behaviors in adolescents with knee pain
89029192|NCT04069273|Experimental|Arm A|Pembrolizumab will be administered every 3 weeks in combination with ramucirumab + paclitaxel. The paclitaxel schedule differs between the 2 arms.
89029193|NCT04069273|Experimental|Arm B|Pembrolizumab will be administered every 3 weeks in combination with ramucirumab + paclitaxel. The paclitaxel schedule differs between the 2 arms.
89575147|NCT03897907|Placebo Comparator|Control Education|This arm will provide education of basic knee anatomy and will not address maladaptive psychological behaviors.
89575148|NCT03879109|Experimental|Arm A: Induction Chemotherapy followed by Pelvic reirradiation|"Protocol of chemotherapy FOLFIRINOX*, 6 cycles :~oxaliplatin: 85 mg/m2~irinotecan: 180 mg/m²~folinic acid: 400 mg/m2~5FU : 400 mg/m2 (bolus)~5FU : 2400 mg/m2 (continuous infusion)~Protocol of reirradiation consists in conformational intensity modulated external irradiation, delivering a 30.6 Gy dose (1.8 Gy/day), with concomitant chemotherapy including Capecitabine 1600 mg/m²/day, five days a week."
89575149|NCT03879109|Active Comparator|Arm B: Chemotherapy alone|"Protocol of chemotherapy FOLFIRINOX*, 6 cycles :~oxaliplatin: 85 mg/m2~irinotecan: 180 mg/m²~folinic acid: 400 mg/m2~5FU : 400 mg/m2 (bolus)~5FU : 2400 mg/m2 (continuous infusion)"
89575150|NCT05485129|Experimental|Intervention|
89575151|NCT04032535|Experimental|SAD|"Single Ascending Dose of 2 cohorts:~Cohort A will be administered three ascending dose levels: 0.2 mg (dose 1), 2 mg (anticipated dose 3), 8 mg (anticipated dose 5) or placebo; Cohort B will be administered three ascending dose levels: 1 mg (anticipated dose 2), 4 mg (anticipated dose 4), 14 mg (anticipated dose 6, maximum dose) or placebo."
89575152|NCT04032535|Experimental|MAD|"Multiple Ascending Dose of 4 cohorts:~Cohort A will be administered with 2 mg (anticipated dose 1) or placebo; Cohort B will be administered with 4 mg (anticipated dose 2) or placebo; Cohort C will be administered with 8 mg (anticipated dose 3) or placebo; Cohort D will be administered with 12 mg (anticipated dose 4) or placebo;"
89575153|NCT04032535|Experimental|2way crossover|Two 28-day treatment periods (Period 1 and Period 2), separated each by 32 days (up to 40 days) wash-out period, in crossover design. The treatment period will consist in repeated administrations of CHF 6523 at one dose level or placebo.
89575154|NCT05488327|Experimental|Intervention with lenalidomide|All subjects will be treated with lenalidomide 5mg/day.
89029194|NCT04066283||Older transgender women|This cohort will consist of transgender women aged 50-75 years old who have taken estradiol and spironolactone for at least one year.
89575155|NCT05488171|Experimental|Methylone|Methylone (3,4-methylenedioxy-N-methylcathinone) 200 mg, single dose, oral administration
89029195|NCT04066283||Younger transgender women|This cohort will consist of transgender women aged 18-40 years old who have taken estradiol and spironolactone for at least one year.
89575156|NCT05488171|Active Comparator|3,4-methylenedioxymethamphetamine (MDMA)|MDMA (3,4-methylenedioxymethamphetamine) 100 mg, single dose, oral administration
89575157|NCT05488171|Placebo Comparator|Maltodextrin|Placebo, single dose, oral administration
89575158|NCT05480137|Other|plain balloon|plain balloon is used in BPA
89575159|NCT05480137|Other|NSE scoring balloon|NSE scoring balloon is used in BPA
89575160|NCT05479903|Experimental|acupuncture stroke group|
89575161|NCT05479903|Sham Comparator|sham acupuncture stroke group|
89575162|NCT05479903|Placebo Comparator|no acupuncture stroke group|
89575163|NCT05479903|Placebo Comparator|acupuncture healthy group|
89029196|NCT04052334|Experimental|Infusion of Tumor-infiltrating lymphocyte|"Participants will undergo tumor resection from which the tumor infiltrating lymphocyte (TIL) product will be generated. All participants will receive nonmyeloablative lymphodepleting chemotherapy with cyclophosphamide and fludarabine to enhance T-cell persistence and effectiveness in vivo. Cyclophosphamide will be administered at 60 mg/kg/day IV in 250 mL normal saline (NS). Fludarabine will then be infused at 25 mg/m^2 intravenous piggyback (IVPB). All participants will receive not less than 10^9, and up to 1x10^12 T cells in ≥250 mL NS as an inpatient by intravenously (IV).~Eight (8) to sixteen (16) hours after completing the T cell infusion, all participants will receive high-dose interleukin-2 (IL-2) on an inpatient basis at the standard dose of 600 000 IU/kg as an intravenous bolus over an approximate 15-minute period every 8 to 16 hours for up to 15 doses on days 1 to 5, as tolerated."
89575164|NCT05479903|Experimental|computerized cognitive training group|
89575165|NCT05479903|Placebo Comparator|tranditional cognitive training group|
89575166|NCT05479903|Experimental|aerobics group|
89575167|NCT05484817||Normal cardiac function groups|Patients admitted to the hospital or recruited from the community with diabetes mellitus are screened for cardiovascular diseases by echocardiography. Global longitudinal strain (GLS) is measured by speckle tracking echocardiography. The 2015 American Society of Echocardiography guidelines recommended a mean of -20% for GLS in healthy subjects, while the upper normal limit is -18%. Therefore, the normal cardiac function groups are defined as GLS < -18%.
89575168|NCT05484817||Impaired cardiac function groups|Patients admitted to the hospital or recruited from the community with diabetes mellitus are screened for cardiovascular diseases by echocardiography. Global longitudinal strain (GLS) is measured by speckle tracking echocardiography. The 2015 American Society of Echocardiography guidelines recommended a mean of -20% for GLS in healthy subjects, while the upper normal limit is -18%. Therefore, the impaired cardiac function groups are defined as GLS ≥ -18%.
89575169|NCT05479825|Experimental|inflation- deflation line combined with ICG fluorography|Identification of the intersegmental plane using inflation- deflation line combined with ICG fluorography under the status of tubeless
89575170|NCT05484583|Experimental|Radiotherapy combined with Durvalumab, etoposide, and cisplatin/carboplatin|Radiotherapy combined with Durvalumab, etoposide, and cisplatin/carboplatin
89575171|NCT05487937||Toleriane Ultra|Participants are asked to apply the study product twice daily (morning and evening) at home for 28 days.
89575172|NCT05487781|Experimental|Group 1|Tyrphostin AG-17 content 10 mg with 700 mg of L-Carnitine tartrate
89575173|NCT05487781|Experimental|Group 2|Tyrphostin AG-17 content 3.3 mg with 700 mg of L-Carnitine tartrate
89575174|NCT05487781|Experimental|Group 3|Tyrphostin AG-17 content 1 mg with 700 mg of L-Carnitine tartrate
89575175|NCT05487469|Experimental|Thymosin alpha 1|
89575176|NCT05487469|Sham Comparator|Blank control|
89575177|NCT05484427|Experimental|Telemedicine arm|Participants in this arm will be follow up by telemedicine control (via emails) instead of regular controls. They will upload the data from their devices (pump, CGM) to cloud system on their own. All instructions what to change they will recive by email only.
89575178|NCT05484427|No Intervention|Outpatient clinic meetings arm|Participants in this arm will normally come for the regular meetings with their diabetologist to the outpatient clinic.
89575179|NCT05484271||Leaf-like and Cord-like type|Under arthroscopy, the anatomy of middle glenohumeral ligament was leaf-like or cord-like.
89575180|NCT05484271||Absent type|Under arthroscopy, the anatomy of middle glenohumeral ligament was absent.
89575181|NCT05484271||Burford complex type|Under arthroscopy, the anatomy of middle glenohumeral ligament manifested the burford complex.
89575182|NCT05479435|Experimental|Blue Prescription Group|Participants will get an exercise program, which is designed by their needs, desires and abilities. They will perform a desired exercise program 3 days a week and they will make an interview for motivation and/or modifying the program one day a week. They will write an activity diary.
89575183|NCT05479435|Active Comparator|Video Based Home Exercise Group|Participants will get videos by different ways (closed link youtube, whatsapp, flash driver etc.). They will perform exercises 3 days a week. İnvestigator will phone them to ask whether they do the program or not. They will write an activity diary.
89575184|NCT05479435|Active Comparator|Supervised Exercise Group|Participants will perform an exercise program 3 days a week with a physiotherapist. The group will be held maximum 10 people.
89575185|NCT05479357|Active Comparator|Oxytocin|the control group will be given 10 iu intravenously.
89575186|NCT05479357|Active Comparator|Carbetocin|the treatment group will be given 100 microgram intravenously.
89575187|NCT05487391|Experimental|QL1706 plus Platinum-based chemotherapy|QL1706(5mg/kg Q3W IV) plus Platinum-based chemotherapy
88971310|NCT03890666|Experimental|Digital System (DS)|Participants will be trained on the use of the albuterol eMDPI DS (including instructions on how to use both the eMDPI and the App) and, upon demonstrating competency, will receive 2 albuterol eMDPI devices for use as reliever bronchodilators to replace their reliever treatment during the study. The eMDPI Digital System consists of 4 devices: Device 1: albuterol eMDPI (the test investigational medicinal product [IMP]); Device 2: Patient-facing App; Device 3: Digital health platform (DHP) (Cloud solution); and Device 4: Provider-facing Dashboard. Participants will receive 90 micrograms (mcg) albuterol, 1 to 2 oral inhalations every 4 to 6 hours, as needed for 12 weeks.
89575188|NCT05487391|Placebo Comparator|Placebo plus Platinum-based chemotherapy|Placebo(5mg/kg Q3W IV) plus Platinum-based chemotherapy
89575189|NCT05484193|Experimental|GnRH-agonist group|In the GnRH-a group, LPS was initiated on the evening after the OPU, using Nafareline (Synarel nasal spray 200mg used once), followed by twice daily (total 400mg/day) until the day of serum β-hCG pregnancy test, and then stopped, regardless of the test results
89575190|NCT05484193|Active Comparator|Progesterone group|In the progesterone group, LPS was initiated on the morning after OPU, using micronized progesterone ( PV Utrogestan 300mg, 3 times daily), until serum β-hCG pregnancy tests results were available. If a β-hCG pregnancy was confirmed, LPS was continued until the end of the 8th gestational week
89575191|NCT05479279|Experimental|Neck Stabilization Training Program|Patient education Tens Hot pack Cervical muscle stretching trigger/ tender point release postural re-education cranio-cervical isometrics training of intrascapular, shoulder and upper extremity musculature resistance training with theraband
89575192|NCT05479279|Active Comparator|Conventional physical therapy|Patient education Tens Hot pack Cervical muscle stretching trigger/ tender point release
89575193|NCT03796195|Experimental|.5% Bupivacaine|Guided right sided stelate ganglion block using .5% bupivacaine (5mLs)
88971311|NCT03890666|Active Comparator|Concurrent Control (CC)|Participants will be treated with their standard of care albuterol-administering reliever inhalers and will use the digital system during the treatment period. Participants will be reimbursed or given a voucher to use to purchase their existing reliever medications.
88971312|NCT00139360|Experimental|1|Active drug
88971313|NCT03150654|Experimental|Laser pan-retinal photocoagulation|Conventional laser pan-retinal photocoagulations were performed by using green laser photocoagulator, every month for 3 months
88971314|NCT00139594|Experimental|licarbazepine|
88971315|NCT03150615|Experimental|Early enteral nutrition|Nasojejunal tube insertion was done intraopratively. Early enteral nutrition with standard enteral formulas administered through the nasojejunal tube. Oral intake was encouraged as long as the patient can tolerate.
89575194|NCT05484037|Experimental|Intervention group|Intervention group/telehealth Arm: will be provided access to their electronic asthma action plan (eAAP) via a web Uniform Resource Locator (URL), receive weekly short message service (SMS) check-ins for one year, and be able to communicate with the site's research coordinator (RC) and Certified Respiratory Educator (CRE) via an integrated and interactive (two-way) SMS feature to manage their asthma
88971316|NCT03150615|Placebo Comparator|Saline Group|Nasojejunal tube insertion was done intraopratively. Saline was administered through the nasojejunal tube. Oral intake was encouraged as long as the patient can tolerate.
88971317|NCT03150615|Other|ERAS Group|Nasojejunal tube insertion was done intraopratively. None was administered through the nasojejunal tube. Oral intake was encouraged as long as the patient can tolerate.
88971318|NCT03837977|Active Comparator|nal-IRI, 5-FU and racemic folinic acid|liposomal Irinotecan (naI-IRI) (80mg/m*2 intravenously over 90 minutes (± 10 minutes) prior to Fluorouracil (5-FU) 5-FU 2400 mg /m*2 BSA infusor over 46 hours racemic folinic acid (as per local standard practice) every 14 days
89575195|NCT05484037|Active Comparator|Control group|Control group/standard care Arm: will receive their written Asthma Action Plan (wAAP) and information on how to use it by the site's Certified Respiratory Educator to manage their asthma
89575196|NCT05487079||Diabetic|"Diabetes will be defined as below (any or combination):~2h-OGTT: ≥ 11.1 mmol/L~FPG (fasting plasma glucose): ≥ 7.0 mmol/L~HbA1c; ≥ 48 mmol/mol (6.5%)"
88971319|NCT03837977|Active Comparator|docetaxel|75mg/m*2 intravenously over 60 minutes) every 21 days]
88971320|NCT00404287|Active Comparator|fluvastatin|fluvastatin 80 mg
89575197|NCT05487079||Pre-Diabetic|"Prediabetes will be defined as as below (any or combination)~2h-OGTT is between 140 and 199 mg/dL (7.8-11.0 mmol/L)~FPG values is between 100 and 125 mg/dL (5.6-6.9 mmol/L)~HbA1c is between 42 and 47 mmol/mol (6.0 - 6.4%)"
88971321|NCT00404287|Placebo Comparator|placebo|
88971322|NCT03150537|Active Comparator|Jet injector|40 participants will receive Fluviral influenza vaccine using the Med-Jet H4
89575198|NCT05487079||Non-Diabetics|"Normal glucose tolerance (NGT)~2h-OGTT; < 140 mg/dL (7.8 mmol/L).~FPG; < 100 mg/dL (5.6 mmol/L) and~HbA1c; < 42 mmol/mol"
89575199|NCT05478967|Experimental|IVA group|Received an IVA (0.5 mg/0.05 ml) injection before surgery (1 to 5 days before surgery)
89575200|NCT05478967|No Intervention|control group|Did not receive IVA injection before vitrectomy
89575201|NCT05483959|Experimental|BIPAP group|Mechanically ventilated ARDS patients on BIPAP mode of ventilation
89575202|NCT05483959|Experimental|SIMV PC group|Mechanically ventilated ARDS patients on SIMV PC mode of ventilation
89575203|NCT04268407|Experimental|2-day prophylactic antibiotics|use prophylactic antibiotic for 2 days after transoral thyroidectomy
89575204|NCT04268407|Other|7-day prophylactic antibiotic|use prophylactic antibiotic for 7 days after transoral thyroidectomy
89575205|NCT04014751||Symptom Monitoring Cohort|This cohort will include up to1,050 cancer patients being seen at regional Northwestern Medicine (NM) cancer centers for their cancer care. Patients who have recently completed an on-line, EHR-integrated patient-reported symptom and needs assessment as part of their regular care will be invited to complete a survey at baseline, 6- and 12-months targeting the assessment of their symptoms, healthcare experiences and utilization. Patients may also be invited to participate in a one-time interview or focus group designed to help study investigators better understand the value of the symptom and needs assessment from the patient perspective.
89575206|NCT05489653|Experimental|mixed music group|If assigned to the mixed music group, in order to synchronize active daytime music and passive music at bedtime, active daytime music will require patients to perform physical music activities once a week and watch a recorded music intervention video three times a week during the study period (The content is the same as the physical music activities) and follow the activities, and the intervention content before going to bed is the same as the intervention content of the pure passive music group.
89575207|NCT05489653|Active Comparator|pure passive music group|If assigned to the pure passive music group, they are required to listen to soft and low-pitched music at about 60 beats per minute 30 minutes before bed every day for four weeks.
89575208|NCT05489653|No Intervention|conventional treatment|Conventional treatment group maintained their original lifestyle and were post-tested with the assistance of a single-blind study evaluator.
89575209|NCT05483725||First booster dose group|
89575210|NCT05486845|Experimental|adults|People who use the lower back pillow.
89575211|NCT05478889||Minimally invasive pancreatoduodenectomy|Whipple or pylorus preserving pancreatoduodenectomy following minimally invasive approach (laparoscopic or robotic). Hybrid (hand assisted) precedures will be included in the minimally invasive cohort.
89575212|NCT05478889||Open pancreatoduodenectomy|Whipple or pylorus preserving pancreatoduodenectomy following open (laparotomy) approach.
89575213|NCT05478811|Active Comparator|Er,Cr:YSSG laser|NaOCl, Er,Cr:YSSG will be activated by laser during the final irrigation
89575214|NCT05478811|Active Comparator|Control|Routine final irrigation procedure will be done, NaOCl will not be activated by any method.
88971323|NCT03150537|Active Comparator|IM injection (pre-filled syringe)|20 participants will receive Fluviral influenza vaccine using pre-filled syringes for time-motion comparison to Med-Jet H4
88971324|NCT03150537|Active Comparator|IM injection (multi-dose vial)|20 participants will receive Fluviral influenza vaccine using a multi-dose vial for time-motion comparison to Med-Jet H4
88971325|NCT03803228|Experimental|DUOSTIM|(stim 1) flexible antagonist protocol with pre-treatment with estrogen (S1 between J1 and J8 under E2) and stimulation with Fertistartkit® 300 IU / d; triggering by rHCG (Ovitrelle®250μg) and puncture at 36h; oocyte freezing; (stim 2) resumption of stimulation only by Fertistratkit® 300 IU / day from the day after the puncture; introduction of Progestan® 7 days later to avoid menstruation during the second puncture; triggering with rHCG and second puncture at 36h associated with the devitrification of stim 1 oocytes, with sperm collection and embryonic vitrification. Transfer of frozen embryos to the subsequent cycle in the natural cycle (without HCG) and until the frozen embryos are exhausted.
89029197|NCT04044794|Active Comparator|Standard Care|Participants randomly assigned to this arm will receive standardized weight management educational materials plus a monetary gift of $60 that can be used to purchase health-promoting supplies to support weight management.
89209193|NCT00810524|Experimental|C|180 subjects (have no family history of hepatic carcinoma or liver cirrhosis). Antiviral treatment are started when ALT is lower than 80u/L (early antiviral treatment).
89575215|NCT05486767||Community cohort|SIRIUS study team will travel to pre-determined sociomes and perform transient elastography and other examinations
88971326|NCT03803228|Active Comparator|Conventional stimuli|"(stim 1) flexible antagonist protocol with pre-treatment with estrogen (S1 between J1 and J8 under E2) and stimulation with Fertistartkit® 300 IU / d; triggering by rHCG (Ovitrelle®250μg) and puncture at 36h; fresh embryonic transfer if satisfactory endometrial conditions with luteal phase support by vaginal micronized progesterone Progestan® 600 mg / d; otherwise embryonic freezing and transfer of frozen embryos to the subsequent cycle in the natural cycle until the frozen embryos are exhausted.~(stim 2) ditto starting on the next cycle if possible or the next one. Hormonal Controls + Ultrasound During Stimulation: Blocking / S1 - S5 / S6 - S8 / S9 - SHCG / SHCG-1"
88971327|NCT00139828|Other|A|The amount of Nonafact® to be administered and the frequency of treatment is based on the SmPC and should always be determined on the basis of the clinical effectiveness in the individual patient
88971328|NCT02964481||Malignant Hyperthermia Phenotype cases|Samples from persons who identify as having the malignant hyperthermia phenotype by the North American MH Registry (NAMHR)
89575216|NCT05486767||Outpatient cohort|Patients recruited during the elective / preventive examinations at the primary-care clinics or at other outpatient-clinics will have performed Hep-calculator for FIB-4 w/wo transient elastography
89575217|NCT05478655||retrospective analysis|A retrospective analysis of disease histories for the period from 2014 to 2021 was carried out. Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation In all patients, the assessment of anesthetic risk was carried out according to the ASA scale.The basic tool for pain intensity research was a visual analog scale.The study of the neuropathic component of pain was carried out using the diagnostic questionnaire for the detection of neuropathic pain Didier Bouhassiraa, Nadine Attala et al. Pain, 2005, 114: 29-36. Study of the presence of an acute stress reaction scale The Hospital Anxiety and Depression Scale. The presence of post-traumatic stress disorders was studied using the Mississippi scale of post-traumatic stress disorders (military version). Satisfaction with the results of treatment was studied using the Chaban Quality of Life Scale.
89575218|NCT05478655||prospective study|"Recruitment of patients for the prospective study was carried out in the period from 02.24.2022 to 05.24.2022. Data collection was carried out during the Russian invasion of Ukraine and the offensive on Kyiv. All patients with gunshot wounds were evacuated to the stage of treatment - the National Military Medical Clinical Center Main Military Clinical Hospital. The research was conducted using the same methods as during the retrospective analysis. The exception was the study period during treatment at the military medical clinical center: here it was 14 days."
89575219|NCT05483647|Active Comparator|G1|Intravenous sedation with infiltrative local anaesthesia
89575220|NCT05483647|Experimental|G2|Intravenous sedation with bilateral Erector Spine Plane Block
89575221|NCT05486299|Experimental|Single-port Endoscopic Surgical System|A novel robotic surgical system that can be configured for multi-port, single-port, or hybrid-port procedures. In the single-port configuration, a four-channel trocar shall be used. The surgical tools are steered through the curved access channels in the trocar to enter a patient's abdomen.
88971329|NCT02964481||Caffeine Halothane Contracture Test negative controls|Controls who had negative Caffeine Halothane Contracture Test (CHCT) from North American MH Registry (NAMHR)
88971330|NCT03150498|Experimental|BTD-001 (fed)|
88971331|NCT03150498|Experimental|BTD-001 (fasted)|
88971332|NCT03761615||type 1 diabetes and pregnancy|Pregnant women with T1D on insulin pumps (CSII/SAP/PLGS) will be offered enrollment in a prospective study that will capture: 1) Dexcom G6 CGM data, 2) self-monitoring of blood glucose (SMBG), 3) insulin pump settings, 4) insulin delivery records, and 5) maternal and fetal outcomes.
88971333|NCT03150459|Experimental|Simvastatin 20 mg + Rifaximin 400 mg (group 1)|Simvastatin 20 mg/day and rifaximin 400 mg/8 hours orally for 12 weeks
88971334|NCT03150459|Experimental|Simvastatin 40 mg + Rifaximin 400 mg (group 2)|Simvastatin 40 mg/day and rifaximin 400 mg/8 hours orally for 12 weeks
88971335|NCT03150459|Placebo Comparator|Placebo of Simvastatin + Placebo of Rifaximin (group 3)|Placebo simvastatin and placebo rifaximin orally for 12 weeks
88971336|NCT03748550|No Intervention|Control|Participants will receive standard of care treatment for their breast cancer.
88971337|NCT03748550|Experimental|Exercise|Participants will receive standard of care treatment for their breast cancer plus be given a 12-week home based aerobic exercise program.
88971338|NCT00140101|Experimental|1|ZoMaxx™ Drug-Eluting Stent System
88971339|NCT00140101|Active Comparator|2|TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent System
88971340|NCT03150420|Experimental|Sodium Thiosulfate|Sodium Thiosulfate Injection (25 grams sodium thiosulfate)
88971341|NCT03150420|Placebo Comparator|Placebo-Normal Saline|0.9% sodium chloride injection, USP (normal saline)
88971342|NCT03748121|Experimental|Pranayama assisted Trauma-focused Cognitive Behavioral Therapy (TF-CBT)|To prepare patients for the TF-CBT, they received 5-10 minutes of pranayama at the begin of each of the 10 TF-CBT units.
88971343|NCT03748121|Active Comparator|Trauma-focused Cognitive Behavioral Therapy (TF-CBT)|Patients wait for 10 TF-CBT units and then are offered to learn pranayama.
88971344|NCT03150381|Active Comparator|Weight Loss Only|Group-based behavioral weight loss intervention designed to reach clinically significant weight loss (~5-10% of baseline weight).
88971345|NCT03150381|Experimental|Weight Loss Plus|Group-based behavioral weight loss intervention designed to reach clinically significant weight loss (~5-10% of baseline weight) plus community-level strategies to support healthy weight. Strategies are based on CDC's recommended community strategies and are developed by local contractors. They include expanded farmers markets/gardens, improvement to walking trails, etc.
88971346|NCT03150381|Active Comparator|Control|Educational materials and optional participation in community-wide cancer awareness activities.
88971347|NCT00140530|Experimental|1|Due to randomisation patients got a Paclitaxel-eluting stent
88971348|NCT00140530|Experimental|2|Due to randomization patients got a Rapamycin-eluting stent.
88971349|NCT03737825|Active Comparator|Program 1|Computerized gaming rehabilitation Program 1.
88971350|NCT03737825|Placebo Comparator|Program 2|Computerized gaming rehabilitation Program 2.
88971351|NCT03150303||Vitamin K Antagonists (VKA)|Patients on VKA
88971352|NCT03150303||Direct Oral Anticoagulant (DOAC)|Patients on OAD
89575222|NCT05478421|No Intervention|Control group|Patients in control group will be treated by cyst enucleation.
89575223|NCT05478421|Experimental|Collagen sponge group|Cystic lesions in collagen sponge group will be filled by collagen sponge.
89575224|NCT05478421|Experimental|GBR group|Cystic lesions in GBR group will be filled by deproteinized bovine substitute (DBBM, Bio-Oss®, granulometry 0.25-1 mm; Geistlich Pharma AG) and covered by absorbable collagen membrane (Bio-Gide®, Geistlich Pharma AG).
89575225|NCT05478421|Experimental|CS/GBR group|Cystic lesions in GBR group will be filled by collagen sponge and deproteinized bovine substitute (DBBM, Bio-Oss®, granulometry 0.25-1 mm; Geistlich Pharma AG) and covered by absorbable collagen membrane (Bio-Gide®, Geistlich Pharma AG).
89575226|NCT05483569|Other|Complex Decongestive Physiotherapy|CDP program consisting of 4 parameters will be applied to this group. These parameters are MLD, Skin care, Multi-layer bandage application and decongestive exercises. In addition, the Placebo Facial Release technique will be performed by keeping the physiotherapist's hand in contact with the patient's abdominal region without applying any pressure and tension during the breathing exercises. Participants will be treated for a total of 3 weeks, 5 days a week. Each treatment session will last 45 minutes.
89575227|NCT05483569|Experimental|Multidimensional Diaphragmatic Breathing Exercises and Facial Release Technique|"CDP program consisting of 4 parameters will be applied to this group. These parameters are MLD, Skin care, Multi-layer bandage application and decongestive exercises. In addition, Multidimensional Diaphragmatic Breathing Exercises and Facial Release technique will be applied. These two treatments consist of these sub-exercises. These; Mechanical nose opening techniques, Intermittent Sniffing exercise, Diaphragm Awareness and Exercise Short Protocol, Thorax mobilization exercises, Myofascial diaphragm release techniques, Myofascial release exercises and postures and, Pelvic floor myofascial release postures.~Participants will be treated for a total of 3 weeks, 5 days a week. Each treatment session will last 45 minutes."
89575228|NCT05478343|Experimental|IM21 CAR-T cells|
89575229|NCT05478187|Experimental|QWalk Study Group|10 individual sessions (5 sessions/week for 2 consecutive weeks). Each session consisted of 60 minutes of conventional physiotherapy plus an additional session of gait training (30 minutes), performed by means of the new wearable cueing system (QWalk)
89575230|NCT05478187|Active Comparator|Control Group|10 individual sessions (5 sessions/week for 2 consecutive weeks). Each session consisted of 60 minutes of conventional physiotherapy plus an additional session of gait training (30 minutes), performed by means of traditional visual cues consisting of stripes on the floor
89575231|NCT05478109|Experimental|[14C]XZP-3287|Eligible healthy male subjects received a single oral 360 mg (radioactivity of 50µCi) dose of [14C]XZP-3287
89575232|NCT05475535|Active Comparator|Active Control|
89575233|NCT05475535|Experimental|Cognitive Behavioural Therapy (CBT)|
89575234|NCT05475535|Experimental|Self-Compassion (SC)|
89575235|NCT05475535|Experimental|Cognitive Behavioural Therapy and Self-Compassion (CBT+SC)|
89575236|NCT05475457||Oregon County 1|First cohort to be trained and monitored with coaching in the R3 model.
88971353|NCT00404365|Experimental|Arm I (control)|Arm I (control): Patients complete screening questionnaires about their mood and experience with lung cancer once before and once after a visit with their physician. Neither the patient nor physician receives the screening results before the visit.
88971354|NCT00404365|Experimental|Arm II|Arm II: Patients complete screening questionnaires as in arm I. Only the patient receives the screening results before their visit with the physician; the physician remains blinded to the results.
88971355|NCT00404365|Experimental|Arm III|Arm III: Patients complete screening questionnaires as in arm I. Only the physician receives the screening results before their visit with the patient; the patient remains blinded to the results.
88971356|NCT00404365|Experimental|Arm IV|"Arm IV: Patients complete screening questionnaires as in arm I. Both physician and patient receive the screening results before the visit.~All patients and physicians are notified of the screening results before the patient leaves the clinic. All patients are offered supportive counseling."
88971357|NCT03150264|Experimental|PCV-VG+PEEP5cmH₂O|Patients in this group are ventilated with pressure-controlled ventilation volume-guaranteed mode. And we use PEEP of 5cmH₂O to open the collapsed alveoli.
88971358|NCT03150264|Active Comparator|PCV+PEEP5cmH₂O|Patients in this group are ventilated with pressure-controlled ventilation mode. And we use PEEP of 5cmH₂O to open the collapsed alveoli.
88971359|NCT03730688|Experimental|Conventional and experimental compartment pressure measurement|Compartment pressure in the patients in this group will be measured using the conventional Intra-Compartmental Pressure Monitor System (Stryker) and using the newly-developed measuring device.
89209194|NCT00810524|Active Comparator|D|180 subjects (have no family history of hepatic carcinoma or liver cirrhosis). Antiviral treatment are started when ALT is higher than 80u/L (regular antiviral treatment).
89209195|NCT00810680|Experimental|Valproic acid|
89575237|NCT05475457||Oregon County 2|Second cohort to be trained and monitored with coaching in the R3 model.
89575238|NCT05475379|Experimental|Test vaccine group|"300 participants will receive Typhoid Vi polysaccharide-diphtheria toxoid conjugate vaccine (Vi-DT)~Trade name: Typhocon®, Incepta Vaccine Ltd."
89209196|NCT00806936||A|
89575239|NCT05475379|Active Comparator|Reference vaccine group|"300 participants will receive Vi polysaccharide-tetanus toxoid conjugate vaccine (Vi-TCV)~Trade name: Typbar-TCV®, Bharat-Biotech International Limited."
89575240|NCT05475223|Other|Prospective|Standard of Care for Diagnosis and management of neonatal jaundice + End Tidal Carbon Monoxide measurement value
89575241|NCT03699553|Experimental|Intervention|Participants will receive the online LARKSPUR intervention which lasts about 5-6 weeks, receiving the positive emotions skills through the website, and logging on to the website for about 5-10 minutes each day for that period. Assessments will be taken at baseline, post-intervention (8 weeks after the baseline), and 12 weeks after baseline (1 month post intervention).
89575242|NCT03699553|Active Comparator|Emotion Reporting Control|Participants will report their emotions for 5-6 weeks by logging on to the website for about 5 minutes each day. Assessments will be taken at baseline, 8 weeks after baseline, and 12 weeks after baseline. After 12 weeks, participants will receive access to the LARKSPUR intervention online.
89575243|NCT05474677|Experimental|intervention group|intervention group with the abdomen will be closed with continuous PDS 2\0 sutures
89575244|NCT05474677|Experimental|control group|the abdomen will be closed with continuous sutures size zero
89575245|NCT04424017||Healthcare workers (HCWs)|
89575246|NCT04424017||Healthy blood donors and healthy subjects in blood bank|
89575247|NCT04424017||Convalescents|
89575248|NCT05477797|Experimental|Ixazomib DX|Id: Ixazomib 4mg po d1,8,15; Dexamethasone 20mg po d1,8,15,22; （28 days /cycle）. The treatment will be maintained for 2 years （if no disease progression or intolerant side effects appear）.
89575249|NCT05477797|Placebo Comparator|Lenalidomide DX|Rd: Lenalidomide 25mg qd d1-21; Dexamethasone 20mg po d1,8,15,22; （28 days /cycle）. The treatment will be maintained for 2 years （if no disease progression or intolerant side effects appear）.
89575250|NCT05483179||Patients with colorectal cancer Patients with colorectal cancer who underwent elective surgery.|Diagnostic Test: Preoperative cardiopulmonary exercise tetsing Patients underwent a cardiopulmonary exercise test prior to surgery.
89575251|NCT05477641|Active Comparator|pericapsular nerve group block and lateral femoral cutaneous nerve block|Nerve blocks
89575252|NCT05477641|Active Comparator|fascia iliaca compartment block|Nerve block
89575253|NCT05472259|Active Comparator|Arm A NALIRI|"Cycle length: 14 days~Day 1:~Leucovorin: 400 mg/m² IV - Dilute in 250 mL DSW and administer over two hours~Liposomal irinotecan (FBE): 70 mg/m² IV* - Dilute in 500 mL DSW and administer over 90 min~5 FU: 2400 mg/m² IV - Dilute in 500 to 1000 mL 0,9% NS of DSW and administer as a continuous IV infusion over 46 hours. To accommodate an ambulatory pump for outpatient treatment can be administered undiluted (50 mg/mL) or the total dose diluted in 100 to 150 mL NS.~Patients who are known to be homozygous for UGT1A1*28 should start treatment with 50 mg/m2 ONIVYDE. If they do not encounter drug related toxicities during the first cycle of therapy (started at a reduced dose of 50 mg/m2), they may have the dose of ONIVYDE increased to a dose of 70 mg/m2 in subsequent cycles based on individual patient tolerance."
89575254|NCT05472259|Experimental|Arm B NALIRINOX|"Cycle length: 14 days~Day 1:~Oxaliplatin 60 mg IV - Dilute in 500 mL D5W and administer over two hours (prior to leucovorin). Shorter oxaliplatin administration schedules (eg. 1mg/m2 per minute) appear to be safe.~Leucovorin: 400 mg/m² IV - Dilute in 250 mL DSW and administer over two hours (after oxaliplatin)~Nanoliposomal irinotecan (FBE): 50 mg/m² IV - Dilute in 500 mL D5W and administer over 90 min~5 FU: 2400 mg/m² IV - Dilute in 500 to 1000 mL 0,9% NS of DSW and administer as a continuous IV infusion over 46 hours. To accommodate an ambulatory pump for outpatient treatment can be administered undiluted (50 mg/mL) or the total dose diluted in 100 to 150 mL NS."
89575255|NCT04266145|Active Comparator|intravenous dexmedetomidine|20 mL 0.25% levobupivacaine plus 1 mL normal saline will be administrated for adductor-canal-blockade while for intravenous solution; 0.5µg.kg-1 dexmedetomidine diluted in 20 mL normal saline will be prepared
89575256|NCT04266145|Active Comparator|adductor-canal-blockade dexmedetomidine|20 mL 0.25% levobupivacaine containing 1 mL of 0.5 mcg.kg-1 dexmedetomidine will be used for adductor-canal-blockade whereas, 20 mL 0.9% saline will be prepared for intravenous infusion
89575257|NCT05477329|Experimental|Myopia control design spectacle lens|Test lenses
89575258|NCT05477329|Other|Single Vision design spectacle lens|Control lenses
89575259|NCT05477251|Experimental|microwave ablation|
89575260|NCT05477251|Active Comparator|lobectomy|
89575261|NCT02554513|Active Comparator|EPG Tx|An articulatory-kinematic treatment in conjunction with visual biofeedback specifically tongue to palate contact to improve speech production
88971360|NCT03150225|Experimental|Exercise group + supplementation|"It will be composed of participants randomly assigned to this group, reinforcing the importance of attendance in classes (minimum of 75% of frequency) for significant health benefits. The evaluation measures will be made through a self-administered questionnaire and physical evaluations (cardiorespiratory fitness, body mass index, percentage of fat, waist circumference and muscular strength). The intervention with the concurrent training will be carried out in a gymnasium in Florianópolis, Santa Catarina. After all the evaluation procedures have been performed, the intervention period will begin, being three times a week, lasting 60 minutes, according to the study protocol.~In addition participants will receive supplementation of Eurycoma longifolia in 200mg capsules with standardized extract in aqueous-soluble extract and should be taken daily."
88971361|NCT03150225|Active Comparator|Control group + supplementation|Will be reinforced to the participants of this group the importance of maintaining their daily activities. In addition participants will receive supplementation of Eurycoma longifolia in 200mg capsules with standardized extract in aqueous-soluble extract and should be taken daily.
88971362|NCT03150225|Experimental|Exercise group + placebo|"It will be composed of participants randomly assigned to this group, reinforcing the importance of attendance in classes (minimum of 75% of frequency) for significant health benefits. The evaluation measures will be made through a self-administered questionnaire and physical evaluations (cardiorespiratory fitness, body mass index, percentage of fat, waist circumference and muscular strength). The intervention with the concurrent training will be carried out in a gymnasium in Florianópolis, Santa Catarina. After all the evaluation procedures have been performed, the intervention period will begin, being three times a week, lasting 60 minutes, according to the study protocol.~In addition participants will receive starch capsules to be taken daily."
88971363|NCT03150225|No Intervention|Control group + placebo|Will be reinforced to the participants of this group the importance of maintaining their daily activities. In addition participants will receive starch capsules to be taken daily.
88971364|NCT02964598|Experimental|Control|Minimal information on sleep timing
88971365|NCT02964598|Experimental|Psychoeducation|An extensive psychoeducational platform
88971366|NCT02964598|Experimental|Bright light|Bright light treatment with 10 000 lux at max
88971367|NCT02964598|Experimental|Gamified intervention|A new gamified intervention designed for mobile phones
88971368|NCT02964598|Experimental|Bright light and gamified intervention|A combination of the two
88971369|NCT02964598|Experimental|Sleep coaching|A new intervention protocol including a personified approach to solve problems and increase motivation for better sleep behavior
88971370|NCT02964598|Experimental|Sleep coaching + bright light|A combination of the two
88971371|NCT00138736|Experimental|A|MBL until the patient's absolute neutrophil count (ANC) is above 500/microL blood.
88971372|NCT03136497|Experimental|ABT-199 Plus Ibrutinib and Rituximab|Cycle length will be 28 days. Venetoclax will be administered orally QD (Once Daily), continuously for 24 cycles. Ibrutinib will be administered orally QD, continuously for 24 cycles. Rituximab will be administered IV per institutional standards. weekly X 4 (Cycle 1); once on Day 1 of cycles 2-6 only, then every other cycle until Cycle 24 (total 18 doses of Rituxan from C1D1), Commercially available rituximab IV will be used.
88971373|NCT00141193|Placebo Comparator|A|
88971374|NCT03093051|Experimental|UPT Treatment|Investigational therapy (UPT)
89575262|NCT02554513|Active Comparator|Sound Production Treatment (SPT)|An articulatory-kinematic treatment that uses integral stimulation to improve speech production.
89575263|NCT04570969|No Intervention|standard of care|Peri-operative analgesia by opioids
89575264|NCT04570969|Experimental|Peri operative regional analgesia|Peri-operative analgesia by Continuous bilateral Erector Spinae Catheters
89575265|NCT05471635||Countries worldwide|Every country in the world for which vaccination data were available and variables of interest were accessible.
89575266|NCT03383419|Experimental|Treatment|Epclusa® will be started within 14 days of quantifiable viremia and continued for 12 weeks. Within 24 hours prior to first-dose of treatment, HCV genotype will be sent from transplant recipient.
89575267|NCT02554903|Experimental|Macitentan 10 mg po|Approximately 78 adult subjects with PH post-LVAD implantation will be randomized (1:1) to receive either macitentan 10 mg, or matching placebo, once daily orally.
89575268|NCT02554903|Placebo Comparator|Placebo sugar pill|Approximately 78 adult subjects with PH post-LVAD implantation will be randomized (1:1) to receive either macitentan 10 mg, or matching placebo, once daily orally.
89575269|NCT03329131|Experimental|Cryotherapy|Each patient will receive cryotherapy administered during each neurotoxic chemotherapy agent infused treatments by Elasto gel™ Hypothermia gloves and socks. Patients will wear the glove and sock for 15 minutes prior to treatment start and 15 minutes following treatment completion, for a total of 30 minutes.
89575270|NCT03328195|Active Comparator|Neuro RX Gamma synchronous|Neuro RX Gamma device delivering near infra-red light through four diodes positioned over the scalp and one positioned inside the nostril.The synchronous device delivers a synchronized pulse frequency of 40 Hz from all LED clusters.
89575271|NCT03328195|Sham Comparator|Sham light therapy|Sham Neuro RX Gamma device having the same appearance and sound as the Neuro RX Gamma device but does not emit the near-infrared light.
89575272|NCT03328195|Active Comparator|Neuro RX Gamma asynchronous|Neuro RX Gamma device delivering near infra-red light through four diodes positioned over the scalp and one positioned inside the nostril. The asynchronous device alternatively delivers pulses from the intranasal and anterior LEDs vs. from the posterior LEDS.
89575273|NCT05482087|Experimental|XZP-3621|XZP-3621 single agent,500 mg oral tables，QD，continuously
89575274|NCT02332707|Experimental|A1: GT1 NC GZR+UPR+EBR (8 weeks)|In Part A, HCV GT1-infected NC participants will take GZR 100 mg + UPR 300 mg + EBR 50 mg q.d. by mouth for 8 weeks.
89575275|NCT02332707|Experimental|A2: GT1 NC GZR+UPR+RZR (8 weeks)|In Part A, HCV GT1-infected NC participants will take GZR 100 mg + UPR 300 mg + RZR 60 mg q.d. by mouth for 8 weeks.
89575276|NCT02332707|Experimental|A3: GT2 NC GZR+UPR+EBR (8 weeks)|In Part A, HCV GT2-infected NC participants will take GZR 100 mg + UPR 300 mg + EBR 50 mg q.d. by mouth for 8 weeks.
89575277|NCT02332707|Experimental|A4: GT2 NC GZR+UPR+RZR (8 weeks)|In Part A, HCV GT2-infected NC participants will take GZR 100 mg + UPR 300 mg + RZR 60 mg q.d. by mouth for 8 weeks.
88971375|NCT00404443|Sham Comparator|1|arm 1: placebo needle
88971376|NCT00404521|Experimental|Arm 1|
88971377|NCT04726696|No Intervention|Control group|None intervention to be administered, they continue their normal routine.
88971378|NCT04726696|Experimental|Intervention group|ROLE-AP is a multifaceted program offered over a month period to participating primary care nurses and includes three interactive workshops. Each workshop will be 4 hours long.
88971379|NCT02972073|Experimental|Exercise intervention|"There are 4 different exercise interventions (4 independent intervention studies) based on different concepts in this entire project. Interventions include:~core stabilization exercise~movement system impairment approach~neuromuscular activation using suspension~kinematic linkage imbalance"
88971380|NCT02972073|No Intervention|Healthy control|This healthy control group will be informed to maintain usual daily activities and avoid participating in activities that involve trunk muscle exercise
88971381|NCT00141544|Experimental|1|
88971382|NCT00141544|Active Comparator|2|
88971383|NCT03584594||Presepsin assessment|Residual blood samples after performing all necessary blood examinations and analyses will be used to determine the level of presepsin, as the potential new biomarker of infection.
88971384|NCT00141661|Experimental|Low Dose Arm|
88971385|NCT00141661|Experimental|High Dose Arm|
88971386|NCT00141661|Placebo Comparator|Placebo Control|
88971387|NCT00141856|Other|1|
88971388|NCT00141895|Active Comparator|A|Vaginal Cytotec at doses of 400 microgram every 4 hours until delivery
88971389|NCT00141895|Active Comparator|B|Sublingual Cytotec at doses of 400 microgram every 4 hours until delivery
88971390|NCT00142051|Experimental|1|inhaled NO
88971391|NCT00142051|Placebo Comparator|2|room air inhalation
88971392|NCT00142090|Experimental|2|3% Hypertonic saline
88971393|NCT00142090|Placebo Comparator|1|Normal saline
88971394|NCT02825979|Active Comparator|Cryoballoon-based PVI|"Sinus rhythm control via a pulmonary vein isolation (PVI) (first-line) procedure utilizing the the Arctic Front Cryoballoon Procedure."
88971395|NCT02825979|Active Comparator|Anti-Arrhythmic Drug Therapy|"Sinus rhythm control via the use of anti-arrhythmic drug (AAD) therapy (first-line) based on local clinical practice, and according to guideline-suggested drug management for symptomatic patients with paroxysmal AF."
89209197|NCT00806936||B|
89209198|NCT00807170|Experimental|ZACTIMA TM|
88971396|NCT00142207|Active Comparator|1|Drug: Intermittent preventive treatment:sulphadoxine-pyrimethamine
88971397|NCT00142207|Active Comparator|2|Device: Insecticide-treated mosquito bed net
88971398|NCT00142207|Active Comparator|3|"Combination of Drug + Device:~Drug: Intermittent preventive treatment:sulphadoxine-pyrimethamine Device: Insecticide-treated mosquito bed net"
88971399|NCT02290886|Placebo Comparator|Placebo|Intravenous administration of placebo
88971400|NCT02290886|Experimental|1 million of MSC|Intravenous administration of 1 million of MSC/ kg
88971401|NCT02290886|Experimental|2 million of MSC|Intravenous administration of 2 million of MSC/ kg
89575278|NCT02332707|Experimental|A5: GT1 NC GZR+UPR+EBR (8 weeks)|In Part A, HCV GT1-infected NC participants will take GZR 100 mg + UPR 450 mg + EBR 50 mg q.d. by mouth for 8 weeks.
89575279|NCT02332707|Experimental|A6: GT1 NC GZR+UPR+RZR (8 weeks)|In Part A, HCV GT1-infected NC participants will take GZR 100 mg + UPR 450 mg + RZR 60 mg q.d. by mouth for 8 weeks.
89575280|NCT02332707|Experimental|B7: GT2 NC GZR+UPR+EBR (8 weeks)|In Part A, HCV GT2-infected NC participants will take GZR 100 mg + UPR 450 mg + EBR 50 mg q.d. by mouth for 8 weeks.
89575281|NCT02332707|Experimental|A8: GT2 NC GZR+UPR+RZR (8 weeks)|In Part A, HCV GT2-infected NC participants will take GZR 100 mg + UPR 450 mg + RZR 60 mg q.d. by mouth for 8 weeks. In Part B, HCV GT2-infected NC participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 8 weeks.
89575282|NCT02332707|Experimental|B9: GT1 NC GZR+UPR+RZR (12 weeks)|In Part B, HCV GT1-infected NC participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 12 weeks.
89575283|NCT02332707|Experimental|B10: GT2 NC GZR+UPR+RZR (8 weeks) + RBV|In Part B, HCV GT2-infected NC participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 8 weeks. Participants will also take RBV b.i.d. at a total daily dose of 800-1600 mg based on body weight.
89575284|NCT02332707|Experimental|B11: GT2 NC GZR+UPR+RZR (12 weeks)|In Part B, HCV GT2-infected NC participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 12 weeks.
89575285|NCT02332707|Experimental|B12: GT1 C GZR+UPR+RZR (8 weeks)|In Part B, HCV GT1-infected C participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 8 weeks.
89575286|NCT02332707|Experimental|B13: GT1 C GZR+UPR+RZR (12 weeks)|In Part B, HCV GT1-infected C participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 12 weeks.
89575287|NCT02332707|Experimental|B14: GT2 C GZR+UPR+RZR (12 weeks)|In Part B, HCV GT2-infected C participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 12 weeks.
89575288|NCT02332707|Experimental|B15: GT2 C GZR+UPR+RZR (12 weeks) + RBV|In Part B, HCV GT2-infected C participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 12 weeks. Participants will also take RBV b.i.d. at a total daily dose of 800-1600 mg based on body weight.
89575289|NCT02332707|Experimental|B16: GT2 C GZR+UPR+RZR (16 weeks)|In Part B, HCV GT2-infected C participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 16 weeks.
89575290|NCT02332707|Experimental|B6: GT1 NC GZR+UPR+RZR (8 weeks)|In Part B, HCV GT1-infected NC participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 8 weeks.
89575291|NCT02332707|Experimental|B8: GT2 NC GZR+UPR+RZR (8 weeks)|In Part B, HCV GT2-infected NC participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 8 weeks.
89575292|NCT02370615|Experimental|Cohort 1: TAK-272 + Itraconazole|TAK-272 40 mg, tablet, orally, once on Day 1 and 10, followed by Itraconazole 200 mg, solution, orally, twice on Day 4, further followed by Itraconazole 200 mg, solution, orally, once from Day 5 to 12.
89575293|NCT02370615|Experimental|Cohort 2: Midazolam + Digoxin + TAK-272|Midazolam 2 mg, syrup, and Digoxin 0.25 mg, tablet, orally, once on Day 1 and 7, followed by TAK-272 80 mg, tablet, orally, once from Day 3 to 8.
89575294|NCT02307513|Experimental|Placebo / Apremilast|Participants randomized to this arm will receive placebo tablets twice daily by mouth for the first twelve weeks followed by 52 weeks of 30 mg apremilast tablets twice daily by mouth.
88811141|NCT04199117|Experimental|Incentive,Untailored,No Care Manage,Standard Treatment|Participants randomly assigned to this condition will have access to incentives for completing a first smoking cessation counseling call up to 4 times over 2 years, will receive 5 untailored letters promoting use of smoking cessation treatment over 2 years, will not receive Tobacco Care Management support and motivational encouragement calls, and will have access to standard smoking cessation treatment (referral to the state tobacco quitline and/or their primary care provider) over 2 years.
88811142|NCT04199117|Experimental|No Incentive,Tailored,Care Manage,Intensive Treatment|Participants randomly assigned to this condition will have not access to incentives for completing smoking cessation counseling, will receive 5 tailored letters promoting use of smoking cessation treatment over 2 years, will receive 5 Tobacco Care Management support and motivational encouragement calls over 2 years, and will have access to 3 smoking cessation quit counseling calls and 12-weeks of either combination nicotine replacement or varenicline up to 4 times over 2 years.
88971402|NCT02290886|Experimental|4 million of MSC|Intravenous administration of 4 million of MSC/ kg
89575295|NCT02307513|Experimental|Apremilast|Participants randomized to this arm will receive 30 mg apremilast tablets twice daily by mouth for 64 weeks.
88971403|NCT00142246|Experimental|1|Intermittent preventive treatment with antimalarial drug combination(SP and amodiaquine)
88971404|NCT00142246|Placebo Comparator|2|Dual placebo comparator
89029198|NCT04044794|Experimental|Daily Self-Weighing|Participants randomly assigned to this arm will receive standardized weight management educational materials plus a commercially available wireless scale. Participants will be instructed to weigh daily and view their weight on the scale's digital display.
89029199|NCT04004416|Placebo Comparator|Healthy Controls|
89029200|NCT04004416|Experimental|Early Psychosis patients|
89029201|NCT04004416|Experimental|Schizophrenia or Schizoaffective disorder patients|
89029202|NCT04004416|Experimental|Bipolar disorder patients|
89029203|NCT04003363||Participants with Myotonic Dystrophy|
89575296|NCT02332239|Experimental|iDOVE Intervention (ED+text)|"In-ED brief session, introducing basic principles of cognitive behavioral theory and the structure of the text-message portion of the intervention~Eight-week longitudinal tailored CBT-based text-message program"
89575297|NCT02332239|Placebo Comparator|Control (EUC)|"In-ED brief session, discussing home safety & nutrition~Eight-week longitudinal home safety & nutrition text-message program"
89575298|NCT02370537|Experimental|Sequence AB|A single dose of EPANOVA® 4 g (administered as 4 x 1 g capsules) at Visit 4, followed by 10 to 14 days washout, followed by a single dose of OMACOR® 4 g (administered as 4 x 1 g capsules) at Visit 7.
89575299|NCT02370537|Experimental|Sequence BA|A single dose of OMACOR® 4 g (administered as 4 x 1 g capsules) at Visit 4, followed by 10 to 14 days washout, followed by a single dose of EPANOVA® 4 g (administered as 4 x 1 g capsules) at Visit 7.
88971405|NCT00142480|Experimental|Capecitabine, Oxaliplatin, Bevacizumab|There are two phases of study treatment. Phase I includes all patients and will last 6 weeks. During this phase, oxaliplatin will be given intravenously (IV) on days 1, 8, 22, and 29; bevacizumab will be given IV on days 1, 15, and 29; capecitabine will be administered orally on days 1-14 and 22-35. Radiation therapy will be given once daily for 5 days (Monday-Friday) per week for a total of 28 treatments. Phase II has two groups: 1) patients who had tumors removed prior to entering study and 2) patients who entered the study with advanced disease. Patients who had their tumors removed prior to entering the study will be treated with the above 6-week regimen twice for a total of 12 weeks of treatment. Patients who were unresectable prior to entering the study but then were deemed resectable after treatment on trial will undergo resection. Following surgical recovery (8-10 weeks) they will be treated again with the above 6-week regimen twice for a total of 12 weeks of treatment.
88971406|NCT02806050|Experimental|Palbociclib and FES PET|To evaluate whether low uptake on FES-PET at baseline is related to non-response to letrozole plus palbociclib treatment.
89575300|NCT02330055|Active Comparator|Forty-five degrees elevated upper body position|"If the patient is randomized in this study arm after enrollment, the investigators will elevate the patients upper body to 45 degree prior to sleeping. The patient will wear a pulseoximeter (WristOx Model 3150) during the night. The investigators will collect the SpO2 and pulse rate with this device and then quantify desaturation events.~The investigators will ask the patient to fill out a questionnaire, which includes the P-SAP score, the STOP-BANG score, the Epworth Sleepiness Scale and the self-reported pain."
89575301|NCT02330055|Placebo Comparator|Non-elevated upper body position|"If the patient is randomized in this study arm after enrollment, the investigators will flatten the patients upper body to a supine position prior to sleeping. The patient will wear a pulseoximeter (WristOx Model 3150) during the night. The investigators will collect the SpO2 and pulse rate with this device and then quantify desaturation events.~The investigators will ask the patient to fill out a questionnaire, which includes the P-SAP score, the STOP-BANG score, the Epworth Sleepiness Scale and the self-reported pain."
89575302|NCT02306265|Other|DBT and FFDM|Subjects will undergo 2D breast imaging with full-field digital mammography (FFDM) device (active comparator) and 3D breast imaging with digital breast tomosynthesis (DBT) device (experimental).
89575303|NCT02329743|Experimental|RX-10045 0.05% nanomicellar solution|topical eye drops
89575304|NCT02329743|Experimental|RX-10045 0.1% nanomicellar solution|topical eye drops
89575305|NCT02329743|Placebo Comparator|Vehicle|topical eye drops
89575306|NCT04896567|Experimental|Intervention|Patients will have kidney biopsy designated for cell isolation and culture.
89575307|NCT02329431|Experimental|activation curriculum|Psycho-social curriculum teaching activation skills
89575308|NCT02329431|Active Comparator|support group|Parent-directed support group
89575309|NCT02328105|Experimental|Carboplatin + Abraxane|Carboplatin (AUC = 6; on Day 1) plus Abraxane (nab-paclitaxel; 100 mg/m^2; Days 1, 8, 15) for 6 21-day cycles. Treatment was discontinued if: disease progression, unacceptable toxicity, withdrawn consent, or completion of treatment
89575310|NCT02305797|Experimental|EDG004|EDG004 - Extended release lorazepam capsules
89575311|NCT02305797|Placebo Comparator|Placebo|Placebo
89575312|NCT01646073|Experimental|Adalimumab|Adalimumab 40 mg every other week (eow)
88971407|NCT00142753|Active Comparator|A1: ATN 024 Energix-B Standard Adult Dose|
88971408|NCT00142753|Experimental|A2: ATN 024 Engerix-B Increased Adult Dose|
88971409|NCT00142753|Active Comparator|A3: ATN 024 Twinrix Standard Adult Dose|
88971410|NCT00142753|Experimental|B1: ATN 025 Recombivax|
89575313|NCT01646073|Placebo Comparator|Placebo|placebo
89575314|NCT02328027|Experimental|99mTc-rhAnnexin V-128, i.v.|Patients will receive 2 administrations of the 99mTc-rhAnnexin V-128 medical imaging agent: one at Day 1 and the other at Day 42.
89575315|NCT02551159|Experimental|Monotherapy|MEDI4736 monotherapy.
89575316|NCT02551159|Experimental|Combination Therapy|MEDI4736+Tremelimumab combination therapy
89575317|NCT02551159|Active Comparator|Standard of Care|Standard of Care treatment
89575318|NCT05482009||Strong exposure group of traditional Chinese medicine|receiving traditional Chinese medicine treatment + basic western medicine treatment, the cumulative time of traditional Chinese medicine treatment reaches more than 80% of the total course of treatment
88971411|NCT00142753|Experimental|B2: ATN 025 Twinrix|
88971412|NCT00142831|Experimental|1|Bupropion-SR, 150 mg/day x 3 days, then 300 mg/day for 13 weeks
89209199|NCT00799526|Experimental|Ex Vivo Transplantation|Autologous Ex Vivo Conjunctival Epithelial Cell Expansion for Symblepharon Transplantation
89575319|NCT05482009||Moderate Chinese medicine exposure group|received Chinese medicine treatment + western medicine basic treatment, the cumulative time of Chinese medicine treatment reached 30%-79% of the total course of treatment
89575320|NCT05482009||Weak exposure group of traditional Chinese medicine|receiving traditional Chinese medicine treatment + basic western medicine treatment, the cumulative time of traditional Chinese medicine treatment is less than 30% of the total course of treatment
89575321|NCT05482009||Western medicine group|receive basic western medicine treatment only
88971413|NCT00142831|Placebo Comparator|2|Identical Placebo
88971414|NCT00142870|Placebo Comparator|A|
88971415|NCT00142948|Experimental|Naltrexone|Naltrexone Oral 50 mgs daily
89575322|NCT04539379|Active Comparator|magnesium sulfate|intravenous infusion of magnesium sulfate at a dose of 4 gm intravenously over 20 min as a loading dose then MgSO4 intravenous infusion is continued at a rate of 1 gm/h for 24 h or until obtain and stabilize the targeted blood pressure..
89575323|NCT04539379|Active Comparator|labetolol|The patients will be given intravenous infusion of labetolol (Trandate™, 5mg/ml) available in 20 ml ampoules containing 100mg labetalol (5mg/ml). Starting the infusion with 20mg/h and then titrate to obtain and stabilize the targeted blood pressure by adjusting the infusion as required every 15 - 30min to a maximum dose of 160mg/hr.
89575324|NCT04529473|Placebo Comparator|Placebo|1 capsule per day, consumed orally, before breakfast for the duration of the study.
89575325|NCT04529473|Experimental|Eubacterium hallii|1 capsule per day, consumed orally, before breakfast for the duration of the study.
89575326|NCT05470153|Active Comparator|Asthma with Obstructive Sleep Apnea on treatment|"Over the following 6 months of recruiting the study population with severe asthma the following will be monitored EVERY MONTH:~Level of asthma control: Asthma Control Test/GINA guidelines Excessive Daytime Sleepiness using Epworth Sleepiness Scale. Rate of exacerbations/hospitalization Continuous Positive Airway Pressure (CPAP) compliance: where acceptable compliance is defined as minimum of CPAP use of >/= 4 hrs/70% nights (if applicable), In one month, 3month, 6 month duration Apnea/Hypopnea Index as per CPAP reading (if applicable)"
89575327|NCT05470153|No Intervention|Asthma with Obstructive Sleep Apnea whom refused treatment|"Over the following 6 months of recruiting the study population with severe asthma the following will be monitored EVERY MONTH:~Level of asthma control: Asthma Control Test/GINA guidelines Excessive Daytime Sleepiness using Epworth Sleepiness Scale. Rate of exacerbations/hospitalization"
89575328|NCT05470153|No Intervention|Asthma without Obstructive Sleep Apnea|"Over the following 6 months of recruiting the study population with severe asthma the following will be monitored EVERY MONTH:~Level of asthma control: Asthma Control Test/GINA guidelines Excessive Daytime Sleepiness using Epworth Sleepiness Scale. Rate of exacerbations/hospitalization"
89575329|NCT05470075|Experimental|Experimental A: HR18042 175mg|
89575330|NCT05470075|Experimental|Experimental B: HR18042 225mg|
89575331|NCT05470075|Experimental|Experimental C: HR18042 275mg|
89575332|NCT05470075|Active Comparator|Active Drug Comparator：Tramadol hydrochloride SR Tablets 100mg|
89575333|NCT05470075|Placebo Comparator|Placebo Comparator: Placebos match to HR18042 and Tramadol hydrochloride SR Tablets|
89575334|NCT05476627||Hypertension Group|
89575335|NCT05476627||Diabetes Group|
89575336|NCT05476627||Hyperuricemia|
89575337|NCT05476627||Obesity|
89575338|NCT05481619|Active Comparator|Group of UC patients treated with vedolizumab|Generic Name：vedolizumab Specification：300mg/bottle Dosage and Method of Administration：Usual adult dose for ulcerative colitis.300 mg IV every 30 minutes at weeks 0, 2, and 6, then every 8 weeks
89575339|NCT05481619|No Intervention|Normal control group|On the basis of the exclusion criteria, there are no significant intestinal inflammatory, autoimmune or neoplastic disorders.
89575340|NCT05476471|Experimental|intervention arm|The intervention consisted of one 60-minutes group exercise session once a week in first 8 weeks, and self-management in next 8 weeks
89575341|NCT05476471|No Intervention|control arm|The control arm received an education leaflet.
89575342|NCT05481385|Experimental|Test preparation|Ezetimibe tablets: specification: 10mg; Package specification: 7 pieces / plate, 1 plate / box; Produced and provided by Changzhou Pharmaceutical Factory Co., Ltd.
89575343|NCT05481385|Active Comparator|Reference preparation|Ezetimibe Tablets Ezetrol ®; Specification: 10mg, packaging specification: 10 pieces / plate, 1 plate / box; Licensee: MSD Pharma (Singapore) PTE. Ltd
89575344|NCT02305563|Experimental|Ulocuplumab + low dose Cytarabine|Ulocuplumab + low dose Cytarabine (LDAC) Phase 1 (escalation cohort) - closed for enrollment
89575345|NCT02305563|Experimental|Ulocuplumab Dose A + low dose Cytarabine|Ulocuplumab Dose A + low dose Cytarabine Phase 2 (expansion cohort)
89575346|NCT02305563|Experimental|Ulocuplumab Dose B + low dose Cytarabine|Ulocuplumab Dose B + low dose Cytarabine Phase 2 (expansion cohort)
89575347|NCT02305563|Other|low dose Cytarabine only|Low Dose Cytarabine only Phase 2 (expansion cohort)
89575348|NCT02327325|Experimental|Physical Activity Only|12-week home-based physical activity program with telephone support. Delivered by a physical therapist and exercise counselor. Comprehensive program including stretching, strengthening and aerobic activity.
89575349|NCT02327325|Experimental|Physical Activity + Cognitive Behavioral Therapy|12-week combined home-based physical activity and cognitive behavioral program with telephone support. Delivered by a physical therapist and exercise counselor. Comprehensive physical activity program including stretching, strengthening and aerobic activity. Cognitive behavioral component includes training in multiple skills for managing pain.
89575350|NCT02327325|No Intervention|Wait List Control Group|Will receive the physical activity only or physical activity + cognitive behavioral therapy (based on participant choice) after completing all follow-up assessments.
89575351|NCT02304705|Placebo Comparator|Placebo|Placebo three times per day, orally
89575352|NCT02304705|Active Comparator|Sildenafil|Sildenafil 20 mg three times per day, orally
89575353|NCT02553499|Experimental|MK-1248|Participants received escalating doses of MK-1248 at assigned dose (dose range: 0.12 mg to 170 mg MK-1248) via intravenous (IV) infusion on Day 1 of each 21-day cycle for up to 4 cycles (up to ~3 months).
89575354|NCT02553499|Experimental|MK-1248 + Pembrolizumab|Participants received escalating doses of MK-1248 at assigned dose (dose range: 0.12 mg to 60 mg MK-1248) via IV infusion on Day 1 of each 21-day cycle for a maximum of 4 cycles (up to ~3 months) PLUS pembrolizumab 200 mg via IV infusion on Day 1 of each 21-day cycle for up to 35 cycles (up to ~24 months).
89575355|NCT04507009|Active Comparator|Control|Traditional treatment group which alvogyl applied to the socket after irrigation
89575356|NCT04507009|Experimental|Ozone|Ozone group which Ozone (O3) applied after irrigation of the socket
89575357|NCT04507009|Experimental|CGF +Ozone|CGF + Ozone group which concentrated growth factor (CGF) after Ozone (O3) applied followed by irrigation of the socket.
88971416|NCT00142948|Placebo Comparator|Placebo|1 to 1 comparison of Naltrexone to placebo
88971417|NCT02780427|Active Comparator|1-6 months (Group 1)|
88971418|NCT02780427|Active Comparator|7-12 months (Group 2)|
89575358|NCT04468789||Comparison group|Patients eligible for six-month dispensing receiving care at comparison sites.
89575359|NCT04468789||Intervention group|Patients eligible for six-month dispensing receiving care at intervention sites.
89575360|NCT02553421|Experimental|Pilot|A non-alarming ivWatch device will monitor the IV sites of these subjects. The goal of this small pilot study is to give clinicians an opportunity to perform the protocol and operate the ivWatch device and to give researchers the ability to make adjustments prior to starting the subsequent non-alarming group.
89575361|NCT02553421|Experimental|Non-alarming|150 patients will be enrolled in the non-alarming group. The ivWatch device will monitor the IV sites but will not issue infiltration notifications.
89575362|NCT02553421|Experimental|Alarming|150 patients will be enrolled in the alarming group. The IV sites will be monitored with the ivWatch Model 400 infiltration notifications enabled.
89575363|NCT04270591|Other|SCC244 300mg|Phase Ib: SCC244 300mg, QD Phase II: SCC244 300mg, QD
89575364|NCT02549287|Experimental|SafeCare|SafeCare, an evidence-based home visiting program
89575365|NCT02549287|Active Comparator|Supportive Case Management|Child welfare services as usual
89575366|NCT05469451|Experimental|Group 1: irradiated with low power laser (940nm)|Irradiated with a low power density laser of 940 (nm), 100 megawatt, which will be calibrated and the result of the calibration will be checked with the use of the power meter. The equipment used will be a diode laser (BIOLASE™), the area to be irradiated will be the anterior segment of the lower arch, each tooth will be irradiated for a time of 10 seconds on the vestibular surfaces of the teeth and 10 seconds on the lingual surfaces of the teeth, both at gingival level and at apical level in scanning mode.
89575367|NCT05469451|Placebo Comparator|Group 2: Simulated that they were irradiated.|Group 2: it was simulated that they were irradiated.
89575368|NCT04505527|Active Comparator|Recurrent fallers - control group|In this control arm, older adults will have a typical forward walking training that mirror the lateral stepping intervention: 3 days/week for 6 weeks, resulting in a total of eighteen sessions. Each session consists of six trials of 3 min forward walking. The participants can increase their pace at the start of each trial but may not decrease it at the next session.
89575369|NCT04505527|Experimental|Recurrent fallers - intervention group|In this experimental arm, older adults will have a lateral stepping intervention: 3 days/week for 6 weeks, resulting in a total of eighteen sessions. Each session consists of six trials of 3 min sideways walking across a 10 m walkway changing body direction at the ends, thus alternating lead and lag limbs. The participants can increase their pace at the start of each trial but may not decrease it at the next session.
89575370|NCT04505527|Experimental|Older non-fallers intervention group|In this experimental arm, older adults will have a lateral stepping intervention: 3 days/week for 6 weeks, resulting in a total of eighteen sessions. Each session consists of six trials of 3 min sideways walking across a 10 m walkway changing body direction at the ends, thus alternating lead and lag limbs. The participants can increase their pace at the start of each trial but may not decrease it at the next session.
89575371|NCT04505527|Active Comparator|Younger adult control group|Outcome measures from a young healthy group will also be measured as a reference. Will be used to compare outcome measured between older and young adults. Young adults will have a lateral stepping intervention: 3 days/week for 6 weeks, resulting in a total of eighteen sessions. Each session consists of six trials of 3 min sideways walking across a 10 m walkway changing body direction at the ends, thus alternating lead and lag limbs. The participants can increase their pace at the start of each trial but may not decrease it at the next session.
88971419|NCT02780427|Active Comparator|13-18 months (Group 3)|
88971420|NCT02780427|Active Comparator|19-24 months (Group 4)|
88971421|NCT03487913|Experimental|High dose lixivaptan / CKD1 or CKD2|Oral high dose lixivaptan in participants with CKD1 or CKD2
88971422|NCT03487913|Experimental|Low dose lixivaptan / CKD1 or CKD2|Oral low dose lixivaptan in participants with CKD1 or CKD2
88971423|NCT03487913|Experimental|High dose lixivaptan / CKD3|Oral high dose lixivaptan in participants with CKD3
88971424|NCT03487913|Experimental|Low dose lixivaptan / CKD3|Oral low dose lixivaptan in participants with CKD3
88971425|NCT02756247|Experimental|Buparlisib and Ibrutinib|"This is a two stage protocol comprised of a single institution phase Ib dose escalation trial. The first stage is a standard 3+3 phase I dose escalation trial to assess the safety of buparlisib and ibrutinib. The second stage is a single center expansion cohort in MCL, FL and DLBCL respectively evaluating the efficacy of buparlisib and ibrutinib combination.~Treatment will be with ibrutinib orally daily and buparlisib orally daily. A cycle is defined as 4 weeks of therapy. Therapy will continue until disease progression, intolerable toxicities or death with a maximum duration for 36 cycles, not exceeding 36 months on therapy."
88971426|NCT00404677|Placebo Comparator|Standard|Methacholine challenges are performed using the standardized two minute tidal breathing method
88971427|NCT00404677|Active Comparator|Modified|Five deep inhalation maneouvers are incorporated into the standardized methacholine challenge
88971428|NCT03387878|Other|Single Arm Study|This is a single arm study with no comparator
88971429|NCT02431923||EVD Close Contacts|At least one of the following:-Household contact of survivor at time of or since EVD event-Sexual contact with survivor since EVD event-Other selected contacts
89575372|NCT02553265|Placebo Comparator|Placebo|Matching placebo
89575373|NCT02553265|Experimental|Low-Dose Carbidopa|
89575374|NCT02553265|Active Comparator|High-Dose Carbidopa|
89575375|NCT04269967||Tele-rehabilitation|Patients who choose tele-rehabilitation
88971430|NCT02431923||EVD Survivors|Subject listed on the Ministry of Health registry for Ebola survivors
88971431|NCT02431923||Non Contact Controls|Selected Controls
88971432|NCT04726267|Other|Glaucoma patients who was scheduled for trabeculectomy|Wide-field OCT was performed 1-2 weeks before the trabeculectomy. The OCT was done postoperatively at 1 month, 3 months, 6 months and 12 months after surgery.
88971433|NCT02972216||Nolbaxol|For Nonsmall Cell Lung Cancer (NSCLC) Docetaxel (either Group I or Group II) 60 mg/m2 will be administrated by intravenous infusion for 1 hour every 3 weeks (a study medication cycle) and up to 4 study medication cycles throughout this study. For Squamous Cell Carcinoma of the Head and Neck (SCCHN) Docetaxel (either Group I or Group II) 60 mg/m2 will be administrated by intravenous infusion for 1 hour followed by cisplatin 60 ~ 75 mg/m2 for 1-3 hours or based on the general practice of the site every 3 weeks and up to 4 study medication cycles throughout this study.
89575376|NCT04269967||Usual care|Patients who choose usual (rehabilitation) care
89575377|NCT05480839|Experimental|Manual Immediately Sequential Bilateral Cataract Surgery (MCS)|
89575378|NCT05480839|Experimental|Refractive Laser-Assisted Immediately Sequential Bilateral Cataract Surgery (ReLA-ISBCS) Early|
89575379|NCT05480839|Experimental|Refractive Laser-Assisted Immediately Sequential Bilateral Cataract Surgery (ReLA-ISBCS) Standard|
89575380|NCT02561195|Experimental|Low-dose C. difficile Vaccine (accelerated schedule)|
89575381|NCT02561195|Experimental|High-dose C. difficile Vaccine (accelerated schedule)|
89575382|NCT02561195|Placebo Comparator|Placebo (accelerated schedule)|
89575383|NCT02561195|Experimental|Low-dose C. difficile Vaccine (non-accelerated schedule)|
89575384|NCT02561195|Experimental|High-Dose C. difficile Vaccine (non-accelerated schedule)|
89575385|NCT02561195|Placebo Comparator|Placebo (non-accelerated schedule)|
89575386|NCT01663103|Experimental|Rilonacept|12 weeks of treatment with rilonacept
89575387|NCT01663103|Placebo Comparator|Placebo|Twelve weeks of treatment with placebo
89575388|NCT05509673|Experimental|Intervention group|The intervention group received a fat grafting under the wound bed and into the wound edges.
89575389|NCT05509673|No Intervention|Control group|The control group received an injection of saline solution (0.9%) under the wound bed and into the wound edges.
89575390|NCT05501951|Experimental|right DLPFC tDCS|Participants in this group will receive 10 sessions of right DLPFC tDCS
89575391|NCT05501951|Experimental|right OFC tDCS|Participants in this group will receive 10 sessions of right OFC tDCS
89575392|NCT05501951|Sham Comparator|Control group|Participants in this group will receive 10 sessions of sham stimulation
89575393|NCT05303753|Other|Single group|During a 3-week baseline period, participants with self-reported GI complaints consume their own protein supplement that they use for recovery purposes after exercise, followed by a 3-week intervention period in which they maintain usage of their own product, but replace a part of this product with a fermented dairy protein with prebiotic fiber. An additional reference group of athletes without self-reported GI complaints will also be followed during a 3-week period in which they consume their own protein supplement that they use for recovery purposes after exercise.
89575394|NCT04281797||Kidney transplant recipients|Patients received kidney transplantation, with a baseline pre-transplant fecal sample and post-transplant samples collected. Standard transplantation procedures and precautions are being performed.
89575395|NCT04281797||HSCT-recipients|Patients received hematopoietic stem cells transplantation, with a baseline pre-transplant fecal sample and post-transplant samples collected. Standard transplantation procedures and precautions are being performed.
89575396|NCT04281797||MSCT-recipients|Patients received mesenchymal stem cells transplantation, with a baseline pre-transplant fecal sample and post-transplant samples collected. Standard transplantation procedures and precautions are being performed.
89575397|NCT04281797||Liver transplant recipients|Patients received liver transplantation, with a baseline pre-transplant fecal sample and post-transplant samples collected. Standard transplantation procedures and precautions are being performed.
89575398|NCT05501639||tiotropium + inhaled corticosteroids (ICS) group|
89575399|NCT05501639||long-acting β2-agonists (LABA) + inhaled corticosteroids (ICS) group|
89575400|NCT05501405|Experimental|Schizophrenic patients|Electroencephalogram and eye-tracking recordings Behavorial tests
89575401|NCT05501405|Experimental|Autism Spectrum Disorder (ASD) patients|Electroencephalogram and eye-tracking recordings
89029204|NCT03972202|Experimental|Patients with cerebellar ataxia (CA)|Behavioral testing including various speaking tasks Magnetic resonance imaging (MRI)
89029205|NCT03972202|Active Comparator|Matched controls|Behavioral testing including various speaking tasks Magnetic resonance imaging (MRI)
89575402|NCT05501405|Experimental|22q11.2 DS patients|Electroencephalogram and eye-tracking recordings Behavorial tests
89575403|NCT05501405|Experimental|Williams syndrome patients|Electroencephalogram and eye-tracking recordings Behavorial tests
89575404|NCT05501405|Experimental|Präder Willi syndrome patients|Electroencephalogram and eye-tracking recordings Behavorial tests
88811143|NCT04199117|Experimental|No Incentive,Tailored,Care Manage,Standard Treatment|Participants randomly assigned to this condition will not have access to incentives for completing smoking cessation counseling, will receive 5 tailored letters promoting use of smoking cessation treatment over 2 years, will receive 5 Tobacco Care Management support and motivational encouragement calls over 2 years, and will have access to standard smoking cessation treatment (referral to the state tobacco quitline and/or their primary care provider) over 2 years.
89029206|NCT03972202|Experimental|Additional healthy volunteers|Behavioral testing including various speaking tasks Magnetic resonance imaging (MRI) Transcranial magnetic stimulation (TMS)
89575405|NCT05501405|Active Comparator|Control participants|Electroencephalogram and eye-tracking recordings Behavorial tests
89575406|NCT05509361|Experimental|AK101 135mg|"Subjects who have completed AK101-302 receive AK101 135mg injection subcutaneously every 12 weeks.~Subjects newly enrolled receive AK101 135mg injection subcutaneously at Week 0, 4 and then every 12 weeks."
89575407|NCT05509205||Patients with stroke|In this study 130 patients with stroke who are treating with stroke rehabilitation programs, will be included.
89575408|NCT04285697|Experimental|group 1|During the outpatient clinic visit, an information leaflet will be given about the subjects that should be considered for prevention of SSI before surgery. 2% mupirocin ointment will be applied to the nostrils with the swab twice-daily before surgery and once on the morning of surgery. Body cleaning will be done with 4% chlorhexidine gluconate shower the night before the surgery. Prophylactic antibiotics by weight will be administered within 60 minutes of anesthesia induction. The planned aseptic technique will be applied and a strict draping will be used in the incision site. Body temperature, blood pressure, respiratory rate, heart rate and O2 saturation of the patients will be monitored every 1 hour during the operation and data will be recorded on the data collection form. Before the skin closes, the surgical site will be washed with warm Isotonic NaCl solution. Wound care education will be provided to the patient and family before discharge.
89575409|NCT04285697|No Intervention|group 2 control|The pre-operative service sociodemographic characteristics form, preoperative, intra and postoperative evaluation forms will be completed. Body temperature, blood pressure, respiratory rate, heart rate and O2 saturation of the patients will be monitored every 1 hour during the operation and data will be recorded on the data collection form.
89575410|NCT05501015|No Intervention|Group A - Standard Dysphagia Treatment|Group A will serve as the control group. This group will receive oral hygiene followed by traditional dysphagia exercises, including effortful swallow, Masako Maneuver, and Tongue Press.
89575411|NCT05501015|Experimental|Group B - Ice Chip Treatment|Group B will serve as the experimental group. In place of traditional dysphagia exercises, participants in Group B will receive oral hygiene and will consume small amounts of ice chips with supervision, three times a day. The ice chip protocol is based on the same findings as the Frazier Free Water Protocol, in that small amounts of clean water or ice chips are not harmful to the lungs and relatively benign if aspirated. Ice chips provide additional advantages in rehabilitating dysphagia as they are a cohesive bolus that are easier for patients with severe dysphagia to control in their mouth and swallow.
89575412|NCT04535531|Experimental|SB206 10.3% berdazimer|SB206 10.3% berdazimer topically once daily
89575413|NCT04535531|Placebo Comparator|vehicle gel|Vehicle gel topically once daily
89575414|NCT04532645||Patients with BRCA mutated ovarian cancer|BRCA mutated advanced (FIGO stage III-IV) ovarian cancer patients who received first dose maintenance olaparib in 1L setting
89575415|NCT02560025|Experimental|Alisertib / MLN8237|"Participants will initially receive 7+3 induction chemotherapy, consisting of cytarabine and concurrent idarubicin (or daunorubicin if appropriate). Oral alisertib, at 30mg twice daily, will begin on day 8, and will continue for 7 days. During induction, patients with residual disease at day 14 may have re-induction with 5+2 chemotherapy, but will not receive additional dosing of alisertib at that time. Following count recovery after induction, if patients proceed to consolidative cycles of therapy with cytarabine, they will receive alisertib at day 6 following conclusion of cytarabine administration. Upon count recovery following consolidation, alisertib will be resumed for 7 days, followed by 14 days off, and will be continued as 21-day cycles of maintenance, for up to 12 cycles."
89575416|NCT05500937|Active Comparator|UDCA 500mg per day|This group of participants receive UDCA 500mg per day.
89575417|NCT05500937|Placebo Comparator|Placebo|This group of participants receive placebo.
89575418|NCT04744025|Experimental|Microfluidics|Half of participants eggs will be injected with sperm processed using a microfluidics chamber.
89575419|NCT04744025|Active Comparator|Density gradient centrifugation|Half of participants eggs will be injected with sperm processed using a density gradient centrifugation (the standard method).
89575420|NCT05500781|Experimental|Coaching HER|Participants in the interventional condition will take part in an online program consisting of 6 modules over 2 weeks
89575421|NCT05500781|No Intervention|Waitlist Control|Participants will not be explicitly told their study condition, although they will be made aware of the assessment time points and whether they receive the intervention between T1 and T2 (intervention) or after T2 (waitlist control). Following completion of post-intervention assessments (T2), the control condition will participate in the intervention; but, they will not be monitored or assessed.
89575422|NCT04524455|Experimental|Blinatumomab and AMG 404|
89575423|NCT05508893|Other|CT Angiography|Coronary CT Angiography will be performed on all individuals
89575424|NCT05508893|Other|Exercise stress test|An bicycle exercise stress test will be performed on all individuals
88971434|NCT02972216||Taxotere|For Nonsmall Cell Lung Cancer (NSCLC) Docetaxel (either Group I or Group II) 60 mg/m2 will be administrated by intravenous infusion for 1 hour every 3 weeks (a study medication cycle) and up to 4 study medication cycles throughout this study. For Squamous Cell Carcinoma of the Head and Neck (SCCHN) Docetaxel (either Group I or Group II) 60 mg/m2 will be administrated by intravenous infusion for 1 hour followed by cisplatin 60 ~ 75 mg/m2 for 1-3 hours or based on the general practice of the site every 3 weeks and up to 4 study medication cycles throughout this study.
88971435|NCT00143494|Experimental|1|Critically hill, mechanically ventilated patients
89029207|NCT03964116|Other|AYA|Questionnaires set all 3 months and psychological interviews if needed
89575425|NCT05500625|Experimental|EUS-guided coil embolization combined with endoscopic cyanoacrylate injection|
89575426|NCT05500625|Experimental|Ballon-occluded retrograde transvenous obliteration|
89575427|NCT04789889|Experimental|IORT|intraoperative radiotherapy(IORT) in BCS.
89575428|NCT04789889|Active Comparator|PORT|traditional postoperative radiotherapy following BCS.
89575429|NCT04640519|Experimental|TASC Intervention|TASC patients will receive a BP monitoring kit and electronic tablet and tailored infographics, and attend 5 telehealth visits over 3 months, including primary care nurse practitioner, pharmacy and stroke neurologist.
89575430|NCT04640519|Active Comparator|TASC Control|Usual care patients will be seen by a primary care nurse practitioner and a stroke neurologist.
89575431|NCT04411901|Experimental|vitamin D 3|oral vitamin D3 drops and tablets
89575432|NCT05500547|Experimental|Universal single shade resin composite restorative material|Dental restorative material
89575433|NCT05500547|Active Comparator|Nano-hybrid multi-shade resin composite restorative material|Dental restorative material
89575434|NCT05508737|Experimental|Single arm, Pembrolizumab, trifluridine/tipiracil|
89575435|NCT04333511|Experimental|Sequence 1|TPS first with crossover to Sham-TPS
89575436|NCT04333511|Experimental|Sequence 2|Sham-TPS first with crossover to TPS
89575437|NCT04231799|Experimental|Bathing within 24-48|Participants who will have their first bath in 24-48th hours after birth.
89575438|NCT04231799|Experimental|Bathing within 48-72|Participants who will have their first bath in 48-72th hours after birth.
89575439|NCT05508659|Experimental|Combined therapy (cohort A)|Duvelisib combine with SG001 injection regimen in patients who had failed with prior PD-1/PD-L1 therapy
89575440|NCT05508659|Experimental|Combined therapy (cohort C)|Duvelisib combine with SG001 injection regimen in patients who had failed with prior systemic therapy but naïve with prior PD-1/PD-L1.
89209200|NCT02553902|Active Comparator|Combination therapy|"Sleep Position Trainer + Mandibular Advancement device combination The SPT is a sensor that measures the sleeping position, and gives the user feedback about wrong positions with a soft vibration. A user is then able to react to the signal and turn into a non-supine position. To stimulate compliance, information is provided about nightly behaviour, implicating a learning pattern by viewing the data on a home computer.~MRA or oral appliances (OA) works by advancing the mandible and its attached soft tissue structures forward they aim to increase upper airway size."
89575441|NCT05508659|Active Comparator|SG001 injection monotherapy (cohort B)|SG001 monotherapy in patients who had failed with prior systemic therapy but naïve with prior PD-1/PD-L1
89209201|NCT02553902|Active Comparator|CPAPContinuous positive airway pressure|Continuous positive airway pressure (CPAP) functions as a pneumatic splint to maintain upper airway patency. Possible side effect can be related to the interface, pressure and negative social factors.
89575442|NCT05508581|Other|Varicose veins|Ablation of varicose veins by microwaves
89575443|NCT05500157|Active Comparator|Aspiration sclerotherapy|Aspiration sclerotherapy is a percutaneous procedure that evacuates fluid from the liver cyst and subsequently exposes cyst lining to a sclerosing agent (e.g. ethanol, minocycline) for a limited period of time.
89575444|NCT05500157|Active Comparator|Laparoscopic Fenestration|Laparoscopic fenestration exposes the liver through laparoscopic surgery. During this procedure the cyst is punctured and drained followed by resection of the extra-hepatic cyst wall
89575445|NCT05499923|Active Comparator|Wing method of debonding|In this method after removal of the orthodontic wire, each bracket would be gripped mesiodistally by a conventional bracket debonding plier at the level of wings and a squeezing force would be applied.
89575446|NCT05499923|Active Comparator|Base method of debonding|In this method after removal of the orthodontic wire, each bracket would be gripped mesiodistally by a conventional bracket debonding plier at the level of the bracket base and a squeezing force would be applied.
89575447|NCT05508425|Active Comparator|water at room temperature|
89575448|NCT05508425|Experimental|hot water|
89575449|NCT05508425|Experimental|cold water|
89575450|NCT05508425|Experimental|hot water with tea bag|
89575451|NCT05508425|Experimental|room temperature water with tea bag|
89575452|NCT05508425|Experimental|cold water with tea bag|
89575453|NCT05508425|Experimental|bubble water at room temperature|
89575454|NCT05508425|Experimental|cold bubble water|
89575455|NCT05508347|Experimental|Experimental group|3 cycles of docetaxel combined with cisplatin induction chemotherapy combined with 9 times of 200mg nituzumab targeted therapy, and sequential 2-3 cycles of concurrent chemoradiotherapy based on cisplatin chemotherapy combined with 7 times of nituzumab targeted therapy.
89575456|NCT05508347|Placebo Comparator|control group|3 cycles of docetaxel combined with cisplatin induction chemotherapy combined with 9 times of placebo treatment, and sequential 2-3 cycles of concurrent chemoradiotherapy based on cisplatin chemotherapy combined with 7 times of nituzumab targeted therapy
89575457|NCT05499845||Group P (n=40) (Propofol),|
89575458|NCT05499845||Group PS (n=40) (Propofol-Sevoflurane),|
89575459|NCT05499845||Group S (n=40) (Sevoflurane).|
89575460|NCT05508113|No Intervention|Control|No intervention was given to this group of patients
89575461|NCT05508113|Experimental|20-40ug/ml ozone|ozone autohemotherapy
89575462|NCT05499533|Experimental|Hybrid Funnel Technique|Hybrid funnel technique for implant site preparation
89209202|NCT00615264|Experimental|DiaPep277|DiaPep277 1.0 mg + 40 mg Mannitol in 0.5 mL lipid emulsion.
89209203|NCT00615264|Placebo Comparator|Placebo|Mannitol 40 mg in 0.5 mL lipid emulsion.
89209204|NCT00799682|Active Comparator|Xalatan®|
89575463|NCT05499533|Active Comparator|Conventional Technique|Conventional subtractive Drill technique for implant site preparation
89575464|NCT05508035|Experimental|sacubitril / valsartan|sacubitril / valsartan 200 mg twice a day PLUS placebo for ramipril 5 mg twice a day
89575465|NCT05508035|Active Comparator|ramipril|ramipril 5 mg twice a day PLUS placebo for sacubitril / valsartan 200 mg twice a day
89575466|NCT04411355|No Intervention|control group patients|non intervention. only rutin care
89575467|NCT04411355|Experimental|intervention group patients|The intervention group was trained and monitored by a professional team in line with the components of the model. Life quality scale, hypertension information questions and chronic care assessment scale were applied to both groups at the beginning and in the sixth month of the study.
89575468|NCT04390139|Experimental|Treatment A|Wharton-Jelly mesenchymal stromal cells on D1 and D3
89575469|NCT04390139|Placebo Comparator|Treatment B|Placebo on D1 and D3
89575470|NCT04381637|Experimental|NIPE|
89575471|NCT03834545||cycling group|They attended three sessions of exercise on three different conditions : a classic ergometric bicycle without chairback, an ergometric bicycle with chairback with virtual environment and the other session without virtual environment
89575472|NCT02566889|Experimental|Dose Escalation Group|Participants must have completed: a) recommended infliximab induction dosing regimen of 5 milligram (mg)/kilogram (kg) at Weeks 0, 2, and 6, followed by at least 1 maintenance doses of 5 mg/kg every 8 weeks (q8wk); or b) induction regimen with doses >6 mg/kg and have received at least 2 maintenance doses of 5 mg/kg q8wk with clinical response for at least 28 days after the most recent 5 mg/kg maintenance dose; or c) maintenance doses >6 mg/kg within past 6 months and at least 2 maintenance doses of 5 mg/kg q8wk with clinical response for at least 28 days after the most recent 5 mg/kg maintenance dose; d) must have lost clinical response, after first or subsequent q8wk maintenance dose of infliximab 5 mg/kg for participants who have completed the recommended infliximab induction dosing regimen or, after most recent (second or later) q8wk maintenance dose of infliximab 5 mg/kg for participants with an induction regimen with doses >6 mg/kg or with previous maintenance doses >6 mg/kg.
89575473|NCT02566889|Experimental|Reference Group|Participants must have completed: a) the recommended infliximab induction dosing regimen of 5 mg/kg at Weeks 0, 2, and 6, and have maintained a stable clinical response to infliximab after at least 1 maintenance doses of 5 mg/kg q8wk; or b) an induction regimen with doses >6 mg/kg and have received at least 2 maintenance doses of 5 mg/kg q8wk and have maintained clinical response for at least 28 days after the most recent 5 mg/kg maintenance dose 5 mg/kg maintenance dose; or c) maintenance doses >6 mg/kg within the past 6 months and at least 2 maintenance doses of 5 mg/kg q8wk and have maintained a clinical response for at least 28 days after the most recent 5 mg/kg maintenance dose 5 mg/kg maintenance dose.
89575474|NCT05564585|Experimental|Kinesio Tape|Kinesio Tape was applied over the Calf Muscle on Either leg.
89575475|NCT05564585|Sham Comparator|Sham Tape|Sham Tape was applied over the Calf Muscle on Either leg.
89575476|NCT05564507|Experimental|TEE simulation-based training group|"All participants of the TEE simulation group received:~1) a traditional didactic training using e-learning with a national free-access online course; and 2) two teaching sessions using a TEE simulator for 2 hours per session."
89575477|NCT05564507|No Intervention|TEE traditional group|All participants of the TEE traditional group received only a traditional didactic training using e-learning with a national free-access online course (same e-learning program allocated for the TEE simulation group).
89575478|NCT03713255|Active Comparator|PVB group|paravertebral blocks with 0.5% ropivacaine and epinephrine 2.5 mcg/mL
89575479|NCT03713255|Experimental|MTP block group|MTP blocks with 0.5% ropivacaine and epinephrine 2.5 mcg/mL
88971436|NCT04726345|Experimental|Fexofenadine|Participants in this arm will receive fexofenadine 180mg once daily, in addition to standard of care pain medications (NSAIDs).
88971437|NCT04726345|Placebo Comparator|Placebo|Participants in this arm will receive placebo once daily, in addition to standard of care pain medications (NSAIDs).
88971438|NCT00393276|Experimental|A|HCV-infected defined as a positive result using polymerase chain reaction (PCR) without previous HCV-based therapy and without the presence of Child's B or C cirrhosis. These participants will be HIV-uninfected.
88971439|NCT00393276|Experimental|B|HIV-infected and ARV naive, with a CD4 cell count of 300 cells/mm3 or greater, with no prior or current opportunistic infection, and with no indication for HIV therapy. These participants will be HCV-uninfected.
88971440|NCT00393276|Experimental|C|HCV/HIV-coinfected as defined above in Arms A and B.
88971441|NCT00143533|Other|1|
88971442|NCT00143572|Other|1|
89575480|NCT03713255|Sham Comparator|control group|local anesthetic infiltration subcutaneous 1% lidocaine
88971443|NCT00143611|Experimental|Resatorvid 1.2 mg/kg/day|
89209205|NCT00799682|Active Comparator|Travatan Z®|
89575481|NCT05564351|Experimental|Ear plug group|
89575482|NCT05564351|Experimental|Eye mask group|
89575483|NCT05564351|Experimental|Eye mask+Ear plug group|
89575484|NCT05564351|No Intervention|Control group|
89575485|NCT04283201|Experimental|Diet|
89575486|NCT04283201|Experimental|Physical activity|
89575487|NCT03673553||Association of people with fibromyalgia|Control group included people affiliated to the FM Patient Association of Terres de l'Ebre, Spain.
88971444|NCT00143611|Experimental|Resatorvid 2.4 mg/kg/day|
88971445|NCT00143611|Placebo Comparator|Placebo|
88971446|NCT02247752|Other|Inactive carriers|
88971447|NCT00143689|Experimental|Lopinavir/ritonavir, Zidovudine, Lamivudine|"Participants will be randomly assigned to receive one of the following drug combinations:~lopinavir/ritonavir (Kaletra) and nevirapine (Viramune) twice a day;~Combivir (Zidovudine (AZT) plus lamivudine (3TC)) and nevirapine twice a day;~Combivir and lopinavir/ritonavir twice a day."
88971448|NCT00144001||Group 1|
88971449|NCT00390767|Experimental|MultiGeneAngio|Escalating doses of MultiGeneAngio
88971450|NCT00144040|Other|Arm 1|
88971451|NCT05595343||Early adopting surgeons|Surgeons who started performing LDP during phase 3 of the IDEAL framework; the Assessment phase. They received training in the form of fellowships, proctoring, and courses
88971452|NCT05595343||Pioneering surgeons|Surgeons who started performing LDP during phase 2 of the IDEAL framework; the Development and Exploration phase. They did not receive any specific form of training and were therefore considered self-taught.
88971453|NCT05595304|Experimental|Oral Functionalization|Prosthesis repairment: prosthetic reline and occlusal stabilization through repair of missing pieces and recovery of occlusal contacts and follow up with conventional prosthesis treatment
88971454|NCT05595304|Active Comparator|control|conventional prosthetic treatment (new prosthesis)
88971455|NCT04726540||Group I|
88971456|NCT04726540||Group II|
89209206|NCT00810758|Experimental|PF-04878691|
89575488|NCT03673553||Multimodal treatment of patients with FM|The intervention group was made up of patients from the specialist FM Unit in the Hospital of Lleida, Spain.
89575489|NCT02566577|Active Comparator|Fresh RBC transfusion/Storage-aged RBC transfusion|Subjects will receive a transfusion of packed red blood cell (RBC) units of fresh blood (<10 days old) followed by a transfusion of packed RBC units of storage-aged (>21 days old) blood.
89575490|NCT02566577|Active Comparator|Storage-aged RBC transfusion/Fresh RBC transfusion|Subjects will receive a transfusion of packed red blood cell (RBC) units of storage-aged (>21 days old) blood followed by a transfusion of packed RBC units of fresh blood (<10 days old).
89575491|NCT05507801|Experimental|High Physically Active Group|Based on accelerometer data, women with 162 ≥ min/per day moderate and vigorous activity or men 133.25 ≥ min/per day moderate and vigorous activity.
89575492|NCT05507801|Experimental|Low Physically Active Group|Based on accelerometer data, women with 108.25 ≤ min/per day moderate and vigorous activity or men 100.1 ≤ min/per day moderate and vigorous activity.
89575493|NCT03300713|Experimental|F+ group (Mocitraining program)|including 8 pediatricians' clusters. F+ pediatricians will attend a specific training focused on mother-child interactions, maternal psychiatric disorders, particularly PND screening and early interventions for non-psychiatric physician.
89575494|NCT03300713|Sham Comparator|F- group (usual follow-up)|grouping 8 pediatricians' clusters. They will not receive the initial training on early interactional disorders and PND screening
89575495|NCT04424693|Active Comparator|Tdap vaccinations at gestational week 28|Pregnant women entering into this clinical research study and signing informed consent at week 12 will be randomized to either receive Tdap vaccination at week 28 or week 36. Subjects receiving Tdap vaccination at week 28 will receive a placebo injection at week 36. Subject will be followed with routine standard of care throughout their pregnancy and have routine clinic visits from which study visits will include weeks 12, 20, 28, 36, and 2 weeks postpartum. Data will be collected at each of these visits with special attention to the development of preeclampsia and fetal health
89575496|NCT04424693|Active Comparator|Tdap vaccinations at gestational week 36|Pregnant women entering into this clinical research study and signing informed consent at week 12 will be randomized to either receive Tdap vaccination at week 28 or week 36. Subjects receiving Tdap vaccination at week 36 will receive a placebo injection at week 28. Subjects will be followed with routine standard of care throughout their pregnancy and have routine clinic visits from which study visits will include weeks 12, 20, 28, 36, and 2 weeks postpartum. Data will be collected at each of these visits with special attention to the development of preeclampsia and fetal health
89575497|NCT05563571|Active Comparator|Intra-articular cortisone injection|Ultra-sound guided single injection of Methylprednisolon 40 mg (1 ml) + 1 ml 10 % Lidocaine to shoulder joint
89575498|NCT05563571|Active Comparator|pulsed radiofrequency of shoulder joint and suprascapular nerve|Ultra-sound guided single treatment of shoulder joint and suprascapular nerve with pulsed radiofrequency (PRF) STP (Sluijter Teixeira pulse) 45 V 4 minutes each with 1 ml 10% Lidocaine to both shoulder joint and suprascapular nerve.
89575499|NCT02489903|Experimental|Small Cell Lung Cancer (Arm 1)|RRx-001 weekly for 3 weeks followed by up to 4 cycles of carboplatin or cisplatin plus etoposide and then RRx-001 and carboplatin or cisplatin (for patients with stable disease (SD) or better at discontinuation of platinum).
89575500|NCT02489903|Active Comparator|Small Cell Lung Cancer (Arm 2)|Carboplatin or cisplatin plus etoposide or irinotecan or vinorelbine until progression or intolerable toxicity
89575501|NCT02489903|Experimental|Non Small Cell Lung Cancer|RRx-001 weekly for 3 weeks followed by up to 6 cycles of cisplatin or carboplatin plus paclitaxel or nab-paclitaxel or pemetrexed and then RRx-001 maintenance (for patients with stable disease or better at discontinuation of platinum).
89575502|NCT02489903|Experimental|Neuroendocrine tumors|RRx-001 weekly until progression followed by up to 6 cycles of carboplatin or cisplatin plus etoposide and then RRx-001 maintenance (for patients with stable disease or better at discontinuation of platinum).
89575503|NCT02489903|Experimental|Ovarian epithelial cancer (Arm 1)|RRx-001 weekly for 2 weeks followed by 2 cycles of Carboplatin chemotherapy and then RRx-001/Carboplatin maintenance (for patients with stable disease or better at discontinuation of platinum).
89575504|NCT02489903|Active Comparator|Ovarian epithelial cancer (Arm 2)|Carboplatin, Etoposide, Doxil, Gemcitabine or Vinorelbine or Taxane until progression or intolerable toxicity
89575505|NCT01815281|Experimental|Foot Mechanical Stimulation|The FMS stimulation will be given to all participants using GONDOLA equipment (Ecker Technologies Sagl, Switzerland).
89575506|NCT01815281|Sham Comparator|Footh Mechanical Stimulation|The sham stimulation will be given to all participants using GONDOLA equipment (Ecker Technologies Sagl, Switzerland).
89575507|NCT01658111|Active Comparator|Traditional physiotherapy|Each subject will receive 4 weeks of traditional upper limb rehabilitation treatment (20 sessions, 5 days a week for 4 weeks).
89575508|NCT01658111|Experimental|Robot Group|Each subject will be asked to perform five sessions per week goal-directed, planar reaching tasks, which emphasizes shoulder and elbow movements, moving from the centre target to each of 8 peripheral targets equally spaced on a 0.14 m radius circumference around a centre target using the InMotion2 (IM2) system (20 sessions- 5 days a week for 4 weeks).
88971457|NCT05595109|Placebo Comparator|Group one: (Placebo group)|"which will receive four cycles of AC regimen (doxorubicin and cyclophosphamide; each cycle was given every 21 day)~followed by 12 cycles of paclitaxel (each cycle was given in a weekly basis) plus placebo tablets once daily."
88971458|NCT05595109|Active Comparator|Group two: (Silymarin group)|which will receive the same regimen plus silymarin 140mg once daily.
88971459|NCT05594914|Experimental|AK104 plus concurrent chemoradiation therapy|AK104 10mg/kg plus TC regimen(paclitaxel liposome 135mg/m2, carboplatin AUC=5), once every 3 weeks (Q3W), induction treatment for 2 cycles; Subsequently, AK104 10 mg/kg plus TC regimen(paclitaxel liposome 135mg/m2, carboplatin AUC=5) is combined with radiotherapy(50Gy/25F) for 2 cycles.
88971460|NCT05594719|Experimental|Light group 1|Sun-like spectrum, color temperature of 5000K, shorter-wavelength dominant;
88971461|NCT05594719|Placebo Comparator|Light group 2|Sun-like spectrum, color temperature of 5000K, wavelength proportion similar to the sunlight
88971462|NCT05594719|Experimental|Light group 3|Sun-like spectrum, color temperature of 5000K, longer-wavelength dominant.
88971463|NCT00404911|Experimental|MFG therapy|Participants will receive multi-family group therapy
88971464|NCT00404911|Active Comparator|Standard of Care|Participants will receive standard care
89209207|NCT00732641|Experimental|Peginterferon α-2b|Peginterferon α-2b 35 μg, weekly, subcutaneous (SC), until disease progression or relapse, or for up to a maximum of 5 years.
89209208|NCT00732641|No Intervention|No Treatment|Participants will be observed and will receive no treatment.
89209209|NCT03829020|Experimental|Treatment (metformin, nelfinavir)|Patients receive metformin hydrochloride PO on days 1-14, nelfinavir mesylate PO BID on days 1-14, and bortezomib SC on days 1, 8, and 15. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
89575509|NCT01174199|Experimental|Arm I|Patients receive oral vorinostat once daily on days 1-14 and temsirolimus IV on days 1, 8, and 15. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89575510|NCT04475549|Experimental|IW-6463|Open-label IW-6463 15 mg once daily (QD), with possibility to dose reduce to 10 mg.
89575511|NCT05497895|Experimental|Group I (SRP and TQ gel)|In Group I patients, the lipid based TQ gel (5%) will be applied topically to the affected areas, twice daily for two weeks following SRP. The investigator performs the treatment of gingivitis based on the patient's response to therapy. For home care, the patients will be instructed to clean and dry the affected area prior to the gel application and hands will be washed prior and after its application. The patients will be instructed to not eat for 30 minutes following its application
89575512|NCT05497895|Placebo Comparator|Group II (SRP and Placebo)|In Group II patients, the placebo gel will be applied topically to the affected areas, twice daily for two weeks following SRP. The investigator performs the treatment of gingivitis based on the patient's response to therapy. For home care, the patients will be instructed to clean and dry the affected area prior to the gel application and hands will be washed prior to and after its application. The patients will be instructed to not eat for 30 minutes following its application
89575513|NCT05497895|Active Comparator|Group III (Only SRP and one stage prophylaxis)|The Group III patients will be subjected to one-stage oral prophylaxis.
89575514|NCT04356599|Experimental|Intervention Group|All participants will receive study intervention
88971465|NCT01891695|Experimental|Reduced Intensity Radiation|39.6 Gy radiation to clinically uninvolved cervical lymphatics
88971466|NCT01807494|Active Comparator|Posterior approach|Subjects in this group will total hip replacement performed with a posterior surgical approach and total hip replacement components.
88971467|NCT01807494|Active Comparator|Anterior Approach|Subjects in this group will have total hip replacement performed with a direct anterior surgical approach and total hip replacement components.
89209210|NCT00810836|Active Comparator|1|BG00012 480 mg/day
89575515|NCT05562869|Experimental|Experimental: transient belatacept|IV, 5mg/Kg days 1, 15, 30, 45 and 60 then every months
88971468|NCT05594212|Experimental|The effectiveness of receiving abdominal breathing training|The effectiveness of receiving abdominal breathing training Training for 8 weeks (1 time a week, 15 minutes each time). Performed one-on-one by a trainer in a sleep center. At home, you can use the abdominal breathing training video to train yourself (10 minutes a day, can be divided into 10 minutes), and you need to fill in the abdominal breathing training log.
88971469|NCT05594212|No Intervention|The effectiveness of not receiving abdominal breathing training|The effectiveness of not receiving abdominal breathing training The trainer does not provide abdominal breathing training, does not perform abdominal breathing exercises at home, and does not need to fill in abdominal breathing training logs.
88971470|NCT01807455|Experimental|Restylane Vital Lidocaine|
88971471|NCT02964169|Experimental|Family Planning Support|Family planning voucher and phone reminders
88971472|NCT02964169|No Intervention|No Family Planning Support|Routine care
88971473|NCT01807416|Active Comparator|standard platform , standard abutment|implant insertion and abutment connection Osseointegrated implants with regular collar connected to standard designed prosthetic abutments
88971474|NCT01807416|Active Comparator|standard platform, flat abutment|implant insertion and abutment connection Osseointegrated implants with regular collar connected to flat designed prosthetic abutments
88971475|NCT01807416|Active Comparator|switching platform, standard abutment|implant insertion and abutment connection Osseointegrated implants with switched platform collar connected to standard designed prosthetic abutments
88971476|NCT01807416|Active Comparator|switching platform, flat abutment|implant insertion and abutment connection Osseointegrated implants with switched platform collar connected to flat designed prosthetic abutments
88971477|NCT03092453|Experimental|Mature dendritic cell (DC) vaccine|Mature DC 7.5-15 million/peptide given day 1, every six weeks for 2 doses followed by standard of care anti PD-1 therapy
88971478|NCT05572489||patients with cervicogenic headache|visual pain scale Beck depression scale Pain catastrophizing scale Short Form-36 Standard Mini mental test Montreal cognitive assessment scale
89575516|NCT05497661|Experimental|Effects of Capacitive Resistive Monopolar Radiofrequency in patellar tendon|448 kilohertz Capacitive Resistive Monopolar Radiofrequency stimulus on the dominant patellar tendon.
88971479|NCT05572489||healthy controls|visual pain scale Beck depression scale Pain catastrophizing scale Short Form-36 Standard Mini mental test Montreal cognitive assessment scale
88971480|NCT04726384||Observed group|The group was monitored for physical activity levels using the SenseWear Armband device. The group was informed of the purpose of the study and asked to wear the device 24 hours a day for the next 4 days (Friday-Monday) excluding bath time, no more than 30 minutes. Patients received the device on Thursday afternoon and returned it on Tuesday. However, the days Friday-Monday were analyzed to have a record of the entire days
89209211|NCT00810836|Active Comparator|2|BG00012 720 mg/day
89209212|NCT00810836|Placebo Comparator|3|
89209213|NCT00874926||Group 1|
89209214|NCT00810914|Experimental|1|Continuous epidural infusion of medication for method of pain relief
89209215|NCT00810914|Experimental|2|continuous epidural infusion in conjuction with patient controlled anesthesia (PCA)
89209216|NCT00810914|Experimental|3|patient controlled anesthesia only this arm has pt controlled medication delivery. (PCA)
89209217|NCT00878904|Experimental|treatment with Panobinostat and Epirubicin|
88971481|NCT01807377|Experimental|PF-05175157, Midazolam|Day 0: Midazolam 2 mg administered alone Days 1-14: 200 mg PF-05175157 administered BID Day 11: Midazolam and PF-05175157
88971482|NCT01807377|Experimental|Placebo, Midazolam|Day 0: Midazolam 2 mg administered alone Days 1-14: Placebo administered BID Day 11: Midazolam and Placebo
89575517|NCT05497661|Placebo Comparator|Placebo Comparator: Placebo Monopolar Radiofrequency stimulus|To simulate the application of Monopolar Radiofrequency stimulus on the dominant patellar tendon
88971483|NCT05552911||De novo coronary lesions: cutting balloon group|De novo coronary lesions were pretreated with a cutting balloon and then treated with a drug-coated balloon.
88971484|NCT05552911||De novo coronary lesions: non-cutting balloon group|De novo coronary lesions were pretreated with a non-cutting (Compliance balloon or/and non-compliant balloon) balloon and then treated with a drug-coated balloon.
88971485|NCT05552911||In-stent restenosis: Type-I|Body stenosis: restenosis of the stent body, not beyond the edge of the stent.The lesions were pretreated with balloon dilation and then treated with drug-coated balloons.
88971486|NCT05552911||In-stent restenosis: Type-II|Marginal stenosis type: restenosis at the edge of the stent, stenosis ≥50% within 5mm of the stent edge, which can continue into the stent.The lesions were pretreated with balloon dilation and then treated with drug-coated balloons.
88971487|NCT05552911||In-stent restenosis:Type-III|Diffuse proliferative type: the lesion extends to the whole scaffold body and beyond the edge of both ends.The lesions were pretreated with balloon dilation and then treated with drug-coated balloons.
88971488|NCT05552911||In-stent restenosis:Type-IV|Complete occlusion type: complete occlusion in the stent.The lesions were pretreated with balloon dilation and then treated with drug-coated balloons.
89575518|NCT04080869|Experimental|retinyl palmitate ethosomes arm|All patients will be instructed to apply a thin film of the new formula on one side of the face
89575519|NCT04080869|Active Comparator|tretinoin arm|All patients will be instructed to apply a thin film of topical retinoid cream on the other side of the face
88971489|NCT05551663|Experimental|Isometric exercise training|
88971490|NCT05551663|No Intervention|Control group|
88971491|NCT03090737|Experimental|Nivolumab|Specified Dose on Specified Days
88971492|NCT05550103|Active Comparator|RIC+Standard medical treatment|RIC+Standard medical treatment. Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mm Hg. RIC will be conducted twice daily for 7 consecutive days from thrombolysis.
88971493|NCT05550103|Placebo Comparator|Sham RIC+Standard medical treatment|Sham RIC+Standard medical treatment. Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mm Hg. RIC will be conducted twice daily for 7 consecutive days from thrombolysis.
88971494|NCT01807338||saline|Saline administration to patients with idiopathic Parkinson's disease (PD) of moderate severity, who have previously been treated with sNN0031
88971495|NCT05545657||Type 2 Diabetes|These patients must have a definite diagnosis of type 2 diabetes mellitus (T2DM) according to the American Diabetes Association (ADA) standards. Some of these patients have symptoms of cognitive impairment, while others have normal cognition.
88971496|NCT05545657||Healthy Control|These participants have normal glucose tolerance and normal cognition.
88971497|NCT05504941|Experimental|Study Intervention: DSA|additional diagnostic cerebral DSA
88971498|NCT01807260|Active Comparator|conventional Shock wave lithotripsy group|All procedures were performed under continu¬ous intravenous sedo-analgesia (using a combi-nation of ketamine 1 mg/kg and propofol 0,5-1 mg/kg) with fluoroscopic or ultrasonograpic imaging in a supine position. Shock wave number was limited to a maximum of 3000 waves/session. In the conventional group the voltage was only 13 kV. The stone burden was defined as the stone area that was calculated by multiply¬ing the largest length and width of the individual stones measured from the abdominal plain X-ray.
88971499|NCT01807260|Active Comparator|stepwise Shock wave lithotripsy group|All procedures were performed under continu¬ous intravenous sedo-analgesia (using a combi-nation of ketamine 1 mg/kg and propofol 0,5-1 mg/kg) with fluoroscopic or ultrasonograpic imaging in a supine position. Shock wave number was limited to a maximum of 3000 waves/session. In the stepwise group, the voltage was started at 10 kV and increased stepwise (every 250 shock waves) to 13 kV. The stone burden was defined as the stone area that was calculated by multiply¬ing the largest length and width of the individual stones measured from the abdominal plain X-ray.
88971500|NCT02972255|Experimental|Part I: RO7079901|Participants will be randomized in two dose cohorts to receive single dose of RO7079901 1000 and 2000 milligrams (mg) intravenous (IV) infusion on Days 1 through Day 7 every 8 hours (q8h), for a total of 19 doses, with the last dose administered on the morning of Day 7.
89209218|NCT00810992|Active Comparator|1 Program A|Recommendation for nutrition and behavior for patients with coronary artery disease according to the German Society of Nutritional Medicine and the International Task Force for the Prevention of Coronary Artery Disease
89209219|NCT00810992|Experimental|2 Program B|Recommendation for nutrition and behavior for patients with coronary artery disease according to the system of the Traditional Tibetan Medicine
89209220|NCT00737711|Experimental|Mircera|
89575520|NCT05562791|Experimental|68Gallium PSMA-PET/CT|Patients will initially undergo a standard of care FDG PET with diagnostic CT scan followed by an investigational 68Ga PSMA PET/CT scan.
89575521|NCT05497505||Discharged patients with decision support (On-period)|For patients that have been evaluated as eligible for discharge: the current ICU discharge process will be followed based on routine clinical evaluation by the treatment team in combination with ICU discharge protocols. In addition, Pacmed Critical will be used as an additional source of information. Final discharge decision will be made by lead unit intensivist responsible for medical care.
89575522|NCT05497505||Discharged patients without decision support (Off-period)|For patients that have been evaluated as eligible for discharge: the current ICU discharge process will be followed based on routine clinical evaluation by the treatment team in combination with ICU discharge protocols. Final discharge decision will be made by lead unit intensivist responsible for medical care.
89209221|NCT00881946|Experimental|GSK2119183|
89209222|NCT00807326|Experimental|Loperamide/simeticone Caplets|Drug (including placebo)
89209223|NCT00807326|Active Comparator|Loperamide/simeticone Chewable Tablets|Drug (including placebo)
89575523|NCT05499299|Active Comparator|Government|Participants were shown with the government slogan for the COVID-19 vaccine campaign in 2021. This was the control arm.
89575524|NCT05499299|Experimental|Comparison|The ad emphasized that vaccine uptake in Hong Kong substantially lagged behind that in comparable populations such as Singapore and the UK.
89575525|NCT05499299|Experimental|Exemption|The ad emphasized that vaccinated people could be exempted from some disruptive control measures such as mandatory testing
89575526|NCT05499299|Experimental|Family|The ad prompted people to get vaccinated in order to protect their family.
88971501|NCT02972255|Placebo Comparator|Part I: Placebo|Participants will be randomized in two dose cohorts to receive single dose of placebo matching to RO7079901 on Days 1 through Day 7 q8h, for a total of 19 doses, with the last dose administered on the morning of Day 7.
88971502|NCT02972255|Experimental|Part II - Single Dose and Repeat Dose: RO7079901|Participants will be randomized in two dose cohorts to receive single dose of RO7079901 IV infusion at a dose above the previously studied dose levels in Part I (greater than [>] 2000 mg) on Day 1, with the option to extend to q8h dosing for 7 days (i.e., starting on Day 3 through Day 9); once PK, safety and tolerability have been confirmed up to 48 hrs after the single dose.
89575527|NCT05499299|Experimental|Lottery|The ad prompted people to get vaccinated in order to be eligible for the numerous COVID-19 lotteries in Hong Kong
89575528|NCT05499299|Experimental|Mortality|The ad emphasized that COVID-19 has caused millions of deaths worldwide.
89575529|NCT05499299|Experimental|Reopen|The ad prompted people to get vaccinated to help Hong Kong reopen sooner.
89575530|NCT05499221|Active Comparator|Conventional anchorage|Buccal tubes will be bonded on the lower first molars, an alginate impression will be taken for the lower arch with the buccal tubes in place, and a cast will be poured. A hard vacuum sheet of 1.5- mm thickness will be used to fabricate the Essix appliance. The posterior end of the buccal surface will be trimmed in each lower first molar region, creating a window to allow for attachment of the elastics. Class II elastics will be attached from the maxillary canine to the mandibular first molar bilaterally. During the first month, 1/4-inch heavy elastics will be used. In the following months, 3/16-inch heavy elastics will be used. The patients will be instructed to wear the elastics 24 hours per day, except during mealtimes, and to change them daily.
89575531|NCT05499221|Experimental|Skeletal anchorage|Closing coil springs will be attached from the maxillary canine to the infrazygomatic miniscrews bilaterally
89575532|NCT02559713|Experimental|Vedolizumab 300 milligram (mg)|Vedolizumab 300 mg, IV infusion over 30-minutes, single dose on Day 1.
88971503|NCT02972255|Placebo Comparator|Part II - Single Dose and Repeat Dose: Placebo|Participants will be randomized in two dose cohorts to receive single dose placebo matching to RO7079901 on Day 1, with the option to extend to q8h dosing for 7 days (i.e., starting on Day 3 through Day 9); once PK, safety and tolerability have been confirmed up to 48 hrs after the single dose.
89209224|NCT00807326|Active Comparator|Probiotic Capsules|Drug (including placebo)
88971504|NCT02972255|Experimental|Part III: RO7079901 + Meropenem|Participants will be randomized in three dose cohorts to receive RO7079901 and Meropenem IV infusion in one of the 2 treatment sequences. Participants randomized to Sequence 1 will receive a single dose of 2000 mg meropenem IV infusion on Day 1. On Day 2, participants will receive a single dose of RO7079901 IV infusion. Participants randomized to Sequence 2 will receive a single dose of RO7079901 IV infusion on Day 1. On Day 2, participants will receive a single dose of 2000 mg meropenem IV infusion. Starting on Day 3 and continuing through Day 9 (i.e., for a total of 19 doses, last dose in the morning of Day 9) all participants will receive RO7079901 in combination with meropenem IV infusion q8h, regardless of sequence. Escalation to a maximum dose of RO7079901 5000 mg q8h may be considered on the basis of safety and tolerability data from the previous cohorts.
88971505|NCT02972255|Placebo Comparator|Part III: RO7079901 Placebo + Meropenem Placebo|Participants will be randomized in three dose cohorts to receive RO7079901 and Meropenem matching placebos in one of the 2 treatment sequences. Participants randomized to Sequence 1 will receive a single dose of placebo matching to meropenem on Day 1. On Day 2, participants will receive a single dose of placebo matching to RO7079901. Participants randomized to Sequence 2 will receive a single dose of placebo matching to RO7079901 on Day 1. On Day 2, participants will receive a single dose of placebo matching to meropenem. Starting on Day 3 and continuing through Day 9 (i.e., for a total of 19 doses, last dose in the morning of Day 9) all participants will receive RO7079901 and meropenem matching placebos q8h, regardless of sequence.
88971506|NCT05488015|Experimental|Intervention|1 week of familiarisation through videos, audios and information documents, followed by 8 weeks of self-treatment with two GPR postures.
89209225|NCT00875082|Active Comparator|Montelukast|Montelukast chewing tablets once daily per os, plus inhaled short acting beta2 agonist as needed
89209226|NCT00875082|Placebo Comparator|placebo|placebo chewing tablets per os once daily, plus inhaled short acting beta 2 agonist as needed
89209227|NCT02552342|Active Comparator|methylprednisolone|This group was entitled to receive methylprednisolone 80mg/day for 3 days，then 40mg/day for 3 days
89575533|NCT01358981|Experimental|LY2881835|"One cohort of healthy participants will receive single oral doses of LY2881835 in up to 3 of the 4 periods in Part A (dose escalation: 0.5 milligram (mg), 1.5 mg, subsequent doses determined based on review of safety, tolerability, glycaemic response and available pharmacokinetic (PK) data from the first 2 dose levels). One cohort of participants with Type 2 Diabetes Mellitus (T2DM) will receive single oral doses of LY2881835 in up to 2 of the 3 periods in Part B (dose escalation: starting dose based on review of safety, tolerability, glycaemic response and available PK data from Part A).~There is a washout period of at least 5 days between periods (doses)."
89575534|NCT01358981|Placebo Comparator|placebo|"One cohort of healthy participants will receive a single oral dose of placebo in 1 of the 4 periods in Part A. Another cohort of participants with T2DM will receive a single oral dose of placebo in 1 of the 3 periods in Part B.~There is a washout period of at least 5 days between periods (doses)."
89575535|NCT05499065|Experimental|75mg cetuximab + 15mg cetuximab-800CW|To investigate if study drugs can assist in tumor-positive margin detection
89575536|NCT04317599||Non interventional|All BRAFV600E mutant patients having initiated a first-line treatment for mCRC between 01 January, 2016 and 31 December, 2018 (both days inclusive) with drugs registered for mCRC in respective country
89575537|NCT04230161||Standard LLIN|This group receives Yahe LN ITNs during the mass distribution campaign.
88971507|NCT05488015|Active Comparator|Control|No change in lifestyle habits during the 8-week trial.
88971508|NCT01807143||Correlative studies|Tissue samples are analyzed for translocations and deletions and analyzed using PCR or FISH.
89575538|NCT04230161||Chlorfenapyr ITN|This group receives Interceptor G2 ITNs during the mass distribution campaign.
89575539|NCT04230161||Standard LLIN and IRS|This group receives Yahe LN ITNs during the mass distribution campaign and IRS.
88971509|NCT03088943|Other|TTE Apical 4 Chamber View|Patients will receive TTE apical 4chamber echo examinations prior to induction and after induction
88971510|NCT03088943|Other|TEE dTG View|Patients will receive TEE deep transgastric echo examinations after induction and after cardiopulmonary bypass induction (paced at 80, 100, and 120 bpm)
88971511|NCT03088943|Other|TEE ME 4C View|Patients will receive TEE midesophageal 4chamber echo examinations after induction and after cardiopulmonary bypass induction (paced at 80, 100, and 120 bpm)
88971512|NCT05468671|Experimental|Remazolam general anesthesia group (R group)|Remazolam 0.4 mg/kg, oxycodone 0.2 mg/kg and rocuronium 0.9 mg/kg were given for anesthesia induction.Group R was given remazolam 1mg/kg/h and remifentanil 6-8ug/kg/h for maintenance.
88971513|NCT05468671|Active Comparator|Propofol general anesthesia control group (P group)|Propofol 1.5mg/kg, oxycodone 0.2mg/kg and rocuronium 0.9mg/kg were given for induction of anesthesia.Group P was given propofol 4-8 mg/kg/h and remifentanil 6-8ug/kg/h for anesthesia maintenance.
88971514|NCT05463991|Experimental|Bioengineered collagen implant|Standard technique of doing a substitution urethroplasty with no modification to the surgical steps. Instead of an autologous oral bucal mucosa graft, the bioengineered collagen implant is sutured to the healty urethral area after incision of the urethra at the stricture location.
88971515|NCT01807104|Active Comparator|Anterior Approach Total Hip|Total hip arthroplasty performed through an anterior surgical approach. Compare results of total hip arthroplasty performed through either an Anterior or Posterior Surgical Approach
88971516|NCT01807104|Active Comparator|Posterior Approach Total Hip|The additional arm is the posterior approach total hip, which the Anterior Approach is being compared too. Compare results of total hip arthroplasty performed through either an Anterior or Posterior Surgical Approach.
89029208|NCT03963843|Experimental|SCI internet delivered cognitive behavioural therapy|An 8-week internet- delivered cognitive behavioural therapy (ICBT) will be delivered to participants who have sustained a spinal cord injury. In addition to the online program, a health educator with experience delivering ICBT will provide support by email once a week. The health educator will spend approximately 15 minutes per week/per client.
89209228|NCT02552342|Placebo Comparator|Placebo|This group was meant to receive placebo (sterile normal saline in a volume equal to the study drug
89209229|NCT00811226||Patients|Patients with arterial hypertension Stade I or Stade II
89209230|NCT00238303|Experimental|Stratum 1 (not undergoing surgery)|Patients receive oral vorinostat (SAHA) twice daily for 2 weeks. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
89575540|NCT05498909||Treatment group|"Treatment group（Multidisciplinary assisted treatment model group）： Those who received any of the following treatments, as recommended by the standard medical procedure, were considered to have received the standard medical treatment; otherwise, they were not.~Surgical procedures: left atrial appendage ligation, left atrial appendage clip, valve repair or replacement, etc.~Medical procedures: atrial fibrillation radiofrequency ablation, valvular closure, left atrial appendage closure, etc.~Anticoagulant drug therapy: standardized anticoagulant drug therapy."
89575541|NCT05498909||Control group|"Control group（Routine diagnosis and treatment model group）:~Patients who did not agree to enter the multidisciplinary treatment mode were automatically admitted to the routine treatment mode group"
89575542|NCT04038437|Experimental|CPX-351 and Venetoclax|CPX-351 and Venetoclax will be administered over 28 day cycles
89575543|NCT05498753||Control|Healthy infants
89575544|NCT05498753||Experimental|Preterm Infants
89575545|NCT05491343|No Intervention|Conservative management|
89575546|NCT05491343|Experimental|Progesterone treatment|
89575547|NCT05498285|Experimental|Intervention|Use of UPSCALER App
89575548|NCT05498285|No Intervention|Control|No app used. Conventional treatment.
89575549|NCT05491265|Experimental|Kangaroo mother care|To see the impact of intermittent kangaroo mother care on temperature ,oxygen saturation and heart rate.
89575550|NCT05491265|No Intervention|standard of care|To observe temperature ,oxygen saturation and heart rate in preterm neonates not given kangaroo care
89575551|NCT05486195|Experimental|SDI-118 Dose 1|
89575552|NCT05486195|Experimental|SDI-118 Dose 2|
89575553|NCT05486195|Experimental|SDI-118 Dose 3|
89575554|NCT05486195|Experimental|SDI-118 Dose 4|
89575555|NCT05486195|Experimental|SDI-118 Dose 5|
89575556|NCT05486195|Experimental|SDI-118 Dose 6|
89575557|NCT05486195|Placebo Comparator|SDI-118 Placebo|
89575558|NCT05486039||Normal Posture|
89575559|NCT05486039||Lordotic Posture|
89575560|NCT05486039||Sway Back Posture|
89575561|NCT05486039||Hypolordotic Back Posture|
89575562|NCT05486039||Head Anterior Tilt Posture|
89575563|NCT05486039||Scoliotic Posture|
88971517|NCT05461807||Cancer patients with venous thromboembolism (VTE)|Adults diagnosed with active (primary or metastatic) cancer excluding oesophageal, gastric, unresected colorectal, bladder, central nervous system cancers (except brain) and leukaemia (a cohort of CAT (Cancer-associated thrombosis) patients at a low risk for bleeding, which is defined as per the ISTH (International Society on Thrombosis and Haemostasis) guidelines), admitted to the hospital, emergency department or observation unit for acute DVT (Deep vein thrombosis) and/or PE (Pulmonary embolism) on or after January 1, 2013 (to correspond with the US availability of rivaroxaban for VTE treatment), being treated with a therapeutic VTE dose of rivaroxaban or apixaban on day 7 post-acute VTE diagnosis (index date).
89575564|NCT05486039||Kyphotic Posture|
89575565|NCT05497739|Experimental|Intraperitoneal chemotherapy group|In this study, patients with positive peritoneal lavage fluid cancer cell DNA will be given intraperitoneal chemotherapy followed by adjuvant systemic chemotherapy.
89575566|NCT04276727|Active Comparator|Menthol|Menthol gel to be applied twice a day for 6 weeks - toes to knees, fingertips to elbows, top and base of spine.
89575567|NCT04276727|Placebo Comparator|Placebo|Placebo gel to be applied twice a day for 6 weeks - toes to knees, fingertips to elbows, top and base of spine.
89575568|NCT05485883|Experimental|Advanced Renal Cell|Patients will receive treatment with Tislelizumab every 3 weeks,and take Lenvatinib 8mg every day
89575569|NCT05485727|Experimental|RG(Robotic group= study group)|14, Robotic-assisted gait training group (RG) will receive Lokomat gait training and conventional physiotherapy
88971518|NCT03079427|Active Comparator|Capecitabine|Adjuvant Capecitabine
88971519|NCT03079427|Experimental|Gemcitabine plus cisplatin|Adjuvant Gemcitabine plus Cisplatin
89575570|NCT05485727|Active Comparator|& CG( Control group)|control group (CG) will only receive conventional physiotherapy
89575571|NCT04273607|Experimental|No anticoagulation|Participants in this arm will not receive unfractionated heparin during the course of ECMO. They will receive standard venous thromboembolism prophylaxis with subcutaneous enoxaparin or unfractionated heparin
89575572|NCT04273607|No Intervention|Anticoagulation, ECMO standard of care|Participants in this arm will receive the standard of care anticoagulation with unfractionated heparin during the course of ECMO.
89575573|NCT02548585|Placebo Comparator|Placebo|Participants will receive placebo (matched to either 100 micrograms [mcg], or 150 mcg or 200 mcg or 300 mcg of MEDI0382) subcutaneously (SC) once daily from Day 1 to Day 7 (Cohort 1); or Day 1 to Day 11 (Cohort 2); or Day 1 to Day 15 (Cohort 3); or Day 1 to Day 41 (Cohort 4); or Day 1 to Day 22 (Cohort 5); or Day 1 to Day 17 (Cohort 6).
89575574|NCT02548585|Experimental|Cohort 1: MEDI0382 100 mcg|Participants will receive MEDI0382 100 mcg SC once daily from Day 1 to Day 7.
89575575|NCT02548585|Experimental|Cohort 2: MEDI0382 150 mcg|Participants will receive MEDI0382 100 mcg SC once daily for at least 4 days (Day 1 to Day 4) and thereafter, an up titrated dose of MEDI0382 150 mcg SC once daily for 7 days (Day 5 to Day 11).
88971520|NCT05433649|Experimental|Experimental group|Participants performing 16 sessions of therapeutic exercise for 8 weeks with a frequency of two sessions per week. All sessions had a practical focus (strength and stretching exercises) with the help of elastic bands.
88971521|NCT05433649|No Intervention|Control group|They do not change their lifestyle and do not receive the therapeutic exercise sessions.
89575576|NCT02548585|Experimental|Cohort 3: MEDI0382 200 mcg|Participants will receive MEDI0382 100 mcg SC once daily for at least 4 days (Day 1 to Day 4); thereafter, an up titrated dose of MEDI0382 150 mcg SC once daily for 4 days (Day 5 to Day 8); followed by second up titrated dose of MEDI0382 200 mcg SC once daily for 7 days (Day 9 to Day 15).
89575577|NCT02548585|Experimental|Cohort 4: MEDI0382 200 mcg|Participants will receive MEDI0382 100 mcg SC once daily for at least 4 days (Day 1 to Day 4); thereafter, an up titrated dose of MEDI0382 150 mcg SC once daily for 4 days (Day 5 to Day 8); followed by second up titrated dose of MEDI0382 200 mcg SC once daily for 4 days (Day 9 to Day 12), then a further MEDI0382 200 mcg SC once daily for 28 days (Day 13 to Day 40) at home-dosing; followed by MEDI0382 200 mcg SC once daily for 1 day in hospital (Day 41).
89575578|NCT02548585|Experimental|Cohort 5: MEDI0382 300 mcg|Participants will receive MEDI0382 100 mcg SC once daily for at least 5 days (Day 1 to Day 5); thereafter, an up titrated dose of MEDI0382 150 mcg SC once daily for 5 days (Day 6 to Day 10); then a second up titrated dose of MEDI0382 200 mcg SC once daily for 5 days (Day 11 to Day 15); followed by third up titrated dose of MEDI0382 300 mcg SC once daily for 7 days (Day 16 to Day 22).
89575579|NCT02548585|Experimental|Cohort 6: MEDI0382 300 mcg|Participants will receive MEDI0382 100 mcg SC once daily for at least 5 days (Day 1 to Day 5); thereafter, an up titrated dose of MEDI0382 200 mcg SC once daily for 5 days (Day 6 to Day 10); followed by a second up titrated dose of MEDI0382 300 mcg SC once daily for 7 days (Day 11 to Day 17).
88971522|NCT01807026|Experimental|Cohort A: 70 mg LY2886721|Participants with Alzheimer's disease received a single, 70-milligrams (mg) (1 capsule), oral dose of LY2886721.
88971523|NCT01807026|Placebo Comparator|Cohort A: Placebo|Participants with Alzheimer's disease received a single, oral dose of LY2886721-matching placebo (1 capsule).
89575580|NCT05480371|Active Comparator|Conventional endotracheal suctioning|Tracheal suctioning will be performed following the American Association for Respiratory Care recommendations: closed suction system, suction catheter with maximal internal-to-external diameter ratio of 0.5, delivery of 100% oxygen 30 s immediately before and 1 min after the procedure, duration of 15 s, and vacuum pressure of ±150 mmHg
89575581|NCT05480371|Experimental|mechanical insufflation exsufflation|The mechanical insufflation-exsufflation will be performed with the which will be applied 5 times in 5cough cycles in automatic mode, with insufflation and exsufflation pressures of + 40/-40 cmH2O, respectively. The duration of each phase was 3 s, without pause, and tracheal suctioning will be performed at the end of the procedure. Hyperoxygenation (100% O2) will be performed for 1 min before applying each technique and a 20 s interval will be allowed between repetitions. The secretion collected after each procedure will be stored in a disposable bronchial secretion collector for later weighing
89575582|NCT05476081||Patients (single cohort study)|Patients presenting with a mild-to-moderate ischemic stroke or high risk TIA
89575583|NCT05480215|Experimental|Experimental: TAPS delivered by Cala device with Trio band|Two 40-minute TAPS sessions daily for 14 days
89575584|NCT05480215|Experimental|Experimental: TAPS delivered by Cala device with Trio+ band|Two 40-minute TAPS sessions daily for 14 days
89575585|NCT04479553||Qizhi Tongluo Capsules|Qizhi Tongluo Capsules will be given to the patients, and the investigators will record all the information including ADR, application of Qizhi Tongluo Capsules and the combined medications, etc.
89575586|NCT05476003|Sham Comparator|Sham Technique|Patients will receive general anesthesia plus Ultrasound-guided Bilateral superficial cervical plexus block with injection of 10 ml normal saline bilaterally.
89575587|NCT05476003|Active Comparator|Ultrasound-guided Bilateral superficial cervical plexus block|Patients will receive general anesthesia plus Ultrasound-guided Bilateral superficial cervical plexus block with injection of total volume 10 ml containing Bupivacaine 0.25% (5 ml Bupivacaine 0.5 % and 5 ml normal saline).
89029209|NCT03963843|Active Comparator|SCI rehabilitation mental health education|Participants will receive information provided to SCI patients in usual care at specialized SCI rehabilitation units (the Spinal Cord Injury Rehabilitation Evidence (SCIRE) Community handouts available at: https://scireproject.com/community/handouts/). The lessons will include information on spinal cord injury rehabilitation: 1)spinal cord injury basics, 2)mental health after SCI, 3)pain after SCI, 4)understanding rehabilitation 5)summary of lessons through an online platform over 8 weeks. A health educator will check in with participants once a week to answer any content related questions. The health educator will spend approximately 15 minutes per week/per client.
89029210|NCT03947515|Experimental|cancer group|
89029211|NCT03947515|Experimental|control group|
89575588|NCT02547649|Experimental|V114 Formulation A|Participants receive a single 0.5 mL intramuscular injection of V114 Formulation A on Day 1
89575589|NCT02547649|Experimental|V114 Formulation B|Participants receive a single 0.5 mL intramuscular injection of V114 Formulation B on Day 1
89575590|NCT02547649|Active Comparator|Prevnar 13®|Participants receive a single 0.5 mL intramuscular injection of Prevnar 13® on Day 1
89575591|NCT05460949|Experimental|HOLD RELAX STRETCHING OF ILIOPSOAS|"10-second isometric contraction of iliopsoas muscle (HR), 10-second rest, 20-second static stretch, 5 repetitions.~The stretching exercise was performed 2 times a week for 8 weeks."
89575592|NCT05460949|Experimental|• WILLIAM'S PROTOCOL|"Pelvic tilt~Single Knee to chest~Double knee to chest~Partial sit-up~Hamstring stretch~Hip Flexor stretch~Squat~Each group performed special trainings for 8 weeks, 2 sessions per week; each session took about 1 hour. Duration of each exercise was 8 to 10 seconds in each set. Protocols were started with 1 set of 10 repetitions at starting baseline and by improving performance and patients' compatibility with trainings, all eventually finished with 3 sets of 20 repetitions at the end of protocols."
89575593|NCT03097081|Experimental|No orthosis|The intervention consists of a deviation of the standard protocol; patients post-operatively do not receive an orthosis.
89575594|NCT03097081|Active Comparator|Orthosis|As in correspondence with local and international guidelines, patients receive an orthosis as standard post-operative care. This is considered the control group.
89575595|NCT03079297|Experimental|L-leucine|4 gm L-leucine by mouth twice daily for two weeks
89575596|NCT03079297|Placebo Comparator|Maltodextrin|4 gm maltodextrin by mouth twice daily for two weeks
89575597|NCT05475847|Experimental|C-TIL052A treatment group|C-TIL052A autologous infiltrating lymphocytes injection followed by injection of Interleukin 2 (IL-2)
89575598|NCT02535715|Experimental|ORAMED ORMD-0801 capsules- 2x8mg 1st; 3x8mg 2nd, 1x16mg 3rd|Two 8 mg ORAMED capsules containing insulin then 3X8mg ORAMED capsules containing insulin, second study then 1X16mg ORAMED capsules containing insulin, third study
89575599|NCT02535715|Experimental|ORAMED ORMD-0801 capsules- 3x8mg 1st, 1x16mg 2nd, 2x8mg 3rd|Three 8mg ORAMED capsules containing insulin then 1X16mg ORAMED capsules containing insulin, second study then 2X8mg ORAMED capsules containing insulin, third study
89575600|NCT02535715|Experimental|ORAMED ORMD-0801 capsules-1x16mg 1st, 2x8mg 2nd, 3x8mg 3rd|One 16mg ORAMED capsule containing insulin then 2X8mg ORAMED capsule containing insulin, second study then 3X8mg ORAMED capsule containing insulin, third study
89575601|NCT05460247|Experimental|Pea protein diet|
88971524|NCT01807026|Experimental|Cohort B: 70 mg LY2886721|Healthy participants received a single, 70-mg (1 capsule), oral dose of LY2886721.
88971525|NCT01807026|Placebo Comparator|Cohort B: Placebo|Healthy participants received a single, oral dose of LY2886721-matching placebo (1 capsule).
88971526|NCT01807026|Experimental|Cohort C: 280 mg LY2886721|Healthy participants received a single, 280-mg (4 x 70 mg capsules), oral dose of LY2886721.
89029212|NCT03906422|Experimental|"A: 0.016 Nitinol"|"0.016 Nitinol (3M Unitek, Monrovia, CA) archwire to be tied to the fixed orthodontic brackets at the initial bonding appointment."
89029213|NCT03906422|Experimental|"B: 0.016 Ormco 27oC NiTi"|"0.016 Ormco 27oC NiTi (Ormco, Glendora, CA) archwire to be tied to the fixed orthodontic brackets at the initial bonding appointment."
89575602|NCT05460247|Experimental|Whey protein diet|
89575603|NCT05460247|Experimental|Soy protein|
88971527|NCT01807026|Placebo Comparator|Cohort C: Placebo|Healthy participants received a single, oral dose of LY2886721-matching placebo (4 capsules).
88971528|NCT00390923|Experimental|1|
89575604|NCT05460247|Experimental|Rice protein|
89575605|NCT02336815|Experimental|Part 1|Participants with quad-exposed, double-class-refractory (i.e. previously treated with lenalidomide, pomalidomide, bortezomib, carfilzomib, but not an anti-CD38 mab) and penta-exposed, triple-class-refractory multiple myeloma (MM) (i.e. previously treated with lenalidomide, pomalidomide, bortezomib, carfilzomib, and daratumumab, and refractory to prior treatment with glucocorticoids, an immunomodulatory agent (IMiD), a proteasome inhibitor (PI), and the anti-CD38 mAb daratumumab) received, two dosing schedules (1) Selinexor 80 milligrams (mg) plus low-dose dexamethasone 20 mg (Sd) twice-weekly on Days 1 and 3 for 3 weeks of each 4-week cycle (2) Selinexor 80 mg plus low-dose dexamethasone 20 mg (Sd) twice-weekly continuously in 4-week cycles; until disease progression, death, or unacceptable toxicity (maximum duration of approximately 13 months).
89575606|NCT02336815|Experimental|Part 2|Participants who previously had received more than 3 anti-MM regimens and had penta-exposed, triple class-refractory MM (i.e. previously treated with lenalidomide, pomalidomide, bortezomib, carfilzomib, and daratumumab, and refractory to prior treatment with glucocorticoids, an IMiD, a PI, and the anti-CD38 mAb daratumumab) received, Selinexor 80 mg post oral (PO) plus low-dose dexamethasone 20 mg Sd twice-weekly on Days 1 and 3 until disease progression, death, or unacceptable toxicity (maximum duration of approximately 17 months).
89575607|NCT05466643|Experimental|DWP16001|
89575608|NCT05466643|Placebo Comparator|Placebo|
89575609|NCT02543203|Active Comparator|A/C - Reconnect, Then Coconut Oil Comparator|"Participants randomized to treatment order A/C, received Reconnect for 3-months each day, morning and evening. After a washout period of one-month, they received the Coconut Oil Comparator morning and evening for 3-months.~AM: Children received a topical application of one drop of oil to the back of the neck and 1 drop to the feet.~PM: Children received the oil blend by the aromatic method as it was diffused throughout their bedrooms while they slept. Each bottle has an orifice that allows the oil to be expelled drop by drop the evening dose was 8-12 drops added to the diffuser."
89575610|NCT02543203|Sham Comparator|C/A - Coconut oil Blend, Then Reconnect|"Participants randomized to treatment order C/A received the Coconut Oil Comparator for 3-months each day, morning and evening. After a washout period of one-month, they received Reconnect morning and evening for 3-months.~AM: Children received a topical application of one drop of oil to the back of the neck and 1 drop to the feet.~PM: Children received the oil blend by the aromatic method as it was diffused throughout their bedrooms while they slept. Each bottle has an orifice that allows the oil to be expelled drop by drop the evening dose was 8-12 drops added to the diffuser."
89575611|NCT05434039|Experimental|diclofenac phonophoresis|the patients will receive diclofenac phonophoresis and traditional therapy three times a week for four weeks
89575612|NCT05434039|Experimental|high power pain threshold ultrasound|the patients will receive high power pain threshold ultrasound and traditional therapy three times a week for four weeks
89575613|NCT05434039|Active Comparator|conventional therapy|the patients will receive traditional therapy three times a week for four weeks
89575614|NCT05466175|Experimental|Treatment Group|combination of Olverembatinib with chemotherapy
89575615|NCT02546323|Experimental|Rosuvastatin|20 mg tablets, Daily oral dose
89575616|NCT02546323|Placebo Comparator|Placebo|Matching placebo tablets
89575617|NCT02545933|Experimental|DAPT plus vorapaxar|Aspirin plus prasugrel or ticagrelor plus vorapaxar 2.5mg od
89575618|NCT02545933|Experimental|Prasugrel/ticagrelor plus vorapaxar|Prasugrel or ticagrelor plus vorapaxar 2.5mg od
89575619|NCT02545933|Active Comparator|DAPT|Aspirin in addition to prasugrel or ticagrelor
88971529|NCT00390923|Placebo Comparator|2|
88971530|NCT02972112|Active Comparator|Study group|will receive 2 sessions of 90 minutes each of a cognitive behavioral protocol for the treatment of Tokophobia administered by a CBT trained midwife.
88971531|NCT02972112|Sham Comparator|Control group|will receive 2 sessions of a delivery preparation course (practice as usual).
88971532|NCT05397847|Experimental|Experiment|Education, rational drug use guide and consultancy services will be provided to elderly individuals through home visits.
88971533|NCT05397847|No Intervention|Control|No intervention will be made to the control group, and after the post-test, the rational drug use guide and the medicine box will also be given to the control group.
89575620|NCT01661179|Experimental|Vandetanib 300mg|300 mg/day vandetanib
89575621|NCT05458063||Patients admitted in Surgical intensive care unit and trauma intensive care unit|all surgical patients who planned to admit in surgical and trauma intensive care unit in emergency room
88971534|NCT05387629|Experimental|Experimental|Social media increases the academic success of nursing students.
88971535|NCT05387629|No Intervention|Control|Social media does not affect the academic success of nursing students.
88971536|NCT01806987|Experimental|KITS Program|The KITS Program consists of: (a) child school readiness play groups to facilitate the development of self-regulatory, social, and early literacy skills (2 times per week in summer, 1 time per week in the fall); and (b) a 12 session psychoeducational workshop to promote parent involvement in the child's early literacy and schooling and the use of effective parenting techniques (once per week in summer, bi-weekly in the fall).
88971537|NCT01806987|No Intervention|Services as usual|These include any services that the child and family might already be receiving in the community.
89575622|NCT05457517|Experimental|YL-13027+Sintilimab|"YL-13027 tablets will be given daily for 21 days in 21-day cycles until there appears evidence of progressive disease, intolerable toxicity, or the patient discontinues from the study treatment for other reasons.~Sindilizumab injection will be given 200mg every three weeks."
89575623|NCT02545543|Experimental|Seqirus Quadrivalent Inactivated Influenza Vaccine|The Seqirus study vaccine is a sterile, thimerosal-free suspension containing 60 mcg total hemagglutinin antigen per 0.5 mL dose (15 mcg each of the four recommended influenza strains for the Northern Hemisphere 2015/2016 influenza season).
89575624|NCT02545543|Active Comparator|Comparator Quadrivalent Influenza Vaccine|The comparator Quadrivalent Inactivated Influenza vaccine is a US-licensed product containing four recommended influenza strains for the Northern Hemisphere 2015/2016 influenza season.
89575625|NCT02545075|Experimental|Ipilimumab|Intravenously (IV) 3 mg/kg every 3 weeks (at week 1,4,7,10) and thereafter (q3w/4 doses) at the time of progression
89575626|NCT02545075|Experimental|Dacarbazine|IV solution 250 mg/m2 (Day 1-5, every 3weeks/at week 1, 4, 7, 10,13,16,19,22)
89575627|NCT03007537|Placebo Comparator|control group|0.9% sodium chloride 1ml, subcutaneous injection, once, applied 1day before cardiac surgery
89575628|NCT03007537|Experimental|Erythropoietin group|10000 IU erythropoietin, subcutaneous injection, once, applied 1day before cardiac surgery
89575629|NCT02544763|Experimental|25 mg/kg/day GWP42003-P|100 mg/mL GWP42003-P oral solution taken twice daily (morning and evening).
89575630|NCT02544763|Experimental|50 mg/kg/day GWP42003-P|100 mg/mL GWP42003-P oral solution taken twice daily (morning and evening).
89575631|NCT02544763|Placebo Comparator|Placebo|Placebo oral solution matching 100 mg/mL GWP42003-P.
89575632|NCT05464771||Patients experiencing adverse event while in hospital|Patients that have experienced a patient safety incident according to the Patient Safety Indicators (PSIs) developed by the U.S. Agency for Healthcare Research and Quality (AHRQ)
89575633|NCT02556203|Experimental|Rivaroxaban (Xarelto, BAY59-7939)|Subjects were treated with Rivaroxaban (10mg once-daily) and ASA (75-100mg once-daily) within first 90 days after randomization. After 90 days, ASA was discontinued and rivaroxaban (10mg once-daily) was to be continued alone. In the event of NOAF (New Onset of Atrial Fibrillation), subjects should be switched to rivaroxaban (20/15mg once-daily) and ASA (75-100mg once-daily) within first 90 days. After 90 days, ASA was discontinued and rivaroxaban (20/15mg once-daily) was to be continued alone.
89575634|NCT02556203|Active Comparator|Antiplatelet|Subjects were treated with clopidogrel (75mg once-daily) and ASA (75-100mg once-daily) within first 90 days after randomization. After 90 days, clopidogrel was discontinued and ASA (75-100mg once-daily) was to be continued alone. In the event of NOAF, subjects should start treatment of open-label VKA to target INR 2 to 3 (according to guidelines) and ASA (75-100mg once-daily) within first 90 days. After 90 days, ASA was discontinued and VKA was to be continued alone.
89575635|NCT05485571|Active Comparator|GROUP 1|15 patient with alopecia areata treated by microneedling only one session weekly for 12 weeks
89575636|NCT05485571|Active Comparator|GROUP 2|15 patient with alopecia areata treated by combined therapy with Microneedling and methotrexate After microneedling we applied methotrexate topically (25mg/ml) at dose 0.02ml/cm2 , A maximum of 0.1-0.2ml (2.5-5 mg) on the affected areas and rub it gently then Microneedling again, patient will take session weekly for 12 weeks.
89575637|NCT05485337||retrospective analysis|A retrospective analysis of disease histories for the period from 2014 to 2021 was carried out. Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury.
88971538|NCT01806948|Placebo Comparator|Control|Single dose of antiemetics. Specifically, Ramosetron 0.3 mg will be intravenously injected when surgery is ended. Additionally, placebo will be intravenously injected at 4 hours after surgery.
88971539|NCT01806948|Experimental|Experimental|Double dose of antiemetics. Specifically, Ramosetron 0.3 mg will be intravenously injected when surgery is ended. Additionally, Ramosetron 0.3 mg will be intravenously injected at 4 hours after surgery.
88971540|NCT03004976|Experimental|Umbilical Cord Blood|A single intravenous infusion of umbilical cord blood within 3-10 days following stroke.
88971541|NCT03004976|Placebo Comparator|Placebo|A single intravenous infusion of diluent with the same appearance and odor as a cord blood unit within 3-10 days following stroke.
88971542|NCT02958163|Active Comparator|Trans-Arterial Chemo-embolization (TACE)|"Trans-arterial Embolisation will be performed with drug-eluting beads loaded with Doxorubicin. First session will be given within 4 weeks after randomization.~4-phase MRI will be performed every 2 months to assess the response. In case of insufficient response according to the MRI performed at 2 or 4 months, a second or third session of DEB-TACE will be allowed, according to the physician's choice.~Once complete response is achieved, the follow-up period will start. The date of the last session of TACE corresponds to the treatment completion date."
88971543|NCT02958163|Experimental|TACE+Stereotactic Ablative Radiotherapy|"The first part of the treatment, which is the DEB-TACE delivery, will be exactly the same than in arm A. The radiotherapy (SABR) will then start within 4 to 6 weeks after.~Afterwards, 4-phase MRI will be performed every 2 months to assess the response. In case of insufficient response according to the MRI performed at 2 or 4 months, a second or third session of DEB-TACE will be allowed, according to the physician's choice.~Once complete response is achieved, the follow-up period will start. The date of the last SABR fraction or the last session of TACE corresponds to the treatment completion date."
88971544|NCT01806909|Other|Intranasal|Ad4-H5-VTN intranasal vaccine administered in cohorts of 3 at increasing dosages
89209231|NCT00238303|Experimental|Stratum 2 (undergoing surgery)|Beginning 3 days prior to surgery, patients receive oral SAHA once or twice daily for a total of 6 doses. Patients then undergo surgery to remove the tumor. Beginning within 1-4 weeks after surgery, patients receive oral SAHA twice daily for 2 weeks. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
89575638|NCT05485337||prospective study|Recruitment of patients for the prospective study was carried out in the period from 02.24.2022 to 05.24.2022
89575639|NCT05496803|Other|study group|parents receiving routine education plus digital video disk before catheterization:pre-catheterization educational videos plus routine education
89575640|NCT05496803|Other|control group|parents receiving routine education: pre-catheterization routine education
89575641|NCT05496725|Experimental|Micafungin (Product name:Myfungin)|Single dose micafungin 50mg
89575642|NCT05496725|Active Comparator|Micafungin (Product name:Mycamine)|Single dose micafungin 50mg
89575643|NCT05490719|Experimental|QL1706 plus Chemotherapy and Radiotherapy|"Radiotherapy: Total 50.4Gy/28 fraction ,1.8Gy per time，5 fractions per week.~QL1706 will be administered at a dose of 5 mg/kg intravenously (IV), every 3 weeks, until progressive disease or intolerable or other reasons according to the criteria for termination of treatment). QL1706 will be administered up to 1 year.~Chemotherapy: Taxol 135 mg/m2, days 1, 22; Cisplatin 25 mg/m2, day 1-3, day 22-24."
89575644|NCT04424459||Patients included from 10/01/19 to 12/31/19.|Patients included from 10/01/19 to 12/31/19. (the study will be extended to a larger number of patients according to the first results), continued according to the first results. DCNC patients treated at the Montpellier Pain Assessment and Treatment Center hospitalized during the period from 10/01/19 to 12/31/19, for misuse of opioid treatment.
89575645|NCT05496569|Experimental|TQB3616 capsules|TQB3616 capsule (180mg, quaque die, oral), 4 weeks (28 days) as a treatment cycle.
89575646|NCT05496569|Placebo Comparator|TQB3616 placebo|TQB3616 placebo (0mg, quaque die, oral), 4 weeks (28 days) as a treatment cycle.
89575647|NCT04179383|Other|Patient|"Patient presenting a Reversible Cerebral Vasoconstriction Syndrome (RCVS) :~Questionnaires about anxiety, depression ;~Constitution of a biobank (if specific consent) at inclusion and at 3 months"
89575648|NCT04179383|Other|Volunteers|"Volunteers admitted for a non neurological or non vascular pathology or healthy volunteers accompanying a patient :~Questionnaires about anxiety, depression ;~Constitution of a blood biobank (if specific consent)"
89575649|NCT05485259|Experimental|DL-alpha lipoic acid|600 mg (2x300 mg) of DL-alpha lipoic acid in capsules, per os daily for 3 months
89575650|NCT05485259|Placebo Comparator|Placebo|600 mg (2*300 mg) of placebo (rice starch) in capsules, per os, daily for 3 months
89575651|NCT04027049|Experimental|Supine cycle ergometry of the lower extremities|Patients will receive two 20 minute cycle ergometry sessions separated by at least 4 hours in addition to usual care. The cycle will be set to a gear of zero and will begin in passive mode, the patient will be able to actively cycle if patients are able.
89029214|NCT03906422|Experimental|"C: 0.016 Ormco 35oC NiTi"|"0.016 Ormco 35oC NiTi (Ormco, Glendora, CA) archwire to be tied to the fixed orthodontic brackets at the initial bonding appointment."
89575652|NCT04027049|No Intervention|Control|Patients will receive usual care only.
89575653|NCT05490407|Other|HGSOC|high-grade serous ovarian cancer patients (FIGO stages III and IV) with ascites, for whom neoadjuvant chemotherapy is recommended.
89575654|NCT04424849||COVID-19 patients|Patient tested positive for COVID-19 who had a CT scan
89575655|NCT05490173|Experimental|Intranasal exosomes administration|ELWB newborns who will receive intranasal exosomes
89575656|NCT05490173|No Intervention|Control|ELWB newborns who will not receive intranasal exosomes
89575657|NCT05485025|Experimental|Tai chi training plus group activity|"Tai chi training: a teacher will give two 60-min lessons per week. Participants will play Tai Chi in the lessons, following teacher's instruction.~Group activity: a organizer will lead the subjects to participate in group activities, once per quarter."
89575658|NCT05485025|Experimental|Only group activity|Group activity: a organizer will lead the subjects to participate in group activities, once per quarter.
89575659|NCT05484947||HIV-positive|Those that were actually tested and had HIV-positive results
89575660|NCT05484947||HIV-Negative|Those tested and had HIV-negative results
89575661|NCT05484947||HIV-Unknown|those who had not volunteered for HIV testing
89575662|NCT05484869||Early Adolescent Pregnant Women (n:80)|Perinatal and neonatal results of adolescent pregnancies of 16 years and below
89575663|NCT05484869||Very Advanced Maternal Aged Pregnants (n:67)|Perinatal and neonatal results of pregnancies 45 years and older
89575664|NCT05484869||Reproductive period Control Group (n:150)|Reproductive period Pregnant Between 25-35 years
89575665|NCT05484791|Experimental|The Lumbar Rotational Spinal Mobilization Technique|Patients included in the study underwent the lumbar rotational spinal mobilization technique during two sessions per week
89575666|NCT05496413|Experimental|Active comparator Within group|This project will use the StarStim DC stimulator manufactured by Neuroelectrics that was imported with TFDA approval. At the beginning, the participants would be allowed to perform the task which would be followed by application of tACS. The tACS application would be comprised of sham vs active where the sham condition would be given for 30 seconds while the active session would be applied for 15 mins. In tACS, 1mA of theta (6Hz) tACS would be given at the right F4 and P4 electrodes (5*5 cm2, Sponstim® 25). After tACS, the participants would be asked to perform the same task again and the scores (before and after tACS) will be compared and analyzed statistically. Therefore, each patient will need to participate in 2 sessions (active vs. sham), and they will not know which day is which (randomized order).
89575667|NCT05496413|Sham Comparator|Sham comparator Within group|This project will use the StarStim DC stimulator manufactured by Neuroelectrics that was imported with TFDA approval. At the beginning, the participants would be allowed to perform the task which would be followed by application of tACS. The tACS application would be comprised of sham vs active where the sham condition would be given for 30 seconds while the active session would be applied for 15 mins. In tACS, 1mA of theta (6Hz) tACS would be given at the right F4 and P4 electrodes (5*5 cm2, Sponstim® 25). After tACS, the participants would be asked to perform the same task again and the scores (before and after tACS) will be compared and analyzed statistically. Therefore, each patient will need to participate in 2 sessions (active vs. sham), and they will not know which day is which (randomized order).
89575668|NCT05496257|Active Comparator|Group I (control): Calcium hydroxide cement|Pulp capping material
89575669|NCT05496257|Active Comparator|Group 2: Premixed bioceramic putty|Pulp capping material
89575670|NCT05490095|Experimental|Group I|"13 subjects will receive~First Dose: Afinitor 5mg, single dose~Wash out period : more than 10 days~Second Dose: SVG101 5mg, single dose"
89575671|NCT05490095|Experimental|Group II|"13 subjects will receive~First Dose: SVG101 5mg, single dose~Wash out period : more than 10 days~Second Dose: Afinitor 5mg, single dose"
89029215|NCT03906175|Experimental|Whole-body hyperthermia|Whole-body hyperthermia will be applied 2 times during 4 weeks. At week 6, the primary outcome will be assessed. The participants will be reassessed 12 weeks after the start of the treatment with whole-body hyperthermia.
89029216|NCT03906175|No Intervention|Wait list|Participants will wait for 6 weeks (primary outcome assessment point). They will then receive the same treatment procedure as the experimental group. They will also be reassessed 12 weeks after the start of the treatment with whole-body hyperthermia.
89575672|NCT05484635|Active Comparator|Diagnostic laparoscopy|Minimally invasive incisions will be made, and a diagnostic laparoscopy will be performed. The surgeon will evaluate the mesh configuration, ensuring proper positioning, perform adhesiolysis if indicated for bowel involvement with the mesh and assess the abdomen for alternative sources of chronic pain.
89575673|NCT05484635|Experimental|Laparoscopic mesh removal|Minimally invasive incisions will be made, and a diagnostic laparoscopy will be performed. The surgeon will evaluate the mesh configuration, ensuring proper positioning, perform adhesiolysis if indicated for bowel involvement with the mesh and assess the abdomen for alternative sources of chronic pain. If randomized to mesh removal, laparoscopic or robotic preperitoneal mesh removal.
89575674|NCT04424381|Active Comparator|Rivaroxaban 20 MG Oral Tablet [Xarelto]|rivaroxaban oral tablet [Xarelto] at a single oral dose of 20 mg
88971545|NCT00424138|Experimental|Group A - 3 FDG-PET/CT Scans|Two FDG-PET/CT scans prior to 1st cycle of chemotherapy, plus 2 optional volumetric CT scans. One FDG-PET/CT after 1st cycle of chemotherapy, plus 1 optional volumetric CT scan.
89575675|NCT04424381|Experimental|Rivaroxaban 20 MG Oral Tablet|rivaroxaban oral tablet at a single oral dose of 20 mg
89575676|NCT05496179|Active Comparator|Prucalopride|Patients will receive prucalopride (2 mg) once daily for 7 days.
89575677|NCT05496179|Active Comparator|Metoclopramide|Patients will receive metoclopramide (10 mg) three times daily for 7 days.
89575678|NCT04157621|Active Comparator|Active taVNS|
88971546|NCT00424138|Experimental|Group B - 2 FDG-PET/CT + 1 Optional|One FDG-PET/CT prior to 1st cycle of chemotherapy; 1 FDG-PET/CT after the 1st cycle of chemotherapy; 1 optional FDG-PET/CT after the 2nd cycle of chemotherapy. All three with optional volumetric CT scans.
88971547|NCT00424138|Experimental|Group C - Test-Retest|Test-retest sequence for FDG-PET/CT; two scans with optional volumetric CT to be completed prior to 1st cycle of chemotherapy.
88971548|NCT05336032|Active Comparator|Oral glucose tolerance test|The volunteer will be performing the standardized oral glucose tolerance test with 75 gm of glucose. After an overnight fast of 10 hours the venous blood will be collected at fasting, 30, 60 and 120 minutes post-prandial and hunger-satiety scale recorded at the same interval.
88971549|NCT05336032|Experimental|Post prandial response to Rice|The participants will be served cooked basmati rice (70-gram available glucose). After an overnight fast of 10 hours the venous blood will be collected at fasting, 30, 60 and 120 minutes post-prandial and hunger-satiety scale recorded at the same interval.
88971550|NCT05329831|Experimental|Experimental|"Patients will be asked to fill out the Introductory Information Form, the Numerical Rating Scale, the Oxford Happiness Scale Short Form, and the Life Activities Scale scales. Then, the educational needs of the patients in the experimental group will be determined. Trainings will be planned individually for each patient according to the needs of the patients.~After the patients go to their homes, telehealth will be implemented. Patients included in the experimental group will continue their routine physician appointments and prescriptions. In addition, telehealth education initiative will be made for the patients. Structured training will be applied to the patients once a week for 12 weeks, each training will be 20-40 minutes. The researcher will develop a trusting relationship with the patient and evaluate the patient's compliance with treatment, obstacles to happiness, information needs related to pain management, and difficulties in life activities."
88971551|NCT05329831|No Intervention|Control|No application will be made by the researcher to the patients in the control group. Patients will continue with their prescriptions and physician visit routines. The scales will be administered to the patients in this group at the beginning of the study and at the 4th, 8th, and 12th weeks.
88971552|NCT01806870|Experimental|Nutritional Supplements Zinc and SAMe|Each subject will receive 1600mg of SAMe per day Men subjects will receive 30mg Zinc Women subjects will receive 25mg Zinc
89575679|NCT04157621|Sham Comparator|Sham Stimulation|
89575680|NCT05496101|Other|Breast Cancer undergoing BCS|Intraoperative CLI + FAR LightPath imaging compared with Standard-of-care histopathology (gold standard)
89575681|NCT05496023||Pre PCI state|The current study will analyze the angio-FFR and generate the virtual pullback. The pullback will be co-registered by overlaying the pullback onto coronary angiogram.
89575682|NCT05496023||Post-PCI state|The post-PCI FFR and angio-FFR will be meaured.
89575683|NCT05484323|Experimental|Glucose as reference food|Thirteen healthy participants (male: 4, female: 9) after 10-14h fast, consumed 50 g available carbohydrates from D-glucose, in different visits as reference food, tested two times; and 50 g available carbohydrates from white bread, tested two times; and 50 g available carbohydrates from cookies containing 0 and 2.5g spirulina, tested once, in different visits, along with 250 mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose and salivary insulin samples were taken at 0, 15, 30, 45, 60, 90 and 120 min postmeal. The first glucose and salivary insulin sample were taken exactly 15 min after the first bite of food or drink.
89575684|NCT05484323|Experimental|White bread|Thirteen healthy participants (male: 4, female: 9) after 10-14h fast, consumed 50 g available carbohydrates from D-glucose, in different visits as reference food, tested two times; and 50 g available carbohydrates from white bread, tested two times; and 50 g available carbohydrates from cookies containing 0 and 2.5g spirulina, tested once, in different visits, along with 250 mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose and salivary insulin samples were taken at 0, 15, 30, 45, 60, 90 and 120 min postmeal. The first glucose and salivary insulin sample were taken exactly 15 min after the first bite of food or drink.
89209232|NCT00811304||US group|All patients admitted to the labor and delivery suite who request an epidural for labor analgesia.
89575685|NCT05484323|Experimental|Cookie containing 0 g spirulina|Thirteen healthy participants (male: 4, female: 9) after 10-14h fast, consumed 50 g available carbohydrates from D-glucose, in different visits as reference food, tested two times; and 50 g available carbohydrates from white bread, tested two times; and 50 g available carbohydrates from cookies containing 0 and 2.5g spirulina, tested once, in different visits, along with 250 mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose and salivary insulin samples were taken at 0, 15, 30, 45, 60, 90 and 120 min postmeal. The first glucose and salivary insulin sample were taken exactly 15 min after the first bite of food or drink.
89575686|NCT05484323|Experimental|Cookie containing 2.5 g spirulina|Thirteen healthy participants (male: 4, female: 9) after 10-14h fast, consumed 50 g available carbohydrates from D-glucose, in different visits as reference food, tested two times; and 50 g available carbohydrates from white bread, tested two times; and 50 g available carbohydrates from cookies containing 0 and 2.5g spirulina, tested once, in different visits, along with 250 mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose and salivary insulin samples were taken at 0, 15, 30, 45, 60, 90 and 120 min postmeal. The first glucose and salivary insulin sample were taken exactly 15 min after the first bite of food or drink.
89575687|NCT05495867|Experimental|NINA- MultiNeO NH|implant with bioactive surface
89575688|NCT05495867|Active Comparator|MultiNeO CS|implant with traditional surface
89575689|NCT05489861|Experimental|Experimental group A The Group to which the Mother Applies Affirmation and Massage|"15 minutes of affirmation and massage practices, 3 days a week for 5 weeks, will be taught.~Affirmation and massage practices will be shown once in the practice hall of the center as an example for the mother to apply to their baby.~Afterward, affirmation and massage applications will be applied by the mother and father at the baby's home.~Parents will be informed about the importance of having the same characteristics of the practice room for each application.~In addition, the massage video material will be given to the mother with an affirmation note as a reminder."
89209233|NCT00737633|Experimental|16-Week population|Placebo subjects in OB-202 (NCT00486291) and DM-230 (NCT00600067)
89575690|NCT05489861|Experimental|Experimental group B The Group to which the Father Applies Affirmation and Massage|"15 minutes of affirmation and massage practices, 3 days a week for 5 weeks, will be taught.~Affirmation and massage practices will be shown once in the practice hall of the center as an example for the father to apply to their baby.~Afterward, affirmation and massage applications will be applied by the mother and father at the baby's home.~Parents will be informed about the importance of having the same characteristics of the practice room for each application.~In addition, the massage video material will be given to the father with an affirmation note as a reminder."
89575691|NCT05489861|No Intervention|Control Group (C)|Parents will be asked to continue the implementation of routine sleeping techniques without being taught any practices.
89575692|NCT04423991|Experimental|Exposed group|All patients were exposed to the algorithm and were characterized as being likely responders to hydroxychloroquine treatment. Treatment decisions regarding the administration of hydroxychloroquine were made independently by care providers.
89575693|NCT05483699|Experimental|Squeezing a ball during intravenous cannulation reduces the child's pain and fear.|The soft ball has a diameter of about 8-10 cm and can return to its old form when it is squeezed.
89575694|NCT05483699|Experimental|Using a kaleidoscope during intravenous cannulation reduces the child's pain and fear.|Kaleidoscope includes shapes of flowers and mirrors in the shape of triangle placed with an angle of 600. While rotating one of the cylinders, various shapes and colourful eyes are formed when viewed with one eye. When the kaleidoscope is rotated, the patterns look different all the time because the colourful parts are moving, attracting the child's attention.
89575695|NCT05483699|Experimental|Blowing bubbles during intravenous cannulation reduces the child's pain and fear.|Children in this group were shown bubble blower before intravenous cannulation and they were shown how bubbles formed and how to blow. Children blew bubbles during intravenous cannulation
89575696|NCT05489315|Other|Traditional Positioning|Participants who are randomly assigned to NOT receive a peanut ball will undergo placement on a wedge pillow and/or traditional positioning during their labor progression at 6cm cervical dilation.
89575697|NCT05489315|Experimental|Peanut Ball Positioning|Participants who are randomly assigned to receive a peanut ball will be positioned with a peanut ball at 6cm cervical dilation.
89575698|NCT05495477|Active Comparator|Spontaneous breathing|Electrical impedance tomography (EIT).
89575699|NCT05495477|Active Comparator|CPAP mode|Electrical impedance tomography (EIT).
89575700|NCT05495477|Active Comparator|NIV- S/T mode|Electrical impedance tomography (EIT).
89575701|NCT05483543|Experimental|Pamiparib monoagent|Drug: Pamiparib 40mg bid orally
89575702|NCT04139213|Active Comparator|Usual care|usual medication assisted treatment for maintenance care of opioid use disorder
89575703|NCT04139213|Experimental|Pharmacy MAT|pharmacy-based medication assisted treatment for maintenance care of opioid use disorder
89575704|NCT05489003||Patients with fatigue|Chronic pancreatitis patients with fatigue measured by professional assessment scales.
89575705|NCT05489003||Patients without fatigue|Chronic pancreatitis patients without fatigue measured by professional assessment scales.
89575706|NCT05495165|Other|Nutritional educative programme|5 days educative programme before treatment
89575707|NCT04112849||Heart failure subjects|Subjects who have heart failure, and meet inclusion/exclusion criteria, who will be enrolled in this study and will have their heart sounds measured with Nanowear vest (NCHFMS).
89575708|NCT05495009|No Intervention|Standard of care|Introductory information form (IIF), labor follow-up form (FFL) and VAS-P, VAS-A were filled in the latent phase (1-3 cm). At the beginning of the active (4 cm) and transitional phases (8 cm), FFL, VAS-P and VAS-A were filled and no intervention was applied. 20 min in active phase. then, FFL, VAS-P and VAS-A were filled after 10 min in the transition phase. The Perception of Birth Scale is filled after birth.
89209234|NCT00737633|Experimental|72-Week population|Active treatment subjects in OB-202 (NCT00486291) and DM-230 (NCT00600067)
89209235|NCT00811460|Experimental|1|
89575709|NCT05495009|Experimental|Standard of care+ virtual reality glasses|Introductory information form (IIF), labor follow-up form (FFL) and VAS-P, VAS-A were filled in the latent phase (1-3 cm). At the beginning of the active (4 cm) and transitional phases (8 cm), after filling FFL, VAS-P and VAS-A, video was watched with virtual reality glasses. 20 minutes in active phase after watching the video. then, FFL, VAS-P and VAS-A were filled after 10 min in the transition phase. After the birth, the Perception of Birth Scale and Virtual Reality Satisfaction Form were filled.
89575710|NCT05494931|No Intervention|control group|In this first group, the same classic method of Gunderson conjunctival flap surgery will be used.
89575711|NCT05494931|Active Comparator|intervention group|in the this group, Gunderson conjunctival flap surgery will be performed adjuncted by corneal neurotomy
89575712|NCT04071587|Experimental|BCI training|Patients randomized to this group will receive up to12 (minimum 8) sessions of BCI training with the RecoveriX system (gtec, Austria). The system combines EEG driven functional electrical stimulation with visual feedback. BCI training is provided as a part of standard training of the impaired upper limb.
88971553|NCT02985866|Experimental|Artificial Pancreas|Subjects will be provided the Artificial Pancreas (AP) system which includes the inControl Diabetes Management Platform, a study insulin pump, study continuous glucose monitor (CGM), and a study glucometer. This AP system is designed to help control blood sugar in people living with type 1 diabetes.
89575713|NCT04071587|Active Comparator|Control|Patients randomized to this control group will receive standard physiotherapy and occupational therapy for their impaired upper limb.
89575714|NCT05494853||HCC|HCC positive
89575715|NCT05494853||Non HCC|HCC negative
89575716|NCT05494775|Active Comparator|Diabetic macular edema|Cases with diabetic macular edema that are prepared for intravitreal injection of anti-vascular endothelial growth factors.
89575717|NCT05494775|Active Comparator|Wet age related macular edema|Cases with wet age related macular degenerations that are prepared for intravitreal injection of anti-vascular endothelial growth factors.
89575718|NCT05494775|Active Comparator|Retinal vein occlusion|Cases with macular edema secondary to retinal vein occlusion that are prepared for intravitreal injection of anti-vascular endothelial growth factors.
89575719|NCT05494775|Active Comparator|Myopic choroidal new vascularization|Cases with myopic choroidal new vascularization that are prepared for intravitreal injection of anti-vascular endothelial growth factors.
89575720|NCT03937037|Experimental|Saline irrigation|CBD stone removal after routine ERCP procedure,100ml saline irrigation after a balloon occlusion cholangiogram confirming the absence of stones.
89575721|NCT03937037|No Intervention|None saline irrigation|CBD stone removal after routine ERCP procedure, a balloon occlusion cholangiogram confirms the absence of stones.
89575722|NCT04272203|Experimental|Dose Escalation: Participants With AML|Participants with relapsed or refractory (R/R) AML will receive escalating doses of ABBV-184
89575723|NCT04272203|Experimental|Dose Escalation: Participants With NSCLC|Participants with relapsed or refractory (R/R) NSCLC will receive escalating doses of ABBV-184
89575724|NCT04272203|Experimental|Dose Expansion: Participants With AML|Participants with R/R AML will receive ABBV-184 at recommended Phase 2 dose (RP2D) determined in dose escalation phase for AML
89575725|NCT04272203|Experimental|Dose Expansion: Participants With NSCLC|Participants with R/R NSCLC will receive ABBV-184 at RP2D determined in dose escalation phase for NSCLC
89575726|NCT05494463|No Intervention|Macintosh blade|laryngoscopy with Macintosh blade
89575727|NCT05494463|Active Comparator|Miller blade|laryngoscopy with Miller blade in the same patient
89575728|NCT05488925|Placebo Comparator|Vitamin E|
89575729|NCT05488925|Experimental|Diclofenac sodium|
89575730|NCT05488925|Experimental|Piroxicam|
89575731|NCT05488925|Experimental|Tramadol|
89575732|NCT05482763||Patients with onychomycosis|All patients with clinical suspicion of onychomycosis at the Tor Vergata Polyclinic center will be enrolled according to the inclusion and exclusion criteria of the study. After signing the informed consent, the subjects will be subjected to scraping or clipping of the nail unit affected by the disease. The collected material will be stored in a sterile container to be sent to the Microbiology laboratory.
89575733|NCT05482685||Demographic variables|Include gender, age, BMI, education level, marital status, attended health promotion program or not, average monthly income, years of experience, average hours of work per week, chronic illness, smoking habit, drinking habit
89575734|NCT05482685||health literacy|The number of points scored by completing the scale
89575735|NCT05482685||self-perceived health|The number of points scored by completing the scale
89575736|NCT05482685||health-promoting behavior|The number of points scored by completing the scale
89575737|NCT05482529||colorectal cancer with metastasis|colorectal cancer patients with at least one distant metastasis(liver, lung)
89575738|NCT05482373|Placebo Comparator|Placebo|Patients will receive hard gelatin capsules containing placebo (only the excipients).
89575739|NCT05482373|Experimental|Oleuropein|Patients will receive the same hard gelatin capsules but containing 200 mg of an olive leaf extract.
88971554|NCT02985866|Active Comparator|Sensor Augmented Therapy|Subjects will continue to use their personal insulin pump with a study continuous glucose monitor (CGM) and study glucometer.
88971555|NCT05310955|Experimental|Control group|daily rehabilitation interventions
88971556|NCT05310955|Experimental|Interventional group|daily rehabilitation interventions and shen-based Qigong exercise
88971557|NCT05275933|Placebo Comparator|PC+SC|Placebo Control Capsules (PC) are provided in addition to Standard Care medications
88971558|NCT05275933|Active Comparator|LH+SC|Lian Hua Qing Wen Capsules (LH) are provided in addition to Standard Care medications.
88971559|NCT02942108|Active Comparator|healthy, conventional surgery|Surgical bone removal by conventional rotary burs in healthy patients during third molar surgery
88971560|NCT02942108|Experimental|healthy, piezo surgery|Surgical bone removal by piezoelectric vibrations in healthy patients during third molar surgery
88971561|NCT01806792|Experimental|Risendronate and Cholecalciferol combination|risedronate 150mg and cholecalciferol 30,000 IU 1 tablet + Placebo(for risedronate 150mg) 1 tablet by once a month.
88971562|NCT01806792|Active Comparator|Risedronate|risedronate 150mg 1 tablet + Placebo(for risedronate 150mg and cholecalciferol 30,000 IU) 1 tablet by once a month.
89575740|NCT05482295|Experimental|Hepatitis B vaccine lot 1|3 doses Recombinant Hepatitis B new Bulk vaccine lot 1
89575741|NCT05482295|Experimental|Hepatitis B vaccine lot 2|3 doses Recombinant Hepatitis B new Bulk vaccine lot 2
89575742|NCT05482295|Experimental|Hepatitis B vaccine lot 3|3 doses Recombinant Hepatitis B new Bulk vaccine lot 3
89575743|NCT05482295|Active Comparator|Active Control: Hepatitis B vaccine (registered)|3 doses Recombinant Hepatitis B vaccine (registered)
89575744|NCT05482217|Experimental|Intervention group|This group was exposed to psychoeducational and problem-solving sessions for five weeks.
89575745|NCT05482217|No Intervention|The control group|No intervention was given: only the regular clinic advice for five weeks or treatment as usual.
89575746|NCT04069091|Experimental|CBT intervention|Participants in the CBT intervention arm will undergo standard antenatal care and the 'Enjoy your Bump' (iloodottaa.fi) online self-help intervention employing elements of cognitive behavioral therapy (CBT)
88971563|NCT05228431|Experimental|Sandwich Regimen|All rectal patients in this group will receive standard surgical resection.
88971564|NCT01806753|Experimental|midazolam/propofol injection|Intermittent midazolam/propofol injection controlled by endoscopist
89209236|NCT02552498|Experimental|vertical|Strangulation is applied on the the buccal side of the attached gingiva, parallel to the long axis of tooth 12, at the distal third of the tooth.
89209237|NCT02552498|Experimental|horizontal|Strangulation is applied on the buccal side of the attached gingiva, perpendicular to the long axis of the tooth 12, 2 mm far from the gingival margin.
89209238|NCT02552498|Experimental|papilla base|Strangulation is applied on the the buccal side of the attached gingiva, on the base of the mesial papilla of tooth 12, in straight line going from one side of papilla to the other.
89209239|NCT00732251|Experimental|Allopurinol|Using an open label, naturalistic design, subjects will continue with their current psychiatric medications during the study. Allopurinol will be given at a fixed dose of 300 mg/day for the first week and then 600mg/d for the remainder of the study. Subjects who cannot tolerate the 600mg dose will be given a dose of 300mg/d. Subjects will participate in monthly follow up visits for 24 months. Subjects who develop a substance abuse or substance dependence disorder during the study will be terminated from the study. Also, subjects who develop a medical condition which can affect their mood stability will be terminated from the study.
89209240|NCT00811538||1 1 (Liv*)|i.v. thrombolysis with rtPA
89575747|NCT04069091|No Intervention|Standard care|Participants in the Standard Care arm will undergo standard antenatal care.
89575748|NCT05494307|Experimental|Terbutaline plus danazol|Terbutaline: A dose of 2.5 mg three times daily for 16 weeks Danazol: A dose of 200 mg twice daily for 16 weeks
89575749|NCT05494307|Active Comparator|Danazol monotherapy|Danazol: A dose of 200 mg twice daily for 16 weeks
89575750|NCT05488379|No Intervention|Individual well child care|Individuals randomized to the control arm will receive routine individualized well child care after birth hospital discharge.
89575751|NCT05488379|Experimental|Group well child care|Individuals randomized to the intervention arm will participate in group well child care after birth hospital discharge.
88971565|NCT01806753|Active Comparator|propofol infusion|Continuous propofol infusion with opioid administration
88971566|NCT05211661||Invasively ventilated patients (n=15)|"First measurement (comprehensive protocol) within 48 hours from initiation of MV.~Serial measurements every third day including 2 measurements after extubation."
88971567|NCT02776787||Patients|Patients with diverticulitis
88971568|NCT02776787||Surgeons|Surgeons who perform elective colon resections
88971569|NCT05208424||Normal glycemia|100 patients without evidence of dysglycemia.
88971570|NCT05208424||Prediabetes|100 patients with evidence of pre-diabetes defined as hemoglobin A1C (HbA1c) 5.7-6.4% with or without fasting plasma glucose (FPG) of 100 mg/dL to 125 mg/dL.
88971571|NCT05208424||Diabetes|100 patients without evidence diabetes defined as hemoglobin HbA1c > 6.4% with or without FPG >125 mg/dL.
89209241|NCT00811538||2 (L*)|intraarterial thrombolysis
88971572|NCT01806675|Experimental|Glioblastoma Multiforme (GBM)|Patients with glioblastoma multiforme (GBM) undergo 18F-FDG and 18F-FPPRGD2 positron emission tomography / computed tomography (PET/CT) imaging at baseline and 6 weeks (or standard of care follow-up)
88971573|NCT01806675|Experimental|Gynecological Cancers|Patients with gynecological cancer undergo 18F-FDG and 18F-FPPRGD2 positron emission tomography / computed tomography (PET/CT) imaging at baseline and at 9 t0 12 weeks (or standard of care follow-up)
89209242|NCT00882024|Experimental|1 Tranilast|Tranilast, 300 mg/day
89209243|NCT00882024|Experimental|2 Tranilast|Tranilast, 150 mg/day
89209244|NCT00882024|Placebo Comparator|3|Placebo
89209245|NCT00799760|Experimental|1|oral oseltamivir 75mg twice daily + zanamivir 10 mg inhaled by mouth twice daily during 5 days
89575752|NCT05494151||SMuRFs|Patients with acute myocardial infraction with a history of at least one standard modifiable risk factor (SMuRF; smoking, diabetes mellitus, dyslipidemia, hypertension)
89575753|NCT05494151||SMuRF-less|Patients with acute myocardial infraction without history of any SMuRF
89575754|NCT05482061||retrospective analysis|A retrospective analysis of disease histories for the period from 2014 to 2021 was carried out. Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury. The basic tool for pain intensity research was the VAS. The study of the neuropathic component of pain was carried out using the DN4. Study of the presence of an acute stress reaction - anamnesis + HADS. The diagnosis of ASR was established by a psychiatrist upon admission to the military mobile hospital. The presence of post-traumatic stress disorders (PTSD) was investigated using the Mississippi scale of post-traumatic stress disorders (military version). The presence of PTSD according to the MS PTSD (c). Satisfaction with treatment results was studied using the Chaban Quality of Life Scale.
89575755|NCT05482061||prospective study|"Recruitment of patients for the prospective study was carried out in the period from 02.24.2022 to 05.24.2022. Data collection was carried out during the Russian invasion of Ukraine and the offensive on Kyiv. All patients who took part in the study with gunshot wounds were evacuated to the stage of treatment - the National Military Medical Clinical Center Main Military Clinical Hospital. The research was conducted using the same methods as during the retrospective analysis. The exception is the study period during treatment at the military medical clinical center: here it was 14 days.~In all patients with gunshot wounds, the outcome and effectiveness of pain management were assessed using the Visual Analogue Scale (VAS) and the Diagnostic Questionnaire for the Detection of the Neuropathic Pain Component Didier Bouhassiraa, Nadine Attala et al. Pain, 2005, 114: 29-36 (DN4)."
89575756|NCT05481983|Other|control group|Walk exercise
89575757|NCT05481983|Active Comparator|study group|One-on-one clinical exercise training
89575758|NCT05488223|Experimental|PUFA ω-3 (1.8g/day)|"ω-3 PUFAs (Triple Strength Fish Oil®) were purchased in advance, each capsule contained 540 mg of eicosapentaenoic acid (20:5 n-3) and 360 mg of docosahexaenoic acid (22:6 n-3), for a 0.9g total. Children and parents were told that they should take 2 capsules of ω-3 PUFAs daily, that is, they took 1.8g/day.~Parents and children were informed that the duration of the study would be 5 months, in the first three months, the children should take the capsules of the assigned treatment; in the fourth and fifth months they should continue their surveillance with the researchers. At the beginning, they were given 2 bottles of 30 capsules each, identified as formula A or B, according to the assigned group, and they were given a calendar sheet indicating that they should cross out a box if they had consumed the breakfast capsule and cross out another box if the consumed during the meal; Likewise, they were asked to write down any adverse effect, if any, on the same sheet."
89575759|NCT05488223|Active Comparator|PUFAs ω-3 0.9 g/day + MUFAs (avocado oil) 0.9 g/day.|A commercial brand of avocado oil (MUFA) was purchased in advance by putting 0.9g in each capsule. The appearance of the ω-3 PUFA capsules and the avocado oil capsules were the same. Then we worked with the company that prepared the blinding of the treatments, packaging bottles of 30 capsules each, labeling them as bottles A and B. The design contemplated giving each child two bottles, one marked to take it for breakfast and another marked to take it with food. The child was instructed to take 1 capsule per day of PUFA ω-3 (0.9g/d) and 1 capsule of avocado oil (0.9g/d)
88971574|NCT01806675|Experimental|Renal Cell Cancer (RCC)|Patients with renal cell cancer (RCC) undergo 18F-FDG and 18F-FPPRGD2 positron emission tomography / computed tomography (PET/CT) imaging at baseline and at 9 t0 12 weeks (or standard of care follow-up)
88971575|NCT02762981|Experimental|Relacorilant with nab-paclitaxel|Participants will be treated with relacorilant in combination with nab-paclitaxel at escalating dose levels in either a Continuous-Dosing Regimen or an Intermittent-Dosing Regimen.
88971576|NCT01806636||Treatment|Patients treated with PneumRx Coil System
88971577|NCT02762825|Experimental|Higher Intensity Interval Training (HIIT)|
88971578|NCT02762825|Active Comparator|Moderate Continuous Training (MCT)|
88971579|NCT05015920|Experimental|Mobilization,harvest,transduction,conditioning,treatment,engraftment|Subjects will participate in this study for a total of approximately 27 months, consisting of an up to 3 months pre-transplant period(consisting of a screening period followed by autologous cell harvest, followed by a waiting period during which the harvested cells are transduced and undergo release testing, followed by treatment with busulfan IV, and a single infusion of BD211 Drug Product) and a 24-month post-transplant evaluation period. Following completion of this study, all subjects will be asked to provided consent to participate in a follow-up study for another 13 years, which will focus on long-term safety, with an emphasis on integration site analysis, and long-term efficacy.
88971580|NCT01806480|Experimental|Person-centred proactive breastfeeding telephone support|Proactive breastfeeding telephone support initiated by the Breastfeeding Support Team (BST) at the NICU from which the infant is discharged. Daily phone calls from one member in the BST to the mother will be performed from day 1 until day 14 after discharge. In addition to this, the mother has the option to call someone in the BST during the same period (reactive). The telephone support will be conducted with a person-centered approach. Thus, the mother is enabled to talk about whatever feels important to her including the situation with the new infant at home and her breastfeeding. The feeding support team member should during the telephone support session: have an authentic presence, characterized by being there for the mother, having an empathic approach, taking time touching base, providing affirmation, being responsive, sharing the mother's experience and enabling a relationship.
88971581|NCT01806480|No Intervention|Person-centred reactive breastfeeding telephone support|The control group (and the intervention group) will be offered the possibility to person-centred reactive telephone support initiated by the mother who can phone the feeding support team from day 1 after discharge until day 14 after discharge, between 08.00-16.00 every day. Each NICU will set up a specific telephone number for their telephone support, and schedule the members in the BST for availability. The same level of person-centeredness will be provided in both reactive and proactive telephone support.
88971582|NCT02964130|Other|Follow-up patient|Medical follow-up visit
88971583|NCT04958044|Experimental|Calcium electroporation|Calcium gluconate 0.23 mmol/ml Maxium dosage 20 ml Intra tumoral injection
88971584|NCT01806441|Experimental|3-days high fat diet|During 3 days, subjects eat a diet high in fat (percent of total caloric intake: 15.0% from proteins; 49,8% from carbohydrates; 37.0% from fat).
88971585|NCT01806441|Active Comparator|3-days low fat diet|During 3 days, subjects eat a diet low in fat (percent of caloric intake: 15.0% from proteins; 61,8% from carbohydrates; 25.0% from fats).
88971586|NCT04923412|Experimental|Pulmonary branch of vagus nerve preserved|Pulmonary branch of vagus nerve is preserved during the mediastinal lymph node dissection using minimally invasive surgery
89575760|NCT05488223|Placebo Comparator|MUFAs (avocado oil) 1.8 g/day.|The child was instructed to take 2 capsules per day, 1.8g of avocado oil per day.
89575761|NCT05493839||Plateau Criteria|mild ： 142mmHg < PaO2/ FiO2 ≤ 213 mmHg moderate ： 71mmHg < PaO2/ FiO2 ≤ 142mmHg severe： PaO2/ FiO2 ≤ 71 mmHg
89575762|NCT05493839||Berlin Definition|mild ： 200mmHg < PaO2/ FiO2 ≤ 300 mmHg moderate ： 100mmHg < PaO2/ FiO2 ≤ 200mmHg severe： PaO2/ FiO2 ≤ 100 mmHg
89575763|NCT05493839||zhang|ARDS：PaO2/FiO2≤100mmHg ALI ：100mmHg<PaO2/FiO2≤150mmHg
89575764|NCT05481515||Critically ill adults|Adult patients admitted to an intensive care unit who require mechanical ventilation and supplemental oxygen
89575765|NCT05487521|No Intervention|Patients without EEG changes or clinical seizures|
89575766|NCT05487521|Experimental|Patients with EEG changes or clinical seizures|
89575767|NCT05481281|Experimental|Group Dexmedetomidine|Group Dexmedetomidine receiving I/V bolus of dexmedetomidine 0.1 mg/kg as a 20 ml solution, followed by 0.04mg/kg/hr infusion till surgery completion
89575768|NCT05481281|Experimental|Group Ketamine|Group Ketamine receiving 0.2 mg/kg iv of ketamine diluted to 20 ml followed by 0.1 mg/kg/hr infusion till surgery completion
89575769|NCT05487443|Experimental|Chemotherapy combined with immunotherapy|Gemcitabine-based chemotherapy regimen combined with immunocheckpoint inhibitors for first-line treatment of advanced biliary malignancies
89575770|NCT05481203|Experimental|The Kaleidescope Group|Kaleidoscope Group: it and asking about the colors and shapes seen within it. This distraction procedure started before the procedure and continued until it ended.
89575771|NCT05481203|Experimental|The Visual Illusion Cards Group|The Visual Illusion Cards Group: Just before the nasopharyngeal swab participants were allowed to check the cards and were asked what they saw in them.
89575772|NCT05481203|No Intervention|The Control Group|The control group received the routine nasopharyngeal swab procedure and did not receive any other nonpharmacological intervention
89575773|NCT05493527|Experimental|noninvasive high frequency oscillatory ventilation (NHFOV)|After documenting parental consent, the ventilated infants eligible for extubation were randomly assigned to NHFOV as post extubation noninvasive respiratory support
89575774|NCT05493527|Active Comparator|noninvasive positive pressure ventilation (NIPPV)|After documenting parental consent, the ventilated infants eligible for extubation were randomly assigned to NIPPV as post extubation noninvasive respiratory support
88971587|NCT04923412|Experimental|Pulmonary branch of vagus nerve not-preserved|Pulmonary branch of vagus nerve is not preserved during the mediastinal lymph node dissection using minimally invasive surgery
88971588|NCT01806402||Retina|Having clinical diagnosis of retina pathology
88971589|NCT01806402||Glaucoma|Having clinical diagnosis of glaucoma
89575775|NCT02558231|Experimental|Triple oral combination treatment|Macitentan, tadalafil, and selexipag
89575776|NCT02558231|Placebo Comparator|Dual oral combination treatment|Macitentan, tadalafil, and placebo
89575777|NCT05487365|Experimental|Patients with application|"Eligible patients are consecutive patients that are hospitalised for HF decompensation. The patients will be included in the programme during their hospitalisation or up to one month after hospitalisation. All eligible patients will be offered to participate. At the time of inclusion, patients must be in NYHA class II, III, or IV with a left ventricular ejection fraction (LVEF) of ≤50%. A total of 165 patients with app will be included over 6 month. Patients are not randomised and will all be participating in the smartphone digital support intervention.~Patients are not randomised and will all be participating in the smartphone digital support intervention.~So the app will be made available to 165 patients for home monitoring and another group of 165 patients without an application will be asked to answer quality of life questionnaires.~Patients who agree to use the application can continue to use it after the study, if they wish."
89575778|NCT05487365|Active Comparator|Patients without application|"Patients refusing participation will also be asked to complete a quality of life (QOL)-questionnaire at 6 months and 12 months which will be answered online. A total of 165 patients (who do not want to participate) will be asked to answer this questionnaire.~So the app will be made available to 165 patients for home monitoring and another group of 165 patients without an application will be asked to answer quality of life questionnaires.~Patients who agree to use the application can continue to use it after the study, if they wish."
89575779|NCT05487287||Ischemic stroke patients with functional deficit of the hand|
89575780|NCT05487287||Healthy subjects|
89575781|NCT04269785|Active Comparator|Radiofrequency ablation|These patients will receive ablation by radiofrequency catheter, guided by of 3-dimensional electro-anatomic mapping technology
88971590|NCT01806363|Active Comparator|Part A: Telmisartan, Chlorthalidone + Telmisartan|telmisartan 80mg : multiple dose administered orally chlorthalidone 25mg : multiple dose administered orally
88971591|NCT01806363|Active Comparator|Part B: Chlorthalidone, Chlorthalidone + Telmisartan|telmisartan 80mg : multiple dose administered orally chlorthalidone 25mg : multiple dose administered orally
88971592|NCT04829227|Experimental|face and/or neck and/or submental zones|the full face and/or neck and/or submental zones including 1. -The forehead and temples (left and right including the peri orbital zone) to lift the eyebrows 2. The cheeks (left and right including perioral zone and nasolabial folds) 3. Submental and sides of the neck
89209246|NCT00799760|Active Comparator|2|oral oseltamivir 75mg twice daily+ placebo inhaled by mouth twice daily during 5 days
89575782|NCT04269785|Active Comparator|Cryoballoon ablation|These patients will receive ablation by cryoballoon catheter, guided by X-ray fluoroscopy
89575783|NCT04275011|Active Comparator|Static Posture and Balance Exercise|Participants in the control group will receive equal attention through a static posture and balance exercise class two times per week, in a small group setting.
88971593|NCT04829227|Experimental|"off the face areas"|"off the face areas: abdomen, or arms or thighs or Décolleté."
88971594|NCT02709161|Experimental|real-time fMRI neurofeedback: Amygdala|Amygdala neurofeedback - attempt to upregulate the left amygdala during positive autobiographical memory recall via real time fMRI neurofeedback from the amygdala. Two sessions will be performed one week apart.
88971595|NCT02709161|Active Comparator|real-time fMRI neurofeedback: HIPS|HIPS neurofeedback - attempt to upregulate the left horizontal segment of the intraparietal sulcus (HIPS), a region not involved in emotional processing, during positive autobiographical memory recall via real time fMRI neurofeedback from the HIPS. Two sessions will be performed one week apart.
88971596|NCT01806285||Patients with Respiratory Symptoms|
89209247|NCT00799760|Active Comparator|3|oral placebo twice daily + zanamivir 10 mg inhaled by mouth twice daily during 5 day
89209248|NCT00875316|Experimental|Cohort A|
89209249|NCT00875316|Experimental|Cohort B|
89209250|NCT00875316|Experimental|Cohort C|
89209251|NCT00875316|Experimental|Cohort D (Optional)|
89575784|NCT04275011|Experimental|Progressive Resistance and Impact Exercise|The exercise program will include two progressive resistance and impact exercise training sessions per week in a small group setting. Exercises will be individually tailored to the participants' abilities and designed to achieve a maximum 80-85% 1RM.
89575785|NCT05481047|Experimental|prevention|investigator will prevent intraoperative arterial hypotension based on HPI index
89575786|NCT05481047|No Intervention|treatment|investigators will treat intraoperative arterial hypotension based on standard hemodynamic parameters
89575787|NCT05480969|Experimental|Intervention group 1|Heart failure educational sessions will be provided by the heart failure-trained nurse to patients and caregivers. These will be delivered through a combination of home visits and telephone calls performed at regular time intervals for a total period of 6 months.
89575788|NCT05480969|Experimental|Intervention group 2|Heart failure educational sessions will be provided by the heart failure-trained nurse to patients and caregivers. These will be delivered through telephone calls performed at regular time intervals for a total period of 6 months.
89575789|NCT05480969|No Intervention|Control group|Control patients and caregivers will receive usual care for heart failure.
89575790|NCT05480813|Other|Prof. Dr. K. Corten|The one participant of the study is an orthopaedic surgeon. He will execute 48 THA procedures during 4 study days. 24 THA procedures will be executed using the automated KINCISE™ impaction system and 24 THA procedures will be executed using a standard mallet. He will undergo physical and cognitive test before and after the OR day and during lunch breaks. Next to that, operational efficiency and ergonomic impaction will be analysed
89575791|NCT05480501|Experimental|IM19 CAR-T cells|
89575792|NCT05486819|Active Comparator|Group (L)|receive 3 ml (60 mg) of lignocaine 2% added to propofol during injection
89575793|NCT05486819|Active Comparator|Group (B)|receive 3 ml of sodium bicarbonate 8.5% added to propofol during injection
88971597|NCT04803331|Experimental|cT1-2N0M0 oral cancer patients|Patients undergo routine sentinel lymph node procedure (99mTc injection, planar imaging, SPECT-CT and surgery) for clinical purposes. After 99mTc injections and imaging has been executed peritumoral SPIO injections are performed by a medical doctor. A T2*-weighted iron sensitive MRI scan is made 1 hour later.
88971598|NCT04799860|Experimental|health promotive work-way|Six primary care units that voluntarily enrolls as experimental units. The units will receive implementation support based on previous research and tailored to the specific prerequisits and context for each unit. Strategies includes involvement of target groups; informationa and interactive education;use of external and internal facilitators tarined for the purpose; systematic feedback and learning dialogs during the project. The implementation support will take approximately 12 months.
88971599|NCT04799860|No Intervention|Control|Six primary care centers of similar size and socioeconomic background in the population listed to each center.
89575794|NCT05486819|Placebo Comparator|Group (S)|receive 3 ml of normal saline added to propofol during injection
89575795|NCT05480423|Experimental|Online mindfulness-based intervention|The online programme lasts for 28 days. Parents will receive the links of daily mini-lectures that introduced basic principles in mindfulness and mindful parenting, audio files of guided mindfulness practice, and exercises that facilitates parents to integrate mindfulness in their daily lives. The total time spent in each session will be around 15 to 20 minutes. Weekly meeting will be arranged with mindfulness instructor and participants.
89575796|NCT05480423|No Intervention|Waitlist controlled group|Participants will be offered same intervention three months later
89575797|NCT05480345|Experimental|Impedance cardiography|Impedance cardiography parameters recorded with ICG monitor (niccomoTM; Medis, Ilmenau, Germany)
88971600|NCT04794907||DR|Patients with diabetes
88971601|NCT04794907||AMD|Patients age 55 and older
88971602|NCT04787029|Experimental|prophylactic medical compression therapy group|"This study provides medical compression stockings from the start date of Docetaxel administration for patients who have undergone mastectomy and axillary lymphectomy for breast cancer, and who are planning to receive Docetaxel adjuvant chemotherapy. The intervention group wears medical compression stockings for upper limbs with a pressure level of 1 (15-21mmHg) during the day from the start of docetaxel administration to 3 months after the end of administration.~Basic education of upper limb exercises (joint motion range enhancement exercises and upper limb muscle pumping exercises) is provided to both the intervention group and the control group."
88971603|NCT04787029|No Intervention|control group|"The control group proceeds as an observation, but interventions such as providing stockings in the event of lymphedema are performed.~Basic education of upper limb exercises (joint motion range enhancement exercises and upper limb muscle pumping exercises) is provided to both the intervention group and the control group."
88971604|NCT01806246|Experimental|integrative rehabilitation program|28 sessions during 12 months with focus on psychoeducation, activity planning, and thoughts and feelings connected to having a serious chronic disease. From week 13 to week 32 a training programme aiming at balancing heart rate variability.
89575798|NCT02554877|Placebo Comparator|Placebo|
89575799|NCT02554877|Experimental|PF-06291874, 30 mg|
89575800|NCT02554877|Experimental|PF-06291874, 60 mg|
89575801|NCT02554877|Experimental|PF-06291874, 100 mg|
89575802|NCT05486741||Myopes|myopes (≤ -1.0 D)
89575803|NCT05486741||Hyperopes|hyperopia (≥ +1.0D).
89575804|NCT05486741||Emmetropes|"emmetropes (> -1.0 to <~1.0 D)"
89575805|NCT05480267|Experimental|UBE|The patient treated with unilateral biportal endoscopy (UBE)
88971605|NCT04774198||Occurrence of persistent postoperative hypotension|Patients with need for noradrenaline the morning after surgery to maintain middle arterial blood-pressure (MAP)>65 mmHg, after pancreaticoduodenectomy.
88971606|NCT04774198||No occurrence of persistent postoperative hypotension|Patients without need for noradrenaline the morning after surgery to maintain middle arterial blood-pressure (MAP)>65 mmHg, after pancreaticoduodenectomy.
88971607|NCT02964403|Experimental|Cox-2|Cox-2 inhibitor ParecoxibNa 40mg pre-ERCP injection
89575806|NCT05480267|Active Comparator|MIS-TLIF|The patient treated with classical minimally invasive posterior spinal interbody fusion (MIS-TLIF)
89575807|NCT05480189||patients in breast cancer with bone metastasis|patients in breast cancer with bone metastasis
88971608|NCT02964403|Active Comparator|Indomethacin|Rectal Indomethacin was administrated immediately after ERCP in high-risk patients, while average risk patients did not.
88971609|NCT00405262|Active Comparator|1|
88971610|NCT00405262|Experimental|2|
88971611|NCT00405262|Experimental|3|
88971612|NCT00405301|Other|Arm 1|Arm 1: will receive Isoniazide(5mg/kg/day), Rifampicin(10mg/kg/day) and Pyrazinamide(25mg/kg/day) in full doses on day 1 and continued further
88971613|NCT00405301|Other|Arm 2|Arm 2 : will receive Rifampicin(10mg/kg/day) in full dose on day 1 and continued, Isoniazide(5mg/kg/day)in full dose on day 8 and continued, Pyrazinamide(25mg/kg/day)on day 15 and continued
88971614|NCT00405301|Other|Arm 3|Arm 3 will receive 100 mg/day of Isoniazide on day 1 which is gradually increased to maximum dose (5mg/kg/day) by day 4 and continued. Rifampicin is introduced on day 8 in a dose of 150 mg/day which is gradually increased to maximum dose (10mg/kg/day) by day 11 and continued. Pyrazinamide is introduced on day 15 in a dose of 500mg/day which is gradually increased to maximum dose (25mg/kg/day) by day 18 and continued.
88971615|NCT00405340|Experimental|Drug|Rituximab
88971616|NCT00391001|Experimental|1|
88971617|NCT00391001|Placebo Comparator|2|
88971618|NCT04713826|Experimental|BAY2586116_Placebo|"Male or female participants aged above or equal to 18 years diagnosed with moderate to severe OSA will be allocated randomly to this intervention sequence.~Participants will receive BAY2586116 in treatment period 1, and placebo in treatment period 2.~Each intervention will be applied at home for 6 days (+1 optional day) followed by one in-house application for the overnight PSG (polysomnography).~In total, each participant will receive up to a maximum of 7 single doses (8 single doses if optional day is used) of BAY2586116 and up to 7 single doses of placebo (8 single doses if optional day is used)."
88971619|NCT04713826|Experimental|Placebo_BAY2586116|"Male or female participants aged above or equal to 18 years diagnosed with moderate to severe OSA will be allocated randomly to this intervention sequence.~Participants will receive placebo in treatment period 1, and BAY2586116 in treatment period 2.~Each intervention will be applied at home for 6 days (+1 optional day) followed by one in-house application for the overnight PSG.~In total, each participant will receive up to a maximum of 7 single doses (8 single doses if optional day is used) of BAY2586116 and up to 7 single doses of placebo (8 single doses if optional day is used)."
88971620|NCT04713319|Placebo Comparator|Placebo|"Ten participants were randomly selected to the placebo group.~Calcium chloride (E509) dissolved into water. Extremely small equimolar calcium dose with the test item."
88971621|NCT04713319|Active Comparator|RH013001 (DGA)|D-glyceric acid (DGA) calcium salt dehydrate (RH013001) dissolved into 1.8 dl of water. Effective dose of DGA was 3.33 mg / kg body weigh for the first 4 days. Thereafter the dose was reduced to half for the 14 days follow up period. Frequency: 2 times a day.
89209252|NCT00799838|Experimental|Ketoprofen + Amoxicillin|Ketoprofen + Amoxicillin for 3 days, then Amoxicillin alone for 7 days
89209253|NCT00799838|Placebo Comparator|Amoxicillin|Placebo (for ketoprofen) + Amoxicillin for 3 days, then Amoxicillin alone for 7 days
89209254|NCT00799916|Active Comparator|Voluven|Resuscitation fluid: Voluven (R)
88971622|NCT02669576|Experimental|Mind body medicine day care clinic|Patients recieve an 11-week mind body day care clinic including elements of mindfullness based stress reduction (MBSR), yoga, acupuncture, education
88971623|NCT02669576|Other|Usual care|Patients continue usual care by their practitioner
88971624|NCT04635904|Experimental|Imaginal exposure|A behavioral intervention in imagery
88971625|NCT04635904|Experimental|Imagery rescripting|A different behavioral intervention in imagery
88971626|NCT02647892|Active Comparator|Arm A|10 mg/mL lidocaine; Frequency: 1
88971627|NCT02647892|Active Comparator|Arm B|9 mg/mL of 10% sodium bicarbonate-90% lidocaine; Frequency: 1
88971628|NCT02647892|Active Comparator|Arm C|7.5 mg/Ml of 25% sodium bicarbonate-75% lidocaine Frequency: 1
88971629|NCT02647892|Active Comparator|Arm D|5 mg/mL 50% sodium bicarbonate-50% lidocaine Frequency: 1
89033208|NCT05319704|Active Comparator|Kinetic in eccentric mode|"The subjects will have to carry out a test of effort in eccentric or concentric mode during 30 minutes performed at 30% of VO2max.~The exercise will be followed by indirect oxygen calorimetry (with canopy) extended over a period of 6 hours to measure the energy expenditure, the nature of the oxidized substrates (carbohydrates and lipids) and oxidation rates. During each kinetic, 6 other blood samples will be collected at several times. On these samples, insulin and blood sugar will be measured."
89575808|NCT05493059||Patients|"Mucocutaneous Leishmaniasis proven by culture and/or polymerase chain reaction (PCR)~Seen in French Guiana between 01/01/2017 and 01/04/2022, in dispensaries (CDPS) or in the Dermatology Department of the CHC~Having received treatment with Miltefosine~Patient who consented to participate in the study~Age equal or superior to 18 years"
89575809|NCT05492981|Experimental|Intervention|The intervention was a 16-minute educational video created by the study investigators which provided information about Down syndrome, diagnostic tests and screening tests. The screening tests covered in the video included the triple test, the combined first trimester screen and non-invasive prenatal screening. Information about how and when each of the tests were performed, their detection rates and possible results and their interpretations were covered in the video. The video was viewed by several healthcare providers and experts in the field of prenatal screening before the commencement of this study to ensure that the content was appropriate and adequate. The intervention was viewed by subjects on a portable tablet in a quiet room in the antenatal clinic. Subjects were then invited to ask their doctor any questions that they may have had about the video during the clinic consult which followed.
89575810|NCT05492981|No Intervention|Control|Women in the control group were counselled by the referring doctor regarding the aneuploidy screening options of FTS or NIPS, and provided information about the procedures involved for each test, their detection rates, cost, and possible results of testing. The use of a written information leaflet was available to doctors as an adjunct to providing this information.
89575811|NCT04235465||Dyslexia Group|30 patients will be included. Dynamic Gait Index and other assessments will be performed twice with a 7-day interval by two evaluators
89575812|NCT04235465||Healthy Control Group|30 healthy children will be included. Dynamic Gait Index will be performed.
89575813|NCT05492903|Experimental|Intervention|Intervention during weeks 0-10 (10 weekly group sessions). Follow-up with no treatment during weeks 11-20.
89575814|NCT05492903|Other|Waitlist Control|Usual practice during weeks 0-10. Intervention during weeks 11-20 (10 weekly group sessions).
89575815|NCT05486351||Mantainance of anticoagulation therapy|Patients with acute ischemic stroke of cardioembolic source and previosly anticoagulated in which anticoagulant therapy is mantained
89575816|NCT05486351||Interruption of anticoagulation therapy|Patients with acute ischemic stroke of cardioembolic source and previosly anticoagulated in which anticoagulant therapy is interrupted.
88811144|NCT04199117|Experimental|No Incentive,Tailored,No Care Manage,Intensive Treatment|Participants randomly assigned to this condition will not have access to incentives for completing smoking cessation counseling, will receive 5 tailored letters promoting use of smoking cessation treatment over 2 years, will not receive Tobacco Care Management support and motivational encouragement calls, and will have access to 3 smoking cessation quit counseling calls and 12-weeks of either combination nicotine replacement or varenicline up to 4 times over 2 years.
89029217|NCT03871361|Experimental|Abatacept 125 MG/ML Prefilled Syringe|"Participants will inject the drug at home on a weekly basis. Participants will receive the syringes on the visit dates, supplying them for the period until the next visit. At baseline, participants will be explained and shown how to inject the drug themselves.~Subject will have to stop all concomitant immunosuppressive drugs at baseline, e.g. Corticosteroids, Methotrexate, Mofetil Mycophenolate, Azathioprine, Tacrolimus, Sirolimus or Cyclosporin. Other drugs can be continued. In case of recurrence in the abatacept group, the study will end for that subject.~Patients treated with abatacept (ORENCIA) may receive concurrent vaccinations, except for live vaccines. Live vaccines should not be given concurrently with abatacept or within 3 months of its discontinuation."
89029218|NCT03870334|Experimental|BT-11 880 mg|Oral once daily tablet
89029219|NCT03870334|Placebo Comparator|Placebo|Oral once daily tablet
89029220|NCT03799718|Experimental|NurOwn (MSC-NTF cells)|Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors
89209255|NCT00799916|Active Comparator|Saline|Resuscitation fluid: Saline solution
89575817|NCT05475587||Prediabetes cases|
89575818|NCT05475587||Healthy controls|
89575819|NCT05480033|Experimental|Intervention group|The imagery technique was applied to the students in this group on the day of the laboratory practice, before the lesson, once a week for 4 weeks. The laboratory practice consisted of 6 weeks. Pre-test was performed on the first week, followed by 4 weeks of imagery technique, and the pre-test was performed on the final week. In each application of the imagery technique, four scenarios that could be encountered in clinical practice that required skill practice were used for 30 minutes. The imagery technique was applied by the second author who had expertise and training in nursing and imagery technique. The stages of the imagery technique included preparation of a suitable environment, preparation of the students, setting the background music (ney sound), relaxation, focusing on the technique, visualising the situation to be imagined, loading positive and constructive expressions on the individual, distracting the student from the imagined situation, relaxation and ending the session.
89029221|NCT03795701|Placebo Comparator|Placebo|Subjects in placebo group will receive placebo plus behavioral weight loss counselling to portion control to achieve 500 kcal daily deficit based on MedGem required maintenance calories (not to be reduced below 1000 kcal per day for any subject). Subjects will also be asked to maintain physical activity.
89029222|NCT03795701|Experimental|Liraglutide 3.0|Subjects in Liraglutide 3.0 group will receive Saxenda® plus behavioral weight loss counselling to portion control to achieve 500 kcal daily deficit based on MedGem required maintenance calories (not to be reduced below 1000 kcal per day for any subject). Subjects will be asked to maintain physical activity. The dose of Saxenda® will be increased weekly in the first 4 weeks (.6; 1.2; 1.8; 2.4 mg) and maintained on 3 mg for 12 weeks.
89029223|NCT03786471|Active Comparator|Health Systems-Based Dementia Care|Dementia care that is based in the health care system, which partners with community-based organizations to provide comprehensive, coordinated, patient-centered care. The health system-based dementia care arm uses a Dementia Care Specialist (Nurse Practitioner or Physician Assistant) supervised by a physician to tailor and facilitate dementia care delivery in collaboration with the primary care physician (co-management). The Health Systems-Based Dementia Care arm is based on UCLA's Alzheimer's and Dementia Care Program.
89033209|NCT05319704|Placebo Comparator|Kinetic in concentric mode|"The subjects will have to carry out a test of effort in eccentric or concentric mode during 30 minutes performed at 30% of VO2max.~The exercise will be followed by indirect oxygen calorimetry (with canopy) extended over a period of 6 hours to measure the energy expenditure, the nature of the oxidized substrates (carbohydrates and lipids) and oxidation rates. During each kinetic, 6 other blood samples will be collected at several times. On these samples, insulin and blood sugar will be measured."
89575820|NCT05480033|No Intervention|Control group|No intervention was performed on the students in this group.
89575821|NCT05479955|Experimental|5 minutes skin to skin contact|Participants were provided care in different rooms, blinded to the differences in practice used between the two groups. Skin-to-skin contact was applied to the babies of the women in this group for 5 minutes immediately after birth. After the application, routine follow-up and care of the newborn was performed and kept under a radiant heater. When the woman became stable, her baby was given and breastfeeding was supported.
89575822|NCT05479955|Experimental|60 minutes skin to skin contact|Participants were provided care in different rooms, blinded to the differences in practice used between the two groups. Skin-to-skin contact application was initiated to the babies of the women in this group immediately after birth and was applied continuously for 60 minutes as recommended by WHO. Follow-up and care of the newborn were done during the application. At the end of 60 minutes, the baby was dressed and given to its mother.
89575823|NCT05479877|Experimental|(Experimental group) collagen based Pulpotomy|(sterile medicated collagen particles, Biofil-AB ,Eucare Pharmaceuticals Pvt. Ltd, Chennai, India)
89575824|NCT05479877|Active Comparator|(Control group) Biodentine pulpotomy|Biodentine (Septodont, Saint-Maur-des-Fossés, France)
89575825|NCT05479799||Anemia group|anemia was diagnosed with a hemoglobin level of less than 11.0 g/dl
89575826|NCT05479799||Non-anemia group|Normal hemoglobin was diagnosed with a hemoglobin level of more than 11.0 g/dl
89575827|NCT05492747|Experimental|Kangaroo Care Effects on Feeding|The researcher allocated the mothers blindly. Eligible mothers and their preterm babies were randomized to either the kangaroo care group or the standard care group (1:1) (Figure 1). The mothers' surnames were written and put in a bag. The surnames were drawn from the bag by lot. The lots were drawn by a neonatal nurse. Neonatal nurse is a research independent person. The first drawn surname was included in the kangaroo group, while the next one was included in the control group, respectively.
89575828|NCT05492669|Experimental|Lidocaine group|General anesthesia is induced in the lidocaine group with intravenous lidocaine 1.5mg/kg for ten minutes, followed by continuous injection of lidocaine 1.5mg/kg.h. At the end of the operation, the patient controlled intravenous analgesia with lidocaine is used, and the dose of lidocaine is 30mg/kg(no more than 2000mg at most).
89575829|NCT05492669|Placebo Comparator|Conventional analgesia group|The lidocaine is replaced by identical volumes and rates of 0.9% saline. At the end of the operation, the patient controlled intravenous analgesia without lidocaine is used.
89575830|NCT02554721|Experimental|Group 1 (CYP2C19 Wild Type)|Trial period A: Cilostazol 100 mg twice daily for 1 week (Days 1-7) Trial period B: Wash out period (Days 8-14) Trial period C: Acetylsalicylic acid 100 mg once daily for 1 week (Days 15-21) Trial period D: Cilostazol 100 mg twice daily and Acetylsalicylic acid 100mg once daily for 1 week (Days 22-28)
89575831|NCT02554721|Experimental|Group 2 (CYP2C19 Wild Type)|Trial period A: Cilostazol 100 mg twice daily for 1 week (Days 1-7) Trial period B: Wash out period (Days 8-14) Trial period C: Clopidogrel 75 mg once daily for 1 week (Days 15-21) Trial period D: Cilostazol 100 mg twice daily and Clopidogrel 75 mg once daily for 1 week (Days 22-28)
89575832|NCT02554721|Experimental|Group 3 (CYP2C19 heterozygous (*1/*2) )|Trial period A: Cilostazol 100 mg twice daily for 1 week (Days 1-7) Trial period B: Wash out period (Days 8-14) Trial period C: Clopidogrel 75 mg once daily for 1 week (Days 15-21) Trial period D: Cilostazol 100 mg twice daily and Clopidogrel 75 mg once daily for 1 week (Days 22-28)
89575833|NCT02554721|Experimental|Group 4 (CYP2C19 homozygous (*2/*2))|Trial period A: Cilostazol 100 mg twice daily for 1 week (Days 1-7) Trial period B: Wash out period (Days 8-14) Trial period C: Clopidogrel 75 mg once daily for 1 week (Days 15-21) Trial period D: Cilostazol 100 mg twice daily and Clopidogrel 75 mg once daily for 1 week (Days 22-28)
89033210|NCT05318456|Experimental|MoodElite T-4003-1|Participants will be instructed to take two capsules of MoodElite T-4003-1 once daily with water, after dinner without food starting on Day 0 for 42 days. If a dose is missed participants are instructed to take the dose as soon as they remember. Participants will be advised not to exceed 4 capsules daily.
89033211|NCT05318456|Active Comparator|Comparator|Participants will be instructed to take two capsules of comparator once daily with water, after dinner without food starting on Day 0 for 42 days. If a dose is missed participants are instructed to take the dose as soon as they remember. Participants will be advised not to exceed 4 capsules daily.
89575834|NCT02552225|Experimental|amitriptyline|Subjects in this arm will receive pills composed of amitriptyline and Avicel (cellulose filler)
89575835|NCT02552225|Placebo Comparator|placebo|Subjects in this arm will receive pills composed only of Avicel (cellulose filler)
89575836|NCT05479721||LITMUS Imaging Study Group|Patients within the European NAFLD Registry who have also consented to participate in the LITMUS Imaging study
89575837|NCT05474261||GROUP A-NO Valsalva maneuver|
89575838|NCT05474261||GROUP B- Valsalva maneuver|
89575839|NCT05473949|Active Comparator|Propofol|"ASA Standard monitorization and nasal spectacle capnography (OC) were used. Supplementary supply of O2 is placed at 2-3 L/min also by OC.~The drugs were randomized of the study begins. The investigators didn't know whether ketamine is present in syringes prepared with propofol or not, acting in the same way for both drug combinations.~Sedation was performed with:~1. Propofol: induction with a bolus of 1% propofol (10mL syringe) administered at a dose of 0.75mg/kg; maintenance with 1% propofol infusion (20mL syringe), at an infusion rate of 6-7mg/kg/h.~In both arms:~4 mg of I.V. dexamethasone were administered.~At the beginning of the procedure and atropine and ephedrine were prepared.~At the end of the procedure, paracetamol I.V. 15mg/kg was administered.~If the patient reports VAS>3 pain in recovery, metamizole magnesium 15mg/kg is also administered.~In case of post-procedure nausea and/or vomiting, 4 mg of ondansetron would be administered as a rescue."
89209256|NCT00737477|Experimental|Mircera in Renal Anemia|Participants will receive SC methoxy polyethylene glycol-epoetin beta (Mircera) every 4 weeks for a total of 48 weeks in this single-arm study. The first dose of 120 or 200 micrograms (mcg) will be determined by the dose of ESA received prior to administration of study treatment, while subsequent doses will be adjusted to maintain hemoglobin within the target range.
89575840|NCT05473949|Active Comparator|Ketofol|"2. Sedation with ketofol in a 1:4 dilution: induction of sedation with bolus of ketofol (dilution containing 9.5 mL of 1% propofol + 0.5 mL of 5% ketamine) (10mL syringe), administered at a dose of 0.75 mg/kg; maintenance with ketofol infusion (dilution containing 19 mL of 1% Propofol + 1 mL of 5% Ketamine), (20mL syringe), at an infusion rate of 6-7mg/kg/h.~The dose used for bolus induction of sedation in both arms of the study is titrated to the needs of each individual patient, although the target approximates the usual recommended dose. If a propofol or ketofol syringe is insufficient considering the patient's weight, another syringe will be prepared with exactly the same dilution as the first.~The study was always blind to the investigators."
89575841|NCT04424069|Active Comparator|LASIK group|Patients will do excimer laser LASIK operation for correction of myopia with flap creation by mechanical keratome
89575842|NCT04424069|Active Comparator|SMILE group|Patients will do Femtosecond laser assisted corneal refractive surgery for correction of myopia
89575843|NCT04424069|Active Comparator|Photorefractive keratectomy group|Patients that will undergo photorefractive keratectomy for correction of myopia
89575844|NCT04424069|Active Comparator|Refractive lens exchange|Include eyes that will undergo refractive lens exchange
89575845|NCT04424069|No Intervention|Control group|Myopic control eyes with no surgical intervention
89575846|NCT05492279|Experimental|intervention|10 gr Sheep ghee
89575847|NCT05492279|Active Comparator|control group|10 gr sunflower oil
89575848|NCT02552147|Experimental|Transdermal nicotine first, placebo last|Subject will receive transdermal nicotine 7 mg daily for 7 days, placebo patch for 7 days, then placebo patch for a final 7 days.
89575849|NCT02552147|Experimental|Transdermal placebo first, nicotine last|Subject will receive transdermal placebo daily for 7 days, placebo patch for another 7 days, then transdermal nicotine 7 mg daily for a final 7 days.
89575850|NCT05479487|Experimental|Fluzoparib+Apatinib combination|
89209257|NCT00799994||1|Patients that have medical intervention in an attempt to lower intraocular pressure (oral or topical)
89209258|NCT00799994||2|Patients who have received no intervention
89209259|NCT03838458||Study|Children with isolated hypospadias
89209260|NCT03838458||Control|Children with planned circumcision
89209261|NCT00800072|Experimental|oxygen therapy|one experimental device assigned to each of the 10 patients including in the study for an experiemental session duration of 6 hours
89209262|NCT04019717|Experimental|8 weeks|
89575851|NCT05479487|Active Comparator|Fluzoparib Monotherapy|
89575852|NCT05479409|Experimental|Neoadjuvant radiotherapy|Group 1:Patients undergo mastectomy or Breast conserving surgery after radiotherapy Group 2:Patients receive boost in the area of residual breast mass and regional lymph node. A total dose of 66Gy will be given.
89575853|NCT01662635||ALK-BREAK APART|"We reviewed 230 consecutive cases of NSCLC that were retrieved from oncologic molecular laboratory and diagnostic pathology unit at the Instituto Nacional de Cancerologia, Mexico city, between 2011 and 2014. Samples were sent to the unit of pathological anatomy, a Pathologist confirmed the histologic diagnosis. The only inclusion criterion was the availability of tissue for biomarker studies. Clinical and pathologic details of these patients were included in a database, obtained from medical records.~For ALK fusion testing, we applied dual-color, break-apart FISH, RT-qPCR, and immunohistochemistry. Interpretation of the results was done in double-blind manner without knowing the results by other methods."
89575854|NCT05479331||sarcopenia|CKD patients with sarcopenia, meeting the following two criteria (1) male LTI (lean tissue index)< 7.0 kg/m2, female LTI < 5.7 kg/m2; (2) Male HGS)(handgrip strength < 26 kg, female HGS < 18 kg.
89575855|NCT05479331||non-sarcopenia|CKD patients with non-sarcopenia
89209263|NCT04019717|Experimental|12 weeks|
89209264|NCT00879216|Placebo Comparator|Sugar pill|
89209265|NCT00879216|Experimental|VA106483|
89575856|NCT05479253|Experimental|with Artificial intelligence assistant system|Endoscopists would complete the endoscopy report with the assistance of the artificial intelligence system.
89575857|NCT05479253|No Intervention|without Artificial intelligence assistant system|Endoscopists would complete the endoscopy report without special prompts.
89575858|NCT05479175|Active Comparator|Ibuprofen|Ibuprofen 600 mg will be given to the patient one hour before starting root canal treatment.
89575859|NCT05479175|Active Comparator|Diode laser|Low-level laser therapy will be applied with an 810 nm wavelength diode laser device for 30 seconds in the area of mesial root and 30 seconds in the area of distal root , total of 60 seconds.
88971630|NCT04585087|Experimental|Healthy adult men|"Participants will initially be seen for a pre-study assessment (2 hours). They will then be studied for up to 6 times (6 different levels of threonine intake). Each set of experiments will be 9-days in length. During the first 2 days, a pre-adaptation (milkshake) diet will be consumed. For the remaining 7 days, a protein liquid drink and protein-free cookies will be consumed. All of the diets will be provided by the investigators.~During each 9-day experiment, participants are expected to come to the Clinical Research Centre at the Hospital for Sick Children for breath and urine collection (5 hours total for each visit)"
89575860|NCT05479175|Active Comparator|Nonactive Diode laser|Placebo, will be explained to the patients that laser treatment will be applied as in group 2, but laser will not be activated.
88971631|NCT02624804|Experimental|Stem Cell Educator Therapy|"Patients will have apheresis performed and then have their own blood returned to them with the educated lymphocytes"
88971632|NCT04528810||Child injuries|pediatric patients under the age of 18 years newly diagnosed with injuries in the emergency department
88971633|NCT00393627|Experimental|1|Sleep Education Program: The Sleep Education Program (SEP) is conducted by a licensed MS- or PhD-level mental health professional experienced in working with persons with dementia and their caregivers. The therapist meets with the AFH owner/operator and staff for four weekly sessions at the AFH. The SEP content includes information about the causes of sleep problems in dementia, and provides staff with assistance in developing customized resident behavioral sleep plans focused on environmental (light and noise), dietary (eliminating caffeine and excessive nighttime fluids), and sleep scheduling (reducing afternoon/ evening napping; consistent, appropriate bed and rising times) factors that are commonly associated with resident nighttime awakenings. A written manual is used.
88971634|NCT00393627|Placebo Comparator|2|Routine medical care
88971635|NCT04516408|Experimental|Recombinant zoster vaccine|Eligible patients were randomized in a 1:1 ratio to recombinant zoster vaccine/placebo on the background of standard of care (SOC). Participants received two intramuscular doses of the vaccine 2 months apart.
89575861|NCT05479175|No Intervention|Control|Control, routine root canal treatment will be done. No medication or laser will be applied before the treatment procedure.
89575862|NCT05472857|Experimental|anti-claudin18.2 chimeric antigen receptor T-cell therapy|anti-claudin18.2 chimeric antigen receptor T-cell therapy，infusion
89575863|NCT05491889||HCC patients with PPVT after TACE|determine frequency of short-term mortality (< 3month) among HCC patients with PPVT after TACE, and to explore its predictors.
89575864|NCT02534935|Experimental|rLP2086 vaccine|"Arm stratified by age:~≥12 to <18 months and ≥18 to <24 months"
88971636|NCT04516408|Placebo Comparator|Placebo|Eligible patients were randomized in a 1:1 ratio to recombinant zoster vaccine/placebo on the background of standard of care (SOC). Participants received two intramuscular doses of the placebo (sterilized water) 2 months apart.
88971637|NCT01806207|Active Comparator|Durolane injection|Intraarticular injection of 3 ml Durolane.
88971638|NCT01806207|Placebo Comparator|Saline injection|Intraarticular injection of physiological sodium chloride (0.9% NaCl) solution pH 7.
89209266|NCT02592161|Experimental|Experimental|Test drug : Granules, Chung A Won 3g (Eucommiaceae, Psoralea corylifolia, Walnut, Ginger) Three times a day, oral administration for 24weeks
89575865|NCT02534935|Active Comparator|Control|"Arm stratified by age:~≥12 to <18 months and ≥18 to <24 months"
89575866|NCT05430295|Active Comparator|Eyhance intraocular lens|10 patients bilaterally implanted with Eyhance intraocular lens
89575867|NCT05430295|Active Comparator|Tecnis 1 piece intraocular lens|10 patients bilaterally implanted with Tecnis 1 piece intraocular lens
89575868|NCT05429359|Active Comparator|CSII users|Patients using Continuous Subcutaneous Insulin Infusion (only hybrid closed loop pumps)
88971639|NCT04453969||Breastfeeding mothers positive for COVID-19|
88971640|NCT04437355|Active Comparator|Control Group|Young and healthy Group of People (18-50 years) without any pathology of the lower limb
88971641|NCT04437355|Active Comparator|Ankle Fracture Type Weber B|Young and healthy patients with an operative treated fracture of the ankle (type Weber B)
89209267|NCT02592161|Placebo Comparator|Placebo comparator|Reference drug : Granules, Placebo 3g (Lactose hydrate, Corn starch, Caramel pigment) Three times a day, oral administration for 24weeks
89575869|NCT05429359|Active Comparator|MDI users|Patients using Multiple Daily Injections (only Tresiba and Toujeo as basal insulin)
89575870|NCT02544451|Experimental|Treatment Period 1: LUM/IVA to LUM/IVA|
89575871|NCT02544451|Experimental|Treatment Period 1: Placebo (PBO) to LUM/IVA|
89575872|NCT02544451|No Intervention|Treatment Period 1: Observational Cohort|
89575873|NCT02544451|Experimental|Treatment Period 2: LUM/IVA|
89575874|NCT02544373|Active Comparator|Immediate PAP therapy (Group 1)|Subjects will receive PAP treatment for OSA as soon as possible after baseline PSG and repeat baseline cognitive testing 3 months after initiation of PAP therapy. PAP therapy is considered standard clinical care for OSA. It involves wearing an apparatus that includes a hose and a mask (that covers the nose, or nose and mouth), connected to a small machine that blows air into the airway during sleep. The degree of air pressure given depends on your apnea severity, and the supplied air pressure can be continuous or change with your breathing pattern (bilevel).
89575875|NCT02544373|Other|Standard Care PAP therapy (Group 2)|Subjects will delay PAP treatment for 3 months following their baseline sleep study, and repeat their baseline cognitive testing prior to PAP treatment for sleep apnea. PAP therapy is considered standard clinical care for OSA. It involves wearing an apparatus that includes a hose and a mask (that covers the nose, or nose and mouth), connected to a small machine that blows air into the airway during sleep. The degree of air pressure given depends on your apnea severity, and the supplied air pressure can be continuous or change with your breathing pattern (bilevel).
89575876|NCT02551991|Experimental|nal-IRI + 5-FU/LV + oxaliplatin|
89575877|NCT04268615|Experimental|Patients|Patients suffering from chronic bilateral vestibular hypofunction
89575878|NCT04268615|Active Comparator|healthy subject group|
89575879|NCT05491811|Experimental|Ensartinib and Bevacizumab|Ensartinib 225 mg oral once daily with Bevacizumab 7.5mg/kg intravenous every 3 weeks
89575880|NCT05472233|Active Comparator|2weeks|Suture removal at 2 weeks post intervention
89575881|NCT05472233|Experimental|3+weeks|Suture removal at 3 weeks minimum post intervention
89575882|NCT05491733|Active Comparator|APX001 Treatment A|Oral tablet with a 25% drug load (low-load) in fasted participants
89575883|NCT05491733|Experimental|APX001A Treatment B|Oral tablet with a high drug load in fasted participants
89575884|NCT05491733|Experimental|APX001A Treatment C|Oral tablet with a high drug load in participants that are not fasted.
89575885|NCT05478785|Experimental|Cisplatin micelle injection (HA132)|"Dose-escalation: Five dose levels have been selected for evaluation in the Phase Ⅰ of the study. Dose escalation decisions will be determined based on toxicities observed during the first cycle.~Dose-expansion: Patients will be administered HA132 at one or two dose levels (e.g. MTD and the dose below MTD).~Cohort-expansion: Patients will be administered HA132 at one or two dose levels (e.g. MTD and the dose below MTD)."
89575886|NCT05471297||Handball players|Professional handball players
89575887|NCT05478395||Questionnaires assessed adolescents and young adults|"Internet users aged 14-35;~Be able to read and communicate in Chinese."
89575888|NCT05478317|Active Comparator|Control group: Crown lengthening using a traditional open-flap approach (OF).|Esthetic Crown lengthening done using a traditional open-flap approach (OF).
89575889|NCT05478317|Experimental|Test group: Crown lengthening using a minimally invasive approach by piezoelectric (PZ).|Esthetic Crown lengthening done using a minimally invasive approach using piezoelectric (PZ).
89575890|NCT01661933|Experimental|Necator americanus, gluten challenge|Single arm, vertical.
89209268|NCT00800228||1|Eight men and eight women to define the time course of changes in MBG \ and OLC accompanying sodium loading
89209269|NCT00800228||2|32 additional women to determine whether breathing pattern is predictive of sodium sensitivity in that gender. Women are being studied in the second experiment because they, but not men, have been shown to have an association of breathing pattern with high perceived stress11 and an association of high resting end tidal CO2 with high resting blood pressure.
89575891|NCT02865551|Experimental|Extended catheterization|Participants in which a foley catheter will be inserted adjacent to epidural anesthesia during labor.
89575892|NCT02865551|Experimental|Intermittent catheterization|Participants in which a short term catheter will be inserted every 4 hours during labor after epidural anesthesia until delivery.
89575893|NCT02797769||Non-TNFi Biologics|Real world patients with RA with a dispensing history for non-TNFi biologics (such as abatacept or tofacitinib) will be included.
89575894|NCT02797769||TNFi Biologics|Real world patients with RA with a dispensing history for TNFi biologics will be included.
89575895|NCT02797769||Tocilizumab|Real world patients with RA with a dispensing history for tocilizumab will be included.
89575896|NCT05471219|Experimental|Çalışma grubu|Primiparous pregnant women who will undergo vaginal examination by focusing on visual traces
89575897|NCT05471219|No Intervention|Kontrol grubu|Primiparous pregnant women who will undergo vaginal examination with standard care
89575898|NCT05478083|Active Comparator|Direct start|36 months of treatment with study medication
89575899|NCT05478083|Other|Delayed start|First 18 months standard care, hereafter 18 months treatment with study medication
89575900|NCT02750657||Patients with advanced pancreatic ductal adenocarcinoma|
89575901|NCT02544217|Experimental|Single Escalating|2 alternating groups receiving escalating single doses of active/placebo
89575902|NCT02544217|Experimental|Multiple Escalating|3 multiple escalating groups, receiving active/placebo
89575903|NCT05427565|Experimental|Cortical hemodynamic variability of four weeks iTBS|"One healthy participant will be included in this study, which lasts for 4 weeks, 5 visits per week, involving 20 visits in total.~The participant will receive the following instructions the night before: to take 200 mg of caffeine one hour before the visit (no other caffeine intake since the wake-up) or avoid caffeine intake at all before the visit; to attend the visit in the morning or afternoon. These assignments will be randomized in a counterbalanced manner."
89575904|NCT02533999|Experimental|Surgical Instrument|"PEAK® Plasma Surgery System [PEAK PlasmaBlade® TnA Tonsil and Adenoid Tissue Dissection Device] (Medtronic, Inc) is a marketed device. The PEAK® system generates plasma, an electrically conductive cloud produced when radiofrequency energy contacting tissue and the tissue breaks down. The system was designed to have the precision of a scalpel, minimal bleeding as with electrosurgery, but reduced collateral thermal tissue damage. The PEAK® Plasma System setting will be standardized for tonsils, to 2 for coagulation and 1 for cutting; and for adenoids, to 7 for coagulation, and 7 for cutting."
89575905|NCT02533999|Active Comparator|Electrosurgery|Electrosurgery, also known as thermal cautery, refers to a process in which a direct or alternating current is passed through a resistant metal wire electrode, generating heat. The heated electrode is then applied to living tissue to achieve hemostasis or varying degrees of tissue destruction. It is commonly used for tonsillectomy and adenoidectomy in pediatric patients. The electrocautery setting will be standardized to 12 for tonsils and 30 for adenoids.
89575906|NCT02306551||Psychotic Disorder|Biological and psycho-social risk and resilience factors
89575907|NCT02306551||Bipolar Disorder|Biological and psycho-social risk and resilience factors
89575908|NCT02306551||Depressive Disorder|Biological and psycho-social risk and resilience factors
89575909|NCT02306551||Non-psychiatric Control|Biological and psycho-social risk and resilience factors
89575910|NCT02533531|Experimental|1-Lead Outpatient Telemetry|1-Lead Outpatient Patch study participants. Patients assigned to outpatient telemetry monitoring will receive the 1-Lead patch upon discharge from hospital inpatient status. ECG data will be submitted by the 1-lead patch to a central database.
89575911|NCT04423549||tested group|
89575912|NCT04423549||controlled group|
89575913|NCT05426707|Experimental|RIC group|RIC is a non-invasive therapy that is performed by automated pneumatic cuffs placed on bilateral arms. The RIC protocol includes five cycles of 5-min inflation to 200mmHg and 5-min deflation.
88971642|NCT04437355|Active Comparator|Ankle Fracture Weber C and complex|Young and healthy patients with an operative treated fracture of the ankle (type Weber C or complex fracture)
88971643|NCT01806090|Active Comparator|Clopidogrel|Continue clopidogrel for 7 days prior to the endoscopic procedure
88971644|NCT01806090|Placebo Comparator|Placebo|Placebo daily for 7 days prior to the endoscopic procedure
88971645|NCT04414150|Experimental|SHR-1802|
88971646|NCT04396444|Experimental|Lavender Aromastick Group|The aromastick is a plastic tube, similar in size to a lipstick. A study team member will prepare the aromastick by infusing ten drops of lavender essential oil onto a blank cotton wick inside the tube and sealing the cap.
88971647|NCT04396444|Placebo Comparator|Blank Aromastick Group|A study team member will prepare the blank aromastick by placing a blank cotton wick inside the aromastick tube and sealing the cap.
88971648|NCT01806012|Experimental|Enseal|Tissue sealing with Enseal device
88971649|NCT01806012|Active Comparator|Supracervical hysterectomy using conventional instruments|Supracervical hysterectomy using conventional instruments
88971650|NCT02496416|Experimental|Treatment|The treatment group will participate in an eight week aquatic exercise program during weeks 2-9 of the study. The aquatic exercise program will consist of 45 minute classes held 3 days/week for 8 weeks (18 hours total). The program is based on guidelines provided by the National Multiple Sclerosis Society (NMSS) and will be led by an aquatic fitness instructor certified to teach individuals with MS at the YMCA in Randolph, NJ.. The exercises will focus on improving flexibility, balance and strength. Equipment such as water mitts, paddles, noodles and bands will be used to increase the level of difficulty as needed.
89575914|NCT05426707|Sham Comparator|Sham RIC group|The Sham-RIC protocol include five cycles of 5-min inflation to 60 mmHg and 5-min deflation by placing automated pneumatic cuffs on bilateral arms.
89575915|NCT02533453|Experimental|Bydureon|exenatide once weekly
89575916|NCT05424835|Experimental|SHR-A1811|
89575917|NCT05424835|Experimental|Pyrotinib in combination with Capecitabine.|
89575918|NCT05424601|Experimental|Rethink game plus PsyPills|Rethink game followed by PsyPills
89575919|NCT05424601|Experimental|Rethink Game|Rethink game only
89575920|NCT05424601|No Intervention|Control|Control group
89575921|NCT02533375|Experimental|Participants receiving adalimumab|80 mg at Week 0 by subcutaneous (SC) injection, followed by 40 mg every other week (eow) on and after Week 2 until Week 50. Dose escalation to 80 mg eow was allowed for participants who did not have adequate response on or after Week 8.
89575922|NCT05410873|Experimental|MitoQ|Mitoquinol mesylate 40mg daily
89575923|NCT05410873|Placebo Comparator|Placebo|
89575924|NCT05410795||Healthy people|Healthy people refer to those who exclude pancreatic related diseases, such as acute and chronic pancreatitis, pancreatic trauma, pancreatic tumor, peripancreatic lesions, diabetes and other diseases that may affect the volume of the pancreas.
89575925|NCT05410795||Chronic pancreatitis|Patients with chronic pancreatitis are considered as study subjects.
89575926|NCT05410795||Acute pancreatitis|Patients with acute pancreatitis within 144 hours after the onset of typical symptoms are considered as study subjects.
89575927|NCT02551055|Experimental|MLN1117 300 mg + Alisertib|MLN1117 300 mg, tablets, orally, once daily for 3 days on (Days 1, 2, 3; 8, 9, 10; 15, 16, 17; 22, 23, and 24) and 4 days off per week and alisertib 40 mg, tablets, orally, twice daily for 3 days on (Days 1, 2, 3; 8, 9, 10; 15,16, and 17) and 4 days off per week on Weeks 1-3, and 1 week off in 28-day treatment cycles until PD or unacceptable toxicity.
89575928|NCT02551055|Experimental|MLN1117 600 mg + Alisertib|MLN1117 600 mg, tablets, orally, once daily for 3 days on (Days 1, 2, 3; 8, 9, 10; 15, 16, 17; 22, 23, and 24) and 4 days off per week and alisertib 40 mg, tablets, orally, twice daily for 3 days on (Days 1, 2, 3; 8, 9, 10; 15,16, and 17) and 4 days off per week on Weeks 1-3, and 1 week off in 28-day treatment cycles until PD or unacceptable toxicity.
89575929|NCT02551055|Experimental|MLN1117 300 mg + Paclitaxel|MLN1117 300 mg, tablets, orally, once daily for 3 days on (Days 2, 3, 4; 9, 10, 11; 16, 17, 18; 23, 24, and 25) and 4 days off per week and paclitaxel 80 mg/m^2, infusion, intravenously, once weekly on (Days 1, 8, and 15) and 1 week off, in 28-day treatment cycles until PD or unacceptable toxicity.
89575930|NCT02551055|Experimental|MLN1117 600 mg + Paclitaxel|MLN1117 600 mg, tablets, orally, once daily for 3 days on (Days 2, 3, 4; 9, 10, 11; 16, 17, 18; 23, 24, and 25) and 4 days off per week and paclitaxel 80 mg/m^2, infusion, intravenously, once weekly on (Days 1, 8, and 15) and 1 week off, in 28-day treatment cycles until PD or unacceptable toxicity.
89575931|NCT02551055|Experimental|MLN1117 300 mg + TAK-659|MLN1117 300 mg, tablets, orally, once daily for 3 days on (Days 1, 2, 3; 8, 9, 10; 15, 16, 17; and 22, 23, and 24) and 4 days off per week and TAK-659 100 mg (as determined in study C34001 [NCT02000934]), tablets, orally, once daily, in 28-day treatment cycles until progressive disease (PD) or unacceptable toxicity.
89575932|NCT02551055|Experimental|MLN1117 200 mg + Docetaxel|MLN1117 200 mg, orally, once daily for 3 days on (Days 2, 3, 4; 9, 10, 11; 16, 17, and 18) and 4 days off per week and docetaxel 75 mg/m^2, infusion, intravenously, on Day 1 once every 3 weeks in 21-day treatment cycles until PD or unacceptable toxicity.
89575933|NCT02551055|Experimental|MLN1117 300 mg + Docetaxel|MLN1117 300 mg, orally, once daily for 3 days on (Days 2, 3, 4; 9, 10, 11; 16, 17, and 18) and 4 days off per week and docetaxel 75 mg/m^2, infusion, intravenously, on Day 1 once every 3 weeks in 21-day treatment cycles until PD or unacceptable toxicity.
89575934|NCT05470673|Experimental|Alveolar ridge preservation using demineralized dentin combined with I-PRF + metronidazole|Atraumatic extraction of non-restorable teeth, then the extracted tooth will be prepared and demineralized using hydrochloric acid (HCL) acid as particulate demineralized dentin graft and processed with injectable platelet rich fibrin. The injectable PRF will be mixed with 5mg/ml metronidazole first then added to the particulate demineralized dentin graft then inserted in the extraction socket and covered then suturing
88971651|NCT02496416|Active Comparator|Control|The control group will participate in an eight week stretching program during weeks 2-9 of the study. The stretching program will consist of 45 minute classes held 3 days/week for 8 weeks (18 hours total). The program is based on guidelines provided by the National Multiple Sclerosis Society (NMSS) and will be conducted online via a secure video-conferencing website.
88971652|NCT04341181|Experimental|Alectinib|Alectinib for patients with a molecular tumor profile that can potentially be targeted by Alectinib.
88971653|NCT04341181|Experimental|Atezolizumab|Atezolizumab for patients with a molecular tumor profile that can potentially be targeted by Atezolizumab.
88971654|NCT04341181|Experimental|Avelumab|Avelumab for patients with a molecular tumor profile that can potentially be targeted by Avelumab.
88971655|NCT04341181|Experimental|Axitinib|Axitinib for patients with a molecular tumor profile that can potentially be targeted by Axitinib.
88971656|NCT04341181|Experimental|Erlotinib|Erlotinib for patients with a molecular tumor profile that can potentially be targeted by Erlotinib.
88971657|NCT04341181|Experimental|Vemurafenib plus Cobimetinib (combination)|Vemurafenib plus Cobimetinib (combination treatment) for patients with a molecular tumor profile that can potentially be targeted by Vemurafenib plus Cobimetinib.
88971658|NCT04341181|Experimental|Trastuzumab plus Pertuzumab (combination)|Trastuzumab plus Pertuzumab (combination treatment) for patients with a molecular tumor profile that can potentially be targeted by Trastuzumab plus Pertuzumab.
88971659|NCT04341181|Experimental|Trastuzumab emtansin|Trastuzumab emtansin for patients with a molecular tumor profile that can potentially be targeted by Trastuzumab emtansin.
88971660|NCT04341181|Experimental|Vismodegib|Vismodegib for patients with a molecular tumor profile that can potentially be targeted by Vismodegib.
88971661|NCT04341181|Experimental|Niraparib|Niraparib for patients with a molecular tumor profile that can potentially be targeted by Niraparib.
88971662|NCT01806324|Experimental|HL040XC(Atorvastatin+Losartan)|HL040XC lag time released combination drug
88971663|NCT01806324|Active Comparator|Losartan + Atorvastatin|Coadministration group
88971664|NCT01805973|No Intervention|Control|Standard pre-operative care, no active intervention
89209270|NCT04938570||University-level and amateur rugby players|"University-level and amateur rugby players will be recruited and assessed (motor, visual and symptom assessment) over one season ( June 2021 to August 2022).~Participants will be stratified according to gender (males n≈100, and females n≈100). Although the number of SRC that will be observed during the season is not known, the investigators will compare a number of head injuries/SRC to the results from cohort baseline testing. Participants that do not sustain a concussion will also have follow up testing at the end of the season."
89209271|NCT00800306|Experimental|levosimendan|
89209272|NCT00800306|Active Comparator|Control|
89575935|NCT05470673|Active Comparator|Alveolar ridge preservation using autogenous demineralized dentin graft alone|Atraumatic extraction of non-restorable teeth, then the extracted tooth will be prepared and demineralized using hydrochloric acid (HCL) acid as particulate demineralized dentin graft and inserted in the extraction socket and covered then suturing
89575936|NCT05470361||People who suffer from PTSD|The sample will be composed of 30 patients from Stella's Chicago practice: 712 N Dearborn St, Chicago, Illinois 60654
89575937|NCT05459285|Experimental|14028 injection|Subjects receive 14028 injection in the study, 0.75mg, once
89575938|NCT05459285|Active Comparator|dulaglutide injection (TRULICITY®)|Subjects receive dulaglutide injection (TRULICITY®) in the study, 0.75mg, once
89575939|NCT02542943|Experimental|Experimental Oral Rinse1|Brushing with fluoride toothpaste for 1 minute followed by rinsing with 10 ml of Experimental Oral Rinse 1 for 1 minute. This regimen will be performed twice daily for 8 weeks.
89575940|NCT02542943|Experimental|Experimental Oral Rinse 2|Brushing with fluoride toothpaste for 1 minute followed by rinsing with 10 ml of Experimental Oral Rinse 2 for 1 minute. This regimen will be performed twice daily for 8 weeks.
89575941|NCT02542943|Placebo Comparator|Placebo Oral Rinse|Brushing with fluoride toothpaste for 1 minute followed by rinsing with 10 ml of Placebo Oral Rinse 2 for 1 minute. This regimen will be performed twice daily for 8 weeks.
89575942|NCT03284957|Experimental|Amcenestrant Monotherapy: Arm #1 Part A Dose Escalation, Part B Dose Expansion|"Part A: Amcenestrant will be administered orally once daily (QD). Treatment will begin with an identified starting dose. Administration of higher doses to subsequent participants is based on occurrence of DLTs and evaluation of target saturation and PK parameters at initial and subsequent doses, until maximum administered dose (MAD) is reached. Drug will be administered in a 28-day cycle.~Part B: When the dose escalation phase ends, the recommended dose will be administered for the expansion cohort. Drug will be administered in a 28-day cycle."
89575943|NCT03284957|Experimental|Amcenestrant/Palbociclib: Arm #2 Part C Dose Escalation, Part D Dose Expansion|"Part C: Amcenestrant will be administered in combination with palbociclib: amcenestrant starting oral daily dose will be one dose level below monotherapy RD and palbociclib will be dosed at fixed standard dose. Administration of higher dose of amcenestrant (with standard palbociclib dose) to subsequent participants will be based on occurrence of DLTs at initial and subsequent doses, until MAD of amcenestrant is reached. Drugs will be administered in a 28-day cycle (palbociclib will be administered for 21 days of cycle).~Part D: Based on the results in Part C, participants will be administered either: 1) a determined amcenestrant dose (RD) with standard dose of palbociclib in combination therapy, or 2) one of two randomized dose levels of amcenestrant with standard dose of palbociclib in combination therapy. Drugs will be administered in a 28-day cycle (palbociclib will be administered for 21 days of cycle)."
88971665|NCT01805973|Experimental|Exercise Training|"Supervised Exercise Training Programme Patients will be required to attend three 50 minute exercise sessions per week for 18 weeks. They will exercise in groups of 8-12 and will be supervised by an experienced exercise physiologist. Each session will comprise a 15 minute warm up, 30 minutes of moderate intensity aerobic exercise followed by a 10 minute cool down period.~The patients will have the option to choose from three different exercise programmes tailored to individuals of mixed abilities (and co-morbidities)."
88971666|NCT04304677||Pre PCI state|The current study will analyze the pre-PCI pullback recording and amount of FFR step-up. The association of the amount of FFR step-up with post-PCI percent FFR increase, post-PCI FFR, and clinical outcome at 2 years will be analyzed
88971667|NCT02423876|Experimental|Arm I (epidural placement, ERP)|Patients undergo epidural placement in the First Day Surgery pre-operative area or similar areas suitable for insertion of epidural catheters. In the post-operative anesthesia care unit, patients may receive medication via the epidural on an as needed basis, as determined by the anesthesia team. Dosing and rate of standardized medication will be managed by the anesthesia team until the epidural is removed. Patients complete the ERP comprising increased activity, dietary restrictions, fluid balance, as well as anti-nausea, anti-inflammatory and pain medications at specific times. Patients will have access to additional pain medications as needed to control their pain.
88971668|NCT02423876|Active Comparator|Arm II (ERP)|Patients complete the ERP comprising increased activity, dietary restrictions, fluid balance, as well as anti-nausea, anti-inflammatory and pain medications at specific times. Patients will have access to additional pain medications as needed to control their pain.
88971669|NCT01805934|Active Comparator|Group RBLF|receive a 14-day quadruple therapy,including rabeprazole(10mg bid),bismuth citrate(220mg bid),levofloxacin(200mg qm) and furazolidone(100mg bid).
89209273|NCT01581775|Experimental|Divalproex Sodium ER Tablets, 500 mg|Divalproex Sodium ER Tablets, 500 mg of Dr. Reddy's Laboratories Limited
89209274|NCT01581775|Active Comparator|Depakote ER Tablets, 500 mg|Depakote ER Tablets, 500 mg of Abbott Laboratories
89209275|NCT04039152||Pre- interventions group|Without clinical pharmacists recommendations to optimize antibiotics use
89209276|NCT04039152||Post - interventions group|interventions include clinical pharmacists recommendations to optimize antibiotics use
89575944|NCT03284957|Experimental|Amcenestrant/Alpelisib: Arm #3 Part F Safety Run-In, Part G Dose Expansion|"Part F: Amcenestrant will be administered in combination with alpelisib at a fixed standard dose. Additional dose levels of amcenestrant with alpelisib could be explored if needed based on the safety and PK results. Lower dose of alpelisib could be explored based on the PK results and safety profile from the initial combination administration. Both amcenestrant and alpelisib will be administered in a 28-day cycle.~Part G: Based on the conclusion in Part F, participants will be administered the determined RD of amcenestrant and alpelisib given in the combination in an expansion cohort. Both study drugs will be administered in a 28-day cycle."
89575945|NCT03284957|Experimental|Amcenestrant/Everolimus: Arm #4 Part H Dose Escalation, Part I Dose Expansion|"Part H: Amcenestrant will be administered at the determined RD in combination with 2 dose levels of everolimus. Additional dose levels of amcenestrant with everolimus could be explored if needed based on the safety and PK results. Both amcenestrant and everolimus will be administered in a 28-day cycle.~Part I: Based on the conclusion in Part H, participants will be administered the determined RD of amcenestrant and RD of everolimus given in the combination in an expansion cohort. Both study drugs will be administered in a 28-day cycle."
89575946|NCT03284957|Experimental|Amcenestrant/Abemaciclib: Arm #5 Part J Dose Escalation, Part K Dose Expansion|"Part J: Amcenestrant will be administered at the determined RD in combination with 2 dose levels of abemaciclib. Additional dose levels of amcenestrant with abemaciclib could be explored if needed based on the safety and PK results. Both amcenestrant and abemaciclib will be administered in a 28-day cycle.~Part K: Based on the conclusion in Part J, participants will be administered the determined RD of amcenestrant and RD of abemaciclib given in the combination in an expansion cohort. Both study drugs will be administered in a 28-day cycle."
89575947|NCT02542865|Experimental|Test Group|Fortified malt based food (27 grams) made up in 150 mL lukewarm water administered twice daily
89575948|NCT02542865|No Intervention|Control Group|No treatment was administered
88971670|NCT01805934|Active Comparator|Group RA|receive a 14-day dual therapy with high doses of rabeprazole(20mg bid) and amoxicillin(1000mg tid).
88971671|NCT04302259|Experimental|SCI Patient|Complete or Incomplete Spinal Cord Injury (SCI) patients with Asia Impairment Score (AIS) of A or B between the levels of C7/T1 and T10
88971672|NCT01805895|Experimental|Minocycline|This intervention arm will receive a total of 5 doses of Minocycline. Dose 1 of Minocycline will be 400mg IV within 12-hours of onset of symptoms. Dose 2 of Minocycline will be 400mg oral, given daily on days 2-5 . Each dose is 24 hours apart.
88971673|NCT01805895|No Intervention|Control|This arm will not receive any minocycline. This arm will receive standard of care treatment.
88971674|NCT04278274||patients will be evaluated by artificial intelligence system and expert radiologist|the patients with locally advanced rectal cancer (LARC) finished the neoadjuvant treatment, and not yet receive total mesorectum excision (TME) surgery will be enrolled. The post-neoadjuvant treatment MRI images features of each enrolled patients will be captured by the artificial intelligence system, and evaluated by experienced radiologists as well. Blind to the pathologic report of TME specimen, both approaches further respectively yield a predicted pathologic response to neoadjuvant treatment for each enrolled patient, shown as pCR or non-pCR.
89209277|NCT04046276|Placebo Comparator|Conventional Physical Therapy|Three sessions a week of hospital-based conventional physical therapy, all in presence and with the guidance of a registered physical therapist, for nine months
89209278|NCT04046276|Sham Comparator|Medium Intensity Aerobic exercise (50% VO2 max)|Three sessions a week of hospital-based Medium Intensity Aerobic exercise (50% VO2 max); on a stationary bicycle, all in presence and with the guidance of a physical education teacher, for nine months
89209279|NCT04046276|Experimental|High Intensity Aerobic exercise|Three sessions a week of hospital-based High Intensity Aerobic exercise (70% VO2 max) on a stationary bicycle, all in presence and with the guidance of a physical education teacher, for nine months
89209280|NCT00731939|Other|Titan® OTR IPP|Subjects implanted with Titan® One Touch Release (OTR) Inflatable Penile Prosthesis (IPP)
89209281|NCT01072591|Experimental|1|
89209282|NCT01072591|Placebo Comparator|2|
89209283|NCT00882258|Experimental|12.5 mg Proellex|Proellex 12.5 mg daily
89209284|NCT00882258|Experimental|25 mg Proellex daily|Proellex 25 mg
89209285|NCT00882258|Placebo Comparator|Placebo|Placebo daily
89209286|NCT00811694||a|15 male and 15 female patients with glaucoma
89209287|NCT00811694||b|30 sex matched healthy volunteers
88971675|NCT04265443||Post PCI state|The study population of this study underwent percutaneous coronary intervention(PCI) with 2nd generation drug-eluting stent (DES) and measured invasive physiologic indices after PCI
88971676|NCT04255030|Experimental|First stage: Self-directed Coping Together|
89209288|NCT01070719||Relapsing form of MS treated with natalizumab|Only patients diagnosed with a relapsing form of Multiple Sclerosis (MS) and who are being treated with Tysabri (natalizumab) will be included in this Phase IV observational study.
89209289|NCT04038606|Active Comparator|acceptance of mastectomy|Assess the determinants of acceptance of mastectomy based on personal background,Measured by questionnaires: self-image (Rosenberg),personal background (level of fragility, self-image),quality of life SF-36, QLQC30,pain (BPI-SF) and Big Five Inventory.
89209290|NCT04038606|Experimental|rejection of mastectomy|Assess the determinants of rejection of mastectomy based on personal background, Measured by questionnaires: self-image (Rosenberg),personal background (level of fragility, self-image),quality of life SF-36, QLQC30,pain (BPI-SF) and Big Five Inventory.
89209291|NCT03741595|Experimental|Single Arm|
89209292|NCT00879294|Sham Comparator|1 Wristband|Some patients will be randomized to wear a motion sickness wristband which does not have any drug effect.
89209293|NCT00879294|Experimental|Chewing Gum|Patients will be randomized to use chewing gum after surgery.
89209294|NCT00879294|No Intervention|Control|Usual post-operative care.
89209295|NCT01072747|Experimental|heparin of bovine origin|Laboratory Bergamo Ltda. 5.000UI/mL bottle with 5mL
89209296|NCT01072747|Active Comparator|heparin of porcine origin|APP Pharmaceuticals
89209297|NCT02594657|Experimental|pedal rate ON 50 RPM|
89575949|NCT05477771|Experimental|Anterior tear group|The rotator cuff was divided into three parts according to the arthroscopic discovery: (1) the anterior part which contained the subsacpularis and one third of the suprascapularis forward; (2) the middle part which contained the two thirds of the suprascapularis backward and one third of the subscapularis forward; (3) the posterior part which contained two thirds of subscapularis backward and teres minor. The patients with rotator cuff tear at the anterior part were categorized in the anterior tear group.
89575950|NCT05477771|Experimental|Middle tear group|The rotator cuff was divided into three parts according to the arthroscopic discovery: (1) the anterior part which contained the subsacpularis and one third of the suprascapularis forward; (2) the middle part which contained the two thirds of the suprascapularis backward and one third of the subscapularis forward; (3) the posterior part which contained two thirds of subscapularis backward and teres minor. The patients with rotator cuff tear at the middle part were categorized in the middle tear group.
88971677|NCT04255030|Experimental|First stage: Minimally guided telephone support (lay coaching)|
88971678|NCT04255030|Experimental|Second stage: High intensity Motivational Interviewing (MI)|
88971679|NCT01805856|Experimental|Group A (intervention PIPC)|Patients in group A (intervention PIPC) were given AMP of 2g PIPC intravenously just after intubation. If the operation time was longer than 3 hours, additional infusion of same dose PIPC was done. After coming back to the patients' own room, one more infusion of same dose of same drug was done.
88971680|NCT01805856|Experimental|Group B (intervention CEZ)|Patients in Group B (intervention CEZ) were given AMP of 1g CEZ intravenously just after intubation. If the operation time was longer than 3 hours, additional infusion of same dose CEZ was done. After coming back to the patients' own room, one more infusion of same dose of same drug was done.
89575951|NCT05477771|Experimental|Posterior tear group|The rotator cuff was divided into three parts according to the arthroscopic discovery: (1) the anterior part which contained the subsacpularis and one third of the suprascapularis forward; (2) the middle part which contained the two thirds of the suprascapularis backward and one third of the subscapularis forward; (3) the posterior part which contained two thirds of subscapularis backward and teres minor. The patients with rotator cuff tear at the posterior part were categorized in the posterior tear group.
89575952|NCT03644927|Experimental|Progressive exercise program|"Based on the Active Physical Treatment Model individuals with chronic pain are typically and primarily sedentary or physically deconditioned and need a progressive approach to work up to standard exercise prescriptions as defined by the American College of Sports Medicine. Thus, progressive exercise training can help to minimize the risk or occurrence of a range of exercise-related adverse medical events, particularly with the complex study population which will be starting at a sedentary level and therefore, may not be able to initially achieve the heart rate goals prescribed in standard exercise training protocols. The exercise prescription will be individually designed and geared toward an intensity manageable by the individual."
89575953|NCT03644927|Active Comparator|Waitlist Control|The waitlist control participants will be fully screened for eligibility and asked to wait 12 weeks before beginning the 12-week progressive exercise program. They will be assessed again at the end of the 12-week waiting period. These patients will then be compared to patients in the experimental arm and then compared against their own waitlist control data after completing the 12-week exercise program. The exercise program that the waitlist control patients will participate in is identical to the experimental arm.
88971681|NCT01805856|No Intervention|Group C (without AMP)|Patients in Group C underwent surgery without any AMP.
89209298|NCT02594657|Experimental|pedal rate on 80 RPM|
89575954|NCT03611153|Experimental|AZD4831 Oral myeloperoxidase inhibitor|Patient may take 30 mg of oral myeloperoxidase inhibitor following baseline right heart catheterization.
89575955|NCT03611153|Placebo Comparator|Placebo|Patient may take 30 mg of placebo oral capsule following baseline right heart catheterization.
89575956|NCT02542631|Experimental|Bolus Insulin Patch (Calibra Finesse)|Use of the wearable patch to deliver meal-related bolus insulin dose
89575957|NCT02542631|Active Comparator|Insulin Pen (Novo-Nordisk FlexPen®)|Use of the pen device to deliver meal-related bolus insulin dose
89575958|NCT05459051||Patients with stable angina|"Symptomatic~Anatomically severe single-vessel coronary artery disease~Physiological evidence of myocardial ischaemia"
89575959|NCT05458973||Frontline cohort|
89575960|NCT05458973||recurrent cohort|
89575961|NCT02542397|Experimental|Pharmacogenomic Testing|Pharmacogenomic test results to guide drug/dose modifications
88971682|NCT01805817|Experimental|Levonorgestrel releasing intrauterine device, contraception|LNG-IUS - Mirena ®,20μgr, once intrauterine insertion per 5 year, 1 year
88971683|NCT01805817|Experimental|YASMIN® (Drospirenone/Ethinyl Estradiol), contraception|oral, once a day, 1 year
88971684|NCT01805817|Experimental|Copper T 380 A , contraception|intrauterine device, once per 10 year, 1 year period
88971685|NCT04220320||Classic BISHOP score|Gynecological evaluation based on vaginal examination including cervical dilatation, effacement, texture, station and position.
88971686|NCT04220320||Modified BISHOP score|Gynecological evaluation based on vaginal examination including cervical dilatation and effacement alone.
88971687|NCT04220320||Cervical Length|Gynecological evaluation based on cervical length measured by transvaginal sonography.
88971688|NCT01805778||Acute Cohort|Patients newly diagnosed with cancer who will be receiving anthracycline chemotherapy
88971689|NCT01805778||Survivor Cohort|Survivors of childhood cancer who are at least 3 years or more from their last dose of anthracycline therapy.
88971690|NCT04206046|Active Comparator|General Anaesthesia|Patients will receive a general anaesthetic, together with a femoral nerve block.
89209299|NCT00875628|Other|Cohort 1|PF-00868554 100 mg or placebo
89209300|NCT00875628|Other|Cohort 2|PF-00868554 300 mg or placebo
88971691|NCT04206046|Active Comparator|Spinal Anaesthesia|Patients will receive a spinal anaesthetic
88971692|NCT00405418|Experimental|1|Insulin Glargine
89209301|NCT00875628|Other|Cohort 3|PF-00868554 600 mg or placebo
89575962|NCT05457491|Experimental|Human platelet extract (HPE)|Subjects will follow a standardized twice daily skin care regimen of applying morning and night. Morning skin care routine includes Vanicream Gentle Facial Cleanser, human platelet extract, and EltaMD UV Daily Broad-Spectrum SPF 40, or Vanicream Lite Lotion. Evening skin care routine includes Vanicream Gentle Facial cleanser, human platelet extract, and EltaMD PM Therapy Facial Moisturizer or Vanicream Lite Lotion
89575963|NCT05477615|Experimental|lazertinib/pemetrexed/carboplatin|"combination of lazertinib with pemetrexed/carboplatin chemotherapy~- Lazertinib 240mg once daily and chemotherapy (pemetrexed and carboplatin) is administered on the 1st day every 3 weeks."
89575964|NCT05477537|Experimental|Add-on group|Subjects with Anorexia Nervosa (AN) involved in a day hospital or an inpatient program following HAS guidelines for anorexia nervosa treatment (treatment as usual) who will receive in addition an adapted physical activity program (one lesson per week, during 8 weeks)
89575965|NCT05477537|Active Comparator|Treatment as usual group|Subjects with Anorexia Nervosa involved in a day hospital or an inpatient program following HAS guidelines for AN treatment (treatment as usual).
89575966|NCT02549339|Experimental|LEO 43204 gel|Treatment once daily for 3 days
89575967|NCT02549339|Placebo Comparator|Vehicle gel|Treatment once daily for 3 days
89575968|NCT05469503|Experimental|TOTUM-854|Experimental active diet supplement TOTUM-854 3.71-g dose. Seven capsules per day to consume orally in two intakes
89575969|NCT05469503|Placebo Comparator|Placebo|Placebo comparator Seven capsules per day to consume orally in two intakes
89575970|NCT02549027|Experimental|Sequence (MK-1064): 50 mg→250 mg→Placebo→120 mg|For overall study population, 5 participants each were to be allocated to one of 4 sequences. In this sequence, participants received the following: Period 1 - single dose of 50 mg MK-1064, Period 2 - single dose of 250 mg MK-1064, Period 3 - single dose of placebo, Period 4 - single dose of 120 mg MK-1064. Participants completing the first 4 periods also were to receive the following: Period 5 - single dose of 20 mg MK-6096 or placebo, in an 18:2 ratio for overall study population, according to separate allocation. There was a minimum 7-day washout between doses.
89575971|NCT02549027|Experimental|Sequence (MK-1064): Placebo→50 mg→120 mg→250 mg|For overall study population, 5 participants each were to be allocated to one of 4 sequences. In this sequence, participants received the following: Period 1 - single dose of placebo, Period 2 - single dose of 50 mg MK-1064, Period 3 - single dose of 120 mg MK-1064, Period 4 - single dose of 250 mg MK-1064. Participants completing the first 4 periods also were to receive the following: Period 5 - single dose of 20 mg MK-6096 or placebo, in an 18:2 ratio for overall study population, according to separate allocation. There was a minimum 7-day washout between doses.
89575972|NCT02549027|Experimental|Sequence (MK-1064): 120 mg→Placebo→250 mg→50 mg|For overall study population, 5 participants each were to be allocated to one of 4 sequences. In this sequence, participants received the following: Period 1 - single dose of 120 mg MK-1064, Period 2 - single dose of placebo, Period 3 - single dose of 250 mg MK-1064, Period 4 - single dose of 50 mg MK-1064. Participants completing the first 4 periods also were to receive the following: Period 5 - single dose of 20 mg MK-6096 or placebo, in an 18:2 ratio for overall study population, according to separate allocation. There was a minimum 7-day washout between doses.
89209302|NCT01326013||Blinded, Prospective Arm|Diagnostic accuracy for higher prevalence targets will be evaluated in prospectively collected, anonymized, leftover, stool specimens.
89575973|NCT02549027|Experimental|Sequence (MK-1064): 250 mg→120 mg→50 mg→Placebo|For overall study population, 5 participants each were to be allocated to one of 4 sequences. In this sequence, participants received the following: Period 1 - single dose of 250 mg MK-1064, Period 2 - single dose of 120 mg MK-1064, Period 3 - single dose of 50 mg MK-1064, Period 4 - single dose of placebo. Participants completing the first 4 periods also were to receive the following: Period 5 - single dose of 20 mg MK-6096 or placebo, in an 18:2 ratio for overall study population, according to separate allocation. There was a minimum 7-day washout between doses.
89575974|NCT02709395|Experimental|Navina Smart|Navina Smart will be used, during 4 weeks, for transanal irrigation (TAI).
89575975|NCT02529553|Experimental|LY3076226|"Part A (dose escalation in advanced cancer): LY3076226 administered intravenously (IV) on day 1 of each 21 day cycle.~Part B (dose expansion in advanced urothelial carcinoma): LY3076226 administered IV on day 1 of each 21 day cycle."
89575976|NCT02547935|Experimental|Dapagliflozin 10mg|Tablets administered orally once daily for 24 weeks
89575977|NCT02547935|Experimental|Dapagliflozin 10mg + Saxagliptin 2.5mg|Tablets administered orally once daily for 24 weeks
89575978|NCT02547935|Placebo Comparator|Placebo|Tablets administered orally once daily for 24 weeks
89575979|NCT04258111|Experimental|IBI310 + Sintilimab|
89575980|NCT02554019|Experimental|BT063|50 mg BT063 administered by intravenous (IV) infusion 8 times
89575981|NCT02554019|Placebo Comparator|Placebo|Placebo administered by IV infusion 8 times
89575982|NCT05468411|Active Comparator|Miracle fruit pill|A freeze-dried miracle fruit pill is orally administered prior to eating food samples.
89575983|NCT05468411|Placebo Comparator|Sugar candy|A chewable sugar candy is orally administered as a placebo prior to eating food samples.
89575984|NCT05476835|Experimental|experimental group (group A) - control group (groupB)|The experimental group (group A) performed respiratory exercises (in form of diaphragmatic breathing, pursed lip breathing exercise and incentive spirometer), rehab exercise program and walking exercise.
89575985|NCT05476835|No Intervention|control group (group B)|The control group (group B) did not receive any physical therapy program
89575986|NCT02327169|Experimental|MLN2480 + MLN0128|Dose Escalation Phase: MLN2480 100 mg, tablets, orally, once on protocol specified days of a 28-day cycle for up to 12 cycles, and MLN0128 2 mg, capsules, orally, once on protocol specified days of a 28-day cycle for up to 12 cycles.
88971693|NCT00405418|Active Comparator|2|Insulin Detemir
88971694|NCT04102852|Experimental|LGG regular dose|Patients taking LGG 1.2 × 10^10 CFU/day, 2 capsules a day, for 1 month
89209303|NCT01326013||Blinded, Pre-selected Arm|For targets that exhibit lower prevalence rates in the intended use population, banked, pre-selected, positive clinical specimens will be tested.
89209304|NCT00879372|Placebo Comparator|1|Placebo
89209305|NCT00879372|Active Comparator|2|Tianeptine
89209306|NCT00731783|Active Comparator|Index patient only|Only the child recently treated for a skin or soft tissue infection will undergo the decolonization regimen.
89209307|NCT00731783|Active Comparator|Household|All members of the household (over the age of 6 months) will be asked to follow the study protocol.
89575987|NCT02327169|Experimental|MLN2480 + Alisertib|Dose Escalation Phase: MLN2480 100-200 mg, tablets, orally, once on protocol specified days of a 28-day cycle for up to 12 cycles, and alisertib 30-40 mg, tablets, orally, twice daily (BID) on protocol specified days of a 28-day cycle for up to 12 cycles. The doses of MLN2480 and alisertib were modified during this phase based on tolerability during each 28-day cycle.
89575988|NCT02327169|Experimental|MLN2480 + Paclitaxel|Dose Escalation Phase: MLN2480 100-200 mg, tablets, orally, once on protocol specified days of a 28-day cycle for up to 12 cycles, and paclitaxel 80 milligram per square meter (mg/m^2), intravenous (IV) infusion, once weekly (QW) for 3 weeks in each 28-day cycle for up to 12 cycles or MLN2480 400-600 mg tablets, orally, QW on protocol specified days of a 28-day cycle for up to 12 cycles, and paclitaxel 80 mg/m^2, IV infusion, QW for 3 weeks in each 28-day cycle for up to 12 cycles The dose of MLN2480 was modified during this phase based on tolerability during each 28-day cycle. Any changes in paclitaxel dose was based on the standard of care.
89575989|NCT02327169|Experimental|MLN2480 + Cetuximab|Dose Escalation Phase: MLN2480 400-600 mg, tablets, orally, once on protocol specified days of a 28-day cycle for up to 12 cycles, and cetuximab administered intravenously at a loading dose of 400 mg/m^2 (cycle 1 Day 1), then at 250 mg/m^2 QW on Days 8, 15, and 22 of cycle 1 and Days 1, 8, 15, and 22 in each additional 28-day cycle for up to 12 cycles. The dose of MLN2480 was modified during this phase based on tolerability during each 28-day cycle. Any changes in cetuximab dose was based on the standard of care.
89575990|NCT02327169|Experimental|ML2480 + Irinotecan|Dose Escalation Phase: MLN2480 400-600 mg, tablets, orally, once on protocol specified days of a 28-day cycle for up to 12 cycles, and irinotecan 180 mg/m^2, IV infusion over 90 minutes, every other week (Q2W) for 2 weeks in each 28-day cycle for up to 12 cycles. The dose of MLN2480 was modified during this phase based on tolerability during each 28-day cycle. Any changes in irinotecan dose was based on the standard of care.
89575991|NCT02327169|Experimental|MLN2480 600 mg + Paclitaxel 80 mg (Dose Expansion Phase)|Dose Expansion Phase: MLN2480 600 mg, tablets, orally, once per week on Days 2, 9, 16 and 23 of a 28-day cycle for up to 12 cycles, and paclitaxel 80 mg, capsules, orally, once on 1, 8, and 15 of a 28-day cycle for up to 12 cycles.
89575992|NCT02327013|Experimental|vortioxetine 10 mg tablet|"In Stage 1, patients will receive vortioxetine 10mg/day for 6 weeks.~In Stage 2, patients who received vortioxetine 10mg/day in Stage 1 will continue on the same treatment for additionally 6 weeks. Placebo non-responders will be re-randomized to placebo, or vortioxetine 10 or 20mg/day for additionally 6 weeks."
89575993|NCT02327013|Experimental|vortioxetine 20 mg tablet|"In Stage 1, patients will receive vortioxetine 20mg/day for 6 weeks.~In Stage 2, patients who received vortioxetine 20mg/day in Stage 1 will continue on the same treatment for additionally 6 weeks. Placebo non-responders will be re-randomized to placebo, or vortioxetine 10 or 20mg/day for additionally 6 weeks."
89575994|NCT02327013|Placebo Comparator|Placebo tablet|"In Stage 1, the patients will receive placebo for 6 weeks.~In Stage 2, placebo responders will continue on placebo for additionally 6 weeks. Placebo non-responders will be re-randomized to placebo, or vortioxetine 10 or 20mg/day for additionally 6 weeks."
89575995|NCT02301975|Experimental|Fluticasone Furoate/Vilanterol 100/25 mcg|FF/VI 100/25 mcg by inhalation OD (PM) via ELLIPTA plus placebo by inhalation BD (AM and PM) via ACCUHALER/DISKUS for 24 weeks.
89575996|NCT02301975|Experimental|Fluticasone Propionate/Salmeterol 250/50 mcg|FP/Salmeterol 250/50 mcg by inhalation BD (AM and PM) via ACCUHALER/DISKUS plus placebo by inhalation OD (PM) via ELLIPTA for 24 weeks.
89575997|NCT02301975|Experimental|Fluticasone Propionate 250 mcg|FP 250 mcg by inhalation BD (AM and PM) via ACCUHALER/DISKUS plus placebo by inhalation OD (PM) via ELLIPTA for 24 weeks.
89575998|NCT02301897|Placebo Comparator|Placebo|Following the baseline assessment no treatment period, matching placebo, orally, once daily for 18 weeks (Treatment Course 1) and repeated for an additional 18 weeks (Treatment Course 2) following the off drug interval (ODI).
89575999|NCT02301897|Experimental|Telapristone Acetate 6 mg|Following the baseline assessment no treatment period, telapristone acetate 6 milligrams (mg), orally, once daily for 18 weeks (Treatment Course 1) and repeated for an additional 18 weeks (Treatment Course 2) following the ODI.
89576000|NCT02301897|Experimental|Telapristone Acetate 12 mg|Following the baseline assessment no treatment period, telapristone acetate 12 mg, orally, once daily for 18 weeks (Treatment Course 1) and repeated for an additional 18 weeks (Treatment Course 2) following the ODI.
89576001|NCT02301429|Experimental|Model 20105|Receiving the model 20105 Lead
89576002|NCT04883229|Experimental|tDCS +speech therapy followed by sham tDCS + speech therapy|
89576003|NCT04883229|Active Comparator|sham tDCS +speech therapy followed by tDCS + speech therapy|
89576004|NCT04882839|Experimental|Active participants|Participants undertaking to full therapeutic protocol including psychotherapy sessions and Psilocybin sessions
89576005|NCT02300259|Experimental|LY2623091 (Group 1)|LY2623091 administered orally once on Day 1 of Period 1.
89576006|NCT02300259|Experimental|Itraconazole + LY2623091 (Group 1)|200 mg itraconazole administered orally twice daily on Day 1 of Period 2 and once daily on Days 2 - 20 of Period 2. Single oral dose of LY2623091 coadministered on Day 6 of Period 2.
89576007|NCT02300259|Experimental|Simvastatin (Group 2)|20 mg simvastatin administered orally once daily on Day 1.
89576008|NCT02300259|Experimental|LY2623091 + Simvastatin (Group 2)|LY2623091 administered orally once daily on Days 3 - 13. Single oral dose of 20 mg simvastatin coadministered on Day 12.
89576009|NCT02300259|Experimental|Tadalafil (Group 3)|5 mg tadalafil administered on Day 1 of Period 1. Arm is contingent on interim results from Groups 1 and 2.
89209308|NCT00879450|Experimental|1 Booklet|
89209309|NCT00879450|Active Comparator|2 standard|
89209310|NCT02592083|Active Comparator|A: Endocrine treatment|Pre- or perimenopausal women are treated with tamoxifen, alternatively with an LHRH analogue in combination with an aromatase inhibitor (only women); postmenopausal women receive an aromatase inhibitor. The preoperative treatment is continued for further 12 weeks, provided that re-evaluation after 6 weeks, week 10 of the preoperative treatment, does not indicate progression. Upon progression (PD), individualized management, preferentially surgery, is the primary option
89576010|NCT02300259|Experimental|Tadalafil + LY2623091 (Group 3)|LY2623091 administered orally once daily on Day 1 up to Day 15 of Period 2. 5 mg tadalafil co-administered once daily on Day 10 of Period 2. Arm is contingent on interim results from Groups 1 and 2.
89576011|NCT02300259|Experimental|LY2623091 (Group 4)|LY2623091 administered orally once on Day 1 of Period 1. Arm is contingent on interim results from Groups 1 and 2.
88971695|NCT04102852|Experimental|LGG double dose|Patients taking LGG 2.4 × 10^10 CFU/day, 4 capsules a day, for 1 month
88971696|NCT04078321|Experimental|Single case design|Single case studies
89576012|NCT02300259|Experimental|Diltiazem + LY2623091 (Group 4)|240 mg diltiazem administered once daily on Days 1 to 13 of Period 2. Single oral dose of LY2623091 coadministered on Day 4 of Period 2. Arm is contingent on interim results from Groups 1 and 2.
89576013|NCT02367885|Experimental|TAK-850 0.5 mL injection (13-19 years of age)|Single intramuscular injection of TAK-850 0.5 mL in participants aged 13-19 years
88971697|NCT02157077|Experimental|Aflibercept|Patients will receive 2 mg of aflibercept by intravitreal injection every 4 weeks until week 8, followed by every 6 weeks to week 26
88971698|NCT01805700|Experimental|Regular caffeine enhanced energy drink|Regular caffeine enhanced energy drink (containing 240mg caffeine & 84g glucose) e.g. regular red bull cans (x3)
89576014|NCT02367885|Experimental|TAK-850 0.5 mL injection (3-12 years of age)|Two intramuscular injections of TAK-850 0.5 mL in participants aged 3-12 years old.
88971699|NCT01805700|Experimental|Diet Caffeine enhanced energy drink|Diet Caffeine enhanced energy drink ( containing 240mg of caffeine alone) e.g. Red Bull light)
88971700|NCT01805700|Active Comparator|Glucose drink|Glucose drink (containing 84g glucose alone)
89576015|NCT02367885|Experimental|TAK-850 0.25 mL injection (6-35 months of age)|Two intramuscular injections of TAK-850 0.25 mL in participants aged 6-35 months old.
89576016|NCT02367729|Experimental|Neurostimulator|Auricular neurostimulator treatment x 5 days each week for 4 consecutive weeks
89576017|NCT02367729|Sham Comparator|Sham Neurostimulator|Inactive auricular neurostimulator treatment x 5 days each week for 4 consecutive weeks
89576018|NCT02366637|Placebo Comparator|Placebo|Double blind placebo for PF-03715455
88971701|NCT04057378|Active Comparator|0.5 ms pulse width stimulus|Electroconvulsive therapy initiated with 0.5 ms pulse width stimulus
88971702|NCT04057378|Active Comparator|1.0 ms pulse width stimulus|Electroconvulsive therapy initiated with 1.0 ms pulse width stimulus
88971703|NCT04033276|Active Comparator|Rituximab|Inj Rituximab 375mg/m2 IV given on day 0
88971704|NCT04033276|Active Comparator|Combination of high-dose IVIG and Rituximab|IV Rituximab 375mg/m2 on day 0 and IV high-dose IVIG 2g/kg on day 0
88971705|NCT01805661|Active Comparator|Femoral With Tibial Nerve Block|Continuous femoral nerve block with catheter and selective tibial nerve block in the popliteal fossa
88971706|NCT01805661|Experimental|Canal Block and Capsular Injection|Adductor canal block with a continuous catheter and ultrasound guided posterior capsular injection with local anesthetic solution.
88971707|NCT04725799||MESS with and without stressful stimuli|The subjects participate in meal, exercise, sleep activities alone or in combination with stressful stimuli.
88971708|NCT04726072|Experimental|Kundalini Yoga|The Kundalini yoga intervention is a mixture of basic yoga, breathing exercises and meditation. Participants were also asked to do at-home practice for half an hour daily.
88971709|NCT04726072|Active Comparator|Psychoeducation|The psychoeducation group consisted of teaching participants about healthy aging. Participants were asked to do at-home practice for half an hour daily
88971710|NCT01805622|Experimental|Passive Arm #1|Active Arm #1, 2; Passive Arm #1, 2 Community coalitions randomized to the Passive Arm #1-Web Access Without Technical Assistance will receive access to EPICS facilitator training materials and toolkits via the Research-Tested Intervention Programs (RTIPs) website and will not participate in monthly technical assistance teleconferences.
88971711|NCT01805622|Experimental|Passive Arm #2|Active Arm #1, #2; Passive Arm #1, #2 Community coalitions randomized to the Passive Arm #2-Web Access With Technical Assistance will receive access to EPICS facilitator training materials and toolkits via the Research-Tested Intervention Programs (RTIPs) website and will participate in monthly technical assistance teleconferences.
88971712|NCT01805622|Active Comparator|Active Arm #1|Active Arm #1, #2; Passive Arm #1, #2 Community coalitions randomized to Active Arm #1-In-Person Access Without Technical Assistance will receive training from intervention developers with access to facilitator training materials but will not participate in monthly technical assistance teleconferences.
88971713|NCT01805622|Active Comparator|Active Arm #2|Active Arm #1, #2; Passive Arm #1, #2 Community coalitions randomized to Active Arm #2-In-Person Access with Technical Assistance will receive training from intervention developers with access to facilitator training materials and will participate in monthly technical assistance teleconferences.
88971714|NCT00391235||BPD|Children with bipolar disorder
88971715|NCT00391235||HC|Healthy comparison children
88971716|NCT01805583|Experimental|ACT|The ACT intervention consists of 6 manual-based face-to-face sessions and internet-based homework modules. The manual is based on the six core processes in the ACT-model: acceptance, mindfulness, defusion, self as context, values and committed action.
88971717|NCT01805583|Experimental|WPI|"This interventions aims at the facilitation of dialogue between the participant and the workplace through a series of steps consisting of individual interviews with the participant and his/her nearest supervisor and a so called convergence dialogue meeting in order to agree upon short- and long-term solutions."
89033212|NCT05318456|Placebo Comparator|Placebo|Participants will be instructed to take two capsules of placebo once daily with water, after dinner without food starting on Day 0 for 42 days. If a dose is missed participants are instructed to take the dose as soon as they remember. Participants will be advised not to exceed 4 capsules daily.
89576019|NCT02366637|Experimental|PF-03715455|
89576020|NCT02300103|Experimental|SOF/VEL+RBV|Participants will receive SOF/VEL fixed dose combination (FDC) and RBV for 24 weeks.
89576021|NCT02326467|Experimental|Chlorhexidine gluconate bath|All subjects will receive a bath twice a week with 2% CHG bathing cloths. The baths will be followed by blood sampling for CHG levels prior to initiation of baths and every Friday for the duration of study participation. The study team will monitor the infant's skin for evidence of untoward lesions prior to the first bath and every 12 hours during the course of the study. CHG blood levels will be monitored for associated adverse events and accumulation.
89576022|NCT02299635|Experimental|PF-03084014|PF-03084014 will be administered orally, continuously, twice daily at 150 mg, but the dose can be reduced to 100 mg or 80 mg.
89576023|NCT02366091|Experimental|Methotrexate|Methotrexate 15 mg weekly by mouth and placebo for colchicine 1 tablet by mouth daily and folate 1 mg by mouth daily
89576024|NCT02366091|Experimental|Colchicine|Colchicine 0.6 mg daily by mouth and placebo for methotrexate 1 tablet weekly by mouth and folate 1 mg by mouth daily
89576025|NCT02366091|Experimental|Methotrexate & Colchicine|Methotrexate 15 mg by mouth weekly and colchicine 0.6 mg by mouth daily and folate 1 mg by mouth daily
89576026|NCT02366091|Experimental|Placebo|Placebo for methotrexate 1 tablet by mouth weekly and placebo for colchicine 1 tablet by mouth daily and folate 1 mg by mouth daily
89576027|NCT02326155||Remsima™|Patients were not treated with infliximab before enrollment. Patients were administered CT-P13 5mg/kg by intravenous infusion at weeks 0, 2, and 6, and every 8 weeks thereafter.
89576028|NCT02326155||Switched to Remsima|Patients were treated with infliximab prior to enrollment of the study. Patients were administered CT-P13 5mg/kg by intravenous infusion at weeks 0, 2, and 6, and every 8 weeks thereafter.
89576029|NCT02299167|Experimental|Saddle block|The dose of bupivacaine given to each patient was determined by the response of the previously tested patient using a modified Dixon's up-and-down method
89576030|NCT01647711|Experimental|Afatinib|Establish the Maximal Tolerated Dose of a pulsatile, high-dose regimen of afatinib in patients with advanced solid tumors followed by treatment at that dose or a lower dose in patients with stage IV non-small cell lung cancer harboring EGFR T790M mutations who have progressed on therapy with a reversible tyrosine kinase inhibitor
89576031|NCT05476757|Experimental|Flavivirus naïve|
89576032|NCT02547233|Experimental|LEO 43204 gel|Treatment once daily for 3 days
89576033|NCT02547233|Placebo Comparator|Vehicle gel|Treatment once daily for 3 days
89576034|NCT05476679|Experimental|RZL-012 50mg/ml|
89576035|NCT02546765|Experimental|IV acetaminophen & IV propofol|"20-100 µg/kg/min IV propofol given for 4-6 hours before the patients are woken up in the ICU~1g IV acetaminophen every 6 hours for 48 hours during the first 2 days postoperatively"
89576036|NCT02546765|Experimental|IV acetaminophen & IV dexmedetomidine|"A loading infusion of 0.5 - 1 µg/kg given over 10 minutes will be administered. After the loading infusion, a maintenance infusion of 0.1-1.4 µg/kg/hr will be initiated.~1 g IV acetaminophen every 6 hours for 48 hours during the first 2 days postoperatively"
89576037|NCT02546765|Active Comparator|IV propofol & placebo|20-100 µg/kg/min IV propofol given for 4-6 hours before the patients are woken up in the ICU Volume of the placebo (saline) will match that of IV acetaminophen at 100ml 0.9% NaCl.
89576038|NCT02546765|Active Comparator|IV dexmedetomidine & placebo|0.1-1.0 µg/kg/hour IV dexmedetomidine given for 4-6 hours before the patients are woken up in the ICU Volume of the placebo (saline) will match that of i.v. acetaminophen at 100ml 0.9% NaCl.
89576039|NCT02553629|Active Comparator|moderate neuromuscular block|rocuronium 0.1-0.6 mg/kg aimed at a train of four of 1 - 2 twitches
89576040|NCT02553629|Experimental|deep neuromuscular block|rocuronium 0.1-0.6 mg/kg aimed at a post tetanic count of 1 - 2 twitches
89576041|NCT05453981|Experimental|TranS-C group|The TranS-C group will receive weekly 2 hour TranS-C group intervention delivered by 2 clinical psychology trainees for 6 weeks, contents being core modules from Harvey et al. (2016)'s protocol.
89576042|NCT05453981|No Intervention|CAU group|The CAU group will receive care as usual.
89576043|NCT03073031|Active Comparator|Intervention|Patients report their adverse events on a tablet once a week (intervention) as a supplement to having them monitored every 3 weeks by a physician
89576044|NCT03073031|No Intervention|Control|Patients have their side effects monitored by a physician every 3 weeks (control)
89576045|NCT05476445|Active Comparator|Control|After the carious tissue was removed and the endodontic cavity was opened, isolation was provided with a rubber-dam. After the canal length was determined with the Apex locater, the canals were prepared using Ni-Ti endodontic rotary instrument files at the torque value recommended by the manufacturer in an endodontic motor. Irrigation needles were kept 4-5 mm shorter than the working length, and irrigation of the channels was performed. A total of 5 ml of 1% NaOCl was washed for each canal, with 2 ml between each pecking movement of the files. The final washing of the channels was carried out using 5 ml of saline at room temperature.After the canals were dried with the help of a paper cone, the canals were filled by injecting iodoform and calcium hydroxide-containing canals. Then the restoration was completed with compomer.
89576046|NCT05476445|Experimental|Low level laser therapy|After the carious tissue was removed and the endodontic cavity was opened, isolation was provided with a rubber-dam. After the canal length was determined with the Apex locater, the canals were prepared using Ni-Ti endodontic rotary instrument files at the torque value recommended by the manufacturer in an endodontic motor. A total of 5 ml of 1% NaOCl was washed for each canal, with 2 ml between each pecking movement of the files. The final washing of the channels was carried out using 5 ml of saline at room temperature.After the canals were dried with the help of a paper cone, the canals were filled by injecting iodoform and calcium hydroxide-containing canals. Then the restoration was completed with compomer. Following the restoration in the LLLT group, the diode laser was activated in biostimulation mode for a total of 1 minute, 30 seconds in the buccal and lingual/palatal regions at the root apex.
89576047|NCT05476445|Experimental|Cryotherapy|"After the carious tissue was removed and the endodontic cavity was opened, isolation was provided with a rubber-dam. After the canal length was determined with the Apex locater, the canals were prepared using Ni-Ti endodontic rotary instrument files at the torque value recommended by the manufacturer in an endodontic motor. Irrigation needles were kept 4-5 mm shorter than the working length, and irrigation of the channels was performed. A total of 5 ml of 1% NaOCl was washed for each canal, with 2 ml between each pecking movement of the files. The final washing of the channels was carried out using 5 ml of saline at room temperature.~After the last wash, in the cryotherapy group, unlike the first two groups, each canal was washed with 5 ml of 2°C cold physiological saline for 5 minutes. After the canals were dried with the help of a paper cone, the canals were filled by injecting iodoform and calcium hydroxide-containing canals. Then the restoration was completed with compomer."
89576048|NCT05476367||patients with normal uric acid level|The uric acid level is below 420 μmol/L in men and 360 μmol/L in women
89576049|NCT05476367||patients with high uric acid level|The uric acid level is higher than 420 μmol/L in men and 360 μmol/L in women.
89576050|NCT05466461|Experimental|Beautifil Flow Plus X.|Giomers is a hybrid material category which contains Surface Pre-Reacted Glass-ionomer filler or S-PRG filler is produced from fluoroboro-alumino-silicate glass and polyacrylic acid through an acid-base reaction to form a stable glass ionomer phase on glass filler particle surfaces. S-PRG fillers can release and recharge fluoride. Also, the S-PRG filler-containing resinous materials are able to release various ions, such as aluminum (Al3+), boron (BO3 3-), fluoride (F- ), sodium (Na+), silicon (SiO3 2-), and strontium (Sr2+), in neutral and acidic conditions.
89576051|NCT05466461|Active Comparator|Activa bioactive restorative|Activa BioACTIVE Restorative (Activa), developed by Pulpdent (Watertown, MA, USA), is a new bioactive restorative material that combines the advantages of an RMGIC (resin modified glass ionomer cement) and RBC (resin based composite), representing a new category of restorative materials that are ion releasing. It contains methacrylate- based monomers, a modified polyacrylic acid, modified Diurethane Dimethacrylate (rubberized resin), and fillers
89033213|NCT02920905|Experimental|lidocaine|• Patients in group A will receive 3 mg/kg of lidocaine 2% diluted with saline to a total volume of 40 ml.
89576052|NCT02546609|Experimental|Leu Met Sil 0.5mg|Leu-Met-Sil 0.5: 3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 500 mg metformin and 0.5 mg of sildenafil.
89576053|NCT02546609|Experimental|Leu Met Sil 1.0mg|Leu-Met-Sil 1.0: 3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 500 mg metformin and 1.0 mg of sildenafil.
89576054|NCT02546609|Placebo Comparator|Placebo|Placebo: 3 capsules BID containing 99% Avicel PH302 and 1% magnesium stearate (w/w)
89033214|NCT02920905|Experimental|lidocaine & atracurium|• Patients in group B receive 3 mg/kg of lidocaine 2% + 2 mg atracurium diluted with saline to a total volume of 40 ml.
89576055|NCT02534909|Experimental|LFG316 then LNP023|LFG316: Treatment periods 1-3 and first 4 weeks of period 4. LNP023: Treatment Period 4
89576056|NCT02553317|Experimental|Caplacizumab|Caplacizumab 10 mg once daily
89576057|NCT02553317|Placebo Comparator|Placebo|Placebo once daily
89576058|NCT03029351|Experimental|Exenatide extended release|Exenatide extended release treatment for 1 year on albuminuria levels in T2DM patients with micro- and macroalbuminuria compared to placebo.
89576059|NCT03029351|Placebo Comparator|Placebo|Placebo treatment for 1 year on albuminuria levels in T2DM patients with micro- and macroalbuminuria compared to Exenatide extended release.
89576060|NCT02325219|Experimental|Group 1|Participants will receive subcutaneous injection of CNTO 1959 50 milligram (mg) and placebo 100 mg at Week 0, 4 and then every 8 weeks thereafter.
89576061|NCT02325219|Experimental|Group 2|Participants will receive subcutaneous injection of CNTO 1959 100 milligram (mg) and placebo 50 mg at Week 0, 4 and then every 8 weeks thereafter.
89576062|NCT02325219|Experimental|Group 3|Participants will receive subcutaneous injection of placebo 50 mg and 100 mg at Weeks 0, 4 and 12. At Week 16, participants will be randomized in sub-group 3a to receive either CNTO1959 50 mg and placebo 100 mg at Week 16, 20 and then every 8 weeks thereafter or sub-group 3b to receive CNTO 1959 100 mg and placebo 50 mg at Week 16, 20 and then every 8 weeks thereafter.
89576063|NCT02297841|Experimental|Human Repeat Insult Patch Test|Approximately 0.2ml of each intervention (Experimental: Novel lubricant Miami Fragrance, Experimental: Novel lubricant Miami no Fragrance, KY Liquid lubricant, Astroglide Gel lubricant) was applied to an occlusive patch and applied to participant's back.
89576064|NCT02324361|Experimental|Facebook group|"The intervention consists of evidence-based information on healthy family routines and parenting strategies adapted for Facebook posts on a private study Facebook group.~Participating parents/guardians will have access to all features of the secret study Facebook group (e.g., create and view postings, comment and like existing posts and view user names of other members of the group (existing study participants and staff) for the duration of the study.~All index children will be provided with a Physical Activity Monitor to wear during waking hours for the duration of the study."
89576065|NCT02324361|Experimental|Text messaging|"The intervention consists of evidence-based information on healthy family routines and parenting strategies adapted for 140-character text messages.~The automated text-messaging algorithm consists of the delivery of two types of text messages: 1-way messages, in which participating parents/guardians will receive a piece of education or motivation on the dimension topic that they're being coached on and 2-way messages, in which participants are able to respond to an educational message containing a number response prompt that will provide them with personalized feedback regarding a dimension they are being coached on.~All index children will be provided with a Physical Activity Monitor to wear during waking hours for the duration of the study."
89576066|NCT02365233|Active Comparator|Thiazolidinedione|(Pioglitazone, 15 mg/day)
89576067|NCT02365233|Active Comparator|Lantus Insulin|0.35 U per kg body weight once daily
89576068|NCT02365233|Active Comparator|DPP4 inhibitor|Sitagliptin, 100 mg/day or Saxagliptin, 5 mg/day
89576069|NCT02324205|Experimental|DBT and FFDM|Subjects underwent 2D breast imaging with full-field digital mammography (FFDM) followed by 3D breast imaging with digital breast tomosynthesis (DBT). Digital Breast Tomosynthesis: 3D imaging of the breast using Digital Breast Tomosynthesis (DBT) device. Full-Field Digital Mammography: 2D imaging of the breast using Full-Field Digital Mammography (FFDM) device.
89033215|NCT02920905|Experimental|lidocaine & atracurium & Mg sulphate|• Patients in group C will receive 3 mg/kg of lidocaine 2% + 2 mg atracurium mixed with 10 mg /kg magnesium sulphate diluted with saline to a total volume of 40 ml.
89033216|NCT02920944|Experimental|EUS-FNB with 20-gauge|EUS-FNB with 20-gauge procore needle
89033217|NCT02920944|Active Comparator|EUS-FNB with 22-gauge|EUS-FNB with 22-gauge procore needle
89576070|NCT02324049|Experimental|SBC-103|"Part A (Initial therapy): Participants received SBC-103, 0.3, 1.0, or 3.0 mg/kg QOW for 24 weeks, followed by a ≥ 4-week treatment break. Participants enrolled in the lowest dosage first.~Part B: Participants were escalated to the next highest dose that was considered safe (1.0 or 3.0 mg/kg QOW) for ≥ 8 weeks. Participants who received doses of 0.3 mg/kg in Part A were considered for a second dose escalation to 3.0 mg/kg at any time during Part B provided that they tolerated at least 2 doses of 1.0 mg/kg in Part B. Participants who received and tolerated at least 4 doses of SBC-103 QOW at 3.0 mg/kg were considered for participation in Part C.~Part C: Participants received SBC-103 5.0 or 10.0 mg/kg administered IV QOW. Dosing in Part C began at the 5.0 mg/kg dose level. The decision to begin dosing the first participant at 10.0 mg/kg was based on the review of safety data at 5.0 mg/kg."
89576071|NCT02364999|Experimental|Bevacizumab-Pfizer|Bevacizumab-Pfizer plus paclitaxel and carboplatin
89576072|NCT02364999|Active Comparator|Bevacizumab-EU|Bevacizumab-EU plus paclitaxel and carboplatin
88971718|NCT01805583|Experimental|ACT and WPI|"The study participants receive both ACT and WPI. The ACT intervention consists of 6 manual-based face-to-face sessions and internet-based homework modules. The manual is based on the six core processes in the ACT-model: acceptance, mindfulness, defusion, self as context, values and committed action. WPI aims at the facilitation of dialogue between the participant and the workplace through a series of steps consisting of individual interviews with the participant and his/her nearest supervisor and a so called convergence dialogue meeting in order to agree upon short- and long-term solutions."
88971719|NCT01805583|No Intervention|Control group|Treatment as usual (TAU) which means that the participant continues in ordinary health care and does not receive interventions other than the initial assessment.
89576073|NCT02322879|Experimental|Acetaminophen first, then Acetaminophen + Propylene Glycol|"Subjects in this arm will receive 4 grams of solid acetaminophen formulation for two weeks, followed by a two week wash out period.~Then, subjects will receive 4 grams of solid acetaminophen formulation in addition to 70 mg/kg/day of liquid propylene glycol for two weeks.~The total study time is 6 weeks."
89576074|NCT02322879|Experimental|Acetaminophen + Propylene Glycol first, then Acetaminophen|"Subjects in this arm will receive 4 grams of solid acetaminophen formulation in addition to 70 mg/kg/day of liquid propylene glycol for two weeks, followed by a two week wash out period.~Then, subjects will receive 4 grams of solid acetaminophen formulation for two weeks.~The total study time is 6 weeks."
89576075|NCT02322411|Active Comparator|Compensatory|This group will receive standard swallowing intervention, which is identified by the SLP as appropriate to treat the patient's dysphagia and is common clinical practice. Their therapy may include: 1) modifying their foods and fluids; 2) changing their posture when they eat or drink; or 3) having them eat more slowly or in a quiet environment to make swallowing easier and safer. These compensatory approaches will ensure safety while swallowing foods and fluids. Range of motion, vocal exercises, and other oromotor exercises, such as the Shaker Exercise, as well as any other potential strengthening regimens for swallowing or speech will be delayed until subjects have completed participation.
89576076|NCT02322411|Experimental|I-PRO + compensatory|The Device-Facilitated Isometric Progressive Resistance Oropharyngeal (D-F I-PRO) intervention will be completed using the SwallowSTRONG® device. Tongue press exercises consist of pressing the tongue against the sensors located along the hard palate. Isometric exercises will focus on the anterior and posterior sensor. Subjects will take the SwallowStrong® device home with them and will complete 20 repetitions of the exercise (10 repetitions at the front sensor; 10 repetitions at the back sensor), three times per day on three days per week for twelve weeks.
88971720|NCT01981148||Healthy patients|Healthy patients
88971721|NCT01981148||Patients with various retinal diseases|Various retinal diseases (vascular, hereditary, degenerative)
88971722|NCT03781063|Experimental|Lasofoxifene|5 mg/d of oral lasofoxifene
88971723|NCT03781063|Active Comparator|Fulvestrant|500 mg fulvestrant intramuscular (IM)
88971724|NCT01805544||Rivaroxaban|20 mg po once daily, which is also the recommended maximum dose. SmPC recommendations are to be followed for renal impairment
88971725|NCT03773419|Experimental|Texting Intervention (T-WRITE)|Computer-based treatment targeting written language via texting (90 minutes a day, 5 days a week for 4 weeks)
88971726|NCT03773419|Active Comparator|HandWriting Intervention (ORLA+WTG)|Computer-based treatment targeting written language via handwriting (90 minutes a day, 5 days a week for 4 weeks)
89576077|NCT02322021|Experimental|MCI/Prodromal Cohort: Low Dose|A low dose of E2609 will be assessed.
89576078|NCT02322021|Experimental|MCI/Prodromal Cohort: Middle Dose|A middle dose of E2609 will be assessed.
89576079|NCT02322021|Experimental|MCI/Prodromal Cohort: High Dose|A high dose of E2609 will be assessed.
89576080|NCT02322021|Placebo Comparator|MCI/Prodromal Cohort: Placebo|
89576081|NCT02322021|Experimental|Mild to Moderate AD Cohort: Low Dose|A low dose of E2609 will be assessed.
89576082|NCT02322021|Experimental|Mild to Moderate AD Cohort: High Dose|A high dose of E2609 will be assessed.
89576083|NCT02322021|Placebo Comparator|Mild to Moderate AD Cohort: Placebo|
89576084|NCT02322021|Experimental|Mild to Moderate AD cohort: Middle Dose|A middle dose of E2609 will be assessed.
89576085|NCT02363439|Experimental|IMO-8400 0.6 mg/kg/wk or 1.2 mg/kg 2xwk|Subcutaneous injection of IMO-8400 0.6 mg/kg/wk or 1.2 mg/kg twice weekly per Protocol 8400-401
88971727|NCT01903421|Active Comparator|Spinal anesthesia group|Spinal anesthesia group will receive bupivacaine 10-15mg anesthesia according to the standard practice. Supplemental sedation with intravenous anesthetics (midazolam/propofol) will be optional.
88971728|NCT01903421|Active Comparator|General anesthesia group|Induction of anesthesia will be achieved with propofol 1.5-2mg/kg and fentanyl 1-3g/kg. Anesthesia will be maintained with inhalational anesthesia (isoflurane or sevoflurane) at the discretion of anesthesiologist in charge of the case. A mixture of Air/O2 will be used to maintain adequate oxygenation. Nitrous oxide will not be used.
88971729|NCT03748888|Experimental|Exercise group|An antenatal physical activity (APA) programme will be designed for participants in the exercise group.
88971730|NCT03748888|No Intervention|Control Group|Sedentary participants.
88971731|NCT01805505|Experimental|Transvaginal ultrasound-guided embryo transfer|Transvaginal ultrasound-guided transfer of two day-3 embryos
88971732|NCT01805505|Active Comparator|Transabdominal ultrasound-guided embryo transfer|Transabdominal ultrasound-guided transfer of two day-3 embryos
89576086|NCT02363283|Experimental|Treatment (glembatumumab vedotin)|Patients receive glembatumumab vedotin IV over 90 minutes every 3 weeks in the absence of disease progression or unacceptable toxicity.
89576087|NCT02321319|Experimental|Hydromorphone HCl ER Tablets|Participants receive Hydromorphone HCl ER Tablets (4-16 mg, based on standard conversion ratios for common opioids)
89576088|NCT02294175|Active Comparator|Larval Debridement Therapy|Larval debridement therapy intervention (Biobags) filled with sterile green bottle fly maggots (larvae) placed in open, chronic lower extremity or diabetic foot ulcer once every 4 days for total of 2 applications over the 8 day study period.
89576089|NCT02294175|Active Comparator|Sharp Debridement Therapy|Bedside sharp debridement therapy as a comparator performed by wound care clinician once every 7 days in a chronic lower extremity or diabetic foot ulcer for a total of 2 sharp debridements over the 8 day study period.
89576090|NCT02088541|Experimental|Selinexor approximately 55 mg/m^2 (60 to 120 mg based on BSA)|Participants under protocol versions (PV) less than (<) 5.0 (those who had one prior line of acute myeloid leukemia (AML) therapy), receive oral selinexor tablets at a dose of approximately 55 mg/m^2 (milligrams per square meter) (60 to 120 mg based on body surface area [BSA]) twice weekly, on Day 1 and 3 of each week of 4-week cycle (28 days per cycle).
89576091|NCT02088541|Experimental|Selinexor 60 mg (PV <5) (Equivalent to 35 mg/m^2)|Participants under PV < 5.0 (those who had one prior line of AML therapy), receive oral selinexor tablets at a fixed dose of 60 mg (equivalent to 35 mg/m^2), based on BSA, twice weekly, on Day 1 and 3 of each week of 4-week cycle (28 days per cycle).
88971733|NCT03744286|Experimental|Balance Slip|"Perform standard clinical balance assessments~Determine the optimal slip distance by 10 passes each with plank movement of 2, 4, 6 and 8 on visit 1"
88971734|NCT03663907|Experimental|Telemonitoring|Structured follow-up in the basis of using telemedicine. Telemedicine will include daily signs and symptoms telemonitoring and structured follow-up by the means of video or audio-conference.
88971735|NCT03663907|No Intervention|Usual Care|Patients with usual care follow-up in a heart failure program.
88971736|NCT01805427||patients treated with efavirenz|HIV-infected on stable HAART regimen with efavirenz
89576092|NCT02088541|Experimental|Selinexor 60 mg (PV >=5) (Equivalent to 35 mg/m^2)|Participants under PV >= 5 (PV 5: those who had at least one prior line of AML therapy, PV 5.1: who had at least two prior line of AML therapy), receive oral selinexor tablets at a dose of 60 mg (equivalent to 35 mg/m^2) twice weekly, on Day 1 and 3 of each week of 4-week cycle (28 days per cycle).
89576093|NCT02088541|Active Comparator|Physician's Choice 1 (PV <5)|Participants under PV < 5.0 (those who had one prior line of AML therapy) received Best Supportive Care (BSC) which included blood product transfusions, antimicrobials, growth factors as needed, and hydroxyurea.
89576094|NCT02088541|Active Comparator|Physician's Choice 2 (PV >=5)|Participants under PV >= 5 (PV 5: those who had at least one prior line of AML therapy, PV 5.1: who had at least two prior line of AML therapy), received BSC along with subcutaneous injection of arabinoside cytosine (Ara-C), 20 mg, twice daily, for 10 days, repeated at 28 to 42 day intervals.
89576095|NCT02294019|Experimental|Ibuprofen caplet arm|
89576096|NCT02320149|Experimental|Sarecycline|Sarecycline tablets, 1.5 milligram(mg)/kilogram(kg)/day, taken orally once daily for 12 weeks.
89576097|NCT02320149|Placebo Comparator|Placebo|Placebo-matching sarecycline tablets, taken orally once daily for 12 weeks.
89576098|NCT05407909|Experimental|SYHX2001|SYHX2001 will be administered orally.
89576099|NCT02073409||CF patients|Male and female subjects with CF age 6 years and older who have a positive sputum culture for NTM.
89576100|NCT05423509|Other|Standard treatment for AIS|These are the participants with AIS that recieved the standard treatment with observation or bracing depending on the size of their curve.
89576101|NCT05423509|Experimental|Treatment with Dynamic Myofascial Manipulation|These are the participants that still received the standard treatment with observation or bracing depending on the size of their curve, but also had weekly treatment with a chiropractor for 6 months for dynamic myofascial manipulation
88971737|NCT01805427||patients treated with atazanavir|HIV-infected patients on stable HAART regimen with atazanavir
88971738|NCT01805427||patients treated with darunavir|HIV-infected patients on stable HAART regimen with darunavir
88971739|NCT01723839|Other|FCR with Lenalidomide|Fludarabine, Cyclophosphamide, Rituximab, Lenalidomide - 19 subjects are treated in stage-1 with FCR plus 5mg lenalidomide increasing to 10mg and 15mg in subsequent cycles depending on toxicity. If there are at least 5 CRs after 4 cycles of FCR plus lenalidomide the study will accrue an additional 35 subjects.
88971740|NCT03421483|Active Comparator|Folic Acid supplementation|Participants receive an adult multivitamin supplement along with a folic acid supplement
88971741|NCT03421483|Placebo Comparator|No supplementation|Participants only receive an adult multivitamin supplement
88971742|NCT03410407||AML patients|AML patients according to the French-American-British (FAB) criteria, previously enrolled in GIMEMA Studies for AML treatment. AML patients with CNS involvement defined by the confirmation of leukemic blast cells in the centrifuged cerebrospinal fluid (CSF) with the presence of more than five WBCs in the CSF or the detection of a CNS granulocytic sarcoma using computed tomography or magnetic resonance imaging.
89576102|NCT05422417|Experimental|Prolonged intermittent theta-burst(iTBS)-DMPFC|This active group will receive prolonged intermittent theta-burst(iTBS) on the dorsomedial prefrontal cortex(DMPFC)
89576103|NCT05422417|Experimental|20Hz rTMS-DMPFC|This active group will receive 20Hz rTMS on the DMPFC
89576104|NCT05422417|Sham Comparator|Sham prolonged iTBS-DMPFC or 20Hz rTMS-DMPFC|Patients in the sham group will receive the same prolonged iTBS or 20Hz rTMS performed by a sham coil.
89576105|NCT05450653|Experimental|FETO with GOLDBAL2|A detachable balloon will be inserted in the fetal airway during the FETO procedure.
89576106|NCT05405725|Experimental|ENZ215|ENZ215 Injection:- 60 mg Denosumab (ENZ215) will be administered subcutaneously on day 1.
89576107|NCT05405725|Active Comparator|Prolia|Prolia Injection:- 60 mg Denosumab (Prolia) will be administered subcutaneously on day 1.
89576108|NCT02540083|Experimental|Experimental: DBT and FFDM|Subjects underwent 2D breast imaging with full-field digital mammography (FFDM) followed by 3D breast imaging with digital breast tomosynthesis (DBT).
89576109|NCT02293863|Experimental|A: MHAA4549A 3600 mg + Oseltamivir|Participants will receive a single low IV dose of MHAA4549A on Day 1 and standard oseltamivir therapy for minimum of 5 days.
89576110|NCT02293863|Experimental|B: MHAA4549A 8400 mg + Oseltamivir|Participants will receive a single high IV dose of MHAA4549A on Day 1 and standard oseltamivir therapy for minimum of 5 days.
89576111|NCT02293863|Placebo Comparator|C: Placebo + Oseltamivir|Participants will receive a single IV dose of placebo matched to MHAA4549A on Day 1 and standard oseltamivir therapy (75 or 150 mg BID) for minimum of 5 days.
89576112|NCT02293395|Active Comparator|Stratum 1/ASA|Acetylsalicylic acid (ASA) 100 milligram (mg) enteric-coated tablet once daily orally along with clopidogrel 75 mg once daily orally, up to either 180 days after randomization of the last enrolled participant in the study or Day 360, whichever occurs earlier.
89576113|NCT02293395|Experimental|Stratum 1/Rivaroxaban|Rivaroxaban 2.5 mg tablet twice daily orally along with clopidogrel 75 mg once daily orally, up to either 180 days after randomization of the last enrolled participant in the study or Day 360, whichever occurs earlier.
89576114|NCT02293395|Active Comparator|Stratum 2/ASA|ASA 100 mg enteric-coated tablet once daily orally along with ticagrelor 90 mg twice daily orally, up to either 180 days after randomization of the last enrolled participant in the study or Day 360, whichever occurs earlier.
89576115|NCT02293395|Experimental|Stratum 2/Rivaroxaban|Rivaroxaban 2.5 mg tablet twice daily orally along with ticagrelor 90 mg twice daily orally, up to either 180 days after randomization of the last enrolled participant in the study or Day 360, whichever occurs earlier.
89576116|NCT02025985|Experimental|Part 1: Cohort A-Ovarian carcinoma: Selinexor up to 60 mg/m^2 BIW|Participants with ovarian carcinoma who were platinum refractory or platinum resistant and had received at least one line of chemotherapy for relapsed disease received a dose of 50 milligram per meter square (mg/m^2) of selinexor oral tablets twice weekly (BIW) (doses at least 36 hours apart) with light meal and 120 milliliters (mL) of water in a 4-week treatment cycles. After 12 weeks of treatment, a dose of 60 mg/m^2 of selinexor oral tablets BIW were administrated if the participants had no major toxicity. During dose reduction, participants received a minimum dose of 35 mg/m^2 once weekly (QW). This treatment continued until progression of disease (PD) or unacceptable toxicity or any discontinuation criteria or withdrawal of consent by the participant, or non-compliance by the participant with protocol requirements.
89576117|NCT02025985|Experimental|Part 1: Cohort B-Endometrial carcinoma: Selinexor up to 60 mg/m^2 BIW|Participants with endometrial carcinoma who had received at least one line of chemotherapy for relapsed or advanced (Stage IVb, IIIc) disease received a dose of 50 mg/m^2 of selinexor oral tablets BIW (doses at least 36 hours apart) with light meal and 120 mL of water in a 4-week treatment cycles. After 12 weeks of treatment, a dose of 60 mg/m^2 of selinexor oral tablets BIW were administrated if the participants had no major toxicity. During dose reduction, participants received a minimum dose of 35 mg/m^2 QW. This treatment continued until PD or unacceptable toxicity or any discontinuation criteria or withdrawal of consent by the participant, or non-compliance by the participant with protocol requirements.
89576118|NCT02025985|Experimental|Part 1: Cohort C-Cervical carcinoma: Selinexor up to 60 mg/m^2 BIW|Participants with cervical carcinoma who had received at least one line of chemotherapy for relapsed or advanced (Stage IV) disease received a dose of 50 mg/m^2 of selinexor oral tablets BIW (doses at least 36 hours apart) with light meal and 120 mL of water in a 4-week treatment cycles. After 12 weeks of treatment, a dose of 60 mg/m^2 of selinexor oral tablets BIW were administrated if the participants had no major toxicity. During dose reduction, participants received a minimum dose of 35 mg/m^2 QW. This treatment continued until PD or unacceptable toxicity or any discontinuation criteria or withdrawal of consent by the participant, or non-compliance by the participant with protocol requirements.
89576119|NCT02025985|Experimental|Part 2: Cohort A-Ovarian carcinoma Schedule 1: Selinexor up to 50 mg/m^2 BIW|Participants with ovarian carcinoma who were platinum refractory or platinum resistant and had received at least one line of chemotherapy for relapsed disease received a dose of 35 mg/m^2 of selinexor oral tablets BIW (doses at least 36 hours apart) with light meal and 120 mL of water in a 4-week treatment cycles. After 6 weeks of treatment, a dose of 50 mg/m^2 of selinexor oral tablets BIW were administrated if the participants had no major toxicity. During dose reduction, participants received a minimum dose of 35 mg/m^2 QW. This treatment continued until PD or unacceptable toxicity or any discontinuation criteria or withdrawal of consent by the participant, or non-compliance by the participant with protocol requirements.
89576120|NCT02025985|Experimental|Part 2: Cohort A-Ovarian carcinoma Schedule 2: Selinexor up to 60 mg/m^2 QW|Participants with ovarian carcinoma who were platinum refractory or platinum resistant and had received at least one line of chemotherapy for relapsed disease received a dose of 50 mg/m^2 of selinexor oral tablets QW (doses at least 5 days apart) with light meal and 120 mL of water in a 4-week treatment cycles. After 6 weeks of treatment, a dose of 60 mg/m^2 of selinexor oral tablets QW were administrated if the participants had no major toxicity. During dose reduction, participants received a minimum dose of 35 mg/m^2 QW. This treatment continued until PD or unacceptable toxicity or any discontinuation criteria or withdrawal of consent by the participant, or non-compliance by the participant with protocol requirements.
89576121|NCT05450341|Experimental|Right frontal 1 Hz rTMS|"Low-frequency (1 Hz) inhibitory rTMS will be administered to right inferior frontal gyrus with the following parameters:~Frequency: 1 Hz Stimulation site: Right IFG (as determined using EEG 10-20 system) Intensity: 100% of motor threshold Dosage: 20 minutes per day Duration: 10 days over 2 weeks (no stimulation during weekends)"
89576122|NCT05450341|Active Comparator|Right temporal 1 Hz rTMS|"Low-frequency (1 Hz) inhibitory rTMS will be administered to right posterior superior temporal gyrus with the following parameters:~Frequency: 1 Hz Stimulation site: Right posterior superior temporal gyrus (as determined using EEG 10-20 system) Intensity: 100% of motor threshold Dosage: 20 minutes per day Duration: 10 days over 2 weeks (no stimulation during weekends)"
89576123|NCT02528305|Experimental|High-intensity Interval Training (HIT)|6 week control period with no intervention then 6 weeks of twice weekly HIT
89576124|NCT05450263|Active Comparator|Sub-acute low back pain active intervention|To assess the efficacy of IET on the chronification of LBP, participants who are found to have a higher risk of pain chronification due to the presence of a biomarker (positive mPFC-Nac connectivity) will be randomized to the intervention group (IET)
89576125|NCT05450263|Sham Comparator|Sub-acute low back pain passive intervention|Control group, treatment as usual.
89576126|NCT05450263|No Intervention|No intervention|
89576127|NCT05403775|Experimental|3D printing guide plate group|3D-printed customized guide plate will be used to guide the puncture in TFESI combined with dorsal root ganglion PRF.
89576128|NCT05403775|Active Comparator|Conventional guidance group|The surgeons would place the needle according to his/her previous experience under the guidance of C-arm fluoroscopy.
89576129|NCT05420701|No Intervention|Left Atrial Appendage Occlusion|
89576130|NCT05420701|Active Comparator|Left Atrial Appendage Closure,|
89576131|NCT05420311|Experimental|A balanced hypocaloric diet in macronutrients (MedDiet).|Mediterranean diet based on olive oil as main fat and regular consumption of vegetables (2 daily rations), fruits (3 daily rations), legumes (3 weekly rations), fish (3 weekly rations), with low consumption of red meat and meat products (less than twice a week), dairy foods (less than once a week) and no sweets, pastries or sugary drinks. Diet will produce a 600 kcal per day caloric deficit, according to the Harris-Benedict equation for each subject. Diet will include 45% carbohydrates, 35% fat, 20% protein distributed in at least 4 meals (breakfast, lunch, afternoon snack and dinner).
89576132|NCT05420311|Experimental|A very low carbohydrate diet (KetoDiet).|Diet will produce a 600 kcal per day caloric deficit, according to the Harris-Benedict equation for each subject. Diet will include 5 % carbohydrates, 65% fat and 30% high biological value protein
89576133|NCT05420311|Experimental|An intermittent fasting (IF) approach.|In this diet subjects alternate norm caloric diet during 24 h (according to Harris-Benedict equation) and a diet including only 25% of caloric requirements the following 24 h (this day diet will include 5 % carbohydrates, 65% fat and 30% high biological value protein).
89576134|NCT05402761|Experimental|Nurse-guided BBTi group|Participants will experience 4-week treatment period (2 in person and 2 via telephone).
89576135|NCT05402761|Experimental|Mobile-delivered BBTi group|Participants will be shown how to download and use the app in their own mobile device after the baseline assessment.
89576136|NCT05402761|No Intervention|Sleep hygiene control group|Participants will receive sleep hygiene at the enrollment of the study and be required to maintain their usual lifestyle and medical treatment for 4 weeks.
89576137|NCT05447065|Experimental|Participants using vitamin D supplements|Participants in the experimental group were given 150,000 IU (10 ml) of vitamin D3 supplementation, and it was used regularly for 2 months. From the first measurement, 2 more measurements were taken, 28 days apart, and a total of 3 measurements were taken from the participants.
89576138|NCT05447065|No Intervention|Participants not using vitamin D supplements|No supplement was given to the control group. From the first measurement, 2 more measurements were taken, 28 days apart, and a total of 3 measurements were taken from the participants.
89576139|NCT05402605|Active Comparator|ICSI with AOA|"The oocytes were transferred into the calcium ionophore activation solution for two times of post-ICSI AOA (Ionomycin concentration of 10 µM).~Then the oocytes will be washed several times using the medium drops in dish AOA and dish ICSI, then divided into drops with maximum 3 oocytes per drop for culturing. After that, the culture dish will be put in the K-system G185 incubator at 37oC, 6% CO2, and 5% O2."
89576140|NCT05402605|Active Comparator|ICSI without AOA|Post-ICSI oocytes will be cultured in drops containing the Sage - 1 - StepSM medium (maximum 3 oocytes per drop) at 37oC, 6% CO2 and 5% O2 in K-system G185 incubator.
89576141|NCT05401357|Experimental|Bimatoprost 0.01% Ophthalmic Solution|Pharmaceutical dosage form contains LUMIGAN® (bimatoprost ophthalmic solution) 0.01% of Allergan, Inc.
89576142|NCT05401357|Active Comparator|LUMIGAN® 0.01% Ophthalmic Solution|Pharmaceutical dosage form contains LUMIGAN® (bimatoprost ophthalmic solution) 0.01% of Allergan, Inc.
89576143|NCT05401279|Experimental|Gemcitabine, Cisplatin and Tislelizumab|Patients will receive transurethral resection or partial cystectomy to remove all visible tumors with no residual disease left. 2-4 weeks after the surgery, patients will receive 8 cycles of tislelizumab combined with 4-6 cycles of gemcitabine and cisplatin.
89576144|NCT05420077|Experimental|RVM-V001 10 µg|RVM-V001-10 µg administered as a single dose of by intramuscular injection on Day 1
89576145|NCT05420077|Experimental|RVM-V001 30 µg|RVM-V001-30 µg administered as a single dose of by intramuscular injection on Day 1
89576146|NCT05420077|Experimental|RVM-V001 60 µg|RVM-V001-60 µg administered as a single dose of by intramuscular injection on Day 1
89576147|NCT02532517|Experimental|Enterprise|
89576148|NCT05418595||Group-1|PCOS patients intraovarian stromal conventional and SMI doppler findings
89576149|NCT02545049|Experimental|BAY94-8862|Finerenone tablet
89576150|NCT02545049|Placebo Comparator|Placebo|Matching placebo
89576151|NCT05451095|Experimental|Treatment sequence T1-T2-R|T1: Lower dose of BI 474121 and higher dose of placebo followed by intravenous ketamine infusion T2: Higher dose of BI 474121 and lower dose of placebo followed by intravenous ketamine infusion R: Lower dose of placebo and higher dose of placebo followed by intravenous ketamine infusion
89576152|NCT05451095|Experimental|Treatment sequence T2-T1-R|
89576153|NCT05451095|Experimental|Treatment sequence T1-R-T2|
89576154|NCT05451095|Experimental|Treatment sequence T2-R-T1|
89576155|NCT05451095|Experimental|Treatment sequence R-T1-T2|
89576156|NCT05451095|Experimental|Treatment sequence R-T2-T1|
89576157|NCT05476133|Experimental|study group|single group who had intervention and comparison of pre and post intervention assessment
89576158|NCT05476055||conventional NBS+ infants|Disease diagnosis is carried out using conventional diagnosis and treatment methods.
89576159|NCT05476055||conventional NBS+ infants (NGS)|Disease diagnosis is carried out using conventional diagnosis and treatment methods, as well as NGS.
89576160|NCT05476055||NICU infants|Disease diagnosis is carried out using conventional diagnosis and treatment methods.
89576161|NCT05476055||NICU infants (NGS)|Disease diagnosis is carried out using conventional diagnosis and treatment methods, as well as NGS.
89576162|NCT05476055||Premature infants|Disease diagnosis is carried out using conventional diagnosis and treatment methods.
89576163|NCT05476055||Premature infants (NGS)|Disease diagnosis is carried out using conventional diagnosis and treatment methods, as well as NGS.
89576164|NCT04423835||lateral closing osteotomy for cubitus varus deformity|The osteotomy line of all patients was designed according to Paley's principles. The lateral incision was applied in all patients and the osteotomy lines were marked on the humerus with the assistance of C-arm radiographs.
89576165|NCT05450705|Experimental|9 to 14 Years Old: Day 1 and Month 6|Chinese females 9 to 14 years old will receive a 0.5 mL intramuscular (IM) injection of 9-valent HPV (9vHPV) vaccine on Day 1 and Month 6
89576166|NCT05450705|Experimental|9 to 14 Years Old: Day 1 and Month 12|Chinese females 9 to 14 years old will receive a 0.5 mL iIM injection of 9-valent HPV (9vHPV) vaccine on Day 1 and Month 12
89576167|NCT05450705|Experimental|20 to 26 Years Old: Day 1, Month 2 and Month 6|Chinese females 20 to 26 years old will receive a 0.5 mL IM injection of 9-valent HPV (9vHPV) vaccine on Day 1, Month 2 and Month 6
89576168|NCT02532283|Experimental|JNJ-63623872 plus Oseltamivir|Participants will be administered JNJ-63623872 600 milligram (mg) tablets and oseltamivir 75 mg capsules orally twice daily for 7 days.
89576169|NCT02532283|Experimental|Placebo plus Oseltamivir|Participants will be administered placebo tablets and oseltamivir 75 mg capsules orally twice daily for 7 days.
89576170|NCT01807897|Experimental|CPAP|Nocturnal continuous positive airway pressure
89576171|NCT01807897|Experimental|NSO|Nocturnal supplemental oxygen
89576172|NCT01807897|Other|HLSE|Healthy lifestyle and sleep education control
89576173|NCT05446831|Experimental|Baricitinib|Oral baricitinib was given at a dose of 4 mg daily for 6 months. Treatment was discontinued if very severe or life-threatening adverse events developed or at the patients' request.
89576174|NCT02431351|Experimental|Selinexor|60 mg once weekly
89576175|NCT01295125|Experimental|XenMATRIX|Use of XenMATRIX mesh to repair hernia
89576176|NCT05398705|Experimental|Low-dose cepharanthine + standardized medical treatment|Drug: cepharanthine (tablet) Day 1~5: 20mg, Q8H X 5 days + standardized medical treatment
89576177|NCT05398705|Experimental|High-dose cepharanthine + standardized medical treatment|Drug: cepharanthine (tablet) Day 1~5: 40mg, Q8H X 5 days + standardized medical treatment
89576178|NCT05398705|Placebo Comparator|placebo+standardized medical treatment|Drug: cepharanthine placebo (tablet) Day 1~5: placebo + standardized medical treatment
89576179|NCT02540291|Experimental|E7046|Participants with tumor types that harbor high levels of myeloid infiltrate based on the Cancer Genome Atlas (TCGA).
89576180|NCT05397769|Experimental|Envafolimab group|Envafolimab is a PD-L1 antibody by hypodermic injection. Envafolimab will be administrated with 300mg each time, every three weeks for a total of 22 cycles since the first day of induction chemotherapy.
89576181|NCT05475977||First Group|Thirty patients of COPD smokers patients.
89576182|NCT05475977||Second group|Thirty patients of COPD ex-smokers patients.
89576183|NCT05475977||Third group|Thirty patients of COPD non-smokers patients.
89576184|NCT05464043|Experimental|diabetic cohort|"Patients who receive liver or kidney transplants and immunosuppressive drugs with diabetogenic risk.~After 14 days of immunosuppressive therapy, all admitted patients will be evaluated for first-line glucose homeostasis. This patient cohort will be referred to as the diabetes risk cohort.~Subjects will then be stratified into two groups of patients: those who have developed glycemic dysregulation or diabetes during immunosuppressive therapy, the diabetic cohort, and those who have not developed glycemic dysregulation or diabetes, the control cohort. Only those who have developed glycemic dysregulation or diabetes during immunosuppressive therapy, i.e. the diabetic cohort, will be analysed in more detail with the evaluation of second-line glucose homeostasis at three different times."
89532332|NCT06321263|Experimental|Inspiratory Muscle Training Group:|Older people in this group will perform aerobic and resistance training for 1 hour a day, twice a week for ten weeks, under the supervision of a researcher physiotherapist. As for Inspiratory Muscle Training, they will participate in training with 30 breathing cycles a day, six days a week, for ten weeks (two days in the clinic, four days at home).
89532333|NCT06319105||Standard intervention: Offer PrEP choice|Offer pre-exposure prophylaxis choice between oral and long-acting injectable cabotegravir for pre-exposure prophylaxis across 36 study sites.
89532334|NCT06318013||Control|Group receiving only local anesthesia
89532335|NCT06318013||Intravenous Dexamethasone|Group using dexamethasone IV
89532336|NCT06318013||Perineural Dexamethasone|group administered perineural dexamethasone
89532337|NCT06316934|Placebo Comparator|Placebo|Prior to starting the procedure, the clinic nurse will prepare the distilled water on a paper towel by applying two drops of each solution on a paper towel. The patients will hold the paper towel over their nose and then they will be asked to take two deep breaths. Before the physician comes in, the nurse will ask the participant to take a deep breath while holding the towel 3 inches from her face and will instruct the participant to continue to take normal breaths subsequently
89532338|NCT06316934|Experimental|Experimental|Prior to starting the procedure, the clinic nurse will prepare the aromatherapy Lavender essential oil on a paper towel by applying two drops of each solution on a paper towel. The patients will hold the paper towel over their nose and then they will be asked to take two deep breaths. Before the physician comes in, the nurse will ask the participant to take a deep breath while holding the towel 3 inches from her face and will instruct the participant to continue to take normal breaths subsequently
89532339|NCT06314321|Experimental|Baduanjin exercise group|Before starting dialysis，Patients perform Baduanjin exercises. All Baduanjin training is provided by a professional doctor who has received training on BaduanJin and obtained certificate. Each session is approximately 30 minutes in duration, consisting of 5 minutes of warm-up exercises, 20 minutes of Baduanjinpractice, and 5 minutes of cool-down exercises.
89532340|NCT06314321|No Intervention|Control group|Patients in this group maintain their conventional therapy and daily life activities, and there is no intervention given.
89532341|NCT06313398|Experimental|RBC survival in patients with SCD|RBC lifespan, determined by the mean number of days from biotin-labeled RBC infusion until biotin-labeled RBCs are below limit of detection, in patients with inherited hemoglobinopathies prior to and post initiation of disease modifying therapy or HSCT
89532342|NCT06313294|Experimental|App Group|In this group the patients will use the app for asking about related to pain, patient satisfaction and another complications.
89532343|NCT06313294|Active Comparator|Telephone interview group|In this group the patients will receive the calling by one member of the healthcare team asking items related to pain, patient satisfaction and another complications.
89532344|NCT06311487|Experimental|TANDEM Exercise|Participants in this arm will engage in morning aerobic exercise while in a fasted state, morning aerobic exercise while in a fed state, evening aerobic exercise while in a fasted state, and evening aerobic exercise while in a fed state in a randomly assigned order
89532345|NCT06310876|Experimental|Sequence 1|Subjects will receive ABBV-CLS-7262 dose 1, ABBV-CLS-7262 dose 2, placebo, or moxifloxacin 400 mg tablet
89532346|NCT06310876|Experimental|Sequence 2|Subjects will receive ABBV-CLS-7262 dose 1, ABBV-CLS-7262 dose 2, placebo, or moxifloxacin 400 mg tablet
89532347|NCT06310876|Experimental|Sequence 3|Subjects will receive ABBV-CLS-7262 dose 1, ABBV-CLS-7262 dose 2, placebo, or moxifloxacin 400 mg tablet
89532348|NCT06310876|Experimental|Sequence 4|Subjects will receive ABBV-CLS-7262 dose 1, ABBV-CLS-7262 dose 2, placebo, or moxifloxacin 400 mg tablet
89532349|NCT06303193|Experimental|1/Phase I - Pediatric|Escalating doses of pacritinib (cohort 1)
89532350|NCT06303193|Experimental|2/Phase II - Adult|Low-risk cohort (cohort 2): Initiated on pacritinib 100 mg BID. After three cycles, pacritinib dose escalated to 200 mg BID, the adult phase II recommended dose, if not in complete remission.High-risk cohort (cohort 3): Initiated on pacritnib 200 mg BID, the adult phase II recommended dose.
89532351|NCT06302959||healthy controls|"For healthy controls, participation in this study lasts only one day. The following samples will be collected at three time-points on the same day (4 am, 12 pm, 8 pm):~Blood sampling: 80 mL citrated whole blood and 10 mL serum will be collected. Collection of spontaneous sputum: at least 5 ml of sputum are collected. Saliva collection: Saliva is also collected at all three time-points."
89532352|NCT06302959||mild-to-moderate asthma|"For patients with mild-to-moderate asthma, participation in this study lasts only one day.~The following samples will be collected at three time-points on the same day (4 am, 12 pm, 8 pm):~Blood sampling: 80 mL citrated whole blood and 10 mL serum will be collected. Collection of spontaneous sputum: at least 5 ml of sputum are collected. Saliva collection: Saliva is also collected at all three time-points."
89532353|NCT06302959||severe eosinophilic asthma|"Patients with severe eosinophilic asthma, will be monitored (i) before mepolizumab treatment, (ii) after 4 months of mepolizumab treatment, (iii) once they reach remission under mepolizumab treatment. Mepolizumab is already approved for the treatment of severe eosinophilic asthma and is not administered for study purposes but as a standard treatment.~On the day of participation, the following samples will be collected at three time-points (4 am, 12 pm, 8 pm):~Blood sampling: 80 mL citrated whole blood and 10 mL serum will be collected. Collection of spontaneous sputum: at least 5 ml of sputum are collected. Saliva collection: Saliva is also collected at all three time-points."
89532354|NCT06302465|Active Comparator|neoadjuvant chemotherapy|
89532355|NCT06302465|Experimental|narlumosbartmab plus neoadjuvant chemotherapy|
89532356|NCT06302140|Experimental|Part A: [14C]-Nanatinostat|
89532357|NCT06302140|Experimental|Part B (Treatment A): Nanatinostat (free base) tablets in combination with Valganciclovir|Patients will be randomized into 2 treatment sequences (AB and BA) in Periods 1 and 2. Each treatment period is 24 hours.
89532358|NCT06302140|Experimental|Part B (Treatment B): Nanatinostat mesylate tablets in combination with Valganciclovir|Patients will be randomized into 2 treatment sequences (AB and BA) in Periods 1 and 2. Each treatment period is 24 hours.
89532359|NCT06302140|Experimental|Part C: Single-agent Nanatinostat (free base) tablets|
88971743|NCT03205696||Cases|36 youth with new diagnosis of acute/recent HIV as defined by laboratory assays Fiebig1-V with standard care of antiretrovirals (ARV) regimen provided by the clinician
89576185|NCT05475899|Active Comparator|Instrument assisted soft tissue mobilization|Patients in group A will be treated with the help of Instrument Assisted soft tissue mobilization GRASTON technique along with the conventional treatment. • Patient will be prone position with the foot over the edge of the table. Instrument will be applied from downward to upward direction with maximum of 10 - 15 strokes per session. These strokes will be applied in two sets of 10 strokes followed by stretches after each set. Conventional treatment includes icing and stretching of the calf muscles. Icing will be done for the total of 3-5 minutes. Both groups will be given session of 40 min/day, 3 days/week for 4 weeks, assessment will be done at baseline, at the end of 2nd week & at the end of 4th week.
89576186|NCT05475899|Experimental|kinesiology taping|Patients in group B will be treated with the help of kinesiology taping along with the conventional treatment. Patient will be in prone position with the dorsiflexion of the foot supported on the bed. Fan shaped taping will be applied with 60 - 100 % tension in the centre of the tape. The ends of the tape; the anchor will be applied without any stretch while centre of the tape will be stretched to approximately 60 - 100 %. Length of the tape may vary from person to person depending upon the size of the foot. Patient will be instructed to keep the tape till the next session. Conventional treatment includes icing and stretching of the calf muscles. Icing will be done for the total of 3-5 minutes. Both groups will be given session of 40 min/day, 3 days/week for 4 weeks, assessment will be done at baseline, at the end of 2nd week & at the end of 4th week.
89576187|NCT05416255|Active Comparator|Dextrose injection|Injection of 10 ml of 12.5% dextrose
89576188|NCT05416255|Active Comparator|Hematopoietic stem cells|Injection of 10 ml of of 7.5 ml hematopoietic stem cells, 2 ml of 25% dextrose (5% diluted), 0.5 ml of 1% lidocaine (0.05% diluted),and 0.25 ml dexamethasone (1.5 mg)
89576189|NCT05416255|Active Comparator|Platelet Rich Plasma injection|Injection of 10 ml of leukocyte rich platelet rich plasma
89576190|NCT05416255|Active Comparator|No injection|Aspiration of synovial fluid may be an active comparator.
89576191|NCT02540213||MIRCERA Ready-To-Use-Syringe|Participants will use MIRCERA ready-to-use-syringes (methoxy polyethylene glycol epoetin beta 0.6 micrograms per kilogram [mcg/kg]) every 2 weeks (q2w) up to 9 months
89576192|NCT05444413|Experimental|ultrasound-guided platelet rich plasma nerve block combined with drugs|selected patients were treated by the ultrasound-guided platelet rich plasma nerve block once a week for the 4 consecutive weeks while they were given the regular medicine which are taking pregabalin and amitriptyline hydrochloride orally, and the dosage shall be increased or decreased according to the patient's condition.
89576193|NCT05415865|Active Comparator|Alkalinized Lidocaine, then Placebo|"Participants will have Lidocaine Hydrochloride 20 mg/ml, 20 ml and Sodium hydrogen carbonate 1 mmol/ml, 10 ml (ie a total of 30 ml) installed in the bladder for 15 minutes prior to the BTXA-injection procedure.~When signing up for the next BTXA-injection with a wash out period of minimum three months, participants will have the matching placebo containing Sodium Chloride 9 g/L, 20 ml and Sodium Chloride 9 g/L, 10 ml, a total of 30 ml installed in the bladder for 15 minutes prior to the BTXA-injection procedure."
89576194|NCT05415865|Active Comparator|Placebo, then Alkalinized Lidocaine|"Participants will have placebo containing Sodium Chloride 9 g/L, 20 ml and Sodium Chloride 9 g/L, 10 ml, a total of 30 ml installed in the bladder 15 minutes prior to the BTXA-injection procedure.~When signing up for the next BTXA-injection with a wash out period of minimum three months, participants will have Lidocaine Hydrochloride 20 mg/ml, 20 ml and Sodium hydrogen carbonate 1 mmol/ml, 10 ml (ie a total of 30 ml) installed in the bladder for 15 minutes prior to the BTXA-injection procedure."
89576195|NCT05463887|No Intervention|Usual care|Control arm: Participants will not receive individualized preventive care recommendations (decision tool).
89576196|NCT05463887|Active Comparator|Individualized preventive care recommendations (decision tool)|Intervention arm: Providers will receive individualized preventive care recommendations (decision tool) for eligible patients, and discuss them with patients using shared decision-making.
89576197|NCT05463575|Experimental|PF-06835919|KHKi
89576198|NCT05463575|Placebo Comparator|Placebo|Placebo
89576199|NCT05415553|Experimental|IOBT group|For IOBT, the whole belly of inferior oblique muscle is anchored to the sclera 5 mm behind the temporal insertion of the inferior rectus muscle.
89576200|NCT05415553|Active Comparator|IO-Rec group|For IO-Rec, the insertion of inferior oblique muscle is excised and anchored to the sclera 4 mm behind and 2 mm beside the temporal insertion of the inferior rectus muscle.
89576201|NCT05394649|Experimental|Intravascular lithotripsy arm|Preparation of calcified lesions by intravascular lithotripsy before stenting
89576202|NCT05394649|Active Comparator|Rotational Atherectomy arm|Preparation of calcified lesions by rotational atherectomy before stenting
89576203|NCT02552303|Active Comparator|CBT for Insomnia (CBTI) + Armodafinil|CBT-I with Armodafinil (active medication)
89576204|NCT02552303|Placebo Comparator|CBTI + Placebo|Cognitive Behavioral Therapy for Insomnia with Placebo medication
89576205|NCT02552303|Active Comparator|Armodafinil|Medication (armodafinil) only, without CBTI.
89576206|NCT02552303|Placebo Comparator|Placebo|Placebo only, without CBTI.
89576207|NCT05394571||Newly diagnosed diabetes|Patients who have been diagnosed with type 2 diabetes within a month
89576208|NCT05394571||Had controlled diabetes before|Patients who had at least two HbA1c levels =<%7,5 before enrollment
89576209|NCT05394571||Had moderately uncontrolled diabetes|Patients who had at least two HbA1c levels between %7,5 and %9,49 before enrollment
89576210|NCT05394571||Had poorly controlled diabetes|Patients who had at least two HbA1c levels above %9,5 before enrollment
88971744|NCT03205696||Controls|36 youth with newly diagnosed HIV but established HIV infection (Fiebig VI) with standard care of antiretrovirals (ARV) regimen provided by the clinician
88971745|NCT04710823|Experimental|Thoracic paravertebral block|Patients will receive ultrasound-guided continuous thoracic paravertebral blockusing bupivacaine 0.25% for 4 days.
88971746|NCT04710823|Experimental|Serratus anterior plane block|Patients will receive ultrasound-guided continuous SAP block using bupivacaine 0.25% for 4 days.
88971747|NCT00405535|Experimental|A|glycine powder
89576211|NCT01660711|Experimental|FOLFIRINOX chemotherapy|"5FU 2400 mg/m2 IV over 48 hours Irinotecan 180 mg/m2 IV day 1 Oxaliplatin 85 mg/m2 IV day 1 Leucovorin 400 mg/m2 IV day 1~Cycles administered every 14 days for 4 cycles before and 4 cycles after surgery."
89576212|NCT02544113|Experimental|Thymo|Subjects randomized to the (Delay CNI) group will be treated with Thymoglobulin® (total dose of 4.5 mg/kg) administered in three doses; (each dose being 1.5 mg/kg - administered Day 0 [after transplant], Day 2, and Day 4 post transplant), along with CNI delay for 10 days. CNI will be initiated on postoperative (post-transplant) Day 10. Subjects will also receive a maintenance immunosuppression regimen of corticosteroids and MMF in accordance with the standard practice at each clinical center.
89576213|NCT02544113|Placebo Comparator|Control|Subjects randomized to the (Early CNI) group (Control group) will receive no antibody therapy for induction and will start CNI therapy on postoperative (post-transplant) Day 2. Subjects will also receive a maintenance immunosuppression regimen of corticosteroids and MMF in accordance with the standard practice at each clinical center.
89576214|NCT02538965|Experimental|Lenalidomide|Lenalidomide API will administered at a starting dose of 2 mg/kg/day. Lenalidomide will be provided as either a capsule (2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg or 25 mg) or as an oral suspension (10mg/mL).
89576215|NCT02543801|Active Comparator|Hip Cohort Liposomal Bupivacaine|Liposomal bupivacaine Bupivacaine Clonidine Epinephrine Ketorolac
89576216|NCT02543801|Active Comparator|Hip Cohort Ropivacaine|Ropivacaine Clonidine Epinephrine Ketorolac
89576217|NCT02543801|Active Comparator|Knee Cohort Liposomal Bupivacaine|Liposomal bupivacaine Bupivacaine Clonidine Epinephrine Ketorolac
89576218|NCT02543801|Active Comparator|Knee Cohort Ropivacaine|Ropivacaine Clonidine Epinephrine Ketorolac
89576219|NCT02481635|Experimental|Gemcitabine/Nab-paclitaxel, Radiation and Surgery|"Gemcitabine (neoadjuvant and adjuvant), intravenously, at a dose of 1000 mg/m2 given over 30-40 minutes, on Day 1 of every 28 day cycle for 2 cycles.~Nab-paclitaxel, intravenously, at a dose of 125 mg/m2 given over 30-40 minutes, on Days 1, 8, and 15 of every 28 day cycle for 2 cycles.~Radiation Therapy: 50.4 Gy in 28 fractions (1.8 Gy/fraction)~Surgery: Tumor resection and arterial resection/reconstruction"
89576220|NCT02535065|Experimental|Endovascular Graft|The Zenith Low Profile AAA Endovascular Graft and ancillary components
89576221|NCT05461313|Other|Constrained Liner|
89576222|NCT05461313|Other|Dual Mobility Cup|
89576223|NCT05411159|Experimental|Opioid-Free Anesthesia (OFA froup)|Opioid-free anesthesia group, avoid patients receive any kind of opioid during VATs.
89576224|NCT05411159|Active Comparator|Standard general anesthesia (OA)|Standard general anesthesia. Opioids allowed, including sufentanil, remifentanil, tramadol during VATs.
89576225|NCT05431907|Experimental|Cohorts 1-2|Escalating doses of Allocetra-OTS up to 10 x 10^9 cells.
89576226|NCT05431907|Experimental|Cohorts 3-4|Allocetra-OTS at the maximal tolerated dose.
89576227|NCT05448911|Experimental|Experimental group|It uses minimally invasive small incisions, physiological access to the pelvis, and hollow screws for Pelvic and Acetabular fractures
88971748|NCT00405535|Placebo Comparator|B|placebo powder
88971749|NCT01457183|Experimental|Lavage group|Healthy subjects with intact skin will be lavaged within the device in 3 locations on their bodies.
88971750|NCT01682304||History of Preeclampsia|Chronic hypertension with history of preeclampsia Chronic hypertension without history of preeclampsia
89576228|NCT05448911|Other|Control Group|This approach typically requires extensive surgical exposure and large-scale soft-tissue dissection, which quickly leads to some serious complications, including increased rates of infection, poor wound healing, increased damage to large vessels or nerves, and heterotopic ossification
89209311|NCT02592083|Experimental|B: Endocrine treatment + palbociclib|Patients receive the same endocrine treatment as in arm A together with palbociclib 125 mg orally days 1-21, followed by a 7-days rest period. The combined treatment is continued for further 12 weeks, provided that re-evaluation after 6 weeks, week 10 of the preoperative treatment, does not indicate progression. Upon progression (PD), individualized management, preferentially surgery, is the primary option
89576229|NCT02530619|Experimental|Treatment (alisertib)|Patients receive alisertib PO BID on days 1-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89576230|NCT02530385|Experimental|FMT|Active FMT capsules
89576231|NCT02530385|Placebo Comparator|Placebo|Placebo capsules
89576232|NCT02362425|Active Comparator|RYR1-RM Patients Administered N-acetylcysteine|N-acetylcysteine
89576233|NCT02362425|Placebo Comparator|RYR1-RM Patients Administered Placebo|Placebo
89576234|NCT02362425|No Intervention|Healthy Volunteers|Healthy volunteers who had physical exam, study biomarker, Near Infrared Spectroscopy (NIRS) testing and muscle ultrasound only, in one visit.
89576235|NCT02362269|Active Comparator|Control Group|The control group will receive 2500 IU of vitamin D3 daily.
89576236|NCT02362269|Experimental|Dosing Algorithm Group|The dosing algorithm group will initially receive 1000, 2500, or 4000 IU of vitamin D3 daily based on the baseline 25(OH)D. This group's dosing may be adjusted at the 3-month visit.
89576237|NCT02529995|Experimental|AZD9291 40 mg|Cohort 1: 40 mg once daily
89576238|NCT02529995|Experimental|AZD9291 80 mg|Cohort 2: 80 mg once daily
89576239|NCT05431517||Non-migration group|Cases without migration after pancreatic stenting under ERCP.
88971751|NCT00405574|Experimental|High Dose|ATN-224 dose 300mg
88971752|NCT00405574|Experimental|Low Dose|ATN-224 dose: 30mg
88971753|NCT01415180||Children: previously healthy|Previously healthy children, without chronic disease prior to the sepsis episode, expected to comprise about 50-60% of the total study population.
88971754|NCT01415180||Children: chronic, complex conditions|Children with chronic, complex conditions prior to the sepsis episode, expected to comprise about 40-50% of the study population.
88971755|NCT02962726||Patients|100 female patients between the age of 12 and 18 years suffering from anorexia nervosa.
88971756|NCT02962726||Age matched Controls|100 females volunteers between the age of 12 and 18 years old without eating disorder.
88971757|NCT02825641|Active Comparator|Expectant Management-Dinoprostone|"Women with premature rupture of membranes who are not in active labor and have an unfavorable cervix (Bishop score<6).~Labor induction will be initiated with Dinoprostone after 24 hours of waiting depending on obstetric history and cervical conditions."
88971758|NCT02825641|Active Comparator|Expectant Management-Oxytocin|"Women with premature rupture of membranes who are not in active labor and have an unfavorable cervix (Bishop score<6).~Labor induction will be initiated with oxytocin after 24 hours of waiting depending on obstetric history and cervical conditions."
89209312|NCT02592083|Experimental|C: Endocrine treatment + palbociclib|Patients receive the same endocrine treatment as in arm A together with palbociclib 125 mg orally days 1-21, followed by a 7-days rest period. The combined treatment is continued for further 12 weeks, if re-evaluation after 6 weeks, week 10 of the preoperative treatment, does not indicate progression. Upon progression (PD), individualized management, preferentially surgery, is the primary option
89209313|NCT04589676|Active Comparator|Personal recruitment|Participants in this training condition will receive recruitment messages that appeal to their personal sense of identity (e.g., you could be a hero if you get trained with naloxone).
89209314|NCT04589676|Experimental|Online training|Participants in this training condition will receive recruitment messages that appeal to their communal sense of identity (e.g., your family and friends will thank you for getting trained with naloxone).
89209315|NCT00882336||1|Patients 50+ years old, with at least one additional CV risk factor (with no previous CV event or hospitalization for a CV event)
89209316|NCT00724451||Participants with Chronic Hepatitis C (CHC)|Peginterferon-naïve participants with CHC seen in general clinical practice in Italy and treated with either pegylated interferon alfa-2a or alfa-2b + ribavirin.
89209317|NCT00724373||Participants with genotype 1 Hepatitis C Virus infection.|Participants with genotype 1 Hepatitis C Virus (HCV) infection who have been treated with pegylated interferon alfa-2b and ribavirin in the preceding 48 months
89209318|NCT02594579|Active Comparator|Vitamin D|Dietary Supplement: Vitamin D3
89209319|NCT02594579|Placebo Comparator|Placebo|Dietary Supplement: Placebo
89209320|NCT02593409|Other|TDF/FTC|All participants receive pre-exposure prophylaxis in the form of a daily tablet containing 300 mg of tenofovir disoproxil fumarate and 200 mg emtricitabine (Truvada®, Gilead) for one year, with an optional extension for 6 months.
89209321|NCT00724061|Experimental|PEG-IFN-α-2b + UV therapy|Pegylated interferon α-2b in combination with UV therapy (either PUVA or NB-UVB).
89209322|NCT04936386||Healthcare professionals|Healthcare professionals (medical specialists and general practitioners, medical residents, midwives, professional nurses, medical students).
89576240|NCT05431517||Migration group|Cases with migration after pancreatic stenting under ERCP.
89576241|NCT04260425|Experimental|High then low avenanthramides content oats|This arm will receive the high avenanthramides content oatmeal at the first session and the low avenanthramides content oatmeal at the second session. Sessions will be at least 5 days apart.
89576242|NCT04260425|Experimental|Low then high avenanthramides content oats|This arm will receive the low avenanthramides content oatmeal at the first session and the high avenanthramides content oatmeal at the second session. Sessions will be at least 5 days apart.
89576243|NCT05447819|Experimental|DELTA Xtend Reverse Shoulder System Lateralized Glenosphere Line Extension|"By using a lateralized glensphere complications can be reduced and patients can achieve an improved outcome.~Currently, little is known about the results of the lateralized design. The initial results have been promising, but migration and eventually loosening of the prosthesis can lead to poor results and, in some cases, revision"
89576244|NCT05447819|Active Comparator|Standard DELTA Xtend Reverse Shoulder System|A design with a standard glenosphere is currently regarded as the standard treatment
89576245|NCT02529137||Surgical pathology cases|Cases will be selected from the sites Laboratory Information Systems using the in- and exclusion criteria.
89576246|NCT05447585|Experimental|Coronary Atherectomy System|Subjects in experimental arm will be treated with the Coronary Atherectomy System manufactured by Shanghai Microport Rhythm Co. Ltd.
89576247|NCT05447585|Active Comparator|Rotablator Rotational Atherectomy System|Subjects in control arm will be treated with Rotablator Rotational Atherectomy System manufactured by Boston Scientific Corporation
89576248|NCT05429021|Experimental|IV Cohort 1|Single intravenous (IV) dose 1 of IMM-BCP-01 or matching placebo
89576249|NCT05429021|Experimental|IV Cohort 2|Single intravenous (IV) dose 2 of IMM-BCP-01 or matching placebo
89576250|NCT05429021|Experimental|IV Cohort 3|Single intravenous (IV) dose 1 of IMM-BCP-01 or matching placebo
89576251|NCT05429021|Experimental|IV Cohort 4 (optional)|Single intravenous (IV) dose 4 of IMM-BCP-01 or matching placebo
89576252|NCT02319759|Experimental|Guselkumab|Participants will receive guselkumab 100 milligram (mg) subcutaneous injection (injected under the skin by way of a needle) at Weeks 0, 4, 12, 20, 28, 36, and 44, and placebo for guselkumab at Week 24 to maintain the blind. Participants who enter early escape at Week 16 will switch to open label therapy with ustekinumab 45 mg or 90 mg at Weeks 16, 20, 32, and 44 based on the approved dosage in the particular country of the study.
89576253|NCT02319759|Experimental|Placebo|Participants will receive placebo for guselkumab at Weeks 0, 4, 12, and 20, and guselkumab 100 mg subcutaneous injection at Weeks 24, 28, 36, and 44. Participants who enter early escape at Week 16 will switch to open label therapy with ustekinumab 45 mg or 90 mg at Weeks 16, 20, 32, and 44 based on the approved dosage in the particular country of the study.
89576254|NCT02293005|Experimental|Alisertib|Alisertib administered by mouth at 50 mg twice a day for 7 days in each treatment cycle, followed by a 14-day, treatment-free period.
89576255|NCT02319525|Experimental|Computerized patient decision-aid|A computerized decision-aid showing benefits and harms of medications in words patients prefer
89576256|NCT02319525|Active Comparator|Usual care (lupus pamphlet)|A handout/pamphlet from a non-profit organization on lupus and lupus medications (American College of Rheumatology [ACR])
89576257|NCT02292927|No Intervention|Pre-intervention|Patients treated as standard before intervention
89576258|NCT02292927|Active Comparator|Post-intervention arm = Prehabilitation|Introduction of rehabilitation program
89532360|NCT06298084|Experimental|Part 1a (safety run-in module 0)|Patients with HER2-low ABC who have progressed on T-DXd. Patients in part 1a will receive intravenous infusion of HER3-DXd monotherapy (5.6 mg/kg every 21 days)
89532361|NCT06298084|Experimental|Part 1b (dose finding module 1 + dose expansion module 0)|In the dose expansion part, patients will receive the RP2D defined in the dose finding part of different combinations (module 1) and HER3-DXd single agent 5.6 mg/kg IV D1 every 21 days in module 0.
89576259|NCT02292849|Experimental|Peer to Peer|These individuals will receive a standard mental health referral to a community agency and in addition meet with a trained peer coach for 12 weekly meetings.
89576260|NCT02292849|Active Comparator|Referral|These individuals will receive a standard mental health referral to a community agency.
89576261|NCT02318667|Experimental|Golimumab treatment|Golimumab 200 mg initially administered by subcutaneous (SC) injection at Week 0, followed by 100 mg at Week 2 and then 50 mg or 100 mg every 4 weeks (per prescribing information) up to 16 weeks.
89576262|NCT02292771|Experimental|Retosiban + Atosiban Placebo|Participants will receive retosiban 6 milligrams (mg) intravenous (IV) loading dose over 5 minutes, followed by a 6mg/hour continuous infusion over 48 hours. For subjects with an inadequate response after the first hour of treatment, investigators will administer another 6mg IV loading dose and increase the infusion rate to 12 mg/hour for the remainder of the 48-hour treatment period. Participants will also receive placebo infusion matched for the atosiban loading (bolus) dose and continuous infusion to ensure blinding.
89576263|NCT02292771|Active Comparator|Atosiban + Retosiban Placebo|Participants will receive atosiban in 3 successive stages: an initial bolus dose (6.75 mg) over 1 minute, immediately followed by a continuous infusion at 18 mg/hour for 3 hours, followed by a 6 mg/hour infusion for the remainder of the 48-hour treatment period. Participants will also receive placebo infusion matched for retosiban loading (bolus) dose and continuous infusion to ensure blinding.
89576264|NCT04880187|Experimental|AXA1125 22.6g|22.6 g AXA1125 administered orally BID with or without food
89576265|NCT04880187|Experimental|AXA1125 33.9g|33.9 g AXA1125 administered orally BID with or without food
89576266|NCT04880187|Placebo Comparator|Placebo|Matching Placebo administered orally BID with or without food
89576267|NCT02291913|Experimental|everolimus|Everolimus will be administered at a dose of 10 mg PO daily combined with any one of the following anti-estrogen therapies on which the patient most recently progressed (tamoxifen, fulvestrant, anastrozole, letrozole, exemestane, toremifine, or LHRH agonists in conjunction with anti-estrogen therapy). Anti-estrogen therapy will be administered at the US Food and Drug Administration (FDA) prescribed doses.
89576268|NCT02291679|Experimental|72 μg linaclotide|72 μg oral linaclotide, once daily for 12 weeks
89576269|NCT02291679|Experimental|145 μg linaclotide|145 μg oral linaclotide, once daily for 12 weeks
89576270|NCT02291679|Placebo Comparator|Placebo|matching placebo, once daily for 12 weeks
89576271|NCT02291601|Experimental|Chlorhexidine Gluconate Cloth|2% CHG, single application
89576272|NCT02291601|Placebo Comparator|Vehicle Cloth|Excipients on cloth
89576273|NCT02291601|Active Comparator|Active Chlorhexidine gluconate solution|Dynahex 2% CHG
89576274|NCT02360475|Experimental|RSV vaccine formulation 1 Group|Subjects in this group will receive a single dose of formulation 1 of the RSV vaccine
89576275|NCT02360475|Experimental|RSV vaccine formulation 2 Group|Subjects in this group will receive a single dose of formulation 2 of RSV vaccine
89576276|NCT02360475|Experimental|RSV vaccine formulation 3 Group|Subjects in this group will receive a single dose of formulation 3 of RSV vaccine
89576277|NCT02360475|Active Comparator|Boostrix Group|Subjects in this group will receive a single dose of Boostrix
89576278|NCT02360397|Experimental|Ranolazine|Ranolazine 1000 mg tablet twice daily for 30 days
89576279|NCT02317809|Experimental|First Liquid Pergoveris, Then Freeze-dried Pergoveris|
89576280|NCT02317809|Experimental|First Freeze-dried Pergoveris, Then Liquid Pergoveris|
89576281|NCT02359851|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for 24 months in the absence of disease progression or unacceptable toxicity.
89576282|NCT01607905|Experimental|Arm A (Colorectal Cancer)|Participants with colorectal cancer and liver metastasis received oral selinexor as single agent in 8 schedules, Schedule1: ≤12milligrams per meter square(mg/m^2) 3 times weekly(TIW) during Weeks 1 and 3, twice weekly(BIW) during Weeks 2 and 4 up to 10 doses/cycle(28 days/cycle); Schedule2: >12mg/m^2 TIW during Weeks 1 and 3, BIW in Weeks 2 and 4 up to 10 doses/cycle(28 days/cycle); Schedule3: ≥30mg/m^2 BIW(Days 1 and 3) up to 8 doses/cycle(28 days/cycle); Schedule4: ≥20mg/m^2 BIW(Days 1 and 2) up to 8 doses/cycle(28 days/cycle); Schedule5: ≥35mg/m^2 BIW(Days 1 and 4) up to 8 doses(28 days/cycle); Schedule6: ≥20mg/m^2 BIW(Days 1 and 4) after 500 mg(Week 1) to 1000 mg(Week 2 onwards) acetaminophen(given 1 hour prior to each selinexor dose) up to 8 doses/cycle (28 days/cycle); Schedule7: ≥50mg/m^2 once weekly(QW) up to 4 doses/cycle(28 days per cycle); Schedule8: ≥45mg/m^2 BIW(Days 1 and 3) up to 4 doses/cycle(21 days/cycle), until disease progression, death, or unacceptable toxicity.
89576283|NCT01607905|Experimental|Arm B (Gynecological Cancer)|Participants with gynecological cancer received oral selinexor as a single agent in eight schedules, Schedule 1: ≤12 mg/m^2 TIW during Weeks 1 and 3, BIW during Weeks 2 and 4 up to 10 doses/cycle (28 days/cycle); Schedule 2: >12 mg/m^2 TIW during Weeks 1 and 3, BIW in Weeks 2 and 4 up to 10 doses/cycle (28 days/cycle); Schedule 3: ≥30 mg/m^2 BIW (Days 1 and 3) up to 8 doses/cycle (28 days/cycle); Schedule 4: ≥20 mg/m^2 BIW (Days 1 and 2) up to 8 doses/cycle (28 days/cycle); Schedule 5: ≥35 mg/m^2 BIW (Days 1 and 4) up to 8 doses (28 days/cycle); Schedule 7: ≥50 mg/m^2 QW up to 4 doses/cycle (28 days per cycle); Schedule 8: ≥45 mg/m^2 BIW (Days 1 and 3) up to 4 doses/cycle (21 days/cycle), until disease progression, death, or unacceptable toxicity.
89576284|NCT01607905|Experimental|Arm C (Squamous Cell Cancer)|Participants with squamous cell cancer received oral selinexor as a single agent in eight schedules, Schedule 1: ≤12 mg/m^2 TIW during Weeks 1 and 3, BIW during Weeks 2 and 4 up to 10 doses/cycle (28 days/cycle); Schedule 2: >12 mg/m^2 TIW during Weeks 1 and 3, BIW in Weeks 2 and 4 up to 10 doses/cycle (28 days/cycle); Schedule 3: ≥30 mg/m^2 BIW (Days 1 and 3) up to 8 doses/cycle (28 days/cycle); Schedule 4: ≥20 mg/m^2 BIW (Days 1 and 2) up to 8 doses/cycle (28 days/cycle); Schedule 5: ≥35 mg/m^2 BIW (Days 1 and 4) up to 8 doses (28 days/cycle); Schedule 7: ≥50 mg/m^2 QW up to 4 doses/cycle (28 days per cycle); Schedule 8: ≥45 mg/m^2 BIW (Days 1 and 3) up to 4 doses/cycle (21 days/cycle), until disease progression, death, or unacceptable toxicity.
89209323|NCT02594423|Active Comparator|Fine needle Diathermy|Fine needle Diathermy(FND) will be applied under topical anaesthesia under an operating microscope. This involves the insertion of a fine corneal suture needle in the vicinity of the vessels and using this as an extension of the probe of a monopolar cautery to deliver the energy in the corneal tissue at the site at which it is required to occlude the vessels.
89532362|NCT06298084|Experimental|Part 2 (dose expansion module 1 + module 0)|In the dose expansion part, patients will receive the RP2D defined in the dose finding part of different combinations (module 1) and HER3-DXd single agent 5.6 mg/kg IV D1 every 21 days in module 0.
89532363|NCT06297226|Experimental|BMS-986393|
89532364|NCT06295939|Experimental|Group 1, the control group|Group 1 the control group receive routine nursing care from the assigned nurse.
89532365|NCT06295939|Experimental|Group 2: the experimental group|Group 2, the experimental group, will receive regular nursing care from the assigned nurse and a social support program provided by the researcher Phase 1 (Before Pregnancy Termination) Phase 2 (After Pregnancy Termination, Before Returning Home)
89532366|NCT06295796|Experimental|Moderate Renal Impairment|Participants with moderate renal impairment receive a single dose of MK-8527 on Day 1.
89532367|NCT06295796|Experimental|Severe Renal Impairment|Participants with severe renal impairment receive a single dose of MK-8527 on Day 1.
89532368|NCT06295796|Experimental|Healthy|Healthy participants receive a single dose of MK-8527 on Day 1.
89532369|NCT06294600|Placebo Comparator|Placebo|These patients will be treated with 1 placebo tablet every 12 hours and it is suggested that all patients receive at least one of antibiotics based on the current ESCMID guidelines for severe CAP13 (Ampicillin/sulbactam, Amoxicillin/clavulanate, Piperacillin/tazobactam, Ceftriaxone, Cefotaxime, Ceftaroline, Moxifloxacin). The total duration of treatment will be seven days.Τhe dosage, the dosage regime, the route and mode of administration, and the treatment period for the aforementioned antibiotics can be found in the relevant SmPCs (available in References). However, the attending physician may modify the antimicrobial treatment based on risk factors for multidrug-resistance pathogens, microbiology results and local epidemiology. All SoC treatment products and clarithromycin are authorised for use in Greece, where the trial will be conducted.
89532370|NCT06294600|Active Comparator|Clarithromycin|These patients will be treated with oral clarithromycin 500 mg twice daily for seven days and it is suggested that all patients receive at least one of antibiotics based on the current ESCMID guidelines for severe CAP13 (Ampicillin/sulbactam, Amoxicillin/clavulanate, Piperacillin/tazobactam, Ceftriaxone, Cefotaxime, Ceftaroline, Moxifloxacin). The total duration of treatment will be seven days.Τhe dosage, the dosage regime, the route and mode of administration, and the treatment period for the aforementioned antibiotics can be found in the relevant SmPCs (available in References). However, the attending physician may modify the antimicrobial treatment based on risk factors for multidrug-resistance pathogens, microbiology results and local epidemiology. All SoC treatment products and clarithromycin are authorised for use in Greece, where the trial will be conducted.
89532371|NCT06294236|Experimental|LN Cohort|SC291 with lymphodepleting therapy
89532372|NCT06294236|Experimental|ERL Cohort|SC291 with lymphodepleting therapy
89532373|NCT06294236|Experimental|AAV Cohort|SC291 with lymphodepleting therapy
89532374|NCT06292000|Experimental|Crossover - AM first|Crossover design with AM exercise first
89532375|NCT06292000|Experimental|Crossover - PM first|Crossover design with PM exercise first
89532376|NCT06291090|Experimental|OUD intervention|Participants received education on the diagnosis and management of OUD, have access to protocols to walk them through assessment of OUD using Diagnostic and Statistical Manual, fifth Edition (DSM)-5, COWS score to calculate severity of opioid withdrawal, buprenorphine or methadone initiation with pre-populated orders, and clickable links for OUD treatment referral post discharge.
89532377|NCT06290206|Experimental|Automated Intervention (Auto)|Auto intervention participants will be eligible for outreach delivered using automated phone calls, text, or email messages with the mode, frequency, timing of reminders, and message content refined using BCT. Automated outreach may also include innovative communication strategies, such as text-linked videos, P/C, or patient narratives (based on BCT). Auto outreach to P/C will invite P/Cs to attend free HPV vaccination visits and emphasize family-friendly hours.
89532378|NCT06290206|Experimental|Automated Intervention Plus (Auto-Plus)|Auto-Plus intervention participants will be eligible for automated reminders, plus additional P/C prompts for patients who do not undergo vaccination within three weeks. These prompts may be delivered via live phone call outreach or patient navigation. Working with clinic leadership and using the findings of BCT, activities will be selected from a list of possible options from the National HPV Vaccination Roundtable (previously chaired by Dr. Brewer) and our ranking of the effectiveness of language- and culturally- tailored intervention materials.
89532379|NCT06290206|No Intervention|Usual Care (UC)|The UC group will not receive tailored reminders but will only receive opportunistic vaccine reminders that are delivered during clinic visits or MyChart EHR-based patient portal reminders.
89532380|NCT06290141|Experimental|Riliprubart Arm|Riliprubart + Placebo IVIg for 24 weeks followed by open-label extension phase with riliprubart for 24 weeks
89532381|NCT06290141|Active Comparator|IVIg Arm|IVIg (IVIg continuation) + Placebo riliprubart for 24 weeks followed by open-label extension phase with riliprubart for 24 weeks
89532382|NCT06288412|Experimental|Insulin icodec|Participants will receive subcutaneous (s.c.) injections of insulin degludec once daily in the run-in period and insulin icodec once weekly in the treatment period.
89532383|NCT06286592|Experimental|Conditions 1, 2 & 3|"Condition 1 = Brief Mindfulness Video Condition 2 = Forgiveness Video Condition 3 = ACT Video~*Details of the specific interventions will be selected in collaboration with the Community Advisory Board."
89532384|NCT06286592|Experimental|Conditions 1 & 2|"Condition 1 = Brief Mindfulness Video Condition 2 = Forgiveness Video~*Details of the specific interventions will be selected in collaboration with the Community Advisory Board."
89532385|NCT06286592|Experimental|Condition 1|"Condition 1 = Brief Mindfulness Video~*Details of the specific interventions will be selected in collaboration with the Community Advisory Board."
89532386|NCT06286592|Experimental|Conditions 1 & 3|"Condition 1 = Brief Mindfulness Video Condition 3 = ACT Video~*Details of the specific interventions will be selected in collaboration with the Community Advisory Board."
89532387|NCT06286592|Experimental|Conditions 2 & 3|"Condition 2 = Forgiveness Video Condition 3 = ACT Video~*Details of the specific interventions will be selected in collaboration with the Community Advisory Board."
89532388|NCT06286592|Experimental|Condition 2|"Condition 2 = Forgiveness Video~*Details of the specific interventions will be selected in collaboration with the Community Advisory Board."
89576285|NCT01607905|Experimental|Arm D (Castrate-resistant Prostate Cancer)|Participants with castrate-resistant prostate cancer (CRPC) received oral selinexor as a single agent in eight schedules, Schedule 1: ≤12 mg/m^2 TIW during Weeks 1 and 3, BIW during Weeks 2 and 4 up to 10 doses/cycle (28 days/cycle); Schedule 2: >12 mg/m^2 TIW during Weeks 1 and 3, BIW in Weeks 2 and 4 up to 10 doses/cycle (28 days/cycle); Schedule 3: ≥30 mg/m^2 BIW (Days 1 and 3) up to 8 doses/cycle (28 days/cycle); Schedule 4: ≥20 mg/m^2 BIW (Days 1 and 2) up to 8 doses/cycle (28 days/cycle); Schedule 5: ≥35 mg/m^2 BIW (Days 1 and 4) up to 8 doses (28 days/cycle); Schedule 7: ≥50 mg/m^2 QW up to 4 doses/cycle (28 days per cycle); Schedule 8: ≥45 mg/m^2 BIW (Days 1 and 3) up to 4 doses/cycle (21 days/cycle), until disease progression, death, or unacceptable toxicity.
89576286|NCT01607905|Experimental|Arm E (Glioblastoma Multiforme)|Participants with glioblastoma multiforme (GBM) received oral selinexor as a single agent in eight schedules, Schedule 1: ≤12 mg/m^2 TIW during Weeks 1 and 3, BIW during Weeks 2 and 4 up to 10 doses/cycle (28 days/cycle); Schedule 2: >12 mg/m^2 TIW during Weeks 1 and 3, BIW in Weeks 2 and 4 up to 10 doses/cycle (28 days/cycle); Schedule 3: ≥30 mg/m^2 BIW (Days 1 and 3) up to 8 doses/cycle (28 days/cycle); Schedule 4: ≥20 mg/m^2 BIW (Days 1 and 2) up to 8 doses/cycle (28 days/cycle); Schedule 5: ≥35 mg/m^2 BIW (Days 1 and 4) up to 8 doses (28 days/cycle); Schedule 7: ≥50 mg/m^2 QW up to 4 doses/cycle (28 days per cycle); Schedule 8: ≥45 mg/m^2 BIW (Days 1 and 3) up to 4 doses/cycle (21 days/cycle), until disease progression, death, or unacceptable toxicity.
89576287|NCT01607905|Experimental|Arm F (Melanoma)|Participants with Melanoma received oral selinexor as a single agent in eight schedules, Schedule 1: ≤12 mg/m^2 TIW during Weeks 1 and 3, BIW during Weeks 2 and 4 up to 10 doses/cycle (28 days/cycle); Schedule 2: >12 mg/m^2 TIW during Weeks 1 and 3, BIW in Weeks 2 and 4 up to 10 doses/cycle (28 days/cycle); Schedule 3: ≥30 mg/m^2 BIW (Days 1 and 3) up to 8 doses/cycle (28 days/cycle); Schedule 4: ≥20 mg/m^2 BIW (Days 1 and 2) up to 8 doses/cycle (28 days/cycle); Schedule 5: ≥35 mg/m^2 BIW (Days 1 and 4) up to 8 doses (28 days/cycle); Schedule 7: ≥50 mg/m^2 QW up to 4 doses/cycle (28 days per cycle); Schedule 8: ≥45 mg/m^2 BIW (Days 1 and 3) up to 4 doses/cycle (21 days/cycle), until disease progression, death, or unacceptable toxicity.
89576288|NCT01607905|Experimental|Arm G (Other Solid Tumors)|Participants with other solid tumors received oral selinexor as a single agent in eight schedules, Schedule 1: ≤12 mg/m^2 TIW during Weeks 1 and 3, BIW during Weeks 2 and 4 up to 10 doses/cycle (28 days/cycle); Schedule 2: >12 mg/m^2 TIW during Weeks 1 and 3, BIW in Weeks 2 and 4 up to 10 doses/cycle (28 days/cycle); Schedule 3: ≥30 mg/m^2 BIW (Days 1 and 3) up to 8 doses/cycle (28 days/cycle); Schedule 4: ≥20 mg/m^2 BIW (Days 1 and 2) up to 8 doses/cycle (28 days/cycle); Schedule 5: ≥35 mg/m^2 BIW (Days 1 and 4) up to 8 doses (28 days/cycle); Schedule 7: ≥50 mg/m^2 QW up to 4 doses/cycle (28 days per cycle); Schedule 8: ≥45 mg/m^2 BIW (Days 1 and 3) up to 4 doses/cycle (21 days/cycle), until disease progression, death, or unacceptable toxicity.
88971759|NCT02825641|Experimental|Active Management-Dinoprostone|"Women with premature rupture of membranes who are not in active labor and have an unfavorable cervix (Bishop score<6).~Labor induction will be initiated with Dinoprostone on presentation depending on obstetric history and cervical conditions."
88971760|NCT02825641|Experimental|Active Management-Oxytocin|"Women with premature rupture of membranes who are not in active labor and have an unfavorable cervix (Bishop score<6).~Labor induction will be initiated with oxytocin on presentation depending on obstetric history and cervical conditions."
88971761|NCT02777047|Experimental|Intervention|The interdisciplinary multimodal intervention is led by a clinical pharmacologist and includes: a detailed discharge medication reconciliation and management plan focused on oral anticoagulants at hospital discharge; a circle of care handover and coordination with patient, hospital team and community providers; and early post-discharge follow-up virtual medication check-up visits at 24 hours, 1 week, and 1 month.
88971762|NCT02777047|No Intervention|Control|Patients allocated to the control group will receive usual care, plus the URL to Thrombosis Canada website. Usual care in the participating sites includes OAC management by family doctors except for new thromboembolic events which will be followed short term by thromboembolism or hematology specialists, complicated atrial fibrillation which will have cardiology involved temporarily, and a small proportion of warfarin management which is provided in an anticoagulation clinic. This choice of control group is the most relevant for generalizability to both academic and community practices.
88971763|NCT01646034|Experimental|intensified alkylating chemotherapy|a course chemotherapy with high dose cyclophosphamide, G-CSF and peripheral blood progenitor cell (PBPC) harvest followed by tandem intermediate-dose alkylating therapy (miniCTC, carboplatin 800 mg/m2, thiotepa 240 mg/m2, and cyclophosphamide 3000 mg/m2) with PBPC-reinfusion.
88971764|NCT01646034|Active Comparator|three cycles of chemotherapy|"three cycles of chemotherapy depending on previously received agents~chemotherapy naïve;three cycles of docetaxel, doxorubicin, and cyclophosphamide previously received anthracyclines without taxanes;three cycles of carboplatin and paclitaxel previously received anthracyclines and taxanes;three cycles of carboplatin and gemcitabine"
88971765|NCT01346618||children ages 4-17 years|Participants are children and youth ages 4-17 years (inclusive) who performed or will perform a X-ray of the left hand for bone age assessment as part of any clinical work up, within 2 months of enrollment in this study.
88971766|NCT02708368||Patients on dialysis|16 patients on dialysis with a sex ratio 1:1; 8 patients on hemodialysis and 8 patients on hemodiafiltration
88971767|NCT02708368||Healthy Subjects|16 healthy subjects with a sex ratio 1:1
88971768|NCT00982982|Active Comparator|THC and Iomazenil|"Iomazenil: 3.7 μg/kg intravenously over 10 minutes~Delta-9-THC (0.015 mg/kg = 1.05 mg in a 70kg individual), dissolved in alcohol. This dose is roughly equivalent to smoking approximately 1/4th of a marijuana cigarette, or joint. It is administered intravenously for 10 minutes"
88971769|NCT00982982|Placebo Comparator|Placebo|Control: small amount of alcohol intravenous (quarter teaspoon), with no THC
88971770|NCT01466556||Obese children|
88971771|NCT01466517|Active Comparator|Reference Drug|
88971772|NCT01466517|Active Comparator|Test Drug|
88971773|NCT01466478|Experimental|LEO 29102 plus calcipotriol|
88971774|NCT01466439|Other|high frequency rTMS|
88971775|NCT01466439|Other|low frequency rTMS|
88971776|NCT01466400||infants two to six months of age|
89209324|NCT02594423|Active Comparator|Fine Needle Diathermy and Bevacizumab|Fine needle Diathermy(FND) will be applied under topical anaesthesia under an operating microscope. This involves the insertion of a fine corneal suture needle in the vicinity of the vessels and using this as an extension of the probe of a monopolar cautery to deliver the energy in the corneal tissue at the site at which it is required to occlude the vessels. Patients will receive subconjunctival injections of bevacizumab in the conjunctiva near the limbus in the quadrant(s) affected (total volume of between 0.2 ml-0.3 ml of the 2.5 mg/0.1 ml solution). The subconjunctival injections will be administered after FND in the same treated quadrants.
89209325|NCT04087187|Experimental|Arm1: AZD5718 Dose A + AZD5718 Dose B + AZD5718 Dose C|"Subjects will receive one tablet once daily (QD) of each treatment according to treatment arm.~Treatment A: AZD5718 Dose A, Treatment B: AZD5718 Dose B, Treatment C: AZD5718 Dose C, with a minimum washout period of 4 days between each dose administration."
89209326|NCT04087187|Experimental|Arm2: AZD5718 Dose A + AZD5718 Dose C + AZD5718 Dose B|"Subjects will receive one tablet once daily (QD) of each treatment according to treatment arm.~Treatment A: AZD5718 Dose A, Treatment C: AZD5718 Dose C, Treatment B: AZD5718 Dose B, with a minimum washout period of 4 days between each dose administration."
89209327|NCT04087187|Experimental|Arm3: AZD5718 Dose B + AZD5718 Dose A + AZD5718 Dose C|"Subjects will receive one tablet once daily (QD) of each treatment according to treatment arm.~Treatment B: AZD5718 Dose B, Treatment A: AZD5718 Dose A, Treatment C: AZD5718 Dose C, with a minimum washout period of 4 days between each dose administration."
89576289|NCT02389543|Experimental|A: Selinexor (1x/week), Lenalidomide, & Dexamethasone|Lenalidomide will be dosed initially at 15 mg daily, and if that dose is tolerated per dose-limiting toxicity (DLT criteria,) it will be increased to 25 mg for that arm. Selinexor will be started at 80 mg (~45 mg/m2) once weekly in combination with dexamethasone 40 mg once weekly with each dose of selinexor. If the selinexor 80 mg dose is tolerated per DLT criteria, the dose will be increased to 100 mg (~60 mg/m2) and evaluated for MTD, tolerability and efficacy.
89576290|NCT02389543|Experimental|B: Selinexor (2x/week), Lenalidomide, & Dexamethasone|Lenalidomide will be dosed initially at 15 mg daily, and if that dose is tolerated per DLT criteria, it will be increased to 25 mg for that arm. Selinexor will be started at 60 mg (~35 mg/m2) twice weekly in combination with dexamethasone 20 mg twice weekly with each dose of selinexor; dexamethasone 20 mg will also be given, without selinexor, on Days 22 and 24. If the selinexor 60 mg dose is tolerated per DLT criteria, the dose will be increased to 80 mg (~45 mg/m2) and evaluated for MTD, tolerability and efficacy.
89576291|NCT02536963||PVS Screening and reference examination|All enrolled participants will be screened with the Pediatric Vision Scanner (PVS screening) during a well-child visit to compare whether the results of the PVS match the results of the regular eye examination performed during the well-visit. They will then receive a reference examination performed by a fellowship-trained pediatric ophthalmologist. Results will be compared with PVS screening results.
89576292|NCT00843037|Experimental|Open label - Sunitinib|Sunitinib, 50mg daily, once daily for 4 weeks followed by a 2-week break
89576293|NCT05392543|Experimental|Group A|Brunnstrom movement therapy
89576294|NCT05392543|Experimental|Group B|Mirror therapy
89576295|NCT05414773|Experimental|Corneal Topography with IOLMaster and Sirius topography.|The experimental group will have the two exams: the topography with the IOLMAster and the topography with Sirius topography.
89576296|NCT05391919|Experimental|MT in early recovery period of IS|"Patients in early recovery period of IS receive a course of rehabilitation with multimodal correction using BFB-stabilometric training, cognitive-motor training in a virtual environment (VR), functional individually programmed stimulation of antagonist muscles of the lower limb (FES), subject-manipulative activity training to restore fine movements of the hand on a glove simulator SensoRehab, if moderate paresis of the upper limb - the neurointerface Exokist-3 with EEG registration."
89576297|NCT05391919|Experimental|MT in late recovery period of IS|"Patients in late recovery period of IS receive a course of rehabilitation with multimodal correction using BFB-stabilometric training, cognitive-motor training in a virtual environment (VR), functional individually programmed stimulation of antagonist muscles of the lower limb (FES), subject-manipulative activity training to restore fine movements of the hand on a glove simulator SensoRehab, if moderate paresis of the upper limb - the neurointerface Exokist-3 with EEG registration."
89576298|NCT05391919|Active Comparator|No MT Intervention: Conventional IS rehabilitation|Patients in early and late recovery period of IS recieve conventional complex rehabilitation: kinesiotherapy, physiotherapy, occupational therapy.
89576299|NCT05440435||Center A|Study center A that observe cohort populations (sample size=400).
89576300|NCT05440435||Center B|Study center B that observe cohort populations (sample size=400).
89576301|NCT05440435||Center C|Study center C that observe cohort populations (sample size=400).
89576302|NCT05440435||Center D|Study center D that observe cohort populations (sample size=400).
89209328|NCT04087187|Experimental|Arm4: AZD5718 Dose B + AZD5718 Dose C + AZD5718 Dose A|"Subjects will receive one tablet once daily (QD) of each treatment according to treatment arm.~Treatment B: AZD5718 Dose B, Treatment C: AZD5718 Dose C, Treatment A: AZD5718 Dose A, with a minimum washout period of 4 days between each dose administration."
89209329|NCT04087187|Experimental|Arm5: AZD5718 Dose C + AZD5718 Dose A + AZD5718 Dose B|"Subjects will receive one tablet once daily (QD) of each treatment according to treatment arm.~Treatment C: AZD5718 Dose C, Treatment A: AZD5718 Dose A, Treatment B: AZD5718 Dose B, with a minimum washout period of 4 days between each dose administration."
89576303|NCT05440435||Center E|Study center E that observe cohort populations (sample size=400).
89576304|NCT05440045|Experimental|6MW3211|6MW3211 injection, 30mg/kg
89576305|NCT02531035|Placebo Comparator|Placebo|Two placebo-matching to sotagliflozin tablets daily, orally, before the first meal of the day for 24 weeks.
89576306|NCT02531035|Experimental|Sotagliflozin 400 mg|Sotagliflozin 400 milligram (mg) (two 200 mg tablets) once daily, orally, before the first meal of the day for 24 weeks.
89576307|NCT05389111|Experimental|Internal discourses|Introduction to internal discourses with a brief definition and key elements for implementation.
88971777|NCT01466361|Active Comparator|Lower dose Nicotine|lower dose nicotine lozenge
89576308|NCT05389111|Sham Comparator|Non-internal discourses|Introduction to the risks associated with the practice of activity in the mountain environment and practical tips to prevent the risks
89576309|NCT05387395||complete vaccination|Complete vaccination was defined as administering two doses of mRNA or AstraZeneca vaccine, administration of one dose of Jansen vaccine, or administration of one dose of any vaccine in patients with a history of COVID19 infection.
89576310|NCT05387395||incomplete vaccination|Other cases were defined as incomplete or absent vaccination.
89576311|NCT05004805|Experimental|Methylene blue Arm|The intervention is carried out in addition to the standard treatment. Administered Intervention is topical application of 0.02% Methylene blue solution in the form of repeated nasopharyngeal irrigation. The investigational drug is equipped with a spray nozzle to perform three administrations into both lower nasal passages. After three administrations on each side, it is recommended to take a deep breath so that the injected solution is distributed along the nasopharynx and oropharynx every 4 hours (5-6 times a day with a break for sleep). Duration is the period of stay of the subject, as long as there is no need for non-invasive or invasive mechanical ventilation. If the subject refuses further treatment in a hospital but does not withdraw consent to participate in the study, they should continue to take study drug after discharge from hospital, but not later than the date of the follow-up visit.
89576312|NCT05004805|Placebo Comparator|Saline solution Arm|The intervention is carried out in addition to the standard treatment. Adminestered Intervention is saline solution in the form of repeated nasopharyngeal irrigation. Dosage form, dosage, frequency and duration of intervention are the same.
89576313|NCT05412823||Hypoxic group|Participants with hypoxia during intubation (after induction and before endotracheal tube placement)
89576314|NCT05412823||Non-hypoxic group|Participants without hypoxia during intubation (after induction and before endotracheal tube placement)
89576315|NCT05412745|Experimental|group A|class I pullulan based medical device containing Allium cepa & HA
89576316|NCT05412745|Active Comparator|Group B|class I medical device silicone gel
89576317|NCT04261387|Experimental|LUT014 Gel|LUT014 Gel topical application to the dermatitis area qd for 28 days
89576318|NCT04261387|Placebo Comparator|Placebo for LUT014 Gel|
89576319|NCT05412199|Experimental|Percussion Massage Therapy Group|The group to which percussion massage therapy will be applied to the posterior leg muscles.
89576320|NCT05412199|Experimental|Graston (IASTM) Group|The group in which instrument-assisted soft tissue mobilization will be applied to the posterior leg muscles.
89576321|NCT05412199|Experimental|Dynamic Stretching Group|The group to which dynamic stretching exercises will be applied to the posterior leg muscles.
89576322|NCT05411965|Experimental|Sequence Group A|"The investigational products will be administered according to the treatment groups assigned to each sequence group in Period 1 and Period 2.~*Sequence A [Period 1] Co-administration of BR3003B(R1) and BR3003C(R2) (single dose)~- Wash out for 7 days [Period 2] Administration of BR3003(T) (single dose)"
89576323|NCT05411965|Experimental|Sequence Group B|"The investigational products will be administered according to the treatment groups assigned to each sequence group in Period 1 and Period 2.~*Sequence B [Period 1] Administration of BR3003(T) (single dose)~- Wash out for 7 days [Period 2] Co-administration of BR3003B(R1) and BR3003C(R2) (single dose)"
89576324|NCT04261075|Experimental|IPH5201 monotherapy dose escalation|IPH5201 monotherapy
89576325|NCT04261075|Experimental|IPH5201 dose escalation with durvalumab|IPH5201 plus durvalumab
89576326|NCT04261075|Experimental|IPH5201 dose escalation with durvalumab + oleclumab|IPH5201 plus durvalumab and oleclumab
89576327|NCT04452019|Active Comparator|Standing frame|Use of standard standing frame
89576328|NCT04452019|Experimental|"Innowalk Pro"|"Use of a new device; Innowalk Pro"
89576329|NCT04451473|Experimental|ERAS- Group|Patients underwent surgery for lung cancer accepted the enhanced recovery after surgery (ERAS).
89576330|NCT04451473|Other|Control- Group|Patients underwent surgery for lung cancer without enhanced recovery after surgery (ERAS).
89576331|NCT05438017|Experimental|Dreem + PSG|
89576332|NCT05436769|Experimental|Test Drug|Klaribact (Clarithromycin 500 mg) Film Coated Tablet (Merck Pvt. Ltd, Pakistan)
89576333|NCT05436769|Active Comparator|Reference Drug|Klaricid 500 mg (Clarithromycin 500 mg) Film Coated Tablet (Abbot Laboratories (Pakistan) Limited)
89576334|NCT03937999|Experimental|Bezlotoxumab Arm|Single dose of Bezlotoxumab 10mg/kg iv over 60 minutes on Day 0
89576335|NCT03937999|No Intervention|No Bezlotoxumab|Control group who are eligible as per the inclusion/exclusion criteria to the Bezlotoxumab arm, but not given Bezlotoxumab (Day 0) .
89576336|NCT05436067|Experimental|Older adults with dizziness|Clinical trial only has one arm or participant group. All participants undergo the same experiment. They will perform exercises with the Vestibular Rehabilitation App as well as without the App. The order is randomized.
89576337|NCT05377567|Experimental|TAU + FIBRO-On|FIBRO-On is a virtual multicomponent non-pharmacological program based on Pain Neuroscience Education (PNE), therapeutic exercise, Cognitive Behavioural Therapy (CBT) and Mindfulness Training
89576338|NCT05377567|Active Comparator|TAU + FIBRO-Out|FIBRO-Out is a outdoor multicomponent non-pharmacological program based on Pain Neuroscience Education (PNE), therapeutic exercise, Cognitive Behavioural Therapy (CBT) and Mindfulness Training
89576339|NCT05377567|Active Comparator|Treatment as Usual (TAU)|Treatment-as-Usual (TAU) consisted of the prescribed drugs adapted to the symptomatic profile of each patient and basic face to face and written advice on PNE and aerobic exercise adapted to the physical capacities of the patients at the beginning of the study.patient
89576340|NCT01659853|Experimental|Overall Study|"In this crossover study of CD07805/47 gel 0.5%/CD07805/47 Vehicle and azelaic acid gel 15%, 70 subjects were randomly assigned to treatment sequence.~During Period 1 (15 days), 35 subjects received topical CD07805/47 gel 0.5% in the morning and topical CD07805/47 gel vehicle in the evening, and 35 received topical azelaic acid gel twice daily according to FDA approved prescribing information. Subjects crossed over to the other treatment in Period 2 (15 days)."
89576341|NCT05376631|Active Comparator|Group Five|For emergence from general anesthesia, a fresh gas flow of 5 L/min is used.
89576342|NCT05376631|Experimental|Group Ten|For emergence from general anesthesia, a fresh gas flow of 10 L/min is used.
89576343|NCT05610631||Pulmonary arterial hypertension|Pulmonary arterial hypertension
89576344|NCT05610631||PH due to left heart diseases|PH due to left heart diseases
89576345|NCT05610631||PH due to lung disease and/or hypoxia|PH due to lung disease and/or hypoxia
89576346|NCT05610631||Chronic thromboembolic PH|Chronic thromboembolic PH
88971778|NCT01466361|Active Comparator|Higher dose Nicotine|higher dose Nicotine lozenge
88971779|NCT01466361|Placebo Comparator|Placebo|Placebo
88971780|NCT01466322|Experimental|Oral formulations of GSK2018682|Three oral formulations of GSK2018682. A: CD2 Capsule; B: CD3 non-micronised Tablet; C: CD3 micronised Tablet; D: CD3 non-micronised Tablet in fed state
88971781|NCT00001832|Experimental|Abl Cells in culture|"Peripheral blood mononuclear cells (PBMC) and/or tumor infiltrating lymphocytes (TIL) obtained by apheresis or lesion excision to be cloned and expanded in the lab.The patients underwent an apheresis and/or an excision of their tumor.~They didn't receive any drugs."
88971782|NCT00001832|Experimental|Abl Cells IV + Cyclophosphamide 30 mg/kg|Phase 1 Cyclophosphamide Dose Escalation: Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x30mg/kg + Cells intravenous (IV) Abl cells intravenous (IV) = Lymphocytes 10^9-10^11 IV over 30 minutes on day 0, repeated in 14 to 21 days
88971783|NCT00001832|Experimental|Abl Cells IV + Cyclophosphamide 60 mg/kg|Phase 1 Cyclophosphamide Dose Escalation: Fludarabine 5x25mg/m2 + Cyclophosphamide 2x60mg/kg + Cells intravenous (IV) Abl cells IV = Lymphocytes 10^9-10^11 IV over 30 minutes on day 0, repeated in 14 to 21 days
88971784|NCT00001832|Experimental|Abl Cells IV+Low Dose IV IL-2 (Initial)|Phase 1 interleukin-2 (IL-2) Dose Escalation: Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x60mg/kg + Cells intravenous (IV) + IV IL-2 (72,000 IU/kg q8h for a maximum of 15 doses) Abl cells IV = Lymphocytes 10^9-10^11 IV over 30 minutes on day 0, repeated in 14 to 21 days
88971785|NCT00001832|Experimental|Abl Cells IV+High Dose IV IL-2 (Initial)|Phase 1 interleukin-2 (IL-2) Dose Escalation: Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x60mg/kg + Cells intravenous (IV) + IV IL-2 (720,000 IU/kg q8h for a maximum of 12 doses) Abl cells IV = Lymphocytes 10^9-10^11 IV over 30 minutes on day 0, repeated in 14 to 21 days
89576347|NCT05610631||Miscellaneous PH|Miscellaneous PH
89576348|NCT05610553|Experimental|3D printing guide plate group|3D-printed customized guide plate will be used to guide the puncture in percutaneous disc decompression surgeries.
89576349|NCT05610553|Active Comparator|Conventional guidance group|The surgeons would place the needle according to his/her previous experience under the guidance of C-arm fluoroscopy or CT.
89576350|NCT05376163||Individuals with headache|Individuals with headaches caused by neck problems
89576351|NCT05374369||Subjects with positive SDC2 Gene Methylation Test|"Subjects must meet both of the following criteria to be eligible for the study:~Subjects with positive SDC2 Gene Methylation Test;~Subjects with colonoscopy results and/or pathological results."
89576352|NCT05374369||Subjects with positive Q-FIT Test|"Subjects must meet both of the following criteria to be eligible for the study:~Subjects with positive Q-FIT Test;~Subjects with colonoscopy results and/or pathological results."
89576353|NCT05374369||Subjects with positive SDC2 Gene Methylation Test and Q-FIT Test|"Subjects must meet both of the following criteria to be eligible for the study:~Subjects with positive SDC2 Gene Methylation Test and Q-FIT Test;~Subjects with colonoscopy results and/or pathological results."
89576354|NCT05610475|Active Comparator|Lung injury group|
89576355|NCT05610475|Sham Comparator|Non-lung injury group|
89576356|NCT05576389|Experimental|Camrelizumab+Fluzoparib|
89576357|NCT04252807|Experimental|Intervention arm|"Distressed mothers randomized to intervention arm will receive a common elements based integrated intervention that combines evidence based elements from packages of care addressing early stimulation, responsive feeding and perinatal depression. The integrated intervention is expected to a) improve mother psychological distress, b) improve family support, c) improve child development and d) promote mother-infant interaction.~The participants will receive 15 monthly sessions at home by lay health workers. First three sessions will be delivered to the participants in the third trimester of pregnancy, followed by 12 monthly sessions afterwards."
89576358|NCT04252807|Active Comparator|Treatment as Usual (TAU)|The participants in the control arm will receive the routine monthly visits by the trained Lady Health Workers (LHWs) of their respective areas.
89576359|NCT05568511|Experimental|Home-based, digitally delivered exercise training program|
89576360|NCT05568511|Active Comparator|Standard care control group|
89576361|NCT05372341||post-covid elective surgery patients|data of postcovid patients underwent elective surgery will be collected.
89576362|NCT01660243|Active Comparator|MT-9938 2.5μg|
89576363|NCT01660243|Active Comparator|MT-9938 5μg|
89576364|NCT01660243|Active Comparator|MT-9938 10μg|
89576365|NCT01660243|Placebo Comparator|Placebo|
89576366|NCT05567263|Active Comparator|Bulk- Fill|Restorative procedure of the teeth will be performed using Filtek-Bulk Fill Posterior Restorative, Bulk-fill resin composite, (3M, ESPE) following application of an etch-and-rinse single bottle adhesive (3M, ESPE).
89576367|NCT05567263|Experimental|Surefill One|Restorative procedure of the teeth will be performed using Surefil one™ Self-Adhesive Composite Hybrid (Dentsply, Sirona),
89576368|NCT05341609|Experimental|JT001(VV116)|Day 1: 600mg, Q12H X 1 day; Day 2~5: 300mg, Q12H X 4 days
89576369|NCT05341609|Active Comparator|Paxlovid|Day 1~5: 300 mg of Nirmatrelvir and 100 mg of ritonavir, Q12H X 5 days
89576370|NCT05604391|Active Comparator|Free gingival grafts to be placed apical to the gingival recession.|It is the application of free gingival graft to the apical part of the recession area of mandibular anterior teeth with gingival recession and keratinized gingival height deficiency.
89576371|NCT05604391|Active Comparator|Free gingival grafts to be placed coronal to the gingival recession.|It is the application of free gingival graft to the coronal part of the recession area of mandibular anterior teeth with gingival recession and keratinized gingival height deficiency.
89576372|NCT05380375||Short-course|Group with short treatment of antibiotic of <= 5 days
89576373|NCT05380375||Very short-course|Group with short treatment of antibiotic of <= 3 days
89576374|NCT05565079|Experimental|Coronally positioned tunnel with AlloDerm RTM and Enamel Matrix Derivative|12 patients will receive a coronally positioned tunnel with a regenerative tissue matrix (AlloDerm RTM, BioHorizons) and a porcine derived enamel matrix derivative (Emdogain, Straumann).
89576375|NCT05565079|Active Comparator|Coronally positioned tunnel with AlloDerm RTM|12 patients will receive a coronally positioned tunnel with a regenerative tissue matrix (AlloDerm RTM, BioHorizons).
89576376|NCT05341453|Active Comparator|Individual physiotherapy (SMA-SOC)|Individual physiotherapy will be performed according to the recommended SMA-SOC guidelines.
88971786|NCT00001832|Experimental|Abl Cells IV + MTD IL-2|Phase 2 Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x60mg/kg + Cells intravenous (IV) + IV interleukin-2 (IL-2) (720,000 IU/kg q8h for a maximum of 12 doses) + growth colony stimulating factor (G-CSF) (to shorten time to neutrophil recovery) Abl cells IV = Lymphocytes 10^9-10^11 IV over 30 minutes on day 0, repeated in 14 to 21 days
88971787|NCT00001832|Experimental|Abl Cells IA + MTD (prior cells IV on 6)|Phase 2 Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x60mg/kg + Cells intra-arterial (IA) + intravenous (IV) interleukin-2 (IL-2) (720,000 IU/kg q8h for a maximum of 12 doses) Prior Cells IV + growth colony stimulating factor (G-CSF) Abl cells IA = Lymphocytes 10^9-10^11 IA over 30 minutes on day 0, repeated in 14 to 21 days
88971788|NCT00001832|Experimental|Abl Cells IA + MTD IL-2|Phase 2 Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x60mg/kg + Cells intra-arterial (IA) + intravenous (IV) interleukin-2 (IL-2) (720,000 IU/kg q8h for a maximum of 12 doses) + growth colony stimulating factor (G-CSF) Abl cells IA = Lymphocytes 10^9-10^11 IA over 30 minutes on day 0, repeated in 14 to 21 days
89576377|NCT05341453|Experimental|Hippotherapy by the children with cerebral palsy|Hippotherapy by the children with cerebral palsy is an accredited form of hippotherapy, whose methodology is based on the clinical picture of cerebral palsy, but its procedures are applicable to a wider group of children with disabilities. Therefore, investigators assume its effect for children with SMA.
89576378|NCT05341453|Other|Therapeutic grooming|In order to influence the psychomotor development in a comprehensive way, the psychosocial activity of therapeutic grooming will also be included in the study. Its goal is to support children's communication, their interaction with the environment, the ability to establish contact with the horse and the overall emotional support of children with SMA.
89576379|NCT05538013||obese women|The study will consist of 70 obese women volunteers aged between 18-65 years.
89576380|NCT05598463|Experimental|Augmented reality and wearable sensor-based home rehabilitation exercise|Experimental group performs augmented reality and wearable sensor-based home rehabilitation exercise for 4 weeks. And then, their exercise compliance is monitored by medical staff.
89576381|NCT05598463|No Intervention|Control group|Control group is asked to maintain their own physical activity amount, not involve the regular exercise program additionally for 4 weeks after enrollment.
89576382|NCT05340907|No Intervention|Patient undergoing Bronchoscopy without use of VR device|patients undergoing flexible bronchoscopy without the VR device on, they will be shown a video consisting of calming nature scene together with soothing instrumental music. Sedation will be given as per standard practice.
89576383|NCT05340907|Experimental|Patient Undergoing Bronchoscopy with the use of VR device|patients undergoing flexible bronchoscopy with the VR device on, they will be shown a video consisting of calming nature scene together with soothing instrumental music. Sedation will be given as per standard practice.
89576384|NCT05309161|Placebo Comparator|A group (placebo)|Placebo
89576385|NCT05309161|Active Comparator|B group (experimental)|Crassocephalum rabens extract
89576386|NCT05339659|Active Comparator|Control|mHealth app consisting of standard, best-practice information and guidance to help people stop smoking.
89576387|NCT05339659|Experimental|Experimental|mHealth app consisting of standard, best-practice information and guidance to help people stop smoking + additional experimental content targeted to smokers living with HIV who are ambivalent about quitting smoking.
89576388|NCT02531113|Experimental|RPC1063 (Ozanimod)|
89576389|NCT05308069|Other|Single vision contact lens|Subjects will wear a single vision soft contact lens during the study visit
89576390|NCT05308069|Other|Multifocal contact lens|Subjects will wear a multifocal soft contact lens during the study visit
89576391|NCT05368519|Experimental|Right chest with Brijjit® FMTB|Patients will be assigned to have their right chest closure completed via Brijjit® FMTB. While the other chest (not selected for intervention) will be closed via traditional suture-based methods and will serve as an internal control.
89576392|NCT05368519|Experimental|Left chest with Brijjit® FMTB|Patients will be assigned to have their left chest closure completed via Brijjit® FMTB. While the other chest (not selected for intervention) will be closed via traditional suture-based methods and will serve as an internal control.
89576393|NCT04255693|Experimental|Change in disease manifestations|The data of all the patients will be assessed from the viewpoint of changes in the disease flow (severity and frequency of symptoms, grade of oesophagitis). They will be compared to the changes of the major factors that could influence the disease flow: adherence to anti-secretory agents, presence of concomitant medications and their doses, adherence to diet, change in physical activity. These will be compared to the initial data. Thus, it would be possible to make a multivariate comparison and try to establish the influence (and, possibly, weight) of each of the con-founder on the disease flow.
89576394|NCT04255693|Active Comparator|No change in disease flow|"To this arm patients with no change in the disease manifestations will be assigned, based on the end-point evaluation. The same as in the experimental groups factors will be analysed to establish the difference."
89576395|NCT04248595|Experimental|Azacitidine plus HAG|"Patients of de novo or relapsed AML(age≥60y or ineligibility to receive intensive chemotherapy) will receive AZA+HAG (homoharringtonie, cytarabine, G-CSF) regiment as induction therapy. After complete remission(CR), the AZA+HAG regimen was further given 4-6 cycles and followed by azacitidine maintenance or until the disease progresses.~AZA -Azacitidine HAG -Homoharringtonie, Cytarabine, G-CSF"
89576396|NCT04248595|Experimental|Azacitidine plus HIA|"Patients of de novo or relapsed AML(age<60y or eligible for intensive chemotherapy) will receive AZA +HIA(homoharringtonie, Idarubicin, cytarabine) regiments as introduction therapy. After CR, post-remission therapy will follow with NCCN guidelines.~AZA -Azacitidine HIA -Homoharringtonie, Cytarabine, Idarubicin"
89576397|NCT04248595|Experimental|Azacitidine plus HDA|"Patients of de novo or relapsed AML(age<60y or eligible for intensive chemotherapy) will receive AZA +HDA(homoharringtonie, daunorubicin, cytarabine) regiments as introduction therapy., After CR, post-remission therapy will follow with NCCN guidelines.~AZA -Azacitidine HDA -Homoharringtonie, Cytarabine, Daunorubicin"
89576398|NCT04247425|Experimental|Supportive Care (resistance training, exercise counseling)|Patients complete a series of progressive resistance training exercises at home twice weekly over 1 hour and receive instructional guidance from an exercise physiologist via videoconferencing once per week during one of these sessions for up to 12 weeks.
89576399|NCT05337709|Experimental|treatment group|Patients from the pharmacies assigned as treatment group will receive intervention. Intervention are education (aid with leaflet and video) and medication review with counselling.
89576400|NCT05337709|No Intervention|control group|Patients from the pharmacies assigned as control group will receive as usual care they have been provided regularly.
89576401|NCT05337397||Prior pTa low grade Non-Muscle invasive bladder cancer|Patient with recurrent Pta low grade Non-Muscle invasive bladder cancer, with negative urine cytology, and tumor size between 1 and 3 cm.
89576402|NCT05337241|Experimental|Single arm treatment|All subjects meeting inclusion/exclusion criteria and successfully consented will be treated with the study device.
89576403|NCT05366335|Experimental|Live Combined Bifidobacterium and Lactobacillus|The experimental group receive basic treatment and a single infusion of Live Combined Bifidobacterium and Lactobacillus solution through colonoscopy.
89576404|NCT05366335|Placebo Comparator|Control|The control group receive basic treatment and a single injection of normal saline through colonoscopy.
89576405|NCT05530915|Experimental|Active capsule 1: Lower dose guayusa ingredient|Oral administration of 175 mg guayusa extract providing 35 mg caffeine
89576406|NCT05530915|Experimental|Active capsule 2: Higher dose guayusa ingredient|Oral administration of 300 mg guayusa extract providing 60 mg caffeine
89576407|NCT05530915|Placebo Comparator|Placebo capsule|Oral administration of 0 mg guayusa extract, 0 mg caffeine. Capsule color-matched to actives 1 and 2 to disguise potential differences in color of contents.
89576408|NCT05365399|Other|Enable high qualitative estimation of bilirubin levels in the blood of new-borns|In this study we aim to collect data of newborns with wider range of bilirubin levels and high melanin content, and additionally measurements of skin color reflectance with a spectrophotometer, to adjust the Picterus JP algorithm and optimize the app performance. This will enable a high qualitative estimation of bilirubin levels in the blood of new-borns for all skin colors. .
89576409|NCT05334277|Experimental|Group A: Furmonertinib 80mg QD|Furmonertinib (AST2818) 80mg QD. All patients enrolled into this group will receive furmonertinib 80mg daily.
89576410|NCT05334277|Experimental|Group B1: Furmonertinib 80mg QD|Furmonertinib (AST2818) 80mg QD. All patients enrolled into this group will receive furmonertinib 80mg daily.
89209330|NCT04087187|Experimental|Arm6: AZD5718 Dose C + AZD5718 Dose B + AZD5718 Dose A|"Subjects will receive one tablet once daily (QD) of each treatment according to treatment arm.~Treatment C: AZD5718 Dose C, Treatment B: AZD5718 Dose B, Treatment A: AZD5718 Dose A, with a minimum washout period of 4 days between each dose administration."
89209331|NCT04924764|Active Comparator|Follow-up on daily basis|Patient receiving treatments on daily basis (5 days a week)
89576411|NCT05334277|Experimental|Group B2: Furmonertinib plus chemotherapy|Furmonertinib 80 mg QD and platinum-based chemotherapy All patients enrolled into this group will receive furmonertinib 80 mg daily, in combination with Pemetrexed (500 mg/m2) plus carboplatin (AUC 5) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by pemetrexed maintenance (500 mg/m2) every 3 weeks.
89576412|NCT05334277|Experimental|Group B3: Furmonertinib plus chemotherapy and bevacizumab|Furmonertinib 80 mg QD plus platinum-based chemotherapy and bevacizumab All patients enrolled into this group will receive furmonertinib 80 mg daily, in combination with Pemetrexed (500 mg/m2) plus carboplatin (AUC 5) plus bevacizumab (7.5mg/kg) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by pemetrexed (500 mg/m2) with bevacizumab (7.5mg/kg) maintenance every 3 weeks.
89576413|NCT05363371|Experimental|Mindfulness based relapse prevention and peer mentoring|Treatment will utilize a group format. The twelve-week mindfulness based relapsed prevention group therapy intervention is co-led by a licensed counselor and a peer mentor for eight weeks, followed by group sessions led by peer mentors for an additional four weeks.
89576414|NCT05363371|Active Comparator|12 Step Treatment Program|Participants in the attentional control group will attend 12 weeks of a enhanced 12 step treatment program.
89576415|NCT05363137|Experimental|Experimental|
89576416|NCT05363137|Active Comparator|Control|
89576417|NCT05332717|Experimental|Melatonin Group (Experimental)|Patients who will take one (1) 5mg Melatonin tablet 30 minutes before bedtime daily for the 6 weeks following surgery.
89033218|NCT02917395|Experimental|echo|"Population study- patients with obstructive hypertrophic cardiomyopathy that are treated with disopyramide.~Tow echo examination, few hours apart, that includes strain rate will be done to each patient. The first, after taking the regular medical treatment excluding disopyramide and the last one after taking the disopyramide."
89576418|NCT05332717|Sham Comparator|Placebo Group (Control)|Patients who will take one (1) placebo (Vitamin C) tablet 30 minutes before bedtime daily for the 6 weeks following surgery.
89576419|NCT05506813|Experimental|experimental group|cognitive training and conventional training
89576420|NCT05506813|Active Comparator|control group|motor dual task training and conventional training
89033219|NCT05319392||Patients with Gastric Adenocarcinoma|Patients with origin of tumor in distal part of stomach who underwent total or partial gastrectomy after biopsy examination with availability of follow-up and archived FFPE tissue will be considered for this study.
89033220|NCT02917200|Active Comparator|MOX + CTRL|Moxifloxacin, 400 mg/day oad, 5 days + Negative control, tid, 7 days
89576421|NCT05300269|Experimental|Perioperative treatment|Eligible subjects will receive standard chemoradiotherapy with SHR-1701 followed by XELOX combined with SHR-1701 and surgery. Adjuvant XELOX combined with SHR-1701 will be given after surgery.
89576422|NCT05329285|Experimental|Percutaneous Coronary Intervention (PCI)|Patients will be revascularized by PCI
89576423|NCT05329285|No Intervention|Coronary artery bypass grafting (CABG)|Patients will be revascularized by CABG
89576424|NCT05356273|Experimental|Massage Group|The incubator temperature was adjusted between 28-30 C, and it was administered while the baby was awake and one hour after feeding. Before the massage, the hands were washed and warmed. Just before each phototherapy application, 10-minute baby massage was performed by the researcher.Then phototherapy was applied.
89576425|NCT05356273|No Intervention|Control Group|Just received phototherapy twice a day
89576426|NCT05299177|Experimental|Automated Insulin Delivery|The components of the automated insulin delivery system are the Dexcom G6 continuous glucose monitor (CGM), the InControl algorithm and an insulin pump (Ypsomed Ypsopump). The Dexcom G6 continuous glucose monitoring device is an approved device and is licensed to be used to inform insulin dosing decisions without confirmation. The algorithm (inControl 1.0) is approved when used embedded in the Tandem X2 insulin pump. We are using the algorithm for its intended purpose but are implementing it in a smartphone app to be installed in a compatible smartphone (Android). We are additionally assessing incremental benefit with the next software version of the algorithm. This will be the first time this updated software has been assessed in people with type 1 diabetes. The compatible insulin pump is a continuous subcutaneous insulin infusion device and is being used in line with its intended purpose, according to the manufacturer's instructions (YpsoMed Ypsopump).
89576427|NCT05327569|Experimental|Experimental group|"xperimental group will consist of 30 patients with diagnosed Patellofemoral pain syndrome, aged between 25-50 years. In addition to the conventional physiotherapy program, myofascial chain release techniques will be applied to this group.~Myofascial release technique will be applied to the center of coordination points in the anterior superficial myofascial chain of the body. There are a total of 8 points on this myofascial chain. Pressure will be applied to each point with 6 repetitions and lasting approximately 5-6 seconds.~Participants will be treated for a total of 6 weeks, 2 days a week. Each treatment session will last 45 minutes."
89209332|NCT04924764|Active Comparator|Follow-up on alternate days|Patients receiving treatment on alternate days (3 days a week)
88971789|NCT00001832|Experimental|Abl Cells IA+MTD IL-2 (MART-1 reactive)|Phase 2 Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x60mg/kg + Cells intra-arterial (IA) + intravenous (IV) interleukin-2 (IL-2) (720,000 IU/kg q8h for a maximum of 12 doses) + growth colony stimulating factor (G-CSF) + melanoma- associated antigen recognized by T cells (MART-1):26-35(27L) Peptide 1mg/day (5-8 days) in patients with MART-1 reactive cells Abl cells IA = Lymphocytes 10^9-10^11 IA over 30 minutes on day 0, repeated in 14 to 21 days gp100 = gp100:209-217(210M) peptide - 1 mg in IFA SQ (in the subcutaneous tissue of each thigh) on the morning of the cell infusion, plus gp100:209-217(210M) peptide, 1 mg, in IFA injected into the subcutaneous tissue in two equal volumes, 1.0 mL for each injection, within 2cm of each other, in the thigh daily for five days starting on the morning of the cell infusion and then weekly for 3 more injections.
88971790|NCT00001832|Experimental|Abl Cells IV + MTD IL-2 no GCSF|Phase 2 Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x60mg/kg + Cells intravenous (IV) + IV interleukin-2 (IL-2) (720,000 IU/kg q8h for a maximum of 12 doses) without growth colony stimulating factor (G-CSF) (to determine if G-CSF has harmful effects when adoptively transferring lymphocytes following a nonmyeloablative chemotherapy regimen) Abl cells IV = Lymphocytes 10^9-10^11 IV over 30 minutes on day 0, repeated in 14 to 21 days
89209333|NCT00882414|Placebo Comparator|ThromboVIT Placebo|Patients will receive 1 placebo infusion of 100ml 0.9% sodium chloride every 7 days for a total of 3 infusions.
89209334|NCT00882414|Experimental|ThromboVIT 1000|ThromboVIT 1000: Patients will receive 1 infusion of 500mg Ferinject® diluted in 100ml 0.9% sodium chloride every 7 days for a total of 2 infusions (1000 mg) followed by 1 placebo infusion of 100ml 0.9% sodium chloride.
89209335|NCT00882414|Experimental|ThromboVIT 1500|Patients will receive 1 infusion of 500mg Ferinject® diluted in 100ml 0.9% sodium chloride every 7 days for a total of 3 infusions (1500 mg).
88971791|NCT00001832|Experimental|Abl Cells IV+MTD IL-2 no GCSF|"Abl Cells intravenous (IV) + maximum tolerated dose (MTD) interleukin-2 (IL-2) no growth colony stimulating factor (GCSF)(gp100 reactive).~Phase 2 Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x60mg/kg + Cells IV + IV IL-2 (720,000 IU/kg q8h for a maximum of 12 doses) without G-CSF + gp100:209-217(210M) 1mg/day (2-8 days) in patients with gp100 reactive cells Abl cells IV = Lymphocytes 10^9-10^11 IV over 30 minutes on day 0, repeated in 14 to 21 days"
89209336|NCT00882414|Experimental|ThromboVIT 500|ThromboVIT 500: Patients will receive 1 infusion of 500mg Ferinject® diluted in 100ml 0.9% sodium chloride (500 mg) followed by 2 placebo infusions of 100ml 0.9% sodium chloride every 7 days.
89209337|NCT02593487|Experimental|Rosuvastatin 10mg/d group|rosuvastatin 10mg table by mouth, qd
89209338|NCT02593487|Active Comparator|Rosuvastatin 20mg/d group|rosuvastatin 20mg table by mouth, qd
89209339|NCT00875784|Experimental|TREXIMA tablet followed by IMITREX injection (4mg)|TREXIMA™ (sumatriptan succinate / naproxen sodium) Tablet followed by IMITREX® (sumatriptan succinate) Injection 4mg administered using the IMITREX STATdose System®
88971792|NCT00001832|Experimental|Abl Cells IV+MTD IL-2|"Abl Cells intravenous (IV)+ maximum tolerated dose (MTD) interleukin-2 (IL-2) no growth colony stimulating factor (GCSF) (melanoma-associated antigen recognized by T cells (MART-1)reactive).~Phase 2 Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x60mg/kg + Cells IV + IV interleukin-2 (IL-2) (720,000 IU/kg q8h for a maximum of 12 doses) without G-CSF + MART-1:26-35(27L) Peptide 1mg/day (5-8 days) in patients with MART-1 reactive cells Abl cells IV = Lymphocytes 10^9-10^11 IV over 30 minutes on day 0, repeated in 14 to 21 days"
89033221|NCT02917200|Experimental|MOX + DAV132 7.5 g tid|Moxifloxacin, 400 mg/day oad, 5 days + DAV132 7.5 g tid, 7 days
89033222|NCT02917200|Experimental|MOX + DAV132 7.5 g bid|Moxifloxacin, 400 mg/day oad, 5 days + DAV132 7.5 g bid, 7 days
89033223|NCT02917200|Experimental|MOX + DAV132 5 g tid|Moxifloxacin, 400 mg/day oad, 5 days + DAV132 5 g tid, 7 days
89033224|NCT02917200|Experimental|MOX + DAV132 5 g bid|Moxifloxacin, 400 mg/day oad, 5 days + DAV132 5 g bid, 7 days
89209340|NCT00875784|Experimental|TREXIMA tablet followed by IMITREX injection (6mg)|TREXIMA tablet followed by IMITREX® (sumatriptan succinate) Injection 6mg administered using the IMITREX STATdose System®
89033225|NCT02917200|Experimental|MOX + DAV132 3.3 g tid|Moxifloxacin, 400 mg/day oad, 5 days + DAV132 3.3 g tid, 7 days
89033226|NCT02917200|Experimental|MOX + DAV132 3 g bid|Moxifloxacin, 400 mg/day oad, 5 days + DAV132 3 g bid, 7 days
89033227|NCT02917200|Experimental|MOX + DAV132 2 g tid|Moxifloxacin, 400 mg/day oad, 5 days + DAV132 2 g tid, 7 days
89033228|NCT02917200|Experimental|MOX + DAV132 1.5 g bid|Moxifloxacin, 400 mg/day oad, 5 days + DAV132 1.5 g bid, 7 days
89576428|NCT05327569|No Intervention|Control group|"Control group will consist of 30 patients with diagnosed Patellofemoral pain syndrome, aged between 25-50 years. Only conventional physiotherapy program will be applied to this group.~Conventional treatment will consist of muscle strengthening, stretching exercises and patellar mobilization. The muscle groups to be strengthened are: M. gluteus maximus, M. gluteus medius, M. Quadriceps, Core group of muscles. The muscle groups and tendons to be stretched are: M. Hamstrings, achilles tendon and iliotibial band. The exercises will be performed as 10 repetitions and 3 sets. Participants will be treated for a total of 6 weeks, 2 days a week. Each treatment session will last 45 minutes."
89576429|NCT04254367|Experimental|Intervention group - experimental TAU + intervention|Patient education in study circles, aiming to empower patients to participate in health care and rehabilitation by increasing health literacy and sense of coherence. The study circles will meet half a day each week for eight following weeks.
89576430|NCT04254367|No Intervention|TAU - no intervention|Treatment as usual following local routines on each primary care center
89576431|NCT05326945|No Intervention|Measurement without sheath|"Sample A: Investigator will take culture from the inside of the BPC, which will contact the patient's right upper arm, wearing sterile gloves, and will remove the gloves.~B:Investigator will wipe the right upper arm area of the patient with (70% alcohol+2% chlorhexidine) solution in accordance after wearing sterile gloves, wait for 30 seconds and after the alcohol dries investigator will take culture from the patient's right upper arm, wearing a new sterile glove.~C:investigator will measure ABP on the right upper arm of the patient with the same sterile glove, and after the measurement, the first investigator will take culture from the patient's right upper arm by wearing a new sterile glove, both researchers will remove the gloves.~D:investigator wore a new sterile glove after ABP measurement and wiped the inside and outside of the BPC with solution, the first investigator would wear a new sterile glove to take culture, both researchers will remove the gloves."
89576432|NCT05326945|Experimental|Sheathed Measurement|"Sample E: DCC sterile package will be opened the investigator will hold the sphygmomanometer, after investigator wears sterile gloves, DCC will put it cuff of the same cuff. Culture will be taken investigator from the inside of the DCC that will contact the patient's left upper arm, before the ABP measurement, the first investigator will remove the gloves.~F:Sterile gloves will be worn by the investigator and the left upper arm area of the patient will be wiped with solution before the ABP measurement wait 30 seconds, and after the solution dries, the first investigator will use a new sterile After wearing gloves, he will take a swab culture from the left upper arm region.~G:The investigator will measure ABP from the patient's left upper arm with the same glove, and after the measurement, the first investigator will take culture from the patient's left upper arm after wearing a new sterile glove.~Culture results taken from the patients will be compared statistically."
89029224|NCT03786471|Active Comparator|Community-Based Dementia Care|Dementia care that is based in community organizations, which gives equal attention to patients and their primary family or friend caregivers. The community-based dementia care arm uses Care Consultants (social workers, nurses, or licensed therapist). Patients with dementia are engaged in the program whenever possible. Caregivers can be the sole program participant, when patients are too impaired. The program establishes a long-term relationship between Care Consultants and families. The exact content of assistance provided is tailored to the preferences of individual patients and caregivers, and is holistic in the range of potential concerns of problems addressed. The Community-Based Dementia Care arm is based on the Benjamin Rose Institute on Aging's Care Consultation Program.
88971793|NCT00001832|Experimental|Abl Cells IV + SQ IL-2 with GCSF|Phase 2 Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x60mg/kg + Cells intravenous (IV) + subcutaneous (SQ) interleukin-2 (IL-2) (125,000 IU/kg/dose for 5 days for six weeks with 2 days rest per week) + growth colony stimulating factor (G-CSF) (to shorten time to neutrophil recovery), reactivity not specified Abl cells IV = Lymphocytes 10^9-10^11 IV over 30 minutes on day 0, repeated in 14 to 21 days
89029225|NCT03786471|Other|Usual Care|Dementia care that most closely corresponds to traditional care. This arm will also receive standardized educational materials (hard copies and internet-based resources), referral to the Alzheimer's Association 1-800 national helpline to speak to a master's level consultant for decision-making support, crisis assistance, and caregiver education, as well as referral to local programs and services.
89029226|NCT03781791|Experimental|Active Treatment|ENT-01 tablet will be taken once daily by mouth.
89029227|NCT03781791|Placebo Comparator|Placebo Treatment|Placebo tablet will be taken once daily by mouth.
89029228|NCT03776643|Experimental|ILT-101 (ld-IL2)|Subcutaneous injections of ILT-101
89029229|NCT03776643|Placebo Comparator|placebo|Subcutaneous injections of placebo
89029230|NCT03763838|Experimental|Acupressure plus standard of care|Using AcuWand, participants will apply acupressure to points that are known to affect physiology. Participants will also receive standard of care.
89576433|NCT05354167|Experimental|muscle energy technique|the subject to sit comfortably and then stabilize the subject's distal humerus with one hand, then the forearm was supinated with the therapist another hand until resistance appeared. Holding the position the subject was asked to slowly pronate the forearm that is Isometric contraction against resistance for a period of 6-10 seconds with inhale and exhale, followed by slightly increasing supination until resistance was met once again. After 5 seconds of relaxation, the procedure was repeated 5 times during a single treatment session.
89576434|NCT05354167|Experimental|oscillating manual energy therapy|It is also known as V-spread .The subject was asked to sit on a chair with the affected painful arm resting on the treatment table. Tender points were palpated. Then the therapist places the index and middle fingers of one hand in a V-shape around the tender point and placed the index finger of the other hand in the medial side of the elbow, diagonally across the located tender point. Gentle pressure was applied a few times using fingertips to the tissues alternatively from the medial and lateral sides to start the oscillations. On the initiation of oscillations, the application of pressure should be stopped and allow the oscillations to continue between the two points of contact on the subject's elbow. This technique was repeated until there were no tender points on palpation. The duration varied from 30 seconds to 2 minutes.
89576435|NCT05353933|Experimental|TEA + PPI|Thread embedding acupuncture (TEA) every 2 weeks in 4 weeks (twice). Combined with oral pantoprazole 40 mg capsules (Pantostad 40 CAP) once daily for 4 weeks.
89576436|NCT05353933|Active Comparator|PPI|Oral pantoprazole 40 mg capsules (Pantostad 40 CAP) once daily for 4 weeks.
89576437|NCT05325463|Experimental|conventional|
89576438|NCT05325463|Active Comparator|ultrasound- guided|
89576439|NCT05353855||Early unmedicated PD patients converted from iRBD|"Chinese aged 50 or above;~Being capable of giving informed consent for participation of the study;~Having a diagnosis of PD confirmed by neurologists according to the United Kingdom Parkinson's Disease Survey Brain Bank.~Onset of PD motor symptoms of < 3 years;~In view of the heterogeneity of PD, the investigator will only include those patients with RBD preceding the onset of motor symptoms of PD.~Drug naïve (dopaminergic medications have not been started)"
89576440|NCT05353855||Early medicated PD patients converted from iRBD|Inclusion criteria will be the same as that of early unmedicated PD except that they should be on dopaminergic medications.
89576441|NCT05353855||iRBD patients|"Chinese aged 50 or above;~Being capable of giving informed consent for participation of the study;~Having a diagnosis of RBD according to the International classification of sleep disorder 3rd edition (ICSD 3rd), fulfilling both the clinical and video-polysomnography (vPSG) criteria."
89576442|NCT05353855||Healthy controls|"Age-and sex-matched with the groups;~Being capable of giving informed consent for participation of the study;~Without a personal history or a family history of PD or RBD;~A total score on REM Sleep Behavior Questionnaire (RBDQ-HK) less than 19, which is the suggestive cut-off of a diagnosis of RBD;~Absence of self-report dream enactment behaviors and RSWA as measured by v-PSG."
89576443|NCT05352685|Active Comparator|Healthy volunteers|
89576444|NCT05352685|Experimental|supratentorial glioma patients|
89576445|NCT05321875|Experimental|Candesartan|Candesartan, 16 mg oral tablets. Target dose 32 mg or maximum tolerated dose after dose escalation from 16 mg
89576446|NCT05321875|Placebo Comparator|Placebo|Matching placebo. Target dose 2 tablets or maximum tolerated dose after dose escalation from 1 tablet
89576447|NCT02522767|Experimental|Mesalamine|4 g extended release granules (sachet)
89576448|NCT02522767|Placebo Comparator|Placebo|Matching placebo
89576449|NCT05319847|Experimental|Intervention arm|Daily Skin Supplement - Fountain of Youth
89576450|NCT02522377|Experimental|Ketamine Infusions|Subjects who are randomized to be on this group will receive a standard dose of ketamine interleaved with Electroconvulsive Treatments.
89576451|NCT02522377|Active Comparator|Midazolam|Subjects who are randomized to be on this group will receive midazolam infusions interleaved with Electroconvulsive Treatments.
89576452|NCT05319613|Other|Telemedicine Clinical Care|Rural participants who enter PrEP clinical care with University of Colorado HIV Prevention Program will receive care via telemedicine with mailed lab kits and mailed HIV PrEP.
89576453|NCT05318599||IPF patients (group 1)|Consenting adult patients >18 years old with with already-diagnosed IPF
89576454|NCT05318599||NSIP patients (group 2)|Consenting adult patients >18 years old with with already-diagnosed non-specific interstitial pneumonia (NSIP)
88971794|NCT00001832|Experimental|Abl Cells IV + SQ|Abl Cells intravenous (IV) + subcutaneous (SQ) interleukin-2 (IL-2) with growth colony stimulating factor (GCSF) (melanoma-associated antigen recognized by T cells (MART-1) reactive) Phase 2 Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x60mg/kg + Cells IV + SQ IL-2 (125,000 IU/kg/dose for 5 days for six weeks with 2 days rest per week) + G-CSF + MART-1:26-35(27L) Peptide 1mg/day (5-8 days) in patients with MART-1 reactive cells Abl cells IV = Lymphocytes 10^9-10^11 IV over 30 minutes on day 0, repeated in 14 to 21 days
88971795|NCT00001832|Experimental|Abl Cells IV + SQ IL-2 with GCSF (no reactivity)|Phase 2 Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x60mg/kg + Cells intravenous (IV) + subcutaneous (SQ) interleukin-2 ( IL-2) (125,000 IU/kg/dose for 5 days for six weeks with 2 days rest per week) + growth colony stimulating factor (G-CSF) in patients with no reactivity Abl cells IV = Lymphocytes 10^9-10^11 IV over 30 minutes on day 0, repeated in 14 to 21 days
88971796|NCT01466205|Experimental|DAR 0-100A|The examination of SPD subjects, who are more likely than schizophrenia patients to show significant cognitive improvement after the use of single doses of dopamine agonists, such as DAR-0100A provides an excellent opportunity to demonstrate the effectiveness of D1 agonists on cognition in the schizophrenia spectrum.
88971797|NCT01466205|Placebo Comparator|Placebo|Some subjects receive placebo, instead of the study drug, in a double-blind randomized fashion. This allows for performance comparison between SPD subjects on DAR-0100A and those on placebo. The hypothesis is that SPD subjects on DAR-100A will show improvement on primary measures greater than SPD subjects randomized to placebo between baseline and post-drug.
88971798|NCT01466127|Placebo Comparator|Placebo|Matched nasal spray placebo.
88971799|NCT01466127|Experimental|Oxytocin|Liquid intranasal oxytocin administered in a nasal spray.
88971800|NCT01466088|Experimental|AZD3480|
89576455|NCT05318599||COPD patients (group 3)|Consenting adult patients >18 years old with with already-diagnosed chronic obstructive pulmonary disease (COPD)
88971801|NCT01466088|Active Comparator|Donepezil|Donepezil will be administered at 5 mg daily for 4 weeks and escalated to 10 mg daily for the remainder of the study.
88971802|NCT01466010||osteoid osteoma|patients with osteoid osteoma at any location
88971803|NCT00009620|Experimental|Phenobarbital|
88971804|NCT00009620|Placebo Comparator|Placebo|
88971805|NCT01465971||not acclimatized|no stay in an altitude above 2500 m within the last 3 Months
88971806|NCT01465971||acclimatized|stay above 2500 m with the last 14 days
88971807|NCT01465932|Active Comparator|No proprioception|Nursing professionals to diagnose disorders of the rotator cuff previously randomly allocated in this group did stretching exercises of the muscles of the cervical spine and chest, strengthening the muscles of the rotator cuff and stabilizers of the scapula, in addition to cryotherapy reduction of pain.
88971808|NCT01465932|Experimental|Proprioceptive exercises|Nursing professionals to diagnose disorders of the rotator cuff previously randomly allocated in this group did stretching exercises of the muscles of the cervical spine and chest, strengthening the muscles of the rotator cuff and stabilizers of the scapula, proprioception exercises to improve motor control, besides cryotherapy for reduction of pain.
88971809|NCT00009698|Experimental|All patients|Day 1 through day 7, days 9-14 and days 16-22: The assigned dose of IL-2 will be administered SQ. On days 8 and 15, IL-2 will be administered as a 2 hour intravenous infusion of one million units/M2 of IL-2. After day 22 there will be a 7 day rest period before beginning the next cycle. The next cycle will repeat just as above. This will be repeated for a maximum of 4 total cycles of 21 days of IL-2 therapy. The maintenance dose of IL-2 will always be the same as given during cycle one, unless there is dose limiting toxicity.
88971810|NCT01465893|Active Comparator|vitamin D|vitamin d 50000/w
88971811|NCT01465893|Sham Comparator|control|follow up
88971812|NCT01465815|Experimental|Treatment (adjuvant enzyme inhibitor and radiation therapy)|"Optional non-therapeutic (biomarker) portion: Patients are randomized to 1 of 3 treatment arms.~Arm A: Patients receive erlotinib hydrochloride PO QD and linsitinib PO BID on days 1-7 or 1-14.~Treatment continues until 1 day before planned surgical resection (for up to 28 days if surgery is delayed).~Therapeutic portion: This is a phase I dose-escalation study of linsitinib followed by a phase II study.~Patients undergo standard QD conventional radiotherapy at the discretion of the treating physician. Patients receive concurrent linsitinib PO BID and erlotinib hydrochloride PO QD during the entire course of radiation in the absence of disease progression or unacceptable toxicity."
88971813|NCT01465815|Experimental|Erlotinib and Placebo (Sugar Pill)|"Arm B: Patients receive erlotinib hydrochloride PO QD and placebo PO QD or BID on days 1-7 or 1-14.~Treatment continues until 1 day before planned surgical resection (for up to 28 days if surgery is delayed).~Therapeutic portion: This is a phase I dose-escalation study of linsitinib followed by a phase II study.~Patients undergo standard QD conventional radiotherapy at the discretion of the treating physician. Patients receive concurrent linsitinib PO BID and erlotinib hydrochloride PO QD during the entire course of radiation in the absence of disease progression or unacceptable toxicity."
88971814|NCT01465815|Experimental|OSI-906 and Placebo (Sugar Pill)|"Arm C: Patients receive linsitinib PO BID and placebo PO QD or BID on days 1-7 or 1-14.~Treatment continues until 1 day before planned surgical resection (for up to 28 days if surgery is delayed).~Therapeutic portion: This is a phase I dose-escalation study of linsitinib followed by a phase II study.~Patients undergo standard QD conventional radiotherapy at the discretion of the treating physician. Patients receive concurrent linsitinib PO BID and erlotinib hydrochloride PO QD during the entire course of radiation in the absence of disease progression or unacceptable toxicity."
88971815|NCT01465776|Experimental|Treatment (chemoprevention)|
88971816|NCT00009893|Experimental|gemcitabine + leucovorin + fluorouracil|Patients receive gemcitabine IV over 30 minutes followed by leucovorin calcium IV and fluorouracil IV over 5-10 minutes on days 1, 8, and 15. Treatment repeats every 4 weeks for a minimum of 2 courses in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 1 year and then every 6 months for 4 years.
88971817|NCT01465737||Patients with uterine cancer|All patients diagnosed with uterine cancer in Taiwan between 1979-2008
88971818|NCT01465698|Experimental|Exercise|
88971819|NCT01465698|Experimental|Counseling|
88971820|NCT01465698|Experimental|Exercise and counseling|
88971821|NCT01465698|Other|Control group|Participants in the control group only participate in study measurements.
89029231|NCT03763838|Sham Comparator|Sham acupressure plus standard of care|Using AcuWand, participants will apply acupressure to points that are not known to affect physiology. Participants will also receive standard of care.
88971822|NCT00009971|Experimental|Arm I|Patients receive oral fenretinide twice daily on days 1-7. Treatment continues every 21 days for at least 2 courses in the absence of disease progression or unacceptable toxicity.
88971823|NCT01465620|Experimental|Coaching|active hygienic-dietetic coaching
88971824|NCT01465620|Active Comparator|control|reference hygienic-dietetic recommendations
88971825|NCT01465581||Neurogenic incontinence|The target population of this study is children with primary or secondary daytime urinary incontinence, who have failed to improve adequately despite compliance with at least 6 months of standard medical therapy. These children will have abnormal urodynamics, a normal bladder ultrasound and an MR imaging showing that the conus of the spinal cord is at a normal position and that there is no other significant dysraphic lesion present.
89576456|NCT05318599||Control subjects (group 4)|"Consenting age-matched (+/- 2.5 years) never smokers patients with normal lung function (spirometry, lung volume and Transfer Factor for Carbon Monoxide (TLCO)) followed in the pulmonology outpatient clinic with similar quality of electronic medical records but for diseases other than the outcome of interest, namely:~patients with obstructive sleep apnea.~patients followed-up for occupational lung diseases (miners, chemical workers, etc.).~patients followed-up for pulmonary nodules (considered benign after 2 years)."
88971826|NCT01465503|Placebo Comparator|Unfractionated Heparin|Patients randomized to the Control group will receive unfractionated heparin (UFH) before and during the procedure. UFH bolus will be of 70 UI/kg. If the activated clotting time measured 5 minutes after the study drug administration is lower than 270 seconds, an additional bolus of the randomised drug (UFH 20 U/kg) will be given.
88971827|NCT01465503|Active Comparator|Bivalirudin|Patients randomized to Bivalirudin group will be treated by bivalirudin before and during the procedure. Bivalirudin will be given as bolus of 0.75 mg/kg prior to the start of the intervention, followed by infusion of 1.75 mg/kg per hour for the duration of the procedure.The infusion will be lowered to 1.0 mg/kg per hour in patients with eGFR <30 ml/min/1.73 m2.
88971828|NCT01465425||E3/E4 Case Group|The Case Group will target consenting 141 participants from the cases with indeterminate but potentially significant findings (E3/E4s) other than pulmonary nodules.
88971829|NCT01465425||Pulmonary Nodules Case Group|The Pulmonary Nodules Case Group will comprise 119 cases with E3/E4 ECFs characterized as pulmonary nodules.
88971830|NCT01465425||E1 Control Group|The E1 Control Group will be drawn from the 866 E1 ECF cases from ACRIN 6664 to create a cohort of 260 E1 ECF cases. The Control Group for comparison with the Case Group and the Pulmonary Nodules Case Group will be selected at the Biostatistics and Data Management Center (BDMC). The BDMC will match E1 141 controls to the 141 case-group participants with indeterminate but potentially significant findings (E3/E4s). The BDMC will also match 119 E1 controls to the 119 E3/E4 pulmonary nodules cases. Controls will be matched by site, age caliper (5 years), and sex where possible.
89029232|NCT03763838|Other|Standard of care|Participants will receive standard of care only.
89576457|NCT04422691||Covid-19 suspected|Emergency department patients with suspected or diagnosed COVID-19 disease. All patients will be screened at triage and put into isolation if suspected disease. Ultrasound of the patients lungs will be performed after patient consent and findings will be recorded and categorized (Soldati et al., 2020). The use of ultrasound and registration of data will not affect the regular patient evaluation, treatment or logistics.
89576458|NCT05268757|Experimental|Probiotic|In this group participants will receive probiotic supplements twice a day (morning and evening) for at period of 28 days (14 days with oral hygiene discontinuation followed by 14 days with regular oral care).
89576459|NCT05268757|Placebo Comparator|Placebo|In this group participants will receiveplacebo twice a day (morning and evening) for at period of 28 days (14 days with oral hygiene discontinuation followed by 14 days with regular oral care).
89576460|NCT05267743|Experimental|Tegoprazan 50mg QD|Tegoprazan 50mg tablet, once daily, oral administration
89576461|NCT05267743|Active Comparator|Lansoprazole 30mg QD|Lansoprazole 30mg capsule, once dauly, oral administration
89576462|NCT05291845|Experimental|Candida antigen group|25 patients will be treated with Candida antigen. All patients will be directly injected with Candida antigen into the largest wart using an insulin syringe. Injections will be done at 2-week intervals until complete clearance will be achieved or for a maximum of five treatment sessions.
89576463|NCT05291845|Experimental|Bivalent HPV vaccine|25 patients will be treated with the Bivalent HPV vaccine. All patients will be directly injected with the vaccine into the largest wart using an insulin syringe. Injections will be done at 2-week intervals until complete clearance will be achieved or for a maximum of five treatment sessions.
89576464|NCT05291845|Experimental|both agents group|25 patients will be treated with Both agents at the same session. Injections will be done at 2-week intervals until complete clearance will be achieved or for a maximum of five treatment sessions.
89576465|NCT05317195|Experimental|NP-1|Nicotine Pouch 1.0 (variant NP-1)
89576466|NCT05317195|Experimental|NP-2|Nicotine Pouch 1.0 (variant NP-2)
89576467|NCT05317195|Experimental|NP-3|Nicotine Pouch 1.0 (variant NP-3)
89576468|NCT05317195|Experimental|NP-4|Nicotine Pouch 1.0 (variant NP-4)
89576469|NCT05317195|Active Comparator|Velo-NP|Velo® Ice Cool
89576470|NCT05317195|Active Comparator|Zyn-NP|Zyn® Cool Mint Mini Dry
89576471|NCT05317117|Other|NxTek™ Malaria P.f plus Rapid Diagnostic Test (RDT) and NxTek™ Malaria P.f/P.v RDT|All participants will be tested with two investigational IVDs at the point of care, the NxTek™ Malaria P.f plus Rapid Diagnostic Test (RDT) and the NxTek™ Malaria P.f/P.v RDT, in addition to comparator tests and the standard of care (microscopy). The investigational tests will not be used to determine any treatment or case management.
89576472|NCT05314621|Active Comparator|Pataday® Once Daily Relief Extra Strength and Saline Nasal Spray|Pataday® Once Daily Relief Extra Strength (olopatadine hydrochloride ophthalmic solution 0.7%) will be administered bilaterally and saline nasal spray will be administered nasally (within 5 minutes of eyedrop) at Visits 3 and 4a.
89576473|NCT05314621|Active Comparator|Tears Naturale® II and Flonase® Allergy Relief|Tears Naturale® II will be administered bilaterally and Flonase® Allergy Relief (fluticasone propionate) will be administered nasally (within 5 minutes of eyedrop) at Visits 3 and 4a.
89576474|NCT05290597|Experimental|IBI363|Single arm
89576475|NCT05314465|Experimental|Median nerve mobilization|Experimental arm given Median nerve mobilization for 12mins 3sets for 3mins each with 1 minute interval in between for 5times a week for 4weeks
89576476|NCT05263609|Experimental|Arm A|"Arm A (CR/oPR on pembrolizumab monotherapy):~Patients will continue pembrolizumab monotherapy if CR/oPR on initial treatment with pembrolizumab monotherapy. If CR/oPR persists at 8 cycles (24 weeks) after assignment on arm A, pembrolizumab break will commence. Patients will be monitored for disease progression with imaging every 9 weeks (+/- 1 week). If patients develop progression, pembrolizumab will be resumed and continued until subsequent PD. At that point, axitinib may be added to pembrolizumab as part of the study or patients may discontinue study treatment per the treating investigator's discretion."
89576477|NCT05263609|Experimental|Arm B|"Arm B (sPR/SD/PD):~Patients with sPR, SD or PD after 6 cycles of pembrolizumab monotherapy will be started on axitinib in addition to continuing pembrolizumab. If patients develop subsequent PD, treatment will be discontinued. If the subsequent scans show SD/PR/CR, the combination treatment will be continued until PD or unacceptable toxicity."
89576478|NCT05263375|Experimental|MV replacement with Innovalve TMVR system|MV replacement with Innovalve TMVR system
89576479|NCT05259241|Other|Single arm study|"Cohort A: patients undergoing TAVR to evaluate which point-of-care test (ACT or aPTT) gives the best correlation with the coagulation status~Cohort B: patients undergoing PCI to evaluate which point-of-care test (ACT or aPTT) gives the best correlation with the coagulation status"
89576480|NCT05219227|Experimental|body fat mass (BFM)|body fat mass will be measured before and after interventions
89576481|NCT05219227|Experimental|Body mass index (BMI)|BMI will be calculated before and after interventions
89576482|NCT01657903|Experimental|NaF/KNO3 toothpaste, Low RDA|Participants to brush with 1.5 g of low RDA gel to foam toothpaste containing 1450 ppm F - EU level as NaF. All study treatments contain 5% weight by weight (w/w) KNO3.
89576483|NCT01657903|Experimental|NaF/KNO3 toothpaste, Medium RDA|Participants to brush with 1.5 g of medium RDA gel to foam toothpaste containing 1450 ppm F - EU level as NaF. All study treatments contain 5% w/w KNO3.
89576484|NCT01657903|Active Comparator|NaF/KNO3 toothpaste|Participants to brush with 1.5 g of NaF/KNO3 toothpaste containing 1450 ppm F - EU level as NaF. All study treatments contain 5% w/w KNO3.
89576485|NCT01657903|Placebo Comparator|No fluoride/KNO3 toothpaste|Participants to brush with a fluoride free toothpaste (0 ppmF). All study treatments contain 5% w/w KNO3.
89576486|NCT05256823|Experimental|Experimental Group|Patients will be given a combination of Celecoxib and one nucleos(t)ide analogue (Entecavir or Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide Fumarate) therapy for 48 weeks
89576487|NCT05256823|Other|Control group|Patients will continue ongoing nucleos(t)ide analogue (Entecavir or Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide Fumarate) therapy for 48 weeks
89576488|NCT05218681|Other|"Control: Unit-based Person First Anti-stigma Awareness Rounds"|"The Person First Initiative was developed independent of this study by bedside nurses (including McFadden) in collaboration with HUP Nursing Executive Leadership. The objective of this initiative is to provide (1) unit-based huddles on person-first language as a mechanism to reduce the stigma around substance use; (2) socialize best practices and resources for patients with substance use disorder; and (3) provide overdose reversal training and kits, including Narcan nasal spray, to nurses. The planning and implementation of these activities fall under the purview of Nursing Shared Governance (NOT the research team), and oversight for these activities will be provided by HUP Nursing Executive Leadership."
89576489|NCT05218681|Other|"Unit-based Person First stigma rounds + Text-based Messaging"|Participating nurses will be randomized to receive weekly short text messages that employ evidence-based strategies to reduce stigma towards individuals with substance use disorder over the course of 6-months.
89576490|NCT05284357||Group 1: Subjects implanted with HUMELOCK I & II® Anatomic Shoulder System|"The number of patients implanted was defined by comparing sales' database of FX Solutions.~97 patients were identified who could be included in this cohort in 11 investigational centers.~subjects implanted in 2011 to 2013"
89576491|NCT05284357||Group 2: Subjects implanted with HUMELOCK II® Reversible System|"The number of patients implanted was defined by comparing sales' database of FX Solutions.~Number of patient to be determined following patients files in 4 investigational centers.~subjects implanted in 2011 to 2013"
89576492|NCT05284357||Group 3: Subjects implanted with HUMELOCK Reversed® Shoulder System|"The number of patients implanted was defined by comparing sales' database of FX Solutions.~154 patients were identified who could be included in this cohort in 5 investigational centers.~subjects implanted in 2012 and 2013"
89576493|NCT05284357||Group 4: Subjects implanted with EASYTECH® Anatomic Shoulder System|"The number of patients implanted was defined by comparing sales' database of FX Solutions.~66 patients were identified who could be included in this cohort in 5 investigational centers subjects implanted in 2013 and 2014"
89576494|NCT05284357||Group 5: Subjects implanted with EASYTECH® Reversed System (Primary intention)|"The number of patients implanted was defined by comparing sales' database of FX Solutions.~7 patients were identified who could be included in this cohort in 5 investigational centers subjects implanted in 2013 and 2014"
89576495|NCT05284357||Group 6:Subjects implanted with EASYTECH® Reversible System (Revision of Easytech Anatomic)|"The number of patients implanted was defined by comparing sales' database of FX Solutions.~the number of subjects will depend of revised subjects primary implanted with Easytech Anatomic® along the dedicated period subjects implanted in 2013 to 2014"
88971831|NCT01465308|Experimental|receiving Honey|The patients will receive honey mouthwash rinses
89576496|NCT05284357||Group 7: Subjects implanted with HUMERIS® Anatomic Shoulder System|"The number of patients implanted was defined by comparing sales' database of FX Solutions.~11 patients were identified who could be included in this cohort in 3 investigational centers Subjects implanted in 2014 to 2015"
89576497|NCT05284357||Group 8: Subjects implanted with HUMERIS® Reversible Shoulder System|"The number of patients implanted was defined by comparing sales' database of FX Solutions.~72 patients were identified who could be included in this cohort in 2 investigational centers Subjects implanted in 2014 to 2015"
89576498|NCT05284201|Experimental|Functional task practice and ARC Therapy|FTP and ARC Therapy with the LIFT System at home for 1 month.
88971832|NCT01465308|Active Comparator|Saline mouthwash|The patients in this group will receive saline rinses
88971833|NCT00391352||MS|MS patient is matched to healthy volunteer
88971834|NCT00391352||Control|
88971835|NCT01465269|Experimental|GIST Intervention|
88971836|NCT01465269|Active Comparator|Alternative Intervention|
88971837|NCT00010205|Experimental|Treatment (benzoylphenylurea)|Patients receive oral benzoylphenylurea weekly for 6 weeks. Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of benzoylphenylurea until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 6 patients experience dose-limiting toxicity.
88971838|NCT01465152|Experimental|Met|
88971839|NCT01465152|Active Comparator|Rep|
88971840|NCT01465152|Active Comparator|Met+Rep|
88971841|NCT01465113|Experimental|Indefinite, LGD or no dysplasia arm|Barrett's esophagus patients who have no dysplasia or low grade dysplasia
88971842|NCT01465113|Experimental|high grade dysplasia|Barrett's esophagus with high grade dysplasia
88971843|NCT01465113|Experimental|Indefinite, LGD or no dysplasia arm:Vitamin D/Metformin Subarm|Barrett's esophagus patients who have no dysplasia or low grade dysplasia
88971844|NCT01465074|Active Comparator|Nicotine gum (4 mg)|Nicotine gum will be given once on one of the two test days in a randomized, double-blinded fashion. Gum will be chewed for 30 min before the plasticity induction occurs.
88971845|NCT01465074|Placebo Comparator|Regular Mint Gum|Regular, taste-, texture- and color matched with the Nicotine Gum will be ingested once on one of the two testing days, 30 min before plasticity induction.
89576499|NCT05492149||Pulmonary rehabilitation group|Patients referred for a pulmonary rehabilitation program will be follow up.
89576500|NCT05482867||Cohort 1|Cohort 1, healthy adults (n = 5), will receive an ICG infusion of 1 mg/min for 120 minutes.
89576501|NCT05482867||Cohort 2|If no dose limiting adverse effects are observed in Cohort 1, then Cohort 2, healthy adults (n = 10), will receive an ICG infusion of 2 mg/min for 120 minutes. If there are no dose limiting adverse events and there is evidence of ICG-labeling of PBMCs, the 2 mg/min infusion rate will be used for the remainder of the study.
89576502|NCT05482867||Cohort 3|Cohort 3, healthy elderly adults, will receive an ICG infusion of 2 mg/min for 120 minutes. The first 5 subjects will serve as a satellite group. If no adverse effects are observed in the satellite group, then a further 10 healthy elderly adults will receive a 2 mg/min ICG infusion (n = 15 total for Cohort 3).
89576503|NCT05482867||Cohort 4|Cohort 4, AD patients, will receive an ICG infusion of 2 mg/min for 120 minutes. The first 5 subjects will serve as a satellite group. If no adverse effects are observed, then a further 10 AD patients will receive a 2 mg/min ICG infusion (n = 15 total for Cohort 4). Recruitment of AD patients will begin if there are no dose limiting adverse effects observed in the satellite group of healthy elderly.
88971846|NCT01465035|Experimental|TIV and MVA-NP+M1|"Co-administration group~1 dose of seasonal influenza vaccine (TIV) and 1 dose of 1.5 x108pfu MVA-NP+M1"
88971847|NCT01465035|Placebo Comparator|Saline placebo and seasonal influenza vaccine TIV|"Control group~1 dose of seasonal influenza vaccine (TIV) and 1 dose of a saline placebo"
88971848|NCT01464996|Experimental|Adhesive OptiBond XTR|Adhesive OptiBond XTR will include composite restorations placed using the dental adhesive OptiBond XTR.
88971849|NCT01464996|Active Comparator|Adhesive OptiBond FL|Adhesive OptiBond FL will include composite restorations placed using the dental adhesive OptiBond FL.
88971850|NCT01464957|Experimental|Newsletter intervention|Semi-tailored newsletter intervention for parents and children
88971851|NCT01464957|No Intervention|Usual care|No newsletter intervention
88971852|NCT02061605|Experimental|Laser Tissue Welding Device|"The laser tissue welding device is intended for use in patients requiring laparoscopic surgery requiring hemostasis and sealing of the resected kidney after partial nephrectomy, and including those patients who are fully heparinized or have hemodilutional coagulation failure.~The device's intended use is to seal the kidney surface using a laser to weld human albumin based biomaterials after surgical removal of kidney tumors during a laparoscopic partial nephrectomy."
88971853|NCT01464918|Experimental|ESD using the MASTER device|Endoscopic submucosal dissection of gastric/colon cancer using the device, MASTER
88971854|NCT01464840||15 minutes|500 mg of intravenous azithromycin will be administered 15 minutes prior to incision.
88971855|NCT01464840||30 minutes|500 mg of intravenous azithromycin will be administered 30 minutes prior to incision.
88971856|NCT01464840||60 minutes|500 mg of intravenous azithromycin will be administered 60 minutes prior to incision.
88971857|NCT01464801|Experimental|Resveratrol|Subjects are given resveratrol 500 mg 3 times daily for 6 months.
88971858|NCT01464801|Placebo Comparator|Placebo|Subjects are given Placebo tablets 3 times daily for 6 months.
88971859|NCT02035358|Experimental|HyperAcute®-Renal Immunotherapy|Cells will be injected intradermally every 1 week x 4 weeks and then every 2 weeks for 10 immunizations to total 14 immunizations. Dose Cohort 1 will receive 150 million cells per immunization; Dose Cohort 2 will receive 300 million cells per immunization. Once the first three months of immunizations are completed, patients may receive other systemic treatment (non-investigational) while continuing to receive the remaining 6 immunizations.
88971860|NCT01464723|Experimental|Lucentis|Consented, enrolled subjects will receive multiple open-label intravitreally administered 0.5 mg ranibizumab administered monthly for the first 4 months, and then as needed for a total duration of 12 months.
88971861|NCT01464645||Primary|Post Market Study
88971862|NCT01464606|Experimental|Type I PPB therapy|PPB Type I therapy: All patients will be treated with surgery. Chemotherapy after surgery is per the treating physician(s) discretion. If chemotherapy is used the Registry will suggest that it be combination chemotherapy with Vincristine, Dactinomycin, Cyclophosphamide (VAC).
88971863|NCT01464606|Experimental|Types II and III PPB therapy|"Combination chemotherapy with Ifosfamide, Vincristine, Dactinomycin and Doxorubicin (IVADo). Second look and possible 3rd look surgery may be required. Radiation therapy is recommended only for residual disease after maximum surgery."
88971864|NCT01464567|Active Comparator|"T Tube Spontaneous Breathing Trial"|"Spontaneous Breathing Trial wuth T Tube for 30 minutes."
88971865|NCT01464567|Experimental|Pressure Support Ventilation|Spontaneous Breathing Trial wuth Ventilation on Pressure-Support mode set at 10cmH2O for 30 minutes
88971866|NCT01464528|Active Comparator|Hyaluronan|Use of hyaluronic acid gel
88971867|NCT01464528|No Intervention|control|
88971868|NCT00393744|Experimental|1|
88971869|NCT00393744|Active Comparator|2|
88971870|NCT04711980|Experimental|Mudan granule|"Based on the standard medical care, experimental group were treated with Mudan Granule 7g , 3 times/d.~Intervention: Drug: Mudan granule"
88971871|NCT04711980|Placebo Comparator|Placebo|Based on the standard medical care, placebo-controlled group were treated with Placebo 7g , 3 times/d Intervention: Drug: Placebo
88971872|NCT00393822|Experimental|Palifermin|50 subjects to receive palifermin 3 days prior to the first day (day 1) of each cycle of 5-FU/ LV chemotherapy.
89033229|NCT02917200|Experimental|MOX + DAV132 1 g tid|Moxifloxacin, 400 mg/day oad, 5 days + DAV132 1 g tid, 7 days
89576504|NCT05255263|Active Comparator|Programmed Intermittent Epidural Bolus|Intermittent epidural bolus as the first line labor epidural analgesia maintenance infusion
89576505|NCT05255263|Active Comparator|Continuous Epidural Infusion|Continuous epidural infusion as the first line labor epidural analgesia maintenance infusion
89576506|NCT05254717|Experimental|Interventional arm|Following baseline study, the interventional arm assigned to receive counselling intervention on complementary food flour soaking
89576507|NCT05254717|No Intervention|control arm|The control group will be monitored for presence of any other intervention that might have a potential to mask the effect of the current intervention.
89576508|NCT05253937||Intracoronary Epinephrine administration during cardiac arrest|
89576509|NCT05253937||Peripheral intravenous Epinephrine administration during cardiac arrest|
89576510|NCT05253937||Central intravenous Epinephrine administration during cardiac arrest|
89576511|NCT05253703|Other|Virtual Reality Bicycling|This is a single arm study in which all participants will execute the same three bicycling tasks over one session. Exercise intensity and enjoyment are measured while participants bicycle in a virtual reality environment (wearing virtual reality goggles) in three different conditions lasting approximately 5 minutes each.
89576512|NCT05218603||Maintenance with V-Dara after receiving VMP-Dara as induction regimen|Maintenance with bortezomib plus daratumumab (V-Dara) after induction with bortezomib, melphalan, prednisone plus daratumumab (VMP-Dara)
89576513|NCT05217121|Active Comparator|Group Q = QLB group|Patients will be administered paracetamol 1 gr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by a pain nurse blinded to the procedure. Tramodol will be performed for rescue analgesia.
89576514|NCT05217121|Active Comparator|Group M = mTLIP block group|Patients will be administered paracetamol 1 gr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by a pain nurse blinded to the procedure. Tramodol will be performed for rescue analgesia.
89576515|NCT05252377|Experimental|Breathing Exercise Group|Breathing exercise program; It was prepared by the researchers in accordance with the literature and based on the studies in which breathing exercise was applied to reduce invasive pain experienced during cannulation, blood collection and postoperative pain. Patients will be given an exercise based on rhythmic breathing. The exercise will be started before the cannulation application, the patient will be told to perform the breathing exercise twice, and he will be asked to continue doing the breathing exercise until the cannulation process is completed. The patient will wait by taking five normal breaths between each breathing exercise. The patient will be told that he can count by using his fingers in the steps he is asked to count up to three.
89576516|NCT05252377|No Intervention|Control Group|No intervention will be made by the researcher on the patients in this group, and a pain assessment will be made by the nurse in charge of dialysis immediately after the cannulation procedure by the dialysis nurse working in the unit.
89576517|NCT04422535||Critical care patients|Patients admitted to critical care units for COVID-19, where ECG records and relevant clinical information are available to assess the impact of the disease and its concomitant treatment on electrocardiographic parameters of ventricular repolarization
89576518|NCT04900831||Group 1|
89576519|NCT05251519|Experimental|Kinesio Taping Group (KTG)|Conventional rehabilitation application will be performed in addition to Kinesio Tex tape derotation taping.
89576520|NCT05251519|Active Comparator|Conventional Rehabilitation Group (CRG)|A conventional rehabilitation program will be applied to the patients through a pediatric physiotherapist.
89576521|NCT05214001|Experimental|Almotriptan|12.5 mg almotriptan taken orally once
89576522|NCT05214001|Active Comparator|Ubrogepant|50 mg ubrogepant taken orally once
89576523|NCT05249881|Other|semaglutide|semaglutide is an anti-diabetic medication used for the treatment of type 2 diabetes and long-term weight management. Semaglutide acts like human glucagon-like peptide-1 in that it increases insulin secretion, thereby increasing sugar metabolism
89576524|NCT05279989|Experimental|Seated Tai Chi Qigong|Participants will receive daily text messages and emails to distribute videos and record which sessions were completed. Participants can participate in 10-, 20-, or 30- min TCQ practices. Total weekly practice time will be recommended between 50-150 minutes/week (~10-30 min/day on most days). A library of existing TCQ videos will be used. All videos will demonstrate seated practice with discussions on how to accommodate mobility limitations of various types.
89576525|NCT05279989|Placebo Comparator|Control|The control arm will receive text messages and emails with links to health information videos for the same time lengths as the intervention group. Existing video content will be reviewed and adapted to assure avoidance of topics that can impact outcome variables.
88971873|NCT00393822|Placebo Comparator|Control Group|50 subjects to receive matched placebo 3 days prior to the first day (day 1) of each cycle of 5-FU/ LV chemotherapy.
88971874|NCT00393900||1|Children with tympanostomy tubes for chronic OME
88971875|NCT00011180||Incident Cohort with VTE|Olmsted County, Minnesota residents with with a first-lifetime deep vein thrombosis (DVT) or pulmonary embolism (PE) during the five year period, 1996-2000.
88971876|NCT00011180||Controls without VTE|Two Olmsted County, Minnesota residents without venous thromboembolism (VTE) were matched by age and gender to each definite or probable case of VTE within the 1996-2000 cohort.
89576526|NCT05279677|Experimental|FMT|Fecal microbiota transplantation plus Sintilimab and Fruquintinib
89576527|NCT05486923||KPS less than 70|"The patients in this group have Karnofsky performance Status less than 70，and the proportion of them is not less than 15%.~Patients need regular follow-up surveys within 2 years after the date of surgery."
89576528|NCT05486923||KPS more than 70|The patients in this group have Karnofsky performance Status more than 70. Patients need regular follow-up surveys within 2 years after the date of surgery.
88971877|NCT00847977|Active Comparator|1|Heafusine - Physiologic serum
88971878|NCT00847977|Experimental|2|Isofundine - Tetraspan
88971879|NCT00847938|Active Comparator|1|neostigmine 0.04 mg.kg associated with atropine 0.02 mg/kg
88971880|NCT00847938|Active Comparator|2|neostigmine 0.02 mg.kg associated with atropine 0.01 mg/kg
88971881|NCT00847938|Active Comparator|3|neostigmine 0.1 mg.kg associated with atropine 0.05 mg/kg
88971882|NCT00847938|No Intervention|4|no injection of neostigmine
88971883|NCT00011414|Experimental|1|Intervention given with dose escalation of tariquidar
88971884|NCT00847899|Active Comparator|1|AR9281
89576529|NCT05278117|Experimental|complete burst abdomen repair|complete burst abdomen repair
89576530|NCT05248945|Experimental|Evobrutinib plus Carbamazepine|
89576531|NCT05248711|Experimental|Daily Move|Participants (n=107) will be provided free access to and asked to register for the consumer-based mobile meditation app, Calm, on their phone. Participants will then receive an email containing one year of free access to Calm. Participants will be asked to use the Daily Move component on the Calm app for ~10 minutes per day for 8 weeks.
89576532|NCT05248711|No Intervention|Usual Care|Participants (n=107) will be asked to continue with usual care/routine and complete survey measures at each time point. Participants will be provided with access to the intervention after their study participation.
89576533|NCT04239313|Experimental|Population I|Population I has 10 subjects,and it is considered as Tuberculin purified protein derivative(TB-PPD) skin test and specific gamma-interferon (γ-IFN) detection result all negative.Population I are coxal muscle injection of low dose vaccine.
89576534|NCT04239313|Active Comparator|Population II|Population I has 10 subjects,and it is considered as Tuberculin purified protein derivative(TB-PPD) skin test and specific gamma-interferon (γ-IFN) detection result all negative.Population I are coxal muscle injection of low dose adjuvant.
89576535|NCT04239313|Placebo Comparator|Population III|Population I has 10 subjects,and it is considered as Tuberculin purified protein derivative(TB-PPD) skin test and specific gamma-interferon (γ-IFN) detection result all negative.Population I are coxal muscle injection of placebo.
89576536|NCT05276167|Experimental|The experimental group|Participants in the experimental group will be treated with hyperthermic intravesical perfusion before receiving radical cystectomy.
89576537|NCT05276167|No Intervention|The control group|Participants in the control group will receive radical cystectomy alone.
89576538|NCT05211973||Fried Frailty Phenotype 0|Those who are considered Robust under the Fried Frailty Criteria. Sensor technology and digital measures will be used to evaluate movement and body weight composition in healthy adults.
89576539|NCT05211973||Fried Frailty Phenotype 1-2|Those who are considered Intermediate/Pre-frail under the Fried Frailty Criteria. Sensor technology and digital measures will be used to evaluate movement and body weight composition in healthy adults.
89576540|NCT05211973||Fried Frailty Phenotype 3+|Those who are considered Frail under the Fried Frailty Criteria. Sensor technology and digital measures will be used to evaluate movement and body weight composition in healthy adults.
89576541|NCT05273983|Experimental|Behavioural Activation Treatment|Two intervention sessions with a psychologist and an use of a mobile scheduling app over the course of 6 weeks.
89576542|NCT05273515|Experimental|Pilot|3D scanning of participants. Images used to created 3D reconstruction of 15% and 25% total body weight loss. These are shown to participants using virtual reality. Qualitative outcomes measured using group discussion and questionnaires.
89576543|NCT05273437|Experimental|System Identification|All participants in the study will go through a system identification experiment everyday for 270 days.
89576544|NCT05209711|Other|FN blockade under ultrasound control with a peripheral nerve stimulator 7.5 ml 1% lidocaine|Patients undergoing surgery on the shin, ankle or foot
89576545|NCT05209711|Other|FN blockade under ultrasound control without a peripheral nerve stimulator 7.5 ml 1% lidocaine|Patients undergoing surgery on the shin, ankle or foot
89576546|NCT05272969||LOPD group|50 Patients with genetically confirmed late-onset Pompe disease.
89576547|NCT05272969||Control group|15 Patients with histologically confirmed inclusion body myositis (IBM), 15 patients with genetically confirmed spinal muscular atrophy type 3 (SMA3) and 15 patients with genetically confirmed facio-scapulo-humeral muscle dystrophy (FSHD) will serve as a control group.
89576548|NCT05272033|Active Comparator|GROUP TEAS|Patients in the TEAS group will receive preoperative TEAS for 30 min before the spinal anesthesia at PC-5, PC-6, and ST-36 with an electronic acupuncture device.
89576549|NCT05272033|Sham Comparator|Sham TEAS|In the sham TEAS group, the gel electrodes will be applied at the same anatomical points without stimulation.
89576550|NCT05209087||Children with Duchenne Muscular Dystrophy|Children with Duchenne Muscular Dystrophy who are between Levels 1-4 (continuing ambulation) according to Brooke Lower Extremity Functional Classification will be included in the study. This classification method was designed on the basis of the classification method to determine the functional status of the lower and upper extremities in the clinical evaluation of Duchenne Muscular Dystrophy.
89576551|NCT05207917|Active Comparator|Gastric bypass|Gastric bypass
88971885|NCT00847899|Active Comparator|2|AR9281
88971886|NCT00847899|Placebo Comparator|3|Placebo
88971887|NCT00847899|Placebo Comparator|4|Placebo
88971888|NCT00847860|Experimental|1|Cilostazol
88971889|NCT00847860|Active Comparator|2|Asprin
88971890|NCT00011492||1/All Patients|All eligible patients
88971891|NCT00847821||Bazedoxifene 10 mg/CE 0.625 mg|
88971892|NCT00847821||Bazedoxifene 20 mg/CE 0.625 mg|
88971893|NCT00847821||Bazedoxifene 40 mg/CE 0.625 mg|
89576552|NCT05207917|Active Comparator|Sleeve gastrectomy|Sleeve gastrectomy
89576553|NCT05207917|Experimental|Single anastomosis sleeve ileal (SASI) bypass|Exploratory small arm with a small number of particpants
89576554|NCT05269147|Placebo Comparator|SBGB with normal saline|patients will receive standardized general anesthesia + SBGB with normal saline.
89576555|NCT05269147|Active Comparator|SBGB with lidocaine 2%|patients will receive standardized general anesthesia + SBGB with lidocaine 2%
89576556|NCT05269147|Active Comparator|SBGB with bupivacaine 0.5%|patients will receive standardized general anesthesia+ SBGB with bupivacaine 0.5%
89576557|NCT05241691||Pediatric patients treated with GGPSP for the correction of femur and/or tibia deformities|
89576558|NCT05206747|Experimental|Blue-blocking glasses|Participants will wear orange/amber colored lenses that filter wavelengths of light in the blue spectrum while awake from 6 p.m. to 8 a.m.
89576559|NCT05206747|Sham Comparator|Lightly-tinted glasses|This control will involve glasses that selectively filter short wavelength (e.g., ultraviolet), but not visible blue light during the same time window. Participants will wear these glasses while awake from 6 p.m. to 8 a.m.
89576560|NCT05205811|Experimental|Combination zonisamide and bupropion with e-cigarette|After the first week of e-cigarette use (JUUL), participants will be given bupropion (150 mg each morning for days 1-3, then 300 mg daily) with zonisamide (100 mg daily). The combination of zonisamide and bupropion use will continue for 7 weeks of treatment, and e-cigarette use will continue until the end of the study (an additional 4 weeks).
89576561|NCT05205811|Experimental|Bupropion with e-cigarette|After the first week of e-cigarette use (JUUL), participants will be given bupropion (150 mg each morning for days 1-3, then 300 mg daily) with placebo zonisamide. The combination of placebo and bupropion use will continue for 7 weeks of treatment, and e-cigarette use will continue until the end of the study (an additional 4 weeks).
89576562|NCT05205811|Placebo Comparator|Placebo with e-cigarette|After the first week of e-cigarette use (JUUL), participants will be given placebo bupropion with placebo zonisamide. The combination of these placebos will continue for 7 weeks of treatment, and e-cigarette use will continue until the end of the study (an additional 4 weeks).
89576563|NCT05166967|Experimental|Individual dose of ATG|Individual dose of ATG: Individual dose of ATG was Intravenous infused every day from day -5 to day -2 (total ATG dose was calculated based on pharmacokinetic index, within a range of 6 mg/kg to 13mg/kg), and the active ATG concentration ranges from 110 to 148.5UE/ml.
89576564|NCT05166967|Active Comparator|Fixed dose of ATG|A total amount of 10mg/kg ATG was divided into 4 days (from day -5 to day -2). The specific usage: 1.5mg/kg for day -5, 2.5mg/kg for day -4 and day -3, 3.5 mg/kg for day -2.
89576565|NCT05238337|Experimental|[14C]-PBI-200 Treated|[14C]-labeled PBI-200 will be administered as a single dose
89576566|NCT05205421|Experimental|Oncolytic Virus Injection(RT-01)|RT-01 will be administered by intravenously;
89576567|NCT05166109|Experimental|Vamorolone 500mg/day [250mg if <50kg body weight]|Subjects will be randomized to one of two treatment groups in a 1:2 ratio (placebo:vamorolone).
89576568|NCT05166109|Placebo Comparator|Placebo|Subjects will be randomized to one of two treatment groups in a 1:2 ratio (placebo:vamorolone).
89576569|NCT05204407|Active Comparator|Luteolin|
89576570|NCT05204407|Placebo Comparator|Placebo|
89576571|NCT01656733|Experimental|Nicotrol Inhaler|Nicotrol Inhaler, 1-12 cartridges per day, for 6 weeks with a 6 week taper.
89576572|NCT01656733|Placebo Comparator|Placebo Inhaler|Placebo inhaler, 1-12 cartridges per day, for 6 weeks with a 6 week taper
89576573|NCT05236543|Experimental|Treatment Arm|Subjects will receive AZD4831 on Day 1; Itraconazole only on Days 8 through 10 , and AZD4831 and Itraconazole on Day 11 oral dosing of Itraconazole only on Days 12 through 17.
89576574|NCT05163769|Experimental|Multimodal Training|The participants in the Multimodal training arm (mBCI) will undergo 48 physical and cognitive training sessions over 24 weeks on the NeeuroCycle BCI Physical and Cognitive training system. Sessions are scheduled three times a week for the first 12 weeks and then once a week for the subsequent 12 weeks. Sessions are spaced at least one day apart and will take about one hour per session.The mBCI training program will deliver cognitive training modules in tandem with a stationary cycling regime. The cognitive training program consists of six different gamified tasks that target attention, immediate/working and delayed memory, decision-making, and visuospatial abilities delivered on an electronic tablet. The cycling regime is divided into seven non-consecutive sections. The participant will be tasked to complete a cognitive training activity that will last about 2-3 minutes between each cycling session.
89576575|NCT05163769|Experimental|Neurocognitive-Training only|The participants in the Neurocognitive training-only arm (nBCI) will undergo 48 cognitive training sessions over 24 weeks on the NeeuroCycle BCI Cognitive training system. The sessions are scheduled three times a week for the first 12 weeks and then once a week for the subsequent 12 weeks. Sessions are spaced at least one day apart and will take about one hour per session. The nBCI training protocol will deliver cognitive training modules that consists of six different gamified tasks that target attention, immediate/working and delayed memory, decision-making, and visuospatial abilities delivered on an electronic tablet. Participants will navigate the virtual space of the cognitive training program by using arrow keys on the tablet.
89576576|NCT05163769|No Intervention|Active Control|The participants in the Active Control arm (AC) will undergo 48 sessions over 24 weeks. The sessions are scheduled three times a week for the first 12 weeks and then once a week for the subsequent 12 weeks. Sessions are spaced at least one day apart and will take about one hour per session. Participants in this arm will view informative documentaries on an electronic tablet and answer three general questions about documentary.
89576577|NCT05161663|Experimental|PDI group|In this group, participants will receive education about HIV and pre-exposure prophylaxis (PrEP) and be referred to our study by peer educators. Referred participants will have free PrEP counseling and receive referrals if interested. We will follow up at three and six months and check participants' PrEP status.
89576578|NCT05161663|No Intervention|Control group|In the control group, participants do not receive any education from peers and will be directly recruited by research assistants from venues (e.g. gay bars, LGBTQ communities, LGBTQ events, and social media advertisements). Participants will receive PrEP counseling and referral if interested. We will follow up at three and six months and check participants' PrEP status.
89576579|NCT05161117|Experimental|virtual reality education|The experimental group will receive both an online fall prevention education module and additional education using a virtual reality simulation app for mobile devices designed for specifically for hospital caregivers
88971894|NCT00847821||Bazedoxifene 10 mg/CE 0.45 mg|
89576580|NCT05161117|Active Comparator|online education only|The control group will receive an online fall prevention education module
89576581|NCT05202535|Experimental|Aerobic exercise training|hospital-based aerobic exercise training on treadmill/cycle ergometer with the intensity of 40-70% of HR max, for 15-30 mints for 8 weeks
88971895|NCT00847821||Bazedoxifene 20 mg/CE 0.45 mg|
88971896|NCT00847821||Bazedoxifene 40 mg/CE 0.45 mg|
88971897|NCT00847821||Raloxifene 60 mg|
88971898|NCT00847821||Placebo|
88971899|NCT00011531|Other|1|
88971900|NCT00011570|Other|1|
88971901|NCT00847782|Other|Blood draw (Group 1)|"Normocholesterolemic Subjects~Normal Healthy Volunteers"
88971902|NCT00847782|Other|Blood draw (Group 2)|Hypercholesterolemic Subjects
88971903|NCT00847782|Other|Blood draw (Group 3)|Hypercholesterolemic Subjects with Statin Treatment
88971904|NCT00847587|Experimental|1|Early postpartum insertion
88971905|NCT00847587|Active Comparator|2|Standard postpartum insertion
89576582|NCT05202535|Active Comparator|Conventional therapy|Patient education and counseling with diet plan.Walking 3 days15min/day for 8 weeks
89576583|NCT05201911|Experimental|Injection of I-124 AT03.|Single arm only, no placebo or comparator
89576584|NCT05201755|Other|A|"Investigators will evaluate the diameter of the basilica vein and venous flow-velocity after 5 minutes of breathing at room air. Investigators will collect basic vital parameters (heart rate, blood pressure, pulsoximetry).~Afterwards, the investigators will administer CPAP through a helmet, with the straps placed under the armpits. After 5 minutes, the investigators will collect again ultrasound data (venous diameter of basilica vein, flow-velocity) and basic vital parameters (heart rate, blood pressure, pulsoximetry).~Then the CPAP helmet will be tied to the bed and the armpit straps removed. After 5 minutes the investigators will collect ultrasound data and basic vital parameters as in the steps before (venous diameter, flow-velocity, heart rate, blood pressure, pulsoximetry). After this three steps, the protocol ends."
89576585|NCT05201755|Other|B|Same interventions and measurements as A, in different order (breathing room air, then with a CPAP helmet tied to the bed, then with a CPAP helmet fastened with armpit straps).
89576586|NCT05201755|Other|C|Same interventions and measurements as A, in different order (breathing with a CPAP fastened with armpit straps, breathing with a CPAP helmet tied to the bed and breathing at room air).
89576587|NCT05201755|Other|D|Same interventions and measurements as A, in different order (breathing with a CPAP helmet tied to the bed, breathing with a CPAP helmet fastened with armpit straps and breathing at room air).
89576588|NCT04232371|Active Comparator|New Ablation Technique|Will undergo ablation using voltage mapping and triangle of Koch propagation wave collision mapping. Ablation will be performed at or slightly above the site of wave front collision.
89576589|NCT04232371|Active Comparator|Standard Ablation Technique|Ablation performed using the traditional anatomical / electrogram guided ablation approach.
89576590|NCT05230381|Active Comparator|Continous infusion group|Infusion with 20mg/kg tranexamic acid and 5mg/kg/h tranexamic acid.
89576591|NCT05230381|Active Comparator|Single infusion group|Infusion with 20mg/kg tranexamic acid and same volume 0.9% saline.
89576592|NCT05230381|Placebo Comparator|Placebo group|Infusion with same volume of 0.9% saline.
89576593|NCT05227417|Experimental|Intervention|SMS-based intervention delivered with a web-based system, which will include weekly health check-ins, appointment reminders all delivered via SMS (text messages).
89576594|NCT05227417|No Intervention|Control|Standard of care: Those who test positive in both tests receive post-test counseling, including emotional support, and are linked to a facility for antiretroviral (ART) initiation, ideally within one week. During the 1st medical appointment after diagnosis, lab tests are requested including CD4 and viral load. In most cases, ART initiation occurs at the second medical appointment when safety lab results are available. Currently, it is not mandatory to have CD4/VL results available to start ART. It is recommended that patients have CD4 counts and viral load assessed twice during the first year. A one-month supply of ART is provided initially. If clients are adherent, ART is dispensed every 3 months by nurses who also assess adherence. Standard follow-up is performed by nurses when clients visit the center for their appointments.
89209341|NCT00875784|Active Comparator|IMITREX tablet (100mg)|IMITREX 100mg tablet followed 2 hours later by a second IMITREX 100mg tablet
89209342|NCT00875862|Active Comparator|1. 0.2% Ropivicaine perinueral infusion|Patients will receive normal standard of care post-manipulation (single-injection brachial plexus nerve block, oral analgesics, and cold therapy). They will then be randomized to 0.2% Ropivicaine attached to the perineural catheter and an infusion will be initiated. The outcome measures will be assessed by study staff on the phone and at regular visits to the surgeon's office.
89576595|NCT05157841|Experimental|Part A: EXPAREL 266 mg arm|subjects randomized to this treatment arm will receive 20 mL (266 mg) EXPAREL mixed with 10 mL saline
89576596|NCT05157841|Experimental|Part A: EXPAREL 133 mg arm|subjects randomized to this treatment arm will receive 10 mL (133 mg) EXPAREL mixed with 20 mL saline
89576597|NCT05157841|Active Comparator|Part A: Bupivacaine HCl arm|Subjects randomized to this treatment arm will receive 20 mL (50 mg) 0.25% bupivacaine HCl mixed with 10 mL saline
89576598|NCT05157841|Experimental|Part B: EXPAREL 133 mg arm OR EXPAREL 266 mg arm|Subjects randomized to this treatment arm will receive 20 mL (266 mg) EXPAREL mixed with 10 mL saline OR 10 mL (133 mg) EXPAREL mixed with 20 mL saline. Dose will be determined following interim analysis of Part A.
88971906|NCT00847548|Experimental|combined treatment|A combined treatment containing cognitive behavioral therapy addressing partner violence and cognitive behavioral therapy addressing substance abuse
88971907|NCT00847548|Active Comparator|control condition|Cognitive behavioral therapy addressing partner violence
88971908|NCT00847509|Experimental|FLT PET scan|Open label, nonrandomized, uncontrolled, single group assignment, multi-center clinical trial to evaluate [F-18] FLT as a PET imaging tool in cancer patients clinically scheduled for treatment with radiation or radiation - chemotherapy. Standard [F-18] FDG PET will be the active comparator.
89033230|NCT02917200|Experimental|MOX + DAV132 1 g bid|Moxifloxacin, 400 mg/day oad, 5 days + DAV132 1 g bid, 7 days
89576599|NCT05157841|Active Comparator|Part B: Bupivacaine HCl arm|subjects randomized to this treatment arm will receive 20 mL (50 mg) 0.25% bupivacaine HCl mixed with 10 mL saline
89576600|NCT05157217||Group 1|COVID-19 carriers who were infected with SARS-CoV-2 and healed without suffering from any respiratory complications or the need for hospitalization
89576601|NCT05157217||Group 2|COVID-19 patients who suffered from serious respiratory complications that needed hospitalization or admission to the ICU
89576602|NCT04241965|Experimental|Intervention 1|Single dose; up to 400 mg capsule; adaptive dosage determined by initial dosing from cohort 1.Potential for a matching placebo dose to be administered.
88971909|NCT00847431||STN DBS Group|PD patients with deep brain stimulators in the subthalamic nucleus. Subjects within this group will be placed into either a 1 contact group, or 2 contact group, depending on contact location requirements for this study.
88971910|NCT00847431||Control Group|PD patients without deep brain stimulator surgery, with similar symptoms to the study group.
88971911|NCT00847392|Experimental|Ultrasound|Bladder ultrasound prior to catheterization
88971912|NCT00847392|No Intervention|Standard catheterization|No ultrasound prior to bladder catheterization
88971913|NCT00847314||Group 1|
89576603|NCT04241965|Placebo Comparator|Placebo|Single dose; potential for a matching OPC-214870 dose to be administered.
89532389|NCT06286592|Experimental|Condition 3|"Condition 3 = ACT Video~*Details of the specific interventions will be selected in collaboration with the Community Advisory Board."
89532390|NCT06286592|No Intervention|No Intervention|Treatment as usual.
89576604|NCT05193643|Experimental|Sonovein Treatment|
89576605|NCT05225155||Control|Women without thrombophilia, submitted to in vitro fertilization techniques
89033231|NCT02917200|Other|CTRL|Negative control, tid, 7 days
89532391|NCT06285253|Experimental|miroliverELAP treatment|48 hour treatment with miroliverELAP
89532392|NCT06281561|Placebo Comparator|Control|Nasal spray with nomal saline before anesthesia
89532393|NCT06281561|Experimental|Dexmedetomidine|Nasal spray with dexmedetomidine before anesthesia
89532394|NCT06280833||Genetic counselor|Genetic counselor at NIH
89532395|NCT06280820||Participants with heart condition|Heart Failure
89532396|NCT06280807||Androgen Excess States|Polycystic Ovary Syndrome (PCOS);Women who meet criteria for PCOS based on NIH/ Rotterdam or other clinical criteria
89532397|NCT06280807||Congenital Adrenal Hyperplasia / Hyperandrogenism|Women who exhibit evidence of hyperandrogenism not related to Polycystic Ovarian Syndrome (PCOS); Nonclassic Congenital Adrenal Hyperplasia, Extreme hyperinsulism, Idiopathic etc.
89532398|NCT06280807||Exhibiting signs of a diagnosis of hypogonadism|for example: Bosma arrhinia microphthalmia syndrome (BAMS)
89532399|NCT06280807||Hypogonadism / Infertility|Isolated hypogonadotropic hypogonadism
89532400|NCT06280807||Hypothalamic Amenorrhea (HA) (female) Functional Hypogonadism (male)|Participants who experience secondary or primary amenorrhea, or male hypogonadism, in the setting of negative energy balance such dieting, eating disorders or exercise training
89532401|NCT06280807||Miscellaneous|Reproductive disorders not related to the above categories. (e.g., secondary to endocrine dysfunction, thyroid disorders, Cushing syndrome, pharmacotherapy, etc.)
89532402|NCT06280807||Precocious or Delayed Puberty|Participants who display clinical evidence of delayed or precocious puberty based on standard criteria.
89532403|NCT06280807||Premature Ovarian InsufficiencyPerimenopause or post-menopausal states|Women who attain menopause before age 40 years (or as defined by clinical criteria). Perimenopausal women are those typically above age 40 years and experience secondary amenorrhea/ oligomenorrhea.
89532404|NCT06280807||Weight *Overweight/Underweight|BMI below or above reference standard (Adult Reference: Asians/ Asian Americans- 18.5-22.9 kg/m2; Other races- 18.5-24.9 kg/m2*Participants may simultaneously belong to cohort of weight and any other cohort.
89532405|NCT06276036|Experimental|Identification of specific markers|Analysis of the immunological profile, Genetic analysis using next-generation sequencing (NGS) technology, Bioinformatic analysis, Functional studies.
89532406|NCT06274749|Placebo Comparator|Placebo|50% of participants
89532407|NCT06274749|Active Comparator|Urolithin A|50% of participants
89532408|NCT06274528|Experimental|Lemborexant 10 mg|Lemborexant is a capsule, taken by mouth once a night, approximately 30 minutes prior to bed for 6 months.
89532409|NCT06274528|Experimental|Lemborexant 20 mg|Lemborexant is a capsule, taken by mouth once a night, approximately 30 minutes prior to bed for 6 months.
89532410|NCT06274528|Placebo Comparator|Placebo|Placebo is in capsule form and contains an inactive substance. It is taken by mouth once a night, approximately 30 minutes prior to bed for 6 months.
89532411|NCT06274060|No Intervention|Standard of care|"The TB HIV Care programme standard of care includes full-time peer educators employed by the programme to engage women, layered PrEP promotion across prevention programmes, and refer a friend strategies, information, education and communication (IEC) materials, service user testimonials, risk reduction posters to better align young women's perception of risk, working after hours/weekends to reach young women, working with school governing bodies, and door-to-door outreach."
89532412|NCT06274060|Experimental|Case management|Participants will receive case management layered on existing standard of care.
89532413|NCT06274060|Experimental|Food vouchers|Participants will receive food vouchers layered on existing standard of care.
89532414|NCT06274060|Experimental|PrEP support buddy|Participants will receive the PrEP support buddy intervention layered on existing standard of care.
89532415|NCT06274060|Experimental|Community-based PrEP pickup points|Participants will receive the community-based PrEP pickup point intervention layered on existing standard of care.
89532416|NCT06274060|Experimental|PrEP support buddy + Community-based PrEP pickup points|Participants in this arm will receive both the PrEP support buddy and community-based PrEP pickup point interventions in combination.
89532417|NCT06274060|Experimental|Food vouchers + Community-based PrEP pickup points|Participants in this arm will receive both the food voucher and community-based PrEP pickup point interventions in combination.
89532418|NCT06274060|Experimental|Food vouchers + PrEP support buddy|Participants in this arm will receive both the food voucher and PrEP support buddy interventions in combination.
89532419|NCT06274060|Experimental|Case management + Community-based PrEP pickup points|Participants in this arm will receive both the case management and community-based PrEP pickup point interventions in combination.
89532420|NCT06274060|Experimental|Case management + PrEP support buddy|Participants in this arm will receive both the case management and PrEP support buddy interventions in combination.
89532421|NCT06274060|Experimental|Case management + Food vouchers|Participants in this arm will receive both the case management and food voucher interventions in combination.
89532422|NCT06274060|Experimental|Food voucher + PrEP support buddy + Community-based PrEP pickup points|Participants in this arm will receive the food voucher, PrEP support buddy, and community-based PrEP pickup point interventions in combination.
89532423|NCT06274060|Experimental|Case management + PrEP support buddy + Community-based PrEP pickup points|Participants in this arm will receive the case management, PrEP support buddy, and community-based PrEP pickup point interventions in combination.
89532424|NCT06274060|Experimental|Case management + Food vouchers + Community-based PrEP pickup points|Participants in this arm will receive the case management, food vouchers, and community-based PrEP pickup point interventions in combination.
89532425|NCT06274060|Experimental|Case management + Food vouchers + PrEP support buddy|Participants in this arm will receive the case management, food vouchers, and PrEP support buddy interventions in combination.
89576606|NCT05225155||Untreated Thrombophilia|Women with laboratorial thrombophilia, submitted to in vitro fertilization techniques, without treatment with enoxaparin
89576607|NCT05225155||Treated Thrombophilia|Women with laboratorial thrombophilia, submitted to in vitro fertilization techniques, and treated with enoxaparin
89576608|NCT05192239|Placebo Comparator|Placebo|Delta-9-tetrahydrocannabinol (THC) free fruit snack gummy. One time, two gummies will be ingested prior to an exercise bout.
89576609|NCT05192239|Active Comparator|10 mg THC|Delta-9-tetrahydrocannabinol (THC) 5 milligrams (mg) in gummy form. One time, two gummies will be ingested prior to an exercise bout.
89576610|NCT05190445|Experimental|Cinrebafusp alfa (PRS-343) in combination with ramucirumab and paclitaxel|Patients aged 18 years or older with HER2-positive gastric or GEJ adenocarcinoma who have progressed on prior treatment with a regimen containing a platinum and fluoropyrimidine and a HER2-directed therapy such as trastuzumab and now are candidates for treatment with ramucirumab and paclitaxel
88971914|NCT00011999|Experimental|Surgery, chemotherapy and radiation therapy|Early post-operative paclitaxel followed by paclitaxel and cisplatin concurrent with radiation therapy for resected head and neck cancer.
89576611|NCT05190445|Experimental|Cinrebafusp alfa (PRS-343) in combination with tucatinib|Patients aged 18 years or older with HER2 low (IHC 1+ or IHC 2+ without HER2/neu amplification) gastric or GEJ adenocarcinoma who have received at least one prior treatment regimen
89576612|NCT05149417|Placebo Comparator|Standard group|Patients enrolled in this group were discharged and they didn't undergo any intervention within the treatment period.
89576613|NCT05149417|Active Comparator|SMS group|patients received SMS at day 2 , day 4 and day 7 after emergency departement discharge to remind them to take their treatment .
89576614|NCT05149417|Active Comparator|telemonitoring group|Patients received a phone call on day 2 and day 4 to evaluate the adherence , to detect any problem that can affect the adherence to the treatment and modify the analgesic protocol treatment if needed.
89576615|NCT05148949|Experimental|Investigational vaccine group 1|100 tuberculosis patients will receive two doses of standard dosage CoronaVac plus one dose of double dosage CoronaVac at a schedule of 0, 28, 56 days.
89576616|NCT05148949|Experimental|Investigational vaccine group 2|100 tuberculosis patients will receive two doses of standard dosage CoronaVac plus one dose of standard dosage CoronaVac at a schedule of 0, 28, 56 days.
89576617|NCT05148949|Active Comparator|Standard regimen group|40 healthy subjects will receive two doses of standard dosage CoronaVac at a schedule of 0, 28 days.
89576618|NCT04422067||Case group (Retrognatism)|All pregnant patients with one or more fetuses suffering from a microretrognathia, diagnosed prenatally and integrated into a Pierre Robin Sequence, were included. All cases were confirmed postnatally, either by a pediatric examination or by a fetopathological examination in the case of a medical termination of the pregnancy. We had 21 cases.
89576619|NCT04422067||Control group|47 pregnant patients with fetus without facial abnormalities
89576620|NCT04422301|Experimental|High intensity eccentric training|"High intensity eccentric training high intensity (80% isometric peak) eccentric training of the knee extensors in the isokinetic will be performed during 6 weeks, 3 times a week.~eccentric exercise with blood flow restriction High/low intensity eccentric training group (80% and 40% of isometric peak torque) with or not blood flow restriction."
89576621|NCT04422301|Experimental|High intensity eccentric training with blood flow restriction|High intensity eccentric training with blood flow restriction high intensity (80% isometric peak) eccentric training of the knee extensors in the isokinetic associated with a pressure cuff placed in the proximal thigh (40% of absolute occlusion pressure) will be performed during 6 weeks, 3 times a week. eccentric exercise with blood flow restriction High/low intensity eccentric training group (80% and 40% of isometric peak torque) with or not blood flow restriction
89576622|NCT04422301|Experimental|Low intensity eccentric training|A low intensity (40% isometric peak) eccentric training of the knee extensors in the isokinetic will be performed during 6 weeks, 3 times a week. eccentric exercise with blood flow restriction High/low intensity eccentric training group (80% and 40% of isometric peak torque) with or not blood flow restriction.
89576623|NCT04422301|Experimental|Low intensity eccentric training with blood flow restriction|A low intensity (40% isometric peak) eccentric training of the knee extensors in the isokinetic associated with a pressure cuff placed in the proximal thigh (40% of absolute occlusion pressure)will be performed during 6 weeks, 3 times a week. eccentric exercise with blood flow restriction High/low intensity eccentric training group (80% and 40% of isometric peak torque) with or not blood flow restriction.
89576624|NCT05107999|Experimental|Zhizhu Kuanzhong（ZZKZ） group|Patients in ZZKZ group were given ZZKZ (2 capsules tid) plus omeprazole (20 mg bid). ZZKZ was applied after each meal. Omeprazole was applied twice daily, before breakfast and supper.
89576625|NCT05107999|Active Comparator|Doxepin group|Patients in doxepin group were given doxepin (25 mg tid) plus omeprazole (20 mg bid). Doxepin was applied after each meal. Omeprazole was applied twice daily, before breakfast and supper.
88971915|NCT00847275|Placebo Comparator|1|"Exclusive nephrology follow-up arm"
88971916|NCT00847275|Experimental|2|"Geriatric follow-up arm"
88971917|NCT00847236||Subjects with Polymyalgia Rheumatica|50 subjects with Polymyalgia Rheumatica, both acute and chronic
88971918|NCT00847236||Subjects w/o Polymyalgia Rheumatica|50 subjects with Rheumatic Disease other than polymyalgia Rheumatica
88971919|NCT00847236||Subjects w/o Rheumatic Disease|50-Non Rheumatic disease subjects
89576626|NCT05146921|Active Comparator|food supplement: multi-strain probiotic (Symprove)|70 ml daily for 12 weeks
89576627|NCT05146921|Placebo Comparator|Placebo|70 ml daily for 12 weeks
89576628|NCT05186545|Experimental|Experimental|surufatinib + fulvestrant + chidamide
89576629|NCT05107765|Experimental|Pioglitazone|
89576630|NCT05107765|Placebo Comparator|Placebo|
89576631|NCT05146141|Experimental|Intervention Group|The participants will have to perform a bent-arm throw program 5 minutes before each training session
89576632|NCT05146141|Sham Comparator|Control group|No intervention. They will perform their usual warm-up.
89576633|NCT05106985|Experimental|ApplTree Reminder app|Following a randomised baseline period, each participant will use the ApplTree reminder app for 22 days to support adherence to goal-related tasks
89576634|NCT04421833|Active Comparator|group starting with TOVERTAFEL activities|Participants will benefit from TOVERTAFEL activities for 6 weeks then the usual animation techniques for 6 weeks with a week of wash-out between the two periods.
89576635|NCT04421833|Sham Comparator|group ending with TOVERTAFEL activities|Participants will benefit from the usual animation techniques for 6 weeks then from TOVERTAFEL activities for 6 weeks with a week of wash-out between the two periods.
89576636|NCT05106283|Active Comparator|Deep Serratus Anterior Plane Block|Following the visualization of the anatomical structures, the nerve block needle will be advanced via the in-plane technique beneath the serratus anterior muscles until the interfascial space was reached. After hydrodissection with 2 ml normal saline, 20 ml 0.25% bupivacaine will be injected into the area.
89576637|NCT05106283|Active Comparator|Deep and Superficial Serratus Anterior Plane Block|In patients who are planned to have combined deep and superficial serratus anterior plane block, following the visualization of the anatomical structures, the nerve block needle will be advanced via the in-plane technique beneath the serratus anterior muscles until the interfascial space was reached. After hydrodissection with 2 ml normal saline, 10 ml 0.25% bupivacaine will be injected into the area. Then, with the same needle, will be returned 1-2 cm from the deep serratus anteror area to superficial serratus anteror area above the serratus anterior muscle and will be injected 2 ml normal saline for hydrodissection. Finally 10 ml of 0.25% bupivacaine will be injected for superficial serratus anetrior block into the interfacial area.
89576638|NCT05184205|Experimental|Active Intervention|The procedure is initiated by swabbing the Formulation Applicator, pre-saturated with photosensitizer formulation, inside the patient's nares. The operator then connects the Nasal Light Illuminator (NLI) to the Light Source and inserts the NLIs into the patient's nostrils. The Light Source is turned on, and a 4-minute illumination cycle provides two channels of diffused red light (one for each nostril) to activate the applied formulation. Illumination stops automatically upon completion of the 4-minute cycle. The process is then repeated using two new Formulation Applicators to ensure full disinfection coverage.
89576639|NCT05184205|Sham Comparator|Sham Comparator: Control|Sham comparator
89576640|NCT05183581|Other|Visually aroused erection (naked, clothing, blankets)|"Randomisation of the order of visually aroused erection will be conducted:~Naked - Naked & Blanket - Clothing & Blanket~Naked - Clothing & Blanket - Naked & Blanket~Naked & Blanket - Naked - Clothing & Blanket~Naked & Blanket - Clothing & Blanket - Naked~Clothing & Blanket - Naked - Naked & Blanket~Clothing & Blanket - Naked & Blanket - Naked"
89576641|NCT05183347|Experimental|SRD: Dose Group 1|SRD: single-rising dose
89576642|NCT05183347|Experimental|SRD: Dose Group 2|SRD: single-rising dose
89576643|NCT05183347|Experimental|SRD: Dose Group 3|SRD: single-rising dose
89576644|NCT05183347|Experimental|MD: Dose Group 4|MD: multiple doses
89576645|NCT05183347|Placebo Comparator|Placebo|
89576646|NCT05182411||Patients with spasticity|adult neurological patients with spasticities in their lower extremities
89576647|NCT05102851||Patient with acute coronary syndrome|All patients with the acute coronary syndrome were included in the study. Pre-diabetic patient. Non-diabetic patient(Controlled)
89576648|NCT01656967|Experimental|AMBU Aura-I/aScope 2|First, the AMBU Aura-I LMA will be inserted. Then, the patient will be intubated with assistance of the AMBU aScope 2 disposable fiberoptic system.
89576649|NCT01656967|Experimental|LMA Fastrach|The LMA Fastrach Single Use Laryngeal Mask Airway will be placed, followed by blind intubation using the LMA Fastrach EndoTracheal Tube.
89576650|NCT05180539|Experimental|SPLASH Intervention Condition|
89576651|NCT05180539|Other|Diet and Physical Activity Condition|
89576652|NCT05100589|Experimental|PeakATP|PeakATP formula dissolved in 8 ounces water, taken 30 minutes before breakfast on an empty stomach, or within 30 minutes of waking.
89576653|NCT05100589|Placebo Comparator|Placebo|Placebo formula (same as experimental with no PeakATP) dissolved in 8 ounces water, taken 30 minutes before breakfast on an empty stomach, or within 30 minutes of waking.
89576654|NCT05142397||Treated women|HPV positive，pathology result indicate cervical intraepithelial neoplasia
89576655|NCT05142397||Healthy controls|HPV negative, normal cytology
89576656|NCT05142007|Experimental|Hypnosis|"The first treatment arm (targeted suggestion) consist of suggestions about enhancing working memory functions through the instantiation of preinjury working memory ability in the present using age regression, visualizations of neuroplasticity in the present, and posthypnotic suggestions about continued improvement. The overarching theme of the suggestions is that thinking itself will become effortless and reliable, leading to reduced fatigue, better memory, and the absence of information overload."
89576657|NCT05142007|Active Comparator|Mindfulness-based stress reduction|"The second treatment arm (non-targeted suggestion or MBSR) contains no explicit mentioning of brain injury or working memory-related abilities and thus serves to isolate the 'targetedness' of suggestion as well as factoring out other influences from placebo, retest effects, etc."
89576658|NCT05142007|No Intervention|Control group|The (passive) control group receives no contact over and beyond testing.
89576659|NCT05141695|Experimental|therapeutic group|therapeutic repetitive peripheral magnetic stimulation
89576660|NCT05141695|Sham Comparator|sham group|sham repetitive peripheral magnetic stimulation
89576661|NCT05141071|Experimental|Ivabradine|In the study group, Ivabradine(I) group; patients will receive an enteral Ivabradine (dissolved in distilled water) 5mg twice daily (every 12 hours) via a naso-gastric tube.
89576662|NCT05141071|Placebo Comparator|Placebo|the control group, Placebo (P) group; patients will receive 50 ml of saline twice daily also via a naso-gastric tube.
89576663|NCT01656889|Experimental|HP802-247|HP802-247 (fibrinogen solution & thrombin solution containing living, irradiated, growth arrested keratinocytes and fibroblasts) 260 µL (130 µL, one spray, of each solution) containing 0.5 x 106 cells per mL every 14 days.
88971920|NCT00847158|Active Comparator|1|phacoemulsification alone
88971921|NCT00847158|Active Comparator|2|phacoemulsification and implantation of the iStent® trabecular micro-bypass stent
88971922|NCT00012116|Experimental|temozolomide|Administered in a fasting state, once a day for 6 weeks followed by 4 weeks of rest. Cycles may be repeated every 10 weeks until patients have evidence of progressive disease, intolerable toxicity or unwillingness to continue therapy. Daily dose: 75mg/m2.
89033232|NCT05318144||PCR (-) symptomatic|control group, pregnant women with negative COVID-19 Polymerase Chain Reaction (PCR) test
89209343|NCT00875862|Placebo Comparator|2. Normal Saline perineural infusion|Patients will receive normal standard of care post-manipulation (single-injection brachial plexus nerve block, oral analgesics, and cold therapy). They will then be randomized to normal saline attached to the perineural catheter and an infusion will be initiated. The outcome measures will be assessed by study staff on the phone and at regular visits to the surgeon's office.
89576664|NCT01656889|Placebo Comparator|Vehicle|Vehicle Control (fibrinogen solution & thrombin solution without cells)
89576665|NCT05097001|Experimental|Computer|Programming based on computer-guided assessment
89576666|NCT05097001|Active Comparator|CLINICAL|Programming based on clinically-guided assessment
89576667|NCT05139745|Experimental|Histological evaluation of BTL-899 device´s effect on fat tissue|This group will be treated with 100% of the treatment parameter settings
89576668|NCT05139745|Sham Comparator|Sham treatment|This group will be treated with 5% of the treatment parameter settings
89576669|NCT04229329|Experimental|Intervention|The patient hand will be restrained to a robotic arm AMADEO(TM) which enables the measurement and manipulation of forces at each finger individually. After appropriate calibration, the force measurements obtained from the robot will be used to move a cursor on the screen. The patient will be rewarded visually and auditory when a higher degree of finger individuation will be measured. Specifically, when the applied force of the instructed fingers hit the predefined force target and at the same, the force in the non-instructed fingers stay as low as possible
89576670|NCT04229329|Sham Comparator|Control|The patient hand will be restrained to a robotic arm AMADEO(TM) which enables the measurement and manipulation of forces at each finger individually. After appropriate calibration, the force measurements obtained from the robot will be used to move a cursor on the screen. The patient will be rewarded in a way that is unrelated to the degree of individuation. In other words, a successful trial considered when the applied force of the instructed fingers hits the predefined force target regardless of the force exerted in the non-instructed fingers.
89576671|NCT05094427||Lumbar spine surgery with preoperative fluoroscopically-guided DR block|Patients who have undergone lumbar spine surgery with a fluoroscopically-guided DR block placed by the operative neurosurgeon prior to surgery. These patients subsequently received standard of care general anesthesia and standard multimodality postoperative pain control.
89576672|NCT05094427||Lumbar spine surgery without preoperative fluoroscopically-guided DR block|Patients who have undergone lumbar spine surgery without placement of a fluoroscopically-guided DR block. These patients received standard of care general anesthesia and standard multimodality postoperative pain control.
89576673|NCT05092711||in patients with coronary heart disease and COVID 19|
89576674|NCT05176405|Experimental|Elissa's EE Song|Participants will have to click on the watch button to start the YouTube video as it is without manipulation. Right after exposure, the first and second arms will be asked if they have seen either of the presented materials before.
89576675|NCT05176405|Active Comparator|Standard of Care|Participants will be assigned to read general infographic messages adopted from the Saudi Ministry of Health (MOH) in the breast cancer early screening context in Arabic/English. Right after exposure, the first and second arms will be asked if they have seen either of the presented materials before.
89576676|NCT05176405|No Intervention|Control Group|The third arm of this trial is the control group who will not be exposed to any preventative messages.
89576677|NCT05175781|Active Comparator|Dexmedetomidine|"patients will receive two NIV sessions during which intravenous continuous infusion of dexmedetomidine will be given.~The infusion was initiated 60 min prior to NIV at the same rate for all treatments, corresponding to 0.7 mcg/kg/h of dexmedetomidine without a loading dose. Dexmedetomidine will then titrate by 0.2 mcg/kg/h every 60 min (up to a maximum dose of 1.3 mcg/kg/h) to maintain a RASS score between 0 and 3. A 6-h washout period was observed between two NIV sessions accounting for 1-h contextual half-life of dexmedetomidine. Patients received neither tested drug nor NIV during this 6-h interval."
89576678|NCT05175781|Active Comparator|Ketamine|"patients will receive two NIV sessions during which intravenous continuous infusion of ketamine will be given.~The infusion was initiated 60 min prior to NIV at the same rate for all treatments, infusion of ketamine will be at the dose of 0.20 mg/kg/h (or 3.3 mg/kg/min). to maintain a RASS score between 0 and 3. A 6-h washout period was observed between two NIV sessions . Patients received neither tested drug nor NIV during this 6-h interval.~Following the start of the infusion, the patient could have a morphine dose if the 10-cm Visual Analog Scale (VAS) exceeded 3."
89576679|NCT05175781|Placebo Comparator|Placebo|"patients will receive two NIV sessions during which intravenous continuous infusion of placebo (0.9% sodium chloride solution) will be given.~The infusion was initiated 60 min prior to NIV at the same rate for all treatments, corresponding to 0.7 mcg/kg/h of dexmedetomidine without a loading dose. will then titrate by 0.2 mcg/kg/h every 60 min (up to a maximum dose of 1.3 mcg/kg/h) to maintain a RASS score between 0 and 3. A 6-h washout period was observed between two . Patients received neither tested drug nor NIV during this 6-h interval.~Following the start of any infusion, the patient could have a morphine dose if the 10-cm Visual Analog Scale (VAS) exceeded 3."
89576680|NCT04421911|Experimental|ketoprofen|
89576681|NCT04421911|Active Comparator|Diclofenac|
89576682|NCT04422223||Cohort|Patients newly diagnosed with liver cirrhosis form the Gastro Unit, Amager Hvidovre Hospital, Denmark. All patients with clinically verified diagnosis, irrepsective of disease stage and etiology is included.
89576683|NCT05173753|Active Comparator|Novel self-adhesive composite restoration (Surefil one)|
89576684|NCT05173753|Active Comparator|conventional composite resin restoration(VOCO Grandio)|
89209344|NCT00882492|Active Comparator|1|This active arm is a continuous infusion of GLP-1 during cardiac surgery
89576685|NCT04226209|Experimental|PSSE|Physiotherapeutic Scoliosis-Specific Exercises PSSE group will receive corrective exercise for scoliosis
89576686|NCT04226209|No Intervention|Control|Control group will be taken to the queue list.
89209345|NCT00882492|Placebo Comparator|2|This is a continuous infusion of normal saline solution infusion as placebo at (1.5 pmol/kg/min)
89209346|NCT04038450||Practicing Physical Therapists|licensed physical therapists currently practicing
89209347|NCT04038450||Student Physical Therapists|students currently enrolled in DPT program
89576687|NCT05173207||Cardiothoracic surgical patients|Subjects will undergo one simultaneous instrumental examination of swallowing and concurrent monitoring of metrics of respiratory-swallow physiology. Research exam will be performed at bedside within Cardiac & Thoracic Intensive Care Units during their early postoperative recovery.
89576688|NCT05173129|Experimental|Haemophilic boys|Adolescent boys with haemophilia
89576689|NCT05173129|Active Comparator|Healthy boys|Healthy adolescent boys
89576690|NCT05172349|Experimental|LV-Visio-AMTRIX|Sutureless amniotic membrane supported by a biological ring positioned by the investigator during patients' hospital visits.
89576691|NCT05133973|Experimental|Cohort A|"Subjects will wear 3 FiberSense systems (2x arm and 1x abdomen) and one comparator. The subjects will participate in six clinic in-house sessions on Day 00, 3x between days 01-07, on Days 21 and 28. There will be safety visit at Day 14.~Finger pricking at home use will be intensified during days 00-07."
89576692|NCT05133973|Experimental|Cohort B|"Subjects will wear 3 FiberSense systems (2x arm and 1x abdomen) and one comparator. The subjects will participate in six clinic in-house sessions on Day 00, 4x between days 07-14 and on Day 28. There will be safety visit at Day 21.~Finger pricking at home use will be intensified during days 07-14."
89576693|NCT05133817|Placebo Comparator|Control group|Simultaneous with spinal anesthesia, 500 mL 6% Hydroxyethyl starch (130/0.4) coload was given and a maintenance dose of normal saline by IV infusion.
89576694|NCT05133817|Experimental|0.025 μg/kg/min group|Simultaneous with spinal anesthesia, 500 mL 6% Hydroxyethyl starch (130/0.4) coload was given and a maintenance dose of norepinephrine (0.025 μg/kg/min) by IV infusion.
89576695|NCT05133817|Experimental|0.05 μg/kg/min group|Simultaneous with spinal anesthesia, 500 mL 6% Hydroxyethyl starch (130/0.4) coload was given and a maintenance dose of norepinephrine (0.05 μg/kg/min) by IV infusion.
88971923|NCT00847119|Experimental|Bevacizumab & capecitabine & radiotheraphy|"Bevacizumab 4 cycles each 15 days, the first 10 mg/kg and the rest of cycles with 5 mg/kg.~Radiotherapy 45 Gy starting on Bevacizumab 2nd cycle during 5 weeks, 1.8 Gy per day, 5 days at week.~Capecitabine 900 mg/m2 two times a day concomitant during radiotherapy period."
88971924|NCT00847080|Experimental|Sitagliptin|
88971925|NCT00847080|Placebo Comparator|Placebo|
89576696|NCT05133817|Experimental|0.075 μg/kg/min group|Simultaneous with spinal anesthesia, 500 mL 6% Hydroxyethyl starch (130/0.4) coload was given and a maintenance dose of norepinephrine (0.075 μg/kg/min) by IV infusion.
89576697|NCT05133817|Experimental|0.1μg/kg/min group|Simultaneous with spinal anesthesia, 500 mL 6% Hydroxyethyl starch (130/0.4) coload was given and a maintenance dose of norepinephrine (0.1μg/kg/min) by IV infusion.
89576698|NCT05172193|Experimental|SARS-COV-2 Vaccine (Vero Cell-Sinopharm) Inactivated|One booster dose 0.5 mL IM injection of SARS-COV-2 Vaccine (Vero Cell) Inactivated
89576699|NCT05171335|Experimental|Lenvatinib in Combination with TACE Prior to Liver Transplantation|Regimen of six months neoadjuvant lenvatinib in combination with TACE prior to liver transplantation in patients with hepatocellular carcinoma (HCC) beyond Milan Criteria.
88971926|NCT00012194|Experimental|Treatment (7-hydroxystaurosporine, cisplatin)|Patients receive cisplatin IV over 1 hour on day 1 and UCN-01 IV continuously over 36-72 hours on day 2. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
88971927|NCT01818323|Experimental|Intra-tumoral T4 immunotherapy|Treatment arms comprise escalating doses of T4 immunotherapy, administered alone or in combination with lymph-depleting chemotherapy
88971928|NCT00847002|Active Comparator|Standard Wound Care|Gentle wound ulcer cleansing with saline solution at each visit, maintaining moisture balance in the wound and periwound with appropriate dressings (e.g Acticoat, Aquacel Ag, or Mepilex Ag foam dressings), reminding subjects of importance of proper nutrition, leg elevation at rest and activity, including frequent ambulation and ankle range of motion exercises through the day. The FarrowWrap Classic device is applied over the dressing to achieve suitable compression pressures as an important component of the standard treatment.
88971929|NCT00847002|Active Comparator|Flexitouch system with Standard Wound Care|In addition to standard wound care, patients who have been randomized to this group will be provided a home Flexitouch unit. They will be given instructions to use it on a twice daily basis (FarrowWrap will be removed during the time they are using Flexitouch). The Flexitouch System works by applying dynamic low-pressure compression to the trunk and affected limbs using gentle, rhythmic massage action.
88971930|NCT00012350|Experimental|Oral FTI (R115777) Treatment|"Patients will be administered oral FTI (R115777) at a dose of 300-mg by mouth (PO) twice a day (BID). Drug will be taken without regard to meals.~The study regimen will consist of 3 weeks of treatment followed by one week off for a total cycle duration of 4 weeks."
88971931|NCT00846963|Experimental|Ursodiol|Participants assigned in this arm receive an ursodiol suspension at 20mg/ml.
88971932|NCT00846963|Placebo Comparator|placebo|A placebo suspension that looks like the ursodiol suspension used.
88971933|NCT00846924|Active Comparator|repeat 24-hour Holter monitor|
88971934|NCT00846924|Experimental|30-day ambulatory cardiac event monitor|
88971935|NCT00846885|Experimental|1|
88971936|NCT00846885|Active Comparator|2|
88971937|NCT00846690|Active Comparator|Benzocaine|"serves as active control"
88971938|NCT00846690|Experimental|TAC|serves as comparator
88971939|NCT00012623||Group 1|
88971940|NCT00846651|Experimental|colloid, then phenylephrine infusion|colloid administration; with 0.5 L Hydroxyethylstarch solution at a rate of 17 ml/min and completed over 30 min. A phenylephrine infusion will be started immediately after performing the spinal anesthesia and continued until time of uterine incision.
88971941|NCT00846651|Active Comparator|crystalloid, then phenylephrine infusion|crystalloid administration; The patients received 1.5 L Ringer's lactate infusion at a rate of 50 ml/min and completed over 30 min prior to spinal anesthesia for cesarean section. A phenylephrine infusion will be started immediately after performing the spinal anesthesia and continued until time of uterine incision.
88971942|NCT00012662|Other|Arm 1|
88971943|NCT00846612|Experimental|Avastin-Doxil|
88971944|NCT00012701||Group 1|
89029233|NCT03749499|No Intervention|Usual Care|Participants randomized to usual care will receive preprinted discharge instructions on HTN and a 48-72-hour referral to our FQHC (or other community health center if pre-assigned though Illinois Medicaid) to schedule their follow-up appointment (current standard of care)
89576700|NCT05171335|Other|Matched Historical Control Patients|Historical controls will be liver transplant recipients matched on age, etiology of liver disease (viral vs. non-viral), listing tumor size, and number of TACE procedures to cases in the intervention group who receive a transplant.
89576701|NCT02522299|Experimental|GSK2269557 1000 microgram (mcg)|Subjects will receive 2 inhalations of GSK2269557 (30 seconds apart, 2 x 500 mcg, total dose of 1000 mcg) once daily for 84 consecutive days via DISKUS™ device.
89576702|NCT02522299|Placebo Comparator|Placebo via DISKUS|Subjects will receive 2 inhalations of placebo once daily for 84 days via DISKUS device.
89576703|NCT02522299|Experimental|GSK2269557 700 mcg|Subjects will receive 2 inhalations of GSK2269557 700 mcg once daily for 84 consecutive days via ELLIPTA.
88971945|NCT00846573|Experimental|Asthmatic Participants|This population is made up of only confirmed asthmatics. Participants will inhale Hyperpolarized Helium-3: Participants will be required to breath in individual 1 liter bags of gas while in an MRI to produce lung images. These bags of gas are each made up of 333mL of Helium-3 gas and 667mL of Nitrogen. Three bags will be administered to acquire three different scans.
88971946|NCT00846573|Experimental|Healthy|"This population is made up of subjects who are considered clinically healthy. This means that there are no records of any chronic disorders or pulmonary history.~Participants will inhale Hyperpolarized Helium-3: Participants will be required to breath in individual 1 liter bags of gas while in an MRI to produce lung images. These bags of gas are each made up of 333mL of Helium-3 gas and 667mL of Nitrogen. Three bags will be administered to acquire three different scans."
88971947|NCT00846573|Experimental|COPD Patients|"This population is made up of only confirmed COPD patients. Diagnosis must be confirmed through their doctor prior to enrollment.~Participants will inhale Hyperpolarized Helium-3: Participants will be required to breath in individual 1 liter bags of gas while in an MRI to produce lung images. These bags of gas are each made up of 333mL of Helium-3 gas and 667mL of Nitrogen. Three bags will be administered to acquire three different scans."
88971948|NCT00846573|Experimental|Cystic Fibrosis Patients|"This population is made up entirely of confirmed cystic fibrosis patients. Diagnosis must be confirmed through their physician.~Participants will inhale Hyperpolarized Helium-3: Participants will be required to breath in individual 1 liter bags of gas while in an MRI to produce lung images. These bags of gas are each made up of 333mL of Helium-3 gas and 667mL of Nitrogen. Three bags will be administered to acquire three different scans."
89576704|NCT02522299|Placebo Comparator|Placebo via ELLIPTA|Subjects will receive Placebo once daily for 84 consecutive days via ELLIPTA.
89576705|NCT05170945|No Intervention|Retrospective Cohort|Colonoscopy was performed, either early bowel preparation, late bowel preparation or no bowel preparation patients.
89576706|NCT05170945|Experimental|Prospective Cohort|Early bowel preparation for colonoscopy patients
89576707|NCT05130307|Experimental|Treatment Order 1|Treatment order 1: Low Tech (less interactive) Virtual Reality for 1st pain stimulus+ High Tech for 2nd pain stimulus
89576708|NCT05130307|Active Comparator|Treatment Order 2|Treatment order 2: High Tech VR (more interactive) for 1st pain stimulus + Low Tech for 2nd pain stimulus.
89576709|NCT01365091|Experimental|Arm 1: Treatments A,B/B,A|"Period 1: Participants received a single oral dose of saxagliptin, 5 mg/metformin, 500 mg fixed-dose combination (FDC) in the fasted state (Treatment A), followed by a washout period of at least 7 days. Then, participants received single oral doses of saxagliptin, 5-mg, and metformin extended-release (XR), 500-mg, tablets together in the fasted state (Treatment B). Followed by a washout period of at least 4 days.~Period 2: Participants received single oral doses of saxagliptin, 5-mg and metformin XR, 500-mg tablets together in the fasted state (Treatment B), followed by a washout period of at least 7 days. Then, participants received a single oral dose of saxagliptin, 5 mg/metformin, 500 mg FDC, in the fasted state (Treatment A)."
89576710|NCT01365091|Experimental|Arm 2: Treatments C,D/D,C|"Period 1: Participants received a single oral dose of saxagliptin, 5 mg/metformin, 500 mg fixed-dose combination (FDC), in the fed state (Treatment C), followed by a washout period of at least 7 days. Then, participants received a single oral dose of saxagliptin, 5-mg, and metformin extended-release (XR), 500-mg tablets together in the fed state (Treatment D). Followed by a washout period of at least 4 days.~Period 2: Participants received a single oral dose of saxagliptin, 5-mg and metforminXR, 500-mg tablets together in the fed state (Treatment D), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5 mg/metformin, 500 mg FDC, in the fed state (Treatment C)."
88971949|NCT00012740|Other|Arm 1|
88971950|NCT00846534||Post operative atrial fibrillation|To evaluate the ability of oxidative stress markers to predict postoperative atrial fibrillation in subjects undergoing cardiac surgery.
88971951|NCT00012779|Other|Arm 1|
88971952|NCT00394017|Active Comparator|Intervention group|Reminder letters and usual implementations vs. usual implementation
88971953|NCT00394017|No Intervention|Control group|usual implementations
88971954|NCT00012818|Other|Arm 1|
88971955|NCT00012857|Other|Arm 1|
88971956|NCT00394056|Other|Period 1|
88971957|NCT00394056|Other|Period 2|
88971958|NCT00394056|Other|Period 3|
88971959|NCT00012896|Other|Arm 1|
88971960|NCT00846417||Case|Patients with ICDs who attend the ICD Support Groups.
88971961|NCT00846417||Control|Patients with ICDs who do not attend the ICD support groups.
88971962|NCT00012935|Other|Arm 1|
88971963|NCT00846378|Experimental|Post conditioning|After 30 seconds of re-established coronary flow following the therapeutic balloon dilatation and deflation, the same balloon will be re-inflated for 30 seconds and then again deflated for 30 seconds. The balloon should be inflated to only occlude the coronary artery. This procedure of balloon inflation/deflation will be performed a total of 3 to 4 times.
89033233|NCT05318144||PCR (+) asymptomatic|Pregnant women who have a positive COVID-19 PCR test and have had the infection without symptoms
89209348|NCT00731549|Experimental|1|Active Treatment of aripiprazole IM depot (300mg or 400mg)
89029234|NCT03749499|Active Comparator|Educational and Empowerment Intervention|"Participants receive:~HTN Educational Video about high BP, how it is diagnosed, and importance of treatment to prevent secondary complications.~Visual Echocardiogram Image Clips of age/gender-matched echocardiograms will be used to educate and motivate patients to change behavior and improve their BP.~Mobile Health and Remote BP monitoring- participants receive an FDA-approved home blood pressure monitoring (HBPM) kit that includes the Nokia wireless BPM+ monitor and Health Mate mobile app. The app automatically launches when the patient slips on the cuff. Synced data are automatically uploaded from the mobile app to the iCardia server of our study.~A Post-Acute Care HTN Transition consultation (PACHT-c) with a clinical pharmacist or advanced practice nurse (APN)."
89029235|NCT03744871|Active Comparator|Respirator|Open label use of N95 respirators (worn outdoors) (active limb, n=100)
89029236|NCT03744871|No Intervention|No intervention|No respirators will be worn by the control group (control limb, n=100)
89029237|NCT03735212|Experimental|Program Group|Participants in this group receive enhanced services as the intervention. These services include Motivational Enhancement, Incredible Years, and Contingency Management. Participants also receive case management services to support referrals to substance use.
89029238|NCT03735212|No Intervention|Control Group|Participants in this group receive services as usual.
89029239|NCT03733067|Experimental|abatacept|Adult and pediatric dosing will be based on weight per protocol
89029240|NCT03733067|Placebo Comparator|placebo|will be given as the same IV volume as abatacept
89029241|NCT03711929|Experimental|Test Arm: DE-109 Injectable Solution|Intravitreal injection of DE-109 440 µg in the study eye(s) every 2 months (Day 1, Month 2, and Month 4).
89029242|NCT03711929|Sham Comparator|Control Arm: Sham Procedure|Sham procedure administered to the study eye(s) every 2 months (Day 1, Month 2, and Month 4). The sham procedure mimics an intravitreal injection without penetrating the eye.
89029243|NCT03711929|Other|Dummy Arm: DE-109 Injectable Solution|Dummy Arm: Intravitreal injection of DE-109 at an undisclosed, fixed dose (within the range of 44 µg to 880 µg) in the study eye(s) every 2 months (Day 1, Month 2, and Month 4).
89576711|NCT01365091|Experimental|Arm 3: Treatments E, F/F,E|"Period 1: Participants received a single oral dose of saxagliptin, 5 mg/metformin, 1000 mg fixed-dose combination (FDC), in the fasted state (Treatment E), followed by a washout period of at least 7 days. Participants received single oral doses of saxagliptin, 5-mg and metformin extended-release (XR), 1000-mg tablets together in the fasted state (Treatment F). Followed by a washout period of at least 4 days.~Period 2: Participants received single oral doses of saxagliptin, 5- mg and metformin XR, 1000-mg tablets together in the fasted state (Treatment F), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5 mg/metformin, 1000 mg FDC, in the fasted state (Treatment E)."
89576712|NCT01365091|Experimental|Arm 4: Treatments G,H/H,G|"Period 1: Participants received a single oral dose of saxagliptin , 5 mg/metformin, 1000 mg fixed-dose combination (FDC), in the fed state (Treatment G), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5-mg and metformin extended-release (XR), 1000-mg tablets together in the fed state (Treatment H). Followed by a washout period of at least 4 days.~Period 2: Participants received a single oral dose of saxagliptin, 5-mg and metformin XR, 1000-mg tablets together in the fed state (Treatment H), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5 mg/metformin, 1000 mg FDC, in the fed state (Treatment G)."
89576713|NCT05082571|Experimental|Vadadustat|Cohort 1: participants with ≥12 years to <17 years; Cohort 2: participants with ≥6 years to <12 years; Cohort 3(a): participants with ≥2 years to <6 years; and Cohort 3(b): participants with ≥4 months to <2 years
89029244|NCT03711929|Experimental|Open-label:DE-109 Injectable Solution|Subjects completing the Month 6 pre-dose evaluations (the final evaluations in the double-masked period) began the open-label period of the study, in which all subjects received intravitreal injection of DE-109 440 μg in the study eye(s) every 2 months for an additional 6 months of dosing.
89029245|NCT03697980||HVAD Left Ventricular Assist Device|"Device: HeartWare Ventricular Assist Device~Other Names:~HVAD The HVAD is an implantable centrifugal rotary blood pump that is implanted in the pericardial space and is designed to provide up to 10 L/min of blood flow from the left ventricular to the aorta. The HVAD System is comprised of three major components: the HVAD (pump) with inflow and outflow conduits, a Controller (microprocessor unit that controls the operation of the HVAD), and power sources (AC and DC power adapters that provide power to the Controller and implanted HVAD)."
89576714|NCT04422145|Active Comparator|Interventional/intensive|Participants received a structured nurse led education programme surrounding hypoglycaemia. They were encouraged to use self monitoring of blood glucose (SMBG) and had their diabetes medications adjusted according to this. They also received information on how to avoid hypoglycaemia (including the effects of diet, exercise, alcohol and their medications) and how to treat hypoglycaemia should it occur.
89029246|NCT03664895|No Intervention|observation arm(TMX, MDR≥5%)|keep go on TMX
89029247|NCT03664895|No Intervention|control arm(TMX, MDR<5%)|keep go on TMX
89029248|NCT03664895|Active Comparator|OFS add arm(TMX + OFS, MDR<5%)|OFS add on to TMX
89029249|NCT03658395|Active Comparator|LSCP Only|A Y-shaped polypropylene mesh graft, 10 cm in standard length and tailored to each patient's anatomic specifications during surgery, is used utilizing robot-assisted Laparoscopic Sacrocolopopexy.
89029250|NCT03658395|Active Comparator|LSCP + PR|"The Laparoscopic Sacrocolopopexy involves a Y-shaped polypropylene mesh graft, 10 cm in standard length and tailored to each patient's anatomic specifications during surgery, utilizing robot-assisted Laparoscopic Sacrocolopopexy.~In addition, patients will receive posterior repair. Posterior repair is performed by midline fascial plication. Plication of superficial perineal muscles (perineorrhaphy) is performed in conjunction with posterior repair. All repairs are performed using polydioxanone 2/0 for fascial repair and 4/0 polyglactin suture for skin closure."
89029251|NCT03631420|Experimental|UMC119-01|UMC119-01 is ex vivo cultured human umbilical cord tissue-derived mensenchymal stem cells product
89029252|NCT03599544|Active Comparator|Robot-Assisted Therapy (RT)|Armeo & Amadeo robot-assisted intensive upper limb therapy 1 hour sessions 3x week for 6 weeks.
89033234|NCT05318144||PCR (+) mild-moderate|Pregnant women with positive COVID-19 PCR test and mild to moderate symptoms and inpatient treatment
89033235|NCT05318144||PCR (+) severe COVID-19|Pregnant women with positive COVID-19 PCR test and severe symptoms
89033236|NCT05319275|Experimental|Acetyllevocarnitine Hydrochloride Tablets|
89576715|NCT04422145|Placebo Comparator|Standard|Participants returned to their standard diabetes care provider with no intervention.
89576716|NCT04422145|No Intervention|Observational|Participants were happy to have baseline characteristics collected and be followed up using electronic records in a longitudinal fashion but did not wish to be randomized. The observational and standard groups therefore received the same diabetes care.
89576717|NCT05081869|Experimental|Online Yoga Based Exercise Program|A 50-minute online exercise program consisting of 5 categories will be created. The program will last 8 weeks, twice a week. In the first category, 20-30 seconds of stretching was applied to iliopsoas, hamstring, adductor, tensor fascia lata, piriformis, quadratus lumborum, quadriceps femoris and gastrocnemius muscles. In the second category, stabilization and pelvic mobilization exercises will be applied to the core muscles. Each exercise will be performed in 3 sets of 10 repetitions. In the third category, strengthening exercises will be done for the gluteal muscles, abdominal muscles, erector spine, quadriceps femoris and latissimus dorsi. Each exercise will be performed as 10 repetitions and 3 sets. In the fourth category, 3 sets and 10 repetitions of kegel exercises will be done. minute diaphragmatic breathing will be applied.
89576718|NCT05081869|Sham Comparator|Education Program|The informative training was given to both group members individually and online. In the training program; The female reproductive system organs, the structure of the pelvis, the location and functions of the pelvic floor muscles, the definition and physiology of menstruation, the types and risk factors of dysmenorrhea, the definition and symptoms of primary dysmenorrhea, treatment methods for coping with pain in primary dysmenorrhea were mentioned.
89576719|NCT05053711|Experimental|rTMS+rPMS_iTBS_M|In this group, they received iTBS on affected hemisphere after following iTBS at median nerve on affected hand.
89576720|NCT05053711|Experimental|rTMS+rPMS_cTBS_M|In this group, they received iTBS on affected hemisphere after following cTBS at median nerve on affected hand.
89576721|NCT05053711|Sham Comparator|rTMS+sham rPMS_M|In this group, they received iTBS on affected hemisphere after following sham TBS stimulation at median nerve on affected hand.
89576722|NCT05053711|Experimental|rTMS+rPMS_iTBS_U|In this group, they received iTBS on affected hemisphere after following iTBS at ulnar nerve on affected hand.
89576723|NCT05053711|Experimental|rTMS+rPMS_cTBS_U|In this group, they received iTBS on affected hemisphere after following cTBS at ulnar nerve on affected hand.
89576724|NCT05053711|Sham Comparator|rTMS+sham rPMS_U|In this group, they received iTBS on affected hemisphere after following sham TBS stimulation at ulnar nerve on affected hand.
89576725|NCT04421287|Experimental|Zhenyuan capsule|
89576726|NCT04421287|Placebo Comparator|Zhenyuan capsule placebo|
89576727|NCT03824275|Experimental|18F- DCFPyL PET/CT|Upon enrollment, subjects will undergo standard of care imaging (defined as a CT or MRI of the chest, abdomen, and pelvis, and 99mTc bone scans) if not obtained within 45 days of enrollment. Subjects will have standard of care laboratory evaluations including complete blood count (CBC), serum chemistries, hepatic panel, lactate dehydrogenase (LDH), and PSA. Liquid biopsies for circulating tumor DNA (ctDNA) and exosome analysis will occur at the same time. Subjects will then undergo 18F- DCFPyL PET/CT.
89576728|NCT05126329|Experimental|Participants with mild hepatic impairment|Amcenestrant 200 mg single dose on Day 1 in fed condition
89576729|NCT05126329|Experimental|Participants with moderate hepatic impairment|Amcenestrant 200 mg single dose on Day 1 in fed condition
89576730|NCT05126329|Experimental|Participants with normal hepatic function|Amcenestrant 200 mg single dose on Day 1 in fed condition
89576731|NCT05053165|Experimental|A (LB-P6)|Healthy volunteers will be administered once daily orally
89576732|NCT05053165|Experimental|B (LB-P8)|Healthy volunteers will be administered once daily orally
89576733|NCT05053165|Experimental|C (Placebo)|Healthy volunteers will be administered once daily orally
89576734|NCT05079763|Experimental|Experimental arm|Application of bacterial cellulose-monolaurin hydrogel in the prescribed area for every 12 hours starting from receipt of first radiotherapy until development of moist desquamation or two week after completion of radiotherapy plan
89576735|NCT05079763|Placebo Comparator|Placebo Arm|Application of placebo cream in the prescribed area for every 12 hours starting from receipt of first radiotherapy until development of moist desquamation or two week after completion of radiotherapy plan
89576736|NCT04421521|Experimental|Acupuncture Group|
89576737|NCT04421521|No Intervention|Standard Therapy Group|
89576738|NCT05050981||Hormone Therapy|Women using hormone replacement therapy (estrogen only or oestrogen and progestin) for treating climacteric symptoms.
89576739|NCT05050981||Selective Serotonin Reuptake Inhibitors|Women using selective serotonin reuptake inhibitors for treating climacteric symptoms.
89033237|NCT05319275|Placebo Comparator|Placebo|
89576740|NCT05050981||Control Group|Women not using hormone replacement therapy or selective serotonin reuptake inhibitors
89576741|NCT05078983||HIGH RISK|HIGH RISK MEANS PATIENTS HAVE ASA SCORE OVER 2
89576742|NCT05078983||LOW RISK|LOW RISK MEANS PATIENTS HAVE ASA SCORE BELOW 3
89576743|NCT05050903||Asthma|
89576744|NCT05050903||Healthy controls|
89576745|NCT05049889|Active Comparator|History of Immersion Pulmonary Edema|"The participants will have 2 visits:~At visit 1 (Day 0), the participants will perform a terrestrial exercise, have a transthoracic cardiac ultrasound, a transthoracic pulmonary ultrasound and several blood samples will be collected.~At visit 2 (Day 7), the participants will perform a swimming exercise, have a transthoracic cardiac ultrasound, a transthoracic pulmonary ultrasound and several blood samples will be collected."
89033238|NCT02920515|Experimental|GnRHa(Triptorlin or Leuprorelin)|Triptorlin or Leuprelin 100ug/kg per 28 days
89576746|NCT05049889|Active Comparator|No history of Immersion Pulmonary Edema|"The participants will have 2 visits:~At visit 1 (Day 0), the participants will perform a terrestrial exercise, have a transthoracic cardiac ultrasound, a transthoracic pulmonary ultrasound and several blood samples will be collected.~At visit 2 (Day 7), the participants will perform a swimming exercise, have a transthoracic cardiac ultrasound, a transthoracic pulmonary ultrasound and several blood samples will be collected."
89576747|NCT04421599|Experimental|Experimental Group A|Experimental Group A who were administered intramuscular injection during which aspiration lasted for 5-10 seconds.
89576748|NCT04421599|No Intervention|Control Group|Control Group who were administered intramuscular injection during which aspiration lasted for 1-2 seconds.
88971964|NCT00846378|Active Comparator|Usual Care|Usual care for treatment of thrombolysis in myocardial infarction (TIMI) 0 to TIMI 1 flow in occluded infarct related artery. Usual care includes reperfusion of the artery per operator discretion, i.e. primary stenting, thrombectomy, balloon inflation/deflation without timed intervals.
88971965|NCT00012974|Other|Arm 1|
88971966|NCT00846339|Experimental|1|DRD2 Taq1A1 allele
88971967|NCT00846339|Experimental|2|DRD Taq1 A2 homozygote2
88971968|NCT00013013|Other|Arm 1|
88971969|NCT00013052|Other|Arm 1|
88971970|NCT00846261|Experimental|Ilzarov|
88971971|NCT00013091|Other|Arm 1|
88971972|NCT00013130|Other|Arm 1|
88971973|NCT00846222|Experimental|Mild theraputic hypothermia|
89576749|NCT04421599|Experimental|Experimental Group B|Experimental Group B who were not administered aspiration during IM injection.
88971974|NCT00013169|Other|Arm 1|
88971975|NCT00846183|Active Comparator|local ingury|In one group, on the day of oocyte retrieval, local injury to endometrium with a Novak curet to anterior and posterior wall of endometrium are performed.
88971976|NCT00846183|No Intervention|control|in 60 patients routine IVF are performed
88971977|NCT00013208|Other|Arm 1|
88971978|NCT01790360|Active Comparator|Patient Navigation (PN)|Behavioral Intervention: 'Patient Navigation (PN) Intervention' participants will receive support from navigators in choosing a provider and remembering to attend appointments
88971979|NCT01790360|Experimental|Financial Incentives (FI)|Behavioral Intervention: 'Financial Incentives (FI) Intervention' participants will receive gift cards and money for attending clinic visits
88971980|NCT00846105|Experimental|Rapid PCR screen|Rapid PCR screen test for detection of MRSA carriers upon hospital admission
88971981|NCT00846105|Active Comparator|Conventional culture|Conventional culture screen for detection of MRSA carriers upon hospital admission
89576750|NCT05074459|Experimental|Eptinezumab Mammalian Cell Line|Participants will receive a single intravenous (IV) infusion of eptinezumab mammalian cell line on Day 1.
89576751|NCT05074459|Active Comparator|Eptinezumab Yeast Cell Line|Participants will receive a single IV infusion of eptinezumab yeast cell line on Day 1.
89576752|NCT05120557|Experimental|Main arm|Main study arm
89576753|NCT05120011|Experimental|carnitine + leucine|1000 mg L-carnitine with 3000 mg L-leucine per day for 24 weeks
89576754|NCT05120011|Placebo Comparator|leucine|4000 mg L-leucine per day for 24 weeks
89576755|NCT05043259|Active Comparator|Inactivated vaccine group|Subjects who have been vaccinated with two doses of inactivated SARS-CoV-2 vaccine will receive one dose of inactivated SARS-CoV-2 vaccine
89576756|NCT05043259|Experimental|Low dose aerosolized Ad5-nCoV group|Subjects who have been vaccinated with two doses of inactivated SARS-CoV-2 vaccine will receive one dose of the low dose of aerosolized Ad5-nCoV.
89576757|NCT05043259|Experimental|High dose aerosolized Ad5-nCoV group|Subjects who have been vaccinated with two doses of inactivated SARS-CoV-2 vaccine will receive one dose of the high dose of aerosolized Ad5-nCoV.
89576758|NCT05071495|Experimental|Intervention group|
89576759|NCT05071495|No Intervention|Control group|
89576760|NCT05069311|Experimental|Hysterectomy|Patients who undergo surgical hysterectomy that fits inclusion and exclusion criteria
89576761|NCT05036863||Patients with multiple myeloma|
89576762|NCT05065645|Active Comparator|APN01|Angiotensin Converting Enzyme 2: 1.25 mg/ml, 2.5 mg/ml or 5 mg/ml
89576763|NCT05065645|Placebo Comparator|NaCl|Sodium Chloride: 0.9% NaCl solution
88971982|NCT00013247|Other|Arm 1|
88971983|NCT00846066|Experimental|Hands on Training|Hands on Training by a pediatric dentist
89576764|NCT01364467|Placebo Comparator|Placebo|Placebo is provided by the sponsor and is identical in composition to the treatment only lacking active drug.
88971984|NCT00846066|Active Comparator|Web Based Training|Web Based Training for all residents before randomization
88971985|NCT00845988|Active Comparator|treatment as usual|patients showing weight gain while receiving treatment with risperidone, olanzapine, quetiapine, or clozapine
89576765|NCT01364467|Active Comparator|Guaifenesin|
88971986|NCT00845988|Experimental|switch to aripiprazole|aripiprazole
88971987|NCT00845910|Experimental|1|
88971988|NCT00778206||1. PKUDOS Registry|Patients with a confirmed diagnosis of Phenylketonuria (PKU) with hyperphenylalaninemia who have either received Kuvan therapy, or currently receive Kuvan therapy, or intend to begin receiving Kuvan therapy within 90 days of entering the registry.
88971989|NCT00778206||2. PKU MOMS Subregistry|Patients with PKU who are pregnant at enrollment in the registry or who become pregnant while participating in the registry.
88971990|NCT00013481|Other|1|
88971991|NCT00680628|Placebo Comparator|2|Saline + Enoxaparin
88971992|NCT00680628|Experimental|1|Tenecteplase + Enoxaparin
89209349|NCT00875940||Group 1|Patients having both Tc-99m perfusion scan and echocardiogram.
89576766|NCT05470387|Experimental|LB1148|
89576767|NCT05470387|Placebo Comparator|Placebo|
89576768|NCT05468125|Active Comparator|care bundle|will be subjected to a bundle of care of four elements
89576769|NCT05468125|Active Comparator|best-evidenced practice|will be guided according to the best-evidenced performance consisting of three elements
89576770|NCT05033899|Experimental|group E: ERAS group|36 non-insulin dependent diabetic patients will undergo lumbar decompression surgery following ERAS protocol.
89576771|NCT05033899|No Intervention|group C: conventional group|conventional perioperative care.
89576772|NCT05110417|Experimental|Pyridostigmine (Mestinon)|Pyridostigmine (Mestinon) will be assigned to patients in this arm.
89576773|NCT02520661|No Intervention|Usual Care|Older adults discharged from an ED to home who receive the usual processes and services.
89576774|NCT02520661|Active Comparator|Care Transitions Intervention|Older adults discharged from an ED to home who receive the Care Transitions Intervention.
89576775|NCT05109871|Experimental|Kforce Link|
89576776|NCT05031481|Experimental|VENUS 20 + 0,064|Venus association vaginal cream, single dose.
89576777|NCT05031481|Experimental|VENUS 20 + 1|Venus association vaginal cream, single dose.
89576778|NCT05031481|Experimental|VENUS 20 + 4|Venus association vaginal cream, single dose.
88971993|NCT00394134|Other|Interview|Interviews to describe the sun exposure and sun protection practices of patients and their children.
88971994|NCT04711746|Experimental|Previous proximal unprovoked pulmonary embolism|
88971995|NCT04711746|Active Comparator|Previous proximal provoked pulmonary embolism|
88971996|NCT02972177|Experimental|Radiofrequency ablation group|Patients with inoperable peripheral lung tumor will be performed transbronchial radiofrequency ablation with the guidance of navigation bronchoscopy. Post treatment response will be evaluated and follow up will be carried out according to the standard procedure.
88971997|NCT02972177|Experimental|Microwave ablation group|Patients with inoperable peripheral lung tumor will be performed transbronchial microwave ablation with the guidance of navigation bronchoscopy. Post treatment response will be evaluated and follow up will be carried out according to the standard procedure.
89576779|NCT05031481|Active Comparator|Butoconazole nitrate 100 mg|Butoconazole nitrate vaginal cream, single-dose containing 100 mg.
89576780|NCT05061121|Experimental|sustained natural apophyseal glides|Investigate the short- and mid-term effects of Mulligan's SNAGs on pain intensity, pain pressure sensitivity, cervical function, range of motion (ROM) and postural stability in CNSNP patients
89576781|NCT05061121|Experimental|Myofascial release|Investigate the short- and mid-term effects of Myofascial release on pain intensity, pain pressure sensitivity, cervical function, range of motion (ROM) and postural stability in CNSNP patients
89576782|NCT05061121|Experimental|sustained natural apophyseal glides in addition to myofascial release|Investigate the short- and mid-term effects of Mulligan's SNAGs combined with Myofascial release on pain intensity, pain pressure sensitivity, cervical function, range of motion (ROM) and postural stability in CNSNP patients
89576783|NCT05109559|Experimental|Ad26.COV2.S given at the interval ≥ 90 days after completing 2 doses of either Sinovac or Sinopharm|"Study Part A is a prospective, multi-center, Phase 2 study to assess a booster dose (3rd dose) of Ad26.COV2.S as an IM injection in the deltoid muscle in adults who have completed the two-dose homologous primary series of inactivated vaccine of Sinovac or Sinopharm, 21 to 35 days apart and who meet eligibility criteria.~In study part A1, a total of 360 adult volunteers aged 18 years or older, will receive the full-dose (5x10^10 vp) of the study product, at later (90 days or more) time interval since the 2nd dose and followed from Visit 1 (V1) to Visit 7 (V7) at 336 days."
89576784|NCT05109559|Experimental|Ad26.COV2.S given at 45-75 days after completing 2 doses of either Sinovac or Sinopharm|"Study Part A is a prospective, multi-center, Phase 2 study to assess a booster dose (3rd dose) of Ad26.COV2.S as an IM injection in the deltoid muscle in adults who have completed the two-dose homologous primary series of inactivated vaccine of Sinovac or Sinopharm, 21 to 35 days apart and who meet eligibility criteria.~In study part A2, a total of 110 adult volunteers aged 18 years or older, will receive the full-dose (5x10^10 vp) of the study product, at early (45-75 days) time interval since the 2nd dose and followed from Visit 1 (V1) to Visit 7 (V7) at 336 days."
89576785|NCT05109559|Experimental|Half dose of Ad26.COV2.S given ≥ 90 days after completing 2 doses of either Sinovac or Sinopharm|"Study Part A is a prospective, multi-center, Phase 2 study to assess a booster dose (3rd dose) of Ad26.COV2.S as an IM injection in the deltoid muscle in adults who have completed the two-dose homologous primary series of inactivated vaccine of Sinovac or Sinopharm, 21 to 35 days apart and who meet eligibility criteria.~In study part A3, a total of 110 adult volunteers aged 18 years or older, will receive the half-dose (2.5x10^10 vp) of the study product, at later (90 days or more) time interval since the 2nd dose and followed from Visit 1 (V1) to Visit 7 (V7) at 336 days."
89576786|NCT05109559|Experimental|Ad26.COV2.S given 28 days after receiving 1 dose of either Sinovac or Sinopharm|Study Part B is a prospective, multi-center, open-label Phase 1/2 heterologous prime-boost study to assess the Ad26.COV2.S (full dose 5x10^10 vp) as the 2nd vaccination in subjects who are documented to all have received the 1st dose of Sinovac or all received the 1st dose of Sinopharm COVID-19 vaccine, with an interval of 28 days +/- 3 days, followed from Visit 1 (V1) to Visit 7 (V7) at 336 days.
89576787|NCT05031247|Experimental|Community Navigator Social Support|More intensive case management and weekly check-ins with older adults. The Community Navigator will be focused on increasing social contact and connection for older adult refugees and immigrants. Those who receive the intervention will be offered up to ten (30-minute-long) meetings with a Community Navigator and access to up to three group sessions over a 3-month period, alongside the standard services they receive for enrollment with the organization.
89576788|NCT05031247|No Intervention|Program Support as Usual|Standard program support will be provided to participants enrolled. These services are offered to all enrolled in the program and may include, but is not limited to the following: financial assistance services, case management, healthcare access services, employment and tax services, education services, citizenship and immigration services, community services and civic engagement, and refugee services.
89576789|NCT04218097||Addict patients|"Obese type 2 and 3 with food addict according to the Yale Food Addiction Scale (YFAS) questionnaire.~Cohort design: identification of patients treated in hospital for obesity assessment over the period 1 January 2017 to 1 January 2018 whose addictive or non-addictive status was characterised by the YFAS questionnaire. To talk about food addiction, the person must have at least 3 out of 7 positive criteria AND also meet the marked suffering criterion."
89576790|NCT04218097||Control patients|"Obese type 2 and 3, non food addict Cohort design: identification of patients treated in hospital for obesity assessment over the period 1 January 2017 to 1 January 2018 whose addictive or non-addictive status was characterised by the YFAS questionnaire. To talk about food addiction, the person must have at least 3 out of 7 positive criteria AND also meet the marked suffering criterion."
89576791|NCT05057767|Experimental|Pre-induction Group (I)|will receive intravenous midazolam premedication 2mg in a volume of 3 ml, 15 minutes before induction of anesthesia
89576792|NCT05057767|Experimental|Pre-extubation Group (II)|will receive intravenous midazolam 2mg in a volume of 3 ml 30 minutes before extubation at the end of surgery
89576793|NCT05057767|Placebo Comparator|Control Group (III)|will receive 3 ml normal saline 15 minutes before induction of anesthesia plus 3 ml normal saline 30 minutes before extubation at the end of surgery.
88971998|NCT00276978|Experimental|Aripiprazole|Aripiprazol augmentation therapy
89209350|NCT00882570|Experimental|1|Cefdinir 250 mg/5 ml Oral Suspension (Sandoz, Austria)
89576794|NCT04997317|Active Comparator|Phase 0: Group A|"Cycle 1: 4.5 GBq 177Lu-DOTA-JR11 (300-1300 μg) will be administered once intravenously.~Cycle 2: 4.5 GBq 177Lu-DOTATOC (≈200 μg) will be administered once intravenously (following a cross-over design).~Cycle 3 and Cycle 4 will be performed for group A patients with 7.4 GBq 177Lu-DOTATOC (clinically established amount of activity). Cycle 3 and 4 are standard of care (i.e. not part of the study)."
89576795|NCT04997317|Active Comparator|Phase 0: Group B|"Cycle 1: 4.5 GBq 177Lu-DOTATOC (≈200 μg) will be administered once intravenously.~Cycle 2: 4.5 GBq 177Lu-DOTA-JR11 (300-1300 μg) will be administered once intravenously (following a cross-over design).~Cycle 3 and Cycle 4 will be performed for group B patients with 7.4 GBq 177Lu-DOTATOC (clinically established amount of activity). Cycle 3 and 4 are standard of care (i.e. not part of the study)."
89576796|NCT04997317|Active Comparator|Phase I/II|3 cycles of 177Lu-DOTA-JR11 will be administered with an activity of 4.5-7.4 GBq. Two additional 177Lu-DOTA-JR11 treatment cycles can be performed if clinically indicated
89576797|NCT04997239|Experimental|Experimental Group ：Vaccine-unprimed subjects with two doses|200 vaccine-unprimed children will receive two doses of quadrivalent influenza vaccine on the immunization schedule of day 0,28.
89576798|NCT04997239|Experimental|Experimental Group ：Vaccine-unprimed subjects with one dose|200 vaccine-unprimed children will receive one dose of quadrivalent influenza vaccine.
89576799|NCT04997239|Experimental|Experimental Group：Vaccine-primed subjects with one dose|200 vaccine-primed children will receive one dose of quadrivalent influenza vaccine.
89576800|NCT04216693|Experimental|Digoxin tablet|Patients will be given digoxin orally daily for 24 weeks. The initial dose will be selected with the goal of achieving a serum digoxin concentration of 0.7-1 ng/ml, a dose range recommended for heart failure patients. A dose of 0.0625, 0.125 or 0.25 mg daily will be selected based on a normogram.
89576801|NCT04216693|Placebo Comparator|Placebo|Digoxin-like oral placebo
89576802|NCT05057611|Active Comparator|Usual Care Group (UC)|- Patients allocated to the usual care group will be managed by the clinical staff according to usual practice at their sites including decisions about hemodynamic and perfusion monitoring, and all treatments, but should follow general recommendations of the Surviving Sepsis Campaign to avoid extremes of clinical practice. This includes basic hemodynamic targets such as a MAP >65 mmHg, HR (heart rate) <120 beats per minute (BPM), arterial oxygen saturation (SaO2) >94%, Hb > 7 gr/dl, and the use of NE as the first vasopressor and crystalloids as the fluid of choice.
89576803|NCT05057611|Experimental|Capillary-refill time and phenotyping group|"Patients w/normal baseline CRT will be periodically monitored. Patients with abnormal CRT and septic shock will be categorized according to pulse pressure (PP). If <40 mmHg, will go to fluid responsiveness (FR) assessment. FR (-) patients will undergo cardiac echo to rule out significant dysfunction. Fluid boluses will be administered in 30 min intervals and repeated as needed if CRT is still abnormal. Patients with PP ≥40 mmHg will proceed according to diastolic pressure (DAP). If ≥50 mmHg will move to FR assessment. If <50 mmHg NE will be increased for MAP >65 mmHg and DAP ≥50 mmHg w/CRT assessed 1 h after. NE will be increased in 0.1 mcg/k/m increments up to 0.5 mcg/k/m.~If CRT is normal, patients will proceed to periodic monitoring. Patients with persistent abnormal CRT or that reached NE safety limit will proceed directly to echo.~Patients that correct CRT with first tier interventions will not be subjected to obligatory echo but will just proceed to periodic monitoring."
89576804|NCT01364389|Experimental|ACZ885|On day 1, patients received a single intravenous dose of ACZ885 3mg/kg along with a placebo intravenous infusion in a double dummy manner to maintain the blind. On day 15, partial and complete responders continued in the open label phase of this treatment arm where they were eligible to receive one re-dose of ACZ885 upon confirmed disease flare. Non-responders started a 20 mg dose cycle of prednisone or prednisolone followed by standard steroid tapering.
89576805|NCT01364389|Experimental|AIN457|On day 1, patients received a single intravenous dose of AIN457 3mg/kg along with a placebo intravenous infusion in a double dummy manner to maintain the blind. On day 15, partial and complete responders continued in the open label phase of this treatment arm where they were eligible to receive one re-dose of AIN457 upon confirmed disease flare. Non-responders started a 20 mg dose cycle of prednisone or prednisolone followed by standard steroid tapering.
89576806|NCT01364389|Other|Prednisone|On day 1, patients received daily oral doses of prednisone 20 mg along with daily oral placebo doses to in a double-dummy manner to maintain the blind. On day 15, partial and complete responders continued in the study and tapered their steroid treatment according to standard care. Non-responders were discontinued from the study.
89576807|NCT05027737|Experimental|Early Ileostomy Closure|Following a negative leak test (CT scan with rectally-administered water-soluble contrast on post-operative day 7, 8 or 9), patients will undergo standardized reversal of their diverting loop ileostomy (stapled side-side functional end-to end anastomosis, purse-string closure of the ileostomy wound, and no use of epidural analgesia) between post-operative days 10-14.
89576808|NCT05027737|No Intervention|Traditional closure (control)|Following a negative leak test (CT scan with rectally-administered water-soluble contrast on post-operative day 7, 8 or 9), patients will undergo a standardized reversal of their diverting loop ileostomy. The latter will be performed with a stapled side-side functional end-to end anastomosis, purse-string closure of the ileostomy wound, and no use of epidural analgesia and will be performed no earlier than 12 weeks following their index surgery.
89576809|NCT05054881|Other|Sciatic nerve block under ultrasound control with a electrostimulator peripheral nerves|Patients undergoing surgery on the knee, shin, ankle or foot
89576810|NCT05054881|Other|Sciatic nerve block under ultrasound control without a electrostimulator peripheral nerves|Patients undergoing surgery on the knee, shin, ankle or foot
89576811|NCT04950283||Magnetic resonance examination and anthropometric, metabolic characterization|
88971999|NCT00276939|Experimental|1|Low-fat, low-Glycemic Index, vegan diet
88972000|NCT00276939|Active Comparator|2|ADA diet
88972001|NCT00276783|Experimental|Treatment Arm|Pemetrexed 900 mg/m2 every 21 days until disease progression.
88972002|NCT00276627|Active Comparator|communication lecture|
89209351|NCT00882570|Active Comparator|2|Omnicef 250 mg/5 ml Oral Suspension of Cefdinir (Abbot Laboratories, USA)
89209352|NCT00885456|Experimental|PREVENT program|12-week program of exercise and education to induce physiological and behavioral changes needed to reduce vascular risk factors.
88972003|NCT00276627|Experimental|lecture plus CD-ROM|
88972004|NCT00014144|Experimental|ZD 1839|
88972005|NCT00276549|Experimental|Gemcitabine and Docetaxel i|
88972006|NCT00276510|Experimental|1|
88972007|NCT00276510|Placebo Comparator|2|
88972008|NCT00014378|Experimental|Chinese Herb Huanglian (Coptis chinesis)|
89576812|NCT04949425|Experimental|Patients with advanced solid tumours|Patients with advanced solid tumours will receive Adavosertib once daily for 5 days followed by 2 days off for 2 weeks out of a 21-day cycle.
89576813|NCT05023525|Experimental|HSK31858, single dose|5 cohorts with single doses starting with 5 mg HSK31858 as tablet.
89576814|NCT05023525|Placebo Comparator|Placebe, single dose|5 cohorts with matching placebo to HSK31858 as tablet.
89576815|NCT05022589|Experimental|Experimental Treatment|Computerized plasticity-based adaptive cognitive training requiring a total maximum of 50 treatment sessions, 5 sessions per week, ~30 minutes per session.
89576816|NCT04421209|Experimental|Propranolol treatment|"Subjects randomized to the propranolol treatment arm will be administered propranolol 40mg BID for three days prior to surgery, 40mg BID the day of surgery and on post-operative days 1 and 2. Subjects and researchers will be blinded and will not know if propranolol or placebo control is administered.~Patients will be evaluated for opioid usend pain scores at 24 hrs, 48 hrs, 1 week, 4 weeks, and 12 weeks post-op.~Blood will also be obtained pre-operatively, 8 hours and 24 hours post-operatively to measure the level of inflammatory markers. We will use these samples to evaluate if treatment with propranolol decreases the levels of inflammatory markers, and if this correlates to decreased opioid use and pain scores post-operatively.~All other pre-, intra-, and post-operative interventions will be equivalent between the experimental and placebo groups, and this study's interventions will not affect surgical management."
89576817|NCT04421209|Placebo Comparator|Placebo|"Subjects randomized to the placebo treatment arm will be administered placebo tablets with the same schedule as propranolol in the experimental arm. Subjects and researchers will be blinded and will not know if propranolol or placebo control is administered.~Patients will be evaluated for opioid use and pain scores at 24 hrs, 48 hrs, 1 week, 4 weeks, and 12 weeks post-op.~Blood will also be obtained pre-operatively, 8 hours and 24 hours post-operatively to measure the level of inflammatory markers. We will use these samples to evaluate if treatment with propranolol decreases the levels of inflammatory markers compared to placebo, and if this correlates to decreased opioid use and pain scores post-operatively.~All other pre-, intra-, and post-operative interventions will be equivalent between the experimental and placebo groups, and this study's interventions will not affect surgical management."
89576818|NCT04986397|Experimental|Cold Therapy & Standard Post Operative Analgesia|Patients in the cryotherapy group will have the ice water in their cryotherapy device maintained continuously for 2 days from initial application as this is the reported time of average patient disability and children typically return to school by post-operative day 3. The device will not be placed directly on the skin to minimize tissue damage. An additional protective barrier pad included with the cold therapy device will provide a barrier between the skin and the cooling device. This allows for continuous cooling at a higher target skin temperature. Aside from the cryotherapy, all surgical treatment will be standard of care.
89576819|NCT04986397|Active Comparator|Standard Post Operative Analgesia|
89576820|NCT04944199|No Intervention|Control Group|
89576821|NCT04944199|Active Comparator|Intervention Group|
89576822|NCT01364233|Other|MotifMesh|Condensed polytetrafluoroethylene (cPTFE, MotifMESH) mesh
89576823|NCT04985539||PD de novo|Observational.
89576824|NCT05014945|Experimental|Atelocollagen group|After obtaining informed consent for the study, epidural nerve block was performed. The patient is asked to return to the outpatient clinic of the pain center after 2 weeks. At this time, when the NRS of back pain does not improve by more than 50% compared to before the epidural nerve block and the cross-sectional area of the multifidus muscle using ultrasound is 5 cm2 or less, final enrollment is decided. The evaluation of the cross-sectional area and thickness of the multifidus muscle using ultrasound is performed with the patient prone, and the cross-sectional area of the multifidus muscle is measured at the same position as the level of the lesion on MRI.
88972009|NCT00014534|Active Comparator|Gemcitabine + cisplatin|
88972010|NCT00014534|Active Comparator|Gemcitabine + Doxorubicin + Pegfilgrastim|
88972011|NCT00014612|Active Comparator|axillary lymph node dissection|complete axillary lymph node dissection
88972012|NCT00014612|Experimental|axillary radiotherapy|axillary radiotherapy, daily for 5 days a week, for 5 weeks
88972013|NCT00394173|Experimental|1|
88972014|NCT00394173|Placebo Comparator|2|
88972015|NCT02971904||Human milk collection|Lactating mothers should have enough milk to provide enough maternal milk their preterm infant(s) require plus additional collection of samples (3mL). After consenting to the study, milk from lactating mothers of preterm infants in the local ICU will be analyzed daily from the moment they express sufficient milk volume beyond their child's requirement until discharge (from 4th day of admission until 15th day of hospitalization ). Three mL of sample milk will be collected every morning and analyzed, according to hospital routine. Personal details of mothers and their infants will be collected by applying a questionnaire on the first day of analysis. The nutritional composition of the last meal before the milk sample collection and also a nutrition questionnaire intake will be evaluated.
88972016|NCT00394290|Experimental|PPC|Night time device for positive pulmonary pressure
88972017|NCT00276198|Experimental|1|Supplementation with daily sprinkle package
88972018|NCT00276198|Active Comparator|2|Supplementation with Iron tonic 15mg, vitamins A 300 micrograms, vitamin D 10 micrograms. According to Ministry of Health routine recommendations.
88972019|NCT00276198|No Intervention|3|No intervention except for checking outcomes at approprite times.
88972020|NCT00391703|Experimental|1|Quadriceps electrostimulation program, performed prior to an endurance retraining program using a cycloergometer
88972021|NCT00391703|Active Comparator|2|Usual sport activity, performed prior to an endurance retraining program using a cycloergometer
88972022|NCT00275613|Experimental|Rituximab, IV infusion|The Rituximab dose is 1000 mg (1 gm) given as an IV infusion every two weeks for 2 doses (days 1 and 15)
88972023|NCT00275574|Experimental|acupuncture|four acupuncture treatments over a period of two weeks
89532426|NCT06274060|Experimental|Case management + Food vouchers + PrEP support buddy + Community-based PrEP pickup points|Participants in this arm will receive the case management, food vouchers, PrEP support buddy, and community-based PrEP pickup point interventions in combination.
89532427|NCT06273800|Other|Blood sample|Collection of serum blood sample at day of start neo adjuvant treatment
89532428|NCT06269744|Experimental|Proactive Screening Outreach|Participants assigned to the interventional arm will receive proactive outreach of mailed Fecal Immunochemical Tests (FIT) to screen for colorectal cancer.
88972024|NCT00275535|Active Comparator|Tacrolimus|Calcineurin inhibitor arm, consisting of treatment with tacrolimus, mycophenolate mofetil, and prednisone.
88972025|NCT00275535|Active Comparator|Sirolimus|Calcineurin inhibitor-free arm, consisting of treatment with rapamycin, mycophenolate mofetil, and prednisone.
88972026|NCT00275496|Active Comparator|WEX only|
88972027|NCT00275496|Active Comparator|WEX + SLND|
88972028|NCT00275496|Active Comparator|WEX+SLND+CLND|
89532429|NCT06269744|No Intervention|Standard of Care|Participants assigned to the standard of care group will receive usual care (i.e., opportunistic screening for colorectal cancer).
89532430|NCT06269653||Healthy Individuals: 20 - 29 years of age|Age group: 20 -29 (3 men and 3 women)
89532431|NCT06269653||Healthy Individuals: 30 - 39 year of age|Age group: 30 - 39 (3 men and 3 women)
89532432|NCT06269653||Healthy Individuals: 40 - 49 years of age|Age group 40 - 49 (3 men and 3 women)
89532433|NCT06269653||Healthy Individuals: 50 - 59 years of age|Age group: 50 - 59 (3 men and 3 women)
89532434|NCT06269653||Healthy Individuals: 60 - 69 years of age|Age group: 60 - 69 (3 men and 3 women)
89532435|NCT06269653||Healthy Individuals: 70 +|Age group: 70+ (3 men and 3 women)
89532436|NCT06269640|Experimental|SESAME Arm|
89532437|NCT06269627|Active Comparator|Active|This arm has participants receiving acamprosate for 21 day as inpatients.
89532438|NCT06269627|Placebo Comparator|Placebo|This arm has participants receiving placebo for 21 day as inpatients.
89532439|NCT06268730|Experimental|SinuSonic|Participants are asked to use the SinuSonic twice daily for 5 consecutive weeks. The duration of each use is 2 minutes.
89532440|NCT06268704|Experimental|Non-Particulate Steroid|Patients in this arm will receive an injection of 1 milliliter of 2% lidocaine with 10 milligrams of dexamethasone to one or both sacroiliac joints. If participants initially achieve relief from the injection but then have a return of pain they may be offered a second injection with the same drug at the same dose.
89532441|NCT06268704|Active Comparator|Particulate Steroid|Patients in this arm will receive an injection of 1 milliliter of 2% lidocaine with 40 milligrams of methylprednisolone to one or both sacroiliac joints. If participants initially achieve relief from the injection but then have a return of pain they may be offered a second injection with the same drug at the same dose.
89532442|NCT06267274|Experimental|Bimatoprost Ophthalmic Solution, 0.01%|Test Product: Bimatoprost Ophthalmic Solution, 0.01%
89532443|NCT06267274|Active Comparator|LUMIGAN® (bimatoprost ophthalmic solution) 0.01%|Reference Product: LUMIGAN® (bimatoprost ophthalmic solution) 0.01%
89532444|NCT06260007|Experimental|Tribulus terrestris 94mg|
89532445|NCT06260007|Experimental|Tribulus terrestris 280mg|
89532446|NCT06260007|Experimental|Tribulus terrestris 250mg|
89532447|NCT06260007|Placebo Comparator|Placebo|
89532448|NCT06256445|Experimental|AYP-101|0.2 mL injections, 1.0 cm apart, up to 10.0 ml per treatment session at intervals of approximately 2 weeks for up to a maximum of 6 treatments
89532449|NCT06256445|Placebo Comparator|Placebo|0.2 mL injections, 1.0 cm apart, up to 10.0 ml per treatment session at intervals of approximately 2 weeks for up to a maximum of 6 treatments
89532450|NCT06253624|Other|ATFL surgery|All participants will undergo all arthroscopic ATFL repair surgery.
89532451|NCT06253520|Experimental|1/ KRAS TCR + vaccine|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + KRAS TCR-Transduced PBL + high-dose aldesleukin + vaccine (Day 0, weeks 4 and 8 and at week 12 (if no progression)
89532452|NCT06253507|Experimental|Single arm|
89532453|NCT06253494|Experimental|Arm 1|AdHER2DC vaccine + pembrolizumab + de-escalating doses of lenvatinib
89532454|NCT06253494|Experimental|Arm 2|AdHER2DC vaccine + N-803 + pembrolizumab + RP2D of lenvatinib
89532455|NCT06252415||parent-to-be|Pregnant women and the biological father
89532456|NCT06251245|Experimental|Experimental Group (Oral Injector)|Children who use oral injectors to give oral medication will constitute the experimental group.
89532457|NCT06251245|Other|Control group (Spoon)|Children who use spoons to give oral medication will constitute the control group.
89532458|NCT06250634|Experimental|Double group ( Esomeprazole )|
89532459|NCT06250634|Active Comparator|Quadruple group ( Esomeprazole )|
89532460|NCT06250634|Experimental|Double group ( Vonoprazan )|
89532461|NCT06250634|Active Comparator|Triple group (Vonoprazan )|
89532462|NCT06247046|Experimental|Live SK08 powder|Live SK08 powder, (1-25)×10^9 CFU, oral, twice daily for up to 52 weeks period.
89532463|NCT06247046|Placebo Comparator|Placebo|SK08 placebo matching powder, oral, twice daily for up to 52 weeks period.
89532464|NCT06246357|Experimental|1/[68Ga]Ga-PentixaFor PET/CT or PET/MR|Participants will undergo [68Ga]Ga-PentixaFor PET/CT or PET/MR
89532465|NCT06244355||Lung cancer|Metastatic, with complete mutational status, without anterior treatment
89532466|NCT06244355||Chronic obstructive pulmonary disease (COPD)|Diagnosis of post-smoking COPD (without diagnosis of CP)
89576825|NCT04983355|Experimental|Peptidyss|"Dietary supplement : fish hydrolysate~The experimental product is a dietary supplement composed of a hydrolysate of fish containing low molecular weight peptides (4 capsules/day providing 1,4 g of fish hydrolysate)"
89576826|NCT04983355|Placebo Comparator|Placebo|The placebo product containing mainly silica is presented in the same form as the active product, so that people handling the product cannot distinguish both formula (4 capsules/day)
89576827|NCT04983121|Experimental|combine treatment group|This study adopts a single-arm, multi-center, open design. As per the initial plan, 30 stage II-III human epidermal growth factor receptor 2(HER2)-positive breast cancer patients who have received neoadjuvant therapy containing trastuzumab and pertuzumab and have been assessed as stable disease (SD) during the neoadjuvant treatment (an increase of 0-20%), disease progression (PD), inoperable or failing to meet the breast-conserving requirements will be enrolled to receive pyrotinib combined with Next-generation Site-specific HER2-targeting Antibody-drug Conjugate (ARX788) neoadjuvant therapy. The main purpose of the study is to observe the efficacy and safety of pyrotinib combined with ARX788 neoadjuvant treatment in stage II-III HER2-positive breast cancer.
89576828|NCT04420897||Normoxy: PaO2 = 80-120 mm Hg|Data collection explained below: Arterial blood samples from all groups shall be taken after induction, 5 minutes after graft perfusion, and end of surgery in the intraoperative period, in the operating room. The duration of the intensive care unit (ICU), the duration of mechanical ventilation in intensive care, Whether or not to re-intubate, hospital stay, intraoperative and postoperative laboratory data, immunosuppression regimen, postoperative complications (surgical site infection, ischemic vascular conditions, complications from respiratory) and interventions will be included for the study analysis. The survival of the patients will be enrolled, and the relationship between the obtained data and survival will be investigated. For early-stage graft survival, postoperatively; Data such as renal replacement therapy, the total amount of urine levels, creatinine values, presence of delayed graft function will be recorded.
89576829|NCT04420897||Moderate hyperoxemia: PaO2 =120-200 mm Hg|Data collection explained below: Arterial blood samples from all groups shall be taken after induction, 5 minutes after graft perfusion, and end of surgery in the intraoperative period, in the operating room. The duration of the intensive care unit (ICU), the duration of mechanical ventilation in intensive care, Whether or not to re-intubate, hospital stay, intraoperative and postoperative laboratory data, immunosuppression regimen, postoperative complications (surgical site infection, ischemic vascular conditions, complications from respiratory) and interventions will be included for the study analysis. The survival of the patients will be enrolled, and the relationship between the obtained data and survival will be investigated. For early-stage graft survival, postoperatively; Data such as renal replacement therapy, the total amount of urine levels, creatinine values, presence of delayed graft function will be recorded.
89576830|NCT04420897||Severe hyperoxemia: PaO2 >200 mm Hg|Data collection explained below: Arterial blood samples from all groups shall be taken after induction, 5 minutes after graft perfusion, and end of surgery in the intraoperative period, in the operating room. The duration of the intensive care unit (ICU), the duration of mechanical ventilation in intensive care, Whether or not to re-intubate, hospital stay, intraoperative and postoperative laboratory data, immunosuppression regimen, postoperative complications (surgical site infection, ischemic vascular conditions, complications from respiratory) and interventions will be included for the study analysis. The survival of the patients will be enrolled, and the relationship between the obtained data and survival will be investigated. For early-stage graft survival, postoperatively; Data such as renal replacement therapy, the total amount of urine levels, creatinine values, presence of delayed graft function will be recorded.
89576831|NCT04208971||BEAGLE Participants|Adult patients who have not been previously diagnosed with AF, are eligible for anticoagulation and have AI-predicted risks based on a normal sinus rhythm ECG.
89576832|NCT02291289|Experimental|Cohort 1: 5-FU/LV,cetuximab,vemurafenib|Participants with v-raf murine sarcoma viral oncogene homolog B1 mutation positive (BRAFmut)/human epidermal growth factor receptor 2 negative (HER2-)/microsatellite stable (MSS)/rat sarcoma wild type (RASwt) will receive 1600-2400 milligrams per square meter (mg/m^2) 5-FU via 46-hour intravenous (IV) infusion in combination with 400 mg/m^2 LV via 2-hour infusion on Day 1 of every 2-week cycle with 500 mg/m^2 cetuximab via infusion on Day 1 of every 2-week cycle and 960 milligrams (mg) vemurafenib twice daily (BID) by mouth.
88972029|NCT00015821|Experimental|Treatment (thalidomide)|Patients receive oral thalidomide once daily for 1 year in the absence of disease progression or unacceptable toxicity. Patients with stable or responding disease may receive 1 additional year of therapy.
88972030|NCT00275145|Experimental|Resistance Training|8 months of Resistance Exercise Training
88972031|NCT00275145|Experimental|Aerobic Exercise|8 months of Aerobic Exercise Training
88972032|NCT00275145|Experimental|Combination RT & AT|8 months of Combined Aerobic and Resistance Exercise Training
88972033|NCT00275145|Experimental|Control|Control/sedentary intervention
88972034|NCT01745783|Experimental|Experimental|"Receive a single IV administration of cellular product (Bone marrow mesenchymal stem cells autologous) on Day 0 and placebo infusion on day + 180.~Dose: 1-2x10^6 cells/Kg"
88972035|NCT01745783|Placebo Comparator|Placebo Comparator|Receive a placebo infusion on day 0 and a single administration cellular product on day +180. Dose: 1-2x10^6 cells/Kg
88972036|NCT00015938|Experimental|treatment|docetaxel and vinorelbine with filgrastim support
89532467|NCT06244355||Healthy volunteers|Healthy volunteers (based on biological and clinical data already available from the partner)
89532468|NCT06243692|Active Comparator|lacosamide arm|The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. All patients will receive Lacosamide 50 mg twice daily and Acetaminophen 500-1000 mg only in acute migraine attacks for 3 months. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of lacosamide was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
89576833|NCT02291289|Experimental|Cohort 2: 5-FU/LV or capecitabine,bevacizumab,atezolizumab|Participants with BRAFwt will receive fluoropyrimidine (1600-2400 mg/m^2 5-FU via 46-hour IV infusion in combination with 400 mg/m^2 LV via 2-hour infusion on Day 1 of every 2-week cycle or 1000 mg/m^2 twice-daily capecitabine BID by mouth on Days 1-14 every 2 weeks followed by a 1-week break) with 5 milligrams per kilogram (mg/kg) bevacizumab via 15-30 minute IV infusion on Day 1 of every 2-week cycle and 800 mg atezolizumab via 60-minute IV infusion on Day 1 of every 2-week cycle.
88972037|NCT00275067|Experimental|Radiation + temozolomide and arsenic trioxide|Radiation therapy followed by the combination of temozolomide and arsenic trioxide at the maximum tolerated dose determined in phase 1
89576834|NCT02291289|Experimental|Cohort 3: capecitabine,trastuzumab,pertuzumab|Participants with human epidermal growth factor receptor 2 positive (HER2+) will receive 1000 mg/m^2 twice-daily capecitabine BID by mouth on Days 1-14 every 2 weeks followed by a 1-week break with trastuzumab by IV infusion on Day 1 of every 3-week treatment cycle at an initial loading dose of 8 mg/kg followed by 6 mg/kg for subsequent doses, and pertuzumab by IV infusion on Day 1 of each 3-week treatment cycle at an initial fixed loading dose of 840 mg followed by 420 mg for subsequent doses.
89576835|NCT02291289|Experimental|Cohort 4: Cobimetinib,atezolizumab|Participants with HER2-/high microsatellite instability (MSI-H); HER2-/MSS/v-raf murine sarcoma viral oncogene homolog B1 wild type (BRAFwt); HER2-/MSS/BRAFmut/rat sarcoma mutation positive (RASmut) will receive 60 mg cobimetinib orally for 3 weeks followed by a 1-week treatment break and atezolizumab at a fixed dose of 840 mg via 60-minute IV infusion on Day 1 of every 2-week cycle.
89576836|NCT02291289|Active Comparator|Cohort 1 Control: 5-FU/LV or capecitabin, bevacizumab|Per Investigator discretion, participants will receive fluoropyrimidine (5-FU/LV or capecitabine) at a dose and schedule per the Investigator's discretion in accordance with locally approved prescribing information and 5 mg/kg bevacizumab via 1-30 minute IV on Day 1 of every 2-week cycle.
89576837|NCT02291289|Active Comparator|Cohort 2 Control: 5-FU/LV or capecitabin, bevacizumab|Per Investigator discretion, participants will receive fluoropyrimidine (5-FU/LV or capecitabine) at a dose and schedule per the Investigator's discretion in accordance with locally approved prescribing information and 5 mg/kg bevacizumab via 1-30 minute IV on Day 1 of every 2-week cycle.
89576838|NCT02291289|Active Comparator|Cohort 3 Control: 5-FU/LV or capecitabin, bevacizumab|Per Investigator discretion, participants will receive fluoropyrimidine (5-FU/LV or capecitabine) at a dose and schedule per the Investigator's discretion in accordance with locally approved prescribing information and 5 mg/kg bevacizumab via 1-30 minute IV on Day 1 of every 2-week cycle.
89576839|NCT02291289|Active Comparator|Cohort 4 Control: 5-FU/LV or capecitabin, bevacizumab|Per Investigator discretion, participants will receive fluoropyrimidine (5-FU/LV or capecitabine) at a dose and schedule per the Investigator's discretion in accordance with locally approved prescribing information and 5 mg/kg bevacizumab via 1-30 minute IV on Day 1 of every 2-week cycle.
89576840|NCT02291289|Other|Cohort 1: Induction Treatment|All participants will receive either eight 2-week cycles of 5-fluorouracil (5-FU)/ leucovorin calcium (LV) and oxaliplatin (FOLFOX) in combination with bevacizumab, or six 2-week cycles of FOLFOX in combination with bevacizumab, followed by two 2-week cycles of 5-FU/LV with bevacizumab.
89576841|NCT02291289|Other|Cohort 2: Induction Treatment|All participants will receive either eight 2-week cycles of 5-fluorouracil (5-FU)/ leucovorin calcium (LV) and oxaliplatin (FOLFOX) in combination with bevacizumab, or six 2-week cycles of FOLFOX in combination with bevacizumab, followed by two 2-week cycles of 5-FU/LV with bevacizumab.
89576842|NCT02291289|Other|Cohort 3: Induction Treatment|All participants will receive either eight 2-week cycles of 5-fluorouracil (5-FU)/ leucovorin calcium (LV) and oxaliplatin (FOLFOX) in combination with bevacizumab, or six 2-week cycles of FOLFOX in combination with bevacizumab, followed by two 2-week cycles of 5-FU/LV with bevacizumab.
89576843|NCT02291289|Other|Cohort 4: Induction Treatment|All participants will receive either eight 2-week cycles of 5-fluorouracil (5-FU)/ leucovorin calcium (LV) and oxaliplatin (FOLFOX) in combination with bevacizumab, or six 2-week cycles of FOLFOX in combination with bevacizumab, followed by two 2-week cycles of 5-FU/LV with bevacizumab.
89576844|NCT02317575|Experimental|Part A: LY900014 Test A|Test Formulation A. Single dose of LY900014 administered subcutaneously (SC) in one of five periods.
89576845|NCT02317575|Experimental|Part A:Insulin Lispro|Reference formulation. 15 U insulin lispro administered SC in one of five periods.
89576846|NCT02317575|Experimental|Part A: LY900014 Test B|Test Formulation B. Single dose LY900014 administered subcutaneously (SC) in one of five periods.
89576847|NCT02317575|Experimental|Part A: LY900014 Test C|Test Formulation C. Single dose LY900014administered subcutaneously (SC) in one of five periods.
89576848|NCT02317575|Experimental|Part A: LY900014 Test D|Test Formulation D. Single dose LY900014administered subcutaneously (SC) in one of five periods.
89576849|NCT02317575|Experimental|Part B: LY900014|Test formulation selected from Part A. Single dose of LY900014 administered SC in one of four periods.
89576850|NCT02316717|Experimental|Treatment Arm A|IMM-124E, 600 mg three times daily, orally plus matching placebo
89576851|NCT02316717|Experimental|Treatment Arm B|IMM-124E, 1200 mg three times daily, orally
88972038|NCT00274989|Experimental|Bendamustine plus Rituximab|
88972039|NCT00015977|Experimental|PSMA peptide vaccine|Immunization with PSMA peptide vaccine followed by injection of Interleukin-12 (IL-12) on Day 1 of a 21-day cycle. Additional injections of IL-12 given on Days 3 and 5 of each cycle.
88972040|NCT01678586|Active Comparator|True Acupuncture|Pain subjects with radicular pain receiving 6, 30 minute acupuncture treatments.
88972041|NCT01678586|Sham Comparator|Sham Acupuncture|Pain subjects with radicular pain receiving 6, 30 minute sham acupuncture treatments.
89576852|NCT02316717|Placebo Comparator|Treatment Arm C|Matching placebo, three times daily, orally
89576853|NCT02290821|Experimental|diclofenac sodium gel 1%|diclofenac sodium gel 1%
89576854|NCT02290821|Placebo Comparator|Placebo|Placebo
89576855|NCT02289963|Placebo Comparator|Placebo Q2W|Placebo (for alirocumab) subcutaneous (SC) injection every 2 weeks (Q2W) added to stable Lipid-Modifying Therapy (LMT) for 24 weeks.
89576856|NCT02289963|Placebo Comparator|Alirocumab 75 mg Q2W/Up to 150 mg Q2W|Alirocumab 75 mg SC injection Q2W added to stable LMT for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when LDL-C levels ≥70 mg/dL (1.81 mmol/L) at Week 8.
89576857|NCT02358369|Experimental|13 mg Bimatoprost Ocular Insert|Washout + Placebo Ocular Insert in each eye for 4 to 6 weeks, followed by 13 mg Bimatoprost Ocular Insert in each eye (OU) for 12 weeks. Note: participants also self-administered placebo ophthalmic eye drops to each eye twice a day (BID) for the first 6 weeks. After 12 weeks, 13 mg Bimatoprost Ocular Insert in each eye for an additional 12 weeks.
89576858|NCT02358369|Experimental|2.2 mg Bimatoprost Ocular Insert|Washout + Placebo Ocular Insert in each eye for 4 to 6 weeks, followed by 2.2 mg Bimatoprost Ocular Insert in each eye for 12 weeks. Note: participants also self-administered placebo ophthalmic eye drops in each eye twice a day for the first 6 weeks. After 12 weeks, 13 mg Bimatoprost Ocular Insert in each eye for an additional 12 weeks.
89576859|NCT02358369|Active Comparator|Timolol 0.5%|"Washout + Placebo Ocular Insert in each eye for 4 to 6 weeks, followed by 0.5% timolol ophthalmic solution in each eye for 6 weeks. Note: participants simultaneously wore placebo ocular inserts for 12 weeks.~After 12 weeks, 13 mg Bimatoprost Ocular Insert in each eye for an additional 12 weeks."
89576860|NCT02316171|Experimental|CVA21|CVA21 was administered by intravesical instillation at one of three (3) ascending dose levels or schedules.
89576861|NCT02316171|Experimental|CVA21/Mitomycin C|Mitomycin C (MMC) was administered at 10 mg by intravesical instillation on Day 1. Four hours after instillation of MMC, CVA21 was administered by intravesical instillation of one of 2 ascending dose levels or schedules. Subjects received a second instillation of CVA21 alone on Day 2 without pretreatment with MMC.
89576862|NCT02289729||All Participants|Levodopa/carbidopa intestinal gel (LCIG) prescribed in the usual manner, in accordance with the terms of the local marketing authorization, for participants with advanced Parkinson's disease with motor fluctuation not well responding to conventional therapies.
89576863|NCT02315625|Experimental|1/ Arm 1 Sunitinib|Sunitinib
89576864|NCT02315625|Experimental|2/ Arm 2 Everolimus|Everolimus
89576865|NCT02357979|Experimental|Laser & Fluoride|In the split mouth design the molar on one side of the mouth receives the intervention CO2 9.3 μm short pulsed laser treatment and fluoride varnish (experimental side) in the occlusal fissure areas.
89576866|NCT02357979|Active Comparator|Fluoride alone|In the split mouth design this arm (this side in the mouth - the contralateral tooth to the experimental site in the same jaw) will receive only fluoride varnish treatment. In the split mouth design this opposite side of the jaw is functioning as control.
89576867|NCT04886973|Experimental|Subjects with a Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) ≥ 2.5|Administration of an 8% crystalline L-amino acid solution with high concentrations of branched chain amino acids. The dose will be calculated considering the 25% of the estimated protein per day (1 g/kg/day). This dose will be placed in a short peripheral intravenous catheter and administered at a rate of 1.5ml per minute, using an infusion pump. The patient will be monitored all the time by a physician.
89576868|NCT04886973|Experimental|Subjects with a Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) < 2.5|Administration of an 8% crystalline L-amino acid solution with high concentrations of branched chain amino acids. The dose will be calculated considering the 25% of the estimated protein per day (1 g/kg/day). This dose will be placed in a short peripheral intravenous catheter and administered at a rate of 1.5ml per minute, using an infusion pump. The patient will be monitored all the time by a physician.
89576869|NCT02357901|Experimental|RBP-6000 300mg/100mg|"During the Run-In Period, participants are inducted onto SUBOXONE sublingual film (SL) followed by a 4- to 11-day SUBOXONE sublingual film open-label run-in dose-adjustment period to achieve buprenorphine dosages ranging from 8 to 24 mg according to the SUBOXONE sublingual film prescribing information. Participants are then randomized. As of protocol Amendment 2 (21 August 2015) SUBOXONE use is tapered from 6 mg to 2 mg from Days 1-5 and then discontinued.~Participants in this treatment arm are given RBP-6000 300 mg injections on Days 1 and 29. Injections 3-6 are separated by 28 days (Day 57-Day 141) and contain RBP-6000 100 mg.~In addition, participants received individual drug counseling (IDC) at least once a week."
89576870|NCT02357901|Experimental|RBP-6000 300mg/300mg|"During the Run-In Period, participants are inducted onto SUBOXONE sublingual film (SL) followed by a 4- to 11-day SUBOXONE sublingual film open-label run-in dose-adjustment period to achieve buprenorphine dosages ranging from 8 to 24 mg according to the SUBOXONE sublingual film prescribing information. Participants are then randomized. As of protocol Amendment 2 (21 August 2015) SUBOXONE use is tapered from 6 mg to 2 mg from Days 1-5 and then discontinued.~Participants in this treatment arm are given six RBP-6000 300 mg injections on Days 1 to 141 with injections separated by 28 days.~In addition, participants received individual drug counseling (IDC) at least once a week."
89029253|NCT03599544|Experimental|Robot + Active Learning Program(RT-ALPS)|Armeo & Amadeo robot-assisted intensive upper limb therapy 1 hour sessions 3x week for 6 weeks plus training in active problem solving, analysis of performance, and goal-setting focused on the transfer of acquired motor skills to daily activities in the home and community.
89029254|NCT03592368|Active Comparator|Active IBT, Out of MRI|
89029255|NCT03592368|Sham Comparator|Sham IBT, Out of MRI|
89029256|NCT03592368|Active Comparator|Active IBT, In MRI|
89029257|NCT03592368|Sham Comparator|Sham IBT, In MRI|
89029258|NCT03559413|Experimental|Intervention group|
89029259|NCT03546335|Experimental|1 mCi injection of 89Zr-DFO-CZP|The first 2 patients will receive 1 mCi of 89Zr-DFO-CZP.
89029260|NCT03546335|Experimental|0.5 mCi injection of 89Zr-DFO-CZP|Subsequent groups of two patients will receive 0.5 mCi decrease or increase dose (up to 2 mCi) to determine the acceptable optimal imaging dose.
89576871|NCT02357901|Placebo Comparator|Placebo Matching 300 mg/100 mg RBP-6000|"During the Run-In Period, participants are inducted onto SUBOXONE sublingual film (SL) followed by a 4- to 11-day SUBOXONE sublingual film open-label run-in dose-adjustment period to achieve buprenorphine dosages ranging from 8 to 24 mg according to the SUBOXONE sublingual film prescribing information. Participants are then randomized. As of protocol Amendment 2 (21 August 2015) SUBOXONE use is tapered from 6 mg to 2 mg from Days 1-5 and then discontinued.~Participants in this treatment arm are given placebo injections on Days 1 and 29 (matching the RBP-6000 300 mg dose volume). Injections 3-6 are separated by 28 days (Day 57-Day 141) and also contain placebo (matching the RBP-6000 100 mg volume).~In addition, participants received individual drug counseling (IDC) at least once a week."
89576872|NCT02357901|Placebo Comparator|Placebo Matching 300 mg RBP-6000|"During the Run-In Period, participants are inducted onto SUBOXONE sublingual film (SL) followed by a 4- to 11-day SUBOXONE sublingual film open-label run-in dose-adjustment period to achieve buprenorphine dosages ranging from 8 to 24 mg according to the SUBOXONE sublingual film prescribing information. Participants are then randomized. As of protocol Amendment 2 (21 August 2015) SUBOXONE use is tapered from 6 mg to 2 mg from Days 1-5 and then discontinued.~Participants in this treatment arm are given six placebo injections (volume-matched to RBP-6000 300 mg dose) on Days 1 to 141 with injections separated by 28 days.~In addition, participants received individual drug counseling (IDC) at least once a week."
89576873|NCT01601847|Active Comparator|Sustained|Infants will remain on 400 IU/day of cholecalciferol until 6 months of age adjusted for prematurity, regardless of dietary intake
89576874|NCT01601847|Placebo Comparator|Diet-Limited|Infants will receive placebo once their dietary intake of vitamin D has exceeded 200 IU/day
89576875|NCT04886739|Experimental|CGB-400 Topical Gel|Topical administration twice daily for 12 weeks
89576876|NCT04886739|Placebo Comparator|Vehicle Gel|Topical administration twice daily for 12 weeks
89576877|NCT02515669|Active Comparator|RO7239361|RO7239361 subcutaneous injections on specified days
89576878|NCT02515669|Placebo Comparator|Placebo|Placebo subcutaneous injections on specified days
89576879|NCT02515279||Participants With Hepatitis C|All participants were treated with Peginterferon alfa-2a+Ribavirin (Pegasys/Copegus) according to the summary of product characteristics and to the investigator's discretion. The daily recommended dose for Pegasys, for the treatment of chronic Hepatitis C, was 180 micrograms once weekly by subcutaneous administration. Copegus was administered orally in doses according to the physician's decision (depending on the participant's weight and genotype). All participants were observed for 12 months.
89576880|NCT02515045|Active Comparator|TriMoxiVanc|The formulation containing triamcinolone acetonide, moxifloxacin hydrochloride and vancomycin used as an injection at the end of the uneventful phacoemulsification procedure. The compounded Tri-Moxy-Vanco will be delivered into the vitreous cavity using a transzonular approach after IOL implantation before removal of the OVD.
89576881|NCT02515045|Active Comparator|TriMoxiVanc + Ilevro|Nepafenac ophthalmic suspension 0.3% will be started 3 days prior to surgery QD and continue QD for 4 weeks after surgery. The compounded Tri-Moxy-Vanco will be injected into the vitreous cavity using a transzonular approach after IOL implantation before removal of the OVD.
89576882|NCT02515045|Active Comparator|Control|"Moxifloxacin HCl 0.1%, 1 drop, QID for 3 days prior to surgery and will continue for 2 weeks after surgery and then discontinue.~Nepafenac ophthalmic suspension 0.3% : 1 drop QD starting 3 days before surgery and QD for 4 weeks after surgery.~Prednisolone acetate 1% will be started after surgery QID for 2 weeks, tapered to BID for 2 weeks, and then discontinued."
89576883|NCT02514577|Experimental|IDP-122 Lotion|Participants will apply IDP-122 Lotion (halobetasol propionate [HP] 0.01%) topically once daily for 8 weeks.
89576884|NCT02514577|Active Comparator|IDP-122 Vehicle Lotion|Participants will apply IDP-122 Vehicle Lotion topically once daily for 8 weeks.
89576885|NCT04943887|Experimental|PwMS eSupport Groups|12-weeks active treatment of eSupport Health's Weekly Group Sessions, a formal semi-structured program of psychoeducational support delivered in a small group format by licensed therapists who specialize in MS. The active treatment period will follow a 12-week waitlist period that will be used to enable a within-subject control design. Note that the very first group enrolled (N~10) will not have a 12-week waitlist period but will instead enter directly into the 12-week treatment.
89576886|NCT05463055|Experimental|single-arm objective performance criteria, OPC|According to the NMPA Guidance on Proton and Carbon Ion treatment system clinical evaluation and clinical trial, the objective performance criteria for the validity of medical device treatment for trial use should be at least 80%, with an expected target of 95% in which the validity is defined as: Complete Response + Partial Response + Stable Disease (CR+PR+SD), and the definition of tumor disease control rate in this clinical trial is basically identical. Therefore, the clinical trial did not have a control group, but using single-arm objective performance criteria, when evaluating ProBeam radiotherapy for tumor patients, the main validity evaluation index of tumor disease control rate whether reach the objective performance criteria (80%); the main safety evaluation index of CTCAE level 3 toxic reaction ratio whether is lower than the acceptable value (5%), CTCAE level 4 and 5 toxic reaction ratio whether is acceptable value (0%).
89576887|NCT02513485|Active Comparator|Sinemet/Placebo|Subjects with major depression will be given Sinemet (a combination of 250 mg of levodopa and 50 mg of carbidopa) at one study visit and placebo at the other study visit. Sinemet will be given first followed by placebo at the subsequent visit.
89576888|NCT02513485|Active Comparator|Placebo/Sinemet|Subjects with major depression will be given placebo at one study visit and Sinemet (a combination of 250 mg of levodopa and 50 mg of carbidopa) at the other study visit. Placebo will be given first followed by Sinemet at the subsequent visit.
89576889|NCT02289417|Experimental|Apremilast 30 mg PO BID|"Apremilast 30 mg by mouth (PO) twice a day (BID) for 12 weeks~After 12 weeks:~Participants who achieve at least a 20% decrease from baseline in the total Mayo score (TMS) will continue to receive apremilast 30 mg BID for an additional 40 weeks. (Wk 52)~Participants who do not achieve at least a 20% decrease from baseline in the TMS will receive apremilast 40 mg BID for an additional 40 weeks (Wk 52)~After 52 weeks, participants who are eligible for the Extension Phase will continue to receive the same dose of apremilast assigned at Wk 12 (30 mg BID or 40 mg BID) for an additional 52 weeks (Wk 104)"
89576890|NCT02289417|Experimental|Apremilast 40 mg PO BID|"Apremilast 40 mg by mouth (PO) twice a day (BID) for 12 weeks~After 12 weeks, participants assigned to the 40 mg BID dose of apremilast at baseline will continue to receive apremilast 40 mg BID for an additional 40 weeks (Wk 52)~After 52 weeks, participants who are eligible for the extension Phase will continue to receive apremilast 40 mg BID for an additional 52 weeks (Wk 104)"
89576891|NCT02289417|Placebo Comparator|Placebo BID|"Identically matching placebo by mouth (PO) twice a day (BID) for 12 weeks. After 12 weeks all participants randomized to placebo at baseline will be re-randomized to receive apremilast 30 mg or 40 mg BID for an additional 40 weeks (Wk 52)~After Wk 52, participants who are eligible for the extension phase will continue to receive the same dose of apremilast assigned at Wk 12 (30 mg BID or 40 mg BID) for an additional 52 weeks (Wk 104)"
89576892|NCT02512861|Active Comparator|Bupivacaine|Bupivacaine as a parasternal nerve block following pediatric cardiothoracic surgery
89576893|NCT02512861|Placebo Comparator|Placebo|Normal Saline
89576894|NCT04979299|Experimental|wheelchair group|"Patients included in the  wheelchair  group will be asked to sit in a wheelchair during the interview;"
89576895|NCT04979299|No Intervention|Control group|Patients included in the control group will sit in a regular chair during the interview.
89576896|NCT05012761|Experimental|SR419 capsules|Ascending single and multiple doses of SR419 orally
89576897|NCT05012761|Placebo Comparator|Placebo|Ascending single and multiple doses of SR419 placebo orally
89576898|NCT04979065|Experimental|Experimental Group|Probiotics and Vitamin D
89576899|NCT04979065|Placebo Comparator|Control Group|Placebo and placebo
89576900|NCT02288559|Experimental|Lampalizumab: Open-label Safety Run-In|Participants will receive 10 milligrams (mg) lampalizumab intravitreally Q2W during the safety run-in period.
89576901|NCT02288559|Experimental|Q2W Lampalizumab: Randomized Treatment|Participants will receive 10 mg dose of lampalizumab intravitreally Q2W during the 24-week treatment period.
89576902|NCT02288559|Experimental|Q4W Lampalizumab: Randomized Treatment|Participants will receive 10 mg dose of lampalizumab intravitreally Q4W during the 24-week treatment period.
89576903|NCT02288559|Sham Comparator|Sham: Randomized Treatment|Participants randomized to control arms will receive sham injections, that mimics intravitreal injection of lampalizumab.
89576904|NCT02288325|Experimental|Open-Label FETZIMA®|FETZIMA® (levomilnacipran extended release [ER]) taken orally during flexible dose titration up to 40, 80 or 120 mg once daily in 8-week run-in period followed by fixed dose of 40, 80 or 120 mg once daily in 12-week stabilization period.
89576905|NCT02288325|Placebo Comparator|Double-Blind Placebo|Dose-matched placebo taken orally once daily for 26 weeks during double-blind treatment period.
89576906|NCT02288325|Experimental|Double-Blind FETZIMA®|FETZIMA® (levomilnacipran ER) taken orally at fixed dose of 40, 80 or 120 mg once daily for 26 weeks during double-blind treatment period.
89576907|NCT02509117|Experimental|Single Ascending Dose Cross-over|Single Ascending Dose in 4-way cross-over design (PF-06751979/Placebo).
89576908|NCT02509117|Experimental|Multiple Ascending Dose PF-06751979|Multiple dose administration to Healthy Subjects in parallel cohorts(PF-06751979)
89576909|NCT02509117|Placebo Comparator|Multiple Ascending Dose Placebo|Multiple dose administration to Healthy Subjects in parallel cohorts(Placebo)
88972042|NCT01678586|Active Comparator|Gabapentin|Pain subjects with radicular pain receiving gabapentin. Medication treatment groups will titrate up to the standard clinical treatment dosage for one week and maintain that dosage for 1.5 weeks.
88972043|NCT01678586|Sham Comparator|Sham Gabapentin|Pain subjects with radicular pain receiving sham gabapentin. Medication treatment groups will titrate up to the standard clinical treatment dosage for one week and maintain that dosage for 1.5 weeks.
88972044|NCT00016016|Experimental|Treatment (flavopiridol, cytarabine, mitoxantrone)|Patients receive flavopiridol IV over 1 hour on days 1-3 and cytarabine IV continuously on days 6-9 followed by mitoxantrone IV over 30-150 minutes on day 9. Patients achieving a partial or complete response after the first course of therapy may receive an additional course of therapy beginning 35 ± 7 days after blood count recovery.
88972045|NCT00016094|Experimental|Treatment (bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days for a maximum of 24 courses in the absence of disease progression or unacceptable toxicity.
88972046|NCT00130377|Experimental|cell therapy|Patient receiving active biologic
88972047|NCT00130377|Placebo Comparator|control|Patient receiving placebo or standard of care
88972048|NCT00130260|Experimental|vaccine, schedule 1|3rd and 4th dose of vaccine, on original schedule
88972049|NCT00130260|Experimental|vaccine, schedule 2|3rd and 4th dose of vaccine on modified schedule
88972050|NCT00130260|Placebo Comparator|placebo, schedule 1|3rd and 4th dose of placebo, on original schedule
88972051|NCT00130260|Placebo Comparator|placebo, schedule 2|3rd and 4th dose of placebo on modified schedule
88972052|NCT01470716|Experimental|Study arm|Neo-adjuvant Erlotinib treatment arm.
88972053|NCT01441349|Active Comparator|Control arm|IP chemotherapy arm
88972054|NCT01441349|Experimental|Treatment arm|IP chemotherapy plus simvastatin arm
88972055|NCT00394407|Active Comparator|sliding scale regular insulin|sliding scale insulin given acqhs
88972056|NCT00394407|Active Comparator|glargine insulin and glulisine insulin|glargine basal insulin once a day with prandial glulisine insulin tid
88972057|NCT01394900|Experimental|CNU intervention|African American/Black men who have sex with men (MSM) in same sex intimate relationships in which at least one partner is illicitly using psychostimulants and/or psychoactive substances will receive 4 sessions of CNU intervention
89576910|NCT02509117|Experimental|Multiple Dose Elderly PF-06751979|Multiple dose administration to Healthy Elderly Subjects (PF-06751979)
89576911|NCT02509117|Placebo Comparator|Multiple Dose Elderly Placebo|Multiple dose administration to Healthy Elderly Subjects (Placebo)
89576912|NCT01654549|No Intervention|Lifestyle modification|Obtaining ideal body weight by calorie restriction diet and programmed physical activity
89576913|NCT01654549|Experimental|H.pylori eradication|H.pylori eradication by quadruple antibiotic therapy for two weeks plus obtaining ideal body weight by calorie restriction diet and programmed physical activity
89576914|NCT04978051|Active Comparator|Standard of Care (SoC)|
89576915|NCT04978051|Experimental|SoC + Icatibant|
89576916|NCT04214353|Experimental|Experimental arm|Salivary duct carcinoma patients with R/M disease, who will start androgen deprivation therapy as standard of care will receive PET/CT scans before and after ADT.
89576917|NCT04977817||Control Group|By using the Baby Steps Program, neonates less than or equal to 1500 grams and less than 32 weeks GA will be identified. The control group will contain those that did not receive probiotics.
89576918|NCT04977817||Treatment Group|By using the Baby Steps Program, neonates less than or equal to 1500 grams and less than 32 weeks GA will be identified. The treatment group will contain those neonates that did receive the probiotic nutritional supplement.
89576919|NCT04977739||those with a condition|
89576920|NCT04977739||those without a condition|
89576921|NCT04976803||Group A|Deceased patients with archival tissue
89576922|NCT04976803||Group B|Living patients with archival tissue
89576923|NCT04976803||Group C|Living patients without archival tissue
89576924|NCT02508649|Placebo Comparator|Placebo|
89576925|NCT02508649|Experimental|Selepressin 1|Starting dose 1.7 ng/kg/min
89576926|NCT02508649|Experimental|Selepressin 2|Starting dose 2.5 ng/kg/min
89576927|NCT02508649|Experimental|Selepressin 3|Starting dose 3.5 ng/kg/min
89576928|NCT02508649|Experimental|Selepressin 4|"Starting dose 5.0 ng/kg/min~The highest dosing regimen of selepressin was not investigated in the trial as the desired primary outcome for selepressin 3 arm was not achieved, and the trial was terminated for futility."
89576929|NCT05010421|Active Comparator|Clobetasol Group|Treatment with clobetasol-0,05% over 3 months (month 1: daily, month 2: every other day, month 3: 3x per week)
89576930|NCT05010421|Experimental|Laser Group|3 applications every 14 days of a non-ablative CO2 laser treatment
89576931|NCT02504827|Experimental|IV Ceftazidime/Avibactam|Ceftazidime/avibactam 2.5gm IV q8h for 3 doses
89576932|NCT02504671|Experimental|GSK3196165, Dose 1 + MTX and Folic acid|Subject will receive GSK3196165 Dose 1 (initially weekly, then every other week) in combination with MTX (at a dose between 15-25 mg/week) and folic acid >=5 mg/week.
89576933|NCT02504671|Experimental|GSK3196165, Dose 2 + MTX and folic acid|Subject will receive GSK3196165 Dose 2 (initially weekly, then every other week) in combination with MTX (at a dose between 15-25 mg/week) and folic acid >=5 mg/week.
89576934|NCT02504671|Experimental|GSK3196165, Dose 3 + MTX and folic acid|Subject will receive GSK3196165 Dose 3 (initially weekly, then every other week) in combination with MTX (at a dose between 15-25 mg/week) and folic acid >=5 mg/week.
89576935|NCT02504671|Experimental|GSK3196165, Dose 4 + MTX and folic acid|Subject will receive GSK3196165 Dose 4 (initially weekly, then every other week) in combination with MTX (at a dose between 15-25 mg/week) and folic acid >=5 mg/week.
89576936|NCT02504671|Experimental|GSK3196165, Dose 5 + MTX and folic acid|Subject will receive GSK3196165 Dose 5 (initially weekly, then every other week) in combination with MTX (at a dose between 15-25 mg/week) and folic acid >=5 mg/week.
89576937|NCT02504671|Placebo Comparator|Placebo + MTX and folic acid|Subjects will receive placebo (initially weekly, then every other week) in combination with MTX (at a dose between 15-25 mg/week) and folic acid >=5 mg/week.
89576938|NCT02314143|Experimental|Dabrafenib followed by combination therapy|Eligible subjects will receive dabrafenib 150 milligrams (mg) twice a day (BID) continuously during 8 weeks of monotherapy treatment followed by the combination of trametinib 2 mg once daily with dabrafenib 150 mg BID until disease progression, death or unacceptable toxicity.
89576939|NCT02314143|Experimental|Trametinib followed by combination therapy|Eligible subjects will receive trametinib 2 mg per day continuously during 8 weeks of monotherapy treatment followed by the combination of trametinib 2 mg once daily with dabrafenib 150 mg BID until disease progression, death or unacceptable toxicity.
89576940|NCT02314143|Experimental|Combination therapy|Eligible subjects will receive trametinib 2 mg per day plus dabrafenib 150 mg BID continuously until disease progression, death or unacceptable toxicity.
89576941|NCT02288091|Experimental|Open-label|Subjects will receive oral inosine daily.
89576942|NCT04420065|Active Comparator|Classical biventricular pacing|Commercially available LV-pacing capable CRT devices and quadripolar leads will be implanted. Right ventricular (RV) and right atrial (RA) leads will be placed according to standard practice. The LV lead will also be placed according to standard practice, targeting to a lateral, posterolateral, or anterolateral branch of the coronary sinus (CS). Interventricular delay programmed will be determined based on stroke volume maximization, and will be used as a criterion for BVP optimization. Atrioventricular delay optimization shall be automatically performed by the device.
89576943|NCT04420065|Experimental|Preferential left ventricular pacing|In G2 patients, an algorithm for preferential left ventricular pacing will be activated. Following selection of the dipole maximizing stroke volume during simultaneous LV-RV pacing, subsequent V-V delay optimization shall be delegated to the algorithm. Based on previous studies, a subgroup analysis of G2 will be performed, comparing those receiving ≥50% with those receiving <50% preferential LV pacing evaluated over the total duration of the study (12 months).
89029261|NCT03546335|Experimental|1.5 mCi injection of 89Zr-DFO-CZP|Subsequent groups of two patients will receive 0.5 mCi decrease or increase dose (up to 2 mCi) to determine the acceptable optimal imaging dose.
89576944|NCT04973527|Experimental|LCAR-T2C CAR-T cells in relapsed or refractory CD4+ T lymphocyte tumor|An open label, multi center, single arm Phase I study to evaluate the safety, tolerability, and efficacy of LCAR-T2C CAR-T cells in relapsed or refractory CD4+ T lymphocyte tumor.
89576945|NCT05009329|Experimental|Phase 1 Dose Exploration|Dose escalation of JAB-21822 to determine maximum tolerated dose
89576946|NCT05009329|Experimental|Phase 1 Dose Expansion|Conditionally required
89576947|NCT04972279|Experimental|Aggressive adaptation strategy|Participants receive up to 6 messages/day to support achievement of their behavior change goal. Messages are only delivered outside of a participant-specific Do Not Disturb window (e.g., 11pm-8am). Messages with coordinating images are selected from three content domains: Move More, Sit Less, and Inspirational Quotes Unrelated to Movement within the first month. The decision rule for each participant will be refined on a monthly basis throughout the 6-month study based upon the accumulating data on how each participant is responding to different messages under different conditions.
89576948|NCT04972279|Experimental|Moderate adaptation strategy|Participants receive up to 3 messages/day to support achievement of their behavior change goal. Messages are only delivered outside of a participant-specific Do Not Disturb window (e.g., 11pm-8am). Messages with coordinating images are selected randomly from three content domains: Move More, Sit Less, and Inspirational Quotes Unrelated to Movement within the first month. The decision rule for each participant will be refined on a monthly basis throughout the 6-month study based upon the accumulating data on how each participant is responding to different messages under different conditions.
89576949|NCT02503501|Experimental|Insulin Glulisine|Insulin Glulisine 20 IU (0.1ml/10 units in each nostril) per intranasal dose, 2 times per day for 6 months
89576950|NCT02503501|Placebo Comparator|Placebo|Saline 20 IU (0.1 ml in each nostril) per intranasal dose, 2 times per day for 6 months
89576951|NCT04971889|Active Comparator|Diabetes MNT plus MI|--Group-based dietary/dietary motivation intervention
89576952|NCT04971889|Active Comparator|Diabetes MNT|-Group-based dietary intervention
89576953|NCT05007613|Experimental|cabozantinib plus atezolizumab|cabozantinib 40mg PO QD atezolizumab 1200mg IVD 30-60mins Q3W
89576954|NCT04971265|Experimental|Low SES/High Supports|"Participants assigned to the Low SES/High Supports arm will see the Low SES/High Supports intervention"
89576955|NCT04971265|Experimental|Low SES/Low Supports|"Participants assigned to the Low SES/Low Supports arm will see the Low SES/Low Supports intervention"
89576956|NCT04971265|Experimental|High SES/High Supports|"Participants assigned to the High SES/High Supports arm will see the High SES/High Supports intervention"
89576957|NCT04971265|Experimental|High SES/Low Supports|"Participants assigned to the Low SES/High Supports arm will see the High SES/Low Supports intervention"
89576958|NCT04970407|Experimental|Dysport®|40 Units (U) Intramuscular (IM) injection at day 1.
89576959|NCT04970407|Active Comparator|Botox®|16U IM at day 1.
89029262|NCT03546335|Experimental|2 mCi injection of 89Zr-DFO-CZP|Subsequent groups of two patients will receive 0.5 mCi decrease or increase dose (up to 2 mCi) to determine the acceptable optimal imaging dose.
89576960|NCT04970407|Active Comparator|Xeomin®|16U IM at day 1.
89576961|NCT02502097|Experimental|Gefapixant>Placebo Pre-Amendment 3|Gefapixant 50 mg twice daily (BID) for 10 days, then 150 mg BID for 4 days in Period 1, followed by a 14-21 day washout period, then placebo BID for 14 days in Period 2
89576962|NCT02502097|Experimental|Placebo>Gefapixant Pre-Amendment 3|Placebo BID for 14 days in Period 1, followed by a 14-21 day washout period, then gefapixant 50 mg BID for 10 days, then 150 mg for 4 days in Period 2
89576963|NCT02502097|Experimental|Gefapixant>Placebo Post-Amendment 3|Gefapixant 50 mg twice daily (BID) for 14 days in Period 1, followed by a 14-21 day washout period, then placebo BID for 14 days in Period 2
89576964|NCT02502097|Experimental|Placebo>Gefapixant Post-Amendment 3|Placebo BID for 14 days in Period 1, followed by a 14-21 day washout period, then gefapixant 50 mg BID for 14 days in Period 2
89576965|NCT02501629|Experimental|Reslizumab 110 mg|Reslizumab was administered by subcutaneous injection (sc) in a dosage of 110 mg (1.0 mL) every 4 weeks for a total of six doses.
89576966|NCT02501629|Placebo Comparator|Placebo|Matching placebo was administered by subcutaneous injection (sc) 1.0 mL every 4 weeks for a total of six doses.
89576967|NCT02501473|Experimental|Part 1: Local Radiation + G100 5μg/tumor|Part 1: Local radiation and G100 [glucopyranosyl lipid A stable emulsion, GLA-SE] at 5μg/tumor administered intratumorally (IT) into accessible tumors for up to 8 weeks.
89576968|NCT02501473|Experimental|Part 1: Local Radiation + G100 10μg/tumor|Part 1: Local radiation and G100 at 10μg/tumor administered IT into accessible tumors for up to 8 weeks.
89576969|NCT02501473|Experimental|Part 2: Local Radiation + G100 10μg/tumor|Part 2: Local radiation and G100 at 10μg/tumor administered IT into accessible tumors for up to 8 weeks.
89576970|NCT02501473|Experimental|Part 2: Local Radiation + G100 10μg/tumor+Pembrolizumab 200mg|Part 2: Local radiation and G100 at 10μg/tumor administered IT into accessible tumors for up to 8 weeks; pembrolizumab 200mg intravenously (IV) administered every 3 weeks (Q3W) IV for up to 2 years.
89576971|NCT02501473|Experimental|Part 2: Local Radiation, G100 20 μg/tumor in Large Tumors|Part 2: Local radiation and G100 at 20 μg/tumor administered IT into accessible large tumors [injectable lymphoma mass(es) ≥ 4 cm in total size] for up to 8 weeks.
89576972|NCT02501473|Experimental|Part 3: Local Radiation + G100 20μg/tumor|Part 3: Local radiation and G100 at 20μg/tumor administered IT into accessible tumors for up to 8 weeks.
89576973|NCT02501473|Experimental|Part 4: G100 20μg/tumor and pembrolizumab 200mg|Part 4: G100 at 20μg/tumor administered IT into accessible tumors for up to 8 weeks and pembrolizumab 200mg IV and administered Q3W for up to 2 years.
89576974|NCT02501473|Experimental|Part 5: G100 + Rituximab 375mg/m^2|Part 5: G100 at 20, 40, 60, or 80μg/tumor administered IT for up to 6 weeks and rituximab administered as an IV infusion at 375mg/m^2 on Day 0 and then QW for up to 3 weeks.
89576975|NCT02501161|Experimental|Insulin degludec/liraglutide QD + OAD(s)|
89576976|NCT02501161|Active Comparator|insulin glargine QD + OAD(s)|
89029263|NCT03495427|Experimental|Radioactive Diagnostic Imaging|Participants will receive F-DCFPyL PSMA PET imaging annually for 4 years. An administered dose of 9 ± 1 mCi (333 ±37 MBq) F-DCFPyL Injection will be administered via an in-dwelling catheter placed in an antecubital vein or an equivalent venous access.
89029264|NCT03467867|Experimental|Venetoclax + Rituximab|Participants will be initially placed in a venetoclax 5 weeks ramp-up period, and will be administered an initial 20 mg oral tablet dose once daily (QD), incrementing weekly up to a maximum dose of 400 mg. Participants will then continue taking venetoclax 400 mg QD from Week 5 onwards, as directed by the investigator in combination with rituximab 375 mg/m^2 IV on Day 1 of Cycle 1 followed by 13.4 mL of rituximab SC 1,600 mg/26,800 Units vial (1,600 mg rituximab and 26,800 Units hyaluronidase human) on Day 1 of Cycle 2-6.
89029265|NCT03458728|Experimental|Dose escalation of BAY806946 in Phase 1|It is estimated that 2 or 3 dose cohorts may be evaluated in phase 1 of the study. Safety and MTD/RP2D dose will be evaluated in 2 age groups (< 1 year old and ≥ 1 year old).
89576977|NCT02500537|Experimental|Abdominal Procedures|"Abdominal procedures may include, but are not limited to, laparoscopic sleeve gastrectomy (LSG), laparoscopic Roux-en-Y gastric bypass (LRYGB), and biliopancreatic diversion, as well as hepatic and pancreatic resection.~Device: Endo GIA™ Reinforced Reload with Tri-Staple™ Technology"
89029266|NCT03458728|Experimental|Patients with Neuroblastoma in Phase 2|Recommended Phase 2 dose (RP2D) for copanlisib in pediatric patients, as defined in the Phase I part of the study, will be used.
89029267|NCT03458728|Experimental|Patients with Osteosarcoma in Phase 2|RP2D for copanlisib in pediatric patients, as defined in the Phase I part of the study, will be used.
89029268|NCT03458728|Experimental|Patients with Rhabdomyosarcoma in Phase 2|RP2D for copanlisib in pediatric patients, as defined in the Phase I part of the study, will be used.
89029269|NCT03458728|Experimental|Patients with Ewing sarcoma in Phase 2|RP2D for copanlisib in pediatric patients, as defined in the Phase I part of the study, will be used.
89029270|NCT03432806||presumptive Stage II or III colon cancer|
89029271|NCT03432806||Stage IV colon cancer with resectable hepatic metastases|
89029272|NCT03432806||Stage IV colon cancer with unresectable hepatic metastases|
89029273|NCT03432806||Stage I colon cancer, pre-neoplastic or benign colon lesions|
89029274|NCT03352765|Experimental|rituximab, bendamustine & melphalan and ASCT|This is a phase I study of rituximab, bendamustine and melphalan (RBM) conditioning followed by ASCT in elderly patients with B-cell NHL. Conditioning regimen consist of rituximab 375 mg/m2 on days -11 and -4, bendamustine 160 mg/m2 intravenously on days -3 and -2; melphalan 140 mg/m2 intravenously on day -1 before the reinfusion of autologous stem cells on day 0. The conditioning timeline can be modified if there are patient scheduling conflicts. Patients who are deemed inevaluable will be replaced for the primary objective. Patients will be considered inevaluable if they don't receive one dose of conditioning regimen and are removed from the study.
89576978|NCT02500537|Experimental|Thoracic Procedures|"Thoracic procedures may include, but are not limited to wedge resection and lobectomy, and may include video assisted thoracic surgery (VATS) or open procedures.~Device: Endo GIA™ Reinforced Reload with Tri-Staple™ Technology"
89576979|NCT05003635|Active Comparator|AFT+ EVEBRA device (intervention arm)|"Before and after the AFT surgery, patients are required to wear the EVEBRA expansion device for a total duration of 4 weeks. Thereafter patients will receive a PexyBra over the reconstructed breast.~Pre-operatively patients are required to wear the device for a total of 200 hours."
89576980|NCT05003635|No Intervention|AFT without EVEBRA device (control arm)|Patients will receive the AFT treatment for total reconstruction without the requirement of wearing the EVEBRA device.
89576981|NCT04966819|Experimental|Survivorship Care|"Survivorship care will consist of:~Regular meetings with the rectal cancer oncology pivot nurse~Identification of a primary care physician~Development of an individualized survivorship plan~Educational resources for patients"
89576982|NCT04966819|No Intervention|Standard Care|The control arm will consist of patients treated at the same institution who are receiving standard of care. Standard of care consists of meeting with colorectal oncology pivot nurse as needed (i.e. by referral from specialist based on patient needs).
89576983|NCT02498821|Other|Standard of Care (Chest X-ray)|Correct placement of the Peripherally Inserted Central Catheter (PICC) will be confirmed using standard of care (Chest X-ray).
89576984|NCT02498821|Other|Sherlock 3CG® TCS|Correct placement of the Peripherally Inserted Central Catheter (PICC) will be confirmed using Sherlock 3CG® TCS magnetic tracking PICC placement and ECG-based tip confirmation.
89576985|NCT04205539|Experimental|Dexmedetomidine|All patients will complete neurocognitive testing inclusive of the Quick Dementia Rating Scale (QDRS) and Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)) to assess cognitive impairment. A Clinical Dementia Rating (CDR) score of 1 or above will be considered dementia. Lumbar punctures will be used to determine Alzheimer's disease status.The subjects will have three fMRI scans: structural T1 and two NOODI DTI scans. The dexmedetomidine will be given to the patient after the first DTI scan with a dosage that will be congruent with patient height, weight, and medical history.
89576986|NCT02313909|Experimental|Rivaroxaban|Rivaroxaban 15 mg orally once daily
89576987|NCT02313909|Active Comparator|Aspirin|Aspirin 100 mg orally once daily
89029275|NCT03252249|Active Comparator|3 months dual anti-platelet therapy|3 months dual anti-platelet therapy.
89029276|NCT03252249|Active Comparator|12 months dual anti-platelet therapy|12 months dual anti-platelet therapy.
89029277|NCT03241732|Active Comparator|Dietary (AID) Cohort|Anti-inflammatory Diet: This arm will focus on adjusting dietary practices to eat foods that have lower amounts of inflammatory foods that might help reduce overall inflammation in the brain and body. This arm will introduce patients to an integrative diet that reduces saturated fats and carbohydrates and emphasizes proteins and omega-3 fats that help reduce inflammation and oxidative damage.
89029278|NCT03241732|Active Comparator|Intravenous/Oral NAC Cohort|N-acetyl Cysteine: This arm provide patients with a natural supplement, n-acetyl cysteine (NAC) which is the N-acetyl derivative of the naturally occurring amino acid, L-cysteine, that supports antioxidants to reduce oxidative damage in the body. NAC is a common over-the-counter supplement. It is used as an injectable pharmaceutical to protect the liver in cases of acetaminophen overdose. Laboratory studies have suggested that NAC might have a beneficial effect in neurodegenerative disorders such as TBI. Patients in this arm will receive IV NAC once a week plus oral NAC supplement 500 mg twice per day for approximately 3 months until the follow up evaluation.
89576988|NCT02287467|Experimental|Arm A: hIVIG|Participants will receive a single infusion of intravenous hyperimmune immunoglobulin (hIVIG), administered over approximately 2 hours on Day 0. Participants will also receive SOC treatment for the flu.
89576989|NCT02287467|Placebo Comparator|Arm B: Placebo|Participants will receive a single infusion of placebo for hIVIG, administered over approximately 2 hours on Day 0. Participants will also receive SOC treatment for the flu.
89576990|NCT02287233|Experimental|Phase 1: 600 mg Venetoclax + LDAC|"Venetoclax was administered orally once daily (QD) on Days 2 through 28 of Cycle 1. Dosing started at 50 mg (Day 2) and increased up to 600 mg by Day 6. Beginning with Cycle 2, 600 mg venetoclax was administered Days 1 through 28 of each 28-day cycle. Participants also received low-dose cytarabine (LDAC; 20 mg/m²) administered by subcutaneous injection once daily on Days 1 to 10 of each cycle.~Participants could continue receiving treatment until disease progression or until discontinuation criteria were met."
89576991|NCT02287233|Experimental|Phase 1: 800 mg Venetoclax + LDAC|"Venetoclax was administered orally once daily (QD) on Days 2 through 28 of Cycle 1. Dosing started at 100 mg (Day 2) and increased up to 800 mg by Day 6. Beginning with Cycle 2, 800 mg venetoclax was administered Days 1 through 28 of each 28-day cycle. Participants also received LDAC (20 mg/m²) administered by subcutaneous injection once daily on Days 1 to 10 of each cycle.~Participants could continue receiving treatment until disease progression or until discontinuation criteria were met."
89576992|NCT02287233|Experimental|Phase 2: 600 mg Venetoclax + LDAC|"Venetoclax was administered orally once daily (QD) on Days 2 through 28 of Cycle 1. Dosing started at 50 mg, and increased up to 600 mg by Day 6. Beginning with Cycle 2, 600 mg venetoclax was administered Days 1 through 28 of each 28-day cycle. Participants also received LDAC (20 mg/m²) administered by subcutaneous injection once daily on Days 1 to 10 of each cycle.~Participants could continue receiving treatment until disease progression or until discontinuation criteria were met."
89576993|NCT01646385||etanercept|adult rheumatoid arthritis patients initiating therapy with etanercept as their first biologic therapy
89576994|NCT01646385||nbDMARD|biologic-naive adult rheumatoid arthritis patients with DAS28 >4.2 treated with non-biologic anti-rheumatic drugs(s).
89576995|NCT02286843|Experimental|HER2-targeted PET/CT|Pts with confirmed HER2- breast cancer will then undergo HER2-targeted PET/CT. 89Zr-trastuzumab is a novel radiotracer which allows excellent visualization of HER2+ lesions. 89Zr-pertuzumab is a novel radiotracer which may allow for specific visualization of HER2+ lesions. PET/CT imaging with these novel radiotracers will allow evaluation of all identifiable malignant lesions, rather than evaluation of only single lesions by biopsy. Avid lesions will be considered suspicious for HER2+ malignancy. Pts with at least one 89Zr-trastuzumab or 89Zr-pertuzumab avid lesion will be biopsied to confirm HER2+ pathology. From these 50 pts, we will determine the proportion of HER2- primary breast cancer pts that express HER2+ malignancy imagable by HER2-targeted PET/CT. Pts recruited to the protocol, but then drop out prior to HER2-targeted PET/CT due HER2+ disease being identified on retesting of the patient's archived tissue samples, will be replaced with newly recruited pts.
89576996|NCT02282163|Experimental|Lumason|All patients were administered, Lumason (sulphur hexafluoride lipid-type A microspheres) an ultrasound contrast agent as a single 0.03 mL/kg bolus injection during echocardiography.
89576997|NCT02281773|Experimental|dose 1|
89576998|NCT02281773|Experimental|dose 2|
89576999|NCT02281773|Experimental|dose 3|
89577000|NCT02281773|Experimental|dose 4|
89577001|NCT02281773|Placebo Comparator|placebo|
89577002|NCT02285361||GIOTRIF|
89577003|NCT02354235|Experimental|Canagliflozin + Teneligliptin|Patients receive Canagliflozin for 24 weeks in combination with Teneligliptin.
89577004|NCT02354235|Placebo Comparator|Placebo + Teneligliptin|Patients receive placebo for 24 weeks in combination with Teneligliptin.
89577005|NCT02280291|Active Comparator|Ankle Single Shot Block (SSB)|
89029279|NCT03241732|No Intervention|Control Cohort|Control Group: Standard of Care Treatment for at least 3 months. After the first 3 month, participants in this arm may crossover to the NAC study arm.
89577006|NCT02280291|Experimental|Ankle OnQ (Continuos Sedation OnQ Pump)|
89577007|NCT02280291|Experimental|DR SSB|
89577008|NCT02280291|Experimental|DR OnQ|
89577009|NCT02284893|Experimental|A1:Saxagliptin / Placebo + Dapagliflozin / Placebo|Saxagliptin 5 mg and matching placebo 0 mg (once daily) plus Dapagliflozin 10 mg and matching placebo 0 mg (once daily)
89033239|NCT02920515|Active Comparator|Traditional Chinese Medicines|Zhibo dihuang pills: 8 tablets twice a day by mouth for 6 months and Dabu ying pills: 6g twice a day by mouth for 6 months
89033240|NCT02920515|No Intervention|blank group|without therapy
89577010|NCT02284893|Experimental|A2: Sitagliptin / placebo|Sitagliptin 100 mg and matching placebo 0 mg (once daily)
89577011|NCT02284347|Experimental|NuVent™|Revision patients treated with NuVent™
89577012|NCT02279043|Experimental|Intervention|IUC users and non-IUC user participants randomized to the intervention arm will take part in small intervention groups in an online community called Birth Control Connect for twelve days. There will be up to 35 intervention groups with 9 members each. Non-IUC users in these groups will receive the intervention of Interaction with users of IUC and non-IUC users in the context of the online community. About 50% of participants in intervention groups will be current IUC users, and 50% will not be current IUC users. We will measure the attitudes and behaviors of those who do not have IUC before and after the intervention, considering social exposure to IUC users as a possible predictor of changes in knowledge, attitude and behavior.
89577013|NCT02279043|Placebo Comparator|Control|Participants randomized to the control arm will take part in Birth Control Connect control groups identical to those in the intervention arm, except no participants in the control arm will be current IUC users. Therefore, participants in the control arm will have interaction with non-IUC users only. We will measure these participants' attitudes and behavior related to IUC use before and after the twelve-day study period, and compare results to those of participants in the intervention arm. There will be up to 35 control groups of 9 members each.
89577014|NCT02279043|No Intervention|IUC users|IUC users will be recruited to populate intervention groups. Interaction with IUC users will be the intervention for non-IUC users randomized to the intervention arm. IUC users will receive no intervention.
89577015|NCT02283411|Other|Diabetes Mellitus, Type 1 and Type 2|Subjects will wear the Abbott Sensor Based Glucose Monitoring Systems and will receive no treatment except for safety purposes.
89577016|NCT02351817|Experimental|Baseline - Test A - Test B|"Three period investigation. First each subject tests baseline product, then Test A and finally Test B.~Baseline product: the subject's usual product~Test A: A newly developed 1-piece, open ostomy appliance for collecting feces~Test B: A newly developed 1-piece, open ostomy appliance for collecting feces"
89577017|NCT02351817|Experimental|Baseline - Test B - Test A|"First each subject tests baseline product, then Test B and finally Test A.~Baseline product: the subject's usual product~Test A: A newly developed 1-piece, open ostomy appliance for collecting feces~Test B: A newly developed 1-piece, open ostomy appliance for collecting feces"
89577018|NCT02351349|Experimental|multidisciplinary intervention|Due to the problem of randomization, the study became a before and after assessment in the one group that completed the 12 week exercise program and received nutritional support
89577019|NCT02351349|No Intervention|Non adherence|Those who were offered the program but did not complete the prescription
89577020|NCT02484547|Experimental|Low Dose|Monthly intravenous (IV) infusions
89577021|NCT02484547|Experimental|High Dose|Monthly intravenous (IV) infusions
89577022|NCT02517541|Experimental|Test period|The arm consists of a two-week baseline period where subjects apply their own product and a 12 weeks test period where the subjects apply the intervention (SenSura Mio Convex Soft)
89577023|NCT02496091||ATLANTIS Abutment|The investigational product (ATLANTIS abutment) is already included in a restoration in the subject at enrollment, thus this study does not involve the installation of any investigational products.
89577024|NCT02483611|Experimental|Group M|"Magnesium Sulfate. In this group, the patients received magnesium sulfate 40 mg/Kg as a bolus and 20 mg/kg/h by continuous IV infusion during surgery.~After the bolus of magnesium sulfate, 0.15 mg/kg of cisatracurium was infused over 5 seconds."
89029280|NCT03241732|Active Comparator|Neuro Emotive Technique|This arm measures effects of NET in individuals with TBI symptoms by evaluating measures of distress, autonomic reactivity, neuroimaging markers, anxiety, health-related, physiological and psychology-related symptoms. Participants would be evaluated (or re-evaluated) with a battery of neurocognitive tests, and receive baseline PET-MRI and follow up MRI imaging. Subjects will receive a pre-screening evaluation that measures distress by the Subjective Units of Distress interview, biofeedback measures of heart rate variability (HRV) and galvanic skin resistance (GSR) in conjunction with recollection of distress. Subjects will receive five sessions of Neuro-emotive Technique. Subjects who have participated in the initial study will be re-consented if enrolled in the Neuro Emotive Technique Substudy for approximately 2-3 months until the follow up evaluation. SUDS, biofeedback and surveys will be completed again after the NET sessions are complete.
89029281|NCT03215706|Experimental|Module A|Chemotherapy/Biologics combined
89029282|NCT03215706|Active Comparator|Module B|Chemotherapy Combination
89029283|NCT03214354|Experimental|Non-myeloablative conditioning|Non-myeloablative conditioning
89029284|NCT03184038|Experimental|Supportive care (SRS/SBRT, neurocognitive testing)|Patients undergo SRS on day 1 or SBRT for 3 fractions over days 1-7 and undergo neurocognitive testing at baseline, 4, and 12 months after undergoing SRS or SBRT.
89029285|NCT03151005|Experimental|Metformin-GLP-1 Receptor Agonist|Metformin-GLP-1 Receptor Agonist Therapy: metformin 0.5 g/time by mouth, 3 times per day, with 5 ug exenatide subcutaneous injection twice per day, for 4 weeks, then change to 10ug exenatide subcutaneous injection twice per day for 8 weeks; or metformin 0.5 g/time by mouth, 3 times per day, with 0.6mg liraglutide subcutaneous injection once per day, for 1 weeks, then change to 1.2-1.8 mg liraglutide subcutaneous injection according to patient's blood glucose condition, twice per day for 8 weeks.
89029286|NCT03151005|Active Comparator|Metformin-Oral Contraceptive(OC)|Metformin-Oral Contraceptive(OC) Therapy: metformin 0.5 g/ time by mouth, 3 times per day, with Diane 35(OC) 1 piece per day by mouth, for 12 weeks.
89029287|NCT03143153|Experimental|Nivolumab + Ipilimumab|
89029288|NCT03143153|Experimental|Nivolumab + Cisplatin + Fluorouacil|
89029289|NCT03143153|Active Comparator|Cisplatin + Fluorouracil|
89029290|NCT03076242||Gem Registry|Men with a personal history of PCA; Unaffected males who are at higher risk for prostate cancer
89577025|NCT02483611|Experimental|Group ML|"Magnesium Sulfate plus Lidocaine. In this group, the patients received 40 mg/kg of Magnesium Sulfate plus 3 mg kg-1 lidocaine as a bolus and 20 mg/kg/h and 3 mg/kg/h, respectively, by infusion continuously during the surgery.~After the bolus of magnesium sulfate and lidocaine, 0.15 mg/kg of cisatracurium was infused over 5 seconds"
89577026|NCT02483611|Placebo Comparator|Group C|"Isotonic Solution. In this group, the patients received the volume of isotonic solution equivalent to the volume of solution infused into experimental groups.~After the bolus of the isotonic solution , 0.15 mg/kg of cisatracurium was infused over 5 seconds"
89577027|NCT04963933|Experimental|Patients treated with the device|Patients treated with the Nautilus will be followed up
89577028|NCT02483533|Experimental|Experimental: LIPO-202|Subjects received either LIPO-202 or Placebo for LIPO-202 in the parent study (LIPO-202-CL-18 or LIPO-202-CL-19). Subjects will not receive any additional treatment in this follow-on study.
89577029|NCT02483533|Placebo Comparator|Placebo Comparator: Placebo|Subjects received either LIPO-202 or Placebo for LIPO-202 in the parent study (LIPO-202-CL-18 or LIPO-202-CL-19). Subjects will not receive any additional treatment in this follow-on study.
89577030|NCT02482129|Experimental|LME636|LME636 60 mg/mL ophthalmic solution, maximum drop frequency administered for 2 weeks, followed by a tapering for 1 week (Week 3) and 1 week of masked Vehicle administration (Week 4)
89577031|NCT02482129|Active Comparator|Dexamethasone|Dexamethasone 0.1% ophthalmic solution, maximum drop frequency administered for 2 weeks, followed by a tapering for 2 weeks (Weeks 3 and 4)
89029291|NCT02979574|Active Comparator|Electro-Acupuncture (EA) Procedure|Participants will receive 10 treatment of EA acupuncture over the course of 10 weeks (with a maximum of 2 treatments per week).
89577032|NCT04962529||Arm 1: Metastatic Breast Cancer Patients With Contemporaneous Tissue Biopsy|"Investigators plan to enroll patients previously diagnosed with a primary breast cancer of any subtype at least six (6) months before presentation with suspected metastases or be presenting with de novo metastasis The suspected metastases in these patients must be outside the ipsilateral breast, axilla infra/supraclavicular areas. In those with suspected metastases in contralateral axilla, infra/supraclavicular areas only a new contralateral breast primary must be excluded by physical exam, mammogram or MRI~If a tissue biopsy is performed, the matched tissue will be sent to the central pathology lab for reanalysis. If a tissue biopsy was performed, but the tissue block is exhausted or unavailable, patients are still eligible to participate in the study."
89577033|NCT04962529||Arm 2: Metastatic Breast Cancer Patients Without Contemporaneous Tissue Biopsy|"Investigators plan to enroll patients previously diagnosed with a primary breast cancer of any subtype at least six (6) months before presentation with suspected metastases or be presenting with de novo metastasis The suspected metastases in these patients must be outside the ipsilateral breast, axilla infra/supraclavicular areas. In those with suspected metastases in contralateral axilla, infra/supraclavicular areas only a new contralateral breast primary must be excluded by physical exam, mammogram or MRI.~A contemporaneous tissue biopsy is optional for this cohort."
89577034|NCT02495857|Experimental|Hyaluronate Injectable Viscosupplement|Hyaluronate Injectable Viscosupplement (1% sodium hyaluronate). IA injection to the knee once weekly for 3 weeks
89577035|NCT02495857|Active Comparator|Euflexxa IA injection|Euflexxa IA injection to the knee once weekly for 3 weeks
89577036|NCT02495857|Placebo Comparator|Placebo|Placebo (normal saline). IA injection to the knee once weekly for 3 weeks
89577037|NCT02495389|Experimental|Mirabegron|Participants received mirabegron (Myrbetriq) daily for 12 weeks
89577038|NCT02495233|Experimental|Gilteritinib 120mg + Erlotinib 150mg|Gilteritinib was administered in combination with erlotinib orally once daily.
89577039|NCT02495233|Experimental|Gilteritinib 80mg+ Erlotinib 150mg|Gilteritinib was administered in combination with erlotinib orally once daily.
89577040|NCT02495077|Experimental|Experimental|rATG is co-administered with anti-TNFa (infliximab/Remicade®) plus maintenance therapy with tacrolimus, a mycophenolic acid derivative (either MMF or enteric coated MPA) and prednisone.
89577041|NCT02495077|Active Comparator|Control|Rabbit anti-thymocyte globulin (rATG/Thymoglobulin®) plus placebo (Sterile normal saline) induction followed by maintenance therapy with tacrolimus, a mycophenolic acid derivative (either MMF or enteric coated MPA) and prednisone.
89577042|NCT02278341|Experimental|Roxadustat|Participants received roxadustat three times a week (TIW) for at least 52 weeks up to a maximum of 104 weeks. Participants received initial dose of roxadustat in doses of 100 mg, 150 mg or 200 mg, according to the average weekly dose of epoetin or darbepoetin alfa prior to randomization. Participants' roxadustat dosage was adjusted every 4 weeks to maintain Hb level within the target range 10.0 to 12.0 g/dL. Dose adjustment steps were as follows: 20, 40, 50, 70, 100, 150, 200, 250, 300, and 400 mg. Oral iron treatment of 200 mg was allowed for supplementation to support erythropoiesis. Treatment with intravenous iron was allowed only if certain protocol criteria were met.
89577043|NCT02278341|Active Comparator|ESA (Erythropoiesis Stimulating Agent) treatment|Participants received epoetin alfa once weekly, twice weekly or TIW and darbepoetin alfa once a week or once every other week. Participants were treated for at least 52 weeks up to a maximum of 104 weeks. Treatment dosage was adjusted according to the pre-specified rule of keeping the participant's Hb levels between 10.0 to 12.0 g/dL. Participants were not allowed to switch from the epoetin alfa to darbepoetin alfa or vice versa.
89577044|NCT02282631|Experimental|Intervention group school|School where the incentive scheme will be run.
89577045|NCT02282631|No Intervention|Control group school|School with no intervention; ongoing advice on active school travel.
89577046|NCT02278263|Placebo Comparator|Control|Application of 20ml of normal saline (NaCl 0.9%) topically after implantation of prosthesis and left to sit for two minutes, excess carefully suctioned followed by standard closure with no drains; application of 15ml of normal saline intravenously at the same time prior to release of tourniquet.
89577047|NCT02278263|Experimental|Topical|Application of 1.5g in 20ml tranexamic acid topically after implantation of prosthesis with excess carefully suctioned followed by standard closure with no drains; application of 15ml of normal saline intravenously at the same time prior to release of tourniquet.
89577048|NCT02278263|Experimental|Systemic|Application of 20ml of normal saline topically after implantation of prosthesis with excess carefully suctioned followed by standard closure with no drains; Application of tranexamic acid intravenously (1.5g/15ml) at the same time prior to release of tourniquet
89577049|NCT02349711|Placebo Comparator|Placebo|Placebo will be taken as a capsule twice daily for 8 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
89577050|NCT02349711|Experimental|Probiotic mixture|A commercially available probiotic mixture of Lactobacillus gasseri, Bifidobacterium bifidum, and Bifidobacterium longum will be taken as a capsule twice daily for 8 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
89577051|NCT02494921|Experimental|Treatment (Phase 1b)|The starting cohort dose level (1) for docetaxel will be 75 mg/m2, administered on day 1 of each cycle. Prednisone will be fixed at 5 mg twice a day. The starting dose level and schedule for ribociclib will begin at 200 mg orally once daily, starting on day 1 of the 21-day cycle. If dose level 1 is not tolerated, then alternative dosing schedules of docetaxel will be evaluated, starting with dose level 1A of 60mg/m2 docetaxel.
89029292|NCT02979574|Active Comparator|Battle Field Acupuncture (BFA) Procedure|Participants will receive 10 treatment of BFA acupuncture over the course of 10 weeks (with a maximum of 2 treatments per week).
89033241|NCT02917356|Experimental|Spiritual laying on of hands group|"Spiritist Passe - performed by spiritual healers from the religion Spiritism (5 min, once a week, for 8 weeks)~Physical therapy: Kinesiotherapy (45 min, twice a week, for 8 weeks)"
89577052|NCT02494921|Experimental|Treatment (Phase 2)|Participants in Phase 2 will receive the Recommended Phase 2 Dose for docetaxel and ribociclib
89577053|NCT01653847|Active Comparator|Group 1: Tacrolimus with MMF.|This group will receive a standard dose Tacrolimus and MMF. This will follow standard of care protocol at Northwestern Memorial Hospital's Comprehensive Transplant Center.
89577054|NCT01653847|Active Comparator|Group 2: Tacrolimus with Everolimus|This group will receive a low dose Tacrolimus with concentration controlled Everolimus
89577055|NCT01653847|No Intervention|Donors|One time blood samples will be collected from kidney donors to recipients in this study
89577056|NCT02493751|Experimental|Dose finding phase and dose expansion phase.|To test the maximum tolerated dose of avelumab (MSB0010718C) in combination with axitinib (AG-013736)
89577057|NCT02493517|Experimental|Lanreotide Autogel® 60mg, 90mg and 120mg|Lanreotide Autogel 90mg from day 1 to week 13, 1 injection every 4 weeks (4 in total), titrated to 60mg, 90mg, or 120mg at week 17, then from week 17 to week 29 each group receives 1 injection every 4 weeks (4 in total/group).
89577058|NCT02493517|Active Comparator|Lanreotide 40mg PR (Lanreotide Acetate for Injection )|Lanreotide PR 40mg from day 1 to week 15, 1 injection every 10 days, then at dose titration (week 16) injection frequency will either remain at 10 days or increase to 14 days or decrease to 7 days up until week 30 or 31.
89577059|NCT02493361|Experimental|Treatment|Pembrolizumab: 200 mg IV, Day 1 of each cycle pIL-12: 1/4 tumor volume at concentration of 0.5 mg/mL intratumoral, Days 1, 5, and 8 of each odd cycle
89577060|NCT02493127|Experimental|Standard PCS|Grip strength measurements and completes standard PCS
89577061|NCT02493127|Experimental|Positive PCS|Grip strength measurements and completes positively adjusted PCS
89577062|NCT02478463|Experimental|Cabotegravir|Subject will receive CAB 30 mg tablet once daily oral dose for 28 days (4 weeks) followed by a washout period of 14 to 42 days. After the washout, subject will receive a single dose of CAB LA 600 mg IM to gluteal region.
89577063|NCT02491411|Experimental|Treatment (dexamethasone and enzalutamide)|Patients receive dexamethasone PO once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity until there is evidence of PSA progression, clinical disease progression, or radiographic disease progression. At time of progression, dexamethasone will be stopped via a rapid taper over one week if patients were treated for over 30 days. Patients then receive enzalutamide PO once daily on days 1-28. Treatment repeats every 28 days for up to 3 courses in the absence of clinical disease progression or unacceptable toxicity.
89577064|NCT02517463||Pre-ovulatory|Ulipristal acetate 30 mg single oral dose
89577065|NCT02517463||Post-ovulatory|Ulipristal acetate 30 mg single oral dose
89577066|NCT02516605|Experimental|LJN452|
89029293|NCT02979574|Active Comparator|Wait List Control (WLC) Usual Care Procedure|Subjects in the WLC group continue to receive their standard medical care and pain management as prescribed by their physicians or other health care providers, including analgesic medications. After the 12 week follow up period, patients in the WLC will receive up to ten treatments of either EA or BFA based on their personal preference.
89577067|NCT02516605|Placebo Comparator|Placebo|
89577068|NCT02490475|Experimental|RhuMab 2C4 + Docetaxel 100 mg/m^2 (Level 3)|Docetaxel will be administered via intravenous (IV) infusion on Day 1 of each 3-week cycle at a dose of 100 mg/m^2 per day, and rhuMab 2C4 will be given on Day 1 of each 3-week cycle as a fixed-dose 420-mg IV infusion. For Cycle 1 only, rhuMab 2C4 administration will be delayed to Day 2 with an initial 840-mg loading dose. The incidence of DLTs will be used to guide intrapatient dose modification, as well as subsequent enrollment.
89577069|NCT02490475|Experimental|RhuMab 2C4 + Docetaxel 60 mg/m^2 (Level 1)|Docetaxel will be administered via IV infusion on Day 1 of each 3-week cycle at a dose of 60 mg/m^2 per day, and rhuMab 2C4 will be given on Day 1 of each 3-week cycle as a fixed-dose 420-mg IV infusion. For Cycle 1 only, rhuMab 2C4 administration will be delayed to Day 2 with an initial 840-mg loading dose. The incidence of DLTs will be used to guide intrapatient dose modification, as well as subsequent enrollment.
89577070|NCT02490475|Experimental|RhuMab 2C4 + Docetaxel 75 mg/m^2 (Level 2)|Docetaxel will be administered via IV infusion on Day 1 of each 3-week cycle at a dose of 75 mg/m^2 per day, and rhuMab 2C4 will be given on Day 1 of each 3-week cycle as a fixed-dose 420-mg IV infusion. For Cycle 1 only, rhuMab 2C4 administration will be delayed to Day 2 with an initial 840-mg loading dose. The incidence of DLTs will be used to guide intrapatient dose modification, as well as subsequent enrollment.
89577071|NCT02477839|Experimental|Lacosamide|Lacosamide syrup 8 mg/kg/day to 12 mg/kg/day
89577072|NCT02477839|Placebo Comparator|Placebo|Matching placebo syrup
89577073|NCT02489773||Group 1|HbA1c values ranged from 7.5% to 12% (or higher)
89577074|NCT02489773||Group 2|HbA1c values <7.5%
89577075|NCT04940611||Participants With CPF-CD|Participants diagnosed with CPF-CD will undergo surgical intervention according to their clinic's standard practice to treat the index fistula, and will be observed prospectively for 24 months post-index surgery.
89577076|NCT04940611||Participants With CD-RVF|Participants diagnosed with CD-RVF will undergo surgical intervention according to their clinic's standard practice to treat the index fistula, and will be observed prospectively for 24 months post-index surgery.
89577077|NCT04940611||Participants With CCF|Participants diagnosed with CCF will undergo surgical intervention according to their clinic's standard practice to treat the index fistula, and will be observed prospectively for 24 months post-index surgery.
89577078|NCT04939987|Active Comparator|Opioid Control Cohort|"One treatment selected:~Tramadol (50mg) Hydrocodone-Acetaminophen (2.5mg/325mg) Oxycodone-Acetaminophen (2.5mg/325mg)"
89577079|NCT04939987|Experimental|Experimental Cohort|"Multimodal Approach:~Gabapentin (100mg TID) Ketorolac (15mg q6) Acetaminophen (1mg IV q6) Ketamine (1.5mg/kg) Ketorolac tromethamine (15mg or 30mg Q4)"
89029294|NCT02927392|Experimental|Pre-menopausal women|To determine if natural declines in endogenous E2 contribute to changes in BAT activity, the investigators will compare BAT activity in pre-and post-menopausal women. We will also explore whether suppression of ovarian hormones in pre-menopausal women (using leuprolide acetate) impairs BAT activity.
89577080|NCT04953559|Experimental|Active cTBS first, then sham cTBS|Participants complete an Enrollment Visit followed by one week of at-home actigraphy. Participants return to the lab for Overnight Visit 1 and undergo a MRI scan followed by active cTBS and then another MRI scan followed by a night of polysomnographic monitored in-lab sleep. Participants return home and complete another week of at-home actigraphy. Participants then return to the lab for Overnight Visit 2 where they undergo a MRI scan followed by sham cTBS and then another MRI scan followed by a night of polysomnographic monitored in-lab sleep.
89577081|NCT04953559|Experimental|Sham cTBS first, then active cTBS|Participants complete an Enrollment Visit followed by one week of at-home actigraphy. Participants return to the lab for Overnight Visit 1 and undergo a MRI scan followed by sham cTBS and then another MRI scan followed by a night of polysomnographic monitored in-lab sleep. Participants return home and complete another week of at-home actigraphy. Participants then return to the lab for Overnight Visit 2 where they undergo a MRI scan followed by active cTBS and then another MRI scan followed by a night of polysomnographic monitored in-lab sleep.
89577082|NCT02488915|Experimental|EmboTrap® Revascularization Device|Mechanical Thrombectomy with EmboTrap
89577083|NCT02488681|Experimental|Micra Pacemaker Implant|Micra Pacemaker Implant
89577084|NCT02477605|Experimental|27-gauge pak|CONSTELLATION® 27-gauge combined surgical pak used during vitrectomy surgery
89577085|NCT02477605|Active Comparator|23-gauge pak|CONSTELLATION® 23-gauge combined surgical pak used during vitrectomy surgery
89577086|NCT02477527|Experimental|Stribild|Patients to be changed from Atripla to elvitegravir/ cobicistat/ emtricitabine/ tenofovir disoproxil and observed for changes in sleep patterns / sleep disturbances.
89577087|NCT02477215|Experimental|MLN9708, Bendamustine and Dexamethasone Dose Escalation|"Ixazomib 4 mg, days 1, 8, 15.~Dexamethasone 40 mg oral weekly.~Bendamustine dose levels: 70 mg/m^2, 80mg/m^2, or 90 mg/m^2 given on days 1 and 2"
89577088|NCT02477215|Experimental|MLN9708, Bendamustine and Dexamethasone MTD|"Ixazomib 4 mg, days 1, 8, 15.~Dexamethasone 40 mg oral weekly.~Bendamustine dose levels: MTD given on days 1 and 2"
89577089|NCT02487199|Experimental|HCV GT1a (3-DAA)|Participants with hepatitis C virus (HCV) genotype 1a (GT1a) infection received 3-direct-acting antiviral agent (3-DAA: ombitasvir/paritaprevir/ritonavir [25 mg/150 mg/100 mg once daily] and dasabuvir [250 mg twice daily]) for 12 weeks.
89577090|NCT02487199|Experimental|HCV GT4 (2-DAA)|Participants with hepatitis C virus (HCV) genotype 4 (GT4) infection received 2-direct-acting antiviral agent (2-DAA: ombitasvir/paritaprevir/ritonavir [25 mg/150 mg/100 mg once daily]) for 12 weeks.
89577091|NCT02475733|Experimental|CAZ-AVI and metronidazole|CAZ-AVI to be administered every 8 hours as a 2 hour infusion (CAZ-AVI dose and frequency of IV administration will depend upon body weight and renal function) followed by metronidazole (no later than 30 minutes after CAZ-AVI infusion ) to be administered every 8 hours as 20 to 30 minutes infusion
89577092|NCT02475733|Active Comparator|Meropenem|administered every 8 hours infused over 15 to 30 minutes or up to 1 hour or infusion duration as per local guidelines.
89577093|NCT04925947|Experimental|KN046|KN046 will be given intravenously every 2 weeks.
89577094|NCT04942639|Experimental|Standard + JOE|Standard Maintenance Treatment plus JOE robot
89577095|NCT04942639|No Intervention|Standard|Standard maintenance Treatment
89577096|NCT02486653|Experimental|Tamsulosin|
89577097|NCT02486653|Placebo Comparator|Placebo|
89577098|NCT02475655|Experimental|Arm A: Ruxolitinib|Participants received ruxolitinib twice a day for 5 weeks. Participants were required to remain on ART regimen (not provided by the study) for the duration of the study.
88972058|NCT01394900|Active Comparator|WP intervention|African American/Black men who have sex with men (MSM) in same sex intimate relationships in which at least one partner is illicitly using psychostimulants and/or psychoactive substances will receive 4 sessions of general wellness promotion (WP) intervention
88972059|NCT00130104|Experimental|MCB|randomized to receive the metacarpal block for anesthesia
88972060|NCT00016289|Experimental|Treatment (recombinant interleukin-12)|Patients receive interleukin-12 intraperitoneally once weekly. Treatment repeats every 4 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Patients with stable or responding disease receive 2 additional courses.
88972061|NCT00016328|Experimental|Treatment (temsirolimus)|Patients receive CCI-779 IV over 30 minutes once weekly for 4 weeks. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
88972062|NCT00130026|Placebo Comparator|I|Saline placebo
88972063|NCT00016367|Experimental|Regimen A|Gemcitabine IV followed by Cisplatin IV Day 1 and Trastuzumab (Herceptin) IV Day 2; Trastuzumab IV followed by Gemcitabine IV Day 8 and Trastuzumab IV Day 15.
88972064|NCT00016367|Experimental|Regimen B|Starting Day 22 of regimen A, Trastuzumab IV, Gemcitabine IV, and Cisplatin IV Day 1. Trastuzumab IV followed by Gemcitabine IV Day 8 and Trastuzumab IV Day 15. Repeats every 21 days for up to 5 courses.
88972065|NCT00016406|Active Comparator|AC followed by P|doxorubicin and cyclophosphamide followed by paclitaxel followed by surgery
88972066|NCT00016406|Experimental|AC+G followed by P|weekly doxorubicin and daily cyclophosphamide with filgrastim followed by paclitaxel followed by surgery
88972067|NCT00129792|Experimental|1|Has 100% expectation of receiving supplement
88972068|NCT00129792|Sham Comparator|2|Has 50% expectation of receiving supplement
88972069|NCT00129792|Other|3|Has 0% expectation of receiving supplement.
88972070|NCT00129753|Experimental|Alemtuzumab|
88972071|NCT00016523|Experimental|Inhaled Nitric Oxide|Inhaled Nitric Oxide
88972072|NCT00016523|Active Comparator|Placebo|Inhaled Oxygen
88972073|NCT00129714|No Intervention|wait and see|
88972074|NCT00129714|Experimental|collar|
88972075|NCT00129714|Experimental|physiotherapy|
88972076|NCT00129675|Experimental|[123I]ß CIT|To assess [123I]ß CIT and SPECT imaging
88972077|NCT01119365|Experimental|Light|Sequence of bright light flashes of varying durations, interflash intervals, flash lengths, flash brightness, and flash color.
89577099|NCT02475655|No Intervention|Arm B: No Study Treatment|Participants did not receive any study treatment. Participants were required to remain on ART regimen (not provided by the study) for the duration of the study.
89577100|NCT02475265|Experimental|estradiol 0.045mg/levonorgestrel 0.015mg|6 months of estradiol 0.045mg/levonorgestrel 0.015mg (once weekly patch).
89577101|NCT02485717|Experimental|Natroba (spinosad)|spinosad topical suspension, 0.9% up to 120 mL (enough product is used to cover the body from the neck down to the soles of the feet), one treatment left on for 6 hours
89577102|NCT02485717|Placebo Comparator|Placebo|placebo is a topical suspension that is the same formulation as Natroba without the active ingredient spinosad. Up to 120 mL (enough product is used to cover the body from the neck down to the soles of the feet), one treatment left on for 6 hours.
89577103|NCT05460559|Active Comparator|Group A (p-PCNL) procedure|In lithotomy position, . Under fluoroscopic guidance, the desired calyces will be punctured using an 18 G coaxial needle. Then 0.038 mm hydrophilic guidewires will be passed percutaneously through the needle into the pelvis. Using metal dilators dilatation will be carried out. Amplatz sheath will be inserted to allow nephroscope to enter the collecting system. Stone disintegration will be performed using pneumatic, ultrasonic or laser lithotripsy. Eventually after removal of all stone fragments, a nephrostomy tube will be placed.
89577104|NCT05460559|Experimental|Group B (s-ECIRS) procedure|The patients will be in Galdakao-Modified Supine Valdivia (GMSV) position . Under fluoroscopic guidance, the desired calyces will be punctured using an 18 G coaxial needle. Then 0.038 mm hydrophilic guidewires will be passed percutaneously through the needle into the pelvis. Using metal dilators dilatation will be carried out till 30 Fr. Amplatz sheath will be inserted to allow a 26 Fr nephroscope to enter the collecting system. Retrograde intrarenal surgery will be applied simultaneously by a second surgeon using flexible ureteroscopy. The stones will be fragmented with holmium-yttrium-aluminum-garnet (YAG) laser and stone fragments will be evacuated by basket or removed through PCNL tract under nephroscopy.
89577105|NCT02451007|Experimental|A (lurbinectedin)|lurbinectedin (PM01183) 4 mg vials of powder for concentrate for solution for infusion
88972078|NCT00129636|Other|Patient attending hospital clinic|patients were sent a letter especially dictated for them and a copy of the letter written by the hospital consultant to their GP to review
88972079|NCT00129519|Active Comparator|Imiquimod cream|Imiquimod 5% cream applied once daily 5x/week for up to 6 weeks
88972080|NCT00129480|Experimental|Assistance with Pain Treatment|Care management intervention including assessment, decision support, patient activation, education and followup, provider education, feedback to providers
88972081|NCT00129480|No Intervention|Treatment as usual|Treatment as usual
88972082|NCT00016835|Active Comparator|Supra-gingival scaling and placebo|"This group receives a placebo (instead of systemic antibiotic), supra-gingival oral prophylaxis, and ultrasonic removal of supra-gingival calculus with water irrigation at the initial treatment visit. At the 9-month follow-up visit, this group will receive sub-gingival ultrasonic scaling with povidone-iodine irrigation.~This group also receives regular follow-up evaluations and site-specific mechanical periodontal therapy, at 3-month intervals, for approximately 15 months."
88972083|NCT00016835|Experimental|Subgingival scaling and metronidazole|"This group receives ultrasonic scaling with local anesthesia (as needed), local antimicrobial treatment with povidone-iodine irrigation, and metronidazole as an oral systemic antibiotic at the initial treatment visit.~This group also receives regular follow-up evaluations and site-specific mechanical periodontal therapy, at 3-month intervals, for approximately 15 months."
88972084|NCT00016835|Experimental|Subgingival scaling and doxycycline|"This group receives ultrasonic scaling with local anesthesia (as needed), local antimicrobial treatment with povidone-iodine irrigation, and doxycycline as an oral systemic antibiotic at the initial treatment visit.~This group also receives regular follow-up evaluations and site-specific mechanical periodontal therapy, at 3-month intervals, for approximately 15 months."
89029295|NCT02927392|No Intervention|Post-menopausal women|To determine if natural declines in endogenous E2 contribute to changes in BAT activity, the investigators will compare BAT activity in pre-and post-menopausal women.
89033242|NCT02917356|Active Comparator|Non-spiritual Laying on of Hands group|"Non-spiritual Laying on of Hands - performed by lay persons (5 min, once a week, for 8 weeks)~Physical therapy: Kinesiotherapy (45 min, twice a week, for 8 weeks)"
89577106|NCT02485483||VADERA I|RA participants without a concurrent history of depression and who have not received psychotherapy, antidepressants, or inpatient psychiatric treatment in the 3 months before baseline (T0) will be asked to complete the World Health Organization Five Well-Being Index (WHO-5), Patient Health Questionnaire-9 (PHQ-9) and Beck Depression Inventory (2nd edition) (BDI-II) questionnaires and a subsequent structured interview using Montgomery-Åsberg Depression Rating Scale (MADRS) at 2 time-points (T0 and T1 [12 ± 2 weeks]) with a 10-14 week interval between assessments.
88972085|NCT00129441|Experimental|Merck L-830982|
88972086|NCT00129441|Placebo Comparator|Sugar pill|
89577107|NCT02485483||VADERA II|All RA participants who are able to complete the PHQ-9 and BDI-II questionnaires, and have been scheduled for a RA consultation at one of the participating clinics will be eligible for participation.
89577108|NCT02473471|Experimental|MOP side|Three small holes in cortical bone can be created by Miniscrews.Before application of the MOPs, Patient will be asked to wash their mouth twice by chlorhexidine for 1 minute. Local anesthesia will be given (2% lidocaine with 1:100,000 epinephrine). Microosteoperforation (MOPs) will be performed distal to canine.
89577109|NCT02473471|No Intervention|control side|No intervention in the other side of maxilla (control side)
89577110|NCT02450539|Experimental|Abemaciclib|200 milligram (mg) abemaciclib given orally every 12 hours (Q12H) on days 1 to 21 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
89577111|NCT02450539|Active Comparator|Docetaxel|75 milligram per meter squared (mg/m²) docetaxel given intravenously (IV) on day 1 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
89577112|NCT02449915|Experimental|Bupivacaine Arm|Those subjects in the liposomal bupivacaine arm will have 30mL dilutional volume injected. Ten mL will be injected into the perineum in the posterior vaginal area and 20 mL will be injected the port site wounds in the abdomen (5 sites, 4 ml per incision).
89577113|NCT02449915|Placebo Comparator|Placebo Arm|Those subjects in the placebo arm will have 30 mL sterile normal saline injected. Ten mL will be injected into the perineum in the posterior vaginal area and 20 mL will be injected into the port site wounds in the abdomen (5 sites, 4 mL per incision).
89577114|NCT02473393|Experimental|OPS-2071 50mg/day|OPS-2071 50 mg/day：25 mg tablet administered orally twice daily
89577115|NCT02473393|Experimental|OPS-2071 100 mg/day|OPS-2071 100 mg/day：50 mg tablet administered orally twice daily
89577116|NCT02473393|Experimental|OPS-2071 200 mg/day|OPS-2071 200 mg/day：100 mg tablet administered orally twice daily
89577117|NCT02473393|Experimental|OPS-2071 400 mg/day|OPS-2071 400 mg/day：100 mg two tablets administered orally twice daily
89577118|NCT02419573|Active Comparator|Endotracheal Intubation|The insertion of a plastic breathing tube through the mouth and into the trachea.
89577119|NCT02419573|Active Comparator|Laryngeal Tube (King)|Insertion of a supraglottic airway (SGA)
89577120|NCT02472847|Placebo Comparator|Placebo|In a randomized, double-blind, placebo-controlled, between-subjects design, the investigators will couple a standard Pavlovian fear extinction paradigm in fMRI with an acute pharmacological challenge with oral dronabinol (synthetic THC) or placebo 2 hours prior to extinction learning in healthy adult volunteers and test extinction retention and maintenance 24 hours and 1 week later, respectively, after extinction learning.
89577121|NCT02472847|Active Comparator|Dronabinol|In a randomized, double-blind, placebo-controlled, between-subjects design, the investigators will couple a standard Pavlovian fear extinction paradigm in fMRI with an acute pharmacological challenge with oral dronabinol (synthetic THC) or placebo 2 hours prior to extinction learning in healthy adult volunteers and test extinction retention and maintenance 24 hours and 1 week later, respectively, after extinction learning
89577122|NCT02472145|Experimental|Decitabine plus Talacotuzumab|"Part A: For Cycle 1 of Part A, participants will receive talacotuzumab on Day 1. Starting from Cycle 2 of Part A, participants may receive decitabine on Day 1, 2, 3, 4, and 5, and talacotuzumab on Day 8 and 22 of a 28-day cycle.~Part B Arm 1: Participants will receive decitabine on Day 1, 2, 3, 4, and 5, and talacotuzumab on Day 8 and 22 of a 28-day cycle."
89577123|NCT02472145|Active Comparator|Decitabine|Participants in Part B Arm 2 will receive decitabine on Day 1,2, 3, 4 and 5 of a 28-day cycle.
89577124|NCT02448043|Other|Right Hand Bimatoprost 0.01% drops, Left Hand Placebo|"Bimatoprost 0.01% drops placed on the proximal nail folds of the right hand digits two times per day for 30 days.~Saline solution drops placed on the proximal nail folds of the left hand digits two times per day for 30 days."
89577125|NCT02448043|Other|Left Hand Bimatoprost 0.01% drops, Right Hand Placebo|"Bimatoprost 0.01% drops placed on the proximal nail folds of the left hand digits two times per day for 30 days.~Saline solution drops placed on the proximal nail folds of the right hand digits two times per day for 30 days."
89577126|NCT02447887|Experimental|Ixazomib and pegylated IFN alfa - 2b|Ixazomib capsules and pegylated IFN alfa 2b injections weekly. Ixazomib will be taken for the last 3 weeks of 28 day cycle. Pegylated IFN alfa 2b injection will be administered weekly, each week of the 28 day cycle.
89577127|NCT02471755|Active Comparator|Electro-acupuncture Group|
89577128|NCT02471755|Placebo Comparator|Sham Electro-acupuncture Group|
89029296|NCT02914067|Experimental|Cohort 1|"Prior to surgery, subjects will have a complete standard of care history and physical exam by the neurosurgeon and then undergo peri-diagnostic neurocognitive testing utilizing the NIH Toolbox Cognitive Battery computer testing software for iPad (will take 45 minutes). The peri-diagnostic period will be defined as the period from first presentation to 2 weeks post-diagnosis or two weeks post-op, whichever is later.~Participants will also undergo a rsfcMRI during their standard of care MRI imaging which will add 15 minutes to their scan time"
89577129|NCT02470429|Experimental|SYSTANE HYDRATION|SYSTANE HYDRATION lubricant eye drops, 1 drop 4 times per day (QID) in each eye for 42 days
89577130|NCT02470429|Active Comparator|Hyabak 0.15%|Hyabak 0.15% eye drops, 1 drop 4 times per day (QID) in each eye for 42 days
89577131|NCT02447497|Experimental|3M CHG/IPA - Abdominal Region|Apply Chlorhexidine (CHG) 2% / Isopropyl alcohol (IPA) 70% for 30 seconds and allow to dry for 3 minutes.
89577132|NCT02447497|Placebo Comparator|Normal Saline - Abdominal Region|Apply 0.9% sodium chloride with applicator for 30 seconds and allow to dry for 3 minutes.
89577133|NCT02447497|Experimental|3M CHG/IPA - Inguinal Region|Apply Chlorhexidine (CHG) 2% / Isopropyl alcohol (IPA) 70% for 30 seconds and allow to dry for 3 minutes.
89577134|NCT02447497|Placebo Comparator|Normal Saline - Inguinal Region|Apply 0.9% sodium chloride with applicator for 30 seconds and allow to dry for 3 minutes.
89577135|NCT02417935|Experimental|Duloxetine|20 milligrams (mg) duloxetine orally once a day (QD) for one week and then 40 mg duloxetine orally QD for 3 weeks. Duloxetine dosage may be increased up to 60 mg QD at week 4 or week 8. Placebo will be given with duloxetine for blinding. Dosage will be tapered down during the final week of the study.
89577136|NCT02417935|Active Comparator|Pregabalin|150 mg pregabalin orally twice a day (BID) for 1 week and then 300 mg pregabalin orally BID for 3 weeks. Pregabalin dosage may be increased up to 450 mg BID at week 4 or 8, and increased up to 600 mg BID at week 8. Placebo will be given with pregabalin for blinding. Dosage will be tapered down during the final week of the study.
89577137|NCT02417233|No Intervention|Standard of Care|Participants are administered baseline, 6 month, and 12 month questionnaires and provided with the study incentive (mobile phone airtime) only. This group will not receive any additional engagement to care intervention.
89577138|NCT02417233|Active Comparator|SMS text message|"Participants are administered baseline, 6 month, and 12 month questionnaires and provided with the study incentive (mobile phone airtime). In addition, they receive automated bi-weekly behavioral text messages aimed at improving health and reducing transmission risk and also automated bi-weekly check-in text messages that will trigger a phone call from clinic staff if the participant reports not being well."
89577139|NCT02417233|Active Comparator|SMS text message + Peer Navigation|Participants are administered baseline, 6 month, and 12 month questionnaires and provided with the study incentive (mobile phone airtime). In addition, they receive automated bi-weekly behavioral text messages aimed at improving health and reducing transmission risk and also bi-weekly contact from an HIV-positive peer who provides personalized support and with health or other service systems navigation assistance.
89577140|NCT04938661|Active Comparator|Conventional Center-Based Cardiac Rehab (CON)|Participants will be prescribed 36 sessions of center-based CR. This includes supervised exercise sessions, cooking demonstrations, didactic lectures, video presentations, group support, and stress management education. During sessions, participants have direct access to the medical director, case manager, registered nurse, exercise physiologist, and stress management specialists.
89577141|NCT04938661|Active Comparator|Conventional Center-Based Cardiac Rehab + mHealth (CON+)|"Participants will be prescribed 36 sessions of center-based CR as noted above. In addition, participants will be provided access to the mHealth platform which provides e-Learning modules with factsheets, videos, quizzes, and questionnaires (coinciding with activities being conducted during the CON program), a Social Network Module will allow patients to communicate via secure network with other patients who are part of their invited network. The Social Network Module also allows for secure two-way interaction with healthcare providers in the event that patients are experiencing signs or symptoms suggestive of worsening condition. This platform also contains a Personal Health Record Module allowing patients to upload, archive, and retrieve personal health data (e.g. fitness tracker data, heart rate monitor data, blood pressure recordings, etc.) and record vital signs, symptoms, treatments, and medical history."
89577142|NCT04938661|Active Comparator|Home-Based Cardiac Rehab + mHealth (HOM+)|Participants will be provided paper copies of educational content at the time of event/discharge. In addition, these participants will be provided access to the same mHealth platform as the CON+ group. Participants in this group will be encouraged to exercise three days per week while also completing the additional questionnaires and educational content provided by the mHealth platform in accordance with the CR program. Participation will be tracked using web/internet analytics.
89577143|NCT02416453|Experimental|Group 1|Participants will receive intramuscular (IM) injection of Ad26.ZEBOV/Placebo on Day 1 followed by IM injection of MVA-BN-Filo/Placebo on Day 29.
89577144|NCT02416453|Experimental|Group 2|Participants will receive IM injection of Ad26.ZEBOV/Placebo on Day 1 followed by IM injection of MVA-BN-Filo/Placebo on Day 57.
89577145|NCT02416453|Experimental|Group 3|Participants will receive IM injection of Ad26.ZEBOV/Placebo on Day 1 followed by IM injection of MVA-BN-Filo/Placebo on Day 85.
89577146|NCT02469961|Experimental|dexmedetomidine|Participants will receive an interscalene block and be sedated with dexmedetomidine
89577147|NCT02469961|Active Comparator|Propofol|Participants will receive an interscalene block and be sedated with propofol
89577148|NCT02415595|Experimental|Arm 1: BMS-955176 60 mg + TDF/FTC|BMS-955176 at 60 mg active dose per day + BMS-955176 placebo matching 120 mg + efavirenz (EFV) placebo matching 600 mg + tenofovir/emtricitabine (TDF/FTC) 300/200 mg per day, orally
89577149|NCT02415595|Experimental|Arm 2: BMS-955176 120 mg + TDF/FTC|BMS-955176 placebo matching 60 mg + BMS-955176 at 120mg active dose per day + EFV placebo matching 600mg + TDF/FTC 300/200mg per day, orally
89577150|NCT02415595|Experimental|Arm 3: BMS-955176 180 mg + TDF/FTC|BMS-955176 at 60mg active dose per day + BMS-955176 at 120mg active dose per day + EFV placebo matching 600mg + TDF/FTC at 300/200mg per day, orally
89577151|NCT02415595|Active Comparator|Arm 4: EFV + TDF/FTC|BMS-955176 placebo matching 60mg + BMS-955176 placebo matching 120mg + EFV at 600mg per day + TDF/FTC 300/200mg per day
89577152|NCT02446717|Experimental|Arm A|ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (80 mg) QD for 12 weeks in chronic HCV genotype 1- infected participants without cirrhosis.
89577153|NCT02446717|Experimental|Arm B|ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD plus ribavirin (RBV) for 12 weeks in chronic HCV genotype 1- infected participants without cirrhosis.
89577154|NCT02446717|Experimental|Arm C|ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 12 weeks in chronic HCV genotype 1- infected participants without cirrhosis.
89577155|NCT02446717|Experimental|Arm D|ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 12 weeks in HCV genotypes 1- or 4-6- infected participants with or without cirrhosis.
89577156|NCT02446717|Experimental|Arm E|ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 16 weeks in HCV genotype 1- or 4-6- infected participants with or without cirrhosis.
89577157|NCT02469415|Experimental|Pacritinib + Azacitidine or Decitabine|"Part 1: Pacritinib 200 mg taken by mouth twice daily. Study cycles administered every 28 days.~Part 2: After 4 cycles of treatment, Pacritinib combined with 5-azacitidine or Decitabine. Pacritinib decreased to 200 mg in morning and 100 mg in evening for first cycle of combined therapy with Pacritinib increased to 200 mg twice a day on subsequent cycles of combined therapy. Those with disease progression prior to 4 cycles of Pacritinib may initiate Pacritinib + HMA study portion prior to completion of 4 cycles. Starting dose of either 5-azacitidine 75 mg/m2 by vein (IV) or Decitabine 20 mg/m2 IVon Days 1 - 5 of Cycles 5 and beyond."
89577158|NCT02446171|Experimental|Treatments A-D-B-C sequence|Treatment A in Period 1, Treatment D in Period 2, Treatment B in Period 3 and Treatment C in Period 4
89577159|NCT02446171|Experimental|Treatments B-A-C-D sequence|Treatment B in Period 1, Treatment A in Period 2, Treatment C in Period 3 and Treatment D in Period 4
88972087|NCT00016952|Experimental|irinotecan|"Prior oxaliplatin-based chemotherapy: Patients receive irinotecan IV over 90 minutes on day 1. Treatment repeats every 3 weeks.~Treatment continues in the absence of disease progression or unacceptable toxicity. Patients with a confirmed complete response for 2 consecutive courses may discontinue treatment at investigator's discretion.~Quality of life is assessed at baseline, approximately every 6 weeks during treatment, and then after the last course of treatment.~Patients are followed every 3 months for 5 years."
88972088|NCT00016952|Experimental|leucovorin + fluorouracil|"Prior to irinotecan and oxaliplatin combination chemotherapy: Patients receive leucovorin calcium IV over 2 hours and fluorouracil IV continuously on days 1 and 2. Treatment repeats every 2 weeks.~Treatment continues in the absence of disease progression or unacceptable toxicity. Patients with a confirmed complete response for 2 consecutive courses may discontinue treatment at investigator's discretion.~Quality of life is assessed at baseline, approximately every 6 weeks during treatment, and then after the last course of treatment.~Patients are followed every 3 months for 5 years."
88972089|NCT00129324|Other|Lead Reduction Arm|random assignment to receive lead hazard control intervention. Assessing lead hazards in the home. Reducing lead hazards by cleaning, painting, covering, and/or replacing/repairing interior and exterior components of the home.
88972090|NCT00129324|Other|Injury Reduction Arm|random assignment to receive injury hazard control intervention. Assessing home for potential injury hazards. Controlling hazards by 1) installing safety equipment such as stairway gates, cabinet locks, smoke & CO detectors, etc. 2) removing the hazards from the reach of a child and/or 3) restricting access to the hazards.
88972091|NCT00129285|Experimental|Low Dose Modafinil|Low Dose Modafinil 200 mg daily
89577160|NCT02446171|Experimental|Treatments C-B-D-A sequence|Treatment C in Period 1, Treatment B in Period 2, Treatment D in Period 3 and Treatment A in Period 4
88972092|NCT00129285|Experimental|High Dose Modafinil|High dose modafinil 400 mg daily
89577161|NCT02446171|Experimental|Treatments D-C-A-B sequence|Treatment D in Period 1, Treatment C in Period 2, Treatment A in Period 3 and Treatment B in Period 4
89577162|NCT02446015|Experimental|Systane Ultra QID|SYSTANE® ULTRA lubricant eye drops,1 drop in each eye, 4 times per day (QID) for 28 days
89577163|NCT02446015|Active Comparator|Systane Ultra PRN|SYSTANE® ULTRA lubricant eye drops, 1 drop in each eye, as needed (PRN) for 28 days
89577164|NCT02415127|Experimental|Interferon γ-1b|Approximately 45 participants will receive subcutaneous (SC) doses of ACTIMMUNE® 3 times a week (TIW) for a total of 26 weeks.
89577165|NCT02415127|Placebo Comparator|Placebo|Approximately 45 participants will receive SC doses of placebo TIW for a total of 26 weeks.
89577166|NCT02468557|Experimental|Idelalisib 150 mg|Participants were administered with idelalisib (IDL) 150 mg tablets orally, twice daily (morning and evening) for 8 weeks.
89577167|NCT02468557|Experimental|Idelalisib + nab-paclitaxel|Participants will receive escalating doses of idelalisib at a dose level of up to 150mg + nab-paclitaxel.
89577168|NCT02468557|Experimental|Idelalisib + mFOLFOX6|Participants will receive escalating doses of idelalisib at a dose level of up to 150mg + mFOLFOX6.
89577169|NCT02413489|Experimental|Daratumumab|Participants will receive daratumumab (16 milligram per kilogram [mg/kg]) as intravenous infusion once every week for 8 weeks; then once every other week for 16 weeks; thereafter once every 4 weeks until documented progression, unacceptable toxicity, or study end.
89577170|NCT02413333|Other|Clear Care Plus, then PeroxiClear|Clear Care Plus contact lens solution in Period 1, followed by PeroxiClear contact lens solution in Period 2. Each product used daily per packaging instructions with participant's habitual silicone hydrogel contact lenses for approximately 30 cleaning cycles.
89577171|NCT02413333|Other|PeroxiClear, then Clear Care Plus|PeroxiClear contact lens solution in Period 1, followed by Clear Care Plus contact lens solution in Period 2. Each product used daily per packaging instructions with participant's habitual silicone hydrogel contact lenses for approximately 30 cleaning cycles.
89577172|NCT02413255|Placebo Comparator|Part 1 Cohort 1-9: Placebo|TAK-020 placebo-matching solution, orally, once on Day 1.
89577173|NCT02413255|Experimental|Part 1 Cohort 1: TAK-020 0.1 mg|TAK-020 0.1 mg, solution, orally once on Day 1.
89577174|NCT02413255|Experimental|Part 1 Cohort 2: TAK-020 0.5 mg|TAK-020 0.5 mg, solution, orally, once on Day 1 following review of safety, tolerability and pharmacokinetic (PK) data from Cohort 1.
89577175|NCT02413255|Experimental|Part 1 Cohort 3: TAK-020 2.5 mg|TAK-020 2.5 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 2.
89577176|NCT02413255|Experimental|Part 1 Cohort 4: TAK-020 4.4 mg|TAK-020 4.4 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 3.
89577177|NCT02413255|Experimental|Part 1 Cohort 5: TAK-020 8.8 mg|TAK-020 8.8 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 4.
89577178|NCT02413255|Experimental|Part 1 Cohort 6: TAK-020 17.5 mg|TAK-020 17.5 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 5.
89577179|NCT02413255|Experimental|Part 1 Cohort 7: TAK-020 35 mg|TAK-020 35 mg, solution, orally once on Day 1. TAK-020 dose will be determined based on review of safety, tolerability and PK data from Cohort 6.
89577180|NCT02413255|Experimental|Part 1 Cohort 8: TAK-020 70 mg|TAK-020 70 mg, solution, orally once on Day 1. TAK-020 dose will be determined based on review of safety, tolerability and PK data from Cohort 7.
89577181|NCT02413255|Experimental|Part 1 Cohort 9: TAK-020 105 mg|TAK-020 105 mg, solution, orally once on Day 1. TAK-020 dose will be determined based on review of safety, tolerability and PK data from Cohort 8.
89577182|NCT02413255|Placebo Comparator|Part 2 Cohort 1-6: Placebo|TAK-020 placebo-matching solution, orally, once on Day 1 and Days 3 to 9.
89577183|NCT02413255|Experimental|Part 2 Cohort 1: TAK-020 3.75 mg|TAK-020 3.75 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose are determined based on data from Part 1 of the study.
89577184|NCT02413255|Experimental|Part 2 Cohort 2: TAK-020 5.75 mg|TAK-020 5.75 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose will be determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 1 in Part 2.
89577185|NCT02413255|Experimental|Part 2 Cohort 3: TAK-020 13 mg|TAK-020 13 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose will be determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 2 in Part 2.
89577186|NCT02413255|Experimental|Part 2 Cohort 4: TAK-020 25 mg|TAK-020 25 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose will be determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 3 in Part 2.
89577187|NCT02413255|Experimental|Part 2 Cohort 5: TAK-020 45 mg|TAK-020 45 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 4 in Part 2.
89577188|NCT02413255|Experimental|Part 2 Cohort 6: TAK-020 60 mg|TAK-020 60 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 5 in Part 2.
89577189|NCT02444533|Active Comparator|Liposomal Bupivacaine|Patient will receive liposomal bupivacaine in the tonsillar fossae after tonsillectomy
89577190|NCT02444533|No Intervention|No treatment|Patient will not be given any medications in the tonsillar fossae after tonsillectomy
89577191|NCT05458219|Experimental|Single arm|"Phase 1a Dose Escalation: IBI343 will be administered intravenously (IV) at different dose levels following accelerated titration for the first 2 dose levels and traditional 3+3 dose escalation design for following levels.~Phase 1a Dose Expansion: IBI343 will be administered at dose levels which is equal or lower than MTD. Each dose level contains no more than 30 subjects (including subjects in dose escalation)~Phase 1b Dose Extension: IBI343 will be administered at RP2D."
89577192|NCT01651039|Experimental|Panobinostat, Lenalidomide and Dexamethasone|All patients will receive oral panobinostat, lenalidomide and dexamethasone as per protocol.
89577193|NCT02349633|Experimental|Cohort 1|Cohort 1 will be initiated (current dose 200 mg)
89577194|NCT02349633|Experimental|Cohort 2A|Cohort 2A will evaluate PF-06747775 200 mg by mouth (PO) daily (QD) in combination with palbociclib continuous PO QD dosing in 21-day cycles. The starting dose (DL1) for palbociclib will be 100 mg PO daily. Dose finding will follow mTPI method with adjustments using DLT rate.
89577195|NCT02349633|Experimental|Cohort 2B|Cohort 2B will be initiated once the RP2D of the PF-06747775 and palbociclib combination is determined.
89577196|NCT02349633|Experimental|Cohort 3|Cohort 3 combination is PF-06747775 200 mg PO QD and avelumab 10 mg/kg IV Q2W in 28-day (4-week) cycles. Dose finding will follow the mTPI design. Once RP2D of PF-06747775 in combination with avelumab is determined, the Dose Expansion Phase will be opened.
89577197|NCT05650125||Patients with solid organ cancer|Prospective biosampling of blood/tissue
89577198|NCT02275611|Active Comparator|Intranasal oxytocin spray (Syntocinon Spray)|TID inpatient; BID outpatient for 12 wks
89577199|NCT02275611|Placebo Comparator|Intranasal Placebo Spray|TID inpatient; BID outpatient for 12 wks
89577200|NCT05649891|Experimental|Patients managed with Emergency Manual access|Consecutive priority 1 patients managed by resuscitation teams with access to an Emergency Manual
89577201|NCT05649813||CRSwNP|Participants with CRSwNP in the Gulf region
89577202|NCT05649735|Experimental|GROUP A- LOGUSGYN/CANDIDEP vaginal ovules,|At baseline, eligible and PAP test negative patients were randomly assigned to receive LOGUSGYN/CANDIDEP vaginal ovules treatment for 10 consecutive days.
89577203|NCT05649735|Experimental|GROUP B- LOGUSGYN/CANDIDEP lavander|At baseline, eligible and PAP test negative patients were randomly assigned to receive LOGUSGYN/CANDIDEP lavender treatment for 10 consecutive days.
89577204|NCT05649735|Placebo Comparator|GROUP C- vaginal irrigation with sterile saline AELAV PURLING|At the baseline visit, eligible and PAP test negative patients were randomly assigned to receive the vaginal irrigation with sterile saline AELAV PURLING treatment for 10 consecutive days.
89577205|NCT05649735|Experimental|GROUP D- Patients pap test positive|Patients eligible at baseline and PAP test positive will be assigned to GROUP D and treated for 10 days with sterile saline-based vaginal irrigation (Placebo/control group) AELAV PURLING- Subsequently after the initial 10-day treatment they will be randomised into two further groups, E and F, and treated for 30 days with: GROUP E- LOGUSGYN/CANDIDEP vaginal ova, GROUP F- LOGUSGYN/CANDIDEP vaginal ova, + LOGUSGYN/CANDIDEP lavage, and treated for 30 days with: GROUP E- LOGUSGYN/CANDIDEP vaginal ova, GROUP F- LOGUSGYN/CANDIDEP vaginal ova, + LOGUSGYN/CANDIDEP douche
89577206|NCT05649657|Experimental|CKD patients with exercise training intervention|The participants with 3-5 CKD will go through three phases: 3-month control, 6-month intervention, and 3-month maintenance. No intervention will be performed in the control and maintenance phases
89577207|NCT05649657|No Intervention|CKD stage 1 and 2|no inervention
89577208|NCT05649657|No Intervention|CKD stage 1 and 2 respectively, and 20 healthy subjects|no inervention
89577209|NCT02275065|Experimental|Bictegravir 5 mg|Bictegravir 5 mg (1 × 5 mg tablet) for 10 days
89577210|NCT02275065|Experimental|Bictegravir 25 mg|Bictegravir 25 mg (1 × 25 mg tablet) for 10 days
89577211|NCT02275065|Experimental|Bictegravir 50 mg|Bictegravir 50 mg (2 × 25 mg tablets) for 10 days
89577212|NCT02275065|Experimental|Bictegravir 100 mg|Bictegravir 100 mg (1 × 100 mg tablet) for 10 days
89577213|NCT02275065|Placebo Comparator|Placebo|Placebo matched to bictegravir tablet for 10 days
89577214|NCT04875585|Experimental|Treatment Arm|neoadjuvant therapy with Pembrolizumab/Lenvatinib in combination with surgical resection of primary tumor followed by adjuvant Pembrolizumab therapy
89577215|NCT02273973|Placebo Comparator|Letrozole + Placebo|Participants will receive 2.5 mg letrozole tablets orally QD along with placebo on a 5-days-on/2-days-off schedule for a total of 16 weeks.
89577216|NCT02273973|Experimental|Letrozole + Taselisib|Participants will receive 2.5 milligrams (mg) letrozole tablets orally once daily (QD) along with taselisib tablets at 4 mg (two 2 mg tablets) orally on a 5 days-on/2 days-off schedule for a total of 16 weeks.
89577217|NCT02273739|Experimental|Enasidenib|During the dose escalation phase, consented eligible participants will be enrolled into sequential cohorts of increasing doses of enasidenib.The starting dose for this study is 100 mg administered every 24 hours,
89577218|NCT05649111|Active Comparator|Group A|will receive Difluprednate 4 times per day for 1 week, then twice per day for 1 week and then once per day for 5 days starting 24 hours after the operation
89577219|NCT05649111|Active Comparator|Group B|will receive Difluprednate 3 times per day for 4 days, then twice per day for 4 days and then once per day for 4 days starting 4 hours after the operation
89577220|NCT02273037|Placebo Comparator|Pinard horn|Pinard horn (current practice) used to monitor the fetal heart rate in labour in this arm of the study.
88811145|NCT04199117|Experimental|No Incentive,Tailored,No Care Manage,Standard Treatment|Participants randomly assigned to this condition will not have access to incentives for completing smoking cessation counseling, will receive 5 tailored letters promoting use of smoking cessation treatment over 2 years, will not receive Tobacco Care Management support and motivational encouragement calls, and will have access to standard smoking cessation treatment (referral to the state tobacco quitline and/or their primary care provider) over 2 years.
89577221|NCT02273037|Experimental|Fetal heart rate Doppler|Doppler used to monitor the fetal heart rate in labour in this arm of the study.
89577222|NCT02465515|Experimental|Albiglutide|Albiglutide once weekly by subcutaneous injection. Starting dose 30 mg may be increased to 50 mg if needed. Albiglutide will be administered in addition to standard therapy for diabetes and cardiovascular health.
89577223|NCT02465515|Placebo Comparator|Placebo|Placebo once weekly by subcutaneous injection. Placebo will be administered in addition to standard therapy for diabetes and cardiovascular health.
89577224|NCT05561361||SAAE group|Subjects received super selective adrenal artery embolization treatment
89577225|NCT05561361||Spironolactone group|Subjects received spironolactone treatment
89577226|NCT02412631|Placebo Comparator|Varenicline plus placebo|Subjects will receive open label varenicline (12 weeks) plus a placebo for lorcaserin (24 weeks)
89577227|NCT02412631|Experimental|Varenicline plus lorcaserin|Subjects will receive open label varenicline (12 weeks) plus lorcaserin (24 weeks)
89577228|NCT02272803|Experimental|Arm A: Lenalidomide + Dexamethasone + Elotuzumab (BMS-901608)|"Drug: Lenalidomide~Capsules, Oral, 25 mg, once daily, on Days 1-21, Repeat every 28 days until subject meets criteria for discontinuation of study drug~Drug: Dexamethasone~Tablets, Oral 28 mg and Intravenous (IV) 8 mg, once daily, on Days 1, 8, 15, 22 (cycles 1&2) ; Days 1 &15 (cycles 3-18); Day 1 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug~Tablets, Oral, 40 mg, once daily, on Days 8 & 22 (cycles 3-18); Days 8, 15, 22 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug~Biological: Elotuzumab (BMS-901608)~Solution, Intravenous (IV), 10 mg/kg, weekly, on Days 1, 8, 15, 22 (cycles 1&2); Days 1 and 15 (cycles 3-18), Repeat every 28 days until subject meets criteria for discontinuation of study drug~Solution, Intravenous (IV), 20 mg/kg, Day 1 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug"
89577229|NCT02272803|Active Comparator|Arm B: Lenalidomide + Dexamethasone|"Drug: Lenalidomide~Capsules, Oral, 25 mg, once daily, on Days 1-21, Repeat every 28 days until subject meets criteria for discontinuation of study drug~Drug: Dexamethasone~Tablets, Oral, 40 mg, weekly, on Days 1, 8, 15, 22, Repeat every 28 days until subject meets criteria for discontinuation of study drug"
89577230|NCT02272725|Placebo Comparator|Placebo|tasteless and inert tablets
89577231|NCT02272725|Active Comparator|Ibuprofen|Each tablet containing 400mg of ibuprofen
89577232|NCT01650805|Experimental|ponatinib|
89577233|NCT01650805|Active Comparator|imatinib|
89577234|NCT02442349|Experimental|AZD9291|Once daily tablet 80 mg
89577235|NCT02411539|Experimental|Arm A: VRC01 followed by placebo|Participants received an infusion of VRC01 at Day 0 and Week 3 and an infusion of placebo (normal saline) at Weeks 6 and 9.
89577236|NCT02411539|Experimental|Arm B: placebo followed by VRC01|Participants received an infusion of placebo (normal saline) at Day 0 and Week 3 and an infusion of VRC01 at Weeks 6 and 9.
89577237|NCT02465437|Experimental|JBT-101 5 mg/20 mg bid|JBT-101 5 mg q am and placebo q pm on Days 1-28, then JBT-101 20 mg twice a day (bid) on Days 29-84.
89577238|NCT02465437|Experimental|JBT-101 20 mg/20 mg bid|JBT-101 20 mg q am and placebo q pm on Days 1-28, then JBT-101 20 mg bid on Days 29-84.
89577239|NCT02465437|Experimental|JBT-101 20 mg bid/20 mg bid|JBT-101 20 mg bid on Days 1-84.
89577240|NCT02465437|Placebo Comparator|Placebo|Placebo bid on Days 1-84.
89577241|NCT02465437|Experimental|Part B Open-label|JBT-101 20 mg bid on Days 1-364
89577242|NCT02442271|Experimental|3-DAA ± RBV|3-DAA (ombitasvir/paritaprevir/ritonavir [25 mg/150 mg/100 mg once daily] and dasabuvir [250 mg twice daily]) with or without weight-based ribavirin (± RBV; dosed 1,000 or 1,200 mg daily divided twice a day) for 12 or 24 weeks.
89577243|NCT02465203|Other|Follow up from feeder studies|Follow up arm
89577244|NCT02463409|Experimental|Theophylline|Patients will receive a 24 hour continuous infusion of intravenous theophylline.
89577245|NCT02528357|Experimental|Part 1A: GSK3174998 Monotherapy- Dose escalation|Participants will receive GSK3174998 intravenously (IV) (dose range 0.003 to 10.0 milligram per kilogram [mg/kg]) every 3 weeks (Q3W) for up to 2 years or 35 cycles, whichever comes first.
89577246|NCT02528357|Experimental|Part 2A: GSK3174998+ pembrolizumab - Dose escalation|Participants will receive GSK3174998 IV (dose range 0.003 to 10.0 mg/kg) Q3W for up to 2 years or 35 cycles, whichever comes first + Pembrolizumab 200 mg IV Q3W for up to 2 years or 35 cycles, whichever comes first.
89577247|NCT02528357|Experimental|Part 2B: GSK3174998+ pembrolizumab - Cohort expansion|Participants will receive GSK3174998 IV (at one dose level shown to be tolerable in dose escalation of part 2A) Q3W for up to 2 years or 35 cycles, whichever comes first + Pembrolizumab 200 mg IV Q3W for 2 years or 35 cycles, whichever comes first.
89577248|NCT04910425|Experimental|Diagnostic (18F-DCFPyL PET/MRI, mpMRI)|Patients receive fluorine F 18 DCFPyL IV and undergo PET/MRI. Patients also receive either gadobutrol IV or gadobenate dimeglumine IV (per radiologist preference), and undergo mpMRI. Within approximately 60 days after PET/MRI and mpMRI, patients undergo TRUS guided prostate biopsy per standard of care.
88972093|NCT00129285|Placebo Comparator|Placebo|Placebo
88972094|NCT00129246|Active Comparator|Bupropion only|The placebo comparator was a group of matched controls who received an identical psychosocial intervention and bupropion SR treatment regimen in a similar 7-week study investigation compared to naltrexone hydrochloride (25 mg/day) in combination with bupropion hydrochloride SR (300 mg/day).
88972095|NCT00129246|Experimental|Naltrexone +Bupropion|The active comparator in this 7-week open label study investigation was naltrexone hydrochloride (25 mg/day) in combination with bupropion hydrochloride SR (300 mg/day) compared to matched controls who received an identical psychosocial intervention and bupropion SR treatment regimen (bupropion only).
89577249|NCT02463331|Active Comparator|chloroquine plus prednisone|Chloroquine diphosphate 250mg/day associated to prednisone in variable doses
89577250|NCT02463331|Experimental|azathioprine plus prednisone|azathioprine in variable doses (50-150mg/day) associated to prednisone in variable doses
89577251|NCT02314247|Experimental|Selinexor|60 mg dose (equivalent to ~35 mg/m²)
89577252|NCT02463097|Experimental|Study Arm|All subjects wearing the MMT-670G insulin pump, using it with the closed loop algorithm
89577253|NCT05427149|Active Comparator|Group C|Patients receiving intrathecal 10 mg hyperbaric bupivacaine (Marcaine® Spinal Heavy %0.5, Sanofi, Kırklareli, Turkey) + 1 mL normal saline (Polifleks %0.9 İzotonik Sodyum Klorür, Polifarma, Ankara, Turkey)
89577254|NCT05427149|Active Comparator|Group M25|Patients receiving intrathecal 10 mg hyperbaric bupivacaine (Marcaine® Spinal Heavy %0.5, Sanofi, Kırklareli, Turkey) + 25 mg MgSO4 (Magnezyum Sulfat %15, Biofarma, Istanbul, Turkey). MgSO4 diluted to 25mg/mL with normal saline (Polifleks %0.9 İzotonik Sodyum Klorür, Polifarma, Ankara, Turkey).
89577255|NCT05427149|Active Comparator|Group M50|Patients receiving intrathecal 10 mg hyperbaric bupivacaine (Marcaine® Spinal Heavy %0.5, Sanofi, Kırklareli, Turkey) + 50 mg/mL MgSO4 (Magnezyum Sulfat %15, Biofarma, Istanbul, Turkey). MgSO4 diluted to 50mg/mL with normal saline (Polifleks %0.9 İzotonik Sodyum Klorür, Polifarma, Ankara, Turkey).
89577256|NCT05427149|Active Comparator|Group M100|Patients receiving intrathecal 10 mg hyperbaric bupivacaine (Marcaine® Spinal Heavy %0.5, Sanofi, Kırklareli, Turkey) + 100 mg MgSO4 (Magnezyum Sulfat %15, Biofarma, Istanbul, Turkey). MgSO4 diluted to 100mg/mL with normal saline (Polifleks %0.9 İzotonik Sodyum Klorür, Polifarma, Ankara, Turkey)
89577257|NCT02441179|Experimental|Acute Intermittent Hypoxia Arm|AIH protocol: it consists of 15, 90-second hypoxic episodes (FiO2=0.09) interspersed with 15, 90-second normoxic intervals (FiO2=0.21) for a total time of 45 minutes. This protocol will be repeated every day for 5 consecutive days and then 3 times per week for 3 weeks. Total time: 4 weeks. After this AIH protocol, patients will received body weight-assisted treadmill training (BWSTT) for 45 minutes.
89577258|NCT02441179|Placebo Comparator|Normoxia Arm|Sham protocol: it consists of continuous normoxia (FiO2=0.21) for 45 minutes for 5 consecutive days and then 3 times per week for 3 weeks. Total time: 4 weeks.After this AIH protocol, patients will received body weight-assisted treadmill training (BWSTT) for 45 minutes.
89577259|NCT05406167||Stereotactic Body Radiotherapy [SBRT]|Patients treated with Reflexion X1 with SBRT as the standard of care
89577260|NCT05406167||Intensity -Modulated Radiation Therapy [IMRT]|Patients treated with Reflexion X1 with IMRT as the standard of care
89577261|NCT02462473|Experimental|Cohort 1|Participants will receive treatment as usual (TAU) which include one or more of the 5 antipsychotic medications (aripiprazole, olanzapine, paliperidone, quetiapine, and risperidone) for 12 weeks as determined by the treating clinician and the antipsychotic medication plasma level (AMPL) results will not be available to the clinicians until all participants in this cohort at a given site have completed their study participation.
89577262|NCT02462473|Experimental|Cohort 2|Participants will receive treatment as usual (TAU) which include one or more of the 5 antipsychotic medications (aripiprazole, olanzapine, paliperidone, quetiapine, and risperidone) for 12 weeks as determined by the treating clinician and the antipsychotic medication plasma level (AMPL) results will be provided to the clinician as they become available.
89577263|NCT02462473|Experimental|Cohort 3|Participants will receive treatment as usual (TAU) which include one or more of the 5 antipsychotic medications (aripiprazole, olanzapine, paliperidone, quetiapine, and risperidone) for 12 weeks as determined by the treating clinician and the antipsychotic medication plasma level (AMPL) results will not be available to the clinicians until all participants in cohorts 2 and 3 at a given site have completed participation in the active assessment phase.
89577264|NCT04465799|Experimental|ENTREN Programme|This intervention consists in a total of 12 biweekly sessions: 9 sessions of 2-hr only for children, with a further three 3-hr sessions attended by both families and children together: nutrition, physical activity sessions, and a closing event session. Children content was developed based a cognitive-behavioural perspective, and included motivational interviewing tools. The aim of the children's programme is, to promote healthy eating habits, problem awareness, motivation to change unhealthy behaviours, health commitment, emotional regulation, social skills and self-esteem. One 2-hr session at 6, 12 and 18-month follow-up was provided to refresh skills, their physical activity, and nutritional behaviours.
89577265|NCT04465799|Experimental|ENTREN-F Programme|ENTREN-F has the same children's intervention than ENTREN. It has extra 6 2-hr sessions to work on family environment and communication, plus three 2-hr sessions attended by both families and children together. One 2-hr session at 6, 12 and 18-month follow-up was provided to refresh skills, their physical activity, and nutritional behaviours.
89577266|NCT04465799|Other|Control group|The intervention of this group consists in usual treatment in Primary Care provided by Endocrinology Services. 3 monthly face-to-face consultations and continuous online monitoring are provided to these families, oriented to promote healthy habits of nutrition and physical activity for 6 months. It works from an exclusively behavioural perspective. A token economy is used with the families as a system of contingency management based on the systematic reinforcement of target behaviour.
89577267|NCT01462097|Experimental|Aerobic exercise|12 months of treadmill walking and strength training exercise. Exercise is gradually progressed in walking speed and time on the treadmill based on the individual's tolerance, abilities, and safety. For months 1-6 exercise will take place 3 times per week at the research center. For months 6-12 exercise will take place 2 times per week at the center and 1 time per week at home.
89577268|NCT01462097|Active Comparator|Health Education|12 months of Health education sessions which will cover topics important to older adults (safe travel, age-appropriate preventative screenings, resources for reliable health information, and topics relevant to chronic kidney disease). For months 1-6 classes will take place 1 time per week. For months 6-12 classes will take place 1 time per month.
89577269|NCT02440789|Experimental|Sirolimus|
89577270|NCT02462083|Experimental|IDP-118 Lotion|IDP-118 lotion (halobetasol propionate 0.01%, tazarotene 0.045%) will be applied topically on the affected area once daily for 8 weeks and then as needed once daily for up to 1 year.
89577271|NCT02538341|Active Comparator|Zostavax (Zoster Vaccine Live)|Zostavax (zoster vaccine live) is used to prevent herpes zoster (HZ) virus (shingles) in people age 50 and older. Patients randomized to this arm will receive active herpes zoster (HZ) vaccine. It is administered as a single 0.65 mL dose subcutaneously in the deltoid region of the upper arm.
89577272|NCT02538341|Placebo Comparator|Placebo Normal Saline|Saline injection: patients randomized to this arm will receive a single 0.65 mL dose subcutaneously in the deltoid region of the upper arm.
89577273|NCT05446181||Old with postoperative delirium|
89577274|NCT05446181||Old without postoperative delirium|
89577275|NCT05446181||Young|
89577276|NCT02538107||Kidney Transplant Participants|Participants with kidney transplant and a chronic kidney disease who were receiving methoxy polyethylene glycol epoetin beta (Mircera) as part of their medical care.
88811146|NCT04199117|Experimental|No Incentive,Untailored,Care Manage,Intensive Treatment|Participants randomly assigned to this condition will not have access to incentives for completing smoking cessation counseling, will receive 5 untailored letters promoting use of smoking cessation treatment over 2 years, will receive 5 Tobacco Care Management support and motivational encouragement calls over 2 years, and will have access to 3 smoking cessation quit counseling calls and 12-weeks of either combination nicotine replacement or varenicline up to 4 times over 2 years.
89577277|NCT02538029|Experimental|Dual Task Group|This group will complete an exercise intervention that involves performing dual tasking activities (simultaneously performing 2 things at once). This group will exercise 3x/wk for 8 weeks.
89577278|NCT02538029|Active Comparator|Single Task Group|This group will complete an exercise intervention that involves performing single task activities. The participant will perform motor tasks and cognitive tasks individually. This group will exercise 3x/wk for 8 weeks.
89577279|NCT05445401|Experimental|Pre-rehabilitation group|Triple pre-rehabilitation interventions of exercise, nutrition and psychology during the neoadjuvant period
89577280|NCT05445401|Placebo Comparator|Conventional group|Conventional group
89577281|NCT05401331|Other|Hemodynamic changes due to mask use|Hemodynamic changes due to mask use
89577282|NCT05401331|Other|Hemodynamic responses when we do not use masks|Hemodynamic responses when we do not use masks
89577283|NCT02272413|Experimental|BI 695502|
89577284|NCT02272413|Active Comparator|Avastin|
89577285|NCT02396381|Experimental|THS 2.2|Ad libitum use of THS 2.2
89577286|NCT02396381|Active Comparator|CC|Ad libitum use of CC
89577287|NCT05426291||Group I|At least two of the preoperative biomarkers (Mg<0.85 mmol/L, Hgb<8.5 mmol/L, proBNP>480 pg/mL, CRP>5 mg/L) that are thought to be closely related to acute kidney injury after cardiac surgery Group I,
89577288|NCT05426291||Group II|Patients who meet at least two of the preoperative biomarkers (Mg>0.85 mmol/L, Hgb>8.5 mmol/L, proBNP<480 pg/mL, CRP<5 mg/L) Group II .
89577289|NCT05648877|Experimental|43 semirigid ureteropyeloscopy|43 Patients underwent semirigid ureteropyeloscopy
89577290|NCT05648877|Active Comparator|34 flexible ureteropyeloscopy|34 patients with flexible ureteropyeloscopy
89577291|NCT05424809|Experimental|Shared decision-making model|In the intervention group, the shared decision-making model will be carried out. This model was proposed and designed through a participatory and deliberative process.
89577292|NCT05424809|No Intervention|Usual care|Information without an estructured shared decision-making model
89577293|NCT05648799|Experimental|GP30341 capsules 200 mg|4 capsules containing 200 mg of molnupiravir p.o. twice a day during 5 days (daily dose 1600 mg) in combination with Standard therapy in accordance with the current version of the guidelines for the prevention, diagnosis and treatment of a new coronavirus infection 2019 (COVID-19).
89577294|NCT05648799|Active Comparator|Standart therapy|Standard therapy in accordance with the current version of the guidelines for the prevention, diagnosis and treatment of a new coronavirus infection 2019 (COVID-19).
89577295|NCT02120807|Experimental|certolizumab, cisplatin and pemetrexed|Patients will receive certolizumab with 6 cycles of cisplatin & pemetrexed. Cycle of chemo will be 3 weeks. Certolizumab will be adm in the following fashion: first dose administered at the time of treatment initiation, second dose will be given after 2 weeks of treatment, third dose after four weeks of treatment, & subsequent doses given every 4 weeks thereafter. Patients will be monitored for progression of disease using RECIST 1.1 with scans to be performed every 6 weeks. Posttreatment biopsies will be performed at the time of treatment discontinuation. Two dose levels of certolizumab will be tested, 200mg & 400mg. A non-therapeutic cohort of 10 patients with adenocarcinomas who will be undergoing standard of care treatment with platinum based chemotherapy + pemetrexed +/- bevacizumab will be consented for blood draws before each cycle of treatment. This blood will be analyzed for cytokines and will serve as a reference for the experimental arm.
89577296|NCT04457531|Experimental|LiuWeiLuoBi Group|Patients will receive the treatment of LiuWeiLuoBi Granule for 12 weeks,twice a day added to the standard medical treatment.
89577297|NCT04457531|Other|Control Group|Patients will receive the standard medical treatment for 12 weeks.
89577298|NCT02532647|Experimental|Remimazolam|"Remimazolam 2.5 - 5.0 mg initially, followed by 1.25 - 2.5 mg top-up doses as required to maintain sedation.~Fentanyl pre-treatment: 25-50 μg (or less for elderly/disabled subjects), and 25 μg top-up doses"
89577299|NCT02532647|Active Comparator|Midazolam|"Midazolam 1.0 mg initially, followed by 0.5 mg top-up doses as required to maintain sedation.~Fentanyl pre-treatment: 25-50 μg (or less for elderly/disabled subjects), and 25 μg top-up doses"
89577300|NCT02532647|Placebo Comparator|Placebo|"Placebo administered in double-blind manner.~Fentanyl pre-treatment: 25-50 μg (or less for elderly/disabled subjects), and 25 μg top-up doses"
89577301|NCT02537015|Experimental|13 mg Bimatoprost Ocular Insert|13 mg Bimatoprost Ocular Insert in each eye used continuously for 12 weeks, then replaced with a new 13 mg Bimatoprost Ocular Insert in each eye used continuously for another 26 weeks.
89577302|NCT05397119|Experimental|BW-1014: 25 µg rH5 in 20% NE - pipette - IN|20% Nanoemulsion and 25 µg recombinant H5 antigen administered intranasally by an electronic pipette (500µL) Two doses administered 4 weeks apart
89577303|NCT05397119|Experimental|BW-1014: 50 µg rH5 in 20% NE - pipette - IN|20% Nanoemulsion and 50 µg recombinant H5 antigen administered intranasally by an electronic pipette (500µL) Two doses administered 4 weeks apart
89577304|NCT05397119|Experimental|BW-1014: 100 µg rH5 in 20% NE - pipette - IN|20% Nanoemulsion and 100 µg recombinant H5 antigen administered intranasally by an electronic pipette (500µL) Two doses administered 4 weeks apart
89577305|NCT05397119|Placebo Comparator|rH5 (100 µg) control - pipette - IN|100 µg recombinant H5 antigen (without adjuvant) administered intranasally by an electronic pipette (500µL) Two doses administered 4 weeks apart
89577306|NCT05397119|Sham Comparator|Saline (Placebo) - pipette - IN|Saline (negative control) administered intranasally by an electronic pipette (500µL) Two doses administered 4 weeks apart
89577307|NCT02271945|Experimental|MEDI-551 12 mg/kg and MEDI0680 2.5 mg/kg|Participants will receive intravenous (IV) infusion of MEDI-551 12 mg/kg on Days 1 and 8 of Cycle 1 and Day 1 of Cycle 2 through Cycle 13 (each cycle of 28 days) and IV infusion of MEDI0680 2.5 mg/kg on Days 2 and 15 of Cycle 1 and Days 1 and 15 of Cycle 2 through Cycle 13.
89577308|NCT02271945|Experimental|MEDI-551 12 mg/kg and MEDI0680 10 mg/kg|Participants will receive IV infusion of MEDI-551 12 mg/kg on Days 1 and 8 of Cycle 1 and Day 1 of Cycle 2 through Cycle 13 (each cycle of 28 days) and IV infusion of MEDI0680 10 mg/kg on Days 2 and 15 of Cycle 1 and Days 1 and 15 of Cycle 2 through Cycle 13.
89577309|NCT05420909||Cohort 1|Participants diagnosed with metastatic colorectal cancer (mCRC) selected from the Flatiron Electronic Health Record database
89577310|NCT05555199|Experimental|Intervention|One interventional arm that will undergo all interventional procedures (when applicable).
89577311|NCT01660763|Experimental|Sufentanil NanoTab PCA System/15 mcg|
89577312|NCT01660763|Placebo Comparator|Placebo Sufentanil NanoTab PCA System|
89577313|NCT04875273|No Intervention|Pre: pain assessment in the spinous processes of the spine with 1kg|press on the spinous processes with the algometer perpendicularly.
89577314|NCT04875273|No Intervention|Pre: pain assessment in the spinous processes of the spine with 2 kg|press on the spinous processes with the algometer perpendicularly.
89577315|NCT04875273|No Intervention|Pre: pain assessment in the spinous processes of the spine with 3 kg|press on the spinous processes with the algometer perpendicularly.
89577316|NCT04875273|No Intervention|Pre: pain assessment in the spinous processes of the spine with maximum pressure|press on the spinous processes with the algometer perpendicularly.
89577317|NCT04875273|Experimental|Post Exp: pain assessment in the spinous processes of the spine with 1kg|press on the spinous processes with the algometer perpendicularly.
89577318|NCT04875273|Experimental|Post Exp: pain assessment in the spinous processes of the spine with 2kg|press on the spinous processes with the algometer perpendicularly.
89577319|NCT04875273|Experimental|Post Exp: pain assessment in the spinous processes of the spine with 3kg|press on the spinous processes with the algometer perpendicularly.
89577320|NCT04875273|Experimental|Post Exp: pain assessment in the spinous processes of the spine with maximum pressure|press on the spinous processes with the algometer perpendicularly.
89577321|NCT04875273|Placebo Comparator|Post Pla: pain assessment in the spinous processes of the spine with 1kg|press on the spinous processes with the algometer perpendicularly.
89577322|NCT04875273|Placebo Comparator|Post Pla: pain assessment in the spinous processes of the spine with 2kg|press on the spinous processes with the algometer perpendicularly.
89577323|NCT04875273|Placebo Comparator|Post Pla: pain assessment in the spinous processes of the spine with 3kg|press on the spinous processes with the algometer perpendicularly.
89577324|NCT04875273|Placebo Comparator|Post Pla: pain assessment in the spinous processes of the spine with maximum pressure|press on the spinous processes with the algometer perpendicularly.
89577325|NCT04875273|No Intervention|Pre: Right Ankle Dorsiflexion|Range of motion in right ankle dorsiflexion is measured with LegMOtion®
89577326|NCT04875273|Placebo Comparator|Post Pla: Right Ankle Dorsiflexion|Range of motion in right ankle dorsiflexion is measured with LegMOtion®
89577327|NCT04875273|Experimental|Post Exp: Right Ankle Dorsiflexion|Range of motion in right ankle dorsiflexion is measured with LegMOtion®
89577328|NCT04875273|No Intervention|Pre: Left Ankle Dorsiflexion|Range of motion in left ankle dorsiflexion is measured with LegMOtion®
89577329|NCT04875273|Placebo Comparator|Post Pla: Left Ankle Dorsiflexion|Range of motion in left ankle dorsiflexion is measured with LegMOtion®
89577330|NCT04875273|Experimental|Post Exp: Left Ankle Dorsiflexion|Range of motion in left ankle dorsiflexion is measured with LegMOtion®
89577331|NCT04859049|Experimental|Group 1|Infra- medial injection of local anesthesia mixture
89577332|NCT04859049|Experimental|Group 2|medial canthus injection of the local anesthesia mixture
89577333|NCT02268045|Experimental|RTXM83|Active Ingredient: Rituximab (Biosimilar)
89577334|NCT02268045|Active Comparator|MabThera|Active Ingredient: Rituximab
89577335|NCT02536781|Placebo Comparator|Placebol|Placebo
89577336|NCT02536781|Active Comparator|Anthocynin|Anthocyanin
89577337|NCT05440253|Experimental|dry needling group|
89577338|NCT05440253|Active Comparator|ischaemic compression group|
89577339|NCT05544747|Experimental|Action Observation Therapy|The patients in the action observation therapy group will be required to observe the upper limb movements or functional actions in video clips. (i.e., the observation phase) and to execute what they had observed to the best of their ability (i.e., the execution phase). Three common categories of movements and tasks will be elected in the action observation therapy protocol based on the related literature
89577340|NCT05544747|Active Comparator|Mirror Therapy|During the mirror therapy, the patients will be seated in front of a mirror box placed at their mid-sagittal plane. The affected arm of the participants will be placed inside the mirror box and the unaffected arm in front of the mirror. The patient will be instructed to watch the mirror reflection of the movement performed by his/her unaffected hand carefully and to imagine that the movement was performed by the affected hand.
89577341|NCT05439863||TAVR in aortic valve disease|
89577342|NCT05392283|Experimental|Vacuum cupping|
89577343|NCT05647785||cerena™|Subjects who took part in the cerena™ group during the original RESTORE study
89577344|NCT05647785||attune™|Subjects who took part in the attune™ group during the original RESTORE study
89577345|NCT02267187|Experimental|Fat Graftting|For the purpose of this study the fat grafting procedure is a research procedure. It is very important to note that this research procedure is not an experimental procedure. Fat grafting is a minimally invasive clinical procedure that has been widely used by plastic surgeons within reconstructive surgery for many years. Fat grafting is known as a filler providing an accurate means to restoring facial soft tissue structure.
89577346|NCT02532179|Experimental|Mouse Allergenic Extract|Participants will receive escalating doses of glycerinated mouse allergenic extract administered via the subcutaneous route up to a Maximum Study Dose (MSD) of 0.4 mL of extract at a concentration of 1:10 wt/vol.
89577347|NCT04422977|Other|CoVID exposure|
89577348|NCT05389241|Experimental|Method A|Subjects in this arm will perform the task on the liver phantom with Method A (2D-CT). Then they will do the NASA task load index questionnaire. After that they will perform the tasks with Method B (2D-CT + 3D augmented reality model). After that again a NASA Task load index questionnaire is performed
89577349|NCT05389241|Experimental|Method B|Subjects in this arm will perform the task on the liver phantom with method B (2D-CT + 3D augmented reality model). Then they will do the NASA task load index questionnaire. After that they will perform the tasks with Method A (2D-CT). After that again a NASA Task load index questionnaire is performed
89577350|NCT05438615|Experimental|Corneal Refractive Therapy - spherical|Subjects eyes shall be treated with two pair of the proximity control lenses in Paragon paflufocon D material by the qualified clinical investigator. The subjects shall be randomized for which of the two designs are applied first. The first pair shall be dispensed and follow-up examinations shall be conducted at 1 day, 1 week, and 2 weeks. Each subject shall then cease wearing lenses for at least 7 days and be re-examined to determine that the corneal curvature has returned to its baseline measure. The second design shall be dispensed and follow-up examinations shall be conducted at 1 day, 1 week, and 2 weeks. Each subject shall then cease wearing lenses for at least 7 days and be re-examined to determine that the corneal curvature has returned to its baseline measure.
89577351|NCT05438615|Experimental|Corneal Refractive Therapy - aspherical|Subjects eyes shall be treated with two pair of the proximity control lenses in Paragon paflufocon D material by the qualified clinical investigator. The subjects shall be randomized for which of the two designs are applied first. The first pair shall be dispensed and follow-up examinations shall be conducted at 1 day, 1 week, and 2 weeks. Each subject shall then cease wearing lenses for at least 7 days and be re-examined to determine that the corneal curvature has returned to its baseline measure. The second design shall be dispensed and follow-up examinations shall be conducted at 1 day, 1 week, and 2 weeks. Each subject shall then cease wearing lenses for at least 7 days and be re-examined to determine that the corneal curvature has returned to its baseline measure.
89577352|NCT04422665|Experimental|Single Exercise|Subjects allocated to this group will perform a single bout of one-legged resistance exercise. This bout will take place 1 day prior to the start of the bed rest. The resistance exercise will consist of 8 sets of leg extensions and 8 sets of leg curls. The non-exercising leg will serve as an internal control. The dominant leg will perform the exercise.
89577353|NCT04422665|Experimental|Multi Exercise|Subjects allocated to this group will perform 4 bouts of one-legged resistance exercise. These bouts will take place on alternate days the week leading up to the bed rest. Each resistance exercise bout will consist of 8 sets of leg extensions and 8 sets of leg curls. The non-exercising leg will serve as an internal control. The dominant leg will perform the exercise.
89577354|NCT05388539|Active Comparator|Active Group - protocol of Theta Burst Stimulation|3 sessions of theta burst stimulation, 1200 pulses per session of 6 minutes duration, 30-minute interval between sessions. Stimulation directed to the left dorsolateral pre-frontal cortex. The protocol will be applied for 15 days, totalizing 45 sessions of stimulation.
89577355|NCT05388539|Placebo Comparator|Placebo Group - Sham Stimulation|The placebo will consist of a sham stimulation activity. A noise generator, which makes the same noise as active stimulation, and a surface electrode placed over the patient's eyebrow, mimicking the tactile sensory effects of TBS.
89577356|NCT05416853|Active Comparator|Transradial artery|Carotid stent implantation via radial artery approach
89577357|NCT05416853|Active Comparator|Transfemoral artery|Carotid stent implantation via femoral artery approach
89577358|NCT05416775|Experimental|SHR-8068 in combination with adebrelimab|
89577359|NCT05416775|Experimental|SHR-8068 in combination with adebrelimab and platinum-based chemotherapy|
89577360|NCT05416775|Experimental|Adebrelimab in combination with platinum-based chemotherapy|
89577361|NCT05388227||Pole Walking|Attending pole walking sessions.
89577362|NCT02409667|Active Comparator|Secukinumab 300mg in PASI 90 responders (every 4 weeks)|Participants with moderate to severe plaque psoriasis who had reached PASI 90 response after 24 weeks of treatment with secukinumab 300 mg subcutanous (s.c.) every 4 weeks were treated with Secukinumab 300 mg subcutanous (s.c.) from week 24 until Week 52 every 4 weeks.
89577363|NCT02409667|Experimental|Secukinumab 300mg in PASI 90 responders (longer intervals)|Participants with moderate to severe plaque psoriasis who had reached PASI 90 response after 24 weeks of treatment with secukinumab 300 mg subcutanous (s.c.) every 4 weeks were treated with Secukinumab 300 mg subcutanous (s.c.) from week 24 until Week 52 every 6 weeks.
89209353|NCT00885456|Active Comparator|Usual Care|Average of three visits to the Neurovascular Clinic for a neurological and health assessment, counseling regarding stroke/TIA and diagnostic test results, and assessment, modification and education of secondary prevention factors
89577364|NCT02409667|Experimental|Secukinumab 300mg in PASI 75-90 responders (every 4 weeks)|Participants with moderate to severe plaque psoriasis who had reached PASI 75 to <90 response after 24 weeks of treatment with secukinumab 300 mg subcutanous (s.c.) every 4 weeks will be treated with Secukinumab 300 mg subcutanous (s.c.) from week 24 until Week 52 every 4 weeks.
89577365|NCT02409667|Active Comparator|Secukinumab 300mg in PASI 75-90 responders (shorter intervals)|Participants with moderate to severe plaque psoriasis who had reached PASI 75 to <90 response after 24 weeks of treatment with secukinumab 300 mg subcutanous (s.c.) every 4 weeks were treated with Secukinumab 300 mg subcutanous (s.c.) from week 24 until Week 52 every 2 weeks.
89577366|NCT01641939|Active Comparator|Standard taxane therapy|Docetaxel will be administered at 75 milligram per meter square (mg/m^2) intravenous (IV) on Day 1 of a 21-day cycle, or paclitaxel will administered at 80 mg/m^2 IV weekly (Days 1, 8, and 15 of a 21 day cycle) according to investigator choice until progression of disease, intolerable toxicity, initiation of another anticancer therapy, or participants and/or physician decision to discontinue.
89577367|NCT01641939|Experimental|trastuzumab emtansine 2.4 mg|Trastuzumab emtansine will be administered on Day 1, 8, and 15 of a 21-day cycle at 2.4 mg/kg IV infusion until progression of disease, intolerable toxicity, initiation of another anticancer therapy, or participants and/or physician decision to discontinue.
89577368|NCT01641939|Experimental|trastuzumab emtansine 3.6 mg|Trastuzumab emtansine will be administered on Day 1 of a 21-day cycle at 3.6 mg/kg IV infusion until progression of disease, intolerable toxicity, initiation of another anticancer therapy, or participants and/or physician decision to discontinue.
89577369|NCT01641861|Experimental|Control arm|control arm is dental caries removal using the conventional method. Dental caries will be removed using rotary instrument following the usual procedures employed by the dentist.
89577370|NCT01641861|Experimental|Intervention arm|Intervention arm is dental caries removal using Papacarie®. The dentist will apply Papacarie® to dental cavity in order to soften the carious dentine. Dental caries will be removed using hand instrument.
89577371|NCT05511285|Experimental|Behavioural: Digital cognitive behavioural therapy for insomnia|6-10 weeks of digital cognitive behavioural therapy for insomnia (Sleepio) delivered online.
89577372|NCT05511285|No Intervention|Treatment as usual|Participants will receive treatment as usual.
89577373|NCT02409355|Experimental|Atezolizumab|Participants will receive intravenous (IV) infusion of atezolizumab once on Day 1 of each 21-day cycle until loss of clinical benefit.
89577374|NCT02409355|Active Comparator|Gemcitabine + Cisplatin/Carboplatin|Participants will receive IV infusion of gemcitabine + cisplatin or gemcitabine + carboplatin once on Day 1 of each 21-day cycle for four or six cycles as per local standard of care.
89577375|NCT04874259|Experimental|Colorectal cancer liver metastasis|Liver transplantation for the treatment of unresectable colorectal cancer liver metastasis
89577376|NCT05647707|No Intervention|Conventional Group|"This group will comprise 36 patients who will receive conventional supportive treatment for the management of acute CO poisoning that include the following:~Airway: maintaining clear patent airways.~Breathing:~High-flow normobaric oxygen (NBO)~Hyperbaric oxygen (HBO) (if indicated).~Mechanical ventilation ( if required).~Circulation: intravenous fluids, and treatment of arrhythmias according to ECG abnormalities."
89577377|NCT05647707|Experimental|L-Carnitine Group|The 36 patients will receive conventional supportive care as in the conventional group in addition to IV L-carnitine.
89577378|NCT02408887|Active Comparator|Arm 2/Total Thyroidectomy (TT) Plus Prophylactic Central Neck Dissection (pCND)|TT plus pCND
89577379|NCT02408887|Active Comparator|Arm 1/Total Thyroidectomy (TT) alone|TT alone
89577380|NCT02266875|Experimental|Hypertonic Saline|"Patients will receive nebulized hypertonic (3%) saline along with standard 2.5 mg. albuterol treatments once every 6 hours for 24 hour, with allowance for PRN (as needed use).~Dyspnea will be assessed prior to treatment and at completion of the 24 hour period using the Modified Borg Dyspnea Scale."
89577381|NCT02266875|Active Comparator|Standard Saline|"Patients will receive standard saline (0.9%) saline along with standard 2.5 mg. albuterol treatments once every 6 hours for 24 hour, with allowance for PRN (as needed use).~Dyspnea will be assessed prior to treatment and at completion of the 24 hour period using the Modified Borg Dyspnea Scale."
89577382|NCT04135443|Experimental|3T Tune in! Turn on! Turn up!|The intervention is a mobile app delivered sexual health promotion program designed specifically for young black men who have sex with men or who are attracted to men. The mobile app will include more than 30 interactive activities including resource maps, pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) content, and communication forums. The app helps participants to become clearer about what they do/don't want to do sexually, to communicate their choices. It also focuses on ways to increase healthy relationships, enhance sexual experience if having sex while reducing HIV/STI risk. The intervention/app is intended to be used regularly (e.g., two times per week) during the 90 day active participation period.
89577383|NCT04135443|Active Comparator|General Health App|Participants will download a general health mobile app (focused on promoting drinking water). The control mobile app is intended to be used regularly during the 90 day active participation period.
89029297|NCT02914067|Experimental|Cohort 2|"Patients with diagnosis of a posterior tumor will undergo neurocognitive testing utilizing the NIH Toolbox. Testing will be every 6 months for children currently receiving therapy and annually for those that have completed all therapy for a total of 3 sessions. During standard of care MRI images, rsfcMRI imaging will be performed which will add 15 minutes of time. rsfcMRI will be obtained every 6 months for children currently receiving therapy and annually for those that have completed therapy for a total of 3 rsfcMRIs for each patient.~Patients in Cohort 1 will also be eligible to continue with the longitudinal assessment as just described. These participants will then undergo repeat neurocognitive testing using the NIH toolbox 6-9 months for an additional 3 testing sessions. rsfcMRI will be obtained during their follow-up imaging at 6-9 month intervals for a total of 3 additional rsfcMRIs (4 total scans)."
89577384|NCT05647395|Experimental|Slowly and evenly draw the gas in the cuff|
89577385|NCT05647395|No Intervention|One-time aspiration of tracheal catheter cuff gas|
89577386|NCT02438371|Active Comparator|Nifedipine|Participants will receive nifedipine 10 mg orally every 20 minutes for 3 doses, then nifedipine 10 mg every 6 hours for a total of 48 hours.
89577387|NCT02438371|Active Comparator|Nifedipine plus Indomethacin|Participants will receive will receive nifedipine 10 mg orally every 20 minutes for 3 doses, then nifedipine 10 mg every 6 hours for a total of 48 hours, as well as indomethacin 100 mg orally, then indomethacin 50 mg orally every 6 hours for a total of 48 hours.
89577388|NCT04419987|Experimental|constitutional platelet patholog|Patient and relatives having a constitutional platelet pathology
89577389|NCT05647239|Experimental|Intervention|Since the patients included in the study were discharged early (mean hospitalization duration was 3 days), the first, third and fifth SC heparin injection (0.6 ml) administrations were performed by the researcher for three days. The application was made to the arm area due to the fact that Shotblocker was difficult to place in the abdominal area, and the outer side of the arm was preferred for subcutaneous injection administrations in the clinic where the study was conducted. Shotblocker was placed on the injection site determined on the outer side of the upper arm of the patient and the injection was administered by gently pressing the tool with the fingertips during the injection. Shotblocker was removed after removal of the injector. Injections were completed in 20 seconds and the injection site was supported with cotton for 30 seconds.
89577390|NCT05647239|No Intervention|Control|"Verbal and written informed consents of the patients included in the control group were obtained after they were informed by the researcher. Before the application, questions in patient information form were asked to each patient and how to use the VAS pain and injection satisfaction scale was explained. During injection, SC Clexan (0.6 ml) was injected on the site without using Shotblocker. Injections were completed in 20 seconds and the site was supported for 30 seconds. In the first minute after each SC injection administration, the patients were asked about pain level felt during the injection and injection satisfaction status.~In this study, the researcher administered all SC injections by throughout the study by considering the reliability of the study results."
89577391|NCT02438137|Active Comparator|Dimethyl Fumarate (Tecfidera®) capsules|The starting dose for dimethyl fumarate (Tecfidera®, http://www.tecfidera.com/pdfs/full-prescribing-information.pdf) is 120 mg twice a day orally. After 7 days, the dose should be increased to the maintenance dose of 240 mg twice a day, though slower dose escalations are possible to increase tolerability, if necessary. Participants randomized to dimethyl fumarate will be instructed to take this medication twice a day with breakfast and dinner for a period of 4 months.
89577392|NCT02438137|Placebo Comparator|Placebo|The placebo is an inert product that looks like a pill and is identical to dimethyl fumarate capsules, but it contains no medicine. Participants randomized to placebo will be instructed to take placebo twice a day with breakfast and dinner for a period of 4 months.
89577393|NCT02437903|Other|JUVÉDERM VOLUMA™ XC|Subjects will be injected with JUVÉDERM VOLUMA™ XC to their right and left facial temporal regions at the baseline visit.
89577394|NCT02437513||NewBreez|"The study group is composed only of patients who have already opted to receive the NewBreez device as part of their routine care from their physician.~Patients who have the device implanted, and consent to be part of the 12 week observational study, will be enrolled and have standard clinical parameters measured over the 12 week period as well as complete quality of life assessments in the form of patient questionnaires."
89577395|NCT04909021|Experimental|Dosage Group 1: RSV Vaccine Dosage 1|Participants in this arm will receive a single intranasal dose of the investigational RSV vaccine at Dosage 1
89577396|NCT04909021|Experimental|Dosage Group 2: RSV Vaccine Dosage 2|Participants in this arm will receive a single intranasal dose of the investigational RSV vaccine at Dosage 2
89577397|NCT04909021|Experimental|Dosage Group 3: RSV Vaccine Dosage 3 (Single-dose)|Participants in this arm will receive a single intranasal dose of the investigational RSV vaccine at Dosage 3
89577398|NCT04909021|Experimental|Dosage Group 3a: RSV Vaccine Dosage 3 (Two-dose)|Participants in this arm will receive a single intranasal dose of the investigational RSV vaccine at Dosage 3 followed by a second identical dose of the investigational RSV vaccine 28 days later
89577399|NCT04909021|Placebo Comparator|Placebo (Single-dose)|Participants in this arm will receive a single intranasal dose of placebo
89577400|NCT04909021|Placebo Comparator|Placebo (Two-dose)|Participants in this arm will receive a single intranasal dose of placebo followed by a second identical dose of placebo 28 days later
89577401|NCT02460991|Experimental|DEB-TACE|ONCO-DOX (Doxorubicin loaded Microspheres) up to 150 mg per treatment; treatments can be repeated every 4-8 weeks until complete tumor response is achieved.
88972096|NCT00017147|Experimental|O6-BG + BCNU + Radiation Therapy|O6-BG: 120 mg/m^2 IV over 1 hour on day 1 of each cycle BCNU: 40 mg/m^2 IV over 1 hour on day 1 of each cycle 6 hours after O6-BG dose. Radiation Therapy: 5 days/week using one fraction per day and a dose of 180 cGy per fraction. Initial target volume is dose of 5040 cGy in 28 fractions with boost target volume of 1080 cGy in 6 fractions.
88972097|NCT00017147|Active Comparator|BCNU + Radiation Therapy|BCNU: 40 mg/m^2 IV over 1 hour on day 1 of each cycle. Radiation Therapy: 5 days/week using one fraction per day and a dose of 180 cGy per fraction. Initial target volume is dose of 5040 cGy in 28 fractions with boost target volume of 1080 cGy in 6 fractions.
88972098|NCT04734236|Active Comparator|New technique group|
88972099|NCT04734236|Sham Comparator|Xpert group|
88972100|NCT00017186|Experimental|gemcitabine + epirubicin|"Patients receive gemcitabine IV over 30 minutes on days 1 and 8 and epirubicin IV on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients achieving complete response (CR) receive 2 additional courses beyond CR.~Quality of life is assessed at baseline, prior to course 3, at 3 months, and then at 1 year.~Patients are followed every 3 months for 1 year, every 4 months for 1 year, and then every 6 months for 3 years."
89577402|NCT02460991|Active Comparator|Sorafenib|200 mg Sorafenib twice daily; continue until unacceptable toxicity or unequivocal tumor progression
89577403|NCT02460679|Experimental|EPI-589|Participants will receive EPI-589 500 milligrams (mg) (2 tablets of 250 mg each) twice daily (BID) for 3 months, unless discontinued for safety or tolerability issues.
89577404|NCT02459899|Placebo Comparator|Placebo|Two placebo-matching sotagliflozin tablets, once daily, orally for 12 weeks.
89577405|NCT02459899|Experimental|Sotagliflozin 75 mg|Sotagliflozin 75 mg (one 75 mg tablet and one placebo tablet), once daily, orally for 12 weeks.
89577406|NCT02459899|Experimental|Sotagliflozin 200 mg|Sotagliflozin 200 mg (one 200 mg tablet and one placebo tablet), once daily, orally for 12 weeks.
89577407|NCT02459899|Experimental|Sotagliflozin 400 mg|Sotagliflozin 400 mg (two 200 mg tablets), once daily, orally for 12 weeks.
89577408|NCT02436889|Experimental|Mirabegron|Participants will be instructed to take one tablet and 1 capsule (total of 2) of blinded study medication once a day, orally, for 8 weeks. They will start with Mirabegron (25mg) dose of study medication and will have the option of dose escalation to 2 tablets and 2 capsules (total of 4) per day (Mirabegron 50mg).
89577409|NCT02436889|Active Comparator|Tolterodine Tartrate|Participants will be instructed to take one tablet and 1 capsule (total of 2) of blinded study medication once a day, orally, for 8 weeks. They will start with tolterodine tartrate (4 mg) dose of study medication and will have the option of dose escalation to 2 tablets and 2 capsules (total of 4) per day tolterodine tartrate 4 mg + identical placebo.
89577410|NCT02436811|Experimental|Standardized oral instruction|60 women aged between 12 and 50 and gestational period of up to 32nd weeks. A trained individual will present the same information arranged in the educational brochure in the intervention group on standardized oral form. This examiner will be trained in a unified way in relation to the instructions available in the form of written guidance. Thus, the only difference between the two measures is the interaction between the participant and researcher orally.
89577411|NCT02436811|Experimental|Written form instruction|60 women aged between 12 and 50 and gestational period of up to 32nd weeks. Participants in writing intervention will receive a brochure containing information on diet and oral health. This leaflet was produced in accordance with the recommendations of the Ministry of Health regarding eating habits for children under two years (BRAZIL, 2002) and according to the Health Book of the Child: Growth and Development (BRAZIL, 2012).
89577412|NCT02436811|Experimental|Control|60 women aged between 12 and 50 and gestational period until 32nd weeks.The control group will receive a leaflet on oral cancer.
89577413|NCT02436577|Experimental|Sequence ABC|Treatment A in Period 1, Treatment B in Period 2 and Treatment C in Period 3
89577414|NCT02436577|Experimental|Sequence BCA|Treatment B in Period 1, Treatment C in Period 2 and Treatment A in Period 3
89577415|NCT02436577|Experimental|Sequence CAB|Treatment C in Period 1, Treatment A in Period 2 and Treatment B in Period 3
89577416|NCT02436577|Experimental|Sequence ACB|Treatment A in Period 1, Treatment C in Period 2 and Treatment B in Period 3
89577417|NCT02436577|Experimental|Sequence BAC|Treatment B in Period 1, Treatment A in Period 2 and Treatment C in Period 3
89577418|NCT02436577|Experimental|Sequence CBA|Treatment C in Period 1, Treatment B in Period 2 and Treatment A in Period 3
89577419|NCT02265705|Experimental|Baricitinib|"4 milligrams (mg) baricitinib administered orally once a day for 52 weeks. Participants with renal impairment will receive 2 mg baricitinib orally once a day for 52 weeks.~Participants will continue to take background methotrexate (MTX) therapy throughout study. Other background therapies, including non-steroidal anti-inflammatory drugs (NSAIDs) and low dose oral corticosteroids, are permitted during the study for participants who are on stable doses of these treatments at baseline."
89577420|NCT02265705|Placebo Comparator|Placebo|"Placebo administered orally once a day through week 24. At week 24, participants will be given 4 mg or 2 mg (participants with renal impairment) baricitinib orally once a day through Week 52.~Participants will continue to take background MTX therapy throughout study. Other background therapies, including NSAIDs and low dose oral corticosteroids, are permitted during the study for participants who are on stable doses of these treatments at baseline."
89577421|NCT02459665|No Intervention|Group 1|Negative control group: After initial treatment for BV/TV, no intervention.
88972101|NCT00128895|Active Comparator|azathioprine, standard|standard azathioprine maintenance upto one year after diagnosis, subsequently tapering of azathioprine with 25 mg per 3 months
88972102|NCT00128895|Experimental|azathioprine, longterm|longterm maintenance with azathioprine upto four years after diagnosis, subsequently azathioprine will be tapered with 25 mg per 3 months
88972103|NCT00128817|Experimental|1|Concurrent Chemoradiation
88972104|NCT00128817|Active Comparator|2|Laryngectomy + adjuvant radiotherapy/chemoradiotherapy
89577422|NCT02459665|Other|Group 2|Positive control group: After initial treatment for BV/TV, metronidazole pills (500 mg) twice per week for 2 months.
89577423|NCT02459665|Active Comparator|Group 3|After initial treatment for BV/TV, Ecologic Femi+ vaginal capsule (a vaginal probiotic) once per day for 5 days immediately after the initial treatment followed by thrice weekly for two months.
89577424|NCT02459665|Active Comparator|Group 4|After initial treatment for BV/TV, Gynophilus LP vaginal tablet (a vaginal probiotic) once every 4 days for two months.
89577425|NCT02265237|Experimental|Arm A|Ombitasvir/paritaprevir/ritonavir (25/150/100 mg) and Ribavirin dosed for 12 weeks for genotype 4 treatment-naïve or treatment-experienced with IFN/RBV.
89577426|NCT02265237|Experimental|Arm B|Ombitasvir/paritaprevir/ritonavir (25/150/100 mg) and Ribavirin dosed for 16 weeks for genotype 4 treatment-naive or treatment-experienced with IFN/RBV.
89577427|NCT02265237|Experimental|Arm C|Ombitasvir/paritaprevir/ritonavir (25/150/100 mg) and Ribavirin dosed for 24 weeks for genotype 4 treatment-naive and treatment-experienced with IFN/RBV.
89577428|NCT02265237|Experimental|Arm D|Ombitasvir/paritaprevir/ritonavir (25/150/100 mg) and Ribavirin dosed for 24 weeks for genotype 4 SOF/pegIFN/RBV or SOF/RBV treatment-experienced.
89577429|NCT05484219|Experimental|Surgery|Image-guided resection of brain tumors and vascular malformations
89577430|NCT02263365|No Intervention|Control|
89577431|NCT02263365|Experimental|Therapeutic|Patients randomized to this arm will be administered 4mg tid (three times daily) of loperamide from the day of discharge onwards. A total of duration of 14 days of medication will be administered
89029298|NCT02914067|Experimental|Cohort 3|"During standard of care MRI images, rsfcMRI imaging will be performed which will add 15 minutes of scan time.~rsfcMRI will be obtained annually for total of 3 rsfcMRIs for each patient."
89577432|NCT05647083|Experimental|Intervention group|A total of 24 massage sessions will be applied to the intervention group, 2 times a week during the 12-week working period. Sesame oil will be used as the main oil in the massage application. Massage times are recommended as 10-15 minutes for upper extremity massage and 15-20 minutes for lower extremity massage.
89029299|NCT02914067|Experimental|Cohort 4 Arm A|"Undergo the following MRI images: RSFC MRI, T2/T1 MRI, and DTI.~Will complete cognitive testing using the NIH Toolbox Cognitive Battery~All patients will complete the Attention Deficit/Hyperactivity Disorder (ADHD) Rating Scale - 5 questionnaire. All patients will complete a self-reported assessment of neurological quality of life (QOL). Adult patients (age ≥ 18 years) will complete the adult version of the Quality of Life in Neurological Disorders (Neuro-QOL) Cognitive Function measure. All pediatric patients will complete the pediatric version of the Neuro-QOL Cognitive Function measure. For patients <18 years of age and for adult patients with parent present, parent/caregiver will complete the PROMIS® Parent Proxy for cognition. All adult patients will complete the Colorado Learning Difficulties Questionnaire (CLDQ). This questionnaire will be completed by parent/caregiver for patients < 18 years of age."
89033243|NCT02917356|Sham Comparator|Control Group (CG)|"Sham/ Control Group (CG) - performed by lay persons. They will stay in the room and move slowly and randomly in order to sham the presence of someone performing the laying on of hands. However, they will not perform the laying on of hands (5 min, once a week, for 8 weeks)~Physical therapy: Kinesiotherapy (45 min, twice a week, for 8 weeks)"
89577433|NCT05647083|No Intervention|Control group|Participants in the control group will continue their medical treatment protocols and massage will not be applied. Measurement tools and physiological measurements will be evaluated at the frequency specified in the intervention group, using the same measurement tools and the same measurement methods.
89577434|NCT02261493|Experimental|OnabotulinumtoxinA Dose A|OnabotulinumtoxinA Dose A injected into the protocol-specified areas on Day 1. Subjects will receive at least 1 and up to 3 treatments.
89577435|NCT02261493|Experimental|OnabotulinumtoxinA Dose B|OnabotulinumtoxinA Dose B injected into the protocol-specified areas on Day 1. Subjects will receive at least 1 and up to 3 treatments.
89577436|NCT02261493|Placebo Comparator|Placebo followed by OnabotulinumtoxinA Dose A|Placebo (normal saline) injected into the protocol-specified areas on Day 1. If the subject meets the re-treatment criteria, the subject will receive up to 2 treatments with onabotulinumtoxinA Dose A into the protocol-specified areas.
89577437|NCT04855773|Experimental|PrEPmate|Participants randomized to this study arm will receive the PrEPmate mHealth intervention (bi-directional text messaging with PrEP navigators/clinic staff) to support PrEP adherence and continuation.
89577438|NCT04855773|Experimental|Dot Diary mobile application|Participants randomized to this study arm will download and use the Dot Diary mobile application on a personal device, to support PrEP adherence and continuation.
89577439|NCT02260791|Experimental|FKB327|Patients will receive FKB327 40 mg every other week by subcutaneous injection. The treatment period will continue for 22 weeks.
89577440|NCT02260791|Active Comparator|Humira®|Patients will receive Humira® 40 mg every other week by subcutaneous injection. The treatment period will continue for 22 weeks.
89577441|NCT02260635|Experimental|Evacetrapib|130 milligrams (mg) evacetrapib given orally (PO) once a day for 12 weeks. Participants begin open label extension (130 mg evacetrapib given orally once a day for 40 weeks) after week 12.
89577442|NCT02260635|Placebo Comparator|Placebo|Placebo given PO once a day for 12 weeks. Participants begin open label extension (130 mg evacetrapib given PO once a day for 40 weeks) after week 12.
89577443|NCT05466201|Other|supportive care|patients in this group will receive supportive care, including blood products transfusion, anti-infective therapy rather than rhTPO or TPO-RAs.
89577444|NCT05466201|Experimental|Eltrombopag group|Eltrombopag treatment will be started at the dose of 50mg/d from the 1st day post hematopoietic stem cell transplantation, and the dose will be titrated by 25mg each every 7 days up to 100mg/d according to the tolerability. If not tolerable, reduce the dose to the previous tolerable level (if not tolerable at 50mg/d, reduce to 25mg/d) and maintain this dose for the following 7 days, with the attempt to restart dose escalation after this 7-day period.
89577445|NCT02258529|Experimental|Idelalisib + rituximab|Idelalisib + rituximab for up to 104 weeks
89577446|NCT05646225|Experimental|chest physiotherapy and early mobilization|"Chest Physiotherapy: Each session included a series of exercises, lasting a total of 15 minutes and including positioning,self-conscious breathing control, diaphragmatic breathing control, and exercises for the chest wall and abdominal muscle walls.~Early mobilization: Each session included abdominal and upper and lower limb exercises, shoulder and full arm circling, lying to sit, sit to stand, walk and other exercises. This training has been described previously and used in other clinical trials. Each exercise was repeated 8-10 times over 30 minutes"
89033244|NCT05319119||1.CT-FFR Related Group|Coronary diseased artery CTFFR>80%, secondary prevention of coronary heart disease;Coronary diseased artery CTFFR≤80% revascularization at the lesion site and regular medication after PCI
89577447|NCT05646225|Active Comparator|early mobilization|Each session included abdominal and upper and lower limb exercises, shoulder and full arm circling, lying to sit, sit to stand, walk and other exercises. This training has been described previously and used in other clinical trials. Each exercise was repeated 8-10 times over 30 minutes.
89577448|NCT05449275|Experimental|Faradic current|This study will use the faradic current for treating foot drop. In Group A 15 number of patient with foot drop will get the 40 minutes of session with the frequency of 50-100hz alternative three days / week for 25 weeks
89577449|NCT05449275|Experimental|Ankle foot orthosis|Group B will get the treatment by Ankle foot orthosis.In group B 15 patients with foot drop will get the session alternative three days/week for 25 weeks. All participants have to use Ankle foot orthosis on a daily basis and patients have to walk for 10 minutes without walking aid.
89577450|NCT02256969|Other|Meibomian Gland Probing plus lubricant|"Meibomian Gland Probing: Stainless steel probes were used to probe all the meibomian glands of upper lids of both eyes at the slit lamp. All patients were probed with a 1-mm probe followed by a 2-mm probe for all glands.~Lubricant: GenTeal PM Night-Time Ointment (Alcon), a sterile ophthalmic lubricant that is commonly used to relieve symptoms in patients with dry eye disease, was applied topically to both eyes for 4 weeks with the following regimen: twice daily for 2 weeks and then once daily for 2 weeks."
89577451|NCT02256969|Other|Sham Meibomian Gland Probing plus lubricant|"Sham Meibomian Gland Probing: The patient's the lid margin was touched with the probes without actual probing occurring.~Lubricant: GenTeal PM Night-Time Ointment, ophthalmic lubricant used to relieve symptoms in patients with dry eye disease, was applied topically to both eyes for 4 weeks: twice daily for 2 weeks and then once daily for 2 weeks."
89577452|NCT02256969|Active Comparator|Meibomian Gland Probing plus Blephamide|"Meibomian Gland Probing: Stainless steel probes were used to probe all the meibomian glands of upper lids of both eyes at the slit lamp. All patients were probed with a 1-mm probe followed by a 2-mm probe for all glands.~Blephamide: is a combination of an antibiotic and an anti-inflammatory agent commonly used to treat various ocular conditions. Blephamide was applied topically to both eyes for 4 weeks with a regimen of: twice daily for 2 weeks and then once daily for 2 weeks."
89577453|NCT05438121||Patients with multivessel CAD undergoing DCB PCI|"I. Patients with significant multi-vessel coronary artery disease will be screened.~II. If the patient is found to have at least one lipid-rich plaque (LRP, LCBI>250) requiring revascularization (DS>70%) will undergo multi-vessel IVUS-NIRS imaging.~III. If multi-vessel NIRS screening revealed another LRP (LCBI>250) with DS<70%, the patient will be enrolled.~IV. The stenotic LRP lesion (DS>70%) will be subjected to DCB angioplasty while non-stenotic LRP lesion (DS<70%) will be left unintervened and treated medically.~V. Comparative lesions:~DCB-treated LRP (DS>70%, maxLCBI>250)~Unintervened, medically-treated LRP (DS<70%, maxLCBI>250)"
89577454|NCT05645991|Placebo Comparator|Placebo|Capsules containing aspartame (1.5 g/day) were taken orally once daily for 8 weeks.
89577455|NCT05645991|Experimental|Coconut Sap Powder|Capsules containing coconut sap powder (CSP; 1.5 g/day) were taken orally once daily for 8 weeks.
89577456|NCT02256891|Experimental|Double Row|Double Row
89577457|NCT02256891|Experimental|Double Row with PRFM|Double Row with PRFM
89577458|NCT02256267|Experimental|LY2835219|Single oral dose of LY2835219
89577459|NCT02256267|Experimental|LY2835219 + Rifampin|Single oral dose of LY2835219 with rifampin orally, once daily for 14 days
89577460|NCT01641471|Experimental|Active TENS|Active TENS (EMPI Select TENS) in combination with a femoral nerve catheter. Patients will begin using the TENS unit immediately following surgery and continuing throughout the 6 weeks postoperatively.
89577461|NCT01641471|Placebo Comparator|Placebo TENS|Placebo TENS (Placebo EMPI Select TENS) in combination with a femoral nerve catheter. Patients will begin using a sham TENS unit (appears identical to Active TENS unit, yet is created to deliver low-level, non-therapeutic electrical stimulation) immediately following surgery and continuing throughout the 6 weeks postoperatively.
89577462|NCT05429463|Experimental|Arm A(3 cycles of neoadjuvant therapy)|"Neoadjuvant: Prior to surgery, participants receive up to 3 cycles (cycle length: 3 weeks) of sintilimab [200 mg, intravenous (IV); given on cycle day 1] in combination with neoadjuvant chemotherapy, consisting of albumin-bound paclitaxel [260 mg/m^2, IV; given on cycle day 1] and carboplatin [AUC 5- 6mg/mL/min, IV; given on cycle day 1 ] .~Adjuvant: Followed by surgery within the 3-5th week after the last dose of sintilimab, the researcher will decide whether to radiotherapy or not according to the clinical situation and pathological stage of the patient. The maintenance treatment of sintilimab [200 mg, intravenous (IV); given on cycle day 1; cycle length: 3 weeks] may be selected upon subject request for up to 1 year."
89577463|NCT05429463|Experimental|Arm B(4 cycles of neoadjuvant therapy)|"Neoadjuvant: Prior to surgery, participants receive up to 4 cycles (cycle length: 3 weeks) of sintilimab [200 mg, intravenous (IV); given on cycle day 1] in combination with neoadjuvant chemotherapy, consisting of albumin-bound paclitaxel [260 mg/m^2, IV; given on cycle day 1] and carboplatin [AUC 5- 6mg/mL/min, IV; given on cycle day 1 ] .~Adjuvant: Followed by surgery within the 3-5th week after the last dose of sintilimab, the researcher will decide whether to radiotherapy or not according to the clinical situation and pathological stage of the patient. The maintenance treatment of sintilimab [200 mg, intravenous (IV); given on cycle day 1; cycle length: 3 weeks] may be selected upon subject request for up to 1 year."
89577464|NCT02255565|Experimental|Very Low Dose Quillivant XR|Patients in this treatment arm are given Quillivant XR (a liquid medication) to treat ADHD at a very low dose level for 6 weeks.
88972105|NCT00017381|Experimental|Treatment|"PART I: Patients receive rituximab IV on days 1, 8, 15, and 22 and cyclophosphamide IV over 1 hour on day 25. G-CSF is administered SC daily beginning on day 26 and continuing until autologous PBSC are harvested.~PART II: Beginning 4-6 weeks after completion of the fourth rituximab infusion, patients receive indium In 111 ibritumomab tiuxetan IV over 10 minutes on day 1 followed by dosimetry imaging on days 1, 2, 4, and 7. Patients then receive IDEC-Y2B8 IV over 10 minutes once between days 8-15.~PART III: All patients undergo PBSCT beginning after residual bone marrow radioactivity resolves. G-CSF is administered SC beginning 1 day after PBSCT and continuing until blood counts recover."
88972106|NCT00128622|Experimental|Denileukin Diftitox plus vaccine|This is a single arm Phase I safety study.
88972107|NCT00017537|Experimental|Dose #1|dose #1 administered
88972108|NCT00017537|Experimental|Dose #2|dose #2 administered
88972109|NCT00017537|Experimental|Dose #3|Dose #3 administered
88972110|NCT00017537|Experimental|Dose #4|Dose #4 administered
88972111|NCT00017537|Experimental|Dose #5|Administered dose #5
88972112|NCT00128505|Experimental|mifepristone|
88972113|NCT00017693|Experimental|0.75mg rsIL-4R|Recombinant human soluble IL-4 receptor (rsIL-4R) given by means of inhalation once weekly for 12 weeks. The study drug was administered in the clinic at a final volume of 2.5 mL in sterile normal saline solution with a breath-assisted Pari LC Star nebulizer powered by a Proneb Turbo portable compressor.
88972114|NCT00017693|Experimental|1.5mg rsIL-4R|Recombinant human soluble IL-4 receptor (rsIL-4R) given by means of inhalation once weekly for 12 weeks. The study drug was administered in the clinic at a final volume of 2.5 mL in sterile normal saline solution with a breath-assisted Pari LC Star nebulizer powered by a Proneb Turbo portable compressor.
89577465|NCT02255565|Experimental|Low Dose Quillivant XR|Patients in this treatment arm are given Quillivant XR (a liquid medication) to treat ADHD at a low dose level for 6 weeks.
89577466|NCT02255565|Experimental|Moderate dose Quillivant XR|Patients in this treatment arm are given Quillivant XR (a liquid medication) to treat ADHD at a moderate dose level for 6 weeks.
89577467|NCT01640301|Experimental|Arm I (high-risk for relapse after HCT)|Patients with no evidence of leukemia or MDS post-HCT receive WT1-sensitized T cells IV over 45 minutes (or longer for patients who are 15-30 kg) on days 0 and 14 and aldesleukin SC BID on days 14-28.
89577468|NCT01640301|Experimental|Arm II (relapsed after HCT)|Patients with evidence of AML (minimal residual disease or overt relapse) post-HCT receive cyclophosphamide IV and fludarabine phosphate IV daily on days -4 to -2. Patients also receive WT1-sensitized T cells IV over 45 minutes (or longer for patients who are 15-30 kg) on days 0 and 21 and aldesleukin SC BID on days 14-28.
89577469|NCT01642407|Experimental|Sildenafil|
89577470|NCT02255097|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 3-week cycle (Q3W) for up to 24 months
89577471|NCT02254551|Experimental|LDE225 Plus Bortezomib|"Lead-In Portion: The lead-in portion of this study will investigate the safety and tolerability, and determine the MTD of LDE225, in combination with bortezomib in this patient population.~Expansion Portion: Eligible patients will receive LDE225 orally once daily for 21 days with the dose-level determined in the lead-in portion of the study. Eligible patients will also receive a standard regimen of bortezomib 1.3 mg/m2 on days 1, 4, 8, and 11 of each 21 day cycle.~Maintenance Therapy: Patients who complete 16 cycles of therapy with stable disease or better will be eligible for single agent maintenance therapy of LDE225 at the MTD orally for up to 2 years or until progressive disease or unacceptable toxicity."
89577472|NCT05651139|Experimental|Receiving vibration stimulation post-injection|Using a vibration device post-injection on the affected area.
89577473|NCT05651139|No Intervention|control group|No intervention will be conducted
89577474|NCT05642793|Experimental|group 1 (proactive use of conbercept after vitrectomy)|proactive use of conbercept after vitrectomy
89577475|NCT05642793|Experimental|group 2 (passive use of conbercept after vitrectomy)|passive use of conbercept after vitrectomy
89577476|NCT05642013|Experimental|Prospective group|50 patients prospectively included with early prosthesis reimplantation
89577477|NCT05642013|Other|Retrospective group|Last 50 patients with hip or knee prosthetic-joint infection managed with classical two-stage implant exchange
89577478|NCT05650983|Experimental|1.Aerobic exercise|play balloon volleyball for Aerobic exercise and aimed at maximizing the strain on the cardiovascular system (60-70% of heart rate recovery). Aerobic exercise intervention five times a week, one hour each time，for three months.
89577479|NCT05650983|Experimental|2.Resistance exercise|Resistance strength training for Resistance exercise and aimed at promoting the greatest hypertrophy response(65% of 1 repetition maximum and repeated up to 15 times). Resistance exercise intervention five times a week, one hour each time,for three months.
89577480|NCT05405985|Experimental|Nemolizumab With Auto-Injector (AI)|Participants will receive a 60-mg dose of nemolizumab as a 2 successive subcutaneous injections of 30 mg nemolizumab at either of the same location i.e., abdomen, front upper thigh, or outer upper arm and on the same side with injection sites at least 1 inch (2.5 cm) apart with Auto-Injector (AI).
89209354|NCT00882648||Drug dependent women|All drug dependent women enrolled in comprehensive substance abuse treatment at the Center for Addiction and Pregnancy of Johns Hopkins University between 2004 and 2009; retrospective chart review.
89209355|NCT00882726|Experimental|CNTO 3649 IV (Healthy participants)|
89577481|NCT05405985|Experimental|Nemolizumab With Dual Chamber Syringe (DCS)|Participants will receive a 60-mg dose of nemolizumab as a 2 successive subcutaneous injections of 30 mg nemolizumab at either of the same location i.e., abdomen, front upper thigh, or outer upper arm and on the same side with injection sites at least 1 inch (2.5 cm) apart with Dual Chamber Syringe (DCS).
89577482|NCT05640375|No Intervention|Follow-up|Intussuception diagnosed, Informed consent was obtained by explaining treatment options to their families, no tenderness on abdominal examination, the duration of complaints is less than 24 hours, no findings of complication, Just IV hydration and ultrasonography is repeated 4 hours later (clinical and physical examination findings are monitored)
89577483|NCT05640375|Experimental|Single dose Steroid treatment|Intussuception diagnosed, Informed consent was obtained by explaining treatment options to their families, no tenderness on abdominal examination, the duration of complaints is less than 24 hours, no findings of complication, Methylprednisolone 1 mg/ kg single dose was given and ultrasonography is repeated 4 hours later (clinical and physical examination findings are monitored)
89577484|NCT05650671||"wheelchair user-seat group"|healthy subjects agreeing to participate in the study
88972115|NCT00017693|Experimental|3.0mg rsIL-4R|Recombinant human soluble IL-4 receptor (rsIL-4R) given by means of inhalation once weekly for 12 weeks. The study drug was administered in the clinic at a final volume of 2.5 mL in sterile normal saline solution with a breath-assisted Pari LC Star nebulizer powered by a Proneb Turbo portable compressor.
88972116|NCT00017693|Placebo Comparator|Placebo for rsIL-4R|The placebo for recombinant human soluble IL-4 receptor (rsIL-4R) consisted of identically prepared excipient in the same volume (2.5 mL). To maintain blinding, medication was dispensed by an individual who was not responsible for patient care or assessment. Treatment assignment was blinded to all personnel involved in direct conduct or monitoring of the study.
89209356|NCT00882726|Experimental|CNTO 3649 SC (Healthy participants)|
89209357|NCT00882726|Experimental|CNTO 3649 SC (Diabetic patients)|
89209358|NCT00882804|Experimental|Hemin|
89209359|NCT00882804|Placebo Comparator|placebo|
89209360|NCT00882882|Experimental|1|Metformin HCL 500 mg Extended-Release Tablets, Geneva PTC
89209361|NCT00882882|Experimental|2|Metformin HCL 500 mg Extended-Release Tablets, Geneva PTC
89209362|NCT00882882|Active Comparator|3|GLUCOPHAGE XR 500 mg Extended-Release Tablets Bristol-Myers Squibb
89577485|NCT01641237|Experimental|Low ppm fluoride dentifrice|Low ppm fluoride as sodium fluoride in a silica base dentifrice
89577486|NCT01641237|Experimental|Medium ppm fluoride dentifrice|Medium ppm fluoride as sodium fluoride in a silica base dentifrice
89577487|NCT01641237|Experimental|High ppm fluoride dentifrice|High ppm fluoride as sodium fluoride in a silica base dentifrice
88972117|NCT00017810|Experimental|Condition 1: Dietary Intervention|Patients will receive behavioral dietary intervention using normal foods.
88972118|NCT00017810|Active Comparator|Condition 2 (Control): HIV Self-Care|Patients will receive HIV self-care information, and be given the dietary intervention at the completion of the last study session (post study).
88972119|NCT00128388|Experimental|1 PFPP|Panic Focused Psychodynamic Psychotherapy
88972120|NCT00128388|Active Comparator|2 ART|Applied Relaxation Training
88972121|NCT00391859|Experimental|Health service provision|Health service provision within the first few months of diagnosis which includes physical examination, radiographs, education, exercise, weight loss, assistive devices and pharmacologic therapy.
88972122|NCT00018200|Experimental|Arm 1|Desipramine, low, middle or high exposure
88972123|NCT00018200|Experimental|Arm 2|Fluoxetine, low, middle, or high exposure
88972124|NCT00018200|Placebo Comparator|Arm 3|Benztropine .125-.5mg daily
89577488|NCT01641237|Placebo Comparator|No fluoride dentifrice|no added fluoride in a silica base dentifrice
88972125|NCT04734353|Experimental|E5 group|Escalation in CHIP
88972126|NCT04734353|Active Comparator|T60 group|Escalation in CHIP
88972127|NCT00018798||Bi-weekly telephone calls|34 participants received bi-weekly telephone calls in addition to the annual reviews
88972128|NCT00018798||Annual review only|23 participants received annual reviews only
89577489|NCT04861779|Experimental|Phase 1a Dose Escalation|Multiple dose levels of HSK29116 to be evaluated; determination of MTD/Phase 1b recommended dose
89577490|NCT04861779|Experimental|Phase 1b Dose Expansion in R/R CLL or SLL|CLL/SLL patients must have received at least one systemic treatment and failed or relapsed, of which at least half of the subjects must have received covalent BTK inhibitors and have BTK C481 mutation.
89577491|NCT04861779|Experimental|Phase 1b Dose Expansion in R/R MCL|MCL patients must have received at least one systemic treatment and failed or relapsed, of which at least half of the subjects must have received covalent BTK inhibitors and have BTK C481 mutation.
89577492|NCT04861779|Experimental|Phase 1b Dose Expansion in other R/R B-cell Malignancy|Patients must have received at least one systemic treatment and failed or relapsed, of which at least half of the subjects must have received covalent BTK inhibitors and have BTK C481 mutation.
89577493|NCT05624307||Patient with chronic back pain|Patients admitted to the chronic pain service at the Calot Institute with chronic low back pain for at least three months, not responding to well-conducted conservative treatment
89577494|NCT05623605|Experimental|Moringa mouthwash|5 ml Moringa mouthwash two times per day for 1 week
89577495|NCT05623605|Experimental|Star Anis mouthwash|5 ml Star Anis mouthwash two times per day for 1 week
89577496|NCT05623605|Experimental|Indian Costus mouthwash|5 ml Indian Costus mouthwash two times per day for 1 week
89577497|NCT05617209||Severe and/or moderate haemophilia A and B|At the end of the consultation and follow-up of the disease, an additional blood sample of 35 ml (8 tubes) will be taken
89577498|NCT01639833|Experimental|Veriset Hemostatic Patch|Topical Hemostat
89577499|NCT01639833|Active Comparator|TachoSil®|Topical Hemostat
88972129|NCT04734314|Experimental|conventional treatment of back pain|Group A: received conventional treatment of back pain which included; TENS 20 min and hot packs 10 min .The total treatment session is 30 min three session per week for four weeks
88972130|NCT04734314|Experimental|vojta therapy|received conventional treatment of back pain in addition to Vojta therapy . The total treatment session is 40 min.
88972131|NCT04734119||Group A- same anesthesiologist|In Group A patients were evaluated preoperatively and anesthetized by the same anesthesiologist.
88972132|NCT04734119||Group B- different anesthesiologist|In Group B the preoperative assessment and actual anesthesia was performed by two different anesthesiologists
88972133|NCT00018356|Other|1|
88972134|NCT04734041|Other|Integrative Medicine|Anti-inflammatory (Mediterranean) diet, as well as general behavioral and psychosocial support.
88972135|NCT00018434||Group 1|
88972136|NCT04312919|Experimental|Intervention Group|3 in-person visit group
88972137|NCT04312919|Active Comparator|Control/Crossover Group|5 in-person visit group
88972138|NCT03229811|No Intervention|Standard pre-dialysis education|Standard pre-dialysis options education including hemodialysis, peritoneal dialysis, and kidney transplantation
88972139|NCT03229811|Active Comparator|ESRD education + ACP|Standard ESRD education + conservative kidney management and advance care planning education
88972140|NCT03174314|Experimental|Visually impaired|Visually impaired subjects will provide continuity across iterations of the testing, allowing for direct comparisons of responses within an individual for a single behavioral measure across different iterations of the device architecture and output configuration.
88972141|NCT03174314|Active Comparator|Healthy controls|Healthy (naive) subjects invaluable insights as well as a range of body types, cognitive abilities, and other idiosyncrasies that will keep our design and testing process from tailoring the device to a small set of individuals rather than the broader population.
88972142|NCT03174314|Experimental|Thailand Site - Group A: Assistive Mode then Passive Mode|During the first 15 days, group A will go through an assistive mode and then a passive mode for the next 15 days
89577500|NCT01639131|Experimental|Gemcitabine and Docetaxel|Patients were treated with gemcitabine 800 mg/m2 on days 1 and 8 and docetaxel 70 mg/m2 on day 8 of each 21-day cycle. Patients received filgrastim (granulocyte colony-stimulating factor [G-CSF]) on days 9 through 15 or pegfilgrastim 6 mg on day 9 or 10 of each cycle. Patients were treated until disease progression or unacceptable adverse events (AEs), or withdrawn of the consent.
89577501|NCT01641159|Active Comparator|Buspirone plus TAU|Buspirone titrated to 60 mg/day for the 15-week active study
89577502|NCT01641159|Placebo Comparator|Placebo plus TAU|Placebo taken daily for the 15-week active study
89577503|NCT01641081|Experimental|Experimental 1|Formoterol Fumarate in the Pressair Pressair Dry Powder Inhaler (DPI), Low Dose
89577504|NCT01641081|Experimental|Experimental 2|Formoterol fumarate in the Pressair Dry Powder Inhaler (DPI), High Dose
89577505|NCT01641081|Active Comparator|Active Comparator 1|Foradil Aerolizer, Low Dose
89577506|NCT01641081|Active Comparator|Active Comparator 2|Foradil Aerolizer, High Dose
89577507|NCT01641081|Placebo Comparator|Placebo|Dose matched placebo
89577508|NCT01640925|Active Comparator|Chlorhexidine gluconate bathing|Upon study enrollment, patients will be bathed with a 2% chlorhexidine gluconate solution on study day 1 and every 48 hours until study completion. The patient will be bathed using standard bathing (non-medicated cloths or soap and water) on study day 2 and every 48 hours after that.
89577509|NCT01640925|Placebo Comparator|Standard bathing|Upon study enrollment, patients will be bathed using standard bathing (non-medicated cloths or soap and water) daily.
89577510|NCT05369481|Experimental|Sildenafil 2%|will receive topical sildenafil 2% twice daily for 6 months.
89577511|NCT05369481|Experimental|Minoxidil 5 %|will receive topical minoxidil 5 % twice daily for 6 months
89577512|NCT04853979|Experimental|PRONE|Any combination of prone or side position for 3 hours, 3 times a day for 3 days.
89577513|NCT04853979|Active Comparator|NO PRONE|Usual care
89577514|NCT04853589|Active Comparator|Hyaluronic acid|hyaluronic acid gel application
89577515|NCT04853589|Active Comparator|Hyaluronic acid+carrier|hyaluronic acid gel application together with a carrier
89577516|NCT04853589|No Intervention|Standard treatment|standard treatment (i.e., blood clot only)
89577517|NCT01638429|Experimental|Obese/overweight, prediabetic methane positive|Neomycin Rifaximin
89577518|NCT04834401||Natalizumab|Natalizumab (minimum of 6 doses at standard interval)
89577519|NCT04834401||Fumarates|Fumarates (dimethyl fumarate or diroximel fumarate)
89577520|NCT04834401||Interferon Beta 1a|Interferon Beta 1a (or pegylated Interferon Beta-1a)
89577521|NCT04834401||Ocrelizumab|Ocrelizumab (minimum of 2 full cycles of 600mg)
89577522|NCT05058807|Experimental|Whole body vibration group|"Experimental Group will receive WBV training and balance exercises under the supervision of a physical therapist by using a vibration platform. Balance exercises include:~Double leg stance with eyes open and eyes closed 10 Reps * 3 minutes Tandem walk for 3 minutes Sideways walk for 3 minutes Single leg stance for 1 minute with 5 Reps, with 30 sec rest interval~WHOLE BODY VIBRATION:~The patient stood on the platform with his/her feet barefoot shoulder width and stared at the front, delivered on a side alternating vibration platform in an intermittent way: five repetitions of 1 min vibration followed by a 1 min rest. The vibration frequency and amplitude were 20 Hz and 3.0 mm respectively.~These outcomes will be evaluated at baseline, and after 4 week and at 8th week"
89577523|NCT05058807|Active Comparator|TAI CHI Group|"Control group will receive Balance exercises include:~Double leg stance with eyes open and eyes closed 10 Reps * 3 minutes Tandem walk for 3 minutes Sideways walk for 3 minutes Single leg stance for 1 minute with 5 Reps ,with 30 sec rest interval Yang style Tai chi exercise which consist of 10 positions.~1. Hold the ball ward off 2: Grasping the sparrows tail left; 3.Grasping the sparrows tail Right;; 5.Repulse Monkey; 6. Part wild horse's Mane; 7.Brush knee Twist step; 8.Lift kick left;~.Lift kick Right; 10.Cross hands with double leg stance~1st and 2nd week will last for 5reps, 3rd and 4th week will last for 10reps,5th and 6th week will last for 15reps,7th and 8th week will last for 20reps, starting with 10 minutes warming- up and ending with 10 minutes cool-down. These outcomes will be evaluated at baseline, and after 4 week and at 8th week."
89577524|NCT04853511||OCT-FLIM dual modal intravascular imaging with serial 18F-FDG-PET/CT assessment|Group of patients undergoing PCI with comprehensive assessment of coronary plaque with OCT-FLIM dual modal intravascular imaging followed by serial 18F-FDG-PET/CT imaging
89577525|NCT04853355|Experimental|Spironolactone Treatment|Patients with non-responsive Diabetic Macular Edema will be treated with Spironolactone in addition to the regular course of monthly aflibercept (Eylea).
89577526|NCT04419285|Experimental|Retinitis Pigmentosa patients|50 patients with very severe Retinitis Pigmentosa
89577527|NCT01639755|Experimental|All Participants|Al participants who had new texture shaped breast implants surgically implanted.
89577528|NCT04844853|Experimental|Preterm 2|2-year-olds born prematurely
89577529|NCT04844853|Experimental|Term 2|2-year-olds born at term
89577530|NCT04844853|Experimental|Typical 6|6-year-olds with typical developement
89577531|NCT04844853|Experimental|NDD 6|6-year-olds with neurodevelopmental disorders
89577532|NCT05310981|Experimental|Experimental: CHAMPS and mEIS|"Brief mobile application-based psychological intervention based on the principles of motivational interviewing (MI) and cognitive behavioural therapy (CBT). This e-intervention will be completed by the participant using a smart phone. There will be up to a maximum of 24 individual sessions (which includes 3 booster sessions) each lasting approximately 10-15 minutes.~mEIS: iCC will be administered adjunctively to modified EIS (mEIS), which will include all interventions usually provided through EIS except for any specific psychological interventions (MI, CBT, contingency management) for CUD."
88972143|NCT03174314|Active Comparator|Thailand Site - Group B: Passive Mode then Assistive Mode|Group B will go through a passive mode for the first 15 days and then an assistive mode for the second half of the month
88972144|NCT00394602||Patients|Patients receiving chemoradiation for abdominal-pelvic tumors.
89577533|NCT05310981|No Intervention|No Intervention: EIS alone|Early intervention services will be offered as per standard of care following EIS for psychosis and CUD guidelines, at participating clinical sites. Any visits and services offered in control arm will be considered 'usual care' and administered either through in-person clinic visits, community visits, phone calls, or video calls. Relevant service information will be collected for study purposes.
89577534|NCT05369091|No Intervention|Placebo|Atraumatic Extraction Only (placement of gelatin sponge mixed with normal saline without SIMVASTATIN).
89577535|NCT05369091|Experimental|Simvastatin|Atraumatic Extraction and administration of SIMVASTATIN (10 mg tablet grounded and added with normal saline, with gelatin sponge as a transporter) into the socket.
89577536|NCT04652037|Experimental|Acrysof IQ Vivity Toric Extended Vision Intraocular Lens Implantation|
89577537|NCT01601535|Experimental|Treatment|"Every course will be 21 days. MLN8237 will be administered orally daily starting on day 1 through day 7.~Irinotecan will be administered intravenously during each course on study day 1 through day 5.~Temozolomide will be administered orally during each course on study day 1 through day 5."
89577538|NCT05422365|Experimental|Main Group|"Patients included in the study will receive the intravenous immunoglobulin (IVIG, Bioven), 10% solution for infusion according to the protocol for the use of IVIG in ITP treatment - at a dose of 0.8-1.0 g / kg once a day for 2 consecutive days, the course dose is 1.6-2.0 g / kg.~The next day after the administration of the drug, the patient undergoes blood sampling to determine the level of platelets, the level of immunoglobulin G (IgG), and the Coombs test.~This procedure will also be carried out on days 7, 14, 21, and 28 after the first injection of the drug to monitor the patient's performance."
89577539|NCT04844151||Acute myocarditis|Patients hospitalized for an acute myocarditis.
89577540|NCT04641273|Experimental|Part A: BAY1817080 150 mg BID|In Part A, Participants will be randomized to this arm with BAY1817080 150 mg BID.
89577541|NCT04641273|Placebo Comparator|Part A: Placebo BID|In Part A, Participants will be randomized to this arm with placebo for BAY1817080.
89577542|NCT04641273|Experimental|Part B: BAY1817080 25 mg BID|In Part B, New participants will be screened for this part of the study and will be randomized to this arm with BAY1817080 25 mg BID and placebo for pregabalin.
89577543|NCT04641273|Experimental|Part B: BAY1817080 75 mg BID|In Part B, New participants will be screened for this part of the study and will be randomized to this arm with BAY1817080 75 mg BID and placebo for pregabalin.
89577544|NCT04641273|Experimental|Part B: BAY1817080 150 mg BID|In Part B, New participants will be screened for this part of the study and will be randomized to this arm with BAY1817080 150 mg BID and placebo for pregabalin.
89577545|NCT04641273|Placebo Comparator|Part B: Placebo BID|In Part B, New participants will be screened for this part of the study and will be randomized to this arm with placebo for BAY1817080 and placebo for pregabalin.
89577546|NCT04641273|Active Comparator|Part B: Pregabalin|In Part B, New participants will be screened for this part of the study and will be randomized to this arm with placebo for BAY1817080 and pregabalin.
89577547|NCT04832763|Experimental|Physical function testing, questionnaire|Patients on active treatment complete questionnaires and undergo collection of blood samples and physical function assessments at baseline, and at 3 and 6 months. Survivors in surveillance complete questionnaires and undergo collection of blood sample and physical function assessment at baseline.
89577548|NCT04852731|Experimental|Group A (a) : patients without mitral regurgitation without ventricular extrasystole (≤10/hour)|"These patients will undergo at the inclusion and 36 months after the inclusion :~According to recommendations : echocardiography, 24-hour external loop recording and exercise ECG,~And specifically for research purposes : injected cardiac MRI and a blood collection."
89577549|NCT04852731|Experimental|Group A (b) : patients without mitral regurgitation with ventricular extrasystole (>10/hour)|"These patients will undergo at the inclusion and 36 months after the inclusion :~According to recommendations : echocardiography, 24-hour external loop recording, exercise ECG, injected cardiac MRI,~And specifically for research purposes : prolongation of the MRI examination (4D flow sequence) and a blood collection."
89577550|NCT04852731|Experimental|Group B : patients with Mitral valve prolapse with trivial mitral regurgitation|"These patients will undergo at the inclusion and 36 months after the inclusion :~According to recommendations : echocardiography, 24-hour external loop recording, exercise ECG, injected cardiac MRI,~And specifically for research purposes : prolongation of the MRI examination (4D flow sequence) and a blood collection."
89577551|NCT04852731|Experimental|Group C : patients with Mitral valve prolapse with moderate or mild mitral regurgitation|"These patients will undergo at the inclusion and 36 months after the inclusion :~According to recommendations : echocardiography, 24-hour external loop recording, exercise ECG, injected cardiac MRI,~And specifically for research purposes : prolongation of the MRI examination (4D flow sequence) and a blood collection."
89577552|NCT04852731|Experimental|Group D : patients with asymptomatic Mitral valve prolapse with severe mitral regurgitation|"These patients will undergo at the inclusion and 36 months after the inclusion :~According to recommendations : echocardiography, 24-hour external loop recording, exercise ECG, injected cardiac MRI,~And specifically for research purposes : prolongation of the MRI examination (4D flow sequence) and a blood collection."
89577553|NCT04635891||MOVE FSHD Study Visits|Patients will receive standard of care as determined by their treating physician. Study visits will occur per standard of care and are anticipated to occur at least once a year.
88972145|NCT00394602||Caregiver Controls|Healthy controls with no prior cancer diagnosis.
88972146|NCT00142454|Experimental|Imiquimod + NY-ESO-1|Patients applied topical imiquimod followed by vaccination with intradermal injections of the NY-ESO-1 protein.
89209363|NCT00882882|Active Comparator|4|GLUCOPHAGE XR 500 mg Extended-Release Tablets Bristol-Myers Squibb
89577554|NCT05000853||Patients with iron deficiency|
89209364|NCT00882960|Active Comparator|1|patients who are randomized to receive intravenous fentanyl for control of their pain
89209365|NCT00882960|Active Comparator|2|patients who are randomized to receive intra-nasal fentanyl for control of their pain
89577555|NCT05000853||Patients without iron deficiency|
89577556|NCT04832529|Active Comparator|Perianal abscess cavity packing|
89577557|NCT04832529|Experimental|Perianal abscess cavity no packing|
89577558|NCT04998591|Experimental|Fasting group|Participants will be councelled and accompanied to follow a fasting regime of 7 days in an outpatient setting under medical supervision.
88972147|NCT05576675|Experimental|SN group|sufentanil 100 μ g + nalbuphine 40 mg
88972148|NCT05576675|Experimental|HN group|hydromorphone 10 mg+ nalbuphine 40 mg
88972149|NCT05576675|Experimental|S group|sufentanil 200 μ g,
89577559|NCT04998591|No Intervention|Waiting list|This group maintains their individual diet during the whole time of the study. In case that the first cycle of In-Vitro-Fertilization fails, they are offered a fasting intervention before a next cycle.
89577560|NCT04419129|Active Comparator|Mobile bearing unicompartmental knee arthroplasty|50 mobile bearing UKA
89577561|NCT04419129|Active Comparator|posterior stabilized fixed bearing total knee arthroplasty|50 posterior stabilized fixed bearing cemented total knee arthroplasty
88972150|NCT05576480|Experimental|SCRT sequential Penpulimab in combination with CAPEOX|"Short-course radiotherapy (SCRT) + one dose of immunotherapy in week 1：Radiotherapy once daily at 5Gy, D1-D5 (5×5Gy); Penpulimab, 200mg, intravenous for 60±5min, D6 or D7.~Rest at week 2, 4 cycles of chemotherapy (CAPEOX) + immunotherapy from week 3 in cycles of 3 weeks: Capecitabine, 1000 mg/m2 orally, administered twice daily, D1-D14 per cycle; Oxaliplatin, 135 mg/m2, intravenous >2h, administered every cycle D1; Penpulimab, 200 mg, administered intravenously for 60 ± 5 min every cycle D1.~Clinical re-staging assessment at the end of neoadjuvant therapy allows for a watch-and-wait strategy if cCR is achieved. If any residual lesions remained, radical rectal cancer surgery would be performed at least 2 weeks after the last dose of capecitabine. Whether post-operative adjuvant treatment is performed and the option of post-operative adjuvant treatment is decided by the investigator."
89577562|NCT04586985|Experimental|Single Ascending Dose (SAD) cohorts in Healthy Subjects (Part A)|Subjects will be randomized to receive a single dose of FTX-6058 or placebo. Cohorts 1 and 2 will enroll 5 subjects per cohort randomized 3:2. Cohorts 3-8 will enroll 7 subjects per cohort randomized 5:2. Planned doses are 2 mg (Cohort 1), 4 mg (Cohort 2), 10 mg (Cohort 3), 20 mg (Cohort 4), 30 mg (Cohort 5), 40 mg (Cohort 6), 60 mg (Cohort 7), and 90 mg (Cohort 8).
89577563|NCT04586985|Experimental|Multiple Ascending Dose (MAD) cohorts in Healthy Subjects (Part B)|Subjects will be randomized 3:1 to receive once daily FTX-6058 or placebo by mouth for 14 days. Up to 6 cohorts of 8 subjects per cohort will be enrolled. Planned doses are 2 mg (Cohort 1), 6 mg (Cohort 2), 10 mg (Cohort 3), 20 mg (Cohort 4), 30 mg (Cohort 5), and 40 mg (Cohort 6).
89577564|NCT04586985|Experimental|Pilot Food Effect Cohort in Healthy Subjects (Part C)|Ten subjects will be randomized to receive a single 20 mg dose of FTX-6058 with and without a high-fat meal with a washout period of 4 days.
89577565|NCT04586985|Experimental|Potential for CYP3A Induction in Healthy Subjects (Part D)|Sixteen subjects will receive 3 mg Midazolam once by mouth on Day 1. On Days 3-12, subjects will receive FTX-6058 by mouth once daily. On Day 12, a second dose of 3 mg Midazolam will be given once by mouth. The dose of FTX-6058 will be the highest tolerated dose from Part B.
89577566|NCT04586985|Experimental|Multiple Dose Cohort in Sickle Cell Disease Subjects (Part E)|Subjects will be randomized 3:1 to receive FTX-6058 or placebo once daily by mouth for 14 days. Up to 8 subjects will be enrolled. The planned dose is 6mg.
89577567|NCT05260749|Experimental|Neurofeedback training|Subjects in the neurofeedback training group are instructed to regulate their anterior insula activity based on the visual neurofeedback.
89577568|NCT05260749|Sham Comparator|Sham control1|Subjects in the sham control group receive the same instruction but perform the regulation based on neurofeedback from a whole slice of top brain (a controlled sham region).
89577569|NCT05260749|Sham Comparator|Sham control2|Subjects in the sham control group receive the same instruction but perform the regulation based on neurofeedback from the middle temporal gyrus (a controlled sham region).
89577570|NCT04852419|Experimental|ZN-c5 50mg QD dose cohort|Phase 1b trial of monotherapy cohort with ZN-c5 as single agent will be evaluated with ZN-c5 50 mg administered orally, once daily. Safety lead in phase will be applied.
89577571|NCT04852419|Experimental|Zn-c5 150mg QD dose cohort|Once safety and tolerability are established in ZN-c5 150 mg Dose QD in Chinese population, then it is possible to initiate the second monotherapy cohort with 150 mg QD or alternative dose well established in oversea population for preliminary efficacy and safety.
89577572|NCT05249673|Experimental|global postural reeducation|"global postural reeducation (GPR) interventions will last 9 sessions, 1 hour each, with one-to-one supervision, once or twice a week according to the participant's needs. All participants will receive advice to follow written ergonomic suggestions and to repeat the exercises in the first physical therapy session at home twice a week for 15 minutes. Each group will get a home exercise program, which will differ according to the type of treatment received. Participants in the GPR group will execute one posture routine."
89577573|NCT05249673|Active Comparator|neck stabilization training|Each exercise session will be comprised of 10-minute warm-up exercises, 40-minute stabilization exercises, and 10-minute cool-down and stretching exercises, including neck and shoulder girdle muscles. The whole program will be carried out 3 days per week for 4 weeks.The participants will be asked to maintain the positions and contractions during the exercises and throughout the day as much as possible. The combination and progression of the exercises will be designed according to condition of the patient.
89577574|NCT05245539|Experimental|CVL-231 Dose Level 1|10 mg once daily
89577575|NCT05245539|Experimental|CVL-231 Dose Level 2|30 mg once daily
89577576|NCT04840875|Experimental|chimeric antigen receptor T cell treatment|
89577577|NCT05408403|Active Comparator|Transversalis Fascia Plane Block|Transversalis Fascia Plane Block (TFPB) will be performed the patients in Group A after the cesarean section surgery. Patient controlled analgesia device (PCA) is used for all the patients in the first 24 hours postoperatively
89577578|NCT05408403|Active Comparator|Quadratus Lumborum Block|Anterior Quadratus Lumborum Block ( Anterior QLB) will be performed the patients in Group B after the cesarean section surgery. Patient controlled analgesia device (PCA) is used for all the patients in the first 24 hours postoperatively
89577579|NCT05620797|Experimental|Immediate loading implants|
88972151|NCT05576363||Maternal|Second trimester
89577580|NCT05620797|Active Comparator|Delayed loading implants|
89577581|NCT04916223|Experimental|3 x 10-minute massage|Subject receives a 10-minute massage daily for three consecutive days
89577582|NCT04916223|Experimental|3 x 20-minute massage|Subject receives a 20-minute massage daily for three consecutive days
89577583|NCT04916223|Active Comparator|Single 20-minute massage|Subject receives one 20-minute massage
89577584|NCT04830735|Experimental|Arm I (dasatinib anhydrous)|Patients receive dasatinib anhydrous PO QD for 14 days in the absence of disease progression or unacceptable toxicity.
89577585|NCT04830735|Placebo Comparator|Arm II (placebo administration)|Patients receive placebo PO QD for 14 days in the absence of disease progression or unacceptable toxicity.
89577586|NCT04489095|Experimental|Electrophysiology Study pre and Post TAVR|In all patient's undergoing TAVR after informed consent will undergo an electrophysiology study pre and post device deployment in order to determine the need for permanent pacemaker implantation or further testing/monitoring.
89577587|NCT04840173|Experimental|Music at home|Caregivers will use Singing, music listening, or moving with music twice a week for 30 minutes with their care recipient.
89577588|NCT04829721|Experimental|Educational Video Workshop|A single 20 minute video workshop on pelvic floor disorders.
89577589|NCT04419441||treated patients|patients with relapsed/refractory Hodgkin lymphoma who received a treatment with the combination of radiotherapy and an immune checkpoint inhibitor
89577590|NCT05329779|Experimental|brexanolone|Participants will receive a continuous 60-hr intravenous infusion of brexanolone
89577591|NCT05329779|Placebo Comparator|placebo|Participants will receive a continuous 60-hr infusion of placebo
89577592|NCT04419753|Active Comparator|No Attention Focus Walking Group (NAFWG)|In each training session, the NAFWG will have warm-up (5 minutes), balance training (5 minutes), body transport training (5 minutes), body transport with hand manipulation training (5 minutes), walking training with various levels of difficulties in a 40-meter walkway without attention focus instruction (20 minutes) and cool down (5 minutes).
89577593|NCT04419753|Experimental|External Attention Focus Walking Group (EAFWG)|In each training session, the EAFWG will have warm-up (5 minutes), balance training (5 minutes), body transport training (5 minutes), body transport with hand manipulation training (5 minutes), walking training with various levels of difficulties in a 40-meter walkway with external attention focus instructions (20 minutes) and cool down (5 minutes).
89577594|NCT04419753|Experimental|Internal Attention Focus Walking Group (IAFWG)|In each training session, the IAFWG will have warm-up (5 minutes), balance training (5 minutes), body transport training (5 minutes), body transport with hand manipulation training (5 minutes), walking training with various levels of difficulties in a 40-meter walkway with internal attention focus instructions (20 minutes) and cool down (5 minutes).
89577595|NCT04850937|Experimental|Group S|The experimental group will be given 0.25mg/kg esketamine slowly intravenously after anesthesia induction During administration, blood pressure and heart rate were observed.
89577596|NCT04850937|Placebo Comparator|Group C|The control group will receive the same amount of normal saline after anesthesia induction
89577597|NCT04851717|Experimental|All Patients|All paediatric patients undergoing diagnostic and/or therapeutic procedures
89577598|NCT04464057|Experimental|experimental group|The patients in the experimental group would be given early oral feeding within 24-48 hours after intestinal anastomosis. Start taking it at 24-48 hours after surgery until discharged. The initial dose is 1ml/kg.h, which is gradually increased to 100ml/kg daily.
89577599|NCT04464057|No Intervention|control group|The control group would be given early oral feeding within 4-5 days after intestinal anastomosis. Start taking it at 4-5 days after surgery until discharged. The initial dose is 1ml/kg.h, which is gradually increased to 100ml/kg daily.
89577600|NCT01638819|Experimental|Autologous Cord Blood Stem Cells|
89577601|NCT01638819|Placebo Comparator|Placebo|Saline
89577602|NCT04849143|Experimental|Honey dressing group|A thin layer of honey will be applied to the wounds
89577603|NCT04849143|Active Comparator|Gel dressing group|A thin layer of gel will be applied to the wounds
89577604|NCT01363713|Experimental|1|
89577605|NCT04411329|Active Comparator|group A|patients will receive 30 ml of 0.125% bupivacaine with 8 mg dexamethasone (20 ml before skin incision and 10 ml at end of surgery
89577606|NCT04411329|Active Comparator|group B|we will add 50µg dexmedetomidine to the previous mixture given to group A (20 ml before skin incision and 10 ml at end of surgery
89577607|NCT04411329|Active Comparator|group c|we will add 1500 IU hyalurodinase to the mixture given to group A. (20 ml before skin incision and 10 ml at end of surgery
89577608|NCT05171673|Experimental|Investigational|LicartTM topical system application once per day for a maximum of 14 days or until pain resolution, whichever occurs first.
89577609|NCT04811937|Experimental|Artificial intelligence for real-time Computer decision support of resection of colorectal polyps|A standard colonoscopy will be performed according to the standard of routine care. All optically diagnosed polyps will be removed and sent to the CHUM pathology laboratory for histopathological evaluation according to institutional standards. The AI system will capture video of the procedure in real time, and provide additional information about polypectomy procedures.
89577610|NCT05147415|Placebo Comparator|Placebo|Once-daily PO for 36 weeks during the double-blind period; then if continued eligible for OLE, once-daily dosing for 36 weeks at the highest tolerated Tesomet dose from the double-blind period
89577611|NCT05147415|Experimental|Tesomet Low Dose|Once-daily PO for 36 weeks during the double-blind period; then if continued eligible for OLE, once-daily dosing for 36 weeks at the highest tolerated dose from the double-blind period
88972152|NCT05576324||longitudinal|Inclusion of patients with diagnosed CF prior ETI therapy, follow-up visit after 6 months
88972153|NCT05576324||under ETI|Patients with diagnosed CF already receiving ETI therapy for 6 months
89577612|NCT05147415|Experimental|Tesomet Medium Dose|Once-daily PO for 36 weeks during the double-blind period; then if continued eligible for OLE, once-daily dosing for 36 weeks at the highest tolerated dose from the double-blind period
89577613|NCT05147415|Experimental|Tesomet High Dose|Once-daily PO for 36 weeks during the double-blind period; then if continued eligible for OLE, once-daily dosing for 36 weeks at the highest tolerated dose from the double-blind period
89577614|NCT04827069|Experimental|Arm 1|Clifutinib Besylate:10 mg
89577615|NCT04827069|Experimental|Arm 2|Clifutinib Besylate:20 mg
88972154|NCT05576324||no ETI|Patients with diagnosed CF that have refused an ETI treatment or are not eligible for ETI therapy
88972155|NCT05576324||Healthy Individuals|Healthy, age- and gender-matched probands
89577616|NCT04827069|Experimental|Arm 3|Clifutinib Besylate:40 mg
89577617|NCT04827069|Experimental|Arm 4|Clifutinib Besylate:55 mg
89577618|NCT04827069|Experimental|Arm 5|Clifutinib Besylate:70 mg
89577619|NCT04786743|Experimental|non-urgent endoscopy group|undergo endoscopy between 6 and 24 hours after gastroenterological consultation
89577620|NCT04786743|Other|urgent endoscopy group|undergo endoscopy within 6 hours after gastroenterological consultation
89577621|NCT04390581|Experimental|Juvéderm® VOLIFT with Lidocaine|All participants to be injected with Juvéderm® VOLIFT with Lidocaine in both hands no more than 6ml total per both hands. Optional touch-up will be done on Day 30 according to aesthetic results.
89577622|NCT01637961|Experimental|Treatment (alisertib)|Patients receive alisertib PO BID on days 1-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
88972156|NCT00020709|Experimental|Arm I (gefitinib, combination chemotherapy, radiation)|"Patients receive induction therapy comprising cisplatin IV over 1 hour on days 1, 8, 29, and 36 and etoposide IV over 1 hour on days 1-5 and 29-33. Beginning within 24 hours after starting chemotherapy, patients receive concurrent induction radiotherapy 5 days a week for 5 weeks and then boost radiotherapy 5 days a week for 1.5 weeks.~Beginning approximately 4-8 weeks after completion of chemoradiotherapy, patients with stable or responding disease receive consolidation therapy comprising docetaxel IV over 1 hour on day 1. Treatment repeats every 21 days for 3 courses.~Patients with stable or responding disease are randomized to one of two treatment arms for maintenance therapy. Patients begin maintenance therapy approximately 4-7 weeks after completion of consolidation therapy.~Patients receive oral gefitinib daily."
88972157|NCT00020709|Experimental|Arm II (placebo, combination chemotherapy, radiation)|"Patients receive induction therapy comprising cisplatin IV over 1 hour on days 1, 8, 29, and 36 and etoposide IV over 1 hour on days 1-5 and 29-33. Beginning within 24 hours after starting chemotherapy, patients receive concurrent induction radiotherapy 5 days a week for 5 weeks and then boost radiotherapy 5 days a week for 1.5 weeks.~Beginning approximately 4-8 weeks after completion of chemoradiotherapy, patients with stable or responding disease receive consolidation therapy comprising docetaxel IV over 1 hour on day 1. Treatment repeats every 21 days for 3 courses.~Patients with stable or responding disease are randomized to one of two treatment arms for maintenance therapy. Patients begin maintenance therapy approximately 4-7 weeks after completion of consolidation therapy.~Patients receive oral placebo daily. In both arms, maintenance therapy continues for a maximum of 5 years in the absence of disease progression or unacceptable toxicity."
88972158|NCT04733690||Healthy Volunteers (Glycemic Index)|The glycemic index (GI) of the common bean product will be assessed in this cohort among 10 study participants. The GI of the product will be assessed on 3 test days over a 120 min period on each study day.
88972159|NCT04733690||Healthy Volunteers(Food Insulin Index)|The food insulin index (FII) of the common bean product will be assessed in this cohort among 10 study participants. This study will recruit 10 participants. The FII of the product will be assessed on 3 test days over a 120 min period on each study day.
88972160|NCT04733690||Type-2 diabetes (T2DM) patients|Glycemic, insulinemic and satiety responses associated with the consumption of the common bean product will be assessed in this cohort among 10 T2DM patients. Participants will attend one study visit lasting approximately 120 min.
88972161|NCT02971865|Experimental|CBT/CMT|The CBT/CMT program does not focus specifically on a particular condition such as diabetes. All treatment included patient education on nutrition content and mindfulness practice (emotions, and sensations in the present moment without trying to change them, awareness of breathing, and social economic problems) with manual therapy.
89577623|NCT05114577|Experimental|Recovery Sleepers program.|
89577624|NCT05114577|Placebo Comparator|Email recommendations|
89577625|NCT05114265|Experimental|Part 1: Single ascending dose|Single dose of oral KUR-101 or oral placebo
89577626|NCT05114265|Experimental|Part 2: Three-way crossover|Single dose of oral KUR-101, oral placebo and oral OxyNorm
89577627|NCT04770831||Single Arm|QOL following MIBG
89577628|NCT04277715|Experimental|Parent training|Parents of participating children with chronic symptoms will receive the intervention in a virtual group format. Groups will last 90-minutes and run for 6-8 weeks. Groups will be co-led by a clinical psychologist and pediatric physician with expertise in child behavioral interventions and medically unexplained symptoms.
89577629|NCT04183335|Experimental|Dupilumab|Participants received dupilumab at a loading dose of 600 milligrams (mg), subcutaneously (SC) on Day 1 followed by dupilumab 300 mg once every 2 weeks (q2w) for 24 weeks added to background therapy of topical corticosteroids/topical calcineurin inhibitors (TCS/TCI) at stable dose.
89577630|NCT04183335|Placebo Comparator|Placebo|Participants received placebo matched to dupilumab 600 mg (loading dose), SC on Day 1 followed by placebo matched to dupilumab 300 mg q2w for 24 weeks added to background therapy of TCS/TCI at stable dose.
89577631|NCT04419363|Experimental|The whole cohort|Children affected with X-linked hypophosphatemia of average age of 9.8 years were switch from conventional therapy to burosumab
89577632|NCT04825431|Experimental|TAS-205, [14C]TAS-205|
89577633|NCT04241679|Experimental|Intervention Group|Patients undergoing a translabyrinthine approach for vestibular schwannoma resection will have the health of their auditory nerve monitored during tumor dissection. If the auditory nerve is visually confirmed to be intact, then concurrent cochlear implantation will be performed.
89577634|NCT04225767|Experimental|Calcium electroporation treatment|Experimental treatment with calcium electroporation for malignant cutaneous and subcutaneous tumours
89577635|NCT04212273|Experimental|Diagnostic Sonazoid-CEUS and EOB-MRI|Patients with high risk of HCC having suspicious lesions on US will receive Sonazoid-CEUS and EOB-MRI examinations.
89577636|NCT04824183|Experimental|Music intervention|Music intervention that begins with patient education on WhatsApp will be delivered to participants 3 times within 48 hours before surgery followed by face-to-face monitoring of intervention usage.
89577637|NCT04824183|No Intervention|Usual care|Participants in the control group will receive preoperative pain education via a one-on-one WhatsApp chat. The pain education will focus mainly on the type of pain to expect after surgery, how to report pain and how to request pain medication. MI will not be introduced to the participants in this group neither will there be any phone call for psychological support. Other preoperative care and postoperative care will be provided according to the hospital and ward practices.
89577638|NCT04199793|Active Comparator|Lavare Cycle On|"For the patients randomized to Lavare On group, the Lavare™ cycle will be turned on upon device interrogation after patients return to intensive care unit from the operating room."
88972162|NCT02971865|Active Comparator|traditional primary care visit|Provide high quality primary care for men, women, and children of all ages. Our providers work together to ensure that you receive the most comprehensive care possible. Primary care is described as the medical setting in which patients receive most of their medical care and, therefore, is typically their first source for treatment
88972163|NCT00020787|Experimental|Treatment|See intervention description.
88972164|NCT05576168|Experimental|T2DM group|patients with T2DM
89577639|NCT04199793|Active Comparator|Lavare Cycle Off|"For the patients randomized to Lavare Off group, the Lavare™ cycle will be turned off upon device interrogation after patients return to intensive care unit from the operating room."
89577640|NCT04823871|Other|High risk patients for breast and/or ovarian cancer|Procedure/Surgery: Lavage of the Cavum uteri and proximal Fallopian tubes, performed in the luteal phase of the female cycle
89577641|NCT04823871|Other|Suspected Ovarian Epithelial Cancer|Procedure/Surgery: Lavage of the Cavum uteri and proximal Fallopian tubes, performed in the luteal phase of the female cycle
88972165|NCT05576168|Active Comparator|control group|patients without T2DM
88972166|NCT00020826||gastric adenocarcinoma|No protocol specific interventions. Both palliative or curative treatment allowed.
88972167|NCT00391937|Experimental|1|ASR prosthesis placed using CAS
88972168|NCT00391937|Active Comparator|2|ASR prosthesis placed by conventional method
88972169|NCT05574647|No Intervention|Standard: mpMRI|Participants will undergo mpMRI. Blinding will not be possible. Once the MRI report is issued, the local clinical team will make a decision about advising whether a biopsy is necessary or not.
88972170|NCT05574647|Active Comparator|Intervention 1: bpMRI|Participants will undergo bpMRI. Blinding will not be possible. Once the MRI report is issued, the local clinical team will make a decision about advising whether a biopsy is necessary or not.
89577642|NCT04820673||Sarecycline|Eligible patients prescribed with commercially available sarecycline will be followed-up for 12 weeks post-initiation of treatment.
89577643|NCT05298579|Experimental|Group A|"Yoga exercises applied by video-conference method accompanied by a physiotherapist.~Evaluations and yoga exercises will be applied to the participants in this group through the Zoom program. Yoga exercises were created with reference to studies in the literature. It will be applied for 8 weeks, 3 days a week and 40-45 minutes, at a time determined jointly by the physiotherapist and the participant (Table 1). Before starting the program, an informative broadcast will be made to the participants and groups of 6-8 people will be formed."
88972171|NCT05574647|No Intervention|Standard: Visual estimation targeted and systematic biopsy|Randomisation 2 will only be relevant if participants are advised by their clinical team to have a biopsy based on their MRI and other clinical factors. Participants advised to have a biopsy will undergo a visual estimation targeted biopsy
88972172|NCT05574647|Active Comparator|Intervention 2: Image-fusion targeted and systematic biopsy|Randomisation 2 will only be relevant if participants are advised by their clinical team to have a biopsy based on their MRI and other clinical factors. Participants advised to have a biopsy will undergo an image fusion targeted biopsy.
88972173|NCT00020943|Experimental|Chemo/immuno/autolog transplant|Intensive chemotherapy followed by autologous stem cell transplant and immunotherapy for mantle cell lymphoma
88972174|NCT00021060|Experimental|Arm I (paclitaxel and carboplatin)|"Patients receive paclitaxel IV over 3 hours followed by carboplatin IV over 15-30 minutes on day 1.~Treatment in both arms repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity."
88972175|NCT00021060|Experimental|Arm II (paclitaxel, carboplatin, and bevacizumab)|"Patients receive paclitaxel and carboplatin as in arm I followed by bevacizumab IV over 30-90 minutes on day 1.~Treatment in both arms repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.~After completion of 6 courses, patients in arm II with stable or responding disease continue to receive bevacizumab only. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity."
88972176|NCT00021099|Experimental|Treatment (ixabepilone)|Patients receive ixabepilone IV over 3 hours on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
88972177|NCT05574257|Active Comparator|Group P|The group received propofol injection at 25-100ug/kg/min (immediately after spinal anesthesia to the end of surgery).
88972178|NCT05574257|Experimental|Group R|The group received remimazolam injection at 1-20ug/kg/min (immediately after spinal anesthesia to the end of surgery).
89033245|NCT05319119||Coronary Angiography Related Group|Coronary diseased artery CTFFR≤80%, coronary angiography decision does not require revascularization but apply coronary heart disease secondary prevention medication;Coronary diseased artery CTFFR>80%,However, revascularization was performed according to conventional angiographic decisions and postoperative regular service was performed.For multivessel disease, although coronary revascularization is performed, there are still diseased artery with CTFFR≤80% and no revascularization is performed.
89577644|NCT05298579|Active Comparator|Group B|"Yoga exercises performed asynchronously accompanied by videos. Exercise videos will be broadcast to the participants in this group through the YouTube program. The shooting of the exercise videos will be completed in advance and uploaded to a channel opened on YouTube. All posts made in this channel will only be open to individuals participating in the research during the duration of the study. Yoga exercises were created with reference to studies in the literature. It will be applied for 8 weeks, 3 days a week and 40-45 minutes. Participants will be able to access the exercise videos at a time they want (Table 2). Participants will be encouraged to achieve weekly targeted training sessions and to keep an exercise diary."
89577645|NCT03280719|Active Comparator|Supine Hypofractionated Radiotherapy|"Supine Radiotherapy and Hypofractionation:~Whole breast + regional nodal irradiation in supine position with a median dose of 15 x 2.67 Gy prescribed to the whole breast and nodal regions. Median dose of the simultaneously integrated boost is 3.12 Gy per fraction."
89577646|NCT03280719|Experimental|Prone Hypofractionated Radiotherapy|"Prone Radiotherapy and Hypofractionation:~Whole breast + regional nodal irradiation in prone position with a 15 x 2.67 Gy dose prescription to the whole breast and nodal regions. Median dose of the simultaneously integrated boost is 3.12 Gy per fraction."
89577647|NCT03280719|Experimental|Supine Accelerated Radiotherapy|"Supine Radiotherapy and Acceleration:~Whole breast + regional nodal irradiation in supine position with a median dose of 5 x 5.7 Gy to the whole breast. Lymph node regions receive a median dose of 5 x 5.4 Gy. Median dose of the simultaneously integrated boost is 6.2 Gy per fraction."
89577648|NCT03280719|Experimental|Prone Accelerated Radiotherapy|"Prone Radiotherapy and Acceleration:~Whole breast + regional nodal irradiation in prone position with a median dose of 5 x 5.7 Gy to the whole breast. Lymph node regions receive a median dose of 5 x 5.4 Gy. Median dose of the simultaneously integrated boost is 6.2 Gy per fraction."
89577649|NCT04699929|Experimental|Intervention/treatment|All subject will receive YH001 intravenously as single agent every three weeks (Q3W) for up to 1 years, until intolerable toxicity, confirmed disease progression, withdrawal of consent, or Investigator decision, whichever comes first.
89577650|NCT03256149|Experimental|Treatment group|Dexamethasone, 4 mg IV given at 8 hours interval, first dose received at the time of surgery (induction), 3 doses total
89577651|NCT03256149|Placebo Comparator|Placebo group|Saline given at 8 hours interval, first dose received at the time of surgery (induction), 3 doses total
89577652|NCT04105257|Other|All patients|All patients seen at emergency with acute neurological deficit will be assessed if eligible to CTP/MRI
89577653|NCT04097769|Other|HX009|Study treatment: HX009 administered every 2 weeks (14 [±1] days) via intravenous infusion.
89577654|NCT04089033||Primary Retinal Detachment 1|Patients presenting with primary macula-off rhegmatogenous retinal detachment being treated with Pneumatic Retinopexy
89577655|NCT04089033||Primary Retinal Detachment 2|Patients presenting with primary macula-off rhegmatogenous retinal detachment being treated with Pars Plana Vitrectomy
89577656|NCT03253263|Experimental|OHB-607|Participants will receive continuous IV infusion of OHB-607 through from birth up to PMA 29 weeks +6 days.
89577657|NCT03253263|No Intervention|Standard Neonatal Care|Standard neonatal care alone will be provided.
89577658|NCT04797117|Other|blood sample|The blood samples for the study for each patient will be collected in the form of additional tubes.
89577659|NCT03180411||Cognitive Testing Phase Group|Participants take part in one-on-one interview with research staff and asked questions about participant's health and the disease.
89577660|NCT03180411||Pilot Testing Phase Group|"After Cognitive Testing Phase interview, participants may be asked to have a second one-on-one interview with research staff.~Participants may also be asked to complete a questionnaire about the disease, what participant understands about it, and the treatment plan recommended. Participant also asked to give participant's opinion about colorectal cancer follow-up materials."
89577661|NCT03107247||Patients receiving Tc-99m MDP studies|All patients within the specified age ranges scheduled at Boston Children's Hospital for a nuclear medicine study utilizing Tc-99m MDP will be eligible to volunteer for inclusion in this study.
89577662|NCT05652621|Experimental|Probiotic intervention group|"Adjuvant treatment of UC and IBS with Three-high Probiotics is given to patients three times a day, one pack of 2g, lasting for 1-4 months."
89577663|NCT01636947|Experimental|Aprepitant Regimen|Participants receive one aprepitant 125 mg capsule by mouth (PO) once daily (QD) on Day 1 and one aprepitant 80 mg capsule PO QD on Days 2 and 3 of Cycle 1. Participants also receive ondansetron 16 mg intravenously (IV) QD and dexamethasone 12 mg PO on Day 1 and placebo for ondansetron 8 mg PO twice daily (BID) on Days 2 and 3.
89577664|NCT01636947|Active Comparator|Control Regimen|Participants receive one placebo capsule PO QD on Day 1 and one placebo capsule PO QD on Days 2 and 3 of Cycle 1. Participants also receive ondansetron 16 mg IV QD and dexamethasone 20 mg PO on Day 1 and ondansetron 8 mg PO BID on Days 2 and 3.
89577665|NCT05652387|Experimental|Father Inclusive Prenatal Care|Co parenting, parenting education, employment and educational readiness training and support.
89577666|NCT05652387|No Intervention|Standard Care|Participants will receive usual prenatal care services and information about community resources.
89577667|NCT05214027||Participants|This study follows a randomised crossover design. All participants will undergo a single 60-minute treadmill-based exercise intervention, and a resting period for equal duration in a randomised order.
89577668|NCT01635933|Experimental|AIR OPTIX® COLORS|Lotrafilcon B contact lens with color worn in daily wear modality for 4 weeks. Lenses were worn bilaterally for a minimum of 5 days per week, 8 hours per day.
89577669|NCT01635933|Active Comparator|FRESHLOOK® COLORBLENDS|Phemfilcon A contact lens with color worn in daily wear modality for 4 weeks, with a replacement pair dispensed at 14 days. Lenses were worn bilaterally for a minimum of 5 days per week, 8 hours per day.
89577670|NCT01635855|Experimental|Belotero|Belotero® Hyaluronic acid dermal filler
89033246|NCT02920554|Active Comparator|wedge resection|The extent of hepatic resection is wedge resection of gallbladder fossa
89029300|NCT02914067|Experimental|Cohort 4 Arm B|"During standard of care MRI images, rsfcMRI imaging will be performed which will add 15 minutes of scan time.~Will complete cognitive testing using the NIH Toolbox Cognitive Battery~All patients will complete the Attention Deficit/Hyperactivity Disorder (ADHD) Rating Scale - 5 questionnaire. All patients will complete a self-reported assessment of neurological quality of life (QOL). Adult patients (age ≥ 18 years) will complete the adult version of the Quality of Life in Neurological Disorders (Neuro-QOL) Cognitive Function measure. All pediatric patients will complete the pediatric version of the Neuro-QOL Cognitive Function measure. For patients <18 years of age and for adult patients with parent present, parent/caregiver will complete the PROMIS® Parent Proxy for cognition. All adult patients will complete the Colorado Learning Difficulties Questionnaire (CLDQ). This questionnaire will be completed by parent/caregiver for patients < 18 years of age."
89029301|NCT02902757|Experimental|Treatment (FDG PET/CT)|Patients undergo standard FDG PET/CT scan 6-8 weeks before start of chemotherapy and one additional FDG PET/CT scan within 48 hours of the start of chemotherapy.
89029302|NCT02872116|Experimental|Nivolumab + Ipilimumab|"Nivolumab + Ipilimumab for 4 doses, followed by Nivolumab monotherapy~Enrollment is closed for this arm"
89577671|NCT04808115|Experimental|KDS-1001|KDS-1001 is infused on Day 1 of each 14 day cycle. Patients will receive 6 cycles of KDS-1001 treatment.
89577672|NCT05652309||spinal anesthesia|spinal block will be performed to patients after monitoring
89577673|NCT05652309||spinal anesthesia and obturator nerve block|spinal block will be performed to patients after monitoring, and then the patients in the ONB block group will be given the appropriate position, with a USG-assisted distal approach, 5 cc %2 prilocain into the anterior and 5cc %2 prilocain into the posterior branch of the obturator nerve.
89577674|NCT03052725|Experimental|reslizumab 110 mg|Reslizumab was administered as 110 mg subcutaneous (sc) injection in the thigh, abdomen, or upper arm(s) once every 4 weeks for a total of 9 doses.
89577675|NCT03032055||VOC|"Patients who won't develop a secondary Acute chest syndrome during a vaso occlusive crisis within 15 days after admission.~Secondary Acute chest syndrome is defined by a new auscultatory abnormality (crepitation or bronchial breathing) OR the association of a new radiologic infiltrate and chest pain or decreased breath sounds .~A vaso-occlusive crisis is a common painful complication of sickle cell anemia in adolescents and adults. It is a form of sickle cell crisis. Sickle cell anemia - most common in those of African, Hispanic, and Mediterranean origin - leads to sickle cell crisis when the circulation of blood vessels is obstructed by sickled red blood cells, causing ischemic injuries."
89577676|NCT03032055||2°ACS|"Patients who will develop a secondary acute chest syndrome during a vaso occlusive crisis within 15 days after admission.~Secondary Acute chest syndrome is defined by a new auscultatory abnormality (crepitation or bronchial breathing) OR the association of a new radiologic infiltrate AND chest pain or decreased breath sounds .~A vaso-occlusive crisis is a common painful complication of sickle cell anemia in adolescents and adults.It is a form of sickle cell crisis. Sickle cell anemia - most common in those of African, Hispanic, and Mediterranean origin - leads to sickle cell crisis when the circulation of blood vessels is obstructed by sickled red blood cells, causing ischemic injuries."
89029303|NCT02872116|Active Comparator|XELOX (Oxaliplatin + Capecitabine)|
89029304|NCT02872116|Active Comparator|FOLFOX (Oxaliplatin + Leucovorin + Fluorouracil)|
89029305|NCT02872116|Experimental|Nivolumab + XELOX|
89029306|NCT02872116|Experimental|Nivolumab + FOLFOX|
89029307|NCT02867384|Active Comparator|Obinutuzumab|"Obinutuzumab or will be administered at a pre- determine dose, intravenously, at 3, 6, 9 and 12 months from transplantation.~Premedication with histamine blockers and acetaminophen will be provided~All subjects will undergo allogeneic stem cell transplantation according to locally approved clinical trials"
89029308|NCT02867384|Sham Comparator|Placebo|"Placebo will be administered at a pre- determine dose, intravenously, at 3, 6, 9 and 12 months from transplantation.~Premedication with histamine blockers and acetaminophen will be provided~All subjects will undergo allogeneic stem cell transplantation according to locally approved clinical trials"
89029309|NCT02852486|Experimental|Pioglitazone|Pioglitazone will be given 30 mg/day, orally, for 3 months, before imatinib discontinuation
89029310|NCT02721732|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 24 months in the absence of disease progression or toxicity. Patients with clinical response or disease stabilization may continue treatment for up to an additional 12 months.
89029311|NCT02679430|Other|Prostate Arterial Embolization|"Intervention: Patients will undergo prostatic artery embolization.~The purpose of this study is to demonstrate the safety and efficacy of the device, Embosphere Microspheres, in prostatic arterial embolization (PAE). PAE, is now an accepted form of treatment for BPH outside of the United States, however few studies have been performed demonstrating safety and efficacy in the US. Embosphere Microsphere is a device that may be used to reduce blood flow to targeted organs. With this research, we would like to show that Embosphere Microsphere may be used for patients with benign hyperplasia of prostate (BPH to reduce blood flow to the prostate gland. This current study is designed to understand the rate of improved BPH symptoms."
89029312|NCT02676050|Experimental|Imaging agents and imaging devices|All participants in Cohort 1 will be dosed on one occasion with the optical imaging agents and Cohort 2 can be dosed twice per agent. The final dosage will be <100ug per agent. The agents will be delivered using a novel delivery catheter and imaged with a novel imaging fibre and microendoscopy system.
89033247|NCT02920554|Active Comparator|bisegmentectomy|The extent of hepatic resection is 4b/5 bisegmentectomy
89033248|NCT02917005|Experimental|Palbociclib Arm|Palbociclib (Pfizer) 125mg/day orally for 3 weeks followed by 1 week off plus Exemestane (Pfizer) 25mg/day orally continuously plus Goserelin (Astrazeneca) 3.6 mg SC given every 28 days
89033249|NCT02917005|Active Comparator|Control Arm|Exemestane (Pfizer) 25mg/day orally continuously plus Goserelin (Astrazeneca) 3.6 mg SC given every 28 days
89033250|NCT02920632|Experimental|Online cognitive training 1 (N=70)|Eight-week, three times a week during 45 minutes cognitive training
89577677|NCT04818801|Experimental|Recombinant two-component COVID-19 vaccine (CHO cell)|Participants received Recombinant two-component COVID-19 vaccine (CHO cell) 0.5ml reconstituted by adjuvant solution, 2 shots at a interval 21 days, intramuscular injection
89577678|NCT04818801|Placebo Comparator|Placebo|Participants received placebo of 0.5ml normal saline (0.9% sodium chloride solution), 2 shots at a interval 21 days, intramuscular injection
89577679|NCT04793919|Active Comparator|Standard Risk (SR)|Patient with APL and WBC less than 10x10e9/L at presentation before start treatment
89577680|NCT04793919|Experimental|High Risk (HR)|Patient with APL, with the highest pre-treatment WBC count equal to or greater than 10x10e9/L at presentation
89577681|NCT05356767||post-thromboticsyndrome|suffering from PTS (Villalta score) at 2 years after operation.
89577682|NCT05356767||n-post-thromboticsyndrome|none of PTS (Villalta score) at 2 years after operation.
89577683|NCT05651763|Experimental|Stimulation and exercise group|30-minute exercise program (based on Pilates method) associated with active transcranial direct current stimulation.
89577684|NCT05651763|Sham Comparator|Exercise and sham stimulation group|30-minute exercise program (based on Pilates method) associated with sham transcranial direct current stimulation.
89577685|NCT02837445|Active Comparator|Treatment|Eligible patients randomized after optimization phase to PHC ON for 6 months Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator
89577686|NCT02837445|Placebo Comparator|Control|Eligible patients randomized after optimization phase to pacemaker only (PHC OFF) for 6 months. Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator
89577687|NCT02817633|Experimental|Part 1a: TSR-022 monotherapy|
89577688|NCT02817633|Experimental|Part 1b: TSR-022 in combination with nivolumab|
89577689|NCT02817633|Experimental|Part 1c: TSR-022 in combination with TSR-042|
89577690|NCT02817633|Experimental|Part 1d: TSR-022 in combination with TSR-042 and TSR-033|
89577691|NCT02817633|Experimental|Part 1e: TSR-022 with TSR-042 (not previously treated with anti-programmed death ligand [PD-{L}]1)|
89577692|NCT02817633|Experimental|Part 1f: TSR-022 in combination with TSR-042 and Docetaxel|
89029313|NCT02641145|Experimental|Active AL cardiac amyloidosis|75 individuals with light chain systemic amyloidosis with active plasma cell dyscrasia and cardiac involvement will undergo a research F-18 florbetapir PET, C-11 acetate PET, and MRI of blood of the heart, as well as the heavy metal analysis of the blood at baseline, 6 months and 12 months after initiation of chemotherapy. 25 of these individuals will also undergo a N-13 ammonia PET scan of the heart following supine bicycle stress at baseline and at 6 months after initiation of chemotherapy.
89577693|NCT02817633|Experimental|Part 1g: TSR-022 in combination with TSR-042, pemetrexed, and cisplatin|
89577694|NCT02817633|Experimental|Part 1h: TSR-022 in combination with TSR-042, pemetrexed, and carboplatin|
89577695|NCT02817633|Experimental|Part 2: Cohort A Melanoma-TSR-022 as monotherapy|
89577696|NCT02817633|Experimental|Part 2: Cohort A Melanoma-TSR-022 with TSR-042|
89577697|NCT02817633|Experimental|Part 2:Cohort B Non-small cell lung cancer-TSR-022-monotherapy|
89577698|NCT02817633|Experimental|Part 2:Cohort B Non-small cell lung cancer-TSR-022 with TSR-042|
89577699|NCT02817633|Experimental|Part 2:Cohort C Colorectal cancer-TSR-022 as monotherapy|
89029314|NCT02641145|Active Comparator|Remission AL cardiac amyloidosis|25 individuals with light chain systemic amyloidosis with cardiac involvement and plasma cell dyscrasia in hematological remission (complete hematological remission or very good partial response-differential free light chain (dFLC)<40 mg/dL for > 1 year prior to enrollment) will undergo a research F-18 florbetapir PET, C-11 acetate PET, and MRI scan of the heart as well as a heavy metal analysis of the blood at baseline.
89029315|NCT02641145|Experimental|Active AL Pre-CMP|36 individuals with light chain systemic amyloidosis with active plasma cell dyscrasia and without cardiac involvement will undergo a research F-18 florbetapir PET, C-11 acetate PET, and MRI of the heart, as well as a heavy metal analysis of the blood at baseline. At 6 months they will undergo a research MRI of the heart and at 12 months they will have a clinical follow up. Subjects with contraindications to Cardiac MRI or gadolinium contrast may still be eligible for study participation.
89029316|NCT02641145|No Intervention|Multiple Myeloma Controls|25 individuals with diagnosis of multiple myeloma without concomitant amyloidosis by standard criteria will undergo urine and blood testing only.
89577700|NCT02817633|Experimental|Part 2:Cohort C Colorectal cancer-TSR-022 with TSR-042|
89577701|NCT02817633|Experimental|Part 2: Cohort D-TIM-3 selected non-small cell lung cancer (NSCLC)-TSR-022 with TSR-042|
89577702|NCT02817633|Experimental|Part 2: Cohort E-Non-small cell lung cancer-TSR-022 with docetaxel|
89577703|NCT02817399|Active Comparator|Neuro-muscular electrical stimulation|Active exercises & Neuro-muscular electrical stimulation in a stationary position (lying and/or sitting).
89577704|NCT02817399|Experimental|Functional electrical stimulation|Active exercises & Functional electrical stimulation while walking.
89577705|NCT05651451|Active Comparator|Laser acupuncture group|All women in group (B) were received 24 activated laser acupuncture treatments. Treatments was performed 3 times per week for 8 weeks.Laser acupuncture was applied withwavelength of 810 nm, power output of 150 mW in continuous wave mode and energy density laser of 4 J/cm2 with irradiation time 3 min/point. Total duration of the training session was 30 minutes.Before starting the first treatment session, each woman was instructed briefly about the nature of the treatment to gain her confidence and cooperation. The surface of the treated skin was cleaned with alcohol wipe in order to remove any material that could absorb or disperse the radiationon the surface.The laser handheld device (laser beam spot size ≤ 36 mm2) was applied directly and perpendicularly to avoid scattering the beam, The Laser probe was applied to the surface of skin before switching on apparatus.
89577706|NCT05651451|Active Comparator|Diet regimen group|All post-menopausal women followed an energy-restricted diet for 8 weeks. Meal plan that creates an energy deficit of 500 to 1000 Kcal per day less than the individual's average daily intake was suitable for weight reduction.Each post-menopausal woman followed Dietary Approaches to Stop Hypertension (DASH) which : low in total fat, cholesterol, red meat, sweets and sugar containing beverages, emphasize fish, nuts, fruits, vegetables and whole grains and it also rich in Potassium(6900mg), Calcium(1200-1500mg) and Magnesium, as well as vitamins A, C and E
89577707|NCT05651373||patients not using TNF inhibitors(TNFi)|"The cohort includes the RA patients in pregnancy.~Drug: Hydroxychloroquine(HCQ)，200mg, po, twice per day (Bid) prescribed at the beginning and adjusted due to patient response.~Drug: Prednisone(Pred)，5-30mg, po, once per day (qd) prescribed at the beginning and adjusted due to patient response."
89577708|NCT05651373||patients using TNF inhibitor (TNFi)|"The cohort includes the RA patients in pregnancy.~Drug: Hydroxychloroquine(HCQ)，200mg, po, twice per day (Bid) prescribed at the beginning and adjusted due to patient response.~Drug: Prednisone(Pred)，5-30mg, po, once per day (qd) prescribed at the beginning and adjusted due to patient response.~Drug: TNFi ,such as Certolizumab Pegol (Cimzia)，200mg, iH,q2w, once two weeks (q2w) prescribed from the beginning and adjusted due to patient response."
89577709|NCT05198583|Experimental|Intervention|The intervention group will have a play-based intervention, including online games, analogue card games as well as a weekly coaching session to enhance executive functions.
88972179|NCT05574218|Experimental|Glycine - Test|Polishing treatment with glycine powder air-polishing after ultrasonic plaque debridement.
89577710|NCT05198583|No Intervention|Control|The control group does not receive any intervention.
89577711|NCT02607033|Experimental|Exercise and Weight Loss|Individuals assigned to this group will be asked to complete both the exercise and weight loss intervention for six months
89577712|NCT02607033|Active Comparator|Exercise|Individuals assigned to this group will be asked to complete the exercise intervention for xic months
89577713|NCT03905889|Experimental|Experimental Abemaciclib and Sunitinib|For the dose escalation phase, Subjects will receive a 21-day cycle of continuous oral daily Sunitinib in combination with Abemaciclib every 12 hours for 14 days followed by 7 days off. Using a traditional 3 x 3 study design assessing dose limiting toxicity, if the initial prescribed dosing of these 2 medications (Dose Level 1) is tolerated by the first 3 subjects, the study will pause for a 30 day time period between cohorts to assess toxicity. If no dose limiting toxicity is identified, the next cohort of 3 new subjects will be treated at the next higher dose level (Dose Level 2). If the original cohort treated at Dose Level 1 do not tolerate the combination of medications, the medication regimen will be modified to a lower dose (Dose Level - 1). A dose expansion phase is included which will evaluate the combination of Abemaciclib in combination with Sunitinib when given at the maximum tolerated dose as determined from the from dose escalation phase.
89577714|NCT04804059|Experimental|Cohort A|[14C]-APX001 Oral Solution
89577715|NCT04804059|Experimental|Cohort B|[14C]-APX001 Solution for Infusion
89577716|NCT03846765|Experimental|Phenylephrine continuous infusion|
89577717|NCT03846765|Experimental|Dobutamine continuous infusion|
89577718|NCT05474469|Experimental|Diaphragmatic breathing in combination with abdominal muscle strengthening exercises|Exprimental Group ( Group A) will receive diaphragmatic breathing in combination with abdominal muscle strengthening exercises .12 treatment sessions for 4 weeks period, which consisted of 03 treatment sessions per week.
89577719|NCT05474469|Active Comparator|Diaphragmatic breathing Exercises only without abdominal muscle strengthening exercises|Active comparator (Group B) will receive diaphragmatic breathing only. 12 treatment sessions for 4 weeks period, which consisted of 03 treatment sessions per week.
89577720|NCT02426307||Transcatheter Aortic Valve Replacement|TAVR: Portico (St Jude Medical), CoreValve (Medtronic), Lotus (Boston Scientific), Edwards Sapien 3 (Edwards LifeSciences),
89577721|NCT02426307||Surgical aortic valve replacement|SAVR: Perimount (Edwards), Epic (St Jude Medical), Trifecta (St Jude Medical)
89577722|NCT02325531|Other|Low support|"In this pragmatic comparative effectiveness trial, clinics NOT patients were randomized. Clinics were randomly assigned to one of the arms and support was provided to the clinic, not the patient.~EHR-based toolkit Basic webinar"
89577723|NCT02325531|Other|Medium support|"In this pragmatic comparative effectiveness trial, clinics NOT patients were randomized. Clinics were randomly assigned to one of the arms and support was provided to the clinic, not the patient.~Support provided to the low support arm, PLUS Staff training Adaptive webinars"
89577724|NCT02325531|Other|High support|"In this pragmatic comparative effectiveness trial, clinics NOT patients were randomized. Clinics were randomly assigned to one of the arms and support was provided to the clinic, not the patient.~Support provided to the low and medium support arms, PLUS Practice facilitation"
89577725|NCT02325531|Other|Comparison|"In this pragmatic comparative effectiveness trial, clinics NOT patients were randomized. Clinics were randomly assigned to one of the arms and support was provided to the clinic, not the patient.~No support was provided by the researchers. The EHR-based toolkit was available to all clinics in the network if they actively searched it out in the EHR."
88972180|NCT05574218|Active Comparator|Rubber cup - Control|Polishing treatment with a rubber cup and polishing paste after ultrasonic debridement
88972181|NCT00020670|Experimental|CD40 Cell Vaccination|Patients will undergo tumor cell collection followed by vaccine preparation and then vaccination. Autologous acute lymphoblastic leukemia (ALL) cells are harvested, cultured with CD40 ligand, pulsed with keyhole limpet hemocyanin (KLH), and then irradiated to produce the vaccine. Patients receive either 1 x 10^7 or 1 x 10^8 CD40 cells/vaccination depending on the number of tumor cells obtained. Vaccinations are administered every two weeks as outpatient therapy. Evaluable patients receive the course of at least 4 vaccinations at weeks 0, 2, 4, 6. Patients may continue receiving vaccinations every 2 weeks if chemotherapy is not required for symptomatic disease.
88972182|NCT05574179|Experimental|midazola.|Inj.midazolam
88972183|NCT05574179|Experimental|Dexnedetomidine|inj.dexmedetomidine
89577726|NCT05366985|Experimental|Socket shield with guided root sectioning|Tooth extraction and immediate implant placement using the socket shield technique with computer guided sectioning of the root.
89577727|NCT02204787|Experimental|active tDCS|Transcranial Direct Current Stimulation : 10 sessions twice a day during 5 days, with a 2 mA intensity during 20 minutes.
89577728|NCT02204787|Sham Comparator|Sham tDCS|Transcranial Direct Current Stimulation : 10 sessions twice a day during 5 days, with a sham stimulation during 20 minutes. Initial stimulation followed by turning off the device as to ensure blinding.
89577729|NCT05393895|Experimental|CSF-1|One drop bilaterally twice daily for approximately 6 weeks
89577730|NCT05393895|Placebo Comparator|Vehicle|One drop bilaterally twice daily for approximately 6 weeks
89577731|NCT05365737|Placebo Comparator|placebo oral rinse|Placebo comparator Volume Time Active molecule 15 mL 1 min No
89577732|NCT05365737|Active Comparator|CPC oral rinse|Volume Time Active molecule 15 mL 1 min CPC containing oral rinse
89577733|NCT05365737|Active Comparator|Cymenol oral rinse|Volume Time Active molecule 15 mL 1 min Cymenol containing oral rinse
89577734|NCT05365737|Active Comparator|CPC + Cymenol oral rinse|Volume Time Active molecule 15 mL 1 min CPC+cymenol containing oral rinse
89577735|NCT05355831|Active Comparator|Active Transcranial Direct Current Stimulation|Anodal TDCS 1mV for 2x 20 minutes.
89577736|NCT05355831|Sham Comparator|Sham stimulation|2x 20 minutes of sham stimulation (30 sec ramp up, followed by current of 0 for 18.5 minutes followed by 30 sec ramp down).
89577737|NCT04787367|Experimental|Early-operative TAP block|The TAP block will be administered after the placement of the camera port.
89577738|NCT04787367|Experimental|Late-operative TAP block|The TAP block will be administered at the completion of the case just before removing the camera port.
89577739|NCT02061891|Active Comparator|Deferred invasive evaluation|Deferred invasive coronary evaluation and revascularization (PCI/CABG) within 72 hours from time of clinical diagnosis (CONTROL group)
89577740|NCT02061891|Experimental|Very early invasive evaluation|Acute invasive coronary evaluation within 12 hours from time of diagnosis - INTERVENTION group
89577741|NCT03797157|Experimental|H2MF|Human milk-based breast milk fortifier
89577742|NCT03797157|Active Comparator|Standard fortifier|Standard care: bovine milk-based breast milk fortifier
89577743|NCT02039739||Orsiro™ Drug Eluting Stent|
89577744|NCT05210049|Other|Patients undergoing routine screening via upper endoscopy (EGD)|All enrolled patients will complete upper endoscopy for screening for Barrett's esophagus and esophageal adenocarcinoma.
88972184|NCT00021216|Experimental|Treatment (bortezomib)|Patients receive bortezomib IV on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
88972185|NCT05574023|Experimental|Predictive Alarm (PA)|Patients use the CGM sensor with Predictive Alarm on set at 70 mg/dl in 20 minutes for hypoglycemia and at 250 mg/dl in 20 minutes for hyperglycemia.
88972186|NCT05574023|Active Comparator|Alarm on Threshold (AoT)|Patients use the CGM sensor with alarms on a threshold of 70 mg/dl for hypoglycemia and 250 mg/dl for hyperglycemia.
89029317|NCT02641145|Experimental|Heart Failure|10 individuals with diagnosis of heart failure without amyloidosis by standard criteria will undergo a research F-18 florbetapir PET, C-11 acetate PET, and MRI of the heart, as well as a heavy metal analysis of the blood at baseline..
89033251|NCT02920632|Active Comparator|Online cognitive training 2 (N=70)|Eight-week, three times a week during 45 minutes cognitive activities
89577745|NCT03766113|Other|Healthy volunteer|"50 subjects~A single neurofeedback coupling electroencephalogram and functional MRI in time actual ."
89577746|NCT03766113|Other|Patients at the early stage after stroke|"30 subjects~Effectiveness of an electroencephalogram-neurofeedback"
89577747|NCT03766113|Other|Patients at the chronic stage after stroke|"36 subjects~Effectiveness of a neurofeedback coupling electroencephalogram and functional MRI in time actual"
89577748|NCT04785339|Experimental|one-arm, pre-post design|This study will test an intervention in adult Latinx immigrants. There will be no control condition or other comparators. One condition will only provide data at pre (baseline) and post. The only comparison will be across time, but not across conditions as this will be the only condition and all participants will receive the same intervention.
89577749|NCT03757377|Active Comparator|BackBeat Moderato System (PHC ON)|Eligible patients randomized after optimization phase to PHC ON (PHC algorithm active) for 12 months. Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator.
89577750|NCT03757377|Placebo Comparator|BackBeat Moderato System (PHC OFF)|Eligible patients randomized after optimization phase to pacemaker only (PHC OFF or PHC algorithm not active) for 12 months. Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator.
89577751|NCT04418505|No Intervention|Standard of Care|This group will not receive Vielight RX Plus treatment. Instead, they will follow the COVID-19 standard of treatment recommended by Health Canada.
89577752|NCT04418505|Experimental|Standard of Care + Vielight RX Plus Treatment|The is group will receive Vielight RX Plus treatment and follow the COVID-19 standard of treatment recommended by Health Canada.
89577753|NCT03746847||Patients with Suspected Cardiac Sarcoidosis|patients with biopsy proven or suspected sarcoidosis (based on standard clinical imaging findings).
89577754|NCT01635153|Active Comparator|Protein calorie supplement plus micronutrient|
89577755|NCT01635153|Placebo Comparator|Micronutrient alone|
89577756|NCT04446039||1. Escitalopram Cohort|
89577757|NCT04446039||2. Paroxetine Cohort|
89577758|NCT04446039||3. Fluoxetine Cohort|
89577759|NCT04446039||4. Mirtazapine Cohort|
89577760|NCT04446039||5. Duloxetine Cohort|
89577761|NCT04446039||6. Sertraline Cohort|
89577762|NCT04446039||7. Venlafaxine Cohort|
89577763|NCT04446039||8. Tianeptine Cohort|
89577764|NCT04446039||9. Vortioxetine Cohort|
89577765|NCT04446039||10. Desvenlafaxine Cohort|
89577766|NCT04446039||11. Bupropion Cohort|
89577767|NCT05087979|Experimental|Intervention|An investigational device will be used to hold patient's head and airway in a stable position.
89577768|NCT05087979|No Intervention|Standard of care|Pillows and towels will be used to hold patient's head and airway in a stable position.
89577769|NCT05036967||Heart Failure (HF) patients|Patients diagnosed with incident HF, in an outpatient setting in Colombia during the time period of 01 JUN 2019 to 31 MAY 2020
89577770|NCT03647007|No Intervention|Standard group|The Standard programme on the Christmas Seal Homes.
89577771|NCT03647007|Experimental|FIFA Group|The Standard programme including FIFA 11 for Health programme - health knowledge on the football pitch.
89577772|NCT02014311|Experimental|CTA+CTP guided treatment strategy|Patients with adenosine stress induced regional myocardial hypoperfusion (CT perfusion imaging) in combination with a corresponding epicardial coronary vessel with >50% stenosis (Coronary CT angiography) will be referred for invasive investigation within 30 days after study inclusion - CTP-INTERVENTION
89577773|NCT02014311|Active Comparator|CTA guided treatment strategy|Patients with at least one epicardial coronary artery stenosis >50% (Coronary CT angiography) will be referred for invasive investigation within 30 days after initial discharge from the hospital - CONTROL
89577774|NCT05034861|Experimental|cCTG|cCTG group, that will undergo a following process: EFW and Doppler assessment biweekly, and instead of additional weekly Doppler-only assessment, the patients will be provided with an electronic cCTG device at no cost (Carebits). Women will be asked to apply Carebits device at least twice weekly for at least 30 minutes (e.g. Mondays-Thursdays) with minimum 72 hours interval in case of 2 sessions per week. The trace will be examined by an independent centre, available 24 hours daily. The person examining the trace is trained or already specialized in Obs&Gynae. In case of situation requiring medical intervention, the patient will be immediately contacted by phone and advised to self-refer to the nearest Antenatal Unit. In case of normal trace, a full report will follow within 30 minutes after last reading of the trace.
88972187|NCT05573945|Experimental|Family Education Only|"Family Education Only. Parents will be asked to participate in an evidence based program s that includes 6-8 visits with a a trained healthcare provider.~This program of early intervention based on the promotion of the parent-child relationship through the recognition of behavioral states, methods of interaction, facilitation strategies in the relationship.~Active listening Visits includes a cycle of 5-6 consecutive meetings lasting about an hour. The meetings will take place in a defined and dedicated space (private room) or if possible (if no other parents are present) at the baby's cradle. The meeting will take place between a single parent and a trained direct operator. This is not a psychotherapeutic intervention but a support that is provided to the parent. The support is mainly based on active listening, on the problems posed by the parent and on the subject's empowerment."
89577775|NCT05034861|Active Comparator|Doppler|Doppler group, that will undergo a standard process of antenatal care in case of FGR. The EFW and CTG STV will be assessed biweekly. In case of positive end-diastolic flow in UA, Doppler assessment (MCA PI, UA PI, DV PI, Ut PI) will be provided on a weekly basis. In case of deterioration to AEDF/REDF, further management will depend on clinical situation and the patient will be excluded from the study group (applies to both arms).
89577776|NCT05032677|Experimental|Conventional Epidural Technique|
89577777|NCT05032677|Active Comparator|Dural Puncture Epidural technique using pencil-point 25G Whitacre needle|
89577778|NCT05002959||TESS Anatomic|Subjects who received the Anatomic T.E.S.S.® V3 Modular Total Shoulder System to relieve pain and restore the joint function and who met the inclusion/exclusion criteria.
88972188|NCT05573945|Active Comparator|Family Education and Active Listening|"Family Education and Active Listening. Parents of infants will be asked to participate in an evidence based program for parents of NICU infants that includes 6-8 visits with a a trained healthcare provider operator.~This evidence-based program of early intervention based on the promotion of the parent-child relationship through the recognition of behavioral states, methods of interaction, facilitation strategies in the relationship.~The program takes its conceptual basis from the Mother Infant Transaction Program (MITP).~It involves about 6 meetings (1-2 a week) of 30-45 minutes that are carried out during the hospitalisation in the NICU directly at the child's bed between the operator and one or both parents."
88972189|NCT05573633|Experimental|smartwatches group|
88972190|NCT05573633|Active Comparator|no smartwatche group|
88972191|NCT05573594|Experimental|MET Group|"the participants in the study group were under 8 sessions of MET, 2 times a week, in addition to the conventional physiotherapy program.~In the content of conventional physiotherapy program for both groups; Hot Pack (20 min), Ultrasound (ITO brand 1 MHz and 1.5 W/cm2, 5 min), Transcutaneous Electrical Nerve Stimulation (TENS, 50-100 Hz, 20 min) and standard home exercises were included. The program went 5 times a week, 10 consecutive sessions. Each session lasted an average of 45 minutes."
88972192|NCT05573594|Experimental|Control Group|"In this study, the participants in the control group were under conventional physiotherapy program for 5 times a week, a total of 10 sessions~In the content of conventional physiotherapy program for both groups; Hot Pack (20 min), Ultrasound (ITO brand 1 MHz and 1.5 W/cm2, 5 min), Transcutaneous Electrical Nerve Stimulation (TENS, 50-100 Hz, 20 min) and standard home exercises were included. The program went 5 times a week, 10 consecutive sessions. Each session lasted an average of 45 minutes"
88972193|NCT05573516|Experimental|Fixation with 4mm lag screws|
88972194|NCT05573516|Active Comparator|Fixation with 4mm fully-threaded positional screws|
88972195|NCT05573438|Experimental|Fructose|Participants received a standardized meal of bread, ham, and margarine plus a sweetened drink (200mL) with fructose. The meals provided 25% of the energy requirements. The meal consisted of 15% of protein, 30% of fat, and 55% of carbohydrate (30% of complex carbohydrates and 25% of fructose).
88972196|NCT05573438|Experimental|Sucrose|Participants received a standardized meal of bread, ham, and margarine plus a sweetened drink (200mL) with sucrose. The meals provided 25% of the energy requirements. The meal consisted of 15% of protein, 30% of fat, and 55% of carbohydrate (30% of complex carbohydrates and 25% of sucrose).
89033252|NCT02920632|No Intervention|Healthy control subjects (N=30)|Reference group to compare cognitive training effects to
89577779|NCT05002959||TESS Reverse|Subjects who received the Reverse T.E.S.S.® V3 Modular Total Shoulder System to relieve pain and restore the joint function and who met the inclusion/exclusion criteria.
89577780|NCT01871727|Experimental|E7777|
89577781|NCT05266989||Fibromyalgia|All participants will randomly participate through three tDCS conditions (1mA, 2mA and sham)
89577782|NCT05266989||Healthy Controls|All participants will randomly participate through three tDCS conditions (1mA, 2mA and sham)
88972197|NCT05573438|Placebo Comparator|Glucose|Participants received a standardized meal of bread, ham, and margarine plus a sweetened drink (200mL) with glucose. The meals provided 25% of the energy requirements. The meal consisted of 15% of protein, 30% of fat, and 55% of carbohydrate (30% of complex carbohydrates and 25% of glucose).
88972198|NCT00021840||Homogen Hispanic pop/Cent Valley CRA|Homogeneous Hispanic population from the Central Valley of Costa Rica
88972199|NCT05573087|Active Comparator|Aquatic Based Exercise|maximal jump squats in a pool
88972200|NCT05573087|Active Comparator|Land Based Exercise|cycle ergometer
88972201|NCT02972021|Other|control|Pure oxygen by nasal cannula group
88972202|NCT02972021|Experimental|HFNC|oxygen by High-flow nasal cannula
88972203|NCT00022113|Experimental|Treatment (cilengitide)|Patients receive EMD 121974 IV over 1 hour twice weekly. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
88972204|NCT00022152|Experimental|vinorelbine|"Patients receive oral vinorelbine once weekly. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed at baseline and then after completion of the second course.~Patients are followed every 3 months for 5 years."
88972205|NCT05572814|No Intervention|Usual Care|Teaching - CardioSmart Resources + Clinician Education
88972206|NCT05572814|Active Comparator|Decision Support|Technology - Facilitated Solution (Existing Team)
89577783|NCT01636713|Experimental|GSK573719/VI 62.5/25|Inhalation via Novel Dry Powder Inhaler Once a day
89577784|NCT01636713|Experimental|GSK573719/VI 125/25|Inhalation via Novel Dry Powder Inhaler Once a day
89577785|NCT01636713|Placebo Comparator|Placebo|Inhalation via Novel Dry Powder Inhaler Once a day
89577786|NCT04801095|Experimental|WM-S1-030|Dose escalation (part 1) and Dose expansion (part 2)
89577787|NCT03591861|Experimental|Ketogenic Diet|"Caregivers (and participating children) attend intro ketogenic diet class (4 - 30 min lectures)~Clinic visit with neurologist, nurse, and dietitian prior to hospital admission and then once every 3 months~Laboratory studies prior to hospital admission and then at each follow-up visit~Hospital admission (3-5 day) to start the ketogenic diet~Standard of care chemotherapy with BCNU for up to 2 years~Ketogenic diet can continue for up to 2 years"
89577788|NCT04832919|Experimental|Nurse-Community Health Worker-Family Partnership|The experimental arm will receive the Nurse-Community Health Worker-Family Partnership intervention
89577789|NCT04832919|No Intervention|Standard of Care|The control arm will receive standard access to NYC Department of Health COVID-19 testing sites and standard COVID-19 public health messaging
89577790|NCT01600053|Experimental|Lenalidomide|Lenalidomide will be taken orally days 1-21 for up to six 28-day cycles
89577791|NCT04821297|Experimental|Supportive care (message)|Patients receive text messages for 1-2 months before scheduled appointment. Patients also complete a survey at baseline and after standard of care colposcopy and an interview after standard of care colposcopy.
89577792|NCT03569241|Other|MDT + ADT|Metastasis-directed therapy (salvage lymph node dissection OR stereotactic body radiotherapy) + 6 months androgen deprivation therapy
89577793|NCT03569241|Experimental|MDT + WPRT + ADT|Metastasis-directed therapy (salvage lymph node dissection OR stereotactic body radiotherapy) + whole pelvic radiotherapy + 6 months androgen deprivation therapy
89577794|NCT04716387||Chlorfenapyr ITN|These study districts will receive Interceptor G2 ITNs during the mass distribution campaign.
89577795|NCT04716387||Piperonyl butoxide ITN|This study district will receive piperonyl butoxide ITN during the mass distribution campaign.
89577796|NCT04716387||Standard LLIN|These study districts will receive standard ITNs during the mass distribution campaign.
89577797|NCT04716387||Pyriproxyfen ITN|This study district will receive Royal Guard ITNs during the mass distribution campaign.
89577798|NCT01158807||HHT- Brain Arteriovenous Malformation|"Definite clinical HHT diagnosis (at least 3 Curacao criteria) or genetic diagnosis of HHT and~Presence of Brain Arteriovenous Malformation"
89577799|NCT01158807||HHT -NO BAVM|1. Definite clinical HHT diagnosis (at least 3 Curacao criteria) or genetic diagnosis of HHT
89577800|NCT01068249|Experimental|Letrozole + RAD001|Letrozole and RAD001 (Everolimus)
89577801|NCT01035099|Experimental|Titrated dose Letrozole|Patients who are randomized to the titrated dose of Letrozole, will start gonadotropins in the evening of day #2 of their menstrual cycle with injectable follicle stimulating hormone (FSH) and human menopausal gonadotropin (HMG). Oral Letrozole will be added to the stimulation in the following titrated regimen.
89577802|NCT01035099|Active Comparator|Fixed dose Letrozole|Patients who are randomized to fixed dose Letrozole will start Letrozole 5mg daily (orally) on the second day of their menstrual cycle and then gonadotropins on the fourth day of their menstrual cycle.
89577803|NCT05362383|Experimental|Experimental group|transcutaneous electrical nerve stimulation (TENS) is applied
89577804|NCT05362383|No Intervention|Control group|no intervention
89577805|NCT00973011|Experimental|A|
89577806|NCT03560349|Experimental|Lidocaine|Transnasal blockade of SPG approach involving the application of 2 cc (approximately the size of a pea) of 2% lidocaine jelly on a cotton swab directed posteriorly towards the SPG in the nasal passage bilaterally. Cotton swab will be inserted to the back of the nasal passage until it can no longer be inserted any further. The cotton swab should remain in place for 15 minutes on both sides simultaneously. The patient will be instructed on how to perform this procedure on themselves, and they will be given supplies for a 7-day supply of medication to be administered two times per day at approximately 12 hour intervals.
89577807|NCT03560349|Placebo Comparator|Placebo|Transnasal blockade of SPG approach involving the application of 2 cc (approximately the size of a pea) of nasal saline jelly on a cotton swab directed posteriorly towards the SPG in the nasal passage bilaterally. Cotton swab will be inserted to the back of the nasal passage until it can no longer be inserted any further. The cotton swab should remain in place for 15 minutes. The patient will be instructed on how to perform this procedure on themselves, and they will be given supplies for a 7-day supply of medication to be administered up to two times per day at approximately 12 hour intervals.
89577808|NCT04812639|Experimental|buccal infiltartion technique|local anesthetic technique
88972207|NCT05572814|Active Comparator|Referral|Teams - Protocol-Supported Team, (Virtual GDMT Team)
88972208|NCT05571956|Experimental|Pancreatic ductal adenocarcinoma organoids and cancer-associated fibroblasts establishment group|If a sufficient visible core was obtained on macroscopic inspection, the tissue materials from the following one needle pass were placed into the transfer medium for organoid generation. Using a tiny portion (about 20%) of the FNB sample, we isolated CAFs u
88972209|NCT05571020|Experimental|Mat Pilates Group|"Two days a week, approximately one hour a day, for a total of eight weeks, in groups of 5-6 people, they were included in the mat pilates exercise program.~Before starting the exercise program, the study group participants were informed about the principles of the pilates working system (I am not sure if this statement is correct terminologically), the training program and the 5 key elements of the pilates approach, neutral spine (head-neck-shoulder-waist-abdominal placement), lumbopelvic stabilization, Informative training on scapular stabilization, focusing and breathing was given."
89577809|NCT04812639|Active Comparator|Inferior alveolar nerve block technique|local anesthetic technique
89577810|NCT04418583|Experimental|Three-dimensional imaging|Participants receive a three-dimensional image of their chest, just prior to and after application of the Crane technique.
89577811|NCT05157399|Experimental|OtoBand Efficacy on Vertigo and Dizziness|During the single site visit, participants will wear the Otoband, on the flat part of the right mastoid bone, about an inch behind the pinna and level with the ear canal. OtoBand will be set to 92dB or 98dB bone conduction level (Re: 1 Dyne). The participants will be fitted with the Otoband and will undergo the vestibular battery test. The investigator will record the outcome measurements.
89577812|NCT05157399|Placebo Comparator|Placebo Device Efficacy on Vertigo and Dizziness|Participants will wear the Otoband, on the flat part of the right mastoid bone, about an inch behind the pinna and level with the ear canal. OtoBand set to a bone conduction level 10dB lower than the level used in the experimental condition. Once fitted with the Otoband, participants will undergo the vestibular battery test. The investigator will record the outcome measurements.
89577813|NCT05157399|No Intervention|No Device|Participants will wear the OtoBand, but turned off, to collect baseline data. This will be randomized. The participants will be fitted with the Otoband and will undergo the vestibular battery test. The investigator will record the outcome measurements.
89577814|NCT04418973|Experimental|A - load/apnea|Threshold inspiratory load then apnea
89577815|NCT04418973|Experimental|B- apnea/load|apnea than threshold inspiratory load
89577816|NCT00434343|Placebo Comparator|Global Therapeutic Massage (GTM)|Weekly massages consisting of full body Western massage for 1hour.
89577817|NCT00434343|Active Comparator|Myofascial physical therapy (MPT)|Connective tissue manipulation to all body wall tissues of the abdominal wall, back, buttocks and thighs that clinically were found to contain connective tissue abnormalities and/or myofascial trigger point release to painful myofascial trigger points
89577818|NCT04435431|Experimental|Mesdopetam dose 1|Mesdopetam capsule (mg), dose 1, 1 capsule b.i.d. for 84 days.
89577819|NCT04435431|Experimental|Mesdopetam dose 2|Mesdopetam capsule (mg), dose 2, 1 capsule b.i.d. for 84 days.
89577820|NCT04435431|Experimental|Mesdopetam dose 3|Mesdopetam capsule (mg), dose 3, 1 capsule b.i.d. for 84 days.
89577821|NCT04435431|Placebo Comparator|Placebo|Placebo capsule, 1 capsule b.i.d. for 84 days
89577822|NCT02246673|Experimental|RDEA3170 10 mg|Once daily (qd) with febuxostat 40mg (qd) for 7 days, and with febuxostat 80 mg (qd) for 7 days; febuxostat 40 mg (qd) only for 7 days, and febuxostat 80 mg (qd) only for 7 days.
89577823|NCT02246673|Experimental|RDEA3170 15 mg|Once daily with febuxostat 40mg (qd) for 7 days and with febuxostat 80mg (qd) for 7 days; febuxostat 40 mg (qd) only for 7 days, and febuxostat 80 mg (qd) only for 7 days.
89577824|NCT02246673|Experimental|RDEA3170 5 mg|Once daily with febuxostat 40mg (qd) for 7 days and with febuxostat 80mg (qd) for 7 days; febuxostat 40 mg (qd) only for 7 days, and febuxostat 80 mg (qd) only for 7 days.
89577825|NCT02246673|Experimental|RDEA3170 2.5 mg|Once daily with febuxostat 40mg (qd) for 7 days and with febuxostat 80mg (qd) for 7 days; febuxostat 40 mg (qd) only for 7 days, and febuxostat 80 mg (qd) only for 7 days.
89577826|NCT03532425|Experimental|B/F/TAF|"B/F/TAF + Atripla Placebo~Each pill is taken once daily, (total of 2 tablets) The blinded treatment phase of this study will last for 52 weeks"
89577827|NCT03532425|Active Comparator|Atripla|"Atripla + B/F/TAF Placebo~Each pill is taken once daily, (total of 2 tablets) The blinded treatment phase of this study will last for 52 weeks"
89577828|NCT03503877|Other|SAGE Media|SAGE single-step MEDIA
89577829|NCT03503877|Other|GLOBAL Media|LIFE GLOBAL single-step MEDIA
89577830|NCT04811469|Experimental|CBP-174|CBP-174 oral solution
89577831|NCT04811469|Experimental|Placebo|placebo oral solution
89577832|NCT02246439|Experimental|RHB-102|RHB-102, Bimodal Release Ondansetron Tablets
89577833|NCT02246439|Placebo Comparator|Placebo|Placebo
89577834|NCT02245737|Experimental|Lanabecestat 20 milligrams (mg)|Lanabecestat 20 mg given orally once daily for 104 weeks.
89577835|NCT02245737|Experimental|Lanabecestat 50 mg|Lanabecestat 50 mg given orally once daily for 104 weeks.
89577836|NCT02245737|Placebo Comparator|Placebo|Placebo given orally once daily for 104 weeks.
89577837|NCT04191447|Experimental|FLAMBOYANT 200/12|"The study is double-dummy. Thus, the participant must inhale 2 (two) capsules twice a day (12/12h), as follow:~1 Flamboyant 200/12 capsule~1 Budesonide/formoterol Placebo capsule."
89577838|NCT04191447|Active Comparator|Budesonide/formoterol 400/12|"The study is double-dummy. Thus, the participant must inhale 2 (two) capsules twice a day (12/12h), as follow:~1 Budesonide/formoterol 400/12 capsule~1 Flamboyant 200/12 Placebo capsule."
89577839|NCT02244957|Active Comparator|Bi-level positive airway pressure (BPAP)|Bi-level positive airway pressure (BPAP)
88972210|NCT05571020|No Intervention|Control Group|Control group participants did not participate in any exercise program.
89577840|NCT02244957|Active Comparator|Nocturnal oxygen|Nocturnal oxygen
89577841|NCT02243865|Experimental|Chordate S200 + control module (CT100), active|Chordate System S200 giving Kinetic Oscillation Stimulation Treatment for 15 minutes in each nostril
89577842|NCT02243865|Placebo Comparator|Chordate S200 + control module (CT100), placebo|Chordate System S200 giving Kinetic Oscillation Stimulation in placebo mode. Non-inflated and non-vibrating treatment
89577843|NCT02243631|Experimental|Probenecid|These patients will receive 5 days of probenecid.
89577844|NCT02243631|No Intervention|No intervention|These patients will receive no intervention.
89577845|NCT04183413|No Intervention|Standard of Care|Health services for diabetes and hypertension are provided as was the standard of care prior to the healthcare reform after the emergency decentralization motivated by the COVID-19 outbreak. Healthcare for diabetes and hypertension for complicated cases is provided through physician-led teams at hospitals and health centers. Healthcare for diabetes and hypertension for uncomplicated cases is provided at primary care clinics through nurses.
89577846|NCT04183413|Experimental|DSD|Clients are invited to participate in one of three Differentiated Service Delivery models tailored to their needs.
89577847|NCT04183413|Experimental|CDP|Health services for diabetes and hypertension are provided in the scope of outreach activities set up on a monthly basis in communities.
89577848|NCT03986229|Active Comparator|With compression garments|"Evaluation of the variation in the travel speed of the center of pressure with compression garments and the standing static balance."
89577849|NCT03986229|Active Comparator|Without compression garments|"Evaluation of the variation in the travel speed of the center of pressure with compression garments and the standing static balance."
89577850|NCT03396783|Experimental|SPP|during the visit, nurse will make a blood test for biological and immunological analysis, electromyogram and walk test
89577851|NCT03396783|Other|Control|during the visit, nurse will make a blood test for biological and immunological analysis
89577852|NCT05233449|Experimental|Children anesthetized|Inhalatory general anesthesia with sevoflurane 0.9 Minimal Alveolar Concentration and alfentanil 10 µg/kg
89577853|NCT02242305|Experimental|Hyoscine Butylbromide - Tablet|
89577854|NCT02242305|Active Comparator|Hyoscine Butylbromide - Capsule|
88972211|NCT05570903||Awake prone position Group|Patients in awake prone position will be included.
88972212|NCT05570903||Non awake prone position Group|Patients in non awake prone position will be included.
88972213|NCT05569928|Active Comparator|Homozygous FHBL2 subjects|
88972214|NCT05569928|Active Comparator|Heterozygous FHBL2 carriers|
88972215|NCT05569928|Active Comparator|ANGPTL3 wild-type Campodimele residents|
88972216|NCT05569889||control group|The medical staff was using the traditional surgical draping kit and single-packed sterile instruments (SPSI) that have to be opened separately
88972217|NCT05569889||experimental group|The medical staff was using only the single packed CST, and containing all the necessary single-use items like surgical blades, sutures, dressing, surgical drapes, syringes, compresses, surgical gloves, jerseys.
89577855|NCT02240121|Experimental|Rifaximin EIR 800 mg|Participants will receive rifaximin EIR 400 milligrams (mg) tablets orally twice daily for 52 weeks.
89577856|NCT02240121|Placebo Comparator|Placebo|Participants will receive placebo matching to rifaximin EIR tablets orally twice daily for 52 weeks.
89577857|NCT04780425|Experimental|DESMOND|receive usual care plus a structured diabetes self-management education program delivered once over 6hours
89577858|NCT04780425|Active Comparator|USUAL CARE|Receive usual care as per standard treatment guidelines of ghana unstructured education during clinic visits for routine care
89577859|NCT02239263|Experimental|N6 Input Processing Features|
89577860|NCT02238483|Experimental|AZD7624|Active treatment
89577861|NCT02238483|Placebo Comparator|Placebo|Placebo Comparator
89577862|NCT01632891|Experimental|LPV/r-based ART|Participants were prescribed to LPV/r-based antiretroviral therapy (ART) for 15 days, which includes lopinavir/ritonavir plus emtricitabine/tenofovir disoproxil fumarate; followed by an nNRTI-based ART, which includes efavirenz, nevirapine, plus emtricitabine/tenofovir disoproxil fumarate, and Trimethoprim/sulfamethoxazole prophylaxis to take from day 16 through day 30.
89577863|NCT01632891|Experimental|nNRTI-based ART|Participants were prescribed to nNRTI-based ART for 15 days, which includes efavirenz, nevirapine, plus emtricitabine/tenofovir disoproxil fumarate, followed by an nNRTI-based ART and Trimethoprim/sulfamethoxazole prophylaxis to take from day 16 through day 30.
89577864|NCT02208999||Neurostimulator Precision|Patients implanted or reimplanted with the neurostimulator Precision
88972218|NCT00022542|Experimental|Treatment (ixabepilone)|Patients receive BMS-247550 IV over 1 hour on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity. Patients achieving complete response receive 2 additional courses.
88972219|NCT00022581|Experimental|Treatment (thalidomide)|Patients receive oral thalidomide once daily. Treatment continues in the absence of disease progression or unacceptable toxicity.
88972220|NCT05554445||Adult CD patients who are prescribed the Crohn disease exclusion diet|Clinically stable CD patients with active disease by CD symptoms score 4 <Harvey-Bradshaw index (HBI) at baseline and Calprotectin>50g/l / endoscopy / imaging proven active disease from the previous 4 months
88972221|NCT04733313|Active Comparator|quadratus lumborum-2|
88972222|NCT04733313|Active Comparator|quadratus lumborum-3|
88972223|NCT05551871|Active Comparator|Simvastatin|the patient will receive simvastatin 40mg
88972224|NCT05551871|Placebo Comparator|Placebo|the patient will receive placebo drug
88972225|NCT00022737|Experimental|Arm I|See Design Details.
88972226|NCT00022776|Experimental|1|Participants will undergo surgery for spinal stenosis. Participants in this group will undergo surgical decompression as described by Rothman and Simeone.
89033253|NCT02942810|Experimental|WCK 5222 (Cefepime and zidebactam combination)|IV infusion over a period of 60 minutes
89577865|NCT02208843|Experimental|Afatinib|Afatinib tablet once daily until progression
89577866|NCT02208063|Experimental|Telavancin|7.5 mg/kg administered intravenously once every 24 hours daily over 60 minutes
89577867|NCT02208063|Active Comparator|Standard of care|Vancomycin, Daptomycin, synthetic penicillin or Cefazolin
89577868|NCT02207907|Experimental|Sodium bicarbonate plus sodium fluoride|Experimental dentifrice containing sodium bicarbonate plus 1150 parts per million (ppm) fluoride as sodium fluoride
89577869|NCT02207907|Active Comparator|Sodium fluoride|Toothpaste containing 1100 ppm fluoride as sodium fluoride
89577870|NCT02207829|Experimental|Umeclidinium 62.5 mcg + placebo|Subjects will receive UMEC Inhalation Powder 62.5 mcg once daily via nDPI plus placebo once daily via HANDIHALER inhaler for 12 weeks (24 weeks in Germany). Subjects will be instructed to take one inhalation each morning from both the nDPI and the HANDIHALER inhaler
89577871|NCT02207829|Active Comparator|Tiotropium 18mcg + placebo|Subjects will receive Tiotropium 18 mcg once daily via HANDIHALER inhaler plus placebo once daily via nDPI for 12 weeks (24 weeks in Germany). Subjects will be instructed to take one inhalation each morning from both the nDPI and the HANDIHALER inhaler
89577872|NCT02237157|Other|Gemcitabine, Local Delivery (Dose 1)|Gemcitabine; 1 cycle, two doses per cycle; 250mg/m2 dose
89577873|NCT02237157|Other|Gemcitabine, Local Delivery (Dose 2)|Gemcitabine; 1 cycle, two doses per cycle; 500mg/m2 dose
89577874|NCT02237157|Other|Gemcitabine, Local Delivery (Dose 3)|Gemcitabine; 1 cycle, two doses per cycle; 750mg/m2 dose
89577875|NCT02237157|Other|Gemcitabine, Local Delivery (Dose 4)|Gemcitabine; 1 cycle, two doses per cycle; 1000mg/m2 dose
89577876|NCT02237001|Experimental|Treatment|Suture-based meniscal repair
89577877|NCT02236611|Experimental|Umeclidinium 62.5 mcg|Randomized subjects will receive umeclidinium inhalation powder 62.5 mcg, once daily over a period of 12 weeks via a nDPI. Subjects will be instructed to take one dose each morning.
89577878|NCT02236611|Experimental|Glycopyrronium 44 mcg|Randomized subjects will receive glycopyrronium 44 mcg, once daily over a period of 12 weeks via a BREEZHALER inhaler. Subjects will be instructed to take one dose each morning.
89577879|NCT02234583|Experimental|DS-5565|Participants receive 15 mg DS-5565 administered once or twice daily. Each participant's dose can be titrated up or down based on the investigator's decision. Analysis will be based on the dose modality at the time of data collection.
89577880|NCT03705663||Women interested in HIV PrEP|Cis-gender women at high risk for HIV interested in or initiating HIV PrEP
88972227|NCT00022776|Experimental|2|Participants will undergo physical therapy for spinal stenosis. These participants will undergo a physical therapy program emphasizing lumbar flexion exercises, general conditioning exercises, and patient education for six weeks, with a frequency of 1-2 visits per week. Each patient will receive instruction in a home exercise program.
88972228|NCT05521646|Experimental|Intervention|QiC implemented
88972229|NCT05521646|No Intervention|Control|
88972230|NCT00022854|Placebo Comparator|1|
88972231|NCT00022854|Experimental|2|Nerve block bolus with 30 mL levobupivacaine 0.25%, followed by continuous saline infusion
88972232|NCT00022854|Experimental|3|Nerve block bolus with 30 mL levobupivacaine 0.25%, followed by continuous levobupivacaine infusion of 5 mL/hr for 50 hr
89577881|NCT03686397|Experimental|SVT-15652|1 vial twice daily
89577882|NCT03686397|Placebo Comparator|Placebo|1 vial twice daily
89577883|NCT02233803|Experimental|Sequence 1: BFF 400/12mcg to BFF 320/9mcg|Subjects will receive Regimen A in Treatment Period 1 followed by Regimen B in Treatment Period 2. The treatment periods will be separated by a wash out period of 4 weeks. Regimen A: Subjects will be instructed to take each morning and evening, 1 inhalation from a single capsule containing BFF (400/12 mcg) by single capsule inhaler. Regimen B: Subjects will be instructed to take each morning and evening,1 inhalation from BFF (320/9 mcg) TURBUHALER inhaler.
89577884|NCT02233803|Experimental|Sequence 2: BFF 320/9mcg to BFF 400/12mcg|Subjects will receive Regimen B in Treatment Period 1 followed by Regimen A in Treatment Period 2. The treatment periods will be separated by a wash out period of 4 weeks. Regimen A: Subjects will be instructed to take each morning and evening, 1 inhalation from a single capsule containing BFF (400/12 mcg) by single capsule inhaler. Regimen B: Subjects will be instructed to take each morning and evening,1 inhalation from BFF (320/9 mcg) TURBUHALER inhaler.
89577885|NCT02233647|Placebo Comparator|Placebo|Subjects will be maintained on oral placebo. Cocaine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.
89577886|NCT02233647|Experimental|Phendimetrazine Dose 1|"Subjects will be maintained on the low phendimetrazine dose. Cocaine will be administered acutely during low dose phendimetrazine maintenance.~Placebo will be administered acutely during low dose phendimetrazine maintenance."
88972233|NCT05514860|Active Comparator|Cryoballoon-based PVI|"Sinus rhythm control via a pulmonary vein isolation (PVI) (first-line) procedure utilizing the the Arctic Front Cryoballoon Procedure."
88972234|NCT05514860|Active Comparator|Anti-Arrhythmic Drug Therapy|"Sinus rhythm control via the use of anti-arrhythmic drug (AAD) therapy (first-line) based on local clinical practice, and according to guideline-suggested drug management for symptomatic patients with paroxysmal AF."
88972235|NCT05513066||Ephedrine/phenylephrine mixture|10 mL of 0.75 mg/ml ephedrine and 10 mL of 37.5 μg/ml phenylephrine are mixed in a 20 mL syringe. The speed is generally started at 20 ml/h and then adapted according to blood pressure.
89577887|NCT02233647|Experimental|Phendimetrazine Dose 2|"Subjects will be maintained on the intermediate phendimetrazine dose. Cocaine will be administered acutely during intermediate dose phendimetrazine maintenance.~Placebo will be administered acutely during intermediate dose phendimetrazine maintenance."
89577888|NCT02233647|Experimental|Phendimetrazine Dose 3|"Subjects will be maintained on the high phendimetrazine dose. Cocaine will be administered acutely during high dose phendimetrazine maintenance.~Placebo will be administered acutely during high dose phendimetrazine maintenance."
89577889|NCT02233413|Sham Comparator|Non-active LLLT helmet application|A helmet containing near infrared LED's (LLLT helmet) will be applied to the head, however, the LEDs will not be turned on / activated.
89577890|NCT02233413|Active Comparator|Active LLLT helmet application|A helmet containing near infrared LEDs (LLLT helmet) will be applied and the LEDs will be turned on/activated
89577891|NCT04778631|Experimental|Heat therapy|Local perineal heat therapy during active second stage of labor
89577892|NCT04778631|Experimental|Cryotherapy|Local perineal cryotherapy during the immediate postpartum period
89577893|NCT04778631|No Intervention|Active second stage usual car|Standard obstetrical care and perineal protection during active second stage of labor
89577894|NCT04778631|No Intervention|Postpartum usual care|Standard immediate (<2 hours) postpartum care
88972236|NCT05513066||baby noradrenaline|20 mL of baby norepinephrine 10µg/mL is prepared in a 50 mL syringe. The speed is generally started at 30 ml/h and then adapted according to blood pressure.
88972237|NCT00022971|Experimental|1|Apolizumab followed by rituixmab every 4 weeks
88972238|NCT05507840|Experimental|Intervention|Near or infra red light provided by the Valeda machine will be applied in the intervention eye
88972239|NCT05507840|Sham Comparator|Control|Light with very low intensity provided by the same Valeda machine will be applied in the control eye
88972240|NCT02971878|No Intervention|Control|Culture media without addition of antioxidants
88972241|NCT02971878|Active Comparator|Treatment|Culture media with the addition of antioxidants
88972242|NCT00023205|Experimental|Individualized education|Individualized education with materials written in plain language. Follow-up sessions/ phone contact as requested by the subject.
88972243|NCT00023205|Active Comparator|Standard care|1 session of education with provision of standard Arthritis Foundation materials.
88972244|NCT05481671||Questionnaires assessed patients with traumatic fractures|"①Age 18 and above.~②Patients who were diagnosed as fractures due to accidental trauma and were diagnosed by X-rays and clinicians and required surgical treatment.~③Have the normal cognitive ability, expression ability and social participation ability."
88972245|NCT05478980|Experimental|Active Tea - Good Sleepers|
88972246|NCT05478980|Active Comparator|Control Tea - Good Sleepers|
88972247|NCT05478980|Experimental|Active Tea - Poor Sleepers|
88972248|NCT05478980|Active Comparator|Control Tea - Poor Sleepers|
88972249|NCT00394992|Active Comparator|1 oxaliplatin+capecitabine|postoperatively oxaliplatin 130 mg/m2 i.v. day 1 plus capecitabine 1000 mg/m2 b.i.d. on day 1-14, q3w
88972250|NCT00394992|Experimental|2 oxaliplatin+capecitabine+bevacizumab|postoperatively oxaliplatin 130 mg/m2 i.v. day 1 plus bevacizumab 7.5 mg/kg on day 1 plus capecitabine 1000 mg/m2 b.i.d. on day 1-14, q3w
88972251|NCT00395031|Other|Ziprasidone|Open label
88972252|NCT05460806|Experimental|Aerobic Exercise|Participants assigned to aerobic exercise training will walk on a treadmill (RodbyTM, RL 1600E, Enhorna, Sweden) for 40 minutes at an intensity of 60-75% of maximum heart rate (220-age formula) three times per week for 8 weeks. The heart rate of the participants will be measured with an electric heart rate monitor throughout the session.
88972253|NCT05460806|No Intervention|Control|
88972254|NCT00395070|Experimental|Treatment Arm|Allovectin-7® 2 mg intralesional injection into a single lesion weekly for six consecutive weeks, repeated beginning after each 8th week.
88972255|NCT00395070|Active Comparator|Control Arm|DTIC 1000 mg/m2 intravenous infusion over 60 minutes, repeated every 28 days, OR TMZ 150 to 200 mg/m2 orally once daily for five consecutive days, repeated every 28 days.
88972256|NCT05447624|Active Comparator|Patients undergoing ablation of two of the genicular nerve branches|
88972257|NCT05447624|Active Comparator|Patients undergoing ablation of three of the genicular nerve branches|
88972258|NCT00023244|Experimental|Corticosteroid (steroid) withdrawal|All enrolled subjects who have not experienced an episode of acute rejection or other event resulting in removal from the study in the first 6 months after transplantation will undergo a protocol-driven biopsy at 6 months. Subjects with no clinical or histologic evidence of rejection will be eligible to be randomized and treated in a double-blinded (e.g., masked-neither subject nor health care providers will know treatment being received) fashion while continuing other immunosuppressive medications. Subjects in this arm will undergo complete steroid withdrawal by the end of 12 months post-transplant.
88972259|NCT00023244|Active Comparator|Control Treatment|All enrolled subjects who have not experienced an episode of acute rejection or other event resulting in removal from the study in the first 6 months after transplantation will undergo a protocol-driven biopsy at 6 months. Subjects with no clinical or histologic evidence of rejection will be eligible to be randomized and treated in a double-blinded (e.g., masked-neither subject nor health care providers will know treatment being received) fashion while continuing other immunosuppressive medications. Subjects in this arm will be maintained on low-dose (0.15 mg/kg/day) daily steroids.
88972260|NCT00023283|Experimental|1|Standard Medical Management with once-weekly medication dispensing
88972261|NCT00023283|Experimental|2|Standard Medical Management with thrice-weekly medication dispensing
88972262|NCT00023283|Experimental|3|Enhanced Medical Management with thrice-weekly medication dispensing
89577895|NCT01632579|Placebo Comparator|Placebo|Single dose of placebo administered orally on up to one occasion separated by at least a 3 week wash out period.
89577896|NCT01632579|Experimental|LY3023703|Up to 6 single escalating doses of LY3023703 [0.1 milligram (mg) up to 60 mg] administered orally on up to two occasions per participant separated by at least a 3 week wash out period.
89577897|NCT01632579|Active Comparator|400 mg Celecoxib|Positive control. Single 400 mg dose of celecoxib administered orally, open label, on one occasion separated by at least a 3 week washout period.
89577898|NCT01632345|Experimental|Doravirine 25 mg|Doravirine 25 mg + TRUVADA® Participants in this arm will receive doravirine 25 mg in Part I and the selected doravirine dose (either 25 mg, 50 mg, 100 mg, or 200 mg) in Part II. These participants also receive placebo that matches efavirenz.
89577899|NCT01632345|Experimental|Doravirine 50 mg|Doravirine 50 mg + TRUVADA® Participants in this arm will receive doravirine 50 mg in Part I and the selected doravirine dose (either 25 mg, 50 mg, 100 mg, or 200 mg) in Part II. These participants also receive placebo that matches efavirenz.
89577900|NCT01632345|Experimental|Doravirine 100 mg|Doravirine 100 mg + TRUVADA® Participants in this arm will receive doravirine 100 mg in Part I and the selected doravirine dose (either 25 mg, 50 mg, 100 mg, or 200 mg) in Part II. These participants also receive placebo that matches efavirenz.
89577901|NCT01632345|Experimental|Doravirine 200 mg|Doravirine 200 mg + TRUVADA® Participants in this arm will receive doravirine 200 mg in Part I and the selected doravirine dose (either 25 mg, 50 mg, 100 mg, or 200 mg) in Part II. These participants also receive placebo that matches efavirenz.
89577902|NCT01632345|Active Comparator|Efavirenz|Efavirenz + TRUVADA® Participants in this arm will receive efavirenz in Part I and in Part II. These participants also receive placebo that matches doravirine.
89577903|NCT02232243|Experimental|Initial: Hydroxychloroquine 400mg HCQ|These initial 3 patients received 200mg hydroxychloroquine (HCQ) twice daily (400mg/day total) for 14 days prior to surgery.
89577904|NCT02232243|Experimental|Secondary: Hydroxychloroquine 800mg HCQ|Based on data analysis from the initial patients, these patients received 400mg hydroxychloroquine (HCQ) twice daily (800mg/day total) for 14 days prior to surgery.
89577905|NCT02232243|Experimental|Tertiary: Hydroxychloroquine 400mg HCQ|Based on data from the primary and secondary groups, patients received 200mg hydroxychloroquine (HCQ) twice daily (400mg/day total) for 14 days prior to surgery.
89577906|NCT04776837||Main Cohort|"Patient-reported outcomes (e.g. symptoms, quality of life) and biomarkers compare to standard of care clinical assessments such as imaging and tumor markers in predicting the clinical outcomes (e.g. disease progression and survival)~Prior to starting anti-cancer therapy and at subsequent designated visits (every one month)~Collections include:~Blood sample~Questionnaires quality of life, mood, and symptoms~Tissue may be obtained for next-generation sequencing."
89577907|NCT02205333|Experimental|MEDI6469 6 mg/kg|Participants received MEDI6469 6 milligram/kilogram (mg/kg) as a single intravenous (IV) administration on Day 1
89577908|NCT02205333|Experimental|MEDI6469 10 mg/kg|Participants received MEDI6469 10 mg/kg as a single IV administration on Day 1
89577909|NCT02205333|Experimental|MEDI6469 2 mg/kg+Tremelimumab 3 mg/k|Participants received MEDI6469 2 mg/kg as a single IV administration on Day 1 plus tremelimumab 3 mg/kg as IV administration on Day 1 then every 4 weeks (Q4W) for 6 doses, after which every 12 weeks (Q12W) for 2 doses or until PD
89577910|NCT02205333|Experimental|MEDI6469 2 mg/kg+Tremelimumab 10 mg/kg|Participants received MEDI6469 2 mg/kg as a single IV administration on Day 1 plus tremelimumab 10 mg/kg as IV administration on Day 1 then Q4W for 6 doses after which Q12W for 2 doses or until progression of disease (PD)
89577911|NCT02205333|Experimental|MEDI6469 2 mg/kg+Durvalumab 3 mg/kg|Participants received MEDI6469 2 mg/kg as a single IV administration on Day 1 plus durvalumab 3 mg/kg as IV administration on Day 1 then every 2 weeks (Q2W) for 12 months or until PD
89577912|NCT02205333|Experimental|MEDI6469 2 mg/kg+Durvalumab 10 mg/kg|Participants received MEDI6469 2 mg/kg as a single IV administration on Day 1 plus durvalumab 10 mg/kg as IV administration on Day 1, then Q2W for 12 months or until PD
89577913|NCT02205333|Experimental|MEDI6469 10 mg/kg+Durvalumab 10 mg/kg|Participants received MEDI6469 10 mg/kg as a single IV administration on Day 1 plus durvalumab 10 mg/kg as IV administration on Day 1, then Q2W for 12 months or until PD
89577914|NCT02205333|Experimental|MEDI6469 2 mg/kg+Rituximab 375 mg/m^2|Participants received MEDI6469 2 mg/kg as a repeat IV administration on Day 3 then Q4W for 11 doses, or until confirmed complete response (CR) plus 1 cycle, or PD plus rituximab 375 mg/m^2 as IV administration on Days 1, 8, and 29; then Q4W for 10 doses, or until confirmed CR plus 1 cycle, or PD
89577915|NCT02205333|Experimental|MEDI6469 10 mg/kg+Rituximab 375 mg/m^2|Participants received MEDI6469 10 mg/kg as a repeat IV administration on Day 3 then Q4W for 11 doses, or until confirmed CR plus 1 cycle, or PD plus rituximab 375 mg/m2 as IV administration on Days 1, 8, and 29; then Q4W for 10 doses, or until confirmed CR plus 1 cycle, or PD
89577916|NCT04776369|Active Comparator|Lidocaine group|30 patients will receive IV lidocaine 4 mg/kg in 50 ml volume over 30 min. plus IV saline 50 ml after induction of anesthesia.
89577917|NCT04776369|Active Comparator|Magnesium group|30 patients will receive IV magnesium sulfate 30 mg/kg in 50 ml volume over 30 min. plus IV saline 50 ml after induction of anesthesia.
89577918|NCT04776369|Active Comparator|Combination group|30 patients will receive IV lidocaine 4 mg/kg in 50 ml volume over 30 min. plus IV magnesium sulfate 30 mg/kg in 50 ml volume over 30 min. after induction of anesthesia.
89577919|NCT04776369|Placebo Comparator|control group|30 patients will receive IV saline 50 ml plus IV saline 50 ml over 30 min. after induction of anesthesia.
89577920|NCT02230683|Experimental|IDN-6556 - Overall population|Overall evaluable population treated with IDN-6556 25 mg twice daily
89577921|NCT02230683|Experimental|IDN-6556 - Subgroup with Baseline HVPG < 12 mmHg|Subgroup for patients with Baseline HVPG < 12 mmHg that have been treated with IDN-6556 25 mg twice daily
89577922|NCT02230683|Experimental|IDN-6556 - Subgroup Baseline HVPG ≥ 12 mmHg|Subgroup for patients with Baseline HVPG ≥ 12 mmHg that have been treated with IDN-6556 25 mg twice daily
89577923|NCT02230527|Active Comparator|Clopidogrel|Clopidogrel 75mg by mouth daily
89577924|NCT02230527|Experimental|Ticagrelor|Ticagrelor 90mg by mouth twice daily
88972263|NCT05418335||stroke group|stroke history at least 3 months ago
88972264|NCT05418335||Control group|Healthy control
88972265|NCT05367323||Group A|22 women who underwent cesarean delivery using spinal anesthesia
88972266|NCT05367323||Group B|22 women who were in the control group (they never experience pregnancy, or anaesthesia)
88972267|NCT05359172||Tranexamic acid|They will receive preoperative intravenous tranexamic acid infusions.
88972268|NCT05359172||Controls|They will not receive intravenous tranexamic acid infusions.
88972269|NCT00023634|Experimental|EGFR vaccine with GMCSF|EGFR antisense DNA 500 mcg peptide w/GMCSF monthly x 6 m
88972270|NCT00023634|Experimental|EGFR vaccine with KLH|EGFR antisense DNA 500 mcg peptide w/KLH monthly x 6 m
89033254|NCT02920710|Experimental|Experimental: H.P. Achtar Gel 80 U|H.P. Acthar Gel (repository corticotropin) Injection, 80 U daily for 10 days, then 80 U twice weekly for up to a total of 48 weeks on therapy.
89033255|NCT02941913|Experimental|Fixed Dose Palonosetron group|patient will receive a fix dose of 75 μg of palonosetron
89033256|NCT02941913|Experimental|Bodyweight-adjusted Dose Palonosetron|patient will receive a bodyweight-adjusted dose of 1mcg/kg of palonosetron
89033257|NCT05319002|Experimental|Group EMDR|Participants in the experimental group will undergo a 3-week group EMDR intervention with weekly 60-minute group sessions.
89033258|NCT05319002|No Intervention|Control|The control group will follow routine daily school activities
88972271|NCT00023751|Experimental|surgery + leucovorin + fluorouracil + radiation|"Patients with T3 disease or positive surgical margins after surgery are removed from study. Patients with T1 disease and negative surgical margins after surgery are observed. Patients with T2 disease and negative surgical margins after surgery receive adjuvant therapy.~Beginning 42 days after surgery, T2 patients receive leucovorin calcium (CF) IV over 2 hours with fluorouracil (5-FU) IV bolus 1 hour into the infusion once weekly for 6 weeks. Beginning 2 weeks after the completion of chemotherapy, patients receive chemoradiotherapy comprising radiotherapy once daily 5 times a week for 5 weeks and 5-FU IV continuously while receiving radiotherapy. Beginning 2 weeks after the completion of chemoradiotherapy, patients again receive CF IV over 2 hours with 5-FU IV bolus 1 hour into the infusion once weekly for 6 weeks. Chemotherapy repeats after 2 weeks rest for a total of 2 courses.~Patients are followed every 3 months for 2 years and then every 6 months for 5 years."
88972272|NCT05338424||Sprint Interval Training (SIT)|"The 1-session SIT protocol will include Work bouts performed at maximal intensity targets. Three Work bouts will be performed at 20-second intervals separated by 2 recovery bouts consisting of 2 minutes of low-intensity cycling. The SIT session will employ a standardized warm up and cool down of 3 minutes at a self-selected light intensity, per current guidelines. SIT sessions will take 15 minutes to complete."
89577925|NCT04767945||Adults with liver cirrhosis admitted to hospital liver unit|Consenting adults admitted with liver cirrhosis; recorded/uploaded are demographic, clinical, laboratory and imaging data
89577926|NCT02204319|Experimental|Cold Laser Treatment|Cold laser used off of the body over the vulvar involved area. The device to be used in this study is the Erchonia Corporation variable frequency pulsed wave low level laser device employing three independent 7 milliWatt, 635 nanometer red light diodes mounted in a hand-held device and is a variable frequency pulsed wave device. Weekly visits x 6 with 5 minute treatments over vulva and sacral nerve roots each.
89577927|NCT02204007|Experimental|3D imaging, surrogate bone model|3D imaging & surrogate bone model
89577928|NCT02204007|No Intervention|Standard of Care Preoperative Imaging|Patients receiving standard of care preoperative planning prior to total hip arthroplasty.
89577929|NCT02203851|Experimental|Risankizumab 90 mg|Participants entered the study receiving risankizumab 90 mg by subcutaneous (SC) injection and had achieved ≥90% improvement in Psoriasis Area and Severity Index (PASI90) Score at Week 12 continued to receive open-label (OL) risankizumab 90 mg by SC injection at Week 12 and every 12 weeks for approximately 4 years from the first dose in either the lead-in or extension study.
89577930|NCT02203851|Experimental|Risankizumab 180 mg|Participants entered the study receiving risankizumab 90 mg by subcutaneous (SC) injection and had achieved <90% improvement in Psoriasis Area and Severity Index (PASI90) Score at Week 12 switched to open-label (OL) risankizumab 180 mg by SC injection at Week 12 and every 12 weeks for approximately 4 years from the first dose in either the lead-in or extension study.
89577931|NCT02228967|No Intervention|Usual Care|Those participants assigned to the usual care control group will be given a brochure on safe drinking limits, will be reminded of the 6-month follow-up, and thanked for their time.
89577932|NCT02228967|Active Comparator|SBIRT|"Those assigned to the SBIRT intervention group will receive 1 of 3 tracks:~Brief Intervention (BI) for At Risk Individuals (scores lower than 15) - Brief motivational intervention with feedback related to their use and change strategies.~Brief Treatment (BT) for High Risk Individuals (scores of 16-19) - Brief Intervention on site and be offered 6 individual confidential sessions with a civilian Brief Treatment Counselor over the phone.~Referral to Treatment (RT) for Severe Risk Individuals (scores of 20-40) - Brief Intervention on site and will be given a list of services where they may self-refer for further assessment and support."
89577933|NCT02985411|Active Comparator|Immediate Gardening Intervention|Wait-listed, will receive the gardening intervention after a 1-year period
89577934|NCT02985411|Active Comparator|Delayed Gardening Intervention|Individuals in this group will serve as their own control
89577935|NCT02227875|Experimental|Mylan's insulin Glargine|receive Mylan's insulin Glargine
89577936|NCT02227875|Active Comparator|Lantus®|receive Lantus®
89577937|NCT02203149|Experimental|Part 1 Grazoprevir 50 mg + Elbasvir|Non-cirrhotic participants take 50 mg grazoprevir in combination with 50 mg elbasvir by mouth (p.o.) once daily (q.d.) for 12 weeks during the blinded period of Part 1 and are followed-up for 24 weeks during the open-label period of Part 1.
89577938|NCT02203149|Experimental|Part 1 Grazoprevir 100 mg + Elbasvir|Non-cirrhotic participants take 100 mg grazoprevir in combination with 50 mg elbasvir p.o. q.d. for 12 weeks during the blinded period of Part 1 and are followed-up for 24 weeks during the open-label period of Part 1.
89577939|NCT02203149|Experimental|Part 2 Non-cirrhotic Immediate: Grazoprevir + Elbasvir|Non-cirrhotic participants take grazoprevir (50 mg or 100 mg dose selected from Part I) and 50 mg elbasvir p.o. q.d. for 12 weeks during the blinded period of Part 2 and are followed-up for 24 weeks during the open-label period of Part 2.
89577940|NCT02203149|Placebo Comparator|Part 2 Non-cirrhotic Deferred: Placebo► Grazoprevir + Elbasvir|Non-cirrhotic participants take dose-matched placebo p.o. q.d. for 12 weeks during the blinded period of Part 2 followed by a 4-week follow-up. Afterwards, participants take grazoprevir (50 mg or 100 mg dose selected from Part I) and 50 mg elbasvir p.o. q.d. for 12 weeks and are followed-up for 24 weeks during the open-label period of Part 2.
89577941|NCT02203149|Experimental|Part 2 Cirrhotic: Grazoprevir + Elbasvir|Cirrhotic participants take grazoprevir (50 mg or 100 mg dose selected from Part 1) and 50 mg elbasvir p.o. q.d. for 12 weeks during the blinded period of Part 2, and are followed-up for 24 weeks during the open-label period of Part 2.
89577942|NCT02203071||MSP with BioCartilage|Patients receiving marrow stimulating procedure with BioCartilage adjunct.
89577943|NCT02203071||MSP without BioCartilage|Patients receiving marrow stimulating procedure without BioCartilage.
89577944|NCT02202837||Etanercept First|Adult patients with RA who receive etanercept as first biologic, according to prevailing Belgian reimbursement criteria
89577945|NCT02202837||Etanercept second|Adult patients who receive etanercept as second biologic, according to prevailing Belgian reimbursement criteria
89577946|NCT02202759|Experimental|MLN0264 1.8 mg/kg|MLN0264 1.8 mg/kg, 30-minute intravenous (IV) infusion, Day 1 of each 21-day cycle, for up to 1 year or until disease progression or unacceptable toxicity occurs (Up to 14 cycles). The dose may be decreased, delayed or discontinued in participants who develop treatment-associated nonhematologic and hematologic toxicity to MLN0264.
89577947|NCT02226549|Experimental|LDV/SOF+VDV|Participants will receive LDV/SOF+VDV for 8 weeks.
89577948|NCT02226549|Experimental|LDV/SOF+VDV+RBV|Participants will receive LDV/SOF+VDV+RBV for 8 weeks.
89577949|NCT02226003|Experimental|Ertugliflozin 5 mg and Sitagliptin 100 mg|Ertugliflozin, 5 mg, administered orally, once daily for 26 weeks. Sitagliptin, 100 mg, administered orally, once daily for 26 weeks. Placebo to ertugliflozin, 10 mg, administered orally, once daily for 26 weeks.
89577950|NCT02226003|Experimental|Ertugliflozin 15 mg and Sitagliptin 100 mg|Ertugliflozin, 15 mg, administered orally, once daily for 26 weeks. Sitagliptin, 100 mg, administered orally, once daily for 26 weeks.
89577951|NCT02226003|Placebo Comparator|Placebo to Ertugliflozin and Placebo to Sitagliptin|Placebo to ertugliflozin, 5 mg and 10 mg, administered orally, once daily for 26 weeks. Placebo to sitagliptin, 100 mg, administered orally, once daily for 26 weeks.
89577952|NCT02225223|Other|No previous Radiation Therapy|Targeted radio-frequency ablation using the STAR™ Tumor Ablation System and vertebral augmentation using the StabiliT® Vertebral Augmentation System.
89577953|NCT02225223|Other|Failed/Refuse further Radiation Therapy|Targeted radio-frequency ablation using the STAR™ Tumor Ablation System and vertebral augmentation using the StabiliT® Vertebral Augmentation System.
89577954|NCT02469519|Experimental|Betamethasone - ACTIVE|Booster Course of Antenatal Steroids consists of Betamethasone [12 mg intramuscular injection, 24 hours apart X 2 doses] or if unavailable may give Dexamethasone [6 mg intramuscularly 12 hours apart x 4 doses]
89577955|NCT02469519|Placebo Comparator|normal saline - PLACEBO|Normal saline of equivalent volume given intramuscularly at the equivalent dosing regimes listed in experimental arm.
89577956|NCT02443389||Neonates admitted to NICU|Retrospective cohort of neonates admitted to NICU with stated inclusion and exclusion criteria
89577957|NCT01634139|Experimental|Tiotropium high dose QD|
89577958|NCT01634139|Experimental|Tiotropium low dose QD|
89577959|NCT01634139|Experimental|Placebo QD|
89577960|NCT02224755|Experimental|HeartMate 3 LVAS (HM3 LVAS)|Evaluation of the safety and effectiveness of the HeartMate 3 LVAS by demonstrating non-inferiority to the HMII LVAS (HMII) when used for the treatment of advanced, refractory, left ventricular heart failure.
89577961|NCT02224755|Active Comparator|HeartMate II LVAS|Evaluation of the safety and effectiveness of the HeartMate 3 LVAS by demonstrating non-inferiority to the HMII LVAS (HMII) when used for the treatment of advanced, refractory, left ventricular heart failure.
89577962|NCT02404441|Other|patients with solid tumors|Phase I Dose escalation cohorts
89577963|NCT02404441|Other|Selected tumor types|Phase II expansion: Selected tumor types: melanoma, NSCLC, triple negative breast cancer, anaplastic thyroid cancer
89577964|NCT02101281|Experimental|Group 1 - rhNGF 20 μg/mL|(first planned dose): drop (35 μL) corresponding to 0.70 μg of rhNGF (recombinant human Nerve Growth Factor) was instilled into each eye twice a day (b.i.d.) every 12±2 h for a total daily dose of 2.8 μg (both eyes), for 28 consecutive days. The total dose was 78.4 μg/28 days.
89577965|NCT02101281|Experimental|Group 2 - rhNGF 4 μg/mL|after completion of Group 1 treatment, one drop (35 μL) corresponding to 0.14 μg of rhNGF (recombinant human Nerve Growth Factor) instilled into each eye b.i.d. every 12±2 h for a total daily dose of 0.56 μg, for 28 consecutive days. Total dose was 15.68 μg/28 days.
89577966|NCT02224599|Experimental|CYP, TAPA-pulsed DC vaccine, Imiquimod|TAPA-Pulsed DC Vaccine Cyclophosphamide Pill Imiquimod Topical Cream
89577967|NCT02201901|Experimental|SOF/VEL 12 weeks|Participants will receive SOF/VEL FDC for 12 weeks.
89577968|NCT02201901|Experimental|SOF/VEL+RBV 12 weeks|Participants will receive SOF/VEL FDC plus RBV for 12 weeks.
89577969|NCT02201901|Experimental|SOF/VEL 24 weeks|Participants will receive SOF/VEL FDC for 24 weeks.
89577970|NCT04775043||Control population|First part of the study for the HFRDIS Questionnaire French validation
89577971|NCT04775043||Patients on hormone therapy for breast cancer|Second par of the study for the HFRDIS questionnaire use on patients on hormone therapy for breast cancer
89577972|NCT02201277|Experimental|Denali|Denali IVC Filter
88972273|NCT05338424||Stretching|Stretching will include a low-intensity range of motion and stretching exercises with session duration (15 minutes) being matched to SIT.
89209366|NCT03964649||Truven Health MarketScan Research Database|To compare RA-related costs among patients treated with tofacitinib (IR, XR and combined groups) to patients treated with each of the bDMARDs (individually, as well as to TNFi and to non-TNFi each combined as groups).
88972274|NCT02971982|Experimental|rituximab /Dex/CTX|rituximab /Dexamethasone/cyclophosphamide 6 cycles followed by rituximab (at least 2 cycles) rituximab:375mg/m2 d1 Dexamethasone:40mg d1-4 cyclophosphamide:750mg/m2,d1-28
88972275|NCT02971982|Experimental|Velcade/Dex/CTX|Velcade/Dexamethasone/cyclophosphamide 6 cycles followed by velcade (at least 2 cycles) Velcade:1.3mg/m2 d1,d4,d8,d11 Dexamethasone:20mg d1-2,d4-5,d8-9,d11-12 cyclophosphamide:750mg/m2,d1-28
88972276|NCT00023829|Experimental|LH-RH agonist plus radiation therapy|Luteinizing hormone-releasing hormone (LH-RH) agonist x 2 years plus radiation therapy (RT) to 63.0 - 66.6 Gy
89577973|NCT02201277|Experimental|Option|Option Elite IVC Filter
89577974|NCT02224053|Experimental|AZD9291 and omeprazole|Sequential treatments of AZD9291 + omeprazole followed by AZD9291 alone, with a washout period in between.
89577975|NCT04774731|Experimental|Whole Body Vibration|
89577976|NCT04774731|No Intervention|Control|
89577977|NCT04774107|Experimental|P1101 + Ribavirin|P1101 400 µg SC Ribavirin 800-1400 mg PO
89577978|NCT02457793|Experimental|Not assigned|One participant was assigned to receive intermittent cobimetinib 80 milligrams (mg) + GDC 0994 200 mg) and did receive study drug. However, the participant diary was not returned, and the site was unable to document study dose administration.
89577979|NCT02457793|Experimental|COB 20 mg + GDC 200 mg|Concurrent or intermittent dosing of cobimetinib 20 mg, concurrent with GDC-0994 200 mg for 21 consecutive days, followed by 7 days off.
89577980|NCT02457793|Experimental|COB 40 mg + GDC 200 mg|Concurrent or intermittent dosing of cobimetinib 40 mg, concurrent with GDC-0994 200 mg for 21 consecutive days, followed by 7 days off.
89577981|NCT02457793|Experimental|COB 80 mg + GDC 200 mg|Concurrent or intermittent dosing of cobimetinib 80 mg, concurrent with GDC-0994 200 mg for 21 consecutive days, followed by 7 days off.
88972277|NCT00023829|Active Comparator|Radiation therapy alone|Radiation therapy alone to 63.0 - 66.6 Gy
89209367|NCT00883038|Active Comparator|Active Comparator|Diabetic diet following the DNSG guidelines
89577982|NCT02457793|Experimental|COB 80 mg + GDC 400 mg|Concurrent or intermittent dosing of cobimetinib 80 mg, concurrent with GDC-0994 400 mg for 21 consecutive days, followed by 7 days off.
89577983|NCT02457793|Experimental|COB 100 mg + GDC 200 mg|Concurrent or intermittent dosing of cobimetinib 100 mg, concurrent with GDC-0994 200 mg for 21 consecutive days, followed by 7 days off.
89577984|NCT01650259||Oral antidiabetic drug (OAD)|
89577985|NCT01650259||Trazenta|
89577986|NCT04908085|Experimental|OPC|Occupational Performance Coaching delivered by telephone
89577987|NCT04908085|No Intervention|Waitlist control|Intervention provided after post intervention assessment
89577988|NCT02434939|Experimental|Low dose ketamine|Low dose ketamine 1mg/kg given as an IV infusion via syringe pump over 10 minutes. Maximum of 2 doses to be given during study period that will last 2 hours.
89577989|NCT02434939|Active Comparator|Morphine|Morphine 0.1mg/kg given as an IV infusion via a syringe pump over 10 minutes. Maximum of 2 doses to be given during the study period that will last 2 hours.
88972278|NCT00023829|Active Comparator|LH-RH agonist alone|Luteinizing hormone-releasing hormone (LH-RH) agonist x 2 years
88972279|NCT00023946|Experimental|Treatment (ixabepilone)|Patients receive BMS-247550 IV over 3 hours on day 1. Treatment repeats every 21 days for at least 2 courses in the absence of disease progression or unacceptable toxicity.
88972280|NCT05268185|Active Comparator|Moderna Booster Recommendation|Participants assigned to this arm will be recommended to receive the Moderna vaccine for their Covid-19 booster shot.
88972281|NCT05268185|Active Comparator|Pfizer Booster Recommendation|Participants assigned to this arm will be recommended to receive the Pfizer vaccine for their Covid-19 booster shot.
88972282|NCT00024024|Experimental|Arm I|Patients receive oral BMS-275291 1-2 times daily. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 6 patients receive escalating doses of BMS-275291 until the recommended phase II dose (RPTD) is determined. The RPTD is the dose at which no more than 1 of 6 patients experiences dose-limiting toxicity and more than 1 of 6 patients experiences clinical response or at least 5 of 6 patients demonstrate biologic activity. An additional 29 patients are treated at the RPTD.
88972283|NCT05258864|Experimental|Check Your Drinking (CYD)|The CYD is a brief online intervention designed to provide personalized normative feedback aimed at motivating reductions in drinking
88972284|NCT05258864|No Intervention|Control|No Intervention Control
88972285|NCT02971995|Experimental|Prostate cancer/TEP scan|
88972286|NCT02971995|Active Comparator|Prostate cancer/mpMRI|
88972287|NCT05239286|Active Comparator|Group conventional|
88972288|NCT05239286|Experimental|Group PVI|
88972289|NCT05217134|Experimental|Dural Puncture Epidural Analgesia (DPEA)|A 27-Whitacre spinal needle puncture will be performed with confirmation of LCR return, before the introduction of epidural catheter.
88972290|NCT05217134|No Intervention|Epidural Analgesia (EA)|Standard epidural anesthesia wil be performed.
88972291|NCT05158283|Experimental|Intervention: Chocolate balloon|Chocolate balloon group
88972292|NCT05158283|Experimental|Intervention: plain balloon|plain balloon group
88972293|NCT05142449|Experimental|Amoxilan|Patients receive 8 capsules Amoxilan perioperatively and for the next 3 days 6 capsules per day.
88972294|NCT05142449|Placebo Comparator|Placebo|Patients receive 8 capsules Placebo perioperatively and for the next 3 days 6 capsules per day.
89577990|NCT02434471|No Intervention|Breath hold Liver Acquisition with Volume Acquisition (LAVA)|Subjects will undergo abdominal MRI with LAVA with conventional breath holds (typically four or more breath holds) per standard of care.
89577991|NCT02434471|Active Comparator|Respiratory-triggered T1w DISCO LAVA|The study will acquire extra image sets using DISCO LAVA with one breath hold during the arterial imaging phase. No additional breath holds will be required.
89577992|NCT02457637||Acute-on-Chronic Liver Disease Inpatient|"chronic liver disease: including chronic liver hepatitis patients without cirrhosis, compensated cirrhosis patients, decompensated cirrhosis patients; and non-alcoholic fatty liver disease patients.~ALI(acute liver injury): including [ALT>3NL(normal level),AST>3NL or TB>2NL within 1 week before enrollment] or AD(acute decompensation) : including [(having ascites, hepatic encephalopathy, bacterial infection gastrointestinal bleeding or jaundice(TB>5NL)within 1 month before enrollment)].~Standary therapy"
89577993|NCT02457325|Experimental|Surgery With 2% Articaine first, then Surgery With 4%Articaine|First Intervention (1 day - third molar surgery with infiltration of one cartridge of 2% articaíne), Washout (1-2 months), and Second Intervention (1 day - third molar surgery with infiltration of one cartridge of 4% articaíne)
89577994|NCT02457325|Experimental|Surgery With 4%Articaine first, then Surgery With 2% Articaine|First Intervention (1 day - third molar surgery with infiltration of one cartridge of 4% articaíne), Washout (1-2 months), and Second Intervention (1 day - third molar surgery with infiltration of one cartridge of 2% articaíne)
89577995|NCT02434081|Experimental|Chemo-radiotherapy with concurrent nivolumab|4 doses of nivolumab 360mg concurrently with standard chemo-radiotherapy, followed by 480mg for up to 1 year from start of nivolumab treatment.
89577996|NCT02222493|Experimental|PF-06438179|
89577997|NCT02222493|Active Comparator|Infliximab|
88811147|NCT04199117|Experimental|No Incentive,Untailored,Care Manage,Standard Treatment|Participants randomly assigned to this condition will not have access to incentives for completing smoking cessation counseling, will receive 5 untailored letters promoting use of smoking cessation treatment over 2 years, will receive 5 Tobacco Care Management support and motivational encouragement calls over 2 years, and will have access to standard smoking cessation treatment (referral to the state tobacco quitline and/or their primary care provider) over 2 years.
88972295|NCT05093894|Active Comparator|Group 1: Microlyte will be cut into strips and placed on the surgical incision|Microlyte will be cut into strips and placed on the surgical incision
88972296|NCT05093894|No Intervention|Group 2: Nothing will be placed on the surgical incision|Nothing will be placed on the surgical incision
88972297|NCT05080049|Experimental|erythropoietin|Erythropoietin alpha or theta 40,000 UI (1 ml) sc each week if Hb <12 g/dL (for maximum 5 weeks)
88972298|NCT05080049|Placebo Comparator|Placebo|saline sc injection (1 ml) each weeks if Hb <12 g/dL, for a maximum of 5 weeks,
88972299|NCT05079581|Other|Intervention group|Pelvic floor exercises
89577998|NCT02433379|Experimental|Single Arm|Subjects implanted with an EMBLEM S-ICD with rate zones set at 200 bpm and 250 bpm per protocol.
89577999|NCT01439997|Experimental|Desmopressin Melt Therapy in Nocturnal Polyuria Patients|
89578000|NCT02199795|Experimental|CCNMES|Contralaterally Controlled Neuromuscular Electrical Stimulation (CCNMES): CCNMES uses electrical stimulation to move the weaker ankle up and down. The user will control the stimulation using the other (stronger) ankle. A special sock is worn on the stronger ankle. When the stronger ankle is moved, a signal is sent from a sensor on the sock to the electrical stimulator. The stimulator then sends stimulation to the weaker ankle which causes it to move. Sound and light cues coming from the stimulator will tell the user when to move the stronger ankle and when to relax.
89578001|NCT02199795|Active Comparator|Cyclic NMES|Cyclic Neuromuscular Electrical Stimulation (NMES) uses automatic, repetitive electrical stimulation to stimulate the muscles in order to move the weaker ankle up and down.
89578002|NCT02403817|Experimental|Eye Movement Game Control|Cognitive Training Eye Motor Training
89578003|NCT02403817|Active Comparator|Hand Movement Game Control|Cognitive Training Hand Motor Training
89578004|NCT04773249|Experimental|Lateral Epicondylitis Bandage|A lateral epicondylitis bandage will be given to the patient for 6 weeks. The bandage will be positioned 5 cm distal to the lateral epicondyle to allow for elbow flexion. After the application, patients will be asked to punch and the belt on the band will be tightened. After the patients are asked to open the fist, the suitability of the pressure applied to the forearm will be evaluated. Patients will be asked to repeat this application while wearing the band. The patients will also be asked to use the bandage throughout the day, and to remove them during bathing and sleeping.
89578005|NCT04773249|Experimental|Wrist Extension Splint|A wrist extension splint will be given to the patient for 6 weeks. The splint will be used to keep the wrist at 15-20 degrees of extension and to wrap the distal wrist and forearm without hindering finger movements. The patients will be asked to use the splint throughout the day, and to remove them during bathing and sleeping.
89578006|NCT04773249|No Intervention|Wait-and-see Policy|These patients will be monitored with a wait-and-see policy. No splint or band will be given to the patient.
89578007|NCT00930423||cases|patients with endstage renal failure due to atypical uraemic syndrome treated with hemodialysis.
89578008|NCT00930423||controls|patiënts with endstage renal failure due to a non complement consuming nephropathy treated with hemodialysis.
88972300|NCT05079581|No Intervention|Control group|Education session
88972301|NCT05072444|Experimental|QPX7728|Drug: QPX7728 beta lactamase inhibitor Other names: IV
88972302|NCT05072444|Experimental|QPX2014|Drug: QPX2014 antibiotic Other names: IV
88972303|NCT05068739|Experimental|PA-EMR (Partial ampullary endoscopic mucosal resection)|Partial ampullary endoscopic mucosal resection
88972304|NCT05068739|Active Comparator|NKF(Needle knife fistulotomy)|Needle knife fistulotomy
88972305|NCT05056688|Experimental|Application of training set to experimental group|Testicular Model BSE/TSE Training Set
88972306|NCT05056688|No Intervention|Control Group|
88972307|NCT02971722|Experimental|0.3mg JY09(cohort 1)|0.3mg JY09 administered once subcutaneous injection to healthy participants in 1 of 3 treatment periods
88972308|NCT02971722|Experimental|1.5mg JY09(cohort 1)|1.5mg JY09 administered once subcutaneous injection to healthy participants in 1 of 3 treatment periods
88972309|NCT02971722|Experimental|6.0mg JY09(cohort 1)|6.0mg JY09 administered once subcutaneous injection to healthy participants in 1 of 3 treatment periods
88972310|NCT02971722|Placebo Comparator|Placebo(cohort 1)|Placebo administered once subcutaneous injection to healthy participants in 1 of 3 treatment periods
88972311|NCT02971722|Experimental|0.7mg JY09(cohort2)|0.7mg JY09 administered once subcutaneous injection to healthy participants in 1 of 3 treatment periods
88972312|NCT02971722|Experimental|3.0mg JY09(cohort2)|3.0mg JY09 administered once subcutaneous injection to healthy participants in 1 of 3 treatment periods
88972313|NCT02971722|Experimental|12.0mg JY09(cohort2)|12.0mg JY09 administered once subcutaneous injection to healthy participants in 1 of 3 treatment periods
88972314|NCT02971722|Placebo Comparator|Placebo(cohort 2)|Placebo administered once subcutaneous injection to healthy participants in 1 of 3 treatment periods
88972315|NCT00025038|Experimental|Treatment (tipifarnib, bone marrow/umbilical cord transplant)|See detailed description.
88972316|NCT05051891|Experimental|the experimental group|Orelabrutinib in Combinaion with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP)
88972317|NCT05051891|Experimental|The control group|R-CHOP
88972318|NCT05042414|Experimental|Breastmilk|Randomized intervention order.
88972319|NCT05006300|Experimental|Group 1|One application of Topialyse Baume Barrière per day
88972320|NCT05006300|Experimental|Group 2|Two applications of Topialyse Baume Barrière per day
88972321|NCT00025389|Experimental|Arm A|Bevacizumab (15mg/kg, q3wk x 2), Paclitaxel (200 mg/m2, q3wk x 2), carboplatin (AUC of 6, q3wk x 2), followed by surgery 4 to 6 weeks after last dose of Bevacizumab
88972322|NCT04994366||Intervention Group|The cohort receiving Thank you cards during their stay.
88972323|NCT04994366||Control Group|The cohort not receiving thank you cards during their stay.
88972324|NCT00025467|Experimental|Treatment (thalidomide)|Patients receive oral thalidomide once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88972325|NCT00025584|Experimental|Treatment (bortezomib)|Patients receive PS-341 IV over 3-5 seconds twice weekly on weeks 1 and 2. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
88972326|NCT04946318|Placebo Comparator|24-week Placebo|Participants who will enter the extension study after the last treatment visit (week 12) of the core study and will be treated with Placebo inhaled once daily for 24 weeks
88972327|NCT04946318|Placebo Comparator|12-week wash out + 12-week Placebo|"Participants who will enter the extension study after the last treatment visit (week 12) of the core study and will be treated with Placebo inhaled once daily for 12 weeks washout period and Placebo inhaled once daily for 12 weeks"
88972328|NCT04946318|Placebo Comparator|12-week Placebo|Participants who will enter the extension study after the last follow-up visit (week 24) of the core study will be treated with Placebo inhaled once daily for 12 weeks
89033259|NCT02917161|Experimental|Prostatic Artery Embolization (PAE)|PAE is performed 6weeks before RALP
89209368|NCT00883038|Experimental|Experimental|Low-fat vegetarian diet
89029318|NCT02598219|Experimental|Pre-operative SN mapping with radionucleide|"1 Pre-operative Sentinel Node (SN) mapping with Nanocis or Nanocoll or Rotop-nanoHSA~2- Intra-operative SN mapping with patent V blue dye, or Intra-operative SN mapping with indocyanin green for patients with known hypersensitivity, allergy to patent V blue dye~3- Full bilateral laparoscopic lymphadenectomy and Hysterectomy: If bilateral SN are detected, all positive SN are removed, then the surgeon proceeds to a total hysterectomy.~If unilateral SN are detected, surgeon will complete intervention with pelvic LN dissection on the opposite side, in accordance with risk group definition (ex: omentectomy for high-risk non endometrioid carcinomas).~If non SN are detected, surgeon will proceed to a total hysterectomy, a bilateral salpingo-oophorectomy, a complete and bilateral pelvic LND with more enlarged dissection regardless the pathology"
89029319|NCT02598219|Other|B : Current initial staging protocols|Current initial staging protocols
89578009|NCT04189653||General Ward Inpatients 2017-2018|ALL General Ward Inpatients on our Gastro-Enterology Surgery ward and Internal Medicine ward in the period august 1st 2017-august 31st 2018.
89578010|NCT04189653||General Ward Inpatients 2018-2019|ALL General Ward Inpatients on our Gastro-Enterology Surgery ward and Internal Medicine ward in the period august 1st 2018-august 31st 2019.
89578011|NCT02403271|Experimental|Phase 1b|In the Phase 1b (safety portion) of the study, a starting dose of 560 mg of ibrutinib and 10 mg/kg of MEDI4736 will be explored and will follow a 6+3 dose de-escalation design and will include a sentinel participant which will have a 3-day observation period prior to dosing of subsequent participants. Participants with one of the following three tumor types will be eligible for enrollment: NSCLC (adenocarcinoma and squamous-cell carcinoma), Breast cancer (triple-negative and HER2-positive cancer), and Pancreatic cancer (adenocarcinoma).
89578012|NCT02403271|Experimental|Phase 2|Participants with one of three solid tumor types (Stage III/IV) will be enrolled in the Phase 2 portion of this protocol: NSCLC (adenocarcinoma and squamous-cell carcinoma), Breast cancer (triple-negative and HER2-positive cancer), and Pancreatic cancer (adenocarcinoma) and treated at the R2PD of ibrutinib and durvalumab determined in Phase 1b. An interim analysis will be performed to evaluate the response and the safety profile, and the study may be discontinued based on the interim efficacy and/or safety results.
89578013|NCT02219685|Experimental|LDV/SOF|Participants will receive LDV/SOF FDC for 12 weeks.
89578014|NCT02219685|Placebo Comparator|Placebo|Participants will receive LDV/SOF placebo for 12 weeks.
89578015|NCT02219685|Experimental|Open-Label Treatment Phase|Following Posttreatment Week 4, participants in the placebo group will be offered open-label treatment with LDV/SOF FDC for 12 weeks.
89578016|NCT02457247|Experimental|Test Group 1: Sequence AB|Calcichew D3 500/400 (Calcium 500 mg/400 IU Vitamin D3) [A], chewable tablets, orally, twice, daily, on Days 1 through 14, followed by Adcal-D3 (Calcium 600 mg / 400 IU Vitamin D3) [B], chewable tablets, orally, twice, daily, on Days 15 through 28.
89578017|NCT02457247|Experimental|Test Group 1: Sequence BA|Adcal-D3 (Calcium 600 mg / 400 IU Vitamin D3), chewable tablets, orally, twice, daily, on Days 1 through 14, followed by, Calcichew D3 500/400 (Calcium 500 mg/400 IU Vitamin D3), chewable tablets, orally, twice, daily, on Days 15 through 28.
89578018|NCT02457247|Experimental|Test Group 2: Sequence CD|Calcichew D3 500/800 (Calcium 500 mg/800 IU Vitamin D3) [C], chewable tablets, orally, once, daily, on Days 1 through 14, followed by Kalcipos-D (Calcium 500 mg/800 IU Vitamin D3) [D], chewable tablets, orally, once, daily, on Days 15 through 28.
89029320|NCT02592824|Active Comparator|Intravenous glutamate infusion|Intravenous infusion of 0.125M L-glutamic acid solution at a rate of 1.65 ml/kg BW and hour commencing at or up to 20 minutes before the release of aortic cross-clamp. The infusion is continued for two hours after declamping the aorta after which an additional 50 ml is given at a halved infusion rate.
89029321|NCT02592824|Placebo Comparator|Intravenous saline infusion|Intravenous infusion of saline at a rate of 1.65 ml/kg BW and hour commencing at or up to 20 minutes before the release of aortic cross-clamp. The infusion is continued for two hours after declamping the aorta after which an additional 50 ml is given at a halved infusion rate.
89029322|NCT02551068|Experimental|60% Oxgyen|While participants are exercising, they will be breathing 60% oxygen through a mask.
89029323|NCT02551068|Placebo Comparator|Standard of Care|While participants are exercising, they will be breathing air through a mask that will be titrated to keep oxygen saturation at least 88%, allowing a maximum inhaled oxygen percentage of 40%.
89029324|NCT02519140|Experimental|Cook medical EMR Gel|"Prospective study involving excised human stomachs and colon harvested from sleeve gastrectomies and colectomies performed for benign or malignant disease.~Different Cook submucosal injections of varying viscosities will be injected into different areas of the excised stomachs or colons.~Data collected will involve lifting characteristics and dissection adequacy of the varying viscosities of gel."
89029325|NCT02414399|Experimental|Azithromycin|Azithromycin 10mg/kg for one day, then 5mg/kg for four days, a total of five days of experimental treatment.
89029326|NCT02414399|Placebo Comparator|Placebo|5 days of taste/appearance/bottle-matched placebo
89209369|NCT00883194|Experimental|1|PRF-108 Gel, 4% ropivacaine
89578019|NCT02457247|Experimental|Test Group 2: Sequence DC|Kalcipos-D (Calcium 500 mg/800 IU Vitamin D3), chewable tablets, orally, once, daily, on Days 1 through 14, followed by, Calcichew D3 500/800 (Calcium 500 mg/800 IU Vitamin D3), chewable tablets, orally, once, daily, on Days 15 through 28.
89578020|NCT04929535|Experimental|30% hydrogen peroxide|30% hydrogen peroxide liquid topical application. 2 drops (0.10 ml) of hydrogen peroxide solution per centimeter of lesion. Once every week for continuous 4 weeks. If there is complete clinical response, further hydrogen peroxide will not be done.
89578021|NCT04929535|Placebo Comparator|3% hydrogen peroxide|3% hydrogen peroxide liquid topical application. 2 drops (0.10 ml) of hydrogen peroxide solution per centimeter of lesion. Once every week for continuous 4 weeks. If there is complete clinical response, further hydrogen peroxide will not be done.
89029327|NCT02363374|Active Comparator|Arm A: Chemotherapy -> Chemoradiotherapy|Induction chemotherapy followed by chemoradiotherapy before surgery
89029328|NCT02363374|Experimental|Arm B: Chemoradiotherapy -> Chemotherapy|Combined chemoradiotherapy followed by three cycles chemotherapy before surgery
89029329|NCT02348112||Altis arm|Subjects will have an Altis sling placed to treat stress urinary incontinence.
89209370|NCT00883194|Placebo Comparator|2|PRF-108 Gel, Vehicle
89209371|NCT00883194|Active Comparator|3|Ropivacaine Solution 0.5%
89209372|NCT00883194|Experimental|PRF-110, 4%|PRF-110, 4% ropivacaine
89578022|NCT02402647|Experimental|CREST|"Compensatory Cognitive Training (CCT) is a manualized, low-tech, cognitive training intervention designed to target cognitive impairments common in people with psychiatric illness. The CCT modules specifically selected for CREST map onto known areas of HD neurocognitive deficits or weakness and include training in prospective memory, prioritizing, problem solving, planning, and cognitive flexibility.~Symptoms of acquiring and saving are themselves avoidance behaviors that are performed to avoid internal distress related to negative thoughts and emotions. Avoidance serves to reduce distress related to the beliefs regarding the necessity and utility of possessions. In the CREST condition, the second part and the majority of treatment is dedicated to exposure therapy (ET) for discarding and not acquiring while in the control condition, the entire treatment will consist of ET."
89578023|NCT02402647|Active Comparator|ET|The investigators propose to use a robust control condition, ET, with the same frequency and amount of therapist contact as CREST. Twenty-six weekly, individual ET sessions (6 months) will be delivered. The control group will receive ET for all 26 sessions and no cognitive training. As in CREST, the ET sessions will be manualized and copies utilized during session by both the patient and therapist.
89578024|NCT00752583|Experimental|1|Peritoneal dialysis
89578025|NCT00752583|Active Comparator|2|Haemodialysis
89578026|NCT02198235|Active Comparator|Control NB + IV Dex + IV Bup|IV Dexamethasone (4 mg) + IV Buprenorphine (150 mcg)
89578027|NCT02198235|Active Comparator|Control NB + IV Dex|IV Dexamethasone (4 mg)
89578028|NCT02198235|Experimental|NB with Dex + Bup in block.|Dexamethasone (4 mg) Buprenorphine (150 mcg)
89578029|NCT04917133|Experimental|Adapted Physical workshops|The experimental APA group will have in addition of the classic program, 6 APA workshops per week with collective care : Adapted Physical workshops, adapted cycling, therapeutic (horseback/equestrian) riding, cultural or leisure outings, situation tests
89578030|NCT04917133|Other|Control|"Standard of care The control group will have the classic program performed in the standard of care with : kinesitherapy, soft gym, medico-social workshop, cognitive workshop, creative workshop, individual care (rehabilitation, rest, creation)."
89578031|NCT04916431|Experimental|mRNA-6231 Dose Level 1|"In the single dose part of the study (Sentinel and Expansion Cohorts), each participant will receive 1 dose of Dose Level 1 of mRNA-6231 by subcutaneous injection on Day 1.~In the repeat dose part of the study (Sentinel and Expansion Cohorts), each participant will receive up to 3 doses of Dose Level 1 of mRNA-6231 once every 2 weeks."
89578032|NCT04916431|Experimental|mRNA-6231 Dose Level 2|"In the single dose part of the study (Sentinel and Expansion Cohorts), each participant will receive 1 dose of Dose Level 2 of mRNA-6231 by subcutaneous injection on Day 1.~In the repeat dose part of the study (Sentinel and Expansion Cohorts), each participant will receive up to 3 doses of Dose Level 2 of mRNA-6231 once every 2 weeks."
89578033|NCT04916431|Experimental|mRNA-6231 Dose Level 3|"In the single dose part of the study (Sentinel and Expansion Cohorts), each participant will receive 1 dose of Dose Level 3 of mRNA-6231 by subcutaneous injection on Day 1.~In the repeat dose part of the study (Sentinel and Expansion Cohorts), each participant will receive up to 3 doses of Dose Level 3 of mRNA-6231 once every 2 weeks."
89578034|NCT00346125|Active Comparator|Preferred Standard Regimen|Subjects with soft tissue sarcoma who are receiving pegylated liposomal doxorubicin hydrochloride, Ifosfamide with mesna and pegfilgrastim - Repeat every 28 days for 4 cycles total
89578035|NCT00346125|Active Comparator|Alternative Treatment Regimen|Subjects with soft tissue sarcoma who are receiving Doxorubicin hydrochloride, Ifosfamide with mesna and pegfilgrastim - Repeat every 28 days for 4 cycles total
89578036|NCT02253147|Experimental|Left side TEOSYAL® RHA Ultra Deep, Right side Perlane-L®|Split-face injection of TEOSYAL® RHA Ultra Deep into the left Naso Labial Folds (NLFs) and Perlane-L® into the right NLF (n=120). Up to 3.0 mL injected per NLF. Touch-up treatment provided at 2 weeks (up to 3.0 mL per NLF).
88972329|NCT04946318|Experimental|24-week CSJ117|Participants who will enter the extension study after the last treatment visit (week 12) of the core study and will be treated once daily for 24 weeks with the same dose of CSJ117 they received in the core study. CSJ117 (0.5 mg, 1 mg, 2 mg, 4 mg and 8 mg) inhaled once daily for 24 weeks.
88972330|NCT04946318|Experimental|12-week wash out + 12-week CSJ117|"Participants who will enter the extension study after the last treatment visit (week 12) of the core study and will be treated with Placebo inhaled once daily for 12 weeks washout period and then they will be treated once daily for 12 weeks with the same dose of CSJ117 they received in the core study. CSJ117 (0.5 mg, 1 mg, 2 mg, 4 mg and 8 mg) inhaled once daily for 12 weeks."
88972331|NCT04946318|Experimental|12-week CSJ117|Participants who will enter the extension study after the last follow-up visit (week 24) of the core study will be treated with once daily for 12 weeks with the same dose of CSJ117 they received in the core study. CSJ117 (0.5 mg, 1 mg, 2 mg, 4 mg and 8 mg) inhaled once daily for 24 weeks.
88972332|NCT04733820|Experimental|Adjuvant chemotherapy group|"Participant will receive at least 2 cycles of adjuvant chemotherapy. If having any of the following factors, participant will receive additional 2 cycles of adjuvant chemotherapy per risk factor. All patients received maximum 6 cycles of postoperative chemotherapy.~Risk factors: (1) Deep cervical invasion（≥ 2/3）；（2）Differentiation grade 2-3；（3）Lymphatic vascular space infiltration；（4）Adenocarcinoma or adenosquamous carcinoma；（5）Tumor size ≥ 4cm before surgery."
88972333|NCT04733820|No Intervention|Control group|The participants receive no intervention.
88972334|NCT00026091|Experimental|Treatment (fenretinide)|Patients receive oral fenretinide twice daily on days 1-7. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
89578037|NCT02253147|Experimental|Left side Perlane-L®, Right side TEOSYAL® RHA Ultra Deep|Split-face injection of Perlane-L® into the left Naso Labial Folds (NLFs) and TEOSYAL® RHA Ultra Deep into the right NLF (n=120). Up to 3.0 mL injected per NLF. Touch-up treatment provided at 2 weeks (up to 3.0 mL per NLF).
88972335|NCT04733651|Active Comparator|Control arm|In this arm subjects will receive the hospital COVID-19 standard care
88972336|NCT04733651|Experimental|Isoquercetin arm|In this arm subjects will receive the hospital COVID-19 standard care + Isoquercetin
88972337|NCT04733001|Experimental|HSG4112 Treatment Arm: Fasted|Single oral dosing of HSG4112 480 mg under fasted conditions
88972338|NCT04733001|Experimental|HSG4112 Treatment Arm: Low-Calorie Diet|Single oral dosing of HSG4112 480 mg under low-calorie (400-500 kcal with 100-125 kcal fat) diet conditions
88972339|NCT04733001|Experimental|HSG4112 Treatment Arm: High-Calorie Diet|Single oral dosing of HSG4112 480 mg under high-calorie (800-1000 kcal with 500-600 kcal fat) diet conditions
88972340|NCT00026130|Experimental|Gemcitabine + 5FU + XRT|Chemo and radiation therapy in the treatment of non-metastatic pancreatic cancer
88972341|NCT00026169|Experimental|Treatment (imatinib mesylate)|"Patients receive oral imatinib mesylate once or twice daily on days 1 and 4-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients in each stratum receive escalating doses of imatinib mesylate until the MTD is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
88972342|NCT00026247|Experimental|RFA as pain therapy|Changes in the severity of pain as measured using using the Memorial Pain Assessment Cards (MPAC) before and after RadioFrequency Ablation (RFA) will be statistically analyzed
88972343|NCT04808414|Experimental|QPX9003 for IV infusion|IV novel polymyxin antibiotic Single and Multiple IV doses x 7 days via IV infusion q6hrs
88972344|NCT04808414|Placebo Comparator|Placebo for Infusion|IV saline Single and Multiple IV doses x 7 days via IV infusion q6hrs
89578038|NCT02217501|Experimental|DAPT - clinically indicated duration+12m|Clopidogrel 75 mg daily and Acetylsalicylic acid (ASA) 75-100 mg daily for clinically indicated duration plus an additional 12 months
89578039|NCT02217501|Active Comparator|DAPT - clinically indicated duration|Clopidogrel 75 mg daily and Acetylsalicylic acid (ASA) 75-100 mg daily for clinically indicated duration with a minimum of 30 days
88972345|NCT00026364|Experimental|Arm I|"Patients receive oral ZD 1839 daily. Beginning on day 15, patients receive irinotecan IV over 90 minutes, leucovorin calcium IV over 15 minutes, and fluorouracil IV weekly on weeks 1-2. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of ZD 1839 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, 10 additional patients are accrued to receive treatment at the MTD."
88972346|NCT00026403|Experimental|radiotherapy + gemcitabine + cisplatin|"Patients undergo radiotherapy once daily five days a week for 5.5 weeks. Patients receive gemcitabine IV over 30 minutes followed by cisplatin IV over 1 hour twice a week for the first 3 weeks of radiotherapy. Beginning 4 weeks after the completion of radiotherapy, patients receive gemcitabine IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for a total of 3 courses in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed at baseline, at completion of radiotherapy, at completion of chemotherapy, and 3 months after completion of therapy.~Patients are followed every 3 months for 2 years and then every 6 months for 1 year."
88972347|NCT04704791|Experimental|Procedure arm|At the time of surgery a covered stent will be inserted through the atriotomy into the left pulmonary artery and balloon dilated to stabilize the device. The target shunt diameter will be 3.5-4 mm to minimize LAA stasis.
88972348|NCT04699487|Experimental|Patient receiving Photobiomodulation|
88972349|NCT00026637|Active Comparator|Sertraline|
88972350|NCT00026637|Active Comparator|CBT|
88972351|NCT04678115|Experimental|MLP first, KTFS second|Participants in this arm will receive the MLP in the first period of the crossover and the KTFS in the second period.
88972352|NCT04678115|Experimental|KTFS first, MLP second|Participants in this arm will receive the KTFS in the first period of the crossover and the MLP in the second period.
88972353|NCT04669067|Experimental|Phase 1b - Dose Level 1|KRT-232 240mg QD, orally administered on days 1 through 7 of each 28-day cycle in combination with TL-895 150mg BID continuously for each 28-day cycle.
88972354|NCT04669067|Experimental|Phase 1b - Dose Level 2|KRT-232 300mg QD, orally administered on days 1 through 7 of each 28-day cycle in combination with TL-895 150mg BID continuously for each 28-day cycle.
89578040|NCT01649869|Active Comparator|Active|27 Children between 1 month and 3 years of age (up to 4th birthday) with sensoneural hearing loss and documented CMV infection will receive valganciclovir HCl 16.0 mg/kg orally twice a day for 6 weeks
89578041|NCT01649869|Placebo Comparator|Placebo|27 Children between 1 month and 3 years of age (up to 4th birthday) with sensoneural hearing loss and documented CMV infection will receive placebo orally twice a day for 6 weeks
89578042|NCT02197377|Active Comparator|Group LMA Unique|The supraglottic airway devices were deflated fully before insertion. Size 4 LMA was used for those with a weight of 50-70 kg and size 5 LMA for those between 70-100 kg. After insertion, each device was inflated with a hand-held airway manometer (Rusch, Germany) to an intracuff pressure of 60 cm H2O.The oropharyngeal leak pressure was determined by transiently stopping ventilation and closing the adjustable pressure-limiting valve with a fresh gas flow of 3 L/min until airway pressure reached a steady state and a voice of leakage was heard. The airway pressure was not allowed to exceed 40 cm H2O.
89578043|NCT02197377|Experimental|Group LMA Supreme|The supraglottic airway devices were deflated fully before insertion. Size 4 LMA was used for those with a weight of 50-70 kg and size 5 LMA for those between 70-100 kg. After insertion, each device was inflated with a hand-held airway manometer (Rusch, Germany) to an intracuff pressure of 60 cm H2O.The oropharyngeal leak pressure was determined by transiently stopping ventilation and closing the adjustable pressure-limiting valve with a fresh gas flow of 3 L/min until airway pressure reached a steady state and a voice of leakage was heard. The airway pressure was not allowed to exceed 40 cm H2O.
89578044|NCT02400307|Experimental|Severe Renal Impairment|Participants with severe renal impairment and matched healthy controls will receive a single dose of bictegravir.
89578045|NCT02400307|Experimental|Moderate Renal Impairment|Participants with moderate renal impairment and matched healthy controls will receive a single dose of bictegravir.
89578046|NCT02400307|Experimental|Mild Renal Impairment|Participants with mild renal impairment and matched healthy controls will receive a single dose of bictegravir.
89578047|NCT02196675||VATS wedge resection or lobectomy|Single arm study Intervention: Device: Endocutter
89578048|NCT02399449|Experimental|Brand sodium ferric gluconate then Generic sodium ferric gluconate|Crossover trial. Each arm will receive Brand sodium ferric gluconate (single dose of 125mg) then Generic sodium ferric gluconate (single dose of 125mg)
89578049|NCT02399449|Experimental|Generic sodium ferric gluconate then Brand sodium ferric gluconate|Crossover trial. Each arm will receive Generic sodium ferric gluconate (single dose of 125mg) then Brand sodium ferric gluconate (single dose of 125mg)
89578050|NCT02217345|Experimental|Growth hormone|Growth hormone (somatropin) administered by daily injection at starting dose of 0.3 mg daily for women and 0.2 mg daily for men, with dose titration for goal IGF-1 in the upper quartile of normal for age.
89578051|NCT02217345|Placebo Comparator|Placebo|Placebo will be administered by daily injection in this double blind study design. Sham dosing will be performed to maintain blinding.
89578052|NCT02251743|Experimental|Neurofeedback treatment|The intended treatment is downtraining of theta power and uptraining of beta power for 38 treatments of active NF.
89578053|NCT02251743|Placebo Comparator|Sham neurofeedback treatment|"Participants assigned to sham and their trainers will be fed EEG data from pre-recorded files (recorded during live clinical NF) rather than from the participant's live signal. In order to prevent unblinding of experienced NF trainers/technicians, artifacts from the participant's EMG and EOG are blended into the pre-recorded EEG so that the trainer controlling the feedback cannot differentiate between live and simulated data. To insure trainer/technician blindness, the pre-recorded EEG will be 38 consecutive EEGs from the same age-matched clinical case so that EEGs of the sham group will also show training progress over successive sessions, like real NF."
89578054|NCT04189575|Experimental|SMS Intervention|All subjects will receive customized text messages twice a day, every day for 9 months that will include reminders to adhere to the individualized medication regimen, reminders to call their clinician for a prescription refill followed by reminders to pick up medication from the pharmacy, and educational reminders about ADHD and its treatment.
89578055|NCT02428855|Experimental|Dasatinib|"Patients with advanced intrahepatic cholangiocarcinoma who have either IDH1 or IDH2 mutations and have received at least one prior platinum containing regimen~Dasatinib, oral, daily, predetermined dosage per cycle~Radiologic Response Assessment every 2 cycles"
89578056|NCT02428699|Experimental|Test|30mL Test contains 10%w/w cod oil + 10%w/w cod liver oil in an emulsion formulation
89578057|NCT02428699|Active Comparator|Control|5.8mL of cod liver oil in a free flowing non-emulsified formulation
89578058|NCT02428231|Active Comparator|Standard Treatment (One-Week Titration)|120 mg DMF twice daily for 1 week, then 240 mg (as 2 120-mg capsules) DMF twice daily for 11 weeks
88972355|NCT04669067|Experimental|Phase 1b - Dose Level 3|"Cycle 1 only: KRT-232 360 mg QD orally administered on Days 1 through 7 of the first 28-day cycle in combination with TL-895 150 mg BID continuously for the first 28-day cycle~Cycle 2 and beyond: KRT-232 300 mg QD orally administered on Days 1 through 7 of each 28-day cycle in combination with TL-895 150 mg BID continuously for each 28-day cycle."
88972356|NCT04669067|Experimental|Phase 1b - Dose Level 4|"Cycle 1 only: KRT-232 360 mg QD orally administered on Days 1 through 7 of the first 28-day cycle in combination with TL-895 300 mg BID continuously for the first 28-day cycle.~Cycle 2 and beyond: KRT-232 300 mg QD orally administered on Days 1 through 7 of each 28-day cycle in combination with TL-895 300 mg BID continuously for each 28-day cycle."
88972357|NCT04669067|Experimental|Phase 1b - Dose Level 5|"Cycle 1 only: KRT-232 360 mg QD orally administered on Days 1 through 7 of the first 28-day cycle in combination with TL-895 450 mg BID continuously for the first 28-day cycle.~Cycle 2 and beyond: KRT-232 300 mg QD orally administered on Days 1 through 7 of each 28-day cycle in combination with TL-895 450 mg BID continuously for each 28-day cycle."
88972358|NCT04669067|Experimental|Phase 2 - Dose Expansion|Dose expansion of the recommended phase 2 dose of TL-895 in combination with KRT-232 as determined in Phase 1b.
88972359|NCT04611230||Adult Volunteers (Low Risk Group)|Volunteers with jobs that do not require close contact with (i.e., within 6 feet of) the general public or co-workers.
88972360|NCT04611230||Adult Volunteers (Medium - Low Risk Group)|Volunteers with jobs that require in-frequent contact with (i.e., within 6 feet of) the general public or co-workers.
88972361|NCT04611230||Adult Volunteers (Medium - High Risk Group)|Volunteers with jobs that require frequent contact with (i.e., within 6 feet of) the general public or co-workers.
88972362|NCT04611230||Adult Volunteers (High Risk Group)|Volunteers with jobs that require frequent and/or close contact with (i.e., within 6 feet of) individuals with high potential for exposure to known or suspected sources of COVID-19.
89578059|NCT02428231|Experimental|Slow Up-Titration (Six-Week Titration)|120 mg DMF once daily (morning dose) and placebo once daily (evening dose) for 2 weeks, then 120 mg DMF twice daily for 2 weeks, then 240 mg (as 2 120-mg capsules) DMF in the morning and 120 mg in the evening for 2 weeks, then 240 mg (as 2 120-mg capsules) DMF twice daily for 6 weeks
89578060|NCT02397889|Experimental|Experimental ketamine group|This arm will receive 0.5mg/kg repeated dose ketamine (6 infusions, 3 per week for 2 weeks).
89578061|NCT02397889|Active Comparator|Active control midazolam group|This arm will receive 0.045mg/kg repeated dose midazolam (6 infusions, 3 per week for 2 weeks).
89578062|NCT02396953|Experimental|lanreotide PRF|One single dose of lanreotide PRF (via subcutaneous injection) either 180mg or 270mg or 360mg.
89578063|NCT04905589|Placebo Comparator|ARM A|"Subsequent order of intake :~Iso-voluminous water, breakfast, iso-voluminous water, lunch, iso-voluminous water, dinner"
89578064|NCT04905589|Active Comparator|ARM B|"Subsequent order of intake :~MCT in liquid form (75 ml of BetaQuik™), breakfast, iso-voluminous water, lunch, iso-voluminous water, dinner"
89578065|NCT04905589|Active Comparator|ARM C|"Subsequent order of intake:~MCT in liquid form (75 ml of BetaQuik™), breakfast, WPI in liquid from (12.5g of WheyBasics in 200ml water), lunch, WPI in liquid from (12.5g of WheyBasics in 200ml water)), dinner"
89578066|NCT02387983|Experimental|Posaconazole|Posaconazole 300 mg tablet (3 x 100 mg tablets) once every 12 hours on Day 1 and once-daily on Days 2 to 28
88972363|NCT00027066|Active Comparator|Active Warfarin and Aspirin Placebo|One 2 mg scored tablet daily of Warfarin and one 325 mg tablet daily of aspirin placebo.
88972364|NCT00027066|Active Comparator|Active Aspirin and Warfarin Placebo|One 325 mg tablet daily of aspirin and one 2 mg scored tablet daily of Warfarin placebo.
88972365|NCT04733261|Active Comparator|Diaphragmatic mobility|The patient will be in supine, supported on one/two pillows under her head, and a bolster under her knees.
88972366|NCT04733261|Experimental|Chest Physiotherapy|Give passive ROM exercise to all joints of the upper and lower extremities.
88972367|NCT04567940|Experimental|Intervention group|Behavioural multicomponent intervention
88972368|NCT04567940|No Intervention|Control group|Usual care
88972369|NCT04473950|Experimental|Pain Group|Patients with chronic pain who are maintained on methadone for opioid use disorder
89578067|NCT02395627|Experimental|Pembrolizumab Cycle 1 (Group A)|Tamoxifen: 20 mg daily orally (starting at Cycle 1) Vorinostat: 400 mg 5 days every 7 orally (starting at Cycle 1) Pembrolizumab: 200 mg every 3 weeks intravenously (starting at Cycle 1)
89578068|NCT02395627|Experimental|Pembrolizumab Cycle 2 (Group B)|Tamoxifen: 20 mg daily orally (starting at Cycle 1) Vorinostat: 400 mg 5 days every 7 orally (starting at Cycle 1) Pembrolizumab: 200 mg every 3 weeks intravenously (starting at Cycle 2)
89578069|NCT02395627|Experimental|Pembrolizumab Cycle 1 (Group C)|Vorinostat: 400 mg 5 days every 7 orally (starting at Cycle 1) Pembrolizumab: 200 mg every 3 weeks intravenously (starting at Cycle 1)
89578070|NCT02395471|Experimental|Patient wth Barrett's|Subjects presenting for routine endoscopic BE surveillance examinations
89578071|NCT02395471|Experimental|Patients with GERD|Subjects with gastroesophageal reflux disease (GERD) symptoms undergoing upper endoscopy for screening for BE
89578072|NCT02395081|Placebo Comparator|600 IU|Women will receive prenatal vitamins containing 600 IU of Vitamin D.
89578073|NCT02395081|Experimental|2000 IU|Women will receive prenatal vitamins containing 2000 IU of Vitamin D.
89578074|NCT02395081|Experimental|4000 IU|Women will receive prenatal vitamins containing 4000 IU of Vitamin D.
88972370|NCT04473950|Placebo Comparator|No Pain Group|Patients who are maintained on methadone for opioid use disorder but who do not have chronic pain.
88972371|NCT00027300|Experimental|Group 1|Natalizumab 300 mg, IV
88972372|NCT00027300|Placebo Comparator|Group 2|Placebo IV infusion
88972373|NCT00395382|Active Comparator|1|Alendronate
88972374|NCT00395382|Placebo Comparator|2|Placebo
88972375|NCT04227353|Experimental|HEAL ABC|Participants allocated to the intervention will be encouraged to follow the HEAL ABC resources in order to make a healthy eating and active lifestyle change. This will be achieved by setting specific goal(s) and by making concrete plan(s) to implement changes in their everyday life. Interventions will be delivered in the form of written resources that will guide participants. Supportive phone calls using motivational interviewing techniques will be provided to participants every two weeks to encourage lifestyle changes.
88972376|NCT04227353|No Intervention|HEALTH|Participants allocated to the control group will be referred to publicly available resources on healthy lifestyle recommendations but will not receive any additional support.
88972377|NCT04206488|Experimental|JNJ-70033093 + Digoxin|Participants will receive JNJ-70033093 as oral capsules (Treatment A) in Period 1, followed by digoxin tablets as loading dose and maintenance doses (Treatment B) in Period 2, and then digoxin tablets along with JNJ-70033093 (Treatment C) in Period 3. There will be a washout period of minimum 5 days (and maximum 7 days) between the last dosing day of Period 1 and the first dosing day of Period 2. There is no washout between Periods 2 and 3 (that is, the last day of Treatment B is to be followed by the first day of Treatment C).
88972378|NCT00027417|Active Comparator|Liothyronine Sodium/Triiodothyronine|bolus administration of Liothyronine Sodium/Triiodothyronine (Triostat) immediately prior to CPB institution and after removal of aortic cross clamp, followed by repeated boluses, will be safe and will result in significant improvements in postoperative and clinical outcome parameters and cardiac contractile function.
89578075|NCT02394925|Experimental|Multifocal Test Contact Lens|Subjects will wear the test lenses at least six hours per day, at least five days per week
88972379|NCT00027417|Placebo Comparator|Placebo|bolus administration of Placebo immediately prior to CPB institution and after removal of aortic cross clamp, followed by repeated boluses
88972380|NCT04197011||Prosthesis users|Individuals with unilateral transfemoral amputation.
88972381|NCT04197011||Control|Individuals without unilateral transfemoral amputation.
88972382|NCT04163003|Experimental|TAPAS|Participants will participate in the TAPAS intervention, which will consist of one in-person engagement session with a therapist and 8 weeks of web-based automated intervention prompts. The program will utilize empirically supported approaches for promoting sleep health, delivered in-person and via text-message, focusing on: tailored psychoeducation, motivation and efficacy to change sleep, extending sleep duration, and regularizing sleep timing across the week.
88972383|NCT04163003|Experimental|Sleep monitoring only, then TAPAS|Participants will participate in sleep monitoring only first, then participate in the TAPAS intervention. First, participants will monitor sleep with sleep diary, but they will not receive feedback or any other information on to sleep.TAPAS will consist of one engagement session with a therapist and 4 weeks of web-based automated intervention prompts. The program will utilize empirically supported approaches for promoting sleep health, delivered in-person and via text-message, focusing on: tailored psychoeducation, motivation and efficacy to change sleep, extending sleep duration, and regularizing sleep timing across the week. Sleep monitoring is proposed to last the same duration as the targeted intervention in this arm.
88972384|NCT00027534|Experimental|TRICOM-CEA(6D)|Subjects receiving TRICOM-CEA(6D)
89029330|NCT02348112||Comparator arm|Subjects will have a transobturator or retropubic sling placed to treat stress urinary incontinence.
89029331|NCT02317328||Affected participants|Participants with ocular conditions
89029332|NCT02317328||Healthy Volunteers|Healthy volunteers
89209373|NCT04038528||Telemedicine Group|Patients in this group monitor blood sugar levels at home and upload their data through a telemedicine systems.
89578076|NCT02427607|Experimental|Perampanel|Participants started the study with the dose that they were receiving at the end of their participation in the previously participated Study E2007-G000-332 (Study 332) [NCT02307578]. Doses of perampanel were allowed to be adjusted based on clinical judgment. A minimum perampanel dose of 2 milligram (mg) per day was required to continue in the study. The maximum daily dose of perampanel permitted was 12 mg per day.
89578077|NCT02425111|Experimental|Vedolizumab 300 mg|Part A: Vedolizumab 300 mg, intravenously (IV), once on Day 1 and Weeks 2, 6, 14 and 22, followed by Part B: Vedolizumab 300 mg, intravenously (IV), once at Weeks 30, 38, and 46.
89578078|NCT04916119|Experimental|IBI323|Phase Ia enrolls patients with advanced malignancies. Phase Ib cohort A enrolls patients with NSCLC(IO-refractory), cohort B NSCLC(IO-naive), cohort C NSCLC(PD-L1 TPS≥1%), cohort D ES-SCLC or neuroendocrine tumors, cohort E MPM, cohort F UC, cohort G nccRCC, cohort H HCC, cohort I NPC, cohort J CC or HNSCC, cohort K GC or GEJC with HER2 negative, cohort L TNBC
89209374|NCT04038528||Control Group|The control group will attend their routine appointments scheduled by their GPs and specialists in outpatient clinics and will record blood sugar levels according to the traditional method as per GP or specialist physician's indications.
88972385|NCT00027573|Experimental|Chemotherapy + stem cell transplantation|"Patients receive fludarabine IV over 30 minutes on days -7 to -3 and cyclophosphamide IV over 1-2 hours on days -4 and -3. Allogeneic peripheral blood stem cells are infused on day 0. Patients then receive filgrastim (G-CSF) subcutaneously daily beginning on day 5 and continuing until blood counts recover.~Patients receive graft-versus-host disease (GVHD) prophylaxis comprising oral tacrolimus twice daily on days -1 to 90 and methotrexate IV on days 1, 3, and 6.~After day 120, patients with persistent disease and no signs of active GVHD may receive donor lymphocyte infusion (DLI). DLI may be repeated every 8 weeks for a total of 2 infusions.~Patients are followed every 2 months for 1 year and then every 6 months for 4 years OR every 2 months for 6 months and then every 6 months for 4.5 years if patient receives DLI."
88972386|NCT00027612|Experimental|irinotecan + carmustine and radiation|"Phase II (patients receiving concurrent EIACs or non-EIACs open to accrual as of 3/5/2005): Patients receive irinotecan at the recommended dose, carmustine, and cranial irradiation as in phase I.~Patients with disease progression are followed every 3 months for 5 years and then annually for up to 10 years.~Patients taken off study for reasons other than disease progression are followed every 3 months for 1 year, every 6 months for 4 years, and then annually for 5 years."
88972387|NCT00027690|Experimental|Treatment (gefitinib)|Patients receive oral gefitinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89578079|NCT02424565|Experimental|Test|2 ± 0.2 g of product will be gently rubbed for 15 seconds on the affected knee joint.
89578080|NCT02424565|Placebo Comparator|Placebo|2 ± 0.2 g of product will be gently rubbed for 15 seconds on the affected knee joint.
89578081|NCT02424253|Experimental|ZPL-3893787|30 mg ZPL-3893787 orally once daily for 8 weeks.
89578082|NCT02424253|Placebo Comparator|Placebo|1 capsule orally once daily for 8 weeks.
89578083|NCT02393755|Experimental|Treatment (capecitabine, nintedanib)|Patients received capecitabine PO BID (every 12 hours) on days 1-14 and nintedanib PO BID (every 12 hours) on days 1-21. Courses repeated every 21 days in the absence of disease progression or unacceptable toxicity.
89578084|NCT02393755|Experimental|Treatment (capecitabine , nintendanib)|Patients receive the highest safe dose of the combination of nintedanib and capcitabine.
89578085|NCT05454319|Experimental|Biofeedback Treatment Group|Medical device
89578086|NCT02393209|Experimental|TAK-117 200 mg + Docetaxel (36 mg/m^2)|TAK-117 200 mg, tablets, orally on Days 2, 3, 4, 9, 10, 11, 16, 17, and 18 of the 21-day cycle and docetaxel 36 mg/m^2, intravenous (IV) infusion, on Days 1 and 8 of the 21-day cycle up ro Cycle 9 (approximately 189 days).
89578087|NCT02393209|Experimental|TAK-117 300 mg + Docetaxel 36 mg/m^2|TAK-117 200 mg, tablets, orally on Days 2, 3, 4, 9, 10, 11, 16, 17, and 18 of the 21-day cycle and docetaxel 36 mg/m^2, IV infusion, on Days 1 and 8 of the 21-day cycle up to 6 cycles (approximately 126 days).
89578088|NCT02393209|Experimental|Phase 2 - TAK-117 + Docetaxel 36 mg/m^2|TAK-117 tablets, at the dose determined in the dose escalation phase, on Days 2, 3, 4, 9, 10, 11, 16, 17, and 18 of a 21-day cycle plus Docetaxel 36 mg/m^2 IV infusion on Days 1 and 8 of a 21-day cycle.
89578089|NCT02393209|Experimental|Phase 2 - Docetaxel 75 mg/m^2|Docetaxel 75 mg/m^2, IV infusion once every 3 weeks (per approved prescribing information) with dosing on Day 1 of each 21-day cycle.
89578090|NCT02424097|Experimental|MI Paste & MI Varnish|MI past will be applied by the patient every night; MI varnish will be applied every three months in the office
89578091|NCT02424097|Active Comparator|Standard of Care|Subjects will use at home regal toothpaste every night and F-mouth rinse as recommended
89578092|NCT02392507|Experimental|Necitumumab + Nab-Paclitaxel + Carboplatin|"Induction: Necitumumab administered intravenously (IV) at 800 milligram (mg) on day 1 and 8 of each cycle (3 week cycles); nab-paclitaxel administered IV at 100 milligram per square meter (mg/m²) on day 1, 8 and 15 of each cycle; carboplatin administered IV at a concentration of AUC (area under curve) 6 milligram per milliliter over time (mg*min/mL) on day 1 of each cycle, for a maximum of 4 cycles.~Maintenance: Necitumumab administered IV at 800 mg on day 1 and 8 of each cycle; nab-paclitaxel administered IV at 100mg/m² on day 1 and 8 of each cycle (3 week cycles).~Participants may continue to receive treatment until discontinuation criteria are met."
89578093|NCT04904341|Experimental|active|The first Cerebrolysin infusion (30 ml mixed with 250 mL of saline) is intended to be initiated as soon as possible after successful recanalization is achieved and within 8h of AIS stroke onset. Cerebrolysin treatment will be continued (30 ml/d) once daily until day 21 (first cycle). The patients will receive a second cycle of treatment (30 ml/d for 21 days given in the Outpatient Department or Neurorehabilitation Clinic) from day 69 to 90 (± 3 days).
89578094|NCT04904341|No Intervention|historical control|Historical data will be obtained by retrospective clinical chart reviews of patients hospitalized in the study center between 2017 and Dec.2020 and fulfilling the same clinical and radiological inclusion criteria in whom 12-month follow-up (including mRS, NIHSS, BI, EQ-5D-5L) could be obtained.
89578095|NCT01651117|No Intervention|Usual Care|Enrolled in two different time frames. No interventions will be provided to this arm. They will complete planned surveys, and blood draws (baseline, 6 months, and 12 months).
89578096|NCT01651117|Experimental|Peer Mentoring|Participants in this arm will be mentored for 6 months by a veteran who was once in poor control but is now in good control. They will then be further randomized to either becoming a mentor for 6 months or having no other additional active intervention. All participants in this arm will be evaluated in person at baseline, 6 months, 12 months, and 18 months.
89578097|NCT01651117|Experimental|Peer Mentoring FFM (from former mentee)|Participants in this arm will be mentored by the former mentee for 6 months and will be followed in person for an additional 6 months after the completion of the active intervention.
89578098|NCT02386189|No Intervention|Usual Care|Veterans randomized to usual care will not receive any training on using their patient portal(s) to access and share information. They will be contacted via phone and/or secure messaging to remind him/her to take the VA or non-VA provider packet to their appointment. At the conclusion of the study, Veterans assigned to usual care will be provided the training information on the VA health summary for their own reference.
89578099|NCT02386189|Active Comparator|Care Coordination|Veterans in this group will share a comprehensive list of all of their providers (VA and non-VA) at future appointments. He/she will also be trained on how to create a VA Health Summary in My HealtheVet to share with their non-VA providers and how to use their community portals (if available) to share information back to VA providers. A VA and non-VA provider visit will be evaluated.
89578100|NCT02385799|Placebo Comparator|Sertraline Liquid Placebo|The placebo will be dosed in an age depended manner. Participants aged 2-3 years of age will be given 2.5 mg of liquid placebo once per day for a period of six months. Participants aged 4 years to 6 years will be given 5 mg of liquid placebo once per day for a period of six months.
89578101|NCT02385799|Active Comparator|Sertraline Active Medication|Liquid sertraline (20 mg/cc) will be dosed in an age depended manner. Participants aged 2-3 years of age will be given 2.5 mg of liquid sertraline once per day for a period of six months. Participants aged 4 years to 6 years will be given 5 mg of liquid sertraline once per day for a period of six months.
89578102|NCT02422303|Active Comparator|Ketamine Group|This group will receive ketamine 0.5mg/kg IV at induction of general anesthesia.
89578103|NCT02422303|No Intervention|No ketamine group|This group will not receive ketamine at induction of general anesthesia.
88972388|NCT04110626||Expériences Animées Programme|The Expériences Animées programme involves supervised short movies and talks with secondary school and high school pupils about the use of psychoactive substances.
88972389|NCT00027807|Experimental|Aldesleukin, Sargramostim & therapeutic autologous lymphocytes|Peripheral blood mononuclear cells (PBMC) for the generation of ATC will be collected using 1 or 2 phereses to obtain 8-20 × 109 PBMC for T cell expansion. The PBMC will be activated with OKT3 and expanded in IL-2 to generate from 20-320 ×109 ATC during a maximum of 14 days of culture. Three patients will be treated at each dose level. The dose levels for each infusion are: 5, 10, 20, and 40 billion. Each patient will receive a total of 8 doses of armed ATC given twice weekly for 4 weeks. If the patients encounter toxicities related to armed ATC, the dose and administration will be modified as delineated per the protocol. The patients will also receive subcutaneous injections of IL-2 (3.0 × 105 IU/m2/day) starting 3 days before the 1st armed ATC infusion and ending 7 days after the last armed ATC infusion. GM-CSF (250μg/m2 twice per week) will given subcutaneously to start 3 days before the 1st armed ATC infusion and ending 7 days after the last dose of armed ATC.
88972390|NCT00027885|Active Comparator|Docetaxel|Patients receive docetaxel IV over 1 hour once weekly on weeks 1-6.
88972391|NCT00027885|Experimental|Combine bevacizumab and docetaxel.|Patients receive docetaxel IV over 1 hour once weekly on weeks 1-6 and bevacizumab IV over 60 minutes once every 2 weeks on weeks 1-8.
88972392|NCT04022876|Experimental|Part 2 NSCLC: ALRN-6924+Carboplatin+Pemetrexed|
88972393|NCT04022876|Experimental|Part 2 NSCLC: Placebo+Carboplatin+Pemetrexed|
88972394|NCT04022876|Experimental|Part 1 SCLC: ALRN-6924+Topotecan|
88972395|NCT00027963|Experimental|gabapentin|"Patients receive titrating doses of oral gabapentin twice daily and then three times daily for 3 weeks. Patients then receive a fixed dose of oral gabapentin three times daily for 3 weeks. Patients cross-over to therapy as in arm II at week 8.~Quality of life is assessed at baseline and then at the end of weeks 6, 8, and 14."
88972396|NCT00027963|Placebo Comparator|placebo|"Patients receive titrating doses of oral placebo and then a fixed dose of oral placebo as in arm I. Patients cross-over to therapy as in arm I at week 8.~Quality of life is assessed at baseline and then at the end of weeks 6, 8, and 14."
88972397|NCT04001114|Other|Smokers with schizophrenia|This is a diagnostic group, defined independently from this study.
88972398|NCT04001114|Other|Smokers without schizophrenia|This is a diagnostic group (i.e., no diagnosis of schizophrenia), defined independently from this study.
88972399|NCT03999476|Experimental|ambu scope|intubation of cancer tongue patients with ambu scope device
88972400|NCT03999476|Active Comparator|fiberoptic|intubation of cancer tongue patients with fiberoptic device
88972401|NCT00395421|Experimental|A|NM283(200 mg QD)plus Peg-IFNα-2a (180 µg QW)
88972402|NCT02972099|Experimental|TcPRF Group|"According to the standard application of the device, for the PRF procedure one 5 x 13 cm skin electrode will be placed over the forehead, the other one over the posterior aspect of the neck. PRF with a duty load of 14.8 msec/sec and an average pulse frequency of 5.11 Hz will be applied for 25min. The voltage will be set to generate a current of 1 A.~Voltage and impedance will be monitored continuously during treatment and if necessary the voltage will be corrected to ensure the proper current."
88972403|NCT02972099|Placebo Comparator|Placebo Group|The setup will be made as for active treatment but no current will be delivered. The patients will not be able to feel any difference to the real treatment.
88972404|NCT03960125|Experimental|4% Imipramine Cream on Upper Forearm Site|Base cream will be applied to the lower forearm site.
88972405|NCT03960125|Experimental|4% Imipramine Cream on Lower Forearm Site|Base cream will be applied to the upper forearm site.
88972406|NCT00392561|Experimental|1|Selenium
89578104|NCT02392195||Single arm; Non-interventional|A convenience sample of 10-15 infants born at term gestation, that are </= 6 months of age with significant DP (defined as head flattening requiring helmet therapy) and no major health issues will be recruited into this phase 1 descriptive pilot study
88972407|NCT00392561|Experimental|2|Vitamin E
88972408|NCT00392561|Experimental|3|Vitamin E + Selenium
88972409|NCT00392561|No Intervention|Arm 4|
88972410|NCT03960086|Experimental|Custom-made foot orthoses|"Children in the experimental group received as treatment intervention custom-made polypropylene foot orthoses (Podoactiva®, Spain). They were advised pragmatically to wear the orthoses at least 8 to 10 hours per day for the daily life and during sport activity.~Treatment period of 12 weeks"
88972411|NCT03960086|Active Comparator|Heel Lifts|"Children in the experimental group received as treatment intervention custom-made polypropylene foot orthoses (Podoactiva®, Spain). They were advised pragmatically to wear the orthoses at least 8 to 10 hours per day for the daily life and during sport activity.~Treatment period of 12 weeks"
88972412|NCT03960047|Experimental|Intervention: Virtual Reality Training|Uses virtual reality to train children to cross streets
88972413|NCT03960047|Experimental|Intervention: Streetside Training|Train children to cross streets using real traffic in curbside locations
88972414|NCT03960047|No Intervention|Control|Receives no intervention
88972415|NCT03959969|Experimental|Educational Video Recipients|Participants will be shown educational video on pain management after cesarean delivery on day of discharge. Upon discharge, participants will be given twenty tablets of oxycodone 5 mg by mouth every four hours as needed for pain and forty tablets of ibuprofen 600 mg by mouth every six hours as needed for pain.
89578105|NCT02391961|Experimental|dalfampridine|10-week randomized, placebo controlled, double-blind, crossover trial, which includes a period of wash out of two weeks between treatment with dalfampridine and placebo. Within the trial, each patient serves as his own control.
89578106|NCT02391961|Placebo Comparator|placebo|10-week randomized, placebo controlled, double-blind, crossover trial, which includes a period of wash out of two weeks between treatment with dalfampridine and placebo. Within the trial, each patient serves as his own control.
89578107|NCT02384941|Placebo Comparator|Placebo|Two placebo-matching sotagliflozin tables, orally for 24 weeks followed by a 28 week extension period.
89578108|NCT02384941|Experimental|Sotagliflozin 200 milligrams (mg)|Sotagliflozin 200 mg (one 200 mg tablet and one placebo tablet), orally, for 24 weeks followed by a 28 week extension period.
89578109|NCT02384941|Experimental|Sotagliflozin 400 mg|Sotagliflozin 400 mg (two 200 mg tablets), orally, for 24 weeks followed by a 28 week extension period.
89578110|NCT02384551|Active Comparator|HTHS|High total carbohydrate with high total simple carbohydrate diet
89578111|NCT02384551|Experimental|HTLS|High total carbohydrate with low total simple carbohydrate diet
89578112|NCT02384551|Experimental|LTHS|Low total carbohydrate with low total simple carbohydrate diet
89578113|NCT02384551|Experimental|LTLS|Low total carbohydrate with low total simple carbohydrate diet
89578114|NCT02384395|Experimental|DTG/3TC/ABC FDC|Dolutegravir (DTG 50 mg), abacavir sulfate (ABC 600 mg) and lamivudine (3TC 300 mg) formulated in a single tablet fixed dose combination (FDC) (DTG/ABC/3TC, GSK2619619), administered orally, once daily
89578115|NCT02420353|Active Comparator|Somatropin|Somatropin of rDNA origin
89578116|NCT02420353|Placebo Comparator|Placebo|A placebo vehicle that contains somatropin diluent but no active hormone.
89578117|NCT02391337|Active Comparator|Beta-blocker|In Group B, oral bisoprolol will be commenced at either 1.25mg, 2.5mg or 5mg according to the treatment schedule and uptitrated, as required, to 15mg daily. Recommended additional therapy in this arm includes diltiazem. Use of digoxin is explicitly discouraged but will not terminate participation in the study. If intolerance to bisoprolol occurs, investigators will be advised to try an alternate beta-blocker of their choosing (typically carvedilol, nebivolol, or metoprolol) at equivalent dosage.
89578118|NCT02391337|Active Comparator|Digoxin|In Group A, the maintenance dose of oral digoxin will be either 62.5mcg or 125mcg according to the pre-defined treatment schedule and uptitrated, as required, to 250mcg daily. A single loading dose of four tablets (250 or 500mcg according to target maintenance dose) will be prescribed in digoxin-naïve participants, where necessary. Recommended additional therapy in this arm includes the calcium-channel blocker diltiazem. Use of beta-blockers is explicitly discouraged but will not terminate participation in the study.
89578119|NCT02382991|Other|NMPK-3C60|D0 + 30 days: evaluation with the non-microprocessor knee. D1 + 90 days: evaluation with the 3C60 knee.
89578120|NCT02382991|Other|3C60-NMPK|"D0 + 90 days: evaluation with the 3C60 knee. A period of 10 days of wash out. D1 + 30 days: evaluation with the non-microprocessor knee."
88972416|NCT03959969|Active Comparator|Standard of Care Recipients|Participants will be given standard of care discharge instructions for pain management on day of discharge. Upon discharge, participants will be given twenty tablets of oxycodone 5 mg by mouth every four hours as needed for pain and forty tablets of ibuprofen 600 mg by mouth every six hours as needed for pain.
88972417|NCT03959852|Active Comparator|Sub-Dissociative Ketamine alone|0.3 mg/kg of Sub-Dissociative Ketamine IV administered over at least 1 minute
88972418|NCT03959852|Active Comparator|Fentanyl alone|1 mg/kg of Fentanyl IV administered over at least 1 minute
88972419|NCT03959852|Experimental|Sub-dissociative Ketamine and Fentanyl|Combined dose of 0.15 mg/kg of Sub-dissociative Ketamine and 0.5 mg/kg of Fentanyl IV administered over at least 1 minute
88972420|NCT03959774|Experimental|breast or colorectal or lung cancer, age 70 or older|breast or colorectal or lung cancer, age 70 or older
88972421|NCT00028548|Experimental|XK469|
88972422|NCT03959735|Experimental|High Intensity Interval Training (HIIT)|"50% of participants (inpatients with a diagnosis of severe mental illness) will be randomised to HIIT. HIIT will be conducted twice a week for 12 weeks using a stationary bike. Each session will have the following structure: 4-minute warm-up, followed by 5X1 minute intervals at 85-95% of maximum heart rate, interspersed with active pauses of 90 seconds cycling at approximately 60-70% of maximum heart rate, and a 4-minute cool-down. Each exercise session will take 19 minutes to complete (11 minutes of HIIT + warm-up and cool-down). However, the amount of HIIT will be adapted for people who may be unable to complete the above target and gradually build up until they can complete the recommended amount.~All exercise sessions will be conducted in a 1:1 environment with a participant and a member of the research team who will supervise the exercise session."
88972423|NCT03959735|No Intervention|Treatment As Usual (TAU)|50% of participants will be randomised to TAU. They will be provided with details of the local hospital gym availability and instructed to maintain their usual dietary habits
88972424|NCT00028587|Experimental|Group I (paclitaxel, carboplatin, bortezomib)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1 and bortezomib IV over 3-5 seconds on days 2, 5, and 8.
88972425|NCT00028587|Experimental|Group II (bortezomib, paclitaxel, carboplatin)|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, and 8 and paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 2
88972426|NCT03959696|Active Comparator|Notification only arm|Clinician participants will be notified of their patients aged 76-85 with an upcoming visit who are due for colorectal cancer screening.
88972427|NCT03959696|Experimental|Training and Notification arm|Clinician participants will be notified of their patients aged 76-85 with an upcoming visit who are due for colorectal cancer screening and will complete a two-hour shared decision making communication skills training course that includes case studies, interactive exercises, and lecture content.
88972428|NCT04733196|Experimental|Essential oils|Mouthwash based on essential oils - menthol, eucalypts oil, thymol, alcohol
88972429|NCT04733196|Experimental|Essential oils in combination with clorhexidine 0,12%|Mouthwash based on essential oils - mentol, eucalypt oil, thymol, alcohol, and 0,12% chlorhexidine
88972430|NCT04733196|Placebo Comparator|Placebo mouthwash|Water, colorant, sweetener
88972431|NCT04733196|Experimental|Clorhexidine 0,20% in combination with aroma oils|Mouthwash based on 0,20% chorhexidine without alcohol in combination with aroma oils of rose and lavender
89578121|NCT02390557|No Intervention|Control - Standard Practice|Standard measures of quality at baseline. No intervention reports sent to providers
89578122|NCT02390557|Experimental|Survey|Persons with Disabilities Quality Survey.PDQS Survey Reports Intervention.reports sent to providers of OneCare enrollees
89578123|NCT02390557|Experimental|YESHealth|Arm 3: YESHealth Reports and PDQS Survey Reports sent to providers of OneCare enrollees
89578124|NCT01649791|Experimental|Treatment (lenalidomide as chemoprevention)|Patients receive lenalidomide PO once daily for 4 weeks. Treatment repeats every 4 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.
89578125|NCT01649557|Experimental|Open-label OPDC-34712|
89578126|NCT02390245|Experimental|Phase 1: Telemedicine Screening Participants|Participants across the Philadelphia, PA region were invited to participate in free eye screenings at primary care physician offices or health centers. Screenings included images of optic nerve and macula using non-contact, autofocus, hand-held fundus cameras (Volk Optical, Mentor, Ohio, USA) and measuring Intraocular Pressure (IOP) in millimeters of mercury (mm Hg) with non-contact rebound tonometers TA01I (ICare, Helsinki, Finland).
89578127|NCT02390245|Experimental|Phases 2 and 3: Enhanced Intervention Group|"From eye screening results (visit 1), Phase 2 includes participants requiring further evaluation received comprehensive eye exam to confirm diagnosis (visit 2). Following confirmation diagnosis, patients were randomized to the Enhanced Intervention Group and were referred to a general ophthalmologist for follow-up eye care. Patient navigation and a social worker and referred to a general ophthalmologist close to the current health center or primary care physician office where they received the non dilated eye exam. Prior to all follow-up visits, patients in the Enhanced Intervention Group were provided a scheduled appointment and received a personal phone call reminding them to attend. Patients received necessary interpretation services and educational materials.~Phase 3. Includes following this group over a 5 year period for adherence to eye care."
89578128|NCT02390245|Experimental|Phases 2 and 3: Usual Care Group|"From eye screening results (visit 1), Phase 2 includes participants requiring further evaluation received comprehensive eye exam to confirm diagnosis (visit 2). Following confirmation diagnosis, patients were randomized to the Usual Care Group and were referred to a general ophthalmologist for follow-up eye care. These patients were scheduled for their initial follow-up visit based on the recommendations of our study physicians so the research team was able to track outcomes. This group represents a realistic choice currently available for patients. Practice patterns vary depending on the resources, staff time, and services available within each local ophthalmology practice.~Phase 3. Includes following this group over a 5 year period for adherence to eye care."
89578129|NCT02390167|Experimental|Persons With Diabetes|Untrained Subjects WITH Diabetes Use the ONYX NEXT BGMS (Blood Glucose Monitoring System).
89578130|NCT02347657|Placebo Comparator|Placebo|Placebo matched to VX-661 plus IVA FDC tablet administered orally in the morning and placebo matched to IVA tablet administered orally in the evening up to Week 24.
89578131|NCT02347657|Experimental|VX-661/IVA|VX-661 100 mg plus IVA 150 mg FDC tablet administered orally in the morning and IVA 150 mg tablet administered orally in the evening up to Week 24.
89578132|NCT02347189|Other|Melody TPV PB1016|
89578133|NCT02382133|Other|Nasal alar oxygen sensor|Application of a nasal alar oxygen sensor
89578134|NCT02346877|No Intervention|Standard of Care Cohort|The first 100 participants will be enrolled in the standard of care (control) cohort. These participants will receive treatment with Enbrel® (etanercept) in routine clinical practice and will complete a 52 week study period as per the investigator's standard of care.
88972432|NCT04733196|Experimental|Prebiotic|Mouthwash based on prebiotic
88972433|NCT04733196|Experimental|Hydrogen peroxide|Mouthwash based on 0,8% hydrogen peroxide in combination with menthol and eucalypts oil
88972434|NCT03959618||dietary supplements group|dietary supplements questionary
88972435|NCT00028665|Experimental|Arm I: with rituximab IV|
88972436|NCT00028665|Active Comparator|Arm II: without rituximab IV|
88972437|NCT03959579||"1st cohort = derivation cohort:"|"1st cohort = derivation cohort: 1990-1998: cardiac echo + simultaneous systematic endomyocardial biopsy"
88972438|NCT03959579||"2nd cohort = validation cohort"|"2nd cohort = validation cohort: 1999-2016: only cardiac echo with same protocol (endomyocardial biopsy only in case of doubt)"
88972439|NCT03959540||Cohort 1|Standard of care (including L-DOPA) + starting opicapone
88972440|NCT03959540||Cohort 2|Standard of care (including L-DOPA)
88972441|NCT00028743|Active Comparator|Cisplatin, Topotecan, Paclitaxel plus Carboplatin|Arm 1
88972442|NCT00028743|Active Comparator|Paclitaxel plus Carboplatin|Arm 2
88972443|NCT03959501|Experimental|Dapagliflozin|Dapagliflozin 10mg daily PO for 24 weeks
88972444|NCT03959501|Active Comparator|Sitagliptin|Sitagliptin 100mg daily PO for 24 weeks
88972445|NCT00028782|Experimental|Diagnostic (etanidazole)|Patients receive etanidazole derivative EF5 IV over 1-2 hours. Approximately 48 hours after EF5 administration, patients with intraperitoneal tumors undergo surgical resection. Patients with pleural tumors undergo surgical resection approximately 24 hours after EF5 administration. Tumors are then analyzed for EF5 binding and microvascular density by immunohistochemistry and fluorescent antibody techniques.
88972446|NCT00028821|Experimental|Treatment (2-methoxyestradiol)|Patients receive oral 2-methoxyestradiol (2-ME) once daily. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88972447|NCT03959384|Experimental|Surfactant replacement (Curosurf)|"Broncho-alveolar lavage (BAL) with 25 mg / kg of Curosurf, diluted 1:10 with physiological solution, divided in two aliquots administered with a endotracheal tube in two different postures (1st BAL on right decubitus, 2nd BAL on left decubitus).~Following supplementation of a dose of 25 mg / kg of Curosurf, diluted with physiological solution 1: 2 (1 ml = 40 mg of surfactant), given in two aliquots with endotracheal tube in two different postures (1st on right decubitus, 2nd on left decubitus). The treatment assigned may be repeated at least 12 hours later and in any case within 24 hours from the first treatment, at the same dosage and with the same method of administration"
89578135|NCT02346877|Other|Personalized Patient Counselling Cohort|Initiation of the personalized patient counselling cohort will begin after 75% of participants in the control cohort have been analyzed and shown not to have high persistence. Participants will receive Enbrel® (etanercept) therapy in routine clinical practice and personalized patient counselling based on the Information-Motivation-Strategy (IMS) model based on Beliefs about Medicines Questionnaire (BMQ) baseline results through a patient assistance program for patients on Enbrel (etanercept) therapy.
89578136|NCT02346721|Experimental|SOF/VEL|SOF/VEL for 12 weeks
89578137|NCT02389621|Experimental|Lusutrombopag|Lusutrombopag 3 mg once daily for up to 7 days.
89578138|NCT02389621|Placebo Comparator|Placebo|Placebo once daily for up to 7 days.
89578139|NCT04900207||Observed Group|Participants will be enrolled in the study at the time of their first-trimester screen (10w3d-13w6d weeks of gestation) to the time of their delivery. Collection of first-trimester 3D-volume ultrasound imaging to measure the placental volume, blood flow, and vascularity and maternal serum markers will occur over a 6-12 months period. Collection of descriptive and pregnancy outcome information will be obtained from the electronic medical records will continue through their pregnancy episode (typical 9 months).
89578140|NCT02388997|Active Comparator|Mild asthmatics treated with omalizumab|Subjects with mild asthma will be treated with omalizumab for 8 weeks before and for 3 weeks after an experimental challenge with rhinovirus. Omalizumab will be given subcutaneously every 2 to 4 weeks according to the manufacturer's recommendations.
89578141|NCT02388997|Placebo Comparator|Mild asthmatics treated with placebo medication|Subjects with mild asthma will be treated with placebo medication for 8 weeks before and for 3 weeks after an experimental challenge with rhinovirus. The placebo mediation will consist of the same diluent used for suspending the omalizumab without omalizumab added.
89578142|NCT02388763|Other|MyDay, then 1DAVTE|Stenfilcon A contact lenses, followed by narafilcon A contact lenses. Each product worn bilaterally (in both eyes) for 10 days in a daily wear, daily disposable modality.
89578143|NCT02388763|Other|1DAVTE, then MyDay|Narafilcon A contact lenses, followed by stenfilcon A contact lenses. Each product worn bilaterally for 10 days in a daily wear, daily disposable modality.
89578144|NCT02388295|Experimental|AZD3241|Subjects will be randomized to one of the two doses of AZD3241 or placebo in a 1:1:1 ratio.
89578145|NCT02388295|Placebo Comparator|Placebo to match AZD3241|Subjects will be randomized to one of the two doses of AZD3241 or placebo in a 1:1:1 ratio.
89578146|NCT02345161|Experimental|FF/UMEC/VI (100 mcg/62.5 mcg/25 mcg)|Each subject will inhale once from their ELLIPTA DPI and once from the reservoir inhaler in the morning and once from the reservoir inhaler in the evening, for 24 weeks (or 52 weeks for subjects participating in the extension part of the study). Subjects will receive FF/UMEC/VI (100mcg/62.5mcg/25mcg) via the ELLIPTA DPI and placebo via reservoir inhaler.
89578147|NCT02345161|Experimental|Budesonide/formoterol (400 mcg/12 mcg)|Each subject will inhale once from their ELLIPTA DPI and once from the reservoir inhaler in the morning and once from the reservoir inhaler in the evening, for 24 weeks (or 52 weeks for subjects participating in the extension part of the study). Subjects will receive Budesonide/formoterol (400mcg/12mcg) via reservoir inhaler and placebo via the ELLIPTA DPI.
89578148|NCT02251275|Experimental|Tolvaptan|"Tolvaptan was self-administered orally as split-dose regimens. The dose regimens used in this trial were 15/15 milligram (mg), 30/15 mg, 45/15 mg, 60/30 mg, or 90/30 mg. Starting doses were dependent upon the participant's previous trial as follows:~Trial 156-13-210: initiated on tolvaptan at a split-dose of 45/15 mg with upward titration every 3 to 4 days to 60/30 mg or 90/30 mg per day according to tolerability.~Trial 156-08-271: retained the last dose level of tolvaptan received in the trial (45/15 mg, 60/30 mg, or 90/30 mg) and started at that same dose in Trial 156-13-211.~Other Trials (156-04-251 and 156-09-290): initiated on tolvaptan at a split-dose of 45/15 mg with upward titration every 3 to 4 days to 60/30 mg or 90/30 mg per day according to tolerability."
89578149|NCT02379637|Experimental|A N-acetylcysteine|N-acetylcysteine
89578150|NCT02379637|Placebo Comparator|B Placebo|Placebo
89578151|NCT02195583|Experimental|Sodium fluoride (1426 ppm)|Non-zinc, 1426ppm fluoride as sodium fluoride in a silica gel base
89578152|NCT02195583|Experimental|Sodium fluoride (1150 ppm)|Non-zinc, 1150ppm fluoride as sodium fluoride in a silica gel base
89578153|NCT02195583|Experimental|Sodium fluoride (250 ppm)|Non-zinc, 250ppm fluoride as sodium fluoride in a silica gel base
89578154|NCT02195583|Experimental|Sodium fluoride (1426 ppm) + zinc base A|Zinc base A, 1426ppm fluoride as sodium fluoride in a silica gel base
89578155|NCT02195583|Experimental|Sodium fluoride (1426 ppm) + zinc base B|Zinc base B, 1426ppm fluoride as sodium fluoride in a silica gel base
89578156|NCT02195583|Placebo Comparator|Fluoride (0 ppm)|Non-zinc, 0ppm fluoride in a silica gel base
89578157|NCT02379091|Placebo Comparator|Placebo|Namilumab placebo-matching, SC injection, once on Days 1, 15, 43, 71 and every 4 weeks for 12 weeks. Participants were assessed for response (a 20% improvement from Baseline in both swollen and tender joint counts). If the participant was a responder, the current treatment continued every 4 weeks up to Week 24. If the participant was a non-responder, the participant entered an open-label period and received namilumab 150 mg/mL, SC injection, every 4 Weeks up to Week 24. All participants were on a stable dose of methotrexate tablets (15-25 mg weekly) and folic acid (at least 5 mg/week) orally throughout the duration of the study.
88972448|NCT03959384|Placebo Comparator|Ambient Air|"Broncho-alveolar lavage (BAL) with air, administered with a endotracheal tube in two different postures (1st BAL on right decubitus, 2nd BAL on left decubitus).~Following supplementation of air given with endotracheal tube in two different postures (1st on right decubitus, 2nd on left decubitus). The treatment assigned may be repeated at least 12 hours later and in any case within 24 hours from the first treatment, at the same dosage and with the same method of administration"
88972449|NCT03959345|Experimental|Combination therapy group|intravenous cloxacillin 2g/4h and fosfomycin 3 g/6h for the duration of 7 days treatment
88972450|NCT03959345|Active Comparator|Standard therapy group|intravenous cloxacillin 2g/4h for the duration of 7 days IV treatment
88972451|NCT03959306|Experimental|Group I|this group of patients will receive their standard anti-diabetic treatment in addition to 1800 mg of black seed oil soft gelatin capsule (900 mg twice daily) for three months
88972452|NCT03959306|Active Comparator|Group II|this group of patients will receive their standard anti-diabetic treatment only
89578158|NCT02379091|Experimental|Namilumab 20 mg/mL|Namilumab 20 mg/mL, subcutaneous (SC) injection, once on Days 1, 15, 43, 71 and every 4 weeks for 12 Weeks. Participants were assessed for response (a 20% improvement from Baseline in both swollen and tender joint counts). If the participant was a responder, the current treatment continued every 4 weeks up to Week 24. If the participant was a non-responder, the participant entered an open-label period and received namilumab 150 mg/mL, SC injection, every 4 Weeks up to Week 24. All participants were on a stable dose of methotrexate tablets (15-25 mg weekly) and folic acid (at least 5 mg/week) orally throughout the duration of the study.
89578159|NCT02379091|Experimental|Namilumab 80 mg/mL|Namilumab 80 mg/mL, SC injection, once on Days 1, 15, 43, 71 and every 4 weeks for 12 Weeks. Participants were assessed for response (a 20% improvement from Baseline in both swollen and tender joint counts). If the participant was a responder, the current treatment continued every 4 weeks up to Week 24. If the participant was a non-responder, the participant entered an open-label period and received namilumab 150 mg/mL, SC injection, every 4 Weeks up to Week 24. All participants were on a stable dose of methotrexate tablets (15-25 mg weekly) and folic acid (at least 5 mg/week) orally throughout the duration of the study.
89578160|NCT02379091|Experimental|Namilumab 150 mg/mL|Namilumab 150 mg/mL, SC injection, once on Days 1, 15, 43, 71 and every 4 weeks for 12 Weeks. Participants were assessed for response (a 20% improvement from Baseline in both swollen and tender joint counts). If the participant was a responder, the current treatment continued every 4 weeks up to Week 24. If the participant was a non-responder, the participant was discontinued from the study. All participants were on a stable dose of methotrexate tablets (15-25 mg weekly) and folic acid (at least 5 mg/week) orally throughout the duration of the study.
89578161|NCT02378935|Experimental|VOX+SOF/VEL 6 wk, TN, without cirrhosis|VOX + SOF/VEL for 6 weeks (treatment naive (TN), without cirrhosis)
89578162|NCT02378935|Experimental|VOX+SOF/VEL 8 wk, TN, without cirrhosis|VOX + SOF/VEL for 8 weeks (treatment naive, without cirrhosis)
89578163|NCT02378935|Experimental|VOX+SOF/VEL 6 wk, TN, with cirrhosis|VOX + SOF/VEL for 6 weeks (treatment naive, with cirrhosis)
89578164|NCT02378935|Experimental|VOX+SOF/VEL 8 wk, TN, with cirrhosis|VOX + SOF/VEL for 8 weeks (treatment naive, with cirrhosis)
89578165|NCT02378935|Experimental|VOX+SOF/VEL+RBV 8 wk, TN, with cirrhosis|VOX + SOF/VEL+RBV for 8 weeks (treatment naive, with cirrhosis)
89578166|NCT02378935|Experimental|VOX+SOF/VEL 8 wk, DAA-E, without cirrhosis|VOX + SOF/VEL for 8 weeks (direct-acting antiviral experienced (DAA-E), without cirrhosis)
89578167|NCT02378935|Experimental|VOX+SOF/VEL 12 wk, DAA-E, without cirrhosis|VOX + SOF/VEL for 12 weeks (direct-acting antiviral experienced, without cirrhosis)
89578168|NCT02378935|Experimental|VOX+SOF/VEL 8 wk, DAA-E, with cirrhosis|GS-9857 + SOF/VEL for 8 weeks (direct-acting antiviral experienced, with cirrhosis)
89578169|NCT02378935|Experimental|VOX+SOF/VEL 12 wk, DAA-E, with cirrhosis|GS-9857 + SOF/VEL for 12 weeks (direct-acting antiviral experienced, with cirrhosis)
89578170|NCT02378935|Experimental|VOX+SOF/VEL 12 wk (GS-US-338-1121)|VOX + SOF/VEL for 12 weeks (participants who were previously enrolled in GS-US-338-1121 phase 1b study)
89578171|NCT02250651|Experimental|Bimatoprost SR 15 μg|Study Eye: bimatoprost sustained-release (SR) 15 micrograms (μg) administered on Day 1 (Period 1), Week 16 (Period 2), and Week 32 (Period 3); timolol vehicle administered once in the morning and once in the evening for up to 20 months. Non-Study Eye: sham administration on Day 1 (Period 1), Week 16 (Period 2), and Week 32 (Period 3); timolol 0.5% administered once in the morning and once in the evening for up to 20 months.
89578172|NCT02250651|Experimental|Bimatoprost SR 10 μg|Study Eye: bimatoprost SR 10 μg administered on Day 1 (Period 1), Week 16 (Period 2), and Week 32 (Period 3); timolol vehicle administered once in the morning and once in the evening for up to 20 months. Non-Study Eye: sham administration on Day 1 (Period 1), Week 16 (Period 2), and Week 32 (Period 3); timolol 0.5% administered once in the morning and once in the evening for up to 20 months.
89578173|NCT02250651|Active Comparator|Timolol 0.5%: Comparator|Both Eyes: sham administered on Day 1 (Period 1), Week 16 (Period 2), and Week 32 (Period 3); timolol 0.5% administered once in the morning and once in the evening for up to 20 months.
89578174|NCT02377921|Experimental|Aceneuramic Acid Extended-Release (Ace-ER)|Ace-ER 6 g/day, divided 3 times per day (TID) for 48 weeks.
89578175|NCT02377921|Placebo Comparator|Placebo|Matching placebo TID for 48 weeks.
89578176|NCT02311153|Active Comparator|Endotracheal intubation|Endotracheal intubation for airway management and ventilation during sinonasal surgical procedure
89578177|NCT02311153|Experimental|Laryngeal mask airway|Laryngeal mask for airway management and ventilation during sinonasal surgical procedure
89578178|NCT02195427|Experimental|TEOSYAL RHA Global Action/Juvederm Ultra XC|Split-face injection of TEOSYAL® RHA Global Action into one NLF and Juvederm® Ultra XC into the contralateral NLF (n=75). Up to 3.0 mL injected per NLF (mid-dermis to deep-dermis). Touch-up treatment provided at 2 weeks (up to 3.0 mL per NLF).
89578179|NCT02195427|Experimental|TEOSYAL RHA Deep Lines/Juvederm Ultra XC|Split-face injection of TEOSYAL® RHA Deep Lines into one NLF and Juvederm® Ultra XC into the contralateral NLF (n=75). Up to 3.0 mL injected per NLF (mid-dermis to deep-dermis). Touch-up treatment provided at 2 weeks (up to 3.0 mL per NLF).
88972453|NCT04733612|Experimental|SMS Group|In addition to traditional treatment received three to four informative SMS messages per week during the 6-month period
88972454|NCT04733612|No Intervention|Control Group|Followed in accordance with the traditional treatment schedule
88972455|NCT03959228|No Intervention|referencial diet|0.8 g/kg/day of protein
88972456|NCT03959228|Experimental|protein very poor diet with additional keto-analogs|0.4 g/kg/day of protein and 1 pill of Ketosteril/ 5kg.
88972457|NCT03959189|Experimental|ERX-963 then placebo|Participants in this arm will receive ERX-963 followed by a washout period. After the washout period, participants will receive placebo.
88972458|NCT03959189|Experimental|Placebo then ERX-963|Participants in this arm will receive placebo followed by a washout period. After the washout period, participants will receive ERX-963.
88972459|NCT03959150|Experimental|Capecitabine metronomic chemotherapy|Capecitabine 500mg/m2 po qd
88972460|NCT03959150|No Intervention|Observation|Observation
88972461|NCT00392639|Experimental|1-2|Comparison of 2 cooling procedures
88972462|NCT03958799|Experimental|Group 1: Investigational Product (IP) Formulation A|IP Formulation A administration, participation in Stage 1 and Stage 2
88972463|NCT03958799|Experimental|Group 2: IP Formulation A|IP Formulation A administration, participation in Stage 1
88972464|NCT03958799|Experimental|Group 3: IP Formulation B|IP Formulation B administration, participation in Stage 1 and Stage 2
88972465|NCT03958799|Experimental|Group 4: IP Formulation B|IP Formulation B administration, participation in Stage 1
88972466|NCT03958799|Experimental|Group 5: IP Formulation C|IP Formulation C administration, participation in Stage 1 and Stage 2
88972467|NCT03958799|Experimental|Group 6: IP Formulation C|IP Formulation C administration, participation in Stage 1 and Stage 2
88972468|NCT03958799|Experimental|Group 7: IP Formulation D|IP Formulation D administration, participation in Stage 1 and Stage 2
88972469|NCT03958799|Active Comparator|Group 8: Tdap|TdaP administration, participation in Stage 1 and Stage 2
88972470|NCT03958799|Active Comparator|Group 9: Tdap|TdaP administration, participation in Stage 1
88972471|NCT03958682|Experimental|experimental group|During the rescue, the doctor is asked to wear the special helmet , through the device's camera system and headset, we can obtain graphics and sound of the helicopter cabin .At the same time, it also receives the historical data of patients and real-time diagnosis as well as rescue guidance from the ground medical institutions.Patients can receive timely diagnosis and appropriate treatment
88972472|NCT03958604|Experimental|Burst Spinal Cord Neurostimulation|Burst spinal cord stimulation. When this fails, tonic stimulation targeting the DRG wil be applied
88972473|NCT00395772|Active Comparator|Arm 4|
88972474|NCT00395772|Experimental|Arm 1|
88972475|NCT00395772|Experimental|Arm 2|
88972476|NCT00395772|Experimental|Arm 3|
88972477|NCT00395889|Experimental|Rehabilitation + Lifestyle Counseling|Multicomponent Pulmonary Rehabilitation Program including structured exercise training
88972478|NCT00395889|Active Comparator|Lifestyle Counseling|
88972479|NCT03958526|Active Comparator|Active|Active stimulation over M1
88972480|NCT03958526|Placebo Comparator|Sham|Sham stimulation over M1
88972481|NCT03958448|Experimental|Short Group|In each side of the posterior region of the maxilla, one tissue level implant, 4 mm long and 4.1 mm in diameter, will be installed
88972482|NCT03958448|Experimental|Standard group|sinus floor elevation with will be performed using natural bovine bone graft as filler material and porcine dermis collagen membrane to cover the antrostomy. After 4 months of healing, one bone level implant, 10 mm long and 4.1 mm in diameter, will be installed into each augmented sinus.
89578180|NCT02214225|Experimental|Quadrivalent Influenza Vaccine (QIV)|The bioCSL study vaccine is a sterile, thiomersal-free suspension containing 60 mcg total hemagglutinin antigen per 0.5 mL dose (15 mcg each of the four recommended influenza strains for the Northern Hemisphere 2014/2015 influenza season).
89578181|NCT02214225|Active Comparator|Trivalent Influenza Vaccine (TIV-1)|The bioCSL study vaccine is a sterile, thiomersal-free suspension containing 45 mcg total hemagglutinin antigen per 0.5 mL dose (15 mcg each of the three recommended influenza strains for the Northern Hemisphere 2014/2015 influenza season).
89578182|NCT02214225|Active Comparator|Trivalent Influenza Vaccine (TIV-2)|The bioCSL study vaccine is a sterile, thiomersal-free suspension containing 45 mcg total hemagglutinin antigen per 0.5 mL dose (15 mcg each of the recommended influenza A (H1N1-, H3N2-like) strains and the alternate B strain for the Northern Hemisphere 2014/2015 influenza season).
89578183|NCT02250183|Other|Medihoney & Santyl|Each patient will receive both interventions simultaneously, but on non-contiguous parts of the body that each consist of partial thickness burn injuries of similar depth. For example, if a patient presents with bilateral second-degree burns to the lower extremities, one leg will be treated with MEDIHONEY® GEL with Active leptospermum honey dressing, while the other leg will be treated with SANTYL® ointment dressing. MEDIHONEY® is the target treatment for this study, while SANTYL® is standard care.
89578184|NCT02249949|Experimental|efatutazone dihydrochloride|Patients receive efatutazone dihydrochloride PO BID continuously. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89578185|NCT02249091|Experimental|Cohort 1 / Selinexor 40 mg/m^2 in combination with cytarabine and idarubicin|"All enrolled patients are treated with cytarabine at a dose of 100 mg/m² continuous infusion (day 1-7) and idarubicin at a dose of 10 mg/m^2 iv (day 1,3,5) every 4 weeks and selinexor for up to 2 induction cycles. If a second cycle is applied idarubicin is only given on day 1 and 3.~Selinexor is administered at a dose of 40 mg/m^2 twice weekly orally starting on day 2 (total of 8 doses per induction cycle)."
88972483|NCT03958370||Fitbit|
88972484|NCT00029913||1|Observation of participants includes a physical exam and collection of fluids. Study visits occur at Days 0, 7, 14, 28 and at Months 2, 3, 6 and every 6 months thereafter.
88972485|NCT03958292|Experimental|Patients undergoing routine cataract surgery|"Two eye drops containing PVP-Iodine instillation in the eye undergoing cataract surgery three times for three days before surgery.~Each patient was evaluated for conjunctival flora variation by means of two conjunctival swabs before starting the treatment and at the end of the treatment before the surgery."
88972486|NCT03958253|Experimental|Lung Cancer Screening Toolbox|"WU Staff will train local screening staff using a train-the-trainer model three months prior to the intervention and will provide technical assistance on an ongoing basis.~During the 3 hour train-the-trainer session, the selected staff from the referral sites will learn about the program, receive an orientation to the toolbox elements, and discuss how to adapt the elements of the toolbox to their referral sites."
88972487|NCT03958214|Experimental|Recipe 4 Success|For 12 weeks, home visitors will stop delivering the usual practice Early Head Start home visits and deliver the Recipe 4 Success curriculum instead. At the end of 12 weeks, home visitors will resume usual practice Early Head Start home visits.
88972488|NCT03958214|Active Comparator|Usual practice Early Head Start|Home visitors will continue to deliver usual practice Early Head Start home visits that follow a standard curriculum and are tailored on an ongoing basis to meet individual family needs.
89578186|NCT02249091|Experimental|Cohort 2 / Selinexor 60 mg flat dose in combination with cytarabine and idarubicin|"All enrolled patients are treated with cytarabine at a dose of 100 mg/m^2 continuous infusion (day 1-7) and idarubicin at a dose of 10 mg/m^2 iv (day 1,3,5) every 4 weeks and selinexor for up to 2 induction cycles. If a second cycle is applied idarubicin is only given on day 1 and 3.~Selinexor is administered at a flat dose of 60 mg twice weekly orally in weeks 1-3 of a 4-week cycle starting on day 2 (total of 6 doses per induction cycle)."
89578187|NCT02248857|No Intervention|Usual Care|Employ the current standard of care. No intervention.
89578188|NCT02248857|Experimental|UMS strategy|"Patients of providers randomized to the UMS arm will receive study-related educational tools at their primary care visit to support the understanding, regimen consolidation, and use of prescriptions.~Prescription instructions will be adapted to UMS to establish four standard time intervals for prescribing and dispensing of medicine. UMS instructions also use simplified text and numeric characters instead of words to detail dose.~Single-page, plain language medication information sheets with content from a patient's perspective and following health literacy best practices.~A list of their current medications each corresponding to a set of instructions and a checkbox for morning, noon, evening, and bedtime medicine to help patients visually depict when to take their medicines."
89578189|NCT02248857|Experimental|UMS strategy + SMS texting reminders|In addition to the components from the UMS strategy arm, patients will receive daily text reminders for 7 days, with the option of extending reminders, following a study medication prescription.
89578190|NCT02213055|Experimental|LICEMD|Infested children whose parents agree to use the investigational product will be enrolled on the experimental arm of the study using the LiceMD product as treatment.
89578191|NCT02213055|Active Comparator|Standard Head lice product|Parents/guardians who do not agree to use the investigational product and choose a standard head lice treatment will be asked to participate in the comparison arm of the study.
89578192|NCT02310763|Experimental|PF-06252616|3 dose levels (5mg/kg, 20mg/kg and 40 mg/kg) of IV infused PF-06252616 will be investigated within each subject
89578193|NCT02310763|Placebo Comparator|Placebo|Matching Placebo
89578194|NCT02342743|Experimental|Active|Daily trigeminal nerve stimulation session of 20 minutes with CEFALY
89578195|NCT04891315||Pregnant women|Women aged 16+ in early pregnancy (before 20 weeks of gestation).
88972489|NCT03958175||Patients with Parkinson's Disease|Patients with Parkinson's Disease (PD) were evaluated for reading disorders using a screening method validated for dyslexia.
88972490|NCT03958175||Patients without Parkinson's Disease = control group|Patients without Parkinson's Disease (PD) were evaluated for reading disorders using a screening method validated for dyslexia.
88972491|NCT03958097|Experimental|NK cell combined with PD-L1 antibody|"Autologous peripheral blood mononuclear cells (PBMCs) are collected by apheresis on D0, then induced into NK cells and infused into the patients 14 days later (D14) as the initial transfusion. There are 3 consecutive transfusion days (D14-D16), total NK cells infused at least 3×10^9 .~200mg PD-L1 antibody(Sintilimab Injection) will be given on D14, 1 hour after NK cells infusion.~NK cells and PD-L1 antibody will be infused every 21 days until disease progression or unacceptable adverse events."
88972492|NCT00030225|Experimental|ELAD|Treatment with ELAD, extracorporeal liver assist system and standard of care
88972493|NCT00030225|Other|Standard of care (Control)|Standard of care for patients with fulminant hepatic (liver) failure
88972494|NCT03934229|Experimental|Group Active|Bifidobacterium animalis ssp. lactis 420 at 1*10^10 colony forming units (CFU) per day
88972495|NCT03934229|Placebo Comparator|Group Placebo|Placebo
88972496|NCT00030303|Experimental|vaccine|recombinant 70-kD heat-shock protein
88972497|NCT03933059|Active Comparator|R&R Park City, Utah|This group will receive 12 daily individual sessions of CPT at the National Ability Center in Park City, Utah. They will also participate in daily recreational activities.
88972498|NCT03933059|Active Comparator|R&R Salt Lake City, Utah|This group will receive 12 daily individual sessions of CPT at the National Center for Veterans Studies located on the University of Utah campus in Salt Lake City, Utah.
89578196|NCT02377063|Other|pressed juice 6 bottles|Subjects will consume pressed juice daily for 3 days.
89578197|NCT02309515|Experimental|Arm I (lenalidomide, pneumococcal 13-valent conjugate vaccine)|Patients receive lenalidomide PO QD on days 1-42 and pneumococcal 13-valent conjugate vaccine IM on day 15.
89578198|NCT02309515|Active Comparator|Arm II (pneumococcal 13-valent conjugate vaccine)|Patients receive pneumococcal 13-valent conjugate vaccine IM on day 15.
89578199|NCT02309359|Placebo Comparator|Placebo q2w + MTX|Placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
88972499|NCT03933059|Active Comparator|Weekly Treatment Salt Lake City, Utah|This group will receive 12 individual sessions of CPT on a weekly basis at the National Center for Veterans Studies located on the University of Utah campus in Salt Lake City, Utah.
88972500|NCT03959930|Experimental|Interventional arm|Total and segmental body fluid volumes (total water, extracellular water and interstitial water) will be measured by Segmental Bioelectrical Impedance Spectroscopy (as per manufacturer instructions of use). Areas with most significant oedema and skin in a suitable condition shall be selected for the TFR application. Moisture Meter shall be used at the selected site to measure the skin water content at 4 depths (0.5mm, 1.5mm, 2.5mm and 5mm).
88972501|NCT00030381|Experimental|Treatment (iododoxorubicin)|Patients receive iododoxorubicin IV over 15 minutes on days 1, 8, 15, and 22. Treatment repeats every 12 weeks for a total of 4 courses or a cumulative dose of 400 mg/m^2 in the absence of disease progression or unacceptable toxicity.
88972502|NCT01349816|Experimental|PT003 (Dose 1)|PT003 MDI Dose 1
88972503|NCT01349816|Experimental|PT003 (Dose 2)|PT003 MDI Dose 2
88972504|NCT01349816|Experimental|PT003 (Dose 3)|PT003 MDI Dose 3
88972505|NCT01349816|Experimental|PT003 (Dose 4)|PT003 MDI Dose 4
88972506|NCT01349816|Experimental|PT001|PT001 MDI
88972507|NCT01349816|Experimental|PT005|PT005 MDI
88972508|NCT00030420|Experimental|Celecoxib & Docetaxel|"Celecoxib: 400mg by mouth, twice a day, each dose given with meals, to start -7 days prior to first cycle of treatment.~Doctaxel: Day 1, 75mg/m2 IV over 60 minutes, repeated every 21 days"
89578200|NCT02309359|Experimental|ALX-0061 75 mg q4w + MTX|ALX-0061 75 mg every 4 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
89578201|NCT02309359|Experimental|ALX-0061 150 mg q4w + MTX|ALX-0061 150 mg every 4 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
89578202|NCT02309359|Experimental|ALX-0061 150 mg q2w + MTX|ALX-0061 150 mg every 2 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
89578203|NCT02309359|Experimental|ALX-0061 225 mg q2w + MTX|"ALX-0061 225 mg every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24.~The last study drug administration was at the Week 22 visit."
89578204|NCT02247531|Experimental|Lampalizumab once in every 4 weeks (Q4W)|Participants will receive 10 mg (milligrams) dose of lampalizumab by intravitreal injection, Q4W, starting at the Day 1 visit for approximately 92 weeks.
89578205|NCT02247531|Experimental|Lampalizumab once in every 6 weeks (Q6W)|Participants will receive 10 mg dose of lampalizumab by intravitreal injection, Q6W, starting at the Day 1 visit for approximately 90 weeks.
89578206|NCT02247531|Sham Comparator|Sham Comparator|Participants will receive sham comparator, Q4W, starting at the Day 1 visit for approximately 92 weeks or Q6W, starting at the Day 1 visit for approximately 90 weeks.
89578207|NCT02375971|Experimental|Ranibizumab 0.2 mg|1 intravitreal injection in both eyes on Day 1 (Baseline), with up to 2 re-treatments allowed for each eye if required
89578208|NCT02375971|Experimental|Ranibizumab 0.1 mg|1 intravitreal injection in both eyes on Day 1 (Baseline), with up to 2 re-treatments allowed for each eye if required
89578209|NCT02375971|Active Comparator|Laser therapy|Laser treatment to each eye on Day 1 (Baseline), with supplementary treatments allowed
89578210|NCT02308735||Control|Pregnant women without either gestational or pre-gestational diabetes mellitus (and their offspring).
89578211|NCT02308735||A1 IDM|Pregnant women with abnormal glucose tolerance test but normal fasting serum glucose levels (and their offspring).
89578212|NCT02308735||A2 IDM|Pregnant women with abnormal glucose tolerance test and fasting hyperglycemia (and their offspring).
89578213|NCT02308735||PGDM - IDM|Pregnant women with diabetes mellitus diagnosed prior to current pregnancy (and their offspring).
89578214|NCT02212197|Experimental|CAM2032 3.75 mg|Single subcutaneous buttock injections of CAM2032 (leuprolide acetate FluidCrystal® injection depot) 3.75 mg on Days 0, 28 and 56.
89578215|NCT02212197|Experimental|CAM2032 7.5 mg|Single subcutaneous buttock injections of CAM2032 (leuprolide acetate FluidCrystal® injection depot) 7.5 mg on Days 0, 28 and 56.
89578216|NCT02212197|Active Comparator|Eligard 7.5 mg|Single subcutaneous buttock injections of Eligard® (leuprolide acetate) 7.5 mg on Days 0, 28 and 56.
89578217|NCT02193165|Active Comparator|Regimen 1|triclosan/fluoride toothpaste + cetylpyridinium chloride Mouthwash
88972509|NCT00030498|Experimental|Treatment (erlotinib hydrochloride)|Patients receive oral erlotinib once daily. Treatment continues in the absence of disease progression or unacceptable toxicity.
88972510|NCT03873857||Venetoclax|"Participants in this observational study will receive treatment with venetoclax for up to 24 months for treatment of relapsed or refractory CLL.~The prescription of a treatment regimen is at the discretion of the physician in accordance with local clinical practice and label, is made independently from this observational study and precedes the decision to offer the patient the opportunity to participate in this study."
88972511|NCT02971527|Experimental|Oste-scan 500A-SONOST3000|In this group, the investigators will measure calcaneal bone strength index of each subject by experimental device firstly and then by control device.
88972512|NCT02971527|Experimental|SONOST3000-Oste-scan 500A|In this group, the investigators will measure calcaneal bone strength index of each subject by control device firstly and then by experimental device.
88972513|NCT00030576|Experimental|OSI-774 and cisplatin|HNSCC patients treated in three escalating dose cohorts of daily continous oral erlotinib (OSI-774) and intermittent IV cisplatin given every 21 days
88972514|NCT00030615|Experimental|Treatment (decitabine)|"Patients receive decitabine IV over 30 minutes on days 1-5 weekly for 4 weeks. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of decitabine until the MTD is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
88972515|NCT03857087||Diagnostic 68Ga PSMA PET/MRI|Patients receive gallium Ga 68-labeled PSMA-11 IV over 1-2 minutes. After about 60 minutes, patients undergo PET/MRI for approximately over 50-60 minutes. Patients may undergo an optional repeat gallium Ga 68-labeled PSMA-11 PET between 8 and 12 weeks after completion of the first PET/MRI.
89578218|NCT02193165|Active Comparator|Regimen 2|stannous fluoride toothpaste + cetylpyridinium chloride Mouthwash
88972516|NCT00030654|Experimental|Androgen blockade + immediate chemotherapy|Androgen blockade with immediate chemotherapy
89578219|NCT02193165|Placebo Comparator|Regimen 3 - Control group|fluoride toothpaste + fluoride Mouthwash
89578220|NCT01617460|Experimental|Aripiprazole|administered orally once daily
89578221|NCT01890148|Experimental|1|oral BD administration of 45 mg AZD5069
89578222|NCT01889602|Experimental|Topiramate 100mg|Participant will receive 3 single-dose treatments with 2-week washout between each treatment. At each of 3 treatments, participants will receive 100mg torpiramate, 2mg lorazepam, or placebo. Treatment order is randomized. All participants in this arm will receive all 3 treatments.
89578223|NCT01889602|Experimental|Topiramate 150mg|Participant will receive 3 single-dose treatments with 2-week washout between each treatment. At each of 3 treatments, participants will receive 150mg torpiramate, 2mg lorazepam, or placebo. Treatment order is randomized. All participants in this arm will receive all 3 treatments.
89578224|NCT01889602|Experimental|Topiramate 200mg|Participant will receive 3 single-dose treatments with 2-week washout between each treatment. At each of 3 treatments, participants will receive 200mg torpiramate, 2mg lorazepam, or placebo. Treatment order is randomized. All participants in this arm will receive all 3 treatments.
88972517|NCT00030654|Experimental|Androgen blockade + delayed chemotherapy|Androgen blockade with delayed chemotherapy
89578225|NCT01935700|Experimental|colchicine treated patients|2 tablets (0.5 mg/tablet) of colchicine three times per day (after breakfast, lunch and dinner); continue 4 days and stop for 3 days (1 cycle); repeat this cycle until patients quit this trial
89578226|NCT01618162|Experimental|Insulin degludec/liraglutide|
89578227|NCT01618162|Placebo Comparator|Placebo|
89578228|NCT02193087|Active Comparator|Group A: TDV Liquid + Placebo|Takeda's Tetravalent Dengue Vaccine Candidate (TDV) Liquid Formulation 1, diluted 1:5 with vaccine diluent, subcutaneous injection on Day 1, and TDV Liquid Formulation placebo-matching solution, subcutaneous injection, once on Day 90 (Month 3).
89578229|NCT02193087|Active Comparator|Group B: TDV Liquid|TDV Liquid Formulation 1, diluted 1:5 with vaccine diluent, subcutaneous injection on Day 1 and Day 90 (Month 3).
89578230|NCT02193087|Experimental|Group C: TDV Liquid|TDV Liquid Formulation 2, subcutaneous injection on Day 1 and Day 90 (Month 3).
89578231|NCT02193087|Experimental|Group D: TDV Lyophilized|TDV Lyophilized Formulation reconstituted with water, subcutaneous injection on Day 1 and Day 90 (Month 3).
89578232|NCT01617070|Experimental|LNAA, washout, Kuvan, and LNAA+Kuvan|One group of 12 subjects, each under 4 conditions (each phase is 4 weeks)
89578233|NCT04771767|Experimental|Ketamine + eCBT|Over 12 weeks, participants receive weekly sessions of asynchronous online cognitive-behavioural therapy as well as 6 sub-anesthetic infusions of Ketamine
89578234|NCT04771767|No Intervention|Control|Participants are in a control condition receiving treatment as usual, during which time they will not receive the experimental treatment and will have no change in their treatment regimen.
89578235|NCT02341417|Experimental|Cinacalcet|"Participants received cinacalcet daily for 24 weeks in this extension study. For participants who received standard of care (SOC) in parent study 20130356, the starting dose was 0.20 mg/kg/day. For participants who received SOC and cinacalcet in parent study 20130356 or 20110100 the starting dose was either the same as the last dose received in the parent study or 0.20 mg/kg/day if the last dose of cinacalcet in the parent study was received > 14 days before day 1 of this study.~Dose adjustments and withholding were based on weekly assessments of ionized calcium as well as plasma intact parathyroid hormone (iPTH) and corrected serum calcium levels assessed monthly."
89578236|NCT01888900|Experimental|Hepatitis C Virus Genotype 1A with QUAD|Subjects will be started on combination therapy with asunaprevir, daclatasvir, peginterferon alfa-2a and ribavirin for 24 weeks.
88972518|NCT03852407|Experimental|Fludarabine-Melphalan-Cyclophosphamide|FM-PTCy conditioning will consist in IV fludarabine 30 mg/m2 on days -6, -5, -4, -3, and -2 (total dose 150 mg/m2), melphalan given at the dose of 100 mg/m2 on day -2, and cyclophosphamide 50 mg/kg on days +3 and +4.
88972519|NCT03852407|Experimental|Fludarabine-Melphalan-thymoglobulin|FM-ATG conditioning will consist in IV fludarabine 30 mg/m2 on days -6, -5, -4, -3, and -2 (total dose 150 mg/m2), melphalan given at the dose of 100 mg/m2 on day -2, and ATG (Thymoglobulin®, Genzyme), at a dose of 2.5 mg/kg/d on days -2 and -1.
88972520|NCT00030693|Experimental|Arm I (recombinant fowlpox-B7.1 vaccine)|Patients receive rF-B7.1 vaccine intratumorally on day 1.
89578237|NCT01888900|Experimental|Hepatitis C Virus Genotype 1B with DUAL|Subjects will receive combination therapy with asunaprevir and daclatasvir alone for 24 weeks and undergo paired liver biopsies, pre-treatment and either at 2 or 4 weeks after starting therapy.
88972521|NCT00030693|Experimental|Arm II (recombinant fowlpox-TRICOM vaccine)|Patients receive fowlpox-TRICOM vaccine intratumorally on day 1.
88972522|NCT00030732|Active Comparator|Gemcitabine + Capecitabine|Gemcitabine + Capecitabine
88972523|NCT00030732|Active Comparator|Gemcitabine alone|Gemcitabine alone
88972524|NCT03797456|Experimental|ICP-022|
88972525|NCT00030966|Experimental|Group 1|Adding natalizumab monthly infusion to Avonex weekly injection for up to 116 weeks.
88972526|NCT00030966|Placebo Comparator|Group 2|Adding placebo monthly infusion to Avonex weekly injection for up to 116 weeks.
88972527|NCT03959267|No Intervention|Usual Care|Participants will continue with their usual medical care. Usual care may vary at different sites. Based on the investigator's preliminary data usual care can result in not GCRA referral, referral directly to testing, or referral to genetic counseling with an interpreter. The investigators will document usual care for participants from the sites randomized to usual care.
88972528|NCT03959267|Other|Telephone Genetic Counseling|Participants will receive telephone genetic counseling with the culturally adapted protocol and booklet
88972529|NCT03715205|Experimental|Cohort A: Melanoma|Participants with unresectable or metastatic melanoma receive 200 mg of pembrolizumab as an intravenous (IV) infusion every 3 weeks (Q3W) for up to 35 cycles.
88972530|NCT03715205|Experimental|Cohort B: NSCLC|Participants with NSCLC who are either treatment naïve or have progressed after prior treatment receive 200 mg of pembrolizumab as an IV infusion every Q3W for up to 35 cycles.
88972531|NCT03698006|Experimental|Tibial nerve block|Adductor canal and tibial nerve blocks performed by the anesthetist under ultrasound guidance before spinal block.
88972532|NCT03698006|Active Comparator|Local infiltration analgesia|Adductor canal block by the anesthetist under ultrasound guidance before spinal block. Infiltration of the knee by the surgeon with local anesthetic at the end of the surgery.
88972533|NCT03559985|Other|Paracetamol and placebo comparator (Group 1)|Neuropathic pain patients taking either paracetamol or placebo according to the randomization plan
88972534|NCT03559985|Other|Paracetamol and placebo comparator (Group 2)|Neuropathic pain patients taking either paracetamol (if during period 1 they received placebo) or placebo (if during period 1 they received paracetamol)
88972535|NCT04711707|Experimental|Community navigator|This group is guided through the resources and provided bi-monthly support with a community navigator
88972536|NCT04711707|Other|Self-Navigation|This group receives the social needs resources to self-navigation
88972537|NCT03553394|Active Comparator|Standard of care group|Will receive a fluid bolus 5 ml/kg Ringer's Acetate infusion immediately if oliguric/anuric for two consecutive hours (standard of care).
88972538|NCT03553394|No Intervention|Expectant management group|Await fluid therapy for 2 hours. Will NOT receive a fluid bolus if oliguric/anuric for two consecutive hours and a now assessment will be made after two more hours.
88972539|NCT04712448||Healthy subjects|Donors of the Transfusion Center of Venice Healthy volunteers afferent to BioBIM
89578238|NCT02340949|Experimental|mFOLFOX6 + Aflibercept|"- mFOLFOX-6 scheme: 5-Fluoruracil [5-FU], oxaliplatin and leucovorin will be administered intravenously once every 14 days according to mFOLFOX-6 scheme:~Day 1: Oxaliplatin 85 mg/m² IV infusion in 250-500 mL and leucovorin 200 mg/m² IV, both over two hours, followed by 5-FU 400 mg/m² IV bolus and a 46 h infusion of 5-FU 2400 mg/m².~- Aflibercept, will be administered intravenously (I.V.) at doses of 4 mg/Kg on Day 1 every 14 days. Aflibercept will be supplied to sites by the study Sponsor as 4 ml vials at a concentration of 25 mg/ml.~Treatment will continue until six cycles are administered unless unacceptable toxicity or progression occurs."
89578239|NCT02340949|Active Comparator|mFOLFOX6|"- mFOLFOX-6 scheme: 5-Fluoruracil [5-FU], oxaliplatin and leucovorin will be administered intravenously once every 14 days according to mFOLFOX-6 scheme:~Day 1: Oxaliplatin 85 mg/m² IV infusion in 250-500 mL and leucovorin 200 mg/m² IV, both over two hours, followed by 5-FU 400 mg/m² IV bolus and a 46 h infusion of 5-FU 2400 mg/m².~Treatment will continue until six cycles are administered unless unacceptable toxicity or progression occurs."
89578240|NCT01646203|Experimental|IMC-TR1|"Part A - Dose Escalation:~Cohort 1A: 1.25 mg/kg, intravenously (IV), every 2 weeks of the 6-week treatment cycle~Cohorts 1B-9: Dose Escalation from 12.5 mg to 1600 mg (flat dose), intravenously (IV), every 2 weeks of the 6-week treatment cycles~Cohorts 10-12: Dose escalation from 800 mg to 1600 mg (flat dose), intravenously (IV), weekly during the 6-week treatment cycles~Part B - Disease Specific Cohort Expansion:~Participants will be enrolled into each of three tumor-specific cohort expansions. Participants will be treated with recommended Phase 2 dose."
89578241|NCT02375347|Experimental|Chickpea Enhanced Diet|Fed an enhanced Chickpea diet over a short term period (Chickpea Enhanced Diet Short Term)
89578242|NCT02374957|Active Comparator|Cilostazol|Administer Cilostazol100 mg twice daily for 90 days.
89578243|NCT02374957|No Intervention|Control|No Cilostazol
89578244|NCT02374255|Experimental|GoC intervention|Oncologists trained using OncoTalk to have Goals of Care discussions.
89578245|NCT02374255|No Intervention|Usual Care|
89578246|NCT02308033|Active Comparator|Metronidazole vaginal gel|One applicator full at bedtime
89578247|NCT02308033|Placebo Comparator|Gel vehicle|One applicator full at bedtime
89578248|NCT02211261|Experimental|Cohort 1-PF-06293620 or placebo|Single Ascending Dose PF-06293620 or placebo
89578249|NCT02211261|Experimental|Cohort 2-PF-06293620 or placebo|Single Ascending Dose PF-06293620 or placebo
89578250|NCT02211261|Experimental|Cohort 3-PF-06293620 or placebo|Single Ascending Dose PF-06293620 or placebo
89578251|NCT02211261|Experimental|Cohort 4-PF-06293620 or placebo|Single Ascending Dose PF-06293620 or placebo
89578252|NCT02211261|Experimental|Cohort 5-PF-06293620 or placebo|Single Ascending Dose PF-06293620 or placebo
89578253|NCT02211261|Experimental|Cohort 6-PF-06293620 or placebo|Multiple Ascending Dose PF-06293620 or placebo
89578254|NCT02211261|Experimental|Cohort 7 PF-06293620 or placebo|Multiple Ascending Dose PF-06293620 or placebo
89578255|NCT02211261|Experimental|Cohort 8-PF-06293620 or placebo|Multiple Ascending Dose PF-06293620 or placebo
89578256|NCT02211261|Experimental|Cohort 9-PF-06293620 or placebo|Multiple Ascending Dose PF-06293620 or placebo
89578257|NCT02170077|Experimental|ODG - once-daily group|BIA 2-093 once-daily; Daily doses of BIA 2-093 were increased at four-weekly periods (400 mg, 800 mg and 1200 mg).
89578258|NCT02170077|Experimental|TDG - twice-daily group|BIA 2-093 twice-daily; Daily doses of BIA 2-093 were increased at four-weekly periods (400 mg, 800 mg and 1200 mg).
89578259|NCT02170077|Placebo Comparator|PLG - placebo group|placebo
89578260|NCT02210091|Experimental|<6 years old|
89578261|NCT02210091|Experimental|≥6 to <12 years|
89578262|NCT02338999|Experimental|Pioglitazone, then placebo|Treatment with pioglitazone up to 45 mg orally daily for three months. Followed by a two-month washout period before cross over to placebo orally daily for three months. A randomly selected subset of subjects underwent optional FDG-PET/CT for measurement of inflammatory activity in the blood vessels.
89578263|NCT02338999|Experimental|Placebo, then Pioglitazone|Treatment with placebo orally daily for three months. Followed by a two-month washout period before cross over to pioglitazone up to 45 mg daily orally for an additional three months. A randomly selected subset of subjects underwent optional FDG-PET/CT for measurement of inflammatory activity in the blood vessels.
89578264|NCT02169219|Experimental|Glucocorticoids and Rituximab|This is a single-arm trial. All patients receive both rituximab and glucocorticoids. The protocol calls for the discontinuation of prednisone within two months of the baseline visit.
89578265|NCT02191605|Experimental|electronic SBIRT (eSBIRT)|Participants in this condition will receive empathic exploration of their thoughts regarding marijuana use, provision of information on possible consequences of marijuana use during pregnancy and potential benefits of changing use (with permission), normed feedback, use of Motivational Interviewing techniques to elicit their own reasons for change, video testimonials modeling successful change, and information on change methods with optional goal setting.
89578266|NCT02191605|Experimental|Tailored texting|Participants in this condition will chose the frequency and time of text messages that will continue until childbirth or the participant opts out. The text messages will be a mix of marijuana targeted content (without directly referring to marijuana in a way that implies use by the participant) and general content related to healthy pregnancy; using appropriate humor and tips for community resources. Tailoring will focus on gestational age, self-efficacy, and social support.
88972540|NCT04712448||Patients|Patients with chronic diseases afferent to BioBIM
88972541|NCT00392873|Experimental|EAMD+Calories|This group contains women with exercise-associated menstrual disturbances (EAMD) and receives an intervention of increased caloric intake during the 12-month intervention. The targeted increase in caloric intake is 20-30% of baseline energy expenditure.
88972542|NCT00392873|No Intervention|EAMD Control|This group contains women with exercise-associated menstrual disturbances (EAMD) and undergoes the same procedures as the EAMD+Calories group. However, this group is instructed to maintain exercise and eating habits.
88972543|NCT00392873|No Intervention|Heathy Control|This group contains exercising women with regular, ovulatory menstrual cycles. this group is instructed to maintain body weight and exercise and eating habits.
88972544|NCT04711863|Experimental|Fluvoxamine|Start fluvoxamine 50 mg once, then 100 mg twice daily until discharge from community treatment center or for approximately 10 days. The maintenance dose may be reduced for tolerability reasons.
88972545|NCT04711863|Placebo Comparator|Placebo|Start ursodeoxycholate (UDCA) 100 mg once, then 100 mg twice daily until discharge from community treatment center or for approximately 10 days. The maintenance dose may be reduced for tolerability reasons.
88972546|NCT04712058|Experimental|Same-day initiation with BIC/F/TAF|
88972547|NCT04711668|Experimental|Group Ketamin|0.5 mg / kg i.v. ketamine bolus at induction and 0.25 mg / kg / hr i.v. ketamine infusion intraoperatively
88972548|NCT04711668|Experimental|Group Lidokain|1.5 mg / kg i.v. lidocaine bolus at induction and 1.5 mg / kg / hr i.v. lidocaine infusion intraoperatively
88972549|NCT04711668|Placebo Comparator|Group Placebo|i.v. saline (in the same volume and duration like group ketamine/lidokain)
88972550|NCT03526094|Active Comparator|Flavanols-capsules|Capsules containing 541 mg cocoa flavanols (75 mg epicatechin) and 315 g of milk (1% fat)
88972551|NCT03526094|Experimental|Flavanol-banana blend|Fruit blend prepared by mixing 177 g ripe, frozen bananas, 240 g almond milk and a chocolate flavored powder containing 638 mg cocoa flavanols (88 mg epicatechin)
88972552|NCT03526094|Experimental|Flavanol-high protein drink|Drink prepared by mixing 225 mL of a chocolate flavored high protein dairy drink with a CF powder containing 565 mg cocoa flavanols (78 mg epicatechin)
88972553|NCT03526094|Experimental|Flavanol-berry blend|Fruit blend prepared by mixing 120 g almond milk, 70 g water, 95 g yogurt, 50 g each strawberries, blueberries, blackberries, raspberries, 105 g crushed ice and a fruit-flavored powder containing 484 mg cocoa flavanols (68 mg epicatechin)
88972554|NCT03526094|Experimental|Flavanol-sports drink|Drink prepared by mixing 488 g of a sports drink with a CF powder containing 565 mg cocoa flavanols (78 mg epicatechin)
88972555|NCT03526094|Experimental|Flavanol-peanut butter toast|Prepared by mixing 32 g peanut butter with a chocolate flavored powder containing 653 mg cocoa flavanols (85 mg epicatechin) and spread on 1 slice toasted bread (50 g) and 50 g sliced strawberries
88972556|NCT03526094|Experimental|Flavanol-oats|Prepared by mixing 40 g quick oats with 237 g boiling water and combined with a chocolate flavored powder containing 653 mg cocoa flavanols (85 mg epicatechin)
88972557|NCT03526094|Experimental|Flavanol-yogurt|Prepared by 227 g yogurt (0% fat) mixed with a fruit-flavored powder containing 484 mg cocoa flavanols (68 mg epicatechin)
88972558|NCT03526094|Active Comparator|II- Flavanol drink|Drink prepared by mixing 240 g almond milk with a chocolate flavored powder containing 638 mg cocoa flavanols (88 mg epicatechin)
88972559|NCT03526094|Experimental|II- Flavanol drink + banana blend|Drink 1 (Flavanol drink): prepared by mixing 120 g almond milk with 638 mg cocoa flavanols (88 mg epicatechin) Drink 2 (Fruit blend): prepared by mixing 120 g almond milk blended with 177 g ripe, frozen bananas
89578267|NCT02191605|Experimental|eSBIRT & texting|Participants in this arm will receive both the computerized intervention and tailored text messaging intervention as described in the eSBIRT and Tailored texting arms.
89578268|NCT02191605|No Intervention|Assessment only|Participants in the arm will participant in screening and the baseline assessment conducted on the computer only. They will not receive an intervention.
89578269|NCT02191605|No Intervention|Screening only|Participants in this arm of the study will only answer the screening questions and will not be asked the baseline assessment or participate in an intervention.
89578270|NCT02191137|Experimental|Riociguat 0.5mg to 2.5 mg|Single arm, open label
89578271|NCT02168439|Experimental|Dexmedetomidine|Intranasal Dexmedetomidine 2 micrograms/kilogram once
89578272|NCT02168439|Experimental|Midazolam|Intranasal Midazolam 0.4 milligram/kilogram
89578273|NCT02190591|No Intervention|Pillow and Wedge|Receiving standard care for positioning during labor using pillows and wedges
88972560|NCT00031122||SBRR|Families with a child/pregnancy affected with spina bifida or anencephaly
88972561|NCT03465449|Active Comparator|usual care|
88972562|NCT03465449|Experimental|CKD-EDU arm|
88972563|NCT00031278|Experimental|Cohort 1|0.01 mg/kg CPG 7909 plus Herceptin®
88972564|NCT00031278|Experimental|Cohort 2|0.04 mg/kg CPG 7909 plus Herceptin®
88972565|NCT00031278|Experimental|Cohort 3|0.16 mg/kg CPG 7909 plus Herceptin®
88972566|NCT00031278|Experimental|Cohort 4|0.32 mg/kg CPG 7909 plus Herceptin®
88972567|NCT03228953|Experimental|Pharmacogenomic-guided therapy group|In this group, results of pharmacogenomic testing will be provided to the treating physician within 2-5 working days. Thus, the patient's treatment provider will be able begin antidepressant adjustments based on pharmacogenomic testing report within a week of the baseline visit.
88972568|NCT03228953|No Intervention|Treatment as usual (TAU) group|For patients randomized to this group, medication treatment decisions by the treating clinicians will be made without the availability of the pharmacogenomic report; however, the test results will be provided after the study completion to the patient treating physician.
89578274|NCT02190591|Experimental|Peanut Labor Ball|Use of the peanut labor ball within 30 minutes after epidural placement
89578275|NCT02190435|Experimental|ADAPT|Patients that receive intramedullary nail fixation with use of the Stryker ADAPT computer-assisted navigation system
89578276|NCT02190435|Active Comparator|Control|Patients that receive conventional technique intramedullary nail fixation without use of the Stryker ADAPT computer-assisted navigation system
89578277|NCT02338843|Experimental|LJPC-501 (angiotensin II)|Treatment arm
89578278|NCT02338843|Placebo Comparator|Placebo (0.9% sodium chloride solution)|Placebo arm
89578279|NCT02190279|Experimental|Suspected Localized Prostate Cancer|Patients with known localized prostate cancer with a soft tissue lesion at least 6mm or greater.
89578280|NCT02190279|Experimental|Biochemical Recurrence|Patients with biochemical prostate cancer relapse after definitive treatment
89578281|NCT02190279|Experimental|Known Metastatic Disease|Patients with identifiable metastatic disease on a conventional imaging modality. If only soft tissue metastasis, one lesion must measure 6mm or greater. Patients must have confirmation of prostate cancer prior to investigational imaging.
89578282|NCT02135445|Experimental|TAK-385|TAK-385 320 mg, tablets, orally, once, on Day 1, followed by TAK-385 120 mg, orally, once daily for 24 weeks. Each participant may have one upward dose adjustment of 40 mg for efficacy and/or one downward dose adjustment of 40 mg for safety during the study.
89578283|NCT02135445|Active Comparator|Degarelix|Degarelix 240 mg, injection, subcutaneous, on Day 1, followed by degarelix 80 mg, injection, subcutaneous, once every four weeks, for 24 weeks.
89578284|NCT02374099|Experimental|CC-486 and fulvestrant|CC-486 300 mg by mouth (PO) daily on days 1-21 of each 28 day cycle and fulvestrant 500mg by intramuscular (IM) injection on Days 1 and 15 of cycle 1 and day 1 of each subsequent cycle every 28 days.
89578285|NCT02374099|Experimental|Fulvestrant|Fulvestrant will be administered by intramuscular injection at a dose of 500 mg on days 1 and 15 of cycle 1 and day 1 of subsequent cycles.
89578286|NCT02134977||Leuprorelin Acetate|Subcutaneous administration of leuprorelin acetate 11.25 mg once every 12 weeks
89578287|NCT02374021|Active Comparator|Triple therapy (MTX+SSZ+HCQ)|Sulfasalazine (SSZ) 1 g bid and hydroxychloroquine (HCQ) 200 mg twice daily, not to exceed 6.5mg/kg HCQ (in addition to concomitant methotrexate [MTX]).
89578288|NCT02374021|Active Comparator|TNF inhibitor (etanercept or adalimumab)|etanercept 50 mg subcutaneously weekly or adalimumab 40 mg subcutaneously every other week (in addition to concomitant methotrexate, plus hydroxychloroquine, for subjects who were taking this at screening). Biologic treatment will be assigned randomly.
89578289|NCT02372383|Experimental|Fasting|"Subjects with CF will be given the antimycobacterial drugs in the fasting state, without supplemental pancreatic enzymes~Rifampin 10mg/kg oral once daily (max 600mg, round to closest 150mg)~Ethambutol 15mg/kg oral once daily (max 2500mg, round to nearest 100mg)~Azithromycin 10mg/kg oral once daily (max 500mg, rounded to the nearest 250mg)~Blood will be drawn at time points 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post dose"
89578290|NCT02372383|Experimental|Food/Enzymes|"Subjects with CF will be given the antimycobacterial drugs with a standardized meal plus a typical meal-dose of pancreatic enzymes (Pancrelipase).~Rifampin 10mg/kg oral once daily (max 600mg, round to closest 150mg)~Ethambutol 15mg/kg oral once daily (max 2500mg, round to nearest 100mg)~Azithromycin 10mg/kg oral once daily (max 500mg, rounded to the nearest 250mg)~Blood will be drawn at time points 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post dose"
89578291|NCT02372383|Active Comparator|Healthy Controls|"Healthy subjects without CF will be given the antimycobacterial drugs in the fasting state, without supplemental pancreatic enzymes~Rifampin 10mg/kg oral once daily (max 600mg, round to closest 150mg)~Ethambutol 15mg/kg oral once daily (max 2500mg, round to nearest 100mg)~Azithromycin 10mg/kg oral once daily (max 500mg, rounded to the nearest 250mg)~Blood will be drawn at time points 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post dose"
89578292|NCT01648699|Experimental|Osmotic Release Oral System (OROS) Hydromorphone|OROS Hydromorphone will be administered as either 8, 12, 16, 20, 24, 32, 36 or 40 mg oral tablet once daily in the morning. For all participants, 24-hour stable opioid dose (of either morphine or oxycodone) will be converted to a single daily dose of OROS hydromorphone using standard equi-analgesic ratios and dose will be increased if needed, but not more than 40 mg and not more frequently than every two days. The study drug will be administered up to 28 days.
89578293|NCT02134353|Experimental|Experimental arm A|Active treatment. Inhaled Mannitol
89578294|NCT02134353|Placebo Comparator|Arm B - Control|Arm B
89578295|NCT01646125|Experimental|AUY922 arm|"Participants were assigned to one of two treatment arms in a ratio of 1:1. This was the investigational drug arm.~AUY922 was to be administered weekly."
89578296|NCT01646125|Active Comparator|chemotherapy arm|"Participants were assigned to one of two treatment arms in a ratio of 1:1. This was the control arm drug arm.~Pemetrexed or docetaxel was to be was to be given once every three weeks."
88972569|NCT03152279||Celiac Disease|Patients with suspected Celiac Disease who plan to undergo duodenal biopsy as part of routine clinical care
88972570|NCT03152279||Control|Patients scheduled for an upper endoscopy for indication other than evaluation of Celiac Disease or concern for CeD as part of routine clinical care
88972571|NCT03152240||Women patients|Women patients
88972572|NCT03152240||Men patients|Men patients
88972573|NCT00031395|Active Comparator|1|
88972574|NCT00031395|Active Comparator|2|
88972575|NCT00031395|Active Comparator|3|
88972576|NCT00031395|Placebo Comparator|4|
88972577|NCT00031434|Experimental|1|All subjects enrolled into this study will receive 6 weeks (42 days) of antiviral therapy (valganciclovir/ganciclovir).
88972578|NCT03152123|Experimental|Pitolisant HCl, 40 mg|Pitolisant HCl, 40 mg administered as 2 capsules, each containing 1 × 20 mg pitolisant HCl tablet (over-encapsulated), and 2 capsules, each containing 1 × 100 mg lactose tablet (over-encapsulated)
88972579|NCT03152123|Experimental|Pitolisant HCl, 240 mg|Pitolisant HCl, 240 mg administered as 4 capsules, each containing 60 mg pitolisant HCl (3 x 20 mg pitolisant HCl tablets, encapsulated in 1 capsule)
88972580|NCT03152123|Active Comparator|Phentermine HCl, 60 mg|Phentermine HCl, 60 mg administered as 2 capsules, each containing 1 × 30 mg phentermine HCl capsule (over- encapsulated), and 2 capsules, each containing 1 × 100 mg lactose tablet (over-encapsulated)
88972581|NCT03152123|Placebo Comparator|Placebo|Placebo administered as 4 capsules, each containing 1 × 100 mg lactose tablet (over-encapsulated)
89029333|NCT02314481|Experimental|No actionable mutation - MPDL3280A|"MPDL3280A 1200mg IV infusion - 3 weekly until progression or unacceptable toxicity.~Or in combination with chemotherapy:~For non-squamous: Cisplatin or Carboplatin plus pemetrexed & MPDL3280A - 3 weekly for 4 cycles followed by MPDL3280A and pemetrexed 3 weekly until progression or unacceptable toxicity or completion of a total of 35 cycles. MPDL3280A will then continue 3 weekly until progression or unacceptable toxicity.~For squamous: Carboplatin plus paclitaxel & MPDL3280A - 3 weekly for 4 cycles followed by MPDL3280A 3 weekly until progression or unacceptable toxicity."
89578297|NCT01362790|Experimental|Mesothelioma Pilot Phase Regimen A|"Drug: Pentostatin Regimen A: Cycle 1: 4 mg/m^2 on days 1, 5 and 9 of 30 day cycle Cycles 2-4: 4 mg/m^2 on day 1 of 21 day cycle~Other Names:~• Nipent Drug: Cyclophosphamide Regimen A:Cycle 1: 200 mg/day on days 1-12 of 30 day cycle Cycles 2-4: 200 mg/day on days 1-4 of 21 day cycle~Other Names:~• Cytoxan Drug: SS1 (dsFv)PE38 Regimen A: Cycle 1: 35 mcg/kg days 10, 12, and 14. Cycles 2-4: Days 2, 4, and 6, for a maximum of six treatment cycles."
89578298|NCT01362790|Experimental|Mesothelioma Pilot Phase Regimen B|"Drug: Pentostatin Regimen B: Cycle 1: 4 mg/m^2 or 2 mg/m^2 on days 1, 5, 9, 13 and 17 of 38 day cycle Cycles 2-6: 4 mg/m^2 on days 1 and 5 of 25 day cycle Regimen B: Cycle 1: 4 mg/m^2 on days 1, 5, 9, 13 and 17 of 38 day cycle Cycles 2-6: 4 mg/m^2 on days 1 and 5 of 25 day cycle~Other Names:~• Nipent Drug: Cyclophosphamide Regimen B:Cycle 1: 200 mg/day on days 1-20 of 38 day cycle Cycles 2-4: 200 mg/day on days 1-8 of 25 day cycle~Other Names:~• Cytoxan Drug: SS1 (dsFv)PE38 Regimen B: Cycle 1: 35mcg/kg days 18, 20, and 22. Cycles 2-4: (Days 6, 8, and 10), for a maximum of six treatment cycles."
89578299|NCT01362790|Experimental|Phase 2 Peritoneal Mesothelioma Pilot Expansion Phase|"Drug: Pentostatin Regimen B: Cycle 1: 4 mg/m^2 or 2 mg/m^2 on days 1, 5 and 9 of 38 day cycle Cycles 2-6: 4 mg/m^2 on day 1 and 5 of 25 day cycle~Other Names:~• Nipent Drug: Cyclophosphamide Regimen B:Cycle 1: 200 mg/day on days 1-20 of 38 day cycle Cycles 2-4: 200 mg/day on days 1-8 of 25 day cycle~Other Names:~• Cytoxan Drug: SS1(dsFv)PE38 Regimen B: Cycle 1: 35 mcg/kg or 25 mcg/kg days 18, 20 and 22. Cycles 2-4: Days 6, 8, and 10, for a maximum of six treatment cycles."
89578300|NCT01362790|Experimental|Phase 2 Pleural Mesothelioma Pilot Expansion Phase|"Drug: Pentostatin Regimen A: Cycle 1: 4 mg/m^2 on days 1, 5 and 9 of 30 day cycle Cycles 2-4: 4 mg/m^2 on day 1 of 21 day cycle~Other Names:~• Nipent Drug: Cyclophosphamide Regimen A:Cycle 1: 200 mg/day on days 1-12 of 30 day cycle Cycles 2-4: 200 mg/day on days 1-4 of 21 day cycle~Other Names:~• Cytoxan Drug: SS1(dsFv)PE38 Regimen A: Cycle 1: 35 mcg/kg or 25 mcg/kg days 10, 12 and 14. Cycles 2-4: Days 2, 4, and 6, for a maximum of six treatment cycles."
89578301|NCT01362790|Experimental|Mesothelioma Positive Ca Dose De-escalation Pilot Regimen A|"Drug: Pentostatin Regimen A: Cycle 1: 4 mg/m^2 on days 1, 5 and 9 of 30 day cycle Cycles 2-4: 4 mg/m^2 on day 1 of 21 day cycle~Other Names:~• Nipent Drug: Cyclophosphamide Regimen A:Cycle 1: 200 mg/day on days 1-12 of 30 day cycle Cycles 2-4: 200 mg/day on days 1-4 of 21 day cycle~Other Names:~• Cytoxan Drug: SS1(dsFv)PE38 Regimen A: Cycle 1: 35 mcg/kg or 25 mcg/kg days 10, 12 and 14. Cycles 2-4: Days 2, 4, and 6, for a maximum of six treatment cycles."
89029334|NCT02314481|Experimental|BRAF V600 - vemurafenib|Vemurafenib 960mg twice daily until PD
89578302|NCT01362790|Experimental|Phase 2 Pancreatic Adenocarcinoma Pilot Phase Regimen A|"Drug: Pentostatin Regimen A: Cycle 1: 4 mg/m^2 on days 1, 5 and 9 of 30 day cycle Cycles 2-4: 4 mg/m^2 on day 1 of 21 day cycle~Other Names:~• Nipent Drug: Cyclophosphamide Regimen A:Cycle 1: 200 mg/day on days 1-12 of 30 day cycle Cycles 2-4: 200 mg/day on days 1-4 of 21 day cycle~Other Names:~• Cytoxan Drug: SS1(dsFv)PE38 Regimen A: Cycle 1: 35 mcg/kg or 25 mcg/kg days 10, 12 and 14. Cycles 2-4: Days 2, 4, and 6, for a maximum of six treatment cycles."
89578303|NCT01362790|Experimental|Phase 2 Lung Adenocarcinoma Pilot Expansion Phase Regimen A|"Drug: Pentostatin Regimen A: Cycle 1: 4 mg/m^2 on days 1, 5 and 9 of 30 day cycle Cycles 2-4: 4 mg/m^2 on day 1 of 21 day cycle~Other Names:~• Nipent Drug: Cyclophosphamide Regimen A:Cycle 1: 200 mg/day on days 1-12 of 30 day cycle Cycles 2-4: 200 mg/day on days 1-4 of 21 day cycle~Other Names:~• Cytoxan Drug: SS1(dsFv)PE38 Regimen A: Cycle 1: 35 mcg/kg or 25 mcg/kg days 10, 12 and 14. Cycles 2-4: Days 2, 4, and 6, for a maximum of six treatment cycles."
89578304|NCT02167893||Subcutaneous administration of leuprorelin acetate|Subcutaneous administration of leuprorelin acetate once every 12 weeks as daily medicinal practice.
89578305|NCT04759989|Active Comparator|30cc/kg ideal body weight (IBW)|"30cc/kg intravenous fluids based on the patients calculated ideal body weight will be administered when randomized to this arm~Using Devine's formula. (men: 50kg + 2.3kg * (height(in) - 60); women: 45.5kg + 2.3kg * (height(in) - 60)"
89029335|NCT02314481|Experimental|ALK/RET gene rearrangement - alectinib|Alectinib 600mg twice daily until PD
89029336|NCT02314481|Experimental|HER2 amplification - T-DM1|Trastuzumab emtansine (T-DM1) 3.6mg/kg - 3 weekly until PD IV infusion
89029337|NCT02307630|Experimental|PET Imaging using 124I-Humanized 3F8|124I-hu3F8 at a dose of 3mCi/m2 (with a maximum dose of 5mCi) will be injected IV. 124I-hu3F8 PET/CT scans will be performed at approximately 2-4 hours, 18-26hours, 48-72 hours and 96-144 hours after injection of 124I-hu3F8. A low dose CT scan will be obtained with each PET scans. PET/CT scan images will be analyzed to determine biodistribution of 124I-hu3F8 and to determine dosimetry to organs and sites of disease. Comparison of tumor targeting and tumor dosimetry will be made between the two cohorts of patients: (a) NB and (b) other solid tumors. Blood will be drawn where feasible at multiple time points: approximately 0h, 0.5h, 1h, 2h, 4-8h, 24h, 48h, 96h and 120h-144h after injection of 124I-hu3F8 and radioactivity measured to determine pharmacokinetics of 124I-hu3F8.
89029338|NCT02217540|Experimental|Experimental Group|Experimental Group consist of the physiotherapy standard protocol and active movement plus accessory mobilizations of the humeral head using Mulligan Concept Mobilisation with Movement.
89029339|NCT02217540|Active Comparator|Control Group|Standard protocol proposed by the Spanish Rheumatology Society for shoulder dysfunction
89029340|NCT02174666|Active Comparator|Red clover extract|Group recieving daily red clover extract containing isoflavones (80 mg/d), along with calcium (1040 mg/d), vitamin D (25µg/d) and magnesium (487mg/d).
89029341|NCT02174666|Placebo Comparator|Placebo group|Group recieving daily placebo extract (with no isoflavone content), calcium (1040 mg/d), vitamin D (25µg/d) and magnesium (487mg/d).
89029342|NCT02074631|Active Comparator|Control group|Subjects will receive a standard recommended dose of calcium and vitamin D.
89578306|NCT04759989|Active Comparator|30cc/kg adjusted body weight (AdjBW)|"30cc/kg intravenous fluids based on the patients calculated adjusted body weight will be administered when randomized to this arm~Calculated by the following formula: AdjBW = IBW + 0.4(ABW - IBW)."
89578307|NCT04759989|Active Comparator|30cc/kg actual body weight (ABW)|"30cc/kg intravenous fluids based on the patients actual body weight will be administered when randomized to this arm~Patients will receive an initial fluid bolus of 30 cc/kg of actual body weight"
89578308|NCT02167035|Active Comparator|Combigan Two Times Daily (BID)|Combigan 0.2%/0.5% one drop Two Times Daily (BID)
89578309|NCT02167035|Active Comparator|Simbrinza Three Times Daily (TID)|Simbrinza 1/0.2% one drop Three Times Daily (TID)
89578310|NCT01615198|Experimental|LCZ696|Participants were treated with one LCZ696 100 mg tablet and one placebo of LCZ696 every day (qd) for 4 weeks along with placebo of Olmesartan 10 mg capsule qd. Participants were then up-titrated to LCZ 200 mg tablet and one placebo of LCZ696 qd for 6 weeks along with placebo of Olmesartan 20 mg capsule qd. Participants, who did not achieve their goal BP, were uptitrated to 2 LCZ696 200 mg tablets (LCZ696 400 mg) qd for 4 weeks along with placebo of Olmesartan 40 mg capsule qd.
89578311|NCT01615198|Active Comparator|Olmesartan|Participants were treated with olmesartan 10 mg qd for 4 weeks along with 2 placebo of LCZ696 tablets qd. Participants were then uptitrated to olmesartan 20 mg qd for 6 weeks along with 2 placebo of LCZ696 tablets qd. Participants, who did not achieve their goal BP, were uptitrated to olmesartan 40 mg qd for the remaining 4 weeks and 2 placebo LCZ696 tablets qd.
89578312|NCT02337907|Placebo Comparator|Placebo comparator|
89578313|NCT02337907|Experimental|BI 409306 dose 1|
89578314|NCT02337907|Experimental|BI 409306 dose 2|
89578315|NCT02337907|Experimental|BI 409306 dose 3|
89578316|NCT02337907|Active Comparator|Active Comparator Donepezil|
89578317|NCT02337907|Experimental|BI 409306 dose 4|
89578318|NCT01913470|Experimental|Losartan then Placebo|0.4mg/kg/day (max 25mg) for one week and then increase to 0.8mg/kg/day (max 50mg) for 7 additional weeks then placebo pill for 8 weeks
89578319|NCT01913470|Experimental|Sugar pill|placebo pill taken for 8 weeks then 0.4mg/kg/day (max 25mg) for one week and then increase to 0.8mg/kg/day (max 50mg) for 7 additional weeks
89578320|NCT02372071|Other|BiliCare|Two measurements with the BiliCare device
88972582|NCT00031629|Experimental|Treatment (gemcitabine, docetaxel, G-CSF, pegfilgrastim)|Patients receive gemcitabine IV over 90 minutes on days 1 and 8, docetaxel IV over 1 hour on day 8, and G-CSF SC on days 9-15 or pegfilgrastim SC on day 9 only. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
89578321|NCT02337751|Experimental|TVP-1012 1mg Group|TVP-1012 (1 mg/day) once daily, either before or after breakfast.
89578322|NCT02166333|Active Comparator|200 IU/d|200 IU/d cholecalciferol (vitamin D3) tablets that can be swallowed or consumed sublingually
89578323|NCT02166333|Active Comparator|1000 IU/d|1000 IU/d cholecalciferol (vitamin D3) tablets that can be swallowed or consumed sublingually
89578324|NCT02166333|Active Comparator|2000 IU/d|2000 IU/d cholecalciferol (vitamin D3) tablets that can be swallowed or consumed sublingually
89578325|NCT02166333|Active Comparator|4000 IU/d|4000 IU/d cholecalciferol (vitamin D3) tablets that can be swallowed or consumed sublingually
89578326|NCT02132949|Experimental|Cohort A: ddAC, Paclitaxel, Pertuzumab, Trastuzumab|Participants received neoadjuvant treatment with dose-dense doxorubicin and cyclophosphamide (ddAC), with administration of doxorubicin 60 milligrams per square meter (mg/m^2) intravenously (IV) once every 2 weeks (q2w) and cyclophosphamide 600mg/m^2 IV q2w for 4 cycles, followed by paclitaxel 80mg/m^2 IV once weekly (qw) for 12 weeks. Pertuzumab (840 milligrams [mg] IV loading dose then 420mg IV q3w) and trastuzumab (8 milligrams per kilogram [mg/kg] IV loading dose then 4mg/kg IV q3w) were administered along with paclitaxel for 4 cycles (8 cycles of chemotherapy in total prior to surgery). Following surgery, participants received adjuvant treatment with pertuzumab and trastuzumab IV q3w (up to 13 cycles), for a total of 17 cycles of pertuzumab and trastuzumab therapy during the study. Radiotherapy and adjuvant hormonal therapy were also given as clinically indicated. Following treatment completion/discontinuation, participants were followed for safety and efficacy for up to 5 years.
88972583|NCT03152084|Experimental|Arm 1|T2DM subjects with an eGFR (CKD-EPI) between ≥25 and ≤50 mL/min/1.73m2 at the Screening Visit.
88972584|NCT03152084|Experimental|Arm 2|T2DM subjects with an eGFR (CKD-EPI) between >90 and ≤130 mL/min/1.73m2 for patients aged 59 or younger, between >85 and ≤130 mL/min/1.73m2 for patients aged 60 to 69, and between >75 and ≤130 mL/min/1.73m2 for patients aged 70 or older at the Screening Visit.
88972585|NCT03152084|Experimental|Arm 3|Non-diabetic subjects with an eGFR (CKD-EPI) between ≥25 and ≤50 mL/min/1.73m2 at the Screening Visit.
88972586|NCT02971449|Experimental|Tablets only|100 VHTs will receive Amazon Fire Tablets with pre-loaded instructional videos; this is the intervention arm since this involves introduction of a new technology to this realm
88972587|NCT02971449|Active Comparator|ICCM traditional training|100 VHTs will receive traditional 1 day 'in-person' training as an active comparator intervention, but participants in this arm will not receive any tablets
88972588|NCT03152045|Experimental|Communication Intervention|Investigators are testing the feasibility, acceptability, and preliminary efficacy of a systems intervention that asks adolescents to report their risk behaviors before their encounter. Both clinicians and patients will receive a Feedback Guide that gives them tips on effective ways to communicate about these behaviors.
88972589|NCT03152045|No Intervention|Standard Of Care|Investigators will compare patients randomized into the intervention group to those who receive standard of care.
88972590|NCT03152006|No Intervention|Control|The control arm does not receive the ACT intervention.
89029343|NCT02074631|Experimental|Pamidronate Group|Subjects randomized to pamidronate treatment will receive infusions approximately 100, 180, and 270 days after HCT along with calcium and vitamin D.
89578327|NCT02132949|Experimental|Cohort B: FEC, Docetaxel, Pertuzumab, Trastuzumab|Participants received neoadjuvant treatment with 5-fluorouracil, epirubicin, and cyclophosphamide (FEC), with administration of 5-fluorouracil 500mg/m^2 intravenously (IV) q3w, epirubicin 100mg/m^2 IV q3w, and cyclophosphamide 600mg/m^2 IV q3w for 4 cycles, followed by docetaxel (with starting dose of 75mg/m^2 in Cycle 5, then 100mg/m^2 for Cycles 6-8) q3w for 4 cycles. Pertuzumab (840 mg IV loading dose then 420mg IV q3w) and trastuzumab (8 mg/kg IV loading dose then 4mg/kg IV q3w) were given along with doectaxel for 4 cycles (8 cycles of chemotherapy in total prior to surgery). Following surgery, participants received adjuvant treatment with pertuzumab and trastuzumab IV q3w (up to 13 cycles), for a total of 17 cycles of pertuzumab and trastuzumab therapy during the study. Radiotherapy and adjuvant hormonal therapy were also given as clinically indicated. Following treatment completion/discontinuation, participants were followed for safety and efficacy for up to 5 years.
89578328|NCT02165397|Experimental|Randomized Study (Ibrutinib + Rituximab)|Ibrutinib: 420 mg (3 capsules x 140 mg) orally administered daily beginning from Day 1. Rituximab: 375 mg/m^2 intravenous (IV) per package insert weekly for four consecutive weeks, followed by a second four-weekly rituximab course after a three-month interval.
89578329|NCT02165397|Experimental|Randomized Study (Placebo + Rituximab)|Placebo: 3 capsules of placebo orally administered daily beginning from Day 1. Rituximab: 375 mg/m^2 IV per package insert weekly for four consecutive weeks, followed by a second four-weekly rituximab course after a three-month interval.
89578330|NCT02165397|Experimental|Open-Label Substudy (Ibrutinib)|Ibrutinib: 420 mg (3 capsules) orally administered daily beginning from Day 1.
89578331|NCT02132637|Experimental|Insulin Peglispro|Standard dose of insulin peglispro administered subcutaneously (SQ) once daily for 4 weeks in one of two study periods. Double dose of insulin peglispro administered once, SQ on day 3 of the inpatient stay.
89578332|NCT02132637|Experimental|Insulin Glargine|Standard dose of insulin glargine administered subcutaneously (SQ) once daily for 4 weeks in one of two study periods. Double dose of insulin glargine administered once, SQ on day 3 of the inpatient stay.
89578333|NCT02164929|Active Comparator|Paravertebral block|Bilateral PVB will be placed between T7-T10 interspaces preoperatively. Patients will be in a sitting position which allows easy identification of landmarks, and the patients are often more comfortable. Ultrasound will be used to identify the paravertebral space. At the appropriate dermatome under aseptic precautions, the needle (22-gauge, 8-10-cm short beveled spinal needle) will inserted 2.5-3 cm lateral to the most cephalad aspect of the spinous process and advanced perpendicular to the skin in all planes to contact the transverse process 3 of the vertebra below at a variable depth (2-4 cm). A 10 mL ropivacaine 0.25% will be injected at both T7 and T9 levels on each side (40 mL in total).
89578334|NCT02164929|Active Comparator|TAP block|Bilateral posterior and subcostal TAP blocks guided by ultrasound will be performed in the preoperative holding area. A total of 80 mL ropivacaine 0.25% (4 injections, 20 mL per injection) will be injected evenly upon identification of the appropriate planes. In the event the placement of block is uncomfortable for the patients, it will be performed after induction of anesthesia. This approach is currently practiced in the OR. Extent and degree of anesthetic blockage will be measured using a 5-point sensation scale following the procedure at 4 areas on the anterior abdominal wall (above and below the umbilicus bilaterally).
89578335|NCT02164929|Active Comparator|Epidural|"An epidural catheter will be inserted between T8-10 in the preoperative holding area, and a test dose of 1.5% lidocaine with 1:200,000 epinephrine will be given. Extent and degree of anesthetic blockage will be measured using a 5-point sensation following the procedure and postoperatively at 4 areas on the anterior abdominal wall (above and below the umbilicus bilaterally).~A bolus does of epidural hydromorphone (400-800 mcg) will be given preoperatively. An infusion of bupivacaine 0.25% at 4-6 ml/hour will be commenced before incision, and if tolerated, continued throughout surgery. Adjustments that may be required secondary to specific patient hemodynamic status will be left to the discretion of the individual anesthesiologist and guided by the specific patient requirements."
89578336|NCT02164929|Active Comparator|No block (PCA alone)|Premedication with midazolam up to 2 mg. General anesthesia is induced with propofol 1-2.5 mg/kg. Dexamethasone 4 mg IV will be administered after induction of anesthesia. Anesthesia will be maintained with sevoflurane to keep a bispectral index of between 40-60. Neuromuscular blocking drug and reversal agent of choice may be used. Local infiltration with 10 mL of plain ropivacaine 0.25% will be administered at the surgical incision site at the end of surgery. Acetaminophen 1g IV will be administered following induction of anesthesia will be administered at the end of the procedure
89578337|NCT04749615|Placebo Comparator|No PAI + ACB & IPACK|Control: saline injection (same injection technique and volumes as described for the active intervention, of normal saline)
88972591|NCT03152006|Experimental|ACT Intervention|Intervention activities include the three components of the ACT intervention: (1) alternating pediatric and adult clinic visits in the 12 month pre-transfer period (2) peer facilitated organized support group during the 24-month graduated transition period and (3) patient advocate and case management team to coordinate transfer process.
88972592|NCT03151928||women presenting with vaginitis symptoms|"Women with vaginitis seeking routine care will be approached to have five additional swabs collected during their pelvic exam~vaginal swab for qualitative PCR using the BD Max Vaginal Panel on the automated BDMAX System~Vaginal smear for evaluation with Gram's stain and Nuget's criteria~Vaginal swab for yeast culture~Vaginal swab for Trichomonas vaginalis NAAT~Vaginal swab for discrepant analysis testing"
88972593|NCT00031707|Active Comparator|megestrol + placebo|"Patients receive oral megestrol once daily and oral placebo twice daily. Treatment continues in the absence of unacceptable toxicity and as long as the patient and physician feel it is beneficial.~Quality of life is assessed at baseline, weekly for 1 month, and then monthly thereafter during study treatment.~Patients are followed every 6 months for 5 years."
88972594|NCT00031707|Active Comparator|eicosapentaenoic acid + placebo|"Patients receive oral placebo once daily and an eicosapentaenoic acid (EPA)-enriched nutritional supplement twice daily. Treatment continues in the absence of unacceptable toxicity and as long as the patient and physician feel it is beneficial.~Quality of life is assessed at baseline, weekly for 1 month, and then monthly thereafter during study treatment.~Patients are followed every 6 months for 5 years."
89029344|NCT02004691|Placebo Comparator|Placebo|Placebo (saline) administered intravenously once every 2 weeks during the 52 weeks of the primary analysis period for patients randomized to placebo.
89029345|NCT02004691|Experimental|GZ402665|Olipudase alfa dose (3 mg/kg body weight) in saline administered intravenously once every 2 weeks during the 52 weeks of the primary analysis period for patients randomized to olipudase alfa, and during the extension treatment period for all patients.
89029346|NCT01991379|Experimental|MEK162 in Combination With Imatinib Mesylate|Pts will be treated with the combination therapy of MEK162 & imatinib. The phase Ib portion of the study, pts will receive imatinib at 400 mg once daily & MEK162 at the standard 3+3 escalation doses. Phase Ib expansion cohort, pts will receive the RP2D: imatinib 400 mg once daily (standard of care first line imatinib dose) & MEK162 at the RP2D twice daily. The phase II portion of the study, pts will receive imatinib at 400 mg once daily & MEK162 at the RP2D. The MEK162 RP2D was originally determined based on the phase Ib escalation data & it was established as 45 mg BID. After the completion of the phase Ib dose expansion & initiation of phase II, the MEK162 RP2D was reduced to 30 mg BID30 for better long term tolerability. Patient's will now begin MEK162 at the revised RP2D of 30 mg BID. 1 cycle is 28 days. If no progression of the tumor is seen, pts will continue on therapy. Pts who have progression of disease will proceed directly to second line therapy as per standard of care.
89029347|NCT01936935|Experimental|Low-fat dairy|3 servings/d of low-fat dairy
89029348|NCT01936935|Placebo Comparator|Sugar-sweetened beverages|3 servings/d of sugar-sweetened foods
89029349|NCT01893710||Control|'Biopsy sampling': Peritoneal biopsies without kidney disease, i.e. diseases not related to the kidney and not affecting the peritoneum. This group is accomplished.
89029350|NCT01893710||chronic kidney disease|Samples will obtained from patients with chronic kidney disease stage 5 (at time of catheter Insertion)
89029351|NCT01893710||Peritoneal dialysis|Patients on PD with different PD fluids and intercurrent abdominal surgery and at time of renal transplantation.
89578338|NCT04749615|Active Comparator|PAI + ACB & IPACK|Active intervention: Periarticular injection: one deep injection prior to cementation and then a second more superficial injection prior to closure. The deep injection will consist of bupivacaine 0.25% with 1:200,000 epinephrine, 30 cc; morphine, 8 mg/ml, 1cc; methylprednisolone, 40 mg/ml, 1 ml; cefazolin, 500 in 10 ml; normal saline, 22cc. The superficial injection will be 20 ml 0.25% bupivacaine
89578339|NCT01888432|Experimental|Everolimus + reduced tacrolimus|Everolimus + reduced tacrolimus ± corticosteroids
89578340|NCT01888432|Active Comparator|Standard tacrolimus|Standard tacrolimus ± corticosteroids
89578341|NCT02188719|Experimental|Cohort 1 - Treg-supportive IS only|3 subjects (Cohort 1a) at site 1 (UCSF) and 3 subjects (Cohort 1b) from site 2 (Mayo Rochester) will receive Treg-Supportive immunosuppression (IS) regimen and will not receive Donor-Alloantigen-Reactive T Regulatory Cells (darTregs). Progression from one cohort to the next will depend on the cumulative incidence of sentinel adverse events.
89578342|NCT02188719|Experimental|Cohort 2 - darTreg infusion,50 million(range 25 to 60 million)|At least 3 subjects will receive a single infusion of 50 million darTregs. Progression from one cohort to the next will depend on the cumulative incidence of sentinel adverse events.
89578343|NCT02188719|Experimental|Cohort 3 - darTreg infusion,200 million(range100-240 million)|At least 3 subjects will receive a single infusion dose of 200 million darTregs. Progression from one cohort to the next will depend on the cumulative incidence of sentinel adverse events.
89578344|NCT02188719|Experimental|Cohort 4 - darTreg infusion,800 million(range 400-960 million)|Six subjects will receive a single infusion of 800 million darTregs.
89578345|NCT01934140|Experimental|ACWY-TT group|All subjects vaccinated with MenACWY-TT in study MENACWY-TT-015 will be assigned to this group. At Month 120 after primary vaccination, these subjects will be vaccinated with a booster dose of MenACWY-TT in this study.
89578346|NCT01934140|Active Comparator|MenPS group|All subjects vaccinated with Mencevax ACWY in study MENACWY-TT-015 will be assigned to this group. At Month 120 after primary vaccination, these subjects will be vaccinated with a dose of MenACWY-TT in this study.
89578347|NCT01933672|Experimental|PF-04937319 once-daily|
89578348|NCT01933672|Experimental|PF-04937319 split-dose|
89578349|NCT01933672|Active Comparator|Sitagliptin once-daily|
89578350|NCT02164539|Experimental|Treatment Phase A|Eligible subjects will enter a 4-week run-in period and will receive fluticasone propionate/salmeterol. Subjects will then be randomized to receive fluticasone furoate 100 mcg, fluticasone furoate/umeclidinium bromide 100/15.6 mcg, fluticasone furoate/umeclidinium bromide 100/62.5 mcg, fluticasone furoate/umeclidinium bromide 100/125 mcg, fluticasone furoate/umeclidinium bromide 100/250 mcg, or fluticasone furoate/vilanterol 100/25 mcg, respectively for 4 weeks
89578351|NCT02164539|Experimental|Treatment Phase B|Subjects completing Treatment Phase A will be randomized to receive either fluticasone furoate/umeclidinium bromide100/250 mcg or fluticasone furoate/umeclidinium bromide/vilanterol 100/250/25 mcg for 1 week.
89578352|NCT02164539|Experimental|Treatment Phase C|Subjects completing Treatment Phase B will be randomized to receive either the same treatment as in Treatment Phase B, or the same treatment minus the umeclidinium bromide component, for 1 week.
89578353|NCT02188485|Experimental|ENGAGE: a social engagement intervention|ENGAGE is a brief psychotherapy that specifically targets increased social engagement and activity. The study will use the ENGAGE manual developed by Drs. Alexopoulos, Arean and their colleagues, focusing on increased engagement in activities that allow subjects to be social (targeting thwarted belongingness) or contribute to the well-being of others (targeting perceived burdensomeness).
89578354|NCT02188485|No Intervention|Care-as-Usual|Care as usual in primary care with study assessments.
89578355|NCT02132247|Experimental|Flector Patch|Flector Patch is a transdermal delivery system containing 180 mg of diclofenac hydroxyethylpyrrolidine. The patch will be used twice-a-day for up to two weeks, or until pain resolution, whichever comes first.
89578356|NCT01629381|Experimental|Rivaroxaban|Oral Rivaroxaban 10 mg od for 7 days
89578357|NCT01629381|Placebo Comparator|Placebo|oral placebo od for 7 days
89578358|NCT02131311|Experimental|pessary|disposable, single-use pessary
89578359|NCT05269017|Experimental|Case group|The case group patients will receive vitamin D3 nasal drops
89578360|NCT05269017|Active Comparator|Control group|The control group will remove local corticosteroid spray
89578361|NCT01628913|Experimental|BEZ235|Patients received BEZ235 400 mg bid p.o. (by mouth, twice daily)
89029352|NCT01893710||Post PD and with functioning graft|Samples will also be collected and analysed from patients with renal transplantation after PD at time of and tenckhoff catheter removal several weeks after Tx or other intercurrent abdominal surgery.
89578362|NCT01628913|Active Comparator|Everolimus|Patients received Everolimus 10 mg qd p.o. (by mouth, daily)
89578363|NCT02164383|Experimental|Mobile Games|"This arm of the project will address the following question:~How effective is the following intervention? Nicotine patch plus behavioral cessation counseling with access to Mobile Games."
89029353|NCT01859858|Experimental|curcumin + irinotecan (part 1)|Oral Curcumin (1, 2, 3,or 4 grams per day) for 4 days prior to irinotecan + 200 mg/m2 irinotecan IV, days 1 and 15
89029354|NCT01859858|Experimental|curcumin + irinotecan (part 2)|MTD oral Curcumin as determined in part 1 + 200 mg/m2 irinotecan IV, days 1 and 15
89578364|NCT02164383|Experimental|No Mobile Games|"This arm of the project will address the following question:~How effective is the following intervention:~Nicotine patch plus behavioral cessation counseling without access to Mobile Games."
89578365|NCT02131233|Experimental|Reformulated Raltegravir|Reformulated raltegravir 1200 mg (2x 600 mg tablets) orally once daily plus placebo to raltegravir 1 tablet orally twice daily plus TRUVADA™ orally once daily for 96 weeks
89578366|NCT02131233|Active Comparator|Raltegravir|Raltegravir 400 mg tablet orally twice daily plus placebo to reformulated raltegravir 2 tablets orally once daily plus TRUVADA™ orally once daily for 96 weeks
89578367|NCT02131155|Experimental|Afatinib (BIBW2992)|Once daily
89578368|NCT02131155|Placebo Comparator|Placebo|Once daily
89578369|NCT04749225||45° group|Uses the video stylet with 45 degree(The tip of the trachway in 45°-55°) to assist the nasotracheal tube passing the nasal cavity, oropharynx and advanced into the trachea
89578370|NCT04749225||70° group|Uses the video stylet with 70 degree(The tip of the trachway in 60°-70°)to assist the nasotracheal tube passing the nasal cavity, oropharynx and advanced into the trachea
89578371|NCT04749225||90° group|Uses the video stylet with 90 degree(The tip of the trachway in 80°-90°)to assist the nasotracheal tube passing the nasal cavity, oropharynx and advanced into the trachea
89578372|NCT01933594|Experimental|Cohort 1-Arm 1A (Romidepsin)|Participants in Cohort 1, Arm 1A received Romidepsin intravenously (IV) over 4 hours (beginning at Hour 0) at the Day 0 study visit. Dose of Romidepsin was 0.5 mg/m^2, with total dose based on the participant's body surface area (determined by participant's height and weight).
89578373|NCT01933594|Placebo Comparator|Cohort 1-Arm 1B (Placebo for Romidepsin)|Participants in Cohort 1, Arm 1B received 0.9% sodium chloride for injection IV over 4 hours (beginning at Hour 0) at the Day 0 study visit. Dose of sodium chloride for injection placebo was 0.5 mg/m^2, with total dose based on the participant's body surface area (determined by participant's height and weight).
89578374|NCT01933594|Experimental|Cohort 2-Arm 2A (Romidepsin)|Participants in Cohort 2, Arm 2A received Romidepsin IV over 4 hours (beginning at Hour 0) at the Day 0 study visit. Dose of Romidepsin was 2 mg/m^2, with total dose based on the participant's body surface area (determined by participant's height and weight).
89578375|NCT01933594|Placebo Comparator|Cohort 2-Arm 2B (Placebo for Romidepsin)|Participants in Cohort 2, Arm 2B received 0.9% sodium chloride for injection IV over 4 hours (beginning at Hour 0) at the Day 0 study visit. Dose of sodium chloride for injection placebo was 2 mg/m^2, with total dose based on the participant's body surface area (determined by participant's height and weight).
89578376|NCT01933594|Experimental|Cohort 3-Arm 3A (Romidepsin)|Participants in Cohort 3, Arm 3A received Romidepsin IV over 4 hours (beginning at Hour 0) at the Day 0 study visit. Dose of Romidepsin was 5 mg/m^2, with total dose based on the participant's body surface area (determined by participant's height and weight).
89578377|NCT01933594|Placebo Comparator|Cohort 3-Arm 3B (Placebo for Romidepsin)|Participants in Cohort 3, Arm 3B received 0.9% sodium chloride for injection IV over 4 hours (beginning at Hour 0) at the Day 0 study visit. Dose of sodium chloride for injection placebo was 5 mg/m^2, with total dose based on the participant's body surface area (determined by participant's height and weight).
89578378|NCT01933594|Experimental|Cohort 4-Arm 4A (Romidepsin)|Participants in Cohort 4, Arm 4A received Romidepsin IV over 4 hours (beginning at Hour 0) at the Day 0, 14, 28, and 42 study visits. Dose of Romidepsin was 5 mg/m^2, with total dose based on the participant's body surface area (determined by participant's height and weight).
89578379|NCT01933594|Placebo Comparator|Cohort 4-Arm 4B (Placebo for Romidepsin)|Participants in Cohort 4, Arm 4B received 0.9% sodium chloride for injection IV over 4 hours (beginning at Hour 0) at the Day 0, 14, 28, and 42 study visits. Dose of sodium chloride for injection placebo was 5 mg/m^2, with total dose based on the participant's body surface area (determined by participant's height and weight).
89029355|NCT01739062|Experimental|Genetic risk assessment|At least 40 SNP (single nucleotide polymorphisms)increase the risk of PCa. The individual risk of PCa accumulates with the increasing number of these genetic variants. The risk is doubled if patient has familial disposition as well. In retrospective studies, non-genetic risk-prediction models were compared to risk-prediction models containing both non-genetic factors and SNPs analyses. The genetic models had a significantly higher specificity than the non-genetic models. It has been argued that genetic PCa risk assessment could reduce the inexpedient use of PSA tests, saving it for patients at high risk of PCa.
89029356|NCT01739062|No Intervention|Familial disposition risk assessment|
89029357|NCT01613118|Experimental|RE-021 (Sparsentan) 200 mg|"RE-021 (Sparsentan) will be administered as a single oral morning dose. In this ARM the RE-021 (Sparsentan) dose will be 200mg.~Patients at </= 50kg will receive half of the RE-021 (Sparsentan) dose for the 8 week duration."
89029358|NCT01613118|Experimental|RE-021 (Sparsentan) 400 mg|"RE-021 (Sparsentan) will be administered as a single oral morning dose. In this ARM the RE-021 (Sparsentan) dose will be 400mg.~Patients at </= 50kg will receive half of the RE-021 (Sparsentan) dose for the 8 week duration."
89029359|NCT01613118|Experimental|RE-021 (Sparsentan) 800 mg|"RE-021 (Sparsentan) will be administered as a single oral morning dose. In this ARM the RE-021 (Sparsentan) dose will be 800mg.~Patients at </= 50kg will receive half of the RE-021 (Sparsentan) dose for the 8 week duration."
89029360|NCT01613118|Active Comparator|Irbesartan 300 mg|"The control will be administered irbesartan as a single oral dose of 150mg for the first week before escalating to 300mg for the remaining 7 weeks.~Patients at </= 50kg will receive 150mg irbesartan for the 8 week duration."
89578380|NCT04623190|Experimental|Providers|-All eligible providers will be sent questionnaires electronically to their email at baseline and follow-up. Providers will be invited to attend a training session to educate them on the PREVENT tool at baseline. The providers will be delivering the PREVENT tool.
89578381|NCT04623190|Active Comparator|Patients - Wait-List Control|"Complete questionnaires and accelerometry at baseline (administered electronically or by mail; accelerometers administered by mail). Following baseline measurement, patients will be randomized and attend their clinic visit. Follow-up measures will be administered 3-months and 6-months after the clinic visit electronically and by mail~A PREVENT action plan (behavior change prescription, community resources, and education) will be provided to the patient via email after the completion of the follow-up measurement."
89578382|NCT04623190|Experimental|Patients - PREVENT Tool|"Complete questionnaires and accelerometry at baseline (administered electronically or by mail; accelerometers administered by mail). Following baseline measurement, patients will be randomized and attend their clinic visit. Follow-up measures will be administered 3-months and 6-months after the clinic visit electronically and by mail~At the clinic visit, the provider will use PREVENT tool to discuss risk and deliver a tailored behavioral change plan inclusive of patient-centered community resources. PREVENT will calculate patient's overall risk for developing cardiovascular disease. Physical activity and food intake recommendations are tailored to current weight status and health behaviors using evidence-based recommendations."
89578383|NCT01932970|Experimental|Etelcalcetide|Participants were treated with 5 mg etelcalcetide administered by intravenous bolus injection at the end of each hemodialysis session three times per week (TIW) for 4 weeks.
89578384|NCT01912768|Experimental|FID 120947A|FID 120947A contact lens disinfecting solution used with soft contact lenses (study lenses) on a daily basis for 90 days
89578385|NCT01912768|Active Comparator|renu fresh|Renu fresh multi-purpose solution used with soft contact lenses (study lenses) on a daily basis for 90 days
89578386|NCT02305849|Experimental|Peficitinib 100 mg|Participants received 100 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.
89578387|NCT02305849|Experimental|Peficitinib 150 mg|Participants received 150 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.
89578388|NCT02305849|Placebo Comparator|Placebo|Participants who received placebo matching to peficitinib 100 mg or 150 mg orally once daily in combination with MTX until week 12 or 28 were switched to receive 100 mg or 150 mg tablet of peficitinib orally once daily in combination with MTX from week 12 or 28 to week 52.
89578389|NCT02371759|Experimental|Diabetics: L+C maxillary anesthesia|Single dose intraoral local anesthesia with 2ml lidocaine (2%) + clonidine (15 mcg/ml) for maxillary infiltration anesthesia
89578390|NCT02371759|Experimental|Diabetics: L+C mandibular anesthesia|Single dose intraoral local anesthesia with 2ml lidocaine (2%) + clonidine (15 mcg/ml) for mandibular block anesthesia
89578391|NCT02371759|Active Comparator|Diabetics: L+E maxillary anesthesia|Single dose intraoral local anesthesia with 2ml lidocaine (2%)+ epinephrine (1:80.000) for maxillary infiltration anesthesia
89578392|NCT02371759|Active Comparator|Diabetics: L+E mandibular anesthesia|Single dose intraoral local anesthesia with 2ml lidocaine (2%) + epinephrine (1:80.000) for mandibular block anesthesia
89578393|NCT02371759|Experimental|Healthy: L+C maxillary anesthesia|Single dose intraoral local anesthesia with 2ml lidocaine (2%) + clonidine (15 mcg/ml) for maxillary infiltration anesthesia
89578394|NCT02371759|Experimental|Healthy: L+C mandibular anesthesia|Single dose intraoral local anesthesia with 2ml lidocaine (2%) + clonidine (15 mcg/ml) for mandibular block anesthesia
88972595|NCT00031707|Experimental|megestrol + eicosapentaenoic acid|"Patients receive oral megestrol once daily and an EPA-enriched nutritional supplement twice daily. Treatment continues in the absence of unacceptable toxicity and as long as the patient and physician feel it is beneficial.~Quality of life is assessed at baseline, weekly for 1 month, and then monthly thereafter during study treatment.~Patients are followed every 6 months for 5 years."
88972596|NCT03151889|Experimental|TENS Group|TENS Group: Pre-test evaluations (Clinic Conditions; Live Quality; Salivary Flux); TENS treatments (50Hz / pulse duration of 250 ms / high intensities tolerated / continuously for 20 minutes / 2 sessions a week / 4 weeks / total of the 8 TENS sessions) and Post-test evaluations.
88972597|NCT03151889|No Intervention|Control Group|Control Group: Pre-test evaluations (Clinic Conditions; Live Quality; Salivary Flux) and Post-test evaluations.
88972598|NCT00031746|Active Comparator|soy protein + isoflavones|
88972599|NCT00031746|Active Comparator|casein proteins|
88972600|NCT03151850||ulcerative colitis|We analysed the diversity of the fungal and bacterial in patients with Ulcerative Colitis (UC). We take 2 pieces of biopsies in the sigmoid colon mucosa inflammation area during the colonoscopy and then perform gene sequencing.
88972601|NCT03151850||Control|Analysing the diversity of the fungal and bacterial in patients without ulcerative colitis. We take 2 pieces of biopsies in the sigmoid colon mucosa during the colonoscopy and then perform gene sequencing.
88972602|NCT03151772|Experimental|Disulfiram|Disulfiram 200 mg twice daily and copper 2,5 mg once daily. For bioavailability purpose only, treatment is withdrawn postoperatively
88972603|NCT03151772|Experimental|Metformin|Metformin 850 mg x 3 daily. For bioavailability purpose only, treatment is withdrawn postoperatively
88972604|NCT02971644|Experimental|cobalt alloy pedicle screw implantation|The spinal tuberculosis patients with severe kyphosis deformity who will undergo cobalt alloy pedicle screw implantation.
89578395|NCT02371759|Active Comparator|Healthy: L+E maxillary anesthesia|Single dose intraoral local anesthesia with 2ml lidocaine (2%)+ epinephrine (1:80.000) for maxillary infiltration anesthesia
89578396|NCT02371759|Active Comparator|Healthy: L+E mandibular anesthesia|Single dose intraoral local anesthesia with 2ml lidocaine (2%) + epinephrine (1:80.000) for mandibular block anesthesia
89578397|NCT02531633|Experimental|Part A: Sirukumab, Dose 1+prednisone (6-month taper)|Subjects will receive blinded sirukumab 100 mg subcutaneously (SC) every 2 weeks (q2w) for 52 weeks plus a pre-specified maximum of 6-month oral prednisone taper regimen.
89578398|NCT02531633|Experimental|Part A: Sirukumab, Dose 1+prednisone (3-month taper)|Subjects will receive blinded sirukumab 100 mg SC q2w for 52 weeks plus a pre-specified maximum of 3-month oral prednisone taper regimen.
89578399|NCT02531633|Experimental|Part A: Sirukumab, Dose 2+prednisone (6-month taper)|Subjects will receive blinded sirukumab 50 mg SC every 4 weeks (q4w) for 52 weeks plus a pre-specified maximum of 6-month oral prednisone taper regimen.
89578400|NCT02531633|Placebo Comparator|Part A:Placebo to match sirutkumab+prednisone (6-month taper)|Subjects will receive blinded placebo to match sirutkumab q2w for 52 weeks plus a pre-specified maximum of 6-month oral prednisone taper regimen.
89578401|NCT02531633|Placebo Comparator|Part A:Placebo to match sirukumab+prednisone (12-month taper)|Subjects will receive blinded placebo to match sirutkumab q2w for 52 weeks plus a pre-specified maximum of 12-month oral prednisone taper regimen.
89578402|NCT02531633|Experimental|Part B:Open-label sirukumab 100 mg SC (if applicable)|Subjects completing Part A will receive open label 100 mg SC q2w for a maximum of 52 weeks based on remission status and disease activity at the primary 52-week endpoint or prednisone tapering status of subject during Part A. Methotrexate will be provided to subjects, alone or in addition to sirukumab treatment during Part B, based on the discretion of the investigator.
89578403|NCT05415605|Experimental|healthy Volunteers|Healthy male or female volunteers between 18 and 50 years old
89578404|NCT02536313|Experimental|SOF/VEL/VOX|SOF/VEL/VOX for 12 weeks
89578405|NCT02536313|Experimental|SOF/VEL/VOX + RBV|SOF/VEL/VOX + RBV for 12 weeks
89578406|NCT05415059|Other|Main Cohort|Cohort of healthy volunteers to have device affixed
89578407|NCT05610761|Experimental|Core Stabilization Exercises with Kegel Exercises|
89578408|NCT05610761|Active Comparator|Kegel Exercises|
89578409|NCT05414825||11 to 14 years old teenagers|Semi-structured discussion group with only young teenagers, moderated by a neutral facilitator in the presence of an observer, which aims to collect information on the feelings of the young teenagers suffering from severe dysmenorrhea.
89578410|NCT05414825||15 to 17 years old teenagers|Semi-structured discussion group with older teenagers, moderated by a neutral facilitator in the presence of an observer, which aims to collect information on the feelings of these patients suffering from severe dysmenorrhea.
89578411|NCT05414825||11 to 14 years old teenagers' parents|Semi-structured discussion group with parents of young teenagers, moderated by a neutral facilitator in the presence of an observer, which aims to collect information on the feelings of the parents on the care and feelings of their child suffering from severe dysmenorrhea.
89578412|NCT05414825||15 to 17 years old teenagers' parents|Semi-structured discussion group with parents of older teenagers, moderated by a neutral facilitator in the presence of an observer, which aims to collect information on the feelings of the parents on the care and feelings of their child suffering from severe dysmenorrhea.
89578413|NCT05414825||caregivers|Semi-structured discussion group with medical staff in services potentially treating dysmenorrhea patients, moderated by a neutral facilitator in the presence of an observer, which aims to collect information on the feelings of the caregivers on the care and feelings of the patients suffering from severe dysmenorrhea.
89578414|NCT04423133|Experimental|Online Family Literacy Program|The Ready and Healthy for Kindergarten program is a bilingual family literacy program that uses anticipatory guidance on health routines (e.g., physical activity) to introduce language and literacy skills to children and their families delivered via an online video conference format.
89578415|NCT04423289|Experimental|Farmalarm|Farmalarm app for the follow-up
89578416|NCT04423289|No Intervention|Control|Regular primary care follow-up
89578417|NCT04423445|Experimental|Laser acupuncture combined with acupressure (LAA)|A 4-week LAA intervention included low-level laser acupuncture and auricular acupressure. Six acupuncture points were selected, and three auricular points. Participants received laser acupuncture on the six selected acupuncture points bilaterally twice a week for 4 weeks. A seed was taped onto each of the three points of the unilateral ear (initially, the left ear), where it remained for five days. Pressing on each of the seeds for one minute three times a day was required, but the stimulation intensity was adjusted depending on the participant's individual tolerance. After five days, the seed was removed, and a new seed was taped on the other ear.
89578418|NCT04423445|No Intervention|Control group|Control participants received a similar intervention, but without laser energy output or acupressure.
89578419|NCT04258787||Group A: No Surgery Group|This group consists of adults ages 18 or older who have been diagnosed with Fuchs' dystrophy or pseudophakic bullous keratopathy but do not require surgery per standard-of-care guidelines.
89578420|NCT04258787||Group B: Surgery Group|This group consists of adults ages 18 or older who have been diagnosed with Fuchs' dystrophy or pseudophakic bullous keratopathy, who require Descemet's Stripping Endothelial Keratoplasty (DSAEK), Descemet's Membrane Endothelial Keratoplasty (DMEK), or Descemet's Stripping Only (DSO) surgery. All treatment decisions will be made by the attending physician based on standard-of-care guidelines. (The study does not designate a treatment modality or pay for the treatment.)
89029361|NCT01514643||tibial plateau or plafond fracture|Tibial plateau or plafond fracture based on radiographs and/or CT scan will have synovial fluid aspirated from both the injured and uninjured joints in either the operating room if a procedure is planned for within 24 hours or in the emergency department. While the patient is under anesthesia in the operating room, the investigators will obtain blood samples.
89029362|NCT01470105||pts bone metastases|This is a prospective, cross sectional, human use study conducted using patients with bone metastases requiring orthopaedic stabilization. Though this is an observational study, blood sampling, the SF-36 questionnaire, and ECOG performance status, and correlative studies will be performed.
89029363|NCT01416077|No Intervention|standard treatment|Fluid and inotropic drugs are given based on conventional parameters such as blood pressure and heart rate as judged by the individual anesthesiologists judgement.
89029364|NCT01416077|Active Comparator|goal-directed fluid treatment|Stroke Volume and Cardiac Index are measured with the Flotrac/Vigileo system and circulation is optimised
89029365|NCT01300962|Experimental|BYL719 ARM B|Treatment with BYL719 and Capecitabine
89029366|NCT01300962|Experimental|BKM120 ARM A|Treatment with BKM120 and capecitabine
89029367|NCT01300962|Experimental|ARM C|BKM 120 plus capecitabine plus trastuzumab
89029368|NCT01300962|Experimental|ARM D|BKM120 plus capecitabine plus lapatinib
89029369|NCT01107340|Other|AMIStem Hip System|Patients who comply with the protocol and received an AMIStem femoral component.
89029370|NCT00930280||Hemorrhagic stroke cases|People who have had a hemorrhagic stroke, specifically an intracerebral hemorrhage, and live within a 100 mile radius of the University of Cincinnati.
89578421|NCT02187861|Experimental|Chemotherapy-Containing Cohort:Safety Run-In (Venetoclax + BR)|Participants will receive venetoclax no more than 600 milligrams (mg) orally once daily continuously along with rituximab 375 milligrams per square meter (mg/m^2) intravenous (IV) infusion on Day 1 of 28-day cycle and bendamustine 90 mg/m^2 IV infusion on Days 1 and 2 of the 28-day cycle. Safety run-in will continue until first 9 participants complete the safety observation window of 28 days. Participants will continue receiving the same treatment as decided for Arm B.
89578422|NCT02187861|Experimental|Chemotherapy-Free Cohort: Arm A (Venetoclax + Rituximab)|Participants will receive venetoclax 800 mg orally once daily for 1 year along with rituximab 375 mg/m^2 IV infusion on Days 1, 8, 15, 22 of Cycle 1 and Day 1 of Cycles 4, 6, 8, 10, and 12. Each cycle will be of 28 days.
89578423|NCT02187861|Experimental|Chemotherapy-Containing Cohort: Arm B (Venetoclax + BR)|Participants will receive venetoclax at doses decided from safety run-in orally once daily continuously for 1 year along with rituximab 375 mg/m^2 IV infusion on Day 1 of each 28-day cycle and bendamustine 90 mg/m^2 IV infusion on Days 1 and 2 of each 28-day cycle, for 6 cycles.
89578424|NCT02187861|Active Comparator|Chemotherapy-Containing Cohort: Arm C (BR)|Participants will receive rituximab 375 mg/m^2 IV infusion on Day 1 of each 28-day cycle and bendamustine 90 mg/m^2 IV infusion on Days 1 and 2 of each 28-day cycle, for 6 cycles.
89578425|NCT03958487|Experimental|executive/monitoring training|All participants will be part of the same group and their performance after treatment will be compared to their own performance prior to treatment (baseline)
89578426|NCT05435261||Group I|with a score below 14
89578427|NCT05435261||Group II|with a score above 14
89578428|NCT05434091|Experimental|PF-07291177 and Placebo (Cohort 1)|Single dose administration of PF-07291177 and placebo; Within a cohort, participants will receive 3 doses of PF-07291177 and 1 dose of placebo.
89578429|NCT05434091|Experimental|PF-07291177 and Placebo (Cohort 2)|Single dose administration of PF-07291177 and placebo; Within a cohort, participants will receive 3 doses of PF-07291177 and 1 dose of placebo.
89578430|NCT05434091|Experimental|PF-07291177 and Placebo (Cohort 3)|Single dose administration of PF-07291177 and placebo; Within a cohort, participants will receive 3 doses of PF-07291177 and 1 dose of placebo.
89578431|NCT05378477|Experimental|Test product|Hemisqualane & beeswax-based lotion (X92001752), killing lice and nits via suffocation.
89578432|NCT05378477|Active Comparator|RID Super Max Solution|Oligodecene oil-based lotion, killing lice and nits via suffocation.
89578433|NCT05378477|Active Comparator|Nix Crème|Conventional pesticide, containing 1% permethrin.
89578434|NCT05378477|Active Comparator|Pouxit Végétal|Fatty acid salt-based lotion, killing lice and nits via suffocation.
89578435|NCT05377385||Study group|Children and adolescents with type 1 diabetes mellitus who started in 2021 in the Jessa Hospital with the Omnipod DASH insulin administration device.
89578436|NCT02163993|Experimental|5mg Galcanezumab|5mg of galcanezumab given as subcutaneous (SQ) injections once every 28 days during a 12 week treatment period.
89578437|NCT02163993|Experimental|50mg Galcanezumab|50mg of galcanezumab given as SQ injections once every 28 days during a 12 week treatment period.
89578438|NCT02163993|Experimental|120mg Galcanezumab|120mg of galcanezumab given as SQ injections once every 28 days during a 12 week treatment period.
89578439|NCT02163993|Experimental|300mg Galcanezumab|300mg of galcanezumab given as SQ injections once every 28 days during a 12 week treatment period.
89578440|NCT02163993|Placebo Comparator|Placebo|Placebo given as SQ injections once every 28 days during a 12 week treatment period.
89578441|NCT05383001|Experimental|Arm A: tremelimumab /durvalumab (1 cycle), subsequently Durvalumab maintenance therapy|
89578442|NCT05383001|Other|Arm B: platinum-based chemotherapy (SoC)|
89578443|NCT02163915|Experimental|Cohort 1: TAK-137 0.5 mg|TAK-137 0.5 mg, tablets, orally once on Days 1-7.
88972605|NCT03151733|Experimental|single incision laparoscopic surgery|patients with colorectal cancer and undergo single incision laparoscopic surgery
88972606|NCT03151733|Placebo Comparator|Conventional laparoscopic surgery|patients with colorectal cancer and undergo conventional laparoscopic surgery
88972607|NCT03151694||DRD4 and DRD2 Polymorphism Detection|The genetic component of endophenotype for responsiveness to environment (ERE) will be characterized with reference to Taq1A allele in dopamine-2 receptor (DRD2) gene and the exon 3 7-repeat allele of the dopamine-4 receptor (DRD4) gene. This will assist in understanding the role of DRD2 and DRD4 in shaping the neurocognitive functions and link to the eating behaviors of the children and other primary outcome variables.
88972608|NCT03151655|Experimental|MATTeRS Video|
88972609|NCT03151655|Active Comparator|Didactic Video|
88972610|NCT03151616||No anticholinergic exposure|People with an anticholinergic risk scale score of 0
88972611|NCT03151616||Moderate anticholinergic exposure|People with an anticholinergic risk scale score of 1-2
88972612|NCT03151616||High anticholinergic exposure|People with an anticholinergic risk scale score of >=3
88972613|NCT03151577|Other|Evolution of IOP after XEN® Gel Stent implantation|To study the efficacy of the XEN® Gel Stent in lowering the IOP.
88972614|NCT03151538|Experimental|Pes Planus Group|This group of patients received children with pes planus. It will be applied exercise training mixed with play
88972615|NCT03151538|Other|Controlled Group|This group of patients received healthy children.
89578444|NCT02163915|Experimental|Cohort 2: TAK-137 2 mg|TAK-137 2 mg, tablets, orally once on Days 1-7.
89578445|NCT02163915|Experimental|Cohort 3: TAK-137 5 mg|TAK-137 5 mg, tablets, orally once on Days 1-7.
89578446|NCT02163915|Experimental|Cohort 4: TAK-137 10 mg|TAK-137 10 mg, tablets, orally once on Days 1-7.
89578447|NCT02163915|Experimental|Cohort 5: TAK-137 TBD|TAK-137, tablets, orally once on Days 1-7. Dose to be determined from data collected in Cohorts 1-3.
89578448|NCT02163915|Experimental|Cohorts 1-5: Placebo|TAK-137 placebo-matching tablets, orally, once on Days 1-7.
89578449|NCT05610371|Experimental|Lidocaine The study group|The study group underwent hysteroscopy using saline to which 10ml of 2% lidocaine was added to the first 1000 ml.
89578450|NCT05610371|Placebo Comparator|Saline The control group|The control group underwent hysteroscopy using a saline distension medium.
89578451|NCT05344001||Midlife former athletes with a prior knee injury|"Inclusion Criteria: Age 40-64 years. Prior participation in a collision, contact, or jumping/cutting/pivoting sport (e.g., baseball, basketball, field hockey, football, ice hockey, lacrosse, soccer, softball, volleyball, etc.) at the collegiate varsity level for at least 1 season; history of at least 1 prior traumatic knee injury including but not limited to ACL or PCL rupture and/or reconstruction, medial and/or lateral meniscus tear or surgery, osteochondral defect, and/or intra-articular (i.e., tibiofemoral or patellofemoral) fracture.~Exclusion Criteria: Neurologic (e.g., stroke, Parkinson's) and/or degenerative disease that impairs function; current pregnancy; lower extremity joint replacement (e.g., hip or knee replacement)."
89578452|NCT05344001||Midlife former athletes without a prior major lower extremity injury|"Inclusion Criteria: Age 40-64 years. Prior participation in a collision, contact, or jumping/cutting/pivoting sport (e.g., football, baseball, basketball, field hockey, ice hockey, lacrosse, soccer, softball, volleyball, etc.) at the collegiate varsity level for at least 1 season.~Exclusion Criteria: Neurologic (e.g., stroke, Parkinson's) and/or degenerative disease that impairs function; current pregnancy; lower extremity joint replacement (e.g., hip or knee replacement); prior major lower extremity injury (e.g., ACL tear, Achilles tendon rupture, compound ankle or femur fracture, hip dislocation)."
89578453|NCT05344001||Midlife controls|"Inclusion Criteria: Age 40-64 years.~Exclusion Criteria: Prior participation in a collegiate varsity sport or professional sport; neurologic (e.g., stroke, Parkinson's) and/or degenerative disease that impairs function; current pregnancy; lower extremity joint replacement (e.g., hip or knee replacement); prior major lower extremity injury (e.g., ACL tear, Achilles tendon rupture, compound ankle or femur fracture, hip dislocation)."
89578454|NCT05344001||Young adult athletes|"Inclusion Criteria: Age 18-25 years. Participation in a collision, contact, or jumping/cutting/pivoting sport (e.g., baseball, basketball, field hockey, football, ice hockey, lacrosse, soccer, softball, volleyball, etc.) at the varsity collegiate level.~Exclusion Criteria: Neurologic (e.g., stroke, Parkinson's) and/or degenerative disease that impairs function; current pregnancy; lower extremity joint replacement (e.g., hip or knee replacement)."
89578455|NCT05344001||Young adult controls|"Inclusion Criteria: Age 18-25 years.~Exclusion Criteria: Prior or current participation in any collegiate varsity sport; prior major lower extremity injury or surgery (e.g., ACL tear, Achilles tendon rupture, compound ankle or femur fracture, hip dislocation); current participation in competitive sport (e.g., collegiate club sport) more than 3x/week; joint replacement in the lower extremity (i.e., knee or hip replacement); current pregnancy; or neurologic condition (e.g., stroke, Parkinson's) and/or degenerative condition that impairs function."
89578456|NCT02163759|Placebo Comparator|Placebo|Participants will receive placebo matching to etrolizumab up to Week 12 and placebo matching to adalimumab up to Week 8.
89029371|NCT00930280||Healthy Control Subjects|Healthy volunteers who are randomly identified in the same 100 mile radius of the University of Cincinnati and have not had a hemorrhagic stroke.
89029372|NCT00752479|Experimental|1|
89029373|NCT00752479|Active Comparator|2|
89029374|NCT00732212|Experimental|Doppler endoscopic probe hemostasis|In addition to stigmata of hemorrhage and visual cues, Doppler endoscopic probe will be used for detection of blood flow before and after standard endoscopic hemostasis. If residual blood flow in the lesion is found after standard treatment, further endoscopic treatment will be applied as deemed safe by the investigator-endoscopist.
89029375|NCT00732212|Active Comparator|Standard Endoscopic Hemostasis|Standard, visually guided endoscopic hemostasis based on visual cues of stigmata of hemorrhage and endoscopic control of bleeding or treatment of the stigmata according to current guidelines
89029376|NCT00616473||1 Nursing Home Staff|Direct care staff
89029377|NCT00616473||2 Family Members|Family members/Significant other of nursing home resident.
89029378|NCT00592280|Experimental|Pancreas Preservation|The pancreas will be preserved before transplantation in an oxygenated system containing highly oxygenated liquid perfluorocarbon (perfluorodecalin, C10F18. The perfluorocarbon combines low toxicity with a capacity to dissolve 75 times more oxygen than the UW solution used in standard pancreas storage. When preserved under these conditions, the pancreas absorbs oxygen by diffusion and steadily consumes it, supporting sufficient aerobic metabolism to maintain tissue ATP concentrations at near-physiologic levels and prevent, or even reverse, pancreas anoxic injury.
89029379|NCT00589875|Experimental|Single arm|This study is an extension of evaluation of the surgical resection arm, Arm B, from a phase Ib study in which dose escalation on arm B was completed.
89029380|NCT00571792||methodologies to identify characteristics of non-smokers with normal lung function|Imaging, genomic and proteomic methodologies to identify characteristics of individuals with normal lung function who do not smoke
89029381|NCT00571792||methodologies to identify characteristics of smokers but do not demonstrate symptoms of COPD|Imaging, genomic and proteomic methodologies to identify characteristics of individuals who smoke but who do not demonstrate symptoms of chronic obstructive pulmonary disease
89029382|NCT00571792||methodologies to identify characteristics of smokers that demonstrate symptoms of COPD|Imaging, genomic and proteomic methodologies to identify characteristics of individuals who smoke that demonstrate symptoms of COPD
89029383|NCT00503594|Experimental|1|Comparative evaluation of the efficiency of a new protocol of the primitive LYMPHOME of the central nervous system ( LPSNC) to the old subject, associating Methotrexate and Temozolomide with regard to a standard protocol associating Methotrexate, Procarbazine, Vincristine and Cytarabine.
89029384|NCT00503594|Active Comparator|bras conventional|bras conventional
89029385|NCT04696302|Experimental|Focus of attention in individuals post chronic stroke during seated lateral weight shifting|Feasibility study
89029386|NCT04696302|Experimental|Focus of attention in individuals post acute stroke during seated lateral weight shifting|Feasibility study
89029387|NCT05146791||Inlay Bristow Group|Inlay Bristow procedure
89029388|NCT05146791||Onlay Bristow Group|Onlay Bristow procedure
89029389|NCT00499811|Experimental|Treatment (enzyme inhibitor therapy)|"Vorinostat (SAHA) will be administered as a single oral dose on day -6 for all patients. Blood samples are obtained periodically on day -6 for pharmacokinetic studies.~One week later (day 1), the first course of oral vorinostat will be initiated on a continuous daily oral regimen. Each treatment course will consist of 21 days of therapy. Treatment continues in the absence of disease progression or unacceptable toxicity."
89578457|NCT02163759|Active Comparator|Adalimumab|Participants will receive adalimumab up to Week 8 and placebo matching to etrolizumab up to Week 12.
89578458|NCT02163759|Experimental|Etrolizumab|Participants will receive etrolizumab up to Week 12 and placebo matching to adalimumab up to Week 8.
89578459|NCT02371369|Experimental|Part 1 - Pexidartinib|Participants received blinded treatment of pexidartinib,1000 mg (5 capsules per day ) for 2 weeks, then 800 mg (4 capsules per day) for 22 weeks
89578460|NCT02371369|Placebo Comparator|Part 1 - Placebo|Participants received blinded treatment of matching placebo (5 capsules per day) for 2 weeks, then matching placebo (4 capsules per day) for 22 weeks
89578461|NCT02371369|Experimental|Part 2 - All Pexidartinib|Participants received pexidartinib in Part 1 and in Part 2 at their prescribed dose
89578462|NCT02371369|Experimental|Part 2 - Placebo-Pexidartinib|Participants received placebo in Part 1 and pexidartinib in Part 2 at their prescribed dose
89578463|NCT02187783|Experimental|LEE011|LEE011 600 mg (hard gelatin capsules) was administered orally once daily for 3 weeks on/1 week off. A complete treatment cycle was defined as 28 days.
89578464|NCT02337361|Experimental|e-SBI|Single session, Electronic SBI for risky alcohol use
89578465|NCT02337361|No Intervention|Control|Treatment as usual with only assessment
89578466|NCT02336737|Experimental|SiennaXP injection|"Single injection of SiennaXP in addition to comparator single dose of radioisotope (Technetium Tc99m Sulfur Colloid) and single dose of isosulfan blue dye.~Lymph node localization using the SentiMag handheld intraoperative localization system in addition to localization with standard of care handheld gamma probe."
88972616|NCT00031980|Experimental|cyclosporine|"Patients receive oral cyclosporine every 12 hours. Treatment continues in the absence of disease progression or unacceptable toxicity.~Patients are followed every 4 months for 1 year and then every 6 months for 9 years."
89578467|NCT02130765|No Intervention|Drug with ICD/CRT-D|Implantable cardioverter defibrillator (ICD) or Cardiac Resynchronization Therapy-Defibrillator (CRT-D) with routine drug therapy
89578468|NCT02130765|Active Comparator|Cardiac catheter ablation with ICD/CRT-D|Cardiac catheter ablation with ICD/CRT-D with routine drug therapy
89578469|NCT02305381|Experimental|Semaglutide 0.5 mg/Week|
89578470|NCT02305381|Experimental|Semaglutide 1.0 mg/Week|
88972617|NCT00032019|Experimental|EPOCH-Rituximab|Addition of monoclonal antibody therapy to chemotherapy for treatment of pts with aggressive CD20+ NHL
88972618|NCT03151460|Experimental|Parkinson|Patients with Parkinson's disease assuming or not Dopamine Agents
88972619|NCT03151460|No Intervention|Normal Controls|Age and education comparable healthy subjects
88972620|NCT03151421|Experimental|Home air quality monitoring and feedback|Home air quality monitoring and feedback
88972621|NCT03151382|Experimental|Experimental group|
88972622|NCT03151382|Other|Control group|
88972623|NCT03151343|Experimental|Empagliflozin|Empagliflozin, coated tablets, 25mg, once daily, for 13 weeks
88972624|NCT03151343|Placebo Comparator|Placebo|Placebo, coated tablets, once daily, for 13 weeks
88972625|NCT04712279|Active Comparator|Ivermectin 0.6mg/kg/day|
88972626|NCT04712279|Active Comparator|Ivermectin 1.0mg/kg/day|
88972627|NCT04712279|Placebo Comparator|Placebo|
89578471|NCT02305381|Placebo Comparator|Semaglutide Placebo 0.5 mg/Week|
89578472|NCT02305381|Placebo Comparator|Semaglutide Placebo 1.0 mg/Week|
89578473|NCT02336425|Experimental|QGE031 240 mg|QGE031 240 mg subcutaneous injection every 4 weeks
89578474|NCT02336425|Experimental|QGE031 72 mg|QGE031 72 mg subcutaneous injection every 4 weeks
89578475|NCT02336425|Experimental|QGE031 24 mg|QGE031 24 mg subcutaneous injection every 4 weeks
89578476|NCT02336425|Placebo Comparator|Placebo to QGE031|Placebo subcutaneous injection every 4 weeks
89578477|NCT02163447|Active Comparator|3 dose SP pregnancy / 3 monthly DP infancy|"Women will be given SP (3 full strength tabs, 500 mg/25 mg) 3 times during pregnancy at 20, 28, and 36 weeks gestational age. In addition, placebos will be used to mimic the identical dosing strategy such that every 4 weeks women will receive two pills on day 1 (SP and placebo, DP and placebo, or two placebos) followed by one pill on days 2 and 3 (DP or placebo). Two placebos will be used, one that mimics the appearance of SP and one that mimics the appearance of DP.~Infants will be given DP (once a day for 3 consecutive days using weight-based guidelines) every 12 weeks between 8 and 104 weeks of age. Infants randomized to receive DP every 12 weeks will receive placebo mimicking the dosing of DP every 4 weeks when they are not receiving study drug."
88972628|NCT03151265|Experimental|Low Back Pain Group|"Low Back Pain (LBP) group will be assessed on two consecutive days. The first day will have no ThermaCare intervention applied, and is for a Baseline assessment of flexibility, muscle relaxation and low back pain.~The second day will have the ThermaCare Low Back Heat Wrap intervention applied, and will have the same assessments as the Baseline day."
88972629|NCT03151265|Experimental|Active in Sport Group|"Sport group will be assessed on two consecutive days. The first day will have no ThermaCare intervention applied, and is for a baseline assessment of flexibility, muscle relaxation and low back pain.~The second day will have the ThermaCare Low Back Heat Wrap intervention applied, and will have the same assessments as the Baseline day."
88972630|NCT03151187|Experimental|Curriculum administered prior to OSCE|Programs randomized to this arm will receive the teaching intervention (two 2 hour lectures) prior to the OSCE.
88972631|NCT03151187|Active Comparator|Curriculum administered after OSCE|Programs randomized to this arm will receive the teaching intervention (two 2 hour lectures) after the OSCE.
89578478|NCT02163447|Active Comparator|3 dose DP pregnancy / 3 monthly DP infancy|"Women will be given DP (3 full strength tabs, 40 mg/320 mg, given once a day for 3 consecutive days) 3 times during pregnancy at 20, 28, and 36 weeks gestational age. In addition, placebos will be used to mimic the identical dosing strategy such that every 4 weeks women will receive two pills on day 1 (SP and placebo, DP and placebo, or two placebos) followed by one pill on days 2 and 3 (DP or placebo). Two placebos will be used, one that mimics the appearance of SP and one that mimics the appearance of DP.~Infants will be given DP (once a day for 3 consecutive days using weight-based guidelines) every 12 weeks between 8 and 104 weeks of age. Infants randomized to receive DP every 12 weeks will receive placebo mimicking the dosing of DP every 4 weeks when they are not receiving study drug."
89578479|NCT02163447|Active Comparator|3 dose DP pregnancy / monthly DP infancy|"Women will be given DP (3 full strength tabs, 40 mg/320 mg, given once a day for 3 consecutive days) 3 times during pregnancy at 20, 28, and 36 weeks gestational age. In addition, placebos will be used to mimic the identical dosing strategy such that every 4 weeks women will receive two pills on day 1 (SP and placebo, DP and placebo, or two placebos) followed by one pill on days 2 and 3 (DP or placebo). Two placebos will be used, one that mimics the appearance of SP and one that mimics the appearance of DP.~Infants will be given DP (once a day for 3 consecutive days using weight-based guidelines) every 4 weeks between 8 and 104 weeks of age."
88972632|NCT00032370|Other|1|Elective vascular surgery
88972633|NCT00032370|Other|2|Cardiac revascularization prior to vascular surgery.
88972634|NCT00032448|Other|1|Open and laparoscopic herniorrhaphy
88972635|NCT00393224||cohort|hospital based family cohort
88972636|NCT00032565||1|No intervention. Telephone interview.
88972637|NCT03151070||Zone 1|"Zone 1 includes the following communities from Huehuentenango Distric:~San Rafael Petzal~San Sebastian Huehuetenango~San Gaspar Ixchil~Santa Bárbara~Colotenango~Aguacatán"
88972638|NCT03151070||Zone 2|"Zone 2 includes the following communities from Alta Verapaz district:~Tamahú~San Miguel Tucurú~Panzós~Senahú~Telemán"
88972639|NCT03151070||Zone 3|"Zone 3 includes the following communities from Huehuetenango district:~San Idelfonso Ixtahuacán~La Democracia~San Juan Atitán~Tectitán~Santiago Chimaltenango"
88972640|NCT03151070||Zona 4|"Zone 4 includes the following communities from Alta Verapaz district:~Lanquín~Santa María Cahabón~Chisec~Chahal~Raxruhá~Campur"
88972641|NCT03151070||Zona 5|"Zone 5 includes the following communities from Huehuetenango district:~Nenton~Jacaltenango~Todos Santos Cuchumatán~Santa Eulalia~San Mateo Ixtatán~San Juan Ixcoy"
88972642|NCT03151070||Zona 6|"Zone 6 includes the following communities from Alta Verapaz district:~Santa Cruz Verapaz~Tactic~San Pedro Carchá~San Juan Chamelco"
88972643|NCT04711941|Experimental|ToM training|ToM training was composed of six lessons two times a week. Through several types of stimuli, the trainer worked together with the participant to comprehend and hypothesize interpretations of the emotions and social interactions, providing discussion occasions to enhance the attribution of mental states and emotions. Every lesson had a duration of 45/60 minutes in order to avoid excessive fatigue in the participant.
88972644|NCT04711941|Active Comparator|Non mentalistic training|ToM training was composed of six lessons two times a week. Through several types of stimuli, the trainer worked together with the participant to provide a historical and descriptive overview of cinema movies, TV news, documentaries, newspapers, and advertising. Every lesson had a duration of 45/60 minutes in order to avoid excessive fatigue in the participant.
88972645|NCT03151031|Experimental|Experimental Group|In the experimental group, the participants will be asked to perform star excursion balance test (SEBT) under two conditions, before and after the application of cryotherapy
88972646|NCT03151031|No Intervention|Control Group|In the control group, the participants will be asked asked to perform star excursion balance test (SEBT) under two conditions, before and after 10 minutes rest
88972647|NCT00032643|Other|Arm 1|
88972648|NCT03150992|Experimental|Elemental 028 Extra Liquid|All patients will be assessed and given an individual plan for Elemental Diet (ED) introduction. The actual amount of ED prescribed will depend on the tolerance and palatability and not nutritional status. The recommendation of a minimum of 2 cartons of ED will be drunk orally by patients, along with other clear fluids only. Following introduction of ED, patients will be discharged from hospital (if applicable) and followed up for 2 weeks. They will have a telephone follow-up assessment once a week for 2 weeks. All other assessments will follow the standard of care. During the follow-up patients will be assessed using the Memorial Symptom Assessment Scale (MSAS) and will be asked to complete a nutritional diary every day and a quality of life questionnaire at several time points.
88972649|NCT03150953|No Intervention|Standard of Care|Patients will receive standard of care which is 1-2 warm blankets.
88972650|NCT03150953|Experimental|MRI-safe warming device|The MRI-safe bore covering consists of a clear covering sheet positioned over the openings of the MRI scanner.
88972651|NCT03150953|Experimental|MRI-safe warming device and Bair hugger|IN addition to positioning the MRI-safe bore covering over the opening of the MRI scanner, the opening of the covering sheet will be connected to a device which blows warm air called a Bair Hugger. The Bair Hugger is an approved device, and MRI safe.
88972652|NCT03150836|Experimental|Safety Lead-In, Regimen A1 Durvalumab + RT|Durvalumab 1500 mg will be delivered via IV infusion q4wk. Radiation Therapy (RT) will be delivered beginning on day 8 ± 3 of durvalumab. RT (33Gy delivered as 6.6Gy x 5 fractions) should be completed within 14 days from the start of RT ideally over 5 consecutive days. Durvalumab 1500 mg q4wk will be continued to complete either 13 total cycles OR until disease progression, unacceptable toxicity, or patient withdrawal from study, whichever comes first.
89578480|NCT02163447|Active Comparator|monthly DP pregnancy / 3 monthly DP infancy|"Women will be given DP (3 full strength tabs, 40 mg/320 mg, given once a day for 3 consecutive days) every 4 weeks during pregnancy. In addition, placebos will be used to mimic the identical dosing strategy such that every 4 weeks women will receive two pills on day 1 (SP and placebo, DP and placebo, or two placebos) followed by one pill on days 2 and 3 (DP or placebo). Two placebos will be used, one that mimics the appearance of SP and one that mimics the appearance of DP.~Infants will be given DP (once a day for 3 consecutive days) every 12 weeks between 8 and 104 weeks of age. Infants randomized to receive DP every 12 weeks will receive placebo mimicking the dosing of DP every 4 weeks when they are not receiving study drug."
89578481|NCT02163447|Active Comparator|monthly DP pregnancy / monthly DP infancy|"Women will be given DP (3 full strength tabs, 40 mg/320 mg, given once a day for 3 consecutive days) every 4 weeks during pregnancy. In addition, placebos will be used to mimic the identical dosing strategy such that every 4 weeks women will receive two pills on day 1 (SP and placebo, DP and placebo, or two placebos) followed by one pill on days 2 and 3 (DP or placebo). Two placebos will be used, one that mimics the appearance of SP and one that mimics the appearance of DP.~Infants will be given DP (once a day for 3 consecutive days) every 4 weeks between 8 and 104 weeks of age."
89578482|NCT02370667|Experimental|Biomechanical Exercise (BE)|The participants in this arm will be asked to attend 3 group classes per week for 12 weeks at a local yoga studio taught by a certified yoga instructor. Four class times will be offered per week. These classes will include a warm-up, static poses shown to decrease knee joint loading, and a cool down including flexibility exercises. Measurements will be obtained at baseline (before intervention) and at follow-up (following intervention). Outcomes will include clinical mobility; muscle and fat volumes, and cartilage morphology using MRI; pain; isometric leg strength; cardiovascular fitness; and gait analysis.
89578483|NCT02370667|Active Comparator|Traditional Exercise (TE)|The participants in this arm will be prescribed an aerobic and strengthening exercise program often prescribed to those with knee OA. The program will include 15 minutes of walking per class, closed kinetic chain strengthening exercises on machines, and a cool down consisting of stretching. Participants will be asked to come to class 3 times per week for 12 weeks. Certified Kinesiologists as well as student volunteers will be available during all class times for program completion and progression.
89578484|NCT02370667|Other|Meditation Control (M)|The participants in this arm will be asked to attend 3 meditation classes per week for 12 weeks taught by a certified yoga instructor with a specialization in meditation. This will take place at an alternate yoga studio to avoid contamination. Since it is known that exercise is beneficial for pain management and strengthening in knee OA, participants randomized to the control group will be offered a free exercise pass following completion of the study.
89578485|NCT02130297|Active Comparator|Group 1 - day 1|Group 1 will receive laser therapy to half of the scar the day of the excision.
89578486|NCT02130297|Active Comparator|Group 2 - day 14|Group 2 will receive laser therapy at the time of suture removal or post-operative day 14.
89578487|NCT02130297|Active Comparator|Group 3 - week 9|Group 3 will receive laser treatment to half the scar at the 9 week postop visit.
89578488|NCT01931956|Experimental|Non-High Risk|Includes patients who are candidate for mitral valve repair or replacement surgery, including cardiopulmonary bypass (i.e. non-high risk). The patients who are enrolled in this arm will undergo percutaneous mitral valve repair using MitraClip® implant. This arm was evaluated as a separate study NCT00209274.
89578489|NCT01931956|Experimental|High Risk|Includes patients with a predicted procedural mortality risk calculated using the Society For Thoracic Surgeon (STS) surgical risk calculator of ≥12% or, in the judgment of a cardiac surgeon, the patient is considered a high risk surgical candidate due to the presence of pre-defined risk factors. The patients who are enrolled in this arm will undergo percutaneous mitral valve repair using MitraClip® implant. This arm was evaluated as a separate study NCT01940120.
89578490|NCT01931956|Experimental|Compassionate Use|Patients that did not meet REALISM High Risk or Non-High Risk eligibility criteria were evaluated for consideration for either Emergency Use (EU) or Compassionate Use (CU). The objective of the Compassionate and Emergency Use Group of the EVEREST II REALISM study is to provide access to the MitraClip Device, in a non-commercial setting, for patients with serious or life-threatening conditions when conventional therapies have failed, are unsuitable, or unavailable. The patients who are enrolled in this arm will undergo percutaneous mitral valve repair using MitraClip® implant.
89578491|NCT01931956|Experimental|Emergency Use|Patients that did not meet REALISM High Risk or Non-High Risk eligibility criteria were evaluated for consideration for either Emergency Use (EU) or Compassionate Use (CU). The objective of the Compassionate and Emergency Use Group of the EVEREST II REALISM study is to provide access to the MitraClip Device, in a non-commercial setting, for patients with serious or life-threatening conditions when conventional therapies have failed, are unsuitable, or unavailable. The patients who are enrolled in this arm will undergo percutaneous mitral valve repair using MitraClip® implant.
88972653|NCT03150836|Experimental|Safety Lead-In, Regimen A2 Durvalumab + RT|In cohort A2 the dose of radiation will be decreased to a total dose of 30 Gy administered in 5 fractions of 6 Gy. Durvalumab 1500 mg will be delivered via IV infusion q4wk. Radiation Therapy (RT) will be delivered beginning on day 8 ± 3 of durvalumab. RT (30 Gy delivered as 6.0Gy x 5 fractions) should be completed within 14 days from the start of RT ideally over 5 consecutive days. Durvalumab 1500 mg q4wk will be continued to complete either 13 total cycles OR until disease progression, unacceptable toxicity, or patient withdrawal from study, whichever comes first.
88972654|NCT03150836|Experimental|Safety Lead-In, Regimen B1 Durvalumab + Tremelimumab + RT|Tremelimumab 75 mg will be administered via IV infusion q4wk for 2 cycles with durvalumab 1500 mg via IV infusion. Radiation Therapy (RT), at the optimal dose determined in the safety lead-in from Regimen A, will be delivered beginning on day 8 ± 3 of durvalumab. After two doses of tremelimumab and durvalumab, durvalumab 1500 mg q4wk will be continued to complete either 13 total cycles of durvalumab OR until disease progression, unacceptable toxicity, or patient withdrawal from study, whichever comes first.
89029390|NCT05146752|Experimental|Extremely low frequency electromagnetic fields|After parental permission for participation was obtained, the preterm newborns were enrolled and divided into the experimental group, which received ELF-EMF therapy after a pretest in addition to regular medical care, and the control group, which received regular medical care only, using a random number table.
89029391|NCT05146752|Other|control group|routine care
89578492|NCT01887418|Experimental|QuickShot™ - 100 mg Treatment A|QuickShot™Testosterone - Auto-injector device for SC use
89578493|NCT01887418|Experimental|QuickShot™ - 50 mg Treatment B|QuickShot™Testosterone- Auto-injector device for SC use
89578494|NCT01887418|Active Comparator|Delatestryl 200 mg IM Treatment C|Commercially available Testosterone enanthate 200 mg IM dosage - 'standard of care' arm for reference
89578495|NCT01886716|Experimental|Anxiety Attention Training only|Participants will receive Anxiety Attention Training and placebo Alcohol training.
89578496|NCT01886716|Experimental|Alcohol Attention Training only|Participants will receive Alcohol Attention Training and placebo Anxiety training.
89578497|NCT01886716|Experimental|Anxiety + Alcohol Attention Training|Participants will receive both Anxiety Attention Training and Alcohol Attention Training.
89578498|NCT01886716|Placebo Comparator|Control Training|Participants will receive placebo Anxiety Training and placebo Alcohol training.
89578499|NCT01912612|Experimental|Arm 1 (Patients with pain, duloxetine)|Duloxetine 30 mg daily x 1 week, then 60 mg daily x 4 weeks, then 30 mg daily x 2 weeks.
89578500|NCT01912612|No Intervention|Arm 2 (Patients without pain -- control)|Patient reported pain and symptoms assessment for comparison at baseline.
89578501|NCT02370511|Experimental|Native mitral valve with severe MAC|Patients with symptomatic severe calcific native mitral valve disease with severe mitral annular calcification who have extremely high surgical risk for standard surgical mitral valve replacement, will undergo transcatheter mitral valve replacement.
89578502|NCT02370511|Experimental|Valve-in-Ring|Patients with symptomatic failing surgical rings resulting in severe mitral regurgitation or stenosis will undergo transcatheter mitral valve replacement (valve-in-ring).
89578503|NCT02370511|Experimental|Valve-in-Valve|Patients with symptomatic failing surgical bioprostheses resulting in severe mitral regurgitation or stenosis will undergo transcatheter mitral valve replacement (Valve-in-valve).
89578504|NCT02303041|Experimental|BCC Smoothened inhibitor-naive|Participants with locally advanced or metastatic basal cell carcinoma (BCC) and naive to treatment with Smoothened inhibitors receive sonidegib and buparlisib in repeating 28-day cycles in the absence of disease progression or unacceptable toxicity.
89578505|NCT02303041|Experimental|BCC refractory or relapsed after Smoothened inhibitor|Participants with locally advanced or metastatic basal cell carcinoma (BCC) that is refractory or relapsed after treatment with Smoothened inhibitors receive sonidegib and buparlisib in repeating 28-day cycles in the absence of disease progression or unacceptable toxicity.
89578506|NCT02302807|Experimental|Arm A: Atezolizumab|Atezolizumab will be administered intravenously at a fixed dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle. Participants will receive atezolizumab as long as they continue to experience clinical benefit in the opinion of the investigator until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator.
89578507|NCT02302807|Active Comparator|Arm B: Chemotherapy (Vinflunine, Paclitaxel, or Docetaxel)|Participants randomized to the chemotherapy arm will receive vinflunine, paclitaxel, or docetaxel per the investigator's choice. Vinflunine 320 milligrams per square meter (mg/m^2), paclitaxel 175 mg/m^2, or docetaxel 75 mg/m^2 will be administered intravenously on Day 1 of each 21-day cycle until disease progression per standard RECIST v1.1 or unacceptable toxicity.
89578508|NCT02335489||Treated Subjects|All subjects recruited and treated with the Axium neurostimulator
88972655|NCT03150836|Experimental|Safety Lead-In, Regimen B2 Durvalumab + Tremelimumab + RT|Tremelimumab 75 mg will be administered via IV infusion q4wk for 1 cycle with durvalumab 1500 mg via IV infusion. Radiation Therapy (RT), at the optimal dose determined in the safety lead-in from Regimen A, will be delivered beginning on day 8 ± 3 of durvalumab. After one dose of tremelimumab and durvalumab, durvalumab 1500 mg q4wk will be continued to complete either 13 total cycles of durvalumab OR until disease progression, unacceptable toxicity, or patient withdrawal from study, whichever comes first.
88972656|NCT03150836|Experimental|Expansion Cohort, Regimen A: Durvalumab + RT|Durvalumab 1500 mg will be delivered via IV infusion q4wk. Radiation Therapy (RT) will be delivered beginning on day 8 ± 3 of durvalumab. RT (either 33Gy delivered as 6.6Gy x 5 fractions or 30 Gy delivered as 6.0 Gy x 5 fractions, as determined during the safety lead-in for Regimen B) should be completed within 14 days from the start of RT ideally over 5 consecutive days. Durvalumab 1500 mg q4wk will be continued to complete either 13 total cycles OR until disease progression, unacceptable toxicity, or patient withdrawal from study, whichever comes first.
88972657|NCT03150836|Experimental|Expansion Cohort Regimen B: Durvalumab + Tremelimumab + RT|Tremelimumab 75 mg will be administered via IV infusion q4wk for 1 or 2 cycles (as determined during the safety lead-in for Regimen B) with durvalumab 1500 mg via IV infusion. Radiation Therapy (RT), at the optimal dose determined in the safety lead-in from Regimen A, will be delivered beginning on day 8 ± 3 of durvalumab. After 1 or 2 doses of tremelimumab and durvalumab, durvalumab 1500 mg q4wk will be continued to complete either 13 total cycles of durvalumab OR until disease progression, unacceptable toxicity, or patient withdrawal from study, whichever comes first.
88972658|NCT03150758|Experimental|Electrical Stimulation|Each participant will be given 4 electrical stimulants with an amplitude ranging from 1mA to 30mA. The maximum stimulus without causing an erection will be recorded
88972659|NCT03150680||SYNTAX score = 0|Patients with nonobstructive CAD (≤50 % diameter stenosis)
88972660|NCT03150680||0 < SYNTAX score <23|Low SYNTAX group
88972661|NCT03150680||SYNTAX score >= 23|Intermediate-High SYNTAX group
88972662|NCT03150641|Other|Immediate cord clamping|Umbilical cord clamped within 15 seconds of delivery of baby
88972663|NCT03150641|Experimental|Delayed cord clamping|Umbilical cord clamped 60 seconds after delivery of baby
89029392|NCT00503711|Experimental|100 mg Vandetanib eod|100 mg Vandetanib every other day dosing
89578509|NCT02527343|Experimental|Placebo/Volanesorsen|"Randomized Period: Volanesorsen-matching placebo as SC, QW for Weeks 1-52. Participants who received volanesorsen-matching placebo in RT period and not enter in OLE period went straight to 13-week PT follow-up period. Dose adjustment based on monitoring rules were allowed.~OLE Period: Participants who received volanesorsen-matching placebo in RT period and completed RT period, were to receive 300 mg of volanesorsen as SC QW for 52 weeks (Weeks 53-104) in OLE period. Dose adjustment based on monitoring rules were allowed. After Week 104, participants had option of continuing treatment with 300 mg of volanesorsen as SC injection for up to additional 52 weeks (Weeks 105-156). Participants not entered in option for additional 52 weeks of dosing in OLE PT period went straight to 13-week PT follow-up period after completion of first 52 weeks (Weeks 53-104) of OLE. Participants entered in OLE PT period went straight to 13-week PT follow-up period after completion of Week 156 of OLE."
89578510|NCT02527343|Experimental|Volanesorsen|"Randomized Period: 300 mg of volanesorsen as SC, QW for Weeks 1-52. Participants who received 300 mg of volanesorsen in RT period and did not enter in OLE period went straight to 13-week PT follow-up period. Dose adjustment based on monitoring rules were allowed.~OLE Period: Participants who received volanesorsen in RT period and completed RT period, were to receive 300 mg of volanesorsen as SC QW for 52 weeks (Weeks 53-104) in OLE period. Dose adjustment based on monitoring rules were allowed. After Week 104, participants had option of continuing treatment with 300 mg of volanesorsen as SC injection for up to additional 52 weeks (Week 105-156). Participants who were not entered in option for additional 52 weeks of dosing in OLE PT period went straight to 13-week PT follow-up period after completion of first 52 weeks (Weeks 53-104) of OLE. Participants entered in OLE PT period went straight to 13-week PT follow-up period after completion of Week 156 of OLE."
89578511|NCT05582057|Experimental|Experimental Group|Behavioral: Strengths to Grow Program In an online, self-directed format, the Strengths to Grow: Preteen program will present the principles of strength-based parenting using videos, pictures, reflection questions, and written text. The intervention will communicate that a) every child has a unique set of strengths and that b) noticing and developing these strengths can enhance child and family well-being. It will also provide concrete steps that parents can follow to talk with their child about strengths, and it will provide ideas for family activities that would allow family members to express strengths. Participants will be invited to respond to reflection questions at various points throughout the program.
89578512|NCT05582057|No Intervention|Waitlist Control Group|
89578513|NCT05308277|Other|Single Arm - Leo Device Monitoring|Child's respiratory impedance will be continuously recorded using the Leo device during hospital/ED stay after consent and enrollment, and then during 7 days at home after discharge. The Leo device provides no intervention, and will only monitoring chest impedance for the worn period. Oscillometry and spirometry testing and flow volume assessment using PNT will be performed during study visits with Leo device attached.
89578514|NCT05307887|Experimental|Virtual Reality Technology|Group receiving virtual reality technology in addition to standard therapy
89578515|NCT05307887|No Intervention|Standard Therapy Control Group|
89578516|NCT01931566|Placebo Comparator|Low Risk Placebo|Pioglitazone placebo-matching tablets, orally, once daily to participants assigned to low risk group for developing MCI-AD for up to 5 years.
89578517|NCT01931566|Placebo Comparator|High Risk Placebo|Pioglitazone placebo-matching tablets, orally, once daily to participants assigned to high risk group for developing MCI-AD for up to 5 years.
89578518|NCT01931566|Experimental|High Risk Pioglitazone|Pioglitazone 0.8 mg, sustained release (SR) tablets, orally, once daily to participants assigned to high risk group for developing MCI-AD for up to 5 years.
89578519|NCT05511077|Other|Liquid oat product|
89578520|NCT05511077|Other|Solid oat product|
89578521|NCT04248725|Experimental|E-TIPS|The E-TIPS intervention is based upon a cognitive-behavioral intervention for pain that was developed for and shown to be effective in people with chronic pain and a physical disability such as the conditions of interest in this study. Eight, 45-minute telephone sessions will be delivered by a clinician. A patient workbook will be used to facilitate skill acquisition and rehearsal in and outside of sessions. The intervention includes education about the role of unhelpful thoughts, particularly pain catastrophizing, and unhelpful pain coping behaviors; instruction in how to identify and change unhelpful or negative thinking about pain; utilization of helpful coping strategies; relaxation techniques; behavioral activation including setting goals for physical activation, activity pacing and scheduling; and coping with pain flare-ups. Each session includes a brief relaxation exercise. Participants receive digital audio recordings of relaxation exercises to practice at home.
89578522|NCT04248725|No Intervention|Usual care|Participants assigned to the control intervention will continue to pursue standard care (a waitlist). Waitlist control subjects will be offered the opportunity to receive the intervention following completion of the final 6-month follow up outcome assessment.
89578523|NCT05372939|Active Comparator|AMT-101 and Humira (adalimumab)|AMT-101 Tablet
89578524|NCT05372939|Placebo Comparator|Placebo and Humira (adalimumab)|Placebo Tablet
89578525|NCT05372705|Active Comparator|Positive|"~58-second selfie video (TikTok) of an adolescent presenting a can do / climate action / positive perspective on global warming"
89578526|NCT05372705|Active Comparator|Negative|"~58-second selfie video (TikTok) of an adolescent presenting an it's already too late / climate catastrophe / negative perspective on global warming"
89578527|NCT05372705|Active Comparator|Neutral|~58-second selfie video (TikTok) of an adolescent discussing a topic unrelated to climate change or global warming
88972664|NCT03150602|Experimental|Pralatrexate treatment|Pralatrexate will initially be administered at a dose of 30 mg/m2/week on days 1, 8, 15, 22, 29 and 36 for 6 weeks in a 7-week cycle (cycle: 6 weeks + 1 week rest). The scheduled date can be done within a window time of plus or minus 1 day
88972665|NCT00396435|Experimental|Group A|High Hb target
88972666|NCT00396435|Active Comparator|Group B|Low Hb Target
88972667|NCT03150563|No Intervention|Control Group|The subjects of the CG will receive the same orientations of the other groups in relation to the importance of the routines of stretching activities, but during the study period, they will not be able to perform stretches during their day to day life.
88972668|NCT03150563|Experimental|Experimental Group 1|"The experimental group 1 will have the sensation of SENSATION SENSING WITHOUT DESCONFORT as an intensity for the application of the passive stretch protocol."
89029393|NCT00503711|Experimental|100 mg Vandetanib od|100 mg Vandetanib once daily dosing
89578528|NCT05341037||Postoperative complications +|Patients who have postoperative complications during hospital stay after cardiac surgery
89578529|NCT05341037||Postoperative complications -|Patients who have not postoperative complications during hospital stay after cardiac surgery
89578530|NCT04247477|Experimental|A-B-A-C|Four consecutive steps (45 min per step) are tested in the following order: Peep titration strategy according to Express method (A) - Peep titration strategy according to overdistension and collapse estimation (B) - Peep titration strategy according to Express method (A) - Peep titration strategy according to estimation of lung inhomogeneity (C)
89578531|NCT04247477|Experimental|A-C-A-B|Four consecutive steps (45 min per step) are tested in the following order: Peep titration strategy according to Express method (A) - Peep titration strategy according to estimation of lung inhomogeneity (C) - Peep titration strategy according to Express method (A) - Peep titration strategy according to overdistension and collapse estimation (B)
89578532|NCT01912456|Experimental|Higher-volume placebo, then low-volume C1-esterase inhibitor|A higher-volume dose of placebo will be administered subcutaneously twice a week for up to 16 weeks, then a low-volume dose of C1-esterase inhibitor will be administered subcutaneously twice a week for up to 16 weeks.
89578533|NCT01912456|Experimental|Low-volume C1-esterase inhibitor, then higher-volume placebo|A low-volume dose of C1-esterase inhibitor will be administered subcutaneously twice a week for up to 16 weeks, then a higher-volume dose of placebo will be administered subcutaneously twice a week for up to 16 weeks.
89578534|NCT01912456|Experimental|Low-volume placebo, then higher-volume C1-esterase inhibitor|A low-volume dose of placebo will be administered subcutaneously twice a week for up to 16 weeks then a higher-volume dose of C1-esterase inhibitor will be administered subcutaneously twice a week for up to 16 weeks.
89578535|NCT01912456|Experimental|Higher-volume C1-esterase inhibitor, then low-volume placebo|A higher-volume dose of C1-esterase inhibitor will be administered subcutaneously twice a week for up to 16 weeks, then a low-volume dose of placebo will be administered subcutaneously twice a week for up to 16 weeks.
89578536|NCT05307653|Experimental|Penile block|Penile block was performed in supine position. The penis was retracted caudally and then fixed with a leucoplast. After identifying the symphysis pubis (SP), a 22-gauge needle was inserted vertically about 1 cm lateral to the SP, and bupivacaine 0.5% (0.1 ml/kg, maximum 2.5 ml) was injected on each side after penetrating the Scarpa's fascia.
88972669|NCT03150563|Experimental|Experimental Group 2|"The GE2 will have the feeling of MAXIMUM DISORDER WITHOUT PAIN as the as an intensity for the application of the passive stretch protocol."
88972670|NCT03150563|Experimental|Experimental Group 3|"GE3 will have the sensation of MAXIMUM TOLERABLE PAIN as the as an intensity for the application of the passive stretch protocol."
89578537|NCT05307653|Experimental|Erector spinea plain block group|Ultrasound guided ESPB was performed in prone position by Philips © (CX50 Extreme edition). The superficial probe was placed longitudinally at the midline just above the sacrum, and both erector spinae muscles and median sacral crests were identified. Using the in-plane approach, a 22-gauge needle was inserted in a craniocaudal direction till reaching the tip of the fourth median sacral crest. After negative aspiration to avoid intravascular or intrathecal puncture, bupivacaine 0.25% (1 ml/kg, maximum 20 ml) was administered.
89578538|NCT05307653|Experimental|Caudal group|Caudal block was performed in the left lateral position. A 22 G needle was inserted through the sacral hiatus. The loss of resistance method was used to pass through the sacrococcygeal membrane and enter the caudal epidural space. Negative aspiration was then performed. When no blood or cerebrospinal fluid was observed, bupivacaine 0.25% (1 ml/kg, maximum 20 ml) was administered. The patient was returned to the supine position after the procedure was completed.
89578539|NCT05340491|Experimental|Chemoradiotherapy+anti-PD-1|Patients in this arm will receive three cycles of GP chemotherapy plus PD-1 antibody, then receive IMRT and PD-1 antibody maintenance for eight cycles.
89578540|NCT05340491|Active Comparator|Chemoradiotherapy|Patients in this arm will receive three cycles of GP chemotherapy, then receive IMRT.
89578541|NCT05306093|Experimental|Nutraceutical|"Daily, 2 dietary supplements will be taken orally with some water, the first one during the breakfast and the second one during the dinner.~Dietary supplements in capsule form"
89578542|NCT05306093|Placebo Comparator|Maltodextrin|"Daily, 2 dietary supplements will be taken orally with some water, the first one during the breakfast and the second one during the dinner.~Dietary supplements in capsule form"
88972671|NCT03150524|Active Comparator|Nimodipine|Patients in group one will receive short-acting nimodipine every 4 hours.
88972672|NCT03150524|Active Comparator|Verapamil ER|Patients in group two will receive long-acting verapamil every 12 hours.
88972673|NCT03150446|Experimental|The group using flexible cystoscopy|50 patients with large upper ureteral stones underwent laparoscopic ureterolithotomy with flexible cystoscopy to confirm the correct positioning of the double-J stent. After intracorporeal insertion of the double-J catheter, additional endoscopic monitoring with flexible cystoscopy was performed. The surgeon manipulating the double-J catheter used monitor A, while an assistant inserted a flexible cystoscope into the bladder through the urethral route and determined whether the double-J stent was correctly placed in the bladder using monitor B before suturing the site of ureterotomy.
88972674|NCT03150368|Experimental|ModraDoc006/r|Weekly ModraDoc006/r treatment as ModraDoc006 (oral docetaxel) 10mg tablets combined with ritonavir 100mg tablets
88972675|NCT03150290|Other|ALS patients without weight loss.|18-FDG-PET. Indirect Calorimetry.
88972676|NCT03150290|Other|ALS patients with weight loss.|18-FDG-PET. Indirect Calorimetry.
88972677|NCT00033111|Active Comparator|Cabergoline|Subjects received one tablet of 0.5 mg of cabergoline tablet per week for 12 weeks.
88972678|NCT00033111|Placebo Comparator|Placebo|Subjects received one tablet of 0.5 mg of cabergoline matched placebo tablet per week for 12 weeks.
88972679|NCT03150251|Experimental|Overnight Oats|40 g of overnight oats
88972680|NCT03150251|Placebo Comparator|Soaked Cream of Rice|28.8 cream of rice
88972681|NCT03150251|Placebo Comparator|Cooked Cream of Rice|28.8 cooked cream of rice
88972682|NCT03150212|Experimental|Saccharomyces cerevisiae CNCM I-3856|
88972683|NCT03150212|Placebo Comparator|Placebo|
89029394|NCT00503711|Experimental|300 mg Vandetanib od|300 mg Vandetanib once daily dosing
89029395|NCT05146713|Experimental|Propolis nanoparticles extract solution|
89578543|NCT04251065|Experimental|Daratumumab-GDP|"This is an open-label, multicenter, single arm, single-stage phase II trial. After the patient signs the written informed consent the patient will enter the screening phase planning baseline assessments and a concomitant upfront confirmation of diagnosis of PTCL-NOS, AITL or nodal lymphoma of TFH cell origin and a central evaluation of immunohistochemical positivity of CD38 on bioptic material used to perform local diagnosis of relapsed disease, or that used for the more recent biopsy in the case of refractory patients. A core needle biopsy is considered sufficient for review and CD38 evaluation. Evaluation at central laboratory can be performed in bone marrow sections in those patients with only bone marrow lymphoma infiltration.~Only patients with confirmed eligible diagnosis and a percentage of CD38 positive tumor cells ≥ 5% will be considered eligible for study treatment.~The treatment consists of an induction phase and a maintenance phase."
89578544|NCT01885936|Experimental|Albuterol|Initially 4 mg daily for one week, then 4 mg BID per oral daily for the next 5 weeks. If the 4 mg BID per oral is well tolerated, the dose will be increased to 8 mg each morning/4 mg each evening for one week, followed by 8 mg BID per oral for the remainder of the study.
89578545|NCT01885936|Placebo Comparator|Placebo Comparator|Initially one capsule daily for one week, then one capsule BID per oral daily for the next 5 weeks. If the one capsule BID per oral is well tolerated, the dose will be increased to two capsules each morning/one capsule each evening for one week, followed by two capsules BID per oral for the remainder of the study.
89578546|NCT05509127|Experimental|Carious cervical lesions treated with modified universal adhesive|Preparation of class V cavity with removal of caries and beveling of margins is done followed by total etching prior to application of modified universal adhesive. The cavity is then restored with nano-filled resin composite.
89578547|NCT05509127|Active Comparator|Carious cervical lesions treated with conventional universal adhesive|Preparation of class V cavity with removal of caries and beveling of margins is done followed by total etching prior to application of conventional universal adhesive. The cavity is then restored with nano-filled resin composite.
89578548|NCT05338229|Experimental|video game in CP children (pilot study)|The cerebral palsy children will play the engineer-built system, video-game based Kinect sensor 3 times/week for 5 weeks. Each session will last for 40 minutes. The video-game Kinect sensor was developed by the researcher team.
89578549|NCT05336591||Medical doctor|
89578550|NCT05336591||Nurses (Pediatric department and youth healthcare)|
89578551|NCT05336591||Other professionals in treatment (e.g. dieticians, physiotherapists)|
89578552|NCT05336591||Other (such as policy makers)|
89578553|NCT05301491|Experimental|Dance therapy group|This group included in the dance therapy program throughout the study.
89578554|NCT05301491|Experimental|Control group|This group included in the conventional low back pain exercise program throughout the study.
89578555|NCT05368415|Active Comparator|3 mcg grup|this group will receive Norepinephrine bolus of 3 mcg for management of hypotension.
89578556|NCT05368415|Active Comparator|4 mcg group|this group will receive Norepinephrine bolus of 4 mcg for management of hypotension
89578557|NCT05368415|Active Comparator|5 mcg group|this group will receive Norepinephrine bolus of 5 mcg for management of hypotension
89578558|NCT05335109|Experimental|Xenon|
89578559|NCT05335109|Placebo Comparator|Oxygen|
88972684|NCT00033228|Experimental|Cohort 1|The first cohort of 6 patients received 500 ug of Synchrovax SEM plasmid DNA vaccine. All patients were to be monitored for dose limiting toxicities DLTs) for a minimum of 2 weeks after their second infusion of vaccine on Day 15 before allowing patients to enroll at the next dose group. The decision to progress to the next dose group was to be based on occurrence of DLTs observed in 1 or fewer (<33%) patients of a 6 patient cohort.
88972685|NCT00033228|Experimental|Cohort 2|The second cohort of 6 patients received 1000 ug of Synchrovax SEM plasmid DNA vaccine. All patients were to be monitored for dose limiting toxicities DLTs) for a minimum of 2 weeks after their second infusion of vaccine on Day 15 before allowing patients to enroll at the next dose group. The decision to progress to the next dose group was to be based on occurrence of DLTs observed in 1 or fewer (<33%) patients of a 6 patient cohort.
88972686|NCT00033228|Experimental|Cohort 3|The third cohort of 6 patients received 1500 ug of Synchrovax SEM plasmid DNA vaccine. The maximum tolerated dose (MTD) was to be determined by the observation of DLT at each dose group.
88972687|NCT00033267|Experimental|Treatment|Patients receive CCI-779 IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with stable disease receive a maximum of 6 courses. Patients with partial response receive a maximum of 12 courses. Patients with CR receive 2 additional courses beyond CR.
88972688|NCT00033306|Experimental|BMS-247550|
88972689|NCT02984384|Active Comparator|Low Molecular Weight Heparin (LMWH)-Enoxaparin|Injection of 30 mg enoxaparin, twice a day via injection
88972690|NCT02984384|Active Comparator|Acetylsalicylic acid (ASA)-Aspirin|Enteral ingestion or administration of 81 mg ASA, twice a day
89578560|NCT05300399|Experimental|With mHealth app|
89029396|NCT05146713|Active Comparator|sodium hypochlorite|
89578561|NCT05300399|No Intervention|Without mHealth app|
89578562|NCT04137575|Experimental|ConquerFear-Group|ConquerFear-Group is a psychological intervention developed specifically for fear of cancer recurrence
89578563|NCT04137575|Placebo Comparator|Relaxation Training|The Relaxation Training serves as a placebo comparator and is not developed specifically to target fear of cancer recurrence.
89578564|NCT05299229||Heart and vascular function|All study participants will have echocardiography and non-invasive monitoring by chest/back sensors and a finger cuff to determine the best method of monitoring heart and vascular function in preeclampsia.
89578565|NCT05333237|Experimental|Sequence 123|"In this study arm the following sequence of interventions will be administered:~upon first study session, intervention #1 will be administered (Dietary Supplement: ProvideXtra Drink).~upon second study session, intervention #2 will be administered (Dietary Supplement: Fresubin Energy Drink).~upon third study session, intervention #3 will be administered (Dietary Supplement: Generic Glucose Solution)."
89578566|NCT05333237|Experimental|Sequence 132|"In this study arm the following sequence of interventions will be administered:~upon first study session, intervention #1 will be administered (Dietary Supplement: ProvideXtra Drink).~upon second study session, intervention #3 will be administered (Dietary Supplement: Generic Glucose Solution).~upon third study session, intervention #2 will be administered (Dietary Supplement: Fresubin Energy Drink)."
89578567|NCT05333237|Experimental|Sequence 213|"In this study arm the following sequence of interventions will be administered:~upon first study session, intervention #2 will be administered (Dietary Supplement: Fresubin Energy Drink).~upon second study session, intervention #1 will be administered (Dietary Supplement: ProvideXtra Drink).~upon third study session, intervention #3 will be administered (Dietary Supplement: Generic Glucose Solution)."
89578568|NCT05333237|Experimental|Sequence 231|"In this study arm the following sequence of interventions will be administered:~upon first study session, intervention #2 will be administered (Dietary Supplement: Fresubin Energy Drink).~upon second study session, intervention #3 will be administered (Dietary Supplement: Fresubin Energy Drink).~upon third study session, intervention #1 will be administered (Dietary Supplement: ProvideXtra Drink)."
89578569|NCT05333237|Experimental|Sequence 312|"In this study arm the following sequence of interventions will be administered:~upon first study session, intervention #3 will be administered (Dietary Supplement: Generic Glucose Solution).~upon second study session, intervention #1 will be administered (Dietary Supplement: ProvideXtra Drink).~upon third study session, intervention #2 will be administered (Dietary Supplement: Fresubin Energy Drink)."
89578570|NCT05333237|Experimental|Sequence 321|"In this study arm the following sequence of interventions will be administered:~upon first study session, intervention #3 will be administered (Dietary Supplement: Generic Glucose Solution).~upon second study session, intervention #2 will be administered (Dietary Supplement: Fresubin Energy Drink).~upon third study session, intervention #1 will be administered (Dietary Supplement: ProvideXtra Drink)."
89578571|NCT01912222|Experimental|IXAZOMIB Arm 1|"Experimental: Arm 1 (Normal hepatic function) In the 15 day period that constitutes Part A of the trial, patients will receive a single oral 4 mg dose of IXAZOMIB capsule on Day 1.~Patients from Part A will then have the option of continuing the study by participating in Part B, starting immediately after Part A, where they will receive IXAZOMIB on Days 1, 8, and 15 of a 28-day cycle"
89578572|NCT01912222|Experimental|IXAZOMIB Arm 2|"Experimental: Arm 2 (Moderate hepatic impairment) In the 15 day period that constitutes Part A of the trial, patients will receive a single oral 2.3 mg dose of IXAZOMIB capsule on Day 1.~Patients from Part A will then have the option of continuing the study by participating in Part B, starting immediately after Part A, where they will receive IXAZOMIB on Days 1, 8, and 15 of a 28-day cycle"
89578573|NCT01912222|Experimental|IXAZOMIB Arm 3|"Experimental: Arm 3 (Severe hepatic impairment) In the 15 day period that constitutes Part A of the trial, patients will receive a single oral 1.5 mg dose of IXAZOMIB capsule on Day 1.~Patients from Part A will then have the option of continuing the study by participating in Part B, starting immediately after Part A, where they will receive IXAZOMIB on Days 1, 8, and 15 of a 28-day cycle"
89578574|NCT05367791|Other|POSTUR|Postural training only.
89578575|NCT05367791|Other|POSTUR + LV (localized vibration)|Postural training combined with localized vibration
89578576|NCT05367791|Other|POSTUR+SES (somatosensory electrical stimulation)|Postural training combined with somatosensory electrical stimulation
89578577|NCT05367791|Other|POSTUR+LV-SES|Postural training combined with somatosensory electrical stimulation and localized vibration
89578578|NCT05366855|Active Comparator|IV +SC Imsidolimab|IV loading dose followed by subcutaneous Imsidolimab
89578579|NCT05366855|Active Comparator|SC Imsidolimab|Subcutaneous Imsidolimab
89578580|NCT05366855|Placebo Comparator|SC Placebo|Subcutaneous Placebo
89578581|NCT05366855|No Intervention|Standard of Care|Any available therapy
89578582|NCT05332301|Experimental|High-fat test meal|All participants will consume a high-fat breakfast after an overnight fast. This meal will consist of a flour tortilla, eggs, bacon, cheddar cheese, mayonnaise, and hashbrowns. After the initial blood sample (0 min) is drawn during Visit 2, we will ask participants to consume this breakfast within 10 minutes. This meal has been designed to mimic the amount of energy (calories) and fat contained in a typical fast-food breakfast (e.g., from Tim Hortons or McDonalds). Each meal will provide 846 kcal, derived from 54 g fat (58% energy), 61 g carbohydrate (29% energy), and 29 g protein (13% energy).
89578583|NCT04250207|Experimental|K-321 QID|K-321 Ophthalmic Solution Dose A
89578584|NCT04250207|Experimental|K-321 BID|K-321 Ophthalmic Solution Dose B
89578585|NCT04250207|Placebo Comparator|Placebo|Vehicle Solution Dose
89578586|NCT05500703|Experimental|Dexmedetomidine group|1.5 µg kg-1 h-1 dexmedetomidine
89578587|NCT05500703|Active Comparator|Opioid group|0.9% sodium chloride injection
88972691|NCT02971566||Gastrointestinal complications|"Development of one ore more of the following gastrointestinal complications:~necrotizing enterocolitis (stage ≥2)~spontaneous intestinal perforation~feeding intolerance, defined as enteral feeding withholding ≥1 day because of suggestive clinical signs"
88972692|NCT02971566||Controls|no evidence of gastrointestinal complications during the hospitalization
88972693|NCT00033345|Experimental|High-Risk Breast Cancer|All subjects first went through a 4-week placebo run-in period. Next, subjects took Indole-3-carbinol 400mg daily for 4 weeks followed by a 4-week period of Indole-3-carbinol 800mg daily.
88972694|NCT00033423|Experimental|Cohort 1|First radiation dose regimen of yttrium Y 90 ibritumomab tiuxetan
88972695|NCT00033423|Experimental|Cohort II|Second radiation dose regimen of yttrium Y 90 ibritumomab tiuxetan
89578588|NCT05331833||study group|CTV-omitted IMRT under PET-CT guidance
89578589|NCT05331833||control group|CTV-delineated IMRT under PET-CT guidance
89578590|NCT05366231|Experimental|Kesuting syrup group|Kesuting syrup, the tested drug of this study.
89578591|NCT05366231|Active Comparator|LianHuaQingWen Granules Control group|"LianHuaQingWen Granules, referring to Diagnosis and Treatment Protocol for COVID-19 (Trial Version 9), a NMPA approved drug for light and common patients with novel coronavirus during medical observation and clinical treatment,is adopted as active comparator in this study."
89578592|NCT05365295|Experimental|ADHD|- ADHD children aged between 8 to 10 years old
89578593|NCT05330585|Experimental|Participants with hearing loss.|Participants with hearing loss.
88972696|NCT00033423|Experimental|Cohort III|Third radiation dose regimen of yttrium Y 90 ibritumomab tiuxetan
88972697|NCT00033423|Experimental|Cohort IV|Fourth radiation dose regimen of yttrium Y 90 ibritumomab tiuxetan
89029397|NCT00503789|Active Comparator|1|cow-milk based infant formula
89578594|NCT02525861|Experimental|Cohort I: GLASSIA (High-end)|Participants will receive weekly IV infusions of GLASSIA (lot with particle loads representing the high end within) at 60 milligrams per kilogram (mg/kg) BW active A1PI protein administered at a rate of 0.2 milliliters per kilogram of body weight per minute (ml/kg/min) for 25 weeks (25 planned infusions) via an IV administration.
89029398|NCT00503789|Experimental|2|cow milk based infant formula with prebiotics
89029399|NCT00503789|Other|3|human milk reference group
89578595|NCT02525861|Experimental|Cohort II: GLASSIA (Low-end)|Participants will receive weekly IV infusions of GLASSIA (lot with particle loads representing the low end within the normal range) at 60 mg/kg BW active A1PI protein administered at a rate of 0.2 ml/kg/min for 25 weeks (25 planned infusions) via an IV administration.
89578596|NCT05293613|Experimental|Cases|
89578597|NCT02524847|Experimental|Methoxsalen with ECP|Participants receive methoxsalen 20 µg/ml in conjunction with ECP procedure three times per week for Weeks 1 to 4, and two times per week for Weeks 5 to 12.
89578598|NCT05526365|No Intervention|Control|Participants in the control group will receive an initial 12 question baseline test (same as intervention). They will after two weeks receive a second test that is linguistically the same as the national GPhC exam.
89578599|NCT05526365|Experimental|Intervention|Participants in the intervention group will receive an initial 12 question baseline test (same as control). They will after two weeks receive a second test that is reduced in idea density by around 10% overall.
89578600|NCT04422275|Active Comparator|Budesonide & High-Concentration OLF|In this arm, subjects will perform nasal saline lavage (240 ml) with budesonide (0.5mg/capsule) and four different high-concentration (1 ml) essential oils for olfactory training twice daily.
89578601|NCT04422275|Active Comparator|Placebo & High-Concentration OLF|In this arm, subjects will perform nasal saline lavage (240 ml) with placebo (lactose monohydrate) and four different high-concentration (1 ml) essential oils for olfactory training twice daily.
89578602|NCT04422275|Active Comparator|Budesonide & Low-Concentration OLF|In this arm, subjects will perform nasal saline lavage (240 ml) with budesonide (0.5mg/capsule) and four different low-concentration (0.1 ml) essential oils for olfactory training twice daily.
89029400|NCT05149989|Experimental|Proning|Proned on standard and proning pillows
89029401|NCT00503828|Active Comparator|naproxen|Naproxen 500 mg/day for 4 weeks
89029402|NCT00503828|Experimental|Derris Scandens Benth|Derris Scandens Benth
89029403|NCT05149677|No Intervention|Standard of Care for labor pain|Standard of Care of Care for labor pain
89029404|NCT05149677|Experimental|Music therapy intervention + Standard of Care for labor pain|Music therapy intervention + Standard of Care for labor pain
89029405|NCT03455478|Experimental|corrected refractive error|
89029406|NCT03455478|No Intervention|uncorrected refractive error|
89029407|NCT00499967|Experimental|Cohort 1|GS-9191 0.01% ointment
89029408|NCT00499967|Experimental|Cohort 2|GS-9191 0.03% ointment
89578603|NCT04422275|Placebo Comparator|Placebo & Low-Concentration OLF|In this arm, subjects will perform nasal saline lavage (240 ml) with placebo (lactose monohydrate) and four different low-concentration (0.1 ml) essential oils for olfactory training twice daily.
89578604|NCT04422587||RECOP unit patient|All patients admit in RECOP unit for dyspnea can be included in this study if patient is agree. Then, doctor collects demographic variables, the usual history and treatments, the characteristics of the episode (symptomatology, evolution, treatment taken) and the data from the initial clinical examination will be identified.
89578605|NCT02129205|Experimental|PF-06650808|
89578606|NCT05289479|Active Comparator|"No pre-heating control group"|resin composite is used at room temperature without preheating
89578607|NCT05289479|Active Comparator|0ne cycle pre-heating|one cycle preheating of resin composite at 68 degree Celsius before application
89578608|NCT05289479|Active Comparator|ten cycles pre-heating|ten cycles preheating of resin composite at 68 degree Celsius before application
89578609|NCT05360693|Experimental|immediate implant placement without bone grafting|After atraumatic extraction of the non-restorable tooth using periotome and luxators, osteotomy site preparation will be done 3-5mm into the bone apical to the socket according to the manufacturer's instructions. Patients will receive an immediate post-extraction implant without any grafting material in the socket between the residual labial bone and implant surface.
89578610|NCT05360693|Active Comparator|immediate implant placement with bone grafting|After atraumatic extraction of the non-restorable tooth using periotome and luxators, osteotomy site preparation will be done 3-5mm into the bone apical to the socket according to the manufacturer's instructions. Patients will receive an immediate post-extraction implant with placing bovine bone graft (Bio-oss) in the socket between the residual labial bone and implant surface.
89029409|NCT00499967|Experimental|Cohort 3|GS-9191 0.1% ointment
89029410|NCT00499967|Active Comparator|Cohort 4|GS-9191 0.3%
89029411|NCT00499967|Active Comparator|Cohort 5|GS-9191 1.0%
89029412|NCT00499967|Placebo Comparator|Cohorts 1, 2, 3, 4 & 5|Placebo in all cohorts
89029413|NCT00500006|Other|A|Arm A: Drug and comparator
89029414|NCT00500006|Other|B|Arm B: Drug and comparator
89029415|NCT01247051|Experimental|Precoating|
89029416|NCT01247051|Active Comparator|Standard priming|
89029417|NCT00506727|Experimental|Adderall XR|
89029418|NCT00506727|Active Comparator|Atomoxetine hydrochloride|
89029419|NCT01247168|Experimental|1|
89029420|NCT00500162|Active Comparator|1|
89029421|NCT00500162|Active Comparator|2|
89578611|NCT04245605||Early angiography|Patients admitted to hospital with acute heart failure undergoing coronary angiography within 14 days of hospital admission
89578612|NCT04245605||Control|Patients admitted to hospital with acute heart failure not undergoing coronary angiography within 14 days
89578613|NCT02128269|Experimental|ALXN1007- Open label study|ALXN1007
89578614|NCT05324735|Experimental|Pentoxifylline|Pentoxifylline (tablet): 400 mg twice a day for 12 weeks
89578615|NCT05324735|Placebo Comparator|Control group|Placebo (tablet): twice a day for 12 weeks
89578616|NCT05360459||Control|Healthy postmenopausal patients (more than 12 months from the last 37 menstrual period).
89578617|NCT05360459||Gynecological Cancer|Women affected by cervical or endometrial cancer, in early stages, with a good prognosis for life, who have received radiotherapy with or without brachytherapy (radiotherapy) with or without concurrent chemotherapy.
89578618|NCT01626885|Experimental|MP-214 1.5-9 mg|
89578619|NCT05360225||Clinical Performance Study Protocol for therascreen® KRAS RGQ PCR Kit|The KRAS System (extraction kit, analytical kit, instrument and software) will be used to test FFPE biopsy (resected and core needle biopsy [CNB]/fine needle aspiration [FNA]) tumour tissue from NSCLC patients to establish KRAS G12C mutation status. This will be determined using the investigational device at Q2 Solutions Laboratories.
88972698|NCT00033423|Experimental|Cohort V|MTD radiation dose regimen of yttrium Y 90 ibritumomab tiuxetan
88972699|NCT02809235|Experimental|coconut oil|Subjects will be instructed to supplement their diet with 3 tablespoons of coconut oil daily for three weeks.
88972700|NCT00033462|Experimental|Arm I|Patients receive oral erlotinib once daily. Treatment repeats every 28 days for at least 6 courses in the absence of disease progression or unacceptable toxicity.
88972701|NCT00393263|Experimental|1|pimecrolimus
88972702|NCT00393263|Active Comparator|2|clobetasol
88972703|NCT00033618|Experimental|Arm I (ixabepilone)|Patients receive ixabepilone IV over 1 hour on days 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89578620|NCT05359055|Experimental|Cohort 1|SPH3127 tablet, Itraconazole
89578621|NCT05359055|Experimental|Cohort 2|SPH3127 tablet, Rifampin
89578622|NCT02524379|Experimental|Glyburide Treatment Arm|Enrolled patients will receive 12 doses of Glyburide starting within 8 hours of SCI. The dosing regimen involves an initial dose of 1.25 mg followed by eleven consecutive doses of 0.625 mg every 6 hours. The total daily dose of Glyburide on Day 1, Day 2 and Day 3 will be 3.125 mg, 2.5 mg, and 2.5 mg respectively.
89578623|NCT02524145|Active Comparator|Healthy Seniors|"Fifteen healthy senior volunteers > 60 years of age. Subjects will be healthy with no chronic medical problems and on no cardiac medications except for statins. All control subjects will have a Body Mass Index (BMI) <30, with exercise histories of less than 3 days per week of aerobic exercise.~Intervention: Static handgrip and Autonomic Blockade (Dexmedetomidine, Glycopyrrolate, Isoproterenol)"
89578624|NCT02524145|Experimental|HFpEF|"Patients with HFpEF will provide data from their cardiologist or primary care physician that confirm the following: a) signs and symptoms of heart failure; b) an ejection fraction > 0.50; and c) objective evidence of diastolic dysfunction.~Intervention: Static handgrip and Autonomic Blockade (Dexmedetomidine, Glycopyrrolate, Isoproterenol)"
88972704|NCT00033618|Experimental|Arm II (ixabepilone)|Patients receive ixabepilone IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88972705|NCT00033696|Experimental|chemotherapy + radiation therapy|"Induction therapy: Patients receive paclitaxel IV over 3 hours on days 1 and 22, oral topotecan on days 2-4 and 23-25, and oral etoposide on days 5-7 and 26-28. Patients also receive filgrastim (G-CSF) subcutaneously daily beginning on days 8 and 29 and continuing until blood counts recover.~Consolidation therapy: Patients receive carboplatin IV over 1 hour on days 43, 64, and 85 and etoposide IV over 1 hour on days 43-45, 64-66, and 85-87. Patients undergo radiotherapy daily 5 days per week beginning on day 43 and continuing for 6-7 weeks.~Patients with rapid disease progression discontinue study therapy.~Patients are followed at least every 3 months for 2 years, every 6 months for 3 years, and then annually for 5 years."
88972706|NCT00033735|Experimental|fluorouracil|
88972707|NCT00033735|Experimental|Irofulven|
88972708|NCT00393302||1 & 2|"Retrospective chart review: HIV testing rates~Prospective cohort group: HIV testing rates"
89578625|NCT02524145|Active Comparator|Healthy Young|"Fifteen volunteers <45 yrs will be enrolled. Subjects will be healthy with no chronic medical problems and on no cardiac medications except for statins and have BMI <30.~Intervention: Autonomic Blockade (Dexmedetomidine, Glycopyrrolate, Isoproterenol)"
89578626|NCT05357417|Experimental|cohort 1|HER2-negative advanced breast cancer with brain metastases who have received at least one prior anthracycline and one prior taxane
89578627|NCT05357417|Experimental|cohort 2|HER2-positive advanced breast cancer with brain metastases who have failed trastuzumab and pyrotinib
89578628|NCT01658813|Experimental|5-Fluorouracil and Interferon|"5-Fluorouracil~Interferon-alfa-2b"
89578629|NCT02187471|Placebo Comparator|Placebo|Participants take one each of placebo tablet and capsule, twice daily (BID)
89578630|NCT02187471|Other|Pregabalin|Participants take one pregabalin capsule and one placebo tablet BID
89578631|NCT02187471|Experimental|DS-5565 15 mg QD|Participants take one each of placebo tablet and capsule in the morning and one placebo capsule in the evening with one DS-5565 tablet once daily (QD)
89578632|NCT02187471|Experimental|DS-5565 15 mg BID|Participants take one placebo capsule with one DS-5565 tablet BID
89029422|NCT00500201|Experimental|Subjects in treatment sequence AB|In treatment sequence AB first subjects will be randomized to receive treatment A (two tablets of 60 milligram [mg] of SB-773812) and one placebo tablet. Then subjects will receive treatment B (one tablet of 120 mg of SB-773812) and two placebo tablets . There will be a wash-out period of 20 days between.
89029423|NCT00500201|Experimental|Subjects in treatment sequence BA|In treatment sequence BA first subjects will be randomized to receive treatment B (one tablet of 120 mg of SB-773812) and two placebo tablets. Then subjects will receive treatment A (two tablets of 60 mg of SB-773812) and one placebo tablet. There will be a wash-out period of 20 days between.
89029424|NCT01247246|Placebo Comparator|Placebo|
89578633|NCT02525471|Experimental|RNS60|"Following screening visit to determine eligibility, enrolled subjects will undergo the baseline visit within 6 weeks where the first intravenous (IV) infusion of study medication, RNS60, will be administered. Study medication for inhalation use will be dispensed at this time, and again at weeks 7 and 15. Subjects will continue once a week follow ups to receive RNS60 by IV infusion, continuing inhalation use the remaining 6 days per week, for 23 weeks total. Additionally, eligible subjects will undergo PET imaging at baseline and again between weeks 18 and 23.~In addition, upon nearing completion of the core study, subjects will be given the option to continue to receive drug for approximately an additional 24 weeks, for a total of approximately 48 weeks on study drug, following the optional extension phase schedule of activities."
89578634|NCT05285423|Experimental|Prolene suture technique.|The Group of Patients who were offered Vocal Cord Lateralization with prolene suture technique.
89578635|NCT05284409|Active Comparator|Pethidine|(control group) 36 patients will receive 0.5 mg/kg Pethidine IVI for management of shivering induced by Single Shot Spinal Anesthesia.
89578636|NCT05284409|Experimental|Acetaminophen|36 patients will receive 15 mg/kg Acetaminophen IVI for management of shivering induced by Single Shot Spinal Anesthesia.
89578637|NCT05284409|Experimental|Dexamethasone|36 patients will receive 0.1 mg/kg Dexamethasone IVI for management of shivering induced by Single Shot Spinal Anesthesia.
89578638|NCT01658735|Active Comparator|H-Wave Device|H-Wave Device with Usual Care
89578639|NCT01658735|Active Comparator|TENS|Transcutaneous electrical nerve stimulation (TENS) Device with Usual Care
89578640|NCT01658735|Sham Comparator|Sham Electrotherapy|Sham Device plus Usual Care.
89578641|NCT05322551||Obese only|"Definition of Obese:~Body Mass Index ≥ 30kg/m^2 (WHO classification)~Definition of Non Diabetes: Fasting Plasma Glucose (FPG) < FPG 100 mg/dL (5.6 mmol/L)"
89578642|NCT05322551||Obese with prediabetes|"Definition of Obese:~Body Mass Index ≥ 30kg/m^2 (WHO classification)~Definition of Prediabetes: FPG 100 mg/dL (5.6 mmol/L) to 125 mg/dL (6.9 mmol/L) (IFG) OR A1C 5.7-6.4% (39-47 mmol/mol)"
89578643|NCT05322551||Obese with diabetes|"Definition of Obese:~Body Mass Index ≥ 30kg/m^2 (WHO classification)~Definition of Diabetes: (American Diabetes Association, 2020) FPG ≥126 mg/dL (7.0 mmol/L). Fasting is defined as no caloric intake for at least 8 h.* OR A1C ≥6.5% (48 mmol/mol)."
89578644|NCT02523599|Experimental|XaraColl|3 XaraColl Bupivacaine Implants each containing 100 mg of bupivacaine hydrochloride, for a 300 mg total dose
89578645|NCT02523599|Placebo Comparator|Placebo|3 placebo implants
89578646|NCT05492357|Experimental|Advanced platelet-rich fibrin plus + Liquid platelet-rich fibrin|A-PRF plus + Liquid-PRF are prepared from the patient's blood.
89578647|NCT05492357|Experimental|Advanced platelet-rich fibrin plus alone|A-PRF+ is prepared from the patient's blood.
89029425|NCT01247246|Active Comparator|SCV-07 0.1mg/kg|
89029426|NCT01247246|Active Comparator|SCV-07 0.3mg/kg|
89029427|NCT01247246|Active Comparator|SCV-07 1.0mg/kg|
89029428|NCT04696536|Experimental|Group 1: Listerine Cool Mint Mouth Rinse (Marketed product)|Participants will receive Alcohol-containing Essential Oil (AEO) containing mouth rinse (Listerine Cool Mint, marketed) orally for 12 weeks. Participant will brush their teeth and rinse once daily under supervision during the week (five days) for 30 seconds with 20 milliliter (mL) of mouth rinse and brush their teeth and rinse a second time each day during the week at home. During the weekends, participants will brush twice daily in their usual manner, following rinsing with their assigned mouth rinse, unsupervised at home.
89578648|NCT05490797|Experimental|app based training with conventional therapy|In experimental group app based training will be performed along with conventional hand fine motor skills and dexterity therapy.
89578649|NCT05490797|Active Comparator|conventional therapy|The control group will receive conventional hand function rehabilitation therapy including, strengthening exercises which consist of palm down wrist flexion exercise, dexterity( shifting exercise) and fine motor skills(nine peg hole exercise)
89578650|NCT05321303|Experimental|Experimental: Serious game Experimental group|"The participants spend on one MetaHospital scenario in which Nursing Care (management of diabetic ketoacidosis)."
89578651|NCT05321303|Experimental|Experimental: Standardized Patients Control group|The participants spend one scenario 10 minutes; on a scenario designed to train Nursing Care (management of diabetic ketoacidosis).
89578652|NCT04422353|Experimental|video Dance classes|"The dance program consists of dance lessons inspired by Forró rhythm and Samba rhythm.~Classes will be divided into four stages: Joint warm-up and stretching on the chairs; strengthening, balance, and rhythm exercises with the support of the chair; exercises inspired by the samba and forró (Brazilian ballroom dance) basic steps; and Final cool down. The classes will be held through a recorded video that must be played twice a week. Each video class lasts 30 minutes.~The video Dance classes will happen in the period of self-isolation and social distance during the Covid-19 pandemic."
89578653|NCT04422353|Active Comparator|Unsupervised physical activities|The unsupervised physical activity programs will happen in the period of self-isolation and social distance during the Covid-19 pandemic. The classes will be held through a recorded video that must be played twice a week. Each video class lasts 30 minutes.
89578654|NCT04422353|No Intervention|control group|The control group will be people with PD, engaged, before the Covid-19 pandemic, in the Dance, the Nordic Walk and the Aquatic Jogging extension projects at Federal University of Rio Grande do Sul but did not do any type of physical activity during the Covid-19 pandemic.
89578655|NCT05354999|Experimental|Creatine|Subjects ingest creatine monohydrate daily.
89578656|NCT05354999|Placebo Comparator|Placebo|Subjects ingest placebo daily.
89578657|NCT02187159|Experimental|DS-5565 QD|Participants take one each of placebo tablet and capsule in the morning, and one DS-5565 tablet once daily (QD) with a placebo capsule in the evening
89578658|NCT02187159|Experimental|DS-5565 BID|Participants take one DS-5565 tablet and one placebo capsule, twice daily (BID)
89578659|NCT02187159|Active Comparator|Pregabalin|Participants take one pregabalin capsule and one placebo tablet BID
89578660|NCT02187159|Placebo Comparator|Placebo|Participants take one each of placebo tablet and capsule BID
89578661|NCT02335411|Experimental|Cohort 1: Pembrolizumab monotherapy, previously treated|Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 3-week cycle (Q3W)
89578662|NCT02335411|Experimental|Cohort 2: Pembrolizumab combination therapy, treatment naive|Participants receive pembrolizumab 200 mg IV each 3-week cycle (Q3W) + cisplatin 80 mg/m^2 IV Q3W for up to 6 cycles + 5-FU 800 mg/m^2 IV on Days 1-5 every 3 weeks or (Japan only) capecitabine 1000 mg/m^2 orally, twice per day (BID) on Days 1-14 of each 3-week cycle
89578663|NCT02335411|Experimental|Cohort 3: Pembrolizumab monotherapy, treatment naive, PD-L1 positive|Programmed death-ligand 1 (PD-L1) positive participants receive pembrolizumab 200 mg IV on Day 1 of each 3-week cycle (Q3W)
89578664|NCT02186301|Active Comparator|Erlotinib Mono-Therapy|
89578665|NCT02186301|Experimental|Rociletinib Mono-Therapy|
89578666|NCT02186223|Experimental|The Angel® Catheter|All eligible subjects will receive an Angel® Catheter.
89578667|NCT02163057|Other|Cohort 1: Surgery Cohort|Participants received up to two doses of INO-3112 immunotherapy 3 weeks (± 3 days) apart before surgery and up to three doses of INO-3112 immunotherapy 3 weeks (± 3 days) apart after surgery for a total of no more than four doses of INO-3112 immunotherapy delivered IM followed by EP with CELLECTRA™-5P device.
89578668|NCT02163057|Other|Cohort 2: Chemoradiation|Participants received four doses of INO-3112 immunotherapy delivered IM followed by EP with CELLECTRA™-5P device 3 weeks (± 3 days) apart beginning approximately 2 to 6 months after chemoradiation therapy.
89578669|NCT02185521|Experimental|visible HII - patient assessment|"Clinical team from study unit will observe the Hemodynamic Instability Index created by the HIRBA 2.0 system for individual subjects randomized into HII group arm.~If the HII value will cross the threshold, indicative of hemodynamic deterioration, subject from the study arm will receive intervention: clinical assessment."
89578670|NCT01599585|Experimental|In Home|Participants in this condition will receive 8 sessions of BA treatment over the course of approximately 8 weeks (one session per week). The sessions will be conducted in their homes using an Army approved secure web-based video conferencing system. BA has been successfully delivered in this time frame, and it has been delivered via in-home video conferencing technology.
89578671|NCT01599585|Active Comparator|In-Person|Participants in this condition will receive 8 sessions of BA treatment over the course of approximately 8 weeks (one session per week with allowance for rescheduled sessions). The sessions will be conducted in a clinic setting at The National Center for Telehealth & Technology.
88972709|NCT02271893|Experimental|Dextromethorphan|The aim of this study is to assess if dextromethorphan administered during 4 weeks induces a decrease of pain intensity in breast cancer patients suffering from chemotherapy-induced peripheral neuropathy compared to placebo group.
88972710|NCT02271893|Placebo Comparator|placebo|The aim of this study is to assess if dextromethorphan administered during 4 weeks induces a decrease of pain intensity in breast cancer patients suffering from chemotherapy-induced peripheral neuropathy compared to placebo group.
88972711|NCT02149823|Active Comparator|Intranasal Oxytocin Group 1|Placebo on visit 1, oxytocin 24IU on visit 2, then 40 IU on visit 3
88972712|NCT02149823|Active Comparator|Intranasal Oxytocin Group 2|oxytocin 24IU on visit 1, placebo on visit 2, then oxytocin 40IU on visit 3
88972713|NCT02149823|Active Comparator|Intranasal Oxytocin Group 3|oxytocin 40IU on visit 1, oxytocin 24IU on visit 2, then placebo on visit 3.
88972714|NCT02149823|Active Comparator|Intranasal Oxytocin Group 4|after visit 4, placebo on subsequent visit , then oxytocin 40IU at following visit
89578672|NCT02185053|Experimental|CPC-201|
89578673|NCT02161731|Active Comparator|Warfarin|15 milligram (mg) warfarin administered as a single oral dose on Day 1
88972715|NCT02149823|Active Comparator|Intranasal Oxytocin Group 5|after visit 4, oxytocin 40IU on subsequent visit, then placebo at following visit
88972716|NCT02971410|Experimental|Treatment (simvastatin)|Patients receive standard of care chemotherapy for up to 3 courses and simvastatin (PO) daily 2 days before the first dose of chemotherapy for up to 2 days after the last dose of chemotherapy. Treatment with simvastatin continues in the absence of disease progression or unacceptable toxicity.
88972717|NCT02035397|Experimental|Botulinum toxin A|Botulinum toxin type A injection in muscles of stomach wall
88972718|NCT02035397|Placebo Comparator|Saline solution|Placebo (saline solution) injection first 6 months, then active treatment
88972719|NCT01807481|Experimental|Mircera Arm|Once Monthly Mircera
89578674|NCT02161731|Experimental|Evacetrapib + Warfarin|Evacetrapib administered once daily (QD), orally, for 16 days with 15 mg warfarin co-administered once orally on Day 17
89578675|NCT02124759|Placebo Comparator|Placebo|Placebo: maltodextrin, 6 g three times a day
89578676|NCT02124759|Active Comparator|Sevelamer|Sevelamer: (1.6 g sevelamer + 4.4 g maltodextrin three times a day)
89578677|NCT02124759|Active Comparator|Synbiotic|Synbiotic: 5g Oligofructose + 4x1010 Bifidobacterium longum CFU 3x daily during diet
89578678|NCT02302339|Experimental|Glembatumumab vedotin|glembatumumab vedotin administered as an intravenous infusion on Day 1 of each 21 day cycle.
89578679|NCT02302339|Experimental|Glembatumumab vedotin and varlilumab|glembatumumab vedotin administered as an intravenous infusion on Day 1 of each 21 day cycle. Varlilumab administered as an intravenous infusion on Day 1 of cycles 1, 2, 4, 6, 8 and 10.
89578680|NCT02302339|Experimental|Glembatumumab vedotin and PD-1 targeted checkpoint inhibitor|glembatumumab vedotin administered as an intravenous infusion on Day 1 of each 21 day cycle. Nivolumab OR pembrolizumab administered according to institutional standard of care.
89578681|NCT02302339|Experimental|Glembatumumab vedotin and CDX-301|glembatumumab vedotin administered as an intravenous infusion on Day 1 of each 21 day cycle. CDX-301 is injected once a day for five days before cycles 1 and 2.
89578682|NCT04895917|Experimental|Pomalidomide and daratumumab|
89578683|NCT02161575|Experimental|Ranibizumab|All patients received 3 monthly intraveal injections of 0.5mg ranibizumab followed by monthly injections of ranibizumab 0.5mg for a further 3 months on a prn (as required) basis, as determined by the study doctor.
89578684|NCT02370121|Placebo Comparator|Placebo|600 mg dose per day. Two capsules of 300 mg, one in the morning with the first meal and the other at dinner during 90 days.
89578685|NCT02370121|Experimental|Gymnema Sylvestre|600 mg dose per day. Two capsules of 300 mg, one in the morning with the first meal and the other at dinner during 90 days.
89578686|NCT02161185|Other|USL261|
89578687|NCT02159469|Experimental|Testosterone enanthate auto-injector|Testosterone enanthate 50 mg / 75 mg / 100 mg administered subcutaneously once each week with possible titration to a higher or lower dose at scheduled intervals during study.
89578688|NCT02123511|Experimental|Arm I (acetylcysteine)|Patients receive acetylcysteine oral rinse and gargle or swish for 60 seconds then spit 5 times per day beginning within 3 days of the initiation of radiotherapy to 14 days following completion of radiotherapy.
89578689|NCT02123511|Placebo Comparator|Arm II (placebo)|Patients receive a placebo oral rinse and gargle or swish for 60 seconds and then spit 5 times per day beginning within 3 days of the initiation of radiotherapy to 14 days following completion of radiotherapy.
89578690|NCT04746339|Active Comparator|Apixaban Group|
89578691|NCT04746339|Placebo Comparator|Placebo Group|
89578692|NCT02122887|No Intervention|control group|no intervention for 3 months
89578693|NCT02122887|Experimental|experimental group|Peace-Building Intervention Process- The intervention process consists of eight sessions and adheres to a manualized protocol that we developed. Each session lasts 120 minutes.
89578694|NCT02182947|Experimental|Endoscopy Imaging|Wireless-video capsule endoscopy (WCE) compared to the findings of MRE magnetic resonance enterography in same group of patients.
89578695|NCT04755075|Experimental|Cohort 1|Subjects with Normal Hepatic Function: All patients to receive study drug (Surufatinib 250mg) on Day 1
89578696|NCT04755075|Experimental|Cohort 2|Subjects with Moderate Hepatic Impairment: All patients to receive study drug (Surufatnib 250mg) on Day 1
89578697|NCT04755075|Experimental|Cohort 3 (if enrolled)|Subjects with Mild Hepatic Impairment: All patients to receive study drug (Surufatnib 250mg) on Day 1
89578698|NCT02370043|Experimental|KQ-791|Escalating doses of KQ-791, starting at 15 milligrams
89578699|NCT02370043|Experimental|KQ-791 (after meal)|Single dose of KQ-791 in capsule form, after a meal
89578700|NCT02370043|Placebo Comparator|Placebo|Single dose of placebo matching KQ-791 dose
89578701|NCT02301403|Active Comparator|Modern Usual Care|Participants assigned to the M-UC will receive 8 weeks of nicotine patch, a single brief, in-person counseling session, a faxed referral to the Wisconsin Tobacco Quit Line (WTQL), and will be signed up for either the QUITNOW app or the Web Coach (both provided by Alere Wellbeing, the vendor that provides the WTQL services).
89578702|NCT02301403|Experimental|Abstinence-Optimized Cessation Treatment|There are 5 intervention components to include in the AOCT package: 1) Preparation Nicotine Mini-Lozenges; 2) 26-week postquit Combination NRT (nicotine patch + nicotine mini-lozenges); 3) Intensive In-Person Cessation Counseling; 4) Extended Maintenance Counseling Calls; and 5) Automated Adherence Calls.
88972720|NCT01807442|Other|Optimal adherence|"Participants receive the qualitative interview and adherence intervention.~This arm includes participants with scores of greater than or equal to 15 on the Medical Outcomes Study Specific Adherence Scale. This scale ranges from a score of 3 (extremely low adherence to health behaviors) to a score of 18 (extremely high adherence to health behaviors). A score of greater than or equal to 15 suggests optimal adherence to health behaviors."
88972721|NCT01807442|Other|Sub-optimal adherence|"Participants receive the qualitative interview and adherence intervention.~This arm includes participants with scores of less than 15 on the Medical Outcomes Study Specific Adherence Scale. This scale ranges from a score of 3 (extremely low adherence to health behaviors) to a score of 18 (extremely high adherence to health behaviors). A score of less than 15 suggests sub-optimal adherence to health behaviors."
89578703|NCT02301169|Active Comparator|T4P1001|
89578704|NCT02301169|Sham Comparator|Placebo|
89578705|NCT02333383||Participants with Ankylosing Spondylitis|Adalimumab 40 mg every other week by subcutaneous (SC) injection for 52 weeks
89578706|NCT02332915|Experimental|SPT - Intense First|Participants will receive intense application in the first phase of treatment, followed by the non intense application of treatment.
89578707|NCT02332915|Experimental|SPT - Traditional First|"Participants will receive non intense, traditional application of treatment in the first phase of treatment, followed by the intense application of treatment."
89578708|NCT02369341|Experimental|Fluarix Tetra (Southern Hemisphere) Adult Group|Subjects aged 18-60 years received 1 dose of Fluarix™ Tetra (Southern Hemisphere) vaccine at Day 0. The vaccine was administered intramuscularly in the deltoid of the non-dominant arm.
89578709|NCT02369341|Experimental|Fluarix Tetra (Southern Hemisphere) Elderly Group|Subjects aged >60 years received 1 dose of Fluarix™ Tetra (Southern Hemisphere) vaccine at Day 0. The vaccine was administered intramuscularly in the deltoid of the non-dominant arm.
89578710|NCT02121795|Experimental|F/TAF + 3rd Agent|Participants will receive F/TAF (200/25 mg or 200/10 mg) plus FTC/TDF placebo while remaining on an allowed third antiretroviral agent of the participant's pre-existing treatment regimen, for 96 weeks. Dosing of F/TAF will be dependent on the third agent of the participants' pre-existing treatment regimen.
89578711|NCT02121795|Active Comparator|FTC/TDF + 3rd Agent|Participants will receive FTC/TDF plus F/TAF placebo while remaining on an allowed third antiretroviral agent of the participant's pre-existing treatment regimen, for 96 weeks.
89578712|NCT02158533|Experimental|High Dose|
89578713|NCT02158533|Experimental|Low Dose|
89578714|NCT02158533|Placebo Comparator|Placebo|
89578715|NCT02120781|Experimental|Azficel-T (autologous fibroblasts)|Azficel-T will be injected into the vocal fold(s) three times at two week intervals.
89578716|NCT02120781|Placebo Comparator|Control|Sterile saline will be injected into the vocal fold(s) three times at two week intervals.
88972722|NCT01807403|Experimental|Deep brain stimulation of subthalamic nucleus|Pose of bilateral subthalamic and caudate stimulating macroelectrodes with subclavicular pacemaker.Stimulation of subthalamic nucleus
88972723|NCT01807403|Experimental|Deep brain stimulation of caudate nucleus|Pose of bilateral subthalamic and caudate stimulating macroelectrodes with subclavicular pacemaker. Caudate nucleus stimulation
88972724|NCT01807403|Experimental|Deep brain stimulation of nucleus accumbens|Pose of bilateral subthalamic and caudate stimulating macroelectrodes with subclavicular pacemaker.Nucleus accumbens stimulation.
88972725|NCT01807364||Congenital adrenal hyperplasia|Patients > 18 yrs with classical or non classical CAH diagnosed during childhood
88972726|NCT01807364||controls|control patients
88972727|NCT02971371|Experimental|Virtual Reality|This group performed 40 45-min Lokomat sessions, five times a week, by using a visual feedback showing a Virtual Reality run game where the patient had to collect or avoid objects, to motivate him/her to walk actively.
88972728|NCT02971371|Active Comparator|Only RAGT|This groups performed 40 Lokomat sessions (40-45min), five times a week, between 9am and 11am, in this case was not provided an avatar, and a smile indicating the goodness of each leg movement.
88972729|NCT01807325||pancreas cysts and solid masses|patents referred for solid and cystic lesions of the pancreas who will have a biopsy for usual medical care.
88972730|NCT00034281|Experimental|TAK-165 QD|
88972731|NCT01807286|Experimental|Pomalidomide + Melphalan + Dexamethasone|Starting dose of Pomalidomide 1 mg/day by mouth on days 1-21. Melphalan 9 mg/m2 by mouth on days 1-4 of every 28-day cycle. Dexamethasone 40 mg/day by mouth on days 1-4. Questionnaires completed at different time points during study.
88972732|NCT01807247||Hemiparetic|Intensive lower limbs muscles strengthening
88972733|NCT01807247||Spinal cord injury|Intensive lower limbs muscles strengthening
88972734|NCT01807247||Multiple sclerosis|Intensive lower limbs muscles strengthening
88972735|NCT01807208|Experimental|Educational tool|Patients randomized to the educational tool arm of the study will receive mailed educational materials at 1 week post hospital discharge and again at 3 months after discharge.
88972736|NCT01807208|No Intervention|Usual care|Patients in this arm of the study will receive usual care.
88972737|NCT04712045|Experimental|New PPE|Use of Short sleeve gown and single pair of gloves
88972738|NCT04712045|Active Comparator|Old PPE|Use of Long sleeve gown and double pairs of gloves
88972739|NCT01807169|Experimental|Colonic polypectomy or endoscopic mucosal resection|Resection of colonic polyps using polypectomy tehnique (with electrocoagulation) or mucosal resection (EMR or mucosectomy) with injection of physiological serum thus resection with electrocoagulation
88972740|NCT01807130|Placebo Comparator|Registry|Patients randomized to the registry arm will be followed per usual standard of care by their primary providers. Those providers may refer to subspecialty HF or electrophysiology care as they see fit.
88972741|NCT01807130|Experimental|Intervention|Patients in the intervention arm without compelling contraindications to HF therapies will be referred automatically to specialists in HF or electrophysiology with recommendations to consider those therapies that are not in compliance with guidelines.
88972742|NCT00396474||SGA patients|Infants born small for SGA who either received GH, no GH, or growth within normal ranges.
88972743|NCT01807091|Experimental|Treatment (chemotherapy)|Participants received intensive initial or salvage induction chemotherapy regimens. These regimens would usually be administered in the inpatient setting, however participants received them outpatient. This study did not dictate the choice of induction chemotherapy regimen. The regimen was decided upon by patient and their treating oncologist and clinical care team. The induction chemotherapy regimens administrations spanned 4-7 days.
88972744|NCT00034554|Experimental|1|0.1mg
89578717|NCT02120625||Lumbar MB RFN|Patients undergoing lumbar medial branch radiofrequency ablation using the Nimbus MEE Probe who undergo MRI and EMG validation testing of efficacy of intended lesion production.
89578718|NCT02120469|Experimental|Treatment (everolimus, eribulin mesylate)|Patients receive everolimus PO QD on days 1-21 and eribulin mesylate IV on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89578719|NCT02157519|Experimental|Mobile Application Intervention|Participants in the intervention group will receive the mobile application for improving symptoms and adherence to oral chemotherapy along with their standard oncology care. The proposed elements of the mobile application include the following: 1) specification of an oral chemotherapy treatment plan; 2) weekly collection of patient-reported symptoms and medication adherence; and 3) delivery of real-time, tailored feedback to patients as well as immediate transmission of survey results to oncology clinicians.
89578720|NCT02157519|No Intervention|Standard Oncology Care|Participants in the control group will receive standard oncology care only.
89578721|NCT02180061|Experimental|Advanced Cutaneous Melanoma|Participants with advanced cutaneous melanoma received pembrolizumab, 2 mg/kg, intravenously (IV) over 30 minutes on Day 1 of each 3-week dosing cycle (Q3W).
89578722|NCT02180061|Experimental|Advanced Mucosal Melanoma|Participants with advanced mucosal melanoma received pembrolizumab, 2 mg/kg, IV over 30 minutes on Day 1 Q3W.
89578723|NCT02179515|Experimental|modified vaccinia Ankara (MVA)-brachyury-TRICOM vaccine|Three cohorts will receive modified vaccinia Ankara (MVA)-brachyury-B7-1, ICAM-1 (Intercellular Adhesion Molecule 1), and LFA-3 (lymphocyte function-associated antigen 3) TRICOM vaccine administered subcutaneously as either 1, 2, or 4 injections of study drug at monthly (28 days +/4 days) intervals for 3 months. Patients with stable disease may continue to receive vaccine for up to 6 monthly doses.
89578724|NCT02120157|Experimental|Haploidentical BMT with PTCy for acute leukemias and MDS|"Patients with AML and MDS:~Days -6 through -3: Busulfan q 5-6h IV q24h x 4 days~Days -2 and -1: Cyclophosphamide 50mg/kg/day IV x 2 days+ Mesna 40 mg/kg/day IV~For patients with ALL and lymphoblastic lymphoma:~Days -5 through -4: Cyclophosphamide 50mg/kg/day IV q24h x 2 days+Mesna 40 mg/kg/day IV~Days -3 through -1: TBI 200 Centigray (cGy) twice a day for 3 days~All patients Day 0: Infuse unmanipulated bone marrow~Day +3 and +4: Cyclophosphamide 50 mg/kg/day IV + Mesna 40 mg/kg IBW/day IV~Day +5: Begin tacrolimus 0.015mg/kg IBW/dose IV over 4 hours q 12h and mycophenolate mofetil (MMF)15mg/kg po/IV tid with maximum daily dose 3 gm/day~Day +30: Assess chimerism and disease status in bone marrow~Day +35: Discontinue MMF~Day +60: Assess chimerism and disease status in bone marrow~Day 180: Discontinue tacrolimus"
89578725|NCT02119299|Experimental|SMART device|Use of Sensor Monitored Alimentary Restriction Therapy (SMART) device
89578726|NCT04753827|Experimental|Experimental Group Stent only|Stents were implanted in MV and SB respectively, and DKcrush or Culotte technology was selected according to the lesion characteristics.
89578727|NCT04753827|Experimental|Experimental Group Stent+DCB|The MV was stented and the SB were treated with just drug-coated balloon(DCB)
89578728|NCT04753827|Experimental|Experimental Group L-Sandwich|Stents were implanted in the MV and the shaft of side branch SB respectively, then a DCB was applied to the ostium of the SB
89578729|NCT02156271|Active Comparator|ramelteon|Subjects will take ramelteon 8mg one time daily 30 minutes before bedtime with approximately 8 ounces of water. Subjects have a 2 out of 3 chance of receiving ramelteon.
89578730|NCT02156271|Placebo Comparator|placebo|15 subjects will be randomized to receive the placebo
89578731|NCT01365455|Experimental|AIN457 150 mg|AIN457 secukinumab 150 mg subcutaneous (s.c.) injection plus a placebo secukinumab s.c. injection once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4 and until Week 48, except for Weeks 13, 14, and 15 when they received two s.c. injections of placebo per week
89578732|NCT01365455|Experimental|AIN457 300 mg|AIN457 secukinumab 300 mg (two s.c. injections of 150 mg) once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4, and until Week 48, except for Weeks 13, 14, and 15 when they received two s.c. injections of placebo per week
89578733|NCT01365455|Placebo Comparator|placebo|placebo secukinumab (two s.c. injections per dose) once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks (Weeks 4 and 8). Prior to receiving the Week 12 dose, all patients in the placebo group were assigned to the following treatment groups based on their PASI 75 response at Week 12. PASI 75 responders: continued on placebo and received their placebo injections at Weeks 12, 13, 14, 15, and then every 4 weeks starting at Week 16 until Week 48.
89578734|NCT01365455|Experimental|AIN457 150mg from Placebo|Patients randomized to AIN457 150mg in Maintenance phase when they were on Placebo in Induction Phase because they were PASI 75 non-responders and received their treatment on Weeks 12, 13, 14, 15, and then every 4 weeks starting at Week 16 until Week 48.
89578735|NCT01365455|Experimental|AIN457 300mg from Placebo|Patients randomized to AIN457 300mg in Maintenance phase when they were on Placebo in Induction Phase. PASI 75 non-responders and received their treatment on Weeks 12, 13, 14, 15, and then every 4 weeks starting at Week 16 until Week 48.
89578736|NCT02155881|Experimental|Ciclesonide 200 mcg|Ciclesonide 200 mcg nasal spray, 2 actuations (sprays) per nostril (50 mcg ciclesonide/actuation), daily, for 2 weeks.
89578737|NCT02155881|Placebo Comparator|Placebo|Ciclesonide placebo-matching nasal spray, 2 actuations (sprays) per nostril, daily, for 2 weeks.
89578738|NCT05279807|Active Comparator|Zofenopril 30mg|Single dose Phase (4 weeks): patients will be treated with Zofenopril 30 mg. Combination Phase (8 weeks) uncontrolled patients will be treated with the extemporaneous combination of Zofenopril 30 mg and Amlodipine 5mg for 4 weeks. Amlodipine 10mg will replace Amlodipine 5mg in uncontrolled patients for further 4 weeks while controlled patients with Zofenopril 30mg/Amlodipine 5mg will continue with the same therapy.
89578739|NCT05279807|Active Comparator|Amlodipine 5mg|Single dose Phase (4 weeks): patients will be treated with Amlodipine 5 mg. Combination Phase (8 weeks) uncontrolled patients will be treated with the extemporaneous combination of Zofenopril 30 mg and Amlodipine 5mg for 4 weeks. Amlodipine 10mg will replace Amlodipine 5mg in uncontrolled patients for further 4 weeks while controlled patients with Zofenopril 30mg/Amlodipine 5mg will continue with the same therapy.
89578740|NCT05319431|Experimental|AK104+Lenvatinib+TACE|Participants will receive AK104 IV every 3 weeks (Q3W) and Lenvatinib 12mg weight≥60kg or 8mg weight<60kg,PO QD The first Transarterial chemoembolization will be performed at the beginning of study.
89578741|NCT05276531|Experimental|subcutaneous progesterone|PROLUTEX® 25 mg Solution for injection, IBSA Group, Lugano, Switzerland
89578742|NCT05276531|Active Comparator|vaginal progesterone|LUTINUS® 100 mg vaginal tablets, Ferring GmbH Wittland/Kiel/Germany
89578743|NCT05352581||BD Veritor|"Each subject will:~Self collect a nasal swab for testing on the BD Veritor At-home test (test device) Have a clinician collected nasal swab for testing on the BD Veritor Professional Test (test device) Have a clinical collected nasal swab for testing on an FDA cleared/approved RT-PCR assay (control device)"
89578744|NCT05318651|Experimental|mobile app users|
89578745|NCT01658579|Experimental|HOE901-U300 Morning Then Evening|HOE901-U300 (new insulin glargine 300 units per milliliter [U/mL]) subcutaneous (SC) injection once daily in morning for 8 weeks during treatment period A, followed by once daily in evening for 8 weeks during treatment period B. Dose titration seeking fasting plasma glucose 4.4-7.2 millimole per liter (mmol/L).
89578746|NCT01658579|Experimental|HOE901-U300 Evening Then Morning|HOE901-U300 (new insulin glargine 300 U/mL) SC injection once daily in evening for 8 weeks during treatment period A, followed by once daily in morning for 8 weeks during treatment period B. Dose titration seeking fasting plasma glucose 4.4-7.2 mmol/L.
88972745|NCT00034554|Experimental|2|0.5mg
89578747|NCT01658579|Active Comparator|Lantus Morning Then Evening|Lantus (HOE901-U100, insulin glargine 100 U/mL) SC injection once daily in morning for 8 weeks during treatment period A, followed by once daily in evening for 8 weeks during treatment period B. Dose titration seeking fasting plasma glucose 4.4-7.2 mmol/L.
89578748|NCT01658579|Active Comparator|Lantus Evening Then Morning|Lantus (HOE901-U100, insulin glargine 100 U/mL) SC injection once daily in evening for 8 weeks during treatment period A, followed by once daily in morning for 8 weeks during treatment period B. Dose titration seeking fasting plasma glucose 4.4-7.2 mmol/L.
89578749|NCT05352503|Experimental|watching video with virtual reality glasses|
89578750|NCT05352503|No Intervention|routine maintenance, no intervention|
89578751|NCT05270525|Experimental|Treatment Sequence 1|Treatment Period 1 (blinded Ensifentrine) followed by Treatment Period 2 (blinded Placebo)
89578752|NCT05270525|Experimental|Treatment Sequence 2|Treatment Period 1 (blinded Placebo) followed by Treatment Period 2 (blinded Ensifentrine)
89578753|NCT05317013|Experimental|Group A - 100 mg CBD|100 mg CBD per day
89578754|NCT05317013|Experimental|Group B - 300 mg CBD|300 mg CBD per day
89578755|NCT05317013|Placebo Comparator|Group C - Placebo|Placebo
89578756|NCT05316077||Vectorio® kit|
89578757|NCT04422509|Experimental|lanadelumab|20 Patients will receive an intravenous dose of 300 mg lanadelumab on day 1, followed by a second dose of lanadelumab 300mg iv on day 4 (if needed).
89578758|NCT04422509|Other|controls|20 patients will received standard of care In additiona, for every index patient we will match one historical controls. Controls will be matched based on age, bodyweight and gender.
89578759|NCT05313893|Experimental|Quadrivalent influenza vaccine|Subjects received 2 doses of 0.5 mL of quadrivalentinfluenza vaccine, 4 weeks apart. Each 0.5-ml dosecontained 15 μg of hemagglutinin per strain.
89578760|NCT05349773||endoscopic left radial artery harvesting|single group of 32 patients listed for coronary artery bypass surgery with endoscopic radial artery harvesting.
89578761|NCT05268497|Experimental|Esketamine|Participants will receive esketamine nasal spray (Dose 1 or Dose 2) twice weekly for 4 weeks (Induction Phase), followed by once a week dose (Dose 1 or Dose 2) for 8 weeks (Maintenance Phase), in conjunction with an oral antidepressant. Clinician-directed cognitive behavioral therapy (CBT) supplemented with the Mindset app will be administered by a clinician following esketamine dosing once the participants is considered ready to engage in therapy, based on the clinician judgement of CBT readiness.
89578762|NCT05311943|Experimental|olverembatinib|40mg, taken orally once every other day of a 28-day cycle
88972746|NCT00034554|Experimental|3|2.0mg
88972747|NCT00034554|Experimental|4|4.0mg
88972748|NCT00034554|Experimental|5|8.0mg
88972749|NCT01807052||Observational|Tissue samples are analyzed for tumor factor expression levels by immunohistochemistry.
89578763|NCT05557175|Experimental|Active rTMS group|
89578764|NCT05557175|Sham Comparator|Sham rTMS group|
89578765|NCT05266859|Active Comparator|Group I- Calcium hydroxide (Control)|"Group I will receive Calcium hydroxide . Calcium hydroxide is a gold standard medicament for the pulpotomy in deciduous teeth. It has antibacterial effects and widely used to disinfect the root canals.~This group will act as a control"
88972750|NCT00393341||Case|Women with breast cancer
88972751|NCT00393341||Control|Women without breast cancer
89578766|NCT05266859|Experimental|Group II- MTA (Experimental)|Group II will receive MTA (Mineral Trioxide Aggregate). MTA is a calcium silicate based highly biocompatible material that is commonly used for pulpotomies in deciduous teeth along with the regenerative procedures in permanent and deciduous teeth
88972752|NCT01806974|Other|patient with parodontitis|Patient with rheumatoid arthritis and pparodontitis.
88972753|NCT01806974|Other|Patient without parodontitis|Patient with rheumatoid arthritis but periodontally healthy
88972754|NCT01806935|Experimental|DC086|cream
88972755|NCT01806935|Placebo Comparator|placebo|
88972756|NCT01806857|Other|Nuedexta then Matching Placebo|Subjects in this arm will receive treatment with Nuedexta first for 28 days (±3 days) and then crossed over to receive treatment with matching placebo for 28 days (±3 days).
88972757|NCT01806857|Other|Matching Placebo then Nuedexta|Subjects in this arm will receive treatment with matching placebo first for 28 days (±3 days) and then crossed over to receive treatment with Nuedexta for 28 days (±3 days).
88972758|NCT01806818|Experimental|Eperisone 50mg BID|Administrate Eperisone 50mg tablet after the breakfast and dinner, and pacebo tablet after the lunch for 7 days
88972759|NCT01806818|Experimental|Epirisone 50mg TID|
88972760|NCT01806818|Placebo Comparator|Placebo comparator|
88972761|NCT01806701|Experimental|Psychotherapy|Trauma-focused Cognitive Behavioral Therapy
88972762|NCT01806467||critically ill patients|patients admitted to the medical-surgical ICU
88972763|NCT01806467||post-cardiac surgical patients|patients admitted to the post-cardiac surgical ICU
88972764|NCT01806428||aPC treatment group|Septic patients with at least two sepsis-induced organ failures occurring within 48 hours of the onset of sepsis treated with activated protein C at 24 mcg/Kg/h for 96 hours
88972765|NCT01806428||Control group|Septic patients with at least two sepsis-induced organ failures occurring within 48 hours of the onset of sepsis not treated with activated protein C because of contraindications
89578767|NCT05266859|Experimental|Group III- PRF (Experimental)|Group III will receive PRF. PRF is platelet-rich fibrin that is a biocompatible product derived from patient's own blood. It is formed by centrifugation of the blood of the patient. It provides the growth factors and promotes regeneration of the pulp
89578768|NCT05310851|Experimental|PIOMI group|Infants in the PIOMI group will receive a 5-minute PIOMI 30 minutes before feeding time. PIOMI will be applied once daily for 14 days.
89578769|NCT05310851|Experimental|Non-nutritive sucking group|Infants in the non-nutritive sucking group will receive pacifier 3 minutes before 1 hour any feeding time and, 2 minutes before 10 minutes. Non-nutritive sucking will be applied once daily for 14 days.
89578770|NCT05310851|No Intervention|control group|only feeding follow-up will be done in the infants in the control group.
89578771|NCT02154087|Experimental|HP802-247|
89578772|NCT05219201|Sham Comparator|Sham cryotherapy full time patient (inpatient)|"Patients benefiting from 15 session of sham partial-body cryotherapy session (-30°C) during their full-time rehabilitation stay"
89578773|NCT05219201|Sham Comparator|sham cryotherapy part-time hospitalized patient (outpatient)|"Patients benefiting from 15 session of sham partial-body cryotherapy session (-30°C) during their part-time rehabilitation stay"
89578774|NCT05219201|Active Comparator|cryotherapy full-time hospitalized patient (inpatient)|"Patients benefiting from 15 session of sham partial-body cryotherapy session (-120°C) during their full-time rehabilitation stay"
89578775|NCT05219201|Active Comparator|cryotherapy part-time hospitalized patient (outpatient)|"Patients benefiting from 15 session of sham partial-body cryotherapy session (-120°C) during their part-time rehabilitation stay"
89578776|NCT05346731|Active Comparator|Control group|"Weight category 30-40 kg will receive: dexamethasone (5 mg/m2), ondansetron (0.15 mg/kg), aprepitant (80 mg)~Weight category > 40 kg will receive:~dexamethasone (5 mg/m2), ondansetron (0.15 mg/kg), aprepitant (125 mg) Note: aprepitant at a dose of 80 mg/day. applied for another 2 days, regardless of the number of days of chemotherapy."
89578777|NCT05346731|Experimental|Olanzapine|"Weight category 30-40 kg will receive:~dexamethasone (5 mg/m2), ondansetron (0.15 mg/kg), aprepitant (80 mg), olanzapine (2.5 mg)~Weight category > 40 kg will receive: dexamethasone (5 mg/m2), ondansetron (0.15 mg/kg), aprepitant (125 mg), olanzapine (2.5 mg for <55 kg, 5 mg for >55 kg) Note: aprepitant at a dose of 80 mg/day. applied for another 2 days, regardless of the number of days of chemotherapy."
89578778|NCT02118597||Triple Combination Therapy|Participants who demonstrated genotype 1 chronic hepatitis C infection and had a history of unsuccessful treatment with pegylated interferon (peginterferon) alfa + ribavirin, and who were subjected to receive a triple combination therapy with simeprevir or boceprevir plus peginterferon alfa-2a and ribavirin were observed.
89578779|NCT01659125|Experimental|OCFighter|OCFighter
89029429|NCT04696536|Experimental|Group 2: Negative Control (5 Percent (%) Hydroalcohol Mouth Rinse)|Participants will receive negative control mouth rinse (5% Hydroalcohol mouth rinse) orally for 12 weeks. Participant will brush their teeth and rinse once daily under supervision during the week (five days) for 30 seconds with 20 milliliter (mL) of mouth rinse and brush their teeth and rinse a second time each day during the week at home. During the weekends, participants will brush twice daily in their usual manner, following rinsing with their assigned mouth rinse, unsupervised at home.
89029430|NCT04696536|Experimental|Group 3: Flossing Performed by Dental Hygienist|Participants will brush their teeth and then undergo instructions on flossing technique using reach dental floss orally for 12 Weeks. Dental hygienist will floss participant's teeth at the site once daily during the week (five days). The second brushing will be done unsupervised at home. The remaining weekend days flossing and brushing will be done unsupervised at home.
89029431|NCT04696536|Experimental|Group 4: Flossing under Supervision|Participants will brush their teeth and then undergo instructions on flossing technique using reach dental floss orally for 12 Weeks. Participants floss their teeth under supervision at the site once daily during the week (five days). The second brushing will be done unsupervised at home. The remaining weekend days flossing and brushing will be done unsupervised at home.
89578780|NCT05218889|Experimental|surufatinib + camrelizumab + nab-paclitaxel + S-1|
89578781|NCT05218889|Active Comparator|nab-paclitaxel + gemcitabine|
89578782|NCT05262569||ileus group|Patients developed postoperative ileus
89029432|NCT03459651|Experimental|ANS training|
89578783|NCT05262569||control group|Patients did not develop postoperative ileus
89209375|NCT04037436|Experimental|Intervention|"At regular intervals (the steps) one cluster (i.e., one site) is randomised to cross from the control to the intervention under evaluation. This process continues until all clusters have crossed over to be exposed to the intervention. At the end of the study there will be a period when all clusters are exposed. Four sites are cluster-randomized to implement MoveSTroNg at one of four start times, each three weeks apart."
89578784|NCT01657253|Experimental|PRO-148|"PRO-148 containing: xanthan gum and sulphate chondroitin, ophthalmic solution~doses: 1 drop in each eye, quarter in day"
89578785|NCT01657253|Active Comparator|Systane®|"Systane containing: polyethylene glycol 400 0.4%, propylene glycol 0.3% and hydroxypropyl guar~doses: 1 drop in each eye, quarter in day"
89578786|NCT05215457||development set|50 cases are the development set, which is used to develop the prediction model of diquat acute poisoning. These patients are all from the First Affiliated Hospital of Nanjing Medical University.
89578787|NCT05215457||validation set|50 patients are the validation set, from more than ten tertiary a-level hospitals in the surrounding area, to verify the prediction model.
89578788|NCT02117427|Experimental|Group A|MDGN201 TARGTEPO secreting EPO (18-25 IU/Kg/day)
89578789|NCT02117427|Experimental|Group B|MDGN201 TARGTEPO secreting EPO (35-45 IU/Kg/day)
89578790|NCT02117427|Experimental|Group C|MDGN201 TARGTEPO secreting EPO (55-65 IU/Kg/day)
89578791|NCT02117349|Experimental|Raplixa plus Gelfoam|"During a single predefined surgical procedure, participants receive the assigned treatment on an appropriate target bleeding site (TBS). The treatment is topically applied using 1 of the following 3 methods:~A thin layer of Raplixa is sprinkled directly from the vial onto the TBS, followed by application of Gelfoam.~A thin layer of Raplixa is sprayed onto the TBS using the RaplixaSpray device, followed by application of Gelfoam.~Raplixa is applied onto moistened Gelfoam which is then applied to the TBS.~Manual pressure is applied over the treatments using sterile gauze. The amount of Raplixa and Gelfoam used is at the discretion of the investigator, within the maximum of two 1 gram (g) vials of Raplixa that are permitted for each participant.~Thrombin-containing hemostats included in standard of care at the site are permitted as rescue therapy after the 5-minute time-to-hemostasis (TTH) evaluation."
89578792|NCT02117349|Other|Gelfoam Only|"During a single predefined surgical procedure, participants receive the assigned treatment on an appropriate TBS. Gelfoam is cut to the appropriate size and applied topically, according to the manufacturer's package insert, followed by manual pressure using sterile gauze.~Thrombin-containing hemostats included in standard of care at the site are permitted as rescue therapy after the 5-minute TTH evaluation, if necessary."
89578793|NCT05213663||1/parents of the Cerebral Palsy children|parents of the children with cerebral palsy will be evaluated about the awereness of their children's disease, physical and social activities and physiotherapy and rehabilitation.
89029433|NCT01245881|Experimental|Treatment group|Broad-spectrum UV block plus non-ablative 1,550-nm fractional treatment
89029434|NCT01245881|Active Comparator|Control group|
89578794|NCT05167253|Experimental|UB-612 100 μg, 0.5 mL|All subjects will be enrolled to receive one dose of 100 μg UB-612 vaccine
89578795|NCT01626495|Experimental|CART-19 T Cells|The subject's thawed T cells will be modified in one or two different ways that will allow the cells to identify and kill the tumor cells (B cells). The T cells will be infused over 10-15 minutes on days Days 0, and 1. Day 14 is tentative based on response.
89578796|NCT02177175|Experimental|Carvedilol|Treatment in both carvedilol and placebo groups will be systematically up-titrated at weeks 3, 6, and 9 (+/- 1 week) after randomization to a goal dose of 25mg twice daily.
89578797|NCT02177175|Placebo Comparator|placebo|Treatment in both carvedilol and placebo groups will be systematically up-titrated at weeks 3, 6, and 9 (+/- 1 week) after randomization to a goal dose of 25mg twice daily.
89578798|NCT02153073||Omega-3 fatty acid ethyl esters 2 g|Omega-3 fatty acid ethyl esters 2 g, administered orally once or twice daily after meals
89578799|NCT01657877|Experimental|CSP/SMFP Dentifrice|Dentifrice containing high fluoride content as SMFP and CSP
89578800|NCT01657877|Active Comparator|SMFP Dentifrice Prototype 1|Dentifrice containing high fluoride content as SMFP and no CSP
89578801|NCT01657877|Active Comparator|SMFP Dentifrice Prototype 2|Dentifrice containing low fluoride content as SMFP and no CSP
89578802|NCT01657877|Active Comparator|CSP Dentifrice|Dentifrice containing CSP but no fluoride
88972766|NCT01806350|Experimental|Arm I (PFMT)|Patients receive a handout describing behavioral management tips for urinary incontinence, including information and suggestions about optimal volume fluid intake, constipation management, measures to reduce urgency by spreading fluid intake, and avoiding caffeine and other bladder irritants that have proved effective in other intervention trials. Patients undergo PFMT over 20-30 minutes teaching them to contract the pelvic floor muscles correctly and receive feedback to avoid the contraction of abdominal, gluteal or adductor muscles. Patients are asked to perform 3 sets of 10 pelvic muscle contractions with a goal of holding the contraction for 5 seconds daily for 12 weeks and also receive a reminder phone call to address concerns and review the instructions at 4 weeks.
88972767|NCT01806350|Active Comparator|Arm II (usual care)|Patients receive usual care for urinary incontinence, with an option to join the training program after completion of study.
88972768|NCT01806311|Active Comparator|PartA: Candesartan, Candesartan + Amolodipine|Candesartan : multiple dose 32mg administered orally Amlodipine : multiple dose 10mg administered orally
88972769|NCT01806311|Active Comparator|PartB: Amlodipine, Amlodipine+Candesartan|Candesartan : multiple dose 32mg administered orally Amlodipine : multiple dose 10mg administered orally
88972770|NCT01806272|Experimental|Arm A|"Local use of rhGM-CSF + Compound Vitamin B12 solution: The rhGM-CSF is prepared as a mouthwash solution,diluting 150μg in 100ml water(final concentration of 1.5μg/ml).Patient is instructed to use the solution five times daily.~Compound Vitamin B12 solution 5ml being sprayed to mouth five times daily~Radiotherapy: Intensity modulated radiation therapy(IMRT)~Chemotherapy:Docetaxel or cisplatin weekly or cisplatin once every three weeks during radiotherapy."
88972771|NCT01806272|Active Comparator|Arm B|"Compound Vitamin B12 solution 5ml being sprayed to mouth five times daily~Radiotherapy: Intensity modulated radiation therapy(IMRT)~Chemotherapy:Docetaxel or cisplatin weekly or cisplatin once every three weeks during radiotherapy."
88972772|NCT01806233|Experimental|Acupuncture|acupuncture
88972773|NCT01806233|Experimental|Rehabilitation|rehabilitation exercise
88972774|NCT00035100|Experimental|EPO906|
89209376|NCT04037436|Other|Control|Each cluster contributes observations under both control and intervention observation periods.
89209377|NCT00888576||1|Non-intervention
89578803|NCT01657877|Placebo Comparator|Placebo Dentifrice|Dentifrice containing no CSP and no fluoride
89209378|NCT00888732|Experimental|Insulin therapy|Insulin Aspart, Biphasic Insulin Aspart 70 and 50 & Fast-acting Human Insulin
89578804|NCT05254925|Active Comparator|Phototoxicity evaluation of sunscreen oil with 6% BEMT (SU E 101413 85)|"Assessment of the phototoxicity potential of sunscreen oil with 6% BEMT (PARSOL® Shield) and 10% ethanol as penetration enhancer a test material (formulation: SU E 101413 85).~The phototoxic response of the investigational product: SU E 101413 85 will be assessed following the determination of each subject's Minimal Erythema Dose (MED). Approximately 0.15 g or 0.15 ml of the investigational product will be applied to the skin of human subjects which will then be exposed to UV radiation an a erythema and dermal response scoring system will be used to evaluate the phototoxic response of the irradiated area within the treated test site of each subject."
89578805|NCT05254925|Other|Phototoxicity evaluation of sunscreen oil vehicle (SU E 101413 91)|"Vehicle Control: Assessment of the phototoxicity potential of sunscreen oil vehicle with 10% ethanol as penetration enhancer without BEMT (formulation: SU E 101413 91).~The phototoxic response of the investigational product: SU E 101413 91 will be assessed following the determination of each subject's Minimal Erythema Dose (MED). Approximately 0.15 g or 0.15 ml of the investigational product will be applied to the skin of human subjects which will then be exposed to UV radiation an a erythema and dermal response scoring system will be used to evaluate the phototoxic response of the irradiated area within the treated test site of each subject."
89578806|NCT05254925|Active Comparator|Phototoxicity evaluation of dispersion of 6% BEMT in petrolatum (SU E 101413 82)|"Assessment of the phototoxicity potential of a dispersion of 6% BEMT (PARSOL® Shield) in petrolatum (formulation: SU E 101413 82).~The phototoxic response of the investigational product: SU E 101413 82 will be assessed following the determination of each subject's Minimal Erythema Dose (MED). Approximately 0.15 g or 0.15 ml of the investigational product will be applied to the skin of human subjects which will then be exposed to UV radiation an a erythema and dermal response scoring system will be used to evaluate the phototoxic response of the irradiated area within the treated test site of each subject."
89578807|NCT05254925|Other|Phototoxicity evaluation of petrolatum vehicle (SU-E-101413-83)|"Vehicle Control: Assessment of the phototoxicity potential of petrolatum vehicle (SU-E-101413-83).~The phototoxic response of the investigational product: SU E 101413 83 will be assessed following the determination of each subject's Minimal Erythema Dose (MED). Approximately 0.15 g or 0.15 ml of the investigational product will be applied to the skin of human subjects which will then be exposed to UV radiation an a erythema and dermal response scoring system will be used to evaluate the phototoxic response of the irradiated area within the treated test site of each subject."
89578808|NCT05205941|Other|MMV533 (single, oral doses).|Approximately 12 volunteers in 1 cohort, Up to six dose levels between 10 and 160mg
89578809|NCT05205473|Active Comparator|SN blockade under ultrasound control with a peripheral nerve stimulator 12.5 ml 1% lidocaine|Patients undergoing surgery on the knee, shin, ankle or foot
89578810|NCT05205473|Experimental|SN blockade under ultrasound control without a peripheral nerve stimulator|Patients undergoing surgery on the knee, shin, ankle or foot
89578811|NCT05160935|Experimental|Coronary Angiography Training Manual|It is the form prepared by the researchers in line with the literature information and the opinion of the specialist physician was taken. It contains information about coronary artery disease, what to do before coronary angiography procedure and what kind of situations await individuals after the procedure.
89578812|NCT04422197|Active Comparator|Patients with ultrasound-guided botox injection|Effect of Botox injection on lateral abdominal wall muscles after major open abdominal surgery
89578813|NCT04422197|Active Comparator|Patients with no botox injection|Patients with major abdominal surgery without botox injection
89578814|NCT05204303||Patients with symptoms of LPR and objective evidence of GORD|
89578815|NCT05204303||Patients with symptoms of LPR and no objective evidence of GORD|
89578816|NCT05204303||Healthy volunteers|
89578817|NCT05203367|Experimental|BAR 502|Each subject will receive an oral single-dose of BAR 502.
89578818|NCT05203367|Placebo Comparator|Placebo|Each subject will receive an oral single-dose of placebo.
89578819|NCT05370755|Experimental|Phase Ia: ICP-189 Dose Escalation|
89578820|NCT02175771|Experimental|Fp MDPI 100 mcg|"Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate (Fp) for a total daily dose of 200 mcg Fp for 26 weeks. This was the mid-strength experimental intervention in the inhaled corticosteroid (ICS) cohort.~Albuterol/salbutamol HFA metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
89578821|NCT02175771|Active Comparator|FLOVENT HFA 110 mcg|"Participants took 2 inhalations using a hydrofluoroalkane (HFA) inhaler twice a day of fluticasone propionate (Fp) for a total daily dose of 440 mcg Fp for 26 weeks. This was the mid-strength active comparator intervention in the inhaled corticosteroid (ICS) cohort.~Albuterol/salbutamol HFA metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
89578822|NCT02175771|Experimental|Fp MDPI 200 mcg|"Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate (Fp) for a total daily dose of 400 mcg Fp for 26 weeks. This was the high-strength experimental intervention in the inhaled corticosteroid (ICS) cohort.~Albuterol/salbutamol HFA metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
89578823|NCT02175771|Active Comparator|FLOVENT HFA 220 mcg|"Participants took 2 inhalations using a hydrofluoroalkane (HFA) inhaler twice a day of fluticasone propionate (Fp) for a total daily dose of 880 mcg Fp for 26 weeks. This was the high-strength active comparator intervention in the inhaled corticosteroid (ICS) cohort.~Albuterol/salbutamol HFA metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
89578824|NCT02175771|Experimental|FS MDPI 100/12.5 mcg|"Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate/salmeterol (FS) 100/12.5 mcg for a total daily dose of 200/25 mcg FS for 26 weeks. This was the mid-strength experimental intervention in the inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) cohort.~Albuterol/salbutamol HFA metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
89578825|NCT02175771|Active Comparator|ADVAIR DISKUS 250/50 mcg|"Participants took 1 inhalation of a dry-powder formulation twice a day of fluticasone propionate/salmeterol (FS) 250/50 mcg for a total daily dose of 500/100 mcg FS for 26 weeks. This was the mid-strength active comparator intervention in the inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) cohort.~Albuterol/salbutamol HFA metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
89578826|NCT02175771|Experimental|FS MDPI 200/12.5 mcg|"Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate/salmeterol (FS) 200/12.5 mcg for a total daily dose of 400/25 mcg FS for 26 weeks. This was the high-strength experimental intervention in the inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) cohort.~Albuterol/salbutamol HFA metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
88972775|NCT00393575|Experimental|Community Mobilization|The intervention population is defined as the community each site is attempting to mobilize.
89578827|NCT02175771|Active Comparator|ADVAIR DISKUS 500/50 mcg|"Participants took 1 inhalation of a dry-powder formulation twice a day of fluticasone propionate/salmeterol (FS) 500/50 mcg for a total daily dose of 1000/100 mcg FS for 26 weeks. This was the high-strength active comparator intervention in the inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) cohort.~Albuterol/salbutamol HFA metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
89578828|NCT01657799|Experimental|Veliparib 200 mg BID + WBRT|Participants received veliparib 200 mg twice a day (BID) orally concomitantly with whole brain radiation therapy (WBRT). Participants received a total of 30.0 Gy of WBRT given in 10 daily fractions of 3.0 Gy, excluding weekends and holidays.
89578829|NCT01657799|Experimental|Veliparib 50 mg BID + WBRT|Participants received veliparib 50 mg twice a day (BID) orally concomitantly with whole brain radiation therapy (WBRT). Participants received a total of 30.0 Gy of WBRT given in 10 daily fractions of 3.0 Gy, excluding weekends and holidays.
88972776|NCT01806194|Active Comparator|Educational control arm|Control group receives 16 mailings of diabetes educational materials but no regular contact with community health workers
89578830|NCT01657799|Placebo Comparator|Placebo BID + WBRT|Participants received placebo twice a day (BID) orally concomitantly with whole brain radiation therapy (WBRT). Participants received a total of 30.0 Gy of WBRT given in 10 daily fractions of 3.0 Gy, excluding weekends and holidays.
89578831|NCT05249777|Experimental|TD0069|Standard dose, 3 capsules/time x 3 times/day x 14 days before breakfast, lunch, and dinner combined with standard treatment.
89578832|NCT05249777|Placebo Comparator|Placebo|Standard dose, 3 capsules/time x 3 times/day x 14 days before breakfast, lunch, and dinner combined with standard treatment
89578833|NCT02116803|Experimental|dovitinib|Participants were given single agent dovitinib starting with last assigned dose and regimen which patient received in parent study. Additional dose modifications were given at the discretion of the investigator based on guidance provided in the protocol and investigative brochure (IB).
89578834|NCT02116803|Experimental|dovitinib + fulvestrant|Participants were given dovitinib and fulvestrant coadministration starting with last assigned dose and regimen which patient received in parent study. Additional dose modifications were at the discretion of the investigator based on guidance provided in the protocol and IB.
89578835|NCT05201027|Experimental|trifocal intraocular lens|Implantation of new trifocal intraocular lens
89578836|NCT05156411|Experimental|Eccentric Training|This Group will train on the KREHA for 20 Trainings
89578837|NCT04231487||Essential tremor|"This is not an intervention study.~Specific to group: a) Diagnosis of ET, b) stable dose of medication for 30 days"
89578838|NCT04231487||Parkinson's Disease|"This is not an intervention study.~Specific to group: a) Diagnosis of PD, b) stable dose of medication for 30 days"
89578839|NCT04231487||Huntington's Disease|"This is not an intervention study.~Specific to group: a) Diagnosis of HD, b) stable dose of medication for 30 days"
89578840|NCT04231487||Primary Focal Dystonia|"This is not an intervention study.~Specific to group: a) Diagnosis of PFD, b) stable dose of medication for 30 days"
89578841|NCT04231487||Spinocerebellar Ataxia|This is not an intervention study. Specific to group: a) Diagnosis of SCA, b) stable dose of medication for 30 days
89578842|NCT04231487||Functional Movement Disorder|This is not an intervention study. Specific to group: a) Diagnosis of FMD, b) stable dose of medication for 30 days
89578843|NCT04231487||Healthy Controls|"This is not an intervention study.~People with Healthy Controls"
89578844|NCT02115321|Experimental|Part A: CP-B GZR 50 mg + EBR 50 mg|CP-B participants take GZR 50 mg + EBR 50 mg once daily (q.d.) by mouth for 12 weeks.
89578845|NCT02115321|Experimental|Part A: NC GZR 100 mg + EBR 50 mg|NC participants take GZR 100 mg + EBR 50 mg q.d. by mouth for 12 weeks.
89578846|NCT02115321|Experimental|Part B: CP-B GZR 100 mg + EBR 50 mg|CP-B participants take GZR 100 mg + EBR 50 mg q.d. by mouth for 12 weeks.
88972777|NCT01806194|Experimental|Lifestyle counseling|Small changes behavioral counseling and social support, delivered in 16 sessions by community health workers.
88972778|NCT01806155||Craniotomy|Patient undergoing major craniotomy
88972779|NCT01806116|Experimental|decitabine + transplantation|
88972780|NCT01806077|Experimental|PZ-128|
88972781|NCT00035451|Placebo Comparator|1|placebo tablets
88972782|NCT00035451|Active Comparator|2|Sotalol
88972783|NCT00035451|Experimental|3|azimilide
88972784|NCT01806038|Experimental|RPh Counseling + Outpatient Dispensing|On the day of discharge, a pharmacist will perform a chart review and medication reconciliation on all patients' discharge medications (for patients randomized to the intervention arm). Any medication discrepancies will be addressed with the patient's primary care team. At the time of discharge, the patient will receive his/her discharge medications dispensed from the Duke Outpatient Pharmacy, along with medication counseling by a licensed pharmacist.
88972785|NCT01806038|Active Comparator|Routine Med Dispensing + Counseling|At hospital discharge, patients will receive standard discharge procedures and obtain discharge medications per their usual process
88972786|NCT01805999|Experimental|7 g Ispaghula|Volunteer will take 7 g of ispaghula 3 times daily for one week
88972787|NCT01805999|Placebo Comparator|7 g placebo|Volunteer will take 7 g of a placebo 3 times a day for one week
88972788|NCT01805999|Active Comparator|3.5g ispaghula + 3.5 g placebo|Volunteers will take 3.5 g of ispaghula with 3.5 g placebo 3 times daily for one week
88972789|NCT00035490|Placebo Comparator|1|Placebo tablets
88972790|NCT00035490|Experimental|2|75 mg azimilide
88972791|NCT00035490|Experimental|3|125 mg azimilide
88972792|NCT00035607|Active Comparator|Darbepoetin alfa SC|
88972793|NCT00035607|Experimental|Darbepoetin alfa IV|
88972794|NCT01805960|Experimental|Canakinumab|1 s.c. injection of canakinumab 150mg directly after cardioversion
88972795|NCT01805960|Placebo Comparator|Placebo|1 s.c. injection directly after cardioversion
88972796|NCT01805921|Experimental|Arm 1. Prime PanAd3-RSV (IM), boost MVA-RSV (IM)|"Group 1A. Low dose prime PanAd3-RSV given by intra-muscular injection (IM) - low dose boost MVA-RSV given by intra-muscular injection (IM). 2 volunteers, 18-50 years. Interval: 8 weeks.~Group 1B. High dose prime PanAd3-RSV given by intra-muscular injection (IM) - high dose boost MVA-RSV given by intra-muscular injection (IM). 8 volunteers, 18-50 years. Interval: 8 weeks."
89029435|NCT00500435||Laparoscopy Procedure|Laparoscopy procedure in abdomen to remove para aortic lymph nodes of patients diagnosed with cervical cancer.
89029436|NCT05149404||ERAS group|
89029437|NCT05149404||Conventional group|
89029438|NCT01247402|Active Comparator|Paclitaxel eluting balloon|Freeway 0.035 Paclitaxel eluting balloon (3 microgram Paclitaxel/mm2)
89578847|NCT02115321|Experimental|Part C: CP-B GZR 50 mg or 100 mg + EBR 50 mg|CP-B participants take GZR 50 mg or GZR 100 mg + EBR 50 mg q.d. by mouth for 12 weeks (GZR dose chosen based on results of Part A CP-B arm).
89578848|NCT05248841|Experimental|HEC-Glargine Treatment A (Test)|Subjects will receive single doses of Test Formulation HEC-Glargine on Day 1 of Treatment periods 1 and 2 followed by at least 7-21 days washout.
89578849|NCT05248841|Active Comparator|US-Lantus Treatment B (Reference)|Subjects will receive single doses of Reference Formulation Lantus on Day 1 followed of Treatment periods 1 and 2 by at least 7-21 days washout.
89578850|NCT05248139|Experimental|Single-dose steroid medication delivered during surgery|Subconjunctival injection of Triamcinolone acetonide.
89578851|NCT05248139|Active Comparator|Standard of care post-operative steroid drops|Prednisolone acetate ophthalmic solution, 4-week taper.
89578852|NCT04230239|Experimental|CPX-351|
89578853|NCT05199389|Experimental|PBM1 group|The patients allocated to the first PBM-group will receive six PBM sessions of 6 J/cm² over three weeks (2x/week).
89578854|NCT05199389|Experimental|PBM2 group|The patients allocated to the first PBM-group will receive six PBM sessions of 8 J/cm² over three weeks (2x/week).
89578855|NCT05154383|Experimental|High-Dose Quadrivalent Influenza Vaccine|One injection of the high-dose Efluelda vaccine will be given to the patient
89578856|NCT05154383|Active Comparator|Standard-Dose Quadrivalent Influenza Vaccine|One injection of the standard-dose Influvactetra vaccine will be given to the patient
89578857|NCT05245877|Experimental|Preoperative thromboprophylaxis|Preoperatively initiated tromboprophylaxis
89578858|NCT05245877|No Intervention|Postoperative thromboprophylaxis|Postoperatively initiated thromboprophylaxis
89578859|NCT05194475|Experimental|Thermogenic Ready-to-drink Beverage|Arm in which a thermogenic ready-to-drink beverage is ingested.
89578860|NCT05194475|Placebo Comparator|Placebo Ready-to-drink Beverage|Arm in which a placebo ready-to-drink beverage is ingested.
89578861|NCT05245175|Experimental|Sodium chloride particles|Patients are exposed to sodium chloride particles alone for 4 hours in the Fraunhofer Allergen Challenge Chamber.
89578862|NCT05245175|Experimental|Lactose particles|Patients are exposed to lactose particles alone for 4 hours in the Fraunhofer Allergen Challenge Chamber.
89578863|NCT05245175|Placebo Comparator|Clean air|Patients are exposed to clean air for 4 hours in the Fraunhofer Allergen Challenge Chamber.
89578864|NCT05245175|Experimental|Sodium chloride particles with house dust mite|Patients are exposed to sodium chloride particles coupled with D. pteronyssinus for 4 hours in the Fraunhofer Allergen Challenge Chamber.
89578865|NCT05245175|Experimental|Lactose particles with house dust mite|Patients are exposed to lactose particles coupled with D. pteronyssinus for 4 hours in the Fraunhofer Allergen Challenge Chamber.
89578866|NCT05152277|Experimental|Single dose escalation of HRS9531 injection in healthy subjects|
89578867|NCT05152277|Placebo Comparator|Single dose of placebo in healthy adults|
89578868|NCT05152277|Experimental|Multiple dose escalation of HRS9531 injection in healthy subjects|
89578869|NCT05152277|Placebo Comparator|Multiple dose of placebo in healthy adults|
89578870|NCT05243381|Other|Immune non-responder patients|"HIV viral load < 50 copies/ml in the past 2 years~CD4+ T-cell count < 350 cells/mm3 on the last two tests"
89578871|NCT05243381|Other|Immune responder patients|"HIV viral load < 50 copies/ml in the past 2 years~CD4+ T-cell count > 500 cells/mm3 on the last two tests"
89578872|NCT05150171|Experimental|e-self-management intervention|Patients will receive the HAPPY Hands e-self-management intervention delivered through a smartphone app.
89578873|NCT05192837|Experimental|Intervention group|The study intervention consists of a smoking cessation counselling meeting by a Tabacco Treatment Specialist (TSS) 4 weeks before surgery. The goal of this first intervention meeting is to implement an individual treatment plan for preoperative smoking cessation.
89029439|NCT01247402|Active Comparator|Standard balloon angioplasty|standard balloon angioplasty
89578874|NCT05192837|No Intervention|Control group|Patients randomised to the control arm will get advice only. Their preoperative course will be as if they were not participating in this study, meaning they will receive inconsistent perioperative smoking cessation advice from nurses, surgeons, or anaesthesiologists but no further study-specific smoking cessation intervention. Importantly, participants in the control group will not be discouraged from using perioperative smoking cessation aids and can still obtain help on one's own initiative.
89578875|NCT05192525|Experimental|mChemotherapy group|"The intervention group participants will adopt an app mChemotherapy to self-manage their symptoms under nurse-led supervision for six weeks."
89578876|NCT05192525|No Intervention|Control group|"Participants in control group will receive routine care, with no use of mChemotherapy during six weeks. Routine care is composed of a pre-chemotherapy visit and two follow-up visits. Through the Official WeChat platform, the patients in control group will be informed about the chemotherapy regimen, and chemotherapy-related symptoms and how to deal with them, during the pre-chemotherapy visit. The control group will have two scheduled visits by telephone with the follow-up nurse. Patients will be given a phone number for consulting the follow-up nurse should they have questions related to their symptoms, or concerns related to the chemotherapy. Patients in the control group cannot access the mChemotherapy until they have completed the pilot study."
89578877|NCT05475197|Experimental|Kinesio taping Type 1|"For the first group; While the wrist is 30° extension, the forearm is supinated and the elbow is extended, the distance between the 1st metacarpal joint and the medial epicondyles of the patient up to 5 cm below the median epicondyle will be measured. Two strips with width of 2.5 cm will be prepared. For the median nerve, the first band will be adhered along the nerve trachea by stretching of moderate intensity (50%) from the 2nd and 3rd metacarpophalangeal joint to 5 cm below the medial epicondyle.~The second strip will be applied without stretching to a distance of 5 cm under the medial epicondyle from the 4th and 5th metacarpophalangeal joint. In addition, a strip half the length of the wrist circumference will be adhered to the volar face of the wrist by applying tension to the middle 1/3 of it, without applying tension to both ends."
89578878|NCT05475197|Experimental|Kinesio taping Type 2|"For the second group; While the elbow is in full extension and the wrist in the extension and supination position, the distal two free ends of the tape will be adhered to the thenar and hypothenar regions without stretching. The middle 1/3 of the X-shaped tape will be adhered to the forearm volar face by applying moderate stretching.The first half of the two proximal free ends will have adhered to the medial and lateral epicondyle with little or no stretching, and the last half without any stretching.~The I-shaped tape will be adhered to the radial region of the wrist with the elbow in full extension, the wrist in a neutral position, and the palm closed. The middle of the tape will be stretched lightly and moderately, and the last 1/3 of it will be adhered to the ulnar part of the wrist without stretching. Kinesio taping will be applied to both groups once."
89029440|NCT00508170||Patients with Oropharyngeal Cancer|
89029441|NCT00508170||Patients with Non-Oropharyngeal Cancer|
89029442|NCT03458247|Active Comparator|Abiraterone acetate standard dose|1000 mg/day
89029443|NCT03458247|Experimental|Abiraterone acetate escalated dose|2000 mg/day
89029444|NCT01247519|No Intervention|observation|
89029445|NCT01247519|Experimental|Intervention|
89029446|NCT03453216|Experimental|Behavioral test and fMRI|Neuropsychological tests and training in behavioral tasks and a Functional Magnetic Resonance Imaging (fMRI) exam
89029447|NCT00500513|Experimental|Implanted Markers + CT + RT|
89029448|NCT02954718|Experimental|1|patient-centered task oriented activity training in real life
89029449|NCT02954718|Experimental|2|patient-centered video-based task oriented activity training
89029450|NCT01247558||Test Cohort|100 randomized subjects administered Metanx®
89029451|NCT01247558||Control Cohort|400 subjects with diabetes mellitus meeting the same inclusion and exclusion criteria as the test cohort who have not been treated with Metanx®.
89029452|NCT02954445|Experimental|B Cell Malignancies|The trial will be conducted in a manner of simon two-stage design with Anti-BCMA-CAR-transduced T cells, beginning in the first stage with the aim of over 30% reaction rate among 15 patients with B cell malignancies. Only when the expected reaction rate is achieved the 30 patients left can be recruited.
89029453|NCT02954250|No Intervention|Control|Patients randomized to the control group will be offered literature on mental health promotion and Treatment as usual
89029454|NCT02954250|Experimental|Mindfulness Group|The intervention will consist of group, lasting 90 minutes in one session per week for 8 weeks. The exercises will be 5 minutes long alternating between 4 or 5 each session.
89029455|NCT00500591||Obese Women|
89029456|NCT02954289|Other|Dietary intervention|Dietary intervention
89029457|NCT04696913||Pulmonary Embolism Positive|As determined by CT Pulmonary Angiogram
89029458|NCT04696913||Pulmonary Embolism Negative|As determined by CT Pulmonary Angiogram
89029459|NCT02954016|Experimental|ePass|Subjects implanted with the investigational ValenTx Endo Bypass System
89029460|NCT00500669|Experimental|Betadine|
89029461|NCT00500669|Active Comparator|Saline|
89029462|NCT00507585|Experimental|Oxaliplatin + Fluorouracil + Leucovorin + Avastin|
89029463|NCT01247636|Experimental|Home-exercise|
89029464|NCT00508248|Active Comparator|A1|1 g omega 3 fatty acid supplements
89029465|NCT00508248|Placebo Comparator|A2|
89209379|NCT00730925|Experimental|BIBW 2992|patient to receive tablets of BIBW 2992 once a day, starting at high dose until progression of the disease
89578879|NCT02367781|Experimental|Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin)|Participants received intravenous (IV) infusion of atezolizumab and carboplatin on Day 1 of each 21-day cycle, and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurred first during induction treatment phase. Participants received IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit.
89578880|NCT02367781|Active Comparator|Arm B (Nab-Paclitaxel+Carboplatin)|Participants received IV infusion of carboplatin on Day 1 and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until disease progression whichever occurred first during induction treatment phase. Participants received best supportive care during maintenance treatment phase. Switch maintenance to pemetrexed was also permitted. Participants who were consented prior to approval of protocol Version 5 were given the option to cross over to receive atezolizumab as monotherapy until disease progression.
89578881|NCT02152761|Experimental|bimagrumab 700 mg|Approximately 70 patients who met all inclusion criteria and none of the exclusion criteria were treated with the bimagrumab high dose administered via intravenous infusion starting Day 1 until Week 20
89578882|NCT02152761|Experimental|bimagrumab 210 mg|Approximately 70 patients who met all inclusion criteria and none of the exclusion criteria were treated with the bimagrumab medium dose administered via intravenous infusion starting Day 1 until Week 20
89578883|NCT02152761|Placebo Comparator|placebo|Approximately 70 patients who met all inclusion criteria and none of the exclusion criteria received matching placbo administered via intravenous infusion starting Day 1 until Week 20
89578884|NCT02152761|Experimental|Bimagrumab 70 mg|Approximately 35 patients who met all inclusion criteria and none of the exclusion criteria were treated with bimagrumad low dose administered via intravenous infusion starting Day 1 until Week 20
89578885|NCT04242173|Experimental|Cemiplimab-rwlc treatment|Immunocompromised patients will be given Cemiplimab-rwlc every 3 weeks
89578886|NCT02152605|Experimental|Umeclidinium/Vilanterol 62.5/25 mcg once daily|The subjects will receive UMEC/VI 62.5/25 mcg, administered as one inhalation once-daily in the morning via a dry powder inhaler (DPI)
89578887|NCT02152605|Placebo Comparator|Placebo once daily|The subjects will receive placebo, administered as one inhalation once-daily in the morning via a DPI
89578888|NCT05147129||Postmenopausal with vulvar lichen sclerosus|Includes postmenopausal patients with clinically-active vulvar lichen sclerosus, as determined by biopsy or examination by a vulvar specialist
89578889|NCT05147129||Postmenopausal without vulvar lichen sclerosus|Includes postmenopausal patients without vulvar lichen sclerosus
89578890|NCT02152371|Experimental|Dulaglutide + Insulin Glargine|1.5 milligrams (mg) dulaglutide administered subcutaneously (SQ) once weekly for 28 weeks. Titrated insulin glargine administered SQ once daily for 28 weeks. Participants who are taking metformin should remain on stable doses.
89578891|NCT02152371|Placebo Comparator|Placebo + Insulin Glargine|Placebo administered SQ once weekly for 28 weeks. Titrated insulin glargine administered SQ once daily for 28 weeks. Participants who are taking metformin should remain on stable doses.
89578892|NCT02332291|Active Comparator|Blinded Escitalopram / Open-Label Bupropion|8 weeks of blinded escitalopram, followed by 8 weeks of open-label bupropion xl for nonremitters
89578893|NCT02332291|Placebo Comparator|Blinded Placebo / Open-Label Bupropion|8 weeks of blinded placebo, followed by 8 weeks of open-label bupropion xl for nonremitters.
89578894|NCT01656395|Experimental|MK-1029 10 mg|Participants receive MK-1029 10 mg tablets once daily (QD) for 12 weeks
89578895|NCT01656395|Experimental|MK-1029 30 mg|Participants receive MK-1029 30 mg tablets QD for 12 weeks
89578896|NCT01656395|Experimental|MK-1029 60 mg|Participants will receive MK-1029 two 30 mg tablets QD for 12 weeks
89578897|NCT01656395|Experimental|MK-1029 150 mg|Participants will receive MK-1029 150 mg tablets QD for 12 weeks
89578898|NCT01656395|Active Comparator|Montelukast 10 mg|Participants will receive Montelukast 10 mg tablets QD for 12 weeks
89578899|NCT01656395|Placebo Comparator|Placebo|Participants will receive Placebo tablets QD for 12 weeks
89578900|NCT01656395|Experimental|MK-1029 1 mg or 3 mg|Participants will receive either MK-1029 1 mg or 3 mg tablets (dose to be determined based on results of interim analysis from Part I) QD.
89578901|NCT01656395|Experimental|Montelukast 10 mg + MK-1029|Participants will receive Montelukast 10 mg tablets QD and MK-1029 tablets (dose to be determined based on results of interim analysis from Part I) QD
89578902|NCT02114931|Experimental|ABP 501|Participants received ABP 501 40 mg subcutaneously (SC) every other week for up to 18 months.
89578903|NCT05185739|Active Comparator|Pembrolizumab|
89578904|NCT05185739|Active Comparator|Lenvatinib.|
89578905|NCT05185739|Experimental|Pembrolizumab and Lenvatinib.|
89578906|NCT05144711|Active Comparator|Selective excavation|Cries will be removed from the peripheries of the cavity, while only soft caries will be removed from the plural side leaving stained leathery dentine that can not be removed by hand instruments. Biodentine will be placed and the cavity will be restored.
89578907|NCT05144711|Active Comparator|Non selective excavation|Caries will be cleaned form all cavity peripheries and floor. Biodentine will be placed and the toothy will be restored.
89578908|NCT05238935|No Intervention|control group|this group will be treated as per the common practice postoperatively and will have the home program prescribed by the orthopedic surgeon
89578909|NCT05238935|Experimental|intervention (treatment) group|Patients in the intervention group will be treated with conventional physiotherapy 3 times a week for 6 weeks (18 times treatment).
89578910|NCT05184725|No Intervention|Control Group|Patients will follow the usual care procedures and after each procedure they answer questionnaires related to pain and stress levels (VAS), Anxiety and depression levels (HADS), health-related quality of life (HRQoL), mental wellbeing (SWEMWBS), self-efficacy (GSE) and Patient Activation status (PAM-13).
89578911|NCT05184725|Experimental|SaMD CARINAE|Intervention group will be exposed to the use of SaMD CARINAE for 2 months approximately, a patientcentred digital health support program. The intervention trial will include a total of 4 visits: 1. Baseline (2-4 weeks before surgery); 2. Hospital admission (1-3 days before surgery); 3. Hospital discharge (1 week after the surgery approx.); 4. Post-operative day 14 (2 weeks after the surgery approx). After each visit and intervention trial with SaMD CARINAE the experimental group answer the same questionnaires of the control group, above mentioned Participants allocated to the intervention group will also be asked to complete questionnaires about usability, satisfaction and subjective experience.
89578912|NCT05184413|Experimental|Multimodal treatment|Therapeutic Exercise plus Pain Neuroscience Education
89578913|NCT05184413|Active Comparator|Unimodal treatment|Therapeutic Exercise
89578914|NCT05183789||Cases|Malnourished children with acute diarrhea
89578915|NCT05183789||Control|Non-malnourished children with acute diarrhea
89578916|NCT01657019|Experimental|Lisdexamfetamine dimesylate|
89578917|NCT02329327|Experimental|Andexanet|Participants received andexanet as an intravenous bolus administered over ~15 to 30 minutes, followed immediately by a continuous infusion administered over ~120 minutes.
89578918|NCT05235269|Other|Single arm|I-124 AT-01
89029466|NCT01247714|Active Comparator|Group 1|The group 1 will receive the experimental product T-Diet plus Diabet NP for the first month followed by a reference diet corresponding to a current marketed product (Glucerna SR, Abbott) for the second month, then the patients will receive a control product non specific for diabetic patients (T-Diet plus Standard)for the third month, and finally a specific diet for diabetic patients (Novasource, Nestlé Healthcare Nutrition)for the fourth month.
89029467|NCT01247714|Active Comparator|Group 2|The group 2 will receive a reference diet corresponding to a current marketed product (Glucerna SR, Abbott)for the first month, followed by the experimental product T-Diet plus Diabet NP for the second month, then the patients will receive a specific diet for diabetic patients (Novasource, Nestlé Healthcare Nutrition)for the third month, and finally a control product non specific for diabetic patients (T-Diet plus Standard)for the fourth month
89029468|NCT00507663|Experimental|Atenolol|Atenolol given prior to and for up to 7 days after surgery
89029469|NCT00507663|No Intervention|routine care|routine clinical care
89029470|NCT00508287|Experimental|A|
89029471|NCT00508287|Active Comparator|B|
89029472|NCT00508287|Placebo Comparator|C|
89209380|NCT00730925|Experimental|BIBW 2992 + paclitaxel|patient whose disease progressed on treatment with BIBW 2992 monotherapy to receive tablet of BIBW 2992 once a day in combination with i.v. paclitaxel 3 weekly
89578919|NCT02328937|Active Comparator|etafilcon A/lotrafilcon B/comfilcon A|Subjects that were randomized to receive the etafilcon A lens 1st, the lotrafilcon B lens 2nd and the comfilcon A lens 3rd.
89578920|NCT02328937|Active Comparator|etafilcon A/comfilcon A/lotrafilcon B|Subjects that were randomized to receive the etafilcon A lens 1st, the comfilcon A lens 2nd and the lotrafilcon B lens 3rd.
89578921|NCT02328937|Active Comparator|comfilcon A/etafilcon A/lotrafilcon B|Subjects that were randomized to receive the comfilcon A lens 1st, the etafilcon A lens 2nd and the lotrafilcon B lens 3rd.
89578922|NCT02328937|Active Comparator|comfilcon A/lotrafilcon B/etafilcon A|Subjects that were randomized to receive the comfilcon A lens 1st, the lotrafilcon B lens 2nd and the etafilcon A lens 3rd.
89578923|NCT02328937|Active Comparator|lotrafilcon B/etafilcon A/comfilcon A|Subjects that were randomized to receive the lotrafilcon B lens 1st, the etafilcon A lens 2nd and the comfilcon A lens 3rd.
89578924|NCT02328937|Active Comparator|lotrafilcon B/comfilcon A/etafilcon A|Subjects that were randomized to receive the lotrafilcon B lens 1st, the comfilcon A lens 2nd and the etafilcon A lens 3rd.
89578925|NCT05181605|No Intervention|No Intervention: No intervention - standard of care|A group of patients with pancreatic carcinoma plus risk factors will be treated per standard of care on site (surgical resection and adjuvant therapy)
89029473|NCT00500747|Experimental|Group C: 100 mcg HCV E1E2/MF59 vaccine|Sixteen subjects receive four doses of 100 mcg HCV E1E2/MF59 vaccine (0.5 mL total volume) and 4 subjects receive placebo at 0, 4, 24, and 48 weeks.
89029474|NCT00500747|Experimental|Group B: 20 mcg HCV E1E2/MF59 vaccine|Sixteen subjects receive four doses of 20 mcg HCV E1E2/MF59 vaccine (0.5 mL total volume) and 4 subjects receive placebo at 0, 4, 24, and 48 weeks.
89029475|NCT00500747|Experimental|Group A: 4 mcg HCV E1E2/MF59 vaccine|Sixteen subjects receive four doses of 4 mcg HCV E1E2/MF59 vaccine (0.5 mL total volume) and 4 subjects receive placebo at 0, 4, 24, and 48 weeks.
89029476|NCT00508326|Experimental|HAI Paclitaxel|Paclitaxel via Hepatic Artery Infusion (HAI)
89029477|NCT01247753|Experimental|Intervention|
89209381|NCT00236899|Experimental|A: Docetaxel and Gemcitabine (Tri-weekly)|Docetaxel and Gemcitabine (Tri-weekly)
89578926|NCT05181605|Experimental|Experimental: Neoadyuvant therapy plus standard of care|A group of patients with pancreatic carcinoma plus risk factors will be treated with neoadjuvant therapy before surgical resection and adjuvant therapy
89578927|NCT02328547|Experimental|FMT capsules|Intervention: Fecal microbiota transplantation capsules containing extensively screened donor stool, prepared by OpenBiome, Medford, MA. 25 FMT capsules will be take on three consecutive days.
89578928|NCT02328547|Placebo Comparator|Placebo capsules|Intervention: Placebo capsules that do not contain donor stool or any active drug, prepared by OpenBiome, Medford, MA. 25 placebo capsules will be taken on three consecutive days.
89209382|NCT00236899|Experimental|B: Paclitaxel and Gemcitabine (Tri-weekly)|Paclitaxel and Gemcitabine (Tri-weekly)
89209383|NCT00236899|Experimental|C: Docetaxel and Gemcitabine (Weekly)|Docetaxel and Gemcitabine (Weekly)
89209384|NCT00236899|Experimental|D: Paclitaxel and Gemcitabine (Weekly)|Paclitaxel and Gemcitabine (Weekly)
89209385|NCT00611130|Experimental|1|3 Vigabatrin Tablets, 500 mg, bid, for 9 weeks
89209386|NCT00611130|Placebo Comparator|2|3 Placebo Tablets, bid, for 9 weeks
89209387|NCT00885690|Active Comparator|Sertindole|Sertindole 16-24 mg
89209388|NCT00885690|Active Comparator|Olanzapine|Olanzapine 10-20 mg
89029478|NCT01247753|No Intervention|Control|
89209389|NCT01071733||ultrasound wrist|
89209390|NCT01071733||ultrasound finger|
89209391|NCT01071733||ultrasound ankle|
89209392|NCT02542176|Experimental|Freeze-dried Whole Grape Powder|
89209393|NCT02542176|Placebo Comparator|Grape Powder Placebo|
89578929|NCT02300311|Experimental|nonivamide + nicoboxil (Finalgon cream)|2 cm cream line for a skin area of approximately 20 x 20 cm2 up to 3 times in a 24h period
89578930|NCT02300311|Placebo Comparator|placebo|2 cm cream line for a skin area of approximately 20 x 20 cm2 up to 3 times in a 24h period
89578931|NCT05141903||Arm 1|Antibiotic conditioning
89578932|NCT05141903||Arm 2|Antibiotic conditioning, Dose ranging of dietary supplement with and probiotic.
89578933|NCT05141903||Arm 3|Antibiotic conditioning, Dose ranging of dietary supplement with and probiotic.
89578934|NCT05141903||Arm 4|Antibiotic conditioning, Dose ranging of dietary supplement with and probiotic.
89578935|NCT05141903||Arm 5|Antibiotic conditioning and probiotic treatment.
89578936|NCT04229381|Experimental|Supportive Care (physical therapy, muscle relaxation)|Patients participate physical therapy sessions consisting of cardiovascular and resistance training exercises in person or online and also undergo progressive muscle relaxation sessions once weekly for up to 12 weeks.
89578937|NCT05178485|Experimental|The experimental group|At each clinic visit for a subject's injection, the study coordinator will inform the clinic nurse of the group assignment, and the nurse will draw up the corresponding 2 mL injectate (either the bupivacaine/triamcinolone mixture) and wrap the syringe in foil. The syringe will then be provided to the physician for the injection.
89578938|NCT05178485|Placebo Comparator|The control group|At each clinic visit for a subject's injection, the study coordinator will inform the clinic nurse of the group assignment, and the nurse will draw up the corresponding 2 mL saline and wrap the syringe in foil. The syringe will then be provided to the physician for the injection.
89578939|NCT05229185|Experimental|DeXtreme (Error-enhacement)|Training (error-enhancement): 5 consecutive days, 1 hour per day
89578940|NCT05175365|Experimental|Dance|Patients allocated to this group will attend dance classes for patients with Parkinson's disease given once a week over a 4-month period for a total of 16 dance sessions.
89578941|NCT05175365|No Intervention|Control|The control group will receive its rehabilitation care.
89578942|NCT05228951|Experimental|Pyrotinib maleate, dalpiciclib, Trastuzumab, letrozole|After providing written informed consent, the participants will undergo combined treatment of pyrotinib maleate, CDK4/6 inhibitor dalpiciclib, trastuzumab and letrozole. The effectiveness of the combined treatment will be evaluated by MRI every two treatment cycles. If the disease progresses, the participant will withdraw from the trial. If the combined treatment has identified effectiveness, the participant will undergo surgical treatment within 4 weeks (over 2 weeks) after termination of the neoadjuvant treatment. The patients will be followed up for 5 years.
89578943|NCT05174039|Experimental|Oral miglustat|The proposed dosing regimen is daily oral miglustat (MTD, up to 200 mg TID)
89578944|NCT04422119|Experimental|Multi-layer foam dressing|Patients in experimental group will receive the application of a multi-layer foam dressing with Safetac in surgical wound
89578945|NCT04422119|Active Comparator|Usual care|Patients in control group will receive standard treatment with povidone-iodine and a gauze dressing with plaster.
89578946|NCT02300233|Placebo Comparator|Placebo|Volanesorsen-matching placebo administered subcutaneously once-weekly for 26 weeks.
89578947|NCT02300233|Experimental|Volanesorsen 300 mg weekly|Volanesorsen 300 mg administered subcutaneously once-weekly for 26 weeks.
89578948|NCT02300233|Experimental|Volanesorsen 300 mg biweekly, post Week 13|Volanesorsen 300 mg administered subcutaneously once-weekly for 13 weeks, then bi-weekly for 13 weeks.
89578949|NCT05137379||Elher-Danlos syndrome patients treated with orthopedic surgery|
89578950|NCT02175225|Experimental|Deferoxamine Mesylate|Deferoxamine Mesylate (32 mg/kg/day) given by an intravenous infusion for 3 consecutive days
89578951|NCT02175225|Placebo Comparator|Normal Saline|Normal saline (0.9% sodium chloride) given by intravenous infusion for 3 consecutive days
89578952|NCT05170841|Active Comparator|Dexketoprofen Trometamol 25 mg/Tramadol Hydrochloride 75 mg treatment|Two phase intervention. Single dose phase (time 0 - time 8h) and Multiple dose phase (time 8h - Day 5) In this arm patients will receive during each phase film coated tablets (administered as one tablet)
89578953|NCT05170841|Active Comparator|Tramadol Hydrochloride 100 mg treatment|Two phase intervention. Single dose phase (time 0 - time 8h) and Multiple dose phase (time 8h - Day 5) In this arm patients will receive during each phase (administered as 2 capsules of Tramadol 50 mg)
89578954|NCT05170841|Placebo Comparator|Placebo and Dexketoprofen Trometamol 25 mg/Tramadol Hydrochloride 75 mg treatment|"Two phase intervention. Single dose phase (time 0 - time 8h) and Multiple dose phase (time 8h - Day 5).~SINGLE DOSE PHASE: Placebo film-coated tablets matching Dexketoprofen Trometamol 25 mg/Tramadol Hydrochloride 75 mg MULTIPLE DOSE PHASE: Dexketoprofen Trometamol 25 mg/Tramadol Hydrochloride 75 mg film coated tablets (administered as one tablet)"
89578955|NCT05170841|Placebo Comparator|Placebo and Tramadol Hydrochloride 100 mg|"Two phase intervention. Single dose phase (time 0 - time 8h) and Multiple dose phase (time 8h - Day 5).~SINGLE DOSE PHASE: Placebo capsules matching active comparator (administered as 2 capsules of Tramadol 50 mg) MULTIPLE DOSE PHASE: Tramadol Hydrochloride 100 mg (administered as 2 capsules of Tramadol 50 mg)"
89578956|NCT05169671|Experimental|ATH-1020|ATH-1020 in oral form. Participants in the single ascending dose cohort (Cohort A) will receive a single dose of ATH-1020. Participants in the multiple ascending dose cohort (Cohort B) will receive up to nine doses of ATH-1020 (up to 4 for cohort B5).
89578957|NCT05169671|Placebo Comparator|Placebo|Placebo in oral form. Participants in the single ascending dose cohort (Cohort A) will receive a single dose of Placebo. Participants in the multiple ascending dose cohort (Cohort B) will receive up to nine doses of placebo.
89578958|NCT05107583|Experimental|Low-Carbohydrate Pre-Exercise Meal|Participants will consume a low-carbohydrate (<10% carbohydrate) lunch meal at 13:30 - 2.5 hours prior to commencing exercise at 16:00.
89578959|NCT05107583|Experimental|High-Carbohydrate Pre-Exercise Meal|Participants will consume a high-carbohydrate (~2.2 g/kg carbohydrate) lunch meal at 13:30 - 2.5 hours prior to commencing exercise at 16:00.
89578960|NCT05107583|Experimental|Fasted Exercise|Participants will skip lunch, and continue fasting since breakfast (08:00) before commencing exercise at 16:00. Therefore, exercise will commence after an 8 hour period of fasting.
89578961|NCT05106491|Other|venoarterial extracorporeal membrane oxygenation (VA ECMO) for cardiocirculatory stabilization|Patients with cardiogenic shock, requiring a venoarterial extracorporeal membrane oxygenation (VA ECMO) for cardiocirculatory stabilization will be treated with Synchronized Cardiac Support (SCS).
89029479|NCT00500786|Experimental|100 mcg CYT006-AngQb Healthy Volunteers|
89578962|NCT05135273|Experimental|1a (Pilot Group)|(n=5) to receive 12.5 µg Pfs230D1-EPA/25 µg Matrix-M on D1, D29, D57
89578963|NCT05135273|Experimental|1b (Pilot Group)|(n=5) to receive 20 µg Pfs230D1-EPA/50 µg Matrix-M on D1, D29, D57
89578964|NCT05135273|Experimental|1c (Pilot Group)|(n=5) to receive 40 µg Pfs230D1-EPA/50 µg Matrix-M on D1, D29, D57
89029480|NCT00500786|Experimental|100 mcg CYT006-AngQb Hypertensives|
89578965|NCT05135273|Active Comparator|1d (Pilot Group)|(n=4) to receive rabies vaccine (standard dose) on D1, D29, D57
89578966|NCT05135273|Experimental|2a (Main Group)|(n=15) to receive 12.5 µg Pfs230D1-EPA/25 µg Matrix-M on D1, D29, D57
89578967|NCT05135273|Experimental|2b (Main Group)|(n=15) to receive 20 µg Pfs230D1-EPA/50 µg Matrix-M on D1, D29, D57
89578968|NCT05135273|Experimental|2c (Main Group)|(n=15) to receive 40 µg Pfs230D1-EPA/50 µg Matrix-M on D1, D29, D57
89578969|NCT05135273|Active Comparator|2d (Main Group)|(n=16) to receive rabies vaccine (standard dose) on D1, D29, D57
89578970|NCT05133713||Catheter directed thrombectomy|
89578971|NCT05133713||Systemic anticoagulation|
89578972|NCT05129423|Experimental|Part 1: MTPS9579A Dose A|In Part 1, participants will receive MTPS9579A dose A every 4 weeks from randomization to Week 12.
89578973|NCT05129423|Placebo Comparator|Part 1: Placebo|In Part 1, participants will receive placebo matched with MTPS9579A, every 4 weeks from randomization through Week 12.
89578974|NCT05129423|Experimental|Part 2: MTPS9579A Dose A|In Part 2, participants will receive MTPS9579A dose A, every 4 weeks from randomization to Week 12.
89578975|NCT05129423|Experimental|Part 2: MTPS9579A Dose B|In Part 2, participants will receive MTPS9579A dose B, every 4 weeks from randomization to Week 12.
89578976|NCT05129423|Experimental|Part 2: MTPS9579A Dose C|In Part 2, participants will receive MTPS9579A dose C, every 4 weeks from randomization to Week 12.
89578977|NCT05129423|Experimental|Part 2: MTPS9579A Dose D|In Part 2, participants will receive MTPS9579A dose D, every 4 weeks from randomization to Week 12.
89578978|NCT05129423|Placebo Comparator|Part 2: Placebo Dose A|In Part 2, participants will receive placebo matched with MTPS9579A dose A and B, every 4 weeks from randomization through Week 12.
89578979|NCT05129423|Placebo Comparator|Part 2: Placebo Dose B|In Part 2, participants will receive placebo matched with MTPS9579A dose C and D, every 4 weeks from randomization through Week 12.
89578980|NCT05129189|Experimental|ASC22 group|ASC22 1mg/kg hypodermic injection Q4W+Chidamide 10mg PO BIW
89578981|NCT02299375|Experimental|Losmapimod 15 mg|Subjects with COPD will receive losmapimod 15 mg tablets orally, twice daily, approximately 12 hours apart and within 30 minutes after meals with a full glass of water for the duration of the treatment period in addition to standard of care, stratified according to whether a center collects sputum or not and current use of inhaled corticosteroid (ICS). Salbutamol metered dose inhaler (MDI) will be provided as a rescue medication.
89578982|NCT02299375|Experimental|Placebo|Subjects with COPD will receive placebo orally, twice daily, approximately 12 hours apart and within 30 minutes after meals with a full glass of water for the duration of the treatment period in addition to standard of care, stratified according to whether a center collects sputum or not and current use of ICS. Salbutamol MDI will be provided as a rescue medication.
89578983|NCT04421651|Experimental|Treatment group|The participants in the treatment group were offered 20 Dance movement therapy sessions in addition to standard care.
89578984|NCT04421651|No Intervention|Control group|Participants in the control group continued treatment as usual in the health services.
89578985|NCT05223959|Experimental|CaPE Intervention|CaPE is a manualized intervention consisting of 12 one-to-one psychoeducation sessions, one session per week. Each session will last for 60 minutes. All sessions will be delivered by a trained therapist who will receive two months training from senior therapists before starting intervention.
89578986|NCT05223959|No Intervention|Treatment as Usual|Treatment as usual (TAU) will be ascertained by the participant's treating physician. Research staff will record the nature and intensity of TAU delivered to each participant over a period of 3 months.
89578987|NCT02151903|Experimental|DI-Leu16-IL2 1.0 mg/m^2|Participants will receive DI-Leu16-IL2 1.0 milligrams per square meter (mg/m^2) subcutaneously (SC) for 3 consecutive days every 3 weeks (21-day cycle). Participants will continue to receive therapy through the duration of the study as long as they will have clinical benefit and will not experience any untoward side effects.
89578988|NCT02151903|Experimental|DI-Leu16-IL2 2.0 mg/m^2|Participants will receive DI-Leu16-IL2 2.0 mg/m^2 SC for 3 consecutive days every 3 weeks (21-day cycle). Participants will continue to receive therapy through the duration of the study as long as they will have clinical benefit and will not experience any untoward side effects.
89578989|NCT05221307|Experimental|1/Children with cerebral palsy|Modified Pilates Exercises (MPEs) will be applied 3 days a week, 45 minutes a day for 8 weeks.
89578990|NCT05221307|Active Comparator|2/children with cerebral palsy|Traditional Neurodevelopmental Therapy (NGT-Bobath) approach will be applied for 45 minutes a day, 3 days a week for 8 weeks.
89578991|NCT05102201|Experimental|Paro intervention group|Participants in the Paro intervention group will receive a group (6-8 people as a group), facilitated, and 30-minute weekly session Paro intervention for 6 weeks.
89578992|NCT05102201|No Intervention|control group|The control group will receive care as usual activities, such as painting, drawing, and craft, which are provided by each facility.
89578993|NCT02151591|Experimental|Integrated Counseling for Tobacco and Alcohol (INT)|Integrated counseling for smoking and alcohol entails weekly counseling for 12-weeks targeting both behaviors. Participants in this condition will also receive 12 weeks of varenicline (Chantix).
89578994|NCT02151591|Other|Standard Care for Primary Presenting Concern (SC)|Standard care (SC) for primary presenting concern only. For those presenting with the primary concern of tobacco, standard care will involve weekly smoking counseling alone for 12-weeks. For those presenting with the primary concern of alcohol, standard care will involve weekly alcohol counseling alone. Participants in this condition will also receive 12 weeks of varenicline (Chantix).
89578995|NCT05101421|Experimental|Treatment arm|To receive rice ceramide supplementation for 3 months
89578996|NCT02174523|Experimental|40mg lurasidone|Single oral administration of 40 mg study drug lurasidone after the over 350 kcal breakfast on Day 1. Administration was suspended on Days 2 and 3. Continuous oral administration of 40 mg study drug lurasidone, once daily between Day 4 and Day 8.
89578997|NCT02174523|Placebo Comparator|placebo|Single oral administration of 40 mg study drug placebo after the over 350 kcal breakfast on Day 1. Administration was suspended on Days 2 and 3. Continuous oral administration of 40 mg placebo, once daily between Day 4 and Day 8.
89578998|NCT05128877|No Intervention|Control group|No intervention was made in the control group.
89578999|NCT05128877|Experimental|intervention group|Progressive relaxation techniques were applied to the intervention group.
89029481|NCT00500786|Experimental|300 mcg CYT006-AngQb Hypertensives|
89029482|NCT00500786|Placebo Comparator|Placebo Healthy Volunteers|
89579000|NCT04226729||Healthy group|
89579001|NCT04226729||Mild visual impairment group|
89029483|NCT00500786|Placebo Comparator|Placebo Hypertensives|
89029484|NCT00507858|Experimental|Pemetrexed|Starting dose 500 mg/m^2 IV once every 3 weeks
89579002|NCT04226729||Moderate and severe visual impairment group|
89579003|NCT02297815||Broad-spectrum antibiotics|Children diagnosed with an acute respiratory tract infections (ARTI) and prescribed Broad-spectrum antibiotics.
89579004|NCT02297815||Narrow-spectrum|Children diagnosed with an acute respiratory tract infections (ARTI) and prescribed Narrow-spectrum antibiotics.
89579005|NCT02114385|Experimental|V503|9-valent HPV [Types 6, 11, 16, 18, 31, 33, 45, 52, and 58] L1 virus-like particle vaccine, 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6
89579006|NCT02114385|Active Comparator|GARDASIL|Quadrivalent HPV [Types 6, 11, 16, and 18] L1 virus-like particle vaccine, 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6
89579007|NCT05220605|Experimental|Bromac (100ug/20mg)|"The nurse/investigator will fill the jet nebuliser canister supplied on the ward with the 5ml of BromAc (100micrograms bromelain and 20mg acetylcysteine). The cannister will be collected to the mask and attached to the wall compressed air supply, with flow of between 6-8L per minute. The mask will be placed on the participant immediately upon generating aerosol. The nebulisation will continue until the chamber is empty, estimated 15 minutes, unless otherwise indicated, such as adverse event.~The nurse/investigator will undertake clinical observations including heart rate, respiratory rate, SpO2 and blood pressure, every 5 minutes during nebulisation and then at 30 minutes, 1 hour and 2 hours. Cardiorespiratory auscultation will occur at the end of nebulisation and prior to discharge.~This will be repeated once daily for three consecutive days.~Blood tests will be taken before the first dose is given on day 1, and two hours after the last dose is given on day 3."
89029485|NCT00507858|Experimental|Pemetrexed + IV Dexamethasone|Pemetrexed Starting dose 500 mg/m^2 IV once every 3 weeks + Dexamethasone 20 mg intravenous (IV) Day 1.
89029486|NCT00507858|Experimental|Pemetrexed + Oral Dexamethasone|Pemetrexed starting dose 500 mg/m^2 IV once every 3 weeks + Dexamethasone 4 mg orally twice daily for 3 Days.
89029487|NCT01245920|Experimental|FDBA + Membrane Group|For patients in the FDBA + membrane group, a layer 4 mm thick of cancellous allograft bone (Puros Cancellous, Zimmer Dental inc., Carlsbad, CA) will be placed over the buccal bone in the area of the implant. A resorbable collagen membrane (Bio-Gide, 13 x 25 mm, Osteohealth, Shirley, NY) will be trimmed to extend 5 mm beyond the implant borders and to cover the implant head. Following membrane placement over the bone graft, the gingival flaps will be closed and sutured with 4-0 Vicryl (Ethicon Inc., Sommerville, NJ) with passive tension flap closure.
89579008|NCT05220605|Experimental|Bromac (150ug/20mg)|"The nurse/investigator will fill the jet nebuliser canister supplied on the ward with the 5ml of BromAc (150micrograms bromelain and 20mg acetylcysteine). The cannister will be collected to the mask and attached to the wall compressed air supply, with flow of between 6-8L per minute. The mask will be placed on the participant immediately upon generating aerosol. The nebulisation will continue until the chamber is empty, estimated 15 minutes, unless otherwise indicated, such as adverse event.~The nurse/investigator will undertake clinical observations including heart rate, respiratory rate, SpO2 and blood pressure, every 5 minutes during nebulisation and then at 30 minutes, 1 hour and 2 hours. Cardiorespiratory auscultation will occur at the end of nebulisation and prior to discharge.~This will be repeated once daily for three consecutive days.~Blood tests will be taken before the first dose is given on day 1, and two hours after the last dose is given on day 3."
89579009|NCT05220605|Experimental|Bromac (200ug/20mg)|"The nurse/investigator will fill the jet nebuliser canister supplied on the ward with the 5ml of BromAc (200 micrograms bromelain and 20mg acetylcysteine). The cannister will be collected to the mask and attached to the wall compressed air supply, with flow of between 6-8L per minute. The mask will be placed on the participant immediately upon generating aerosol. The nebulisation will continue until the chamber is empty, estimated 15 minutes, unless otherwise indicated, such as adverse event.~The nurse/investigator will undertake clinical observations including heart rate, respiratory rate, SpO2 and blood pressure, every 5 minutes during nebulisation and then at 30 minutes, 1 hour and 2 hours. Cardiorespiratory auscultation will occur at the end of nebulisation and prior to discharge.~This will be repeated once daily for three consecutive days.~Blood tests will be taken before the first dose is given on day 1, and two hours after the last dose is given on day 3."
89579010|NCT05098457|Experimental|GP0112|Single injection and optional touch up injection with GP0112
89579011|NCT05098457|Active Comparator|Restylane Lyft Lidocaine|Single injection and optional touch up injection with Restylane Lyft Lidocaine
89579012|NCT02114151|Experimental|Arm 1 (Simeprevir/Sofosbuvir)|100 participants will receive 1 capsule of 150 mg simeprevir and 1 tablet of 400 mg sofosbuvir orally (by mouth) once daily for 12 weeks.
89579013|NCT05098379|Experimental|Tele-Rehabilitation Home Exercise Program|Subjects will participate in an 8-week customized home exercise program with weekly virtual exercise coaching sessions.
89579014|NCT05220293|Experimental|Betamethasone Dipropionate Nasal Cream 0.0644% Treatment|Betamethasone Dipropionate Nasal Cream 0.0644% is applied topically to the inflamed tissue of the sinus using a pre-filled syringe and applicator under the guidance of an endoscope. Up to 5g on each side of the sinus (10g in total).
89579015|NCT04752189|Active Comparator|Standard MMH Curriculum Implementation|Teachers will receive the MMH curriculum manual, standard training and as-needed technical assistance, provided to them by the health coordinators
89029488|NCT01245920|Active Comparator|Non-FDBA|Patients in the non-FDBA group will have gingival flaps closed with the same suturing technique.
89029489|NCT00507897||A|Cohort: Patients with normal blood pressure scheduled to have thyroid nodules surgically removed
89029490|NCT00507897||A1|Patients from group A not receiving any drugs and who lack other pathology, gender and age matched group B1
89029491|NCT00507897||B|Cohort: Patients with increased blood pressure scheduled to have thyroid nodules surgically removed
89029492|NCT00507897||B1|Patients from group B not receiving any drugs and who lack other pathology, gender and age matched group A1
89029493|NCT00500825||1|Patients successfully resuscitated after cardiac arrest undergoing therapeutic hypothermia
89579016|NCT04752189|Experimental|Michigan Model for Health: Learning to Enhance and Adapt for Prevention (MI-LEAP)|We will deploy Enhanced REP to include additional tailoring of the MMH curriculum to include trauma-informed approaches, tailored trauma-focused curriculum training, and implementation facilitation, ongoing specialized implementation support.
88972797|NCT01805921|Experimental|Arm 2. Prime PanAd3-RSV (IM), boost PanAd3-RSV (IM)|"Group 2A. Low dose prime PanAd3-RSV given by intra-muscular injection (IM) - low dose boost PanAd3-RSV given by intra-muscular injection (IM). 2 volunteers, 18-50 years. Interval: 4 weeks.~Group 2B. High dose prime PanAd3-RSV given by intra-muscular injection (IM) - high dose boost PanAd3-RSV given by intra-muscular injection (IM). 8 volunteers, 18-50 years. Interval: 4 weeks."
88972798|NCT01805921|Experimental|Arm 3. Prime PanAd3-RSV (IN), boost MVA-RSV (IM)|"Group 3A. Low dose prime PanAd3-RSV given intra-nasally (IN) - low dose boost MVA-RSV given by intra-muscular injection (IM). 2 volunteers, 18-50 years. Interval: 8 weeks.~Group 3B. High dose prime PanAd3-RSV given intra-nasally (IN) - high dose boost MVA-RSV given by intra-muscular injection (IM). 8 volunteers, 18-50 years. Interval: 8 weeks."
88972799|NCT01805921|Experimental|Arm 4. Prime PanAd3-RSV (IN), boost PanAd3-RSV (IM)|"Group 4A. Low dose prime PanAd3-RSV given intra-nasally (IN) - low dose boost PanAd3-RSV given by intra-muscular injection (IM). 2 volunteers, 18-50 years. Interval: 8 weeks.~Group 4B. High dose prime PanAd3-RSV given intra-nasally (IN) - high dose boost PanAd3-RSV given by intra-muscular injection (IM). 8 volunteers, 18-50 years. Interval: 8 weeks."
88972800|NCT01805921|No Intervention|Arm 5. No vaccine|Group 5. Non-vaccinated control group. 6 volunteers, 60-75 years.
88972801|NCT01805921|Experimental|Arm 6. MVA-RSV (IM)|Group 6. Single high dose MVA-RSV given by intra-muscular injection (IM). 6 volunteers, 60-75 years.
88972802|NCT01805921|Experimental|Arm 7. Prime PanAd3-RSV (IM), boost PanAd3-RSV (IM)|Group 7. High dose prime PanAd3-RSV given by intra-muscular injection (IM) - high dose boost PanAd3-RSV given by intra-muscular injection (IM). 6 volunteers, 60-75 years. Interval: 4 weeks.
88972803|NCT01805921|Experimental|Arm 8. Prime PanAd3-RSV (IN), boost MVA-RSV (IM)|Group 8. High dose prime PanAd3-RSV given intra-nasally - high dose boost MVA-RSV given by intra-muscular injection (IM). 6 volunteers, 60-75 years. Interval: 8 weeks.
88972804|NCT01805921|Experimental|Arm 9. Prime PanAd3-RSV (IM), boost MVA-RSV (IM)|Group 9. High dose prime PanAd3-RSV given by intra-muscular injection (IM) - high dose boost MVA-RSV given by intra-muscular injection (IM). 6 volunteers, 60-75 years. Interval: 8 weeks.
88972805|NCT02971254|Active Comparator|Sevoflurane group|inhalation anaesthetic Sevoflurane, 1 M.A.C. during surgery
88972806|NCT02971254|Active Comparator|Desflurane group|inhalation anaesthetic Desflurane, 1 M.A.C. during surgery
88972807|NCT01805882|Experimental|A: HCV GT-1, tx naïve, 12 wks Sofosbuvir/Ledipasvir|Oral treatment with Sofosbuvir 400mg (GS-7977) and Ledipasvir 90mg (GS-5885), once daily, for 12 weeks in HCV genotype 1, treatment naïve patients
88972808|NCT01805882|Experimental|B: HCV GT-1, tx naïve, 6 wks Sofosbuvir/Ledipasvir/GS-9669|Oral treatment with Sofosbuvir 400mg (GS-7977), Ledipasvir 90mg (GS-5885), GS-9669 500mg, once daily, for 6 weeks in HCV genotype 1, treatment naïve patients
88972809|NCT01805882|Experimental|C: HCV GT-1, tx naïve, 6 wks Sofosbuvir/Ledipasvir/GS-9451|Oral treatment with Sofosbuvir 400mg (GS-7977), Ledipasvir 90mg (GS-5885), GS-9451 80mg, once daily, for 6 weeks in HCV genotype 1, treatment naïve patients
88972810|NCT01805882|Experimental|D: HCV GT-1, tx-relapsed, 12 wks Sofosbuvir/Ledipasvir|Oral treatment with Sofosbuvir 400mg (GS-7977) and Ledipasvir 90mg (GS-5885), once daily, for 12 weeks in HCV genotype 1, treatment-relapsed patients who previously received Sofosbuvir plus Ribavirin
88972811|NCT01805882|Experimental|E: HCV GT-4, tx naïve/expd, 12 wks Sofosbuvir/Ledipasvir|Oral treatment with Sofosbuvir 400mg (GS-7977) and Ledipasvir 90mg (GS-5885), once daily, 12 weeks in HCV genotype 4 treatment naïve subjects and interferon treament experienced subjects
88972812|NCT01805882|Experimental|F: HCV GT-1, tx naïve/expd 6 wks Sofosbuvir/Ledipasvir/GS-9451|Oral treatment with Sofosbuvir 400mg (GS-7977) and Ledipasvir 90mg (GS-5885) and GS-9451 80mg, once daily, 6 weeks in HCV genotype 1 treatment naïve and treatment experienced subjects with advanced liver disease
88972813|NCT01805882|Experimental|G: HCV GT-1, tx naïve, 4 wks Sofosbuvir, Ledipasvir, GS-9451|Oral Treatment with Sofosbuvir 400mg (GS-7977) and Ledipasvir 90mg (GS-5885) with GS-9451 80mg, once daily, 4 weeks in HCV genotype 1 treatment naïve subjects with early stage liver disease
88972814|NCT01805882|Experimental|H: HCV GT-1, tx naïve, 4 wks Sofos/Ledip/GS-9451/GS-9669|Oral Treatment with Sofosbuvir 400mg (GS-7977) and Ledipasvir 90mg (GS-5885) with GS-9451 80mg, and GS-9669 250mg, once daily, 4 weeks in HCV genotype 1 treatment naïve subjects with early stage liver disease
88972815|NCT01805882|Experimental|D Retx: HCV GT-1, Re-Treatment, 12 wks Sofosbuvir, Ledipasvir|Oral treatment with Sofosbuvir 400mg (GS-7977) and Ledipasvir 90mg (GS-5885), once daily, 12 weeks in HCV genotype 1 subjects who failed HCV therapy in Arm B or Arm G or Arm H
88972816|NCT00035802|Experimental|001|"Topiramate Double-blind period: Up to 400 mg/day (two 100-mg tablets twice a day) for 28 days.~OL period: Up to 600 mg/day (three 100-mg tablets twice a day) for at least 6 months."
88972817|NCT00035802|Placebo Comparator|002|Placebo Double-blind period: Equal number of matching placebo tablets for each of the topiramate tablet strengths twice a day for 28 days.
88972818|NCT01805843||chronic meloid leukemia|echo, exercise echo, and if indicated, right heart catheter
88972819|NCT04732377|Placebo Comparator|GROUP(A) (CONTROL GROUP)|Patient will receive 20 ml 0.25% levobupivacaine into interfascial plane below erector spinae muscle at level of T5.
88972820|NCT04732377|Active Comparator|Group (D)|Patient will receive 20ml 0.25% levobupivacaine above + 1μ/kg dexmedetomidine into interfascial plane below erector spinae muscle at level of T5.
88972821|NCT01805765|Active Comparator|Qing'E pills|9 g pills,twice a day for 12 weeks
88972822|NCT01805765|Placebo Comparator|Placebo|9 g pills,twice a day for 12 weeks
88972823|NCT01805726|Placebo Comparator|Xylocain (C)|(C): Local anesthesia
88972824|NCT01805726|Active Comparator|Alfentanil Group + Xylocain (A)|Local anesthesia and Alfentanil
88972825|NCT01805726|Active Comparator|Dexmedetomidine Group + Xylocain (D)|Local anesthesia and dexmedetomidine
88972826|NCT01805687|Other|Zileuton extended release|Oral, 1200 mg (2 x 600 mg tablets)
88972827|NCT01805648|Experimental|rhTPO|Active investigational product
88972828|NCT01805570|Active Comparator|Prasugrel loading dose|25 patients with STEMI undergoing PPCI with bivalirudin (GP IIb/IIIa not allowed) will be randomized to receive Prasugrel before PPCI.
89029494|NCT00508365|Experimental|Subjects receiving treatment sequence AB|Eligible subjects will receive treatment sequence AB; A= Placebo to match COREG CR 20 milligrams once daily plus lisinopril 10 milligrams once daily (Days 1-7). Placebo to match COREG CR 40 milligrams once daily plus lisinopril 10 milligrams once daily (Days 8-14). B=COREG CR 20 milligrams once daily plus lisinopril 10 milligrams once daily (Days 1-7). COREG CR 40 milligrams once daily plus lisinopril 10 milligrams once daily (Days 8-14).
89029495|NCT00508365|Experimental|Subjects receiving treatment sequence BA|Eligible subjects will receive treatment sequence BA; B=COREG CR 20 milligrams once daily plus lisinopril 10 milligrams once daily (Days 1-7). COREG CR 40 milligrams once daily plus lisinopril 10 milligrams once daily (Days 8-14). A= Placebo to match COREG CR 20 milligrams once daily plus lisinopril 10 milligrams once daily (Days 1-7). Placebo to match COREG CR 40 milligrams once daily plus lisinopril 10 milligrams once daily (Days 8-14).
89579017|NCT02297503|Experimental|Azzalure alone as single treatment|Azzalure alone as single treatment at initial treatment followed by two combined treatments with Azzalure, HA filler and Skinboosters at Month 6 and Month 12.
89579018|NCT02297503|Experimental|Filler alone as single treatment|HA filler alone as single treatment at initial treatment followed by two combined treatments with Azzalure, HA filler and Skinboosters at Month 6 and Month 12.
89579019|NCT04421885|Experimental|A: TBPM-PI-HBr (Reference - fasted)|600 mg (2 x 300 mg tablets) clinical study drug product batch TBPM-PI-HBr administered at Hour 0 on Day 1, under fasted conditions.
89579020|NCT04421885|Experimental|B: TBPM-PI-HBr (Test - fasted)|600 mg (2 x 300 mg tablets) registration drug product batch TBPM-PI-HBr administered at Hour 0 on Day 1, under fasted conditions.
89579021|NCT04421885|Experimental|C: TBPM-PI-HBr (Test - fed)|600 mg (2 x 300 mg tablets) registration drug product batch TBPM-PI-HBr administered at Hour 0 on Day 1, under fed conditions.
89579022|NCT02113449|Experimental|Treatment Group|Participants will receive one dose of nasal carbon dioxide (CO2) in the study clinic under medical supervision, followed by an additional six days of at home use, up to 4 times per day.
89579023|NCT02366923|Experimental|stenfilcon A|Each subject will be randomized to wear the test lens in one eye and control lens in the other eye (contra lateral design).
89579024|NCT02366923|Active Comparator|delefilcon A|Each subject will be randomized to wear the test lens in one eye and control lens in the other eye (contra lateral design).
89579025|NCT02326597|Active Comparator|Standard Practice|Participants will receive education regarding treatment consideration from their healthcare provider/team as per standard practice (usual care).
89579026|NCT02326597|Experimental|Standard Practice + Decision Aid|Participants will receive standard of care teaching and discussion in addition to web-based decision aid tool access.
89579027|NCT02366767|Experimental|automatic closed-loop insulin delivery|The closed-loop arm will consist of participants wearing a sensor and transmitter which transmits sensor glucose data. The algorithm determines insulin delivery rates and this is delivered in microboluses every 5 minutes
89579028|NCT02366767|Active Comparator|Control|The subjects in the control arm will wear the 530G system using Enlite and MiniLink transmitter and threshold suspend.
89579029|NCT02150343|Experimental|HMD-SPIRE Treatment 1|4 x 12 nmol HDM-SPIRE followed by 4 x placebo 4 weeks apart
89579030|NCT02150343|Experimental|HDM-SPIRE Treatment 2|4 x 12 nmol HDM-SPIRE 4 weeks apart followed by a second course of 4 x 12 nmol HDM-SPIRE 4 weeks apart
89579031|NCT02150343|Experimental|HDM-SPIRE Treatment 3|4 x 20 nmol HDM-SPIRE followed by 4 x placebo 4 weeks apart
89579032|NCT02150343|Placebo Comparator|Placebo|8 x placebo 4 weeks apart
89209394|NCT00256243|Experimental|Chemotherapy with GM-CSF|"Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Carboplatin/Paclitaxel with GM-CSF (day 2-6)~This regimen consists of intravenous administration of doxorubicin (Adriamycin) followed by cyclophosphamide (Cytoxan) every 14 days for a total of four cycles, unless stable disease or clinical progression is documented. Two weeks after completion of the last dose of AC, weekly Carboplatin/paclitaxel will be given for 3 weeks, followed by 1 week of rest, for a total of 12. Each clinic visit will last approximately 1 hour.~Patients who are her-2 overexpressors by FISH will also receive Trastuzumab with weekly carboplatin and paclitaxel as the combination has been found to be synergistic in advanced breast cancer with improved clinical outcome."
89579033|NCT02149875|Experimental|Dl-3-n-butylphthalide|Intravenous infusion of 25mg dl-3-n-butylphthalide b.i.d.for 10 days
89579034|NCT02149875|Experimental|Cerebrolysin|Intravenous infusion of 30 ml cerebrolysin q.d. for 10 days
89579035|NCT02149875|Placebo Comparator|Placebo|Intravenous infusion of 100 ml saline intravenous q.d. for 10 days
89579036|NCT05096507||Study group|People age 65 years and older undergoing primary hip fracture surgery
89029496|NCT01316393|Experimental|XER2020|mucoprotective product
89029497|NCT01316393|Active Comparator|Saliva Natura|salivary substitute
89579037|NCT05125367||multivessel coronary artery disease|From BEST trial study population_NCT00997828
89579038|NCT05124899|Experimental|CAP UnScented|Single topical application: 80 +/- 2 milligrams (mg) (2.0 +/- 0.05 mg per square centimeter [mg/cm^2]) of CAP UnScented will be applied to the assigned test site using a fingercot. Test material will be evenly spread over the test site using light pressure for 35 +/- 15 seconds.
89579039|NCT05124899|Experimental|CAP Herbal Mint Flavour|Single topical application: 80 +/- 2 mg (2.0 +/- 0.05 mg/cm^2) of CAP Herbal Mint Flavour will be applied to the assigned test site using a fingercot. Test material will be evenly spread over the test site using light pressure for 35 +/- 15 seconds.
89579040|NCT05124899|Experimental|CAP Mountain Berry Flavour|Single topical application: 80 +/- 2 mg (2.0 +/- 0.05 mg/cm^2) of CAP Mountain Berry Flavour will be applied to the assigned test site using a fingercot. Test material will be evenly spread over the test site using light pressure for 35 +/- 15 seconds.
89579041|NCT05124899|Active Comparator|SPF Standard|Single topical application: 80 +/- 2 mg (2.0 +/- 0.05 mg/cm^2) of SPF Standard will be applied to the assigned test site using a fingercot. Test material will be evenly spread over the test site using light pressure for 35 +/- 15 seconds.
89029498|NCT01316393|Placebo Comparator|XER2020 placebo|
89029499|NCT00508560|Experimental|Arm 1|Experimental
89579042|NCT05122013|Other|intervention group|The comprehensive 3-month remote intervention program by the multidisciplinary study team includes 6-weeks of online meetings with the study registered dietitian, sleep and physical activity consultants, followed by another 6-weeks of online meetings with the study's registered dietitian, overall 12 weeks containing a total of 12 remote consultations (6 dietitian, 3 physical activity consultant, 3 sleep consultant). In addition, the intervention group will receive weekly text messages to their mobile phone, meant to enhance happiness and subjective wellbeing.
89579043|NCT05122013|Other|control group|The control group will receive standard nutrition care: A one-time meeting with the study's registered dietitian at the clinic, focusing on nutrition and behavioral recommendations, followed by the standard recommendation to continue follow up, engage in physical activity and general lifestyle recommendations.
89579044|NCT02112045|Experimental|Experimental: Granix and high dose melphalan (HDM)|"Granix on Day -7 through Day -2.~HDM intravenously (IV) on Day -2.~Autologous stem cell transplantation on Day 0"
89579045|NCT02112045|Active Comparator|Control: High dose melphalan (HDM)|"HDM intravenously (IV) on Day -2.~Autologous stem cell transplantation on Day 0."
89579046|NCT01629693|Experimental|Air Optix|Lotrafilcon B contact lenses worn bilaterally (in both eyes) for at least 4 hours a day, 5 days a week, for 4 weeks, on a daily wear basis (removed nightly for cleaning and disinfection).
89579047|NCT01629693|Active Comparator|Biofinity|Comfilcon A contact lenses worn bilaterally (in both eyes) for at least 4 hours a day, 5 days a week, for 4 weeks, on a daily wear basis (removed nightly for cleaning and disinfection).
89579048|NCT02147691|Experimental|Azelaic acid 15%, Brimonidine 0.33 % Gel|"Azelaic acid 15% to the face each AM followed 30 minutes later by Brimonidine 0.33%~Azelaic acid 15% to the face each PM"
89579049|NCT02147691|Active Comparator|Brimonidine 0.33% Gel|Brimonidine 0.33% Gel
89579050|NCT02111811|Experimental|Be Well At Work intervention + IC|CBT based intervention focused on work productivity plus integrated care as usual
89579051|NCT02111811|No Intervention|Integrated Care Only|usual care group (Behavioral Health lab care at the PVAMC)
89579052|NCT01655693|Experimental|Doxorubicin Transdrug (DT) at 20 mg/m2|DT will be infused over 6 hours through the intravenous (IV) route at dose of 20 mg/m2 on Day 1 and will be repeated every 4 weeks until disease progression or unacceptable toxicity
89579053|NCT01655693|Experimental|Doxorubicin Transdrug (DT) at 30 mg/m2|DT will be infused over 6 hours through the IV route at dose of 30 mg/m2 on Day 1 and will be repeated every 4 weeks until disease progression or unacceptable toxicity
89579054|NCT01655693|Active Comparator|Best Standard of Care|Patients randomized in the control group will receive treatment according to the investigator's choice, until disease progression or unacceptable toxicity
89579055|NCT05090657|Other|Open label presurgical nasal decolonization|All patients presenting for surgery will be offered nasal decolonization with the combination product. After informed consent a nasal culture will be obtained followed by a 4-minute nasal decolonization treatment and a post-treatment culture. The intervention consists of swabbing the nose with a methylene blue/chlorhexidine gluconate solution followed by non-thermal nasal illumination with red light. There will only be a single treatment.
89579056|NCT05120765|Experimental|Intervention|"Intervention to be administered is The CONNECT Program. This is a 6-week, group-based, telephone-based, mental health intervention for socially isolated older adults. This group-therapy intervention is based on principles of Acceptance and Commitment Therapy (ACT)."
89579057|NCT05120765|No Intervention|Waitlist|Waitlist intervention requires participants to wait 6 weeks. This waitlist group will receive the intervention after this 6 week waiting period, due to the exploratory nature of this Pilot Randomized Controlled Trial (RCT).
89579058|NCT05089019|Experimental|Selpercatinib (Test)|Selpercatinib given orally on days 1 and 15.
89579059|NCT05089019|Active Comparator|Selpercatinib (Reference)|Selpercatinib given orally on days 1 and 15.
89579060|NCT04226339|Experimental|total knee arthroplasty with a kinetic alignment|
89579061|NCT04226339|Active Comparator|total knee arthroplasty with a mechanical alignment|
89579062|NCT05048849|Experimental|MVC-COV1901(S protein with adjuvant)|S-2P protein with CpG and Aluminum Hydroxide/0.5mL
89579063|NCT01655381|Experimental|Tocilizumab|Tocilizumab 8 milligrams per kilogram (mg/kg) administered intravenously once every 4 weeks during a minimum of 104 weeks.
88972829|NCT01805570|Active Comparator|Ticagrelor loading dose|25 patients with STEMI undergoing PPCI with bivalirudin (GP IIb/IIIa not allowed) will be randomized to receive Ticagrelor before PPCI.
89579064|NCT05117333|Active Comparator|Basic letter|This reminder states that if healthcare is not consumed at the right time, health may deteriorate and diagnoses and treatment may be delayed.
89579065|NCT05117333|Active Comparator|Co-pay|This reminder states that if healthcare is not consumed at the right time, health may deteriorate and diagnoses and treatment may be delayed AND informs recipients about a new law that abolished all co-payments for all primary care nurse visits in Finland.
89579066|NCT05117333|Active Comparator|GP-Co-pay|This reminder states that if healthcare is not consumed at the right time, health may deteriorate and diagnoses and treatment may be delayed AND informs recipients about a new law that abolished all co-payments for all primary care nurse visits in Finland, AND informs recipients that the new law did not abolish co-payments related to general practitioner visits.
89579067|NCT05117333|No Intervention|Control treatment|There is no intervention in the control treatment. The entire population aged 55 and above in the treatment regions will serve as a control group.
89579068|NCT05048537|Other|18F-FACBC PET/CT and the PSA kinetics for PCa patients with BCR.|
88972830|NCT01805531||Rivaroxaban|
88972831|NCT01805492|Experimental|Intervention|Dr. Dean Ornish Program for Reversing Heart Disease
88972832|NCT01805492|No Intervention|Control|Non-intervention controls retrospectively matched to intervention participants
88972833|NCT04732611|Experimental|Pilates|Pilates group participants will perform 3 weekly Pilates sessions lasting approximately 50 minutes for 20 weeks.
88972834|NCT04732611|Active Comparator|Walking|Walking group participants will perform 3 weekly walking sessions lasting approximately 50 minutes for 20 weeks
88972835|NCT01805453|Active Comparator|Arm A: Losartan|Arm A: Standard of care (Radiotherapy with concomitant temozolomide followed by monthly cures of temozolomide ) + Losartan 50mg*2/day until the halting for any reason
89579069|NCT01656161|Experimental|Triptorelin embonate 22.5 mg|Participants received subcutaneous injections of triptorelin embonate 22.5 mg 6-month formulation administered on Day 1 and on Day 169.
89579070|NCT05081141||SOT Donors|Solid organ transplantation donors
89579071|NCT05081141||LuTx candidates and recipients|Lung transplant candidates and recipients
89579072|NCT05081141||LTx candidates and recipients|Liver transplant candidates and recipients
89579073|NCT05081141||KTx candidates and recipients|Kidney transplant candidates and recipients
89579074|NCT05114993|Experimental|Effects of donning a disposable surgical mask|"Participants will be observed and monitored without wearing a mask for a 5-minute control period. Measurements will include End Tidal CO2, Inspired CO2, Pulse Oximetry, Respiratory Rate, and Heart Rate each minute without a mask x 5 minutes.~After 5 minutes, all study subjects will don the same model of disposable surgical mask. The same measurements will be taken, including End Tidal CO2, Inspired CO2, Pulse Oximetry, Respiratory Rate, and Heart Rate each minute with a mask x 15 minutes."
89579075|NCT05080283|Experimental|CP1110 Sound Processor System with ForwardFocus On (SCAN)|
89579076|NCT05080283|Experimental|CP1110 Sound Processor System with ForwardFocus Off (SCAN)|
89579077|NCT05080283|Active Comparator|Nucleus 7 Sound Processor (model: CP1000) system|
89579078|NCT04422041|Active Comparator|Early discharge|Discharge between 24 and 48 hours
89579079|NCT04422041|Experimental|Very early discharge|Discharge in less than 24 hours
88972836|NCT01805453|Placebo Comparator|Arm B: Placebo|Arm B: Standard of care (Radiotherapy with concomitant temozolomide followed by monthly cures of temozolomide + Placebo 2/day until the halting for any reason
88972837|NCT01788917|Experimental|Vegetarians|Dietary supplement: 10 mL linseed oil per day
88972838|NCT01788917|Placebo Comparator|Omnivores|Dietary supplement: 10 mL linseed oil per day
88972839|NCT01466543|Active Comparator|Zydena (Udenafil)|Zydena (Udenafil) 100 mg, once
88972840|NCT01466543|Placebo Comparator|Placebo|placebo medication
88972841|NCT02971332||Treatment Group|Patients candidated to STARR after the failure of medical and dietary therapy and after a complete radiological and functional study.
88972842|NCT01466465|Experimental|Vigantol|
88972843|NCT01466465|Placebo Comparator|neutral oil (vigantol carrier)|
88972844|NCT01466426||DVT confirmed|
88972845|NCT01466426||DVT ruled out|
88972846|NCT01466426||PE confirmed|
89579080|NCT05045027|Experimental|Basic science (MRI, metabolic imaging, tissue collection)|"AIM 1: Previous scan data from healthy subjects is collected and analyzed.~AIM 2: Patients undergo MRI. Patients also undergo collection of tissue samples for IHC analysis.~AIM 3: Patients undergo multinuclear metabolic imaging before and after immunotherapy and prior to surgical resection."
89579081|NCT05043857|Experimental|Adjuvant Stereotactic Pancreatic Radiotherapy|"Postoperative Stereotactic Body Radiation Therapy (SBRT) after pancreatic tumor resection.~Stereotactic Body Radiotherapy (SBRT) is a novel radiotherapy technique consisting of highly focused irradiation with a steep dose gradient, thus allowing the delivery of ablative radiation doses and significant sparing of proximity critical structures. Higher doses per fraction allows for more intensive treatments and shorter duration of the radiation course."
89579082|NCT04421807|Experimental|Exercise+Complex decongestive therapy (CDT) group|The patients diagnosed with lymphedema with 18-65years of age followed by routine controls and who were volunteered will be included in the study
89579083|NCT04421807|Active Comparator|Only Complex decongestive therapy (CDT) group|The patients diagnosed with lymphedema with 18-65years of age followed by routine controls and who were volunteered will be included in the study
89579084|NCT02111577|Experimental|DCVAC/PCa with standard of care chemotherapy|Combination therapy with DCVAC/PCa and standard of care chemotherapy (docetaxel and prednisone)
89579085|NCT02111577|Placebo Comparator|Placebo with standard of care chemotherapy|Combination therapy with placebo and standard of care chemotherapy (docetaxel and prednisone) as comparator
89579086|NCT05216445|Experimental|Mindfulness Training|The participants in this group will receive the training for 8 weeks, with 60 minute online weekly sessions. The first session will be for 90 minutes.
89579087|NCT05216445|No Intervention|Wait-list Control|The wait-list control group will not receive any intervention. Once the study has been completed they will be offered the Mindfulness Training course.
89579088|NCT04751877|Experimental|Isatuximab/Lenalidomide/Dexamethasone/Bortezomib|
89579089|NCT04751877|Active Comparator|Isatuximab/Lenalidomide/Dexamethasone|
89579090|NCT02170779|Experimental|A Spasticity: Take Control|4 visits: baseline, view and discuss DVDs, practice stretching, outcome measures
89579091|NCT02170779|Other|B Usual care|2 visits: baseline and given usual treatment of brochure for stretching, outcome measures
89579092|NCT04751799|No Intervention|Control Group (no VR)|Patients undergoing colposcopy and colposcopically-guided biopsy without further intervention
89579093|NCT04751799|Experimental|VR before and during colposcopy|Patients undergoing colposcopy and colposcopically-guided biopsy with a VR headset for 15 minutes before colposcopy as well as during colposcopy.
89579094|NCT04751799|Experimental|VR before colposcopy|Patients undergoing colposcopy and colposcopically-guided biopsy with a VR headset for 15 minutes before colposcopy but not during colposcopy.
89579095|NCT02147067|Experimental|Ranolazine|Ranolazine 1,000 mg twice daily
89579096|NCT02147067|Placebo Comparator|Placebo|Placebo twice daily
88972847|NCT01466426||PE ruled out|
88972848|NCT01466309|Experimental|treatment|patients treated with Somnoguard
88972849|NCT01466231|Experimental|everolimus 10 mg po daily|everolimus 10 mg po daily
88972850|NCT01466114|Experimental|Group A: Estriol|Standard MS Treatment + Estriol
88972851|NCT01466114|Placebo Comparator|Group B: Placebo|Standard MS Treatment + Placebo
88972852|NCT00036777|Experimental|Treatment (carboplatin, 7-hydroxystaurosporine)|"Patients receive carboplatin IV over 1 hour followed by UCN-01 IV over 3 hours on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of carboplatin and UCN-01 until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
89579097|NCT02170389|Experimental|Treatment (AGS-003 immunotherapy, nephrectomy)|Patients receive 3 injections of renal cell carcinoma/cluster of CD40L RNA-transfected autologous dendritic cell vaccine AGS-003 ID once every 7 days during weeks 6-8 in the absence of disease progression or unacceptable toxicity. Patients then undergo partial or radical nephrectomy on week 10.
89579098|NCT02146599||Pseudophakic|
89579099|NCT02146365||PATH-wSP 300 µg + Booster|Toddlers who enrolled in Cohort 1 of Study VAC-010 and received 300 µg PATH-wSP plus the two booster vaccines (Synflorix and Pentavac) followed by a 2nd injection of 300 µg PATH-wSP 8 weeks later.
89579100|NCT02146365||PATH-wSP 300 µg Only|Toddlers who enrolled in Cohort 1 of Study VAC-010 and received 300 µg PATH-wSP and 2 saline injections followed by a 2nd injection of 300 µg PATH-wSP 8 weeks later.
89579101|NCT02146365||PATH-wSP 600 µg + Booster|Toddlers who enrolled in Cohort 2 of Study VAC-010 and received 600 µg PATH-wSP plus the two booster vaccines (Synflorix and Pentavac) followed by a 2nd injection of 600 µg PATH-wSP 8 weeks later.
89579102|NCT02146365||PATH-wSP 600 µg Only|Toddlers who enrolled in Cohort 2 of Study VAC-010 and received 600 µg PATH-wSP and 2 saline injections followed by a 2nd injection of 600 µg PATH-wSP 8 weeks later.
89579103|NCT02146365||Booster Only (300 µg)|Toddlers who enrolled in Cohort 1 of Study VAC-010 and received one saline injection and the two booster vaccines (Synflorix and Pentavac) followed by a 2nd saline injection 8 weeks later.
89579104|NCT02146365||Booster Only (600 µg)|Toddlers who enrolled in Cohort 2 of Study VAC-010 and received one saline injection and the two booster vaccines (Synflorix and Pentavac) followed by a 2nd saline injection 8 weeks later.
88972853|NCT01466075|Experimental|Intended Users of the Monitoring System|Untrained subjects with diabetes use the Apollo Evolution Investigational BG Monitoring System.
88972854|NCT02971059|Experimental|Adult Males >65 years|Participants will be seen initially for pre-study assessment (3 hour). They will then be studied weekly for up to 7 levels of phenylalanine intake (7 Study periods). Each study period will include a period of 3 days. The first 2 days they will consume a liquid milkshake based diet at home. On the 3rd day they will come to the hospital for a total of 8 hours.
89579105|NCT02146365||No Intervention (300 µg)|Toddlers who enrolled during Cohort 1 who did not participate in Study VAC-010 and did not receive either PATH-wSP or either of the booster vaccines (Pentavac or Synflorix).
89579106|NCT02146365||No Intervention (600 µg)|Toddlers who enrolled during Cohort 2 who did not participate in Study VAC-010 and did not receive either PATH-wSP or either of the booster vaccines (Pentavac or Synflorix).
89579107|NCT02146131|Active Comparator|Standard FB with fluoroscopy|Administration of moderate or deep sedation, introduction of standard adult bronchoscope into the airway. Following application of topical anesthesia on vocal cord, trachea, bronchoscope is advanced distally under direct visualization. Localization of the lesion using fluoroscopy followed by the acquisition of pathologic and cytologic specimens using standard bronchial brush and standard transbronchial biopsy forceps. Evaluation of acquired samples for pathology. Performance of a portable chest X-ray to look for pneumothorax (PTX).
89579108|NCT02146131|Active Comparator|R-EBUS with ultrathin bronchoscope|"Administration of moderate or deep sedation, introduction of ultrathin bronchoscope into the airway. Following application of topical anesthesia on vocal cord, trachea, bronchoscope is advanced distally under direct visualization. Attempt to definitively locate the lesion with mechanical R-EBUS probe.~Acquisition of pathologic and cytologic specimens using standard bronchial brush and standard transbronchial biopsy forceps. Performance of a portable chest X-ray to look for PTX."
89579109|NCT02107131|Active Comparator|Monthly Intravitreal ranibizumab 0.3mg|Monthly Intravitreal ranibizumab 0.3mg injections.
89579110|NCT02107131|Active Comparator|PRN Intravitreal ranibizumab 0.3mg|PRN Intravitreal ranibizumab 0.3mg injections.
89579111|NCT02106975|Active Comparator|Ascorbic Acid|200mg/kg/day divided over 4 doses. Administered every 6 hours for 96 hours
89579112|NCT02106975|Placebo Comparator|5% Dextrose in Water|50ml every 6 hours for 96 hours
89579113|NCT02145429|Experimental|problem solving therapy + Behavioral Treatment of Insomnia|Problem Solving Therapy + Brief Behavioral Treatment of Insomnia as needed
89579114|NCT02145429|No Intervention|Enhanced Usual Care|Care as usual with scheduled assessments of clinical status
89579115|NCT05133765|Experimental|SMART B1 - Usual care insulin pump|Usual care pump therapy arm with carbohydrate consumption before exercise
89579116|NCT05133765|Experimental|SMART B2 - Advanced hybrid closed loop insulin pump with carbohydrates before exercise|Advanced hybrid closed loop therapy arm with carbohydrate consumption before exercise
89579117|NCT05133765|Experimental|SMART B3 - Advanced hybrid closed loop insulin pump with carbohydrates during exercise|Advanced hybrid closed loop therapy arm with carbohydrate consumption during exercise
89579118|NCT02144337|Experimental|Intervention group|Steps To Active Kids (STAK) programme (6 weeks) includes: StreetDance DVD designed to be completed at home (4 weeks in total). A dance routine is taught over 4 weeks with new elements introduced each day. Activity diary aims to encourage children to record daily activities in a logbook and to educate children about physical activity. Step counter: Children are given a pedometer and encouraged to record steps in the activity diary and to set personal goals to increase their steps. Weekly group activity sessions for 4 - 6 weeks. Involve a circuit of activity stations varying in intensity. The group sessions are designed to be fun and non-competitive. Children can record their scores at each station and monitor their own progress.
89579119|NCT02144337|No Intervention|Control group|Control group. Children in the Control group are asked to continue normal daily activities.
89579120|NCT04417881||patients with acurate heart failure|
89029500|NCT00508560|Active Comparator|Arm 2|Active Comparator
89579121|NCT02520011|Experimental|ACM (Stage 1 / Stage 2)|A: alvocidib, 30 mg/m2 as a 30 minute intravenous (IV) bolus followed by 60 mg/m2 over 4 hours as an IV infusion administered daily on Days 1-3; C: cytarabine (ara-c), 2 gm/m2 by continuous IV infusion over 72 hours on Days 6-8; M: mitoxantrone (mitoxantrone hydrochloride), 40 mg/m2 by IV infusion over 1-2 hours starting 12 hours after completing cytarabine
89579122|NCT02520011|Active Comparator|CM (Stage 2)|C: cytarabine (ara-c), 2 gm/m2 by continuous IV infusion over 72 hours on Days 1-3; M: mitoxantrone (mitoxantrone hydrochloride), 40 mg/m2 by IV infusion over 1-2 hours starting 12 hours after completing cytarabine
89579123|NCT05110625|Experimental|Intervention A|Participants will receive Messaging Intervention
89579124|NCT05110625|Experimental|Intervention B|Participants will receive messaging intervention plus online education to their primary healthcare workers
89579125|NCT05110625|No Intervention|Control|Participants will receive usual care only, and their healthcare workers will not receive online education
89579126|NCT04224233|Experimental|Home-based physical activity group|The experimental group will receive the iLiFE.
89579127|NCT04224233|Active Comparator|Control group|The control group will receive a leaflet with exercises and PA recommendations.
89579128|NCT04222829||Megadose Shinbaro Pharmacopuncture Group|"The Megadose Shinbaro Pharmacopuncture group who are treated with korean medical treatment including Megadose Shinbaro Pharmacopuncture will be evaluated on first, second, third visit and 2weeks after baseline. And the patients will receive telephone inquires after 3months from the baseline.~The Korean medical treatment includes acupuncture, chuna and Korean herbal medicine."
89579129|NCT04222829||Control Group|"The control group who are treated with Korean medical treatment not including Megadose Shinbaro Pharmacopuncture will be evaluated on first, second, third visit and 2weeks after baseline. And the patients will receive telephone inquires after 3months from the baseline.~The Korean medical treatment includes acupuncture, chuna and Korean herbal medicine."
89579130|NCT05037539|Experimental|Injectable Fentanyl in Sublingual Route|Injectable Fentanyl in Sublingual Route that given after the first time Breakthrough Pain is occurred 50 mcg in sublingual route
89579131|NCT05037539|Active Comparator|Oral Morphine Syrup|Oral Morphine Syrup 2.5 ml ( 5 mg) in oral router that first time given after Breakthrough Pain is occurred
89579132|NCT02519231|Active Comparator|Treatment|This study arm includes naproxen as potential treatment for heavy or prolonged bleeding or dysmenorrhea may provide useful preliminary data for a larger, adequately powered placebo-controlled comparative trial testing additional promising treatments, such as tranexamic acid.
89029501|NCT01247831|Other|glaucoma patients|All of the patients treated with SLT need further IOP reduction for control of their glaucoma.
89579133|NCT02519231|Placebo Comparator|placebo|This study arm includes capsules that are exactly like the active treatment medication (naproxen), but there is no active treatment medication in these tablets.
89579134|NCT02106351|Experimental|Group A|Group A - Treatments 1, 2, 3 and 4: Dysport 16 Units (U)/kg in one upper extremity (the study limb).
89579135|NCT02106351|Experimental|Group B|Group B - Treatments 1, 2, 3 and 4: Dysport 8 U/kg in one upper extremity (the study limb).
89579136|NCT02106351|Experimental|Group C|"Group C - Treatment 1: Dysport 2 U/kg in one upper extremity (the study limb).~Group C - Treatments 2, 3 and 4: Dysport 8 or 16 U/kg in one upper extremity (the study limb)."
89579137|NCT04998539|Experimental|Upright wheelchair forward and occupant upright|Participant will push an upright wheelchair forward over a 5 m soft surface with the wheelchair occupant in the upright body position. The participant will perform the task once.
89579138|NCT04998539|Experimental|Upright wheelchair backward and occupant upright|Participant will pull an upright wheelchair backwards over a 5 m soft surface with the wheelchair occupant in the upright body position. The participant will perform the task once.
89579139|NCT04998539|Experimental|Wheelie wheelchair forward and occupant upright|Participant will push a wheelchair using the wheelie technique forward over a 5 m soft surface with the wheelchair occupant in the upright body position.The participant will perform the task once.
89579140|NCT04998539|Experimental|Wheelie wheelchair backward and occupant upright|Participant will pull a wheelchair using the wheelie technique backwards over a 5 m soft surface with the wheelchair occupant in the upright body position.The participant will perform the task once.
89579141|NCT05036603|No Intervention|1/routin medical care and neonatal intensive care unit's daily care|Group 1 (n=20) routine medical treatment for newborns on mechanical ventilator respiratory support and CPAP; Appropriate antibiotics given according to the needs of the baby, enteral-parenteral nutrition, oral or nebulizer drugs for softening the secretion, vitamin supplements and routine nursing care will be provided.
89579142|NCT05036603|Experimental|2/active chest physiotherapy in modified drainage positions|Group 2 (n=20) newborns on mechanical ventilator respiratory support and CPAP; A single session of active chest physiotherapy (CP) will be applied using modified drainage positions (avoiding the trendelenburg position, excessive position change and avoiding hand contact in babies younger than 30 weeks or who are sensitive to position change). Active CP in various modified drainage positions; It will consist of percussion and vibration methods with proprioceptive replacement stimulations. After these methods, aspiration will be performed and a suitable position will be given to the lobe that is desired to be ventilated. In addition, these patients will be given routine medical treatment consisting of appropriate antibiotics, enteral-parenteral nutrition, oral or nebulizer drugs for softening the secretion, vitamin supplements and routine nursing care.
89029502|NCT00507975|Placebo Comparator|A|The main aim of this study is to assess the effectiveness of nicotine patch comparatively to a placebo patch in pregnant women on birth weight and maternal smoking abstinence. The main secondary objective is the assessment of safety of these treatments for the fetus/newborn and for the mother.
89579143|NCT05036603|Experimental|3/active chest physiotherapy in prone positions|Group 3 (n=20) newborns on mechanical ventilator respiratory support and CPAP; a single session of active chest physiotherapy treatment to be applied only in the prone position; Starting with proprioceptive stimulation, percussion and vibration methods will be applied. After these methods, aspiration will be performed and a suitable position will be given to the lobe that is desired to be ventilated. In addition, these patients will be given routine medical treatment consisting of appropriate antibiotics, enteral-parenteral nutrition, oral or nebulizer drugs for softening the secretion, vitamin supplements and routine nursing care.
89579144|NCT02143947|Experimental|Full Contact Orthosis|Full Contact Orthosis
89579145|NCT02143947|Experimental|Maximal Arch Subtalar Stabilization|Maximal Arch Subtalar Stabilization Orthoses
89579146|NCT02075073|Experimental|SB3|SB3, single dose of 6 mg/kg via intravenous infusion (study drug)
89579147|NCT02075073|Active Comparator|EU sourced Herceptin®|EU sourced Herceptin®, single dose of 6 mg/kg via intravenous infusion (reference drug)
89579148|NCT02075073|Active Comparator|US sourced Herceptin®|US sourced Herceptin®, single dose of 6 mg/kg via intravenous infusion (reference drug)
89579149|NCT02074059|Experimental|Aerosolized lucinactant (25 mg/kg)|25 mg total phospholipids (TPL)/kg: Lucinactant for inhalation with nCPAP
89579150|NCT02074059|Experimental|Aerosolized lucinactant (50 mg/kg)|50 mg TPL/kg: Lucinactant for inhalation with nCPAP
89579151|NCT02074059|Experimental|Aerosolized lucinactant (75 mg/kg)|75 mg TPL/kg: Lucinactant for inhalation with nCPAP
89579152|NCT02074059|Experimental|Aerosolized lucinactant (100 mg/kg)|100 mg TPL/kg: Lucinactant for inhalation with nCPAP; repeat dosing possible if criteria met.
88972855|NCT02971059|Experimental|Adult Females >65 years|Participants will be seen initially for pre-study assessment (3 hour). They will then be studied weekly for up to 7 levels of phenylalanine intake (7 Study periods). Each study period will include a period of 3 days. The first 2 days they will consume a liquid milkshake based diet at home. On the 3rd day they will come to the hospital for a total of 8 hours.
89579153|NCT02074059|Experimental|Aerosolized lucinactant (150 mg/kg)|150 mg TPL/kg: Lucinactant for inhalation with nCPAP; repeat dosing possible if criteria met.
89579154|NCT02074059|Active Comparator|nCPAP alone|nCPAP therapy alone
89579155|NCT02143713|Experimental|Elagolix 150 mg QD|Participants received elagolix 150 mg tablets once a day (QD) for 6 months.
89579156|NCT02143713|Experimental|Elagolix 200 mg BID|Participants received elagolix 200 mg tablets twice a day (BID) for 6 months.
89579157|NCT04738149|Experimental|Area 1: Excimer laser, bimatoprost, and microneedling|
89579158|NCT04738149|Active Comparator|Area 2: Excimer laser|
89579159|NCT02519855|Experimental|Concomitant Vaccination|ZOSTAVAX™ concomitantly with influenza vaccine on Day 1, placebo to ZOSTAVAX™ at Week 4
89579160|NCT02519855|Experimental|Nonconcomitant Vaccination|Influenza vaccine and placebo to ZOSTAVAX™ on Day 1, ZOSTAVAX™ at Week 4
89579161|NCT02142387|Active Comparator|New DA-BLS training program|A one-hour training course that includes a 30-minute video-based self-instruction (VSI) training session, a short role-play, and a debriefing. The video consists of a bystander CPR simulation with dispatcher instructions using the trainee's own phone and practice session following demonstration by a simulated layperson. After watching the video clip, all trainees are divided into two groups and conduct a role-play as dispatchers and laypersons for 15 minutes. Finally, there is a 15-minute debriefing session with several assignments. The HEROS program focuses on cooperation with a dispatcher, from recognition of cardiac arrest to performing DA-CPR, with hands-on practice so that laypersons can provide bystander CPR immediately in a real situation. Moreover, the HEROS program emphasizes practice for providing the correct address of the scene and switching to speakerphone mode, especially for the elderly.
89579162|NCT02142387|No Intervention|Current Basic Life Support (BLS) training program|A one-hour training program that was developed by the Korea Center for Disease Control and Prevention (CDC) and it was based on the American Heart Association (AHA) guideline (http://www.cdc.go.kr/board.es?mid=a20503050000&bid=0021&tag=&act=view&list_no=127655). The program consists of a 30-minute VSI, and a 30-minute practice debriefing session. It focuses on detailed techniques for performing high-quality chest compressions including the correct hands and body position of the bystanders.
89579163|NCT05070455|Experimental|Asceniv|Asceniv™ will be given as an intravenous infusion at the same dose, or higher dose where medically appropriate, as the subject's previous IV Immunoglobulin G treatment (300-800 mg/kg) every 21 or 28 days.
89579164|NCT05034575|Experimental|Novice and experienced medical personnel|Participants will be asked to complete two tasks each taking approximately 10 minutes while wearing eye-tracking technology to understand focus of gaze during laryngeal endoscopy and stroboscopy interpretation.
89579165|NCT05069987|Experimental|VR-immersion|
89579166|NCT05069987|No Intervention|Non-VR control|
89579167|NCT05069207||Monosymptomatic Enuresis|Quality of Life Scale in Children with Urinary Incontinence (PIN-Q) Voiding Disorders Symptom Score (IBSS) Dynamic Neuromuscular Stabilization (DNS) Maximum inspiratory pressure (MIP) and volume (Volume (V)) parameters will be evaluated with the POWER breathe K5 to evaluate
88972856|NCT01465919|Experimental|mirtazapine|mirtazapine
88972857|NCT01465919|Other|Supportive psychotherapy|Supportive psychotherapy will be given by a specialized psychiatrist.
88972858|NCT01465880|No Intervention|Part B. Healthy Caucasian adult non-smokers|Non-smokers
88972859|NCT01465880|Experimental|Part A.Healthy Caucasian adult smokers|No product will be investigated in this study. Smokers will smoke their own conventional cigarettes only.
88972860|NCT00036855|Experimental|Group A (no planned PBSC support)|"Patients receive rituximab IV over 4-6 hours followed by IDEC-In2B8 IV over 10 minutes on day 0 and undergo whole body imaging. Patients may then receive rituximab IV over 4-6 hours followed by IDEC-Y2B8 IV over 10 minutes on day 7.~Some patients receive autologous PBSC IV over 30-60 minutes on day 35."
89579168|NCT05069207||Non-monosymptomatic Enuresis|Quality of Life Scale in Children with Urinary Incontinence (PIN-Q) Voiding Disorders Symptom Score (IBSS) Dynamic Neuromuscular Stabilization (DNS) Maximum inspiratory pressure (MIP) and volume (Volume (V)) parameters will be evaluated with the POWER breathe K5 to evaluate
89579169|NCT05069207||Daytime Urinary Incontinence|Quality of Life Scale in Children with Urinary Incontinence (PIN-Q) Voiding Disorders Symptom Score (IBSS) Dynamic Neuromuscular Stabilization (DNS) Maximum inspiratory pressure (MIP) and volume (Volume (V)) parameters will be evaluated with the POWER breathe K5 to evaluate
89579170|NCT05069207||Control Group Healthy Individuals|Quality of Life Scale in Children with Urinary Incontinence (PIN-Q) Voiding Disorders Symptom Score (IBSS) Dynamic Neuromuscular Stabilization (DNS) Maximum inspiratory pressure (MIP) and volume (Volume (V)) parameters will be evaluated with the POWER breathe K5 to evaluate
89579171|NCT05068817|Experimental|Pilates mat exercises|one hour Pilates exercises with 10 min warm up and 5-10 min cooling down
89209395|NCT04037202|Experimental|Study Group|"The first session of the foot massage was performed after mothers were taken to the postpartum service and after the effect of the first analgesia had elapsed (4-6 hours after birth).~The researcher prepared the mother for foot massage (foot care, proper position, etc.) and gave a total of 20-minute massage of foot massage, 10 minutes for each foot. VAS was repeated immediately after the first session (in the 20th minute) and after 30 minutes (in the 50th minute). The second session was performed on the second day, 20-24 hours after the first session (before the discharge). The VAS was analyzed before the second (last) session (0th minute), and the VAS was repeated immediately after the application (20th minute) and 30 minutes (50th minute), and the PCS was administered for the last time. Administered analgesics were recorded in the DFC and the administration made with package leaflet was supported."
89579172|NCT05068817|Experimental|cervical stabilization exercises|training of deep cervical flexor muscles with pressure biofeedback unit
89579173|NCT05068817|Active Comparator|conventional physiotherapy|10 min hot pack on cervical area range of motion exercises and isometric neck exercises as a home program
89579174|NCT04421183||1|preeclampsia
89579175|NCT04421183||4|normal pregnancy without complication
89579176|NCT04421183||2|hellp
89579177|NCT04421183||3|eclampsia
89579178|NCT04219319|Experimental|Experimental: LCAR-T2C CAR-T cells in relapsed or refractory CD4+ T lymphocyte tumor|An open label, multi center, single arm Phase I study to evaluate the safety, tolerability, and efficacy of LCAR-T2C CAR-T cells in relapsed or refractory CD4+ T lymphocyte tumor.
89579179|NCT04996121|Experimental|XZP-5955 tablets|XZP-5955 tablets
89209396|NCT04037202|No Intervention|Control Group|Routine procedures were applied and VAS was repeated at the same time periodical as the study group mothers (0th, 20th and 50th minute) and after 20-24 hours (before discharge), at the same time intervals (0th, 20th and 50th minute) pain status was measured by using VAS and PCS was administered for the last time and analgesics administered were recorded on the DFC.
89579180|NCT02518919|No Intervention|Standard|Patients will receive intravenous ketamine (1-2mg/kg)
89209397|NCT01325857|Experimental|Group B|Group B = Nerve block group
89209398|NCT01325857|Placebo Comparator|Group L|Group L = Local wound infiltration group
89209399|NCT01325857|Active Comparator|Group C|Group C = Control group
89209400|NCT00888888||Cohort: Patients with colonic resections|Colonic resections in patients submitted to appendicectomy for suspected acute appendicitis
89579181|NCT02518919|Experimental|Child Life Intervention|Child life therapist will comfort the child during all painful procedures(including IV insertion) and during sedation
89579182|NCT02518919|Experimental|Music Listening|Patients will listen to music of their choice using headphones during sedation
89579183|NCT04995887||C-Section Delivery with EBL ≥ 1500 mL|Patients with ≥ 1500 mL estimated blood loss (EBL) at time of Jada insertion for cesarean delivery; data collection will continue until a minimum of 100 patients are enrolled in each group/category or until March 31, 2022 (whichever occurs first).
89579184|NCT04995887||C-Section Delivery with EBL < 1500 mL|Patients with < 1500 mL EBL at time of Jada insertion for cesarean delivery; data collection will continue until a minimum of 100 patients are enrolled in each group/category or until March 31, 2022 (whichever occurs first).
89579185|NCT04995887||Vaginal Delivery with EBL ≥ 1000 mL|Patients with ≥ 1000 mL EBL at time of Jada insertion for vaginal delivery; data collection will continue until a minimum of 100 patients are enrolled in each group/category or until March 31, 2022 (whichever occurs first).
89579186|NCT04995887||Vaginal Delivery with EBL < 1000 mL|Patients with < 1000 mL EBL at time of Jada insertion for vaginal delivery; data collection will continue until a minimum of 100 patients are enrolled in each group/category or until March 31, 2022 (whichever occurs first).
89579187|NCT04995731||Women with pre or peri-menopausal abnormal uterine bleeding or post menopausal bleeding|Eligible women presenting to Women's Health hospital with pre or peri-menopausal AUB or PMB will be prospectively enrolled after obtaining their informed consent. AUB will be deﬁned by symptoms of heavy menstrual bleeding, inter-menstrual bleeding, meno-metrorrhagia, irregular menses, or other AUB among women aged ≥40 years who are not in menopause. Peri-menopausal bleeding will be defined as vaginal bleeding after 6 months of menopause after the age of 40 years. Postmenopausal status will be defined as the absence of menstruation for at least 12 months after the age of 40 years, where any pathological condition of amenorrhea is excluded.
89579188|NCT05066321|Experimental|Mindfulness Oriented Recovery Enhancement (MORE) Arm|During hospitalization, participants will receive brief mindfulness training individually in person and complete a series of quantitative baseline questionnaires. Participants will complete 1 MORE session weekly for 8 sessions delivered in small groups of up to 10 people. These sessions will be delivered by a social worker in-person at baseline, and via telehealth after discharge. Follow-up surveys will be conducted at 3-, 6-. 9-, and 12- weeks, and an audio-recorded qualitative exit interview (45-60 minutes) will be completed upon completion of the intervention and the 12-week follow-up survey.
89209401|NCT00236197|Experimental|1|
89579189|NCT05063279|Experimental|Resistance training group|Participants in two age groups will receive moderate (three sets of per exercise per session) and low-volume (one set of resistance per session) training allocated to either right or left upper- and lower extremities. A total of 24 sessions will be performed over 10-12 weeks.
89579190|NCT05063279|No Intervention|Negative control group|A negative control group is included in the study which will not receive any resistance training.
89579191|NCT05060627|Experimental|Belantamab-Mafodotin + Carfilzomib+ dexametasona|"In the phase 1 of the study, aiming to establish the recommended phase 2 dose (RP2D), patients will be included following the classic 3 + 3 design.~Once the DLT assessment period is completed and the MTD is defined, the recruitment will continue in the expansion phase 2.~Combination treatment will be administered at the recommended Phase 2 dose (RP2D) based on the results of the phase 1 dose escalation part of the study:~Belantamab mafodotin on day 1 at the RP2D, every 8 weeks, intravenously (IV).~Carfilzomib will be given at the RP2D weekly IV on days: 1, 8, and 15 of every 4-week cycle (Q4W).~Dexamethasone will be given at the dose of 40 mg (or 20 mg if patient > 75 years old) on days: 1, 8, 15 and 22 Q4W.~From month 13 onwards carfilzomib treatment will be given on day 1 and 15 of every 4-weeks cycles. Belantamab will be given at the RP2D every 8 weeks and Dexamethasone 40mg on days 1, 8, and 15 of every 4-week cycle."
89579192|NCT04421105|Experimental|Group 1 N=12|6 doses at 4-day intervals for 21 days (on Study Days 1, 5, 9, 13, 17, and 21). A follow-up visit was conducted approximately 4 weeks after the last dose.
89579193|NCT04421105|Experimental|Group 2 N=12|6 doses at 4-day intervals for 21 days (on Study Days 1, 5, 9, 13, 17, and 21). A follow-up visit was conducted approximately 4 weeks after the last dose.
89579194|NCT04421105|Experimental|Group 3 N=12|6 doses at 4-day intervals for 21 days (on Study Days 1, 5, 9, 13, 17, and 21). A follow-up visit was conducted approximately 4 weeks after the last dose.
89579195|NCT04421105|Placebo Comparator|Group 4 N=12|6 doses 4-day intervals for 21 days (on Study Days 1, 5, 9, 13, 17, and 21). A follow-up visit was conducted approximately 4 weeks after the last dose.
89579196|NCT02518685|Experimental|TransPyloric Shuttle (TPS)|TransPyloric Shuttle plus Lifestyle Counseling
89579197|NCT02518685|Sham Comparator|Control|Sham procedure plus Lifestyle Counseling
89579198|NCT05058833||Patients with cardiac diastolic dysfunction|Echocardiographic grades of diastolic function was defined according to 2016 ASE/EACVI recommendations for the evaluation of LV diastolic function. Cardiac diastolic dysfunction was defined as elevated E/e'≥15.
89579199|NCT05058833||Patients with coronary microcirculatory dysfunction|Patients with coronary microcirculatory dysfunction was defined as having both depressed CFR (≤2.0) and elevated IMR (≥23U).
88972861|NCT00036855|Experimental|Group B (planned PBSC support)|Patients receive rituximab, IDEC-In2B8, and IDEC-Y2B8 as in group A. Patients also receive autologous PBSC IV over 30-60 minutes on day 21 and G-CSF subcutaneously beginning on day 22 and continuing until blood counts recover or day 35.
88972862|NCT01465841|Experimental|Embolization with the PC 400 coils|
88972863|NCT01465724|Experimental|Renal denervation|
88972864|NCT00036933|Experimental|vaccine|"Patients receive glycosylated MUC-2-Globo H-KLH conjugate vaccine with adjuvant QS21 subcutaneously once weekly on weeks 0-2, 6, 14, and 26 in the absence of unacceptable toxicity. Patients whose antibody titers against Globo-H or MUC-2 antigens fall below 1/40 and who have no disease progression may receive a seventh vaccination after week 50.~Patients are followed every 3 months for 1 year or until biochemical relapse or radiographic disease progression."
88972865|NCT01465685|Experimental|MDMA, methylphenidate, placebo|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but two (actually 4) treatment conditions in the same subject.
88972866|NCT01465646|Active Comparator|with idodine|
88972867|NCT01465646|Experimental|without iodine|
89579200|NCT02520089|Active Comparator|Bone autograft|The investigator it will obtain bone autograft of iliac crest ipsilateral of each patient. And apply into the pseudoarthrosis focus at the moment of the fixation with a locking compression plates.
88972868|NCT01805414|Experimental|Intervention Breakfast|40-45g carbs (300-350 kcal)
88972869|NCT01805414|Active Comparator|Control Breakfast|These patients received the usual hospital breakfast which contained 40-45 g carbs.
88972870|NCT01465607|Experimental|Theory-based counseling (Mujer Segura)|Will consist of 40 FSWs at each of 12 clinics, randomized into this condition from a pool of 80 eligible participants.
88972871|NCT01465607|Active Comparator|CENSIDA counseling program (didactic)|Will consist of 40 FSWs at each of 12 clinics, randomized into this condition from a pool of 80 eligible participants.
88972872|NCT01465568|Active Comparator|Denosumab|denosumab
88972873|NCT01465568|Active Comparator|bisphosphonates|continuation of bisphosphonates
88972874|NCT01465529|Experimental|Active|
88972875|NCT01465529|Placebo Comparator|Placebo|
88972876|NCT02971176|Experimental|Low-dose protocol|Patients undergo low-dose protocol computed tomography-guided lung biopsy on day 1.
88972877|NCT02971176|Active Comparator|Standard-dose protocol|Patients undergo standard-dose protocol computed tomography-guided lung biopsy on day 1.
88972878|NCT01465451|Active Comparator|ARM A- surgery alone|all cases will receive standard surgical procedures of curative resection for colorectal cancer, without intra-operative chemotherapy.
88972879|NCT01465451|Experimental|ARM B surgery plus chemotherapy|all cases will receive standard surgical procedures described as arm A. In addition, all cases will receive 5-FU chemotherapy during operation.
89209402|NCT00236197|Placebo Comparator|2|
89209403|NCT02541708|Experimental|IV ferric carboxymaltose|IV Ferric carboxymaltose is given at a dose calculated according to the severity of anemia and patients weight. The maximal weekly dose is 1000mg. If total dose exceeds 1000mg the dose is split in 1-3 infusions with one infusion per week.
88972880|NCT01465412|Experimental|Mild Hepatic Impaired (HI) Part 1|Participants with mild chronic liver disease enrolled in Part 1 received one 5-mg preladenant tablet, orally, on Day 1.
89579201|NCT02520089|Experimental|platelet rich plasma plus Bone autograft|Other group of patients it will be extracted 40 mL of peripheric blood sample, and processed with a double-centrifugation technique to obtain 5 mL of platelet rich plasma, and collocated into the focus of pseudoarthrosis after standard fixation with locking compression plates and Bone Autograft of Iliac Crest.
89579202|NCT05056883|Experimental|Treatment A|K-237 0.3-0.4mg/kg (once daily)
89579203|NCT05056883|Placebo Comparator|Control A|Placebo (once daily)
89579204|NCT04991597|Experimental|Left Forearm Injection Sites Cooled, Right Forearm Injection Sites at Room Temperature|Palmar aspect of participants left forearm will have a cold compress pack placed on it. The palmar aspect of the right forearm will have a room temperature compress pack placed on it. Each forearm will be injected with 1mL of lidocaine with epinephrine buffered with sodium bicarbonate. Each forearm will be injected once with the experimental ratio (3:1) and once with the standard control ratio (9:1). Injections will be administered in a randomized order.
89579205|NCT04991597|Experimental|Right Forearm Injection Sites Cooled, Left Forearm Injection Sites at Room Temperature|Palmar aspect of participants right forearm will have a cold compress pack placed on it. The palmar aspect of the left forearm will have a room temperature compress pack placed on it. Each forearm will be injected with 1mL of lidocaine with epinephrine buffered with sodium bicarbonate. Each forearm will be injected once with the experimental ratio (3:1) and once with the standard control ratio (9:1). Injections will be administered in a randomized order.
89579206|NCT02105961|Experimental|Arm 1|Each subject will receive 100 mg mepolizumab SC injection every 4 weeks (13 administrations during 52 week treatment period) along with their baseline standard of care COPD medication
89579207|NCT02105961|Experimental|Arm 2|Each subject will receive 300 mg mepolizumab SC injection every 4 weeks (13 administrations during 52 week treatment period) along with their baseline standard of care COPD medication
89579208|NCT02105961|Experimental|Arm 3|Each subject will receive placebo (0.9percent sodium chloride) SC injection every 4 weeks (13 administrations during 52 week treatment period) their baseline standard of care COPD medication
89579209|NCT04950101|Active Comparator|HAS-N|In this arm the patient without HIV using PrEP will be included
89579210|NCT04950101|Active Comparator|HAS-P|In this arm the patient with HIV will be included
89579211|NCT04949867|Active Comparator|Dual-hormone Closed-loop|FiAsp® and GlucaGen®.
89579212|NCT04949867|Placebo Comparator|Single-Hormone Closed-loop|FiAsp® and isotonic saline.
89579213|NCT05018897|Experimental|To Share or Not to Share|"Manualized, peer-led, strategic disclosure program to guide participants in disclosing suicidality, held in group format, consisting of six sessions, each one hour in duration, once per week.~Pre-survey, post-survey, and 3-month follow-up survey"
89579214|NCT05018897|Active Comparator|Peer Support|"Peer-led support group, held in group format, consisting of six sessions, each one hour in duration, once per week.~Pre-survey, post-survey, and 3-month follow-up survey"
89579215|NCT05018117|Experimental|Young (18-28 years) participants - nicotine gum|6 mg nicotine gum, one time before fMRI measurements
89579216|NCT05018117|Experimental|Old (60-85 years) participants - nicotine gum|6 mg nicotine gum, one time before fMRI measurements
89029503|NCT00507975|Experimental|B|The main aim of this study is to assess the effectiveness of nicotine patch comparatively to a placebo patch in pregnant women on birth weight and maternal smoking abstinence. The main secondary objective is the assessment of safety of these treatments for the fetus/newborn and for the mother.
89579217|NCT05018117|Placebo Comparator|Young (18-28 years) participants - placebo gum|placebo gum, one time before fMRI measurements
89579218|NCT05018117|Placebo Comparator|Old (60-85 years) participants - placebo gum|placebo gum, one time before fMRI measurements
89579219|NCT05017181||BioVal|BioVal is a single site validation study to determine the histological correlates underpinning signals derived from 13C-pyruvate HYP-MRI in men with known prostate cancer scheduled for prostatectomy.
89029504|NCT01247909|Experimental|Ceftriaxone|Ceftriaxone in infants with sepsis and bacterial meningitis
89029505|NCT01247909|Active Comparator|Penicillin and gentamicin|Penicillin and Gentamicin in infants with sepsis and bacterial meningitis
89579220|NCT05017181||ProVal|ProVal is a single site, prospective, longitudinal observational cohort study to determine the prognostic value of signals derived from VERDICT, Luminal Index MRI and 13C-pyruvate HYP-MRI in men with known early prostate cancer on active surveillance.
89579221|NCT05017181||TecVal|TecVal is a multi-site validation study to determine the inter-site repeatability and intra-site reproducibility of signals derived from VERDICT, Luminal Index MRI and 13C-pyruvate HYP-MRI in men with known prostate cancer.
89579222|NCT04203329||Paroxysmal A-Fib|
89579223|NCT04203329||Persistent A-Fib|
89579224|NCT04203329||A-Fib|
89579225|NCT05016869|Experimental|Experimental|fruquintinib plus capecitabine
89579226|NCT02141997|Active Comparator|Adalimumab 40 mg EOW|Adalimumab 40 mg every other week (EOW) for 11 weeks.
89579227|NCT02141997|Experimental|ABT-122 60 mg EOW|ABT-122 60 mg every other week (EOW) for 11 weeks.
89579228|NCT02141997|Experimental|ABT-122 120 mg EOW|ABT-122 120 mg every other week (EOW) for 11 weeks.
89579229|NCT02141997|Experimental|ABT-122 120 mg EW|ABT-122 120 mg every week (EW) for 11 weeks.
89579230|NCT04411433|Experimental|Favipiravir (3200 mg + 1200 mg)|"Dosage and method of administration: in a regimen of 2x1600 mg (oral) loading dose on day-1 followed by 1200 mg maintenance dose (2x600 mg, 2 times daily) on day-2 to day-5 (5 days in total).~The treatment duration may be extended up to 14 days with the evaluation of principle investigator."
89029506|NCT02954328|Experimental|tDCS|"The active tDCS condition will consist of 4 visit:~During each visit, subject will receive a single 20-minute session targeting the prefrontal cortices of either real (1.5 mA) or sham tDCS. Total 4 different targets:~Sham~motor M1 area~motor M1 + Dorsolateral Prefrontal cortex~Dorsolateral Prefrontal cortex.~The tDCS condition will be randomized and double blinded"
89029507|NCT01247948|Experimental|navigation assisted spine surgery|
89029508|NCT02954211|Experimental|rTMS/PT|There will be only one group. All participants will receive 10 treatments of active repetitive transcranial magnetic stimulation combined with physical therapy.
89579231|NCT04411433|Experimental|Favipiravir (3600 mg + 1600 mg)|"Dosage and method of administration: in a regimen of 2x1800 mg (oral) loading dose on day-1 followed by 1600 mg maintenance dose (2x800 mg, 2 times daily) on day-2 to day-5 (5 days in total).~The treatment duration may be extended up to 14 days with the evaluation of principle investigator."
89579232|NCT04411433|Experimental|Favipiravir combined with Hydroxychloroquine|"Hydroxychloroquine Dosage and method of administration: in a regimen of 2x400 mg (oral) loading dose on day-1 followed by 400 mg maintenance dose (2x200 mg oral, 2 times daily) on day-2 to day-5 (5 days in total).~Favipiravir Dosage and method of administration: in a regimen of 2x1600 mg (oral) loading dose on day-1 followed by 1200 mg maintenance dose (2x600 mg, 2 times daily) on day-2 to day-5 (5 days in total). The treatment duration may be extended up to 14 days with the evaluation of principle investigator."
89579233|NCT04411433|Experimental|Favipiravir combined with Azithromycin|"Azithromycin Dosage and method of administration: in a regimen of 1x500 mg (oral) loading dose on day-1 followed by 250 mg maintenance dose (oral daily) on day-2 to day-5 (5 days in total).~Favipiravir Dosage and method of administration: in a regimen of 2x1600 mg (oral) loading dose on day-1 followed by 1200 mg maintenance dose (2x600 mg, 2 times daily) on day-2 to day-5 (5 days in total). The treatment duration may be extended up to 14 days with the evaluation of principle investigator."
89579234|NCT04411433|Active Comparator|Hydroxychloroquine|"Dosage and method of administration for patients with mild possible or confirmed COVID-19 pneumonia (no severe pneumonia symptoms): in a regimen of 2x400 mg (oral) loading dose on day-1 followed by 400 mg maintenance dose (200 mg oral 2 times daily) on day-2 to day-5 (5 days in total).~Dosage and method of administration for patients with uncomplicated possible or confirmed COVID-19: in a regimen of 400 mg (200 mg oral 2 times daily) throughout 5 days (5 days in total)."
89579235|NCT04411433|Active Comparator|Hydroxychloroquine combined with Azithromycin|"Hydroxychloroquine Dosage and method of administration for patients with mild possible or confirmed COVID-19 pneumonia (no severe pneumonia symptoms): in a regimen of 2x400 mg (oral) loading dose on day-1 followed by 400 mg maintenance dose (2x200 mg oral, 2 times daily) on day-2 to day-5 (5 days in total).~Hydroxychloroquine Dosage and method of administration for patients with uncomplicated possible or confirmed COVID-19: in a regimen of 400 mg (2x200 mg oral, 2 times daily) throughout 5 days (5 days in total).~Azithromycin Dosage and method of administration: in a regimen of 1x500 mg (oral) loading dose on day-1 followed by 250 mg maintenance dose (oral daily) on day-2 to day-5 (5 days in total)."
89579236|NCT01628367|Experimental|Membrane|Test (membrane): Extraction and immediate implant placement will be performed. The gaps between the implant and socket walls will be filled with a bone graft material. Sites in the test group will receive a high-density PTFE (d-PTFE) membrane over the socket.
89579237|NCT01628367|Active Comparator|Collagen plug|Control (collagen plug): Extraction and immediate implant placement will be performed. The gaps between the implant and socket walls will be filled with a bone graft material. Sites in the control group will receive a collagen wound dressing over the socket.
89579238|NCT01627899|Other|VerioIQ|Subjects replaced own Blood Glucose Monitoring system with VerioIQ.
89579239|NCT05012735|Experimental|Treatment Group: Prototype Ultrathin Hydrocolloid Bandage and Study Cleanser|Participants will wash their faces with the study cleanser (Neutrogena Ultra Gentle Daily Cleanser with Pro Vitamin B5) in the evening prior to bandage application and in the morning after removing the bandage(s) on Days 0 through 7. On Days 7 through 14, no bandages will be worn and participants will wash their faces with the study cleanser (Neutrogena Ultra Gentle Daily Cleanser with Pro Vitamin B5) in the morning and evening. Participants will cover their closed and popped pimples in the evening with 1 or 2 bandages on Days 0 through 6.
89579240|NCT05012735|Active Comparator|Control Group: Study Cleanser (Neutrogena Ultra Gentle Daily Cleanser with Pro Vitamin B5)|Participants will wash their face twice daily using the study cleanser (Neutrogena Ultra Gentle Daily Cleanser with Pro Vitamin B5) for up to 14 days.
89579241|NCT04946903|Experimental|Sequence 1|"Period 1: Fasted state + RLD2007 +RLD2008,~Period 2: Fasted state + HCP1902"
89579242|NCT04946903|Experimental|Sequence 2|"Period 1: Fasted state + HCP1902,~Period 2: Fasted state + RLD2007 + RLD2008"
89579243|NCT04985825|Experimental|Imgatuzumab monotherapy|
89579244|NCT02519777|Placebo Comparator|Arm A: Placebo MVC and placebo DTG|In addition to their existing ART regimens, participants in Arm A received placebo for MVC and placebo for DTG.
89579245|NCT02519777|Experimental|Arm B: DTG and placebo MVC|In addition to their existing ART regimens, participants in Arm B received DTG and placebo for MVC.
89579246|NCT02519777|Experimental|Arm C: MVC and DTG|In addition to their existing ART regimens, participants in Arm C received MVC and DTG
89579247|NCT05008913|Experimental|[14C]Adavosertib|Patients will receive a single administration of [14C]adavosertib as an oral solution on Day 1.
89579248|NCT04982705|Experimental|[Part 1.1] IDG-16177|6 subjects in each cohort (Cohort 1-5). The SAD study (Part 1.1) will consist of 5 cohorts of 8 healthy subjects who will be randomised to receive a single oral dose of IDG-16177 or placebo (6 active treatments and 2 placebo/3:1 ratio). Subjects in Cohort 4 will participate in a food-effect study.
89579249|NCT04982705|Placebo Comparator|[Part 1.1] Placebo of IDG-16177|2 subjects in each cohort (Cohort 1-5). The SAD study (Part 1.1) will consist of 5 cohorts of 8 healthy subjects who will be randomised to receive a single oral dose of IDG-16177 or placebo (6 active treatments and 2 placebo/3:1 ratio). Subjects in Cohort 4 will participate in a food-effect study.
89579250|NCT04982705|Experimental|[Part 1.2] IDG-16177|8 subjects in each cohort (Cohort 6-8). The MAD study (Part 1.2) will consist of 3 cohorts of 10 healthy subjects (8 active treatments and 2 placebo/4:1 ratio), each receiving an oral dose of IDG-16177 or placebo.
89579251|NCT04982705|Placebo Comparator|[Part 1.2] Placebo|2 subjects in each cohort (Cohort 6-8). The MAD study (Part 1.2) will consist of 3 cohorts of 10 healthy subjects (8 active treatments and 2 placebo/4:1 ratio), each receiving an oral dose of IDG-16177 or placebo (QD).
89579252|NCT04982705|Experimental|[Part 2] IDG-16177|This part will consist of 3 separate arms of 8 patients per arm. Each arm will receive one of the following treatments: IDG-16177, placebo or DPP-4i as comparator.
88972881|NCT01465412|Active Comparator|Healthy to Match Mild HI Part 1|Healthy volunteers with normal hepatic function matched to participants with mild chronic liver disease by race, age, BMI, and gender, enrolled in Part 1 received one 5-mg preladenant tablet, orally, on Day 1.
89579253|NCT04982705|Placebo Comparator|[Part 2] Placebo|This part will consist of 3 separate arms of 8 patients per arm. Each arm will receive one of the following treatments: IDG-16177, placebo or DPP-4i as comparator.
89579254|NCT04982705|Active Comparator|[Part 2] Sitagliptin|This part will consist of 3 separate arms of 8 patients per arm. Each arm will receive one of the following treatments: IDG-16177, placebo or DPP-4i as comparator (1:1:1 ratio).
89579255|NCT04202783|Experimental|Treatment of Craniofacial Neuralgia|All patients will receive the same amount (5mL concentrated) of exosomes delivered via ultrasound-guided, regional epineural injection and the same amount (5mL unconcentrated) delivered via IV. Patients will be given 3 mL of the exosome product intravenously, which contains about 45mg of the exosome product containing 15-21 million neonatal stem cell products, and 3 mL of the exosome hyperconcentrate product delivered epineurally using ultrasound guidance, which contains about 15mg of the exosome product carrying 5-7 million neonatal stem cell products.
89579256|NCT04944095||SARS-CoV-2 Antibody Levels|This is a single arm study by Southlake Diagnostics Inc. whereby changes in plasma antibody levels (IgG and total) are determined over 12 months on individuals residing in over 300 associated nursing homes, extended care facilities and over-55 residences following vaccination with one of the authorized SARS-CoV-2 vaccines (Pfizer, Moderna or J &J). No interventions are involved. The investigators are not responsible for administering the vaccines or determining subject eligibility or willingness to receive the vaccine. Blood samples will be drawn and plasma IgG and total antibodies will be determined at baseline, 3, 6, 9 and 12 months post-vaccination.
89579257|NCT02515331|Experimental|LHW090 100 mg|LHW090 100 mg once daily for 28 days
89579258|NCT02515331|Experimental|LHW090 200 mg|LHW090 200 mg once daily for 28 days
89579259|NCT02515331|Placebo Comparator|Placebo|Matching placebo to LHW090 oral dose for 28 days
89579260|NCT02515097|Experimental|IDP-122 Lotion|Participants will apply IDP-122 Lotion (halobetasol propionate [HP] 0.01%) topically once daily for 8 weeks.
89579261|NCT02515097|Placebo Comparator|IDP-122 Vehicle Lotion|Participants will apply IDP-122 Vehicle Lotion topically once daily for 8 weeks.
89579262|NCT02141295|Experimental|Part 1 (Induction): Vanucizumab + mFOLFOX-6|Participants will receive vanucizumab at a dose of 2000 milligram (mg) as intravenous (IV) infusion; oxaliplatin at a dose of 85 mg per meter-squared (mg/m^2) as IV infusion; folinic acid at a dose of 400 mg/m^2 as IV infusion; and 5-FU at a dose of 400 mg/m^2 as starting IV bolus followed by 2400 mg/m^2 as IV infusion every 2 weeks for up to 8 cycles (approximately 4 months).
89579263|NCT02141295|Experimental|Part 1 (Maintenance): Vanucizumab + 5-FU + Folinic acid|Participants will receive vanucizumab at a dose confirmed during induction as IV infusion; folinic acid at a dose of 400 mg/m^2 as IV infusion; and 5-FU at a dose of 400 mg/m^2 as starting IV bolus followed by 2400 mg/m^2 as IV infusion every 2 weeks until disease progression, unacceptable toxicities, consent withdrawal or Investigator's decision for a maximum of 24 months.
89579264|NCT02141295|Active Comparator|Part 2 (Induction): Bevacizumab + mFOLFOX-6|Participants will receive bevacizumab at a dose of 5 milligram per kilogram (mg/kg) as IV infusion; oxaliplatin at a dose of 85 mg/m^2 as IV infusion; folinic acid at a dose of 400 mg/m^2 as IV infusion; and 5-FU at a dose of 400 mg/m^2 as starting IV bolus followed by 2400 mg/m^2 as IV infusion every 2 weeks for up to 8 cycles (approximately 4 months).
89579265|NCT02141295|Experimental|Part 2 (Induction): Vanucizumab + mFOLFOX-6|Participants will receive vanucizumab at a dose confirmed during part 1 as IV infusion; oxaliplatin at a dose of 85 mg/m^2 as IV infusion; folinic acid at a dose of 400 mg/m^2 as IV infusion; and 5-FU at a dose of 400 mg/m^2 as starting IV bolus followed by 2400 mg/m^2 as IV infusion every 2 weeks for up to 8 cycles (approximately 4 months).
89579266|NCT02141295|Active Comparator|Part 2 (Maintenance): Bevacizumab + 5-FU + Folinic acid|Participants will receive bevacizumab at a dose of 5 mg/kg as IV infusion; folinic acid at a dose of 400 mg/m^2 as IV infusion; and 5-FU at a dose of 400 mg/m^2 as starting IV bolus followed by 2400 mg/m^2 as IV infusion every 2 weeks until disease progression, unacceptable toxicities, consent withdrawal or Investigator's decision for a maximum of 24 months.
89579267|NCT02141295|Experimental|Part 2 (Maintenance): Vanucizumab + 5-FU + Folinic acid|Participants will receive vanucizumab at a dose confirmed during part 1 as IV infusion; folinic acid at a dose of 400 mg/m^2 as IV infusion; and 5-FU at a dose of 400 mg/m^2 as starting IV bolus followed by 2400 mg/m^2 as IV infusion every 2 weeks until disease progression, unacceptable toxicities, consent withdrawal or Investigator's decision for a maximum of 24 months.
89579268|NCT02514551|Experimental|12mg/kg Ramucirumab + 80 mg/m² Paclitaxel|12 milligram per kilogram (mg/kg) ramucirumab administered intravenously (IV) on day 1 and day 15 (28 day cycles) in combination with 80 milligram per square meter (mg/m²) paclitaxel administered IV on day 1, day 8 and day 15.
88972882|NCT01465412|Experimental|Moderate HI Part 2|Participants with moderate chronic liver disease enrolled in Part 2 received one 5-mg preladenant tablet, orally, on Day 1.
88972883|NCT01465412|Active Comparator|Healthy to Match Moderate HI Part 2|Healthy volunteers with normal hepatic function matched to participants with moderate chronic liver disease by race, age, BMI, and gender, enrolled in Part 2 received one 5-mg preladenant tablet, orally, on Day 1.
88972884|NCT01465373|Active Comparator|Progesterone in Oil|"Donor egg recipients will begin progesterone 50 mg IM injection starting the day after donor egg fertilization, and continue daily until pregnancy results can be determined.~If pregnant, donor egg recipient will continue progesterone 50 mg IM injections daily until approximately 9 weeks of pregnancy."
88972885|NCT01465373|Active Comparator|Endometrin|"Donor egg recipients will begin Endometrin 100 mg per vagina three times daily starting the day after donor egg fertilization and continue until pregnancy result can be determined.~If pregnant, donor egg recipients will continue Endometrin 100 mg TID until approximately 9 weeks of pregnancy."
88972886|NCT01465295|Experimental|HemiBridge|Patients meeting eligibility criteria will be treated with the HemiBridge System.
88972887|NCT01465256|No Intervention|Aspirin holding group|Aspirin holding group (group 1): the patients enrolled into group 1 can stop taking aspirin during colon polypectomy. The patients are usually taking aspirin for primary prevention of vascular disease and have no risk of thromboembolism despite of they stop taking aspirin temporary
88972888|NCT01465256|Experimental|Aspirin continuing group|Aspirin continuing group (group 2): the patients enrolled into group 2 should take aspirin during colon polypectomy because these patients are usually take thienopyridines and aspirin, and if they would stop taking aspirin during colon polypectomy, they have a thromboembolism risk.
89579269|NCT02514551|Active Comparator|8 mg/kg Ramucirumab + 80 mg/m² Paclitaxel|8 mg/kg ramucirumab administered IV on day 1 and day 15 (28 day cycles) in combination with 80 mg/m² paclitaxel administered IV on day 1, day 8 and day 15.
89579270|NCT02141217|Active Comparator|Amoxicillin/clavulanate|Amoxicillin/ clavulanate 1 g bd for for at least 5 days upto seven days depending on treament response
89579271|NCT02141217|Active Comparator|Clindamycin|Clindamycin 150 mg qid for at least 5 days or maximum 7 days depending upon treatment response
89579272|NCT02138253|Experimental|IDN-6556|IDN-6556 25 mg BID
89579273|NCT02138253|Placebo Comparator|Placebo|Placebo BID
89579274|NCT02514473|Experimental|LUM/IVA|Fixed-dose combination with lumacaftor (LUM) 200 mg every 12 hours (q12h)/ ivacaftor (IVA) 250 mg q12h
89579275|NCT02514473|Placebo Comparator|Placebo|Matching placebo q12h
89579276|NCT02513771|Active Comparator|Sitagliptin Arm|Sitagliptin (Januvia) 100 mg one tablet daily p.o. for 16 weeks, followed by a 4-week post-treatment follow-up.
89579277|NCT02513771|Placebo Comparator|Placebo Arm|Placebo for sitagliptin one tablet daily p.o.for 16 weeks, followed by a 4-week post-treatment follow-up.
89579278|NCT02104947|Experimental|idarucizumab|idarucizumab Only 1 treatment, no placebo or comparator
89579279|NCT02513459|Experimental|Risankizumab|Maintenance treatment with risankizumab 180 mg administered subcutaneously (SC) every 8 weeks (q8w) from Visit 2 through the end of trial (EOT) visit. Participants who re-gained their clinical response following the re-induction treatment could continue with maintenance treatment beginning at Visit 5.
89579280|NCT02104557||prevention of pregnancy|Non intervention
89579281|NCT02104557||management of endometriosis-associated pain|Non intervention
89579282|NCT04209023|Experimental|navigated TMS|All patients are required to have an advanced MRI of the brain including a structural T1, volume measurements of various brain regions, ASL, and BOLD sequences. Patients will also undergo an in-scanner task designed to activate key neurofunctional regions of interest; these areas will provide the cerebral coordinates to be validated by TMS.
89579283|NCT04982081|Experimental|hiPSC-CM therapy low dosage|
89579284|NCT04982081|Experimental|hiPSC-CM therapy high dosage|
89579285|NCT05006105|Experimental|PPG-based mHealth on smartphone|Participants used PPG-based mHealth on a smartphone for 6 months. Participants were asked to perform two spot-check measurements and additional measurements in case of symptoms. The use of PPG-based mHealth on a smartphone was initiated on the day of insertable loop recorder insertion.
89579286|NCT05006105|Experimental|PPG-based mHealth on smartwatch|Participants used PPG-based mHealth on a smartwatch for 6 months. Participants were asked to wear the smartwatch continuously (except during battery charging). The use of PPG-based mHealth on a smartwatch was initiated on the day of insertable loop recorder insertion.
89579287|NCT02069379|No Intervention|Controls|metabolically healthy controls will participate in baseline assessments only, and will not be randomized to the placebo and metformin treatment arms.
89579288|NCT02069379|Experimental|Metformin|16 weeks treatment with metformin (insulin sensitizing treatment)
89579289|NCT02069379|Placebo Comparator|Placebo|Placebo comparator to metformin treatment
89579290|NCT02511431|Experimental|Group 1|Lonafarnib/Ritonavir at 50 mg/100 mg daily for 24 weeks followed by 24 weeks of off therapy follow-up.
89579291|NCT02511431|Experimental|Group 2|Lonafarnib/Ritonavir at 75 mg/100 mg daily for 24 weeks followed by 24 weeks of off therapy follow-up.
89579292|NCT02511431|Experimental|Group 3|Lonafarnib/Ritonavir at 100 mg/100 mg daily for 24 weeks followed by 24 weeks of off therapy follow-up.
89579293|NCT02511431|Experimental|Group 4|Placebo for 12 weeks then Lonafarnib/Ritonavir at 50 mg/100 mg daily for 12 weeks followed by 24 weeks of off therapy follow-up.
88972889|NCT01465217|Experimental|text message medication reminders|
88972890|NCT01465217|No Intervention|control|
89029509|NCT01245998|Active Comparator|dalteparin 5000 I.U./24 h s.c.|
89579294|NCT02511431|Experimental|Group 5|Placebo for 12 weeks then Lonafarnib/Ritonavir at 75 mg/100 mg daily for 12 weeks followed by 24 weeks of off therapy follow-up.
89579295|NCT02511431|Experimental|Group 6|Placebo for 12 weeks then Lonafarnib/Ritonavir at 100 mg/100 mg daily for 12 weeks followed by 24 weeks of off therapy follow-up.
89579296|NCT05005247|Experimental|GBS-NN/NN2|Single dose 0.5 millilitre (mL) intramuscular injection of GBS-NN/NN2 containing 50 μg of GBS-NN and 50 μg of GBS/NN2
89579297|NCT02137785|Experimental|ALA|
89579298|NCT02137785|Placebo Comparator|Vehicle|
89579299|NCT01655069|Experimental|Children Treated with Placebo in 905-CL-076|Male and female children aged 5 to less than 12 years old who received placebo in Study 905-CL-076 and received open-label solifenacin once daily in this study. The mean time on study drug in this study was 247.9 days in children.
89579300|NCT01655069|Experimental|Children Treated with Solifenacin in 905-CL-076|Male and female children aged 5 to less than 12 years old who received solifenacin in Study 905-CL-076 and received open-label solifenacin once daily in this study. The mean time on study drug in this study was 247.9 days in children.
89579301|NCT01655069|Experimental|Adolescents Treated with Placebo in 905-CL-076|Male and female adolescents aged 12 to less than 18 years old who received placebo in Study 905-CL-076 and received open-label solifenacin once daily in this study. The mean time on study drug in this study was 240.1 days in adolescents.
89029510|NCT01245998|Active Comparator|dalteparin 15000 I.U./24 h s.c.|
89579302|NCT01655069|Experimental|Adolescents Treated with Solifenacin in 905-CL-076|Male and female adolescents aged 12 to less than 18 years old who received solifenacin in Study 905- CL-076 and received open-label solifenacin once daily in this study. The mean time on study drug in this study was 240.1 days in adolescents.
89579303|NCT02068599|Experimental|TV-45070 4%|TV-45070 ointment in a 4% strength applied topically twice daily to the target knee during the treatment period from day 1 through day 28.
89579304|NCT02068599|Experimental|TV-45070 8%|TV-45070 ointment in a 8% strength applied topically twice daily to the target knee during the treatment period from day 1 through day 28.
89579305|NCT02068599|Placebo Comparator|Placebo|Placebo ointment applied topically twice daily to the target knee during the treatment period from day 1 through day 28.
89579306|NCT04708509|Experimental|Intervention Arm|Wave form data from participants' spontaneous breathing trials (SBT) will be analyzed using Extubation Advisor (EA) to generate an EA report that provides clinical decision support regarding extubation.
89579307|NCT01654601|Experimental|A Group|"1.1st Administration - DWCZP tablet 100mg Mutiple dose~2.2nd Administration - Clozaril tablet 100mg Mutiple dose"
89579308|NCT01654601|Experimental|B Group|"1.1st Administration - Clozaril tablet 100mg Mutiple dose~2.2nd Administration - DWCZP tablet 100mg Mutiple dose"
89579309|NCT01654523|Other|Treatment arm|Open trial with no randomization
89579310|NCT05001113|Experimental|the subxiphoid approach thoracoscopic thymectomy|The subxiphoid approach thoracoscopic thymectomy is performed in enrolled patients.
89579311|NCT05001113|Active Comparator|the lateral intercostal approach thoracoscopic thymectomy|The lateral intercostal approach thoracoscopic thymectomy is performed in enrolled patients.
89579312|NCT04978649|Active Comparator|intensive treatment group|Real antihypertensive agents will be provided for this arm, to decrease systolic BP to lower than 120 mm Hg. In this group, the following study medications will be used: tablets with Allisartan Isoproxil 240 mg (first-line medication); tablets with Amlodipine 5 mg (second-line medication). Treatment will be started with Allisartan 240 mg. If necessary to reach the BP goal, Amlodipine (first 5 mg or then 10 mg daily) will be given in addition. If intolerable side effects occur, first-line medication may be replaced by second-line medication.
89579313|NCT04978649|Placebo Comparator|standard treatment group|In this arm participants are followed up and no medications be used until BP becomes ≥ 140 mm Hg systolic and/or 90 mm Hg diastolic. Medications are determined by investigators in lines with recommendations by current Chinese guidelines to decrease BP to lower than 140 mm Hg systolic and to lower than 90 mm Hg diastolic.
88972891|NCT00037440||BHS Whites|Whites from Bogalusa, Louisiana; initially recruited as schoolchildren and followed at irregular intervals (about 3 years apart on average) into adolescence and early adulthood. There were no interventions of any kind-- this was an observational study only.
88972892|NCT00037440||BHS African Americans|African Americans from Bogalusa, Louisiana, initially recruited as schoolchildren and followed at irregular intervals (about 3 years apart on average) into adolescence and early adulthood. There were no interventions of any kind-- this was an observational study only.
89579314|NCT04978415|Experimental|subtenon's block|we use the subtenon cannula to inject the local anesthetic mixture
88972893|NCT01465139|Experimental|CDX-301|CDX-301 (rhuFlt3L), administered to healthy patients.
88972894|NCT00396552|Experimental|1|
88972895|NCT00396552|Sham Comparator|2|
88972896|NCT01465061||Online support user|
88972897|NCT01464983|Active Comparator|Arm 1|
88972898|NCT01464983|Experimental|Arm 2|
88972899|NCT01464983|Active Comparator|Arm 3|
88972900|NCT01464983|Active Comparator|Arm 4|
88972901|NCT01464983|Placebo Comparator|Arm 5|
88972902|NCT01464944|Experimental|Arm 2|
88972903|NCT01464944|Active Comparator|Arm 3|
88972904|NCT01464944|Active Comparator|Arm 4|
88972905|NCT01464944|Placebo Comparator|Arm 5|
88972906|NCT01464944|Experimental|Arm 1|
88972907|NCT01464905|Experimental|NU100|
89579315|NCT04978415|Experimental|peribulbar block|we use the usual 25G sharp needle to inject the local anesthetic mixture
89579316|NCT02508935|Experimental|XARTEMIS XR|All participants received XARTEMIS XR
89579317|NCT02508701|Other|Altruistic inside-dorm|"Altruistic & personal message with direct recommendation and access to the vaccine on-site~The intervention is a message asking students to get the vaccine that tell students the vaccine is available in the dorm and provides a direct recommendation to get the vaccine"
89579318|NCT02508701|Other|Generic inside-dorm|"Generic message and access to the vaccine on-site~The intervention is a message asking students to get the vaccine that tell students the vaccine is available in the dorm but provides no recommendation"
89579319|NCT02508701|Other|Generic outside-dorm|"Generic message and off-site access to the vaccine~The intervention is a message asking students to get the vaccine that tell students the vaccine is available at the health center but provides no recommendation"
89579320|NCT02508701|Other|Altruistic outside-dorm|"Altruistic & personal message with direct recommendation and off-site access to the vaccine~The intervention is a message asking students to get the vaccine that tell students the vaccine is available at the student health center and provides a direct appeal to get the vaccine"
89579321|NCT02507375|Experimental|Cohort 1|Participants will receive IV infusion of pertuzumab at a loading dose of 840 mg on Day 1, followed by a dose of 420 mg every 3 weeks. Erlotinib will be administered daily, at a dose level of 100 mg orally (PO).
89579322|NCT02507375|Experimental|Cohort 2|Participants will receive IV infusion of pertuzumab at a loading dose of 840 mg on Day 1, followed by a dose of 420 mg every 3 weeks. Erlotinib will be administered daily, at a dose level of 150 mg orally (PO).
89579323|NCT05000177|Other|Experimental group: Non-specific chronic neck pain group|Subjects with non-specific chronic neck pain will be included to perform 30-minute computer typing task and assess neurophysiological measurements of scapular muscles, scapular kinematics and muscle activation.
88972908|NCT01464905|Placebo Comparator|Placebo|
88972909|NCT01464905|Active Comparator|recombinant human interferon beta- 1b|
88972910|NCT00037635|Experimental|AMG 073|
88972911|NCT00037635|Placebo Comparator|placebo|
88972912|NCT01464866|Active Comparator|Hospital Feed|Standard hospital food
88972913|NCT01464866|Experimental|Hospital Feed plus nutritional supplement|Standard hospital food plus nutritional supplement
89579324|NCT05000177|Other|Control group: Healthy subjects group|Healthy subjects will be included to compare the differences in neurophysiological measurements of scapular muscles, scapular kinematics and muscle activation between healthy subjects and subjects with non-specific chronic neck pain. Subjects in this group will received the same assessment as the NCNP group.
89579325|NCT05000177|Other|Pilot study: Healthy subjects group|Healthy subjects will be included to test reliability of single-pulse and paired-pulse TMS, including its associated neurophysiological measurements, and also to test reliability of Liberty electromagnetic tracing system and surface electromyography. Subjects in this group will received the same assessment as the NCNP group.
89579326|NCT02507219|Placebo Comparator|Placebo|Subjects will receive one dose of placebo (sugar pill) at one of the three testing sessions . Placebo capsules will be produced in the same manner as the ibuprofen by a local compounding pharmacy in Tulsa, OK.
89579327|NCT02507219|Active Comparator|Ibuprofen, 200mg|Subjects will receive one oral dose of 200mg at one of the three testing sessions. Ibuprofen capsules will be produced by a local compounding pharmacy in Tulsa, OK.
89579328|NCT02507219|Active Comparator|Ibuprofen, 600mg|Subjects will receive one oral dose of 600mg at one of the three testing sessions. Ibuprofen capsules will be produced by a local compounding pharmacy in Tulsa, OK.
89579329|NCT02483975|Experimental|FF 50 mcg|Subjects will receive by oral inhalation FF 50 mcg once daily in the morning via ELLIPTA for 42 days. Subjects will continue to receive oral montelukast once daily in the evening and may use albuterol/salbutamol inhalation aerosol as needed.
89579330|NCT02483975|Placebo Comparator|Placebo|Subjects will receive by oral inhalation placebo once daily in the morning via ELLIPTA for 42 days. Subjects will continue to receive oral montelukast once daily in the evening and may use albuterol/salbutamol inhalation aerosol as needed.
89579331|NCT02047227|Experimental|Pergoveris®|
89579332|NCT02047227|Active Comparator|GONAL-f®|
89579333|NCT02483585|Placebo Comparator|Placebo|Participants received placebo on day 1 and at weeks 4 and 8 by subcutaneous injection in the double-blind treatment phase. At week 12 participants began treatment with erenumab 70 mg administered by subcutaneous injection at weeks 12, 16, 20, 24, 28, 32, and 36 in the open-label treatment phase.
89579334|NCT02483585|Experimental|Erenumab|Participants received erenumab 70 mg on day 1 and at weeks 4 and 8 by subcutaneous injection in the double-blind treatment phase. Participants continued to receive erenumab 70 mg administered by subcutaneous injection at weeks 12, 16, 20, 24, 28, 32, and 36 in the open-label treatment phase.
89579335|NCT02046993|Experimental|Smart phone based telemonitoring of HBP|". Patients do HBP monitoring~. record their BP readings into the smart phone with downloaded application."
89579336|NCT02046993|Active Comparator|Enhanced usual care|". Patients to do HBP measurement~. Record BP readings in their diary"
89579337|NCT02101983|Experimental|Outpatient HiDAC Consolidation|Patients will receive 2 cycles of 1.5 grams/m2/day of intravenous cytarabine once daily for six consecutive days. Toxicity will be monitored through the duration of treatment. Observation will be complete upon count recovery and resolution of toxicity after the second cycle.
89579338|NCT02101983|Active Comparator|Quality of Life Comparison Group|Patients receiving outpatient intravenous cytarabine will complete the EORTC QLQ-C30 quality of life form on the last day of each cycle of chemotherapy.
88972914|NCT01464749|Experimental|Task-oriented circuit class training|"Functional Circuit include 6 different work-stations in which patients exercise for 5 minutes in each one : 3 minutes exercises and 2 minutes rest. Total training takes about 30 minutes (2 laps/session over 60 minutes).~Walking endurance is trained by 30 minutes walking on the treadmill including rests if necessary.~It is a progressive circuit and subjects, while exercising, receives feedback (visual and auditory) by the physiotherapist. Rests are used to discuss about difficulties and to provide further feedbacks. One task oriented session may include up to 3 patients and lasts 120 minutes. At the end of the 2 weeks an exercises brochure will be given to patients so that they can independently train for 3 month. Independent home training takes about 90 minutes."
89029511|NCT02954484|Active Comparator|PREGABALIN|All subjects receive intravenous PCA morphine, paracetamol 1g po six hourly and etoricoxib 120mg po once daily. Subjects receive pregabalin 75mg orally preoperatively followed by 75mg at night for two days. During surgery, patients received general anaesthesia with femoral nerve block on the side of surgery.
89579339|NCT04974593|Experimental|H2BT-positive|
89579340|NCT04974593|Experimental|H2BT-negative|
89579341|NCT04974281|Other|PD-1+TACE+Len|PD-1 Antibody and Lenvatinib Plus TACE
89579342|NCT02482805|Experimental|Power Posing|Individuals hold two, 1-minute postures associated with dominance and high power prior to exposure therapy.
89579343|NCT02482805|Experimental|Submissive Posing|Individuals hold two, 1-minute postures associated with submissiveness and low power prior to exposure therapy.
89579344|NCT02482805|Experimental|Rest|Individuals rest (no postures) for 2 minutes prior to exposure therapy.
89579345|NCT02503865|Active Comparator|Conventional Patient group|Xenical, Pionorm, Diroton, Diltiazem, Atorvastatin
89579346|NCT02503865|Experimental|"Analimentary detoxication Weight loss"|Vegetables and salt diet
89579347|NCT02503865|No Intervention|Healthy people|64 healthy people
89579348|NCT01623531|Active Comparator|RiaSTAP|Intravenous fibrinogen(RiaSTAP) will be administered according to FIBTEM based calculation formula
89579349|NCT01623531|Placebo Comparator|Intravenous saline|Intravenous saline (placebo) will be calculated according to FIBTEM based calculation formula
89579350|NCT02503787|Other|Open label treatment|Spinal Cord Stimulation (SCS)
89579351|NCT04943471||All patients will be given a questionnaire|All patients will be given the Big Five Questionnaire
89579352|NCT02482571|Experimental|Mild Hypoxia|Subjects are exposed to an intervention that controls the composition of breathed air by using a gas blender (RespirAct). Subjects undergo MRI and MRS while breathing air with both normal oxygen concentration (normoxia) and reduced oxygen concentration (mild hypoxia).
89579353|NCT02481947|Experimental|BLI400 Laxative|21 gm BLI400 powder
89579354|NCT02481947|Active Comparator|Lubiprostone|24 mcg capsule bid
89579355|NCT02503085|Experimental|Nurofen for Children® (fasted)|Nurofen for Children® suspension 400 mg/20 mL single-oral dose under fasted condition
89579356|NCT02503085|Experimental|Nurofen for Children® (fed)|Nurofen for Children® suspension 400 mg/20 mL single-oral dose under fed condition
89579357|NCT02503085|Active Comparator|Algifor Dolo Junior® (fasted)|Algifor Dolo Junior® suspension 400 mg/20 mL single-oral dose under fasted condition
89579358|NCT02503085|Active Comparator|Algifor Dolo Junior® (fed)|Algifor Dolo Junior® suspension 400 mg/20 mL single-oral dose under fed condition
89579359|NCT02481869|Active Comparator|Arthrocentesis/PRP|"At the time of surgery, the participant will have both injured and uninjured ankles cleaned with surgical soap. An needle will be placed into the injured ankle joint and synovial fluid will be drawn out of the ankle and collected into a syringe. Using the same needle, the PRP will be delivered into the same arthrocentesis needle.~Next the uninjured ankle will have the same procedure as the injured ankle, except there will be no injection of PRP. There will only be a aspiration of synovial fluid from the uninjured ankle joint using a different clean needle.~Another aspiration of the synovial fluid will be done at the time of the second surgery in the same manner as before, except there will be no injection of PRP, just an aspiration of both injured and uninjured ankles."
89579360|NCT02481869|Placebo Comparator|Arthrocentesis/Saline|"At the time of surgery, the participant will have both injured and uninjured ankles cleaned with surgical soap. An needle will be placed into the injured ankle joint and synovial fluid will be drawn out of the ankle and collected into a syringe. Using the same needle, the Saline will be delivered into the same arthrocentesis needle.~Next the uninjured ankle will have the same procedure as the injured ankle, except there will be no injection of Saline. There will only be a aspiration of synovial fluid from the uninjured ankle joint using a different clean needle.~Another aspiration of the synovial fluid will be done at the time of the second surgery in the same manner as before, except there will be no injection of Saline, just an aspiration of both injured and uninjured ankles."
89579361|NCT02502149|Experimental|rFVIIIFc (15K scale) 1000 IU vial|Single injection of rFVIIIFc (current 2K scale) followed by 2 single injections of rFVIIIFc (15K scale) 1000 IU vial at PK2 and PK3 timepoints. Participants will be on prophylaxis regimen along with treatment for bleeding episodes for 26 weeks of treatment period using the rFVIIIFc (15K scale) 1000 IU vial.
89579362|NCT02502149|Experimental|rFVIIIFc (15K scale) 6000 IU vial|Single injection of rFVIIIFc (current 2K scale) followed by 2 single injections of rFVIIIFc high strength vial (15K scale) at PK2 and PK3 timepoints. Participants will be on prophylaxis regimen along with treatment for bleeding episodes for 26 weeks of treatment period using the rFVIIIFc (15K scale) 6000 IU vial.
89579363|NCT02480621|No Intervention|Control|Standard of care: Open Reduction Internal Fixation with no injection of pain medications around the affected ankle.
89579364|NCT02480621|Experimental|Liposomal Bupivacaine with Bupivacaine|Intra-operatively, patients receive a local injection of liposomal bupivacaine with bupivacaine around the affected ankle.
89579365|NCT02046603|Experimental|Tocilizumab Monotherapy|Participants will receive a weekly SC injection of tocilizumab 162 mg as monotherapy for 52 weeks.
89579366|NCT02046603|Experimental|Tocilizumab in Combination With Methotrexate or Other DMARDs|Participants will receive a weekly SC injection of tocilizumab 162 mg in combination with methotrexate or other non-biologic DMARDs for 52 weeks.
89579367|NCT01885078|Experimental|4 milligram (mg) Baricitinib|"4 mg Baricitinib administered orally once daily.~Participants received baricitinib doses according to the dose received at the completion of the originating study. Participants may continue to receive the background non-investigational, open-label conventional disease-modifying antirheumatic drugs (cDMARD), nonsteroidal anti-inflammatory drug (NSAID), corticosteroid, and other analgesic therapies they were receiving at completion of the originating study."
89579368|NCT01885078|Experimental|2 mg Baricitinib|"2 mg Baricitinib administered orally once daily.~Participants received baricitinib doses according to the dose received at the completion of the originating study. Participants may continue to receive the background non-investigational, open-label cDMARD, NSAID, corticosteroid, and other analgesic therapies they were receiving at completion of the originating study."
89579369|NCT01885078|Experimental|2 mg Baricitinib Step-down|"2 mg Baricitinib administered orally once daily in the 96-week Step-down period.~Participants may continue to receive the background non-investigational, open-label cDMARD, NSAID, corticosteroid, and other analgesic therapies they were receiving at completion of the originating study."
88972915|NCT01464749|Active Comparator|Usual Care|The control group will not receive any specific rehabilitation treatment for gait performance and mobility improvement (usual care). At any case, the control group will be authorized, at will, to exercise in non-rehabilitative contexts (i.e. swimming, walking, yoga) or do physical rehabilitation in rehabilitative gyms not directly addressed to gait, mobility or balance training such as stretching exercises, active and passive mobilization and Bobath neurorehabilitation or similar.
88972916|NCT00037713|No Intervention|1|Best supportive care, but no cancer specific therapy (cytotoxic, radiation or other tumor reductive therapy) can be given until documented progression of disease.
89209404|NCT02541708|Active Comparator|Ferrous sulphate 60mg+Folic acid 0.25mg|Three dried ferrous sulphate and folic acid tablets every morning 30 mins before the meal. If side effects occur the drug may be taken with the meal or in 2 separate doses per day. The treatment will be pursued for 3 months after correction of anemia.
89209405|NCT00888966||Out of hospital cardiac arrest|Out of hospital cardiac patients successfully resuscitated and admitted to ICU
89579370|NCT01885078|Experimental|4 mg Baricitinib Step-down|"4 mg Baricitinib administered orally once daily in the 96-week Step-down period.~Participants may continue to receive the background non-investigational, open-label cDMARD, NSAID, corticosteroid, and other analgesic therapies they were receiving at completion of the originating study."
89579371|NCT02046369|Experimental|Luradisone|Luradisone 20- 80 mg administered once daily
89579372|NCT02046369|Placebo Comparator|Placebo|Placebo administered once daily
89579373|NCT02101359|Experimental|T2380|"Topical anaesthetic: Tetracaine was instilled in the eye to be operated before surgery.~At the beginning of surgery, 200 μL of T2380 were administrated intracamerally."
88972917|NCT00037713|Experimental|2|"Treatment will consist of 5 vaccinations (each consisting of 8 single intradermal injections) over a period of 10 to 12 weeks unless one of the following occur:~intolerable toxicity precluding further treatment progression of disease~patient refusal~occurrence of pregnancy"
88972918|NCT00037752|Active Comparator|1|Sibutramine plus a behavioral smoking cessation program
88972919|NCT00037752|Active Comparator|2|Placebo sibutramine plus a behavioral smoking cessation program
88972920|NCT01464671|Active Comparator|Bivalirudin|Anticoagulation during percutaneous coronary intervention
89579374|NCT02101359|Active Comparator|Mydriatics and anesthetic|"Topical anaesthetic: Tetracaine was instilled in the eye to be operated before surgery.~Topical Mydriatic treatments were instilled three times before surgery."
89579375|NCT02100969|Experimental|HIZENTRA ®|Hizentra is a subcutaneous (under the skin) immunoglobin (SCIg). Participants will receive Hizentra in a minimum of one infusion per week and a maximum of 4 infusions per week. Dose and rate depend on the visit and how each participant tolerates the drug. Max cc per site is 50 cc per site per hour.
89579376|NCT01885000|Experimental|Brimonidine tartrate 0.5% gel|Participants applied brimonidine tartrate 0.5% gel topically once daily for 8 days.
89579377|NCT01885000|Placebo Comparator|Vehicle|Participants applied brimonidine tartrate vehicle gel topically once daily for 8 days.
89579378|NCT04735341||Subjects with planned Ion Endoluminal Procedure with pulmonary nodule|
89579379|NCT01884688|Experimental|ENK Cell Infusion|Expanded Natural Killer Cell Infusion
89579380|NCT01883362|Experimental|Standard of Care with Midostaurin|Patients received standard of care in the post stem cell transplant (SCT) setting in addition to Midostaurin 50mg twice a day for 12 months (cycles).
89579381|NCT01883362|Active Comparator|Standard of Care|Patients received standard of care alone in the post SCT setting
89579382|NCT02100813|Other|Part 1: LEO 43204|Open-label, dose escalation, 2 days treatment
89579383|NCT02100813|Active Comparator|Part 2: LEO 43204 x dose|X dose for 2 days treatment
89579384|NCT02100813|Active Comparator|Part 2: LEO 43204 Y dose|Y dose for 2 days treatment
89579385|NCT02100813|Placebo Comparator|Part 2: Placebo|Placebo for 2 days treatment
89579386|NCT04724967|Experimental|CeraVe Group|Participants in this group will receive the CeraVe Hydrating Cleanser and Moisturizing Cream for 28 days.
88972921|NCT01464671|Active Comparator|Unfractionated Heparin|Anticoagulation during percutaneous coronary intervention
88972922|NCT01464632||Primary|Post Market Study
88972923|NCT00037869|Experimental|MIBG|High Dose I-131 Metaiodobenzylguanidine
89579387|NCT01930162|Experimental|HSC835|Patients with hematologic malignancies requiring UCB transplant with a NMA conditioning regimen.
89579388|NCT04630912|Experimental|Acceptance and Commitment Therapy|12 weekly, 90 minute ACT sessions with person with dementia (with a review at week 6)
89579389|NCT02045979|Experimental|BI 695501|Subject to receive one subcutaneous (s.c.) injection from a prefilled syringe containing BI 695501
89579390|NCT02045979|Active Comparator|adalimumab-EU source|Subject to receive one subcutaneous (s.c.) injection from a prefilled syringe containing adalimumab-EU source
89579391|NCT02045979|Active Comparator|adalimumab-US source|Subject to receive one subcutaneous (s.c.) injection from a prefilled syringe containing adalimumab-US source
89579392|NCT01929226|Experimental|ETI-204|A single intravenous dose of 16 mg/kg ETI-204 infused over 90 minutes on Day 1
88972924|NCT01464554|Active Comparator|Usual Care|Teens will receive six sessions of an alcohol and drug education group
88972925|NCT01464554|Experimental|Project Free Talk|Teens will receive six sessions of and evidenced based motivational interviewing alcohol and drug program
88972926|NCT01464515|Active Comparator|Real TMS|this group will receive high frequency deep TMS treatment of 10HZ
88972927|NCT01464515|Sham Comparator|SHAM TMS|this group will receive SHAM treatment of deep TMS
88972928|NCT00037986|Other|1|
88972929|NCT00038025|Experimental|Deoxycoformycin (DCF)/Pentostatin|
88972930|NCT00393770|Experimental|L-acetylcarnitine|
88972931|NCT00038064|Active Comparator|rHuEPO|
88972932|NCT00038064|Experimental|Darbepoetin alfa|
88972933|NCT00848003|Active Comparator|1. Active|"Bifidobacterium animalis subsp. lactis (B. lactis) strain BB-12 (BB-12)~Probiotic, BB-12, supplemented yogurt, 4 ounces taken orally for 10 days"
88972934|NCT00848003|Placebo Comparator|2. Placebo|Strawberry flavored yogurt
89579393|NCT01929226|Placebo Comparator|Placebo for ETI-204|A single intravenous dose of ETI-204-placebo infused over 90 minutes on Day 1
89579394|NCT04703751|Experimental|CIRCULATE Catheter|CIRCULATE Catheter will be used to deliver nitroglycerin and CardioCell to evaluate safety and efficacy of the device
89579395|NCT05122702|Experimental|Active Arm|"18.75g of Modified Shenling Baizhu San granules will be taken twice daily for 12 weeks."
89579396|NCT05122702|Placebo Comparator|Placebo Arm|18.75g of placebo granules will be taken twice daily for 12 weeks.
89579397|NCT04734405|Experimental|ProF-001 Group|"ProF-001 Group:~• During induction period: app. 5 g of ProF-001 for 6 days (twice daily app. 2.5 g vulvar/ intravaginal application of cream), followed by 4 days of app. 2.5 g of ProF-001 at bedtime and 1 placebo capsule on days 1, 4, and 7 and~• During maintenance period: 2 doses of app. 2.5 g of ProF-001 per week for 22 weeks (total of 44 single doses) and 1 placebo capsule per week for 24 weeks"
89579398|NCT04734405|Active Comparator|Fluconazole Group|"Fluconazole Group:~During induction period:~1 Fluconazole 150 mg capsule on days 1, 4, and 7 and a daily dose of app. 5 g of placebo cream for 6 days (twice daily 2.5 g vulvar/ intravaginal application of cream), followed by 4 days of 2.5 g of placebo cream at bedtime and~During maintenance period:~capsule of fluconazole 150 mg per week for 24 weeks and two doses of 2.5 g of placebo cream per week for 22 weeks (total of 44 single doses)"
89579399|NCT02045433|Experimental|SABR Boost Therapy|
89579400|NCT01911442|Experimental|Lurasidone 20 mg|Lurasidone 20 mg once daily
89579401|NCT01911442|Experimental|Lurasidone 60 mg|Lurasidone 60 mg once daily
89579402|NCT01911442|Placebo Comparator|Placebo|Placebo once daily
88972935|NCT00038298|Experimental|50 mg|50 mg 3 times weekly
88972936|NCT00038298|Experimental|400 mg|400 mg 3 times weekly
88972937|NCT00038298|Experimental|200 mg|200 mg 3 times weekly
88972938|NCT00038298|Placebo Comparator|Placebo|Placebo comparator associated with each active arm. (3:1 active vs placebo)
88972939|NCT00847964|Experimental|Algisyl-LVR implants|Algisyl-LVR implants to the left ventricular wall
88972940|NCT05434260|Active Comparator|Surgiphor: sterile povidone iodine irrigation solution|Surgiphor Wound Irrigation Solution, bottle consisting of sterile 0.5% PVP-I formulation with 0.9% saline, Potassium Iodide, Phosphate Buffer, Vitamin E TPGS
89579403|NCT01928758|Experimental|Reduced Nicotine Content Cigarettes|The experimental group will smoke cigarettes with gradually Reduced Nicotine Content (11.6, 7.4, 3.3, 1.4, 0.7 and 0.2 mg per cigarette) cigarettes, with each nicotine level smoked for 3 weeks, except the lowest level which continues for 6 weeks
89579404|NCT01928758|Placebo Comparator|Usual Nicotine Content Cigarettes|Research cigarettes with a usual nicotine content (around 11.6mg per cigarette)
89579405|NCT01910116|Placebo Comparator|Placebo|Placebo 2 capsules, twice daily, for 12 weeks.
89579406|NCT01910116|Active Comparator|Shinbaro|Shinbaro, 2 capsules (300mg), twice daily, for 12 weeks
89579407|NCT01614886|Experimental|1 step|
89579408|NCT01614886|Active Comparator|3 step|
89579409|NCT04622254|Experimental|MP: NT 201 (incobotulinumtoxinA): UFL|Intramuscular injection.
89579410|NCT04622254|Experimental|MP: NT201 (incobotulinumtoxinA): LCL, Placebo: GFL/ HFL|Intramuscular injection.
89579411|NCT04622254|Placebo Comparator|MP: Placebo: UFL|Intramuscular injection.
89579412|NCT04622254|Experimental|OLEX: NT201 (incobotulinumtoxinA): UFL|Intramuscular injection.
89579413|NCT01880554|Other|Contrast-enhanced intraoperative ultrasound|Contrast-enhanced intraoperative ultrasound
89579414|NCT04171726|Experimental|Edoxaban|treatment with edoxaban
89579415|NCT02100657|Experimental|plitidepsin + bortezomib + dexamethasone|"Plitidepsin will be administered as a 3-hour (h) intravenous (i.v.) infusion on Day (D) 1 and 15, every four weeks (q4wk).~Bortezomib will be administered as a subcutaneous (s.c.) injection on D1, 4, 8 and 11, q4wk, for a maximum of eight cycles.~Dexamethasone will be taken orally on D1, 8, 15 and 22, q4wk"
89579416|NCT02067663||Mirena Group|Women who have a postplacental Mirena IUD placed. (LNG-IUS)
89579417|NCT02067663||Paragard Group|Women who have a postplacental Paragard IUD placed. (Copper IUD - T380A)
89579418|NCT01909804|Experimental|SOF+VEL 25 mg (GT3) without cirrhosis|Participants with genotype 3 HCV infection without cirrhosis will receive SOF+VEL 25 mg for 12 weeks.
89579419|NCT01909804|Experimental|SOF+VEL 25mg+RBV (GT3) without cirrhosis|Participants with genotype 3 HCV infection without cirrhosis will receive SOF+VEL 25 mg plus RBV for 12 weeks.
89579420|NCT01909804|Experimental|SOF+VEL 100 mg (GT3) without cirrhosis|Participants with genotype 3 HCV infection without cirrhosis will receive SOF+VEL 100 mg for 12 weeks.
89579421|NCT01909804|Experimental|SOF+VEL 100 mg+RBV (GT3) without cirrhosis|Participants with genotype 3 HCV infection without cirrhosis will receive SOF+VEL 100 mg plus RBV for 12 weeks.
89579422|NCT01909804|Experimental|SOF+VEL 25 mg (GT3) with cirrhosis|Participants with genotype 3 HCV infection with cirrhosis will receive SOF+VEL 25 mg for 12 weeks.
89579423|NCT01909804|Experimental|SOF+VEL 25 mg+RBV (GT3) with cirrhosis|Participants with genotype 3 HCV infection with cirrhosis will receive SOF+VEL 25 mg plus RBV for 12 weeks.
89579424|NCT01909804|Experimental|SOF+VEL 100 mg (GT3) with cirrhosis|Participants with genotype 3 HCV infection with cirrhosis will receive SOF+VEL 100 mg for 12 weeks.
89579425|NCT01909804|Experimental|SOF+VEL 100 mg+RBV (GT3) with cirrhosis|Participants with genotype 3 HCV infection with cirrhosis will receive SOF+VEL 100 mg plus RBV for 12 weeks.
89579426|NCT01909804|Experimental|SOF+VEL 25 mg (GT1)|Participants with genotype 1 HCV infection will receive SOF+VEL 25 mg for 12 weeks.
89579427|NCT01909804|Experimental|SOF+VEL 25 mg+RBV (GT1)|Participants with genotype 1 HCV infection will receive SOF+VEL 25 mg plus RBV for 12 weeks.
89579428|NCT01909804|Experimental|SOF+VEL 100 mg (GT1)|Participants with genotype 1 HCV infection will receive SOF+VEL 100 mg for 12 weeks.
89579429|NCT01909804|Experimental|SOF+VEL 100 mg+RBV (GT1)|Participants with genotype 1 HCV infection will receive SOF+VEL 100 mg plus RBV for 12 weeks.
88972941|NCT05434260|Placebo Comparator|Sterile saline|
88972942|NCT00847925|Other|A|50ng Avotermin/100ul
88972943|NCT00847925|Other|B|20ng Avotermin/100ul
89579430|NCT01880086|Experimental|Clomiphene citrate|The initial dose of clomiphene citrate will be 25 mg (po, pill by mouth) every other day. This will be started at visit 2, week 0 of the study following diagnosis of low baseline testosterone (serum total testosterone <350 ng/dl in men <55 years, <300 ng/dl in men 55-65 years). Clomiphene citrate dose will be titrated up to a maximum of 50 mg daily according to serum total testosterone levels measured at follow-up visits during the 3 month duration of the study.
89579431|NCT01880086|Placebo Comparator|Placebo|Placebo pill will be administered (po, pill by mouth) every other day starting at week 0 of the study in men diagnosed with low testosterone. Treatment will be delayed in these men until the 3 month completion of the study, at which time this group may also receive testosterone replacement therapy.
89579432|NCT01879852|Active Comparator|Standard Rehabilitation|Standard meniscectomy rehabilitation including knee range of motion and strengthening exercises.
89579433|NCT01879852|Experimental|Standard Rehabilitation + Quadriceps intensive strengthening|The intervention includes high-intensity neuromuscular electrical stimulation and eccentric exercises for the quadriceps muscle in addition to the standard rehabilitation protocol.
89579434|NCT01879618|Experimental|Fragmin|Fragmin given according to the flexible dosing regimen outlined in the protocol
89579435|NCT01926886|Experimental|Trastuzumab|Participants with HER2+ eBC who completed the first 6 cycles of trastuzumab IV infusion as part of the (neo) adjuvant treatment will be included to continue to receive 12 cycles of trastuzumab to complete a total of 18 cycles of trastuzumab. Participants will receive trastuzumab IV infusion at initial loading dose of 8 mg/kg BW for q3w regimen as a part of neo adjuvant treatment before entering in the study and then recommended maintenance dose of 6 mg/kg BW q3w for the first 3 cycles (cycles 7-9) in hospital followed by SC administration of trastuzumab at a fixed dose of 600 mg q3w for next 3 cycles (Cycles 10-12) at hospital and SC administration of trastuzumab at a fixed dose of 600 mg q3w at home for the next 6 cycles (Cycles 13-18) (Each cycle=21 days).
88972944|NCT00847925|Other|C|5ng Avotermin/100ul
88972945|NCT00847925|Other|D|100ng Avotermin/100ul
88972946|NCT00847925|Other|E|500ng Avotermin/100ul
88972947|NCT00847925|Other|F|0.25ng Avotermin/100ul
88972948|NCT00847925|Other|G|1ng Avotermin/100ul
89579436|NCT01926886|No Intervention|Health Care Professionals|Health Care Professionals (HCPs) included for polling purposes. HCPs were not enrolled in the study.
89579437|NCT01909336|Active Comparator|Group 1: 0.3% Saline in 3.3% dextrose (intravenous)|Group 1: 0.3% Saline in 3.3% dextrose (intravenous)
89579438|NCT01909336|Active Comparator|Group 2: 0.45% Saline in 5% dextrose (intravenous)|Group 2: 0.45% Saline in 5% dextrose (intravenous)
89579439|NCT01909336|Active Comparator|Group 3: 0.9% Saline in 5% dextrose (intravenous)|Group 3: 0.9% Saline in 5% dextrose (intravenous)
89579440|NCT01926028|Experimental|NDV-3A|Experimental Vaccine: a purified, recombinant antigen (rAls3) formulated with aluminum hydroxide adjuvant
89579441|NCT01926028|Experimental|NDV-3|Experimental Vaccine: a purified, recombinant antigen (rAls3 with 6-His tag) formulated with aluminum hydroxide adjuvant
89579442|NCT01926028|Placebo Comparator|Placebo|Placebo: aluminum hydroxide adjuvant
89579443|NCT01925950|Placebo Comparator|Placebo|Control
89579444|NCT01925950|Experimental|orBec|Investigational drug
89579445|NCT04415320|Experimental|X-396(Ensartinib) Capsule|
89579446|NCT01878292|Placebo Comparator|Placebo|Dose-matched placebo tablets, once per day, oral administration
89579447|NCT01878292|Experimental|Vilazodone 15 mg|15 mg vilazodone tablets, once per day, oral administration
89579448|NCT01878292|Experimental|vilazodone 30 mg|30 mg vilazodone tablets, once per day, oral administration
89579449|NCT01908634|Active Comparator|Milk-based Strawberry Beverage no meal|Milk-based Strawberry beverage without meal
89579450|NCT01908634|Experimental|Water-based Strawberry Beverage no meal|Water-based Strawberry beverage without meal
89579451|NCT01908634|Active Comparator|Milk-based strawberry Beverage with meal|Milk-based Strawberry beverage with meal
89579452|NCT01908634|Experimental|Water-based strawberry Beverage with meal|Water-based Strawberry beverage with meal
89579453|NCT01878214|Experimental|Intervention group|Targeted messaging
89579454|NCT01878214|Active Comparator|Control group|Standard messaging
89579455|NCT01907854|Experimental|Liraglutide + metformin + sitagliptin placebo|
89579456|NCT01907854|Experimental|Sitagliptin + metformin + liraglutide placebo|
88972949|NCT00847925|Other|H|20ng Avotermin/100ul
89579457|NCT02480153|Experimental|PF-06410293|
89579458|NCT02480153|Active Comparator|Adalimumab|
89579459|NCT04972253|Experimental|Infigratinib|"Infigratinib daily dosage per protocol 3-week on/1-week off schedule. 4 weeks will constitute 1 cycle of therapy.~Participants will receive 2 cycles (i.e. 8 weeks) and the treatment will be administered as an outpatient.~After completion of therapy, patients will undergo a CT of the chest, abdomen and pelvis (within 2 weeks of the last dose of therapy) and then proceed to Radical cystectomy 2-4 weeks after the last dose of therapy."
89579460|NCT02500979|Experimental|Pramlintide acetate & regular insulin|Pramlintide will be adiministered by sc infusion at a concentration of 1000ug/mL
89579461|NCT02500979|Placebo Comparator|Placebo and regular insulin|Placebo is similar sterile solution without pramlintide.
89579462|NCT02500901|Experimental|Experimental Treatment|Subjects will receive enzalutamide 160 mg/day PO in a 28-day lead-in cycle to assess tolerability. If well-tolerated, cycle 1 of combined enzalutamide and niraparib will commence. Enzalutamide will continue at 160 mg PO daily. Niraparib will be administered in three dose-escalation cohorts of 100mg PO, 200mg PO or 300 mg PO daily. Six subjects will be enrolled at each dose level. Each cycle will be 28 days. Combination treatment will continue until documented progression, unmanageable toxicity, or subject or treating investigator decision to discontinue for any reason.
89579463|NCT02479139|Placebo Comparator|Vehicle|Vehicle for botulinum toxin Type A topical liniment (ANT-1207) applied topically in a volume of 12 drops per axilla (armpit) once on Day 0.
89579464|NCT02479139|Experimental|ANT-1207 Dose 1|Botulinum toxin Type A topical liniment (ANT-1207) Dose 1 (lowest dose) applied topically in a volume of 12 drops per axilla (armpit) once on Day 0.
89579465|NCT02479139|Experimental|ANT-1207 Dose 2|Botulinum toxin Type A topical liniment (ANT-1207) Dose 2 (second lowest dose) applied topically in a volume of 12 drops per axilla (armpit) once on Day 0.
89579466|NCT02479139|Experimental|ANT-1207 Dose 3|Botulinum toxin Type A topical liniment (ANT-1207) Dose 3 (mid-level dose) applied topically in a volume of 12 drops per axilla (armpit) once on Day 0.
89579467|NCT02479139|Experimental|ANT-1207 Dose 4|Botulinum toxin Type A topical liniment (ANT-1207) Dose 4 (second highest dose) applied topically in a volume of 12 drops per axilla (armpit) once on Day 0.
89579468|NCT02479139|Experimental|ANT-1207 Dose 5|Botulinum toxin Type A topical liniment (ANT-1207) Dose 5 (highest dose) applied topically in a volume of 12 drops per axilla (armpit) once on Day 0.
89579469|NCT02478359|No Intervention|Standard Care|Standard care patients received their routine care from Kaiser Permanente Southern California and had access to all health services in accordance with their health plan
89579470|NCT02478359|Experimental|Physical Activity Coaching (Walk On!)|The 12-month Walk On! intervention included a baseline in-person assessment, collaborative monitoring of steps using two types of activity sensors, semi-automated step goal recommendations using an interactive voice response system or web application, ongoing individualized reinforcement from a physical activity coach, and peer/family support.
89579471|NCT01877668|Experimental|Tofacitinib 5 mgBID x 12 months|
89579472|NCT01877668|Experimental|Tofacitinib 10 mg BID x 12 months|
89579473|NCT01877668|Active Comparator|Adalimumab 40 mg q2 weeks x 12 months|
89579474|NCT01877668|Placebo Comparator|Placebo x3 months, then tofacitinib 5 mg BIDx 9 months|
89579475|NCT01877668|Placebo Comparator|Placebo x 3 months, then tofacitinib 10 mg BID x 9 months|
89579476|NCT01877278|Active Comparator|active|Group wearing the active device emitting pulsed electromagnetic fileds
88972950|NCT00847925|Other|I|50ng Avotermin/100ul
89579477|NCT01877278|Placebo Comparator|placebo|Group wearing the device non-emitting pulsed electromagnetic fileds
89579478|NCT01906372|Experimental|Acthar Gel|Acthar Gel (Adrenocorticotropic Hormone Gel)in refractory PM and DM patients using an open label design for 6 months. We will enroll 10 active and refractory PM/DM patients over a 15 month period, followed by 6 months of additional follow-up for each subject. Study subjects will self-administer subcutaneously H.P. Acthar Gel 80 units (1 ml) twice a week for a period of six months. Outcome measures were not evaluated on subjects who did not reach the 8 week time point in the trial.
89579479|NCT01925170|Experimental|Mammography and Molecular Breast Imaging|Participants underwent conventional mammography and molecular breast imaging after a 740-millibecquerel (mBQ) (8-mCi) Technetium (99mTc) sestamibi injection.
89579480|NCT01925014|Experimental|Low-dose CT|Diagnostic CT with low-dose radiation
89579481|NCT01925014|Active Comparator|Standard-dose CT|Diagnostic CT with standard-dose radiation
89579482|NCT01876810|Experimental|Gemfibrozil|600 mg of gemfibrozil (one capsule) twice daily for two weeks.
89579483|NCT01876810|Placebo Comparator|Placebo pill|One lactose pill twice a day for two weeks.
89579484|NCT01876732|Experimental|Vitamin B12|Those with an MMA over 800nmol/L are given 1000mcg of intramuscular (IM) vitamin B12 weekly for the first month and then monthly for 3 consecutive months.
89579485|NCT01905592|Active Comparator|Physician's choice|Physician may select from 4 active comparators
89579486|NCT01905592|Experimental|niraparib|Patients will be randomized 2:1 to receive niraparib 300 mg (3x100 mg capsules) once daily for 21 continuous days
89579487|NCT01876420|Experimental|The CoreValve™ Evolut R TAV™ system|CoreValve™ Evolut R™ System which consists of the Evolut R™ Transcatheter Aortic Valve (26 & 29 mm sizes), EnVeo R™ Delivery Catheter System with Enveo InLine™ Sheath, and EnVeo R™ Loading System
89579488|NCT04608682|Experimental|Sugammadex group|
89579489|NCT04608682|Sham Comparator|control group|
89579490|NCT01875874|Experimental|ELAD plus standard of care|Continuous ELAD treatment for a minimum of 3 days to a maximum of 10 days in addition to a standard of care for subjects with acute liver failure.
89579491|NCT04619446||Removable Twin Block appliance group|Patient to be treated with removable twin block appliance that are known Class II skeletal and dental subjects.
89579492|NCT04619446||Fixed Functional Appliance AdvanSync group|Patients to be treated with fixed functional appliance, AdvanSync (Molar-to-Molar) Class II Corrector
89579493|NCT02500121|Placebo Comparator|Control Arm A|Commercially available normal saline will be used as the placebo. No active placebo drug will be mixed with the normal saline. Treatment will continue, in the absence of prohibitive toxicities or disease progression, for up to 24 months.
89579494|NCT02500121|Experimental|Experimental Arm B|Pembrolizumab, 200mg IV every 3 weeks. Treatment will continue, in the absence of prohibitive toxicities or disease progression, for up to 24 months.
89579495|NCT01875250|Experimental|Arm A - Enzalutamide for 3 months|Enzalutamide for 3 months
89579496|NCT01875250|Experimental|Arm B - Enzalutamide for 3 months + PSA-TRICOM|Enzalutamide 3 months + PSA-TRICOM (Prostvac-V/F) on weeks 1, 3, 5, 9,13,17 and 21
89579497|NCT01904032|Experimental|Vitamin D3|50,000 international units (IUs) weekly Vitamin D3
89579498|NCT01904032|Active Comparator|Vitamin D3 comparator|5,000 international units (IUs) of a weekly Vitamin D3 comparator
89579499|NCT01903876|Placebo Comparator|General Health promotion|A 3-hour general mental health web-based program.
89579500|NCT01903876|Experimental|Bystander & Sexual Violence Prevention|A 3-hour web-based program designed to teach male college student bystanders to intervene.
89579501|NCT01921348|Experimental|Treatment|34 participants will be randomized to wear acupressure pellets in the designated acupressure points and apply pressure as instructed by the study personnel.
89579502|NCT01921348|Sham Comparator|Sham|33 participants will be randomized to wear acupressure pellets in non-specific areas of the ear and apply pressure as instructed by the study personnel.
89579503|NCT01921270|Experimental|Dysport Injections|Participants with OMD who have been previously treated with any botulinum toxin Type A will be injected with Dysport®.
89579504|NCT02325739|Experimental|Phase I: FGF401 50 mg fasted|Participants received single agent FGF401 50 mg while fasted
89579505|NCT02325739|Experimental|Phase I: FGF401 80 mg fasted|Participants received single agent FGF401 80 mg while fasted
89579506|NCT02325739|Experimental|Phase I: FGF401 80 mg fed|Participants received single agent FGF401 80 mg while fed
89579507|NCT02325739|Experimental|Phase I: FGF401 120 mg fasted|Participants received single agent FGF401 120 mg while fasted
89579508|NCT02325739|Experimental|Phase I: FGF401 120 mg fed|Participants received single agent FGF401 120 mg while fed
89579509|NCT02325739|Experimental|Phase I: FGF401 150 mg fasted|Participants received single agent FGF401 150 mg while fasted
89579510|NCT02325739|Experimental|Phase I: FGF401 80 mg + PDR001 300 mg|Participants received FGF401 80 mg in combination with PDR001 300 mg while fasted
89579511|NCT02325739|Experimental|Phase I: FGF401 120 mg + PDR001 300 mg|Participants received FGF401 120 mg in combination with PDR001 300 mg while fasted
89579512|NCT02325739|Experimental|Phase II: Group 1 - FGF401 120 mg QD|Group 1 was comprised of HCC participants from Asian countries who received single agent FGF401 120 mg QD while fasted
89579513|NCT02325739|Experimental|Phase II: Group 2 - FGF401 120 mg QD|Group 2 was comprised of HCC participants from non-Asian countries who took single agent FGF401 120 mg QD while fasted
89579514|NCT02325739|Experimental|Phase II: Group 3 - FGF401 120 mg QD|Group 3 was comprised of participants with other solid malignancies regardless of geography who took single agent FGF401 120 mg QD while fasted
89579515|NCT05121922|Experimental|Intervention|All patients recieve active treatment
89579516|NCT01903720|Experimental|OZURDEX®|OZURDEX® (700 µg dexamethasone implant) administered intravitreally on day 0, and approximately every 4 months as needed (based on physician judgment) for up to 12 months.
89579517|NCT02366689|Active Comparator|Toothpaste|Triclosan/fluoride toothpaste
89579518|NCT02366689|Active Comparator|Toothpaste + mouthwash|stannous fluoride toothpaste + cetylpyridinium chloride Mouthwash
89579519|NCT02366689|Placebo Comparator|Fluoride only Toothpaste + mouthwash|Fluoride only toothpaste + Fluoride only Mouthwash
89579520|NCT01903252|Experimental|TP05 (Mesalazine) 1600mg|week 1 - week 12 (blinded), week 13 - week 38 (OpenLabel)
89579521|NCT01903252|Active Comparator|Asacol 400 mg (Tillotts Pharma)|week 1 - week 12 (blinded), switch to TP05 for weeks 13-38 (open label)
89579522|NCT01920958||TachoSil®|TachoSil®, sterile absorbable patch, topical application, used during surgery in participants who had lymphadenectomy according to the Summary of Product Characteristics.
89029512|NCT02954484|Placebo Comparator|PLACEBO|All subjects receive intravenous PCA morphine, paracetamol 1g po six hourly and etoricoxib 120mg po once daily. Subjects receive either placebo tablet (of identical appearance to pregabalin) orally preoperatively followed by 75mg at night for two days. During surgery, patients received general anaesthesia with femoral nerve block on the side of surgery.
89029513|NCT01247987|Active Comparator|Blastocyst cryopreservation|Subjects randomly assigned to this arm of the study will have all of their embryos cryopreserved at the blastocyst stage, followed by thaw and transfer in a subsequent menstrual cycle.
89029514|NCT01247987|Experimental|Bipronuclear oocyte cryopreservation|Subjects randomly assigned to this arm of the study will have all of their bipronuclear oocytes cryopreserved, followed by thaw, extended culture, and transfer in a subsequent menstrual cycle.
89579523|NCT04415398|Experimental|Delivery of automated external defibrillators using drones|"Three drone systems are setup to be deployed in suspected OHCA cases as a complement to EMS. This is a single-arm intervention evaluating feasibility in:~Operational feasibility (Legislation, Weather conditions, conflict in airspace)~Participant feasibility (Failure to respond; Dispatcher, Drone-pilot, Air traffic controller)~Technological feasibility (Drone technology, software, winch-system , 4G network, radio communication"
89579524|NCT01613716|Experimental|Ozurdex|Subjects will receive Ozurdex injections and will be monitored for macular edema.
89579525|NCT01872910|Placebo Comparator|Placebo|"Part A: Single oral administration of placebo matching corresponding LY3023703 dose administered orally once as a capsule post dental surgery.~Part B: Single oral administration of placebo matching corresponding LY3023703 administered orally once as a capsule, post dental surgery and post dialysate probe placement.~Part B of this study assessed whether LY3023703 selectively inhibited the prostaglandin E(PGE) surge in the wound dialysate during the postoperative period."
89579526|NCT01872910|Experimental|30 milligrams (mg) LY3023703|"Part A: Single oral administration of 30 milligrams (mg) LY3023703 administered orally once as a 30-milligrams (mg) capsule post dental surgery.~Part B: Single oral administration of 30 milligrams (mg) LY3023703 administered orally once as a 30-mg capsule, post dental surgery and post dialysate probe placement.~Part B of this study assessed whether LY3023703 selectively inhibited the prostaglandin E(PGE) surge in the wound dialysate during the postoperative period."
89579527|NCT01872910|Active Comparator|400 mg Celecoxib|"Part A: Single oral administration of 400 mg celecoxib (Positive control) administered orally once as two 200-mg capsules post dental surgery (Positive control).~Participants received two 200-mg celecoxib capsules during Pre-Part B.The purpose of Pre-Part B was to develop proficiency in the dialysate placement, collection, and maintenance techniques before moving to Part B.~Celecoxib was not administered in Part B.~Part B of this study assessed whether LY3023703 selectively inhibited the prostaglandin E(PGE) surge in the wound dialysate during the postoperative period."
89579528|NCT01920568|Experimental|Denosumab 120 mg|Subjects will be administered with Denosumab 120 mg subcutaneous (SC) injection for a maximum of 13 doses and placebo IV infusion over &gt;=15 minutes once every 4 weeks.
89579529|NCT01920568|Experimental|Zoledronic acid 4 mg|Subjects will be administered with Zoledronic acid 4 mg IV infusion over a minimum of 15 minutes for a maximum of 13 doses and placebo SC once every 4 weeks.
89579530|NCT01902628||Participants with CKD|This single cohort included participants with CKD not receiving dialysis (Stages 3 and 4), with renal anemia, treated with MIRCERA according to usual clinical practice.
89579531|NCT01920178|Active Comparator|PinPointe Foot Laser|Active laser
89029515|NCT02954367|Experimental|PROTEIN (MEAT + WHEY)|Post workout (training days) or breakfast (non training days) 20g of meat protein (10g meat + 10g whey) mixed with 200ml of orange juice and water
89029516|NCT02954367|Placebo Comparator|CARBOHYDRATE (CHO)|Post workout (training days) or breakfast (non training days) 20g of maltodextrin mixed with 200ml orange juice and water
89029517|NCT01248026|Experimental|Buttermilk|
89029518|NCT01248026|Placebo Comparator|Placebo|
89579532|NCT01920178|Sham Comparator|Sham laser group|Treatment with only localizing (aiming) beam of Pinpointe Foot Laser
89579533|NCT01901848|Experimental|CPT+ICSC|This arm includes 12 sessions of combined Cognitive Processing Therapy (CPT) and Integrated Care for Smoking Cessation (ICSC), involvement in smokefreeVET.gov's text messaging program for smoking cessation, Bupropion use, and nicotine replacement therapy.
89579534|NCT01901848|Active Comparator|ICSC only|This arm includes 12 sessions of Integrated Care for Smoking Cessation (ICSC), involvement in smokefreeVET.gov's text messaging program for smoking cessation, Bupropion use, and nicotine replacement therapy.
89579535|NCT04415632|Experimental|LGI Diet|low glycemic index diet
89579536|NCT04415632|Other|HGI Diet|High glycemic index diet
89579537|NCT01901614|Experimental|LALAK|laser-assisted lamellar anterior keratoplasty. Optical Coherence Tomography, femtosecond laser, topical anesthesia, and Retrobulbar Block or General Anesthesia will be used.
89579538|NCT01901614|Active Comparator|IEK|Intralase-enabled keratoplasty. Femtosecond laser and Retrobulbar Block or General Anesthesia will be used.
89029519|NCT02954133|Experimental|I7: Control|Subjects assigned to this group receive no OrthoPulse™ treatment, and switch Invisalign aligners every 7 days.
89029520|NCT02954133|Experimental|OP7: OrthoPulse Treatment|Subjects assigned to this group receive daily OrthoPulse™ treatments, and switch Invisalign aligners every 7 days.
89029521|NCT02954133|Experimental|OP5: OrthoPulse Treatment|Subjects assigned to this group receive daily OrthoPulse™ treatments, and switch Invisalign aligners every 5 days.
89029522|NCT02954133|Experimental|OP3.5: OrthoPulse Treatment|Subjects assigned to this group receive daily OrthoPulse™ treatments, and switch Invisalign aligners every 3.5 days.
89029523|NCT00500942||1|Patients having a standard procedure performed in Interventional Radiology.
89029524|NCT00500981|Experimental|Intravenous fluid bolus|Administration of 500 ml of 10% pentastarch
89029525|NCT00508014|Active Comparator|Control|usual care
89029526|NCT00508014|Experimental|Concurrent Peer Review Visit|See description of interventioin
89029527|NCT00501098|Experimental|I|"Patients will receive caspofungin, starting from the first day of induction chemotherapy for leukemia, as a single daily dose intravenously at the dosage of 70 mg q.d. and followed by 50 mg q.d. thereafter until documentation of complete hematologic remission after the first induction cycle or of leukemia persistence after one cycle of induction and one cycle of salvage chemotherapy.~No stratification is planned."
89029528|NCT00508053|Active Comparator|1|Mass closure
89029529|NCT00508053|Experimental|2|Small stitches
89029530|NCT00501137|Active Comparator|16-26 year olds 3 doses HPV Vaccine|Group 3 - 16-26 year olds receiving 3 doses HPV (Human Papillomavirus) Vaccine at 0, 2, 6 mths
89029531|NCT00501137|Active Comparator|3 dose 9-13 HPV Vaccine|Group 2 - 9-13 year olds receiving 3 doses HPV (Human Papillomavirus) Vaccine at 0,2,6 mths
89579539|NCT01901302|Experimental|CB-5945|0.25 milligrams (mg) CB-5945 administered orally twice daily (BID) for a 12-week treatment period
89579540|NCT01901302|Placebo Comparator|Placebo|Placebo BID for a 12-week treatment period
89579541|NCT04606420|Experimental|Experimental (Intervention) Group|These patients will receive the comprehensive lifestyle medicine intervention from day 1 through the end of the study. They will be tested at baseline, after 20 weeks, and after 40 weeks.
89579542|NCT04606420|No Intervention|Control (Non-Intervention) Group|"These patients will be asked to continue their current diet and lifestyle without making any changes for 20 weeks. They will be tested at baseline and after 20 weeks. Then, they will cross over and receive the same lifestyle medicine intervention for 20 weeks and will be tested again after 20 weeks of the intervention and also after 40 weeks of the intervention. After 20 weeks in the randomized control group, patients who no longer meet these eligibility criteria (e.g, a MoCA score <18) will not cross over and will not receive the lifestyle intervention; their data during the first 20 weeks in the control group (when they met the entry criteria) will be used."
89579543|NCT04415242|Active Comparator|suspension group|Arm on the side operated at 90 ° abduction, 90 ° anti-drive, resting on an arm support.
89579544|NCT04415242|Experimental|supported group|Arm on the operated side at 0 ° abduction, 90 ° anti-pulsation, resting on an adjustable support arm support located opposite the patient's head.
89579545|NCT01919398|Experimental|LY2940680|"Cohort 1: 100 mg LY2940680 administered orally daily in 28-day cycles. Cohort 2: 200 mg LY2940680 administered orally daily in 28-day cycles. Cohort 3: 400 mg LY2940680 administered orally daily in 28-day cycles.~Treatment with LY2940680 continued until disease progression, unacceptable toxicity, or other discontinuation criteria were met."
89579546|NCT04626154|Active Comparator|Respiratory insufficiency or distress|Patients demonstrating respiratory insufficiency or distress.
88972951|NCT05434221|Experimental|Experiment group|interns in the experiment group receive COPE during their internship.
88972952|NCT05434221|No Intervention|Control group|interns in the control group do not receive any specific communication training during their internship.
88972953|NCT00847847|Other|2|control subjects with muscle biopsy
88972954|NCT00847847|Other|1|ALS patients with muscle biopsy
88972955|NCT00847769|Experimental|High velocity, low amplitude stretch|With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface. A thrust will be delivered parallel to the long axis of the subject's lower leg after the treating therapist induces passive ankle dorsiflexion to end range.
88972956|NCT00847769|Active Comparator|Slow, mobilization stretch|With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface. Traction will be delivered to the talocrural joint at the treating therapist's second perception of tissue resistance in 3 bouts of 30-second holds, separated by 10 seconds of rest.
88972957|NCT00847769|Sham Comparator|Passive positioning|With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface, which is similar to the positioning used for the active comparator groups. The treating investigator will maintain passive positioning of the ankle for the duration of 1 deep inhalation and exhalation by the subject rather than induce an iatrogenic force.
88972958|NCT04711772||DOR group|Genomic DNA will be extracted from peripheral blood leukocytes to perform whole-genome sequencing in participates with diminished ovarian reserve.
88972959|NCT04711772||Control group|Participants with normal ovarian reserve will be recruited as control group and peripheral blood leukocytes genomic DNA will be extracted to perform whole-genome sequencing.
88972960|NCT00847691||Sarcoma|patients with biopsy or excision of sarcoma (suspected or diagnosed)
88972961|NCT04732299||Acute thrombus group|Within 14 days after onset
88972962|NCT04732299||Subacute thrombus group|During 15-30 days after onset
88972963|NCT04732299||Chronic thrombosis group|More than 15-30 days after onset
88972964|NCT00847496|Experimental|1|AWBAT
88972965|NCT00847496|Active Comparator|2|BIOBRANE(R)
88972966|NCT04733339||'Traditional' group|10 stroke patients
88972967|NCT04733339||'Technology-supported' group|10 stroke patients
88972968|NCT02971020|Other|Surgical Aortic Valve Replacement|Montreal Cognitive Assessment (MoCA); Trail Making Test Part A; Trail Making Test Part B; Phonemic Fluency (letter fluency) and Semantic Fluency (category).
88972969|NCT02971020|Other|Transcatheter Aortic Valve Replacement|Montreal Cognitive Assessment (MoCA); Trail Making Test Part A; Trail Making Test Part B; Phonemic Fluency (letter fluency) and Semantic Fluency (category).
88972970|NCT00847457|Experimental|Aerobic exercise|Participants will perform aerobic exercise regularly for 12 weeks.
88972971|NCT00847457|Active Comparator|Stretch|Participants will stretch regularly for 12 weeks.
88972972|NCT00847418|Experimental|Esketamine|
88972973|NCT02971943|Other|internal fixation for ankle fractures|The patients with ankle injury underwent internal fixation for ankle fractures and ligament repair. Ankle was observed with X-ray and magnetic resonance imaging preoperatively and 3 months postoperatively.
88972974|NCT05433597|Placebo Comparator|Control group|"Chemotherapy: 5-fu: 200mg/m2/d, continuous intravenous infusion on the 1st to 30th day of each cycle; Cisplatin: 80mg/m2, used on the 1st and 28th day of each cycle; Q60d; Every 2 months for a treatment cycle, use 2 cycles, a total of 4 months.~Radiotherapy: Radiotherapy was initiated on day 15 of the first cycle of chemotherapy GTV: 6810cGy (227 cGy/30f) Or 6996 cGy (212 cGy/ 33F); CTV: 5400-6000 cGy (180-200 cGy/f); Radiotherapy once a day, 5 times a week, a total of 30-33 times, a total of about 6 weeks.~Placebo: Normal saline 1-2ml, intramuscular injection, QD, 30 days in the first and third months, once a day."
89029532|NCT00501137|Active Comparator|2 dose 9-13 yrs HPV Vaccine|Group 1 9-13 year olds 2 doses HPV (Human Papillomavirus) Vaccine at 0 and 6 mths
89029533|NCT00508131|Active Comparator|A|Milk fortified with, iron, zinc and vitamin C
89029534|NCT00508131|Placebo Comparator|B|Milk not fortified
89029535|NCT01248260|Experimental|Higher-strength folic acid|Higher-strength folic acid (4mg).
89029536|NCT01248260|No Intervention|Low-strength folic acid|Low-strength (0.8mg) folic acid (standard of care)
89029537|NCT00508950|Other|All subjects|All subjects
89029538|NCT01246037|Experimental|First placebo|First half year placebo, second half year bisoprolol
89029539|NCT01246037|Experimental|First Bisoprolol|First half year bisoprolol, second half year placebo
89029540|NCT00501215|Experimental|Parathyroidectomy + Observation|
89029541|NCT00501215|Other|Observation Alone|
89029542|NCT00509301|Experimental|1|1.5 mCi/cc
89029543|NCT00509301|Experimental|2|2.0 mCi/cc
89579547|NCT04626154|Sham Comparator|No respiratory insufficiency or distress.|Patients NOT demonstrating respiratory insufficiency or distress.
89579548|NCT02500043|Experimental|TAS-102+BSC|Participants received 35 milligrams per meter square (mg/m^2) of TAS-102 tablets orally twice daily (BID) for 5 days per week (i.e., from Days 1 to 5 and Days 8 to 12) for 2 weeks followed by 14 days rest in each 28-day cycle along with BSC until a discontinuation criterion (participant withdrawal, disease progression, irreversible treatment-related Grade 4 non-hematologic event, physician's decision, pregnancy or death) was met.
89029544|NCT00509301|Experimental|3|2.5 mCi/cc
89029545|NCT01248338|Active Comparator|metoprolol, tablets|metoprolol succinate 50-100 mg orally daily for one year
89029546|NCT01248338|Experimental|nebivolol|nebivolol 5 mg capsule once daily for one year
89029547|NCT01248377||Cephalosporins allergic patients|
89029548|NCT01246154||EXERCISE TOLERANCE|
89029549|NCT02953743|Experimental|Lenvatinib 12 mg|Participants weighing ≥ 60 kg will be enrolled in this arm.
89029550|NCT02953743|Experimental|Lenvatinib 8 mg|Participants weighing < 60 kg will be enrolled in this arm.
89029551|NCT01246193|Experimental|CKD-828(Fixed Dose Combination)|Single oral dose of a FDC tablet consisting of Telmisatan 80mg/S-Amlodipine 2.5mg
89029552|NCT01246193|Active Comparator|Combination Therapy|Co-administration of single oral doses of a 80mg tablet of Telmisatan and a 2.5 mg tablet of S-Amlodipine
89029553|NCT00509340|No Intervention|1|Participants will receive usual clinical care, which may or may not include mental health treatment
89029554|NCT00509340|Experimental|2|Participants will receive cognitive behavioral intervention
89029555|NCT02274935|Experimental|Gait and balance exercise|Traditional exercises focusing on gait and balance
89029556|NCT02274935|Experimental|Cognitive training and physical exercise|Gait and balance exercises done in combination with cognitive training (i.e. counting backwards by 7s from 98)
89029557|NCT00509379|Experimental|1|All patients will be treated with six courses of therapy with a thirteen day rest period between them. Courses will be restarted at day 36.
89029558|NCT01246271||Sub urethral sling|
89029559|NCT01246271||sus with anterior vainal wall repair|
89029560|NCT00509418|Experimental|A|Viusid, a nutritional supplement, in combination with controlled diet and exercise
89579549|NCT02500043|Experimental|Placebo+BSC|Participants received 35 mg/m^2 of matching placebo for TAS-102 tablets orally BID for 5 days per week (i.e., from Days 1 to 5 and Days 8 to 12) for 2 weeks followed by 14 days rest in each 28-day cycle along with BSC until discontinuation criterion (participant withdrawal, disease progression, irreversible treatment-related Grade 4 non-hematologic event, physician's decision, pregnancy or death) was met.
89579550|NCT02499575|Active Comparator|Regional Block|Group A patients will receive only a pre-operative adductor canal block with 10 mL 0.5% ropivacaine plus a popliteal block with 30 mL 0.5% ropivacaine (total block 40 mL/200 mg).
89579551|NCT02499575|Experimental|Regional Block Plus Exparel|Group B patients will receive the standard of care pre-operative adductor and popliteal block as described (40 mL/200 mg of 0.5% ropivacaine) in addition to a postoperative pericapsular injection of Exparel using 106 mg (8 mL, equivalent to 120 mg bupivacaine HCl), per the same total dose as provided in manufacturer recommendations.
89579552|NCT02065791|Experimental|Canagliflozin 100 mg|Each participant will receive 100 mg of canagliflozin once daily
89579553|NCT02065791|Placebo Comparator|Placebo|Each participant will receive matching placebo once daily
89029561|NCT00509418|Active Comparator|B|Controlled diet and exercise
89029562|NCT02274974|Active Comparator|lidocaine|20 ml of 2% lidocaine.
89029563|NCT02274974|Experimental|lidocaine and epinephrine.|20 ml of 2% lidocaine and epinephrine in related dose manner 1:200.000. I.e.: by adding 1/4 from ampoule of adrenaline 1mg./1ml to bottle of lidocaine Hydrochloric acid (HCL) 2% 50 ml(20mg/ml).
89029564|NCT02274545|Experimental|H7N9 live attenuated vaccine & inactivated subvirion H7N9 vac.|Participants will receive one dose of the H7N9 vaccine at Days 0 and 28. They will receive one dose of the inactivated subvirion H7N9 vaccine on Day 98.
89029565|NCT02953470|Experimental|Individual tailored functional exercise|Receives general advice about physical activity with the goal to be physically active at least 30 minutes per day at 5 of 7 days per week. The intervention group, which is based on a behavioural medicine approach in physiotherapy, also receive individual tailored functional exercise with the goal to enhance the ability to perform everyday activities by reduce pain-related disability and pain-related beliefs and increase physical function. The participants receive 9 visits from a physiotherapist during the 12 weeks period. The participants will also fill in a activity diary to check the compliance to the intervention and to enhance their self-efficacy in relation to perform everyday activities, exercise and physical activity.
89579554|NCT02499263||Participants with Ulcerative Colitis (UC)|Adalimumab 160 mg at week 0, 80 mg at week 2, and then 40 mg every other week per the Korean label in participants with active moderate-to-severe UC.
89579555|NCT01654289|Experimental|Mindfulness Meditation|Training will consist of a standardized 8-week Mindfulness Based Stress Reduction (MBSR) program, including 2½ hour weekly sessions and approximately 45 minutes per day at-home daily practice.
89579556|NCT01654289|Experimental|Exercise|The exercise intervention structure is consistent with many standardized exercise programs. The exercise program will match the meditation program in duration (8 weeks), attention (weekly 2½ hour group sessions), and intensity (daily 45 minute at-home practice).
88972975|NCT05433597|Active Comparator|Experimental group|"Chemotherapy: 5-fu: 200mg/m2/d, continuous intravenous infusion on the 1st to 30th day of each cycle; Cisplatin: 80mg/m2, used on the 1st and 28th day of each cycle; Q60d; Every 2 months for a treatment cycle, use 2 cycles, a total of 4 months.~Radiotherapy: Radiotherapy was initiated on day 15 of the first cycle of chemotherapy GTV: 6810cGy (227 cGy/30f) Or 6996 cGy (212 cGy/ 33F); CTV: 5400-6000 cGy (180-200 cGy/f); Radiotherapy once a day, 5 times a week, a total of 30-33 times, a total of about 6 weeks.~Tianenfu (recombinant human tumor necrosis factor for injection) : 1 million IU (BSA<2.0m2) or 1.5 million IU (BSA≥2.0m2), dissolved in normal saline 1-2mL, intrascularization, QD, 30 days in the first and third months, once a day."
88972976|NCT00847262|Experimental|Telmisartan Group|Telmisartan intervention group
88972977|NCT00847262|Active Comparator|Amlodipine Group|Amlodipine intervention group
88972978|NCT05433363||normal control|normal, cognitive test normal, PET(-)
88972979|NCT05433363||cognitive disorder due to AD|PET Aβ（+），MCI-AD and AD dementia
88972980|NCT05433363||cognitive disorder NOT due to AD|PET Aβ（-），MCI or dementia not due to AD
88972981|NCT00847223|Experimental|ZARNESTRA (Tipifarnib)|
88972982|NCT00847184|Active Comparator|1. Airtraq|Intubation with the use of the Airtraq technique
88972983|NCT00847184|Active Comparator|2. MacIntosh|Intubation using the standard MacIntosh blade
88972984|NCT05432973|Experimental|PENS|
88972985|NCT05432973|Active Comparator|Neurodynamics and manual therapy|
88972986|NCT04733456||IBD Patients (UC and CD)|"Participants will complete a Mayo Clinic Score (UC) or HBI score (CD), short IBDQ73, *EQ5D-5L, *GAD-774, *PHQ-975, *PROMIS (Gastrointestinal Belly Pain), Multidimensional Assessment of Interoceptive Awareness (MAIA)77, *Pain Catastrophizing Scale, Pittsburg Sleep Quality Index (PSQI) and Fatigue Severity Scale (FSS) at baseline and 16 weeks after the start of anti-TNF therapy (*questionnaires available through the CIHR IMAGINE grant).~Stool will be collected at baseline and after 16 weeks for assessment of the known biomarker fecal calprotectin, in addition to fecal bacterial and fungal microbiome (through the International Microbiome Center [IMC], U of C). Blood will be drawn and urine collected at baseline and after 16 weeks for inflammatory markers and metabolomic [IMC] analysis"
88972987|NCT02971215|Experimental|High-intensity laser therapy|High-intensity laser therapy application through iLux Laser device
88972988|NCT02971215|Sham Comparator|Sham device|Sham high-intensity laser therapy application through sham iLux Laser device
88972989|NCT00847067|Active Comparator|Block|
88972990|NCT00847067|Sham Comparator|Sham injection|Skin injections with Normal Saline
88972991|NCT00396669|Experimental|Dopamine release|
88972992|NCT00847028|Experimental|1|glucose 10%
88972993|NCT00847028|Experimental|2|glucose 20%
88972994|NCT00847028|Experimental|3|glucose 30%
88972995|NCT00847028|Placebo Comparator|4|placebo: sterile water
88972996|NCT02970903|Experimental|VitalPAD|Using VitalPAD prototype device
88972997|NCT02970903|Active Comparator|Control|Using traditional tools (monitors, paper records)
88972998|NCT00846989|Experimental|1|
88972999|NCT00846989|Experimental|2|
89209406|NCT00278629|Experimental|Hematopoietic Stem Cell Transplantation in CIDP|Autologous hematopoietic stem cell transplantation will be performed after conditioning regimen of cyclophosphamide 200 mg/kg/intravenously(IV), rATG(thymoglobulin) 5.5 mg/kg/IV and rituximab 1000mg/IV.
89209407|NCT00883350|Experimental|RIDE|Participants randomized to utilize the RIDE e-health application for the duration of the 12 week intervention.
89579557|NCT01654289|No Intervention|Wait-list control|"Apart from not attending any of the specific meditation or exercise training sessions, those in the control group will be treated in essentially the same manner as experimental participants."
89579558|NCT02499029|Experimental|N-Acetylcysteine|Eligible participants were randomized to either NAC (2400 mg/day) or placebo for 8 weeks. The starting dose of NAC was 1200 mg twice daily (2400 mg/day). All NAC and placebo capsules contained riboflavin 25 mg, which was used as a biomarker for medication compliance.
89579559|NCT02499029|Placebo Comparator|Placebo|Identical appearing placebo capsules were dispensed. All NAC and placebo capsules contained riboflavin 25 mg, which was used as a biomarker for medication compliance. Study medications (USP-grade NAC and matched placebo capsules) dispensed to participants by the medical clinician or study staff. Treatment assignment followed a pre-arranged randomization scheme and was carried out by study personnel at the pharmacy (i.e., personnel not involved in clinical management of participants to preserve the double-blind design).
89579560|NCT04968353|Active Comparator|Incisally-beveled|Use of incisally-beveled attachment to extrude lateral incisor
89579561|NCT04968353|Active Comparator|Gingivally-beveled|Use of gingivally-beveled attachment to extrude lateral incisor
89579562|NCT04968353|Active Comparator|Optimized|Use of optimized attachment to extrude lateral incisor
88973000|NCT00846989|Active Comparator|3|
88973001|NCT00396747|Active Comparator|A|Methotrexate
88973002|NCT00396747|Active Comparator|B|MTX + MP
88973003|NCT00396747|Active Comparator|C|MTX + IFX
88973004|NCT00846950|Experimental|healthy volunteers|
88973005|NCT00846911||Group 1|
88973006|NCT05432895|Active Comparator|Control( static splinting)|conventional static splint
89579563|NCT04968353|Active Comparator|Horizontal|Use of horizontal (unbeveled) attachment to extrude lateral incisor
89579564|NCT02065713|Experimental|Golimumab in combination with methotrexate|"Golimumab 50mg, subcutaneous, once monthly, for 24 weeks, in combination with MTX.~MTX started at 15mg/weekly at baseline, increased to 20mg/weekly at week 4 and to 25mg/weekly at week 8, maintaining the dose of 25mg/weekly throughout the trial period of 24 weeks, except in case of intolerance or toxicity"
89579565|NCT02065713|Active Comparator|Placebo in combination with methotrexate|MTX started at 15mg/weekly at baseline, increased to 20mg/weekly at week 4 and to 25mg/weekly at week 8, maintaining the dose of 25mg/weekly throughout the trial period of 24 weeks, except in case of intolerance or toxicity.
89579566|NCT04701489|Experimental|Ultrasound Group|Daily ultrasound application to the spleen of approximately 10 minutes for up to 7 days, in addition to standard clinical care.
89579567|NCT04701489|No Intervention|Control Group|Standard clinical care with no ultrasound stimulation.
89579568|NCT02497781|Experimental|ceftazidime-avibactam (CAZ-AVI)|CAZ-AVI to be administered every 8 hours as a 2-hour infusion (CAZ-AVI dose and frequency of IV administration will depend upon body weight and renal function)
89579569|NCT02497781|Active Comparator|Cefepime|Patients randomised to receive cefepime should receive the dose, schedule and infusion duration as recommended in the local prescribing information or as prescribed by the investigator. The maximum dose of cefepime in any single infusion should not exceed 2000 mg
89579570|NCT02497469|Experimental|Vedolizumab IV 300 mg|Vedolizumab 300 milligram (mg), infusion, intravenously over 30 minutes on Day 1 and Weeks 2, 6, 14, 22, 30, 38, and 46. Adalimumab placebo-matching injection, subcutaneously on Day 1, Week 2, and every 2 weeks thereafter up to Week 50.
89579571|NCT02497469|Active Comparator|Adalimumab SC 160/80/40 mg|Adalimumab 160 mg, injection, subcutaneously on Day 1, adalimumab 80 mg, injection, subcutaneously at Week 2, then adalimumab 40 mg, injection, subcutaneously every 2 weeks thereafter up to Week 50. Vedolizumab placebo-matching infusion, intravenously on Day 1 and Weeks 2, 6, 14, 22, 30, 38, and 46.
89579572|NCT02497391|Experimental|Evacetrapib Reference (R)|Single oral dose of 130 mg evacetrapib tablet given one time during one study period.
89579573|NCT02497391|Experimental|Evacetrapib Test 1 (T1)|Single oral dose of 130 mg evacetrapib tablet given one time during one study period.
89579574|NCT02497391|Experimental|Evacetrapib Test 2 (T2)|Single oral dose of 130 mg evacetrapib tablet given one time during one study period.
89579575|NCT02476175|Experimental|Add-on Mirabegron|Experimental: Add-on Mirabegron Patients without symptom improvement or with partial response under intensive behavioural protocol and medical therapy (at least 2 different antimuscarinic agents) will be recruited. They will keep the antimuscarinic and Mirabegron will be added (dual therapy).
89579576|NCT02065557|Experimental|Adalimumab Induction Standard Dose|Participants randomized to receive adalimumab 2.4 mg/kg (maximum dose of 160 mg) at Baseline and matching placebo at Week 1, 1.2 mg/kg (maximum dose of 80 mg) at Week 2, followed by 0.6 mg/kg (maximum dose of 40 mg) at Week 4 and Week 6.
89579577|NCT02065557|Experimental|Adalimumab Induction High Dose|Participants randomized to receive adalimumab 2.4 mg/kg (maximum dose of 160 mg) at Baseline and at Week 1, 1.2 mg/kg (maximum dose of 80 mg) at Week 2, followed by 0.6 mg/kg (maximum dose of 40 mg) at Week 4 and Week 6.
89579578|NCT02065557|Experimental|Adalimumab Induction High Dose - Open Label|(After Amendment 4) participants assigned to open-label adalimumab 2.4 mg/kg (maximum dose of 160 mg) at Baseline and at Week 1, 1.2 mg/kg (maximum dose of 80 mg) at Week 2, followed by 0.6 mg/kg (maximum dose of 40 mg) at Week 4 and Week 6.
89579579|NCT02065557|Placebo Comparator|Maintenance Placebo|(Prior to Amendment 4) participants demonstrating a clinical response per PMS (defined as a decrease in PMS ≥ 2 points and ≥ 30% from Baseline) at Week 8 randomized to maintenance placebo. Participants were to continue their blinded treatment during the maintenance period until Week 52 unless they had ≥ 2 flares and got open label rescue therapy after the second flare.
89579580|NCT02065557|Experimental|Adalimumab Maintenance Standard Dose|Participants demonstrating a clinical response per PMS (defined as a decrease in PMS ≥ 2 points and ≥ 30% from Baseline) at Week 8 randomized to adalimumab maintenance standard dose (0.6 mg/kg [maximum dose of 40 mg] every other week). Participants were to continue their blinded treatment during the maintenance period until Week 52 unless they had ≥ 2 flares and got open label rescue therapy after second flare.
89579581|NCT02065557|Experimental|Adalimumab Maintenance High Dose|Participants demonstrating a clinical response per PMS (defined as a decrease in PMS ≥ 2 points and ≥ 30% from Baseline) at Week 8 randomized to adalimumab maintenance high dose (0.6 mg/kg [maximum dose of 40 mg] every week). Participants were to continue their blinded treatment during the maintenance period until Week 52 unless they had ≥ 2 flares and got open label rescue therapy after second flare.
89579582|NCT04180527||Pre-Quality Improvement Initiative|This group of patients have not received previous patients' stories about their hip or knee surgery before undergoing their own hip or knee surgery.
89579583|NCT04180527||Post-Quality Improvement Initiative|This group of patients have received previous patients' stories regarding about their hip or knee surgery before undergoing their own hip or knee surgery.
89579584|NCT02065245|Experimental|Pilot phase - Group 1|Group 1 participants will receive Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 20 million allo-hMSCs/kg delivered via peripheral intravenous infusion. Participants in this group have the option to receive an additional 3 infusions of 100million allo-hMSCs/kg per infusion with a 12 to 18 month interval.
89579585|NCT02065245|Experimental|Pilot Phase - Group 2|Group 2 - Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 100 million allo-hMSCs/kg delivered via peripheral intravenous infusion. Participants in this group have the option to receive an additional 3 infusions of 100million allo-hMSCs/kg per infusion with a 12 to 18 month interval.
89579586|NCT02065245|Experimental|Pilot Phase - Group 3|Group 3 - Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 200 million allo-hMSCs/kg delivered via peripheral intravenous infusion. Participants in this group have the option to receive an additional 3 infusions of 100million allo-hMSCs/kg per infusion with a 12 to 18 month interval.
89579587|NCT02065245|Experimental|Randomized Phase - Group A|Group A - Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 100 million allo-hMSCs/kg delivered via peripheral intravenous infusion.
89579588|NCT02065245|Experimental|Randomized phase - Group B|Group B - Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 200 million allo-hMSCs/kg delivered via peripheral intravenous infusion.
89579589|NCT02065245|Experimental|Randomized Phase - Group C|Group C - Placebo delivered via peripheral intravenous infusion. Participants in this group have the option to receive one additional infusion of 100million allo-hMSCs/kg with a 12 to 18 month interval.
89579590|NCT02065245|Experimental|Addendum B - Antibiotic free cell Group|Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 100 million penicillin/streptomycin-free allo-hMSCs/kg delivered via peripheral intravenous infusion. Participants in this group have the option to receive an additional 3 infusions of 100million allo-hMSCs/kg per infusion with a 12 to 18 month interval.
89579591|NCT02043015|Other|Comprehensive HIV prevention services|A comprehensive package of HIV prevention services, including condom choices, Condom-compatible lubricant choices, Couples HIV counseling and testing (CVCT), Staff and provider MSM and LGBT sensitization training, HIV Testing and Risk-reduction counseling, Linkage to care, Pre-exposure prophylaxis with FTC/TDF
89579592|NCT02064231|Experimental|Coloplast Test A, Coloplast Test B, Own product|The subjects first test Coloplast Test A and thereafter Coloplast Test B and finally their own product for 14 days
89579593|NCT02064231|Experimental|Coloplast Test C , Coloplast Test D, Own product|The subjects first test Coloplast Test C and thereafter Coloplast Test D and finally their own product for 14 days
89579594|NCT02063217|Experimental|Sleep Induction|7.5 grams of sodium oxybate
89579595|NCT02063217|Experimental|Sleep Deprivation|Sleep deprivation for up to 36 hours with no naps or other sleep periods
89579596|NCT02063217|No Intervention|Control|Participant will sleep as normal under the same controlled conditions in a clinical research unit
89579597|NCT02497001|Experimental|BGF MDI (PT010) 320/14.4/9.6 μg ex-actuator|BGF MDI 320/14.4/9.6 μg,Budesonide, Glycopyrronium, Formoterol Fumarate Inhalation Aerosol
89579598|NCT02497001|Experimental|GFF MDI (PT003) 14.4/9.6 μg ex-actuator|GFF MDI 14.4/9.6 μg ex-actuator Glycopyrronium, Formoterol Fumarate Inhalation Aerosol
89579599|NCT02497001|Experimental|BFF MDI (PT009) 320/9.6 μg ex-actuator|BFF MDI 320/9.6 μg, Budesonide, Formoterol Fumarate Inhalation Aerosol
89579600|NCT02497001|Active Comparator|Symbicort|Symbicort® Turbuhaler® (TBH) Inhalation Powder 200/6 μg
89579601|NCT04182555|Experimental|Newborns in St.Olavs Hospital and Haugesund Hospital|All newborns will be examined through 4 different methods of determining jaundice.
89579602|NCT04733079|Experimental|E-mail follow-up group|Email-led treat-to-target strategy with regular adaptation of ULT via electronic messaging
89579603|NCT04733079|Active Comparator|Usual follow-up group|Adaptation and follow-up of ULT according to referring physician's habits
89579604|NCT02366143|Experimental|Arm A (Atezolizumab+Paclitaxel+Carboplatin)|Participants received intravenous (IV) infusion of atezolizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit.
89579605|NCT02366143|Experimental|Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin)|Participants received IV infusion of atezolizumab and bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab until loss of clinical benefit and bevacizumab until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.
89579606|NCT02366143|Active Comparator|Arm C (Bevacizumab+Paclitaxel+Carboplatin)|Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.
89579607|NCT02098395|Experimental|Liraglutide 1.8 mg + insulin|
89579608|NCT02098395|Experimental|Liraglutide 1.2 mg + insulin|
89579609|NCT02098395|Experimental|Liraglutide 0.6 mg + insulin|
89579610|NCT02098395|Placebo Comparator|Liraglutide placebo 0.3 ml + insulin|
89579611|NCT02098395|Placebo Comparator|Liraglutide placebo 0.2 ml + insulin|
89579612|NCT02098395|Placebo Comparator|Liraglutide placebo 0.1 ml + insulin|
89579613|NCT02041923|Placebo Comparator|Attention Control|Mothers received equal amount of attention from the team. Attention consisted of additional teaching regarding premature infant care.
89579614|NCT02041923|Experimental|H-HOPE Intervention|H-HOPE was administered twice daily by the mother.
89579615|NCT02062437||Total hip replacement using a ceramic friction pair|Patients treated with total hip replacement using a ceramic friction pair Biolox® Delta, with Meije Duo® stem associated with Dynacup® cup
89579616|NCT02365519|Experimental|LME636|LME636 ophthalmic solution, 1 drop (approx. 40 µL; 2.4 mg) administered topically in each eye 3 times a day (TID) for 6 weeks
89579617|NCT02365519|Placebo Comparator|Vehicle|LME636 Vehicle, 1 drop administered topically in each eye TID for 6 weeks
89579618|NCT04700163|Experimental|S1 - low dose|100 mg of C144-LS and 100 mg of C135-LS, subcutaneously
89579619|NCT04700163|Experimental|S2 - mid dose|200 mg of C144-LS and 200 mg of C135-LS, subcutaneously
89579620|NCT04700163|Experimental|V1 - low dose|1.5 mg/kg of C144-LS and 1.5 mg/kg of C135-LS, intravenously
89579621|NCT04700163|Experimental|V2 - mid dose|5 mg/kg of C144-LS and 5 mg/kg of C135-LS, intravenously
89579622|NCT04700163|Experimental|V3 - high dose|15 mg/kg of C144-LS and 15 mg/kg of C135-LS, intravenously
89579623|NCT02061813|Experimental|Abametapir lotion 0.74% w/w|Applied 0.2 mL topically under occlusive condition
89579624|NCT02061813|Placebo Comparator|Vehicle lotion|Applied 0.2 mL topically under occlusive condition
89579625|NCT02061813|Other|Sodium Lauryl Sulfate|Positive control applied 0.2 mL topically under occlusive condition
89579626|NCT02061813|Other|Saline 0.9%|Negative control applied 0.2 mL topically under occlusive condition
89579627|NCT02096835|Experimental|Acustimulation|Transcutaneous electrical acupoint stimulation (TEAS) starts 30 min before surgery and lasts until patient leaves the postanesthetic care unit.Dexamethasone 10mg i.v. after induction.
89579628|NCT02096835|Active Comparator|Tropisetron|Tropisetron 5mg iv. at the start of skin closure.Sham transcutaneous electrical acupoint stimulation.Dexamethasone 10mg i.v.after induction.
89579629|NCT02096835|Sham Comparator|Control|Sham transcutaneous electrical acupoint stimulation. Dexamethasone 10mg i.v.after induction.
89579630|NCT02294773|Active Comparator|Day Of|This group takes either clomiphene or letrozole on cycle days 3-7 and then receives intrauterine insemination on the day the home ovulation predictor kit first turns positive.
89579631|NCT02294773|Active Comparator|Day After|This group takes either clomiphene or letrozole on cycle days 3-7 and then receives intrauterine insemination on the day after the home ovulation predictor kit first turns positive.
89579632|NCT02365285|Experimental|Galantamine 16 mg then placebo|Galantamine 16 mg po one time dose then placebo on 2nd visit
89579633|NCT02365285|Placebo Comparator|Placebo then Galantamine 16 mg|Placebo capsule po one time dose then Galantamine 16 mg on 2nd visit
89579634|NCT02041299|Experimental|Deferiprone|Patients randomized to the deferiprone arm will be prescribed either tablets or liquid medication. Deferiprone is taken orally, at a dosage that is calculated in terms of milligrams per kilogram of body weight (mg/kg) and is divided into 3 equal doses taken approximately 8 hours apart. The daily dosage is 75 mg/kg (25 mg/kg per dose) for patients with less severe iron load, and 99 mg/kg (33 mg/kg per dose) for those with more severe iron load.
89579635|NCT02041299|Active Comparator|Deferoxamine|Patients randomized to the deferoxamine arm will be prescribed the drug as per the approved US prescribing information. Deferoxamine is administered as a subcutaneous infusion over 8-12 hours, 5 to 7 days a week. The dosage is 20 mg/kg (children) or 40 mg/kg (adults) in patients with less severe iron load, and up to 40 mg/kg (children) or 50 mg/kg (adults) in those with more severe iron load.
89579636|NCT01645735|Experimental|Ceftaroline|Ceftaroline fosamil 600 mg Intravenous (IV) administration over 60 minutes, every 8 hours (q8h); dosing to be adjusted for renal function; treatment duration 5 to 14 days
89579637|NCT01645735|Active Comparator|Ceftriaxone plus vancomycin|Ceftriaxone 2 g IV over 30 minutes once per day (q24h) plus vancomycin 15 mg/kg IV every 12 hours (q12h) initially and then dose adjusted based on trough concentrations; treatment duration 5 to 14 days
89579638|NCT02365207|Experimental|BCG treatment of invasive bladder cancer|Invasive bladder cancer treated with 3-6 weeks of intravesical BCG
89579639|NCT01645111|Active Comparator|Clevidipine|
89579640|NCT02364037|Other|Phase 1: Enhanced Care|Women in Phase 1 of the prospective study will receive the CHOICE Project structured contraceptive counseling in addition to usual care by their health care provider. Contraceptive coverage will be by the usual mechanism such as insurance or financial assistance programs.
89579641|NCT02364037|Other|Phase 2: Complete CHOICE|Women in Phase 2 of the prospective study (Complete CHOICE) will receive the CHOICE Project structured contraceptive counseling. Immediately prior to the start of Phase 2, health care providers in participating health centers will undergo a contraceptive education session with a focus on evidence-based guideline for LARC provision and same-day insertion. Participating women will receive cost support for IUDs and implants if she chooses either as her contraceptive method and does not have appropriate insurance coverage.
89579642|NCT01919164|Placebo Comparator|Placebo|Participants received Placebo matched to Sprifermin as intra-articular injection once every week for 3 consecutive weeks for 4 cycles, that is at week 0, 1, 2 in Cycle 1; at week 26, 27, 28 in Cycle 2; at week 52, 53, 54 in Cycle 3 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.
89579643|NCT01919164|Experimental|Sprifermin (AS902330) 30 mcg/placebo - 2 Cycles|Participants received Sprifermin 30 mcg as intra-articular injection once every week for 3 consecutive weeks for 2 alternative cycles, that is at week 0, 1, 2 in Cycle 1 and at week 52, 53, 54 in Cycle 3; and received placebo matched to Sprifermin once every week for 3 consecutive weeks for 2 alternative cycles, that is at week 26, 27, 28 in Cycle 2 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.
89579644|NCT01919164|Experimental|Sprifermin (AS902330) 30 mcg- 4 Cycles|Participants received Sprifermin 30 micrograms (mcg) as intra-articular injection once every week for 3 consecutive weeks for 4 cycles, that is at week 0, 1, 2 in Cycle 1; at week 26, 27, 28 in Cycle 2; at week 52, 53, 54 in Cycle 3 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.
89579645|NCT01919164|Experimental|Sprifermin (AS902330) 100 mcg/Placebo (2 cycles)|Participants received Sprifermin 100 mcg as intra-articular injection once every week for 3 consecutive weeks for 2 alternative cycles, that is at week 0, 1, 2 in Cycle 1 and at week 52, 53, 54 in Cycle 3; and received placebo matched to Sprifermin once every week for 3 consecutive weeks for 2 alternative cycles, that is at week 26, 27, 28 in Cycle 2 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.
89579646|NCT01919164|Placebo Comparator|Sprifermin (AS902330) 100 mcg- 4 Cycles|Participants received Sprifermin 100 mcg as intra-articular injection once every week for 3 consecutive weeks for 4 cycles, that is at week 0, 1, 2 in Cycle 1; at week 26, 27, 28 in Cycle 2; at week 52, 53, 54 in Cycle 3 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.
89579647|NCT01901224|Experimental|Metformin 1000 mg|metformin 1000 mg twice daily: In order to avoid gastrointestinal side effects, the starting dose of metformin will be 500 mg twice daily. After one week, the dose will be increased to 1000 mg twice daily (as two 500 mg tablets twice daily). Subjects will be instructed to take medications with breakfast and with dinner.
89579648|NCT01901224|Placebo Comparator|Control|placebo twice daily: In order to maintain blinding during the titration period, individuals randomized to placebo will receive one placebo tablet twice daily for one week, followed by an increase to 2 placebo tablets twice daily. Subjects will be instructed to take medications with breakfast and with dinner.
89579649|NCT05109676|Experimental|Patients having embryo transfert|Patients benefit from the usual treatment for frozen embryo transfer with a preparatory cycle of the artificial endometrium: 150 µg of percutaneous estradiol for approximately 11 days and 200 mg of progesterone morning and evening to be taken vaginally for 2 days in case of embryo transfer at day 2 stage, 3 days in case of embryo transfer at day 3 stage, 5 days in case of day 5 embryo transfer or 6 days in case of day 6 embryo transfer.
89579650|NCT01901146|Experimental|ABP 980|"Participants received ABP 980 at an initial dose of 8 mg/kg by intravenous (IV) infusion, then 6 mg/kg IV infusion every 3 weeks (Q3W) for 3 additional cycles plus 175 mg/m² paclitaxel Q3W for 4 cycles during the neoadjuvant phase.~Surgery (lumpectomy or mastectomy with sentinel lymph node dissection or axillary lymph node dissection) was completed 3 to 7 weeks after the last dose of study drug in the neoadjuvant phase.~After surgery (adjuvant phase) participants continued receiving 6 mg/kg ABP 980 IV Q3W for up to 1 year from the first day of study drug administration in the neoadjuvant phase."
89579651|NCT01901146|Active Comparator|Trastuzumab|"Participants received trastuzumab at an initial dose of 8 mg/kg IV infusion, then 6 mg/kg IV infusion Q3W for 3 additional cycles plus 175 mg/m² paclitaxel Q3W for 4 cycles during the neoadjuvant phase.~Surgery (lumpectomy or mastectomy with sentinel lymph node dissection or axillary lymph node dissection) was completed 3 to 7 weeks after the last dose of study drug in the neoadjuvant phase.~After surgery (adjuvant phase) participants were re-randomized to either continue receiving 6 mg/kg trastuzumab IV Q3W or transition to 6 mg/kg ABP 980 IV Q3W for up to 1 year from the first day of study drug administration in the neoadjuvant phase."
89579652|NCT01644643|Experimental|Ceftazidime - Avibactam ( CAZ-AVI)|IV treatment
89579653|NCT01644643|Active Comparator|Best Available Therapy|IV treatment
89579654|NCT01864564|No Intervention|Routine Screening|"Obese women will be screened at 24-28 weeks of gestation for gestational diabetes using the standard U.S. screening method of a 1-hour, 50-g glucose challenge test followed by a 3-hour, 100-g glucose tolerance test if abnormal. Women identified as having diabetes will be treated according to standards of care.~All women will have a hemoglobin A1c and 1,5-anhydroglucitol checked at 14-18 weeks and 24-28 weeks gestation."
89579655|NCT01864564|Experimental|Early Screening|"Obese women will be randomized to be screened at 14-19.9 weeks of gestation for gestational diabetes using the standard U.S. screening method of a 1-hour, 50-g glucose challenge test followed by a 3-hour, 100-g glucose tolerance test if abnormal. Women identified as having diabetes will be treated according to standards of care. Women who do not have diabetes at 14-19.9 weeks will be re-screened at 24-28 weeks per the standard of care.~All women will have a hemoglobin A1c and 1,5-anhydroglucitol checked at 14-18 weeks and 24-28 weeks gestation."
89579656|NCT01864174|Active Comparator|Arm 1: Metformin XR and Placebo matching with Metformin XR|"Metformin Extended Release (XR) 500 mg tablets (500-2000 mg per day) by mouth twice daily (BID) for 24 weeks~Placebo matching with Metformin XR 0 mg tablets by mouth twice daily (BID) for 24 weeks"
89579657|NCT01864174|Active Comparator|Arm 2: Metformin IR and Placebo matching with Metformin IR|"Metformin Immediate Release (IR) 500 mg tablets (500-2000 mg per day) by mouth twice daily (BID) for 24 weeks~Placebo matching with Metformin IR 0 mg tablets by mouth twice daily (BID) for 24 weeks"
89579658|NCT01900444|Experimental|IMOJEV Group|Participants who received a single dose of IMOJEV in study JEC12 (NCT01396512) will receive a booster dose in this study.
88973007|NCT05432895|Experimental|Experiment( dynamic splinting)|Device treats plantar fasciitis and replacing boot immobilization
88973008|NCT00846872|Active Comparator|Low dose GHRP-3|Subjects will receive the infusion for 14 ± 2 days. On day 1 of the test period, patients will report to the CTRC in a fasting state stay there for 3 - 4 hrs after the initiation of the infusion. Blood will be drawn in a fasting state and urine sample will be collected prior to insertion of the OmniPod and the CGMS. On day 7 +/- 2 days and on day 12 +/- 2 days, patients will report to the CTRC for blood draw and CGMS insertion. On day 14 +/- 2 days, patients will again report to CTRC for 24 hour admit. They will undergo urine sample collection, periodic blood draws and BP monitoring. After the 24 hour period, the CGMS will be disconnected and the patient will undergo FMD after which the test period will be terminated. There will be a washout period of 2 weeks between each test period.
88973009|NCT00846872|Active Comparator|High dose GHRP -3|Subjects will receive the infusion for 14 ± 2 days. On day 1 of the test period, patients will report to the CTRC in a fasting state stay there for 3 - 4 hrs after the initiation of the infusion. Blood will be drawn in a fasting state and urine sample will be collected prior to insertion of the OmniPod and the CGMS. On day 7 +/- 2 days and on day 12 +/- 2 days, patients will report to the CTRC for blood draw and CGMS insertion. On day 14 +/- 2 days, patients will again report to CTRC for 24 hour admit. They will undergo urine sample collection, periodic blood draws and BP monitoring. After the 24 hour period, the CGMS will be disconnected and the patient will undergo FMD after which the test period will be terminated. There will be a washout period of 2 weeks between each test period.
88973010|NCT00846872|Placebo Comparator|Saline Infusion|Subjects will receive Placebo for 14 ± 2 days. On day 1 of the test period, patients will report to the CTRC in a fasting state stay there for 3 - 4 hrs after the initiation of the infusion. Blood will be drawn in a fasting state and urine sample will be collected prior to insertion of the OmniPod and the CGMS. On day 7 +/- 2 days and on day 12 +/- 2 days, patients will report to the CTRC for blood draw and CGMS insertion. On day 14 +/- 2 days, patients will again report to CTRC for 24 hour admit. They will undergo urine sample collection, periodic blood draws and BP monitoring. After the 24 hour period, the CGMS will be disconnected and the patient will undergo FMD after which the test period will be terminated. There will be a washout period of 2 weeks between each test period.
88973011|NCT05432661||1 nasal kanul|The data of a total of 60 patients in the group will be recorded. Those with saturation below 92% will be included in the study. The data of the nasal cannula group will be obtained from retrospective file and archive scanning. After providing standard monitoring, preoxygenation was performed for 3 minutes. After preoxygenation, 2-4 L/min oxygen was given to the patients who would receive oxygen support by nasal cannula. Patients were followed for at least 15 minutes after the procedure or until the patient recovered. Our aim is the early recovery of patients without complications.
88973012|NCT05432661||2 HİGH-FLOW NASAL OXYGEN|The data of a total of 60 patients in the group will be recorded. Those with saturation below 92% will be included in the study. After the standard monitoring is established, preoxygenation will be performed for 3 minutes. . After preoxygenation, 40 L/min oxygen will be administered through a HFNO system to patients who will receive oxygen support with HFNO ( Inspired O2 FLO High Flow Oxygen Therapy ). Patients will be followed for a minimum of 15 minutes after the procedure or until the patient recovers.
88973013|NCT00846833|Experimental|Cyclophosphamide, high-dose interleukin-2, NK cell|
88973014|NCT00846794||1 Asymptomatic|students with conditions being studied
88973015|NCT00846794||2 Symptomatic|students without conditions being studied
88973016|NCT00846755|Active Comparator|Levothyroxine, Propylthiouracil|Drugs for the treatment of thyroid disease, are administered, when necessary, in high risk women, either in case finding, or in Universal Screening Group
88973017|NCT00846755|No Intervention|clinical checks|Low risk women whose sera are tested postpartum. Then patients with undiagnosed thyroid disease, are not treated
88973018|NCT00846716|Experimental|Pioglitazone add on to SU or biguanide|
88973019|NCT00846716|Active Comparator|SU or Biguanide|
89029566|NCT02953470|Active Comparator|Standard care|The participants in the comparison Group will receive standard care which means that they receives one visit from physiotherapist where the participant receive general advice about physical activity with the goal to be physically active at least 30 minutes per day at 5 of 7 days per week. During intervention week 1-8 and 10 the participants receive telephone calls once a week where they will be reminded to follow the advice about physical activity.
89029567|NCT02275013||Early|Levosimendan administration within first hour of post-operative ICU admission
89029568|NCT02275013||Late|Levosimendan administration within 24 hours of post-operative ICU admission but after first hour
89029569|NCT02274584|Experimental|CAR T cells|Autologous 4th generation anti-CD30 CAR T cells
89029570|NCT02274623|Experimental|CTAP101 Capsules|CTAP101 Capsules daily
89579659|NCT02294227|Experimental|Secukinumab 150 mg|Secukinumab 150 mg s.c. with loading: Secukinumab 150 mg at Baseline, Weeks 1, 2 and 3, followed by dosing every four weeks starting at Week 4. After primary outcome evaluation, approval and implementation of Amendment 2 Secukinumab dose may have been escalated to 300 mg as judged appropriate by the investigator
89029571|NCT02275091||Diabetes|Children with diabetes type 1 , 12-21 years old
89029572|NCT02275091||Healthy|Healthy children 12-21 years old
89029573|NCT02953626|Experimental|Immediate Treatment Condition (ITC)|Mother Matters Online Postpartum Support Group. Participants will be assigned to begin immediately after randomization.
89029574|NCT02953626|No Intervention|Waitlist Control Condition (WLC)|Mother Matters Online Postpartum Support Group. Participants will receive the intervention after the Immediate Treatment Condition group completes the intervention, and after follow-up data are collected from both groups.
89029575|NCT00501332|Active Comparator|2|
89579660|NCT02294227|Experimental|Secukinumab 150 mg No load|Secukinumab 150 mg s.c. without loading: Secukinumab 150 mg at baseline, followed by dosing every four weeks starting at Week 4, with Placebo at Weeks 1, 2 and 3. After primary outcome evaluation, approval and implementation of Amendment 2 Secukinumab dose may have been escalated to 300 mg as judged appropriate by the investigator
89579661|NCT02294227|Placebo Comparator|Placebo|Placebo to Secukinumab at Baseline, Weeks 1, 2 and 3, followed by dosing every four weeks starting at Week 4 until Week 16/24, depending on patients responder status. From Week 16/24, patients were switched to Secukinumab 150 mg every four weeks. After primary outcome evaluation, approval and implementation of Amendment 2 Secukinumab dose may have been escalated to 300 mg as judged appropriate by the investigator
89579662|NCT02496767|Placebo Comparator|Group 1 - Placebo|Day 1 through Week 48: 2 placebo tablets twice daily
89579663|NCT02496767|Experimental|Group 2 - 250 mg tirasemtiv|Day 1 through Week 48: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the PM
89579664|NCT02496767|Experimental|Group 3 - 375 mg tirasemtiv|Day 1 through Week 2: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the PM; Weeks 3 through 48: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 2 tablets of tirasemtiv (250 mg) in the PM
89579665|NCT02496767|Experimental|Group 4 - 500 mg tirasemtiv|Day 1 through Week 2: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in PM; Weeks 3 and 4: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 2 tablets of tirasemtiv (250 mg) in the PM; Weeks 5 through 48: 2 tablets of tirasemtiv (250 mg) in the AM and 2 tablets of tirasemtiv (250 mg) in the PM
89579666|NCT02496533|No Intervention|No Massage|Subjects in this arm will complete rate their anxiety by visual analog scale (VAS). Blood pressure, pulse and respiration will be recorded before and after imaging. The anxiety VAS will be repeated after the imaging procedure. Subjects in this arm will not receive the hand massage prior to the imaging procedure.
89579667|NCT02496533|Experimental|Hand Massage|Subjects in this arm will complete rate their anxiety by visual analog scale (VAS). Blood pressure, pulse and respiration will be recorded before massage, after massage but before imaging, and after imaging.The subjects will receive hand massage prior to the imaging procedure. The anxiety VAS will be repeated after the imaging procedure.
89029576|NCT02953353|Active Comparator|Active group|Active transcranial direct current stimulation (tDCS) and hypocaloric diet.
89029577|NCT02953353|Sham Comparator|Control group|Sham transcranial direct current stimulation (tDCS) and hypocaloric diet.
89029578|NCT00501371|Active Comparator|MCS|Group A: MCS 30 mg/day for 12 weeks
89029579|NCT00501371|Placebo Comparator|Placebo|Placebo, 2 capsules per day
89029580|NCT00509652|Experimental|Arm 1|Erythrocyte apheresis
89029581|NCT00509652|Active Comparator|Arm 2|Phlebotomy
89029582|NCT00501410|Experimental|FOLFOX + Dasatinib + Cetuximab|5-FU 2400 mg/m^2 by vein over 46 Hours On Days 1 & 2. Cetuximab initial dose = 400 mg/m^2 by vein, then 250 mg/m^2 Weekly On Days 1 & 8. Dasatinib 100 mg by mouth daily on days 1-14. Leucovorin 400 mg/m^2 by vein on day 1. Oxaliplatin 85 mg/m^2 by vein on day 1.
89029583|NCT02953392|Active Comparator|Arm 1|Transcrestal Sinus Floor Elevation using platform switched implant with bone graft material.
89029584|NCT02953392|Active Comparator|Arm 2|Transcrestal Sinus Floor Elevation using platform switched implant with no bone graft material.
89029585|NCT02953392|Active Comparator|Arm 3|Transcrestal Sinus Floor Elevation using platform matching implant with bone graft material.
89029586|NCT02953392|Active Comparator|Arm 4|Transcrestal Sinus Floor Elevation using platform matching implant with no bone graft material.
89029587|NCT00501449||Multiple Endocrine Neoplasia (MEN)|Patients with multiple endocrine neoplasia (MEN).
89029588|NCT02955953|Experimental|LY2963016 U-200 Formulation (Test)|LY2963016 test formulation administered as a subcutaneous (SC) injection in one of two or two of four study periods.
89029589|NCT02955953|Experimental|LY2963016 U-100 Formulation (Reference)|LY2963016 reference formulation administered as a SC injection in one of two or two of four study periods.
89029590|NCT02953275|Experimental|vedolizumab plus pentoxifylline|Patients will receive standard induction and maintenance dosing of vedolizumab 300 mg intravenously as well as pentoxifylline 400 mg orally thrice daily.
89029591|NCT02953275|Placebo Comparator|vedolizumab plus placebo|Patients will receive standard induction and maintenance dosing of vedolizumab 300 mg intravenously as well as placebo orally thrice daily.
89579668|NCT02496221|Experimental|Albiglutide / Placebo or Placebo / Albiglutide|In treatment period 1, subjects will receive Albiglutide 50 mg or Placebo subcutaneously (SC) after fasting overnight for at least 10 hours according to randomization schedule on Day 1. Subject will also receive CCK (Kinevac) infusion intravenously for a period of 50 minutes after fasting overnight for at least 10 hours on Day 4. After washout period of a minimum of 42 days in treatment period 2, subjects will receive same treatment according to randomization schedule in a cross-over fashion
89579669|NCT02475629|Experimental|Open-Label Ibalizumab plus OBR|2000 mg intravenous ibalizumab (loading dose) on Day 7 followed in 14 days (on Day 21) by 800 mg intravenous ibalizumab administered once every two weeks, plus an Optimized Background Regimen (OBR) beginning on Day 14.
89579670|NCT02475395|Experimental|Donor/Tester Subjects|Male subjects use the TRAK device to attain a measurement of sperm concentration from their semen specimen
89579671|NCT02475395|Experimental|Tester Only Subjects|Male or female subjects use the TRAK device to attain a measurement of sperm concentration from another donor's semen specimen.
89579672|NCT01653743|Experimental|MSJ-0011|
89579673|NCT01653743|Active Comparator|urinary hCG|
89579674|NCT02293993|Experimental|Cohort1|SGI-110 36mg/m2 will be administered subcutaneously once daily for 5 consecutive days (Day 1 to Day 5), followed by a 23-day non-dosing period (Day 6 to Day 28).
89579675|NCT02293993|Experimental|Cohort2|SGI-110 60mg/m2 will be administered subcutaneously once daily for 5 consecutive days (Day 1 to Day 5), followed by a 23-day non-dosing period (Day 6 to Day 28).
89579676|NCT02293993|Experimental|Cohort3|SGI-110 90mg/m2 will be administered subcutaneously once daily for 5 consecutive days (Day 1 to Day 5), followed by a 23-day non-dosing period (Day 6 to Day 28).
89579677|NCT02293993|Experimental|Cohort4|SGI-110 60mg/m2 will be administered subcutaneously once daily for 10 days (Day 1 to Day 5 and Day 8 to Day 12 with dosing, Day 6 and 7 with non-dosing), followed by a 16-day non-dosing period (Day 13 to Day 28).
89579678|NCT02322775|Experimental|Arm A|Benralizumab administered subcutaneously every 4 weeks
89579679|NCT02322775|Experimental|Arm B|Placebo administered subcutaneously every 4 weeks
89579680|NCT04888273|Experimental|All adolescents and parents who meet the eligibility criteria|The adolescents and parents will be invited to participate in a 5-component intervention that will hopefully empower and prepare the pair for the transition to adult care.
89579681|NCT02322229|Experimental|Ocriplasmin|Ocriplasmin 0.125 mg in a 0.1 mL volume administered as a single dose by intravitreal (IVT) injection
89579682|NCT02362789|Experimental|Secukinumab|300 mg secukinumab (administered as two injections of 150 mg each) at Weeks 16, 20, 24, and 28
89579683|NCT02362789|Placebo Comparator|Placebo|Inactive ingredients administered as a matching placebo at Weeks 16, 20, 24, and 28
89579684|NCT01646827|Experimental|Deltoid|Deltoid injection site
89579685|NCT01646827|Experimental|Gluteal|Gluteal injection site
89579686|NCT02293837|Experimental|Tocilizumab (TCZ) + SOC|Subjects will receive intravenous (IV) infusions of either 8.0 mg/kg (body weight ≥30 kg) or 10.0 mg/kg (body weight <30kg) tocilizumab every 4 weeks for 24 weeks. Participants will also receive standard intensive diabetes management (in accordance with the American Diabetes Association guidelines [Standard of Care, SOC])
89579687|NCT02293837|Placebo Comparator|Tocilizumab Placebo Group + SOC|Subjects will receive IV infusions of either 8.0 mg/kg (body weight ≥ 30kg) or 10.0 mg/kg (body weight <30kg) placebo every 4 weeks for 24 weeks. Participants will also receive standard intensive diabetes management (in accordance with the American Diabetes Association guidelines [Standard of Care, SOC])
89579688|NCT02361307|Placebo Comparator|conventional ADL training|The control group receive the conventional ADL training programme
89579689|NCT02361307|Active Comparator|seamless ADL training|The experimental group receive the seamless ADL training programme which occupational therapist and nurse work with effective communication and cooperate in dressing and bathing training.
89579690|NCT02320903|Experimental|Use of VillageWhere App Prototype|In this single-arm study design, all enrolled caregivers and teens will use the VillageWhere App Prototype that has been developed for this study. They are requested to use it as often as they would like throughout the duration of the trial. The app is designed to be used several times throughout each day.
89579691|NCT02320123|Experimental|Patients - intervention|For the intervention arm of the study, patients will be invited to view the educational DVD explaining end-of-life care options and meet with a lay health advisor for discussion.
88973020|NCT05432427|Experimental|Group A, B, C, D, E, F, G|Scans
89579692|NCT02320123|No Intervention|Patients - Control|Patients will receive usual care (nor view the DVD or meet with the lay health advisor).
89579693|NCT02360995|Active Comparator|Total Toothpaste|Triclosan/fluoride toothpaste
89579694|NCT02360995|Active Comparator|Toothpaste + Mouthwash|Stannous fluoride toothpaste & cetylpyridinium chloride Mouthwash
89579695|NCT02360995|Placebo Comparator|Control group|fluoride toothpaste +fluoride mouthwash
89579696|NCT04197037||People with schizophrenia treated with clozapine|People more than 18 with diagnosis of schizophrenia and treated with clozapine in a stable dose and stable status of the disease (at least 2-3 weeks).
89579697|NCT02360605|Active Comparator|automated telephone reminder arm|Patients will receive Health literacy appropriate education and demonstration of FIT kits with simplified instructions. Patients will receive reminders to complete their FIT screening kits by an automated call.
88973021|NCT00846677|Experimental|1|Vitamin D quick dissolve strip
88973022|NCT00846677|Active Comparator|2|Vitamin D syrup
88973023|NCT00846638|Experimental|1|Diagnostic assessment with brief intervention and 3, 6, and 12 month follow-up
88973024|NCT00846638|Active Comparator|2|Diagnostic assessment with 12 month follow-up
88973025|NCT00846599||1|High omega-3
88973026|NCT00846599||2|High saturated fat
88973027|NCT00846560||1 ALS patients|
88973028|NCT00846560||2 Healthy subjects|
88973029|NCT05431647|Active Comparator|İntervention group: Physiotherapy and Sensory Integration Therapy|"Physiotherapy program~8 weeks 2 days in a week 45 minutes per session Conventional physiotherapy~Sensory integration therapy program~8 weeks 2 days in a week 45 minutes per session Sensory integration therapy"
89579698|NCT02360605|Active Comparator|prevention coordinator arm|Patients will receive Health literacy appropriate education and demonstration of FIT kits with simplified instructions.Patients will receive reminders to complete their FIT screening kits by a prevention coordinator.
89579699|NCT02360293|Experimental|Stay Strong w/coaching|participants in the Stay Strong w/coaching (Experimental) arm are provided a wearable device, scale, telephone coaching, tailored push notifications, personalized goals, and enhanced online/app support.
89579700|NCT02360293|Active Comparator|Stay Strong|participants in the Stay Strong (active comparison) arm will only be provided a wearable device with standard online/app support.
89579701|NCT02359903|Experimental|BCD-055 group|BCD-055 (infliximab) at a dose of 5 mg/kg, administered as a slow intravenous infusion, which will be performed on week 0, 2, 6, 14 and 22
89579702|NCT02359903|Active Comparator|Remicade group|Remicade (infliximab) at a dose of 5 mg/kg, administered as a slow intravenous infusion, which will be performed on week 0, 2, 6, 14 and 22
89579703|NCT02291419|Experimental|ticagrelor|ticagrelor 90mg bid
89579704|NCT02291419|Active Comparator|aspirin|Patients in the aspirin arm will receive aspirin 81 mg daily orally
89579705|NCT02319031|Active Comparator|Arm1: Daclatasvir + Sofosbuvir + Ribavirin (12 Weeks)|Oral dosing Daclatasvir 60mg once daily, Sofosbuvir 400mg once daily, and Ribavirin 1000-1200mg (weight based dosing) split into am and pm dosing
89579706|NCT02319031|Active Comparator|Arm2 : Daclatasvir + Sofosbuvir + Ribavirin (16 Weeks)|Oral dosing Daclatasvir 60mg once daily, Sofosbuvir 400mg once daily, and Ribavirin 1000-1200mg (weight based dosing) split into am and pm dosing
89579707|NCT02318797|Active Comparator|Patient Self-Directed Care|See intervention description
89579708|NCT02318797|Active Comparator|Provider-Supported Integrated Care|See intervention description
89579709|NCT02359435|Experimental|Reverse hybrid therapy|pantoprazole 40 mg, amoxicillin 1 g, clarithromycin 500 mg and metronidazole 500 mg for the first 7 days, followed by pantoprazole 40 mg and amoxicillin 1 g for another 5 days; with all drugs given twice daily
89579710|NCT02359435|Active Comparator|Standard triple therapy|pantoprazole 40 mg, clarithromycin 500 mg, and amoxicillin 1 g for 12 days; with all drugs given twice daily
89579711|NCT02318719|Placebo Comparator|Placebo|Placebo (14-weeks)
89579712|NCT02318719|Experimental|DS-5565 15 mg Group|DS-5565 15 mg, oral administration, Treatment period; 2-weeks titration and 12-weeks fixed dose
89579713|NCT02318719|Experimental|DS-5565 20 mg Group|DS-5565 20 mg, oral administration, Treatment period; 1-week titration and 13-weeks fixed dose
89579714|NCT02318719|Experimental|DS-5565 30 mg Group|DS-5565 30 mg, oral administration, Treatment period; 2-weeks titration and 12-weeks fixed dose
89579715|NCT01870726|Experimental|Phase Ib|To estimate the safe dose of the combination INC280 and buparlisib
89579716|NCT01870726|Experimental|Phase II|To estimate anti-tumor efficacy of INC280 single agent and in combination with buparlisib
89579717|NCT04599868|Active Comparator|Low dose of magnesium sulfate group|patients will receive 4 g intravenous loading dose of magnesium sulfate on 150 ml saline over 20 minute period. Patients then will receive maintenance therapy with magnesium sulfate 1g / h
89579718|NCT04599868|Active Comparator|High dose of magnesium sulfate group|patients will receive 4 g intravenous loading dose of magnesium sulfate on 150 ml saline over 20 minute period. Patients then will receive maintenance therapy with magnesium sulfate 2g/h
89579719|NCT01900054|Experimental|TAU-284|Two TAU-284 5mg tablets will be taken orally twice a day, once after breakfast and once after dinner (or before bed).
89579720|NCT01612156|Active Comparator|2% lidocaine gel|Subjects in this arm will have all urethral catheters and urethral cotton tipped swabs prepared with 2% lidocaine gel before use in the examination.
89579721|NCT01612156|Active Comparator|water based lubricant|Subjects in this arm will have all urethral catheters and urethral cotton tipped swabs prepared wtih water based lubricant before use in the pelvic floor examination.
89579722|NCT01899742|Experimental|Umeclidinium/Vilanterol|Long-acting muscarinic antagonist (LAMA)/Long-acting Beta agonist (LABA)
89579723|NCT01899742|Active Comparator|Tiotropium|Long-acting muscarinic antagonist (LAMA)
89579724|NCT04602988||Patients admitted to an inpatient hospital unit|Patients admitted to an inpatient hospital unit will receive EEG based monitoring of mental status
89579725|NCT01615822|Experimental|OZ439 100mg single dose|OZ439 100mg single dose oral suspension
89579726|NCT01615822|Experimental|OZ439 100mg plus MQ 250mg single doses|Single dose OZ439 100mg oral suspension in combination with single dose MQ 250mg tablet
89579727|NCT01615822|Experimental|OZ439 400mg single dose|OZ439 400mg single dose oral suspension
89579728|NCT01615822|Experimental|OZ439 400mg plus MQ 750mg single doses|Single dose OZ439 400mg oral suspension in combination with single dose MQ 750mg tablets
89579729|NCT01615822|Placebo Comparator|Placebo|Placebo
89579730|NCT01898884|Experimental|Single dose of VP 20629 or placebo|Four groups of 8 subjects each will receive a single dose of VP 20629 (150 mg, 450 mg, 900 mg, or 1200 mg) or placebo.
89579731|NCT01898884|Experimental|Multiple doses of VP 20629 or placebo|Three groups of 8 subjects each will receive multiple doses of VP 20629 (300 mg, 600 mg, or 900 mg total daily dose) or placebo. VP 20629 or placebo will be administered every 8 hours for 7 days with a single morning dose on Day 8.
89579732|NCT01613326|Experimental|NVA237|NVA237 50 μg once a day and placebo to tiotropium once a day during 85 days. Salbutamol/albuterol was provided as rescue medication.
89579733|NCT01613326|Active Comparator|Tiotropium|Tiotropium 18 μg once a day and placebo to NVA237 once a day during 85 days. Salbutamol/albuterol was provided as rescue medication.
89579734|NCT01613248|Experimental|MK-1602 1 mg|MK-1602 1 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.
89579735|NCT01613248|Experimental|MK-1602 10 mg|MK-1602 10 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.
89579736|NCT01613248|Experimental|MK-1602 25 mg|MK-1602 25 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.
89579737|NCT01613248|Experimental|MK-1602 50 mg|MK-1602 50 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.
89579738|NCT01613248|Experimental|MK-1602 100 mg|MK-1602 100 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.
89579739|NCT01613248|Placebo Comparator|Placebo|Placebo-matching MK-1602 single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.
89579740|NCT01898806|Experimental|IL TAC 2.5 mg/ml|"Intralesional Triamcinolone 2.5 mg/ml (IL TAC 2.5 mg/ml):~Patients will receive intradermal injection of study medication once per month to all, or as many as possible, areas of hair loss up to the maximum dose of 30 mg IL TAC per month, for a total of 6 months. Injections will be performed at baseline, weeks 4, 8, 12, 16 and 20"
89579741|NCT01898806|Experimental|IL TAC 5 mg/ml|"Intralesional Triamcinolone 5mg/ml (IL TAC 5 mg/ml):~Patients will receive intradermal injection of study medication once per month to all, or as many as possible, areas of hair loss up to the maximum dose of 30 mg IL TAC per month, for a total of 6 months. Injections will be performed at baseline, weeks 4, 8, 12, 16 and 20."
89579742|NCT01898806|Experimental|IL TAC 10 mg/ml|"Intralesional Triamcinolone 10mg/ml (IL TAC 10 mg/ml):~Patients will receive intradermal injection of study medication once per month to all, or as many as possible, areas of hair loss up to the maximum dose of 30 mg IL TAC per month, for a total of 6 months. Injections will be performed at baseline, weeks 4, 8, 12, 16 and 20."
89579743|NCT01898806|Placebo Comparator|Placebo|"Intralesional Saline (Placebo):~Patients will receive intradermal injection of study medication once per month to all, or as many as possible, areas of hair loss for a total of 6 months. Injections will be performed at baseline, weeks 4, 8, 12, 16 and 20. Open label treatment with IL kenalog at the dose deemed most appropriate may be administered after the 1st 6 months in nonresponders or partial responders."
89579744|NCT02291029|Experimental|CFZ533 active- Cohort 2|multiple doses of CFZ533 intravenous infusion
89579745|NCT02291029|Placebo Comparator|CFZ533 placebo- Cohort 2|multiple doses of placebo intravenous infusion
89579746|NCT02291029|Experimental|CFZ533 active - Cohort 1|multiple doses of CFZ533 s.c. injection
89579747|NCT02291029|Placebo Comparator|CFZ533 placebo - Cohort 1|multiple doses of placebo s.c. injection
89579748|NCT02291029|Experimental|CFZ533 Treatment Arm 1 - Cohort 3|multiple doses of CFZ533 s.c. injection
89579749|NCT02291029|Experimental|CFZ533 Treatment Arm 2 - Cohort 3|Single dose of CFZ533 i.v. infusion and multiple doses of CFZ533 s.c. injection
89579750|NCT02290873|Experimental|Remimazolam|"Remimazolam iv 5 mg for sedation induction, and 2.5 mg top-ups for sedation maintenance.~Fentanyl pre-treatment: 50 μg (or less for elderly/disabled subjects) and 25 μg top-up doses"
89579751|NCT02290873|Placebo Comparator|Placebo|"Inactive control arm~Fentanyl pre-treatment: 50 μg (or less for elderly/disabled subjects) and 25 μg top-up doses"
89579752|NCT02290873|Active Comparator|Midazolam|"Midazolam iv 1.75 mg* for sedation induction and 1.0 mg* for sedation maintenance.~*1.0 mg for induction and 0.5 mg for maintenance in adults over 60, debilitated or chronically ill~Fentanyl pre-treatment: 50 μg (or less for elderly/disabled subjects) and 25 μg top-up doses"
88973030|NCT05431647|Active Comparator|Control group only Physiotherapy|"Physiotherapy program~8 weeks 2 days in a week 45 minutes per session Conventional physiotherapy"
88973031|NCT00846482|Experimental|Resected or metastatic CRC|All patients with advanced or stage II or III colorectal cancer being treated with oxaliplatin
88973032|NCT05429346||Genital herpes treated before third trimester|Pregnant women with genital herpes infection receiving treatment before the 3rd trimester.
88973033|NCT05429346||Genital herpes treated during third trimester|Pregnant women with genital herpes infection receiving treatment during the 3rd trimester.
88973034|NCT05429346||Genital herpes untreated|Pregnant women with untreated genital herpes infection.
88973035|NCT05429346||Control Group|Pregnant women (controls) with neither genital herpes infection nor treatment.
88973036|NCT05428683|Other|prophylactic measures against post-operative inflammations|Usage of triamcinolone and moxifloxacin combination to be injected intravitreally by using 30 G needle.
88973037|NCT00394043|Experimental|Osteopathic Manipulative Treatment|A protocol of specific osteopathic manipulative techniques was applied.
88973038|NCT00394043|Placebo Comparator|Placebo ultrasound|Sub-therapeutic ultrasound was applied.
88973039|NCT00394043|No Intervention|Standard Medical care|Subjects did not receive either study treatment, but continued to receive standard medical care.
88973040|NCT05424549|Experimental|Reproxalap Ophthalmic Solution (0.25%)|
88973041|NCT05424549|Placebo Comparator|Vehicle Ophthalmic Solution|
88973042|NCT00846443|Experimental|1|pemetrexed:400 mg/m2, IV, day 1 and day 22; cisplatin: 25 mg/m2, IV, days 1-3 and 22-24; radiotherapy:66 Gy in 33 fractions
88973043|NCT00846443|Experimental|2|pemetrexed:500 mg/m2, IV, day 1 and day 22; cisplatin: 25 mg/m2, IV, days 1-3 and 22-24; radiotherapy:66 Gy in 33 fractions
88973044|NCT00846443|Experimental|3|pemetrexed:500 mg/m2, IV, day 1 and day 22; cisplatin: 25 mg/m2, IV, days 1-3 and 22-24; radiotherapy:70 Gy in 35 fractions
88973045|NCT00846443|Experimental|4|pemetrexed:500 mg/m2, IV, day 1 and day 22; cisplatin: 25 mg/m2, IV, days 1-3 and 22-24; radiotherapy:74 Gy in 37 fractions
88973046|NCT05424432|Experimental|short course neoadjuvant chemoradiotherapy plus toripalimab|"Paclitaxel, carboplatin and toripalimab every 3 weeks for two cycles. Concurrent short course neoadjuvant radiotherapy (30 Gy in 12 fractions, 5 days per week, D3-D18).~Surgery will be performed within 8-10 weeks after the completion of preoperative therapy described above."
88973047|NCT00846404||Case|Patients with Diastolic Dysfunction
88973048|NCT00846404||Control|Patients without Diastolic Dysfunction
88973049|NCT05364255|Experimental|[14C]AZD9833 (D8532C00005)|Oral Solution, 75 mg (NMT 0.67 MBq)
88973050|NCT00846326|Experimental|Oxymetazoline-Fluticasone Propionate|Combination nasal spray with oxymetazoline 0.05% and fluticasone propionate 0.05%
88973051|NCT00846326|Placebo Comparator|Oxymetazoline-placebo|oxymetazoline 0.05% w/v and placebo fluticasone propionate
88973052|NCT05330013|Other|Control|Healthy volunteers who are age and sex matched
89579753|NCT02290405||Primary Insomnia (PI)|PI sufferers enrolled will meet Research Diagnostic Criteria for insomnia disorder, score > 14 on the Insomnia Severity Index, report insomnia for > 3 months, have sleep difficulties > 3 nights per week, score < 3 on the Epworth Sleepiness Scale (ESS), score > 40 on the Hyperarousal Scale10 and report an inability to nap in the daytime.
89579754|NCT02290405||Normal Sleepers (NS)|The normal sleepers enrolled will report general satisfaction with sleep and no sleep/wake complaints, score < 10 on the ESS, score < 35 on the Hyperarousal Scale10, and deny a practice of routine daytime napping.
89579755|NCT02359045|Experimental|Part 1: Treatment A-B-C-D|Subjects received a single dose of D1400147 (Treatment A: Omega-3-carboxylic acids 2000 mg uncoated capsules), D14000136 (Treatment B: Omega-3-carboxylic acids 2000 mg coated capsules coat 1), D14000137 (Treatment C: Omega-3-carboxylic acids 2000 mg coated capsules coat 2) and Epanova® (Treatment D: Epanova capsules 1000 mg) under fasted condition.
89579756|NCT02359045|Experimental|Part 2: Treatment A-B/C-D|Subjects received a single dose of D1400147 (Treatment A: Omega-3-carboxylic acids 2000 mg uncoated capsules), D14000136 (Treatment B: Omega-3-carboxylic acids 2000 mg coated capsules coat 1) or D14000137 (Treatment C: Omega-3-carboxylic acids 2000 mg coated capsules coat 2) and Epanova® (Treatment D: Epanova capsules 1000 mg) under fed condition.
89579757|NCT02358343|Active Comparator|Engagement Interview|Subjects will be randomly assigned to engagement interview or a control visit.Trained CBT therapists at each of the three sites will conduct the engagement interview. The session will be aimed at improving the acceptance of the diagnosis of depression by patients and treatment for the same.
89579758|NCT02358343|No Intervention|Control Visit|Subjects will be randomly assigned to engagement interview or a control visit. Individuals assigned to control visit will be scheduled for a follow-up discussion with a member of the research team. During this session, they will be informed of the diagnosis of major depression or dysthymia, the options for treatment available through the clinical trial, and alternatives should they decline participation in the clinical trial.
89579759|NCT02358343|Active Comparator|Cognitive Behavioral Therapy|"The subjects will be randomly assigned to individual CBT or sertraline drug therapy using block randomization.~Individuals will undergo 10 CBT sessions of 60 minutes each, by a trained therapist in the dialysis facility (8 weekly sessions; then every other week x 2). The CBT will be administered while the patient is undergoing HD; however, alternative arrangements will be made upon individual patient's preferences."
89579760|NCT02358343|Active Comparator|Antidepressant Drug Therapy|The subjects will be randomly assigned to individual CBT or sertraline drug therapy using block randomization. Anti-Depressant Drug Therapy will be delivered with sertraline, a selective serotonin reuptake inhibitor, and the dose will be titrated using the Measurement Based Care Protocol.
89579761|NCT02358343|No Intervention|Observational Cohort|Subjects who (1) are not willing to participate in the clinical trial and (2) do not find any treatment acceptable outside the clinical trial will be invited to participate in the prospective observational cohort for serial assessment of depressive symptoms.These subjects will only undergo assessment of severity of depressive symptoms at weeks 0, 6, and 12 using QIDS-C.
89579762|NCT02356783|Other|Interlaminar|"Approach for lumbar epidural steroid injection for this arm will be interlaminar.~We will be implementing a wireless pedometer to each of the 15 patients in this group to measure our primary and secondary outcomes."
89579763|NCT02356783|Other|Transforaminal|"Approach for lumbar epidural steroid injection for this arm will be transforaminal.~We will be implementing a wireless pedometer to each of the 15 patients in this group to measure our primary and secondary outcomes."
89029592|NCT02953119|Experimental|Prehabilitation|"The patients will undergo an exercise test on a cycle ergometer (VO2 max), a grip strength test (Jamar dynamometer), a Time Up and Go (TUG) test and a 6 Minutes Walking Test (6-MWT), before and after prehabilitation. Intervention involves 3 training sessions per week during 3 weeks preoperatively, according to the high intensity interval training model, wich consists of:~5 minute warm-up (50% of Cardiopulmonary exercise testing, CPET)~Two 10 minute series of 15 sec sprint intervals (100%) interspersed by 15 sec pauses and a 4 min rest between the two series~Cool down with a 5 min active recovery period (30%) The grip strength test (Jamar dynamometer), TUG-test and 6-MWT will be repeated between 4 and 6 weeks and 8 and 10 week postoperatively."
89029593|NCT02953119|No Intervention|Controls|The patients will also undergo an exercise test on a cycle ergometer, a grip strength test (Jamar dynamometer), a TUG-test and a 6-MWT, but only once preoperatively, and between 4 and 6 weeks and 8 and 10 week postoperatively.
89579764|NCT02289469|Experimental|PictureRx|PictureRx medication history platform
89579765|NCT02289469|No Intervention|Usual care|Usual medication history process
89579766|NCT02318095|Other|Chemotherapy/radiation/surgery|This is a single arm prospective study. All eligible subjects will recieve 2 cycles of neoadjuvant Gemcitabine/nab-Paclitaxel, followed by hypofractionated radiation therapy followed by surgical resection. Subjects may receive adjuvant chemotherapy post surgical resection at the clinical discretion of the medical oncologist.
89579767|NCT02317705|Experimental|Patients Receiving OTL38|All patients in this arm will receive OTL38 for injection and undergo intraoperative imaging.
89579768|NCT02474069|Active Comparator|Secukinumab Interval Shortening|
89579769|NCT02474069|Active Comparator|Secukinumab 4-weekly|
89579770|NCT02317627|Experimental|Cohort 1|KD025 400 mg QD PO for 12 weeks
89579771|NCT02317627|Experimental|Cohort 2|KD025 200 mg BID PO for 12 weeks
89579772|NCT02317627|Experimental|Cohort 3|KD025 400 mg BID PO for 12 weeks
89029594|NCT02955563|Experimental|CSDM Tool|Surrogate will complete educational sessions on CSDM tool prior to each family meeting with clinical team.
89579773|NCT02517905|Experimental|EXPAREL 133 mg|10 mL EXPAREL (bupivacaine liposome injectable suspension) injected into the maxilla (4 mL; 2 mL per side) and mandible (6 mL; 3 mL per side) at the end of surgery and ≥20 min after lidocaine administration
89579774|NCT02517905|Placebo Comparator|Placebo|10 mL normal saline injected into the maxilla (4 mL; 2 mL per side) and mandible (6 mL; 3 mL per side) at the end of surgery and ≥20 min after lidocaine administration
89029595|NCT02955563|No Intervention|Control|Surrogates will receive augmented usual care. The augmentation is that there will be 2 family meetings scheduled during the first 10 days of enrollment.
89029596|NCT00508911|Experimental|Healthy female subjects|Each subject will be administered a monophasic combined oral contraceptive (COC) containing ethinylestradiol 30 micrograms and levonorgestrel 150 micrograms for two complete cycles (Day 8 to Day 28) in Session 1. The subjects will be administered COC on Day 8 to Day 28 and GW876008 125 milligrams on Days 1 to 35 in Session 2.
89579775|NCT02473913|Experimental|Milk Thistle|Each subject will have a 6 week treatment phase with milk thistle.
89029597|NCT02955719|Experimental|Enrolled Cases|"Integrated Care Pathway with different treatment interventions~Interventions include:~Sertraline, Venlafaxine, CBT/Psychological therapy, Psychiatric consultation, lifestyle intervention resources"
89579776|NCT02473913|Placebo Comparator|Placebo|6 week placebo phase before or after milk thistle phase depending on randomization.
89579777|NCT02316847|Experimental|diazepam nasal spray (Adults)|One dose of diazepam nasal spray is two intranasal sprays; one in each nostril using a nasal spray device. The dose is administered while the subject is sitting up or lying down.
89579778|NCT02316847|Experimental|Diazepam Nasal Spray (Adolescents)|One dose of diazepam nasal spray is two intranasal sprays; one in each nostril using a nasal spray device. The dose is administered while the subject is sitting up or lying down.
89579779|NCT02473523|Experimental|Participants|"Leukemia, Hodgkin Lymphoma and non-Hodgkin's Lymphoma patients who meet eligibility requirements and consent to participate in the study.~Interventions: Yoga Therapy, PedsQL Multidimensional Fatigue Scale, PedsQL Cancer Module, Verbal Numeric Pain Scale. Biodex System 3 Dynamometer, Jamar Hydraulic Hand Dynamometer, Sit and Reach Test, and Test of Motor Proficiency."
89029598|NCT02955719|No Intervention|Enrolled Controls|No intervention: Treatment as usual (TAU) will be provided by the primary care practice staff
89029599|NCT00509691|Experimental|Single arm study|
89029600|NCT00501527|Experimental|A: Biological vaccine|The first active arm will receive a dose that is 10x less than the dose of the other arm
89029601|NCT00501527|Experimental|B: biological vaccine|The first active arm will receive a dose that is 10x more than the dose of the other arm
89029602|NCT00501527|Placebo Comparator|C|
89579780|NCT02316769|Active Comparator|King Vision Video Laryngoscope|Patient intubated with the King Vision Video Laryngoscope
89579781|NCT02316769|Active Comparator|McGrath MAC Video Laryngoscope|Patient intubated with the McGrath MAC Video Laryngoscope
89579782|NCT02473445|Experimental|Cysteamine Bitartrate Delayed-release|Participants received cysteamine bitartrate delayed-release capsules (RP103) twice daily for up to 2 years. The starting dose was the same as the last dose received in study RP103-MITO-001, the maximum dose was 1.3 g/m²/day.
89579783|NCT02473367|Experimental|Raltegravir Pre- and 4 Period Sequence|Starting five days prior to Period 1 participants will be treated with 1200 mg raltegravir, once daily for five days. In Period 1 participants will be treated with 1200 raltegravir alone; this is followed by Period 2 where participants will be treated with 1200 mg raltegravir and TUMS concomitantly; this is followed by Period 3 where participants will be treated with 1200 mg raltegravir and 12 hours later with Leader Antacid; followed by Period 4 where participants will be treated with 1200 mg raltegravir and 12 hours later with TUMS. The wait between Periods is 2-7 days.
89579784|NCT02316613||All Participants|Participants with histologically confirmed, refractory/relapsed cluster of differentiation-20 (CD20) positive follicular non-Hodgkin's lymphoma (grade IIII), whatever the first-line treatment was (chemotherapy and/or immunotherapy and/or radio-immunoconjugate and/or radiochemotherapy), and eligible for salvage treatment were observed for approximately 6 years. All participants received at least one cycle of rituximab (MabThera) during maintenance therapy or observation period.
89579785|NCT02492165|Experimental|Age 9 Months through 4 Years Group|Participants age 9 Months through 4 Years old at enrollment
89579786|NCT02492165|Experimental|Age 5 Years through 11 Years Group|Participants age 5 Years through 11 Years old at enrollment
89579787|NCT02492165|Experimental|Age 12 Years through 17 Years Group|Participants age 12 Years through 17 Years old at enrollment
89579788|NCT02492165|Experimental|Age 18 Years through 60 Years Group|Participants age 18 Years through 60 Years old at enrollment
89029603|NCT02955524|Experimental|Treatment session 1a|"Topical ophthalmic anesthesia to participants (#) on each session (letter) of intra-arterial chemotherapy.~where #1 is the participant identifier and letter-a is the start session with study protocol (most candidates will receive more than 4 sessions in a 6 month period)"
89029604|NCT02953041|Experimental|LAMA Treatment|Inhalation of 50mcg glycopyrronium from Breezhaler device 1 hour prior to methacholine challenge
89029605|NCT02953041|Experimental|uLABA Treatment|Inhalation of 75mcg indacaterol from Breezhaler device 1 hour prior to methacholine challenge
89029606|NCT02953041|Experimental|Combo Treatment|Inhalation of 50mcg glycopyrronium from one Breezhaler device, and 75mcg indacaterol from a second Breezhaler device, all one hour prior to methacholine challenge
89029607|NCT00509808|Sham Comparator|electrostimulation|Use of device for predetermined length
89029608|NCT01248494|Experimental|BEZ235 + Letrozole|
89029609|NCT01248494|Experimental|BKM120 + Letrozole|
89029610|NCT01248494|Experimental|Intermittent BKM120 + Letrozole|
89029611|NCT00509886|Experimental|1|ARMs were randomized. One side of the body received treatment with one antiperspirant and the contralateral side with a different antiperspirant.
89029612|NCT00509886|Experimental|2|ARMs were randomized. One side of the body received treatment with one antiperspirant and the contralateral side with a different antiperspirant.
89579789|NCT02355691|Experimental|PREVENA Group|Patients will be treated with the PREVENA negative pressure device following total hip arthroplasty. This dressing will be used for a period of seven days.
89579790|NCT02355691|No Intervention|Standard group|Patients will be treated with the standard absorptive dressing following total hip arthroplasty.
89579791|NCT02473289|Experimental|Sirukumab 50 milligram (mg)|Participants will receive sirukumab 50 mg as subcutaneous injection on Day 1, 28 and 56.
89579792|NCT02473289|Placebo Comparator|Placebo|Participants will receive matching placebo on Day 1, 28 and 56.
89029613|NCT02952573|Experimental|FGFR3 wild-type|"JNJ-42756493: For the first cycle, 8 mg orally (by mouth), once each day for 14 days of each 28-day periods called cycles. Then dose of JNJ-42756493 may then be increased to 9 mg taken orally if no significant side effects related to JNJ-42756493 are seen during the first 14 days.~Dexamethasone: 40 mg, orally, on days 1-4, 9-12, 17-20 for the first two cycles. Starting cycle 3, dexamethasone will be taken on days 1, 8, 15 and 22 (once weekly).~Patients over the age of 75 will take a reduced dose of dexamethasone of 20 mg on starting cycle 1 on days 1-4, 9-12, 17-20 for the first two cycles. Starting cycle 3, dexamethasone will be taken on days 1, 8, 15 and 22 (once weekly)."
89029614|NCT02952573|Experimental|FGFR3 mutated|"JNJ-42756493: For the first cycle, 8 mg orally (by mouth), once each day for 14 days of each 28-day periods called cycles. Then dose of JNJ-42756493 may then be increased to 9 mg taken orally if no significant side effects related to JNJ-42756493 are seen during the first 14 days.~Dexamethasone: 40 mg, orally, on days 1-4, 9-12, 17-20 for the first two cycles. Starting cycle 3, dexamethasone will be taken on days 1, 8, 15 and 22 (once weekly).~Patients over the age of 75 will take a reduced dose of dexamethasone of 20 mg on starting cycle 1 on days 1-4, 9-12, 17-20 for the first two cycles. Starting cycle 3, dexamethasone will be taken on days 1, 8, 15 and 22 (once weekly)."
89579793|NCT02354599|Experimental|Cohort 1: MT203 80 mg|Six Japanese participants will be randomized to receive a single dose of MT203 80 mg and 2 participants will be randomized to receive matched placebo subcutaneously.
89579794|NCT02354599|Placebo Comparator|Cohort 1: MT203 80 mg matching placebo|Six Japanese participants will be randomized to receive a single dose of MT203 80 mg and 2 participants will be randomized to receive matched placebo subcutaneously.
89579795|NCT02354599|Experimental|Cohort 2: MT203 150 mg|Six Japanese participants will be randomized to receive a single dose of MT203 150 mg and 2 participants will be randomized to receive matched placebo subcutaneously.
89579796|NCT02354599|Placebo Comparator|Cohort 2: MT203 150 mg matching placebo|Six Caucasian participants will be randomized to receive a single dose of MT203 150 mg and 2 participants will be randomized to receive matched placebo subcutaneously.
89579797|NCT02354599|Experimental|Cohort 3: MT203 300 mg|Six Japanese participants will be randomized to receive a single dose of MT203 300 mg and 2 participants will be randomized to receive matched placebo subcutaneously.
89579798|NCT02354599|Placebo Comparator|Cohort 3: MT203 300 mg matching placebo|Six Japanese participants will be randomized to receive a single dose of MT203 300 mg and 2 participants will be randomized to receive matched placebo subcutaneously.
89029615|NCT03459963|Experimental|group C|indwelling urinary catheter
89579799|NCT02354599|Experimental|Cohort 4: MT203 150 mg|Six Caucasian participants will be randomized to receive a single dose of MT203 150 mg and 2 participants will be randomized to receive matched placebo subcutaneously.
89579800|NCT02354599|Placebo Comparator|Cohort 4: MT203 150 mg matching placebo|Six Caucasian participants will be randomized to receive a single dose of MT203 150 mg and 2 participants will be randomized to receive matched placebo subcutaneously
89579801|NCT02316223|Experimental|Clinic-based care coordination|The ACC and CHW programs for asthma CC/SMS will have the same objectives and provide the same general services at the office/clinic. The ACC and CHW programs were developed from existing, successfully operating programs at the participating sites, and in the East Harlem and South Bronx communities.
89579802|NCT02316223|Active Comparator|Home-based care coordination|The ACC and CHW programs for asthma CC/SMS will have the same objectives and provide the same general services at participant's home. The ACC and CHW programs were developed from existing, successfully operating programs at the participating sites, and in the East Harlem and South Bronx communities.
89579803|NCT02316223|No Intervention|Usual care|Clinician-centric strategy and EMR-based clinician decision support
89579804|NCT02286895|Active Comparator|Group A (without rotavirus vaccine)|Group A will receive measles vaccine (MV), yellow fever vaccine (YFV), and meningitis conjugate vaccine (PsA-TT-5μg).
89579805|NCT02286895|Experimental|Group B (with rotavirus vaccine)|Group A will receive measles vaccine (MV), yellow fever vaccine (YFV), and meningitis conjugate vaccine (PsA-TT-5μg) plus one oral dose of pentavalent rotavirus vaccine (PRV).
89579806|NCT02472977|Active Comparator|BMS-936564 (Ulocuplumab) + Nivolumab, Tumor type arm (SCLC)|Small cell lung cancer (SCLC)
89579807|NCT02472977|Active Comparator|BMS-936564 (Ulocuplumab) + Nivolumab, Tumor type arm (PAC)|Pancreatic cancer (PAC)
89579808|NCT02060487|Experimental|Low dose|
89579809|NCT02060487|Experimental|Medium dose|
89579810|NCT02060487|Experimental|High dose|
89579811|NCT02059395|Active Comparator|Time based|Participants follow the traditional Canadian Heart and Stroke Foundation Heartsaver Course
89579812|NCT02059395|Experimental|Mastery based|Participants do follow the content of the Canadian Heart and Stroke Foundation Heartsaver Course content based on their own pace (timeframe)
89579813|NCT02059239|Experimental|Chemo plus Autologous Transplantation|Bendamustine 200 mg/ m2/ day on Days - 24 and Day - 23 followed by a short break of 10 - 14 days, followed by Melphalan, Carmustine, Etoposide, Cytarabine (BEAM) and alemtuzumab, plus rituximab for all b-cell malignancies, followed by autologous transplant
89579814|NCT02059239|Experimental|Chemo plus Allogeneic Transplantation|Bendamustine 200 mg/ m2/ day on Days - 24 and Day - 23 followed by a short break of 10 - 14 days, followed by Melphalan, Carmustine, Etoposide, Cytarabine (BEAM) and alemtuzumab, plus rituximab for all b-cell malignancies, followed by allogeneic transplant
89579815|NCT04722783|Experimental|ESDM and PCIT-A|Participants in this arm receive 2 years ESDM and after 4 months PCIT-A for 8 months (see Study Protocol, Figure 2).
89029616|NCT03459963|No Intervention|group N|Non cathetrized patients
89029617|NCT01248572|Experimental|Softec HD IOL|
89579816|NCT04722783|Experimental|ESDM and active control for PCIT-A|Participants in this arm receive 2 years ESDM and after 4 months 1h-ESDM as active control instead of 1h-PCIT-A for 8 months
89579817|NCT04722783|Experimental|PCIT-A and active control for ESDM|Participants receive after 4 month PCIT-A for 8 months and early special needs education as an active control for ESDM.
89579818|NCT04722783|Active Comparator|Active control for ESDM and PCIT-A|Participants receive early special needs education as an active control for ESDM and PCIT-A.
89579819|NCT02059161|Experimental|MK-1293|MK-1293 dosed subcutaneously once daily at bedtime for 52 weeks. Doses were individually titrated post randomization to the suggested target for fasting fingerstick glucose levels of >70 mg/dL (3.9 mmol/L) and ≤100 mg/dL (5.6 mmol/L).
89579820|NCT02059161|Active Comparator|Lantus|Lantus dosed subcutaneously once daily at bedtime for 52 weeks. Doses were individually titrated post-randomization to the suggested target for fasting fingerstick glucose levels of >70 mg/dL (3.9 mmol/L) and ≤100 mg/dL (5.6 mmol/L).
89579821|NCT04417647|Experimental|Group 1|Proximal wound SoC treatment - Distal wound VZ application
89579822|NCT04417647|Experimental|Group 2|Distal wound SoC treatment - Proximal wound VZ application
89579823|NCT01897714|Experimental|Phase I: Melflufen 15 mg + Dexamethasone|Intravenous (IV) infusion of 15 milligram (mg) melflufen on Day 1 of each 21-day treatment cycle, in combination with 40 mg dexamethasone (oral or IV) on Days 1, 8 and 15 of each 21-day treatment cycle.
89579824|NCT01897714|Experimental|Phase I: Melflufen 25 mg + Dexamethasone|IV infusion of 25 mg melflufen on Day 1 of each 21-day treatment cycle, in combination with 40 mg dexamethasone (oral or IV) on Days 1, 8 and 15 of each 21-day treatment cycle.
89579825|NCT01897714|Experimental|Phase I: Melflufen 40 mg + Dexamethasone|IV infusion of 40 mg melflufen on Day 1 of each 21-day treatment cycle, in combination with 40 mg dexamethasone (oral or IV) on Days 1, 8 and 15 of each 21-day treatment cycle.
89579826|NCT01897714|Experimental|Phase I: Melflufen 55 mg + Dexamethasone|IV infusion of 55 mg melflufen on Day 1 of each 21-day treatment cycle, in combination with 40 mg dexamethasone (oral or IV) on Days 1, 8 and 15 of each 21-day treatment cycle.
89579827|NCT01897714|Experimental|Phase I + II: Melflufen 40 mg + Dexamethasone|IV infusion of 40 mg melflufen on Day 1 of each 21-day or 28-day treatment cycles, in combination with 40 mg dexamethasone (oral or IV) on Days 1, 8 and 15 of each 21-day treatment cycles. For any patients on the 28-day treatment schedule, an additional dose of 40 mg dexamethasone was administered on Day 22 of each treatment cycle.
89579828|NCT01897714|Experimental|Phase II: Melflufen 40 mg (Single Agent)|IV infusion of 40 mg melflufen on Day 1 of each 28-day treatment cycle.
89579829|NCT05131737|Experimental|Constant work-rate at altitude 2500 m above sea level (high altitude)|Cycling at high altitude
89579830|NCT05131737|Active Comparator|Constant work-rate at altitude 470 m above sea level (low altitude)|Cycling at low altitude
89579831|NCT01861522|Experimental|TAU-284|Two TAU-284 5mg tablets will be taken orally twice a day, once after breakfast and once after dinner (or before bed).
89579832|NCT01861522|Placebo Comparator|Placebo|Two placebo tablets will be taken orally twice a day, once after breakfast and once after dinner (or before bed).
88973053|NCT05330013|Experimental|Subjects with HFpEF|Subjects are defined as patients with a diagnosis of HFpEF clinically confirmed by a licensed physician or advanced practitioner who meet the inclusion and exclusion criteria and are able to provide informed consent.
88973054|NCT00846287|Active Comparator|Drug Subjects|Patients will be required to breath in individual 1 liter bags of gas while in an MRI to produce lung images. These bags of gas are each made up of 333mL of Helium-3 gas and 667mL of Nitrogen. The first three bags will be administered with a break between each of five to ten minutes. Then the drug aformoterol will be administered and an hour will pass. BROVANA (arformoterol tartrate) Inhalation Solution is supplied as 2 mL of arformoterol tartrate solution packaged in 2.1 mL unit-dose, low-density polyethylene (LDPE) unit-dose vials. Each unit-dose vial contains 15 mcg of arformoterol (equivalent to 22 mcg of arformoterol tartrate) in a sterile, isotonic saline solution, pH-adjusted to 5.0 with citric acid and sodium citrate. After administration of the drug, three additional bags of hyperpolarized helium-3 will be administered, again with five to ten minutes between each bag.
88973055|NCT00846287|Placebo Comparator|Saline|Patients will be required to breath in individual 1 liter bags of gas while in an MRI to produce lung images. These bags of gas are each made up of 333mL of Helium-3 gas and 667mL of Nitrogen. The first three bags will be administered with a break between each of five to ten minutes. Then the placebo (nebulized saline solution) will be administered (2.1 mL). After administration of the placebo, three additional bags of hyperpolarized helium-3 will be administered, again with five to ten minutes between each bag.
88973056|NCT05284188|Active Comparator|Open Modified Broström operation group|Patients who accept an open modified Broström operation
88973057|NCT05284188|Active Comparator|Arthroscopic Modified Broström operation group|Patients who accept an arthroscopic modified Broström operation
88973058|NCT00846248|Active Comparator|1|Chromium picolinate
89579833|NCT01860976|Experimental|Abatacept|Abatacept 125 mg/syringe (125 mg/mL) solution subcutaneously once a week for 168 days double blind/197 days open label/365 days long term extension
89579834|NCT01860976|Placebo Comparator|Placebo|Placebo matching with Abatacept 0 mg solution subcutaneously once a week 168 days double blind
89579835|NCT01860040|Experimental|Cisplatin and pemetrexed|Cisplatin on day 1 and pemetrexed on day 1, 1 cycle = 21 days, deliver 4 neoadjuvant cycles
89579836|NCT01860040|Experimental|Cisplatin and gemcitabine|Cisplatin on day 1 and gemcitabine on days 1 and 8, 1 cycle = 21 days, deliver 4 neoadjuvant cycles
89579837|NCT04618744|Placebo Comparator|Placebo|Fish oil
89579838|NCT04618744|Experimental|ORMD-0801 (Insulin) capsule 8 mg BD|ORMD-0801 (insulin) capsule Dose: 8 mg BD Dosage Regimen: 1 capsule twice a day (once in the morning approximately 30 to 45 minutes prior to breakfast and no later than 10 AM, and once at night between 8 PM to Midnight and no sooner than 1 hour after dinner) Mode of Administration: Oral
89579839|NCT01896934|Experimental|Sertraline|50-200mg daily
89579840|NCT02039505|Placebo Comparator|Induction Phase: Cohort 1, Placebo|Vedolizumab placebo-matching, intravenous (IV) infusion, once at Weeks 0, 2 and 6 in the induction phase.
89579841|NCT02039505|Experimental|Induction Phase: Cohort 1, Vedolizumab 300 mg|Vedolizumab 300 mg, IV infusion, once at Weeks 0, 2, and 6 in the induction phase.
89579842|NCT02039505|Experimental|Induction Phase: Cohort 2, Vedolizumab 300 mg|Vedolizumab 300 mg, IV infusion, once at Weeks 0, 2 and 6 in the induction phase.
89579843|NCT02039505|Experimental|Maintenance Phase: Placebo|Vedolizumab placebo-matching, IV infusion, once at Weeks 14, 22, 30, 38, 46 and 54 in maintenance phase. Participants received vedolizumab in induction phase and achieved clinical response at Week 10 and were randomized to receive placebo in maintenance phase.
89579844|NCT02039505|Experimental|Maintenance Phase: Vedolizumab 300 mg|Vedolizumab 300 mg, IV infusion, once at Weeks 14, 22, 30, 38, 46 and 54 in maintenance phase. Participants received vedolizumab in induction phase and achieved clinical response at Week 10 and were randomized to receive vedolizumab in maintenance phase.
89579845|NCT02039505|Placebo Comparator|Maintenance Phase: Placebo continuation|Vedolizumab placebo-matching, IV infusion, once at Weeks 14, 22, 30, 38, 46 and 54 in maintenance phase. Participants received vedolizumab placebo-matching in induction phase and achieved clinical response at Week 10 received placebo in maintenance phase without randomization.
89579846|NCT02039505|Experimental|Open-Label Cohort: Vedolizumab 300 mg|Vedolizumab 300 mg, IV infusion, once at Weeks 0, 2 and 6 and then every 8 weeks thereafter up to Week 94 in open-label cohort.
89579847|NCT02095197|Other|No Catheter delivery|"Cervical epidural steroid injection with Triamcinolone 80mg and 1 mL 1% lidocaine. Total volume is 2 cc.~No Catheter Delivery will be used to deliver the medication."
89029618|NCT02953080|Active Comparator|Call for Life Mobile phone support|"The intervention is Call for life mHealth adherence support tool  through basic mobile phone-based interactive voice response."
89579848|NCT02095197|Active Comparator|Catheter targeted delivery|"Cervical epidural steroid injection with Triamcinolone 80mg and 1 mL 1% lidocaine. Total volume is 2 cc.~Catheter targeted delivery will be used to deliver the medication."
89579849|NCT02039427|Placebo Comparator|Placebo|Normal saline(Placebo) 2 ml 5 min before induction Normal saline 2 ml 10 min before end of surgery
89579850|NCT02039427|Active Comparator|Preketorolac|Ketorolac 30 mg 5 min before induction Normal saline 2 ml 10 min before end of surgery
89579851|NCT02039427|Active Comparator|Postketorolac|Normal saline 2 ml 5 min before induction Ketorolac 30 mg 10 min before end of surgery
89579852|NCT02039427|Active Comparator|Dexamethasone|Dexamethasone 10 mg (total volume 2 ml) 5 min before induction Normal saline 2 ml 10 min before end of surgery
89579853|NCT02094885|Experimental|Bioseal Fibrin Sealant|A porcine-derived fibrin sealant consisting of thrombin and fibrinogen
89029619|NCT02953080|No Intervention|Standard of Care|No call for life Uganda: Patients are randomized to standard of Care
89579854|NCT02094885|Other|Manual compression|Manual compresssion (MC) include any active or inactive adjunctive treatment to hemostasis methods currently used based on each surgeons surgical practice except for the use of other fibrin sealants.
89579855|NCT01896856|Experimental|Phase 1: Dose Escalation|"Subjects receive SGI-110 on days 1-5 and irinotecan on days 8 and 15 of each 28-day cycle.~Various doses of SGI-110 are tested to determine the maximum tolerated dose in combination with irinotecan."
89579856|NCT01896856|Experimental|Phase 2: Arm A SGI-110 + irinotecan|"Subjects receive SGI-110 on days 1-5 and irinotecan on days 8 and 15 of each 28-day cycle.~Growth factor support (filgrastim and peg-filgrastim) is given during cycle 1 with option to give additional growth factor support at subsequent cycles per clinician judgement."
89579857|NCT01896856|Active Comparator|Phase 2: Arm B regorafenib or TAS-102|"Subjects received either regorafenib or TAS-102 based on physician and patient preference. Subjects that had received one of these standard of care drugs (regorafenib or TAS-102) prior to enrollment received the other on study.~Regorafenib taken daily from days 1-21 of each 28-day cycle or TAS-102 taken twice daily on days 1-5 and 8-12 of each 28-day cycle.~Subjects who had disease progression on Arm B were given the option to receive Arm A study drugs after a 14 day wash-out period."
89579858|NCT02038959|No Intervention|Usual Care and Educational Materials|Participants with Parkinson disease will receive educational materials from the National Parkinson Foundation, complete a baseline assessment survey and virtual visit with a physician independent rater, then continue with their usual care in their communities for the duration of the study. After 12 months, they will have another virtual study assessment with an independent rater, after which they will receive a free, one-time virtual consultation with a Parkinson disease specialist in their state.
89579859|NCT02038959|Experimental|Virtual Visits and Educational Materials|Participants with Parkinson disease randomized to the virtual visit intervention will receive educational materials from the National Parkinson Foundation, complete a baseline assessment and virtual study assessment with a physician independent rater, and then receive four virtual care visits with a Parkinson disease specialist in their state. Specialists will provide recommendations for care to participants and their designated local health care provider. At 12 months, these individuals will again be assessed by the independent rater, who will be blind to treatment assignment.
89029620|NCT02952768|Other|ultrasound training|The aims were to develop a novel, resuscitative ultrasound-circulation-airway-breathing (US-C-A-B) protocol, to implement a short curriculum for ultrasound training and to assess the feasibility.
89579860|NCT01896700|Experimental|Methylphenidate|"Intervention: An escalating dose of methylphenidate taken by mouth: 20mg for 2 weeks, 40mg for 2 weeks, 60mg for 2 weeks. All doses divided twice/day.~Other name: Ritalin"
89579861|NCT01896700|Placebo Comparator|Placebo|Placebo pill, bid for 6 weeks
89579862|NCT02352493|Active Comparator|ALN-CC5|
89029621|NCT01248611|Experimental|fentanyl|cancer patients with pain
89029622|NCT00509964|Active Comparator|1|Patients will receive irinotecan 150 mg/m2 intravenously on day 1 every 2 weeks.
89029623|NCT00509964|Active Comparator|2|Patients will receive irinotecan 150 mg/m2 intravenously, in combination with leucovorin and infusional 5-fluorouracil, on day 1 every 2 weeks.
89579863|NCT02352493|Placebo Comparator|Sterile Normal Saline (0.9% NaCl)|
89579864|NCT02286193||Patients presenting to Community Resource Specialist (CRS)|Primary care patients who are referred or self-refer to the CRS for education and linkage to community resources that can help support health goals
89579865|NCT01896232|Active Comparator|Cinacalcet|Participants were randomized to receive oral cinacalcet once daily and placebo intravenous bolus injection at the end of each hemodialysis session, three times per week (TIW) for 26 weeks. The starting dose of cinacalcet was 30 mg daily and could have been titrated at weeks 5, 9, 13, and 17 to target predialysis serum PTH ≤ 300 pg/mL but no lower than 100 pg/mL while maintaining corrected calcium (cCa) ≥ 8.3 mg/dL.
89579866|NCT01896232|Experimental|Etelcalcetide|Participants were randomized to receive etelcalcetide administered by intravenous bolus injection at the end of each hemodialysis session TIW, and daily oral doses of placebo tablets for 26 weeks. The starting dose of etelcalcetide was 5 mg, and could have been titrated at weeks 5, 9, 13, and 17 to target predialysis serum PTH ≤ 300 pg/mL but no lower than 100 pg/mL while maintaining cCa ≥ 8.3 mg/dL.
89579867|NCT02460224|Experimental|Phase 1: LAG525 1 mg/kg Q2W|Single-agent LAG525 1 mg/kg Q2W
89579868|NCT02460224|Experimental|Phase 1: LAG525 3 mg/kg Q2W|Single-agent LAG525 3 mg/kg Q2W
89579869|NCT02460224|Experimental|Phase 1: LAG525 5 mg/kg Q2W|Single-agent LAG525 5 mg/kg Q2W
89579870|NCT02460224|Experimental|Phase 1: LAG525 10 mg/kg Q2W|Single-agent LAG525 10 mg/kg Q2W
88973059|NCT00846248|Placebo Comparator|2|2 sugar pills taken twice daily
88973060|NCT00846170|Active Comparator|probiotics|patients with IBS that will receive investigational treatment for 4 weeks
88973061|NCT00846170|Placebo Comparator|Placebo|cross over of patients from arm 1
88973062|NCT05185050||AIS with MPS|the participants who has Cobb angle above 10 degrees and diagnosed with myofascial pain syndrome
88973063|NCT05185050||AIS with no pain|the participants who has Cobb angle above 10 degrees and without pain
88973064|NCT00846131|Active Comparator|A: Y-90 alone|Patients randomized to Arm A will proceed to Y-90 treatment alone in the Northwestern standard of care procedure
88973065|NCT00846131|Experimental|B: Sorafenib + Y-90|Patients randomized to Arm B will start sorafenib at a dose of 400 mg twice daily for bilirubin ≤ 1.5 x ULN and 200 mg twice daily for bilirubin > 1.5 x ULN to ≤ 3 x ULN. After 14 days of sorafenib therapy (+/- 3 days) patients will proceed to Y-90 in the Northwestern standard of care procedure
88973066|NCT00846092|Experimental|Device|"The study will require 20 subjects.~Each subject will have one study eye that will be designated for treatment.~Subjects will be exposed to light emitted from Warp 10 LED's (Quantum Devices, Barneveld, WI) at wavelengths of 670 nm (+/-15nm) with a minimum exposure of 4 J/cm2 (4.0 - 7.68J/cm2). This is accomplished by applying the 50 mW/cm2 (50 - 80 mw/cm2) LED-generated light to the study eye.~Treatments involve application of the LED-generated light for 80 seconds, twice daily.~Primary efficacy and toxicity outcomes are determined by measuring excess retinal thickness via Ocular Coherence Tomography at 1 month, 3 months, and 6 months, prior to conclusion of the study.~• This protocol will be stopped if, at any point in the study, a 50% increase in excess retinal thickness is demonstrated via OCT in 25% of subjects in the experimental group."
88973067|NCT05081154|Experimental|Product usage order A B G C F D E|Subjects will use each of the 7 products (A B G C F D E) during an evaluation period, followed by a 4 hour Test Session
88973068|NCT05081154|Experimental|Product usage order B C A D G E F|Subjects will use each of the 7 products (B C A D G E F) during an evaluation period, followed by a 4 hour Test Session
88973069|NCT05081154|Experimental|Product usage order C D B E A F G|Subjects will use each of the 7 products (C D B E A F G) during an evaluation period, followed by a 4 hour Test Session
88973070|NCT05081154|Experimental|Product usage order D E C F B G A|Subjects will use each of the 7 products (D E C F B G A) during an evaluation period, followed by a 4 hour Test Session
88973071|NCT05081154|Experimental|Product usage order E F D G C A B|Subjects will use each of the 7 products (E F D G C A B) during an evaluation period, followed by a 4 hour Test Session
88973072|NCT05081154|Experimental|Product usage order F G E A D B C|Subjects will use each of the 7 products (F G E A D B C) during an evaluation period, followed by a 4 hour Test Session
88973073|NCT05081154|Experimental|Product usage order G A F B E C D|Subjects will use each of the 7 products (G A F B E C D) during an evaluation period, followed by a 4 hour Test Session
89579871|NCT02460224|Experimental|Phase 1: LAG525 15 mg/kg Q2W|Single-agent LAG525 15 mg/kg Q2W
89579872|NCT02460224|Experimental|Phase 1: LAG525 240 mg Q2W|Single-agent LAG525 240 mg Q2W
89579873|NCT02460224|Experimental|Phase 1: LAG525 400 mg Q2W|Single-agent LAG525 400 mg Q2W
89579874|NCT02460224|Experimental|Phase 1: LAG525 3 mg/kg Q4W|Single-agent LAG525 3 mg/kg Q4W
88973074|NCT05081154|Experimental|Product usage order E D F C G B A|Subjects will use each of the 7 products (E D F C G B A) during an evaluation period, followed by a 4 hour Test Session
88973075|NCT05081154|Experimental|Product usage order F E G D A C B|Subjects will use each of the 7 products (F E G D A C B) during an evaluation period, followed by a 4 hour Test Session
88973076|NCT05081154|Experimental|Product usage order G F A E B D C|Subjects will use each of the 7 products (G F A E B D C) during an evaluation period, followed by a 4 hour Test Session
88973077|NCT05081154|Experimental|Product usage order A G B F C E D|Subjects will use each of the 7 products (A G B F C E D) during an evaluation period, followed by a 4 hour Test Session
88973078|NCT05081154|Experimental|Product usage order B A C G D F E|Subjects will use each of the 7 products (B A C G D F E) during an evaluation period, followed by a 4 hour Test Session
88973079|NCT05081154|Experimental|Product usage order C B D A E G F|Subjects will use each of the 7 products (C B D A E G F) during an evaluation period, followed by a 4 hour Test Session
88973080|NCT05081154|Experimental|Product usage order D C E B F A G|Subjects will use each of the 7 products (D C E B F A G) during an evaluation period, followed by a 4 hour Test Session
88973081|NCT00846014|Experimental|Asthmatics|All subjects will be asthmatics that have had an exacerbation (asthma attack) no more than 48 hours before the imaging session.
88973082|NCT05051553|Experimental|Treatment 1A|
88973083|NCT05051553|Experimental|Treatment 1B|
88973084|NCT05051553|Experimental|Treatment 2A|
88973085|NCT05051553|Experimental|Treatment 2B|
88973086|NCT05051553|Experimental|Treatment 2C|
89579875|NCT02460224|Experimental|Phase 1: LAG525 5 mg/kg Q4W|Single-agent LAG525 5 mg/kg Q4W
89579876|NCT02460224|Experimental|Phase 1: LAG525 10 mg/kg Q4W|Single-agent LAG525 10 mg/kg Q4W
89579877|NCT02460224|Experimental|Phase 1: LAG525 400 mg Q4W|Single-agent LAG525 400 mg Q4W
89579878|NCT02460224|Experimental|Phase 1: LAG525 0.3 mg/kg Q2W + PDR001 1 mg/kg Q2W|Combination LAG525 0.3 mg/kg + PDR001 1 mg/kg (Q2W/Q2W)
89579879|NCT02460224|Experimental|Phase 1: LAG525 1 mg/kg Q2W + PDR001 1 mg/kg Q2W|Combination LAG525 1 mg/kg + PDR001 1 mg/kg (Q2W/Q2W)
89579880|NCT02460224|Experimental|Phase 1: LAG525 80 mg Q2W + PDR001 80 mg Q2W|Combination LAG525 80 mg + PDR001 80 mg (Q2W/Q2W)
89579881|NCT02460224|Experimental|Phase 1: LAG525 80 mg Q2W + PDR001 240 mg Q2W|Combination LAG525 80 mg + PDR001 240 mg (Q2W/Q2W)
89579882|NCT02460224|Experimental|Phase 1: LAG525 240 mg Q2W + PDR001 240 mg Q2W|Combination LAG525 240 mg + PDR001 240 mg (Q2W/Q2W)
89579883|NCT02460224|Experimental|Phase 1: LAG525 240 mg Q3W + PDR001 300 mg Q3W|Combination LAG525 240 mg + PDR001 300 mg (Q3W/Q3W)
89579884|NCT02460224|Experimental|Phase 1: LAG525 400 mg Q3W + PDR001 300 mg Q3W|Combination LAG525 400 mg + PDR001 300 mg (Q3W/Q3W)
89579885|NCT02460224|Experimental|Phase 1: LAG525 600 mg Q3W + PDR001 300 mg Q3W|Combination LAG525 600 mg + PDR001 300 mg (Q3W/Q3W)
89579886|NCT02460224|Experimental|Phase 1: LAG525 80 mg Q4W + PDR001 240 mg Q4W|Combination LAG525 80 mg + PDR001 240 mg (Q4W/Q4W)
89579887|NCT02460224|Experimental|Phase 1: LAG525 400 mg Q4W + PDR001 400 mg Q4W|Combination LAG525 400 mg + PDR001 400 mg (Q4W/Q4W)
89579888|NCT02460224|Experimental|Phase 1: LAG525 800 mg Q4W + PDR001 400 mg Q4W|Combination LAG525 800 mg + PDR001 400 mg (Q4W/Q4W)
89579889|NCT02460224|Experimental|Phase 1: LAG525 1000 mg Q4W + PDR001 400 mg Q4W|Combination LAG525 1000 mg + PDR001 400 mg (Q4W/Q4W)
89579890|NCT02460224|Experimental|Phase 1: LAG525 80 mg Q2W + PDR001 400 mg Q4W|Combination LAG525 80 mg + PDR001 400 mg (Q2W/Q4W)
89579891|NCT02460224|Experimental|Phase 1: LAG525 240 mg Q2W + PDR001 400 mg Q4W|Combination LAG525 240 mg + PDR001 400 mg (Q2W/Q4W)
89579892|NCT02460224|Experimental|Phase 1: LAG525 300 mg Q2W + PDR001 400 mg Q4W|Combination LAG525 300 mg + PDR001 400 mg (Q2W/Q4W)
89579893|NCT02460224|Experimental|Phase 2: Naive - LAG525 400 mg Q3W + PDR001 300 mg Q3W|Combination LAG525 400 mg + PDR001 300 mg (Q3W/Q3W) in patients naïve to anti-PD-1/PD-L1
89579894|NCT02460224|Experimental|Phase 2: Naive - LAG525 600 mg Q4W + PDR001 400 mg Q4W|Combination LAG525 600 mg + PDR001 400 mg (Q4W/Q4W) in patients naïve to anti-PD-1/PD-L1
89579895|NCT02460224|Experimental|Phase 2: Pre-treated - LAG525 400 mg Q3W + PDR001 300 mg Q3W|Combination LAG525 400 mg + PDR001 300 mg (Q3W/Q3W) in patients pre-treated with anti-PD-1/PD-L1
89579896|NCT02094573|Experimental|Brigatinib 90 mg|Brigatinib 90 mg, tablets, orally, once daily in each Cycle of 28 days until disease progression or intolerable toxicity (median duration of exposure was 402 days).
89579897|NCT02094573|Experimental|Brigatinib 90 mg - 180 mg|Brigatinib 90 mg, tablets, orally, once daily for 7 days followed by brigatinib 180 mg, orally once daily in Cycle 1 of 28 days followed by brigatinib 180 mg, orally once daily in Cycle 2 and onward Cycles of 28 days until disease progression or intolerable toxicity (median duration of exposure was 522 days).
89579898|NCT01859494|Experimental|Users of the Monitoring System|Untrained subjects with diabetes used the NINJA 3 Investigational Blood Glucose Monitoring System.
89579899|NCT01858636||Angio-Seal VIP Vascular Closure|
88973087|NCT00845975|Active Comparator|Erchonia Hearing Lasers #1 & #2|"Erchonia Hearing Laser #1 is a dual laser system composed of a pulsed red 7.5 milliwatts (mW) laser of 635 nm +/- 5 nm and a pulsed green 7.5 mW laser of 532 nm, both lasers in simultaneous operation when the laser is activated.~Erchonia Hearing Laser #2 is a single diode laser that in pulsed mode emits 4.9 mW of red 635 nm +/- 5 nm light."
88973088|NCT00845975|Placebo Comparator|Placebo Lasers|Inactive lasers that do not emit any therapeutic light.
89579900|NCT02058849|Experimental|Beetroot|Beetroot 10 grams concentrated organic beetroot crystals
89579901|NCT02058849|Placebo Comparator|Placebo|Placebo
88973089|NCT00845936|Experimental|1|850 mg of Metformin bid
88973090|NCT00845936|Placebo Comparator|placebo|Tablets Identical to Metformin, bid
88973091|NCT04941378|Experimental|OTL 38|The study drug in question is an Investigational New Drug (IND), folate analog ligand conjugated with an indole cyanine green-like dye called OTL38. There will be a single dose of 0.025 mg/kg for intravenous injection over approximately 60 minutes, completed at least 1 hour prior to intraoperative imaging
88973092|NCT04888377||Antenatal exposure to low dose aspirin|Mothers in the Global Networks ASPIRIN trial were given 81 mg of Aspirin throughout their pregnancy with the follow-up studies participant.
88973093|NCT04888377||Antenatal exposure to Placebo|Mothers in the Global Networks ASPIRIN trial were given placebo throughout their pregnancy with the follow-up studies participant.
88973094|NCT00277043|Experimental|1 Test Dose|
88973095|NCT00277043|Active Comparator|2) Non test dose arm|
89579902|NCT01858558|Experimental|aMIL Arm|Patients receive activated Marrow Infiltrating Lymphocytes (aMIL)
89579903|NCT01858558|Active Comparator|No aMIL|Patients do not receive activated Marrow Infiltrating Lymphocytes (aMIL)
89579904|NCT02058537|Experimental|Bethanechol|Oral administration of 25 milligrams of bethanechol taken twice daily for a minimum of 7 days. Total dose taken daily for a minimum of 7 days is 50 mg.
89579905|NCT01612000|Experimental|PanBlok 15µg in 2% SE|15µg recombinant hemagglutinin in a 2% oil-in-water stable emulsion (rHA adjuvant). 0.5mL intramuscular injection on Day 0 and Day 21 in the deltoid muscle
89579906|NCT01612000|Experimental|PanBlok 3.8µg in 2% SE|3.8µg recombinant hemagglutinin in a 2% oil-in-water stable emulsion (rHA adjuvant). 0.5mL intramuscular injection on Day 0 and Day 21 in the deltoid muscle
89579907|NCT01612000|Experimental|PanBlok 7.5µg No Adjuvant|7.5µg recombinant hemagglutinin, no adjuvant. 0.5mL intramuscular injection on Day 0 and Day 21 in the deltoid muscle
89579908|NCT01612000|Experimental|PanBlok 7.5µg in 2% SE|7.5µg recombinant hemagglutinin in a 2% oil-in-water stable emulsion (rHA adjuvant). 0.5mL intramuscular injection on Day 0 and Day 21 in the deltoid muscle
89579909|NCT01895608|Experimental|Balance rehabilitation + dual-tasking|Balance rehabilitation will involve a structured framework of balance activities that require increasing levels of complexity and multimodal stimuli and response demands with the addition of cognitive tasks, (e.g., counting backwards or reciting lists) to be added when the participant can safely perform the primary balance or gait task.
89579910|NCT01895608|Active Comparator|Standard balance rehabilitation|Standard balance rehabilitation will involve a structured framework of balance activities that require increasing levels of complexity and multimodal stimuli and response demands.
89579911|NCT01895608|Experimental|Cognitive training (speed of processing)|Speed of processing cognitive training involves systematically increasing the complexity of visual tasks. Task demands are increased by reducing stimulus duration, adding visual or auditory distractors, increasing number of concurrent tasks or increasing the visual field.
89579912|NCT01895608|Active Comparator|Cognitive training (general cognition)|General cognitive training involves systematic training of 14 key cognitive abilities, including visual scanning, response time, eye-hand coordination, spatial perception, and working memory. Initial starting point is determined by the software using baseline evaluation.
89579913|NCT02409680|Active Comparator|Intervention Arm|Women will be randomized equally to receive daily low dose aspirin (LDA) [also known as acetylsalicylic acid (ASA)] of 81 mg beginning between 6 0/7 weeks and 13 6/7 weeks GA and continuing until 36 0/7 weeks GA or delivery.
89579914|NCT02409680|Placebo Comparator|Placebo Arm|Women will be randomized equally to receive an identical appearing placebo beginning between 6 0/7 weeks and 13 6/7 weeks GA and continuing until 36 0/7 weeks GA or delivery.
89579915|NCT04618354||LADA group|The patient was diagnosed with late-onset autoimmune diabetes (LADA).
89579916|NCT04618354||T2DM group|The patient was diagnosed with type 2 diabetes (T2DM).
89579917|NCT04618354||T1DM group|The patient was diagnosed with type 1 diabetes (T1DM).
89579918|NCT01895452|Experimental|ALKS 9072, Low Dose|
89579919|NCT01895452|Experimental|ALKS 9072, High Dose|
88973096|NCT04732572|Experimental|Adenotonsillectomy|Within 1 to 4 weeks (30 days) of randomization, participants randomized to the adenotonsillectomy arm will undergo surgery under general anesthesia, as occurs as part of routine standard of care.
88973097|NCT04732572|Active Comparator|Watchful waiting with supportive care|Within 1 to 4 weeks after the 7-month visit, participants in the Arm 2 group will be referred for re-evaluation of surgical candidacy. Symptoms and polysomnographic findings (baseline and month 7) will be reviewed by the ENT and a decision whether to proceed with adenotonsillectomy as part of routine clinical care will be made.
88973098|NCT00276965|Experimental|A|Participants will take lithium only.
88973099|NCT00276965|Experimental|B|Participants will take lithium and sertraline.
88973100|NCT00276965|Experimental|C|Participants will take sertraline only.
88973101|NCT00396786|Experimental|Arm 1|
89579920|NCT02094417|Experimental|AMG531 (Dose 1)|
89579921|NCT02094417|Experimental|AMG531 (Dose 2)|
89579922|NCT02094417|Experimental|AMG531 (Dose 3)|
89579923|NCT02094417|Experimental|AMG531 (Dose 4)|
89579924|NCT01894984||Risperidone|Risperidone will be administered as intramuscular injection at a starting dose of either 25 milligram (mg) or 37.5 mg or 50 mg (starting dose will be decided on the basis of the disease severity), every two weeks, up to Week 24, wherein after Week 8, dose may be increased or decreased at physician discretion. For first three weeks, previous oral antipsychotic drug (Benzodiazepines or Selective serotonin reuptake inhibitor [SSRI]) will be maintained and will cease at Week 3.
89579925|NCT01894984||Oral atypical anti-psychotic|Oral atypical anti-psychotic for example, olanzapine, risperidone, quetiapine etc will be administered as per Investigator's discretion.
89579926|NCT02375672|Experimental|Pembrolizumab (MK-3475) + mFOLFOX6|"Following the safety run-in cohort:~mFOLFOX6 Treatment D1 and D15 (every 2 weeks); Pembrolizumab (MK-3475) IV over 30 minutes (every 3 weeks)"
89579927|NCT01894516|Placebo Comparator|Placebo|Participants received GLPG0634 matching placebo capsules, orally, once daily (QD) during Weeks 1 to 12 and GLPG0634 100 milligram (mg) QD during Weeks 13 to 24.
88973102|NCT00396786|Experimental|Arm 2|
88973103|NCT00396786|Experimental|Arm 3|
88973104|NCT00396786|Experimental|Arm 4|
88973105|NCT00396786|Experimental|Arm 5|
88973106|NCT00396786|Active Comparator|Arm 6|
88973107|NCT00396825|Experimental|Active treatment|Subjects randomized to this arm will receive the Family Caregiver Kit composed of the Williams LifeSkills Family Caregiver Video and Workbook and will also receive telephone coaching
88973108|NCT00396825|No Intervention|Control|Subjects randomized to this arm will receive no intervention and serve as wait list controls. They will undergo the same evaluations as the Intervention arm subjects at comparable times. In a crossover design, once subjects have finished serving as controls, they will be given the video, workbook, and telephone calls from a social worker and tested one more time.
88973109|NCT00276848|Active Comparator|Fludarabine plus Cyclophosphamide|
88973110|NCT00276848|Active Comparator|Fludarabine|
88973111|NCT00396864|Experimental|NPI-0052|Advanced Solid Tumor Malignancies and Refractory Lymphoma
88973112|NCT04845165||Patients with FPL2 genetically confirmed|patients suffering with FPL2 with the R482 codon mutation of the LMNA gene.
88973113|NCT04810689|Experimental|XFBD Arm|XFBD (administered as 1 packet of granules dissolved in warm water) orally twice daily for 14 day, 1 hour after food in the morning and at night with at least 8 hours in between doses
88973114|NCT04810689|Placebo Comparator|Placebo Arm|Placebo (administered as 1 packet of granules dissolved in warm water) orally twice daily for 14 day, 1 hour after food in the morning and at night with at least 8 hours in between doses
88973115|NCT04434885||Psoriatic arthritis|Patients diagnosed with PsA and fulfilling the classification criteria for PsA with symptom duration of up to 10 years and not receiving biological or targeted synthetic disease modifying antirheumatic drugs (b or tsDMARDs).
89579928|NCT01894516|Experimental|GLPG0634 50 mg QD|Participants received GLPG0634 50 mg capsules, orally, QD during Weeks 1 to 12. Participants who were responders (having at least 20% improvement on TJC68 and SJC66) remained on 50 mg QD while nonresponders were re-randomized to 100 mg QD during Weeks 13 to 24.
89579929|NCT01894516|Experimental|GLPG0634 100 mg QD|Participants received GLPG0634 100 mg capsules, orally, QD during Weeks 1 to 24.
89579930|NCT01894516|Experimental|GLPG0634 200 mg QD|Participants received GLPG0634 200 mg capsules, orally, QD during Weeks 1 to 24.
89579931|NCT02491463|Experimental|GSK3389245A_LD GROUP|Subjects in this group will receive 2 doses, one month apart of the GSK3389245A vaccine low dose
89579932|NCT02491463|Experimental|GSK3389245A_HD GROUP|Subjects in this group will receive 2 doses, one month apart, of the GSK3389245A vaccine high dose
89579933|NCT02491463|Active Comparator|Bexsero Group|Subjects in this group will receive 2 doses, one month apart, of Bexsero
89579934|NCT02491463|Placebo Comparator|Placebo Group|Subjects in this group will receive 2 doses, one month apart, of placebo
89579935|NCT02038881|Experimental|Group 1 (standard regimen)|One injection at Day 0 and Day 28 with IMVAMUNE® (MVA-BN®)
89579936|NCT02038881|Experimental|Group 2 (double dose regimen)|Two injections at Day 0 and two injections at Day 28 with IMVAMUNE® (MVA-BN®)
89579937|NCT02038881|Experimental|Group 3 (booster regimen)|One injection at Day 0 and Day 28 and one booster injection at week 12 with IMVAMUNE® (MVA-BN®)
89579938|NCT01857622|Experimental|SRI 15mg|DU-176b was orally administered at a dose of 15 mg once daily for 12 weeks.
89579939|NCT01857622|Experimental|Normal/MiRI low-dose group|DU-176b was orally administered at a dose of 30 mg once daily for 12 weeks in subjects who had none of the dose adjustment factors (body weight of ≤ 60 kg or the presence of concurrent treatment with quinidine or verapamil). DU-176b was orally administered at a dose of 15 mg once daily for 12 weeks to subjects who had any of the dose adjustment factors, irrespective of the number of dose adjustment factors.
89579940|NCT01857622|Experimental|Normal/MiRI high-dose group|DU-176b was orally administered at a dose of 60 mg once daily for 12 weeks in subjects who had none of the dose adjustment factors. DU-176b was orally administered at a dose of 30 mg once daily for 12 weeks to subjects who had any of the dose adjustment factors, irrespective of the number of dose adjustment factors.
89579941|NCT01857310|Experimental|Folic acid and zinc supplementation|5 mg folic acid and 30 mg elemental zinc, taken orally, daily for 6 months.
89579942|NCT01857310|Placebo Comparator|Placebo|Matching placebo, taken orally daily for 6 months.
89579943|NCT02472353|Active Comparator|Standard of Care|Patients will receive standard of care for their breast cancer with no metformin during their treatment with doxorubicin.
89579944|NCT02472353|Experimental|Metformin + Standard of Care|Patients will receive metformin during their treatment with doxorubicin for their breast cancer.
89579945|NCT02491073||Eslicarbazepine acetate treated|
89579946|NCT02491073||Non-Eslicarbazepine acetate treated|
89579947|NCT02314117|Experimental|Ramucirumab + Cisplatin + Capecitabine|8 milligrams/kilogram (mg/kg) ramucirumab given intravenously (IV) on days 1 and 8 in combination with 80 mg/square meter (m^2) cisplatin given IV on day 1 of each 21-day cycle (for up to 6 cycles) and 1000 mg/m^2 capecitabine given orally twice a day on days 1 through 14. Participants that were unable to take capecitabine will be given 800 mg/m^2/day fluorouracil (5-FU) IV on days 1 to 5 of each 21-day cycle.
89579948|NCT02314117|Active Comparator|Placebo + Cisplatin + Capecitabine|Placebo for blinding given IV on days 1 and 8 in combination with 80 mg/m^2 cisplatin given IV on day 1 of each 21-day cycle (for up to 6 cycles) and 1000 mg/m^2 capecitabine given orally twice a day on days 1 through 14. Participants that were unable to take capecitabine will be given 800 mg/m^2/day 5-FU IV on days 1 to 5 of each 21-day cycle.
88973116|NCT04434222|Active Comparator|Compressive stockings group|Group receives postoperatively compressive stockings for a period of 6 weeks.
89579949|NCT01893346|Experimental|CAZ-AVI|This arm will include 4 cohorts. Patients will be stratified by age.
89579950|NCT02490371|Experimental|(1) rTMS- PT Ex Group|"1 Hz low frequency rTMS over contra-lesional M1 region for 1200 pulse (20 minutes) at 90% resting motor threshold (rMT) will conduct for 10 consecutive sessions (5 days per week for 2 weeks) and immediately followed by 30- minutes structured physiotherapy upper limb training.~After the 10 sessions of brain stimulation, the 30-minute structured physiotherapy upper limb training program will continue for another 12 weeks (2 sessions per week)"
88973117|NCT04434222|No Intervention|Control group|The control group is treated without compressive stockings.
89579951|NCT02490371|Placebo Comparator|(2) Placebo- PT Ex Group|"placebo stimulation over contra-lesional M1 region will be conducted for 10 consecutive sessions (5 sessions per week for 2 weeks) of and immediately followed by 30- minutes of structured physiotherapy upper limb training.~Then, the structured physiotherapy upper limb training will continue for another 12 weeks (2 sessions per week)."
89579952|NCT02058147|Experimental|Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC)|FRC once daily (QD) for 30 weeks. Dose individually adjusted.
89579953|NCT02058147|Active Comparator|Insulin Glargine|Insulin glargine QD for 30 weeks. Dose individually adjusted.
89579954|NCT02058147|Active Comparator|Lixisenatide|Lixisenatide 10 mcg QD for 2 weeks, then 20 mcg QD (maintenance dose).
89579955|NCT02489981||Spiriva|Patients with severe persistent asthma
89579956|NCT04205045||Non-Habitual Milk Consumers (NHMC)|"Healthy subjects who are non-habitual milk consumers because of gastrointestinal discomforts upon milk consumption.~Lactose breath test; Gut permeability test; Milk test."
89579957|NCT04205045||Habitual Milk Consumers (HMC)|"Healthy subjects with regular milk consumption.~Intervention to be performed:~Lactose breath test; Gut permeability test; Milk test."
89579958|NCT04415554||exposure to aminoglicosides|preterm receiving aminoglycosides
89579959|NCT04415554||non exposure to aminoglycosides|preterm not receiving aminoglycosides
88973118|NCT00276575|Experimental|Bevacizumab, Everolimus, and Erlotinib|"Dose Level Dose Bevacizumab (mg/kg q2wks) Everolimus (mg daily) Erlotinib (mg daily) -1 5 5 ---~10 5 ---~10 10 ---~10* 10* 75~10* 10* 150"
88973119|NCT00276536|Experimental|Treatment|IFN weekly
88973120|NCT00276302|Experimental|1|Schedule A: Doses occur on Days 1, 4, 8, and 11 followed by 10 days with no study drug administration.
88973121|NCT00276302|Experimental|2|Schedule B: Doses occur on Days 1, 4, 8, 11, 15, and 18 (twice weekly for 3 weeks continuously).
88973122|NCT00276263|Experimental|1|
89579960|NCT02471183|Experimental|Selexipag, Open Label|"Subjects on inhaled treprostinil treatment participate in a 16-week main treatment period including down-titration of treprostinil to end of Week 8 and parallel up-titration of selexipag to the maximum tolerated dose (MTD) up to Week 12, for each individual patient but not above 1600 mcg twice daily.~From Week 12 up to Week 16, patients continue selexipag at their individual MTD. Patients could continue the study drug selexipag during the extended treatment period from Week 16 until commercial availability of selexipag."
89579961|NCT01855828|Experimental|Chemo plus Pertuzumab,Trastuzumab|During weeks 1-12, patients will receive pertuzumab, trastuzumab, and paclitaxel at the same time; during weeks 13-24 patients will receive pertuzumab and trastuzumab at the same time with 5-fluorouracil, epirubicin, and cyclophosphamide (FEC).
89579962|NCT04417335|Experimental|Treatment|BCG vaccine (Danish strain 1331, SSI, Denmark)
89579963|NCT04417335|Placebo Comparator|Placebo|0.9% NaCl
89579964|NCT02489279|Experimental|Active - SAC|Behavioral learning by using the Sustained Attention Control (SAC) Method's mobile software to increase sustained attention skills and self-awareness of attention control.
89579965|NCT02489279|Active Comparator|Control - Scrabble|"Behavioral learning using the mobile software game Scrabble to exercise word processing and executive control functions."
89579966|NCT04417491|Experimental|Dry Needling|The intervention group will receive real dry needling (fast in and fast out needling technique) in an active MTrP within upper trapezius muscle.
89579967|NCT04417491|Sham Comparator|Sham Needling|The placebo group will receive sham needling in an active MTrP within the upper trapezius muscle. A sham needle will be used as placebo. This needle has a blunt tip and retractable handle that created the illusion of a needle penetrating the skin.
89579968|NCT02489045|Experimental|SHAPE measurement|48 µl of Sonazoid microbubbles (GE Healthcare, Oslo, Norway) will be co-infused at a rate of 0.024 µl/kg body weight/minute together with a 0.9% NaCl solution infused at a rate of at least 2 ml/min.
89579969|NCT02488109|Active Comparator|Higher Calorie Refeeding Protocol|Participants in this arm will receive a higher calorie meal-based refeeding treatment plan in hospital.
89579970|NCT02488109|Active Comparator|Lower Calorie Refeeding Protocol|Participants in this arm will receive a lower calorie meal-based refeeding treatment plan in hospital.
89579971|NCT02351167|Active Comparator|Combination NRT and Counseling|Combination Nicotine replacement therapy (cNRT) (patch and lozenge) and smoking cessation counseling will be provided to participants. Lozenges will be given for 12 weeks with a 1 week pre-quit titration and patch for 12 weeks. Seven smoking counseling sessions will be given during treatment.
89579972|NCT02351167|Active Comparator|Varenicline (Chantix) and Counseling|Varenicline (pill) and smoking cessation counseling will be provided to participants for 12 weeks with 1 week pre-quit titration. Seven smoking cessation counseling sessions will be given during treatment.
89579973|NCT02351167|Placebo Comparator|Placebo Medicine and Counseling|Placebo pill and smoking cessation counseling will be provided to participants for 12 weeks with 1 week pre-quit titration. Placebo lozenges will be given for 12 weeks with a 1 week pre-quit titration and patch for 12 weeks. Seven smoking counseling sessions will be given during treatment.
89579974|NCT02350309|Experimental|Lemborexant 5 mg|Participants will receive a single, oral tablet formulation dose of lemborexant 5 mg within 5 minutes before bedtime.
89579975|NCT02350309|Experimental|Lemborexant 10 mg|Participants will receive a single, oral tablet formulation dose of lemborexant 10 mg within 5 minutes before bedtime.
89579976|NCT02350309|Placebo Comparator|Lemborexant-matched Placebo|Participants will receive a single, oral tablet formulation dose of lemborexant-matched placebo within 5 minutes before bedtime.
89579977|NCT02350309|Active Comparator|Flurazepam 30 mg|Participants will receive a single, oral capsule formulation dose of flurazepam 30 mg within 5 minutes before bedtime.
89579978|NCT02038647|Experimental|Alisertib (MLN8237) + Paclitaxel|Alisertib 40 mg, tablets, orally, twice a day, 3 days on/4 days off for 3 weeks on Days 1-3, 8-10, and 15-17 in a 28-day cycle along with paclitaxel 60 mg/m^2 intravenously (IV) once a week for 3 weeks on Days 1, 8, and 15 in a 28-day until disease progression (Up to 17 Cycles).
89579979|NCT02038647|Placebo Comparator|Placebo + Paclitaxel|Alisertib placebo-matching tablets, orally, twice a day, 3 days on/4 days off for 3 weeks on Days 1-3, 8-10, and 15-17 in a 28-day cycle along with paclitaxel 80 mg/m^2 IV once a week for 3 weeks on Days 1, 8, and 15 in a 28-day cycle until disease progression (Up to 22 Cycles).
89209408|NCT00883350|No Intervention|Control|Participants assigned to the Health-Ed (control) group will receive health information via the cell phone throughout the 84-day study. We have generated numerous health information tips for other studies on a variety of topics, including stress management, the benefits of eating fruits and vegetables, etc. [6-9]. These lessons will be modified for delivery via cell phone. We have found that participants assigned to these health information control groups report being satisfied with the information and their assignment. Importantly, our data also indicate that such health information results in very little behavior change or weight loss, e.g., [6].
89579980|NCT02058069|Experimental|Robotic Assisted Total Knee Arthroplasty|
89579981|NCT02057835|Experimental|BI 691751 low dose 1|BI 691751 low dose 1
89579982|NCT02057835|Experimental|BI 691751 low dose 2|BI 691751 low dose 2
89579983|NCT02057835|Experimental|BI 691751 middle dose|BI 691751 middle dose
89579984|NCT02057835|Experimental|BI 691751 high dose|BI 691751 high dose
89579985|NCT02057757|Experimental|Nitazoxanide (NTZ)|Participants will receive NTZ for 5 days. Participants younger than 12 years will receive an oral suspension formulation of NTZ; participants 12 years and older will receive NTZ tablets.
89579986|NCT02057757|Placebo Comparator|Placebo|Participants will receive placebo for 5 days. Participants younger than 12 years will receive an oral suspension formulation of placebo; participants 12 years and older will receive placebo tablets.
88973123|NCT00041340|Experimental|Treatment (imatinib mesylate)|Patients receive oral imatinib mesylate twice daily. Treatment continues for 8 weeks in the absence of disease progression or unacceptable toxicity. Patients with stable disease or better continue therapy until disease progression or 1 year after complete response.
88973124|NCT04201665|Experimental|carbetocin|Patients will receive a single dose of carbetocin 100 mcg (Pabal ®) at admission to high dependency obstetric unit after cesarean section.
88973125|NCT04201665|Active Comparator|oxytocin|Patients will receive 5 units of oxytocin ( Syntocinon ®) as a 250 ml 0.9% NaCl infusion at admission to high dependency obstetric unit after cesarean section.
88973126|NCT00275990|Experimental|thrombectomy before stenting|thrombectomy before stenting
88973127|NCT00275990|Active Comparator|directing stenting alone|directing stenting alone
88973128|NCT00275951|Experimental|Cetuximab Plus P-HDFL|Cetuximab 400 mg/m2, IV, day 1 of cycle 1; then weekly IV 250 mg/m2. Cisplatin 24-hour IV infusion 35 mg/m2/day, plus HDFL (5-FU 2,000 mg/m2 and leucovorin 300 mg/m2), day 1 and day 8. HDFL IV, day 15.
88973129|NCT00397137|Experimental|Stapled Anopexy|Circular stapled anopexy
88973130|NCT00397137|Active Comparator|Conventional Haemorrhoidectomy|Closed diathermy haemorrhoidectomy
88973131|NCT00275834|Experimental|A|Zonisamide 400 mg
88973132|NCT00275834|Experimental|B|Zonisamide 200 mg
88973133|NCT00275834|Placebo Comparator|C|matching placebo
88973134|NCT00275756|Experimental|1|
88973135|NCT00275756|Experimental|2|
88973136|NCT00275756|Experimental|3|
88973137|NCT03957057|Experimental|Iron carboxymaltose group|Iron carboxymaltose group. Total dose of intravenous ferric carboxymaltose (Iroprem®) needed to correct anemia and replenish iron stores will be calculated using the Ganzoni formula (28) modified to include adjustment for baseline iron status: prepregnancy weight in kilograms X (15-baseline Hb) X 2.4 + 500. Fifteen is the target Hb in g/dL, 2.4 is a unit less conversion constant and 500 is the target iron stores in mg. The maximal dose administered in a single day will not exceed 15 mg/kg (current weight) or 1000 mg (for participants with body weight > 67 kg). If total calculated dose will exceed 15 mg/kg or 1000 mg, subsequent doses will be administered weekly until the total calculated dose will be reached.
88973138|NCT03957057|Experimental|Iron isomaltoside group|Total dose of intravenous iron isomaltoside (Monofer®) needed to correct anemia and replenish iron stores will be calculated as described above. The maximal dose administered in a single day will not exceed 20 mg/kg (current weight) or 1500 mg (for participants with body weight > 75 kg). If total calculated dose will exceed 20 mg/kg or 1500 mg, subsequent doses will be administered weekly until the total calculated dose will be reached.
88973139|NCT03957057|Active Comparator|Iron sulphate group|Iron sulphate group. Participants will receive oral ferrous sulphate (Tardyfer®) 160 mg daily for 6 weeks with instruction to take two tablets by mouth once daily 1 hour before meal. They will receive no additional iron supplementation.
88973140|NCT00275366|Other|1|
88973141|NCT00041457||Physicians' Health Study I|
88973142|NCT00041457||Physicians' Health Study II|
88973143|NCT00041457||Women's Health Study|
89579987|NCT04731831||Patient with arthritis starting infliximab or adalimumab|Patients with Rheumatoid Artritis, Psoriatic Arthritis, Anchylosing Spondylitis starting treament with infliximab or adalimumab
88973144|NCT00041457||Women's Antioxidant Cardiovascular Health Study|
88973145|NCT00275288||Healthy Normal|
88973146|NCT00275288||Active Disease|
88973147|NCT00041496|Experimental|Arm 1|Patients with Symptomatic Persistent Atrial Fibrillation (AF) will be randomized with either SB207266 or placebo
88973148|NCT00041496|Placebo Comparator|Arm 2|Patients with Symptomatic Persistent Atrial Fibrillation (AF) will be randomized with either SB207266 or Placebo
88973149|NCT00041574|Experimental|1|Inhaled Nitric Oxide will be delivered through the INOpulse® at a Low Dose Range (3mL to 10mL; in 1mL increments) and Ultra Low Dose Ranges (0.5mL to 4mL; 0.5mL, then 1 to 4mL in 1mL increments).
88973150|NCT00275171|Active Comparator|rhTSH|proceeded by 0.1 mg rhTSH
88973151|NCT00275171|Placebo Comparator|Placebo|1 ml isotonic saline
88973152|NCT00275132|Experimental|Erlotinib|Tarceva (OSI-774, erlotinib) PO 150mg daily
88973153|NCT00275132|Placebo Comparator|Matched placebo|Matched placebo PO daily
89579988|NCT02037477|Experimental|Sequence A (Cohort 1): Vonoprazan + Esomeprazole|Vonoprazan (TAK-438) 20 mg, orally, once daily for 7 days, followed by a washout period of at least 7 days; then esomeprazole 20 mg, orally, once daily for 7 days.
89029624|NCT02952729|Experimental|Dose Escalation and Confirmation|XMT-1522 treatment will administered in groups of patients who will receive doses that increase over time. Once the maximum tolerated dose or recommended Phase 2 dose is achieved, new groups of patients will receive XMT-1522 at this fixed dose.
89029625|NCT00501761||1: Endometrial Cancer Survivors|
89579989|NCT02037477|Experimental|Sequence B (Cohort 1): Esomeprazole + Vonoprazan|Esomeprazole 20 mg, orally, once daily for 7 days, followed by a washout period of at least 7 days; then vonoprazan 20 mg, orally, once daily for 7 days.
89579990|NCT02037477|Experimental|Sequence C (Cohort 2): Vonoprazan + Rabeprazole Sodium|Vonoprazan 20 mg, orally, once daily for 7 days, followed by a washout period of at least 7 days; then Rabeprazole sodium 10 mg, orally, once daily for 7 days.
89579991|NCT02037477|Experimental|Sequence D (Cohort 2): Rabeprazole Sodium + Vonoprazan|Rabeprazole sodium 10 mg, orally, once daily for 7 days, followed by a washout period of at least 7 days; then vonoprazan 20 mg, orally, once daily for 7 days.
89579992|NCT02057523|Experimental|Acthar|Acthar 80 units twice weekly for 6 months. If endpoint is not reached, duration may be increased to 12 months.
89579993|NCT02037165|Experimental|Test Treatment 1: BI 1026706|BI 1026706 plus matching placebo to BI 1026706 Powder for Oral Solution (PfOS) and placebo tablet
89579994|NCT02037165|Experimental|Test Treatment 2: BI 1026706|BI 1026706 and placebo tablet
89579995|NCT02037165|Experimental|Reference Treatment 1: BI 1026706|Matching placebo to BI 1026706 PfOS and placebo tablet
88973154|NCT00275093|Experimental|Treatment (temsirolimus)|"Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of temsirolimus until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Up to 12 patients are treated at the MTD."
88973155|NCT03430596|Experimental|pramipexole|pramipexole ,flexible dose (0.375mg/d-0.75mg/d)
88973156|NCT03430596|Active Comparator|Antan|Antan,flexible dose (2-4mg/d)
88973157|NCT00275054|Experimental|Cohort I (FCR)|Patients with 2 or more risk factors out of 4 (1. unfavorable molecular cytogenetics, 2. high serum thymidine kinase levels, 3. lymphocyte doubling time shorter than 12 months, 4. unmutated IgVH gene) who are randomized into cohort I receive Fludarabine, Cyclophosphamide and Rituximab (FCR) chemoimmunotherapy.
88973158|NCT00275054|No Intervention|Cohort II (W&W)|Patients with 2 or more risk factors out of 4 (1. unfavorable molecular cytogenetics, 2. high serum thymidine kinase levels, 3. lymphocyte doubling time shorter than 12 months, 4. unmutated IgVH gene) who are randomized into cohort II receive no treatment at all (watch & wait).
88973159|NCT00275054|No Intervention|Cohort III (W&W)|Patients with less than 2 risk factors out of 4 (1. unfavorable molecular cytogenetics, 2. high serum thymidine kinase levels, 3. lymphocyte doubling time shorter than 12 months, 4. unmutated IgVH gene) are assigned directly to cohort III and receive no treatment at all (watch & wait).
88973160|NCT03208179|Active Comparator|IPTp-SP|Stat course of 3 tablets of quality-assured SP (tablets of 500 mg of sulphadoxine and 25 mg of pyrimethamine) at each scheduled antenatal visit
88973161|NCT03208179|Experimental|IPTp-DP|Dihydroartemisinin-piperaquine [3 to 5 tablets of DP (tablets of 40 mg of dihydroartemisinin and 320 mg of piperaquine, based on bodyweight) daily for 3 days] + placebo AZ at each scheduled antenatal visit
88973162|NCT03208179|Experimental|IPTp-DPAZ|Dihydroartemisinin-piperaquine [3 to 5 tablets of DP (tablets of 40 mg of dihydroartemisinin and 320 mg of piperaquine, based on bodyweight) daily for 3 days] + AZ tablet [1.5g over 3 days as 500mg per day] at each scheduled antenatal visit.
88973163|NCT00275015|Experimental|High dose therapy + autologous PBSCT|"Cytoreductive treatment: (preferentially) FC (2-4 cycles)~Mobilization: Dexa-BEAM + G-CSF (1-2 cycles)~Myeloablation:~fractionated TBI (e.g. 6x2Gy) + Cyclophosphamide (2 x 60 mg/kg; d -4 to -3)~autologous peripheral blood stem cell transplantation (PBSCT) (d 0)"
88973164|NCT03062826||Patients with STEMI treated medically|Drug: dual antiplatelet therapy (aspirin + ticagrelor or aspirin + clopidogrel) for at least 12 months.
88973165|NCT00130364|Experimental|1|Pimecrolimus
88973166|NCT00130364|Placebo Comparator|2|Pimecrolimus vehicle cream
88973167|NCT02950428|Experimental|ACURATE neo™TA Delivery System|Patients implanted with ACURATE neo™ Aortic Bioprosthesis and ACURATE neo™ TA Transapical Delivery System
88973168|NCT00130325|Active Comparator|A|Isoniazid arm
88973169|NCT00130325|Placebo Comparator|B|Placebo of Isoniazid tablet 300mg
88973170|NCT00130169|Experimental|1|
88973171|NCT02970708|Experimental|EFG group|amblyopia in EFG group will receive Eyetronix Flicker Glassess treatment.
88973172|NCT02970708|Active Comparator|Patching group|amblyopia in patching group will receive patching treatment.
88973173|NCT00130091|Experimental|Clonidine|administer with local anesthetic
88973174|NCT00130091|Placebo Comparator|Local anesthetic|Local anesthetic without clonidine
89579996|NCT02037165|Experimental|Reference Treatment 2: Celecoxib|Celecoxib hard capsule as active comparator plus matching placebo to BI 1026706 PfOS
89579997|NCT02037165|Experimental|Reference Treatment 3: Pregabalin|Pregabalin hard capsule as active comparator plus matching placebo to BI 1026706 PfOS
89579998|NCT02470403|Experimental|Part 1: LIK066 150 mg once daily (qd)|LIK066 150 mg qd within 15 minutes before starting lunch
89579999|NCT02470403|Placebo Comparator|Part 1: Placebo once daily|Matching placebo tablets of LCZ696 150 mg within 15 minutes before starting lunch.
89580000|NCT02470403|Experimental|Part 2: LIK066 75 mg twice daily (bid)|LIK066 75 mg bid before breakfast and dinner
89580001|NCT02470403|Experimental|Part 2: LIK066 50 mg three times daily (tid)|LIK066 50 mg tid before all 3 meals;
89580002|NCT02470403|Placebo Comparator|Part 2: Placebo three times daily|Matching placebo tablets tid before meals.
89580003|NCT01855750|Placebo Comparator|Treatment Arm A: placebo + R-CHOP|Treatment Arm A = placebo + R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone)
89580004|NCT01855750|Experimental|Treatment Arm B: ibrutinib + R-CHOP|Treatment Arm B = ibrutinib + R-CHOP
89580005|NCT04963439|Experimental|Treatment Sequence AB|Participants will receive single oral dose of macitentan formulated as final market image (FMI) in fasted conditions (test) (Treatment A) in treatment period 1 followed by a single oral dose of macitentan as the clinical service formulation (CSF) in fasted conditions (reference) (Treatment B) in treatment period 2 on Day 1. Study intervention intake in subsequent intervention periods in an individual participant will be separated by a washout period of at least 10 days.
88973175|NCT00129740|Experimental|Nilotinib|400 mg orally twice daily
89580006|NCT04963439|Experimental|Treatment Sequence BA|Participants will receive Treatment B in treatment period 1 followed by Treatment A in treatment period 2 on Day 1. Study intervention intake in subsequent intervention periods in an individual participant will be separated by a washout period of at least 10 days.
89580007|NCT04939103||1|Those patients with rectal cancer after neoadjuvant treatment and completed the examination of TRUS-FNA, TRUS, CT, MR, enteroscopy and superficial biopsy
89580008|NCT04937777||Group pre-2010|Patients who initiated first-line treatment between 2004 and 2010 (pre-2010).
89580009|NCT04937777||Group post-2010|Patients who initiated first-line treatment between 2011 and 2018 (post-2010).
89580010|NCT04962581||Group 1 : Covidien|This cohort will be monitored with the Covidien capnography, which will be connected to the isolated non-ventilated lung during the whole procedure.
88973176|NCT00129662|Experimental|Intervention arm|Pictorial action plan
88973177|NCT00129428|Experimental|UVB Irradiation|A dose of up to 320 mJ/cm2 from a UVB irradiation device will be administered at maximum 5 times per week for 16 weeks.
88973178|NCT01909167|Active Comparator|Treatment as usual (TAU)|Patients randomized to the treatment as usual arm will follow advice by their GP(general practitioner), mental health midwife or perinatal psychiatric team concerning treatment.
88973179|NCT01909167|Active Comparator|Online Cognitive Behavioral Therapy|CBT treatment: Patients randomized to the online treatment will have, in total, 10 real time individual sessions of 40min each, starting at the 20-23rd gestational week and lasting until 6 weeks postpartum. The therapy will be delivered every two weeks, with a break from the 36th gestational week until the 4th week postpartum.
88973180|NCT00129233|Active Comparator|Valsartan|Valsartan group treated with 80-160mg daily valsartan without Ca channel blockers or ACE inhibitors.
88973181|NCT00129233|Active Comparator|Amlodipine|Amlodipine group treated with 5-10mg daily amlodipine without ACE inhibitors or angiotensin receptor blockers.
88973182|NCT01568424|Other|Treatment Group|Patients with acute right ventricular failure from any cause requiring use of the CentriMag RVAS to sustain life.
88973183|NCT01547442|Experimental|Artisan Aphakia Intraocular Lens|Implantation of an Artisan intraocular lens to correct aphakia in children
88973184|NCT00103389|Active Comparator|docetaxel|treated with docetaxel alone
88973185|NCT00103389|Experimental|PI-88+docetaxel|treated with docetaxel and PI-88
88973186|NCT00128921|Experimental|Velcade, Cohort A|Treatment: 1.3 mg/m^2
88973187|NCT00128921|Experimental|Velcade, Cohort B|Treatment: 1.0 mg/m^2
88973188|NCT00128921|Experimental|Velcade, Cohort C|Treatment: 0.7 mg/m^2
88973189|NCT00128765|Active Comparator|usual care|usual care, i.e. COPD care at patient's own initiative, mostly for medical help during exacerbations
88973190|NCT00128765|Experimental|monitoring controls|regular COPD care (monitoring) provided by practice nurse according to current COPD guidelines
88973191|NCT00128765|Experimental|self-management|disease specific self-management program 'Living Well with COPD'
88973192|NCT00038376|Experimental|1|Alpha-interferon + Isotretinoin
89209409|NCT03973567|Experimental|refractory FD patients using antidepressants|Sixty FD patients who met the criteria were selected as the experimental group after more than two kinds of treatment, including acid-making, proton pump inhibitors (PPI), motivation and anti-Helicobacter pylori（HP） treatment, including 30 in the conventional treatment group and 30 in the combined antidepressant treatment group.
89580011|NCT04962581||Group 2: General Électrique|This cohort will be monitored with the General Electrique capnography, which will be connected to the isolated non-ventilated lung during the whole procedure.
89580012|NCT01855126|Experimental|Blue light|The study protocol consisted of two 8-week intervention/control periods in which each participant wore either the intervention (blue light) or control (red light) mask every night, with the order of presentation of the two conditions randomized by the study's biostatistician. A light mask housing two blue Light Emitting Diodes (LED) arrays delivered a train of blue or red light pulses of 2 second duration that were presented every 30 s for no longer than 2 hr, resulting in a maximum total of approximately 240 pulses per night. the blue light mask was worn nightly for 8 weeks. There will be a two week washout period between each intervention
89580013|NCT01855126|Placebo Comparator|Red light|The study protocol consisted of two 8-week intervention/control periods in which each participant wore either the intervention (blue light) or control (red light) mask every night, with the order of presentation of the two conditions randomized by the study's biostatistician. A light mask housing two red Light Emitting Diodes (LED) arrays delivered a train of blue or red light pulses of 2 second duration that were presented every 30 s for no longer than 2 hr, resulting in a maximum total of approximately 240 pulses per night. the red light mask was worn nightly for 8 weeks, with a two week washout period between each intervention
88973193|NCT00128687|Experimental|Immediate Intervention|Participants in both arms continue to receive usual medical care throughout the study period. In addition, participants randomized to Immediate Intervention receive intensive case management for Coronary heart disease (CHD) risk reduction for 15 months and then a maintenance program for a minimum of 12 months to assess the durability of initial intervention changes.
88973194|NCT00128687|Placebo Comparator|Delayed Intervention|Participants randomized to Delayed Intervention serve as control for Immediate Intervention patients for the first 15 months and then receive intensive case management for 15 months. The switching-over design not only addresses ethical concerns about withholding treatment from half the study sample, but will also enable us to assess whether the intervention had equal impact whether provided to a naïve population or to a group followed in usual care for 15 months.
88973195|NCT00038415|Experimental|Vaccine|
88973196|NCT00394511|Experimental|Arm I|Radiotherapy. Irradiation of the prostatic bed using megavoltage equipment with effective photon energies of greater than 4 MV.
88973197|NCT00394511|No Intervention|Arm II|No further treatment.
88973198|NCT00128453|Placebo Comparator|Placebo|Conventional therapy plus placebo
88973199|NCT00128453|Active Comparator|Colchicine|Conventional therapy plus colchicine
89580014|NCT01622673|Experimental|RAL, TUMS+RAL, MINTOX+RAL, MINTOX Before RAL, MINTOX After RAL|Participants received Raltegravir in treatment period 1, followed by TUMS® + Raltegravir in treatment period 2, followed by MINTOX® + Raltegravir in treatment period 3, followed by MINTOX® 2 hours before Raltegravir in treatment period 4, followed by MINTOX® 2 hours After Raltegravir in treatment period 5. There was a 2-day washout between treatment periods.
89580015|NCT01622673|Experimental|TUMS+RAL, MINTOX+RAL, RAL, MINTOX Before RAL, MINTOX After RAL|Participants received TUMS® + Raltegravir in treatment period 1, followed by MINTOX® + Raltegravir in treatment period 2, followed by Raltegravir in treatment period 3, followed by MINTOX® 2 hours before Raltegravir in treatment period 4, followed by MINTOX® 2 hours after Raltegravir in treatment period 5. There was a minimum 2-day washout between treatment periods.
89580016|NCT01622673|Experimental|MINTOX+RAL, RAL, TUMS+RAL, MINTOX Before RAL, MINTOX After RAL|Participants received MINTOX® + Raltegravir in treatment period 1, followed by Raltegravir in treatment period 2, followed by TUMS® + Raltegravir in treatment period 3, followed by MINTOX® 2 hours before Raltegravir in treatment period 4, followed by MINTOX® 2 hours after Raltegravir in treatment period 5. There was a minimum 2-day washout between treatment periods.
89580017|NCT01622673|Experimental|RAL, MINTOX+RAL, TUMS+RAL, MINTOX After RAL, MINTOX Before RAL|Participants received Raltegravir in treatment period 1, followed by MINTOX® + Raltegravir in treatment period 2, followed by TUMS® + Raltegravir in treatment period 3, followed by MINTOX® 2 hours after Raltegravir in treatment period 4, followed by MINTOX® 2 hours before Raltegravir in treatment period 5. There was a minimum 2-day washout between treatment periods.
89580018|NCT01622673|Experimental|TUMS+RAL, RAL, MINTOX+RAL, MINTOX After RAL, MINTOX Before RAL|Participants received TUMS® + Raltegravir in treatment period 1, followed by Raltegravir in treatment period 2, followed by MINTOX® + Raltegravir in treatment period 3, followed by MINTOX® 2 hours after Raltegravir in treatment period 4, followed by MINTOX® 2 hours before Raltegravir in treatment period 5. There was a minimum 2-day washout between treatment periods.
89580019|NCT01622673|Experimental|MINTOX+RAL, TUMS+RAL, RAL, MINTOX After RAL, MINTOX Before RAL|Participants received MINTOX® + Raltegravir in treatment period 1, followed by TUMS® + Raltegravir in treatment period 2, followed by Raltegravir in treatment period 3, followed by MINTOX® 2 hours after Raltegravir in treatment period 4, followed by MINTOX® 2 hours before Raltegravir in treatment period 5. There was a minimum 2-day washout between treatment periods.
89580020|NCT01855048|Experimental|N-Rephasin® SAL200|N-Rephasin® SAL200, 0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg
89580021|NCT01855048|Placebo Comparator|INT200-Placebo|Placebo
89580022|NCT02469857|Experimental|AB103 0.5 mg/kg|AB103 0.5 mg/kg, IV, single dose
89580023|NCT02469857|Placebo Comparator|NaCl 0.9%|NaCl 0.9%, IV, single dose
89580024|NCT04960865|Experimental|Experimental Group|Participants will be applied Kinesio tape with 50% tension.
89580025|NCT04960865|Sham Comparator|Sham Group|Participants will be applied Kinesio tape without any tension.
89580026|NCT04960865|Placebo Comparator|Placebo Group|Participants will be applied rigid tape without any tension
89580027|NCT02036853|Experimental|Schedule A|Subjects previously treated with triheptanoin
89580028|NCT02036853|Experimental|Schedule B|Naïve to triheptanoin
89580029|NCT02469623|Experimental|Dipole Density Mapping|
89580030|NCT02469077|Experimental|6 week aerobic exercise intervention|Participants randomly assigned to the exercise condition will complete an 18 session aerobic exercise manipulation supervised by an American College of Sports Medicine-certified personal trainer (3 exercise sessions per week for 6 weeks). Immediately before and after participating in this intervention arm, participants will undergo laboratory evoked thermal pain response testing with placebo-controlled morphine and naloxone administration to assess mechanisms of exercise-related changes.
89580031|NCT02469077|Active Comparator|Normal exercise (control)|Participants assigned to the control condition will not undergo any exercise manipulation during this 6 week period, and will be asked to continue their current activity levels and not engage in any additional exercise activity during the study period. Immediately before and after participating in this intervention arm, participants will undergo laboratory evoked thermal pain response testing with placebo-controlled morphine and naloxone administration to assess mechanisms of exercise-related changes.
89580032|NCT02486627|Experimental|Plazomicin|Patients received 15 milligrams per kilogram (mg/kg) plazomicin as an intravenous (IV) infusion once daily followed by matching placebo infusions 8 and 16 hours later. After a minimum of 4 days of IV plazomicin, patients could switch to 250 or 500 mg oral levofloxacin for a total duration of 7 to 10 days (IV plus oral).
89580033|NCT02486627|Active Comparator|Meropenem|Patients received 1.0 g meropenem as an IV infusion every 8 hours (q8h). After a minimum of 4 days of IV meropenem, patients could switch to 250 or 500 mg oral levofloxacin for a total duration of 7 to 10 days (IV plus oral).
89580034|NCT01644565|Experimental|Group A-1|Recombinant fimbrial adhesin dscCfaE: 1 ug of dscCfaE ID on study days 0, 21 and 42
89580035|NCT01644565|Experimental|Group A-2|Recombinant fimbrial adhesin dsc14CfaE-sCTA2/LTB5: 2.6 ug of Chimera ID on study days 0, 21 and 42
89580036|NCT01644565|Experimental|Group A-3|Modified E. coli heat labile enterotoxin LTR192G: 100 ng of LTR192G ID on study days 0, 21 and 42
89209410|NCT03973567|Placebo Comparator|refractory FD patienTS using conventional treatment|Sixty FD patients who met the criteria were selected as the experimental group after more than two kinds of treatment, including acid-making, PPI, motivation and anti-HP treatment, including 30 in the conventional treatment group and 30 in the combined antidepressant treatment group.
89580037|NCT01644565|Experimental|Group B-1|Recombinant fimbrial adhesin dscCfaE and Modified E. coli heat labile enterotoxin LTR192G: 1 ug of dscCfaE + 100 ng of LTR192G ID on study days 0, 21 and 42
89580038|NCT01644565|Experimental|Group B-2|Recombinant fimbrial adhesin dsc14CfaE-sCTA2/LTB5 and Modified E. coli heat labile enterotoxin LTR192G: 2.6 ug of Chimera + 100 ng of LTR192G ID on study days 0, 21 and 42
89029626|NCT00501761||2: Healthy Participants|Healthy participants that have no history of invasive cancer.
89580039|NCT01644565|Experimental|Group C-1|Recombinant fimbrial adhesin dscCfaE and Modified E. coli heat labile enterotoxin LTR192G: 5 ug of dscCfaE + 100 ng of LTR192G ID on study days 0, 21 and 42
89580040|NCT01644565|Experimental|Group C-2|Recombinant fimbrial adhesin dsc14CfaE-sCTA2/LTB5 and Modified E. coli heat labile enterotoxin LTR192G: 12.9 ug of Chimera + 100 ng of LTR192G ID on study days 0, 21 and 42
89580041|NCT01644565|Experimental|Group D-1|Recombinant fimbrial adhesin dscCfaE and Modified E. coli heat labile enterotoxin LTR192G: 25 ug dscCfaE + 100 ng LTR192G ID on study days 0, 21 and 42
89029627|NCT00510432||s.c. anticoagulant therapy|All patients with s.c. anticoagulant therapy (UFH, LMWH, heparinoids, fondaparinux)
89029628|NCT01248650|Active Comparator|TRK-820 5 μg|Taking TRK-820 5μg(two 2.5μg soft capsules) once on the first day of hospitalization by oral route
89029629|NCT01248650|Active Comparator|TRK-820 2.5μg|Taking TRK-820 2.5μg(one 2.5μg soft capsule) once on the first day of hospitalization by oral route
89580042|NCT01644565|Experimental|Group D-2|Recombinant fimbrial adhesin dscCfaE and Modified E. coli heat labile enterotoxin LTR192G: 1250 ug dscCfaE + 50 ng LTR192G TCI on study days 0, 21 and 42
89580043|NCT02485925|Experimental|Treatment group|THERMOCOOL® SMARTTOUCH™
89580044|NCT04936217||Patients operated for Continent Cutaneous Urinary Diversion, April 2004 - October 2017|The study focuses of a population of 70 patients operated between April 2004 and October 2017 au Nîmes University Hospital for Cutaneous Urinary Diversion.
89580045|NCT02282293|Active Comparator|Daily TS + Monthly DP pregnancy|Women will be given DP (3 full strength tabs, 40 mg/320 mg, given once a day for 3 consecutive days) every 4 weeks during pregnancy. During pregancy, TS will be given to women at a dose of 960mg once daily.
89580046|NCT02282293|Placebo Comparator|Daily TS + DP Placebo pregnancy|Women will be given DP placebo (3 tabs, given once a day for 3 consecutive days) every 4 weeks during pregnancy. During pregnancy, TS will be given to women at a dose of 960mg once daily.
89580047|NCT01854658|Experimental|FF MDI (PT005)|FF MDI administered as two puffs BID
89580048|NCT01854658|Experimental|GP MDI (PT001)|GP MDI administered as two puffs BID
89580049|NCT01854658|Experimental|GFF MDI (PT003)|GFF MDI administered as two puffs BID
89580050|NCT01854658|Placebo Comparator|Placebo MDI|Inhaled placebo administered as two puffs BID
89580051|NCT01892020|Experimental|Treatment sequence 1 (Group A)|Group A will receive BIAsp 50 BID during the first 4 weeks (treatment period 1) then switch to BHI 50 BID for further 4 weeks (treatment period 2)
89580052|NCT01892020|Experimental|Treatment sequence 2 (Group B)|Group B will receive BHI 50 BID during the first 4 weeks (treatment period 1), then switch to BIAsp 50 BID for further 4 weeks (treatment period 2)
89580053|NCT02485691|Experimental|Cabazitaxel|Participants received Cabazitaxel 25 mg/m^2 intravenous (IV) infusion for over 1 hour on Day 1 of each 3 week treatment cycle in combination with Prednisone 10 mg orally once daily and primary prophylactic granulocyte-colony stimulating factor (G-CSF) as per investigator decision, until radiographic disease progression, unacceptable toxicity, or participant's refusal of further study treatment (median duration = 22 weeks).
89580054|NCT02485691|Experimental|Abiraterone acetate or enzalutamide|Participants received either abiraterone acetate 1000 mg orally once daily from Day 1 to Day 21 of each 3 week treatment cycle in combination with prednisone 5 mg orally twice daily; or enzalutamide 160 mg orally once daily continuously from Day 1 to Day 21 of each 3 week treatment cycle, until radiographic disease progression, unacceptable toxicity, or participant's refusal of further study treatment (median duration = 12.5 weeks).
89580055|NCT02517515|Experimental|Double-blind 3-DAA|Double-blind 3-DAA (ombitasvir/paritaprevir/ritonavir [25 mg/150 mg/100 mg once daily] and dasabuvir [250 mg twice daily]) for 12 weeks.
89580056|NCT02517515|Experimental|Double-blind Placebo Followed by Open-label 3-DAA|Double-blind placebo for 12 weeks, followed by open-label 3-DAA (ombitasvir/paritaprevir/ritonavir [25 mg/150 mg/100 mg once daily] and dasabuvir [250 mg twice daily]) for 12 weeks.
89580057|NCT02466659|Experimental|CIAO Therapy|Intervention with wearing 3-hour daily CIAO therapy glasses
89580058|NCT02466659|No Intervention|Observation|To observe as one kind of standard care for IXT.
89580059|NCT01891864|Experimental|GP2015 Etanercept|Solution for subcutaneous injection in pre-filled syringe. The drug is administered in a dose of 50 mg twice weekly for the first 12 weeks and 50 mg once weekly thereafter
89580060|NCT01891864|Active Comparator|Enbrel ® Etanercept|Solution for subcutaneous injection in pre-filled syringe. The drug is administered in a dose of 50 mg twice weekly for the first 12 weeks and 50 mg once weekly thereafter
89029630|NCT00501839|Active Comparator|Group A|Cyclic progestogens for nine months
89029631|NCT00501839|Active Comparator|Group B|CC treatment for further three cycles at the same ovulating doses followed by six months of cyclic progestogens
89580061|NCT02485301|Experimental|Group EBO-Z|The subjects in the Group EBO-Z will receive the vaccine at Day 0 of the study
89580062|NCT02485301|Placebo Comparator|Group Placebo/ EBO-Z|The subjects in the Group Placebo/ EBO-Z will receive a placebo at Day 0 (as a control) and will receive the investigational ChAd3-EBO-Z vaccine at Month 6
89029632|NCT00501839|Active Comparator|Group C|CC administration at the same ovulating doses for nine cycles
89029633|NCT00510549|Active Comparator|1, PD|Peritoneal Dialysis
89029634|NCT00510549|Active Comparator|2, HD|Hemodialysis
89029635|NCT00510588|Other|1|regular physical exercise training
89029636|NCT00510588|Other|2|regular physical exercise training + metformin
89029637|NCT00510588|Other|3|regular physical exercise training + glitazon
89029638|NCT00510588|No Intervention|4|Control
89029639|NCT00501956|Experimental|Intradialytic parenteral nutrition|Individually compounded intradialytic parenteral nutrition (IDPN) including glucose, amino acids, lipids, L-Carnitine, trace elements and water-soluable vitamins 3x / week over 16 weeks + 12 weeks postinterventional observation.
89029640|NCT00501956|No Intervention|Control Group|Observation over 28 weeks (16 + 12 weeks).
89029641|NCT00510627|Experimental|A|Radiofrequency ablation in conjunction with chemotherapy
89029642|NCT00510627|Active Comparator|B|Standard of care chemotherapy regimen
89029643|NCT02953236|Experimental|Instrumented massage|
89029644|NCT02953236|Active Comparator|Manual massage|
89029645|NCT00502034|Experimental|A-immunotherapy|Immunotherapy with interferon-alpha and interleukin
89029646|NCT00502034|No Intervention|B-follow-up|Wait-and-see
89029647|NCT00510666|Experimental|1|Butorphanol basal infusion adjunct to morphine PCA
89029648|NCT00510666|Experimental|2|Saline infusion adjunct to morphine PCA
89029649|NCT00510666|Experimental|3|Premedication of Tramadol
89029650|NCT00510666|Experimental|4|Preemptive saline for morphine PCA
89029651|NCT00508092|Active Comparator|A|lanz incision appendectomy
89029652|NCT00508092|Active Comparator|B|lanz incision appendectomy
89029653|NCT00510705|Other|1|Regular physical exercise training alone
89580063|NCT02484911|Experimental|Olanzapine regimen|Olanzapine in combination with aprepitant ,palonosetron and dexamethasone.
89580064|NCT02484911|Other|Control regimen|Aprepitant in combination with palonosetron and dexamethasone
89580065|NCT04306367|Experimental|Experimental|"Pembrolizumab Q3W, IV infusion (day 1 of each 3 week cycle)~Olaparib bid, Oral tablet continuously"
89580066|NCT04925609|Other|Phase 1|"Phase 1:~To estimate the MTD/RP2D regimen of brigatinib monotherapy when administered in pediatric and AYA patients with ALK+ ALCL or ALK+ solid tumors.~To characterize the PK of brigatinib administered as monotherapy in pediatric and AYA patients with ALK+ ALCL or ALK+ solid tumors.~Note that:~If the MTD is not reached at the highest proposed test dose, no further dose-escalation will be performed.~Pediatric PK data, compared to exposure in adults, and cumulative toxicity, will be taken into consideration to determine the RP2D regimen."
89580067|NCT04925609|Other|Phase 2|"Phase 2:~• B1, ALK+ IMT: To establish the activity (ORR by RECIST 1.1) of single agent brigatinib when administered to children with ALK+ IMT.~• B2, ALK+ ALCL: To establish the efficacy (EFS) of single agent brigatinib when administered to children with ALK+ ALCL for a duration of 2 years, without SCT in consolidation."
89580068|NCT02466425|Experimental|SHP465|Subjects will receive SHP465 (12.5mg and 25mg capsules) or matching placebo. Subjects will take 1 capsule daily throughout the study at approximately 7:00am (+/- 2 hours)
89580069|NCT02466425|Placebo Comparator|Placebo|Subjects will receive SHP465 (12.5mg and 25mg capsules) or matching placebo. Subjects will take 1 capsule daily throughout the study at approximately 7:00am (+/- 2 hours)
89580070|NCT04925453|Experimental|Active tDCS|"Based on previous studies targeting working memory, focality of current delivery, and comfort and tolerance levels, (Paulo S. Boggio et al., 2006; Hill et al., 2016; Hoy et al., 2013; Teo, Hoy, Daskalakis, & Fitzgerald, 2011), we will use a 2 mA current administered via two circular carbon rubber core electrodes in saline-soaked surface sponges (25 cm2), placed in a neoprene headcap with marked locations based on the 10-10 EEG system. The anodal stimulating electrode will be at location F3, over left dorsolateral prefrontal cortex (DLPFC) and the cathodal electrode at location F4, over right DLPFC. Two reference electrodes, CMS and DRL, will be attached to the EarClip and applied to the earlobe with conductive gel.~Before each training session, the impedance of the electrodes will be checked and verified to be ≤15 KOhm. Additionally, the stimulation will be terminated if the impedance of the electrodes is > 20 KOhm. The current and impedance will be recorded for every session."
89029654|NCT00510705|Other|2|Regular physical exercise training + metformin
89029655|NCT00510705|Other|3|Regular physical exercise training + glitazone
89029656|NCT00510705|No Intervention|4|Control
89029657|NCT01248923|Experimental|ARRY-520 (Schedule 1) + bortezomib + G-CSF|
89029658|NCT01248923|Experimental|ARRY-520 (Schedule 1) + bortezomib + dexamethasone + G-CSF|
89029659|NCT01248923|Experimental|ARRY-520 (Schedule 2) + bortezomib + dexamethasone + G-CSF|
89029660|NCT01249001|Experimental|Group 1|This group will receive oral aprepitant on the first day of the first study cycle of chemotherapy. They will then cross-over to receive the capsule on the first day of the second study cycle of chemotherapy.
89029661|NCT01249001|Experimental|Group 2|This group will receive an aprepitant capsule on the first day of the first study cycle of chemotherapy. They will then cross-over to receive the oral aprepitant on the first day of the second study cycle of chemotherapy.
89029662|NCT00502112|Experimental|1|lintuzumab and lenalidomide
89029663|NCT04695912|Other|Initial activity tracker with feedback followed by control period|Initial activity tracker with feedback followed by control period
89029664|NCT04695912|Other|Initial control period followed by activity tracker with feedback|Initial control period followed by activity tracker with feedback
89029665|NCT03459495|Active Comparator|Group A|Group A: ultrasound group
89029666|NCT03459495|Placebo Comparator|Group P|Group P: placebo ultrasound group
89029667|NCT00502190|Experimental|1|Silicon ring positioned in the vagina, around the cervix
89029668|NCT00502190|Experimental|2|Silicon ring positioned in the vagina, around the cervix
89029669|NCT01249079||Schizophrenia Family|
89029670|NCT00510822|Placebo Comparator|Placebo|Placebo + Sertraline
89029671|NCT00510822|Experimental|Cimicoxib|Sertraline + Cimicoxib
89029672|NCT00502229|Active Comparator|Group A|Continuing treatment
89029673|NCT00502229|Active Comparator|Group B|Gonadotrophins
89029674|NCT02953158|Experimental|Haas Avocado|Haas Avocado commercially available Behavioral: Dietary recommendations Recommendation: a hypocaloric weight loss diet
89029675|NCT02953158|Active Comparator|Dietary Counseling|Behavioral: Dietary Counseling Recommendation: equally hypocaloric usual American diet.
89029676|NCT00502268|Placebo Comparator|Group 1|Doxercalciferol administration by DOQI and 2nd Gen PTH assay
89029677|NCT00502268|Active Comparator|Group 2|Doxercalciferol administered by 1-84-7-84 ratio between 1.4-1.6
89029678|NCT02953197|Experimental|Single arm radiotherapy dose escalation|FDG-PET guided radiation dose escalation Selective dose escalation
89029679|NCT01249196|Placebo Comparator|Placebo|
89029680|NCT01249196|Experimental|SK-PC-B70M 200mg bid|
89029681|NCT01249196|Experimental|SK-PC-B70M 300mg bid|
89029682|NCT01249196|Other|Donepezil|
89029683|NCT00510081|Experimental|1|subjects will receive filler injections
89029684|NCT02952651|Experimental|Children with hypovolemic state|Pulse oximeter plethysmography (POP) waveforms are obtained for 90 seconds in children with hypovolemic signs including hypotension, decreased urine output and central venous pressure less than 5 mmHg. Then, intravenous crystalloid fluid 10 mL/kg is infused for 15 min. Delta POP is calculated, and diagnostic power of delta POP for fluid responsiveness will be evaluated.
89029685|NCT01249235|Active Comparator|Patch|The operative eye will be patched.
89029686|NCT01249235|Experimental|Bandage Contact Lens|The operative eye will have a bandage contact lens
89029687|NCT00510120|Experimental|1|Participants will receive collaborative problem solving.
89029688|NCT00510120|Active Comparator|2|Participants will receive parent management training.
89029689|NCT00510120|Active Comparator|3|Participants assigned to waitlist control will receive one of the two treatments after a 10-weeks waitlist period.
89029690|NCT00502502||Symptom-Related Cytokines Questionnaire|
89029691|NCT01249391|Active Comparator|Intervention (splinting)|Splinting of nominated joint in this group
89580071|NCT04925453|Sham Comparator|Sham tDCS|"For sham stimulation, the electrodes will be placed at the same positions as for active stimulation (F3 and F4). After an initial ramp-up period of 30 seconds, stimulation fades out over a period of 30 seconds. Additionally, at the end of the sham stimulation period, stimulation will fade in over a period of 30 seconds and then end with a final 30 second ramp-down period. Participants will feel the initial itching sensation associated with tDCS and experience the ramp-down period at the end of the sham stimulation period but will receive no active current during the rest of the sham stimulation period. This method of sham stimulation has been shown to be reliable (Gandiga et al., 2006).~Before each training session, the impedance of the electrodes will be checked and verified to be ≤15 KOhm. Additionally, the stimulation will be terminated if the impedance of the electrodes is > 20 KOhm. The current and impedance will be recorded for every session."
89580072|NCT02451917|Experimental|Glargine insulin|This is an open-label, randomized, two-way crossover study , one is IGlar/INPH treatment sequence and, another is INPH/IGlar sequence. Wherein, IGlar refers to glargine insulin and INPH refers to NPH insulin. At the end of the study, all data acquired during the use of insulin glargine, regardless of the sequence were grouped as glargine.
89580073|NCT02451917|Active Comparator|NPH insulin|"This is an open-label, randomized, two-way crossover study , one is IGlar/INPH treatment sequence and, another is INPH/IGlar sequence. Wherein, IGlar refers to glargine insulin and INPH refers to NPH insulin.~At the end of the study, all data acquired during the use of NPH insulin, regardless of the sequence were grouped as NPH."
89580074|NCT02349451|Active Comparator|Adalimumab|Double-blind adalimumab 40 mg administered every other week (EOW) for 12 weeks
89580075|NCT02349451|Placebo Comparator|Placebo|Double-blind placebo administered every week (EW) for 12 weeks
89029692|NCT01249391|No Intervention|Control|Observation and usual treatment only.
89029693|NCT02952807|Active Comparator|sequential|sequential use of vaginal misoprotol Plus Foley Catheter for Induction of Labor.
89029694|NCT02952807|Active Comparator|Concurrent|Concurrent Use of Vaginal misoprostol Plus Foley Catheter for Induction of Labor.
89580076|NCT02349451|Experimental|ABT-122 120 mg|Double-blind ABT-122 120 mg administered EW for 12 weeks
89029695|NCT02275130|Experimental|Calcium Hydroxyapatite|30 patients with glottic insufficiency treated operatively with augmentation of vocal cords with injection technique
89029696|NCT03459417|Active Comparator|intrathecal morphine+LA|patients will receive intrathecal 15 mg (3 mL) of LA (hyperbaric bupivacaine 0.5%) intrathecal with 0.5 mg preservative free morphine.
89029697|NCT03459417|Active Comparator|intrathecal morphine+LA+Mg sulp. 50|patients will receive intrathecal 15 mg (3 mL) of LA (hyperbaric bupivacaine 0.5%) intrathecal with 0.5 mg preservative free morphine + magnesium sulfate 50 mg.
89029698|NCT03459417|Active Comparator|intrathecal morphine+LA+ Mg sulp.100|patients will receive intrathecal 15 mg (3 mL) of LA (hyperbaric bupivacaine 0.5%) intrathecal with 0.5 mg preservative free morphine + magnesium sulfate 100 mg.
89029699|NCT00502541|Experimental|Fluocinolone acetonide|Fluocinolone acetonide intravitreal implant
89029700|NCT00502541|Active Comparator|Standard of Care|Standard of care
89029701|NCT01249430|Experimental|Treatment (azacitidine, mitoxantrone, etoposide, cytarabine)|Patients receive azacitidine IV over 30 minutes on days 1-8 and mitoxantrone hydrochloride IV over 10 minutes, etoposide phosphate IV over 30-60 minutes, and cytarabine IV over 6 hours on days 3-8. Treatment continues for 1 course in the absence of disease progression or unacceptable toxicity.
89029702|NCT02952963|Experimental|Chenodeoxycholic Acid|Chenodeoxycholic Acid (1250 mg) dissolved in 200 ml water. Here after 50 ml clean water.
89029703|NCT02952963|Experimental|Chenodeoxycholic Acid and Colesevelam|Chenodeoxycholic Acid (1250 mg) and Colesevelam (3,75 g) dissolved in 200 ml water. Here after 50 ml clean water.
89029704|NCT03459339|Experimental|Experimental OFDI capsule imaging|"Subject will swallow the OFDI capsule and imaging will be acquired using the OFDI imaging system.~Intervention: 'Tethered Capsule Endomicroscopy (TCE) Imaging of Barrett's esophagus using OFDI capsule"
89029705|NCT02955914||Optimism|Based on quality of life assessment
89029706|NCT02955914||Pessimism|Based on quality of life assessment
89029707|NCT00510978|Active Comparator|1|Bifidobacterium infantis 35624
89029708|NCT00510978|Active Comparator|2|Lactobacillus salivarius UCC118
89029709|NCT00510978|Placebo Comparator|3|Placebo
89029710|NCT02952690|Active Comparator|standard curve group|The style is curved in accordance with the curve of GVL blade in this group.
89029711|NCT02952690|Experimental|tip-manipulated curve group|The style is curved in accordance with the curve of GVL blade and the distal tip of style is additionally bended to the left (15-20 degree) in this group.
89580077|NCT02349451|Experimental|ABT-122 240 mg|Double-blind ABT-122 240 mg administered EW for 12 weeks
88973200|NCT00042198|Experimental|1|Cognitive Behavior Therapy. The treatment modality was individual, face-to-face therapy with an experienced cognitive therapist. Treatment consisted of up to 12 weekly, hour-long sessions.
88973201|NCT00042198|Active Comparator|2|Supportive Stress Management. The treatment modality was individual, face-to-face therapy with an experienced psychotherapist. Treatment consisted of up to 12 weekly, hour-long sessions.
88973202|NCT00042198|No Intervention|3|Usual Care, minimally enhanced. Participants in all three arms were given information about depression. There were no restrictions in any of the arms on usual care for depression, heart disease, or any other conditions, except that concurrent participation in nonstudy psychotherapy was not allowed. Participants were allowed to continue or start on nonstudy antidepressants during the study, as prescribed by the participant's personal physician.
88973203|NCT00128414|Placebo Comparator|Placebo|Placebo Comparator
88973204|NCT00128414|Experimental|Colchicine|Colchicine 1.0 mg twice daily for the first day followed by a maintenance dose of 0.5 mg twice daily for 6 month in patients ≥70 kg, and halved doses for patients <70 kg or intolerant to the highest dose.
88973205|NCT00128336|Active Comparator|Nurse support|
88973206|NCT00128336|Experimental|Intensive support|
88973207|NCT00128336|Active Comparator|High carbohydrate diet|
88973208|NCT00128336|Experimental|High mono-unsaturated fat diet|
88973209|NCT00038571|Experimental|Arm A (mantle-cell lymphoma)|
88973210|NCT00038571|Experimental|Arm B (other B-cell lymphomas)|
88973211|NCT05770791|Active Comparator|Group A|Group A Obese Grade I
88973212|NCT05770791|Active Comparator|Group B|Group B Obese Grade I
88973213|NCT05770778|Active Comparator|Inclined Backward Intervention Group|Hemiplegic Cerebral Palsy Children
88973214|NCT05770778|Active Comparator|Kneel Walk Intervention Group|Hemiplegic Cerebral Palsy Children
88973215|NCT05770739|Other|ERAS group|To apply accelerated rehabilitation surgery to children with biliary dilatation during perioperative period
88973216|NCT05770739|Other|placebo group|In this gruop,Children with cholangiectasia were given traditional perioperative treatment
88973217|NCT05770713||Female patients with HR+/HER2- ABC/MBC who received a CDK4/6i based therapy for their ABC/MBC.|Female patients who received an oral treatment of CDK4/6i based therapy for their ABC/MBC.
88973218|NCT05770687||SGLT-2 inhibitor|Patients with naive use of SGLT-2 inhibitors after PCI
88973219|NCT05770674|Active Comparator|1 Month DAPT|Patients will receive 300 mg of aspirin and 300 mg of clopidogrel before PCI unless previously medicated with antiplatelet agents. Aspirin 100 mg plus clopidogrel 75 mg once daily will be given for 1 month following PCI. Following 1 month, clopidogrel 75 mg once daily will be given for 11 months.
88973220|NCT05770674|Active Comparator|12 Months DAPT|Patients will receive 300 mg of aspirin and 300 mg of clopidogrel before PCI unless previously medicated with antiplatelet agents. Aspirin 100 mg plus clopidogrel 75 mg once daily will be given for 12 months following PCI.
88973221|NCT05770661||Myopes|To collect the ocular data among myopic children.
88973222|NCT05770661||Non-myopes|To collect the ocular data among non-myopic children.
88973223|NCT05770648|Experimental|K-clipTM transcatheter annuloplasty system+Guideline Directed Medical Therapy GDMT|
88973224|NCT05770648|Other|Guideline Directed Medical Therapy, GDMT|
88973225|NCT05770635|Experimental|Polyvinyl alcohol embolization microspheres (Huihe Medical) and chemotherapy drug|The experimental group received chemotherapy drug + polyvinyl alcohol embolized microspheres (Huihe Medical) for target lesion TACE (Trans-Arterial Chemoembolization)treatment.Experimental group and control group were selected to use iodide oil according to the condition of subjects.
88973226|NCT05770635|Other|Embosphere and chemotherapy drug|
88973227|NCT05770492||Epithelial Basement Membrane Dystrophy|Patients with epithelial basement membrane dystrophy
88973228|NCT05770492||Healthy|Patients/Subjects without corneal pathologies
88973229|NCT05770466|Experimental|Experimental group|Treated with P1101 (Ropeginterferon alfa-2b) plus standard of care (SOC)
88973230|NCT05770466|Active Comparator|Control group|Treated with SOC alone
88973231|NCT05770388|Active Comparator|Control Group|Participants will receive a brief contact intervention (via phone call or chat) in which a clinical psychologist will assess their general mental health status and level of suicidal risk, and will provide an intervention based on the principles of motivational interviewing and psycho-educational information along with a list of mental health services available within and outside the University. Participants will also receive instructions on how to download and use a mobile app.
88973232|NCT05770388|Experimental|Intervention Group|Participants will receive a brief contact intervention (via phone call or chat) in which a clinical psychologist will assess their mental health status and level of suicidal risk and will provide an intervention based on the principles of motivational interviewing and psycho-educational information along with a list of mental health services available within and outside the University. Participants will also receive instructions on how to download and use a mobile app. Additionally, participants will also receive reminder messages (by email and chat) encouraging them to use the app and to request a counseling session (via phone call, videoconference or chat) with a clinical psychologist if they think it is necessary. After two months, this group will receive a new contact with a clinical psychologist via phone call or chat. In this contact, mood and level of suicidal risk will be assessed, and participants will be encouraged to seek mental health help if they have not already done so.
88973233|NCT05770336||Patient with previous hospitalization for Covid-19 infection|
88973234|NCT05770323||Patients with normal uric acid levels|Patient with uric acid level (2.5_6)for femal and (3_7)for males
89580078|NCT04956731|Experimental|Pharmacist provision of medication abortion|This is a single arm study with 10 participants undergoing start to finish medication abortion provided by a pharmacist.
89580079|NCT04956263|Experimental|Treatment A|YG1699 10 mg
89580080|NCT04956263|Experimental|Treatment B|YG1699 25 mg
89580081|NCT04956263|Active Comparator|Treatment C|Dapagliflozin 10 mg
89580082|NCT02409368|Experimental|Cohort A: Treatment - Nivolumab|Nivolumab IV infusion
89580083|NCT01853878|Experimental|GSK2302032A Group|The patients received 13 administrations GSK2302032A product, as per the following schedule: For the first five doses: 1 dose every 3 weeks. For the remaining 8 doses: 1 dose every 12 weeks.
89580084|NCT01853878|Placebo Comparator|Placebo group|The patients received 13 administrations of a placebo, as per the following schedule: For the first five doses: 1 dose every 3 weeks. For the remaining 8 doses: 1 dose every 12 weeks.
89580085|NCT04891484|Experimental|Ondansetron group|Group O :patients will be injected with 4 mg Ondansetron diluted with normal saline IV 5 minutes before spinal anesthesia
89580086|NCT04891484|Placebo Comparator|Control group|Group S:patients will be injected with 10 ml normal saline intravenous 5 min before spinal anesthesia
89580087|NCT02342678|Experimental|Yoga Therapy Group|Participants will take part in twice weekly group yoga classes focusing on selected Iyengar-based yoga techniques as well as practice study-specific yoga techniques at home for at least one hour per week for a total of 12 weeks. During a 12-week post-treatment follow-up period, participants will also be encouraged to continue practicing yoga exercises for at least an hour per week.
89580088|NCT02342678|Experimental|Physical Conditioning Group|Patricipants will take part in twice weekly group physical conditioning classes and practice stretching exercises at least one hour per week at home for 12 weeks. During a 12-week post-treatment follow-up period, participants will also be encouraged to continue practicing stretching exercises for at least an hour per week.
89580089|NCT02342288|Experimental|Head raised 10 degrees|Head raised 10 degrees from neutral position using Gardner Wells tongs
89580090|NCT02342288|Active Comparator|Head in neutral position|Head in neutral position
89580091|NCT01853644|Experimental|Treatment (Tivozanib)|Tivozanib 1.5mg orally given daily for 3 weeks with one week off to complete a 4 week cycle until disease progression or adverse effects prohibit further therapy
89580092|NCT01853254|Experimental|Peginterferon alfa-2a monotherapy or combined with ribavirin|The treating investigator decided the most appropriate treatment. It was recommended that participants receive combination therapy.
89580093|NCT02373098|Experimental|FTY720|
89580094|NCT02373098|No Intervention|Healthy volunteers|Healthy volunteers with no intervention or drug administered.
89580095|NCT01853176|Experimental|Liposomal injection bupivicaine (Exparel)|Patients will have the maximum approved dose of Exparel, 266 mg, diluted in 20 mL normal saline, infiltrated into the rectus fascia and subcutaneous tissues at the time of abdominoplasty.
89580096|NCT01853176|Active Comparator|Standard bupivicaine|Patients will receive the maximum safe allowance of 0.25% bupivacaine, or 1.5 mg/kg (eg. 150 mg or 60 mL for a 100 kg patient) infiltrated into the rectus fascia and subcutaneous tissues at the time of abdominoplasty.
89580097|NCT02372396|Experimental|Compassion Meditation|Compassion Meditation delivered in 10 2-hour group treatment sessions.
89580098|NCT02372396|Active Comparator|Relaxation|Relaxation delivered in 10 2-hour group treatment sessions.
89580099|NCT01835548|Experimental|NT0102|After the screening/washout period, all participants will receive study drug NT0102 once daily for 4 weeks during the dose optimization period. After completion of the dose optimization period, the optimized dose of the study drug will be selected, and participants will stay on that dose for 1 week (dose stabilization period). At the end of this period, participants will be randomized to a treatment. Participants in this arm will be given 20-60 mg of NT0102 as oral disintegrating tablet (ODT) once daily for one week during the double-blind treatment period.
89580100|NCT01835548|Placebo Comparator|Placebo|After the screening/washout period, all participants will receive study drug NT0102 once daily for 4 weeks during the dose optimization period. After completion of the dose optimization period, the optimized dose of the study drug will be selected, and participants will stay on that dose for 1 week (dose stabilization period). At the end of this period, participants will be randomized to a treatment. Participants in this arm will be given placebo as matching ODT once daily for one week during the double-blind treatment period.
88973235|NCT05770323||Patients with elevated uric acid level (hyperurecemia)|Uric acid level more than 7 for males and more than 6 for female
88973236|NCT05770310|Experimental|JS015|
88973237|NCT05770284|Experimental|Subject will receive 12 weeks of exercise with standard medical management (SMT)|"Subjects will be given exercise protocol Pre-exercise safety assessment: Careful assessment as per exclusion criteria; especially Portal Hypertension, Cardiopulmonary status etc~Frequency: Aerobic and Resistance Exercises for total 50 minutes/day for 2-5 days per week (see protocol)~Aerobic exercises consist of Brisk walking~Resistance Exercises consist of movements targeting the major muscle groups with weight lifting~Intensity:~Talk test: Short of breath but still can speak a full sentence Borg Scale: Keep between 5-6 out of 10.~Time duration of aerobic exercise decided by 6MWT, and resistance exercise by Hand grip strength~End point: 12 weeks~Stopping rule:~Interruption of Exercise for > 7 consecutive days due to non-compliance or clinical events.~Progression to exclusion criteria i.e. decompensation etc~Both groups will be advised a calorie intake of 150cal/kg/day and protein intake of 3 gm/kg/day"
88973238|NCT05770284|Active Comparator|standard medical management (SMT)|standard medical management (SMT)
88973239|NCT05770206|Experimental|experimental Group|Subjects in the experimental group will receive treatment by using Hydrogen-Oxygen Generator with Nebulizer (manufactured by Shanghai Asclepius Meditec Co., Ltd., flow rate: 3L/min) combined with conventional basic supportive treatment (symptomatic support treatment determined by the investigator based on the condition of the subjects);
88973240|NCT05770206|Active Comparator|Control Group|subjects in the control group will receive treatment by using Medical Molecular Sieve Oxygen Generator (manufactured by Shanghai Ouliang Medical Devices Co., Ltd., flow rate: 3L/min, provided by the sponsor) combined with conventional basic supportive treatment (same with that in the test group).
88973241|NCT05770141|Other|LHP GROUP|patients received Laser Hemorrhoidoplasty procedure
89580101|NCT01852942|Experimental|Losartan|
89580102|NCT01852942|Placebo Comparator|Sugar Pill|
89580103|NCT01852162|Experimental|Dabigatran|Dabigatran 150mg
89580104|NCT01852162|Placebo Comparator|Placebo|Placebo
89580105|NCT04596124|Experimental|fitostimoline plus cream|
89580106|NCT04596124|Experimental|fitostimoline plus gauze|
89580107|NCT04596124|Active Comparator|connettivina bio plus cream|
89580108|NCT04596124|Active Comparator|connettivina bio plus gauze|
89580109|NCT01835470|Experimental|Abatacept|Abatacept 10 mg/kg (for body weight less than 75 kg), 750 mg (for body weight between 75 and 100 kg), and 1g (for body weight above 100kg) intravenous infusion on Week 0 (Day 1), Week 2 (Day 15), Week 4 (Day 29) and every 4 weeks (28 days) thereafter up to the end of the study
89580110|NCT02451137|Experimental|Toujeo|Toujeo® (Insulin glargine, 300 units per millilitre [U/mL]) subcutaneous (SC) injection once daily up to Month 12, with or without available participant support program.
89580111|NCT02451137|Active Comparator|Standard of Care|Lantus® (Insulin glargine, 100 U/mL) SC injection administered once daily; or Levemir® (Insulin detemir) SC injection administered either once or twice daily up to Month 12, with or without available participant support program.
89580112|NCT02372006|Experimental|afatinib|dose escalation
89580113|NCT02406248|Experimental|single arm|Ticagrelor 180mg loading dose taken orally, followed by 90mg twice daily (bd)
89580114|NCT02450903|Experimental|LDK378 (Ceritinib)|Participants who received LDK378 750mg once daily on a 28 day cycle.
89580115|NCT02371616|Experimental|Test dentifrice|Test dentifrice containing 5% w/w calcium sodium phosphosilicate and 1426 ppm fluoride as sodium flouride
89580116|NCT02371616|Active Comparator|Comparator dentifrice|Comparator dentifrice containing 5% w/w calcium sodium phosphosilicate and 1426 ppm fluoride as sodium monofluorophosphate
89580117|NCT02370914||Suspected Concussive Event (SCE)|When a subject is suspected of a concussion, a Nautilus NeuroWaveTM System recording is obtained from the subject and the recording is evaluated by a Jan Medical concussion algorithm. The subject is declared concussed or not per the algorithm. This is compared to a Sport Concussion Assessment Tool (SCAT) test.
89580118|NCT02370914||Control|All subjects at the start of study have a baseline recording using the Nautilus NeuroWaveTM System. These subjects are enrolled into the study as non-concussed and these recordings serve as control recordings. Additionally, some subjects from this cohort will be recorded again at the end of the study to obtain end of season recordings. These results are compared to a Sport Concussion Assessment Tool (SCAT) test.
88973242|NCT05770141|Other|MM GROUP|patients received conventional open surgical hemorrhoidectomy
88973243|NCT05770115|Experimental|Group A|vicryl 2/0
88973244|NCT05770115|Active Comparator|Group B|vicryl 1
88973245|NCT05770063|Experimental|intervention group|compound amino acid supplement
88973246|NCT05770063|Placebo Comparator|control group|placebo
88973247|NCT05769998|Experimental|Acceptance and Commitment-based treatment|Acceptance and Commitment-based (ACT) treatment including a face-to-face component administered during the patient stay in the rehabilitation unit and an online component including 4 ACT modules with an estimated duration of one month. The treatment is added to the Treatment as Usual provided in the rehabilitation unit.
88973248|NCT05769998|Other|Treatment as usual|Usual care including pharmacological therapy and exercise therapy, administered in the rehabilitation unit independently from the project.
88973249|NCT05769972|Experimental|Immersive Virtual Reality (Parkinson's disease)|
88973250|NCT05769972|Active Comparator|Computer-based cognitive rehabilitation (Parkinson's disease)|
88973251|NCT05769972|Experimental|Computer-based cognitive rehabilitation (Huntington's disease)|
88973252|NCT05769972|Active Comparator|Music-therapy (Huntington's disease)|
88973253|NCT05769933||Healthy participants|Healthy volunteers with no history of neurological problems or mental disorders; normal vision or corrected-to-normal using contact lenses. Interventions: MRI and combined EEG-fMRI.
88973254|NCT05769933||Essential tremor patients|Non-hospitalized volunteers who have been diagnosed with essential tremor and are indicated for thalamic surgery. Interventions: MRI.
88973255|NCT05769933||Psychosis patients|Non-hospitalized volunteers who have been diagnosed with early psychosis, and clinically assessed; normal vision or corrected-to-normal using contact lenses. Interventions: MRI and combined EEG-fMRI.
88973256|NCT05769933||Healthy controls|Healthy volunteers who have been clinically assessed and determined to be suitable matched controls with respect to the psychosis group; normal vision or corrected-to-normal using contact lenses. Interventions: MRI and combined EEG-fMRI.
88973257|NCT05769933||Epilepsy patients|Non-hospitalized volunteers who have been diagnosed with epilepsy.
88973258|NCT05769907|Experimental|single arm|The single-arm pilot study will be a feasibility study of the Motivation to Lose Weight version 1 (MLW v.1). The study includes presential and online sessions. Participants will be recruited through advertisements on social media and selected according to the inclusion criteria. Participants will receive 8 sessions of approximately 30-45 minutes of motivational interviewing (MI) according to the processes of change in weight loss, as measured by the S-Weight scale.
88973259|NCT05769738|Experimental|Furosemide group|Inhaled furosemide
88973260|NCT05769738|Placebo Comparator|Placebo group|Inhaled saline
88973261|NCT05769725|Experimental|Serplulimab in Combination With Docetaxel +S-1|
88973262|NCT05769725|Placebo Comparator|Docetaxel +S-1|
88973263|NCT05769712||healthy people|"Inclusion criteria：① Age range (above 18 years old); ② Non-professional athletes; ③ No medical history of shoulder and neck pain; ④ Ultrasound examination (-).~Exclusion criteria: ① pregnant women or postpartum 1 year; ② Shoulder pain with active or passive cervical motion; ③ History of upper extremity trauma; (4) Shoulder surgery or treatment history, intra-articular injection history, use history of glucocorticoids, estrogens, quinolones and cholesterol drugs; (5) Shoulder joint fear test (shoulder joint abduction 90°, slowly increasing external rotation, the subject had a positive expression of fear); (6) Evidence of adhesive shoulder joint bursitis, such as the passive range of motion of the 2 motion planes of the shoulder joint is obviously limited; ⑦ Systemic autoimmune diseases, metabolic diseases, endocrine diseases, psoriasis; ⑧ unable to complete the relevant movements and positions; ⑨ Those who are reluctant to continue the experiment and ask to quit."
89029712|NCT00510237|Experimental|1|5-7 females per group at each of the four sites.
89029713|NCT00510237|Experimental|2|5-7 males per group at each of the four sites.
89029714|NCT00504140|Experimental|Interferon Alpha + Etoposide|Interferon Alpha 5x10^6 mu/m^2 subcutaneously and Etoposide 100 mg/m^2 intravenously, both daily for 5 days
89029715|NCT00510315||Women treated with SCT/TBI|
89580119|NCT02370602|Experimental|Pilot Cohort: [^11C]T-773 + TAK-063|[^11C]T-773 <8 μg; 400MBq ± 10%, intravenous (IV), once on Days 1 and 2 prior to PET scans and TAK-063 30 mg or 1000 mg, tablets, orally, once on Day 2 and after PET scan #2 and prior to PET scan #3 and [^11C]T-773 IV after TAK-063 and prior to PET scan #3 on Day 2.
89580120|NCT02370602|Experimental|Main Cohort: TAK-063 + [^11C]T-773|TAK-063 3 to 100 mg, tablets, orally, once, on Day 1, and [^11C]T-773 <8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, twice on Day 1 (before and after administration of TAK-063) and once on Day 2 .
89580121|NCT02370368|Experimental|Dance Group|"Training: participants will engage in dance training with the Xbox Kinect 360 using the Just Dance 2014 disc.~Duration : 45 minutes per session. Frequency: three times per week for six weeks."
89580122|NCT02370368|Active Comparator|Ladder Drills|Intervention: Agility ladder drill training. Duration: 45 minutes per session. Frequency: three times per week for six weeks
89580123|NCT04897256|Experimental|TURN-IT group|Participants in the treatment group will attend supervised, 1-hour classes, 3 times per week for 6 weeks, one-on-one with the same exercise trainer, overseen by a physical therapist investigator.
89580124|NCT04897256|No Intervention|No Intervention Control Group|Participants in this group will be tested at baseline and 6 weeks later. They will go about their normal daily life during the 6 week period.
89580125|NCT02340806|Experimental|High rate bolus (CADD-Solis pump)|Labor analgesia will be maintained using timed-intermittent boluses of local anesthetic with PCEA using the CADD-Solis pump. The bolus rate will be 300 mL/h in the high-rate bolus group.
89580126|NCT02340806|Experimental|Low rate bolus (CADD-Solis pump)|Labor analgesia will be maintained using timed-intermittent boluses of local anesthetic with PCEA using the CADD-Solis pump. The bolus rate will be 100 mL/h in the low-rate bolus group.
89580127|NCT01835158|Active Comparator|Arm I (cabozantinib-s-malate)|Patients receive cabozantinib-s-malate PO QD for 6 weeks. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
89580128|NCT01835158|Active Comparator|Arm II (sunitinib malate)|Patients receive sunitinib malate PO QD for 4 weeks. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
89580129|NCT02337764|Experimental|TVP-1012 1mg|TVP-1012 1 mg once daily orally, either before or after breakfast, concomitantly with levodopa tablet for 52 weeks as treatment period after 2 weeks of run-in period.
89580130|NCT04420442|Active Comparator|Intervention Group|In addition to the comparison between arm 1 and 2, there will be an intraindividual comparison within arm 1.
89580131|NCT04420442|No Intervention|Control Group|No Intervention.
89580132|NCT01834222||1|Korean adults aged 50 years and older who receive Prevenar13™ in a routine clinical setting
89580133|NCT01833832|Experimental|Cytoreductive surgery followed by HIPEC|Cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin
89580134|NCT01833520|Experimental|Ra-223 Dichloride|"Phase I Starting Dose of Ra-223 Dichloride: 50 kBq/kg by vein over several minutes on Day 1 of each 4-week cycle.~Phase II Starting Dose of Ra-223 Dichloride: MTD from Phase I.~Up to 3 groups of 3 participants will be enrolled in the Phase I portion of the study, and up to 6 participants will be enrolled in Phase II."
89580135|NCT01850602|Experimental|PA21|
88973264|NCT05769712||diabetic|"Inclusion criteria：① Age range (above 18 years old); ② Non-professional athletes; (3) Patients who meet the clinical guidelines for diabetes diagnosis and treatment and are diagnosed with diabetes (ADA guidelines 2020: patients with typical diabetes symptoms and random blood glucose ≥11.1 mmol/L or fasting blood glucose ≥7.0 mmol/L or 2h blood glucose ≥11.1 mmol/L after glucose loading without typical diabetes symptoms); ④ Medical history ≥2 years.~Exclusion criteria: as above."
88973265|NCT05769699|Experimental|Biomarkers|
88973266|NCT05769673|Experimental|Customized Healing Abutments|Placement of a customized CAD/CAM healing abutment after implant placement.
88973267|NCT05769673|Active Comparator|Stock Healing Abutments|Placement of a stock healing abutment after implant placement.
88973268|NCT05769660|Experimental|BEY1107 + Temozolomide|Administer BEY1107 in combination with Temozolomide, 4-weeks as 1 cycle.
88973269|NCT05769634|Experimental|Interoceptive Challenge Battery|During simultaneous stereoelectroencephalography recording (n=30) patients will complete a series of three computer-based tasks designed to evoke changes in interoceptive attention, arousal and anticipation.
88973270|NCT05769569|Experimental|Antiretroviral therapy + Investigational Products|Active Group (ART with the addition of VRC07-523LS, PGDM1400LS and N-803 in combination with Ad26.Mos4.HIV, MVA-BN-HIV, A244d11 gp120 and ALFQ vaccination)
88973271|NCT05769569|Active Comparator|Antiretroviral therapy only|Control Group (continue only with ART without further interventions)
88973272|NCT05769452|Experimental|BD Nexiva™|The intervention group was given a closed IV catheter system called BD Nexiva™.
89580136|NCT01850602|Active Comparator|Sevelamer hydrochloride|
89580137|NCT01832818|Experimental|NuNec Cervical Disc|Each patient will be implanted with the NuNec Cervical Disc in a single level from C3 to C7. Postoperatively, patient evaluated at discharge, 6 weeks, 3, 6, 12 and 24 months.
89580138|NCT02405780|Experimental|FKB327|Patients will receive the drug 40 mg every other week by subcutaneous injection. The treatment period may continue for 76 weeks.
89580139|NCT02405780|Active Comparator|Humira®|Patients will receive the drug 40 mg every other week by subcutaneous injection. The treatment period may continue for 76 weeks.
89580140|NCT02369510|Experimental|Low-dose epinephrine|100micrograms of epinephrine group
89580141|NCT02369510|Experimental|High-dose epinephrine|200micrograms of epinephrine group
89580142|NCT02369510|Placebo Comparator|No epinephrine|0.2ml saline
89580143|NCT01650194|Experimental|Enzalutamide + Abiraterone + Prednisone|Participants received enzalutamide combined with abiraterone acetate once daily plus prednisone twice daily.
89580144|NCT02366936|Experimental|Use of Tortle midliner|This study will be an interventional, longitudinal study of 30 preterm infants using the Tortle Midliner.
88973273|NCT05769452|Experimental|BD Insyte™ Autoguard™|The control group received an open IV catheter called BD Insyte™ Autoguard™.
89209411|NCT03973567|No Intervention|normal control|Age, sex and education matched, right-handed 30 normal people.
89580145|NCT05369936|Experimental|Lavender group|On the day of the lavender group, after filling the first phase questionnaire, 20 drops of the lavender oil will be added to the electrical aromatherapy vaporizer near the patient's chair at a distance of 20 cm in the waiting room. After 20 minutes, the second phase questionnaire will be given to the patient, and then the patient will be transformed to dental clinics in which the lavender vaporizer will be placed near the dental unit at a distance of 20 cm. The vaporizer will be also prepared by adding 20 drops of the lavender which will be added added every 20 minutes until the dental sitting will be finalized, and the third questionnaire will be answered. At home, the patients will be asked to pour 3 drops of the lavender on a pad and inhale it for 5 minutes from 10 cm distance every one hour until they attend on the next day to answer the fourth questionnaire.
89580146|NCT05369936|Placebo Comparator|Placebo group|The plain distal water vapors will be used as placebo, the good ventilation of the waiting room and clinics will be performed to ensure that the lavender scent is completely removed from the environment. The patients will inhale the vapors of the plain distal water
89580147|NCT01648166||lung cancer cases|subjects with lung cancer who are greater than 17 years of age and live in Appalachian Kentucky
89580148|NCT01648166||control subjects|subjects without lung cancer, greater than 17 who reside in Appalachian Kentucky
89580149|NCT02404220|Experimental|ENTO 200 mg + VCR 0.5 mg|"Monotherapy Lead-In (Day -7 to Day -1): Entospletinib (ENTO) 200 mg tablet orally twice daily as a single agent.~Induction (two 28-day cycles): ENTO 200 mg twice daily continuously in combination with vincristine (VCR) 0.5 mg intravenously (IV) on Days 1, 8, 15, and 22 of each cycle; dexamethasone (DEX) 20 mg twice daily orally on Days 8-11 and Days 22-25 (Cycle 1) and on Days 1-4 and Days 15-18 (Cycle 2); and central nervous system (CNS) prophylaxis per institutional standards on Day 28 of each cycle.~Maintenance (up to 36, 28-day cycles): Participants who achieved a complete remission (CR) received stem cell transplant (SCT) (if eligible) per investigator's discretion; others who obtained clinical benefit (ie, at least a partial response [PR]) after induction were offered maintenance therapy with ENTO 200 mg twice daily continuously in combination with VCR 0.5 mg on Day 1 of each cycle and DEX (20 mg daily or 10 mg twice daily) on Days 1-4 and Days 15-18 of each cycle."
89580150|NCT02404220|Experimental|ENTO 400 mg + VCR 0.5 mg|"Monotherapy Lead-In (Day -7 to Day -1): ENTO 400 mg tablet orally twice daily as a single agent.~Induction (two 28-day cycles): ENTO 400 mg twice daily continuously in combination with VCR 0.5 mg IV on Days 1, 8, 15, and 22 of each cycle; DEX 20 mg twice daily orally on Days 8-11 and Days 22-25 (Cycle 1) and on Days 1-4 and Days 15-18 (Cycle 2); and CNS prophylaxis per institutional standards on Day 28 of each cycle.~Maintenance (up to 36, 28-day cycles): Participants who achieved a CR received SCT (if eligible) per investigator's discretion; others who obtained clinical benefit (ie, at least a PR) after induction were offered maintenance therapy with ENTO 400 mg twice daily continuously in combination with VCR 0.5 mg on Day 1 of each cycle and DEX (20 mg daily or 10 mg twice daily) on Days 1-4 and Days 15-18 of each cycle."
89580151|NCT02404220|Experimental|ENTO 400 mg + VCR 1.0 mg|"Monotherapy Lead-In (Day -7 to Day -1): ENTO 400 mg tablet orally twice daily as a single agent.~Induction (two 28-day cycles): ENTO 400 mg twice daily continuously in combination with VCR 1.0 mg IV on Days 1, 8, 15, and 22 of each cycle; DEX 20 mg twice daily orally on Days 8-11 and Days 22-25 (Cycle 1) and on Days 1-4 and Days 15-18 (Cycle 2); and CNS prophylaxis per institutional standards on Day 28 of each cycle.~Maintenance (up to 36, 28-day cycles): Participants who achieved a CR received SCT (if eligible) per investigator's discretion; others who obtained clinical benefit (ie, at least a PR) after induction were offered maintenance therapy with ENTO 400 mg twice daily continuously in combination with VCR 1.0 mg on Day 1 of each cycle and DEX (20 mg daily or 10 mg twice daily) on Days 1-4 and Days 15-18 of each cycle."
89580152|NCT02404220|Experimental|ENTO 400 mg + VCR 2.0 mg|"Monotherapy Lead-In (Day -7 to Day -1): ENTO 400 mg tablet orally twice daily as a single agent.~Induction (two 28-day cycles): ENTO 400 mg twice daily continuously in combination with VCR 2.0 mg IV on Days 1, 8, 15, and 22 of each cycle; DEX 20 mg twice daily orally on Days 8-11 and Days 22-25 (Cycle 1) and on Days 1-4 and Days 15-18 (Cycle 2); and CNS prophylaxis per institutional standards on Day 28 of each cycle.~Maintenance (up to 36, 28-day cycles): Participants who achieved a CR received SCT (if eligible) per investigator's discretion; others who obtained clinical benefit (ie, at least a PR) after induction were offered maintenance therapy with ENTO 400 mg twice daily continuously in combination with VCR 2.0 mg on Day 1 of each cycle and DEX (20 mg daily or 10 mg twice daily) on Days 1-4 and Days 15-18 of each cycle."
89580153|NCT02335658|Experimental|DSP-5423P|Percutaneous
88973274|NCT05769439||NTS iT2D-dTwin case-co-twin-control cohort|The twin pairs discordant for incident type 2 diabetes (iT2D) [17 monozygotic (MZ) and 20 dizygotic twin pairs (DZ)] are included from the National Heart, Lung, and Blood Institute (NHLBI) Twin Study (NTS). In a discordant twin pair, one co-twin developed iT2D while his co-twin did not or develop iT2D at least one year later.
88973275|NCT05769439||NTS iOB-dTwin case-co-twin-control cohort|The twin pairs discordant for incident obesity (iOB) [11 monozygotic (MZ) and 15 dizygotic twin pairs (DZ)] are included from the National Heart, Lung, and Blood Institute (NHLBI) Twin Study (NTS). In a discordant twin pair, one co-twin developed iOB while his co-twin did not or develop iOB at least one year later.
88973276|NCT05769387||Patients with no hormonal deficit|
88973277|NCT05769387||Patients with hormonal deficiencies|
88973278|NCT05769374|Experimental|Two player mode(parental involvement) in AVG play|the parent involvement group requires one parent to accompany the child to complete the experimental task
88973279|NCT05769374|Experimental|Single player mode in AVG play|the single-person model and the child need to complete the experimental task under the parent's supervision.
89580154|NCT02366468|Experimental|Discretion of the investigator (DI)|ranibizumab 0.5 mg, after initial monthly treatment until maximum BCVA and no signs or no further change of disease activity, the investigator treated patients at their own discretion. There were no strict recommendations for retreatment or scheduling of upcoming visits.
89580155|NCT02366468|Active Comparator|Pro re nata (PRN)|ranibizumab 0.5 mg, after initial monthly therapy until maximum BCVA and no signs or no further improvement of disease activity, patients were monitored every month and retreated if any signs of disease activity occurred
89580156|NCT02366312|Experimental|vismodegib|The 150-mg vismodegib drug product is a hard gelatin capsule formulation for oral administration. This study involves one year of treatment with Erivedge (150 mg/day) plus two years of follow-up.
89580157|NCT05370560||Type 2 diabetes mellitus|In this case-control study, T2DM was diagnosed according to the diagnostic criteria recommended by the WHO in 1999. T2DM was confirmed when fasting plasma glucose (FPG) ≥ 7.0 mmol/L and/or 2-h post-glucose load (OGTT2h) ≥ 11.1 mmol/L.
89580158|NCT05370560||Impaired glucose regulation|In this case-control study, IGR was diagnosed according to the diagnostic criteria recommended by the WHO in 1999. IGR was defined as impaired fasting glucose ([FPG] ≥ 6.1 mmol/L and < 7.0 mmol/L, and [OGTT2h] < 7.8 mmol/L) and/or impaired glucose tolerance (FPG < 7.0 mmol/L, and OGTT2h ≥ 7.8 mmol/L and < 11.1 mmol/L).
89580159|NCT05370560||Control|Those with FPG < 6.1 mmol/L and OGTT2h < 7.8 mmol/L were considered controls.
89580160|NCT02335346|Experimental|Duloxetine|Duloxetine 20 milligram (mg) for first week, 40 mg for second week and 60 mg for next 48 weeks administered orally once daily. During tapering period, dose of 40 mg for one week and then 20 mg for the last week.
89580161|NCT02403206|Experimental|Laser|Femtosecond laser assisted capsulotomy and corneal incision performed during cataract surgery
89580162|NCT02403206|Active Comparator|Manual|Continuous curvilinear capsulorhexis performed during cataract surgery
89580163|NCT02333630|Experimental|AsthmaCare intervention|Participants randomized to this arm will have the AsthmaCare app downloaded to their mobile device at time of study recruitment. They will have access to AsthmaCare indefinitely after enrollment.
89580164|NCT02333630|Active Comparator|Control group|Participants randomized to this arm will receive a link to a website containing asthma education videos and information. They will be able to access this link at their discretion.
89580165|NCT02401412|Other|Test Ostomy Barrier|The test product is a new Hollister ostomy barrier.
89580166|NCT02401412|Other|Control Ostomy Barrier|The control product is a currently marketed Hollister ostomy barrier.
89580167|NCT02365298|Experimental|etafilcon A|Worn in a daily disposable modality
89580168|NCT02365298|Active Comparator|nelfilcon A|Worn in a daily disposable modality
89580169|NCT02365064|Active Comparator|Continuous Positive Airway Pressure|Continuous positive airway pressure (CPAP) intervention as active comparator. Provides a fixed pressure for both inspiration and expiration.
89580170|NCT02365064|Experimental|Adaptive Servo-Ventilation|Adaptive servo-ventilation (ASV) positive airway pressure as experimental intervention. Provides a higher pressure for inspiration and a lower pressure for expiration with changes in the pressure support level to meet a target minute ventilation.
89580171|NCT02401256|Experimental|CYP2B6|"This is a fixed-order, open label prospective cohort study to determine: a) the contribution of CYP2B6 autoinhibition/autoinduction processes to variable CYP2B6 activity and efavirenz exposure; b) the impact of CYP2B6 genetic variants on these processes; and c) drug interactions that ensue.~Included drugs:~Efavirenz (600mg) - The volunteers will receive it in two of three inpatient visits and also during 17 days at home~Bupropion (100mg), Montelukast (10mg) and Rosuvastatin (5mg) - These drugs will be administrated on 3 occasions (at the begging each inpatient visit of Phase 1, 2 and 4)."
89580172|NCT02349295|Experimental|Ixekizumab 80 milligram (mg) every 2 Weeks (Q2W)|Blinded Treatment Period (Week(wk) 0-24): Participants (pts) received a starting dose of 160 mg of ixekizumab (ixe) given as 2 subcutaneous (SC) injections at Wk 0 followed by 1 SC injection of 80 mg of ixe Q2W given on Wks 2,4,6,8,10,12,14,16,18,20,22, and 24.Week 16 inadequate responders (IR) from the placebo treatment group who were re-randomized (1:1) to ixe 80 mg Q2W and IR from ixekizumab 80 mg Q2W who continued on ixekizumab 80 mg Q2W. Pts receive rescue therapy while receiving ixekizumab given as 1 injection of 80 mg Q2W given on Wks 16,18,20,22,24. Extension Period (Wk24-156):Pts who were randomized to ixe 80 mg Q2W at week 0 and continued on ixe 80 mg Q2W during the Extension Period. Pts who received ixekizumab 80 mg Q2W,who were either completed the study or discontinued the study early entered the post-treatment follow-up period (12-24 weeks).
89580173|NCT02349295|Experimental|Ixekizumab 80 mg Q4W|Blinded Treatment Period (Week 0-24): Participants (pts) received a starting dose of 160 mg of ixekizumab (ixe) given as 2 subcutaneous (SC) injections at Wk 0 followed by 1 SC injection of 80 mg of ixe Q4W given on Wks 4, 8 and 12 alternating with placebo for ixe injections Q4W given on Wks 2,6,10,14,18, and 22.Week 16 inadequate responders (IR) from the placebo treatment group who were re-randomized (1:1) to ixe 80 mg Q4W and IR from ixekizumab 80 mg Q4W who continued on ixekizumab 80 mg Q4W. Pts receive rescue therapy while receiving ixekizumab given as 1 injection of 80 mg Q4W given on Wks 16 and 20 alternating with placebo for ixe injections Q4W given on Wks 18 and 22.Extension Period (Wk24-156):Pts who were randomized to ixe 80 mg Q4W at week 0 and continued on ixe 80 mg Q4W during the Extension Period.Pts who received ixekizumab 80 mg Q4W,who were either completed the study or discontinued the study early entered the post-treatment follow-up period (12-24 weeks).
88973280|NCT05769374|Active Comparator|children did not engage in any AVGs play|children did not engage in any AVGs play nor any other structured school-based PA programs beyond physical education.
88973281|NCT05769361|Experimental|UNST|Training protocol with unstable devices
88973282|NCT05769361|Experimental|ST|Training protocol with stable devices
88973283|NCT05769361|No Intervention|CTRL|
88973288|NCT05769335|Experimental|early calorie restriction (eCR)|Individuals will be provided with menus prescribed at 70% of calculated energy requirements and instructed to eat within 8 h/day (e.g. 8:00 - 16:00) every day for 8 weeks, except 1 evening meal per week off the program (i.e. Saturday nights) to assist with overall adherence.
88973289|NCT05769335|Experimental|delayed calorie restriction (dCR)|Individuals will be provided with menus prescribed at 70% of calculated energy requirements and instructed to eat within 8 h/day (e.g 12:00 - 20:00) every day for 8 weeks, except 1 evening meal per week off the program (i.e. Saturday nights) to assist with overall adherence.
88973290|NCT05769335|Active Comparator|Calorie restriction (CR)|Individuals will be provided with menus prescribed at 70% of calculated energy requirements every day for 8 weeks. The menus will encourage breakfast and after-dinner consumption of the snack to eat over at least a 12 hour time frame per day (e.g. 8:00 - 20:00), except 1 evening meal per week off the program (i.e. Saturday nights) to assist with overall adherence.
88973291|NCT05769231|Experimental|Intervention group|
88973292|NCT05769231|No Intervention|Control group|Waitlist control
88973293|NCT05769205|Experimental|female with ovarian masses|MRI with contrast according to the kidney function test of the patients
88973294|NCT05769192|Experimental|Group 1|Group 1 will be applied classical physiotherapy and classical massage
88973295|NCT05769192|Placebo Comparator|Group 2|Group 2 will be applied classical physiotherapy and placebo massage
88973296|NCT05769179|Experimental|Massage group|Massage group will be applied classic massage+cervical stabilisation exercises
88973297|NCT05769179|Experimental|Connective tissue massage group|Connective tissue group will be applied connective tissue massage+cervical stabilisation exercises
88973298|NCT05769179|Experimental|Mobilization group|Mobilization group will be applied cervical mobilization techniques+cervical stabilisation exercises
88973299|NCT05769166||School children|school children aged from five to seven years
88973300|NCT05769101|Experimental|Multi-Ingredient Post-Workout Supplement|A 60 g dose of a commercially available Recovery supplement providing ~205 kcal including Proteins (+EAA), Carbohydrates, Creatine, and Vitamin D. Diluted in 350 ml of water.
88973301|NCT05769101|Placebo Comparator|Maltodextrin Supplement|An isoenergetic Maltodextrin supplement will be administered as placebo. Dissolved in 350 ml of water.
88973302|NCT05769088|Experimental|Multi-Ingredient Pre-Workout Supplement|"A 60 g dose of a commercially available preworkout supplement providing 159 kcal including carbohydrates 15 g, essential amino acids 12 g, citrulline 3.5 g, Arginine, 3.5 g Taurine 1 g, L-Tyrosine~1 g, yerba mate 0.3 g and caffeine 0.4 g. With 350 ml of water."
88973303|NCT05769088|Placebo Comparator|Maltodextrin Supplement|A isoenergetic Maltodextrin supplement will be administered as placebo. With 350 ml of water.
88973305|NCT05768997|Experimental|High dose IV iron plus ESA combination arm|
88973306|NCT05768997|Active Comparator|ESA monotherapy arm|
88973307|NCT05768984|Experimental|Experimental group|Empowerment program will be implemented.
88973308|NCT05768984|No Intervention|Control group|No program will be implemented.
88973309|NCT05768971||Active Crohn´s disease|Ultrasound in patients with proven active Crohn´s disease scheduled for therapy with anti tumor necrosis factor alpha antibodies
88973310|NCT05768971||Patients with Food allergy|Patients with proven food allergy
88973311|NCT05768971||Healthy controls|Healthy, food-tolerant volunteers without any abdominal complaint
88973312|NCT05768945||Semaglutide|Exposure group
88973313|NCT05768945||DPP4 inhibitors (sitagliptin, saxagliptin, linagliptin, and alogliptin)|Reference group
88973314|NCT05767645|Experimental|Mistral device|"The Mistral is an investigational device intended for percutaneous trans-catheter repair in high risk for surgery individuals suffering from functional Tricuspid Regurgitation (TR).~The device system is to be used only in accordance with the approved Investigational Plan on subjects who have signed an informed consent form. Device use is limited to the approved study investigators."
88973315|NCT05767606|Active Comparator|NVX arm|NVX plus placebo
88973316|NCT05767606|Active Comparator|PCV20 arm|PCV20 (Apexxnar®) plus placebo
88973317|NCT05767606|Experimental|Combination arm|NVX plus PCV20
88973318|NCT05767606|Placebo Comparator|Placebo arm|Placebo (normal saline) plus placebo
89209412|NCT00883428||Pergnant women|Pregnant women, of 28 weeks or more of gestation, who are seen in the Health Centers participating in the study.
89209413|NCT03975361|Other|Bliss-Believe|Patients included in the BLISS-BELIEVE study (NCT03312907).
88973321|NCT05765305||Letrozole|Letrozole versus letrozole with chromium
88973322|NCT05765006|Experimental|Relma-cel be administrated in four dose level|
88973323|NCT05764408|Experimental|Retractor|Research team members will apply a pannus retractor adhesive according to manufacturer's directions. The sonographer will be asked to attempt all views of the detailed anatomic survey before the adhesive is removed. If the sonographer thinks that additional views could be obtained with the adhesive removed using transabdominal or transvaginal imaging, this is acceptable based on the pragmatic design of this study.
88973324|NCT05764408|No Intervention|No retractor|The detailed anatomic survey will proceed per normal protocol. Approaches may include transabdominal and transvaginal imaging.
88973325|NCT05763316||Study participants|Neonates admitted to NICU and fulfilling eligibility criteria
88973326|NCT05762120|No Intervention|Control|Usual Care
88973327|NCT05762120|Other|Intervention|Weight Management Programme
88973328|NCT05762094||CAR-R|Patients with impaired renal function (eGFR < 60ml/min/1.73m2) treated by carbapenem
88973329|NCT05762094||CAR-L|Patients with liver cirrhosis or impaired liver function (Child-Pugh grade B or C) treated by carbapenem
88973330|NCT05762094||CAR-LR|Patients with co-morbidity of both liver cirrhosis or impaired liver function (Child-Pugh grade B or C) and impaired renal function (eGFR < 60ml/min/1.73m2) treated by carbapenem
88973331|NCT05762094||CAR-N|Patients with normal liver function or renal function treated by carbapenem
88973332|NCT05760612|Active Comparator|Trastuzumab combined with Parstuzumab|Trastuzumab（6mg/KG） and Parstuzumab（420mg/ONCE），once every three weeks，18 times in total with preoperative treatment
88973333|NCT05760612|Experimental|Trastuzumab combined with nelatinib|Trastuzumab（6mg/KG), once every three weeks, 18 times in total with preoperative treatment, during Trastuzumab treatment, take nelatinib（240mg） per day during treatment.
89029716|NCT00510315||1:1 Matched group of women|"Current age + or - 2 years~Race and ethnicity~Cancer diagnosis~Interval from completion of cancer therapy to study + or - 2 years"
89209414|NCT00885924|Active Comparator|Active treatment|Desmopressin 0.3 microgram/kg
89580174|NCT02349295|Placebo Comparator|Placebo|Blinded Treatment Period (Wk 0-24): Pts received placebo for Ixe as 2 SC injections followed by 1 SC injection Q2W given on Wks 2,4,6,8,10,12,14,16,18,20,22 and 24. Pts initially randomized to placebo treatment group in the double blind treatment period,flagged as IR at Wk 16,re-randomized to ixe 80 mg Q2W/Q4W for the remainder of the current period and following period. Extended Treatment Period (Wk 24-156): Pts who were randomized to placebo at Week 0 then randomized to ixekizumab 80 mg Q2W/Q4W during the Extension Period.Pts who remained on placebo at the completion of the double blind treatment period received the first dose of ixe (160 mg starting dose) at Wk 24.Pts who were IRs at Wk 16 and were re-randomized to ixe at Wk 16 received the first dose of ixe (160 mg starting dose) at Wk 16. Pts who received placebo,who were either completed the study or discontinued the study early entered the post-treatment follow-up period (12-24 weeks).
89580175|NCT04877587|Experimental|Ascorbate in combination with Gemcitabine|"The study will begin with a safety run-in.~A patient-individualized pharmacokinetically-guided dose escalation design will be used for Ascorbate. Gemcitabine is administered following standard fixed dose infusion practice adopted at The University of Iowa Hospitals & Clinics. Ascorbate is infused prior to gemcitabine. Cycles are 28 days. Patients will be treated for a total of 6 cycles and assessed every 2 cycles for disease response."
89580176|NCT02281357|Experimental|Tralokinumab|Tralokinumab subcutaneous injection
89580177|NCT02281357|Placebo Comparator|Placebo|Placebo subcutaneous injection
89580178|NCT02284243|Experimental|DEX-IN 50mcg|DEX-IN (Intranasal dexmedetomidine) 50mcg every 6 hours for 48 hours.
89580179|NCT02284243|Placebo Comparator|IN Placebo|IN Placebo every 6 hours for 48 hours.
88973334|NCT05760469|Other|Screening Rash|This is an exploratory study to assess the usefulness and reliability of the ITD-IAD-M for diagnosing, tracking, and treating IAD and ITD in hospitals.Participants for the study will be identified by nursing staff from admitted patients. After informed consent, the primary care nurse will collect qualitative information from the patient based on the history of their skin condition, whether the rash is new or recurring for them, and their pain, irritation, and discomfort measures. All patients participating in the study will receive the standard of care for patients presenting with MASD as prescribed by their primary care physician. The nurse will complete the ITD-IAD-M tool daily along with routine patient care. Each day the nurse documents the rash status and whether the treatment can be stopped based on the nursing assessment. The nurse/research assistant will also take a standardized digital live picture of the rash (without any identifying features) daily for a maximum of 7 days.
88973335|NCT05760144|Active Comparator|DMPA|
88973336|NCT05760144|Active Comparator|Etonogestrel implant|
88973337|NCT05752682||Syncope and fall|Consecutive patients aged ≥40 years referred to the Faint & Fall Clinics for assessment of an episode of faint or fall.
88973338|NCT05751928|Experimental|Subjects with pCR and pnCR (Group 1A)|"Subjects will receive 2 cycles of BCD-217 neoadjuvant therapy, followed by index lymph node removal.~Subjects with pathological complete (pCR) and near complete response (pnCR) (Group 1A): excision of the primary lesion (if not previously performed) without regional lymphadenectomy, followed by up to 12 months of anti-PD1 agent in the adjuvant setting."
88973339|NCT05751928|Experimental|Subjects with a pPR or pNR to neoadjuvant therapy (Group 1B)|"Subjects will receive 2 cycles of BCD-217 neoadjuvant therapy, followed by index lymph node removal.~Subjects with a pathological partial response (pPR) or non-responders (pNR) to neoadjuvant therapy (Group 1B): excision of the primary lesion (if not performed earlier), regional lymphadenectomy, then up to 12 months of adjuvant therapy with anti-PD1 agent."
88973340|NCT05751928|Active Comparator|Control Group (Group 2)|Subjects start treatment with excision of the primary lesion (if not previously performed), regional lymphadenectomy followed by adjuvant therapy with anti-PD1 agent (up to 12 months). This approach is considered the standard therapy for patients in the target population.
88973341|NCT05744674|Experimental|HR18034|
88973342|NCT05744674|Active Comparator|Ropivacaine Hydrochloride Injection|
88973343|NCT05736978|Experimental|Treatment regimen based on C1D14 MRD|Untreated acute myeloid leukemia who are ineligible for intensive chemotherapy will be given azacitidine 75mg/m2, d1-7 and venetoclax 100mg on day 1 and 200mg on day 2, 400mg on day 3-28. Based on MRD results on C1D14, MRD negative patients will go on azacitidine and venetoclax regimen and for patients with MRD positive, selinexor 60mg on D15 and D22 will be added. Patients can receive transplants at any time once they achieved complete remission and other patients will continue to receive treatment until disease progression or unacceptable toxic effects.
88973344|NCT05736965|Experimental|SAV arm|Untreated acute myeloid leukemia who are ineligible for intensive chemotherapy or who refuse to receive intensive chemotherapy will receive selinexor in combination with azacitidine and venetoclax, 28 days per cycle, patients can receive transplants at any time once they achieved complete remission and other patients will continue to receive SAV regimen until disease progression or unacceptable toxic effects.
88973345|NCT05721664|Experimental|Evidence-based nursing practices training program|Evidence-based nursing practices training program for nurses caring mechanically ventilated patients
88973346|NCT05721664|Active Comparator|control group taking the traditional education|control group taking the traditional education related to caring of mechanically ventilated patients
88973347|NCT05716282||NMB estimation group|All patients undergoing surgery with a single dose of 0.6 mg/kg rocuronium and quantitative neuromuscular transmission monitoring by TOFScan at the adductor pollicis.
88973348|NCT05713929|Active Comparator|Recruitment maneuver (RM) group 1|
88973349|NCT05713929|Active Comparator|Reverse Trend (REV TREND) group 2|
88973350|NCT05712109||ACL group|The patients were referred to the sport medicine department for the post ACL-R follow-up including isokinetic knee muscle strength evaluations at 4 months and 8 months after the surgery
88973351|NCT05707884|Active Comparator|volatile sedation|Patients receive volatile sedation for the intended 72 hours of deep sedation after complex free flap surgery.
88973352|NCT05707884|No Intervention|intravenous sedation|Patients receive intravenous sedation (e.g. propofol) for the intended 72 hours of deep sedation after complex free flap surgery.
89580180|NCT02284009|Experimental|Albiglutide|Approximately 51 subjects will be assigned to albiglutide 30 mg weekly (with treatment-masked increase to 50 mg weekly at Week 6) + background insulin. The starting dose of albiglutide will be 30 mg once weekly and will be increased at Week 6 to 50 mg, once weekly, if the 30-mg weekly dose is tolerated.
89580181|NCT02284009|Experimental|Placebo|Approximately 17 subjects will be assigned to albiglutide matching placebo + background insulin
89580182|NCT02400476|Experimental|Loperamide|240 mg Neratinib orally once daily with food for thirteen 28-day cycles. Loperamide daily for two 28-day cycles and then as needed.
89580183|NCT02400476|Experimental|Budesonide and Loperamide|240 mg Neratinib orally once daily with food for thirteen 28-day cycles. Anti-inflammatory treatment for 1 cycle and Loperamide to be administered daily for two 28-day cycles and then as needed, thereafter.
89580184|NCT02400476|Experimental|Colestipol and Loperamide|240 mg Neratinib orally once daily with food for thirteen 28-day cycles. Colestipol for 1 cycle and loperamide to be administered 1 cycle and then as needed, thereafter.
89580185|NCT02400476|Experimental|Colestipol with Loperamide as needed|240 mg Neratinib orally once daily with food for thirteen 28-day cycles. Colestipol for 1 cycle and loperamide to be administered as needed.
89580186|NCT02400476|Experimental|Neratinib Dose Escalation 1|120 mg Neratinib for Week 1, followed by 160 mg Neratinib starting for Week 2, followed by 240 mg Neratinib starting at Week 3 and thereafter (C1D15 to End of Treatment). Loperamide administered as needed.
89580187|NCT02400476|Experimental|Neratinib Dose Escalation 2|160 mg neratinib for the first 2 weeks, followed by 200 mg neratinib for the next 2 weeks, followed by 240 mg neratinib thereafter (C2D1 to End of treatment. Loperamide will be administered on an as-needed basis only.
89580188|NCT02363738|Experimental|Infliximab|Intravenous infliximab (5mg/kg) at baseline, week 2 and 6 under clinical observation
89580189|NCT02363738|Placebo Comparator|Saline (Placebo)|Intravenous placebo (saline solution) at baseline, week 2 and 6 under clinical observation. Placebo will be matched to infliximab in color and consistency.
89580190|NCT04894526|Experimental|Alternating energy intake schedule|To alternate between caloric overconsumption and caloric underconsumption from day-to-day
89580191|NCT04894526|Active Comparator|Regular energy intake schedule|To consume the usual energy intake on a daily basis
89580192|NCT02331680|Experimental|OPC-41061 15mg/day|Will be orally administered once daily after breakfast on all days on which subjects do not undergo dialysis. OPC-41061 at 15 mg/day will be administered for 24 week.
89580193|NCT02331680|Experimental|OPC-41061 30mg/day|Will be orally administered once daily after breakfast on all days on which subjects do not undergo dialysis. OPC-41061 at 15 mg/day will be administered for 1 week and then OPC-41061 30 mg/day for 23 weeks
88973353|NCT05704569||the outcome group|The composite endpoint included the presence of any of the following events: cardiovascular death, MI, stroke, hospitalization and/or application due to CHD, and transient ischemic attack
88973354|NCT05704569||no-outcome group|individuals who did not experience any events during the observation period
88973355|NCT05699291||Patient eligible for the sentinel lymph node technique by lndocyanine Green.|To evaluate the overall cost at 1 month of the sentinel lymph node detection technique using Indocyanine Green in patients with breast cancer, from the point of view of the health insurance and the hospital.
88973356|NCT05699291||Patient eligible for the sentinel lymph node technique by isotopes.|To evaluate the overall cost at 1 month of the sentinel lymph node detection technique using isotopes in patients with breast cancer, from the point of view of health insurance and the hospital.
88973357|NCT05698238|Experimental|Treatment arm|
88973358|NCT05690724|Experimental|Mitocholine™|Mitocholine™ is a novel formulation of three nutrients choline, succinic acid, and nicotinamide (a vitamin B3)
88973359|NCT05690724|Placebo Comparator|Placebo|The Placebo product will be identical in appearance and taste to the investigational product
88973360|NCT05686486|Experimental|Tai Chi inspired gymnastics practiced in a family caregiver-resident dyad|15 dyads will be recruited: 3 groups of 5 dyads where in each group, 10 participants (5 family caregivers and 5 residents) will benefit together from the Tai Chi inspired gymnastics programme at a rate of two one-hour sessions per week for 12 weeks.
88973361|NCT05686486|Active Comparator|Tai Chi inspired gymnastics practised individually|30 dyads will be recruited: 3 groups of 10 family caregivers and 3 groups of 10 residents. The 30 family caregivers recruited will be the caregivers of the 30 residents recruited. Each group will benefit separately from the Tai Chi inspired gymnastics programme at a rate of two one-hour sessions per week for 12 weeks.
88973362|NCT05686486|No Intervention|Control group|15 dyads will be recruited: 3 groups of 5 dyads. The family caregivers and the residents will not receive the intervention during the study. They will be able to continue their usual activities. At the end of the study, they will be offered the 24 sessions of the Tai Chi inspired gymnastics programme in family caregiver-resident dyad.
88973363|NCT05664295||insomnia patients|Jenkins Sleep Disorders scale skor >1 and Epworth Sleepiness scale skor >9
88973364|NCT05664295||noninsomniacs|Jenkins Sleep Disorders scale skor <2 and Epworth Sleepiness scale skor <10
89029717|NCT02955992|No Intervention|standard of care|
89580194|NCT02331680|Placebo Comparator|Placebo|Will be orally administered once daily after breakfast on all days on which subjects do not undergo dialysis. Placebo will be administered for 24 week.
89580195|NCT02331446|No Intervention|Control|The control group will be oriented to maintain their normal activity and habits and will not receive the intervention.
89580196|NCT02331446|Experimental|90 minutes per week|The group of 90 minutes per week will do three sessions of 30 minutes per week of concurrent training, which consists on 15 minutes of aerobic exercise and 15 minutes of strength training.
89580197|NCT02331446|Experimental|150 minutes per week|The group of 150 minutes will do three sessions of 50 minutes per week, which consists on 25 minutes of aerobic exercise and 25 minutes of strength training.
89580198|NCT02331446|Experimental|210 minutes per week|The group pf 210 minutes per week will do three sessions of 70 minutes per week, which consists on 35 minutes of aerobic exercise and 35 minutes of strength training.
89580199|NCT02349061|Experimental|Ustekinumab plus Concomitant Medication|Participants will receive weight-range based dosing of approximately 6 mg/kg of ustekinumab intravenously at Week 0 followed by ustekinumab 90 mg subcutaneously (SC) every 8 weeks (q8w) up to Week 40. Participants who meet the study extension inclusion criteria will continue to receive ustekinumab 90 mg SC q8w starting at Week 48 or 56 through Week 104. Participants will continue stable concomitant treatment through Week 48, as well as through the study extension although tapering of corticosteroids is encouraged beyond Week 48. Participants who complete or discontinue study treatment will be evaluated for 16 additional Weeks of safety follow-up.
89580200|NCT02349061|Experimental|Placebo followed by Ustekinumab plus Concomitant Medication|Participants will receive placebo intravenously at Week 0 followed by placebo subcutaneously at Weeks 8 and 16. At week 24 participants will receive ustekinumab SC q8w up to Week 40. Participants who meet the study extension inclusion criteria will continue to receive ustekinumab 90 mg SC q8w starting at Week 48 or 56 through Week 104. Participants will continue stable concomitant treatment through Week 48, as well as through the study extension although tapering of corticosteroids is encouraged beyond Week 48. Participants who complete or discontinue study treatment will be evaluated for 16 additional Weeks of safety follow-up.
89580201|NCT02331368|Experimental|Anti-PD-1 (MK-3475)|"Standard Treatment:~High-dose Melphalan and autologous stem cell transplantation with post-transplant maintenance of Lenalidomide.~Study Treatment:~200 mg/day of MK-3475 administered every 3 weeks, starting day +14 post-transplant for a total of 9 doses."
89580202|NCT02362724|Experimental|Sapphire|Subjects randomized to the experimental contact lens over the study duration
89580203|NCT02362724|Active Comparator|Pearl|Subjects randomized to the active comparator contact lens over the study duration
89580204|NCT02362646|Experimental|MPC Intramyocardial Injection|Intramyocardial injections of 150 million MPCs
89580205|NCT02362646|Sham Comparator|Control Solution|Intramyocardial injections of 50% Alpha-MEM/42.5% ProFreeze NAO Freezing Medium/7.5% DMSO
89580206|NCT04907162||Neuromuscular disease (NMD) Patients|"The patient has one of the following neuromuscular diagnoses:~histologically (muscle biopsy) confirmed inclusion body myositis (IBM), or~genetically confirmed late-onset Pompe disease (LOPD), or~genetically confirmed spinal muscular atrophy type 3 (SMA3), or~genetically confirmed myotonic dystrophy type 1, or~genetically confirmed myotonic dystrophy type 2, or~genetically confirmed facio-scapulo-humeral muscle dystrophy (FSHD)."
89580207|NCT04907162||Healthy control|no known neuromuscular disorder
88973365|NCT05662176|Experimental|Experimental: Supportive Care based on trauma informed care|Participants were provided care in different rooms, blinded to the differences in practice used between the two groups. In the same clinic, a room was designed as a positive delivery room by the researchers and a relaxing environment was created. In this room, supportive care based on trauma informed care was provided to the experimental group during birth.
88973366|NCT05662176|Other|Control: Standart care|Participants in the control group, on the other hand, received the routine care given in the hospital by other midwives in the clinic, and there was a change of caregiver midwife during shift changes. The care provided in the hospital during delivery is mostly focused on low level of physical comfort and high level of follow-up.
88973367|NCT05657860|Sham Comparator|Placebo|
88973368|NCT05657860|Experimental|GXR|Immediately following the 8-week blinded randomized trial, an 8-week open-label continuation phase will be pursued to further define efficacy and tolerability of GXR, and to establish its safety with specific focus on metabolic profile.
88973369|NCT05640401|Experimental|Endoscopy procedure + mixed reality|This group is comprised by expert gastrointestinal endoscopists designated to perform diagnostic procedures. The procedure will be performed without physical surgical monitors, and through the guidance of Mixed Reality by using the HXtend™ application holographic monitors.
88973370|NCT05626907|Experimental|Assigned Diet #1|
88973371|NCT05626907|Experimental|Assigned Diet #2|
88973372|NCT05626907|Other|Assigned Diet #3|
88973373|NCT05605444|Experimental|Isometric exercise-one repetition|Isometric exercise consisting of 1 session only. The session will last for around 5 minutes which will include asking the patient to do 1 repetition of wall squat for 3 min or to volitional fatigue at 100° knee angle.
88973374|NCT05605444|Experimental|Isometric exercise-three repetitions|Isometric exercise consisting of 1 session only. The session will last for around 10 minutes which will include asking the patient to perform 3 repetition of wall squat (each time the exercise will be performed for 3 min or to volitional fatigue at 100°degree knee angle); patient will be given 30 sec rest between repetitions.
88973375|NCT05605444|No Intervention|Control (no intervention)|Will not receive any intervention
88973376|NCT05602077|Experimental|POCUS and Control Intervention|"POCUS: Point of care ultrasound~Control-Intervention: X-ray examination and Cone Beam Computed Tomography (CBCT)"
88973377|NCT05595603|Experimental|Zoledronic Acid loaded bone cement|4mg zoledronic acid-loaded gentamicin bone cement (PMMA)
88973378|NCT05595603|Active Comparator|conventional gentamicin bone cement|gentamicin bone cement (PMMA)
88973379|NCT05593549|Experimental|Trehalose|10g mixed in 500 mL of water, consumed 1 time per day
88973380|NCT05593549|Placebo Comparator|Placebo|10g microcrystalline cellulose in 500 mL, consumed 1 time per day
88973381|NCT05591040|Experimental|Biofeedback|Each participant will attend 5 sessions per week for a total duration of 4 weeks. The duration of each session will take 1 hour, including bio-feedback preparation. At the beginning of the bio-feedback session, two surface electrodes will be applied to the mylohyoid muscle. The patient will be required to swallow at a given time, with food bolus if possible, and perform maneuvers that favour swallowing strength and efficacy: effortful swallow, specific task for timing and coordination, Masako maneuver. The experimental group will perform this training for 45 minutes, plus they will receive a verbal feedback from the speech and language therapist in relation to the efficacy of the performance.
88973382|NCT05591040|Active Comparator|Conventional|Each participant will attend 5 sessions per week for a total duration of 4 weeks. The patient will be required to swallow at a given time, with food bolus if possible, and perform maneuvers that favour swallowing strength and efficacy: effortful swallow, specific task for timing and coordination, Masako maneuver. The control group will perform this training for 45 minutes, with a verbal feedback from the speech and language therapist in relation to the efficacy of the performance.
89029718|NCT02955992|Experimental|Intervention|"All caregivers will receive a leaflet about the importance of end of life (EOL) communication: key elements and recommendations regarding verbal and non-verbal communication.~A local champion (opinion leader) will be designated by each team in order to help implement the strategy. These physicians will help colleagues to connect external knowledge and requirements of the study to the local context.~Development of a 3-step physician-driven support strategy starting after a decision to withhold or withdraw life-sustaining therapies is implemented:~Preparation for the death : Prepare the relative for the patient's imminent death~During the dying and death process: The physician enters the patient's room at least once to check on the relatives~After the patient's death: the physician and the nurse meet the relative"
88973383|NCT05590156|Experimental|Action Observation Therapy (AOT)|"AOT is a method based on the principle that the patient watches the movements of a healthy individual and then tries to imitate them. AOT consists of a monitoring-imitation cycle. A cycle consists of 3 minutes of observation, and 3 minutes of imitation. The intervention will consist of 10 cycles for simple functions. Complex movements will be applied by separating them into their components. The cycle time for each component is the same. Take for example, the cup-reaching function: The first component is the cup-reaching activity. The second component is the glass grip. One cycle will be completed on the first component (6 minutes), then one cycle will be completed for the second component (6 minutes) and one cycle (6 minutes) will be completed for the entire movement. Cycles will follow each other for 60 minutes.~For the AOT, 31 different videos were prepared for the shoulder, elbow, and wrist. Applications will be made in the hospital under the supervision of a physiotherapist."
88973384|NCT05590156|Experimental|Robotic Rehabilitation|"The robotic rehabilitation application will be performed with the ExoRehab X (HoustonBionics, Inc.) device. There is no engine to create any repulsive-pulling force in this device. It is a system that works entirely with the patient's active movement.~Active movements of the shoulder, elbow, and wrist in all directions can be performed with the device. Motion is detected with the help of the device's censor, and the avatar moves on the screen. There are 10 different purposeful games embedded in the device. The device also allows resistance exercise thanks to resistance modules.~Which joint will be trained will be determined according to the potential of the patient. For example, if programming will be done for the shoulder, elbow and wrist, the treatment time will be 20 minutes for each joint.~Applications will be made in the hospital under the supervision of a physiotherapist."
88973385|NCT05579717|Experimental|Equine Assisted Learning group|Participants in this group will receive 16 sessions of Equine Assisted Learning (EAL), facilitated by a trained clinician at Cartier Farms.
88973386|NCT05579717|No Intervention|Waitlist control group|Participants in the waitlist control group will not receive EAL for the duration of the study.
88973387|NCT05565248|Experimental|VCTX211 unit|
88973388|NCT05563454|Experimental|Dose step 1|Each participant will receive an single dose (SD) of dose 1 of BAY2395840 or matching placebo.
88973389|NCT05563454|Experimental|Dose step 2|Each participant will receive an single dose (SD) of dose 2 of BAY2395840 or matching placebo.
88973390|NCT05563454|Experimental|Dose step 3|Each participant will receive an single dose (SD) of dose 3 of BAY2395840 or matching placebo.
88973391|NCT05563454|Experimental|Dose step 4|Each participant will receive multiple doses (MDs) of dose 3 of BAY2395840 or matching placebo.
88973392|NCT05554120||Non-smoking adolescents|Non-smoking youth aged 12-17 years old. As the investigators monitor the cohort, it is possible that some of the cohort will become smokers.
88973393|NCT05554120||Smoking adults from disadvantaged neighbourhoods|Smoking adults aged 18 years and older from disadvantaged neighbourhoods. The investigators distinguish between disadvantaged and non-disadvantaged neighborhoods by using data from CBS Statistics Netherlands (CBS).
88973394|NCT05554120||Smoking adults from non-disadvantaged neighbourhoods|Smoking adults aged 18 years and older from non-disadvantaged neighbourhoods. The investigators distinguish between disadvantaged and non-disadvantaged neighborhoods by using data from CBS Statistics Netherlands (CBS).
88973395|NCT05552261||Group Long-term follow-up|All eligible patients, after completing enrollment in the original DEFENDO Study, will be invited to enter the DEFENDO Long-Term Follow-Up Study (all standard of care is permitted), according to inclusion and exclusion criteria.
88973396|NCT05532800|Experimental|JS002|Cobort 1:150 mg/1mL Q2W PFS,Cobort 2:150 mg/1mL Q2W AI
88973397|NCT05532800|Placebo Comparator|Placebo|Cobort 1:/1mL Q2W PFS,Cobort 2:1mL Q2W AI
88973398|NCT05526742|Experimental|Group 1|"Subjects will receive single-dose of CKD-510 capsule in fasted state (treatment A) on Day 1 of Period 1 and tablet in fasted state (treatment B) on Day 1 of Period 2, and then receive tablet in a fed state (treatment C) on Day 1 of Period 3.~A washout period will be at least 7 days between each treatment period."
88973399|NCT05526742|Experimental|Group 2|"Subjects will receive single-dose of CKD-510 tablet in a fed state (treatment C) on Day 1 of Period 1 and tablet in fasted state (treatment B) on Day 1 of Period 2, and then receive capsule in fasted state (treatment A) on Day 1 of Period 3.~A washout period will be at least 7 days between each treatment period."
88973400|NCT05511389|Active Comparator|Anterolateral shock vector|"Patients with electrodes placed on the chest to obtain an anterolateral (front-to-side placement; also known as anteroapical) shock vector.~If first shock is unsuccessful, participants who proceed to a second shock will be randomized to manual pressure versus none but electrode placement will remain the same."
88973401|NCT05511389|Active Comparator|Anteroposterior shock vector|"Patients with electrodes placed on the chest to obtain an anteroposterior (front-to-back placement) shock vector.~If first shock is unsuccessful, participants who proceed to a second shock will be randomized to manual pressure versus none but electrode placement will remain the same."
88973402|NCT05500313|Experimental|Hypno-breastfeeding Education|An announcement was made on social media platforms for hypno-breastfeeding education programme, and they were invited to the education. Pre-applicant women were informed about the education and research process and their informed consent was signed via e-mail. An average of 4-5 women were included in each group. this group, the training consisted of 4 sessions and a total of 12 hours. It included information about breastfeeding, hypnosis approaches and different techniques. In line with the demands of the group, the session days and hours were decided with together. The Hypno-Breastfeeding Education Programme was offered to each group in a maximum of 2 weeks.
88973403|NCT05500313|Experimental|Standart Breastfeeding Education|An announcement was made on social media platforms for standart breatfeeding education programme, and they were invited to the education. Pre-applicant women were informed about the education and research process and their informed consent was signed via e-mail.This education was done in one go. In this group, the training consisted of 1 sessions and a total of 3 hours. It included only information about breastfeeding.
88973404|NCT05499416|Experimental|Bimekizumab 320 mg SC injections|Bimekizumab 320 mg solution administered via SC injections every 4 weeks for 16 weeks.
88973405|NCT05492864|Experimental|open bite with extrusion arch|single arm study, measures will be recorded before and after
88973406|NCT05491109|Experimental|Venous Assistance and Contracture Management System (VACOM)|Venous Assistance and Contracture Management System (VACOM) + Inpatient rehabilitation (daily Physiotherapy therapy and Occupational therapy)
88973407|NCT05491109|Active Comparator|Intermittent Pneumatic Compression (IPC)|Intermittent Pneumatic Compression (IPC) which is the standard care + Inpatient rehabilitation (daily Physiotherapy therapy and Occupational therapy)
88973408|NCT05480696|Experimental|Oligofructose Inulin Supplementation|The intervention group will receive a daily fibre supplementation of (fructo-oligosaccharide enriched inulin, 4g twice daily; Orafti®Synergy1, BENEO), a tasteless white powder contained within a tear-able, partitioned 4g sachet, sprinkled and dissolved in 125 mL of water.
89580208|NCT02280421|Other|ASP2151 400mg|ASP2151 400mg + 100mg ciclosporin
88973409|NCT05480696|Sham Comparator|Maltodextrin Supplementation|The control group will receive a daily supplementation of carbohydrate placebo (isocaloric maltodextrin), identical in colour, packaging, preparation, and dose (4g, twice daily; C*Dry MD™,Cargill).
88973410|NCT05479773|Other|Group A|"Treatment order:~1) Standard NIV mask ; 2) Lumena mask without suction ; 3) Lumena mask with suction."
88973411|NCT05479773|Other|Group B|"Treatment order:~1) Standard NIV mask ; 2) Lumena mask with suction ; 3) Lumena mask without suction."
88973412|NCT05479773|Other|Group C|"Treatment order:~1) Lumena mask without suction ; 2) Lumena mask with suction ; 3) Standard NIV mask."
88973413|NCT05479773|Other|Group D|"Treatment order:~1) Lumena mask with suction ; 2) Lumena mask without suction ; 3) Standard NIV mask."
88973414|NCT05457465|Experimental|Hemp-Derived Cannabidiol Solution|Patients will administer a custom-formulated, hemp-derived, high-CBD solution twice daily for 4 weeks
88973415|NCT05453955|Experimental|Propofol-Remimazolam|General anesthesia was induced and maintained with propofol, then switched to remimazolam after 60 minutes from incision.
88973416|NCT05453955|Experimental|Remimazolam-Propofol|General anesthesia was induced and maintained with remimazolam, then changed to propofol after 60 minutes from incision.
88973417|NCT05448599|Experimental|6MW3211|Phase I, 6MW3811 monotherapy in 2 dose levels of 30mg/kg or 45mg/kg; phase II, 6MW3811 will be given in combination with AZA( cohort1) and AZA plus VEN(cohort 2)
88973418|NCT05442853|Active Comparator|Continuous Glucose Monitoring|Study subjects in this arm will receive glycemic management based on continuous glucose monitoring with CGM device. CGM readings will be available to patients, nurses, and the treating team. All treatment decisions for this group will be based on CGM readings, confirmatory POC readings (as necessary), and venipuncture.
88973419|NCT05442853|Active Comparator|Point of Care Glucose Monitoring|Study subjects in this arm will receive glycemic management based on point of care blood glucose readings. CGM will be placed in blinded mode and used for study comparison only. Patients, nurses, and other treatment team will be blinded to the CGM readings. All treatment decisions for this group will be based on POC readings and venipuncture
88973420|NCT05435963|Experimental|COPD undergoing pulmonary rehabilitation|45 individuals with COPD will complete the UCLA-LS scale, CRQ, HADS, and 6 minute walk test before and after pulmonary rehabilitation.
88973421|NCT05427786|Experimental|Pre-PCI IC Nicorandil|"If the lipid core burden index at the main lesion site on vascular ultrasound exceeds 353, randomization was performed.~Nicorandil group will be administrated 8cc or more of the prescribed drug (Nicroandil) according to randomization into the coronary artery before starting balloon therapy."
88973422|NCT05427786|No Intervention|Standard PCI|"If the lipid core burden index at the main lesion site on vascular ultrasound exceeds 353, randomization was performed.~Standard PCI group will be performed coronary intervention including starting balloon therapy without pre-administrated nicorandil."
88973423|NCT05423665||Fetal growth restricted|Observation of cardiac remodeling perinatal and postnatal
88973424|NCT05423665||Appropriately grown|Observation of cardiac remodeling perinatal and postnatal
88973425|NCT05417776|Experimental|Subjects with interstitial lung abnormalities (ILAs) or interstitial lung disease (ILD)|Subjects with interstitial lung abnormalities (ILAs) or interstitial lung disease (ILD) will receive [68Ga]CBP8 and undergo PET-MRI.
88973426|NCT05417776|Experimental|First degree relatives of a family member with pulmonary fibrosis|First degree relatives of a family member with pulmonary fibrosis will receive [68Ga]CBP8 and undergo PET-MRI.
88973427|NCT05402553|Active Comparator|Intervention|
88973428|NCT05402553|Placebo Comparator|Control|
88973429|NCT05402072|Active Comparator|Microfracture|As per current standard of care for focal articular cartilage lesions of the acetabulum, the unstable cartilage will be debrided and removed from the subchondral bone using a mechanical shaver until a stable margin is obtained. A ring curette will be used to remove the calcified cartilage layer and create a border of healthy cartilage tissue that can support the marrow clot. Through the mid-anterior portal, specialized 90˚ awls will then be placed with the tip perpendicular to the subchondral bone of the acetabulum, and a mallet will be used to penetrate the subchondral bone with perforations 3 mm deep to access the bone marrow elements. This is done until the defect is homogeneously covered with micro-perforations 2-3 mm apart.
89029719|NCT00511017|Experimental|Doxercalciferol|
89209415|NCT00885924|Placebo Comparator|Placebo|NaCl 0.9%
89580209|NCT02280421|Other|ASP2151 1200mg|ASP2151 1200mg + 100mg ciclosporin
89209416|NCT01071811|No Intervention|Control group|Participants assigned to the control group received a leaflet from the National Board of Health in Denmark recommending all adults to be physical active for 30 minutes each day of moderate intensity.
88973430|NCT05402072|Experimental|Autologous matrix-induced chondrogenesis (AMIC)|Those allocated to the AMIC treatment group will also receive microfracture. Once the walls of the debrided lesion are confirmed to be stable with a probe, the exact size of the defect will be measured for templating of the scaffold. The dry Chondro-Gide® matrix will be prepared by cutting it to 10% smaller than the focal defect (as it increases in size about 10% after moistening). Once the cartilage lesion is dried manually, the implant will then be secured to the defect in a press-fit fashion to the surrounding cartilage. Manual pressure is then applied to secure the implant into the defect and the hip is released from traction and rotated to facilitate further fixation of the graft. Traction is then applied to arthroscopically confirm position and fixation of the implant.
88973431|NCT05397730||TBP|Patients with definite or probable tuberculous pleuritis
88973432|NCT05397730||Non-TBP|Patients without tuberculous pleuritis
88973433|NCT05395663|Active Comparator|Arm 1: Usual practice|People will receive a free well water test kit that is delivered by mail and the results from this water test. They will also be mailed material that is provided by the Oregon Health Authority's Domestic Well Stewardship Program which is the Water Well Owner's Handbook(in English or Spanish) and contaminant guides.
88973434|NCT05395663|Experimental|Arm 2: Health navigator|"People will receive a free well water test kit that is delivered by mail and the results from this water test. They will also be mailed material that is provided by the Oregon Health Authority's Domestic Well Stewardship Program which is the Water Well Owner's Handbook(in English or Spanish) and contaminant guides. In addition, a trained health navigator will meet with the homeowner three times to assist the homeowner's decision-making.~Activities include: i) Interpreting results, ii) Improving health literacy and numeracy through teach-back moments, iii) Assessment of household risk for contaminants from well and septic, iv) Assessment of risk to family members, pets, livestock, etc v) Coaching to resolve ambivalence or lack of motivation and other barriers using elicit-provide-elicit motivational interviewing; vi) Assistance with decision-making and weighing financial options, and vii) Goal-setting and action plans."
88973435|NCT05383118|Experimental|Education Intervention|"Participants in the intervention group will be provided e-learning about dementia prevention and promoting brain health, consisting of following components:~One multimedia e-learning lesson on promoting brain health and preventing dementia;~A series of 12 'micro-learning' emails (3 emails/week) with small segments of content to reinforce the material from the lesson.~Curated resources related to dementia risk factors"
88973436|NCT05383118|Active Comparator|Education Control|"Participants in the control group will be provided e-learning about mild cognitive impairment, consisting of following components:~One multimedia e-learning lesson on mild cognitive impairment;~A series of 12 'micro-learning' emails (3 emails/week) with small segments of content to reinforce the material from the lesson.~Curated resources related to mild cognitive impairment"
88973437|NCT05379322|Experimental|Group A (Anti-TNF)|Rheumatoid arthritis patients that have failed DMARD therapy will undergo a synovial biopsy under ultrasound guidance and sterile technique. Upon analysis of the sample, patients that are falling into the diffuse myeloid phenotype will be assigned to receive anti-TNF medication at the discretion of the treating physician.
88973438|NCT05379322|Experimental|Group B (JAK inhibitor)|Rheumatoid arthritis patients that have failed DMARD therapy will undergo a synovial biopsy under ultrasound guidance and sterile technique. Upon analysis of the sample, patients that are falling into the lymphoid- myeloid phenotype will be assigned to receive JAK inhibitor medication at the discretion of the treating physician.
88973439|NCT05379322|Experimental|Group C (Anti-TNF or JAK inhibitor)|Rheumatoid arthritis patients that have failed DMARD therapy will undergo a synovial biopsy under ultrasound guidance and sterile technique. Upon analysis of the sample, patients that are falling into the pauci-cellular phenotype will be randomized to either anti-TNF or JAK inhibitor medication 1:1.
88973440|NCT05378165|Experimental|Music group|The music group listened to Acemasiran-type classical Turkish music with a headset from an MP3 player starting at about 10 min before colonoscopy until completion of the procedure.
88973441|NCT05378165|Experimental|Stress ball group|"The stress ball group was given stress balls which was medium hard and made of high-quality silicone approximately 10 minutes before colonoscopy. The patients in stress ball group were instructed to squeeze the balls twice after counting up to five and repeat until the end of the entire procedure."
88973442|NCT05378165|Experimental|Video group|"The patients in the video group allowed to watch a licensed virtual reality application, A walk on the beach, through an Android mobile phone placed in Cardboard Super Flex Goggles, started 10 minute before the colonoscopy until the procedure was completed."
88973443|NCT05378165|Other|Control group|Standard colonoscopy was performed on the patients in the control group, without any additional intervention.
88973444|NCT05376696|Experimental|Set for Variability|"Students in the experimental group will receive an average of 10-12 hrs. of small group intervention. All lessons will include (i) a focus on blending and segmenting phonemes within a synthetic phonics model, (ii) teaching common, vocabulary words (iii)shared book reading, and (iv) Set-for-variability component (SfV). This component will focus on teaching students how to find the sound variation of a grapheme-phoneme rule. For example when to use the sound /k/in /ch/ to read words such as stomach"
89029720|NCT00511056||HIVNAT 006|HIVNAT 006 is a long term follow up cohort. The primary objective of this study is to collect and evaluate the long-term clinical outcomes of HIV infected patients have participated in HIV-NAT studies. These subjects will be used to test our hypothesis.
89209417|NCT01071811|Experimental|Pedometer group|Received a pedometer (Yamax Digi-Walker SW-200), a book with a pedometer program, a handout with a summary of the pedometer program, and a calendar for registration of daily steps.
89209418|NCT01071889|Other|Brotizolam|Treatment response will be evaluated for each treatment arm. Good Response (GR) - is considered as an improvement of 30% in efficacy parameters of Flumazenil treatment in comparison to placebo
89580210|NCT04906382|Experimental|Treatment (tislelizumab)|"Chemo naïve patients receive tislelizumab IV over 30-60 minutes on day 1. Cycles repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity. Beginning cycle 4, patients who are chemotherapy naive with progressive disease, stable disease, or partial response, also receive carboplatin IV and paclitaxel IV every 21 days per standard of care for 6-9 cycles at the discretion of the treating physician.~Patients who have received prior chemotherapy will receive single agent tislelizumab IV over 30-60 minutes on day 1. Cycles repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity."
89580211|NCT04892719|Other|Participants who underwent a lung transplant at Duke|Participants will undergo fluoroscopic chest imaging with 4Dx technology software analysis
89580212|NCT02362412|Experimental|FK949E 50 MG / FK949E 150 MG|Participants who received the 50 mg tablet once daily during Treatment Period II (8 weeks) and 150 mg tablet once daily during Treatment Period III (8 weeks).
89580213|NCT02362412|Experimental|FK949E 150 MG / FK949E 50 MG|Participants who received the 150 mg tablet once daily during Treatment Period II (8 weeks) and 50 mg tablet once daily during Treatment Period III (8 weeks).
89580214|NCT02280187||Spine Fusion with InductOs|Patient had spinal fusion surgery with InductOs between 1st January 2011 and 31st December 2012
89580215|NCT02347813|Other|Delayed Intervention|After enrollment, subjects will be observed for 24 weeks for skin cancer tumors. Tumors will be appropriately treated as per standard of care. Then they will begin the pioglitazone regimen for 24 more weeks, during which time skin cancer tumors will be observed and appropriately treated as per standard of care.
89580216|NCT02347813|Other|Immediate Intervention|Subjects will begin the 24 week pioglitazone regimen immediately after enrollment, during which time skin cancer tumors will be observed and appropriately treated as per standard of care. After 24 weeks of drug, subjects will be observed for 24 weeks for skin cancer tumors. Tumors will be appropriately treated as per standard of care.
89580217|NCT02329730|Experimental|the healthy subjects|The healthy subjects inject 1μg/ml ESAT6-CFP10 and tuberculin purified protein derivative only one time , or 5μg/ml ESAT6-CFP10 and tuberculin purified protein derivative only one time , or 10μg/ml ESAT6-CFP10 and tuberculin purified protein derivative only one time , or 20μg/ml ESAT6-CFP10 and tuberculin purified protein derivative only one time .Right arm inject ESAT6-CFP10 and left arm inject tuberculin purified protein derivative. Two drugs must be use in the same subjects.
88973445|NCT05376696|Active Comparator|Current best practices|The control group will receive current-best practices (CBP). The participants will receive a similar approach as in the intervention group without Set-for-Variability. The participants will receive (i) a focus on blending and segmenting phonemes within a synthetic phonics model, (ii) vocabulary, (iii) shared book reading, and (iv) the absence of teaching Set-for-Variability. Instead of Set-for-variability, the participants will receive sight word reading of frequent words. They will learn the most frequent pronunciation of vowels: ee, ea, oo, ou, oa, ai, ay
88973448|NCT05367570||Normal weight group|The first work package of this study is cross-sectional. The investigators will investigate the 24-hour movement behaviors, cardiometabolic parameters and some personal and environmental correlates.
88973449|NCT05367570||Overweight/obesity group|The first work package of this study is cross-sectional The investigators will investigate the 24-hour movement behaviors, cardiometabolic parameters and some personal and environmental correlates.
88973450|NCT05349175|Experimental|Cohort A|Receives AIR device feedback beginning immediately after training
88973451|NCT05349175|Experimental|Cohort B|Receives AIR device feedback beginning 2 months after training
88973452|NCT05349175|Experimental|Cohort C|Receives AIR device feedback beginning 4 months after training
88973453|NCT05342948||pRPL|Primary RPL patients: no prior birth ≥22 weeks
88973454|NCT05342948||sRPL with a first born boy|Secondary RPL patients: ≥ 1prior birth ≥22 weeks of only boy(s)
88973455|NCT05342948||sRPL with a first born girl|Secondary RPL patients: ≥ 1prior birth ≥22 weeks of only girl(s)
88973456|NCT05337046||Tissue removal system|Endometrial polyp removed by hysteroscopic tissue removal system in a previous study.
88973457|NCT05337046||Bipolar resectoscopy|Endometrial polyp removed by hysteroscopic bipolar resectoscopy in a previous study.
88973458|NCT05319106|Experimental|Stem cell preparation combined with silver ion dressing|
88973459|NCT05319106|Placebo Comparator|silver ion dressing|
88973460|NCT05314413|Experimental|Single Leg Immobilization - Males|Males will be subjected to 7-days of single-leg immobilization.
88973461|NCT05314413|Experimental|Single Leg Immobilization - Females|Females will be subjected to 7-days of single-leg immobilization.
88973462|NCT05301023|Experimental|Individual group|In the individual group, the participants receive individualized antibiotic therapy.
88973463|NCT05301023|Active Comparator|Standard group|In the standard group, the participants receive standard antibiotic therapy as defined by the national guideline.
88973464|NCT05298696|Active Comparator|Intervention|Cilostazol 100 mg twice daily for treatment period
88973465|NCT05298696|Placebo Comparator|Control|placebo twice daily for treatment period
88973466|NCT05295823|No Intervention|Healthcare provider performed standard PVR measurement using existing ultrasound technology|The Urologic healthcare provider will perform standard point-of-care PVR measurement on the participant (3 consecutive measurements during the same encounter) using existing ultrasound technology
88973467|NCT05295823|Experimental|Healthcare provider performed PVR measurement using Butterfly and bladder ultrasound images|The Urologic healthcare provider will perform PVR measurement on the participant (3 consecutive measurements during the same encounter) using the Butterfly and bladder ultrasound images
89580218|NCT02329730|Experimental|the first part of tuberculosis subjects|The first part kind of tuberculosis subjects inject 1μg/ml ESAT6-CFP10 and tuberculin purified protein derivative only one time , or 5μg/ml ESAT6-CFP10 and tuberculin purified protein derivative only one time , or 10μg/ml ESAT6-CFP10 and tuberculin purified protein derivative only one time , or 20μg/ml ESAT6-CFP10 and tuberculin purified protein derivative only one time .Right arm inject ESAT6-CFP10 and left arm inject tuberculin purified protein derivative. Two drugs must be use in the same subjects.
89580219|NCT02329730|Experimental|the second part of tuberculosis subjects|The second part of tuberculosis subjects inject 1μg/ml ESAT6-CFP10 and placebo only one time , or 5μg/ml ESAT6-CFP10 and placebo only one time , or 10μg/ml ESAT6-CFP10 and placebo only one time , or 20μg/ml ESAT6-CFP10 and placebo only one time .Right arm inject ESAT6-CFP10 and left arm inject placebo. Two drugs must be use in the same subjects.
89580220|NCT02328326|Experimental|CO-IMPACT|patient and supporter (dyad) receive one coaching session on action planning, communicating with providers, navigation skills and support skills; preparation by phone before patients' primary care visits; after-visit summaries by mail; and biweekly automated phone calls to prompt action on new patient health concerns
89580221|NCT02328326|Active Comparator|PACT|patient and their health supporter (dyad) will receive PACT care for high-risk diabetes, which includes (at primary care team discretion): nurse care manager visits, diabetes education classes, chronic disease self-management groups, telehealth, clinical pharmacist visits
89580222|NCT01649804|Experimental|RoActemra/Actemra single arm|
89580223|NCT02397278|Active Comparator|Platelet rich plasma (PRP)|Patients will receive three PRP injections into the symptomatic knee; they will also be fitted with a hinged brace locked in extension, with weight bearing as tolerated and crutches for those with pain upon weight bear, complete rest from impact activities with progression to weight bearing as tolerated for 6 weeks, and then followed according to the Sports Medicine department's protocol for OCD.
89580224|NCT02397278|No Intervention|Conventional therapy|Patients will be fitted with a hinged brace locked in extension, with weight bearing as tolerated and crutches for those with pain upon weight bear, complete rest from impact activities with progression to weight bearing as tolerated for 6 weeks, and then followed according to the Sports Medicine department's protocol for OCD.
89580225|NCT02360228|Experimental|tACS (alpha)|20 participants: 10Hz tACS with a peak-to-peak amplitude of 2mA for 20 minutes twice daily
89580226|NCT02360228|Experimental|tDCS|20 participants: 2mA stimulation for 20 minutes twice daily
89580227|NCT02360228|Sham Comparator|Sham stimulation|20 participants: Will include 10 seconds of ramp in to 1 minutes of 10 Hz tACS with a ramp out of 10 seconds for a total of 80 seconds of stimulation twice daily.
89580228|NCT02359994|Experimental|Cardiac Surgery|For cardiac procedures, the site of evaluation for satisfaction of intraoperative eligibility criteria will be any bleeding sites on the epicardium, along an aortic anastomotic suture line, or an aortotomy suture line. For example, the surgeon will perform dissection of adhesions per his or her conventional methods and bleeding will be controlled using means continually employed by the surgeon prior to surgical closure. Prior to application along an aortic anastomotic suture line or an aortotomy suture line, suture line gaps > 2mm and large needle holes > 2mm will be ligated prior to assessment of intraoperative eligibility criteria. Any bleeding site on the epicardium, or along an aortic anastomotic suture line, or an aortotomy suture line meeting the eligibility criteria will be evaluated for satisfaction. PerClot should be applied after drug reversal and the patient is taken off by-pass.
88973468|NCT05295823|Experimental|Healthcare provider performed PVR measurement using Butterfly and abstract bladder images|The Urologic healthcare provider will perform PVR measurement on the participant (3 consecutive measurements during the same encounter) using the Butterfly and abstract bladder images
88973469|NCT05295823|Experimental|Self PVR measurement using Butterfly and bladder ultrasound images|The participant will perform self PVR measurement (3 consecutive measurements during the same encounter) using the Butterfly and bladder ultrasound images (prior to catheterization, if needed)
88973470|NCT05295823|Experimental|Self PVR measurement using Butterfly and abstract bladder images|The participant will perform self PVR measurement (3 consecutive measurements during the same encounter) using the Butterfly and abstract bladder images (prior to catheterization, if needed)
88973471|NCT05293782|Active Comparator|Kinesiotaping on trunk flexor muscles|Kinesiotaping
88973472|NCT05293782|Active Comparator|Kinesiotaping on trunk extensor muscles|Kinesiotaping
88973473|NCT05293782|Placebo Comparator|Placebo Kinesiotaping on trunk flexor muscles|Kinesiotaping
88973474|NCT05293782|Placebo Comparator|Placebo Kinesiotaping on trunk extensor muscles|Kinesiotaping
88973475|NCT05287425|Experimental|Gentamicin eye drops|4 drops daily in both eyes for 7 ± 1 days
88973476|NCT05287425|Experimental|Ciprofloxacin eye drops|4 drops daily in both eyes for 7 ± 1 days
88973477|NCT05287425|Active Comparator|Povidone eye drops unpreserved|4 drops daily in both eyes for 7 ± 1 days
88973478|NCT05287425|Active Comparator|Povidone eye drops preserved|4 drops daily in both eyes for 7 ± 1 days
88973479|NCT05276466|Other|Single arm|All subject's samples will undergo the same diagnostic test utilizing Polymerase Chain Reaction and Next-Generation DNA Sequencing
88973480|NCT05270902|Active Comparator|Adsorber Group|"Surgery with CPB will be performed according to institutional standards, depending on indications and surgical preferences.~For the intervention group (adsorber-group), the CytoSorb adsorber will be installed on the CPB machine in a parallel circuit to the body circulation. The flow through the filter will be driven by a roller pump with 300-400 ml.min-1."
88973481|NCT05270902|No Intervention|Control|The control group (no-adsorber group) will be treated similarly, but no filter circuit will be installed.
88973482|NCT05266898|Experimental|Gardasil-9 recipients|Participants receive 3-dose Gardasil-9 vaccine series.
88973483|NCT05266872||PD patients|Subjects with neurodegenerative disease or having degenerative parkinsonism (typical PD or atypical parkinsonism)
88973484|NCT05266872||Healthy controls|Gender- and age-matched healthy controls
89029721|NCT02955875|Experimental|Pharmaceutical care|Participants received systematically organized pharmaceutical care services, which were provided by pharmacists, in addition to the usual care. The usual care includes traditional consultation with pharmacists as well as traditional medical services provided by physicians, nurses, and dietitian.
89580229|NCT02359994|Experimental|General Surgery|"For liver resection procedures, the resected liver surface will be the site of evaluation. The surgeon will perform resection of the diseased portion of the liver per his/her conventional methods. Bleeding from discrete vessels will be controlled using means conventionally employed by the surgeon. Vessels > 2mm in diameter will be ligated and any observed bile leaks controlled prior to assessment of intraoperative eligibility criteria.~For total splenectomy procedures, the site of evaluation for satisfaction of the intraoperative eligibility criteria will be the retroperitoneal surface. The surgeon will perform the splenectomy per his/her conventional methods. Vessels > 2mm in diameter will be ligated prior to assessment of intraoperative eligibility criteria.~Any bleeding site on the retroperitoneal surface/cavity or exposed parenchymal surface will be evaluated for satisfaction of the eligibility criteria."
88973485|NCT05259657|Experimental|Lymfit intervention|Participants randomized to the intervention group will be allocated a pre-registered Inspire II model Fitbit. The kinesiologist will design a personalized exercise prescription for the participant. The kinesiologist will follow up with the participants every 2 weeks for 3 months to discuss their progress and to modify or advance their exercise prescriptions as needed.
88973486|NCT05259657|Other|Wait-list control arm|The control group participants will begin receiving the Lymfit intervention 3 months after they sign the consent form.
88973487|NCT05258721|Experimental|Treatment Group|Participants with gingivitis or periodontitis (Stage I or II) brush with ClōSYS® Sensitive Fluoride Toothpaste twice daily and rinse with ClōSYS® Sensitive Rinse twice daily after brushing.
88973488|NCT05257785|Experimental|Lymfit exercise intervention|Participants randomized to the intervention group will be allocated a pre-registered Fitbit, a personalized exercise prescription designed by the kinesiologist, and 12 weeks of supervision by the kinesiologist.
88973489|NCT05257785|Other|Waitlist control|Participants will receive the exact same Lymfit exercise intervention 3 months after they consent to participate in the study.
88973490|NCT05257057||Endometrial hyperplasia|These are patients with a diagnosis of endometrial hyperplasia at WellSpan in the study time frame diagnosed via endometrial biopsy, dilation and curettage, or hysterectomy.
88973491|NCT05254496|Experimental|US Healthy Diet|Participants in this group will be assigned to follow the Healthy US dietary pattern as presented by the US Dietary Guidelines. As described here https://www.nia.nih.gov/health/usda-food-patterns: This eating pattern is based on the types and amounts of foods Americans typically consume. The main types of food in this eating pattern include a variety of vegetables; fruits; whole grains; fat-free or low-fat dairy; seafood, poultry, meat, and eggs; and nuts, seeds, and soy products.
88973492|NCT05254496|Experimental|Mediterranean diet|Participants in this group will be assigned to follow the Mediterranean dietary pattern as presented by the US Dietary Guidelines. As described here https://www.nia.nih.gov/health/usda-food-patterns: This eating pattern contains more fruits and seafood and less dairy than the Healthy U.S.-Style Eating Pattern.
88973493|NCT05254496|Experimental|Vegetarian diet|Participants in this group will be assigned to follow the Vegetarian dietary pattern as presented by the US Dietary Guidelines. As described here https://www.nia.nih.gov/health/usda-food-patterns: This eating pattern contains no meat, poultry, or seafood. Compared with the Healthy U.S.-Style Eating Pattern, it contains more soy products, eggs, beans and peas, nuts and seeds, and whole grains.
88973494|NCT05249608|Other|Single arm|A single arm study, only investigational product-the Gastric Bypass Stent System is intended to be used in weight loss treatment for obesity in patients with a BMI ≥ 30 kg/m2. to evaluate the safety and performance of the investigational device for the intended use.
88973495|NCT05246137|Experimental|Experimental: COVID-19 Vaccine HIPRA 40 ug/dose|COVID-19 Vaccine HIPRA, where subjects will receive one intramuscular injection of COVID-19 vaccine developed by HIPRA
88973496|NCT05234671|Experimental|Exercise group|The exercise group will perform a supervised combined (e.g., aerobic and resistance training) 12-week exercise programme, twice per week adjunct to the patient's standard care.
88973497|NCT05234671|No Intervention|Control group|The control group will not perform the exercise programme and will receive only the standard care.
88973498|NCT05219890|Experimental|OBESE PATIENTS|Obese patients will be recruited from the outpatient Clinic of Obesity at the INCMNSZ. They will consume the fish oil equivalent to 4.8 g/day of EPA and DHA for 3 months, followed by a one-month period without treatment.
88973499|NCT05219890|Active Comparator|CONTROL GROUP|Healthy normal volunteers will be recruited from friends and family of the investigators, and staff at the INCMNSZ. They will consume the fish oil equivalent to 4.8 g/day of EPA and DHA for 3 months, followed by a one-month period without treatment.
88973500|NCT05219422|Active Comparator|Project ALERT only|Some schools will be randomized to receive Project ALERT only for 3 years starting fall 2022.
88973501|NCT05219422|Active Comparator|Project ALERT plus GTO|Some schools will be randomized to receive Project ALERT plus Getting to Outcomes for 3 years starting fall 2022.
88973502|NCT05219422|No Intervention|Status quo|Some schools not receive either Project ALERT or Project ALERT plus GTO until year 3 of the study.
88973503|NCT05216601|Active Comparator|MVC-COV1901|15 mcg of S-2P protein with adjuvant
88973504|NCT05216601|Experimental|MVC-COV1901(Beta)-15|15 mcg of S-2P protein(Beta) with adjuvant
88973505|NCT05216601|Experimental|MVC-COV1901(Beta)-25|25 mcg of S-2P protein(Beta) with adjuvant
88973506|NCT05211427|Experimental|Patients|Patients with oropharynx cancer
88973507|NCT05211427|Experimental|Healthy subjects|Patients with non malignant pharynx pathology
88973508|NCT05210556||No Antibiotic Bowel Prep|Patients who did not receive a preoperative antibiotic bowel preparation
88973509|NCT05210556||Antibiotic Bowel Prep|Patients who did receive a preoperative antibiotic bowel preparation
88973510|NCT05201807|Experimental|TEST Lens|Eligible subjects who are habitual soft contact lens wearers will be given the TEST Lens for the duration of the study.
88973511|NCT05197153|Experimental|Half dose of MVC-COV1901|7.5 mcg of S-2P protein with adjuvant
89580230|NCT02359994|Experimental|Urologic Surgery|"For on-clamp partial nephrectomies, the site of evaluation will be the kidney bed surface. The surgeon will perform resection of the kidney per his or her conventional methods. Vessels > 2mm in diameter will be ligated and entries into the collecting system controlled prior to assessment of intraoperative eligibility criteria. Any bleeding site on the kidney bed will be evaluated for satisfaction of the eligibility criteria after clamp release.~For radical nephrectomies, the site of evaluation will be the retroperitoneal surface/cavity. The surgeon will perform the procedure per his or her conventional methods. Vessels > 2mm in diameter will be ligated prior to assessment of intraoperative eligibility criteria. Any bleeding site on the retroperitoneal surface/cavity will be evaluated for satisfaction of the eligibility criteria."
89580231|NCT02326298|Experimental|CZP 200 mg|"CZP 400 mg at Weeks 0, 2, 4, followed by CZP 200 mg every two weeks (Q2W) from Week 6 to Week 14.~Treatment received from Week 16-48 is based on initial treatment and response to treatment:~PASI50 responders at Week 16 continue to receive CZP 200 mg Q2W.~PASI50 non-responders at Week 16 will be removed from blinded study medication and escape to unblinded CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study.~PASI50 non-responders at Week 32 or a later time point will be withdrawn from the study.~Subjects who complete the Maintenance Period (with PASI50 response at Week 48) enter the Open-label Extension Period on CZP 200 mg Q2W.~Week 48 completers in the escape arm continue to receive CZP 400 mg Q2W or may switch to CZP 200 mg Q2W.~Depending on PASI50 or PASI75 responses at Week 60 or a later time point, subjects may switch to CZP 400 mg Q2W or withdraw from the study."
89580232|NCT02326298|Experimental|CZP 400 mg|"CZP 400 mg every two weeks (Q2W) through Week 14.~Treatment received from Week 16 - 48 is based on initial treatment and response to treatment:~PASI50 responders at Week 16 continue to receive CZP 400 mg Q2W.~PASI50 non-responders at Week 16 will be removed from blinded study medication and escape to CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study.~PASI50 non-responders at Week 32 or a later time point will be withdrawn from the study.~Subjects who complete the Maintenance Period (with PASI50 response at Week 48) enter the Open-label Extension (OLE) Period on CZP 200 mg Q2W. Week 48 completers in the escape arm continue to receive CZP 400 mg Q2W or may switch to CZP 200 mg Q2W.~Subjects who achieve a PASI75 response during the OLE Phase may switch to CZP 200 mg Q2W."
89580233|NCT02326298|Placebo Comparator|Placebo|"Placebo subcutaneous (sc) injection every two weeks (Q2W).~Treatment received from Week 16 - 48 is based on initial treatment and response to treatment:~PASI50 responders at Week 16, who do not achieve a PASI75 response at Week 16 receive CZP 400 mg at Weeks 16, 18 and 20 (loading doses) followed by CZP 200 mg Q2W starting at Week 22.~PASI75 responders at Week 16 continue to receive Placebo.~PASI50 non-responders at Week 16 will be removed from blinded study medication and escape to CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study.~PASI50 non-responders at Week 32 or a later time point will be withdrawn from the study.~Subjects who complete the Maintenance Period (with PASI50 response at Week 48) enter the Open-label Extension Period on CZP 200 mg Q2W. Week 48 completers in the escape arm continue to receive CZP 400 mg Q2W or may switch to CZP 200 mg Q2W."
89580234|NCT02396420|Experimental|Treatment arm|Patients will receive prostate artery embolization (PAE) with Embosphere Microspheres.
89580235|NCT02279719|Experimental|BBI608 and Sorafenib|
88973512|NCT05197153|Experimental|Full dose of MVC-COV1901|15 mcg of S-2P protein with adjuvant
88973513|NCT05197153|Experimental|AZD1222|5*10^10 viral particles of AZD1222
88973514|NCT05197153|Active Comparator|Half dose of mRNA-1273|50 mcg mRNA encoding the pre-fusion stabilized S protein
88973515|NCT05194982|Experimental|Study treatment|Participants receive BL-B01D1 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
88973516|NCT05194241|Experimental|One MORE|
88973517|NCT05194241|No Intervention|Waitlist Control|
88973518|NCT05192850||Metformin use|These participants were on metformin for any duration at any point in time in the study period
88973519|NCT05192850||No metformin use|These participants were never on metformin for any duration at any point in time in the study period
88973520|NCT05188963|Active Comparator|Women with postvoid residual volume cut-off at 150 ml|
88973521|NCT05188963|Experimental|Women with postvoid residual volume cut-off at 250 ml|
88973522|NCT05182034|Experimental|Study Group 1: SMUP-IA-01 (low dose)|Investigational Product - 4.0×10^6 cells/2 mL of SMUP-IA-01 (2 ml of 1% sodium hyaluronate injection is administered before administration of SMUP-IA-01)
88973523|NCT05182034|Experimental|Study Group 2:SMUP-IA-01 (mid dose)|Investigational Product - 1.0×10^7 cells/2 mL of SMUP-IA-01 (2 ml of 1% sodium hyaluronate injection is administered before administration of SMUP-IA-01)
88973524|NCT05182034|Active Comparator|Active Control Group|Investigational Product - 2 ml of 1% sodium hyaluronate (2 ml of sodium chloride injection is administered before administration of 1% sodium hyaluronate)
88973525|NCT05179655|Experimental|ERITA + TAU (Treatment as usual)|The Emotion Regulation Individual Therapy for Adolescents (ERITA) intervention as add-on to TAU consists of 11 weeks, manualized online therapy based on the methods of Cognitive Behavioral Therapy (CBT), Dialectical Behavior Therapy (DBT), and Acceptance and Commitment Therapy (ACT) adapted for youth
88973526|NCT05179655|Other|TAU (Treatment as usual)|Within mental health services in Denmark child and adolescent psychiatrists provide specialized treatment for young psychiatric patients as outpatient services. In this study the control intervention (TAU) consists of clinical assessment and treatment for patient's current primary psychiatric condition (referral condition and A-diagnosis).
88973527|NCT05171881|Experimental|Interventional Arm|All infants will undergo non-invasive NIRS monitoring of cerebral oxygen saturation and will have algorithm-driven clinical interventions to maintain cerebral saturation within target range during the first 72 hours of life.
89580236|NCT02279719|Experimental|BBI503 and Sorafenib|
89580237|NCT02279719|Active Comparator|Sorafenib|
89580238|NCT02279407|Placebo Comparator|placebo|
89580239|NCT02279407|Experimental|Omega-3 carboxylic acids 4g / day|
89580240|NCT02279407|Experimental|Dapagliflozin, 10mg / day|
89580241|NCT02279407|Experimental|Omega-3 carboxylic acids 4g/day+Dapagliflozin 10mg/day|
89580242|NCT02326220|Experimental|Placebo Q2W (Double Blind Period)|Placebo (for alirocumab) subcutaneous (SC) injection Q2W up to Week 16.
89580243|NCT02326220|Experimental|Alirocumab 150 mg Q2W (Double Blind Period)|Alirocumab 150 mg SC injection Q2W up to Week 16.
88973528|NCT05170243|Active Comparator|9MW1911 Injection|Experimental drug administered IV infusion
88973529|NCT05170243|Placebo Comparator|9MW1911 Injection Placebo|Placebo administered IV infusion
88973530|NCT05130359|Placebo Comparator|Placebo|consume 2 sachet per day for 4 weeks
88973531|NCT05130359|Experimental|Banana peel extract|consume 2 sachet per day for 4 weeks
88973532|NCT05130034|Experimental|Home-based pulmonary rehab for fibrotic interstitial lung disease|Subjects diagnosed with fibrotic interstitial lung disease will participate in a home-rehab program that promotes more physical activity in daily life.
88973533|NCT05127720||patients with severe sleep apnea|defined by a pacemaker-derived mean RDI ≥ 20/h in the first 12 months after enrollment
88973534|NCT05127720||patients with autonomic imbalance|defined by PRD ≥ 5.75deg2 assessed within the first 12 months of enrollment
88973535|NCT05127720||patients with a sedentary lifestyle|defined by a pacemaker-derived mean daily physical activity level < 2h in the first 12 months after enrollment
88973536|NCT05127577|Experimental|Abdominal massage group|Abdominal massage will be applied to the experimental group 2 times a day, morning and evening, until defecation, starting in the evening of the first day after the surgical intervention.
88973537|NCT05127577|No Intervention|Control group|The control group will be received routine treatment and care in the unit.
88973538|NCT05111717||group 1|Peripheral venous blood samples will collected at two time points as follows: before the premedication and the induction of anesthesia (T₁): 120 minutes after the beginning of anesthesia (T₂). DNA will be obtained from blood samples , and global DNA methylation analysis will be done.
88973539|NCT05104632||Breast conserving surgery only|Patients who receive breast conserving surgery.
88973540|NCT05104632||Mastectomy only|Patients who receive mastectomy surgery.
88973541|NCT05104632||Mastectomy & breast reconstruction|Patients who receive mastectomy and breast reconstruction.
88973542|NCT05095909|Experimental|Cryo-compression|"Fitted with compression sleeve for the NICE Recovery SystemTM applied to the operative shoulder immediately post - operatively Minimum 6 hours treatment per day post-operatively. Utilize cyro-compression unit with a Medium compression level (inflate to 35 mmHg for 2 minutes and then deflate to 5 mmHg for 30 seconds) and Level 3 cooling (50F (10C)) for the first 24 hours. After that time, the compression and cooling levels will be up to the patients' discretion."
88973543|NCT05095909|Active Comparator|Cryo-therapy|Fitted with a standard gel ice pack with wrap immediately post-operatively. Minimum 6 hours treatment per day using gel ice packs.
88973544|NCT05070169||Early Surgical Fixation|Prospective cohort of patients with intertrochanteric fractures with DOAC (direct oral anticoagulation) therapy undergoing early surgical fixation (within 24 hours).
88973545|NCT05070169||Delayed Surgical Fixation|Retrospective control group of patients with intertrochanteric fractures with DOAC medication who underwent delayed surgical fixation (≥48 hours) from January 2014 to December 2018.
88973546|NCT05059054|Experimental|Strengthening group|Strengthening exercise
88973547|NCT05059054|Active Comparator|Insole group|Insole application
88973548|NCT05050006|Experimental|Cohort 1|Patients who relapsed after or were refractory to at least 1 prior line of systemic therapy including a PD-1 inhibitor.
88973549|NCT05050006|Experimental|Cohort 2|Patients who were intolerant to a PD-1 inhibitor and have persistent disease after stopping PD-1 therapy.
88973550|NCT05050006|Experimental|Cohort 3|Patients who had a best response of stable disease despite being treated with at least 4 doses of a PD-1 inhibitor in the previous line of therapy.
88973551|NCT05049603|Experimental|Atorvastatin|Atorvastatin 20 mg/day (the experimental treatment), one tablet/day, given approximately at 10 pm, after dinner and before going to bed, for 24 weeks, associated with intravenous methylprednisolone pulse therapy (the standard treatment), given over a period of 12 weeks
88973552|NCT05049603|Placebo Comparator|Placebo|Intravenous methylprednisolone pulse therapy (the standard treatment), given over a period of 12 weeks, and placebo (one tablet/day, given approximately at 10 pm, after dinner and before going to bed) for 24 weeks
88973553|NCT05037162|Experimental|Arm 1 - CimetrA-1|CimetrA-1, with a total dose containing a combination of Curcumin 40 mg, Boswellia 30 mg and Vitamin C 120 mg in spray administration - divided in 4 separate doses given as an add on therapy, total of 4 doses over 48 hours (day 1 and day 2), twice a day (morning and evening).
89580244|NCT02326220|Experimental|Alirocumab 150 Q2W (Open Label Treatment Period)|Alirocumab 150 mg SC injection Q2W starting from Week 18 up to Week 76.
89580245|NCT02279173|Experimental|Romiplostim|Participants received romiplostim administered weekly by subcutaneous injection for up to 3 years. The starting dose was 1 µg/kg titrated in 1 µg/kg increments up to a maximum of 10 µg/kg to reach a target platelet count ≥ 50 x 10⁹/L.
89580246|NCT02282917|Experimental|AR-42 Administration|AR-42 will be administered three times per week beginning 3 weeks prior to surgery.
89580247|NCT02358668|Experimental|BTI320 4 grams|three times daily, oral for 16 weeks
89580248|NCT02358668|Experimental|BTI320 8 grams|three times daily, oral for 16 weeks
89580249|NCT02358668|Placebo Comparator|BTI320 matching placebo|2 tablets three times daily, oral for 16 weeks
89580250|NCT02282605|Experimental|XF-73 2.0 mg/g nasal gel|0.3mL (nominal 300 microgram) XF-73 nasal gel will be applied to each naris, twice daily for two days. Each dose will be 0.3mL per naris/0.6mL per dose delivering 0.6mg XF-73 per naris/1.2mg XF-73 per dose. Prior to each morning dose, subjects will use chlorhexidine gluconate 2% body and face cloths.
89580251|NCT02282605|Experimental|XF-73 0.5 mg/g nasal gel|0.3mL (nominal 300 microgram) XF-73 nasal gel will be applied to each naris twice daily for two days. Each dose will be 0.3mL per naris/0.6mL per dose delivering 0.15mg XF-73 per naris/0.3mg XF-73 per dose. Prior to each morning dose, subjects will use chlorhexidine gluconate 2% body and face cloths.
89580252|NCT02282605|Placebo Comparator|Placebo nasal gel|0.3mL nasal gel will be applied to each naris twice daily for two days. Prior to each morning dose, subjects will use chlorhexidine gluconate 2% body and face cloths.
89580253|NCT02282527|Other|Treatment Sequence 1|Subjects were treated first with Liquid Alpha₁-PI and then treated with Prolastin-C
89580254|NCT02282527|Other|Treatment Sequence 2|Subjects were treated first with Prolastin-C and then treated with Liquid Alpha₁-PI
89029722|NCT02955875|No Intervention|Usual care|Participants received the usual care, which includes traditional consultation with pharmacists as well as traditional medical services provided by physicians, nurses, and dietitian.
89580255|NCT05650099||Implants in the posterior region|126 patients with one or two missing tooth/teeth in the posterior region were treated 10 years ago with dental implant treatment and implant-supported restorations
89580256|NCT02278939|Experimental|Fit and Trim group|This groups will start with the Filipinos Fit and Trim Weight Loss Program mobile phone based (smartphone) intervention with social networking for 3 months, a pedometer/accelerometer, access to a study private Facebook virtual social networking group, and and 4 in-person intervention session with individually tailored goals for physical activity, diet, and weight. At 3months, the Fit and Trim group will transition to a maintenance phase for 3 months, receive one in-person session for maintenance support (at 4.5 months) and complete the study at month 6.
89580257|NCT02278939|Active Comparator|Pedometer only group|This group will start with the pedometer/accelerometer only to monitor/ track their physical activity step-counts for the initial 3 months. In addition, subjects will receive an educational materials on Hepatitis B and Tuberculosis. At 3 months the pedometer only group will transition to receive the Filipinos Fit and Trim Weight Loss Program intervention (as previously described) for the next 3 months and complete the study at month 6.
89580258|NCT02278471|No Intervention|Usual Care|Subjects in this arm will not receive any investigational medications. They will remain on the same care that they are use to receiving.
89580259|NCT02278471|Experimental|Polypill|"The study medication will be a fixed-dose combination pill (polypill) containing: Atorvastatin 10 mg, amlodipine 2.5 mg, losartan 25 mg, and hydrochlorothiazide 12.5 mg.~Polypill will be taken once daily."
89580260|NCT05565235|Active Comparator|Group B|bupivacaine
89580261|NCT05565235|Active Comparator|Group BMG|bupivacaine/ magnesium.
89580262|NCT05565235|Active Comparator|Group BN|bupivacaine /nalbuphine.
89580263|NCT04420039||1- Single biliary LAMS|Unresectable/inoperable biliopancreatic cases with distal biliary obstruction who underwent EUS-BD with a single lumen-apposing stent after failed ERCP cannulation or inaccessible papilla.
89580264|NCT04420039||2- Biliary LAMS plus Doublu-Pigtail plastic Etent|Unresectable/inoperable biliopancreatic cases with distal biliary obstruction who underwent EUS-BD with a single lumen-apposing stent (plus double-pigtail plastic stent) after failed ERCP cannulation or inaccessible papilla.
89580265|NCT02278003|Experimental|children going under sedation with propofol|"Children who will undergo sedation as part of their clinical management and give them a memory encoding task during propofol infusion to measure the effects of sedation. The mere task of naming a picture will encode that picture into memory. When the anesthesia has worn off (at approximately 1 hour later), children will be given a memory recognition task to measure the amnesic effects of propofol.~measure the amnesic effects of propofol."
89580266|NCT02278003|Active Comparator|children not going under sedation|A control group of children of similar age and undergoing similar minor therapeutic procedures will be recruited to perform memory.
89029723|NCT00510354|Experimental|RAD001 + Imatinib|
89029724|NCT01241006|Active Comparator|Dexamethasone|Single dose of Dexamethasone 12 mg PO and 4 days of placebo capsules
89029725|NCT01241006|Active Comparator|Prednisone|Prednisone 60mg PO capsules for 5 days
89029726|NCT04695951|Experimental|Renalof|A total of 120 patients treated with the study product Renalof® at a dose of 650 mg twice daily were followed for 4 months. A preliminary analysis of the types of stones present in the study patients was performed according to the main compound, using a biophysical profile by biochemical analysis and the clinical characteristics, medical history and biochemical profile of the creatinine values of the test patients. Imaging and quality of life tests were carried out during the trial to check the efficacy and possible adverse effects of the test product in patients with kidney stones.
89029727|NCT04695951|Placebo Comparator|Control|A total of 35 patients treated with the study product Placebo at a dose of 650 mg twice daily were followed for 4 months. A preliminary analysis of the types of stones present in the study patients was performed according to the main compound, using a biophysical profile by biochemical analysis and the clinical characteristics, medical history and biochemical profile of the creatinine values of the test patients. Imaging and quality of life tests were carried out during the trial to check the efficacy and possible adverse effects of the test product in patients with kidney stones.
89209419|NCT01071889|Other|Zolpidem|Treatment response will be evaluated for each treatment arm. Good Response (GR) - is considered as an improvement of 30% in efficacy parameters of Flumazenil treatment in comparison to placebo.
89209420|NCT00612690|Experimental|Links to Learning|Participants received the community mental health consultation model program.
89580267|NCT02277769|Placebo Comparator|Placebo|Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 followed by a single injection once weekly (qw) from Week 1 to Week 15.
89580268|NCT02277769|Experimental|Dupilumab 300 mg every 2 weeks (q2w)|Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a placebo alternating with single 300 mg injection of Dupilumab qw from Week 1 to Week 15.
89580269|NCT02277769|Experimental|Dupilumab 300 mg qw|Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection of Dupilumab qw from Week 1 to Week 15.
89580270|NCT01641991|Experimental|Arm B: 0.50mL BioThrax®|BioThrax® 0.50mL subcutaneously on Days 0, 28 and 0.50mL BioThrax® intramuscular 6 month boost; 75 subjects
89209421|NCT00612690|Active Comparator|Services as Usual|Participants received treatment as usual and referrals.
89209422|NCT03973411|Active Comparator|Ondansetron group|Patients will receive intravenous ondansetron before spinal anesthesia
89580271|NCT01641991|Experimental|Arm C: 0.50mL BioThrax®|BioThrax® 0.50mL subcutaneously on Days 0, 14, 28 and 0.50mL BioThrax® intramuscular 6 month boost; 75 subjects
89580272|NCT01641991|Experimental|Arm D: 0.25mL BioThrax®|BioThrax® 0.25mL subcutaneously on Days 0,14, and 28,and 0.50mL BioThrax® intramuscular 6 month boost; 75 subjects
89580273|NCT01641991|Experimental|Arm A: 0.50mL BioThrax®|BioThrax® 0.50 ml subcutaneously on Days 0, 14, and 0.50mL BioThrax® intramuscular 6 month boost; 75 subjects
89580274|NCT05649709|Experimental|vonoprazan and low-dose amoxicillin dual therapy|1000 mg amoxicillin capsules twice daily and 20 mg vonoprazan Fumarate Tablets twice daily for 14 days
89580275|NCT05649709|Active Comparator|vonoprazan and high-dose amoxicillin dual therapy|1000mg amoxicillin capsules three times daily and 20mg vonoprazan Fumarate Tablets twice daily for 14 days
89580276|NCT05649631|Experimental|Normal sodium diet(100mmol/d)|
89580277|NCT05649631|Experimental|Low sodium diet(50mmol/d)|
89580278|NCT02277691|Experimental|TAK-536TCH|"For 4 weeks during the run-in period, one tablet of TAK-536CCB (as TAK-536/AML, 20 mg/5 mg, respectively) orally, once daily, before or after breakfast.~For 48 weeks during 52 weeks of the treatment period, one tablet of TAK-536TCH (as TAK-536/AML/HCTZ, 20 mg/5 mg/12.5 mg, respectively) orally, once daily, before or after breakfast. For the remaining 4 weeks of the treatment period, one tablet each of TAK-536CCB and HCTZ 12.5 mg orally, once daily, before or after breakfast."
88973554|NCT05037162|Experimental|Arm 2 - CimetrA-2|CimetrA-2, with a total dose containing a combination of Curcumin 28 mg, Boswellia 21 mg and Vitamin C 84 mg in spray administration - divided in 4 separate doses given as an add on therapy, total of 4 doses over 48 hours (day 1 and day 2), twice a day (morning and evening).
88973555|NCT05037162|Placebo Comparator|Arm 3 - Placebo|Placebo, composed of the same solvent but without active ingredients, given as an add on therapy in spray administration, total of 4 doses over 48 hours (day 1 and day 2), twice a day (morning and evening).
88973556|NCT05020444|Experimental|TriPRIL CAR T Cells-Dose Escalation|"Prior to receiving TriPRIL CAR T Cells, participants will undergo two preparatory processes:~Leukapheresis: On day -8 white blood cells will be collected.~Lymphodepletion: On days, -5, -4. -3 participants will receive 3 days of chemotherapy to decrease the number of lymphocytes~TriPRIL CAR T Cells will be administered intravenously on day 0 using a 3+3 dose escalation design"
88973557|NCT05020444|Experimental|TriPRIL CAR T Cells-Dose Expansion|"Prior to receiving TriPRIL CAR T Cells, participants will undergo two preparatory processes:~Leukapheresis: On day -8 white blood cells will be collected.~Lymphodepletion: On days, -5, -4. -3 participants will receive 3 days of chemotherapy to decrease the number of lymphocytes~TriPRIL CAR T Cells will be administered intravenously on day 0 using the respective dose (at or below the Maximum Tolerated Dose-MTD), as determined during the dose escalation part."
88973558|NCT05012189|Active Comparator|Oseltamivir|Nursing homes randomized to receive oseltamivir for treatment and chemoprophylaxis for influenza.
88973559|NCT05012189|Experimental|Baloxavir|Nursing homes randomized to receive baloxavir for treatment and chemoprophylaxis for influenza.
88973560|NCT04995068||Included patients|See inclusion and exclusion criteria
88973561|NCT04986228|Experimental|Digital aftercare|The group with the new digital aftercare is compared with the active control group with regular aftercare.
88973562|NCT04986228|Active Comparator|Treatment-as-usual (TAU)|The group with regular aftercare (TAU) serves as an active control group.
88973563|NCT04985721|Experimental|Pamiparib and Tiselizumab|
88973564|NCT04983680|Experimental|Mindfulness-Based Cognitive Therapy|Mindfulness-Based Cognitive Therapy (MBCT) is an 8-week group intervention (1.5-hour weekly sessions) that combines cognitive-behavioral therapy and mindfulness training to treat emotional problems.
88973565|NCT04978337|Experimental|Treatment A: Rilematovir|Participants will receive oral dose of rilematovir 250 milligrams (mg), twice daily (bid) for 7 days.
88973566|NCT04978337|Placebo Comparator|Treatment B: Placebo|Participants will receive oral dose of placebo matching to rilematovir, bid for 7 days.
88973567|NCT04891224|Other|Pathway Platform application use|Study participants will download the Pathway app to their mobile device. This app will gather patient health data, present standardized questionnaires and research data collection tools. Subject responses will be visible to their provider via interface with the electronic medical record.
88973568|NCT04876339|Experimental|"Gait rehabilitation with sonification"|"The rehabilitation exercises with sonification are supported by the musical component (see Interventions section for details)."
88973569|NCT04876339|Active Comparator|Standard gait rehabilitation (without sonification)|The same rehabilitation exercises are performed without musical support.
89209423|NCT03973411|Placebo Comparator|Control group|Patients will receive intravenous saline before spinal anesthesia
89209424|NCT00883506|Experimental|1|Lisinopril 40 mg Tablet under fed conditions.
89580279|NCT02395172|Experimental|Avelumab|
89580280|NCT02395172|Active Comparator|Docetaxel|
89580281|NCT04876027|Experimental|GLP-1 RAs and calorie restrict diet group|Intervention with GLP-1 RAs and calorie restrict diet until reaching the target weight loss(7%)
89580282|NCT04876027|Active Comparator|calorie restrict diet group|Intervention with calorie restrict diet until reaching the target weight loss(7%)
88973570|NCT04872959|No Intervention|Usual Care Arm|Will not use HealthReveal to titrate the doses of Entresto/ other treatments for HFrEF.
88973571|NCT04872959|Experimental|Interventional- Health Reveal|"The interventional arm will be provided tools to augment quality of care and build the patient and physician relationship through trust and shared goal-setting.~Prior to each patient appointment, on a customized GDMT Dashboard, the site will receive a pre-visit assessment of GDMT accompanied by recommended adjustment(s) using information extracted weekly from the sites' electronic health record (EHR). The recommended adjustment(s) will be conveyed using proprietary software from HealthReveal, with a suggested follow up plan. All reminders regarding dosing targets are based on the 2020 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment.~Additionally, during visits at baseline, 3 months, and 6 months, patient-reported outcomes/QOL will be assessed."
89580283|NCT04859101|Experimental|Gum|Group 1 will receive gum immediately prior to transport to the operating room. They will be asked to chew the gum for 2 minutes and then spit the gum in the garbage.
89580284|NCT04859101|Other|Control|Group 2 will not receive any gum. They will be asked to swallow twice and have no other intervention.
89580285|NCT02276053||BTRE patients|Patients with brain tumor-related epilepsy (BTRE) routinely treated with lacosamide as add on to one or two baseline anti-epileptic drugs.
89580286|NCT02275819|No Intervention|control|Will not receive intervention with exercise
89580287|NCT02275819|Active Comparator|Intervention group|2 groups will receive 2 different types of therapy (exercise or Inspiratory Muscle Therapy)
89580288|NCT02358044|Experimental|Grazoprevir + Elbasvir|Participants receive a fixed-dose combination (FDC) tablet of 100 mg grazoprevir and 50 mg elbasvir for 12 weeks, followed by 24 weeks of follow-up.
89580289|NCT02358044|Active Comparator|SOF + PR|Participants receive SOF (400 mg) combined with PegIntron (1.5 mcg/kg) plus RBV (1000-1200 mg weight-based dose) for 12 weeks, followed by 24 weeks of follow-up.
89580290|NCT02275117|Experimental|ALD403 Dose Level 1|ALD403 Dose Level 1 (IV)
89580291|NCT02275117|Experimental|ALD403 Dose Level 2|ALD403 Dose Level 2 (IV)
89580292|NCT02275117|Experimental|ALD403 Dose Level 3|ALD403 Dose Level 3 (IV)
88973572|NCT04872491||Participants With UC or CD|Participants diagnosed with UC or CD who are prescribed and will start treatment with vedolizumab 300 milligram (mg), infusion, intravenously, at Weeks 0, 2, 6, and every 8 weeks thereafter for up to 54 weeks will be observed prospectively for 72 weeks.
88973573|NCT04864951|Other|Transpeople|"1x urine sampling for HPV analysis~1x survey"
88973574|NCT04864366||Treatment naive patients|"HBV DNA> 20000 IU/ml~ALT>2×ULN；or ALT>1×ULN，but liver biopsy showed inflammation greater than or equal to G2, or/and liver fibrosis greater than or equal to S2~No treatment with NA or/or αIFN within 1 year"
88973575|NCT04864366||ETV treatment experienced patients|"ETV treatment for 1 to 2 years before~HBsAg>3000IU/mL~HBV DNA<20IU/mL~ALT<1×ULN~No other NA therapy prior to entecavir treatment~Patients had a desire to convert to TAF therapy"
88973576|NCT04861688|Active Comparator|NeuroAiD II™ (MLC901)|Recommended treatment is 2 capsules orally, 3 times a day (i.e. 6 capsules per day). Treatment is 12 weeks.
88973577|NCT04861688|Placebo Comparator|Placebo|Capsule 2 capsules orally, 3 times a day
88973578|NCT04859296|Placebo Comparator|Placebo|0 mg CBG, 0 mg THC
88973579|NCT04859296|Active Comparator|Low strength CBG|5 mg CBG, 0 mg THC
88973580|NCT04859296|Active Comparator|High strength CBG|15 mg CBG, 0 mg THC
88973581|NCT04859296|Active Comparator|Low strength THC|0 mg CBG, 5 mg THC
89209425|NCT00883506|Active Comparator|2|Lisinopril 40 mg Tablet (Zestril)
89209426|NCT00883506|Experimental|3|Lisinopril 40 mg Tablet under fasting conditions.
89580293|NCT02275117|Experimental|ALD403 Dose Level 4|ALD403 Dose Level 4 (IV)
89580294|NCT02275117|Placebo Comparator|Placebo|Placebo (IV)
89580295|NCT05649475||Patients receiving neoadjuvant therapy|
89580296|NCT05649319|Experimental|ERAS group|Perioperative care for laparoscopic distal gastrectomy is managed according to ERAS protocol.
89580297|NCT05649319|No Intervention|Conventional group|Perioperative care for laparoscopic distal gastrectomy is managed according to our current perioperative practice.
89580298|NCT05649241|Experimental|QuitAid, 8 weeks, Patch + Gum|Participants received QuitAid, a medication therapy management delivered by their pharmacists and 8 weeks of Nicotine Replacement Therapy (NRT) in the form of the NRT Patch and the NRT Gum
89580299|NCT05649241|Experimental|QuitAid, 4 weeks, Patch + Gum|Participants received QuitAid, a medication therapy management delivered by their pharmacists and 4 weeks of Nicotine Replacement Therapy (NRT) in the form of the NRT Patch and the NRT Gum
89580300|NCT05649241|Experimental|QuitAid, 8 weeks, Patch|Participants received QuitAid, a medication therapy management delivered by their pharmacists and 8 weeks of Nicotine Replacement Therapy (NRT) in the form of the NRT Patch
88973582|NCT04859296|Active Comparator|High strength THC|0 mg CBG, 30 mg THC
88973583|NCT04859296|Active Comparator|Low strength CBG + Low strength THC|5 mg CBG + 5 mg THC
88973584|NCT04859296|Active Comparator|Low strength CBG + High strength THC|5 mg CBG + 15 mg THC
88973585|NCT04859296|Active Comparator|High strength CBG + Low strength THC|15 mg CBG + 5 mg THC
88973586|NCT04859296|Active Comparator|High strength CBG + High strength THC|15 mg CBG + 15 mg THC
88973587|NCT04857684|Experimental|Stereotactic beam radiation therapy (SBRT) +Atezolizumab + Bevacizumab|"Participants will:~undergo a pre-treatment biopsy with fiducial marker placement~receive Stereotactic beam radiation therapy (SBRT) on three treatment days which will be arranged on an every-other-day basis~receive two 3-week (21 days) cycles of atezolizumab plus bevacizumab~receive Atezolizumab on day 1 for 2 study cycles.~receive Bevacizumab 1x weekly for 2 study cycles~Surgery after SBRT and the two cycles of atezolizumab and bevacizumab, unless participants are otherwise informed by their doctor. The planned surgery will take place 6-8 weeks after the last infusions of atezolizumab and bevacizumab."
88973588|NCT04846348|Experimental|Skin Guard|"Skin cream combination of ingredients includes 2 agents which target mast cell mediators and one agent which globally reduces mast cell degranulation combined in an emollient cream base:~Vanicream: Over the counter emollient cream Diphenhydramine Antihistamine Trolamine salicylate Prostaglandin inhibitor, antiinflammatory Cromolyn Sodium Mast cell degranulation inhibitor"
88973589|NCT04837677|Experimental|PRT1419|PRT1419 will be administered by intravenous infusion
88973590|NCT04828707|Active Comparator|Migraine prevention treatment with active Nerivio|Participants will treat with an active Nerivio device every other day for migraine prevention.
88973591|NCT04828707|Sham Comparator|Migraine prevention treatment with sham Nerivio|Participants will treat with a sham (placebo) Nerivio device every other day for migraine prevention.
89209427|NCT04268784|Experimental|DNL343|Cohort A: Single-ascending dose; Cohort B: Multiple-ascending doses
89209428|NCT04268784|Placebo Comparator|Placebo|Cohort A: Single-ascending dose; Cohort B: Multiple-ascending doses
89209429|NCT00278473|Experimental|Meta-Cognitive Therapy|Cognitive behavioral group. Cognitive behavioral therapy focuses on changing patterns of thinking and behavior. Each group consists of 6 to 8 members and sessions are led by a psychologist.
89209430|NCT00278473|Active Comparator|Supportive Therapy|Social support problem-solving group. Social support problem-solving focuses on general support, problem solving, and information sharing. Each group consists of 6 to 8 members and sessions are led by a psychologist.
88973592|NCT04792541|Placebo Comparator|control group|saline solution
88973593|NCT04792541|Experimental|test group|HY containing gel; GUM® Afta Clear Gel, Sunstar
88973594|NCT04774575|No Intervention|routine group|Patients will follow a standard clinical follow-up based on kidney allograft function (serum creatinine, estimated glomerular filtration rate (eGFR), proteinuria) and a surveillance allograft biopsies performed at 3 and 12 months after transplantation (M3 and M12). Visits with biopsies for clinical indication are left to the appreciation of the investigator
88973595|NCT04774575|Experimental|biomarker guided follow-up|"Patients will follow a biomarker-guided strategy based on specific non-invasive biomarkers as defined in EUTRAIN-1 study on the basis of its detection and prediction capacities for rejection at M3 to decide whether a biopsy is performed. At M12 a routine biopsy is performed.~Visits with biopsies for clinical indication are left to the appreciation of the investigator"
88973596|NCT04771793||Group A- before implentation of physical restraint protocols|
88973597|NCT04771793||Group B- after implentation of physical restraint protocols|
88973598|NCT04771520|Experimental|Treatment (avapritinib)|Patients receive avapritinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88973599|NCT04769453|Active Comparator|iTrack canaloplasty microcatheter with Healon GV Pro|Patients will be randomized to the iTrack microcatheter (canaloplasty) with Healon GV Pro (ophthalmic viscoelastic device)
88973600|NCT04769453|Active Comparator|OMNI surgical system with Healon GV Pro|Patients will be randomized to the OMNI surgical system (canaloplasty) with Healon GV Pro (ophthalmic viscoelastic device)
88973601|NCT04769453|Active Comparator|iTrack canaloplasty microcatheter with Healon Pro|Patients will be randomized to the iTrack microcatheter (canaloplasty) with Healon Pro (ophthalmic viscoelastic device)
88973602|NCT04769453|Active Comparator|OMNI surgical system with Healon Pro|Patients will be randomized to the OMNI surgical system (canaloplasty) with Healon Pro (ophthalmic viscoelastic device)
88973603|NCT04767360|Other|Open labele BIONESS-Training|Four-week therapeutic treatment of foot drop with the electrical stimulation device Bioness L300. This treatment will be performed five times a week for at least 30 minutes
88973604|NCT04765722|Experimental|Mepolizumab arm|Mepolizumab Dosage form: 1ml pre-filled syringe Dosage: 100mg Frequency: 3 doses at days 0, 28, 56 and 84 Duration: 12 weeks
88973605|NCT04765722|Placebo Comparator|Placebo arm|Normal Saline (0.09% normal saline) Dosage form: 1ml pre-filled syringe Dosage: n/a Frequency: 3 doses at days 0, 28, 56 and 84 Duration: 12 weeks
88973606|NCT04758351||Cases - Patients with chronic cough|Patients referred to secondary care clinic for investigation and treatment for explained chronic cough, refractory chronic cough, and unexplained chronic.
88973607|NCT04742699|Experimental|Z-Drug-mono cohort|Patients being treated with Z-drug monotherapy at registration
88973608|NCT04742699|Experimental|SUV-mono cohort|Patients being treated with SUV monotherapy at registration
88973609|NCT04742699|Experimental|SUV-combination cohort|Patients being treated with SUV and BZRA combination therapy at registration
88973610|NCT04742699|Experimental|RMT-combination cohort|Patients being treated with RMT and BZRA combination therapy at registration
88973611|NCT04740723|Experimental|Renal denervation|Renal denervation with the iRF system
88973612|NCT04685707|Active Comparator|Active-Sedentary Control|
88973613|NCT04685707|Experimental|Active-Sedentary Experimental|
89209431|NCT04037280|Experimental|Isometric strenghtening 1|once a day (1RI): patients in this group will have to play 20 tonic contractions of Pelvic Floor Muscle with a duration of 5 seconds each, performed in supine position), in sitting position and in standing position.
89209432|NCT04037280|Experimental|Isometric strenghtening 2|twice a day (2RI): patients in this group will have to play the same typology of exercises in the same way just described (see above), but twice a day (in the morning and in the evening).
88973616|NCT04672889|Placebo Comparator|Placebo|consume 1 sachet per day for 1 months
88973617|NCT04672889|Experimental|Babyguard® Breast Milk Probiotics|consume 1 sachet per day for 1 months
88973618|NCT04642963|Experimental|Cardiac Radiosurgery|Patients with ventricular tachycardia will undergo a non-invasive cardiac radiosurgery using one fraction of 25 Gy to the arrhythmia substrate, as determined by the electrophysiological cardiac mapping.
88973619|NCT04629534|Experimental|Group A|
88973620|NCT04629534|Placebo Comparator|Group B|
89580301|NCT05649241|Experimental|QuitAid, 4 weeks, Patch|Participants received QuitAid, a medication therapy management delivered by their pharmacists and 4 weeks of Nicotine Replacement Therapy (NRT) in the form of the NRT Patch
89580302|NCT05649241|Experimental|No QuitAid, 8 weeks, Patch + Gum|Participants received 8 weeks of Nicotine Replacement Therapy (NRT) in the form of the NRT Patch and the NRT Gum
89580303|NCT05649241|Experimental|No QuitAid, 4 weeks, Patch + Gum|Participants received 4 weeks of Nicotine Replacement Therapy (NRT) in the form of the NRT Patch and the NRT Gum
89580304|NCT05649241|Experimental|No QuitAid, 8 weeks, Patch|Participants received 8 weeks of Nicotine Replacement Therapy (NRT) in the form of the NRT Patch
89580305|NCT05649241|Experimental|No QuitAid, 4 weeks, Patch|Participants received 4 weeks of Nicotine Replacement Therapy (NRT) in the form of the NRT Patch
88973621|NCT04628728||Current referral letters|One letter will be chosen from the selection of current referral letters (of average quality according to the results of the study mentioned above). Any data that would allow identification of the respective patient (i.e. name, date of birth, social insurance number, address) will be anonymised (not blackened in order not to disturb fluent reading).
88973622|NCT04628728||New referral letters|The other one will be a corrected version of the first letter according to the ELGA (Elektronische Gesundheitsakte) requirements and the identified needs of patients and stakeholders (see Previous Work 1).
88973623|NCT04621708|Experimental|Left DLPFC iTBS rTMS|
88973624|NCT04612335|Experimental|Watchful waiting|the watchful-waiting approach consists of administration of rate control medication to obtain relief of symptoms and a heart rate <110 beats per minute, followed by a telemetric rhythm monitoring period of four weeks to guide rate control therapy.
88973625|NCT04612335|Other|Routine care|Routine care consists of the standard treatment for an acute episode of recent-onset symptomatic atrial fibrillation, namely acute or delayed cardioversion, followed by a telemetric rhythm monitoring period of four weeks to guide rate control therapy.
88973626|NCT04610944|Experimental|Intervention|Intervention nursing homes will receive the training and control nursing homes will complete assessments, but not receive the training.
88973627|NCT04610944|Active Comparator|Waitlist Control|After the intervention nursing homes complete the training, the waitlist control nursing homes will crossover and complete the training.
88973628|NCT04606433|Experimental|Study treatment|The patients received intravenous infusion of GNC-038 for 1 cycle. After the completion of 2 cycles of treatment, participants with no unbearable ae could proceed to the 3rd and 4th cycles of treatment. After four cycles of treatment, participants with clinical benefits could also receive four additional cycles of the same dose.
88973629|NCT04602806||Moderate to Severe TBI Subjects|Adult patients (age 18-65y inclusive) presenting to the Emergency Department (ED) with a history of acute TBI as per American Congress of Rehabilitation Medicine (ACRM) Criteria (i.e., patient has sustained a traumatically-induced physiological disruption of brain function).
88973630|NCT04602065|Experimental|Previously received anti-PD1/PD-L1 antibodies|Patients previously received anti-PD1/PD-L1 antibodies, except for those were primarily refractory to them.
88973631|NCT04602065|Experimental|Patients previously never received anti-PD1/PD-L1 antibodies|Patients previously never received anti-PD1/PD-L1 antibodies.
88973632|NCT04598815|Experimental|Sirolimus|Sirolimus for 12 weeks
88973633|NCT04598815|Experimental|Methylprendnisolone|Methylprednisolone for 12 weeks
88973634|NCT04584112|Experimental|Cohort A: Tiragolumab and Atezolizumab + Nab-paclitaxel|Participants with first-line metastatic TNBC will receive tiragolumab and atezolizumab on Day 1 of every 28-day cycle plus nab-paclitaxel on Days 1, 8, and 15 of every 28-day cycle.
88973635|NCT04584112|Experimental|Cohort B: Tiragolumab and Atezolizumab + Nab-pac-carbo-AC|Participants with early TNBC in the neoadjuvant setting, who are eligible for surgery, will receive tiragolumab and atezolizumab every 2 weeks (Q2W) in combination with nab-paclitaxel weekly (QW) and carboplatin every 3 weeks (Q3W) for four cycles, followed by tiragolumab and atezolizumab in combination with doxorubicin and cyclophosphamide Q2W with granulocyte colony-stimulating factor (G-CSF; filgrastim or pegfilgrastim) or granulocyte-macrophage colony-stimulating factor (GM-CSF) support for four doses.
88973636|NCT04584112|Experimental|Cohort B: Tiragolumab and Atezolizumab + Nab-pac-AC|Participantswith early TNBC in the neoadjuvant setting, who are eligible for surgery, will receive tiragolumab and atezolizumab Q2W in combination with nab-paclitaxel QW for 12 weeks, followed by tiragolumab and atezolizumab in combination with doxorubicin and cyclophosphamide Q2W with G-CSF (filgrastim or pegfilgrastim) or GM-CSF support for four doses.
88973637|NCT04580238|Experimental|Treatment Arm|The treatment group will consist of 40 patients randomly allocated to receiving Botox according to the treatment regime.
88973638|NCT04580238|Active Comparator|Control|The control group will consist of 40 patients randomly allocated to Non-Botox, standard of care treatments, to a total study population of 80 patients.
88973639|NCT04573777|Experimental|Intervention Repatha|
88973640|NCT04567004|Other|Control|The control arm will show the products with no label.
88973641|NCT04567004|Experimental|Nutriscore Label|The Nutriscore label applies a letter grade (A, B, C, D or E) to a product based on certain nutrient criteria.
88973642|NCT04567004|Experimental|Adapted Peruvian Nutrient Label|"The adapted label is a black octagon with the words in Spanish saying Excess of sugar,Excess of saturated fat, or Excess of salt/sodium depending on the nutrition contents of the product. Below the octagon is a box with words in Spanish saying Avoid high consumption"
88973643|NCT04567004|Experimental|Guideline Daily Amount Label|The Guideline Daily Amount label highlights the nutrient contents of the product by serving. It lists the calories, total fat, saturated fat, sugar, and sodium, as well are their % of the daily value.
88973644|NCT04564105|Other|Staff of the ICU|The whole staff (nurses and doctors) of the ICU will be recruited to this trial. When they give their informed consent, video-recording of the intubations will be started. After 20 videos, simulations will be run. Also simulations will be recorded. Thereafter 20 further real-life intubations will be recorded. Staff intubating patients before and after won't be same but they will be adjusted for experience related to intubations.
88973645|NCT04555590|No Intervention|Pre H-HOPE Cohort|The Pre-H-HOPE Comparison Cohort will not receive the H-HOPE intervention, and represents the prior standard (non-HOPE).
88973646|NCT04555590|Experimental|H-HOPE Cohort|The H-HOPE Cohort will receive the H-HOPE intervention.
88973647|NCT04521972|Active Comparator|Group 1|Natural non-augmented labor with room lights ON. This is what is currently done in the hospital, and thus does not change any current medical practices.
88973648|NCT04521972|Active Comparator|Group 2|Augmented labor with room lights ON. This group will be a subgroup of Group 1 (Natural non-augmented labor with room lights ON), as labor-augmentation cannot be planned for until the patient is in labor or labor needs to be augmented for medical reasons.
88973649|NCT04521972|Experimental|Group 3|Natural non-augmented labor with reduced or red room lights.
89029728|NCT01249508|Experimental|implemented nutrition label|A one-group pre-/post-design is used for the evaluation of the university canteen-based nutrition labeling program. This means that all participants of the program are exposed to the nutrition label implemented in the university canteen. The subject essentially serves as its own control based on pre-test behaviour. The nutrition label implemented is a star rating label calculated and assigned to each meal offered at the university canteens and based on the content of energy, saturated fat, sodium and fibre (expressed as vegetable portion).
89029729|NCT00510393|Experimental|1|drug eluting stent
89029730|NCT00510393|Placebo Comparator|2|Bare Metal Stent
89029731|NCT01249547|Experimental|axitinib arm|
89029732|NCT02952339|Experimental|RSV LID ΔM2-2 1030s vaccine|Participants will receive a single dose of the RSV LID ΔM2-2 1030s vaccine at Day 0.
89029733|NCT02952339|Placebo Comparator|Placebo|Participants will receive a single dose of placebo vaccine at Day 0.
89029734|NCT02952495|Experimental|Online alcohol educational class|Participants will be asked to review an online alcohol education class. This is a web-based patient educational program designed to prevent hazardous and harmful drinking in older adults.
89029735|NCT02952495|No Intervention|No intervention|Participants will NOT Participate in the online alcohol education class.
89029736|NCT01249586|Placebo Comparator|Traditional teaching|A traditional class of blindness prevention.
89029737|NCT00511719|Experimental|Technosphere Insulin|Technosphere Insulin Inhalation Powder
89029738|NCT00511719|Active Comparator|Actrapid|Subcutaneous regular human insulin
89029739|NCT00504686|Active Comparator|1|manual therapy - thoracic spine thrust manipulation
89029740|NCT00504686|Active Comparator|2|therapeutic exercise
89029741|NCT00511758||Digital Imaging Device|Patients with a diagnosis of cervical dysplasia that are scheduled for a colposcopy.
89029742|NCT01245335|Active Comparator|BMAC Treatment|Intervention- Injection of 40 ml of autologous bone marrow concentrate (BMAC injection) prepared with the SmartPReP2 BMAC System
89029743|NCT01245335|Placebo Comparator|Placebo Injection|Injection of placebo (diluted peripheral blood) into ischemic tissue of the lower extremity
89029744|NCT00511368|Placebo Comparator|1|placebo
89029745|NCT00511368|Experimental|2|Bevirimat
89029746|NCT01246232|Experimental|Amisulpride|400mg, 2 x 200mg amisulpride capsules for the first 4 weeks, then the option of titrating up to 800mg, 4 x 200mg amisulpride capsules for the remaining 8 weeks.
89029747|NCT01246232|Placebo Comparator|Placebo|400mg, 2 x 200mg amisulpride capsules, or 2 matching placebo capsules for the first 4 weeks, then the option of titrating up to 800mg, 4 x 200mg amisulpride capsules, or 4 matching placebo capsules for the remaining 8 weeks.
89029748|NCT00511407|Experimental|I|RAD Treatment
89029749|NCT00511407|No Intervention|II|Conventional CVVHD
89029750|NCT01248962|Experimental|Standard 30-minute infusion|This is a non-blinded randomized study comparing standard 30-minute infusion carboplatin to extended 3-hour infusion carboplatin in women with recurrent, ovary, fallopian tube, and primary peritoneal cancer who will be treated with a carboplatin containing chemotherapy regimen.
89029751|NCT01248962|Experimental|extended 3-hour infusion|This is a non-blinded randomized study comparing standard 30-minute infusion carboplatin to extended 3-hour infusion carboplatin in women with recurrent, ovary, fallopian tube, and primary peritoneal cancer who will be treated with a carboplatincontaining chemotherapy regimen.
89029752|NCT02952183|Experimental|PAMS I|During operation, autonomic nerve monitoring will be performed by PAMS I which is composed of two urodynamic systems.
89029753|NCT00511446|Experimental|1|docetaxel, oxaliplatin, capecitabine
89029754|NCT02956109|Active Comparator|Adult formulation: Finerenone tablet_Fasting|Single oral dose of 10 mg finerenone tablet fasting
89029755|NCT02956109|Experimental|Pediatric formulation: 5X 0.25 mg Finerenone ODT_Fasting|Single oral dose of 5 x 0.25 mg finerenone oro-dispersible tablets fasting
89029756|NCT02956109|Experimental|Pediatric formulation: 1.25 mg Finerenone ODT_Fasting|Single oral dose of 1.25 mg finerenone oro-dispersible tablet fasting
89029757|NCT02956109|Experimental|Pediatric formulation: 1.25 mg Finerenone ODT_Fed|Single oral dose of 1.25 mg finerenone oro-dispersible tablet fed; 30 minutes after start of an American breakfast
89029758|NCT02952300|Experimental|neolix|single full rotation file (Neolix ® Neolix ,France) the first file used is C1 file size 25 taper 12% as orifice opener and for coronal flaring for 2/3 of canal length the A1 file size 25 taper 8% in narrow or curved canals if size 10 K file (Mani Inc., Japan). is passively fit in the canal (most of the canals) , but in case of K-file (Mani Inc., Japan) size 20 loose in the canal so we choose large file size 40 taper 4% either of them to the full working length of the canal
89029759|NCT02952300|Active Comparator|wave one|single reciprocating file (Wave One ® Dentsply , Switzerland) the canal preparation is done by primary file size 25 taper 8% in narrow or curved canals if size 10 K file (Mani Inc., Japan) is passively fit in the canal ( most of canals ) , but in case of K-file (Mani Inc., Japan) size 20 loose in the canal so we choose large large file size 40 taper 8% either of them to the full working length of the canal
89029760|NCT00511524|Experimental|Subjects receiving GW842166|Subjects will receive single oral dose of 400 milligram (mg) un-labeled GW842166X. After 2-5 hours subjects will receive [carbonyl-^11C]GW842166.
89029761|NCT01249781||resilience in caregivers whose child with ALL|
89029762|NCT00511563|Experimental|GW876008 and GSK561679|GW876008 and GSK561679
89029763|NCT02955368|Experimental|DP-R212 group|DP-R212 + C1-R212 placebo + C2-R212 placebo
89029764|NCT02955368|Active Comparator|C1-R212 group|DP-R212 placebo + C1-R212 + C2-R212 placebo
89029765|NCT02955368|Active Comparator|C2-R212 group|DP-R212 placebo + C1-R212 placebo + C2-R212
89580306|NCT02274493|Experimental|Robotic Harvest of the LD Muscles|Surgical harvesting of the Latissimus Dorsi (LD) Muscles using da Vinci® robotic surgical system in participants undergoing LD muscle flap harvest procedures in conjunction with breast, scalp, upper extremity and lower extremity reconstructive surgery procedures.
89580307|NCT02273167|Experimental|NER1006, 2-Day Split-Dosing|NER1006: 2-Day Split-Dosing Regimen (to commence in the evening of the day before colonoscopy).
89580308|NCT02273167|Experimental|NER1006,1-Day Morning Split-Dosing|NER1006: 1-Day Morning Split-Dosing Regimen (to commence in the morning of the day of colonoscopy).
89580309|NCT02273167|Active Comparator|MOVIPREP, 2-Day Split-Dosing|MOVIPREP®: 2-Day Split-Dosing Regimen (to commence in the evening of the day before colonoscopy).
89580310|NCT02272777|Active Comparator|Imatinib|Eligible patients from imatinib arm in core study CAMN107ECN02 were enrolled into imatinib arm in this study. Patients in imatinib 400 mg daily arm received imatinib daily dose of 300 mg, 400 mg or 600 mg all at once every day.
89580311|NCT02272777|Experimental|Nilotinib|Eligible patients from nilotinib arm in core study CAMN107ECN02 were enrolled into imatinib arm in this study. Patients in nilotinib arm received 300 mg BID by mouth each morning and evening approximately 12 hours apart, or 400 mg QD.
89580312|NCT02357810|Experimental|Treatment (pazopanib hydrochloride, topotecan hydrochloride)|Patients receive pazopanib hydrochloride PO QD on days 1-28 and topotecan hydrochloride PO on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89029766|NCT00511602|Experimental|Technosphere Insulin Inhalation Powder|
89029767|NCT00511602|Placebo Comparator|Technosphere Inhalation Powder|
89029768|NCT00511641||Low Risk OVCA|Patient that is participating in an ovarian cancer (OVCA) screening program.
89029769|NCT01248455|Experimental|anti-KIR in Smoldering Multiple Myeloma Patients|Patients will receive anti-KIR(IPH2101) (1mg/kg) every other month for 6 cycles
89029770|NCT00511680|Experimental|Behavioral based In-home Intervention|This group will recieve up to 10 1-hour sessions over a 4 month period.
89029771|NCT00511953|Active Comparator|Gabapentin ER|Active drug, Gabapentin extended release
89029772|NCT00511953|Placebo Comparator|Sugar Pill|Comparator arm is Placebo
89029773|NCT01249820|Experimental|group A|Day 1-15: anidulafungin 200 mg q48h IV maintenance dose (8 dosages)
89029774|NCT01249820|Experimental|group B|Day 1-13: anidulafungin 300 mg q72h IV maintenance dose (5 dosages)
89029775|NCT02952378|Experimental|Burn patients|Patients with burns exceeding 6-8 Total Burned Surface Area %
89029776|NCT02952378|Experimental|Healthy individuals|Healthy individuals without allergies.
89580313|NCT04858243|Active Comparator|Facility-Based ART|Men escorted to nearest health facility for ART initiation and continuation.
89580314|NCT04858243|Experimental|Home-Based ART|Home-based ART initiation and continuation provided for 3-months.
89029777|NCT01249859||Signet ring cell carcinoma|
89029778|NCT01249859||non signet ring cell adenocarcinoma|
89029779|NCT01247090|Active Comparator|Group 1: Vasopressin - Very Low Dose|0.15 mU per kg per minute
89029780|NCT01247090|Active Comparator|Group 2: Vasopressin - Low Dose|0.30 mU per kg per minute
89029781|NCT01247090|Placebo Comparator|Group 3: Placebo|No Dose
89029782|NCT02952105||defibrillation patients|shockable rhythm, defibrillated
89029783|NCT02952105||non defibrillation patients|non-shockable rhythm, non defibrillated
89029784|NCT02952417||STEMI and NSTEMI Women|Women with ST-segment elevation myocardial infarction (STEMI) and women non-STEMI (NSTEMI) who survived following acute myocardial infarction and at risk of excess mortality.
89580315|NCT02357576|Experimental|Reduced Lipid|Subjects will receive a minimized dose (1 g/kg/day) of the soybean-based lipid component of parenteral nutrition.
89580316|NCT02357576|Active Comparator|Standard Lipid|Subjects will receive the standard dose (up to 3 g/kg/day) of the soybean-based lipid component of parenteral nutrition.
89580317|NCT01850446|Experimental|Ergoferon|The treatment period is 5 days. Oral Dose per administration: 1 tablet. The tablet should be kept in the mouth until completely dissolution, the drug is taken without regard to food intake.
89580318|NCT01850446|Active Comparator|Oseltamivir (Tamiflu)|"The treatment period is 5 days.~1 capsule (75 mg) twice a day during the meal or regardless of meal."
89580319|NCT02465567|Experimental|BGF (PT010) MDI 320/14.4/9.6 μg|BGF MDI 320/14.4/9.6 μg, Budesonide, Glycopyrronium, Formoterol Fumarate Aerosol (PT010, BGF metered dose inhaler [MDI])
89580320|NCT02465567|Experimental|BGF (PT010) MDI 160/14.4/9.6 μg|BGF MDI 160/14.4/9.6 μg, Budesonide, Glycopyrronium, Formoterol Fumarate Aerosol (PT010, BGF metered dose inhaler [MDI])
89580321|NCT02465567|Experimental|BFF (PT009) MDI 320/9.6 μg|BFF MDI 320/9.6 μg Budesonide, Formoterol Fumarate Aerosol Glycopyrronium and Formoterol Fumarate Inhalation Aerosol (PT009)
89580322|NCT02465567|Experimental|GFF (PT003) MDI 14.4/9.6 μg|GFF MDI 14.4/9.6 μg Glycopyrronium, Formoterol Fumarate Aerosol Budesonide and Formoterol Fumarate Inhalation Aerosol (PT003)
89580323|NCT01644175|Placebo Comparator|Placebo Q2W|Placebo (for alirocumab) every 2 weeks (Q2W) added to stable Lipid-Modifying Therapy (LMT) for 52 weeks.
89580324|NCT01644175|Experimental|Alirocumab|Alirocumab 75 mg Q2W added to stable LMT for 52 weeks. Alirocumab dose up-titrated to 150 mg from Week 12 when LDL-C levels ≥70 mg/dL (1.81 mmol/L) at Week 8.
89580325|NCT02357420|Experimental|Relamorelin 10 μg|Relamorelin 10 microgram (μg) was administered subcutaneously (SC) by injection twice daily (BID) for 12 weeks.
88973650|NCT04521972|Experimental|Group 4|Augmented labor with reduced or red room lights. This group will be a subgroup of Group 3, as augmented labor cannot be planned for until the patient is in labor or labor needs to be augmented for medical reasons.
88973651|NCT04507711|Experimental|0 ng/ml|Blood specimen which was added of 0 ul of palonosetron
88973652|NCT04507711|Experimental|25 ng/ml|Blood specimen which was added of 1 ul of palonosetron
88973653|NCT04507711|Experimental|250 ng/ml|Blood specimen which was added of 10 ul of palonosetron
88973654|NCT04507711|Experimental|2500 ng/ml|Blood specimen which was added of 100 ul of palonosetron
88973655|NCT04499274|Experimental|0 ng/ml|Blood specimen which was added 0 ul of ondansetron
88973656|NCT04499274|Experimental|200 ng/ml|Blood specimen which was added 0.20 ul of ondansetron
88973657|NCT04499274|Experimental|2000 ng/ml|Blood specimen which was added 2 ul of ondansetron
88973658|NCT04499274|Experimental|20000 ng/ml|Blood specimen which was added 20 ul of ondansetron
88973659|NCT04496895|Placebo Comparator|Placebo|consume 1 sachet per day for 2 months
88973660|NCT04496895|Experimental|orange peel fermentation|consume 1 sachet per day for 2 months
88973661|NCT04492605|Placebo Comparator|Placebo|Placebo
88973662|NCT04492605|Experimental|TCI378 Probiotics|TCI378 Probiotics
88973663|NCT04492605|Experimental|TCI507 Probiotics|TCI507 Probiotics
88973664|NCT04490720|Placebo Comparator|Placebo|consume 1 sachet per day for 2 months
88973665|NCT04490720|Experimental|Buckwheat husk extract|consume 1 sachet per day for 2 months
88973666|NCT04481191|Experimental|Concomitant RotaTeq and IPV|Participants will receive RotaTeq (2 mL oral dose) and IPV (0.5 mL intramuscular [IM] injection ) concomitantly at Visit 2 (15 to 21 days after Visit 1 [Day 1]), Visit 4 (30 to 42 days after Visit 2), and Visit 6 (30 to 42 days after Visit 4).
89580326|NCT02357420|Experimental|Relamorelin 30 μg|Relamorelin 30 μg was administered SC by injection BID for 12 weeks.
89580327|NCT02357420|Experimental|Relamorelin 100 μg|Relamorelin 100 μg was administered SC by injection BID for 12 weeks.
88973667|NCT04481191|Active Comparator|Staggered RotaTeq and IPV|Participants will receive RotaTeq (2 mL oral dose) at Visit 1 (Day 1), Visit 3 (30 to 42 days after Visit 1), and Visit 5 (30 to 42 days after Visit 3); and IPV (0.5 mL IM injection) at Visit 2 (15 to 21 days Visit 1), Visit 4 (30 to 42 days after Visit 2), and Visit 6 (30 to 42 days after Visit 4).
88973668|NCT04478578||Patients with febrile illness|Participants from approximately 650 villages, with a target number of 100,000 episodes of febrile illness, will be enrolled into this study.
88973669|NCT04448327|Experimental|Active tVNS|Expiratory-gated transcutaneous vagus nerve stimulation on the left auricle
88973670|NCT04448327|Sham Comparator|Sham tVNS|Sham transcutaneous vagus nerve stimulation on the left auricle
88973671|NCT04445909||VA-ECMO patients|VA-ECMO support because of low cardiac output.
89580328|NCT02357420|Placebo Comparator|Placebo|Placebo-matching relamorelin was administered SC by injection BID for 12 weeks.
89580329|NCT05648461|Experimental|Five fraction of post operative Radiotherapy|The present study is a non -randomised phase II study that will enroll 50 patients and test feasibility of 30 Gy in 5 fractions of the primary disease and ipsilateral level I-III disease.
89580330|NCT04856761||Cape Group|In this group, capecitabine was administered at a dose of 1250 mg/m² bid on 14 days of a tri-weekly cycle for 8 cycles.
89580331|NCT04856761||S-1 Group|In this group, S-1 was administered at a dose of 80-120 mg/day on 14 days of a tri-weekly cycle for 8 cycles.
89580332|NCT01832038|Experimental|Lacosamide|Lacosamide treatment of 100 - 400 mg/day for long-term
88973672|NCT04421690|Experimental|Cognitive Training|8 week computerized cognitive training
88973673|NCT04421690|Active Comparator|Trivia Training|8 week computerized trivia training
89029785|NCT02952417||STEMI and NSTEMI Men|Men with ST-segment elevation myocardial infarction (STEMI) and women non-STEMI (NSTEMI) who survived following acute myocardial infarction and at risk of excess mortality.
89029786|NCT00512967||sarcoidosis|21 onset patients, non-treated
89029787|NCT00512967||IPF|15 IPF patients, partially treated
88973674|NCT04406948|Experimental|MGCND00EP1|"Participants who will assigned to receive add on MGCND00EP1 will receive carrier oil containing THC and CBD in ratio 20:1, (10% of cannabidiol and 0.5 % and (-)-trans-Δ9-tetrahydrocannabinol) .~Titration Dose: 1 to 2 mg/kg body weight/day. dose will be increased every week by 2 mg/kg body weight/day up to a maximum 25 mg/kg body weigh/day or maximum daily dose 800 mg (the smaller of those 2 values) (divided into two daily doses).~After titration, patients will be receiving a stable maintenance dose of IMP (up to 25 mg/kg BW per day or maximum daily dose 800 mg (whichever smaller)) for 6 weeks period.~During forth treatment period participants will commence a 2 weeks down-titration taper period, followed by 4 weeks observational follow up period of previous standard AE treatment without IMP."
88973675|NCT04406948|Placebo Comparator|PLACEBO|"Participants who are assigned to receive add on PLACEBO will be administered the carrier oil (without the active ingredients).~Titration Dose: 1 to 2 mg/kg body weight/day. dose will be increased every week by 2 mg/kg body weight/day up to a maximum 25 mg/kg body weigh/day or maximum daily dose 800 mg (the smaller of those 2 values) (divided into two daily doses).~After titration, patients will be receiving a stable maintenance dose of IMP (up to 25 mg/kg BW per day or maximum daily dose 800 mg (whichever smaller)) for 6 weeks period.~During forth treatment period participants will commence a 2 weeks down-titration taper period, followed by 4 weeks observational follow up period of previous standard AE treatment without IMP."
88973676|NCT04376827|Experimental|Guselkumab+Standard of Care|Participants will receive guselkumab Dose 1 intravenously (IV) at Weeks 0, 4 and 8 and guselkumab Dose 2 subcutaneous (SC) every 4 weeks (q4w) from Week 12 through Week 48 along with standard-of-care treatment of mycophenolate mofetil (MMF)/mycophenolic acid (MPA) and glucocorticoids. Participants who achieved complete renal response (CRR) at Week 48 and 52 and have completed the Week 52 assessment may have the option to participate in the long-term extension (LTE).
88973677|NCT04376827|Placebo Comparator|Placebo+Standard of Care|Participants will receive placebo IV at Weeks 0, 4 and 8 and placebo SC q4w from Week 12 through Week 48 along with standard-of-care treatment of MMF/MPA and glucocorticoids. Participants who achieved complete renal response (CRR) at Week 48 and 52 and have completed the Week 52 assessment may have the option to participate in the LTE of the study.
88973678|NCT04369274|Experimental|Interventional|All subjects will briefly be placed on the automated BVM compressor device. Measurements obtained while on this device will be compared to those obtained in the same subject prior to mechanical ventilation and while on a conventional ventilator.
88973679|NCT04339504|Experimental|SMUP-IA-01(low-dose)|A single knee administration of SMUP-IA-01 (low-dose, 4.0 x 10^6 cells/2mL) (2 ml of 1% sodium hyaluronate injection is administered before administration of SMUP-IA-01)
88973680|NCT04339504|Experimental|SMUP-IA-01(mid-dose)|A single knee administration of SMUP-IA-01 (mid-dose, 1.0 x 10^7 cells/2mL) (2 ml of 1% sodium hyaluronate injection is administered before administration of SMUP-IA-01)
88973681|NCT04339504|Experimental|SMUP-IA-01(high-dose)|A single knee administration of SMUP-IA-01 (high-dose, 2.0 x 10^7 cells/2mL) (2 ml of 1% sodium hyaluronate injection is administered before administration of SMUP-IA-01)
88973682|NCT04319913|Experimental|ANI-guided|ANI-guided narcotics use to maintain ANI value between 50 to 70
88973683|NCT04319913|No Intervention|Control|narcotics use guided by clinical experience, ANI is still recorded but would be covered up intraoperatively
88973684|NCT04301609|Active Comparator|ImmunoVita®|250 mg Yeast beta-glucan + 3.75 microg Vitamin D3 + 1.05 mg Vitamin B6 + 7.5 mg zinc)
88973685|NCT04301609|Placebo Comparator|Placebo|473,2 mg microcristalline cellulose + 0,06 mg Brown Oxide dye + 0,27 mg yellow A oxide dye
88973686|NCT04300348|Active Comparator|Heel2Toe Group|The Heel2Toe group will have 5 therapy sessions to learn to trigger the sensor with a strong heel strike and how to use device for home practice for 3 months. During the home practice, participants will be instructed to walk with the device for a minimum of 10 minutes per day in feedback mode. They will be provided with a workbook outlining simple exercises targeting functions needed to walk well (Walk-BEST Workbook) in paper and as a mobile app.
88973687|NCT04300348|Other|No-feedback Control Group (Control group)|The Control group will do the same 5 sessions of training and 3 months of practice but without the Heel2Toe device in feedback mode, just in data acquisition mode. They will be provided with a workbook outlining simple exercises targeting functions needed to walk well (Walk-BEST Workbook) in paper and as a mobile app.
88973688|NCT04295304|Experimental|NR600 device implantation|Retinal surgery and implantation of epi-retinal prosthesis
88973689|NCT04292067||patients with SPA|100 SPA patients
88973690|NCT04292067||Healthy subjets|200 healthy subjets in control group
88973691|NCT04292067||patients with RA|100 RA patients
88973692|NCT04285554|Experimental|Hepatic Denervation|
88973693|NCT04282460|Experimental|Baduanjin practice|Baduanjin practice group will be asked to use the Baduanjin training system to practice the whole set of Baduanjin at least once a day and at least 5 days each week for 3 months.
88973694|NCT04282460|Active Comparator|Regular physical exercise|The regular physical exercise group will be asked to take physical exercise for at least half an hour every day in addition to regular physical activities at school.
88973695|NCT04266418|Placebo Comparator|Placebo|consume 1 sachet per day for 2 months
88973696|NCT04266418|Experimental|Banana flower stamens extract|consume 1 sachet per day for 2 months
88973697|NCT04266236|Active Comparator|L3 LPB technique (P group)|ultrasound-guided shamrock approach L3 lumbar plexus block with single-needle technique
88973698|NCT04266236|Active Comparator|T12 combined with L3 and L4 LPB technique (TP group)|ultrasound-guided posterior approach thoracic 12 combined with L3 and L4 lumbar plexus block with mulitple-needle technique
88973699|NCT04266236|Experimental|L3 LPB combined with QLB (LPQLB-SNT, PQ group)|ultrasound-guided shamrock approach L3 lumbar plexus block combined with quadratus lumborum block with single-needle technique
88973700|NCT04256343|Experimental|D2O Dose 1|Lower dose of D2O for MPS
88973701|NCT04256343|Experimental|D2O Dose 2|Moderate dose of D2O MPS
88973702|NCT04256343|Experimental|D2O Dose 3|Higher dose of D2O for MPS
88973703|NCT04252716||VISTHESIA 1.5|Ophtalmologic surgery supported by Visthesia OVD
88973704|NCT04252716||ProVisc|Ophtalmologic surgery supported by Provisc OVD
88973705|NCT04243629|Experimental|Rapid Insulin-Plus-Pramlintide|Rapid insulin and pramlintide infusion in two insulin pumps
88973706|NCT04243629|Placebo Comparator|Rapid Insulin-Plus-Placebo|Rapid insulin and placebo (saline) infusion in two insulin pumps
89580333|NCT05648383|Experimental|Pre-diabetes group, mHealth intervention|Participants will receive mHealth intervention (mobile apps) and counseling sessions along with standard care
89580334|NCT05648383|Experimental|Diabetes group, mHealth intervention|Participants will receive mHealth intervention (mobile apps) and counseling sessions along with standard care
89580335|NCT05648383|Active Comparator|Prediabetes group, control|Participants will receive standard care, including lifestyle recommendations
89580336|NCT05648383|Active Comparator|Diabetes group, control|Participants will receive standard care, including lifestyle recommendations
89580337|NCT05369689||spinal tumors, CT, MRI, PET-CT stereotactic radiosurgery|Patients who had spinal tumors and completed the CT, MRI or PET-CT examination before and after stereotactic radiosurgery.
88973707|NCT04202835|Experimental|ATG/PTCy|Anti-Thymocyte Globulin (ATG, Thymoglobulin) 4.5 mg/kg IV (divided 0.5, 2.0, 2.0 mg/kg on days -2, -1 and +1); cyclophosphamide (Post Transplant Cyclophosphamide, PTCy) 50 mg/kg IV daily on days +3 and +4.
88973708|NCT04202835|Active Comparator|ATG|Anti-Thymocyte Globulin (ATG, Thymoglobulin) 4.5 mg/kg IV (divided 0.5, 2.0, 2.0 mg/kg on days -2, -1 and +1).
88973709|NCT04187443|Experimental|MS-553 low dose|low dose of MS-553 taken orally
88973710|NCT04187443|Experimental|MS-553 mid dose|mid dose of MS-553 taken orally
88973711|NCT04187443|Experimental|MS-553 high dose|high dose of MS-553 taken orally
89580338|NCT01849588|Experimental|Treatment Arm|Sorafenib taken orally twice per day
89580339|NCT05648305||General Dental Practitioners|Cohort 1 consisted UK Armed Forces Personnel that received root canal treatment within the study period by General Dental Practitioners.
88973714|NCT04172441|Experimental|dasiglucagon first then placebo|48 hours of dasiglucagon subcutaneous (sc) infusion starting at 10 µg/hour with crossover to 48 hours placebo sc infusion (part 1) followed by 21 days of dasiglucagon sc infusion (part 2).
88973715|NCT04172441|Experimental|placebo first then dasiglucagon|48 hours of placebo sc infusion with crossover to 48 hours dasiglucagon sc infusion starting at 10 µg/hour (part 1) followed by 21 days of dasiglucagon sc infusion (part 2).
88973716|NCT04139603|Active Comparator|Lumbopelvic kinesio taping (LPKT)|Two I-shaped kinesio tapes in 40 cm length will be applied bilaterally, beginning from 5 cm below the spina iliaca posterior superiors (SIPSs) to the level of the 12th costae, in maximum trunk flexion position, on the paravertebral muscles, by inhibition technique of muscle correction techniques. The tapes will be placed with no tension at 5 cm of both ends, and with 15-25% tension in between. In addition, an extra I-shaped tape will be placed perpendicullar to these tapes with the ligament correction technique, while the pregnant women are in the vertical upright position, at the level of the sacroiliac joints, starting with a tensile strength of 75-100% from the middle, and then with no tension at two ends.
88973717|NCT04139603|Experimental|Abdominal supported lumbopelvic kinesio taping (ALPKT)|An abdominal support tape will be added to the LPKT. In order to reduce the tension of the uterus ligaments, and to help perception of the normal elasticity of the target tissues, ligament technique will be used. The middle part of an I-shaped tape will be placed to the midpoint of the lower abdomen, and then will be progressed laterally and above with 50% tension.
88973718|NCT04139603|Placebo Comparator|Placebo taping|A Micropore™ surgical plaster of the same color with KT will be applied with no tension, as described in the LPKT technique.
88973719|NCT04134936|Experimental|Arm A|Tafasitamab in addition to R-CHOP
88973720|NCT04134936|Experimental|Arm B|Tafasitamab plus lenalidomide in addition to R-CHOP
88973721|NCT04115111|Experimental|Durvalumab arm|"Patients will receive Durvalumab at the dose and regimens described above every 4 weeks until evidence of disease progression or occurrence of unacceptable toxicity.~Patients who show evidence of disease progression but appear to tolerate Durvalumab well, for whom no other treatment options exist and who, at the judgement of the investigator, may still enjoy clinical benefit, will be classified as failures and offered the possibility to continue treatment with extended follow up."
88973722|NCT04084483|Experimental|Group 1|K-161 Ophthalmic Solution Dose A.
88973723|NCT04084483|Experimental|Group 2|K-161 Ophthalmic Solution Dose B.
88973724|NCT04084483|Experimental|Group 3|K-161 Ophthalmic Solution Dose C.
88973725|NCT04084483|Placebo Comparator|Group 4|Vehicle Solution Dose.
88973726|NCT04079179|Experimental|Patients < 21 years with recurrent LCH (Grp1)|Children (≥ 6 months) and young adults (<21 years) with recurrent active LCH lesions (may also have LCH-ND).
88973727|NCT04079179|Experimental|Patients of any age with LCH-ND (Grp2)|Patients of any age (≥ 6 months) with progressive LCH Neurodegenerative Disease (LCH-ND) without other sites of active LCH.
88973728|NCT04079179|Experimental|Patients <21 years with other histiocytic disorders (Grp3)|Newly diagnosed or relapsed/refractory children (≥ 6 months) and young adults (<21 years) with other histiocytic disorders including juvenile xanthogranuloma, Erdheim-Chester disease, histiocytic sarcoma and Rosai-Dorfman disease.
88973729|NCT04079179|Experimental|Patients ≥ 21 years with LCH/histiocytic disorders (Grp4)|Adults (≥21 years) with LCH or other histiocytic disorder with recurrent active lesions (may also have LCH-ND).
88973730|NCT04043039|Experimental|FULL THICKNESS PALATAL GRAFT|the full thickness palatal wound will be protected by a quadruple layer of Platelet Rich Fibrin obtained by folding on itself 2 Platelet Rich Fibrin membrane or by gelatine sponge
88973731|NCT04043039|Active Comparator|FREE GINGIVAL GRAFT|the Epithelialized Free Gingival Grafts palatal wound will be protected by a quadruple layer of Platelet Rich Fibrin obtained by folding on itself 2 Platelet Rich Fibrin membrane or by gelatine sponge
88973732|NCT04042233|Active Comparator|IV administration of vancomycin|Standard IV vancomycin administration protocol.
88973733|NCT04042233|Experimental|IO Vancomycin 500mg in 250 mL NS|Experimental Intraosseous administration protocol.
89580340|NCT05648305||Dentists with Specialist Interest (DWSI)|Cohort 2 consisted UK Armed Forces Personnel that received root canal treatment within the study period by DWSI, clinicians that had undertaken a 1-year post-graduate programme in Endodontics.
89580341|NCT02357342|Experimental|Sirolimus|Intravitreal Sirolimus
89580342|NCT02357342|Active Comparator|Standard of Care intravitreal anti-VEGF|anti-VEGF intravitreal injections
89580343|NCT02271529|Experimental|Drug Eluting Stent|Zilver® Paclitaxel(PTX)® Drug-Eluting Peripheral Stent
88973734|NCT04039984|Experimental|Prime Cup|The study group will receive a Prime cementless acetabular cup (manufactured by Microport located in Arlington, Tennessee). All patients will also receive a cementless Profemur femoral stem with a 32 mm CoCr femoral head, articulating on a highly crosslinked acetabular liner.
88973735|NCT04029597|Experimental|Remote Patient Monitoring|Families participating in the study will receive standard medical care as well as the Remote Patient Monitoring System.
89029788|NCT00512967||COPD|15 COPD patients within 24 hours after their last exacerbation
89029789|NCT00512967||controls|25 healthy controls, matched for age and gender
89580344|NCT02325518|Experimental|BRI/TIM|Brinzolamide 1%/Timolol maleate 0.5% fixed combination ophthalmic suspension, 1 drop in each eye twice daily, and habitual PGA monotherapy, 1 drop in each eye once daily for 8 weeks.
89580345|NCT02325518|Active Comparator|DOR/TIM|Dorzolamide hydrochloride 1%/Timolol maleate 0.5% ophthalmic solution, 1 drop in each eye twice daily, and habitual PGA monotherapy, 1 drop in each eye once daily for 8 weeks.
89580346|NCT02270983|Experimental|Linaclotide 145 micrograms|Oral capsule, taken once daily each morning at least 30 minutes before breakfast, with the exception of the first Treatment Period dose which will be taken at the study center after at least a 2-hour fast.
89580347|NCT02270983|Experimental|Linaclotide 290 micrograms|Oral capsule, taken once daily each morning at least 30 minutes before breakfast, with the exception of the first Treatment Period dose which will be taken at the study center after at least a 2-hour fast.
89580348|NCT02270983|Experimental|Placebo|Oral capsule, taken once daily each morning at least 30 minutes before breakfast, with the exception of the first Treatment Period dose which will be taken at the study center after at least a 2-hour fast.
89580349|NCT02449889|Experimental|HP-hCG IM|highly purified human chorionic gonadotropin, intramuscularly (IM)
89580350|NCT02449889|Experimental|HP-hCG SC|highly purified human chorionic gonadotropin, subcutaneously (SC)
89580351|NCT02449889|Active Comparator|rhCG|recombinant human chorionic gonadotropin
89580352|NCT01831804|Experimental|Cohort 1 Part A|Healthy subjects in this arm will receive single applications of GSK1278863 or placebo (with 6:2 ratio) on intact skin in two escalating dosing periods each separated by 10 days. The first application will be with a single dose of 0.3 mg and second application will be single dose of 3 mg.
89580353|NCT01831804|Experimental|Cohort 2 Part A|Subjects with diabetic foot ulcer (DFU) will receive a single application of GSK1278863 or placebo (with 6:2 ratio) in two dosing periods separated by 10 days. The first application will be made on intact skin and second application directly on DFU. Dose will be based on wound area and review from previous cohort data.
89580354|NCT01831804|Experimental|Cohort 3 Part A|Subjects with DFU will receive single application of GSK1278863 or placebo directly on DFU. Dose will be based on wound area and review from previous cohort data.
89580355|NCT01831804|Experimental|Cohort 4 Part A|Subjects with DFU will receive a single application of GSK1278863 or placebo (with 6:2 ratio) in two dosing periods separated by 10 days. The first application will be made on DFU and second application on intact skin. Dose will be based on wound area and review from previous cohort data.
89580356|NCT01831804|Experimental|Cohort 5 Part B|Subjects with DFU will receive Standard of care (SOC) up to 15 days and then will be randomized to one of the three arms: GSK1278863 + SOC, or SOC only, or placebo + SOC with ratio of 12:2:2. Doses for the cohorts in Part B will be determined from safety, tolerability and PK data from Part A. subjects will first be given a single application of GSK1278863 or placebo at the dose chosen for that cohort, followed by a 7-day washout period, and then repeat applications for 14 days, starting on Day 8.
89580357|NCT01831804|Experimental|Cohort 6 Part B|Subjects with DFU will receive Standard of care (SOC) up to 15 days and then will be randomized to one of the three arms: GSK1278863 + SOC, or SOC only, or placebo + SOC with ratio of 12:2:2. Doses for the cohorts in Part B will be determined from safety, tolerability and PK data from Part A. subjects will first be given a single application of GSK1278863 or placebo at the dose chosen for that cohort, followed by a 7-day washout period, and then repeat applications for 14 days, starting on Day 8.
89580358|NCT01831804|Experimental|Cohort 7 Part B|Subjects with DFU will receive Standard of care (SOC) up to 15 days and then will be randomized to one of the three arms: GSK1278863 + SOC, or SOC only, or placebo + SOC with ratio of 12:2:2. Doses for the cohorts in Part B will be determined from safety, tolerability and PK data from Part A. subjects will first be given a single application of GSK1278863 or placebo at the dose chosen for that cohort, followed by a 7-day washout period, and then repeat applications for 14 days, starting on Day 8.
89029790|NCT04519073|Placebo Comparator|Placebo|0.5 mL of diluent (phosphate buffer)
89029791|NCT04519073|Experimental|V-306 low dose|V-306 at 15 µg
89029792|NCT04519073|Experimental|V-306 intermediate dose|V-306 at 50 µg
89580359|NCT02270671|Placebo Comparator|Placebo|The placebo protocol consists of 160 trials (120 angry-neutral face pair and 40 neutral-neutral face pair presentations). In this condition, angry-face location, probe location and actor are fully counterbalanced in presentation. A short break is delivered every 40 trials (1 block). An accuracy of 70% or above for each block is necessary to continue training. The task takes 7 minutes.
89580360|NCT02270671|Experimental|Intervention|The attention bias modification training (ABMT) protocol consists of 160 trials (120 angry-neutral face pair presentations and 40 neutral-neutral face pair presentations). In the ABM condition, the target-probe appears at the neutral-face locations in all angry-neutral trials. A short break is delivered every 40 trials (1 block). An accuracy of 70% or above for each block is necessary to continue training. The task takes 7 minutes.
89580361|NCT04415164|Experimental|Xueshuantong|Patients will receive intravenously administered Xueshuantong, combined with guidelines-based standard care.
89580362|NCT04415164|Placebo Comparator|Placebo|Patients will receive intravenously administered Xueshuantong placebo, combined with guidelines-based standard care.
89580363|NCT04875481||ASD group|450 ASD from cohort established at Department of Psychiatry, National Taiwan University Hospital (NTUH) starting from 2007.
89029793|NCT04519073|Experimental|V-306 high dose|V-306 at 150 µg
89029794|NCT02952027|Experimental|Bell On|Subjects in the Bell On arm will receive a timer where the alarm will sound every hour.
89029795|NCT02952027|Placebo Comparator|Bell Off|Subjects in the Bell Off arm will receive a timer where the alarm will not sound, but still record incentive spirometer usage
89029796|NCT00504335|Experimental|500 BIO 300 capsule|The first cohort will receive one 500 BIO 300 capsule and pharmacokinetic blood sampling will be conducted over the first 4 days in an outpatient setting
89029797|NCT00504335|Experimental|1000 BIO 300 capsule|the second cohort will be treated with 1000 mg BIO 300 using the same PK sampling program
89029798|NCT00504335|Experimental|1500 BIO 300 capsule|the third cohort will be treated with 1500 mg BIO 300using the same PK sampling program
88973736|NCT04028414|Experimental|Early Weight Bearing|Patients with ankle fractures will be instructed to weight bear as tolerated (WBAT) while in a boot with a heel to toe normal gait and wean from walker or crutches to a cane or no support device. At the 6 week post op visit, patients with ankle fractures will be instructed to wean from the boot and continue full weight bearing as tolerated until full weight bearing is achieved. Patients with plateau fractures will be instructed to begin WBAT until full weight bearing is achieved.
88973737|NCT04028414|No Intervention|Delayed Weight Bearing|Patients with ankle fractures will be instructed to touch-down (toe touch or foot flat) weight bear (approximately 10% of body weight) while in the boot for. Patients will be instructed to keep foot off of floor or set ball of foot or heal on ground for balance using walker or crutches at all times. After the 6 week post op visit, patients may begin weight bearing as tolerated. Patients with tibial plateau fractures will be instructed to touch down (toe touch or foot flat) weight bear (approximately 10% of body weight) for at least 6 weeks. After the 6 week post op visit, patients may begin weight bearing as tolerated until full weight bearing is achieved.
88973738|NCT04003857|Experimental|PNEUMOSTEM®|A single intratracheal administration of Pneumostem® (10.0 x 10^6 cells/kg)
88973739|NCT04003857|Placebo Comparator|normal saline|A single intratracheal administration of normal saline
88973740|NCT03977038||TRD sample|Individuals in the treatment resistant depression (TRD) sample suffer from the condition called TRD. The intervention that will be administered to this group is the standardized rTMS treatment using High Frequency dTMS (HF-dTMS) stimulation over L-DLPFC, at the frequency of 18Hz, at 120% value of the individual's motor threshold, in 5 daily sessions per week, taking place each weekday, over the course of 6 weeks.
88973741|NCT03977038||Healthy Controls (HC) sample|Individuals in the HC sample are age-, sex-, education-matched to the individuals in the TRD sample. HC sample does not receive any therapeutic treatment and are solely examined as a comparative measure of normal cognitive capabilities.
88973742|NCT03974087|Active Comparator|MCI patients with real transcranial direct current stimulation|Patients will receive 2mA stimulation in 10 consecutive sessions.
88973743|NCT03974087|Sham Comparator|MCI patients with sham transcranial direct current stimulation|Patients will receive sham stimulation in 10 consecutive sessions.
88973744|NCT03973541|Experimental|Virtual Reality Exposure Therapy|VRET will include 360° videos with three scenarios a) riding a bus, b) going to a school cafeteria and c) a job interview. These scenarios were chosen based on clinical experience and frequently reported difficult situations in the literature . The order of the scenarios is jointly decided by the patient and therapist. In the videos the patients can make choices which determine the further course of the exposure scenario. For example, in the bus scenario the information system is out of order. Therefore, the patient has to ask the driver to announce, when they are at a particular stop. Depending on whether or not the patient decides to do so, the video will skip to one of two alternative continuations of the scenario. During the exposures the therapist will also motivate the patient towards acting in ways they consider unacceptable to provoke fear of ridicule, and make the patient act against him or her excessively rigid rules for social interaction to observe the consequences.
88973745|NCT03973541|Active Comparator|In Vivo Exposure Therapy|In vivo exposure consists of role-playing and guided exposure either inside or outside the therapist's office with active modelling from the therapist in early sessions. Staff members are called upon to conduct exposure. Similarly to the VRET during in vivo exposure the therapist will motivate the patient towards acting in ways they consider unacceptable.
88973746|NCT03973541|Placebo Comparator|Virtual Reality Relaxation Therapy|VR relaxation therapy will consist of a VR scenario of swimming with dolphins, created by the dolphin swim club (www.thedolphinswimclub.com). Swimming with real wild dolphins has been shown to have a positive effect on anxiety, although not specifically on SAD
88973747|NCT03965195|Experimental|RIV4|Nursing homes randomized to receive quadrivalent recombinant influenza vaccine (Flublok) for the residents and staff
88973748|NCT03965195|Active Comparator|IV4|Nursing homes randomized to receive standard dose quadrivalent influenza vaccine for the residents and staff
88973749|NCT03924063|Other|conservative treatment|conservative treatment with physical therapy and non steroidal anti-inflammatory drugs
88973750|NCT03921931|Experimental|healthy volunteers|light stimulation
88973751|NCT03921931|Experimental|primary open angle glaucoma patients|light stimulation
88973752|NCT03921931|Experimental|age-related macular degeneration patients|light stimulation
88973753|NCT03878082|Active Comparator|propacetamol 1g|pain control with IVPCA and propacetamol 1g every 6 hours for 2 days
88973754|NCT03878082|Active Comparator|propacetamol 2g|pain control with IVPCA and propacetamol 2g every 6 hours for 2 days
88973755|NCT03878082|Placebo Comparator|IVPCA|pain control with IVPCA
88973756|NCT03869853|Experimental|intervention|Entrepreneurial stimulation and integrated education
88973757|NCT03869853|Experimental|control|no intervention
88973758|NCT03815981||Allergic|Collection of blood, stool, urin samples
88973759|NCT03815981||Sensitized|Collection of blood, stool, urin samples
88973760|NCT03815981||Non-Allergic|Collection of blood, stool, urin samples
88973761|NCT03814941||paper-based anesthesia record|"The AIMS sampled the vital signs from the monitor every minute and stored in the database.~The incidence of artifacts in the AIMS database was evaluated by paper-based documented anesthesia record."
88973762|NCT03814941||electronic documents|"The AIMS sampled the vital signs from the monitor every minute and stored in the database.~The incidence of artifacts in the AIMS database was evaluated by electric documented anesthesia record."
88973763|NCT03807310|Experimental|Group Long-drink|"83 COPD patients will receive:~Targeted nutrient supplementation (Long-drink) once daily~Counselling once monthly"
88973764|NCT03807310|Placebo Comparator|Group Placebo|"83 COPD patients will receive:~Isocaloric placebo supplement once daily~Counselling once monthly"
88973765|NCT03807310|No Intervention|Healthy control group|30 healthy controls will be included for baseline comparison of the microbiome composition. These healthy controls will only perform a subset of baseline measurements and will not be included in the intervention.
88973766|NCT03804853|Experimental|Immediate Active Shoulder Rehabilitation|
88973767|NCT03804853|Active Comparator|Traditional Should Rehabilitation|
88973768|NCT03799419|Experimental|Cognitive bias modification with treatment as usual|Participants in this group will receive usual treatment in the program and 8 sessions of a computerized cognitive training targeting interpretation bias
89580364|NCT04875481||TD group|100 healthy typical developing control (TDC) from cohort established at Department of Psychiatry, National Taiwan University Hospital (NTUH) starting from 2007.
89580365|NCT02324270|Active Comparator|Diclofenac epolamine|Flector® (Diclofenac Epolamine Topical Patch 1.3%) (Pfizer)
89580366|NCT02324270|Experimental|generic diclofenac epolamine patch|Generic Diclofenac Epolamine Topical Patch 1.3% (Watson Laboratories, Inc.)
89580367|NCT02324270|Placebo Comparator|Placebo|Placebo patch of the test product (Watson Laboratories, Inc.); Identical in appearance and formulated as the test product, omitting the active ingredient, diclofenac epolamine
89580368|NCT02270515|Experimental|PCMH-KD dialysis care|Dialysis care team is expanded to include a primary care doctor, nurse coordinator, community health worker, and pharmacist. Enrolled patients are observed for an initial baseline period receiving care under the usual dialysis care model called the 'usual dialysis care phase'.
89580369|NCT02448875|Active Comparator|CyPass|CyPass Micro-Stent without adjunct viscoelastic implanted in the study eye
89580370|NCT02448875|Experimental|CyPass30|CyPass Micro-Stent implantation followed by targeted delivery of 30 μl ophthalmic viscoelastic
89580371|NCT02448875|Experimental|CyPass60|CyPass Micro-Stent implantation followed by targeted delivery of 60 μl ophthalmic viscoelastic
89580372|NCT05648149|Experimental|hierarchical multi-dimensional cognitive training scheme based on computer|Cognitive training was carried out by three trained and certified nurses in accordance with the cognitive training program. Twice a day, 30min each time, for 4 weeks, the difficulty of the training content is divided into 2 levels, the correct rate of more than 80% can enter the next level. During hospitalization, the patients and their families were taught how to use cognitive training programs. After discharge, special personnel were assigned to supervise and urge the patients to carry out cognitive training through the background.
89580373|NCT05648149|No Intervention|routine rehabilitation|Routine treatment, rehabilitation and care
89580374|NCT05648071|Experimental|Sintilimab Plus Bevacizumab and Platinum-Based Doublet Chemotherapy|The specific treatment regimen is as follows :Non-squamous NSCLC: Sintilimab (200 mg) plus Bevacizumab (7.5mg/kg) is started on the first day of each treatment cycle and administered every three weeks. Nedaplatin (80-100 mg/m2) (d2) +pemetrexed 500 mg/m2 (d2) Q3W is administered in this regimen for 4 cycles followed by sintilimab plus bevacizumab until disease progression or intolerable toxicity.
89580375|NCT04924361||Early onset dementia|Dementia patients with onset age lower than 65y/o
89580376|NCT04924361||Late onset dementia|Dementia patients with onset age between 65y/o and 85y/o
89580377|NCT04924361||Oldest old dementia|Dementia patients with onset age older than 85y/o
89580378|NCT04924361||Cognitive normal control|cognitive normal control
88973769|NCT03799419|Sham Comparator|Psychoeducation with treatment as usual|Participants in this group will receive usual treatment in the program and 8 sessions of psychoeducation
88973770|NCT03799419|Experimental|Approach avoidance training with treatment as usual|Participants in this group will receive usual treatment in the program and 8 sessions of a computerized cognitive training targeting automatic approach tendencies
88973771|NCT03799419|Sham Comparator|Inactive sham approach avoidance training|Participants in this group will receive usual treatment in the program and 8 sessions of a sham approach avoidance training
88973772|NCT03793673|Other|Standard Care: Standard appointments|"Usual in-person medical appointments. See previous detailed description.~COVID-19 Update: Current clinic appointments consist of telehealth appointments only. Any additional community and CHLA based educational and support events will be following COVID-19 guidelines."
89580379|NCT01831726|Experimental|TKI258|Dovitinib (TKI) will be dosed on a flat scale of 500 mg on a 5 days on/2 days off dosing schedule.
89580380|NCT04868617|Experimental|Test Product|The non-CE marked test product is a stoma product based on the flat SenSura® Mio 1-piece (1-pc) and the flat 2-piece with mechanical coupling (2-pc MC) product that includes a novel skin protective layer in the baseplate.
89580381|NCT04868617|Active Comparator|Sensura Mio Comparator - Standard of Care|"The following comparator products will be used in this investigation:~SenSura® Mio 1-piece (1-pc) flat, Midi bag with normal outlet and~SenSura® Mio 2-piece with mechanical coupling (2-pc MC) flat, Maxi or Midi bag with normal outlet"
89580382|NCT05464069||Postpartum with migraine who used Nerivio during their pregnancy|Postpartum patients with migraine who used Nerivio at least 3 times during their pregnancy. Participants will be recruited from Nerivio's user database
89580383|NCT05464069||Postpartum with migraine who used other migraine therapy during their pregnancy|Postpartum patients with migraine who used did not used Nerivio prior to their pregnancy, during their pregnancy and at least 3 months postpartum. Participants will be referred to the study by site co-investigators, who are US-licensed healthcare providers seeing women with headache disorders and/or women during their pre-pregnancy and/or pregnancy period
88973773|NCT03793673|Other|Standard Care: Telehealth appointments|Telehealth - with provider and/or team. See previous detailed description.
88973774|NCT03793673|Other|CoYoT1 Care: Standard Appointment|"In-person - medical appointments with provider and/or team. See previous detailed description.~COVID-19 Update: Current clinic appointments consist of telehealth appointments only. Any additional community and CHLA based educational and support events will be following COVID-19 guidelines."
89580384|NCT01831258|Experimental|SensAwake On|The comfort feature 'SensAwake' will be turned on
89580385|NCT01831258|Active Comparator|SensAwake Off|The comfort feature 'SensAwake' will be turned off
89580386|NCT01849276|Experimental|Treatment (enzyme inhibitor and chemotherapy)|Patients receive metformin hydrochloride orally twice a day on days 1-15 and cytarabine IV over 3 hours twice on days 4-10.
89580387|NCT02465489|Experimental|ER, fasting conditions|A single 1000 mg dose of deferiprone extended release tablet formulation administered under fasting conditions
89580388|NCT02465489|Experimental|ER, fed conditions|A single 1000 mg dose of deferiprone extended release tablet formulation administered under fed conditions
89580389|NCT02465489|Experimental|ER half-tablets, fed conditions|A single 1000 mg dose of deferiprone extended release tablet formulation (one 1000 mg tablet divided in two) administered under fed conditions
89580390|NCT02465489|Active Comparator|IR, fasting conditions|A single 1000 mg dose of deferiprone immediate release tablet formulation administered under fasting conditions
89580391|NCT02465489|Active Comparator|IR, fed conditions|A single 1000 mg dose of deferiprone immediate release tablet formulation administered under fed conditions
89580392|NCT01829464|Placebo Comparator|Placebo|TAK-875 placebo-matching tablets, orally, once daily and sitagliptin 100 mg, tablets, orally for up 24 weeks.
89580393|NCT01829464|Experimental|TAK-875 25 mg|TAK-875 25 mg, tablets, orally, once daily and sitagliptin 100 mg, tablets, orally for up to 24 weeks
89580394|NCT01829464|Experimental|TAK-875 50 mg|TAK-875 50 mg, tablets, orally, once daily and sitagliptin 100 mg, tablets, orally for up to 24 weeks
89580395|NCT04953923|Experimental|Treatment A|Cedazuridine at a therapeutic dose
89580396|NCT04953923|Experimental|Treatment B|Cedazuridine at a supratherapeutic dose
89580397|NCT04953923|Placebo Comparator|Treatment C|Placebo control
89580398|NCT04953923|Active Comparator|Treatment D|Moxifloxacin positive control
89580399|NCT01847092|Active Comparator|AZD1722|AZD1722 in 5, 15, 30, or 60 mg capsules. Starting dose is 15 mg BID PO for 12 Weeks
89580400|NCT01847092|Placebo Comparator|Placebo|Placebo capsule BID PO for 12 Weeks
89580401|NCT01601821|Active Comparator|Arm A (CsA+Rapamune+CS)|
89580402|NCT01601821|Experimental|Arm B (CsA+MMF+CS)|
89580403|NCT02323646|Placebo Comparator|Placebo|Following the baseline assessment no treatment period, matching placebo, vaginally, once daily for 18 weeks (Course 1) and repeated for an additional 18 weeks (Course 2) following the ODI.
88973775|NCT03793673|Other|CoYoT1 Care: Telehealth appointments|Telehealth - with provider and/or team. See previous detailed description.
88973776|NCT03779009|Experimental|Tracer injection|
88973777|NCT03759938|Experimental|Early initiation of DOAC|Early initiation of any direct oral anticoagulant (DOAC) at a dose licensed for stroke prevention in AF, within four days (96hrs) of onset of acute ischaemic stroke
88973778|NCT03759938|Active Comparator|Standard Initiation of DOAC|Standard initiation of any DOAC at a dose licensed for stroke prevention in AF, no sooner than day 7 and no later than day 14 after the onset of acute ischaemic stroke (i.e. between 144hrs and 336hrs from onset).
88973779|NCT03742596|Experimental|Probiotic Formula Capsule|In this intervention arm the patients will receive oral viable capsules of probiotic contain (1*10 10 colony forming unit (CFU)/g) of lactobacillus (Lactobacillus rhamnosus , Lactobacillus acidophilus , Lactobacillus reuteri, Lactobacillus paracasei, Lactobacillus casei, Lactobacillus gasseri, Lactobacillus plantarum) and bifidobacteria (Bifidobacterium lactis, Bifidobacterium breve, Bifidobacterium bifidum, Bifidobacterium longum, Bifidobacterium infantis) species three times a per day
88973780|NCT03742596|Other|Control|In this intervention arm, the control arm will receive normal treatment without any probiotic
88973781|NCT03695185|Experimental|Ravagalimab 600 mg/300 mg|Participants received ravagalimab 600 mg intravenous (IV) at Week 0 followed by ravagalimab 300 mg subcutaneously (SC) at Weeks 2, 4, 6, 8, and 10 in a 12-week Induction Period. Participants who achieved clinical response per partial adapted Mayo score at Week 12 of the Induction Period entered the Maintenance Period to receive ravagalimab 300 mg SC every other week (EOW) from Week 12 through Week 102.
89029799|NCT00504335|Experimental|2000 BIO 300 capsule|the forth cohort will be treated with 2000 mg BIO 300using the same PK sampling program
89029800|NCT02951910|Experimental|Intervention|Patients receiving zinc-hyaluronate eye drop
89029801|NCT04516577||Shanghai Pulmonary Hospital|Shanghai Pulmonary Hospital is a hospital specializing in the treatment of lung diseases. Many patients with pulmonary alveolar proteinosis receive treatment in this hospital.
89580404|NCT02323646|Experimental|Telapristone Acetate 6 mg|Following the baseline assessment no treatment period, telapristone acetate 6 milligrams (mg), vaginally, once daily for 18 weeks (Course 1) and repeated for an additional 18 weeks (Course 2) following the ODI.
89580405|NCT02323646|Experimental|Telapristone Acetate 12 mg|Following the baseline assessment no treatment period, telapristone acetate 12mg, vaginally, once daily for 18 weeks (Course 1) and repeated for an additional 18 weeks (Course 2) following the ODI.
89580406|NCT01846624|Experimental|Decitabine, then midostaurin|"INDUCTION THERAPY Subjects receive decitabine intravenously (IV) over 1 hour on days 1 to 10 and midostaurin orally (PO) twice daily (BID) on days 11 to 28. Treatment repeats every 28 days until documented bone marrow response is achieved or for up to 12 courses in the absence of disease progression or unacceptable toxicity. Patients achieving documented bone marrow response by course 6 continue treatment with induction therapy; patients achieving response after course 6 proceed to post-remission therapy.~POST-REMISSION THERAPY Subjects receive decitabine IV over 1 hour on days 1 to 5 and midostaurin PO BID on days 6 to 28. Treatment repeats every 28 days for up to 12 courses (including induction therapy) in the absence of disease progression or unacceptable toxicity.~After completion of study treatment, patients are followed up for up to 1 year."
89580407|NCT05647915|Experimental|berberine group|Berberine hydrochloride plus lifestyle intervention
89580408|NCT05647915|Placebo Comparator|placebo group|Placebo plus lifestyle intervention
89580409|NCT01829230|Experimental|Test lens C|Test lens C from previous study
89580410|NCT01829230|Active Comparator|Test lens A|Test lens A from previous study
89580411|NCT02269657||Subject Cohort|Two bi-planar full spinal X-rays will be taken using the EOS® imaging system with subjects standing in two different positions. The first x-ray will be taken while the subject's hands and forearms in front of them on the wall vertically. A second image will be taken while the subject's knuckles loosely placed on ipsi-lateral clavicles. A pressure mat will record the magnitude of pressure under the subjects' feet during each set of images. A third set of pressure mat recordings will be obtained while the subject is in a natural standing position with both arms hanging on either side (no x-ray images will be taking in this position).
89580412|NCT04588714|Experimental|Resilience-based, Energy Management to Enhance Wellbeing (RENEW)|"RENEW is a 12-week program in which participants are paired with a peer mentor who serves as their health coach throughout the intervention period. The website serves as the program workbook to help promote skill practice and attainment in areas like goal setting, pacing, relaxation, etc."
89580413|NCT02269423|Experimental|3x10^6 plaque-forming units (pfu) Vaccine Cohort|Participants will receive a 1-mL intramuscular injection of V920 3x10^6 pfu in one deltoid and a 1-mL intramuscular injection of placebo in the contralateral deltoid on Day 0.
89580414|NCT02269423|Experimental|2x10^7 pfu Vaccine Cohort|Participants will receive a 1-mL intramuscular injection of V920 2x10^7 pfu in one deltoid and a 1-mL intramuscular injection of placebo in the contralateral deltoid on Day 0.
89580415|NCT02269423|Experimental|1x10^8 pfu Vaccine Cohort|Participants will receive a 1-mL intramuscular injection of V920 1x10^8 pfu in one deltoid and a 1-mL intramuscular injection of placebo in the contralateral deltoid on Day 0.
89580416|NCT02269423|Placebo Comparator|Placebo Cohort|Participants will receive a 1-mL intramuscular injection of placebo in each deltoid on Day 0.
89580417|NCT05647837|Experimental|patients wit IIH|"patient that complains of symptoms of chronic increase intracranial pressure especially visual with absent of organic cause through visual assessment, routine laboratory investigation and brain imaging.~these patients will undergo lumper puncture to assess CSF opening pressure and Neurofilament Light Chain (NFL) and HYpoxia Induced Factor (HIF) both in CSF and blood."
89580418|NCT01827670|Experimental|0.454% stannous fluoride dentifrice|Participants to brush whole mouth with 1-inch strip of the test dentifrice (0.454% SnF) for one timed minute, followed by rinsing with 5 milliliter (mL) of water.
89580419|NCT01827670|Active Comparator|0.76% sodium monofluorophosphate dentifrice|Participants to brush whole mouth with 1-inch strip of the control dentifrice (0.76% NaMFP) for one timed minute, followed by rinsing with 5 mL of water.
89580420|NCT02267317|Active Comparator|Obese Group-D5W|Obese subjects receive IV administration of 5% Dextrose in water/D5W (vehicle) 12 mg every 12 hours
88973782|NCT03685461|Other|Arm 1: Audible ECochG Response Off|Arm 1: Audible ECochG Response Off This condition is identical to the current standard-of-care for conventional CI surgery used worldwide. The surgeon will perform his or her electrode insertion without ECochG monitoring. Minute manipulations of the electrode are a normal part of conventional electrode insertion; manipulations such as redirecting the insertion vector or slowing down insertion speed will be made, as deemed necessary by the surgeon. A full electrode insertion will be performed, as appropriate. The ECochG responses will be recorded, but the surgeon will be blinded to this information during surgery.
88973783|NCT03685461|Experimental|Arm 2: Audible ECochG Response On|This condition will have the audible ECochG response on and available to the surgeon. In this condition, the surgeon perform a conventional electrode insertion while listening to the running ECochG signal for drop in amplitude (suggesting impending trauma). If no drop is detected, insertion will proceed to the full electrode length according to the standard-of-care. If an ECochG amplitude drop is observed, the surgeon will place this observation in its clinical context and evaluate insertion parameters, (i.e., insertion vector, insertion speed, etc.), customary practice with conventional CI surgery, but here supplemented by the ECochG response. In the case of an ECochG amplitude drop that does not recover, the standard-of-care practice of achieving a full electrode insertion will be followed.
88973784|NCT03677648|Active Comparator|SHR0302 dose A|Participants randomized in this arm will receive dose A of SHR0302 until end of study at week 24.
88973785|NCT03677648|Experimental|SHR0302 dose B|Participants randomized in this arm will receive dose B of SHR0302 until end of study at week 24.
88973786|NCT03677648|Experimental|SHR0302 dose C|Participants randomized in this arm will receive dose C of SHR0302 until end of study at week 24.
88973787|NCT03677648|Placebo Comparator|Placebo|Participants randomized in this arm will receive placebo until week 12, and then will be re-randomized into one of the 3 active arms (dose A, dose B, and dose C of SHR0302) in a 1:1:1 allocation ratio until the end of study at week 24.
89580421|NCT02267317|Active Comparator|Obese Group - Eritoran|Obese subjects receive IV administration of Eritoran 12 mg every 12 hours
89580422|NCT02267317|Active Comparator|Diabetes (T2DM) Group - D5W|T2DM subjects receive IV administration of 5% Dextrose in water/D5W (vehicle) 12 mg every 12 hours
89580423|NCT02267317|Active Comparator|Diabetes (T2DM) Group - Eritoran|T2DM subjects receive IV administration of Eritoran 12 mg every 12 hours
89580424|NCT01844830|Experimental|Kovacaine Mist|Tetracaine HCl 3% and Oxymetazoline HCl 0.05% - Subjects weighing more than 10kg and less than 20kg, will receive 1 spray of 100µL; Subjects weighing more than 20kg and less than 40kg, will receive 2 sprays of 100µL (200µL total); subjects weighting more than 40kg will receive 2 sprays of 200µL (400µL total);
89580425|NCT01844830|Placebo Comparator|Placebo|Placebo - Subjects weighing more than 10kg and less than 20kg, will receive 1 spray of 100µL; Subjects weighing more than 20kg and less than 40kg, will receive 2 sprays of 100µL (200µL total); subjects weighting more than 40kg will receive 2 sprays of 200µL (400µL total);
89580426|NCT05426473|Experimental|Patients with a completed form|
89580427|NCT04874467|Experimental|Keratinized Mucosa ≥ 2 mm|Supportive periodontal therapy, in teeth by means of ultrasonic devices and manual curettes. In implants using the same devices but made of titanium. Oral hygiene instructions
89580428|NCT04874467|Experimental|Keratinized Mucosa < 2 mm|Supportive periodontal therapy, in teeth by means of ultrasonic devices and manual curettes. In implants using the same devices but made of titanium. Oral hygiene instructions
89580429|NCT01827592|Experimental|EBX 10|Elobixibat 10 mg/day
89580430|NCT01827592|Experimental|EBX 5|Elobixibat 5 mg/day
89580431|NCT01827592|Placebo Comparator|PLCBO|Placebo
89580432|NCT02323334|Placebo Comparator|Part A Cohort 1 Sequence1: 0.1mg, 1.6mg, Placcebo; 15mg|"Part A Cohort 1 involved healthy participants and was comprised of 4 treatment periods with a washout period of approximately 14 days between doses.~Period 1: 0.1mg LY3202626 Period 2: 1.6mg LY3202626 Period 3: 15 mg placebo (PBO) Period 4: 15mg LY3202626."
89580433|NCT02323334|Experimental|Part A Cohort 1 Sequence 2: 0.1mg, PBO, 15mg, 15mg|"Part A Cohort 1 involved healthy participants and comprised of 4 treatment periods with a washout period of approximately 14 days between doses.~Period 1: 0.1mg Period 2: PBO Period 3: 15mg LY3202626 Period 4: 15mg LY3202626."
88973788|NCT03626363|Experimental|Mindfulness-Based Stress Reduction|
88973789|NCT03626363|Active Comparator|Stress Management Education|
88973790|NCT03596164|Experimental|Teduglutide 0.05 mg|Participants will receive Teduglutide 0.05 milligram per kilogram (mg/kg) subcutaneous (SC) injection once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm until Teduglutide is commercially available, the participant's participation in this study is discontinued, or the study is discontinued.
89580434|NCT02323334|Experimental|Part A Cohort 1 Sequence 3: PBO, 1.6mg, 15mg, Placebo|"Part A Cohort 1 involved healthy participants and comprised of 4 treatment periods with a washout period of approximately 14 days between doses.~Period 1: PBO Period 2: 1.6mg LY3202626 Period 3: 15mg LY3202626 Period 4: PBO."
89580435|NCT02323334|Experimental|Part A Cohort 2 Sequence 1:0.4mg, 5mg, PBO, 0.4mg/Itraconazole|"Part A Cohort 2 involved healthy participants and comprised of 4 treatment periods with a washout period of approximately 14 days between doses.~Period 1: 0.4mg LY3202626 Period 2: 5mg LY3202626 Period 3: 45mg, PBO Period 4: 0.4mg LY3202626/200mg Itraconazole."
89580436|NCT02323334|Experimental|Part A Cohort 2 Sequence 2: 0.4mg, PBO, 45mg. 0.4mg/Itra|"Part A Cohort 2 involved healthy participants and comprised of 4 treatment periods with a washout period of approximately 14 days between doses.~Period 1: 0.4mg LY3202626 Period 2: 5mg, PBO Period 3: 45mg LY3202626 Period 4: 0.4mg LY3202626/200mg Itraconazole."
89580437|NCT02323334|Experimental|Part A Cohort 2 Sequence 3:PBO, 5mg, 45mg,0.4mg/200mg Itra|"Part A Cohort 2 involved healthy participants and was comprised of 4 treatment periods with a washout period of approximately 14 days between doses.~Period 1: 0.4mg, PBO Period 2: 5mg LY3202626 Period 3: 45mg LY3202626 Period 4: 0.4mg LY3202626/200mg Itraconazole."
89580438|NCT02323334|Experimental|Part A Cohort 3 Sequence 1: Food Effect Fed/Fasted|Part A Cohort 3 involved healthy participants and was comprised of two treatment periods with a washout period of approximately 14 days between doses. Single dose of 10mg LY3202626 given PO in Period 1 and 2. Period 1: Fed 2: Fasted.
89580439|NCT02323334|Experimental|Part A Cohort 3 Sequence 2: Food Effect Fasted/Fed|Part A Cohort 3 involved healthy participants and was comprised of two treatment periods with a washout period of approximately 14 days between doses. Single dose 10mg LY3202626 given PO in Period 1 and 2. Period 1: Fasted 2: Fed.
89580440|NCT02323334|Experimental|Part B Cohort 4: 1.6mg|Part B Cohort 4 involved healthy participants and was comprised of one period. Single dose of 1.6mg LY3202626 given PO in Period 1. Dose determined by Part A.
89580441|NCT02323334|Experimental|Part B Cohort 5: 10mg|Part B Cohort 5 involved healthy participants and was comprised of one period. Single dose of 10mg LY3202626 given PO in Period 1. Dose determined by Part A.
89580442|NCT02323334|Experimental|Part B Cohort 6: 26mg|Part B Cohort 6 involved healthy participants and was comprised of one period. Single dose of 26mg LY3202626 given PO in Period 1. Dose determined by Part A.
89580443|NCT02323334|Placebo Comparator|Part B Cohort 4, 5, 6: Placebo Comparator|Part B Cohort 4,5,6 involved healthy participants and was comprised of one period. Single dose of PBO given PO in Period 1.
89580444|NCT02323334|Experimental|Part C Cohort 7: 1mg|Part C Cohort 7 involved healthy participants and was comprised of one period. 1mg LY3202626 given PO once daily for 14 days. Dose determined by Part B.
89580445|NCT02323334|Experimental|Part C Cohort 8: 6mg|Part C Cohort 8 involved healthy participants and was comprised of one period. 6mg LY3202626 was given PO once daily for 14 days. Dose determined by Part B.
89580446|NCT02323334|Experimental|Part C Cohort 9: 26mg|Part C Cohort 9 included healthy participants and was comprised of one period. 26mg LY3202626 was given PO once daily for 14 days. Dose determined by Part B.
89580447|NCT02323334|Placebo Comparator|Part C Cohort 7, 8 ,9: Placebo Comparator|Part C Cohort 7,8,9 involved healthy participants and was comprised of one period. Placebo given PO once daily for 14 days.
89580448|NCT02323334|Experimental|Part D Cohort 10: 6mg|Part D Cohort 10 involved participants with Alzheimer's disease and was comprised of one period. 6mg LY3202626 was given PO once daily for 14 days. Dose determined by Part B.
89580449|NCT02448719|Experimental|Cohort 1-active|Single oral administration of TAK-792 30 milligram (mg) in Japanese participants
89580450|NCT02448719|Placebo Comparator|Cohort 1-placebo|Single oral administration of TAK-792 30 mg placebo in Japanese participants
89580451|NCT02448719|Experimental|Cohort 2-active|Single oral administration of TAK-792 100 mg in Japanese participants
89580452|NCT02448719|Placebo Comparator|Cohort 2-placebo|Single oral administration of TAK-792 100 mg placebo in Japanese participants
89580453|NCT02448719|Experimental|Cohort 3-active|Single oral administration of TAK-792 250 mg in Japanese participants
88973791|NCT03578887|Active Comparator|Lifestyle Cohort|Participants Undergoing Behavioral Weight Loss Program
89580454|NCT02448719|Placebo Comparator|Cohort 3-placebo|Single oral administration of TAK-792 250 mg placebo in Japanese participants
89580455|NCT02448719|Experimental|Cohort 4-active|Single oral administration of TAK-792 500 mg in Japanese and Caucasian participants
89580456|NCT02448719|Placebo Comparator|Cohort 4-placebo|Single oral administration of TAK-792 500 mg placebo in Japanese and Caucasian participants
89580457|NCT02448719|Experimental|Cohort 5-active|Single oral administration of TAK-792 750 mg in Japanese and Caucasian participants
89580458|NCT02448719|Placebo Comparator|Cohort 5-placebo|Single oral administration of TAK-792 750 mg placebo in Japanese and Caucasian participants
88973792|NCT03578887|Active Comparator|Surgical Cohort|Participants Scheduled for Roux-en-Y Gastric Bypass Surgery
88973793|NCT03578887|No Intervention|Healthy Weight Control Cohort|Healthy Weight Controls With No Intervention
88973794|NCT03557944|Experimental|TAPER|"The intervention is medication reduction. This arm is comprised of:~Medication reconciliation~Identification of patient priorities for care~Identification of medications that are potentially appropriate for discontinuation/dose reduction~Linked pharmacist/family physician consultations with patient to discuss medication with intention to reduce~Identification of medications for trial of discontinuation/dose reduction (shared decision making)~Pause of medication and clinical monitoring"
89029802|NCT04516577||Peking Union Medical College Hospital|Peking Union Medical College Hospital is a famous hospital in China. Many patients with rare pulmonary disease receive treatment in this hospital.
89580459|NCT02448719|Experimental|Cohort 6-active|Single oral administration of TAK-792 1250 mg in Japanese and Caucasian participants
89580460|NCT02448719|Placebo Comparator|Cohort 6-placebo|Single oral administration of TAK-792 1250 mg placebo in Japanese and Caucasian participants
89580461|NCT02322866|Experimental|Sarecycline|Sarecycline tablets, 1.5 milligram(mg)/kilogram(kg)/day, taken orally once daily for 12 weeks.
89580462|NCT02322866|Placebo Comparator|Placebo|Placebo-matching sarecycline tablets, taken orally once daily for 12 weeks.
89580463|NCT04198376|Experimental|The Laterally Closed Tunnel Technique with SCTG|Following the administration of local anaesthesia 2% lignocaine hydrochloride.In the LCT technique a bevelled intrasulcular incisions will be made around the necks of the affected teeth with Orban Knife.The tunnelling will be accomplished with tunneling instrument (TKN2).A mucoperiosteal tunnel will be prepared using a specially designed tunneling instrument.The muscle and collagen fibres will be released using surgical blades and gracey curettes. Subepithelial CTG will be harvested from palate using single incision technique.The graft will be removed and will be placed on saline soaked gauze and kept wet until its transfer to the recipient bed.An immediate closure of the donor site is performed using modified mattress sutures.The graft will be adapted to the CEJ by means of sling suture.Finally the margins of the pouch will be pulled together over the graft and sutured with interrupted sutures
89580464|NCT04198376|Experimental|Modified Coronally Advanced Tunnel Technique with SCTG.|In MCAT technique all the buccal tissues will be undermined and connected only the papillary region will be left attached.A full thickness preparation of the papillary region will be created this will be done with a small elevator .A second surgical site will be prepared to obtain the subepithelial CTG using single incision technique.A support suture will be performed to guide the CTG into the recipient site. After sutures are slid through each tunnelled interdental area the needle will be pushed through the CTG before it is guided back through the undermined tissues.The graft will be gently pushed into the pouch with a packing instrument and by pulling the support suture.The entire gingival papillary complex will be moved coronally using a vertical mattress suture anchored in the lingual gingiva.The anchorage in the lingual gingiva will be placed far apically.The suture must capture the buccal flap and graft to avail optimal stabilization.
89580465|NCT02463071|Experimental|AZD0585 2g group|AZD0585 1g × 2 capsules and AZD0585 placebo 1g × 2 capsules once daily
89580466|NCT02463071|Experimental|AZD0585 4g group|AZD0585 1g × 4 capsules once daily
89580467|NCT02463071|Placebo Comparator|Placebo control group|AZD0585 placebo 1g × 4 capsules once daily
89580468|NCT02266381|Other|US-guided group|Patients in US-guided group undergo MPCNL using only US-guided renal access.
89580469|NCT02266381|Other|Fluoroscopy-guided group|Patients in Fluoroscopy-guided group undergo MPCNL using only fluoroscopy-guided renal access.
89580470|NCT02266381|Other|Combined-guided group|Patients in Combined-guided group undergo MPCNL using US combined with fluoroscopy-guided renal access.
89580471|NCT01827046|Experimental|MIS plus rt-PA management|Subjects randomized to the Minimally Invasive Surgery (MIS) plus rt-PA management arm will undergo minimally invasive surgery followed by up to 9 doses of 1.0 mg of rt-PA (Activase/Alteplase/CathFlo) for intracerebral hemorrhage clot resolution.
89580472|NCT01827046|No Intervention|Medical management|Subjects randomized to medical management will receive the standard medical therapies for the treatment of intracerebral hemorrhage, which includes ICU care only and no planned surgical intervention.
89580473|NCT02356562|Experimental|3-DAA with or without SOF and RBV|3-DAA (ombitasvir/paritaprevir/ritonavir once daily [QD] and dasabuvir twice daily [BID]) with and without sofosbuvir (SOF) QD and with or without ribavirin (RBV) BID for 12 or 24 weeks
89580474|NCT02448563|Experimental|Intervention|Weekly, in-person, support groups providing nutrition and physical activity education
89580475|NCT02448563|No Intervention|Control|Standard of care - one counseling visit with a study dietitian
89580476|NCT02266225|Experimental|Lifestyle-integrated functional exercise|Lifestyle-integrated functional exercise- one individual and four group-based sessions led by a physiotherapist over two months, and two phone calls one week and one month following final group-based exercise session.
89580477|NCT02354690|Experimental|A|7 days before tumor harvest, patients will begin taking vemurafenib until admission for lymphodepleting chemotherapy regimen of cyclophosphamide and fludarabine, followed by TIL infusion and interleukin-2.
88973795|NCT03549845|Experimental|CHAP Intervention|The Cardiovascular Health Awareness Program (CHAP) intervention is an on-site drop-in, monthly, cardiovascular risk assessment program run by trained volunteers with community-led group health sessions that deliver education and information about access to community health resources. The education sessions will be delivered by national and provincial and local community organizations utilizing already developed material as much as possible, but maintaining consistency across both provinces. Health education sessions will include topics such as: Physical Activity, Healthy Eating, Stress, Tobacco Use, High Blood Pressure, Role of Pharmacist: How they can assist people, and Appropriate use of 9-1-1. This intervention will be held in a common room in selected subsidized housing buildings.
88973796|NCT03549845|No Intervention|Control|The control buildings will receive usual care which will be wellness programs already present in the building prior to the RCT if these are present. Not all control buildings will have wellness programs.
88973797|NCT03533504||Variability in individual PK|Patients with hemophilia A or B, of any severity, who are registered on the web-accessible population pharmacokinetics- hemophilia (WAPPS-Hemo) database, and for whom infusion and/or PK data is available.
88973798|NCT03525873|Experimental|ARM I (methylphenidate, physical activity)|Patients receive methylphenidate PO BID for up to 2 weeks in the absence of disease progression or unacceptable toxicity. Patients also complete physical activity consisting of walking and resistance exercise over 25-40 minutes QD 4 days a week. After 2 weeks, patients may continue methylphenidate at the discretion of the treating physician for up to 12 weeks in the absence of disease progression or unacceptable toxicity.
88973799|NCT03525873|Placebo Comparator|ARM II (placebo, physical activity)|Patients receive a matched placebo PO BID and complete physical activity as in Arm I. Treatment continues for up to 2 weeks in the absence of disease progression or unacceptable toxicity.
89580478|NCT02354222|Experimental|Teneligliptin + Canagliflozin|Patients receive Teneligliptin for 24 weeks in combination with Canagliflozin.
89580479|NCT02354222|Placebo Comparator|Placebo + Canagliflozin|Patients receive placebo for 24 weeks in combination with Canagliflozin.
89580480|NCT02353442|Placebo Comparator|Control group|"This group will perform during 4 weeks:~placebo ultrasound during 5min ;~scapular squeezing in the sitting position (3x10repetitions);~upper trapezius stretching (in sitting position, 3x30s and 30s of rest)."
89580481|NCT02353442|Active Comparator|Experimental group|"This group will perform during 4 weeks:~posterior shoulder mobilizations during 5min (mobilizations during 30s and 30s of rest);~external rotators strengthening in sidelying positions with load (3x10repetitions);~posterior capsule stretching (sleeper stretch in sidelying position, 3x30s and 30s of rest)."
89580482|NCT02351960|Experimental|Dexlansoprazole 30 mg|Dexlansoprazole 30 mg, capsules, orally, once daily for up to 4 weeks to participants with non-erosive reflux disease (NERD).
89580483|NCT02351960|Experimental|Dexlansoprazole 60 mg|Dexlansoprazole 60 mg, capsules orally, once daily for up to 8 weeks to participants with erosive esophagitis (EE).
89580484|NCT02351180|Experimental|Inhaled beclomethasone|Inhaled beclomethasone 320 mcg twice daily for 180 days.
89580485|NCT02351180|Placebo Comparator|Placebo|Inhaled placebo twice daily for 180 days.
89580486|NCT02350478|Active Comparator|Linagliptin|The subjects will receive Linagliptin 5mg (licensed dose for treatment of type 2 diabetes) .
89580487|NCT02350478|Placebo Comparator|Placebo|The subjects will receive placebo.
89580488|NCT02349542|Experimental|Liposomal bupivacaine|Patients will receive liposomal bupivacaine following simultaneous bilateral total knee arthroplasty.
89580489|NCT02321930|Other|tofacitinib 5mg po bid|Open label with tofacitinib 5mg po bid
89580490|NCT01647542|Experimental|TAK-875 25 mg|TAK-875 25 mg tablets, orally, once daily for up to 24 weeks.
89580491|NCT01647542|Experimental|TAK-875 50 mg|TAK-875 50 mg tablets, orally, once daily for up to 24 weeks.
89580492|NCT01647542|Placebo Comparator|Placebo|TAK-875 placebo-matching tablets, orally, once daily for up to 24 weeks.
89580493|NCT02321462|Experimental|Eziclen|
89580494|NCT02321462|Active Comparator|Fortrans®|
89029803|NCT04516577||Nanjing Drum Tower Hospital|The Department of Respiratory and Critical Care Medicine of Nanjing Drum Tower Hospital has been focusing on the research of rare pulmonary diseases for many years.
89580495|NCT02391584|Experimental|XprESS|Balloon dilation of the Eustachian tube
89580496|NCT02391584|Other|Control|Continued medical management
89580497|NCT02266147|Experimental|SD-101 in combination with low-dose radiation|"PART 1~Radiation: 2 fractions of 2 Gy over 2 days at Days -1 and 1~COHORT 1: 1 mg/mL at Days 1, 8, 15, 22, and 29~COHORT 2: 2 mg/mL at Days 1, 8, 15, 22, and 29~COHORT 3: 4 mg/mL at Days 1, 8, 15, 22, and 29~COHORT 4: 8 mg/mL at Days 1, 8, 15, 22, and 29~PART 2~Cycle 1: Required~Radiation: 2 fractions of 2 Gy over 2 days at Days -1 and 1~COHORT 1: 1 mg/mL at Days 1, 8, 15, 22, and 29~COHORT 2: 8 mg/mL at Days 1, 8, 15, 22, and 29~Cycle 2: Optional~Radiation: 2 fractions of 2 Gy over 2 days at Days 180 and 181~COHORT 1: 1 mg/mL at Days 181, 188, 195, 202, and 209~COHORT 2: 8 mg/mL at Days 181, 188, 195, 202, and 209"
89580498|NCT04873843|Experimental|Functional digital game training group|These functional digital game programs have been developed to improve the intelligence and vitality in the community-dwelling elderly. The program includes sub-categories such as attention, working memory, memory and executive functions with various levels of difficulty.
89580499|NCT04873843|Experimental|Individual cognitive training|Individual cognitive training has been used to improve the intelligence and cognitive function in community-dwelling elderly. The program includes sub-categories such as attention, working memory, memory and executive functions with various levels of difficulty.
89580500|NCT05647135||Group A|Group A - enteral formula with 6.3 g/100 ml protein
89580501|NCT05647135||Group B|enteral formula with 10 g/100 ml protein
89029804|NCT02951754|Experimental|IR-MPH|Immediate-release methylphenidate (IR-MPH) 10 mg two or three times daily with doses increasing weekly until symptom control
89029805|NCT00504374||Symptoms Questionnaire|Patients with lung cancer.
89580502|NCT05402917||Thoracic Epidural Analgesia (TEA)|For patients undergoing TEA is done under general anesthesia after surgery procedure.Once the catheter is secured, a bolus dose of 15 ml of 0.25% bupivacaine will be administered as an epidural injection through the catheter, followed by a continuous infusion of 0.125% bupivacaine at a rate of 0.1 mL/kg/h for the postoperative 24-hour period.
89580503|NCT05402917||Erector Spina Plan Block (ESPB)|For patients undergoing ESPB is done under general anesthesia after surgery procedure.A bolus dose of 15 mL of 0.25% bupivacaine will be administered from the inserted catheter. Subsequently, 0.125% bupivacaine will be given continuously at a rate of 0.1 mL/kg/h for up to 24 hours post-operatively.
89580504|NCT02264977|Experimental|Branched TAG® Device|Treatment with the GORE® TAG® Thoracic Branch Endoprosthesis
89029806|NCT02952066|Experimental|TRP1 Density|Bronchial Biopsy: During the biopsy procedure the investigator will collect five bronchial specimens (1-2 cubic millimeters) each the major, lobar and segmental bronchi.
89029807|NCT00513045|Experimental|IRT|Intervention based on Imagery Rehearsal Therapy
89029808|NCT00513045|Active Comparator|Exposure|Treatment based on exposure
89580505|NCT02264821|Experimental|ropivacaine infiltration|ropivacaine 2 mg/ml bolus 15 ml continuous 10 ml/h wound infusion and intrathecal saline
89580506|NCT02264821|Experimental|rachi morphine|100 µg intrathecal morphine and saline infiltration
89580507|NCT02264821|Placebo Comparator|placebo|intrathecal saline and saline infiltration
89580508|NCT04854889|Experimental|Decitabine|Subjects will receive low-dose decitabine for 4 cycles and for another 6 cycles in extension study for patients achieving response during the first 4 cycles.
89580509|NCT02261467|Experimental|OnabotulinumtoxinA|OnabotulinumtoxinA injected into the protocol-specified areas on Day 1. Subjects will receive at least 1 and up to 3 treatments.
89029809|NCT00513045|No Intervention|Nightmare diary|Recording nightmares in a diary
89029810|NCT00513045|No Intervention|Waiting list|Waiting list
89029811|NCT00513084|Experimental|SDT Intervention|This arm will follow main experimental intervention, as described elsewhere
88973800|NCT03503929|Other|LaparoGuard System|All patients receiving laparoscopic surgery, candidates for prolonged time under anesthesia, and are admitted for gynecological, urological or general surgery procedures who consent to use of the LaparoGuard System.
88973801|NCT03492125|Experimental|Phase I Dose Escalation Cohort A1 (MS-553 Monotherapy)|R/R CLL/SLL patients
88973802|NCT03492125|Experimental|Phase II Expansion Cohort A2 (MS-553 Monotherapy)|R/R CLL/SLL patients
88973803|NCT03492125|Experimental|Phase II Expansion Cohort A3 (MS-553 Monotherapy)|patients with aggressive lymphoma
88973804|NCT03492125|Experimental|Phase I Combination Dose Escalation Cohort B1|BTK inhibitor naïve CLL/SLL patients
88973805|NCT03492125|Experimental|Phase II Expansion Cohort B2|BTK inhibitor naïve CLL/SLL patients
88973806|NCT03492125|Experimental|Phase II Expansion Cohort B3|BTK inhibitor naïve CLL/SLL patients with certain gene mutations
88973807|NCT03492125|Experimental|Phase I Combination Dose Escalation Cohort C1|Bcl-2 inhibitor naïve CLL/SLL patients
88973808|NCT03492125|Experimental|Experimental: Phase II Expansion Cohort C2|Bcl-2 inhibitor naïve CLL/SLL patients
88973809|NCT03490630||All patients|Patients undergoing elective surgery with anesthesia
88973810|NCT03489499||All patients|Patients undergoing elective surgery with anesthesia
88973811|NCT03476590|No Intervention|standard care|In standard care group the patients will be recommended to visit physician/cardiologists in standard healthcare system. Two non-interventional visits will be performed: recruitment visit (day of enrolment) and summary visit (12th month after the enrolment)
88973812|NCT03476590|Experimental|intervention group|"In intervention group patients will be referred to ambulatory care point (ACP) and the physicians will perform remote teleconsultations. The visits will be realized by nurses supported with vital sign assessment based on bioimpedance diagnostic methods (impedance cardiography, bioimpedance scale). The ambulatory visits will be performed according to the schedule: (1') recruitment visit (1st day of enrolment) performed by physician -> 7 ambulatory visits: (1) 1st day of enrolment (performed by nurse and physician), (2) 7th-10th day (performed by nurse and physician), (3) 1st month, (4) 3th month, (5) 6th month, (6) 9th month, (7) 12th month after the enrolment (visits no 3-7 performed by nurse with tele-supervision by physician) and -> (7') summary visit (12th month after the enrolment) performed by physician.~The plan of visits may be modified if required by the clinical status change, i.e. deterioration of clinical parameters and interim hospitalizations for worsening heart failure."
88973813|NCT03459677|Experimental|Back2School Condition|"The Back2School condition is a Modular Trans-Diagnostic Cognitive Behavioral Therapy (MTCBT) treating school absenteeism in youths.~The MTCBT intervention consist of 10 sessions and 4 school meetings, conducted over a period of 4 months."
88973814|NCT03459677|Active Comparator|Treatment As Usual Condition|"The Treatment As Usual condition (TAU) consist of an array of interventions that the municipality is required to give youths presenting school absenteeism.~The TAU condition will last for 4 months."
88973815|NCT03356873|Experimental|Active|Vitamin D 5000 units capsules, 20 capsules per week during four weeks (total 400,000 units)
88973816|NCT03356873|Placebo Comparator|Placebo|Identical placebo capsules, 20 capsules per week during four weeks
88973817|NCT03305341|Experimental|Assess for therapeutic biologics activity (proof-of-concept)|"0.1mg Spike-GM-CSF Protein~0.5 ml Lactated Ringer's Injection, USP"
88973818|NCT03255473|Active Comparator|Dexamethasone|All subject identification (ID) numbers will be randomly assigned to the dexamethasone or the prednisone arm of the trial prior to the initiation of the study.
88973819|NCT03255473|Active Comparator|Prednisone|All subject ID numbers will be randomly assigned to the dexamethasone or the prednisone arm of the trial prior to the initiation of the study.
88973820|NCT03253835||Myocardial Injury|patients with myocardial injuries due to ischemic heart disease, patients with myocardial injuries due to non-ischemic heart disease.
88973821|NCT03253835||No Myocardial Injury|subjects without myocardial injuries with normal cardiac function subjects without myocardial injuries with altered cardiac function
88973822|NCT03956706|Experimental|Dose Escalation (18Gy)|Receive additional dose of 18Gy to the subventricular zone
88973823|NCT03956706|Experimental|Dose Escalation (20Gy)|Receive additional dose of 20Gy to the subventricular zone
88973824|NCT03956706|Experimental|Dose Escalation (22Gy)|Receive additional dose of 22Gy to the subventricular zone
88973825|NCT03197363||Białystok PLUS|Participation in the study will be offered to 10000 inhabitants of Bialystok aged 20-80 years. They will be randomly selected from the registry of Bialystok inhabitants. The goal of study is to discover novel risk factors and mechanisms underlying civilization diseases.
88973826|NCT03176277|Experimental|ONO-7475 (Part A)|Successive dose escalation cohorts to determine MTD/OBD
88973827|NCT03176277|Experimental|ONO-7475 + venetoclax (Part D)|Successive dose escalation of ONO-7475 cohorts + venetoclax
89580510|NCT02261467|Placebo Comparator|Placebo followed by OnabotulinumtoxinA in Period 2|Placebo (normal saline) injected into the protocol-specified areas on Day 1. If the subject meets the re-treatment criteria in Period 2, the subject will receive up to 2 open-label treatments with onabotulinumtoxinA into the protocol-specified areas.
89580511|NCT05646823|Placebo Comparator|Placebo|vehicle only - Maltodextrin gluten free
89580512|NCT05646823|Experimental|Treatment|Bifidobacterium longum CCT 1934; Bifidobacterium lactis CCT 7858; Lactobacillus rhamnosus CCT 7863; Streptococcus thermophilus ATCC 19258) Final concentration: 1 x 10e10 CFU/ day
89580513|NCT01643473|Active Comparator|Attention Control|Health education videos on topics unrelated to medication adherence, hypertension or type 2 diabetes
89580514|NCT01643473|Experimental|Tailored Adherence Intervention|Tablet-based tailored adherence intervention matched to patients' most salient adherence barriers
89580515|NCT05646277||Test|first remote-assisted orthodontic teleconsultation
89580516|NCT05646277||Control|classic first consultation (face-to-face consultation)
88973828|NCT03172117|Experimental|NEUROSTEM® (hUCB-MSCs)- low dose|human umbilical cord blood derived mesenchymal stem cells Low dose: 1 x 10^7cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals
88973829|NCT03172117|Experimental|NEUROSTEM® (hUCB-MSCs) - high dose|human umbilical cord blood derived mesenchymal stem cells High dose: 3 x 10^7 cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals
88973830|NCT03172117|Placebo Comparator|Placebo|normal saline 2mL, doses separated by 4 weeks for a total of 3 doses
88973831|NCT03098225|Experimental|Radiotherapy|Patients with moderately severe GO treated with Intravenous glucocorticoids associated with orbital radiotherapy
88973832|NCT03098225|Active Comparator|No Radiotherapy|Patients with moderately severe GO treated with Intravenous glucocorticoids alone
88973833|NCT03088839||30 ALS patients|
88973834|NCT03088839||30 healthy controls|
88973835|NCT03071341|Experimental|AGT-181|Human Insulin Receptor Monoclonal Antibody-Human alpha-L-iduronidase (HIRMAb-IDUA) fusion protein
89580517|NCT05344651|Active Comparator|Baerveldt glaucoma drainage device|
89580518|NCT05344651|Experimental|Paul glaucoma drainage device|
88973836|NCT03053089|Experimental|Stage 1 (adult)|AGT-181
88973837|NCT03053089|Experimental|Stage 2 (children)|AGT-181
88973838|NCT02990468|Experimental|Radiation Therapy, Cisplatin and BMX-001|In Phase 1, safety and tolerability of BMX-001 will be assessed using a Continual Reassessment Method and a maximum tolerated dose (MTD) will be determined using a single arm design. In Phase 2, the severity of radiation-induced mucositis and xerostomia will be assessed using a single arm design.
88973839|NCT02952170|Experimental|MRI for steatosis assessment|Abdominal MRI for assessment of hepatic steatosis
88973840|NCT02882100|Experimental|aTIV|NH facilities randomized to receive adjuvanted trivalent influenza vaccine (aTIV, FLUAD) for the residents
88973841|NCT02882100|Active Comparator|TIV|NH facilities randomized to receive standard trivalent influenza vaccine (TIV, Fluvirin) for the residents
88973842|NCT02855944|Experimental|Rucaparib|"Drug: Oral rucaparib~600 mg BID (twice a day)~Other Names:~CO-338~PF 01367338~AG 14699~Rubraca"
88973843|NCT02855944|Active Comparator|Chemotherapy|"Monotherapy platinum (cisplatin or carboplatin) or platinum-based doublet chemotherapy (carboplatin/paclitaxel, carboplatin/gemcitabine, or cisplatin/gemcitabine administered per local standard of care and regulations. Specific comparator will depend on platinum status and investigator decision.~Single agent paclitaxel will be administered per local standard of care and regulations. Specific comparator will depend on platinum status and investigator decision."
88973844|NCT02730338|Active Comparator|Arm A: Supervised exercise group|Supervised high intensity aerobic and resistance exercise tapering to self management with psychosocial support
88973845|NCT02730338|Other|Arm B: Self directed exercise group|Self directed exercise and psychosocial support group
88973846|NCT02688569|Experimental|CBT-CWP|Participants in this condition will receive Cognitive Behavioral Therapy for Chronic Widespread Pain (CBT-CWP)
88973847|NCT02688569|No Intervention|Control|Participants in the Control condition will not receive CBT-CWP. They will however, continue completing the weekly assessments.
89580519|NCT05341843|Experimental|sertraline|they will receive sertraline at the intended dose of 50 mg twice daily for 8 weeks.
89580520|NCT05341843|Placebo Comparator|placebo|They will receive a placebo in the form of multivitamin tablets similar to the experimental drug with the same regimen, as one tablet /day for 8 weeks
89580521|NCT02320058|Experimental|Nivolumab and Ipilimumab|"Induction Phase: Nivolumab + Ipilimumab infusion intravenously~Maintenance Phase: Nivolumab infusion intravenously"
89580522|NCT02319668|Experimental|Test product|Mouthwash containing 0.2% w/v Chlorhexidine digluconate
89580523|NCT02319668|Placebo Comparator|Control|Sodium fluoride toothpaste (Aquafresh Mild & Minty)
89580524|NCT02092467|Experimental|Treatment Arm 1|
89580525|NCT02092467|Experimental|Treatment Arm 2|
88973848|NCT02681055|Experimental|open label arm|All 40 subjects will receive MN-001 for the first 4 weeks. At Week 4 subjects will increase their dosage frequency for remaining 8 weeks. Subjects will receive MN-001 for a total of 12 weeks.
88973849|NCT02603848|Experimental|Ibuprofen suspension|Ibuprofen suspension (Advil) will be administered orally at a dose of 10mg/kg every 6 hours for 72 hours post-surgery.
88973850|NCT02603848|Active Comparator|Morphine Sulfate suspension|Morphine sulfate suspension will be administered orally at a dose of 0.02 - 0.04 mg/kg every 6 hours for 72 hours post-surgery.
88973851|NCT02580539|Experimental|Autologous or allogenic (stem cell donor) T cells|Subjects receive an autologous anti-EBV T-cell line or a T-cell line derived from the patient's allogeneic (stem cell transplant) donor.
89580526|NCT02092467|Active Comparator|Treatment Arm 3|TNF inhibitor Arm - adalimumab will be used in US, Canada and Puerto Rico; etanercept will be used in all other countries.
89580527|NCT02462759|Experimental|Nusinersen|Administered by intrathecal injection.
89580528|NCT02462759|Sham Comparator|Sham Procedure|Small needle prick on the lower back at the location where the IT injection is normally made.
89580529|NCT04420871|Active Comparator|capecitabine reference formulation at a single dose of 150 mg|150 mg of Xeloda® produced by Genentech USA, Inc., a subsidiary of the company, was used as the reference intervention in this study.
89580530|NCT04420871|Experimental|capecitabine test formulation at a single dose of 150 mg|The tablet of 150 mg of capecitabine from Qilu Pharmaceutical Co., Ltd. (17H0053DE4, Jinan, Shandong Province, China) was used as the test formulation.
89580531|NCT02349386|Experimental|BHR-200 Low Dose|3 mg estradiol per 1 mL 0.36% BHR-200 (transdermal 17β-estradiol gel) applied daily to the skin for up to 52 weeks.
88973852|NCT02580539|Experimental|"Allogeneic third party T cells"|Subjects receive a T-cell line from a matched or partially matched related donor.
88973853|NCT02512887|Experimental|Caudal Block Anesthesia|Anesthesia will be delivered via inhalation induction with air/nitrous oxide and sevoflurane, and injection of 0.25% bupivacaine 1mL/kg without epinephrine into the caudal canal, which is the sacral portion of the spinal canal.
88973854|NCT02512887|Active Comparator|Dorsal Penile Block Anesthesia|Anesthesia will be delivered via inhalation induction with air/nitrous oxide and sevoflurane, and injection of 0.25% bupivacaine without epinephrine into the dorsal portion of the penis.
88973855|NCT02484261|No Intervention|Monitoring phase|Patients who have received a Stem cell transplant for Hematologic malignancies will be monitored for signs of relapse with blood tests for CD34+ chimerism. Patients with signs of relapse will have bone marrow aspirate and/or other appropriate tests to confirm presence of relapse. All patients who are confirmed to have relapsed and meet eligibility criteria to receive study drug will be eligible to receive treatment on the treatment arm.
88973856|NCT02484261|Experimental|Treatment phase|Patients with confirmed disease will initiate therapy with bortezomib and pravastatin, a regimen that has efficacy in treatment of leukemia and graft-versus-host disease, while sparing healthy donor hematopoietic stem cells may improve the dismal survival of relapse post allogeneic transplant. Depending on response, patients may receive up to 13 cycles of therapy
88973857|NCT02459002||NSCLC - Current Palliative Care Referral Practices|Early palliative consultation impact assessment via questionnaires during a regularly scheduled clinic visit or during inpatient stay.
88973858|NCT02459002||Primary Caregiver|Caregiver satisfaction with quality of care and early palliative consultation impact assessed via questionnaires during a regularly scheduled clinic visit or during inpatient stay.
88973859|NCT02459002||NSCLC - After Early Palliative Care Consult System|Palliative consultation impact assessment via questionnaires during a regularly scheduled clinic visit or during inpatient stay.
88973860|NCT02438007|Experimental|Galeterone|
88973861|NCT02438007|Active Comparator|Enzalutamide|
88973862|NCT02409342|Active Comparator|(Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine)|Participants with non-squamous NSCLC will receive chemotherapy with pemetrexed in combination with either cisplatin or carboplatin (per investigator discretion) on Day 1 of each 21-day cycle for 4 or 6 cycles as per local standard of care, followed by maintenance therapy with pemetrexed alone as per local standard of care until disease progression (per RECIST v1.1), unacceptable toxicity, or death (maximum up to approximately 58 months). Participants with squamous NSCLC will receive chemotherapy with gemcitabine on Days 1 and 8 of each 21-day cycle in combination with either cisplatin or carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles as per local standard of care, followed by best supportive care as per local standard of care until disease progression, unacceptable toxicity, or death (maximum up to approximately 58 months).
88973863|NCT02409342|Experimental|Atezolizumab|Participants with squamous or non-squamous NSCLC will receive atezolizumab on Day 1 of each 21-day cycle until loss of clinical benefit (as assessed by the investigator), unacceptable toxicity, or death (maximum up to approximately 58 months).
88973864|NCT02356523||Delirium patients|Patients positive to Confusion Assessment Method (CAM) assessment ad admission and during hospital stay
88973865|NCT02356523||control group|Patients negative to Confusion Assessment Method (CAM) assessment ad admission and during hospital stay
88973866|NCT02352506||AKI|Patients developing AKI during the ICU stay
88973867|NCT02352506||No AKI|Matched controls not developing AKI during the ICU stay
88973868|NCT02336503|Experimental|BBI-4000 Gel, 5%|Low concentration of BBI-4000; BBI-4000 Gel, 5%
89580532|NCT02349386|Experimental|BHR-200 Mid Dose|6 mg estradiol per 2 mL 0.36% BHR-200 (transdermal 17β-estradiol gel) applied daily to the skin for up to 52 weeks.
89580533|NCT02349386|Experimental|BHR-200 High Dose|9 mg estradiol per 3 mL 0.36% BHR-200 (transdermal 17β-estradiol gel) applied daily to the skin for up to 52 weeks.
89580534|NCT02349386|Placebo Comparator|Placebo|1, 2 or 3 mL of Placebo gel containing 0 mg estradiol applied daily for up to 52 weeks.
89580535|NCT04935047|Experimental|Experimental (Multilingual Support)|The treatment group will receive seven hours multilingual support weekly.
89580536|NCT04935047|No Intervention|Control group|The control group will receive the same amount of support as the experimental group, but from a person without multilingual qualifications.
88973869|NCT02336503|Experimental|BBI-4000 Gel, 10%|Middle concentration of BBI-4000; BBI-4000 Gel, 10%
88973870|NCT02336503|Experimental|BBI-4000 Gel, 15%|High concentration of BBI-4000; BBI-4000 Gel, 15%
88973871|NCT02336503|Placebo Comparator|Vehicle|Vehicle (placebo); BBI-4000 Gel, 0%
88973872|NCT02255409|Experimental|aQIV|Adjuvanted Quadrivalent Subunit Influenza
88973873|NCT02255409|Active Comparator|QIV|Non-Adjuvanted Quadrivalent Subunit Influenza
88973874|NCT02230826||Patients with Hip arthroplasty|Patients with Hip implants.
88973875|NCT02213757|Experimental|Premarin vaginal cream|Premarin vaginal cream to be applied intra-vaginally and to vulva as follows: 1 gram nightly for 2 weeks, followed by 0.5 gram twice weekly for 6 weeks.
88973876|NCT02213757|Placebo Comparator|Placebo vaginal cream|Placebo vaginal cream to be applied intra-vaginally and to vulva as follows: 1 gram nightly for 2 weeks, followed by 0.5 gram twice weekly for 6 weeks.
88973877|NCT02137824|Experimental|sinus floor elevation|
88973878|NCT02124499||All patients|Patients undergoing elective surgery with anesthesia
88973879|NCT02102243|Experimental|Hyperinsulinemic euglycemic clamp|"We will perform following procedures:~DEFINITY® infusion Flow mediated vasodilation Endothelial cell collection Microvascular perfusion assessment using Definity Microneurography"
89029812|NCT00513084|No Intervention|Comparison Group|Comparison Group receiving standard care health promotion intervention
89580537|NCT04934891|Experimental|ION547|Ascending single multiple doses of ION547 will be administered by SC injection.
89580538|NCT04934891|Placebo Comparator|Placebo|Ascending single multiple doses of ION547-matching placebo will be administered by SC injection.
89580539|NCT04892888||COVID-19 Vaccine Intramuscular Injection 0.5 mL|COVID-19 vaccine intramuscular injection, 2 doses of 0.5 mL per dose administered intramuscularly at an interval of 4 weeks.
89580540|NCT02036775|Experimental|Treatment sequence 1|Treatment 1, Washout 6 days, Reference product, Washout 6 days, Treatment 2
89580541|NCT02036775|Experimental|Treatment sequence 2|Treatment 2, Washout period 6 days, Treatment 1, Washout 6 days, Reference product
89580542|NCT02036775|Experimental|Treatment sequence 3|Reference product, Washout 6 days, Treatment 2, Washout 6 days, Treatment 1
89580543|NCT02036775|Experimental|Treatment Sequence 4|Treatment 2, Washout 6 days, Reference product, Washout 6 days, Treatment 1
89580544|NCT02036775|Experimental|Treatment sequence 5|Reference product, Washout 6 days, Treatment 1, Washout 6 days, Treatment 2
89580545|NCT02036775|Experimental|Treatment Sequence 6|Treatment 1, Washout 6 days, Treatment 2, Washout 6 days, Reference product
89580546|NCT02092389||Moderate to Severe Ulcerative Colitis|Patients with moderate to severe ulcerative colitis (UC) who have not responded despite a full and adequate course of therapy with a corticosteroid and an immunosuppressant (azathioprine [AZA]/ 6-mercaptopurine [6-MP]); or who are intolerant to or have medical contraindications for such therapies and are hence prescribed adalimumab for the treatment of moderate to severely active UC.
89580547|NCT02034591|Experimental|Arm A-Apixaban|Solution Apixaban 5 mg ( 0.4 mg/ml oral solution x 12.5 ml) through mouth or oral syringe
89580548|NCT02034591|Experimental|Arm B-Apixaban|Oral Solution Apixaban 5 mg single dose (0.4 mg/mL oral solution x 12.5 mL) after 180 mL of Boost Plus®, followed by 60 mL of Boost Plus® via same NGT
89580549|NCT02034591|Experimental|Arm C-Apixaban|Single dose crushed Apixaban tablet 5 mg (5 mg tablet crushed and suspended in 60 mL Dextrose 5% in water (D5W)) through NGT
89580550|NCT02391116|Experimental|Copanlisib (Aliqopa, BAY80-6946)|Copanlisib (Aliqopa, BAY80-6946) solution for IV infusion (test drug/investigational medicinal product)
89580551|NCT02091921|Experimental|Experimental|All subjects will receive Ticagrelor.
89580552|NCT02447081||Subjects implanted with Amulet Device|All subjects who receive the Amulet device will be followed.
89580553|NCT02391038|Experimental|MLN0264|"Phase 1: MLN0264 1.2 milligram per kilogram (mg/kg) starting dose, Intravenous (IV), on Day 1 of 3 week cycles, for up to 1 year or until disease progression or unacceptable toxicity. Dosage of MLN0264 will be increased to 1.5 mg/kg then 1.8 mg/kg using a 3 + 3 dose escalation design to determine a maximum tolerated dose (MTD) and/or recommended Phase 2 Dose (RP2D).~Phase 2: MLN0264, IV, on Day 1 of 3 week cycles, for up to 1 year or until disease progression or unacceptable toxicity. Dosage for this phase will be determined from results of Phase 1 MTD/RP2D."
89580554|NCT02260921|Experimental|iovera° Treatment|Treatment with the iovera° device administered by a trained investigator to treat knee pain.
89580555|NCT02260921|Sham Comparator|Sham Treatment|Sham Treatment (similar device with no active therapeutic treatment) administered by a trained investigator to treat knee pain.
89580556|NCT02462603|Experimental|PTC589|Participants with Parkinson's disease (idiopathic and mitochondrial genetic subtype participants) will receive PTC589 at a dose of 500 milligrams (mg) (2 tablets of 250 mg each) orally twice daily (BID) for up to 3 months unless discontinued for safety or tolerability issues.
88973880|NCT02102243|Experimental|Initial Saline Infusion|"We will perform the following procedures:~DEFINITY® infusion Human Recombinant Regular Insulin infusion Dextrose infusion Flow mediated vasodilation Endothelial cell collection Microvascular perfusion assessment using Definity Microneurography"
88973881|NCT02081924|Active Comparator|Kisspeptin 0.1|Participants will receive kisspeptin hormone at a dose rate of 0.1nmol/kg/hour via a subcutaneous pump device for 8 days during the early follicular phase of their menstrual cycle.
88973882|NCT02081924|Placebo Comparator|Saline|Participants will receive placebo (saline) via a subcutaneous pump device for 8 days during the early follicular phase of their menstrual cycle.
88973883|NCT02081924|Active Comparator|Kisspeptin 0.3|Participants will receive kisspeptin hormone at a dose rate of 0.3nmol/kg/hour via a subcutaneous pump device for 8 days during the early follicular phase of their menstrual cycle.
88973884|NCT02081924|Active Comparator|Kisspeptin 1.0|Participants will receive kisspeptin hormone at a dose rate of 1.0nmol/kg/hour via a subcutaneous pump device for 8 days during the early follicular phase of their menstrual cycle.
88973885|NCT01969227|Experimental|Cohort|Adult mechanically ventilated patients who are deemed eligible for a spontaneous breathing trial and are candidates to receive subanesthetic ketamine by the primary critical care team.
88973886|NCT01845571||Retinal detachment group|400 patients patients, who received surgery due to retinal detachment exclusion: if patients had prior vitrectomy or scleral buckel if patients have no adequate follow-up
88973887|NCT01778322||Index Embolization Cohort|WEB Aneurysm Embolization System
88973888|NCT01771536|Active Comparator|PCI Choice decision|Decision Aid intervention is provided to clinician to share with patient
88973889|NCT01771536|No Intervention|Usual Care|
88973890|NCT01758042|Other|Haploidentical Bone Marrow/Kidney|Single Arm Study
88973891|NCT01728597||healthy volunteers|MR compliant volunteers with no history of cardiovascular diseases
88973892|NCT01725763|Other|suspected PH|60 minute Cardiac MRI
88973893|NCT01709734|Experimental|Dose Confirmation|"Dose A - galeterone tablets once daily PO for three months + extension~Dose B - galeterone tablets once daily PO for three months + extension~Dose C - galeterone tablets once daily PO for three months + extension"
88973894|NCT01709734|Experimental|Dose Expansion|Single dose expansion (from part 1) of galeterone tablets once daily PO for three months + extension
88973895|NCT01662713|Experimental|NMSC Imaging|Optical Frequency Domain Imaging (OFDI) will be used to look at non melanoma skin cancer (NMSC) lesion(s).
88973896|NCT01604135|Active Comparator|Corneal Collagen Crosslinking|The keratokonic eye which progresses most is included and randomized. Significant progression is defined in the eligibility criteria section. If randomized to the treatment arm the cornea is treated with collagen crosslinking as described below.
89580557|NCT02034513|Experimental|IDeg OD + IAsp followed by IGlar OD + IAsp|Each treatment period consists of a 16-week wash-out period and a 16-week maintenance period
89580558|NCT02034513|Active Comparator|IGlar OD + IAsp followed by IDeg OD + IAsp|Each treatment period consists of a 16-week wash-out period and a 16-week maintenance period
89580559|NCT05370248|Experimental|The six|The group who received tidal volume of 6 ml/kg from mechanical ventilation
89580560|NCT05370248|Active Comparator|The ten|The group who received tidal volume of 10 ml/kg from mechanical ventilation
89580561|NCT02348840|Experimental|mHealth midwives|Midwives will receive access to mHealth technology immediately and use it for 12 months
89580562|NCT02348840|Active Comparator|mHealth midwives - control|Midwives will not have access to mHealth technology for the first six months, and then will receive the technology for the remaining six months.
89580563|NCT02348840|Active Comparator|Pregnant Women|Pregnant women may or may not receive mHealth technology, based on the collaborating midwife they are assigned.
89580564|NCT02462057|No Intervention|Control Arm|This arm will represent current practice. This group will receive no contact from the research team. They may receive information regarding the benefit from the Vitality marketing team during the intervention period and can enroll in the benefit at any time during the study period.
89580565|NCT02462057|Active Comparator|Diabetes-specific|This group will receive a message which simply cites the two specific benefits of the eating more healthy foods for individuals with diabetes. This message contains a link to start the enrolment process.
89580566|NCT02462057|Active Comparator|Experience of another member|This group will receive a message that includes a quote from the perspective of a Vitality member with diabetes who uses the HealthyFood benefit. Given the need to standardise message content across study arms, the quote was written by the study team and not an actual member. The quote emphasizes the positive impact the benefit has had for the member-both the financial benefit, as well as the two specific diabetes health benefits.
89580567|NCT02462057|Active Comparator|Input from a diabetes expert|This group will receive a message that includes a quote from a South African physician who specializes in diabetes. The quote emphasises the financial benefit and the two specific diabetes health benefits of the HealthyFood program included in the other messages. It concludes with the doctor's recommendation of the benefit for all individuals with diabetes.
89580568|NCT02462057|Active Comparator|Enhanced active choice|"This group will receive a message whose first portion is identical to those in the diabetes-specific message group. The second portion of the message differs in that instead of just asking recipients to click on the provided link if interested, the message asks people to choose and click on one of following possible responses:~Yes! I want to active the HealthyFood benefit and get up to 25% cash back on the healthy food I buy at Pick n Pay or Woolworths~No, I'd prefer not to activate and continue paying full price for my healthy food purchases"
89580569|NCT02461745|Active Comparator|Genotype 1a|Study participants with chronic Hepatitis C Genotype 1A receiving VIEKIRA PAK (two 12.5/75/50 mg ombitasvir, paritaprevir, ritonavir tablets, and two 250 mg dasabuvir tablets) and RBV (ribavirin tablets) for 12 weeks.
89580570|NCT02461745|Active Comparator|Genotype 1b|Study participants with chronic Hepatitis C Genotype 1B receiving VIEKIRA PAK (two 12.5/75/50 mg ombitasvir, paritaprevir, ritonavir tablets, and two 250 mg dasabuvir tablets) for 12 weeks.
89580571|NCT02034435|Active Comparator|Aim1-Low Sodium then High Sodium|"Subjects will be provided with a low sodium diet from the Vanderbilt Clinical Research Center that will be controlled for salt content.~Participants will be given low sodium diet (50mEq/d) and Placebo tablets for 8 days and assessments will be made, washout and then cross over to a low sodium diet (50mEq/d) plus Salt tables (150mEq) for 8days and assessments will be made."
89580572|NCT02034435|Active Comparator|Aim 1-high salt diet then low salt diet|"Subjects will be provided with a diet from the Vanderbilt Clinical Research Center that will be controlled for salt content.~Participants will be given low sodium diet (50mEq/d) and Salt tables (150mEq) for 8 days and assessments will be made, washout and then cross over to a low sodium diet (50mEq/d) plus Placebo tablets for 8days and assessments will be made."
89580573|NCT02034435|Active Comparator|Aim2- low salt diet and epleronone then amlodipine|Subjects on a low salt diet will receive Epleronone 50mg for 8 days and assessments will be made, then cross over to a low salt diet with Amlodipine 5mg for 8days and assessments will be made.
89580574|NCT02034435|Active Comparator|aim2- low salt diet and amlodipine then epleronone|Subjects on a low salt diet will receive Amlodipine 5mg for 8 days and assessments will be made, then cross over to a low salt diet with Epleronone 50mg for 8days and assessments will be made.
89580575|NCT04691427|Experimental|Active Virtual Reality-Based Vision Therapy|Virtual reality vision therapy where participants will be playing a custom-designed video game to act as a therapeutic intervention on a consumer-available virtual reality headset.
88811148|NCT04199117|Experimental|No Incentive,Untailored,No Care Manage,IntensiveTreatment|Participants randomly assigned to this condition will not have access to incentives for completing smoking cessation counseling, will receive 5 untailored letters promoting use of smoking cessation treatment over 2 years, will not Tobacco Care Management support and motivational encouragement calls, and will have access to 3 smoking cessation quit counseling calls and 12-weeks of either combination nicotine replacement or varenicline up to 4 times over 2 years.
88973897|NCT01604135|No Intervention|Control group|The keratokonic eye which progresses most is included and randomized to either the treatment group (CXL) or the control group.
88973898|NCT00852657|Active Comparator|Surgical treatment|Open or mini-open tendon repair with acromioplasty
88973899|NCT00852657|Active Comparator|Physiotherapy|Physiotherapy by exercises
88811149|NCT04199117|Active Comparator|No Incentive,Untailored,No Care Manage,Standard Treatment|Participants randomly assigned to this condition will not have access to incentives for completing smoking cessation counseling, will receive 5 untailored letters promoting use of smoking cessation treatment over 2 years, will not receive Tobacco Care Management support and motivational encouragement calls, and will have access to standard smoking cessation treatment (referral to the state tobacco quitline and/or their primary care provider) over 2 years.
88811150|NCT04185402|Active Comparator|Azithromycin Continuation|In study communities randomized to the Azithromycin Continuation arm, all individuals aged 1 month and older will receive a single mass distribution of azithromycin several weeks after the baseline and 36-month monitoring visits. Oral azithromycin, 20 mg/kg for children and 1 g for adults, will be offered to all households identified on the preceding census in the communities randomized to continuing treatment. Study drug will be distributed by health extension workers and organized by PNSO. Individuals with a known macrolide allergy will be offered a two-week course of daily ophthalmic tetracycline ointment (two tubes).
88973900|NCT00644189|Other|Clofarabine|Taken orally once a day (in the AM) on days 1 through 21 of a 28-day cycle for a maximum of 6 cycles.
88811151|NCT04185402|No Intervention|Azithromycin Discontinuation|In study communities randomized to the Azithromycin Discontinuation arm, individuals will receive no treatment.
88811152|NCT04183023||Single arm|"There is a unique arm in which all the participants will be included. The intervention consists in the collection of a salivary sample Volunteers who agreed to participate will have to collect their saliva with the self-collection device. They will then send back their saliva sample and a dated and signed copy of the informed consent form in the pre-paid return envelope.~All DNA of the saliva samples will be automatically extracted, then DNA samples will be genotyped and a subset of 4,000 DNA will be sequenced.~The genotyping will consist of measurement of general genetic variation, including the Single Nucleotide Polymorphisms. The SNP genotyping will be carried out using Illumina high density chips, in CNRGH production platform.~Sequencing will be performed in order to reach a mean coverage of 30X for each sample and a minimum of 25X mean coverage.~Finally, a bioinformatics analysis will be performed on sequencing data."
88811153|NCT04174560|Experimental|Cohort 1|Single dose (3.5x10^3 copies) of norovirus GII.4 CIN-3 Batch No.: 01-16C3 inoculum (with 60 mL of a 2% sodium bicarbonate before and after inoculum administration) will be given orally to subjects with functional FUT-2 gene (secretor positive), n=15, and single dose (3.5x10^3 copies) of norovirus GII.4 CIN-3 Batch No.: 01-16C3 inoculum (with 60 mL of a 2% sodium bicarbonate before and after inoculum administration) will be given to subjects with a lack a non-functional FUT-2 gene (non-secretor), n=1, on Day 1
88811154|NCT04174560|Experimental|Cohort 2|Single dose (3.5x10^4 copies) of norovirus GII.4 CIN-3 Batch No.: 01-16C3 inoculum (with 60 mL of a 2% sodium bicarbonate before and after inoculum administration) will be given orally to subjects with functional FUT-2 gene (secretor positive), n=15, and single dose (3.5x10^4 copies) of norovirus GII.4 CIN-3 Batch No.: 01-16C3 inoculum (with 60 mL of a 2% sodium bicarbonate before and after inoculum administration) will be given to subjects with a lack a non-functional FUT-2 gene (non-secretor), n=1, on Day 1
88811155|NCT04174560|Experimental|Cohort 3|Single dose (3.5x10^5 copies) of norovirus GII.4 CIN-3 Batch No.: 01-16C3 inoculum (with 60 mL of a 2% sodium bicarbonate before and after inoculum administration) will be given orally to subjects with functional FUT-2 gene (secretor positive), n=15, and single dose (3.5x10^5 copies) of norovirus GII.4 CIN-3 Batch No.: 01-16C3 inoculum (with 60 mL of a 2% sodium bicarbonate before and after inoculum administration) will be given to subjects with a lack a non-functional FUT-2 gene (non-secretor), n=1, on Day 1
88811156|NCT04163614|No Intervention|Control|Participants in the control group will have their blood pressure, fluid status, as well as all other aspects of clinical care managed in entirety by their treating nephrologists.
88811157|NCT04163614|Experimental|IBPS (Intradialytic Blood Pressure Slope) Arm|IBPS participants will have their target weight adjusted each month by the study investigator based on recent assessment of intradialytic blood pressure slopes.
88811158|NCT04139200|Experimental|Type 1 tele coaching group|Coaching with daily interaction with the coaching application, based on a adaptive physical activity goal
88811159|NCT04139200|Sham Comparator|Type 2 tele coaching group|Coaching with fixed physical activity goal and limited interaction with the smartphone application
88811160|NCT04118283|Experimental|Cognitive Behavioral Therapy for Chronic Pain|Cognitive Behavioral Therapy for Chronic Pain (CBT-CP) will be conducted in accordance with the Cognitive Behavioral Therapy for Chronic Pain: Therapist Manual and the VA Evidence-Based Practice (EBP) roll-out training. CBT-CP consists of a 12-session protocol, including an initial assessment session (BL assessment; Session 1), 10 content-specific sessions (pain education, goal-setting, cognitive and behavioral skill building; Sessions 2-11), and a booster session scheduled approximately one month after the final CBT-CP session (Session 12). Participants randomized to the CBT-CP condition (n = 30) will complete one 60-minute individual session per week. Each CBT-CP session will be led by a trained study interventionist using a manualized curriculum, following a basic structure including review of previous session material, introduction of new information or skills, and discussion of how to implement learned material into a home action plan.
88811161|NCT04118283|Active Comparator|Health and Wellness|Health & Wellness was developed by VISN 5 MIRECC investigators and consists of psychoeducation on topics related to physical and emotional wellbeing. Its structure is similar to CBT-CP (10 weekly individual 60-minute sessions, no booster session). Each Health & Wellness session will be led by a trained interventionist using a manualized curriculum that includes review of previous session material, introduction of new information, and discussion of a range of health-related topics (physical activity/exercise, nutrition/healthy eating, managing medications and side effects, and addictive behaviors (e.g., substance use, gambling, eating) that do not include pain. Typical sessions include discussion of the impact of the topic on overall health and well-being, identifying benefits and challenges to improving or maintaining health in that area, and strategies to address challenges in that area.
88811162|NCT04118114|Experimental|PRL3-ZUMAB Monotherapy|
88811163|NCT04112641|Placebo Comparator|Placebo capsules|Subjects will take 2 capsules in the a.m. and 2 capsules in the p.m. daily for 84 days.
88811164|NCT04112641|Experimental|Nicotinamide Riboside (NIAGEN)|Subjects will take 2 250-mg capsules in the a.m. and 2 250- mg capsules in the p.m. daily (total daily dose is 1 g) for 84 days.
88811165|NCT04105088||Randomly-Sampled|Adults aged 30+ living in one of the First Nations communities whose household was randomly-sampled.
89580576|NCT02033889|Experimental|Ertuglifozin 5 mg|Ertugliflozin 5 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose ≥110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated.
89580577|NCT02033889|Experimental|Ertugliflozin 15 mg|Ertugliflozin 15 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose ≥110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated.
89580578|NCT02033889|Placebo Comparator|Placebo/Glimepiride|Placebo to ertugliflozin, orally once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose ≥110 mg/dL received blinded glimepiride. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated.
89580579|NCT02447003|Experimental|Cohort A: Pembrolizumab|Participants in Cohort A previously received at least one prior systemic treatment for metastatic breast cancer. Participants will be administered pembrolizumab 200 mg intravenously (IV) on Day 1 of each 3-week cycle (Q3W) for up to 35 cycles (up to ~ 2 years).
89580580|NCT02447003|Experimental|Cohort B: Pembrolizumab|Participants in Cohort B previously received no prior systemic treatment for metastatic breast cancer AND had a programmed cell death-ligand 1 (PD-L1) positive tumor expression. Participants will be administered pembrolizumab 200 mg IV on Day 1 of each 3-week cycle (Q3W) for up to 35 cycles (up to ~ 2 years).
89580581|NCT01844284|Experimental|Absorb™ BVS|Subjects receiving Absorb™ BVS
88811166|NCT04105088||Walk-in Volunteers|Adults aged 30+ living in one of the First Nations communities who is a walk-in study volunteer, not randomly-sampled.
88973901|NCT00465517|Experimental|ganaxolone|active study drug
88973902|NCT00465517|Placebo Comparator|non-active drug|placebo
88973903|NCT00289952|Experimental|Group 1|HAART + valproic acid for 16 weeks followed by HAART alone for 32 weeks.
88973904|NCT00289952|Experimental|Group 2|HAART alone for 16 weeks followed by HAART + valproic acid for 32 weeks.
88973905|NCT05772858|Experimental|Family Therapy Training and Implementation Platform (FTTIP)|Participants will be trained for 20 hours on an online platform practicing family therapy competencies with animated families and provided recorded video responses to receive feedback from trainers.
88973906|NCT05772858|Active Comparator|Traditional in person Training as Usual|Participants will attend 20 hours of a traditional in person training learning about the family therapy evidenced based treatment.
88973907|NCT05772858|Experimental|Culturally Informed and Flexible Family-Based Treatment for Adolescents (CIFFTA).|All of the 150 families will receive Family Therapy, Individual Therapy, and Psycho-educational Modules, delivered over 16 weeks in a two session (60 minutes each) per week format.
88973908|NCT05772858|Experimental|Agency Readiness Consultation- Family Therapy Training and Implementation Platform (FTTIP)|Agency leaders assigned to this condition will complete an online assessment of agency readiness, participate in a webinar and live discussion, complete an online meeting with leaders and clinical supervisors
88973909|NCT05772858|Active Comparator|Agency Engagement and Orientation as Usual|Agency leaders assigned to this condition will receive a traditional engagement of leadership at their agency including a description of study procedures and engagement with study team.
88973910|NCT05772832||GROUP USING REMIFENTANYL|THE GROUP USING PEROPERATIVE REMIFENTANYL AND PROPOFOL IN TRANSSPHENOIDAL Pituitary Surgery 0.01-0.2 μg /kg /min Remifentanyl and 3-12 mg/kg/h propofol
88973911|NCT05772832||GROUP USING DEXMEDETOMIDINE|THE GROUP USING PEROPERATIVE DEXMEDETOMIDINE AND PROPOFOL IN TRANSSPHENOIDAL Pituitary Surgery 0.01-0.02 μg/kg/min (~0.5 μg/kg/h) continuous infusion of dexmedetomidine 1 mcg/kg 10 minutes after a loading dose and 3-12 mg/kg/h propofol
88973912|NCT05772819|Experimental|Imaging arm|Participants are subjected to in-magnet exercise test consisting of in vivo exercise cardiac magnetic resonance (exCMR) imaging and 31P-magnetic resonance spectroscopy (31P-MRS) during exercise testing in a MR-compatible ergometer, before and after the 4-week prehabilitation program.
88973913|NCT05772793||Group A|
88973914|NCT05772780|Experimental|Group A|Training will be performed for two days a week
88973915|NCT05772780|Experimental|Group B|Training will be performed three days a week
88811167|NCT04090411|Experimental|Cohort 1|Induction - Placebo SC Q4W, (sub-cutaneous every 4 weeks) Chronic- PF-06480605 50 mg SC Q4W
88811168|NCT04090411|Experimental|Cohort 2|Induction - Placebo SC Q4W, Chronic- PF-06480605 150 mg SC Q4W
88811169|NCT04090411|Experimental|Cohort 3|Induction - Placebo SC Q4W, Chronic- PF-06480605 450 mg SC Q4W
88811170|NCT04090411|Placebo Comparator|Cohort 4|Induction- PF-06480605 50 mg SC Q4W, Chronic- PF-06480605 50 mg SC Q4W
88811171|NCT04090411|Experimental|Cohort 5|Induction- PF-06480605 150 mg SC Q4W, Chronic- PF-06480605 50 mg SC Q4W
88973916|NCT05772767|Other|Biological sample collection|Collection of tumor tissue and PBMC for the generation of glioblastoma stem cell cultures and brain organoids.
88973917|NCT05772741|Other|Biological sample collection|Tumor tissue for glioma stem-like cell culture generation. Skin or PBMC for organoid generation
88973918|NCT05772728|Experimental|CAG Group|Cidapenem combined with azacitidine and mitoxantrone liposomes
88973919|NCT05772676|Experimental|Aprepitant|Aprepitant (80 or 125 mg) + Ondansetron 8 mg + Metoclopramide 10 mg + Dexamethasone 8 mg
88973920|NCT05772676|Placebo Comparator|Placebo|Placebo + Ondansetron 8 mg + Metoclopramide 10 mg + Dexamethasone 8 mg
88973921|NCT03392467|Experimental|PNEUMOSTEM|human umbilical cord blood derived mesenchymal stem cell (hUCB-MSC)
88973922|NCT03392467|Placebo Comparator|Placebo|normal saline
88811172|NCT04090411|Experimental|Cohort 6|Induction- PF-06480605 150 mg SC Q4W, Chronic- PF-06480605 150 mg SC Q4W
88811173|NCT04090411|Experimental|Cohort 7|Induction- PF-06480605 450 mg SC Q4W, Chronic- PF-06480605 50 mg SC Q4W
88811174|NCT04090411|Experimental|Cohort 8|Induction- PF-06480605 450 mg SC Q4W, Chronic- PF-06480605 150 mg SC Q4W
88811175|NCT04090411|Experimental|Cohort 9|Induction- PF-06480605 450 mg SC Q4W, Chronic- PF-06480605 450 mg SC Q4W
88811176|NCT04074967|Experimental|Phase Ib ARRY-614 + nivolumab|"Participants with advanced solid tumors will receive ARRY-614 in combination with nivolumab.~(histologically confirmed metastatic or unresectable malignancy with lacking curative measures; nivolumab must be available and appropriate for proposed therapy)"
88811177|NCT04074967|Experimental|Phase Ib ARRY-614 + nivolumab + ipilimumab|"Participants with advanced solid tumors will received ARRY-614 in combination with nivolumab + ipilimumab.~(histologically confirmed metastatic or unresectable malignancy with lacking curative measures; nivolumab and ipilimumab must be available and appropriate for proposed therapy)"
88811178|NCT04074967|Experimental|Phase II ARRY-614 + nivolumab|Participants with of NSCLC and HNSCCC will receive ARRY-614 combined with nivolumab.
88811179|NCT04074967|Experimental|Phase II ARRY-614 + nivolumab + ipilimumab (melanoma)|Participants with melanoma will receive ARRY-614 combined with nivolumab + ipilimumab.
88811180|NCT04074967|Experimental|Phase II ARRY-614 + nivolumab + ipilimumab (RCC)|Participants with RCC will receive ARRY-614 combined with nivolumab + ipilimumab.
88811181|NCT04060927|Experimental|Group 1|Freebreathing SBRT with SGRT
88811182|NCT04060927|Experimental|Group 2|Breath hold SBRT with SGRT
88811183|NCT04060927|Experimental|Group 3|Breath hold SBRT with SGRT in combination with implanted fiducials
88811184|NCT04051151|Experimental|Gameification Arm|Participants and partners that have randomized to the gamification group will receive instructions and help in setting up a game.
88811185|NCT04051151|No Intervention|Education Arm|Participants and partners that randomized to the control group will receive standard of care educational resources on the importance of physical activity in Parkinson's patients.
88811186|NCT04027699|Experimental|Mini-bolus|"First injection of 2ml/kg (saline solution)~Second injection of 18ml/kg (saline solution)"
88811187|NCT03973268|Experimental|1|Individuals in Arm 1 will receive double-blinded perampanel and open-label ketamine on the first day, then double-blinded perampanel on the second day.
88811188|NCT03973268|Experimental|2|Individuals in Arm 2 will receive double-blinded placebo and open-label ketamine on the first day, then double-blinded perampanel on the second day.
88811189|NCT03973268|Experimental|3|Individuals in Arm 3 will receive double-blinded placebo and open-label ketamine on the first day, then double-blinded placebo on the second day.
88811190|NCT03947827|Active Comparator|Active|Minocycline will start at an oral dose of 100mg daily and will be increased after one week to 100mg twice daily.
88811191|NCT03947827|Placebo Comparator|Placebo|Placebo capsules will start at one capsule daily, and will be increased after one week to one capsule twice daily
88811192|NCT03932032|Experimental|Attention Bias Modification Treatment|Attention Bias Modification Treatment is a computer-based attention training program.
88811193|NCT03932032|Sham Comparator|Neutral Control Task|Neutral Control Task uses the same computer-based format as Attention Bias Modification Treatment, but includes only neutral stimuli and does not train attention.
88811194|NCT03908632||Step 1|Subjects 14 years or older diagnosed with Community Acquired Pneumonia (CAP) and positive serology for primary pulmonary coccidioidomycosis (PPC) will enroll in Step 1 within 14 days of symptom onset, n=750
88811195|NCT03908632||Step 2|Subjects with a diagnosis of primary pulmonary coccidioidomycosis (PPC) confirmed by positive serologic testing during Step 1 will enter Step 2 within 21 days of their test collection date, n=200
88811196|NCT03902223|Experimental|Enhanced Screening Protocol For Cardiac Sarcoidosis|Arm will be randomly assigned to undergo enhanced screening methods (ambulatory ECG and echocardiogram) at month 0 and month 24, as well as a phone call/chart review at month 12.
88811197|NCT03902223|Active Comparator|Routine Screening for Suspected Cardiac Sarcoidosis|Arm will be randomly assigned for the routine standard of care/no intervention with enhanced screening methods. They will be offered the EKG and symptom check at months 0 and 24, as well as a phone call/chart review at month 12.
88811198|NCT03860987|Experimental|1|Treatment
88811199|NCT03854214|Active Comparator|Functional Electric Stimulation cycling|The Functional Electrical Stimulation (FES) cycling group will use RT300 ergometer (Restorative Therapies, Inc) with stimulation on.
88811200|NCT03854214|Sham Comparator|Passive Cycling|The passive cycling group will use the same RT300 ergometer with stimulation off.
88811201|NCT03849651|Experimental|Transplant participants|"Participants receive a conditioning regimen of ATG (rabbit),Cyclophosphamide 60 mg/kg intravenous once daily, mesna, fludarabine, thiotepa, melphalan, followed by HPC,A Infusion(TCRα/β+ and CD19+ depleted),HPC, A infusion (if needed to achieve goal CD34+ cell dose.CD45RA-depleted DLI will be given at least two weeks after engraftment. Blinatumomab will be given at least one week post-DLI, and only to patients with CD19+ malignancies. G-csf 5mcg/kg subcutaneous or intravenous daily until ANC >2000 for 2 consecutive days.~Cells for infusion are prepared using the CliniMACS system."
88811202|NCT03819478|Active Comparator|RecProt|Subjects receiving the following interventions in the parent trial (UPLIFT; NCT03074643): Lower protein / higher CHO diet for the 6-month weight loss phase. Exercise intervention months 0-6. Weight loss intervention months 0-6. Carbohydrate supplement for months 0-6 (blinded). Follow-up months 7-18.
88811203|NCT03819478|Active Comparator|6-mo HiProt|Subjects receiving the following interventions in the parent trial (UPLIFT; NCT03074643): Higher protein / lower CHO diet for the 6-month weight loss phase. Exercise intervention months 0-6. Weight loss intervention months 0-6. Protein supplement for months 0-6 (blinded). Follow-up months 7-18.
88811204|NCT03819478|Active Comparator|18-mo HiProt|"Subjects receiving the following interventions in the parent trial (UPLIFT; NCT03074643):~Higher protein / lower CHO diet for the 6-month weight loss and 12-month follow-up phases. Exercise intervention months 0-6. Weight loss intervention months 0-6. Protein supplement for months 0-6 (blinded). Protein supplement for follow-up months 7-18."
88811205|NCT03810417|Active Comparator|Digifab|Digifab intravenous
88811206|NCT03810417|Placebo Comparator|Placebo|saline intravenous
89580582|NCT01844284|Active Comparator|XIENCE PRIME®/XIENCE Xpedition™|Subjects receiving XIENCE PRIME®/XIENCE Xpedition™
89580583|NCT02054715|Experimental|Arm I (print educational)|Participants undergo a print educational intervention during which they meet with a site coordinator and are instructed to read the NCI booklet titled Taking Part in Cancer Treatment Studies, comprised primarily of information about the nature and conduct of cancer clinical trials.
89580584|NCT02054715|Experimental|Arm II (multimedia psychoeducational)|Participants undergo a multimedia psychoeducational intervention during which they meet with a site coordinator and are instructed to view a DVD and read a booklet titled Clinical Trials: Are They Right For You? Participants are encouraged to watch the DVD and read the booklet again at home.
88973923|NCT05772624|Experimental|LowN-AVD|classic Hodgkin's lymphoma patients receiving low dose nivolumab in combination with AVD
88973924|NCT05772611||Antibody characterized|Patients with well-characterized antibody (HU, YO, RI, CASPR2, NMDAr, GAD, …)
88973925|NCT05772611||Atypical|Patients with atypical antibody
88973926|NCT05772611||Without antibody|Patients without antibody
88973927|NCT05772585||patients ALF and ACLF|patients with acute liver failure (ALF) and acute-on-chronic liver failure (ACLF) with hepatic encephalopathy
88973928|NCT05772559||Cohort 1 : Patients with acute myeloid leukemia|Patients with acute myeloid leukemia at initial diagnosis or relapse, aged less than 25 years
88973929|NCT05772559||Cohort 2 : Patients with genetic predisposition to develop acute myeloid leukemia|
88973930|NCT05772559||Cohort 3 : Patients who undergo bone marrow aspirate|Patients who undergo bone marrow aspirate as part of standard of care but without AML nor predisposition to develop AML, as controls
88973931|NCT05772507|Experimental|medical device under investigation|URGO AWC_008 or URGO AWC_022 dressing. These 2 dressings are similar and only the adhesive constitutes a difference. The choice of study dressing will be left to the discretion of the investigator during the treatment of the patient, depending on the nature of the wound and the condition of the peri-wound skin.
88973932|NCT05772494|Experimental|Assessment of activity limitation|Assessment and analysis of activity limitation by occupational therapist using 2 registered instruments (SDO and DOA).
88973933|NCT05772494|Active Comparator|Control group: treatment as usual|Assessment of activity limitations according to usual routines
88973934|NCT05772468|Experimental|Virtual Reality Therapy (Intervention group 1)|In addition to the standard wound care procedure, the Virtual Reality Therapy group (intervention group 1) will receive the VR system during the wound care. The VR system consists of Virtual Reality glasses, and a headphone. The application VRelax will be used, which will contain various videos for the patient those from to relax and be distracted. This group wears the VR system 10 minutes before the start of the wound care, until 1 minute after the wound care has ended.
88973935|NCT05772468|No Intervention|Care as usual (control group/group 2)|The control group (group 2), also known as the care as usual group, receives the standard procedure during wound care without 'VRelax' VR system.
88973936|NCT05772455|Experimental|XZB-0004|
88973937|NCT05772377|Experimental|Anlotinib+TP then CCRT+Anlotinib|Induction regimen:Anlotinib: 10 mg, po, qd, d1-d14, q3w, 2 consecutive cycles Paclitaxel 175mg/m2 intravenous injection for 3 hours, d1；Cisplatin 75mg/m2, iv, divided into 3 days, q3w;Unable to tolerate, nedaplatin 75mg/m2, iv, d1 can be used instead;21 days as a cycle, a total of 2 cycles;Treatment programs:Anlotinib: 10 mg, po, qd, d1-d14, q3w, 2 consecutive cycles;Cisplatin: 30-35 mg/m2, iv, d1, qw, 5 consecutive cycles;Pelvic external radiation therapy: once a day, 1.8-2 Gy/time, 5 days a week, for 5 consecutive weeks, a total of 45-50 Gy;sequential;High dose rate intracavitary radiotherapy: 6 Gy/time, twice a week, 5 consecutive times, a total of 30 Gy/2.5 weeks, bioequivalent dose of 40 Gy sequential Taxane drugs: including but not limited to paclitaxel, nab-paclitaxel, paclitaxel liposome, etc. The dosage regimen is determined by the investigator;Cisplatin 75mg/m2, iv, divided into 3 days, q3w; Unable to tolerate, nedaplatin 75mg/m2, iv, d1 can be used instead;2 cycles
88973938|NCT05772247||PS application|
88973939|NCT05772247||non-PS application|
88973940|NCT05772208|Experimental|the combination of camrelizumab and standard treatment|camrelizumab 200mg q3w 2 cycle combinted with the second and third cycle neoajuvant chemotherapy and camrelizumab 200mg q3w 8 cycle starting one month after concurrent chemo-radiotherapy.
88973941|NCT05772208|Experimental|the combination of nimotuzumab and standard treatment|nimotuzumab 200mg qw combined with the second and third cycle neoajuvant chemotherapy and nimotuzumab 200mg qw used during chemo-radiotherapy.
88973942|NCT05772208|Active Comparator|standard treatment|the second and third neoajuvant chemotherapy with GP regimen (gemcitabine 1g/m2 d1，8 plus cisplatin 75mg/m2 ) concurrent chemotherapy: single cisplatin (80mg/m2) for two cycle definitive radiotherapy for primay lesion and lymph node region.
88973943|NCT05772182||Groups/Cohorts|Patients undergoing intervention for arrhythmia (electrophysiologic study and/or intracardiac device implantation) with clinical indication
88973944|NCT05772143||Lumbar disc herniation|Patient over 18 years of age suffering from radiculalgia related to lumbar disc herniation visualized on MRI with radio-clinical concordance, failure of conservative treatment and nerve root infiltrations
88973945|NCT05772104|Experimental|Experimental: Shugan Jieyu Capsules|Participants received Shugan Jieyu Capsules 4 capsules,BID,once in the morning and once in the evening, at an interval of more than 8 hours, for up tp 12 weeks.
88973946|NCT05772104|Experimental|Experimental: Shugan Jieyu Capsules+Placepo|Participants received Shugan Jieyu Capsules 3 capsules + Placebo 1 capsules,BID,once in the morning and once in the evening, at an interval of more than 8 hours, for up tp 12 weeks.
88973947|NCT05772104|Placebo Comparator|Experimental: Placebo|Participants received placebo 4 capsules,BID,once in the morning and once in the evening, at an interval of more than 8 hours, for up tp 12 weeks.
88973948|NCT05772039|Active Comparator|Topical application of 38% Silver Diammine Fluoride Solution at Baseline|"SDF is known for its corrosive nature therefore a plastic container or dappen dish will be used.~1 drop (0.05 ml) will be dispensed on a plastic container.~1 drop (2.24 F-ion mg/dose) SDF treats up to 5 tooth surfaces.~Ultrafine microbrushes will be used to apply varnish."
89029813|NCT02275325|Experimental|Preoperative rehabilitation|Patients that have a preoperative vestibular rehabilitation before vestibular schwannoma surgery in addition to the usual postoperative vestibular rehabilitation
89029814|NCT02275325|No Intervention|Usual|Group of patients that solely have a postoperative vestibular rehabilitation after vestibular schwannoma surgery
89029815|NCT00513123||Digital Colposcopy|Digital Colposcopy for Fluorescence (DCF)
89029816|NCT02275403|Experimental|Arm A: Standard care plus acupuncture|Medication taken to manage the symptom burden of CIPN plus acupuncture
89029817|NCT02275403|Active Comparator|Arm B: Standard care alone|Medication taken to manage the symptom burden of CIPN
89580585|NCT02446769|Experimental|AVAPS-AE Non-invasive ventilation therapy|Participants will be initiated on AVAPS-AE therapy (intervention arm) for 60 days. AVAPS-AE is a mode of therapy (Philips Respironics Inc, Monroeville, Pa) with potential advantages over the currently established modes of non-invasive positive pressure ventilation (CPAP and bilevel therapy). This mode of therapy incorporates AVAPS (automated adjustable Inspiratory Positive Airway Pressure (IPAP) setting to maintain target ventilation with a settable rate of change), Auto Expiratory Positive Airway Pressure (EPAP) and Auto Back up Rate.
89029818|NCT02951949||Postmenopausal women|Postmenopausal women attending the outpatient service of a third level hospital for health control.
89029819|NCT04517825||Target Population|HIV positive individuals attending Bugoye ART clinic
89029820|NCT01249976|Experimental|catheter-spearing diagnostic methods|experimental
89580586|NCT02446769|No Intervention|Standard of Care Group|Evaluation and treatment of the participant's sleep disordered breathing will be per their participant's health care provider's usual care pathway.
89580587|NCT02420093|Experimental|Experimental Group|"The experimental group will use the Pelvis Support Assembly per US Patent number US 8,857,906 B2, in the seat of their work or home desk chairs as tolerated during the 3 weeks intervention interval. This pelvic support device supports the user from the pelvis and aids in maintaining a more anatomically neutral lumbar and pelvic position in sitting."
89029821|NCT02951832||observational group|Observational Study about Lymphocytes Change during Menstrual Cycle in Women of Child-bearing Age
89029822|NCT01244438|Experimental|FP-1039|FP-1039
89029823|NCT02951793||AUDIT-C > 4|Significant alcohol use within 1 year prior to ICU admission (AUDIT-C>4)
89580588|NCT02420093|No Intervention|Control Group|"The control group will not use the Pelvis Support Assembly per US Patent number US 8,857,906 B2 but will continue in their current sitting arrangement during the same 3 week interval"
89580589|NCT02419937|Active Comparator|Tocilizumab|Blinded subjects will be randomized to tocilizumab 162 mg subcutaneously once.
89580590|NCT02419937|Placebo Comparator|Placebo|Blinded subjects will be randomized to placebo
89580591|NCT02054481|Experimental|Arm 1|BI 655066 s.c.
89029824|NCT02951793||AUDIT-C <=4|No significant alcohol use within 1 year prior to ICU admission (AUDIT-C: equal or less than 4)
89029825|NCT02951793||Smoking history positive last year|Who smoke cigarette within 1-year prior to ICU admission
89029826|NCT02951793||Smoking history negative last year|Who did not smoke cigarette within 1-year prior to ICU admission
89029827|NCT02951793||Prior psychotropic medication use - yes|Who used psychotropic medication within 1-year prior to ICU admission
89580592|NCT02054481|Experimental|Arm 2|BI 655066 s.c.
89580593|NCT02054481|Experimental|Arm 3|BI 655066 s.c.
89580594|NCT02054481|Active Comparator|Arm 4|Ustekinumab s.c.
89580595|NCT01610752|Experimental|SmartMoms-Clinic|If picked for this group, you will attend study meetings with a weight management counselor. During the second trimester study meetings occur 4 times per month. During the third trimester you will attend study meetings 2 times per month. These meetings will cover many topics to help you learn about weight management during pregnancy. You will be taught how to use different tools provided to help you monitor your weight. We will ask you to record your body weight (using a scale we will provide) as well as your food intake and exercise habits.
89029828|NCT02951793||Prior psychotropic medication use - no|Who did not use psychotropic medication within 1-year prior to ICU admission
89029829|NCT01244750||First line TKI treatment: Imatinib|Diagnosed CML patients who receive first line TKI treatment: Imatinib
89029830|NCT01244750||First line TKI treatment: Nilotinib|Diagnosed CML patients who receive first line TKI treatment: Nilotinib
89029831|NCT01244750||First line TKI treatment: Dasatinib|Diagnosed CML patients who receive first line TKI treatment: Dasatinib
89029832|NCT01244750||Imatinib treated patients|Imatinib treated patients if their study index date is between January 2, 2008 and September 30, 2010
89029833|NCT00512187|Experimental|first group|patients who adhered to a low-calorie diet associated to sub-optimal cyclosporine dose (2.5 mg/Kg/day)for 24 weeks
89029834|NCT02951871||LP: Lymphoma Progression|
89029835|NCT02951871||TRM: Treatment Related Mortality|
89029836|NCT02951871||NHM: Non hematologic malignancy|
89029837|NCT02951871||OC: Other Cause|
89029838|NCT02951715|Experimental|Zinc|A full medical history assessment was performed, and each patient completed the NIHL questionnaire (Supplementary S1), audiogram, tympanogram, speech discrimination test, distortion product otoacoustic emissions (DPOAE) testing, pitch and loudness match of the tinnitus, Tinnitus Handicap Inventory (THI) and serum zinc level analyses. All tests were repeated after 2 months of treatment with zinc gluconate (Zinga 78 mg, 10 mg elemental zinc), two tablets twice per day (40 mg per day).
89029839|NCT01243658|Experimental|Oxytocin|Oxytocin
89029840|NCT01243658|Placebo Comparator|Placebo|Placebo
89029841|NCT02951676||EA - Extraction with antibiotics|"Patients undergoing third molar extraction with antibiotic treatment.~Amoxicillin 250 mg , three times daily for five days."
89029842|NCT02951676||E - Extraction without antibiotics|Patients undergoing third molar extraction with antibiotic treatment.
89029843|NCT02951676||Control|Age and sex matched controls who are not undergoing extractions or antibiotic treatment
89029844|NCT01249664|Experimental|Arm 1|
89029845|NCT01249664|Sham Comparator|Arm 2|
89029846|NCT00513162|Experimental|Valproate + Etoposide|Valproate Starting Dose of 10 mg/kg By Mouth Daily. Etoposide 25 - 50 mg/m^2 By Mouth Daily.
89029847|NCT04513418|Experimental|Interventional group|Patients receive omega-3 fatty-acid enriched enteral nutritional emulsion during the neoadjuvant chemoradiotherapy. Patients are meanwhile encouraged to intake 25-30kcal/kg through regular food.
89029848|NCT04513418|No Intervention|Control group|Patients are encouraged to intake 25-30kcal/kg through regular food without supplemental nutritional support before esophagectomy.
89029849|NCT00513279|Experimental|Cohort 1|Subjects in Cohort 1 will be randomized to one of the following sequences: ABDFH, BADFH, BDAFH, BDFAH and BDFHA in a 1:1:1:1:1 ratio where A = Placebo, B= GSK618334 dose 1 (2.5 mg), D = GSK618334 dose 3, F = GSK618334 dose 5, H = GSK618334 dose 7. On day 1, subjects will be administered a starting dose of 2.5 milligrams (mg) GSK618334. The planned doses of GSK618334 to be administered in Cohort 1 are 2.5, 25, 100 and 400mg. In each dosing period 2 subjects will receive placebo and 8 subjects will receive GSK618334. Subjects within a cohort will have a washout period of at least two weeks from last dose before receiving another dose.
89029850|NCT00513279|Experimental|Cohort 2|Subjects in Cohort 2 will be randomized to one of the following sequences: ACEGI, CAEGI, CEAGI, CEGAI, CEGIA in a 1:1:1:1:1 ratio where A = Placebo, C= GSK618334 dose 2, E = GSK618334dose 4, G = GSK618334 dose 6, I= GSK618334 dose 8. In each dosing period 2 subjects will receive placebo and 8 subjects will receive GSK618334. Subjects within a cohort will have a washout period of at least two weeks from last dose before receiving another dose.
89029851|NCT00512265|Active Comparator|1|150mg/kg N-Acetylcysteine in 250mL Glucose 5% at time of induction of anaesthesia 50mg/kg N-Acetylcysteine in 250mL Glucose 5% on post-op days 1-3
89029852|NCT00512265|Placebo Comparator|2|placebo (250mL glucose 5%) at time of induction of anaesthesia placebo (250mL glucose 5%) on post-op days 1-3
89029853|NCT00504803|Experimental|1|MSC co-infusion with either HLA-mismatched PBSC or cord blood
89029854|NCT00513396|Experimental|1|
89029855|NCT00513396|Active Comparator|2|
89029856|NCT00513396|Placebo Comparator|3|
89029857|NCT01249274|Placebo Comparator|Placebo|Matched placebo pills to be taken twice daily
89029858|NCT01249274|Experimental|Progesterone|100 mgs progesterone twice daily
89580596|NCT01610752|Experimental|SmartMoms-Phone|If picked for this group, you will have two individual sessions with a weight management counselor. At the first session, you will receive a scale and other technology to help manage your weight during pregnancy. Each week you will receive information from a weight management counselor via a Smartphone (you can use your own Smartphone or one will be provided to you). The information will cover topics to help manage your weight during pregnancy. You will be taught how to use different tools provided to help you monitor your weight. We will ask you to measure your body weight (using a scale we will provide) as well as monitor your food intake and exercise habits with the Smartphone.
89029859|NCT00512304|Experimental|Preoperative chemoradiotherapy|
89580597|NCT01610752|No Intervention|Physician Directed|If picked for this group, you will receive weight management advice from your physician's office.
89580598|NCT02054325|Active Comparator|Polidocanol with Glucose|An application session 0.2% Polidocanol + 70% Glucose to treat reticular veins of the lower limb selected, with a maximum volume of 5 ml.
89580599|NCT02054325|Active Comparator|Glucose|An application session 75% Glucose to treat reticular veins of the lower limb selected, with a maximum volume of 5ml.
89580600|NCT02446691|Experimental|MenACWY Group|Healthy male and female infants approximately 2 months (55-89 days) of age on the day of consent, who will receive 4 doses of the GSK MenACWY Conjugate Vaccine, administered intramuscularly at 2,4,6 ad 12 months of age.
89580601|NCT02091375|Experimental|GWP42003-P 20 mg/kg/day Dose|Participants received 20 mg/kg/day of GWP42003-P administered orally, half in the morning and half in the evening. Participants titrated GWP42003-P to 20 mg/kg/day over 11 days and remained at this dose for the 12-week maintenance period. If the participant did not immediately enter the OLE study, the maintenance period was followed by a 10-day taper (10% per day) period.
89580602|NCT02091375|Placebo Comparator|Placebo|Participants received placebo (0 mg/mL CBD), volume-matched to the 20 mg/kg/day dose level, administered orally, half in the morning and half in the evening. To maintain the blinded aspect of the study, participants titrated the placebo dose over 11 days and remained at this dose for the 12-week maintenance period. If the participant did not immediately enter the OLE study, the maintenance period was followed by a 10-day taper (10% per day of the matched dose) period.
89580603|NCT04690335|Experimental|MV-012-968|Dose: 1 x10^6 Plaque Forming Unit (PFU), given intranasally, followed approximately 28 days later by inoculation with RSV-A (Memphis 37b).
89580604|NCT04690335|Placebo Comparator|Placebo|Sodium Chloride 0.9% w/v intravenous infusion B.P (Normal Saline) matched to reference article product, given intranasally.
89580605|NCT02032875|Experimental|Post-liver Transplant Cohort|Participants with liver transplant received daclatasvir 60 mg, sofosbuvir 400 mg, and ribavirin (based on baseline hemoglobin and creatinine clearance and tolerated dose) tablets daily for 12 weeks and were followed for 24 weeks post treatment.
89580606|NCT02032875|Experimental|Cirrhotic Cohort|Cirrhotic participants received daclatasvir 60 mg, sofosbuvir 400 mg, and ribavirin (based on baseline hemoglobin and creatinine clearance and tolerated dose) tablets orally for 12 weeks and were followed for 24 weeks post-treatment. Cirrhotic participants who received a liver transplant while on study treatment were eligible (>3 months post transplant) for a treatment extension of daclatasvir 60 mg, sofosbuvir 400 mg, and ribavirin (dose based on hemoglobin level) tablets orally for an additional 12 weeks
89580607|NCT02032407|Experimental|Dapsone Gel|Dapsone Gel (Aczone®) applied twice daily to the face for 12 weeks.
89580608|NCT04689867|Experimental|CBSPp|Cognitive Behavioral Suicide Prevention for psychosis is a behavioral treatment and will be delivered in 10 weekly individual therapy sessions.
89580609|NCT01843972|Experimental|BI 691751 dose 2 (part I)|single dose given as oral solution
89029860|NCT00512304|Experimental|Postoperative chemoradiotherapy|
89029861|NCT04695834|Active Comparator|Conservative treatment|"Patients that are randomized to the conservative arm of the trial. These patients will not be operated until primary endpoint is reached.~If necessary, cross-over can occur after primary endpoint is reached.~Conservative treatment is considered standard of care."
89029862|NCT04695834|Active Comparator|Surgical treatment|"Patients randomized to the surgical arm will be operated within 1 week after randomization (if possible within 2 days).~Neurolysis is considered standard of care."
89029863|NCT04695756||People who require liver transplant|We will compare the year before the beginning of the COVID-19 Pandemia with the period during the COVID-19 Pandemia.
89029864|NCT00512382||A|Babies and small children 1-24 months
89029865|NCT00512382||B|Children 2-18 years old
89029866|NCT00512421||A|navigation technique
89029867|NCT00512421||B|conservative surgery
89029868|NCT00512421||C|Historical control
89029869|NCT00512460|Experimental|RTA 744|
89580610|NCT01843972|Experimental|BI 691751 dose 3 (part I)|single dose given as oral solution
89580611|NCT01843972|Experimental|BI 691751 dose 4 (part I)|single dose given as oral solution
89580612|NCT01843972|Experimental|BI 691751 dose 5 (part I)|single dose given as oral solution
89580613|NCT01843972|Experimental|BI 691751 dose 6 (part I)|single dose given as oral solution
89580614|NCT01843972|Experimental|BI 691751 dose 7 (part I)|single dose given as oral solution
89580615|NCT01843972|Experimental|BI 691751dose 1 (part I)|single dose given as oral solution
89580616|NCT01843972|Placebo Comparator|Placebo (part I)|placebo solution
89580617|NCT01843972|Experimental|BI 691751 tablet (part II)|single dose given as 1 tablet
89580618|NCT01843972|Active Comparator|BI 691751 solution (part II)|single dose given as oral solution
89580619|NCT01826422|Experimental|EPA and DHA|Supplementation of 2.7 g/d of EPA and DHA were provided in 10 capsules per day (4 in the morning, 3 in the afternoon and 3 at night) during a period of 6 months. The capsules sizes were specially for children to improved the feeding process and its presentation is in gelatin capsules. The supplement is purified fish oil with pharmaceutical grade.
89580620|NCT01826422|Placebo Comparator|Placebo Comparator|Supplementation of placebo with sunflower fatty at doses of 2.7 g/d were provided in 10 capsules per day (4 in the morning, 3 in the afternoon and 3 at night) during a period of 6 months. The capsules sizes are specially for children to improved the feeding process. This placebo is sunflower oil, so, it did not present anti-inflammatory or insulin sensitivity effects.
89580621|NCT01843660|Experimental|Tramadol Hydrochloride (HCl)-Paracetamol|
89580622|NCT02090283|Experimental|SD-101 Dermal Cream (6%)|All participants applied SD-101 dermal cream topically, once a day, to the entire body for the duration of the study.
89580623|NCT02032173|Experimental|Ranibizumab 0.5mg|Intravitreal injection with standard dose of 0.5 mg/0.05mL Pro re nata (PRN)
89580624|NCT04712409|Active Comparator|SADI-S as a primary surgery|
89580625|NCT04712409|Active Comparator|BPD-DS as a primary surgery|
89580626|NCT04712409|Active Comparator|SADI-S as a revisional procedure|
89580627|NCT04712409|Active Comparator|BPD-DS as a revisional procedure|
89580628|NCT04689477||COVID-19|Hospitalized patients diagnosed with COVID-19, presenting with arterial hypoxemia.
89580629|NCT04689477||Control|Healthy subjects
89580630|NCT04689477||Non-COVID critically ill patients|Non-COVID critically ill patients admitted to the ICU.
89580631|NCT02031471|Experimental|Tocilizumab|Adults with rheumatoid arthritis received a fixed dose of tocilizumab during the 24-week open-label core study and those entering the long term extension (LTE) period further received a fixed dose up to a maximum of 28 weeks or until tocilizumab was commercially available and/or reimbursed whichever came first. A fixed dose of 162 mg tocilizumab was administered subcutaneously once weekly.
89580632|NCT02461589|Experimental|Semaglutide 0.05 mg/day|
89580633|NCT02461589|Active Comparator|Liraglutide 0.3 mg/day|
89580634|NCT02461589|Placebo Comparator|Placebo 50 µL|
89580635|NCT02461589|Experimental|Semaglutide 0.05/0.1 mg/day|
89580636|NCT02461589|Active Comparator|Liraglutide 0.3/0.6 mg/day|
89580637|NCT02461589|Placebo Comparator|Placebo 50/100 µL|
89580638|NCT02461589|Experimental|Semaglutide 0.05/0.1/0.2 mg/day|
88811207|NCT03808818|Active Comparator|Arm A (smoking assessment, quitting advice, Quitline referral)|Patients receive an assessment of smoking status and provision of quitting advice through the screening and referral process, and are referred to the NCI Smoking Quitline.
88811208|NCT03808818|Experimental|Arm B (virtual counseling sessions, NRT)|Patients receive an initial virtual counseling session with a study-designated tobacco treatment coach via MGH TeleHealth over 40 minutes and up to 10 more virtual counseling sessions over 15 minutes for approximately 6 months. Patients also receive up to 12 weeks of NRT (patch and lozenge combined or alone).
89580639|NCT02461589|Active Comparator|Liraglutide 0.3/0.6/1.2 mg/day|
88811209|NCT03797794|Experimental|PESF-treatment|The group undergoing the pulsating electrostatic field intervention
88811210|NCT03797794|Sham Comparator|Placebo-treatment|The group undergoing the SHAM Pulsating Electrostatic Field
88811211|NCT03780452||Tibiotalocalcaneal arthrodesis with DynaNail|Tibiotalocalcaneal arthrodesis with a novel dynamic compression intramedullary nail
88811212|NCT03750838|Experimental|Text Messaging Intervention Group|Participants in the Text Messaging Intervention condition will be provided a predetermined number of messages per week (based partially on responses from Phase 2 focus group) for 6 weeks delivered on Thursdays, Fridays, and Saturdays, which are the most common days of the week that heavy drinking occurs as well as other days and times that focus group participants indicated would be the most helpful.
89580640|NCT02461589|Placebo Comparator|Placebo 50/100/200 µL|
89580641|NCT02461589|Experimental|Semaglutide 0.05/0.1/0.2/0.3 mg/day|
89580642|NCT02461589|Active Comparator|Liraglutide 0.3/0.6/1.2/1.8 mg/day|
89580643|NCT02461589|Placebo Comparator|Placebo 50/100/200/300 µL|
89580644|NCT02461589|Experimental|Semaglutide flexible escalation from 0.05 mg/day to 0.3 mg/day|
89580645|NCT04420793||ECT and Voice Recorded Group|This is an add-on study of voice samples to be gathered during ECT clinical treatments. The ONLY research procedures are four tasks on an online form, one text task and three voice recording tasks. These voice recordings will take place in a private room on the 5th floor of the Institute of Psychiatry on the same day of a patient's ECT treatment. The questionnaire will take less than 10 minutes.
89580646|NCT04934189|Other|Empowerment Self-Defense Training- Pre-Post Single Arm Design Pilot Trial|Refinement and assessment of the feasibility and acceptability of the Empowerment Self-Defense curriculum will occur in Phase 2 through the delivery of the tailored ESD curriculum to 3 groups of 16 TW.
89580647|NCT02089737||Panitumumab 6 mg/kg|Panitumumab 6 mg/kg, intravenous drip infusion over a 60-minute period, once every 2 weeks
89580648|NCT04688853|Experimental|Single Arm, Open label|"This is a single arm, open-label, multicenter phase I study with a dose escalation and an expansion segment.~For the Dose escalation segment, 3-9 patients per dose cohort will receive:~Dose level 1: Low~Dose level 2: Medium~Dose level 3: High~For the expansion segment, additional patients may be enrolled until a maximum of 20 patients have received the recommended dose"
89029870|NCT01249157|Experimental|MRI and PEM scans|All consenting patients who are to have staging breast MRI, will be offered 18FDG PEM (Positron Emission Mammography) within 30 days. If the patient had a previous breast MRI that was done within 30 days at an outside institution, this MRI can be used if a radiologist determines that it is an adequate study. The surgery date will not be affected by the additional PEM evaluation. All imaging will be done and reviewed by MSKCC breast imagers. MRI and PEM findings suggestive of malignancy will be prospectively recorded in both the ipsilateral and contralateral breast.
89029871|NCT00512499|Placebo Comparator|Group 1|CONTROL GROUP (first year only; maximum 300 patients): patients seen by CHUS orthopedists at the Hotel-Dieu site, where no nurse coordinator is available for inclusion. This is random but not randomized.
89029872|NCT00512499|Active Comparator|Group 2|"MINIMAL INTERVENTION GROUP: 1/2 of patients, randomly selected.~INTERVENTION: A nurse coordinator will identify patients with fragility fractures and inform the patient about osteoporosis as the cause of the fracture, the benefit of treatment, and the options of treatment adapted to the individual patient. Written information will be sent to his/her family physician containing a presumed osteoporosis diagnosis, investigation to be performed, correct interpretation of any osteodensitometry results in the context of a fragility fracture, the options of treatment, and alternatives if the first prescriptions are not tolerated or stopped. Intervention"
89580649|NCT02460575|Experimental|Lactobacillus|Active Product: Description Lactobacillus reuteri 17938 suspended in sunflower oil, medium chain triglyceride oil, silicone dioxide. Total viable count of L. reuteri 17938 1 x 108 CFU/5 drops.
89029873|NCT00512499|Experimental|Group 3|INTENSIVE INTERVENTION GROUP: 1/2 of patients, randomly selected Multiple layers of intervention will be added: results of the basic blood investigation for osteoporosis will be transmitted to the family physician with a personal letter explaining the importance of seeing the patient rapidly and indicating the urgency of initiating a treatment and indicating detailed instructions of treatment. The patient will be called at 4, 8, 12,16 and 24 months to monitor drug adherence, correct inadequate intake, and try to improve adherence. If the patient is not taking an adequate treatment at 4, 8 or 12 months, a letter will be sent again to the family physician asking to treat the patient according to recommendations.
89029874|NCT00504920||Symptom Assessment|Drawing blood samples and matching the test results with questionnaire responses for symptoms patients experience from transplant treatment.
89029875|NCT00504959|Experimental|1|ranibizumab
89029876|NCT00504998|Experimental|1|Dose Level 1 of escalating doses of Rexin-G i.v.
89029877|NCT00504998|Experimental|2|Dose Level 2 of escalating doses of Rexin-G i.v.
89029878|NCT00504998|Experimental|3|Dose Level 3 of escalating doses of Rexin-G i.v.
89029879|NCT00504998|Experimental|4|Dose Level 4 of escalating doses of Rexin-G i.v.
89029880|NCT00504998|Experimental|5|Dose Level 5 of escalating doses of Rexin-G i.v.
89029881|NCT04695561|Experimental|Self Myofascial Relaxation|In addition to the exercises applied to the participants in the control group, the participants in this group used Foam Roller, which was performed with the principle of painless movement 2 times a week for a total of 12 times a week for 6 weeks.
89029882|NCT04695561|Experimental|Instrument Assisted Soft Tissue Mobilization|In addition to the exercises applied to the participants in the control group, the participants in this group used Instrument Assisted Soft Tissue Mobilization, which was performed with the principle of painless movement 2 times a week for a total of 12 times a week for 6 weeks.
89029883|NCT04695561|Active Comparator|Only Exercise (Control)|Stretching and strengthening exercises for the hip flexors, hip extensors and iliotibial band were shown to the participants in the control group for 6 weeks every day of the week.
89580650|NCT02460575|Placebo Comparator|Placebo|Composition Sunflower oil, medium chain triglyceride oil and silicon dioxide. Total viable count of L. reuteri is zero CFU/ 5 drops.
89580651|NCT02089347|Experimental|SP306 Group|Participants randomized to receive SP306 vaccine intramuscularly
89580652|NCT02089347|Active Comparator|DT Group|Participants randomized to receive DT vaccine subcutaneously
89580653|NCT02419469|Experimental|Augmented BFM Therapy + Ofatumumab or Rituximab|Participants receive the study drugs in Induction, Consolidation, and Maintenance Courses.
89580654|NCT04687761|Experimental|AZA-Based|"Azacitidine 75 mg/m2/daily SC on a 5-on/2-off [weekend]/2-on schedule in 28-day cycle plus Venetoclax (ramp-up) 400 mg/daily oral, days 1 to 28 plus Quizartinib phase I/RP2D mg/daily oral, days 8 to 14-28.~If 1 DLT is observed among these 3 patients, additional 3 subjects will receive the level 2 dose, and it will be recommended in the absence of DLT between them. If >1 DLT occurs in these 6 level 2 patients, the dose administered in the level 1 will be the RP2D of the AZA-based schedule.~AZA and Venetoclax doses will remain the same in all levels and only the dose of Quizartinib will be modificated according to the following table:~Escalation-Quizartinib dose-Quizartinib duration; Level-2 -30 mg/daily-Days 8 to 14; Level-1 -30 mg/daily-Days 8 to 21; Level1-40 mg/daily Days 8 to 28; Level2-60 mg/daily-Days 8 to 28.~In phase II, patients randomized to this arm, will receive the recommended phase 2 dose (RP2D) regimen of AZA + Venetoclax + Quizartinib regimen (30 patients)."
89608651|NCT04149327|Experimental|Antibiotics group|Patients will receive full-mouth mechanical cleansing of both implants and remaining dentition using ultrasonic instruments (EMS®) and hand instruments (scalers and curettes) in one or multiple sessions (max. 4). Prior to each session patients will rinse their mouth using 0.12% chlorhexidine + 0.05% cetylpyridinium chloride without alcohol during 30 seconds. At the final session all previously cleaned areas will be re-examined and cleaned. At the end of the final treatment session, the dental hygienist will give the patients an envelop containing a recipe for medication consisting of 500 mg amoxicillin and 500 mg metronidazole to be taken every 8 hours for the following 7 days plus a recipe for 500 ml mouthrinse (0.12% chlorhexidine + 0.05% cetylpyridinium chloride without alcohol, Perio-Aid®). After the final session patients will rinse their mouth using that mouthrinse twice daily during 30 seconds for 2 weeks.
89029884|NCT04512794|Other|Non-randomized|All subjects with de novo ablation procedure for an atrial arrhythmia using the AcQMap System.
89029885|NCT01249118|Experimental|Part 1: GDC-0973 IV Infusion First, Then GDC-0973 Capsules|Participants will receive single dose of GDC-0973 2 milligrams (mg) IV infusion in first intervention period followed by single dose of GDC-0973 20 mg oral capsules (four 5-mg capsules) in second intervention period. The washout period between each period will be a minimum of 10 days.
89580655|NCT04687761|Experimental|LDAC-Based|"Low-dose subcutaneous cytarabine 20 mg/m2/daily SC, days 1 to 10 plus Venetoclax (ramp-up) 600 mg/daily oral, days 1 to 28 plus Quizartinib phase I/RP2D mg/daily oral, days 8 to 14-28.~If 1 DLT is observed among these 3 patients, additional 3 subjects will receive the level 2 dose, and it will be recommended in the absence of DLT between them. If >1 DLT occurs in these 6 level 2 patients, the dose administered in the level 1 will be the RP2D of the LDAC-based schedule.~LDAC and Venetoclax doses will remain the same in all levels and only the dose of Quizartinib will be modificated according to the following table:~Escalation-Quizartinib dose-Quizartinib duration; Level-2 -30 mg/daily-Days 8 to 14; Level-1 -30 mg/daily-Days 8 to 21; Level1-40 mg/daily-Days 8 to 28; Level2-60 mg/daily-Days 8 to 28.~In phase II, patients randomized to this arm, will receive the recommended phase 2 dose (RP2D) regimen of LDAC + Venetoclax + Quizartinib regimen (30 patients)."
89580656|NCT02419313|Active Comparator|Placebo, then Xeomin|Subjects randomized to receive the placebo ( saline) will receive an equivalent volume as the active study drug (1cc). The injections will be into -10 hand and forearm muscles. A series of rating scale and an examination will take place prior to treatment and at 4 and 8 weeks post treatment. The subject will then cross over to an Active Intervention arm to receive incobotulinumtoxinA which will be injected in the same pattern as the saline.
89580657|NCT02419313|Active Comparator|Xeomin, then Placebo|Subjects will all receive injections with incobotulinumtoxinA injections, 100unit/cc into 6-10 muscles of the forearm. A series of rating scale and an examination will take place prior to treatment and at 4 and 8 weeks post treatment. These subjects will then cross over and receive placebo ( saline) in the same distribution as their second treatment.
89580658|NCT04730193|Placebo Comparator|Control|Participants randomized to placebo group will receive placebo capsule
89580659|NCT04730193|Experimental|Caffeine|Participants randomized to caffeine group will receive 100mg caffeine capsule
89580660|NCT02419001|Experimental|Period 1 - Treatment Sequence AB|"Treatment Sequence AB:~Period 1: Ceftriaxone 1 g infused IV over 30 minutes~[Period 2: Ceftriaxone 1 g infused IV over 30 minutes and SYN-004 75 mg (1 x 75 mg capsule) orally administered 30 minutes before and 5.5 hours after the start of the ceftriaxone infusion]"
89580661|NCT02419001|Experimental|Period 1 - Treatment Sequence AC|"Period 1: Ceftriaxone 1 g infused IV over 30 minutes~[Period 2: Ceftriaxone 1 g infused IV over 30 minutes and SYN-004 150 mg (2 x 75 mg capsules) orally administered 30 minutes before and 5.5 hours after the start of the ceftriaxone infusion]"
89580662|NCT02419001|Experimental|Period 2 - Treatment Sequence AB|"Treatment Sequence AB:~[Period 1: Ceftriaxone 1 g infused IV over 30 minutes]~Period 2: Ceftriaxone 1 g infused IV over 30 minutes and SYN-004 75 mg (1 x 75 mg capsule) orally administered 30 minutes before and 5.5 hours after the start of the ceftriaxone infusion"
89580663|NCT02419001|Experimental|Period 2 - Treatment Sequence AC|"[Period 1: Ceftriaxone 1 g infused IV over 30 minutes]~Period 2: Ceftriaxone 1 g infused IV over 30 minutes and SYN-004 150 mg (2 x 75 mg capsules) orally administered 30 minutes before and 5.5 hours after the start of the ceftriaxone infusion"
89580664|NCT02031237||Stereotactic Radiosurgery (SRS)|"Patients with brain metastases receiving single fraction Stereotactic Radiosurgery (SRS). This intervention is not assigned by the investigator. Treatment has been decided prior to study enrollment.~MRI scans will be performed approximately 1-2 weeks prior to SRS, and 1-2 weeks and 1 month after SRS. The MRI scan will include a routine clinical MRI series."
89580665|NCT02031237||Whole Brain Radiation Therapy|"Patients with brain metastases receiving fractionated (spread out over time) Whole Brain Radiation Therapy (WBRT). This intervention is not assigned by the investigator. Treatment has been decided prior to study enrollment.~MRI scans will be performed approximately 1-2 weeks prior to RT, at the end of RT and 1 month after RT. The MRI scan will include a routine clinical MRI series."
89580666|NCT02031237||Stereotactic Radiation Therapy|"Patients with brain metastases receiving fractionated (spread out over time) Stereotactic Radiation Therapy (FSRT). This intervention is not assigned by the investigator. Treatment has been decided prior to study enrollment.~MRI scans will be performed approximately 1-2 weeks prior to FSRT, during the last week of RT but before the last fraction and 1 month after RT. The MRI scan will include a routine clinical MRI series."
89029886|NCT01249118|Experimental|Part 2: GDC-0973 IV Infusion First, Then GDC-0973 Capsules|Participants will receive single dose of GDC-0973 2 mg IV infusion in first intervention period followed by single dose of GDC-0973 20 mg oral capsules (four 5-mg capsules) in second intervention period. The washout period between each period will be a minimum of 10 days.
89580667|NCT02088957|Experimental|Brivaracetam|"Subjects will receive an acute intravenous (iv) dose of Brivaracetam (BRV) 200 mg as a bolus on Day 1. If seizures recur, a second iv bolus of BRV 100 mg can be given no sooner than 15 minutes after the first bolus. If the second acute bolus is not needed within12 hours after first iv bolus, BRV will be continued as 100 mg iv dose every 12 hours (bid). The total dose for the first 24 hours of treatment should not exceed a maximum dose of 400 mg. The rate of bolus administration is 50 mg (5 mL) undiluted BRV/min. On study Day 5 (or earlier), subjects will transition from iv to oral formulation, at comparable dosing for a maximum of 6 months.~Subjects should transition to oral medication as soon as they are able to swallow tablets."
89580668|NCT02088957|Active Comparator|Phenytoin|"Subjects will receive an acute intravenous (iv) dose of Phenytoin (PHT) 20 mg/kg at a rate of 50 mg/min on Day 1. If seizures recur, a second acute dose of PHT iv will be given no sooner than 15 minutes after the first dose. Treatment with PHT iv will be continued with at least 2 daily divided doses according to site practice. Daily PHT dose can be adapted according to investigator's clinical judgment. On study Day 5 (or earlier), subjects will transition from iv to oral formulation at comparable dosing for a maximum of 6 months.~Subjects should transition to oral medication as soon as they are able to swallow tablets."
89580669|NCT04687215||Diabetic patients receiving a spinal cord stimulator|Patients that have been seen in the diabetic foot clinic will be evaluated for participation in the study once they have been referred to one of our pain clinics.
89580670|NCT02418845|Experimental|SYM-1219|Administered orally
89580671|NCT02418845|Placebo Comparator|Placebo|Administered orally
89580672|NCT02088177|Experimental|Long-acting injectable naltrexone|Two doses of long-acting injectable naltrexone, 380 mg by intramuscular injection in the gluteal muscle at study day 1 and again between study days 28-30.
89580673|NCT02030535|Experimental|Tiotropium/Olodaterol FDC|patient will receive tiotropium and olodaterol in a fixed dose combination
89580674|NCT02030535|Experimental|Tiotropium and Olodaterol FC|patient will receive tiotropium and olodaterol in a free combination
89580675|NCT02030535|Placebo Comparator|Placebo|patient will receive placebo
89580676|NCT04710537|Active Comparator|AlloDerm|AlloDerm will be surgically implanted into each participant (either in their left or right breast) at the time of their breast reconstruction surgery. AlloDERM will be placed in the breast opposite to the breast in which DermACELL is placed, so that the patient has AlloDERM in the right breast and DermACELL in the left breast, or vice versa.
89580677|NCT04710537|Active Comparator|DermACELL|DermACELL will be surgically implanted into each participant (either in their left or right breast) at the time of their breast reconstruction surgery. DermACELL will be placed in the breast opposite to the breast in which AlloDERM is placed, so that the patient has AlloDERM in the right breast and DermACELL in the left breast, or vice versa.
89580678|NCT02029989|Experimental|Extended Treatment Group|Glucose and Lipids and Glycosylated Hemoglobin A1c and Blood Pressure and Heart Rate and Body Mass Index and Waist and Hip Circumference and Comprehensive Medication Management
89580679|NCT02029989|Active Comparator|Usual Treatment Group|Glucose and Lipids and Glycosylated Hemoglobin A1c and Blood Pressure and Heart Rate and Body Mass Index and Waist and Hip Circumference
89580680|NCT02048241|Other|Placebo plus Parent Management Training|Pills matching Intuniv Tablets without active medication combined with weekly Parent Management Training
89580681|NCT02048241|Experimental|Intuniv plus Parent Management Training|Administration of Intuniv in increasing doses from 1 mg to 2 mgs to 3 mgs to 4 mgs as tolerated over a period of 4-6 weeks, combined with weekly Parent Management Training
89580682|NCT02087943|Experimental|Apremilast 40 mg|Apremilast 40 mg administered orally twice daily (BID) for 12 weeks (following dose titration) during the placebo controlled phase followed by 40 mg Apremilast tablets orally administered BID for an additional 12 weeks in the active treatment phase
89580683|NCT02087943|Experimental|Apremilast 30 mg|Apremilast 30 mg administered orally BID for 12 weeks (following dose titration) during the placebo controlled phase followed by 30 mg Apremilast tablets orally administered BID for an additional 12 weeks in the active treatment phase
89580684|NCT02087943|Experimental|Placebo + Apremilast 40 mg|Placebo administered orally BID for 12 weeks, during the placebo controlled phase followed by 40 mg Apremilast tablets orally BID for an additional 12 weeks in the active treatment phase
89580685|NCT02087943|Experimental|Placebo + Apremilast 30 mg|Placebo administered orally BID for 12 weeks, during the placebo controlled phase followed by 30 mg Apremilast tablets orally BID for an additional 12 weeks in the active treatment phase
89580686|NCT02087943|Placebo Comparator|Placebo|Oral Placebo tablets administered twice daily (BID) for 12 weeks during the placebo-controlled phase.
89580687|NCT02029521|Experimental|Oral reduced l-glutathione|The treatment was pharmaceutical-grade Reduced L-Glutathione (GSH) with a daily dose of 65 mg/kg.
89580688|NCT02029521|Placebo Comparator|Placebo Calcium Citrate|The placebo was calcium citrate with a daily dose of 65 mg/kg. The daily dose of each substance was divided into three doses given at mealtime.
89580689|NCT04685811|Experimental|68Ga-PSMA-generator vs. 68Ga-PSMA-cyclotron|Patients with metastatic prostate cancer will undergo two protocol 68Ga-PET scans within 24-48 hours with 68Ga-PSMA-cyclotron and 68Ga-PSMA-generator radiotracers.
89580690|NCT04709211|Active Comparator|Group I: Facia Iliaca block|patients will receive Ultrasound-guided Facia Iliaca Block using bupivacaine 0.25%
89580691|NCT04709211|Active Comparator|Group Q: Anterior Quadratus lumbroum block|patients will receive Ultrasound-guided Anterior Quadratus Lumbroum block using bupivacaine 0.25%
89580692|NCT02443883|Experimental|Ramucirumab Regimen 1|Standard dose of 8 milligram per kilogram (mg/kg) ramucirumab given intravenously (IV) on day 1 and day 15 of each cycle (28-day cycle) until discontinuation criteria are met.
89580693|NCT02443883|Experimental|Ramucirumab Regimen 2|Experimental dose of 12 mg/kg ramucirumab given IV on day 1 and day 15 of each cycle (28-day cycle) until discontinuation criteria are met.
89580694|NCT02443883|Experimental|Ramucirumab Regimen 3|Experimental dose of 6 mg/kg ramucirumab given IV on day 1, 8, 15 and 22 of each cycle (28-day cycle) until discontinuation criteria are met.
89580695|NCT02443883|Experimental|Ramucirumab Regimen 4|Experimental dose of 8 mg/kg ramucirumab given IV on day 1 and day 8 of each cycle (21-day cycle) until discontinuation criteria are met.
89580696|NCT02460263|Placebo Comparator|In-Center|Staff administered treatments in-center using the device
89580697|NCT02460263|Experimental|In-Home|Patient administered treatments in-home using the device
88973949|NCT05772039|Active Comparator|Topical application of 38% Silver Diammine Fluoride Solution at 6 months|"SDF is known for its corrosive nature therefore a plastic container or dappen dish will be used.~1 drop (0.05 ml) will be dispensed on a plastic container.~1 drop (2.24 F-ion mg/dose) SDF treats up to 5 tooth surfaces.~Ultrafine microbrushes will be used to apply varnish."
88973950|NCT05772039|Active Comparator|Topical application of 38% Silver Diammine Fluoride Solution at 12 months|"SDF is known for its corrosive nature therefore a plastic container or dappen dish will be used.~1 drop (0.05 ml) will be dispensed on a plastic container.~1 drop (2.24 F-ion mg/dose) SDF treats up to 5 tooth surfaces.~Ultrafine microbrushes will be used to apply varnish."
88973951|NCT05772039|Experimental|Topical application of 5% Sodium Fluoride with functional Tricalcium phosphate Varnish at baseline|"0.25 ml of the solution will be used which contains 12.5 mg of fluoride.~Thin layer will be applied with sweeping horizontal brush strokes to all teeth present."
88973952|NCT05772039|Experimental|Topical application of 5% Sodium Fluoride with functional Tricalcium phosphate Varnish at 6 months|"0.25 ml of the solution will be used which contains 12.5 mg of fluoride.~Thin layer will be applied with sweeping horizontal brush strokes to all teeth present."
88973953|NCT05772039|Experimental|Topical application of 5% Sodium Fluoride with functional Tricalcium phosphate Varnish at 12 months|"0.25 ml of the solution will be used which contains 12.5 mg of fluoride.~Thin layer will be applied with sweeping horizontal brush strokes to all teeth present."
88973954|NCT05772026||POD group|According to the occurrence of postoperative delirium, the patients were divided into POD group and non-POD group
88973955|NCT05772026||non-POD group|According to the occurrence of postoperative delirium, the patients were divided into POD group and non-POD group
88973956|NCT05772013|Active Comparator|Continuous azithromycin|Participants in this arm will continue with their standard of care (i.e. continuous dose of azithromycin according to their standard prescription) throughout the trial.
88973957|NCT05772013|Other|Seasonal azithromycin|"Azithromycin will be taken by participants during the autumn-winter (October - March).~Matched placebo will be taken by the participants in the spring-summer (April - September)."
88973958|NCT05772013|Placebo Comparator|Complete Discontinuation of azithromycin|Participants will take continuous matched placebo throughout the trial.
88973959|NCT05771987|Experimental|HCM patients with LVOT obstruction|Patients with obstructive HCM are considered for this study if 1) symptomatic, 2) refractory to optimized medical therapy and 3) not or poorly* eligible for septal myectomy or with an indication to implant a pacing device (pacemaker or ICD) independent on the ventricular obstruction.
88973960|NCT05771870|Experimental|Peer mentoring|The clinical practice day of the Child Health and Diseases Nursing course included mentoring practice. This is a 3rd-grade (5th semester) course that includes 6 hours of theory and 8 hours of practice in the applicable curriculum. The clinical practice of the Child Health and Diseases Nursing course is carried out for 14 weeks (one semester) 1 day a week at the Children's Units of the Karabük Training and Research Hospital in the program in which the study was done. Throughout all clinical practice days, mentors chosen from graduate students followed the students in the peer mentorship group during the medication preparation and administration processes, providing feedback on their positive, negative, or inadequacies.
88973961|NCT05771870|Experimental|Nurse mentoring|The clinical practice day of the Child Health and Diseases Nursing course included mentoring practice. This is a 3rd-grade (5th semester) course that includes 6 hours of theory and 8 hours of practice in the applicable curriculum. The clinical practice of the Child Health and Diseases Nursing course is carried out for 14 weeks (one semester) 1 day a week at the Children's Units of the Karabük Training and Research Hospital in the program in which the study was done. Mentors from the clinical nursing community attended the students in the nurse mentoring group during the drug preparation and administration processes and provided feedback on their positive, negative, or inadequacies.
88973962|NCT05771844|Experimental|Deep Sleep Enhancement with TES|Transcranial Electrical Stimulation, 0.5 Hz sine wave, 0.5 mA, between frontal (frontopolar and inferior lateral frontal) and posterior (mastoid and occipital) electrodes.
88973963|NCT05771831|Experimental|Thrombosomes®|Thrombosomes® (TBX®) up to 3 doses
88973964|NCT05771831|Active Comparator|Standard platelet concentrate|Standard platelet concentrate up to 3 doses
88973965|NCT05771818|Experimental|Falls Prevention training|The intervention consists of 10 sessions. One session a week consists of obstacle course training. The other session consists of falls strategies and walking and balance exercises. Each session lasts approximately 1.5 hours
88973966|NCT05771753|Experimental|Stretching Exercises|6 stretching exercise for 8 weeks
88973967|NCT05771753|Experimental|Dynamic core stabilizing exercises|6 strengthening exercises for 8 weeks
88973968|NCT05771727||Parents of children with pediatric neuromuscular diseases|Parents of a total of 169 children with pediatric neuromuscular diseases, including 63 Duchnenne Muscular Dystrophy, 53 Spinal Muscular Atrophy and 18 other pediatric neuromuscular diseases (Congenital Muscular Dystrophy, Hereditary Motor and Sensory Neuropathy, Becker Muscular Dystrophy, Limb-Girdle Muscular Dystrophy, etc.) were included in the study
88973969|NCT05771675|Experimental|Simvastatin|Participants receive Simvastatin 40mg capsule once daily for 6 months.
88973970|NCT05771675|Placebo Comparator|Placebo|Participants receive Placebo capsule matching Simvastatin once daily for 6 months.
88973971|NCT05771597|Experimental|Home Biofeedback Therapy (HBT)|"HBT for patients with constipation and dyssynergic defecation:~HBT for patients with FI~HBT for patients with UI~All patients will be advised to practice HBT at least once or twice a day for six weeks."
88973972|NCT05771597|Active Comparator|Office Biofeedback Therapy (OBT)|"OBT for patients with constipation and dyssynergic defecation.~OBT for patients with FI.~OBT for patients with UI.~All patients will receive office biofeedback, once weekly, over six weeks."
88973973|NCT05771532|Experimental|The experimental group|"The experimental group (n=33) received a gender-sensitive and transtheoretical model (TTM)-based sexual health education program, which includes a 10-15-minute individual sexual health education and a sexual health pamphlet. The TTM-based sexual health education program was performed by a nurse educator with more than one year of clinical experience in gynecological nursing, who received formal training through enrollment in a course entitled  a gender-sensitive and transtheoretical model (TTM)-based sexual health education training program."
89029887|NCT01249118|Experimental|Part 2: GDC-0973 Capsules First, Then GDC-0973 IV Infusion|Participants will receive single dose of GDC-0973 20 mg oral capsules (four 5-mg capsules) in first intervention period followed by single dose of GDC-0973 2 mg IV infusion in second intervention period. The washout period between each period will be a minimum of 10 days.
89580698|NCT03669809||male, non-obese|male with BMI<28
89580699|NCT03669809||male, obese|male with BMI≥28
89580700|NCT03669809||female, non-obese|female with BMI<28
89580701|NCT03669809||female, obese|female with BMI≥28
89580702|NCT02443805|Active Comparator|300 IR|300 IR tablet of HDM Allergen Extracts
89580703|NCT02443805|Placebo Comparator|Placebo|Placebo tablet
89580704|NCT01652885|Experimental|AN2728 Topical Ointment, 2%|AN2728 Topical Ointment, 2%, applied twice daily for up to 28 days
89580705|NCT02459951||clenched fist|Adult participants with upper limb hemiparesis secondary to stroke and greater than 12 months duration. Medical determination that .botulinum toxin injections are indicated for treatment of spasticity.
89580706|NCT04931927|Active Comparator|Control|Participants are randomized to treatment as usual (TAU)
89580707|NCT04931927|Experimental|MCI-T|Participants are randomized to the Making Connections Intervention-Telehealth (MCI-T) plus treatment as usual (TAU)
89580708|NCT02087241|Experimental|AZD1775 + carboplatin + pemetrexed|Randomised: AZD1775 + pemetrexed + carboplatin followed by maintenance AZD1775 + pemetrexed versus pemetrexed and carboplatin followed by maintenance pemetrexed.
89580709|NCT02087241|Experimental|Placebo + carboplatin + pemetrexed|Randomised: AZD1775 + pemetrexed + carboplatin followed by maintenance AZD1775 + pemetrexed versus pemetrexed and carboplatin followed by maintenance pemetrexed.
89580710|NCT02087085|Experimental|400 µg Brimonidine Implant|400 µg brimonidine implant in the study eye, administered by intravitreal injections using the Brimonidine Drug Delivery System (Brimo DDS®) applicator every 3 months from Baseline (Day 1) through Month 21.
89580711|NCT02087085|Sham Comparator|Sham|Sham treatment (control) in the study eye, administered by intravitreal injections using a needleless drug delivery system (DDS) applicator every 3 months from Baseline (Day 1) through Month 21.
89580712|NCT02443337|Experimental|LY3023414 + Necitumumab|200 milligrams (mg) LY3023414 administered orally twice daily and 800 mg necitumumab administered intravenously (IV) on day 1 and day 8 of each cycle (21 day cycles). Participants may continue to receive treatment until discontinuation criteria are met.
89580713|NCT04684251|Experimental|Treatment arm|The treatment arm will undergo the intervention with embolisation of their hemorrhoidal arteries. The embolisation will be performed using a standard right femoral puncture and after inserting a 5 Fr introducer sheath. The inferior mesenteric artery will be catheterised using a Simmons catheter (radiofocus-Terumo). The superior rectal arteries will be then catheterized with a rapid transit microcatheter Progreat microcatheter (Radiofocus-Terumo) and embolised with coils. The treatment will include the use of fluoroscopy for which the radiation protection department of Oxford University Hospitals NHS Foundation Trust has been consulted. The technical success of the procedure will be assessed fluoroscopically by achieving stasis of blood flow distally to the site of the embolization. CE marked coils will be used for the embolisation of the arteries feeding the haemorrhoids.
89580714|NCT02443103|Experimental|Guanabenz|
89580715|NCT02022657|Active Comparator|33%/67%|Participants will be randomized to one of 6 sequences consisting of two directly observed dosing regimens expressed as % of daily dosing of Truvada
89580716|NCT02022657|Active Comparator|33%/100%|Participants will be randomized to one of 6 sequences consisting of two directly observed dosing regimens expressed as % of daily dosing of Truvada
89580717|NCT02022657|Active Comparator|67%/33%|Participants will be randomized to one of 6 sequences consisting of two directly observed dosing regimens expressed as % of daily dosing of Truvada
89580718|NCT02022657|Active Comparator|67%/100%|Participants will be randomized to one of 6 sequences consisting of two directly observed dosing regimens expressed as % of daily dosing of Truvada
89580719|NCT02022657|Active Comparator|100%/33%|Participants will be randomized to one of 6 sequences consisting of two directly observed dosing regimens expressed as % of daily dosing of Truvada
89580720|NCT02022657|Active Comparator|100%/67%|Participants will be randomized to one of 6 sequences consisting of two directly observed dosing regimens expressed as % of daily dosing of Truvada
89580721|NCT02418455|Experimental|UX003|UX003 4 mg/kg every other week (QOW). Initial treatment period 48 weeks. Continuation period up to 240 weeks.
89580722|NCT02417753|Experimental|AZD9150 in People with Malignant Ascites|AZD9150 over a 28 day cycle
89580723|NCT02417441|Experimental|Early Embryo Viability Assessment + Morphological Grading|Embryos of subjects randomized in this group were assessed using Early Embryo Viability Assessment (Eeva) System and morphological grading to identify optimal embryos for transfer.
89580724|NCT02417441|No Intervention|Morphological Grading|Embryos of subjects randomized in this group were assessed only using morphological grading to identify optimal embryos for transfer.
89580725|NCT02021643|Experimental|Sofosbuvir+RBV+PEG 12 weeks|Participants with genotype 1 or 6 will receive sofosbuvir+RBV+Peg-IFNα-2a for 12 weeks.
89580726|NCT02021643|Experimental|Sofosbuvir+RBV 12 weeks|Participants with genotype 1, 2 or 6 will receive sofosbuvir+RBV for 12 weeks.
89580727|NCT02021643|Experimental|Sofosbuvir+RBV 16 weeks|Participants with genotype 1, 6 will receive sofosbuvir+RBV for 16 weeks.
89580728|NCT02021643|Experimental|Sofosbuvir+RBV 24 Weeks|Participants with genotype 1, 3, or 6 will receive sofosbuvir+RBV for 24 weeks.
89580729|NCT02415959|Experimental|Creon IR low dose|Creon IR 300 Ph. Eur. U lipase/g fat/day, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 30,000 lipase units)
89580730|NCT02415959|Experimental|Creon IR medium dose|Creon IR 1,200 Ph. Eur. U lipase/g fat/day, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 120,000 lipase units)
89580731|NCT02415959|Experimental|Creon IR high dose|Creon IR 2,400 Ph. Eur. U lipase/g fat/day, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 240,000 lipase units)
89029888|NCT00512655|Experimental|1|Intervention: 5 week training program, 2 sessions per week (total of 10 sessions). Training includes both the patient and the caregiver. The training consists of two components: a cognitive and a physical component.
89029889|NCT00512655|No Intervention|2|Usual care.
89029890|NCT00505037|Experimental|ASP1585 dose #1|
89029891|NCT00505037|Experimental|ASP1585 dose #2|
89580732|NCT02415959|Experimental|Creon IR maximum dose|Creon IR 4,000 Ph. Eur. U lipase/g fat/day, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 400,000 lipase units)
89580733|NCT02415959|Active Comparator|Creon® (DR/GR)|Creon® (DR/GR) 4,000 Ph. Eur. U lipase/g fat/day, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 400,000 lipase units)
89580734|NCT02021565|Experimental|Immediate Intervention Group|"Receives the in-home training intervention immediately after completing the baseline assessment.~The intervention includes three home visits from an AT Specialist (Occupational or Physical Therapist) who observes the dyad perform three ADL transfers, provides recommendations, equipment, home modifications, training, and follow-up training as needed."
89029892|NCT00505037|Experimental|ASP1585 dose #3|
89580735|NCT02021565|Other|Delayed Intervention Control Group|Receives the in-home training intervention six weeks after completing the initial baseline assessment. This allows for a control comparison group while still providing the intervention to all participants.
89580736|NCT02021331|Active Comparator|immediate implant placement without provisionalization|The subject will have the tooth removed and an implant placed right away. In this arm the subject will have no temporary crown on the implant.
89580737|NCT02021331|Experimental|immediate implant placement with immediate provisionalization|The subject will have the tooth removed and an implant placed right away. In this arm the subject will get a temporary crown on the implant.
89580738|NCT04682535||Cohort 1|Spousal/partner family caregivers to persons living with dementia. Participants will complete 14-days of surveys about their relationships, social interactions, as well as health and health behaviors. A subsample of n=15 may volunteer to provide diurnal saliva samples.
89580739|NCT04684173||Term infants|The inclusion criteria for term infants are: gestational age 37-42 weeks, birth weight >2,500 grams, and no congenital/genetic abnormalities. Their mothers are older than 20 years of age, have no history of alcohol or drug abuse, and are married or live with fathers.
89580740|NCT04684173||Preterm infants|The inclusion criteria for preterm infants are: gestational age <37 weeks, birth weight <2,500 grams, and no congenital/genetic abnormalities. Their mothers are older than 20 years of age, have no history of alcohol or drug abuse, and are married or live with fathers.
89580741|NCT02085135|Experimental|Titration Schedule 1|
89580742|NCT02085135|Experimental|Titration Schedule 2|
89580743|NCT02441309|Experimental|A. Mifamurtide only|"Treatment Weeks 1-6 (post 1st biopsy/resection):~Mifamurtide 2mg/m2, IV infusion, twice/week, with each infusion given at least 3 days apart, for 6 weeks.~Treatment Weeks 7-12 (post 2nd biopsy/resection):~Mifamurtide 2mg/m2, IV infusion, twice/week, with each infusion given at least 3 days apart, for 6 weeks.~Treatment Weeks 13-36:~Mifamurtide 2mg/m2, IV infusion, once/week."
89580744|NCT02441309|Experimental|B. Ifosfamide (Followed by Mifamurtide)|"Treatment Weeks 1-6: Day 1 of 21: Ifosfamide 12-15g/m2 IV infused over 4-5 days as per local practice. Repeated every 21 days for 2 cycles (3 weeks=1 cycle).~Treatment Weeks 7-12 (post 2nd biopsy/resection): Day 1 of 21: Ifosfamide 12-15g/m2 IV infused over 4-5 days once every 21 days for two cycles (3 weeks=1 cycle). Ifosfamide administered as per local practice, including concurrent dosing with mesna. Plus mifamurtide 2mg/m2, IV infusion, twice/week. Ifosfamide infusion started 24 hours prior to mifamurtide. Mifamurtide given on day 2 and either day 5 or day 6.~Treatment Weeks 13-18: Mifamurtide 2mg/m2, IV infusion, twice/week. Treatment Weeks 19-42: Mifamurtide 2mg/m2, IV infusion, once/week."
89580745|NCT02441309|Experimental|C. Ifosfamide + Mifamurtide|"Treatment Weeks 1-6:~Day 1 of 21: Ifosfamide 12-15g/m2 IV infusion over 4-5 days once every 21 days for two cycles (3 weeks=1 cycle).~Plus Mifamurtide 2mg/m2, IV infusion, twice per week, each given at least 3 days apart, for 6 weeks.~Ifosfamide infusion started 24 hours prior to mifamurtide. Mifamurtide given on day 2 and either day 5 or day 6.~Treatment Weeks 7-12 (post 2nd biopsy/resection):~Day 1 of 21: Ifosfamide 12-15g/m2 IV infusion over 4-5 days once every 21 days for two cycles (3 weeks = 1 cycle).~Plus Mifamurtide 2mg/m2, IV infusion, twice per week, given at least 3 days apart, for 6 weeks. Ifosfamide infusion started 24 hours prior to mifamurtide. Mifamurtide given on day 2 and either day 5 or day 6.~Treatment Weeks 13-36: Mifamurtide 2mg/m2, IV infusion, once/week."
89580746|NCT02027025|Active Comparator|SPARC 1103 low dose|The subjects will receive SPARC 1103 low dose
89580747|NCT02027025|Active Comparator|SPARC1103 high dose|The subjects will receive SPARC1103 high dose
89580748|NCT02027025|Placebo Comparator|SPARC Placebo|The subjects will receive SPARC Placebo
89029893|NCT00505037|Placebo Comparator|Placebo|
89029894|NCT00505037|Active Comparator|Sevelamer hydrochloride|
89029895|NCT00513552|Experimental|Antibiotics|Antibiotics
89029896|NCT02275169|Experimental|Treated|Urofollitropin 150 IU ampoules three times a week for three months
89029897|NCT02275169|Placebo Comparator|Controls|Placebo ampoules three times a week for three months
89029898|NCT00513591||1|Women with lupus
89029899|NCT00513591||2|Health women who are matched to women with lupus by age and race
89029900|NCT00513591||3|Women with other autoimmune diseases
89029901|NCT00513630|Active Comparator|metformin|
89029902|NCT00513630|Active Comparator|glipizide|
89029903|NCT02275247|Experimental|Intervention 'Stellate Ganglion Block'|Experimental patients will receive a stellate ganglion block with 0.25% ropivacaine 6-8mL on the right side at the level of the sixth cervical vertebrae (C6) before surgery.Then the catheter will be attached to a single use patient-controlled analgesia pump containing 0.2% ropivacaine 150 mL, which will be infused at 2 mL/h.
89580749|NCT01652729|Experimental|Exenatide once weekly suspension|Exenatide once weekly suspension 2mg subcutaneous injection
89580750|NCT01652729|Active Comparator|Sitagliptin 100mg|Overencapsulated Sitagliptin 100mg oral tablet once daily
89580751|NCT01652729|Placebo Comparator|Placebo|Placebo oral capsule once daily
88973974|NCT05771532|No Intervention|The control group|"The control group (n=30) received a 10-15-minute routine sexual health education and a sexual health pamphlet without a gender-sensitive and theoretically based design. Both were provided by nursing staff with no formal training in  a gender-sensitive and transtheoretical model (TTM)-based sexual health education training program."
89580752|NCT02083965|Experimental|rFVIIIFc 1000 / 3000 PK Assessment|"A single intravenous (IV) injection of rFVIIIFc 50 IU/kg at a strength of 1000 IU/vial followed by a single IV injection of rFVIIIFc 50 IU/kg at a strength of 3000 IU/vial.~Following the PK assessment, participants will receive either an episodic (on-demand) regimen with doses between 20 and 50 IU/kg based on the severity of the bleeding episode, or 1 of 2 prophylactic regimens: 50 IU/kg every 3 to 5 days or 65 IU/kg weekly. Participants will be allowed to switch from one regimen to another if approved by the Investigator."
89580753|NCT02083965|Experimental|rFVIIIFc 3000 / 1000 PK Assessment|"A single IV injection of rFVIIIFc 50 IU/kg at a strength of 3000 IU/vial followed by a single IV injection of rFVIIIFc 50 IU/kg at a strength of 1000 IU/vial.~Following the PK assessment, participants will receive either an episodic (on-demand) regimen with doses between 20 and 50 IU/kg based on the severity of the bleeding episode, or 1 of 2 prophylactic regimens: 50 IU/kg every 3 to 5 days or 65 IU/kg weekly. Participants will be allowed to switch from one regimen to another if approved by the Investigator."
89580754|NCT02438813||All Enrolled Participants|All enrolled participants who signed informed consent whether or not they elected to receive treatment as per standard of care in clinical practice for submental fat (SMF). Treatments for SMF included: ATX1-101, Surgical Procedures, Laser Liposuction, Energy Devices or Other Treatments.
89580755|NCT02459093|Experimental|poliglecaprone 25 suture|Subcuticular skin approximation with poliglecaprone 25 suture at cesarean birth surgery
89580756|NCT02459093|Experimental|polyglactin 910 suture|Subcuticular skin approximation with polyglactin 910 suture at cesarean birth surgery
89580757|NCT02458469|Active Comparator|Buspirone|This drug will be taken for two week period
89580758|NCT02458469|Active Comparator|Trazodone|This drug will be taken for two week period
89580759|NCT02458469|Placebo Comparator|Placebo|A placebo pill will be taken at bed time for two week period
89580760|NCT01843348|Active Comparator|TAC+MPA|
89580761|NCT01843348|Experimental|TAC+Certican|
89580762|NCT01843348|Experimental|CycA+Certican|
89580763|NCT01843192||VATS for suspected or confirmed NSCLC|Single arm study
89580764|NCT01825876|Active Comparator|Warfarin|15 milligrams (mg) warfarin administered as a single oral dose
89580765|NCT01825876|Experimental|Evacetrapib + Warfarin|130 mg evacetrapib administered once daily (QD), orally, for 16 days with 15 mg warfarin co-administered once orally on Day 10
89580766|NCT01842958|Active Comparator|4.1 mm implant diameter|Placement of a Straumann Bone Level Implants, 4.1 mm implant diameter, for single tooth replacement in the anterior and pre-molar region
89580767|NCT01842958|Experimental|3.3 mm implant diameter|Placement of a Straumann Bone Level Implants, 3.3 mm implant diameter, for single tooth replacement in the anterior and pre-molar region
89029904|NCT02275247|No Intervention|without 'Stellate Ganglion Block'|In the control group, every thing will be conducted as a matter of routine without intervention.
89580768|NCT02413229|Experimental|DSXS1411|DSXS applied once a day for a total of 28 days.
89580769|NCT02413229|Placebo Comparator|Placebo|Placebo (vehicle) applied once a day for a total of 28 days.
89580770|NCT01825798|Placebo Comparator|Placebo Hydrochloride Oral Solution|
89580771|NCT01825798|Experimental|Metformin|
89580772|NCT01824472|Active Comparator|CPAP+CC|Continuous Positive Airway Pressure (CPAP) therapy for sleep apnea and contact control (CC) (placebo/sham for cognitive-behavioral therapy for insomnia)
89580773|NCT01824472|Sham Comparator|sham CPAP+CC|sham CPAP (ineffective CPAP--placebo/sham for sleep apnea) and contact control (placebo/sham for cognitive-behavioral therapy for insomnia)
89580774|NCT01824472|Active Comparator|CPAP+CBT|CPAP therapy for sleep apnea and cognitive-behavioral therapy (CBT) for insomnia
89580775|NCT02412761|Active Comparator|Amlodipine, then HCTZ, then Lisinopril|Participants first received amlodipine once daily for 2 weeks, then crossed over to hydrochlorothiazide (HCTZ) once daily for 2 weeks, then lisinopril once daily for 2 weeks. Subsequent treatments varied depending on individual patient response.
89580776|NCT02412761|Active Comparator|Amlodipine, then Lisinopril, then HCTZ|Participants first received amlodipine once daily for 2 weeks, then crossed over to lisinopril once daily for 2 weeks, then hydrochlorothiazide (HCTZ) once daily for 2 weeks. Subsequent treatments varied depending on individual patient response.
89580777|NCT02412761|Active Comparator|HCTZ, then Amlodipine, then Lisinopril|Participants first received hydrochlorothiazide (HCTZ) once daily for 2 weeks, then crossed over to amlodipine once daily for 2 weeks, then lisinopril once daily for 2 weeks. Subsequent treatments varied depending on individual patient response.
89580778|NCT02412761|Active Comparator|HCTZ, then Lisinopril, then Amlodipine|Participants first received hydrochlorothiazide (HCTZ) once daily for 2 weeks, then crossed over to lisinopril once daily for 2 weeks, then amlodipine once daily for 2 weeks. Subsequent treatments varied depending on individual patient response.
89580779|NCT02412761|Active Comparator|Lisinopril, then Amlodipine, then HCTZ|Participants first received lisinopril once daily for 2 weeks, then crossed over to amlodipine once daily for 2 weeks, then hydrochlorothiazide (HCTZ) once daily for 2 weeks. Subsequent treatments varied depending on individual patient response.
89580780|NCT02412761|Active Comparator|Lisinopril, then HCTZ, then Amlodipine|Participants first received lisinopril once daily for 2 weeks, then crossed over to hydrochlorothiazide (HCTZ) once daily for 2 weeks, then amlodipine once daily for 2 weeks. Subsequent treatments varied depending on individual patient response.
89580781|NCT01842334|Experimental|D-cycloserine|250 mg D-cycloserine once weekly an hour before receiving cognitive behavioral therapy treatment along with Nicotine Replacement Therapy.
89580782|NCT01842334|Placebo Comparator|Placebo|one placebo capsule once weekly an hour before receiving cognitive behavioral therapy treatment along with Nicotine Replacement Therapy
89580783|NCT02457611|Experimental|LDV/SOF|LDV/SOF FDC for 6 weeks
89580784|NCT04593628|Experimental|All Participants|
89580785|NCT04931381|Experimental|Organoid-Guided Chemotherapy|The pancreatic cancer specimens are obtained from biopsy to be cultured for organoids. Then drug sensitivity is tested using organoid to obtain the sensitivity to the first-line drugs for pancreatic cancer (Gemcitabine, 5-fluorouracil, Paclitaxel, Oxaliplatin, Irinotecan). Patients will receive relatively sensitive chemotherapy regimen based on the test results. Chemotherapy should start within 1 months after biopsy, and be given at least 1 cycle.
89580786|NCT04931381|No Intervention|Physician-decided Chemotherapy|The pancreatic cancer specimens are obtained from biopsy to be cultured for organoids. Then drug sensitivity is tested using organoid to obtain the sensitivity to the first-line drugs for pancreatic cancer (Gemcitabine, 5-fluorouracil, Paclitaxel, Oxaliplatin, Irinotecan). Physician will decide the the adjuvant chemotherapy regimen, according to National Comprehensive Cancer Network (NCCN) guideline for pancreatic ductal adenocarcinoma. And they don't know the drug sensitivity test results. Chemotherapy should start within 1 months after biopsy, and be given at least 1 cycle.
89580787|NCT04931303||Study Group|Enrolled patients receive a medical device which monitors gait quality and collects information about the patients health status. Possible changes of intervention (drug or physical therapy) within the observational phase (8 weeks) are initiated and prescribed by physicians as a result of routine care process or patient contact based on their (deteriorated) health status. With the chosen endpoints, changes of patients empowerment, gait quality and system usability by using a monitoring device are monitored.
89029905|NCT00513669|Experimental|1 PEV301&302|The vaccine includes two antigens (CSP and AMA1- derived)in combination and formulated with virosomes
89580788|NCT02457065|Experimental|Receive Plaque|"Treatment~Melanoma Survivor plaque: After the patients enrolled in the study and completed the initial survey, the investigators gave the patients a small 3.5 by 2 inch wooden plaque that celebrates their survival of melanoma and reminds them to engage in skin cancer prevention behaviors."
89029906|NCT00513669|Active Comparator|2 Influenza vaccine|Inflexal V is the comparator that includes 3 antigens from flu formulated in virosomes
89029907|NCT04696679||Very preterm children group|
89029908|NCT04696679||Control group|
89029909|NCT04515719|Experimental|Belimumab 2mg/kg|Eligible patients were randomized in a 1:1 ratio to belimumab/placebo on the background of standard therapy. Belimumab 2mg/kg is administered intravenously at week 0, week 2, week 4 and then every 4 weeks until 48 weeks.
89029910|NCT04515719|Placebo Comparator|Placebo|Eligible patients were randomized in a 1:1 ratio to belimumab/placebo on the background of standard therapy. Placebo (normal saline) is administered intravenously at week 0, week 2, week 4 and then every 4 weeks until 48 weeks.
89029911|NCT00513786|Experimental|carboplatin/paclitaxel with bevacizumab|A regimen of Carboplatin and paclitaxel combined with bevacizumab given every 21 days in patients with advanced stage endometrial cancer for a maximum of 6 cycles.
89029912|NCT00504491|Experimental|1|"Four Rituximab - CHOP courses will be given The courses will be given every 21 days Drug Dose Day Rituximab (Mabthera) 500mg/m2 1(*) (**) Cyclophosphamide 750mg/m2 1 Adriamycin 50mg/m2 1 Vincristine 1,4 mg/m2 1 Prednisone 60mg/m2 1 to 5~(**) 1st course, 375 mg/m2 (*) If lymphocyte count is > 30 X 10 9/l, dose will be split up in two, which will be given in days 0 and 1"
89029913|NCT00513825|Active Comparator|1|1075 cc of 77 mEq/L solution of NaCl 0.45% , prepared by adding 75 cc of 77 mEq/L NaCl 0.45 % to 1000 cc of 77 mEq/L NaCl 0.45%
89029914|NCT00513825|Active Comparator|2|1075 cc fluid made by adding 75 cc of sodium bicarbonate solution 8.4% to 1000 cc of NaCl 0.45%.
89029915|NCT04518254|Experimental|Tyrosine - Test|4 similar visits (day 0, day 3, day 6, day 9): Administration of L-tyrosine No stress exposure
89029916|NCT04518254|Experimental|Tyrosine - Stress|4 similar visits (day 0, day 3, day 6, day 9): Administration of L-tyrosine Stress exposure
89580789|NCT02457065|No Intervention|Do Not Receive Plaque|"Control~No Melanoma Survivor plaque: After the patients enrolled in the study and completed the initial survey, the investigators did not give the patients a small 3.5 by 2 inch wooden plaque that celebrates their survival of melanoma and reminds them to engage in skin cancer prevention behaviors or any other intervention."
89029917|NCT04518254|Experimental|Placebo - Test|4 similar visits (day 0, day 3, day 6, day 9): Administration of Placebo No stress exposure
89029918|NCT04518254|Experimental|Placebo - Stress|4 similar visits (day 0, day 3, day 6, day 9): Administration of Placebo Stress exposure
89029919|NCT00513864|Active Comparator|CYP2D6-|This arm consists of subjects that are poor metabolizers (PM) and intermediate metabolizers (IM).
89580790|NCT02083653|Experimental|Arm A: Sym004 (12 mg/kg)|Sym004 will be administered as an intravenous infusion at a dose of 12 milligrams per kilogram (mg/kg) weekly until unacceptable toxicity, disease progression, or consent withdrawal.
89580791|NCT02083653|Experimental|Arm B: Sym004 (9/6 mg/kg)|Sym004 will be administered as an intravenous infusion at a loading dose of 9 mg/kg followed by 6 mg/kg weekly until unacceptable toxicity, disease progression, or consent withdrawal.
89580792|NCT02083653|Active Comparator|Arm C: Investigator's Choice|Best supportive care (BSC) or Fluorouracil (5-FU) or Capecitabine will be given as per Investigator's discretion.
89580793|NCT02436239|Experimental|Vilazodone|
89580794|NCT02026011|Experimental|Naltrexone|Naltrexone 50 mg/day
89029920|NCT00513864|Active Comparator|CYP2D6+|Extensive metabolizers (EM) of codeine
89029921|NCT01248884|Experimental|GSK217744 Group 1|Subjects aged between and including 60 and 90 days of age at the time of first vaccination received 3 doses of GSK217744 formulation A vaccine, co-administered with Prevenar 13® at 2, 3 and 4 months of age. The GSK217744 and Prevenar 13® vaccines were administered intramuscularly into the left and right sides of the thigh, respectively.
89029922|NCT01248884|Experimental|GSK217744 Group 2|Subjects aged between and including 60 and 90 days of age at the time of first vaccination received 3 doses of GSK217744 formulation B vaccine, co-administered with Prevenar 13® at 2, 3 and 4 months of age. The GSK217744 and Prevenar 13® vaccines were administered intramuscularly into the left and right sides of the thigh, respectively.
89029923|NCT01248884|Active Comparator|Infanrix hexa Group|Subjects aged between and including 60 and 90 days of age at the time of first vaccination received 3 doses of Infanrix hexa™ vaccine, co-administered with Prevenar 13® at 2, 3 and 4 months of age. The Infanrix hexa™ and Prevenar 13® vaccines were administered intramuscularly into the left and right sides of the thigh, respectively.
89029924|NCT00512850|Other|Folic acid|Folic acid supplement 1g/day
89029925|NCT00512850|Other|Placebo|Placebo pill once per day
89580795|NCT02026011|Placebo Comparator|Sugar pill|Matched placebo
89580796|NCT02436005|Experimental|Phenacite|Subjects will be randomized to wear the Phenacite contact lenses binocularly.
89580797|NCT02436005|Active Comparator|comfilcon A|Subjects will be randomized to wear the comfilcon A contact lenses binocularly.
89580798|NCT02456909|Experimental|Cues|The PCA pump will be programmed to provide a cue to the end of the lockout period.
89580799|NCT02456909|Placebo Comparator|No Cues|The PCA pump will be programmed such that no cues will be provided to the end of the lockout period (current standard of care).
89580800|NCT04199273|Experimental|Magnetic stimulation and electric stimulation|The patient receive first the magnetic stimulation with MagStim 200 tool. Then 15 min after he will receive the electric stimulation with the SonoStim tool : ultrasonography phrenic nerve tracking and targeted electric stimulation with a nerve stimulator usually used for neuromuscular transmission monitoring (TOFScan, Drager)
89580801|NCT04199273|Experimental|Electric stimulation and magnetic stimulation|The patient receive first electric stimulation with the SonoStim tool : ultrasonography phrenic nerve tracking and targeted electric stimulation with a nerve stimulator usually used for neuromuscular transmission monitoring (TOFScan, Drager). Then 15 min after he will receive the magnetic stimulation with MagStim 200 tool
89580802|NCT02025621|Experimental|Levosimendan|levosimendan 0.2 µg/kg/min for first hour, followed by 0.1 µg/kg/min for an additional 23 hours
89580803|NCT02025621|Placebo Comparator|Placebo|placebo 0.2 µg/kg/min for first hour, followed by 0.1 µg/kg/min for an additional 23 hours
89580804|NCT04729023|Experimental|Combined surgery group|In this group, all eligible patients will receive pars plana vitrectomy combined with phacoemulsification cataract surgery.
89580805|NCT04729023|Active Comparator|Subsequent surgery group|In this group, all eligible patients will receive pars plana vitrectomy first. And a subsequent phacoemulsification will be systematically performed 6 months after the PPV surgery.
89580806|NCT02020941|Experimental|Treatment (carfilzomib, dexamethasone)|"TREATMENT PHASE (COURSES 1-8): Patients receive carfilzomib IV over 30 minutes on days 1, 2, 8, 9, 15, and 16. Treatment repeats every 28 days for 8 courses in the absence of disease progression or unacceptable toxicity. Patients achieving less than PR also receive dexamethasone PO or IV weekly in courses 4-8.~MAINTENANCE PHASE (COURSES 9-14): Patients receive carfilzomib IV over 30 minutes on days 1, 2, 15, and 16. Patients who received dexamethasone in the Treatment Phase continue to receive dexamethasone PO or IV weekly. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity."
89580807|NCT02024529|Experimental|AMPION™ 4 mL dose|4 mL injection of Ampion
89580808|NCT02024529|Placebo Comparator|Placebo 4 mL dose|4 mL injection of placebo
89580809|NCT02020863|Experimental|Closed Loop|Study patients will receive a baseline crystalloid infusion of 3 cc/kg/hr and all additional fluid management will be performed via a closed loop (automated) system that will determine rate, amount, and timing of fluid administration.
89580810|NCT01824394|Experimental|nMARQ Catheter|nMARQ Catheter System
89580811|NCT01824394|Active Comparator|NaviStar ThermoCool Catheters|THERMOCOOL® Navigational family of catheters
88973975|NCT05771454||Prophylactic risk reducing mastectomy|"Patients who underwent genetic testing and came out positive for BRCA and other genes of breast cancer; afterwards opted for prophylactic risk-reducing mastectomy.~After mastectomy, the specimens will be assessed for the presence of occult breast cancers in removed specimens. Histopathology is set as gold standard for occult breast cancer confirmation."
88973976|NCT05771441|Active Comparator|neck stabilization exercise (NSE)|the patients who had NSE
88973977|NCT05771441|Active Comparator|NSE + HOT PACK THERAPY|the patients who had NSE+ hot pack
89580812|NCT01823536|Experimental|MenACWY-CRM (≥7-≤10 years of age)|Subjects, who had previously received 2 injections of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine at 2-5 years of age, were administered 1 injection of the same vaccine at 7-10 years of age.
89580813|NCT01823536|Experimental|MenACWY-CRM_1 (≥7-≤10 years of age)|Subjects, who had previously received 1 injection of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine at 2-5 years of age, were administered 1 injection of the same vaccine at 7-10 years of age.
89580814|NCT01823536|Experimental|Vaccine naive (≥7-≤10 years of age)|Vaccine naive subjects, age-matched to the ≥7-≤10 years of age groups, received 1 injection of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.
89580815|NCT01823536|Experimental|MenACWY-CRM_1 (≥11-≤15 years of age)|Subjects, who had previously received 1 injection of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine at 7-10 years of age, were administered 1 injection of the same vaccine at 11-15 years of age.
89580816|NCT01823536|Experimental|Vaccine naive (≥11-≤15 years of age)|Vaccine naive subjects, age-matched to the ≥11-≤15 years of age group, received 1 injection of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.
88973978|NCT05771441|Active Comparator|NSE + infrared therapy|the patients who had NSE+ infrared therapy
88973979|NCT05771441|Active Comparator|NSE + ultrasound therapy|the patients who had NSE+ ultrasound therapy
89580817|NCT01841554|Experimental|Single|
89580818|NCT01823224|Experimental|Group 1|"Group 1 will receive IV acetaminophen 1000mg plus 2 oral capsules sugar pills 1 hour prior to surgical incision and 4 hours after initial dose, for a total of two doses of acetaminophen totaling or equaling 2000mg"
89580819|NCT01823224|Experimental|Group 2|"Group 2 will receive an IV salt water infusion plus 2 capsules of oral acetaminophen 1 hour prior to surgical incision and 4 hours after initial dose, for a total of two doses totaling or equaling 2000mg."
89580820|NCT01840228|Active Comparator|Micronized progesterone suppository|Micronized progesterone suppository 200 mg vaginally daily until 36 6/7 weeks' gestation.
89580821|NCT01840228|Placebo Comparator|Placebo suppository|One placebo suppository vaginally daily until 36 6/7 weeks' gestation.
89580822|NCT01839916|Experimental|Treatment (DLI)|Patients receive DLI IV. Treatment repeats every 4-8 weeks for 5 doses in the absence of disease progression or unacceptable toxicity.
89580823|NCT01823146|Experimental|Oxytocin spray|single dose of 24 IU oxytocin, self-administered intranasally (IN)
88973980|NCT05771350|Experimental|online hemodiafiltration|
88973981|NCT05771350|Active Comparator|high flux hemodialysis|
88973982|NCT05771350|Active Comparator|low flux hemodialysis|
89580824|NCT01823146|Placebo Comparator|Placebo spray|single dose of 24 IU placebo (same solution as oxytocin spray but without oxytocin), self-administered intranasally (IN)
89580825|NCT02083185|Experimental|Relugolix 80 mg|Relugolix 320 mg (loading dose), tablets, orally, on Day 1 followed by relugolix 80 mg, tablets, orally, once daily for 48 weeks plus an optional 48 week extension at the investigator's discretion.
89580826|NCT02083185|Experimental|Relugolix 120 mg|Relugolix 320 mg (loading dose), tablets, orally, on Day 1 followed by relugolix 120 mg, tablets, orally, once daily for 48 weeks plus an optional 48 week extension at the investigator's discretion.
89580827|NCT02083185|Active Comparator|Leuprorelin 22.5 mg|Leuprorelin 22.5 mg, subcutaneous, injection on Day 1 and every 12 Weeks for up to 4 injections (48 weeks).
89580828|NCT02019927|Experimental|Non-arthritic ischemic optic neuropathy|Treatment of decreased vision due to NAION with the transcorneal electrical stimulation device (6+ months post-event).
88973983|NCT05771337||breast cancer leasion|
88973984|NCT05771337||benign breast lesion|
88973985|NCT05771324|Experimental|Baby-Led Weaning (BLW)|The group named for infants who received complementary feeding education with the BLW method and who were fed with the BLW method.
88973986|NCT05771324|Experimental|Traditional Complementary Feeding (TCF)|The group named for infants who received complementary nutrition education with the TCF method and who were fed with the TCF method.
88973987|NCT05771311|Active Comparator|Potassium Titanyle Phosphate (KTP) Laser|split-side, 1 - 5 sessions at intervals of 6 - 8 weeks
88973988|NCT05771311|Active Comparator|Pulsed Dye Laser|split-side, 1 - 5 sessions at intervals of 6 - 8 weeks
88973989|NCT05771298|Other|Potassium Titanyle Phosphate (KTP) Laser|Subjects will be treated with a KTP laser in 1 - 3 sessions at intervals of 4 - 6 weeks.
88973990|NCT05771298|Other|Pulsed Dye Laser|Subjects will be treated with a PDL in 1 - 3 sessions at intervals of 4 - 6 weeks.
88973991|NCT05771285|Active Comparator|Group with two-minute pre-injection application of cold|Before applying the subcutaneous injection, cold application pack was applied on the injection site for two minutes. Then, the low molecular weight heparin injection was applied to this cold-applied area in accordance with the subcutaneous heparin injection protocol. VAS assessment was made after the injection and bruise and haematoma assessments were conducted after 48 and 72 hours.
88973992|NCT05771285|Active Comparator|Group with five-minute pre-injection application of cold|Before applying the subcutaneous injection, cold application pack was applied on the injection site for five minutes. Then, the low molecular weight heparin injection was applied to this cold-applied area in accordance with the subcutaneous heparin injection protocol. VAS assessment was made after the injection and bruise and haematoma assessments were conducted after 48 and 72 hours.
88973993|NCT05771285|No Intervention|Control group|Without applying any tools or processes, the low molecular weight heparin injection was applied in accordance with the subcutaneous heparin injection protocol. VAS assessment was made after the injection and bruise and haematoma assessments were conducted after 48 and 72 hours.
88973994|NCT05771272|Other|Elite Rowers|They are young men rowers aged between 16-18 years, rowing age of at least 2 years, and continuing to row sport actively.
88973995|NCT05771259||Group A|Participants who didn't undergo body contouring surgery after bariatric surgery.
88973996|NCT05771259||Group B|Participants who underwent body contouring surgery after bariatric surgery.
89580829|NCT02019927|Experimental|Multiple Sclerosis|Treatment of decreased vision due to multiple sclerosis with the transcorneal electrical stimulation device (3+ months post visual changes).
89580830|NCT02019927|Experimental|Ocular Trauma|Treatment of decreased vision due to ocular trauma with the transcorneal electrical stimulation device (3+ months post-trauma).
89580831|NCT02019927|Sham Comparator|Sham - Non-arthritic ischemic optic neuropathy|Sham treatment of decreased vision due to NAION with the transcorneal electrical stimulation device (6+ months post-event).
89580832|NCT02019927|Sham Comparator|Sham - Multiple Sclerosis|Sham treatment of decreased vision due to multiple sclerosis with the transcorneal electrical stimulation device (3+ months post visual changes).
89580833|NCT02019927|Sham Comparator|Sham - Ocular Trauma|Sham treatment of decreased vision due to ocular trauma with the transcorneal electrical stimulation device (3+ months post-trauma).
89580834|NCT04185441|Experimental|TANZÂNIA|"The study is double-dummy. The patient must take 2 pills, as follow:~1 capsule Tanzânia association, oral, once a day, and~1 tablet tamsulosin placebo, oral, once a day."
89580835|NCT04185441|Active Comparator|Omnic Ocas|"The study is double-dummy. The patient must take 2 pills, as follow:~1 tablet Omnic Ocas, oral, once a day, and~1 capsule Tanzânia association placebo, oral, once a day."
88973997|NCT05771233|Experimental|Prevention|The group will consist of 20 participants (6 classical dancers, 4 Spanish dancers, 5 flamenco dancers and 5 contemporary dancers) who will be divided into groups according to their specialties, with a one-hour session per week for 7 weeks of physical exercise to strengthen core muscles and lumbo-pelvic stability.
89029926|NCT04695522|Experimental|Group of subjects undergoing cell transplantation|
89029927|NCT04695522|Sham Comparator|Group of subjects undergoing sham operation|
89029928|NCT00512889|Experimental|Cohort 1|Different dose of CTL
89580836|NCT04416945|Experimental|RACD|Reactive case detection led by VMWs in response to cases in study area HCCA, with follow up testing with HS-RDTs/RDTs in both villages and forest workers; referrals for qualitative G6PD testing for P. vivax cases and 14-day PQ for G6PD non-deficient
89580837|NCT04416945|Active Comparator|Control|Standard of care including case management through health facilities and malaria posts/VMWs; village-based RACD conducted by district staff in some areas
89580838|NCT02412371|Experimental|Phase 1: Veliparib + Carboplatin + Paclitaxel + Radiotherapy|"Participants in Phase 1 will be sequentially assigned to ascending dose levels of 60 mg, 80 mg, 120 mg, 200 mg, and 240 mg of twice daily (BID) veliparib in combination with carboplatin at an area under the concentration-time curve (AUC) 2 mg/mL/min and paclitaxel 45 mg/m² once a week plus thoracic radiotherapy for 7 weeks.~After completion of concurrent chemoradiotherapy participants will receive up to 2 cycles of consolidation therapy consisting of veliparib 120 mg or 240 mg BID, carboplatin AUC 6 mg/mL/min and paclitaxel 200 mg/m² administered on Day 1 of each 21-day cycle."
89580839|NCT02412371|Experimental|Phase 2: Veliparib + CRT -> Paclitaxel/Carboplatin/Veliparib|"Participants will receive veliparib at the recommended phase 2 dose determined in Phase 1 in combination with carboplatin at an AUC 2 mg/mL/min and paclitaxel 45 mg/m² once a week plus thoracic radiotherapy for 7 weeks.~After completion of concurrent chemoradiotherapy participants will receive up to 2 cycles of consolidation therapy consisting of veliparib 120 mg or 240 mg BID, carboplatin AUC 6 mg/mL/min and paclitaxel 200 mg/m² administered on Day 1 of each 21-day cycle."
89580840|NCT02412371|Experimental|Phase 2: Veliparib + CRT -> Paclitaxel/Carboplatin/Placebo|"Participants will receive veliparib at the recommended phase 2 dose determined in Phase 1 in combination with carboplatin at an AUC 2 mg/mL/min and paclitaxel 45 mg/m² once a week plus thoracic radiotherapy for 7 weeks.~After completion of concurrent chemoradiotherapy participants will receive up to 2 cycles of consolidation therapy consisting of placebo to veliparib BID, carboplatin AUC 6 mg/mL/min and paclitaxel 200 mg/m² administered on Day 1 of each 21-day cycle."
89580841|NCT02412371|Active Comparator|Phase 2: Placebo + CRT -> Paclitaxel/Carboplatin/Placebo|"Participants will receive placebo to veliparib with carboplatin at an AUC 2 mg/mL/min and paclitaxel 45 mg/m² once a week plus thoracic radiotherapy for 7 weeks.~After completion of concurrent chemoradiotherapy participants will receive up to 2 cycles of consolidation therapy consisting of placebo to veliparib BID, carboplatin AUC 6 mg/mL/min and paclitaxel 200 mg/m² administered on Day 1 of each 21-day cycle."
89580842|NCT02411747|Experimental|Testing+endoscopic simulation training|Endoscopic training in flexible cystoscopy by directed self-regulated training with knowledge of a test afterwards, max. time cap 1h45min. 15 minutes of testing with a expert in the procedure. Total max time: 2 hours.
89580843|NCT02411747|Active Comparator|Oral lecture+endoscopic simulation training|Endoscopic training in flexible cystoscopy by directed self-regulated training, max. time cap 1h45min after a 15 minute oral theoretical lecture by a expert in the procedure. Total max. time: 2 hours.
88973998|NCT05771233|No Intervention|Control|The experimental group will consist of 20 participants (4 classical dancers, 6 Spanish dancers, 5 flamenco dancers and 5 contemporary dancers) who will not receive any strength training. They will be evaluated at the beginning and at the end of the study to compare the physical conditions of the participants of this group with those of the experimental group.
88973999|NCT05771220|Experimental|ESWT+ traditional physical therapy treatment|ESWT+ traditional physical therapy treatment
88974000|NCT05771220|Placebo Comparator|Placebo shockwave + traditional physical therapy treatment|Placebo shockwave + traditional physical therapy treatment
88974001|NCT05771207|Experimental|soy protein intervention|This group received dietary guidance and soy protein intervention for 3 months
88974002|NCT05771207|Experimental|whey protein intervention|This group received dietary guidance and whey protein intervention for 3 months
88974003|NCT05771207|Placebo Comparator|control|This group received dietary guidance and ｍltodextrin for 3 months
88974004|NCT05771194|Experimental|group A|Group A received conventional preoperative and postoperative anti-infective therapy.
88974005|NCT05771194|Active Comparator|group B|On the basis of group A,Group B was given 0.1% sodium hyaluronate eye drops 4 times daily for 3 days before surgery (Jiang Xi, Zhen Shiming Pharmaceutical Co., Ltd.) and 3 months after surgery, and one cleaning, hot compresses and massage of the meibomian gland.
88974006|NCT05771181|Experimental|Vitamin E in combination with Fuquinitinib and Tislelizumab|Patients will be treated with Vitamin E, Fuquinitinib and Tislelizumab.
88974007|NCT05771168||AUS|Male patients undergoing surgery for stress urinary incontinence using artificial urinary sphincter (AUS)
88974008|NCT05771168||Sling|Male patients undergoing surgery for stress urinary incontinence using slings
88974009|NCT05771155|Experimental|PB016 (300 mg IV)|PB016 will be administered to patients with moderately to severely active UC on Weeks 0, 2 and 6, and once every 8 weeks thereafter, per the approved dosing regimen of Entyvio®
88974010|NCT05771155|Active Comparator|Entyvio® (300 mg IV)|Entyvio® will be administered to patients with moderately to severely active UC on Weeks 0, 2 and 6, and once every 8 weeks thereafter, per the approved dosing regimen of Entyvio®
88974011|NCT05771142||Smart t-shirt, ECG Holter and smartwatch patients|24h ECG Monitoring - All participants will wear the smart t-shirt, the ECG Holter and the smartwatch at the same time
88974012|NCT05771129|Experimental|Pulsed Electric Field Ablation System was used in treating chronic bronchitis|All participants meet inclusion and exclusion criteria and signed the ICF will be enrolled to experimental arm.
88974013|NCT05771077|Experimental|patients have White spot lesions|White spot lesions (WSLs) are defined as enamel surface and subsurface demineralization, without cavitation. These manifestations represent the first clinical observation of the progression of dental caries, with the possibility of being reversed
88974014|NCT05771051||Concussed|Diagnosis of concussion
88974015|NCT05771051||Controls|Athletes with no concussion with the preceding year
89029929|NCT00512889|Experimental|Cohort 2|Different dose of CTL
89029930|NCT00512889|Experimental|Cohort 3|Combination of CTL with GMCSF +/- radiation
88974016|NCT05771038|Active Comparator|sodium alendronate group|prepared sodium alendronate gel will be placed in defective extraction sockets.
89029931|NCT01248728|Active Comparator|Omega-3 Fatty Acids|Children will be administered 3.75ml of the liquid formulation of Nutra Sea high-EPA (HP) (containing 1.5 gr of EPA+DHA). The starting dose will be 1.875ml (0.75 gr of EPA+DHA) and the dose will be doubled on week 2.
89580844|NCT01822756|Experimental|Regimen A -ruxolitinib, gemcitabine|Ruxolitinib (RUX) was self-administered by the subject orally in the morning and evening, approximately 12 hours apart, without regard to food. The morning dose of RUX was to be taken before the chemotherapy infusion, Gemcitabine IV, on days when they were given together (Days 1, 8, and 15 of each cycle).
89029932|NCT01248728|Placebo Comparator|Placebo|Children will be administered 3.75ml of the liquid formulation of Placebo. The starting dose will be 1.875ml and the dose will be doubled on week 2.
89029933|NCT04695405||Treatment-Resistant Depression|Patients, who previously received intravenous ketamine, will be asked to provide genetic samples in order to assess relationships between response and genetic markers.
89029934|NCT02951442|Experimental|Renal Transplant|
89029935|NCT00505154|Placebo Comparator|2|Placebo tablets
89029936|NCT00505154|Active Comparator|1|rosuvastatin
89029937|NCT00513903|Active Comparator|Minimal intervention|Minimal intervention group patients will be seen by a clinical pharmacist in the hospital but will not receive followup after hospital discharge.
89029938|NCT00513903|Experimental|Enhanced intervention|Enhanced intervention patients will receive care from a clinical pharmacist during hospitalization and followup by phone after hospitalization.
89029939|NCT00513903|No Intervention|Control|Control arm patients will not be seen by the clinical pharmacist.
89029940|NCT00513942|No Intervention|A|These women will follow standard antenatal care according to the Norwegian Guidelines
89580845|NCT01822756|Experimental|Regimen B-ruxolitinib, gemcitabine, nab-paclitaxel, filgrastim|"Ruxolitinib (RUX) was self-administered by the subject orally in the morning and evening, approximately 12 hours apart, without regard to food.~Gemcitabine was provided as open-label, commercial product and was administered intravenously (IV) over 30 minutes on Days 1, 8, and 15 of each 28-day cycle. Reduced doses of gemcitabine administered IV over 30 minutes on Days 1, 8, and 15 of each 28-day cycle could also be explored.~nab-Paclitaxel, as open-label, commercial product, was administered IV over 30 minutes on Days 1, 8, and 15 of each 28-day cycle."
89029941|NCT00513942|Active Comparator|B|Intervention group for Fetal Movement Counting
89029942|NCT01246973|Experimental|curcumin|4 Curcumin C3 Complex 500mg capsules (2.0 g) taken orally 3 times/day throughout course of radiation treatments plus one week
89029943|NCT01246973|Placebo Comparator|Placebo|4 placebo capsules taken orally 3 times/day throughout course of radiation treatments plus one week
89029944|NCT01246466|Experimental|AtriCure Bipolar System combined with a catheter ablation|procedure using the AtriCure Bipolar System plus a catheter ablation
89029945|NCT00505232|Experimental|Rituximab-HCVAD,Methotrexate/Cytarabine and Zevalin|Induction Treatment (Rituximab-HCVAD and Methotrexate/Cytarabine) followed by Consolidation Treatment (Rituximab and Y-90 Ibritumomab tiuxetan)
89029946|NCT00514644|Experimental|Panorama to Ultrasound|100 asymptotic patients that have findings of calcifications in the area of the carotid arteries when examined with panorama. These persons are examined with carotid ultrasound.
89029947|NCT00514644|Experimental|Ultrasound to Panorama|100 patients with a known carotid stenosis seen on ultrasound will be examined with panorama before any intervention is made. These patients must undergo surgery to be finally included.
89029948|NCT01245764|Experimental|GARDASIL™ 9 to 12 Years Old|GARDASIL™ 0.5 mL injection at the Day 1, Month 2, and Month 6 visits in study Phase A. Participants will not continue to study Phase B.
89029949|NCT01245764|Experimental|GARDASIL™ 13 to 15 Years Old|GARDASIL™ 0.5 mL injection at the Day 1, Month 2, and Month 6 visits in study Phase A. Participants will not continue to study Phase B.
89029950|NCT01245764|Experimental|GARDASIL™ 16 to 26 Years Old|GARDASIL™ 0.5 mL injection at the Day 1, Month 2, and Month 6 visits in study Phase A. Participants will not continue to study Phase B.
89029951|NCT01245764|Placebo Comparator|Placebo 9 to 12 Years Old|Placebo to GARDASIL™ 0.5 mL injection at the Day 1, Month 2, and Month 6 visits in study Phase A. After database lock and unblinding for study Phase A, participants will have the option to receive GARDASIL™ 0.5 mL injection at the Day 1, Month 2, and Month 6 visits in study Phase B.
89580846|NCT01822678|Experimental|Group 1|Group 1: Eslicarbazepine Acetate, starting with 800 mg per day and up-titrated in 800 mg steps until 2400 mg (maximum dose) according to clinical response.
89580847|NCT01822678|Experimental|Group 2|Group 2: Eslicarbazepine Acetate, starting with 600 mg per day and up-titrated in 600 mg steps until 1800 mg (maximum dose) according to clinical response.
89580848|NCT01822678|Placebo Comparator|Group 3|Group 3: Placebo (change in daily number of tablets administered, according to clinical response).
89029952|NCT00514059|Other|1|
89029953|NCT00514761|Active Comparator|1|Xeloda
89029954|NCT00514761|Experimental|2|AZD6244
89029955|NCT04514315||Minimally invasive aortic valve surgery|Patients undergoing minimally invasive aortic valve surgery
89029956|NCT04514315||Minimally invasive mitral valve surgery|Patients undergoing minimally invasive mitral valve surgery
89029957|NCT04514315||Conventional aortic valve surgery|Patients undergoing conventional aortic valve surgery
89029958|NCT03459261||POM|post-traumatic osteomyelitis group (POM), the participants who developed post-traumatic osteomyelitis after primary surgical treatment and were taken blood sample on admission (ADD), first postoperative day (POD1) and fourth postoperative day (POD4). Patients were included in POM group after additional assessment of meeting the CDC/NHSN surveillance definition criteria for osteomyelitis: positive intraoperative withdrawal bone and soft tissue sample, types of cultured bacteria, histopathologic proof of osteomyelitis and clinical signs of surgical site infection.
89029959|NCT03459261||NO POM|No POM group, the participants who did not develop postraumatic osteomyelitis to tibia after primary surgical treatment and were taken blood sample on admission (ADD), first postoperative day (POD1) and fourth postoperative day (POD4) in follow up interval of 6 months /control group/. Patients were included in No POM group after assessment of not meeting the CDC/NHSN surveillance definition criteria for osteomyelitis.
89029960|NCT01245140|Active Comparator|Active|to receive study drug (alitretinoin, 20 patients)
89029961|NCT01245140|Placebo Comparator|Placebo|to receive placebo (dummy drug, 10 patients)
89580849|NCT01822366|No Intervention|Usual Care Comparison Condition|Half of the participating children/guardian dyads will receive no intervention (usual care) to serve as a control.
88811213|NCT03750838|No Intervention|Assessment Only Control|Participants in the assessment only control will not receive any text messages, but will complete all survey assessments on the same schedule as the Text Message Intervention Group.
88811214|NCT03742349|Experimental|1: spartalizumab + LAG525 + NIR178|phase Ib (escalation and expansion)
88811215|NCT03742349|Experimental|2: spartalizumab +LAG525 +capmatinib|phase Ib (escalation and expansion)
88811216|NCT03742349|Experimental|3: spartalizumab + LAG525 + MCS110|phase Ib (escalation and expansion)
88811217|NCT03742349|Experimental|4: spartalizumab +LAG525 +canakinumab|phase Ib (escalation and expansion)
88811218|NCT03734705|Experimental|Imaginal Exposure Writing|People with hoarding disorder will write for 20 minutes on each of 3 consecutive days about their worst-case scenario regarding discarding a possession (i.e., imaginal exposure).
88811219|NCT03734705|Sham Comparator|Neutral Writing|People with hoarding disorder will write for 20 minutes on each of 3 consecutive days about what they would do if they had a day off work or school.
88811220|NCT03733314|Experimental|E6011|
88811221|NCT03733314|Placebo Comparator|Placebo|
88811222|NCT03728985|Active Comparator|Primary Study Arm|TAAA requiring only TAMBE System. Crawford Type IV TAAA and Pararenal (n= 102)
88811223|NCT03728985|Experimental|Secondary Study Arm|TAAA requiring TAMBE System and CTAG Device(s). Crawford Type I-III (n= 20 - 100)
88811224|NCT03703492|Experimental|Research Arm|Directed breast PET/MRI with 18F-FES; 18F-FES uptake of the known malignancy to be measured on the PET/MRI examination
88811225|NCT03680872|Experimental|Spinal Cord Injury Participants|This group consists of individuals with tetraplegia receiving an investigational device called the Bidirectional Neural Bypass System.
88811226|NCT03651076|Experimental|Traxi panniculus retraction group|The method of panniculus retraction will be the Traxi panniculus retraction (Clinical Innovations, LLC) by the provider.
88811227|NCT03651076|No Intervention|Standard of care|Standard methods of panniculus retraction as determined by individual provider (including medical taping, extra personnel for retraction)
88811228|NCT03604198|Experimental|relacorilant (CORT125134)|
88811229|NCT03600103|No Intervention|Control|Participants will receive standard of care.
88811230|NCT03600103|Experimental|Intervention|TECH2CHECK involves field visits by a CHN trained in disease intervention protocols, including clinical assessment, case management, counseling, and a behavioral intervention coupled with text messaging support for medication and self-care reminders.
88811231|NCT03578419|Active Comparator|Control Period|Standard-Volume Blood Collection Tubes
88811232|NCT03578419|Experimental|Intervention Period|"Small-Volume Blood Collection Tubes (soft-draw)"
88811233|NCT03568656|Experimental|CCS1477 dose escalation - mCRPC|CCS1477 monotherapy in patients with mCRPC
88811234|NCT03568656|Experimental|CCS1477 expansion phase - mCRPC|CCS1477 monotherapy in patients with mCRPC
88811235|NCT03568656|Experimental|CCS1477 and abiraterone acetate, combination dose finding and expansion - mCRPC|CCS1477 plus abiraterone acetate in patients with mCRPC
88811236|NCT03568656|Experimental|CCS1477 and enzalutamide, combination dose finding and expansion - mCRPC|CCS1477 plus enzalutamide in patients with mCRPC
88811237|NCT03568656|Experimental|CCS1477 Monotherapy - Solid tumours|CCS1477 expansion phase in patients with advanced solid tumours with molecular markers which may indicate potential for response to p300/CBP inhibition
88811238|NCT03568656|Experimental|CCS1477 and darolutamide, combination dose finding and expansion - mCRPC|CCS1477 plus darolutamide in patients with mCRPC
88811239|NCT03568656|Experimental|CCS1477 and olaparib, combination dose finding and expansion - mCRPC and metastatic breast cancer|CCS1477 plus olaparib in patients with mCRPC or metastatic breast cancer.
88811240|NCT03568656|Experimental|CCS1477 and atezolizumab, combination dose finding and expansion - non-small cell lung cancer|CCS1477 plus atezolizumab in patients with non-small cell lung cancer
88811241|NCT03554798|Experimental|nOPV2 Candidate 1 (monovalent oral poliovirus type1)|"Cohort A: IPV and/or OPV vaccinated participants aged 1 to 5 years vaccinated with candidate 1.~Cohort B: 6 weeks Infants vaccinated with 3 doses of bOPV and 1 dose of IPV, followed with 1 dose of candidate 1."
88811242|NCT03554798|Experimental|nOPV2 Candidate 2 (monovalent oral poliovirus type2)|"Cohort A: IPV and/or OPV vaccinated participants aged 1 to 5 years vaccinated with candidate 2.~Cohort B: Infants vaccinated with 3 doses of bOPV and 1 dose of IPV, followed with 1 dose of candidate 2."
88811243|NCT03549507|Experimental|Contrast-enhanced Ultrasonography|Intravenous administration of contrast agent Sulfur hexafluoride lipid-type A microspheres before performing contrast-enhanced ultrasound (CEUS). In pediatric patients, after reconstitution 0.03 mL per kg is administered intravenously. The weight-based dose of 0.03 mL per kg will be repeated one time during a single examination. Following each injection, an intravenous flush of 0.9% Sodium Chloride is injected. The study duration per subject will be approximately 15 minutes including the time to prepare the contrast agent and perform the CEUS, as well as the 60 minute monitoring period after the first and second injection (if there are two injections of contrast) of the contrast agent.
88811244|NCT03539536|Experimental|Telisotuzumab vedotin|Telisotuzumab vedotin administered via intravenous (IV) infusion every 14 days.
88811245|NCT03517852|Experimental|Arm 1|Determine the feasibility and clinical utility of performing Human Intravital Microscopy (HIVM) in patients with peritoneal carcinomatosis during standard course of treatment (cytoreductive surgery with hyperthermic intraperitoneal chemotherapy, or CRS-HIPEC).
88811246|NCT03516942||Observational (questionnaire)|Patients complete questionnaires over 20-60 minutes at baseline and at 3, 6, 12, and 24 months after cancer diagnosis.
88811247|NCT03496571|Placebo Comparator|Placebo|Subjects in this arm will receive 4 monthly doses of placebo.
88811248|NCT03496571|Experimental|1 mg/kg of AK002|Subjects in this arm will receive 4 monthly doses of AK002: a first dose of 0.3 mg/kg, a second dose of 1 mg/kg, a third dose of 1 mg/kg, and a fourth dose of 1 mg/kg
89580850|NCT01822366|Experimental|Trauma-focused CBT group therapy|Half of the participating children/guardian dyads will receive the 12-week Trauma-focused Cognitive Behavioral Therapy (TF-CBT) group treatment.
89580851|NCT01838590|Experimental|SOF+RBV 12 Weeks|Participants will receive SOF+RBV for 12 weeks.
89580852|NCT01838590|Experimental|SOF+RBV 24 Weeks|Participants will receive SOF+RBV for 24 weeks.
89580853|NCT01611454|Experimental|XPF thyroid collar|Administration of the XPF Thyroid Collar during the same type of interventional radiology procedures as Comparator arm above
89580854|NCT01611454|Active Comparator|Equivalent collar|Administration of the Standard 0.5mm lead-equivalent thyroid collar during the same type of interventional radiology procedures as Comparator arm above.
89580855|NCT01611298|Experimental|Single arm: Tetanus Toxoid|SCT Donors will receive one dose of tetanus toxoid 0.5mL intramuscularly into deltoid or medial lateral thigh 7-10 days prior to bone marrow or peripheral blood stem cell harvest
89580856|NCT01822132|Experimental|Extended release naltrexone|One dose of intramuscular injection of 380mg extended-release naltrexone.
89580857|NCT01822132|Placebo Comparator|Placebo|One dose of intramuscular injection of placebo.
89580858|NCT04593004|Experimental|Teledermatology|
89580859|NCT04593004|Active Comparator|Face-to-face consultation|
89580860|NCT01821898|Active Comparator|Positive for food allergy: Group A|Oral Budesonide
89580861|NCT01821898|Active Comparator|Positive for food allergy: Group B|Elimination diet
89580862|NCT02411591|Experimental|Necitumumab + Abemaciclib|"Cohort 1 Part A: Necitumumab 800 mg administered intravenously (IV) on Days 1 and 8, followed by abemaciclib 100 mg given orally every 12 hours on Days 1 to 21. (21 day cycles.) Treatment may continue until discontinuation criterion is met.~Cohort 2 Part A: Necitumumab 800 mg administered IV on Days 1 and 8, followed by abemaciclib 150 mg given orally every 12 hours on Days 1 to 21. Treatment may continue until discontinuation criterion is met.~Cohort 3 Part A: Necitumumab 800 mg administered IV on Days 1 and 8, followed by abemaciclib 200 mg given orally every 12 hours on Days 1 to 21. Treatment may continue until discontinuation criterion is met.~Part B (expansion cohort): Necitumumab 800 mg administered IV on Days 1 and 8, followed by abemaciclib 150 mg given orally every 12 hours on Days 1 to 21. Treatment may continue until discontinuation criterion is met."
89580863|NCT02454959|Experimental|GFF MDI (PT003) with Aerochamber|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI) with Aerochamber Plus Valved Holding Chamber
89580864|NCT02454959|Experimental|GFF MDI (PT003) without Aerochamber|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI) without Aerochamber Plus Valved Holding Chamber
89580865|NCT01821118|Experimental|1|
89580866|NCT01821118|Placebo Comparator|2|
89580867|NCT01650779|Experimental|Agalsidase beta|
89580868|NCT02411201|Experimental|DOTAREM|
89580869|NCT01838044|Experimental|Arm A|The group of patients who are randomized to receive concomitant treatment of pregabalin and celecoxib during the first study period.
89580870|NCT01838044|Other|Arm B|The group of patients who are randomized to receive celecoxib monotherapy during the first study period.
89580871|NCT02410811||Age Stratum A|"Age 6 to 13.99 years~Cardiac magnetic resonance imaging (CMR)"
89580872|NCT02410811||Age Stratum B|"Age 14 to 20.99 years~Detectible and quantifiable TRJV with reported value~Cardiac magnetic resonance imaging (CMR)"
89580873|NCT02410811||Age Stratum C|"Age ≥21 years~Detectible and quantifiable TRJV with reported value~Cardiac magnetic resonance imaging (CMR)"
89580874|NCT02410811||Age Stratum D|"Age ≥6 years.~Current use of disease-modifying therapy [hydroxyurea, chronic transfusions, or both (given concurrently, sequentially, or both)] that was initiated at <3 years of age, and for which there has been no interruption of therapy for >6 consecutive months since the initiation of disease-modifying therapy.~Cardiac magnetic resonance imaging (CMR)"
89580875|NCT02435381|Placebo Comparator|Placebo|Participants will receive placebo from days 2- 4.
89580876|NCT02435381|Active Comparator|Carisbamate|Participants will receive carisbamate 600mg qd from days 2- 4.
89580877|NCT01837966|Active Comparator|Lavender oil|Lavender oil aromatherapy
89580878|NCT01837966|Placebo Comparator|Placebo|Placebo -- unscented oil aromatherapy
89580879|NCT02435069|No Intervention|Pre-operative Baseline Phase|Baseline data including frequency and severity of fecal soiling and frequency and severity of abdominal pain were collected for a minimum of 2 weeks prior to surgical construction of the ACE stoma. Baseline stool calprotectin and serum electrolytes were collected in the baseline phase prior to initiation of the preoperative bowel prep. Pre-operative data served as the control.
89580880|NCT02435069|Experimental|Dose Response - NS and USP Glycerin - First Intervention|Initial flush used NS or USP Glycerin randomized to treatment sequence. The starting volume and administration frequency for NS was 10mL/kg and glycerin 20 mL administered every other day. The NS dose was titrated in 10 mL increments to achieve continence so as not to exceed 500 mL daily for a child under five years of age and 1000 mL daily for a child over 5 years of age. USP Glycerin was titrated in 5 mL increments so as not to exceed 50 mL daily. For side effects greater than Wong Bailey Faces Pain Rating Scale (WBFPRS) level 4, NS was decreased by 2.5 mL/kg to the lowest dose of 5 mL/kg daily. USP Glycerin was decreased in 5 mL increments to the lowest dose of 5 mL daily. If the maximum dose did not result in continence, if the dose necessary to minimize side effects resulted in fecal soiling, or if there were side effects greater than WBFPRS level 4 at the lowest dose of administration, the child was be trialed on the alternate therapy and then dropped from the study.
89580881|NCT02435069|Experimental|NS and USP Glycerin - Effectiveness - Second Intervention|To prevent statistical bias from subject loss due to treatment failure, each child was randomized to a second treatment sequence once they achieved continence on optimal dosing with minimal side effects.This arm evaluated the long term effectiveness of NS and glycerin at optimal dose and administration frequency for 4 weeks and served as comparison between flush solutions. The study concluded with the child being placed back on 2 weeks of the initial flush in the randomized sequence.
89580882|NCT04917731|Experimental|Botox|The patients in this arm will receive Botox injection to the digital arteries of all affected digits.
89580883|NCT04917731|Placebo Comparator|Placebo|The patients in this arm will receive placebo injection of saline to the digital arteries of all affected digits.
89580884|NCT02454101|Other|cord milking|milking of the umbilical cord 5 times toward the neonate
89580885|NCT02454101|Other|delayed cord clamping|delayed cord clamping for 120 seconds
89580886|NCT02409719|Active Comparator|Control - Verbal information and Booklet|Verbal information will be provided in order to explain how the patient should perform physical rehabilitation exercises. Furthermore, an illustrative booklet with representative exercises will be given.
89580887|NCT02409719|Experimental|Study - Verbal information, Booklet & Schedule.|Verbal information will be provided in order to explain how the patient should perform physical rehabilitation exercises. Furthermore, an illustrative booklet with representative exercises will be given. Also, an illustrative daily schedule to mark on the exact day in which the exercise was performed
89580888|NCT01820572|Experimental|Belatacept|Belatacept 5 mg/kg intravenous 30 minute infusion on Days 1, 15, 29, 43, 57 then every 28 days for 24 months
89580889|NCT01820572|Active Comparator|CNI|"Tacrolimus 4-11 ng/mL tablet orally according to package insert for 24 months~Cyclosporine 50-250 ng/mL tablet orally according to package insert for 24 months"
89580890|NCT01820260|Experimental|Part 1A: Ingenol mebutate gel 0.005%|Open-label, dose escalation, 3 days treatment
89580891|NCT01820260|Active Comparator|Part 2: Ingenol mebutate gel 0.018% for 3 days treatment|Randomized, 3 days treatment
89580892|NCT01820260|Active Comparator|Part 2: Ingenol mebutate gel 0.018% for 2 days treatment|Randomized 2 days treatment
89580893|NCT01820260|Active Comparator|Part 2: Ingenol mebutate gel 0.027% for 3 days treatment|Randomized 3 days treatment
89580894|NCT01820260|Active Comparator|Part 2: Ingenol mebutate gel 0.027% for 2 days treatment|Randomized 2 days treatment
89580895|NCT01820260|Placebo Comparator|Part 2: Placebo for 3 days treatment|Randomized 3 days treatment
89580896|NCT01820260|Placebo Comparator|Part 2: Placebo for 2 days treatment|Randomized 2 days treatment
89580897|NCT01820260|Experimental|Part 1A: Ingenol mebutate gel 0.008%|Open-label, dose escalation, 3 days treatment
89580898|NCT01820260|Experimental|Part 1A: Ingenol mebutate gel 0.012%|Open-label, dose escalation, 3 days treatment
89580899|NCT01820260|Experimental|Part 1A: Ingenol mebutate gel 0.027%|Open-label, dose escalation, 3 days treatment
89580900|NCT01820260|Experimental|Part 1A: Ingenol mebutate gel 0.04%|Open-label, dose escalation, 3 days treatment
89580901|NCT01820260|Experimental|Part 1B: Ingenol mebutate gel 0.06%|Open-label, dose escalation, 2 days treatment
89580902|NCT01820260|Experimental|Part 1A: Ingenol mebutate gel 0.018%|Open-label, dose escalation, 3 days treatment
89580903|NCT01820260|Experimental|Part 1B: Ingenol mebutate gel 0.04%|Open-label, dose escalation, 2 days treatment
88974017|NCT05771038|Active Comparator|stickybone group|20cc of venous blood is collected from the patient's forearm into silica-coated tube (10 ml) and 1 non coated vacutainer. Blood will be used to make injectable prf by spinning in centrifuge(2400-2700) for 2 minutes to produce autologous fibrin glue and then for 12 minutes+/- 2 minutes to obtain the concentrated growth factor layer. and sticky bone will be prepared then inserted into the socket.
88974018|NCT05771012|Experimental|group A|patients receive only medical treatment in the form of topical 0.05% cyclosporin (Restasis®, Allergan Inc) twice daily for 6 months.
88974019|NCT05771012|Active Comparator|group B|patients receive mini-Monoka stent insertion in the lower canaliculus for 6 months.
88974020|NCT05770999|Experimental|Lavender massage|A mixture of 20 cc of sweet almond oil and 1 cc of lavender oil will be used. Sweet almond oil has been used to dilute lavender oil. lavender massage lasted about 10 minutes.
88974021|NCT05770999|Experimental|Lavender bath|A mixture of 20 cc bath water and 1 cc lavender oil will be used. lavender bath lasted about 10 minutes.
88974022|NCT05770999|No Intervention|Control group|The newborns in the control group did not receive any treatment other than their clinical routines (vital signs monitoring, skin care with sunflower oil, eye and mouth care, changing diapers, changing bed linen, feeding and clinical treatments).
88974023|NCT05770986|Experimental|Group A ( power's group)|Patients will receive the eight phases of the power's program plus a conventional treatment of flexibility exercises, hot pack, transcutaneous electrical stimulation (TENS), prone resisted hip extension for 12 sessions (3 sessions per week for 4 weeks).
88974024|NCT05770986|Active Comparator|Group B ( control)|Patients will receive a conventional treatment of flexibility exercises, hot pack, transcutaneous electrical stimulation (TENS), prone resisted hip extension for 12 sessions (3 sessions per week for 4 weeks).
88974025|NCT05770973|Active Comparator|Compression dressing|Randomized, eyes were patched with a compression dressing after surgery.
88974026|NCT05770973|No Intervention|No Compression dressing|Randomized, eyes were not patched with a dressing.
89580904|NCT01610596|Experimental|Halobetasol Propionate Lotion 0.05%|Topical lotion, applied twice daily
89580905|NCT01610596|Placebo Comparator|Vehicle Lotion|Topical lotion, applied twice daily
89580906|NCT01818700|Other|Single arm-Norspan patch (Buprenorphine)|This trial is single arm with Norspan patch. Treatment with NORSPAN Ò will be started from 5 μg/h (1 patch a week) for 2 weeks, and proper titration (up-titration) will be allowed at visit 2(wk 2) and at visit 3(wk 4) according to the investigator's decision. The up-titration will be considered by investigator's judgement as follows; (1) if the rescue medication was used more than 2 times per day, on average or (2) based on the daily average NRS(Numeric Rating Scale), if the NRS was changed to worsen since the previous visit, (3) Investigator's judgement by considering any titration needed situation (e.g. dose, frequency of rescue medication).
89580907|NCT01817764|Experimental|Umeclidinium/vilanterol Arm|The subjects will receive UMEC/VI 62.5/25 mcg, administered as one inhalation once-daily in the morning via the NDPI and placebo administered as one inhalation each morning and evening via ACCUHALER/DISKUS
89580908|NCT01817764|Active Comparator|Fluticasone propionate/salmeterol Arm|The subjects will receive FSC 250/50 mcg, administered as one inhalation each morning and evening via ACCUHALER/DISKUS and placebo administered once-daily in the morning via NDPI
89580909|NCT01803880|Active Comparator|Mechanical Debridement|Mechanical shaver removes areas of damaged tissue
89580910|NCT01803880|Active Comparator|RF-based Debridement|Electrical energy removes areas of damaged tissue (Coblation®)
89580911|NCT01803646|Experimental|AM-101 injection|AM-101
89580912|NCT01803646|Placebo Comparator|Placebo injection|Placebo
89580913|NCT01817530|Placebo Comparator|Cohort 1: Placebo|Placebo for elagolix and placebo for E2/NETA twice daily (BID)
89580914|NCT01817530|Experimental|Cohort 1: Elagolix 300 mg BID|Elagolix 300 mg BID alone
89580915|NCT01817530|Experimental|Cohort 1: Elagolix 300 mg BID plus LD E2/NETA QD|Elagolix 300 mg BID plus low-dose (LD) E2/NETA once daily (QD)
89580916|NCT01817530|Experimental|Cohort 1: Elagolix 300 mg BID plus SD E2/NETA QD|Elagolix 300 mg BID plus standard-dose (SD) E2/NETA QD
89580917|NCT01817530|Placebo Comparator|Cohort 2: Placebo|Placebo for elagolix and E2/NETA QD
89580918|NCT01817530|Experimental|Cohort 2: Elagolix 600 mg QD|Elagolix 600 mg QD alone
89580919|NCT01817530|Experimental|Cohort 2: Elagolix 600 mg QD plus LD E2/NETA QD|Elagolix 600 mg QD plus LD E2/NETA QD
89580920|NCT01817530|Experimental|Cohort 2: Elagolix 600 mg QD plus SD E2/NETA QD|Elagolix 600 mg QD plus SD E2/NETA QD
89580921|NCT01816984|Experimental|Arm I (BKM120 PO and cetuximab 500 mg IV 14 days)|"Patients receive PI3K inhibitor BKM120 PO QD 100 mg/day on days -7 to 0. Patients complete 1 week washout. 3 patients receive BKM120 PO 80mg / day and cetuximab 500 mg IV /14 days and after dose escalation, 9 patients receive BKM120 PO 100mg / day and cetuximab 500 mg IV /14 days thereafter.~All patients receive PI3K inhibitor BKM120 PO QD day on days 1-28 and cetuximab IV over 60-120 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
89580922|NCT01816906|Active Comparator|MCP Insole|"The intervention is Footwear: MCP. MCP insoles are commonly used within Diabetic sandals in India."
89580923|NCT01816906|Active Comparator|PU insole|"The intervention is Footwear: PU. Insoles made of Polyurethane(PU) are given to the participants in the intervention arm."
89580924|NCT01816594|Experimental|BKM120 + Trastuzumab + paclitaxel|BKM120 (oral, pan-class I PI3K inhibitor) in combination with trastuzumab and paclitaxel.
89580925|NCT01816594|Placebo Comparator|BKM120 PBO + Trastuzumab + paclitaxel|BKM120 placebo in combination with trastuzumab and paclitaxel
89580926|NCT01802320|Experimental|Treatment (Akt inhibitor MK2206)|Akt inhibitor MK2206 orally (PO) on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
89580927|NCT02453711|Experimental|Sema 0.05 mg|Dose 0.05 mg
89580928|NCT02453711|Experimental|Sema 0.1 mg|Dose 0.05 or 0.1 mg with dose escalation every fourth week
89580929|NCT02453711|Experimental|Sema 0.2 mg|Dose 0.05, 0.1 or 0.2 mg with dose escalation every fourth week
89580930|NCT02453711|Experimental|Sema 0.3 mg|Dose 0.05, 0.1, 0.2 or 0.3 mg with dose escalation every fourth week
88974027|NCT05770960|Active Comparator|Naloxegol - Codeine phosphate|Participants will receive Naloxegol 25 mg and Codeine syrup in 30 mL and an additional 15 mL at a later stage during the day.
89580931|NCT02453711|Experimental|Sema 0.4 mg|Dose 0.05, 0.1, 0.2, 0.3, or 0.4 mg with dose escalation every fourth week
89580932|NCT02453711|Experimental|Sema 0.3 mg (fast dose escalation)|Dose 0.05, 0.1, 0.2 or 0.3 mg with dose escalation every second week
89580933|NCT02453711|Experimental|Sema 0.4 mg (fast dose escalation)|Dose 0.05, 0.1, 0.2, 0.3, or 0.4 mg with dose escalation every second week
89580934|NCT02453711|Active Comparator|Lira 3.0 mg|Dose 0.6, 1.2, 1.8, 2.4, 3.0 mg with dose escalation every week
89580935|NCT02453711|Placebo Comparator|Placebo Sema 0.05 mg|Placebo arm matching active arm Sema 0.05 mg
89580936|NCT02453711|Placebo Comparator|Placebo Sema 0.1 mg|Placebo arm matching active arm Sema 0.1 mg
89580937|NCT02453711|Placebo Comparator|Placebo Sema 0.2 mg|Placebo arm matching active arm Sema 0.2 mg
89580938|NCT02453711|Placebo Comparator|Placebo Sema 0.3 mg|Placebo arm matching active arm Sema 0.3 mg
89580939|NCT02453711|Placebo Comparator|Placebo Sema 0.4 mg|Placebo arm matching active arm Sema 0.4 mg
89580940|NCT02453711|Placebo Comparator|Placebo Sema 0.3 mg (fast dose escalation)|Placebo arm matching active arm Sema 0.3 mg (fast dose escalation)
89580941|NCT02453711|Placebo Comparator|Placebo Sema 0.4 mg (fast dose escalation)|Placebo arm matching active arm Sema 0.4 mg (fast dose escalation)
89580942|NCT02453711|Placebo Comparator|Placebo Lira 3.0 mg|Placebo arm matching active arm Lira 3.0 mg
89580943|NCT02453555|Active Comparator|Linagliptin|patient to receive 5 mg linagliptin once daily
89580944|NCT02453555|Experimental|Empagliflozin + linagliptin low dose|patient to receive one tablet once daily
89580945|NCT02453555|Experimental|Empagliflozin + linagliptin high dose|patient to receive one tablet once daily
89580946|NCT02453555|Placebo Comparator|Linagliptin placebo|
89580947|NCT02453555|Placebo Comparator|Empagliflozin + linagliptin high dose placebo|
89580948|NCT02453555|Placebo Comparator|Empagliflozin + linagliptin low dose placebo|
89580949|NCT02453321|Active Comparator|Cont. Femoral Block - Low Dose Group|Arm is named by the intervention the group receives. Continuous Femoral Block - Low Dose. The Block/catheter is placed about 5cm below groin at ultrasonographic apex of femoral triangle. Rate of 2ml/hr of bupivacaine 0.0625% until morning of POD#2.
89580950|NCT02453321|Experimental|Cont. Femoral Block - Higher Dose|Place the CPNB in same manner as low-dose group, but rate will be 4ml/hr. Hypothesis is that this group may experience better pain control, but likely will have more dense motor blockade of thigh and less participation in physical therapy
89580951|NCT02453321|Experimental|Continuous Adductor Canal|Placed at mid-thigh in proximal adductor canal near femoral artery with a bupivacaine infusion rate of 4ml/hr. Hypothesis is that this group may experience less motor blockade of thigh but may have more pain than the femoral nerve groups.
89580952|NCT01610284|Experimental|BKM120 100mg + Fulvestrant|BKM120 100 mg per day and fulvestrant given until progression or as described in the protocol.
89580953|NCT01610284|Placebo Comparator|Placebo + Fulvestrant|BKM120 matching placebo daily and fulvestrant given until progression or as described in the protocol.
89580954|NCT02452463|Experimental|Arm I (nintedanib)|Beginning 4-8 weeks after completion of radiation therapy, patients receive nintedanib PO BID on days 1-28. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
89580955|NCT02452463|Placebo Comparator|Arm II (placebo)|Beginning 4-8 weeks after completion of radiation therapy, patients receive placebo capsules PO BID on days 1-28. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
89580956|NCT02452463|Experimental|Arm III (nintedanib, durvalumab)|Beginning 4-8 weeks after completion of radiation therapy, patients receive nintedanib PO BID on days 1-28 and standard of care durvalumab IV over 60 minutes on days 1 and 15. Treatment with nintedanib repeats every 28 days for up to 6 cycles and treatment with durvalumab repeats every 2 weeks in the absence of disease progression or unacceptable toxicity.
89580957|NCT02432105|Experimental|EXE844 for 7 Days + Tubes|EXE844 Sterile Otic Suspension, 0.3%, ototopical, 4 drops, twice daily (BID) in each ear for 7 days after Tympanostomy Tube Insertion
89580958|NCT02432105|Experimental|EXE844 for 3 Days + Tubes|EXE844 Sterile Otic Suspension, 0.3%, ototopical, 4 drops BID in each ear for 3 days after Tympanostomy Tube Insertion
89580959|NCT02432105|Active Comparator|Tubes Only|Bilateral myringotomy and tympanostomy tube insertion
89580960|NCT02431793|No Intervention|Usual Care|Employ the standard of care, no intervention
89580961|NCT02431793|Experimental|EMC2 strategy|"Patients of providers randomized to EMC2 arm will received educational tool from the ED to support the understanding and safe use of opioids.~A single-page medication information sheet with content from a patients perspective and following health literacy best practices.~Prescribing instructions will be adapted to the Universal Medication Scheduled Take-Wait-Stop regimen for both the prescribing and dispensing of the medicine. This format uses simplified text and numeric characters to detail dose.~Provider counseling prompts: The providers for patients in this arm will be prompted to encourage counseling both in the ED and at follow-up time points. These prompts include: 1) An automated prompt to the ED physician upon signing the order; 2) an automated message to the PCP (if an in-system PCP) notifying them of the ED visit, new prescription, and counseling request; and 3) a request for the pharmacist to counsel patient printed automatically on the prescription."
89580962|NCT02431793|Experimental|EMC2 strategy + SMS Text Reminders|In addition to the EMC2 Strategy Arm, patients will received daily text message reminders about the safe use of opioids for 7 days.
88974028|NCT05770960|Other|Placebo - Codeine phosphate|Participants will receive Placebo instaid of Naloxegol 25 mg and Codeine syrup in 30 mL and an additional 15 mL at a later stage during the day.
88974029|NCT05770960|Other|Naloxegol - Placebo|Participants will receive Naloxegol 25 mg and Sirupus simplex syrup (as a placebo alternative for Codeine syrup) in 30 mL and an additional 15 mL at a later stage during the day.
88974030|NCT05770947|Experimental|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy for adolescents with higher weight seeking treatment for bulimia nervosa (CBT-BNh).Designed for adolescents, CBT-BNh will include psychoeducation, cognitive restructuring, and relapse prevention planning. The focus of therapy will include reducing extreme/unhealthy weight-control behaviors (purging) as well as binge eating, and self-compassion coping skills will address weight stigma and self-directed weight criticism.
88974031|NCT05770947|Active Comparator|Mindfulness|Learning to Breathe (L2B) is an existing, evidence-based program for adolescents that teaches mindfulness skills each week, including time to practice and reflect. the skills are grouped into six themes: Body, Reflections, Emotions, Attention, Tenderness, Habits, and Empowerment.
88974032|NCT05770583|Active Comparator|Control group|Fraction of inspired oxygen (FiO2) is titrated guided by oxygen saturation in that range; %95<oxygen saturation≤%98
89580963|NCT03628391|Active Comparator|haloperidol|"study drug will be titrated based on delirium, diagnosed with a validated screening instrument (CAM-ICU or ICDSC), starting with 2.5mg IV q8h and titrated to a maximum of 5mg IV q8h.~Agitation and hallucinations will be managed according to a pre-specified protocol in both treatment arms. First the study drug will be increased when agitation or delirium remain present. Further options include mainly the use of alfa-2 agonists (agitation) or atypical antipsychotic drugs (hallucinations)."
89580964|NCT03628391|Placebo Comparator|placebo|"study drug will be titrated based on delirium, diagnosed with a validated screening instrument (CAM-ICU or ICDSC), starting with 2.5mg IV q8h and titrated to a maximum of 5mg IV q8h.~Agitation and hallucinations will be managed according to a pre-specified protocol in both treatment arms. First the study drug will be increased when agitation or delirium remain present. Further options include mainly the use of alfa-2 agonists (agitation) or atypical antipsychotic drugs (hallucinations)."
89580965|NCT01801930|Experimental|Dose level 1|
89580966|NCT01801930|Experimental|Dose level 2|
89580967|NCT01801930|Experimental|Dose level 3|
89580968|NCT01801930|Experimental|Dose level 4|
89580969|NCT01610206|Active Comparator|gemcitabine|
89580970|NCT01610206|Experimental|Gemcitabine + pazopanib|
89580971|NCT04414462|Experimental|Group I|Group I will receive following exergaming training: heading, tightrope tension,snowboard slalom and table tilt game
89580972|NCT04414462|Active Comparator|Group II|Group II will receive Habituation,wobble board exercises,double leg,single leg and tandem stance training.
89580973|NCT01816048|Experimental|TAK-700|"TAK-700 will be administered at 300 mg orally (PO)twice daily (BID) continuously on 28-day treatment cycles.~The most common way of assessing bone metastasis is planar bone scintigraphy or single photon emission computed tomography (SPECT), though both lack high spatial resolution and thus make small metastases detection inaccurate. Positron emission tomography (PET) is a successful imaging modality with a higher resolution than SPECT, but has not been widely adopted in bone imaging. One of the most promising PET imaging agents for detection of bone metastasis is 18F-Sodium Fluoride (Fluorine F 18 Sodium Fluoride, or NaF). NaF uptake is characterized by high and rapid bone uptake accompanied by very rapid blood clearance, which results in a high bone-to-background ration in a short time."
89580974|NCT01612858|Experimental|Metformin|
89580975|NCT01612858|Experimental|Pioglitazone|
89580976|NCT01612780|Experimental|XprESS Multi-Sinus Dilation Tool|Balloon sinus dilation
89580977|NCT01612702|Experimental|Dexamethasone|dexamethasone 10 mg administration 1 hour before surgery
89580978|NCT01612702|No Intervention|Control|No dexamethasone
89580979|NCT02431559|Experimental|Phase 1, Dose Level 0a|Subjects received PLD (40 mg/m^2 IV on Day 1 of every cycle) + durvalumab (3 mg/kg Q2W [equivalent to 450 mg Q4W] IV on Days 3 and 17 of every cycle) for up to 12 continuous 28-day cycles (Core Study), with extended durvalumab monotherapy permitted for subjects tolerating and benefiting from treatment. Prior to removal of motolimod from the study, subjects received motolimod (2.5 mg/m^2 SC) on Days 3, 10, and 17 of Cycles 1-3 and Days 3 and 17 of Cycles 4-12.
89580980|NCT02431559|Experimental|Phase 1, Dose Level 0b|Subjects received PLD (40 mg/m^2 IV on Day 1 of every cycle) + durvalumab (1500 mg Q4W IV on Day 3 of every cycle) for up to 12 continuous 28-day cycles (Core Study), with extended durvalumab monotherapy permitted for subjects tolerating and benefiting from treatment. Prior to removal of motolimod from the study, subjects received motolimod (2.0 mg/m^2 SC) on Days 3, 10, and 17 of Cycles 1-3 and Day 3 of Cycles 4-12.
89580981|NCT02431559|Experimental|Phase 1, Dose Level +1|Subjects received PLD (40 mg/m^2 IV on Day 1 of every cycle) + durvalumab (1500 mg Q4W IV on Day 3 of every cycle) for up to 12 continuous 28-day cycles (Core Study), with extended durvalumab monotherapy permitted for subjects tolerating and benefiting from treatment. Prior to removal of motolimod from the study, subjects received motolimod (2.5 mg/m^2 SC) on Days 3, 10, and 17 of Cycles 1-3 and Day 3 of Cycles 4-12.
89580982|NCT02431559|Experimental|Phase 2|Subjects received the MTD determined in Phase 1 (Dose Level +1), comprising PLD (40 mg/m^2 IV on Day 1 of every cycle) + durvalumab (1500 mg Q4W IV on Day 3 of every cycle) for up to 12 continuous 28-day cycles (Core Study), with extended durvalumab monotherapy permitted for subjects tolerating and benefiting from treatment.
89580983|NCT02388269|Active Comparator|gammaCore®-G|"The user/operator applies the gammaCore®-G device to the skin on the right side and left side of the neck. The 2 stimulations should be performed on the same side of the neck before stimulating the other side. This is also applies with the doses increase in the open label phase. The user applies conductive gel to the stimulation surfaces to maintain an uninterrupted conductive path from the stimulation surfaces to the skin.~The device is capable of delivering multiple patient treatments (doses). Each dose consists of 90 seconds of stimulation; for each dose, the device is active for 120 seconds before automatically stopping stimulation.The extra 30 seconds allows ."
89580984|NCT02388269|Sham Comparator|gammaCore®-G sham|"The sham device is a hand-held portable device that appears identical to the gammaCore®-G, in look, weight, visual and audible feedback, user application and control. It passes a low frequency (0.1 Hz) biphasic DC signal into the tissue, which can be felt as a tingling sensation but does not stimulate the vagus nerve or cause muscle contraction. Similar to the active device, the sensation becomes more pronounced as the amplitude is increased, until it is uncomfortable, at which point the amplitude is decreased slightly until tolerable.~Like the active device, the sham device is a multi-use device capable programmed to deliver up to 150, 90-second treatments with a 30-second margin for set-up and operator adjustment of the stimulation intensity."
89580985|NCT01652573|Experimental|Nasal calictonin|Subjects will received nasal calcitonin once daily
89580986|NCT01652573|Placebo Comparator|Saline Nasal spray|Patients will receive saline nasal spray once daily
89580987|NCT02388191|Experimental|Naproxen sodium|550 mg naproxen sodium
89580988|NCT02388191|Placebo Comparator|Placebo|Placebo
89580989|NCT01815736|Experimental|E/C/F/TAF|"Randomized Phase: Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) for up to 96 weeks.~Extension Phase: After completing 96 weeks of randomized treatment, all participants will be given the opportunity to receive open-label E/C/F/TAF until it becomes commercially available, or until Gilead elects to terminate the development of E/C/F/TAF."
89580990|NCT01815736|Active Comparator|Stay on Baseline Treatment Regimen (SBR)|"Randomized Phase: Participants stayed on their baseline emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)-containing regimen E/C/F/TDF; efavirenz (EFV)/FTC/TDF; ritonavir (RTV)-boosted atazanavir (ATV)+FTC/TDF; or cobicistat (COBI-boosted ATV+FTC/TDF) administered according to prescribing information for up to 96 weeks.~Extension Phase: After completing 96 weeks of randomized treatment (SBR), all participants will be given the opportunity to receive open-label E/C/F/TAF until it becomes commercially available, or until Gilead elects to terminate the development of E/C/F/TAF."
89580991|NCT01651949|Active Comparator|Females|Healthy females 16 to 26 years of age received 9vHPV vaccine 0.5 mL intramuscular injection on Day 1, Month 2, and Month 6
89580992|NCT01651949|Experimental|Heterosexual Males|Healthy heterosexual males 16 to 26 years of age received 9vHPV 0.5 mL intramuscular injection on Day 1, Month 2, and Month 6
89580993|NCT01651949|Experimental|Men who have Sex with Men|Healthy MSM 16 to 26 years of age received 9vHPV 0.5 mL intramuscular injection on Day 1, Month 2, and Month 6
89580994|NCT01800916|Experimental|Treatment sequence 1|"The subjects randomised to Treatment sequence 1 are going to test~Coloplast Adhesive baseplate A (A)~Coloplast Adhesive baseplate B (B)~SenSura 1-piece (S)~The subjects test the three test products in a randomised order: ABS; BSA; SAB"
89580995|NCT01800916|Experimental|Treatment sequence 2|"The subjects randomised to Treatment sequence 2 are going to test~Coloplast Adhesive baseplate B (B)~Coloplast Adhesive baseplate C (C)~SenSura 1-piece (S)~The subjects test the three test products in a randomised order: CBS; BSC; SCB"
89580996|NCT01800916|Experimental|Treatment sequence 3|"The subjects randomised to Treatment sequence 3 are going to test~Coloplast Adhesive baseplate A (A)~Coloplast Adhesive baseplate B (C)~SenSura 1-piece (S)~The subjects test the three test products in a randomised order: ACS; CSA; SAC"
89580997|NCT01800058||Circulating prostatic tumor cells in the peripheral blood|"Patients that satisfy inclusion criteria, and after signing informed consent, will extract 1 blood sample (7.5 mL):~prior to any treatment;~following AD and prior to RT; and~following the end of RT (1-3 months afterwards).~six to twelve months following the end of RT in those patients with 0 CTCs in the first determination and positive CTCs in the second or third determination~The quantification of CTC in blood samples will be done with the CellSearch® system."
89209433|NCT04037280|Experimental|Functional strenghtening 1|once a day (1RF): patients in this group will have to play 10 times the postural passage from supine position to sitting position on a bed and 10 times the postural passage from sitting position to erect position (STS), maintaining the contraction of Pelvic Floor Muscle during the execution of each functional act. In sequence, starting from erect position, they will have to play 10 trunk flexion bending their knees (as to pick up an object on the ground), maintaining the contraction of Pelvic Floor Muscle during the execution of each functional movement.
89209434|NCT04037280|Experimental|Functional strenghtening 2|twice a day (2RF): patients in this group will have to play the same typology of exercises in the same way just described (see above), but twice a day (in the morning and in the evening).
89209435|NCT00278395|Experimental|Arm I|Patients receive oral vorinostat (SAHA) twice daily on days 1-3, 8-10, 15-17, and 22-24. Courses repeat every 28 days for up to 52 weeks in the absence of disease progression or unacceptable toxicity. Patients may have the option of continuing treatment beyond 52 weeks at the discretion of the investigator.
89209436|NCT00889044|Experimental|clopidogrel by chewing|
89209437|NCT00889044|Placebo Comparator|Placebo|
89209438|NCT00889122|Experimental|Lifestyle Counseling|
89209439|NCT00883584|Active Comparator|1|IMD-1041
89209440|NCT00883584|Placebo Comparator|2|
89209441|NCT00883662||Group 1|
89580998|NCT01815580|Active Comparator|Immediate ART (Atripla or Stribild)|Daily Atripla or Stribild will be provided to these patients for the duration of the study beginning at enrollment.
89580999|NCT01815580|Placebo Comparator|Deferred ART (Atripla or Stribild)|Daily Atripla or Stribild will be provided to these patients for the duration of the study beginning at 24 weeks.
88974033|NCT05770583|Experimental|ORi+SpO2 (oxygen saturation) group|"FiO2 will be titrated by reducing 10% if Ori>0.01 andSpO2 ≥ 98% until Ori is 0.00.~FiO2 will not be changed if Ori is 0.00 and %95<oxygen saturation≤%98~FiO2 will be increased by 10% if oxygen saturation <95 or PaO2<60 mmHg"
89209442|NCT00883818|Experimental|Antibiotics therapy|
89209443|NCT00889356|Experimental|Clindamycin 100mg and Ketoconazole 400mg|
89209444|NCT00889356|Active Comparator|Tetracycline 100mg and Amphotericin B 50mg|
89209445|NCT00886080|Experimental|Add-on arrhythmia surgery|"Adjuvant anti-arrhythmic surgery consists of a beating heart epicardial box isolation of all pulmonary veins using microwave energy (Flex 4 or Flex 10 ablation probes and Microwave generator by Guidant/Afix, Fremont, CA, USA). The surgical ablation procedure is the first step during surgery and is performed before institution of cardiopulmonary bypass allowing off-pump beating heart ablation. In addition excision or exclusion of the left atrial appendage is performed in both the treated as the control group."
89209446|NCT00889434|Active Comparator|EGCG|Two cycles comprising 28 days of continuous daily treatment with EGCGgiven 2 times/6 soft gel capsules (total 600 mg) /day (BID) in the morning and in the evening with food followed by a 14 day wash out period without drug.
89209447|NCT00889434|Active Comparator|Tocotrienol|
89581000|NCT01799590|Experimental|Topiramate|
89581001|NCT04902131|Experimental|MENOPUR pen|
89581002|NCT04902131|Active Comparator|MENOPUR powder|
89581003|NCT01815424|Placebo Comparator|Placebo BID|
89581004|NCT01815424|Experimental|5mg BID CP-690,550|
89581005|NCT01815424|Experimental|10mg BID CP-690,550|
89209448|NCT00889434|Other|EGCG + Tocotrienol|Combination of both arms
89209449|NCT00612534|Experimental|1|
89209450|NCT00612534|Experimental|2|
89209451|NCT00612534|Experimental|3|
89209452|NCT00612534|Placebo Comparator|4|
89209453|NCT02542254|Active Comparator|Salbutamol alone|200 micrograms salbutamol, ipratropium matched placebo and RPL554 matched placebo
89209454|NCT02542254|Experimental|Salbutamol and RPL554|200 micrograms salbutamol, ipratropium matched placebo and 6 mg RPL554
89209455|NCT02542254|Active Comparator|Ipratropium|Salbutamol matched placebo, 40 micrograms ipratropium and RPL554 matched placebo
89209456|NCT02542254|Experimental|Ipratropium and RPL554|Salbutamol matched placebo, 40 micrograms ipratropium and 6 mg RPL554
89209457|NCT02542254|Experimental|RPL554|Salbutamol matched placebo, ipratropium matched placebo and 6 mg RPL554
89581006|NCT02431247|Experimental|Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide|Subject will receive a single oral tablet containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg (D/C/F/TAF fixed dose combination [FDC]) once daily along with DRV/COBI FDC-matching and FTC/TDF FDC-matching placebo tablets once daily up to Week 48 analysis unblinding visit (i.e. after last subject has reached Week 48). After Week 48 analysis unblinding visit, subjects will receive a single tablet containing D/C/F/TAF FDC once daily up to Week 96.
89581007|NCT02431247|Active Comparator|DRV/COBI fixed dose combination (FDC) and FTC/TDF FDC|Subject will receive DRV 800 mg/COBI 150 mg FDC and FTC 200 mg/TDF 300 mg FDC along with D/C/F/TAF FDC-matching placebo tablet once daily up to Week 48 analysis unblinding (i.e. after last subject has reached Week 48). After Week 48 analysis unblinding, subjects will receive a single tablet containing D/C/F/TAF FDC once daily up to Week 96.
89581008|NCT01814878|Experimental|Tramadol Hydrochloride/Acetaminophen ER|Participants will be administered 2 oral tablets of extended release (ER) tramadol HCl (75 milligram [mg])/acetaminophen (650 mg) and 2 tablets of placebo matching to immediate release (IR) tramadol HCl/acetaminophen orally every 12 hours up to 36 hours, and 2 tablets of placebo matching to IR tramadol HCl/acetaminophen every 6 hours up to 42 hours.
89581009|NCT01814878|Active Comparator|Tramadol HCl/Acetaminophen IR|Participants will be administered 2 oral tablets of IR tramadol HCl (37.5 mg)/acetaminophen (325 mg) and 2 tablets of placebo matching to ER tramadol HCl/acetaminophen at 0, 12, 24 and 36 hours, and 2 tablets of IR tramadol HCl/acetaminophen at 6, 18, 30 and 42 hours.
89581010|NCT02407457|Active Comparator|AFX EVAR AAA Graft System|Subjects randomized to receive the Endologix AFX Endovascular Graft System for implantation to repair Abdominal Aortic Aneurysm via femoral access.
89581011|NCT02407457|Active Comparator|FDA Approved EVAR AAA Graft Systems|Subjects randomized to receive the comparator AAA Endovascular Graft System for implantation to repair Abdominal Aortic Aneurysm via femoral access.
88974034|NCT05768321|Experimental|GEC255 treatment|Oral tablet(s), once daily in 28-day cycles
88974035|NCT05768282|Experimental|Administration of oral prednisolone|Oral prednisolone start at a dose of 30 mg/day on the third day after RFA, and continue for 4 weeks.
88974036|NCT05768009|Experimental|Interscalene brachial plexus block (ISB)|• Group A will include 21 patients who will undergo the procedure under general anesthesia and ultrasound guided Interscalene brachial plexus block using 10 ml bupivacaine 0.25%.the interscalene block will be performed when the patient is in a supine position, with his/her head slightly elevated and turned away from the side to be blocked. The linear ultrasound probe (frequency 10-15 MHz) will be used with the depth setting of 2-4 cm. The probe will be initially placed near the midline of clavicle at the level of cricoid cartilage and scanned laterally to identify the carotid artery and internal jugular vein underneath the sternocleidomastoid muscle. By moving the probe laterally, the anterior scalene muscle will be identified below the lateral edge of the sternocleidomastoid. A groove containing the hypoechoic nerve structures will usually be identified. 10 mL of 0.25 bupivacaine will be injected into scalene groove around the nerve roots.
88974037|NCT05768009|Experimental|pericapsular nerve block and superficial cervical plexus blocks|"• Group B will include 21 patients who will undergo the procedure under general anesthesia and combined pericapsular nerve block and superficial cervical plexus blocks (using 10 and 5 ml bupivacaine 0.25% respectively).~the patient's arm will be placed in external rotation and abducted at 45 degrees. The linear ultrasound probe will be placed longitudinally between the coracoid process and the humeral head. After identification of the humeral head, the subscapularis tendon and the deltoid muscle over it, a 50-mm sonovisible needle will be inserted using the in plane technique. The needle tip will be placed between the deltoid muscle and subscapularis tendon, and 10 ml of 0.25% bupivacaine will be injected."
88974038|NCT05771740||Pulmonary Fibrosis Patient|Participants under the clinical care of the interstitial lung disease team at the Royal Devon University Healthcare NHS Trust, UK
88974039|NCT05771740||Healthy Control|Healthy participants visiting the Royal Devon University Healthcare NHS Trust, UK
88974040|NCT05766800|Experimental|Downstaged arm with surgical treatment|In this arm, patients with tumors resectable after chemoimmunotherapy will receive surgical treatment in department of thoracic surgery.
88974041|NCT05766800|Active Comparator|Downstaged arm with radiotherapy|In this arm, patients with tumors resectable after chemoimmunotherapy will receive radiotherapy in department of medical oncology.
88974042|NCT05766800|Other|Unresectable arm|In this arm, patients with tumors still unresectable after chemoimmunotherapy will receive therapy in department of medical oncology.
88974043|NCT05766566||Cohort|"Will be enrolled patients referring to the Department of General Surgery of the IRCCS Saverio de Bellis - Castellana Grotte (BA) Italy, affected by perianal fistulas from Crohn's disease."
88974044|NCT05766410|Experimental|Palbociclib/Letrozole|CDK4, 6 inhibitor and endocrine therapy
88974045|NCT05766410|Active Comparator|Ribociclib/Letrozole|CDK4, 6 inhibitor and endocrine therapy
88974046|NCT05766410|Active Comparator|Abemaciclib/Letrozole|CDK4, 6 inhibitor and endocrine therapy
88974047|NCT05757011|Placebo Comparator|Placebo|Before the removal of uterus and the closure of vaginal cuff, insertion of 6inch 22G needle 2 to 3 cm below the umbilicus, 30 ml normal saline (sodium chloride solution 0.9%, FIPCO, Egypt)will be administered , then the uterus will be removed, and the operation will be terminated
88974048|NCT05757011|Experimental|pre-sacral nerve block|"Uterosacral nerve block will be performed before the removal of uterus and the closure of vaginal cuff, and before the removal of trocars from abdominal cavity, insertion of 6-inch 22G needle 2 to 3 cm below the umbilicus, injection of the SHP area which situated anterior to L5-S1 vertebral bodies, Caudal to the bifurcation of the abdominal aorta with 30 ml 0.25% bupivacaine (Marcaine®0.25% , Astra Zeneca, Egypt) will be administered. Following the injection of local anesthetic, patient will be placed from Trendelenburg position to horizontal position. The we will remove the uterus and trocars , and the operation will be terminated.~Data will be recorded in a case report form (CRF) and statistical analysis will be done."
89581012|NCT01814800|Experimental|RI-002 Treatment|Drug: RI-002 Dose: 300-800 mg/kg infusion Frequency: Once every 3 to 4 Weeks
89581013|NCT01814332|Experimental|GSK561679|GSK561679, oral administration, 350mg/day, 6 week administration
89581014|NCT01814332|Placebo Comparator|Placebo|Placebo compound treatment for comparison with IP
89581015|NCT02407223|Placebo Comparator|Group 1: Placebo|Participants will receive placebo subcutaneously (SC) at Weeks 0, 4, 16, and 20. At Week 24, all participants (except those who early escaped) will crossover to receive ustekinumab 45 or 90 milligram (mg) SC at Weeks 24 and 28 followed by every 12 weeks up to Week 52. At Week 16, participants in placebo group with < 10% improvement from baseline in both total back pain and morning stiffness measures at Week 12 and 16 will enter early escape to receive ustekinumab 45 mg or 90 mg at Weeks 16, 20, and 28 followed by every 12 weeks up to Week 52. At Week 52, participants who achieved inactive disease by ASDAS (ESR) <1.3 at both Week 40 and 52 will be re-randomized to receive placebo or ustekinumab every 12 weeks up to Week 88. At Week 52, participants who did not achieve inactive disease by ASDAS (ESR) <1.3 at Week 40 or 52 will continue with ustekinumab every 12 weeks up to Week 88. NOTE: Intervention Description should have no more than 800 characters.
88974049|NCT05756790|No Intervention|Enhanced Usual Care|Couples in this condition will receive the standard of care for alcohol use in addition to a brief alcohol counseling session modeled after WHO guidelines and Dr. Conroy's intervention in Malawi, which uses participants' baseline AUDIT scores for messaging around alcohol reduction and lasts 5-10 minutes.
88974050|NCT05756790|Experimental|Motivational Interviewing (MI)|Couples will have three MI sessions over a 60-day period. These sessions will focus on communication between the couple, alcohol consumption patterns, and setting goals for alcohol-use reduction.
88974051|NCT05756790|Experimental|Motivational Interviewing Plus Breathalyzer (MI Plus)|In addition to three MI sessions, drinkers in this condition will be prompted via SMS message twice per day to use a mobile app and a breathalyzer to test their blood alcohol levels (BAC). Both the drinker and their partner will receive real-time feedback about alcohol use.
88974052|NCT05754827||1-CKD patients without cardiovascular complications|
88974053|NCT05754827||2-CKD patients with cardiovascular complications|
88974054|NCT05750875|Active Comparator|Loratadine|
88974055|NCT05750875|Active Comparator|Gabapentin|
88974056|NCT05730569||Preterm Neonates|"Neonate born between the 34th and 37th week of pregnancy~Birth weight ≤2500g and ≥1500g"
88974057|NCT05730569||Full-Term Neonates|"Neonate born after the 37th week of pregnancy~Birth weight >2500g"
88974058|NCT05724888|Experimental|Intervention_Winnipeg|The intervention arm will take place in a 12 week intervention (3 sessions per week) which will use a peer mentoring network based on the circle of courage to encourage adolescents with T2D to achieve the WHO recommended target of 300 minutes of moderate to vigorous PA weekly.
88974059|NCT05724888|No Intervention|Control_Winnipeg|The control group will receive standard recommendations for increasing daily PA from the Canadian Society of Exercise Physiology and the American Heart Association.
88974060|NCT05724888|Experimental|Intervention_STP|The intervention arm will take place in a 12 week intervention (3 sessions per week) which will use a peer mentoring network based on the circle of courage to encourage adolescents with T2D to achieve the WHO recommended target of 300 minutes of moderate to vigorous PA weekly.
88974061|NCT05724888|No Intervention|Control_STP|The control group will receive standard recommendations for increasing daily PA from the Canadian Society of Exercise Physiology and the American Heart Association.
88974062|NCT05712785|Experimental|Shuotong Ureteroscopy group|Shuotong Ureteroscopy: a ureteroscope that can lithotripsy and lithotripsy simultaneously
88974063|NCT05712785|No Intervention|Ureteroscopy group|Ureteroscopy group：using conventional ureteroscopy
88974064|NCT05712317|Experimental|Exergame Intervention|8-week exergame-based intervention consisting of 3 sessions per week lasting between 20-40 Minutes. The intervention will consist of playing the game Sphery racer in the exergame called ExerCube.
88974065|NCT05712317|Active Comparator|Moderate-intensity endurance exercise|8-week moderate-intensity endurance exercise consisting of 3 sessions per week lasting between 20-40 minutes. The intervention will consist of a running exercise on a treadmill or riding on a bicycle ergometer.
88974066|NCT05711498|Experimental|Anodal thoracic tsDCS|Anodal tsDCS will be applied over the T12 vertebra
88974067|NCT05711498|Experimental|Cathodal thoracic tsDCS|Cathodal tsDCS will be applied over the T12 vertebra
88974068|NCT05711498|Sham Comparator|Sham thoracic tsDCS|Sham tsDCS will be applied over the T12 vertebra
88974069|NCT05690074|Experimental|Patients with chronic spinal cord injury|80 sessions each of epidural spinal cord stimulation for 1) autonomic functions 2) voluntary movement; and 3) standing
88974070|NCT05680584|Active Comparator|Melatonin|Preoperative oral melatonin 0.1mg/ kg in 10ml apple juice one hour before induction of anesthesia
88974071|NCT05680584|Active Comparator|Hydroxyzine|Preoperative oral hydroxyzine 1mg/ kg in 10ml apple juice one hour before induction of anesthesia
88974072|NCT05680584|Placebo Comparator|placebo|10ml apple juice one hour before induction of anesthesia
88974073|NCT05676697|Experimental|PI3K Delta Inhibitor|
88974074|NCT05673824|Experimental|Huaier Granule Group|Huaier Granule+VEGFR-TKIs
88974075|NCT05663918|Active Comparator|Exercise Training in Individuals with Mild Cognitive Impairment|Individuals will participate in 3 sessions of Self Determined Intensity Interval training per week for 4 weeks, using a stationary bike at an intensity whereby their Ratings of Perceived exertion (RPE) is challenging. RPE will be measured using a Borg's 6-20 scale. (44). The cycling protocol will include a 3-minute warm-up, five, 1-minute cycling intervals, interspersed with 1.5 minutes of recovery. and a 2-minute cool-down. The RPE will be acquired by asking the participant to provide their rating at the end of the last interval.
88974076|NCT05663918|No Intervention|Individuals with Mild Cognitive Impairment and No exercise|Group B: Participants in this arm will not experience any intervention during a 4 week period of time.
88974077|NCT05663918|Active Comparator|Exercise Training in age and sex matched healthy controls|Individuals will participate in 3 sessions of Self Determined Intensity Interval training per week for 4 weeks, using a stationary bike at an intensity whereby their Ratings of Perceived exertion (RPE) is challenging. RPE will be measured using a Borg's 6-20 scale. (44). The cycling protocol will include a 3-minute warm-up, five, 1-minute cycling intervals, interspersed with 1.5 minutes of recovery. and a 2-minute cool-down. The RPE will be acquired by asking the participant to provide their rating at the end of the last interval.
88974078|NCT05661435||Participants|
88974079|NCT05661422||Participants|
88974080|NCT05655611|Experimental|first rib mobilization|To perform the first rib mobilization, the patient remained lying supine with the head in the examiner's right hand. Examiner then palpated the left first rib and passively side-bended the patient's head to the left to relieve any muscular tension on the first rib. Patient was then asked to take a deep breath in and out. During exhalation, the examiner applied pressure to depress the first rib, holding it in place at the end of the exhalation. Then, holding the first rib in place, the patient was asked to inhale and exhale deeply again. The examiner continued applying pressure to hold the first rib in a position of relative depression during inhalation, and further depressed the first rib as able during exhalation. This process was repeated three times in two sets, for a total of six first rib depression mobilizations
88974081|NCT05655611|Active Comparator|muscle energy technique|All the patients will receive conventional physical therapy treatment and muscle energy techniques for shoulder flexion, abduction, internal and external rotation. Muscle energy technique was applied for five repetitions per set, five sets per session, one session per day, three days a week for three weeks with each repetition maintained for the duration of 7-10 seconds
88974082|NCT05646992|Experimental|Uterus Transplant Recipient|Uterus recipients, who are otherwise healthy, adult, genotypic females affected by uterine factor infertility, will undergo the surgically innovative uterus transplantation procedure combined with short-term use of conventional calcineurin inhibitor-based immunosuppression in to support a fetus to a viable delivery via Caesarian section.
88974083|NCT05630469||Depression|Depressive patients (pharmaco-resistant) undergoing electroconvulsive therapy
88974084|NCT05610722|Other|DreaMed Endo Digital|"At each visit, participants who use pump therapy will download their pump and glucose data (V1-V5) as they use to do at clinic visit. Participants who use MDI therapy will use the Endo.Digital App for insulin and glucose documentation and will upload data from their CGM/FGM or glucometer as they use to do at clinic visit.~In addition, participants will be offered to download data also at home in between study visits, every 3-6 weeks as they feel needed (Phone visits: P1-up to P8). Each time, optimization of pump settings or MDI will be done according to the downloaded data using the Endo.DigitalTM system. The device recommendations for insulin dosing adjustments and diabetes management tips will be reviewed by the treating physician. Each new treatment settings will be approved or edit by the study physician prior to implementation by the participant."
88974085|NCT05602012|Experimental|Mindfulness Based Cognitive Counseling|The intervention was conducted in two groups with 25 participants/12-13 for each groups and two researchers per group. The program which consisted of eight sessions in total, was held once a week and each session lasted approximately 90-120 minutes.
88974086|NCT05602012|No Intervention|No Intervention|Participants will not be given an intervention until after they have completed the study. Data collection tools were applied to the students simultaneously with the intervention group, and after the follow-up test of the intervention group, a single-session information meeting will be held by the researchers for the students in the control group.
88974087|NCT05591599||Case group|Women diagnosed with tubal pregnancy
88974088|NCT05591599||Control group|Women with the age corresponding to the case group (matched with the same age or +/- 2 years difference compared with the case group), diagnosed with spontaneous abortion or viable intrauterine pregnancy
88974089|NCT05566938|Other|Tailored nutritional recommendations for each metabotype|Volunteers that will be clustered into metabotypes and will recieve tailored nutritional recommendations according to their metabotype.
88974090|NCT05561075|Experimental|Pterostilbene cocrystal|
88974091|NCT05561075|Active Comparator|Pterostilbene free form|
88974092|NCT05557006||All patients|Patients who meet the inclusion criteria
88974093|NCT05552027|Experimental|Intervention|Participants will harness the car seat in 3 separate scenarios with the sensor system enabled to provide feedback.
88974094|NCT05552027|Other|Control|Participants will harness the car seat in 3 separate scenarios with the sensor system disabled in order to not provide feedback.
88974095|NCT05549206|Experimental|SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine 50μg|Two doses were administered by intramuscular injection, 28 days apart
88974096|NCT05549206|Experimental|SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine 100μg|Two doses were administered by intramuscular injection, 28 days apart
88974097|NCT05549206|Placebo Comparator|Placebo|Two doses were administered by intramuscular injection, 28 days apart
88974098|NCT05547204|Experimental|Coffeeberry beverage|300 ml drink containing 300 mg coffeeberry extract
88974099|NCT05547204|Placebo Comparator|Color and flavor matched beverage|300 ml drink (0 mg coffeeberry extract, 0 mg caffeine)
88974100|NCT05545566|Experimental|All patients|
88974101|NCT05539404|Experimental|Experimental Strategy Group|endovascular treatment in addition to best medical treatment
88974102|NCT05539404|No Intervention|Control Strategy Group|best medical treatment
88974103|NCT05533684|No Intervention|postoperative pain|Measuring postoperative pain using the visual analogue scale
88974104|NCT05533684|Other|total analgesic consumption|Recording the total amount of analgesia consumed by the patients
88974105|NCT05530382|Experimental|self-guided learning (video and hands-on simulation)|video-based self-directed learning
88974106|NCT05530382|No Intervention|traditional instructor-led learning|traditional instructor-led learning in face-to-face workshop
88974107|NCT05528107|Active Comparator|Laparoscopic Intraperitoneal Onlay Mesh plus ventral hernia repair|Laparoscopic Intraperitoneal Onlay Mesh plus repair will be used to perform a minimally invasive ventral hernia repair with intraperitoneal mesh placement and suturing hernia defect.
89209458|NCT02542254|Placebo Comparator|Placebo|Salbutamol matched placebo, ipratropium matched placebo and RPL554 matched placebo
89581016|NCT02407223|Experimental|Group 2: Ustekinumab 45 milligram (mg)|Participants will receive ustekinumab 45 mg subcutaneously at Weeks 0 and 4, followed by every 12 weeks through Week 52. At Weeks 20 and 24, participants will receive placebo subcutaneously to maintain the blind. At Week 52, participants who achieved inactive disease by ASDAS (ESR) <1.3 at both Week 40 and Week 52 will be re-randomized to receive either placebo or ustekinumab 45 mg every 12 weeks in a blinded fashion. At Week 52, participants who did not achieve inactive disease by ASDAS (ESR) <1.3 at Week 40 or Week 52 will continue receiving ustekinumab 45 mg every 12 weeks through Week 88.
89581017|NCT02407223|Experimental|Group 3: Ustekinumab 90 mg|Participants will receive ustekinumab 90 mg subcutaneously at Weeks 0 and 4, followed by every four weeks through Week 52. At Weeks 20 and 24, participants will receive placebo subcutaneously to maintain the blind. At Week 52, participants who achieved inactive disease by ASDAS (ESR) <1.3 at both Week 40 and Week 52 will receive either placebo or ustekinumab 90 mg every 12 weeks in a blinded fashion. At Week 52, participants who did not achieve inactive disease by ASDAS (ESR) <1.3 at Week 40 or Week 52 will continue receiving ustekinumab 90 mg every 12 weeks through Week 88.
89581018|NCT01797562|Experimental|Positive Response Rates: 7 new and 4 reformulated allergens|Subjects will be patched with TRUE Test Panels 1.3, 2,2 and 3.2. Panel 1 allergens nickel sulfate (0.60 mg/cm2), potassium dichromate (0.054 mg/cm2), fragrance mix (0.050 mg/cm2) and ethylenediamine dihydrochloride (0.050 mg/cm2), Panel 2 allergen Methyldibromoglutaronitrile (0.0053 mg/cm2) and Panel 3 allergens Gold sodium thiosulfate (0.075 mg/cm2), Hydrocortisone-17-butyrate (0.020 mg/cm2), Bacitracin (0.60 mg/cm2), Parthenolide (0.0030 mg/cm2), Disperse blue 106 (0.050 mg/cm2 in PVP), 2-Bromo-2-nitropropane-1,3-diol (Bronopol) (0.25 mg/cm2) will be evaluated
89581019|NCT01813474|Experimental|olaparib tablet monotherapy|olaparib tablet
89581020|NCT01868542|Experimental|3-0-3 Algorithm|A once daily dosage of Insulin detemir (Levemir®) 100 U/mL 3 mL FlexPen® for subcutaneous administration was selected for this trial.During the treatment period insulin detemir was adjusted by the subject themselves (self-titration). Self-titration was performed every 3 days based on the lowest of three previous consecutive pre-breakfast SMPG values.Based on this glucose value, self-adjustment of insulin detemir dose was done. Metformin and Sulfonlylurea were allowed as OADs. For SMPG values, the following insulin detemir dose adjustments were done : >6.1 mmol/L (>110 mg/dL) +3U insulin detemir, 4.4-6.1 mmol/L (80-100 mg/dL) No adjustment in insulin detemir, < 4.4 mmol/L (<80 mg/dL) -3U insulin detemir.
89581021|NCT01868542|Experimental|2-4-6-8 Algorithm|A once daily dosage of Insulin detemir (Levemir®) 100 U/mL 3 mL FlexPen® for subcutaneous administration was selected for this trial. During the treatment period insulin detemir was adjusted by the subject themselves (self-titration). Self-titration was performed every 3 days based on the lowest of three previous consecutive pre-breakfast SMPG values.Based on this glucose value, self-adjustment of insulin detemir dose was done. Metformin and Sulfonlylurea were allowed as OADs. For SMPG values , the following insulin detemir dose adjustments were done : >10.0 mmol/L (180 mg/dL) +8U insulin detemir, 9.1-10.0 mmol/L (163-180 mg/dL) +6U insulin detemir, 8.1-9.0 mmol/L (145-162 mg/dL) +4 U insulin detemir, 7.1-8.0 mmol/L (127-144 mg/dL) +2U insulin detemir, 6.1-7.0 mmol/L (109-126 mg/dL) +2U insulin detemir, 4.1-6.0 mmol/L (73-108 mg/dL) No adjustment in insulin detemir, 3.1-4.0 mmol/L (56-72 mg/dL) -2U insulin detemir, <3.1 mmol/L (<56 mg/dL) -4U insulin detemir.
89581022|NCT04602364||Miga-Fab patients|Miga-Fab is a French prospective, observational cohort study of patients with Fabry disease treated with migalastat
89581023|NCT01797094|Experimental|Botulinum toxin Type A (44U)|44 units (U) botulinum toxin Type A (total dose) per treatment. 24 U injected into bilateral Crow's Feet Line areas and 20 U injected into Frown Line area on Day 1. Based on retreatment criteria participants were eligible for up to 5 treatment cycles.
89581024|NCT01797094|Experimental|Botulinum toxin Type A (32U)|32 units (U) botulinum toxin Type A (total dose) per treatment. 12 U injected into bilateral Crow's Feet Line areas and 20 U injected into Frown Line area on Day 1. Based on retreatment criteria participants were eligible for up to 5 treatment cycles.
89581025|NCT02383589|Active Comparator|Mycophenolate Mofetil (MMF)|Participants will receive MMF orally twice daily (every 12 hours, Q12H) from Day 1 to Week 52. Participants will also receive rituximab matching placebo by intravenous (IV) infusion on Days 1 and 15 with repeat administration on Days 168 and 182 provided specific safety criteria have been met.
89581026|NCT02383589|Experimental|Rituximab (RTX)|Participants will receive rituximab by IV infusion on Days 1 and 15 with repeat administration on Days 168 and 182 provided specific safety criteria have been met. Participants will also receive MMF matching placebo orally twice daily Q12H from Day 1 to Week 52.
89581027|NCT01810432|Experimental|Evacetrapib (Fasted)|130 milligram (mg) oral dose of evacetrapib once daily in a fasted state for 10 days.
89581028|NCT01810432|Experimental|Evacetrapib (Fed)|130 mg oral dose of evacetrapib once daily following a high-fat breakfast for 10 days.
89581029|NCT01796860|Other|AFO|All persons in the study will be fit with the same AFO (Tamarack joint with adjustable check strap).
89581030|NCT01796548|Experimental|Oxybutynin Extended-Release|Oxybutynin chloride 5, 10, 15 milligram (mg) per tablet 10-30 mg per day orally
89581031|NCT02406677|Experimental|Copayment Intervention Arm|Sites in the intervention arm will provide patients with a study voucher card to offset any patient copayments or medication card for the filling of any prescriptions of clopidogrel or ticagrelor.
89581032|NCT02406677|No Intervention|Usual Care Arm|For hospitals randomized to the control arm, all patients receive usual care and no study intervention is performed.
88974108|NCT05528107|Active Comparator|Extended-view totally extraperitoneal ventral hernia repair|Extended-view totally extraperitoneal ventral hernia repair will be used to perform minimally invasive ventral hernia repair with retrorectus mesh placement
89209459|NCT00883974|Experimental|1|
88974109|NCT05520411|Experimental|HUM Flatter Me|Come to Citruslabs Office twice (1 Week Gap Between Visits) Visit 1: Take Placebo or Test Product; Eat Test Meal; Outcome Measures Visit 2: Take Placebo or Test Product; Eat Test Meal; Outcome Measures
88974110|NCT05505747|Experimental|Fisetin|Subjects assigned to the experimental group will take approximately 20 mg/kg/day of fisetin for 2 consecutive days, followed by a 28-day senescence washout period, and then another 2-day administration. Fisetin treatment begins at 8 weeks after surgery.
89581033|NCT02404805|Experimental|Sequence 1a|Sequence 1,2,3: simeprevir only, then dolutegravir only, then both simeprevir and dolutegravir.
89581034|NCT02404805|Experimental|Sequence 1b|Sequence 1,3,2: simeprevir only, then both simeprevir and dolutegravir, then dolutegravir only.
89581035|NCT02404805|Experimental|Sequence 2a|Sequence 2,1,3: dolutegravir only, then simeprevir only, then both simeprevir and dolutegravir.
89581036|NCT02404805|Experimental|Sequence 2b|Sequence 2,3,1: dolutegravir only, then both simeprevir and dolutegravir, then simeprevir only.
89581037|NCT02404805|Experimental|Sequence 3a|Sequence 3,1,2: both simeprevir and dolutegravir, then simeprevir only, then dolutegravir only.
89581038|NCT02404805|Experimental|Sequence 3b|Sequence 3,2,1: Both simeprevir and dolutegravir, then dolutegravir only, then simeprevir only.
89581039|NCT02430311|Experimental|Cohort 1|Treat 15 patients, single dose olaparib 300mg followed by multiple dose olaparib 300mg twice a day
89581040|NCT02430311|Experimental|Cohort 2|Treat 15 patients, single dose olaparib 100mg followed by multiple dose olaparib 100 mg twice a day and then in combination with paclitaxel (80mg/m2 weekly on days 1, 8 and 15 of a single 28-day cycle)
89581041|NCT02404649|Active Comparator|Bone Augmention|Two implant designs in a Sinus Bone Augmentation Procedure. Sinus bone augmentation with Puros Cortico-Cancellous Particulate Allograft (70% Cortico and 30% Cancelleous) (Zimmer Dental- Carlsbad, CA, USA)- one implant will be TMDI (Zimmer Dental- Carlsbad, CA, USA) and the second will be Tapered Screw-Vent TSV-MTX (Zimmer Dental- Carlsbad, CA,USA). Implant stability will be determined by the initial insertion torque and RFV values at time of implant placement and after 1 month of healing on a monthly basis up until 12 months post implant placement.
89581042|NCT02404649|Active Comparator|Sinus elevation only|Two implant designs in a Sinus Floor Elevation Procedure. Placement of two dental implants as mentioned above in sinus bone augmentation by sinus elevation procedure, blood clot and CopiOs Pericardium Membrane (Zimmer Dental- Carlsbad, CA, USA) only. One implant will be TMDI (Zimmer Dental- Carlsbad, CA, USA) and the second will be Tapered Screw-Vent TSV-MTX (Zimmer Dental- Carlsbad, CA,USA). Implant stability will be determined by the insertion torque and RFV values at time of implant placement and after 1 month of healing on a monthly basis up until 12 months post implant placement.
89581043|NCT02383355|Experimental|Switch group|Raltegravir 400mg tablets administered twice daily together with continuation of their own backbone therapy for 10 weeks
89581044|NCT02383355|Active Comparator|Continuation group|Individuals in the continuation group will continue the regimen, which consists of antiretroviral therapy as indicated in the inclusion criteria
89581045|NCT02381795|Experimental|Nasal Carbon Dioxide|0.17 liters (L) of carbon dioxide (CO2) will be delivered through two 10 second administrations in each nostril, up to 6 times, to treat one attack (total of 1.0 L CO2). Subjects may treat up to three cluster headache attacks during the treatment phase of this study (total of 3.0 L (CO2).
89581046|NCT02404493|Active Comparator|EpiCeram Skin Barrier Emulsion|Marketed. Apply in a thin layer to the affected skin areas two times per day (or as needed) and massage gently into the skin.
89581047|NCT02404493|Experimental|1% Colloidal Oatmeal Balm|Not Yet Marketed. Apply in a thin layer to the affected skin areas at least once at night or more if needed (anytime), and massage gently into the skin.
88974111|NCT05505747|Placebo Comparator|Placebo|Subjects assigned to the experimental group will take approximately 20 mg/kg/day of placebo (corn starch) for 2 consecutive days, followed by a 28-day washout period, and then another 2-day administration. Placebo treatment begins at 8 weeks after surgery.
88974112|NCT05499546|Experimental|Intervention arm|All patients within the study are included in the intervention arm: polyp detected within these patients will be measured according to the study protocol using four different methods.
88974113|NCT05476783|Experimental|TB006 4000 mg|TB006 4000 milligram (mg) via a 1-hour continuous intravenous (IV) infusion will be administered once every 28 day
88974114|NCT05434299|Experimental|Dose escalation|Single agent dose escalation
88974115|NCT05434299|Experimental|Dose expansion|Single agent dose expansion
88974116|NCT05426408|Other|Patients with MINOCA undergoing CMR|Patients will be their own controls
88974117|NCT05408247|Experimental|N-acetyl Cysteine|"Generic name: N-acetyl cysteine. Brand: ACC-600 (Acetylcysteine). Strength: 600mg per capsule. Form: capsule Route: oral Frequency: 2x capsules twice per day = total 4 capsules/day Duration: 12 weeks~+ Standard of Care: Medical Management."
88974118|NCT05408247|Placebo Comparator|Placebo|"Matched placebo~Generic name: dicalcium phosphate Strength: 600mg per capsule Form: capsule Route: oral Frequency: 2x capsules twice per day = total 4 capsules/day Duration: 12 weeks.~+ Standard of Care: Medical Management."
88974119|NCT05397015||postmenopausal women|A cohort of 200 postmenopausal women
88974120|NCT05392335|Active Comparator|myofascial stretch group|Patients will be given myofascial stretch
88974121|NCT05392335|Experimental|Functional massage along with myofascial stretch group|patients will be given functional massage along with myofascial stretching
88974122|NCT05390411|No Intervention|Control Sites|No Intervention
88974123|NCT05390411|Experimental|Sites Randomized to SOCIAL HF|SOCIAL HF is composed of evidence-based bias reduction training, employment of objective measures of social support, and changes to facilitate group dynamics.
88974124|NCT05385965|Experimental|Meaning-Centered Pain Coping Skills Training|Four, 45-60 minute, videoconference-delivered sessions focus on training participants in cognitive and behavioral skills (e.g., guided imagery, activity pacing) for managing pain.
88974125|NCT05385965|No Intervention|Standard Care|Information and referrals for free services available through the Duke Cancer Patient Support Program.
88974126|NCT05375942||characteristics of patients newly initiated on Inflectra|
88974127|NCT05375942||outcomes after initiating Inflectra|
89029962|NCT00514800|Experimental|Intervention|"Patients will be given a home blood pressure monitor and taught how to use it and how to respond to the readings using a standardised protocol and blood pressure targets. The study nurse will follow up patients at home after a month with additional telephone support according to a defined protocol. Patients will consult their own GP for medication changes when above target.~GPs will be sent information about the study design, current guidelines and interpretation of home blood pressure readings."
89029963|NCT00514800|Active Comparator|Control|
89029964|NCT02951637|Experimental|Group A|Patient will be administrated with Pemetrexed plus carboplatin combined with gefitinib
89029965|NCT02951637|Experimental|Group B|Patient will be administrated with gefitinib
89029966|NCT01245101|Experimental|Raltegravir and then Observation|The total duration of the study will be 40 weeks. This will include Part 1 (16 weeks) followed by Part 2 (8 weeks) followed by the crossover to Part 2 (16 weeks). During Part 1 participants in Group A will receive open-label raltegravir in addition to their established antiretroviral regimen while Group B participants will continue taking their established antiretroviral regimen for 16 weeks. After completion of Part 1, both groups will enter Part 2 that will consist of a washout period of 8 weeks during which both groups will only take their established antiretroviral regimen without raltegravir. This will be followed by Part 3 during which the two study groups will undergo a crossover with respect to the treatment assignment during Part 1 so that Group A will continue to receive their established antiretroviral regimen while Group B will receive open-label raltegravir in addition to their established antiretroviral regimen for 16 weeks.
89581048|NCT02380859|Active Comparator|Prism adaptation|Patients will undergo twice daily adaptation to upward shifts in vision. Participants will be provided with goggles fitted with prismatic lenses that shift vision upward by 25 dioptres (about 17 degrees). While wearing the lenses, participants point to two 10cm-diameter visual targets positioned one above the other (about 20cm apart) on a wall, returning their pointing arm to their chest between each pointing movement. Participants make 50 pointing movements, as fast and as accurately as possible. Such a procedure induces a downward sensorimotor adaptation of pointing movements. Participants undergo this training twice a day (morning and evening) for two weeks in a self-guided fashion.
89581049|NCT02380859|Sham Comparator|Sham adaptation|Participants undergo the same treatment protocol as described in the active comparator arm, with the exception that they wear goggles fitted with neutral lenses that do not induce sensorimotor adaptation.
89581050|NCT02380703|Experimental|Aggression Prevention Training (APT)|APT will use active learning tools, including didactics, role-playing, and multimedia (eg, books and DVDs) to educate and provide skill training for the caregiver. The 6-8 modules in the intervention will include 4 core modules that address 4 main aggression risk factors: a) recognizing pain, b) treating pain, c) increasing pleasant activities, and d) improving patient-caregiver communication. Caregivers can select 2 to 3 additional elective sessions; elective selection is guided by the needs of the dyad to further enhance skills related to these core topics. Sessions will take place in the patient's home.
89581051|NCT02380703|Placebo Comparator|Enhanced Usual Primary Care (EU-PC)|EU-PC provides the patient and caregiver educational materials on pain, notifies the primary care provider of the PWD's level of pain and depression, and provides 8 weekly supportive telephone calls to caregivers.
89581052|NCT02379923|Experimental|Crossing of Coronary Artery CTO|This is a single arm intent to treat study. A subject is considered enrolled when the subject has given informed consent and meets all inclusion and exclusion criteria, including angiographic inclusion and exclusion criteria, which includes an attempt to cross the target lesion with an investigational device (ASAHI PTCA Guidewire or ASAHI Corsair Microcatheter). Clinical evaluation up to hospital discharge is conducted on all enrolled subjects. The purpose of the clinical follow-up is to determine if the subject has experienced or is experiencing any adverse events
89581053|NCT04916171||Endometriosis and or Adenomyosis in Patients Diagnosed With Polycystic Ovary Syndrome|"The diagnosis of endometriosis will be made by the presence of ovarian endometrioma and/or a deep infiltrating endometriosis nodule determined by transvaginal ultrasonography or by palpation of the endometriotic nodule on pelvic examination or surgical confirmation.~The diagnosis of adenomyosis will be made by transvaginal ultrasonography or surgical confirmation."
89581054|NCT04916171||Polycystic Ovary Syndrome in Patients Diagnosed With Endometriosis and or Adenomyosis|For the diagnosis of polycystic ovary syndrome, Rotterdam Criteria will be used.
89581055|NCT02379221|Experimental|Injectable / Topical|Half of the face is injected with local anesthesia (lidocaine-epinephrine), the other half is treated with topical anesthesia (topicaine gel) per randomize method.
89581056|NCT02404103|Active Comparator|Flunisolide 160 mcg per day|Patients will receive inhaled Flunisolide HFA 80 mcg twice per day for a total of 160 mcg per day over the 6 week study period
89581057|NCT02404103|Active Comparator|Flunisolide 320 mcg per day|Patients will receive inhaled Flunisolide HFA 160 mcg twice per day for a total of 320 mcg per day over the 6 week study period
89033260|NCT02917044|Active Comparator|Group A - Standard Care|The operator will attempt to complete the WACA lesion set using standard techniques. These include ablating any obvious gaps in the lesion set, ablating at the WACA line in a location radial to the earliest PV signal measured by the Orion catheter situated within the PV, and guided by amplitude and dV/dt of signals along the WACA lesion set measured using the mapping catheter. If this fails the operator will resort to OSA as per their usual practice.
89209460|NCT00883974|No Intervention|2|Standard Neonatal Intensive Care Unit (NICU) procedures for the care of pre-term infants
89581058|NCT02404025|Experimental|Eltrombopag+rabbit ATG/CsA arm|Subjects received rabbit ATG diluted by 500 mL of saline or 5% glucose injection at a dose of 2.5 to 3.75 mg per kilogram (kg) per day for 5 days as a slow intravenous infusion over 6 hours. CsA was administered at a dose of 3 mg per kg twice a day from day 0. The dose level was adjusted based on the monitoring of blood level or renal function. Eltrombopag was initiated on day 14 and it could be delayed up to 2 weeks if the subject had infection, serum sickness, or other adverse events. Eltrombopag wasadministered orally once a day at fasting at an initial dose of 75 mg, and the dose adjusted every 2 weeks according to the platelet count. Eltrombopag and CsA were continued until Week 26.After Week 26, eligible subjects received eltrombopag; and CsA was tapered or maintained as per the investigator's discretion.
89581059|NCT02377817|Experimental|PrenaBelt on First Sleep Test Night|Participants will be randomized to treatment order: sham PrenaBelt on first night, then PrenaBelt on second night, or vice versa. This will avoid the potential impact of changes to sleep across the two nights resulting from familiarization with the polysomnography equipment, which could bias the results.
89581060|NCT02377817|Sham Comparator|Sham PrenaBelt on First Sleep Test Night|Participants will be randomized to treatment order: sham PrenaBelt on first night, then PrenaBelt on second night, or vice versa. This will avoid the potential impact of changes to sleep across the two nights resulting from familiarization with the polysomnography equipment, which could bias the results.
89581061|NCT02403635|Other|Midazolam + ASP2151|400 mg ASP2151 followed by 7.5 mg midazolam
89581062|NCT04907903|Experimental|RinasciMENTE|Participants will receive the internet-based intervention.
89581063|NCT04907903|No Intervention|Waiting-list|Participants will no receive the internet-based intervention.
89581064|NCT02402933|Experimental|Nasal Glucagon|A single dose of 3mg glucagon nasal powder administered using a nasal powder delivery device for the treatment of moderate or severe hypoglycemic events; a maximum of 4 events per participant during the study.
89581065|NCT05370365|Experimental|4 week cast|Patients over 65 years old with a distal radius fracture will be treated conservatively with a cast for 4 weeks. Once the immobilization will be removed, the standard rehabilitation protocol of our center used in these fractures will be carried out. The usual clinical and radiological follow-up will be performed at 3, 6 and 12 months.
89581066|NCT05370365|Experimental|6 week cast|Patients over 65 years old with a distal radius fracture will be treated conservatively with a cast for 6 weeks. Once the immobilization will be removed, the standard rehabilitation protocol of our center used in these fractures will be carried out. The usual clinical and radiological follow-up will be performed at 3, 6 and 12 months.
89581067|NCT01796470|Experimental|Entospletinib + idelalisib|"Entospletinib plus idelalisib at one of 4 dose combinations (400 mg/100 mg; 600 mg/100 mg; 800 mg/100 mg; 800 mg/150 mg).~After discontinuation of entospletinib+idelalisib combination therapy, and following a washout period, participants may continue to receive entospletinib 400 mg monotherapy."
89581068|NCT05102890|Experimental|Intervention group|Patients 65 years old and older will receive a pre-consultation screening questionnaire by phone prior to their virtual or in-person visit. A summary report based on the results of the questionnaire will be placed in the patient electronic chart for use by the clinician at the time of visit.
88974128|NCT05367817|Experimental|Exercise therapy|The program consists of two parts. The first part of the program contains unloaded active ROM exercises for the wrist in flexion/extension, radial-/ulnardeviation and pronation/supination. The second part of the program consists of three neuromuscular exercises that focus on coordination, wrist stability and strength. The participants will perform the program twice a day for 12 weeks.
88974129|NCT05367817|Active Comparator|Training program|The training program for the control group will consist of ROM exercises only that will be also be performed twice a day for 12 weeks.
88974130|NCT05364697|Experimental|IoNIR Ridaforolimus-Eluting Coronary Stent|IoNIR Ridaforolimus-Eluting Coronary Stent System
88974131|NCT05360485|Active Comparator|Fitbit-Only Self-Monitoring|Control participants will be sent a Fitbit and study-provided account and will self-monitor physical activity for the duration of the study period (2 months).
88974132|NCT05360485|Experimental|MOV'D plus Fitbit Self-Monitoring|Treatment participants will be sent a Fitbit and study-provided account, and assigned to a private, study-created Twitter support group of 10 participants. Within the private group of 10, each participant is also further paired with a peer to be that person's peer coach, setting weekly exercise snack goals and practicing behavior change techniques.
88974133|NCT05360303||Trial population|No Intervention but evaluation of the electroneuromyography at the M1 visit for patients with a clinical diagnostic of thoracic outlet syndrome.
88974134|NCT05340738|Active Comparator|LyssnCBT|Therapists will use the LyssnCBT tool with clients for recording and session-sharing functionalities. Therapists and supervisors will also have access to LyssnCBT features like speech-to-text transcription, annotation tools, and AI-generated metrics.
88974135|NCT05340738|No Intervention|SAU (services-as-usual)|Therapists will use the LyssnCBT tool with clients for recording and session-sharing functionalities. No other LyssnCBT features will be available for therapist or supervisor review.
88974136|NCT05338944|Experimental|DBT + lifestyle|Participants will receive 90 minutes of dialectical behavioral therapy and 60 minutes of lifestyle sessions each week for 16 weeks.
88974137|NCT05338944|Experimental|Lifestyle alone|Participants will receive 2 lifestyle sessions per week, one 90 minutes in length and the other 60 minutes for 16 weeks.
88974138|NCT05338944|No Intervention|Control|Participants will be included in baseline, endpoint and follow up measurements, but will receive no form of intervention.
88974139|NCT05317221||All patients|The is only 1 arm: all breast cancer patients undergoing surgery.
88974140|NCT05290805|Experimental|ECMO flow rate reduction|In the intervention cohort ECMO flow rate is reduced for the duration of CT image acquisition (max. 1-2 min.), if the hemodynamic and respiratory situation allows it. Feasibility is determined by the accompanying emergency physician right before the CT scan and adapted to the individually tolerable level (max. 50% of initial flow, no less than 1,5 litre/min). After image acquisition, ECMO flow rate is immediately returned to the initial or clinically optimal value at this moment.
88974141|NCT05290805|No Intervention|no ECMO flow rate reduction|In this cohort ECMO flow rate is not reduced for CT image acquisition.
88974142|NCT05289947|Placebo Comparator|Placebo|500-mg placebo capsule, 4 capsules twice a day for 24 weeks
89581069|NCT05102890|No Intervention|Control Group|Usual care in the primary care clinic
89581070|NCT01868074|No Intervention|Usual|Participants who are not randomized to the fitted insole intervention
89581071|NCT01868074|Experimental|Insole|Participants randomized to use of a custom-molded insole during pregnancy
89581072|NCT04414852|Experimental|mild renal impairment|
89581073|NCT04414852|Experimental|moderate remal impairment|
89581074|NCT04414852|Active Comparator|normal renal impairment|
89581075|NCT04171024|Sham Comparator|Sham Group|"Two channels with two electrodes each were placed above and below the right and left sides of the xiphoid process within the seventh and eighth anterior intercostal space. In addition, two channels with two electrodes each were placed on the right and left midaxillary line of the seventh and eighth anterior intercostal space.~Transcutaneous electrical stimulation settings: Frequency (2 hertz); wave length (300 µs);"
88974143|NCT05289947|Active Comparator|MLC1501 Low-dose|MLC1501 low-dose 500-mg capsule, 4 capsules twice a day for 24 weeks
89209461|NCT00889590|Experimental|Zoledronic acid|Adjuvant zoledronic acid
89209462|NCT00889590|No Intervention|Control|Standard care
89581076|NCT04171024|Experimental|Transcutaneous diaphragm electrical stimulation group|"Two channels with two electrodes each were placed above and below the right and left sides of the xiphoid process within the seventh and eighth anterior intercostal space. In addition, two channels with two electrodes each were placed on the right and left midaxillary line of the seventh and eighth anterior intercostal space.~Transcutaneous electrical stimulation settings: Frequency (35 hertz); wave length (300 µs); Intensity to achieve a visual contraction"
89581077|NCT01810042|Experimental|ranibizumab|0.5mg of ranibizumab is injected into the vitreous cavity monthly 3 times for the 3 months then pro-re-nata (PRN) for following 3 months.
88811249|NCT03496571|Experimental|3 mg/kg of AK002|Subjects in this arm will receive 4 monthly doses of AK002: a first dose of 0.3 mg/kg, a second dose of 1 mg/kg, a third dose of 3 mg/kg, and a fourth dose of 3 mg/kg
88811250|NCT03461354|Experimental|A|Mucolox Arm
88811251|NCT03461354|Active Comparator|B|Sodium Bicarb Control Arm
88811252|NCT03434509|Experimental|Tai Chi|Ongoing, continuous Tai Chi and mindful movement instruction, 1 hour, twice per week
88811253|NCT03396601|Experimental|NRX-100 infusion|Infusion of IV NRX-100 (ketamine)
88811254|NCT03396601|Experimental|Saline (placebo) infusion|Infusion of IV Saline
88811255|NCT03388619|Experimental|1/Prostate bed with integrated boost|Dose to prostate bed with integrated boost
88811256|NCT03388619|Experimental|2/Prostate bed irradiation only|Dose to prostate bed irradiation only
88811257|NCT03323463|Experimental|Arm A: HPV associated oropharyngeal carcinoma|HPV associated oropharyngeal carcinoma subjects who also have no evidence of hypoxia. This arm is closed to accrual.
88811258|NCT03323463|Experimental|Arm B: HPV associated oropharyngeal carcinoma|HPV associated oropharyngeal carcinoma subjects who also have no evidence of hypoxia.
88811259|NCT03321552|Experimental|Percutaneous deep vein arterialization|Creation of an arterio-venous fistula in the below-the-knee vasculature using the LimFlow System endovascular, minimally invasive approach
88811260|NCT03320902|Active Comparator|Sudden death counselling|The emergency physician of the prehospital EMS who intervenes at the scene will systematically give the family member allocated to the intervention the option to attend a sudden death counselling during the first month after the event.
88811261|NCT03320902|No Intervention|Usual practice|The physician will act as usual. The relatives will not systematically benefit from this option.
88811262|NCT03247660|Experimental|PFMT&HE group|A directly pelvic floor muscle (PFM) training protocol will be applied. Participants will performed PFM exercises in the way proposed by the PERFECT scheme. Biofeedback exercises will be also performed in lithotomy position. If the evolution of the women will allow it, the last two treatment biofeedback sessions will be conducted in standing position, to train PFM in more challenging and functional situation. In this group participants will be also trained hypopressive breathing and will perform five hypopressive exercises: two postures in supine, one on four-kneeling, and two in standing position. Educational strategy will also be applied. The intervention will last 8 weeks, 2 sessions per week. Each session will last 40/50 minutes.
88811263|NCT03247660|Experimental|HE group|"Women will be instructed in thirty-three Hypopressives exercises (HE) described by the developer of the Hypopressive Abdominal Gymnastics, Dr. Caufriez plus Educational strategy.~The intervention will last 8 weeks, 2 sessions per week. Each session will last 40/50 minutes."
88811264|NCT03247660|Active Comparator|Control group|The educational strategy will consist of instruction of printed materials and dimensional anatomical models about the anatomy of the pelvic floor and the physiology of the pelvic organs. It will be recommended to avoid risk factors, such as gaining weight, weight lifting, high impact sports, constipation, smoking, or drinking too much caffeine. They will also instruct in toilet habits, and will be taught to use the knack maneuver before and during increases of intra-abdominal pressure. The intervention will last 8 weeks, 1 session per week. Each session will last 40/50 minutes.
88811265|NCT03182335||Mechanical Ventilation (MV) with vasoactive infusions|adult ICU patients who are mechanically ventilated with sedative infusion and/or analgesic infusion and also requiring vasoactive drug infusions for the treatment of shock. Patients will be excluded if receiving dexmedetomidine as sedative.
88811266|NCT03175302||Surgical group|Baseline preoperative digital cognitive testing performance in adults to predict frequency and severity of clinician reported outcomes within the first three months post-surgery.
88811267|NCT03175302||Control|Non-surgery matched peers with the same testing.
88811268|NCT03172468||Survivors|Patients suffering from out-of-hospital cardiac arrest (OHCA), who achieve sustained return of spontaneous circulation (ROSC) following prehospital cardiopulmonary resuscitation.
88811269|NCT03172468||Non-Survivors|Patients suffering from out-of-hospital cardiac arrest (OHCA), who are declared dead after prehospital cardiopulmonary resuscitation.
88811270|NCT03170375|Experimental|Motivational Interviewing + WHEELS-I|In addition to motivational interviewing-based counseling with a registered dietitian to promote adoption of the sodium-restricted Dietary Approaches to Stop Hypertension (DASH/SRD) eating plan., participants in this arm will also receive an electronically-delivered tailored messaging intervention called Women's and Men's Hypertension Experiences and Emerging Lifestyle Intervention (WHEELS-I).
89581078|NCT02424539|Experimental|FFNS 55 mcg Arm|Each subject will be dispensed with two nasal spray device labelled as Device A and Device B containing either FF or Placebo. Subject's on their own or with assistance from parent/guardian will administer FFNS 55 mcg per day, one intranasal spray from Device A, once daily into each nostril (27.5 mcg per spray) and another spray of placebo nasal spray from Device B, once daily into each nostril, in the morning for 4 Weeks.
89581079|NCT02424539|Experimental|FFNS 110 mcg Arm|Each subject will be dispensed with two nasal spray device labelled as Device A and Device B containing FF or Placebo. Subject's on their own or with assistance from parent/guardian will administer FFNS 110 mcg per day, one intranasal spray from Device A, once daily into each nostril (27.5 mcg per spray) and another spray of placebo nasal spray from Device B, once daily into each nostril, in the morning for 4 Weeks.
89581080|NCT02424539|Placebo Comparator|Placebo Arm|Each subject will be dispensed with two nasal spray device labelled as Device A and Device B containing only placebo. Subject's on their own or with assistance from parent/guardian will administer one intranasal spray of placebo, from Device A and Device B, once daily into each nostril in the morning for 4 Weeks.
89581081|NCT01809262|Experimental|olodaterol 2 mcg|solution for inhalation
89581082|NCT01809262|Experimental|olodaterol 5 mcg|solution for inhalation
89581083|NCT01809262|Experimental|olodaterol 10 mcg|solution for inhalation
89581084|NCT01809262|Experimental|olodaterol 20 mcg|solution for inhalation
89581085|NCT01809262|Experimental|olodaterol 40 mcg|solution for inhalation
89581086|NCT01809262|Placebo Comparator|placebo|solution for inhalation
89581087|NCT04915703|Experimental|Intervention|flushing of internal external PTBD catheter 3 times a day
89581088|NCT04915703|No Intervention|Standard of Care|no flushing of PTBD catheter
89581089|NCT01808248|Experimental|SOF+PEG+RBV|Participants will receive SOF+PEG+RBV for 12 weeks.
89581090|NCT02424383|Experimental|PTA (Lutonix® 035 DCB Catheter)|Treatment with the Lutonix 035 DCB will be per the investigational site's standard of care and adhering to the IFU.
89581091|NCT01867294|Experimental|Arm I (Study I)|Patients apply spironolactone topically to face BID for 4 weeks.
89581092|NCT01867294|Experimental|Arm I (Study II)|Patients apply spironolactone topically to face and body BID for 4 weeks.
89581093|NCT01867294|Placebo Comparator|Arm II (Study I)|Patients apply placebo topically to face BID for 4 weeks.
89581094|NCT01867294|Active Comparator|Arm II (Study II)|Patients receive modified preemptive therapy regimen consisting of skin moisturizer topically BID, sunscreen topically as needed, hydrocortisone topically QD, and doxycycline PO BID for 4 weeks.
89581095|NCT02424149|No Intervention|Control|No preoperative phenazopyridine
89581096|NCT02424149|Experimental|Phenazopyridine|Preoperative phenazopyridine
89581097|NCT02423291|Experimental|Vial for IV infusion|This is a single-arm, open-label, multicenter, Phase 2 clinical trial to evaluate the efficacy and safety of Brentuximab vedotin as a single agent in patients with relapsed or refractory PMLBCL who have previously received a first line of treatment with chemotherapy or immunotherapy.20 patients will be treated in this study and All patients will receive 1.8 mg/kg Brentuximab vedotin administered as a single outpatient IV infusion on Day 1 of each 21-day treatment cycle. Patients may continue on study treatment until disease progression or unacceptable toxicity. Patients who achieve stable disease or better as assessed by investigator should receive a minimum of 8, but no more than 16 cycles of study treatment.
89581098|NCT02401529|Experimental|IV dexamethasone and oral Prednisolone|Single dose of intravenous dexamethasone given immediately following surgery (0.15 mg/kg), followed by oral Prednisolone (0.25mg/kg/day for 7 days then tapering for next 7 days) and paracetamol (acetaminophen 15 mg/kg/dose every 6 hours).
89581099|NCT02401529|Active Comparator|Placebo|Placebo (IV saline) and paracetamol (acetaminophen 15 mg/kg/dose every 6 hours).
89033261|NCT02917044|Experimental|Group B - Rhythmia mapping|The operator will form Rhythmia maps focussing on the region of the WACA line surrounding the non-isolated vein(s) whilst pacing from CS. This will be used as a means of targeting RF ablation to gaps in the WACA line (in addition to use of standard observation of signals as per group A). If this fails then the operator will resort to OSA as per their usual practice.
89581100|NCT01867216|Placebo Comparator|Placebo|Multiple oral dose of placebo administered to participants with diabetes once or twice daily for 28 days
89581101|NCT01867216|Experimental|LY2922470|Multiple ascending dose of LY292470 (starting at 60 mg) administered orally to participants with diabetes once or twice daily for 28 days
89581102|NCT01866826|Experimental|HIV Infected Subjects|Human immunodeficiency virus (HIV) infected subjects with viral suppression on antiretroviral (ART). Double-blinded/placebo controlled trial with cross-over design. Rifaximin
89581103|NCT01866826|Placebo Comparator|HIV Infected Subjects Placebo|HIV infected subjects with viral suppression on ART. Double-blinded/placebo controlled trial with cross-over design. Placebo
89581104|NCT04579276|Experimental|"surgical method"|
89581105|NCT04579276|Active Comparator|"anesthetic method"|
89581106|NCT04584970|Experimental|Virtual reality device|Participants will be offered a virtual reality (VR) device for up to 30 minutes for two separate sessions on postoperative day 1. The device will be pre-loaded with a variety of vetted and screened age-appropriate games.
89581107|NCT04584970|Active Comparator|iPad device|Participants will be offered an iPad device for up to 30 minutes for two separate sessions on postoperative day 1. The device will be pre-loaded with a variety of vetted and screened age-appropriate games.
89581108|NCT01791244|Active Comparator|Technical support for the RebiSmart™ device|Subjects will be administered Rebif® by the RebiSmart™ device at a dose of either 22 or 44 microgram (mcg) subcutaneously (SC) 3 times a week in accordance to the summary of product characteristics (SPC) along with technical support for RebiSmart.
89581109|NCT01791244|Experimental|Subject support program (MinSupport Plus)|Subjects will be administered Rebif® by the RebiSmart™ device at a dose of either 22 or 44 mcg SC 3 times a week in accordance to the SPC along with subject support program MinSupport Plus which includes technical support for RebiSmart™ device, personal coaching regarding treatment and understanding of the disease, lifestyle guide and web support.
89581110|NCT01865812|Experimental|OCA: 10 mg|Obeticholic acid, oral administration, 10 milligrams (mg), 8 weeks
89581111|NCT01808092|Experimental|CAZ-AVI|Intra-Venous treatment
89581112|NCT01808092|Active Comparator|Meropenem|Intra-Venous treatment
89581113|NCT04584814|Experimental|Babies born Preterm|Preterm babies, healthy at the time of the study, free of neonatal diseases and/or sequelae or malformations or genetic diseases. They were random assigned to two-hours blocks of basal, and dorsal stimulation protocol at 20 or 40 times per minute, each.
88974144|NCT05289947|Active Comparator|MLC1501 High-dose|MLC1501 high-dose 500-mg capsule, 4 capsules twice a day for 24 weeks
89581114|NCT01774084|Active Comparator|PreOp, NutriciaNordica AB|PreOp: 50 kcal/100 mL in the form of maltodextrin and fructose. One bottle of 800 ml to be ingested at bedtime, and at midnight by the latest, and another bottle with 400 ml approximately 2 hours before surgery started.
89581115|NCT01774084|Placebo Comparator|Water|Water: One bottle of 800 ml to be ingested at bedtime, and at midnight by the latest, and another bottle with 400 ml approximately 2 hours before surgery started.
88974145|NCT05280730||Boys with DMD|Boys ages 3 and above will be enrolled.
88974146|NCT05280730||Healthy boys|Healthy boys as a control group for brain imaging.
88974147|NCT05264701|Experimental|Physiotherapist Supervised Exercise Training Group|Physiotherapist supervised exercise training in patients with coronary artery disease
88974148|NCT05264701|Experimental|Exercise Training Tracking from Phone-app Group|Exercise training tracking from phone app in patients with coronary artery disease
88974149|NCT05264701|Experimental|Control Group|General physical activity recommendations for home
88974150|NCT05243615|Experimental|Stroke internet delivered cognitive behavioural therapy|A 10-week internet-delivered cognitive behavioural therapy (ICBT) will be delivered to participants who have sustained a stroke. In addition to the online program, a Guide with experience delivering ICBT will provide support by email or phone call once a week. The Guide will spend approximately 15 minutes per week/per client.
88974151|NCT05243615|Active Comparator|Stroke Rehabilitation Education|A 10-week stroke-specific rehabilitation education program for stroke patients in usual care at specialized stroke rehabilitation units. The lessons will include information on spinal cord injury rehabilitation: 1)stroke basics, 2)mental health after stroke, 3)pain after stroke, 4)understanding rehabilitation 5)summary of lessons through an online platform. A Guide will check in with participants once a week to answer any content-related questions. The Guide will spend approximately 15 minutes per week/per client.
88974152|NCT05240664|Experimental|ACP intervention|It is a theory-driven ACP programme specifically designed for PWEDs and their family caregivers. The intervention is underpinned by the Bandura's self-efficacy model.
88974153|NCT05240664|Placebo Comparator|Attention-control health talks|Dyads of participants in the control group will receive health talks. This is to differentiate the effect of the intervention from the effect of the extra time and attention given to the participants.
88974154|NCT05235828|Experimental|Active intervention (ACT) group|8-12 participants will meet for 3-hour sessions for the first 5 days of the intervention. This is followed by five weeks of 1-hour sessions twice per week. In total, the intervention will be 15 sessions that run for a total of 25 hours over 6-weeks. Experienced and licensed SKY instructors from the International Association for Human Values (IAHV) and Art of Living Foundation (AOLF) will provide the intervention through video calls. Instructors will guide participants through the v-SKY intervention through visual demonstrations and verbal guidance. All sessions will be delivered virtually using Zoom. Sessions will not be recorded.
88974155|NCT05235828|No Intervention|Waitlist control (WLC) group|8-12 participants will not receive the intervention for 6-weeks. The 6-weeks will line up with the v-SKY intervention that the ACT group receives. After the waitlist period, the WLC group will receive the same v-SKY intervention as the ACT group. According to our earlier estimates, a high number of veterans with PTSD may not be actively receiving treatment for their illness. For these reasons, a waitlist control design may better reflect the current treatment environment for veterans with PTSD.
88974156|NCT05217940|Experimental|Women With Prior HPV for Anal Neoplasia|Standard of care anal cancer screening with anal cytology, HPV testing and high resolution anoscopy.
88974157|NCT05212480|Active Comparator|Zinc arm|patients received a pill containing 25 mg of zinc twice a day for 15 days
88974158|NCT05212480|Placebo Comparator|Placebo|patients received identical shape, smell, taste and color pill like the protocol treatment twice a day for 15 days
88974159|NCT05209308|Experimental|Cohort A|"Ven low dose + Rituximab + Zandelisib"
88974160|NCT05209308|Experimental|Cohort B|"Ven standard dose + Rituximab + Zandelisib"
88974161|NCT05208528|Experimental|ES1 group|Participants treated with Bifidobacterium longum ES1 for 2 months.
88974162|NCT05208528|Experimental|HT-ES1 group|Participants treated with heat treated version of ES1 for 2 months.
88974163|NCT05208528|Placebo Comparator|Control group|Participants treated with maltodextrin for 2 months.
88974164|NCT05198492||Patients with hospitalizations or emergency room visits due to acute coronary syndromes|Data on hospitalization for acute coronary syndromes were obtained and extracted from the National Health Fund reports. In the present analysis, we used data from patients registered as residents in the Podlaskie, Lubelskie, Podkarpackie, Świetokrzyskie, and Warminsko-Mazurskie voivodeships from January 1, 2011 to December 31, 2020. The set of variables that were subjected to the analysis included demographic features and ICD-10 codes. The diagnosis was based on reports obtained from to the National Health Fund, and these reports have not been reviewed with patient hospital documentation.
89033262|NCT02942693|Experimental|Apatinib with Particle Therapy|Participants will receive apatinib (0.5g, daily) for 6 weekly followed by particle radiotherapy (proton: 56 GyE/28 Fx, plus carbon: 15 GyE/5 Fx for boost).
89209463|NCT00736853|Experimental|Tramadol Hydrochloride Plus Acetaminophen (Open-Label)|
89581116|NCT01807234|Experimental|Ketorolac/Placebo|Ketorolac 31.5 mg single dose nasal spray and Placebo
89581117|NCT01807234|Experimental|Sumatriptan/Placebo|Sumatriptan 20 mg single dose nasal spray and placebo
89581118|NCT01807234|Placebo Comparator|Ketorolac Placebo/Sumatriptan placebo|single dose Ketorolac placebo, single dose Sumatriptan placebo
89581119|NCT01790932|Experimental|BKM120|"BKM120: 100 mg capsule once daily each day of a 28 day cycle .~Treatment with BKM120 will continue until disease progression, unacceptable toxicity or withdrawal for other reasons."
89581120|NCT02377427|Experimental|Mepolizumab 40 mg in Part A and B|Participants with bodyweight < 40 kg will receive 0.4 milliliter (mL) of reconstituted mepolizumab subcutaneously, in upper arm or thigh.
89581121|NCT02377427|Experimental|Mepolizumab 100 mg in Part A and B|Participants with bodyweight >= 40 kg will receive 1.0 mL of reconstituted mepolizumab subcutaneously, in upper arm or thigh.
89581122|NCT02421887|Active Comparator|Antioxidant Supplement|Tablet: Vitamin C, 500 mg; Vitamin D3, 1000 IU; Vitamin E, 400 IU; Folic Acid 1000 mcg; Zinc, 20 mg; Selenium 200 mcg; Lycopene, 10 mg; Capsule: Vitamin D3, 1000 IU, L-Carnitine, 1000 mg
89581123|NCT02421887|Placebo Comparator|Placebo|
89581124|NCT01609582|Experimental|TAK-875 50 mg|TAK-875 50 mg tablets, orally, once daily for up to 6 years.
89581125|NCT01609582|Placebo Comparator|Placebo|TAK-875 placebo-matching tablets, orally, once daily for up to 6 years.
89581126|NCT01789606|Experimental|Ibuprofen 600 mg Immediate Release/Extended Release Caplet|
89581127|NCT01788358|Experimental|Nifedipine GITS/Candesartan Cilexetil FDC (BAY98-7106)|Subjects received nifedipine gastrointestinal therapeutic system (GITS) / candesartan cilexetil fixed dose combination (FDC) (BAY98-7106) tablet orally, once daily in the morning of Visit 1 (Week 0) for 28 or 52 weeks. The starting dose (30/8 milligram [mg] or 30/16 mg) was determined based on local practice and clinical judgment by the investigator. Based on the experience of symptomatic and asymptomatic hypotension, peripheral edema or significant tolerability, the doses were up-titrated to the highest target dose (60/32 mg).
89581128|NCT01773226|Experimental|"Autologous Protein Solution APS(TM)"|Patients who have been treated with a single, intra-articular injection.
89581129|NCT01773070|Other|All Participants|Participants who received ABT-450, ABT-333 or ABT-267 at any dose level in an eligible prior AbbVie Phase 2 or 3 study for the treatment of chronic HCV, followed for up to 3 years post-treatment.
89581130|NCT01772368|Experimental|FS MDPI 100/6.25 mcg|Subjects inhaled a single dose of 100 mcg fluticasone propionate and 6.25 mcg salmeterol xinafoate.
88974165|NCT05198492||Patients with hospitalizations or emergency room visits due to atrial fibrillation|Data on hospitalization for atrial fibrillation were obtained and extracted from the National Health Fund reports. In the present analysis, we used data from patients registered as residents in the Podlaskie, Lubelskie, Podkarpackie, Świetokrzyskie, and Warminsko-Mazurskie voivodeships from January 1, 2011 to December 31, 2020. The set of variables that were subjected to the analysis included demographic features and ICD-10 codes. The diagnosis was based on reports obtained from to the National Health Fund, and these reports have not been reviewed with patient hospital documentation.
88974166|NCT05198492||Patients with hospitalizations or emergency room visits due to kidney diseases|Data on hospitalization for kidney diseases were obtained and extracted from the National Health Fund reports. In the present analysis, we used data from patients registered as residents in the Podlaskie, Lubelskie, Podkarpackie, Świetokrzyskie, and Warminsko-Mazurskie voivodeships from January 1, 2011 to December 31, 2020. The set of variables that were subjected to the analysis included demographic features and ICD-10 codes. The diagnosis was based on reports obtained from to the National Health Fund, and these reports have not been reviewed with patient hospital documentation.
88974167|NCT05198492||Patients who died due to cardiovascular diseases|Data on mortality were collected from the National Statistical Office in Poland. These include information on all the deaths recorded in the Podlaskie, Lubelskie, Podkarpackie, Świetokrzyskie, and Warminsko-Mazurskie voivodeships from January 1, 2011 to December 31, 2020 The records included sex and age of people who had died, and the causes of deaths were classified according to codes in the International Classification of Diseases-10th Revision (ICD-10).
88974168|NCT05198492||Patients who died due to neoplasm diseases|Data on mortality were collected from the National Statistical Office in Poland. These include information on all the deaths recorded in the Podlaskie, Lubelskie, Podkarpackie, Świetokrzyskie, and Warminsko-Mazurskie voivodeships from January 1, 2011 to December 31, 2020 The records included sex and age of people who had died, and the causes of deaths were classified according to codes in the International Classification of Diseases-10th Revision (ICD-10).
88974169|NCT05198492||Patients who died due to kidney diseases|Data on mortality were collected from the National Statistical Office in Poland. These include information on all the deaths recorded in the Podlaskie, Lubelskie, Podkarpackie, Świetokrzyskie, and Warminsko-Mazurskie voivodeships from January 1, 2011 to December 31, 2020 The records included sex and age of people who had died, and the causes of deaths were classified according to codes in the International Classification of Diseases-10th Revision (ICD-10).
89033263|NCT02942693|Experimental|Particle Therapy|Participants will receive particle radiotherapy alone (proton: 56 GyE/28 Fx, plus carbon: 15 GyE/5 Fx for boost).
89033264|NCT02916888||Care provided by general pediatrician|Standard of care management of atopic dermatitis by general pediatrician. This includes an initial visit with a 2-week follow-up.
89581131|NCT01772368|Experimental|FS MDPI 100/12.5mcg|Subjects inhaled a single dose of 100 mcg fluticasone propionate and 12.5 mcg salmeterol xinafoate.
89581132|NCT01772368|Experimental|FS MDPI 100/25|Subjects inhaled a single dose of 100 mcg fluticasone propionate and 25 mcg salmeterol xinafoate.
89581133|NCT01772368|Experimental|FS MDPI 100/50|Subjects inhaled a single dose of 100 mcg fluticasone propionate and 50 mcg salmeterol xinafoate.
89581134|NCT01772368|Active Comparator|Fp MDPI 100 mcg|Subjects inhaled a single dose of 100 mcg fluticasone propionate.
89581135|NCT01772368|Active Comparator|Advair Diskus 100/50 mcg|Subjects inhaled a single dose of 100 mcg fluticasone propionate and 50 mcg salmeterol xinafoate. This arm is the only arm which is open-label because the inhaler device was different than the MDPI used in the other treatment arms.
89581136|NCT01788046|Placebo Comparator|Placebo|Participants received placebo administered by intravenous bolus injection at the end of each hemodialysis session, three times per week (TIW) for 26 weeks.
89581137|NCT01788046|Experimental|Etelcalcetide|Participants received etelcalcetide administered by intravenous bolus injection at the end of each hemodialysis session TIW for 26 weeks.
89581138|NCT01806298|Experimental|Saizen®|
89581139|NCT01772134|Experimental|Umeclidinium bromide 62.5 + Fluticasone propionate/Salmeterol|Long-acting muscarinic antagonist (LAMA), 62.5mcg plus Inhaled corticosteriod (ICS), 250mcg/ Long acting Beta agonist (LABA), 50mcg
89581140|NCT01772134|Active Comparator|Umeclidinium bromide 125 + Fluticasone propionate/Salmeterol|Long-acting muscarinic antagonist (LAMA), 125mcg plus Inhaled corticosteriod (ICS), 250mcg/ Long acting Beta agonist (LABA), 50mcg
89581141|NCT01772134|Placebo Comparator|Placebo + Fluticasone propionate/Salmeterol|Inhaled corticosteriod (ICS), 250mcg/ Long acting Beta agonist (LABA), 50mcg
89581142|NCT01994889|Experimental|Tafamidis - 20 mg|Active Treatment-Low dose
89581143|NCT01994889|Experimental|Tafamidis - 80 mg|Active Treatment-High Dose
88974170|NCT05171192|Experimental|CMAP Plus LTP added to TAU|"C-MAP is a manual assisted intervention based on the principles of CBT which is focused on evaluation of the self-harm attempt, crisis skills, problem solving and basic cognitive techniques to manage emotions, negative thinking, and relapse prevention strategies. As family conflicts are a common issue with this group one session is focused on the use of culturally sensitive training in assertiveness and conflict management. The LTP is a community-based parenting intervention designed to deal with early child development. The central feature of the LTP intervention is a pictorial calendar devised for parents which depicts eight successive stages of child development from birth to 3 years along with illustrations of parent-child play and other activities that promote parental involvement, learning, and attachment.~This will be added to Treatment as Usual"
88974171|NCT05171192|No Intervention|TAU alone|TAU alone will include routine follow up by Community Health Workers (CHWs) in Pakistan. Their work includes assisting with all aspects of maternal, new-born and childcare. Participants in treatment as usual arm will receive routine care.
88974172|NCT05170035|Experimental|MMS + Autologous patch|Mohs micrographic surgery + Autologus patch formed from 18 ml venous blood sample collected from the patient + polymycin-terramycin B ointment and a Jelonet applied on top of the patch.
88974173|NCT05170035|Active Comparator|MMS + Secondary intention healing|Mohs micropgraphic surgery + Polymycin-terramycin B ointment + dry wound dressing
88974174|NCT05157854||SH residents|Participants in the AiMH intervention
88974175|NCT05157854||SH staff|Staff in the SH, acting as AiMH supporters
88974176|NCT05157048|Experimental|Marketing condition A|Participants will be randomized to a marketing condition.
88974177|NCT05157048|Experimental|Marketing condition B|Participants will be randomized to a marketing condition.
88974178|NCT05156242|Experimental|Active-tDCS priming MCE|The subjects in active-tDCS priming with MCE group will receive the tDCS using 5X7 cm electrodes in which anodal electrode will be placed on M1 representing the back muscles (1 cm anterior and 4 cm lateral to the vertex), while cathodal electrode will be placed on contralateral supraorbital area. The intensity will be set at 2 mA with 10-second fade in/out. The subject will be stimulated by tDCS for 20 minutes. After that, the subjects will receive 20-minute MCE.
88974179|NCT05156242|Sham Comparator|Sham-tDCCS priming MCE|The subjects in sham-tDCS priming with MCE group will receive a 20-minute sham tDCS by setting the intensity at zero mA. After that, the subjects will receive 20-minute MCE.
88974180|NCT05156242|Active Comparator|NMES priming MCE|The subjects in NMES priming with MCE group will receive the NMES using interferential mode (6000 Hz, beat frequency 20-50 Hz, scanning effect) on bilateral LM. The intensity will be set at the subject's maximum tolerance. Stimulation will be set at 10 seconds on and 60 seconds off to minimize muscle fatigue. The total NMES time is 20 minutes. After that, the subjects will receive 20-minute MCE.
88974181|NCT05156242|Active Comparator|Conventional physical therapy|The subjects in conventional physical therapy group will receive physical therapy modality (e.g., ultrasound, TENS, etc.) and general exercises.
88974182|NCT05153707|Experimental|Clinical Pharmacist-led discharge education program|Clinical pharmacist-led services
88974183|NCT05153707|No Intervention|Control group|Usual care
88974184|NCT05134948|Experimental|Cohort A: BMS-986213 Fixed Dose Combination|
88974185|NCT05134948|Experimental|Cohort B: BMS-986213 Fixed Dose Combination|
88974186|NCT05133271|Experimental|Scheduled cesarean section|Patient with scheduled cesarean section under spinal anesthesia.
89209464|NCT00736853|Experimental|Tramadol Hydrochloride Plus Acetaminophen (Double Blind)|
89209465|NCT00736853|Placebo Comparator|Placebo (Double-Blind)|
89581144|NCT01994889|Placebo Comparator|Placebo|Placebo control
89581145|NCT02082483|Experimental|Selective Screening|Patients randomized to selective-use of screening tests will not routinely undergo Myocardial Perfusion Scintography or Dobutamine Stress Echocardiography. If patients develop symptoms of CAD at any time, they will undergo investigations as per the usual standard of care.
89581146|NCT02082483|No Intervention|Regular Screening|Patients randomized to regular screening will be tested as per the current standard described in guidelines published by the National Kidney Foundation (e.g. annually while wait-listed for transplantation). If patients develop symptoms of CAD at any time, they will undergo investigations as per the usual standard of care.
89581147|NCT02017899|Experimental|S. sonnei 1790GAHB - 1 mcg|Subjects enrolled in COHORT A receiving 3 injections of S. sonnei 1790GAHB - 1 mcg
89581148|NCT02017899|Experimental|S. sonnei 1790GAHB - 5 mcg|Subjects enrolled in COHORT B receiving 3 injections of S. sonnei 1790GAHB - 5 mcg
88974187|NCT05119985|Active Comparator|Ultrasound guided cannulation|Ultrasound guided insertion of peripheral vein cannula.
88974188|NCT05119985|Active Comparator|Cannulation without ultrasound|Catheter insertion by conventional approach, without ultrasound guidance
88974189|NCT05112848|Experimental|Group 1 PLWH|"Two doses of 5μg monovalent prototype vaccine+50µg Matrix-M adjuvant, given on Day 0 and Day 21.~Alternating IM (deltoid) injection of placebo (0.5mL) given on Day 70."
88974190|NCT05112848|Experimental|Group 2 PLWH|Three doses of 5μg monovalent prototype vaccine+50µg Matrix-M adjuvant, given on Day 0, Day 21, and Day 70.
88974191|NCT05112848|Experimental|Group 3 PLWH|"Two doses of 5μg monovalent prototype vaccine+50µg Matrix-M adjuvant, given on Day 0 and Day 70.~Alternating IM (deltoid) injection of placebo (0.5mL) given on Day 21."
89209466|NCT04037514|Experimental|Paracetamol|Intravenous paracetamol 15 mg/kg/6h for 3 or 6 days
89209467|NCT04037514|Active Comparator|Ibuprofen|Intravenous ibuprofen 10 mg/kg/24 h (day 1) and 5 mg/kg/24h (day 2 and 3) for 3 or 6 days
89581149|NCT02017899|Experimental|S. sonnei 1790GAHB - 25 mcg|Subjects enrolled in COHORT C receiving 3 injections of S. sonnei 1790GAHB - 25 mcg
89581150|NCT02017899|Experimental|S. sonnei 1790GAHB - 50 mcg|Subjects enrolled in COHORT D receiving 3 injections of S. sonnei 1790GAHB - 50 mcg
89029967|NCT01245101|Active Comparator|Observation and then Raltegravir|The total duration of the study will be 40 weeks. This will include Part 1 (16 weeks) followed by Part 2 (8 weeks) followed by the crossover to Part 2 (16 weeks). During Part 1 participants in Group A will receive open-label raltegravir in addition to their established antiretroviral regimen while Group B participants will continue taking their established antiretroviral regimen for 16 weeks. After completion of Part 1, both groups will enter Part 2 that will consist of a washout period of 8 weeks during which both groups will only take their established antiretroviral regimen without raltegravir. This will be followed by Part 3 during which the two study groups will undergo a crossover with respect to the treatment assignment during Part 1 so that Group A will continue to receive their established antiretroviral regimen while Group B will receive open-label raltegravir in addition to their established antiretroviral regimen for 16 weeks.
89029968|NCT00514839|No Intervention|C|Control group receiving a booklet on health behavior
89581151|NCT02017899|Experimental|S. sonnei 1790GAHB - 100 mcg|Subjects enrolled in COHORT E receiving 3 injections of S. sonnei 1790GAHB - 100 mcg
89581152|NCT02017899|Placebo Comparator|Placebo|2 subjects enrolled in each COHORT A, B, C, D, E receiving 3 injections of Placebo. These were pooled in one Placebo group in the analyses
89581153|NCT01993329|Experimental|Gefapixant 50/ Gefapixant 300/ Placebo|Gefapixant 50 mg and placebo (for gefapixant 300 mg) twice daily for 3.5 days during Period 1, gefapixant 300 mg and placebo (for gefapixant 50 mg) twice daily for 3.5 days during Period 2, placebo to match gefapixant 50 mg and placebo to match gefapixant 300 mg twice daily for 3.5 days during Period 3. Each period is separated by at least a 7-day wash-out period.
89581154|NCT01993329|Experimental|Gefapixant 50/ Placebo/ Gefapixant 300|Gefapixant 50 mg and placebo (for gefapixant 300 mg) twice daily for 3.5 days during Period 1, placebo to match gefapixant 50 mg and placebo to match gefapixant 300 mg twice daily for 3.5 days during Period 2, gefapixant 300 mg and placebo (for gefapixant 50 mg) twice daily for 3.5 days during Period 3. Each period is separated by at least a 7-day wash-out period.
89581155|NCT01993329|Experimental|Gefapixant 300/ Gefapixant 50/ Placebo|Gefapixant 300 mg and placebo (for gefapixant 50 mg) twice daily for 3.5 days during Period 1, gefapixant 50 mg and placebo (for gefapixant 300 mg) twice daily for 3.5 days during Period 2, placebo to match gefapixant 50 mg and placebo to match gefapixant 300 mg twice daily for 3.5 days during Period 3. Each period is separated by at least a 7-day wash-out period.
89581156|NCT01993329|Experimental|Gefapixant 300/ Placebo/ Gefapixant 50|Gefapixant 300 mg and placebo (for gefapixant 50 mg) twice daily for 3.5 days during Period 1, placebo to match gefapixant 50 mg and placebo to match gefapixant 300 mg twice daily for 3.5 days during Period 2, gefapixant 50 mg and placebo (for gefapixant 300 mg) twice daily for 3.5 days during Period 3. Each period is separated by at least a 7-day wash-out period.
89581157|NCT01993329|Experimental|Placebo/ Gefapixant 50/ Gefapixant 300|Placebo to match gefapixant 50 mg and placebo to match gefapixant 300 mg twice daily for 3.5 days during Period 1, gefapixant 50 mg and placebo (for gefapixant 300 mg) twice daily for 3.5 days during Period 2, gefapixant 300 mg and placebo (for gefapixant 50 mg) twice daily for 3.5 days during Period 3. Each period is separated by at least a 7-day wash-out period.
89581158|NCT01993329|Experimental|Placebo/ Gefapixant 300/ Gefapixant 50|Placebo to match gefapixant 50 mg and placebo to match gefapixant 300 mg twice daily for 3.5 days during Period 1, gefapixant 300 mg and placebo (for gefapixant 50 mg) twice daily for 3.5 days during Period 2, gefapixant 50 mg and placebo (for gefapixant 300 mg) twice daily for 3.5 days during Period 3. Each period is separated by at least a 7-day wash-out period.
89581159|NCT04417101|Experimental|JBT treatment|The participants will be instructed to take their Chinese herbal medicine formula (CHM), which named Juan Bi Tang, and take it as a dose of 3 g (per bag) each time, trice daily for 4 weeks.
89581160|NCT04417101|No Intervention|No treatment|Participants in the non-treatment period will receive conventional self-care management for myofascial pain syndrome.
89581161|NCT02016183||Candesartan cilexetil / hydrochlorothiazide|Candesartan cilexetil/Hydrochlorothiazide 4 mg/6.25 mg or 8 mg/6.25 mg combination tablets, orally, once daily for up to 12 months. This drug should not be used as a first-line drug for hypertension treatment. Participants received interventions as part of routine medical care.
89581162|NCT02377349|Experimental|dTpa Group|This group will consist of pregnant women who will receive a single dose of Boostrix™ at 27-36 weeks (i.e. completed 27 weeks until 36 weeks) of gestation (Visit 1) and will receive a dose of the placebo post-delivery (within 72 hours).
89581163|NCT02377349|Placebo Comparator|Control Group|This group will consist of pregnant women who will receive a single dose of placebo at 27-36 weeks (i.e. completed 27 weeks until 36 weeks) of gestation (Visit 1) and will receive a dose of Boostrix™ post-delivery (within 72 hours).
89581164|NCT02421419|Active Comparator|Corticosteroid alone (CS) Group|1 cc dexamethasone sodium phosphate (4mg/ml) injectable
89581165|NCT02421419|Active Comparator|Corticosteroid/Lidocaine (CSL) Group|1 cc dexamethasone sodium phosphate (4 mg/ml) injectable and 1 cc 1% Xylocaine (lidocaine) injectable
89581166|NCT02421419|Active Comparator|Corticosteroid/Saline (CSS) Group|1 cc dexamethasone sodium phosphate (4mg/ml) injectable and 1 cc 0.9% injectable Sodium Chloride (saline)
89581167|NCT02016105|Experimental|GP2017 Adalimumab|Study arm with intervention being studied in the protocol. Adalimumab Solution for subcutaneous injection with an initial dose of 80 mg s.c. in Week 0, followed by 40 mg s.c. eow, starting at Week 1 and ending at Week 51.
89029969|NCT00514839|Experimental|MI|Counselling based on Motivational Interviewing plus individualized feedback
89029970|NCT02951520|Experimental|SOFT block|Fifty patients will form the study group (one group). All the patients will receive supine ultrasound guided (US) sciatic, obturator, femoral nerve block technique using a single skin puncture (SOFT block).
89029971|NCT01245062|Experimental|GSK1120212|MEK inhibitor
89029972|NCT01245062|Active Comparator|Chemotherapy|Investigator Choice of DTIC or paclitaxel
89029973|NCT01245062|Experimental|Crossover|MEK inhibitor after documented progression on Chemotherapy Arm
89029974|NCT00514878||1|Adult same-day outpatients scheduled for general anesthesia
89029975|NCT02951286|Experimental|high pull headgear + OBA|A modified version of the Open Bite Appliance (OBA),introduced by Erverdi and Usumez, will be applied with high pull headgear for Orthoclassic ®1300 NE Alpha Drive, McMinnville, OR 97128 USA 866.752.0065.
89029976|NCT02951286|Experimental|OBA (control group)|A modified version of the Open Bite Appliance (OBA),introduced by Erverdi and Usumez, will be applied only.
89581168|NCT02016105|Active Comparator|Humira ® Adalimumab|Humira® Adalimumab as a subcutaneous injection with an initial dose of 80 mg s.c. in Week 0, followed by 40 mg s.c. eow, starting at Week 1 and ending at Week 51.
89581169|NCT02400905|Experimental|BioMimics 3D Vascular Stent|Implantation of BioMimics 3D nitinol stent using the BioMimics 3D Vascular Stent System
89581170|NCT02400749|Experimental|Apremilast|Patients will receive Apremilast until week 32.
89581171|NCT02400749|Placebo Comparator|Placebo followed by Apremilast|Patients will receive Placebo until week 16 and then receive Apremilast until week 32
89581172|NCT02420327|Experimental|Placebo patch and placebo capsule|On the double-placebo test day, participants receive a placebo patch and a placebo capsule.
89581173|NCT02420327|Experimental|Nicotine patch and placebo capsule|On the nicotine test day, participants receive a nicotine patch (7 mg/24 hrs) and a placebo capsule.
89581174|NCT02420327|Experimental|Placebo patch and galantamine capsule|On the galantamine test day, participants receive a placebo patch and a capsule containing 4 mg of galantamine.
89581175|NCT02420327|Experimental|Nicotine patch and galantamine capsule|On the nicotine + galantamine test day, participants receive a nicotine patch (7 mg/24 hrs) and a capsule containing 4 mg of galantamine.
89581176|NCT04420559|Experimental|Virtual Reality|
89581177|NCT04420559|Experimental|Distraction Card|
89581178|NCT04420559|No Intervention|Control|
89581179|NCT02374853|Experimental|Vancomycin|During open heart surgery, patients will have a 4 x 8 inch piece of sterile gauze covering each side of the divided sternum. The gauze will be soaked in the following solution: 5 g vancomycin dissolved in 50 mL sterile water
89581180|NCT02374853|Placebo Comparator|Control|During open heart surgery, patients will have a 4 x 8 inch piece of sterile gauze covering each side of the divided sternum. The gauze will be soaked in 50 mL sterile water. No Vancomycin
89581181|NCT02015793|Experimental|Low Induction Dose|Participants received the low loading dose of adalimumab (80 mg at Week 0) followed by the standard maintenance dose of adalimumab (40 mg every other week) at Weeks 2, 4, and 6.
89581182|NCT02015793|Experimental|Standard Induction Dose|Participants received the standard loading dose of adalimumab (160 mg at Week 0 and 80 mg at Week 2) followed by the standard maintenance dose of adalimumab (40 mg every other week) at Weeks 4 and 6.
89581183|NCT02347631|Experimental|Alcon DAILIES TOTAL1, and ACUVUE TruEye|Intervention: Soft Contact Lens - Daily Disposable Name - Alcon Dailies Total 1 Material - Delefilcon A Water Content - 33% Oxygen Permeability - 140 x10-11 (cm2/sec)(mL O2/mL mmHg) Oxygen Transmissibility - 156 x10-9 (cm/sec)(mL O2/mL mmHg) Base Curve - 8.5mm Manner of Wear - Daily Disposables Wearing Time - 2 months
88974192|NCT05112848|Experimental|Group 4 HIV-Negative Participants|"2 doses of 5μg monovalent prototype vaccine+50µg Matrix-M adjuvant, given on Day 0 and Day 21.~Alternating IM (deltoid) injection of placebo (0.5mL) given on Day 70."
88974193|NCT05112848|Experimental|Group 5 HIV-Negative Participants|"Two doses of 5μg monovalent prototype vaccine+50µg Matrix-M adjuvant, given on Day 0 and Day 70.~Alternating IM (deltoid) injection of placebo (0.5mL) given on Day 21."
89581184|NCT02347631|Active Comparator|ACUVUE TruEye and Alcon Dailies Total 1|Intervention: Soft Contact Lens - Daily Disposable Name - Acuvue TruEye Material - Narafilcon A Water Content - 46% Oxygen Permeability - 100 x10-11 (cm2/sec)(mL O2/mL mmHg) Oxygen Transmissibility - 118 x10-9 (cm/sec)(mL O2/mL mmHg) Base Curve - 8.5mm & 9.0mm Manner of Wear - Daily Disposables Wearing Time - 2 months
89581185|NCT02015637|Experimental|Delafloxacin|900mg orally (2 x 450 mg tablets) administered once
89581186|NCT02015637|Active Comparator|ceftriaxone|Ceftriaxone 250 mg intramuscular injection administered once
89581187|NCT02347085|Experimental|GFF MDI (PT003)|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI)
89581188|NCT02347085|Placebo Comparator|Placebo MDI|Placebo Metered Dose Inhaler (MDI) for Glycopyrronium and Formoterol Fumarate Inhalation Aerosol
89581189|NCT02374463|Experimental|Multimodality Balance Intervention (MMBI)|Multimodality Balance Intervention (MMBI)
88974194|NCT05111678||Indoor air pollutant groups|50 patients that have been exposed to indoor air pollutants
88974195|NCT05111678||Neurological symptoms groups|50 patients with neurological symptoms possibly due to adverse external exposure without any exposure to indoor air pollutants
88974196|NCT05111678||Healthy controls|25 healthy age- and gender-matched controls
89029977|NCT01244984|Experimental|Fluticasone Furoate/GW642444|Combination inhaled corticosteroid and long-acting beta2-agonist
89581190|NCT02374463|Active Comparator|Tai Chi|Tai Chi Intervention
89581191|NCT02015481|Experimental|Cabaletta 30gr.|weekly IV of Cabaletta 30gr.
89581192|NCT02374307|Experimental|Exercise and education|This group performs a 12-week individual tailored home exercise programme in accordance with the manual of Otago exercise programme. Physiotherapists visit the participants 5 times during the 12 weeks (at week 1,2,4,8 and 10) to prescribe and progress exercises. Motivational conversations on telephone are performed the weeks when no visits are scheduled. Additionally, the participants receive information on the first visit which will focus on motivation, importance of adherence and effectiveness of falls prevention. The participants are expected to do exercises on their own, and in that way perform exercises 3 times weekly. If safe, the participant are provided with a walking plan and be encouraged to walk twice weekly.
89581193|NCT02374307|No Intervention|Control|The control group performs activities as usual.
89581194|NCT02397473|Experimental|Galcanezumab 300mg|Galcanezumab 300mg administered subcutaneously (SC) every 30 days during an 8 week treatment period.
89581195|NCT02397473|Placebo Comparator|Placebo|Placebo administered SC every 30 days during an 8 week treatment period.
89581196|NCT02344745|Placebo Comparator|Control|Distilled water
88974197|NCT05079412||NIV-NAVA group|Premature infants (22 0/7 to 29 6/7 weeks gestation) with respiratory distress syndrome who are admitted to Mount Sinai NICU and are supported by NIV-NAVA for at least 24 hours are enrolled in this arm after obtaining parents' consent.
88974198|NCT05079412||NIPPV group|Premature infants (22 0/7 to 29 6/7 weeks gestation) with respiratory distress syndrome who are admitted to Mount Sinai NICU and are supported by NIPPV for at least 24 hours are enrolled in this arm after obtaining parents' consent.
89581197|NCT02344745|Experimental|Lavender|Lavandula angustifolia essential oil (Aura Cacia)
89581198|NCT02370641|Active Comparator|urolithin excretors|The excretor status will be determined by analysis for urolithin A glucuronide in 24 hour urine after one dose of POMx. A blood sample and stool sample will be obtained before administering the extract.
89581199|NCT02370641|Active Comparator|non excretors|The excretor status will be determined by analysis for urolithin A glucuronide in 24 hour urine after one dose of POMx. A blood sample and stool sample will be obtained before administering the extract.
89581200|NCT01621191|Experimental|60 mg Duloxetine|Duloxetine 20 milligrams (mg) taken orally once every day for 1 week, followed by 40 mg taken orally once every day for 1 week, and then 60 mg taken orally once every day for 48 weeks
88974199|NCT05075694|Experimental|Experiment|Therapeutic touch (TT) is a treatment that takes an average of 15-20 min, in which energy in the universe is transferred through the hands of the practitioner to eliminate the imbalance in the individual's energy field and facilitate healing. The intervention group (TT group) received therapeutic touch for 10 minutes a day for five consecutive days. The practice was implemented in line with Therapeutic Practice Procedure.
89581201|NCT02343263|No Intervention|Control|44 patients will be randomized to receive no topical treatment to their tonsillectomy (or adenotonsillectomy) wound bed as is the current standard of care at our institution. The wound bed will be treated with instrumentation in the operating room to ensure adequate hemostasis alone.
89581202|NCT02343263|Active Comparator|Fibrin Sealant Alone|44 patients will be randomized to receive application of topical fibrin sealant to their tonsillectomy (or adenotonsillectomy) wound bed to assess the pain reduction benefits of fibrin sealant alone. Prior to application of fibrin sealant, the wound bed will be treated with instrumentation in the operating room to ensure adequate hemostasis.
89581203|NCT02343263|Experimental|Bupivacaine-infused Fibrin Sealant|44 patients will be randomized to receive application of topical bupivacaine-infused fibrin sealant to their tonsillectomy (or adenotonsillectomy) wound bed to assess the pain reduction benefits of fibrin sealant alone. Prior to application of fibrin sealant, the wound bed will be treated with instrumentation in the operating room to ensure adequate hemostasis.
89581204|NCT02081859|Placebo Comparator|Conventional grading|Embryos will be scored based on conventional criteria.
89581205|NCT02081859|Active Comparator|Embryoscope data|Embryos will be scored based on both conventional rating and embryoscope data.
89581206|NCT04420715|Experimental|Less-experienced group|The participant who has completed the number of PCI less than 200 before recruiting
89581207|NCT04420715|Experimental|Experienced group|The participant who has completed the number of PCI more than 200 before recruiting
89581208|NCT04897451||Women with cervical ripening in the context of artificial labor induction|
89581209|NCT02342639|Experimental|Rifaximin|Participants will receive a 10-day course of Rifaximin.
89581210|NCT02342639|Placebo Comparator|Placebo|Participants will receive a 10-day course of placebo.
89581211|NCT01625091|Active Comparator|naltrexone|The investigators will administer Naltrexone to women with hazardous drinking and assess the study outcomes.
89581212|NCT01625091|Placebo Comparator|placebo pill|The investigators will administer an inert placebo that looks similar to Naltrexone, to women with hazardous drinking and assess the study outcomes.
89581213|NCT02396849|Experimental|Continuous Positive Airway Pressure (CPAP)|Use of a CPAP machine for at least 5 days per week for 28 days
89581214|NCT02396849|Sham Comparator|Continuous Positive Airway Pressure (CPAP) Sham|Use of a sham CPAP machine for at least 5 days per week for 28 days
89581215|NCT02370251|Experimental|Omegaven|Children will receive Omegaven at a maximum of 1 g/kg/day upon enrollment in this arm.
89581216|NCT02396537|Experimental|Intranasal Lidocaine|Patient to receive 4% lidocaine intranasally prior to midazolam
89581217|NCT02396537|Placebo Comparator|Intranasal 0.9% saline|Patient to receive 0.9% Saline intranasally prior to midazolam
89581218|NCT04891367|Experimental|Group CBT|Group cognitive behavioral therapy for obsessive compulsive disorder in youth
89581219|NCT02342171|Experimental|Convalescent Plasma|Convalescent Plasma: 400-500 mL from two donors (2 x 200-250 ml) and 10mL/kg for small adults and children <45kg
89581220|NCT02342171|No Intervention|standard care|The control arm will consist of historical controls having being treated with standard of care
89581221|NCT01624467|Experimental|Necitumumab|800 mg necitumumab, administered once per week as an intravenous infusion (IV)
89581222|NCT01624233|Experimental|80 mg ixekizumab|Administered by two 80 milligram (mg) subcutaneous (SC) injections at Week 0, followed by one 80 mg SC injection per Dosing Regimen 1 up to Week 12. Then administered by one 80 mg SC injection per Dosing Regimen 2 from Week 12 up to Week 52, and for up to 192 weeks following disease relapse occurring during a drug-free period beyond 52 weeks.
88974200|NCT05075694|Sham Comparator|Control|Placebo: Sham Therapeutic Touch (STT) The control group was administered STT instead of TT for 10 minutes for successive 5 days. The practice was implemented in line with Sham Therapeutic Touch Practice Procedure (STTPP).
88974201|NCT05072197|Experimental|Mobile device application group|routine care and mobile device application providing medical care information and social support for breast cancer women during their chemotherapy treatment
88974202|NCT05072197|No Intervention|control group|routine care for breast cancer women during their chemotherapy treatment
88974203|NCT05059262|Experimental|Part 1/Part 2 - vimseltinib/vimseltinib|Participants receive blinded treatment of 30 mg twice a week (biw) vimseltinib for 24 weeks in Part 1 and continue on 30 mg biw vimseltinib in Part 2
88974204|NCT05059262|Placebo Comparator|Part 1/Part 2 - placebo/vimseltinib|Participants receive blinded treatment of 30 mg twice a week (biw) matching placebo for 24 weeks in Part 1 and have option to receive 30 mg biw vimseltinib in Part 2
88974205|NCT05050578|Other|LID018869, then AOHP|Lehfilcon A contact lenses worn in Period 1, followed by senofilcon A contact lenses worn in Period 2, as randomized. Each product will be worn in both eyes during waking hours only for at least 10 hours per day for 30 days. CLEAR CARE will be used for daily contact lens cleaning and disinfection.
89581223|NCT01993017|Experimental|AHA Depression Screen & Treat|"Participants randomized to this arm will complete the Depressive symptom screener (8-item Patient Health Questionnaire, PHQ-8) after randomization. Those with clinically significant score (>=10) will be offered treatment. Treatment will be delivered according to participant preference, and will be managed according to stepped care. Stepped care includes, a) participant preference for either brief, cognitive behavioral therapy (CBT), delivered centrally by telephone, or antidepressant medication managed at the local site, or both, or neither, and b) review of progress at approximately 2-month intervals, with stepping up of care if sufficient progress is not being realized."
89581224|NCT01993017|Active Comparator|Depression Screen & Notify Arm Type :|Participants randomized to this arm will complete the depressive symptom screener (8-item Patient Health Questionnaire, PHQ-8) after randomization. Those with clinically significant score (>=10) will have a letter sent to their primary care provider about their positive screen for depressive symptoms, with subsequent actions at the provider's discretion.
89581225|NCT01993017|Placebo Comparator|No Depression Screen|Participants randomized to this arm will not complete a PHQ-8 assessment at randomization, and so will not be screened for depressive symptoms.
89581226|NCT01992549|Experimental|Human-cl rhFVIII|
89581227|NCT01992159|Placebo Comparator|Placebo|Participants received placebo matching to romosozumab administered by subcutaneous injection once a month for 12 months.
89581228|NCT01992159|Experimental|Romosozumab 70 mg|Participants received 70 mg romosozumab administered by subcutaneous injection once a month for 12 months.
89581229|NCT01992159|Experimental|Romosozumab 140 mg|Participants received 140 mg romosozumab administered by subcutaneous injection once a month for 12 months.
89581230|NCT01992159|Experimental|Romosozumab 210 mg|Participants received 210 mg romosozumab administered by subcutaneous injection once a month for 12 months.
89581231|NCT01988493|Experimental|Phase 1b: Tepotinib 300 mg|Participants received Tepotinib 300 milligram (mg) orally once daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
89581232|NCT01988493|Experimental|Phase 1b: Tepotinib 500 mg|Participants received Tepotinib 500 mg orally once daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
89581233|NCT01988493|Experimental|Phase 1b: Tepotinib 1000 mg|Participants received Tepotinib 1000 mg orally once daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
89581234|NCT01988493|Experimental|Phase 2: Tepotinib|Participants randomized to receive Tepotinib recommended Phase 2 dose (RP2D) determined from Phase 1b over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
89581235|NCT01988493|Experimental|Phase 2 Sorafenib|Participants randomized to receive Sorafenib 400 mg orally twice daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
89581236|NCT02081079|Experimental|Genotype 4|LDV/SOF for up to 12 weeks in treatment-naive and treatment-experienced participants with genotype 4 hepatitis C virus (HCV) infection
89029978|NCT01244984|Experimental|Fluticasone Furoate|Inhaled corticosteroid
89029979|NCT04695483|Experimental|Corifollitropin alpha group|Patients treated with Corifollitropin-alpha in a long-acting controlled ovarian stimulation
89209468|NCT00889668|Experimental|Experimental|subjects with a diagnosis of type 1 or 2 diabetes; GlucoTrack results will be compared with the readings from approved invasive glucose meter device.
89209469|NCT00886158||Solid Organ Transplant Recipients|Solid organ transplant recipients receiving their care at Seattle Children's Hospital
89581237|NCT02081079|Experimental|Genotype 5|LDV/SOF for up to 12 weeks in treatment-naive and treatment-experienced participants with genotype 5 hepatitis C virus (HCV) infection
89581238|NCT02081001|Experimental|G-Pump™ (glucagon infusion)|G-Pump™ (glucagon infusion); single subcutaneous infusion doses at 0.3 μg/kg, 1.2 μg/kg and 2.0 μg/kg
89581239|NCT02081001|Active Comparator|Novo Nordisk GlucaGen®|Novo Nordisk GlucaGen®; single subcutaneous infusion doses 0.3 μg/kg, 1.2 μg/kg and 2.0 μg/kg
89581240|NCT02080221|Experimental|FOLFOXA|"1 cycle = 14 days Abraxane ®: 150mg/m2 IV over 30 minutes, day 1 (administered first) every 14 days.~Oxaliplatin: 85mg/m2, IV over 2 hours, day 1 every 14 days Leucovorin: 400mg/m2, IV over 2 hours, day 1 every 14 days 5-FU infusion:1200mg/m2/day, as a continuous IV infusion over 2 days, day 1 and day 2 (for a total dose of 2400mg/m2 over 46 hours.)"
89581241|NCT02079909|Experimental|T-817MA-H|224 mg T-817MA once daily for first 4 weeks and 448 mg T-817MA once daily for the following weeks.
88811271|NCT03170375|Active Comparator|Motivational Interviewing|Participants in this arm will receive motivational interviewing-based counseling with a registered dietitian to promote adoption of the sodium-restricted Dietary Approaches to Stop Hypertension (DASH/SRD) eating plan.
88811272|NCT03170375|Experimental|DASH/SRD Diet|Participants in this arm will receive prepared, pre-packaged meals containing 1150mg of sodium.
88811273|NCT03170375|Placebo Comparator|Control Diet|Participants in this arm will receive prepared, pre-packaged meals containing 5750mg of sodium.
88811274|NCT03141359|Experimental|Single Arm|SBRT + Concurrent Mediastinal Chemoradiation +/- Consolidation Chemotherapy/Adjuvant Immunotherapy
88811275|NCT02983682|Experimental|Lidocaine Infusion|All participants will receive intravenous lidocaine infusion of 42 mcg/kg/minute over 2 hours, for a total of 5 mg/kg. No bolus dose will be given.
88811276|NCT02980029|Experimental|TVB-2640|TVB-2640 is a potent and reversible inhibitor of the FASN enzyme.
88811277|NCT02980029|Placebo Comparator|Placebo|Placebo
88811278|NCT02971748|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
89209470|NCT00884130||Laparoscopic|Patients having a laparoscopic colorectal resection
89581242|NCT02079909|Experimental|T-817MA-L|224 mg T-817MA once daily
89581243|NCT02079909|Placebo Comparator|Placebo|Placebo once daily
89581244|NCT04178031|Experimental|IUD insertion group|All participants will have IUD inserted and follow up for occurance of complications
89581245|NCT02014467|Experimental|Denosumab 60mg|injection
89581246|NCT02014467|Placebo Comparator|Placebo|injection
89581247|NCT02013765|Experimental|Trastuzumab Monotherapy|Participants received an initial dose of trastuzumab 4 milligrams per kilogram (mg/kg) intravenously (IV) on Day 1, followed by weekly doses of 2 mg/kg IV beginning on Day 8 and continuing for up to 37 weeks.
89581248|NCT02013687|Experimental|2 µg + Alhydrogel|vaccine
89581249|NCT02013687|Experimental|10 µg + Alhydrogel|vaccine
89581250|NCT02013687|Experimental|30 µg + Alhydrogel|vaccine
89581251|NCT02013687|Experimental|100 µg + Alhydrogel|vaccine
89581252|NCT02013609|Experimental|Brexpiprazole|Up to 3mg/day, once daily dose, tablets, orally
89581253|NCT01988337|Experimental|Resin infiltration|"One proximal caries lesion (split mouth design) per patient will be treated using the resin infiltrant Icon (DMG, Hamburg, Germany) according to manufactures´ instructions."
89581254|NCT01988337|Sham Comparator|Mock treatment|"A second proximal caries lesion of each patient (split mouth design) will receive a placebo treatment to mimic resin infiltration."
88974206|NCT05050578|Other|AOHP, then LID018869|Senofilcon A contact lenses worn in Period 1, followed by lehfilcon A contact lenses worn in Period 2, as randomized. Each product will be worn in both eyes during waking hours only for at least 10 hours per day for 30 days. CLEAR CARE will be used for daily contact lens cleaning and disinfection.
88974207|NCT05046106|Placebo Comparator|Placebo|500-mg placebo capsule, 4 capsules twice a day for 24 weeks.
88974208|NCT05046106|Active Comparator|MLC1501 Low-dose|MLC1501 low-dose 500-mg capsule, 4 capsules twice a day for 24 weeks.
88974209|NCT05046106|Active Comparator|MLC1501 High-dose|MLC1501 high-dose 500-mg capsule, 4 capsules twice a day for 24 weeks.
89209471|NCT00884130||Open|Patients having an open colorectal resection
89581255|NCT02013531|Experimental|Brexpiprazole|Up to 3 mg/day, once daily dose, tablets, orally
89581256|NCT01988103|Experimental|Apremilast 20mg|Apremilast 20 mg tablets orally twice a day (BID)
89581257|NCT01988103|Experimental|Apremilast 30mg|Apremilast 30 mg tablets orally BID
89581258|NCT01988103|Placebo Comparator|Placebo|Identically-appearing placebo tablets BID for 16 weeks followed by participants being re-randomized in a blinded fasion to apremilast 20 mg or 30mg tablets BID for 52 weeks
89581259|NCT02013375|Experimental|Haploidentical Transplant|All subjects will undergo pre-conditioning treatment with alemtuzumab (0.3 mg/kg Day -5, Day -4, Day -3) and total body irradiation (300cGy), followed by stem cell transplant, and post-transplant treatment with cyclophosphamide (50mg/kg/day) and sirolimus (target trough level of 10-15ng/mL).
89581260|NCT02079519|Experimental|Bevacizumab 5 mg/kg|Participants received bevacizumab 5 mg/kg intravenously every 2 weeks for 6 months until disease progression or termination of the study. Participants showing a continuous benefit of therapy could receive treatment for a maximum of 12 months.
89581261|NCT01987557|Experimental|Treadmill Intervention 1: Rate Group|Participants in this condition will walk with a cadence (steps per minute) that is approximately 35% faster than comfortable walking pace. In this condition, participants will maintain a step length that is similar to that of their comfortable walking pace.
89581262|NCT01987557|Experimental|Magnitude treadmill group|In this condition participants will walk on a treadmill with weights on their ankles to elicit a greater magnitude of instrinsic feedback from force sensitive golgi tendon organs
89581263|NCT01987557|Placebo Comparator|regular treadmill walking|participants will walk at a comfortable self-selected pace on a treadmill
89581264|NCT02078817|Experimental|ketamine|Intravenous ketamine 0.5 mg/kg over 40 minutes will be given 6 times over 2 weeks.
89581265|NCT02011893|Experimental|Burst Stimulation|Burst Stimulation using the Prodigy system
89581266|NCT02011893|Active Comparator|Tonic Stimulation|Tonic Stimulation using the Prodigy system
89581267|NCT02011113|Experimental|Pomalidomide plus dexamethasone|
89581268|NCT01807156|Experimental|Tivozanib|Patients would receive Tivozanib 1.0 mg/day orally, 3 weeks on, one week off, for one cycle starting day 1. If no adverse event is encountered, patients will continue subsequent cycles of Tivozanib 1.5 mg/day orally; 3 weeks on/1 week off, dosing schedule. Patients will continue on treatment until disease progression, unacceptable toxicity, or patient withdrawal from the study.
89581269|NCT01987479|Experimental|Tocilizumab Alone or in Combination with Methotrexate or DMARD|Participants will receive a weekly SC injection of tocilizumab 162 milligrams (mg) as monotherapy or in combination with methotrexate or other non-biologic DMARDs for 24 weeks.
88811279|NCT02943681|Experimental|Measles vaccine|Measles vaccine, 1 dose of 0.5 ml
88811280|NCT02943681|No Intervention|Control|Nothing
88811281|NCT02861573|Experimental|Pembrolizumab+Olaparib|Participants with adenocarcinoma (AC) mCRPC in Cohort A will receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 3-week dosing cycle (Q3W) and olaparib 400 mg capsules or 300 mg tablets by mouth (PO) twice a day (BID) continuously from Day 1 of Cycle 1. Treatment with pembrolizumab will continue until progression or a maximum of 35 treatment cycles (up to 2 years). Treatment with olaparib will continue until progression. Participants who must discontinue 1 of the 2 drugs in the combination due to adverse events may continue the study with the other combination drug.
88811282|NCT02861573|Experimental|Pembrolizumab+Docetaxel+Prednisone|Participants with AC mCRPC in Cohort B will receive pembrolizumab 200 mg IV on Day 1 Q3W, docetaxel 75 mg/m^2 IV on Day 1 Q3W, and prednisone 5 mg tablet PO BID continuously from Day 1 of Cycle 1. Participants will only be permitted to receive a maximum of 10 cycles of docetaxel and prednisone. Treatment with pembrolizumab will continue for a maximum of 35 cycles (up to 2 years) or until progression. Participants who must discontinue 1 of the 2 drugs due to adverse events in the combination may continue the study with the other combination drug.
88811283|NCT02861573|Experimental|Pembrolizumab+Enzalutamide|Participants with AC mCRPC in Cohort C will receive pembrolizumab 200 mg IV on Day 1 Q3W and enzalutamide 160 mg PO every day (QD) continuously from Day 1 of Cycle 1. Treatment with pembrolizumab will continue until progression or a maximum of 35 treatment cycles (up to 2 years). Treatment with enzalutamide will continue until progression. Participants who must discontinue 1 of the 2 drugs in the combination due to adverse events may continue the study with the other combination drug.
89581270|NCT01620489|Experimental|Lira 1.8 mg|
89581271|NCT01620489|Placebo Comparator|Placebo|
89581272|NCT02076165|Experimental|ABC-I|"Participants completed a 5 session intervention, Acceptance and the Behavioral Changes to Treat Insomnia (ABC-I). This was considered the new treatment being studied."
89581273|NCT02076165|Active Comparator|CBT-I|"Participants received a 5-session intervention, cognitive-behavioral therapy for insomnia (CBT-I). This was considered the standard care treatment."
89581274|NCT01620255|Placebo Comparator|Placebo|
89581275|NCT01620255|Experimental|Drug Dose Level 1|
89581276|NCT01620255|Experimental|Drug Dose Level 2|
89581277|NCT01620255|Experimental|Drug Dose Level 3|
89581278|NCT01620255|Experimental|Drug Dose Level 4|
89581279|NCT02010567|Experimental|CLRX101 MTD/RP2D|During Phase Ib, we will evaluate the safety and determine the MTD/RP2D of CRLX101 + capecitabine (Cape) and radiation therapy (XRT) in patients with rectal cancer using the traditional 3+3 dose escalation design. Adverse events (AEs) will be evaluated via the CTCAE version 4.0. Patients in Phase Ib will also be followed for pathological response if they have resectable disease.
89581280|NCT02010567|Experimental|Chemoradiotherapy + Surgery|In Phase II, CRLX101 will be administered at the RP2D in combination with capecitabine and radiation in patients with locally advanced rectal cancer for a total of 5-6 weeks, depending on the total radiation dose. A total of 3 doses of CRLX101 will be administered every other week. Surgery will take place at least 6 weeks after the completion of chemoradiotherapy.
89581281|NCT01806064|Experimental|TRC105 and Axitinib|Patients randomized to receive TRC105 at 3 mg/kg on day 1, 7 mg/kg on day 4, and 10 mg/kg on day 8 and weekly thereafter in combination with axitinib 5 mg twice daily
89581282|NCT01806064|Active Comparator|Axitinib|Patients randomized to receive axitinib 5 mg twice daily
89581283|NCT01804582|Experimental|Family Navigator Consultation|"This group of parents will be contacted by a Family Navigator to assist them in accessing psychosocial resources based on their child and family needs. Components of this intervention are the following:~(1)family engagement; (2) inquiry about psychosocial resource needs related to schools, outpatient child treatment, support programs, or mental health resources for other household family members; (3) discuss potential benefits/challenges of options and parent preferences/priorities for care; (4) assessment on perceived barriers to seeking resources; (5) collaborative problem solving to address barriers; (6) discuss options for follow up plan."
89581284|NCT01804582|No Intervention|Usual Care|No specific study intervention is provided to this group of parents. This control group will received the usual care that they have been receiving from their child's providers.
89581285|NCT01787188|Experimental|Meloxicam Test Capsules low dose QD|Meloxicam Test Capsules low dose QD
89581286|NCT01787188|Experimental|Meloxicam Test Capsules high dose QD|Meloxicam Test Capsules high dose QD
89581287|NCT01787188|Placebo Comparator|Placebo Capsule QD|Placebo Capsule QD
89581288|NCT01787032|Experimental|Period 3: BI 113608+Voriconazole|tablets with 240 ml water
89581289|NCT01787032|Experimental|Period 2: BI 113608+Ketoconazole|tablets with 240 ml water
89581290|NCT01787032|Experimental|Period 1: BI 113608|tablets with 240 ml water
88974210|NCT05041491|Experimental|BREAK Intervention|Participants in the BREAK condition will perform 5-minute bouts of brisk walking hourly for 9 hours/day, 5 days/week for 3 months.
88974211|NCT05041491|Active Comparator|ONE Intervention|Participants in the ONE condition will perform 45 minutes of brisk walking as a single continuous bout, 5 days/week for 3 months.
88974212|NCT05040646||Patients|Patients who follow the watch-and-wait program for rectal cancer.
88974213|NCT05040646||Experts|Surgeons, radiotherapists, medical oncologist and other medical personnel who are involved in the treatment of rectal cancer and the watch-and-wait program.
88974214|NCT05039931|Experimental|GNC-035|Patients receive GNC-035 as a 24-hour continuous intravenous infusion (cIV, QD) for 2 weeks (a 2-week cycle). Participants with no intolerable AEs could continue for another three cycles.
88974215|NCT05029622|Experimental|Triptorelin formulation for Intramuscular injection (IM).|
89029980|NCT04695483|Active Comparator|FSH group|Patients treated with Follitropin beta in a daily controlled ovarian stimulation protocol
89581291|NCT01737268|Experimental|FK949E Elderly Participants|After 2 days of dose-titration, elderly participants received either FK949E 150 mg or FK949E 300 mg once daily at bedtime from day 3 to week 52. Dose increase and reduction was allowed following dose increase or reduction guidelines and at the investigator's discretion. After which, participants went through a follow-up period of 1 week. For participants, who completed or discontinued treatment at FK949E 300 mg, a dose-tapering period was placed before proceeding to the follow-up period, and FK949E 150 mg was administered once daily for 1 week in this period.
89581292|NCT01769404|Experimental|LY2605541|Stable dose of LY2605541 (0.2 to 0.6 units per kilogram [U/kg]) administered subcutaneously (SQ) once daily for at least 14 days in 1 of 2 treatment periods. Dose based on prestudy basal insulin dosing regimen.
89581293|NCT01769404|Active Comparator|Insulin Glargine|Stable dose of insulin glargine (0.2 to 0.6 U/kg) administered SQ once daily for at least 14 days in 1 of 2 treatment periods. Dose based on prestudy basal insulin dosing regimen.
89581294|NCT04562662|Experimental|Intervention group|Single arm (all participants receive interventions)
89581295|NCT01769326|Experimental|MusicGlove Group|Subject participates in 3 weeks of exercising with the experimental device: MusicGlove at a minimum of 3 days per week, 1 hour per day with the exercise program
89581296|NCT01769326|Active Comparator|Control Group for Music Glove|Subject participates in 3 weeks of conventional hand exercise program, at a minimum of 3 days per week, 1 hour per day with the exercise program.
89581297|NCT01769326|Experimental|Resonating Arm Exerciser (RAE)|Subject participates in 3 weeks of exercising with the experimental device: RAE at a minimum of 3 days per week, 1 hour per day with the exercise program
89581298|NCT01769326|Active Comparator|Control Group for RAE|Subject participates in 3 weeks of conventional arm exercise program, at a minimum of 3 days per week, 1 hour per day with the exercise program.
89581299|NCT01786330|Experimental|Intervention|Group receives elastic abdominal binders after surgery. Binder used is Procare manufactured by DJO, LLC. Binders are to be worn for 24 hours after surgery.
89581300|NCT01786330|Active Comparator|Control|Group receives standard of care
89581301|NCT01786174|Experimental|Gilenya (fingolimod)|0.5mg Gilenya (fingolimod) orally once daily for 28 days +/- 3 days
89581302|NCT01786174|Placebo Comparator|Placebo|0.5mg placebo (sugar pill) orally once daily for 28 days +/- 3 days
89581303|NCT01736566|Experimental|Family History + Whole Genome Sequencing|Doctors and their patients receive a Genome Report and an Annotated Family History Report.
89581304|NCT01736566|Active Comparator|Family History Only|Doctors and their patients receive an Annotated Family History Report only.
89581305|NCT01768858||Participants receiving adalimumab|Adults with rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), plaque psoriasis (PS), Crohn´s disease (CD), or ulcerative colitis (UC) received 40 mg adalimumab every two weeks.
89581306|NCT01736254|Experimental|Gemfibrozil|Single oral dose of 600 milligrams (mg) gemfibrozil on Day 1
89581307|NCT01736254|Experimental|Evacetrapib|Oral doses of 130 mg evacetrapib once a day (QD) for 10 days (Day 2 through Day 12)
89581308|NCT01736254|Experimental|Evacetrapib + Gemfibrozil|Oral doses of 600 mg gemfibrozil twice a day (BID) and 130 mg evacetrapib QD for 10 days (Day 13 through Day 22). Single oral dose of 600 mg gemfibrozil on Day 23.
89581309|NCT01767376|Experimental|Nimenrix+ Boostrix Group|Healthy male or female subjects, between and including 11 and 25 years of age, who received one dose of Nimenrix vaccine co-administered with one dose of Boostrix vaccine, at Month 0, administered by intramuscular injection into the deltoid muscle.
89581310|NCT01767376|Experimental|Nimenrix Group|Healthy male or female subjects, between and including 11 and 25 years of age, who received one dose of Nimenrix vaccine at Month 0 and one dose of Boostrix vaccine at Month 1. Both vaccines were administered by intramuscular injection into the deltoid muscle.
89581311|NCT01767376|Experimental|Boostrix Group|Healthy male or female subjects, between and including 11 and 25 years of age, who received one dose of Boostrix vaccine at Month 0 and one dose of Nimenrix vaccine at Month 1. Both vaccines were administered by intramuscular injection into the deltoid muscle.
89581312|NCT01767142|Experimental|Outer Thigh CoolSculpting Treatment|Treatment with the CoolSculpting System and a modified belt applicator will be performed on one outer thigh; the remaining thigh is considered the untreated control. Subjects will receive one cooling cycle applied to the thigh area intended for treatment with a protocol-defined cooling rate and duration of 120 minutes.
89581313|NCT01785628|Experimental|Sarcosine capsule|Oral capsules of Sarcosine (0.5g capsule) 1g / bid for 8 weeks.
89581314|NCT01785628|Placebo Comparator|Placebo capsule|Oral capsules of Placebo (Dextrin 0.5g capsule) 1g / bid for 8 weeks.
89581315|NCT01785472|Experimental|LCZ696 200 mg|Patients will be treated with one LCZ696 200 mg tablet and one placebo of LCZ696 once daily(qd) for eight weeks along with placebo of Olmesartan 20 mg capsule once daily.
89581316|NCT01785472|Experimental|LCZ696 400 mg|Patients will start with one LCZ696 200 mg tablet and one placebo of LCZ696 once daily (qd) for one week, thereafter all patients in the treatment group will be up-titrated to two LCZ696 200 mg tablets (400 mg of LCZ696) qd for the remaining seven weeks. Placebo of Olmesartan 20 mg capsule once daily also will be taken.
89581317|NCT01785472|Active Comparator|Olmesartan 20 mg|Patients will be treated with Olmesartan 20 mg for eight weeks once daily along with placebo of LCZ696 tablets once daily.
89581318|NCT01785160|Active Comparator|Raltegravir|coated tablets, oral administration with 240 ml water
89581319|NCT01785160|Experimental|Raltegravir + Faldaprevir|coated tablets and soft gelatine capsule, oral administration with 240 ml water
89581320|NCT01736176|Experimental|Levodopa-Carbidopa Intestinal Gel|"Participants had the PEG-J tube placement procedure performed on Study Day 1 and, at the discretion of the investigator, began initiation and titration of LCIG infusion. Dosing was determined individually. The starting total daily dose of LCIG was based solely on the daily dose of the oral levodopa taken immediately prior to Study Day 1 and was adjusted to obtain the optimal clinical response for the individual participant.~Participants received treatment for up to 60 weeks; participants who completed their Week 60 visit before LCIG was commercially available had the option to extend their LCIG therapy, if in the opinion of the investigator, the participant would benefit from continued LCIG treatment."
89581321|NCT01735630|Experimental|ELND005|ELND005 film coated tablets, BID for 12 weeks
89581322|NCT01735630|Placebo Comparator|Placebo|Matched placebo BID for 12 weeks
89581323|NCT04575922|Experimental|Nivolumab+Ipilimumab+Radiation Therapy (RT)|"Study cycles are 6 weeks long, participants will receive:~Cycle 1: Nivolumab every 2 weeks during cycle, Ipilimumab 1x on Day 1 of cycle, and Radiation Therapy every other weekday or 2 days for a total of 3 treatments during week 1 of Cycle 1 only.~Cycles 2-4: Nivolumab every 2 weeks during each cycle, Ipilimumab 1x on Day 1 of each cycle~Cycles 5-Disease Progression: Nivolumab every 2 weeks during each cycle"
89581324|NCT01735396|Experimental|Abiraterone Acetate|Abiraterone acetate 1000mg orally daily until the time of disease progression, in the absence of prohibitive toxicities.
89581325|NCT01766206|Experimental|MenACWY-CRM Group|Healthy subjects from 2 months to 55 years of age in South Korea, who received MenACWY-CRM (Menveo) vaccination, according to routine clinical care.
89581326|NCT01734850|Experimental|No busulfan pre-conditioning|Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes without busulfan preconditioning
89581327|NCT01734850|Experimental|1 x 4mg/kg busulfan preconditioning|Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes, with single 4mg/kg busulfan dose administered as pre-conditioning for transplant
89581328|NCT01734850|Experimental|2 x 4mg/kg busulfan pre-conditioning|Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes, with two 4mg/kg busulfan doses administered as pre-conditioning for transplant
89581329|NCT01766050|Experimental|Arm: Inje Cocktail + Belatacept|"Inje Cocktail consisting of (200 mg Caffeine, 50 mg losartan tablet, 40 mg Omeprazole capsule, 30 mg Dextromethorphan capsule and 5 mg Midazolam oral syrup) administered on Days 1, 4, 7 and 11~Belatacept 10 mg/kg Intravenous (IV) solution, administered on Day 4"
88974216|NCT05028361|Other|Simultaneous Vaccination Group|Subjects will receive a dose of mRNA COVID-19 vaccine (either as a study procedure or standard of care) and IIV4 at Visit 1, saline placebo at Visit 2, and mRNA COVID-19 vaccine at Visit 3 (only for participants receiving their primary series of mRNA COVID-19 vaccine.)
89581330|NCT02341625|Experimental|Part 1: Ascending dose of BMS-986148|BMS-986148 Intravenous injection at increasing doses on specific days until the maximum tolerated dose is reached. Five cancers will be studied in this part: mesothelioma, pancreatic, ovarian, gastric, and non-small cell lung cancer. Alternate dose and schedules may be explored.
89581331|NCT02341625|Experimental|Part 2: Expansion dose of BMS-986148|BMS-986148 Intravenous injection of Maximum tolerated dose (MTD) on specific days. Five cancers will be studied in this part: mesothelioma, pancreatic, ovarian, gastric, and non-small cell lung cancer.
89581332|NCT02341625|Experimental|Part 3A: Ascending dose of BMS-986148|Set dose of nivolumab and BMS-986148 intravenous injection at increasing doses on specific days until the maximum tolerated dose is reached. Five cancers will be studied in this part: mesothelioma, pancreatic, ovarian, gastric, and non-small cell lung cancer.
89581333|NCT02341625|Experimental|Part 3B: Expansion dose of BMS-986148|Set dose of nivolumab and BMS-986148 intravenous injection at or below maximum tolerated dose on specific days. Five cancers will be studied in this part: mesothelioma, pancreatic, ovarian, gastric, and non-small cell lung cancer.
89581334|NCT02370095|Active Comparator|Treprostinil inhalation solution|Treprostinil will be randomized 2:1 to placebo. Treprostinil (6 mcg per breath) will be administered every 4 hours. The dose will increase from 6 to12 breaths (maximum 72 mcg) over the first 20 hours, maintained for 7 days, and tapered down over 3 days.
89581335|NCT02370095|Placebo Comparator|Placebo|Placebo administration will be administered as above for the active arm
89581336|NCT05370053|Experimental|ELF-test|Patients receive ELF testing (a blood draw) and their hepatologist receives the result within a week.
88974217|NCT05028361|Other|Sequential Vaccination Group|Subjects will receive a dose of mRNA COVID-19 vaccine (either as a study procedure or standard of care) and saline placebo at Visit 1, IIV4 at Visit 2, and mRNA COVID-19 vaccine at Visit 3 (only for participants receiving their primary series of mRNA COVID-19 vaccine.)
88974218|NCT05001594|No Intervention|Usual care+ Sham device|"Each participant will go through the normal rehabilitation process that follows ACL reconstruction+ a sham device used in the same was as the intervention group.~The sham device will look the same, will gave the same pressure around the leg, but will not vibrate."
88974219|NCT05001594|Experimental|Usual care+ knee vibratory device|Each participant will go through the normal rehabilitation process that follows ACL reconstruction. Additionally, each participant will receive the active device that applies non-invasive vibrational stimulation to the leg for two months, and will be asked to wear it during ambulation for at least an hour per day.
88974220|NCT05001594|No Intervention|Normative data|"Healthy participants will go through one session of the full protocol (excluding blood tests):~Questionnaires (IKDC, TSK, GAD-7).~Biomechanical analysis during walking, stair ambulation, and hoping.~Quadriceps and Hamstring strength testing"
88974221|NCT04992936|Experimental|Extract from the wine industry|Participants will consume the extract from the wine industry for 5 weeks.
89581337|NCT05370053|No Intervention|Control|No intervention.
89581338|NCT01783678|Experimental|Genotype 2 treatment-naive|Treatment-naive (TN) participants with HIV-1 and genotype 2 HCV coinfection will receive sofosbuvir plus RBV for 12 weeks.
89581339|NCT01783678|Experimental|Genotype 2/3 treatment-experienced|Treatment-experienced (TE) participants with HIV-1 and genotype 2 or 3 HCV co-infection will receive sofosbuvir plus RBV for 24 weeks.
89581340|NCT01783678|Experimental|Genotype 1/3/4 treatment-naive|Treatment naive (TN) participants with HIV-1 and genotype 1, 3, or 4 HCV co-infection will receive sofosbuvir plus RBV for 24 weeks.
89029981|NCT02951403|Experimental|Operative treatment|Patients to whom the elbow arthroscopy will be performed.
89029982|NCT02951403|Other|Conservative treatment|Patients to whom special physiotherapy will be advised.
88974222|NCT04992936|Placebo Comparator|Placebo|Participants will consume maltodextrin for 5 weeks.
88974223|NCT04981847|Experimental|US Healthy Diet|Participants in this group will be assigned to follow the Healthy US dietary pattern as presented by the US Dietary Guidelines. As described here https://www.nia.nih.gov/health/usda-food-patterns: This eating pattern is based on the types and amounts of foods Americans typically consume. The main types of food in this eating pattern include a variety of vegetables; fruits; whole grains; fat-free or low-fat dairy; seafood, poultry, meat, and eggs; and nuts, seeds, and soy products.
88974224|NCT04981847|Experimental|Mediterranean diet|Participants in this group will be assigned to follow the Mediterranean dietary pattern as presented by the US Dietary Guidelines. As described here https://www.nia.nih.gov/health/usda-food-patterns: This eating pattern contains more fruits and seafood and less dairy than the Healthy U.S.-Style Eating Pattern. There is also less calcium and vitamin D because it includes fewer dairy foods.
88974225|NCT04981847|Experimental|Vegetarian diet|Participants in this group will be assigned to follow the Vegetarian dietary pattern as presented by the US Dietary Guidelines. As described here https://www.nia.nih.gov/health/usda-food-patterns: This eating pattern contains no meat, poultry, or seafood. Compared with the Healthy U.S.-Style Eating Pattern, it contains more soy products, eggs, beans and peas, nuts and seeds, and whole grains.
89209472|NCT00730847|Experimental|Cervarix Group|Healthy female subjects who received three doses of the Cervarix vaccine, administered intramuscularly in the deltoid region according to a 0, 1 and 6-month schedule.
89209473|NCT00573066|Experimental|Dosing level|A predetermined dose of Dexmedetomidine
89209474|NCT00889980||Melanoma|Patients with primary melanoma
89209475|NCT02541552|Experimental|Knee arthroscopic patient|"1) Male and females 2) Age 16-60 years 3) Scheduled surgery 4) Knee arthroscopy 5) ASA Class I - III~Volume finding study to follow up-and-down design using a single cohort of patients. Intervention of patient will be dependent on effect of previous patients dose of and response to Ropivacaine 0.5% injectate."
89209476|NCT00890058||Cases|Postmenopausal breast cancer patients with hand pain receiving aromatase inhibitors
89209477|NCT00890058||Controls|Postmenopausal breast cancer patients with hand pain not receiving aromatase inhibitors
89209478|NCT00886314|Active Comparator|midazolam|
89209479|NCT00886314|Active Comparator|clown doctor|
89209480|NCT00890214|Active Comparator|1 prostacyclin group|prostacyclin analogue (PGIA) used as circuit anticoagulant during continuous venovenous hemodiafiltration (CVVHDF) in acute kidney failure patients
89209481|NCT00890214|Active Comparator|2 heparin group|unfractionated heparin used as circuit anticoagulant during continuous venovenous hemodiafiltration (CVVHDF) in acute kidney failure patients
89209482|NCT00886392||diabetic macular edema|Type 2 diabetes patients who had clinically significant macular edema by the criterion of the ETDRS
89209483|NCT02543736|Other|Instrumented Treadmill System|The Instrumented Treadmill System records vertical ground reaction force and pressures.
89581341|NCT01734772|Experimental|Reference (Part 1/A, Part 2/C)|multiple doses of dabigatran (alone)
89581342|NCT01734772|Experimental|Test 1 (Part 1/Treatment B)|concomitant administration of dabigatran and ticagrelor
89581343|NCT01734772|Experimental|Test 2 (Part 2/Treatment D)|staggered administration of ticagrelor and dabigatran
89581344|NCT02340221|Experimental|Taselisib + Fulvestrant|Participants received taselisib 4 milligrams (mg) taken orally QD beginning at Cycle 1, Day 1 and fulvestrant 500 mg by IM injection at Cycle 1, Days 1 and 15, and then on Day 1 of each subsequent 28-day cycle until disease progression, unacceptable toxicity, or study termination by the Sponsor.
89581345|NCT02340221|Placebo Comparator|Placebo + Fulvestrant|Participants received placebo taken orally once daily (QD) beginning at Cycle 1, Day 1, and fulvestrant 500 mg administered by intramuscular (IM) injection at Cycle 1, Days 1 and 15, and then on Day 1 of each subsequent 28-day cycle until disease progression, unacceptable toxicity, or study termination by the Sponsor.
89581346|NCT02395133|Placebo Comparator|Placebo|Subcutaneous injection of Placebo (for Dupilumab) was administered once weekly (QW) from Week 1 (Day 1) to Week 36.
89581347|NCT02395133|Experimental|Dupilumab 300 mg Q8W|Subcutaneous injection of Dupilumab 300 milligram (mg) alternatively with placebo (matched to Dupilumab) was administered once every eight week (Q8W) from Week 1 to Week 36.
89581348|NCT02395133|Experimental|Dupilumab 300 mg Q4W|Subcutaneous injection of Dupilumab 300 mg alternatively with placebo (matched to Dupilumab) was administered once every four week (Q4W) from Week 1 to Week 36.
89581349|NCT02395133|Experimental|Dupilumab 300 mg Q2W/QW|Subcutaneous injection of Dupilumab 300 mg alternatively with placebo (matched to Dupilumab) was administered once every week (QW) or twice a week (Q2W) from Week 1 to Week 36.
89581350|NCT02395055|Experimental|BCD-057 group|BCD-057 (adalimumab) at a dose of 40 mg, administered as a single subcutaneous injection, which will be performed on week 0.
89581351|NCT02395055|Active Comparator|Humira group|Humira (adalimumab) at a dose of 40 mg, administered as a single subcutaneous injection, which will be performed on week 0.
89581352|NCT02369159|Experimental|Peramivir (IV)|"Subjects randomized to peramivir will receive an age appropriate single dose, diluted to a maximum volume of 100 mL in normal saline, administered as a short intravenous infusion over a minimum of 15 minutes.~Subjects ≥12 years will receive a dose of 600 mg.~Subjects <12 years will receive a dose of 12 mg/kg (to a maximum dose of 600 mg).~Subjects < 6 months will receive a dose of 8 mg/kg."
89581353|NCT02369159|Active Comparator|Oseltamivir|"Subjects randomized to oral oseltamivir will receive an age appropriate dose twice daily for 5 days.~Subjects ≥ 13 years will receive a 75mg dose administered as a capsule or oral suspension (twice daily for 5 days).~Subjects < 13 years of age will receive a weight-based dose administered as a capsule or oral suspension (twice daily for 5 days)."
89581354|NCT02368691|Experimental|GTx-024|GTx-024 capsules, 18 mg PO once-daily for up to 12 months
89581355|NCT02394665|Experimental|Group 1: SIB + IMRT|"Simultaneous Integrated Boost (SIB) plus Fractionated Intensity Modulated Radiation therapy (IMRT), with concurrent Temozolomide therapy for 6 weeks;~3D MRSI during week 3, end of RT and other protocol-defined time points during adjuvant Temozolomide therapy;~Functional Assessment of Cancer Therapy-Brain (FACT-Br) questionnaire administered at protocol-defined time points;~Adjuvant Temozolomide Therapy for up to 12 cycles."
89581356|NCT02394665|Experimental|Group 2: SRS Boost + IMRT|"For patients with High-Risk Tumor Volumes (HTV) <= 4cm; or multiple HTVs <= 3 cm:~Stereotactic Radiosurgery Boost (SRS Boost) followed one week later by Fractionated Intensity Modulated Radiation therapy (IMRT), and concurrent Temozolomide therapy for 6 weeks;~3D MRSI during week 3, end of RT and other protocol-defined time points during adjuvant Temozolomide therapy;~Functional Assessment of Cancer Therapy-Brain (FACT-Br) questionnaire administered at protocol-defined time points;~Adjuvant Temozolomide Therapy for up to 12 cycles."
89581357|NCT02367911|Experimental|Active Arm|122-0551 Foam, topically applied twice daily for two weeks
89581358|NCT02367911|Placebo Comparator|Vehicle Arm|Vehicle Foam, topically applied twice daily for two weeks
89581359|NCT02339285|Experimental|tACS (alpha)|10 Hz tACS with a peak-to-peak amplitude of 2 milliamps (mA) for 40 minutes. Uses tACS (alpha) device.
89581360|NCT02339285|Experimental|tACS (gamma)|40 Hz tACS with a peak-to-peak amplitude of 2 milliamps (mA) for 40 minutes. Uses tACS (gamma) device.
89581361|NCT02339285|Sham Comparator|Sham stimulation|Will include 10 seconds of ramp in to 1 minute of 10 Hz tACS with a ramp out of 10 seconds for a total of 80 seconds of stimulation. Uses tACS (alpha) device.
89581362|NCT02367833|Experimental|Combined Oral Contraceptives (COC)|Apri (or generic equivalent - Reclipsen) (30µg/d EE, 150 µg/d desogestrel) is a monophasic dosing regimen of 21 active and 7 placebo pills. On Day 1 of the Intervention, participants in the COC group will begin taking the COC pill. Each participant in this group will ingest active pills from the first pack each day for the first 21 days. Pills ingested on days 22 through 28 are placebo pills. A second pill pack will begin on day 29 and pills with active ingredients will be ingested from the second pack each day for days 29-49. On day 50, the participants will immediately begin a 3rd pill pack, if the post-study testing is still occurring, and will ingest a pill with active ingredients from the third pack for days 50-56 (or for as long as the post-study testing is occurring).
89581363|NCT02367833|Experimental|Transdermal Contraceptive (TDC)|Participants in the TDC group will apply a 20 cm2 patch (Xulane: 20µg/d EE,150µg/d norelgestromin) to the abdomen, upper arm or buttock. The patch will be changed once weekly on the same day each week for weeks 1-3 (days 1-21, removed on day 22) and weeks 5-8 (days 29-56). Week 4 (days 22-28) will be a patch-free week. As soon as the post-study testing is complete, subjects will remove the patch.
89209484|NCT00884208||Group 1|Recommend assistive device
89209485|NCT00884208||Group 2|Consultation for PT assessment
88974230|NCT04940949|Experimental|Single Intravenous (IV) Dose of Lu AF90103|Participants will receive a single IV dose of Lu AF90103.
88974231|NCT04940949|Placebo Comparator|Single IV Dose of Placebo|Participants will receive a single IV dose of placebo matching to Lu AF90103.
89209486|NCT00923520|Experimental|1|DMS 612 on day 1 and 2 with doses starting at 3.5mg/m2 to 18.5mg/m2 every 21 days until MTD is reached
89209487|NCT02543424|Experimental|Patient group|Brain damaged adults with either hemiparesis and/or hemineglect. Brain damaged children with developmental and/or acquired disease inducing hemiparesis and/or hemineglect.
89581364|NCT02367833|Experimental|Contraceptive Vaginal Ring (CVR)|Participants in the CVR group (NuvaRing - 15µg/d EE/120µg/d etonogestrel) will insert a vaginal ring into the vagina on Day 1 of the intervention. The vaginal ring will be removed and discarded after 3 weeks of continuous use (days 1-21 of continuous use and removed on day 22). There will be one week (days 22-28) that will be ring-free. A new ring will be inserted for days 29-49. On day 50, the second ring will be removed, and a third ring will be immediately inserted into the vagina (if the post-study testing is still occurring). The third ring will remain in the vagina for the last week of the post-study period (days 50-56). As soon as the post-study testing is complete, subjects will remove the ring.
89581365|NCT02367833|No Intervention|Control Group|The Control group will complete all procedures with the exception of contraceptive therapy.
89581366|NCT02367521|Experimental|LFR rTMS|Investigators propose to deliver 1200 pulses daily at 110% Motor threshold for 4 weeks using four trains of 300 pulses daily separated by an intertrain interval of 60 seconds.
89581367|NCT02367521|Placebo Comparator|Sham Treatment|Control patients will receive treatment using an identically appearing coil that produces the same sound and is the same weight as the active coil, but has negligible magnetic field strength
89581368|NCT02338193|Experimental|DAPA/MET Extended Release (XR)|Dapagliflozin plus metformin XR- 5 mg/1000 mg with meal for 4 weeks DAPA/MET XR- 5mg/1000 mg BID final dose for 20 weeks
89581369|NCT02338193|Active Comparator|Dapaglifloxin|Dapagliflozin- 10 mg once daily before first meal for 24 weeks
89581370|NCT02338193|Active Comparator|Metformin XR|Metformin XR with 500 mg once a day for 2 weeks, followed by 500 mg twice a day for 2 weeks, followed by 500 mg in the morning (AM), 1000 mg in the evening ( PM) for 2 weeks, with 1000 mg twice a day as the final dose for 20 weeks
89581371|NCT01783444|Experimental|Capecitabine 1250 mg/m2|Capecitabine (1250 mg/m2 twice daily) for two weeks, followed by one week rest period in 3-weeks cycles (investigational arm).
89581372|NCT01783444|Experimental|Everolimus 10 mg|Everolimus (10 mg daily) (investigational arm).
89581373|NCT01783444|Active Comparator|Everolimus 10 mg + Exemestane 25 mg|Everolimus (10 mg daily) with Exemestane (25 mg daily) (control arm).
89581374|NCT02394275|Experimental|Single arm:|Eligible patients with receive intervention: frozen fecal microbiota transplantation (FMT), kept at -20 oC and will be thawed prior to administration. Patients on antibiotic to control CDI will discontinue antibiotic 24 hours prior to FMT.
89581375|NCT01608724|Experimental|Open label|Saxagliptin, oral 5mg once a day(Q. D.)
89209488|NCT02543424|Sham Comparator|Control group|Healthy adults and children.
89581376|NCT02366195|Experimental|Talimogene Laherparepvec|Talimogene laherparepvec was administered by intralesional injection into injectable cutaneous, subcutaneous, and nodal lesions at an initial dose of 10⁶ plaque-forming units (PFU) per mL on day 1 followed by a dose of 10⁸ PFU/mL 21 days after the initial dose and every 14 days thereafter. Participants were treated with talimogene laherparepvec until they achieved a complete response, all injectable tumors had disappeared, clinically significant (resulting in clinical deterioration or requiring change of therapy) disease progression beyond 6 months of treatment, per modified World Health Organization (WHO) response criteria, or intolerance of study treatment, whichever occurred first.
89581377|NCT02364947|Experimental|Nalmefene hydrochloride 10 mg|
89581378|NCT02364947|Experimental|Nalmefene hydrochloride 20 mg|
89581379|NCT02364947|Placebo Comparator|Placebo|
89581380|NCT02392481||Healthy subjects|
89581381|NCT02392481||Mild asthma|
88974232|NCT04940949|Experimental|2 Single IV Doses of Lu AF90103|Participants will receive 2 single IV doses of Lu AF90103 separated by at least 5 days.
88974233|NCT04929457||Individuals screened for Familial Hypercholesterolemia|Individuals participating in diagnostic activities in the digiphysical health care screening program for Familial Hypercholesterolemia and have provided informed consent are included in the cohort.
88974234|NCT04921514|Experimental|Patient and relatives|
88974235|NCT04916418|Placebo Comparator|G1, Placebo|Intravenous saline (NaCl 0,9%) will be administered. G1 group will be administered an initial dose of placebo (20ml) per catheter bilaterally (total volume 40ml) after TTP has been placed. This is followed by 20ml doses of placebo per catheter every 8 hours until 72 hours from the first dose has passed.
88974236|NCT04916418|Active Comparator|G2, Ropivacaine|Ropivacaine 0.5%. G2 group will be administered an initial dose of ropivacaine (20 ml) per catheter bilaterally (total volume 40ml) after the TTP has been placed. This is followed by 20 ml doses of ropivacain per catheter every 8 hours until 72 hours from the first dose has passed.
88974237|NCT04899518|Placebo Comparator|Vehicle Ophthalmic Solution|
88974238|NCT04899518|Experimental|ALY688 Ophthalmic Solution Concentration 1|
88974239|NCT04899518|Experimental|ALY688 Ophthalmic Solution Concentration 2|
89029983|NCT01244516|Other|galyfilcon A|Subjects that were randomized to receive the galyfilcon A lens with a base curve of 8.30 throughout the entire course of the study.
89209489|NCT00612456|Experimental|Arm 1|Pazopanib eye drops formulation 5 mg/mL daily for 28 days
89209490|NCT00612456|Experimental|Arm 2|Pazopanib eye drop formulation 5mg/mL TID for 28 days
89209491|NCT00612456|Experimental|Arm 3|Pazopanib eye drop formulation 2mg/mL TID for 28 days
89209492|NCT00730691|Placebo Comparator|Placebo|Placebo-matching capsules, orally, once daily for up to 9 weeks.
89581382|NCT02392481||Moderate asthma|
89581383|NCT02392481||Severe asthma|
89581384|NCT02392403|Experimental|Nucleus CI532 cochlear implant|
89581385|NCT02392247||Cardiac Surgery Patients|Single cohort of 50 consecutive cardiac surgery patients undergoing cardiopulmonary bypass. The study compares output of two technologies for determination of point of care coagulation function: thromboelastography (TEG; current care option) and the new technology Sonic Estimation of Elasticity via Resonance (SEER) Sonorheometry
89581386|NCT02337725|Experimental|TVP-1012 1 mg|For 2 weeks during the run-in period, one tablet of placebo orally, once daily before or after breakfast, followed by 26 weeks during the treatment period, one tablet of TVP-1012 1 mg orally, once daily before or after breakfast.
89581387|NCT02337725|Placebo Comparator|Placebo|For 2 weeks during the run-in period, one tablet of placebo orally, once daily before or after breakfast, followed by 26 weeks during the treatment period, one tablet of placebo orally, once daily before or after breakfast.
89581388|NCT02337491|Experimental|Cohort A Safety Lead-In: Pembrolizumab (DL 0) + Bevacizumab|"Pembrolizumab (Dose Level 0): 200 mg administered intravenously on days 1 and 22 of each 42 day cycle Bevacizumab: 10 mg/kg administered Intravenously on days 1, 15 and 29 of each 42 day cycle~Participants were treated until disease progression or unacceptable toxicity up to 16 cycles."
89581389|NCT02337491|Experimental|Cohort A: Pembrolizumab + Bevacizumab|"Pembrolizumab: 200 mg administered intravenously on days 1 and 22 of each 42 day cycle Bevacizumab: 10 mg/kg administered Intravenously on days 1, 15 and 29 of each 42 day cycle~Participants were treated until disease progression or unacceptable toxicity up to 16 cycles."
89581390|NCT02337491|Experimental|Cohort B: Pembrolizumab|"Pembrolizumab: 200 mg administered intravenously on days 1 and 22 of each 42 day cycle~Participants were treated until disease progression or unacceptable toxicity up to 16 cycles."
89581391|NCT01765582|Experimental|Arm A: Concurrent FOLFOXIRI + Bevacizumab|Participants will receive concurrent FOLFOXIRI along with 5 mg/kg of bevacizumab with treatment cycle of 2 weeks during first 4 month induction phase (plus optional 2 months of induction for participants who exhibit good response and tolerate the regimen) followed by administration of 5-FU with bevacizumab or capecitabine with bevacizumab as per investigator's discretion in maintenance phase. Following progression on first-line therapy (PD1), bevacizumab (dose equivalent, 2.5 mg/kg/week) will be administered as second-line therapy in combination with fluoropyrimidine based chemotherapy at the investigator's discretion.
89581392|NCT01765582|Experimental|Arm B: Sequential FOLFOXIRI + Bevacizumab|Participants will receive alternating 4-week administrations of FOLFOX/bevacizumab and folinic acid (leucovorin), 5-FU, and irinotecan (FOLFIRI) /Bevacizumab with a treatment cycle of 2 weeks during first 4-month induction phase (plus optional 2 months of induction for participants who exhibit good response and tolerate the regimen) followed by administration of 5-FU with bevacizumab or capecitabine with bevacizumab as per investigator's discretion in maintenance phase. Following progression on first-line therapy (PD1), bevacizumab (dose equivalent, 2.5 mg/kg/week) will be administered as second-line therapy in combination with fluoropyrimidine based chemotherapy at the investigator's discretion.
89581393|NCT01765582|Experimental|Arm C: FOLFOX + Bevacizumab|Participants will receive FOLFOX along with 5 mg/kg of bevacizumab with treatment cycle of 2 weeks during first 4-month induction phase (plus optional 2 months of induction for participants who exhibit good response and tolerate the regimen) followed by administration of 5-FU with bevacizumab or capecitabine with bevacizumab as per investigator's discretion in maintenance phase. Following progression on first-line therapy (PD1), bevacizumab (dose equivalent, 2.5 mg/kg/week) will be administered as second-line therapy in combination with fluoropyrimidine based chemotherapy at the investigator's discretion.
89581394|NCT04413838|Experimental|NIVOLUMAB on top of routine standard of care|This correspond to COVID-19+ patients diagnosed upon biological testing (PCR Coronavirus SARS-CoV2), hospitalized, obese (BMI≥30kg/m²), with low lymphocyte counts, without high biological probability of macrophage activation syndrome (hemoglobin < 9.2 g/dl AND a blood platelets < 110000/mm3 AND aspartate aminotransferase (AST) > 30 U/l AND ferritin > 600 mg/l) and upon oxygen (either using mask or nasal cannula) but without criteria for ICU admission benefiting from a NIVOLUMAB treatment and routine standard of care for COVID-19 infection at the time of study inclusion
89581395|NCT04413838|Other|Standard of care for COVID-19 infection|This correspond to COVID-19+ patients diagnosed upon biological testing (PCR Coronavirus SARS-CoV2), hospitalized, obese (BMI≥30kg/m²), with low lymphocyte counts, without high biological probability of macrophage activation syndrome (hemoglobin < 9.2 g/dl AND a blood platelets < 110000/mm3 AND AST > 30 U/l AND ferritin > 600 mg/l) and upon oxygen (either using mask or nasal cannula) but without criteria for ICU admission benefiting from a routine standard of care for COVID-19 infection at the time of study inclusion
89581396|NCT01649375|Experimental|Secukinumab 75 mg|Secukinumab 75 mg subcutaneous injection once weekly at baseline, Weeks 1, 2, 3 and 4, followed by dosing every 4 weeks.
89581397|NCT01649375|Experimental|Secukinumab 150 mg|Secukinumab 150 mg subcutaneous injection once weekly at baseline, Weeks 1, 2, 3 and 4, followed by dosing every 4 weeks
89581398|NCT01649375|Placebo Comparator|Placebo|Placebo subcutaneous injection once weekly at baseline, Weeks 1, 2, 3 and 4, followed by dosing every 4 weeks
89581399|NCT02336555|Experimental|MK-8291 → Placebo|In Treatment Period 1, participants were orally administered 10 mg MK-8291 once daily on Days 1 and 2, twice daily on Days 3 to 27, and once daily on Day 28 of the period. After Treatment Period 1, participants were to undergo a minimum of a 7-day Washout Period, which was followed by Treatment Period 2. In Treatment Period 2, participants were orally administered Placebo once daily on Days 1 and 2, twice daily on Days 3 to 27, and once daily on Day 28 of the period. (Total duration of treatment: up to approximately 63 days)
89581400|NCT02336555|Experimental|Placebo → MK-8291|In Treatment Period 1, participants were orally administered Placebo once daily on Days 1 and 2, twice daily on Days 3 to 27, and once daily on Day 28 of the period. After Treatment Period 1, participants were to undergo a minimum of a 7-day Washout Period, which was followed by Treatment Period 2. In Treatment Period 2, participants were orally administered 10 mg MK-8291 once daily on Days 1 and 2, twice daily on Days 3 to 27, and once daily on Day 28 of the period. (Total duration of treatment: up to approximately 63 days)
89581401|NCT01648283|Experimental|Methadone arm|"Intravenous racemic methadone HCl, 6.0 mg bolus~Oral deuterated racemic methadone HCl, 11 mg capsule (IND#58,511)"
89581402|NCT01649297|Experimental|empagliflozin (high dose qd)|Patients receive Empagliflozin high dose once daily
89581403|NCT01649297|Experimental|empagliflozin (high dose bid)|Patients receive Empagliflozin high dose split twice daily
89581404|NCT01649297|Experimental|empagliflozin (low dose qd)|Patients receive Empagliflozin low dose once daily
89581405|NCT01649297|Experimental|empagliflozin (low dose bid)|Patients receive Empagliflozin low dose split twice daily
89581406|NCT01649297|Placebo Comparator|Placebo|Patients receive placebo matching Empagliflozin
89581407|NCT01648205|Experimental|Placebo followed by Ranolazine Administration|Placebo for 1 month and Ranolazine for 5 months.
89581408|NCT04894253||Single group of 30 patients with systemic lupus|
89581409|NCT02362451|Experimental|1/Lead-in T-cell Receptor g Alternate Reading Frame Protein Dendritic Cell (DC) Vaccine Treatment|All patients to receive autologous multi-epitope T-cell receptor g alternate reading frame protein (TARP) DC vaccine before randomization
89581410|NCT02362451|Experimental|2/Active T-cell Receptor g Alternate Reading Frame Protein Dendritic Cell (DC) Vaccine Treatment|Autologous multi-epitope T-cell receptor g alternate reading frame protein (TARP) DC vaccine after randomization
89581411|NCT02362451|Placebo Comparator|3/Placebo|Autologous elutriated monocyte vaccine placebo after randomization
89581412|NCT01734382|Experimental|Part 1: Tocilizumab (TCZ) Q2W|Participants will receive tocilizumab intravenous (IV) infusions (12 mg/kg for participants < 30 kg; 8 mg/kg for participants >/= 30 kg) once every other week (Q2W) up to 24 weeks or until occurrence of a protocol defined laboratory abnormality in Part 1 of the study.
89581413|NCT01734382|Experimental|Part 2: TCZ IV 12 mg/kg Q3W/Q4W|Participants with weight < 30 kg will receive tocilizumab IV infusions of 12 mg/kg once every three weeks (Q3W) up to 52 weeks or until occurrence of neutropenia, thrombocytopenia, or liver enzyme abnormality as per protocol criteria. Participants who complete 5 consecutive infusions of Q3W and have a laboratory abnormality of neutropenia, thrombocytopenia or elevated liver enzymes as per protocol criteria, after resolution of this laboratory abnormality will switch to tocilizumab IV infusions of 12 mg/kg once every four weeks (Q4W) up to Week 52 in Part 2 of the study.
89581414|NCT01734382|Experimental|Part 2: TCZ IV 8 mg/kg Q3W/Q4W|Participants with weight >/= 30 kg will receive tocilizumab IV infusions of 8 mg/kg Q3W up to 52 weeks or until occurrence of neutropenia, thrombocytopenia, or liver enzyme abnormality as per protocol criteria. Participants who complete 5 consecutive infusions of Q3W and have a laboratory abnormality of neutropenia, thrombocytopenia or elevated liver enzymes as per protocol criteria, after resolution of this laboratory abnormality will switch to tocilizumab IV infusions of 8 mg/kg Q4W up to Week 52 in Part 2 of the study.
89581415|NCT02391311|Active Comparator|Sham tDCS + Cognitive Remediation|Subjects in the sham arm will be administered sham transcranial direct current stimulation (tDCS) (i.e., tDCS will be administered for 30 seconds and then will automatically turn off). Sham group will have identical intervention of engagement in 10 1-hour computerized cognitive remediation therapy sessions during sham tDCS as with the active tDCS condition.
89581416|NCT02391311|Experimental|Active tDCS + Cognitive Remediation|Subjects in the active arm will be administered active transcranial direct current stimulation (tDCS) (i.e., 2.0 mA tDCS will be administered for 20 minutes and then will automatically turn off). Active group will have identical intervention engagement in 10 1-hour computerized cognitive remediation therapy sessions during active tDCS as with the sham tDCS condition.
88974240|NCT04892511|No Intervention|Standard treatment|"Post-thrombectomy patients will have their blood pressure measured every hour for the first 24 hours after thrombectomy, and every 6 hours from 24 to 72 hours. The target blood pressure is not predefined by the study, but in patients who have received previous treatment with rt-PA, it is advisable to keep it below 180/110 mmHg. If the patient has not received rt-PA, there is no limitation, although the guidelines recommend keeping the pressure below 200/120 mmHg.~The hypotensive or hypertensive treatments used will be noted."
89581417|NCT01765426|Experimental|Group 1: TDV using PharmaJet® Injector|Takeda's Tetravalent Dengue Vaccine Candidate (TDV) [previously DENVax] one dose injection in arm 1 and placebo: phosphate buffered saline (PBS) one dose injection in arm 2, using needle-free PharmaJet® Injector, intradermal, on Day 0 and TDV, injection using needle-free PharmaJet® Injector, intradermal, one dose on Day 90.
89581418|NCT01765426|Experimental|Group 2: TDV using PharmaJet® Injector|TDV injection, one dose in each arm, using needle-free PharmaJet® Injector, intradermal, on Day 0 and placebo: PBS, injection using needle-free PharmaJet® Injector, intradermal, one dose on Day 90.
89581419|NCT01765426|Experimental|Group 3: TDV using Needle and Syringe|TDV one dose injection in arm 1 and placebo: PBS one dose injection in arm 2, using needle and syringe, intradermal, on Day 0 and TDV injection using needle and syringe, intradermal, one dose on Day 90.
89581420|NCT01765426|Experimental|Group 4: TDV using PharmaJet® Injector|TDV injection, one dose in each arm, using needle-free PharmaJet® Injector, intradermal, on Day 0 and TDV, injection using needle-free PharmaJet® Injector, intradermal, one dose on Day 90.
89581421|NCT01765270|Active Comparator|Saxagliptin|Treatments to be administered are saxagliptin 5 mg (once daily) to begin at randomization 5 to 7 days before CABG surgery, continuing through the peri-CABG surgery period and discharge, and for a total of 30 (± 5) days post-CABG surgery.
89581422|NCT01765270|Placebo Comparator|Placebo|Treatments to be administered are placebo 5 mg (once daily) to begin at randomization 5 to 7 days before CABG surgery, continuing through the peri-CABG surgery period and discharge, and for a total of 30 (± 5) days post-CABG surgery.
89581423|NCT01733758|Experimental|Albiglutide 30 mg weekly|Subjects will be randomly assigned to double blind albiglutide 30 mg weekly treatment for 52 weeks
89581424|NCT01733758|Experimental|Albiglutide 50 mg weekly|Subjects will be randomly assigned to double blind albiglutide 50 mg weekly until Week 52
89581425|NCT01733758|Placebo Comparator|Placebo|Subjects will be randomly assigned to double blind matching albiglutide placebo administered weekly. Subjects will then cross-over to double-blind treatment with albiglutide 30 mg weekly at Week 24 until Week 52
89581426|NCT01733758|Active Comparator|Liraglutide 0.9 mg daily|Subjects will be randomly assigned to open-label liraglutide for 52 weeks
89581427|NCT01607554|Experimental|Irinotecan|The starting dose of irinotecan for the study is 180 mg/m2, given intravenously every 14 days. Each 14 day period will constitute one cycle of treatment.
89581428|NCT01607476|Experimental|Alzheimer's Disease|"Subjects who have the clinical diagnosis of probable AD ages 50 and older who have a study partner who is the participant's power of attorney (POA) or legally authorized representative (LAR).~Interventions include C11 PiB PET/CT and F-18 Flutametamol PET/CT with C11 PiB PET/CT performed first."
89581429|NCT01607476|Active Comparator|Cognitive Normal Elderly|Cognitive Normal subjects who are greater than 60 years of age. Interventions include C11 PiB PET/CT and F-18 Flutametamol PET/CT with C11 PiB PET/CT performed first.
89581430|NCT01607476|Active Comparator|Cognitive Normal Young|Cognitively normal subjects who are between 30-60 years old. Interventions include C11 PiB PET/CT and F-18 Flutametamol PET/CT with C11 PiB PET/CT performed first.
89581431|NCT01765192|Experimental|Roflumilast plus montelukast, then placebo plus montelukast|Participants in sequence 1 received roflumilast 500 μg plus montelukast 10 mg orally once daily for 4 weeks followed by a 4-week washout period and then received placebo plus montelukast 10 mg orally once daily for 4 weeks.
89581432|NCT01765192|Experimental|Placebo plus montelukast, then roflumilast plus montelukast|Participants in sequence 2 received placebo plus montelukast 10 mg orally once daily for 4 weeks followed by a 4-week washout period and then received roflumilast 500 μg plus montelukast 10 mg orally once daily for 4 weeks.
89581433|NCT01733680|Active Comparator|Amiloride|"Drug: Subjects will take 5mg qd Amiloride for 2 weeks, 10mg qd Amiloride for 3 weeks, 15 mg qd Amiloride for 3 weeks.~Behavioral: Each week subjects will complete the AISRS, BRIEF-A, and CGI."
89581434|NCT01733680|Placebo Comparator|Placebo|Drug: Subjects will take placebo for 8 weeks Behavioral: Each week subjects will complete questionnaires: AISRS, BRIEF-A, and CGI
89581435|NCT04892498|Experimental|RT+PD-1+GM-CSF+IL-2|
89581436|NCT02336165|Experimental|Cohort A|Subjects with newly diagnosed unmethylated MGMT GBM receive durvalumab (10 mg/kg Q2W) + standard radiotherapy.
89581437|NCT02336165|Experimental|Cohort B|Bevacizumab-naïve subjects with recurrent GBM receive durvalumab (10 mg/kg Q2W) as monotherapy.
89581438|NCT02336165|Experimental|Cohort B2|Bevacizumab-naïve subjects with recurrent GBM receive durvalumab (10 mg/kg Q2W) + bevacizumab (10 mg/kg Q2W).
89581439|NCT02336165|Experimental|Cohort B3|Bevacizumab-naïve subjects with recurrent GBM receive durvalumab (10 mg/kg Q2W) + bevacizumab (3 mg/kg Q2W).
88974241|NCT04892511|Experimental|Optimized hemodynamic treatment|"Post-thrombectomy patients will have their blood pressure measured every 30 minutes for the first 24 hours after thrombectomy, and every 1 hour from 24 to 72 hours. Blood pressure objectives will depend on the degree of recanalization achieved after thrombectomy (see intervention section).~The hypotensive or hypertensive treatments used will be noted."
88974242|NCT04890132|Experimental|Normal Controls|normal control participants - no history of neurologic or inner ear disease
88974243|NCT04890132|Experimental|Peripheral Vestibular Dysfunction|"Patients with unilateral vestibular damage due to monophasic illness such as vestibular neuritis or vestibular schwannoma (VS).~For VS patients, the investigators will test them in three states: pre-op, sub-acute post-op (6 weeks), and chronic post-op (6 months)."
88974244|NCT04888598||Type 1 diabetic patients|Recently diagnosed type 1 diabetes patients
89581440|NCT02336165|Experimental|Cohort C|Bevacizumab-refractory subjects with recurrent GBM receive durvalumab (10 mg/kg Q2W) + continued bevacizumab (10 mg/kg Q2W).
89581441|NCT02360111|Experimental|Post Transplant Cyclophosphamide|Melphalan 70 mg/m 2/d will be administered intravenously on d-6 and -5 Fludarabine 25 mg/m 2/d will be administered intravenously on d-6 thru -2 Day -1 will be a day or rest Cyclophosphamide and mesna will be given on d+3 and +4 Siro +/- MMF will be started in those patients who are to receive it on d+5. Neupogen will begin d+7.
89581442|NCT02334683|Experimental|Electrophysiologic guidance|Electrophysiologic guidance, using electrical stimulation
89581443|NCT02334683|Active Comparator|Ultrasound guidance|Ultrasound guidance,using sound waves through a wand directed towards the targeted muscles.
89581444|NCT02319044|Experimental|MEDI4736|MEDI4736 monotherapy
89581445|NCT02319044|Experimental|Tremelimumab|Tremelimumab monotherapy
89581446|NCT02319044|Experimental|MEDI4736 + Tremelimumab|MEDI4736 + Tremelimumab combination therapy
89581447|NCT01649765|Experimental|Arm 1|belimumab 10mg/kg IV monthly
89581448|NCT01649765|Placebo Comparator|Arm 2|Normal Saline IV monthly
89581449|NCT02317562|Experimental|I10E Arm|
89581450|NCT02317016|Experimental|AZD9291 and rosuvastatin|Sequential treatments of rosuvastatin alone followed by AZD9291 alone, followed by rosuvastatin + AZD9291.
89581451|NCT02311478|Experimental|T380A Copper IUD|All participants will receive a T380A copper intrauterine device when enrolled. They can continue using the device for as long as they wish. The study will be completed when 6 months of prospective bleeding data has been collected.
89581452|NCT02388932|Experimental|Treatment (SBRT)|"Participants undergo Stereotactic Body Radiation Therapy in 5 fractions at least 40 hours apart over 10-18 days.~Three dose levels: 40Gy and 45Gy all in 5 fractions. Each initial dose level will have 6 participants allocated to them. All participants are assessed at their 3 month post SBRT visit for Dose-Limiting Toxicities (DLTs). If ≤1 participant experiences a DLT, participants will be enrolled at the next dose level. If ≥3 participants experience a DLT, further accrual will be permanently halted and the study stopped. If 2 participants experience a DLT, then an additional 6 participants will be enrolled at the same dose level. In this setting, if ≤ 3/12 participants have a DLT, participants will be enrolled at the next dose level. If ≥ 4/12 participants have a DLT, further accrual will be permanently halted and the study stopped and 35 Gy will not be recommended as safe.~The dosing strategy for the 2nd (45Gy) cohort will be identical to the first."
89581453|NCT02388776|Experimental|ROTEM|Clinical burn ICU Inpatients receiving blood draws for ROTEM analysis and fibrinogen levels.
89581454|NCT02316548|No Intervention|No Radiation Therapy|Patients do not receive radiation therapy (RT).
89581455|NCT02316548|Experimental|Intensity-modulated radiation therapy (IMRT)|Postoperative adjuvant intensity-modulated radiation therapy (IMRT).
89581456|NCT02281760|Experimental|Combination therapy with dabrafenib and trametinib in patients with ECD|Patients with Erdheim Chester Disease (ECD) and BRAFV600E mutation received combination therapy with dabrafenib, a BRAFV600E inhibitor 150mg orally every twelve hours, and trametinib, an inhibitor of MEK, downstream of BRAF, 2mg orally daily.
89581457|NCT02390531|Experimental|Bevacizumab 0.250 mg|Dosage of injected Bevacizumab to be studied
89581458|NCT02390531|Experimental|Bevacizumab 0.125 mg|Dosage of injected Bevacizumab to be studied
89581459|NCT02390531|Experimental|Bevacizumab 0.063 mg|Dosage of injected Bevacizumab to be studied
89581460|NCT02390531|Experimental|Bevacizumab 0.031 mg|Dosage of injected Bevacizumab to be studied
88974245|NCT04857333||Pulmonary Nodule|Patients are recommended for using antibiotics, solely follow-up or surgical resection according to the current clinical guideline for management of indeterminate pulmonary nodule. No intervention is administered for this observatory study.
88974246|NCT04856449|Experimental|DBT Skills Training|This intervention will consist of a 6-month-group DBT-skills training continuation, in which participants will be trained in mindfulness, emotion regulation, distress tolerance and interpersonal effectiveness.
88974247|NCT04856449|Active Comparator|Eye Movement Desensitization and Reprocessing (EMDR)|EMDR will consist of individual therapy sessions that will be focused on processing traumatic memories. Participants will receive up to 16 individual EMDR sessions, of 60 min each.
88974248|NCT04854603|Experimental|Chocolate milk with a regular added sugar content|Dairy product with a regular sugar content
88974249|NCT04854603|Experimental|Chocolate milk with a reduced added sugar content|Dairy product with a reduced sugar content
89581461|NCT02390531|Experimental|Bevacizumab 0.016 mg|Dosage of injected Bevacizumab to be studied
89581462|NCT02390531|Experimental|Bevacizumab 0.008 mg|Dosage of injected Bevacizumab to be studied
89581463|NCT02390531|Experimental|Bevacizumab 0.004 mg|Dosage of injected Bevacizumab to be studied
89581464|NCT02390531|Experimental|Bevacizumab 0.002 mg|Dosage of injected Bevacizumab to be studied
89581465|NCT02390219|Experimental|Lumacaftor/Ivacaftor combination|Lumacaftor 400 milligram (mg) and ivacaftor 250 mg combination tablet orally twice daily for 24 weeks.
89581466|NCT02334215|Experimental|Methadone plus Patient Navigation|Participants will begin methadone treatment during detention and will have a patient navigator for up to 3 months post-release from detention.
89581467|NCT02334215|Experimental|Methadone|Participants will begin methadone during detention.
89581468|NCT02334215|Active Comparator|Enhanced Treatment as Usual|Participants will receive opioid detoxification during detention, as well as drug abuse education, overdose prevention education, and referral to drug abuse treatment and overdose prevention services in the community.
89581469|NCT02359877|Experimental|BCD-054|Pegylated interferon beta 1a Single doses - 60 mcg, SC/IM Single doses - 120 mcg, SC/IM Single doses - 240 mcg, SC/IM Single doses - 360 mcg, SC/IM Multiple doses - 180 mcg, SC/IM
89581470|NCT02359877|Active Comparator|Rebif|interferon beta 1a 44 mcg, SC, 3 times a week for 2 weeks
89581471|NCT02359877|Active Comparator|Avonex|interferon beta 1a 30 mcg, IM, once a week for 2 weeks
89581472|NCT02389829|Active Comparator|Hydromorphone|Hydromorphone 1mg, administered as intravenous drip over 5 minutes. Patients can receive second 1mg dose at 1 hour.
89581473|NCT02389829|Active Comparator|Prochlorperazine|"Prochlorperazine 10mg, administered as intravenous drip over 5 minutes. Diphenhydramine 25mg co-administered.~Patients can receive second 10mg dose at 1 hour."
89581474|NCT02358863|Experimental|Chemotherapy|"Standard chemotherapy doublet based on molecular testing using one of the following interventions:~Modified FOLFOX6 Docetaxel/Capecitabine Cisplatin/Irinotecan Cisplatin/Docetaxel IRI/EPI EPI/Docetaxel Irinotecan/Docetaxel Docetaxel"
88974250|NCT04854603|Experimental|Yogurt with a regular added sugar content|Dairy product with a regular sugar content
88974251|NCT04854603|Experimental|Yogurt with a reduced added sugar content|Dairy product with a reduced sugar content
88974252|NCT04854603|Experimental|Energy-free control|Potable water
88974253|NCT04844879|Experimental|Single-arm|Patients suitable to receive Medacta GMK® Sphere system for primary TKA will be invited to take part to the study during the preoperative visit. Follow-ups are performed after 2, 6 and 12 months. Data collection includes clinical and radiological data for preoperative and postoperative assessments, as well as intraoperative details.
89581475|NCT02358473|Experimental|mogamulizumab + docetaxel|"Mogamulizumab will be given as monotherapy in a 4-week run-in period. Subjects will then receive up to 6 cycles of mogamulizumab in combination with docetaxel at appropriate intervals.~Subjects may then continue to receive mogamulizumab, at the same dose administered in Cycle 1, once every 3 weeks as monotherapy."
89581476|NCT02357459|Experimental|FX006 32mg|Single 5 mL intra-articular (IA) injection Extended-release Formulation
89581477|NCT02357459|Placebo Comparator|Normal Saline|Single 5 mL intra-articular (IA) injection
89581478|NCT02357459|Active Comparator|TCA IR 40 mg|Single 1 mL intra-articular (IA) injection TCA IR 40 mg: Immediate-release formulation
89581479|NCT04902599|Active Comparator|Vaser ulstrasound-assisted dissection technique|Patient's arm that undergoes treatment using Renuvion/j-Plasma for subdermal skin tightening and contouring with the Vaser ultrasound-assisted dissection technique.
89581480|NCT04902599|Active Comparator|Blunt dissection technique|Patient's arm that undergoes treatment using Renuvion/j-Plasma for subdermal skin tightening and contouring with blunt dissection technique.
89581481|NCT04889729||GENOMED4ALL - MDS patients|Information on targeted mutation screening (NGS including 60 genes related to MDS) from 13284 MDS patients
89581482|NCT02332889|Experimental|Decitabine/Vaccine Therapy|Biological/Vaccine: Vaccine (autologous dendritic cells) and Drug: Decitabine and Hiltonol
89581483|NCT02357147|Experimental|Arm 1|"Combination Phase - Amatuximab + Pemetrexed and Cisplatin~Maintenance Phase - Amatuximab"
89581484|NCT02357147|Experimental|Arm 2|"Combination Phase - Placebo + Pemetrexed and Cisplatin~Maintenance Phase - Placebo"
89581485|NCT02356211|Experimental|Treatment|Geriatric Multifactorial Falls Assessment Clinic
89581486|NCT02356211|No Intervention|Control|Geriatric Evaluation and Management Service (GEM)
89581487|NCT02332655|Experimental|Cannabidiol|All subjects will receive the experimental Epidiolex (cannabidiol) oral solution to be taken at home twice a day, and will be treated on an outpatient basis. The drug will be taken for 48 weeks unless the subject chooses to participate in the extension phase of the study, in which case the subject will continue to receive the drug for one additional year or until the drug is approved for clinical use for the treatment of epilepsy in patients with Sturge-Weber syndrome.
89581488|NCT02388737|Experimental|Vonoprazan 10 mg|"Lansoprazole 30 mg, capsules or tablets, orally, once, daily, for up to 4 or 8 weeks or until confirmed healing of erosive esophagitis (EE) in healing phase for participants with ongoing EE.~Vonoprazan 10 mg, tablets, orally, once, daily, and Vonoprazan 20 mg, placebo-matching tablets, orally, once, daily, and Lansoprazole 15 mg placebo-matching, capsules, orally, once, daily, for up to 24 weeks in maintenance phase for participants with confirmed EE healing."
89581489|NCT02388737|Experimental|Vonoprazan 20 mg|"Lansoprazole 30 mg, capsules or tablets, orally, once, daily, for up to 4 or 8 weeks or until confirmed healing of erosive esophagitis (EE) in healing phase for participants with ongoing EE.~Vonoprazan 20 mg, tablets, orally, once, daily, and Vonoprazan 10 mg, placebo-matching tablets, orally, once, daily, and Lansoprazole 15 mg, placebo-matching capsules, orally, once, daily, for up to 24 weeks in maintenance phase for participants with confirmed EE healing"
89581490|NCT02388737|Active Comparator|Lansoprazole 15 mg|"Lansoprazole 30 mg, capsules or tablets, orally, once, daily, for up to 4 or 8 weeks or until confirmed healing of erosive esophagitis (EE) in healing phase for participants with ongoing EE.~Lansoprazole 15 mg, capsules, orally, once, daily, and Vonoprazan 10 mg, placebo-matching tablets, orally, once, daily, and Vonoprazan 20 mg, placebo-matching tablets, orally, once, daily, for up to 24 weeks in maintenance phase for participants with confirmed EE healing."
89517580|NCT05389501|Experimental|Intervention Group|"The Experiment Group will receive the following services from the community social worker:~1. Developing Database on Digital App 2. Community Needs Assessment 3 Pre-Post Test Survey 4. Existing services by government of Pakistan (BHU/ LHW)~Additionally, the Experiment Group will receive the following services from the health social worker:~Psychosocial needs assessment and mental health awareness~Measurement of Basic Health Clinical Indicators~33. Health Awareness & Literacy for following areas:~Reproductive and Child Health~Hygiene and Sanitation & Nutrition and Immunity Building~Health-Risk Behavior Modification"
89581491|NCT02355743|Experimental|rtPA lock therapy Recipients|rtPA 2 mg/2 ml, or 110% of the volume of the catheter lumen if less than 2 mL, administered locally in a volume to fill the lumen (dead space) of the CVAD, once weekly for a total of 24 weeks
88974256|NCT04820868||Cancer Arm|Participants with new diagnosis of cancer, from whom blood samples will be collected
88974257|NCT04820868||Healthy Arm|Participants without known presence of malignancies or benign diseases, from whom blood samples will be collected
88974258|NCT04814264|Experimental|Sex-matched red blood cell transfusion|All patients will receive red blood cells (RBCs) that are ABO and Rh compatible as per routine blood bank practices. In addition to routine compatibility, subjects in this arm will receive blood that is matched to their sex (donor and recipient sex are the same). Patients in this arm will receive RBCs matched to their sex until discharge from hospital or death.
89581492|NCT02388347|Placebo Comparator|Placebo|Participants will receive a single-dose of Placebo subcutaneous (SC) injection on Day 1.
89581493|NCT02388347|Experimental|MEDI7836 Dose 1|Participants will receive a single-dose of MEDI7836 Dose 1 SC injection on Day 1.
89581494|NCT02388347|Experimental|MEDI7836 Dose 2|Participants will receive a single-dose of MEDI7836 Dose 2 SC injection on Day 1.
89581495|NCT02388347|Experimental|MEDI7836 Dose 3|Participants will receive a single-dose of MEDI7836 Dose 3 SC injection on Day 1.
89581496|NCT02388347|Experimental|MEDI7836 Dose 4|Participants will receive a single-dose of MEDI7836 Dose 4 SC injection on Day 1.
89581497|NCT02355665|Experimental|Nicotine|Nicotine Spray
89581498|NCT02355665|Placebo Comparator|Placebo|Placebo to match Nicotine spray
89581499|NCT02010255|Experimental|Cohort A, Group 1 (12 wk): CPT Class B (7-9)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class B (CPT score 7-9)
89581500|NCT02010255|Experimental|Cohort A, Group 1 (24 wk): CPT Class B (7-9)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class B (CPT score 7-9)
89581501|NCT02010255|Experimental|Cohort A, Group 2 (12 wk): CPT Class C (10-12)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class C (CPT score 10-12)
89581502|NCT02010255|Experimental|Cohort A, Group 2 (24 wk): CPT Class C (10-12)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class C (CPT score 10-12)
89581503|NCT02010255|Experimental|Cohort B, Group 3 (12 wk): F0-F3 Fibrosis|LDV/SOF (90/400 mg) plus RBV (weight-based: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with Fibrosis Stage F0-F3
89581504|NCT02010255|Experimental|Cohort B, Group 3 (24 wk): F0-F3 Fibrosis|LDV/SOF (90/400 mg) plus RBV (weight-based: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with Fibrosis Stage F0-F3
89581505|NCT02010255|Experimental|Cohort B, Group 4 (12 wk): CPT Class A (5-6)|LDV/SOF (90/400 mg) plus RBV (weight-based: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with CPT Class A (CPT score 5-6)
89581506|NCT02010255|Experimental|Cohort B, Group 4 (24 wk): CPT Class A (5-6)|LDV/SOF (90/400 mg) plus RBV (weight-based: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with CPT Class A (CPT score 5-6)
89581507|NCT02010255|Experimental|Cohort B, Group 5 (12 wk): CPT Class B (7-9)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class B (CPT score 7-9)
89581508|NCT02010255|Experimental|Cohort B, Group 5 (24 wk): CPT Class B (7-9)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class B (CPT score 7-9)
89581509|NCT02010255|Experimental|Cohort B, Group 6 (12 wk): CPT Class C (10-12)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class C (CPT score 10-12)
89581510|NCT02010255|Experimental|Cohort B, Group 6 (24 wk): CPT Class C (10-12)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class C (CPT score 10-12)
89581511|NCT02010255|Experimental|Cohort B, Group 7 (12 wk): FCH|LDV/SOF (90/400 mg) plus RBV (weight-based: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with FCH
89581512|NCT02010255|Experimental|Cohort B, Group 7 (24 wk): FCH|LDV/SOF (90/400 mg) plus RBV (weight-based: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with FCH
89581513|NCT02354417|Experimental|ProHema-CB|"All subjects will receive treatment with ProHema-CB (ex-vivo modulated human cord blood cells) transplant.~ProHema-CB (the prostaglandin derivative, 16,16-dimethyl prostaglandin E2 also referred to as FT1050) will be prepared and administered in one of two formulations, based upon subject weight:~For subjects > 35 kg, ProHema-CB will be administered as 150 mL product in a blood bag via gravity infusion. It will be infused at 10 mL to 15 mL per minute, for a total infusion time of 10 to 15 min.~For subject's ≤ 35 kg, ProHema-CB will be administered as a 50 mL product in a syringe via syringe pump.o It will be infused at 5 mL/kg per hour for a total infusion time of up to ~1 hour."
89581514|NCT02332187|Sham Comparator|Sham electrical stimulation|The intervention will consist of sham electrical stimulation using an All Stim stimulator of each quadriceps leg muscle for 30 minutes per day for a total of 7 days.
89581515|NCT02332187|Active Comparator|Active electrical stimulation|The intervention will consist of active electrical stimulation using an All Stim stimulator of each quadriceps leg muscle for 30 minutes per day for a total of 7 days.
89029984|NCT01244516|Other|lotrafilcon B|Subjects that were randomized to wear lotrafilcon B lens throughout the course of the study.
89029985|NCT01244516|Other|comfilcon A|Subjects that were randomized to wear comfilcon A lens throughout the course of the study.
89581516|NCT02330549|Experimental|Cenicriviroc 150 mg|Cenicriviroc (CVC) 150 mg, administered orally once daily and taken every morning with food for up to 24 weeks.
89581517|NCT02330549|Placebo Comparator|Placebo|Placebo-matching CVC, administered orally once daily and taken every morning with food for up to 24 weeks.
89581518|NCT02009865|Experimental|Epanova 2 g/day|Arm 1
89581519|NCT02009865|Placebo Comparator|Olive Oil 2 g/day|Arm 2
88974259|NCT04814264|Experimental|Sex-mismatched red blood cell transfusion|All patients will receive red blood cells (RBCs) that are ABO and Rh compatible as per routine blood bank practices. In addition to routine compatibility, subjects in this arm will receive blood that is not matched to their sex (donor and recipient sex are not the same). Patients in this arm will receive RBCs mismatched to their sex until discharge from hospital or death.
88974260|NCT04810390|Experimental|Bilastine|Daily instillation of one drop in each eye of Bilastine ophthalmic solution 0.6% for 8 weeks.
88974261|NCT04810390|Placebo Comparator|Placebo|Daily instillation of one drop in each eye of placebo for 8 weeks.
88974262|NCT04788446|Experimental|Mini-flipped Game-based Learning|"group diet education, an interactive food card game, and guidance on the Mediterranean diet~once a week for 40 minutes.~lasts for 8 weeks"
88974263|NCT04788446|Placebo Comparator|Balanced diet|"given a leaflet on balanced diet and nutrition among the elderly~lasts for 8 weeks"
89581520|NCT01620177|Experimental|0% THC with 0.065 g/dL BAC|
88974264|NCT04785118|Active Comparator|buscopan|Patients will receive IV hyoscine butyl-bromide 20 mg in 2 ml, just before spinal anaesthesia.
88974265|NCT04785118|Active Comparator|ondansetron|Patients will receive IV ondansetron 4 mg in 2 ml, just before spinal anaesthesia.
88974266|NCT04785118|Placebo Comparator|control|Patients will receive 2 ml of IV normal saline as a placebo just before spinal anaesthesia.
89029986|NCT02951208|Experimental|Active tDCS + Active VR|Active tDCS over the left DLPFC (30 minutes) combined with active VR motivation training (60 minutes), administered 3 times per week for 4 weeks.
89581521|NCT01620177|Experimental|2.5-3.5% THC with 0.065 g/dL BAC|
89581522|NCT01620177|Experimental|6.0-7.5% THC and 0.065 g/dL BAC|
89581523|NCT01620177|Experimental|2.5-3.5% THC with 0 g/dL BAC|
89581524|NCT01620177|Experimental|6.0-7.5% THC with 0 g/dL BAC|
89581525|NCT01620177|Experimental|0% THC with 0 g/dL BAC|
89581526|NCT02075541|Experimental|10-AS01E group|Subjects in this group will receive the investigational NTHi vaccine.
89581527|NCT02075541|Placebo Comparator|Control group|Subjects in this group will receive placebo.
89581528|NCT02330081|Experimental|Mirasol|"Subject will be infused with two products at the same time:~radio-labeled platelets derived from subjects stored whole blood which has been treated with Mirasol.~radio-labeled platelets derived from subjects untreated fresh whole blood."
89581529|NCT01986855|Experimental|Ertugliflozin (5 mg)|Ertugliflozin, 5 mg, oral, one 5 mg ertugliflozin tablet and one placebo tablet, once daily for 52 weeks
89581530|NCT01986855|Experimental|Ertugliflozin (15 mg)|Ertugliflozin, 15 mg, oral, one 5 mg and one 10 mg tablet, once daily for 52 weeks
89581531|NCT01986855|Placebo Comparator|Placebo|Matching placebo
89581532|NCT02075463|Experimental|GSK1278863 Arm|Subjects will receive a fixed starting dose of 12 milligrams (mg) GSK1278863 once daily (QD) orally for first 4 weeks. From Week 4 the dose of GSK1278863 will be adjusted based on Hgb levels and evaluated every 4 weeks until Week 16. This starting dose may be changed during the study if there is an early indication of either lack of efficacy or the rate of rise in Hgb is too rapid
89581533|NCT02353871|Experimental|BTX-A-HAC NG|Clostridium Botulinum Toxin Type A (BTX-A-HAC NG) 50 Unit (U) solution, single dose (intramuscular injection). The total treatment volume (0.25 mL) was divided into five injections (0.05 mL per injection) injected in five predefined sites across the glabellar region. A total of 50 U was injected.
89581534|NCT02353871|Placebo Comparator|Placebo|Single dose (intramuscular injection). The total placebo volume (0.25 mL) was divided into five injections (0.05 mL per injection) injected in five predefined sites across the glabellar region.
89581535|NCT02009397|Experimental|Ipilimumab and GM-CSF|IV ipilimumab followed by subcutaneous GM-CSF, for up to 4 cycles
89581536|NCT04666311||Adult presumptive TB cases|Adult presumptive TB cases (age ≥18years) with one or more TB symptoms (WHO recommended four-symptom screening; cough, weight loss, night sweats, fever) of any duration.
89581537|NCT02312219||Low Dose Methotrexate|Subjects will take 1 mg folic acid once daily plus 5 mg methotrexate (MTX) . If clinically stable at the week 1 visit, the dose of MTX will be increased to 10 mg once weekly through week 12. For subjects who remain clinically stable on 10 mg MTX or placebo through the week 12 visit, the dose of MTX will be increased to 15 mg once weekly through week 24. If the subject does not meet the criteria for dose escalation at the week 1 or 12 study visit, then the subject will remain on his/her current dose until the next study visit at which time he/she will be re-evaluated for dose escalation.
89581538|NCT02312219||Placebo|Subjects will take 1 mg folic acid once daily plus placebo once weekly. If clinically stable at weeks 1 and 12, the number of placebo tablets will be increased in a manner matching those on the MTX.
89581539|NCT01986231|Experimental|Open-Label Glucagon|Subjects will receive 8 doses of glucagon, each dose will be 2.0 mcg per kg.
88974267|NCT04775524|Experimental|Storytelling Through Music (STM)|"Participants will be randomized into two (2) groups: Storytelling Through Music (STM) and Waitlist (Storytelling Through Music-Hybrid)~Storytelling Through Music (STM) group will participate in the study for a total of 19 weeks with 6 weeks of the STM program and 3 months follow up.~Storytelling Through Music (STM) utilizes multiple modalities including storytelling, reflective writing, self-care skills (i.e., breathing exercises, meditation, self-compassion, body scans), and songwriting.~Weeks 1-4: participants are led through weekly writing workshop over an online platform (i.e., Zoom or an equivalent) to develop their stories. Simultaneous with the writing sessions are 10-minute self-care lessons~Week 5: Participants will be paired with a professional songwriter who will put their story into a song.~Week 6: During the last week, participants will have one more writing workshop to debrief about the intervention."
88974268|NCT04775524|Experimental|Wait List / Storytelling Through Music-Hybrid|"Participants will be randomized into two (2) groups: Storytelling Through Music (STM) and Waitlist (Storytelling Through Music-Hybrid)~Waitlist control group (Storytelling Through Music-Hybrid) will participate in the study for a total of 13 weeks with 2 weeks of Storytelling Through Music-Hybrid program and 11 weeks of follow up .~Storytelling Through Music-Hybrid involves participants listening to songs created for other healthcare professionals for 2 weeks."
88974269|NCT04763980|Active Comparator|Cohort A (survey, genetic testing)|Patients complete a survey about knowledge of, attitudes towards, and awareness of genetic testing and technology preferences and use over 30 minutes at baseline and over 20 minutes at exit or follow up. Patients may also undergo genetic testing.
88974270|NCT04763980|Experimental|Cohort B (educational session, survey, genetic testing)|Patients participate in educational session with health coach over 60 minutes. Patients also complete a survey about knowledge of, attitudes towards, and awareness of genetic testing and technology preferences and use over 30 minutes at baseline and over 20 minutes at exit or follow up. Patients may undergo genetic testing.
88974271|NCT04746456||Menopausal women|Women will complete a series of questionnaires, including the VVAQ
88974272|NCT04726722|Experimental|Design of the CBT treatment content|Patient determined CBT content (i.e. person-centered) vs. therapist determined I-CBT content
88974273|NCT04726722|Experimental|Control of support and feedback|Patient-controlled support and feedback (person-centred) vs. therapist -controlled.
88974274|NCT04702256|Experimental|Obinutuzumab arm|Obinutuzumab administration plus oral mycophenolate mofetil (MMF)
88974275|NCT04702256|Active Comparator|Corticosteroids arm|Oral corticosteroids plus MMF
89581540|NCT02312063|Experimental|Sitagliptin|Sitagliptin 50 mg a day for 16 weeks
89581541|NCT02312063|Active Comparator|Glimepiride|Glimepiride 0.5 mg a day for 16 weeks
89581542|NCT02353169|Experimental|Dexmedetomidine 0.25mcg/kg|0.25mcg/kg dexmedetomidine diluted with normal saline in a 10mL syringe, administered intravenously over 60 seconds starting 3 minutes after induction of anesthesia.
89581543|NCT02353169|Experimental|Dexmedetomidine 0.5mcg/kg|0.5mcg/kg dexmedetomidine diluted with normal saline in a 10mL syringe, administered intravenously over 60 seconds starting 3 minutes after induction of anesthesia.
89581544|NCT02353169|Experimental|Dexmedetomidine 0.75mcg/kg|0.75mcg/kg dexmedetomidine diluted with normal saline in a 10mL syringe, administered intravenously over 60 seconds starting 3 minutes after induction of anesthesia.
89581545|NCT02353169|Sham Comparator|Saline bolus|10mL normal saline solution administered intravenously over 60 seconds starting 3 minutes after induction of anesthesia.
89581546|NCT02009163|Experimental|Lisdexamfetamine dimesylate|Administer one capsule (50 or 70 mg) orally daily at approximately 7:00 AM.
89581547|NCT02009163|Placebo Comparator|Placebo|Administer one capsule orally daily at approximately 7:00 AM.
89581548|NCT01983969|Experimental|Azacitidine + Vorinostat + Gemcitabine + Busulfan + Melphalan|Busulfan test dose 32 mg/m2 by vein either as outpatient before Day -12 or as inpatient on Day -11. Busulfan pharmacokinetics performed with test dose and first dose on Day -8. Doses on Days -6 and -5 adjusted to target an AUC of 4,000 microMol.min-1. Dexamethasone 8 mg by vein twice a day from Day -11 AM to Day -2 PM. Caphosol oral rinses 30 mL four times a day used from Day -9. Oral glutamine, 15 g four times a day, swished, gargled and swallowed from Day -9. Pyridoxine 100 mg by vein or mouth three times a day from Day -1. Vorinostat 1000 mg by vein on Day -11 through Day -2. Gemcitabine loading dose 75 mg/m2 by vein followed by 22775 mg/m2 by vein on Day -8. Melphalan 60 mg/m2 by vein on Days -3 and -2. Azacitidine starting dose 15 mg/ m2 by vein on Day -11. Stem cell transplant on Day 0. Patients with CD20+ tumors receive rituximab 375 mg/m2 by vein on Days -9.
89581549|NCT02008773|Active Comparator|valacyclovir|3000mg daily oral 16 weeks
89581550|NCT02008773|Placebo Comparator|placebo|placebo 6 capsules daily oral 16 weeks
89581551|NCT02257567|Experimental|Arm A (Phase II Randomization): Polatuzumab+BR in FL|Polatuzumab vedotin will be administered with bendamustine and rituximab in participants with FL.
89581552|NCT02257567|Active Comparator|Arm B (Phase II Randomization): BR in FL|Bendamustine and rituximab will be administered alone (that is, without polatuzumab vedotin) as a control arm in participants with FL.
89581553|NCT02257567|Experimental|Arm C (Phase II Randomization): Polatuzumab+BR in DLBCL|Polatuzumab vedotin will be administered with bendamustine and rituximab in participants with DLBCL.
89581554|NCT02257567|Active Comparator|Arm D (Phase II Randomization): BR in DLBCL|Bendamustine and rituximab will be administered alone (that is, without polatuzumab vedotin) as a control arm in participants with DLBCL.
89581555|NCT02257567|Experimental|Arm E (Phase II Expansion): Polatuzumab+BG in FL|Polatuzumab vedotin will be administered with bendamustine and obinutuzumab in participants with FL.
89581556|NCT02257567|Experimental|Arm F (Phase II Expansion): Polatuzumab+BG in DLBCL|Polatuzumab vedotin will be administered with bendamustine and obinutuzumab in participants with DLBCL.
89029987|NCT02951208|Sham Comparator|Sham tDCS + Sham VR|Sham tDCS over the left DLPFC (30 minutes) combined with sham VR motivation training (60 minutes), administered 3 times per week for 4 weeks.
89029988|NCT02951325|No Intervention|Standard|"Surgery +/- chemotherapy only~Surgery (Standard/routine care) Cysto-prostatectomy and pelvic nodal dissection as part of their standard care.~Chemotherapy All patients following cysto-prostatectomy (inclusive of those received neo-adjuvant chemotherapy) will receive upto 4 cycles of adjuvant chemotherapy if medically fit for the same. The chemotherapy regimen, doses and schedule will be as per standard institutional practice. No concomitant chemotherapy with radiotherapy is recommended.~No radiation therapy will be given."
89033265|NCT02916888||Care provided by pediatric dermatologist|Standard of care management of atopic dermatitis by pediatric dermatologist. This includes an initial visit with a 2-week follow-up.
89581557|NCT02257567|Experimental|Cohort 1A (Phase Ib Safety Run-In): Polatuzumab+BR in DLBCL|Polatuzumab vedotin will be administered with bendamustine and rituximab in participants with DLBCL.
89581558|NCT02257567|Experimental|Cohort 1A (Phase Ib Safety Run-In): Polatuzumab+BR in FL|Polatuzumab vedotin will be administered with bendamustine and rituximab in participants with FL.
89581559|NCT02257567|Experimental|Cohort 1B (Phase Ib Safety Run-In): Polatuzumab+BG in DLBCL|Polatuzumab vedotin will be administered with bendamustine and obinutuzumab in participants with DLBCL.
89581560|NCT02257567|Experimental|Cohort 1B (Phase Ib Safety Run-In): Polatuzumab+BG in FL|Polatuzumab vedotin will be administered with bendamustine and obinutuzumab in participants with FL.
89033266|NCT02941874||Healthy volunteers IRAP measurement|
89581561|NCT02257567|Experimental|Arm G (Phase II NF Cohort): Polatuzumab+BR in DLBCL|In this New Formulation (NF) cohort, Polatuzumab vedotin (lyophilized) will be administered with bendamustine and rituximab in participants with DLBCL.
89581562|NCT02257567|Experimental|Arm H (Phase II NF Cohort): Polatuzumab+BR in DLBCL|In this NF cohort, Polatuzumab vedotin (lyophilized) will be administered with bendamustine and rituximab in participants with DLBCL.
89581563|NCT04419961|No Intervention|Control|Routine care.
89033267|NCT02941835|Other|radiation|intervention: pre-operative breast irradiation of 21 fx of 2.2Gy and boost 2.66Gy
89033268|NCT02920593|Experimental|Vitamin D Prophylaxis|Participants will be provided Vitamin D 3000 IU daily or Vitamin D 4000 IU daily with and without concurrent use of prenatal vitamins, respectively.
89033269|NCT02920593|No Intervention|No Vitamin D Prophylaxis|Participants will not receive additional Vitamin D in the pregnancy.
89581564|NCT04419961|Experimental|Intervention|Routine care plus participation in an educational program including a group discussion and a booklet.
89581565|NCT05330299|Experimental|COMPASS (single arm)|Participants will be treated with an online CBT program that is specifically tailored to illness-related distress in the context of IBD.
89581566|NCT01642615|Experimental|Healing Phase: Dexlansoprazole 60 mg|Dexlansoprazole 60 mg delayed-release capsules, orally, once daily for up to 8 weeks.
89581567|NCT01642615|Experimental|Maintenance Phase: Dexlansoprazole 30 mg|Participants who are healed at Week 8 will be randomized to receive 30 mg dexlansoprazole delayed-release capsules, orally, once daily for up to 16 weeks.
89581568|NCT01642615|Experimental|Maintenance Phase: Placebo|Participants who are healed at Week 8 will be randomized to receive dexlansoprazole placebo-matching capsules, orally, once daily for up to 16 weeks.
89581569|NCT02311361|Experimental|Durvalumab + 8 Gray (Gy) in 1 fraction|Cohort 1/Dose Level A1 Durvalumab + 8 Gray (Gy) in 1 fraction
89581570|NCT02311361|Experimental|Durvalumab +5 Gy in 5 fractions|Cohort 2/Dose Level A2 Durvalumab +5 Gy in 5 fractions
89581571|NCT02311361|Experimental|Tremelimumab + 8 Gy in 1 fraction|Cohort 3/Dose Level B1 (was removed with Amendment A) Tremelimumab + 8 Gy in 1 fraction
89581572|NCT02311361|Experimental|Tremelimumab + 5 Gy in 5 fractions|Cohort 4/Dose Level B2 (was removed with Amendment A) Tremelimumab + 5 Gy in 5 fractions
88811284|NCT02861573|Experimental|Pembrolizumab+Abiraterone+Prednisone|Participants with AC mCRPC in Cohort D will receive pembrolizumab 200 mg IV on Day 1 Q3W, abiraterone acetate 1000 mg PO QD and prednisone 5 mg tablet PO BID continuously from Day 1 of Cycle 1. Treatment with pembrolizumab will continue for a maximum of 35 cycles (up to 2 years) or until progression. Participants who must discontinue 1 of the 2 drugs due to adverse events in the combination may continue the study with the other combination drug.
89581573|NCT02311361|Experimental|Durvalumab +Tremelimumab + 8 Gy in 1 fraction|Cohort C/ Dose Level C1 Durvalumab +Tremelimumab + 8 Gy in 1 fraction
89581574|NCT02311361|Experimental|Durvalumab +Tremelimumab +5 Gy in 5 fractions|Cohort C/Dose Level C2 Durvalumab +Tremelimumab +5 Gy in 5 fractions
89581575|NCT02352779|Experimental|Arm I (low-dose omega-3 fatty acid)|Patients receive low-dose omega-3 fatty acid supplementation PO BID and placebo PO BID for 6 weeks.
89581576|NCT02352779|Experimental|Arm II (high-dose omega-3 fatty acid)|Patients receive high-dose omega-3 fatty acid supplementation PO BID for 6 weeks.
89581577|NCT02352779|Placebo Comparator|Arm III (placebo)|Patients receive placebo PO BID for 6 weeks.
89581578|NCT04893395|Experimental|Pharmacogenomic Screening|Eligible patients who verbally consent to participate will receive two pharmacogenomics telehealth visits.
89581579|NCT02257489|Experimental|50 mg single dose|8 subjects in total; 6 subjects to received ACE-083 (50 mg) and 2 subjects to receive placebo, single injection, intramuscularly
89581580|NCT02257489|Experimental|100 mg single dose|8 subjects in total; 6 subjects to received ACE-083 (100 mg) and 2 subjects to receive placebo, single injection, intramuscularly
89581581|NCT02257489|Experimental|200 mg single dose|8 subjects in total; 6 subjects to received ACE-083 (200 mg) and 2 subjects to receive placebo, single injection, intramuscularly
88974276|NCT04701359|Experimental|Group A (TiN-coating)|Patients with knee osteoarthritis receive total knee arthroplasty with Titanium-Nitride (TiN)-coated implant.
88974277|NCT04701359|Active Comparator|Group B (CoCr-alloy)|Patients with knee osteoarthritis receive total knee arthroplasty with Cobalt-Chromium (CoCr)-alloy implant.
89517581|NCT05389501|Active Comparator|Control Group|"The Control Group will receive the following services from the community social worker:~Developing Database on Digital App~Community Needs Assessment 3 Pre-Post Test Survey~4. Existing services by government of Pakistan (BHU/ LHW)"
88974279|NCT04650399|Experimental|Active|VLA1553
88974280|NCT04650399|Placebo Comparator|Placebo|Placebo
88974281|NCT04641702|Experimental|Pharmacologic challenge|Measurement of esophageal response toatropine using functional lumen imaging probe (FLIP)
88974282|NCT04636320|Experimental|Patient group COVID-19|120 patients with history of laboratory-proven symptomatic COVID-19 infection managed without hospitalization
88974283|NCT04636320|Active Comparator|Healthy volunteer group|120 healthy volunteers. Age- and sex-matched controls
89581582|NCT02257489|Experimental|100 mg multiple dose|8 subjects in total; 6 subjects to received ACE-083 (100 mg) and 2 subjects to receive placebo, two injections 3 weeks apart, intramuscularly
89581583|NCT02257489|Experimental|200 mg multiple dose|8 subjects in total; 6 subjects to received ACE-083 (200 mg) and 2 subjects to receive placebo, two injections 3 weeks apart, intramuscularly
89581584|NCT02257489|Experimental|100 mg (multiple dose)|9 subjects in total; 6 subjects to received ACE-083 (100 mg) and 3 subjects to receive placebo, two injections 3 weeks apart, intramuscularly
88974284|NCT04635527|Experimental|IBI318 combined with conventional TACE (cTACE)|
88974285|NCT04635527|Placebo Comparator|Placebo combined with conventional TACE (cTACE)|
88974286|NCT04622553|Other|Cohort 1 and 2|7 patients aged 12 to < 18 years , inclusive in cohort-1 7 patients aged 6 to < 12 years, inclusive in cohort-2
88974287|NCT04618978|Other|PSG and actigraphy device evaluations|All patients will be evaluated and diagnosed according to the records by Gold standard for PLMs diagnosis and also by the actigraphy devices recording.
88974288|NCT04608630|Active Comparator|Denosumab|Patients allocated to the Denosumab arm will receive Denosumab 60mg in 1ml, administered via subcutaneous injection on Study Days 1 and 180.
88974289|NCT04608630|Active Comparator|Zoledronic acid|Patients allocated to the Zoledronic acid arm will receive Zoledronic acid 5mg in 100ml 0.9% Sodium Chloride, administered via intravenous infusion over at least 15 minutes on Study Day 1.
88974290|NCT04608630|Placebo Comparator|Placebo|Patients allocated to the placebo arm will receive 0.9% Sodium Chloride 1ml administered via subcutaneous injection on Days 1 and Day 180 and 0.9% Sodium Chloride 100ml administered via intravenous infusion over at least 15 minutes on Day 1.
89581585|NCT02257489|Experimental|150 mg multiple dose|9 subjects in total; 6 subjects to received ACE-083 (150 mg) and 3 subjects to receive placebo, two injections 3 weeks apart, intramuscularly
89581586|NCT05645809|Experimental|MONOFIX® PGCL|An absorbable suture
89581587|NCT05645809|Active Comparator|Quill Monoderm™|An absorbable suture
89581588|NCT02329223|Experimental|Omalizumab 300 mg|Participants received omalizumab 300 mg subcutaneously every 4 weeks during the 12 week treatment period.
88974291|NCT04602520||Dying patients|"Behavioral: Focused end of life conversations to promote connections among patients, family members and clinicians.~All eligible dying patients and families in the 3 participating acute care wards are invited to participate in wish elicitation and implementation. For clinician interviews, criterion sampling will be used, based on involvement in the care of enrolled dying patients. We will use qualitative and quantitative methods to collect and analyze data. Quantitative data will include characteristics of patients, families and clinicians. Qualitative data will be based on interviews. Pending the pandemic burden, and the status of their grief, family members of deceased patients may be invited for an interview later months after the death of their loved one."
88974292|NCT04588623|Active Comparator|Omnibiotic Stress Repair (OBSR)|After randomisation, patients will receive a box with one sachet containing 3g of OBSR for each day.
89517582|NCT02321345|Experimental|Palliative Care Support|Palliative care meetings will address the following issues: 1) values and meaning of life 2) greatest hopes and fears 3) communication preferences 4) proxy readiness to make decisions, and patient preferences, if the patient were to become seriously ill, and 5) symptom management strategies.
89517583|NCT05165953||Group 1: COVID-19 positive with asthma|"data were collected from medical records including: history of COVID -19 infection, presenting symptoms and clinical examination, hospitalization either ICU or ward. For asthma patients, their full data were collected regarding asthma control in last 3 months following GINA criteria for asthma control [8], Investigations included; CBC with differential count, WBC, lymphocytes, eosinophils, HGB and platelets, Inflammatory markers as d-dimer, LDH and ferritin level, electrolytes, BUN, serum creatinine, CXR, and old spirometry reports.~Diagnosis of COVID 19 infection was made by a positive nasopharyngeal and throat swabs COVID 19 polymerase chain reaction (PCR)."
89581589|NCT02329223|Experimental|Omalizumab 150 mg|Participants received omalizumab 150 mg subcutaneously every 4 weeks during the 12 week treatment period.
89581590|NCT02329223|Placebo Comparator|Placebo|Participants will receive placebo subcutaneously every 4 weeks during the 12 week treatment period.
89581591|NCT05645419|Experimental|personalized chronoprevention|the main group (n=30), where patients with T2D, in addition to their traditional prescriptions, will receive the intervention method of personalized chronoprevention
89581592|NCT05645419|No Intervention|traditional prescriptions|the control group (n=30), where patients with T2D will only be under observation in addition to their traditional prescriptions
89581593|NCT01641601|No Intervention|Usual Management|Patients in the usual management arm will have no pre-hospital cervical ripening and will undergo labor induction according to standard labor induction protocols on an inpatient basis.
89581594|NCT01641601|Experimental|Outpatient transcervical Foley balloon|Patients in the experimental group will have a 30 cc transcervical Foley balloon placed in the outpatient setting approximately 12-18 hours prior to their labor induction. Once admitted, they will undergo inpatient labor induction as per usual protocols.
89581595|NCT02350127|Experimental|Immediate Start|The Immediate Start group will participate in the Preventing Loss of Independence through Exercise (PLIE) group movement program for 1 hour, 2-3 days/week, for 4 months. After the intervention has been completed, they will be encouraged to maintain PLIE activities on their own for the next 4 months.
89581596|NCT02350127|Active Comparator|Delayed Start|Study participants who are randomized to the Delayed Start control group will be placed on a waitlist and will be encouraged to continue participating in their usual activities at the adult day center or in their community setting for 4 months. After the 4-month waitlist period ends, they will participate in the PLIE program for 1 hour, 2-3 days/week, for 4 months.
89581597|NCT02256553|Experimental|MK-3641+ MK-7243|Participants receive one MK-7243 tablet, SL QD in the evening for 14 days during Period I; one MK-3641 tablet, SL QD in the morning and one MK-7243 tablet, SL QD in the evening for 14 days during Period II; and one MK-3641 tablet, SL QD, and one MK-7243 tablet, SL QD, within 5 minutes of each other for 14 days during Period III.
89581598|NCT05305807|Experimental|Study group|Postural exercises will be done to this group
89581599|NCT05305807|No Intervention|Control group|Postural exercises will not be done to this group
89581600|NCT05302297||Treatment Group (Cemiplimab)|Patients treated with cemiplimab in monotherapy through the Cohort Temporary Authorization for Use (cATU) or patients included in the Nominative Temporary Authorization for Use( nATU) that evolved into the cATU and meeting the inclusion/exclusion criteria of the study.
89581601|NCT05302297||Control Group|Patients treated with other systemic treatments meeting the inclusion/exclusion criteria of the study who initiated at least one systemic treatment for advanced CSCC before start date of the cemiplimab nATU
89581602|NCT02349425|Experimental|Cohort 1: Gefapixant>Placebo|50, 100, 150, and 200 mg gefapixant twice daily (BID) for 4 days each in Period 1 and placebo BID for 16 days in Period 2. For Cohort 1, there was a 3 to 7 day washout period between treatment periods.
89581603|NCT02349425|Experimental|Cohort 1: Placebo>Gefapixant|Placebo BID for 16 days in Period 1 and gefapixant 50, 100, 150, and 200 mg BID for 4 days each in Period 2. For Cohort 1, there was a 3 to 7 day washout period between treatment periods.
89581604|NCT02349425|Experimental|Cohort 2: Gefapixant>Placebo|Gefapixant 7.5, 15, 30, and 50 mg BID for 4 days each in Period 1 and placebo BID for 16 days in Period 2. For Cohort 2, there was a 14 to 21 day washout period between treatment periods.
89581605|NCT02349425|Experimental|Cohort 2: Placebo>Gefapixant|Placebo BID for 16 days in Period 1 and gefapixant 7.5, 15, 30, and 50 mg BID for 4 days each in Period 2. For Cohort 2, there was a 14 to 21 day washout period between treatment periods.
89581606|NCT02310581|Experimental|Buprenorphine 0.5 mg TID|Participants received buprenorphine 0.5 mg sublingual spray three times daily (TID) and placebo-matching buprenorphine sublingual spray once daily (QD) for two days.
89581607|NCT02310581|Experimental|Buprenorphine 1.0 mg BID|Participants received buprenorphine 1.0 mg sublingual spray twice daily (BID) and placebo-matching buprenorphine sublingual spray BID for two days.
89581608|NCT02310581|Experimental|Buprenorphine 1.0 mg TID|Participants received buprenorphine 1.0 mg sublingual spray TID and placebo-matching buprenorphine sublingual spray QD for two days.
89581609|NCT02310581|Placebo Comparator|Placebo|Participants received placebo-matching buprenorphine sublingual spray four times daily for two days.
89581610|NCT04892693|Experimental|Talazoparib|; Talazoparib should be taken orally once daily (ie, continuous daily dosing) at approximately the same time each day (preferably in the morning). Daily dosing of talazoparib can be interrupted for recovery from toxicity for up to 28 days. For interruptions longer than 28 days, treatment at the same or a reduced dose can be considered based on the discretion of the treating physician.
89581611|NCT02309723|Experimental|Positive beta amyloid findings|Beta amyloid imaging results indicated a positive finding.
89033270|NCT02942732|Other|normal-weight adult subjects|normal-weight adult subjects (n=30, age ≤ 65 years and BMI ≤ 25 kg/m²) All assigned patients received a supplement of 10,000 IU cholecalciferol (Euro-Pharm International, Canada) to be taken three times per week. The treatment was led for a period of 6 months.
88974293|NCT04588623|Placebo Comparator|Placebo|After randomisation, patients will receive an identical box with one sachet containing 3g of Placebo for each day.
88974294|NCT04580134|Experimental|Biotype 1 - Clozapine (B1C)|Target doses will be up to clozapine 500mg po qd. In addition, several concomitant (open label) medications for symptomatic management will be available via the study protocol [non-benzodiazepine sleep aid (melatonin, hydroxyzine); motor side effect treatments (benztropine, propranolol)]. The doses for these medications will be consistent with those routinely used in a clinical practice: melatonin [up to 10mg at bedtime], hydroxyzine [up to 100mg at bedtime]; benztropine [up to 4mg/day (2mg twice/day)], propranolol [up to 40mg/day (20mg twice/day)].
88974295|NCT04580134|Placebo Comparator|Biotype 1 - Risperidone (B1R)|Target doses will be up to risperidone 6mg po qd. In addition, several concomitant (open label) medications for symptomatic management will be available via the study protocol [non-benzodiazepine sleep aid (melatonin, hydroxyzine); motor side effect treatments (benztropine, propranolol)]. The doses for these medications will be consistent with those routinely used in a clinical practice: melatonin [up to 10mg at bedtime], hydroxyzine [up to 100mg at bedtime]; benztropine [up to 4mg/day (2mg twice/day)], propranolol [up to 40mg/day (20mg twice/day)].
89581612|NCT02309723|Experimental|Negative beta amyloid findings|Beta amyloid imaging results indicated a negative finding.
89581613|NCT02309723|No Intervention|No beta amyloid information|
89581614|NCT02309411|Experimental|Rivaroxaban|Age and body weight-adjusted twice daily dosing of rivaroxaban to achieve a similar exposure as that observed in adults treated for venous thromboembolism (VTE) with 20 mg rivaroxaban once daily
89581615|NCT02008227|Experimental|Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody|Atezolizumab 1200 milligrams (mg) was administered via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurs first.
89581616|NCT02008227|Active Comparator|Docetaxel|Docetaxel 75 milligrams per meter square (mg/m^2) was administered via IV infusion on Day 1 of each 21-day cycle until disease progression, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurs first.
89581617|NCT04867551|Experimental|KDT-3594|
89581618|NCT04862871|No Intervention|Healthy Controls|A cohort (n=10) of participants will be recruited who do not have any neurological conditions and are age and sex-matched to participants in Arms 2 and 3.
89581619|NCT04862871|No Intervention|Chronic Widespread Pain|A cohort (n=10) of participants who have not yet begun the exercise program and are currently on the waitlist for the exercise program at the PPRC
89581620|NCT04862871|Active Comparator|Chronic Widespread Pain - Exercise|A cohort (n=10) of participants who have completed the exercise program at the PPRC. These individuals will be evaluated the day of their last treatment visit
89581621|NCT02006979|Experimental|Exercise|an acute bout of exercise performed ≤24 hours prior to each cycle of anthracyclines and no exercise for 48 hours post
89581622|NCT02006979|No Intervention|No exercise|no exercise for 72 hours prior or 48 hours post each cycle of anthracyclines
89581623|NCT02348723|Experimental|Dabigatran Etexilate 150mg|Patients receiving Dabigatran Etexilate 150mg twice daily dosing (BID)
89581624|NCT02348723|Active Comparator|Warfarin|Patients receiving Warfarin to keep International Normalized Ratio (INR) between 2.0 - 3.0
89581625|NCT01967277|Placebo Comparator|Incandescent red light source|A red, incandescent light source replaces all laser output. The treatment sessions are self-administered at home, every other day, for 16 weeks.
89581626|NCT01967277|Active Comparator|Handi-Dome Laser|Study subjects self-administer actual laser treatments, at home, every other day, for 16 weeks.
89581627|NCT04411095|Experimental|Stretching of intrathoracic fascia|A technique will be used to stretch the intrathoracic fascia. The subject lies in his/her back, and a flexion of the upper cervical spine is combined with a retraction movement of the lower cervical and upper thoracic spine, this in combination with inspiration.
89581628|NCT04411095|Placebo Comparator|Test without stretching|A placebo technique is performed by positioning the hands of the therapist on the thorax without pressure or performing a technique. Similar as the stretching technique, a deep inspiration is performed by the patient, for each of the intrathoracic cilinders. This without performing a retraction of the lower cervical and upper thoracic spine.
89581629|NCT02326883|Experimental|Care Management|The Care Management intervention will last up to a year and includes routine outreach to assess ongoing risk of suicide attempt, and care management to monitor and facilitate ongoing engagement in outpatient follow-up. The Care Manager will coordinate care with treating mental health and primary care providers (ongoing usual care) using Epic Staff Messaging (or telephone contacts if necessary).
89581630|NCT02326883|Experimental|Skills Training|The Skills Training intervention will last up to a year and uses an online skills training program to support patients in developing and using self-management skills for emotion regulation and crisis management. A Coach will monitor each participant's use of the program and send periodic messages (using Epic secure messaging) to encourage and support use of the program and practice of program skills.
89581631|NCT02326883|Active Comparator|Usual Care|Those assigned to the Usual Care group will not be approached or contacted.
89209493|NCT00730691|Experimental|Vortioxetine 2.5 mg|Vortioxetine 2.5 mg encapsulated tablets, orally, once daily, for 8 weeks, followed by placebo-matching capsules, orally, once daily, for 1 week.
89581632|NCT02006667|Experimental|Trastuzumab, Gemcitabine, Cisplatin|Participants received an initial loading dose of 4 milligrams per kilogram (mg/kg) trastuzumab intravenous (i.v.) on Day 3 of Cycle 1, followed by weekly doses of 2 mg/kg i.v until disease progression; 1200 mg per square meter (m2) gemcitabine i.v. on Days 1, 8, and 15 of Cycles 1 through 6; and 70 mg/m2 cisplatin i.v. on Day 2 of Cycles 1 through 6.
89581633|NCT01983111|Experimental|buprenorphine|Patch
89581634|NCT01983111|Active Comparator|tramadol/acetaminophen|Oral tablet
89581635|NCT02348489|Experimental|SGI-110 (guadecitabine)|Guadecitabine 60 mg/m^2 administered subcutaneously (SC) daily for 5 days (Days 1-5) in 28-day cycles.
89581636|NCT02348489|Active Comparator|Treatment Choice|One of the following treatment regimens: 20 mg cytarabine administered subcutaneously (SC) twice daily (BID) on Days 1-10 every 28 days; 20 mg/m^2 decitabine given as a 1-hour intravenous (IV) infusion daily on Days 1-5 every 28 days; or 75 mg/m^2 azacitidine given IV or SC daily on Days 1-7 every 28 days.
89581637|NCT02309099|Experimental|Cochlear Implant|Cochlear implantation of the affected ear
89581638|NCT01966107|Experimental|Aclidinium Bromide|Two-week washout/run-in period [for patients on a long-acting muscarinic antagonist (LAMA)] followed by a maximum of 36-month double-blind treatment period.
89581639|NCT01966107|Placebo Comparator|Placebo|Two-week washout/run-in period [for patients on a long-acting muscarinic antagonist (LAMA)] followed by a maximum of 36-month double-blind treatment period.
89581640|NCT01982331|Experimental|LAIV H2N2 vaccine|LAIV H2N2 vaccine A/17/California/66/395 (H2N2) live monovalent influenza vaccine delivered intranasally 2 doses 1 month apart
89581641|NCT01982331|Placebo Comparator|Placebo|Placebo is composed of a lyophilizate containing the same concentrations of stabilizers as LAIV vaccine. It is prepared onsite in an identical fashion to the vaccine and delivered intranasally.
89581642|NCT02326025|Experimental|Part A|"Doxorubicin Alone: On Cycle 1, Day 1, participants received 75 milligram/square meter (mg/m2) of doxorubicin intravenously (IV).~Olaratumab Alone: On Cycle 1, Day 10, participants received 15 milligram/kilogram (mg/kg) of olaratumab IV.~Olaratumab + Doxorubicin: For Cycles 2 to 8, participants received 15 mg/kg of olaratumab on Days 1 and 8 of each 21-day cycle, IV and 75 mg/m2 of doxorubicin IV immediately following the completion of the olaratumab infusion.~Participants continued to receive olaratumab monotherapy (on days 1 and 8 of each cycle) for Cycle 9 onward, until discontinuation criteria are met."
89581643|NCT02326025|Experimental|Part B|"Doxorubicin Alone: On Cycle 1, Day 1, participants received doxorubicin 75 mg/m2 IV~Olaratumab Alone: On Cycle 1, Day 10, participants received 20 mg/kg of olaratumab IV.~Olaratumab + Doxorubicin:~For Cycle 2, participants received 20 mg of olaratumab on Days 1 and 8 of each 21-day cycle, IV. On Day 1 of Cycle 2, doxorubicin 75 mg/m2 was administered IV immediately following the completion of the olaratumab infusion.~For Cycles 3 - 8, Day 1 and 8, olaratumab 15 mg/kg was administered and on Day 1 doxorubicin 75 mg/m2 was administered IV immediately following the completion of the olaratumab infusion.~Participants continued to receive olaratumab monotherapy (on days 1 and 8 of each cycle) for Cycle 9 onwards, until discontinuation criteria are met."
89581644|NCT01619865|Experimental|68Ga-DOTATOC PET/CT|68Ga-DOTATOC Positron Emission Tomography (PET) for Diagnosis, Staging, and Measurement of Response to Treatment in Somatostatin Receptor Positive Tumors
89581645|NCT02006121|Active Comparator|Apomorphine hydrochloride|Apo-go® Apomorphine hydrochloride 5 mg/ml solution for infusion in pre-filled syringe
89581646|NCT02006121|Placebo Comparator|Placebo|Placebo: saline infusion
89581647|NCT02005887|Experimental|triptorelin + letrozole|Arm A: Triptorelin 3.75 mg i.m. on day 1 every 28 days for 6 cycles + letrozole 2.5 mg/day orally for 6 cycles
89581648|NCT02005887|Experimental|degarelix + letrozole|Arm B: Degarelix 240 mg s.c. on day 1 of cycle 1, followed by 80 mg s.c. on day 1 of cycles 2 to 6 + letrozole 2.5 mg every day orally for 6 cycles
89581649|NCT01982253|Placebo Comparator|Placebo|Fasiglifam placebo-matching tablets, orally, twice daily for up to 12 weeks.
89581650|NCT01982253|Experimental|Fasiglifam 25 mg BID|Fasiglifam 25 mg tablets, orally, twice daily (BID) for up to 12 weeks.
89581651|NCT01982253|Experimental|Fasiglifam 50 mg QD +Placebo QD|Fasiglifam 50 mg tablets, orally once daily (QD) and fasiglifam placebo-matching tablets, orally, once daily for up to 12 weeks.
89581652|NCT01981473||etanercept|Participants currently receiving etanercept treatment in a clinical setting for a minimum of 6 months and maximum of 24 months prior to study assessment visit.
89581653|NCT01981473||adalimumab|Participants currently receiving adalimumab treatment in a clinical setting for a minimum of 6 months and maximum of 24 months prior to study assessment visit.
89581654|NCT01981473||infliximab|Participants currently receiving infliximab treatment in a clinical setting for a minimum of 6 months and maximum of 24 months prior to study assessment visit.
89581655|NCT02005029|Placebo Comparator|Placebo|One time IV dose of placebo
89581656|NCT02005029|Experimental|Erythromycin|One time IV dose of 100 mg Erythromycin
89581657|NCT02325791|Experimental|Part A: Suptavumab 30 mg/kg|
89581658|NCT02325791|Experimental|Part B: Placebo Matched to Suptavumab|
89581659|NCT02325791|Experimental|Part B: Suptavumab 30 mg/kg- 1 Dose|
89581660|NCT02325791|Experimental|Part B: Suptavumab 30 mg/kg - 2 Doses|
89581661|NCT02004873|Experimental|Micra Pacemaker Implant|
89581662|NCT02347787|Placebo Comparator|Usual clinician support|Prior to randomization, patients in this arm will already have set a chronic disease management goal with their primary care provider (who will have received training in collaborative goal-setting). After randomization, patients in the usual clinician support arm will receive usual care in accordance with guidelines at each site.
89581663|NCT02347787|Experimental|CHW support|Prior to randomization, patients in this arm will already have set a chronic disease management goal with their primary care provider (who will have received training in collaborative goal-setting). After randomization, patients in the CHW arm will receive the IMPaCT intervention.
89581664|NCT04416399|Experimental|Inhaled budesonide|Budesonide inhaled via dry powder inhaler, 400 micrograms per inhalation, 2 inhalations twice a day
89581665|NCT04416399|No Intervention|Standard of care|Standard of care
89581666|NCT01979835|Experimental|GF|Women who have a GyneFix Viz inserted
89581667|NCT02282345|Experimental|Treatment (talazoparib)|"Patients receive talazoparib PO QD on days 1-28. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then proceed to the standard of care therapy of the treating physician's choice.~This arm was concluded early after 13 patients. An expansion arm of 20 patients was opened in August 2016 to include at least 4 and up to 6 cycles of talazoparib, followed by surgery to estimate residual cancer burden after therapy with single-agent talazoparib."
89581668|NCT01732822|Experimental|Ticagrelor|Ticagrelor 90 mg bd (and Clopidogrel placebo od) taken orally as tablets
89581669|NCT01732822|Active Comparator|Clopidogrel|Clopidogrel 75 mg od (and Ticagrelor placebo bd) taken orally as tablets
89581670|NCT02004093|Experimental|Chemotherapy + Pertuzumab|
89581671|NCT02004093|Active Comparator|Chemotherapy|
88974296|NCT04580134|Active Comparator|Biotype 2 - Clozapine (B2C)|Target doses will be up to clozapine 500mg po qd. In addition, several concomitant (open label) medications for symptomatic management will be available via the study protocol [non-benzodiazepine sleep aid (melatonin, hydroxyzine); motor side effect treatments (benztropine, propranolol)]. The doses for these medications will be consistent with those routinely used in a clinical practice: melatonin [up to 10mg at bedtime], hydroxyzine [up to 100mg at bedtime]; benztropine [up to 4mg/day (2mg twice/day)], propranolol [up to 40mg/day (20mg twice/day)].
89581672|NCT01641367|Experimental|Cohort A|"Under Protocol version 1.0:~No resistance to NRTIs, PIs, or NNRTI~• Continue current second-line regimen; NRTIs could be modified~Changed under LOA#2 to:~No LPV/RTV resistance and susceptible to at least one NRTI, regardless of NNRTI resistance or prior RAL exposure~• Continue second-line regimen which may include LPV/RTV; NRTIs could be modified~Changed under LOA#3 to:~No LPV/RTV resistance and susceptible to at least one NRTI, regardless of NNRTI resistance or prior RAL exposure~• Continue PI backbone; NRTIs could be modified. If on a RAL-containing regimen, RAL must be discontinued."
89581673|NCT01641367|Experimental|Sub-cohort B1|"Under Protocol version 1.0:~Susceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and without active hepatitis B infection at screening~• Best available NRTIs, RAL, & DRV/RTV~Changed under LOA#2 to:~Resistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (and without active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (and without active hepatitis B infection at screening)~• Best available NRTIs, RAL, & DRV/RTV"
89581674|NCT01641367|Experimental|Sub-cohort B2|"Under Protocol version 1.0:~Susceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and without active hepatitis B infection at screening~• ETR, RAL, and DRV/RTV~Changed under LOA#2 to:~Resistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (and without active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (and without active hepatitis B infection at screening)~• ETR, RAL, and DRV/RTV"
89581675|NCT01641367|Experimental|Sub-cohort B3|"Under Protocol version 1.0:~Susceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and with active hepatitis B infection at screening~• RAL, DRV/RTV, and FTC/TDF or TDF+3TC~Changed under LOA#2 to:~Resistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (with active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (with active hepatitis B infection at screening)~• RAL, DRV/RTV, and FTC/TDF or TDF+3TC"
89581676|NCT01641367|Experimental|Cohort C|"Under Protocol version 1.0:~Resistance to NRTIs and ETR or resistance to ETR alone (and may have resistance to PIs other than DRV)~• Best available NRTIs, RAL, and DRV/RTV~Changed under LOA#2:~Resistance to LPV/RTV and ETR but susceptible to DRV/RTV and with no prior RAL exposure and regardless of NRTI resistance OR Resistance to ETR and to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and with no prior RAL exposure~• Best available NRTIs, RAL, and DRV/RTV"
89581677|NCT01641367|Experimental|Cohort D|"Under Protocol version 1.0:~Multiple NRTI resistance and/or DRV/RTV resistance or prior RAL exposure:~• Best available regimen, including study-provided and any locally available drugs~Changed under LOA#2:~Not eligible for Cohort A, B, or C:~• Best available regimen, including study-provided and any locally available drugs~Updated under protocol v2.0:~• Best available ART regimen, including study-provided and any locally available non-experimental drugs"
89581678|NCT02325713|Experimental|Sequence A-B-C1-D1|
89581679|NCT02325713|Experimental|Sequence A-B-C1-D2|
89581680|NCT02325713|Experimental|Sequence A-B-C2-D1|
89581681|NCT02325713|Experimental|Sequence A-B-C2-D2|
89581682|NCT02325713|Experimental|Sequence A-B-D1-C1|
89581683|NCT02325713|Experimental|Sequence A-B-D2-C1|
89581684|NCT02325713|Experimental|Sequence A-B-D1-C2|
89581685|NCT02325713|Experimental|Sequence A-B-D2-C2|
89581686|NCT02325713|Experimental|Sequence B-A-C1-D1|
89581687|NCT02325713|Experimental|Sequence B-A-C1-D2|
89581688|NCT02325713|Experimental|Sequence B-A-C2-D1|
88974297|NCT04580134|Placebo Comparator|Biotype 2 - Risperidone (B2R)|Target doses will be up to risperidone 6mg po qd. In addition, several concomitant (open label) medications for symptomatic management will be available via the study protocol [non-benzodiazepine sleep aid (melatonin, hydroxyzine); motor side effect treatments (benztropine, propranolol)]. The doses for these medications will be consistent with those routinely used in a clinical practice: melatonin [up to 10mg at bedtime], hydroxyzine [up to 100mg at bedtime]; benztropine [up to 4mg/day (2mg twice/day)], propranolol [up to 40mg/day (20mg twice/day
88974298|NCT04564170||ED|Patients with Eating Disorders
89581689|NCT02325713|Experimental|Sequence B-A-C2-D2|
89581690|NCT02325713|Experimental|Sequence B-A-D1-C1|
89581691|NCT02325713|Experimental|Sequence B-A-D2-C1|
89581692|NCT02325713|Experimental|Sequence B-A-D1-C2|
89581693|NCT02325713|Experimental|Sequence B-A-D2-C2|
89581694|NCT04877639|Active Comparator|Esmketamine group|Intravenous injection of 1.0mg/kg esmketamine was given, and nasal endoscopy was started 3 minutes later to maintain 1.0mg/kg/h esmketamine
89581695|NCT04877639|Active Comparator|Dexmedetomidine group|Dexmedetomidine 1 μg/ kg at least 10 min after intravenous injection + maintain 1 μ After intravenous injection of dexmedetomidine 1 ug / kg, sufentanil 0.05 mg / kg was given 5 minutes
89581696|NCT02325401|Experimental|Metformin with Chemoradiation|Metformin administered orally daily to start one week prior to Cisplatin and Radiation Therapy. Metformin dose is escalating.
89581697|NCT02324699|Experimental|Prednisone co-inductive therapy|Prednisone 40 mg/day starting at week 0 for 2 weeks, tapered by 10 mg weekly to achieve 0 mg by end of week 5
89581698|NCT02324699|Placebo Comparator|Placebo|Identical placebo taper
89581699|NCT01764256|Experimental|10 μg P2-VP8|3 doses of P2-VP8 subunit rotavirus vaccine (Lot # 1746) produced in E. coli was adsorbed onto aluminum hydroxide (0.6 mg/dose) adjuvant prior to administration. Each dose contained 10 μg of active ingredient.
88974299|NCT04564170||HC|Healthy Controls without eating disorders
88974300|NCT04541108|Experimental|MK-0482, MK-4830, & Pembrolizumab|Patients with HNSCC or STS who are scheduled for surgical biopsy or tumor resection surgery will be injected two to four days prior to surgery using the CIVO device. Each needle of the CIVO device will deliver up to 8.3 microliters of solution, including a vehicle control (sterile saline) or subtherapeutic microdoses of pembrolizumab as a single agent or in combination with MK-0482 or MK-4830. Each microdose is simultaneously injected in a columnar fashion through each of 5 or 8 needles by the CIVO Microdose Injector,into a single solid tumor or effaced metastatic lymph node.
89581700|NCT01764256|Experimental|30 μg P2-VP8|3 doses of P2-VP8 subunit rotavirus vaccine (Lot # 1746) produced in E. coli was adsorbed onto aluminum hydroxide (0.6 mg/dose) adjuvant prior to administration. Each dose contained 30 μg of active ingredient.
89581701|NCT01764256|Experimental|60 μg P2-VP8|3 doses of P2-VP8 subunit rotavirus vaccine (Lot # 1746) produced in E. coli was adsorbed onto aluminum hydroxide (0.6 mg/dose) adjuvant prior to administration. Each dose contained 60 μg of active ingredient.
89581702|NCT01764256|Placebo Comparator|Placebo|3 doses of placebo delivered intramuscularly.
89581703|NCT01979523|Experimental|Arm A (trametinib)|Patients receive trametinib PO QD on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Patients who experience objective disease progression may crossover to Arm B. (no patients will be enrolled to Arm B or Crossover therapy as of 11/6/2015)
89581704|NCT01979523|Experimental|Arm B (trametinib, Akt inhibitor GSK2141795)|Patients receive trametinib PO QD and Akt inhibitor GSK2141795 PO QD on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
89581705|NCT02255461|Experimental|Treatment (palbociclib isethionate)|Patients receive palbociclib isethionate PO QD on days 1-21. Treatment repeats every 4 weeks for 26 courses in the absence of disease progression or unacceptable toxicity.
89581706|NCT01764022|Experimental|BCD-022|BCD-022 is a product code for trastuzumab biosimilar manufactured by CJSC BIOCAD, Russia. In this arm patients will receive 6 courses of treatment with BCD-022 in combination with paclitaxel. Patients will receive BCD-022 at a loading dose of 8 mg/kg (once), followed by maintenance dose of 6 mg/kg every 3 weeks (5 administrations), + paclitaxel 175 mg/m2 every 3 weeks as 3 hour intravenous infusion (6 administrations).
89581707|NCT01764022|Active Comparator|Herceptin®|In this arm patients will receive 6 courses of treatment with Herceptin® (F. Hoffmann-La Roche Ltd., Switzerland) in combination with paclitaxel. Patients will receive Herceptin® at a loading dose of 8 mg/kg (once), followed by maintenance dose of 6 mg/kg every 3 weeks (5 administrations), + paclitaxel 175 mg/m2 every 3 weeks as 3 hour intravenous infusion (6 administrations).
89581708|NCT02003391|Experimental|DuoTrav|Travoprost 0.004% / timolol 0.5% fixed combination ophthalmic solution, 1 drop instilled in the study eye once daily (evening) for 8 weeks.
89581709|NCT02003391|Active Comparator|Beta-blocker|Participant's current beta-blocker monotherapy, 1 drop instilled in the study eye twice daily (morning and evening) for 4 weeks, followed by travoprost 0.004% / timolol 0.5% fixed combination ophthalmic solution, 1 drop instilled in the study eye once daily (evening) for 4 additional weeks.
89581710|NCT04852627|Active Comparator|Exercise group|Will brisk walk 30 minutes 3 times weekly
89581711|NCT04852627|No Intervention|Control group|No intervention
89581712|NCT04658901|Experimental|test group|use endovenous radiofrequency closure catheter (ERA-C70,ERA-C30) and endovenous radiofrequency closure generator (ERA-G5) made by Acotec Scientific Co.,Ltd.
89581713|NCT04658901|Active Comparator|control group|use the ClosureRFG™ and ClosureFast™ made by Medtronic Inc.
89581714|NCT02254681|Experimental|Treatment|Four three-week treatment cycles. Gemcitabine (1000 gm/m^2) and cisplatin (25 mg/m^2) administered on days one and eight of each cycle. Whole liver and portal lymph node basin low dose radiotherapy on days one, two, eight, and nine of each cycle.
88974301|NCT04533607|Active Comparator|MAAPS|Modular intervention system integrating evidence-based strategies to address core and associated features of ASD and ongoing coaching.
88974302|NCT04533607|No Intervention|Waitlist control|Services as usual.
88974303|NCT04532788|Active Comparator|Customized crosslinking|"In the customized corneal cross-linking protocol (cCXL) a patient-specific treatment pattern, based on the patient's Pentacam images, will be used to treat the cornea. The CXL pattern exists out of 3 concentric circles and is centered on the cone. To estimate the cone location a combination of the thinnest corneal point, maximum anterior elevation and maximum posterior elevation is used. The epithelium is debrided with alcohol within the marked zone. After the application of riboflavin each circle receives a different amount of energy, which gradually decreases with increasing circle size.~The procedure is done with the Avedro Mosaic CXL device (Avedro, Inc. Waltham, Massachusetts, United States)."
88974304|NCT04532788|Active Comparator|Standard crosslinking|"In the standard corneal cross-linking protocol (sCXL) the epithelium is debrided with alcohol over a region with a diameter of 9.0 mm. After the application of riboflavin the cornea is irradiated with UVA with a fluence of 10 mW/cm2 during 9 minutes with a diameter of 9.0 mm, resulting in a total energy of 5.4 J/cm2.~The procedure is done with the Avedro Mosaic CXL device (Avedro, Inc. Waltham, Massachusetts, United States)."
88974305|NCT04513106|Experimental|Advance care planning programme|It is a theory-driven advance care planning programme specifically designed for PWEDs and their family caregivers. The intervention is underpinned by the Bandura's self-efficacy model. Each dyad of participants will receive a 3-session ACP programme, which consists of educational components, guided reflection, and dyadic ACP discussion, guided by ACP facilitators and an ACP booklet. It is composed of 1 group-based sessions and 2 dyadic discussions. One hour for each session, and once weekly. Dyads of participants will be provided with information about the trajectory of dementia, their future healthcare needs and caring options. Their values and care preferences on future care will be elicited in a consistent manner. They will be supported to have an individualized ACP discussion. By the end of the programme, each dyad of participant will be given an ACP booklet documenting the ACP process.
89581715|NCT01965327|Experimental|Interferon Gamma-1b (ACTIMMUNE)|All individuals in this study will be given active medication (interferon gamma-1b) for 12 weeks. This will be administered according to a dose-escalation schedule.
89581716|NCT05651191|Experimental|Human CD19 Targeted DASH CAR-T Cells Injection|Single administration：0.5×10^6 CAR+T, 1.0×10^7 CAR+T, 2.0×10^7 CAR+T
89581717|NCT02002689|Experimental|LDE225|LDE225 800 mg (hard gelatin capsules) will be administered orally once daily on a continuous dosing schedule.
89581718|NCT01639729|Experimental|Sequence 1 - Treatment A, B, C, D|15 mcg: Sufentanil IV, Sufentanil NanoTab Sublingual, Sufentanil NanoTab Buccal, Sufentanil NanoTab Oral
89581719|NCT01639729|Experimental|Sequence 2 - Treatment A, B, D, C|15 mcg: IV, Sufentanil NanoTab Sublingual, Sufentanil NanoTab Oral,Sufentanil NanoTab Buccal
89581720|NCT01639729|Experimental|Sequence 3 - Treatment A, C, B, D|15 mcg: Sufentanil IV, Sufentanil NanoTab Buccal, Sufentanil NanoTab Sublingual, Sufentanil NanoTab Oral
89581721|NCT01639729|Experimental|Sequence 4 - Treatment A, C, D, B|15 mcg: Sufentanil IV, Sufentanil NanoTab Buccal, Sufentanil NanoTab Oral, Sufentanil NanoTab Sublingual
89581722|NCT01639729|Experimental|Sequence 5 - Treatment A, D, B, C|15 mcg: Sufentanil IV, Sufentanil NanoTab Oral, Sufentanil NanoTab Sublingual, Sufentanil NanoTab Buccal
89581723|NCT01639729|Experimental|Sequence 6 - Treatment A, D, C, B|15 mcg: Sufentanil IV, Sufentanil NanoTab Oral, Sufentanil NanoTab Buccal, Sufentanil NanoTab Sublingual
89581724|NCT02002533|Experimental|Arm I (BBT intervention)|Patients undergo BBT intervention, comprising insomnia education, stimulus control, discouragement of napping and encouragement of exercise, and sleep compression over two 60 minute face-to-face sessions in weeks 1 and 3 or 4, and four 15 minute telephone sessions in weeks 2, 3, 5, and 6 or 2, 4, 5, and 6.
89581725|NCT02002533|Active Comparator|Arm II (control)|Patients undergo HEAL comprising nutritional education and suggestions for symptom management over two 60 minute face-to-face sessions in weeks 1 and 3 or 4, and four 15 minute telephone sessions in weeks 2, 3, 5, and 6 or 2, 4, 5, and 6.
89581726|NCT02002221|Experimental|Vildagliptin (LAF237)|Patients received vildagliptin (LAF237) 50 mg tablets twice daily for 12 weeks. Patients continued on a stable dose of long-acting or intermediate-acting or pre-mixed insulin, and metformin if applicable, throughout the study
89581727|NCT02002221|Placebo Comparator|Placebo|In this arm, patients received vildagliptin 50 mg matching placebo tablets twice daily for 12 weeks. Patients continued on a stable dose of long-acting or intermediate-acting or pre-mixed insulin, and metformin if applicable, throughout the study
89581728|NCT01639495|Experimental|THERMOCOOL® SMARTTOUCH™ Catheter|
89581729|NCT05651113||Positive NBS for SCID|Parents whose baby was referred to an immunologist due their SCID screening result (minimum n= 10-25)
89581730|NCT05651113||Normal NBS result|Parents who received a normal screening result (minimum n=10-25)
89581731|NCT05651113||False positive NBS result|Parents who have received a false positive result elsewhere in screening (minimum n=2-10)
89581732|NCT05651113||CFSPID Designation|Parents who received a CFSPID result (minimum n=~10)
89581733|NCT05651113||SCID via family history or clinical presentation|Parents whose baby was identified with SCID due to family history or clinical presentation (minimum n=10)
89581734|NCT05651113||Parents whose babies have died|Parents who have received an abnormal screening result (T cell receptor excision circles (TRECs) or who were identified with SCID due to family history or clinical presentation and whose baby has subsequently died (n=~10)
89581735|NCT05262439|Experimental|New generation CPAP mask|The intended purpose of mask systems is to provide airflow from a CPAP device, through tubing, and to the patient. The air acts as a pneumatic splint to keep the airway open and prevent collapse during sleep. The masks to be used in this study are released masks approved and released.
89581736|NCT05640661|Experimental|Terminal visual feedback therapy plus Immersive Virtual reality|"Active treatment using Virtual Reality software based on pain education and gamified exercise for gradual exposure to shoulder movement.~The brief intervention will last 3 sessions of 15 minutes during a week, thus taking a total duration of one week of treatment. Within the intervention will consist of a pill of education in pain neuroscience (PNE) of 1 minute duration, followed by an exposure level that will last 2:30 minutes where a progression will be made in number of ranges of motion and speed. Each session will consist of 2 intervention blocks (PNE + Gradual Exposure pill). The content of the PNE educational pills have been selected according to the objective of the study. Subjects will be recorded through an Ipad Tablet, and after performing the entire intervention a terminal visual feedback therapy will be performed by observation of actions in holocentric vision."
89581737|NCT05640661|Active Comparator|Immersive Virtual Reality|"Active treatment using Virtual Reality software based on pain education and gamified exercise for gradual exposure to shoulder movement. The game involves visual stimuli and shoulder movement exercises in the shoulder flexion and abduction ranges in real time using immersive glasses located on the head and two controls on both hands. Patients will inhabit an avatar from an egocentric perspective.~The brief intervention will last 3 sessions of 15 minutes during a week, thus taking a total duration of one week of treatment. Within the intervention will consist of a pill of education in pain neuroscience (PNE) of 1 minute duration, followed by an exposure level that will last 2:30 minutes where a progression will be made in number of ranges of motion and speed. Each session will consist of 2 intervention blocks (PNE + Gradual Exposure pill). The content of the PNE educational pills have been selected according to the objective of the study."
89581738|NCT04871971|Placebo Comparator|Glucose|Glucose 50 g available carbohydrate
89581739|NCT04871971|Experimental|10 g NUTRALYS®S85 Plus pea protein|50 g available carbohydrate Glucose + 10 g NUTRALYS®S85 Plus pea protein
89581740|NCT04871971|Experimental|20 g NUTRALYS®S85 Plus pea protein|50 g available carbohydrate Glucose + 20 g NUTRALYS®S85 Plus pea protein
89581741|NCT04871971|Experimental|10 g Whey protein concentrate|50 g available carbohydrate Glucose + 10 g Whey protein concentrate
89581742|NCT04871971|Experimental|20 g Whey protein concentrate|50 g available carbohydrate Glucose + 20 g Whey protein concentrate
89581743|NCT05651035|Experimental|Breastfeeding group|Preterm infants in this group are breastfed by their mothers during their first oral feeding. Before, during and after feeding, the preterm infant's oxygen saturation level and peak heart rate are measured for 30 minutes. In addition, the test test weighing is determined by weighing the baby before and after feeding.
89581744|NCT05651035|No Intervention|Bottle-feeding group|Preterm infants in this group are fed with their mother's milk in the bottle during their first oral feeding.
89581745|NCT05260177|Experimental|Active|Exposure to LTS device set to 40 Hz invisible spectral flicker for 1 hour a day for consecutive days
89581746|NCT05260177|Sham Comparator|Sham|Exposure to LTS device set to continuous color matched white light for 1 hour a day for consecutive days
88974306|NCT04513106|Placebo Comparator|Attention control|Dyads of participants in the control group will receive 3-session health talks. One hour for each session, and once weekly. The contents of the health talks are neither dementia-specific nor related to ACP, and cover general health information for elderly, such as drug safety, home safety, exercise and health. This is to differentiate the effect of the intervention from the effect of the extra time and attention given to the participants.
88974307|NCT04512079|Active Comparator|Prophylactic Enoxaparin|Prophylactic enoxaparin (40 mg SC QD; 30 mg SC QD for CrCl <30 mL/min)
89581747|NCT05431153|Experimental|PF-07104091 Sequence 1|Participants randomized to Sequence 1 will receive Treatments A, B, C, and D in Periods 1 through 4, respectively in the form of tablets by mouth.
89581748|NCT05431153|Experimental|PF-07104091 Sequence 2|Participants randomized to Sequence 2 will receive Treatments B, C, A, and D in Periods 1 through 4, respectively in the form of tablets by mouth.
89581749|NCT05431153|Experimental|PF-07104091 Sequence 3|Participants randomized to Sequence 3 will receive Treatments C, A, B, and D in Periods 1 through 4, respectively in the form of tablets by mouth.
89581750|NCT05431153|Experimental|PF-07104091 Sequence 4|Participants randomized to Sequence 4 will receive Treatments A, B, C, and E in Periods 1 through 4, respectively in the form of tablets by mouth.
89581751|NCT05431153|Experimental|PF-07104091 Sequence 5|Participants randomized to Sequence 5 will receive Treatments B, C, A, and E in Periods 1 through 4, respectively in the form of tablets by mouth.
89581752|NCT05431153|Experimental|PF-07104091 Sequence 6|Participants randomized to Sequence 6 will receive Treatments C, A, B, and E in Periods 1 through 4, respectively in the form of tablets by mouth.
89581753|NCT05650801|Experimental|Intervention Group 1|Participants who will be given music therapy 3 times a week for 4 weeks in a row. This group will get Maslach Burnout Inventory and Heart Rate Variability score evaluated before and after music therapy intervention.
89581754|NCT05650801|Experimental|Intervention Group 2|Participants with burnout syndrome who will be given music therapy 5 times a week for 2 weeks in a row. This group will get Maslach Burnout Inventory and Heart Rate Variability score evaluated before and after music therapy intervention.
89581755|NCT05650801|No Intervention|Neutral Group|Participants in this group will not get any music intervention. The maslach burnout inventory and heart rate variability score will be evaluated before and after four weeks without any intervention
89581756|NCT05650723|Experimental|Double Therapy (Zanubrutinib plus Venetoclax)|All participants will receive an initial 3 cycles of zanubrutinib monotherapy. This lead-in period will then be followed by 12 cycles of zanubrutinib and venetoclax combination therapy. All participants will complete 12 cycles of zanubrutinib and venetoclax combination therapy or 15 cycles of total treatment. Peripheral blood and bone marrow MRD assessments will occur at C16D1. Participants will continue on double combination treatment for an additional 1 month while results of MRD testing are obtained. In total, all participants will be on treatment for at least 16 full cycles. Participants that meet definition of MRD negativity will stop therapy at C17D1 and enter an observation phase with study visits every 3 months. Participants that remain MRD positive at C16D1 will enter the triple therapy (zanubrutinib, venetoclax, and obinutuzumab) arm.
89581757|NCT05650723|Experimental|Triple Therapy (Zanubrutinib, Venetoclax, and Obinutuzumab)|Participants that meet definition of MRD positivity at C16D1 will enter the triple therapy arm (zanubrutinib, venetoclax, and obinutuzumab). These participants will continue combination therapy with zanubrutinib and venetoclax, but will also receive 6 cycles of obinutuzumab starting at C17D1. In this subgroup, peripheral blood and bone marrow MRD assessments will occur after an additional 6 cycles of the triplet combination therapy (C23D1) at which point all participants will stop study treatment regardless of MRD status.
89581758|NCT05636215|Experimental|IBI354|Single arm
89581759|NCT05249647|Experimental|Instrument based fascial abrasion technique|IASTM using tools over Myofascial trigger points of the length of targeted muscles (SCM, descending fiber of trapezius, suboccipitalis muscles) in a multidirectional stroking fashion applied to the skin at 30°- 60° for 5 minutes. Participants were in a comfortable position during treatment. Emollient (anti-allergic) was applied to prevent skin irritation prior to Fascial Abrasion application. Each session included 1 minute of sweeping (longitudinal strokes performed parallel to the muscle fibers similar to compression with oscillations) directly over the Myofascial trigger points, 2 minutes of fanning (one end of the instrument was held in place & the other end moved through a semicircular pattern similar to petrissage) and concluded with 1 min of sweeping.
89581760|NCT05249647|Active Comparator|Myofascial release technique|All participants will get Conventional therapy i.e heating pad for 10 minutes. For the application of technique, the patient position will be supine lying with head fully supported on therapist hands and therapist places 3 middle fingers just inferior to the nucle line, lifts the finger tips towards the ceiling while resting the head on the table and then therapist applied a gentle upward pull. This procedure done for 2-3 minutes, 5-7 repetitions, 3 sessions per week on alternate days given for 6 weeks.
89581761|NCT05247697|Experimental|Treatment|Mirtazapine 7.5 mg
89581762|NCT05247697|Placebo Comparator|Control|Matching placebo
89581763|NCT05232175|Experimental|Part I (Allergy assessment) - ALT-BB4|
89581764|NCT05232175|Placebo Comparator|Part I (Allergy assessment) - 0.9%NaCl|
89581765|NCT05232175|Experimental|Part II-A (PK assessment)|
88974308|NCT04512079|Active Comparator|Full Dose Enoxaparin|Full-dose enoxaparin (1 mg/kg SC Q12h; 1 mg/kg SC QD for CrCl <30 mL/min)
88974309|NCT04512079|Experimental|Apixaban|Apixaban (5 mg Q12h; 2.5 mg Q12h for patients with at least two of three of age ≥80 years, weight ≤60 kg or serum creatinine ≥1.5 mg/dL)
88974310|NCT04498572|Experimental|research group|active exercises and dry needling for the Gluteus medius muscle
88974311|NCT04498572|Sham Comparator|control group|active exercises and sham dry needling for the Gluteus medius muscle
88974312|NCT04491578|Experimental|ACP programme|It is a theory-driven ACP programme specifically designed for PWEDs or persons with MCI and their family caregivers. The intervention is underpinned by the Bandura's self-efficacy model and shared decision-making model.
88974313|NCT04490278|Experimental|Patients with PICS|
89033271|NCT02942732|Other|overweight adult subjects|overweight adult subjects (n=30, age ≤ 65 years and BMI ≥ 25 kg/m²) All assigned patients received a supplement of 10,000 IU cholecalciferol (Euro-Pharm International, Canada) to be taken three times per week. The treatment was led for a period of 6 months.
89581766|NCT05232175|Experimental|Part II-B (Safety assessment) - ALT-BB4|
89581767|NCT05232175|Placebo Comparator|Part II-B (Safety assessment) - 0.9% NaCl|
89581768|NCT05193331|Experimental|DQS group|Participants in DQS group will be administered one drop of 3% DQS (Diquas, Santen Pharmaceutical Co., Ltd., Osaka, Japan) six times per day for 4 weeks (28 days).
89581769|NCT02001987|Experimental|Tocilizumab|Participants will receive tocilizumab at a dose of 162 milligrams (mg) as subcutaneous (SC) injection once a week administered as monotherapy or in combination with methotrexate or other csDMARDs (at investigator's discretion) for 24 weeks. Participants who complete the core study period will be allowed to enter a long-term-extension (LTE) period to continue study treatment for up to a maximum of another 52 weeks or until the commercial availability of SC tocilizumab, whichever occurs first.
89581770|NCT01363765|Experimental|Xpert MTB/Rif|Sputum specimens arriving during intervention period will be submitted to this technology, a real-time automated polymerase chain reaction test
89581771|NCT01363765|Active Comparator|Sputum smear|Sputum smears arriving in the laboratory during the observation period will be submitted to the classic routine smear staining
89581772|NCT02001051|Other|Operative Arm|operative arm
89581773|NCT02001051|Other|Delayed Operative Arm|delayed operative arm
89581774|NCT05577013|Experimental|(Kinesiotaping and motor relearning program group|"The experimental group will receive kinesiotaping; Instructions before applying kinesiotape~Patients' skin must be clean, free of dirt, oil or sweat.~Long hair must be removed for proper adhesion to the skin.~Leave the tape upstretched 2-3 cm at start and end point of tape over the skin"
88974314|NCT04461301|Experimental|Intervention|Patients that meet the inclusion criteria will be randomised and scheduled for surgery at least 2 weeks after the diagnosis/decision to proceed to surgery. This timeframe allows the implementation of a minimal 2 weeks (up to 4 weeks) multidisciplinary prehabilitation program. Prehabilitation program is composed of 4 elements: exercise training, nutritional intervention, correction of anaemia and smoking cessation. An individual treatment strategy will be proposed to the patient by a multidisciplinary team consisting of surgeon, anesthesiologist, dietitian and physiotherapist.
88974315|NCT04461301|No Intervention|Control|Perioperative care of the control group will be based on standardized, multi-element, ERAS recommendations as already implemented in the different participating clinics.
88974316|NCT04436380||Relapsed SAA Patients|Patients with Severe Aplastic Anemia who Relapsed after Immunosuppressive Therapy
88974317|NCT04433364||Screening group|"a general population of women giving birth, called screening group included at routine antenatal visits, their partners, and children"
88974318|NCT04433364||COVID-19 group|"group of women testing positive for SARS-CoV-2 or falling ill with COVID-19, called COVID-19 group, their partners, and children"
88974319|NCT04420000|Experimental|Interventional group|Patients having a Mindfulness program
88974320|NCT04420000|Placebo Comparator|Control group|Patients having a routinary managment
88974321|NCT04402749||Nephrectomy|Patients underwent nephrectomy
88974322|NCT04378374|Experimental|Baked food made of lentil flour|Food prepared with 100% lentil flour
88974323|NCT04378374|Experimental|Baked food made of lentil flour and wheat flour|Food prepared with a mixture of lentil flour and wheat flour
88974324|NCT04378374|Experimental|Baked food made of wheat flour|Food prepared with 100% wheat flour
88974325|NCT04378374|Experimental|Water|Potable water (energy and carbohydrate-free control)
89581775|NCT05577013|Active Comparator|motor relearning program group|"The control group will receive motor relearning programme exercises for 40 minutes.~Hitting a target on table from flexed elbow to extension of elbow~Hitting a target on front of table with shoulder flexion (reaching fwd)~Hitting a target on table with wrist extension~Pronation to supination while holding a bottle of water.~Rolling ball on table in forward, backward and sideways~Holding polystyrene cup and placing it on other side~Picking up blocks and placing them to other side~Holding polystyrene cup and placing them above and below level of sitting to front and sideways~Holding polystyrene cup and placing them above and below level of standing to front and sideways~pick small objects from one container to another"
89581776|NCT05429437|Active Comparator|Group I|will include 9 patients
89581777|NCT05429437|Active Comparator|Group II|will include 9 patients.
89581778|NCT04850677||Total|All subjects in the study belong to the same group/cohort. As this is an observational study there is no intervention planned.
89581779|NCT01763164|Experimental|MEK162|
89581780|NCT01763164|Active Comparator|Dacarbazine|
89581781|NCT01782742|Active Comparator|Bexarotene treatment Arm|"75 mg of Bexarotene BID for week 1, then increasing to 150 mg BID for weeks 2 to 4.~Weeks 5 to 8 is Open-label phase (150 mg BID for 4 weeks)"
89581782|NCT01782742|Placebo Comparator|Placebo|"1 placebo capsule BID for week 1, then increasing to 2 placebo capsules BID for weeks 2 to 4.~Weeks 5 to 8 is Open-label phase (150 mg BID for 4 weeks)"
89581783|NCT01782664|Experimental|100 mg GSK2586184|Subjects will be randomized to 100 mg GSK2586184 twice daily for up to 84 days
89581784|NCT01782664|Experimental|200 mg GSK2586184|Subjects will be randomized to 200 mg GSK2586184 twice daily for up to 84 days
89581785|NCT01782664|Experimental|400 mg GSK2586184|Subjects will be randomized to 400 mg GSK2586184 twice daily for up to 84 days
89581786|NCT01782664|Placebo Comparator|Placebo|Subjects will be randomized to receive Placebo twice daily for up to 84 days
89581787|NCT01782664|Experimental|400 mg GSK2586184 (Cohort B)|Subjects will take 400 mg GSK2586184 twice daily for up to 84 days
89581788|NCT04414072|Active Comparator|laparoscopic sleeve gastrectomy|
89581789|NCT04414072|Active Comparator|mini gastric bypass|
89581790|NCT04414072|Active Comparator|sleeve gastrectomy with loop bipartition|
89581791|NCT01732588|Active Comparator|Regimen A - 120mg OZ439 PIB|120mg single dose of OZ439 as powder in bottle (PIB) formulation
89581792|NCT01732588|Experimental|Regimen B - 120 mg OZ439 IR caplet|120 mg single dose of OZ439 immediate release (IR) caplet formulation containing nanoparticulate, administered directly via the oral route
89581793|NCT01732588|Experimental|Regimen C - 120 mg OZ439 caplet via Enterion capsule|120 mg single dose of OZ439 caplet formulation containing nanoparticulate, administered orally via the Enterion capsule and delivered to the proximal small bowel
89581794|NCT01781962||All Participants|Open-Angle Glaucoma (OAG) and/or Ocular Hypertension (OHT) patients.
89033272|NCT02942732|Other|normal-weight elderly|normal-weight elderly (n=60, age ≥ 65 years and BMI ≤ 25 kg/m²) All assigned patients received a supplement of 10,000 IU cholecalciferol (Euro-Pharm International, Canada) to be taken three times per week. The treatment was led for a period of 6 months.
89581795|NCT04560790|Experimental|BD111 Adults single group Dose|Administered by corneal injection surgery. Dosage form:injection solution. Dose:200uL. Frequency of administration: one time injection.
89581796|NCT01639339|Placebo Comparator|Placebo plus standard therapy|Placebo IV plus standard therapy; placebo administered on Days 0, 14, 28, and then every 28 days thereafter through Week 100, with a final evaluation at Week 104 in the double-blind period. In the open-label extension period, placebo patients who opt to participate will receive belimumab 10 mg/kg IV every 28 days for an additional 6 months.
89581797|NCT01639339|Experimental|Belimumab 10 mg/kg plus standard therapy|Belimumab 10 mg/kg IV plus standard therapy; belimumab administered on Days 0, 14, 28, and then every 28 days thereafter through Week 100, with a final evaluation at Week 104 in the double-blind period. In the open-label extension period, patients who opt to participate will continue to receive belimumab 10 mg/kg IV every 28 days for an additional 6 months.
89581798|NCT02000817|Experimental|Otelixizumab 9 mg|Each subject will receive otelixizumab 1.5 mg diluted with 0.9% weight /volume sodium chloride intravenously daily for 6 consecutive days (cumulative dose-9 mg)
89581799|NCT02000817|Experimental|Otelixizumab 18 mg|Each subject will receive otelixizumab 3 mg diluted with 0.9% weight /volume sodium chloride intravenously daily for 6 consecutive days (cumulative dose-18 mg)
89581800|NCT02000817|Experimental|Otelixizumab 27 mg|Each subject will receive otelixizumab 4.5 mg diluted with 0.9% weight /volume sodium chloride intravenously daily for 6 consecutive days (cumulative dose-27 mg)
89581801|NCT02000817|Experimental|Otelixizumab 36 mg|Each subject will receive otelixizumab 1.5 mg diluted with 0.9% weight /volume sodium chloride intravenously daily for 6 consecutive days (cumulative dose-36 mg)
89581802|NCT02000817|Placebo Comparator|Placebo|Each subject will receive otelixizumab matching placebo diluted with 0.9% weight /volume sodium chloride intravenously daily for 6 consecutive days
89581803|NCT01641133|Active Comparator|Synflorix Group|Subjects who were primed with two doses of Synflorix vaccine, administered intramuscularly into the right or left thigh, at 2 and 4 months of age, received a booster dose of Synflorix vaccine, administered intramuscularly into the right or left anterolateral thigh or in the deltoid, at 12-15 months of age.
89581804|NCT01641133|Experimental|Prevnar 1 Group|Subjects who were primed with Prevnar 13 and Synflorix vaccines, administered intramuscularly into the right or left thigh, at 2 and 4 months of age respectively, received a booster dose of Synflorix vaccine, administered intramuscularly into the right or left thigh or in the deltoid, at 12-15 months of age.
89581805|NCT01641133|Experimental|Prevnar 2 Group|Subjects who were primed with two doses of Prevnar 13 vaccine, administered intramuscularly into the right or left thigh, at 2 and 4 months of age, received a booster dose of Synflorix vaccine, administered intramuscularly into the right or left anterolateral thigh or in the deltoid, at 12-15 months of age.
89581806|NCT04849429|Placebo Comparator|Placebo|Placebo (trigger point injection under C-arm)
89581807|NCT04849429|Experimental|Platelet rich plasma (PRP) with exosomes|PRP with exosomes at the center of the nucleus pulposus (2ml)
89581808|NCT05112757|Experimental|Intervention|Smartphone app use
89581809|NCT04419259|Experimental|Erenumab|30 subjects with rosacea will be allocated to receive monthly subcutaneous injections of 140 mg erenumab at three time points (week 0, week 4, week 8)
89581810|NCT05382013|Experimental|Trial Group|30 patients receive treatment of avatrombopag, DPMAS, LPE, and comprehensive internal medical treatment.
89581811|NCT05382013|Active Comparator|Control Group|30 patients receive treatment of DPMAS, LPE, and comprehensive internal medical treatment.
89581812|NCT04678921|Experimental|Dose Level 1|1mg/kg Q1W
89581813|NCT04678921|Experimental|Dose Level 2|3 mg/kg Q1W
89581814|NCT04678921|Experimental|Dose Level 3|10mg/kg Q1W
89581815|NCT04678921|Experimental|Dose Level 4|15 mg/kg Q1W
89581816|NCT04845217|Experimental|Peppermint Oil|Participants in the intervention (peppermint oil) arm will receive soft gels of enteric-coated peppermint oil (0.2mL=200mg). The enteric coated peppermint oil soft gel utilized in this study is Peptogest Peppermint Oil from Schwabe North America (Nature's Way Brand).
89581817|NCT04845217|Placebo Comparator|Coconut Oil|Participants in the placebo (coconut oil) arm will receive soft gels of enteric coated coconut oil. The enteric coated coconut oil soft gel utilized in this study is Coconut Oil from Schwabe North America (Nature's Way Brand).
89581818|NCT04419883||Anesthesia Providers|Anesthesia providers from 15 different health care facilities in the United States.
89581819|NCT05359393|Experimental|resectable group|In this group, we propose a combination therapy, preoperative short-course radiotherapy followed by neoadjuvant chemotherapy and anti-PD-1 immunotherapy, for microsatellite-stable patients with locally advanced rectal cancer and resectable liver/pulmonary metastasis.
89581820|NCT04833439|Experimental|Fasting Mimicking Diet|2 cycles of 3-day fasting mimicking spaced by a 2 week interval
89581821|NCT04178707|Other|Intervention|Using microdialysis the patients inner enviorment of the anal fistula will be measured - levels of lactate, glucose and pyruvate.
89581822|NCT04650919|Experimental|Experimental arm|
89581823|NCT01600885|Active Comparator|Guanfacine then Placebo|During the first study session, the participant will receive guanfacine before undergoing a ketamine-infusion fMRI. During the second study session, at least two weeks later, the participant will receive a placebo before undergoing a ketamine-infusion fMRI.
89581824|NCT01600885|Active Comparator|Placebo then Guanfacine|During the first study session, the participant will receive a placebo before undergoing a ketamine-infusion fMRI. During the second study session, at least two weeks later, the participant will receive guanfacine before undergoing a ketamine-infusion fMRI.
89581825|NCT05369455|Experimental|group 1|group of ultrasound guided Erector spine plane block:
89581826|NCT05369455|Active Comparator|group 2|group of ultrasound guided Caudal block:
89581827|NCT01732510|Experimental|Part 1: MK-8226 0.3 mg/kg|MK-8226 administered intravenously (IV) at a weight-based dose every 2 weeks for a period of 12 weeks.
89581828|NCT01732510|Experimental|Part 1: MK-8226 1 mg/kg|MK-8226 administered IV at a weight-based dose every 2 weeks for a period of 12 weeks.
89581829|NCT01732510|Experimental|Part 1: MK-8226 3 mg/kg|MK-8226 administered IV at a weight-based dose every 2 weeks for a period of 12 weeks.
89581830|NCT01732510|Experimental|Part 1: MK-8226 10 mg/kg|MK-8226 administered IV at a weight-based dose every 2 weeks for a period of 12 weeks.
89581831|NCT01732510|Placebo Comparator|Part 1: Placebo (pooled)|Dose-matched placebo administered IV every 2 weeks for a period of 12 weeks.
89581832|NCT01732510|Experimental|Part 2: MK-8226 3 mg/kg|MK-8226 administered IV at a weight-based dose every 2 weeks for a period of 12 weeks.
89581833|NCT01732510|Placebo Comparator|Part 2: Placebo|Placebo administered IV every 2 weeks for a period of 12 weeks.
89581834|NCT05369377|Experimental|Zanubrutinib and eltrombopag|Zanubrutinib 80mg po qd 6 weeks and eltrombopag 50 mg qd for up to 6 weeks.
89581835|NCT05369377|Active Comparator|Eltrombopag monotherapy|Eltrombopag is given as 50 mg qd for up to 6 weeks.
89581836|NCT04832269||MP exposed group|children and adolescents (aged 8 to 18 years) of mothers with prenatal exposition to MP in the context of an MS relapse therapy
89581837|NCT04832269||MP non-exposed group/control group|children and adolescents of mothers suffering from MS aged 8 to 18 years
89581838|NCT05353153|Experimental|hypnosis group|
89581839|NCT05353153|Active Comparator|Control group|
89581840|NCT04608331|Experimental|Dexmedetomidine group|Patient-controlled analgesia is established with morphine (0.5 mg/ml) and dexmedetomidine (1.25 microgram/ml) in a total volume of 160 ml. The pump is programmed to deliver 2-ml boluses at 6 to 8-minute lockout intervals with a background infusion rate at 1 ml/h. Patient-controlled analgesia is provided for at least 24 hours after surgery.
89581841|NCT04608331|Placebo Comparator|Placebo group|Patient-controlled analgesia is established with morphine (0.5 mg/ml) in a total volume of 160 ml. The pump is programmed to deliver 2-ml boluses at 6 to 8-minute lockout intervals with a background infusion rate at 1 ml/h. Patient-controlled analgesia is provided for at least 24 hours after surgery.
89581842|NCT04065295|Experimental|Single Rising Dose Part|
89581843|NCT04065295|Experimental|Bioavailability Part|
89581844|NCT05348941|No Intervention|Control|Hypocaloric balanced diet
89581845|NCT05348941|Experimental|TECADRIOL|Hypocaloric balanced diet plus a food supplement with D-chiro-inositol and alpha-lactalbumin
89581846|NCT04842097|Experimental|Mindfulness-based stress reduction intervention|Online 8-week group program, once per week
89581847|NCT04842097|No Intervention|Waiting list|Controls will not receive any intervention during this time. They are on chronic pain clinics waiting list
89581848|NCT01637077|Experimental|Arm I (pain therapy)|Patients receive pregabalin PO BID, beginning on the first night of chemotherapy, for 12 weeks and then QD for 1 week.
89581849|NCT01637077|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID, beginning on the first night of chemotherapy, for 12 weeks and then QD for 1 week.
89581850|NCT02308163|Placebo Comparator|Placebo|Participants were assigned to receive placebo to peficitinib once a day until week 12.
89581851|NCT02308163|Experimental|Peficitinib 100 mg|Participants were assigned to receive peficitinib 100 mg/day for 52 weeks.
89581852|NCT02308163|Experimental|Peficitinib 150 mg|Participants were assigned to receive peficitinib 150 mg/day for 52 weeks.
89581853|NCT02308163|Active Comparator|Etanercept|Participants were administered 50 mg of subcutaneous etanercept once weekly for 52 weeks.
89581854|NCT05347537|Experimental|Mulligan mobilization|Group A will be treated with only mulligan's mobilization with movement at the frequency of 3 sets with 10 repetitions 3 times/ week without the clamshell exercise.
89581855|NCT05347537|Active Comparator|Mulligan mobilization with clamshell exercise|Group B will be treated with mulligan's mobilization with movement and clamshell exercises.
89581856|NCT04819711|Active Comparator|Intervention|Thinking Healthy group intervention integrated into antenatal pregnancy school classes
89581857|NCT04819711|No Intervention|Control|Participants randomized to the control arm will not be offered the THP intervention but will attend the 5 sessions of the routine group antenatal pregnancy school classes. The class provides education about pregnancy, birth and new-born care and offers support to women. The women will also be able to access all usual care and support offered by the participating hospitals
89581858|NCT04556851|Experimental|HSK7653 10 mg|
89581859|NCT04556851|Experimental|HSK7653 25 mg|
89581860|NCT04556851|Placebo Comparator|Placebo|
89581861|NCT04039399|Experimental|Ischemic Conditioning|Study participants will receive one session of ischemic conditioning on their affected leg with cuff inflation to 225 mmHg.
89581862|NCT04039399|Sham Comparator|Sham Ischemic Conditioning|Study participants will receive one session of sham ischemic conditioning on their affected leg with cuff inflation to 10 mmHg.
89581863|NCT04554745|Other|Non-scared uterus of pregnant women|
89581864|NCT04554745|Other|Scared uterus of pregnant women|
89581865|NCT04038697|Experimental|Ischemic Conditioning + Treadmill Training|Study participants with prior history of stroke will receive both ischemic conditioning and treadmill training.
89581866|NCT04038697|Placebo Comparator|Ischemic Conditioning Sham + Treadmill Training|Study participants with prior history of stroke will receive both ischemic conditioning sham and treadmill training.
89581867|NCT04038697|Active Comparator|Ischemic Conditioning Only|Study participants with prior history of stroke will receive only ischemic conditioning.
89581868|NCT04038697|Active Comparator|Healthy Control - Ischemic Conditioning + Treadmill Training|Healthy control participants will receive both ischemic conditioning and treadmill training.
89581869|NCT04818775|Experimental|HemaClear|
89581870|NCT04818775|Active Comparator|Pneumatic Tourniquet|
89581871|NCT04966273|Experimental|Biosensors Microcatheter (BM)|Use of Biosensors Microcatheter
89581872|NCT05344105|Active Comparator|Transversalis fascia plan block (Group T)|After local cleaning of the skin area, the transducer will be placed on the iliac crest in the transverse plane with a low-frequency convex probe, and the skin, subcutaneous tissue, external oblique muscle will be placed with a 20 G, 100 mm needle. After visualization of the internal oblique muscle and transversus abdominis muscles and finally the deep fascia of the transversus abdominis, local anesthetic will be given unilaterally between the last part of the transversus abdominis muscle and the transversalis fascia with the out-off plan technique.
89581873|NCT05344105|Active Comparator|Erector spina plan block (Group E)|After local cleaning of the skin area, a convex probe is determined to be placed longitudinally 3 cm lateral to the spinous process of the T11 vertebra, after determining the erector spina muscle, with a 20 G, 100 mm needle inplane method in the craniocaudal direction will be advanced and a local anesthetic will be administered between the erector spinae muscle and the transverse process.
89581874|NCT04018807|Other|Resource Pamphlet|Participants will receive a pamphlet detailing mental health and social service providers at the local, state, and national level.
89581875|NCT04018807|Experimental|Remote Therapy|Participants will receive eight 30-minute remote therapy sessions over the course of twelve weeks.
89029989|NCT02951325|Experimental|Test|"Surgery +/- chemotherapy as per standard arm and Radiation therapy as experimental intervention~Radiation Therapy:~All patients will be treated with conformal radiotherapy technique with intensity modulated radiotherapy with or without image guidance. The radiotherapy will start within 8 weeks from the date of surgery if adjuvant chemotherapy has not been planned. The radiotherapy will start within 4 weeks from the date of last chemo cycle, in patients who will be given adjuvant chemotherapy.~Dose Prescription:~•50.4 Gray (Gy) in 28 fractions (1.8Gy/#) will be prescribed for the nodal PTV. In case of R1 and/or R2 resection dose to the pelvic nodes and tumour bed may be increased to 54-56 Gy in 28 fractions depending on the constraints achieved during planning.~Patient assessments: Clinical assessment for toxicity evaluation and disease status. QOL evaluation of the patients."
89029990|NCT02955680|Experimental|Group M|At the end of surgery, patients were stimulated to wake up by recorded mother's voice, which was recorded before the operation.
89029991|NCT02955680|Active Comparator|Group S|At the end of surgery, patients were stimulated to wake up by recorded stranger's voice, which was recorded before the operation.
89581876|NCT04830787||hypertrophic cardiomyopathy|patients with hypertrophic cardiomyopathy
89581877|NCT04830787||control without hypertrophic cardiomyopathy|controls without hypertrophic cardiomyopathy
89029992|NCT01244126|Active Comparator|IM morphine|0.1 mg/kg morphine IM
89581878|NCT04018729|Experimental|Endobronchial valve + marrow-derived mesenchymal stromal cell|
89581879|NCT04018729|Active Comparator|Endobronchial valve|
89581880|NCT04817371|Other|Symptomatic patients with positive PCR|Patients with symptoms of COVID-19 and whose PCR result is positive
89581881|NCT04817371|Other|Symptomatic patients with positive PCR for other respiratory virus|Patients with symptomatic respiratory disease of infectious origin with negative RT-PCR for SARS-CoV-2 and positive RT-PCR for other respiratory viruses
89581882|NCT04817371|Other|Asymptomatic patients or healthy volunteers|Patients or healthy volunteers with negative RT-PCR and negative serology
89581883|NCT04817371|Other|Volunteers or patients vaccinated against COVID-19|Volunteers or patients vaccinated against COVID-19 (complete vaccination scheme)
89581884|NCT05408533|Active Comparator|Silver-Coated Catheter|
89581885|NCT05408533|Placebo Comparator|Standard Catheter|
89581886|NCT04001647|Experimental|TUDCA|Young and older healthy weight and obese participants will visit the lab for assessment of vascular function prior to the intervention. Aortic stiffness will be evaluated non-invasively using carotid-femoral pulse-wave velocity. A physician will place a catheter in the brachial artery for endothelial cell biopsies and local vasodilator infusions. A venous catheter will also be placed for the systemic ascorbic acid infusion. Aortic stiffness measures and vascular responses to vasodilator infusions will be performed before and after the ascorbic acid infusion. Following the completion of the vascular assessments, participants will receive 1750 mg/day of the dietary supplement tauroursodeoxycholic acid (TUDCA) for 8 weeks. Participants will return to the lab after the 8 week intervention and the vascular assessments described above will be repeated.
89581887|NCT04001647|Placebo Comparator|Placebo|Older obese participants will visit the lab for assessment of vascular function prior to the intervention. Aortic stiffness will be evaluated non-invasively using carotid-femoral pulse-wave velocity. A physician will place a catheter in the brachial artery for endothelial cell biopsies and local vasodilator infusions. A venous catheter will also be placed for the systemic ascorbic acid infusion. Aortic stiffness measures and vascular responses to vasodilator infusions will be performed before and after the ascorbic acid infusion. Following the completion of the vascular assessments, participants will receive oral capsules containing a placebo treatment for 8 weeks. Participants will return to the lab after the 8 week intervention and the vascular assessments described above will be repeated.
89581888|NCT04419571||Suspected or Confirmed COVID-19|All adult patients (>17 years) undergoing emergency (laparotomy) surgery at a single centre (Queens Hospital, Romford, UK) with clinically or radiologically suspected COVID-19, or with viral PCR confirmation; diagnosis made 7-days before and 30-days after date of surgery in accordance with the COVIDsurg study criteria (3).
89581889|NCT04419571||Negative or non-suspected COVID-19|All adult patients (>17 years) undergoing emergency (laparotomy) surgery at a single centre (Queens Hospital, Romford, UK) without clinically or radiologically suspected COVID-19, or without viral PCR (Polymerase Chain Reaction) confirmation.
89581890|NCT04490161|Experimental|Interventional|Subjects will receive reinstallation of CSF intravenously.
89581891|NCT04490161|No Intervention|Observational|Subjects will not receive study intervention; CSF will be sampled and analyzed in comparison to the Interventional arm,
89581892|NCT04829461|Experimental|Ambu® aScope™ 4 Cysto|Ureteral stent removal procedure performed with Ambu® aScope™ 4 Cysto (single-use cystoscope).
89581893|NCT04829461|Active Comparator|Standard of Care (SOC)|Ureteral stent removal procedure performed with standard of care (reusable cystoscope).
89581894|NCT04193917|Other|conjunctival swab|A conjunctival swab of both eyes will be taken
89581895|NCT04828681||Patients with Angio-IMR>40 Unit|Patients with angio-IMR>40U in the culprit vessel after successful primary PCI.
89581896|NCT04828681||Patients with Angio-IMR≤40 Unit|Patients with angio-IMR≤40U in the culprit vessel after successful primary PCI.
89581897|NCT04828369||EUS group|Patients who received EUS-guided coil embolization combined with endoscopic cyanoacrylate injection
88974326|NCT04362917||FDR-|"Adults with a first degree relative with T1D, who have tested negative for islet autoantibodies.~There is no intervention. Each group will get a MMTT and a clamp to evaluate beta cell function, identify elevations in circulating biomarkers of β cell stress or death, as well as their associations with measures of β cell function, and compare advantages of hyperglycemic clamps in identifying β cell dysfunction in this setting, relative to the mixed meal tolerance test (MMTT). They will repeat both the MMTT and the clamp once, to assess inter-test variability."
88974327|NCT04362917||FDR+|"Adolescents and adults with a first or second degree relative with T1D, who has tested positive for at least one islet autoantibody.~There is no intervention. Each group will get a MMTT and a clamp to evaluate beta cell function, identify elevations in circulating biomarkers of β cell stress or death, as well as their associations with measures of β cell function, and compare advantages of hyperglycemic clamps in identifying β cell dysfunction in this setting, relative to the mixed meal tolerance test (MMTT). They will repeat both the MMTT and the clamp once, to assess inter-test variability."
88974328|NCT04362917||Control|"Adults with no family history of Type 1 Diabetes, who have tested negative for islet autoantibodies~There is no intervention. Each group will get a MMTT and a clamp to evaluate beta cell function, identify elevations in circulating biomarkers of β cell stress or death, as well as their associations with measures of β cell function, and compare advantages of hyperglycemic clamps in identifying β cell dysfunction in this setting, relative to the mixed meal tolerance test (MMTT). They will repeat both the MMTT and the clamp once, to assess inter-test variability."
88974329|NCT04361201||Ligament plastic surgery ankle|Patient treated priorly by ligament plastic surgery of lateral ankle plane under arthroscopy
88974330|NCT04361201||Control group|Controlateral ankle
89581898|NCT04828369||BRTO group|Patients who received balloon-occluded retrograde transvenous obliteration (BRTO)
89581899|NCT04408729|Experimental|PrEP My Way intervention|PrEP My Way is an intervention that involves peer-delivery of a kit containing PrEP and other sexual health services. Participants will be offered PrEP if HIV-negative per a point-of-care test, pregnancy testing, vaginal swabs for gonorrhea and chlamydia testing, condoms, and/or self-injection medroxyprogesterone, as desired.
89581900|NCT04408729|No Intervention|Control|These participants will continue to receive PrEP at the clinic.
88974331|NCT04328402||Children and adolescents submitted to PSG in sleep laboratory|Children (1 to 11 years) and adolescents (12 to 18 years), who were referred to a sleep laboratory and submitted to full-night polysomnography due to suspicious of sleep disorders.
89581901|NCT04402489|Placebo Comparator|Placebo Comparator|Oral tablet of placebo once a day.
89581902|NCT04402489|Experimental|MT-7117 Low Dose|Oral tablet of MT-7117 Low Dose once a day.
89581903|NCT04402489|Experimental|MT-7117 High Dose|Oral tablet of MT-7117 High Dose once a day.
88974332|NCT04323657|Experimental|Phase 1|The Phase 1 portion of the study will proceed according to a standard 3 + 3 dose escalation schema. Patients will be enrolled into 3 cohorts based on disease: NHL cohort, low tumor burden ALL cohort, and high tumor burden ALL cohort.
89581904|NCT04827199|Experimental|ARTUS®|The subjects will be implanted with the experimental medical device ARTUS® Artificial Urinary Sphincter (AUS) during the surgical procedure and will be trained to the use of the Remote Control to control themselves the micturition.
89581905|NCT04399369|Experimental|SDF|38% silver diamine fluoride solution
89581906|NCT04399369|Active Comparator|NaF|5% sodium fluoride varnish
89581907|NCT04419415|Experimental|Skipping breakfast and maintain habitual physical activity|Subject will skip breakfast and maintain habitual physical activity.
89581908|NCT04419415|Experimental|High protein breakfast and maintain habitual physical activity|Subject will consume a high protein dairy breakfast (300 g high protein yoghurt (skyr)) and maintain habitual physical activity.
89581909|NCT04419415|Experimental|Skipping breakfast and exercising three times per week|Subject will skip breakfast and participate in organized exercise-training three times per week (and maintain habitual physical activity)
88974333|NCT04323657|Experimental|Phase 2|The phase 2 portion of the study will evaluate the efficacy of TC-110 T cells administered at the RP2D, preceded by a lymphodepleting regimen.
89209494|NCT00730691|Experimental|Vortioxetine 5 mg|Vortioxetine 5 mg encapsulated tablets, orally, once daily, for 8 weeks, followed by placebo-matching capsules, orally, once daily, for 1 week.
89209495|NCT00730691|Experimental|Vortioxetine 10 mg|Vortioxetine 10 mg encapsulated tablets, orally, once daily, for 8 weeks, followed by placebo-matching capsules, orally, once daily, for 1 week.
89581910|NCT04419415|Experimental|High protein breakfast and exercising three times per week|Subject will consume a high protein dairy breakfast (300 g high protein yoghurt (skyr)) and and participate in organized exercise-training three times per week (and maintain habitual physical activity)
89581911|NCT04815109||critical ill COVID-19|Critically ill COVID-19 patients with need for ventilation and appropriate sedation
89581912|NCT01999335|Experimental|Oprozomib 150 mg 5/14 + Pomalidomide 4 mg + Dexamethasone|Participants received oprozomib 150 mg once daily on days 1 to 5 and days 15 to 19 (5/14 schedule) of each 28-day treatment cycle, in combination with pomalidomide 4 mg/day on days 1 to 21 and dexamethasone 20 mg on days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle until disease progression or unacceptable toxicity.
89581913|NCT01999335|Experimental|Oprozomib 150 mg 5/14 + Pomalidomide 2 mg + Dexamethasone|Participants received oprozomib 150 mg once daily on days 1 to 5 and days 15 to 19 (5/14 schedule) of each 28-day treatment cycle, in combination with pomalidomide 2 mg/day on days 1 to 21 and dexamethasone 20 mg on days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle until disease progression or unacceptable toxicity.
89581914|NCT01999335|Experimental|Oprozomib 210 mg 2/7 + Pomalidomide 4 mg + Dexamethasone|Participants received oprozomib 210 mg once daily on days 1, 2, 8, 9, 15, 16, 22, and 23 (2/7 schedule) of each 28-day treatment cycle, in combination with pomalidomide 4 mg on days 1 through 21 and dexamethasone 20 mg/day on days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle until disease progression or unacceptable toxicity.
89581915|NCT01999335|Experimental|Oprozomib 240 mg 2/7 + Pomalidomide 4 mg + Dexamethasone|Participants received oprozomib 240 mg once daily on days 1, 2, 8, 9, 15, 16, 22, and 23 (2/7 schedule) of each 28-day treatment cycle, in combination with pomalidomide 4 mg on days 1 through 21 and dexamethasone 20 mg/day on days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle until disease progression or unacceptable toxicity.
89581916|NCT01999335|Experimental|Oprozomib 210 mg 2/7 + Pomalidomide 4 mg + Dexamethasone: Expansion Phase|Participants received oprozomib 210 mg once daily on days 1, 2, 8, 9, 15, 16, 22, and 23 (2/7 schedule) of each 28-day treatment cycle, in combination with pomalidomide 4 mg on days 1 through 21 and dexamethasone 20 mg/day on days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle until disease progression or unacceptable toxicity.
89581917|NCT01978119|Experimental|Sequence 1|Subjects in this Arm will receive Regimen A followed by Regimen B. Regimen A: Placebo administered BID by Multi-Dose Inhaler followed by FSC (250/50 mcg) administered BID by Capsule-Based Inhaler. Regimen B: FSC (250/50 mcg) administered BID by Multi-Dose Inhaler followed by Placebo administered BID by Capsule-Based Inhaler
89581918|NCT01978119|Experimental|Sequence 2|Subjects in this Arm will receive Regimen B followed by Regimen A. Regimen B: FSC (250/50 mcg) administered BID by Multi-Dose Inhaler followed by Placebo administered BID by Capsule-Based Inhaler. Regimen A: Placebo administered BID by Multi-Dose Inhaler followed by FSC (250/50 mcg) administered BID by Capsule-Based Inhaler
89581919|NCT01999179|Other|low-molecular-weight heparin or direct oral anticoagulant|"Enoxaparin 1 mg/kg subcutaneously every 12 hours for one month following catheter removal or alternate enoxaparin dose or interval based on anti-factor Xa testing that was obtained by clinical team.~Apixaban, rivaroxaban, dabigatran, or edoxaban at standard dosing per FDA package insert for direct oral anticoagulants."
89581920|NCT01977729|Experimental|CBT with SRT|CBT (Cognitive Behavioral Therapy)+SRT (Sertraline) will be scheduled at weeks 9-12, 14, 16, 18, 20 with telephone visits at weeks 15, 17, and 19. The same therapist as in Phase I will deliver CBT in Phase II, which will occur in conjunction with the psychiatrist visits. Phase II CBT will emphasize continued therapist prescribed in-session and out-of-session exposure tasks (developed with patient) and continued patient cognitive-affective processing of exposure sessions with therapist, with no instruction on new skills or therapeutic strategies. Therapists will be encouraged to discuss clinical status with patients, psychiatrists, and PIs to allow for treatment integration (e.g., psychiatrist could increase the dose of SRT, or not, depending on whether the patient Is making sufficient progress in CBT).
88974334|NCT04320251|Experimental|1|The single observational cohort
88974335|NCT04318691||acute respiratory failure group|60 patients under mechanical ventilation admitted to the intensive care unit for acute respiratory failure
88974336|NCT04318691||vascular surgery control group|10 control patients admitted to the ICU after a planned vascular surgery
88974337|NCT04318691||Healthy volunteers group|10 healthy subjects.
88974338|NCT04278092|Experimental|Paclitaxel plus Cetuximab|Paclitaxel combination with weekly cetuximab will be administered for up to six cycles. Thereafter weekly cetuximab maintenance will be given.
88974339|NCT04273919|Sham Comparator|Mindfulness Mediation|Subjects will undergo virtual reality in a non-embodied (no first person bodily experience) program called Lumen, which was developed by Stanford University's Virtual Human Interaction Lab.
88974340|NCT04273919|Experimental|Graded Motor Imagery|The subjects will engage in 2 therapeutic modules intended to help them practice increasing range of motion safely, and using small movements of the lower back.
88974341|NCT04269759||Pregnancy women|
89209496|NCT00730691|Active Comparator|Duloxetine 60 mg|Duloxetine 60 mg capsules, orally, once daily, for 8 weeks, followed by duloxetine 30 mg capsules, orally, once daily, for 1 week.
89209497|NCT02543502|Experimental|periodontal treatment|Group will receive treatment: periodontal treatment
89209498|NCT02543502|No Intervention|Control Group.|Group will not receive treatment: periodontal treatment
89209499|NCT00890370|Other|1|Active cycle of breathing techniques
89209500|NCT00890370|Other|2|Autogenic drainage
89209501|NCT00890370|Other|3|R-C Cornet
89581921|NCT01977729|Experimental|Switch to SRT alone|Sertraline is a selective serotonin reuptake inhibitor. Sertraline is FDA approved for the treatment of major depressive disorder, obsessive compulsive disorder, posttraumatic stress disorder, panic disorder, social anxiety disorder, and premenstrual dysphoric disorder in adults. Sertraline is also approved for the treatment of obsessive compulsive disorder in children and adolescents. Pharmacotherapy visits will be scheduled at weeks 9-12, 14, 16, 18, 20 with phone visits at weeks 15, 17, and 19. The psychiatrist will meet for ~30 min. with the youth and parents. Efforts will be made to use the most effective and tolerated SRT dose.
89581922|NCT01998477|Experimental|TIVc|flu vaccine
89581923|NCT01998477|Active Comparator|TIV|flu vaccine
89581924|NCT01998399|Experimental|Ticagrelor|Ticagrelor 180 mg loading dose followed by 90 mg BID for 90 days
89581925|NCT01998399|Placebo Comparator|Placebo|Placebo 180 mg loading dose followed by 90 mg BID for 90 days.
89581926|NCT01781572|Experimental|Phase Ib|"The phase Ib is the dose escalation part where successive cohorts of 3-6 newly enrolled patients receiving various dose pairs considering the recommendation from an adaptive BLRM incorporating the EWOC principle until MTD(s)/RP2D is defined. If multiple alternate dosing schedules are explored in parallel, the allocation of patients will proceed in an alternating fashion. Approximately 40 patients are expected to be treated during the phase Ib part of the study.~Dosing Schedule 1: MEK162 administered orally twice daily on a continuous dosing schedule. LEE011 administered orally once daily for 21 days followed by a 1 week break (28-day cycle).~Dosing Schedule 2: MEK162 administered orally twice daily and LEE011 administered orally once daily for 3 weeks followed by a 1 week break (28-day cycle).~Dosing Schedule 3: MEK162 administered orally twice daily and LEE011 administered once daily for 2 weeks followed by a 1 week break (21-day cycle)."
89581927|NCT01781572|Experimental|Phase II|"The Phase II part will begin once the MTD(s)/RP2D have been determined in the Phase Ib in order to assess antitumor activity of the LEE011and MEK162 combination. Patients enrolled in the Phase II part of the study are required to have measurable disease. Approximately 40 patients will be treated in this part.~Phase II part will begin at the RP2D on the chosen schedule in order to assess antitumor activity of the LEE011 and MEK162 combination."
89581928|NCT01998243|Experimental|IGB group A|the intervention in the group A : was to place a preoperative intragastric balloon (IGB-BIB®) in the stomach for 6 months before surgery plus an hypocaloric diet 1200 Kilocalories (Kcal)
89581929|NCT01998243|Placebo Comparator|control group B|the intervention in this control group B was the specified diet (a hypocaloric diet of 1200 Kilocalories (Kcal)
89581930|NCT01977573|Experimental|GSK1278863|Subjects will be administered GSK1278863 QD. Starting dose will be based on data from previous studies with GSK1278863 and dose-response modelling, as well as Baseline Hgb concentration. After 4 Week of fixed dose period, dose may be adjusted to achieve Hgb 9.0 to 10.5 g/dL
89581931|NCT01977573|Other|Control|All subjects who are randomized to the Control arm will receive rhEPO (epoetins or their biosimilars, or darbepoetin) as necessary per standard of care, to maintain Hgb levels within the target range. The decision around whether a subject requires rhEPO, selection of the type of rhEPO and rhEPO dose should be based on Investigator clinical judgment, with the historical rhEPO dose (where applicable) and the current Hgb value being considered.
89581932|NCT01963767|Experimental|NT-020|Participants received two pills of NT-020 plus Biovin (900 mg proprietary formulation of blueberry, carnosine, green tea, plus 200 U Vitamin D3, 40 mg Biovin), with one to be taken in the morning and the other in the evening.
89581933|NCT01963767|Placebo Comparator|Placebo|Subjects took two pills, one in the morning and one in the evening, that were matched in size and shape to the active compound.
89581934|NCT01731886|Active Comparator|Arm A|Subjects will receive the current standard of care treatment. Lenalidomide and dexamethasone for four 28-day cycles followed by steam cell collection and autologous peripheral blood stem cell transplant. After 90 days, start the maintenance phase (lenalidomide days 1-21 every 28 days for two years or until your disease progresses).
89581935|NCT01731886|Active Comparator|Arm B|Subjects will receive the new treatment that will be compared with the standard of care. Lenalidomide and dexamethasone for eight 28-day cycles. After four cycles your stem cells will be collected (stem cell collection). After an additional four cycles of lenalidomide (a total of 8 cycles), start the maintenance phase (lenalidomide days 1-21 every 28 days for two years or until your disease progresses).
89581936|NCT01759420||IV Ondansetron|Adult emergency department patients receiving 4mg of IV ondansetron as part of their treatment plan.
89581937|NCT01781026|Experimental|Vemurafenib Administration|Vemurafenib 960 mg orally, twice per day
89581938|NCT01607398|Experimental|ADOAIR250|ADOAIR 250mcg inhalations, twice daily, from week0 - 12
89581939|NCT01607398|Placebo Comparator|Placebo|Placebo inhalation, twice daily, from week0 -12
89581940|NCT01779856|Other|REVEAL Insertable Cardiac Monitor (ICM)|Monitoring of cardiac arrhythmic events and the relationship between such events and the characteristics.
89581941|NCT01729156|Other|Healthy controls|Healthy controls receiving 1000 mg metformin twice daily for 3 months
89581942|NCT01729156|Placebo Comparator|Placebo|Placebo
88974342|NCT04236492||Fresh osteochondral allografting|Transplantation of a fresh osteochondral allograft in the knee
88974343|NCT04229875|Experimental|CAG Bipolar|"Patients will be treated in a localized CAG Bipolar clinic within each psychiatric centre increasing the number of bipolar patients for each clinician~All clinicians will get certified in diagnosing and treating bipolar disorder by joining an educational course and ongoing courses continuously~Treatment will include a group-based psychoeducation program~Coordinated targets to improve quality of life of patients by increasing concordance between clinicians, patients and relatives on well-defined treatment goals~Continued ongoing supervision of patient cases in CAG Bipolar staff by the Copenhagen Affective Disorder Clinic~Three-month bidirectional exchange of two clinical staff members between the Copenhagen Affective Disorder Clinic and each CAG Bipolar clinic~Recovery mentors"
88974344|NCT04229875|No Intervention|Control group|Standard treatment
88974345|NCT04212962|Experimental|Treatment group|The treatment group receives the TCM intervention while in the hospital and during the first 90 days after returning to the community.
88974346|NCT04212962|Experimental|Control group|The control group receives usual discharge planning and post-discharge care.
89029993|NCT01244126|Active Comparator|IV morphine|0.1 mg/kg morphine IV
89209502|NCT00890370|Other|4|Flutter
88974347|NCT04196933|Experimental|Normal Controls|"normal control subjects - no history of neurologic or inner ear disease~The investigators will characterize vestibular spatial and temporal precision by calculating perceptual thresholds and reaction times for vestibular (yaw rotation, ytranslation) stimuli in normal subjects over a wide age range. Vestibular-visual temporal binding is then performed on each subject and the relationship between the principal parameters (vestibular perceptual thresholds [inversely related to spatial precision], vestibular reaction time variability [inverse of temporal precision], and the PSS and TBW from the temporal binding paradigm) will be examined. The investigators will collect qualitative assessments of dizziness/disbalance (DHI: dizziness handicap index) and quantitative measurements of balance and vestibular function (FGA: functional gait analysis, postural sway, and standard rotational testing - VOR gain, time constant, asymmetry)."
89581943|NCT01729156|Active Comparator|Metformin|"Metformin Sandoz, 1000 mg twice daily for 3 months"
89581944|NCT01779700|Active Comparator|Fingolimod|0.5mg of fingolimod, oral administration, daily, for 8 weeks.
89581945|NCT01779700|Placebo Comparator|placebo|placebo, oral administration, daily, for 8 weeks.
89581946|NCT01778530|Experimental|TRC105 for Recurrent Glioblastoma|
89581947|NCT01778062|Experimental|Indacaterol|Indacaterol 150 µg once daily
89581948|NCT01778062|Placebo Comparator|Placebo|Placebo once daily
89581949|NCT01759264||Moderate-to-severe Crohn's disease|Adalimumab induction therapy participants with moderate-to-severe Crohn's Disease
89581950|NCT01757704|Experimental|Open pleurae & conventional filling of heart|In this group both pleurae will be opened and the ventilator disconnected during cardiopulmonary bypass to ensure bilateral pulmonary collapse. However, after completion of the left heart procedure, the heart will be filled with blood actively from the heart-lung machine and manual de-airing performed in a conventional manner and de-airing monitored by intraoperative trans-esophageal echocardiography (TEE). After de-airing is complete and patient has been weaned off the cardiopulmonary bypass the residual air in the left heart will be quantitatively assessed by TEE and Trans-cranial Echo-Doppler (TCD) over a period of 10 minutes.
89581951|NCT01757704|Experimental|Intact pleurae & staged filling of heart|In this group both pleurae will be left intact and the ventilator disconnected during cardiopulmonary bypass. After completion of the left heart procedure, the heart will be filled with blood actively from the heart-lung machine in a staged manner after adequate cardiac contraction has been established. De-airing will be obtained by active cardiac contraction and staged mechanical ventilation and de-airing monitored by intraoperative trans-esophageal echocardiography (TEE). After de-airing is deemed complete and patient has been weaned off the cardiopulmonary bypass (CPB) the residual air in the left heart will be quantitatively assessed by TEE and Trans-cranial Echo-Doppler (TCD) over a period of 10 minutes.
89581952|NCT01757392|Experimental|Candin® 0.3 mL|Monthly intralesional injections of Candin® 0.3 ml until lesion resolves or up to 6 injections.
89581953|NCT01756846|Other|usual care|Daily practice of the cardiologist or attending emergency doctor, in order to diagnose a patient with chest pain. In this period attending doctors assess the risk of a patient with chest pain, based on his/hers experience and various criteria (for example described in European Society of Cardiology Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation, without a formal risk score).
89581954|NCT01756846|Other|use of HEART risk score|see intervention
89581955|NCT01963611|Experimental|Plovamer acetate 0.5 milligram (mg)|Plovamer acetate was administered at a dose of 0.5 mg as weekly subcutaneous injection for 40 weeks up to a maximum of 14 months.
88974348|NCT04196933|Experimental|Central Vestibular Dysfunction|"Migraine and Vestibular Migraine patients~The investigators intend to evaluate vestibular (yaw rotation or y-translation) - visual temporal binding in people with a wide range of motion sickness sensitivities (as quantified with standard questionnaires), including normal subjects, people with migraine and with vestibular migraine. The investigators will use our standard adaption method to narrow the TBW in these subjects, and will also employ PSS adaptation if a consistent pattern emerges that relates MS sensitivity to the PSS. The investigators will induce motion sickness using a pseudo-Coriolis task (so susceptibility can be quantified pre and post training)."
89029994|NCT01244126|Active Comparator|fentanyl IN|Intranasal fentanyl 2 mcg/kg IN
89209503|NCT00890370|Other|5|PEP
89209504|NCT00890448||Lapaquistat acetate participants|
89581956|NCT01963611|Experimental|Plovamer acetate 3 mg|Plovamer acetate was administered at a dose of 3 mg as weekly subcutaneous injection for 40 weeks up to a maximum of 14 months.
89581957|NCT01963611|Experimental|Plovamer acetate 10 mg|Plovamer acetate was administered at a dose of 10 mg as weekly subcutaneous injection for 40 weeks up to a maximum of 14 months.
89581958|NCT01963611|Experimental|Plovamer acetate 20 mg|Plovamer acetate was administered as two subcutaneous injection of 10 mg weekly for 40 weeks up to a maximum of 14 months.
89581959|NCT01963611|Active Comparator|Copaxone 20 mg|Copaxone was administered at a dose of 20 mg as subcutaneous injection once daily for 40 weeks up to a maximum of 14 months.
89581960|NCT04662645|Experimental|Supportive care (embedded palliative care)|Participants and caregivers undergo embedded palliative care comprising symptom management (physical and psychological), advanced directives and goals of care discussion, caregiver support, and referral for adjunctive supportive services as needed at each clinic visit.
89581961|NCT01975701|Experimental|BGJ398X|To estimate anti-tumor efficacy of BGJ398
89581962|NCT01962987|Experimental|Diclofenac Sodium 3% gel - Test|The diclofenac sodium 3% test gel is applied to lesion areas twice daily. It is to be smoothed onto the affected skin gently. The amount needed depends upon the size of the lesion site. Assure that enough Test Gel is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.
89581963|NCT01962987|Active Comparator|Diclofenac Sodium 3% gel - Reference|The Reference diclofenac sodium 3% gel (Solaraze®) is applied to lesion areas twice daily. It is to be smoothed onto the affected skin gently. The amount needed depends upon the size of the lesion site. Assure that enough Reference (Solaraze®) Gel is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.
89581964|NCT01962987|Placebo Comparator|Placebo gel|The placebo gel (contains no active ingredient) is applied to lesion areas twice daily. It is to be smoothed onto the affected skin gently. The amount needed depends upon the size of the lesion site. Assure that enough placebo gel is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.
89581965|NCT01962441|Experimental|SOF+RBV 16 weeks|SOF+RBV for 16 weeks
89581966|NCT01962441|Experimental|SOF+RBV 24 weeks|SOF+RBV for 24 weeks
89581967|NCT01962441|Experimental|SOF+RBV+Peg-IFN 12 weeks|SOF+RBV+Peg-IFN for 12 weeks
89581968|NCT01962441|Experimental|Retreatment Substudy|Participants from the SOF+RBV arms (16 weeks or 24 weeks) who experienced virologic failure on treatment, or during the posttreatment period at or before Posttreatment Week 24 may be eligible to enroll into the Retreatment Substudy to receive SOF+RBV+Peg-IFN for 12 weeks.
89581969|NCT01638013|Experimental|Participants who completed 015K-CL-RAJ1|Participants who completed 015K-CL-RAJ1 (NCT02305849) study and met eligible criteria received starting dose of 50 milligrams (mg) peficitinib tablet orally once daily after breakfast. Dose can be increased to 100mg or 150mg, and decreased to 50mg. For participants who did not have any safety problem, the dose was increased from 50 mg to 100 mg. For participants who did not have any safety problems, and a lack of clinical response (DAS28-ESR >= 3.2 after 4 weeks of peficitinib treatment), dose was increased to 150mg. The treatment was given in this study up to 6 months after peficitinib was approved.
89581970|NCT01638013|Experimental|Participants who completed 015K-CL-RAJ3|Participants who completed 015K-CL-RAJ3 (NCT02308163) study and met eligible criteria received 100mg peficitinib tablet orally once daily after breakfast. Dose can be increased to 100mg or 150mg, and decreased to 50mg. For participants who did not have any safety problem, the dose was increased from 50 mg to 100 mg. For participants who did not have any safety problems, and confirmed a lack of clinical response (DAS28-ESR >= 3.2 after 4 weeks of peficitinib treatment), dose was increased to 150mg. The treatment was given in this study up to 6 months after peficitinib was approved.
89581971|NCT01638013|Experimental|Participants who completed 015K-CL-RAJ4|Participants who completed 015K-CL-RAJ4 (NCT02305849) study and met eligible criteria received 100mg peficitinib tablet orally once daily after breakfast. Dose can be increased to 100mg or 150mg, and decreased to 50mg. For participants who did not have any safety problem, the dose was increased from 50 mg to 100 mg. For participants who did not have any safety problems, and confirmed a lack of clinical response (DAS28-ESR >= 3.2 after 4 weeks of peficitinib treatment), dose was increased to 150mg. The treatment was given in this study up to 6 months after peficitinib was approved.
89581972|NCT01637623|Active Comparator|Losartan|Losartan 50 mg daily for two weeks, then increased to 100mg daily for 4 weeks if asymptomatic and blood pressure within range.
89581973|NCT01637623|Active Comparator|Allopurinol|Allopurinol 300 mg daily for 6 weeks
89581974|NCT01637623|Placebo Comparator|Placebo|Placebo capsule daily for 6 weeks
89581975|NCT01962207|Experimental|ACWY<2 Group|Subjects will receive a dose of MenACWY-TT 10 years after primary vaccination with MenACWY-TT.
89581976|NCT01962207|Experimental|ACWY≥2 Group|Subjects will receive a dose of MenACWY-TT 10 years after primary vaccination with MenACWY-TT.
89581977|NCT01962207|Experimental|MenCCRM Group|Subjects will receive a dose of MenACWY-TT 10 years after primary vaccination with Meningitec.
89581978|NCT01962207|Experimental|MenPS Group|Subjects will receive a dose of MenACWY-TT 10 years after primary vaccination with Mencevax ACWY.
89581979|NCT01995825|Experimental|Brand lamotrigine then Generic lamotrigine|Crossover trial. Each arm will receive Brand lamotrigine tablet for two periods and Generic lamotrigine for two periods.
89581980|NCT01995825|Experimental|Generic lamotrigine then Brand lamotrigine|Crossover trial. Each arm will receive Generic lamotrigine tablet for two periods and Brand lamotrigine for two periods.
89581981|NCT04829929|Experimental|One arm|Patients with Non-Valvular Atrial Fibrillation and High Bleeding Risk
89581982|NCT03777943||Cytoreductive surgery (CRS)|In patients presenting with colorectal peritoneal carcinomatosis, peritoneal tissue will be sampled during surgery at 4 different locations.
89581983|NCT01995357|Experimental|First Coloplast Teast A; then Coloplast Test B|"There are six arms in this study. The first part of the study investigated the two test products and one comparator product. In the second part of the study the subjects test the two test products again but receive training meanwhile.~The test sequence in this arm is:~Coloplast Test A; Coloplast Test B; Standard product; Training + Coloplast Test A; Training + Coloplast Test B"
89581984|NCT01995357|Experimental|First Coloplast Test A; Then Standard product|"There are six arms in this study. The first part of the study investigated the two test products and one comparator product. In the second part of the study the subjects test the two test products again but receive training meanwhile.~The test sequence in this arm is:~Coloplast Test A; Standard product; Coloplast Test B; ; Training + Coloplast Test A; Training + Coloplast Test B"
89581985|NCT01995357|Experimental|First Coloplast Test B; Then Colopast Test A|"There are six arms in this study. The first part of the study investigated the two test products and one comparator product. In the second part of the study the subjects test the two test products again but receive training meanwhile.~The test sequence in this arm is:~Coloplast Test B; Coloplast Test A; Standard product; Training + Coloplast Test B; Training + Coloplast Test A"
88974349|NCT04196933|Experimental|Peripheral Vestibular Dysfunction|"Vestibular Schwannoma patients~The basic approach is to characterize the precision of their vestibular information (perceptual thresholds for spatial precision, reaction times for temporal precision), and their temporal binding characteristics for vestibular (yaw rotation or y-translation)-visual inputs, in three states: pre-op, sub-acute post-op (2-6 weeks), and chronic post-op (6 months+). At each state the investigators will also assess the quality of their vestibular-mediated behaviors through questionnaires (e.g. DHI), postural sway, functional gait analysis, and standard rotational testing (VOR gain, time constant, and asymmetry)."
89029995|NCT04695639||cohort group|A convenient sample of children with spastic hemiparetic CP of both genders will participate in this study. To avoid type II error, sample size calculation was performed prior to the study, based on data of pilot study, using G*POWER statistical software (version 3.1.9.2; Franz Faul, Universitat Kiel, Germany) [Exact tests- correlational study, α=0.05, β=0.2, and effect size = 0.4] and revealed that the appropriate sample size for this study is N=46.
89029996|NCT01243892||Cohort 1: IGHD participants|Isolated growth hormone deficient (IGHD) participants who initiated somatropin (Deoxyribonucleic acid [DNA] origin) (recombinant human growth hormone [rhGH]) using the NuSpin device, will be observed for at least 2 years. The choice of initiation of NuSpin treatment and the treatment regimen will be as per treating physician's discretion, the study protocol does not enforce or specify any treatment regimen.
89581986|NCT01995357|Experimental|First Coloplast Test B; Then Standard product|"There are six arms in this study. The first part of the study investigated the two test products and one comparator product. In the second part of the study the subjects test the two test products again but receive training meanwhile.~The test sequence in this arm is:~Coloplast Test b; Standard product; Coloplast Test A; Training + Coloplast Test B; Training + Coloplast Test A"
89581987|NCT01995357|Experimental|First Standard product; Then Coloplast Test A|"There are six arms in this study. The first part of the study investigated the two test products and one comparator product. In the second part of the study the subjects test the two test products again but receive training meanwhile.~The test sequence in this arm is:~Standard product; Coloplast Test A; Coloplast Test B; ; Training + Coloplast Test A; Training + Coloplast Test B"
89581988|NCT01995357|Experimental|First Standard Product, Then Coloplast test B|"There are six arms in this study. The first part of the study investigated the two test products and one comparator product. In the second part of the study the subjects test the two test products again but receive training meanwhile.~The test sequence in this arm is:~Standard product; Coloplast Test B; Coloplast Test A; ; Training + Coloplast Test B; Training + Coloplast Test A"
89581989|NCT05270239|Experimental|Working Memory Training in MS patients|This group of patients will perform a computerized n-back training, which includes a sequence of 2-back and 3-back blocks.
89581990|NCT05270239|Experimental|Virtual Reality Training in MS patients|"This group of patients will perform a Virtual Reality Ball Task training. This task contains 6 trials of increasing difficulty."
89581991|NCT04307563|Other|Mindfulness group|Participants will attend 6 weekly educational and mindfulness sessions.
89581992|NCT04817761|Experimental|Calaspargase pegol (S95015)|
89581993|NCT03706963|Experimental|Phone Call|"Patients will be provided with a Fitbit wristband & assistance to set up on smart phone~Preoperative baseline data (activity, sleep, heartrate) will be collected for at least 14 days until the day prior to surgery~The group will receive a phone call 7 days into their preoperative period to identify barriers, provide available resources, & encourage continuation of prehabilitation activities~The physician extender will talk with the patient to identify barriers to prehabilitation activities that the patient may have experienced during the first 7 days of activity tracking & provide recommendations & resources to overcome those barriers when possible. The physician extender will encourage the patient to continue prehabilitation activities until the day of operation to meet goals. Following surgery, we will analyze Fitbit data to determine if the intervention had an impact on the patient's prehabilitation activity with the non-intervened patient group used as a control"
89581994|NCT03706963|No Intervention|No Phone Call|"Eligible patients will be provided with a Fitbit wristband & assistance to set up on smart phone~Preoperative baseline data (activity, sleep, heartrate) will be collected for at least 14 days until the day prior to surgery"
89581995|NCT04267081|Experimental|Arm 1 (de novo AML)|"This arm will recruit the patients with de novo AML unfit for conventional chemotherapy. In validation cohort all the participants will receive azacytidine-venetoclax. In study cohort the patients with ex vivo resistance to venetoclax will be excluded from the study therapy.~All patients in validation and study cohorts (ARM1 and ARM2) will receive azacytidine and venetoclax. The purpose for the validation cohort is to validate the specificity and sensitivity of the ex vivo drug testing. Patients exhibiting ex vivo sensitivity and receiving azacytidine-venetoclax in validation cohort are analyzed also for study cohort."
89581996|NCT04267081|Experimental|Arm 2 (relapsed, refractory or secondary AML)|"This arm will recruit the patients with relapsed, refractory or secondary AML. In validation cohort all the participants will receive azacytidine-venetoclax. In study cohort the patients with ex vivo resistance to venetoclax will be excluded from the study therapy.~All patients in validation and study cohorts (ARM1 and ARM2) will receive azacytidine and venetoclax. The purpose for the validation cohort is to validate the specificity and sensitivity of the ex vivo drug testing. Patients exhibiting ex vivo sensitivity and receiving azacytidine-venetoclax in validation cohort are analyzed also for study cohort."
89581997|NCT04258267|Experimental|Early mobilization|Patients will be allowed to use their shoulder earlier. The immobilization period is shorter.
89581998|NCT04258267|Experimental|Delayed mobilization|The immobilization period is longer.
89581999|NCT05309005||ABI group|The patient group consists of 100 patients with acquired brain injury (e.g. cerebrovascular incidents, anoxia, encephalitis and non-progressive brain tumors)
89582000|NCT05309005||Healthy control group|100 healthy adults will be matched to the patients with respect to age, gender and education.
89582001|NCT04814173|Experimental|One jaw mechanic|Mini-implants anchored total-maxillary-arch-distalization using a one-jaw mechanic (mini-implants in the maxillary arch).
89209505|NCT00235495|Active Comparator|Albumin (ALB)|Albumin (human albumin, 25% solution, 2.0 g/kg), infused intravenously over a period of 2 hours
89582002|NCT04814173|Experimental|Two-jaw mechanic|Mini-implants anchored total-maxillary-arch-distalization using a two-jaw mechanic (mini-implants in the mandibular arch with class II elastics).
89582003|NCT04814173|Experimental|Traditional treatment|traditional en-mass retraction with first premolars extraction with mini-implants in the maxillary arch.
89582004|NCT03698071|Experimental|ANCA associated vasculitis|
89582005|NCT04792567|Experimental|Siponimod - continuous|Continuous treatment with siponimod (oral, daily, dose depending on CYP2C9 genotype: 2mg or 1 mg) during SARS-CoV-2 mRNA vaccination
89582006|NCT04792567|Experimental|Siponimod- interrupted|Siponimod (oral, daily, dose depending on CYP2C9 genotype: 2mg or 1 mg) with treatment interruption (for approx. 2-3 months) for the purpose of a SARS-CoV-2 mRNA vaccination
89582007|NCT04792567|Active Comparator|Comparator|Baseline DMTs or no treatment during SARS-CoV-2 mRNA vaccination
89582008|NCT04825171|Experimental|Bryophyllum pinnatum 50% chewing tablets|Bryophyllum is administered for 3 weeks. Bryophyllum is given in form of chewing tablets, 350mg per tablet, 0-2-2-2/d: 2 tablets at midday, 2 tablets in the evening, 2 tablets before bedtime.
89582009|NCT04419025|Active Comparator|NAC|Patients receiving N-acetylcysteine (NAC)
89582010|NCT04419025|No Intervention|Control|Patients not receiving N-acetylcysteine (NAC)
89209506|NCT00235495|Placebo Comparator|Saline|Saline (isotonic solution), 8 ml/kg, infused intravenously over a 2-hour period
89209507|NCT02541474|Other|Integrated care|All patients fitting inclusion criteria will receive care from The Patient -centered health care team ( PACT ) which is a service model for frail elderly patients with multiple long term conditions.
89582011|NCT04837339|Other|Patients with lung disease requiring transplantation or who have undergone lung transplantation|There is no intervention to be administered.
89582012|NCT04813003||Obesity group (group 1)|"Pilot phase:~5 adults with class II-III obesity (BMI≥35kg/m2) planned for bariatric surgery will undergo functional imaging and neurobehavioural tasks before bariatric surgery.~Refined protocol phase:~20 overweight adults (BMI≥30kg/m2 or BMI≥28kg/m2 with adiposity-related comorbidities (prediabetes, type 2 diabetes mellitus, hypertension, dyslipidemia)), referred for obesity treatment (surgical or non-surgical)."
89582013|NCT04813003||Control group (group 2)|"Pilot phase:~5 healthy adults with normal body mass (BMI 18.5-24.9kg/m2) matched for age-, sex- and education will serve as a control group and undergo the same experiment.~Refined protocol:~20 healthy adults with normal body mass (BMI 18.5-24.9kg/m2) matched for age and sex will serve as a control group and undergo the same experiment."
89582014|NCT01638559|Experimental|Immunosuppression withdrawal|Gradual withdrawal of immunosuppressive treatment withdrawal as per protocol.
89582015|NCT04210999|Experimental|Homebased resistance training|Resistance training at home instructed via a smart phone training app and avoidance of pain aggravating activities for 3 months
89582016|NCT04210999|Active Comparator|Supervised resistance training|Heavy slow resistance training in the gym instructed by a physiotherapist and avoidance of pain aggravating activities for 3 months
89582017|NCT05259787|Experimental|Etomidate combined with propofol（EP）|0.2ml/kg IV
89582018|NCT05259787|Active Comparator|Propofol（P）|0.2ml/kg IV
89582019|NCT04809571|Experimental|Photoacoustic imaging and Confocal Raman spectroscopy measurement|
89582020|NCT05226325|Active Comparator|G0.2|(33) patients will receive after induction of anesthesia DEX at 1 mcg/kg for 10 minutes followed by infusion at the rate of 0.2 mcg/kg/hour
89582021|NCT05226325|Active Comparator|G0.4|(33) patients will receive after induction of anesthesia DEX at 1 mcg/kg for 10 minutes followed by infusion at the rate of 0.4 mcg/kg/hour
89582022|NCT05226325|Active Comparator|G0.6|(33) patients will receive after induction of anesthesia DEX at 1 mcg/kg for 10 minutes followed by infusion at the rate of 0.6 mcg/kg/hour
89582023|NCT04418635|Experimental|Tamsulosin and Prosta-OK® Neo|Tamsulosin 0.2mg once daily and Prosta-OK® Neo 707mg 2 tablets twice daily for 85 days
89582024|NCT04418635|Placebo Comparator|Tamsulosin and Prosta-OK® Neo-matched placebo|Tamsulosin 0.2mg once daily and Prosta-OK® Neo-matched placebo 707mg 2 tablets twice daily for 85 days
89582025|NCT05394883|Experimental|Supervised Exercise|Women randomized to Supervised Exercise group will attend two to three exercise classes/week.
89582026|NCT05394883|Experimental|Home Exercise|Women assigned to Home Exercise group will receive instructions for their home walking and exercise program.
89582027|NCT05394883|No Intervention|Usual Care|The Usual Care group will receive an exercise log to record any weekly activity in addition to a weekly phone call/text/email to remind the individual to complete the weekly exercise log.
89582028|NCT01756300|Experimental|Resistant Hypertension|The catheter-based (device: Celsius® ThermoCool® RD) renal denervation will serve to treat resistant hypertension.
89582029|NCT04811131|Active Comparator|Active IP and Active Phototherapy|ARQ-252 cream 0.3% BID with phototherapy.
89582030|NCT04811131|Active Comparator|Active IP and Sham Phototherapy|ARQ-252 cream 0.3% BID with sham phototherapy
89582031|NCT04811131|Placebo Comparator|Vehicle and Active Phototherapy|ARQ-252 Vehicle cream BID with active phototherapy
89582032|NCT04811131|Placebo Comparator|Vehicle and Sham Phototherapy|ARQ-252 Vehicle cream BID with sham phototherapy
89582033|NCT04724161||Pregnant women attending first ANC visit|Pregnant women attending their first ANC visit at selected health facilities in Changara, Guro, and Chemba districts.
89582034|NCT05221021|Active Comparator|Vaginal Estradiol with placebo oral pill|Patient will receive 0.01% estradiol cream 1/2 gram applied vaginally once nightly for two weeks then three times per week with once daily placebo oral pill
89582035|NCT05221021|Active Comparator|Oral Mirabegron with placebo vaginal cream|Patient will receive 50 milligrams oral Mirabegron once daily and placebo vaginal cream (Medisca's VersaPro Cream Base) once nightly for two weeks then three times per week
89582036|NCT03164473|Experimental|Rituximab|"pre-emptive 500-mg fixed-dose of IV rituximab every 6 months (total duration of 18 months = 4 infusions)~plus orally placebo-azathioprine for 24 months"
89582037|NCT03164473|Active Comparator|Azathioprine|"standard maintenance oral azathioprine therapy (2 mg/kg/day) for 24 months~plus 4 placebo-rituximab infusions given every 6 months for 18 months"
89582038|NCT03162289|Active Comparator|Fasting|60-72 h-modified fasting (36-48 h before and 24 h after chemotherapy)
89582039|NCT03162289|Active Comparator|Vegan|60-72 h-vegan diet (36-48 h before and 24 h after chemotherapy)
89582040|NCT05218915|Experimental|GLP1-ra plus basal insulin (BGLP)|Dulaglutide and insulin degludec in combination with CGM
89582041|NCT05218915|Active Comparator|Basal bolus insulin (BB)|Insulin aspart/lispro and insulin degludec in combination with CGM
89582042|NCT05237089|Active Comparator|EA group：Electroacupuncture+health education|Acupuncture is the most popular adjuvant and alternative therapy in China, and it has been used to treat various diseases for thousands of years. Electroacupuncture is an innovation of traditional Chinese acupuncture, which improves the clinical effect by transmitting electrical pulses to the needles and then enhances the stimulation at the acupoints to receive better effects. Studies show that EA has been used as an alternative therapy for obesity in clinical practice.
89582043|NCT05237089|Sham Comparator|Sham acupuncture group：shallow acupuncture+health education|Sham acupuncture method in this study is set as the superficial acupuncture manipulated at the same main acupoints with the thinner and shorter needles. The aim of the sham acupuncture is to eliminate the possible placebo effect of EA treatment.
89582044|NCT03462511|Active Comparator|Control Group|"Dyads randomized to the control group will receive:~Standard care Education handouts."
89582045|NCT03462511|Experimental|Intervention Group|In addition to standard care and education handouts, dyads randomized to the intervention group will receive the HABIT intervention, which includes CHW support and tailored text messages.
89582046|NCT03424603|Experimental|STRO-001|intravenous
89582047|NCT05384197|Active Comparator|Enhanced regimen|"They will receive two days antibiotic prophylaxis according to the predetermined protocol.~Sulfamethoxazole-Trimethoprim (TMP-SMX) twice daily will be utilized as the first choice AP for 2 days according to the assigned randomization group with the last day of AP course being one day prior to intervention.~In patients with allergy or resistance to TMP-SMX, the following antibiotics will be considered in the following order: 100 mg Nitrofurantoin twice daily, 500 mg Ciprofloxacin twice daily or 200 mg Cefpodoxime twice daily.~Patients with positive culture which is sensitive only to parenteral antibiotics will receive culture-based intramuscular/intravenous antibiotics following the same schedule (2 days with the last day of AP course being one day prior to intervention)"
89582048|NCT05384197|Active Comparator|Extended regimen|"They will receive seven days antibiotic prophylaxis according to the predetermined protocol.~Sulfamethoxazole-Trimethoprim (TMP-SMX) twice daily will be utilized as the first choice AP for 7 days with the last day of AP course being one day prior to intervention.~In patients with allergy or resistance to TMP-SMX, the following antibiotics will be considered in the following order: 100 mg Nitrofurantoin twice daily, 500 mg Ciprofloxacin twice daily or 200 mg Cefpodoxime twice daily.~Patients with positive culture which is sensitive only to parenteral antibiotics will receive culture-based intramuscular/intravenous antibiotics following the same schedule ( 7 days with the last day of AP course being one day prior to intervention)"
89582049|NCT01995201|Experimental|Part 1: All patients|
89582050|NCT01995201|Experimental|Part 2 A: Sustained clinical remission|
89582051|NCT01995201|Experimental|Part 2 B: Low disease activity|
89582052|NCT05383651||Adults|
89582053|NCT05383651||Pediatric/ Neonates|
89582054|NCT04690699|Experimental|Cohort E: Lerapolturev|Subjects will be treated with lerapolturev by intravesical instillation
89582055|NCT04690699|Experimental|Cohort F: Lerapolturev + 5% DDM|Subjects will be treated with lerapolturev by intravesical instillation after a sequence of 5% DDM and saline washes
89582056|NCT04638387|Experimental|PB125|Twice daily oral administration of 1 capsule of PB125 (Pathways Bioscience). Treatment will last 12 weeks.
89582057|NCT04638387|Placebo Comparator|Placebo|Twice daily oral administration of 1 capsule of rice flour placebo (Pathways Bioscience). Treatment will last 12 weeks. Because of pandemic restricting study time frame, enrollment will favor the experimental arm in this pilot study
89582058|NCT01728454|Placebo Comparator|Placebo|Following the Stage 1 no treatment baseline assessment period, placebo matching capsules, orally, once daily for 18 weeks in Stage 2. Eligible participants had the option to receive 2 additional 16-week cycles of active treatment at 12 milligrams (mg)/day separated by an off-drug interval (ODI) in Stage 3.
89582059|NCT01728454|Experimental|Telapristone acetate 6 mg|Following the Stage 1 no treatment baseline assessment period, telapristone acetate (Proellex®) 6 mg capsules, orally once daily for 18 weeks in Stage 2. Eligible participants had the option to receive 2 additional 16-week cycles of active treatment at 6 mg/day separated by an ODI in Stage 3.
89029997|NCT01243892||Cohort 2: ISS participants|Idiopathic short stature (ISS) participants who initiated somatropin (DNA origin) (rhGH) using the NuSpin device, will be observed for at least 2 years. The choice of initiation of NuSpin treatment and the treatment regimen will be as per treating physician's discretion, the study protocol does not enforce or specify any treatment regimen.
89582060|NCT01728454|Experimental|Telapristone acetate 12 mg|Following the Stage 1 no treatment baseline assessment period, telapristone acetate (Proellex®) 12 mg capsules, orally once daily for 18 weeks. Eligible participants had the option to receive 2 additional 16-week cycles of active treatment at 12 mg/day separated by an ODI in Stage 3.
89582061|NCT04568590|Experimental|Vaccine Hesitant|Subjects who consent to this study and deemed vaccine hesitant, they will receive an educational intervention.
89582062|NCT01636687|Placebo Comparator|Placebo|Subjects who were in placebo at Week 52 cannot continue in the extension treatment period
89582063|NCT01636687|Experimental|Secukinumab 150 mg|After the data base lock of week 52 data has been performed, subjects received secukinumab 150 mg treatment as open label for the remainder of the extension treatment period.
89582064|NCT01636687|Experimental|Secukinumab 300 mg|After the data base lock of week 52 data has been performed, subjects received secukinumab 300 mg treatment as open label for the remainder of the extension treatment period.
89582065|NCT05213377|No Intervention|Group C|"Patients undergoing total hip replacement surgery by anterior approach, with general anesthesia and continuous core body temperature measurement via nasopharyngeal thermic probe.~Patients recruited for surgery who will not receive the 30 minutes of preoperative warming through pulsed air thermal coverage."
89582066|NCT05213377|Experimental|Group W|"Patients undergoing total hip replacement surgery by anterior approach, with general anesthesia and continuous core body temperature measurement via nasopharyngeal thermic probe.~Patients recruited for surgery who will receive the 30 minutes of preoperative warming through pulsed air thermal coverage."
89582067|NCT01634659|Other|Delefilcon A, then narafilcon B|Delefilcon A contact lenses (DAILIES TOTAL1®) worn first, followed by narafilcon B contact lenses (1-DAY ACUVUE® TruEye®). Each product was worn bilaterally (ie, in both eyes) in a daily wear, daily disposable mode for 8 days.
89029998|NCT01243775|Experimental|Belotaxel plus Belloxa|Belotaxel 60 mg/m2 3 weekly (day 1) Belloxa 70 mg/m2 3 weekly (day 2)
89582068|NCT01634659|Other|Narafilcon B, then delefilcon A|Narafilcon B contact lenses (1-DAY ACUVUE® TruEye®) worn first, followed by delefilcon A contact lenses (DAILIES TOTAL1®). Each product was worn bilaterally (ie, in both eyes) in a daily wear, daily disposable mode for 8 days.
89029999|NCT02955641|Active Comparator|NSAIDs-Placebo|Will receive Nepafenac 0.1%in the first eye, and Hydroxyethylcellulose 0.19% in the second eye
89582069|NCT05652985|Experimental|interventional group|Inter-professional Collaboration Training
89582070|NCT05652985|No Intervention|control group|Regarding the control group, the participants will receive no training
89582071|NCT05165641|Other|segmental spinal anesthesia|thoracic spinal anesthesia at T 10 level
89582072|NCT04796467|Experimental|68Ga-PSMA617 and 68Ga-P16-093 PET/CT scan|Patients of Prostate cancer PET/CT imaging: In two consecutive days each patient underwent a PET/CT scan after intravenous administration of 68Ga-PSMA617 and 68Ga-P16-093, respectively.
89582073|NCT05814471|Experimental|Cable fastening system|The knee brace is worn for 2 weeks after adjustment period. The knee brace is held in place by a cable fastening system and 3d printed straps.
89582074|NCT05814471|Active Comparator|Velcro straps|The knee brace is worn for 2 weeks after adjustment period. The knee brace is held in place by a velcro straps system.
89582075|NCT05814445|Experimental|Neuromuscular exercise program|Participants on a neuromuscular exercise program
89582076|NCT05814445|Active Comparator|Institutional exercise program|Participants on an institutional exercise program
89582077|NCT05814380||Group 1|grade 1-3 cardiac retention of 99mTc-DPD in scintigraphy
89582078|NCT05814380||Group 2|first-degree relative of a patient with ATTR
89582079|NCT05814328|No Intervention|Standard Care|Targeted inhospital intervention of GMT for patient aged 75 ans more with TRST score ≥2
89582080|NCT05814328|Experimental|Transitional Care|Targeted inhospital intervention of GMT for patient aged 75 ans more with TRST score ≥2 with a follow-up after ED discharge. Transitional Care is defined by a geriatric team having intervention strategies linked to community care: home visits with community professionals and/or multidisciplinary clinical meetings and/or shared professionals and/or shared information systems.
88974350|NCT04196933|Experimental|Implant Subjects|"Cochlear Implant (CI)/Vestibular Implant (VI) patients~A causative role for vestibular precision in temporal binding will be investigated in the VI patients, since the noise characteristics of the vestibular channel will be varied and to determine how this affects thresholds and temporal binding. As part of a second aim, the investigators will use VI and CI prosthetic signals in patients who have never received them together to see how the brain process sensory cues to which it is essentially naïve. Finally, after the acute experiments the investigators will provide 8 hours of 'physiologic' VI and CI stimulation by turning both implants on, sound modulates activity in the CI as usual, and angular head motion modulates activity in the VI while the subject actively explores the hospital environment."
89582081|NCT05814289|Other|Healthy young adults group|To assess telephone head tilt and cervical, thoracic, and lumbar spine mobility and disturbances.
89582082|NCT05814276|Experimental|San Rocco group|The San Rocco study encompasses a training on the non-pharmacological therapies' methodology.
89582083|NCT05814276|No Intervention|As usual control group|Participants will continue the usual care activities and non-pharmacological interventions already in use in the Nursing Homes without participating in the training.
89582084|NCT05814263|Experimental|HIS/LBB pacing|"In this arm a right ventricular (RV) lead or implantable cardioverter defibrillator (ICD) lead is placed first and then implantation of a HIS-pacing lead is attempted. If it is not possible to find and pace HIS, to correct the LBBB or the threshold for correcting the LBBB is > 2.5 V at 1 ms, implantation of a LBB-pacing lead is attempted instead. If that is not possible either, a left ventricular (LV) lead is implanted.~Intervention: Device: HIS/LBB pacing"
89582085|NCT05814263|Active Comparator|LV pacing|"In this arm an RV-lead or ICD-lead is placed first and then implantation of a LV-pacing lead is attempted. If this is not possible due to anatomical difficulties (no coronary sinus (CS) access, no available branches other than v cordis anterior or v cordis media) or electrical difficulties (no capture below 4 V at 1.0 msec or phrenic nerve stimulation < 2x pacing threshold), implantation of a HIS-pacing lead is attempted instead. If that is not possible or the threshold for correcting the LBBB is > 2.5 V at 1 ms, implantation of a LBB-pacing lead is attempted instead.~Intervention: Device: LV pacing"
89582086|NCT05814224|Experimental|Hormone-receptor positive MBC|Women with hormone receptor-positive MBC, that will be eligible for endocrine therapy as first line treatment
89582087|NCT05814185|Experimental|Canine retraction was done by periodontal distractor with two activations per day.|group 1
89582088|NCT05814185|Experimental|Canine retraction was done by periodontal distractor with four activations per day.|group 2
89582089|NCT05814315|Experimental|HOPE Intervention|These participants will have peer support and online support groups.
89582090|NCT05814315|No Intervention|Control|The control will not have any support provided.
89582091|NCT05814120|Experimental|Experimental arm|Geriatric-specific BLS training program
89582092|NCT05814094|Active Comparator|Restrictive Transfusion Trigger Group|if a patient's Hb concentration reads ≤ 70g/L, one unit of RBC will be transfused. Additional units can be prescribed if required to raise the Hb concentration to above 70g/L.
89209508|NCT02541474|No Intervention|Usual care|All patients in the Control hospitals (Bodø and Narvik) that match the index patient from the intervention group, and who consents to participate in the study. Eligible patients receive an invitation to participate from the local study nurse. Included controls receive usual care in control hospital and municipalities. Data collection in intervention and control groups are the same.
89209509|NCT03017105|Active Comparator|Control|Usual rehabilitation: non-operative management of the fracture; will undergo usual physiotherapy rehabilitation for the injured arm
88974353|NCT04189107|Experimental|Experimental|High dose Dexamethasone
89582093|NCT05814094|Active Comparator|Liberal Transfusion Trigger Group|if a patient's Hb concentration reads ≤ 90g/L, one or more units of RBC will be transfused. Additional units can be prescribed to raise the Hb concentration to greater than 90g/L
89582094|NCT05814081||Pressure Control Ventilation Supine Group|20 patients were ventilated in the supine position with pressure control mode.
89582095|NCT05814081||Pressure Control Ventilation Prone Group|20 patients were ventilated in the prone position with pressure control mode.
89582096|NCT05814081||Volume Control Ventilation Supine Group|20 patients were ventilated in the supine position with volume control mode.
89582097|NCT05814081||Volume Control Ventilation Prone Group|20 patients were ventilated in the prone position with volume control mode.
89582098|NCT05814068|Experimental|Intervention|diagnosis and treatment of high blood pressure
89582099|NCT05814003|Experimental|hydroxylate flavones|flavonoids mainly derived from citrus peel and have numerous strong biological activities, including anti-inflammatory , antioxidant , antimicrobial , and anticancer
89582100|NCT05814003|Active Comparator|alveogyl|ALVOGYL is a brown fibrous paste which contains per 100 g the following active ingredients : 25.70 g of butamben, 15.80 g of iodoform and 13.70 g of eugenol.
89582101|NCT05814003|Placebo Comparator|stent|acrylic resin material used to cover denuded soft tissues
89582102|NCT05813977|Experimental|Group 1: Tritube (FCV) used during tracheostomy|The patient is intubated with Tritube® after the removal of the conventional endotracheal tube (ETT) and Tritube® was advanced until proximal to the carina. Before starting the PDT, measurements with ATP bioluminescence-based method (3M Clean-trace®) were made by taking sample from a sterile PVC (poly vinyl chloride) surface (10 cm2) which is held 50 cm over the operation site. After PDT with Griggs method (Portex), the measurements were repeated by taking sample from surface.
89582103|NCT05813977|No Intervention|Group 2: Conventional endotracheal tube used during tracheostomy|In the patient who was intubated with a conventional endotracheal tube (ETT), the tube was withdrawal to the vocal cords. Before starting the PDT, measurements with ATP bioluminescence-based method (3M Clean-trace®) were made by taking sample from a sterile PVC surface (10 cm2) which is held 50 cm over the operation site. After PDT with Griggs method (Portex), the measurements were repeated by taking sample from surface.
89582104|NCT05813951|Active Comparator|continuous infusion|seventy Patients in the continuous infusion group will receive an intravenous loading dose of 600 mg of Linezolid for 60 min, followed by a continuous infusion of 1200 mg/day (50 mg/h)
89582105|NCT05813951|Active Comparator|intermittent infusion|seventy patients in the intermittent infusion group will administrate 600 mg of linezolid IV every 12 h for 60 min
89582106|NCT05813938|Experimental|Intervention arm|
89582107|NCT05813821|Experimental|Patients with antibiotic treatment in surgical departments|All patients admitted for antibiotic treatment in the surgical departments of the participating centres were included.
89582108|NCT05813808|Experimental|chest x-ray and ultra-low-dose computed tomography|
89582109|NCT05813782|No Intervention|No intervention arms|Primiparous mothers in this group answered the postpartum depression scale (pre-test) before discharge from the hospital. No intervention was made in addition to routine postnatal care. Primiparous mothers answered the maternal attachment scale and the postpartum depression scale (post-test) on postpartum 42nd day.
89582110|NCT05813782|Experimental|Experimental arms|"Primiparous mothers in the experimental group answered the postpartum depression scale before baby massage training. Afterwards, baby massage training (30 min.) was given. Baby model, baby massage video CD and brochure were used in the training. Primiparous mothers were told to apply baby massage regularly for 15 minutes, once a day, every day from the 5th to 42nd day after birth. An Baby Massage Follow-up Form was given to primiparous mothers to record the days of massage. Baby massage application order was provided by phone calls twice a week. Primiparous mothers answered the maternal attachment scale and the postpartum depression scale (post-test) on postpartum 42nd day."
89582111|NCT05813756|Experimental|Experimental_Adults with Autism Spectrum Disorder|post diagnostic psychoeducational intervention and filling of scale and questionnaire
89582112|NCT05813756|No Intervention|Adults with Autism Spectrum Disorder|Filling of scale and questionnaire.
88974354|NCT04189107|Placebo Comparator|Control|Standard dexamethasone dosage and placebo
88974355|NCT04179643|Experimental|3 x 10e13vg NAN-101|Intracoronary Infusion of NAN-101 at 3 x 10e13vg up to 4 subjects
89582113|NCT05813665|Experimental|Narlumosbart|Patients will receive narlumosbart 120 mg subcutaneously (SC) once every 4 weeks (Q4W) with a loading dose of 120 mg SC on day 8 and day 15 of the first cycle until one of the following occurred: complete tumor resection, disease progression, intolerable toxicity, decision by the patient to discontinue, or decision by the investigator that the patient could no longer benefit from the treatment.
89582114|NCT05813665|Active Comparator|Denosumab|Patients will receive denosumab 120 mg subcutaneously (SC) once every 4 weeks (Q4W) with a loading dose of 120 mg SC on day 8 and day 15 of the first cycle until one of the following occurred: complete tumor resection, disease progression without clinical benefit, decision by the patient to discontinue, or decision by the investigator that the patient could no longer benefit from the treatment.
89582115|NCT05813652||RIPPLE-C cohort|This is a retrospective closed cohort study using a single-arm, pre-post design. Therefore, we will be selecting patients from the CPCSSN database to create our single-arm cohort. Patients included in this cohort will be 18 years of age or older, and will have had at least one contact with their primary care clinic between the dates of March 13, 2018 and March 13, 2020.
89582116|NCT05813639|Experimental|Lumbar medial branch cryoablation|Lumbar medial branch cryoablation Procedure lumbar medial branch cryoablation Decreasing the electrode temperature to - 85 C for 120 seconds in two cycles. Follow-up: before the procedure, 3 months, 6 months, 12 months, and 24 months after the procedure Repeated cryoablation ablation procedures are allowed (when VAS will be =/> 4 ) Procedure/Surgery: Lumbar medial branch cryo ablation neurotomy A procedure based on positive lumbar Z- joint testing followed by medial branch neurotomy
88974356|NCT04179643|Experimental|1 x 10e14vg NAN-101|Intracoronary Infusion of NAN-101 1 x 10e14vg up to 4 subjects
88974357|NCT04179643|Experimental|3 x 10e14 vg NAN-101|Intracoronary Infusion of NAN-101 3 x 10e14 vg up to 4 subjects
88974358|NCT04127383|Experimental|ABCC-tool|The intervention group will use the ABCC-tool during consultation with their healthcare provider. Healthcare providers in the intervention group will receive a short instructional film about the ABCC-tool before the start of the study. Additionally, healthcare providers from 12 practices will be invited for interviews, evaluating the context and process of implementation.
88974359|NCT04127383|No Intervention|Usual care|The control group will receive usual care, and healthcare providers will not be instructed
89030000|NCT02955641|Active Comparator|Placebo-NSAIDs|Will receive Hydroxyethylcellulose 0.19% in the first eye, and Nepafenac 0.1%in the second eye
89030001|NCT02955641|Active Comparator|Steroid-Placebo|Will receive Dexamethasone Disodium Phosphate 0.1% in the first eye, and Hydroxyethylcellulose 0.19% in the second eye
89582117|NCT05813639|Experimental|Lumbar medial branch RF neurotomy|Lumbar medial branch RF neurotomy Procedure lumbar medial branch RF neurotomy: Raising the temperature of the tip of the electrode to 85 C for 120 seconds. RF generator. Follow-up: before the procedure, 3 months, 6 months, 12 months, and 24 months after the procedure. Repeated cryoablation ablation procedures are allowed (when VAS will be > 4 )
89582118|NCT05813639|Experimental|Lumbar fazet joint decapsulation|Lumbar facet joint decapsulation through an endoscopic approach
89582119|NCT05813626|Experimental|Toripalimab Combined with Induction Chemotherapy|Induction chemotherapy (IC; every 3 weeks × 3 cycles; gemcitabine 1000 mg/m2 day 1, 8 + cisplatin 80 mg/m2 day 1); Toripalimab, 240 mg, day 1; start on day 1 of the first cycle IC and continue every 3 weeks for 3 cycles till the end of IC.
89582120|NCT05813600|No Intervention|lianhua qingwen granule|Patients were given Lianhua Qingwen Capsule orally, 3 times/day, 6 g/time. oral antipyretic (ibuprofen suspension 10ml) and symptomatic supportive treatment for body temperature >38.5 ℃.
89582121|NCT05813600|Experimental|lianhua qingwen granule+Nirmatrelvir/Ritonavir|Patients were given Lianhua Qingwen Capsule orally, 3 times/day, 6 g/time. oral antipyretic (ibuprofen suspension 10ml) and symptomatic supportive treatment for body temperature >38.5 ℃. And given Nirmatrelvir 300mg/Ritonavir 100mg orally, q12h, for 5 days.
89582122|NCT05813561|Experimental|DWP14012|
89582123|NCT05813561|Active Comparator|Lansoprazole|
89582124|NCT05813522|Experimental|Furmonertinib|Furmonertinib 160mg po qd
89582125|NCT05813509|Experimental|Platinum resistant ovarian cancer|Advanced-stage epithelial ovarian cancer (stage III or above) that has received more than 2 lines of chemotherapy and recurred within 6 months after the chemotherapy is stopped;
89582126|NCT05813496|Experimental|IND Arm|200 patients will receive one tablet of 600 mg of alpha-lipoic acid twice a day orally for 24 weeks.
89582127|NCT05813496|Placebo Comparator|Placebo Arm|200 patients will receive one tablet of placebo twice a day orally for 24 weeks.
89582128|NCT05813483|Experimental|Test group|fraxel laser therapy combined with Skinceuticals skin care product(CE) and routine moisturizing and sun protection
89582129|NCT05813483|Other|Control group|fraxel laser therapy combined with routine moisturizing and sun protection
89582130|NCT05813470|Experimental|Omalizumab (CinnaGen)|Omalizumab (CinnaGen) was administered every 2 or 4 weeks to provide a dose of at least 0.016 mg/kg/IgE for a duration of 28 weeks
89582131|NCT05813470|Active Comparator|Omalizumab (Genentech, Inc., USA and Novartis Pharmaceuticals Corp, Switzerland)|Omalizumab (Genentech, Inc., USA and Novartis Pharmaceuticals Corp, Switzerland) was administered every 2 or 4 weeks to provide a dose of at least 0.016 mg/kg/IgE for a duration of 28 weeks
89582132|NCT05813379|Experimental|exosome injection|The Exosome will be injected into each standardized injection point in a superficial manner. The injections points are along the inferior border of cheek and mid-cheek and temple, where will be followed by 10-15 minutes of icing
89582133|NCT05813366|Experimental|Tryptophan rich diet + vitamin B6 supplementation|It will include 13 participants suffering from premenstrual dysphoric disorder (PMDD) who will be treated by diet rich wit tryptophan (high protein diet) for 8 weeks in addition to vitamin B6 tablets 60 mg once/day, throughout two menstrual cycles, starting from the first day of their menstrual cycle
89582134|NCT05813366|Experimental|Acupuncture + Vitamin B6 supplementation|It will include 13 participants suffering from premenstrual dysphoric disorder (PMDD) who will be treated by acupuncture twice a week for 8 weeks, resulting in a total of 16 visits. Each visit, including initial care, needle application and needle retention, will last about 45 min. In addition to vitamin B6 tablet 60mg once/day, throughout two menstrual cycles, starts from the first day of their menstrual cycle
89582135|NCT05813366|Experimental|Acupuncture + Tryptophan rich diet + vitamin B6 supplementation|It will include 13 participants suffering from premenstrual dysphoric disorder (PMDD) who will be treated by diet rich with tryptophan (high protein diet) for 8 weeks and acupuncture twice a week for 8 weeks, resulting in a total of 16 visits. Each visit, including initial care, needle application and needle retention, will last about 45 min. In addition to vitamin B6 tablet 60mg once/day, throughout two menstrual cycles, starts from the first day of their menstrual cycle
89582136|NCT05813340|Experimental|vascularized interpositional periosteal connective tissue flap|Vascularized inter-positional periosteal connective tissue flap (VIPCTF) may have many advantages over traditional collagen membranes such as; high vascularity, decreased cost (as it may substitute membrane), providing an increase in soft tissue thickness, and reusability.
89582137|NCT05813340|Active Comparator|collagen membrane|Collagen membranes are the most commonly used and can inhibit soft tissue growth in bone defects, They achieve better wound healing and bone regeneration.
89582138|NCT05813249|Active Comparator|NAFLD1|Hepatic steatosis
89582139|NCT05813249|Active Comparator|NAFLD2|Hepatic steatosis
89582140|NCT05813249|Active Comparator|NAFLD3|Hepatic steatosis
89582141|NCT05813210|Experimental|Combined stress test (pharmacological and physical stress)|Patients are first stressed ergometrically and perfusion is assessed. Subsequently, drug induced stress perfusion is performed, as in the usual protocol.
89582142|NCT05813210|Active Comparator|Pharmacological stress test|One group receiving only pharmacological stress test with Regadenoson.
89582143|NCT05813197|Experimental|Intervention|This group will receive the test intervention My Choice-My Way!
89582144|NCT05813197|Active Comparator|Control|This group will receive usual services
89582145|NCT05813184||Control|Women not exposed to antibiotics throughout the entire duration of pregnancy
89582146|NCT05813184||Prenatal antibiotics|Women exposed to antibiotics for at least 7 days from the 32nd week of gestation
89582147|NCT05813171|Active Comparator|Experimental: Allicor|Dietary Supplement: Allicor 150 mg capsule by mouth two times a day during the year
89030002|NCT02955641|Active Comparator|Placebo-Steroids|Will receive Hydroxyethylcellulose 0.19%in the first eye, and Dexamethasone Disodium Phosphate 0.1%in the second eye
89582148|NCT05813171|Placebo Comparator|Placebo|Placebo capsule manufactured to mimic Allicor 150 mg capsule by mouth two times a day during the year
89582149|NCT05813145|Placebo Comparator|Placebo Group|n=25: will receive Placebo plus four cycle of AC followed by paclitaxel 80 mg/m2 weekly for 12 week.
89582150|NCT05813145|Active Comparator|fenofibrate group|"n=25: will receive fenofibrate 160mg once daily for 3 month plus four cycle of AC followed by paclitaxel 80 mg/m2 weekly for 12 week.~."
89582151|NCT05813106|Experimental|Dexmedetomidine group|These patients will receive 0.2 mcg/kg dexmedetomidine intravenously 30 minutes before end
89582152|NCT05813106|Placebo Comparator|Control group|These patients will receive normal saline intravenously 30 minutes before end
89582153|NCT05813093|Experimental|Accelerated iTBS treatment|accelerated iTBS treatment protocol over 5 consecutive days
89582154|NCT05813054|Experimental|HA matrix ingredient|1 cap/day
89582155|NCT05813054|Placebo Comparator|Placebo|1 cap/day
89582156|NCT05813028|Experimental|experimental group|"Patients in the experimental group will be interviewed the day before chemotherapy starts.~Personal Information Form, Multidimensional Perceived Social Support Scale, Quality of Life Scale, Beck Anxiety Scale will be filled in these patients.~Mobile application will be installed on the patient's phone by the researcher. The patient will be registered to the program by creating a user name.~The patient will be given 15-20 minutes of online training on the use of the mobile application.~The mobile application will be applied for a total of 12 weeks for 4 cycles (1 cycle/3 weeks) from the first day of chemotherapy treatment."
89582157|NCT05813028|No Intervention|control group|Patients in the control group who will not have a mobile application installed on their phones will receive standard care.
89582158|NCT05813015|Experimental|DS-S group|All patients pathologically confirmed pTNM stage III, will receive 6 cycles of DS chemotherapy, and sequential S-1 chemotherapy till 1 year postoperation.
89582159|NCT05813002|Active Comparator|standard neurodynamic sequence|Participants in the first group will receive the standard neurodynamic sequence. The starting position for this sequence will be shoulder in extension with lateral rotation, elbow in full flexion and wrist in neutral position. Passively the shoulder is abducted till 90 degrees followed by wrist extension then ended by elbow extension. Ipsilateral movement of the head bending till 45 degrees with movement of the wrist towards the body for 10 repetitions
89582160|NCT05813002|Active Comparator|Distal to proximal neurodynamic sequence|The second group participants will receive the distal to proximal neurodynamic sequence. For this sequence the starting position will be shoulder in full extension with lateral rotation, elbow fully extended and wrist in neutral position. the sequence will start with wrist extension, going to elbow extension, and ending with shoulder abduction. Ipsilateral movement of the head bending till 45 degrees with movement of the wrist towards the body for 10 repetitions
89582161|NCT05813002|Active Comparator|proximal to distal neurodynamic sequence|The participants in the third experimental group will receive the proximal to distal sequence which will start with shoulder abduction, elbow extension and then wrist extension. The starting position is shoulder in extension and laterally rotated, elbow in full flexion, and wrist in neutral position. The shoulder will be passively mobilized to 90 degrees of abduction, elbow into full extension and wrist in full extension. Ipsilateral movement of the head bending till 45 degrees with movement of the wrist towards the body for 10 repetitions
89582162|NCT05812937||Women with suspicion of deep bowel endometriosis|Women with suspicion of deep bowel endometriosis undergoing intraoperative ultrasound to assess its diagnostic value for endometriosis patients as well as the predictive potential of changing the therapeutic strategy during the surgery based on the ultrasound findings.
89582163|NCT05812872|Active Comparator|Alveolar ridge preservationwith tooth graft|tooth graft
89582164|NCT05812872|Active Comparator|Alveolar ridge preservation with allograft|Allograft
89582165|NCT05812872|Active Comparator|Alveolar ridge preservation with alloplast|Beta Tri-Calcium phosphate
89582166|NCT05812833|Experimental|Participating in online training and providing active consultancy|Online training will be given to mothers, and then the web link will be shared and online counseling will be given every week. Mothers will be followed for 3 months
88974360|NCT04124991|Experimental|Yttrium-90 Microspheres in Combination with Durvalumab|Transarterial radioembolization (TARE) with yttrium-90 microspheres will be employed in combination with an intravenous (IV) dose of 1500 mg durvalumab every 4 weeks (Q4W) until PD. TARE will be performed 1-2 weeks (7 to 14 days) before the first dose of durvalumab and a maximum of 2 more times during the treatment period, per Investigator discretion. If additional TARE is performed, the interval between additional TARE treatments and administration of durvalumab should be at least 1 week.
88974361|NCT04121741|Active Comparator|Singing intervention 1|Instructional sing-a-long video. A video series will be created and recorded for the purposes of the study. Flow Mediated dilation (FMD) and EndoPAT will be measured before and after singing.
89582167|NCT05812833|No Intervention|Control|Will receive routine maintenance of the institution
89582168|NCT05812729|Experimental|Intervention|"Participants in the intervention group will receive access to the 6-week online resilience intervention resiLIR Basic consisting of 8 modules of about 45-60 minutes addressing evidence-based resilience factors, such as optimism or sense of coherence."
89582169|NCT05812729|No Intervention|Waitlist control group|Participants will receive the intervention after the first follow-up assessment (3 months after post-assessment).
89582170|NCT05812716|Experimental|Intervention|"Participants in the intervention group will gain access to the 6-week online resilience intervention resiLIR Healthcare Professionals."
89582171|NCT05812716|No Intervention|Waitlist control group|Participants will receive the intervention after the first follow up-assessment (3 months post-intervention of the intervention group).
89582172|NCT05812677|Experimental|R130 Treatment Group|Every 7-14 days,1-4 ml R130 （concentration of 1x10^8 plaque-forming Units/mL,PFU/mL）will be injected intratumoral or Intraperitioneal in patients with relapsed/refractory cervical and endometrial Cancer.
89582173|NCT05811624|Experimental|Experimental Intervention|Physiotherapy intervention, including behavioral weight reduction program combined with pain neuroscience education and cognition-targeted exercise therapy.
89582174|NCT05811624|Active Comparator|Control Intervention|Physiotherapy intervention, including pain neuroscience education and cognition-targeted exercise therapy alone.
89582175|NCT05809570||Periodontal examination|Cross- sectional clinical periodontal examinations and measurements were performed using a Williams periodontal probe
89582176|NCT05808582|Experimental|chidamide combined with fulvestrant|fulvestrant
89582177|NCT05808400|Experimental|Exosomes treatment group|Treated with umbilical cord mesenchymal stem cell-derived extracellular vesicles (EVs) preparation (Specification: 5ml, EV concentration of 1*10^9 particles /ml)
89582178|NCT05808400|No Intervention|Non-treatment group|No treatment
89582179|NCT05805787|Experimental|Acupressure group|Acupressure will be applied to the elderly in the experimental group once a day, 5 days a week (Monday-Friday) for a week. The application will last for 2 weeks. A total of 10 sessions of acupressure will be applied. Acupressure application will be applied by researchers who have been trained and certified on this subject. While the elderly are in supine position, pressure will be applied to each acupressure point, respectively, Tianshu (ST25), Guanyuan (CV4) and Hegu (LI4) for 2 minutes for a total of 6 minutes.
89582180|NCT05805787|No Intervention|Control group|No intervention will be applied
89582181|NCT05800002|Experimental|Intravascular ultrasound guidance|
89582182|NCT05800002|Active Comparator|Angiography guidance|
89582183|NCT05796804|Active Comparator|ERECTOR SPINAE PLANE BLOCK|ultrasound guided block at L4
89582184|NCT05796804|Active Comparator|PERICAPSULARE NERVE GROUP AND LATERAL FEMORAL CUTANEOUS NERVE BLOCK|ultrasound guided block below the ileo-psoas muscle tendon, above the ilio-pectineous eminence and ultrasound guided block of lateral femoral cutaneous nerve
89582185|NCT05788887|Placebo Comparator|Control|The meal contained 100g of white wheat bread and 80g of Italian Parmesan PDO cheese.
89582186|NCT05788887|Other|Intervention|The meal contained 100g of white wheat bread and 80g of Authentic Ladotyri Mytilinis PDO cheese.
89582187|NCT05788874||18F-FDG|
89582188|NCT05788874||18F-FAPI|
89582189|NCT05775887|Experimental|UQSC2 vaccine|15mcg of UQSC2 (SARS-CoV-2 Sclamp2 antigen) adjuvanted with MF59
89582190|NCT05775887|Active Comparator|NVX-CoV2373 vaccine|5 mcg SARS-CoV-2 spike protein adjuvanted with Matrix-M
89582191|NCT05766189|Experimental|Intervention arm|Receives communications on level of SARS-CoV-2 as identified in the wastewater
89582192|NCT05766189|No Intervention|Comparison arm|
89582193|NCT05758090|Experimental|Group NIPE|Intraoperative fentanyl administration will be guided by NIPE protocol
89582194|NCT05758090|Placebo Comparator|Group Control|Intraoperative fentanyl administration will be guided by clinical signs
89582195|NCT05757388|Experimental|Group P|Receives the parecoxib 40 mg iv slowly push plus paracetamol 1 gm (100 mL) infusion drip in 30 min after induction.
89582196|NCT05757388|Placebo Comparator|Group C|Receives normal saline in the same process.
89582197|NCT05755334|Active Comparator|Ropivacaine 0.1%|Erector spinae plane block with 2 ml/kg of ropivacaine 0.1%.
89582198|NCT05755334|Experimental|Ropivacaine 0.2%|Erector spinae plane block with 1 ml/kg of ropivacaine 0.2%.
89582199|NCT05746299|Experimental|Immediate Congruent|Participants will learn and be tested on two different semantic categories with the same structure that dictates the co-occurrence of different features.
89582200|NCT05746299|Experimental|Immediate Incongruent|Participants will learn and be tested on two different semantic categories with different structures that dictate the co-occurrence of different features.
89582201|NCT05746299|Experimental|Awake Incongruent|Participants will learn two different semantic categories, neither of which has a Modular structure. After a 2.5-hour break, they will learn and be tested on a novel semantic category with a Modular structure.
89582202|NCT05746299|Experimental|Awake Congruent|Participants will learn two different semantic categories, one of which has a Modular structure. After a 2.5-hour break, they will learn and be tested on a novel semantic category with a Modular structure.
89582203|NCT05746299|Experimental|Sleep Incongruent|Participants will learn two different semantic categories, one of which has a Modular structure. After a 2-hour nap opportunity, during which TMR will be used to reactivate the non-Modular category, participants will take a 30-minute break. After the break, they will learn and be tested on a novel semantic category with a Modular structure.
89582204|NCT05746299|Experimental|Sleep Congruent (SWS)|Participants will learn two different semantic categories, one of which has a Modular structure. After a 2-hour nap opportunity, during which TMR will be used to reactivate the Modular category during slow wave sleep (SWS), participants will take a 30-minute break. After the break, they will learn and be tested on a novel semantic category with a Modular structure.
89582205|NCT05746299|Experimental|Sleep Congruent (REM)|Participants will learn two different semantic categories, one of which has a Modular structure. After a 2-hour nap opportunity, during which TMR will be used to reactivate the Modular category during rapid eye movement (REM) sleep, participants will take a 30-minute break. After the break, they will learn and be tested on a novel semantic category with a Modular structure.
89582206|NCT05741606|Active Comparator|Capsules containing sodium pentaborate pentahydrate 200 mg|Capsules containing sodium pentaborate pentahydrate 200 mg orally once a day
89582207|NCT05741606|Active Comparator|Capsules containing sodium pentaborate pentahydrate 400 mg|Capsules containing sodium pentaborate pentahydrate 400 mg orally once a day
89582208|NCT05741606|Active Comparator|Capsules containing sodium pentaborate pentahydrate 600 mg|Capsules containing sodium pentaborate pentahydrate 600 mg orally once a day
89582209|NCT05741606|Active Comparator|Capsules containing sodium pentaborate pentahydrate 800 mg|Capsules containing sodium pentaborate pentahydrate 800 mg orally once a day
89582210|NCT05741606|Active Comparator|Capsules containing sodium pentaborate pentahydrate 1000 mg|Capsules containing sodium pentaborate pentahydrate 1000 mg orally once a day
89030003|NCT01243268||Patients with essential hypertension|
89030004|NCT00514995|Experimental|1|
89030005|NCT01242371|Active Comparator|Probiotic Supplement|Probiotic supplement 1 tablet by mouth daily for 14 weeks after 2 week placebo run-in
89030006|NCT01242371|Placebo Comparator|Identical-appearing Placebo|Identical appearing placebo 1 tablet by mouth daily for 14 weeks after 2 week placebo run-in
89030007|NCT01242176|Experimental|BI 10773 Final Formulation|one single film-coated tablet in the morning
89582211|NCT05741606|Placebo Comparator|Placebo capsules|Placebo capsules of the same shape, smell, and color orally once a day
89582212|NCT05729334|Experimental|Subjects with skin lesions who meet all inclusion criteria and none of the exclusion criteria|Subjects with skin lesions who meet all inclusion criteria and none of the exclusion criteria.
89582213|NCT05717205|Active Comparator|cases with gastroparesis|patients with a gastroparesis symptom score index (GCSI) of > 1.9 will be considered as cases with gastroparesis and will be subjected to technetium-scintigraphy and gastroscopy with tissuesamples from antrum and fundus and bloodsamples of glucosemetabolism
89582214|NCT05717205|Active Comparator|Controls without gastroparesis|patients with a gastroparesis symptom score index (GCSI) of < 1.9 will be considered as controls without gastroparesis and will be subjected to technetium-scintigraphy and gastroscopy with tissuesamples from antrum and fundus and bloodsamples of glucosemetabolism
89582215|NCT05707182|Experimental|Prostate Cancer|18F-rhPSMA-7.3 PET/MRI in Prostate Cancer Active Surveillance: A Pilot Study
89582216|NCT05704322|No Intervention|Usual care group|The control group will not receive any intervention, they will receive usual care and only participate in the pre and post tests.
89582217|NCT05704322|Experimental|Wim Hof Method - breathing and mindset exercise|The first intervention group will practice the breathing and mindset exercise.
89582218|NCT05704322|Experimental|Wim Hof Method - breathing and mindset exercise and cold exposure|The second intervention group will also practice the cold exposure (i.e, breathing, mindset and cold exposure)
89582219|NCT05701891|Experimental|Physiotherapy with integrated VR|Our intervention will be a 12-week personalised, VR-integrated physiotherapy intervention in which a selection of existing VR modules developed by our partners (i.e. Reducept and SyncVR) will be integrated into physiotherapy treatment. The following VR modules will be used: education (Reducept), relaxation and distraction (SyncVR Relax & Distract), activation (SyncVR Fit). Patients will use the Pico Neo 3 VR headset at the physiotherapy practice and at home 5 days a week for 10-30 minutes. In addition, physiotherapists will help patients transition from movements performed in a VR context to daily activities without VR.
89582220|NCT05701891|Active Comparator|Physiotherapy (usual care)|The control condition is usual physiotherapy care for 12 weeks.
89582221|NCT05692921|Experimental|Remote Home Monitoring (RHM)|Remote Home Monitoring Platform (RHM): will be utilized to help tailor education and support for the patient after they have been discharged from the hospital. The platform will provide access to and delivery of health related education and information for continued self-care within the community. The platform will be used to evaluate post discharge symptoms and for health care providers to access the need for continued direct patient care and education through virtual processes.
89582222|NCT05692921|Active Comparator|Rapid Response Nursing (RRN)|"Rapid Response Nursing Team (RRN): The RRN will help clients/patients to:~Understand their current health conditions, treatments, how to manage symptoms and when/who to ask for help; Specifically; they will~Help clients to understand their hospital discharge plan;~Support patients during their recovery at home;~Reinforce and contribute to in-hospital education about heath health and recovering safely at home;~Review medications to help clients understand the purpose, side effects and how to take prescribed medications correctly, including assisting clients with getting prescriptions filled;~Connect with their Home Clinic, ensuring everyone has the necessary information for follow-up care;~Connect clients with a Home Clinic if they do not have one; and~Access appropriate home supports to help clients remain at home safely for as long as possible."
89582223|NCT05692921|No Intervention|Registry|"Registry Arm:~Patients who fit the criteria for study inclusion and choose not to participate in the main study will be provided with an opportunity to consent to the registry arm of the study. The registry arm of the study is an opportunity to establish a standard of care group free from research bias. Patients who enroll in the registry will only need to complete a short questionnaire before they are discharged home which will take approximately 5 minutes. Additionally, research staff will also complete a medical chart review to identify specific medical information related to their demographics, cardiac procedure, hospital stay, recovery, and to identify any re-admissions to hospital that may have occurred after the patient has been discharged home."
89582224|NCT05691140|Experimental|Cognitive Behavioural Therapy|
89582225|NCT05691140|No Intervention|Treatment as Usual|
89582226|NCT05688735|Active Comparator|Experimental Topical Product|Topical moisturizer With Colloidal Oatmeal and Isosorbide Diesters + Topical Steroids
89582227|NCT05688735|Placebo Comparator|Control Topical Product|Topical moisturizer With Colloidal Oatmeal WITHOUT Isosorbide Diesters + Topical Steroids
89582228|NCT05627596|Active Comparator|Electric Toothbrush|Participants will receive the Ask-Advise-Refer intervention which includes an oral health practitioner asking about their tobacco use, advising them to quit smoking, and referring them to the state quitline. They will also receive a sample bag including information about smoking and oral health, the state quitline, and an electric toothbrush.
89582229|NCT05627596|Experimental|Nicotine Replacement Therapy|Participants will receive the Ask-Advise-Refer intervention which includes an oral health practitioner asking about their tobacco use, advising them to quit smoking, and referring them to the state quitline. They will also receive a sample bag including information about smoking and oral health, the state quitline, and a two week supply of 14mg nicotine patches and 4mg lozenges.
89582230|NCT05619198|Active Comparator|High Intensity Interval Exercise|Plasma and sensor glucose is monitored before, during and after a bout of high intensity interval exercise
89582231|NCT05619198|Active Comparator|Moderate Intensity Continous Exercise|Plasma and sensor glucose is monitored before, during and after a bout of moderate intensity continous exercise
89582232|NCT05593588|Experimental|Fisetin Group|Subjects will receive the supplement, Fisetin, for 2 cycles of 2 consecutive days (first on days 0 & 1 and then repeated on days 28 & 29)
89582233|NCT05593588|Placebo Comparator|Placebo Group|Subjects will receive placebo for 2 cycles of 2 consecutive days (first on days 0 & 1 and then repeated on days 28 & 29)
88974362|NCT04121741|Active Comparator|Singing intervention 2|In-person music therapy session. The music therapist will continue to coach throughout the 30-minute session. Flow Mediated dilation (FMD) and EndoPAT will be measured before and after singing.
89030008|NCT01242176|Experimental|BI 10773 XX Trial Formulation 2|one single dose tablet in the morning
89030009|NCT00515151|Active Comparator|Oct/Alc|
89030010|NCT00515151|Active Comparator|Alc|
89030011|NCT01242020|Other|Lean Healthy Subjects|"Lean defined as (BMI ≥18 and ≤25)"
89582234|NCT05590871|Experimental|Renal Denervation|Percutaneous renal denervation using the FlashPoint radio-frequency ablation system under the Columbus 3D mapping system guidance
89582235|NCT05590871|No Intervention|Control|Maintenance of anti-hypertensive medications
89582236|NCT05588882|Active Comparator|Wavefront-guided LASIK|Wavefront-guided LASIK for myopia and myopic astigmatism
89582237|NCT05588882|Active Comparator|Topography-guided LASIK|Topography-guided LASIK for myopia and myopic astigmatism
89582238|NCT05585294|Experimental|Water based perturbation exercise group|"In both groups, the participants screened for Treatment-based classification of back pain and based on TBC interventions were provided. From second week, water based perturbation exercise were initiated personalized to the level of participants.~Treatment-based classification of back pain intervention was gradually tapered in orderly fashion during 6 weeks, concurrently introduced land based perturbation exercise gradually phased from level 1 to level 4."
89582239|NCT05585294|Active Comparator|Land based perturbation exercise group|All procedures were followed similar to Water based perturbation exercise group except perturbation based exercises were provided in land.
89582240|NCT05582798|Active Comparator|Alpha1-Proteinase Inhibitor 180mg/kg|Alpha1-Proteinase Inhibitor 180mg/kg, intravenous infusion, 50mg/ml
89582241|NCT05582798|Active Comparator|Alpha1-Proteinase Inhibitor 120mg/kg|Alpha1-Proteinase Inhibitor 180mg/kg, intravenous infusion, 50mg/ml
89582242|NCT05582798|Placebo Comparator|Placebo 1|Sodium chloride 0.9% volume to match that of Alpha1-Proteinase Inhibitor 180mg/kg, intravenous infusion.
89582243|NCT05582798|Placebo Comparator|Placebo 2|Sodium chloride 0.9% volume to match that of Alpha1-Proteinase Inhibitor 120mg/kg, intravenous infusion.
89582244|NCT05574309|Sham Comparator|Fallers|population of patients who have fallen from the clinical gerontology department of the CHU of Saint-Etienne and from the PROOF cohort and subjects of the Office Stéphanois pour les Ainés (OSAP)
89582245|NCT05574309|Other|non fallers|population of patients who did not fall from the clinical gerontology department of the CHU of Saint-Etienne and from the PROOF cohort and subjects of the Office Stéphanois pour les Ainés (OSAP)
89582246|NCT05567640|Experimental|The Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (UP)|"Digital, transdiagnostic, emotion-focused CBT intervention that consists of five core modules or components that have been shown to target temperamental characteristics (i.e., neuroticism) and resulting emotion dysregulation that are believed to underlie all anxiety, depressive, and emotional disorders. The core components of the program are psychoeducation, mindfulness, cognitive flexibility, behavioral strategies to counter emotion-driven behaviors, interoceptive, and emotion exposures."
89582247|NCT05567640|Active Comparator|Space from Depression (SFD)|Digital CBT program designed to minimize the impact of depressive symptoms. This program emphasizes the use of cognitive behavioral strategies as well as mindfulness through a series of seven structured modules. The core components of the program include psychoeducation around the relationship between thoughts, feelings, and behaviors; cognitive behavioral practices aimed at restructuring negative beliefs; behavioral strategies to improve self-esteem; and mindfulness techniques that focus attention on the present moment.
89582248|NCT05567640|Active Comparator|Space for Resilience (SFR)|Digital program based on positive psychology principles and designed to promote resilience and well-being through a series of seven modules. The core components of the program include psychoeducation, values exploration, building relationships, promoting self-esteem and self-efficacy, and building gratitude and optimism.
89582249|NCT05536258||RI-Monitoring|"The investigator will evaluate the feasibility of a RI-guided fluid ministration for improving perioperative characteristics.~Feasibility will be defined by:~The investigators will titrate fluid administration to maintain a RI > 90 over at least 85% of the intraoperative period lasting from induction until the end of anesthesia. Specifically, the investigator will consider titration to have been successful if 85% of patients in the RI group sustain a RI > 90 over at least 85% of the intraoperative period;"
89582250|NCT05531916|Experimental|Group A|Participants wear pressurized gloves and foot caps for 15 minutes before their chemotherapy treatment, during the treatment, and for 15 minutes after it ended.
89582251|NCT05531916|No Intervention|Group B|No intervention was done before and after chemotherapy with paclitaxels.
89582252|NCT05502133||Acute Intermittent Porphyria (AIP)|"Symptomatic patients with Acute Intermittent Porphyria (AIP)~A member of an AIP family who possesses an AIP pathogenic mutation and is/has been symptomatic (experienced acute attacks). Parents with no known HMBS mutations or heterozygote with familial mutation or a first, second or third degree relative of the above."
89582253|NCT05496192|Experimental|Nivolumab IV followed by Nivolumab SC|
89582254|NCT05493072|Other|1 - Control (scenarios 1-5) then intervention (scenarios 6-10)|Observation of control arm practice for scenarios 1-5, followed by intervention arm for scenarios 6-10.
89582255|NCT05493072|Other|2- Intervention (scenarios 6-10) then control (scenarios 1-5)|Observation of intervention arm for scenarios 6-10, followed by control arm practice for scenarios 1-5
89582256|NCT05493072|Other|3- Intervention (scenarios 1-5) then control (scenarios 6-10)|Observation of intervention arm practice for scenarios 1-5, followed by control arm for scenarios 6-10.
89582257|NCT05493072|Other|4- Control (scenarios 6-10) then intervention (scenarios 1-5)|Observation of control arm practice for scenarios 6-10, followed by intervention arm for scenarios 1-5.
88974363|NCT04121741|Sham Comparator|Control/sham intervention|"Subjects will have a 30-minute period of rest sitting upright (as they would be positioned for the singing interventions). This arm is meant to isolate the specific effects of the treatment rather than the potential incidental effects related to the research setting and measurements. During this time, subjects will undergo hearing testing. Flow Mediated dilation (FMD) and EndoPAT will be measured before and after the 30 minute rest."
89209510|NCT03017105|Experimental|Experimental|Cross-education of strength-training: non-operative management of the fracture; will undergo usual physiotherapy rehabilitation for the injured arm but will also undergo strength-training for the uninjured arm
89582258|NCT05477758||CASPER|A multi-centred, pragmatic, two-arm parallel open RCT. Participants with Subthreshold depression were individually randomised (1:1) to receive either collaborative care focusing on behavioural activation or usual GP care
89582259|NCT05477758||CASPER+|A multi-centred, pragmatic, two-arm parallel open RCT. Participants with Major depression were individually randomised (1:1) to receive either collaborative care focusing on behavioural activation or usual GP care
89582260|NCT05477758||SHARD|A multi-centred, pragmatic, two-arm parallel open RCT. Participants with Subthreshold depression were individually randomised (1:1) to receive the self-help booklet based on the principles of behavioural activation or usual GP care
89582261|NCT05472623|Active Comparator|Arm A|Arm A treatment: Oral Adagrasib 600 mg twice daily for 6 weeks prior to surgery. Surgical Resection, then standard postoperative therapy(chemo +/- RT).
89582262|NCT05472623|Active Comparator|Arm B|Arm B treatment: Oral Adagrasib 400 mg twice daily for 6 weeks and IV Nivolumab 240mg every 2 weeks for 3 doses prior to surgery. Surgical Resection, then standard postoperative therapy(chemo +/- RT).
89582263|NCT05466110|Experimental|Spinal Cord Stimulation Device|The spinal cord stimulators WaveWriter AlphaTM (Boston Scientific) are designed to treat chronic back or leg pain by electrically stimulating the spinal cord. It is a well established worldwide licensed device. Percutaneous lead(-s) are implanted in the epidural space of the thoracic spine during the initial procedure. After discharge a trial phase is initiated and performed according to local preferences and standard of operations (SOPs). Patients are monitored for any complications and pain reduction. If a significant pain reduction (>50 % on the NRS scale for back pain) is achieved, the permanent implantable pulse generator (IPG) is implanted. Otherwise if the therapy remains non-beneficial throughout the trial phase, the leads will be explanted. Patients are allowed to crossover in the fusion group at any point of time.
89582264|NCT05466110|Active Comparator|Control - Lumbar Fusion surgery|The control group needs to represent the standard of care of current practice. Gold standard is lumbar fusion surgery [Resnik 2005]. Surgical instrumentation will be performed according to local preferences and SOPs. Safety and efficacy of these fusion techniques have been repeatedly proven
89582265|NCT05442775|Experimental|Reldesemtiv 300 mg twice daily|Patients in this arm take 1 reldesemtiv 300 mg oral tablet twice a day for a 600 mg total daily dose (TDD)
89209511|NCT00884364|Active Comparator|Control|
89582266|NCT05438394|Experimental|melphalan hydrochloride for injection|Drug Name: melphalan hydrochloride The dosage of different dosage groups were: 9 mg/m2; 18 mg/m2; 27 mg/m2; 40 mg/m2 Administration frequency: once for each subject
89582267|NCT05407610|Active Comparator|Conventional Radiofrequency of the genicular nerves|In the conventional radiofrequency group a intervention of 80°C at the tip is applied during 90 seconds at each nerve (superolateral, superomedial and inferomedial genicular nerves). The probe stays in place for 150 seconds at each nerve so that the time needed for each procedure is similar.
89582268|NCT05407610|Active Comparator|Cooled Radiofrequency of the genicular nerves|In the cooled radiofrequency group a intervention of 60°C measured at the tip and on average 80°C in the targeted tissue is applied for 150 seconds using the Cooled RF system at each nerve (superolateral, superomedial and inferomedial genicular nerves).
89582269|NCT05407610|Sham Comparator|Sham procedure|In the sham group a 18 gauge introducer and probe will be placed but no RF intervention will be applied. The generator will be turned on without connection to the probe for 150 seconds and the sound of the generator will be mimicked with a recording. The position of the needle will not be checked by fluoroscopy; however, the intervention team will position the fluoroscopy arm and mention the acquisition of the fluoroscopic image to the patient. This way no unnecessary radiation is used.
88974364|NCT04115267||Combined modality|Patients receiving radiotherapy and a molecular agent for the treatment of cancer
88974365|NCT04091191|Active Comparator|Specialized nutraceutical|Specialized nutraceutical formulated in softgel. Participants are instructed to take 2 softgels orally with some water, one before breakfast and one before diner.
88974366|NCT04091191|Placebo Comparator|Placebo|Identical placebo formulated without active ingredients in softgel. Participants are instructed to take 2 softgels orally with some water, one before breakfast and one before diner.
88974367|NCT04079894||LSS Participants|Patients with lumbar spinal stenosis
88974368|NCT04079894||Background population|Populationdata from existing research project
88974369|NCT04079894||LBP Participants|Patients with Low back Pain
88974370|NCT04074070||Psoriasis with and without musculoskeletal complains|psoriasis with and without musculoskeletal complains
88974371|NCT04074070||Healthy individuals|
88974372|NCT04074070||Psoriatic arthritis|
88974373|NCT04035629|Experimental|Hyperpolarized 129Xe MRI for lung diagnosis|All subjects will undergo hyperpolarized 129-Xenon MR imaging (HP MRI) and conventional proton MR imaging of lung.
88974374|NCT04004221|Experimental|Tislelizumab|200mg intravenously (IV) every 3 weeks(Q3W)
88974375|NCT03966391|Experimental|CARD (multi-faceted knowledge translation intervention)|CARD will be integrated into the school vaccination program. This includes pre-vaccination day preparation (e.g., planning of clinic spaces, student and school staff education about CARD) and vaccination day activities (e.g., clinic set-up, processes for triaging students, implementing pain/ fear/fainting mitigation interventions from CARD during vaccination)
88974376|NCT03966391|No Intervention|Control (standard care)|There are no specific procedures being undertaken to plan or execute clinics. Usual practices will be instituted (i.e., no education specific to CARD, nor clinic set-up or execution to incorporate interventions for pain, fear or fainting)
88974377|NCT03965650|Experimental|Intervention group: video coaching exercises|Video coaching exercises group: patients will perform physical exercises according to a video coaching program 3 times weekly during 6 months. The on-line program has been designed especially for this study.
89209512|NCT00884364|Experimental|Exercise|
89582270|NCT05386030|Experimental|saypha® VOLUME Lidocaine|"For injection, either a needle (27G ½'') or cannula (25G 1½) may be used. Randomization will be stratified by injection equipment in a 1:1 ratio.~The volume administered is at the discretion of the treating investigator and depends on the severity of the midface volume deficit to be corrected. However, the maximum volume (left and right side of the midface together) must not exceed 10 mL in total per treatment (initial and repeat-treatment) or 20 mL per 60 kg (130 lbs) body mass per year."
89582271|NCT05386030|Active Comparator|Juvéderm® Voluma™ XC|"For injection, either a needle (27G ½'') or cannula (25G 1½) may be used. Randomization will be stratified by injection equipment in a 1:1 ratio.~The volume administered is at the discretion of the treating investigator and depends on the severity of the midface volume deficit to be corrected. However, the maximum volume (left and right side of the midface together) must not exceed 10 mL in total per treatment (initial and repeat-treatment) or 20 mL per 60 kg (130 lbs) body mass per year."
89582272|NCT05368493|Other|All participants|All participants will be in the same arm.
89582273|NCT05349331|Experimental|Resection group|Surgical resection group: The patients underwent liver cancer resection and were followed up regularly after surgery.
89582274|NCT05349331|No Intervention|Non-surgical resection group|Stop hepatic artery interventional therapy (chemoembolization/infusion chemotherapy), continue the original targeted and immunotherapy for no more than 1 year
89582275|NCT05345730||Mitral valve insufficiency patients undergoing mitral valve repair surgery|The research population consists of mitral valve insufficiency patients scheduled for elective surgical mitral valve repair (N=20) according to the current European guideline criteria. These patients will undergo a cardiac MRI scan 2 weeks prior to surgery and 3 months after surgery.
89582276|NCT05330611|Experimental|Ultrasound-guided Cryoneurolysis: Group A|"Patients who are admitted to the Emergency Department after a traumatic injury. Patients will have rib fractures in any of ribs 3-9. Patients will be 18-64 years of age and will be randomized (1:1) to the ultrasound-guided cryoneurolysis group within 72 hours of admission to the ED.~Intervention is ultrasound-guided cryoneurolysis of intercostal nerves creating lost lasting pain relief. Device used for cryoneurolysis is Iovera Smart tip 190"
88974378|NCT03965650|Active Comparator|Control group: routine exercises|Routine method advising and encouraging patients to perform physical activities according to the WHO recommendations during 3 months then to follow the video coaching physical exercises program during 3 months.
88974379|NCT03959878|Experimental|Gastrostomy Tube|Non-hospitalized outpatients undergoing placement of a gastrointestinal gastrostomy tube (GIG tube) or GI jejunostomy tube (GIJ tube) will receive the usual Standards of Care related to the placement of a GIG or GIJ tube and the Constant Pressure Skin Disk.
88974380|NCT03952611|Active Comparator|High-Definition White-light Colonoscopy|Using an instrument called colonoscope which is used to detect colonic polyps
88974381|NCT03952611|Active Comparator|High-Definition White-light Colonoscopy With Reveal®|Using an instrument called cap at end of colonoscope which is used to straighten colon folds
88974382|NCT03952611|Active Comparator|High-Definition White-light Colonoscopy With Endocuff Vision|Using an instrument called Endocuff at end of colonoscope which is used to straighten colon folds
88974383|NCT03890029|Other|Intervention|"Once potential participants have given consent and determined eligible, they will undergo an initial assessment.Pre, post- and follow-up testing. This consists of verbal scales including emotional well-being scales and mental health symptom scales. They will be administered in a group 30-60 minute session. Neuropsychological testing and psychophysiological tests given will require 90 minutes. Neuropsychological testing will be completed at pre and post testing only. In order to ensure unbiased assessment, pre- and post- and follow-up testing will be conducted by individuals blinded to study condition.~Randomization. After pre-testing, all individuals will be randomly assigned to either the active treatment group or minimal attention control condition. After this, intervention participants will meet in small groups of 10 per group for 90 minutes/week over five weeks for resilience training. After five weeks, all participants will be post-tested."
88974384|NCT03890029|Other|Control|While intervention participants receive resilience training, the control group will not receive training but will receive minimal attention of a bi-monthly telephone call to indicate to participants that they are still enrolled in the study. A monthly flyer will be mailed to them about wellness and PTSD in recent news coverage. Following completion of an intervention group, participants and controls will be scheduled for post-testing that will be identical to the pre-testing and will occur within two weeks after the final treatment session. After the post-testing and 3-month follow up testing, the controls will be offered the resilience training
88974385|NCT03887182|Experimental|confirmed auditory processing disorders|functional MRI, Cortical Brainstem Auditory Evoked Potential, Genetic
88974386|NCT03887182|Experimental|suspected not confirmed auditory processing disorders|functional MRI, Cortical Brainstem Auditory Evoked Potential, Genetic
88974387|NCT03887182|Active Comparator|healthy volunteers|functional MRI, Cortical Brainstem Auditory Evoked Potential, Genetic, multidisciplinary consultation
88974388|NCT03846362|Experimental|intermediate risk MRD2>0,1%|MRD2>0,1% - FLA - MRD3 - HSCT
89030012|NCT01242020|Other|Obese Healthy Subjects|Obese grade I-II defined as (BMI>30 and ≤35)
89030013|NCT00514332|Experimental|A|primary surgery group
89030014|NCT01241786|Experimental|response to Vidaza + Revlimid|response to combination of azacitidine + lenalidomide A Phase II, Single Arm Study Examining the Combination of Revlimid (Lenalidomide) and Vidaza (Azacitidine) (RA-CLL) for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)
89030015|NCT00514410|Experimental|Folic Acid|
89030016|NCT00514410|Placebo Comparator|Placebo|
89582277|NCT05330611|Active Comparator|Standard-of-Care : Group B|Patients who are admitted to the Emergency Department after a traumatic injury. Patients will have rib fractures in any of ribs 3-9. Patients will be 18-64 years of age and will be randomized (1:1) to Standard of Care which typically includes multi-modal pain therapy and pulmonary toilet.
89582278|NCT05289089|Experimental|Positive Psychology Intervention Group|Participants will complete 9 weekly phone sessions with a study trainer and positive psychology exercises between phone sessions. Study trainers will review the positive psychology exercises with the participant on the phone each week. Participants will receive this intervention in addition to their treatment as usual.
89582279|NCT05289089|Active Comparator|Wait list Control Group|After waiting for 9 weeks, participants will complete 9 weekly phone sessions with a study trainer and positive psychology exercises between phone sessions. Study trainers will review the positive psychology exercises with the participant on the phone each week. Participants will receive this intervention in addition to their treatment as usual.
89582280|NCT05287191|Experimental|Experimental arm|Intravenous magnesium sulphate as first line followed by digoxin IV loading as second line and then amiodarone IV as third line treatments for fast AF
89582281|NCT05287191|Active Comparator|Standard of care arm|Intravenous amiodarone as compactor group intervention
89582282|NCT05280652|Experimental|Family intervention group|Families (dyads parent and child) will attend culinary-nutritional workshops with theoretical and practical nutritional and culinary information (knowledge and skills to prepare healthy and easy menus) to follow a sustainable Mediterranean diet.
89582283|NCT05280652|Experimental|Parent-only intervention group|Parents will attend culinary-nutritional workshops with theoretical and practical nutritional and culinary information (knowledge and skills to prepare healthy and easy menus) to follow a sustainable Mediterranean diet.
89582284|NCT05280652|Active Comparator|Control|Families (dyads parent and child) will attend nutritional workshops with theoretical information to follow a sustainable Mediterranean diet.
89582285|NCT05278052|Active Comparator|ARM A: Standard maintenance therapy alone|Maintenance systemic therapy/ observation
89582286|NCT05278052|Experimental|ARM B: Local consolidative radiation therapy (LCRT)|Radiation therapy to all oligometastatic sites including primary loco-regional disease
89582287|NCT05268094|Experimental|Ductal Artery Stent|Transcatheter ductal artery shunt will be placed by the interventional team. Drug-eluting coronary stent brand, length, and diameter are determined by the interventional team.
89582288|NCT05268094|Experimental|Systemic-to-Pulmonary Artery Shunt|Surgical systemic-to-pulmonary artery shunt performed by the interventional team. SPS diameter, length, and material will be determined by the surgeon performing the intervention.
89582289|NCT05259046|Experimental|Intervention|Intervention treatment . Dietary supplementation with Menaquinone-7 (MK-7) tablet (333 µg/day). MK-7 (K2VITAL®DELTA) tablets are manufactured by Kappa Bioscience AS, Oslo, Norway.
89582290|NCT05259046|Placebo Comparator|Placebo|Placebo tablet (no active treatment). The placebo tablets will match the intervention treatment in both taste and appearance. Placebo tablets are manufactured by Kappa Bioscience AS, Oslo, Norway.
89582291|NCT05230212|Experimental|Pecan Breakfast Shake|Participants will be given a breakfast shake consisting primarily of pecans, and 1% milk.
89582292|NCT05230212|Active Comparator|Cream Breakfast Shake|Participants will be given a breakfast shake consisting primarily of heavy whipping cream.
89582293|NCT05221632|Experimental|accelerated continue theta-burst stimulation|Fifty intermittent TBS sessions (1800 pulses per session, 50 minute inter-session interval ) were delivered as ten daily sessions over five consecutive days at 80% resting motor threshold (RMT). The MRI data set should be collected before the first cTBS session and after the last cTBS session.
89582294|NCT05221632|Active Comparator|1-HZ repetition transcranial magnetic stimulation Stimulation|The repetition transcranial magnetic stimulation(rTMS) lasted 30 mins and delivered at 1 Hz with 1s duration, a total of 1800 pulses at 80% of the rest motor threshold (RMT) . MRI dataset should be acquired before the first rTMS session and after the last rTMS session.
89582295|NCT05221632|Sham Comparator|accelerated continue theta-burst stimulation (sham)|Fifty intermittent TBS sessions (1800 pulses per session, 50 minute inter-session interval ) were delivered as ten daily sessions over five consecutive days at 80% resting motor threshold (RMT). The MRI data set should be collected before the first cTBS session and after the last rTMS session. No actual magnetic stimulation was applied on the head of the volunteers. MRI dataset should be acquired before the first cTBS session and after the last cTBS session.
89582296|NCT05208216|Experimental|Intervention arm|Application of the Geko device for mechanical VTE prophylaxis up until day 10 / discharge form critical care (whichever comes sooner).
89582297|NCT05208216|Active Comparator|Usual care arm|Application of our usual intermittent pneumatic compression devices for mechanical VTE prophylaxis up until day 10 / discharge form critical care (whichever comes sooner).
89582298|NCT05207891|Experimental|Intervention mattress|"At every shift during the seven days project period, the nurses will check for pressure wounds, and mark identified pressure wounds and their category on a pressure injury body map. At every shift the nurses will use a custom made form to register resources needed in each position changing of the patient, the number of times the position is changed, as well as the level of physical strain in the nurses. All participants will start with seven days use of the newly developed intervention mattress. At the end of the testing period, the participants will register their feeling of quality of life, bedrest comfort, sleep-wellness, pain and satisfaction in the study period.~A custom made semi-structured interview guide has been conducted asking in more details of experienced quality in use and in managing the mattress. One participant and one nurse will be asked to participate in in-depth interviews after testing both mattresses."
89582299|NCT05207891|No Intervention|Regulare care mattress|"At every shift during the seven days project period, the nurses will check for pressure wounds, and mark identified pressure wounds and their category on a pressure injury body map. At every shift the nurses will use a custom made form to register resources needed in each position changing of the patient, the number of times the position is changed, as well as physical strain in the nurses. At the end of the testing period, the participants will register their feeling of quality of life, bedrest comfort, sleep-wellness, pain and satisfaction in the test period.~A custom made semi-structured interview guide has been conducted asking in more details of experienced quality in use and in managing the mattress. One participant and one nurse will be asked to participate in in-depth interviews after testing both mattresses."
89030017|NCT01241318|Experimental|Chlorhexidine cord care|Mothers located in health facility catchment areas assigned to this arm will apply Chlorhexidine gluconate (4%) to their infants daily until three days after the cord completely separates. Bottles of chlorhexidine is provided to women during antenatal care.
89030018|NCT01241318|Active Comparator|Dry cord care|Mothers in health facility catchment areas assigned to this arm will use dry cord care - keeping their babies' umbilical stumps clean and dry - as per normal routine standard of care and in accordance with Zambia Ministry of Health policy.
89582300|NCT05206682|Experimental|Vaginal Repair with Leuprorelin|CSD patients were treated with vaginal repair of CSD in combination with Leuprorelin . In the group of Vaginal Repair With Leuprorelin, the patients will get 3 times of Leuprorelin per 4 weeks perioperation. The detailed procedure of Vaginal Repair has been described in our previous study.
89582301|NCT05206682|No Intervention|Vaginal Repair without Leuprorelin|The detailed procedure of Vaginal Repair has been described in our previous study.
89582302|NCT05204082|No Intervention|Standard IV Insertion|Pediatric patients in surgical pre-op requiring an IV catheter for surgery will have standard IV insertion
89582303|NCT05204082|Other|SU-VEID assisted IV Insertion|Pediatric patients in surgical pre-op requiring an IV catheter for surgery will have IV insertion using SU-VEID device
89582304|NCT05201937|Experimental|Arm A: Panel 1 (JNJ-64281802 High Dose Regimen)|Participants will receive Loading Dose (LD) 1 of JNJ-64281802 twice daily on Days 1 and 2 followed by maintenance Dose (MD) 1 of JNJ-64281802 once daily on Days 3, 10, 17 and 24.
89582305|NCT05201937|Experimental|Arm A: Panel 2 (JNJ-64281802 High Dose Regimen)|Participants will receive LD 1 of JNJ-64281802 twice daily on Days 1 and 2 followed by MD 2 of JNJ-64281802 once daily on Days 3, 6, 10, 13, 17, 20, 24, and 27.
89582306|NCT05201937|Experimental|Arm B: Panel 3 (JNJ-64281802 Low Dose Regimen)|Participants will receive LD 2 of JNJ-64281802 twice daily on Days 1 and 2 followed by MD 3 of JNJ-64281802 once daily on Days 3, 10, 17 and 24.
89582307|NCT05201937|Experimental|Arm B: Panel 4 (JNJ-64281802 Low Dose Regimen)|Participants will receive LD 2 of JNJ-64281802 twice daily on Days 1 and 2 followed by MD 4 of JNJ-64281802 once daily on Days 3, 6, 10, 13, 17, 20, 24, and 27.
89582308|NCT05201937|Experimental|Arm C: Panel 5 (JNJ-64281802 [Optional])|Participants dosing regimen(s) will be determined based on the results of Study Arm A and Study Arm B.
89582309|NCT05201937|Experimental|Arm C: Panel 6 (JNJ-64281802 [Optional])|Participants dosing regimen(s) will be determined based on the results of Study Arm A and Study Arm B.
89582310|NCT05192564|Experimental|EX Group|Conventional rehabilitation treatment plus exercise intervention under the supervision of exercise specialists two non-consecutive days per week for eight weeks.
89582311|NCT05192564|Active Comparator|AC Group - ATTENTION CONTROL GROUP|Conventional rehabilitation treatment at home with unsupervised exercise intervention
89582312|NCT05153629|No Intervention|Standard care|Participants will follow standard care until the ureteral stent is removed
89582313|NCT05153629|Experimental|TENS device|Participants will use the TENS device until the ureteral stent is removed
89582314|NCT05136612|Experimental|control grup|conventional physiotherapy
89030019|NCT00514527|Experimental|1|
89582315|NCT05136612|Experimental|intervention group|Armeo spring robotic rehabilitation
89582316|NCT05130177|Experimental|Zimberelimab plus Domvanalimab|"Treatment Phase 1: Zimberelimab, 360mg, IV, every 3 weeks for 3 cycles. Domvanalimab, 15mg/kg, IV, every 3 weeks for 3 cycles. After 3 cycles, scans will be performed. If it is determined that the cancer is stable or responding patients will continue with Treatment Phase 2.~Treatment Phase 2: Zimberelimab, 360mg, IV, every 3 weeks for 3 cycles. Domvanalimab, 15mg/kg, IV, every 3 weeks, for up to 24 months."
89582317|NCT05129748|Experimental|Standard Cisplatin-based Chemotherapy + Sodium Thiosulfate + Mannitol|Participants will receive the standard of care (cisplatin-based chemotherapy) plus the experimental treatment of Sodium Thiosulfate and Mannitol. Both drugs will be administered IV 4 - 8 hours following chemotherapy treatment, as part of post-chemotherapy hydration.
89582318|NCT05129748|No Intervention|Standard Cisplatin-based Chemotherapy|Participants will receive the standard of care (cisplatin-based chemotherapy) only.
89582319|NCT05127746|Experimental|Sequence 1|Period 1, Aricept 5mg → DA-5207 A; Period 2, Aricept 5mg → Aricept 10mg
89582320|NCT05127746|Experimental|Sequence 2|Period 1, Aricept 5mg → Aricept 10mg; Period 2, Aricept 5mg → DA-5207 A
89582321|NCT05127746|Experimental|Sequence 3|Period 1, Aricept 5mg → DA-5207 B; Period 2, Aricept 5mg → Aricept 10mg
89582322|NCT05127746|Experimental|Sequence 4|Period 1, Aricept 5mg → Aricept 10mg; Period 2, Aricept 5mg → DA-5207 B
89582323|NCT05062824|Experimental|Intervention|Participants in the intervention will have access to Baby Feed
89582324|NCT05062824|No Intervention|Standard Care|Participants in the standard care group will NOT have access to Baby Feed
89582325|NCT05054218||Participants who receive 3rd dose of mRNA-1273 SARS-CoV-2 vaccine|Cancer patients who have already received their 1st and 2nd doses of mRNA-1273 SARS-CoV-2 vaccine will receive a 3rd dose of the vaccine. The volume of vaccine injected will be 0.5 mL, containing a 100-μg dose of mRNA-1273.
89582326|NCT05048316|Experimental|eHealth|Weekly video conference groups led by a trained facilitator
89582327|NCT05007808|Experimental|G001 Topical Gel|G001 Topical Gel, 4 grams applied to the index knee four times a day over 4 weeks.
89582328|NCT05007808|Placebo Comparator|Vehicle Topical Gel|Vehicle Topical Gel, 4 grams applied to the index knee four times a day over 4 weeks.
89582329|NCT05006040|Experimental|Hybrid Closed-Loop Insulin System During Chemo with Steroid and Asparaginase|Subjects will receive insulin via hybrid closed-loop insulin delivery system during the chemotherapy phases that contains steroid and asparaginase. This treatment will be initiated within 4 days of starting induction chemotherapy treatment.
89582330|NCT04988477|Experimental|Chronic care for tobacco use|Quarterly brief provider interventions about tobacco and 3 quarterly proactive outreach calls to connect patients to telephone cessation counseling and facilitate obtaining cessation medication.
89030020|NCT00514527|Experimental|2|
89030021|NCT00514527|Experimental|3|
89030022|NCT01241279|Experimental|Crystalens AO|A silicone multi-piece accommodating intraocular lens
89030023|NCT01241279|Active Comparator|SoftPort LI61AO|A silicone multi-piece foldable aspheric intraocular lens
89030024|NCT00514566|Active Comparator|1|Surgical Patient undergoing midline laparotomy closure
89030025|NCT01241240|Experimental|Triple Combination Therapy|Triple Combination Therapy with bimatoprost/brimonidine tartrate/timolol ophthalmic solution. One drop of Triple Combination Therapy administered to each eye, twice daily for 12 weeks.
89582331|NCT04974619||Aim 1 Only: Online Survey group|Spanish speaking young Latino men who have sex with men (YLMSM), ages 18-26 (approximately 260 in Florida and Puerto Rico) will be asked to complete a Qualtrics survey.
89582332|NCT04974619||Aim 2 Only: Interview group|Individual interviews will be conducted with key healthcare stakeholders (i.e.,healthcare clinical leadership, providers and staff, community-based organization staff)
89582333|NCT04974619||Aim 3 Only: Focus Groups|Each site will conduct focus groups or individual interviews with English or Spanish speaking young Latino men who have sex with men (YLMSM). The total participants will be 24 with 12 participants per site.
89582334|NCT04944784|Experimental|300 mg reldesemtiv twice daily for a 600 mg total daily dose, from Day 1 until Week 24|Patients in this arm take 2 reldesemtiv 150 mg oral tablets twice a day for a 600 mg total daily dose from Day 1 until Week 24.
89582335|NCT04944784|Placebo Comparator|Placebo twice daily, from Day 1 until Week 24|Patients in this arm take 2 placebo oral tablets twice a day from Day 1 until Week 24.
89582336|NCT04944784|Experimental|300 mg reldesemtiv twice daily for a 600 mg total daily dose, from Week 24 until Week 48|Patients in this arm take 2 reldesemtiv 150 mg oral tablets twice a day for a 600 mg total daily dose from Week 24 until Week 48 for patients who were not down titrated during the 24 weeks of blinded dosing.
89582337|NCT04944784|Experimental|150 mg reldesemtiv twice daily for a 300 mg total daily dose, from Week 24 until Week 48|Patients in this arm take 1 reldesemtiv 150 mg oral tablet twice a day for a 300 mg total daily dose from Week 24 until Week 48 for patients who were down titrated for any reason during the 24 weeks of blinded dosing.
89582338|NCT04932486|Experimental|Transcutaneous electrical stimulation|Participants will be asked to use the stimulator for 6 weeks at home. The study objectives will be evaluated after 6 weeks post-activation of the device.
89582339|NCT04930887|Active Comparator|Exparel|Patients receive an endoscopically guided injection of Exparel (Bupivacaine).
89582340|NCT04930887|Placebo Comparator|Saline|Patients receive an endoscopically guided injection of saline
89582341|NCT04875065|Experimental|Engage Coaching|Engage Coaching helps caregivers bolster motivation for increasing connectedness, teaches problem solving skills, and provides behavioral practice with social engagement. Up to 8 brief sessions (typically 30 minutes) are provided weekly over no more than three months.
89582342|NCT04863248|Experimental|trilaciclib + docetaxel|Patients will receive trilaciclib administered IV prior to docetaxel administered IV on Day 1 of each 21-day cycle.
89582343|NCT04863248|Placebo Comparator|placebo + docetaxel|Patients will receive placebo administered IV prior to docetaxel administered IV on Day 1 of each 21-day cycle.
89582344|NCT04815902|Experimental|Active Fisetin and Active Losartan|Losartan 12.5 mg, PO, BID beginning the first day after BMA Concentrate injection and continuing for 30 days. Fisetin 20mg/kg taken a total of 4 days prior to BMA Concentrate injection (-32 and -31 and -3 and -2) then again after BMA Concentrate injection a for a total of 6 days (32 & 33, 61 & 62 and 90 & 91).
89582345|NCT04815902|Active Comparator|Active Fisetin and Losartan Placebo|Losartan Placebo 12.5 mg, PO, BID beginning the first day after BMA Concentrate injection and continuing for 30 days. Fisetin 20mg/kg taken a total of 4 days prior to BMA Concentrate injection (-32 and -31 and -3 and -2) then again after BMA Concentrate injection a for a total of 6 days (32 & 33, 61 & 62 and 90 & 91).
89582346|NCT04815902|Active Comparator|Fisetin Placebo and Active Losartan|Losartan 12.5 mg, PO, BID beginning the first day after BMA Concentrate injection and continuing for 30 days. Fisetin Placebo 20mg/kg taken a total of 4 days prior to BMA Concentrate injection (-32 and -31 and -3 and -2) then again after BMA Concentrate injection a for a total of 6 days (32 & 33, 61 & 62 and 90 & 91).
89582347|NCT04815902|Placebo Comparator|Control|Losartan placebo 12.5 mg, PO, BID beginning the first day after BMA Concentrate injection and continuing for 30 days. Fisetin Placebo 20mg/kg taken a total of 4 days prior to BMA Concentrate injection (-32 and -31 and -3 and -2) then again after BMA Concentrate injection a for a total of 6 days (32 & 33, 61 & 62 and 90 & 91).
89582348|NCT04807140|Experimental|Toripalimab|Toripalimab (IV), dose= 240mg , day=1 , cycle length: 21 days
89582349|NCT04807140|Experimental|Toripalimab + Carboplatin+ Nab-paclitaxel|"Toripalimab (IV), dose= 240mg , day=1 , cycle length: 21 days.~Carboplatin (IV), dose=300mg/m2, day= 1, cycle length: 21 days.~Nab-paclitaxel (IV), dose=260mg/m2, day= 1, cycle length: 21 days."
89582350|NCT04804566||ERT User- Did Not Switch to Galafold|ERT users with mutation amenable to Galafold who did not switch
89582351|NCT04804566||ERT User- Switched and Stayed on Galafold|ERT users with the mutation amenable to Galafold who switched and stayed on Galafold
89582352|NCT04804566||No Previous Therapy- Started Galafold and Stayed On|Those naïve to therapy with the mutation amenable to Galafold who went on and stayed on Galafold
89030026|NCT01241240|Active Comparator|Combigan®|Fixed Combination brimonidine tartrate/timolol ophthalmic solution (Combigan®). One drop of Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution administered to each eye, twice daily for 12 weeks.
89582353|NCT04804566||No Previous Therapy- No Current Therapy|Those who were naïve to therapy with the mutation amenable to Galafold and have never been on any therapy.
89582354|NCT04804566||ERT Users- Switched and Discontinued Galafold|Participants who are ERT users with an amenable mutation who switched to and later discontinued Galafold
89582355|NCT04804566||No Previous Therapy- Started Galafold and Discontinued|Participants who are naïve to therapy with an amenable mutation, went on Galafold, and discontinued
89582356|NCT04773691|Experimental|test group|
89209513|NCT00886860|Active Comparator|conventional oral misoprostol|misoprostol 50 micrograms oral every 4 hours until cervical dilatation 3 centimeters
89582357|NCT04773691|Placebo Comparator|control group|
89582358|NCT04761575||FFQ validation|All participants to complete all aspects of the study.
89582359|NCT04759248|Experimental|Atezolizumab in combination with Trastuzumab and Vinorelbine|
89582360|NCT04756726|Experimental|Phase 1: Arm A - CFT7455|Participants with r/r NHL or r/r MM will be treated with oral CFT7455 as a single agent administered according to different dosing schedules
89582361|NCT04756726|Experimental|Phase 1: Arm B1 - CFT7455|Participants with r/r MM will be treated with escalating doses of single agent CFT7455 administered according to different dosing schedules until the determination of maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D)
89582362|NCT04756726|Experimental|Phase 1: Arm B2 - CFT7455 in combination with dexamethasone|Participants with r/r MM will be treated with oral CFT7455 in combination with a fixed dose of oral dexamethasone in each cohort
89582363|NCT04756726|Experimental|Phase 1: Arm C - CFT7455|Participants with r/r NHL will be treated with escalating doses of single agent CFT7455 administered according to different dosing schedules in each cohort until determination of MTD/RP2D
89582364|NCT04756726|Experimental|Phase 2: Arm 1 - CFT7455|Participants with r/r MM will be treated with oral CFT7455
89582365|NCT04756726|Experimental|Phase 2: Arm 2 - CFT7455 in combination with dexamethasone|Participants with r/r MM treated with oral CFT7455 in combination with oral dexamethasone
89582366|NCT04756726|Experimental|Phase 2: Arm 3 - CFT7455|Participants with r/r mantle cell lymphoma (MCL) treated with oral CFT7455
89582367|NCT04756726|Experimental|Phase 2: Arm 4 - CFT7455|Participants with r/r peripheral T-cell lymphoma (PTCL) treated with oral CFT7455
89582368|NCT04754932|Experimental|Community Site 1|CST Implementation community site
89582369|NCT04754932|Experimental|Community Site 2|CST Implementation community site
89582370|NCT04754932|Experimental|Community Site 3|CST Implementation community site
89582371|NCT04754932|Experimental|Community Site 4|CST Implementation community site
89582372|NCT04754932|Experimental|Community Site 5|CST Implementation community site
89582373|NCT04708275|Experimental|PaCT|Manualized Psychoanalytic short-term therapy (PaCT) for children with internalizing disorders, 20-25 sessions (1, 2). PaCT helps the child to resolve rigid conflictual internal representations/ working models by using interpretative and mentalizing techniques and drawing on therapeutic transference relationship with the child and the parent.
89582374|NCT04708275|Active Comparator|Waitlist|PaCT after a waiting period (3 months)
89582375|NCT04704505|Experimental|Bipolar Androgen Therapy in addition to RADium-223 (RAD)|Participants will receive Bipolar Androgen Therapy (BAT) plus Radium-223 (RAD).
89582376|NCT04699435|Experimental|Control|Patients with a BMI <25 kg / m² requiring general anesthesia with a pre-oxygenation for 3 minutes
89582377|NCT04699435|Experimental|PreOx_3min|Patients with a BMI between 30 kg / m² and 40 kg / m² requiring general anesthesia randomized to the pre-oxygenation group for 3 minutes
89582378|NCT04699435|Experimental|PreOx_6min|Patients with a BMI between 30 kg / m² and 40 kg / m² requiring general anesthesia randomized to the pre-oxygenation group for 6 minutes
89582379|NCT04689555|Experimental|Novel method without manual compression|
89582380|NCT04689555|Active Comparator|Standard method with manual compression|
89582381|NCT04683692|Experimental|Cerebral protection with the Sentinel device|Subjects who received the Sentinel device in the parent study
89582382|NCT04683692|Active Comparator|Control group without cerebral protection|Subjects who did not received the Sentinel device in the parent study
89582383|NCT04671186|Experimental|Probiotic group|Probiotic group will receive Lactobacillus rhamnosus strain GG one capsule oral daily (10 billion CFU/day) throughout the study
88974389|NCT03844997|Experimental|Palbociclib + CPX-351|"Palbociclib will be administered orally on day -1 and -2 at 125 mg PO during the phase IIaportion (dose level 0).Day 0 will be rest and then CPX-351 at 100 u/m2 will be started on days 1, 3, and 5 along with Palbociclib day 2, 4, and 6 followed by rest/monitoring period (day 7-28).~If Grade 3-4 non-hematologic toxicity is observed in 1 or less of 6 patients treated, the study will move to Phase IIb. If Grade 3-4 non-hematologic toxicity is observed in 2 or more of 6 patients treated, 6 additional patients will be treated on the Phase IIa portion at a lower dose level (100 mg po) until a Phase IIb safe dose schedule is defined at which 1 or less out of 6 patients on the Phase IIa experience Grade 3-4 non-hematologic toxicity. After the Phase IIa portion ensures safety, the study will proceed with phase IIb. The phase IIb component is a Simon 2-stage design trial whose objective is to assess the clinical efficacy of the combination of Palbociclib and CPX-351."
88974390|NCT03832556|Experimental|Preoperative evaluation: CT + MRI|"Preoperative evaluation by 2 examinations: CT scan and MRI.~CT scan with biphasic injection of contrast product;~MRI with injection of contrast."
88974391|NCT03815721|Experimental|daily stimulation|30-minute sessions of transcutaneous spinal cord stimulation using the Stimulette r2x+ will be repetitively applied 7 times per week.
88974392|NCT03815721|Experimental|stimulation every other day|30-minute sessions of transcutaneous spinal cord stimulation using the Stimulette r2x+ will be repetitively applied 3 times per week.
89030027|NCT02950623|Experimental|patients take titanium dioxide denture|patients will receive titanium dioxide denture (made from conventional acrylic resin modified by titanium dioxide nanoparticles ) for 1 month in the initial phase of the trial then in the later phase after one month they will receive( rapid heat cured acrylic resin)denture
89582384|NCT04671186|Placebo Comparator|Placebo Group|Placebo group is to receive placebo oral capsule daily throughout the study.
89582385|NCT04651270|Experimental|SurroundScope|For laparoscopic camera system, the SurroundScope. 270-degree angle videoscope (270Surgical, Israel) was used
89582386|NCT04645693||HIV Subjects with Non-Communicable Diseases|Patients living with HIV on Antiretroviral Therapy drugs for at least one year with no diagnosis of non-communicable diseases (diabetes, insulin resistance, hyperlipidemia/dyslipidemia, vascular disease, and/or osteoporosis).
89582387|NCT04645693||HIV Subjects without Non-Communicable Diseases|Patients living with HIV on Antiretroviral Therapy drugs for at least one year with a diagnosis of one or more systemic non-communicable diseases (diabetes, insulin resistance, hyperlipidemia/dyslipidemia, vascular disease, and/or osteoporosis).
89582388|NCT04617197|Experimental|Variable-frequency combination 1|Non disclosure
89582389|NCT04617197|Active Comparator|Variable-frequency combination 2|Non disclosure
89582390|NCT04617197|Placebo Comparator|Control (Placebo)|Non-disclosure
89582391|NCT04588038|Experimental|Treatment (efineptakin alfa)|Patients receive one dose of efineptakin alfa IM.
89582392|NCT04548479|Active Comparator|PEP group|Chest physiotherapy depending on the location of the ribs fractures techniques are performed: 1. Postural control techniques; 2. Airways clearance techniques; 3. Breathing exercise (diaphragmatic breathing). 4. Early mobilization. 5. Positive expiratory pressure (PEP) breathing
89582393|NCT04548479|No Intervention|INS group|Chest physiotherapy depending on the location of the ribs fractures techniques are performed: 1. Postural control techniques; 2. Airways clearance techniques; 3. Breathing exercise (diaphragmatic breathing). 4. Early mobilization. 5. Inspiratory incentive spirometry breathing
89582394|NCT04529278|Experimental|Liraglutide|"Liraglutide is initiated at 0.6 mg / day during week S1 (initiation D1) during weekly hospitalization in the diabetology department. Then the dose of liraglutide is increased to 1.2 mg / day on week S2 (increase in dose on D8) then to 1.8 mg / day on week S3 (increase in dose on D15).~The daily dose is then 1.8 mg until week W26."
89582395|NCT04503148|Experimental|TIVA group|Patients receiving the total intravenous anesthesia using propofol
89582396|NCT04503148|Active Comparator|inhalation group|Patients receiving inhalation anesthesia using sevoflurane or desflurane
89582397|NCT04484766||Patient after pre-eclampsia|Patients with pre-eclampsia who were treated at the University Hospital of Jena between 1999-2009.
89582398|NCT04484766||Patients after PETN treatment|Patients of the PETN pilot study, with PETN and patients who received PETN as an individual therapy trial
89582399|NCT04429516|Experimental|Morphine Sulfate|
89582400|NCT04429516|Placebo Comparator|Placebo|
89582401|NCT04417452||Mothers / children after diabetes in pregnancy|The study collective is composed of mother-child pairs after gestational diabetes, which were supervised in the Competence Center for Diabetes and Pregnancy at the University Hospital of Jena. The patients can decide to fill in an online questionnaire. For all other parts of the study, only patients who have been informed individually or on behalf of their legal guardian about the nature of the study after a detailed and understandable explanatory discussion with an investigator and who have given written consent will be included in the study.
89582402|NCT04417452||Controls|The control collective is composed of mother-child pairs who were cared for at the same time as the study collective at the University Hospital Jena. This collective is status post singleton pregnancy and term birth. The patients can decide to fill in an online questionnaire. For all other parts of the study, only patients who have been informed individually or on behalf of their legal guardian about the nature of the study after a detailed and understandable explanatory discussion with an investigator and who have given written consent will be included in the study.
89582403|NCT04357951|Experimental|Behavior Therapy + DCS|Youth with TD will receive four, 2-hour long sessions of evidence-based behavior therapy delivered in an intensive format. Participants will arrive an hour early for each session to take the d-cycloserine pill prior to starting each session of behavior therapy. Participants, therapists, and outcome assessors will be masked to pill condition.
89582404|NCT04357951|Active Comparator|Behavior Therapy + Placebo|Youth with TD will receive four, 2-hour long sessions of evidence-based behavior therapy delivered in an intensive format. Participants will arrive an hour early for each session to take the placebo pill prior to starting each session of behavior therapy. Participants, therapists, and outcome assessors will be masked to pill condition.
89582405|NCT04323293|Experimental|CPM - Cold Water Bath|
89582406|NCT04323293|Sham Comparator|CPM - SHAM|
89582407|NCT04285229|Experimental|Ixekizumab|Participants received Ixekizumab during the double-blind and extended treatment periods (i.e.,) starting dose of 160 milligrams (mg) Ixekizumab in the beginning week followed by 80 mg Ixekizumab once every four weeks (Q4W) by subcutaneous injection. No treatments were administered during the follow-up period.
89582408|NCT04285229|Placebo Comparator|Placebo|Participants received placebo every four weeks (Q4W) by subcutaneous (SC) injection during the double-blind period. During the extension period, they received starting dose of 160 milligrams (mg) Ixekizumab in the beginning week followed by 80 mg Ixekizumab once every four weeks (Q4W) by subcutaneous injection. No treatments were administered during follow-up period.
89582409|NCT04282668|Experimental|TAS1440|TAS1440 as a single agent administered once daily (QD) on specific days during each 28-day cycle in Part 1.
89582410|NCT04282668|Experimental|TAS1440 + ATRA|TAS1440 administered QD on specific days during each 28-day cycle in combination with ATRA twice daily (BID) in Part 2.
89582411|NCT04263454|Other|Healthy Control|All healthy control participants will undergo the same screening and experimental procedures. Healthy controls must report no other medical conditions ( including fibromyalgia) to be considered for inclusion. All healthy controls will have an MRI scan performed both before and 3 hours post 0.4ng/kg endotoxin injection.
89582412|NCT04263454|Experimental|Fibromyalgia|All fibromyalgia participants will undergo the same screening and experimental procedures. However, fibromyalgia participants will need to meet 2010 American College of Rheumatology diagnostic criteria for fibromyalgia. All fibromyalgia participants will have an MRI scan performed both before and 3 hours post 0.4ng/kg endotoxin injection.
89582413|NCT04259060|Active Comparator|Hydroxocobalamin with Butyrate|Subjects enrolled will take hydroxocobalamin capsules twice daily for 4 weeks. All subjects will take an oral butyrate dose of 120 mg twice daily for 4 weeks.
89582414|NCT04259060|Placebo Comparator|Placebo with Butyrate|Subjects enrolled will take placebo capsules twice daily for 4 weeks. All subjects will take an oral butyrate dose of 120 mg twice daily for 4 weeks.
89582415|NCT04251195|Experimental|Cognitive Intervention|
89582416|NCT04251195|Active Comparator|Active Control Intervention|
89582417|NCT04218240|Experimental|PGB/LFX;|0.54 mg lofexidine and 200 mg Pregabalin on days 1 -7 with taper for pregabalin and lofexidine starting on day 5
89209514|NCT00886860|Experimental|titrated oral misoprostol|misoprostol 20 micrograms oral every hour until cervical dilatation 3 centimeters
89582418|NCT04218240|Active Comparator|Lofexidine and PLACEBO|0.54 mg lofexidine and Placebo (PLB) on days 1-7 with taper for lofexidine starting on day 5
89582419|NCT04212793|Experimental|NIR endoscopic TSS with 4.5 mg bevacizumab-800CW|IV-administration of 4.5 mg of the fluorescent tracer bevacizumab-800CW to 3 patients with a pituitary neuroendocrine tumor (PitNET) with a Knosp grade of 3 or 4. The optimal dose will be expanded to include 6 patients.
89582420|NCT04212793|Experimental|NIR endoscopic TSS with 10 mg bevacizumab-800CW|IV-administration of 10 mg of the fluorescent tracer bevacizumab-800CW to 3 patients with a pituitary neuroendocrine tumor (PitNET) with a Knosp grade of 3 or 4. The optimal dose will be expanded to include 6 patients.
89582421|NCT04212793|Experimental|NIR endoscopic TSS with 25 mg bevacizumab-800CW|IV-administration of 25 mg of the fluorescent tracer bevacizumab-800CW to 3 patients with a pituitary neuroendocrine tumor (PitNET) with a Knosp grade of 3 or 4. The optimal dose will be expanded to include 6 patients.
89209515|NCT00884442|Active Comparator|1|One tablet of Gen-nifedipine extended release, previously referred to as Gen-Nifedipine XL, fasted state
89209516|NCT00884442|Active Comparator|2|One tablet of Gen-nifedipine extended release, previously referred to as Gen-Nifedipine XL, fed state
89209517|NCT00884442|Active Comparator|3|One tablet of Nifedipine (Bayer Healthcare AG manufactured as Adalat® XL®, Adalat® LA, Adalat® Crono, Adalat® OROS, fasted state
89209518|NCT00884442|Active Comparator|4|One tablet of Nifedipine (Bayer Healthcare AG manufactured as Adalat® XL®, Adalat® LA, Adalat® Crono, Adalat® OROS, fed state
89582422|NCT04212260|Experimental|Oro-pharyngeal exercises|Use of oro-pharyngeal exercises
89582423|NCT04212260|Sham Comparator|Sham control|Use of sham exercises.
89582424|NCT04187547|Active Comparator|AC-SD-03|Tricaprilin SD formulation, twice daily. Administered orally
89582425|NCT04187547|Placebo Comparator|AC-SD-03P|Placebo formulation, twice daily. Administered orally
89582426|NCT04175678|Active Comparator|Normal/Active|No intervention
89582427|NCT04175678|Placebo Comparator|Obese/Inactive|Observational clinic visits
89582428|NCT04175678|Experimental|Diet|low fat/low caloric diet
89582429|NCT04175678|Experimental|Exercise Training|≥3 sessions with fitness trainer per week, for ≥30 min, at moderate to high intensity
89582430|NCT04175678|Experimental|Diet and exercise training|low fat/low caloric diet and ≥3 sessions with fitness trainer per week, for ≥30 min, at moderate to high intensity
89582431|NCT04159662|Experimental|Cognitive Intervention|
89582432|NCT04159662|Active Comparator|Active Control Intervention|
89582433|NCT04155463|Experimental|Organic Diet, Then Conventional Diet:|"These participants first received an organic diet for one week. During that week, daily first morning void urine samples were collected. After a washout period of one day, these participants then received a conventional (non-organic) diet for one week. During that week, daily first morning void urine samples were collected.~For each week, participants ordered all food they anticipated eating that week (up to $150) from a unique account with a local grocery store in accordance with either the organic diet or conventional diet. Study staff verified all food items corresponded with the dietary intervention that week, and then ordered the groceries to be delivered to the participant's home, when possible. For participants living in areas in which delivery was not available (generally rural areas), study staff picked up the food at the grocery store and delivered it to the participant's home."
89582434|NCT04155463|Experimental|Conventional Diet, Then Organic Diet|"These participants first received a conventional (non-organic) diet for one week. During that week, daily first morning void urine samples were collected. After a washout period of one day, these participants then received an organic diet for one week. During that week, daily first morning void urine samples were collected.~For each week, participants ordered all food they anticipated eating that week (up to $150) from a unique account with a local grocery store in accordance with either the organic diet or conventional diet. Study staff verified all food items corresponded with the dietary intervention that week, and then ordered the groceries to be delivered to the participant's home, when possible. For participants living in areas in which delivery was not available (generally rural areas), study staff picked up the food at the grocery store and delivered it to the participant's home."
89582435|NCT04084951|Experimental|Part 1 Monotherapy Dose Escalation Phase|"In Part 1, SQZ-PBMC-HPV as a monotherapy is administered on Day 1 of every 3 week cycles for up to a year. In Cohort 3 (double-priming), SQZ-PBMC-HPV is also administered on Day 2 of Cycle 1. There are at least 3 groups (Cohorts) in this Phase as follows:~Cohort 1: specified dose SQZ-PBMC-HPV~Cohort 2: specified dose SQZ-PBMC-HPV~Cohort 3: specified dose SQZ-PBMC-HPV double-priming"
89209519|NCT04087265|Other|Study Population (All Participants)|Patients who are referring for scheduled screening colonoscopy
89209520|NCT02543580|Experimental|single acupoint|transcutaneous electric acupoint stimulation is given at bilateral neiguan or 30min before anesthesia induction
89582436|NCT04084951|Experimental|Part 2 Combination Safety Phase|"In Part 2, SQZ-PBMC-HPV in combination with immune checkpoint inhibitors (1) atezolizumab, (2) ipilimumab, (3) nivolumab, or (4) nivolumab and ipilimumab, is administered every 3 weeks for up to a year except atezolizumab may be given up to 2 years; and ipilimumab will be administered four times (in a timeframe less than a year) if safety allows. There are 4 groups (Cohorts) in this Phase as follows:~Cohort 4: SQZ-PBMC-HPV RP2D (Recommended Phase 2 Dose) plus atezolizumab~Cohort 5: SQZ-PBMC-HPV RP2D plus ipilimumab~Cohort 6: SQZ-PBMC-HPV RP2D plus nivolumab~Cohort 7: SQZ-PBMC-HPV RP2D plus nivolumab and ipilimumab"
89209521|NCT02543580|Experimental|double acupoints|transcutaneous electric acupoint stimulation is given at Danzhong and bilateral neiguan or 30min before anesthesia induction
89209522|NCT02543580|Experimental|sham electroacupuncture|electrode attached but no stimulation
89209523|NCT02543034|Experimental|Betafoam Wound Dressing|This contains 3% povidone iodine. Dressing will be routinely changed on day 3 and day 7, and can be replaced anytime due to various factors such as exudate control, dislodgement, or by investigators' clinical decision.
89209524|NCT02543034|Active Comparator|Petrolatum Gauze|Dressing will be routinely changed on day 3 and day 7 and can be replaced anytime due to various factors such as exudate control, dislodgement, or by investigators' clinical decision.
89209525|NCT02543034|Active Comparator|Allevyn Wound Dressing|Allevyn adhesive wound dressing will be routinely changed on day 3 and day 7 and can be replaced anytime due to various factors such as exudate control, dislodgement, or by investigators' clinical decision.
89209526|NCT02594345|Experimental|Intervention group|
89209527|NCT00278161|Experimental|R-HiCy|Rituximab (R) and high-dose cyclophosphamide (HiCy) with pegfilgrastim support.
89582437|NCT04084951|Experimental|Part 3 Monotherapy Dose Expansion Phase|"In Part 3, SQZ-PBMC-HPV is administered at the RP2D to patients enrolled in HPV16+ cancer-type specific cohorts. There are 4 groups (Cohorts) in this Phase as follows:~Cohort 8: SQZ-PBMC-HPV RP2D in HPV16+ head and neck cancer patients~Cohort 9: SQZ-PBMC-HPV RP2D in HPV16+ cervical cancer patients~Cohort 10: SQZ-PBMC-HPV RP2D in HPV16+ anal cancer patients~Cohort 11: SQZ-PBMC-HPV RP2D in other HPV16+ cancer patients"
89582438|NCT04058665||Observational group|No intervention performed. This is the overall group that will be retrospectively assessed for different variables pertaining to blood loss.
89582439|NCT04056611|Experimental|Adult cohort: JNJ-53718678 or Placebo|Participants greater than or equal to (>=) 18 to less than or equal to (<=) 75 years of age will receive 250 milligram (mg) JNJ-53718678 twice daily (bid) for 21 days (without coadministration with moderate or strong CYP3A4 inhibitors), or 125 mg JNJ-53718678 bid for 21 days (coadministered with moderate or strong CYP3A4 inhibitors with the exception of posaconazole), or 125 mg once daily (qd) for 21 days (when coadministered with posaconazole), or matching placebo for 21 days.
89582440|NCT04056611|Experimental|Adolescent cohort: JNJ-53718678 or Placebo|Participants >=13 to <18 years of age will receive 250 mg JNJ-53718678 bid for 21 days (without coadministration with moderate or strong CYP3A4 inhibitors), or 125 mg JNJ-53718678 bid for 21 days (coadministered with moderate or strong CYP3A4 inhibitors with the exception of posaconazole), or 125 mg qd for 21 days (when coadministered with posaconazole), or matching placebo for 21 days.
89582441|NCT04040686|Experimental|Injection of 99mTc-NM-02|All breast cancer patients recruited to the study will be administered 3-12 MBq/kg of 99m-Tc-NM-02 (99m-Tc labeled anti-HER2 sdAb) in a single dose injection
89582442|NCT04035837|Experimental|short-course combination group|Nucleoside analogue is used during the first 3 months.
89582443|NCT04035837|Experimental|full-course combination group|Nucleoside analogue is used during all the course of study.
89582444|NCT04035837|Experimental|Monotherapy group|Only Peg-IFN is used during all the course of study.
89582445|NCT04022135|Active Comparator|Folic acid|0.6 mg/day
89582446|NCT04022135|Experimental|(6S)-5-methyltetrahydrofolic acid (Metafolin)|0.625 mg/d (an equimolar dose to folic acid)
89582447|NCT04011254||Healthy Control|Healthy control
89582448|NCT04011254||Haemodialysis %IDWG >4%|Patient on regular haemodialysis with average IDWG >4%
89582449|NCT04011254||Haemodialysis %IDWG <4%|Patient on regular haemodialysis with average IDWG <4%
89582450|NCT04001803|Experimental|Subjects with HIV infection|HIV-infected subjects receiving CAB LA+RPV LA will be included in this arm.
89582451|NCT04001777|Experimental|APG-1252 plus Osimertinib (AZD9291)|APG-1252 will be explored sequentially using a standard 3+3 escalation scheme at the dose escalation phase; Dose of osimertinib will be fixed at 80mg QD based on approved label.
89582452|NCT03994913|Experimental|CAR-CD19-T Cells|The subjects are enrolled into 3 dose levels cohorts in sequence.
89582453|NCT03984994|Experimental|Aerobic exercise training followed by resistance training|Participants in this arm will undergo 3 months of aerobic exercise training, followed by 3 months of strength training
89582454|NCT03984994|Active Comparator|Resistance training followed by aerobic exercise training|Participants in this arm will undergo 3 months of strength training, followed by 3 months of aerobic exercise training
89582455|NCT03977012||Patients with CRPS Type I|"Patients diagnosed with Complex Regional Pain Syndrome Type I who are anticipated to recieve a 8 weeks regime of buprenorphine as a part of routine medical care.~-drug name: norspan patch 5~20 mcg dosage form: patch frequency: every weeks duration: 8 weeks"
89582456|NCT03968055|Other|Patients with Type 1 Diabetes|Participants will wear a continuous glucose monitor (CGM) and receive remote monitoring of the CGM data by the clinical care team.
89582457|NCT03940066|Other|Monitoring group|
89582458|NCT03940066|Other|Standard Care|
89582459|NCT03907423|Experimental|Rosuvastatin|DM-type 2 patients who will receive rosuvastatin -metformin-glimepiride combination (40 patients)
89582460|NCT03907423|Placebo Comparator|Placebo Group|DM-type 2 patient who will receive glimepiride-metformin combination (30 patients).
89030028|NCT02950623|Placebo Comparator|patients take rapid heat denture|patients will receive rapid heat denture for 1 month in the initial phase of the trial then in the later phase patients will receive titanium dioxide denture (made from conventional acrylic resin modified by titanium dioxide nanoparticles )
89030029|NCT04695015||Melanoma and Nevus|Patients diagnosed with melanoma or/and nevus on the skin around the eye before surgery.
89582461|NCT03906409|Active Comparator|Constant|Participants will be provided with their daily energy requirements in a continuous drip across the day (1 ml/minute).
89030030|NCT04695015||Basal cell carcinoma;Squamous cell carcinoma;Sebaceous gland carcinoma|Patients diagnosed with basal cell carcinoma, squamous cell carcinoma, sebaceous gland carcinoma before surgery.
89030031|NCT00515970|Experimental|1|Clinical or histologic diagnosis of nodular BCC
89030032|NCT00515970|Active Comparator|2|Clinical or histologic diagnosis of nodular BCC
89582462|NCT03906409|Experimental|Bolus|Participants will be provided with their daily energy requirements in two bolus feeds. One at 08:00-08:15 and one at 20:00-20:15
89582463|NCT03903874|Experimental|DIAL intervention|Deep south Interactive voice response system Active Lifestyle (DIAL) intervention. Participants will receive 12 months of automated physical activity phone counseling. Participants will report their physical activity to the IVR system each day for 3 months, twice/week in months 3-6, and once/week in months 6-12 and receive progress feedback via IVR system, along with community health worker support.
89582464|NCT03903874|No Intervention|Wait List Control|The wait list control participants will be instructed to maintain their normal routine until completion of the 6-month assessments and then receive the same 12-month DIAL intervention. To maintain engagement, these participants will be involved in monthly lunch and learns, focus groups, etc on cancer topics other than PA (e.g., screening) during the wait period.
89582465|NCT03897621|Experimental|tranexamic acid|Patients undergoing unilateral, primary, total hip arthroplasty with English as their native language
89582466|NCT03897621|Placebo Comparator|Normal saline|Patients undergoing unilateral, primary, total hip arthroplasty with English as their native language
89582467|NCT03882671|Experimental|Monitoring Device|Subjects will be asked to wear up to 3 different noninvasive seizure detection devices including EpiTel EpiLog, Empatica E4, GeneActiv
89582468|NCT03874507|Experimental|Technology-based therapy|Patients who require acute rehabilitation due to deconditioning and surgery will receive either virtual reality (VR) or augmented reality (AR) to improve clinical outcomes such as range of motion, gait progression, strength progression, time to first out of bed, time to first step.
89582469|NCT03874507|No Intervention|Standard of Care therapy|Patients who require acute rehabilitation due to deconditioning and surgery will receive physical therapy based on his/her providers recommendations to improve outcomes such as range of motion, gait progression, strength progression, time to first out of bed, time to first step
89582470|NCT03859167||Participants with AV block with pacemaker|Participants will have a stress test, and results will be collected and recorded.
89582471|NCT03849118|Experimental|89Zr-girentuximab|A single administration of 37 Megabecquerel (MBq) (±10%) 89Zr-girentuximab, containing a mass dose of 10 mg of girentuximab, followed by a diagnostic scan on Day 5 ± 2 days after administration.
89582472|NCT03846726||observation group|Pathologically confirmed stage II/III rectal adenocarcinoma patients who received neoadjuvant chemoradiotherapy followed by a clinical complete response, and refused surgery but went on with the watch and wait approach.
89582473|NCT03846726||surgery group|Pathologically confirmed stage II/III rectal adenocarcinoma patients who received neoadjuvant chemoradiotherapy followed by a clinical complete response, and received radical resection.
89582474|NCT03819192||neonates with signs of EONS|
89030033|NCT00515970|Experimental|3|Clinical or histologic diagnosis of superficial BCC
89030034|NCT00515970|Active Comparator|4|Clinical or histologic diagnosis of superficial BCC
89030035|NCT04695249|Experimental|Exposure intervention|Eleven individual sessions.
89030036|NCT00516009|Experimental|1 TREATMENT GROUP|20 PATIENTS WILL RECEIVE DEXAMETHASONE 30 MG IV 3 DAYS AND 20 AND 10 MG FOR THE OTHER TWO DAYS
89582475|NCT03819192||neonates without signs of EONS|
89030037|NCT00516009|Placebo Comparator|2|20 PATIENTS WILL RECEIVE PLACEBO FOR 5 DAYS
89582476|NCT03819192||pregnant women with PPROM|
89582477|NCT03809884|Experimental|Dietary Counselling|All enrolled patients will undergo a 1:1 counselling with a registered dietitian (with possible inclusion of family members, as appropriate). The dietitian will undertake an assessment of the comorbidities (e.g. diabetes), dietary intake, dietary habits (e.g. eating out, food preparation, socio-cultural aspects) and provide an individually tailored strategy to increase potassium in the diet. Secondly, on a weekly basis, the dietitian will contact the patient by telephone, or electronically (as preferred by the patient) to reinforce the advice and provide support/advice as necessary.
89582478|NCT03809884|Active Comparator|Potassium Citrate Supplement|Patients who are not able to successfully increase their potassium intake at 4 weeks with dietary counselling will receive potassium citrate supplements. They will receive oral potassium supplementation in the form of 50 to 100 mmol of potassium citrate (as 25 to 50 ml of the liquid solution).
89582479|NCT03804138||Patient|patient with COPD
89582480|NCT03804138||control group|patient without COPD
89030038|NCT02950584|Experimental|Patients take titanium dioxide denture|Participants will receive titanium dioxide denture (made from conventional acrylic resin modified by titanium dioxide nanoparticles) for 1 month in the initial phase of the trial then in the later phase after one month they will receive (rapid heat cured acrylic resin) denture
89030039|NCT02950584|Placebo Comparator|Patients take rapid heat denture|Patients will receive rapid heat denture for 1 month in the initial phase of the trial then in the later phase patients will receive titanium dioxide denture (made from conventional acrylic resin modified by titanium dioxide nanoparticles)
89030040|NCT01240811|No Intervention|Control-No IUD|Healthy volunteers not at risk of pregnancy and not using any hormonal contraception.
89030041|NCT01240811|Experimental|Levonorgestrel IUS|Healthy volunteers seeking contraception with IUD. Randomized to LNG IUS.
89030042|NCT01240811|Experimental|Copper T380A IUD|Healthy volunteers seeking contraception with IUD. Randomized to Copper T380A IUD.
89030043|NCT03459144|Experimental|photodynamic therapy|Participants will be given the standard verteporfin photodynamic therapy at baseline followed by additional standard verteporfin PDT as needed (every three months)(namely 1+PRN regimen).
89030044|NCT03459144|Experimental|intravitreal ranibizumab|Participants will receive the intravitreal ranibizumab treatment (0.05mg) at baseline and additional intravitreal ranibizumab will be given to the participants when necessary (every month) (namely 1+PRN regimen).
89030045|NCT03459144|Experimental|combination therapy of PDT and IVR|Participants will be given the standard verteporfin photodynamic therapy followed by intravitreal ranibizumab (0.05mg) 72h after the standard verteporfin PDT treatment at baseline. Additional verteporfin photodynamic therapy and intravitreal ranibizumab (0.05mg) will be given to the participants when necessary (every month)(namely 1+PRN regimen).
89030046|NCT03459105|Experimental|Ultrasound-assisted|Preprocedural ultrasound-assisted paramedian spinal anesthesia will be performed. 0.5% heavy bupivacaine will be injected to intrathecal space for spinal anesthesia.
89030047|NCT03459105|Active Comparator|Landmark-guided|Landmark-guided spinal anesthesia will be performed, via either midline or paramedian approach. 0.5% heavy bupivacaine will be injected to intrathecal space for spinal anesthesia.
89582481|NCT03785366|Experimental|VeraCept|VeraCept subjects will be inserted with VeraCept on Day 1. At Day 57 subjects will be informed that they received VeraCept and may continue in the study for up to 5 years
89582482|NCT03785366|Active Comparator|ParaGard|ParaGard subjects will be inserted with ParaGard on Day 1. At Day 57 subjects will be informed that they received ParaGard and may choose to have the ParaGard removed or continue use per standard of clinical care.
89582483|NCT03768427|Experimental|EZ 10 mg/Ator 10 mg|Single oral dose of EZ10mg/Ator10mg FDC tablet once daily (QD) for 84 days
89582484|NCT03768427|Active Comparator|Atorvastatin 20 mg|2 atorvastatin 10 mg tablets administered orally, QD for 84 days
89582485|NCT03768427|Experimental|EZ 10 mg/Ator 20 mg|Single oral dose of EZ10mg/Ator20mg FDC tablet QD for 84 days
89030048|NCT01240382|Experimental|3% DE-089|
89030049|NCT01240382|Active Comparator|0.1% HA|
89030050|NCT00516087|Experimental|Patients|Patients with NPC in first or subsequent relapse or with primary refractory disease or high risk (T3 or T4, or node positive disease) in whom the EBV genome or antigens have been demonstrated in tissue biopsies.
89582486|NCT03768427|Active Comparator|Atorvastatin 40 mg|2 atorvastatin 20 mg tablets administered orally, QD for 84 days
89582487|NCT03758781|Experimental|IRX-2 Regimen combined with Nivolumab|IRX-2 Regimen (4 ml) combined with Nivolumab (240 mg)
89582488|NCT03747718|Experimental|Fecal Microbiota Follow up Enemas|In this arm subjects will receive 3 fecal microbiota transplants at 1 monthly intervals at 1.5, 2.5 and 3.5 months (+/- 2 weeks) after transplant
89582489|NCT03747718|Placebo Comparator|Placebo Enemas|In this arm subjects will receive 3 placebo transplants at 1 monthly intervals at 1.5, 2.5 and 3.5 months (+/- 2 weeks) after transplant
89582490|NCT03746080|Experimental|Whole Brain Radiotherapy + Plerixafor +Chemoradiotherapy|After completion maximal safe surgical resection, patients undergo radiation therapy for 42 days, initiating whole brain radiation therapy at day 21 (dose 16 of radiation therapy) and receive temozolomide daily on days 1 to 42. Beginning 7 days before the completion of whole brain radiation therapy, patients receive plerixafor by continuous infusion on days to 1 to 28. Beginning 1 week after completion of plerixafor infusion and 35 days after completion of whole brain radiation therapy, patients receive temozolomide monthly for 6 to 12 courses in the absence of disease progression or unacceptable toxicity.
89582491|NCT03724149|Experimental|Direct-acting antiviral treatment for HCV|
89582492|NCT03720002|Experimental|Active treatment|Will receive HF2 add-on
89582493|NCT03720002|Placebo Comparator|Placebo|Will receive placebo
89582494|NCT03595228|Experimental|BN-Brachyury plus radiation|BN-Brachyury as both MVA and FPV are given before radiation, and followed by FPV-Brachyury
89582495|NCT03572933|Experimental|Ganaxolone|ganaxolone suspension (50 mg/ml) 3x's /day for 17 weeks
89582496|NCT03572933|Placebo Comparator|Placebo|placebo suspension 3x's /day for 17 weeks
89582497|NCT03558152|Experimental|Arm 1a: UTTR1147A Dose Level 1 (Part A) + UTTR1147A (Part B)|"Part A: UTTR1147A dose level 1 and Vedolizumab Placebo.~Part B: UTTR1147A maintenance dose and Vedolizumab Placebo."
89582498|NCT03558152|Experimental|Arm 1b: UTTR1147A Dose Level 1 (Part A) + Placebo (Part B)|"Part A: UTTR1147A dose level 1 and Vedolizumab Placebo.~Part B: UTTR1147A Placebo and Vedolizumab Placebo."
89582499|NCT03558152|Experimental|Arm 2a: UTTR1147A Dose Level 2 (Part A) + UTTR1147A (Part B)|"Part A: UTTR1147A dose level 2 and Vedolizumab Placebo.~Part B: UTTR1147A maintenance dose and Vedolizumab Placebo."
89582500|NCT03558152|Experimental|Arm 2b: UTTR1147A Dose Level 2 (Part A) + Placebo (Part B)|"Part A: UTTR1147A dose level 2 and Vedolizumab Placebo.~Part B: UTTR1147A Placebo and Vedolizumab Placebo."
89582501|NCT03558152|Experimental|Arm 3a: UTTR1147A Dose Level 3 (Part A) + UTTR1147A (Part B)|"Part A: UTTR1147A dose level 3 and Vedolizumab Placebo.~Part B: UTTR1147A maintenance dose and Vedolizumab Placebo."
89582502|NCT03558152|Experimental|Arm 3b: UTTR1147A Dose Level 3 (Part A) + Placebo (Part B)|"Part A: UTTR1147A dose level 3 and Vedolizumab Placebo.~Part B: UTTR1147A Placebo and Vedolizumab Placebo."
89582503|NCT03558152|Active Comparator|Arm 4: Vedolizumab|Parts A and B: Vedolizumab and UTTR1147A Placebo.
89582504|NCT03558152|Placebo Comparator|Arm 5: Placebo|Parts A and B: UTTR1147A Placebo and Vedolizumab Placebo.
89582505|NCT03768999||Study group|All participants in the study to receive Non-contrast magnetic resonance coronary angiography (MRCA)
89582506|NCT03482141|Other|Whole Exome Sequencing|Whole exome sequencing (WES) will take place for prenatal patients (pregnancies with fetal structural defects). All patients will get exome sequencing and will follow the same procedures.
88974393|NCT03812705|Experimental|fecal microbiome transplantation|"Perform fecal microbiome transplantation to patient under colonoscopy or gastroscopy: injection of 200~300 ml fecal microbiome fluid as fecal microbiome transplantation to left colon by Colonoscopy or duodenum through duodenum tube by gastroscopy;~If patient's condition is stable or improved within 1 week, second fecal microbiome transplantation may be performed 1 week later, up to 4 times will be performed if patient response;~If patient's condition is not improved after the second fecal microbiome transplantation, stop fecal microbiome transplantation."
88974394|NCT03803436|Experimental|Study arm|Liver transplant
88974395|NCT03803436|Active Comparator|Parallel arm|Chemotherapy
89582507|NCT03474653||Latitude 1 (Bulking)|Women with first line stress incontinence who choose to have Bulkamid as a treatment
89582508|NCT03474653||Latitude 2 (Choice)|Women with first line stress incontinence who choose to have any treatment including Bulking.
89582509|NCT03461406|Experimental|Fibrin Sealant Grifols|Participants topically applied FS Grifols, which consisted of component 1: human fibrinogen (80 mg/mL) and component 2: human thrombin with calcium chloride (500 IU/mL) solutions filled in syringes and assembled on a syringe holder.
89582510|NCT03461406|Active Comparator|EVICEL|Participants topically applied EVICEL, which consisted of component 1: Concentrate of human fibrinogen (BAC 2) (55-85 mg/mL) and component 2: human thrombin (800-1200 IU/mL) solutions. The 2 components (BAC2 and thrombin) were mixed and applied topically.
89582511|NCT03431974|Experimental|LD-Aminopterin oral capsule|LD-Aminopterin tablets (0.5 mg tablet) over-encapsulated, 3.0 mg (6 tablets) once orally each week for 14 weeks (14 doses).
89582512|NCT03431974|Placebo Comparator|Placebo oral capsule|Placebo capsules containing microcrystalline once orally each week for 14 weeks (14 doses).
89582513|NCT03416335|Experimental|Monotherapy Arm - Part A|Dose Escalation Drug DSP-0509
89582514|NCT03416335|Experimental|Combination arm - Part B|Dose Escalation Drug DSP-0509, Pembrolizumab
89582515|NCT03416335|Experimental|Combination arm - Part C|Dose Expansion, Drug DSP-0509, Pembrolizumab
88974396|NCT03803072|Experimental|Time restricted eating (TRE)|prolonging the duration of fasting between the last evening meal and the first meal of the next day
88974397|NCT03803072|No Intervention|control|Standard care. Will receive a booklet about physical activity recommendations and healthy eating in pregnancy
88974398|NCT03786627|Experimental|Combined NMES and motor control|This group will receive combined 15-minute neuromuscular electrical stimulation and 30-minute motor control training based on movement system impairment concept.
88974399|NCT03786627|Placebo Comparator|Motor control and placebo NMES|This group will receive placebo NMES for 15 minutes followed by 30 minutes motor control training based on movement system impairment concept.
88974400|NCT03775512|Experimental|Main Arm|Subjects will be ablated with the QDOT Micro Catheter for Pulmonary Vein Isolation with nMARQ RF Generator
89582516|NCT03408899|Experimental|PC-1005|All participants will receive 3 single escalating doses of PC-1005 gel during Visits 3, 5, and 7, with a 2-to-6-week washout period between dosing visits. Each participant will be on study for approximately 3 to 5 months.
89582517|NCT03348956|Experimental|EPR Oximetry|All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points (pre-exposure, during-exposure or CIPN incidence, and post exposure), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing.
89582518|NCT03311308|Active Comparator|Pembrolizumab|Pembrolizumab (Keytruda), 200 mg, by IV, every three weeks, for up to 2 years; after the first three doses, dosing can be changed to 400mg IV every 6 weeks, at the treating physician's discretion.
89582519|NCT03311308|Experimental|Pembrolizumab and Metformin Combination|Pembrolizumab (Keytruda), 200mg, by IV, every three weeks, for up to 2 years will be taken in combination with Metformin, 500mg, twice a day, for nine weeks; after the first three doses, pembrolizumab dosing can be changed to 400mg IV every 6 weeks, at the treating physician's discretion.
89582520|NCT03308006|Experimental|Stem cells therapy|
89582521|NCT03279393|Active Comparator|PTSD Subjects|
89582522|NCT03279393|Active Comparator|Trauma Control Subjects|
89582523|NCT03279393|Placebo Comparator|Healthy Control Subjects|
89582524|NCT03270098|Experimental|Aerobic Exercise|Using trainer-led video calls with traditional callisthenic body movements (e.g., jumping jacks, burpees, etc.)
89582525|NCT03270098|Active Comparator|Stretching and Toning Exercise|Using trainer-led video calls with stretching and toning exercises.
89582526|NCT03266471||Crohn's disease Patients|Patients that are seen in the Inflammatory Bowel Disease clinic with CD confirmed by endoscopy or radiology assessment who are initiating either an anti-tumor necrosis factor (TNF)-α agent (infliximab, adalimumab, certolizumab, or infliximab biosimilar), ustekinumab, or vedolizumab as part of their routine clinical care will be asked to provide blood samples, stool samples, and intestinal biopsies from standard of care colonoscopy at baseline and post therapy of at least 6 weeks duration but not more than 52 weeks.
89582527|NCT03266471||Controls|Healthy adults without IBD undergoing colonoscopy for colorectal cancer screening or other non-IBD related indication will be asked to provide blood samples, stool samples and intestinal biopsies from standard of care colonoscopy.
89582528|NCT03179449|Experimental|Diagnostic (ferumoxytol-enhanced MRI)|All subjects in the experimental arm will have a single intravenous dose of ferumoxytol (5 mg Fe/kg), to be administered 24 hours before the subject undergoes ferumoxytol-enhanced magnetic resonance imaging (MRI). These subjects will subsequently undergo surgery, and tissue analysis of surgically resected samples (specifically the number of iron-containing and non-iron-containing macrophages) will be correlated with imaging features on ferumoxytol-enhanced MRI.
89582529|NCT02978196|Experimental|Injection of 99m-Tc-NM-01|All patients with NSCLC who have undergone biopsy of primary tumour lesion will be administered 3-12 MBq/kg of 99m-Tc-NM-01 in a single injection.
89582530|NCT02915744|Experimental|NKTR-102|In Group A, NKTR-102 will be administered at a dose level of 145 mg/m2 on a q21d schedule as a 90-minute intravenous (IV) infusion on Day 1 of each treatment cycle.
89582531|NCT02915744|Active Comparator|Treatment of Physician's Choice (TPC)|In Group B, TPC will be administered per standard of care. Patients randomized to TPC will receive single-agent IV chemotherapy, limited to choice of one of the following 7 agents: eribulin, ixabepilone, vinorelbine, gemcitabine, paclitaxel, docetaxel, or nab-paclitaxel.
89582532|NCT02885363|Experimental|Patients with newly diagnosed Left Ventricular Non Compaction|Patient newly diagnosed with Left Ventricular Non Compaction (diagnose < 6 months), confirmed by echocardiography associated or not with MRI, after centralized review
89582533|NCT02885363|Active Comparator|Patients with Idiopathic Dilated Cardiomyopathy|Patient newly diagnosed with Idiopathic Dilated Cardiomyopathy (diagnose < 6 months), confirmed by echocardiography associated or not with MRI, after centralized review
88974401|NCT03775512|Experimental|Second Arm (variable flow)|subjects will be treated with QDOT Micro catheter with variable flow nMARQ RF generator
89582534|NCT02853643|Experimental|25 mg Dose|Single dose of 25 mg ASN002
89582535|NCT02853643|Experimental|50 mg Dose|Single dose of 50 mg ASN002
88974404|NCT03749317|Experimental|Treatment|IVIEW-1201; four times per day (QID) for 7 days
88974405|NCT03749317|Placebo Comparator|Placebo|Placebo; four times per day (QID) for 7 days
88974406|NCT03718754|Active Comparator|En-Bloc TURB|
88974407|NCT03718754|Active Comparator|Conventional TURB|
88974408|NCT03703440|Experimental|Active|≥3 group education sessions (60 minutes per session) in addition to usual diabetes care, every 3 months for 12 months. Each group session (3-8 patients per group) will be facilitated by a diabetes nurse educator and/or dietitian. The group session content will be guided by the needs of the group participants. The group discussion will end with participants setting goals for their next appointment.
88974409|NCT03703440|Other|Control|Usual diabetes care, every 3 months for 12 months, which consists of visits with their diabetes care physician. In addition, as per usual diabetes care, an individual education session and written information will be provided before formal transfer.
88974410|NCT03681795|Experimental|patient|patients with Gilles de la Tourette syndrome
89582536|NCT02853643|Experimental|100 mg Food effect cross over|100 mg single dose under both fasted and fed conditions in a cross over fashion
88974411|NCT03681795|Experimental|Control|healthy control
88974412|NCT03657056|Experimental|BX Pulsar 1002|Low-Intensity Focused Ultrasound Pulsation (LIFUP) sonications will be conducted using the LIFUP experimental device BX Pulsar 1002 produced by the Brainsonix Corporation. For the purposes of safety LIFUP sonications will be initiated at the FDA limit for diagnostic ultrasound. However, the minimally effective dose in humans applications, according to (Lee et al., 2015), when derated is approximately 1125mW/cm2.
88974413|NCT03656146|Active Comparator|Tablet Screening|Food insecurity screening conducted via electronic tablet
89582537|NCT02827955|Experimental|bilateral thalamotomy radiosurgery|Gamma Knife radiosurgery bilateral
89582538|NCT02823327||Chart review, RNA sequencing, microarray|Laboratory Biomarker Analysis. Medical chart review is performed and patient information is collected regarding human immunodeficiency virus HIV/AIDS medical history, staging of AIDS related malignancy, and type of treatment. Previously collected tissue samples are analyzed via RNA sequencing and microarray.
89582539|NCT02803125|Active Comparator|Developed psychosocial intervention|The active intervention in this study that will be compared to support group control
89582540|NCT02803125|Placebo Comparator|Support group control|This is the comparison group
89030051|NCT01244828|Experimental|Asenapine|Asenapine 5 mg twice daily (BID) for the first week of treatment, then either 5 mg or 10 mg BID.
89030052|NCT01243346|Experimental|Crenolanib (CP-868,596)|
89030053|NCT00516126||Point-of-Care managed|This arm includes all patients in which the hemostatic therapy is guided by POC devices e.g. MULTIPLATE (a platelet function analyzer) or ROTEM (thromboelastometry)
89582541|NCT02736656|Experimental|Open-Label Treatment|"Subjects 6-11 yrs of age will be treated with 100 to 400 mg SPN-812 ER (100 mg capsule).~Subjects 12-17 yrs of age will be treated with 100 to 600 mg SPN-812 ER (100, 200 mg capsule).~Subjects are given a choice to extend their participation in the study every 6 months for up to 72 months."
89582542|NCT02664402||Adults|English speaking, physician diagnosed with a life threatening illness.
89582543|NCT02528643|Experimental|Enzalutamide 160 mg|Participants received enzalutamide 160 milligrams (mg) capsules, orally QD during double blind treatment period until disease progression, unacceptable toxicity, or any other discontinuation criterion was met. Eligible participants received enzalutamide 160 mg capsules, orally QD during open label period until disease progression, unacceptable toxicity, or any other discontinuation criterion was met. Median treatment duration was 64 days.
89582544|NCT02528643|Placebo Comparator|Placebo|Participants received enzalutamide matching placebo orally, once daily (QD) during double blind treatment period until disease progression, unacceptable toxicity, or any other discontinuation criterion was met. Median treatment duration was 64 days.
89582545|NCT02409810|Experimental|PCA-DEX Patients|Prior to the burn dressing changes PCA-DEX patients will receive a bolus of dexmedetomidine (Precedex®) 0.25 mcg/kg administered over 10mins by nurse staff, followed by a continuous infusion of Precedex® at 0.4 mcg/kg/hr via a standard infusion pump (LifeCare PCA). Patients will self-medicate as needed for anxiety self-management by self-administering a bolus of Precedex® 0.1 mcg/kg.
89582546|NCT02325804|Active Comparator|Conventional lifestyle counseling|Randomized, open label study to assess effect of 8 weeks of Conventional lifestyle counseling (low calorie diet and exercise) on body composition, physical fitness, and metabolic parameters
89582547|NCT02325804|Active Comparator|Unconventional lifestyle counseling|"Randomized, open label study to assess effect of 8 weeks of unconventional lifestyle counseling (low calorie metabolic stairs diet and circuit-based exercise) on body composition, physical fitness, and metabolic parameters"
89582548|NCT02206815|Active Comparator|Ticagrelor+Warfarin|Ticagrelor:Plain, round, yellow, film-coated tablet, 90mg; Warfarin:Plain, round, white, film-coated tablet, 2.5mg
89582549|NCT02206815|Active Comparator|Clopidogrel+Aspirin+Warfarin|Clopidogrel:Light red bisulfate tablets, containing one 75mg; Aspirin:Plain, round, white, film-coated tablet, 100mg; Warfarin:Plain, round, white, film-coated tablet, 2.5mg
89582550|NCT02186691|Experimental|RV and LV ejection fraction assesment|assesment RV and LV ejection fraction after PVR measured by MRI
89582551|NCT02175680|Experimental|PRO 140|PRO 140 350mg weekly SQ injection.
89582552|NCT02151175|Experimental|LIFUP|
89582553|NCT02125981|Experimental|Limaprost|taking Limaprost α-Cyclodextrin Clathrate 1 Tablets (166.67 μg), three times per day
89582554|NCT02125981|Placebo Comparator|Control|taking placebo drug
89582555|NCT02114944||NIV|Patients with acute respiratory failure or dyspnea and DNI order treated with noninvasive ventilation
89582556|NCT02114944||CPAP|Patients with dyspnea or acute respiratory failure and DNI order treated with continuous positive airways pressure (CPAP)
89582557|NCT02114944||Standard oxygen|Patients with dyspnea and/or acute respiratory failure and DNI order, treated with standard oxygen therapy either via face mask or nasal cannula
89582558|NCT02114944||HFNC|Patients with dyspnea and/or acute respiratory failure and DNI order treated with high-flow nasal cannula (HFNC).
89582559|NCT01983462|Experimental|Clonidine|Oral 0.2 mg/day (0.1 mg bid)for 4 weeks
89582560|NCT01983462|Active Comparator|Hydrochlorothiazide|Oral, 12.5 mg/day qd, 4 weeks
89582561|NCT01983462|Placebo Comparator|Placebo|Placebo
89582562|NCT01936883|Active Comparator|LDR boost|After completion of 46 Gy of external beam radiotherapy subjects will undergo a permanent seed radioactive implant to the prostate using iodine-125 seeds to deliver a dose of 110 Gy
89582563|NCT01936883|Active Comparator|HDR boost|Subjects in this arm will undergo an HDR implant to deliver 15 Gy to the prostate prior to commencing the external beam component of their treatment.
89582564|NCT01779375|Active Comparator|Metformin alone|Metformin will be titrated to the maximum dose tolerated (up to 2000 mg/day).
89030054|NCT00516126||Conventional hemostasis lab managed|This arm includes all patients in which the hemostatic therapy is guided by conventional hemostasis laboratory data e.g. INR, aPTT, fibrinogen concentration, platelet count but no POC devices e.g. MULTIPLATE (a platelet function analyzer) or ROTEM (thromboelastometry)
89030055|NCT01249443|Experimental|Treatment (carboplatin, paclitaxel)|"Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 3. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~Before February 1, 2013, patients also received vorinostat PO once daily on days 1-5 with paclitaxel and carboplatin."
89030056|NCT01243073|Experimental|imetelstat|Induction dosing of 9.4 mg/kg weekly, followed by intermittent maintenance dosing.
89030057|NCT00516204||Patients at very high risk|
89030058|NCT00516204||Patients at high risk|
89030059|NCT00516204||Patients at medium risk|
89582565|NCT01779375|Active Comparator|Glargine followed by Metformin|Basal insulin glargine for 3 months titrated to achieve a morning fasting blood glucose of 85-95 mg/dl, followed by metformin (titrated up to 2000 mg/day) for 9 months.
89582566|NCT00979043|Active Comparator|Dietary weight-loss|The goal of the dietary weight-loss intervention was to produce and maintain a mean weight-loss of 5% initial body weight during the 18-month intervention, using dietary counseling and behavior modification.
89582567|NCT00979043|Active Comparator|Exercise|Participants participated in resistance training (15 minutes) and aerobic exercise (30 minutes) 3d/week for 18-months. The first 4-months of the exercise training were facility-based. After 4-months, participants were allowed to transition to a home-based intervention if they chose to.
89582568|NCT00979043|Active Comparator|Dietary weight-loss & exercise|Participants received both the dietary weight-loss and exercise interventions for 18-months
89582569|NCT00979043|No Intervention|Health lifestyle control|The healthy-lifestyle control served as the usual care comparison group. For 3 months, participants met monthly with a health educator to discuss topics such as osteoarthritis, obesity, and exercise. Regular phone contact was maintained during months 4-18.
89582570|NCT00667069|Other|A Relapse|Radiotherapy and Hormonotherapy only if relapse
89582571|NCT00667069|Experimental|B Immediate treatment|Radiotherapy and Hormonotherapy at randomization
89582572|NCT00565851|Active Comparator|Arm I (paclitaxel, docetaxel, carboplatin)|Patients receive paclitaxel IV over 3 hours or docetaxel IV over 1 hour and carboplatin over 30 minutes on day 1. Treatment repeats every 21 days.
89582573|NCT00565851|Experimental|Arm II (paclitaxel, docetaxel, carboplatin, bevacizumab)|Patients receive chemotherapy as in arm I and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days.
89582574|NCT00565851|Experimental|Arm III (gemcitabine hydrochloride, carboplatin)|Patients receive gemcitabine hydrochloride IV over 60 minutes on days 1 and 8 and carboplatin as in Arm I.
89582575|NCT00565851|Experimental|Arm IV (gemcitabine hydrochloride, bevacizumab, carboplatin)|Patients receive gemcitabine hydrochloride IV as in Arm III, bevacizumab IV and carboplatin IV as in Arm II.
89582576|NCT00305227|Experimental|Lactin-V|Vaginal capsule containing Lactobacillus crispatus in high concentration. Self-administered once daily for 5 days during the 1st week. Self-administered once weekly for 10 weeks.
89582577|NCT00305227|Placebo Comparator|Placebo|Vaginal capsule - placebo. Self-administered once daily for 5 days during the 1st week. Self-administered once weekly for 10 weeks.
89582578|NCT04601467|Experimental|AZD5718|Patients will receive once daily oral dose of AZD5718 for 12 months
89582579|NCT04601467|Placebo Comparator|Placebo|Patients will receive once daily oral dose of placebo matched to AZD5718 for 12 months
89582580|NCT01599793|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive cabozantinib PO QD. Treatment continues in the absence of disease progression or unacceptable toxicity.
89582581|NCT05209633|Experimental|Active treatment (Granules Dendrobii)|6g each, 3 times per day, total 18 weeks
89582582|NCT05209633|Placebo Comparator|Placebo|6g each, 3 times per day, total 18 weeks
89582583|NCT05652829||Children aged 9-12|We are recruiting 30 children aged 9-12 with one parent.
89582584|NCT04499677|Experimental|Favipiravir + Lopinavir/ritonavir (LPV/r)|Oral favipiravir at 1800 mg twice daily on Day 1, followed by 400 mg four (4) times daily from Day 2 to Day 7 PLUS Lopinavir/ritonavir (LPV/r) at 400mg/100 mg twice daily on Day 1, followed by 200mg/50mg four (4) times daily from Day 2 to Day 7
89582585|NCT04499677|Experimental|Favipiravir + Lopinavir/ritonavir (LPV/r) placebo|Oral favipiravir at 1800 mg twice daily on Day 1, followed by 400 mg four (4) times daily from Day 2 to Day 7 PLUS Lopinavir/ritonavir (LPV/r) matched placebo at 400mg/100mg twice daily on Day 1, followed by 200mg/50mg four (4) times daily from Day 2 to Day 7.
89582586|NCT04499677|Experimental|Favipiravir placebo + Lopinavir/ritonavir (LPV/r)|Oral favipiravir matched placebo at 1800 mg twice daily on Day 1, by 400 mg four (4) times daily from Day 2 to Day 7 PLUS Lopinavir/ritonavir (LPV/r) at 400mg/100mg twice daily on Day 1, followed by 200mg/50mg four (4) times daily from Day 2 to Day 7.
89582587|NCT04499677|Placebo Comparator|Favipiravir placebo + Lopinavir/ritonavir (LPV/r) placebo|Oral favipiravir matched placebo at 1800 mg twice daily on Day 1, by 400 mg four (4) times daily from Day 2 to Day 7 PLUS Lopinavir/ritonavir (LPV/r) matched placebo at 400mg/100mg twice daily on Day 1, followed by 200mg/50mg four (4) times daily from Day 2 to Day 7.
89582588|NCT05652751|Placebo Comparator|sham EA + placebo group|The sham EA intervention a is that the stimulator is connected to the needle handle on GV20 and GV26 without power for 40 min intervention,once a day for 4 weeks;The patients will receive 1ml volume of physiological saline (PS) injected into the gluteal muscle, once a day for 4 weeks before the sham EA intervention.
89582589|NCT05652751|Active Comparator|EA + placebo group|"Patients take supine position. After skin disinfection with 75% ethanol routine disinfection, the stainless needle will be inserted in GV20（Baihui) and the stainless needle will be inserted in GV26 (Shuigou), acupoints will be stimulated manually until patients feel soreness, distension or heaviness (the reaction of De Qi). Then, the needles are stimulated by using an acupuncture point nerve stimulator (HANS-200, Nanjing Jinsheng, Ltd., China) with a frequency of 2/100 Hz and an intensity of 3 mA for 40 min (a homemade relay cycled power to the electrode for 6 sec on and 6 sec off), 28 days as a course of treatment, once a day;The patients will receive 1ml volume of physiological saline (PS) injected into the gluteal muscle, once a day for 4 weeks before the EA intervention."
89582590|NCT05652751|Active Comparator|sham EA + NGF group|The sham EA intervention a is that the stimulator is connected to the needle handle on GV20 and GV26 without power for 40 min intervention,once a day for 4 weeks;The 20ug nerve growth factor will be obtained from Hiteck Biopharmaceutical Co., Ltd, Wuhan, China. mNGF will be dissolved in 1 ml sterile water for injection and then injected intramuscularly at gluteal muscle, once a day for 4 weeks before the sham EA intervention. Dose modification is not allowed for mNGF.
89582591|NCT05652751|Active Comparator|EA + NGF group|Patients take supine position. After skin disinfection with 75% ethanol routine disinfection, the stainless needle will be inserted in GV20（Baihui) and the stainless needle will be inserted in GV26 (Shuigou), acupoints will be stimulated manually until patients feel soreness, distension or heaviness . Then, the needles are stimulated by using an acupuncture point nerve stimulator , 28 days as a course of treatment, once a day;The 20ug nerve growth factor will be dissolved in 1 ml sterile water for injection and then injected intramuscularly at gluteal muscle, once a day for 4 weeks before the EA intervention. Dose modification is not allowed for mNGF.
89582592|NCT02909335|Active Comparator|Tacrolimus group|Tacrolimus + mycophenolate mofetil + corticosteroids
89582593|NCT02909335|Experimental|Everolimus group|Everolimus + mycophenolate mofetil + corticosteroids
89030060|NCT00516204||Patients at low risk|
89030061|NCT01242488|Experimental|CDP6038 60 mg sc every 2 weeks plus methotrexate|
89030062|NCT01242488|Experimental|CDP6038 60 mg sc every 4 weeks plus methotrexate|
89030063|NCT01242488|Experimental|CDP6038 120 mg sc every 2 weeks plus methotrexate|
89030064|NCT01242488|Experimental|CDP6038 120 mg sc every 4 weeks plus methotrexate|
89030065|NCT01242488|Experimental|CDP6038 240 mg sc every 2 weeks plus methotrexate|
89209528|NCT04038216||Test|In the test group, patients will be scheduled for bone-anchored hearing implant surgery using the single-stage procedure. The implant and abutment will be placed in one surgery.
89582594|NCT02805517|Experimental|PEAL laparoscopic nephrectomy|Patients will undergo percutaneous externally-assembled laparoscopic donor nephrectomy using 3 mm instruments.
89582595|NCT05652595|Experimental|TR Sequence|first Intervention period - subjects are administered test medecine (GP40141) and in seconde Intervention period subjects are administered reference medecine (Nplate)
89582596|NCT05652595|Experimental|RT Sequence|first Intervention period subjects are administered reference medecine (Nplate) and in seconde Intervention period subjects are administered test medecine (GP40141)
89582597|NCT04418323|Active Comparator|Video-assisted anal fistula treatment (VAAFT|Video-assisted anal fistula treatment (VAAFT) in the Management of anal fistula
89582598|NCT04418323|Active Comparator|Fistula-tract Laser Closure (filac)|Fistula-tract Laser Closure (filac)in the Management of anal fistula
89582599|NCT04418323|Active Comparator|Conventional seton|Conventional seton in the Management of anal fistula
89582600|NCT05652517|Active Comparator|Fluoroscopy-guided VOMEI|Vein of Marshall ethanol infusion guided by fluoroscopy alone
89582601|NCT05652517|Experimental|UNIVU-guided VOMEI|Vein of Marshall ethanol infusion guided by CARTO UNIVU and fluoroscopy
89582602|NCT05163847|Experimental|M2SR only dose|Intranasal M2SR vaccine and intramuscular placebo dose
89582603|NCT05163847|Experimental|M2SR with IIV dose|Intranasal M2SR vaccine and intramuscular IIV dose
89582604|NCT05163847|Active Comparator|IIV only dose|Intranasal placebo dose and intramuscular IIV dose
89582605|NCT05163847|Placebo Comparator|Placebo only dose|Intranasal placebo dose and intramuscular placebo dose
89582606|NCT04807153||Patients|Functional exercise capacity (6 minutes walk test), upper extremity exercise capacity (6 minutes Pegboard and Ring Test), respiratory functions (spirometer), respiratory muscle strength (mouth pressure measurement), peripheral muscle strength (dynamometer), respiratory muscle endurance (incremental threshold loading test), physical activity level (multi-sensor activity monitor), quality of life (European Cancer Research and Treatment Organization Quality of Life Scale (EORTC QOL C-30)), fatigue (Fatigue Severity Scale) and shortness of breath (Modified Medical Research Council (MMRC)) will be evaluated.
89582607|NCT04807153||Healthy Controls|Functional exercise capacity (6 minutes walk test), upper extremity exercise capacity (6 minutes Pegboard and Ring Test), respiratory functions (spirometer), respiratory muscle strength (mouth pressure measurement), peripheral muscle strength (dynamometer), respiratory muscle endurance (incremental threshold loading test), physical activity level (multi-sensor activity monitor), quality of life (European Cancer Research and Treatment Organization Quality of Life Scale (EORTC QOL C-30)), fatigue (Fatigue Severity Scale) and shortness of breath (Modified Medical Research Council (MMRC)) will be evaluated.
89582608|NCT04196569||trifocal intraocular lens|
89582609|NCT05652049||short-term peritoneal dialysis|the time of treatment of peritoneal dialysis less 12 months
89582610|NCT05652049||long-term peritoneal dialysis|the time of treatment of peritoneal dialysis more than 10 years
89582611|NCT04137211|Experimental|Prolonged sitting with social break|
89582612|NCT04137211|Experimental|Prolonged sitting with walk break|
89582613|NCT04137211|Experimental|Prolonged sitting with simple resistance activities|
89582614|NCT05651815|Experimental|Graphene adjuvant therapy combined with conventional therapy group (treatment group)|Graphene adjuvant therapy combined with conventional therapy group (treatment group)：Contrasted to the control groups, the treatment groups will undergo 30-min of graphene adjuvant therapy every day for 7 d.
89582615|NCT05651815|No Intervention|Conventional therapy group (control group)|Conventional therapy group (control group)：Patients will only receive the conventional treatment for COVID-19.
89582616|NCT04132219|Experimental|Immediate Intervention Group|"Dyads randomized to the Immediate Intervention Group will receive a Welcome Box at completion of the baseline assessment. The Welcome Box will include two of each of the following: 1) Letters describing the project logistics and the important roles of each dyad member); 2) WiFi-enabled Scales (with instructions to weigh daily); 3) Portion Doctor ®Tableware (with instructions to use the portion plates at least once a day); 4) Fitbit® Inspire Activity Monitors (with instructions to share data with the dyad member and the study office); and 5) Instructions on how to create a secured account on the DUET website and instructions for logging on."
89582617|NCT04132219|Other|Delayed Intervention Group|"Participants assigned to the Delayed Intervention Group will receive a Welcome Box which on the outside is identical (and also is comparably weighted with bottled water) to that given to the Immediate Intervention group. This box would include: 1) Letters describing the project logistics and the important roles of each dyad member; and 2) monthly online study newsletters on topics unrelated to diet and exercise, but still of interest to cancer survivors and dyad members such as coping with stress, reducing exposure to radiation, sun safety, etc. to enhance retention and will be offered the opportunity to receive the online intervention after completing final 6-month assessments."
89582618|NCT03998293|Other|proinsulin clearance|all participants will be studied once where somatostatin will be used to block endogenous insulin secretion
89582619|NCT05651503|Experimental|Experimental group 1: patients, age 12-18, conventional brackets, Oral probiotics lozenges|30 patients, age 12-18,with conventional brackets,will get Oral probiotics lozenges
89582620|NCT05651503|Experimental|Experimental group 2: patients, age ≥18, Invisalign™ appliances, Oral probiotics lozenges|30 patients, age ≥18, Invisalign™ appliances,wil get Oral probiotics lozenges
89582621|NCT05651503|Placebo Comparator|Control group 1: patients, age 12-18, conventional brackets, placebo lozenges|30 patients, age 12-18, conventional brackets,will get placebo lozenges
89582622|NCT05651503|Placebo Comparator|Control group 2: patients, age ≥18, Invisalign™ appliances, placebo lozenges|30 patients, age ≥18, Invisalign™ appliances,will get placebo lozenges
89582623|NCT05651425||surgeon-independent group|the coiling diameter is predicted by experienced surgeon alone.
89582624|NCT05651425||surgeon-software-assistant group|the coiling diameter is predicted by experienced surgeon with software assistant.
89582625|NCT01755598|Experimental|M72AS01 Group|Subjects, between, and including, 18 and 50 years of age, who received 2 doses of M72/AS01E according to random assignment, one month apart (Day 0 and Day 30) by intramuscular injection in the deltoid region of the arm.
89582626|NCT01755598|Placebo Comparator|Control group|Subjects, between, and including,18 and 50 years of age, who received 2 doses of Placebo according to random assignment, one month apart (Day 0 and Day 30) by intramuscular injection in the deltoid region of the arm.
89582627|NCT01606306|Experimental|Crossover sequence 1|daily fluticasone propionate, followed by daily montelukast, followed by as needed fluticasone propionate
89582628|NCT01606306|Experimental|Crossover sequence 2|daily fluticasone propionate, followed by as needed fluticasone propionate, followed by daily montelukast
89582629|NCT01606306|Experimental|Crossover sequence 3|daily montelukast, followed by as needed fluticasone propionate, followed by daily fluticasone propionate
89582630|NCT01606306|Experimental|Crossover sequence 4|daily montelukast, followed by daily fluticasone propionate, followed by as needed fluticasone propionate
89582631|NCT01606306|Experimental|Crossover sequence 5|as needed fluticasone propionate, followed by daily fluticasone propionate, followed by daily montelukast
89582632|NCT01606306|Experimental|Crossover sequence 6|as needed fluticasone propionate, followed by daily montelukast, followed by daily fluticasone propionate
89582633|NCT01754194||Procedure Type 1|Gastric Sleeve Resection
89582634|NCT01754194||Procedure Type 2|Roux-en-Y Gastric Bypass
89582635|NCT01753570|Experimental|MP-424+RBV+IFN beta, Genotype1|
89582636|NCT01753570|Experimental|RBV+IFN beta, Genotype1|
89582637|NCT01753570|Experimental|MP-424+RBV+IFN beta, Genotype2|
89582638|NCT01753336|Experimental|Dysport®|Dysport®, up to 500 units (U)/vial using 2mL dilution
89582639|NCT01777282|Active Comparator|Albiglutide + Sulfonylurea|Albiglutide in combination with background sulfonylurea
89582640|NCT01777282|Active Comparator|Albiglutide + Biguanide|Albiglutide in combination with background biguanide
89030066|NCT01242488|Experimental|CDP6038 240 mg sc every 4 weeks plus methotrexate|
89030067|NCT01242488|Active Comparator|Tocilizumab 8 mg/kg iv every 4 weeks plus methotrexate|
89030068|NCT01242488|Placebo Comparator|Placebo sc every 2 weeks plus methotrexate|
89582641|NCT01777282|Active Comparator|Albiglutide + Glinide|Albiglutide in combination with background glinide
89582642|NCT01777282|Active Comparator|Albiglutide + Thiazolidinedione|Albiglutide in combination with background thiazolidinedione
89582643|NCT01777282|Active Comparator|Albiglutide + Alpha-glucosidase inhibitor|Albiglutide in combination with background alpha-glucosidase inhibitor
89582644|NCT04169776|Experimental|Steroid Sensitive Frequently-Relapsing Nephrotic Syndrome|Individuals in this arm of the study will have to have a diagnosis of steroid sensitive frequently relapsing idiopathic nephrotic syndrome. They will receive transcutaneous auricular VNS (taVNS) performed for 5minutes every day for 6 months. The settings of the taVNS device will be individualized for each patient. Data will be collected on the the number of nephrotic syndrome relapses, the time between relapses, the time to remission once relapsed, and the level of proteinuria before and while using taVNS therapy.
89030069|NCT01242488|Placebo Comparator|Placebo sc every 4 weeks plus methotrexate|
89030070|NCT00516243|Experimental|Arm I (defined green tea catechin extract)|Patients receive defined green tea catechin extract PO BID for 6 months in the absence of disease progression or unacceptable toxicity.
89030071|NCT00516243|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID for 6 months in the absence of disease progression or unacceptable toxicity.
89030072|NCT01240889|Active Comparator|montelukast|luekotriene inhibitor
89030073|NCT01240889|Active Comparator|Fluticasone|Nasal steroid
89030074|NCT02950389|Experimental|Group A|Six bicarbonate dialysis session with PMMA dialysis filter for 2 weeks, followed by 2 weeks of 6 on-line HFR session with HFR17 dialysis filter, than 6 bicarbonate dialysis session for 2 weeks with F7 dialysis filter.
89030075|NCT02950389|Experimental|Group B|Six on-line HFR session with HFR17 dialysis filter for 2 weeks, followed by 2 weeks of 6 o bicarbonate dialysis session with PMMA dialysis filter for 2 weeks, than 6 bicarbonate dialysis session for 2 weeks with F7 dialysis filter.
89582645|NCT04169776|Experimental|Steroid Resistant Idiopathic Nephrotic Syndrome|Individuals in this arm of the study will have to have a diagnosis of steroid resistant idiopathic nephrotic syndrome. They will receive transcutaneous auricular VNS (taVNS) performed for 5minutes every day for 6 months. The settings of the taVNS device will be individualized for each patient. Data will be collected on the the number of nephrotic syndrome relapses, the time between relapses, the time to remission once relapsed, and level of proteinuria before and while using taVNS therapy.
89582646|NCT04571632|Active Comparator|Immediate treatment arm:|"On day -3, -1 and 1, SBRT fractions of 8 Gy will be administered to subjects. On day 1, approximately 2 hours after the last SBRT fraction, intratumoral injection of ipilimumab (Yervoy®, 50mg/10mL solution) at a maximum total dose of 10 mg (= 2 ml of a 50mg/10ml solution) and avelumab (Bavencio®, 200mg/10mL solution) at maximum total dose of 40 mg (= 2 ml of a 200mg/10ml solution) will be performed. Subject will also receive a standard 200mg (fixed dose) intravenous infusion of pembrolizumab (Keytruda®, 100 mg/4mL solution).~On day 2, autologous, non-substantially manipulated CD1c (BDCA-1)+ / CD141 (BDCA-3)+ myDC will be intratumorally administered. Previously cryopreserved CD1c (BDCA-1)+ / CD141 (BDCA-3)+ myDC will be thawed before administration.~On day 21 and every 21 days thereafter, IT injection of ipilimumab and avelumab and IV pembrolizumab at the same dose as on day 1 will be performed. Treatment will be discontinued upon disease progression"
89582647|NCT04571632|Active Comparator|Contemporary control arm|"On day -3, -1 and 1, SBRT fractions of 8 Gy will be administered to subjects. On day 1 and every + 21 days thereafter, subjects will receive a standard 200mg (fixed dose) IV pembrolizumab (Keytruda®, 100 mg/4mL solution) dose.~On disease progression, intratumoral administration as in the immediate-treatment arm will be conducted. Thus, intratumoral injection of ipilimumab at a maximum total dose of 10 mg and avelumab at maximum total dose of 40 mg will be performed. Administration of pembrolizumab at a dose of 200 mg will be continued.~Tumor response assessments by whole body PET/CT will be scheduled in week 12 and every 12 weeks thereafter during the treatment phase; . Baseline scan will be performed during screening period Procurement of tumor tissue by fine needle aspirates will be performed at the time of every intra-tumoral study drug administration"
89582648|NCT01975389|Experimental|bococizumab (PF-04950615)|150 mg, every 2 weeks, subcutaneous.
89582649|NCT01975389|Placebo Comparator|Placebo|Placebo comparator, every 2 weeks, subcutaneous.
89582650|NCT01974141|Experimental|Dapsone Gel|Dapsone gel applied topically to the face and to affected areas of the trunk once daily for 12 weeks.
89582651|NCT01974141|Placebo Comparator|Dapsone Gel Vehicle|Dapsone gel vehicle applied topically to the face and to affected areas of the trunk once daily for 12 weeks.
89582652|NCT01945593|Experimental|Fixed BAX855 prophylaxis|45-80 IU/kg twice weekly to once per week.
89582653|NCT01945593|Experimental|Pharmacokinetic (PK)-tailored BAX 855 prophylaxis|PK-tailored prophylactic BAX855 regimen based on participant's individual PK profile to maintain a Factor VIII (FVIII) trough level
89582654|NCT01945281|Experimental|Caspofungin|Caspofungin 2 mg/kg intravenous once daily for ≥14 days after documented negative culture and improvement of clinical signs and symptoms, for a maximum of 90 days treatment
89582655|NCT01945281|Active Comparator|Amphotericin B Deoxycholate|Amphotericin B deoxycholate 1 mg/kg intravenous once daily for ≥14 days after documented negative culture and improvement of clinical signs and symptoms, for a maximum of 90 days treatment
89582656|NCT01961349|Placebo Comparator|Group 1|Group 1 (placebo group) is treated by Anaesthesiologist
89582657|NCT01961349|Active Comparator|Group 2|Group 2 (ICI35,868 without EES0000645/A) is treated by Anaesthesiologist
89582658|NCT01961349|Active Comparator|Group 3|Group 3 (ICI35,868 with EES0000645/A) is treated by Endoscopist
89582659|NCT01973595|Experimental|Almonds then no almonds|Adults will consume 1.5 ounces of almonds or almond paste per day and children will consume 0.5 ounces of almonds or almond paste per day for 3 weeks.
89582660|NCT01973595|Other|No almonds then almonds|No almonds will be consumed by participants for 3 weeks.
89582661|NCT01944969|Experimental|Brexpiprazole|Brexpiprazole adjunct to open-label treatment with a commercially available antidepressant (ADT)
89582662|NCT01961115|Experimental|Treatment (epacadostat, MELITAC 12.1)|Patients receive epacadostat PO BID on days 1-98 and receive MELITAC 12.1 peptide vaccine ID/SC on days 21, 28, 35, 56, 77, and 98 for up to 3 additional courses in the absence of disease progression or unacceptable toxicity.
89582663|NCT04661397|Experimental|Treatment A|Participants will receive Treatment A (a single dose of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide [D/C/F/TAF] as one fixed dose combination [FDC] tablet under fed condition on Day 1) as per assigned treatment sequence (Treatment sequence ABBA or BAAB). A wash out period of at least 7 days will be maintained between each treatment period.
89582664|NCT04661397|Active Comparator|Treatment B|Participants will receive Treatment B (a single dose of Darunavir [DRV], Emtricitabine/Tenofovir Alafenamide [F/TAF] and Cobicistat [COBI] tablet under fed condition on Day 1) as per assigned treatment sequence (Treatment sequence ABBA or BAAB). A washout period of at least 7 days will be maintained between each treatment period.
89582665|NCT01973439|Other|Abacavir Once versus Twice Daily|This is a single arm study. Intervention 1: PK assessment while on Twice Daily Abacavir (Week 0) Intervention 2: PK assessment while on Once Daily Abacavir (Week 4)
89582666|NCT01973283|Experimental|Medication Treatment|Participants are treated with a flexible-dose antidepressant medication for a period of 8 weeks.
89582667|NCT01943799|Experimental|OAV Alone|Participants will continue their prebaseline OAV regimen alone from baseline to Week 48.
89582668|NCT01943799|Experimental|OAV + GS-4774 2 YU|Participants will continue their prebaseline OAV regimen from baseline to Week 48, and will receive GS-4774 2 yeast units (YU) from baseline to Week 20.
89582669|NCT01943799|Experimental|OAV + GS-4774 10 YU|Participants will continue their prebaseline OAV regimen from baseline to Week 48, and will receive GS-4774 10 YU from baseline to Week 20.
89582670|NCT01943799|Experimental|OAV + GS-4774 40 YU|Participants will continue their prebaseline OAV regimen from baseline to Week 48, and will receive GS-4774 40 YU from baseline to Week 20.
89582671|NCT01972659|Active Comparator|sugammadex and placebo|sugammadex: 4 mg/kg iv bolus at the end of the surgery at a TOF count of 1 placebo: isotonic saline (%0.9 NaCl) 50 mg/kg iv bolus plus 15 mg/kg continuous infusion until the end of surgery
89582672|NCT01972659|Experimental|sugammadex and magnesium sulphate|sugammadex: 4 mg/kg iv bolus at the end of the surgery at a TOF count of 1 magnesium: 50 mg/kg iv bolus plus continuous infusion until the end of surgery
89030076|NCT04511117|Active Comparator|Control Group|ProTaper Next rotary system and iRoot SP sealer will be used for root canal treatment, followed by composite restorations.
89582673|NCT01971723|Active Comparator|T+ Supplement|This arm requires the participants to take a prescribed dose of the T+ supplement for 4 weeks while completing an exercise regiment.
89582674|NCT01971723|Placebo Comparator|Placebo|This arm requires the participants to take a prescribed dose of a calorie matched placebo for 4 weeks while completing an exercise regiment.
89582675|NCT01942785|Experimental|Brexpiprazole|Brexpiprazole adjunct to open-label commercially available Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI) antidepressant treatment (ADT)
89582676|NCT01774786|Experimental|Pertuzumab + Trastuzumab + Chemotherapy|Participants will receive pertuzumab in combination with trastuzumab and chemotherapy (cisplatin and fluoropyrimidine [capecitabine or 5-fluorouracil]) for the first 6 treatment cycles (cycle length = 21 days). Thereafter, participants will continue to receive pertuzumab and trastuzumab until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason.
89582677|NCT01774786|Placebo Comparator|Placebo + Trastuzumab + Chemotherapy|Participants will receive placebo in combination with trastuzumab and chemotherapy (cisplatin and fluoropyrimidine [capecitabine or 5-fluorouracil]) for the first 6 treatment cycles (cycle length = 21 days). Thereafter, participants will continue to receive placebo and trastuzumab until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason.
89030077|NCT04511117|Experimental|Endocrown Group|ProTaper Next rotary system and iRoot SP sealer will be used for root canal treatment, followed by endocrown restorations.
89030078|NCT01249482||Late eradication|Group B (n=100) will be given rabeprazole 20 mg qd for 8 weeks and discontinued for 2 weeks. Then, H. pylori eradication with triple therapy will be given for one week, followed by rabeprazole 20 mg qd for 7 weeks.
89030079|NCT01249482||Negative HP|For patients with negative H. pylori infection (n=100), proton-pump inhibitor with rabeprazole 20 mg qd will be given for 8 weeks and discontinued.
89582678|NCT01960725|Active Comparator|Standard Dosing Group|Group will receive RV5 vaccine at 2, 4, and 6 months of age
89582679|NCT01960725|Experimental|Alternate Dosing Group|Group will receive RV5 vaccine at 2-5 weeks, 2 and 4 months of age
89582680|NCT04654845|Experimental|Pulpotomy|Only the tissue in the pulp chamber will be removed.
89582681|NCT04654845|Active Comparator|Pulpectomy|Both the chamber´s and root´s pulp tissue will be removed up to a 25 gauge.
89582682|NCT01942161|Experimental|Low (2 mg/day)|Subjects in the 2 mg/day group will be administered 2 mg once daily for 6 weeks (42 days).
89582683|NCT01942161|Experimental|Mid (6 - 12 mg/day)|Subjects in the 6-12 mg/day group will be administered 2 mg once daily for 2 days, followed by a maintenance dose of 6 mg for 40 days. From Day 15 onwards, the dose may be increased to 12 mg in accordance with the criteria below.
89582684|NCT01942161|Experimental|High (24 - 30 mg/day)|Subjects in the 24-30 mg/day group will be administered 2, 6, 12, 18 mg sequentially, each dose once daily for 2 days respectively, followed by a maintenance dose of 24 mg for 34 days. From Day 15 onwards, the dose may be increased to 30 mg in accordance with the criteria below.
89582685|NCT01971645|Experimental|Group D|Group D patients will receive 2 mg/kg of 0.5% ropivacaine (max. dose 100 mg) with 0.1 mg/kg preservative-free dexamethasone (max. dose 4 mg) perineurally for their femoral block. Group D will also receive a gluteal intramuscular injection of saline of volume equivalent to 0.1 mg/kg preservative-free dexamethasone (max. volume 0.4 ml).
89582686|NCT01971645|Placebo Comparator|Group R|Group R patients will receive 2 mg/kg of 0.5% ropivacaine (max. dose 100 mg) combined with a volume of saline equivalent to 0.1 mg/kg preservative-free dexamethasone (max. volume 0.4 ml) perineurally. Group R will also receive a gluteal intramuscular injection of saline of volume equivalent to 0.1 mg/kg preservative-free dexamethasone (max. volume 0.4 ml).
89582687|NCT01971645|Active Comparator|Group M|Group M patients will receive 2 mg/kg of 0.5% ropivacaine (max. dose 100 mg) combined with a volume of saline equivalent to 0.1 mg/kg preservative-free dexamethasone (max. volume 0.4 ml) perineurally. Group M will also receive a gluteal intramuscular injection of 0.1 mg/kg preservative-free dexamethasone (max. dose 4 mg).
89582688|NCT01941537|Experimental|ILV-094|Forty patients will be enrolled in the ILV-094 treatment arm. A loading IV dose of 600 mg of ILV-094 will be given at baseline (Day 0), followed by five additional IV doses of 300 mg of ILV-094 every two weeks (Weeks 2, 4, 6, 8, and 10).
89582689|NCT01941537|Placebo Comparator|Placebo comparator|Twenty patients will be enrolled in the ILV-094 placebo arm. A loading IV dose of placebo will be given at baseline (Day 0), followed by five additional IV doses of placebo every two weeks (Weeks 2, 4, 6, 8, and 10).
89582690|NCT01971567|Active Comparator|HIRREM|High-resolution, relational, resonance-based, electroencephalic mirroring (HIRREM) is a novel, noninvasive, electroencephalic-based feedback technology to facilitate relaxation and auto-calibration of neural oscillations by using auditory tones to reflect brain frequencies in near real time.
89582691|NCT01971567|Placebo Comparator|Placebo|Subjects in this arm will receive a sham-HIRREM placebo, for which the scalp sensors have no active recording capability, and for which the auditory tonal feedback is randomly generated rather than based on current brain frequencies and amplitudes.
89582692|NCT01960413|Experimental|Montelukast added to Hydroxyurea|Oral montelukast therapy taken daily for eight weeks with current hydroxyurea regiment
89582693|NCT01960413|Placebo Comparator|Placebo added to Hydroxyurea|Oral placebo taken daily for eight weeks with current hydroxyurea regiment
89582694|NCT04661241|Experimental|Investigational Scan|The proposed sequence (<15 minutes) will be added as a supplementary sequence only for the preoperative imaging if subjects agree to participate.
89582695|NCT04661241|Active Comparator|Current Clinical Practice|All patients will undergo a routine clinical preoperative MRI of the brain under general anesthesia to reduce movement artifacts.
89582696|NCT01970475|Experimental|ABP 501|Participants received ABP 501 40 mg subcutaneously on day 1 and every 2 weeks thereafter until week 22.
89582697|NCT01970475|Active Comparator|Adalimumab|Participants received adalimumab 40 mg subcutaneously on day 1 and every 2 weeks thereafter until week 22.
89582698|NCT04653753|Experimental|Orthosis Group|Use of kneeSOFT500 device
89030080|NCT01249482||Early eradication|Group A (n=100) will be given initial H. pylori eradication with triple therapy for one week, followed by proton-pump inhibitor with rabeprazole 20 mg qd for 7 weeks.
89582699|NCT04653753|No Intervention|Control Group|No use of the device
89582700|NCT01939977|Experimental|Paricalcitol|Paricalcitol oral capsules.
89582701|NCT01939977|Active Comparator|Calcifediol|Calcifediol oral drops.
89582702|NCT01939899|Experimental|IXAZOMIB|Ixazomib 4, 5.3 and 7 milligram (mg), orally, once on Days 1, 8 and 15 in a 28 day treatment cycle followed by a rest period of 13 days, for up to Cycle 29 or until disease progression or unacceptable toxicity at lead-in phase for participants with NHL. After completion of lead-in phase, participants will continue into Phase 2. Participants in Phase 2 will receive Ixazomib at RP2D dose, orally, once weekly on Days 1, 8 and 15 in a 28 day treatment cycle followed by a rest period of 13 days , for up to Cycle 29 or until disease progression or unacceptable toxicity in Phase 2 for participants with RRFL.
89582703|NCT01970397|Experimental|JUVEDERM® Ultra XC|Perioral lines treated with JUVEDERM® Ultra XC
89582704|NCT01970397|Experimental|Belotero Balance®|Perioral Lines treated with Belotero Balance®
89582705|NCT01970241|Experimental|NPH with steroid dose|"Receive NPH with each corticosteroid dose during the study duration (2-5 days).~Low dose corticosteroids High dose corticosteroids Eating and 6a-8p 0.15 units NPH/kg 0.3 units NPH/kg NPO(nothing by mouth) or 8p-6a 0.1 units NPH/kg 0.2 units NPH/kg"
89582706|NCT01970241|Active Comparator|Control - Background and correction insulin|Receive usual care with background insulin and correction factor for duration of study (2-5 days)
89582707|NCT01939353|Experimental|Centanafadine SR 100-500 mg|Following a 1-week SB placebo run-in treatment, participants with <30% improvement and ≥28 total score on Adult ADHD-RS-IV scale score received centanafadine (CTN) 100 mg, sustained release (SR) tablet, once daily (1 tablet in the morning) on Days 1 and 2, followed by 200 mg, SR tablets, twice daily (1 tablet in the morning and 1 tablet 5 hours later) on Days 3 and 4, followed by 300 mg, SR tablets, twice daily (2 tablets in the morning and 1 tablet 5 hours later) on Days 5, 6, and 7. After 1 week of treatment, CTN doses were maintained or titrated in 100-mg increments up to the maximum of 500 mg daily or reduced based on the safety and tolerability, as judged by the investigator at Weeks 2, 3 and 4.
89582708|NCT01970007|Experimental|Zilver Vena Venous Self-Expanding Stent|
89582709|NCT01728376|Experimental|Daptomycin - 12 to 17 year olds|Participants ages 12-17 years old were administered daptomycin 7 mg/kg infused once daily, intravenously (IV), over 30 minutes; therapy duration (uncomplicated bacteremia) = 5-28 days, therapy duration (complicated bacteremia) = 7-42 days. After conclusion of IV therapy, can continue on oral therapy (not daptomycin, but at discretion of investigator).
89582710|NCT01728376|Active Comparator|Comparator - 12 to 17 year olds|Participants ages 12-17 years old received IV vancomycin or semi-synthetic penicillin or first-generation cephalosporins or clindamycin, given as per local guidelines or site-specific prescribing information; therapy duration (uncomplicated bacteremia) = 5-28 days, therapy duration (complicated bacteremia) = 7-42 days. IV comparator and subsequent oral therapy were at the discretion of the investigator.
89582711|NCT01728376|Experimental|Daptomycin - 7 to 11 year olds|Participants ages 7 to 11 years old were administered daptomycin 9 mg/kg, infused once daily, IV over 30 minutes; therapy duration (uncomplicated bacteremia) = 5-28 days, therapy duration (complicated bacteremia) = 7-28 days. After conclusion of IV therapy, can continue on oral therapy (not daptomycin, but at discretion of investigator).
89582712|NCT01728376|Experimental|Daptomycin - 1 to 6 year olds|Participants ages 1 to 6 years old were administered daptomycin 12 mg/kg, infused once daily, IV over 60 minutes; therapy duration (uncomplicated bacteremia) = 5-28 days, therapy duration (complicated bacteremia) = 7-28 days. After conclusion of IV therapy, can continue on oral therapy (not daptomycin, but at discretion of investigator).
89582713|NCT01728376|Active Comparator|Comparator - 7 to 11 year olds|Participants ages 7-11 years old received IV vancomycin, or semi-synthetic penicillin, or first-generation cephalosporins, clindamycin; given as per local guidelines or site-specific prescribing information; therapy duration (uncomplicated bacteremia) = 5-28 days, therapy duration (complicated bacteremia) = 7-28 days. IV comparator and subsequent oral therapy were at the discretion of the investigator.
89582714|NCT01728376|Active Comparator|Comparator - 1 to 6 year olds|Participants ages 1-6 years old received IV vancomycin, or semi-synthetic penicillin, or first-generation cephalosporins, clindamycin; given as per local guidelines or site-specific prescribing information; therapy duration (uncomplicated bacteremia) = 5-28 days, therapy duration (complicated bacteremia) = 7-28 days. IV comparator and subsequent oral therapy were at the discretion of the investigator.
89582715|NCT01708174|Experimental|Sonidegib (LDE225)|600 mg orally for adults and 500 mg/m2 orally for children
88974414|NCT03656146|Active Comparator|Verbal Screening|Food insecurity screening conducted via verbal face-to-face interview
88974415|NCT03620747|Experimental|Dupilumab|Participants received subcutaneous (SC) dose of dupilumab 300 milligrams (mg) every 2 weeks (q2w) from Week 0 up to Week 132. Participants who discontinued treatment for greater than or equal to (>=) 6 weeks after study LTS12551 (NCT02134028), received a 600 mg loading dose of dupilumab on Week 0. Participants were also on background dose of medium or high dose inhaled corticosteroid (ICS) as maintained in study LTS12551 in combination with controllers (and/or oral corticosteroid [OCS] for those participants from the original parent study EFC13691 [NCT02528214]). Salbutamol/albuterol hydrofluoroalkane pressurized metered dose inhalers (MDI) or levosalbutamol/levalbuterol hydrofluoroalkane pressurized MDI were given as reliever medication as needed during the study.
88974416|NCT03613844|Experimental|DHA|oral DHA supplementation at 2 grams per day
88974417|NCT03613844|Placebo Comparator|Placebo|Placebo for DHA
88974418|NCT03599739||Follow-On Cohort|We will survey 823 nursing facilities who participated in the aTIV Influenza Vaccination and Morbitiy and Mortality in U.S. Nursing Homes study in 2016-2017. We anticipate a 70% response rate from this sample for participation.
88974419|NCT03599739||Parallel Cohort|We will survey an additional 1000 facilities (i.e., facilities not participating in the original 2016-2017 study, but meeting the same entry criteria, except prior use of high dose vaccine will be allowed) in order to capture a cohort that used a wide range of self-selected vaccine choices. We anticipate a 50% response rate from this sample.
88974420|NCT03589729|Experimental|Supportive care (dexrazoxane hydrochloride, chemotherapy)|See detailed description.
88974421|NCT03585686|Experimental|vemurafenib|vemurafenib, Cytarabine, 2-chlorodeoxyadenosine
88974422|NCT03569124||Training group|
88974423|NCT03569124||Non-Training group|
88974424|NCT03543787|Active Comparator|Health IT and Peer Support Intervention|Utilise electronic decision support, tracking of referral list and Peer facilitation for referral completion
88974425|NCT03543787|No Intervention|Non intervention group|2014 - 2018 MoH referral protocol
88974426|NCT03503305|Experimental|Adipose Derived Regenerative Cell group|Subjects in the treated group will receive an Adipose derived regenerative cells (ADRCs) injection into the wrist using a fluoroscopic-guided injection .
88974427|NCT03503305|Active Comparator|Corticosteroid group|Subjects in the active control group will receive a corticosteroid injection into the wrist using a fluoroscopic-guided injection.
88974428|NCT03497663|Experimental|VIA Family intervention|VIA Family is a family based intervention. A multidisciplinary team of specialists from adult mental health services, child and adolescent mental health services and social services will be responsible for providing the basic treatment elements that are: case management and regular contact with the case manager, psychoeducation for the whole family, parental training (Triple P) and early intervention for mental problems of the child.
88974429|NCT03497663|Active Comparator|Treatment as Usual (TAU)|TAU is defined as any kind of help and support focusing on high risk children and parental mental illness. At present, the municipalities and the mental health services do not offer any kind of family focused intervention addressing parental mental illness that can be compared to the VIA Family program.
89582716|NCT01708174|Active Comparator|Temozolamide (TMZ)|150 to 200 mg/m2 for 5 sequential days every 4 weeks according to prescribing information until the study was amended to a single arm study.
89582717|NCT01605916|Experimental|Selumetinib (AZD6244) 25 mg|monotherapy
89582718|NCT01605916|Experimental|Selumetinib (AZD6244) 50 mg|monotherapy
89582719|NCT01605916|Experimental|Selumetinib (AZD6244) 75 mg|monotherapy
89582720|NCT01605916|Experimental|Selumetinib (AZD6244) 75 mg + Doce|Combination
89582721|NCT01605916|Experimental|Selumetinib (AZD6244) 25 mg + Doce|combination
89582722|NCT02416609|Experimental|Gem-based doublets with LDR & sequential SBRT|Four Gem-based doublets cycles will be administered concurrent with LDR. If no progression, three fractions of SBRT will be administered.
89582723|NCT02321137|Active Comparator|BioAVR with surgical closure of LAA|Aortic valve replacement with bioprosthesis according to indications in the current guidelines for the management of valvular heart disease including surgical closure of left atrial appendage
89582724|NCT02321137|Placebo Comparator|BioAVR alone|Aortic valve replacement with bioprosthesis according to indications in the current guidelines for the management of valvular heart disease.
89582725|NCT02217709|Experimental|Treatment (phenelzine sulfate)|Patients receive phenelzine sulfate 30 mg by mouth (PO) twice daily (BID) (starting dose of 15 mg daily escalated to 30 mg BID over 16 plus or minus 5 days). Patients who have been treated at 30 mg BID for over 3 cycles with resolution of any and all toxicities to grade < or = 1 may increase the dose to a maximum of 45 mg BID at the discretion of the treating investigator. Treatment may continue in the absence of disease progression or unacceptable toxicity.
89582726|NCT05651347|Placebo Comparator|Placebo|Visually identical placebo tablets containing no active ingredient to the active treatment, administered three times a day.
89582727|NCT05651347|Active Comparator|Melatonin|10mg Melatonin tablets, administered three times a day (a total daily dose of 30mg per day)
89582728|NCT05651269|Experimental|Milciclib plus gemcitabine|"Name: milciclib Dose: 150 mg/day Mode of administration: oral~Combination product:~Name: gemcitabine Dose: 1000 mg/m2 Mode of administration: intravenous"
89582729|NCT05647525||status epilepticus with autoimmune encephalitis; status epilepticus without autoimmune encephalitis|To study the relationship between autoimmune-related antibody titres and prognosis during the six-month follow-up
89582730|NCT04791163|Experimental|Sub-ischial socket|Start using the sub-ischial socket for four weeks and be tested with this socket.
89582731|NCT04791163|Active Comparator|Ischial containment socket|Start using the ischial containment socket for four weeks and be tested with this socket.
89582732|NCT05638009|No Intervention|Control|regular salt (99% sodium chloride)
89582733|NCT05638009|Experimental|Salt substitute 1|Salt substitute 1 is a potassium-enriched salt substitute composed of 66% potassium chloride and 33% sodium chloride
89582734|NCT05638009|Experimental|Salt substitute 2|Salt substitute 2 is a potassium-enriched salt substitute composed of 33% potassium chloride and 66% sodium chloride
89582735|NCT05636683|Experimental|Periodontitis treated with Root surface debridement|Immediately after inclusion in the study, the patient's examination with saliva sampling will be conducted as follows: At a base line visit (Zero time visit), subjects will be examined for clinical periodontal parameters, their saliva samples will be collected, and then receiving full scaling using ultrasonic device, and oral hygiene instructions and motivation. After one week, the same clinical parameters, saliva sampling will be taken, and received full root surface debridement (RSD) using curette hand instruments (Gracey, USA) (First visit). One month and three months after first visit, the same clinical measurements, saliva will characterize as second and third visits, respectively.
89582736|NCT01635283|Experimental|Treatment (tumor lysate-pulsed autologous dendritic cells)|Patients receive autologous glioma tumor lysate-pulsed autologous dendritic cell vaccine ID on days 0, 14, and 28.
89582737|NCT01707004|Experimental|Treatment (donor bone marrow transplant)|"Beginning between days -29 and -22, patients receive decitabine IV over 1 hour daily for 10 days, fludarabine phosphate IV over 30 minutes on days -5 to -2, and busulfan IV over 3 hours on days -5 to -2.~PREPARATIVE REGIMEN: Patients undergo total-body irradiation BID on day -1.~TRANSPLANT: Patients undergo allogeneic bone marrow transplant on day 0.~GVHD PROPHYLAXIS: Patients receive cyclophosphamide IV over 2 hours on days 3 and 4, tacrolimus PO BID or IV continuously on days 5-180, mycophenolate mofetil PO TID on days 5-35, and filgrastim SC beginning day 5 until ANC >= 1,000/mm^3 for 3 consecutive days."
89582738|NCT01939197|Experimental|ARM A|ABT-450/r/ABT-267 and ABT-333 coadministered with ribavirin (RBV) for 12 weeks for participants receiving atazanavir once-daily or raltegravir twice-daily
88974430|NCT03479307|Experimental|Bilastine Ophthalmic Solution 0.6%|"Bilastine Ophthalmic Solution 0.6%~1 drop in each eye at 2 separate times during an 8 day period."
88974431|NCT03479307|Active Comparator|Ketotifen Ophthalmic Solution 0.025% (Zaditen)|"Ketotifen Ophthalmic Solution 0.025% (Zaditen)~1 drop in each eye at 2 separate times during an 8 day period."
88974432|NCT03479307|Placebo Comparator|Vehicle of Bilastine Ophthalmic Solution|"Vehicle of Bilastine Ophthalmic Solution~1 drop in each eye at 2 separate times during an 8 day period."
88974433|NCT03390933|Experimental|Fluoxetine Group|Approximately 96 patients will be enrolled into the intervention (Phase II) over the duration of the entire study.
88974434|NCT03387787|Experimental|GlucoTab Treatment Arm|Recruited patients will be treated with insulin degludec and insulin aspart. insulin doses will be calculated by the GlucoTab system
88974435|NCT03368677||Teriflunomide group|20 MS patients who are using teriflunomide medication under the supervision of their treating neurologist.
88974436|NCT03368677||No disease modifying treatment|10 MS-patients who do not use any regular disease modifying MS treatment of their own volition
88974437|NCT03364036|Experimental|Mavenclad®|
88974438|NCT03354611|Experimental|Diagnostic Workup|The subjects will first have a pre-contrast CBBCT scan. Iodinated contrast will be injected intravenously, and then another CBBCT scans will be performed to capture the tumor vasculature enhancement.
88974439|NCT03315897|Active Comparator|Erythropoietin|12 intravenous infusions of recombinant human erythropoietin (EPO)
88974440|NCT03315897|Placebo Comparator|Saline|12 intravenous infusions of saline (1 ml NaCl)
89209529|NCT04038216||Control|Historical control group, these patients already underwent BAHI insertion using two-stage surgery. The implant and abutment were inserted in two different procedures.
89582739|NCT01939197|Experimental|ARM B|ABT-450/r/ABT-267 and ABT-333 coadministered with RBV for 24 weeks for participants receiving atazanavir once-daily or raltegravir twice-daily
89582740|NCT01939197|Experimental|ARM C|ABT-450/r/ABT-267 and ABT-333 coadministered with RBV for 12 weeks for participants receiving darunavir once-daily
89582741|NCT01939197|Experimental|ARM D|ABT-450/r/ABT-267 and ABT-333 coadministered with RBV for 12 weeks for participants receiving darunavir twice-daily
89582742|NCT01939197|Experimental|ARM E|ABT-450/r/ABT-267 and ABT-333 for 12 weeks for noncirrhotic (at screening) GT1b-infected participants receiving any of the following: atazanavir once-daily, raltegravir twice-daily
89582743|NCT01939197|Experimental|ARM F|ABT-450/r/ABT-267 and ABT-333 for 12 weeks for cirrhotic (at screening) GT1b-infected sofosbuvir-naive participants receiving any of the following: atazanavir once-daily, raltegravir twice-daily
89582744|NCT01939197|Experimental|ARM G|ABT-450/r/ABT-267 and ABT-333 coadministered with RBV for 12 weeks for cirrhotic (at screening) GT1b-infected sofosbuvir-naive participants receiving any of the following: atazanavir once-daily, raltegravir twice-daily
89582745|NCT01939197|Experimental|ARM H|ABT-450/r/ABT-267 and ABT-333 coadministered with RBV for 12 weeks for cirrhotic (at screening) GT1b-infected sofosbuvir-experienced participants receiving any of the following: atazanavir once-daily, raltegravir twice-daily
89582746|NCT01939197|Experimental|ARM I|ABT-450/r/ABT-267 and ABT-333 coadministered with RBV for 12 weeks for noncirrhotic (at screening) GT1a-infected participants receiving any of the following: atazanavir once-daily, raltegravir twice-daily
89582747|NCT01939197|Experimental|ARM J|ABT-450/r/ABT-267 and ABT-333 coadministered with RBV for 24 weeks for cirrhotic (at screening) GT1a-infected participants receiving any of the following: atazanavir once-daily, raltegravir twice-daily
89582748|NCT01939197|Experimental|ARM K|ABT-450/r/ABT-267 coadministered with RBV for 12 weeks for participants receiving any of the following: atazanavir once-daily, raltegravir twice-daily, dolutegravir once-daily or twice-daily, darunavir once-daily
89582749|NCT01939197|Experimental|ARM L|ABT-450/r/ABT-267 coadministered with RBV for 24 weeks for participants receiving any of the following: atazanavir once-daily, raltegravir twice-daily, dolutegravir once-daily or twice-daily, darunavir once-daily
89582750|NCT05182645|Experimental|lifestyle-modification|Once a week for 10 weeks with a circumference of 60 hours with mindfulness-based stress reduction and further process of the Mind / body medicine.
89582751|NCT05182645|Active Comparator|waiting control group|A unique education unit within the scope of 3 hours on the influence of lifestyle factors on the disease and self-help materials for the independent training. After the follow-up measurement opportunity to participate in the program.
89582752|NCT01969851|Experimental|Lacosamide|
89582753|NCT04661085||Patients with a suspected infection|Acutely admitted patients from the emergency department across 3 sites who have a suspected infection.
89582754|NCT04659759||COVID-19 Positive|Patients diagnosed with COVID-19 during pregnancy or while breastfeeding
89582755|NCT04659759||COVID-19 vaccine|Patients who receive COVID-19 vaccine during pregnancy or while breastfeeding
89582756|NCT04659759||Controls|Reproductive age women exposed to COVID-19 vaccine
89582757|NCT04659759||Pregnant Control|Pregnant women who delivered at TJUH, COVID negative
89582758|NCT01938573|Experimental|Sirolimus, cisplatin, gemcitabine|Sirolimus day -2, cisplatin 70 mg/m2 IV Day 1 and gemcitabine hydrochloride 1000 mg/m2 IV days 1 and 8 every 21 days for 4 cycles followed by cystectomy (surgery)
89582759|NCT05496907|Experimental|Intervention|"After the participants consent, they will be asked to complete 7 validated questionnaires. An interview will also take place to determine severity of psychiatric symptoms using the Brief Psychiatric Rating Scale. A physical assessment will be conducted including Blood pressure, BMI and Blood Tests for HbA1c, Glucose test, Total Cholesterol, Renal Function.~Participants in the intervention arm will see the diabetes nurse up to 10 times, during these sessions motivational interviewing will be used to discuss areas to improve, goal setting and action planning. Participants and the nurse will collaboratively discuss practical strategies to improve their HbA1c, blood pressure, cholesterol, BMI and mental health.~The same measures that were completed at the beginning will be re-assessed again at 6 months."
89582760|NCT05496907|No Intervention|Control|Participants will be asked to complete the same 7 validated questionnaires, the brief psychiatric rating scale and a physical health assessment at the start. The will continue to receive standard care from their usual care professionals. The same measures that were completed at the beginning will be re-assessed again at 6 months.
89582761|NCT04777513||Standard of care: FFR, ICA, CCTA|Patients with medical history for ischaemic heart disease will take part in non-invasive determination of haemodynamic parameters in coronary arteries with Cardiolens FFR-CT Pro technology.
89582762|NCT05169931|Experimental|Study group|Treatment group to receive study drops (RegenerEyes) twice daily for 12 weeks
89582763|NCT04788901|Experimental|Online therapeutic game|Participants in this group will have access to the evaluation module of the REThink game.
89582764|NCT01937871|Placebo Comparator|Placebo|Placebo matching tadalafil or tamsulosin administered once daily by mouth for 16 weeks.
88974441|NCT03299660|Experimental|Avelumab|Long course chemoradiotherapy (LCCRT) comprised of 50.4 Gy radiotherapy in conjunction with 5FU (225mg/m2/day continuous infusion)/Capecitabine (825 mg/m2 BID on RT days) over 5. 5 weeks, followed by 4 cycles of Avelumab. This is then followed up with surgical resection
89209530|NCT02541396|Placebo Comparator|Group A|"Placebo wafers given every 2 hours Placebo capsule given every 4 hours Placebo wafers top-up dose given at hour 1"
89209531|NCT02541396|Active Comparator|Group B|"Placebo wafers given every 2 hours Oxycodone given every 4 hours Placebo wafers top-up dose given at hour 1"
89209532|NCT02541396|Experimental|Group C|"Wafermine™ 35 mg wafer + placebo wafer given every 2 hours Placebo capsule given every 4 hours Wafermine™ 35 mg wafer + placebo wafer top-up dose at hour 1"
89209533|NCT02541396|Experimental|Group D|"Wafermine™ 35 mg wafer + placebo wafer given every 2 hours Oxycodone 5 mg capsule every 4 hours Wafermine™ 35 mg wafer + placebo wafer top-up dose at hour 1"
89582765|NCT01937871|Experimental|5 mg Tadalafil|"Placebo administered once daily by mouth for 4 weeks during the single-blind placebo run-in period.~Tadalafil 5 milligram (mg) tablet administered once daily by mouth for 12 weeks during the double-blind treatment period"
89582766|NCT01937871|Other|0.2 mg Tamsulosin|"Placebo administered once daily by mouth for 4 weeks during the single-blind placebo run-in period.~Tamsulosin 0.2 mg capsule administered once daily by mouth for 12 weeks during the double-blind treatment period"
89582767|NCT04775875|Experimental|Active|Patients will undergo ten to thirty minutes of transcranial ultrasound treatment. The sonification device will be aimed at the caudate. Targeting will include reference to scalp fiducials based on the obtained MRI; confirmation of target accuracy will either be obtained by Doppler waveform confirmation or optical tracking technology which co-registers patient neuroimaging with real space.
89582768|NCT01632631||PROcedure rehearsal|PROcedure rehearsal performed before real EVAR procedure No intervention
89582769|NCT01632631||No PROcedure rehearsal|no PROcedure rehearsal performed before real EVAR procedure No intervention
89582770|NCT01341535|Experimental|adaptive DPBN|"This patient group will be treated by adaptive dose-painting-by-numbers, while patients in the control arm will receive standard treatment.~Patients will have a 50 % chance of being allocated to the experimental arm and a 50 % chance of being allocated to the control arm."
89582771|NCT01341535|Active Comparator|standard IMRT|"This patient group will be treated by standard intensity-modulated radiotherapy (IMRT), while patients in the experimental arm will receive adaptive dose-painting-by-numbers.~Patients will have a 50 % chance of being allocated to the experimental arm and a 50 % chance of being allocated to the control arm."
89582772|NCT04775407||Screening|Serological SARS-CoV-2 test
89582773|NCT05380063|Active Comparator|Dual Antiplatelet Therapy (DAPT)|DAPT with ticagrelor (90mg twice daily) + aspirin (100 mg once daily) for 1 year after CABG.
89582774|NCT05380063|Experimental|De-escalated Dual Antiplatelet Therapy (De-DAPT)|De-DAPT referred to ticagrelor (90mg twice daily) + aspirin (100 mg once daily) during first 3 months post CABG, then switch to aspirin (100 mg once daily) + placebo (twice daily) for 9 months.
89582775|NCT01287091|Experimental|Part 1|
89582776|NCT01287091|Experimental|Part 2|
89582777|NCT01287091|Experimental|Part 3: Group A|
89582778|NCT01287091|Experimental|Part 3: Group B|
89582779|NCT01269463|Experimental|Open Label Phase Then 2-week Double Blind Phase (Placebo First, Then Methylphenidate HCl ER Capsule)|"Open Label Phase: Subjects were dose optimized over a 2 to 4 week period. All subjects began at an initial Methylphenidate hydrochloride extended release capsules dose of 15 mg and were titrated weekly to an optimal dose using strengths of 15, 20, 30, up to the maximum of 40 mg/day.~Double Blind Phase (2-weeks):~Placebo: Capsule without active drug for 1 week Methylphenidate HCl ER Capsule: An optimized dose of Methylphenidate hydrochloride extended release capsules (15, 20, 30, or 40 mg) for 1 week Dosed once daily in the morning"
89582780|NCT01269463|Experimental|Open Label Phase Then 2-week Double Blind Phase (Methylphenidate HCl ER Capsule First, Then Placebo)|"Open Label Phase: Subjects were dose optimized over a 2 to 4 week period. All subjects began at an initial Methylphenidate hydrochloride extended release capsules dose of 15 mg and were titrated weekly to an optimal dose using strengths of 15, 20, 30, up to the maximum of 40 mg/day.~Double Blind Phase (2-weeks):~Methylphenidate HCl ER Capsule: An optimized dose of Methylphenidate hydrochloride extended release capsules (15, 20, 30, or 40 mg) for 1 week Placebo: Capsule without active drug for 1 week Dosed once daily in the morning"
89582781|NCT05362825||Un-resectable synchronous liver limited metastasis colorectal cancer|Un-resectable synchronous liver limited metastasis colorectal cancer patients undergoing neo-adjuvant chemotherapy FOLFOXIRI regimen, up to 12 cycles.
89582782|NCT02539459|Experimental|Treatment (everolimus)|Patients will take 10 mg (1 tablet) of everolimus each day for 4 months
89582783|NCT01706926|Placebo Comparator|Placebo|Placebo matched to mavrilimumab (CAM-3001) injection subcutaneously every 2 weeks for 24 weeks in combination with stable dose of methotrexate (7.5 to 25 milligram [mg] per week) through oral or parenteral route.
88974442|NCT03231969|Experimental|Bilastine 0.2%|"Bilastine Ophthalmic solution 0.2%~1 drop in each eye at 3 separate times during a 25 day period."
88974443|NCT03231969|Experimental|Bilastine 0.4%|"Bilastine Ophthalmic solution 0.4%~1 drop in each eye at 3 separate times during a 25 day period."
88974444|NCT03231969|Experimental|Bilastine 0.6%|"Bilastine Ophthalmic solution 0.6%~1 drop in each eye at 3 separate times during a 25 day period."
88974445|NCT03231969|Placebo Comparator|Bilastine 0%|"Vehicle of Bilastine Ophthalmic Solution~1 drop in each eye at 3 separate times during a 25 day period."
88974446|NCT03174522|Experimental|REX-001|REX-001 is a cell suspension of autologous bone marrow mononuclear cells (BM-MNCs) composed of several mature cell types.
89582784|NCT01706926|Experimental|Mavrilimumab 30 mg|Mavrilimumab (CAM-3001) 30 mg injection subcutaneously every 2 weeks for 24 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) through oral or parenteral route.
89582785|NCT01706926|Experimental|Mavrilimumab 100 mg|Mavrilimumab (CAM-3001) 100 mg injection subcutaneously every 2 weeks for 24 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) through oral or parenteral route.
89582786|NCT01706926|Experimental|Mavrilimumab 150 mg|Mavrilimumab (CAM-3001) 150 mg injection subcutaneously every 2 weeks for 24 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) through oral or parenteral route.
89582787|NCT01634113|Experimental|tiotropium low dose|Once daily, delivered with Respimat® inhaler
88974447|NCT03174522|Placebo Comparator|Placebo|The final formulation of the placebo will be a diluted suspension of red blood cells.
88974448|NCT04118023||7T MRI Group|Patient group that receives 7 Tesla Magnetic Resonance Imaging
88974449|NCT03140358|Active Comparator|Premyopia atropine|On Atropine 0.01%
88974450|NCT03140358|Placebo Comparator|Premyopia placebo|On placebo
88974451|NCT03140358|Active Comparator|Low myopia atropine|On Atropine 0.01% daily or every other day
88974452|NCT03140358|Placebo Comparator|Low myopia placebo|On placebo
88974453|NCT03122470|Experimental|MRI guided biopsy + TRUS biopsy|Patients will undergo an MRI guided biopsy and standard trans-rectal ultrasonography-guided (TRUS) biopsy. Results will be compared to see which can more accurately diagnose and manage prostate cancer
88974454|NCT03101982|Active Comparator|test|HBO, ASIA score, blood taking
88974455|NCT03101982|No Intervention|control|ASIA score, blood taking
89582788|NCT01634113|Experimental|tiotropium high dose|Once daily, delivered with Respimat® inhaler
89582789|NCT01634113|Placebo Comparator|placebo|Once daily, delivered with Respimat® inhaler
89582790|NCT01706770|Experimental|enfilcon A|The test (experimental) lens is a silicone hydrogel contact lens following a daily wear 1 week planned replacement modality.
89582791|NCT01706770|Active Comparator|galyfilcon A|The control (active comparator) lens is a silicone hydrogel contact lens following a daily wear 1 week planned replacement modality.
89582792|NCT01016899||Non-melanoma skin cancer|Early stage squamous or basal cell carcinoma
89582793|NCT04497454|Active Comparator|ARDSNet|ARDSNet protocol (low PEEP-FiO2 table). Ventilatory mode: volume-controlled ventilation Tidal volume (VT) will be adjusted to 4-6 mL/Kg of PBW and Plateau pressure < 30 cmH2O for the at least the first 12 hours after inclusion in the protocol pH should be maintained between 7.35-7.45 Oxygenation (SpO2) target ranges 90-95% Maximum respiratory rate = 35 breaths/min PEEP and FIO2 adjusted according to the low PEEP-FiO2 Table.
89582794|NCT04497454|Experimental|EIT-Group|The goal is to maintain driving pressure (DP) < 16 cmH2O. Ventilatory mode: pressure-controlled ventilation After a recruitment a maneuver, PEEP will be chosen according to a PEEP titration maneuver monitored with electrical impedance tomography Plateau pressure may exceed 30 cmH2O and VT may exceed 6 mL/Kg if DP < 16 cmH2O pH should be maintained between 7.15-7.40 Oxygenation (SpO2) target ranges 90 -95% Maximum respiratory rate = 50 bpm
89582795|NCT01937715|Experimental|Arm A|PF-05212384 plus FOLFIRI
89582796|NCT01937715|Active Comparator|Arm B|Bevacizumab plus FOLFIRI
89582797|NCT01937559|Experimental|Topical Tranexamic acid (TXA)|Tranexamic acid (TXA) applied topically
89582798|NCT01937559|Placebo Comparator|Saline|Normal saline
89582799|NCT01937559|Active Comparator|Tranexamic acid (TXA)|Tranexamic acid (TXA) administered intravenously
89582800|NCT04634331|Active Comparator|Traditional Multi-Modal Training|A physical therapist will provide 1:1 multi-modal training. Multi-modal training is the simultaneous performance of a motor and a cognitive task (i.e. marching while answering math questions)
89582801|NCT04634331|Experimental|Augmented Reality Multi-Modal Training|Multi-modal training will be administered via the Microsoft HoloLens 2 augmented reality head set. Augmented reality allows user to see the real world, and inserts holograms into the environment. For example, the user could see boxes on the ground that they need to step around when walking. The boxes are not real, but rather a hologram that only the user can see. The augmented reality device will instruct the participant on the motor and cognitive task that should be performed simultaneously in a similar manner to the physical therapist in the traditional multi-modal training group. The intervention will be overseen by a physical therapist.
89582802|NCT01960257|Experimental|DHFS with IS-RM|Digital Health Feedback System (DHFS) Rifamate (combination of isoniazid 150 mg and rifampin 300 mg) over-encapsulated with ingestion sensor - 2 capsules orally daily (QD) administered orally preferably on an empty stomach first thing in the morning for 10-16 weeks, depending on time left to complete TB treatment.
89582803|NCT01960257|Active Comparator|SOC DOT|Isoniazid 300 mg -1 tablet orally QD plus rifampin 300 mg - 2 capsules orally QD, OR Rifamate (combination of isoniazid 150 mg and rifampin 300 mg) - 2 capsules orally QD preferably on an empty stomach first thing in the morning for 10-16 weeks, depending on time left to complete TB treatment.
89582804|NCT01918371||Patients with RVO|Patients with retinal vein occlusion (RVO) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.
89582805|NCT01918371||Patients with DME|Patients with diabetic macular edema (DME) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.
89582806|NCT01917747|Active Comparator|Standard scheduling and follow-up|The subjects will have access to discuss any questions or concerns with our office or audiology staff, as is the standard of care practice. They will not be contacted by study personnel or the patient navigator after discharge from the hospital and before the initial diagnostic test or before and after any subsequent auditory brainstem response test. The patients may contact and be contacted by our clinic staff regarding scheduling or rescheduling of the hearing test and any other follow up, as is standard practice.
89209534|NCT02541396|Experimental|Group E|"Wafermine™ 35 mg + placebo wafer given every 4 hours Placebo wafers given every 2 hours Placebo capsule given every 4 hours Wafermine™ 35 mg wafer + placebo wafer top-up dose at hour 1"
89209535|NCT02541396|Experimental|Group F|"Wafermine™ 35 mg + placebo wafer given every 4 hours Placebo wafers given every 2 hours Oxycodone 5 mg given every 4 hours Wafermine™ 35 mg wafer + placebo wafer top-up dose at hour 1"
88974458|NCT02974075|Experimental|Salvage lymph node dissection|Patients will undergo extended pelvic salvage lymph node dissection
88974459|NCT02971358|Experimental|Radical prostatectomy arm|In this arm the investigators will include patients with locally advanced or metastatic prostate cancer, who will undergo cytoreductive radical prostatectomy with extended lymph node dissection.
88974460|NCT02954536|Experimental|Pembrolizumab, trastuzumab,capecitabine/cisplatin|Pembrolizumab 200 mg IV every 3 weeks, trastuzumab (8 mg/kg loading dose; 6 mg/kg maintenance) IV every 3 weeks with cisplatin IV every 3 weeks with oral capecitabine 2 weeks on/1 week off. Each cycle consists of 21 days. Treatment will be administered on an outpatient basis. In Cycle 1, patients will initiate therapy with trastuzumab 8 mg/kg IV with pembrolizumab 200 mg IV. CT/MRI scan will be performed after the initial 3 weeks (1 cycle) to determine response to pembrolizumab and trastuzumab combination. With subsequent cycles, all patients will begin systemic chemotherapy with the capecitabine/cisplatin regimen in addition to pembrolizumab 200 mg IV with trastuzumab 6 mg/kg maintenance. Patients will receive cisplatin 80 mg/m2 IV on Day 1, and capecitabine 850mg/m2 twice a day on Days 1 through 14, every 3 weeks.
88974461|NCT02942173|No Intervention|CD45RA-|
88974462|NCT02942173|Experimental|CD45RA+|
88974463|NCT02931942||A: Acute leukemia|Patients that will receive intensive clinical chemotherapy for acute leukemia or high risk myelodysplasia (RAEB2) Blood withdrawn 5-7 x
88974464|NCT02931942||B: Autologous transplantation|Patients that will receive high dose chemotherapy and autologous stem cell rescue for varies hematological malignancies Blood withdrawn 5-7 x
89582807|NCT01917747|Experimental|Patient Navigator Group|The patient navigator group will involve regular phone contact with the patient navigator. The patient navigator will contact the participant by phone to conduct an interview and provide education on infant hearing and diagnostic hearing services. The timing of the subject child's appointment and the instructions of the outpatient auditory brainstem response test are discussed.
89582808|NCT01597791|Placebo Comparator|Foley catheter|Control group will have a Foley catheter placed after the CSE is performed as is the usual practice at this institution.
89582809|NCT01597791|Experimental|No Foley Catheter|Spontaneous micturition algorithm will be assessed for spontaneous micturition and post void residual (PVR) volumes via ultrasonography at regular time intervals.
89582810|NCT01916967|Experimental|Desloratadine 5 mg|Participants receive desloratadine 5 mg, as one 5-mg tablet and one placebo tablet, orally, once daily in the evening for 2 weeks
89582811|NCT01916967|Experimental|Desloratadine 10 mg|Participants receive desloratadine 10 mg, as two 5-mg tablets, orally, once daily in the evening for 2 weeks
89582812|NCT01916967|Placebo Comparator|Placebo|Participants receive placebo, as two tablets, orally, once daily in the evening for 2 weeks
89582813|NCT01936623|Experimental|Computerized Brief Intervention|Computerized Brief Intervention is delivered using a talking, animated cartoon-like parrot that provides patient feedback, empathic reflection, and personalization regarding their drug use.
89582814|NCT01936623|Other|Delayed Computerized Brief Intervention|Participants receive only a substance abuse assessment at baseline. At three-month follow-up, they then receive the computerized brief intervention.
89582815|NCT04648839||Benralizumab|Patients that received at least one dose of benralizumab according to routine clinical practice
89582816|NCT04625127|Experimental|Aim 2: Efficacy of the GaitBetter to improve motor-cognitive function of chronic stroke survivors|The investigators propose a single-arm, non-randomized study to test the hypothesis that the GaitBetter training is effective in improving gait and cognition in individuals with chronic stroke. This design was chosen given the expected stability of functional recovery in this population.
89582817|NCT04625127|Experimental|Aim 3: Efficacy of the GaitBetter to improve rehabilitation outcomes in sub-acute stroke survivors|The investigators propose a randomized, controlled study to evaluate the effects of using the GaitBetter system in patients with subacute stroke on recovery trajectory.
89582818|NCT01959243|Experimental|Brimonidine Tartrate|Participants will apply 1 drop of brimonidine tartrate ophthalmic solution 0.025% into each eye 4 times daily for up to 4 consecutive weeks.
89582819|NCT01959243|Placebo Comparator|Brimonidine Tartrate Vehicle|Participants will apply 1 drop of the vehicle of brimonidine tartrate ophthalmic solution into each eye 4 times daily for up to 4 consecutive weeks.
89582820|NCT01959165|Experimental|MEDI7183 dose 1|Double blinded
89582821|NCT01959165|Experimental|MEDI7183 dose 2|Double blinded
89582822|NCT01959165|Experimental|MEDI7183 dose 3|Double blinded
88974465|NCT02931942||C: controls|Healthy controls, found amongst family members of patients of group A and B Blood withdrawn 5-7 x
88974466|NCT02931942||D: lung cancer|Patients that will receive relatively mild immunosuppressive chemotherapy for lung cancer, that will mostly be in the outpatient setting Blood withdrawn 5-7 x
88974467|NCT02931942||E: colon cancer|Patients that will receive relatively mild immunosuppressive chemotherapy for colon cancer, that will mostly be in the outpatient setting and mostly adjuvant Blood withdrawn 5-7 x
88974468|NCT02931942||F: controls|Healthy controls, found amongst family members of patients of group D and E Blood withdrawn 5-7 x
88974469|NCT02919670|Experimental|Enterade and Standard Supportive Care|"Two 8 oz. bottles of Enterade will be administered daily~Enterade will be given orally from admission until day +14 or until discharge~Standard Supportive Care will be administered according to institution's practice"
88974470|NCT02919670|Placebo Comparator|Placebo and Standard Supportive Care|"Two 8 oz. bottles of Placebo will be administered daily~Placebo will be given orally from admission until day +14 or until discharge~Standard Supportive Care will be administered according to institution's practice"
88974471|NCT02904811|Experimental|Intervention group|"Testing for Ct infection immediately~Participants will perform self-taken vaginal samples.~The positive results for Ct will be examined and treated and their partner will also be informed to do so."
88974472|NCT02904811|Experimental|Control group|Testing for Ct infection at the end of the study
88974473|NCT02899611|Experimental|ICV Valproate|Patients receive a daily dose of ICV Valproate that increases from 3 mg to 60 mg (or MTD) over 8 weeks. A placebo week is randomly inserted in the dose escalation. During the placebo week, the patient receives normal saline.
88974474|NCT02750371|Experimental|Patients with brain tumors treated by radiotherapy|"Patients with:~- meningioma of the cavernous sinus for which radiotherapy is planned~Or~- a pituitary adenoma for which radiotherapy is planned"
88974475|NCT02750202|Active Comparator|Quadrivalent HPV vaccine|Three doses of 4 HPV vaccine is given at registered intervals.
89582823|NCT01959165|Placebo Comparator|Placebo|Double blinded
88974476|NCT02750202|Sham Comparator|Hepatitis B vaccine|Three doses of Hepatitis B vaccine is given at the same intervals as the quadrivalent HPV vaccine.
88974477|NCT02747758|Sham Comparator|Control|sham transcranial direct current stimulation (tDCS)
89582824|NCT01916109|Experimental|Gemcitabine, Carboplatin, and Panitumumab (GCaP)|Patients will receive four cycles of GCaP administered every 21 days. Panitumumab will be administered intravenously at a dose of 9mg/kg on day 1. Gemcitabine 1,000 mg/m2 on day 1 and 8 and carboplatin AUC 4.5 on day 1 will be administered intravenously on a 21-day cycle. A total of four cycles of therapy will be administered at 21-day intervals followed by radical cystectomy.
88974478|NCT02747758|Experimental|cathodal stimulation|cathodal transcranial direct current stimulation (tDCS)
88974479|NCT02747758|Experimental|anodal stimulation|anodal transcranial direct current stimulation (tDCS)
88974480|NCT02634294|Experimental|Peg interferon alfa-2b|Pegylated Interferon α-2b (PEG INTRON®) , 1~1.5μg/kg qw, subcutaneous injection, 1 to 12 months, until occurrence of grade II or higher grade of acute graft versus host disease, or no response to treatment after 8 doses of treatments.
88974481|NCT02575677||Parturients with oxycodone|Parturients who were given oxycodone
89582825|NCT01915095|Active Comparator|Motor task+ Magnetic stimulation|Participants will be asked to complete a precision grip with the index and thumb finger at the same time as flexing or extending the wrist. magnetic stimulation to the brain will be administered and measurements will be taken during movement.
89582826|NCT01915095|Active Comparator|rTMS/sham rTMS|Participant will be randomly assigned to one of 3 groups: repetitive transcranial magnetic stimulation (rTMS), sham (fake) rTMS, or sham (fake) rTMS over control brain area will be administered to the brain. the stimulation will be targeting finger and wrist muscles during movement.
89582827|NCT01915095|Active Comparator|Training + rTMS/ Sham rTMS|Participants will be asked to follow a target line on the computer as accurately as possible while performing precision grips or foot movement . Magnetic stimulation will be given during rest and movement.
89582828|NCT01958619|Experimental|Treatment A: 1440mg PQP tablets & 800mg OZ439 + TPGS|Piperaquine phosphate tablets (1440mg) and OZ439 (800mg) + TPGS granules for oral suspension under fasted conditions.
89582829|NCT01958619|Experimental|Treatment B: 960mg PQP tablets & 800mg OZ439 + TPGS|Piperaquine phosphate tablets (960mg) and OZ439 (800mg) + TPGS granules for oral suspension under fasted conditions.
89582830|NCT01958619|Experimental|Treatment C: 960mg PQP granules & 800mg OZ439 + TPGS|Piperaquine phosphate granules for oral solution (960mg) and OZ439 (800mg) + TPGS granules for oral suspension under fasted conditions.
89582831|NCT01958619|Experimental|Treatment D: 800mg OZ439 + TPGS|OZ439 (800mg) + TPGS granules for oral suspension under fasted conditions.
89582832|NCT01752634|Experimental|Secukinumab (AIN457) 75 mg s.c.|Secukinumab 75 mg at BSL, Weeks 1, 2, 3 and 4, followed by dosing every four weeks starting at Week 4.
89582833|NCT01752634|Experimental|Secukinumab (AIN457) 150 mg s.c.|Secukinumab 150 mg at BSL, Weeks 1, 2, 3 and 4, followed by dosing every four weeks starting at Week 4.
89582834|NCT01752634|Experimental|Secukinumab (AIN457) 300 mg s.c.|Secukinumab 300 mg at BSL, Weeks 1, 2, 3 and 4, followed by dosing every four weeks starting at Week 4
89582835|NCT01752634|Placebo Comparator|Placebo s.c.|Placebo at BSL, Weeks 1, 2, 3 and 4, followed by dosing every four weeks starting at Week 4. Non-responder (assessed at Week 16) were re-randomized to receive AIN457 150mg or AIN457 300 mg starting at Week 16. Responder (assessed at Week 16) were re-randomized to receive AIN457 150mg or AIN457 300 mg starting at Week 24.
89582836|NCT01726270|Experimental|tamsulosin hydrochloride|patients will take drug for 8 weeks in this exploratory study
89582837|NCT02102269|Active Comparator|actimove sling|standard orthosis: actimove sling
89582838|NCT02102269|Experimental|shoulderlift|newly developed orthosis: shoulderlift
89582839|NCT02102269|No Intervention|controle group|no orthosis
89582840|NCT01914393|Experimental|Lurasidone 20, 40, 60, 80 mg, flexibly dosed|Lurasidone 20, 40, 60, 80 mg, flexibly dosed, once daily
89582841|NCT01545271|Experimental|72h cooling + 18h xenon inhalation|Babies in poor condition at birth and referred to our neonatal unit for standard therapy of cooling to 33.5 degree C body temperature will be randomised to receive xenon gas at 50% concentration for 18 hours
89582842|NCT01545271|Active Comparator|Standard 72 h whole body cooling therapy|Whole body cooling therapy to rectal temperature of 33.5 degree Centigrade (standard therapy)
89582843|NCT00559819|Active Comparator|Alcohol|Alcohol
89582844|NCT00559819|Placebo Comparator|Placebo|Orange juice
89582845|NCT00543907||Pre programmatic development|Patients who have undergone mastectomy for breast cancer prior to implementation of the deep inferior epigastric perforator flap microsurgical breast reconstruction program
89582846|NCT00543907||Post programmatic development|Patients who have undergone mastectomy for breast cancer after implementation of the deep inferior epigastric perforator flap microsurgical breast reconstruction program
89582847|NCT01931865|Experimental|IncobotulinumtoxinA|The total dose will depend on the extent of the area involved by pain. The injections will be carried out through a 1cc syringe using a ½ to 1 inch needle intramuscularly or subcutaneously (or both). The ttoal dose will not exceed 100 units.
89582848|NCT04646889|Experimental|Renal Impairment|Subjects with various degrees of renal impairment
89582849|NCT04646889|Experimental|Normal Renal Function|Subjects with normal renal function
89582850|NCT01617447|Placebo Comparator|Placebo|administered orally once daily
89582851|NCT01617447|Experimental|Aripiprazole|administered orally once daily
89582852|NCT00432679|Experimental|arm 1|study drug
89582853|NCT05232487|Experimental|Swiss low back acupuncture group|Participants in this group will be treated with the Swiss low back acupuncture method.
89582854|NCT05232487|Active Comparator|Standard acupuncture group|Participants in this group will be treated with the standard acupuncture method.
88974482|NCT02573831|Placebo Comparator|Placebo|The patients are given at first placebo and after one hour oxycodone 0,05 mg/kg if needed
89582855|NCT01600105|Experimental|Perfusion MRI|chronic liver disease who underwent/will undergo liver biopsy or will undergo liver transplant or liver resection as part of standard care during the previous 6 months.
89582856|NCT01077895|Experimental|CVVH with fluid removal|
89582857|NCT01077895|Active Comparator|CVVH without fluid removal|
89582858|NCT04785079|Experimental|Graston effect medial arch, plantar fascia, and trapezius|Pre and post Graston change in blood flow at the medial arch foot, plantar fascia, and the trapezius region
89582859|NCT04797325|Active Comparator|vedolizumab|
89582860|NCT04797325|Active Comparator|Standard treatment|
89582861|NCT02246647||Healthy volunteers|Permeability measurement: Ingestion of saccharides {mannitol (regular, 12C) 100 mg, lactulose 1 g and labelled (13C mannitol) 100 mg} in 250ml of water Esophagogastroduodenoscopy Flexible sigmoidoscopy
89582862|NCT02246647||IBS-C|Permeability measurement: Ingestion of saccharides (mannitol (regular, 12C) 100 mg, lactulose 1 g and labelled (13C mannitol) 100 mg} in 250ml of water Esophagogastroduodenoscopy Flexible sigmoidoscopy
89582863|NCT00752245|Experimental|1|Dialysis during 4 hours
89582864|NCT00752245|Active Comparator|2|Dialysis during 6 hours
89582865|NCT00752245|Active Comparator|3|Dialysis during 8 hours
89582866|NCT04771351|Experimental|COVI-AMG 100 mg|A single injection of 100 mg of COVI-AMG will be administered.
89582867|NCT04771351|Experimental|COVI-AMG 200 mg|A single injection of 200 mg of COVI-AMG will be administered.
89582868|NCT04771351|Placebo Comparator|Placebo|A single injection of placebo will be administered.
89582869|NCT04770727|Experimental|Workshop Intervention|A psychoeducation workshop will be provided alongside a workbook containing the content to review and refresh skills learnt. The psychoeducational intervention will be delivered by trainee clinical psychologists with interests in food allergy and delivered in line with a protocol.
89582870|NCT04770727|No Intervention|Treatment as usual|Adolescents randomised to the control arm will continue treatment as usual and receive the workshop materials after the active treatment group have completed their final follow-up at 3 months.
89582871|NCT05107687||Assisted Smoking Cessation|"Subject participates in a structured smoking cessation program hosted at Virtua Health which may be either smoking cessation group sessions or individual sessions and/or both. All participants will be provided with a list of smoking cessation resources.~Description of Group Smoking Education and Support: These sessions are led by a Tobacco Treatment Specialist and include 2-3 sessions in-person or virtually and cover the following topics: Biological changes caused by nicotine, addiction, tips to quit smoking, health benefits to quitting smoking, types of nicotine replacement therapy, e-cigarettes and devices, aromatherapy, meditation and various resources. In addition, access to nicotine replacement therapies is optional."
89582872|NCT05107687||Unassisted Smoking Cessation|The subject receives no professional support but is provided with a list of smoking cessation resources, in this cohort the subject engages in smoking cessation with no assistance from a provider.
89582873|NCT01933113|Experimental|DBS of the Lateral Hypothalamic Area|"Single Arm: Deep Brain Stimulation of LHA for maximum RMR On days 1-4, subjects stayed in the inpatient unit to have metabolic weight, temperature, and resting metabolic rate (RMR) measured at different settings.~Metabolic testing RMR measurement: A clear plastic hood was placed over the head and chest Oxygen intake and carbon dioxide out-put were measured to determine how many calories were burned during the next 15-30 minutes. Each hour for the next seven hours, DBS settings were changed and the above process was repeated. On Day 4, a DXA scan was performed to assess body composition. Primary endpoint is the determination of optimal settings"
89582874|NCT04773067|Experimental|UB-612|A proprietary high-precision designer S1-RBD protein based vaccine incorporating Th/CTL peptides to activate T cells.
89582875|NCT04773067|Placebo Comparator|Placebo|Normal saline 0.9%.
89582876|NCT04784845|Experimental|N. lactamica Y92-1009|Nasal inoculation with 10^5 CFU N. lactamica in 1ml phosphate-buffered saline via pipette to both nostrils; single inoculation at 36+0 to 37+6 weeks gestation
89582877|NCT02244619|Active Comparator|Oral acetaminophen|Subjects receive 2 capsules each containing Tylenol 500 mg caplets. The test article administration will be initiated 60 minutes (± 15 minutes) prior to the scheduled surgery start time.
89582878|NCT02244619|Active Comparator|IV acetaminophen|Subjects receive Ofirmev 1000 mg in 100 ml Normal Saline IV infusion. The test article will be given perioperatively at the discretion of the attending anesthesiologist.
89582879|NCT02243371|Experimental|Arm A: CY/ GVAX/ CRS-207/ nivolumab|
89582880|NCT02243371|Experimental|Arm B: CY/ GVAX/ CRS-207|
89582881|NCT01931475|Experimental|Duloxetine|"Double Blind Treatment Phase:~60 milligram (mg) duloxetine administered by mouth once a day (QD). Started on duloxetine 30 mg QD for 1 week and then titrated up to 60 mg duloxetine QD for 12 weeks.~Extension Treatment Phase:~60 mg duloxetine administered by mouth QD for 13 weeks.~Taper Phase: 1-week taper where participants taking 60 mg QD duloxetine during the study had their dosage reduced to 30 mg to minimize discontinuation-emergent adverse events (DEAEs)."
89582882|NCT01931475|Placebo Comparator|Placebo|"Double Blind Treatment Phase:~Placebo administered by mouth once a day (QD) for 13 weeks.~Extension Treatment Phase:~60 mg duloxetine administered by mouth QD for 13 weeks. Started on duloxetine 30 mg QD for 1 week and then titrated up to 60 mg duloxetine QD.~Taper Phase: 1-week taper - Placebo administered for 1 week if the participant discontinued from double blind treatment phase, or duloxetine 30 mg QD administered for 1 week if the participant discontinued from extension treatment phase or completed treatment. 1 week taper is to minimize discontinuation-emergent adverse events (DEAEs)."
88974483|NCT02573831|Experimental|Oxycodone|The patients are given at first oxycodone 0,05 mg/kg and after one hour oxycodone 0,05 mg/kg if their pain in numerical rating scale from 0 to 10 is 5 or more
89582883|NCT04622787||Tuscany, Italy|Infants at risk of Cerebral Palsy in Tuscany, Italy
89582884|NCT04622787||Infants at risk of Cerebral Palsy in Georgia|Infants at risk of Cerebral Palsy in Georgia
89582885|NCT04622787||Sri-Lanka|Infants at risk of Cerebral Palsy in Sri-Lanka
89582886|NCT04622787||Denmark|Infants at risk of Cerebral Palsy in Denmark
89582887|NCT04622787||Infants at risk of Cerebral Palsy in the Netherlands|the Netherlands
89582888|NCT04622787||remote Queensland, Australia|Infants at risk of Cerebral Palsy in remote Queensland, Australia
89582889|NCT04622787||Medical professionals|Medical/healthcare providers from all involved geographic locations that work with infants at risk or with diagnosis of cerebral palsy will be provided opportunities for the participation in face-to-face and/or e-learning platform trainings on the the international early detection guidelines.
89582890|NCT01929993|Experimental|SWETZ|Straight wire excision of transformation zone is an electrosurgical conization method, which uses a straight wire electrode.
89582891|NCT01929993|Active Comparator|LLETZ cone|LLETZ cone is a electrosurgical conization method, which is performed with a large loop electrode of 20 mm depth.
88974484|NCT02571881|Active Comparator|Oxycodone|Oxycodone 10 mg prolonged release tablet twice a day after caesarean section
88974485|NCT02571881|Experimental|Oxycodone-naloxone|Oxycodone-naloxone 10/5 mg prolonged release tablet twice a day after caesarean section
88974486|NCT02571179|Experimental|Intranasal fentanyl 50 microg/dose|patient was given intranasal fentanyl 50 microg/dose up to 250 microg
88974487|NCT02540616|Experimental|Transcranial Electrical Stimulation-Real|The participant will perform real TES. The forms of TES used in this study will include transcranial direct current stimulation (tDCS), transcranial alternating current stimulation (tACS), or transcranial random noise stimulation (tRNS). Each stimulation session will last for 20-minutes.
89582892|NCT04630821|Experimental|Treatment with Dilute Sodium Hypochlorite solution|Subjects will be treated with the dilute bleach compresses daily (Monday through Friday) for the first 3 weeks of therapy. The bleach solution will be prepared and compresses applied for a 20 minute duration prior to radiation therapy. The compress can be applied within an hour of radiation therapy. Subjects will apply Aquaphor® ointment twice a day, once immediately after the radiation treatment and once in the evening. On days the experimental subjects do not receive radiation therapy, they will continue to moisturize their skin twice a day (AM and PM) with Aquaphor® ointment.
89582893|NCT04645953|Experimental|1mg AZ010|Single orally-inhaled dose
89582894|NCT04645953|Experimental|3mg AZ010|Single orally-inhaled dose
89582895|NCT04645953|Experimental|Placebo|Single orally-inhaled dose
89582896|NCT01912599|Active Comparator|Non-Glaucomatous|Patients with no history of glaucoma. Subjects will be fitted with Sensimed Triggerfish for 24 observation of IOP and with a blood pressure monitor for 24 hour observation of blood pressure trends.
89582897|NCT01912599|Active Comparator|Glaucoma|Patients that are currently being treated for moderate to severe normal-tension glaucoma. Subjects will be fitted with Sensimed Triggerfish for 24 observation of IOP and with a blood pressure monitor for 24 hour observation of blood pressure trends.
89582898|NCT04645017|Experimental|Intergenerational Music Program|An intergenerational music program will be administered by adolescent musicians for older adults with early-stage cognitive decline.
89582899|NCT01929681|Experimental|LFMS - active treatment|"Low Field Magnetic Stimulation (LFMS) active treatment~Active low field magnetic stimulation treatment applied with the LFMS Device; the device is on and magnetic field stimulation is present."
89582900|NCT01929681|Sham Comparator|LFMS - sham treatment|"Low Field Magnetic Stimulation - sham treatment~Inactive low field magnetic stimulation (no stimulation) treatment applied with the LFMS Device; the device is on, however no magnetic field stimulation is present."
89582901|NCT01646177|Placebo Comparator|Placebo|Placebo for ixekizumab administered by two SC injections at Week 0, then one SC injection per Dosing Regimen 1 until Week 12. Placebo for etanercept administered by one SC injection twice weekly starting at Week 0 up to Week 12. At Week 12, participants are assigned to Dosing Regimen 2.
89582902|NCT01646177|Active Comparator|50 mg etanercept|Administered by SC injections twice weekly starting at Week 0 up to Week 12. At Week 12, arm is assigned to Dosing Regimen 2
89582903|NCT01646177|Experimental|80 mg ixekizumab Dosing Regimen 2|Administered by two 80 mg SC injections at Week 0, then one 80 mg SC injection per Dosing Regimen 2 until Week 264.
89582904|NCT01646177|Experimental|80 mg ixekizumab Dosing Regimen 1|Administered by two 80 milligram (mg) subcutaneous (SC) injections at Week 0, then one 80 mg SC injection per Dosing Regimen 1 until Week 12. At Week 12, arm is assigned to Dosing Regimen 2.
89582905|NCT01912287|Experimental|Yoga|The yoga intervention will apply Kundalini Yoga practices as taught by Yogi Bhajan. This is a well-known, accessible style of practice in the U.S. that incorporates all of the traditional components of yoga including physical postures and exercises, breathing techniques, relaxation exercises and meditation practices. It is a safe style of yoga that is registered with the Yoga Alliance that is readily and routinely adapted for therapeutic purposes. The 12-week yoga intervention will consist of 12 group classes and assigned daily home practice led by qualified and certified yoga instructors. Each group yoga session will include physical postures/exercises, breathing techniques, meditation and deep relaxation practice that are all easy to learn and do not require extensive practice or athletic ability to perform.
88974488|NCT02540616|Sham Comparator|Transcranial Electrical Stimulation-Sham|The participant will perform sham TES for 20-minutes. The form of sham TES will depend on the active arm, e.g. if tACS is on the active arm, then the sham tACS will be a different frequency of stimulation. If tDCS is the active arm, then a short ramp up of tDCS followed by a ramp down (about 60-seconds) will be used as the sham arm.
88974489|NCT02489825|Other|Augmentation vertebroplasty|Single level fracture fixation with vertebroplasty
88974490|NCT02489825|Other|Augmentation and prophylactic vertebroplasty|Triple level augmentation with VP fixation of the fracture and additional prophylactic vertebroplasty in both the adjacent levels
88974491|NCT02417766||Family Members|Family members to the patients
88974492|NCT02417766||Patient|Patients here at NIH
88974493|NCT02328573|Experimental|Communal singing|Participants in the study group will join the choir and participate in a weekly hour rehearsal for six months and will be assessed for aphasia, mood, and quality of life outcomes
88974494|NCT02328573|No Intervention|Control|The control group will not participate in the choir for the first six months. At the end of the six months study period, all participants will be evaluated again for changes in aphasia, language, mood and quality of life
88974495|NCT02311322||Children with growth disorders|Children with growth disorders
88974496|NCT02311322||Family members of subjects with growth disorders|Family members of subjects with growth disorders
88974497|NCT02308085|Experimental|Endocrine therapy interruption|Endocrine therapy interruption after having completed between ≥ 18 months and ≤ 30 months.
88974498|NCT02278250|Experimental|Part A: M4344 10 mg BIW|Participants received M4344 at a dose of 10 milligrams (mg) orally twice weekly (BIW) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
88974499|NCT02278250|Experimental|Part A: M4344 20 mg BIW|Participants received M4344 at a dose of 20 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
88974500|NCT02278250|Experimental|Part A: M4344 40 mg BIW|Participants received M4344 at a dose of 40 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
88974501|NCT02278250|Experimental|Part A: M4344 80 mg BIW|Participants received M4344 at a dose of 80 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
89582906|NCT01912287|Active Comparator|Cognitive Behavioral Therapy (CBT)|"The 12 session CBT treatment will be based on the standardized protocol developed at one of our centers (CARD) and widely available [88]. This protocol is comprised of four primary treatment modules including cognitive restructuring, progressive muscle relaxation, worry exposures, and in vivo exposure exercises. The initial sessions describe the cognitive behavioral model of worry and GAD. Each session consists of a different lesson. These lessons initially cover basic information about the nature of the anxiety and worry, the possible function and negative consequences of worrying, the maladaptive and paradoxical effects of attempting to control and suppress one's thoughts, the basic cognitive errors of probability overestimation and catastrophic thinking, adaptive strategies to deal with worries, such as problem solving, worry exposure, which may involve exploring and exposing the patient to negative images and scenarios that might be behind some of the worrisome thoughts."
89582907|NCT01912287|Sham Comparator|Stress Education|SE will also include 12 weeks of group and home practice sessions. SE will control for attention from instructors, expectancy effects, and group support effects, Stress Education (SE) will be employed as an active control intervention. SE is currently used in NIH-funded protocols at the Benson-Henry Institute for Mind-Body Medicine at MGH. In this condition, participants will be provided with detailed and extensive information about stress and health, but will not receive any CBT, yoga, or other mind-body training techniques.
89582908|NCT01929135|Experimental|Medicated 2% atorvastatin dentifrice|A group of 19 patients received non surgical periodontal therapy accompanied by instruction for oral hygiene, using a medicated 2% atorvastatin dentifrice 2 times a day for two minutes each time, for 30 days.
89582909|NCT01929135|Placebo Comparator|Non-medicated dentifrice|A group of 19 patients received non surgical periodontal therapy accompanied by instruction for oral hygiene, using a non-medicated dentifrice as placebo 2 times a day for two minutes each time, for 30 days.
89582910|NCT01911819|Experimental|Sinus augmentation using Bio-oss|Sinus augmentation using Bio-oss
89582911|NCT01911819|Experimental|Sinus augmentation using Equimatrix|Sinus augmentation using Equimatrix
89582912|NCT01911819|Experimental|Sinus augmentation using OSSIF-i sem|Sinus augmentation using OSSIF-i sem
89582913|NCT02280863|Experimental|Adult Cohort|Medtronic Hybrid Closed-Loop System will be used by adults for five days in open-loop (sensor augmented pump) and five days in closed-loop. The first 8 Adults use the Android Platform.
89582914|NCT02280863|Experimental|Adolescent Cohort|Medtronic Hybrid Closed-Loop System will be used by adolescents for four days in open-loop (sensor augmented pump) and four days in closed-loop.
89582915|NCT01911429|Experimental|Lurasidone 40 mg|Lurasidone 40 mg once daily
89582916|NCT01911429|Experimental|Lurasidone 80 mg|Lurasidone 80 mg once daily Arm received the Lurasidone 40mg dose first, from Days 1-3, and then received the Lurasidone 80 mg dose from day 4 to Week 6
89582917|NCT01911429|Placebo Comparator|Placebo|Placebo 40 or 80 mg once daily
89582918|NCT02324465|Active Comparator|King Vision Video Laryngoscope|The patient would be randomized to intubation via use of the King Vision VL
89582919|NCT02324465|Active Comparator|Glidescope Video Laryngoscope|The patient would be randomized to intubation via use of the Glidescope VL
89582920|NCT02324153|Experimental|Treatment|Ramelteon 8 mg oral dose Riboflavin 100 mg (preoperative first dose only)
89582921|NCT02324153|Placebo Comparator|Placebo|Capsule Shells filled with microcrystalline cellulose Riboflavin 100 mg (preoperative first dose only - if received as an outpatient)
89582922|NCT02280473|Experimental|Refresh Optive® Gel Drops|Refresh Optive® Gel Drops; 1-2 drops in each eye as needed at least 2 times daily for 30 days.
89582923|NCT02280473|Active Comparator|REFRESH LIQUIGEL®|REFRESH LIQUIGEL®; 1-2 drops in each eye as needed at least 2 times daily for 30 days.
89582924|NCT04420481|Active Comparator|Growth hormon group|A 12 month study, consisting of a 9 months growth hormone treatment phase followed by a 3 month growth hormone treatment-free period.
89582925|NCT04420481|Placebo Comparator|Control group|A 12 month study, consisting of a 9 month placebo treatment phase followed by a 3 month treatment-free period.
89582926|NCT01911273|Experimental|PF 03446962 plus best supportive care (BSC)|
89582927|NCT01911273|Placebo Comparator|Placebo plus best supportive care (BSC)|Placebo, IV, every 2 weeks, until disease progression, patient refusal or unacceptable toxicity, whichever occurs first
89582928|NCT02308007|Active Comparator|Terconazole vaginal gel|One applicator full at bedtime
89582929|NCT02308007|Active Comparator|Metronidazole vaginal gel|One applicator full at bedtime
89582930|NCT02308007|Active Comparator|Terconazole/metronidazole vaginal gel|One applicator full at bedtime
89582931|NCT02278367|Experimental|Flortaucipir PET Scans|
88974502|NCT02278250|Experimental|Part A: M4344 160 mg BIW|Participants received M4344 at a dose of 160 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
88974503|NCT02278250|Experimental|Part A: M4344 300 mg BIW|Participants received M4344 at a dose of 300 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
89030081|NCT04512092|Experimental|CMT-C group|Compassion Mind Training for Caregivers (CMT-C) is a 12-session structured program to be delivered in a group format, aiming to cultivate a compassionate-self and compassionate care practices in residential youth care.
89582932|NCT04886141|No Intervention|Standard of Care treatment with Scales|Patients will receive the standard of care restorative procedure with the addition of the FLACC pain scale, Wong Baker FACES Pain rating and Houpt scale to create a baseline data of pain to compare with the experimental group.
89582933|NCT04886141|Experimental|Virtual Reality Headset|Instead of receiving the Nitrous that would be used to help calm patients during the standard of care restorative procedure. Patients will be given a the Oculus Quest 2 Virtual realty headset and a video will be played. The FLACC pain scale, Wong Baker FACES Pain rating and Houpt scale data will be collected to compare the patients pain level between the two groups.
88974504|NCT02278250|Experimental|Part A: M4344 450 mg BIW|Participants received M4344 at a dose of 450 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
89209536|NCT02541396|Experimental|Group G|"Wafermine™ 70 mg given every 4 hours Placebo wafer given every 2 hours Placebo capsule given every 4 hours 2 Placebo wafers top-up dose at hour 1"
89209537|NCT00890526|Experimental|1|Full treatment = Counseling + sound therapy.
89209538|NCT00890526|Experimental|2|Counseling + placebo sound therapy.
89209539|NCT00890526|Experimental|3|No Counseling + Sound Therapy
88974505|NCT02278250|Experimental|Part A: M4344 700 mg BIW|Participants received M4344 at a dose of 700 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
88974506|NCT02278250|Experimental|Part A: M4344 1050 mg BIW|Participants received M4344 at a dose of 1050 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
88974507|NCT02278250|Experimental|Part A: M4344 1200 mg BIW|Participants received M4344 at a dose of 1200 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
88974508|NCT02278250|Experimental|Part A2: M4344 100 mg BID|Participants received M4344 at a dose of 100 mg orally twice daily (BID) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
88974509|NCT02278250|Experimental|Part A2: M4344 150 mg QD|Participants received M4344 at a dose of 150 mg orally once daily (QD) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
88974510|NCT02278250|Experimental|Part A2: M4344 250 mg QD|Participants received M4344 at a dose of 250 mg orally QD until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
88974511|NCT02278250|Experimental|Part A2: M4344 350 mg QD|Participants received M4344 at a dose of 350 mg orally QD until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
89209540|NCT00890526|Placebo Comparator|4|No counseling + Placebo sound therapy.
89209541|NCT00255151|Experimental|Dexlansoprazole MR 60 mg QD|
89209542|NCT00255151|Experimental|Dexlansoprazole MR 90 mg QD|
88974512|NCT02278250|Experimental|Part B1: M4344 350 mg + Carboplatin|Participants received M4344 at a dose of 350 mg orally on Day 2 and Day 9 in combination with intravenous infusion of Carboplatin at a dose of Area under the concentration versus time curve 5 (AUC5) on Day 1 of 21-day cycle until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
88974513|NCT02278250|Experimental|Part B1: M4344 400 mg + Carboplatin|Participants received M4344 at a dose of 400 mg orally on Day 2 and Day 9 in combination with intravenous infusion of Carboplatin at a dose of AUC5 on Day 1 of 21-day cycle until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
89209543|NCT00255151|Placebo Comparator|Placebo|
89209544|NCT00890760|Experimental|Group 1|AdCh63 ME-TRAP prime followed by MVA ME-TRAP boost 8 weeks later and challenged by sporozoite 3 weeks after boost
89209545|NCT00890760|Experimental|Group 2|AdCh63 ME-TRAP alone followed by sporozoite challenge 3 weeks later
88974514|NCT02278250|Experimental|Part B1: M4344 500 mg + Carboplatin|Participants received M4344 at a dose of 500 mg orally on Day 2 and Day 9 in combination with intravenous infusion of Carboplatin at a dose of AUC5 on Day 1 of 21-day cycle until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
89030082|NCT04512092|No Intervention|Control group|This group did not receive any mind training or group intervention during the study.
89030083|NCT04513301|Active Comparator|Sintilimab alone|Sintilimab (200 mg q3w ×2cycle)
89030084|NCT04513301|Experimental|Sintilimab+Radiotherapy|Sintilimab (200 mg q3w ×2cycle)+RT 50-60Gy/25-30f
89030085|NCT01249560||raltegravir|"To illustrate the cause and effect relationship between the abnormalities of the distribution(casting) of the molecules of co-activation and the rate of apoptose, we compare also 2 groups: a first group of patients with a rate of apoptose normal ( n=10 ), and another group of patients having a rate of apoptose aggravated ( n=10 ).~20 eligible patients will receive their treatment to J1 and will be estimated for the residual concentration of the raltegravir ®, the antiretroviral activity, the tolerance and the observance at the treatments of the study in the visits of evaluation of M1, M2, M3, M6, M12, and / or in case of premature stop(ruling) of the try(essay). Every visit will give rise to a clinical evaluation of the patient. The arisen of unwanted events"
89582934|NCT01910181|Experimental|Vemurafenib: Pharmacokinetic Cohort|Participants will receive vemurafenib orally as 960 mg twice daily on Days 1 to 21 (morning dose only on Day 21), with a drug holiday from Days 22 to 27, and from Day 28 until progression, unacceptable toxicity, consent withdrawal, decision by the investigator or Sponsor, or protocol/eligibility violation.
89582935|NCT01910181|Experimental|Vemurafenib: Expansion Cohort|Participants will receive vemurafenib orally as 960 mg twice daily from Day 1 until progression, unacceptable toxicity, consent withdrawal, decision by the investigator or Sponsor, or protocol/eligibility violation.
89582936|NCT04885907|Active Comparator|Experimental group|Participants will receive a one dose of mRNA-1273 vaccine 0.5mL i.m. in deltoid muscle
89582937|NCT04885907|Placebo Comparator|Comparator Group|Participants will receive one dose of normal saline injection 0.5mL i.m. in deltoid muscle
89582938|NCT04622241|Experimental|Eave Tubes - Traditional House|Installation of eave tubes in traditional homes.
89582939|NCT04622241|Experimental|Eave Tubes - Modern House|Installation of eave tubes in modern homes.
89582940|NCT04622241|Experimental|Eave Ribbons - Traditional House|Installation of eave ribbons in traditional homes.
89582941|NCT04622241|Experimental|Eave Ribbons - Modern House|Installation of eave ribbons in modern homes.
89582942|NCT04622241|Experimental|Full House Screening - Traditional House|Installation of full house screening, includes screening eaves and windows, in traditional homes.
89582943|NCT04622241|Experimental|Full House Screening - Modern House|Installation of full house screening, includes screening eaves and windows, in modern homes.
89582944|NCT04622241|Experimental|Partial House Screening - Traditional House|Installation of partial screening, includee either screening of the eaves or installing a screened ceiling, in traditional homes.
89582945|NCT04622241|Experimental|Partial House Screening - Modern House|Installation of partial screening, includee either screening of the eaves or installing a screened ceiling, in modern homes.
89582946|NCT04622241|No Intervention|Control - Traditional House|Control group with no intervention in traditional homes
89030086|NCT04516421|Experimental|Experimental group|The experimental group will receive a 12-weeks intervention, with each day a pack of supplementation containing 14g protein, 0.6g fat, 7g carbohydrate, 4.4 g BCAA , 2.4g glutamate, 0.5g arginine and 0.4g taurine with 90 kcal/pack (Affix Health, Taiwan Branch).
89030087|NCT04516421|Placebo Comparator|Control (Placebo) group|The control (placebo) group will receive a 12-week oat drink, with each day a pack of oat tea containing 1.5g protein, 0.5g fat, 0.1g carbohydrate with 8.3kcal/pack (Zhan Xuan, Co. Ltd., Taiwan).
89030088|NCT04512014||major liver surgery|Patients undergoing major liver surgery
89582947|NCT04622241|No Intervention|Control - Modern House|Control group with no intervention in modern homes.
89582948|NCT01957215|Experimental|Indomethacin patch|Indomethacin patch to be applied on the sprained ankle twice a day (BID).
89582949|NCT01957215|Placebo Comparator|Placebo patch|Placebo patch to be applied on the sprained ankle BID.
89582950|NCT02322749|Experimental|Treatment A|AZD6244 blue reference capsules (3 x 25 mg) administered orally
89582951|NCT02322749|Experimental|Treatment B|AZD6244 blue capsules (3 x 25 mg) Variant 1 (free base variant) administered orally
89582952|NCT02322749|Experimental|Treatment C|AZD6244 blue capsules (3 x 25 mg) Variant 2 (vitamin E polyethylene glycol succinate [TPGS] variant) administered orally
89582953|NCT01957137|Other|Continuous|The device parameter will be continuous.
89582954|NCT01957137|Other|Cycling Parameter #1|The device parameter will be cyclic program #1.
89582955|NCT01957137|Other|Cycling Parameter #2|The device parameter will be cyclic program #2.
89582956|NCT01957137|Other|Cycling Parameter #3|The device parameter will be cyclic program #3.
89582957|NCT01957137|Other|No Stimulation|Following the randomized portion of the study, an assessment was conducted to estimate the effect of a month of no stimulation on incontinence.
89582958|NCT01928433|Experimental|Finafloxacin 5 days|"Intervention:~Finafloxacin 800 mg i.v. once daily and Ciprofloxacin placebo i.v. twice daily. Finafloxacin 800 mg tablets once daily and Ciprofloxacin placebo oral twice daily Finafloxacin verum (i.v. and oral) for a total of 5 days."
89582959|NCT01928433|Experimental|Finafloxacin 10 days|"Intervention:~Finafloxacin 800 mg i.v. once daily and Ciprofloxacin placebo i.v. twice daily. Finafloxacin 800 mg tablets once daily and Ciprofloxacin placebo oral twice daily Finafloxacin verum (i.v. and oral) for a total of 10 days."
89582960|NCT01928433|Active Comparator|Ciprofloxacin 10 days|"Intervention:~Ciprofloxacin 400 mg i.v. twice daily and Finafloxacin placebo i.v. once daily Ciprofloxacin 500 mg oral twice daily and Finafloxacin placebo tablets once daily Ciprofloxacin (i.v. and oral) for a total of 10 days."
89582961|NCT02322281|Experimental|Rociletinib Monotherapy (500 mg BID)|Daily oral rociletinib at 500 mg BID with 8 oz (240 mL) of water and with a meal or within 30 minutes after a meal. Treatment with rociletinib is continuous and each cycle will comprise of 21 days.
89582962|NCT02322281|Experimental|Rociletinib Monotherapy (625 mg BID)|Daily oral rociletinib at 625 mg BID with 8 oz (240 mL) of water and with a meal or within 30 minutes after a meal. Treatment with rociletinib is continuous and each cycle will comprise of 21 days.
89582963|NCT02322281|Active Comparator|Pemetrexed or gemcitabine or paclitaxel or docetaxel|"Pemetrexed~500 mg/m2 pemetrexed given intravenously on Day 1 of each 21-day cycle.~Gemcitabine~1250 mg/m2 gemcitabine given intravenously on Day 1 and 8 of each 21-day cycle.~Docetaxel~75 mg/m2 docetaxel (60 mg/m2 for patients residing in East-Asian territories) given intravenously on Day 1 of each 21-day cycle.~or 35 mg/m2 docetaxel given intravenously on a weekly basis as part of a continuous 21-day cycle; i.e. dosing will be on Days 1, 8, and 15 of each 21-day cycle.~Paclitaxel~80 mg/m2 paclitaxel given intravenously on a weekly basis as part of a continuous 21-day cycle; i.e. dosing will be on Days 1, 8, and 15 of each 21-day cycle."
89582964|NCT02322125|Experimental|ReWalk training|ReWalk exoskeleton training: 1.5 hr/day, 4 days/week, for 12-14 weeks (approximately 50 training sessions). Participants will progress through the following: sit-to-stand, stand-to-sit, standing balance and weight shift, walking on smooth ground, stopping, turning while walking, walking on rough ground, ascending and descending slopes, ascending and descending steps and curbs.
89582965|NCT02243293|Experimental|Arm A|ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 12 weeks in HCV genotype 2 (GT2) -infected treatment naïve and treatment experienced participants without cirrhosis.
89582966|NCT02243293|Experimental|Arm B|ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 12 weeks in HCV GT2 -infected treatment naïve and treatment experienced participants without cirrhosis.
89582967|NCT02243293|Experimental|Arm C|ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD and weight-based ribavirin (RBV) divided twice daily (BID) for 12 weeks in HCV GT2 -infected treatment naïve and treatment experienced participants without cirrhosis.
89582968|NCT02243293|Experimental|Arm D|ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 12 weeks in HCV genotype 3 (GT3) -infected treatment naïve and treatment experienced participants without cirrhosis.
89582969|NCT02243293|Experimental|Arm E|ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 12 weeks in HCV GT3 -infected treatment naïve and treatment experienced participants without cirrhosis.
89582970|NCT02243293|Experimental|Arm F|ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD and weight-based ribavirin (RBV) divided BID for 12 weeks in HCV GT3 -infected treatment naïve and treatment experienced participants without cirrhosis.
89582971|NCT02243293|Experimental|Arm G|ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (40 mg) QD for 12 weeks in HCV GT3 -infected treatment naïve and treatment experienced participants without cirrhosis.
89582972|NCT02243293|Experimental|Arm H|ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 8 weeks in HCV GT2 -infected treatment naïve and treatment experienced participants without cirrhosis.
89582973|NCT02243293|Experimental|Arm I|ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (40 mg) QD for 8 weeks in HCV GT2 -infected treatment naïve and treatment experienced participants without cirrhosis.
89582974|NCT02243293|Experimental|Arm J|ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 8 weeks in HCV GT2 -infected treatment naïve and treatment experienced participants without cirrhosis.
89582975|NCT02243293|Experimental|Arm K|ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 8 weeks in HCV GT3 -infected treatment naïve and treatment experienced participants without cirrhosis.
89582976|NCT02243293|Experimental|Arm L|ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 8 weeks in HCV GT3 -infected treatment naïve and for 12 weeks in HCV GT3 -infected treatment experienced participants without cirrhosis.
89582977|NCT02243293|Experimental|Arm M|ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (80 mg) QD for 12 weeks in HCV GT3 -infected treatment naïve participants with compensated cirrhosis.
89582978|NCT02243293|Experimental|Arm N|ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (80 mg) QD and ribavirin (RBV) (800 mg) QD for 12 weeks in HCV GT3 -infected treatment naïve participants with compensated cirrhosis.
89582979|NCT02243293|Experimental|Arm O|ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 12 weeks in HCV GT3 -infected treatment naïve participants with compensated cirrhosis and for 16 weeks in HCV GT3 -infected treatment-experienced participants with compensated cirrhosis.
89582980|NCT02243293|Experimental|Arm P|ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD and RBV (800 mg) QD for 12 weeks in HCV GT3-infected treatment naïve and treatment-experienced participants with compensated cirrhosis.
89582981|NCT02243293|Experimental|Arm Q1|ABT-493/ ABT-530 (300 mg/ 120mg ) once daily (QD) for 12 weeks in HCV GT3 -infected treatment naïve participants with cirrhosis.
89582982|NCT02243293|Experimental|Arm Q2|ABT-493/ ABT-530 (300 mg/ 120mg ) once daily (QD) for 12 weeks in HCV GT3 -infected treatment experienced participants without cirrhosis.
89582983|NCT02243293|Experimental|Arm R1|ABT-493/ ABT-530 (300 mg/ 120 mg) QD for 16 weeks in HCV GT3 -infected treatment experienced participants without cirrhosis.
89582984|NCT02243293|Experimental|Arm R2|ABT-493/ ABT-530 (300 mg/ 120 mg) QD for 16 weeks in HCV GT3 -infected treatment experienced participants with cirrhosis.
89582985|NCT02243293|Experimental|Arm S1|ABT-493/ ABT-530 (300 mg/ 120 mg) QD for 8 weeks in HCV GT2 infected treatment naïve and treatment experienced participants without cirrhosis.
89582986|NCT02243293|Experimental|Arm S2|ABT-493/ ABT-530 (300 mg/ 120 mg) QD for 8 weeks in HCV GT4-6 infected treatment naïve and treatment experienced participants without cirrhosis.
89582987|NCT02322047|Experimental|Praz/Nal|"Prazosin and Naltrexone.~Prazosin will be taken following this titration schedule:~Days 1-2: 1 mg @ 9PM Days 3-4: 1 mg @ 9AM, 3PM, 9PM Days 5-7: 2 mg @ 9AM, 3PM, 9PM Days 8-10: 2mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 11-14: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 15-42: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM~Naltrexone will be taken from day 1 to day 42 at 9 PM. Dose: 50 mg."
88974515|NCT02278250|Experimental|Part C: M4344 250 mg QD|Participants received M4344 at a dose of 250 mg orally QD until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
88974516|NCT02260856|Active Comparator|Percutaneous Drill Epiphysiodesis|A 5 mm incision will be made centered over the physis both medially and laterally. A 4.5 mm drill will be passed repeatedly across the physis in a divergent manner. Curettes will then be used to further remove and disrupt the growth plate. Fluoroscopy will be used throughout to ensure proper passage of the drill and curettes. Omnipaque dye will then be inserted to confirm ablation of the physis.
88974517|NCT02260856|Experimental|Percutaneous Screw Epiphysiodesis|In the distal femur, guide wires will be placed in an antegrade fashion, with an 8 mm skin incision proximal to the physis both medially and laterally. The guide wire will be placed with the medial wire crossing the physis at the junction of the middle and medial third of the physis. The lateral guide wire will cross the physis at the junction of the lateral and middle third of the physis. The wires will extend into the epiphysis, but will not enter the joint. The guide wires will be over drilled with a 5 mm drill, and 7.3 mm fully threaded cannulated screws will be placed across the growth plate. For tibias, screw placement will be retrograde, with 8 mm incisions made medially and laterally distal to the physis, with guide wires aiming proximally.
88974518|NCT02250326|Experimental|Combination arm: nab-paclitaxel and CC-486|Subjects in the combination arm will receive nab-paclitaxel 100 mg^/m2 intravenous (IV) infusion over 30 minutes on Days 8 and 15 and CC-486 200 mg orally daily (QD) on Days 1 to14 of each 21-day treatment cycle
89582988|NCT02322047|Active Comparator|Praz/Pl|"Prazosin and Placebo (Naltrexone)~Prazosin will be taken following this titration schedule:~Days 1-2: 1 mg @ 9PM Days 3-4: 1 mg @ 9AM, 3PM, 9PM Days 5-7: 2 mg @ 9AM, 3PM, 9PM Days 8-10: 2mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 11-14: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 15-42: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM~Naltrexone Placebo will be taken from day 1 to day 42 at 9 PM. Dose: 50 mg."
89582989|NCT02322047|Active Comparator|Nal/Pl|"Naltrexone and Placebo (Prazosin)~Prazosin Placebo will be taken following this titration schedule:~Days 1-2: 1 mg @ 9PM Days 3-4: 1 mg @ 9AM, 3PM, 9PM Days 5-7: 2 mg @ 9AM, 3PM, 9PM Days 8-10: 2mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 11-14: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 15-42: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM~Naltrexone will be taken from day 1 to day 42 at 9 PM. Dose: 50 mg."
89582990|NCT02322047|Placebo Comparator|Pl/Pl|"Placebo (Prazosin) and Placebo (Naltrexone)~Prazosin Placebo will be taken following this titration schedule:~Days 1-2: 1 mg @ 9PM Days 3-4: 1 mg @ 9AM, 3PM, 9PM Days 5-7: 2 mg @ 9AM, 3PM, 9PM Days 8-10: 2mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 11-14: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 15-42: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM~Naltrexone Placebo will be taken from day 1 to day 42 at 9 PM. Dose: 50 mg."
89582991|NCT02254291|Experimental|Semaglutide 0.5 mg|
89209546|NCT00890760|Experimental|Group 3|Non-vaccinated Control for Groups 1 and 2 challenged with sporozoite
89582992|NCT02254291|Experimental|Semaglutide 1.0 mg|
89582993|NCT02254291|Active Comparator|Sitagliptin 100 mg|
89582994|NCT02253433|Experimental|Enhanced Clinic Care|This arm receives enhanced in-clinic care only.
89582995|NCT02253433|Experimental|Enhanced Clinic Care + Home Intervention|This arm receives the enhanced in-clinic care intervention, as well as a home-based intervention.
89582996|NCT02242981|Experimental|LY2623091|Single oral dose of LY2623091
89582997|NCT02277743|Experimental|Placebo|Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 followed by a single injection once weekly (qw) from Week 1 to Week 15.
89582998|NCT02277743|Experimental|Dupilumab 300 mg once weekly (qw)|Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection of Dupilumab qw from Week 1 to Week 15.
89582999|NCT02277743|Experimental|Dupilumab 300 mg every 2 weeks (q2w)|Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a placebo alternating with single 300 mg injection of Dupilumab qw from Week 1 to Week 15.
89583000|NCT02242903|Experimental|LY3079514|Single dose of LY3079514 administered intravenous (IV) or subcutaneous (SC) during a single occasion
89583001|NCT02242903|Placebo Comparator|Placebo|Single dose of placebo matching LY3079514 administered IV infusion or SC injection during a single occasion.
89583002|NCT02320721|Experimental|HOE901-U300|HOE901-U300 (Insulin glargine, 300 U/mL) once daily up to Week 26 on top of stable non-insulin antihyperglycemic therapy.
89583003|NCT02320721|Active Comparator|Lantus|Lantus (Insulin glargine, 100 U/mL) once daily up to Week 26 on top of stable non-insulin antihyperglycemic therapy.
89583004|NCT02320487|Experimental|Obinutuzumab + Bendamustine (BG)|Participants received obinutuzumab + bendamustine (BG) induction therapy in 28-day cycles for 6 cycles.
89583005|NCT04884659|Experimental|Timed restricted feeding|"Time restricted feeding then usual feeding pattern Day 1, testing~Day 2-7 all meals will be consumed as follows:~80% of calories consumed before 2 PM with remaining 20% consumed by 4PM. Fasting except for water, non caloric drinks for 14-16 hours Same number of calories consumed as in usual feeding pattern arm. Day 8 testing. Day 9-14 crossover to usual feeding pattern arm (meals consumed ad lib with 50% of calories consumed after 4 PM) for 6 days."
89583006|NCT04884659|Experimental|Usual feeding pattern|"Usual feeding pattern, then time restricted feeding Day 1 testing~Day 2-7 all meals will be consumed as follows:~Meals consumed ad lib with 50% of calories consumed after 4 PM. Day 8 testing. Day 9-14 crossover to time restricted feeding arm with all meals consumed as follows:~80% of calories consumed before 2 PM with remaining 20% consumed by 4PM. Fasting except for water, non caloric drinks for 14-16 hours Same number of calories consumed as in usual feeding pattern arm for 6 days."
89583007|NCT02277119|Experimental|Normal Eyes|Subjects with no known ocular diseases will be scanned with the iVue and Maestro device
89583008|NCT02277119|Experimental|Glaucomatous Eyes|Subjects presenting with different stages of glaucoma will be scanned with the iVue and Maestro device
89583009|NCT02277119|Experimental|Eyes with Retinal Diseases|Subjects presenting with Retinal pathological eyes will be scanned on the iVue and Maestro device
89583010|NCT02320253|Active Comparator|Medical Nutrition Therapy (MNT)|Participants in this arm will meet with a dietitian at their respective Health Center, not with a study dietitian. The participant and dietitian will decide how frequently to meet and create an individualized treatment plan. The participant's health insurance will be billed for these dietitian visit(s) and the participant is responsible for any copay(s) or deductible(s) associated with the visit(s).
89030089|NCT01249677|Experimental|insulin glargine|patients with type 2 diabetes on previous therapy with metformin were examined before and after eight weeks of treatment with insulin glargin, aimed to normalize fasting plasma glycaemia
89209547|NCT00890760|Experimental|Group 4|AdCh63 ME-TRAP prime followed by MVA ME-TRAP boost 8 weeks later and challenged by sporozoite 11 weeks after boost
89583011|NCT02320253|Experimental|In Person Group (IP)|Participants enrolled to the IP arm will meet weekly for 14 weeks, biweekly for 10 weeks, and then monthly for the next 18 months. Each session will be led by a study dietitian that has been assigned to that specific health center and will last 1.5 hours. Participants will be allowed to have one-on-one sessions with their dietitian throughout the first two years, twice in the first year and three times in the second year.
89583012|NCT02320253|Experimental|Telephone Conference Call Group (TCC)|Participants enrolled in the TCC arm will meet weekly for 14 weeks, biweekly for 10 weeks, and then monthly for the next 18 months. Each session will be led, over-the-phone, by a study dietitian that has been assigned to that specific health center and will last 1.5 hours. Participants will be allowed to have one-on-one sessions with their dietitian throughout the first two years, twice in the first year and three times in the second year.
89583013|NCT04197089|Experimental|Vitamin D treatment|Treatment with 10.000 IU or 50.000 IU Vitamin D weekly during 4 weeks
89583014|NCT02276807|Experimental|Brief Behavioral Activation|This is a 4-session individual workshop using behavioral activation techniques. Emphasis is placed upon understanding the individuals values and increasing the number of pleasurable activities aligned with the individuals values.
89583015|NCT02276807|Active Comparator|Usual Care|This is the usual care condition, where participants often times will be provided with brief treatment in primary care that can take many forms.
89583016|NCT02252965|Active Comparator|Metformin IR|
89583017|NCT02252965|Experimental|Metformin XR|
89583018|NCT02242435|Experimental|Ampion 4ml dose|4 mL intra-articular injection of Ampion
89583019|NCT02242435|Placebo Comparator|Placebo Solution|4 mL placebo intra-articular injection
89583020|NCT02251717|Experimental|LDV/SOF 12 wk|Participants will receive LDV/SOF FDC for 12 weeks.
89583021|NCT02251717|Experimental|LDV/SOF 24 wk|Participants will receive LDV/SOF FDC for 24 weeks.
89583022|NCT02242201|Active Comparator|PNB Bupivacaine|Bupivacaine 0.5% with 1:200,000 epinephrine 30 ml bolus preoperatively followed by an infusion of bupivacaine 0.2% on post anesthesia care unit (PACU) arrival.
89583023|NCT02242201|Active Comparator|PAI Ropivacaine|Patients 50 to 74.9 kg: ropivacaine 200 mg, epinephrine 100 ug, ketorolac 30 mg. Patients 75 to 99.9 kg: ropivacaine 300 mg, epinephrine 200 ug, ketorolac 30 mg. Patients 100 to 125 kg: ropivacaine 400 mg, epinephrine 300 ug, ketorolac 30mg.
89583024|NCT02242201|Active Comparator|PAI liposomal bupivacaine|Liposomal bupivacaine 255 mg, ketorolac 30 mg, bupivacaine 125 mg, epinephrine 125 ug.
89583025|NCT02242045|Experimental|Idelalisib|Participants with iNHL or CLL will receive idelalisib until the earliest of the following: unacceptable toxicity, substantial noncompliance, disease progression, pregnancy, initiation of another anticancer or experimental therapy, investigator discretion, or idelalisib discontinuation.
89583026|NCT02241889|Active Comparator|Standard Insulin Pump Therapy|Subjects will undergo 21 hour study with exercise using Insulin pump therapy and managing their blood glucose as they normally would.
89583027|NCT02241889|Experimental|Closed-loop without adjustment|Subjects will undergo 21 study using the Closed-loop Artificial Pancreas Controller to manage blood sugar. Exercise will not be annouced to the controller and no adjustments to insulin and glucagon delivery will be made.
89583028|NCT02241889|Experimental|Closed-loop with adjustment|Subjects will undergo 21 hour study using the Closed-loop Artificial Pancreas Controller to manage blood sugar. Exercise will be annouced to the controller and adjustments to insulin and glucagon delivery will be made.
89583029|NCT02241733|Active Comparator|exercise|Patients will exercise for 12 weeks and then participate in an adherence program
89583030|NCT02241733|Experimental|exercise plus breathing retraining|Patients will exercise plus breathing retraining for 12 weeks and then participate in an adherence program
89583031|NCT02241343|Other|Trial cohort|Measurements taken before and after venous occlusion applied
89583032|NCT04191577|Placebo Comparator|Placebo|Placebo to be administered once daily.
89583033|NCT04191577|Active Comparator|CVN424 (Low Dose)|Low dose of CVN424 to be administered once daily.
89583034|NCT04191577|Active Comparator|CVN424 (High Dose)|Patients randomized to the high dose will receive low-dose CVN424 once daily from day 1 to day 7, and will then increase their dose to the full high-dose once daily beginning on day 8.
89583035|NCT02241187|Experimental|PEGPH20 And Cetuximab|5 participants will undergo DW- & DCE-MRI for sequence parameter optimization. The 1st stage of the study, patients (n = 5) will have the option to undergo (DW-) & (DCE)-MRI for repeatability investigation & T1 mapping. Optional DW- & DCE-MRI will be repeated 2 to 5 days later, followed shortly by administration of 1 intravenous dose of cetuximab at 250 mg/m2/60 min. Pancreatic tumor resection will be performed 1 to 2 days later.Blood samples will be drawn at various time points. The resected tumor specimen will be studied. If deemed safe, we will proceed to the second stage of the study. Patients (n = 5) will have the option to undergo DW- & DCE-MRI. 1 to 3 days later, patients will receive 1 IV dose of PEGPH20 at 3 μg/kg/10 min. Optional DW- & DCE-MRI will be repeated 1 to 2 days after PEGPH20 administration, followed on that day by administration of 1 IV dose of cetuximab at 250 mg/m2/60 min. Pancreatic tumor resection will be performed 1 to 2 days later.
89583036|NCT02249767|Active Comparator|Generic Tretinoin|Treatment of acne once daily over 12 weeks
89583037|NCT02249767|Active Comparator|Brand Tretinoin|Treatment of Acne once daily over 12 weeks
89030090|NCT04697043|Experimental|systemic therapy followed by surgery|"ُThe main intervention is surgery. After the diagnosis of primary distant metastatic breast cancer, patients will be randomly allocated into two groups: A. systemic therapy followed by surgery if the disease is not progressive; B. Systemic therapy Patient selection criteria~The eligibility criteria for the study are:~- primary distant metastatic breast cancer (M1); - an anticipated survival of at least 6 months; - a histologically proven diagnosis of the breast tumor; - a known hormonal and HER2Neu status; - TNM classification: T1-T3, resectable T4 status, and N0-N3; - performance status and comorbidity should allow surgery and/or systemic therapy; - age ≥ 18 years;- written informed consent."
89583038|NCT02249767|Placebo Comparator|Placebo Vehicle|Treatment of acne once daily over 12 weeks
89583039|NCT02239939|Experimental|Vest + Diet|All participants will undergo a 22 week dietary weight loss. In addition, participants will be asked to wear a weighted vest for >10 hours a day. Weight in the vest is adjusted to match weight lost during the intervention.
89583040|NCT02239939|Active Comparator|No Vest + Diet|All participants will undergo a 22 week dietary weight loss intervention. Participants in this group will be asked not to change their daily habits other than adherence to the diet protocol.
89583041|NCT02248675|Experimental|CBT-I + TAU|Cognitive Behavioral Therapy for Insomnia (CBT-I), an evidence-based insomnia treatment. In this study it will be delivered in four individual sessions as an adjunctive treatment to treatment as usual (TAU).
89583042|NCT02248675|Active Comparator|TAU|Treatment as Usual: All participants will be encouraged to begin or continue treatment of co-occurring conditions as recommended by treatment providers. This may include treatment within the primary care teams, through behavioral telehealth, and/or specialty outpatient mental health. Participants randomized to TAU may receive pharmacotherapy for insomnia, though CBT-I will be precluded until after the post-treatment assessments.
89583043|NCT04783441|Active Comparator|Continuous glucose monitoring (CGM)|Those in the intervention arm will wear a continuous glucose monitoring device. They only need to perform blood glucose fingersticks if the CGM transmission is lost for a prolonged period of time or in cases of hypo- or hyperglycemia when symptoms don't align with blood glucose readings.
89030091|NCT04697043|No Intervention|Systemic therapy|"After the diagnosis of primary distant metastatic breast cancer, patients will be randomly allocated into two groups: A. systemic therapy followed by surgery if the disease is not progressive; B. Systemic therapy Patient selection criteria~The eligibility criteria for the study are:~- primary distant metastatic breast cancer (M1); - an anticipated survival of at least 6 months; - a histologically proven diagnosis of the breast tumor; - a known hormonal and HER2Neu status; - TNM classification: T1-T3, resectable T4 status, and N0-N3; - performance status and comorbidity should allow surgery and/or systemic therapy; - age ≥ 18 years;- written informed consent."
89030092|NCT04511975|Experimental|IBI188 + azacitidine|Participants will receive IBI188 in combination with azacitidine
89583044|NCT04783441|Placebo Comparator|Self monitoring of blood glucose (fingersticks)|The control arm will remain on standard-of-care SMBG while the intervention arm will use their CGM. The control arm utilizing SMBG will be required to have at minimum 4 glucose checks per day.
89583045|NCT02238379|Experimental|Oxytocin|Each participant will receive both the oxytocin nasal spray in one visit AND the placebo nasal spray in another visit (randomized) in this design.
89583046|NCT02238379|Placebo Comparator|Placebo|Each participant will receive both the oxytocin nasal spray in one visit AND the placebo nasal spray in another visit (randomized) in this design.
89583047|NCT02238067||Chronic Renal Anemia Participants|Participants with CKD who are not on dialysis and treated with ESA according to the usual standard of care and best practice guidelines, will be interviewed by physician who will complete the satisfaction surveys on anemia treatment at baseline and at 6 months follow-up visit.
89583048|NCT02237911|Experimental|Clinic-based outpatient exercise group|Subjects will participate in supervised sessions (clinic-based) of exercise followed by a home exercise program 2 times per week during 3 months. Each exercise session will last about 60 minutes. Treatment sessions will utilize a pragmatic approach and will include the exercises designed to increase muscular strength, low impact cardiovascular exercise, range of movement, and activity for daily living skills.
89583049|NCT02237911|Active Comparator|Community-based exercise group|Subjects will attend to exercise classes (community-based) 2 times per week during 3 months. The exercise classes last approximately 60 minutes. The group exercise classes consists of a variety of exercises designed to increase general muscular strength, low impact aerobic exercise, range of movement, and activity for daily living.
89583050|NCT02237911|No Intervention|Wait-listed usual medical care|Wait-listed usual medical care - no intervention provided by study.
89583051|NCT02234479|Active Comparator|Hydrophor (Group A)|Group A (current standard of care): Patients will be instructed (by nurses and with printed study materials) to apply a thin layer of the Hydrophor daily, starting at the onset of radiation therapy (RT) and continuing until 2 weeks after the final RT session or until the RT site is healed (whichever is first). Hydrophor application should include the entire treatment area, including the axillae and shoulder/back area in patients treated with modified radical mastectomy. To avoid possible build-up effects, patients should not apply the Hydrophor within 4 hours of receiving RT. Patients should wash the application area daily with perfume-free soap and tap water. Patients will be asked to refrain from using other topical agents in the irradiated area.
89583052|NCT02234479|Experimental|MediHoney (Group B)|Group B (study target): Patients will be instructed (by nurses and with printed study materials) to apply a thin layer of the Medihoney daily, starting at the onset of RT and continuing until 2 weeks after the final RT session or until the RT site is healed (whichever is first). Medihoney application should include the entire treatment area, including the axillae and shoulder/back area in patients treated with modified radical mastectomy. To avoid possible build-up effects, patients should not apply the Medihoney within 4 hours of receiving RT. Patients should wash the application area daily with perfume-free soap and tap water. Patients will be asked to refrain from using other topical agents in the irradiated area.
89583053|NCT02207491|Experimental|AR-13324 Ophthalmic Solution 0.02% & Placebo|1 drop AR-13324 in the evening (PM) & 1 drop placebo in the morning (AM) in both eyes (OU)
89583054|NCT02207491|Active Comparator|Timolol maleate Ophthalmic Solution 0.5% BID|1 drop Timolol maleate twice daily (BID) in the morning (AM) & evening (PM) in both eyes (OU)
89583055|NCT02315066|Experimental|PF-04518600|OX40 agonist
89583056|NCT02315066|Experimental|PF-04518600 plus PF-05082566|OX40 (CD134) agonist plus 4-1BB (CD137) agonist
89583057|NCT02207413|Experimental|Influsplit Tetra_IP Adult Group|Subjects in the Influsplit Tetra_IP group aged between 18 to 49 years received 1 dose of Influsplit Tetra™ vaccine produced by investigational process (IP) at Day 0. Influsplit Tetra™ vaccine produced by IP was administered intramuscularly in the deltoid region of left or non-dominant arm.
89583058|NCT02207413|Active Comparator|Influsplit Tetra_LP Adult Group|Subjects in the Influsplit Tetra_LP aged between 18 to 49 years received 1 dose of Influsplit Tetra™ vaccine produced by currently licensed process (LP) at Day 0. Influsplit Tetra™ vaccine produced by currently LP was administered intramuscularly in the deltoid region of left or non-dominant arm.
89583059|NCT02207413|Experimental|Influsplit Tetra_IP 3-17y Group|Subjects in the Influsplit Tetra_IP group aged between 3 years to <9 years received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of Influsplit Tetra™ vaccine produced by investigational process (IP). Subjects aged 9-17 years received only 1 dose of Influsplit Tetra™ vaccine produced by IP at Day 0. Influsplit Tetra™ vaccine produced by IP was administered intramuscularly in the deltoid region of left or non-dominant arm (Day 0) and in the deltoid region of right or dominant arm (Day 28).
89583060|NCT02207413|Active Comparator|Influsplit Tetra_LP 3-17y Group|Subjects in the Influsplit Tetra_LP group aged between 3 years to <9 years received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of Influsplit Tetra™ vaccine produced by licensed process (LP). Subjects aged 9-17 years received only 1 dose of Influsplit Tetra™ vaccine produced by LP at Day 0. Influsplit Tetra™ vaccine produced by LP was administered intramuscularly in the deltoid region of left or non-dominant arm (Day 0) and in the deltoid region of right or dominant arm (Day 28).
89030093|NCT01249755||delirious patients|The cohort is divided in delirious and non-delirious patients
89030094|NCT04511663|Active Comparator|intervention group|The intervention group received assertive community treatment, in which the team consisted of psychiatrists, nurses, clinical psychologists, social workers, rehabilitation teachers.
89030095|NCT04511663|Other|control group|The control group received basic public health services which is regular medical follow-up including symptom and medication evaluation, social function evaluation and physical examination after hospital discharge.
89583061|NCT02207413|Experimental|Influsplit Tetra_IP 6-35m Group|Subjects in the Influsplit Tetra_IP group aged between 6 months to 35 months received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of Influsplit Tetra™ vaccine produced by investigational process (IP). Influsplit Tetra™ vaccine produced by IP was administered intramuscularly the anterolateral region of left thigh for subjects below 12 months of age and in the deltoid region of left or non-dominant arm in subjects ≥ 12 months of age (Day 0) and in the anterolateral region of right thigh for subjects below 12 months of age and in the deltoid region of right or dominant arm in subjects ≥ 12 months of age (Day 28).
89583062|NCT02207413|Active Comparator|Influsplit Tetra_LP 6-35m Group|Subjects in the Influsplit Tetra_LP group aged between 6 months to 35 months received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of Influsplit Tetra™ vaccine produced by licensed process (LP). Influsplit Tetra™ vaccine produced by LP was administered intramuscularly the anterolateral region of left thigh for subjects below 12 months of age and in the deltoid region of left or non-dominant arm in subjects ≥ 12 months of age (Day 0) and in the anterolateral region of right thigh for subjects below 12 months of age and in the deltoid region of right or dominant arm in subjects ≥ 12 months of age (Day 28).
89583063|NCT02309372|Experimental|Cognitive Behavioral Therapy (CBT)|Those assigned to the CBT arm will undergo therapy with the Beating the Blues (BtB) computerized intervention.
89583064|NCT02309372|No Intervention|Usual Care|No specific depression care will be provided through this study for those assigned to this arm. However, the participant's caregiver may choose to provide depression treatment outside of this trial.
89583065|NCT02276027|Experimental|BYL719 350 mg QD|Patient's tumor must have molecular alteration of the PIK3CA gene.
89583066|NCT02276027|Experimental|INC280 400 mg BID tab/600 mg BID cap|Patient's tumor must have molecular alteration of the c-MET gene.
89583067|NCT02276027|Experimental|LDK378 750 mg QD|Patient's tumor must have ALK or ROS1 gene rearrangement.
89583068|NCT02276027|Experimental|MEK162 45 mg BID|Patient's tumor must have KRAS, NRAS or BRAF mutation.
89583069|NCT02309294|Experimental|Healthy Subject|Occlusive patches applied each day for 14 days for each intervention (Experimental: Novel lubricant Miami w/ fragrance, Experimental: Novel lubricant Miami no fragrance, KY Liquid lubricant, Astroglide Gel lubricant, Wet Platinum lubricant).
89583070|NCT02233543|Experimental|First QVA149 (indacaterol/glycopyrronium), then Placebo|Participants received 4 weeks of QVA149 85/43 μg delivered dose once daily in the morning between 08:00 and 11:00 AM at approximately the same time every day followed by 2 weeks washout. Then participants received 4 weeks of placebo once daily in the morning between 08:00 and 11:00 AM at approximately the same time every day.
89583071|NCT02233543|Experimental|First Placebo, then QVA149 (indacaterol/glycopyrronium)|Participants received 4 weeks of placebo once daily in the morning between 08:00 and 11:00 AM at approximately the same time every day followed by 2 weeks washout. Then participants received 4 weeks of QVA149 85/43 μg delivered dose once daily in the morning between 08:00 and 11:00 AM at approximately the same time every day.
89583072|NCT02309138|Active Comparator|3 hour 100 gm OGTT (CC Criteria)|Gestational diabetes screening with fasting 3 hour 100 gm. Receive a fasting 3 hour 100 gram oral glucose tolerance test and are diagnosed based on the Carpenter Coustan Criteria: a 50 gm Glucose tolerance test of >130 + fasting 3 hour 100 gram oral glucose tolerance test with two or more values greater than the following diagnostic threshold: Fasting 95, 1-hour 180, 2-hour 155, or 3 hour 140 mg/dL . A positive criteria will be diagnostic for gestational diabetes.
89583073|NCT02309138|Active Comparator|2 hr 75 gm OGTT (IADPSG Criteria)|Gestational diabetes screening with fasting 2 hour 75g. Receive a fasting 2 hour 75 gm oral glucose tolerance test and diagnosed based on the IADPSG which is if one or more values exceed the following diagnostic threshold: Fasting 92, 1-hour 180, or 2-hour 153 mg/dL.
89583074|NCT04761133|Experimental|Pleural irrigation with antiseptic|Two applications of 100-250 ml solution of 2% povidone-iodine will be irrigated into the pleural space of eligible patients 12 hours apart. The tube will be clamped for 15 minutes after irrigation and the patient will be asked to change position frequently during this period. The first dose will be applied 24-72 hours after tube insertion.
89583075|NCT04761133|No Intervention|No pleural irrigation|Standard care
89583076|NCT02233309||Monitoring of pressures during caudal anesthesia|"Patients receiving caudal anesthesia as standard of care for a surgical procedure.~Our study adds a monitoring line to the needle for the caudal. The caudal itself is not part of the study."
89583077|NCT02204917|Experimental|Comparative performance of ceVUS & VCUG|Contrast enhanced Voiding Urosonography (ceVUS) will be performed with the intravesical administration of 0.1%-0.5% OPTISON / normal saline solution. The exact OPTISON dose (ml) that will be adjusted according to the age-related bladder filling capacity with a dose (ml) range from 0.3 mL in newborns to 3 mL in 18 year-old children. Voiding Cystourethrography (VCUG) exam will be subsequently performed using the same bladder catheter with intravesical administration of the x-ray contrast agent.
89583078|NCT02280044|Experimental|rifaximin|Subjects receiving rifaximin prophylaxis will be challenged with C. jejuni
89583079|NCT02280044|Placebo Comparator|placebo|Subjects receiving placebo will be challenged with C. jejuni
89030096|NCT04519931|Experimental|Stress ball|
89030097|NCT04519931|No Intervention|Control group|
89030098|NCT02950194||PPAWI|patients with multidisciplinary PPAWI approach
89030099|NCT04511936|Active Comparator|i-Lumen AMD Active|
89030100|NCT04511936|Sham Comparator|i-Lumen AMD Sham|
89030101|NCT01249794|No Intervention|Best available treatment|
89030102|NCT01249794|Experimental|non invasive ventilation|
89030103|NCT04519736|Active Comparator|Harmony Dye-VL 500-600nm|The left side of the face will be treated with the Single Band Alma Harmony Dye-VL 500-600nm device. Three treatments, administered in intervals of 21 +/- 2 days. Each full face treatment duration will be approximately 20-30 minutes .
89209548|NCT00890760|Experimental|Group 5|AdCh63 ME-TRAP prime followed by MVA ME-TRAP boost 8 weeks later and challenged by sporozoite 3 weeks after boost
89583080|NCT04748653|Experimental|Multi-component reintegration intervention|There is one arm for the feasibility and acceptability study - all intervention participants will receive the intervention: health education, psychosocial counseling, physiotherapy, and economic investment.
89583081|NCT02308748|Active Comparator|Dofetilide|Dofetilide alone arm
89583082|NCT02308748|Active Comparator|Dofetilide + Mexiletine|Dofetilide combined with mexiletine
89583083|NCT02308748|Active Comparator|Dofetilide + Lidocaine|Dofetilide combined with lidocaine
89583084|NCT02308748|Active Comparator|Moxifloxacin + Diltiazem|Moxifloxacin with and without diltiazem.
89583085|NCT02308748|Placebo Comparator|Placebo|Placebo (#2 gelcap and intravenous saline)
89583086|NCT04745689|Experimental|AZD2811 + Durvalumab|"Induction:~Durvalumab + Platinum Chemotherapy (Carboplatin or cisplatin & Etoposide)~Maintenance:~AZD2811 + Durvalumab"
89583087|NCT04768543||Exposure|Patients with moderate to severe OSA treated with UAS (Inspire Medical Systems, Inc)
89583088|NCT01646216|Experimental|Split-belt treadmill training|Split-belt treadmill exercise
89583089|NCT02308124|Experimental|Midodrine|Start midodrine 2.5mg bid, and then dose up to 5mg bid after one month if necessary.
89583090|NCT02308124|Experimental|Pyridostigmine|Start Pyridostigmine 30mg bid, and then dose up to 60mg bid after one month if necessary.
89583091|NCT02308124|Experimental|Midodrine + Pyridostigmine|Start midodrine 2.5mg bid+ Pyridostigmine 30mg bid, and then dose up to midodrine 5mg bid+ Pyridostigmine 60mg bid after one month if necessary.
89583092|NCT02232061|Experimental|Fingolimod|Fingolimod 0.5mg/day tablets taken orally.
89583093|NCT02275481|Experimental|BROVANA|Arformoterol tartrate inhalation solution 15 mcg (BROVANA) will be administered BID (morning and evening, approximately 12 hours between doses) using a standard jet nebulizer with a face mask or mouthpiece connected to an air compressor
89583094|NCT02275481|Active Comparator|SPIRIVA|Tiotropium 18 mcg (SPIRIVA) will be administered QD (morning) via the HandiHaler®.
89583095|NCT02204449|Experimental|Cardiac Rehabilitation Peer Mentorship|Trained cardiac rehabilitation (CR) peer mentors will visit cardiac inpatients in the hospital to provide patients with information on CR. During this visit the CR mentors will discuss the benefits of CR, stress the importance of getting a referral, and arrange a time to call the patient/participant at home to find out about their CR progress. One week post-discharge the peer mentor will mail a card to the patient to remind them of the planned call. Two weeks post-discharge the peer mentor will call the patient at home to determine if they were referred and if they are planning to attend CR. If any barriers are stated by patient the peer mentors will work with the patient to develop possible solutions. Patients can request up to two additional phone calls from the mentors.
88974519|NCT02250326|Experimental|Monotherapy arm: nab-paclitaxel IV infusion|Subjects in the monotherapy arm will receive nab-Paclitaxel 100 mg/m^2 IV infusion over 30 minutes on Days 1 and 8 of each 21-day treatment cycle
88974520|NCT02250326|Experimental|Nab-paclitaxel and Durvalumab combination|subjects in the nab-Paclitaxel/durvalumab combination arm will receive nab-Paclitaxel 100 mg/m2 IV infusion over 30 minutes on Days 1 and 8 and durvalumab 1125 mg IV infusion over approximately 1 hour on Day 15 of each 21-day treatment cycle
88974521|NCT02225600|Other|patients with BPD|cross-over administration of 40 IU oxytocin, 24 IU oxytocin and placebo
88974522|NCT02225600|Active Comparator|healthy patients|Cross-over of 40 IU oxytocin, 24 IU oxytocin and placebo
88974523|NCT02211742|Active Comparator|dapagliflozin|10mg dapagliflozin per 24h for 3 days per cross-over phase (equals 2 x 30mg)
88974524|NCT02211742|Placebo Comparator|placebo sugar pills|placebo tablet, 1 per 24h for 3 days in total per cross-over phase (equals 2 x 3 tablets)
88974525|NCT02081404|Active Comparator|Esomeprazole|proton pump inhibitor
88974526|NCT02081404|Placebo Comparator|Placebo|placebo
89583096|NCT02204449|No Intervention|Usual Care|Cardiac inpatients will not be visited by the cardiac rehabilitation (CR) peer mentor. They will instead receive usual care involving care from health care providers (i.e. nurses and doctors) as well as allied health professionals such as physiotherapists. In addition, some may be visited by general volunteer cardiac mentors.
89583097|NCT02308046|Active Comparator|Terconazole vaginal gel|One applicator full at bedtime
89583098|NCT02308046|Placebo Comparator|Gel vehicle|One applicator full at bedtime
89583099|NCT02318693|Experimental|Sitagliptin 50 mg|Sitagliptin 50 mg administered orally once daily before breakfast for 14 days.
89583100|NCT02318693|Active Comparator|Glibenclamide 2.50 mg TDD|Glibenclamide 1.25 mg administered orally twice daily (2.5 mg TDD) for 14 days. TDD = Total daily dose.
89583101|NCT02230891|Active Comparator|Carvedilol|Approximately 70 subjects will be randomized to carvedilol
89583102|NCT02230891|Active Comparator|Spironolactone|Approximately 70 subjects will be randomized to spironolactone
89583103|NCT02230891|Other|Usual care|Approximately 70 subjects will be randomized to usual care/ standard care by primary care providers
89583104|NCT01646138|Experimental|Challenge Virus|The Ca/04/2009/H1N1 Vero Grown Challenge Virus was administered intranasally to each participant using a nasal sprayer. A total volume of up to 1 mL of virus will be administered.
89583105|NCT02204371|Experimental|Part A- Dose Escalation phase|Part A will be an open label, dose-escalation study in which 4 cohorts of approximately 6 subjects will receive increasing doses of pazopanib for a maximum of 12 weeks. The dose in the first cohort will be 50mg per day and the maximum dose in a cohort will be 400 mg per day. Dose escalation will not occur if the predefined safety stopping criteria are met or at least 4 subjects in a cohort have demonstrated efficacy. Cohort 4 receiving 400 mg dosing schedule may involve cycles of up to 3 weeks of active treatment, followed by up to 3 weeks wash-out (instead of 12 weeks continuous dosing). Decision will be based on safety data obtained from lower doses
89583106|NCT02204371|Experimental|Part B-Dose Optimization phase|If efficacy is demonstrated in Part A with an acceptable safety profile, Part B will be initiated to further define the optimal dose(s) including dose duration/schedule and to provide further support for the proof of mechanism. Approximately 15 subjects will participate and will be randomised to active or placebo in a ratio of 3:2. This part of the study will be double-blind
89583107|NCT02274857|Active Comparator|Standard PVI Ablation|Standard catheter ablation including pulmonary vein isolation (PVI) procedure for the treatment of persistent AF.
89583108|NCT02274857|Experimental|FIRM-guided Procedure and PVI|FIRM-guided procedure followed by standard catheter ablation including PVI.
89583109|NCT02302859|Experimental|Standard Treatment (ST)|"Participants supplied with a 8-week supply of nicotine patches, a smart phone and brief advice to quit smoking. Participants also receive proactive phone counseling (8 sessions) over the 8-week period for support in quitting smoking. The call will last about 15 minutes.~Participants receive weekly assessments to complete for the 8-week treatment period via smartphone.~Participants receive weekly assessments to complete for the 8-week treatment period via smartphone, and again at 3 months after intervention.~Participants complete saliva cotinine test 3 months after intervention."
89583110|NCT02302859|Experimental|Automated Treatment (AT)|"Participants supplied with a 8-week supply of nicotine patches and a smart phone. Participants also receive brief advice to quit smoking (tailored video clips) and an 8-week automated intervention (interactive text messages and graphical messages) for support in quitting smoking via smartphone.~Participants receive weekly assessments to complete for the 8-week treatment period via smartphone, and again at 3 months.~Participants complete saliva cotinine test 3 months after intervention."
89583111|NCT02274311|Experimental|Clomiphene citrate|Patients receiving clomiphene citrate
89583112|NCT02316353|Experimental|C1-INH - low-volume dose|A low-volume dose of C1-INH will be administered subcutaneously twice a week for up to 52 weeks (up to 146 weeks extension period).
89583113|NCT02316353|Experimental|C1-INH - medium-volume dose|A medium-volume dose of C1-INH will be administered subcutaneously twice a week for up to 52 weeks (up to 146 weeks extension period).
89583114|NCT02273141|Experimental|NER1006, Day Before-Only Dosing|NER1006 1-Day Day Before-Only Split-Dosing Regimen (to commence on the evening of the day before colonoscopy).
89583115|NCT02273141|Active Comparator|SP+MS, Day Before-Only Dosing|SP+MS 1-Day Day Before-Only Split-Dosing Regimen (to commence on the morning of the day before colonoscopy).
89583116|NCT02314052|Experimental|DCR-MYC|Patient groups (cohorts) will receive a single dose level of DCR-MYC; the dose level of DCR-MYC will be increased in subsequent cohorts
89583117|NCT02279732|Experimental|Arm 1: Carboplatin + Paclitaxel + Ipilimumab|"Paclitaxel 175 mg/m² IV Solution Every 3 weeks during induction and every 12 weeks during maintenance until disease progression declared by modified WHO (mWHO)~Carboplatin Area Under the Curve (AUC6) IV Solution Every 3 weeks during induction and every 12 weeks during maintenance until disease progression declared by mWHO~Ipilimumab 10 mg/kg IV Solution Every 3 weeks during induction and every 12 weeks during maintenance until disease progression declared by mWHO"
89583118|NCT02279732|Experimental|Arm 2: Carboplatin + Paclitaxel + Placebo|"Carboplatin AUC6 IV Solution Every 3 weeks during induction and every 12 weeks during maintenance until disease progression declared by mWHO~Paclitaxel 175 mg/m² IV Solution Every 3 weeks during induction and every 12 weeks during maintenance until disease progression declared by mWHO~Placebo IV Solution Every 3 weeks during induction and every 12 weeks during maintenance until disease progression declared by mWHO"
89583119|NCT05650034|Experimental|Elective nodal de-escalation arm|Omission of elective nodal irradiation in N0 hemi-neck of well lateralized H&N SCCs ( pN0 or by PETCT). Dose de-escalation of elective nodal irradiation in N0 hemi-neck of midline H&N SCCs ( pN0 or by PETCT).
89583120|NCT02279498|Experimental|Liprotamase|Individually-optimized dose to be administered orally
89583121|NCT02279498|Active Comparator|porcine (pig) PERT|Individually-optimized dose to be administered orally
89583122|NCT02307266|Experimental|Standard of care + supplementary education|Subjects will receive supplementary patient educational material in addition to standard-of-care instructions.
89583123|NCT02307266|Experimental|Standard of care|Subjects will receive standard-of-care instructions only.
89583124|NCT02307266|Experimental|Standard of care + additional visits|Subjects will receive standard-of-care instructions, and two additional clinical visits.
89583125|NCT02279420|Other|Essential Study Sham Cross-over|Device: g-Cath EZ™ Suture Anchor Delivery Catheter This is a multicenter, un-blinded, open label, pivotal supplemental study to G130163 intended to evaluate the safety and efficacy of treating previous sham subjects in the Essential pivotal trial (IDE#G130163) with the active treatment (the placement of g-Cath EZ suture anchors along with diet and exercise). Compliant sham subjects (those who attended all primary IDE follow-up visits AND who continue to meet eligibility criteria as described in this protocol) will be offered this active treatment after their 12 month unblinding visit in the Essential pivotal trial.
89583126|NCT02278328|Experimental|A. Placebo then 15mg then 30mg|"Subjects will receive a single dose of placebo on week 1, 15 mg of STX209 on week 2 and 30 mg of STX209 on week 3.~Subjects will receive STX209 via oral disintegrating tablets, administered in individual 15mg tablets."
89583127|NCT02278328|Experimental|B. 15mg then placebo then 30mg|"Subjects will receive a single dose of 15 mg of STX209 on week 1, placebo on week 2 and 30 mg of STX209 on week 3.~Subjects will receive STX209 via oral disintegrating tablets, administered in individual 15mg tablets."
88974527|NCT01580631||BE with dysplasia.|Patients having Barrett's esophagus with dysplasia.
88974528|NCT01580631||BE without dysplasia.|Patients having Barrett's esophagus without dysplasia.
88974529|NCT01567722||HIV-positive diffuse large B-cell lymphoma cases|Tissue collection for genomic sequencing from persons with a diagnosis of HIV and diffuse large B-cell lymphoma.
88974530|NCT01567722||HIV-positive lung cancer cases|Tissue collection for genomic sequencing from persons with a diagnosis of HIV and lung cancer.
88974531|NCT01567722||HIV-positive cervical cancer cases|Tissue specimen collection from HIV positive patients with a diagnosis of cervical cancer
88974532|NCT00782769|Experimental|Oxybutinyn Vaginal Ring 4mg|inserted daily and replaced every 4 weeks
88974533|NCT00782769|Experimental|Oxybutinyn Vaginal Ring 6mg|inserted daily and replaced every 4 weeks
88974534|NCT00761124|Experimental|1|Educational small group session regarding prostate cancer
88974535|NCT00761124|Other|2|Printed material regarding general prostate cancer information provided.
89583128|NCT02278328|Experimental|C. 15mg then 30mg then placebo|"Subjects will receive a single dose of 15 mg of STX209 on week 1, 30 mg of STX209 on week 2 and placebo on week 3.~Subjects will receive STX209 via oral disintegrating tablets, administered in individual 15mg tablets."
89583129|NCT02314637|Experimental|Teneligliptin|Teneligliptin for 52 weeks
89583130|NCT02314637|Experimental|Teneligliptin + Sulfonylurea|Teneligliptin for 52 weeks in combination with sulfonylurea
89583131|NCT04877054|Experimental|Intervention Arm|Intervention sessions will occur ~once per week, with all 4 sessions being completed within 4-8 weeks. Each session will include an education and motivational interviewing (MI) component.
89583132|NCT04877054|Active Comparator|Education only Arm|Participants in the education-only control arm will receive one education session. The education session will occur via telephone or telehealth. Education will include medication purpose and adherence strategy recommendations delivered in a single telehealth session.
89583133|NCT04876430|Experimental|Meropenem plus Best Available Therapy plus|"Meropenem 2g every 8 hours combined with the best available therapy (BAT). BAT will be defined according to the susceptibility profile and decision of the assistant team before randomization and should include at least one of the antimicrobials that, usually, have in vitro activity against carbapenem-resistant Enterobacterales isolates.~Polymyxin B or colistimethate;~Amikacin or gentamicin;~Tigecycline;~Another antimicrobial with in vitro susceptibility.~Doses will be defined by the assistant team."
89583134|NCT04876430|No Intervention|Best Available Therapy|"The best available therapy will be defined according to the susceptibility profile and decision of the assistant team before randomization and should include at least one of the antimicrobials that, usually, have in vitro activity against carbapenem-resistant Enterobacterales isolates.~Polymyxin B or colistimethate;~Amikacin or gentamicin;~Tigecycline;~Another antimicrobial with in vitro susceptibility.~Doses will be defined by the assistant team."
89583135|NCT01646645|Experimental|Group I|This is a single-arm non-randomized single institution phase 2 trial, designed to evaluate the therapeutic activity of CMVpp65-CTLs generated from seropositive HSCT donors when adoptively transferred into transplant recipients with persistent CMV infection or viremia. Patients eligible for this trial will be consenting recipients of related or unrelated HSCT who have an active CMV infection or persistent CMV viremia for ≥ 2 weeks despite treatment with anti-viral agents or who cannot be maintained on anti-viral therapy due to treatment related toxicity.
89583136|NCT02272985|Other|CBF change during hemodialysis|[15O]H2O PET-CT scan and NIRS (Invos)
89583137|NCT01644149|Experimental|Stratis Jet Injector|Single intramuscular administration of 0.5 mL of 2011-2012 Fluzone trivalent inactivated influenza vaccine using the Stratis Jet Injector
89583138|NCT01644149|Active Comparator|Needle and Syringe|Single intramuscular administration of 0.5 mL of 2011-2012 Fluzone trivalent inactivated influenza vaccine using Needle and Syringe
88974536|NCT00710177||PPHN|Infants born at >= 34 weeks who are diagnosed with clinical and/or echocardiographic evidence of PPHN
88974537|NCT00710177||Control|Randomly selected, normal healthy infants born at >= 34 weeks gestational age and do not have PPHN
88974538|NCT00710112||VLBW|infants less than 1500 grams at birth
88974539|NCT00574327||A- Barrett's Esophagus subjects|Patients with documented Barrett's Esophagus with or without dysplasia (LGD or HGD) that will undergo surveillance endoscopies dictated by the grade of dysplasia.
88974540|NCT00574327||B- gastroesophageal reflux subjects|Patients undergoing endoscopy for evaluation of GERD symptoms.
89583139|NCT02313233|Experimental|Umooze|Tablet oral dosage. Astragalus radix Extracts 480 mg+ Soy extracts 20 mg
89583140|NCT02313233|Placebo Comparator|Placebo|Cornstarch.
89583141|NCT02313155|Experimental|TAK-850 0.5 mL (subcutaneous)|Single subcutaneous injection of TAK-850
89583142|NCT02313155|Experimental|TAK-850 0.5 mL (Intramuscular)|Single intramuscular injection of TAK-850
89583143|NCT02204293|Experimental|Canakinumab|Participants received canakinumab 4 mg/kg up to a maximum of 300 mg subcutaneous (SC) injection, once in morning on Day 0, Weeks 4, 8, and 12 in Part I of the core study. Participants with response (change in DAS score > 1.2 at Week 12) continued to receive same dose of canakinumab in Part II for Weeks 12, 16, and 20. Participants who had remission (change in DAS score > 1.2 and no signs of systemic activity for adult-onset Still's disease at Week 20) entered Long-term extension (LTE) phase and received same dose of canakinumab at Weeks 24 and 28, which was down titrated to 2 mg/kg if applicable from Week 28 up to Month 27.
89583144|NCT02204293|Placebo Comparator|Placebo|Participants received placebo, SC injection, once in morning on Day 0, Weeks 4, 8, and 12 in Part I of the core study. Participants with response (change in DAS score > 1.2 at Week 12) continued to receive placebo at Weeks 12, 16, and 20. Non-responders (who had change in DAS score ≤ 1.2) were unblinded to receive canakinumab 4 mg/kg (up to 300 mg maximum), SC injection, at Weeks 12, 16, and 20. Participants who had remission (change in DAS score > 1.2 and no signs of systemic activity for adult-onset Still's disease at Week 20) entered Long-term extension (LTE) phase and received same dose of canakinumab at Weeks 24 and 28, which was down titrated to 2 mg/kg if applicable from Week 28 up to Month 27.
88974541|NCT00574327||C-subjects without BE or GERD|The control group would include patients undergoing upper endoscopy for reasons other than stated above, such as evaluation of iron deficiency anemia, weight loss, positive fecal occult blood, etc.
88974542|NCT00496041|Experimental|Smart Stent in the Superficial Femoral Artery .|
88974543|NCT04733300|Experimental|Mindfulness-Based College - Standard Dose|MBC standard dose is a 9-week, 9 session program providing systematic and intensive training in mindfulness meditation practices. The curriculum is grounded in the manualized and standardized Mindfulness-Based Stress Reduction (MBSR) curriculum. MBSR was adapted to the young adult life stage by: (1) Training mindfulness skills such as attention control, self-awareness and emotion regulation, using the MBSR curriculum, and (2) applying these skills to the health behaviors and priorities most relevant to young adults. Specific behaviors and priorities targeted are social relationships, sleep, stress, diet, physical activity, obesity, alcohol consumption, substance use, digital media use, and performance (e.g. athletic, artistic and academic). The intervention is administered live, online via a video conferencing platform. The standard dose class meets once a week for 2.5 hours for 9 weeks. There is also an all-day retreat that takes place around week 6 of the program.
89030104|NCT04519736|Active Comparator|Palomar MaxG|Right side of the face will be treated with the Dual Band Palomar MaxG device. Three treatments, administered in intervals of 21 +/- 2 days. Each full face treatment duration will be approximately 20-30 minutes .
89583145|NCT02304926|Experimental|Simvastatin|Hyperlipidemic patients received simvastatin (40 mg/day) for 4 weeks, after they were administered combined therapy (simvastatin, 40 mg/day plus ezetimibe,10 mg/day) for an additional 4-week period. Lipid profile, lipoprotein subfractions of LDL and HDL, inflammatory, oxidative stress and endothelial function parameters were evaluated.
89583146|NCT02304926|Experimental|Ezetimibe|Hyperlipidemic patients received ezetimibe (10 mg/day) for 4 weeks, after they were administered combined therapy (simvastatin, 40 mg/day plus ezetimibe,10 mg/day) for an additional 4-week period. Lipid profile, lipoprotein subfractions of LDL and HDL, inflammatory, oxidative stress and endothelial function parameters were evaluated.
89583147|NCT01646255|Experimental|Rotigotine|Rotigotine, daily doses, treatment group
89583148|NCT01646255|Placebo Comparator|Placebo|Placebo, daily doses, placebo group
89583149|NCT04870229|Active Comparator|Carnosine|Each participant will be given a daily oral dose 1g of methycellulose powder for 6 months
89583150|NCT04870229|Placebo Comparator|Placebo|Each participant will be given a daily oral dose 1g of placebo for 6 months
89583151|NCT05649761|Experimental|QL1604 injection|Participants will receive QL1604 injection 0.3 mg/kg,1mg/kg, 3mg/kg,10mg/kg, or 200mg intravenous every 2 weeks or every 3 weeks and will be continued until disease progression or unacceptable toxicity.
89583152|NCT05649566|Experimental|Virtual Reality Game Group|"A total of 24 interventions will be carried out for each participant, separated by 2 each week for 3 months. Each intervention will consist of a VR session lasting 30 minutes. Each participant must play for 30 minutes in the game Beat know. The game consists of cutting mobile targets, using lightsabers while avoiding obstacles that approach the user. This game is a reference for immersive play since, while distracting, it recreates a physical activity similar to what would be done in reality. It has been shown that the same energy expenditure, on the part of the user, practicing tennis in real life, is what he does playing Beat Saber playing the same period of time."
89583153|NCT05649566|No Intervention|Control Group|No intervention during 12 weeks.
89583154|NCT02203591|Experimental|3M CHG/IPA Prep C|Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
89583155|NCT02203591|Experimental|3M CHG/IPA Prep CH|Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
89583156|NCT02203591|Active Comparator|ChloraPrep|Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
89583157|NCT02203591|Placebo Comparator|Normal Saline|Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
89583158|NCT01642277|Experimental|Women using Solifenacin for OAB treatment|Solifenacin treated women: Women with OAB who are prescribed solifenacin
89583159|NCT01642277|No Intervention|Control: Women without OAB|Women without OAB who are not prescribed solifenacin.
89583160|NCT04869956|Other|Standard diet|Dietary pattern: Standard diet
89583161|NCT04869956|Experimental|High - Fiber diet rich in PUFA|High - Fiber diet rich in PUFA
89583162|NCT02230189|Experimental|Allergen challenge subjects|"Intervention: Segmental airway allergen challenge~Three types of subjects are studied in this arm:~1) Volunteers with neither asthma nor allergy (as established by skin prick testing); 2) Volunteers with allergy (as established by skin prick testing) but without asthma; and 3) Volunteers with both asthma and allergy (as established by skin prick testing)"
89583163|NCT04196348|Active Comparator|Short BPL RYGB in glucose-tolerant participants|Procedure: short biliopancreatic limb (BPL) Roux en Y Gastric Bypass (RYGB) Obese patients without type 2 diabetes mellitus (T2DM) to be submitted to short BPL (n=10)
89583164|NCT04196348|Active Comparator|Long BPL RYGB in glucose-tolerant participants|Procedure: long BPL RYGB Obese patients with metabolic syndrome without T2DM to be submitted to long BPL (n=10)
89583165|NCT04196348|Active Comparator|Long BPL RYGB in diabetic participants|Procedure: long BPL RYGB Obese patients with metabolic syndrome and T2DM to be submitted to long BPL (n=10)
89583166|NCT02304302|Placebo Comparator|Placebo|Identically-looking placebo pills to memantine will be dispensed in a 66-day supply (56 days plus 10 extra days) by the study coordinator to participants receiving the placebo at the end of visits 2 and 3.
89583167|NCT02304302|Experimental|Memantine|Memantine will be dispensed in a 66-day supply (56 days plus 10 extra days) by the study coordinator to participants receiving the placebo at the end of visits 2 and 3.
89583168|NCT02276612|Experimental|E/C/F/TAF|"Treatment-experienced participants will receive open-label E/C/F/TAF for up to 48 weeks.~After completion of 48 weeks of treatment, all eligible participants will be given the option to participate in an open-label extension phase to receive E/C/F/TAF until a) the participant turns 18 years old and E/C/F/TAF is commercially available for use in adults in the country the participant is enrolled, or b) E/C/F/TAF becomes commercially available for use in the participant's current age group in the country the participant is enrolled, or c) E/C/F/TAF becomes accessible to participants through an access program, or d) Gilead Sciences elects to terminate development of E/C/F/TAF in the applicable country."
89583169|NCT02301143|Experimental|nab-Paclitaxel plus Gemcitabine|"nab-Paclitaxel 125 mg/m2 intravenous (IV) infusion over approximately 30 to 45 minutes on Days 1, 8, and 15, followed by gemcitabine 1000 mg/m2 IV infusion over approximately 30 minutes on Days 1, 8, and 15 of each 28-day cycle Subjects who complete 6 cycles of nab-paclitaxel and gemcitabine without disease progression or unacceptable toxicities, the Investigator will then determine the best option for the subject.~Continuation of nab-paclitaxel and gemcitabine therapy to disease progression or unacceptable toxicity OR~Chemoradiation therapy consisting of the concurrent use of capecitabine or gemcitabine with radiation according to institutional practice OR~Surgical intervention"
89583170|NCT02276222|Experimental|SUN-101 50 mcg BID eFlow (CS) nebulizer|SUN-101 (Glycopyrrolate) 50 mcg twice daily (BID) via eFlow Closed System (CS) nebulizer
89583171|NCT02276222|Active Comparator|Spiriva 18 mcg QD Handihaler|Spiriva (tiotropium) 18 mcg once daily (QD) via Handihaler
89583172|NCT02275364|Experimental|Test nasal strip|Marketed Nasal Strip to be applied for up to two hours, and during the third scanning session for approximately 20 minutes.
89583173|NCT02275364|Placebo Comparator|Placebo nasal strip|Placebo nasal strip to be applied for up to two hours in either of the first two scans only.
89583174|NCT02275052|Experimental|UMEC/VI 62.5/25mcg|Participants will self-administer blinded UMEC/VI (62.5 mcg/25 mcg) each morning (once daily) as one inhalation from the double-blind DPI in one of the 2 treatment periods of 12 weeks. The treatment periods will be separated by a wash out period of 12-17 days.
89583175|NCT02275052|Experimental|Placebo|Participants will self-administer blinded placebo each morning (once daily) as one inhalation from the double-blind DPI in one of the 2 treatment periods of 12 weeks. The treatment periods will be separated by a wash out period of 12-17 days
89583176|NCT05649020|Other|Prilocaine dose|to determine the ED50 and ED90 of intrathecal HP for patients undergoing undergoing ambulatory MRI/ultrasound fusión prostate biopsy.
89583177|NCT04869488|Experimental|Fluzoparib|
89583178|NCT04869488|Active Comparator|Enzalutamide OR abiraterone acetate With Prednisone Acetate Tablets|
89583179|NCT04869488|Experimental|Fluzoparib Combined With Apatinib|
89583180|NCT05648942|Experimental|Experimental - anemia testing|"All patients in the experimental group will undergo a point of care test. Patients who meet the higher point-of-care-testing thresholds as possibly having anemia (female: 130g/L; male: 140g/L) will have a formal complete blood count (CBC) test. Formal CBC will not be ordered for all patients in the experimental group to limit the burden on hospital resources. The study co-ordinator will review CBC levels and contact patients to inform them of their results. Patients identified as having anemia in the formal CBC test will be invited to be reviewed in the PBOC.~Patients in the experimental group who do not meet the threshold for possible anemia on the point-of-care test will continue the current pathway and be reassessed in the preoperative assessment clinic at the time of scheduled surgery. Patients in the experimental group who are determined not to have anemia after formal CBC tests will follow the same pathway."
89583181|NCT05648942|No Intervention|Control|Patients in the control group will not be tested at point of care and will continue on the current pathway and be assessed in the preoperative assessment clinic at the time of scheduled surgery.
89583182|NCT02274038|Experimental|All patients will be enrolled in a single arm of the study|All patients enrolled in the study will receive three 18F-thymidine (FLT) PET/CT scans at the following timepoints: before therapy, on the day of starting pemetrexed therapy (within 24 hours of starting pemetrexed) and at 2-4 weeks of starting pemetrexed therapy.
89583183|NCT02300558|Experimental|Eleclazine (Single-blind treatment phase)|Eleclazine and/or eleclazine placebo up to Week 24
89583184|NCT02300558|Experimental|Open-label Extension Phase|Eligible participants will continue to receive open-label eleclazine until this drug is commercially available for the treatment of patients with LQT3, or until Gilead terminates development of eleclazine for the treatment of patients with LQT3, or the investigator deems it no longer in the participant's best interest.
89583185|NCT04882046|Other|patients diagnosed by a clinician who suspects leptospirosis|
89583186|NCT02273960|Experimental|Arm A: BMS-986004|BMS-986004 solution intravenously (IV) as specified
89583187|NCT02273960|Experimental|Arm B: BMS-986004|BMS-986004 solution intravenously as specified
89583188|NCT02273960|Experimental|Arm C: BMS-986004|BMS-986004 solution intravenously as specified
89583189|NCT02273960|Experimental|Arm D: BMS-986004|BMS-986004 solution intravenously as specified
89583190|NCT01646021|Experimental|Ibrutinib|
89583191|NCT01646021|Experimental|Temsirolimus|
89583192|NCT01750918|Experimental|Part 1: Dabrafenib and Panitumumab|In Part 1 subjects will be assigned to escalation cohort of the doublet of dabrafenib and panitumumab based on the monotherapy doses of dabrafenib (150 milligrams [mg] twice daily) and panitumumab (6 milligrams per kilogram [mg/kg] every-2-week [Q2W]). Dose escalation will follow a 3+3 dose escalation procedure. If the initial combination dose of dabrafenib and panitumumab in Cohort 1 (starting dose) is not tolerable, lower dose combination(s) may be evaluated.
89583193|NCT01750918|Experimental|Part 1: Dabrafenib, Trametinib and Panitumumab|In Part 1 after the dabrafenib/panitumumab combination dose is defined, subsequent cohorts will evaluate the addition of trametinib based on a panitumumab dose that is one dose level lower than the dabrafenib/panitumumab dose defined in Cohort 1. Trametinib starting at 1.5 mg once daily will be added to the combination of dabrafenib and panitumumab. Dose escalation will follow a 3+3 dose escalation procedure until the full monotherapy doses of all agents are evaluated or the maximum tolerated dose is determined.
89583194|NCT01750918|Experimental|Part 2: Dabrafenib and panitumumab|In Part 2, subjects will be assigned to expansion cohorts at a selected dose of dabrafenib in combination with panitumumab
89583195|NCT01750918|Experimental|Part 2: Dabrafenib, Trametinib and Panitumumab|In Part 2, subjects will be assigned to expansion cohorts at selected dose of trametinib plus dabrafenib in combination with panitumumab.
89583196|NCT01750918|Experimental|Part 4a: Trametinib and Panitumumab|Subject will be administered starting dose of Trametinib 2 mg once daily and Panitumumab 6mg/kg Q2W. If the initial combination dose of trametinib and panitumumab in Cohort 1 (starting dose) is not tolerable, the lower dose combination defined in de-escalation cohorts (Cohort -1A, -1B and/or -1C) may be evaluated. Cohort -1A: Trametinib 1.5 mg once daily and Panitumumab 6 mg/kg Q2W; Cohort -1B: Trametinib 2 mg once daily and Panitumumab 4.8 mg/kg Q2W; Cohort-1C: Trametinib 1.5 mg once daily and Panitumumab 4.8 mg/kg Q2W
89030105|NCT02950116|Active Comparator|Asthma|Asthmatic patients will perform three multiple breath nitrogen washout tests (N2-MBW-test)
89583197|NCT01750918|Experimental|Part 4b: Trametinib and Panitumumab|In Part 4B cohort expansion, subjects will be assigned to expansion cohorts at a selected dose of trametinib in combination with panitumumab. Enrollment in expansion cohorts will be initiated once dose escalation for the trametinib /panitumumab combination has been completed. Subjects with advanced/metastatic CRC with either a BRAF-mutation (Cohort 1E) or who developed secondary resistance to prior anti-EGFR therapy (Cohort 2E).
89583198|NCT01750918|Experimental|Part 3a: Dabrafenib and Panitumumab|Subjects will be randomized to receive dabrafenib plus panitumumab. Dose levels for dabrafenib, and panitumumab in Part 3 will be chosen based on emerging PK, PD, and tolerability data from Part 1 and Part 2.
89583199|NCT01750918|Experimental|Part 3b: Dabrafenib, Trametinib and Panitumumab|Subjects will be randomized to receive study treatment as dabrafenib plus trametinib plus panitumumab. Dose levels for dabrafenib, trametinib and panitumumab in Part 3 will be chosen based on emerging PK, PD, and tolerability data from Part 1 and Part 2.
89583200|NCT01750918|Experimental|Part 3c: Chemotherapy comparator|Subjects will be randomized to receive chemotherapy comparator. The chemotherapy comparator will consist of a standard chemotherapy regimen with or without the addition of a biological agent, based on local practice preferences. The available chemotherapy regimens includes 5-fluorouracil-based chemotherapy
89583201|NCT02300987|Active Comparator|LEE011|600 mg daily dosing days 1-21 of a 28 day cycle
89583202|NCT02300987|Placebo Comparator|Placebo Arm|600 mg daily dosing days 1-21 of a 28 day cycle
89583203|NCT01750840||Stimulation Group|All patients will receive either the Biomet® EBI Bone Healing System, Biomet OrthoPak® Non-invasive Bone Growth Stimulator System or Biomet SpinalPak® Non-Invasive Spine Fusion Stimulator Systems.
89583204|NCT01606228|Experimental|Paliperidone ER|
89583205|NCT01706536|Placebo Comparator|EP-101 Placebo|EP-101 Placebo AM + EP-101 Placebo PM
89583206|NCT01706536|Experimental|EP 101 12.5 mcg|EP-101 12.5 mcg AM + EP-101 12.5 mcg PM
89583207|NCT01706536|Experimental|EP-101 25 mcg|EP-101 25 mcg AM + EP-101 25 mcg PM
89583208|NCT01706536|Experimental|EP-101 50 mcg|EP-101 50 mcg AM + EP-101 50 mcg PM
89583209|NCT01706536|Experimental|EP-101 100 mcg|EP-101 100 mcg AM + EP-101 100 mcg PM
89583210|NCT02269943|Experimental|CC-486|CC-486 will be administered orally every day on Days 1-14 of a 21 day cycle at a dose of 300 mg. The first 6 participants of Asian-Pacific ethnicity will receive a starting dose of 200 mg. If there are no safety concerns, the 300 mg dose will be administered to all subsequent participants of Asian-Pacific ethnicity.
89583211|NCT04882319|Experimental|HP-5000 Topical Patch|HP-5000, placebo and saline will be administered simultaneously.
89583212|NCT01706458|Active Comparator|sipuleucel-T|Patients receive sipuleucel-T IV on weeks 0, 2, and 4.
89583213|NCT01706458|Experimental|sipuleucel-T with DNA Vaccine|Patients receive sipuleucel-T as patients in arm I and pTVG-HP plasmid DNA vaccine ID on weeks 6, 8, 10, and 12, and then at 6 and 9 months.
89583214|NCT02269787|Experimental|Enhanced Telephone Monitoring|Detox inpatients in the ETM condition will be expected to complete one 15-minute telephone call per week for 12 weeks.
89583215|NCT02269787|No Intervention|Usual Care|Patients in the usual care condition will receive the care they would receive in the absence of a research project.
89583216|NCT01605370|Experimental|Nebivolol|Subjects randomized to this arm will receive Nebivolol 2.5 mg once daily.
89583217|NCT01605370|Other|Metoprolol succinate|Subjects randomized to this arm will receive metoprolol succinate 50 mg once daily.
89583218|NCT02269709|Experimental|ARFI Ultrasound|This study uses ultrasound scanning with acoustic radiation force impulse shear wave velocity imaging to measure pediatric liver fibrosis. Patients will be children who have had the Fontan operation. This is a non-invasive scan that uses sound waves to create images.
89583219|NCT02269475|Experimental|MEDI3250|MEDI3250 Nasal Spray
89583220|NCT02269475|Placebo Comparator|Placebo|Placebo Nasal spray
89583221|NCT01605136|Experimental|Afamelanotide|One 16mg subcutaneous implant every 2 months for 6 months.
89583222|NCT01605136|Placebo Comparator|Placebo|One placebo subcutaneous implant every 2 months for 6 months.
89583223|NCT01706146|Other|Non-Coumadin Oral Anticoagulant|Administration of Non-coumadin Oral Anticoagulant for 30 days following episode of atrial fibrillation as detected by the Reveal XT device.
89583224|NCT04168450|Other|WiSAT Passive|This arm is composed of participants who meet their activity threshold over the 4-week period.
89583225|NCT04168450|Other|WiSAT Active|This arm is composed of participants who do not meet their activity threshold over the 4-week period.
89583226|NCT02269241|Experimental|LF111 (drospirenone)|single treatment arm receives LF111
89583227|NCT01750684|Placebo Comparator|Saline|Patients randomized (1:1) to the placebo arm will receive an initial intravenous infusion of saline for 30 minutes within a pre-specified time window (12, 9, 6 hours post-injury). Patients will receive 5 additional infusions of the same dose and duration at 6 -hour intervals.
89583228|NCT01750684|Active Comparator|AC105|Patients randomized (1:1) to the active drug arm will receive an initial intravenous infusion of AC105 for 30 minutes within a pre-specified time window (12, 9, 6 hours post-injury). Patients will receive 5 additional infusions of the same dose and duration at 6 -hour intervals.
89583229|NCT01749982|Placebo Comparator|Placebo|Placebo tablets
89583230|NCT01749982|Experimental|Choline bitartrate|Choline bitartrate 700 mg by mouth daily
89583231|NCT01749982|Experimental|Betaine|Betaine 1000 mg by mouth daily
89583232|NCT01749982|Experimental|Choline bitartrate + Betaine|Choline bitartrate 700 mg + Betaine 1000 mg daily
89583233|NCT02269163|Active Comparator|Gammargard, Gammaplex, Gamunex, or Octogam Treatment Period|Subjects who enroll in the study while on Gammargard, Gammaplex, Gamunex, or Octogam IGIV Product and need to wait for the scheduled start of Prometic IGIV (10%) treatment will continue on their usual dose and treatment cycle with Gammargard, Gammaplex, Gamunex, or Octogam IVIG Product during this period.
89583234|NCT02269163|Experimental|Prometic IGIV 10% Treatment Period|Subjects will receive Prometic Immune Globulin Intravenous 10%
89583235|NCT01749826|Experimental|Chronic Opioid Exposure|15mg sustained release morphine sulfate, with a maximum dose of 120mg. Patients will be titrated up to a maximum dose of 8 pills a day for one month.
89583236|NCT01749826|Experimental|Acute Opioid Exposure|15mg sustained release morphine sulfate, with a maximum dose of 120mg. Patients will be titrated up to a maximum dose of 8 pills a day for one month.
89583237|NCT02300129|Experimental|CD07805/47, CD07805/47+Placebo, Placebo, CD07805/47, Placebo|"Period 1:~Application of 1g of CD07805/47 0.5% Gel on full face on Day 1 (cross-over design) and 500mg on a half-face (split-face design) on Day 3.~Application of 500mg of Placebo Gel on a half-face (split-face design) on Day 3 and 1g on full face on Day 5 (cross-over design)~Period 2 (cross-over design):~Application of 1g of CD07805/47 0.5% Gel on full face once daily 7 days per week for 2 weeks then 1g of Placebo Gel on full face once daily 7 days per week for 2 weeks"
89583238|NCT02300129|Experimental|Placebo, CD07805/47+Placebo, CD07805/47, CD07805/47, Placebo|"Period 1:~Application of 1g of Placebo Gel on full face on Day 1 (cross-over design) and 500mg on a half-face (split-face design) on Day 3.~Application of 500mg of CD07805/47 0.5% Gel on a half-face (split-face design) on Day 3 and 1g on full face on Day 5 (cross-over design).~Period 2 (cross-over design):~Application of 1g of CD07805/47 0.5% Gel on full face once daily 7 days per week for 2 weeks then 1g of Placebo Gel on full face once daily 7 days per week for 2 weeks."
89583239|NCT02300129|Experimental|CD07805/47, CD07805/47+Placebo, Placebo, Placebo, CD07805/47|"Period 1:~Application of 1g of CD07805/47 0.5% Gel on full face on Day 1 (cross-over design) and 500mg on a half-face (split-face design) on Day 3.~Application of 500mg of Placebo Gel on a half-face (split-face design) on Day 3 and 1g on full face on Day 5 (cross-over design).~Period 2 (cross-over design):~Application of 1g of Placebo Gel on full face once daily 7 days per week for 2 weeks then 1g of CD07805/47 0.5% Gel on full face once daily 7 days per week for 2 weeks."
89583240|NCT02300129|Experimental|Placebo, CD07805/47+Placebo, CD07805/47, Placebo, CD07805/47|"Period 1:~Application of 1g of Placebo Gel on full face on Day 1 (cross-over design) and 500mg on a half-face (split-face design) on Day 3.~Application of 500mg of CD07805/47 0.5% Gel on a half-face (split-face design) on Day 3 and 1g on full face on Day 5 (cross-over design).~Period 2 (cross-over design):~Application of 1g of Placebo Gel on full face once daily 7 days per week for 2 weeks then 1g of CD07805/47 0.5% Gel on full face once daily 7 days per week for 2 weeks."
89583241|NCT02267135|Experimental|Secukinumab|Eligible patients will receive secukinumab 300 mg once weekly at Baseline, Weeks 1, 2, 3 and 4 followed by monthly dosing starting at Week 8 through Week 20 inclusive
89583242|NCT02267135|Placebo Comparator|Placebo|Eligible patients will receive placebo doses once weekly at Baseline, Weeks 1, 2, 3 and 4 followed by a dose after four weeks at Week 8. Prior to taking the Week 12 dose, the patient will be assessed for response to treatment using the Psoriasis Scalp Severity Index (PSSI). If the subject is a responder, the subject will continue on placebo dosing weekly at Weeks 12, 13, 14, 15 and 16 and then after four weeks at Week 20. Subjects who are not responders will be switched to treatment with secukinumab 300 mg and will dose once weekly at Weeks 12, 13, 14, 15 and 16 and then after four weeks at Week 20.
89583243|NCT02299427|Experimental|dog safety|2 weeks of regular use of website on child dog safety developed for this research
89583244|NCT02299427|Active Comparator|transportation safety|2 weeks of regular use of publicly-available website on child transportation safety
89583245|NCT05649527||Main sample|Sample of 880 children spontaneously recruited and representative of the French population according to the criteria defined for the study. Includes breastfed children.
89583246|NCT05649527||Additional sample|Children in the appropriate age group selected because of their specific consumption in order to increase the number of children in the concerned age group to allow a statist test.
89583247|NCT05649371|Experimental|Prehabilitation|
89583248|NCT05649215||Patients group|Patients with low back pain
89583249|NCT01724866|Experimental|Arm 1: SPI-2012 45 µg/kg and Docetaxel + Cyclophosphamide (TC)|"Participants received SPI-2012 45 microgram/kilogram (µg/kg), subcutaneously (SC) once per cycle on Day 2 of each cycle up to cycle 4 (each cycle was 21 days), approximately 24 hours after the administration of TC chemotherapy. TC chemotherapy was administered on Day 1 of each cycle as follows:~Docetaxel 75 milligram/ square metre (mg/m^2) intravenous (IV) infusion over 60 minutes and Cyclophosphamide 600 mg/m^2 IV infusion over 30-60 minutes."
89583250|NCT01724866|Experimental|Arm 2: SPI-2012 135 µg/kg and Docetaxel + Cyclophosphamide (TC)|"Participants received SPI-2012 135 µg/kg, SC once per cycle on Day 2 of each cycle up to cycle 4 (each cycle was 21 days), approximately 24 hours after the administration of TC chemotherapy. TC chemotherapy was administered on Day 1 of each cycle as follows:~Docetaxel 75 mg/m^2 intravenous (IV) infusion over 60 minutes and Cyclophosphamide 600 mg/m^2 IV infusion over 30-60 minutes."
89583251|NCT01724866|Experimental|Arm 3: SPI-2012 270 µg/kg and Docetaxel + Cyclophosphamide (TC)|"Participants received SPI-2012 270 µg/kg, SC once per cycle on Day 2 of each cycle up to cycle 4 (each cycle was 21 days), approximately 24 hours after the administration of TC chemotherapy. TC chemotherapy was administered on Day 1 of each cycle as follows:~Docetaxel 75 mg/m^2 intravenous (IV) infusion over 60 minutes and Cyclophosphamide 600 mg/m^2 IV infusion over 30-60 minutes."
89583252|NCT01724866|Experimental|Arm 4: Pegfilgrastim and Docetaxel + Cyclophosphamide (TC)|"Participants received Pegfilgrastim 6 milligram (mg), SC once per cycle on Day 2 of each cycle up to cycle 4 (each cycle was 21 days), approximately 24 hours after the administration of TC chemotherapy. TC chemotherapy was administered on Day 1 of each cycle as follows:~Docetaxel 75 mg/m^2 intravenous (IV) infusion over 60 minutes and Cyclophosphamide 600 mg/m^2 IV infusion over 30-60 minutes."
89583253|NCT02266433|Active Comparator|Arm Receiving Dexamethasone Injection|"Dexamethasone will be administered as a peritendinous soft tissue injection of 1 mL of dexamethasone sodium phosphate (4mg/mL) and 0.5 mL (5mg) of 1% lidocaine.~Dexamethasone will be administered as a peritendinous soft tissue injection of 1 mL of dexamethasone sodium phosphate (4mg/mL) and 0.5 mL (5mg) of 1% lidocaine~Patients will be followed at the initial office visit, 4-weeks, 8-weeks, 12-weeks, and 6 months post injection to determine clinical response. A second injection can be given only once if the patient desires due to no clinical response at the 4 or 8-week follow-up."
89583254|NCT02266433|Experimental|Arm Receiving Ketorolac Injection|"Ketorolac will be administered as a peritendinous soft tissue injection of 1 mL of ketorolac (30mg/mL) and 0.5 mL (5mg) of 1% lidocaine.~Patients will be followed at the initial office visit, 4-weeks, 8-weeks, 12-weeks, and 6 months post injection to determine clinical response. A second injection can be given only once if the patient desires due to no clinical response at the 4 or 8-week follow-up."
89583255|NCT01748890|Experimental|Sonoelastography|Sonoelastography is an imaging technology predicated on reproducible differences in the backscattered ultrasound signal produced by compression of tissues of varying stiffness.
89583256|NCT05648981|Experimental|Test group|
88974544|NCT04733300|Experimental|Mindfulness-Based College - Low Dose|The MBC low-dose program is mirrored after the standard MBC program (described previously); however, instead of meeting for 2.5 hours each week, the low-dose MBC program is abbreviated to meet for 1.5 hours each week for the 9 weeks. MBC low-dose will be administered live, online via the free video conferencing platform, Zoom.
88974545|NCT04733300|Active Comparator|Health education control group|Those randomized to the health education control group will receive young adult-specific online health resources offered through www.youngwomenshealth.org and www.youngmenshealthsite.org. Both websites provide resources to improve mental and physical health, and include opportunities to ask health questions, and learn ways to improve mental and physical well-being.
88974546|NCT00038766|Experimental|Semapimod 60 mg|Semapimod 60 mg IV x 5 days
88974547|NCT00038766|Experimental|Semapimod IV 30 mg|Semapimod IV 30 mg x 5 days
88974548|NCT00038766|Placebo Comparator|Placebo|Placebo IV x 3 or 5 days
88974549|NCT00070070|Experimental|Cohort 1|"HLA-A2 Status Positive, Previous BCG Therapy; All patients underwent skin testing with the purified protein derivative (PPD) test.~NY-ESO-1 protein, 75 mcg, was administered by intradermal injection every week for 6 weeks. TICE®-strain BCG, 1 x 10E6 viable units in Purified Protein Derivative (PPD) negative patients and 1 x 10E5 viable units in PPD positive (induration greater than or equal to 10 mm) patients, were mixed with each protein vaccination for the first 2 weeks only. For the last 4 weeks GM-CSF, 100 mcg, was mixed with NY-ESO-1 protein given once a week for 4 weeks, intradermally. GM-CSF alone was given subcutaneously on the day prior to the administration of the co-mixture (NY-ESO-1 Protein/GM-CSF) and for 3 days after."
88974550|NCT00070070|Experimental|Cohort 2|"HLA-A2 Status Positive, No Previous BCG Therapy; All patients underwent skin testing with the purified protein derivative (PPD) test.~NY-ESO-1 protein, 75 mcg, was administered by intradermal injection every week for 6 weeks. TICE®-strain BCG, 1 x 10E6 viable units in Purified Protein Derivative (PPD) negative patients and 1 x 10E5 viable units in PPD positive (induration greater than or equal to 10 mm) patients, were mixed with each protein vaccination for the first 2 weeks only. For the last 4 weeks GM-CSF, 100 mcg, was mixed with NY-ESO-1 protein given once a week for 4 weeks, intradermally. GM-CSF alone was given subcutaneously on the day prior to the administration of the co-mixture (NY-ESO-1 Protein/GM-CSF) and for 3 days after."
88974551|NCT00070070|Experimental|Cohort 3|"HLA-A2 Status Negative, Previous BCG Therapy; All patients underwent skin testing with the purified protein derivative (PPD) test.~NY-ESO-1 protein, 75 mcg, was administered by intradermal injection every week for 6 weeks. TICE®-strain BCG, 1 x 10E6 viable units in Purified Protein Derivative (PPD) negative patients and 1 x 10E5 viable units in PPD positive (induration greater than or equal to 10 mm) patients, were mixed with each protein vaccination for the first 2 weeks only. For the last 4 weeks GM-CSF, 100 mcg, was mixed with NY-ESO-1 protein given once a week for 4 weeks, intradermally. GM-CSF alone was given subcutaneously on the day prior to the administration of the co-mixture (NY-ESO-1 Protein/GM-CSF) and for 3 days after."
88974552|NCT00070070|Experimental|Cohort 4|"HLA-A2 Status Negative, No Previous BCG Therapy; All patients underwent skin testing with the purified protein derivative (PPD) test.~NY-ESO-1 protein, 75 mcg, was administered by intradermal injection every week for 6 weeks. TICE®-strain BCG, 1 x 106 viable units in Purified Protein Derivative (PPD) negative patients and 1 x 105 viable units in PPD positive (induration greater than or equal to 10 mm) patients, were mixed with each protein vaccination for the first 2 weeks only. For the last 4 weeks GM-CSF, 100 mcg, was mixed with NY-ESO-1 protein given once a week for 4 weeks, intradermally. GM-CSF alone was given subcutaneously on the day prior to the administration of the co-mixture (NY-ESO-1 Protein/GM-CSF) and for 3 days after."
88974553|NCT02573909|Experimental|Oxycodone intravenously|Oxycodone 0,1 mg/kg IV
88974554|NCT02573909|Experimental|Oxycodone epidurally|Oxycodone 0,1 mg/kg epidurally
89583257|NCT05648981|Active Comparator|Control group|
89583258|NCT04869215|Experimental|EverVita Pro consumed at breakfast followed by an ad lib meal|Before breakfast, a Motivation to Eat and a GI symptom questionnaire will be completed. They will then be given a standard breakfast which will include EverVita Pro bread, followed by an ad lib pizza meal 1.5h later. Subjects will be asked to fill out the VAS Motivation to Eat Questionnaire before being given the meal and at 10-minute intervals after they start consuming the test meal until they are given the ad lib pizza meal and 30 min after the start of the ad lib pizza meal.
89583259|NCT04869215|Placebo Comparator|Control consumed at breakfast followed by an ad lib meal.|Before breakfast, a Motivation to Eat and a GI symptom questionnaire will be completed. They will then be given a standard breakfast which will include the control bread, followed by an ad lib pizza meal 1.5h later. Subjects will be asked to fill out the VAS Motivation to Eat Questionnaire before being given the meal and at 10-minute intervals after they start consuming the test meal until they are given the ad lib pizza meal and 30 min after the start of the ad lib pizza meal.
89583260|NCT01747876|Experimental|LEE011|
89583261|NCT02273726|Experimental|Roxadustat|Participants will receive roxadustat tablets, administered orally 3 times weekly (TIW). Initial roxadustat dose will be based on the participant's average prescribed erythropoietin stimulating agent (ESA) dose in the 4 weeks (if on epoetin or darbepoetin or 8 weeks (if on Mircera®) prior to randomization. Dose adjustments will be permitted to maintain a hemoglobin (Hb) level of approximately 11 grams (g)/deciliter (dL). The maximum roxadustat dose is 3.0 milligrams (mg)/kilogram (kg) per dose or 400 mg per administration (whichever is lower).
89583262|NCT02273726|Active Comparator|Epoetin Alfa|Participants on hemodialysis (HD) will receive epoetin alfa, administered intravenously (IV) TIW and participants on home HD or peritoneal dialysis (PD) will receive epoetin alfa, administered subcutaneously (SC). Initial epoetin alfa dose will be based on the participant's average weekly prescribed ESA dose in 4 weeks prior to randomization if on epoetin or darbepoetin, and average monthly (4-week) prescribed ESA dose in 8 weeks prior to randomization if on Mircera®. In case of a change in route of administration from SC to IV (TIW), the initial dose of IV epoetin alfa will be determined by the investigator per local standard of care (SOC). Dose adjustments will follow the recommendations as per the approved country-specific product label (United States Package Insert [USPI] or Summary of Product Characteristics [SmPC]) or local SOC.
88974555|NCT00042471|Experimental|Pramlintide acetate (AC137) injection|Pramlintide acetate (AC137) injection is a clear, colorless, sterile solution for injection. It consists of pramlintide in sodium acetate buffer, pH 4.0, containing 43mg/mL mannitol as an iso-osmolality modifier and 2.25 mg/mL metacresol as a preservative. The strength of pramlintide is 1.0 mg/mL for SC injection and 0.6 mg/mL for IV bolus injection.
88974556|NCT00042510|Experimental|Treatment Group|500µg G17DT administered on Weeks 1, 5 and 9 and an additional treatment at Week 25. Cisplatin was administered every 4 weeks on the first day of each treatment cycle as a 1 to 3 hour intravenous infusion at a dose of 100mg/m^2. 5-FU was administered every 4 weeks during the first 5 days of each cycle as a continuous intravenous infusion at a dose of 1,000 mg/m^2/d.
88974557|NCT00038805|Experimental|Mylotarg|
88974558|NCT00018824|Experimental|1|Naltrexone
88974559|NCT00018824|Placebo Comparator|2|Placebo
88974560|NCT00038844|Experimental|Campath in Nonmyeloablative Transplantation|Campath-1 H Starting Dose of 15 mg by vein daily, 3 days in a row + Fludarabine 30 mg/m2 by vein daily, 3 days in a row + Cyclophosphamide 1 gm/m2 by vein daily, 3 days in a row + Rituximab 375 mg/m2 by vein, given 8 days before transplant then weekly for 4 total doses.
88974561|NCT00038883|Experimental|Campath-1H|10 mg/day x 5
88974562|NCT00018902|Experimental|1|Participants whose depression does not respond to an initial SSRI will switch to an alternative SSRI.
88974563|NCT00018902|Experimental|2|Participants whose depression does not respond to an initial SSRI will switch to a different non-SSRI antidepressant.
88974564|NCT00018902|Experimental|3|Participants whose depression does not respond to an initial SSRI will switch to an alternative SSRI and receive cognitive behavioral therapy (CBT).
88974565|NCT00018902|Experimental|4|Participants whose depression does not respond to an initial SSRI will switch to a different non-SSRI antidepressant and receive CBT.
88974566|NCT00038961|Placebo Comparator|Placebo + intermittent pneumatic compression (IPC)|
88974567|NCT00038961|Experimental|fondaparinux + intermittent pneumatic compression (IPC)|
88974568|NCT01803906||Mitochondrial disease|Patients with known or suspected DNA mutations that affect mitochondrial function. Patients with suspected mitochondrial disorders
89030106|NCT02950116|Active Comparator|Non-CF bronchiectasis|Patients with non-CF bronchiectasis will perform three multiple breath nitrogen washout tests (N2-MBW-test)
89030107|NCT02950116|Active Comparator|Cystic fibrosis|Patients with cystic fibrosis will perform three multiple breath nitrogen washout tests (N2-MBW-test)
89030108|NCT04511897|Experimental|Experimental group|oral An'ningpai Enteric Soft Capsules (300 mg,three times daily) for 12 months.
89030109|NCT04511897|No Intervention|Control group|No experimental durgs used.
89030110|NCT04695093||London (intervention)|1606 children aged 6-9 yrs old, recruited in 44 London primary schools (years 2-4) within the Central London ULEZ area
89030111|NCT04695093||Luton (comparison)|1706 children aged 6-9 yrs old, recruited in 41 Luton and Dunstable primary schools (years 2-4)
89030112|NCT04519463|Experimental|Xylocaine|30 patients who receive Xylocaine 10% nasal spray
89583263|NCT04557358||Rheumatic diseases outpatients|"All the rheumatic diseases outpatients from the National Institute of Medical Sciences and Nutrition that will assist their usual medical care posterior of stopped it during the COVID-19 pandemic.~In order to explore how the patient´s disease activity, patient´s quality of life, and psychopathology will change with the reintegration at medical care, randomization 200 rheumatic diseases outpatients that will respond RAPID-3 (disease activity/disease severity), WHOQOL-BREF instrument (quality of life), DASS-21 instrument (depression and anxiety), IER-R (posttraumatic stress)"
89583264|NCT01723228|Experimental|Rasagiline 1.0 mg/day|Rasagiline 1 mg oral tablets once daily for 24 weeks
89583265|NCT01723228|Placebo Comparator|Placebo|Placebo oral tablets once daily for 24 weeks
89583266|NCT02273180|Experimental|SAR342434|SAR342434 before meals intake on top of once daily (QD) Insulin Glargine, up to Week 52.
89583267|NCT02273180|Active Comparator|Humalog|Humalog before meals intake on top of QD Insulin Glargine, up to Week 52.
89583268|NCT01746862|Experimental|Saizen Test Group|
89583269|NCT01746862|Active Comparator|Saizen Control Group|
89583270|NCT01745848|Experimental|Study Drug|Roflumilast 500 μcg, once daily, for 30 days
89583271|NCT01745380|Experimental|Kovacaine Mist|Tetracaine HCl 3% and Oxymetazoline HCl 0.05% - 2 sprays will be administered at the start of the procedure, if anesthesia is insufficient, a third spray will be administered.
89583272|NCT01745380|Placebo Comparator|Placebo|Placebo - 2 sprays will be administered at the start of the procedure, if anesthesia is insufficient, a third spray will be administered.
89583273|NCT01745146|Experimental|Anger Self-Management Training (ASMT)|8-session, individual, psycho-educational intervention based on principles of self-monitoring and problem-solving training Significant other (friend or relative) invited to participate in 3 of 8 sessions
89583274|NCT01745146|Active Comparator|Personal Readjustment and Ed (PRE)|8-session, individual, psycho-educational intervention based on principles of education and personal readjustment. Significant other (friend or relative) invited to participate in 3 of 8 sessions
89583275|NCT05648474||Adult undergoing 1- or 2-level lateral lumbar interbody fusion surgery, inclusive of the L4-5 level|
89583276|NCT05648396||Revascularization|Patients undergoing angiogram in which FFRangio is used to assess the physiologic significance of at least one coronary lesion, and based on this assessment are referred for coronary revascularization (PCI/CABG).
89583277|NCT05648396||Deferral|Patients undergoing angiogram in which FFRangio is used to assess the physiologic significance of at least one coronary lesion, and based on this assessment are assigned to conservative management (optimal guidelines directed medical treatment).
89583278|NCT05648318|Experimental|Lactulose oral solution (LOS)|
89583279|NCT05648318|Active Comparator|polyethylene glycol (PEG)|
89583280|NCT02203513|Experimental|Arm 1-Prexasertib|Prexasertib (LY2606368) monotherapy treatment
89583281|NCT04881890|Experimental|Low-Carbohydrate Diabetes Prevention Program|At least 20 individuals with prediabetes will participate in a year-long , group-based program.
89583282|NCT02299934|Other|Subjects who fulfill the criteria for living liver donation|Subjects who fulfill the criteria for living liver donation and are evaluated for the procedure with Computerized Tomography (CT) and Magnetic Resonance Imaging (MRI).
89583283|NCT01703260|Experimental|Roflumilast + pioglitazone|Roflumilast dose and pioglitazone dose, orally for up to 4 months
89583284|NCT01703260|Experimental|Roflumilast|Roflumilast dose and pioglitazone matching-placebo dose orally for up to 4 months.
89583285|NCT01703260|Experimental|Pioglitazone|Pioglitazone dose, orally and roflumilast matching-placebo dose, orally for up to 4 months
89583286|NCT02203357|Active Comparator|20μg, 0-1-6|117 young adults were administered with 20μg of hepatitis B vaccine according to the 0-1-6 mon schedule.
89583287|NCT02203357|Experimental|60μg, 0-1|112 young adults were administered with 60μg of hepatitis B vaccine according to the 0-1 mon schedule.
89583288|NCT02203357|Experimental|60μg, 0-2|125 young adults were administered with 60μg of hepatitis B vaccine according to the 0-2 mon schedule.
89583289|NCT02299388|Active Comparator|Liraglutide|All subjects will be advised a low sodium diet. This will be a placebo controlled, double blind and randomized trial of effects of Liraglutide on systolic BP control. Eligible patients will have ABPM measurements and laboratory blood collection at baseline (prior to initiation of Liraglutide or Placebo), at 4 and 8 weeks of therapy. Patients will return 24 hours following ABPM placement for device and data retrieval. Each subject will be asked to keep a log of activities throughout the day.
89583290|NCT02299388|Placebo Comparator|Placebo|All subjects will be advised a low sodium diet. This will be a placebo controlled, double blind and randomized trial of effects of Liraglutide on systolic BP control. Eligible patients will have ABPM measurements and laboratory blood collection at baseline (prior to initiation of Liraglutide or Placebo), at 4 and 8 weeks of therapy. Patients will return 24 hours following ABPM placement for device and data retrieval. Each subject will be asked to keep a log of activities throughout the day.
89583291|NCT02202577|Experimental|Chlorhexidine - Isopropyl alcohol|Pre-operative skin preparation with Chlorhexidine Gluconate- Isopropyl alcohol
89030113|NCT04519463|Placebo Comparator|Saline|30 patients who receive saline nasal spray
89583292|NCT02202577|Experimental|Povidone-Iodine Scrub and Paint|Pre-operative skin preparation with Povidone-Iodine Scrub and Paint
89583293|NCT02299076|Other|Usual care with minimal incentives|Participants in this arm receive usual care from the Pro-Change smoking cessation program, and receive compensation for enrolling and completing a survey at the end of the study.
89583294|NCT02299076|Active Comparator|Usual care with BE incentives|Participants in this arm receive usual care from the Pro-Change smoking cessation program, the chance to win money based on their behavior (behavioral economics incentives), and receive compensation for enrolling and completing a survey at the end of the study.
89583295|NCT01723072|Experimental|1 Omalizumab|omalizumab once a month via subcutaneous injection.
89583296|NCT01723072|Placebo Comparator|2 Placebo|placebo of omalizumab once a month via subcutaneous injection
89030114|NCT02950311|Experimental|Intranasal xylitol spray|Two sprays each nostril, twice a day.
89030115|NCT02950311|Placebo Comparator|Intranasal saline spray|Two sprays each nostril, twice a day.
89583297|NCT01722994|Experimental|Group 1 Punch Biopsy Wound with chromic gut suture|One of two absorbable sutures is used to close punch wounds.
89583298|NCT01722994|Experimental|Group 2 Punch Biopsy Wound with PDS|This is one of two absorbable sutures used to close punch biopsy wounds.
89583299|NCT02228395|Experimental|Cohort 1|Participants received 1 single dose of placebo, PF-04958242 0.6 mg, and PF-04958242 0.8 mg orally during 3 periods, respectively. There was at least a 10-day washout period between each dosing.
89583300|NCT02228395|Experimental|Cohort 2|Participants received 1 single dose of PF-04958242 0.35 mg, placebo, and PF-04958242 0.8 mg orally during 3 periods, respectively. There was at least a 10-day washout period between each dosing.
89583301|NCT02228395|Experimental|Cohort 3|Participants received 1 single dose of PF-04958242 0.35 mg, PF-04958242 0.6 mg, and placebo orally during 3 periods, respectively. There was at least a 10-day washout period between each dosing.
89583302|NCT02170051|Experimental|CBSST-CCT|Cognitive Behavioral Social Skills Training-Compensatory Cognitive Training
89583303|NCT02170051|Active Comparator|Goal-focused supportive contact|Goal-focused supportive contact
89583304|NCT02169739|No Intervention|Medical therapy only|Intensive standard medical secondary prevention stroke treatment as per the recommendations of the American Heart Association/American Stroke Association national guidelines.
89583305|NCT02169739|Active Comparator|Ischemic Preconditioning + Medical|Patients will receive treatment with Cell Aegis remote ischemic preconditioning device once or twice daily for one year. The procedure will consist of up to four 5-minute cycles of bilateral upper extremity ischemia separated by five minutes of reperfusion. Patients will also receive intensive standard medical secondary prevention stroke treatment as per the American Heart Association/American Stroke Association national guidelines.
89583306|NCT02169505|Experimental|Brentuximab Vedotin|"Brentuximab by vein over 30 minutes every 3 weeks for a total of 6 cycles starting between days 30 and 60 post allogeneic stem cell transplant (SCT).~Brentuximab dose based on actual body weight starting with an initial dose of 1.2 mg/kg for the first 2 cycles and dose increased to 1.8 mg/kg after the second cycle for all subsequent cycles."
89583307|NCT01909791|Experimental|Prompt Laser + Deferred Aflibercept|Focal/grid laser followed by intravitreal aflibercept if vision worsens
89583308|NCT01909791|Active Comparator|Observation + Deferred Aflibercept|No treatment to start followed by intravitreal aflibercept if vision worsens (deferred laser may be added to intravitreal aflibercept if certain criteria are met)
89583309|NCT01909791|Experimental|Prompt Aflibercept|Intravitreal aflibercept at baseline and every 4 weeks as needed (deferred laser may be added to intravitreal aflibercept if certain criteria are met)
89583310|NCT02202499|Active Comparator|Extended Varenicline + Facilitated Extinction|Extended Varenicline plus Facilitated Extinction (EV+FE). Participants in the EV+FE condition will receive varenicline for a 4-week run-in period while continuing to smoke. In addition, the EV+FE condition will receive counseling and support materials (including a review and self-monitoring workbook tentatively titled, Winding Down: A Guide to Quitting Smoking using Varenicline) instructing participants to systematically utilize the FE techniques provided. All groups will undergo periodic laboratory assessments and surveys.
89583311|NCT02202499|Active Comparator|Standard Varenicline (SV)|Participants in the Standard Varenicline (SV) condition will receive varenicline for the usual 1-week run-in period while continuing to smoke. All groups will undergo periodic laboratory assessments and surveys.
89583312|NCT02202499|Active Comparator|Extended Varenicline (EV)|Participants in the Extended Varenicline (EV) condition will receive varenicline for a 4-week run-in period while continuing to smoke. All groups will undergo periodic laboratory assessments and surveys.
89583313|NCT02202109|Active Comparator|CHWs facilitated Self-Sampling|CHW and Self-sampling for Cervical Cancer. Home visit, self-sampler, collection of test
89583314|NCT02202109|Active Comparator|Mailed Self-Sampler|Mailed Self Sampler. Self sampler is mailed to participant; follow up by phone
88974569|NCT00039117|Experimental|Arm I|"INDUCTION THERAPY: Patients receive oblimersen (G3139) IV continuously on days 1-10 and cytarabine IV continuously on days 4-10. Patients also receive daunorubicin IV daily on days 4-6.~Patients with bone marrow cellularity of at least 20% and at least 5% leukemic blasts at day 17 or evidence of refractory disease receive a second induction comprising G3139 IV continuously on days 1-8, cytarabine IV continuously on days 4-8, and daunorubicin IV on days 4-5.~CONSOLIDATION THERAPY: Beginning no sooner than 14 days after hematologic recovery from induction therapy, patients receive G3139 IV continuously on days 1-8 and cytarabine IV over 4 hours on days 4-8. Patients receive a second course of consolidation therapy no sooner than 14 days after hematologic recovery from the first course."
88974570|NCT00039390|Experimental|Treatment (capecitabine, gefitinib)|Patients receive oral gefitinib once daily on days 1-14 and oral capecitabine twice daily on days 8-21. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of gefitinib and capecitabine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 6 patients experience dose-limiting toxicity.
88974571|NCT00039624|Experimental|Brachy|brachytherapy
88974572|NCT02970825|Experimental|Exercise|The experimental, intensive exercise regime will include 50-min sessions four times a week during five weeks (for a total of about 17 hours) combining structured aerobic exercise (at least 20 minutes jogging and moderate to high intensity active games) and anaerobic lactic resistance exercise (power training with gymn weights).
89030116|NCT04519424|Experimental|CSL324|CSL324 administered intravenously
89583315|NCT02227849|Experimental|Canagliflozin (TA-7284) ＋GLP-1 analogue|
89583316|NCT01927497|Experimental|Biological mesh closure|Biological mesh reconstruction of the pelvic floor after extralevator abdomino perineal resection
89583317|NCT01927497|Active Comparator|Primary perineal closure|Primary perineal closure after extralevator abdomino perineal resection
89583318|NCT02169271|Experimental|Arm I (acetylsalicylic acid)|Patients receive acetylsalicylic acid PO QD for 12 months.
89583319|NCT02169271|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD for 12 months.
89583320|NCT02202031|Experimental|Music Therapy|Participants will use an identical appearing device, programmed to play quiet, relaxing music, while monitoring spontaneous breathing. Participants will be instructed to use their devices for at least 15 minutes per day for 12 weeks.
89583321|NCT02202031|Experimental|Paced Respiration|Participants will use a small, commercially-available guided-breathing device to practice breathing at a rate slower than 10 breaths per minute. Participants will be instructed to use their devices for at least 15 minutes per day for 12 weeks.
89583322|NCT01644188|Experimental|Alirocumab 75 /up to 150 mg Q2W|Alirocumab 75 mg every 2 weeks (Q2W) and oral placebo capsule for ezetimibe daily added to stable Lipid Modifying Therapy (LMT) for 104 weeks. Alirocumab dose up-titrated to 150 mg from Week 12 when LDL-C level ≥70 mg/dL (1.81 mmol/L) at Week 8.
89583323|NCT01644188|Active Comparator|Ezetimibe 10 mg|Ezetimibe 10 mg capsule daily and subcutaneous placebo for alirocumab Q2W added to stable LMT for 104 weeks.
89583324|NCT02201953|Experimental|SOF/VEL 12 Weeks|SOF/VEL FDC for 12 weeks
89583325|NCT02201953|Experimental|SOF+RBV 24 Weeks|SOF+RBV for 24 weeks
89583326|NCT02271854|Experimental|diclofenac sodium gel 1%|diclofenac sodium gel 1% applied four times daily
89583327|NCT02271854|Placebo Comparator|Placebo|Placebo gel applied four times daily
89583328|NCT05296993|Experimental|Extracts|The ingredients found in these serums are all naturally occurring ingredients extracted from a variety of plant species: Pinetonal, Thyvolve, Telogenic, Sentophagy, Inflasolve, Stemegenis, and CMEnhance
89583329|NCT02296892|Experimental|Remimazolam|"Double-blind Remimazolam arm: 5 mg iv for sedation induction, and 2.5 mg iv top-ups for sedation maintenance.~Fentanyl pre-treatment: 25-50 μg (or less for elderly/disabled subjects), and 25 μg top-up doses"
89583330|NCT02296892|Placebo Comparator|Placebo|"Double-blind placebo arm as inactive control~Fentanyl pre-treatment: 25-50 μg (or less for elderly/disabled subjects), and 25 μg top-up doses"
89583331|NCT02296892|Active Comparator|Midazolam|"Open-label Midazolam arm: 1.75 mg* iv for sedation induction and 1.0 mg* iv for sedation maintenance. *1.0 mg for induction and 0.5 mg for maintenance in adults over 60, debilitated or chronically ill.~Fentanyl pre-treatment: 25-50 μg (or less for elderly/disabled subjects), and 25 μg top-up doses"
89583332|NCT02270684|Experimental|Device|Participants in this arm will receive the StepRite device. They will have a remote visit with their Physical Therapist in place of one in-person visit per week during the outpatient phase of their treatment
89583333|NCT02270684|No Intervention|Usual and customary care|Participants in this arm will undergo usual care and will not be issued with the StepRite device
89583334|NCT05647928||retinal redetachment after silicone oil removal|
89583335|NCT05647928||NO retinal redetachment after silicone oil removal|
88974573|NCT02970825|Active Comparator|Relaxation|The control activity will include 50-min sessions four times a week during five weeks (for a total of about 17 hours) combining mindfulness, stretching and low intensity active games (breath control, proprioception, walking, social relaxation, flexibility training).
88974574|NCT00040326|Active Comparator|1|anteromesial temporal resection
88974575|NCT00040326|Active Comparator|2|antiepileptic drugs
89583336|NCT02168803|Experimental|Evacetrapib: Single Dose|Single oral dose of evacetrapib on Day 1
89583337|NCT02168803|Experimental|Evacetrapib: Multiple Dose 12 Weeks|Evacetrapib administered orally once daily beginning on Day 8 for 12 consecutive weeks
89583338|NCT02168803|Experimental|Evacetrapib: Multiple Dose 24 Weeks|Evacetrapib administered orally once daily beginning on Day 8 for 24 consecutive weeks
89583339|NCT02168803|Experimental|Evacetrapib: Multiple Dose 52 Weeks|Evacetrapib administered orally once daily beginning on Day 8 for 52 consecutive weeks
89583340|NCT02201329|Experimental|A|Volasertib escalating doses + azacitidine
89583341|NCT01927419|Experimental|Nivolumab + Ipilimumab|Participants received (Part 1) 1 mg/kg of nivolumab + 3 mg/kg of ipilimumab solution intravenously every 3 weeks for 4 doses (4 cycles), then (Part 2) 3 mg/kg of nivolumab intravenously every 2 weeks until documented disease progression, toxicity, withdrawal of consent, or study completion.
89583342|NCT01927419|Experimental|Placebo + Ipilimumab|Participants received (Part 1) placebo-matching nivolumab + 3 mg/kg of ipilimumab solution intravenously every 3 weeks for 4 doses (4 cycles), then (Part 2) placebo-matching nivolumab solution intravenously every 2 weeks until documented disease progression, toxicity, withdrawal of consent, or study completion.
89583343|NCT02168491|Experimental|Intervention group|10 type 2 diabetic patients will be included to perform in this study and will be switched from premixed insulin to insulin glargine and lixisenatide
89583344|NCT02225743||Joint Arthroplasty|Participants undergoing joint replacement
89583345|NCT01721746|Experimental|BMS-936558 3 mg/kg (IV)|BMS-936558 3 mg/kg solution for injection by intravenous (IV), every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
89583346|NCT01721746|Active Comparator|Investigator's Choice (Dacarbazine or Carboplatin+Paclitaxel)|"Dacarbazine: 1000mg/m2, Powder for IV solution, IV, every 3 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends~Carboplatin: Area under the concentration-time curve (AUC) 6, solution for injection, IV, every 3 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends~Paclitaxel: 175 mg/ m2, solution for injection, IV, every 3 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends"
89583347|NCT02225665|Experimental|Cohort 1|
89583348|NCT02225665|Experimental|Cohort 2|
89583349|NCT01721200|Other|Decision Support Tool|This study will examine the efficacy of a web-based educational decision support tool.
89583350|NCT01721200|Other|Usual Care|Usual Care Group will receive their biologic drug teaching from their rheumatologist.
89583351|NCT02225587|Experimental|Group 1: Prevnar 13™ → Pneumovax™ 23 → Placebo|Prevnar 13™ 0.5 mL intramuscular injection on Day 1, Pneumovax™ 23 0.5 mL intramuscular injection at Week 8, and Placebo 0.5 mL intramuscular injection at Week 26. Injections are to be administered in alternating limbs, if possible.
89583352|NCT02225587|Placebo Comparator|Group 2: Prevnar 13™ → Placebo → Pneumovax™ 23|Prevnar 13™ 0.5 mL intramuscular injection on Day 1, Placebo 0.5 mL intramuscular injection at Week 8, and Pneumovax™ 23 0.5 mL intramuscular injection at Week 26. Injections are to be administered in alternating limbs, if possible.
89583353|NCT02296424|Experimental|Canakinumab Dose Reduction|All patients received canakinumab 4mg/kg (300 mg max) every 4 weeks in Part I of the study. Patients eligible for Part II of the study were randomized to one of two treatment arms. This is Treatment Arm 1 in Part II of the study: Canakinumab was administered at a reduced dose (2 mg/kg every 4 weeks). If the patient continued to maintain inactive disease for 24 additional weeks, canakinumab was administered at 1mg/kg every 4 weeks. If the patient continued to maintain inactive disease for another 24 additional weeks, canakinumab treatment was discontinued.
89583354|NCT02296424|Experimental|Canakinumab Dose Interval Prolongation|All participants received canakinumab 4mg/kg (300 mg max) every 4 weeks in Part I of the study. Patients eligible for Part II of the study were randomized to one of two treatment arms. This is Treatment Arm 2 in Part II of the study: Canakinumab dose interval was prolonged to a regimen of 4mg/kg every 8 weeks. If the patient continued to be stable with inactive disease for 24 additional weeks, canakinumab dose interval was prolonged to a regimen of 4mg/kg every 12 weeks. If the patient was clinically stable with inactive disease for another 24 additional weeks, canakinumab treatment was discontinued.
89583355|NCT02296190|Experimental|Etripamil|1 dose of Etripamil via 4 intranasal applications at time 0 (140 mg, 105 mg, 70 mg, or 35 mg)
89583356|NCT02296190|Placebo Comparator|Placebo|1 dose of placebo via 4 intranasal applications at time 0
89583357|NCT04875026|Experimental|5-fluorouracil 4% (Tolak) + Dexeryl|This group will apply 5-FU once daily for 4 weeks, and Dexeryl once daily for 8 weeks.
89583358|NCT04875026|Other|5-fluorouracil 4% (Tolak)|This group will only apply 5-FU once daily for 4 weeks.
89583359|NCT02296112|Experimental|Treatment (trametinib)|Patients receive trametinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89583360|NCT02295644|Experimental|A: 0.4 Watts/Sq cm 50% Duty cycle|0.4 Watts/Sq cm 50% Duty cycle Therapeutic ultrasound (Ultrasound Sonicator 740) used on masseter muscle, 1 (MegaHertz) MHz, 5 minutes
89583361|NCT02295644|Experimental|B: 0.4 Watts/Sq cm 100% Duty cycle|0.4 Watts/Sq cm 100% Duty cycle Therapeutic ultrasound (Ultrasound Sonicator 740) used on masseter muscle, 1 MHz, 5 minutes
89583362|NCT02295644|Experimental|C: 0.8 Watts/Sq cm 50% Duty cycle|0.8 Watts/Sq cm 50% Duty cycle Therapeutic ultrasound (Ultrasound Sonicator 740) used on masseter muscle, 1 MHz, 5 minutes
89583363|NCT02295644|Experimental|D: 0.8 Watts/Sq cm 100% Duty cycle|0.8 Watts/Sq cm 100% Duty cycle Therapeutic ultrasound (Ultrasound Sonicator 740) used on masseter muscle, 1 MHz, 5 minutes
89583364|NCT02269670|Experimental|Treatment (everolimus, hormone therapy)|Patients receive everolimus PO daily and a hormone therapy regimen chosen at the discretion of the investigator (anastrozole PO daily; letrozole PO daily; tamoxifen citrate PO daily; fulvestrant IM or PO on days 1, 15, and 29, and then monthly; megestrol acetate PO QID; or other regimen). Treatment continues in the absence of disease progression or unacceptable toxicity.
89583365|NCT02225353|Experimental|Progesterone Cervical Pessary 6.3 g|90 pregnant women with Progesterone Cervical Pessary
89583366|NCT02225353|Experimental|Progesterone Cervical Pessary 7.7 g|90 pregnant women with Progesterone Cervical Pessary
88974576|NCT02970630|Experimental|Envarsus once a day, everolimus b.i.d.|"Tacrolimus tablets at starting dose of 0.07 mg/kg/day will be administered once daily in the morning.~Everolimus tablets at starting dose of 2 mg/day (1 mg b.i.d.) will be administered twice daily, every 12 hours."
88974577|NCT00020735|Experimental|oral toremifene|
88974578|NCT00020735|Other|observation|
88974579|NCT00040755|Experimental|Arm I (rebimastat once daily)|Patients receive oral BMS-275291 once daily on days 1-28. Treatment repeats every 28 days for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients achieving a CR receive 2 additional courses beyond CR.
88974580|NCT00040755|Experimental|Arm II (rebimastat twice daily)|Patients receive oral BMS-275291 twice daily on days 1-28. Treatment repeats every 28 days for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients achieving a CR receive 2 additional courses beyond CR.
88974581|NCT00040794|Experimental|Stratum I (gefitinib, radiotherapy)|"Patients receive gefitinib orally (PO) daily for 7 weeks. Patients also undergo concurrent radiotherapy once daily 5 days a week for 7 weeks.~Patients then receive gefitinib PO daily in the absence of disease progression or unacceptable toxicity."
88974582|NCT00040794|Experimental|Stratum II (gefitinib, radiotherapy, chemotherapy)|"Patients receive gefitinib and radiotherapy as in stratum I concurrently with paclitaxel IV over 1 hour followed by carboplatin over 30 minutes once weekly for 7 weeks.~Patients then receive gefitinib PO daily in the absence of disease progression or unacceptable toxicity."
88974583|NCT00021242|Experimental|Relapsed or Refractory ALL, AML|Docetaxel 60 mg/m^2 per dose weekly (Days 1,8,15) for 3 weeks followed by 1 week of rest.
88974584|NCT00040911|Experimental|Arm I (alternative medicine procedure)|Patients undergo electroacupuncture therapy to specific acupuncture points on the arms and legs over 25 minutes twice daily on days 1 and 2 and then once daily on days 3-7 during week 1 of chemotherapy course 1 (9 acupuncture treatments total).
88974585|NCT00040911|Sham Comparator|Arm II (alternative medicine procedure)|Patients undergo electroacupuncture therapy to sham points on the arms and legs as in arm I.
89583367|NCT02225353|Active Comparator|Progesterone 200 mg vaginal capsules|90 pregnant women using Progesterone 200 mg vaginal capsules daily
89583368|NCT01641926|Experimental|HBeAg(+) PEG-Intron|HBeAg-positive participants receive 1.5 mcg/kg/wk PEG-Intron subcutaneously (SC) once weekly for 48 weeks.
89583369|NCT01641926|Active Comparator|HBeAg(+) PEGASYS|HBeAg-positive participants receive 180 mcg/kg/wk PEGASYS SC once weekly for 48 weeks.
89583370|NCT01641926|Experimental|HBeAg(-) PEG-Intron|HBeAg-negative participants receive 1.5 mcg/kg/wk PEG-Intron SC once weekly for 48 weeks.
89583371|NCT01641926|Active Comparator|HBeAG(-) PEGASYS|HBeAg-negative participants receive 180 mcg/kg/wk PEGASYS SC once weekly for 48 weeks.
89583372|NCT02295020|Active Comparator|Standard Treatment Only|Group A will receive standard treatment only such as NSAIDs and injections
89583373|NCT02295020|Experimental|Standard Treatment plus Bioskin Ten-7|Group B will receive standard treatment such as NSAIDs and injections and the Bioskin Ten-7 knee brace.
89583374|NCT02200939|Experimental|Partial-Thickness Tear|Intermediate or High partial-thickness tear (PTT) or very small full-thickness tear of the supraspinatus tendon surgically treated by implantation of the bioinductive implant.
89583375|NCT02200939|Experimental|Full Thickness Tear|Medium or large full thickness tear (FTT) of the supraspinatus tendon surgically treated with the bioinductive implant adjunctive to surgical repair.
89583376|NCT05152381|Experimental|Treatment Group (AlloRx)|Single intravenous infusion of 100 million cells
89583377|NCT02294786|Experimental|Octreotide treatment|Subjects randomised to receive Octreotide were administered with Octreotide (Sandostatin LAR™) 40mg 7 days before the start of treatment with Lapatinib and Capecitabine and again 28 days later. All subjects received treatment with Lapatinib 1250milligram (mg) once daily and Capecitabine 1000 milligram/square meter (mg/m^2) twice daily until disease progression. Lapatinib was given every day; Capecitabine was given in 3 week cycles of two weeks treatment followed by one week off treatment. SANDOSTATIN™ is a trademark of Novartis.
89583378|NCT02294786|Experimental|No Octreotide treatment|Subjects randomised to receive no octreotide, treatment with Lapatinib and Capecitabine was initiated immediately following enrolment. All subjects received treatment with Lapatinib 1250mg once daily and Capecitabine 1000mg/m^2 twice daily until disease progression. Lapatinib was given every day; Capecitabine was given in 3 week cycles of two weeks treatment followed by one week off treatment
89583379|NCT04880876|Experimental|Open Label 6-11 years of age: Eluxadoline 50mg|Eluxadoline two 25mg tablets, oral administration, twice daily with food. Take at approximately the same time each day.
89583380|NCT04880876|Experimental|Open Label 12-17 years of age: Eluxadoline 100 mg|Eluxadoline one 100mg tablet, oral administration, twice daily with food. May use 25mg tablets to administer 100mg dose. Take at approximately the same time each day.
89583381|NCT04880876|Experimental|Double Blind 6-11 years of age: Eluxadoline 25mg|Blinding will be accomplished via administration of a constant number of oral tablets in each age group (6 to 11 years of age and 12 to 17 years of age) where all participants in an age group will receive the same total number of oral tablets at each administration. Phase 2 completers who choose to remain on double-blind eluxadoline and received placebo in the lead-in Phase 2 study 3030-202-002 will be assigned to double-blind eluxadoline 25 mg BID
89583382|NCT04880876|Experimental|Double Blind 6-11 years of age: Eluxadoline 50mg|Blinding will be accomplished via administration of a constant number of oral tablets in each age group (6 to 11 years of age and 12 to 17 years of age) where all participants in an age group will receive the same total number of oral tablets at each administration. Phase 2 completers who choose to remain on double-blind eluxadoline and received placebo in the lead-in Phase 2 study 3030-202-002 will be assigned to double-blind eluxadoline 25 mg BID
89583383|NCT04880876|Experimental|Double Blind 12-17 years of age: Eluxadoline 25mg|Blinding will be accomplished via administration of a constant number of oral tablets in each age group (6 to 11 years of age and 12 to 17 years of age) where all participants in an age group will receive the same total number of oral tablets at each administration. Phase 2 completers who choose to remain on double-blind eluxadoline and received placebo in the lead-in Phase 2 study 3030-202-002 will be assigned to double-blind eluxadoline 25 mg BID
89583384|NCT04880876|Experimental|Double Blind 12-17 years of age: Eluxadoline 50mg|Blinding will be accomplished via administration of a constant number of oral tablets in each age group (6 to 11 years of age and 12 to 17 years of age) where all participants in an age group will receive the same total number of oral tablets at each administration. Phase 2 completers who choose to remain on double-blind eluxadoline and received placebo in the lead-in Phase 2 study 3030-202-002 will be assigned to double-blind eluxadoline 25 mg BID
89583385|NCT04880876|Experimental|Double Blind 12-17 years of age: Eluxadoline 100mg|Blinding will be accomplished via administration of a constant number of oral tablets in each age group (6 to 11 years of age and 12 to 17 years of age) where all participants in an age group will receive the same total number of oral tablets at each administration. Phase 2 completers who choose to remain on double-blind eluxadoline and received placebo in the lead-in Phase 2 study 3030-202-002 will be assigned to double-blind eluxadoline 25 mg BID
88974586|NCT00041106|Experimental|Treatment (gemcitabine, cisplatin, and gefitinib)|Patients receive gemcitabine IV over 30 minutes on days 1 and 8 and cisplatin IV over 1 hour on day 1. Patients also receive gefitinib PO QD beginning on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve complete remission, partial remission, or maintain stable disease continue gefitinib PO QD for 5 years or until disease progression or unacceptable toxicity occurs.
89030117|NCT04519424|Placebo Comparator|Placebo|Normal saline administered intravenously
89033273|NCT02942732|Other|overweight elderly|overweight elderly (n=60, age ≥ 65 years and BMI ≥ 25 kg/m²) All assigned patients received a supplement of 10,000 IU cholecalciferol (Euro-Pharm International, Canada) to be taken three times per week. The treatment was led for a period of 6 months.
89209549|NCT00890760|Experimental|Group 6|Protected volunteers from Group 1 re-challenged with sporozoite after 6 months
89583386|NCT02269124|No Intervention|Conventional Measures Only|In arm 1, the child will utilize conventional measures for management of unilateral hearing loss, such as FM system and preferential seating in the classroom. While two basic types of FM systems exist, personal and sound field, subjects in our study will utilize a personal FM system, worn at the ear-level. This will increase the likelihood that the child will receive amplification in all classes, and will help to standardize this intervention. The HEAR-QL, CHILD (child) questionnaire, and LIFE-R student questionnaire will be administered to the child at the beginning, midpoint, and conclusion of this 3-month arm via Redcap. The CHILD (parent) questionnaire will be administered to the parent and the LIFE-R teacher questionnaire will be administered to the teacher at the same intervals.
89583387|NCT02269124|Experimental|Conventional Measures + Hearing Aid|In arm 2, the child will use the conventional measures described above in addition to a digital behind-the-ear hearing aid with a standard ear hook and custom ear mold on the affected ear. The hearing instrument will be customized by an audiologist. The subject will be instructed to wear the hearing aid both at home and at school. In both arms, the FM system will be used in school only. As in the first arm, the HEAR-QL, CHILD (child) questionnaire, and LIFE-R student questionnaire will be administered to the child at the beginning, midpoint, and conclusion of this 3-month arm. The CHILD (parent) questionnaire will be administered to the parent and the LIFE-R teacher questionnaire will be administered to the teacher at the same intervals. No washout period will take place between the two arms. Subjects will be randomized to complete one arm first for 3 months, followed immediately by 3 months in the opposite arm.
89583388|NCT01927341|Experimental|Phase Ib: Dose escalation|Phase Ib: Dose escalation.
89583389|NCT01927341|Experimental|Phase II: Patients with mutant RAS mCRC|Patients with mutant RAS mCRC who have not been pretreated with an EGFR inhibitor (EGFRi), including EGFR tyrosine kinase inhibitor therapy and/or anti-EGFR monoclonal antibody therapy.
89583390|NCT01927341|Experimental|Phase II: Patients with acquired mutant RAS mCRC|Patients with acquired mutant RAS mCRC who have been pretreated with anti-EGFR monoclonal antibody therapy, but have not been pre-treated with EGFR tyrosine kinase inhibitor therapy.
89583391|NCT01927341|Experimental|Phase II: Patients with WT RAS mCRC (pretreated)|Patients with WT RAS mCRC who have been pretreated with an EGFRi, including EGFR tyrosine kinase inhibitor therapy and/or anti-EGFR monoclonal antibody therapy.
89583392|NCT01927341|Experimental|Phase II: Patients with WT RAS mCRC (not pretreated)|Patients with WT RAS mCRC who have not been pretreated with an EGFRi, including EGFR tyrosine kinase inhibitor therapy and/or anti-EGFR monoclonal antibody therapy.
89583393|NCT02294474|Experimental|SAR342434|SAR342434 100 Unit/mL (U/mL) before meals intake on top of once daily (QD) Insulin Glargine, up to Week 26.
89583394|NCT02294474|Active Comparator|Humalog|Humalog 100 U/mL before meals intake on top of QD Insulin Glargine, up to Week 26.
89583395|NCT02168101|Experimental|MLN9708 - 2.3 mg|Patients will be enrolled between Days 45 and 120 after allogeneic transplant and will receive a weekly dose of 2.3 mg of MLN9708 on Days 1, 8, and 15 of each 28-day cycle for 6 cycles.
89583396|NCT02168101|Experimental|MLN9708 - 3 mg|Patients will be enrolled between Days 45 and 120 after allogeneic transplant and will receive a weekly dose of 3 mg of MLN9708 on Days 1, 8, and 15 of each 28-day cycle for 6 cycles.
89583397|NCT02168101|Experimental|MLN9708 - 4 mg|Patients will be enrolled between Days 45 and 120 after allogeneic transplant and will receive a weekly dose of 4 mg of MLN9708 on Days 1, 8, and 15 of each 28-day cycle for 6 cycles.
89583398|NCT02298179|Experimental|RSV F 45 No Adj Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of the low dose RSV F subunit vaccine [45 μg], with no adjuvant.
89583399|NCT02298179|Experimental|RSV F 45 Alum Adj Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of the low dose RSV F subunit vaccine [45 μg], with aluminum hydroxide adjuvant.
89583400|NCT02298179|Experimental|RSV F 45 MF59 Adj Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of the low dose RSV F subunit vaccine [45 μg], with MF59 adjuvant.
89583401|NCT02298179|Placebo Comparator|Placebo 1 Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of saline solution. Subjects were enrolled in a stepwise dosage escalation manner into one of the three cohorts (Cohort 1: low dosage of RSV F subunit vaccine [45 μg], Cohort 2: middle dosage of RSV F subunit vaccine [90 μg], and Cohort 3: high dosage of RSV F subunit vaccine [135 μg]). This placebo group belongs to Cohort 1.
89583402|NCT02298179|Experimental|RSV F 90 No Adj Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of the medium dose RSV F subunit vaccine [90 μg], with no adjuvant.
89583403|NCT02298179|Experimental|RSV F 90 Alum Adj Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of the medium dose RSV F subunit vaccine [90 μg], with aluminum hydroxide adjuvant.
89583404|NCT02298179|Experimental|RSV F 90 MF59 Adj Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of the medium dose RSV F subunit vaccine [90 μg], with MF59 adjuvant.
89583405|NCT02298179|Placebo Comparator|Placebo 2 Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of saline solution. Subjects were enrolled in a stepwise dosage escalation manner into one of the three cohorts (Cohort 1: low dosage of RSV F subunit vaccine [45 μg], Cohort 2: middle dosage of RSV F subunit vaccine [90 μg], and Cohort 3: high dosage of RSV F subunit vaccine [135 μg]). This placebo group belongs to Cohort 2.
89583406|NCT02298179|Experimental|RSV F 135 No Adj Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of the high dose RSV F subunit vaccine [135 μg], with no adjuvant.
89583407|NCT02298179|Experimental|RSV F 135 Alum Adj Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of the high dose RSV F subunit vaccine [135 μg], with aluminum hydroxide adjuvant.
89583408|NCT02298179|Experimental|RSV F 135 MF59 Adj Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of the high dose RSV F subunit vaccine [135 μg], with MF59 adjuvant.
89209550|NCT00890760|Experimental|Group 7|Non vaccinated control for Groups 4-6, 8-10 challenged with sporozoite
89583409|NCT02298179|Placebo Comparator|Placebo 3 Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of saline solution. Subjects were enrolled in a stepwise dosage escalation manner into one of the three cohorts (Cohort 1: low dosage of RSV F subunit vaccine [45 μg], Cohort 2: middle dosage of RSV F subunit vaccine [90 μg], and Cohort 3: high dosage of RSV F subunit vaccine [135 μg]). This placebo group belongs to Cohort 3.
89583410|NCT02298023|Experimental|Mesenchymal stem cell group|Received allogenic adipose tissue-derived adult mesenchymal stem cells (10million cells) in fibrin glue scaffold.
89583411|NCT02298023|Active Comparator|Active control (fibrin glue) group|Received fibrin glue and normal saline.
89583412|NCT02298023|Placebo Comparator|Control (normal saline )group|Received only normal saline.
89583413|NCT02296931|Active Comparator|Healthy Adults|Phase 1 will be an initial validation of the clinical performance of the device delivering only standard IV saline to 10 stable women.
89583414|NCT02296931|Experimental|Pre-eclamptic pregnant women|In Phase 2, the device will deliver MgSO4 to up to 40 women presenting with symptoms of pre-eclampsia.
89583415|NCT02166697||Oral administration of 4-8 mg of candesartan cilexetil|Oral administration of 4-8 milligram (mg) of candesartan cilexetil once daily (increased up to 12 mg, as necessary)
89583416|NCT01909479|Experimental|MOD-4023|
89583417|NCT01909479|Placebo Comparator|Placebo|
89583418|NCT04760977||Trauma patients in shock|The study focuses on hypotensive trauma patients assisted by HEMS teams
89583419|NCT01955733|Experimental|BI 695500|BI 695500, Two infusions separated by 2 weeks, Intravenous infusion
89583420|NCT02197897|Experimental|Tamoxifen|As a single-arm study (single group assignment), Tamoxifen citrate will be given to all patients at a 20mg/day dose for 12 weeks using a marker-lesion study design.
89583421|NCT02223793|Experimental|No information on high risk factor levels but lifestyle advice|This arm of high risk participants will not be informed about their measured levels of the different cardiovascular risk factors at baseline. However, they will receive general information on how to lower risk factor levels in 8 weeks
89583422|NCT02223793|Experimental|No information on high risk factor levels nor lifestyle advice|In this arm, participants will not be informed about their measured levels of the different cardiovascular risk factors, nor receiving lifestyle advices at baseline
89583423|NCT02223793|Experimental|Information on high risk factor levels and lifestyle advice|This arm of high risk participants will not be informed about their measured levels of the different cardiovascular risk factors at baseline, and receive general information on how to lower risk factor levels in 8 weeks
89583424|NCT01926015|Experimental|Concomitant RotaTeq™ and DTP-IPV|RotaTeq™ (2 mL oral dose) and DTP-IPV (0.5 mL subcutaneous injection) administered concomitantly at Visit 2 (>=4 weeks after Visit 1), Visit 4 (6-8 weeks after Visit 2), and Visit 6 (6-8 weeks after Visit 4).
89583425|NCT01926015|Active Comparator|Staggered RotaTeq™ and DTP-IPV|RotaTeq™ (2 mL oral dose) administered at Visit 1 (Day 1), Visit 3 (6-8 weeks after Visit 1), and Visit 5 (6-8 weeks after Visit 3) and DTP-IPV (0.5 mL subcutaneous injection) administered at Visit 2 (>=4 weeks after Visit 1), Visit 4 (6-8 weeks after Visit 2), and Visit 6 (6-8 weeks after Visit 4).
89583426|NCT02223715||CDI|
89583427|NCT02196259|Experimental|Initial MRI|The subject will receive intravenous ketamine anesthesia at a dose of 0.5mg/kg delivered over 40 minutes in a constant infusion or bolus plus infusion method to maintain steady state (10 minutes initial induction, 30 minutes steady-state, for 40 minutes total)
89583428|NCT02196259|Experimental|Initial hospital|The subject will receive intravenous ketamine anesthesia at a dose of 0.5mg/kg delivered over 40 minutes in a constant infusion or bolus plus infusion method to maintain steady state (10 minutes initial induction, 30 minutes steady-state, for 40 minutes total)
89583429|NCT02196259|Experimental|Depression MRI|The subject will receive intravenous ketamine anesthesia at a dose of 0.5mg/kg delivered over 40 minutes in a constant infusion or bolus plus infusion method to maintain steady state (10 minutes initial induction, 30 minutes steady-state, for 40 minutes total)
89583430|NCT02294396|Experimental|Mirabegron + Solifenacin|Participants received mirabegron 50 mg and solifenacin 5 mg once daily after breakfast orally for 8 weeks. In the next 44 weeks, participants continued to receive mirabegron 50 mg, but received an increased dose of solifenacin 10 mg, if the treatment was not effective.
88974587|NCT00041301||QoL in prostate cancer|The study sample will be composed of a consecutive series of prostate cancer patients, stratified by stage of disease, local and locally advanced versus advanced (metastatic) disease, and undergoing active anti-tumor therapy. In order to increase sample homogeneity, and to facilitate evaluation of the responsiveness of the quality of life instruments to changes in patients' health status and symptoms experience over time, the subsample of patients with local or locally advanced disease will be restricted to those undergoing surgery (radical prostatectomy) or radiation therapy, and the subsample of metastatic disease patients will be limited to those receiving hormonal therapy.
89583431|NCT02294396|Experimental|Mirabegron + Propiverine|Participants received mirabegron 50 mg and propiverine 20 mg once daily after breakfast orally for 8 weeks. In the next 44 weeks, participants continued to receive mirabegron 50 mg, but received an increased dose of propiverine 40 mg, if the treatment was not effective.
89583432|NCT02294396|Experimental|Mirabegron + Imidafenacin|Participants received mirabegron 50 mg and imidafenacin 0.2 mg once daily after breakfast orally for 8 weeks. In the next 44 weeks, participants continued to receive mirabegron 50 mg, but received an increased dose of imidafenacin 0.4 mg, if the treatment was not effective.
89583433|NCT02294396|Experimental|Mirabegron + Tolterodine|Participants received mirabegron 50 mg and tolterodine 4 mg once daily after breakfast orally for 52 weeks.
89583434|NCT01721044|Placebo Comparator|Placebo|"Placebo administered orally once daily through Week 24. Starting at Week 16, participants who are nonresponders will be rescued with baricitinib 4 milligram (mg) orally once daily through Week 24.~Participants will continue to take background conventional disease-modifying antirheumatic drug (cDMARD) therapy throughout study."
88974588|NCT00021398|Experimental|Radiation Therapy, Chemotherapy and Surgery|
89209551|NCT00890760|Experimental|Group 8|3 vaccinations of mixture formulation AdCh63 ME-TRAP and MVA ME-TRAP give at 8 weeks interval each followed by sporozoite challenge 3 weeks after last vaccination
89583435|NCT01721044|Experimental|Baricitinib 2 mg|"Baricitinib 2 mg administered orally once daily through Week 24. Starting at Week 16, participants who are nonresponders will be rescued with baricitinib 4 mg orally once daily through Week 24.~Participants will continue to take background cDMARD therapy throughout study."
89583436|NCT01721044|Experimental|Baricitinib 4 mg|"Baricitinib 4 mg administered orally once daily through Week 24. Starting at Week 16, participants who are nonresponders will be rescued with baricitinib 4 mg orally once daily through Week 24.~Participants will continue to take background cDMARD therapy throughout study."
89583437|NCT02164981|Active Comparator|Drug - Drug|Phase 1 - intravenous sodium nitroprusside Phase 2 - intravenous sodium nitroprusside
89583438|NCT02164981|Other|Placebo - Drug|Phase 1 - intravenous dextrose Phase 2 - intravenous sodium nitroprusside
89583439|NCT02164981|Placebo Comparator|Placebo - Placebo|Phase 1 - intravenous dextrose Phase 2 - intravenous dextrose
89583440|NCT02195869|Experimental|Phase 1b: Dose Level 1|Subjects receive daily dose of 420 mg of Ibrutinib capsules
89583441|NCT02195869|Experimental|Phase 1b: Dose Level 2|Subjects receive daily dose of 280 mg of Ibrutinib capsules
89583442|NCT02195869|Experimental|Phase 1b: Dose Level 3|Subjects receive daily dose of 140 mg of Ibrutinib capsules
89583443|NCT02195869|Experimental|Phase 2|Subjects receive daily dose of recommended phase 2 dose
89583444|NCT01908699|Experimental|Beraprost Sodium 314d Modified Release Tablets|Available as 15 μg tablets for oral, 1 or 2 tablets four times daily (QID) administration.
89583445|NCT01908699|Experimental|Placebo|Placebo tablets, which are identical in size and appearance to those containing BPS-314d-MR.
89583446|NCT01599637|Experimental|IGE025|Patients will receive omalizumab administered subcutaneously every 4 weeks at the study center.
89583447|NCT01599637|Placebo Comparator|Placebo to IGE025|Placebo administered subcutaneously every 4 weeks at the study center.
89583448|NCT02264639|Experimental|Cohort 1|First Dose 25mg, Repeated Dose 5 mg/day
89583449|NCT02264639|Experimental|Cohort 2|First Dose 50 mg, Repeated Dose 30 mg/day
89583450|NCT02264639|Experimental|Cohort 3|Repeated Dose 180 mg/day
89583451|NCT02264639|Experimental|Cohort 4|Repeated Dose 270 mg/day
89583452|NCT05648903|Experimental|One-to-one|All participants are offered a choice of three dietary approaches.
89583453|NCT05648903|Experimental|Group|All participants are offered a choice of three dietary approaches.
89583454|NCT01363011|Experimental|E/C/F/TDF (Cohort 1)|"Participants who have not received prior antiretroviral (ARV) treatment and who are virologically unsuppressed at baseline will initiate treatment with elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (E/C/F/TDF) single-tablet regimen (STR) for up to 96 weeks.~Following Week 96, participants continued their treatment until all participants discontinued from the study or commercial approval of E/C/F/TDF was received in the applicable country."
89583455|NCT01363011|Experimental|COBI+PI+2 NRTI (Cohort 2)|"Participants who have received prior ARV treatment and who are virologically suppressed at baseline will continue their treatment regimen, switching the regimen's pharmacoenhancer component from ritonavir to cobicistat (COBI), and continuing their existing protease inhibitor (PI; either atazanavir (ATV) or darunavir (DRV)) plus 2 nucleoside reverse transcriptase inhibitor (NRTI) regimen for up to 96 weeks.~Following Week 96, participants continued their treatment until all participants discontinued from the study or commercial approval of cobicistat was received in the applicable country."
89583456|NCT05648747||Complicated Pelvic Inflammatory Disease|The development of complicated Pelvic Inflammatory Disease diagnosed during laparoscopy or by pre-operative image study
89583457|NCT05648747||Non-Complicated Pelvic Inflammatory Disease|No development of complicated Pelvic Inflammatory Disease diagnosed during laparoscopy or by pre-operative image study
89583458|NCT05648669|Experimental|Elagolix|Elagolix 200 mg twice daily (BID) for the 6-month Treatment Period
89583459|NCT05648669|Placebo Comparator|Elagolix placebo|Placebo BID for the 6-month Treatment Period
89583460|NCT02263547|Other|teriflunomide elimination with colestipol|
89583461|NCT05648513|Experimental|Motivational Interview|"Parent Attitudes About Childhood Vaccines Survey (PACV) will be implemented to the pregnant women consulting to Atatürk City Hospital. Subjects with vaccine hesitancy will be randomly distributed to groups, and in this way, experimental (n=26) and control (n=26) groups will be formed. Routine antenatal monitoring will be kept with the control group. With the experimental group, on the other hand, motivational interviewing method will be implemented for 4 sessions of about 45 minutes each. Interviews will be held at 4 separate weekends, 1 session for each. Interviews will be performed via online means or face to face.~Personal Details Form It is the survey form that includes such socio-demographic aspects of the participants as their ages and educational backgrounds, and their opinions about vaccines."
88974589|NCT00048984||Basic science (biomarker analysis)|Patients undergo various specimen collections, including bone marrow aspirate, paraffin-embedded blocks of tumor tissue or slides of tumor tissue, and blood specimens. These specimens are collected before, during, and after any chemotherapy regimens, during follow-up, and at time of recurrence. Translocation studies are performed on specimens to identify fusion genes, specifically EWS-ETS. Serum IGF1 and IFGBP3 levels are determined. Bone marrow is assessed for minimal residual disease using reverse-transcriptase polymerase chain reaction.
88974590|NCT00049023|Experimental|90Y-DOTA-tyr3-OCTREOTIDE|Dose escalation will proceed so that the single-cycle and three-cycle maximum tolerated doses of 90Y-DOTA-tyr3-Octreotide can be determined. The initial dose of 90Y-DOTA-tyr3-Octreotide to be administered is 30 mCi/m2 in each of three cycles. Dose escalation will proceed in 10 mCi/m2 intervals and will be permitted for the next cohort of subjects pending completion of Cycle 3 by 2 members of the previous cohort with no DLTs. A DLT is defined as a Grade 3 renal toxicity, Grade 4 bone marrow toxicity, or any other Grade 3 toxicity whether or not related to study drug and regardless of duration. Lymphopenia will not be used to define a DLT.
89209552|NCT00890760|Experimental|Group 9|2 vaccinations of mixture formulation AdCh63 ME-TRAP and MVA ME-TRAP give at 8 weeks interval followed by sporozoite challenge 3 weeks after last vaccination
89583462|NCT05648513|No Intervention|Control Group|Control Group Experimental Group ( n=26 ) Routine antenatal monitoring will be kept with the control group. Routine antenatal monitoring Completion of motivational interviewing session Inspection of the vaccine card 1st and 2nd postnatal months and implementation of Parent Attitudes About Childhood Vaccines Survey (PACV) Personal Details Form It is the survey form that includes such socio-demographic aspects of the participants as their ages and educational backgrounds, and their opinions about vaccines.
89583463|NCT01925703|Experimental|Sodium ferric gluconate|Sodium ferric gluconate 250 mg administered intravenously every 12 hours until iron repletion completed (as determined by Ganzoni equation) or patient discharge, whichever comes first.
89583464|NCT01617681|Experimental|Valsartan 0.25 mg/kg|Valsartan oral solution 0.25mg/kg once daily + matching placebo of valsartan oral solution 4 mg/kg once daily for 6 weeks (period 1)
89583465|NCT01617681|Experimental|Valsartan 4 mg/kg|Valsartan oral solution 4 mg/kg once daily + matching placebo of valsartan oral solution 0.25 mg/kg once daily for 6 weeks (period 1)
89583466|NCT01617681|Experimental|Valsartan 1 mg/kg|Open-label (Period 2) valsartan will be optionally titrated from 1 mg/kg to 2 mg/kg. Valsartan will continue to be optionally up titrated in 1 mg/kg increments every 4 weeks until maximum dose of 4 mg/kg is achieved. Duration 20 weeks.
89583467|NCT02263079|Experimental|Peg-IFN-Alfa-2A + Lamivudine or Entecavir|Participants will receive lamivudine or entecavir alone for 8 weeks followed by peg-IFN-alfa-2A in combination with lamivudine or entecavir for 48 weeks.
89583468|NCT02263079|No Intervention|Untreated Control Participants|Untreated control participants will be observed up to 80 weeks.
89583469|NCT02263079|Experimental|Peg-INF-Alfa-2A Monotherapy|Participants will receive Peginterferon Alfa 2A subcutaneously once weekly with dosing based on body surface area (BSA) categories for 48 weeks.
89583470|NCT02295995|Experimental|Physical Activity|Participants randomized to this arm will be enrolled in a 12-week physical activity program.
89583471|NCT02295995|No Intervention|Usual Care Wait-List|Participants randomized to this arm will continue to receive usual care services for PTSD through the Veterans Health Administration (VHA) for 12 weeks after which time they will be offered the physical activity program for 12 weeks.
89583472|NCT02294981|Active Comparator|Conventional Dosing|Patients psoriasis to be treated with Excimer laser phototherapy based on conventional dosing guidelines. These guidelines determine the starting dose based on plaque thickness and the skin type of the patient. Patients will also be evaluated for psoriasis plaque response to test doses. The best dose will be selected from a test matrix of doses.
89583473|NCT02294981|Experimental|Plaque based dosing|Patients will also be evaluated for psoriasis plaque response to test doses. The best dose will be selected from a test matrix of doses.
89583474|NCT02262377|Experimental|Integrative Medicine Group Visits|9-week integrative medicine group visit that meets 1 time per week for 2.5 hours followed by a 3 month Web based curriculum and final group meeting
89583475|NCT02262377|No Intervention|Standard of Care|primary care visits, which include medications and advice
89583476|NCT02260817|Experimental|Expanded Access for 11C-Choline|"The key objective of this study is to provide expanded access to this drug product as currently defined under the reference listed drug as an investigational drug in geographical service areas where 11C-choline injection is not available.~Patients entered into the study will undergo a 11C-choline PET CT scan and MRI scan. The 11C-choline PET CT and MRI images will be evaluated for evidence of metastatic prostate cancer. Patient data obtained in this arm of the study will not be further analyzed beyond that need for clinical diagnosis."
89583477|NCT02260817|Experimental|11C-Choline Comparison of Modalities|"11C-choline injection is approved for use in conjunction with both CT and MR imaging modalities. This arm will attempt to determine which modality is most efficacious and under which conditions.~Patients entered into the study will undergo imaging using GE's Trimodality Imaging System that combines PET, CT, and MR techniques to provide PET/CT and PET/MR fused images"
89583478|NCT05647967||the consolidation perfusion/the consolidation size|Patients with respiratory failure and lung consolidation proved by chest imaging underwent lung ultrasound to evaluate the regional perfusion and the size of consolidation.
89583479|NCT04873193|Other|Oscillometry + Pneumotach Procedure with Leo Device measurements|"All patients will undergo oscillometry procedure, followed by pneumotach procedure to measure tidal volume in different sitting positions. The Leo device will be worn throughout both procedures to measure the chest electrical impedance and compare against pneumotach measurements.~Oscillometry and pneumotach are part of standard of care."
89583480|NCT01642589|Experimental|Menactra® Group|Participants will receive Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®)
89583481|NCT01642589|Active Comparator|Tdap - Adacel® Group|Participants will receive Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Tdap - Adacel®)
89583482|NCT05647499|Experimental|The Back 2 School program (B2S) for problematic school absenteeism|The B2S program is a modular trans-diagnostic cognitive behavioral program aimed at helping children and youth with problematic levels of school absenteeism.
89583483|NCT05647421|Active Comparator|The AcrySof™ IQ Vivity™ intraocular lens group|The AcrySof™ IQ Vivity™ will be implanted in 20 eyes of 10 patients (group 1)
89583484|NCT05647421|Active Comparator|TECNIS Synergy™ Intraocular Lens (Model ZFR00V ) group|The TECNIS Synergy™ Intraocular Lens (Model ZFR00V ) will be implanted in 20 eyes of 10 patients
89583485|NCT02268812||Ziconotide|"No drug will be provided by the sponsor. Treatment decisions will be made by physicians independent of participation in the registry.~IT analgesia may consist of ziconotide or any other drug used in IT therapy, including those used off-label as part of local clinical practice."
89583486|NCT01954251|Experimental|Co-Ad Group|The subjects assigned to the Co-Ad group will receive one injection of the FLU-D-QIV vaccine and one injection of the HZ/su study vaccine during the first visit and a second injection of the HZ/su study vaccine during the third visit, two months later.
89583487|NCT01954251|Active Comparator|Control Group|The subjects assigned to the Control group will receive all vaccines separately: one injection of the FLU-D-QIV vaccine at the first visit, one injection of the HZ/su study vaccine at the third visit and a second injection of the HZ/su study vaccine at the fourth visit, all two months apart.
89583488|NCT01644617|Placebo Comparator|Placebo|Placebo rapidly dissolving tablet administered sublingually once daily (q.d.), at approximately the same time each day, for 24 weeks
89583489|NCT01644617|Experimental|MK-8237 6 Developmental Units (DU)|MK-8237 6 DU rapidly dissolving tablet administered sublingually q.d., at approximately the same time each day, for 24 weeks
89583490|NCT01644617|Experimental|MK-8237 12 DU|MK-8237 12 DU rapidly dissolving tablet administered sublingually q.d., at approximately the same time each day, for 24 weeks
89583491|NCT02294318|Active Comparator|Motivational Interviewing (MI)|Participants will engage in a 30-minute Motivational Interviewing session with the study counselor to discuss participant's drug and alcohol use, its implications for their health, and the possibility of drug and alcohol use reduction. This counseling session is intended to help people reduce their drug and alcohol use if they wish. In the counseling session, participants describe the pros and cons of their drug and alcohol use and whether it might be important to quit using drugs and drinking alcohol. Open discussion of the pros (what they like about drug use and drinking) and cons (what they don't like) can help people think about reducing drug and alcohol use in a more complete way than they might have before. This arm will be compared to the HealthCall+Motivational Interviewing arm.
89583492|NCT02294318|Experimental|HealthCall+Motivational Interviewing|The HealthCall+Motivational Interviewing arm will investigate whether the addition of HealthCall, a smartphone application designed to keep track of the participant's drug and alcohol use and other health-related behaviors through short daily use, will help participants reduce their substance use more than Motivational Interviewing alone. Participants will receive the same 30-minute Motivational Interviewing session as described in the MI arm. After the session, participants will be introduced to HealthCall and will be asked to use the app daily over the next 30 days. Each use lasts 2-3 minutes and can be done anywhere on the phone in the U.S. The purpose of daily HealthCall use is to help participants keep track of their drug and alcohol use.
89583493|NCT04643925|Experimental|hCG priming|"Control cycle: A standard IVF/ICSI cycle in the fixed GnRH-antagonist protocol using a daily dose of 300 IU rFSH initiated from cd 2-3 and the GnRH antagonist (Fyremadel 0.25 mg) from stimulation day 5-6 followed by blastocyst culture and a freeze-all strategy.~Study cycle: hCG priming by Ovitrelle 260 IE once daily for 8 weeks followed by a standard IVF/ICSI cycle in the fixed GnRH-antagonist protocol using a daily dose of 300 IU rFSH initiated from cd 2-3 and the GnRH antagonist (Fyremadel 0.25 mg) from stimulation day 5-6 followed by a single blastocyst transfer at day 5."
89583494|NCT02293499|Active Comparator|Peer Led Asthma Self-Management|Peer-led asthma self-management for adolescents : PLASMA will be implemented in small groups at a camp setting where paired peer-leaders will facilitate learning activities.Paired peer leaders will share and coordinate the responsibilities of facilitating group activities. Training content includes: Day 1: Asthma basics and prevention; Day 2: Asthma monitoring and management; Day 3: Communication/ psychosocial issue management/leadership training/hands-on practice in simulated peer-led group settings (role-play)
89583495|NCT02293499|Active Comparator|Adult Led Asthma Self-Management|The adult led asthma self-management will take place within 2 weeks of the peer-led camp to minimize the history effect. Two healthcare professionals will attend peer-leader training sessions to become familiar with the program content, then lead instructional activities. As in PLASMA, adult leaders will base their instruction on the program manual to ensure comparable program content. Adult leaders will adopt mainly a didactic format and skill demonstration.
89583496|NCT04628949|Experimental|aScope™ Duodeno endoscope and aBox™ Duodeno|Eligible subjects who are undergoing non-emergent, clinically indicated ERCP using aScope™ Duodeno endoscope and aBox™ Duodeno.
89583497|NCT02257385|Experimental|UMEC/VI arm|Participants will be instructed to self-administer one dose each morning of UMEC/VI Inhalation Powder 62.5/25 mcg once daily via ELLIPTA DPI, placebo once daily via HANDIHALER inhaler and placebo once daily via BREEZHALER inhaler
89583498|NCT02257385|Placebo Comparator|Tiotropium + Indacaterol arm|Participants will be instructed to self-administer one dose each morning of Tiotropium bromide 18 mcg once daily via HANDIHALER inhaler, Indacaterol 150 mcg once daily via BREEZHALER inhaler and placebo once daily via ELLIPTA DPI
89583499|NCT01629667|Experimental|Tralokinumab 400 milligram (mg)|Participants will receive Tralokinumab 400 mg intravenous (IV) infusion Q4W for 68 Weeks.
89583500|NCT01629667|Experimental|Tralokinumab 800 mg|Participants will receive Tralokinumab 800 mg IV infusion Q4W for 68 Weeks.
89583501|NCT01629667|Placebo Comparator|Placebo|Participants will receive placebo IV once every 4 Weeks (Q4W) for 68 Weeks.
89583502|NCT01645280|Placebo Comparator|Group 1|
89583503|NCT01645280|Experimental|Group 2|
89583504|NCT01645280|Experimental|Group 3|
89583505|NCT01645280|Experimental|Group 4|
89583506|NCT01645280|Experimental|Group 5|
89583507|NCT02256917|Experimental|Human-cl rhFVIII|
89583508|NCT01629589|Experimental|Adacel® Vaccine Group|Participants randomized to receive a single dose of Adacel® vaccine
89583509|NCT01629589|Active Comparator|Boostrix® Vaccine Group|Participants randomized to receive a single dose of Boostrix® vaccine
89583510|NCT04188223|Experimental|Recombinant Hepatitis B (Bio Farma) Vaccine|Recombinant Hepatitis B vaccine is an inactivated HbsAg produced in yeast cells (Hansenula polymorpha) using recombinant DNA technology. It is a whitish liquid produced by culture genetically engineered yeast cell which carry the relevant gene of the HbsAg and purified and inactivated by several physicochemical steps such as ultracentrifugation, column chromatography and formaldehyde treatment.
89583511|NCT04188223|Active Comparator|Control Product: Recombinant Hepatitis B (Bio Farma) Vaccine®|Registered Recombinant Hepatitis B vaccine is an inactivated HbsAg produced in yeast cells (Hansenula polymorpha) using recombinant DNA technology. It is a whitish liquid produced by culture genetically engineered yeast cell which carry the relevant gene of the HbsAg and purified and inactivated by several physicochemical steps such as ultracentrifugation, column chromatography and formaldehyde treatment.
89583512|NCT02256839||non TB infection|Group tested with CST_001
89209553|NCT00890760|Experimental|Group 10|3 vaccinations of mixture formulation AdCh63 ME-TRAP and MVA ME-TRAP give at 4 weeks interval each followed by sporozoite challenge 3 weeks after last vaccination
89209554|NCT00890838|Active Comparator|Omegaven|will receive IV Omega 3 fatty acids (Omegaven®) for 3 days preoperatively
89583513|NCT02256839||low exposure risk|Group tested with CST_001
89583514|NCT02220907|Experimental|Teneligliptin/Canagliflozin|Patients receive Teneligliptin and Canagliflozin once daily for 52 weeks.
89583515|NCT02255981|Experimental|Acupuncture group|"Acupuncture and massage Therapy of Traditional Chinese Medicine (acupuncture and Massage) for 24 months~."
89583516|NCT01601873|Experimental|PROPATEN|patients with heparin-bonded graft implantation
89583517|NCT01601873|Active Comparator|Standard Graft|patients undergoing ePTFE hemodialysis graft implantation
89583518|NCT02194933|Experimental|Brexpiprazole 2 mg|Brexpiprazole 2 mg/day, once daily dose, tablet, orally
89583519|NCT02194933|Experimental|Brexpiprazole 4 mg|Brexpiprazole 4 mg/day, once daily dose, tablet, orally
89583520|NCT05647109||Set of training|A total of 148 patients with endometrial cancer and atypical endometrial hyperplasia were included in the training set of the prediction model. They were divided into progesterone sensitive group and progesterone insensitive group.
89583521|NCT05647109||Set of verification|A verification set of the prediction model was established, consisting of 96 patients with endometrial cancer and atypical endometrial hyperplasia.
89583522|NCT04420247|Experimental|Intervention|"Treatment with either Chloroquine or Hydroxychloroquine according to what was available in the hospital:~Chloroquine - 900mg on the first day, followed by 450mg in the next 4 days. Hydroxychloroquine - 800mg on the first day, followed by 450mg in the next 4 days.~+~Standard treatment available and recomended by the Brazilian Guidelines for COVID-19."
89583523|NCT04420247|Active Comparator|Control|Standard treatment available and recomended by the Brazilian Guidelines for COVID-19.
89583524|NCT01644890|Experimental|NK105|
89583525|NCT01644890|Active Comparator|Paclitaxel|
89583526|NCT04868006|Experimental|End-range mobilization + proprioception training|End-range Maitland mobilization performed in end-range internal rotation of the shoulder accompanied with 8--week long proprioception training
89583527|NCT04868006|Active Comparator|Non end-range mobilization+ proprioception training|Non end-range Maitland mobilization performed in loose position of the shoulder accompanied with 8--week long proprioception training
89583528|NCT04868006|Sham Comparator|Sham manual therapy technique + proprioception training|Placebo performed in loose position of the shoulder accompanied with 8--week long proprioception training
89583529|NCT04865237|Experimental|Healthy Volunteers|SARS-CoV-2, intranasally, (1x10^1 TCID50, 1x10^2 TCID50 and 1x10^3 TCID50 or higher, as necessary)
89583530|NCT01628965|Experimental|SPM 962|SPM 962 transdermal patch
89583531|NCT05647460|Active Comparator|computer guided plates|computer guided screw holes locating guide and custom-made plates in management of parasymphseal mandibular fracture
89583532|NCT05647460|Active Comparator|conventional plates|conventional plate osteosynthesis in management of parasymphseal mandibular fracture
89583533|NCT05647382|Active Comparator|Lung injury group|Lung injury is defined as lung damage when the patient has an oxygen and index below 300 24 hours after cardiopulmonary bypass
89583534|NCT05647382|Sham Comparator|Non-lung injury group|Patients with oxygen and an index above 300 24 hours after cardiopulmonary bypass are defined as non-lung injury
89583535|NCT02255279|Experimental|aTIV|aTIV is a trivalent influenza virus vaccine, adjuvanted with MF59C.
89583536|NCT02255279|Active Comparator|TIV|TIV is trivalent influenza vaccine licensed in Mexico.
89583537|NCT01643798|Placebo Comparator|Saline|Participants received intravenous saline immediately prior to sham and real rTMS of the left dorsolateral prefrontal cortex. The parameters of the stimulation paradigm are as follows: 10 Hz, 5 seconds on, 10 seconds off, 20 minutes, 4000 pulses).
89583538|NCT01643798|Active Comparator|Naloxone|Participants received intravenous naloxone (0.1mg/kg) immediately prior to sham and real rTMS of the left dorsolateral prefrontal cortex. The parameters of the stimulation paradigm are as follows: 10 Hz, 5 seconds on, 10 seconds off, 20 minutes, 4000 pulses).
89583539|NCT05647031||20 participants were interviewed on a voluntary basis|A total of 20 participants were interviewed on a voluntary basis (7 competitive athletes with 17 physical disabilities, 4 physiotherapists, 5 coaches and 4 psychologists)
89583540|NCT05647226|Experimental|Intervention arm|Intervention participants will be given an initial 12-week low energy-diet (LED) and will have continual use of an intensive behaviour education programme delivered through an app.
89583541|NCT05647226|Other|Standard of care arm|All participants in the control arm will receive standard care provided by the National Health Service.
89583542|NCT02194699|Experimental|Tralokinumab|Tralokinumab subcutaneous injection
89583543|NCT02194699|Placebo Comparator|Placebo|Placebo subcutaneous injection
89583544|NCT04867070|Active Comparator|LLDN with ESPB|The patient will be interviewed for participation in the study, and the pain scores of the patients who will participate in the study will be recorded according to the NAS and W-BAS scores at the first, 2nd, 12th, and 24th hours. At the end of the 24th hour, analgesic consumption will be recorded.
89209555|NCT00890838|No Intervention|Without Omegaven|will not receive IV Omega 3 fatty acids (Omegaven®) for 3 days preoperativel
89583545|NCT04867070|No Intervention|LLDN without ESPB|The patient will be interviewed for participation in the study, and the pain scores of the patients who will participate in the study will be recorded according to the NAS and W-BAS scores at the first, 2nd, 12th, and 24th hours. At the end of the 24th hour, analgesic consumption will be recorded.
89583546|NCT04866524||ICSI technique|In ICSI group, insemination will be performed by using ICSI, 3 - 4 hours after oocyte retrieval. OCCs will be stripped by using hyaluronidase. Only matured oocytes will be inseminated.
89583547|NCT04866524||Conventional IVF|In conventional IVF group, insemination will be performed by conventional IVF. Two hours after retrieval, collected OCCs will be inseminated for another 2 hours, at a concentration of 100,000 motile sperm/ml. Inseminated OCCs will be cultured overnight in culture medium.
89583548|NCT05647148|Experimental|intervention group|progressive relaxiation exercises Will do sixty minutes of progressive relaxation exercise for three consecutive days
89583549|NCT05647148|No Intervention|Control group:|no intervention
89583550|NCT05369858|Experimental|[14C] SKLB1028|Eligible healthy male subjects received a single oral 150 mg (radioactivity of 120µCi) dose of [14C] SKLB1028
89583551|NCT02293538|Experimental|FID 114657|FID 114657 eye drops (10 ml), 1-2 drops instilled in each eye 10 minutes prior to inserting a new pair of habitual contact lenses and after removing them, daily for 2 weeks.
89583552|NCT02293538|Active Comparator|Saline Control|Saline control eye drops (15 ml), 1-2 drops instilled in each eye 10 minutes prior to inserting a new pair of habitual contact lenses and after removing them, daily for 2 weeks.
89583553|NCT02194621|Experimental|Total Flavor Option 1|Total toothpaste containing triclosan/copolymer/sodium fluoride with new OM (oral malodor) complex 1 ingredient - Total Flavor Option 1
89583554|NCT02194621|Experimental|Total Flavor Option 2|Total toothpaste containing triclosan/copolymer/sodium fluoride with new OM (oral malodor) complex 2 ingredient. Total Flavor Option 2
89583555|NCT02194621|Placebo Comparator|Crest Toothpaste|Placebo toothpaste: Crest Cavity Protection toothpaste (currently marketed)
89583556|NCT02220205|Active Comparator|PelvicSim|Participants randomized to this arm practice IUD insertion on the PelvicSim for 30 minutes.
89583557|NCT02220205|Placebo Comparator|Manufacturer model|Participants randomized to this arm practice IUD insertion on models provided by the IUD manufacturer for 30 minutes.
89583558|NCT02266706|Experimental|Cohort 1: ≥12 to <18 years TOL/TAZ 1000/500 mg FDC|Participants ≥12 to <18 years of age received a single dose of ceftolozane/tazobactam (TOL/TAZ) 1000/500 mg FDC as a 60-minute infusion on Day 1.
89583559|NCT02266706|Experimental|Cohort 2: ≥7 to <12 years TOL/TAZ 18/9 mg/kg|Participants ≥7 to <12 years of age received a single dose of TOL/TAZ 18/9 mg/kg as a 60-minute infusion on Day 1.
89583560|NCT02266706|Experimental|Cohort 3: ≥2 to <7 years TOL/TAZ 18/9 or 30/15 mg/kg|Participants ≥2 to <7 years of age received a single dose of TOL/TAZ 18/9 mg/kg as a 60-minute infusion on Day 1. Participants in this cohort enrolled after interim analysis for Cohort 3 received TOL/TAZ 30/15 mg/kg.
89583561|NCT02266706|Experimental|Cohort 4: ≥3 months to <2 years TOL/TAZ 18/9 or 30/15 mg/kg|Participants ≥3 months to <2 years of age received a single dose of TOL/TAZ 18/9 mg/kg as a 60-minute infusion on Day 1. Participants in this cohort enrolled after interim analysis for Cohort 3 received TOL/TAZ 30/15 mg/kg.
89583562|NCT02266706|Experimental|Cohort 5: birth to <3 months TOL/TAZ 20/10 mg/kg|Participants from birth (>32 weeks gestation, 7 days postnatal) to <3 months of age received a single dose of TOL/TAZ 20/10 mg/kg as a 60-minute infusion on Day 1. After interim analysis for Cohort 4, the original regimen of TOL/TAZ 12/6 mg/kg was changed to TOL/TAZ 20/10.
89583563|NCT02266706|Experimental|Cohort 6: birth to <3 months TOL/TAZ 12/6 or 20/10 mg/kg|Participants from birth (≤32 weeks gestation, 7 days postnatal) to <3 months of age with creatinine clearance =20 - 49 mL/min/1.73 m^2 received a single dose of TOL/TAZ 12/6 mg/kg as a 60-minute infusion on Day 1; participants with creatinine clearance ≥50 mL/min/1.73 m^2 received a single dose of TOL/TAZ 20/10 mg/kg as a 60-minute infusion on Day 1. After interim analysis for Cohort 4, the original regimen of TOL/TAZ 12/6 was changed to TOL/TAZ 20/10 mg/kg for participants with creatinine clearance ≥50 mL/min/1.73 m^2.
89583564|NCT02293460|Experimental|I10E Arm|
89583565|NCT04419974||Ataxic carriers|Subjects with a CAG repeat expansion on ATXN3 and Scale for Assessment and Rating of Ataxia (SARA) of 3 points or more.
89583566|NCT04419974||Pre-ataxic carriers|Subjects with a CAG repeat expansion on ATXN3 and Scale for Assessment and Rating of Ataxia (SARA) of less than 3 points.
89583567|NCT04419974||Related controls|Subjects without a CAG repeat expansion on ATXN3, but with a first degree relative affected by the disease.
89583568|NCT05647070|Experimental|Autologous rectus Fascia TOT|"A sterile Foley catheter is placed to drain the bladder, following this, injectable normal saline is utilized using 10 cc syringe for hydro-distention of the anterior vaginal wall, and a midline incision is made based on the mid-urethra. Dissection is carried out bilaterally to the obturator Foramen on both sides.~Through Pfannestiel incision, ~1 cm× ~5 cm rectus fascia strip is isolated from the anterior rectus sheath. Two stay sutures are secured to the corner of the fascial segment on each side. Next, two separate trocar passages are performed on each side using a reusable C-shaped trocar, with care taken to ensure at least a 1 cm tissue bridge in the obturator membrane between the superior and inferior passes. Following this, the stay sutures are tied external to the obturator membrane on both sides, leaving the sling secured and flush with the mid-urethra. Sutures are also placed to secure the sling to the periurethral tissue to prevent rolling or migration"
89583569|NCT02266004|Experimental|tDCS+ LT|Transcranial direct current stimulation(tDCS) plus locomotor training (LT) 3x per week for 3 consecutive weeks.
89583570|NCT04864652|Experimental|Single Arm|CHILLS Procedure
89583571|NCT02292719|Experimental|Arm A (genotype [GT]3, noncirrhotic)|Ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) 25/150/100 mg once daily (QD) and sofosbuvir (SOF) 400 mg QD for 12 weeks.
89583572|NCT02292719|Experimental|Arm B (GT3, noncirrhotic)|OBV/PTV/r (25/150/100) mg QD with SOF (400 mg QD) and ribavirin (RBV; weight-based 1,000 mg or 1,200 mg daily divided twice daily [BID]) for 12 weeks.
89583573|NCT02292719|Experimental|Arm C (GT2, noncirrhotic)|OBV/PTV/r (25/150/100) mg QD with SOF (400 mg QD) and RBV (weight- based 1,000 mg or 1,200 mg daily divided BID) for 8 weeks.
89583574|NCT02292719|Experimental|Arm D (GT2, noncirrhotic)|OBV/PTV/r (25/150/100) mg QD with SOF (400 mg QD) and RBV (weight-based 1,000 mg or 1,200 mg daily divided BID) for 6 weeks.
89583575|NCT02292719|Experimental|Arm E (GT3, cirrhotic)|OBV/PTV/r (25/150/100) mg QD with SOF (400 mg QD) and RBV (weight-based 1,000 mg or 1,200 mg daily divided BID) for 12 weeks.
89583576|NCT02292719|Experimental|Arm F (GT3, noncirrhotic)|OBV/PTV/r (25/150/100) mg QD and SOF (400 mg QD) for 12 weeks.
89583577|NCT02291861|Placebo Comparator|Placebo|Placebo tablets taken twice daily for 12 weeks.
89583578|NCT02291861|Experimental|SD-809 12 mg/day|SD-809 tablets 6 mg taken twice a day (BID) for 12 weeks.
89583579|NCT02291861|Experimental|SD-809 24 mg/day|SD-809 tablets dose starting at 6 mg twice a day (BID) and titrated over 4 weeks to 12 mg BID. The total daily dose of 24 mg was maintained for an additional 8 weeks.
89583580|NCT02291861|Experimental|SD-809 36 mg/day|SD-809 tablets dose starting at 6 mg twice a day (BID) and titrated over 4 weeks to 18 mg BID. The total daily dose of 36 mg was maintained for an additional 8 weeks.
89583581|NCT02291549|Experimental|Treatment|"In-office bilateral placement of the S8 Sinus Implant (mometasone furoate, 1350 mcg) in the ethmoid sinuses~Mometasone furoate nasal spray (200mcg) once daily"
89583582|NCT02291549|Sham Comparator|Control|"In-office bilateral sham procedure~Mometasone furoate nasal spray (200mcg) once daily"
89583583|NCT05651165|Active Comparator|Group A|Patients receiving pharmacoactive balloon angioplasty. Lutonix®
89209556|NCT04037670|Experimental|SASI bypass|Patients with super obesity underwent SASI bypass
89209557|NCT00890994||Suspected breast cancer|
89583584|NCT05651165|Experimental|Group B|Patients receiving mimetic stent. Supera®
89583585|NCT02264990|Experimental|Veliparib + Carboplatin + Paclitaxel|"Participants received 120 mg veliparib twice a day (BID) on Days -2 to 5 (7 days), carboplatin at an area under the curve (AUC) of 6 mg/mL*min on Day 1 and paclitaxel 200 mg/m² on Day 1 of each 21-day cycle for a maximum of 6 cycles.~After completion of up to 6 cycles, optional maintenance pemetrexed was administered as 500 mg/m² on Day 1 of each 21-day cycle until toxicity required cessation of therapy, or radiographic progression occurred."
89583586|NCT02264990|Active Comparator|Investigator's Choice Chemotherapy|"Participants received Investigator's choice of standard doublet chemotherapy consisting of 1 of the following 3 options, administered on Day 1 of each 21-day cycle for a maximum of 6 cycles:~Carboplatin AUC 6 mg/mL*min + paclitaxel 200 mg/m²~Cisplatin 75 mg/m² + pemetrexed 500 mg/m²~Carboplatin AUC 6 or AUC 5 mg/mL*min + pemetrexed 500 mg/m²~After completion of up to 6 cycles, optional maintenance pemetrexed was administered as 500 mg/m² on Day 1 of each 21-day cycle until toxicity required cessation of therapy, or radiographic progression occurred."
89583587|NCT05646914|Experimental|Complex training group|Plyometric exercises along with resistance exercises were performed.
89583588|NCT05646914|Active Comparator|Plyometric training group|Plyometric exercises were performed.
89583589|NCT05646914|No Intervention|Control group|Routine training was performed.
89583590|NCT02291237|Experimental|Eleclazine|Eleclazine 30 mg single loading dose followed by 3 mg daily maintenance dose up until Week 12, then 6 mg daily maintenance dose from Week 12 at least Week 24, followed by eleclazine 6 mg in an open-label extension period.
89583591|NCT02291237|Experimental|Placebo|Placebo to match eleclazine until at least Week 24, followed by active eleclazine 6 mg in an open-label extension period.
89583592|NCT02292446|Experimental|All patients|All patients will receive ruxolitinib at a starting dose of 10 mg twice daily which could be titrated to most appropriate dose. Dose was not to exceed 25 mg bid nor be less than 5 mg once a day
89583593|NCT02290925|Experimental|Kothala Himbutu biscuit|A biscuit containing Kothala Himbutu (Salacia reticulata) extract. This biscuit is available in the supermarkets. Four biscuits twice a day for 3 months.
89583594|NCT02290925|Placebo Comparator|placebo biscuit|An identical biscuit without the herbal extract from Kothala Himbutu (Salacia reticulate)
89583595|NCT05651087|Experimental|Experimental|Breast cancer patient who treated with LACUD
89583596|NCT05651087|No Intervention|Observation|Breast cancer patient who does not treated with LACUD
89583597|NCT02290691|Experimental|Needle- Free|Subjects will receive a single 0.5mL injection of inactivated influenza vaccine in the deltoid region on Day 0.
89583598|NCT02290691|Active Comparator|Needle and Syringe|Subjects will receive a single 0.5mL injection of inactivated Influenza Vaccine in the deltoid region on Day 0.
89583599|NCT02292212|Experimental|Single arm|The dialyzer will be changed from conventional one to ViE-21 for 36 sessions for all the enrolled subjects.
89583600|NCT02291510|Experimental|500 mg Met DR BID|Two doses of 500 mg metformin delayed-release
89583601|NCT02291510|Experimental|1000 mg Met DR BID|Two doses of 1000 mg metformin delayed-release
89583602|NCT02291510|Active Comparator|1000 mg Met IR BID|Two doses of 1000 mg metformin immediate-release
89583603|NCT02291510|Active Comparator|2000 mg Met XR QD|Single dose of 2000 mg metformin extended-release
89583604|NCT02290223|Experimental|Patient Activation Group Intervention|The experimental procedure is a behavioral based treatment model, plus usual care which is is determined by patients' individual providers, according to practice guidelines related to specific conditions.
89583605|NCT02290223|No Intervention|Usual Care|Usual care is determined by patients' individual providers, according to practice guidelines related to specific conditions.
89583606|NCT02289833|Experimental|Cohort IHC2+|Participants with HER2 IHC2-positive (IHC 2+) locally advanced or metastatic NSCLC, who had received at least one prior platinum-based chemotherapy regimen, will receive trastuzumab emtansine.
89583607|NCT02289833|Experimental|Cohort IHC3+|Participants with HER2 IHC3-positive (IHC 3+) locally advanced or metastatic NSCLC, who had received at least one prior platinum-based chemotherapy regimen, will receive trastuzumab emtansine.
89583608|NCT05646329|Experimental|Experimental|The motivational interview to be held with the experimental group was planned as 4 sessions together with the follow-up session. The session will last a maximum of 40 minutes. The session will be once a week. Motivational interview will be conducted individually and online with the experimental group. For individual interviews, the appropriate day and time will be determined with the researcher before the first session and the sessions will continue on the same day and time every week.
89583609|NCT05646329|No Intervention|Waiting list group|"If the students in the control group make a request at the end of the study, an online individual motivational interview will be held. The intervention applied to the experimental group will also be applied to the control group at the end of the study.~Intervention: Behavioural Intervention Based on Problematic Internet Use"
89583610|NCT01702558|Experimental|Phase 1 (mBC) Cohort 1: T-DM1 + Capecitabine|In Phase 1, Cohort 1 participants (with mBC) will receive trastuzumab emtansine (T-DM1) at a dose of 3.6 milligrams per kilogram (mg/kg) via intravenous (IV) infusion (on Day 1 [on Day 2 for Cycle 1] of each 21-day cycle) along with capecitabine at de-escalating dose levels (starting from 750 milligrams per meter squared [mg/m^2]) via tablet orally twice daily on Days 1-14 of each 21-day cycle until unacceptable toxicity, withdrawal of consent, disease progression (PD), death, or study end.
89583611|NCT01702558|Experimental|Phase 1 (LA/mGC) Cohort 2: T-DM1 + Capecitabine|In Phase 1, Cohort 2 participants (with LA/mGC) will receive trastuzumab emtansine at a dose of 2.4 mg/kg via IV infusion on Day 1 (on Day 2 of first week) of every week along with capecitabine at MTD (determined in Cohort 1) via tablet orally twice daily on Days 1-14 followed by a 7-day rest period, in each 21-day cycle until unacceptable toxicity, withdrawal of consent, PD, death, or study end.
89583612|NCT01702558|Active Comparator|Phase 2 (mBC): T-DM1 + Capecitabine|In Phase 2, participants (with mBC) who will be randomized to this group, will receive trastuzumab emtansine at a dose of 3.6 mg/kg via IV infusion on Day 1 of each 21-day cycle along with capecitabine at MTD via tablet orally twice daily on Days 1-14 of each 21-day cycle until unacceptable toxicity, withdrawal of consent, PD, death, or study end.
89583613|NCT01702558|Experimental|Phase 2 (mBC): T-DM1|In Phase 2, participants (with mBC) who will be randomized to this group, will receive trastuzumab emtansine at a dose of 3.6 mg/kg via IV infusion on Day 1 of each 21-day cycle until investigator-assessed PD, unacceptable toxicity, withdrawal of consent, death, or study end.
89583614|NCT05650931|Experimental|Patients who underwent the upper limb amputation and have phantom limb pain|
89583615|NCT02287883||Patients at high PAE clinic|"Patients with diabetes or cardiovascular disease receiving care within two Accountable Care Organizations (ACOs) at clinics with high implementation of patient activation and engagement activities.~Observational: Patient Activation and Engagement (PAE)"
89583616|NCT02287883||Patients at low PAE clinic|"Patients with diabetes or cardiovascular disease receiving care within two Accountable Care Organizations (ACOs) at clinics with low implementation of patient activation and engagement activities.~Observational: Patient Activation and Engagement (PAE)"
89583617|NCT01743040||CADence plus Standard Angiogram|All patients who were indicated for angiogram due to results of SPECT nuclear stress test
89583618|NCT01743040||CADence plus CT Angiogram|All patients who were not indicated for angiogram due to results of SPECT nuclear stress test underwent CT angiogram
89583619|NCT02194465|Experimental|6 milligrams (mg) LY2623091|6 mg LY2623091 with placebo for blinding administered orally once daily for 4 weeks.
89583620|NCT02194465|Experimental|13 mg LY2623091|13 mg LY2623091 with placebo for blinding administered orally once daily for 4 weeks.
89583621|NCT02194465|Experimental|24.5 mg LY2623091|24.5 mg LY2623091 with placebo for blinding administered orally once daily for 4 weeks.
89583622|NCT02194465|Experimental|13 mg LY2623091 + 20 mg tadalafil|13 mg LY2623091 and 20 mg of tadalafil with placebo for blinding administered orally once daily for 4 weeks.
89583623|NCT02194465|Experimental|20 mg tadalafil|20 mg tadalafil with placebo for blinding administered orally once daily for 4 weeks.
89583624|NCT02194465|Active Comparator|Spironolactone|25 mg titrated to 50 mg as tolerated of spironolactone (open label) administered orally once daily for 4 weeks.
89583625|NCT02194465|Placebo Comparator|Placebo|Placebo for blinding administered orally once daily for 4 weeks.
89583626|NCT02287025|Experimental|SMART|Investigators were supported with enhanced drug-specific information via an iPad application (SMART).
89583627|NCT02287025|Active Comparator|Standard of Care|Investigators were supported with standard prescribing information.
89583628|NCT01720264|Experimental|Sitagliptin|Sitagliptin q 12 hours PO starting on Day -1 then given every 12 hours (total 10 doses) on Day 0, Day +1, +2 and Day +3.
89583629|NCT04564846|Placebo Comparator|Placebo|Subjects will be administered a single capsule of placebo( fish oil); placebo will be dispensed and subjects will dose twice a day, once in the morning prior to breakfast and once at night prior to bedtime.
89583630|NCT04564846|Active Comparator|ORMD-0801|Subjects will be administered a single 8mg capsule of ORMD-0801; study medication will be dispensed and subjects will dose twice a day, once in the morning prior to breakfast and once at night prior to bedtime.
89583631|NCT01702246|Experimental|simvastatin|Simvastatin (Zocor), 40mg tablet, 40mg orally once daily, for 3 months
89583632|NCT01631227|Experimental|Eprosartan|Eprosartan + Placebo Eprosartan Mesylate
89583633|NCT01631227|Active Comparator|Eprosartan Mesylate|Eprosartan Mesylate + Placebo Eprosartan
89583634|NCT01719172|Experimental|Veriset™ Hemostatic Patch|Topical hemostat
89583635|NCT02286947|Experimental|Eteplirsen 30 mg/kg|Participants will receive eteplirsen 30 mg/kg/week intravenous (IV) infusions, weekly, for up to 96 weeks.
89583636|NCT02286713|Active Comparator|Patient Decision Aid|Decision Aid study materials including video mailed to participant with 1-week, 3-month, and 6-month Follow-up Assessments
89583637|NCT02286713|Active Comparator|Standard Educational Information|Study materials including education booklet mailed to participant with 1-week, 3-month, and 6-month Follow-up Assessments
89583638|NCT05650385|Experimental|Cohort 1|B1962 0.035mg Open Lable
89583639|NCT05650385|Experimental|Cohort 2|B1962 0.12mg Open Lable
89583640|NCT05650385|Experimental|Cohort 3|B1962 0.4mg Open Lable
89583641|NCT05650385|Experimental|Cohort 4|B1962 1.2mg Open Lable
89583642|NCT05650385|Experimental|Cohort 5|B1962 4mg Open Lable
89583643|NCT05650385|Experimental|Cohort 6|B1962 8mg Open Lable
89583644|NCT05650385|Experimental|Cohort 7|B1962 11mg Open Lable
89583645|NCT05650385|Experimental|Cohort 8|B1962 15mg Open Lable
89583646|NCT05650385|Experimental|Cohort 9|B1962 20mg Open Lable
89583647|NCT05650385|Experimental|Cohort 10|B1962 25mg Open Lable
89583648|NCT02285855|Experimental|Stereotactic body Radiotherapy (SBRT) + Metformin|Participants randomized to Metformin treatment receive Metformin for 3 weeks prior to SBRT treatment and for 1 week during SBRT treatment. Metformin administered at a dose of 2000 mg by mouth in divided dose daily (500 mg am, 1000 mg noon, 500 mg pm). To reduce GI toxicity, participants start Metformin at 1000 mg daily in a divided dose (500mg am, 500 mg pm) for 1 week. SBRTdelivered per standard of care practice.
89583649|NCT02285855|Placebo Comparator|Stereotactic Body Radiotherapy (SBRT) + Placebo|Participants randomized to placebo treatment 3 weeks prior to SBRT treatment and for 1 week during SBRT treatment. Placebo administered by mouth three times a day. SBRT delivered per standard of care practice.
89583650|NCT02285777|Experimental|MenABCWY Group|Subjects who received 2 doses of MenABCWY vaccine in the parent study and a 3rd dose of MenABCWY vaccine in the current study.
89583651|NCT02285777|Active Comparator|MenACWY Group|Subjects who received 1 dose of placebo and 1 dose of MenACWY vaccine in the parent study and 1 dose of placebo in the current study.
89583652|NCT02285153|Experimental|Acetylsalicylic acid lysinate|100mg Acetylsalicylic Acid
89583653|NCT02285153|Placebo Comparator|0.9% sodium-chloride solution|0.9% sodium-chloride solution
89583654|NCT02284373|Other|Randomization Arm 1:|70 subjects with venous ulcers will receive pneumatic compression with the Flexitouch® for the duration of one month in addition to routine care of venous ulcers and lymphedema. A pre- and post-PCD treatment CIVIQ-2 quality of life questionnaire will be administered to the subjects. For subjects with venous ulcers, wound area pre- and post-treatment will be recorded
89030118|NCT04696770|Experimental|Mindfulness Intervention|"Four face-to-face direct coachings on Mindfulness technique at weekly intervals. The following will be the broad theme of each coaching session~Week 1 - On the first encounter, the mothers will learn how to practice an introductory mindfulness technique to develop the awareness of any sensations felt in the body while holding their baby.~Week 2 - On the second encounter, the mothers will learn how to practice a second mindfulness technique to create positive feelings in the body while holding their baby.~During the third and fourth weekly encounters, the mothers will have a chance to ask their questions and explore further both mindfulness techniques as needed."
89030119|NCT04696770|No Intervention|Control|Standard of care will be offered to all mothers in the control group which includes kangaroo care but does not involve any mindfulness practices.
89030120|NCT04511780||Caregivers|• Caregivers (doctors senior and junior, nurses, aid nurses) involved in the staff (permanent or transient, full or partial time) of ICU patients during Covid-19 outbreak
89030121|NCT04696848|Experimental|CKD-516 plus Durvalumab|Stage 1 : dose escalation durvalumab (1500 mg Q4W) plus CKD-516 at dose levels (9, 11, or 13 mg/m2) Stage 2 : durvalumab (1500 mg Q4W) plus CKD-516 at recommended phase 2 dose
89030122|NCT04511585|Experimental|GLMC experimental arm|GLMC experimental arm receiving a 24-month (6 weeks each year) multilevel and TPB-based program aiming to promote PA practice
89030123|NCT04511585|No Intervention|the control arm|the control arm that do not receive any intervention
89583655|NCT02284373|Other|Randomization Arm 2:|70 subjects with venous ulcers will receive routine care of venous ulcers and lymphedema. A quality of life questionnaire will be administered at enrollment and again after one month. For subjects with venous ulcers, wound area pre- and post-treatment will be recorded.
89583656|NCT02284373|Other|Observational Arm 3|50 subjects with lymphedema will ALL receive PCD treatment. A pre-and post- PCD treatment CIVIQ-2 QOL questionnaire will be administered to all subjects at enrollment and again after one month of treatment.
89583657|NCT01632241|Placebo Comparator|Placebo plus standard therapy|Placebo IV plus standard therapy; placebo administered on Days 0, 14, 28, and every 28 days thereafter through Week 48, with a final evaluation at Week 52 in the double-blind period. In the open-label extension period, placebo patients who opt to participate will receive belimumab 10 mg/kilogram (kg) IV every 28 days for an additional 6 months.
89583658|NCT01632241|Experimental|Belimumab 10 mg/kg plus standard therapy|Belimumab 10 mg/kg IV plus standard therapy; belimumab administered on Days 0, 14, 28, and then every 28 days thereafter through Week 48, with a final evaluation at Week 52 in the double-blind period. In the open-label extension period, patients who opt to participate will continue to receive belimumab 10 mg/kg IV every 28 days for an additional 6 months.
89583659|NCT02263508|Experimental|Phase 1b: Talimogene Laherparepvec + Pembrolizumab|Participants received talimogene laherparepvec at an initial dose of up to 4 mL 10⁶ plaque-forming units (PFU)/mL by intralesional injection. Subsequent doses of talimogene laherparepvec at up to 4 mL of 10⁸ PFU/mL began 3 weeks after the first dose and were administered every 2 weeks until disappearance of injectable lesions, complete response (CR), confirmed disease progression (PD) per modified Immune-related Response Criteria (irRC), intolerance of study treatment, 24 months from the date of the first dose of pembrolizumab, or end of study, whichever occurred first. Participants also received 200 mg pembrolizumab administered intravenously every 2 weeks starting at the time of the third dose of talimogene laherparepvec (week 6) until confirmed PD per modified irRC, treatment intolerance, 24 months from the first dose, or end of study, whichever occurred first.
89583660|NCT02263508|Placebo Comparator|Phase 3 : Placebo + Pembrolizumab|Participants received up to 4 mL placebo to talimogene laherparepvec by intralesional injection on day 1 of week 0. Subsequent doses of placebo (up to 4 mL) began 3 weeks after the first dose and were administered every 2 weeks until the fifth injection (week 9), and then synchronously with pembrolizumab thereafter every 3 weeks until disappearance of injectable lesions, complete response per modified Immune-related Response Criteria simulating Response Evaluation Criteria in Solid Tumors (irRC-RECIST) (iCR), confirmed iPD per modified irRC-RECIST, intolerance of study treatment, 24 months from the date of the first dose of placebo, or end of study, whichever occurred first. Participants also received 200 mg pembrolizumab administered intravenously every 3 weeks starting on day 1 of week 0, until confirmed iPD per modified irRC-RECIST, treatment intolerance, 24 months from the first dose, or end of study, whichever occurred first.
89030124|NCT00504387||A: Patients|Patients with a primary burning mouth disorder Pain (VAS 0-10): 3<x<9 Patient understands and speaks german Age: >18 years
89030125|NCT00504387||B: Controls|Age and sex matched persons/patients who do not have any history of an oral burning sensation or a burning mouth disorder.
89030126|NCT04519346|Other|Compare to sistemic treatment and mesotherapy.|This is a prospective parallel randomized controlled trial conducted with patients admitted to our emergency department with migraine pain
89030127|NCT02950077|Experimental|All subjects|Individuals who are under the care of the Yale Liver Center with a diagnosis of autoimmune hepatitis
89030128|NCT04519112|Experimental|Remote magnetic navigation group|PVC ablation with RMN
89030129|NCT04519112|Active Comparator|Mannual control navigation group|PVC ablation with mannual navigation
89030130|NCT01249950||adolescents|adolescents with morbid obesity
89030131|NCT00505271|Experimental|1|Escalating doses of Rexin-G will be given two or three times a week for four weeks, with a 2 week rest period
89583661|NCT02263508|Experimental|Phase 3: Talimogene Laherparepvec + Pembrolizumab|Participants received talimogene laherparepvec at an initial dose of up to 4 mL 10⁶ PFU/mL by intralesional injection on day 1. Subsequent doses of talimogene laherparepvec at 10⁸ PFU/mL (up to 4 mL) began 3 weeks after the first dose and were administered every 2 weeks until the fifth injection of talimogene laherparepvec (week 9), and then synchronously with pembrolizumab thereafter every 3 weeks until disappearance of injectable lesions, iCR, confirmed iPD per modified irRC-RECIST, intolerance of study treatment, 24 months from the date of the first dose of talimogene laherparepvec, or end of study, whichever occurred first. Participants also received 200 mg pembrolizumab administered intravenously every 3 weeks starting on day 1 of week 0, until confirmed iPD per modified irRC-RECIST, treatment intolerance, 24 months from the first dose, or end of study, whichever occurred first.
89583662|NCT02291432|Experimental|AMDC-USR|Cell treatment
89583663|NCT05369780|Experimental|Hydrolized Collagen Peptide|This arm will be allocated randomly and receive 10 g hydrolized collagen peptide (Investigational Product) daily throughout the study.
89583664|NCT05369780|Placebo Comparator|Placebo|This arm will be allocated randomly and receive placebo daily throughout the study.
89583665|NCT02290340|Placebo Comparator|Placebo|Participants will receive placebo intramuscularly.
89583666|NCT02290340|Experimental|MEDI8897 10 mg|Participants will receive a single dose of MEDI8897 10 milligram (mg) intramuscularly.
89583667|NCT02290340|Experimental|MEDI8897 25 mg|Participants will receive a single dose of MEDI8897 25 mg intramuscularly.
89583668|NCT02290340|Experimental|MEDI8897 50 mg|Participants will receive a single dose of MEDI8897 50 mg intramuscularly.
89583669|NCT05647187|Active Comparator|NB-UVB group|fourty patients will be treated with NB-UVB. The initial radiation dose was determined according to the patient's skin type; initial dose will be increased by 20% per session. Sessions will be given three times weekly with 48 hours apart for three months.
89583670|NCT05647187|No Intervention|Control group|fourty healthy controls without psoriasis , any family history of psoriasis or any dermatological diseases.
89583671|NCT02290028|Other|Sentus QP left ventricular lead|Subjects consented and implanted with a Sentus QP left ventricular lead.
89583672|NCT01741792|Experimental|Blinatumomab|By study design, two dose regimens were assessed in this study. In Stage 1, Cohort 1, participants received blinatumomab in a dose-escalating manner: 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during cycle 1. In Cohort 2, the next participants enrolled and received a constant dose of 112 µg/day blinatumomab. The dosing regimen with the more favorable benefit-risk profile was then selected for Stage 2, Cohort 3.
89583673|NCT02289950|Experimental|Farletuzumab|All participants will receive a loading dose for the first 2 weeks of 10 milligram per kilogram (mg/kg) farletuzumab, followed by 5 mg/kg weekly farletuzumab administered intravenously (IV).
89583674|NCT02289950|Placebo Comparator|Placebo|All subjects will receive placebo weekly, administered intravenously (IV).
89583675|NCT01741012|Experimental|Gardasil|0.5 ml single dose Gardasil vaccine given at three separate visits
89583676|NCT02288312|Experimental|BIA 2-093 800 mg fasting|Tablets 800 mg. Administration:Oral.
88974591|NCT00049218|Experimental|Vaccine Administration|"• Phase I: Beginning 9 weeks after completion of chemotherapy, patients receive autologous dendritic cell-adenovirus p53 vaccine subcutaneously (SC) on days 1, 14, and 28. Patients without PD may undergo repeat leukapheresis on day 49. Patients receive vaccine SC again on days 56, 84, and 112 in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of autologous dendritic cell-adenovirus p53 vaccine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.~• Phase II: Patients receive autologous dendritic cell-adenovirus p53 vaccine at the MTD determined in phase I."
88974592|NCT04731402|Experimental|Acupressure|Acupressure group Acupressure application will be applied twice a week, 24 times in total in 12 weeks. Each acupressure point will be massaged for 30 seconds to provide circulation before compression. After the massage, pressures will be applied consecutively for 90 seconds. The session duration for each woman will be 8 minutes in total, with 2 minutes for each point in each attempt.
88974593|NCT04731402|Experimental|Laughter Yoga|Laughter Yoga group Laughter yoga sessions begin with gentle warm-up techniques that include stretching and stretching movements, songs, applause, and body movements. Therapy sessions are between 30-45 minutes.8 sessions of laughter yoga will be done once a week.
88974594|NCT04731402|Experimental|mindfulness stress reduction program|mindfulness stress reduction program mindfulness stress reduction program consists of 8 weeks. each week is 2.5 hours. each week has a different theme. There is a 6-hour silence day in the 6th week of the program.
88974595|NCT04731402|No Intervention|Control Group|INTERVENTION NOT IMPLEMENTED
88974596|NCT00049335|Experimental|Capecitabine|Capecitabine 1,000 mg/m^2/dose (2,000 mg/m^2/day) BID, PO, Days 1-14 of 21 day cycle.
88974597|NCT00021866||Carbamazepine|Children and their mothers exposed to Carbamazepine monotherapy in utero
88974598|NCT00021866||Phenytoin|Children and their mothers exposed to phenytoin in utero
89583677|NCT02288312|Experimental|BIA 2-093 800 mg fed|Tablets 800 mg. Administration:Oral.
89583678|NCT02288312|Experimental|BIA 2-093 400 mg|Tablets 2 x 400 mg. Administration:Oral.
89583679|NCT01740388|Experimental|Besifloxacin|besifloxacin ophthalmic suspension 0.6% administered 2 times daily (BID) for 3 days to participants with a clinical diagnosis of bacterial conjunctivitis
89583680|NCT01740388|Placebo Comparator|Vehicle|vehicle of besifloxacin ophthalmic suspension administered 2 times daily (BID) for 3 days to participants with a clinical diagnosis of bacterial conjunctivitis
89583681|NCT01740154|Experimental|Supportive care (sunitinib malate, neuromuscular testing)|Patients receive sunitinib malate PO daily for 4 weeks. Patients undergo neuromuscular testing at baseline and on day 28 and complete fatigue assessment at baseline and on days 14 and 28.
89583682|NCT02287922|Experimental|ALX-0061 150 mg q4w|ALX-0061 150 mg every 4 weeks from baseline through Week 12 + placebo every 2 weeks from baseline through Week 12. The last injection with study drug was administered at the Week 10 visit.
89583683|NCT02287922|Experimental|ALX-0061 150 mg q2w|ALX-0061 150 mg every 2 weeks from baseline through Week 12 + placebo every 2 weeks from baseline through Week 12. The last injection with study drug was administered at the Week 10 visit.
89583684|NCT02287922|Experimental|ALX-0061 225 mg q2w|ALX-0061 225 mg every 2 weeks from baseline through Week 12. The last injection with study drug was administered at the Week 10 visit.
89583685|NCT02287922|Active Comparator|TCZ 162 mg q1w or q2w|Open-label TCZ. Injections were to be performed q1w or q2w depending on the approved label per region (last injection was administered at Week 10 or Week 11, depending on the dose regimen).
89583686|NCT05646212|No Intervention|Standard of Care|Standard of care (with SSRI medications provided for free).
89583687|NCT05646212|Experimental|SOC+ECHO|Standard of care (with SSRI medications provided for free), plus Project ECHO facilitation (an evidence-based tele-education intervention) for physicians
89583688|NCT05646212|Experimental|SOC+ECHO+P4P|Standard of care (with SSRI medications provided for free), plus Project ECHO facilitation (an evidence-based tele-education intervention) for physicians, plus Payment for Performance intervention
89583689|NCT05646134|Experimental|Low Frequency Experimental Group|Participants in this Arm will receive 10 sessions of Low Frequency (1 Hz) rTMS Participants in this Arm will receive 10 sessions of High Frequency (10 Hz) rTMS
89583690|NCT05646134|Experimental|High Frequency Experimental Group|Participants in this Arm will receive 10 sessions of High Frequency (10 Hz) rTMS
89583691|NCT05646134|Sham Comparator|Sham Stimulation Control Group|Participants in this Arm will receive 10 sessions of Sham rTMS
88974599|NCT00021866||Lamotrigine|Children and their mothers exposed to Lamotrigine in utero
88974600|NCT00021866||Valproate|Children and their mothers exposed to Valproate in utero
88974601|NCT04731285||Pressure wire based FFR|Pressure wire based FFR was reference group
88974602|NCT04731285||CT-FFR|CFD-based RuiXin-FFR was test group
88974603|NCT00022139|Experimental|carboplatin + paclitaxel + fluorouracil + radiation + surgery|"Patients receive carboplatin IV and paclitaxel IV over 3 hours on days 1 and 22 and fluorouracil IV continuously on days 1-42. Beginning on day 1 of chemotherapy, patients undergo radiotherapy to the esophagus 5 days a week for 5 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients with stable or responding disease at 4-8 weeks after completion of radiotherapy undergo esophagectomy and complete dissection of the mediastinal and perigastric lymph nodes. Beginning 8 weeks after surgery, patients who underwent curative resection may receive a maximum of 2 additional courses of paclitaxel and carboplatin in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed at baseline, before chemotherapy on days 1 and 22, and within 2 weeks before surgery.~Patients are followed every 3 months for 4 years."
88974604|NCT00049569|Experimental|Arm I|See detailed description.
88974605|NCT00049569|Experimental|Arm II|See detailed description.
88974606|NCT00049764|Experimental|1|24 microgram/kg/hr for 96 hours (+ or - 1 hour)
88974607|NCT00049764|Placebo Comparator|2|0.9% sodium chloride
88974608|NCT00022334|Experimental|Treatment|See intervention description.
88974609|NCT02971826|Experimental|Thrombectomy using the REVIVETM SE device|Thrombectomy using the REVIVETM SE device in patient with an ischemic stroke
88974610|NCT00022412|Placebo Comparator|Observation, then prostatectomy|Arm 2: Patients undergo observation for 28 days. Patients then undergo prostatectomy.
88974611|NCT00022412|Active Comparator|Doxercalciferol once daily for 28 days|Dietary supplement once daily to treat prostate cancer for 28 days
88974612|NCT00022529|Experimental|Treatment (BMS-214662, trastuzumab)|Patients receive BMS-214662 IV over 1 hour on days 2, 8, 15, and 22 and trastuzumab (Herceptin) IV over 30-90 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
88974613|NCT02970357|Other|Enrolled patient|Every patient of the Mulhouse Hospital with a type 1 diabetes who joins the study will be followed for 10 months. They will fill in the DIAPASON questionnaire and the quality of life WHO-5 questionnaire on the day of enrollment and 10 months after enrollment, at the end of the study. Young patients followed for a type 1 diabetes at the Mulhouse Hospital usually come every two months to see the pediatric endocrinologist, so the data collected for a regular visit will also be collected for the study every two months between the enrollment and the end of study participation.
88974614|NCT00022646|Experimental|Arm I: pemetrexed + gemcitabine|Patients receive pemetrexed disodium IV over 10 minutes on day 1 followed by gemcitabine IV over 30 minutes on days 1 and 8.
88974615|NCT00022646|Experimental|Arm II: pemetrexed + gemcitabine|Patients receive gemcitabine IV over 30 minutes on days 1 and 8 followed by pemetrexed disodium IV over 10 minutes on day 1.
88974616|NCT00022646|Experimental|Arm III: pemetrexed + gemcitabine|Patients receive gemcitabine IV over 30 minutes on day 1 and pemetrexed disodium IV over 10 minutes followed by gemcitabine IV over 30 minutes on day 8.
88974617|NCT00050037|Experimental|CD-ROM based CBT|Group is given a copy of the CD-ROM program to complete at home over 10 weeks. At the end of each week, these patients upload and transmit their encrypted tracking data to the research coordinator. At the end of the treatment, participants who have not improved are offered a course of traditional manual-based group therapy, follow-up in an ongoing maintenance group in an eating disorders program, or an alternative treatment.
89583692|NCT05646056||Healthy subjects|
89583693|NCT05646056||Asymptomatic left ventricular hypertrophy|
89583694|NCT05646056||Asymptomatic subjects with a history of HF|
89583695|NCT05646056||Subjects with a history of hypertrophic cardiomyopathy NYHA Class I, II|
89583696|NCT04873466|Experimental|Enzyme-rich malt extract|Enzyme-rich malt extract (15 ml b.i.d with food)
89583697|NCT02262728|Experimental|Panel 1|Participants with Child-Pugh score <7 with evidence of portal hypertension (confirmed by presence of esophageal varices or hepatic venous pressure gradient [HVPG] greater than or equal to 10 millimeter of mercury [mm Hg]) will receive simeprevir (150 milligram [mg] capsule), daclatasvir (60 mg tablet) and sofosbuvir (400 mg tablet) orally once daily for 12 weeks.
89583698|NCT02262728|Experimental|Panel 2|Participants with Child-Pugh score 7 to 9 (extremes included) will receive simeprevir (150 mg capsule), daclatasvir (60 mg tablet) and sofosbuvir (400 mg tablet) orally once daily for 12 weeks.
89583699|NCT02262260|Experimental|Ranibizumab labeled regime arm|Ranibizumab (Anti VEGF) 0.5mg treatment will be given monthly and will be continued until maximum visual acuity is achieved (the patient's visual acuity is stable for three consecutive monthly assessments performed while on ranibizumab treatment). Thereafter patients should be monitored monthly for visual acuity. Treatment will be resumed when monitoring indicates loss of visual acuity due to DME. Monthly injections should then be administered until stable visual acuity is reached again for three consecutive monthly assessments (implying a minimum of two injections). The interval between two doses should not be shorter than 1 month
89583700|NCT02262260|Experimental|Ranibizumab wait and Extend regime arm|Ranibizumab (Anti VEGF) 0.5 mg will be injected subsequently at baseline, month 1 and 2. After the three initial loading doses, patients will be called for the control visits 1 month later. If the visual acuity has reached a stable level and there is no sign of edema on OCT, patients will not receive intravitreal injection and will be called to come back 6 weeks later. The interval is increased by 2 weeks until a maximum of 8 weeks as long as the patient presents as stable regarding visual acuity, central retinal thickness and clinical findings. If there is a negative change, the interval is shortened back to 4 weeks.
89583701|NCT02285270|Other|Single group assignment|Diagnostic test/procedure - FDG PET/CT
89583702|NCT01717768|Experimental|Part 1: 120 mg BID|Oral TSX-002 120 mg BID (total dose = 240 mg/day) for a duration of 15 days
89583703|NCT01717768|Experimental|Part 1: 240 mg BID|Oral TSX-002 240 mg BID (total dose = 480 mg/day) for a duration of 15 days
89583704|NCT01717768|Experimental|Part 2: 120 mg BID|Single cohort, open-label, nonrandomized oral TSX 002 120 mg BID (total dose = 240 mg/day) for a duration of 15 days
89583705|NCT01717768|Experimental|Part 3: A-B-C 120 mg QD|"Open-label, randomized, 3-way crossover of 3 treatments, A, B, and C.~Treatment A: Oral TSX-002 (1 x 120-mg capsules) administered 30 minutes after a high-calorie, high-fat meal. No food was allowed 4 hours before the high calorie, high-fat meal and no food was allowed for at least 10 hours after dosing.~Treatment B: Oral TSX-002 (1 x 120-mg capsules) administered 4 hours after a high-calorie, high fat meal. No food was allowed 4 hours before the high calorie, high-fat meal and no food was allowed for at least 10 hours after dosing.~Treatment C: Oral TSX-002 (1 x 120-mg capsules) administered 30 minutes before a high-calorie, high-fat meal. No food was allowed 4 hours before the high-calorie, high-fat meal and no food was allowed for at least 10 hours after dosing."
89583706|NCT01717768|Experimental|Part 3: B-C-A 120 mg QD|"Open-label, randomized, 3-way crossover of 3 treatments, A, B, and C.~Treatment A: Oral TSX-002 (1 x 120-mg capsules) administered 30 minutes after a high-calorie, high-fat meal. No food was allowed 4 hours before the high calorie, high-fat meal and no food was allowed for at least 10 hours after dosing.~Treatment B: Oral TSX-002 (1 x 120-mg capsules) administered 4 hours after a high-calorie, high fat meal. No food was allowed 4 hours before the high calorie, high-fat meal and no food was allowed for at least 10 hours after dosing.~Treatment C: Oral TSX-002 (1 x 120-mg capsules) administered 30 minutes before a high-calorie, high-fat meal. No food was allowed 4 hours before the high-calorie, high-fat meal and no food was allowed for at least 10 hours after dosing."
89583707|NCT01717768|Experimental|Part 3: C-A-B 120 mg QD|"Open-label, randomized, 3-way crossover of 3 treatments, A, B, and C.~Treatment A: Oral TSX-002 (1 x 120-mg capsules) administered 30 minutes after a high-calorie, high-fat meal. No food was allowed 4 hours before the high calorie, high-fat meal and no food was allowed for at least 10 hours after dosing.~Treatment B: Oral TSX-002 (1 x 120-mg capsules) administered 4 hours after a high-calorie, high fat meal. No food was allowed 4 hours before the high calorie, high-fat meal and no food was allowed for at least 10 hours after dosing.~Treatment C: Oral TSX-002 (1 x 120-mg capsules) administered 30 minutes before a high-calorie, high-fat meal. No food was allowed 4 hours before the high-calorie, high-fat meal and no food was allowed for at least 10 hours after dosing."
89583708|NCT01717768|Experimental|Part 4 Cohort 1: 60 mg BID/ 60 mg TID|Oral TSX-002 60 mg BID for 15 days then 60 mg TID for 15 days
89583709|NCT01717768|Experimental|Part 4 Cohort 2: 90 mg BID/ 90 mg TID|Oral TSX-002 90 mg BID for 15 days then 90 mg TID for 15 days
89583710|NCT01717768|Experimental|Part 4 Cohort 3: 180 mg QD|Oral TSX-002 180 mg once daily (QD) for 15 days
89583711|NCT01717768|Experimental|Part 4 Cohort 4: 120 mg BID|Oral TSX-002 120 mg BID for 15 days
89583712|NCT02260934|Active Comparator|Rituximab/Cyclophosphamide (RC)|Prednisone taper to 10 mg/day by week 12 and continue prednisone 10 mg/day to week 96.
89583713|NCT02260934|Experimental|Rituximab/Cyclophosphamide/Belimumab (RCB)|"Belimumab (10 mg/kg IV) at weeks 4, 6, 8, and every 4 weeks to week 48.~Prednisone taper to 10 mg/day by week 12, and continue prednisone 10 mg/day to week 96."
89583714|NCT02260388|Experimental|Nortriptyline|Nortriptyline - 25 mg daily for 1 week at bedtime, then 50 mg daily at bedtime for 1 week, then 75 mg daily at bedtime for the remainder of the study.
89583715|NCT02260388|Experimental|Duloxetine|Duloxetine - 20 mg daily for 1 week, then 40 mg daily for 1 week, then 60 mg daily for the remainder of the study.
88974618|NCT00050037|Active Comparator|Standard Group CBT|"Group undergoes standard group CBT. Therapy is administered over 10 weeks in five 90-minute sessions. The key topics are similar to those covered in the CD-ROM group: psychoeducation, developing a personal profile, standardizing meal times, recognizing emotional eating, increasing daily activity, learning the language of CBT, identifying automatic thoughts, restructuring thoughts, identifying cues and consequences, chaining, surfing the urge, and preventing relapses. Therapy sessions include a didactic section followed by group interaction and discussion. All group sessions are audiotaped and monitored."
88974619|NCT00050037|No Intervention|Waiting List|Participants in the wait list control group undergo an initial assessment but receive no active intervention for 10 weeks. After 10 weeks, these patients undergo post-treatment assessment and are offered the opportunity to either enter group treatment in an eating disorders program or enter other appropriate treatment. Three-month follow-up data are not collected from these individuals.
88974620|NCT00050076|Experimental|MCC-135 50 mg BID|
88974621|NCT00050076|Experimental|MCC-135 100 mg QD|
88974622|NCT00050076|Experimental|MCC-135 200 mg QD|
88974623|NCT00050076|Placebo Comparator|Placebo|
88974624|NCT00050115||Hepatitis A + AA cohort|Subjects seen either at Clinical center or by outside physician
88974625|NCT00050349|Experimental|EPO906|
88974626|NCT00050427|Experimental|001|ET743 580 mcg/m2 3-hour i.v. infusion on Days 1 8 and 15 every 28 days for up to approximately 52 weeks in the absence of disease progression. Dexamethasone 10 mg i.v will be administered 30 minutes prior to each trabectedin infusion.
89583716|NCT02260388|Experimental|Pregabalin|Pregabalin - 100 mg at bedtime for 1 week, then 100 mg 2 times per day for 1 week, then 100 mg 3 times per day for the remainder of the study.
89583717|NCT02260388|Experimental|Mexiletine|Mexiletine - 200 mg at bedtime for 1 week, then 200 mg 2 times per day for 1 week, then 200 mg 3 times per day for the remainder of the study.
89583718|NCT02260154||Post-cholecystectomy gastrointestinal spasms|Adult subjects suffering from post-cholecystectomy gastrointestinal spasms not requiring surgical treatment prescribed Duspatalin® 200 mg twice a day
89583719|NCT02284178|Experimental|Enhanced oral suction|Deep oropharyngeal suction with catheter
89583720|NCT02284178|Sham Comparator|Usual Care Oral Suction|Oropharyngeal suction with suction swab
89583721|NCT01643408|Experimental|Open-Label Erwinaze|
89583722|NCT02283788|Experimental|Treatment Sequence ABCD|A - BIA 2-093 1200 mg once daily × 5 days B - BIA 2-093 2400 mg once daily × 5 days C - Moxifloxacin 400 mg × 1 dose D - placebo once daily × 5 days
89583723|NCT02283788|Experimental|Treatment Sequence BDAC|A - BIA 2-093 1200 mg once daily × 5 days B - BIA 2-093 2400 mg once daily × 5 days C - Moxifloxacin 400 mg × 1 dose D - placebo once daily × 5 days
89583724|NCT02283788|Experimental|Treatment Sequence CADB|A - BIA 2-093 1200 mg once daily × 5 days B - BIA 2-093 2400 mg once daily × 5 days C - Moxifloxacin 400 mg × 1 dose D - placebo once daily × 5 days
89583725|NCT02283788|Experimental|Treatment Sequence DCBA|A - BIA 2-093 1200 mg once daily × 5 days B - BIA 2-093 2400 mg once daily × 5 days C - Moxifloxacin 400 mg × 1 dose D - placebo once daily × 5 days
89583726|NCT01739764|Experimental|Vemurafenib 480mg BID|Participants received oral vemurafenib at 480 mg BID, depending on the last dose in the antecedent protocol until progression of disease or as long as the participant is deriving clinical benefit, as judged by the investigator, death, withdrawal of consent, unacceptable toxicity, loss to follow-up, or decision of the sponsor to terminate the study, whichever occurs first.
89583727|NCT01739764|Experimental|Vemurafenib 720mg BID|Participants received oral vemurafenib at 720 mg BID, depending on the last dose in the antecedent protocol until progression of disease or as long as the participant is deriving clinical benefit, as judged by the investigator, death, withdrawal of consent, unacceptable toxicity, loss to follow-up, or decision of the sponsor to terminate the study, whichever occurs first.
89583728|NCT01739764|Experimental|Vemurafenib 960mg BID|Participants received oral vemurafenib at 960 mg BID, depending on the last dose in the antecedent protocol until progression of disease or as long as the participant is deriving clinical benefit, as judged by the investigator, death, withdrawal of consent, unacceptable toxicity, loss to follow-up, or decision of the sponsor to terminate the study, whichever occurs first.
89583729|NCT01700530|Experimental|Statin|Statins (40mg/day)for an average of 12 weeks
89583730|NCT01700530|Experimental|Exercise only|12 weeks of exercise training (5 days a week for 45-50 min a session)
89583731|NCT01700530|Active Comparator|Statins + Exercise|Statins (40mg/day of simvastatin) plus exercise training (5 days/wk) for 12 weeks
89583732|NCT01700140|Experimental|SyB D-0701: high dose group|
89583733|NCT01700140|Experimental|SyB D-0701: low dose group|
89583734|NCT01700140|Placebo Comparator|placebo group|
89030132|NCT01249989|Experimental|Sequential MBC Condition|Participants in the sequential condition will increase F/V consumption and decrease Sed behavior (weeks 1-6), then increase physical activity (weeks 7-12). Smartphones are equipped with customized real-time goal thermometers that provide objective feedback on target behaviors (FV, Sed, and PA). At the start of prescription, the FV and Sed goal thermometers are activated. During week 1-2, participants will close 1/3 of the gap between their baseline behaviors and target behaviors. During week 3-4 they will close 2/3 of the gap, and in weeks 5-6 they will achieve 100% of their goals. Participants will maintain these goals for the remainder of the 12-week intervention. At week 7, a real-time PA goal thermometer wirelessly linked to accelerometers will be activated. Similarly, in weeks 7-8 participants will be asked to close 1/3 of the gap between their baseline PA and target, in week 9-10 they will close 2/3 of the gap, and finally they will reach 100% of their PA goal in weeks 11-12.
89583735|NCT01717456|Active Comparator|Educational-Medical-Behavioral|Educational-Medical-Behavioral intervention includes education, fiber supplements [Metamucil 1-4 packets (3.4-13.6 g)/day], laxatives or anti-diarrheals [Miralax 1-2 packets (17-34 g)/day or Imodium 0.5-2 tablets (1-4 mg)/day], pelvic floor muscle exercises [100 10-second squeezes/day], tips on how to prevent fecal incontinence, daily diary, and protective pads or garments [as needed].
89583736|NCT01717456|Placebo Comparator|Standard Care|Standard care includes fiber supplements 1-4 packets (3.4-13.6 g)/day], daily diary, and protective pads or garments [as needed].
89583737|NCT01699750|Experimental|Air Optix Aqua|Lotrafilcon B contact lenses with OFPM and BIOTRUE for 30 days each
89583738|NCT01699750|Active Comparator|Acuvue Oasys|Senofilcon A contact lenses with OFPM and BIOTRUE for 30 days each
89583739|NCT01716754|Experimental|QGE031 240 mg every 2 weeks (q2w)|Participants received QGE031 240 mg subcutaneously (s.c.) q2w for 16 weeks.
89583740|NCT01716754|Experimental|QGE031 240 mg q4w|Participants received QGE031 240 mg s.c. q4w for 16 weeks.
89583741|NCT01716754|Experimental|QGE031 180 mg q2w|Participants received QGE031 180 mg s.c. q2w for 16 weeks.
89583742|NCT01716754|Experimental|QGE031 120 mg q2w|Participants received QGE031 120 mg s.c. q2w for 16 weeks.
89583743|NCT01716754|Experimental|QGE031 36 mg q2w|Participants received QGE031 36 mg s.c. q2w for 16 weeks.
89583744|NCT01716754|Experimental|QGE031 12 mg q2w|Participants received QGE031 12 mg s.c. q2w for 16 weeks.
89583745|NCT01716754|Active Comparator|Omalizumab (as per locally approved dosing table)|Participants received omalizumab as per locally approved dosing table s.c. q2w or q4w for 16 weeks.
89583746|NCT01716754|Placebo Comparator|Placebo to QGE031 240 mg q2w|Participants received matching placebo to QGE031 240 mg s.c. q2w for 16 weeks.
89583747|NCT01716754|Placebo Comparator|Placebo to QGE031 240 mg q4w|Participants received placebo to QGE031 240 mg s.c. q2w for 16 weeks.
89583748|NCT01716754|Placebo Comparator|Placebo to QGE031 180 mg q2w|Participants received QGE031 180 mg s.c. q2w for 16 weeks.
89583749|NCT01716754|Placebo Comparator|Placebo to QGE031 120 mg q2w|Participants received QGE031 120 mg s.c. q2w for 16 weeks.
89583750|NCT01716754|Placebo Comparator|Placebo to QGE031 36 mg q2w|Participants received QGE031 36 mg s.c. q2w for 16 weeks.
89583751|NCT01716754|Placebo Comparator|Placebo to QGE031 12 mg q2w|Participants received QGE031 12 mg s.c. q2w for 16 weeks.
89583752|NCT01716754|Placebo Comparator|Placebo to omalizumab|Participants received placebo to omalizumab s.c. q2w or q4w for 16 weeks.
89583753|NCT01698814|Experimental|AL-4943A|AL-4943A Ophthalmic Solution, one drop instilled in both eyes once daily for up to 6 weeks
89583754|NCT01698814|Placebo Comparator|AL-4943A Vehicle|AL-4943A Ophthalmic Solution Vehicle, one drop instilled in both eyes once daily for up to 6 weeks
89583755|NCT01738984|Experimental|MomZing Web Program|Features include selection one to three 10-minute videos demonstrating yoga, aerobics, and strengthening, specifically designed for mothers with infants 2 to 8 months of age. Women will sequence together videos personalized to their fitness level, preference for exercise type, and a choice to actively exercise with her baby or alone. Exercises with a baby will be tailored to the infant's weight and include interactions that promote cognitive development and mother-child bonding.
89583756|NCT01738984|Experimental|Standard exercise DVD|Exercise DVD that demonstrates yoga or strengthening exercises a mother can perform with her infant.
89583757|NCT01738594|Experimental|Arm A (carfilzomib)|Patients receive carfilzomib IV over 2-10 minutes on days 1, 2, 8, 9, 15, and 16.
89583758|NCT01738594|Experimental|Arm B (carfilzomib, romidepsin)|Patients receive carfilzomib as in Arm A and romidepsin IV over 4 hours on days 1, 8, and 15.
89583759|NCT01738438|Experimental|Cabozantinib|Cabozantinib was given at a dose of 60 mg orally once per day for 21 day cycles. Treatment continued in the absence of disease progression or unacceptable toxicity.
89583760|NCT01716520|Experimental|Umeclidinium/Vilanterol 62.5/25 mcg|Umeclidinium/Vilanterol 62.5/25 mcg once daily in the morning via novel dry powder inhaler (NDPI)
89583761|NCT01716520|Experimental|Umeclidinium 62.5 mcg|Umeclidinium 62.5 mcg once daily in the morning via novel dry powder inhaler (NDPI)
89583762|NCT01716520|Experimental|Vilanterol 25 mcg|Vilanterol 25 mcg once daily in the morning via novel dry powder inhaler (NDPI)
89583763|NCT04548310||Patients with Multiple Sclerosis|MS patients (EDSS: 0-5,5)
89583764|NCT04548310||Healthy group|Healthy individuals without chronic disease
89583765|NCT04548232||LSG in obese|Patients with obesity underwent LSG. Divided into simple obese patients (without complications) and obese patients with complications
89583766|NCT04548232||Control group|healthy individuals with normal BMI
89583767|NCT01698268|Experimental|TAP Group|Enrolled subjects will receive a TAP block with 0.5cc/kg of 0.25% ropivacaine.
89583768|NCT01698268|Active Comparator|Local Infiltration Group|Enrolled subjects will receive will receive local infiltration of 0.5 cc/kg of 0.25% ropivacaine.
89583769|NCT04555564|Experimental|Technicium 99 MAA|Participants will receive bronchial artery administration of Technicium 99 MAA
89583770|NCT01697956|Experimental|BDP Nasal Aerosol 80 mcg/day|BDP nasal aerosol: 80 mcg dose once daily in the morning. Participants/parents administer 40 mcg BDP (one spray per nostril) during the 42 day (6 week) Treatment Period.
89583771|NCT01697956|Placebo Comparator|Placebo Nasal Aerosol|Participants/parents administer placebo (no medication) (one spray per nostril) once daily in the morning during the 42 day (6 week) Treatment Period.
89583772|NCT01697800|Placebo Comparator|Placebo|Patients received placebo capsules for 2 weeks prior to standard of care treatment and continued for 3 months post standard of care treatment
89583773|NCT01697800|Active Comparator|Tadalafil|Patients received 20 mg tadalafil capsules for 2 weeks prior to standard of care treatment and continued for 3 months post standard of care treatment
89583774|NCT01644500|Experimental|1.5 mg Dulaglutide|1.5 milligrams (mg) dulaglutide administered as one subcutaneous (SC) injection once-weekly plus one to three capsules of placebo each day for blinding purposes for up to 26 weeks.
89583775|NCT01644500|Experimental|0.75 mg Dulaglutide|0.75 mg dulaglutide administered as one SC injection once-weekly plus one to three capsules of placebo each day for blinding purposes for up to 26 weeks.
89583776|NCT01644500|Active Comparator|Glimepiride|1 to 3 mg per day (mg/day) glimepiride administered orally as one to three capsules per day plus one SC injection of placebo once-weekly for blinding purposes for up to 26 weeks.
89583777|NCT05645120|Experimental|Health Professionals|Education intervention for health professionals
89583778|NCT05645120|Experimental|Non-health Professionals|Education intervention for non-health professionals
89583779|NCT01604824|Experimental|GOFm PCSK9 (Cohort 1): Alirocumab From Day 1|Participants with gain-of-function mutation (GOFm) in proprotein convertase subtilisin/kexin type 9 (PCSK9) gene (Cohort 1): Alirocumab 150 mg subcutaneous (SC) injection at Week 0 (Day 1), Week 2 (Day 15), Week 4, 6 and 10 (matching placebo at Week 8, 12 and 14) during the double-blind period (Group A). Afterwards, participants have the possibility to continue in an open-label extension period with 150 mg alirocumab SC twice per week (Q2W) for an additional 3 years.
89583780|NCT01604824|Experimental|GOFm PCSK9 (Cohort 1): Alirocumab From Day 15|Participants with gain-of-function mutation (GOFm) in proprotein convertase subtilisin/kexin type 9 (PCSK9) gene (Cohort 1): Alirocumab 150 mg subcutaneous (SC) injection at Week 2 (Day 15), Week 4, 6, 8 and 12 ([matching placebo at Week 0 (Day 1), 10 and 14]) during the double-blind period (Group B). Afterwards, participants have the possibility to continue in an open-label extension period with 150 mg alirocumab SC twice per week (Q2W) for an additional 3 years.
89583781|NCT01604824|Experimental|GOFm PCSK9 or LOFm ApoB (Cohort 2): Alirocumab from Day 1|Participants with gain-of-function mutation (GOFm) in the proprotein convertase subtilisin/kexin type 9 (PCSK9) gene or loss-of-function mutation (LOFm) in the apolipoprotein (Apo) B gene (Cohort 2): Alirocumab 150 mg subcutaneous (SC) injection at Week 0 (Day 1), Week 2 (Day 15), Week 4, 6 and 10 (matching placebo at Week 8, 12 and 14) during the double-blind period (Group C). Afterwards, participants have the possibility to continue in an open-label extension period with 150 mg alirocumab SC twice per week (Q2W) for an additional 3 years.
89583782|NCT01604824|Experimental|GOFm PCSK9 or LOFm ApoB (Cohort 2): Alirocumab from Day 15|Participants with gain-of-function mutation (GOFm) in proprotein convertase subtilisin/kexin type 9 (PCSK9) gene or loss-of-function mutation (LOFm) in apolipoprotein (Apo) B gene (Cohort 2): Alirocumab 150 mg subcutaneous (SC) injection at Week 2 (Day 15), Week 4, 6, 8 and 12 ([matching placebo at Week 0 (Day 1), 10 and 14]) during the double-blind period (Group D). Afterwards, participants have the possibility to continue in an open-label extension period with 150 mg alirocumab SC twice per week (Q2W) for an additional 3 years.
89583783|NCT01716052|Active Comparator|Ibuprofen|Pfizer 200 mg caplets (Advil)
89583784|NCT01716052|Placebo Comparator|Placebo|Lactulose
89583785|NCT01641692|Experimental|GSK573719 15.6 mcg|GSK573719 (Umeclinidium bromide) 15.6 mcg once-daily
89583786|NCT01641692|Experimental|GSK573719 31.25 mcg|GSK573719 (Umeclinidium bromide) 31.25 mcg once-daily
89583787|NCT01641692|Experimental|GSK573719 62.5 mcg|GSK573719 (Umeclinidium bromide) 62.5 mcg once-daily
89583788|NCT01641692|Experimental|GSK573719 125 mcg|GSK573719 (Umeclinidium bromide) 125 mcg once-daily
89583789|NCT01641692|Experimental|GSK573719 250 mcg|GSK573719 (Umeclinidium bromide) 250 mcg once-daily
89583790|NCT01641692|Experimental|GSK573719 15.6 mcg twice-daily|GSK573719 (Umeclinidium bromide) 15.6 mcg twice-daily
89583791|NCT01641692|Experimental|GSK573719 31.25 mcg twice daily|Gsk573719 (Umeclinidium bromide) 31.25 mcg twice-daily
89583792|NCT01641692|Placebo Comparator|Matched Placebo|Matched Placebo arm
89583793|NCT04859816|Experimental|Roux-en-Y gastric bypass operated participants|Roux-en-Y gastric bypass operated participants in weight stable phase > 1 year from surgery
89583794|NCT04859816|Experimental|Control participants|Age, sex, and BMI-matched un-operated participants.
89583795|NCT01682512|Experimental|Part I BI 695500 group|BI 695500, Two infusions separated by 2 weeks, Intravenous infusion
89583796|NCT01682512|Active Comparator|Part I Rituxan®|rituximab, Two infusions separated by 2 weeks, Intravenous infusion
89583797|NCT01682512|Active Comparator|Part I MabThera®|rituximab, Two infusions separated by 2 weeks, Intravenous infusion
89583798|NCT01682512|Experimental|Part II BI 695500 group|BI 695500, Two infusions separated by 2 weeks, Intravenous infusion
89583799|NCT01682512|Active Comparator|Part II rituximab group|rituximab, Two infusions separated by 2 weeks, Intravenous infusion
89583800|NCT02256488|Experimental|TIVc-Lot A|Subjects 18 to ≤ 49 years of age who received one vaccination with an investigational vaccine TIVc from Lot A
89583801|NCT02256488|Experimental|TIVc-Lot B|Subjects 18 to ≤ 49 years of age who received one vaccination with an investigational vaccine TIVc from Lot B
89583802|NCT02256488|Experimental|TIVc-Lot C|Subjects 18 to ≤ 49 years of age who received one vaccination with an investigational vaccine TIVc from Lot C
89583803|NCT02256488|Active Comparator|TIVf|Subjects 18 to ≤ 49 years of age who received one vaccination of Control vaccine TIVf
89583804|NCT05644886|Experimental|Intervention Arm|"Male Family Physicians allocated to intervention arm will receive following:~Training and technical support and integrates them with the nearest pharmacies or drug shops for vertical referrals.~Technical support will include:~Supportive supervision~Peer-to-peer support~Strengthening referrals for long-acting reversible contraceptives (LARC) and permanent methods~Provision of information, education, and communication (IEC) material and LCD for display of visual material.~Branding of clinics with name boards~Provision of family planning prescription booklets"
89583805|NCT05644886|No Intervention|Control Arm|the providers in the control group will continue to provide their services as usual with no exposure to intervention activities. After the end of the intervention period, providers that fall into control areas will be provided the same training.
89583806|NCT04863794|Experimental|RO7248824|In Part 1 of the study RO7248824 and [89Zr]-labeled RO7248824 will be administered as a single bolus IT injection following a standard IT Administration procedure. In Part 2 of the study, it is planned to test up to 3 additional IT procedures. This part is tentative with regard to its conduct and the number of procedures that may be tested.
89583807|NCT04863716|Active Comparator|Erector Spinae Plane Block|Erector Spinae Plane Block will be administered to this group.
89583808|NCT04863716|Active Comparator|Control Group|No regional anesthesia technique will be applied to the control group.
89583809|NCT04135352|Experimental|V938 Dose A + delayed pembrolizumab|This arm will enroll participants with advanced/metastatic or recurrent solid tumors. Participants receive Dose A of V938 intratumorally in cycles 1-7. Participants also receive 200 mg of pembrolizumab intravenously once every 3 weeks (Q3W) beginning with cycle 2 for a maximum of 35 cycles. Each cycle is 21 days.
89583810|NCT04135352|Experimental|V938 Dose B + delayed pembrolizumab|This arm will enroll participants with advanced/metastatic or recurrent solid tumors. Participants receive Dose B of V938 intratumorally in cycles 1-7. Participants also receive 200 mg of pembrolizumab intravenously Q3W beginning with cycle 2 for a maximum of 35 cycles. Each cycle is 21 days.
89583811|NCT04135352|Experimental|V938 Dose C + delayed pembrolizumab|This arm will enroll participants with advanced/metastatic or recurrent solid tumors. Participants receive Dose C of V938 intratumorally in cycles 1-7. Participants also receive 200 mg of pembrolizumab intravenously Q3W beginning with cycle 2 for a maximum of 35 cycles. Each cycle is 21 days.
89583812|NCT04135352|Experimental|V938 Dose D + delayed pembrolizumab|This arm will enroll participants with advanced/metastatic or recurrent solid tumors. Participants receive Dose D of V938 intratumorally in cycles 1-7. Participants also receive 200 mg of pembrolizumab intravenously Q3W beginning with cycle 2 for a maximum of 35 cycles. Each cycle is 21 days.
89583813|NCT04135352|Experimental|V938 Dose B + immediate pembrolizumab|This arm will enroll participants with advanced/metastatic or recurrent solid tumors. Participants receive Dose B of V938 intratumorally in cycles 1-7. Participants also receive 200 mg of pembrolizumab intravenously Q3W beginning with cycle 1 for a maximum of 35 cycles. Each cycle is 21 days.
89583814|NCT04135352|Experimental|V938 Dose C + immediate pembrolizumab|This arm will enroll participants with advanced/metastatic or recurrent solid tumors. Participants receive Dose C of V938 intratumorally in cycles 1-7. Participants also receive 200 mg of pembrolizumab intravenously Q3W beginning with cycle 1 for a maximum of 35 cycles. Each cycle is 21 days.
89583815|NCT04135352|Experimental|V938 Dose D + immediate pembrolizumab|This arm will enroll participants with advanced/metastatic or recurrent solid tumors. Participants receive Dose D of V938 intratumorally in cycles 1-7. Participants also receive 200 mg of pembrolizumab intravenously Q3W beginning with cycle 1 for a maximum of 35 cycles. Each cycle is 21 days.
89583816|NCT04135352|Experimental|Dose Expansion Arm A, Melanoma|This arm will enroll only participants with with a diagnosis of stage III (unresectable) and Stage IV melanoma (any line of therapy). Participants receive V938 at the recommended Phase 2 Dose, determined by analysis of the Dose A-C arms, intratumorally in cycles 1-7. Participants also receive 200 mg of pembrolizumab intravenously Q3W beginning with cycle 1 for a maximum of 35 cycles. Each cycle is 21 days.
89583817|NCT04135352|Experimental|Dose Expansion Arm B, HNSCC|This arm will only enroll participants with a diagnosis of advanced/metastatic head and neck squamous cell carcinoma (HNSCC). Participants receive V938 at the recommended Phase 2 Dose, determined by analysis of the Dose A-C arms, intratumorally in cycles 1-7. Participants also receive 200 mg of pembrolizumab intravenously Q3W beginning with cycle 1 for a maximum of 35 cycles. Each cycle is 21 days.
89583818|NCT04862312|Experimental|VideoDine|Use of video chat to eat a meal with a dining partner.
89583819|NCT01715896|Experimental|Golimumab 50 mg alternating with Placebo|Participants received alternating doses of golimumab 50 milligram (mg) (Weeks 0, 4, 8, 12, 16, 20, and 24) and placebo matched to mavrilimumab (Weeks 2, 6, 10, 14, 18, and 22) injections subcutaneously every 2 weeks for 24 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) through oral or parenteral route.
89583820|NCT01715896|Experimental|Mavrilimumab 100 mg|Participants received Mavrilimumab 100 mg injection subcutaneously every 2 weeks for 24 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) through oral or parenteral route.
89583821|NCT02255552|Experimental|Treated Group|Approximately 80 patients with genotypically confirmed Duchenne muscular dystrophy (DMD) with genetic deletions amenable to treatment by exon 51 skipping will receive 30 mg/kg of eteplirsen weekly for 96 weeks, followed by a safety extension (not to exceed 48 weeks).
89583822|NCT02255552|No Intervention|Untreated Group|Approximately 30 DMD patients not amenable to exon 51 skipping will not receive eteplirsen.
89583823|NCT01714726|Experimental|1|MEDI2070 iv infusion
89583824|NCT01714726|Placebo Comparator|2|placebo iv infusion
89583825|NCT01714726|Experimental|open-label|MEDI2070 sc injection; open-label arm is available for all subjects upon completion of first placebo-controlled treatment period
89583826|NCT02255474|Active Comparator|Biofinity|Soft spherical contact lens
89517584|NCT05165953||Group 2: COVID-19 positive with no asthma|"data were collected from medical records including: history of COVID -19 infection, presenting symptoms and clinical examination, hospitalization either ICU or ward. Investigations included; CBC with differential count, WBC, lymphocytes, eosinophils, HGB and platelets, Inflammatory markers as d-dimer, LDH and ferritin level, electrolytes, BUN, serum creatinine, CXR, and old spirometry reports.~Diagnosis of COVID 19 infection was made by a positive nasopharyngeal and throat swabs COVID 19 polymerase chain reaction (PCR)."
89583827|NCT02255474|Experimental|Biofinity Multifocal D +1.50 add|"The Biofinity Multifocal D with a +1.50 add is a soft bifocal contact lens that has a medium reading power"
89583828|NCT02255474|Experimental|Biofinity Multifocal D +2.50 add|"The Biofinity Multifocal D with a +2.50 add is a soft bifocal contact lens that has a strong reading power"
89583829|NCT05642702|Experimental|Test Product Code A|Peptide complexed HA Age Defying Gel with Vitamin C & Niacinamide -
89583830|NCT05642702|Experimental|Test Product Code B|Peptide complexed HA Age Defying Gel with Natural Extracts
89583831|NCT05642702|Experimental|Test Product Code C|Peptide complexed HA Age Defying Gel with Vitamin C & Natural Extracts
89583832|NCT05642702|Active Comparator|Positive Control|Sodium Lauryl Sulphate (SLS) analytical grade 1 % w/v
89583833|NCT05642702|Active Comparator|Negative Control|Sodium chloride (Isotonic Saline Solution) Injection IP 0.9 % w/v
89583834|NCT02254772|Experimental|Treatment|Patients receive TLR9 agonist SD-101 via intratumoral injections; ipilimumab via intratumoral injection; and undergo radiation therapy on days 1 and 2.
89583835|NCT02254460|Experimental|Test|Experimental product: Micronutrient fortified beverage powder, packed as 27 g individual sachet, administered orally as a single serve.
89583836|NCT02254460|Placebo Comparator|Control|Energy equivalent beverage powder without micronutrient fortification, packed as 27 g individual sachets, administered orally as a single serve
89583837|NCT01682044|Experimental|Treatment (colony-stimulating factor and monoclonal antibody)|Patients receive pegfilgrastim SC followed by rituximab IV 3 days later in weeks 1, 3, 5, 7, 15, 23, 31, and 39. Treatment continues in the absence of disease progression or unacceptable toxicity.
89583838|NCT05640986|Experimental|Patients|Risky behaviors assessed through BART-EEG among Parkinsonian patients newly treated with dopaminergic agonists
89583839|NCT05640986|Active Comparator|Control|Risky behaviors assessed through BART-EEG among healthy volunteers
89583840|NCT05651204||Dravet|
89583841|NCT05651204||Age-Matched Control|
89583842|NCT05640596||exposed group (121 patients)|"Extrated from the population of full-term newborns (> 36 weeks of amenorrhea + 6 days) between 2014 and 2020 at the Regional Maternity Hospital of Nancy who received at least one course of betamethasone before 34 weeks of amenorrhea for a threat of preterm delivery.~Exposure to an antenatal corticosteroid therapy was defined as the administration of at least one course of betamethasone (i.e. two doses of 12 mg, 24 hours apart). in intramuscular, before 34 weeks of amenorrhea, for a threat of premature delivery."
89583843|NCT05640596||nonexposed group (242 patients)|came from the population of full-term newborns (> 36 weeks of amenorrhea + 6 days) between 2014 and 2020 at the Regional Maternity Hospital of Nancy who who had not been exposed to antenatal steroid therapy. Two controls were selected for a case, appaired on the month and year of birth and on the sex of the case patient.
89583844|NCT01696942|Experimental|Cimzia treatment arm|Beginning at 4 weeks after surgery, patients would be randomly assigned using a pulled card method to receive certolizumab at a dose of 400 mg subcutaneously at weeks 4, 6, and 8 after surgery, and then every 4 weeks thereafter up to 12 months after enrollment.
89583845|NCT01696942|Active Comparator|Mesalamine treatment arm|Beginning at 4 weeks after surgery, patients would be randomly assigned to receive mesalamine 800 mg orally three times daily for twelve months following enrollment.
89583846|NCT05494814|Experimental|Child Care Centers Served Meals Prepared by Central Kitchen|Children ages 3-5 attending a child care center that purchases meals prepared by a central kitchen.
89583847|NCT05494814|No Intervention|Child Care Centers Not Served Meals Prepared by Central Kitchen|Children ages 3-5 attending a child care center that does not purchase meals prepared by a central kitchen.
89583848|NCT05651048|Experimental|BEMER Group|BEMER application with routine treatment protocol
89583849|NCT05651048|Experimental|Kinesiotape Group|Kinesiotape application with routine treatment protocol
89583850|NCT05651048|Experimental|Control Group|routine treatment protocol
89583851|NCT05493020||Questionnaires assessed children with cancer|Children with cancer who received at least one radiotherapy and chemotherapy during hospitalization
89583852|NCT05485922|Experimental|Investigational device - intermittent catheter with a micro-hole zone|A ready-to-use, sterile, hydrophilic-coated male catheter for intermittent catheterisation with a flexible tip and a micro-hole zone for urinary drainage in sizes CH12 and CH14. The catheterization was performed by a trained nurse.
89583853|NCT05485922|Active Comparator|Comparator device - VaPro intermittent catheter|Hollister VaPro, a single-use hydrophilic sleeved soft/flexible catheters in the sizes CH12 or CH14. The catheterization was performed by a trained nurse.
89583854|NCT04871204|No Intervention|Control|Standard treatment
89583855|NCT04871204|Experimental|Octreotide|3 monthly intramuscular injections of 10 mg Octreotide
89583856|NCT05619770|Experimental|101-PGC-005 (Intervention arm)|Bolus Injection containing 30mg of 101-PGC-005 will administered intravenously once daily for 3 consecutive days
89583857|NCT04857710|Active Comparator|Control (CONT)|A control (CONT) modality is used as a reference and is representative of a sedentary behaviour regularly observed in our populations
89583858|NCT04857710|Experimental|Conventional neuromuscular electrostimulation (CONV)|The CONV (conventional) modality allows us to compare with the current clinical application and the majority of the literature on the adaptations induced by NMES (neuromuscular electrostimulation) training.
89583859|NCT04857710|Experimental|Wide-pulse neuromuscular electrostimulation (WP)|The use of wide-pulse (WP) stimulations allows, in addition to the direct activation of the muscle fibers, the use of sensory pathways. This more global solicitation of the neuromuscular system (i.e. information going back to the spinal cord and even to the brain) prejudges more nervous adaptations and therefore a greater functional benefit.
89583860|NCT05465798|Experimental|Beta-Glucans|Patients allocated to this arm will receive MC 3x3, an oral supplement containing 25mg of 1,3 beta-Glucans daily for up to three consecutive days.
89583861|NCT05465798|Placebo Comparator|Placebo|Participants allocated to this arm will receive a placebo that will be identical in form to the MC 3x3 pills used the interventional arm. These doses will be scheduled daily and administered orally for up to three consecutive days.
89583862|NCT04860596|Experimental|collaborative health management model program|nursing education and self care program
89583863|NCT04860596|No Intervention|Routine care|Tranditional education program
89583864|NCT05650424|Active Comparator|Wait-listed Control|wait-listed control group will be put on wait list and receive abdominal massage class training on week 4 (posttest)
89583865|NCT05650424|Experimental|Intervention (Receive abdominal massage training)|Intervention group will receive abdominal massage training class and they will perform abdominal massage on their baby for 4 week. Parental stress level will be assessed on week 0 and week 4
89583866|NCT05650268|Experimental|Vitamin D3|The experimental group will receive 576000 IU in single oral dose of liquid vitamin D3~7 days prior to the surgery.
89583867|NCT05650268|Placebo Comparator|Control group|The control group will receive 95% MCT D3~7 days prior to the surgery.
89583868|NCT05577494||Clinicians|Three hospitals in Shanghai are included: Shanghai Mental Health Center, the Children's Hospital of Fudan University, and Tongji Hospital of Tongji university, and 100 clinicians are recruited in total. Then, they will receive an online questionnaire and complete the Clinician Questionnaire. Finally, the survey results need to be qualitatively analyzed.
89583869|NCT05577494||Clinician interviewers|Three hospitals in Shanghai are included: Shanghai Mental Health Center, the Children's Hospital of Fudan University, and Tongji Hospital of Tongji university, and 30 clinicians are recruited in total (10 in each clinical institution). Each clinical institution shall select 2-3 interviewers, who shall participate in interview consistency training. Semi-structured interviews are conducted with the enrolled clinicians using the Clinician Interview Guide. The interview process needs to be recorded, and the interview results need to be qualitatively analyzed.
89583870|NCT05577494||Outpatients with MDD:|Three hospitals in Shanghai are included: Shanghai Mental Health Center, the Children's Hospital of Fudan University, and Tongji Hospital of Tongji university, and 600 patients with MDD are recruited in outpatient clinics (200 in each institution). The patient questionnaire will be completed online. The enrolled patients need to conduct an online questionnaire survey and complete the Patient Questionnaire. Finally, the survey results need to be qualitatively analyzed.
89583871|NCT05577494||Patients with MDD receiving focus group discussion|Each center will hold 1-2 focus group symposiums for 8-10 patients according to the Patient Focus Group Symposium Manual. The content of the symposium needs to be recorded and written. Finally, the interview results need to be qualitatively analyzed.
89583872|NCT05092178|Experimental|Calorie restricted diet and exercise intervention|"The CR diet and exercise group received a balanced diet with an energy consists carbohydrates 45-65%; fat 20-35%; and protein 10- 35% and a deficit of 600 kcal/day from their daily energy requirement.~The exercise intervention included aerobic exercises and resistance exercise, flexibility exercises about 150 minutes for ≥2 d/week for 6 months."
89583873|NCT05092178|Active Comparator|exercise group|In exercise alone group, participants then underwent their usual habitual dietary diet and the above exercise intervention during the program.
89583874|NCT01640366|Experimental|PICO negative pressure|Single-use Negative Pressure Wound Therapy
89583875|NCT01640366|No Intervention|Standard of care dressing arm|Sterile gauze adhesive strips
89583876|NCT01640288|Other|Normal Subjects|Subjects with Normal Lung Function by Pulmonary Function Tests (e.g. Spirometry) with or without smoking as a risk factor (non-smokers, ex-smokers, current smokers)
89583877|NCT01640288|Other|Subjects with COPD|Subjects diagnosed with COPD by GOLD criteria.
89583878|NCT04688996||Malagasy Participants|Malagasy Participants. Subjects will be recruited at rural health centers throughout Madagascar. Participants will be comprised of rural people with symptoms consistent with plague. The Madagascar Ministry of Public Health requires declaration of all suspected human plague cases and collection of biological samples (sputum and/or bubo aspirates) from these cases for medical workup for confirmation.
89583879|NCT04688996||USN Health Research Center|USN Health Center Participants. The subject population will consist of active duty US Naval personnel and DoD beneficiaries presenting to participating study sites in the United States with influenza-like symptoms (fever, cough, sore throat). Since the US is non-endemic for plague, all participants will be presumed to be negative for Y. pestis.
89583880|NCT04835870|Experimental|R-CHOP + Zanubrutinib|Zanubrutinib plus Rituximab, Cyclosphosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP)
89583881|NCT01639040|Experimental|Placebo QW|Placebo (for Dupilumab) once weekly (QW) for 4 weeks by subcutaneous injection with the background therapy of potent topical corticosteroid (TCS) for up to 28 days
89583882|NCT01639040|Experimental|Dupilumab 300 mg QW|Dupilumab 300 mg once weekly (QW) for 4 weeks by subcutaneous injection with the background therapy of potent TCS for up to 28 days
89583883|NCT04687904|Active Comparator|Therapeutic education group|"The psychologist associated with the project takes care of the patient to receive a 1.5 hour therapeutic education interview (control group)."
89583884|NCT04687904|Experimental|Mindfulness meditation group|"The psychologist associated with the project takes care of the patient to receive training in mindfulness meditation twice (1.5 hours) (active group)"
89583885|NCT05421338|Experimental|BI 456906 (C-14)|
89030133|NCT01249989|Experimental|Simultaneous MBC Condition|Participants in the simultaneous condition will target FV+, Sed- and PA+ simultaneously. Participants will wear accelerometers and enter diet and sedentary activity 5 days/week on their Smartphone. All 3 goal thermometers will be activated from the outset of prescription (FV, Sed, PA). In week 1-2, participants will close 1/3 of the gap between their baseline FV, Sed, and PA behavior and their goals. In week 3-4 participants will close 2/3 of the gap, and 100% of their goals in weeks 5-6. Participants will maintain their target behaviors for FV, Sed and PA through week 12.
89583886|NCT05400746|Experimental|Group 1 - low dose|8-10 volunteers receiving three doses of 10 µg Pfs48/45 in 50 µg Matrix-M on days 0, 28 and 56 via intramuscular injection (IM) in the deltoid region of the arm
89583887|NCT05400746|Experimental|Group 2 - standard dose|8-10 volunteers receiving three doses of 50 µg Pfs48/45 in 50 µg Matrix-M on days 0, 28 and 56 via intramuscular injection (IM) in the deltoid region of the arm
89583888|NCT05400746|Experimental|Group 3 - fractional dose|8-10 volunteers receiving two doses of 50 µg Pfs48/45 in 50 µg Matrix-M on days 0 and 28, followed by one dose of 10 µg Pfs48/45 in 50 µg Matrix-M on day 56 via intramuscular injection (IM) in the deltoid region of the arm
89583889|NCT04834310|Experimental|Intraoperative and Postoperative Antibiotics|The experimental group will receive an intraoperative dose of antibiotics, which is standard protocol at our institution, followed by oral antibiotics for 5 days postoperatively.
89583890|NCT04834310|Placebo Comparator|Intraoperative Antibiotics and Placebo|The control group will receive an intraoperative dose of antibiotics, which is standard protocol at our institution, followed by a placebo for 5 days postoperatively
89583891|NCT05060042|Experimental|Whole body vibration group|WBV will be provided with a frequency of 6-26Hz with amplitude of 1-3mm 4-5 bouts(60 sec each) for 3 times a week.
89583892|NCT05060042|Active Comparator|Bilateral proprioceptive training Group|"Static balance training will be provided in first week for 3-4 times for 10 mints of single session. 3 times a week In 2nd and 3rd week dynamic balance training for 3 times with a session of 10 mints.~In 4th week progressive balance training will be done with same frequency and duration.~Tai chai exercises will be given for 20 mints 3 times a week"
89583893|NCT05390606|No Intervention|Control arm|Women follow routine care only, including prescribed medications and recommended techniques and supplements for attempting to become pregnant at home for up to three months.
89583894|NCT05390606|Experimental|Flourish HEC + BioGenesis arm|In addition to routine care followed by women in control arm, women in this arm also use the Flourish HEC (Hydroxyethylcellulose) vaginal care system and BioGenesis fertility lubricant for up to three months.
89583895|NCT05372198|Experimental|Cohort 1: Surufatinib Monotherapy|Patients who met the eligibility criteria took Surufatinib 300mg qd, every 3 weeks as a cycle
89583896|NCT05372198|Experimental|Cohort 2: Surufatinib with immunotherapy|"Patients who met the eligibility criteria took Surufatinib with immunotherapy:~Surufatinib:250mg qd, every 3 weeks as a cycle Immunotherapy: Refer to the instructions for the use of immunotherapy, every 3 weeks as a cycle"
89583897|NCT05359406|Experimental|unresectable group|Patients will receive tislelizumab in combination with radiotherapy and targeted therapy. 2 weeks after large fractionated radiotherapy for primary rectum lesion and metastasis, patients will be treated with systemic treatment including chemotherapy combined with targeted therapy and immunotherapy. Patients will be evaluated by MDT every 2 months since the beginning of the treatment. Those who are regarded as NED will be treated surgically/locally. Those in stable or partial remission will continue with combination therapy. Those with progressive disease will be withdrawn from study. Patients who are not surgically treatable will continue with combination therapy until disease progression or receiving surgical treatment.
89583898|NCT01640054|Experimental|Dosing regimen|Open label Oral treatment 100mg once daily
89583899|NCT04654208||HR+/HER2- locally advanced or MBC in combination with an aromatase inhibitor (AI)|Group Description: patients with at least one filled prescription of palbociclib (ATC (anatomic therapeutic chemical classification system ) code: L01XE33)
89583900|NCT04654208||HR+/HER2- locally advanced or MBC cancer in combination with fulvestrant|Group Description: patients with at least one filled prescription of palbociclib ATC (code: L01XE33)
89583901|NCT05360420|Experimental|Immediate CEUS group|CEUS (SonoVue) was performed immediately after routine US screening of suspicious lesions. The lesions were classified according to CEUS examination by the diagnosing physician, including consideration of HCC, suspected HCC, and benign lesions. Further hepatobiliary-specific MRI (Modis/Primexian) was performed for lesions considered HCC or suspicious for HCC, and benign lesions were followed up. The diagnostic findings of hepatobiliary-specific MRI were classified by the diagnosing physician and included consideration of HCC, suspected HCC, and benign lesions. For hepatobiliary-specific MRI lesions considered HCC or suspicious for HCC, pathological examination was performed, and benign lesions were followed up.
89030134|NCT01249989|Active Comparator|Stress Management Control|Participants in the stress management control condition target stress, relaxation and sleep. This will serve as an attentional control condition. During the 12-week prescription period, participants will wear accelerometers, log hours slept, enter real-time information about their relaxation exercises and stress, and monitor 3 goal thermometers (sleep, relaxation, stress) to meet behavioral targets. Similarly, their goal is to close 1/3 of the gap between their baseline stress, sleep, and performance of relaxation exercises and the target criterion in weeks 1-2, close 2/3 of the gap in weeks 3-4, reach their targets in weeks 5-6, and then maintain these behavior changes through week 12.
89030135|NCT04511351|Experimental|RT+GDP+Chidamide|IMRT followed by GDP chemotherapy with chidamide during radiation and chemotherapy phase
89030136|NCT04511351|No Intervention|RT+GDP|IMRT followed by GDP chemotherapy without chidamide during radiation and chemotherapy phase
89030137|NCT02950350||radiation and chemotherapy|The patients will receive radiation and chemotherapy
89583902|NCT05360420|No Intervention|Current clinical procedure group|After the suspicious lesions were screened by routine US, CECT, CEMRI and hepatobiliary-specific MRI (the first enhanced imaging examination) were independently selected by clinicians. According to the first examination results of the contrast-enhanced image, the diagnosis was classified by the diagnosing physician, including considering HCC, suspicious HCC, and benign lesions. Another contrast-enhanced imaging examination (CECT or CEMRI or hepatobiliary-specific MRI or CEUS) was performed again for lesions considered or suspected of HCC (second contrast-enhanced imaging study), and negative lesions were followed up. According to the examination results of the second enhanced imaging, the classification includes considering HCC, suspicious HCC, and benign. Pathological examination was performed for lesions considered HCC or suspicious for HCC on the second enhanced image, and benign lesions were followed up.
89583903|NCT04844216|Experimental|Nasolabial fold treated with experimental device|"STYLAGE® L Lidocaine is a hyalorunic acid injectable gel whose intended purpose is the filling of skin depressions on the face by dermal injection.~Up to 2 mL will be injected at Day 0 on a nasolabial fold and, if required, up to 1 mL could be injected 1 month after on the same nasolabial fold (touch-up)."
89583904|NCT04844216|Active Comparator|Nasolabial fold treated with comparator|"The active comparator is a hyalorunic acid injectable gel whose intended purpose is the filling of mid and/or deep depressions of the skin via mid and/or deep dermal injection.~Up to 2 mL will be injected at Day 0 on a nasolabial fold and, if required, up to 1 mL could be injected 1 month after on the same nasolabial fold (touch-up)."
89583905|NCT05345288|Experimental|Intervention|Subjects randomized to the intervention group will complete prescribed cognitive training activities 3 times a week for 20-30 minutes each time for 6 weeks. Subjects randomized to the control group will complete computerized control activities that are not cognitive training on BrainHQ 3 times a week for 20-30 minutes each time for 6 weeks.
89583906|NCT05345288|Active Comparator|Control|Subjects randomized to the control group will complete computerized control activities that are not cognitive training on BrainHQ 3 times a week for 20-30 minutes each time for 6 weeks.
89583907|NCT05327738|Experimental|Treatment (atezolizumab, Y-90, cabozantinib)|"CYCLE 1: Patients receive atezolizumab IV over 60 minutes on day 1. Within 14 days, patients receive Y-90 intra-arterially.~CYCLES 2+: Patients receive atezolizumab IV over 60 minutes on day 1 and cabozantinib PO QD on days 1-21. Treatment repeats every 21 days for a total of 12 cycles in the absence of disease progression or unacceptable toxicity. Patients deriving clinical benefit may continue receiving atezolizumab and cabozantinib beyond cycle 12 at the discretion of the PI."
89583908|NCT04419662|Experimental|All patients included|
89583909|NCT04614740|Experimental|VC004|1. Dose escalation stage: subjects in the 50 mg, 100 mg, 200 mg, and 300 mg dose groups took a single oral dose on the first day; starting from the fourth day, each group of subjects took the corresponding dose twice a day. 2. Dose expansion stage: subjects in the 100mg and 200mg dose groups took the corresponding dose twice a day on an empty stomach; 3. Phase II clinical trial stage: oral administration twice a day before meals, and the dosage is to be determined.
88974627|NCT00050427|Experimental|002|ET743 1 300 mcg/m2 3 hour i.v. infusion once every 21 days for up to approximately 52 weeks in the absence of disease progression. Dexamethasone 10 mg i.v will be administered 30 minutes prior to each trabectedin infusion.
88974628|NCT00050505|Experimental|Cohort C|N=100 to 110 subjects receives 1:10 diluted dose of Dryvax vaccine on Day 0 and 1:5 revaccination dose on Day 56
88974629|NCT00050505|Experimental|Cohort B|N=571 to 581 subjects receives 1:5 diluted dose of Dryvax vaccine on Day 0 and 1:5 revaccination dose on Day 56
88974630|NCT00050505|Experimental|Cohort A|N=226 to 236 subjects receives undiluted dose Dryvax vaccine on Day 0 and 1:5 revaccination dose on Day 56
88974631|NCT00050583|Experimental|1|10 Session modified CBT (including a relaxation component) administered by trained mental health clinicians at the primary care setting
88974632|NCT00050583|No Intervention|2|"Treatment as Usual, defined as the use of a consultation letter and traditional primary care management."
88974633|NCT00050661|Active Comparator|Narrow Band Ultraviolet B|312nm
88974634|NCT00050661|Experimental|anti-TAC or placebo|
88974635|NCT00023231|Experimental|1|Participants will receive immunosuppression therapy using antibody induction (daclizumab), corticosteroids, mycophenolate mofetil, and sirolimus prior to transplantation. Bactrim and ganciclovir will be taken for infection prophylaxis. If the participant has consistent high levels of fasting cholesterol, treatment with lipitor may be given.
88974636|NCT00023504|Active Comparator|Pneumococcal Vaccine|To determine the function of T and B cells in vivo using Pneumococcal vaccine immunization in patients with known or suspected immune disorders.
88974637|NCT00023504|Active Comparator|Rabies Vaccine|To determine the function of T and B cells in vivo using Rabies vaccine immunization in patients with known or suspected immune disorders.
88974638|NCT00023543|Experimental|1|Participants will reduce total fat intake to 17 percent of calories, 1300 kilo calories, and increase moderate activity to 150-240 minutes per week to obtain a 10 percent reduction in weight.
88974639|NCT00051090|Experimental|A|All eligible study participants
88974640|NCT00051246|Active Comparator|1 M-ITG|Mother-infant group psychotherapy
88974641|NCT00051246|Active Comparator|2 - IPT|Individual interpersonal psychotherapy
88974642|NCT00049140|Experimental|EF5|This is a non randomised single arm pilot study.
88974643|NCT00051285|Experimental|Enoximone|
88974644|NCT00051285|Placebo Comparator|Placebo|
88974645|NCT00397917|Active Comparator|400 micrograms of folic acid|Blinded study with two arms one of 400ug in arm 1
88974646|NCT00397917|Active Comparator|4mg of folic acid|Second arm is 4mg of folic acid in arm 2
89583910|NCT05353088|Experimental|Scapular stabilization exercises|Group A performed scapular stabilization exercises for 4 weeks with 2 sets of 10 repetitions. These exercises comprised of four exercise programs (Scapular retraction; Scapular mobilization, Scapular dynamic stabilization I and Scapular dynamic stabilization II).
89583911|NCT05353088|Active Comparator|Thoracic extension exercises|Group B performed thoracic extension exercises for 4 weeks with 2 sets of 10 repetitions. These exercises comprised of three exercise programs.
89583912|NCT05351918||migrain days|"Two methods of acupuncture stimulation will be compared. In all patients, DU 20 point and the same distal points will be used.~In the control group, all patients will receive the same local points, commonly used to treat migraine in our department.~In the study group, local points will be selected according to the site of the headache."
89583913|NCT05351918||consumption of analgesics|"Two methods of acupuncture stimulation will be compared. In all patients, DU 20 point and the same distal points will be used.~In the control group, all patients will receive the same local points, commonly used to treat migraine in our department.~In the study group, local points will be selected according to the site of the headache."
89583914|NCT04589546|Experimental|Vitamin B3|
89583915|NCT04589546|Placebo Comparator|Placebo|
89583916|NCT01600586|Experimental|Pacifier-Activated-Lullaby system (PAL)|Pacifier-Activated-Lullaby system (PAL) group.
89583917|NCT01600586|No Intervention|No PAL group|No PAL. Standard of care procedures.
89583918|NCT04411238||Patients|
89583919|NCT04411238||Caregivers|
89583920|NCT04411238||Home help|
89583921|NCT01639742|Experimental|All Participants|All participants who had new texture round breast implants surgically implanted.
89583922|NCT05416736|Experimental|Experimental Group|"Newborns will be fed with formula or breast milk pumped, according to the age and weight of the baby.~Before the procedure, the newborn's heart rate, saturation and comfort scale score will be recorded.~Genital area will be cleaned.~Newborn will be held under the armpit by a nurse, baby boys will be held with their legs hanging down, and baby girls will be held in hip flexion position.~Newborn with spontaneous voiding during the period from the beginning of the research procedure until the newborn is positioned will be excluded from the study.~The bladder stimulation technique will be repeated sequentially for 3 minutes until micturition begins.~After the maneuvers are started, the newborn's heart rate and saturation comfort scale score will be recorded at the 1st and 3rd minutes.~The success of the procedure and the duration of the procedure will be recorded"
89583923|NCT05416736|Active Comparator|Control Group|"Newborns will be fed with formula or breast milk pumped, according to the age and weight of the baby.~Before the procedure, the newborn's heart rate, saturation and comfort scale score will be recorded.~Genital area will be cleaned.~Newborns will be fitted with a sterile urine bag suitable for their gender.~Babies who urinate spontaneously during the period until the sterile urine bag is fitted, the next feeding hour will be waited.~Newborn will be observed for 3 minutes. Newborn's heart rate and saturation comfort pain scale score will be recorded at the 1st and 3rd minutes.~The success of the procedure and the duration of the procedure will be recorded"
89583924|NCT05291468|Active Comparator|C Acnes present in granulomatous tissue, treatment with antibiotics|patients who are in this arm will receive azithromycin and doxycycline for 3 months
89583925|NCT05291468|Placebo Comparator|C Acnes present in granulomatous tissue, treatment with placebo|patients who are in this arm will receive placebo for 3 months
89583926|NCT05291468|Active Comparator|C Acnes NOT present in granulomatous tissue, treatment with antibiotics|patients who are in this arm will receive azithromycin and doxycycline for 3 months
89583927|NCT05291468|Placebo Comparator|C. Acnes NOT present in granulomatous tissue, treatment with placebo|patients who are in this arm will receive placebo for 3 months
89583928|NCT04981496||Simulated Arrhythmias|Simulate ventricular and/or atrial tachycardia via VVI or AAI pacing an ICD with an implantable loop recorder implant (or a surface bipolar electrogram) and haemodynamics.
89583929|NCT04981496||Clinical Arrhythmias|Genuine clinical VT (acute presentation), RV lead fracture/noise or sinus tachycardia on exercise whilst recording haemodynamics and a surface bipolar electrogram.
89583930|NCT05274854|Experimental|Preconsultation Intervention|Pre-consultation intervention includes 4 arms ((a) standardised dietician supervised intervention, b) exercise intervention, c) internet delivered cognitive behavior therapy or d) nothing)
89583931|NCT05274854|Experimental|Consultation Intervention|Consultation intervention includes 2 arms (a) consultant-led outpatient clinic or b) a integrated care clinic depending on their response to the initial preconsultation intervention.
89583932|NCT05415098|Experimental|Cohort 1 in Dose expansion|
89583933|NCT05415098|Experimental|Cohort 2 in Dose expansion|
89583934|NCT02164513|Experimental|fluticasone furoate/umeclidinium bromide/vilanterol|Eligible Subjects completing 2-weeks run-in period will receive FF/UMEC/VI 100 mcg/62.5 mcg/25 mcg QD (morning) for a period of 52 weeks via DPI
89583935|NCT02164513|Experimental|fluticasone furoate/vilanterol|Eligible Subjects completing 2-weeks run-in period will receive FF/VI 100 mcg/25 mcg QD (morning) for a treatment period of 52 weeks via DPI)
89583936|NCT02164513|Experimental|umeclidinium bromide/vilanterol|Eligible Subjects completing 2-weeks run-in period will receive UMEC/VI 62.5 mcg/25 mcg QD (morning) for a treatment period of 52 weeks via DPI
89583937|NCT05369078|Experimental|THR-1442 20mg Single dose group|THR-1442 20mg Single dose group: subject will be administrated 1 dose of 20mg THR-1442 on day1, the follow up till day 7.
89583938|NCT05369078|Experimental|THR-1442 20mg Multiple dose group|THR-1442 20mg Multiple dose group: subject will be administrated THR-1442 20mg QD on Day1-Day7, the follow up till day 14.
88974647|NCT00023933|Experimental|Treatment (monoclonal antibody)|"Patients receive a tracer dose of iodine I 131 monoclonal antibody CC49-deltaCH2 IV on day 1 and a therapy dose over 30 minutes on day 8.~Cohorts of 3-5 patients receive escalating doses of iodine I 131 monoclonal antibody CC49-deltaCH2 until the MTD is determined. The MTD is defined as the dose at which 3 of 5 patients experience grade 3 or greater toxicity while 0-2 of 5 patients experience reversible grade 4 hematologic toxicity."
88974648|NCT00051714|Experimental|Early Primary Prevention|
89583939|NCT04540016|Other|Arm Ⅰ|25 mg of 80 µCi [14C]HSK7653.
89583940|NCT04953338||Cases|Patients with a confirmed diagnosis of Vitiligo within the study period will be included as cases for analysis.
89583941|NCT04953338||Controls|The controls will be defined by matching cases with people who have never been diagnosed with vitiligo either prior to or during the study period, by age and sex, at General Practice level.
89030138|NCT02950350||removal of pelvic lymph nodes and abdominal aorta lymph nodes|The patients will receive removal of pelvic lymph nodes and abdominal aorta lymph nodes ,and receive concurrent radiation and chemotherapy
89583942|NCT04524104|Experimental|Lumen treatment|Participants will complete functional magnetic resonance imaging (fMRI) and self-report questionnaires at baseline and 16 weeks. Participant will receive an encrypted study iPad enabled with Lumen at baseline. They will complete 8 PST sessions beginning with 4 weekly and then 4 biweekly intervals (i.e., on weeks 1, 2, 3, 4, 6, 8, 10, 12) over 12 weeks on their assigned iPad. Participants will also complete naturalistic end-of-day assessments for 7 days every 2 weeks (on weeks 0, 2, 4, 6, 8, 10, 12, 16), that is, 8 time series. Additionally, participants will complete depressive and anxiety symptoms questionnaire and user experience surveys at all PST sessions.
89583943|NCT04524104|No Intervention|Waitlist Control|"Participants will complete functional magnetic resonance imaging (fMRI) and self-report questionnaires at Baseline and 16 weeks.~Participant will receive an encrypted study iPad at baseline. Participants will complete naturalistic end-of-day assessments for 7 days every 2 weeks (on weeks 0, 2, 4, 6, 8, 10, 12, 16), that is, 8 time series.~Participants in the waitlist control arm will only complete assessments but will have the option to receive Lumen at the end of the study. The PST module on the study iPad will be disabled until their 16-week assessment is completed, at which time they will have the option to complete 8 PST sessions on their assigned iPads."
89583944|NCT05232188|Experimental|22French (Fr)|After renal access, dilatation is provided up to 22Fr with a dilatator set, and fragmentation is started with a 19Fr nephroscope.
89583945|NCT05232188|Experimental|28F|After renal access, dilatation is provided up to 28Fr with a dilatator set, and fragmentation is started with a 25Fr nephroscope.
89583946|NCT05337020|Experimental|Intervention group|240 patients will receive the questionnaire to assess patients vision on telemedicine.
89583947|NCT05230706|No Intervention|Control (CBL)|The control group was kept under normal room light conditions (CBL) 24 hours a day (level of illumination was 275.82±14 lux during the day and 145.28±14 lux at night).
89583948|NCT05230706|Experimental|Experimental (LDC)|The experimental group were allocated to alternating light/darkness conditions as follows: from 07:00 to 19:00 hours the subjects were kept under normal room light conditions; from 19:00 to 07:00 of the following day the conditions were modified by placing the patient under an acrylic cephalic helmet (length: 27 cm; width: 27 cm; height: 17.5 cm; opening: 17x12 cm). The helmet was covered with surgical cloth (green or blue) folded to 50x60cm rectangles, leaving the frontal part open in order to maintain an adequate air flow. This intervention exposed infants in the experimental group to light at 25 lux for 12 hours every day, while during daytime the cloth was removed in order for study subjects to be exposed to regular room lighting.
89583949|NCT05220488||Asthma Group|Asthma Group
89583950|NCT05220488||Healthy Group|Healthy Group
89583951|NCT04513184|Active Comparator|Standard therapy (ST) only|Control. Standard care and treatment only
89583952|NCT04513184|Experimental|DXM|Nasal dexamethasone plus Standard care and treatment
89583953|NCT04756531|Experimental|PF-07321332 Dose 1|Dose level 1 of PF-07321332
89583954|NCT04756531|Experimental|PF-07321332 Dose 2|Dose level 2 of PF-07321332
89583955|NCT04756531|Experimental|PF-07321332 Dose 3|Dose level 3 of PF-07321332
89583956|NCT04756531|Experimental|PF-07321332 Dose 4|Dose level 4 of PF-07321332
89583957|NCT04756531|Experimental|PF-07321332 Dose 5|Dose level 5 of PF-07321332
89583958|NCT04756531|Experimental|PF-07321332 Dose 4 (Fed)|Dose level 4 of PF-07321332 with high fat meal
89583959|NCT02218489|Placebo Comparator|Vehicle|Vehicle (placebo) dosed QID for up to 30 days in subjects with inflammatory meibomian gland disease
89583960|NCT02218489|Active Comparator|KPI-121 0.25% Ophthalmic Suspension|KPI-121 0.25% Ophthalmic Suspension dosed QID for up to 30 days in subjects with inflammatory meibomian gland disease
89583961|NCT04419740|Experimental|Mindfulness based psychological intervention|"Patients allocated to the intervention group will receive an email with a link to a video and a pdf document. The video and the pdf document will introduce them to the principles and the practice of mindfulness. They will also receive an access code to an e-tool valid for 1 month. On this e-tool the patient will have access to short guided meditations both general and specific to infertility. They will be instructed to follow the découverte (discovery) program of 8 meditations of 10 minutes and then the program désir de parentalité (wish to become a parent) of 13 minutes 15 meditations of 13 minutes each. Patients will be given access to all other meditations programs of PetitBambou and instructed to meditate with the program for at least 10-15 minutes on a daily basis."
89583962|NCT04419740|No Intervention|Standard care|The control group will have no additional intervention and will receive standard care in the institution. Women in all 3 study sites have access to counselling/psychological support with a trained professional before treatment initiation. During that consultation coping and stress reduction strategies are discussed.
89583963|NCT02192905|Experimental|Behavioral Weight Loss + Habit|Participants will receive 8 week of an online-delivered weight loss intervention adapted from the Diabetes Prevention Program Lifestyle Intervention and will use the Habit mobile app during the study.
89583964|NCT01713946|Experimental|Everolimus LT target of 3 - 7 ng/mL|Participants received everolimus dispersible tablets for oral suspension with titration to a low trough (LT) range of 3 to 7 ng/mL plus 1 to 3 antiepileptic drugs.
89030139|NCT04519268||Elective Surgical Adult Patients|Adult patients scheduled for an elective general surgical operation.
89030140|NCT01244256|Experimental|Treatment with Clotrimazole + Gentamicin + Beclomethasone|
89030141|NCT01244256|Active Comparator|Treatment with Clotrimazole + Gentamicin|
89030142|NCT04511507||liver failure|patients diagnosed with acute liver failure or acute on chronic liver failure in accordance with national guidelines who require 3 consecutive sessions of hemoadsorption
89030143|NCT01249833|Active Comparator|Oseltamivir|Added to standard of care for influenza
89030144|NCT01249833|No Intervention|Standard of care alone|Standard of care for influenza
89030145|NCT04511546|Experimental|BPET Scan|
89030146|NCT02275143||CT TAP scan|Suitable patients will be identified after consultant radiologists have approved a request for cancer routine CT TAP scan.
89030147|NCT04511390|Experimental|Transparent, reusable respirator|Transparent, reusable elastomeric respirator that has been designed to fit multiple different face sizes and shapes.
89583965|NCT01713946|Experimental|Everolimus HT target of 9 -15 ng/mL|Participants received everolimus dispersible tablets for oral suspension with titration to a high trough (HT) range of 9 to 15 ng/mL plus 1 to 3 antiepileptic drugs.
89583966|NCT01713946|Placebo Comparator|Placebo|Participants received placebo plus 1 to 3 antiepileptic drugs.
89583967|NCT04916444|Active Comparator|Active rTMS|Active rTMS will use a figure of eight TMS coil that will deliver real neurostimulation pulses to the patients.
89583968|NCT04916444|Sham Comparator|Sham rTMS|Sham rTMS will use a sham figure of eight TMS coil that sounds and looks like a real rTMS coil, except no neurostimulation is being delivered to the patient.
89583969|NCT04465136|Experimental|Received CES intervention|CES with the frequency of 0.5 Hertz; current of 100~600micro-ampere, for 60 minutes, everyday for 6 weeks, total 42 sessions intervention
89583970|NCT05329688|Experimental|Arm A|"Novel nutrition program :~Give nutrition health education every week and regular survey and intervention. The education booklets are made based on the guideline and characteristics of the disease."
89583971|NCT05329688|Active Comparator|Arm B|Routine nutrition education Give nutrition education if the patient visits the clinics. Irregular survey and intervention were given to the patients.
89583972|NCT04464512|No Intervention|Standard (control) treatment|"The control group receives 1mcg/kg fentanyl followed by fentanyl 0.5-1mcg/kg q10 minute PRN, ketorolac 0.5mg/kg up to 30mg max IV, and acetaminophen 1000mg IV for pain control intraoperatively. The patient is then treated with hydromorphone 0.005mg/kg q10minutes the post-anesthesia recovery. The patient would then receive hydromorphone 0.005 mg/kg q1hr PRN, 1 gram acetaminophen IV scheduled q6hr, and methocarbamol 750mg QID following discharge from the PACU and transfer to the hospital floor. The patient is converted to oxycodone 10mg (Roxicodone) q4hr PRN and 975 mg PO APAP scheduled for pain control on postoperative day number 1 or when appropriate for PO intake. The patients receives their home dose of suboxone onpostoperative day number 1 or when appropriate for PO intake.~On postoperative day number 2 number 3, patients are transitioned to an increased dose of their Suboxone for pain control in preparation for discharge."
89583973|NCT04464512|Active Comparator|Treatment Group|Buprenorphine-sufentanil group receives sufentanil 0.03mcg/kg followed by sufentanil 0.01-0.03 mcg/kg q10 min PRN, IV ketorolac 0.5mg/kg up to 30mg max and IV acetaminophen 15mg/kg up to 1000mg for pain control intraoperatively. In the PACU, IV buprenorphine 0.3mg IV q30 minutes would be given as the first line choice for pain control for 3 doses. IV PCA sufentanil is used as a second line therapy if patient comfort is not achieved by IV buprenorphine alone. The patient receives 0.3 mg buprenorphine IV Q6hr PRN, scheduled IV acetaminophen 1 gram for 24 hrs and methocarbamol 750mg QID after discharge from the PACU and transfer to the floor. The patient is converted to buprenorphine2mg q6hr PRN and 975 gram PO APAP scheduled for pain control on postoperative day 1. The patient receives their home dose of Suboxone starting on postoperative day 1 if tolerating PO intake. On postoperative day 2, patients would be transitioned to an increased dose of their Suboxone.
89583974|NCT04897412|Experimental|CBL-514 Injection|Participant will receive CBL-514 administered in 2.4 mL injections, up to 120 mL per treatment session at intervals of approximately 4 weeks for up to a maximum of 4 treatments.
89583975|NCT04897412|Placebo Comparator|Placebo: 0.9% Sodium Chloride|Participant will receive 0.9% Sodium Chloride administered in 2.4 mL injections, up to 120 mL per treatment session at intervals of approximately 4 weeks for up to a maximum of 4 treatments.
89583976|NCT05179148|Experimental|intervention|The arm will receive motivational interviewing
89583977|NCT05173766|Experimental|Ergonomic Principals|Ergonomic Principal for computer users will be used.
89583978|NCT02163499|Experimental|Sodium Zirconium Cyclosilicate|
89583979|NCT02163187|Experimental|InterStimTM the device on|The device will be set to stimulate for 4 weeks, then off for two weeks, and then the device will be on but will not stimulate for 4 weeks.
89583980|NCT02163187|Experimental|InterStimTM the device off|The device will be on but will not stimulate for 4 weeks, then off for two weeks, and then the device will be set to stimulate for 4 weeks.
89030148|NCT02950233|Experimental|NMDA active + Steroid placebo|"NMDA active: ketamine (0.5 mg/kg IV bolus pre-incision and 0.1 mg/kg/hr infusion postoperatively up to 24 hours) and oral memantine (5 mg BID [first week]; 10 mg BID [following three weeks]).~Steroid placebo: two doses of normal saline; 25 mg given prior to starting surgery and 25 mg given on the morning of second postoperative day."
89030149|NCT02950233|Experimental|Steroid active + NMDA placebo|"NMDA placebo: normal saline (IV bolus pre-incision and infusion postoperatively up to 24 hours) and oral matching placebo to memantine (one capsule BID [first week]; one capsule BID [following three weeks]).~Steroid active: two doses of dexamethasone; 25 mg given prior to starting surgery and 25 mg given on the morning of second postoperative day."
89030150|NCT02950233|Experimental|NMDA active + Steroid active|"NMDA active: ketamine (0.5 mg/kg IV bolus pre-incision and 0.1 mg/kg/hr infusion postoperatively up to 24 hours) and oral memantine (5 mg BID [first week]; 10 mg BID [following three weeks]).~Steroid active: two doses of dexamethasone; 25 mg given prior to starting surgery and 25 mg given on the morning of second postoperative day."
89030151|NCT02950233|Placebo Comparator|NMDA placebo + Steroid placebo|"NMDA placebo: normal saline (IV bolus pre-incision and infusion postoperatively up to 24 hours) and oral matching placebo to memantine (one capsule BID [first week]; one capsule BID [following three weeks]).~Steroid placebo: two doses of normal saline; 25 mg given prior to starting surgery and 25 mg given on the morning of second postoperative day."
89030152|NCT01249404|Experimental|Dysport® 1000 U, IM|1000 U, I.M. (in the muscle), on day 1 (single treatment cycle)
89030153|NCT01249404|Experimental|Dysport® 1500 U, IM|1500 U, I.M., on day 1 (single treatment cycle)
89030154|NCT01249404|Placebo Comparator|Placebo|I.M., on day 1 (single treatment cycle)
89030155|NCT04511000|Experimental|Experimental group|
89030156|NCT04511000|Active Comparator|Comparator group|
89030157|NCT04519385|Experimental|Tocilizumab|Tocilizumab
89030158|NCT04519385|Active Comparator|Dexamethasone|Dexamethasone therapy
89030159|NCT01249365|Experimental|HPV vaccine|Healthy female subjects aged 26 years and above, who received control vaccine in the primary study NCT00294047, were administrated 3 intramuscular injections of Cervarix vaccine into the deltoid of the non-dominant arm, according to a 0, 1, 6-month schedule in the current study.
89030160|NCT00506051|Experimental|ZD6474 (vandetanib) 100mg|
89030161|NCT00506051|Experimental|ZD6474 (vandetanib) 300mg|
88974649|NCT00024011|Experimental|Treatment (bortezomib)|Patients receive PS-341 IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
88974650|NCT00024089|Experimental|Arm I|Patients receive oral gefitinib daily. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
88974651|NCT00051831|Experimental|1|
88974652|NCT00024206|Experimental|Treatment (orantinib)|"Patients receive oral SU6668 twice daily on days 1-28. Courses repeat every 4 weeks in the absence of unacceptable toxicity or disease progression of 100% or more.~Cohorts of at least 6 patients receive escalating doses of SU6668 until the OBD is determined. Once the OBD is reached, dose escalation continues until the maximum tolerated dose (MTD) is determined (if possible). The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
88974653|NCT00052026|Placebo Comparator|1|Placebo
88974654|NCT00052026|Experimental|2|Low-dose carvedilol
88974655|NCT00052026|Experimental|3|high-dose carvedilol
88974656|NCT00052182|Experimental|1|Immunization on Day 0 and Weeks 4, 8, and 16
88974657|NCT00024518|Placebo Comparator|Placebo|placebo was prepared as saline alone with 6mg human serum albumin (HSA). Subjects orally ingested one vial each morning before breakfast with at least 150mL water.
88974658|NCT00024518|Experimental|5,000 Units hrIFN-alpha|hrIFN-alpha = human recombinant interferon-alpha. 5,000 units was prepared along with saline and 6mg HSA. Subjects orally ingested one vial each morning before breakfast with at least 150mL water.
88974659|NCT00024518|Experimental|30,000 hrIFN-alpha|30,000 units hrIFN-alpha was prepared along with saline and 6mg HSA. Subjects orally ingested one vial each morning before breakfast with at least 150mL water.
88974660|NCT00052221|Experimental|Arm I: Epoetin Alfa|Epoetin alfa subcutaneously (SC) once weekly for 6 weeks
88974661|NCT00052221|Placebo Comparator|Arm II: Placebo|Placebo subcutaneously (SC) once weekly for 6 weeks
88974662|NCT00052299|Experimental|ARM A|GO + MICE for remission induction followed by GO + mini-ICE for consolidation
88974663|NCT00052299|Active Comparator|ARM B|MICE for remission induction followed by mini-ICE for consolidation
88974664|NCT00024596||Caucasian Families|Largest 3-generational Caucasian Families from Family Heart Study (Classic) with average family size of 10 N=2767 Subjects from 512 families. Approximately half are random sample families from FamHS-Classic, and half are high-familial CHD risk families from FamHS-Classic. 4 Field sites were Raleigh-Durham North Carolina; Minneapolis, MN; Framingham MA; and Salt Lake City, UT.
88974665|NCT00024596||African-American Families|622 subjects from 2-3 generational 212 African-American families originally recruited from the HyperGEN study in Birmingham AL. These are hypertension enriched families.
89030162|NCT04518800|Experimental|Jin Youli(PEG-rhG-CSF)|PEG-rhG-CSF Secondary Prevention：patients with pancreatic cancer who met the eligibility criteria were given secondary prophylactic administration of the Jin Youli(PEG-rhG-CSF).
89583981|NCT04419116|Experimental|tibial preservation bone cut|tibial preservation bone cut following mobile bearing UKA
89583982|NCT04419116|Experimental|tibial conventional bone cut|tibial conventional bone cut following mobilebearing UKA
89583983|NCT02191579|Active Comparator|BOTOX®|155U onabotulinumtoxinA (BOTOX®) total dose per treatment by intramuscular injection every 12 weeks for up to 3 treatments.
89583984|NCT02191579|Active Comparator|Topiramate|Topiramate starting at a daily oral dose of 25 mg/day titrated up to a maximum dose of 100 mg/day for 36 weeks. Participants who discontinue topiramate are eligible to receive treatment with BOTOX®.
89583985|NCT05125250|Experimental|Motor Control Group|This group will receive treatment which comprises of therapeutic exercises, During the first 4 weeks, motor control and ROM exercises will be prescribed in order to improve muscular endurance of deep flexors muscles and to improve the ROM of cervical spine in flexion, extension, rotation and side bending and lateral rotation in. These exercises will be performed at a rate of 3 sets and an intensity of 15 repetitions per day
89583986|NCT05125250|Active Comparator|Vestibular Group|This Group will receive vestibular exercises which comprises of postural awareness training; Standing on a balance board, Foveal vision exercises.
89583987|NCT05324462||IDegLira|Adult patients with T2D who have initiated treatment with IDegLira a minimum of 26 weeks
89583988|NCT01363700|Experimental|1|
89583989|NCT01363700|Placebo Comparator|2|
89583990|NCT01363700|Active Comparator|3|
89583991|NCT04372706|Experimental|Part 1: RTX-240 Dose Escalation|Phase 1: RTX-240 monotherapy dose escalation in Solid Tumors
89583992|NCT04372706|Experimental|Part 2: RTX-240 Solid Tumor Expansion|Phase 2: RTX-240 monotherapy dose expansion in Non-small Cell Lung Cancer (NSCLC), Renal Cell Carcinoma (RCC), and anal cancers
89583993|NCT04372706|Experimental|Part 3: RTX-240 Dose Escalation|Phase 1: RTX-240 monotherapy dose escalation in AML
89583994|NCT04372706|Experimental|Part 4: RTX-240 Plus Pembrolizumab Dose Escalation|Phase 1: RTX-240 dose escalation in combination with Pembrolizumab in Solid Tumors
89583995|NCT04178642|Experimental|(experimental group)|Evaluating the efficacy of an adjuvant treatment by hepatic arterial chemo-infusion of Idarubicin-Lipiodol (experimental group)
89583996|NCT04178642|Active Comparator|(standard group)|The absence of adjuvant treatment (standard group).
89583997|NCT04157894||Standard LLIN|This group receives Interceptor ITNs during the mass distribution campaign.
89583998|NCT04157894||Chlorfenapyr ITN|This group receives Interceptor G2 ITNs during the mass distribution campaign.
89583999|NCT04157894||Piperonyl butoxide LLIN|This group receives PBO ITNs during the mass distribution campaign.
89584000|NCT04821752|Experimental|Toxicant avoidance and glucose dysregulation|To investigate whether or not the excretion of urinary toxicant metabolites is reduced by dietary modification and lifestyle intervention in people with glucose dysregulation; whether the participant's ranked glucose dysregulation correlates with the amount and/or type of toxic metabolites excreted at baseline; and whether the body's immediate response to glucose is improved by the reduction of toxicant burden.
89584001|NCT04815278|Experimental|Control Group|Participants will receive usual DSS employment services that include, but are not limited to, consultation with an employments specialist, resume writing guidance, educational classes and attendance at job fairs. Participants will have access to a delayed, attenuated online-only version of the CDPP at the time they complete the 12 month data collection. This version will provide all modules, self-monitoring options (including through use of a Fitbit contingent on the completion of the 12 month data collection) but will not include face-to-face or phone lifestyle coach sessions.
89584002|NCT04815278|Experimental|Employer Intervention Only|Participants will receive usual DSS employment services and an employer level workplace equity, job & health supports intervention. The employer intervention will include an implicit bias workshop and supervisor support training in addition to regular supervisor check-ins every other week.
89584003|NCT04815278|Experimental|CDPP Only|Participants will receive the individual level CDPP intervention and no employer intervention. The CDPP is a 24-week online curriculum that consists of 8 learning modules and 7 lifestyle coach sessions. Content for the program will include healthy lifestyle habits, managing stress and staying motivated.
89584004|NCT04815278|Experimental|CDPP and Employer Intervention|Participants will receive the individual level CDPP intervention and employer level workplace equity, job & health supports intervention. The CDPP is a 24-week online curriculum that consists of 8 learning modules and 7 lifestyle coach sessions and check-ins. Content for the program will include healthy lifestyle habits, managing stress and staying motivated. The employer intervention will include an implicit bias workshop and supervisor support training, in addition to regular supervisor check-ins every other week..
89584005|NCT04821674|Experimental|Cohort A1: DS-5670a 10 µg|Healthy adults participants will be randomized to receive a intramuscular injection of DS-5670a 10 µg.
89584006|NCT04821674|Experimental|Cohort A2: DS-5670a 30 µg|Healthy adults participants will be randomized to receive a intramuscular injection of DS-5670a 30 µg.
89584007|NCT04821674|Experimental|Cohort A3: DS-5670a 60 µg|Healthy adults participants will be randomized to receive a intramuscular injection of DS-5670a 60 µg.
89584008|NCT04821674|Experimental|Cohort A4: DS-5670a 100 µg|Healthy adults participants will be randomized to receive a intramuscular injection of DS-5670a 100 µg.
89584009|NCT04821674|Placebo Comparator|Cohort A: Placebo|Healthy adults participants will be randomized to receive a intramuscular injection of placebo.
88974666|NCT00052338|Experimental|Treatment (gemcitabine hydrochloride, carboplatin, bortezomib)|Patients receive gemcitabine IV over 30 minutes on days 1 and 8, carboplatin IV over 15-30 minutes on day 1, followed 1 hour later by bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with a clinical or radiographic response may continue receiving bortezomib beyond 6 courses.
89584010|NCT04821674|Experimental|Cohort B1: DS-5670a 10 µg|Healthy elderly participants will be randomized to receive a intramuscular injection of DS-5670a 10 µg.
89584011|NCT04821674|Experimental|Cohort B2: DS-5670a 30 µg|Healthy elderly participants will be randomized to receive a intramuscular injection of DS-5670a 30 µg.
89584012|NCT04821674|Experimental|Cohort B3: DS-5670a 60 µg|Healthy elderly participants will be randomized to receive a intramuscular injection of DS-5670a 60 µg.
89584013|NCT04821674|Experimental|Cohort B4: DS-5670a 100 µg|Healthy elderly participants will be randomized to receive a intramuscular injection of DS-5670a 100 µg.
89584014|NCT04821674|Placebo Comparator|Cohort B: Placebo|Healthy elderly participants will be randomized to receive a intramuscular injection of placebo.
89584015|NCT04791566|Active Comparator|Intestinal obstruction, Dexamethasone 1 mg/kg|Dexamethasone 1 mg/kg administered preoperatively as an i.v. infusion over 10-15 minutes
89584016|NCT04791566|Placebo Comparator|Intestinal obstruction, PLACEBO|Physiologic saline, administered preoperatively as an i.v. infusion over 10-15 minutes
89584017|NCT04791566|Active Comparator|Perforated viscus, Dexamethasone 1 mg/kg|Dexamethasone 1 mg/kg administered preoperatively as an i.v. infusion over 10-15 minutes
89584018|NCT04791566|Placebo Comparator|Perforated viscus, PLACEBO|Physiologic saline, administered preoperatively as an i.v. infusion over 10-15 minutes
89584019|NCT04129736|Other|Teriflunomide 14 mg tablets|Single arm
89584020|NCT05301218|Active Comparator|angiography-guided group|the treatment (including lesion preparation, stent sizing and post implantation optimization) will be performed by angiography. Once the result is considered optimal by the operator, a control OCT run will be acquired.
89584021|NCT05301218|Experimental|OCT-guided group|a preliminary OCT run will be recorded. An initial predilation with 1.5 to 2.0 mm balloon could be accepted in order to facilitate OCT catheter delivery through the target lesion. The PCI strategy will be guided by a pre-defined algorithm based on initial OCT findings. Post PCI result will be assessed by control OCT and potential optimization steps could be applied according to the results. The MLD-MAX optimization approach will be applied. Final OCT run will be performed at the end of the procedure.
89584022|NCT04769960||Participants with breast tissue expanders|Participants with breast tissue expanders that require an MRI for clinical purposes are eligible for this study.
89584023|NCT01637402|Experimental|Standard Dose|1000 milligrams (mg) abiraterone acetate in combination with prednisone taken once a day until progression defined by RECIST criteria OR by the Prostate Cancer Working Group 2 (PCWG) criteria
88974667|NCT04733066||Non-treatment Group|"Quality of life assessment (SBS-QoL, SF- 36)~Nutrition status assessment (BIA, BMI)~Assessment of functional absorptive small bowel length (citrulline)~Clinical data (nutritional program, stool characteristics)"
88974668|NCT04733066||Teduglutide-treated Group|"Quality of life assessment (SBS-QoL, SF- 36)~Nutrition status assessment (BIA, BMI)~Assessment of functional absorptive small bowel length (citrulline)~Clinical data (nutritional program, stool characteristics)"
89584024|NCT01637402|Experimental|Escalated Dose|Participants who progressed on the standard dose will be assigned 1000 milligrams (mg) abiraterone acetate in combination with prednisone taken twice a day for at least 12 weeks until progression as defined by RECIST criteria OR by the Prostate Cancer Working Group 2 (PCWG) criteria
89584025|NCT04419350|Experimental|treatment|microneedling.
89584026|NCT04419350|No Intervention|No treatment|No treatment will be done to these hypopigmented lesions
89584027|NCT04419038|Active Comparator|conjunctival autografting with MMC|Group A included 32 eyes of 32 patients who underwent conjunctival autografting augmented with topical application of Mitomycin C (0.2 mg/mL).
89584028|NCT04419038|Active Comparator|conjunctival autografting augmented with Ologen implantation|Group B included 31 eyes of 31 who underwent conjunctival autografting augmented with Ologen implantation.
89030163|NCT00516360|Experimental|1|Chlorhexidien as the antibacterial agent used to cleanse the hub of neonatal central lines
89030164|NCT00516360|Active Comparator|2|Isopropyl alcohol as the antibacterial agent used to cleanse the hub of neonatal central lines
89030165|NCT04510883|Experimental|PACO|Participants are asked to use the intervention for eight weeks.
89584029|NCT04825730|Experimental|Long Term Follow-up after Jointstem Transplantation|
89584030|NCT02217475|Experimental|Cenicriviroc (CVC) 150mg/CVC 150 mg|CVC 150 mg tablet in Years 1 and 2.
89584031|NCT02217475|Experimental|Placebo/CVC 150 mg|Placebo-matching CVC tablet in Year 1 then CVC 150 mg tablet in Year 2.
89584032|NCT02217475|Placebo Comparator|Placebo/Placebo|Placebo-matching cenicriviroc (CVC) tablet in Years 1 and 2.
89584033|NCT05296148|Experimental|Treatment|Treatment with the CroíValve DUO Coaptation Valve System
89584034|NCT02191267|Experimental|Presumed CTE Group|Interventions administered to the Presumed CTE Group include: [F-18]-T807 PET Scan, [F18]-Florbetapir PET Scan, MRI/MRS Scans, and Genetic Analysis for Genetic Risk Score for Tau.
89584035|NCT02191267|Experimental|Control Group|Interventions administered to the Control Group include: [F-18]-T807 PET Scan, [F18]-Florbetapir PET Scan, and MRI/MRS Scans.
89584036|NCT02191267|Experimental|AD Dementia Group|Interventions administered to the AD Dementia Group include: [F-18]-T807 PET Scan, [F18]-Florbetapir PET Scan, MRI/MRS Scans
89584037|NCT04418245||Patients positive for SARS-CoV-2|
89584038|NCT04818944|Experimental|Treatment Arm (tirofiban hydrochloride (AGGRASTAT®))|Subjects will receive an active dose via continuous IV at a rate of 0.10µg/kg/min (actual weight). This rate will begin within one hour of mechanical thrombectomy completion and will be terminated 24 hours after the initial administration time.
89584039|NCT04818944|Placebo Comparator|Placebo Arm|Subjects will receive placebo (saline) via continuous IV. This will begin within one hour of mechanical thrombectomy completion and will be terminated 24 hours after the initial administration time.
89584040|NCT02189941|Experimental|Deferiprone sustained-release (fed)|A single 1000 mg dose of deferiprone sustained-release following a high fat high calorie breakfast.
89030166|NCT04510883|Other|Waiting list + PACO|Participants receive the same intervention, but only after a waiting period of four weeks.
89030167|NCT01249131|Experimental|Treatment A first, then Treatment B, followed by Treatment C|Treatment A: One 20-mg tablet of cobimetinib will be administered orally with 240 milliliter (mL) room temperature water after at least an 8-hour fast, in first intervention period. Treatment B: Four 5-mg capsules of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in second intervention period. Treatment C: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water within 30 minutes of eating a standard Food and Drug Administration (FDA) high-fat meal, in third intervention period. The washout period between each period will be a minimum of 10 days.
89584041|NCT02189941|Experimental|Deferiprone sustained-release (fasting)|A single 1000 mg dose of deferiprone sustained-release under fasting conditions.
89584042|NCT02189941|Active Comparator|Deferiprone immediate-release (fasting)|A single 1000 mg dose of Deferiprone immediate-release under fasting conditions.
89584043|NCT04194476|Experimental|120 neonates less than 28 days old|Each neonate will be tested for blood glucose level twice on the same heel stick site using two glucose meters. additional 200-300 ul blood will be collected and centrifuged. Plasma will be tested blood glucose in the lab analyzer in the clinical laboratory.
89584044|NCT02216773|Active Comparator|Portal vein embolization (PVE)|"Patients allocated to the PVE group will receive pre-intervention blood tests and a contrast enhanced CT scan of the abdomen. They will then have their portal vein embolized radiologically once their pre-intervention investigations have been completed and reviewed by the clinical team.~Post-intervention investigations (blood tests and CT scan) will take place 4 weeks after the completion of the PVE. At this point, they will be listed to receive their definitive surgical hepatectomy."
89584045|NCT02216773|Experimental|Radiofrequency assisted liver partition and ligation (RALPP)|"Patients allocated to the RALPP group will receive pre-intervention blood tests and a contrast enhanced CT scan of the abdomen. They will then have their right portal vein surgically ligated followed by radiofrequency ablation in situ splitting of the liver. Certain patients may additionally have a tumourectomy or wedge resection of the left liver lobe if clinically indicated. The RALPP procedure will occur once the patient's pre-intervention investigations have been completed and reviewed by the clinical team.~Post-intervention investigations (blood tests and CT scan) will take place 2 weeks after the completion of the RALPP. At this point, they will be listed to receive their definitive surgical hepatectomy."
89584046|NCT01601132|Experimental|theophylline|300mg (80mg/15ml elixir) theophylline
89584047|NCT01601132|Experimental|Colchicine|colchicine 0.6mg by mouth twice daily on Days 5-19, co-administered with theophylline 300mg (80mg/15ml) on the morning of Day 19
89584048|NCT04818398|Experimental|DS-6016a dose level 1|Participants will be randomized to receive a single, subcutaneous injection of DS-6016a.
88974669|NCT00052377|Experimental|Treatment (aldesleukin, recombinant interleukin-12)|"Patients receive IL-12 SC twice weekly for 24 weeks.~Disease is assessed at 13 weeks. Patients who do not have progressive disease also receive IL-2 SC 3 consecutive days a week during weeks 13-24. Patients with progressive disease at week 13 receive IL-2 SC at a fixed dose during weeks 13-24.~Patients with responding disease after week 24 may continue to receive IL-2 and IL-12 for another 12 weeks.~Cohorts of 3-6 patients receive escalating doses of IL-2 until the MTD is determined. The MTD is defined as the dose at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. The RD is the dose preceding the MTD. Additional patients are treated at the RD."
88974670|NCT00052494|Experimental|STI-571 with cisplatin and irinotecan|
88974671|NCT00395174|Experimental|FluBlok|"Recombinant Trivalent Hemagglutinin Influenza Vaccine: 2005-2006 formulation containing 45μg of each hemagglutinin derived from A/New Caledonia (H1N1), A/Wisconsin (H3N2) and B/Ohio~135μg total"
88974672|NCT00395174|Active Comparator|TIV (Fluzone)|"Licensed trivalent influenza vaccine (TIV): 2005-2006 formulation containing 15μg of each hemagglutinin derived from A/Wisconsin (H3N2), A/New Caledonia (H1N1) and B/Malaysia~45μg total~(Fluzone, sanofi pasteur)"
88974673|NCT00395213||1|Children and adolescents with a pre-specified anxiety disorder, depressive disorder, eating disorder, or obsessive-compulsive disorder
88974674|NCT00052611|Experimental|Celecoxib|Celecoxib will be given at a pre-determine dose twice daily for 3 months. If there is a favorable change in biomarker expression on biopsy at 3 months, treatment will continue to complete a 12-month treatment period.
88974675|NCT00395252|Experimental|one arm study|Cetuximab (Erbitux®) and Gemcitabine treatment over 6 months
89584049|NCT04818398|Experimental|DS-6016a dose level 2|Participants will be randomized to receive a single, subcutaneous injection of DS-6016a.
89584050|NCT04818398|Experimental|DS-6016a dose level 3|Participants will be randomized to receive a single, subcutaneous injection of DS-6016a.
89584051|NCT04818398|Experimental|DS-6016a dose level 4|Participants will be randomized to receive a single, subcutaneous injection of DS-6016a.
89584052|NCT04818398|Experimental|DS-6016a dose level 5|Participants will be randomized to receive a single, subcutaneous injection of DS-6016a.
89584053|NCT04818398|Experimental|DS-6016a dose level 6|Participants will be randomized to receive a single, subcutaneous injection of DS-6016a.
89584054|NCT04818398|Placebo Comparator|Placebo|Participants will be randomized to receive a single, subcutaneous injection of placebo.
89584055|NCT04824482|Experimental|Robot-assisted treadmill gait training (RTGT)|Locomotor training guided by the robotic device (Lokomat Hocoma) according to a pre-programmed gait pattern with the help of robot-driven exoskeleton orthoses. The process of gait training is automated and controlled by a computer under supervision of a physiotherapist.
89584056|NCT04824482|Active Comparator|Therapist-assisted treadmill gait training (TTGT)|Locomotor training via a repetitive execution of walking movements manually guided by a physiotherapist during treadmill gait training.
88974676|NCT00052689|Experimental|Arm I|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Patients with progressive disease crossover to arm II.
88974677|NCT00052689|Experimental|Arm II|Patients receive bortezomib as in arm I and gemcitabine IV over 30 minutes on days 1 and 8.
89584057|NCT04836962|Placebo Comparator|control|normal saline is administrated to patients.
89584058|NCT04836962|Experimental|dexamethasone|0.5mg/kg dexamethasone is administered to patients.
89584059|NCT05289440|Experimental|Low-dose esketamine infusion on the quality of recovery after radical mastectomy|Patients received a bolus infusion of esketamine (0.5 mg/kg) before cutting the skin, and then esketamine was infused at a rate of 2 µg/kg/min until before suture the skin.
89030168|NCT01249131|Experimental|Treatment A first, then Treatment C, followed by Treatment B|Treatment A: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in first intervention period. Treatment C: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water within 30 minutes of eating a standard FDA high-fat meal, in second intervention period. Treatment B: Four 5-mg capsules of cobimetinib administered will be orally with 240 mL room temperature water after at least an 8-hour fast, in third intervention period.
89030169|NCT01249131|Experimental|Treatment B first, then Treatment A, followed by Treatment C|Treatment B: Four 5-mg capsules of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in first intervention period. Treatment A: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in second intervention period. Treatment C: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water within 30 minutes of eating a standard FDA high-fat meal, in third intervention period.
89584060|NCT05289440|Experimental|High-dose esketamine infusion on the quality of recovery after radical mastectomy|Patients received a bolus infusion of esketamine (0.5 mg/kg) before cutting the skin, and then esketamine was infused at a rate of 4 µg/kg/min until before suture the skin.
89584061|NCT05289440|Experimental|Saline infusion on the quality of recovery after radical mastectomy|Patients received a bolus infusion of the same volume saline before cutting the skin, and then the same volume saline was infused until before suture the skin.
89584062|NCT04709900|Active Comparator|Intervention group|CT angiography, FFR-CT and dynamic CT stress myocardial perfusion guided treatment strategy
89584063|NCT04709900|No Intervention|Standard care group|Evaluation and treatment strategy according to contemporary clinical practice
89584064|NCT04696172||Patients undergoing cardiopulmonary bypass (CPB) with postoperative ARDS|
89584065|NCT04696172||Patients undergoing cardiopulmonary bypass (CPB) without postoperative ARDS|
89584066|NCT05226884||Clareon IOL Group|Patients with bilateral implantation of Clareon IOLs.
89584067|NCT05226884||Eyhance IOL Group|Patients with bilateral implantation of EyhanceIOLs.
89584068|NCT03329612|Experimental|Intervention|This group will undergo remote ischemic preconditioning with serial inflations of the blood pressure cuff to 200 mmHg followed by deflation for reperfusion for a period of 5 minutes each for a total of 4 cycles.
89584069|NCT03329612|Sham Comparator|Control|This group will undergo serial inflations of the blood pressure cuff to 40 mmHg followed by deflation for a period of 5 minutes each for a total of 4 cycles.
89584070|NCT04691960|Experimental|Ketogenic Diet|
89584071|NCT04796792|Experimental|Treatment group|This study is currently in Phase 1 where all subjects undergo the investigational study.
89584072|NCT05279612||neoadjuvant chemoradiotherapy group|preoperative 1 circle chemotherapy(CapeOX) combined with short-course radiotherapy ，Surgical treatment(CME+D3) after four weeks of 2 circle chemotherapy(CapeOX).
89584073|NCT05279612||neadjuvant chemotherapy group|preoperative 3 circle chemotherapy(CapeOX) combined with surgical treatment(CME+D3)
89584074|NCT03948854|Experimental|Registered dietitian education|Subjects with irritable bowel syndrome (IBS) will receive education on FODMAP diet in person by a registered dietitian
89584075|NCT03948854|Experimental|On-line video program education|Subjects with irritable bowel syndrome (IBS) will receive education on FODMAP diet using an on-line video program
89584076|NCT03948854|Experimental|Handout education|Subjects with irritable bowel syndrome (IBS) will receive education on FODMAP diet by a printed handout
89584077|NCT03948854|Experimental|Dietitian-led group education|Subjects with irritable bowel syndrome (IBS) will receive education on FODMAP diet in a dietitian-led group setting
89584078|NCT04816916|Experimental|AXA1665 53.8 g per day|AXA1665 administered orally TID
89584079|NCT04816916|Placebo Comparator|Matching placebo|Placebo administered orally TID
89584080|NCT04809038|Experimental|dry needling|dry needling will be received twice a week for four weeks
89584081|NCT04809038|Experimental|magnesium sulphate iontophoresis|magnesium sulphate iontophoresis will be received twice a week for four weeks
89584082|NCT04809038|Active Comparator|stretching exercise|stretching will be received twice a week for four weeks
88974678|NCT00052845|Experimental|Combined chemotherapy|combination of 3 chemotherapy agents for hormone refractory prostate cancer
88974679|NCT00025025||Arm I|"Participants eat no red meat and take no nonsteroidal anti-inflammatory drugs (NSAIDs) and no vitamin C or multivitamins for 3 days prior to and during stool sample collection. Participants collect stool samples 3 different times and perform fecal occult blood (FOB) test smears from each stool. After each collection, participants ship the whole stool and FOB test smear to their participating center for blinded multitarget DNA-based assay panel (MTAP) testing.~Within 2 months after stool sample collection, participants have their blood drawn for additional MTAP testing and undergo colonoscopy."
89584083|NCT05652998|Active Comparator|Candida antigen|patients will be injected with intralesional C.albicans antigen
89584084|NCT05652998|Active Comparator|Autologous platelets rich plasma|patients will receive intralesional autologous PRP injection
89584085|NCT05652998|Placebo Comparator|Saline|patients will receive intralesional saline
89584086|NCT05362136|Active Comparator|Control|standard sinus floor elevation
89584087|NCT05362136|Experimental|Test|standard sinus floor elevation with additional perforation of the sinus floor
89584088|NCT05221190|Experimental|Single buccal infiltration of articaine anesthesia|The local anesthetic solution will be administered using single buccal infiltration with articaine anesthesia.
89584089|NCT05221190|Active Comparator|Inferior alveolar nerve block of lidocaine anesthesia|The anesthetic solution will be administered using inferior alveolar nerve block with lidocaine anesthesia.
89584090|NCT04816682|Active Comparator|LAGOSA ARM|Consecutively admitted patients will be allocated silymarin tablets (150 mg each) T.I.D. 3-2-2
89584091|NCT04816682|No Intervention|Control arm|Consecutive patients with the same inclusion/exclusion criteria as in active arm, hospitalised at the same department before the initiation of the study (historical controls)
89584092|NCT02162719|Experimental|Ipatasertib + Paclitaxel|Participants randomised to receive paclitaxel 80 mg/m^2, intravenously on Days 1, 8, and 15 along with ipatasertib 400 mg, orally, once daily from Days 1-21 in each cycle of 28 days until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.
89584093|NCT02162719|Placebo Comparator|Placebo + Paclitaxel|Participants randomised to receive paclitaxel 80 mg/m^2, intravenously on Days 1, 8, and 15 along with placebo matching ipatasertib, orally, once daily from Days 1-21 in each cycle of 28 days until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.
89584094|NCT03939728||Chest radiography and lung ultrasound|All patients will be enrolled, during their stay in pediatric intensive care unit, in order to have a pleural or pulmonary diagnosis, a chest radiography and then a lung ultrasound, at less than 2 hours interval.
89584095|NCT05652842||Day workers|Includes people working from 9 a.m. to 5 p.m./8 a.m. to 4 p.m. We will be recruiting 15 day workers.
89584096|NCT05652842||Shift workers|Includes those involved in any arrangement of daily working hours other than the standard daylight hours, 8 a.m. - 5 p.m. It also includes on-call or casual workers. We will be recruiting 15 shift workers.
89584097|NCT05652842||Rotational workers|Includes those who work on a set schedule and whose working hours are rotating on a set schedule. We do not include offshore workers here. We will be recruiting 15 rotational workers.
89584098|NCT02161549||Colonoscopy with MotusGi CleanUp System Rev 1.0|subjects indicated for colonoscopy procedure with CleanUp System Rev 1.0 , enrolled under protocol Rev 1.0
89584099|NCT02161549||Colonoscopy with MotusGi CleanUp System Rev 1.5|subjects indicated for colonoscopy procedure with CleanUp System Rev 1.5 , enrolled under protocol Rev 2.0
89584100|NCT05652530|Experimental|BCMA CAR-NK|
89584101|NCT02189863|Other|AOAMV, then AOAMF|Lotrafilcon B MV contact lenses worn for 2 weeks in Period 1, followed by lotrafilcon B MF contact lenses worn for 2 weeks in Period 2
89584102|NCT02189863|Other|AOAMF, then AOAMV|Lotrafilcon B MF contact lenses worn for 2 weeks in Period 1, followed by lotrafilcon B MV contact lenses worn for 2 weeks in Period 2
89584103|NCT04808882|Experimental|Low dose prophylactic anticoagulation|LD-PA
88974680|NCT00025025||Arm II|"Participants take no vitamin C or multivitamins for 3 days before and during stool sample collection. Participants collect stool samples and FOB test smears and samples are tested as in arm I.~Within 2 months after stool sample collection, participants have their blood drawn for additional MTAP testing and undergo colonoscopy."
89209558|NCT03973957|Active Comparator|Control Arm|If undergoing talc slurry in the control arm, the patient will undergo IPC placement in the pulmonary procedure unit on day one of admission. The IPC will then be connected to a pleur-evac as standard of care protocol for chest tube drainage. At 1-2 hours post-IPC placement a chest x-ray will be obtained to assess for full lung re-expansion. If the lung does not fully expand the patient will be excluded from the study. Once full lung re-expansion has occurred, talc slurry will be ordered and the patient will be given 25 mcg of IV fentanyl. Talc slurry (5 g sterile talc, brand name Steritalc, mixed with 50 cc or sterile normal saline in a syringe, per Cooper University Pharmacy protocol) will be administered via the IPC. The patient will remain in the hospital, with continuous drainage measured daily for 2-5 days, depending on drainage of the effusion.
89584104|NCT04808882|Experimental|High dose prophylactic anticoagulation|HD-PA
88974681|NCT00053040|Experimental|Surgery for tumor resection + IL13-PE38QQR infusion|
88974682|NCT00025220|Experimental|Treatment (thalidomide)|Patients receive oral thalidomide once daily on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
88974683|NCT00053196|Experimental|Non myeloblative allogeneic transplant|Non myeloblative allogeneic hematopoietic cell transplantation after prior autologous transplantation
88974684|NCT00025337|Experimental|Arm I (bevacizumab, oxaliplatin, leucovorin, fluorouracil)|Patients receive bevacizumab IV over 30-90 minutes and oxaliplatin IV over 2 hours on day 1. Patients also receive leucovorin calcium IV over 2 hours and fluorouracil (5-FU) IV over 22 hours on days 1 and 2.
88974685|NCT00025337|Experimental|Arm II (oxaliplatin, leucovorin calcium, fluorouracil)|Patients receive oxaliplatin, leucovorin calcium, and 5-FU as in arm I.
88974686|NCT00025337|Experimental|Arm III (bevacizumab)|Patients receive bevacizumab as in arm I.
89584105|NCT04808882|Experimental|Therapeutic anticoagulation|TA
89584106|NCT02189473|Experimental|5 x 4 Gy in 1 week|radiotherapy with 5 x 4 Gy in 1 week (5 x 4 Gy per week)
89584107|NCT02189473|Active Comparator|10 x 3 Gy in 2 weeks|radiotherapy with 10 x 3 Gy in 2 weeks (5 x 3 Gy per week)
88974687|NCT00398190|Active Comparator|Control|Students receive standard anti-tobacco education
89584108|NCT05652452|Experimental|Neurodynamics|
89584109|NCT05652452|Active Comparator|Static stretch|
89584110|NCT05164796|Experimental|IVUS-guided|
89584111|NCT02188849|Experimental|Creatine|Creatine 5 g/ day
89584112|NCT02188849|Placebo Comparator|Placebo|Maltodextrin 5 g/day to be dissolved in water
89584113|NCT05164484|Other|Transpulmonary thermodilution in patients implanted with VV-ECMO during standard care for ARDS|Standard of care procedure for patient with severe ARDS
89584114|NCT05652374|Experimental|Intervention group|50ml of sterile Ialuril (HA 1.6% CS 2%) bladder instillations weekly for 6 weeks, followed by monthly maintenance therapy for 1 year
89584115|NCT05652374|Active Comparator|Control group|nitrofurantoin 100mg daily (1dd100mg or 2dd50mg) for 1 year. In case of resistance/intolerance/allergy for nitrofurantoin alternatively trimethoprim 100mg daily will be given.
89584116|NCT01636076|Experimental|QMF149|QMF149 (Indacaterol acetate/Mometasone furoate) 150/160 µg o.d. delivered via Concept1 device
89584117|NCT01636076|Active Comparator|Salmeterol xinafoate/fluticasone propionate|Salmeterol xinafoate/fluticasone propionate 50/500 µg b.i.d, delivered via Accuhaler®
89584118|NCT01635998|Experimental|Intervention arm|These subjects will undergo routine catheter ablation of atrial fibrillation PLUS renal sympathetic denervation with the Boston Scientific Vessix Renal Denervation System.
89584119|NCT01635998|No Intervention|Control arm|These subjects will undergo routine catheter ablation of atrial fibrillation only.
89584120|NCT01635920|Experimental|AIR OPTIX® COLORS|Lotrafilcon B contact lens with color worn bilaterally for a minimum of 5 days per week, 8 hours per day, in daily wear modality for 4 weeks.
89584121|NCT01635920|Active Comparator|AIR OPTIX® AQUA|Lotrafilcon B contact lens worn bilaterally for a minimum of 5 days per week, 8 hours per day, in daily wear modality for 4 weeks.
89584122|NCT04793984|Experimental|Inhaleen|Iota-Carrageenan inhalation
89584123|NCT04793984|Placebo Comparator|Placebo|NaCl inhalation
89584124|NCT03029000|Experimental|Tbo-filgrastim (GRANIX)|"Participants will receive tbo-filgrastim 10 mcg/kg of body weight, subcutaneously on the morning of Days 1 to 5.~The actual dose of tbo-filgrastim administered to each, individual participant will be calculated at baseline according to his or her body weight and that specific dose (10 mcg/kg of body weight) for each, individual participant will remain the same for all consecutive daily doses.~If the collection goal will not meet after the first apheresis on Day 5, tbo-filgrastim 10 mcg/kg of body weight will be administered subcutaneously for up to 3 additional days (Days 6 to 8) followed by daily apheresis to reach the cumulative collection goal."
89584125|NCT03023150|Experimental|Ischemic Preconditioning|Inflation of blood pressure cuff to 225 mmHg on paretic leg. 1 session: 5 minutes of inflation, 5 minutes deflation, repeated 5 times.
89584126|NCT03023150|Sham Comparator|Sham|Inflation of blood pressure cuff to 25 mmHg on paretic leg. 1 session: 5 minutes of inflation, 5 minutes deflation, repeated 5 times.
89584127|NCT03783182|Active Comparator|Betapred|16 'Betamethason Sodium Phosphate' tablets dissolved in one ml of water as part of the premedications given to the patient 30 min before the surgery
89584128|NCT03783182|Placebo Comparator|Placebo|One ml of 10% glucose solution as part of the premedications given to the patient 30 min before the surgery
89584129|NCT03780920|Active Comparator|Osteopathic treatment|
89584130|NCT03780920|No Intervention|Control group|
89584131|NCT05651984|Active Comparator|Communication board|The communication board consists of a printed paper interface with a size of 42 x 30 cm.
89584132|NCT05651984|Experimental|Eye tracking|The eye tracking device combines a laptop computer with a screen size of 29 x 16 cm, an eye tracker (PCEye Mini, Tobii dynavox, Danderyd, Sweden), an interface generated by a communication software (Communicator 5, Tobii dynavox) and a telescopic support.
89584133|NCT03760484|Experimental|fecal transplant with fidaxomicin|FMT per rectum x 3 days in conjunction with fidaxomicin (dificid) PO 200 mg bid x 7-10 days
89584134|NCT05651750|Experimental|Montelukast tab|
89584135|NCT05651750|Experimental|Fluticasone nasal spray|
89584136|NCT02917460|Experimental|Enrollees|Enrollment of healthy and affected subjects to collect samples and data for a pediatric genomic Biorepository. Data includes genomic sequencing and resultant molecular diagnostic results, if any.
89584137|NCT05651672|Experimental|experimental group|Pemigatinib
89584138|NCT02160145|Experimental|Tolvaptan|Tolvaptan (OPC-41061)
89584139|NCT02160145|Placebo Comparator|Placebo|Placebo
89584140|NCT04807478||Pediatric patients|Pediatric patients with new-onset PNAC
88974688|NCT00398190|Experimental|Media Literacy|Students receive media literacy based anti-smoking education
88974689|NCT00025376|Experimental|Pre-Treatment biopsy followed by PS-341 administration|Pre-treatment tumor biopsy followed by 3 cycles of PS-341 given by IV infusion. Each cycle will last 3 weeks. PS-341 will be given 2 times a week for 2 weeks followed by a 'rest' week with no drug. After the 3rd cycle, subjects can continue to receive another 3 cycles of the study drug if their disease has not worsened.
88974690|NCT00025376|Experimental|PS-341 administration followed by biopsy|3 cycles of PS-341 given by IV infusion. Each cycle will last 3 weeks. PS-341 will be given 2 times a week for 2 weeks followed by a 'rest' week with no drug. After the 3rd cycle, subjects will have a tumor biopsy and can continue to receive another 3 cycles of the study drug if their disease has not worsened.
88974691|NCT04731324|Experimental|ZYIL1 Capsule|six subjects will be recruited in each cohort. safety data up to day 3 will be evaluated to determine whether progression to the subsequent dose Cohort is indicated. Single dose will be administered in ascending manner starting from 25 mg.
88974692|NCT00025415|Experimental|Treatment (imatinib mesylate)|Patients receive oral imatinib mesylate daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients within each stratum (except normal stratum) receive escalating doses of imatinib mesylate until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity
89584141|NCT01696396|Placebo Comparator|Placebo Q4W/Abrilumab 210 mg Q3M|"Participants received placebo by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24.~During the open-label period, participants received abrilumab 210 mg once every 3 months (Q3M) for 108 weeks."
89584142|NCT01696396|Experimental|Abrilumab 21 mg Q4W/Abrilumab 210 mg Q3M|"Participants received 21 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks (Q4W) thereafter until week 24.~During the open-label period, participants received abrilumab 210 mg once every 3 months (Q3M) for 108 weeks."
89584143|NCT01696396|Experimental|Abrilumab 70 mg Q4W/Abrilumab 210 mg Q3M|"Participants received 70 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24.~During the open-label period, participants received abrilumab 210 mg once every 3 months (Q3M) for 108 weeks."
89584144|NCT01696396|Experimental|Abrilumab 210 mg/Abrilumab 210 mg Q3M|"Participants received a single dose of 210 mg abrilumab by subcutaneous injection on day 1, followed by placebo at week 2, week 4, and every 4 weeks thereafter until week 24.~During the open-label period, participants received abrilumab 210 mg once every 3 months (Q3M)for 108 weeks."
89584145|NCT05269784|Experimental|Completely Tubeless Group|minimally invasive lung surgery under ERAS with completely tubeless protocol: no intubation, no urinary catheter, move the chest drainage as fast as possible according the ERAS guideline on the premise of safety.
89584146|NCT05269784|Active Comparator|Partially Tubeless Group|minimally invasive lung surgery under ERAS with partially tubeless protocol.
89584147|NCT03654638|Experimental|Arm I Soy Bread Intervention|Men who are scheduled to begin androgen deprivation therapy for prostate cancer will begin an intervention to consume 2 slices of soy bread daily for approximately 20 weeks. Blood, urine and toxicity data will be collected at regularly scheduled medical oncology visits.
89584148|NCT03654638|Active Comparator|Arm II Wheat Bread Intervention|Men who are scheduled to begin androgen deprivation therapy for prostate cancer will begin an intervention to consume 2 slices of wheat bread for approximately 20 weeks. Blood, urine and toxicity data will be collected at regularly scheduled medical oncology visits.
89584149|NCT02216071|Active Comparator|Ciprodex®, RLD|Ciprodex®, Otic Suspension, Twice daily for 7 days
89584150|NCT02216071|Experimental|EXL CDOS|EXL CDOS (Ciprofloxacin 0.3% and Dexamethasone 0.1%) Sterile Otic Suspension, Otic Suspension, Twice daily for 7 days
89584151|NCT04418570|Experimental|Cognitive remediation|"Computerized cognitive remediation through Neuropersonal Trainer software, 1.5 h per session twice a week for 12 weeks (36 h of total duration).~Participants will also attend the Early Intervention Service for Psychosis with visits by a psychiatrist, clinical psychologist, social worker, or nurse as scheduled."
89209559|NCT03973957|Active Comparator|Intervention Arm|"An indwelling pleural catheter (IPC) will be placed during this visit. After complete drainage of the effusion, a chest x-ray will be done to determine if full lung reexpansion occurs. If there is lack of full lung re-expansion the patient will be excluded from the study at this time. If full lung re-expansion is present, the patient will receive an intravenous line (IV) by our nursing staff for analgesia prior to talc administration and will be pre-treated with 25 mcg of IV fentanyl.~Talc slurry (5 g sterile talc, brand name Steritalc, mixed with 50 cc or sterile normal saline in a syringe, per Cooper University Pharmacy protocol) will then be administered through the IPC. The IPC will then be connected to a circuit that will consist of the IPC connected to a 4-liter fluid drainage collection bag via a one-way Heimlich valve (picture of set up included in additional documents)."
89584152|NCT04418570|Other|Treatment as usual|Participants will attend the Early Intervention Service for Psychosis with visits by a psychiatrist, clinical psychologist, social worker, or nurse as scheduled.
89584153|NCT01681576|Experimental|LCZ696 followed by Valsartan|Period 1: LCZ696 400mg QD for 4 weeks then washout followed by Period 2: Valsartan 320mg QD for 4 weeks
89584154|NCT01681576|Experimental|Valsartan followed by LCZ696|Period 1: Valsartan 320mg QD for 4 weeks then washout followed by Period 2: LCZ696 400mg QD for 4 weeks
89584155|NCT04418726|Experimental|Intensive Monitoring and Preemptive Intervention|In this group patients receive intensive monitoring and preemptive intervention. AVF surveillance refers to using non-invasive devices to check for the haemodynamic consequences of stenosis by measuring Qa every month. Clinical assessment refers to monitoring for any presence of stenosis by (i) physical examination, by means of visual inspection and presence of abnormal thrill, bruit or pulse and (ii) checking for signs of access dysfunction during dialysis: difficult cannulation, increase in dynamic arterial or venous pressure, inability to achieve the prescribed dialysis blood pump flow (Qb), prolonged bleeding after needle removal, access recirculation or a drop in Kt/V. Preemptive intervention is performed as long as problems are recognized, including health education and timely surgery.
89584156|NCT04418726|No Intervention|Traditional Monitoring and Intervention|In this group patient receive traditional AVF monitoring, includes clinical assessment for any presence of stenosis by (i) physical examination, by means of visual inspection and presence of abnormal thrill, bruit or pulse and (ii) checking for signs of access dysfunction during dialysis: difficult cannulation, increase in dynamic arterial or venous pressure, inability to achieve the prescribed dialysis blood pump flow (Qb), prolonged bleeding after needle removal, access recirculation or a drop in Kt/V.
89584157|NCT02819960|Active Comparator|active probiotic formula|"Intervention: Probiotic formula Probio-Tec® BG-VCap-6.5 will be administered at a dose of 3x1 cps per day orally for 6 weeks. No premedication or patient monitoring after administration of probiotic formula is required. Probiotic formula may be taken after meals or snacks to reduce stomach upset. Swallow the capsule or in case of problems with swallowing, capsule can be opened, content mixed with small amount of food. Food must not be hot.~Patients should receive full supportive care during the study, including transfusion of blood and blood products, treatment with antibiotics, anti-emetics, anti-diarrheal agents, analgesics, erythropoetin, or bisphosphonates, when appropriate."
89584158|NCT02819960|Placebo Comparator|placebo|"Intervention: Maltodextrin will be used for placebo group and will be administered at a the same dose as active formula (3x1 cps per day orally for 6 weeks).~Patients should receive full supportive care during the study, including transfusion of blood and blood products, treatment with antibiotics, anti-emetics, anti-diarrheal agents, analgesics, erythropoetin, or bisphosphonates, when appropriate."
88974693|NCT00053235||Ancillary-Correlative|Genomic DNA is isolated from OCT-embedded tissue and analyzed using comparative genomic hybridization. The chromosomal changes identified by this method are compared to those identified using the Taqman method, a quantitative genomic polymerase chain reaction analysis. Chromosome 8q is of specific interest. Other chromosomal changes may be detected in chromosomes 3q, 7q, 16q, and/or 17pter-q21.
88974694|NCT02970279|Experimental|Enhanced Behavioural Activation Groups|"Behavioural activation group (BAG) psychotherapy delivered with two embedded treatment augmentations;~Implementation intentions~Dose-response psychoeducation"
88974695|NCT00025493|Experimental|docetaxel|docetaxel
88974696|NCT00053430|Experimental|1|Participants will receive low dose thalidomide for 28 days
89584159|NCT04552912|Experimental|Build Stamina Group|The Build StaMINA (Biobehavioral Self-Management INtervention using physical Activity) is a tailored evidence-based physical activity (PA) program designed to improve endurance, strength, and balance which are all areas of physical function, that adults with acute leukemia (AL) post-induction are known to have diminished capacity. The Build StaMINA program will be tailored to their current Physical Function, per assessment. The detailed PA prescription includes each exercise in the program as well as the frequency, number of repetitions each day and rate of perceived exertion (RPE) for each exercise. The repetitions and RPE are based on the participants' current Physical Function Assessment and will be assigned based on our evidence-based algorithm.
89584160|NCT04552912|No Intervention|Attention-Control Group|Participants assigned to the attention control group will have a Physical Function Assessment at baseline after informed consent has been provided and prior to randomization. Participants will also be asked to complete questionnaires regarding at baseline, 6-weeks and 3 months. Those in the attention-control group will also receive a newsletter detailing the benefits of participating in regular PA as well as regular phone calls by study team to discuss general health and wellbeing at the same schedule as intervention group.
89584161|NCT02188459|Active Comparator|Bupropion|Bupropion 150 mg BID, PO for 10 weeks
89584162|NCT02188459|Placebo Comparator|Placebo|Placebo BID, PO for 10 weeks. The formulation appears identical to the bupropion capsules.
89584163|NCT04793282|Placebo Comparator|Control|Post-test satisfaction
89584164|NCT04793282|Experimental|Experimental|Treatment and satisfaction
89584165|NCT04759183|Experimental|Arm I (Angry Birds, TRIPP)|Patients participate in a VR intervention (Angry Birds) over 15 minutes before standard of care surgery and then participate in a VR intervention (TRIPP) over 15 minutes after surgery.
89584166|NCT04759183|Experimental|Arm II (TRIPP, Angry Birds)|Patients participate in a VR intervention (TRIPP) over 15 minutes before standard of care surgery and then participate in a VR intervention (Angry Birds) over 15 minutes after surgery.
89584167|NCT02743364|Experimental|Arm I (simvastatin)|Patients receive simvastatin PO QD for 6 months.
89584168|NCT02743364|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD for 6 months.
89584169|NCT02214121|Other|Ticagrelor Dose 1a + Dose 2a|Part A: Ticagrelor Dose 1a and ticagrelor Dose 2a single doses + 1 week repeated dosing Part B: Ticagrelor or placebo 4 weeks repeated dosing.
89584170|NCT02214121|Other|Ticagrelor Dose 1b + Dose 2b|Part A: Ticagrelor Dose 1b and ticagrelor Dose 2b single doses + 1 week repeated dosing. Part B: Ticagrelor or placebo 4 weeks repeated dosing.
89584171|NCT01681186|Experimental|LY2940680 (Part A)|Single escalating dose (50 mg up to 400 mg) of LY2940680 given once orally in up to 2 of 2 study periods
89584172|NCT01681186|Placebo Comparator|Placebo (Part A)|Placebo given once orally in up to 1 of 2 study periods
89209560|NCT00658658|Experimental|Panitumumab|Participants received panitumumab at planned doses ranging from 2.5 mg/kg weekly (QW) to 9.0 mg/kg every 3 weeks (Q3W) until the patient experienced disease progression, was unable to tolerate study drug, withdrew consent, or other reasons that warranted removal from the study.
89209561|NCT00723203|Experimental|Treatment (panobinostat)|"Patients receive oral panobinostat once on days 1, 3, and 5. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~panobinostat: 40 mg Monday, Wednesday and Friday of every week in a 28 day cycle"
89584173|NCT01681186|Experimental|LY2940680 Capsule Fasted (Part B)|100 mg LY2940680 given once orally as a capsule (reference formulation) in fasted state in 1 of 4 study periods
88974697|NCT00053430|Placebo Comparator|2|Participants will receive low dose thalidomide placebo for 28 days
88974698|NCT00053508|Experimental|Group 1|ACAM1000
88974699|NCT00053508|Experimental|Group 2|ACAM1000
88974700|NCT00053508|Experimental|Group 3|ACAM1000
89209562|NCT00891072|Experimental|Treatment|Patients receive oral R-(-)-gossypol acetic acid twice daily on days 1-3. Patients also receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
89209563|NCT01072903||IBS|Subjects with IBS
89209564|NCT01072903||Healthy|Healthy Controls
89209565|NCT02591927|Active Comparator|Glucose-Insulin-Potassium|Rackley's Glucose-Insulin-Potassium formula consisting of 30% glucose (300 mg/L), 50 units of regular insulin per liter and 80 mEqu of KCL per liter.
89209566|NCT02591927|Placebo Comparator|Glucose 5%|Glucose 5%
89584174|NCT01681186|Experimental|LY2940680 Tablet Fasted (Part B)|100 mg LY2940680 given once orally as a tablet (test formulation) in fasted state in 1 of 4 study periods
89584175|NCT01681186|Experimental|LY2940680 Tablet Fed (Part B)|100 mg LY2940680 given once orally as a tablet (test formulation) in fed state following a standardized, high-fat breakfast in 1 of 4 study periods
89584176|NCT01681186|Experimental|LY2940680 Tablet Fasted + PPI (Part B)|30 mg lansoprazole (PPI) given orally once daily for 7 days. One hour after last dose, 100 mg LY2940680 given orally once as a tablet (test formulation) in fasted state in 1 of 4 study periods
89584177|NCT03597464|Experimental|Voclosporin|Voclosporin
89584178|NCT03597464|Placebo Comparator|Placebo Oral Capsule|Placebo
89584179|NCT01695772|Experimental|Bevacizumab|
89584180|NCT02159521|Experimental|EkoSonic® Endovascular System|Thrombolytic infusion (Alteplase), at an infusion rate of 0.5-1.0 milligrams/hour (mg/hr) will be delivered to the participants with chronic lower extremity venous obstruction after DVT and PTS through the EkoSonic® Endovascular System for at least 12 hours and overnight as needed up to a maximum of 48 hrs. The alteplase dose could be adjusted per investigator discretion, but not to be exceeded 1 mg/hr or a total dose of 48 mg.
88974701|NCT00053508|Active Comparator|Group 4|Dryvax
88974702|NCT00053625|Active Comparator|SA #1 Arm 1: Unilateral DBS in GPi|
88974703|NCT00053625|Active Comparator|SA #1 Arm 2: Unilateral DBS in STN|
88974704|NCT00053625|Active Comparator|SA #2 Arm 1: Bilateral DBS in GPi|Patients with GPi bilateral DBS (previously had unilateral DBS in the GPi, now have bilateral DBS in GPi)
88974705|NCT00053625|Active Comparator|SA #2 Arm 2: Bilateral DBS in STN|Patients with STN bilateral DBS (previously had unilateral DBS in the STN, now have bilateral DBS in STN)
89584181|NCT01636934|Experimental|Minocycline|Two-arm, placebo-controlled pilot study to obtain preliminary estimates of treatment effects of minocycline in patients with non small cell lung cancer (NSCLC) being consented for concurrent chemoradiation (CXRT). Minocycline 100 mg capsules taken by mouth two times a day every day for 7 weeks, starting on the first week of chemoradiation therapy. Questionnaires at baseline, timepoints during chemoradiation, and at treatment completion for 12 weeks.
89584182|NCT01636934|Placebo Comparator|Placebo|Two-arm, placebo-controlled pilot study to obtain preliminary estimates of treatment effects of minocycline in patients with non small cell lung cancer (NSCLC) being consented for concurrent chemoradiation (CXRT). Placebo capsules taken by mouth two times a day every day for 7 weeks, starting on the first week of chemoradiation therapy. Questionnaires at baseline, timepoints during chemoradiation, and at treatment completion for 12 weeks.
89584183|NCT01712854|Experimental|Symbicort|A combination of budesonide + long acting beta agonist (Symbicort): Budesonide 80 mcg and formoterol fumarate dihydrate inhaler 4.5 mcg
89584184|NCT01712854|Placebo Comparator|Budesonide only|Budesonide 80 mcg (Entocort EC) only
89584185|NCT01693120|Experimental|Ablation|Phased RF ablation
89209567|NCT04037046|Experimental|Screening HCV with DBS at primary care centers|Patients assigned to the strategy 1 will receive an invitation letter for HCV screening with DBS at the primary care center to be performed by the general practitioner
89209568|NCT04037046|Active Comparator|Screening HCV and CCR with FOT at primary care centers|Patients assigned to the strategy 2 will receive an invitation letter for HCV screening with DBS and CCR screening with FOT at the primary care center to be performed by the general practitioner
89209569|NCT04037046|Active Comparator|Self-testing at home for screening HCV and CCR|Patients assigned to the strategy 3 will receive an invitation letter for self-testing at home for HCV screening with DBS, and CCR screening with FOT
89584186|NCT02986594|Experimental|aspirin group|low dose aspirin, 75-100mg, bid, after pregnancy
89584187|NCT02986594|Experimental|low molecular weight heparin group|low molecular weight heparin, 4100u, qd, after pregnancy
89584188|NCT02986594|Experimental|combination group|low molecular weight heparin, 4100u, once a day and low dose aspirin, 75-100mg, bid. After pregnancy
89584189|NCT02159365|Experimental|Elotuzumab + Lenalidomide/Dexamethasone|Elotuzumab 10 mg/kg solution intravenously weekly in cycle 1 and 2, then every other week, Lenalidomide 25 mg tablet by mouth Days 1-21 of each cycle / Dexamethasone 40 mg tablet by mouth / solution intravenously weekly until progression or discontinuation of Elotuzumab
89584190|NCT01712074|Experimental|30 mg QD of PF-05212377|
89584191|NCT01712074|Placebo Comparator|Placebo|
89584192|NCT01711216||women received dydrogesterone for irregular menstrual cycle|Adult women received dydrogesterone for irregular menstrual cycle as per standard clinical practice of the treating physician
89584193|NCT02072200|Experimental|Modified release prednisone|Single arm / Lodotra
89584194|NCT04767724|Experimental|Extracorporeal shock wave|Participants received three ESWT sessions once per week for three consecutive weeks. The probe of the ESWT machine (FT-174; Swiss Dolor Class; Switzerland) was placed perpendicularly on the patient's palm over the median nerve on the carpal tunnel after application of the ultrasound gel as a coupling agent. Afterward, the ESWT was administered with 1000 shots, 1.5 bar of pressure, and a frequency of 6 Hz
88974706|NCT00025766|Experimental|1|PCI with stenting of the occluded culprit infarct-related artery plus optimal medical therapy
88974707|NCT00025766|Active Comparator|2|Optimal medical therapy alone without PCI of the occluded culprit artery
88974708|NCT04731597||Cases with hip fracture|Patients afiliated to a HMO Plan de Salud Hospital Italiano who presented hip fracture between 2014 and 2019
88974709|NCT04731597||controls without hip fracture|Patients afiliated to a HMO Plan de Salud Hospital Italiano without hip fracture between 2014 and 2019
88974710|NCT04731090|Active Comparator|Standard antibiotic prophylaxis|IV fluoroquinolone 1 hour preoperatively and oral antibiotics were used for 24h postoperatively.
88974711|NCT04731090|Experimental|enhanced prophylaxis|Patients had urine culture 10 days before the procedure. In addition to the antibiotic prophylaxis, hydrophilic-coated ureteral access sheaths were systematically used.
88974712|NCT00053976|Experimental|Daclizumab|"Patients are randomized to 1 of 2 treatment arms.~Arm I:~Patients receive methylprednisolone or equivalent corticosteroid IV or orally~Daclizumab IV on days 0, 3, 7, 14, and then weekly as indicated until day 100.~Arm II: Patients receive methylprednisolone or equivalent corticosteroid as in arm I and placebo.~Patients are followed at 1 year and then annually thereafter."
88974713|NCT00053976|Placebo Comparator|Placebo|"Patients are randomized to 1 of 2 treatment arms.~Patients receive methylprednisolone or equivalent corticosteroid as in Daclizumab arm~Placebo IV on days 0, 3, 7, 14, and then weekly as indicated until day 100."
88974714|NCT04733573|Active Comparator|Occlusal appliance by Okeson with canone guidance|Occlusal appliance will be used while sleeping for 30 days.
88974715|NCT04733573|Active Comparator|Bimaxillary splint without canine guidance|Bimaxillary splint will be used while sleeping for 30 days.
88974716|NCT00026117|Experimental|BeneFin|"Patients receive oral shark cartilage (BeneFin™) 3-4 times daily. Treatment continues in the absence of unacceptable toxicity. Quality of life is assessed weekly for 1 month and then monthly thereafter during treatment.~Patients are followed every 6 months for 5 years."
88974717|NCT00026117|Other|placebo|"Patients receive oral placebo 3-4 times daily. Treatment continues in the absence of unacceptable toxicity. Quality of life is assessed weekly for 1 month and then monthly thereafter during treatment.~Patients are followed every 6 months for 5 years."
88974718|NCT00398229|Active Comparator|A|receiving hCG injection
88974719|NCT00398229|Placebo Comparator|B|
89584195|NCT04767724|Active Comparator|Local corticosteroid injection|A single injection of one mL (40 mg) of betamethasone into the region surrounding the median nerve.
89584196|NCT01692730|Experimental|Enhanced Web Assisted Intervention|Enhanced Web Assisted Tobacco Intervention. An enhanced and highly interactive website for cessation.
89584197|NCT01692730|Active Comparator|Basic Web Assisted Intervention.|Basic Web Assisted Tobacco Intervention. A basic website for cessation comparable to those for general adult populations, including established evidence-based cessation information and features.
89584198|NCT01691794|Active Comparator|Atazanavir, 150 mg + Ritonavir, 100 mg (weight:15 to <20 kg)|Participants with baseline weight of 15 to <20 kg received 150 mg of atazanavir plus 100 mg of ritonavir once daily with an optimized background therapy of 2 nucleoside reverse transcriptase inhibitors (NRTIs) for 24 weeks. In countries without locally approved pediatric indication for atazanavir, patients may continue to receive study treatment, with regular 12-week visits, until the age of 18 years.
89584199|NCT01691794|Active Comparator|Atazanavir, 200 mg + Ritonavir, 100 mg (weight: 20 to <40 kg)|Participants with baseline weight of 20 to <40 kg received 200 mg of atazanavir plus 100 mg of ritonavir once daily with an optimized background therapy of 2 NRTIs for 24 weeks. In countries without locally approved pediatric indication for atazanavir, patients may continue to receive study treatment, with regular 12-week visits, until the age of 18 years.
89584200|NCT01691794|Active Comparator|Atazanavir, 300 mg + Ritonavir, 100 mg (weight: ≥ 40 kg)|Participants with baseline weight ≥ 40 kg received 300 mg of atazanavir plus 100 mg of ritonavir once daily with an optimized background therapy of 2 NRTIs for 24 weeks. In countries without locally approved pediatric indication for atazanavir, patients may continue to receive study treatment, with regular 12-week visits, until the age of 18 years.
89584201|NCT01710514|Active Comparator|FE 999913 100 mg BID|FE 999913 100 mg vaginal tablet BID
89584202|NCT01710514|Active Comparator|FE 999913 100 mg TID|FE 999913 100 mg vaginal tablet TID
89584203|NCT01592344|Experimental|StimRouter - active stimulation|StimRouter- active electrical stimulation is applied transdermally to a targeted peripheral nerve. This is accomplished via a fully implanted StimRouter lead that receives energy from a rechargeable programmed external pulse transmitter (EPT) with attached gel electrodes. The EPT receives radio frequency (RF) commands from a Patient Programmer. A StimRouter Clinician Programmer is used to program the StimRouter EPT and Patient Programmer. Up to eight stimulation programs may be saved on a Patient Programmer for on-demand selection by the study patient.
89584204|NCT01592344|Sham Comparator|StimRouter - Control|StimRouter- Electrical stimulation is withheld from the targeted peripheral nerve after fully implanting the StimRouter lead. The rechargeable programmed external pulse transmitter (EPT) with attached gel electrodes is placed for transdermal stimulation but no stimulation is delivered. The EPT which normally receives radio frequency (RF) commands from a Patient Programmer is not activated. A StimRouter Clinician Programmer is used to program the StimRouter EPT and Patient Programmer such that no stimulation occurs in the Control Arm of the study.
89584205|NCT01636778|Experimental|SB-497115-GR|investigational product for thrombocytopenia
89584206|NCT02159053|Experimental|Secukinumab 150 mg s.c. with loading|Secukinumab 150 mg at Baseline, Weeks 1, 2, and 3, followed by dosing every four weeks starting at Week 4.
89584207|NCT02159053|Experimental|Secukinumab 150 mg s.c. without loading|Secukinumab 150 mg at Baseline, followed by dosing every four weeks starting at Week 4, with Placebo at Weeks 1, 2, and 3.
89584208|NCT02159053|Placebo Comparator|Placebo|Placebo at Baseline, Weeks 1, 2, 3, 4, 8, and 12, followed by dosing with Secukinumab 150 mg every four weeks starting at Week 16.
89584209|NCT02158975|Experimental|MLN9708|MLN9708 4mg by mouth weekly (days 1, 8, 15) every 28 days.
89584210|NCT02158663|Active Comparator|Right slow prefrontal rTMS|Repetitive Transcranial Magnetic Stimulation
89584211|NCT02158663|Active Comparator|Right fast prefrontal rTMS|Repetitive Transcranial Magnetic Stimulation
89584212|NCT04804124|Experimental|Short Sleepers|Reported nightly sleep time of ≤6 hours
89584213|NCT04804124|Experimental|Long Sleepers|Reported nightly sleep time of ≥9 hours
89584214|NCT04804124|Experimental|Average Duration Sleepers|Reported nightly sleep time of 7-8 hours
89584215|NCT02158039|Experimental|Pancreatic Cyst Ethanol Injection|EUS-guided lavage of a pancreatic cyst with ethanol solution. The ethanol solution was diluted to 80% using normal saline. Final solution also contained 1% lidocaine except in patients allergic to local anesthetics. The ethanol solution was injected into pancreatic cysts at a volume equal to 90% of the aspirated cyst volume. In subjects undergoing re-treatment of a cyst, ethanol was diluted to 90% using normal saline, and injected in a volume equal to 100% of the aspirated cyst volume.
89584216|NCT05261282|Experimental|Mindful Hand Hygiene Intervention|"Participants in the Mindful Hand Hygiene Intervention will complete the same surveys as participants in the Control Arm at baseline, post-intervention, and 6-months post-intervention. Data will also be collected on baseline hand-hygiene rates during the habituation period, intervention period, and 3-12 months post-intervention. In addition, intervention participants will be asked to complete 3 mindfulness online educational modules and attend group-facilitated discussions on mindfulness. They will be offered the option of using a mobile application program Mindfulness Coach to enhance their mindfulness practices. A key message of the intervention is using hand hygiene as a prompt to practice mindfulness."
89584217|NCT05261282|No Intervention|Control Arm|Participants that are assigned to the control arm will be observed for hand hygiene adherence and duration during the habituation period, intervention period, and 3-12 months post-intervention. They will also be asked to complete study surveys at baseline, post-intervention and 6-months post intervention. They will not receive any of the intervention components.
89584218|NCT03563222|Experimental|Smoflipid|"Smoflipid is a sterile, nonpyrogenic, white, homogenous lipid emulsion for intravenous infusion. The lipid content of Smoflipid is 0.20 g/mL, and comprises a mixture of soybean oil, medium chain triglycerides, olive oil, and fish oil. Smoflipid is indicated as a source of calories and essential fatty acids for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated.~The mean essential fatty acid content of Smoflipid is 35 mg/mL linoleic acid (omega-6) and 4.5 mg/mL α-linolenic acid (omega-3)."
88974720|NCT00026195|Experimental|irinotecan|"Patients receive irinotecan IV over 90 minutes once weekly for 4 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.~Patients are followed for survival."
88974721|NCT02971592|Experimental|Experimental|
88974722|NCT02971592|Placebo Comparator|Placebo|
89209570|NCT00807716|Experimental|walking skill group|weight-bearing 12 times, 70 minutes
89209571|NCT00807716|Active Comparator|usual physiotherapy care|partial weight-bearing, 12 times, 40 minutes
89584219|NCT03563222|Active Comparator|Intralipid, 20%|Intralipid 20% is a sterile, non-pyrogenic fat emulsion intended as a source of calories and essential fatty acids. Intralipid 20% is indicated as a source of calories and essential fatty acids for patients requiring parenteral nutrition for extended periods of time and as a source of essential fatty acids for prevention of essential fatty acid deficiency. The major component fatty acids are linoleic acid, oleic acid, palmitic acid, α-linolenic acid and stearic acid.
89584220|NCT05239364|Experimental|Standard approach|Patients will receive a standard approach for ablation of atrial tachycardia.
89584221|NCT05239364|Experimental|Minimalized approach|Patients will receive a minimalized approach for ablation of atrial tachycardia.
89584222|NCT04812392|Experimental|Acute Physical Inactivity|Subjects will undergo 3 days of reduced physical activity.
89584223|NCT02490800|Experimental|Drug: BAL101553|Oral daily administration of BAL101553
89584224|NCT01635764|Experimental|Adalimumab Every Week|Adalimumab 40 mg every week.
89584225|NCT05609162||local treatment group vs non-local treatment group|Participants underwent local treatments such as surgical resection or radiotherapy or surgical resection plus radiotherapy were divided into local treatment group or otherwise into non-local treatment group
89584226|NCT05609162||systemic treatment group vs non-systemic treatment group|Participants underwent systemic treatments such as chemotherapy or target therapy or chemotherapy plus target therapy were divided into systemic treatment group or otherwise into non-systemic treatment group
89584227|NCT05609162||local treatment group vs systemic treatment group|Participants underwent local treatments such as surgical resection or radiotherapy or surgical resection plus radiotherapy were divided into local treatment group; Participants underwent systemic treatments such as chemotherapy or target therapy or chemotherapy plus target therapy were divided into systemic treatment group
89584228|NCT05609162||local treatment group vs local treatment+systemic treatment group|Participants underwent local treatments such as surgical resection or radiotherapy or surgical resection plus radiotherapy were divided into local treatment group; Participants underwent local treatment plus systemic treatment were divided into local treatment+systemic treatment group
89584229|NCT05609162||systemic treatment group vs local treatment+systemic treatment group|Participants underwent systemic treatments such as chemotherapy or target therapy or chemotherapy plus target therapy were divided into systemic treatment group; Participants underwent local treatment plus systemic treatment were divided into local treatment+systemic treatment group
89584230|NCT05609162||local treatment+systemic treatment group vs non-local treatment+systemic treatment group|Participants underwent local treatment plus systemic treatment were divided into local treatment+systemic treatment group or otherwise into non-local treatment+systemic treatment group
89584231|NCT05578430|Experimental|TACE+Cadonilimab+Surgery|After appropriate screening and randomization, patients enrolled will receive TACE plus 2-cycle of Cadonilimab treatment before surgery. Four weeks later after surgery, Cadonilimab treatment will be followed up to 16 cycles.
89584232|NCT03432260|Experimental|Part A (Moderate AH) DUR-928 30 mg|Lowest dose of 3 dose escalation arms: 30mg, 90 mg and 150 mg
89584233|NCT03432260|Experimental|Part A (Moderate AH) DUR-928 90 mg|Middle dose of 3 dose escalation arms: 30mg, 90 mg and 150 mg
89584234|NCT03432260|Experimental|Part A (Moderate AH) DUR-928 150 mg|Highest dose of dose escalation arms: 30mg, 90 mg and 150 mg
89584235|NCT03432260|Experimental|Part B (Severe AH) DUR-928 30 mg|Lowest dose of dose escalation arms: 30mg, 90 mg and 150 mg
89584236|NCT03432260|Experimental|Part B (Severe AH) DUR-928 90 mg|Middle dose of dose escalation arms: 30mg, 90 mg and 150 mg
89584237|NCT03432260|Experimental|Part B (Severe AH) DUR-928 150 mg|Highest dose of dose escalation arms: 30mg, 90 mg and 150 mg
89584238|NCT04790162|Active Comparator|Meditation Intervention|Heartfulness meditation
89584239|NCT04790162|No Intervention|Control|Wait listed control group
89584240|NCT03397628|No Intervention|Control|
89584241|NCT03397628|Experimental|Intervention|
88974723|NCT00026234|Experimental|Treatment (chemotherapy)|Patients receive floxuridine and dexamethasone intra-arterially continuously on days 1-14, oxaliplatin IV over 2 hours on day 22, and oral capecitabine twice daily on days 22-35. Treatment repeats every 6 weeks for 4 courses in the absence of disease recurrence or unacceptable toxicity. After completion of the fourth course, patients receive oxaliplatin IV over 2 hours on day 1 and oral capecitabine twice daily on days 1-14. Treatment repeats every 3 weeks for 2 courses in the absence of disease recurrence or unacceptable toxicity.
89209572|NCT00891150|Active Comparator|oxytocin|group 1 will receive oxytocin solutions with 20U/500ml during cesarean section
89584242|NCT05474456|Experimental|SNAGs Group|Group A sustained natural apophyseal glides will be provided to wrestlers in the sitting position. SNAG technique applied on the dorsal side of the neck. The treatment will be given for 6 weeks, 2 sessions per week.
89584243|NCT05474456|Active Comparator|Manipulation Group|group bWrestlers will be treated with high velocity, low amplitude thrust. The treatment will be given for 6 weeks, 2 sessions per week.
89584244|NCT03342014|Experimental|All patients|All patients will have the same intervention (3DPD and UAD acquisitions ; blood sample)
89584245|NCT05228444|Experimental|Circadiancare|limits the circadian impact of hospitalisation by enhancing circadian rhythmicity through an assessment of the patient's specific circadian features/needs and an ad hoc, personalized light-dark, meal and activity schedule to cover the whole of the inpatient stay.
89584246|NCT05228444|No Intervention|Control|
89584247|NCT01634360|Experimental|Perampanel (1-4 mg)|Subjects entered this open-label extension study from the double-blind core study (E2007-E044-204), and dosed placebo or perampanel. Subjects started this open-label extension study on perampanel 1 mg once daily for two weeks, followed by 2 mg once daily for two weeks; if they did not tolerate the 1 mg dose, subjects were withdrawn from the study. Subjects could be up-titrated to 3 or 4 mg in a sequential manner. Subjects could be down-titrated at any time to either 3, 2 or 1 mg in a sequential manner.
89584248|NCT04810598|Experimental|Group 1: Participants With Normal Renal Function|Participants with normal renal function will receive single dose of venetoclax on Day 1.
89584249|NCT04810598|Experimental|Group 2: Participants With End Stage Renal Disease|Participants with end stage renal disease (ESRD) will receive single dose of venetoclax on Period 1 Day 1 and Period 2 Day 1 (Each period is 3 days separated by 7-day washout period).
89584250|NCT04570280|Placebo Comparator|Range of Motion Exercises|The patients in the control group will be given the practice of range of motion exercises for 12 weeks, 3 days a week for 50 minutes (1 day accompanied by a physiotherapist).
89030170|NCT01249131|Experimental|Treatment B first, then Treatment C, followed by Treatment A|Treatment B: Four 5-mg capsules of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in first intervention period. Treatment C: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water within 30 minutes of eating a standard FDA high-fat meal, in second intervention period. Treatment A: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in third intervention period.
89209573|NCT00891150|Active Comparator|oxytocin2|group 2 will receive oxytocin solutions with 30U/500ml during cesarean section
89584251|NCT04570280|Active Comparator|Range of Motion and Resistive Exercises Group|Patients in this group will be given joint range of motion and resistive exercises with sandbag to the lower extremity for 12 weeks, 3 days a week for 50 minutes (1 day in the presence of a physiotherapist). For the exercises with resistance, the repetition maximum will be calculated and the intensity of the exercises will be adjusted in accordance with the DeLorme protocol.
89584252|NCT04570280|Active Comparator|Range of Motion and Aerobic Exercises Group|Joint range of motion exercises and aerobic exercises on the treadmill will be given to the aerobic exercise arm, 3 days a week for 12 weeks (1 day in the presence of a physiotherapist). For aerobic exercises, the maximum heart rate of the patients will be calculated during exercise and the exercise intensity will be determined by increasing the target heart rate level during the exercise.
89584253|NCT04788758|Experimental|Health Services Research (G8 screening tool, referral)|"PHASE I: Registered Nurses receive training on how to administer the G8 screening tool utilizing an Epic flowsheet to patients using a self-directed education module and by direct assessment by a geriatrician.~PHASE II: Patients complete the G8 screening tool questionnaire over 10 minutes as part of their standard initial assessment, and their answers are entered into their EHR flowsheet. Patients who score =< 14 on the G8 are referred for a CGA at SAOC, and these patients and their medical oncologists are made aware. Within 2 weeks of the initial screening, the results are communicated with the patient and medical oncologist at a 2-hour SAOC visit. Patients with a score of > 15 on the G8 are made aware of their results without any referral generated."
89584254|NCT02158052|Experimental|Bone Marrow and Kidney RECIPIENTS|combined bone marrow and kidney transplantation
89584255|NCT02158052|Other|Bone Marrow and Kidney DONORS|Donors who donate bone marrow and kidney
89209574|NCT00891150|Active Comparator|oxytocin3|group 3 will receive oxytocin solutions with 40U/500ml during cesarean section
89584256|NCT01635218|Experimental|Individualized homeopathic treatment|Selection of the individualized homeopathic remedy based on Hahnemann´s methodology after the case history of each patient.
89584257|NCT01635218|Experimental|Fluoxetine|Selective serotonin reuptake inhibitor.
89584258|NCT01635218|Placebo Comparator|Placebo|Fluoxetine placebo plus individualized homeopathic placebo
89584259|NCT05351684|Experimental|Intensified|Group of patients whose treatment will be intensified with an additional 50mg of dolutegravir on top of regular treatment (Triumeq: ABC/3TC/DTG).
89584260|NCT05351684|No Intervention|Control|Group of patients without modification of baseline treatment (Triumeq: ABC/3TC/DTG).
89584261|NCT02049866|Experimental|Denosumab|Denosumab 60mg, administered every 6 months by subcutaneous injection for 36 months.
89584262|NCT05185856|Sham Comparator|Start with: Concentric (normal) cycling|Patients that are allocated to this arm will start with normal cycling
89584263|NCT05185856|Experimental|Start with: Eccentric cycling|Patients that are allocated to this arm will start with eccentric cycling
89584264|NCT04307186|Experimental|Gadobutrol + Gadoquatrane|Participants will receive one intravenous (IV) injection of gadobutrol 0.1 millimole(s) gadolinium/kilogram body weight (mmol Gd/kg bw) and one IV injection of Gadoquatrane (BAY1747846).
89584265|NCT04297826|Experimental|Harvest for Health|The study is a gardening intervention among 150 older cancer survivors and individuals living with chronic disease (cardiovascular disease and diabetes) in the states of Alabama and Mississippi. This program focuses on 15 counties where a Community Health Advisor training program is in place (Bullock, Calhoun, Dallas Madison, Marengo, Monroe, Sumter, Talladega, Walker Counties in Alabama and Boliver, Granada, Humphrey, Panola, Sunflower, and Yazoo Counties in Mississippi). Participants are paired with Cooperative Extension certified Master Gardeners to plant a vegetable garden at their place of residence (the intervention). Baseline, midpoint, and 1 year follow up will occur. Previous pilot work provides an established relationship with the Cooperative Extension as well as training mechanisms for the Master Gardeners.
89584266|NCT04274894|Experimental|AndroGel 1.62%|AndroGel 1.62% was applied topically once daily in the morning beginning at the Day 1 Visit after confirmed valid ambulatory blood pressure monitoring (ABPM) assessment and was applied at approximately the same time each day after that during the study, for approximately 16 weeks. The starting dose of AndroGel 1.62% was 40.5 mg of T (2 pump actuations, applied to the upper arms and shoulders) and was titrated up or down by 20.25 mg or remained the same as assessed by morning serum T levels at Weeks 2 and 4.
89584267|NCT04786964|Experimental|Cosibelimab|Participants receive cosibelimab 1200 mg intravenously (IV) PLUS pemetrexed 500 mg/m^2 IV (with vitamin supplementation) PLUS cisplatin 75 mg/m^2 IV OR carboplatin Area Under the Curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by cosibelimab 1200 mg IV PLUS pemetrexed 500 mg/m^2 IV Q3W until progression.
89209575|NCT00800462|Active Comparator|Oxybutynin Cl|
89209576|NCT00800462|Active Comparator|Trospium Cl|
89209577|NCT00800462|Active Comparator|Darifenacin Hydrogren Bromide (HBr)|
89209578|NCT00884520|Experimental|VM4-037|Approximately sixteen (16) adult subjects including four (4) healthy volunteers and twelve (12) cancer subjects who have confirmed or highly suspected diagnosis of head & neck, lung, large solitary hepatic and renal cell cancer, as defined by protocol criteria
89209579|NCT01326091|No Intervention|Standard Positioning|
89584268|NCT04786964|Active Comparator|Control|Participants receive pemetrexed 500 mg/m^2 IV (with vitamin supplementation) PLUS cisplatin 75 mg/m^2 IV OR carboplatin AUC 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by pemetrexed 500 mg/m^2 IV Q3W until progression.
89584269|NCT05177120||FMF patients|Patients with diagnosed FMF
89584270|NCT02213263|Experimental|PF-05280586|
89584271|NCT02213263|Active Comparator|MabThera®|
89584272|NCT05190068|Experimental|Relapsed/refractory B-NHL|"The starting dose of HMPL-760 is initially set as 50 mg, and then the doses of 100 mg, 200 mg, 300 mg, and 400 mg are escalated successively (this dose gradient is assumed).~HMPL-760 was administered continuously as a single agent orally every day in sequential 28-day cycles."
89584273|NCT04216784|Active Comparator|Furosemide (Lasix) alone|Cohort 1 will receive furosemide (Lasix) 40 to 80 mg IVP BID for at least 48 hours
89584274|NCT04216784|Active Comparator|Combination of furosemide (Lasix) and albumin|Cohort 2 will receive combination of furosemide (Lasix) 40 to 80 mg IVP BID and albumin (25%) 12.5 grams IV BID for at least 48 hours
89584275|NCT02211313|Active Comparator|Ureteral stent - soft, 6 French|Subjects randomized to soft stent, size 6 French
89584276|NCT02211313|Active Comparator|Ureteral stent - hydrophobic, 6 French|Subjects randomized to hydrophobic stent, size 6 French
89584277|NCT04801472|Other|Patients with oral cavity or oropharyngeal squamous cell carcinoma|
89584278|NCT01975064|Active Comparator|Propofol|Propofol for maintenance of anesthesia
89584279|NCT01975064|Active Comparator|Sevoflurane|Sevoflurane for maintenance of anesthesia
89584280|NCT05051696|Experimental|Oncorine (H101) with or without radiotherapy|The tumor mass was injected with H101 per day for 5 consecutive days, 3 weeks as one treatment cycle, and 1 to 4 cycles according to the condition of the patient, and the patient was treated with or without radiotherapy in sequential. The injection dose of H101 was determined by the tumor volume or maximum tumor diameter:5.0×10^11 virus particles(VP) for if tumor diameter≤5cm; 1×10^12 VP for the tumor diameter between 5cm and 10cm, and 1.5×10^12 VP for the tumor diameter>10cm.
89584281|NCT04025138|Experimental|female subjects involved in races over 100 km (F>100)|Female subjects involved in races over 100 km (F>100) will be included. They will have neuromuscular tests in isometric mode, Transcranial Magnetic Stimulation (TMS), neuromuscular fatigue assessment test, treadmill, blood sample and urinary sample.
89584282|NCT04025138|Experimental|female subjects involved in races less than 60 km (F<60)|Female subjects involved in races less than 60 km (F<60) will be included. They will have neuromuscular tests in isometric mode, Transcranial Magnetic Stimulation (TMS), neuromuscular fatigue assessment test, treadmill, blood sample and urinary sample.
89584283|NCT04025138|Experimental|male subjects involved in races over 100 km (H>100)|Male subjects involved in races over 100 km (H>100) will be included. They will have neuromuscular tests in isometric mode, Transcranial Magnetic Stimulation (TMS), neuromuscular fatigue assessment test, treadmill, blood sample and urinary sample.
89584284|NCT04025138|Experimental|male subjects involved in races less than 60 km (H<60)|Male subjects involved in races less than 60 km (H<60) will be included. They will have neuromuscular tests in isometric mode, Transcranial Magnetic Stimulation (TMS), neuromuscular fatigue assessment test, treadmill, blood sample and urinary sample.
89584285|NCT02210689|Experimental|test product|One single-dose, pre-filled disposable applicator delivering approximately 5 g of cream containing approximately 100 mg of clindamycin phosphate vaginal cream 2% (Watson Laboratories, Inc.)
89584286|NCT02210689|Active Comparator|reference product|One single-dose, pre-filled disposable applicator delivering approximately 5 g of cream containing approximately 100 mg of Clindesse® (clindamycin phosphate vaginal cream 2% ) (Ther-Rx™)
89584287|NCT02210689|Placebo Comparator|placebo|One single-dose, pre-filled disposable applicator delivering approximately 5 g of cream containing vehicle of the test product (Watson Laboratories, Inc.)
89584288|NCT04780178|Experimental|TACTICs|Our ACT intervention will include 6 weekly 1-hour telephone sessions and 1 booster session offered 1 month after session 6 designed to increase psychological flexibility through practice of one or more of the six skills in each session. Although these are ideally spaced 1 week apart, participants will have up to 12 weeks to complete the 6 sessions. Each session will include guided mindfulness practice that encourages non-judgmental awareness of the present moment to increase psychological flexibility; brief (10-minute) study-provided audio recordings will enable participants to practice mindfulness at home. Caregivers will also identify deeply-held values to serve as a guide when choosing how to spend limited time or energy and will set values-based action goals each week. A booster session will be provided one month after session 6 to reinforce skills learned.
89584289|NCT04780178|No Intervention|Minimally Enhanced Usual Care|All caregivers randomized to the mEUC group will receive a mailed packet containing 1) a letter from the Co-PIs thanking them for participating, 2) printed selections from of the NIH Alzheimer's caregiving website (https://www.nia.nih.gov/health/alzheimers/caregiving), and 3) a listing of Alzheimer's Association sponsored support groups closest to the caregiver's home address. Caregivers will also receive a brief phone call from the research coordinator to verify receipt of the packet. Since this is a usual care group with a minimally-enhanced component, it will be up to the mEUC participants to decide whether or not to engage with these intervention materials.
89584290|NCT02209597|Experimental|StudyArm|"Subjects will be studied for 28 weeks in a sequential cross-over study: a~Subjects will be studied in 4 phases for a total of approximately 28 weeks:~Phase 1: an approximately 4-week lead-in phase during which participants remain on their existing bupropion product Phases 2 - 4: randomized cross-over phases of approximately 6 weeks on each of the four bupropion study drugs (brand and 3 generics)."
89584291|NCT04418492|Experimental|SAFE intervention|The single group received the SAFE intervention for 10 weeks.
89584292|NCT01469156|Experimental|Ranibizumab 1.0 or 2.0 mg (HIGH DOSE)|"Intraocular injection of 1.0 or 2.0 mg/0.05 cc ranibizumab.~Photodynamic therapy with visudyne or laser photocoagulation or intravitreal steroids may be considered as monotherapy or in combination with Ranibizumab at the investigator's discretion if rescue criteria are met"
89584293|NCT01469156|Active Comparator|Ranibizumab 0.5 mg|"Intraocular injection of 0.5 mg/0.05 cc ranibizumab.~Photodynamic therapy with visudyne or laser photocoagulation or intravitreal steroids may be considered as monotherapy or in combination with Ranibizumab at the investigator's discretion if rescue criteria are met"
89584294|NCT04191434|Experimental|FLAMBOYANT 125/12|"The study is double-dummy. Thus, the participant must inhale 2 (two) capsules twice a day (12/12h), as follow:~1 Flamboyant 125/12 capsule~1 Budesonide/formoterol 200/6 Placebo capsule."
89584295|NCT04191434|Active Comparator|Budesonide/formoterol 200/6|"The study is double-dummy. Thus, the participant must inhale 2 (two) capsules twice a day (12/12h), as follow:~1 Budesonide/formoterol 200/6 capsule~1 Flamboyant 125/12 Placebo capsule."
89584296|NCT03849716||Participants with atopic dermatitis (AD)|Participants included in observational study OBS15333 (atopic dermatitis pediatric registry) who consent to enter this companion study LPS15496. Participants receive AD therapy as part of their usual care as determined by their physician independent of decision to enter either protocol, and neither protocol OBS15333 nor LPS15496 specifies assignment of any drug intervention
89584297|NCT03835676|Experimental|Pulmonary hypertension treated with Treprostinil|Thirty patients who will be treated with Treprostinil.
89584298|NCT04192760|Active Comparator|Culotte Technique|Both vessels have to be wired. Lesion preparation in the main vessel and side branch may be undertaken according to operator preference. After lesion preparation, the side branch has to be stented first. The first stent is placed from main branch into the side branch, covering the entire diseased segment with a wire jailed in the main vessel. The main vessel is rewired through the stent struts, and after removal of the jailed wire, is dilated with a balloon to separate stent struts. The side branch wire is then removed and the main vessel is stented covering the proximal and distal segment. The side-branch is re-wired and high pressure individual inflations are made in each vessel at the bifurcation point to ensure good stent strut separation. Afterwards, a lower pressure kissing inflation is made. Balloon sizing should be in accordance with the diameter of the vessel itself. Finally, a proximal optimization (POT) procedure is performed.
89584299|NCT04192760|Active Comparator|DK-Crush Technique|"Both vessels have to be wired first. Lesion preparation in the main vessel and side branch may be undertaken according to operator preference (rotablation, if needed).~After lesion preparation, the side branch is stented first. Side branch stent should have a small protrusion into the main branch. Before stent implantation in the side branch, an adequately sized balloon should be placed in the main branch, just opposite to the side branch ostium. After stent implantation in the side branch, stent balloon and wire are removed and the balloon in the main branch must be inflated, to crush the struts into the vessel wall. In next step, the new wire should be crossed into the ostium of the side branch and first kissing balloon dilatation will follow. The next step is to implant the second stent into the main branch, followed by second re-wiring, a second kissing balloon-dilatation and final proximal optimization (POT) procedure (single short balloon inflation in proximal segment)."
89584300|NCT00909740|Experimental|1|
89584301|NCT04783532|Experimental|Telehealth Mindfulness Program|Telehealth mindfulness sessions
89584302|NCT04779008|Experimental|Experimental Group 1|Routine treatment + interventions:The patient underwent one RIPC (Four five-minute cycles of upper limb ischaemia and Four five-minute pauses using a blood pressure cuff air vehicle to 200 mmHg) before surgery, then normal surgery, and RIPC was performed on the second day and Once RIPC/day after CABG for one year.
89584303|NCT04779008|Experimental|Experimental Group 2|Routine treatment + interventions:Patients underwent a RIPC before surgery, and then normal medical procedures were performed with no additional intervention.
88974724|NCT00054405|Experimental|Treatment (IL-12, aldesleukin)|"Cohort A: Patients receive interleukin-12 (IL-12) IV over 5-15 seconds on days 1, 3, 5, 8, 10, and 12.~Cohort B: Patients receive interleukin-2 (IL-2) IV over 15 minutes twice daily on days 1 and 8 and IL-12 IV as in cohort A.~Treatment in both cohorts repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Some patients may receive additional courses at the discretion of the principal investigator.~Cohorts of 3-6 patients in both cohorts receive escalating doses of IL-2 and IL-12 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.~Once the MTD is determined, an additional cohort of 8 patients receives IL-12 and IL-2 at the MTD."
88974725|NCT00054444|Experimental|Treatment (topotecan hydrochloride, radiation, cisplatin)|Patients undergo radiotherapy 5 days a week for 6 weeks. Patients receive cisplatin IV and topotecan IV over 30 minutes once weekly for a total of 6 weeks in the absence of disease progression or unacceptable toxicity.
88974726|NCT00054483|Experimental|Treatment (bortezomib)|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
88974727|NCT00026780||Cohort 1|Children and young adults who are being evaluated for protocols within the Pediatric Oncology Branch.
88974728|NCT00027053|Experimental|Trazodone|
88974729|NCT00027053|Placebo Comparator|Placebo|
89584304|NCT04779008|No Intervention|Control group|routine treatment, no RIPC
89584305|NCT02188303|Placebo Comparator|Placebo (Single Dose, Cohorts 1-3)|Single dose of placebo matching LY2944876 administered subcutaneous (SC) on Day 1
89584306|NCT02188303|Experimental|LY2944876 (Single Dose, Cohorts 1-3)|Single dose of 10 milligrams (mg) of LY2944876 administered SC on Day 1
89584307|NCT02188303|Placebo Comparator|Placebo (Multiple Dose, Cohort 4)|Placebo matching LY2944876 administered once daily SC on Days 1-7
89584308|NCT02188303|Experimental|LY2944876 (Multiple Dose, Cohort 4)|40 mg LY2944876 administered once daily SC on Days 1-7
88974730|NCT00027170||Participants with cardiovascular diseases|Patients may receive an intravenous injection of gadobutrol (Gadavist) not to exceed 0.2 mmol/kg of Gd per bolus injection and per examination.
88974731|NCT00027170||Healthy Participants|Patients may receive an intravenous injection of gadobutrol (Gadavist) not to exceed 0.2 mmol/kg of Gd per bolus injection and per examination.
88974732|NCT00055302|Experimental|1|
88974733|NCT00055419|Experimental|400 mg/m2|
88974734|NCT02970240||ME/CFS group|Patients with a verified diagnosis of ME/CFS according to the Canada criteria
88974735|NCT02970240||Fatigue group|Patients with fatigue, but not ME/CFS
88974736|NCT02970240||Control group|Healthy control persons
89584309|NCT02188303|Placebo Comparator|Placebo (Multiple, Cohort 5)|Placebo matching LY2944876 administered once daily SC on Days 1, 4, 6, 8, 10 and 12
89584310|NCT02188303|Experimental|LY2944876 (Multiple Dose, Cohort 5, Titrated)|LY2944876 in titrated doses of 15 mg on Day 1, 30 mg on Day 4, up to 60 mg on Day 6, and up to 80 mg on Days 8, 10 and 12 administered once daily SC
89584311|NCT03651128|Experimental|Arm A - Administration of bb2121|bb2121 autologous CAR T cells will be infused at a dose ranging from 150 - 450 x 10^6 CAR+ T cells after receiving lymphodepleting chemotherapy
89584312|NCT03651128|Experimental|Arm B- standard regimens as per Investigator's discretion|"The participants will receive one of following regimens dependent on the subject's most recent anti-myeloma treatment regimen:~Daratumumab (DARA) in combination with pomalidomide (POM) and low-dose dexamethasone (dex) (DPd) OR~DARA in combination with bortezomib (BTZ) and low-dose dex (DVd) OR~Ixazomib (IXA) in combination with lenalidomide (LEN) and low-dose dex (IRd) OR~Carfilzomib (CFZ) in combination with low-dose dexamethasone (Kd) OR~Elotuzumab (ELO) in combination with POM and low-dose dexamethasone (EPd)"
89209580|NCT01326091|Active Comparator|Hyperlordotic Positioning|Hyperlordotic positioning will be achieved through pelvic pads positioned low on iliac crest to maximize lumbar hyperlordosis and increased hip flexion with as many pillows as tolerated at thighs and knees to allow for increased sacral slope. Regular position will involve the pelvic pads at above or iliac crest and without extra pillows at thighs and legs.
89584313|NCT00664898|Experimental|1|
89584314|NCT04867382|Experimental|Intervention|This arm received a case-based training on how to use the Opioid Wizard tool, including patient narratives and videos and person-first language.
89584315|NCT04867382|Placebo Comparator|Comparison training|This arm received a case-based training on how to use the Opioid Wizard tool.
89584316|NCT04418336|Active Comparator|Endoscopic Pilonidal sinus treatment (EPSIT)|Endoscopic Pilonidal sinus treatment (EPSIT)
89209581|NCT02543190|Experimental|compliance surveillance|"Prospective audits by study personnel~Call from the clinic nurse practitioner or physician's assistant within 7 days of discharge to administer a screening questionnaire to identify patients at risk of dehydration. Study personnel will ensure this phone call is made."
89209582|NCT02543190|No Intervention|Usual Care|educational session at the start of the study
88974737|NCT00027599|Experimental|Arm I|Autologous dendritic cells (DCs) are harvested and pulsed with prostatic acid phosphatase-sargramostim fusion protein to produce APC8015 (Provenge). Patients receive APC8015 IV over 30 minutes and bevacizumab IV over 30-60 minutes on day 1. Treatment repeats every 14 days for 3 courses. Patients continue to receive bevacizumab alone every 14 days in the absence of disease progression or unacceptable toxicity.
89209583|NCT03973801|Experimental|Auricular acupressure|
89209584|NCT00887094|Experimental|Aerobic exercise|One bout of aerobic physical training will be performed on a cycle ergometer for 50 min
89209585|NCT00887094|Experimental|Aerobic-resistance exercise|One bout of aerobic-resistance physical training will be performed on a cycle ergometer added by a strenght training for 50 min (total)
89209586|NCT00811772|Active Comparator|Bare metal stent|Implantation of one or more bare metal stent(s) to to treat coronary artery stenosis
89209587|NCT00811772|Experimental|Drug eluting stent|Implantation of one or more drug eluting stent(s) to treat coronary artery stenosis
89209588|NCT02542878|Experimental|FOAM ROLLER|"Treatment with foam roller will be applied for 60 seconds to this group. Subjetc lye in supine position over the foam roller placed on back muscle extensors. Then, they must slide the body on the device, from postero-superior iliac spine to the dorsal zone.~A brief explanation of this self-application will be showed prior the intervention."
89209589|NCT02542878|Placebo Comparator|PLACEBO|An intervention similar (position and time) to the experimental group will be done, but the used device will be a very soft roller not compressing the contact zone.
89209590|NCT02552264|Active Comparator|Immediate intervention|Acceptance and Commitment Therapy
89209591|NCT02552264|Placebo Comparator|Waitlist control|Acceptance and Commitment Therapy
89209592|NCT00891306|Experimental|Treatment arm|Gene Therapy
89584317|NCT04418336|Active Comparator|Sinus Laser Closure (SiLaC)|Sinus Laser Closure (SiLaC)
89584318|NCT04418336|Active Comparator|lay open technique|lay open technique
89584319|NCT04776980|Experimental|Ferumoxytol Infused MRI|Ferumoxytol is an iron replacement product that is FDA approved to treat iron deficiency anemia in patients with chronic kidney disease (CKD). In this study, ferumoxytol is used to quantify tumor-associated macrophages. The infused dose would be 5mg/kg.
89584320|NCT02187055|Experimental|Tofacitinib 5 mg twice daily with methotrexate|
89584321|NCT02187055|Experimental|Tofacitinib 5 mg twice daily monotherapy|
89584322|NCT02187055|Active Comparator|Adalimumab with methotrexate|
89584323|NCT00119366|Experimental|Dose Level 1: 12 Gy iodine-131 monoclonal antibody BC8|"RADIOIMMUNOTHERAPY: Patients receive therapeutic iodine I 131 monoclonal antibody BC8 IV on day -12.~CONDITIONING: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.~TRANSPLANTATION: After completion of TBI, patients undergo allogeneic PBSC transplant on day 0.~IMMUNOSUPPRESSION: Patients with a matched related donor receive cyclosporine IV or PO BID on days -3 to 56 followed by a taper to day 180 in the absence of graft-versus-host disease. Beginning 4-6 hours after PBSC transplant, these patients also receive mycophenolate mofetil PO 2 BID on days 0 to 27. Patients with a matched unrelated donor receive cyclosporine IV or PO BID on days -3 to 100 followed by a taper to day 180. Beginning 4-6 hours after PBSC transplant, these patients also receive mycophenolate mofetil PO TID on days 0 to 40 followed by a taper to day 96."
89584324|NCT00119366|Experimental|Dose Level 7: 22 Gy iodine-131 monoclonal antibody BC8|"RADIOIMMUNOTHERAPY: Patients receive therapeutic iodine I 131 monoclonal antibody BC8 IV on day -12.~CONDITIONING: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.~TRANSPLANTATION: After completion of TBI, patients undergo allogeneic PBSC transplant on day 0.~IMMUNOSUPPRESSION: Patients with a matched related donor receive cyclosporine IV or PO BID on days -3 to 56 followed by a taper to day 180 in the absence of graft-versus-host disease. Beginning 4-6 hours after PBSC transplant, these patients also receive mycophenolate mofetil PO 2 BID on days 0 to 27. Patients with a matched unrelated donor receive cyclosporine IV or PO BID on days -3 to 100 followed by a taper to day 180. Beginning 4-6 hours after PBSC transplant, these patients also receive mycophenolate mofetil PO TID on days 0 to 40 followed by a taper to day 96."
89584325|NCT00119366|Experimental|Dose Level 8: 24 Gy iodine-131 monoclonal antibody BC8|"RADIOIMMUNOTHERAPY: Patients receive therapeutic iodine I 131 monoclonal antibody BC8 IV on day -12.~CONDITIONING: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.~TRANSPLANTATION: After completion of TBI, patients undergo allogeneic PBSC transplant on day 0.~IMMUNOSUPPRESSION: Patients with a matched related donor receive cyclosporine IV or PO BID on days -3 to 56 followed by a taper to day 180 in the absence of graft-versus-host disease. Beginning 4-6 hours after PBSC transplant, these patients also receive mycophenolate mofetil PO 2 BID on days 0 to 27. Patients with a matched unrelated donor receive cyclosporine IV or PO BID on days -3 to 100 followed by a taper to day 180. Beginning 4-6 hours after PBSC transplant, these patients also receive mycophenolate mofetil PO TID on days 0 to 40 followed by a taper to day 96."
89584326|NCT00119366|Experimental|Dose Level 9: 26 Gy iodine-131 monoclonal antibody BC8|"RADIOIMMUNOTHERAPY: Patients receive therapeutic iodine I 131 monoclonal antibody BC8 IV on day -12.~CONDITIONING: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.~TRANSPLANTATION: After completion of TBI, patients undergo allogeneic PBSC transplant on day 0.~IMMUNOSUPPRESSION: Patients with a matched related donor receive cyclosporine IV or PO BID on days -3 to 56 followed by a taper to day 180 in the absence of graft-versus-host disease. Beginning 4-6 hours after PBSC transplant, these patients also receive mycophenolate mofetil PO 2 BID on days 0 to 27. Patients with a matched unrelated donor receive cyclosporine IV or PO BID on days -3 to 100 followed by a taper to day 180. Beginning 4-6 hours after PBSC transplant, these patients also receive mycophenolate mofetil PO TID on days 0 to 40 followed by a taper to day 96."
89584327|NCT00119366|Experimental|Dose Level 10: 28 Gy iodine-131 monoclonal antibody BC8|"RADIOIMMUNOTHERAPY: Patients receive therapeutic iodine I 131 monoclonal antibody BC8 IV on day -12.~CONDITIONING: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.~TRANSPLANTATION: After completion of TBI, patients undergo allogeneic PBSC transplant on day 0.~IMMUNOSUPPRESSION: Patients with a matched related donor receive cyclosporine IV or PO BID on days -3 to 56 followed by a taper to day 180 in the absence of graft-versus-host disease. Beginning 4-6 hours after PBSC transplant, these patients also receive mycophenolate mofetil PO 2 BID on days 0 to 27. Patients with a matched unrelated donor receive cyclosporine IV or PO BID on days -3 to 100 followed by a taper to day 180. Beginning 4-6 hours after PBSC transplant, these patients also receive mycophenolate mofetil PO TID on days 0 to 40 followed by a taper to day 96."
89584328|NCT02246660|Active Comparator|Resveratrol - 500 mg/day|The dose of Resveratrol will be 500 mg daily for six months. Resveratrol is taken orally. Resveratrol is a natural plant derivative.
89584329|NCT02246660|Active Comparator|Resveratrol - 125 mg/day|The dose of Resveratrol will be 125 mg daily for six months. Resveratrol is taken orally. Resveratrol is a natural plant derivative.
89584330|NCT02246660|Placebo Comparator|Placebo|Placebo will be taken orally for 6 months.
89584331|NCT04750447||Open Angle Glaucoma|Patients aged 30-90 Primary open angle glaucoma on maximum tolerated medical therapy Going to receive XEN63 ab interno gelatin stent with or without MMC in study eye ± cataract surgery
89584332|NCT03475550|Active Comparator|Standard of care 1|"Patients will receive one of 2 different descriptions of the medication's risks and benefits. Both descriptions meet ethical standards of transparency and respect for person and are commonly used but have never been compared. Standard of Care 1 includes more details than Standard of Care 2."
89584333|NCT03475550|Active Comparator|Standard of care 2|"Patients will receive one of 2 different descriptions of the medication's risks and benefits. Both descriptions meet ethical standards of transparency and respect for person and are commonly used but have never been compared. Standard of Care 2 includes fewer details than Standard of Care 1."
89584334|NCT02246582|Other|Group A|Subjects underwent FST at 30 mins, 50 hrs and 146 hrs from Enlite 3 Sensors connected to GST3C, GST4C Transmitter, and GSR
89584335|NCT02246582|Other|Group B|Subjects underwent FST at 14 hrs, 62 hrs and 158 hrs from Enlite 3 Sensors connected to GST3C, GST4C Transmitter, and GSR
89584336|NCT02137369|Active Comparator|SSRI|Escitalopram, pill form, 20mg-40mg, daily, for 12 weeks or Sertraline, pill form, 50 - 150 mg, daily for 12 weeks
89584337|NCT02137369|Active Comparator|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) CBT will include 16 1-hour sessions provided over 12 weeks.
89584338|NCT02155309|Experimental|Scopolamine|0.2 mg intranasal scopolamine, single dose
89584339|NCT02155309|Placebo Comparator|Placebo|placebo intranasal (0.1 mg per nostril), single dose
88974738|NCT00055770|Experimental|Arm I|"PHASE I: Patients receive oral erlotinib once daily on days 1-28 and docetaxel IV over 1 hour on days 8, 15, and 22. Treatment repeats every 28 days for a total of 6 courses in the absence of disease progression or unacceptable toxicity.~Patients receive escalating doses of erlotinib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, an additional cohort of 6 patients receives erlotinib at the MTD.~PHASE II: Patients receive erlotinib at the MTD and docetaxel as in phase I."
88974739|NCT00055809|Experimental|Arm I (bevacizumab)|Patients receive bevacizumab IV on day 1.
89584340|NCT02186821|Experimental|Ceritinib 750 mg|Ceritinib was dosed on a flat scale of 750 mg (e.g., 5 x 150 mg capsules) orally, once daily, on a continuous dosing cycle. A complete treatment cycle was defined as 28 days with no breaks between dosing cycles.
89584341|NCT01710358|Placebo Comparator|Placebo|"Placebo administered orally once daily through Week 24 and placebo administered by subcutaneous (SC) injection every 2 weeks through Week 50.~At Week 24, participants were given baricitinib 4 milligram (mg) orally once daily through Week 52.~Starting at Week 16, participants who were nonresponders were rescued with baricitinib 4 mg orally daily through Week 52.~Participants continued to take background methotrexate (MTX) therapy throughout study."
89584342|NCT01710358|Experimental|Baricitinib|"Baricitinib 4 mg administered orally once daily through Week 52 and an adalimumab placebo SC injection every 2 weeks through Week 50.~Starting at Week 16, nonresponder participants originally randomized to baricitinib continued to receive baricitinib 4 mg administered orally once daily through Week 52.~Participants continued to take background methotrexate (MTX) therapy throughout study."
89584343|NCT01710358|Active Comparator|Adalimumab|"Adalimumab 40 mg administered by SC injection every 2 weeks through Week 50 and baricitinib placebo orally once daily through Week 52.~Starting at Week 16, participants who were nonresponders were rescued with baricitinib 4 mg orally once daily through Week 52.~Participants continued to take background methotrexate (MTX) therapy throughout study."
89584344|NCT01633112|Experimental|fingolimod 0.5 mg|orally once daily
89584345|NCT01633112|Experimental|fingolimod 0.25mg|orally once daily
89584346|NCT01633112|Active Comparator|glatiramer acetate 20 mg|subcutaneous once daily
89584347|NCT03455270|Experimental|Part 1: Dose Escalation (G1T48)|"Patients in Part 1 will receive a single oral dose of G1T48 on Cycle 1 Day -3 and will begin once-daily dosing on Cycle 1 Day 1.~The initial dose cohort shall receive an identified starting dose and subsequent cohorts shall receive higher doses based on the safety and PK data obtained from the previous dose levels."
89584348|NCT03455270|Experimental|Part 1: Food Effect Cohort (G1T48)|"In Part 1, additional G1T48 cohort(s) of 8 patients may be enrolled to assess the effect of different fat content meals (eg, high fat, moderate fat, or low-fat) on the rate and extent of the absorption of G1T48.~Patients will receive a single oral dose of G1T48 on Cycle 1 Day -10 and on Cycle 1 Day -3. Patients will begin G1T48 once-daily dosing on Cycle 1 Day 1."
89584349|NCT03455270|Experimental|Part 2: Monotherapy Dose Expansion (G1T48)|Patients in Part 2 will receive G1T48 once-daily at the dose determined in Part 1.
89584350|NCT03455270|Experimental|Part 3: Combination Dose Expansion (G1T48+palbociclib)|Patients in Part 3 will receive G1T48 once-daily at the dose determined in Part 2 in combination with palbociclib once-daily on Days 1 to 21 of each 28-day cycle.
89209593|NCT02552108|Experimental|Behavioural experiments (CBT)|"Behavioural experiments involve selecting a specific thought to be tested (e.g., uncertainty makes me unable to act) and designing a detailed experiment to test out the thought."
89584351|NCT01691482|Active Comparator|Albuterol/salbutamol followed by ipratropium|Subjects will recieve daily albuterol/salbutamol followed by ipratropium which will be adminstered one hour after adminstration of albuterol/salbutamol
89584352|NCT01691482|Active Comparator|Ipratropium followed by albuterol/salbutamol|Subjects will recieve daily ipratropium followed by albuterol/salbutamol which will be adminstered one hour after adminstration of ipratropium
89584353|NCT04776044|Experimental|ATR-002|Participants will receive 900mg ATR-002 on day 1 (6 tablets with 150mg ATR-002; once daily), and 600mg ATR-002 on days 2 - 6 (4 tablets; once daily)
89584354|NCT04776044|Placebo Comparator|Placebo|Participants will receive matching tablets placebo on day 1 (6 tablets, once daily), and matching tablets placebo on days 2 - 6 (4 tablets per day, once daily)
89584355|NCT02246114|Experimental|no CO monitor|Not given a piCO+ Smokerlyzer® monitor, will receive daily text messages.
89584356|NCT02246114|Experimental|CO monitor|Given a piCO+ Smokerlyzer® monitor, will receive daily text messages, will receive feedback about the relative level of carbon monoxide.
89209594|NCT02552108|No Intervention|Waiting list|12 week wait (with assessments) before being transferred to the experimental condition.
89584357|NCT01710046|Experimental|Cohort 1|
89584358|NCT01710046|Experimental|Cohort 2|
89584359|NCT03267758|Experimental|Goodbelly First|Subjects in this arm will consume 1 serving of lactobacillus plantarum 299v daily for first 6 weeks.
88974740|NCT00055809|Experimental|Arm II (PEG-interferon alfa-2b)|Patients receive PEG-interferon alfa-2b SC on days 1, 8, and 15.
88974741|NCT00055848||Group 1|"Patients donate blood samples for analysis of colorectal susceptibility genes. Patients also complete a questionnaire regarding family cancer history.~A certificate of confidentiality protecting the identity of research participants in this project has been issued by the National Cancer Institute.~Participants do not receive the results of the genetic testing, and the results do not influence the type or duration of treatment."
89209595|NCT00812084||CAP cohort|Includes cases that were hospitalized because of a community-acquired pneumonia during the study period, and for which we had a baseline EQ-5D score from the start of the study period. These CAP cases are prospectively followed for up to one year using questionnaires for health status and (health) resources.
89209596|NCT00812084||Controls cohort|For each CAP cases, two controls are matched based on age, sex and baseline EQ-5D score measured at the start of the study. These controls are prospectively followed for up to one year using questionnaires for health status and (health) resources.
89209597|NCT00807794|Experimental|1|MEDI-507
89209598|NCT00807794|Experimental|2|MEDI-507
89209599|NCT00807794|Experimental|3|MEDI-507
89209600|NCT00807794|Experimental|4|MEDI-507
89584360|NCT03267758|Placebo Comparator|Placebo|Subjects in this arm will consume 1 serving of heat-killed placebo daily for first 6 weeks.
89584361|NCT04633616|Experimental|Tailored Delivery of Education|Communication will be tailored as the mode of weblink delivery will be customized to patient preference.
89584362|NCT04633616|Placebo Comparator|Non-tailored Delivery of Education|Communication will be non-tailored such that patients will not be able to choose their preferred mode of communication and will receive hardcopy.
89584363|NCT02154529|Experimental|Arm 1: Tesevatinib 150 mg PO QD + Trastuzumab 8 mg/kg IV|Tesevatinib in combination with Trastuzumab: tesevatinib 150 mg PO QD in combination with trastuzumab 8 mg/kg IV initially then 6 mg/kg IV every 3 weeks thereafter.
89584364|NCT02154529|Experimental|Arm 2: Tesevatinib 250 mg PO QD + Trastuzumab 8 mg/kg IV|Tesevatinib in combination with Trastuzumab: tesevatinib 250 mg PO QD in combination with trastuzumab 8 mg/kg IV initially then 6 mg/kg IV every 3 weeks thereafter.
89584365|NCT02154529|Experimental|Arm 3: Tesevatinib 300 mg PO QD + Trastuzumab 8 mg/kg IV|Tesevatinib in combination with Trastuzumab: tesevatinib 300 mg PO QD in combination with trastuzumab 8 mg/kg IV initially then 6 mg/kg IV every 3 weeks thereafter.
89584366|NCT02154529|Experimental|Arm 4: Tesevatinib 350 mg PO QD + Trastuzumab 8 mg/kg IV|Tesevatinib in combination with Trastuzumab: tesevatinib 350 mg PO QD in combination with trastuzumab 8 mg/kg IV initially then 6 mg/kg IV every 3 weeks thereafter.
89584367|NCT01954017|Experimental|STP206|Biological
89584368|NCT01954017|Placebo Comparator|Control|Sterile water
89584369|NCT02154139||leuprorelin acetate|Subcutaneous administration of leuprorelin acetate once every 12 weeks
89584370|NCT02245568|Experimental|LMTM|
89584371|NCT02154061|Experimental|IIV Flu Vaccine with Antibiotics|This arm will receive antibiotics prior and after IIV administration.
89584372|NCT02154061|Active Comparator|IIV Flu Vaccine|This arm will not take antibiotics in conjunction with IIV.
89584373|NCT01907217|Active Comparator|Bilateral ECT Mecta 5000M|Modified bilateral ECT (bitemporal electrode positions) twice weekly at 1.5 times the seizure threshold. Methohexitone (0.75-1.0 mg/kg) is used for anaesthesia with suxamethonium (0.5-1.0mg/kg) for muscle relaxation.
89584374|NCT01907217|Experimental|High-dose unilateral ECT Mecta 5000M|High-dose right modified unilateral ECT twice weekly at 6 times the seizure threshold. Methohexitone (0.75-1.0 mg/kg) is used for anaesthesia with suxamethonium (0.5-1.0mg/kg) for muscle relaxation.
89584375|NCT01953783|Experimental|IXAZOMIB|"Part A: Participants will receive a single dose of 4.1-milligram (mg) [14C]-IXAZOMIB oral solution containing approximately 500-nCurie (nCi) of total radioactivity on Day 1 and remain at the clinic for 8 days. On Days 14 and 21, participants may be administered a single 4.0-mg capsule of IXAZOMIB. Participants will return to the clinic in the evening before Days 14, 21, 28, and 35 for a 24-hour overnight clinic visit.~Part B: Eligible participants from Part A may continue into Part B once they have completed their Day 35 assessments in Part A. Participants may receive IXAZOMIB capsules administered orally at a dose of 4.0-mg once weekly on Days 1, 8, and 15 of 28-day cycles. Participants will continue in this study until disease progression or unacceptable toxicity."
89584376|NCT04416009||mild pneumonia ECW|the covid 19 pneumonia patients who hospitalised to the ward
89584377|NCT04416009||severe pneumonia ECW|the covid 19 pneumonia patients who hospitalised to the intensive care unit
89584378|NCT02134015|Experimental|Placebo + erlotinib|Placebo infusion every 3 weeks and oral erlotinib 150 mg/day
89584379|NCT02134015|Experimental|Patritumab + erlotinib|Infusion of Patritumab (loading dose of 18 mg/kg, followed by 9 mg/kg every 3 weeks) and oral erlotinib 150 mg/day
89584380|NCT04411485||Group of Ankylosing Spondylitis|Patient with ankylosing spondylitis diagnosed by a rheumatologist
89584381|NCT04411485||Group of control|Healthy volunteers of the same age and gender as patients
89584382|NCT04619979||preoperative anxiety group|
89584383|NCT04619979||Non-preoperative anxiety group|
89584384|NCT01924845|Experimental|BMN 701 20 mg/kg|BMN 701 IV Infusion 20mg/kg every 2 weeks for 24 weeks followed by an optional extension of 240 weeks (total duration of therapy 264 weeks)
89584385|NCT01630135|Experimental|GW685698X|GW685698X 55mcg/day
89584386|NCT01630135|Placebo Comparator|Placebo|Placebo
89584387|NCT01691248|Active Comparator|Fidaxomicin|200 mg Fidaxomicin tablet once daily for no longer than 40 days
89584388|NCT01691248|Placebo Comparator|Placebo|Placebo tablet once daily for no longer than 40 days
89584389|NCT01924767|Experimental|BI 10773 (dose group 3)|multiple doses as tablet
89584390|NCT01924767|Experimental|BI 10773 (dose group 4)|multiple doses as tablet
89584391|NCT01924767|Experimental|BI 10773 (dose group 1)|multiple doses as tablet
89584392|NCT01924767|Experimental|BI 10773 (dose group 2)|multiple doses as tablet
89584393|NCT01691092|Experimental|Ketamine|All subjects will receive ketamine
89584394|NCT02133001|Experimental|Esketamine|Esketamine hydrochloride solution (containing 14 milligram (mg) of esketamine base per 100 microliter [mcl] of intranasal spray) will be administered by intranasal route using nasal spray pump as two times a week, for 4 weeks. Dose may be reduced to 56 mg per day based on Investigator's discretion.
89584395|NCT02133001|Placebo Comparator|Placebo|Matching Placebo solution will be administered by intranasal route using nasal spray pump as two times a week, for 4 weeks.
89584396|NCT01709578|Placebo Comparator|Placebo q2w|Placebo matched to sarilumab once every 2 weeks (q2w) was added to one or a combination of the nonbiologic DMARD (hydroxychloroquine, methotrexate, sulfasalazine and/or Leflunomide), except for simultaneous combination use of leflunomide and methotrexate for 24 weeks.
89584397|NCT01709578|Experimental|Sarilumab 150 mg q2w|Sarilumab 150 mg q2w was added to one or a combination of the nonbiologic DMARD (hydroxychloroquine, methotrexate, sulfasalazine and/or Leflunomide), except for simultaneous combination use of leflunomide and methotrexate for 24 weeks.
89584398|NCT01709578|Experimental|Sarilumab 200 mg q2w|Sarilumab 200 mg q2w was added to one or a combination of the nonbiologic DMARD (hydroxychloroquine, methotrexate, sulfasalazine and/or Leflunomide), except for simultaneous combination use of leflunomide and methotrexate for 24 weeks.
89584399|NCT02132767|Active Comparator|Rhythm control|"Rhythm Control in post-operative AF~Amiodarone and/or DC-cardioversion~Amiodarone Initial Dose~Oral: 400 mg po TID for 3 days is recommended~For patients incapable of taking oral: 150 mg IV bolus over 10 min, then 1 mg/min over 6 hours followed by 0.5 mg/min over 18 hours Maintenance Dose~Oral: at least 200 mg/day to be continued until 60 days after randomization~If drug cannot be given orally or via NG tube: 0.5 mg/min administered through central line (e.g., PICC) until oral dosing is started~DC-Cardioversion - frequency and duration determined by medical professional as medically needed"
89584400|NCT02132767|Active Comparator|Rate control|"Rate Control in post-operative AF~Beta-blocker and/or Calcium channel blockers and/or Digoxin~Dose, frequency and duration determined by medical professional as medically needed"
89584401|NCT02153905|Experimental|Phase 1 - Dose Escalation/De-Escalation|Non-myeloablative lymphodepleting preparative regimen of cyclophosphamide and fludarabine + MAGE-A3- A1 transduced peripheral blood lymphocytes (PBL) + high-dose aldesleukin
89584402|NCT02153905|Experimental|Phase II - Maximum Tolerated Dose|Non-myeloablative lymphodepleting preparative regimen of cyclophosphamide and fludarabine + MAGE-A3- A1 transduced peripheral blood lymphocytes (PBL) + high-dose aldesleukin
89584403|NCT02153827|Experimental|Eccentric External rotator training|Eccentric Shoulder External Rotators along with scapular retraction and posterior shoulder stretching exercises.
89584404|NCT02153827|Sham Comparator|General shoulder exercise|General shoulder exercise protocol of active flexion, abduction, scapular retraction and posterior shoulder stretching exercises.
89584405|NCT04752631|Experimental|TNK-tPA|TNK-tPA (0.25mg/kg) given as a single bolus over 5-10 seconds immediately upon randomization.
89584406|NCT04752631|No Intervention|Routine Therapy|Patients will be treated with standard of care in compliance with guidelines for acute stroke
89584407|NCT02153359|Experimental|Air cleaner then sham air cleaner|A High Efficiency Particulate Air Cleaner (HEPA) intervention will be placed in the participant's home for one month. During the last week of the month, health assessments will be conducted, which include in-home health questionnaires, symptom-, and activity- diaries/recalls, blood, and hand-held spirometry. Participants will also be asked to wear a light backpack with air monitoring devices during the course of the day during the last week in order to measure participants' exposures to pollutants. Finally, at the end of the month, participants will be asked to report to the Johns Hopkins outpatient endoscopy suite for bronchoscopy, during which airway sampling will occur under conscious sedation. For the participants who started in the experimental arm, after this one month intervention period, they will then enter a wash-out period where no intervention or outcome measures are undertaken for at least one month prior to cross-over to the sham comparator arm.
89584408|NCT02153359|Sham Comparator|Sham air cleaner then air cleaner|A sham air cleaner will be placed in the participant's home for one month. During the last week of the month, health assessments will be conducted, which include in-home health questionnaires, symptom-, and activity- diaries/recalls, blood, and hand-held spirometry. Participants will also be asked to wear a light backpack with air monitoring devices during the course of the day during the last week in order to measure participants' exposures to pollutants. Finally, at the end of the month, participants will be asked to report to the Johns Hopkins outpatient endoscopy suite for bronchoscopy, during which airway sampling will occur under conscious sedation. For the participants who started in the sham comparator arm, after this one month intervention period, they will then enter a wash-out period where no intervention or outcome measures are undertaken for at least one month prior to cross-over to the experimental arm.
89584409|NCT01691014||adalimumab|
89584410|NCT01691014||Etanercept|
89584411|NCT01691014||infliximab|
89584412|NCT01691014||Certolizumab|
89584413|NCT02245412|Experimental|ALXN1007 10 mg/kg once weekly|Cohort 1, the first dosing cohort, received 10 mg/kg ALXN1007 IV once weekly for 8 weeks.
89584414|NCT02245412|Experimental|ALXN1007 20 mg/kg once weekly|Cohort 2 received 20 mg/kg ALXN1007 IV once weekly for 8 weeks. For the first 2 participants enrolled, the first ALXN1007 dose was not to be administered on the same day and a safety and tolerability review was to take place after the second (and prior to the third) ALXN1007 dose for each participant. If the ALXN1007 dose was determined to be sufficiently tolerated by the participant, dosing was to continue for that participant. For any other participants enrolled in the dosing cohort, participants were not to proceed to the third ALXN1007 dose prior to the completion of the safety and tolerability review (of the first 2 doses) for the first 2 participants.
89584415|NCT02245412|Experimental|ALXN1007 20 mg/kg twice weekly|Cohort 3 received 20 mg/kg ALXN1007 IV twice weekly for 8 weeks. For the first 2 participants enrolled, the first ALXN1007 dose was not to be administered on the same day and a safety and tolerability review was to take place after the second (and prior to the third) ALXN1007 dose for each participant. If the ALXN1007 dose was determined to be sufficiently tolerated by the participant, dosing was to continue for that participant. For any other participants enrolled in the dosing cohort, participants were not to proceed to the third ALXN1007 dose prior to the completion of the safety and tolerability review (of the first 2 doses) for the first 2 participants.
89584416|NCT02244944|Experimental|EZ-URSO Combination Therapy|Ursodiol (URSO Forte) 13-15 mg per kg (250-500 mg b.i.d. or t.i.d depending on body weight) combined with Ezetimibe (Zetia) 10 mg o.p.d.
89584417|NCT01689532|Experimental|Sirukumab 100 mg|
89584418|NCT01689532|Experimental|Sirukumab 50 mg and Placebo|
89584419|NCT01924689|Experimental|Clostridium novyi-NT spores|
89584420|NCT01591330|Experimental|LY2140023 Reference Form|LY2140023: 80 mg, administered once, orally. There is a minimum 3-day washout period between dosing in one period and dosing in the next dosing period.
88974742|NCT00027872|Experimental|Treatment (tipifarnib)|Patients receive oral tipifarnib twice daily on days 1-21. Patients with a complete or partial response, hematologic improvement, or stable disease continue treatment every 29-63 days in the absence of disease progression or unacceptable toxicity. Patients with a complete response after the second course of therapy receive 2 additional courses of therapy.
88974743|NCT02970201|Other|Period I EpxDialysis (SMS Messaging)|SMS Messaging arm receives the intervention (EpxDialysis) first, then resumes standard of care at crossover (8 weeks).
88974744|NCT02970201|Other|Period II EpxDialysis (Control)|Control arm receives standard of care first, then receives the intervention (EpxDialysis) at crossover.
88974745|NCT02969967|Experimental|SaeboFlex|Use of the SaeboFlex orthosis for a set protocol of grasp-release activities
88974746|NCT00028028|Experimental|Arm I|Patients receive low-dose CCI-779 IV over 30 minutes once weekly. Treatment continues in the absence of disease progression or unacceptable toxicity.
88974747|NCT00028028|Experimental|Arm II|Patients receive high-dose CCI-779 as in arm I.
88974748|NCT04730817|Experimental|Intervention group|This arm will undertake VR simultaneous motor-cognitive training in 30 minutes session, twice a week for 8 weeks.
88974749|NCT04730817|No Intervention|Control group|This arm will not be given any kind of treatment and will act as a passive control group.
88974750|NCT00056082|Experimental|Celecoxib 400 mg bid|Celecoxib 400 mg bid
88974751|NCT00028145||1|Pregnant, HIV-infected women
88974752|NCT01349790|Experimental|NewGam|Each participant received 1 g/kg NewGam intravenously on 2 consecutive days.
88974753|NCT04730973|Active Comparator|Evolocumab|Subcutaneous evolocumab 140 mg will be administered every 2 weeks on top of optimal lipid-lowering therapy
88974754|NCT04730973|Placebo Comparator|Standard|No further treatment besides optimal lipid-lowering therapy will be administered
89209601|NCT00807794|Experimental|5|MEDI-507
89584421|NCT01591330|Experimental|LY2140023 Test-Low|LY2140023: 80 mg, low particle size, administered once, orally. There is a minimum 3-day washout period between dosing in one period and dosing in the next dosing period.
89584422|NCT01591330|Experimental|LY2140023 Test-Medium|LY2140023: 80 mg, medium particle size, administered once, orally. There is a minimum 3-day washout period between dosing in one period and dosing in the next dosing period.
89584423|NCT01591330|Experimental|LY2140023 Test-High|LY2140023: 80 mg, high particle size, administered once, orally. There is a minimum 3-day washout period between dosing in one period and dosing in the next dosing period.
89584424|NCT01591096|Experimental|Tissue plasminogen activator|All patients will receive study drug.
89584425|NCT01953003|Experimental|Arm A : iv vinflunine plus Capecitabine|Vinflunine dose 280 mg/m² on day 1 of each cycle every 3 weeks, Capecitabine 825 mg/m² twice daily orally for 14 consecutive days beginning on day 1 of each cycle followed by 1 week of rest.
89584426|NCT01953003|Active Comparator|capecitabineArm B : capecitabine|1250 mg/m² twice daily orally for 14 consecutive days beginning on day 1 of each cycle followed by 1 week of rest
89584427|NCT01952691|Experimental|kinesiotaping|all patients were implemented a kinesiotaping to align the hallux to correct position
89584428|NCT01709500|Experimental|Alirocumab 75 mg/up to 150 mg|Alirocumab 75 mg every two weeks (Q2W) added to stable dose of statin with or without LMT for 78 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when LDL-C levels ≥70 mg/dL at Week 8.
89584429|NCT01709500|Placebo Comparator|Placebo|Placebo matched to alirocumab SC injection for 78-week treatment duration.
89584430|NCT01599806|Experimental|Ceftazidime - Avibactam ( CAZ-AVI)|IV treatment
89584431|NCT01599806|Active Comparator|Doripenem|IV treatment
89584432|NCT01599325|Experimental|Azacitidine|Azacitidine 75 mg/m^2/day subcutaneously (SC) for 7 days every 28 days until disease progression (DP), adverse events (AE), withdrawal of consent from further treatment, withdrawal of consent, death, lost to follow-up, or protocol violation.
89584433|NCT01924299|Experimental|Baricitinib + Ketoconazole|"Baricitinib - 10 milligrams (mg) administered orally once on Day 1 of Period 1 and on Day 6 of Period 2.~Ketoconazole - 400 mg administered orally once daily (QD) for 6 days (Day 3 through Day 8) in Period 2."
89584434|NCT01924299|Experimental|Baricitinib + Fluconazole|"Baricitinib - 10 mg administered orally once on Day 1 of Period 1 and on Day 7 of Period 2.~Fluconazole - 400 mg administered orally once on Day 3 of Period 2, followed by 200 mg administered orally QD for 6 days (Day 4 through Day 9) in Period 2."
89584435|NCT02182999|Placebo Comparator|NaCl 0,9%|Continuous wound infiltration NaCl 0,9% 2 ml/h for first 24 postoperative hours by wound infiltration catheter (InfiltraLong-Katheter 19G x 420mm; Pajunk Medizintechnologie GmbH)
89584436|NCT02182999|Active Comparator|Ropivacaine|Continuous wound infiltration with Ropivacaine 0,2% 2 ml/h for first 24 postoperative hours by wound infiltration catheter (InfiltraLong-Katheter 19G x 420mm; Pajunk Medizintechnologie GmbH)
89584437|NCT01598311|Experimental|CB-183,315|Participants took CB-183,315 250 mg twice daily (b.i.d.) and placebo capsules b.i.d. by mouth for 10 days.
89584438|NCT01598311|Active Comparator|Vancomycin|Participants took vancomycin 125 mg four times daily (q.i.d.) by mouth for 10 days.
88974755|NCT00028496|Experimental|Treatment (vaccine therapy, sargramostim, vaccine adjuvant)|"The first three cohorts of 3-12 patients receive escalating doses of recombinant fowlpox-CEA-TRICOM vaccine (fCEA-TRI) until the maximum tolerated dose (MTD) is determined. fCEA-TRI is administered intradermally every 2 weeks for 4 doses and then every 2 months thereafter (beginning on day 56) in the absence of disease progression or unacceptable toxicity.~The fourth and fifth cohorts of 6 patients receive fCEA-TRI at the MTD in the same manner as the first three cohorts combined with escalating doses of sargramostim (GM-CSF). GM-CSF is administered subcutaneously once daily beginning on the day of each vaccination and continuing for a total of 4 days.~The sixth through eighth cohorts of 6 patients receive fCEA-TRI at the MTD in the same manner as the first three cohorts combined with escalating doses of recombinant fowlpox-GM-CSF (rF-GM-CSF)."
88974756|NCT00028535|Experimental|Arm I|Patients receive trastuzumab (Herceptin®) IV over 30-90 minutes on days 1, 8, and 15 and paclitaxel IV over 3 hours on day 1 of course 1. Beginning with course 2, patients receive trastuzumab and paclitaxel as in course 1 and interleukin-12 subcutaneously on days 2, 5, 9, 12, 16, and 19. Courses repeat every 21 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
88974757|NCT00056277|Other|Arm 1|
88974758|NCT00028574|Active Comparator|Gabapentin (28 days)|Oral Gabapentin 300 mg days 1-28
88974759|NCT00028574|Active Comparator|Gabapentin (7, 21)|Oral Gabapentin 300 mg once daily on days 1-7 days and twice daily days 8-28
88974760|NCT00028574|Active Comparator|Gabapentin (7, 7, 14)|Oral Gabapentin 300 mg once daily on days 1-7, twice daily on days 8-14 and three times daily on days 15-28
88974761|NCT00028574|Placebo Comparator|Placebo|"Oral Placebo 300 mg on one of the following schedules:~once daily on days 1-28~once daily on days 1-7, twice daily on days 8-28~once daily on days 1-7, twice daily on days 8-14 and three times daily on days 15-28"
88974762|NCT00056394|Experimental|1|Participants will receive comprehensive pain coping skills.
88974763|NCT00056394|Active Comparator|2|Participants will receive arthritis education.
88974764|NCT00056394|Active Comparator|3|Participants will receive standard care.
89209602|NCT00812162|Experimental|1|High protein diet.
89209603|NCT00812162|Experimental|2|Lower protein diet.
89209604|NCT04045418||COPD group|This group will include 40 patients with chronic obstructive pulmonary disease (COPD).
89209605|NCT04045418||Healthy control group|This group will include 40 healthy volunteers.
89209606|NCT04045418||Healthy intervention group|This group will include 40 healthy volunteers. Two sessions of moxibustion intervention will be performed in the Heart meridian and Lung meridian successively. The washout period between the two sessions is at least one day.
89209607|NCT00807872|Other|I-124 Mu 11-1F4 sterile injection|Single arm study
89209608|NCT00813644||1|uromentor training
89584439|NCT02182843|Experimental|Cellentra VCBM|Cellentra™ VCBM is an allogenic bone graft containing naturally occurring viable donor cells intended for homologous use in the repair, replacement, reconstruction or supplementation of the recipient's tissue in musculoskeletal defects.
89584440|NCT02208050|Other|Group 1|Patients will be randomised to a 8 week treatment period with the active drug followed by a 2 week washout period before an 8 week treatment period with placebo.
89584441|NCT02208050|Other|Group 2|Patients will be randomised to a 8 week treatment period with the placebo, followed by a 2 week washout period and a further 8 week treatment period with the active drug.
89584442|NCT04770350|Experimental|Experimental|Participants will undergo ten to thirty minutes of transcranial ultrasound treatment. The sanitation device will be aimed at the hypothalamus. Targeting will include reference to scalp fiducials based on the obtained MRI; confirmation of target accuracy will either be obtained by Doppler waveform confirmation or optical tracking technology which co-registers patient neuroimaging with real space.
89584443|NCT02978222|Experimental|FRα peptide plus adjuvant (GM-CSF)|FRα peptide vaccine with GM-CSF adjuvant ID administration monthly for 6 months followed by booster administrations every 3 months for up to 1.5 years
89584444|NCT02978222|Placebo Comparator|Adjuvant (GM-CSF) Alone|GM-CSF adjuvant alone ID administration monthly for 6 months followed by booster administrations every 3 months for up to 1.5 years
89584445|NCT02181673|Placebo Comparator|Treatment Group 1: Placebo|Participants will receive intravenous infusions of placebo at Weeks 0, 4, 12 and 20. At Week 24, all participants receiving placebo will begin receiving intravenous infusions of golimumab 2 milligram per kilogram (mg/kg) at Week 24, 28 and thereafter every 8 weeks up to Week 52.
89584446|NCT02181673|Experimental|Treatment Group 2: Golimumab|Participants will receive intravenous infusions of golimumab 2 mg/kg at Weeks 0, 4 and thereafter every 8 weeks up to Week 52. At Week 24, participants will receive a placebo infusion to maintain the blind.
89584447|NCT02929004|Experimental|Vibrasens|"In addition of classical physiotherapist sessions for the readaptation following anterior cruciate ligament reconstruction, this group will follow a local vibration training, using small and portable vibrator device.~Training programme: vibration training 3/week from Day 1 to Day 60"
89584448|NCT02929004|No Intervention|Usual activities|Usual activities from day 1 to Day 60 during their classical physiotherapist sessions for the readaptation following anterior cruciate ligament reconstruction.
89584449|NCT02131129|Experimental|rTMS|The stimulation sites will be the left and right DLPFC, defined as 5 cm anterior to the scalp positions at which the MTs were determined. Treatments will be delivered within the following stimulation parameters: 110% of MT, 20 Hz, 30 trains, 1.0 second per train, 20 pulses per train, inter-train interval of 30 seconds (600 pulses/hemisphere, for a total of 1200 pulses/session/day).
89584450|NCT02131129|Sham Comparator|Sham|The stimulation sites will be the left and right DLPFC, defined as 5 cm anterior to the scalp positions at which the MTs were determined. Treatments will be delivered within the following stimulation parameters: 110% of MT, 20 Hz, 30 trains, 1.0 second per train, 20 pulses per train, inter-train interval of 30 seconds (600 pulses/hemisphere, for a total of 1200 pulses/session/day).
89584451|NCT02152345|Experimental|Belatacept Immunosuppression|Renal transplant recipients will receive steroids (Methylprednisolone), rATG, Belatacept and Mycophenolate. Subjects will be followed for primary endpoint to Day 7 and Month 3 after transplantation and secondary endpoints of kidney function and patient and graft survival up to month 36 after transplantation.
89584452|NCT02152345|Active Comparator|Standard Immunosuppression (Tacrolimus)|Renal transplant recipients will receive standard immunosuppressive therapy, including steroids (Methylprednisolone), rATG, Tacrolimus and Mycophenolate. Subjects will be followed for primary endpoint to Day 7 and Month 3 after transplantation and secondary endpoints of kidney function and patient and graft survival up to month 36 after transplantation.
89584453|NCT02180659|Experimental|buprenorphine implants + placebo tablets|Four 80 mg Probuphine implants + daily SL placebo tablets
89584454|NCT02180659|Active Comparator|buprenorphine tablets + placebo implants|Daily SL BPN tablets (≤8 mg/daily) + four placebo implants
89209609|NCT00813644||2|non uromentor training
89209610|NCT00813722|Active Comparator|phone calls|patients received phone calls
88974765|NCT02970123|Experimental|SLIMM Intervention|Sit Less, Interact, Move More (SLIMM): instruction and monitoring feedback to promote decrease in sedentary activity duration, increase in casual walking duration, and increase in sedentary breaks
88974766|NCT02970123|No Intervention|Standard of Care|Subjects will receive standard of care treatment for chronic kidney disease, with no instruction or feedback to alter sedentary or casual walking durations
88974767|NCT00056589|Experimental|rFXIII|
88974768|NCT00028730|Experimental|Pts < than or = 18 years with lymphohematopoietic disorders|This is a phase II, single-center study to evaluate a cytoreductive regimen of hyperfractionated TBI, thiotepa and cyclophosphamide (HFTBI/thio/cy) followed by infusions of SBA-E- T-cell depleted marrow in pediatric leukemia recipients of either HLA-identical or HLA-1Ag non-identical related or unrelated donors.
88974769|NCT00056667|Experimental|CBT plus relaxation response|Participants will receive cognitive behavioral therapy plus relaxation response training
88974770|NCT00056667|Active Comparator|Relaxation Response|Participants will receive relaxation response training
88974771|NCT00056667|Placebo Comparator|Education|Participants will receive rheumatoid arthritis education
88974772|NCT00028925|Experimental|Regimen A|"Patients receive oral topotecan once daily on days 1-5, carboplatin IV over 30 minutes on day 5, and filgrastim (G-CSF) subcutaneously once daily beginning on day 6 or 7 and continuing for up to 10 days or until blood counts recover.~Treatment for all patients repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with disease progression limited to CNS only interrupt chemotherapy to have whole-brain radiotherapy (WBRT). Once WBRT is complete, chemotherapy resumes.~Quality of life is assessed at baseline and at the beginning of each course of chemotherapy.~Patients are followed every 3 months for 2 years and then every 6 months for 3 years."
89209611|NCT00813722|Placebo Comparator|no phone calls|patients received no phone calls
89209612|NCT00813722|Active Comparator|current treatment|calcium chanel blocker and at1 antagonist
89209613|NCT00813722|Active Comparator|tradittional treatment|beta blocker and diuretic
89584455|NCT02130427|Other|Lung Imaging|Weekly 3D/4D CT scans during radiation therapy. MRI may be used in addition to or instead of CT depending on the location of the tumor and the decision of the treating physician.
89584456|NCT02207816|Experimental|GSK257049 Group|Male or female infants (between and including 6 to 12 weeks of age)/children (between and including 5 to 17 months of age) received 3 doses of GSK257049 malaria vaccine (co-administered with Polio Sabin and Tritanrix HepB/Hib vaccines, for the infants subgroup) on a 0-1-2-month schedule, and a booster dose of GSK257049 malaria vaccine (co-administered with Polio Sabin, for the infants subgroup) at Month 20 during the primary study MALARIA-055 PRI (NCT00866619). Vaccines were administered intramuscularly: in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); anterolateral right thigh (Tritanrix HepB/Hib vaccine); orally: Polio Sabin vaccine. No vaccination was administered during this study.
89584457|NCT02207816|Active Comparator|GSK257049 Comparator Group|Male or female infants (between and including 6 to 12 weeks of age)/children (between and including 5 to 17 months of age) received 3 doses of GSK257049 malaria vaccine (co-administered with Polio Sabin and Tritanrix HepB/Hib vaccines, for the infants subgroup) on 0-1-2-month schedule, and a booster dose of Menjugate vaccine (co-administered with Polio Sabin, for the infants subgroup) at Month 20 during the primary study MALARIA-055 PRI (NCT00866619). Vaccines were administered intramuscularly: in the anterolateral left thigh (GSK257049 vaccine); anterolateral right thigh (Tritanrix HepB/Hib vaccine); orally: Polio Sabin vaccine. No vaccination was administered during this study.
89584458|NCT02207816|Active Comparator|VeroRab/Menjugate Comparator Group|Male or female infants (between and including 6 to 12 weeks of age)/children (between and including 5 to 17 months of age) received 3 doses of VeroRab vaccine (children subgroup) or Menjugate vaccine (co-administered with Polio Sabin and Tritanrix HepB/Hib vaccines, for the infants subgroup) on 0-1-2-month schedule, and a booster dose of Menjugate vaccine (co-administered with Polio Sabin, for the infants subgroup) at Month 20 during the primary study MALARIA-055 PRI (NCT00866619). Vaccines were administered intramuscularly: left deltoid (VeroRab vaccine and Menjugate vaccine); anterolateral right thigh (Tritanrix HepB/Hib vaccine); orally: Polio Sabin vaccine. No vaccination was administered during this study.
89209614|NCT00812318|Experimental|Treatment A|GSK1265744 10mg oral solution
89584459|NCT02241512|Experimental|Ibuprofen|Single dose IV Ibuprofen at a dose of 10mg/kg (max: 800mg).
89584460|NCT02241512|Placebo Comparator|Placebo|Single dose IV normal saline
89584461|NCT02205476|Experimental|Group 1|The number of doses each subject receives will be consistent with number received in protocol B5301001 (Group 1 = 4 doses).
89584462|NCT02205476|Experimental|Group 2|The number of doses each subject receives will be consistent with number received in protocol B5301001 (Group 2 = 3 doses).
89584463|NCT01709110|Experimental|Teriparatide|"Teriparatide 20 microgram (µg) administered by subcutaneous (SC) injection once daily for 24 months.~Placebo given orally once weekly for 24 months.~Elemental Calcium 500 to 1000 milligram per day and Vitamin D 400 to 800 International Units per day, both administered orally once daily while receiving treatment."
89584464|NCT01709110|Active Comparator|Risedronate|"Risedronate 35 milligram (mg) administered orally once weekly for 24 months.~Placebo given by SC injection once daily for 24 months.~Elemental Calcium 500 to 1000 milligram per day and Vitamin D 400 to 800 International Units per day, both administered orally once daily while receiving treatment."
89584465|NCT02240108|Experimental|Rifaximin EIR 800 mg|Participants will receive rifaximin EIR 400 milligrams (mg) tablets orally twice daily for 52 weeks.
89584466|NCT02240108|Placebo Comparator|Placebo|Participants will receive placebo matching to rifaximin EIR tablets orally twice daily for 52 weeks.
89584467|NCT02239640||Medtronic NV market-released device|Patients experiencing an acute ischemic stroke due to a large vessel occlusion treated with a Medtronic Neurovascular market-released neurothrombectomy device.
89584468|NCT01590628|Experimental|NiCord|NiCord: NiCord® is a cell-based product composed of umbilical cord-derived ex vivo expanded stem and progenitor cells.
89584469|NCT02130193|Experimental|Part A|Subjects will receive 50 mg danirixin twice daily (BID) orally for 14 days. If the exposure to danirixin is lower than expected, after 14 days of dosing, then the dose may be increased to 75 mg BID for Part B.
89584470|NCT02130193|Experimental|Part B|Subjects will be randomized to receive either danirixin BID or placebo BID treatment along with standard care of treatment for 52 weeks. Subjects completing Part A and meeting the eligibility criteria for Part B could also be randomized in Part B.
89584471|NCT01590082|Experimental|Doxycycline, Ipilimumab, and Temozolomide|Doxycycline to start on day -6 of Cycle 1 (1 week before Day 1 of Cycle 1 starts) twice a day until morning of Day 1 of Cycle 1. After the Day 1 of Cycle 1, participants receive first dose of Ipilimumab, and evening of same day, Temozolomide received by mouth once a day for 4 days. Doxycycline administration will continue twice daily for rest of cycle without interruption; Cycle 1 is 4 weeks of treatment. Starting Cycle 2, Doxycycline with temozolomide and ipilimumab administration start on Day 1. Each cycle is 3 weeks. 4 cycles of therapy given over a 3 month period to complete induction phase. After induction therapy, participants continue on Doxycycline.
89584472|NCT01598636|Experimental|Lateral Tibial Tunnel technique|
89584473|NCT01631474|Experimental|Low-dose active, BID|low dose of CB-03-01, 0.1% applied twice a day
89584474|NCT01631474|Experimental|Medium-dose active, BID|medium dose of CB-03-01, 0.5% applied twice a day
89584475|NCT01631474|Experimental|High-dose active, QD|high dose of CB-03-01, 1% applied once a day
89584476|NCT01631474|Experimental|High-dose active, BID|high dose of CB-03-01, 1% applied twice a day
89209615|NCT00812318|Experimental|Treatment B|GSK1265744 5mg tablet, fasted
89209616|NCT00812318|Experimental|Treatment C|GSK1265744 5mg tablet, fed
89209617|NCT00812396|Active Comparator|1|Low dose testosterone
89209618|NCT00812396|Active Comparator|2|High dose testosterone
89584477|NCT01631474|Placebo Comparator|Vehicle, QD or BID|vehicle cream, applied once or twice a day
89584478|NCT02203916|Experimental|Azilsartan Medoxomil 40 mg|Azilsartan medoxomil 40 mg, tablets, orally, once daily for 6 weeks.
89584479|NCT02203916|Experimental|Azilsartan Medoxomil 80 mg|Azilsartan medoxomil 80 mg, tablets, orally, once daily for 6 weeks.
89584480|NCT02203916|Placebo Comparator|Placebo|Azilsartan medoxomil placebo-matching tablets, orally, once daily for 6 weeks.
89584481|NCT04774328|Active Comparator|CA-008 (vocacapsaicin)|Single administration
89584482|NCT04774328|Placebo Comparator|Placebo|Single administration
89584483|NCT02179177|Active Comparator|Apixaban|Active drug Apixaban 2.5mg taken by mouth twice a day
89584484|NCT02179177|Placebo Comparator|Placebo|Sugar pills that look like Apixaban that will be taken by mouth twice a day
89584485|NCT02239328||Lung Cancer, Esophageal Cancer|Lung Cancer and Esophageal Cancer patients will complete the online PROMIS survey. No treatment intervention will be performed.
89584486|NCT02129803|Experimental|Experimental Therapy|High-Flow, 20 LPM (via Optiflow cannula) Heated (34C) Humidified Air
89584487|NCT02129803|Placebo Comparator|Control Therapy (Low Flow)|Low FLow, 5 LPM (via Optiflow cannula) Room Temperature (23-26C) Ambient Air
89584488|NCT02239094|Other|Lurasidone (Latuda)|All study participants will receive open-label Latuda.
89584489|NCT02129647|Experimental|Axitinib|5 mg axitinib orally twice daily, with increase to 7 mg orally twice daily and 10 mg orally twice daily after 2 and 4 weeks, respectively, provided no adverse reactions (i.e., not exceeding grade 2 toxicities) and normotensive and not receiving antihypertension medications. Axitinib will be given continuously in 28-day cycles until disease progression or unacceptable toxicity.
89584490|NCT02238626|Placebo Comparator|Placebo (for MN-166)|Sugar pill manufactured for MN-166 10 mg tablets plus 50 mg riluzole by mouth twice daily for 6 months.
89584491|NCT02238626|Experimental|MN-166|MN-166 10 mg tablets (up to 60 mg/day) by mouth 2-3 times a day plus 50 mg riluzole 2 times a day by mouth for 6 months.
88974773|NCT00028925|Experimental|Regimen B|"Patients receive topotecan and carboplatin as in regimen A. Patients are evaluated after the first 3-week course of chemotherapy. If no patient experiences unacceptable toxicity or febrile neutropenia, the next 33 patients receive treatment as in regimen B; otherwise, patients receive treatment as in regimen A.~Treatment for all patients repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with disease progression limited to CNS only interrupt chemotherapy to have whole-brain radiotherapy (WBRT). Once WBRT is complete, chemotherapy resumes.~Quality of life is assessed at baseline and at the beginning of each course of chemotherapy.~Patients are followed every 3 months for 2 years and then every 6 months for 3 years."
88974774|NCT00398463|Experimental|1|Aspirin, clopidogrel, Unfractioned heparin or bivalirudin plus tirofiban infusion given at high bolus dose
88974775|NCT00398463|Placebo Comparator|2|Aspirin, clopidogrel, Unfractioned heparin or bivalirudin plus placebo
88974776|NCT00423501|Experimental|1|
88974777|NCT00423501|Experimental|2|
88974778|NCT00423501|Experimental|3|
88974779|NCT00423501|Experimental|4|
88974780|NCT00423501|Experimental|5|
88974781|NCT00423501|Placebo Comparator|6|
88974782|NCT00029003|Experimental|Treatment (gefitinib)|Patients receive oral gefitinib once daily. Treatment continues in the absence of disease progression or unacceptable toxicity.
88974783|NCT00029159|Active Comparator|1|
88974784|NCT00029159|Placebo Comparator|2|
89209619|NCT00812396|Placebo Comparator|3|Placebo
89584492|NCT02151643|Experimental|Group 1 - PT20 400 mg tid|"PT20 400 mg tid (1.2 g/day) administered orally.~Dosing was initiated with the subject's first meal/snack following receipt of study medication at Visit 7 (Day 1). There was to be no change in dose administration level with respect to each cohort in this study"
89584493|NCT02151643|Experimental|Group 2 - PT20 800 mg tid|"PT20 800 mg tid (2.4 g/day) administered orally.~Dosing was initiated with the subject's first meal/snack following receipt of study medication at Visit 7 (Day 1). There was to be no change in dose administration level with respect to each cohort in this study"
89584494|NCT02151643|Experimental|Group 3 - PT20 1600 mg tid|"PT20 1600 mg tid (4.8 g/day) administered orally.~Dosing was initiated with the subject's first meal/snack following receipt of study medication at Visit 7 (Day 1). There was to be no change in dose administration level with respect to each cohort in this study"
89584495|NCT02151643|Experimental|Group 4 - PT20 3200 mg tid|"PT20 3200 mg tid (9.6 g/day) administered orally.~Dosing was initiated with the subject's first meal/snack following receipt of study medication at Visit 7 (Day 1). There was to be no change in dose administration level with respect to each cohort in this study"
89584496|NCT02151643|Placebo Comparator|Group 5 - Placebo tid|"Matched Placebo (for PT20) tid administered orally.~Dosing was initiated with the subject's first meal/snack following receipt of study medication at Visit 7 (Day 1). There was to be no change in dose administration level with respect to each cohort in this study"
89584497|NCT02203838|Experimental|RBP-7000 - 120-mg dose|RBP-7000 120-mg subcutaneous (SC) injections every 28 days for 13 doses as open-label therapy. Patients enter the study as 'roll-over' patients from study RB-US-09-0010, or de novo patients. Pre-study procedures vary for de novo patients depending on previous therapy.
89584498|NCT02178787||Type 2 diabetes mellitus|Head-up tilt, vasoreactivity, standing up.
89584499|NCT02178787||Non-diabetic controls|Head-up tilt, vasoreactivity, standing up.
89584500|NCT02178709|Experimental|FOLFIRINOX|"FOLFIRINOX consists of the following combination of drugs:~Oxaliplatin, 85 mg/m2, IV over 2 hours prior to irinotecan, administered on days 1 and 15 of each 28 day cycle~Leucovorin, 400 mg/m2, IV over 2 hours with irinotecan, administered on days 1 and 15 of each 28 day cycle~Irinotecan, 180 mg/m2, IV over 90 minutes with leucovorin, administered on days 1 and 15 of each 28 day cycle~5 FU, 400 mg/m2, IV bolus over 2 minutes after irinotecan, administered on days 1 and 15 of each 28 day cycle.~5FU, 2400 mg/m2, IV infusion over 46 hours after 5FU bolus injection, administered on days 1 and 15 of each 28 day cycle."
88974785|NCT00423618|Active Comparator|Control arm|Radiotherapy Conventional treatment arm A total of 33 fractions each of 2Gy should be given once a day for 5 days per week over 6 weeks and 3 days in week 7, totalling 66Gy. The first 50 Gy in 25 fractions will be given to CTV1 and subsequent 16 Gy in 8 fractions will be delivered to CTV2.
88974786|NCT00423618|Experimental|Research arm|Radiotherapy Research arm A total of 33 fractions each of 2Gy should be given once a day for 5 days per week over 6 weeks and 3 days in week 7, totalling 66Gy. The 66Gy in 33 fractions will be delivered to CTV2 alone. No attempt will be made to include drain/biopsy sites or the surgical scar.
88974787|NCT00029198|Experimental|1|15 minute massage tid
88974788|NCT00029198|Sham Comparator|2|non-massage touch
88974789|NCT00423696|Experimental|bevacizumab + FOLFIRI|
88974790|NCT00423696|Experimental|bevacizumab + XELIRI|
89584501|NCT02238080||Methoxy Polyethylene Glycol-Epoetin Beta|Participants with anemia and CKD who are on dialysis therapy, and who initiate erythropoiesis-stimulating agent (ESA) treatment with methoxy polyethylene glycol-epoetin beta or who are on stable methoxy polyethylene glycol-epoetin beta maintenance therapy, will be treated according to the usual standard of care and current best practice guidelines, and will be observed during the study period.
88974791|NCT02969889|Active Comparator|intubation time|handling the device till the endotracheal tube passing through the glottis
88974792|NCT02969889|Active Comparator|insertion time|handling of the device till the glottic visualization
89584502|NCT02150863|Active Comparator|Ultrapulse laser alone|
89584503|NCT02150863|Active Comparator|Ultrapulse laser plus Cellutome Harvesting system|
89584504|NCT02150863|No Intervention|Control|
89584505|NCT01445366|Experimental|Patients with end-stage renal disease|
88974793|NCT02970084|Experimental|Group with K2|"The nutraceutical product (PLAK2) based on vitamin K2, will be administered once a day (a tablet 800mg) for 12 months.~All patients enrolled will continue to be treated according to the clinical standard (100 mg Cardioaspirin, cp 1 day : Acetylsalicylic acid)"
88974794|NCT02970084|No Intervention|Control group (no vitamin K2)|The control group did not take the supplement of Vitamin K2. All patients enrolled will continue to be treated according to the clinical standard (100 mg Cardioaspirin, cp 1 day : Acetylsalicylic acid)
88974795|NCT04730778||CIN|"STEMI patients who develop CIN contrast induced nephropathy within 1 week from primary PCI."
88974796|NCT04730778||Control|STEMI patients who do not meet criteria of CIN through 1 week post primary PCI
89584506|NCT02178553|Active Comparator|Epidural|In the epidural catheter (TEC) group, a thoracic epidural catheter will be placed at the level of T6-T8 and advanced 5 cm into the epidural space and a 3 ml test dose of lidocaine 1.5% will be administered before the induction of general anesthesia. Patients will be excluded from the study if the catheter cannot be placed. A bolus dose of 0.5 mg hydromorphone plus 4.5 ml 0.125% bupivacaine will be administered before surgical incision. An epidural infusion of 0.075% bupivacaine and 10 mcg/ml hydromorphone, prepared by the hospital pharmacy, will be started intraoperatively at a rate of 5 ml/hr.
89584507|NCT02178553|Active Comparator|Intercostal bupivicaine (Exparel)|In the intercostal block (ICB) group, liposomal bupivacaine 1.3% (4 ml) will injected by the surgeon under direct vision into the proximal intercostal space at the level of the thoracotomy and one interspace above and below. In addition, liposomal bupivacaine 1.3 % (4 ml) will be injected at each of the chest tube exit sites. Thus, a total of 20 ml liposomal bupivacaine 1.3% (260 mg) will be administered.
89584508|NCT01627327|Experimental|fluticasone furoate/vilanterol|inhaled corticosteroid (ICS)/long-acting beta2-agonist (LABA)
89584509|NCT01627327|Active Comparator|tiotropium bromide|anticholinergic
88974797|NCT00056979|Experimental|Fludarabine, CAMPATH-1H , Anti-CD45, FK506|Fludarabine will be given as a daily IV (intravenous, by vein) infusion for a total of 5 days. CAMPATH-1H will be given as a daily 4-hour IV (intravenous, by vein) infusion for three days. Anti-CD45 will be given as a daily 6-hour IV infusion over the next 4 days. To help prevent body from rejecting the transplant, the drug FK506 will be given, starting two days before the transplant and continuing for three months.
88974798|NCT00395681|Active Comparator|propofol|propofol 200 mg versus 350 mg
88974799|NCT00395681|Active Comparator|Propofol|Propofol 350 mg versus 200 mg
88974800|NCT00057057|Other|Arm 1|
88974801|NCT00395720|Active Comparator|1|Group 1 (10 volunteers): 5 x 10^7 pfu
88974802|NCT00395720|Active Comparator|2|Group 2 (10 volunteers): 1 x 10^8 pfu
88974803|NCT00057096|Other|Arm 1|
88974804|NCT04731012||healthy oocyte-donation pregnancy|healthy pregnancy
88974805|NCT04731012||preeclamptic oocyte-donation pregnancy|preeclampsia
88974806|NCT04731012||healthy IVF or ICSI pregnancy|healthy pregnancy
88974807|NCT04731012||preeclamptic IVF or ICSI pregnancy|preeclampsia
88974808|NCT04731012||healthy spontaneous conception pregnancy|healthy pregnancy
88974809|NCT04731012||preeclamptic spontaneous conception pregnancy|preeclampsia
88974810|NCT00057135|Other|Arm 1|
88974811|NCT00057174|Other|Arm 1|
88974812|NCT00057252||1|Patients with medical imaging records
88974813|NCT00057291|Experimental|caregiving intervention|One group received caregiving intervention, another received only training, and a third was business as usual. These were the interventions.
88974814|NCT00057408|Experimental|1|Treatment with olanzapine
88974815|NCT00057408|Placebo Comparator|2|Matching placebo treatment
88974816|NCT00057525|Experimental|Anthrax vaccine with or without PBS|Administor 1 dose 5 μg rPA with PBS (5 Volunteers)
89584510|NCT01627249|Active Comparator|Ranibizumab|
88974817|NCT00057525|Placebo Comparator|Placebo|Doses will range from 5 _g to 100 _g rPA, and at each dose-level, rPA will either be combinedwith phosphate-buffered saline (PBS) or adsorbed to Alhydrogel
88974818|NCT00057564|Experimental|A (Thalidomide & Dexamethasone)|Thalidomide 50mg/day + Dexamethasone 40mg
88974819|NCT00057564|Placebo Comparator|B (Dexamethasone and placebo)|Dexamethasone and placebo
89584511|NCT01627249|Experimental|Aflibercept|
89584512|NCT01627249|Experimental|Bevacizumab|
89584513|NCT01688830|Experimental|BI 655075|
89584514|NCT01688830|Placebo Comparator|Placebo|
89584515|NCT01688830|Experimental|BI 655075 with dabigatran|
89584516|NCT02178475||Chemotherapy + Pegfilgrastim|Patients with non-Hodgkin's lymphoma or breast cancer being treated with a permitted standard-dose chemotherapy regimen with a high FN risk (> 20%) and who had pegfilgrastim prophylaxis initiated in the first cycle of chemotherapy.
89584517|NCT01569022|Active Comparator|CPAP First, MAD|"CPAP treatment for sleep apnea~CPAP: CPAP Treatment for 12 weeks MAD: MAD treatment for 12 weeks"
89584518|NCT01569022|Experimental|MAD First, CPAP|"MAD treatment for sleep apnea~MAD: MAD Treatment for 12 weeks CPAP: CPAP treatment for 12 weeks"
89584519|NCT01629823|Sham Comparator|CPAP less than 1 cm H₂O|
89584520|NCT01629823|Experimental|CPAP 10cm H₂O|
89584521|NCT01629823|Experimental|CPAP 5cm H₂O|
89584522|NCT01688050|Experimental|Endovascular Repair|
89584523|NCT01604278|Active Comparator|NVA237 + indacaterol|
89584524|NCT01604278|Placebo Comparator|Placebo to NVA237 + indacaterol|
89584525|NCT01687270|Experimental|SOF+RBV|Participants will receive sofosbuvir+RBV for 24 weeks.
89584526|NCT01589770|Other|rheumatoid arthritis patients|People who have rheumatoid arthritis underwent cMRI
89584527|NCT01589770|Other|controls|people who do not have RA or other inflammatory disease underwent cMRI
89584528|NCT01588990|Experimental|Bevacizumab: Phase A and Phase B|The trial will consist of 2 phases of treatment. Phase A: Participants will receive bevacizumab 7.5 mg/kg intravenous (IV) infusion on Day 1 every 3 weeks in combination with XELOX (capecitabine and oxaliplatin) or bevacizumab 5 mg/kg IV on Day 1 every 2 weeks in combination with mFOLFOX6 (oxaliplatin, leucovorin, and 5-fluouracil) until first disease progression or occurrence of unmanageable toxicity. Phase B: Upon documented first disease progression, participants will continue receiving bevacizumab 5 mg/kg IV on Day 1 every 2 weeks in combination with FOLFIRI (irinotecan, leucovorin, and 5-fluouracil) until second disease progression or occurrence of unmanageable toxicity. Phase B treatment should commence within 4 weeks of the date of documented first disease progression.
89584529|NCT02176525|Experimental|BI 207127 in patients with cirrhosis|multiple rising doses
89584530|NCT02176525|Experimental|BI 207127 in patients without cirrhosis|multiple rising doses
89584531|NCT02176525|Placebo Comparator|Placebo in patients without cirrhosis|
89584532|NCT02127931|Experimental|ADHD group played Game|Groundskeeper, a Video Game Diagnostic Tool for ADHD is administer to probands with ADHD and age, gender matched controls without ADHD. The game was played on Sifteo cubes.
89584533|NCT02127931|Active Comparator|Control group played game|Groundskeeper, a Video Game Diagnostic Tool for ADHD is administer to probands with ADHD and age, gender matched controls without ADHD. The game was played on Sifteo cubes.
89584534|NCT02126839|Placebo Comparator|Placebo MDPI QID|Placebo multidose dry powder inhaler (MDPI) administered as 2 inhalations QID (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for 3 weeks.
89584535|NCT02126839|Experimental|Albuterol MDPI 180 mcg QID|Albuterol multidose dry powder inhaler (MDPI) 90 mcg/inhalation administered as 2 inhalations QID (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for a total daily dose of 720 mcgs for 3 weeks.
89584536|NCT02125279|Experimental|Calcitriol ointment|
89584537|NCT02124811|Experimental|High CRP|Subjects with a High Baseline CRP will receive Minocycline. During the first week, subjects will receive one 100 mg capsule daily. On weeks 2-12, the subject will receive two 100 mg capsules at bedtime. The blinded psychiatrist (blinded to CRP status) will be allowed to reduce the dose if the subject complains of any side effect. Pending tolerability, the subject will have 200 mg per day.
89584538|NCT02124811|Experimental|Low CRP|Subjects with a Low Baseline CRP will receive Minocycline. During the first week, subjects will receive one 100 mg capsule daily. On weeks 2-12, the subject will receive two 100 mg capsules at bedtime. The blinded psychiatrist (blinded to CRP status) will be allowed to reduce the dose if the subject complains of any side effect. Pending tolerability, the subject will have 200 mg per day.
89584539|NCT02148445|Active Comparator|Standard Smoking Cessation|Participants in the standard smoking cessation (SC) arm will receive a standard approach to smoking cessation, including smoking cessation counseling supplemented with 10 weeks of combination nicotine replacement therapy (NRT) (nicotine patch plus choice of gum or lozenge) if they are willing to make a quit attempt.
89584540|NCT02148445|Experimental|Extended Nicotine Replacement Therapy|Participants in the guided maintenance therapy (GMT) arm will receive counseling focused on medication adherence and smoking reduction plus up to 52 weeks of combination nicotine replacement therapy (NRT) (nicotine patch plus choice of gum or lozenge) regardless of their interest in quitting.
89584541|NCT02148211||Exposed cohort|Pregnant women, vaccinated with any of the 4 GSK seasonal Inactivated Influenza Vaccine(s) (GSK sIIVs): Fluarix/ FluLaval/Fluarix Quadrivalent /FluLaval Quadrivalent during pregnancy or within 28 days preceding conception.
89584542|NCT02147587|Experimental|Tofacitinib 5 mg BID (oral) (70 subjects)|Zoster vaccine will be administered to subjects on background methotrexate; treatment with 5 mg tofacitinib twice daily will begin 2 to 3 weeks following vaccination and continue for 12 weeks.
89584543|NCT02147587|Placebo Comparator|Placebo tofacitinib BID (oral) (70 subjects)|Zoster vaccine will be administered to subjects on background methotrexate; treatment with placebo twice daily will begin 2 to 3 weeks following vaccination and continue for 12 weeks.
89584544|NCT02147353|Active Comparator|Sinecatechins 15% Ointment & Cryotherapy|Cryotherapy and then Sinecatechins 15% Ointment 1 week later.
89584545|NCT02147353|Placebo Comparator|Cryotherapy Alone|Cryotherapy will be standardized in all subjects and for all treated lesions: EGW lesions will be treated with 2 sprays, 5 seconds each, with a 5 second interval. All subjects will be treated with the same cryo-spray regimen.
89209620|NCT02552030|Experimental|Blood pressure-measurement|Seven repetitive blood pressure measurements will be performed the left or right arm of all participants with an iPhone 4s and a conventional oscillometric device 'cuff device (Omron HBP-1300-E Pro)'
89209621|NCT00649220|Experimental|Memantine|
89209622|NCT00812552||Case|Late or very late drug-eluting stent thrombosis
89584546|NCT02147197|Experimental|UPA 5 mg|Ulipristal acetate (UPA) 5 mg tablet plus matching placebo 10 mg tablet, orally, once daily for 12 weeks.
89584547|NCT02147197|Experimental|UPA 10 mg|UPA 10 mg tablet plus matching placebo 5 mg tablet, orally, once daily for 12 weeks.
89584548|NCT02147197|Placebo Comparator|Placebo|Matching placebo tablets (5 mg and 10 mg), orally, once daily for 12 weeks.
89584549|NCT02176291|Experimental|Buprenorphine|Buprenorphine
89584550|NCT02176291|Placebo Comparator|Placebo|Placebo
89209623|NCT00812552||Control|No drug-eluting stent thrombosis
89584551|NCT04769570|Active Comparator|Group IPSB|In the first group of patients (Group IPSB), ultrasound-guided interscalene brachial plexus block will be applied 30 minutes before surgery.
89584552|NCT04769570|Active Comparator|Group SSNB|In the second group of patients, ultrasound-guided interscalene brachial plexus block and suprascapular nerve block will be applied 30 minutes before surgery.
89584553|NCT04769570|Active Comparator|Group Control|Patients in the third group (Group C), will be considered the control group and no block will be performed.
89584554|NCT02175745|Experimental|Diagnostic (FDOPA-PET/CT or PET/MRI)|Patients receive 18F-fluoro-dihydroxyphenylalanine (18F-FDOPA) intravenously (IV) and then undergo positron emission tomography / computed tomography (PET/CT) or PET/magnetic resonance imaging (PET/MRI) scans 10 to 30 minutes later.
89584555|NCT02175277|Experimental|Darbepoetin Alfa|Participants received darbepoetin alfa for up to 73 weeks or until progression to acute myeloid leukemia (AML), whichever occurred first.
89584556|NCT02124265|Experimental|Ceralyte 90|Ceralyte® will be administered during the first 24-hours post-burn. Fluid requirements will be calculated according to the Parkland Formula with 50% administered during the first 8 hours and the second 50% administered over the next 16 hours. During the first 2 hours IV fluids will be started at the Parkland goal minus 250cc, which will be administered using Ceralyte via oral, nasogastric (NG), or dobhoff tube. ORT and IV fluids will be monitored with additional doses given hourly. Urine output will be monitored hourly and gastric residuals will be monitored every 2 hours, with adjustments made as needed to ensure adequate fluid resuscitation.
89584557|NCT02146105|Experimental|Yoga For Knee Osteoarthritis|An tailored arthritis-specific yoga program for women with knee osteoarthritis with the aim of increasing leg strength and alleviating knee pain related to the disease.
89584558|NCT02175199|Experimental|AIR OPTIX COLORS|Lotrafilcon B contact lenses with color printing worn bilaterally in a daily wear modality 5 days/week, 8 hours/day for 30 days.
89584559|NCT02175199|Active Comparator|FreshLook COLORBLENDS|Phemfilcon A contact lenses with color printing worn bilaterally in a daily wear modality 5 days/week, 8 hours/day for 30 days with a 2-week replacement.
89584560|NCT02123797||Multidisciplinary Clinic Patients|: 150 multidisciplinary clinic patients matched 1:2 with 300 serial care patients
89584561|NCT02123797||Serial Care Patients|150 multidisciplinary clinic patients matched 1:2 with 300 serial care patients = 450 patients Since Baptist Health Care System manages >800 new cases each year, 300 of which are expected to be seen in multidisciplinary clinic, in practice, we conservatively expect to be able to recruit 150 cases from multidisciplinary clinic and 300 matched serial care controls (1:2 match) in 18 months.
89584562|NCT02123797||Multidisciplinary Caregivers|Consenting caregivers of consented multidisciplinary clinic patients (patients seen by multiple specialists at a single appointment time).
89584563|NCT02123797||Serial Care Caregivers|Consenting caregivers of consented serial care patients (patients who receive the current system of linear, sequential, referral-based care delivery).
89584564|NCT02123797||Clinical Providers|Clinical providers who referred at least 5 patients to the multidisciplinary program and consented to the study.
89584565|NCT02175121|Placebo Comparator|Treatment A- Placebo|
89584566|NCT02175121|Experimental|Treatment B- PF-06291874|
89584567|NCT02175121|Experimental|Treatment C- PF-06291874|
89584568|NCT02175121|Experimental|Treatment D- PF-06291874|
89584569|NCT02175121|Experimental|Treatment E- PF-06291874|
89584570|NCT01568866|Experimental|Carfilzomib plus Dexamethasone|Participants received 20 mg/m² carfilzomib administered by intravenous (IV) infusion on Days 1 and 2 of Cycle 1, followed by 56 mg/m² on Days 8, 9, 15, and 16 of Cycle 1 and for each 28-day cycle thereafter. Additionally, participants received 20 mg dexamethasone on Days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28 day cycle.
89584571|NCT01568866|Active Comparator|Bortezomib plus Dexamethasone|Participants received bortezomib 1.3 mg/m² administered IV or subcutaneously (SC) on Days 1, 4, 8, and 11 of a 21-day cycle plus dexamethasone 20 mg administered on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each 21-day cycle.
89584572|NCT01568320|Experimental|Endovascular|Endovascular Treatment (Zenith)
89209624|NCT00812630|Experimental|1|In the second part of the trial, subjects will apply MENT or placebo gel transdermally for 12 weeks and will have 24-hour blood pressure monitoring at baseline, Week 6 and Week 12.
89209625|NCT00813878||Normal participants|
89584573|NCT01567852|Experimental|Ketamine First|This arm will receive ketamine for induction first, followed by alternating treatments between methohexital and ketamine
89584574|NCT01567852|Experimental|Methohexital First|This arm will receive Methohexital first for induction, followed by alternating treatments between ketamine and methohexital.
89584575|NCT01588366|Placebo Comparator|Placebo|Part A and B - Up to 4 capsules of placebo administered orally once a day for 28 days.
89584576|NCT01588366|Experimental|15 mg LY2409021|Part B - 1 capsule of 15 mg LY2409021 orally once a day for 28 days. (Arm added in September, 2012, per protocol amendment.)
89209626|NCT00813878||Breast Cancer Patients|
89209627|NCT00808106||Albinism|Patients with albinism
89209628|NCT02551640|Experimental|Group A|"Receive a Samsung smartphone~Receive the FeatForward app~Receive a Samsung smartwatch~Continue to receive medical care as usual"
89209629|NCT02551640|No Intervention|Group B|"Receive a Samsung smartphone~Receive a Samsung smartwatch~Continue to receive medical care as usual"
89584577|NCT01588366|Experimental|60 mg LY2409021|Part A - 4 capsules of 15 mg LY2409021 administered orally once a day for 28 days.
89584578|NCT01686958|Experimental|MR-Guided Transurethral US Ablation|MR-Guided Transurethral US Ablation of Prostate Tissue
89584579|NCT01686568|Experimental|Omega-3|Patients in this group will receive oral supplementation with EPA+DHA (3.9grams/day) for 6 months.
89584580|NCT01686568|Placebo Comparator|Placebo|Patients in this group will be supplemented with placebo capsules containing ethyl oleate.
89584581|NCT01567462|Active Comparator|Monopolar Electrocautery|The current treatment standard of care for patients who present de novo or with a recurrent bladder tumor is transurethral resection of the bladder tumor (TURBT) using monopolar electrocautery in the form a 90-degree loop electrode and has been used since its introduction in 1952. This intervention, accomplished endoscopically through the urethra, is both diagnostic and potentially therapeutic. An adequately performed TURBT will provide the pathologist with enough tissue to provide tumor grade and stage information.
89584582|NCT01567462|Active Comparator|PK Button Vaporization Electrode|Bipolar energy has been available for many years and has been readily adopted for the surgical treatment of benign prostatic enlargement and may provide advantages and solutions to the technical challenges of monopolar electrocautery. A further refinement on bipolar energy has been the recent introduction of the PlasmaKinetic (PK) Button Vaporization electrode which will be used in the intervention arm of this study. This electrode is already approved by the Food and Drug Administration (FDA) for this indication as well. The semi-spherical design of the electrode creates a plasma arc that glides over the tissue, transmitting energy to the cell layers adjacent to the arc which are then quickly vaporized.
89584583|NCT01587898|Experimental|0.5mg GSK1278863|Once daily
89584584|NCT01587898|Experimental|2mg GSK1278863|Once daily
89584585|NCT01587898|Experimental|5mg GSK1278863|Once daily
89584586|NCT01587898|Experimental|Placebo|Once daily
89584587|NCT01567306|Experimental|Allergovac Depot Group 1 Active|
89584588|NCT01567306|Experimental|Allergovac Depot Group 2 Active|
89584589|NCT01567306|Experimental|Allergovac Depot Group 3 Active|
89584590|NCT01567306|Experimental|Allergovac Depot Group 4 Active|
89584591|NCT01567306|Experimental|Allergovac Depot Group 5 Active|
89584592|NCT01567306|Placebo Comparator|Placebo - Group 6|
89584593|NCT01587274|Active Comparator|Opioid|Naproxen + opioid
89584594|NCT01587274|Active Comparator|Skeletal muscle relaxant|Naproxen + skeletal muscle relaxant
89584595|NCT01587274|Active Comparator|Naproxen alone|Naproxen + placebo
89030171|NCT01249131|Experimental|Treatment C first, then Treatment A, followed by Treatment B|Treatment C: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water within 30 minutes of eating a standard FDA high-fat meal, in first intervention period. Treatment A: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in second intervention period. Treatment B: Four 5-mg capsules of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in third intervention period.
89209630|NCT00654368|Active Comparator|Etanercept + Methotrexate|After six months of treatment with 50 mg/week subcutaneous etanercept added to existing methotrexate therapy of at least 15 mg/week (or 10 mg/week in case of documented intolerance to higher doses) participants were randomized to continue both etanercept plus methotrexate for an additional 18 months.
89584596|NCT01587118|Experimental|antidepressant plus asenapine|adjunctive asenapine
89584597|NCT01905657|Experimental|Pembrolizumab 2 mg/kg|Participants received pembrolizumab 2 mg/kg intravenously (IV) over 30 minutes Q3W for up to 2 years.
89584598|NCT01905657|Experimental|Pembrolizumab 10 mg/kg|Participants received pembrolizumab 10 mg/kg IV over 30 minutes Q3W for up to 2 years.
89584599|NCT01905657|Active Comparator|Docetaxel 75 mg/m^2|Participants received docetaxel 75 mg/m^2 IV over 1 hour Q3W for up to 2 years.
89584600|NCT02202980|Experimental|LDV/SOF+RBV 24 Weeks (Cohort 1 Group 1)|Participants who previously received ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) plus ribavirin (RBV) for ≥ 12 weeks without achieving sustained virologic response at 12 weeks following treatment (SVR12) will receive LDV/SOF+RBV for 24 weeks.
89584601|NCT02202980|Experimental|LDV/SOF+RBV 12 Weeks (Cohort 1 Group 2)|Participants who previously received a sofosbuvir-based regimen without achieving SVR12 were initially enrolled to receive LDV/SOF+RBV for 12 weeks (excluding participants who previously received LDV/SOF+RBV for ≥ 12 weeks). Participants who did not achieve sustained virologic response at 12 weeks were then moved to Cohort 1 Group 1.
89584602|NCT02202980|Experimental|LDV/SOF 12 Weeks GT2 (Cohort 2 Group 1)|Participants with genotype 2 (GT2) HCV infection will receive LDV/SOF FDC for 12 weeks.
89584603|NCT02202980|Experimental|LDV/SOF 8 Weeks GT2 (Cohort 2 Group 2)|Participants with GT2 HCV infection will receive LDV/SOF FDC for 8 weeks.
89584604|NCT02202980|Experimental|LDV/SOF 12 Weeks GT1/GT2/GT4 (Cohort 3 Group 1)|Participants with genotypes 1 (GT1), 2 (GT2), or 4 (GT4) HCV infection and extrahepatic manifestations of chronic HCV infection will receive LDV/SOF FDC for 12 weeks.
89584605|NCT02202980|Experimental|LDV/SOF+RBV 12 Weeks GT3 (Cohort 3 Group 2)|Participants with genotype 3 (GT3) HCV infection and extrahepatic manifestations of chronic HCV infection will receive LDV/SOF FDC plus RBV for 12 weeks.
89584606|NCT02202980|Experimental|SOF/VEL+VOX 6 Weeks GT1 (Cohort 4)|Treatment-naive participants with GT1 HCV infection without cirrhosis will receive VOX only on Day 1 followed by sofosbuvir/velpatasvir (SOF/VEL) + voxilaprevir (VOX) for 6 weeks.
89584607|NCT02202980|Experimental|SOF/VEL+VOX 4 Weeks GT1 (Cohort 5 Group 1)|Treatment-naive participants with GT1 HCV infection without cirrhosis will receive SOF/VEL+VOX for 4 weeks.
89584608|NCT02202980|Experimental|SOF/VEL+VOX 6 Weeks GT1 (Cohort 5 Group 2)|Treatment-naive participants with GT1 HCV infection with cirrhosis will receive SOF/VEL+VOX for 6 weeks.
89584609|NCT02202980|Experimental|SOF/VEL+VOX 6 Weeks GT3 (Cohort 5 Group 3)|Treatment-naive participants with GT3 HCV infection with cirrhosis will receive SOF/VEL+VOX for 6 weeks.
89584610|NCT02202980|Experimental|SOF/VEL+VOX 8 Weeks GT1 (Cohort 5 Group 4)|Treatment-experienced participants with GT1 HCV infection with cirrhosis who were previously treated with pegylated interferon (Peg-IFN)+RBV will receive SOF/VEL+VOX for 6 weeks.
89584611|NCT02202980|Experimental|SOF/VEL+VOX 8 Weeks GT3 (Cohort 5 Group 5)|Treatment-experienced participants with GT3 HCV infection with cirrhosis who were previously treated with Peg-IFN+RBV will receive SOF/VEL+VOX for 6 weeks.
89584612|NCT02202980|Experimental|SOF/VEL+VOX 8 Weeks GT1 (Cohort 5 Group 6)|Treatment-experienced participants with GT1 HCV infection with or without cirrhosis who were previously treated with non-structural protein (NS3/4A) protease inhibitor (PI) will receive SOF/VEL+VOX for 6 weeks.
89584613|NCT02202980|Experimental|SOF/VEL+VOX 6 Weeks GT1 (Cohort 5 Group 7)|Treatment-experienced participants with GT1 HCV infection with or without cirrhosis who were previously treated with direct-acting antivirals (DAA) will receive SOF/VEL+VOX for 6 weeks.
89584614|NCT02202980|Experimental|SOF/VEL+VOX 8 Weeks GT3 (Cohort 5 Group 8)|Treatment-experienced participants with GT3 HCV infection with or without cirrhosis who were previously treated with DAA will receive SOF/VEL+VOX for 8 weeks.
89584615|NCT01952145|Experimental|Insulin degludec/liraglutide OD plus metformin|
89584616|NCT01952145|Active Comparator|Insulin glargine OD plus metformin|
89584617|NCT04416087|Experimental|Experimental group|The experiment consists of a supine bicycle exercise in a positron emission tomography (PET) scanner. Each subject will perform the experiment as well as serve as their own control (tumor blood flow at rest vs. blood flow during exercise).
89584618|NCT01923363|Experimental|Standard Dose to High Dose Piperacillin/Tazobactam|Patients will receive a standard dose of piperacillin/tazobactam, then will have subsequent pharmacokinetic analyses on the blood concentrations drawn while on standard dose. Then, they will be switched to higher dose, with subsequent pharmacokinetic analyses performed on those blood concentrations while on higher dose. These pharmacokinetics of each dosing regimen will be compared.
89584619|NCT01905267|Experimental|Treatment|Participants randomized to the experimental condition will receive 8 weeks of individual treatment with Rumination-Focused Cognitive Behavior Therapy
89584620|NCT01905267|No Intervention|Control|Participants randomized to the control arm will complete questionnaires and receive mood monitoring for the duration of the study
89584621|NCT01923285|Experimental|AXIUM Neurostimulator System|The AXIUM Neurostimulator System is an investigational spinal cord stimulation device that is designed to stimulate the dorsal root ganglion (DRG) of the spine located on the back surface of the spinal cord where nerves exit the backbone. The device has 2 parts that are placed surgically (implanted) : 1) a pulse generator which is placed under the skin in the buttocks or abdomen, and 2) up to four wires (leads) that have one end attached to the pulse generator, and the other end secured to the tissue near the target treatment area.
89584622|NCT01923285|Active Comparator|Control Spinal Cord Stimulation Device|The Control Spinal Cord Stimulation Device is a commercially available spinal cord stimulator indicated for the treatment of chronic lower limb pain.
89584623|NCT01904721|Experimental|Stage 1: Bimatoprost Solution 1 Twice Daily|Stage 1: Bimatoprost Solution 1 applied evenly onto pre-specified area on the scalp twice daily for 28 days.
88974820|NCT00030368|Experimental|Treatment (bortezomib, paclitaxel)|Patients receive bortezomib IV on days 2 and 9 and paclitaxel IV over 1 hour on days 1 and 8. For the first course only, patients do not receive paclitaxel on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
89584624|NCT01904721|Experimental|Stage 1: Bimatoprost Solution 1 Once Daily|Stage 1: Bimatoprost Solution 1 applied evenly onto pre-specified area on the scalp once daily for 28 days.
89584625|NCT01904721|Experimental|Stage 1: Bimatoprost Solution 2 Twice Daily|Stage 1: Bimatoprost Solution 2 applied evenly onto pre-specified area on the scalp twice daily for 28 days.
89584626|NCT01904721|Experimental|Stage 1: Bimatoprost Solution 2 Once Daily|Stage 1: Bimatoprost Solution 2 applied evenly onto pre-specified area on the scalp once daily for 28 days.
89584627|NCT01904721|Experimental|Stage 2: Bimatoprost Solution 1 Twice Daily|Stage 2: Bimatoprost Solution 1 applied evenly onto pre-specified area on the scalp twice daily for 6 months.
89584628|NCT01904721|Experimental|Stage 2: Bimatoprost Solution 2 Twice Daily|Stage 2: Bimatoprost Solution 2 applied evenly onto pre-specified area on the scalp twice daily for 6 months.
89584629|NCT01904721|Placebo Comparator|Stage 2: Bimatoprost Vehicle Twice Daily|Stage 2: Bimatoprost Vehicle applied evenly onto pre-specified area on the scalp twice daily for 6 months.
89584630|NCT05122533||Study group|"18-30 year-old, healthy volunteers~Age: 18-30 years~BMI: <30~No previous surgery on lower limb or spine~No known developmental disorder~Without any orthopaedic complaint"
89584631|NCT01922895|Placebo Comparator|Placebo for Probiotic|Placebo capsule that matches the probiotic capsule in appearance will be given once daily for 180 days.
89584632|NCT01922895|Active Comparator|Lactobacillus Rhamnosus GG|Dietary supplement capsule (Lactobacillus Rhamnosus GG) will be given once daily for 180 days.
89584633|NCT01922739|Experimental|Hydrocodone ER|Participants were administered hydrocodone ER tablets orally at dosages of 15, 30, 45, 60, or 90 mg every 12 hours at the dosage deemed successful for managing their pain. If enrolled under the original protocol, there was a double-blind titration period of four weeks to adjust the dose taken in study 3103 (NCT01789970). If enrolled under the amended protocol, there was an open-label adjustment period of three weeks to adjust the dose taken in study 3103 (NCT01789970). Both versions of protocol 3104 followed the titration/adjustment period with a open-label treatment period of 22 weeks.
89584634|NCT02236988|Experimental|Group 1|"Participants received the following 4 treatments, given in 4 possible sequences (ADBC, BACD, CBDA, and DCAB) with 7 to 10 days between each treatment:~A) Two oral doses of 30 mg apremilast immediate release tablets 12 hours apart (reference formulation) B) A single oral dose 75 mg apremilast tablet prototype MR 1 C) A single oral dose 75 mg apremilast tablet prototype MR 2 D) A single oral dose 75 mg apremilast capsule prototype MR 3"
89584635|NCT02236988|Experimental|Group 2|"Participants received the following 4 treatments, given in 4 possible sequences (AGEF, EAFG, FEGA, and GFAE) with 7 to 10 days between each treatment:~A) Two oral doses of 30 mg apremilast immediate release tablets 12 hours apart (reference formulation) E) A single oral dose 75 mg apremilast capsule prototype MR 4 F) A single oral dose 75 mg apremilast capsule prototype MR 5 G) A single oral dose 75 mg apremilast capsule prototype MR 6"
89584636|NCT02236988|Experimental|Group 3|"Participants received the following 3 treatments, given in 6 possible sequences (AIJ, IJA, JAI, AJI, IAJ, or JIA) with 7 to 10 days between each treatment:~A) Two oral doses of 30 mg apremilast immediate release tablets 12 hours apart (reference formulation) I) A single oral dose 80 mg apremilast capsule prototype MR 8 J) A single oral dose 80 mg apremilast capsule prototype MR 9"
88974821|NCT00057603|Experimental|Deep Brain Stimulation|Participants receive deep brain stimulation treatment for 30 months.
89584637|NCT02236988|Experimental|Group 4|"Participants received the following 5 treatments, given in 10 possible sequences (ALOMN, LMANO, MNLOA, NOMAL, OANLM, NMOLA, ONAML, AOLNM, LAMON, or MLNAO) with 7 to 10 days between each treatment:~A) Two oral doses of 30 mg apremilast immediate release tablets 12 hours apart (reference formulation) L) A single oral dose 80 mg apremilast capsule prototype MR 11 M) A single oral dose 80 mg apremilast capsule prototype MR 12 N) A single oral dose 80 mg apremilast capsule prototype MR 13 O) A single oral dose 80 mg apremilast capsule prototype MR 14"
89584638|NCT02236598|Experimental|K+ supplementation|K-supplement- Klor-Con® M10 is an immediately dispersing extended-release oral dosage form of potassium chloride containing 750 mg of microencapsulated potassium chloride, United States Pharmacopeia (USP) equivalent to 10 milliequivalent (mEq) of potassium in a tablet. Participants will be instructed to take two 10 mEq tablets twice daily in a blinded encapsulated form, for 3 months
89584639|NCT02236598|Experimental|Placebo|"Placebo - An inert powdered placebo will be identically encapsulated as the Klor-Con intervention tablets to maintain blinding. Participants will be instructed to take two tablets twice daily in a blinded encapsulated form, for 3 months~Subjects will be instructed to take the pills"
89584640|NCT01922349|Placebo Comparator|Placebo (Multiple dose)|Placebo
89584641|NCT01922349|Experimental|Dose 1, Single dose|Low dose
89584642|NCT01922349|Experimental|Dose 2, Single dose|Medium dose
89584643|NCT01922349|Experimental|Dose 3, Single dose|High dose
89209631|NCT00654368|Experimental|Etanercept Only|After six months of treatment with 50 mg/week subcutaneous etanercept added to existing methotrexate therapy of at least 15 mg/week (or 10 mg/week in case of documented intolerance to higher doses) participants were randomized to discontinue methotrexate (tapered over 6 weeks) and continue etanercept alone for an additional 18 months.
89584644|NCT01922349|Experimental|Dose 4, Multiple dose|Low dose
89584645|NCT01922349|Experimental|Dose 5, Multiple dose|Medium dose
89584646|NCT01922349|Experimental|Dose 6, Multiple dose|High dose
89584647|NCT01922349|Placebo Comparator|Placebo (Single dose)|Placebo
89584648|NCT02236520|Active Comparator|Spironolactone|50 mg capsule of Spironolactone administered orally 1 per day for 8 weeks
89584649|NCT02236520|Active Comparator|Chlorthalidone|25 mg capsule of Chlorthalidone administered orally 1 per day for 8 weeks
89584650|NCT02236520|Active Comparator|Diet|diet of 6 g salt per day for 8 weeks
89584651|NCT02236520|Placebo Comparator|Placebo|placebo capsule administered orally 1 per day for 8 weeks
89584652|NCT04769414|Experimental|Chemotherapy|"Participants will receive the test protocol Gem-5FU on biweekly basis for 6 months with interim evaluation~Doses as follows:~Gemcitabine 1000 mg/m2, infusion over 30 min, D1, D15 Leucovorin 400 mg/m2 infusion over 30 min , D1, D15 5FU 400 mg/m2 I.V. shot D1, D15 5FU 2000 mg/m2 infusion over 46 hours D1 , D15"
89584653|NCT01922271|Experimental|NVA237 followed by tiotropium|Period 1: NVA237 plus placebo to tiotropium on day 1, followed by a 7 day washout. Period 2: tiotropium plus placebo to NVA237 on day 8. Salbutamol was used as rescue medication.
89584654|NCT01922271|Experimental|Tiotropium followed by NVA237|Period 1: tiotropium plus placebo to NVA237 on day 1, followed by a 7 day washout. Period 2: NVA237 plus placebo to tiotropium on day 8. Salbutamol was used as rescue medication.
89584655|NCT02236130|Active Comparator|General|General Anesthesia only
89584656|NCT02236130|Experimental|Regional|General Anesthesia combined with regional block
89584657|NCT02233946|Experimental|screening w/ computer brief intervention|screening with computer-facilitated brief intervention
89584658|NCT02233946|No Intervention|Screening with Treatment as Usual|Screening with Treatment as Usual
89584659|NCT02232698|Experimental|Sensor Based Glucose Monitoring System|Standard sensing system use for 6 months.
89584660|NCT02232698|Active Comparator|Standard Blood Glucose Monitoring|Subjects randomised to the control group will be given blood glucose meters for monitoring for the 6 months study duration.
89584661|NCT01632878||Post Myocardial Infarction|One single cohort of Index post Myocardial Infarction patients
89584662|NCT01632800|Experimental|Single arm study|Each subjects will undergo escalating exposure to magnetic field
89584663|NCT01641809|Experimental|Arm 1 GSK1265744 10 mg|In the Induction Phase subjects will receive oral tablets of GSK1265744 10 mg + matching placebo + investigator-selected background NRTIs (either abacavir/lamivudine or tenofovir/emtricitabine) once daily from Day 1 to Week 24. Subjects continuing in the Maintenance Phase will receive oral tablets of GSK1265744 10 mg + matching placebo + Rilpivirine 25 mg once daily from Week 24 to Week 96.
89584664|NCT01641809|Experimental|Arm 2 GSK1265744 30 mg|In the Induction Phase subjects will receive oral tablets of GSK1265744 30 mg + matching placebo + investigator-selected background NRTIs (either abacavir/lamivudine or tenofovir/emtricitabine) once daily from Day 1 to Week 24. Subjects continuing in the Maintenance Phase will receive oral tablets of GSK1265744 30 mg + matching placebo + Rilpivirine 25 mg once daily from Week 24 to Week 96.
89584665|NCT01641809|Experimental|Arm 3 GSK1265744 60 mg|In the Induction Phase subjects will receive oral tablets of GSK1265744 60 mg + investigator-selected background NRTIs (either abacavir/lamivudine or tenofovir/emtricitabine) once daily from Day 1 to Week 24. Subjects continuing in the Maintenance Phase will receive oral tablets of GSK1265744 60 mg + Rilpivirine 25 mg once daily from Week 24 to Week 96.
89209632|NCT04017026||6 mm implants|Patients were treated with 6mm short implants (Straumann, SLA, SLActive, 4.1 or 4.8 mm in diameter).
89209633|NCT00812864|Experimental|Capecitabine|
89209634|NCT00814034||1:Tamoxifen|
89209635|NCT00814034||2:Steroidal Aromatase Inhibitor|
89209636|NCT00814034||3:Non-steroidal Aromatase Inhibitor|
89209637|NCT00808184|Active Comparator|CPT-11|
89209638|NCT02551562|Placebo Comparator|Group A: Basic Skin Care|Subjects will use a basic skin care regime following a full facial rejuvenation with hyaluronic acid soft-tissue filler and botulinum neurotoxin.
89209639|NCT02551562|Experimental|Group B: NuDerm® System|Subjects will use the Nu-Derm® system following a full facial rejuvenation with hyaluronic acid soft-tissue filler and botulinum neurotoxin.
89584666|NCT01641809|Active Comparator|Arm 4 Efavirenz 600 mg|In the Induction Phase and Maintenance Phase subjects will receive oral tablets of Efavirenz 600 mg + investigator-selected background NRTIs (either abacavir/lamivudine or tenofovir/emtricitabine).
89584667|NCT01632566|Placebo Comparator|Placebo|Daily oral administration of placebo for 28 days. Dose will match corresponding LY3031207 dosage.
89584668|NCT01632566|Experimental|LY3031207|Daily oral administration of 25 milligrams (mg) LY3031207 up to 450 mg LY3031207 for 28 days.
89584669|NCT01632566|Active Comparator|Celecoxib|Daily oral administration of 400 mg celecoxib for 28 days. Positive control for LY3031207.
89584670|NCT01632566|Other|LY3031207 + Simvastatin|Daily oral administration of 75 mg LY3031207 or 225 mg LY3031207 for 28 days. Single, oral 10 mg simvastatin open-label dose administered before and after 28-day dosing of LY3031207.
89584671|NCT00752804|Experimental|1|Dialysis during 4 hours
89584672|NCT00752804|Active Comparator|2|Dialysis during 6 hours
89584673|NCT00752804|Active Comparator|3|Dialysis during 8 hours
89584674|NCT05645081||Healthy Control|A group of participants with no previous symptoms or diagnosis of TIA or stroke.
89584675|NCT05645081||Non-TIA Control|A group of participants who were referred to TIA clinic with symptoms of a TIA, however, were subsequently confirmed as not suffering with a TIA.
89584676|NCT05645081||TIA, non-stroke|A group of participants who were confirmed as suffering a TIA by a stroke clinician following admission to hospital, admission to Accident and Emergency or after being referred to TIA clinic. These participants did not suffer a stroke within 12 months of TIA diagnosis.
89584677|NCT05645081||TIA, stroke|A group of participants who were confirmed as suffering a TIA by a stroke clinician following admission to hospital, admission to Accident and Emergency or after being referred to TIA clinic. These participants went on to suffer a stroke within 12 months of TIA diagnosis.
89584678|NCT04863521|Experimental|MHP Users|A subset of the population within the clinical setting will be requested to participate in this pilot while the rest of the population will receive standard of care.
89584679|NCT02254304|Experimental|Rebif in Relapsing Multiple Sclerosis (RMS) Subjects|
89584680|NCT02254304|Experimental|Rebif in Clinically Isolated Syndromes (CIS) Subjects|
89584681|NCT04863287|Experimental|0.5 mg/kg of 2217LS|Single dose subcutaneous injection
89584682|NCT04863287|Experimental|1.5 mg/kg of 2217LS|Single dose subcutaneous injection
89584683|NCT04863287|Experimental|5 mg/kg of 2217LS|Single dose subcutaneous injection
88974822|NCT00030407|Experimental|Celecoxib & Docetaxel|"Celecoxib: On day -7 of the first cycle, patients will start, Celecoxib 400 mg po bid daily, each dose to give with meals~Docetaxel: On day 1, 8, and 15 of each cycle patients will receive: Docetaxel 36mg/m2 over 60 minutes, duration of each cycle will be 28 days."
89584684|NCT04863287|Experimental|10 mg/kg of 2217LS|Single dose subcutaneous injection
89584685|NCT04863287|Placebo Comparator|0.9% Sodium Chloride (NaCl)|Single dose subcutaneous injection
89584686|NCT04420091|Experimental|Cartidyss|
89584687|NCT04862195|Active Comparator|Attune™|Attune™ is a completely digital, 10-session, cognitive behavioral therapeutic intervention.
88974823|NCT00057642|Other|Sertraline, venlafaxine, bupropion|This is an open trial so there is only one arm using standard antidepressant medications.
89209640|NCT00814112||1 septic shock|septic shock, ICU
89209641|NCT00814112||2 controls|matched controls
89584688|NCT04862195|Active Comparator|Cerena™|Cerena™ is a completely digital, 10-session, health education and wellness intervention.
89584689|NCT04861805|Other|Vienna Aortic Valve|transcatheter aortic valve implantation (TAVI)
89584690|NCT05650151|Experimental|Vitamin D group|
89584691|NCT05650151|Placebo Comparator|Control group|
89584692|NCT02174731|Experimental|Roxadustat|
89584693|NCT02174731|Active Comparator|Epoetin alfa|
89584694|NCT01922037|Experimental|Participants With Allergic Asthma|Participants with allergic asthma, who have decided to initiate treatment with omalizumab will be observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurs first.
89584695|NCT02282813|Experimental|CTAP101 Capsules alone|CTAP101 Capsules 30 or 60 mcg daily for up to 26 weeks
89584696|NCT02282813|Experimental|CTAP101 Capsules +calcitriol|CTAP101 Capsules 60 mcg +calcitriol daily for 14 weeks
89584697|NCT02282813|Experimental|CTAP101 Capsules +doxercalciferol|CTAP101 Capsules 60 mcg +doxercalciferol daily for 14 weeks
89584698|NCT02282813|Experimental|CTAP101 Capsules +paricalcitol|CTAP101 Capsules 60 mcg +paricalcitol daily for 14 weeks
89584699|NCT01903863|Experimental|Scheduled fresh frozen plasma|Patients enrolled in this arm will receive scheduled fresh frozen plasma treatment every 48 hours.
89584700|NCT01903863|Active Comparator|Control|Patients in this arm will receive fresh frozen plasma per current institutional standard of care. This includes supplementation for clotting/bleeding diatheses, volume replacement, or after 3 red blood cell transfusions in a 24 hour period.
89584701|NCT02123251|Experimental|Financial Incentives Group|Participants (159) in the Incentive Group will: 1) continue to receive usual care; 2) are eligible to receive financial incentives based on completion of recommended ADA benchmarks and achievement of goals that are founded on evidence based guidelines for diabetes; and 3) be compensated for completion of surveys.
89584702|NCT02123251|No Intervention|Control Group|Participants (161) in the Control Group will continue to receive usual care and be compensated for the completion of surveys only. They will not receive financial incentives.
89584703|NCT04746469|No Intervention|Control|This group will receive standard FIT mailer protocol (includes mailed FIT kit plus standardized messaging via EHR portal)
89584704|NCT04746469|Experimental|Intervention|This group will receive standard FIT mailer protocol (as above) PLUS delayed automated phone reminder
89584705|NCT05638529|Experimental|Treatment Arm- Group A|A subcutaneous injection of a GnRH agonist (Suprefact 0.5 mg) and a separate intramuscular injection of hCG (Pregnyl 1,500 IU).
89584706|NCT05638529|Placebo Comparator|Control Arm- Group B|A subcutaneous injection of a GnRH agonist (Suprefact 0.5 mg) and a separate intramuscular injection of normal saline (1.5 mL) (sham-placebo).
89209642|NCT00814190|Experimental|Internet Intervention|The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.
89209643|NCT00814190|No Intervention|Standard Care|This arm will receive standard care which includes self-blood glucose monitoring at least 3 times daily and visit to the endocrinologist at least once every 3 months.
89209644|NCT00812942|Active Comparator|fobt|faecal occult blood test
89584707|NCT01902303|Placebo Comparator|Matching Placebo|Matching Placebo
89584708|NCT01902303|Experimental|BTL-TML-HSV|Experimental Product
89584709|NCT02122783|Experimental|Conventional then Experimental brace resistance|Participants received the Default intervention for a period of a month, were evaluated in the lab and then the novel intervention was administered for use for the next month. There was a small period (few hours in the lab) where the subject was transitioned to the second intervention.
89584710|NCT02122783|Experimental|Experimental then Conventional brace resistance|Participants received the the novel elastomer to provide brace support intervention for a period of a month, were evaluated in the lab and then the conventional intervention was administered for use for the next month. There was a small period (few hours in the lab) where the subject was transitioned to the second intervention.
89584711|NCT04859933||AVNA group|Group of historical controls beeing treated with AV-node ablation
89584712|NCT04859933||AVNI group|Inculudes all patients beeing treated with AV-node isolation
89584713|NCT01921257|Experimental|Treatment|Cat-PAD and Placebo
89584714|NCT02121847|Experimental|cyclosporine 0.05% ophthalmic emulsion|Cyclosporine 0.05% ophthalmic emulsion (Restasis®) eye drops administered twice daily and carboxymethylcellulose-based lubricant eye drops (Refresh OPTIVE® Advanced) administered as needed for 6 months.
89584715|NCT05637593|Experimental|the RAS group|The RAS group will receive upper-limb movement training with the aid of RAS;
89584716|NCT05637593|Active Comparator|the no-RAS group|The no-RAS group will receive upper-limb movement training without the aid of RAS.
89584717|NCT01921179|Experimental|GOALS (Goal-Oriented Attentional Regulation)|Goal-Oriented Attentional Regulation (GOALS) will involve 5-weeks of training (20 hours of group training (2 hour sessions, 2 days per week), 3 hours of individual training (1 hour at the beginning, halfway through and at the end of training), and approximately 20 hours of home practice). Some subjects will only receive the GOALS intervention.
89584718|NCT01921179|Active Comparator|EDU (Brain Health Education)|Brain Health Education (EDU) will involve 5-weeks of training (20 hours of group training (2 hour sessions, 2 days per week), 3 hours of individual training (1 hour at the beginning, halfway through and at the end of training), and approximately 20 hours of homework). The EDU intervention involves education on brain health and functioning in a classroom format, with study materials for homework. Some subjects will start with EDU and then cross-over to the GOALS.
89584719|NCT01587040|Experimental|SAR245408: Monotherapy|Participants received SAR245408 400 milligrams (mg) once daily or at the established dose as monotherapy in the parental study until disease progression, unacceptable toxicity, withdrawal of consent, or until commercial supplies of SAR245408 were available (up to 1959 days).
89584720|NCT01587040|Experimental|SAR245408: Combination Regimen|Participants received SAR245408 400 mg once daily or at the established dose as combination regimen in the parental study until disease progression, unacceptable toxicity, withdrawal of consent, or until commercial supplies of SAR245408 were available (up to 1959 days). Commercially available drugs were used as combination medications with SAR245408 (depending on the parental study, the following drugs were used in combination with SAR245408: paclitaxel and carboplatin, letrozole, trastuzumab, paclitaxel and trastuzumab).
89584721|NCT01587040|Experimental|SAR245409: Monotherapy|Participants received SAR245409 50 mg twice daily or at the established dose as monotherapy in the parental study until disease progression, unacceptable toxicity, withdrawal of consent, or until commercial supplies of SAR245409 were available (up to 1917 days).
89584722|NCT01587040|Experimental|SAR245409: Combination Regimen|Participants received SAR245409 50 mg twice daily or at the established dose as combination regimen in the parental study until disease progression, unacceptable toxicity, withdrawal of consent, or until commercial supplies of SAR245409 were available (up to 1917 days). Commercially available drugs were used as combination medications with SAR245409 (depending on the parental study, the following drugs were used in combination with SAR245409: letrozole, temozolomide, rituximab, bendamustine and rituximab).
89584723|NCT02144701|Experimental|Lactobacillus rhamnosus GG|Patients receive Lactobacillus rhamnosus GG PO QD for 1 year.
89209645|NCT00812942|Active Comparator|colonoscopy|colonoscopy screening
89209646|NCT00647426|Experimental|Sorafenib + Docetaxel/Carboplatin|400 mg po BID Sorafenib + 75 mg/m2 IV Docetaxel on day 1 plus AUC 6 on Carboplatin on day 1 of each 21 day cycle
89209647|NCT00647348|Active Comparator|1|Simvastatin 80mg OD
89209648|NCT00647348|Placebo Comparator|2|Placebo
89209649|NCT00813020|Experimental|A|
89209650|NCT00813020|Experimental|B|
89209651|NCT00813020|Experimental|C|
89209652|NCT00647270|Placebo Comparator|Placebo|Placebo 12 weeks, 40mg adalimumab remaining 12 weeks
89209653|NCT00647270|Active Comparator|40 mg|40 mg every other week
89209654|NCT00647270|Active Comparator|80 mg|80 mg monthly
89209655|NCT00813254||Questionnaire|Longitudinal measure of QOL, sexual functioning and symptoms in women with recurrent, platinum-resistant ovarian cancer receiving multiple second-line treatment regimens
89209656|NCT00645944|Experimental|Eszopiclone Group|Participants assigned to this arm will receive Eszopiclone 2mg each night for the first week then Eszopiclone 3mg each night for the remaining weeks.
89209657|NCT00645944|Placebo Comparator|Placebo Group|"Participants assigned to this arm will receive placebo (an inactive substance or a sugar pill) to be taken each night for all weeks of the study."
89584724|NCT02144701|No Intervention|No intervention|Patients receive no intervention.
89584725|NCT05556161|Experimental|Intervention Group|The 12-month general practitioners and diabetes specialists co-management will be received by intervention group participants.
89584726|NCT05556161|No Intervention|Control group|Routine primary health care will be received by control group participants during the course of the Study.
89584727|NCT01921101|Other|intensive medical nutrition|participants will receive intensive medical nutrition from hospital admission to discharge
89584728|NCT01921101|Other|control|participants will not receive intensive nutritional support from hospital admission to discharge
89584729|NCT01586806|Placebo Comparator|Control|
89584730|NCT01586806|Active Comparator|Dexamethasone 1 mg|
89584731|NCT01586806|Active Comparator|Dexamethasone 4 mg|
89584732|NCT02144077|Active Comparator|BF-200 ALA|Topical application of BF-200 ALA gel containing 78 mg/g 5-aminolevulinic acid. Application of a 1 mm thick layer covering each lesion and 0.5 to 1 cm of surrounding margin.
89584733|NCT02144077|Active Comparator|methyl-aminolevulinate|Topical application of Metvix creme containing 160 mg/g methyl-aminolevulinate. Application of a 1 mm thick layer covering each lesion and 0.5 to 1 cm of surrounding margin.
89584734|NCT04860869||symptomatic Post-COVID|32 patients with Post-COVID syndrome
89584735|NCT04860869||non-symptomatic post-COVID|32 patients with that recovered without lingering symptoms after being infected with COVID
89584736|NCT05545553|Experimental|Piezosurgery group|In the experimental group, a piezosurgery device was used to remove the bone surrounding the impacted third molar.
89584737|NCT05545553|Active Comparator|Conventional group|In the control group, conventional burs were used to remove the bone surrounding the impacted third molar.
89584738|NCT02985892|Experimental|SSASG|Stabilization and stretching group, 12 session, 60 minutes each. This group will perform stretching for back muscles in different positions, associated with stabilization exercises using a protocol developed by Richardson, 2005.
89584739|NCT02985892|Experimental|SSPSG|Stabilization Group, 12 session, 60 minutes each. This group will perform placebo stretching for upper limb muscles (the muscle is not stretched in it maximum extent) with stabilization exercises, using a protocol developed by Richardson, 2005.
88974824|NCT02969694||Patients who use psychostimulants products in sexual contexts|"Patients who come to the CSAPA at the Croix-Rousse Hospital, Lyon France following the use of psychostimulants products in sexual contexts.These patients come for an addictologique support.~The patients will answer to the G-STAT questionnaire."
88974825|NCT00057759|Experimental|Sildenafil citrate|Sildenafil with dose escalation as needed from 50 mg to 100 mg/day prn for 12 weeks.
88974826|NCT00057759|Placebo Comparator|Placebo|"Placebo with similar dose escalation opportunity for 12 weeks."
88974827|NCT00057915|Experimental|CEA peptide 1-6D|CAP-1(6D) peptide-pulsed, matured, autologous human DC produced by the AastromReplicell™ Cell Production System
88974828|NCT02969733|Experimental|Xylocaine|intravenous administration
88974829|NCT02969733|Experimental|Ketamine|intravenous administration
88974830|NCT02969733|Placebo Comparator|isotonic saline serum|isotonic saline serum intravenous administration
88974831|NCT04730895|Experimental|Oral 13 cis retinoic acid|The participants will receive 13 cis retinoic acid (0.5 mg/kg/day in 2 divided doses orally for 14 days . All subjects were encouraged to complete the full course of treatment and common side effects were explained. Side effects and compliance will be documented.
89584740|NCT02172625|Placebo Comparator|Placebo Group|Corn starch and food coloring is the placebo comparator. Each subject will ingest 675 mg (1 pill) per day of the placebo comparator
89584741|NCT02172625|Experimental|Protandim Dietary Supplement|Each subject will ingest 675 mg per day (1 pill) of Protandim for about 90 days. Each pill contains 5 botanicals (Bacopa extract 150 mg, milk thistle 225mg, ashwagandha 150 mg, green tea 75 mg, turmeric 75 mg).
88974832|NCT04730895|Experimental|Aerosolized 13 cis retinoic acid|The participants will receive Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days. All subjects were encouraged to complete the full course of treatment and common side effects were explained. Side effects and compliance will be documented.
89209658|NCT00813332|Experimental|1|Endostar combined with Docetaxel for Advanced NSCLC: All eligible patients will receive Endostar in combination with Docetaxel chemotherapy for 2 cycles (21 days for each cycle) and cases of good response(CR+PR+SD) will continue treatment for 2 cycles. Endostar treatment will continue after completion of first 4 cycles until disease progression.
89584742|NCT04410016|Experimental|Staff Wellbeing Centre|Wellbeing Centres are rooms where staff employed at the hospital trust can go for a break, rest, relaxation, quiet time out, advice support or signposting. They are manned by Wellbeing Buddies who are support workers who offer advice and signposting services. The Centres are accessible to all staff at the Trust.
89584743|NCT05425433|Experimental|Serial casted joint|Tailored serial casting intervention following 1 week of usual care
88974833|NCT04730895|Experimental|13 cis retinoic acid doses orally in combination with spike protein based vaccine|The participants will receive 13 cis retinoic acid (0.5 mg/kg/day in 2 divided doses orally for 14 days and also, participants will receive two doses of spike protein based vaccine such as ChAdOx1 nCoV-19 vaccine in deltoid of non-dominant arm, 28 days apart. Participants will have 15 routine visits over a 24 month period.All subjects were encouraged to complete the full course of treatment and common side effects were explained. Side effects and compliance will be documented
89584744|NCT02985970||ČSARIM - questionnaire|Members of Czech society of anesthesiology, resuscitation and intensive care will obtain the questionnaire
89584745|NCT02143843|Experimental|13 mg Bimatoprost Ocular Insert|13 mg Bimatoprost Ocular Insert used continuously for 7 months, then replaced with a new 13 mg Bimatoprost Ocular Insert and used continuously for another 6 months.
89584746|NCT02121535|Experimental|T80/A5/H12.5 mg FDC|A Telmisartan 80 mg/Amlodipine 5 mg/Hydrochlorothiazide 12.5 mg fixed dose combination (FDC) tablet
89584747|NCT02121535|Active Comparator|T80/A5 mg FDC+H12.5 mg mono|A Telmisartan 80 mg/ Amlodipine 5 mg fixed dose combination (FDC) tablet and a Hydrochlorothiazide 12.5 mg tablet
88974834|NCT04730895|Experimental|Aerosolized 13 cis retinoic acid in combination with spike protein based vaccine|The participants will receive Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days and also, participants will receive two doses of 5-7.5x10^10 vp spike protein based vaccine such as ChAdOx1 nCoV-19 vaccine in deltoid of non-dominant arm, 28 days apart. Participants will have 15 routine visits over a 24 month period.All subjects were encouraged to complete the full course of treatment and common side effects were explained. Side effects and compliance will be documented
88974835|NCT04730895|Sham Comparator|spike protein based vaccine such as ChAdOx1 nCoV-19 vaccine|The participants will receive two doses of 5-7.5x10^10 vp spike protein based vaccine such as ChAdOx1 nCoV-19 vaccine in deltoid of non-dominant arm, 28 days apart. Participants will have 15 routine visits over a 24 month period.All subjects were encouraged to complete the full course of treatment and common side effects were explained. Side effects and compliance will be documented
89584748|NCT05535959|Experimental|Sequence 1|Participants will receive a single dose of reference FDC tablet of VX-121/TEZ/D-IVA in dosing period 1, followed by a single dose of test FDC tablet of VX-121/TEZ/D-IVA in dosing period 2. A washout period of 14 days will be maintained between the 2 dosing periods.
89584749|NCT05535959|Experimental|Sequence 2|Participants will receive a single dose of test FDC tablet of VX-121/TEZ/D-IVA in dosing period 1, followed by a single dose of reference FDC tablet of VX-121/TEZ/D-IVA in dosing period 2. A washout period of 14 days will be maintained between the 2 dosing periods.
89584750|NCT01586338|Experimental|Synvisc|Three intra-articular (IA) injections of Synvisc (2.25 ml glass syringe containing 16 mg hylan G-F 20) at intervals of one week. The total duration of observation was 26 weeks.
89584751|NCT02143141|Active Comparator|duramorph|duramorph 150 mcg administered spinally with placebo capsules administered by mouth every 6 hours x 4 doses during first 24 hours
89584752|NCT02143141|Experimental|no duramorph|no duramorph is administered spinally for surgery; subjects receive acetaminophen 1 G orally x 4 doses during first 24 hours postoperatively
89584753|NCT05500469|Active Comparator|GDD-tube in anterior chamber|The Paul glaucoma drainage device consists of a plate and a tube. During surgery the plate is positioned underneath the conjunctiva and two extraocular muscles in the upper temporal or nasal quadrant of the eye. The tube is positioned in the anterior chamber.
89584754|NCT05500469|Experimental|GDD-tube in posterior chamber|The Paul glaucoma drainage device consists of a plate and a tube. During surgery the plate is positioned underneath the conjunctiva and two extraocular muscles in the upper temporal or nasal quadrant of the eye. The tube is positioned in the posterior chamber.
89584755|NCT02171065|Sham Comparator|Guideline Directed Medical Therapy|Guideline Directed Medical Therapy
89584756|NCT02171065|Active Comparator|ABSORB BVS + Guideline Directed Medical Therapy|ABSORB BVS + Guideline Directed Medical Therapy
89584757|NCT05033561|Experimental|2 doses, 1 week apart|Administration of 2 doses of nOPV2, 1 week apart
89584758|NCT05033561|Experimental|2 doses, 2 week apart|Administration of 2 doses of nOPV2, 2 weeks apart
89584759|NCT05033561|Active Comparator|2 doses, 4 week apart|Administration of 2 doses of nOPV2, 4 weeks apart
88974836|NCT02969772|Experimental|Assessment of upper limb variables|Assessment of clinical variables of tetraplegics reach-and-grasp pattern
88974837|NCT02969772|Experimental|Training protocol|Training with electrical stimulation of upper limb
88974838|NCT00030797|Active Comparator|Arm A|Irinotecan i.v. 70 mg/m2, day 1, 8, 15, 22, 29; Capecitabine p.o. 2 x 1000 mg/m2, d1-14, d22-35;
88974839|NCT00030797|Active Comparator|Arm B|Irinotecan i.v. 240 mg/m2 day 1 and day 22; Capecitabine p.o. 2 x 1000 mg/m2, d1-14, d22-35;
88974840|NCT00030914|Experimental|Arm I: venlafaxine|"All patients complete a daily questionnaire regarding number of hot flashes beginning on day 1 and continuing for 7 weeks. Patients receive oral venlafaxine once daily for 6 weeks beginning on day 8. After week 7, patients with satisfactory efficacy may continue venlafaxine for up to 6 months. Patients with unsatisfactory efficacy may cross over to arm III.~Patients are followed at months 2, 3, 4, 5, 6, 8, 10, and 12."
88974841|NCT00030914|Experimental|Arm II: medroxyprogesterone - long term|"All patients complete a daily questionnaire regarding number of hot flashes beginning on day 1 and continuing for 7 weeks. Patients receive medroxyprogesterone intramuscularly (IM) on days 8, 22, and 36 for a total of 3 injections. After week 7, patients with unsatisfactory efficacy may cross over to arm I.~Patients are followed at months 2, 3, 4, 5, 6, 8, 10, and 12."
88974842|NCT00030914|Experimental|Arm III: medroxyprogesterone - short term|"All patients complete a daily questionnaire regarding number of hot flashes beginning on day 1 and continuing for 7 weeks. Patients receive medroxyprogesterone IM once on day 8. After week 7, patients with unsatisfactory efficacy may cross over to arm I.~Patients are followed at months 2, 3, 4, 5, 6, 8, 10, and 12."
89209659|NCT00813332|Placebo Comparator|2|Docetaxel combined with placebo for Advanced NSCLC: All eligible patients will receive placebo in combination with Docetaxel chemotherapy for 2 cycles (21 days for each cycle) and cases of good response(CR+PR+SD) will continue treatment for 2 cycles. Placebo will continue after completion of first 4 cycles until disease progression.
89209660|NCT04708496|Experimental|Standard dose of Artemether lumefantrine|Dose comparison-concurrent control In this arm, Participants receiving Efavirenz400mg based ART will be randomized to standard dose Artemether Lumefantrine when treating uncomplicated malaria in HIV-malaria co-infected participants
89209661|NCT04708496|Experimental|Double dose Artemether lumefantrine|Dose comparison concurrent control In this arm, Participants receiving Efavirenz based ART will be randomized to double dose Artemether Lumefantrine when treating uncomplicated malaria in HIV-malaria co-infected participants
89584760|NCT01566604|Experimental|NVA237|NVA237 50 µg once daily delivered via a single dose dry powder inhaler
89584761|NCT01566604|Placebo Comparator|Placebo|Placebo once daily delivered via a single dose dry powder inhaler
89584762|NCT05497583|Experimental|Acetone based HEMA free Universal Adhesive|Patients with non-carious cervical lesions will be treated with Acetone Based HEMA-free Universal Adhesive (BeautiBond universal adhesive ) applied in a self-etch approach with (SE) selective enamel etching.
89584763|NCT05497583|Active Comparator|Isopropanol based HEMA-free universal Adhesive|Patients with non-carious cervical lesions will be treated with isopropanol-based HEMA-free universal Adhesive (Prime&Bond universal™ Adhesive system) applied in a self-etch approach with (SE) selective enamel etching.
89584764|NCT01684930|Experimental|BR Juice (Beet-It Stamina Shot) and Exercise Training|Subjects consume 70 ml of Beetroot Juice (Beet-It Stamina Shot) to assess acute effects of beverage supplementation at the start (between Testing Visits 1 & 2) and at the end of the trial (between Visits 3 & 4). It also allows for comparisons of the combination of beetroot juice and chronic training effects (between Visits 2 & 3) to when the subject has not consumed the beverage (Visits 1 & 4). All subjects will consume Beet-It Stamina Shot 3 hours prior to all beverage tolerance visits, Testing Visits 2 & 3 and for all supervised exercise training visits during the 12 week intervention.
89584765|NCT01684930|Placebo Comparator|BR Juice Placebo and Exercise Training|Subjects consume 70 ml of Beetroot Juice (Beet-It Stamina Shot; Placebo) to assess acute effects of beverage supplementation at the start (between Testing Visits 1 & 2) and at the end of the trial (between Visits 3 & 4). It also allows for comparisons of the combination of placebo beverage and chronic training effects (between Visits 2 & 3) to when the subject has not consumed the beverage (Visits 1 & 4). All subjects will consume Beet-It Stamina Shot (Placebo) 3 hours prior to all beverage tolerance visits, Testing Visits 2 & 3 and for all supervised exercise training visits during the 12 week intervention.
89584766|NCT01566214|Experimental|Motivational Interview|For those subjects randomly assigned to the treatment group, information from their MIHART assessment interview and medical record review will be used to select intervention scripts optimally tailored to each subjects' unique configuration of beliefs and risk factors and they will be re-contacted by telephone at 2-weeks post-hospital discharge to deliver the Vet-HART intervention. The intervention will be administered by a trained research assistant via telephone, working from a semi-structured script tailored to each subject's representations and risk factors, the call will last about 15-30 minutes.
89584767|NCT01566214|No Intervention|Usual Care|For those randomly assigned to the usual care group, they will receive standard-of-care by their regular primary care provider.
89584768|NCT02253992|Experimental|Dose Escalation and Cohort expansion: Urelumab + Nivolumab|"Nivolumab followed by Urelumab~Nivolumab every 2 weeks up to 12 cycles and Urelumab every 4 weeks up to 6 cycles"
89584769|NCT02252588|Experimental|Chlorhexidine|Oral Rinse
89584770|NCT02252588|Placebo Comparator|Placebo|Oral Rinse
89584771|NCT05153018|Other|A representative random sample of the population|1,200 non-febrile individuals aged older than 6 years old
89584772|NCT01585558|Experimental|Treatment Group 1|
89584773|NCT01585558|Experimental|Treatment Group 2|
89584774|NCT01585558|Placebo Comparator|Treatment Group 3|
89584775|NCT01565980|Active Comparator|symptom assessment|6 weeks of symptom assessment phone calls.
89584776|NCT01565980|Experimental|Mindfulness intervention|Participants receive 6 weeks of the home-based mindfulness intervention, and weekly symptom assessment phone calls.
89584777|NCT01585246|Other|Phase 1: The dose finding phase (DFP)|Patients received Saw Palmetto Soft Gel capsules in 320mg or 640mg or 960mg to determine the maximum therapeutic dose
89584778|NCT01585246|Active Comparator|Phase 2: RCT phase- Saw Palmetto|Patients received the predetermine the maximum therapeutic dose of Saw Palmetto Soft Gel capsules in phase 1, which is 960mg.
88974843|NCT00058227|Experimental|Treatment (alvocidib, fludarabine phosphate, rituximab)|Patients receive fludarabine phosphate IV over 15-30 minutes on days 1-5 and rituximab IV over 3-4 hours on day 1. Alvocidib is administered IV over 60 minutes on day 1 in cohort 1; on days 1 and 2 in cohort 2; and on days 1, 2, and 3 in cohort 3. In cohorts 4 and 5, patients receive fludarabine phosphate and rituximab as above and alvocidib IV over 30 minutes and then IV over 4 hours on day 1 of courses 2-6. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
88974844|NCT00058305|Experimental|Treatment (bryostatin 1, vincristine sulfate)|"Patients receive bryostatin 1 IV over 24 hours on days 1 and 15 and vincristine IV on days 2 and 16. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.~Patients without disease progression after 6 courses may continue therapy with bryostatin 1 IV over 24 hours on days 1 and 22 and vincristine IV on days 2 and 23. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity."
88974845|NCT00058461|Experimental|Treatment (chemotherapy, rituximab)|Patients receive ifosfamide IV over 2 hours and etoposide IV over 1 hour on days 3-5, rituximab IV on days 1 and 3, and carboplatin IV over 1 hour on day 3. Patients receive filgrastim (G-CSF) subcutaneously once daily beginning on day 6 and continuing until blood counts recover. Patients also receive intrathecal (IT) chemotherapy comprising methotrexate and cytarabine. Patients with B-cell large cell lymphoma and negative CSF cytology receive IT chemotherapy on day 3 of the first course only. Patients with small non-cleaved cell lymphoma or B-cell acute lymphoblastic leukemia and negative CSF cytology receive IT chemotherapy on day 3. All patients with positive CSF cytology receive IT chemotherapy on days 3, 10, and 17 of the first and second courses. Treatment repeats every 23 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
88974846|NCT04732754|Placebo Comparator|Control Group (CG)|This group will receive placebo capsules to be consumed for 8 weeks daily and will not exercise;
88974847|NCT04732754|Active Comparator|Aerobic Exercise (AE)|This group will receive placebo capsules and will perform 3 sessions of physical exercise / week, 50 min / session, with moderate intensity of 50-70% of VO2peak for 8 weeks.
89584779|NCT01585246|Placebo Comparator|Phase 2: RCT phase- Placebo|Patients received Soybean Oil Soft Gel as the placebo treatment
89584780|NCT01585168|Experimental|Family history positive, Memantine first, then placebo|Memantine is a low-side-effect NMDA receptor antagonist usually administered therapeutically to elderly persons with moderately severe Alzheimer's disease in typical doses of 10-20 mg daily. In this study, single doses of 40 mg are administered.
89584781|NCT01585168|Placebo Comparator|Family history positive, placebo first, then Memantine|Memantine is a low-side-effect NMDA receptor antagonist usually administered therapeutically to elderly persons with moderately severe Alzheimer's disease in typical doses of 10-20 mg daily. In this study, single doses of 40 mg are administered.
89584782|NCT01585168|Experimental|Family history negative, Memantine first, then placebo|Memantine is a low-side-effect NMDA receptor antagonist usually administered therapeutically to elderly persons with moderately severe Alzheimer's disease in typical doses of 10-20 mg daily. In this study, single doses of 40 mg are administered.
89584783|NCT01585168|Placebo Comparator|Family history negative, placebo first, then Memantine|Memantine is a low-side-effect NMDA receptor antagonist usually administered therapeutically to elderly persons with moderately severe Alzheimer's disease in typical doses of 10-20 mg daily. In this study, single doses of 40 mg are administered.
89584784|NCT02232074|Experimental|Patient navigation enhanced with legal support|In addition to receiving standard navigation, patients will be connected with a Patient Navigator who is partnered with a lawyer from Medical-Legal Partnership to provide personalized assistance with regard to social-legal barriers.
89584785|NCT02232074|No Intervention|Standard patient navigation|These patients will receive standard patient navigation which will work to ensure that services are coordinated amongst medical personnel, while also addressing patients' needs.
89584786|NCT02142283|Experimental|Trevo Thrombectomy Procedure|Trevo Thrombectomy Procedure and Medical Management
89584787|NCT02142283|Active Comparator|Medical Management|Medical Management
89584788|NCT02231918|Experimental|MIRAPEX® - low|
89584789|NCT02231918|Experimental|MIRAPEX® - medium|
89584790|NCT02231918|Experimental|MIRAPEX® - high|
89584791|NCT02199314|Experimental|desflurane MEP's|Transcranial motor evoked potentials are obtained under total intravenous anesthesia (TIVA) and again after desflurane at 3%, for at least 5 minutes.at two different time points. Each subject is his/her own control
89584792|NCT02251652|Active Comparator|Combination Therapy|Cryotherapy followed by Ingenol Mebutate Gel
89584793|NCT02251652|Active Comparator|Cryotherapy Alone|Cryotherapy only
89584794|NCT02197520|Experimental|Insulin Peglispro (with Insulin Lispro)|Insulin peglispro, a once daily subcutaneous(SC) injection at bedtime for 5 weeks
89584795|NCT02197520|Active Comparator|Insulin Glargine (with Insulin Lispro)|Insulin glargine, a once daily subcutaneous(SC) injection at bedtime for 5 weeks
89584796|NCT04772534|Experimental|3-dose in 9 to 15 year old boys|9 to 15 year old boys will receive a 3-dose regimen of 9-valent human papillomavirus (9vHPV) vaccine (Day 1, Month 2 and Month 6).
89584797|NCT04772534|Experimental|2-dose in 9 to 14 year old boys|9 to 14 year old boys receive a 2-dose regimen of 9vHPV vaccine (Day 1 and Month 6).
89584798|NCT04772534|Experimental|2-dose in 9 to 14 year old girls|9 to 14 year old girls receive a 2-dose regimen of 9vHPV vaccine (Day 1 and Month 6).
89584799|NCT02230904|Experimental|Treatment Arm A-B|4 day treatment (Treatment A: Rotigotine transdermal patch 8 mg/24 hours, test product PR 2.3.1 followed by Treatment B: Rotigotine transdermal patch 8 mg/24 hours reference product PR 2.1.1)
89584800|NCT02230904|Experimental|Treatment Arm B-A|4 day treatment (Treatment B: Rotigotine transdermal patch 8 mg/24 hours reference product PR 2.1.1 followed by Treatment A: Rotigotine transdermal patch 8 mg/24 hours, test product PR 2.3.1)
89584801|NCT02230670|Experimental|IDN-6556|25 mg BID of IDN-6556
89584802|NCT02230670|Placebo Comparator|Placebo|Placebo BID
89584803|NCT02197130|Experimental|20 mg PF-02545920 BID|20 mg PF-02545920 BID
89584804|NCT02197130|Experimental|5 mg PF-02545920 BID|5 mg PF-02545920 BID
89584805|NCT02197130|Placebo Comparator|Placebo BID|Matching placebo
89584806|NCT02196506|Experimental|Brexpiprazole + ADT|Brexpiprazole + ADT
89584807|NCT02196506|Placebo Comparator|Placebo + ADT|Placebo + ADT
89584808|NCT02228720|Experimental|Propel Nova Sinus Implant|Bioabsorbable, steroid-releasing sinus implant with 370 mcg of mometasone furoate released over 30 days
89584809|NCT02228564|Experimental|LIFESTREAM™|This is a single arm study. All subjects receive percutaneous transluminal angioplasty (PTA) and implantation of the LIFESTREAM™ covered stent.
89584810|NCT01640951|Experimental|AIN457 150 mg - Fixed Interval (FI)|1 s.c. Secukinumab 150 mg Pre-filled seringue (PFS) injection + 1 s.c. Placebo (PBO) Secukinumab PFS injection every 4 weeks
89584811|NCT01640951|Experimental|AIN457 150 mg - Start of relapse (SoR)|"Start of relapse: 1 s.c. Secukinumab 150 mg PFS injection + 1 s.c. PBO Secukinumab PFS injection every 4 weeks~Otherwise: 2 s.c. PBO Secukinumab PFS injections every 4 weeks"
89584812|NCT01640951|Experimental|AIN457 300 mg - Fixed Interval (FI)|2 s.c. Secukinumab 150 mg PFS injections every 4 weeks
89584813|NCT01640951|Experimental|AIN457 300 mg - Start of Relapse (SoR)|"Start of relapse: 2 s.c. Secukinumab 150 mg PFS injection every 4 weeks~Otherwise: 2 s.c. PBO Secukinumab PFS injections every 4 weeks"
89584814|NCT01640951|Experimental|AIN457 300 mg - Open Label (OL)|Open Label - Secukinumab 300mg every 4 weeks
89584815|NCT02228096|Experimental|tisagenlecleucel (CTL019)|Pediatric patients with relapsed/refractory B-cell ALL
89584816|NCT01640873|Experimental|MK-8655 80 mg/MK-8655 320 mg|Participants received a single dose of MK-8655, 80 mg on Day 1 and then MK-8655 320 mg, once daily, starting on Day 3 for 14 consecutive days.
89584817|NCT01640873|Placebo Comparator|Placebo|Participants received a single dose of placebo to MK-8655, 80 mg on Day 1 and then placebo to MK-8655 320 mg, once daily, starting on Day 3 for 14 consecutive days.
89584818|NCT04419623|Experimental|Dose Finding - 200mg BID|200mg TL-895 orally BID taken continuously in 7-day cycles for 2 - 4 cycles with SAT for COVID-19 (14 - 28 days of treatment).
89584819|NCT04844801|Active Comparator|Risk control strategy|Magnesium sulfate + control of the modifiable NOSVA risk factors
89584820|NCT04844801|Active Comparator|Rate control strategy|"Risk-control + low-dose amiodarone"
89584821|NCT04844801|Active Comparator|Rhythm control strategy|"Risk-control + high-dose amiodarone +/- electrical cardioversion"
89584822|NCT01683994|Experimental|combination of cabozantinib, docetaxel and prednisone|combination of cabozantinib, docetaxel and prednisone
89584823|NCT01683994|Active Comparator|PII/ Arm 1-docetaxel + prednisone only|docetaxel + prednisone only
89584824|NCT01683994|Active Comparator|PII/Arm 2 -docetaxel+ prednisone + cabozantinib|docetaxel+ prednisone + cabozantinib
89584825|NCT02247440|Experimental|PegINF-ribavirin|"Peg-interferon + ribavirin under HIV physician supervision Peg-interferon alpha 2-b initial dosing is 1.5 micrograms/kg (subcutaneous injection) once a week~Ribavirin initial dosing in the morning and in the evening:~For genotypes 2, 3: ribavirin 400 mg (i.e. 800 mg daily).~For genotypes 1, 4, 5 and 6:~800 mg/day, if bodyweight <65 kg,~1000 mg/day, if bodyweight between 66-80 kg,~1200 mg/day, if bodyweight between 81-105 kg,~1400 mg/day, if bodyweight >105 kg.~Duration: 48 weeks"
89584826|NCT05487989||optic neuritis patients|Patients suffering from an acute episode of optic neuritis will be included. There will be only one group of patients prospectively followed-up.
89584827|NCT04760054|Experimental|HUBOD martial arts practice|Participants will be trained in the Hubod exercise over 5 separate training sessions. Sessions will last approximately 30 minutes, involving a warm up, review of material from the previous session and the learning of the next movement in the HUBOD sequence. Heartrate will be monitored periodically to make sure the intensity of exercise is consistent with mild to moderate cardiovascular exercise as in the active comparator.
89584828|NCT04760054|Active Comparator|Active Comparator - Stationary Bicycle|Participants will be given 5 separate sessions, each approximating 30 minutes in duration, of mild to moderate intensity cardiovascular training on a stationary bicycle. Heartrate will be monitored periodically to make sure the intensity of exercise is consistent with mild to moderate exercise as in the Experimental group.
89584829|NCT04760054|Placebo Comparator|Attentional Control Group|Participants will be given 5 separate sessions, each approximating 30 minutes in duration, of watching videos on martial arts training methods and techniques. These sessions will be completely sedentary.
89584830|NCT04857203||Group 1|Low levels of Vitamin D
89584831|NCT04857203||Group 2|High levels of Vitamin D
89584832|NCT01683838|Active Comparator|fampridine-SR 50mg/day|
89584833|NCT01683838|Placebo Comparator|Placebo|
89584834|NCT05474573|Experimental|Fluorescence and Ultrasound|Extent of tumor resection will be intraoperatively assessed using both fluorescence with 5-aminolevulinic acid and sonography
89584835|NCT05474573|Active Comparator|Fluorescence|Extent of tumor resection will be intraoperatively assessed using fluorescence with 5-aminolevulinic acid
89584836|NCT01683604||Rheumatoid Arthritis (RA) Participants (All Groups)|Participants with severe RA were prescribed with tocilizumab in accordance with routine clinic practice, and were observed for 6 months.
89030172|NCT01249131|Experimental|Treatment C first, then Treatment B, followed by Treatment A|Treatment C: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water within 30 minutes of eating a standard FDA high-fat meal, in first intervention period. Treatment B: Four 5-mg capsules of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in second intervention period. Treatment A: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in third intervention period.
89584837|NCT05417243|Experimental|Advanced Trauma Life Support (ATLS)|Training in ATLS for residents providing trauma care.
89584838|NCT05417243|Experimental|Primary Trauma Care (PTC)|Training in PTC for residents providing trauma care.
89584839|NCT05417243|No Intervention|Standard Care|Trauma care according to the current standard with no intervention.
89584840|NCT04843709|Experimental|MRG004A|All patients in Part A (dose escalation) and Part B (dose expansion) will be administrated MRG004A on Day 1 of every 3 weeks (21-day cycle).
89584841|NCT02196038|Other|Attention Control|Usual care group with bi-weekly contact from study staff
89584842|NCT02196038|Active Comparator|multi-domain rehabilitation intervention|Individual, tailored, progressive, physical function rehabilitation intervention
89584843|NCT04660643|Experimental|Tirzepatide|Tirzepatide administered subcutaneously (SC)
89584844|NCT04660643|Placebo Comparator|Placebo|Placebo administered SC
89584845|NCT04659317|Active Comparator|Opioid Group|"Participants will receive encapsulated Oxycodone 5 mg tablets x24, to take po q6 hours as needed after surgery Safety Prescription: Oxycodone5 mg po q6 hours as needed for pain"
89584846|NCT04659317|Experimental|Placebo Group|"Participants will receive encapsulated placebo tablets x24, to take po q6 hours as need for pain after surgery Safety Prescription: Oxycodone5 mg po q6 hours as needed for pain"
89584847|NCT04855643|Experimental|Treatment|
89584848|NCT04855643|Sham Comparator|Control Group|
89584849|NCT03602261|Active Comparator|CTAP101 Capsules 300mcg/weekly|CTAP101 Oral Capsules/Calcifediol, calcidiol, 25-hydroxyvitamin D3, 300mcg/weekly for 26 weeks
89584850|NCT03602261|Active Comparator|CTAP101 Capsules 600mcg/weekly|CTAP101 Oral Capsules/Calcifediol, calcidiol, 25-hydroxyvitamin D3, 600mcg/weekly for 26 weeks
89584851|NCT03602261|Active Comparator|CTAP101 Capsules 900mcg/weekly|CTAP101 Oral Capsules/Calcifediol, calcidiol, 25-hydroxyvitamin D3, 900mcg/weekly for 26 weeks
89584852|NCT03602261|Placebo Comparator|Placebo Capsules weekly|Placebo Oral Capsules/weekly for 26 weeks
89584853|NCT02141659|Experimental|Part A Cohort 1: TAK-385 320 mg + TAK-385 80 mg|TAK-385 320 mg loading dose, tablet, orally, once on Day 1, followed by TAK-385 80 mg maintenance dose, tablet, orally, once daily through Days 2 to 28.
89584854|NCT02141659|Experimental|Part A Cohort 2: TAK-385 320 mg + TAK-385 120 mg|TAK-385 320 mg loading dose, tablet, orally, once on Day 1, followed by TAK-385 120 mg maintenance dose, tablet, orally, once daily through Days 2 to 28.
89584855|NCT02141659|Experimental|Part A Cohort 3: TAK-385 320 mg + TAK-385 160 mg|TAK-385 320 mg loading dose, tablet, orally, once on Day 1, followed by TAK-385 160 mg maintenance dose, tablet, orally, once daily through Days 2 to 28.
89584856|NCT02141659|Experimental|Part A Cohort 4: TAK-385 360 mg + TAK-385 120 mg|TAK-385 360 mg loading dose, tablet, orally, once on Day 1, followed by TAK-385 120 mg maintenance dose, tablet, orally, once daily through Days 2 to 28.
89584857|NCT02141659|Experimental|Part B Cohort 1: TAK-385 320 mg + TAK-385 80 mg|TAK-385 320 mg loading dose, tablet, orally, once on Day 1, followed by TAK-385 80 mg maintenance dose, tablet, orally, once daily through Days 2 to 672.
89584858|NCT02141659|Experimental|Part B Cohort 2: TAK-385 320 mg + TAK-385 120 mg|TAK-385 320 mg loading dose, tablet, orally, once on Day 1, followed by TAK-385 120 mg maintenance dose, tablet, orally, once daily through Days 2 to 672.
89584859|NCT01640249|Placebo Comparator|Placebo|Participants received placebo capsule orally with approximately 200 to 300 milliliter (mL) of room temperature water in the morning.
89584860|NCT01640249|Experimental|LY3006072|Participants received LY3006072 capsules starting at 1 milligram (mg) and escalating doses of 3 mg, 10 mg, 20 mg and 40 mg.
89584861|NCT02121301|Experimental|Low Dose SkQ1|Drug: Low Dose 0.155µg/mL SkQ1 ophthalmic solution administered twice daily for 28 days
89584862|NCT02121301|Experimental|High Dose SkQ1|Drug: High Dose 1.55µg/mL SkQ1 ophthalmic solution administered twice daily for 28 days
89584863|NCT02121301|Placebo Comparator|Placebo (vehicle)|Drug: Placebo (vehicle) ophthalmic solution administered twice daily for 28 days
89584864|NCT05422703|Experimental|Study group|patients who will receive manual therapy and Kinesio taping, in additional to basic post operative care (ice pack , analgesics, Antibiotic treatment and mouth wash daily ) 3 times per week for two weeks.
88974848|NCT04732754|Experimental|Aerobic exercise + Theobroma cocoa (AETC)|This group will receive 500mg cocoa capsules to be consumed daily and will perform 3 sessions of physical exercise / week, 50 min / session, with moderate intensity of 50-70% VO2peak) for 8 weeks
89584865|NCT05422703|Placebo Comparator|Control group|patients who will receive basic post operative care (ice pack , analgesics, Antibiotic treatment and mouth wash daily ).
88974849|NCT04732754|Experimental|Theobroma cocoa (TC)|This group will receive 500mg cocoa capsules to be consumed daily for 8 weeks.
88974850|NCT02969577|Experimental|Staying Strong & Healthy Intervention (SS&H)|Participants will take part in a 6-month exercise program and diet and nutrition coaching program. Also part of this arm is a nutritional and lifestyle counseling program to be lead by a member of the study team. Participants will also receive the usual care they would normally receive if not taking part in this study.
88974851|NCT02969577|Active Comparator|Usual Care with Attention (UCA)|Participants will receive the usual care they would normally receive if not taking part in this study.
88974852|NCT04711967|Experimental|Fecal Microbiota Transplantation group|treat with FMT
88974853|NCT04711967|Active Comparator|Control group|treat with traditional medicine
88974854|NCT04711694|Experimental|Early Mindfulness Intervention|The Early MBI group partake on the mindfulness intervention after first outcome assessment.
88974855|NCT04711694|Placebo Comparator|Late Mindfulness Intervention|"The Late MBI group partake on the mindfulness intervention after the second outcome assessment.~This groups is the control group for the Early MBI group.~After the second assessment, this group engage on the same intervention as the early group."
88974856|NCT00058617|Experimental|Injection of EBV Specific CTLs|Subjects will receive autologous EBV Specific CTLs. Patients that agree will recieve CTLs that have been marked with the neomycin resistance gene.
88974857|NCT04712006|Experimental|Cohort 1: JNJ-64304500|Participants will receive single subcutaneous (SC) Dose 1 of JNJ-64304500 on Day 1.
88974858|NCT04712006|Experimental|Cohort 2: JNJ-64304500|Participants will receive single SC Dose 2 of JNJ-64304500 on Day 1.
88974859|NCT00058773|Experimental|CTL Administration|Infusion of EBV Specific Cytotoxic T-Lymphocytes
88974860|NCT00058812|Experimental|EBV specific T cells|EBV specific T cells
88974861|NCT02971514|Experimental|Floss-Brush group|The participants flossed first followed by brushing
88974862|NCT02971514|Active Comparator|Brush-Floss group|They used dental floss after brushing
88974863|NCT00058890|Experimental|Gabapentin|
88974864|NCT00058890|Placebo Comparator|Placebo|
88974865|NCT02969538|Other|Total etching time|Dentin etching (35% phosphoric acid) by time recommend by manufacturer (15 seconds)
88974866|NCT02969538|Experimental|Half-reduced etching time|Dentin etching (35% phosphoric acid) by 7 seconds
89584866|NCT04841525||Autism Spectrum Disorder|During Screening Visits, the Autism Diagnostic Observational Schedule (ADOS) will be administered to confirm diagnosis. Criteria for group inclusion is: diagnosis of Autism Spectrum Disorder based on Diagnostic and Statistical Manual of Mental Disorders (DSM-5), the Autism Diagnostic Observation Schedule (ADOS-G), and the Autism Diagnostic Interview-Revised, short form (ADI-R). Diagnostic evaluations will be completed by research staff and supervised by a licensed psychologist.
89584867|NCT04841525||Typical Development|Typically Developing (TD) participants from each site will be roughly matched by age and sex to the ASD group.
89584868|NCT02227862|Experimental|Mylan's Insulin Glargine|Receive Mylan's Insulin Glargine plus insulin lispro.
89584869|NCT02227862|Active Comparator|Lantus®|Receive Lantus® plus insulin lispro
88974867|NCT02969460|Experimental|Neurotrack Virtual Cognitive Health Program|This program is a multi-domain lifestyle intervention designed to prevent or delay cognitive decline and impairment in older at-risk adults. The first 6 months of the program emphasizes lifestyle change, while the last 6 months of the program emphasizes habit reinforcement. The program focuses on nutrition, physical exercise, and cognitive training.
88974868|NCT00396149|Placebo Comparator|Placebo|Placebo group
88974869|NCT00396149|Experimental|Active group|rBet v 1 tablets
88974870|NCT00396071|Experimental|1|Vildagliptin 100 mg qd
88974871|NCT00396071|Placebo Comparator|2|Matching placebo
88974872|NCT00396188||Normals|"Patients seeking initial laser vision correction that were screened to be good candidates for the procedure.~No history of refractive or other ocular surgery.~No corneal pathologies.~Normal corneal topography.~Contact lens wearers should discontinue use at least 2 weeks for hard contacts, and 3 days for soft lenses prior to imaging."
88974873|NCT00396188||Keratoconus|"An irregular cornea determined by distorted keratometry mires, distortion of the retinoscopic, or ophthalmoscopic red reflex (or a combination of these)~At least one of the following biomicroscopic signs: Vogt's striae, Fleischer's ring of >2 mm arc, or corneal scarring consistent with keratoconus.~Contact lens wearers should discontinue use preferably 1 day or at least half an hour prior to imaging."
88974874|NCT00396188||Myopic Laser Vision Correction|"Patients who have undergone myopic:~LASIK~PRK~LASEK"
89584870|NCT05422391|Other|Pre- post-dietary intervention|Single arm pre-post dietary intervention (caloric restriction)
89584871|NCT02120833|Active Comparator|EPI|
89584872|NCT02120833|Experimental|NEE|
89584873|NCT04615949|Experimental|Cannabidiol, pharmaceutically produced with < 5 ppm THC|CardiolRx
89584874|NCT04615949|Placebo Comparator|Placebo|Placebo
89584875|NCT04591379|Experimental|Intervention arm|
89584876|NCT02170207||30 mg of lansoprazole|30 mg of lansoprazole is mixed in physiological saline (JP) or 5% glucose solution for injection (JP) and administered twice daily by drip infusion or dissolved in 20 mL of physiological saline (JP) or 5% glucose solution for injection (JP) and administered twice daily by direct slow intravenous injection.
89584877|NCT05399927|Experimental|Intervention|The intervention group underwent exposure to relaxing music with sounds from nature
89584878|NCT05399927|No Intervention|Control|The control group under the usual transfer conditions.
89584879|NCT04968275|Experimental|CHAMPS and EIS|The Cannabis Harm-reducing App for Managing Practices Safely (CHAMPS) is a brief harm reduction e-intervention based on the principles of motivational interviewing and harm reduction approaches. This e-intervention will be completed by the participant using a smart phone. There will be a total of six individual sessions each lasting 15-20 min. There will be one booster session offered at 4 weeks post-intervention to review goal setting, evaluate motivation around changing cannabis use practices. This e-intervention will be administered adjunctively to psychosis early intervention services (EIS).
89584880|NCT04968275|No Intervention|EIS alone|Early intervention services (EIS) for psychosis will be offered as per standard of care at participating clinical sites. Theses services vary but typically include pharmacotherapy and individual and/or group psychotherapy. Any visits and services offered in the EIS arm will be considered 'usual care' and administered either through in-person clinic visits, phone calls, or video calls. Relevant service information will be collected for study purposes.
89584881|NCT04746079|Experimental|Positive Imagery Therapy|"Perform procedural sedation with slow push of ketamine, 1.5mg/kg, over thirty seconds while reading the Positive Imagery Therapy below:~Relax and close your eyes. Take deep breaths in through your nose and out through your mouth as you listen to the sound of my voice. (Three second pause.) I want you to picture yourself lying on a towel on a soft sandy beach. (Three second pause.) You can see a palm trees swaying in the wind beneath a bright blue sky with a few white puffy clouds. (Three second pause.) You can feel the sand between your toes, the warm sunlight on your skin and a cool breeze. (Three second pause) You can smell coconut lotion in the breeze. (Three second pause.) You can hear the sound of waves gently crashing on the beach and seagulls crying in the distance. **End of vignette**"
89584882|NCT04746079|No Intervention|Control|Perform procedural sedation with slow push of ketamine, 1.5mg/kg, over thirty seconds with no positive imagery therapy.
89584883|NCT04855097|Experimental|Standard care group|Blood Volume Analysis will be performed at admission, during inpatient stay if warranted, and prior to hospital discharge. Treating physicians will be blinded to the results and will choose between a low-moderate and high diuretic dose based on usual care clinical assessment of volume status.
89584884|NCT04855097|Experimental|BVA-guided treatment arm|Blood Volume Analysis will be performed at admission, during inpatient stay if warranted, and prior to hospital discharge. Treating physicians will receive the results and will choose between a low-moderate and high diuretic dose based on measured volume status.
88974875|NCT00396188||Hyperopic Laser Vision Correction|"Patients who have undergone hyperopic:~LASIK~PRK~LASEK"
88974876|NCT00396188||Orthokeratology|1. Patients using specially designed rigid contact lenses to reshape the cornea to temporarily reduce or eliminate refractive error.
88974877|NCT00396188||Others|1. Corneal conditions (diseases/ pathologies/surgeries) that can potentially affect the corneal surface that are not listed above (e.g. pellucid marginal degeneration; postoperative corneal transplant, intra-corneal ring segments, refractive keratotomy, conductive keratoplasty; peripheral ulcerative keratitis, Terrien's marginal degeneration; etc.).
88974878|NCT00396227|Experimental|1|Vildagliptin 100mg + Met
88974879|NCT00396227|Active Comparator|TZD|TZD + metformin
88974880|NCT00396305|Experimental|Group 2, Control Double Dose|12 elderly and 6 young participants. This group will be vaccinated with a double dose of vaccine without booster on Day 0. These subjects will receive a double-dose of vaccine administered as 2 consecutive injections (2 injections of 0.5 mL) in the same deltoid. The control group for Group 2 is group 1, Cohort 2.
88974881|NCT00396305|Experimental|Group 3-Control late booster|12 elderly and 6 young participants. This group will be vaccinated with the standard dose of vaccine (0.5 mL) on Day 0 and with a booster dose of vaccine (0.5 mL) on Day 21. The control for Group 3 is Group 1, Cohort 3.
88974882|NCT00396305|Active Comparator|Group 1, Control|12 elderly and 8 young participants. Group 1 will be further divided into 4 equal cohorts (each containing 3 elderly and 2 young adults). Cohorts 2, 3, and 4 will receive the standard dose of vaccine and placebo (0.5 mL saline) on Day 0, 21, or 7 respectively. Cohort 1 will be vaccinated with the standard dose of vaccine without placebo/vaccine booster.
89030173|NCT04510961|Active Comparator|Paraffin baths therapy (PBT) :group A|Patients in treatment group will receive paraffin wax baths for five days per week for 12 weeks.
89030174|NCT04510961|No Intervention|Control group (B)|receive routine skin care program ; lifestyle change, emollients and moisturizers
89030175|NCT04510649|Experimental|Surufatinib and Rabeprazole (Part A)|Part A: Surufatinib 300 mg on study days 1 and 11 Rabeprazole 40 mg on study days 5 - 11
89030176|NCT04510649|Experimental|Surufatinib and Rifampin (Part B)|Part B: Surufatinib 300 mg on study days 1 and 12 Rifampin 600 mg on study days 5-15
89030177|NCT01249092|Experimental|Pentoxifylline 400 mg TID|This study is an open label pilot with only one arm.
89584885|NCT02227784|Experimental|Atorvastatin + Evacetrapib|Atorvastatin 40 milligrams (mg) orally once daily for 28 days during lead in period. Atorvastatin 40 mg plus evacetrapib 130 mg with placebo for blinding orally once daily for 90 days. Open label extension (atorvastatin 40 mg plus evacetrapib 130 mg) is available for compliant participants.
89584886|NCT02227784|Active Comparator|Atorvastatin 80 mg|Atorvastatin 40 mg orally once daily for 28 days during lead in period. Atorvastatin 80 mg orally with placebo for blinding once daily for 90 days. Open label extension (atorvastatin 40 mg plus evacetrapib 130 mg) is available for compliant participants.
89584887|NCT02227784|Active Comparator|Atorvastatin + Ezetimibe|Atorvastatin 40 mg orally once daily for 28 days during lead in period. Atorvastatin 40 mg plus ezetimibe 10 mg with placebo for blinding orally once daily for 90 days. Open label extension (atorvastatin 40 mg plus evacetrapib 130 mg) is available for compliant participants.
89584888|NCT02227784|Active Comparator|Atorvastatin 40 mg|Atorvastatin 40 mg orally once daily for 28 days during lead in period. Atorvastatin 40 mg with placebo for blinding orally once daily for 90 days. Open label extension (atorvastatin 40 mg plus evacetrapib 130 mg) is available for compliant participants.
89584889|NCT04419701|Experimental|periarticular infiltration group|will receive intraoperative periarticular infitration consisting of 89.5 mL of normal saline, 20 mL of 5% bupivacaine and 0.5 mL of adrenaline (4.5 ugm/ml) with a concentration 1:220000 (total volume: 110 mL)
89584890|NCT04419701|Experimental|genicular nerve block group|will receive ultrasound guided genicular nerve block at three nerves, i.e., superomedial, superolateral, and inferomedial genicular nerves consisting of 15 ml bupivacaine 0.25% with adrenaline 2.5 µg/ml with a concentration 1:400000 in the immediate postoperative period.
89584891|NCT04841213|Active Comparator|Group after vitamin D3 level stabilization|Patients with loss of teeth and mineral metabolism disorders due to vitamin D3 imbalance (n=192) who will undergo dental implant placement after stabilization of vitamin D3 levels
89584892|NCT04841213|Active Comparator|Group before vitamin D3 level stabilization|Patients with the loss of teeth and mineral metabolism disorders due to vitamin D3 imbalance (n=192) who undergo the dental implantation during treatment by an endocrinologist
89584893|NCT01565668|Experimental|AC220 Dose Level 1|
89584894|NCT01565668|Experimental|AC220 Dose Level 2|
89584895|NCT04581551|Experimental|Stroke group|"SWE for 6 shoulder muscles will be performed by 2 assessors in randomised order.~m. supraspinatus~m. infraspinatus~m. rhomboideus major~m. deltoideus~m. pectoralis major~m. pectoralis minor"
89584896|NCT04581551|Active Comparator|Healthy controls|"SWE for 6 shoulder muscles will be performed by 1 assessors.~m. supraspinatus~m. infraspinatus~m. rhomboideus major~m. deltoideus~m. pectoralis major~m. pectoralis minor"
89584897|NCT04577417||ADHD|Adolescents, male or female, ages 13-19, diagnosed with ADHD, all subtypes, based on the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) and under treatment with a stimulant medication with the same drug and dosage for at least 12 months before their study participation date
89584898|NCT04577417||Control|Adolescents, male or female, ages 13-19, with normal health status and development
89584899|NCT01683058|Experimental|Aripiprazole IM Depot|Aripiprazole IM Depot 400 mg or 300 mg once monthly (every 28 days) for 24 weeks
89584900|NCT04419545||interstitial pneumonia cases|Chest x-ray diagnosis
89584901|NCT04419545||Negative controls|Chest x-ray Negative for pneumonia
89584902|NCT04574921|Experimental|Active|Exposure to LTS device set to 40 Hz invisible spectral flicker for 1 hour a day for consecutive days
89584903|NCT04574921|Sham Comparator|Sham|Exposure to LTS device set to continues color matched white light for 1 hour a day for consecutive days
89584904|NCT05374421|Active Comparator|Erchonia® THL™|The Erchonia® EVRL™ is made up of (2) 405-nanometer violet laser diodes mounted in a portable handheld device.
89584905|NCT05374421|Placebo Comparator|Placebo Laser|The Placebo Laser has the same appearance as the Erchonia® THL™ but does not emit any therapeutic light.
89584906|NCT01626859|Experimental|MP-214 3mg|
89584907|NCT01626859|Experimental|MP-214 6mg|
89584908|NCT01626859|Experimental|MP-214 9mg|
89584909|NCT04413682|Experimental|Supervised Exercise Group|One session per day, 3 days per week over a 12-weeks structured exercise program under supervision of a physical therapist.
89584910|NCT04413682|Experimental|Telerehabilitation Group|One session per day, 3 days per week over a 12-weeks structured exercise program through Telerehabilitation
88974883|NCT00396305|Experimental|Group 4-Control early booster|12 elderly and 6 young participants. This group will be vaccinated with the standard dose of vaccine (0.5 mL) on Day 0 and with a booster dose of vaccine (0.5 mL) on Day 7. The control for Group 4 is Group 1, Cohort 4.
88974884|NCT00396344|Placebo Comparator|1|Saline control
89584911|NCT02193776|Experimental|DS-TB: J(loading dose/t.i.w.)PaZ|Subjects with DS-TB. J(loading dose/t.i.w.)PaZ: Bedaquiline 400mg once daily Days 1-14, 200mg three times per week Days 15-56; plus PA-824 200mg once daily Days 1-56; plus pyrazinamide 1500mg once daily Days 1-56.
88974885|NCT00396344|Experimental|2|
88974886|NCT00396344|Experimental|3|
89584912|NCT02193776|Experimental|DS-TB: J(200mg)PaZ|Subjects with DS-TB. J(200mg)PaZ: Bedaquiline 200mg once daily Days 1-56; plus PA-824 200mg once daily Days 1-56; plus pyrazinamide 1500mg once daily Days 1-56.
88974887|NCT00059280|Experimental|1|
88974888|NCT00031421||1|16 received ganciclovir at 8 mg/kg/day in the previous study.
88974889|NCT00031421||2|31 received ganciclovir at 12 mg/kg/day in the previous study.
88974890|NCT00031499|Experimental|Azithromycin|Azithromycin 2.0 gram single oral dose.
89584913|NCT02193776|Experimental|MDR-TB: J(200mg)MPaZ|Subjects with MDR-TB. J(200mg)MPaZ: Bedaquiline 200mg once daily Days 1-56; plus moxifloxacin 400mg once daily Days 1-56; plus PA-824 200mg once daily Days 1-56; plus pyrazinamide 1500mg once daily Days 1-56.
89584914|NCT02193776|Active Comparator|DS-TB: HRZE|Subjects with DS-TB. HRZE tablets (Isoniazid 75mg plus rifampicin 150mg plus pyrazinamide 400mg plus ethambutol 275mg combination tablets) dosed once daily Days 1-56 per the Subject's weight as follows: 30-37kg: 2 tablets; 38-54kg: 3 tablets; 55-70kg: 4 tablets; 71kg and over: 5 tablets.
89584915|NCT05373407|Experimental|moderate intensity aerobic training|The exercises were conducted at a heart rate of 50-70% of maximum heart rate for 30 minutes. Exercises were included strengthening muscles groups (shoulder flexors, extensors, abductor's muscles, hip flexors, extensor muscles, knee flexors, extensor muscles, abdominal muscles, and back muscles).
89584916|NCT05373407|Experimental|low intensity aerobic training|"Exercises were performed at 40-50% of the maximum heart rate Starting by 15 minutes of Warm-up time included static stretching of upper and lower body muscles.~After that, participants performed 30 minutes of low-intensity aerobic training exercises, which included 20 minutes on the treadmill, followed by 10 minutes of cooling down.~A set of 5-10 exercises was performed by each muscle group, three sets per exercise were performed, and 10-15 repetitions per series were performed 4 days per week"
89584917|NCT02170064|Experimental|Group 1 (2-6 yrs)|"At the end of the baseline phase, patients meeting the final selection criteria were admitted to three consecutive 4-week treatment periods in which they received Eslicarbazepine acetate once-daily at the following dosage regimens: 5 mg/kg/day in the first 4 weeks, 15 mg/kg/day in weeks 5-8 and 30 mg/kg/day or 1800 mg/day, whichever less, in weeks 9-12. After the last treatment period, dose was down-titrated during a 2-week period or patient continued receiving Eslicarbazepine acetate (compassionate use) if both parent(s)/guardian(s)/patient and his/her physician agreed this was in the best patient's interest.~For Group 1 (2-6 years), oral suspension 50 mg/mL was used. The dose was to be rounded to the nearest 25 mg unit."
89584918|NCT02170064|Experimental|Group 2 (7-11 years)|"At the end of the baseline phase, patients meeting the final selection criteria were admitted to three consecutive 4-week treatment periods in which they received Eslicarbazepine acetate once-daily at the following dosage regimens: 5 mg/kg/day in the first 4 weeks, 15 mg/kg/day in weeks 5-8 and 30 mg/kg/day or 1800 mg/day, whichever less, in weeks 9-12. After the last treatment period, dose was down-titrated during a 2-week period or patient continued receiving Eslicarbazepine acetate (compassionate use) if both parent(s)/guardian(s)/patient and his/her physician agreed this was in the best patient's interest.~For Group 2 (7-11 years) and Group 3 (12-17 years), Eslicarbazepine acetate strengths 200 mg, 400 mg, 600 mg and 800 mg tablets might be used. The dose was to be rounded to the nearest 100 mg unit. Half tablets might be used for dosage adjustment (tablets were scored)."
89584919|NCT02170064|Experimental|Group 3 (12-17 years)|"At the end of the baseline phase, patients meeting the final selection criteria were admitted to three consecutive 4-week treatment periods in which they received Eslicarbazepine acetate once-daily at the following dosage regimens: 5 mg/kg/day in the first 4 weeks, 15 mg/kg/day in weeks 5-8 and 30 mg/kg/day or 1800 mg/day, whichever less, in weeks 9-12. After the last treatment period, dose was down-titrated during a 2-week period or patient continued receiving Eslicarbazepine acetate (compassionate use) if both parent(s)/guardian(s)/patient and his/her physician agreed this was in the best patient's interest.~For Group 2 (7-11 years) and Group 3 (12-17 years), Eslicarbazepine acetate strengths 200 mg, 400 mg, 600 mg and 800 mg tablets might be used. The dose was to be rounded to the nearest 100 mg unit. Half tablets might be used for dosage adjustment (tablets were scored)."
89584920|NCT02169830|Active Comparator|nortriptyline|If after four (4) weeks of diet modification, patients are still experiencing migraines, they may be randomized to nortriptyline for eight (8) weeks. If still experiencing symptoms, they will receive topiramate for eight (8) weeks.
89584921|NCT02169830|Active Comparator|topiramate|If after four (4) weeks of diet modification, patients are still experiencing migraines, they may be randomized to topiramate for eight (8) weeks. If still experiencing symptoms, they will receive nortriptyline for eight (8) weeks.
89584922|NCT02169830|Other|diet modification|Participants will begin with diet modification for four (4) weeks.
89584923|NCT04545905||Pregnant women attending first ANC visit|Pregnant women attending their first ANC visit at selected health facilities in Gaoua, Banfora, and Orodara districts.
89584924|NCT02169674|Active Comparator|10-11 Year-olds|Recombinant hepatitis B virus vaccine (EngerixB, GlaxoSmithKline Vaccines)
89584925|NCT02169674|Active Comparator|15-16 Year-olds|Recombinant hepatitis B virus vaccine (EngerixB, GlaxoSmithKline Vaccines)
89584926|NCT04532489|Other|Group 1|These subjects, 6 planned (3 male, 3 female), will be to obtain normal tissue distribution of [18F]NP-59 and confirm calculated radiation dosimetry and optimal uptake time.
89584927|NCT04946981|Other|Randomized Crossover_Sequence 1|Participants who meet the eligibility criteria will be randomized and will receive first the experimental product Turmipure GOLD® during the first study phase and then the placebo control during the second study phase. Both study phases are separated by a washout period of minimum 14 days.
89584928|NCT04946981|Other|Randomized Crossover_Sequence 2|Participants who meet the eligibility criteria will be randomized and will receive first the placebo control during the first study phase and then the experimental product Turmipure GOLD® during the second study phase. Both study phases are separated by a washout period of minimum 14 days.
89584929|NCT05341349|Experimental|Arm I (SRS, pembrolizumab, TTFields)|Patients receive standard of care pembrolizumab and undergo 3-5 fractions SRS. Patients also undergo TTFields over 8 hours daily using NovoTTF-100M device until intra-cranial progression or until end of immunotherapy treatments at the discretion of the treating physician in the absence of disease progression or unacceptable toxicity.
89584930|NCT05341349|Experimental|Arm II (nivolumab, ipilimumab, SRS, TTFields)|Patients receive standard of care nivolumab and ipilimumab and undergo 3-5 fractions SRS. Patients also undergo TTFields over 8 hours daily using NovoTTF-100M device until intra-cranial progression or until end of immunotherapy treatments at the discretion of the treating physician in the absence of disease progression or unacceptable toxicity.
89584931|NCT02169284|Experimental|Group I (erlotinib hydrochloride)|Patients receive erlotinib hydrochloride PO QD on days 1, 8, and 15. Patients then undergo TURBT or cystectomy on day 16.
89584932|NCT02169284|Placebo Comparator|Group II (placebo)|Patients receive placebo PO QD on days 1, 8, and 15. Patients then undergo TURBT or cystectomy on day 16.
89030178|NCT02275182|Experimental|Dexmedetomidine|0.5μg/kg Dexmedetomidine as initial loading dose is given for 15 minutes before induction of anesthesia, followed by a maintenance infusion of 0.4μg/kg/h and stopped 30 minutes before the surgery over.
89030179|NCT02275182|Placebo Comparator|Controlled|0.5μg/kg Saline as initial loading dose is given for 15 minutes before induction of anesthesia, followed by a maintenance infusion of 0.4μg/kg/h and stopped 30 minutes before the surgery over.
89030180|NCT05653947|Experimental|Vital teeth|root canal instrumentation sodium hypochlorite 2.5% irrigation
89584933|NCT02119819|Experimental|10 mg LY2944876|"10 milligrams (mg) LY2944876 given subcutaneously (SC) once weekly for 24 weeks.~Participants remain on stable doses of metformin, as prescribed by their personal investigator if they were on metformin at study entry."
89584934|NCT02119819|Experimental|15 mg LY2944876|15 mg LY2944876 given SC once weekly for 24 weeks. Participants remain on stable doses of metformin, as prescribed by their personal investigator if they were on metformin at study entry.
89584935|NCT02119819|Experimental|30 mg LY2944876|30 mg LY2944876 given SC once weekly for 24 weeks. Participants remain on stable doses of metformin, as prescribed by their personal investigator if they were on metformin at study entry.
89584936|NCT02119819|Experimental|50 mg LY2944876|50 mg LY2944876 given SC once weekly for 24 weeks. Participants remain on stable doses of metformin, as prescribed by their personal investigator if they were on metformin at study entry.
89584937|NCT02119819|Experimental|Exenatide extended-release|2 mg exenatide extended-release given SC once weekly for 24 weeks. Participants remain on stable doses of metformin, as prescribed by their personal investigator if they were on metformin at study entry.
89584938|NCT02119819|Placebo Comparator|Placebo|"Placebo for LY2944876 and Exenatide given SC once weekly for 12 weeks. Participants assigned to placebo will have no injections during the second 12 weeks of the study.~Participants remain on stable doses of metformin, as prescribed by their personal investigator if they were on metformin at study entry."
89584939|NCT04766450|Active Comparator|Group 1, NAC group|Group 1, NAC group (n=30): Patients will receive conventional therapy for diabetic neuropathy in addition to High Dose N-acetyl cysteine (2400 mg/day divided into two doses) daily for 3 months
89584940|NCT04766450|No Intervention|Group 2, Control group|Group 2, Control group (n= 30): Patients will receive conventional therapy for diabetic neuropathy alone for 3 months.
89584941|NCT04852991|Active Comparator|Modified Purandare cervicopexy|Apical prolapse will be corrected by Modified Purandare cervicopexy
89584942|NCT04852991|Active Comparator|Abdominal sacrohysterpexy|Apical prolapse will be corrected by Abdominal sacrohysterpexy
89584943|NCT04765982|Active Comparator|patients with less than 80% time in range|Better control group
89584944|NCT04765982|Placebo Comparator|patients with more than 80% time in range|poor control group
89584945|NCT02168816|Active Comparator|Midfoot|Individuals with an infection on the midfoot are randomized to an intravenous antibacterial agent or an oral antibacterial agent.
89584946|NCT02168816|Active Comparator|Hindfoot|Individuals with an infection on the hindfoot are randomized to an intravenous antibacterial agent or an oral antibacterial agent.
89584947|NCT02168816|Active Comparator|Toe|Individuals with an infection on the toe are randomized to an intravenous antibacterial agent or an oral antibacterial agent.
89584948|NCT05315921|Experimental|OsrhAAT 1 mg/kg IV|
89584949|NCT05315921|Experimental|OsrhAAT 3 mg/kg IV|
89584950|NCT05315921|Experimental|OsrhAAT 10 mg/kg IV|
89584951|NCT05315921|Experimental|OsrhAAT 20 mg/kg IV|
89584952|NCT05315921|Experimental|OsrhAAT 40 mg/kg IV|
89584953|NCT05315921|Experimental|OsrhAAT 60 mg/kg IV|
89584954|NCT05307107|Experimental|Intervention group (IG)|Participants are educators working in health and social care education receiving 8 work week-SHINE.
89584955|NCT05307107|No Intervention|Control group (CG)|Participants are educators working in health and social care education without the program continuing their normal daily routines receiving SHINE for their voluntary use after this study (waitlist).
89584956|NCT01584232|Experimental|LY2189265 + OAM|"LY2189265: 0.75 milligrams (mg), administered subcutaneously (SC), once weekly for 26 weeks~Participants were to continue on their stable, pre-study, physician-prescribed dose of oral antihyperglycemic medication (OAM) throughout the study. OAMs included sulfonylureas (SU; glibenclamide, gliclazide, or glimepiride) and/or biguanides (BG; metformin or buformin)."
89584957|NCT01584232|Active Comparator|Insulin glargine + OAM|"Insulin glargine: dose based on targeting fasting blood glucose ≤110 milligrams per deciliter (mg/dL), administered subcutaneously (SC), once daily for 26 weeks~Participants were to continue on their stable, pre-study, physician-prescribed dose of oral antihyperglycemic medication (OAM) throughout the study. OAMs included sulfonylureas (SU; glibenclamide, gliclazide, or glimepiride) and/or biguanides (BG; metformin or buformin)."
89584958|NCT01639703|Experimental|CT perfusion|arm with CT perfusion
89584959|NCT04877483|Experimental|Group GB20|Group GB20 will received acupuncture at acupoint GB20 twice a week 8 weeks for efficacy evaluation. And we could use the oral microbiota, Schirmer's test, Tear breakup time, 6-GSI, OSDI, TCM pattern, Traditional Chinese Medicine (TCM) tongue diagnosis, TCM pulse diagnosis, and TCM heart rate variability for this purpose.
89030181|NCT05653947|Other|Non-vital teeth|root canal instrumentation sodium hypochlorite 2.5% irrigation
89030182|NCT01248936|Experimental|Overall Trial|Participants received vemurafenib 960 milligram (mg) orally two times a day for up to one year. Participants were treated until disease progression, unmanageable toxicity most probably attributable to vemurafenib, withdrawal of consent, and study termination by the sponsor
89584960|NCT04877483|Experimental|Group GB20 plus BL2|Group GB20 plus BL2 will received acupuncture at acupoint GB20 plus BL2 twice a week 8 weeks for efficacy evaluation. And we could use the oral microbiota, Schirmer's test, Tear breakup time, 6-GSI, OSDI, TCM pattern, Traditional Chinese Medicine (TCM) tongue diagnosis, TCM pulse diagnosis, and TCM heart rate variability for this purpose.
89584961|NCT04877483|Other|Healthy control|Healthy control group will not received any treatment. And we could use the oral microbiota, TCM pattern, Traditional Chinese Medicine (TCM) tongue diagnosis, TCM pulse diagnosis, and TCM heart rate variability to find the difference with the comparison between the dry eye syndrome and healthy control.
89030183|NCT01248780|Experimental|Golimumab + methotrexate (MTX)|Participants will receive golimumab 50 mg as subcutaneous (SC) (under the skin) injections administered every 4 weeks for up to 48 weeks. In addition, participants will receive a stable dose of MTX.
89030184|NCT01248780|Experimental|Placebo + methotrexate (MTX)|Participants will be administered Placebo SC injections at Weeks 0, 4, 8, 12, 16, and Week 20 followed by golimumab 50 mg SC injections at Week 24 and every 4 weeks thereafter through Week 48. In addition, participants will receive a stable dose of MTX.
88974891|NCT00031499|Active Comparator|Benzathine Penicillin|Benzathine penicillin 2.4 million units administered intramuscularly. Doxycycline will be administered if the patient is allergic to Benzathine Penicillin.
88974892|NCT00059358|Experimental|1|Participants will begin receive either Rebetron or PEG-Intron plus ribavirin therapy from Weeks 2 through 48
88974893|NCT02969343|Experimental|Intervention|Patients and providers on hospital care units where the PSLL patient safety health information technology tools are implemented, during the interventional phase of a stepped wedge randomized trial design.
89584962|NCT04877483|Other|Waiting list|Group Waiting list will not received any treatment. at acupoint GB20 plus BL2 twice a week 8 weeks for efficacy evaluation. And we could use the oral microbiota, Schirmer's test, Tear breakup time, 6-GSI, OSDI, TCM pattern, Traditional Chinese Medicine (TCM) tongue diagnosis, TCM pulse diagnosis, and TCM heart rate variability for this purpose.
88974894|NCT02969343|No Intervention|Usual Care|Patients on hospital care units where the PSLL patient safety health information technology tools have been implemented or are to be implemented, but are not during the usual care phase of a stepped wedge randomized trial design.
89584963|NCT02119663|Experimental|Ruxolitinib plus capecitabine|
89584964|NCT02119663|Active Comparator|Placebo plus capecitabine|
89584965|NCT04481009|Experimental|YH003 with Toripalimab after PD-1/L1 +/- CTLA-4 treatment|YH003 in combination with Toripalimab in subjects with unresectable /metastatic melanoma after having failed PD-1/L1 +/- CTLA-4 treatment.
89584966|NCT04481009|Experimental|YH003 with Toripalimab in subjects with PDAC|YH003 in combination with Toripalimab in subjects with unresectable/ metastatic pancreatic ductal adenocarcinoma (PDAC) as 2nd line treatment.
89584967|NCT04481009|Experimental|YH003 with Toripalimab plus standard chemotherapy|YH003 in combination with Toripalimab plus standard chemotherapy (Nab-paclitaxel + Gemcitabine) in subjects with unresectable/metastatic PDAC as 1st line treatment
89584968|NCT05327231|Experimental|IN10018 Monotherapy|Participants will be instructed to take IN10018 orally once daily at approximately the same time each day, to ensure a dose interval of approximately 24 hours.
89584969|NCT05327231|Experimental|IN10018 Combination with Docetaxel|Participants will be instructed to take IN10018 orally once daily at approximately the same time each day, to ensure a dose interval of approximately 24 hours. Docetaxel 75mg/m2 every 21 days a cycle.
89584970|NCT01639469|Experimental|Structured exercise|Structured exercise instruction by smartphone
89584971|NCT01639469|Active Comparator|lifestyle exercise|Lifestyle exercise program taught via smartphone
89584972|NCT04855721|Experimental|AUR101 400 mg PO BID|Patients will receive AUR101 / placebo in double blind, double dummy manner
89584973|NCT04855721|Experimental|AUR101 200 mg PO BID|Patients will receive AUR101 / placebo in double blind, double dummy manner
89584974|NCT04855721|Experimental|AUR101 400 mg PO QD|Patients will receive AUR101 / placebo in double blind, double dummy manner
89584975|NCT04855721|Placebo Comparator|Placebo|Patients will receive AUR101 / placebo in double blind, double dummy manner
89584976|NCT02193074|Experimental|nusinersen|
89584977|NCT02193074|Sham Comparator|Sham procedure|
89584978|NCT04852601|Experimental|ToolboxDetect Strategy|"All practices randomized to the intervention arm will implement the ToolboxDetect battery as the standard of care routine cognitive assessment to fulfill the Medicare Annual Wellness Visit (AWV) requirement. The 7-8 minute ToolboxDetect battery contains self-administered versions of the NIH ToolBox Picture Sequence Memory Test (PSM) and the NIH ToolBox Dimensional Change Card Sorting (DCCS). PSM measures episodic memory and DCCS tests executive functioning.~The validated ToolboxDetect application will be imparted either as an application on an iPad or on a PC desktop/laptop computer commonly found in a clinical exam room for EHR access."
89584979|NCT04852601|No Intervention|Enhanced Usual Care|"At Northwestern Medicine, cognitive assessments included in Annual Wellness Visits or other routine or sick/problem-based visits vary by practice and also by clinician. However, the choice of test was limited to either a Mini-Cog©, Montreal Cognitive Assessment (MoCA), or Mini Mental Status Exam (MMSE).~While we will not make any explicit recommendations to these practices with regard to their use of a cognitive assessment, we will ensure that 1) any chosen test is linked to an Epic SmartData element, which will allow the clinician to record the results of the test as discrete data (which can then be queried), and that 2) providers receive a compiled list of local medical and non-medical referrals for any detected cases of CI. The Alzheimer's Association recommendations for early detection efforts among primary care practices will also be provided to each clinic's medical leadership."
89584980|NCT04418102|Experimental|Palmitic acid rich interesterified fat|Snacks (muffins) and spread containing palmitic acid rich interesterified fat to replace habitual snacks and spreads, and provide 10% of total daily energy intake with the interesterified fat.
89584981|NCT04418102|Active Comparator|Stearic acid rich interesterified fat|Snacks (muffins) and spread containing stearic acid rich interesterified fat to replace habitual snacks and spreads, and provide 10% of total daily energy intake with the interesterified fat.
88974895|NCT02969304||Off-Label|Any DMF prescription for MS patients <18 years of age, or for patients diagnosed with non-MS indications, such as psoriasis.
88974896|NCT02969304||On-Label|Prescriptions for patients who are ≥18 years of age and diagnosed with MS
88974897|NCT00031655|Experimental|Treatment (nonmyeloablative allogeneic PBSCT)|"NONMYELOALATIVE CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.~TRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0. Patients with minimal residual disease may receive donor lymphocyte infusion IV.~IMMUNOSUPPRESSION: Patients receive cyclosporine PO every 12 hours on days -3 to 100 with taper to day 177 and mycophenolate mofetil PO very 8 hours on days 0 to 40 with taper to day 96."
88974898|NCT02971553|Experimental|Upright Resuscitator with PEEP|Ventilation with the Upright Resuscitator with PEEP
88974899|NCT02971553|Active Comparator|Upright Resuscitator|Ventilation with the Upright Resuscitator (without PEEP)
88974900|NCT00059592|Experimental|Valacyclovir|oral Valacyclovir three times a day for 5 to 10 days.
89584982|NCT04765592|Experimental|WeFlow-Arch Modeler Embedded Branch Stent Graft System|Participants will be treated with WeFlow-Arch Modeler Embedded Branch Stent Graft System
89584983|NCT04764968|No Intervention|Usual care|During the 'usual care' period, participants will manage episodes of manifest or impending hypoglycemia as usual, e.g. through carbohydrate consumption or manual insulin pump suspension.
89584984|NCT04764968|Experimental|Dasiglucagon|During the 'dasiglucagon' period, participants will use pen-administered low-dose (80 µg) dasiglucagon to treat or prevent episodes of hypoglycemia.
89584985|NCT02192606|Active Comparator|2D Laparoscopy|The standard 2D Laparoscopy System to be used at time of the total laparoscopic hysterectomy
89584986|NCT02192606|Active Comparator|3D laparoscopy|The Storz 3D Laparoscopy System is the intervention we are studying at the time of the total laparoscopic hysterectomy.
89584987|NCT01628107|Experimental|Epoetin Hospira|Epoetin Hospira will be administered by IV bolus injection 1 to 3 times per week per each patient's dosing schedule. Other ESAs (except for long-acting) may be used as rescue therapy.
89584988|NCT04764734|Experimental|PSG and NightOwl|During the study, for each execution day, all patients that have been scheduled for a PSG will be presented with the informed consent form. All recruited patients shall be a part of the study during which they wear the NightOwl Sensor while undergoing the PSG exam.
89584989|NCT04740151|Experimental|BEST PEEP|During OLV an individualized PEEP will be applied i.e. the one corresponding to the lower driving pressure, + 2 cmH2O
89584990|NCT04740151|Active Comparator|STANDARD PEEP|During OLV a PEEP of 5 cmH2O will be applied
89584991|NCT04745377||Control Group|Healthy volunteers from hospital personnel vaccinated for covid-19, who sign informed consent for recording of outcomes and monitor of antibody titers in 3 timepoints
89584992|NCT04745377||Cancer patients|Cancer patients with solid tumours, with active disease and/or undergoing active systemic treatment, who will be vaccinated for covid-19
89584993|NCT04739683|Active Comparator|Foley bulb|16F latex or silicone Foley catheter inflated with 30-40 cc of sterile water. The catheter will be taped to the inner thigh with gentle traction.
89584994|NCT04739683|Active Comparator|DILAPAN-S®|Synthetic hydrogel cervical dilator consists of the dilating part, the polypropylene handle, and the marker string. The dilating part is manufactured from an anisotropic xerogel of AQUACRYL.
89584995|NCT01583530|Active Comparator|Belimumab IV 240 mg|
89584996|NCT01583530|Experimental|Belimumab SC 2 x 120 mg|
89584997|NCT01583530|Experimental|Belimumab SC 1 x 240 mg|
89584998|NCT01583530|Experimental|Belimumab SC 1 x 200 mg|
89584999|NCT01583530|Experimental|Belimumab SC 2 x 120 mg weekly|
89585000|NCT01583530|Experimental|Belimumab SC 1 x 200 mg weekly|
89585001|NCT01639001|Experimental|Crizotinib|Crizotinib
89585002|NCT01639001|Active Comparator|Chemotherapy|Chemotherapy [Option at Investigator's Choice]
89585003|NCT02224664|Experimental|Cohort 3|Titration of PF-06649751 up to 5 mg QD
89585004|NCT02224664|Experimental|Cohort 4|Titration of PF-06649751 up to 15 mg QD
89585005|NCT02224664|Experimental|Cohort 5|Titration of PF-06649751 up to 15 mg QDi n subjects with Levodopa-induced dyskinesias (LID)
89585006|NCT02224664|Experimental|Cohort 6|Titration of PF-0649751 up to 25 mg QD
89585007|NCT04443959|Experimental|PUMAS Treatment|Prenatal insomnia program that places behavioral sleep strategies within a mindfulness-based intervention framework that is geared toward pregnant women.
89030185|NCT01248468|Experimental|Aspirin, acetaminophen and caffeine|AAC: 2 tablets, each containing acetaminophen 250 mg, aspiring 250 mg, caffeine 65 mg and 1 placebo tablet matching sumatriptan 100 mg tablets
89030186|NCT01248468|Active Comparator|Sumatriptan (100 mg)|1 tablet containing sumatriptan 100 mg and 2 placebo tablets matching acetaminophen 250 mg, aspirin 250 mg and caffeine 65 mg tablets
89030187|NCT01248468|Placebo Comparator|Placebo|1 placebo tablet matching sumatriptan 100mg and 2 placebo tablets matching acetaminophen 250 mg, aspirin 250 mg and caffeine 65 mg tablets
89585008|NCT02167256|Experimental|AZD0530 100mg daily|Patients in the experimental group (50%) will be started on this dose. After 2 weeks, patients with a plasma drug level of <100ng/ml will receive 125mg AZD0530 daily and remain in the same experimental group as patient receiving 100mg daily.
89585009|NCT02167256|Placebo Comparator|AZD0530 Placebo|50% of patients will receive placebo treatment for the duration of the study,
89585010|NCT02191046|Active Comparator|syringe 20 ml|nasal irrigation with syringe by using buffer hypertonic saline about 100-240 ml until no nasal discharge
89585011|NCT02191046|Experimental|squeezable bottle|nasal irrigation with squeezable bottle by using buffer hypertonic saline about 100-240 ml until no nasal discharge
89585012|NCT04851899|Experimental|Low dose Phaeosol group|1 Phaeosol softgel of 440mg/day and 1 placebo softgel of 440mg/day look like softgel of Phaeosol product) + 1 capsule of 440mg/day of natural stimulant
89585013|NCT04851899|Experimental|High dose Phaeosol group|2 Phaeosol softgels of 440mg/day + 1 capsule of 440mg/day of natural stimulant
89585014|NCT04851899|Placebo Comparator|Placebo group|2 placebo softgels of 440mg/day (look like softgel of Phaeosol product) + 1 capsule of 440mg/day containing Microcellulose (look like capsule of natural stimulant)
89585015|NCT04838171||Specimen collection to support development of engineering Treg|
89585016|NCT02166476|Experimental|Meropenem-Vaborbactam|Meropenem-vaborbactam (meropenem 2 grams [g] plus vaborbactam 2 g), infused in 250 milliliters (mL) normal saline, administered intravenously (IV) over 3 hours, every 8 hours (q8h), with 100 mL saline administered over 30 minutes q8h. Levofloxacin tablets administered orally as a 500-milligram (mg) dose every 24 hours (q24h) after a minimum of 15 doses of IV meropenem-vaborbactam plus saline, if clinically indicated. Total treatment was 10 days, unless a participant had baseline bacteremia where up to 14 days of therapy could be administered IV.
89585017|NCT02166476|Active Comparator|Piperacillin-Tazobactam|Piperacillin-tazobactam (piperacillin 4 g plus tazobactam 0.5 g), infused in 100 mL normal saline, administered IV over 30 minutes, q8h, with 250 mL saline administered over 30 minutes q8h. Levofloxacin tablets administered orally as a 500-mg dose q24h after a minimum of 15 doses of IV piperacillin-tazobactam plus saline, if clinically indicated. Total treatment was 10 days, unless a participant had baseline bacteremia where up to 14 days of therapy could be administered IV.
89585018|NCT05237609|Experimental|rehabilitation with muscle strengthening + Oral Nutritional Supplements|Participants will receive weekly physical therapy sessions for 20 weeks, during their usual follow-up at the day hospital. In addition to the standard treatment, muscle strengthening exercises using elastic bands of varying resistance will be performed. These sessions can be completed by a muscle strengthening session at home during the week, given by a private physiotherapist according to the indication given by a doctor taking care of the patient, during and outside the periods of follow-up at the day hospital. In addition to muscle strengthening, participants will receive a systematic protein intake via Oral Nutritional Supplements (ONS) to improve muscle strength. Compliance with these oral nutritional supplements will be monitored by means of a booklet filled in by the patient or his entourage.
89585019|NCT05237609|Active Comparator|standard rehabilitation +/- Oral Nutritional Supplements|"The participants in the control group will receive the usual care at the day hospital, i.e. a rehabilitation program focused on the prevention of falls. The prescription of ONS will be made on a case-by-case basis by the day hospital's physician. If participants require follow-up by a physiotherapist at home, sessions will be prescribed.~After the treatment, participants in the experimental group will be advised to continue the muscle strengthening sessions independently at least once a week. All participants, regardless of their group, who require follow-up by a physiotherapist will benefit from it."
89585020|NCT02224274|Active Comparator|Clopidogrel|These patients will be treated with clopidogrel 600 mg loading and than 75 mg/24 h.
89585021|NCT02224274|Experimental|Ticagrelor|These patients will be treated with ticagrelor 180 mg loading and than 90 mg/12 h.
89585022|NCT04764110|Experimental|Cyplexinol|900 mg daily (2 capsules) for 15 days
89585023|NCT04764110|Placebo Comparator|Placebo|2 capsules daily for 15 days
89585024|NCT05219669|Experimental|Intranasal Nalmefene 1 spray in 1 nostril|Nalmefene Hydrochloride nasal spray, 3mg, 1 spray in 1 nostril
89585025|NCT05219669|Experimental|Intranasal Nalmefene 2 sprays in 1 nostril|Nalmefene Hydrochloride nasal spray, 6mg, 2 sprays in 1 nostril
89585026|NCT05219669|Experimental|Intranasal Nalmefene 1 spray in each nostril|Nalmefene Hydrochloride nasal spray, 6mg, 1 spray in each nostril
89585027|NCT04763798|Experimental|Dominant|All subjects will receive the three stretching techniques on dominant leg. Interventions will be performed in three different days and only one of the three stretching exercises will be performed in each session. The rest period between sessions will be one week. Stretching exercises will be perform in a random order. A random-number generator will be used for randomization
89585028|NCT04763798|Active Comparator|Non dominant|All subjects will receive the three stretching techniques on non dominant leg. Interventions will be performed in three different days and only one of the three stretching exercises will be performed in each session. The rest period between sessions will bé one week. Stretching exercises will be perform in a random order. A random-number generator will bé used for randomization
89585029|NCT04763252||Canadian|
89585030|NCT05369039|Experimental|Case Group|The case group will receive a 10 days course of Roflumilust in a dose of 500 mg once daily.
89585031|NCT05369039|Active Comparator|Control group|The Control group will receive a 10 days course of systemic steroids in the form of oral prednisolone in a dose of 40 mg per day.
89585032|NCT04373369|Experimental|Vorolanib + Atezolizumab|Consenting and eligible participants who have no evidence of tumor progression after 3 to 4 cycles of standard-of-care induction therapy will receive atezolizumab intravenously (IV) every 3 weeks and vorolanib by mouth daily.
89585033|NCT04791059|Experimental|Combined analgesia group|Patient-controlled analgesia is established with S-ketamine 50 mg, dexmedetomidine 200 microgram, and sufentanil 4 microgram/kg (maximum 250 microgram), diluted with normal saline to 200 ml, and programmed to administer 2-ml boluses with a lock-out interval of 8 minutes and a background infusion rate at 1 ml/h.
89585034|NCT04791059|Placebo Comparator|Control group|Patient-controlled analgesia is established with sufentanil 4 microgram/kg (maximum 250 microgram), diluted with normal saline to 200 ml, and programmed to administer 2-ml boluses with a lock-out interval of 8 minutes and a background infusion rate at 1 ml/h.
89585035|NCT05405855|Experimental|Experimental Group|"The eLIFEwithIBD intervention is an ACT, mindfulness and compassion eHealth intervention for people with inflammatory bowel disease (IBD). The eLIFEwithIBD intervention is delivered through 9 sessions available on an online platform throughout a 9-week period. Each session is composed of real-image videos, texts with illustrative images, exercises in editable text format, and audio files with the experiential exercises and practices targeting topics such as acceptance, mindfulness, compassion, and gratitude.~Participants in this group also continue to receive a standard, personalised treatment for IBD."
89585036|NCT05405855|No Intervention|Control Group|Treatment as Usual (TAU) - Standard, personalised treatment for inflammatory bowel disease.
89585037|NCT02189252|Active Comparator|E4:L4|Crossover Sequence
89585038|NCT02189252|Active Comparator|L4:E4|Crossover Sequence
89585039|NCT02189252|Active Comparator|E2:L4|Crossover Sequence
89585040|NCT02189252|Active Comparator|L4:E2|Crossover Sequence
89585041|NCT05369117|Experimental|indocyanine green labeled fluorescent laparoscopy|The experimental group was marked with indocyanine green, while the control group was not marked with indocyanine green
89585042|NCT05369117|Experimental|The pathological staging|They were grouped by different pathological stages
89585043|NCT04766099|No Intervention|Standard Treatment|Standard bedside coaching by labor and delivery staff
89585044|NCT04766099|Experimental|Educational Video|Patients will watch the provided coaching video in addition to standard bedside coaching by labor and delivery staff
89585045|NCT05399069|Experimental|VGR-R01|Subretinal injection of VGR-R01
89585046|NCT05398913|Placebo Comparator|Placebo|Two pills of placebo will be administered for 5 consecutive days, once per day.
89585047|NCT05398913|Active Comparator|Rimonabant 2.5 mg|One pill of placebo and one pill of Rimonabant 2.5mg will be administered for 5 consecutive days, once per day.
89030188|NCT02275299|Experimental|Iguratimod and MTX combination|Drug:Iguratimod 25 mg/tablet, taken orally, 2 tablets/day (bid) Drug:MTX 2.5 mg/tablet, taken orally once a week, 4 tablets/week
89030189|NCT02275299|Active Comparator|Leflunomide and MTX combination|Drug: Leflunomide 10 mg/tablet, taken orally, 2 tablets/day (bid) Drug: Methotrexate 2.5 mg/tablet, taken orally once a week, 4 tablets/week
89585048|NCT05398913|Active Comparator|Rimonabant 5 mg|Two pills of Rimonabant 2.5mg will be administered for 5 consecutive days, once per day.
88974901|NCT02969265|Experimental|TCV-116CCB (Candesartan 8 mg Plus Amlodipine 5 mg)|"Run-in Period: TCV-116CCB placebo-matching tablets, orally, once daily along with amlodipine placebo-matching capsules, orally, once daily up to 2 weeks.~Single-blind monotherapy treatment period: TCV-116CCB placebo-matching tablets, orally, once daily along with amlodipine 5 mg capsules, orally, once daily up to 4 weeks.~Double-blind treatment period: TCV-116CCB 8/5 mg tablets, orally, once daily along with amlodipine placebo-matching capsules, orally, once daily up to 8 weeks."
88974902|NCT02969265|Experimental|Amlodipine 5 mg|"Run-in Period: TCV-116CCB placebo-matching tablets, orally, once daily along with amlodipine placebo-matching capsules, orally, once daily up to 2 weeks.~Monotherapy treatment period: TCV-116CCB placebo-matching tablets, orally, once daily along with amlodipine 5 mg capsules, orally, once daily up to 4 weeks.~Double-blind treatment period: Amlodipine 5 mg capsules, orally, once daily along with TCV-116CCB placebo-matching tablets, orally, once daily up to 8 weeks."
88974903|NCT00031772|No Intervention|Control|Standard level of support after recurrence diagnosis
88974904|NCT00031772|Experimental|Intervention|Phone intervention for patients experiencing first recurrence with quality of life questionnaires, psychosocial assessment and care.
88974905|NCT02969070|Active Comparator|LopiGLIK™ group|4 weeks of LopiGLIK™ therapy 1 capsule/day
88974906|NCT02969070|Active Comparator|Armolipid Plus group|4 weeks of Armolipid Plus therapy 1 capsule/day
89585049|NCT04256837|Experimental|VNS - Live donor kidney recipients.|Live donor kidney recipients. VNS will be applied for 5 minutes prior to start of surgery. The device to be used for VNS will include a handheld electrical pulse generator and a pair of electrodes to be placed at the left ear for stimulation, targeting the auricular branch of the vagus nerve which innervates the skin overlying the cymba conchae of the ear canal.
89585050|NCT04256837|Sham Comparator|sham VNS - Live donor kidney recipients.|Live donor kidney recipients. As above, but without applying any VNS
89585051|NCT04256837|Experimental|VNS - Deceased donor kidney recipients.|Deceased donor kidney recipients. VNS will be applied for 5 minutes prior to start of surgery. The device to be used for VNS will include a handheld electrical pulse generator and a pair of electrodes to be placed at the left ear for stimulation, targeting the auricular branch of the vagus nerve which innervates the skin overlying the cymba conchae of the ear canal.
89585052|NCT04256837|Sham Comparator|sham VNS - Deceased donor kidney recipients.|Deceased donor kidney recipients. As above, but without applying any VNS
89585053|NCT05396729|Experimental|transcutaneous electrical acupoint stimulation|Electrodes are placed at acupoints and connected to the stimulator. Electrical stimulation is given for 30 minutes
89585054|NCT05396729|No Intervention|Control|Electrodes are placed at acupoints but no electrical stimulation is given
89585055|NCT01583374|Experimental|Apremilast 20 mg|Apremilast 20 mg was taken orally twice a day (BID)
89585056|NCT01583374|Experimental|Apremilast 30 mg|Apremilast 30 mg was taken orally twice a day
89585057|NCT01583374|Placebo Comparator|Placebo|Identically matched placebo tablets were taken orally twice a day
89585058|NCT01583296|Experimental|CBT and HRVB|Cognitive Behavioral Therapy (CBT) and Heart Rate Variability Biofeedback (HRVB)
88974907|NCT02969148|Experimental|The bursectomy and D2 lymphadenectomy|Laparoscopic bursectomy and D2 lymphadenectomy will be performed for the treatment of patients assigned to this group.The key of this approach are that anterior lobe of transverse mesocolon and capsula pancreatis will be dissected with the D2 lymphadenectomy according to the guidelines of National Comprehensive Cancer Network(NCCN)
88974908|NCT02969148|Active Comparator|The D2 lymphadenectomy|Laparoscopic D2 lymphadenectomy will be performed for the treatment of patients assigned to this group.The key of this approach is that D2 lymphadenectomy is carried out according to the guidelines of National Comprehensive Cancer Network(NCCN) without dissociation of anterior lobe of transverse mesocolon and capsula pancreatis.
88974909|NCT02971709|Experimental|Shade Sail|Shade sails were constructed over passive recreation areas in public parks between pretest and posttest. Shade sails maximized available shade in the passive recreation areas from 11 am to 3 pm in the summer.
88974910|NCT02971709|No Intervention|Unshaded Control|Passive recreation areas in public parks that remained unshaded at pretest and posttest.
88974911|NCT00059631|Experimental|Bortezomib + Mitoxantrone|"Bortezomib starting dose of 1.4 mg/m^2, four weekly intravenous injections (on Days 1, 8, 15, and 22) over eight 5 week cycles.~Mitoxantrone starting dose of 3 mg/m^2, four weekly intravenous injections (on Days 1, 8, 15 and 22) over eight 5 week cycles."
88974912|NCT00031889|Active Comparator|Arm I|Patients receive oral exemestane once daily
88974913|NCT00031889|Active Comparator|Arm II|Patients receive exemestane as in arm I and oral bicalutamide once daily
88974914|NCT02969226|Active Comparator|Once daily screening + PS SBTs|In this arm, RTs will screen patients between approximately 06:00 - 08:00 hrs daily. If a screening period is missed inadvertently or due to an investigation or intervention (operation/procedure) necessitating absence from the ICU, it may be conducted later on the same day and ideally within 6 hrs of the scheduled screening period. Regardless of group assignment, if the SBT screening assessment is passed, an SBT will be conducted as per protocol. RTs will conduct SBTs using only PS> 0 and =< 8 cm H2O with PEEP> 0 and =< 5 cm H2O.
89585059|NCT01583296|Active Comparator|Music Relaxation Therapy (MRT)|Music Relaxation Therapy (MRT): music relaxation and breathing at resting respiration rate
89585060|NCT04189835||Kidney transplant recipients|Adults and children undergoing kidney transplantation in Norway and the western part of Denmark.
89585061|NCT04165577|Experimental|OCD, Active TMS|Participants with OCD who receive active rTMS
89585062|NCT04165577|Sham Comparator|OCD, Sham TMS|Participants with OCD who receive sham rTMS
89585063|NCT04165577|Other|Healthy Control, Active TMS|Healthy control participants who receive active rTMS
89585064|NCT04165577|Other|Healthy Control, Sham TMS|Healthy control participants who receive sham rTMS
89585065|NCT04165577|Other|Healthy Control, Active TMS (1 session)|Healthy control participants who receive 1 session of active, open-label rTMS
89585066|NCT04165577|Other|Healthy Control, Active TMS (3 sessions)|Healthy control participants who receive 3 sessions of active, open-label rTMS
89585067|NCT04165577|Other|OCD, Active TMS (3 session)|Participants with OCD who receive 3 sessions of active, open-label rTMS
89585068|NCT02222714|Active Comparator|120 µg/kg of 3K3A-APC|3K3A-APC, q12h for up to 5 doses
89585069|NCT02222714|Active Comparator|240 µg/kg of 3K3A-APC|3K3A-APC, q12h for up to 5 doses
89585070|NCT02222714|Active Comparator|360 µg/kg of 3K3A-APC|3K3A-APC, q12h for up to 5 doses
89585071|NCT02222714|Active Comparator|540 µg/kg of 3K3A-APC|3K3A-APC, q12h for up to 5 doses
89585072|NCT02222714|Placebo Comparator|Placebo|Matching placebo, q12h for up to 5 doses
89585073|NCT04836767||people with a history of COVID-19|"COVID-19 Group Inclusion Criteria~Having been diagnosed with COVID-19 at least 12 weeks ago,~Being literate,~Being in the age range of 18-65,~Volunteering to participate in research,~To be clinically stable, to be under control if any accompanying comorbid conditions (such as hypertension, diabetes),~Not having any orthopedic and neurological problems that might interfere with evaluating peripheral muscle strength, balance and exercise capacity.~COVID-19 Group Exclusion Criteria~Those with an ICU hospitalization history due to the diagnosis of COVID-19,~Recent myocardial infarction and pulmonary embolism.~Having accompanying chronic diseases,~Those who have any orthopedic or neurological disorders that will prevent walking,~Another COVID-19 PCR Test positivity in the last 12 weeks,~Not being able to cooperate and adapt to exercise test due to neurological influences such as cerebrovascular disease or psychiatric disorders,"
89585074|NCT04836767||healthy people|"Healthy Group Inclusion Criteria~Not having COVID-19,~Being literate,~Being in the age range of 18-65,~Volunteering to participate in research. The Criteria for Not Including the Healthy Group in the Study~Those who have any orthopedic or neuromuscular disorders that will prevent walking,~Having any chronic illness or psychiatric conditions or mental afflictions that may interfere with cooperation or compliance with exercise tests."
89585075|NCT04836689|Other|30 breaths per minutes|Using NIPPV with rate of 30 for 1 hour. Measuring trans cutaneous CO2
89585076|NCT04836689|Other|10 breaths per minute|Using NIPPV with rate of 10 for 1 hour. Measuring trans cutaneous CO2
89585077|NCT04821401|Experimental|Males study product|25 men will be randomized to Rejuvant
89585078|NCT04821401|Placebo Comparator|Males placebo|25 man will be randomized to placebo
89585079|NCT04821401|Experimental|Females study product|25 women will be randomized to Rejuvant
89585080|NCT04821401|Placebo Comparator|Females placebo|25 women will be randomized to placebo
89585081|NCT05226143|Experimental|Gel Cream|Participants will be provided with the Gel Cream to apply on clean, dry face (facial skin) once per day and on the target lesion on the face or body at least 2 times per day or more as needed, in the morning and at night for 14 days.
89585082|NCT03291743|Experimental|First Degree Relative|A total of 112 high risk first-degree relatives will be enrolled in total. Patients with Crohn's Disease will be given information about the study when in clinic for routine care to share with their first degree relatives (FDR). Screening will be done using capsule endoscopy.
88974915|NCT02969226|Experimental|At least twice daily screening + PS SBTs|In this arm patients will be screened at a minimum between approximately 06:00 - 08:00 hours and 13:00 - 15:00 hs daily. If a screening period is missed inadvertently or due to an investigation or intervention (operation/procedure) necessitating absence from the ICU, it may be conducted later on the same day and ideally within 6 hrs of the scheduled screening period. Additional screening trials in the 'at least twice daily' screening arm will be permitted at the discretion of the clinical team [RTs and physicians]. Regardless of group assignment, if the SBT screening assessment is passed, an SBT will be conducted as per protocol. RTs will conduct SBTs using only PS>0 and =< 8 cm H2O with PEEP>0 and =< 5 cm H2O.
88974916|NCT02969226|Active Comparator|Once daily screening + T-piece SBTs|In this arm + PS SBT' arm, RTs will screen invasively ventilated patients between approximately 06:00 - 08:00 hrs daily. If a screening period is missed inadvertently or due to an investigation or intervention (operation/procedure) necessitating absence from the ICU, it may be conducted later on the same day and ideally within 6 hrs of the scheduled screening period. Regardless of group assignment, if the SBT screening assessment is passed, an SBT will be conducted as per protocol. RTs will conduct SBTs using only T-piece (off the ventilator).
88974917|NCT02969226|Active Comparator|At least twice daily screening + T-piece SBTs|In this arm, RTs will screen invasively ventilated patients between approximately 06:00 - 08:00 hours daily. If a screening period is missed inadvertently In the 'at least twice daily + PS SBT' screening arm patients will be screened at a minimum between approximately 06:00 - 08:00 hrs and 13:00 - 15:00 hrs daily. If a screening period is missed inadvertently or due to an investigation or intervention (operation/procedure) necessitating absence from the ICU, it may be conducted later on the same day and ideally within 6 hours of the scheduled screening period. Additional screening trials in the 'at least twice daily' screening arm will be permitted at the discretion of the clinical team (RTs and physicians). Regardless of group assignment, if the SBT screening assessment is passed, an SBT will be conducted as per protocol. RTs will conduct SBTs using only T-piece (off the ventilator).
89030190|NCT02955576|Placebo Comparator|Control group|All lesions were treated with topical calcipotriol - betamethasone dipropionate ointment only.
89585083|NCT03291743|Active Comparator|Healthy Controls|This study will also enroll 35 healthy controls who will be age and sex matched to the first degree relative (FDR) population. Enrollment will begin after 20-25 FDR's have passed screening and will continue at this interval until all controls have been enrolled. Controls will be initially screened by colonoscopy. If enrolled they will undergo capsule endoscopy as well
89585084|NCT04145219|Experimental|Active treatment|HDM SLIT-tablet plus allergy and asthma rescue medication
89585085|NCT04145219|Placebo Comparator|Placebo|Placebo oral tablet plus allergy and asthma rescue medication
89585086|NCT04808921|Experimental|SARS-CoV-2 Antigen Rapid Test|The same group of patients participated in two arms of the study, one arm was for obtaining data on the rapid antigen test for COVID-19, the comparator arm was to obtain data from the RT-PCR
89585087|NCT05652881|No Intervention|Standard of care|Standard of care treatment for axially unstable tibial pilon fracture will include temporary external fixation followed by delayed definitive fixation. Arthrocentesis of the injured and uninjured ankles will be performed at the time of initial temporary external fixation and again at the time of definitive fixation.
89585088|NCT05652881|Experimental|Intervention|Additional intra-articular joint lavage with 1L normal saline will be performed at the time of initial temporary external fixation in addition to standard of care treatment.
89585089|NCT04102865|Other|single use NPWT dressing|single use NPWT dressing
89585090|NCT03132155|Experimental|AMG 337|AMG 337 will be administered in patients with advanced or metastatic clear cell sarcoma
89585091|NCT03107195||Tc-99m DMSA|Patients aged 1-6 years old will be enrolled. Routine SPECT imaging will be performed 3-4 h post-administration (PA) with a dual-detector rotating gamma camera over a 360˚ rotation for 8 s per view using a 1282 matrix. In each age group, half of the subjects will also be imaged between 30 and 90 min, post-administration. The 2nd half will be imaged at 4-6 h, post-administration. It is important to note that the patient volunteers will not receive any additional radiation exposure for inclusion in this study. They are only being ask to allow imaging at one additional time point.
89585092|NCT02164916|Active Comparator|Arm I (cetuximab, irinotecan hydrochloride)|Patients receive cetuximab IV and irinotecan hydrochloride IV on days 1 and 14. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may cross over to Arm II.
89585093|NCT02164916|Experimental|Arm II (cetuximab, irinotecan hydrochloride, vemurafenib)|Patients receive cetuximab and irinotecan hydrochloride as in Arm I and vemurafenib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89585094|NCT04091867|Experimental|sEphB4-HSA with CRT|"sEphB4-HSA: Loading dose at fixed dose of 10mg/Kg per below schema on D1 Concurrent dose per below schema D15-43 and given on an every other week basis Concurrent chemotherapy drug (either cisplatin or carboplatin): Per treating physician discretion, and treatment plan is based per NCCN guidelines. These can be administered in tri-weekly or weekly doses during the radiation period. The participant will receive the first infusion on Day 15 (+/- 3 days).~Cetuximab:~Loading dose 400 mg/m2 on D9 Concurrent dose 250mg/m2 weekly D15± 3 day window~RT:~6930 cGy IMRT starting D15-D18"
89585095|NCT05652101||Patients suffering from hereditary hyperekplexia, above 2 years of age|"40 patients suffering from hereditary hyperekplexia will be included. The investigators study patients suffering from hereditary hyperekplexia. The diagnostic is clinical, based on the following symptoms, appearing shortly after birth: stiffness, exaggerating response startles to unexpected stimuli, generalized stiffness after the startles.~Children above 2 years old and adults are included, so the neurodevelopment can be evaluated."
89585096|NCT05290259||Ballroom Basics for Balance Program|The Ballroom Basics for Balance program is a 12-week physical activity program which uses dance to focus on balance for community dwelling adults.
89585097|NCT04818125|Other|Patients with breast cancer|
89585098|NCT05651789|Experimental|Carvedilol|Carvedilol is started at a dose of 6.25mg/d, and titrated to a maximum dose of 12.5mg/d. Doses are increased 3 days later. Avoid systolic blood pressure <90 mmHg.
89585099|NCT05651789|Active Comparator|Propranolol|Propranolol is started at a dose of 20 mg/d and the dose will be increased by 10 mg twice a day steps every 2-3 days until the target (heart rate: 55~60 bpm) or to a maximum dose of 160 mg/d. Systolic arterial pressure is not less than 90 mm Hg and heart rate is not less than 50 bpm.
89585100|NCT05651477||Doctor|Doctors of the Emergency department conduct questionnaires about occupational, mental, physical factors on their health.
89585101|NCT05651477||Nurses|Nurses of the Emergency department conduct questionnaires about occupational, mental, physical factors on their health.
89585102|NCT02999477|Experimental|Nab-Paclitaxel|"2 weeks Nab-Paclitaxel Run in~Biopsy will be performed~Post mono therapy Nab-Paclitaxel administered weekly~Post mono therapy Pembrolizumab administered every 3 weeks~Agents administered for a total of 15 weeks"
89585103|NCT02999477|Experimental|Pembrolizumab|"2 weeks Pembrolizumab Run in~Biopsy will be performed~Post mono therapy Nab-Paclitaxel administered weekly~Post mono therapy Pembrolizumab administered every 3 weeks~Agents administered for a total of 14 weeks"
89585104|NCT02222558|Experimental|Period 1: Single Dose|Period 1: Each study subject will receive an escalating single dose of TSX-002 (60, 90, 120, 180, 240 mg), with a minimum 3 day wash-out between each of the 5 escalating doses. After completing the 240 mg dose, a 7 day wash-out period will occur prior to Period 2.
89585105|NCT02222558|Experimental|Period 2: Two Times Daily Dosing 90 mg|Period 2: Each study subject dose is 90 mg twice daily of TSX-002, fasted for 17 days.
89585106|NCT02222558|Experimental|Period 3: Two Times Daily Dosing 120 mg|"Period 2: Each study subject dose is 90 mg twice daily of TSX-002, fasted for 17 days. On Day 15, a serum Testosterone level will be drawn and used to dose titrate and randomized to BID or TID (as eligible). The TSX-002 dose will be down or up titrated.~Period 3: Begins Day 18 with the first adjusted TSX-002 dose administered fasted two times daily. The Testosterone level on Day 22 will be used to perform the final, TSX-002 dose adjustment."
89585107|NCT02222558|Experimental|Period 3: Three Times Daily Dosing 90 mg|"Period 2: Each study subject dose is 90 mg twice daily of TSX-002, fasted for 17 days. On Day 15, a serum Testosterone level will be drawn and used to dose titrate and randomized to BID or TID (as eligible). The TSX-002 dose will be down or up titrated.~Period 3: Begins Day 18 with the first adjusted TSX-002 dose administered fasted three times daily. The Testosterone level on Day 22 will be used to perform the final, TSX-002 dose adjustment."
89585108|NCT02222558|Experimental|Period 3: Two Times Daily Dosing 180 mg|"Period 2: Each study subject dose is 90 mg twice daily of TSX-002, fasted for 17 days. On Day 15, a serum Testosterone level will be drawn and used to dose titrate and randomized to BID or TID (as eligible). The TSX-002 dose will be down or up titrated.~Period 3: Begins Day 18 with the first adjusted TSX-002 dose administered fasted two times daily. The Testosterone level on Day 22 will be used to perform the final, TSX-002 dose adjustment."
89585109|NCT02222558|Experimental|Period 3: Three Times Daily Dosing 120 mg|"Period 2: Each study subject dose is 90 mg twice daily of TSX-002, fasted for 17 days. On Day 15, a serum Testosterone level will be drawn and used to dose titrate and randomized to BID or TID (as eligible). The TSX-002 dose will be down or up titrated.~Period 3: Begins Day 18 with the first adjusted TSX-002 dose administered fasted three times daily. The Testosterone level on Day 22 will be used to perform the final, TSX-002 dose adjustment."
89585110|NCT02975999|Experimental|Vasopressin|Vasopressin at 0.4mU/kg/min
89585111|NCT02975999|Placebo Comparator|Normal saline|Normal saline will be provided on a drip infusion to the selected group once coming off cardiopulmonary bypass following the Fontan operation.
89585112|NCT05287529|Experimental|8-Week Yoga Class|Randomized to immediately begin an 8-week Yoga Class via Telehealth
89030191|NCT02955576|Active Comparator|Patch group|All lesions were treated with topical calcipotriol - betamethasone dipropionate ointment with patches.
89585113|NCT05287529|Active Comparator|Waitlisted for 8-Week Yoga Class|Randomized to start an 8-week Yoga Class via Telehealth 8-weeks from the start of the study.
88974918|NCT00059826|Experimental|Interferon-based chemoradiation therapy|"Cycle 1: Chemoradiotherapy (CRT)~5-fluorouracil continuous infusion (CI) via an ambulatory infusion pump into a central venous catheter at 175 mg/m2/day for 38 consecutive days, unless toxicity occurs~cisplatin given on the first day only of each week of this cycle (days 1, 8, 15, 22, 29, 36)~IFN-alpha-2b 3 million units given subcutaneously on days 1, 3, and 5 of each week for 5½ weeks~XRT 5040 cGy total, in 28 fractions, at 180 cGy/fraction daily, Monday - Friday, for 5½ weeks~Cycles 2 and 3: Post-CRT Chemotherapy~Post-CRT chemotherapy starts 4 - 6 weeks after completion of Cycle 1, unless the study physician deems further delay is necessary. Patients will be given 2 cycles of chemotherapy (cycles 2 and 3).~-- 5-fluorouracil continuous infusion via an ambulatory infusion pump into a central venous catheter at 200 mg/m2/day for 6 weeks followed by 2 weeks of rest"
88974919|NCT00032006|Experimental|brachytherapy + radiation|"Within 4 weeks after completion of androgen suppression, patients are sequentially enrolled to 2 different cohorts of brachytherapy.~Cohort 1: Patients undergo initial-dose transperineal interstitial permanent prostate brachytherapy with iodine I 125 or palladium Pd 103.~Cohort 2: After a minimum of 1-year follow-up for all patients in cohort 1, if tolerance is acceptable, additional patients undergo higher-dose transperineal interstitial permanent prostate brachytherapy with iodine I 125 or palladium Pd 103.~Quality of life is assessed at baseline, within 2 weeks prior to brachytherapy, every 3 months for 1 year, and then every 6 months for 2 years.~Patients are followed every 3 months for 1 year, every 6 months for 4 years, and then annually for 5 years."
88974920|NCT00059865|Experimental|pemetrexed + gemcitabine|"Phase II: Patients receive pemetrexed disodium as in phase I and gemcitabine at the recommended phase II dose.~Patients are followed every 3 months for 1 year and then every 6 months for 4 years."
88974921|NCT00032084|Placebo Comparator|Behavioral Intervention + Placebo|Smoking cessation intervention , nicotine replacement, psychosocial assessment and care, and placebo.
88974922|NCT00032084|Active Comparator|Behavioral Intervention + Bupropion|Smoking cessation intervention, nicotine replacement, psychosocial assessment and care, and bupropion hydrochloride .
88974923|NCT02968875|Active Comparator|Endurance Training|The first group of 40 people will do endurance training; 20 of them will perform a continuous exercise on cycle ergometer at a power equivalent to 70% of the maximal heart rate, twice a week. The other group will do Interval Training, with a four minute long base and one minute long peak, twice a week. The base workload will be equivalent to an intensity of 60% of the maximal heart rate and the peak will be equivalent to 80% of the maximal heart rate.
88974924|NCT02968875|Active Comparator|Control group|20 persons will be in the control group and they will not perform the endurance training. However, they will have 9 therapeutic education meetings.
88974925|NCT00032162|Experimental|PLD|dose finding study of PLD in combination with Carboplatin
88974926|NCT02958696|Active Comparator|HTL0018318 low dose|low dose aqueous solution and/or equivalent low dose capsule
88974927|NCT02958696|Active Comparator|HTL0018318 mid dose|mid dose aqueous solution and/or equivalent mid dose capsule
88974928|NCT02958696|Active Comparator|HTL0018318 high dose|high dose aqueous solution and/or equivalent high dose capsule(s)
88974929|NCT00032357|Other|Arm 1|Usual care plus Ferritin reduction to a calculated nadir of 25 ng/mL by phlebotomy
88974930|NCT00032357|No Intervention|Arm 2|Usual care only; no intervention control
88974931|NCT00032435|Experimental|1|PAL-40 Active
88974932|NCT00032435|Placebo Comparator|2|PAL-40 Placebo
88974933|NCT00060372|Experimental|Treatment (ipilmumab and donor lymphocyte infusion)|Patients receive ipilimumab IV over 90 minutes. Cohorts of 3-6 patients receive escalating doses of ipilimumab until the MTD is determined. The MTD is the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Patients with persistent or progressive disease at 60 days after ipilimumab administration and no evidence of graft-versus-host disease receive donor lymphocyte infusions every 60 days for a total of 3 infusions.
88974934|NCT00032552||1|
88974935|NCT00060411|Experimental|Treatment (combination chemotherapy)|Patients receive oral elotinib alone once daily for 1 week before the beginning of course 1. Patients then receive oral erlotinib once daily on days 1-28; oxaliplatin IV over 2 hours on day 1; and leucovorin calcium IV over 2 hours and fluorouracil IV over 22 hours on days 1 and 2. Patients also receive bevacizumab IV over 30-90 minutes on day 15 of course 1 and on days 1 and 15 of all subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88974936|NCT00060450|Experimental|1|Inhaled Nitric Oxide
88974937|NCT00060450|Placebo Comparator|2|Placebo gas
88974938|NCT04730934||Healthy population|Healthy individuals aged between 18-65
88974939|NCT04730934||Chronic Low Back Pain Group|Patients aged between 18 and 65 and has at least 3 months of low back pain which started before pandemic.
88974940|NCT04730934||Fibromyalgia Group|Patients aged between 18 and 65 and has a diagnosis of fibromyalgia for at least 6 months
88974941|NCT02968719|Experimental|Donepezil TDS Version A|"Lead-in of 5 mg/day donepezil of target dose (1 x Corplex 5 mg donepezil transdermal delivery system; 7 days) followed by; Target dose of 10 mg/day donepezil (Treatment A); Corplex 10 mg donepezil transdermal delivery system.~1x patch will be worn for 7 days. A total of 4 TDS patches will be applied for 4 consecutive 7 day periods."
88974942|NCT02968719|Experimental|Donepezil TDS Version B|"Lead-in of 5 mg/day donepezil of target dose (1 x Corplex 5 mg donepezil transdermal delivery system; 7 days) followed by; Target dose of 10 mg/day donepezil (Treatment B); Corplex 10 mg donepezil delivery transdermal system.~1x patch will be worn for 7 days. A total of 4 TDS patches will be applied for 4 consecutive 7 day periods."
88974943|NCT02968719|Active Comparator|10 mg Aricept|5 mg/day oral Aricept, once daily for 7 days followed by; 10 mg/day Aricept once daily for 28 days
88974944|NCT02968719|Experimental|Donepezil TDS Version D|Target dose of 5 mg/day donepezil (Treatment D) Corplex 5 mg Donepezil TDS applied for a duration of 1 week.
88974945|NCT02968719|Experimental|Donepezil TDS Version E|Target dose of 5 mg/day donepezil (Treatment E) Corplex 5 mg Donepezil TDS applied for a duration of 1 week
89030192|NCT02955576|Experimental|Microneedle patch group|All lesions were treated with topical calcipotriol - betamethasone dipropionate ointment with microneedle HA patches.
89585114|NCT02188784|Active Comparator|Polysaccharide iron complex 150 mg|oral Fe polysaccharide 150mg twice daily for 16 weeks
89585115|NCT02188784|Placebo Comparator|Placebo (for Polysaccharide Iron Complex 150 mg)|Oral placebo twice a day for 16 weeks
89030193|NCT01247922|Experimental|Erlotinib|Participants who received erlotinib in a continuous oral dose of 85 mg/m^2 per day until dose modification, interruption or study discontinuation occurred.
89030194|NCT04518956|Experimental|Inter maxillary fixation and exposure to shockwave therapy|
89585116|NCT02900339|Experimental|MR parameters optimization|The study will be conducted on the MRI of the Neurinfo platform, in the radiology department of the University Hospital of Rennes.
89585117|NCT02848781|Experimental|ICD with Ablation|Patient will receive an implantable cardioverter defibrillator (ICD) with catheter ablation and standard medical management.
89585118|NCT02848781|Active Comparator|ICD Only|Patient will receive an implantable cardioverter defibrillator (ICD) and standard medical management.
89585119|NCT02848781|Active Comparator|Ablation Only (Registry)|The registry will enroll patients who refuse an implantable cardioverter defibrillator (ICD) and are thus not randomized. This arm will assess the efficacy of catheter ablation in the absence of background ICD therapy.
89585120|NCT02222246|Experimental|Patient Specific dose of Morphine Sulfate or Hydromorphone|A patient-specific analgesic protocol for use in the ED to manage VOC crises. Following randomization, a patient's healthcare team will develop a specific analgesic protocol for use during future ED visits for VOC occurring during the study period (up to 5 visits). Treatment protocols will include either morphine sulfate or hydromorphone (delivered intravenous or sub-cutaneous). Dosage and frequency will be based on a patient's prior treatment history.
89585121|NCT02222246|Active Comparator|Standard dose of Morphine Sulfate or Hydromorphone|A standardized analgesic protocol (based on recent NHLBI recommendations) for use in the ED to manage VOC crises. Treatment protocol will include either morphine sulfate or hydromorphone (delivered intravenous or sub-cutaneous), with dosage based on weight. Repeat doses of opioids may be administered every 20-30 minutes as needed, although dosage will be maintained or provided at no more than 25% above the initial dose.
89585122|NCT04793555|Experimental|Experimental_Arm|Assessment of behavior during day and night by unobtrusive sensors
89585123|NCT02188160|Active Comparator|KPI-121 0.25% Ophthalmic Suspension|KPI-121 0.25% ophthalmic suspension dosed QID for 28 days in subjects with dry eye disease
89585124|NCT02188160|Placebo Comparator|Vehicle|Vehicle (placebo) dosed QID for 28 days in subjects with dry eye disease
89585125|NCT04190030|Experimental|Mindfulness|
89585126|NCT04190030|Active Comparator|Cognitive reappraisal|
89585127|NCT03991949|Experimental|Experimental Infant Formula|Ready-to-feed, milk-based formula
89585128|NCT02220998|Experimental|SOF/VEL|SOF/VEL FDC for 12 weeks
89585129|NCT02220998|Experimental|SOF+RBV|SOF+RBV for 12 weeks
89585130|NCT02220920|Experimental|Canagliflozin (TA-7284) ＋insulin|
89030195|NCT04518956|Experimental|Inter maxillary fixation and exposure to low intensity pulsed|
89030196|NCT04518956|Active Comparator|Inter maxillary fixation only|
89030197|NCT01246206|Experimental|Tacrolimus and Thymoglobulin|Tacrolimus and Thymoglobulin, as Graft-versus-Host-Disease Prophylaxis
89030198|NCT04510610|Experimental|Camrelizumab plus decitabine|Decitabine 10 mg/day, days 1-5; Camrelizumab 200 mg, day 8, every 3 weeks.
89030199|NCT01246011|Experimental|Heparin PF4 antibody positive -Drug (argatroban and warfarin)|Post-CABG heparin PF4 antibody positive with no signs or symptoms of HIT randomized to receive argatroban and warfarin
89030200|NCT01246011|No Intervention|Heparin PF4 antibody positive no drug|Post-CABG heparin PF4 antibody positive with no signs or symptoms of HIT randomized to receive no medication
89585131|NCT02220920|Placebo Comparator|Placebo＋insulin|
89030201|NCT01246011|No Intervention|Heparin PF4 antibody negative|Post-CABG heparin PF4 antibody negative with no signs or symptoms of HIT randomized to receive no medication
89030202|NCT04518878|Experimental|Fixed Low-dose Eltrombopag and rhTPO|Fixed Low-dose Eltrombopag and rhTPO
89585132|NCT03966053|Experimental|Cohort A|"Cohort A: Three subjects will receive Trifluoperazine (TFP) 1 mg PO daily.~If there is no non-neurologic toxicity Grade 3 at the end of the 21 days, Cohort B will start.~If 1/3 subjects in Cohort A demonstrates toxicity Grade 3, an additional 3 subjects will be enrolled in Cohort A.~If 2 or more of the 6 subjects in Cohort A demonstrate toxicity Grade 3, the trial will be stopped; no MTD will be declared.~If less than 2 of the 6 subjects in Cohort A demonstrate toxicity Grade 3 within 21 days of starting therapy, Cohort B will start."
89030203|NCT01244490|Experimental|Extended-release Guanfacine Hydrochloride|
89030204|NCT01244490|Other|Atomoxetine Hydrochloride|Active Reference
89030205|NCT01244490|Placebo Comparator|Placebo|
89030206|NCT00506090|Experimental|A|pulsed dye laser and dynamic cooling device at 3 weeks intervals
89030207|NCT00506090|Active Comparator|B|pulsed dye laser and dynamic cooling device at 6 weeks intervals
89030208|NCT00506090|Sham Comparator|C|dynamic cooling device
89030209|NCT04510376|Experimental|Test article|
89030210|NCT04510376|Active Comparator|Histamine Positive Skin Test Control|
89030211|NCT04510376|Placebo Comparator|Aqueous Negative Control|
89030212|NCT01243944|Experimental|ruxolitinib tablets|Starting dose of 10 mg BID with individualized dose titration ranging from 5 mg once a day (QD) to 25 mg BID based on safety and efficacy
89030213|NCT01243944|Other|Best Available Therapy|Best Available Therapy (BAT) will be selected by the Investigator for each participant. BAT may not include experimental agents (i.e. those not approved for the treatment of any indication) as well as a limited number of other selected drugs in accordance with the protocol-defined requirements.
89585133|NCT03966053|Experimental|Cohort B|"Cohort B: Three subjects will receive TFP 2 mg PO daily.~If there is no non-neurologic toxicity Grade 3 at the end of the 21 days, Cohort C will start.~If 1/3 subjects in Cohort B demonstrates toxicity Grade 3, an additional 3 subjects will be enrolled in Cohort B:~If 2 or more of the 6 subjects in Cohort B demonstrate toxicity Grade 3, the study will be stopped, and 1 mg/day will be declared the MTD.~If < 2 of the 6 subjects in Cohort B demonstrate toxicity Grade 3 within 21 days of starting therapy, Cohort C will start."
89585134|NCT03966053|Experimental|Cohort C|"Cohort C: Three subjects will receive TFP 5 mg PO daily.~If there is no non-neurologic toxicity ≥ Grade 3 at the end of the 21 days, Cohort D will start.~If 1/3 subjects in Cohort C demonstrates toxicity Grade 3, an additional 3 subjects will be enrolled in Cohort C:~If 2 or more of the 6 subjects in Cohort C demonstrate toxicity Grade 3, the study will be stopped, and 2 mg/day will be declared the MTD.~If < 2 of the 6 subjects in Cohort C demonstrate toxicity Grade 3 within 21 days of starting therapy, cohort D will start."
89585135|NCT03966053|Experimental|Cohort D|"Cohort D: Three subjects will receive TFP 10 mg PO daily.~If 0/3 subjects in Cohort D demonstrates toxicity Grade 3, the study will be stopped, and 10 mg/day will be declared the MTD.~If 1/3 subjects in Cohort D demonstrates toxicity Grade 3, an additional 3 subjects will be enrolled in Cohort D.~If 2 or more of the 6 subjects in Cohort D demonstrate toxicity Grade 3, the study will be stopped, and 5 mg/day will be declared the MTD.~If <2 of the 6 subjects in Cohort D demonstrate toxicity > Grade 3 within 21 days of starting therapy, 10mg/day will be declared the MTD."
89585136|NCT05204693|Sham Comparator|Start with: Concentric (normal) cycling|
89585137|NCT05204693|Experimental|Start with: Eccentric cycling|
89585138|NCT03946631||Blood Glucose Test - 2hour GTT|Only one arm: intervention group. The intervention is fasting 2 hour glucose tolerance test in the immediate postpartum period. The screening test consists of fingerstick blood glucose testing after a glucose drink. First, a fasting blood glucose finger stick will be performed. Second, the glucose drink is orally ingested containing 75g glucose. The drink is to be orally ingested over 60 seconds. Lastly, fingerstick blood glucose testing is completed at 1 hour post drink and 2 hours post drink.
89585139|NCT05203133|Experimental|Baseline Assessment (Days -5 to -1)|Participants will complete a a 5-day baseline assessment in which habitual energy intake (remote food photography method) and exercise energy expenditure will be monitored.
89585140|NCT05203133|Experimental|Energy Balance (Days 1 to 5)|Participants will be provided with all food intake for five days, to provide an energy intake of 54 kcal/kg FFM/day. On days 1, 3 and 5, participants will complete aerobic (cycling) exercise at ~60% VO2peak to expend15 kcal/kg FFM. This will achieve a state of energy balance (energy availability = 45 kcal/kg of FFM/day, required for weight maintenance.
89585141|NCT05203133|Experimental|Energy Deficit (Days 6-11)|Participants will be provided with all food intake for five days, to provide an energy intake of 19 kcal/kg FFM/day. On days 6, 8 and 10, participants will complete aerobic (cycling) exercise at ~60% VO2peak to expend15 kcal/kg FFM. This will achieve a state of energy deficit (energy availability = 10 kcal/kg of FFM/day) resulting in ~2.5 kg of weight-loss.
89585142|NCT04791293||Group 1|Patients with postoperative complications
89585143|NCT04791293||Group 2|Patients without postoperative complications
89585144|NCT02710721|Experimental|Fasting|60h-modified fasting (36h before and 24h after chemotherapy)
89585145|NCT02710721|Active Comparator|Control|mediterranean diet
89585146|NCT02673905|Experimental|N-TEC (tissue engineered product)|N-TEC is based on autologous nasal chondrocytes expanded and further cultured on type I/III collagen membrane for 2 weeks to allow the cells to produce extracellular matrix containing cartilage specific Proteins. The IMP is implanted in the knee joint and secured by sutures.
89585147|NCT02673905|Experimental|N-CAM (tissue engineered product)|N-Cell activated Matrix (CAM) is based on autologous nasal chondrocytes expanded and further cultured on type I/III collagen membrane for 2 days only to allow the cells to adhere. The IMP is implanted in the knee joint and secured by sutures.
89585148|NCT04790279|Experimental|Amlodipine|
89585149|NCT04790279|Active Comparator|Nifedipine ER|
89585150|NCT02610023||Observational (Willett FFQ, Fred Hutchinson FFQ, CCAT)|After consenting to participate in this study, participants will visit the Clinical Research Center (CRC) on 3 occasions. One of the three FFQ's will be completed at each visit and there will be 4 to 6 weeks between visits. Participants will also complete a blood draw and assessment of skin carotenoids at this CRC visit. Prior to each visit, participants will complete a 3-day diet record, a daily sun exposure diary, and a 3-day activity record.
89585151|NCT03877289|Experimental|Oxybutynin|Children aged 4 - 6 years: Oxybutynin 2.5 mg (2.5ml) po TID Children aged 7 - 16 years: Oxybutynin 5 mg (5ml) po TID
89585152|NCT03877289|Placebo Comparator|Placebo|Orasweet liquid placebo
89585153|NCT03877055|Experimental|Copanlisib and Ibrutinib|Copanlisib is given intravenously on days 1, 8, and 15 of 28 day cycles. Ibrutinib is given orally every day on 28 days cycles. The maximum duration of treatment is 36 cycles not exceeding 36 months. In the phase II study, the cohort will expand and accrue patients at the recommended phase II dose of copanlisib and ibrutinib determined during phase I dose escalation. In a simon two stage mini-max design, an initial 18 patients will be enrolled, inclusive of 6 patients treated at MTD or RP2D from phase I study, in first stage.
89585154|NCT04194047||RBC group|Patients who received RBC transfusion
89585155|NCT04194047||crystalloids group|Patients who received fluid resuscitation with crystalloids
89585156|NCT04194047||control group|Patients not receiving RBC nor crystalloids
89585157|NCT04792151||PHP Youth|Youth ages 6-17 receiving standard of care treatment (i.e., transdiagnostic intervention for emotional disorders) in a partial hospitalization program
89585158|NCT05494619|Experimental|Crovalimab|Participants will receive a single intravenous (IV) infusion of crovalimab on Day 1 based on body weight, followed by crovalimab subcutaneous (SC) injection on Days 2, 8, 15, and 22 for a total of 4 weeks. Additionally, intravenous immunoglobulin (IVIg) background therapy will be administered once a day (QD) for 5 days.
89585159|NCT05494619|Placebo Comparator|Placebo|Participants will receive a single IV infusion of placebo on Day 1 based on body weight, followed by placebo SC injections on Days 2, 8, 15, and 22 for a total of 4 weeks. Additionally, IVIg background therapy will be administered QD for 5 days.
89585160|NCT03826043|Experimental|Experimental arm|Hospitalized patient
89585161|NCT05474495|Experimental|Pelvic floor muscle training|Experimental Group (Group A) will receive pelvic floor muscle training. Two sessions a week for 6 weeks, each session lasting 45 mins.
89585162|NCT05474495|Active Comparator|Transverse abdominas strength training|Active Comparator (Group B) will receive transverse abdominas strength training. Treatment will be given 5 days a week and continued for 6 weeks.
89585163|NCT01634555|Experimental|ramucirumab (IMC-1121B) and FOLFIRI|Treatment is sequential, Ramucirumab (IMC-1121B) will be administered before FOLFIRI ((Irinotecan + Folinic acid + 5-Fluorouracil). FOLFIRI will be administered each cycle and Ramucirumab (IMC-1121B) will be administered beginning from Cycle 2 (2-week cycle).
89030214|NCT04518488|Active Comparator|Prehabilitation group|The prehabilitation group will receive a set of exercises designed to strengthen both limbs. The exercises will be taught and illustrated by a trained physiotherapist and are to be done daily during the period prior to surgery. The participant will be coached and supported for the exercise program, twice a week during the pre-operative period.
89030215|NCT04518488|Other|Informational support group (control group)|The focus for participants in the Informational Support Group will be on needs for information and psychosocial support during the pre-operative period. The intervention will be in the form of telephone or video calls by a trained health professional. These calls will be scheduled twice a week during the pre-operative period.
89585164|NCT05355155|Experimental|Bevacizumab combine with FOLFOX4|"Bevacizumab biosimilar：7.5mg/kg，IV，D1，Q2W FOLFOX4：~Oxaliplatin: 85 mg/m2 , IV, D1，Q2W~Calcium leovorin: 200 mg/m2 ,IV, D1、D2，Q2W~Fluorouracil: 400 mg/m2 push infusion and given 600mg/m2 intravenously 22 hours later， D1、D2, Q2W Treatment will continue until disease progression, an unacceptable toxicity, or the patient voluntarily discontinues the study, whichever comes first."
89585165|NCT01634243|Experimental|SPM 962|SPM 962 transdermal patch
89585166|NCT02402309|Experimental|Active topical NS2 1% dermatologic cream|NS2 1% topical cream for dermal application
89585167|NCT02402309|Placebo Comparator|Topical vehicle dermatologic|Vehicle placebo for dermal application
89585168|NCT04815317|Active Comparator|Basal|"The impact of these stimulations will be compared to that of a control stimulus.~The auditory control condition will consist of listening to a pink noise. The pink noise, like the white noise, is a normalized noise. The sound produced on a TV set that is out of adjustment during the snow effect is a representative example of such noise. Pink noise is a random signal whose power spectral density decreases by 3dB per octave. This signal is closer to the sensitivity of the ear than white noise.~The sensitive control condition will be achieved by administering fresh air on the calf.~An pressure support (+5) increment will be performed to ensure comparability of subsequent experimental sequences and their effect on dyspnea."
89585169|NCT04815317|Experimental|Intervention|"Patients will be subjected to sensory stimuli that may be auditory or sensitive.~The sensory stimulations will be administered by a research nurse. The auditory stimulation will consist of listening to relaxing pieces of music from MP3 files from the International Center for Music Therapy (Noisy le Grand, France).~Listening will be done through noise-cancelling headphones (PLANTRONICS, Gamecom 780, Santa Cruz, California, USA) for 10 minutes.~Sensitive stimulation will consist of administering fresh air to the patient's face by means of a fan without blades (DYSON AM01, Malmesbury, UK) for 10 minutes."
89585170|NCT01542034|Experimental|Deoxycholic Acid Injection|Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
89585171|NCT01542034|Placebo Comparator|Placebo|Participants received placebo administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
89585172|NCT01564732|Active Comparator|Standard-LAGB|Subjects will be blinded and randomly assigned to the Standard Laparoscopic Gastric Banding(SLAGB)arm of the study. These subjects will receive the standard of care or standard laparoscopic gastric banding surgery.Subjects will be followed for a period of approximately 36 months.
89585173|NCT01564732|Experimental|Plicated-LAGB|"Subjects will be blinded and randomly assigned to the Plicated Laparoscopic Gastric Banding(PLAGB)arm of the study. These subjects will receive the plicated laparoscopic gastric banding surgery with involves the placement of plication sutures to anchor the redundant stomach around the newly placed device. Subjects will be followed for a period of approximately 36 months."
89585174|NCT05271929|Active Comparator|Current standard of care|"Standard of care therapy may include anti-SARS-CoV-2 specific medication such as, but not limited to:~Casirivimab~Casirivimab / Imdevimab (REGN-COV2 or Ronapreve)~Imdevimab~Sotrovimab (Xevudy)~Tixagevimab / Cilgavimab (Evusheld)~Molnupiravir (MK-4482)~Nirmatrevlir / Ritonavir (Paxlovid)~Remdesivir~Centres should ensure that medications used as standard of care are used similarly for patients in both treatment arms."
89585175|NCT05271929|Experimental|Current standard of care and convalescent plasma|Current standard of care and the infusion of two plasma units collected from two different COVID-19 convalescent patients.
89585176|NCT01541644|Experimental|Acupuncture|All participants will receive acupuncture treatments over a total of 10 weeks.
89585177|NCT05428397||Contrast enhanced X-ray based examination with Ultravist|Patients who received a contrast enhanced X-ray based examination with Ultravist for various clinical reasons and having experienced a hypersensitivity reaction.
89585178|NCT05428397||Control group|Patient who received contrast enhanced X-ray based examination with Ultravist for various indications who had not adverse event.
89030216|NCT04510571|Active Comparator|Protaper Next|Protaper Next group (n=25): The instrumentation of mesial and distal canals were done according to manufacturer's recommendations using X1 and X2 (25.06) at a rotational speed of 300 rpm. Then X3 and X4 (40.06) instruments were used to enlarge distal canals in order to compare the results with the Reciproc Blue group. The root canals were irrigated with 2 ml of %2,5 sodium hypochlorite after each instrument exchange.
89585179|NCT04853056|Experimental|Virtual Reality Group|watching the application by wearing virtual glasses to the child during the peripheral IV line insertion
89585180|NCT04853056|Experimental|Cold Vibration Group|Buzzy, connecting and operating 5 cm above the area to be inserted peripheral IV line
89585181|NCT04853056|No Intervention|Control group|Standart care
89585182|NCT04814615|Experimental|CD38-positive multiple myeloma|Patients with CD38 positive multiple myeloma with be enrolled. Patients will undergo pretreatment evaluation with standard of care diagnostic tests, as well as experimental 89Zr-daratumumab PET/CT. Patients will then undergo a course of standard of care therapy as defined by a medical oncologist. Following therapy, patients will repeat standard of care diagnostic tests, as well as experimental 89Zr-daratumumab PET/CT. Data analysis will be performed to evaluate 89Zr-daratumumab against standard of care diagnostic tests for the detection and localization of active disease before and after therapy.
89585183|NCT04814537|Experimental|Dural Puncture Epidural Technique|Laboring women receiving the Dural Puncture Epidural (DPE) Technique with dose of Bupivacaine 0.25% diluted to 20 mL with isotonic sterile 0.9% saline. The first subject in the DPE group will receive an initial dose of bupivacaine 25 mg, with an endpoint being the achievement of an NRS < 3 at 30 min. Subsequent patients are administered bupivacaine doses determined by the response of the previous subject, as per the biased coin method. The subsequent up and down interval doses are bupivacaine 2.5 mg (1 mL) increments, with an anticipated dose range from 20 mg to 40 mg.
89585184|NCT04814537|Active Comparator|Epidural Technique|Laboring women receiving the Conventional Epidural Technique (EPL) with dose of Bupivacaine 0.25% diluted to 20 mL with isotonic sterile 0.9% saline. The first subject in the EPL group will receive an initial dose of bupivacaine 25 mg, with an endpoint being the achievement of an NRS < 3 at 30 min. Subsequent patients are administered bupivacaine doses determined by the response of the previous subject, as per the biased coin method. The subsequent up and down interval doses are bupivacaine 2.5 mg (1 mL) increments, with an anticipated dose range from 20 mg to 40 mg.
89585185|NCT01582282|Placebo Comparator|placebo|matched placebo BID
89585186|NCT01582282|Active Comparator|psyllium 3.4g BID|3.4g psyllium BID for a Total of 6.8g daily
89585187|NCT01582282|Active Comparator|6.8g psyllium BID|6.8g psyllium BID for a total of 13.6 g/day
89585188|NCT01599650|Experimental|1-ranibizumab monotherapy|Ranibizumab 0.5 mg
89585189|NCT01599650|Experimental|2-ranibizumab with laser|Ranibizumab 0.5 mg + laser
89585190|NCT01599650|Active Comparator|3-laser monotherapy|Laser monotherapy with Ranibizumab 0.5 mg from Month 6
89585191|NCT01541254|Other|Single Arm|Low profile Visualized Intraluminal Device (LVIS and LVIS Jr.)
89585192|NCT02163902|Experimental|ATX-101|Participants treated with ATX-101 in previous studies ATX-101-11-22 and ATX-101-11-23.
89585193|NCT02163902|Placebo Comparator|Placebo|Participants treated with placebo in previous studies ATX-101-11-22 and ATX-101-11-23.
89585194|NCT01630616|Experimental|Adolescents Odanacatib 10 mg|Study drug (single oral dose of odanacatib 10 mg) was administered following at least an 8-hour fast to adolescents.
89585195|NCT01630616|Experimental|Adolescents Odanacatib 50 mg|Study drug (single oral dose of odanacatib 50 mg) was administered following at least an 8-hour fast to adolescents.
89585196|NCT01630616|Placebo Comparator|Adolescents Placebo|Study drug (single oral dose of placebo) was administered following at least an 8-hour fast to adolescents.
89585197|NCT01630616|Experimental|Young Adults Odanacatib 50 mg|Study drug (single oral dose of odanacatib 50 mg) was administered following at least an 8-hour fast to young adults.
89030217|NCT04510571|Active Comparator|Reciproc Blue|Reciproc Blue group (n=25) : The canals were shaped with in accordance with the manufacturer's recommendations. R25 (25.08) instrument was introduced into the canal with slow pecking movement within a 3 mm range each time. The flutes and remnants were cleaned after 3 pecking moves. Then R40 instrument (40.06) was selected to shape the distal canals as the #20 K file was passively introduced to the working length. The root canals were irrigated with 2 ml of %2,5 sodium hypochlorite after each instrument exchange.
89585198|NCT01630616|Placebo Comparator|Young Adults Placebo|Study drug (single oral dose of placebo) was administered following at least an 8-hour fast to young adults.
89030218|NCT00516399|Experimental|I:|povidone-iodine 1.25% ophthalmic solution. The associated intervention descriptions contain sufficient information to describe the arm.
89030219|NCT00516399|Active Comparator|II|natamycin ophthalmic suspension, USP 5%. The associated intervention descriptions contain sufficient information to describe the arm.
89585199|NCT03774875|Experimental|Apremilast 30 mg|Participants will take apremilast 30 mg tablets orally twice a day for up to 52 weeks.
89585200|NCT03774875|Placebo Comparator|Placebo / Apremilast 30 mg|Participants will take placebo tablets orally twice a day for 16 weeks. After week 16, participants will be switched to receive apremilast 30 mg twice daily until Week 52.
89585201|NCT02220764|Experimental|Tooth-supported|Long-span tooth-supported zirconia based fixed dental prostheses
89585202|NCT02220764|Active Comparator|Implant-supported|Long-span implant-supported zirconia based fixed dental prostheses
89585203|NCT05264324|Experimental|High altitude 2500 m above sea level (high altitude)|Maximum Exercise Capacity in high altitude
89585204|NCT05264324|Active Comparator|Low altitude 470 m above sea level (low altitude)|Maximum Exercise Capacity in low altitude
89585205|NCT04755920|Experimental|Patients with colorectal brain metastases|10 mg SGM-101, administration 3 to 5 days prior to surgery.
89585206|NCT04758806|Experimental|Fecal microbial transplantation from unrelated donor|Fecal microbial transplant procured (frozen if needed) from healthy unrelated donors is administered via upper GI tract; predefined single dose is repeated at five consecutive days
89030220|NCT04518527|Active Comparator|true taping+ exercise|The true taping method was applied to the first group according to the method determined by Kase. According to this method, a 2-inch (5 cm) wide beige-colored Kinesio tape (Kinesio® Tex Gold FP) was measured from the second-third metacarpal base to the lateral epicondyle while the elbow was extended and the wrist was in the neutral position and the tape was applied in the shape of a 'Y'. In a position where the wrist-ankle extensors were most tense (wrist-ankle extension - forearm pronation), the anchor point of the tape was applied to the insertion of the muscle without creating any tension. Then, the tape was applied to the medial and lateral edges of the wrist extensors by applying a 15-25% tension towards the origin of the muscle. Both ends of the Y-shaped tape were terminated without tension on the lateral epicondyle.
89585207|NCT01563172|Experimental|Experimental dentifrice 0.5g, 45 seconds brushing group|Participants brush twice a daily for 45 seconds with experimental dentifrice.
89585208|NCT01563172|Experimental|Experimental dentifrice 1.5g, 45 seconds brushing group|Participants brush twice a daily for 45 seconds with experimental dentifrice.
89585209|NCT01563172|Experimental|Experimental dentifrice 0.5g, 2 minutes brushing group|Participants brush twice a daily for 2 minutes with experimental dentifrice.
89585210|NCT01563172|Experimental|Experimental dentifrice 1.5g, 2 minutes brushing group|Participants brush twice a daily for 2 minutes with experimental dentifrice.
89585211|NCT01563172|Active Comparator|Contol group|Participants brush twice a daily for 2 minutes with controll dentifrice.
89585212|NCT02161718|Experimental|Samidorphan + olanzapine (ALKS 3831)|Active study drug
89585213|NCT02161718|Placebo Comparator|Placebo + olanzapine|
89585214|NCT05292989|Experimental|Group 1- Personalised tailored approach|If patients are assigned to this group they will be asked to complete a frailty assessment which includes the Fraility Index short form, an assessment of grip strength, time to complete 5 sit-to-stands, balance test, and gait speed along with some questionnaires on comorbid medical condition. The treating Gastroenterologist will then go through the results of the frailty assessment with the patient and based on this information will discuss the benefits and risks associated with having a surveillance colonoscopy. The patient will then decide if they would like to go ahead with a surveillance colonoscopy and the treating Gastroenterologist will provide further advice as required. The frailty assessment is intended to be done at the time of the appointment with the specialist. However, operational requirements may dictate that e.g. a telehealth delivered occasion of service is done at a separate date.
89585215|NCT05292989|Placebo Comparator|Group 2- Standard Care|Patients assigned to this group will discuss the benefits and risks associated with having a surveillance colonoscopy with the treating Gastroenterologist and will decide whether to proceed with the colonoscopy.
89585216|NCT03697343|Other|Radiosurgery with 1 x 18 Gy (2-3 cm) or 1 x 15 Gy (3-4 cm) and|Radiosurgery with 1 x 18 Gy (2-3 cm) or 1 x 15 Gy (3-4 cm) and no margin as defined by the RTOG 9005
89585217|NCT03697343|Other|Fractionated stereotactic radiotherapy with 12 x 4 Gy and 2 mm|Fractionated stereotactic radiotherapy with 12 x 4 Gy and 2 mm margin
89585218|NCT05186987|Sham Comparator|Start with: Concentric (normal) cycling|
89585219|NCT05186987|Experimental|Start with: Eccentric cycling|
89585220|NCT02219048|Placebo Comparator|Placebo|Matched blinded placebo
89585221|NCT02219048|Experimental|PF-03715455|PF-03715455
89585222|NCT03635645|Experimental|Retinal stimulation|Alternative stimulus patterns will be tested (vs. baseline). The intervention is the alternative stimulus pattern. The intervention will be tested only in the clinic vs. baseline. The subject will go home with baseline settings. The two alternative stimulus patterns to be tested are asymmetric waveforms and bipolar stimulus.
89585223|NCT04786145|Active Comparator|Cryoneurolysis|40 patients are randomized to receive one treatment of cryoneurolysis on the facet joints of three lumbar level corresponding to their facet joint pain generator
89585224|NCT04786145|Active Comparator|Radiofrequency ablation|40 patients are randomized to receive one treatment of radiofrequency ablation on the facet joints of three lumbar level corresponding to their facet joint pain generator
89585225|NCT04786145|Sham Comparator|Placebo|40 patients are randomized to receive sham treatment. Subjected to similar procedures as cryoneurolysis and radiofrequency ablation, but without active treatment.
89585226|NCT04813991|Experimental|Arm 1 - Ibuprofen Breakthrough|600 mg Ibuprofen for breakthrough pain.
89585227|NCT04813991|Active Comparator|Arm 2 - Oxycodone Breakthrough|5 mg of Oxycodone for breakthrough pain.
89585228|NCT04801901|Experimental|Distal transradial access (dTRA)|Subjects randomized to the experimental arm will undergo left heart catheterization using distal transradial access (dTRA) to facilitate coronary angiography and/or percutaneous coronary intervention.
89585229|NCT04801901|Active Comparator|Forearm radial access (fTRA)|Cardiac catheterization to facilitate coronary angiography and/or percutaneous coronary intervention using the standard forearm radial artery which is the current standard of care in interventional cardiology.
89585230|NCT02218736|Experimental|CERC-501|Oral dosing of 10 mg CERC-501 (formerly known as LY2456302) administered daily for 8 weeks
89585231|NCT02218736|Placebo Comparator|Placebo|Oral daily administration of 10 mg placebo for 8 weeks
89585232|NCT04418687|Active Comparator|Physiotherapy only|Standard treatment post Total Knee Arthroplasty
89585233|NCT04418687|Experimental|Physiotherapy + Orthoglide intervention|Standard treatment post TKA, with additional Orthoglide device provided.
89585234|NCT05268965||Patients meeting DSM-5 criteria for PTSD.|
89585235|NCT05268965||Group 2: Healthy controls who experienced a traumatic event but did not meet DSM-5 criteria for PTSD|
89585236|NCT05268965||Group 3: Healthy controls who did not experience a traumatic event|
89585237|NCT05266781||Open surgical repair|Aneurysmectomy and aortic reconstruction with a surgical graft
89585238|NCT05266781||Endovascular repair|Off-the-shelf or custom-made Fenestrated/Branched-Endovascular Aortic Repair - F/BEVAR
89585239|NCT03580421|Active Comparator|standard pathway group|this group will benefit from standard care including: one surgical consultation, one anesthesia consultation, surgery followed by 2-4 days of hospitalization and most of the time 3 post-operative consultations (M1, M6, M12) during the first operative year
89585240|NCT03580421|Experimental|ambulatory pathway group|Preoperative and postoperative protocols will be applied for optimizing same-day discharge. Gynaecologists, anaesthetists, and nursing staff will work as a team. A specific anesthesia consultation will focus on ambulatory surgery management. A geriatric evaluation will be offered to women over 70 years old with a score ≤14 according to G8 screening tool. A dietetic evaluation will be offered to women with BMI ≥ 35. A nursing consultation will be offered, as patient and their family preparation prior to ambulatory surgery is important.
89585241|NCT01540474|Experimental|Group 1: 10 ug FMP012 with 2 ug GLA-SE|Single center, non-randomized, open label, dose escalation Phase 1 study with sporozoite challenge. The antigen FMP012 will be adjuvanted with Glucopyranosyl lipd A stable emulsion. This is a first-in-human study of FMP012. 30 subjects, divided into 3 groups, will receive 3 doses of the FMP012/GLA-SE vaccine. Biological/vaccine; E-coli expressed malaria antigen FMP012 adjuvanted with Glucopyranosyl lipid A Stable emulsion (GLA-SE), a proprietary adjuvant
89585242|NCT01540474|Experimental|Group 2: 10 ug FMP012 with 5 ug GLA-SE|Biological/vaccine; E-coli expressed malaria antigen FMP012 adjuvanted with Glucopyranosyl lipid A Stable emulsion (GLA-SE), a proprietary adjuvant
89585243|NCT01540474|Experimental|Group 3: 50 ug FMP012 with 5 ug GLA-SE or 2 ug GLA-SE|Biological/vaccine; E-coli expressed malaria antigen FMP012 adjuvanted with Glucopyranosyl lipid A Stable emulsion (GLA-SE), a proprietary adjuvant
89585244|NCT01540474|Other|Control group-Challenged Only|Biological/vaccine; E-coli expressed malaria antigen FMP012 adjuvanted with Glucopyranosyl lipid A Stable emulsion (GLA-SE), a proprietary adjuvant
89585245|NCT01580020|Experimental|Ranibizumab (Arm A)|"The PRN injection scheme applied in the core study will also be followed during this extension study:~Patients should be monitored monthly (starting at V1E) for VA and treatment is to be resumed when monitoring indicates loss of VA due to disease activity. Monthly injections should then be administered until stable VA is reached again for 3 consecutive monthly assessments (implying a minimum of 2 injections during stable VA). The interval between 2 doses should not be shorter than 1 month"
89585246|NCT01580020|Sham Comparator|Dexamethasone (Arm B)|A PRN re-treatment scheme will be applied for the Ozurdex arm during this extension study, i.e. patients may receive an implant at V1E or later as needed: Patients should be monitored monthly and if there is a decline from stable VA stability due to macular edema patients will receive another intravitreal implant. (700 µg; long acting release (LAR)) given that in the opinion of the investigator the patient would benefit from the re-treatment. However, a minimum period of 5 months in between implantations is required.
89585247|NCT01579474|Experimental|1. BI 201335 low dose plus PegIFN/RBV|low dose BI 201335 NA once daily for 12 or 24 weeks combined with PegIFN/RBV for 24 or 48 weeks in treatment-naive patients
89585248|NCT01579474|Experimental|2. BI 201335 high dose plus PegIFN/RBV|high dose BI 201335 NA once daily for 12 weeks combined with PegIFN/RBV for 24 or 48 weeks in treatment-naive patients
89585249|NCT01579474|Experimental|3. BI 201335 high dose plus PegIFN/RBV|high dose BI 201335 NA once daily for 24 weeks combined with PegIFN/RBV for 24 or 48 weeks in treatment-experienced (relapser) patients
89585250|NCT01579474|Experimental|4. BI 201335 high dose plus PegIFN/RBV|high dose BI 201335 NA once daily for 24 weeks combined with PegIFN/RBV for 48 weeks in treatment-experienced (null responder, partial responder, breakthrough) patients
89585251|NCT01579318|Experimental|Treatment|Participants received up to 4 cycles of treatment (3 daily treatments on Days 1, 5 and 8, in a 12-week cycle) of intratumoral injection(s) of tavo at a concentration of 1.0 mg/mL (maximum volume of 1 mL/day distributed over 2-4 lesions), followed immediately by electrical discharge around the tumor site resulting in electroporation of plasmid deoxyribonucleic acid (DNA) into tumor cells.
89585252|NCT01579006||Cohort|
89585253|NCT01578850|Experimental|Group A|
89585254|NCT01578850|Placebo Comparator|Group B|
89585255|NCT01539538|Experimental|Sufentanil NanoTab PCA System/15 mcg|
89585256|NCT01539538|Active Comparator|morphine IV PCA|
88974946|NCT04730700|Active Comparator|Radiofrequency ablation (RFA) with MEE|Radiofrequency ablation involves a minimally invasive procedural technique. It uses radiofrequency waves to burn the nerve causing pain. This nerve will no longer be able to send pain signals to your brain. For this study, the multi-tined expandable electrode needle will be used. This needle will result in a larger treatment area. This may result in better pain relief and longer lasting pain relief. If you undergo the radiofrequency ablation procedure you will have pain medication injected where the ablation will be done. The procedure will take about 20 mins to complete. You will be allowed to go home afterward.
88974947|NCT04730700|Active Comparator|Conventional Medical Management (CMM) Treatment Only|Your current standard of care treatment may already consist of some CMM therapies. Standard of care includes a variety of intervention types such as medication, physical therapy, home exercise programs, back brace, walking aid, and chiropractic care.
88974948|NCT02971436|Active Comparator|FPH Device with SensAwake On + Pressure Support A|FPH Device with SensAwake On + Pressure Support A
88974949|NCT02971436|Active Comparator|FPH Device with SensAwake Off + Pressure Support A|FPH Device with SensAwake Off + Pressure Support A
89585257|NCT01562548|Experimental|Arm 1|Guaifenesin 1 tablet BID
89585258|NCT01562548|Experimental|Arm 2|Guaifenesin 2 tablets BID
88974950|NCT02971436|Active Comparator|FPH Device with SensAwake On + Pressure Support B|FPH Device with SensAwake On + Pressure Support B
88974951|NCT02971436|Active Comparator|FPH Device with SensAwake Off + Pressure Support B|FPH Device with SensAwake Off + Pressure Support B
88974952|NCT02971436|Active Comparator|Competitor's PAP Released Device + Pressure Support A|Competitor's PAP Released Device + Pressure Support A
88974953|NCT02971436|Active Comparator|Competitor's PAP Released Device + Pressure Support B|Competitor's PAP Released Device + Pressure Support B
88974954|NCT00060645|Experimental|1|There are sequential dosage cohorts ranging from 3 mg - 225 mg per dose. AP23573 is given intravenously over 30 minutes, administered once daily for 5 days every 2 weeks.
88974955|NCT00396461|Active Comparator|TPN A (Group I)|Emulsion based on 20% MCT/LCT (50:50 ratio)
89585259|NCT01562548|Placebo Comparator|Arm 3|Placebo 1 tablet BID
89585260|NCT01562548|Placebo Comparator|Arm 4|Placebo 2 tablets BID
89585261|NCT03027934|Active Comparator|Group 1|
89585262|NCT03027934|Active Comparator|Group 2|
89585263|NCT01562314|Experimental|GWP42003|GWP42003 was administered orally at a dose of 50 mg up to 250 mg, BID, in the fasted state in the morning and evening, for 10 weeks. Following randomization, participants entered a 2-week dose escalation period to achieve their maximum tolerated dose, up to 500 mg, and maintained this dose for the rest of the treatment period. Participants were then followed for 1 week.
89585264|NCT01562314|Placebo Comparator|Placebo|Placebo capsules matching the study drug were administered orally, BID, in the fasted state in the morning and evening, for 10 weeks. Participants were then followed for 1 week.
89585265|NCT01539226|Placebo Comparator|Placebo Vaginal Ring|Vaginal Ring containing 0.0 mg Dapivirine
89585266|NCT01539226|Experimental|Dapivirine Vaginal Ring|Vaginal Ring containing 25mg of Dapivirine
88974956|NCT00396461|Experimental|TPN B (Group II)|Emulsion based on 20% MCT/LCT/w3 (50:40:10 ratio), medium- and long-chain triglycerides and fish oil triglycerides
89585267|NCT01577758|Experimental|MLN0264|MLN0264 starting dose 0.3 mg/kg escalated until Maximum Tolerated Dose (MTD) was determined, 30-minute infusion, on Day 1 of each 21-Day treatment cycle.
89585268|NCT04769674|Experimental|STAR intervention|Each research participant will receive individual 30-minute therapy sessions two times per week for fifteen weeks. Fifteen weekly ten-minute consultations with the teacher will also be conducted for each participant.
89585269|NCT01537432|Placebo Comparator|placebo|placebo
89585270|NCT01537432|Experimental|secukinumab|secukinumab
89585271|NCT01537198||Pediatric Participants at High Risk of RSV|Pediatric participants at high risk of respiratory syncytial virus (RSV) in need of the prevention of serious lower respiratory tract disease caused by RSV were prescribed Synagis prophylaxis in usual practice according to the approved Korean product label. The decision to prescribe or not to prescribe Synagis was taken prior to a participant's enrollment in the study.
89585272|NCT04409938|Experimental|Progressive Muscle Relaxation|PMR participants rested for ten minutes between the sessions and then practiced PMR for 15 minutes. PMR consisted of taking a deep breath five times and then clenching fists, raising the shoulders, bringing the forearms towards the body, stretching the triceps muscle, and tensing and relaxing the forehead, eye, chin, neck, chest, abdomen, back, hips, thigh, and feet muscles. The investigators made a video of exercises in a certain order and uploaded it to the television in the lab prior to the intervention.
89585273|NCT04409938|Experimental|Progressive Muscle Relaxation with Nature Sounds|PMR+NS participants practiced PMR accompanied by nature sounds.
89585274|NCT04409938|No Intervention|Standard Practice|The standard practice of the lab was made.
89585275|NCT01537120|Experimental|Placebo → Vildagliptin|Participants received placebo tablets orally, twice a day for 3 weeks, and then over the next 12 weeks received vildagliptin 50 mg tablets orally, twice daily
89585276|NCT01537042|Experimental|Rotigotine|"Rotigotine Transdermal Patch~1 mg/24 h, 2 mg/24 h or 3 mg/24 h once daily depending on optimal dose; maximal dose is 3 mg/24 h."
89585277|NCT01537042|Placebo Comparator|Placebo|Transdermal patch matched according to patch size and appearance.
88974957|NCT00060723||Adenotonsillectomy group|Children ages 5-12 who are scheduled for adenotonsillectomy for obstructive sleep apnea
88974958|NCT00060723||Comparison group|Children ages 5-12, scheduled for hernia repairs, other procedures not involving the head, chest or neck, or no procedures. Additional exclusions include children with a history of recurrent throat infections, large tonsils, history of or plans for adenoidectomy and/or tonsillectomy or who have been previously diagnosed with sleep-disordered breathing.
88974959|NCT02971475|Experimental|ESWL alone|Patients in this group would be treated with extracorporeal shock wave lithotripsy only. Otherwise, extra endoscopic procedures will be carried out in case of continuous and aggravated pain. Analgesics will be administrated as needed and recorded.
88974960|NCT02971475|Active Comparator|ESWL combined with ERCP|People in this group would be treated with ESWL followed be endoscopic drainage of the main pancreatic duct in 48 hours. Analgesics will be administrated as needed and recorded.
88974961|NCT00060762|Experimental|Interpersonal Therapy|Interpersonal Therapy is a psychotherapy aimed at resolving interpersonal difficulties
88974962|NCT00060762|Active Comparator|Behavioral Weight Loss Treatment|Behavioral Weight Loss Treatment is aimed solely at weight loss, however it has been shown to decrease binge eating
88974963|NCT00060762|Active Comparator|Guided Self Help|Guided Self-Help is a brief psychotherapy based on cognitive-behavioral treatment
88974964|NCT02968485|Experimental|SHR7390|60 subjects with advanced solid tumors were received single and then multiple oral doses of SHR7390(2 cycles,each cycle 28days).
89585278|NCT04111666|Experimental|AL101 IV|"Up to four single ascending doses (SAD IV cohorts)~Multiple doses of AL101 administered IV (MD IV cohort)"
89585279|NCT04111666|Placebo Comparator|Saline Solution|"Saline solution will be administered with the following:~Single IV infusion for four single ascending doses (SAD IV cohorts) in a ratio of 8 active and 3 placebo subjects~Multiple IV infusions for the MD IV cohort in a ratio of 8 active and 2 placebo subjects"
88974965|NCT02968641|Active Comparator|LNF 25 mg bid and RTV 100 mg bid|Patients will take lonafarnib 25 mg BID and ritonavir 100 mg BID. Patients will also take an anti-hepatitis B virus (HBV) nucleos(t)ide analog (NUC) from the first dose of LNF through the end of the study.
88974966|NCT02968641|Active Comparator|LNF 50 mg bid and RTV 100 mg bid|Patients will take lonafarnib 50 mg BID and ritonavir 100 mg BID. Patients will also take an anti-hepatitis B virus (HBV) nucleos(t)ide analog (NUC) from the first dose of LNF through the end of the study.
88974967|NCT02968641|Active Comparator|LNF 100 mg bid|Patients will take lonafarnib 100 mg BID. Patients will also take an anti-hepatitis B virus (HBV) nucleos(t)ide analog (NUC) from the first dose of LNF through the end of the study.
89585280|NCT04111666|Experimental|AL101 SC|"Single fixed dose levels of AL101 administered SC~Multiple fixed dose of AL101 administered SC"
89585281|NCT03897712|Experimental|Custom Samfilcon B Contact Lenses|Participants will wear Bausch + Lomb investigational custom samfilcon B contact lenses daily for 3 months. Participants will be provided with ReNu MultiPlus Lubricating and Rewetting Drops for use as needed during the study. Participants will store their worn study lenses in a lens case filled with Biotrue multi-purpose solution (MPS).
89585282|NCT03897712|Placebo Comparator|Alden Optical HP Sphere contact lenses|Participants will wear Alden Optical HP Sphere contact lenses daily for 3 months. Participants will be provided with ReNu MultiPlus Lubricating and Rewetting Drops for use as needed during the study. Participants will store worn study lenses in a lens case filled with Biotrue MPS.
89585283|NCT01536574|Experimental|Requip PR|Ropinirole PR tablets of 2.0 mg, 4.0mg and 8.0 mg
89585284|NCT01536418|Experimental|GSK1605786A, 500 milligrams, once daily|500 milligrams once daily, orally administered for 12 weeks
89585285|NCT01536418|Experimental|GSK1605786A, 500 milligrams twice daily|500 milligrams twice daily, orally administered for 12 weeks
89585286|NCT04410094|Experimental|Cohort 1: Lazertinib plus Itraconazole|Participants will receive a single oral dose of lazertinib tablets in Treatment Period 1 followed by itraconazole capsules orally along with a single oral dose of lazertinib tablet in Treatment Period 2.
89585287|NCT04410094|Experimental|Cohort 2: Lazertinib plus Rifampin|Participants will receive a single oral dose of lazertinib tablets in Treatment Period 1 followed by rifampin capsules orally along with a single oral dose of lazertinib tablet in Treatment Period 2.
89585288|NCT01576042|Other|Catheter ablation|The only ablation catheter that will be allowed in this study will be the Biosense Webster's NAVI-STAR Thermo-Cool catheter as it is the only catheter that has been approved by the FDA for sustained monomorphic VT due to prior myocardial infarction in adults
89585289|NCT01576042|Other|Antiarrhythmic medication|The choice of antiarrhythmic medications will comply with the ACC/AHA 2006 Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death
89585290|NCT01561300|Placebo Comparator|Control|Nutrition intervention study with a control
89585291|NCT01561300|Experimental|Tea extract|Nutrition intervention study with a black tea extract
89585292|NCT01536262|Other|Tiotropium + Olodaterol (high dose)|Tiotropium and Olodaterol FDC solution for inhalation - RESPIMAT
89585293|NCT01536262|Other|Olodaterol|Olodaterol solution for inhalation - RESPIMAT
89585294|NCT01536262|Other|Tiotropium + Olodaterol (low dose)|Tiotropium and Olodaterol FDC solution for inhalation - RESPIMAT
89585295|NCT01560988|Experimental|Active Borage and Echium Seed Oils|Borage and echium oil capsules administered daily for six weeks, then a 6 week washout period, followed by ingestion of placebo (corn oil capsules) daily for 6 weeks.
89585296|NCT01560988|Experimental|Corn oil pills|Corn oil capsules daily for six weeks, then a 6 week washout period, followed by ingestion of Borage and echium oil capsules daily for 6 weeks.
89585297|NCT03897556|Active Comparator|High-dose|This arm consists of cancer survivors who receive two guarana energy bars to take per day for six weeks; one in the morning and one around lunch time.
89585298|NCT03897556|Active Comparator|Low-Dose|This arm consists of cancer survivors who receive one guarana energy bar to take per day for six weeks; one in the morning only.
89585299|NCT03897556|Other|Usual Care|This arm receives usual-care only as cancer survivors.
89585300|NCT01535638|Active Comparator|BI 207127 NA TFII medium dose|Film-coated tablet for oral administration
89585301|NCT01535638|Active Comparator|BI 207127 NA FF medium dose|Film-coated tablet for oral administration
89585302|NCT01535638|Active Comparator|BI 207127 NA FF modified medium dose|Film-coated tablet for oral administration
89585303|NCT01535560|Experimental|AL-60371|AL-60371, 0.3% otic suspension, 4 drops in the affected ear(s) twice daily for 7 days
89585304|NCT01535560|Placebo Comparator|Vehicle|AL-60371 Vehicle, 4 drops in the affected ear(s) twice daily for 7 days
89585305|NCT04102618|Experimental|Cohort 1 (closed to enrollment)|HR+/HER2-neg patients who will receive pelareorep plus letrozole
89585306|NCT04102618|Experimental|Cohort 2 (closed to enrollment)|HR+/HER2-neg patients who will receive pelareorep plus letrozole plus atezolizumab
89585307|NCT04102618|Experimental|Cohort 3 (closed to enrollment)|TNBC patients who will receive pelareorep plus atezolizumab
89585308|NCT04102618|Experimental|Cohort 4 (closed to enrollment)|HER2+/HR+ patients who will receive pelareorep plus trastuzumab plus atezolizumab
89585309|NCT04102618|Experimental|Cohort 5 (closed to enrollment)|HER2+/HR- patients who will receive pelareorep plus trastuzumab plus atezolizumab
89585310|NCT04102618|Experimental|Cohort 6|HER2+ (irrespective of HR status) (6 patients) who will receive pelareorep + trastuzumab
89585311|NCT01575028|Active Comparator|Local anesthetic infiltration injection|Patients will receive local anesthetic infiltration injected at the surgical site by the surgeon at the end of surgery.
89585312|NCT01575028|Experimental|Transversus abdominis plane (TAP) block|Patients will receive a transversus abdominis plane (TAP) block.
89585313|NCT04443569|Experimental|Lidocaine Patch Group|This group will be women who were randomized to receive a lidocaine patch for postoperative pain following cesarean delivery in addition to routine postoperative pain management.
89585314|NCT04443569|No Intervention|Control Group|This group will be women randomized to routine postoperative pain management following cesarean delivery.
88974968|NCT00033254|Active Comparator|Arm I (radiation therapy)|Patients undergo radiotherapy once daily 5 days a week for 3 weeks.
88974969|NCT00033254|Experimental|Arm II (radiation therapy, thalidomide)|Patients undergo radiotherapy as in arm I. Beginning on the first day of radiotherapy, patients receive oral thalidomide once daily.
88974970|NCT02968680|Experimental|Diagnostic (sonazoid, ultrasound imaging, SLNB)|Patients receive sonazoid ID and undergo ultrasound imaging. Patients also undergo standard of care SLNB.
88974971|NCT00061113|Active Comparator|1|fluoxetine + CBT
88974972|NCT00061113|Placebo Comparator|2|placebo + CBT
88974973|NCT00033449|Experimental|Treatment (gefitinib, radiation therapy, cisplatin)|See detailed description.
88974974|NCT02968329||CVA cases|patients who experienced an ischemic CVA or TIA during the study duration and experienced a recurrence.
88974975|NCT02968329||CVA controls|patients who experienced an ischemic CVA or TIA during the study duration, but who didn't experience a recurrence.
88974976|NCT02968329||AF cases|patients who experienced an ischemic CVA or TIA during the study duration and who got diagnosed with 'new' AF
88974977|NCT02968329||AF controls|patients who experienced an ischemic CVA or TIA during the study duration but who didn't get diagnosed with 'new' AF during the study duration
88974978|NCT02968290|Active Comparator|Hydrofobic material-Alcon AcrySof SA60AT|Intervention- Cataract Surgery with implantation of intraocular lens. In this arm will be implantation hydrofobic material.
89585315|NCT04443335|Sham Comparator|continuous feeding|The total amount of every days' Enteral Nutritional Suspension was fed at constant speed for 24h
89585316|NCT04443335|Experimental|sequential feeding|This feeding mode utilizes a combination of continuous feeding in the beginning, time-restricted feeding in the second stage and oral feeding in the last stage
89585317|NCT04801355|Other|laparoscopic resection|patients with colonic adenomas who will undergo to laparoscopic segmental resection
89585318|NCT04801355|Experimental|full-thickness laparo-endoscopic colon adenomas excision|patients with colonic adenomas who will undergo to laparo-endoscopic full-thickness colon resection
89585319|NCT03511157|Experimental|Ischemic Preconditioning|A standard blood pressure cuff will be placed on the right or left thigh, depending on the affected side, to occlude blood flow. The cuff will be inflated to 225 mmHg to prevent blood flow. Each session will consist of 4 cycles of 5 minute IPC applications, followed by 5 minutes of reperfusion for a total of 35 minutes.
89585320|NCT03511157|Sham Comparator|Control|The sham intervention protocol will be identical to the IPC protocol except blood flow to the affected leg is unchanged as cuff pressure will be raised to between the venous and diastolic pressures
89585321|NCT04800965|No Intervention|Holdout Arm|In the Holdout arm, patients will not receive text messages about COVID-vaccine.
89585322|NCT04800965|Experimental|Simple Text Sub-arm|In the Simple Text sub-arm, participants will not receive any additional information.
89585323|NCT04800965|Experimental|Simple Text + Video Sub-arm|In the Simple Text+Video sub-arm, together with the appointment link, participants will also receive a link to a 2-minute video in the text message. The video contains information about the prevalence of COVID-19 and the effectiveness and safety of the COVID-19 vaccine.
89585324|NCT04800965|Experimental|Enhanced Text sub-Arm|In the Enhanced Text sub-arm, in addition to the appointment link, the text message will use enhanced language aimed at reducing psychological barriers that prevent patients from scheduling their appointment.
89585325|NCT04800965|Experimental|Enhanced Text + Video Sub-arm|In the Enhanced Text+Video sub-arm, in addition to the appointment link, the text message will encourage patients to watch a 2-minute video (the same as in the Simple Text+Video sub-arm) and use enhanced language aimed at reducing patients' psychological barriers of following through on scheduling an appointment.
89585326|NCT01340261||Pediatric Pain Rehab Patients|
89585327|NCT03508895|Experimental|Whole hemp seed protein|25 grams of hemp seed protein powder, twice a day
89585328|NCT03508895|Experimental|Whole hemp seed protein plus bioactive peptides|22.5 grams of hemp seed protein and 2.5 grams of hemp seed protein hydrolysate derived bioactive peptides, twice a day
89585329|NCT03508895|Active Comparator|Casein protein|25 grams of protein powder, twice a day
89585330|NCT01313351||Device testing|Tears were collected from subjects to apply to the RPS InflammaDry detector and were clinically evaluated.
89585331|NCT03418259|Experimental|Active KCS Medical Device|
89585332|NCT03418259|Placebo Comparator|Inactive KCS Medical Device|
89585333|NCT01574716|Experimental|MORAb-004, gemcitabine, docetaxel|
89585334|NCT01574716|Active Comparator|Placebo, gemcitabine, docetaxel|
89585335|NCT02161562|Experimental|omalizumab 150mg|Participants received 150mg omalizumab every 4 weeks during the initial dosing phase (24 weeks). A second dosing period (at 150mg or 300mg) may have been implemented based on protocol-defined assessment criteria.
89585336|NCT02161562|Experimental|omalizumab 300mg|Participants received 300mg omalizumab every 4 weeks during the initial dosing phase (24 weeks). A second dosing period may have been implemented based on protocol-defined assessment criteria.
89585337|NCT01559116|Experimental|tiotropium+olodaterol FDC low dose|tiotropium+olodaterol FDC low dose; 2 inhalations once daily (a.m. dosing)
88974979|NCT02968290|Active Comparator|Hydrophilic material-Bausch Lomb AkreosA|Intervention- Cataract Surgery with implantation of intraocular lens. In this arm will be implantation hydrophilic material.
89585338|NCT01559116|Experimental|tiotropium+olodaterol FDC high dose|tiotropium+olodaterol FDC high dose; 2 inhalations once daily (a.m. dosing)
89585339|NCT01559116|Active Comparator|tiotropium low dose|tiotropium low dose; 2 inhalations once daily (a.m. dosing)
89585340|NCT01559116|Active Comparator|tiotropium high dose|tiotropium high dose; 2 inhalations once daily (a.m. dosing)
89585341|NCT01559116|Active Comparator|olodaterol|one dose only; 2 inhalations once daily (a.m. dosing)
89585342|NCT01559116|Placebo Comparator|placebo|2 inhalations once daily (a.m. dosing)
89585343|NCT01574326|Placebo Comparator|FDP-Placebo for Sevelamer Carbonate, DTP-Sevelamer Carbonate|Participants received placebo for 2 weeks during the fixed dose period (FDP). Participants received sevelamer carbonate for 26 weeks in dose titration period (DTP).
89585344|NCT01574326|Experimental|FDP-Sevelamer Carbonate, DTP-Sevelamer Carbonate|Participants received sevelamer carbonate for 2 weeks during the FDP of the study. Participants received sevelamer carbonate for an additional 26 weeks in DTP.
89585345|NCT01574248|Experimental|icatibant|30 mg icatibant will be administered subcutaneously 0 and 6 hours after randomization
89585346|NCT01574248|Placebo Comparator|Placebo|Subcutaneous at time 0 and 6 hours
89585347|NCT04761094||Insulin pump|All patient treated with insulin pump.
89585348|NCT01573624|Active Comparator|Fluticasone Furoate (FF)|100mcg, inhaled
89585349|NCT01573624|Active Comparator|Fluticasone Furoate /Vilanterol (VI)|100/25mcg inhaled
89585350|NCT01573624|Experimental|Fluticasone Furoate/GSK573719|100/15.6-250mcg inhaled
89585351|NCT01557946|Experimental|Major Depression|Participants with major depressive disorder received citalopram 20-40 mg daily for 6 weeks. MRI scans were acquired at baseline and days 3, 7, and 42.
89585352|NCT01557946|No Intervention|Healthy Volunteers|Healthy volunteer participants did not receive citalopram and performed one MRI scan.
89585353|NCT01534078|Experimental|Treatment Arm|Brentuximab Vedotin in combination with Adriamycin, Vinblastine and Dacarbazine
89585354|NCT03919942|Experimental|OxyFlower gel|pericoronitis treatment with oxyflower gel.
89585355|NCT03919942|Experimental|Chlorhexidine gel|pericoronitis treatment with chlorhexidine gel.
89585356|NCT03919942|Placebo Comparator|Placebo gel|pericoronitis treatment with placebo gel.
89585357|NCT02185040|Experimental|CC-220 0.3mg Every Other Day (QOD)|Part 1: CC-220 0.3mg capsules by mouth every other day (QOD)
89585358|NCT02185040|Experimental|CC-220 0.3mg Every Day (QD)|"Part 1: CC-220 0.3mg capsules by mouth every day (QD)~ATEP: CC-220 0.3 mg capsules by mouth every day (QD)"
89585359|NCT02185040|Experimental|CC-220 0.6mg/0.3mg alternating dose QD|"Part 1: CC-220 0.6 mg and 0.3mg capsules PO on alternating days~ATEP:CC-220 0.6 mg and 0.3 mg capsules PO on alternating days"
89585360|NCT02185040|Experimental|CC-220 0.6mg QD|Part 1: CC-220 0.6mg capsules by mouth QD
89585361|NCT02185040|Placebo Comparator|Placebo QD|Part 1: Identically matching placebo capsules PO QD
89585362|NCT02161406|Active Comparator|Abatacept|125 mg SC abatacept vs SC placebo administered weekly for 12 months, with a 24-week open-label extension
89585363|NCT02161406|Placebo Comparator|Placebo|125mg Placebo
89585364|NCT02161016|Other|map3 allogeneic bone graft|Patients will receive map3® Cellular Allogeneic Bone Graft containing donor matched stem cells.
89585365|NCT01573000|Experimental|Open-label, two-arm, Arm A and Arm B Crossover|Arm A Dosimetric Dose: 450 mg of TST infused over 70 minutes (inclusive of a 10-minute flush) immediately followed by 5 milliCurie (mCi) (35 mg) of I-131 TST infused over 30 minutes (inclusive of a 10-minute flush).• Therapeutic Dose: Seven to 14 days after the dosimetric dose, 450 mg of TST infused over 70 minutes (inclusive of a 10-minute flush) immediately followed by a subject-specific mCi activity (35 mg) of I-131 TST to deliver the desired total body dose (TBD) infused over 30 minutes (inclusive of a 10-minute flush). The desired TBD was 65 cGy for subjects with a baseline platelet count of 100,001-149,999 cells/mm3 and 75 cGy for subjects with a baseline platelet count ≥150,000 cells/mm3. Obese subjects (subjects weighing more than 137% of their calculated lean body weight) were dosed based upon 137% of their calculated lean body mass
89585366|NCT01573000|Experimental|Arm B Crossover|Arm B Dosimetric Dose: 450 mg of TST infused over 70 minutes (inclusive of a 10-minute flush) immediately followed by 35 mg of TST infused over 30 minutes (inclusive of a 10-minute flush).Therapeutic Dose: Seven to 14 days after the dosimetric dose, 450 mg of TST infused over 70 minutes (inclusive of a 10-minute flush) immediately followed by 35 mg of TST infused over 30 minutes (inclusive of a 10-minute flush). Subjects randomized to Arm B were allowed to cross-over and receive TST/ I-131 TST once their disease had progressed.
89585367|NCT01572922|Other|Iron-overloaded|"Patients with iron overload or excessive body iron burden, a serious condition resulting from increased dietary gastro¬intestinal absorption, multiple erythrocyte transfusions, or both.~Interventions: R2*-UTE, R2*-GRE, and if clinically indicated, liver biopsy."
89585368|NCT01572844|Experimental|Treatment lesion|Lesion A, target lesion, 2cm x 2cm (+/- 1cm) treated with 1 pass Fractionated Carbon Dioxide (FCO2) Laser followed by application of 4 ml of 5% topical sodium thiosulfate solution (STS), 8 to 10 treatments over 6 months.
88974980|NCT00033605|Experimental|octreotide + radiation|"Patients receive short-acting octreotide subcutaneously (SC) on day 1 and long-acting octreotide intramuscularly (IM) on days 2 and 29.~Treatment continues in the absence of unacceptable toxicity or the development of severe diarrhea.~Patients complete a bowel function questionnaire at baseline, weekly during radiotherapy, and then weekly for 4 weeks and at 1 and 2 years after completion of radiotherapy.~Patients are followed weekly for 4 weeks and then at 1 and 2 years."
88974981|NCT00033605|Active Comparator|placebo + radiation|"Patients receive placebo SC on day 1 and IM on days 2 and 29. Treatment continues in the absence of unacceptable toxicity or the development of severe diarrhea.~Patients complete a bowel function questionnaire at baseline, weekly during radiotherapy, and then weekly for 4 weeks and at 1 and 2 years after completion of radiotherapy.~Patients are followed weekly for 4 weeks and then at 1 and 2 years."
89030221|NCT04518527|Placebo Comparator|sham taping+exercise|In the placebo group, the 10 cm I-shaped tape was placed 5 cm inferior to the lateral epicondyle using the same Kinesio tape in the study group. It was applied transversely, starting from the painless side of the midline on the forearm extensor face directing towards the lateral side of the forearm without a tension.
89030222|NCT00516438|Experimental|1|Topotecan + KU-0059436
89585369|NCT01572844|No Intervention|No Treatment Lesion|Lesion B, similar area of calcinosis on the same patient, which did not receive treatment is evaluated.
89585370|NCT01557400|Experimental|Ataluren|Ataluren will be provided as a vanilla-flavored powder to be mixed with water, milk, fruit juice (except apple juice) fruit punch, or in semi-solid food (for example, yogurt, pudding, or applesauce). The dose level for ataluren will be 10 milligrams/kilograms (mg/kg) in the morning, 10 mg/kg at midday, and 20 mg/kg in the evening. Administration within 30 minutes after a meal will be recommended. Study drug dosing will be based on milligrams of drug per kilogram of body weight. Because of potential changes in participant body weight over time, weight-based dose adjustment can occur every 24 weeks as required. Study drug will be taken for up to 240 weeks.
89585371|NCT04122118|Experimental|Hearth services research (pharmacist-led education)|"PHASE I: Patients' medical records are reviewed.~PHASE II: Patients receive pharmacist-led education on antineoplastic therapies including what to expect during infusion, general drug facts, common adverse effects, side effect management, and when to contact provider."
89585372|NCT04121806|Experimental|Ulcerative colitis patients with mild to moderate activity|Participants will be followed for 14 days on their traditional diet followed by an 8 week intervention with the specially designed and provided treatment diet.
89585373|NCT01533922|Experimental|Tiotropium + olodaterol High dose QD|patient will receive tiotropium 5 mcg + olodaterol 5 mcg in a fixed dose combination once daily
89585374|NCT01533922|Experimental|Tiotropium + olodaterol Low dose QD|patient will receive tiotropium 2.5 mcg + olodaterol 5 mcg in a fixed dose combination once daily
89585375|NCT01533922|Active Comparator|Tiotropium 5 mcg QD|patient will receive tiotropium 5 mcg once daily
89585376|NCT01533922|Active Comparator|Olodaterol 5 mcg QD|patient will receive olodaterol 5 mcg once daily
89585377|NCT01533922|Placebo Comparator|Placebo QD|
89585378|NCT01533688|Active Comparator|Golytely + placebo|4 liters of polyethylene glycol electrolyte lavage solution (PEG-ELS-(GoLytely)+ placebo pill
89585379|NCT01533688|Placebo Comparator|Golytely Split + placebo|split dose(2 L day before procedure and 2 L day of procedure) of 4 liters of Golytely + placebo pill
89585380|NCT01533688|Experimental|Golytely Split + Bisacodyl|split dose (2 L day prior to procedure and 2 L day of procedure) of 4 liters of Golytely + bisacodyl 10 mg
89585381|NCT01532986|Other|Usual Care (Arm 1)|"Veterans randomized to the usual care arm will continue to receive care they would have received if they had not enrolled in the study; no care or resources that are made available in general by VA will be withheld from participants in either arm or to any Veterans who wish to use those resources.~Educational handout: brief educational handout on Parkinson's disease that is available in the VA's Healthwise for Life handbook."
89585382|NCT01532986|Experimental|Intervention (Arm 2)|"A delivery system redesign, with nurse care managers, using standardized assessment tools and care coordination protocols to address unmet needs of Veterans with Parkinson's Disease (PD) by collaborating with these Veterans and their families, providers, and community partners.~Educational handout: brief educational handout on Parkinson's disease that is available in the VA's Healthwise for Life handbook."
89585383|NCT01532908|Experimental|Part 1: MBL-HCV1 and Telaprevir|
89585384|NCT01532908|Experimental|Part 2: MBL-HCV1 and Sofosbuvir|
89585385|NCT02160782|Experimental|LUM001 (Maralixibat)|"LUM001, also known as Maralixibat (MRX) will be administered orally once a day (QD) up to 400 microgram per kilogram per day (mcg/kg/day) up to Week 52, followed by an increase in dose orally twice a day (BID) during long-term follow-up based on efficacy (serum bile acid [sBA] level and ItchRO[Obs] score) and safety assessment.~Note: 400 mcg/kg maralixibat chloride is equivalent to 380 mcg/kg free maralixibat."
89585386|NCT02160782|Placebo Comparator|Placebo|Placebo will be administered orally once a day during randomized withdrawal period (Week 19 to Week 22)
89585387|NCT02160626|Placebo Comparator|A-101 Vehicle|A-101 Vehicle (placebo) Topical Solution
89585388|NCT02160626|Active Comparator|A-101 (40) Topical Solution|A-101 (40) Topical Solution - high dose
89585389|NCT02160626|Active Comparator|A-101 (32.5) Topical Solution|A-101 (32.5) Topical Solution - low dose
89585390|NCT02160314|Placebo Comparator|pad|absorbent pad control
89585391|NCT02160314|Experimental|pessary|disposable, single-use pessary
89585392|NCT02160002|Active Comparator|Lower Weight (1600 grams)|Weaning from an incubator at a lower weight (1600 grams)
89585393|NCT02160002|Active Comparator|Higher Weight (1800 grams)|Weaning from an incubator at a higher weight (1800 grams)
89585394|NCT02218268||Pre-meal bolus then No meal bolus|"A meal replacement drink (Boost) and bolus of rapid insulin will be given to this group. Glucose will be monitored with a finger prick before they drink the meal replacement, 1 hour later and finally 2 hours after drinking the meal replacement. Stiffness of the blood vessel of the wrist will be determined using radial tonometry and will be done at the same time as the glucose monitoring.~Then 3 months later A meal replacement drink (Boost) will be given but the subject will not receive a meal bolus. Glucose will be monitored with a finger prick before they drink the meal replacement, 1 hour later and finally 2 hours after drinking the meal replacement. Stiffness of the blood vessel of the wrist will be determined using radial tonometry and will be done at the same time as the glucose monitoring"
89585395|NCT02218268||No meal bolus then Pre-meal bolus|"A meal replacement drink (Boost) will be given but the subject will not receive a meal bolus. Glucose will be monitored with a finger prick before they drink the meal replacement, 1 hour later and finally 2 hours after drinking the meal replacement. Stiffness of the blood vessel of the wrist will be determined using radial tonometry and will be done at the same time as the glucose monitoring.~Then 3 months later meal replacement drink (Boost) and bolus of rapid insulin will be given to this group. Glucose will be monitored with a finger prick before they drink the meal replacement, 1 hour later and finally 2 hours after drinking the meal replacement. Stiffness of the blood vessel of the wrist will be determined using radial tonometry and will be done at the same time as the glucose monitoring"
89585396|NCT02217878|Active Comparator|Morphine|morphine sulfate 5 mg IV followed by 180 mg loading dose of ticagrelor
88974982|NCT02968251|Experimental|Hand Washing Program (HWP)|Clusters in this arm will be given a Hand Washing Program (HWP) which will consist of: integrating hand washing practice in the school health policy, setting up proper hand washing facilities in the intervention schools, training to school teachers, delivering of health talk to schoolchildren and their parents, developing reminders and posters of a simplified 5-step hand washing technique, peer briefing session, take home package (5-steps hand washing, commitment letter, poster, leaflet). The program will be delivered once every week.
88974983|NCT02968251|No Intervention|No Hand Washing Program (NHWP)|Clusters in this arm will be allowed to continue with their usual practice regarding hand washing/hygiene
88974984|NCT00061269|Experimental|VARD|Videoscopic-Assisted Retroperitoneal Debridement (VARD)
88974985|NCT00061347|Experimental|1|Placement of fidicual markers under MRI guidance for localization of radiaiton treatment
88974986|NCT00061542|Experimental|Betaxolol|Two doses daily for 12 weeks
88974987|NCT00061542|Experimental|TGFS 0.25%|Two doses daily for 12 weeks
88974988|NCT00061542|Experimental|TGFS 0.5%|Two doses daily for 12 weeks
88974989|NCT04730466|Experimental|Neuropsychological rehabilitation|In the experimental group, patients will receive a 12-session neuropsychological rehabilitation protocol that will be carried out over four weeks (3 weekly sessions). The protocol and the number of sessions has been designed by neuropsychologists following the Díez-Cirarda et al. recommendations
88974990|NCT04730466|No Intervention|Control|The control group will not receive any therapy. The participants will be simply evaluated at the same time as the experimental group
88974991|NCT00061620|Experimental|Tezacitabine|Tezacitabine as a bolus infusion daily x 5
88974992|NCT02968095|Experimental|Text Message Craving Program|Text messages designed to help smokers to modify their thinking styles to be more adaptive, delivered 2-3 times per day.
88974993|NCT02968095|Active Comparator|Self-Help Manual Plus Control Texts|A print, self-help manual plus general motivational text messages delivered 2-3 times per day.
88974994|NCT00061698|Active Comparator|Cognitive Behavior Therapy Child Only|Participants completed 20 sessions of CBT
89585397|NCT02217878|Placebo Comparator|Placebo|sodium chloride 0,9% 5 mg IV followed by 180 mg loading dose of ticagrelor
89585398|NCT04189640|Active Comparator|Group 20 = 20 ml volume adductor canal block|ACB will be performed at the end of the surgery, before extubation. After identifying the adductor canal, by using the in-plane technique, the probe will be placed at the mid-thigh, half the distance between the inguinal crease and the patella, for block location. The superficial femoral artery will be visualized dorsal to the sartorius muscle. Then, the probe will be removed to distally. At this level, the hyperechoic view of the saphenous nerve will be visualized lateral and anterior to the artery in the subsartorial region. 5 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine 20ml will be injected here.
89585399|NCT04189640|Active Comparator|Group 30 = 30 ml volume adductor canal block|ACB will be performed at the end of the surgery, before extubation. After identifying the adductor canal, by using the in-plane technique, the probe will be placed at the mid-thigh, half the distance between the inguinal crease and the patella, for block location. The superficial femoral artery will be visualized dorsal to the sartorius muscle. Then, the probe will be removed to distally. At this level, the hyperechoic view of the saphenous nerve will be visualized lateral and anterior to the artery in the subsartorial region. 5 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine 30ml will be injected here.
89585400|NCT04189640|Active Comparator|Group 40 = 40 ml volume adductor canal block|ACB will be performed at the end of the surgery, before extubation. After identifying the adductor canal, by using the in-plane technique, the probe will be placed at the mid-thigh, half the distance between the inguinal crease and the patella, for block location. The superficial femoral artery will be visualized dorsal to the sartorius muscle. Then, the probe will be removed to distally. At this level, the hyperechoic view of the saphenous nerve will be visualized lateral and anterior to the artery in the subsartorial region. 5 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine 40ml will be injected here.
89585401|NCT02217566|Experimental|Abiraterone Acetate|Participants will receive abiraterone acetate 1000 milligram (mg) orally once daily along with prednisone 5 mg orally once daily and androgen deprivation therapy (ADT) as per Investigator's discretion until prostate-specific Antigen (PSA) progression, clinical progression, consent withdrawal, or the occurrence of unacceptable toxicity.
89585402|NCT02217410|Experimental|Regimen A|CFZ533 administered with the contemporary standard of care (SoC) consists of concentration-controlled tacrolimus (Tac), combined with mycophenolate mofetil (MMF) and corticosteroids (CS).
89585403|NCT02217410|Experimental|Regimen B|CFZ533 administered with mycophenolate mofetil (MMF) and corticosteroids (CS) with anti-IL2 induction
89585404|NCT02217410|Active Comparator|Regimen C|Standard of care (SoC) [concentration-controlled tacrolimus (Tac) combined with mycophenolate mofetil (MMF) and corticosteroids (CS) with anti-IL2 induction]
89585405|NCT02217332|Experimental|dexpramipexole|dexpramipexole 150 mg BID
89585406|NCT02184572|Experimental|INV_MMR|Subjects receive 1 dose of the study vaccine Priorix co-administered with Varivax and Havrix vaccines at Day 0. Subjects recruited in the US also receive Prevnar 13 at Day 0.
89585407|NCT02184572|Active Comparator|COM_MMR|Subjects receive 1 dose of the licensed vaccine M-M-R II or M-M-R VaxPro Lot 1 or Lot 2 co-administered with Varivax and Havrix vaccines at Day 0. Subjects recruited in the US also receive Prevnar 13 at Day 0.
89585408|NCT02181842||Pioglitazone|Pioglitazone 15-30 mg, tablet, orally, once daily for up to 48 weeks before or after breakfast (the dose can be adjusted; however, the maximum daily dose should not exceed 45 mg).
89585409|NCT01632020|Placebo Comparator|Placebo|Placebo 2 capsules by mouth twice daily; minimum of 10 days, maximum of 21 days
89585410|NCT01632020|Active Comparator|Metformin|Metformin 850 mg (2 capsules) by mouth twice daily; minimum of 10 days, maximum of 21 days
89585411|NCT02181296|Active Comparator|High concentration group|0.2% ropivacaine
89585412|NCT02181296|Active Comparator|Lower concentration group|0.1% ropivacaine
89585413|NCT04761692|Experimental|Arm 1|This arm will include 5 churches who will receive all study activities in the Vaccine Education Promotion Management Plan
89585414|NCT04761692|Experimental|Arm 2|This arm will include 5 churches who will receive some study activities in the Vaccine Education Promotion Management Plan
89585415|NCT04761692|Experimental|Arm 3|This arm will include 5 churches who will receive all study activities in the Vaccine Education Promotion Management Plan following completion of Arm 1 and 2.
89585416|NCT02215616|Placebo Comparator|Placebo|Participants will receive 3 capsules of matching laquinimod placebo, orally once daily for 52 weeks.
89585417|NCT02215616|Experimental|Laquinimod 0.5 mg|Participants will receive 1 capsule of laquinimod 0.5 milligrams (mg) and 2 capsules of matching placebo, orally once daily for 52 weeks.
89585418|NCT02215616|Experimental|Laquinimod 1.0 mg|Participants will receive 2 capsule of laquinimod 0.5 mg (total 1.0 mg laquinimod) and 1 capsule of matching placebo, orally once daily for 52 weeks.
89585419|NCT02215616|Experimental|Laquinimod 1.5 mg|"Participants will receive 3 capsules of laquinimod 0.5 mg (total 1.5 mg laquinimod), orally once daily.~Note: The treatment of this high dose arm was discontinued as of 10 January 2016."
89585420|NCT02213666||Intracardiac and Transesophageal Echocardiography|Imaging of the right atrial appendage and left atrial appendage with ICE and TEE
89585421|NCT02213510|Experimental|Zip Surgical Skin Closure device|The Zip Surgical Skin Closure device is a single use, sterile medical device that replaces sutures, staples, and glue for closure of the skin layer for surgical incisions or laceration repair. The device will applied by the surgeon at the end of the CIED procedure and be worn until the two week post-operative wound check.
89585422|NCT02213510|Active Comparator|Standard Suture Closure|The surgeon will perform standard suture closure for the skin layer following CIED procedure.
89585423|NCT02158442|Experimental|Treatment Group|The Treatment Group received intravenous Timentin prior to their PILP procedure.
89585424|NCT02158442|Active Comparator|Control Group|The Control Group received standard dosings of intravenous Timentin plus other standard care.
89585425|NCT02158364||Live attenuated measles/rubella combined vaccine|Live attenuated measles/rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain) is dissolved in 0.7 mL of accompanying reconstitution fluid (water for injection [Japanese Pharmacopoeia]), and a 0.5-mL portion is typically administered subcutaneously as a single dose.
89585426|NCT02180672|Active Comparator|Nasal steroids|Participants randomly assigned to this study arm will receive a 3-month course of nasal steroids (nasal fluticasone).
89030223|NCT02275949|Experimental|Study group|acupuncture, electroacupuncture and intradermal acupuncture are done at every session.
89585427|NCT02180672|Placebo Comparator|Placebo|Participants randomly assigned to this study arm will receive a 3-month course of placebo nasal spray (saline).
89585428|NCT02213198|Experimental|Engagement Focused Care|Engagement Focused Care which includes all components of standard treatment plus both group Access intake process with its flexibility of scheduling and the SDM intervention
89585429|NCT02213198|Active Comparator|Standard Care|Standard Care includes individual intake appointments which are traditional in outpatient service and all services of the clinic including counseling, access to a prescriber, care coordination, and access to home visits.
89585430|NCT02157506|Experimental|CXL-1427 Starting Dose|The Starting dose of CXL-1427 in the dose escalation arms will be 3mcg/kg/min
89585431|NCT02157506|Experimental|CXL-1427 Dose Level 2|The Second Dose level of CXL-1427 will be evaluated in the Dose Escalation Arm of the study as determined by the independent dose escalation committee
89585432|NCT02157506|Experimental|CXL-1427 Dose Level 3|The Third Dose level of CXL-1427 will be evaluated in the Dose Escalation Arm of the study as determined by the independent dose escalation committee
89585433|NCT02157506|Experimental|CXL-1427 Dos Level 3|The Third Dose level of CXL-1427 will be evaluated in the Dose Escalation Arm of the study as determined by the independent dose escalation committee
89585434|NCT02157506|Experimental|CXL-1427 Dose Level 4|The forth level of CXL-1427 will be evaluated in the Dose Escalation Arm of the study as determined by the independent dose escalation committee
89585435|NCT02157506|Experimental|Expansion Cohort 1|Up to 16 Patients will be enrolled across 1 or more of the previously evaluated Dose escalation Levels as determined by the independent dose escalation committee
89585436|NCT02157506|Placebo Comparator|Placebo for Dose Escalation and Expansion Cohort|Each Dose escalation Arm of the study will have a placebo group in a 2:1 ratio to active treatment for the first 3 patients enrolled and 4:1 to active treatment in the remaining 5 patients so that the overall randomization ratio in each Dose escalation arm will be 3:1 active to placebo. In the expansion Cohort of the study, the ratio of patients randomized to receive a 6-hour infusion of active CXL-1427 or placebo will be 3:1
89585437|NCT01920711|Experimental|LCZ696|Single Blind Run-in Period (3-8 weeks): Patients will start on Valsartan 80 mg b.i.d. for 1-2 weeks followed by LCZ696 100 mg b.i.d. for 2-4 weeks prior to randomization into the Double Blind period (up to 57 months). Patients can only be randomized from the run-in period if they meet all of the run-in safety criteria. Target dose of LCZ696 during the double blind period is 200 mg b.i.d.
89585438|NCT01920711|Active Comparator|Valsartan|Single Blind Run-in Period (3-8 weeks): Patients will start on Valsartan 80 mg b.i.d. for 1-2 weeks followed by LCZ696 100 mg b.i.d. for 2-4 weeks prior to randomization into the Double Blind period (up to 57 months). Patients can only be randomized from the run-in period if they meet all of the run-in safety criteria. Target dose of Valsartan during the double blind period is 160 mg b.i.d.
89585439|NCT02180438|Experimental|Open label prospective single arm study of Stribild|
89585440|NCT02179190|Experimental|BARREL VRD|The Barrel VRD was implanted as adjunctive to embolic coils in subjects with wide necked bifurcating aneurysms within the Middle Cerebral and Basilar Arteries.
89585441|NCT02157116|Experimental|Induction Chemotherapy|Cisplatin 75mg/m2 IV days 1, 15, 29; Docetaxel 75mg/m2 IV days 1, 15, 29; and Pegfilgrastim 6mg SC day 2, 16, 30
89585442|NCT01920555|Active Comparator|Ketamine 0.1mg|Patients in this arm will receive 0.1 mg/kg of Ketamine - one single infusion
89585443|NCT01920555|Active Comparator|Ketamine 0.2mg|Patients in this arm will receive 0.2 mg/kg of Ketamine - one single infusion
89585444|NCT01920555|Active Comparator|Ketamine 0.5mg|Patients in this arm will receive 0.5 mg/kg of Ketamine - one single infusion
89585445|NCT01920555|Active Comparator|Ketamine 1.0mg|Patients in this arm will receive 1.0 mg/kg of Ketamine - one single infusion
89585446|NCT01920555|Placebo Comparator|Midazolam (Active Placebo)|Patients in this arm will receive 0.045 mg/kg of midazolam - one single infusion
89585447|NCT02156804|Experimental|Nivolumab (BMS-936558)|Nivolumab (BMS-936558) Intravenous solution every 2 weeks
88974995|NCT00061698|Active Comparator|CBT plus Parent training|Child participants completed 20 sessions of CBT and parents completed 8 sessions of parent training
88974996|NCT00061698|No Intervention|Minimal Contact Control|Participants waited 12 weeks for treatment but their safety and well-being were monitored during this time
88974997|NCT02968056|Experimental|Hybrid group|Minimally invasive surgical radiofrequency ablation of atrial fibrillation followed by catheterized radiofrequency ablation within the same procedure
89030224|NCT02275949|Sham Comparator|Control group|Mock transcutaneous electrical nerve stimulation(mock TENS) and sham intradermal acupuncture are carried out.
89585448|NCT02156492|Experimental|Evacetrapib Single|Part 1, Cohort A, Period 1, Participants will receive a single oral 130 mg dose of evacetrapib.
89585449|NCT02156492|Experimental|Evacetrapib Multiple|Part 1, Cohort A, Period 2, Participants will receive multiple doses of evacetrapib for 14 days.
88974998|NCT02968056|Active Comparator|MIS group|Minimally invasive surgical radiofrequency ablation of atrial fibrillation only
89585450|NCT02156492|Active Comparator|Simvastatin|Part 2, Cohorts B, Participants will receive simvastatin orally, once daily on Days 1 - 4.
88974999|NCT02971397|Experimental|Treatment (cytarabine, daunorubicin hydrochloride, biopsy)|"INDUCTION: Patients receive cytarabine IV continuously over 24 hours on days 1-7 and daunorubicin hydrochloride IV continuously over 24 hours on days 1-3 in the absence of disease progression or unacceptable toxicity. Patients then undergo bone marrow aspirate and biopsy on day 14. Patients with bone marrow cellularity >= 10% and > 5% leukemic blasts, may receive a second induction of cytarabine IV continuously over 24 hours on days 1-5 and daunorubicin hydrochloride IV continuously over 24 hours on days 1-2 in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Patients achieving remission receive cytarabine IV over 3 hours every 12 hours on days 1, 3, and 5. Treatment repeats every 28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients with CBF AML may receive 4 courses of therapy."
89585451|NCT02156492|Experimental|Evacetrapib and Simvastatin|Part 2, Cohorts B, Participants will receive evacetrapib orally once daily on Days 5 - 14 and simvastatin orally, once daily on Days 15 - 22.
89585452|NCT02156492|Active Comparator|Atorvastatin|Part 2, Cohorts C, Participants will receive atorvastatin orally, once daily on Days 1 - 4.
89585453|NCT02156492|Experimental|Evacetrapib and Atorvastatin|Part 2, Cohorts C, Participants will receive evacetrapib orally once daily on Days 5 - 14 and atorvastatin orally, once daily on Days 15 - 22.
89585454|NCT04753892|Experimental|Arm 1|The 3Sm peptide is conjugated to a mutant diphtheria carrier protein (CRM197) and the resulting challenge agent (3SM2-G-CRM197) will be mixed with a squalene adjuvant before intramuscular administration at Months 0, 1, 2 and 4, at a dosage of 32 micrograms of 3SM2-G-CRM197 and 9.7 micrograms of adjuvant.
89585455|NCT04187690|Experimental|Jin-shui Huan-xian granule|Participants in this arm will be given Jin-shui Huan-xian granule.
89585456|NCT04187690|Placebo Comparator|Jin-shui Huan-xian granule placebo|Participants in this arm will be given Jin-shui Huan-xian granule placebo.
89585457|NCT01920477|Experimental|Ofatumumab|Subject received subcutaneous administration of ofatumumab 20 mg once every 4 weeks through Week 56, with an additional 20 mg dose (that is 40mg total) at both Week 0 and Week 4.
89585458|NCT01920477|Placebo Comparator|Placebo|Subject received subcutaneous administration of matching placebo of ofatumumab once every 4 weeks through Week 56, with an additional dose at both Week 0 and Week 4.
89585459|NCT04641195|Placebo Comparator|Placebo- Placebo|Participants in the PLACEBO-PLACEBO group will receive a placebo vitamin D bolus at the hospital followed by placebo daily vitamin D maintenance doses and placebo daily zinc supplements.
89585460|NCT04641195|Experimental|Vitamin D- Placebo|Participants in the VITAMIN D-PLACEBO group will receive an actual vitamin D bolus at the hospital followed by actual daily vitamin D maintenance doses and daily placebo zinc supplements.
89585461|NCT04641195|Experimental|Placebo-Zinc|Participants in the PLACEBO-ZINC group will receive a placebo vitamin D bolus at the hospital followed by placebo daily vitamin D maintenance doses and actual daily zinc supplements.
89585462|NCT04641195|Experimental|Vitamin D- Zinc|Participants in the VITAMIN D-ZINC group will receive an actual vitamin D bolus at the hospital followed by actual daily vitamin D maintenance doses and actual daily zinc supplements.
89585463|NCT02213042|Active Comparator|Lapatinib 1000mg + Trastuzumab in HER2 Enriched|In subjects with HER2-overexpressing MBC with a molecular subtype of HER2 Enriched, Lapatinib 1000mg once daily orally along with Trastuzumab (loading dose of 8 milligram/ kilogram (mg/kg) followed by the maintenance dose of 6 mg/kg Intravenous (IV) Every 3 weeks (q3weekly)) or Lapatinib 1000 milligram (mg) once daily orally along with Weekly Trastuzumab (loading dose of 4 mg/kg) followed by maintenance dose of 2 mg/kg IV weekly. For subjects who were hormone receptor positive, an aromatase inhibitor of the investigator's choice was required.
88975000|NCT00034541|Experimental|1|An initial dose of cetuximab (400 mg/m2 i.v. over 120 minutes) will be administered 1 week prior to the initiation of chemotherapy. Thereafter, cetuximab will be infused weekly at maintenance doses of 250 mg/m2 (over 60 minutes). On the first day of each cycle (every 3 weeks) of therapy, a 3-hour paclitaxel (225 mg/m2) infusion will be administered 1-hour post completion of the cetuximab infusion, immediately followed by a 30-minute carboplatin (AUC=6) infusion.
88975001|NCT00061815|Experimental|Cetuximab+FOLFOX4|"Day 1 - cetuximab loading dose of 400 mg/m2 IV, infused over 2 hours; oxaliplatin (85 mg/m2) simultaneously with leucovorin (200 mg/m2), followed by 5-FU 400 mg/m2 IV bolus followed by 5-FU 600 mg/m2 as a 22-hour continuous infusion~Day 2 - leucovorin 200 mg/m2 followed by 5-FU 400 mg/m2 IV bolus followed by another dose of 5-FU 600 mg/m2 as a 22-hour continuous infusion~Day 8 - cetuximab maintenance dose of 250 mg/m2 IV infused over 60 minutes"
88975002|NCT00061815|Active Comparator|FOLFOX4.|"Day 1 - oxaliplatin (85 mg/m2) simultaneously with leucovorin (200 mg/m2), followed by 5-FU 400 mg/m2 IV bolus followed by 5-FU 600 mg/m2 as a 22-hour continuous infusion.~Day 2 - leucovorin 200 mg/m2 followed by 5-FU 400 mg/m2 IV bolus followed by another dose of 5-FU 600 mg/m2 as a 22-hour continuous infusion."
88975003|NCT02967939|Experimental|DA-2802|DA-2802 319mg tablet qd
88975004|NCT02967939|Active Comparator|Viread®|Viread® 300mg tablet qd
88975005|NCT00034814|Placebo Comparator|1|Enzyme-inducing placebo TID
88975006|NCT00034814|Experimental|2|Enzyme-inducing Talampanel 35 mg TID
88975007|NCT00034814|Experimental|3|Enzyme-inducing TLP 50mg TID
88975008|NCT00034814|Placebo Comparator|4|Non-enzyme-inducing placebo TID
88975009|NCT00034814|Experimental|5|Non-enzyme-inducing TLP 25mg TID
88975010|NCT00034814|Experimental|6|Non-enzyme-inducing TLP 35mg TID
88975011|NCT00062127|Experimental|Arm I (irinotecan hydrochloride and thalidomide)|Patients receive irinotecan IV over 90 minutes on days 1 and 22 and oral thalidomide once daily on days 15-28. All patients undergo disease re-evaluation at 6 weeks. Patients with stable or responsive disease may receive additional courses comprising irinotecan IV on day 1 and oral thalidomide once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
88975012|NCT00062127|Experimental|Arm II (irinotecan hydrochloride and thalidomide)|Patients receive irinotecan as in arm I and oral thalidomide once daily on days -6 to 7. All patients undergo disease re-evaluation at 6 weeks. Patients with stable or responsive disease may receive additional courses comprising irinotecan IV on day 1 and oral thalidomide once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
88975013|NCT02967783|Active Comparator|ID Needle and Syringe|Fractional (0.1mL) dose of inactivated poliovirus vaccine (IPV) administered using a needle and syringe
88975014|NCT02967783|Experimental|ID Adaptor (Helm)|Fractional (0.1mL) dose of inactivated poliovirus vaccine (IPV) administered using a needle and syringe with an ID adaptor
88975015|NCT02967783|Experimental|ID Jet Injector (Tropis, Pharmajet)|Fractional (0.1mL) dose of inactivated poliovirus vaccine (IPV) administered by needle and syringe with a disposable syringe jet injecto
88975016|NCT00062244|Experimental|Arm I|"Phase I: Patients receive oblimersen IV continuously on days 1-7. Treatment repeats every 3 weeks for up to 8 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 1-6 patients receive escalating doses of oblimersen until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity.~Phase II: Patients receive treatment as in phase I at the MTD of oblimersen. Patients are followed every 3 months for 2 years."
89585464|NCT02213042|Active Comparator|Trastuzumab in HER2 Enriched|In subjects with HER2-overexpressing MBC with a molecular subtype of HER2 Enriched, Trastuzumab (loading dose of 8 mg/kg followed by the maintenance dose of 6 mg/kg IV q3weekly) along with chemotherapy of the investigator's choice or Weekly Trastuzumab (loading dose of 4 mg/kg) followed by maintenance dose of 2 mg/kg IV weekly along with chemotherapy of the investigators choice. Subjects randomized to this arm and hormone receptor positive received an aromatase inhibitor at the discretion of the investigator.
89585465|NCT02213042|Active Comparator|Lapatinib 1000mg + Trastuzumab in Non- HER2 Enriched|In subjects with HER2-overexpressing MBC with a molecular subtype of Non- HER2 Enriched (luminal A, luminal B or Basal type), Lapatinib 1000mg once daily orally along with Trastuzumab (loading dose of 8 milligram/ kilogram (mg/kg) followed by the maintenance dose of 6 mg/kg Intravenous (IV) Every 3 weeks (q3weekly)) or Lapatinib 1000 milligram (mg) once daily orally along with Weekly Trastuzumab (loading dose of 4 mg/kg) followed by maintenance dose of 2 mg/kg IV weekly. For subjects who were hormone receptor positive, an aromatase inhibitor of the investigator's choice was required.
89209662|NCT04708496|Experimental|5 day course of Artemether lumefantrine|Dose comparison concurrent control In this arm, Participants receiving Efavirenz based ART will be randomized to 5 day course of Artemether Lumefantrine as opposed to the standard 3day course when treating uncomplicated malaria in HIV-malaria co-infected participants
89585466|NCT04721314|Experimental|Lower rate set to a higher, personalized backup heart rate (myPACE)|Patients randomized to this group will have their pacemaker lower heart rate setting programmed to a personalized lower rate based on a resting heart rate algorithm.
89585467|NCT04721314|Active Comparator|Lower rate left at 60 beats-per-minute|Patients randomized to this group will have their pacemaker lower heart rate setting left at or programmed to the conventional pacemaker lower rate setting of 60bpm.
89209663|NCT00646958|Experimental|1|Radezolid 450 mg PO QD
89585468|NCT04418180|Active Comparator|GROUP1|group receiving single dose fenofibrate
89585469|NCT04418180|Active Comparator|GROUP2|group receiving double dose fenofibrate
89585470|NCT04418180|Placebo Comparator|GROUP3|photo therapy only
89585471|NCT02212730|Experimental|Neoadjuvant Pembrolizumab + RCC Resection|Participants received pembrolizumab, 200 mg intravenously (IV) once every 3-week cycle for up to 2 cycles followed by standard of care (SOC) renal cell carcinoma (RCC) surgical resection; and then received post-resection pembrolizumab 200 mg IV once every 3 week cycle for up to approximately 1 year (17 cycles). Post-resection pembrolizumab was only administered to participants who enrolled after Protocol Amendment 04.
89585472|NCT02212730|Experimental|RCC Resection|Participants received SOC renal cell carcinoma (RCC) surgical resection; and then may have received post-resection pembrolizumab 200 mg IV once every 3 week cycle for up to approximately 1 year (17 cycles). Post-resection pembrolizumab was only administered to participants who enrolled under Protocol Amendment 04.
89585473|NCT02178956|Experimental|BBI608 plus Paclitaxel|
89585474|NCT02178956|Placebo Comparator|Placebo plus Paclitaxel|
89585475|NCT02211638||Candesartan Cilexetil tablets (2 to 12 mg)|Candesartan Cilexetil tablets (2 to 12 mg), orally, once daily for up to 3 months
89585476|NCT02178566|Placebo Comparator|Inhaled Treprostinil Placebo|A dose of placebo resembling inhaled treprostinil will be administered to all study participants in the placebo comparator arm prior to each of their Pulmonary Rehab sessions. A dose of inhaled albuterol will be administered prior to each inhaled agent. Vitals signs will be taken prior to administering the dose and no medication will be given if the systolic blood pressure in < 85 mm Hg. Three puffs of inhaled trepostinil dose will be administered each time to all patients .
89585477|NCT02178566|Active Comparator|Inhaled Treprostinil|A dose of inhaled treprostinil will be administered to all study participants prior to each of their Pulmonary Rehab sessions. A dose of inhaled albuterol will be administered prior to each inhaled agent. Vitals signs will be taken prior to administering the dose and no medication will be given if the systolic blood pressure in < 85 mm Hg. Three puffs of inhaled treprostinil dose will be administered each time to all patients .
89585478|NCT02211014|Experimental|Cohort 1|Acalabrutinib 100 mg twice daily (bid) continuously
89585479|NCT02211014|Experimental|Cohort 2|Acalabrutinib 100 mg bid continuously and 40 mg dexamethasone once weekly
89585480|NCT01631864|Experimental|LCZ696|LCZ696 400 mg plus placebo to amlodipine once daily for 8 weeks
89585481|NCT01631864|Active Comparator|amlodipine|amlodipine 10 mg plus placebo to LCZ696 once daily for 8 weeks
89585482|NCT02210780|Experimental|Placebo qw|Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 followed by a single injection qw from Week 1 to Week 15.
89585483|NCT02210780|Experimental|Dupilumab 300 mg qw|Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection qw from Week 1 to Week 15.
89585484|NCT01557244|Experimental|Fesoterodine PR 4 mg|Fesoterodine PR 4 mg for 12 weeks in active comparator period, followed by 12 weeks in safety extension period
89585485|NCT01557244|Experimental|Fesoterodine PR 8 mg|Fesoterodine 8 mg for first week followed by 11 weeks at 8 mg in active control period, followed by 12 weeks in safety extension period.
89585486|NCT01557244|Active Comparator|Oxybutynin|Oxybutynin
88975017|NCT02967861|Active Comparator|SRP & pranayama (lifestyle modification)|30 chronic periodontitis subjects treated with SRP & pranayama for 3 months
88975018|NCT02967861|Placebo Comparator|Scaling and root planing|30 chronic periodontitis subjects treated with scaling and root planing only
88975019|NCT00035126|Experimental|EPO906|
89209664|NCT00646958|Experimental|2|Radezolid 450 mg PO BID
89209665|NCT00646958|Active Comparator|3|Linezolid 600 mg PO BID
89209666|NCT04045808||CAD(+) group|Participants were included in CAD (+) if they had more than 50% reduction in diameter in one or more major epicardial arteries,
89209667|NCT04045808||CAD(-) group|patients with less than 50% reduction in epicardial artery diameter were enrolled to CAD (-) group
89209668|NCT03870074||Responders|Patients with improvement of at least one NYHA class after one year from CRT.
89209669|NCT03870074||Non-responders|Patients with no improvement of at least one NYHA class after one year from CRT.
89585487|NCT01557244|Experimental|Fesoterodine BIC 2 mg|Fesoterodine BIC 2 mg for 12 weeks in efficicay period, followed by 12 weeks in safety extension period.
89585488|NCT01557244|Experimental|Fesoterodine BIC 4 mg|Fesoterodine BIC 4 mg for first week followed by 11 weeks at 8 mg in the efficacy period, followed by 12 weeks in safety extension period.
89585489|NCT02177942|Experimental|Test beverage powder|30 grams of cereal beverage powder with protein and added micronutrients will be made up to 100 mL drink using luke warm water. Subjects will be administered two doses of the drink (100 mL each) everyday
89585490|NCT02177942|Active Comparator|Control beverage powder|30 grams of cereal beverage powder with low protein and no added micronutrients will be made up to 100 mL using luke warm water. Subjects will be administered two doses of the drink (100 mL each) everyday
89585491|NCT02155322|Experimental|PEG-IFN|6.0 μg/kg/week subcutaneous administration during the Induction Phase of 8 weeks followed by a dose of 3.0 μg/kg/week subcutaneous administration in the Maintenance Period (Week 8 to Month 12)
89585492|NCT02210000|Placebo Comparator|Placebo|Subjects will receive camicinal matching placebo orally once daily (QD) from Day 1 to Day 84
89585493|NCT02210000|Experimental|Camicinal 25mg|Subjects will receive camicinal 25 mg orally QD from Day 1 to Day 84
89585494|NCT01531894|Experimental|GSK2110183 (afuresertib)|All patients received the GSK2110183 (afuresertib) treatment
89585495|NCT02209766|Experimental|D5884|D5884 capsule, Per oral(po)
89585496|NCT02209766|Placebo Comparator|Placebo|Placebo capsule, po
89585497|NCT02209454|Other|Enantyum® oral solution|25mg DKP.TRIS oral solution
89585498|NCT02209454|Other|Keral® tablet|25mg DKP.TRIS tablet
89585499|NCT01571596|Experimental|KRN23|Escalating doses of KRN23 (0.05, 0.10, 0.30, and 0.60 mg/kg) will be administered SC every 28 days (up to 12 doses)
88975020|NCT02967705|Experimental|Pain management group|6 + 1 meetings 2 hours each
88975021|NCT02967705|No Intervention|Treatment as usual|Waiting list - will receive treatment as usual
88975022|NCT00035165|Experimental|EPO906|
88975023|NCT02967822||Patients with MRKH syndrome|"Biological samples for patients.~Inclusion of patients presenting MRKH syndrome, and who are followed in clinical centres participating in the study."
88975024|NCT02967822||Healthy relatives|"Biological samples for healthy relatives.~Inclusion of healthy relatives of patients included in the study (parents, brothers, sisters)"
88975025|NCT00062478|Experimental|1|Karenitecin for intravenous use
88975026|NCT00035243|Experimental|EPO906|
88975027|NCT02968017||MCA-PI|Measurement Middle cerebral artery pulsatility index
88975028|NCT02967666|Experimental|FDG PET/MRI, DOTANOC PET/MRI|FDG PET/MRI and DOTANOC PET/MRI will be performed.
88975029|NCT00035477|Placebo Comparator|1|placebo tablets in hospital and placebo tablets outpatient
88975030|NCT00035477|Experimental|2|Azimilide tablets in hospital and azimilide tablets outpatient
88975031|NCT00062829|Other|Teen Driving: Program for parents|A behavioral intervention targeting driving risks unique to young drivers, including completing a behavioral contract, was administered to the intervention group. The control group received safety information appropriate for new drivers.
88975032|NCT00035594|Placebo Comparator|Placebo|Breast cancer patients receiving docetaxel chemotherapy and placebo.
88975033|NCT00035594|Experimental|Pegfilgrastim|Breast cancer patients receiving docetaxel chemotherapy and pegfilgrastim.
89030225|NCT00516477|Experimental|dose cohort 1|1.5E10 vector genomes voretigene neparvovec-rzyl in 150 microliters administered subretinally
89030226|NCT00516477|Experimental|dose cohort 2|4.8E10 vector genomes voretigene neparvovec-rzyl in 150 microliters administered subretinally
89030227|NCT00516477|Experimental|dose cohort 3|1.5E11 vector genomes voretigene neparvovec-rzyl in 300 microliters administered subretinally
89585500|NCT01557166|Experimental|Liraglutide 3.0 mg|
89585501|NCT01557166|Placebo Comparator|Placebo|
89585502|NCT01556932|Experimental|Placebo then ABH|"All subjects randomized to two sequences of treatments: either placebo-ABH or ABH-placebo. All participants will receive both drug A and drug B.~After applying gel, Drug A or B, on wrists for 2 minutes, time 0. From baseline to 60 minutes of treatment two options will occur. At 60 minutes, if patients have at least 1 point reduction in their nausea score, they must wait 4 hours before switching to opposite drug. After administration of drug, the study procedures will be repeated. Or, at 60 minutes, if no change or increase in nausea score has been recorded, alternative treatment will be given. If the second treatment is ineffective at one hour (total time 2 hours) then alternative usual medications will be given. After completion of study treatment, patients are followed up for up to 8 hours."
89585503|NCT01556932|Experimental|ABH then placebo|"All subjects randomized to two sequences of treatments: either placebo-ABH or ABH-placebo. All participants will receive both drug A and drug B.~After applying gel, Drug A or B, on wrists for 2 minutes, time 0. From baseline to 60 minutes of treatment two options will occur. At 60 minutes, if patients have at least 1 point reduction in their nausea score, they must wait 4 hours before switching to opposite drug. After administration of drug, the study procedures will be repeated. Or, at 60 minutes, if no change or increase in nausea score has been recorded, alternative treatment will be given. If the second treatment is ineffective at one hour (total time 2 hours) then alternative usual medications will be given. After completion of study treatment, patients are followed up for up to 8 hours."
89585504|NCT02985736|Experimental|open label|
89585505|NCT02177786|Experimental|Selonsertib 2 mg|Participants will receive selonsertib 2 mg for 48 weeks.
89585506|NCT02177786|Experimental|Selonsertib 6 mg|Participants will receive selonsertib 6 mg for 48 weeks.
89585507|NCT02177786|Experimental|Selonsertib 18 mg|Participants will receive selonsertib 18 mg for 48 weeks.
89585508|NCT02177786|Placebo Comparator|Placebo to match selonsertib|Participants will receive placebo to match selonsertib for 48 weeks.
89585509|NCT01555762||Cohort|
89585510|NCT02153918|Experimental|Vaccine Plus Booster Shots|PROSTVAC-V/TRICOM followed by PROSTVAC-F/ TRICOM boost monthly until radical prostatectomy or off therapy PROSTVAC
89585511|NCT02176928|Active Comparator|AutoPAP|PAP treatment will be delivered for four months by an auto-titrating device (IntelliPAP AutoAdjust®). These devices automatically set the level of delivered pressure to ensure upper airway patency, to treat detected apneas and hypopneas.
89585512|NCT02176928|Sham Comparator|Sham PAP|Sham PAP treatment will be delivered for four months by an auto-PAP device (IntelliPAP AutoAdjust®) that is set to a fixed low pressure of 3 cmH20 without an ability to titrate according to detected respiratory events.
89209670|NCT00817544|Experimental|ORM-12741|ORM-12741
89585513|NCT01628510|Active Comparator|Traditional NICU Positioning|Methods of positioning in the NICU have been used for several decades. These methods aim at providing containment and flexion and may consist of interventions such as swaddling, use of boundaries around the infant, rolled blankets, Snuggly®, or Bendy Bumper® The continued use of these methods of positioning is the control group in the current study.
89585514|NCT01628510|Experimental|Dandle Roo/Dandle Wrap|The new Dandle Roo and Dandle Wrap were developed by NICU professionals to support the neurodevelopment of the preterm infant, and this device is produced by Dandle Lion Medical. The Dandle Roo/Wrap provides all around contact, containment, and proprioceptive input, (which more closely mimics the uterine environment) and can decrease excitability and promote self-regulation, while also allowing for movement with recoil back to flexion.
89585515|NCT01571362|Experimental|ALO-02|
89585516|NCT01571362|Placebo Comparator|Placebo|
89585517|NCT01571284|Experimental|Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)|Aflibercept 4 mg/kg IV infusion over 60 minutes followed by Irinotecan 180 mg/m^2 IV infusion over 90 minutes and Leucovorin 400 mg/m^2 IV infusion over 120 minutes at the same time followed by 5-Fluorouracil (5-FU) 400 mg/m^2 IV bolus over 2-4 minutes followed by 5-FU 2400 mg/m^2 continuous IV infusion over 46 hours on Day 1 of each cycle (1 Cycle = 2 weeks), until disease progression (DP), unacceptable toxicity, death, Investigator's decision or participant's refusal of further treatment.
89585518|NCT04825756|Experimental|Treatment Group|A total of up to 80 child/caregiver dyads will be enrolled in the study, anticipating that 40 dyads will complete the 10 week intervention. An equine assisted therapy called Reining in Anxiety for children with anxiety and their caregivers.
89585519|NCT02137772|Experimental|Letermovir|Letermovir oral or intravenous (IV) formulation was administered once daily for up to 14 weeks, beginning up to Day 28 days post-transplant. The dose was 240 mg once daily for participants receiving concomitant cyclosporin A and 480 mg once daily for participants not receiving cyclosporin A. Intravenous infusion was administered only to participants who are unable to swallow tablets or who have a condition that may interfere with absorption of the tablets.
89585520|NCT02137772|Placebo Comparator|Placebo|Placebo oral or IV formulation was administered once daily for up to 14 weeks, beginning up to Day 28 post-transplant. The number of placebo tablets was to mimic that for letermovir administration according to the concomitant cyclosporin A status. Intravenous infusion was administered only to participants who are unable to swallow tablets or who have a condition that may interfere with absorption of the tablets.
89585521|NCT02985814||patients with airway obstruction|Patients referred for pulmonary function test diagnosed with airway obstruction (FEV1/FVC < 0.7) willing to sign an informed consent.
89585522|NCT04410250|Active Comparator|Oral hygiene before tooth eruption|"The mothers of the newborns allocated to Group 1 will be instructed to clean the child's oral cavity by massaging the gingival rods with gauze and filtered water once a day at night.~Following the eruption of the child's first tooth, mothers will be instructed to brush twice a day with fluoride toothpaste (1100 ppm fluoride) in a minimum amount, equivalent to one grain of raw rice, using the Fones technique. circular movements in the buccal and lingual faces of all teeth (FONES, 1934)."
89585523|NCT04410250|Experimental|Absence of oral hygiene before tooth eruption|"The mothers of the newborns allocated to Group 2 will be advised not to perform any type of oral cavity cleaning of the newborn.~Following the eruption of the child's first tooth, mothers will be instructed to brush twice a day with fluoride toothpaste (1100 ppm fluoride) in a minimum amount, equivalent to one grain of raw rice, using the Fones technique. circular movements in the buccal and lingual faces of all teeth (FONES, 1934)."
89585524|NCT04418024|Experimental|AG10 800 mg|TTR stabilizer administered orally twice daily (BID)
89585525|NCT04418024|Placebo Comparator|Placebo|Placebo administered orally twice daily (BID)
89585526|NCT03027856|Experimental|Magmaris|Implantation of sirolimus eluting bioresorbable magnesium stent
89585527|NCT01555138|Experimental|Indacaterol|Indacaterol 150 mcg once daily (o.d.) delivered via the Novartis single dose dry power inhaler (SDDPI) (Onbrez® Breezhaler®)
89585528|NCT01555138|Active Comparator|Salmeterol/fluticasone propionate|Salmeterol 50 mcg /fluticasone propionate 500 mcg for inhalation delivered via a proprietary multi dose dry powder inhaler (MDDPI) device (Seretide® Accuhaler®) twice daily (b.i.d.)
88975034|NCT02971241|Experimental|Immediate intervention group|"A randomized, waitlist controlled trial with three hundred fifty older adult subjects with type 2 diabetes and 280 young adult subjects will be conducted in Taipei Tzu Chi Hospital and Hualien Tzu Chi Hospital in Taiwan. The patients who are randomized to the immediate intervention group will be assigned to the training course as soon as a course is available.~The intervention is a 12-week program which consists of 8-week training sessions followed by 4-week consultation service for technical support. Both will be provided by the young volunteers with a lead instructor."
88975035|NCT02971241|Other|Waitlist control group|The patients randomized to the waitlist control group will need to wait for four months to serve as no intervention control, and then assigned to the training course.
88975036|NCT00062985|No Intervention|Control|
88975037|NCT00062985|Experimental|Mail-based weight loss intervention|
88975038|NCT00062985|Experimental|Telephone-based weight loss intervention|
89030228|NCT00516516|Experimental|I|Oral L-Carnitine, 1g PO twice daily
89030229|NCT00516516|Placebo Comparator|II|Placebo, similar in appearance to experimental drug, given orally twice daily.
89030230|NCT00505349|No Intervention|No Intervention Arm|Phase I in this study will involve the evaluation of blood-derived neurotrophic factors in healthy, younger adults (18-30.) Individuals in this group will not undergo computerized, cognitive training.
89209671|NCT00642746|Experimental|FOLFOX with Erlotinib|Subjects received FOLFOX (Leucovorin, Fluorouracil, and Oxaliplatin) and Erlotinib. Treatment consisted of a 28 day cycle. Subjects received FOLFOX on days 1, 2, and 3, and 15-16, followed by Erlotinib on days 3-8, and 17-22.
89209672|NCT00642746|Experimental|FOLFIRI with Erlotinib|Subjects received FOLFIRI (Leucovorin, Fluorouracil, and Irinotecan) and Erlotinib. Treatment consisted of a 28 day cycle. Subjects received FOLFIRI on days 1, 2, and 3, and 15-16, followed by Erlotinib on days 3-8, and 17-22.
89209673|NCT00814268|Experimental|Combination therapy|Administration of Aspirin + Clopidogrel for 30 days
89209674|NCT00814268|Active Comparator|Monotherapy|Administration of Aspirin + Clopidogrel placebo for 30 days
89209675|NCT00808262|Experimental|TNFa Kinoid dose 1|
89585529|NCT02137226|Experimental|BI 695501|one injection every 2 weeks for 48 weeks (25 injections in total)
89585530|NCT02137226|Active Comparator|US-licensed Humira®|one injection every 2 weeks for 48 weeks (25 injections in total)
89585531|NCT01530334|Experimental|open label single arm with Gefitinib 250MG once daily|Gefitinib 250 mg/day open label until progression disease / toxicity / consent withdrawal
89585532|NCT01570192|Experimental|IV meropenem; parenteral aminoglycoside|"Subjects assigned to this group will receive:~IV meropenem (2 g infused over 3 hrs q 8 hr);~a parenteral aminoglycoside (tobramycin or gentamicin-5mg/kg IV Q24h or amikacin 20 mg/kg IV Q24h)~tobramycin nebulization~Linezolid or vancomycin (per institutional guidelines) will be available for MRSA coverage to treat potential Gram-positive pathogens."
89585533|NCT01570192|Active Comparator|I.V. Meropenem|"Subjects assigned to this group will receive IV meropenem (2 g infused over 3 hrs q 8 hr).~Linezolid or vancomycin (per institutional guidelines) will be available for MRSA coverage to treat Gram-positive pathogens.~**NOTE: Empiric MRSA coverage is allowed in both arms. This therapy is advised for any subjects with known or suspected MRSA entering the study. Once microbiologic results are available, this coverage may be discontinued at the investigator's discretion."
89585534|NCT02136914|Experimental|ADS-5102|ADS-5102 (amantadine HCl extended release)
89585535|NCT02136914|Placebo Comparator|Placebo|Placebo
89585536|NCT01530256|Experimental|ALD518|
89585537|NCT01554904|Other|Facial-Flex|The facial flex (FF) exerciser manufactured by Facial Concepts, Inc is an FDA approved Class I medical device for treatment of facial muscle laxity. Facial muscles tend to weaken with age. The combination of deteriorating elastic tissue and facial muscle weakness causes the face to sag. Facial flex consists of two plastic tipped curved lower bars which slide across each other. An external dynamic resistance is provided by elastic bands.
89585538|NCT04108936||Peritoneal Carcinomatosis|Patients suffering from Peritoneal carcinomatoses from either CRC, gastric cancer or primary peritoneal malignancies
89585539|NCT04108936||Control group|Patients suffering from CRC or gastric cancer without peritoneal carcinomatosis
89585540|NCT01529632|Experimental|QVA149|QVA149 plus placebo once daily for 28 days.
89585541|NCT01529632|Active Comparator|QAB149 + NVA237|Indacaterol maleate (QAB149) plus glycopyrronium bromide (NVA237) once daily for 28 days.
89585542|NCT01554514|Experimental|low dose rituximab|this is a single-arm trial
89585543|NCT01553188|Experimental|Abiraterone, Prednisone and AMG|Abiraterone and prednisone will be given with maximum tolerated dose (MTD) of Trebananib (AMG)
89585544|NCT01553188|Active Comparator|Abiraterone and Prednisone only|Abiraterone and prednisone only
89585545|NCT01553188|Other|Run in|Dose escalation phase to determine MTD of AMG
89585546|NCT02175758|Experimental|12 to < 18 Years Old, SOF+RBV 12 Weeks (GT 2)|Participants between 12 to < 18 years of age with genotype (GT) 2 HCV infection weighing ≥ 45 kg will receive SOF (1 x 400 mg tablet, 4 x 100 mg tablets, or 8 x 50 mg oral granules based on swallowability assessment during screening) plus RBV (up to 1400 mg) for 12 weeks.
89585547|NCT02175758|Experimental|12 to < 18 Years Old, SOF+RBV 24 Weeks (GT 3)|Participants between 12 to < 18 years of age with genotype 3 HCV infection weighing ≥ 45 kg will receive SOF (1 x 400 mg tablet, 4 x 100 mg tablets, or 8 x 50 mg oral granules based on swallowability assessment during screening) plus RBV (up to 1400 mg) for 24 weeks.
89585548|NCT02175758|Experimental|6 to < 12 Years Old, SOF+RBV 12 Weeks (GT 2)|Participants between 6 to < 12 years of age with genotype 2 HCV infection weighing ≥ 17 kg and < 45 kg will receive SOF (2 x 100 mg tablets or 4 x 50 mg oral granules based on swallowability assessment during screening) plus RBV (up to 1400 mg) for 12 weeks.
89585549|NCT02175758|Experimental|6 to <12 Years Old, SOF+RBV 24 Weeks (GT 3)|Participants between 6 to < 12 years of age with genotype 3 HCV infection weighing ≥ 17 kg and < 45 kg will receive SOF (2 x 100 mg tablets or 4 x 50 mg oral granules based on swallowability assessment during screening) plus RBV (up to 1400 mg) for 24 weeks.
89585550|NCT02175758|Experimental|3 to < 6 Years Old, SOF+RBV 12 Weeks (GT 2)|Participants between 3 to < 6 years of age with genotype 2 HCV infection weighing ≥ 17kg will receive SOF (4 x 50 mg oral granules) plus RBV (up to 1400 mg) for 12 weeks and those weighing < 17 kg will receive SOF (3 x 50 mg oral granules) + RBV (up to 1400 mg) for 12 weeks.
89585551|NCT02175758|Experimental|3 to < 6 Years Old, SOF+RBV 24 Weeks (GT 3)|Participants between 3 to < 6 years of age with genotype 2 HCV infection weighing ≥ 17kg will receive SOF (4 x 50 mg oral granules) plus RBV (up to 1400 mg) for 24 weeks and those weighing < 17 kg will receive SOF (3 x 50 mg oral granules) + RBV (up to 1400 mg) for 24 weeks.
89585552|NCT01529008|Experimental|Core decompression/PREOB® implantation|
89585553|NCT01529008|Placebo Comparator|Core decompression/placebo implantation|
89585554|NCT01599104|Experimental|LCZ696 200 mg|LCZ696 200 mg tablet and placebo to both LCZ696 (1 tablet) and Olmesartan (1 capsule) tablet once daily for 8 weeks
89585555|NCT01599104|Experimental|LCZ696 400 mg|LCZ696 200 mg tablet and a placebo to both LCZ696 (1 tablet) and Olmesartan (1 capsule) once daily for one week; then up-titrated to LCZ696 400 mg and placebo to Olmesartan (1 capsule) once daily for the remaining 7 weeks
89585556|NCT01599104|Active Comparator|Olmesartan 20 mg|Olmesartan 20 mg capsule and placebo to LCZ696 (2 tablets) once daily for 8 weeks
89209676|NCT00808262|Experimental|TNFa Kinoid dose 2|
89209677|NCT00808262|Experimental|TNFa Kinoid dose 3|
89209678|NCT00817622|Placebo Comparator|A|"Placebo, Placebo :~Placebo pearls,500 mg QID for 12 Weeks (2000 mg corn oil per day) Placebo pearl + corn oil 400 mg per day for 12 weeks"
89209679|NCT00817622|Active Comparator|B|"EPA, Placebo :~EPA pearls,500 mg QID for 12 Weeks (2000 mg per day),From MINAMINUTRITION Company(Belgium)+ Placebo pearl ,corn oil 400 mg per day for 12 weeks"
89209680|NCT00817622|Placebo Comparator|C|"Placebo ,Vitamin E :~Placebo pearls,500 mg QID for 12 Weeks (2000 mg corn oil per day)+ Vitamin E pearls, 400 mg from DANA Company(IRAN) per day for 12 weeks"
89209681|NCT00817622|Active Comparator|D|"EPA, Vitamin E :~EPA pearls,500 mg QID From MINAMINUTRITION Company(Belgium) for 12 Weeks (2000 mg EPA per day)+ Vitamin E pearls, 400 mg from DANA Company ( IRAN) per day for 12 weeks"
89209682|NCT00808418|Experimental|Cohort|
89585557|NCT05255432||Group A|Selection of tasks
89585558|NCT05255432||Group B|Selection of tasks
89585559|NCT02136680|Active Comparator|Patients at Intervention Site|Staff receives CASA Education
89585560|NCT02136680|No Intervention|Patients at CONTROL site|Staff does not receive CASA Education
89585561|NCT03028558||HEALTHY VOLUNTEER RESEARCH SUBJECTS|"Healthy as defined by those not having lung disease and inclusive of: all races, ethnicities, sex, HIV status, smoking status and multiple birth status, etc., within the general population.~Between the ages of 21-35 years old."
89585562|NCT03028558||HEALTHY E-CIGARETTE SMOKING SUBJECTS|Criteria is identical to the healthy never-smoker group except that they must have a history of smoking e-cigarettes >5 days/wk for a minimum of 6 months with no prior traditional tobacco exposure.
89585563|NCT01552954|Experimental|Intensive education of low salt diet|"For 8 weeks, dietitian will call patients to take the information according to pre-defined questionnaire, to check the daily diet habit and daily food taken, and to guide how to lessen sodium intake for 30 min at each call. The call will be done once a week for 8 weeks. (*Intervention in this trial is the intensity of education)"
89585564|NCT01552954|No Intervention|Conventional diet group|Education for low salt diet will be conducted as in office with brief communication with a patient and a physician.
89585565|NCT02175368|Experimental|Adhese One F Upgrade|Adhese One F Upgrade (AOFU) is administered after phosphoric acid etching (etch-and-rinse protocol).
89585566|NCT01518244|Experimental|AZARGA®|Brinzolamide/timolol maleate fixed combination, 1 drop self-administered in study eye(s) twice a day for 8 weeks
89585567|NCT01552408|Active Comparator|0.3 mg Ranibizumab|Cohort 1: Subjects will receive 4 IVT of 0.3 mg ranibizumab every 28 days (+/- 7 days), then will be seen monthly (+/- 7 days) & will receive IVT of 0.3 mg ranibizumab on a pro re nata (PRN) schedule per retreatment criteria.
89585568|NCT01552408|Experimental|Targeted PRP with 0.3 mg Ranibizumab|Cohort 2: Subjects will receive 4 it of 0.3 mg ranibizumab every 28 days (+/- 7 days), then will then be seen monthly (+/- 7 days) & receive IVT of 0.3 mg ranibizumab on a PRN schedule per retreatment criteria based on the evaluating Investigator's assessment of disease activity. In addition, at Day 7 they will receive targeted pan-retinal photocoagulation (PRP) based on ultra wide field angiography. Ultra wide field angiography will be performed every 3 months to indicate areas of peripheral ischemia, which will be selectively be treated with PRP at Month 6, Month 18, and Month 25, preserving areas of more perfused retina.
89585569|NCT01528696|Placebo Comparator|Standard Dressing|Obese patients undergoing cesarean section in this arm will receive a standard island-type dressing
89585570|NCT01528696|Experimental|Silverlon|Obese patients undergoing cesarean section in this arm will receive Silverlon, a silver impregnated dressing
89585571|NCT02174276|Active Comparator|TDF 48 weeks|Participants will receive TDF for 48 weeks. After Week 48, participants will have the option to continue receiving TDF for up to 144 weeks.
89585572|NCT02174276|Experimental|TDF plus GS-4774 2 YU|Participants will receive TDF plus GS-4774 2 yeast units (YU) for 20 weeks. After Week 20, GS-4774 will be discontinued and participants will continue on TDF for an additional 28 weeks. After Week 48, participants will have the option to continue receiving TDF for up to 144 weeks.
89585573|NCT02174276|Experimental|TDF plus GS-4774 10 YU|Participants will receive TDF plus GS-4774 10 YU for 20 weeks. After Week 20, GS-4774 will be discontinued and participants will continue on TDF for an additional 28 weeks. After Week 48, participants will have the option to continue receiving TDF for up to 144 weeks.
89585574|NCT02174276|Experimental|TDF plus GS-4774 40 YU|Participants will receive TDF plus GS-4774 40 YU for 20 weeks. After Week 20, GS-4774 will be discontinued and participants will continue on TDF for an additional 28 weeks. After Week 48, participants will have the option to continue receiving TDF for up to 144 weeks.
89585575|NCT01528072|Experimental|Dynesys System|All patients will receive the Dynesys System and all patients will be compared to historical literature control. Dynesys Spinal System will be used for all subjects.
89585576|NCT01527682|Other|Latanoprost, Dorzolamide|According to intraocular (IOP) assessment, the eye will receive Latanoprost, Dorzolamide or both.
89585577|NCT01527370|Experimental|Zoster Vaccine Live|
89585578|NCT01527292|Active Comparator|Control Group|Baseline Assessments and followup assessments are the same for both arms. Control group Intervention: Stereotactic Radiation Therapy only
89585579|NCT01527292|Experimental|Treatment Group|SRT with Vertebral Augmentation Procedure Baseline Assessments and followup assessments are the same for both arms. Treatment group Intervention: Stereotactic Radiation Therapy with Vertebral Augmentation Procedure
89585580|NCT04748692|Experimental|Local exercise therapy|The local exercise therapy group focused on strengthening knee and hip muscles three times a week for 6 weeks. Once a week, patients trained with the support of a physiotherapist. The physiotherapist gradually increased the intensity of the exercises improving muscle endurance. The exercises were supplemented with mobilisations of the patellofemoral joint. Twice a week, patients trained at home following a prescribed exercise program writing down their work-out in an exercise journal.
89585581|NCT04748692|Experimental|Spinal manual therapy|The spinal manual therapy group was treated one a week for 6 weeks. Before the first intervention an experienced manual therapist performed a clinical examination of the lower back, SIJ, hip and knee. Anatomical maps showing innervation areas of spinal nerve roots were used to explain the regional interdependence model in the treatment of anterior knee pain. Manual therapy treatment included manipulations of the thoracolumbar (T12-L3) region or SIJ as well as hip joint. Manipulation was conducted if a restriction of range of motion was found in any of the regions. Patients were also asked to do home exercises focusing on mobilizing the thoracolumbar region and to write down their performance in an exercise journal.
89585582|NCT01516216|Active Comparator|Chemotherapy + Standard Dose Vitamin D|"FOLFOX-bevacizumab: intravenously on Day 1 (+/- 7 days) of every two-week cycle per institutional standards + 400 IU vitamin D3 orally once daily~Participants were treated until disease progression, unacceptable toxicity or withdrawal for other reasons."
89585583|NCT01516216|Active Comparator|Chemotherapy + Higher Dose|"FOLFOX-bevacizumab: intravenously on Day 1 (+/- 7 days) of every two-week cycle per institutional standards + 8000 IU daily x 2 weeks as loading dose, followed by 4000 IU daily as maintenance dose.~Participants were treated until disease progression, unacceptable toxicity or withdrawal for other reasons."
89209683|NCT00817700|No Intervention|Normal (8 hours) sleep time|Subjects are studied under normal sleep time conditions.
89209684|NCT00817700|Experimental|Sleep restriction|"Sleep restriction to 4 hours of sleep per night.~Overnight sleep recording, measures of endocrine and metabolic (from blood), cardiovascular (measures of blood pressure and heart rate), performance ( before and after sleep restriction and after sleep recovery."
89209685|NCT04572152|Experimental|AK119/ AK104|Single-arm
89209686|NCT00642668|Experimental|Methoxy Polyethylene Glycol-Epoetin Beta|Participants received methoxy polyethylene glycol-epoetin beta treatment monthly for 36 weeks with an efficacy evaluation period (EEP) during weeks 29-36 and followed by a 4 week follow-up period.
89209687|NCT00817934||PREVENTION AND TREATMENT|PATIENTS 50 YEARS AND OLDER REQUIRE SCREENING COLONOSCOPY. PATIENTS WITH FAMILY HISTORY OF COLON CANCER WILL REQUIRE IT BEFORE THE AGE OF 50.
89585584|NCT01950819|Experimental|EVR+rCNI|Everolimus with reduced calcineurin inhibitor- everolimus (target trough level of 3-8 ng/mL) in combination with reduced exposure to CNI (cyclosporine or tacrolimus)
89585585|NCT01950819|Active Comparator|MPA+sCNI|Mycophenolate (mycophenolic acid sodium or mycophenolate mofetil) in combination with standard exposure to calcineurin inhibitor (cyclosporine or tacrolimus).
88975039|NCT02967627|Experimental|Incisional Negative Pressure Wound Therapy (iNPWT)|Patients in the iNPWT group will have their incision covered by a single layer of Mepitel wound contact layer followed by application of a KCI V.A.C Simplace ™ Dressing composed of a strip of black foam covering the entire length of the incision followed by coverage of the incision, Mepitel, and foam with an occlusive Tegederm ™ dressing to establish an airtight seal. Negative pressure will then be applied using a SensaT.R.A.C. Pad ™ to a setting of 100 mmHg continuous suction. Dressings shall remain in place and will be removed by the surgical team on the morning of the third post-operative day and left open to air thereafter. Any loss of seal of the dressing shall be reinforced using occlusive dressings.
88975040|NCT02967627|Active Comparator|Standard Therapy|Patients in the conventional dressings group will receive a standard Mepore ™ dressing applied to cover the entire incision. This will be left in place and and removed by the surgical team on the morning of the second postoperative day and will be left open to air thereafter. Dressings may be either reinforced or changed at the discretion of the surgical team due to drainage or saturation during the first two postoperative days.
89585586|NCT04767490|Active Comparator|BPD-DS|Biliopancreatic diversion with Duodenal Switch (BPD-DS), with Sleeve gastrectomy, including a 100cm common channel and 150cm stric alimentary limb
89585587|NCT04767490|Experimental|SADI|Single-Anastomosis Duodeno-Ileal anastomosis (SADI) with Sleeve Gastrectomy, including a 250cm common channel
89585588|NCT01514422|Experimental|Minocycline|All subjects will be given minocycline over 8 weeks
89585589|NCT03027700|Active Comparator|Health/Normal Controls|Health/normal control subjects will undergo MRI using several different imaging sequences (MR Elastography, T1 mapping, T2 mapping, T1 rho, and magnetization transfer) designed to detect and quantify hepatic fibrosis.
89585590|NCT03027700|Active Comparator|F1/F2 fibrosis|Type 1 and 2 liver fibrosis subjects will undergo MRI using several different imaging sequences (MR Elastography, T1 mapping, T2 mapping, T1 rho, and magnetization transfer) designed to detect and quantify hepatic fibrosis.
88975041|NCT00035984|Experimental|AC2993 5 mcg (0.02 mL)|Placebo, then AC2993 5 mcg, then AC2993 5 mcg
88975042|NCT00035984|Experimental|AC2993 10mcg (0.04 mL)|Placebo, then AC2993 5 mcg, then AC2993 10 mcg
88975043|NCT00035984|Placebo Comparator|Placebo 0.02 mL|Placebo 0.02 mL, then Placebo 0.02 mL, then Placebo 0.02 mL
88975044|NCT00035984|Placebo Comparator|Placebo 0.04 mL|Placebo 0.02 mL, then Placebo 0.02 mL, then Placebo 0.04 mL
89585591|NCT03027700|Active Comparator|F3/F4 fibrosis|Type 2 and 3 liver fibrosis subjects will undergo MRI using several different imaging sequences (MR Elastography, T1 mapping, T2 mapping, T1 rho, and magnetization transfer) designed to detect and quantify hepatic fibrosis.
88975045|NCT00063141|Experimental|Arm A|
88975046|NCT00063141|Active Comparator|Arm B|
89209688|NCT00814424|Active Comparator|1|ERCP patients monitored using currently marketed smart biteblock o2
89209689|NCT00814424|Experimental|2|ERCP patients monitored using experimental biteblock delivering up to 10 lit/min oxygen
89209690|NCT00729833|Experimental|CP-751,871 + Sunitinib|Escalating cohorts of CP-751,871 + Sunitinib
89209691|NCT00645788|Experimental|32.50 mg Ciprofloxacin DPI (BAYQ3939)|32.50 mg ciprofloxacin DPI (Dry Powder for Inhalation) corresponding to 50 mg Ciprofloxacin PulmoSphere Inhalation Powder twice a day for 28 days
89209692|NCT00645788|Experimental|48.75 mg Ciprofloxacin DPI (BAYQ3939)|48.75 mg ciprofloxacin DPI corresponding to 75 mg Ciprofloxacin PulmoSphere Inhalation Powder twice a day for 28 days
89209693|NCT00645788|Placebo Comparator|Matching Placebo for 32.50 mg|Inhalation of placebo powder formulation matching 32.50 mg ciprofloxacin DPI twice a day for 28 days
89209694|NCT00645788|Placebo Comparator|Matching Placebo for 48.75 mg|Inhalation of placebo powder formulation matching 48.75 mg ciprofloxacin DPI twice a day for 28 days
89585592|NCT03027700|Active Comparator|Hepatic steatosis with fibrosis|Hepatic steatosis with liver fibrosis subjects will undergo MRI using several different imaging sequences (MR Elastography, T1 mapping, T2 mapping, T1 rho, and magnetization transfer) designed to detect and quantify hepatic fibrosis.
89585593|NCT01513330|Experimental|First Standard Care, then SenSura Mio|Subjects first test Standard Care (Either SenSura, Nova 1, Moderna/Moderna Flex, Esteem or Flexima/Softima) and after cross-over SenSura Mio
89585594|NCT01513330|Experimental|First SenSura Mio, then Standard Care|Subjects first test SenSura Mio and after cross-over Standard Care(Either SenSura, Nova 1, Moderna/Moderna Flex, Esteem or Flexima/Softima)
89585595|NCT04415775|Experimental|Dual-task walking Intervention|
89585596|NCT04415775|Active Comparator|Conventional Gait Rehabilitation|
89585597|NCT04415775|No Intervention|Healthy Controls|
89585598|NCT05110911||Healthcare Workers|"Eligible participants will be recruited from 1 of 6 participating hospitals in Australia and will meet the following criteria: personnel (including staff, honorary staff, students and volunteers) located at a participating hospital or healthcare service at the time of recruitment who would be eligible for the hospital's free vaccination programme; be aged ≥18 years old and ≤60 years old; have a mobile phone that can receive and send SMS messages; willing and able to provide blood samples; available for follow-up over the next 7 months; able and willing to complete the informed consent process.~There are no restrictions on the type of healthcare worker (HCW) that can be recruited into the study in terms of their job role. HCW will be any hospital staff, including clinical, research, administrative and support staff."
88975047|NCT02967315|Experimental|Study Group|"Procedures include:~Two Cardiac Magnetic Resonance Imaging (CMRIs) A central venous line placement, A chest X-ray Electrocardiogram (ECG) Fluid administration Blood draw Pregnancy test"
88975048|NCT02967588|Experimental|Intervention|
88975049|NCT04732403|No Intervention|0 degree supine position|Surgical bed will be set to a 0 degree supine position
88975050|NCT04732403|Experimental|10-20 degree angle in reverse Trendelenburg|Surgical bed will be set to a 10-20 degree angle in reverse Trendelenburg
88975051|NCT00063336|Experimental|1|Participants will receive cognitive remediation treatment.
88975052|NCT00063336|Experimental|2|Participants will receive computer-skills training.
88975053|NCT00036296|Experimental|1|75mg per day (in 3 doses) Talampanel for 22 days
88975054|NCT00036296|Placebo Comparator|2|3 doses a day for 22 days
88975055|NCT00063453|Experimental|Vitamin E and selenium placebo|Vitamin E alone
88975056|NCT00063453|Experimental|Selenium and vitamin E placebo|Selenium alone
88975057|NCT00063453|Experimental|Vitamin E and selenium|Vitamin E and selenium combined
89585599|NCT01524796||Patients with peripheral neuropathic pain treated with Lyrica|
89585600|NCT01547728|Experimental|Recombinant antithrombin (rhAT)|Subjects will receive an intravenous bolus of 500 units of recombinant, human antithrombin (rhAT, ATRYN ®). If the subject remains heparin-resistant, one more IV bolus of 500 units rhAT is given.
89585601|NCT01523392|Experimental|Ticagrelor|
89585602|NCT01523392|Active Comparator|Clopidogrel|
89585603|NCT01512160|Experimental|PF-04531083 2000 mg|
89585604|NCT01512160|Experimental|PF-04531083 1000 mg|
89585605|NCT01512160|Active Comparator|Ibuprofen 400 mg|
89585606|NCT01512160|Placebo Comparator|Placebo|
89585607|NCT01546168|Experimental|esophageal deviation|esophageal deviation with IDE device during AF ablation
89585608|NCT01546168|No Intervention|temperature monitoring|luminal esophageal temperature monitoring, standard temperature monitoring alone
89585609|NCT01901289|Experimental|Drug-Eluting Stent|
89585610|NCT01950741|Experimental|aflibercept|Aflibercept 2 mg is injected into the vitreous cavity. Injections are given monthly three times, then are given bi-monthly to 12 months (month 0, 1, 2, 4, 6, 8, and 10; total 7 injections for 1 year).
89585611|NCT01950273|Experimental|BI695500|BI695500, once a week for 4 weeks (4 administrations in total)
89585612|NCT01950273|Active Comparator|MabThera|MabThera, once a week for 4 weeks (4 administration in total)
89585613|NCT01919307|Experimental|Auricular acupuncture|Subjects will then receive auricular acupuncture (NADA Protocol) twice weekly for eight consecutive weeks. Subjects will be evaluated for seizure frequency changes by self-reported diary; adverse events; study feasibility; and mental and physiological symptoms at baseline, 12 weeks (completion of acupuncture), and 16 weeks (1 month after treatment follow up, end of study). A single sham procedure will be tested following treatment completion for use in future studies.
89585614|NCT01919229|Active Comparator|Letrozole|Letrozole 2.5 mg alone once daily
89585615|NCT01919229|Experimental|LEE011 400 mg + letrozole|Letrozole 2.5 mg once daily and ribociclib 400 mg (2 capsules of 200 mg each) once daily.
89585616|NCT01919229|Experimental|LEE011 600mg + letrozole|Letrozole 2.5 mg once daily and ribociclib 600 mg (3 capsules of 200 mg each) once daily.
89585617|NCT04626375|Placebo Comparator|Placebo|Placebo (2 vials per os without active substance every 12 hours)
89585618|NCT04626375|Active Comparator|Bioarginine|Bioarginine (2 vials per os of 1.66 g every 12 hours)
88975058|NCT00063453|Placebo Comparator|vitamin E Placebo and Selenium placebo|Double placebo
88975059|NCT02967471||ARDS group|
88975060|NCT02967471||control group|
88975061|NCT02967549|Experimental|NAVA then PAV|Infants randomised to NAVA then PAV
88975062|NCT02967549|Experimental|PAV then NAVA|Infants randomised to PAV then NAVA
88975063|NCT00063531||GeneSTAR participant meeting entry criteria|Healthy siblings of patients with early onset CAD (<60 years old) and the adult offspring of the siblings or probands
89585619|NCT01901055|Experimental|Active CPAP treatment|Treatment of obstructive sleep apnea with continuous positive airway pressure (CPAP)
89585620|NCT01901055|Placebo Comparator|Sham-CPAP|Device that appears like the treatment of obstructive sleep apnea, a continuous positive airway pressure device, but that does not provide treatment.
89585621|NCT04615377|Experimental|Kaia hip and knee pain app|Kaia software application: Kaia Knee and Hip pain app (version 2.37.0) The Kaia Knee and Hip pain app is an investigational device, which is intended as a digital aid for the self-management of osteoarthritis for use by adults (between 22 to 75 years old) without supervision by healthcare professionals in a home setting.
89585622|NCT04615377|Active Comparator|Treatment as usual|Participants will be encouraged to continue the treatment that they have been on without restriction
89585623|NCT01511536|Experimental|Phase 1: Cabazitaxel 20 mg/m^2 + Abiraterone 1000 mg|Cabazitaxel 20 mg/m^2 intravenous (IV) infusion on Day 1 of each 21-day cycle in combination with abiraterone acetate 1000 mg orally once daily and prednisone 5 mg orally twice daily until disease progression, unacceptable toxicity or consent withdrawal.
89585624|NCT01511536|Experimental|Phase 1: Cabazitaxel 25 mg/m^2 + Abiraterone 1000 mg|Cabazitaxel 25 mg/m^2 IV infusion on Day 1 of each 21-day cycle in combination with abiraterone acetate 1000 mg orally once daily and prednisone 5 mg orally twice daily until disease progression, unacceptable toxicity or consent withdrawal.
89585625|NCT01511536|Experimental|Phase 2: Cabazitaxel 25 mg/m^2 + Abiraterone 1000 mg|Cabazitaxel at maximum tolerated dose (MTD) as determined in phase 1 part (25 mg/m^2) IV infusion on Day 1 of each 21-day cycle in combination with abiraterone acetate 1000 mg orally once daily and prednisone 5 mg orally twice daily until disease progression, unacceptable toxicity or consent withdrawal.
89585626|NCT01890759|Experimental|Meningococcal Diphtheria Toxoid Vaccine|Participants at age 9 to 17 months of enrollment will receive 2 doses on Menactra vaccine at 3 to 6 months apart
89585627|NCT01900899|Experimental|ACWY-TT group|Subjects primed and boosted with the MenACWY-TT vaccine.
89585628|NCT01900899|Active Comparator|MenCCRM group|Subjects primed and boosted with the Meningitec vaccine.
89585629|NCT01510912|Experimental|Diclofenac Capsules 35 mg bid or tid|
89585630|NCT04615221|Other|Graft recipient|During each of the visits carried out with a cervical biopsy as part of the uterine transplant project, samples will be taken.
89585631|NCT04615221|Other|Living donor|The donors will benefit from a blood sample and a sample of the vaginal microbiota during the transplant under general anesthesia or after it during a consultation scheduled as part of the uterine transplant protocol.
89585632|NCT04615221|Other|Witness|10 non-menopausal control patients will each have a cervical biopsy (at different times of the cycle) and a smear, samples of the vaginal microbiota and a blood sample. Among the 10 controls, 4 patients will have to undergo a hysterectomy for which multiple staged biopsies and samples uterine microbiota will be produced.
89585633|NCT01510756|Experimental|Sorafenib|Sorafenib 400mg orally twice daily will be administered for three cycles (1 cycle = 28 days).
89585634|NCT01522456|Active Comparator|Epiduo Gel|Adapalene 0.1% and benzoyl peroxide 2.5% gel
89585635|NCT01522456|Active Comparator|Retin-A Micro Microsphere 0.1%|Tretinoin gel, 0.1%
89585636|NCT04409626||Cases|
89585637|NCT04409626||Controls|Matched (5 controls per case) by date of birth +/- 180 days.
88975064|NCT02967276|Experimental|Metformin and HDdexamethasone|"Metformin XR is initially administered at a dose of 500mg / daily by oral administration for 7 days. Patients who have a good tolerance (lack of adverse events of grade 3 or 4) may be staggered metformin dose to 2500 mg / day.~Patients in turn receiving dexamethasone pulse prescription (HDdex). A dose of dexamethasona 40 mg / day taken in a daily for four days every 8 days from 1st to 2nd cycle every 35 days and 1x per week for 4 weeks every 28 days from the 3rd to 6th cycle. The dose will be administered at 4 mg tablets, which are to be swallowed whole by 30 minutes after a meal. Patients over age 75 used 20 mg / day."
88975065|NCT00036491|Experimental|rituximab|375 mg/m^2 administered intravenously
89585638|NCT01545934|No Intervention|Standard Care|
89585639|NCT01545934|Experimental|Lifestyle intervention|
89585640|NCT03027544|Experimental|experimental arm|"Group A: multiple brain metastases: no less than 3 lesions in the brain Group B: Large Brain Metastases: the volume of lesion is no smaller than 6cc or the maximum diameter of the lesion is no shorter than 3cm Group C:Meningeal Metastases.~Intervention：tomotherapy"
88975066|NCT00036686|Experimental|Soy protein isolate|"Administration Prior to Mastectomy or Lumpectomy.~Patients receive oral soy protein isolate twice daily and oral multivitamins once daily.~Treatment continues for 2-4 weeks depending on time from study entry to planned surgical procedure."
88975067|NCT00036686|Placebo Comparator|Placebo|"Administration Prior to Mastectomy or Lumpectomy.~Patients receive oral placebo twice daily and oral multivitamins once daily.~Treatment continues for 2-4 weeks depending on time from study entry to planned surgical procedure."
89585641|NCT01521364|Other|0mg, 250mg, and 500mg claritromycin|"Patients receive 300mg linezolid twice a day during entire study. After one week, 250mg claritromycin once daily is added for a duration of two weeks.~After another two weeks, 250mg claritromycin is replaced by 500mg claritromycin once daily for another two weeks.~After this, there is a wash-out period of one week during which no claritromycine is administered."
89585642|NCT01545388|Experimental|Metformin 500 mg q.d.|Participants will receive sitagliptin daily (continuing their pre-study dose), 2 metformin 250 mg tablets in the morning and 1 matching placebo tablet in the evening.
89585643|NCT01545388|Experimental|Metformin 250 mg b.i.d.|Participants will receive sitagliptin daily (continuing their pre-study dose), 1 metformin 250 mg tablet and 1 matching placebo tablet in the morning and 1 metformin 250 mg tablet in the evening.
89585644|NCT01545388|Placebo Comparator|Placebo|Participants will receive sitagliptin daily (continuing their pre-study dose), 2 matching placebo tablets in the morning and 1 matching placebo tablet in the evening.
89585645|NCT01545076|Experimental|IgPro20 low dose|
89585646|NCT01545076|Experimental|IgPro20 high dose|
89585647|NCT01545076|Placebo Comparator|Placebo|
89585648|NCT01544920|Active Comparator|Arm 1: peg-IFN + RBV|Participants received an initial 4 week lead-in of peg-IFN + RBV. Following HCV RNA analysis at Week 4, participants with undetectable HCV RNA received open label peg-IFN + RBV for an additional 18 weeks (total of 24 weeks of peg-IFN/RBV therapy) [Arm 1a]. Participants with detectable HCV RNA at Week 4 had BOC added to the peg-IFN + RBV regimen at Week 6 and then followed the Response Guided Therapy (RGT) regimen for BOC + peg-IFN + RBV [Arm 1b].
89030231|NCT00505349|Experimental|Cognitive Training|Phase II of this study will involve an evaluation of the pre- and post- cognitive training levels of blood-derived neurotrophic factors in healthy, mature adults. Participants randomized to this arm will receive SAAGE-based computerized cognitive training.
89585649|NCT01544920|Experimental|Arm 2: BOC + peg-IFN + RBV|Participants received an initial 4-week lead-in of peg-IFN + RBV. Following HCV RNA analysis at Week 4, all participants had BOC added to the peg-IFN + RBV regimen at Week 6 regardless of HCV RNA levels. Participants who had undetectable HCV RNA at Week 4 continued on the BOC + peg-IFN + RBV regimen for an additional 20 weeks (total of 24 weeks of BOC + peg-IFN + RBV therapy) [Arm 2a]. Participants with detectable HCV RNA at Week 4 followed the RGT regimen for BOC + peg-IFN + RBV [Arm 2b].
89585650|NCT01509664|Experimental|Discount intervention|Receives 50% discount intervention on selected fruits and vegetables at participating supermarket.
89585651|NCT01509664|No Intervention|Control|Received no discount at the participating supermarket.
89585652|NCT04409704|Experimental|10 Hz|10 Hz repetitive transcranial magnetic stimulation to dorsomedial prefrontal cortex, once daily, 5 days per week for 4-6 weeks
89585653|NCT01543828|Experimental|indacaterol then placebo|In treatment 1: participants received indacaterol 75 µg one dose delivered via single-dose dry-powder inhaler (SDDPI) followed by treatment 2: placebo one dose via SDDPI between day 7 and 10. Albuterol was available for use as rescue medication.
89585654|NCT01543828|Placebo Comparator|placebo then indacaterol|In treatment 1, participants received placebo one dose delivered via SDDPI followed by treatment 2: indacaterol 75 µg one dose delivered via SDDPI between Day 7 and Day 10. Albuterol was available for use as rescue medication.
89585655|NCT04096222||Active pemphigus vulgaris subjects|Subjects with the diagnosis of pemphigus and with active or inactive disease in the skin will be invited to participate. After informed consent, at the enrollment visit the following interventions will be done: 1) two 4 mm punch biopsies in a target lesion, 2) A 34 ml blood sample will be taken, 3) photographs of the subject, 4) demographic, disease, comorbidity and treatment data will be documented, 5) PDAI and ABSIS, 6) Biometric data
89585656|NCT04096222||Inactive pemphigus vulgaris subjects|Subjects with the diagnosis of pemphigus and with active or inactive disease in the skin will be invited to participate. After informed consent, at the enrollment visit the following interventions will be done: 1) two 4 mm punch biopsies in a target lesion, 2) A 34 ml blood sample will be taken, 3) photographs of the subject, 4) demographic, disease, comorbidity and treatment data will be documented, 5) PDAI and ABSIS, 6) Biometric data
89585657|NCT04096222||Healthy subjects|Healthy subjects will be invited to participate. After informed consent, at the enrollment visit the following interventions will be done: 1) Demographic data will be documented, 2) biometric data, 3) A 34 ml blood sample will be taken
89585658|NCT03027622||long term quality of life|to evaluate conservatively managed third molars with mild pericoronitis at first, third and sixth months by using OHIP-14 TR
89585659|NCT01520506|Experimental|Rapid Renal Denervation|
89585660|NCT01519960|Experimental|A Pegasys|
89585661|NCT01519960|No Intervention|B Untreated Control|
89585662|NCT01519960|Experimental|C Fibrosis non-randomized|
89585663|NCT01519960|Experimental|Switch|
89585664|NCT01543204|Experimental|Etanercept 50 mg|Participants received etanercept 50 mg, twice weekly (BIW), subcutaneously (SC) for 12 weeks followed by 50 mg, once weekly (QW), SC for an additional 12 weeks.
89585665|NCT01488994|Experimental|BAX326 < 6 years of age|
89585666|NCT01488994|Experimental|BAX326 6 to <12 years of age|
89585667|NCT01508650|Active Comparator|No intervention|Usual care control group
89585668|NCT01508650|Active Comparator|Active Comparator|Multi domain rehabilitation intervention
89585669|NCT03027154|Experimental|TB subjects in 5-18 years old|24 cases TB subjects in 5-18 years old are injected ESAT6-CFP10 in left arm and TB-PPD in right arm or ESAT6-CFP10 in right arm and TB-PPD in left arm. For each of participant,the person in this clinical research, the study uniform is that every subject injects firstly left arm, observe no obvious adverse reaction, then another drug inject in right arm. Measure the induration and (or) redness of longitudinal diameter size and transverse diameter vernier caliper by vernier caliper after injection 24h, 48h and 72h.
89030232|NCT00516555||A, 07, 001|Pregnant women at term with a baby in breech presentation who will have an external cephalic version.
89030233|NCT02275988|Experimental|K-877|K-877
89585670|NCT03027154|Experimental|non-TB subjects in 5-18 years old|24 cases non-TB subjects in 5-18 years old are injected ESAT6-CFP10 in left arm and TB-PPD in right arm or ESAT6-CFP10 in right arm and TB-PPD in left arm. For each of participant,the person in this clinical research, the study uniform is that every subject injects firstly left arm, observe no obvious adverse reaction, then another drug inject in right arm. Measure the induration and (or) redness of longitudinal diameter size and transverse diameter vernier caliper by vernier caliper after injection 24h, 48h and 72h.
89585671|NCT03027154|Experimental|TB subjects under 5 years old|24 cases TB subjects under 5 years old are injected ESAT6-CFP10 in left arm and TB-PPD in right arm or ESAT6-CFP10 in right arm and TB-PPD in left arm. For each of participant,the person in this clinical research, the study uniform is that every subject injects firstly left arm, observe no obvious adverse reaction, then another drug inject in right arm. Measure the induration and (or) redness of longitudinal diameter size and transverse diameter vernier caliper by vernier caliper after injection 24h, 48h and 72h.
89585672|NCT03027154|Experimental|non-TB subjects under 5 years old|24 cases non-TB subjects under 5 years old are injected ESAT6-CFP10 in left arm and TB-PPD in right arm or ESAT6-CFP10 in right arm and TB-PPD in left arm. For each of participant,the person in this clinical research, the study uniform is that every subject injects firstly left arm, observe no obvious adverse reaction, then another drug inject in right arm. Measure the induration and (or) redness of longitudinal diameter size and transverse diameter vernier caliper by vernier caliper after injection 24h, 48h and 72h.
89585673|NCT01488448|Experimental|Nebulized Hypertonic Saline|4mL nebulized 3% sodium chloride every 4 hours until discharge
89585674|NCT01488448|Placebo Comparator|Nebulized Normal Saline|4 mL nebulized 0.9% sodium chloride every 4 hours until discharge
89030234|NCT02275988|Experimental|K-877 with Clarithromycin|K-877 with Clarithromycin
89030235|NCT02950155|Experimental|Rituximab|A single infusion at a dose of 500 mg of Mabthera/Rituximab.
89030236|NCT02950155|Sham Comparator|Sodium Chloride solution|A single infusion with sodium chloride solution.
89585675|NCT01518946|Active Comparator|Midodrine HCl|
89585676|NCT01518946|Placebo Comparator|Placebo|
89585677|NCT01488370|Active Comparator|Glidescope|A device for endotracheal intubation.
89585678|NCT01488370|Active Comparator|Storz|A device for endotracheal intubation.
89585679|NCT01488370|Active Comparator|Standard Laryngoscope|A device for endotracheal intubation
89585680|NCT01518322||FeNO|All subjects will have their Fractional Exhaled Nitric Oxide (FeNO) measured with the NIOX MINO® device according to instructions for NO measurements.
89585681|NCT01507246|Active Comparator|IV morphine sulfate|Standard of Care (SOC), dosage variable, administered intravenously via PCA pump postsurgically, as need.
89585682|NCT01507246|Experimental|EXPAREL (bupivacaine liposome injectable suspension)|EXPAREL(R), dosage 266 mg, diluted with 0.9% saline to a total volume of 40 cc.
89585683|NCT01507090||Normal Children|Otherwise healthy children 2 months to 16 years of age.
89585684|NCT03870022|Other|18-80 years of age|Single day study collecting 1 paired breath sample from each subject using two non-invasive breath sampling devices, as well as collecting participant responses to user documentation questions and rating scales.
89585685|NCT01464346|Experimental|Enlite sensor, Abdomen/Abdomen|Subjects wearing 2 Enlite sensors in Abdomen
89585686|NCT01464346|Experimental|Enlite sensor, Abdomen/Buttock|Subjects wearing 2 Enlite sensors in Abdomen/Buttock
89585687|NCT01464346|Experimental|Enlite sensor, Buttock/Buttock|Subjects wearing 2 Enlite sensors in Buttock/Buttock
89585688|NCT02073448|Experimental|GK530G|Fixed-dose combination gel of Adapalene and Benzoyl Peroxide
89585689|NCT02073448|Active Comparator|CD0271|Adapalene 01% Gel
89585690|NCT02073448|Active Comparator|CD1579|Benzoyl Peroxide 2.5% Gel
89585691|NCT01487200|Experimental|FX006 10mg|Single 3 mL intra-articular (IA) injection Extended-release formulation
89585692|NCT01487200|Experimental|FX006 40mg|Single 3 mL intra-articular (IA) injection Extended-release formulation
89585693|NCT01487200|Experimental|FX006 60 mg|Single 3 mL intra-articular (IA) injection Extended-release formulation
89585694|NCT01487200|Active Comparator|TCA IR (40 mg)|Single 1 mL intra-articular (IA) injection Immediate-release formulation
89585695|NCT01463878|Experimental|Glycerna|Diabetic specific formula. The volume /rate of glycerna will be determined by the dietician according to standard formula.
89585696|NCT01463878|Active Comparator|Control - Jevity|The control arm of the study. Patients to receive Jevity. The volume /rate of Jevity will be determined by the dietician according to standard formula.
89585697|NCT04080856||Participants with endometriosis|Premenopausal participants with endometriosis receiving elagolix in real-world setting
89585698|NCT01486966|Experimental|Insulin detemir / IAsp|
89585699|NCT01486966|Active Comparator|insulin NPH|
89585700|NCT04080076|Active Comparator|ACTHar gel combined with Tacrolimus|ACTHar Gel units 2 times per week plus oral Tacrolimus (1.0 mg BID) titrating to a trough level of 4-6 ng/ml for 52 weeks
89585701|NCT04080076|Active Comparator|ACTHar gel|ACTHar Gel units 2 times per week for 52 weeks
89585702|NCT01900665|Experimental|Solanezumab|Solanezumab 400 milligrams (mg) every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who complete the full 80 weeks of treatment/assessment and decide to continue will take this regimen for up to an additional 208 weeks.
89585703|NCT01900665|Placebo Comparator|Placebo|Placebo every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who complete the full 80 weeks of treatment/assessment and decide to continue will switch to solanezumab 400 mg every 4 weeks for up to an additional 208 weeks.
89585704|NCT01900431|Placebo Comparator|Placebo|Placebo (for Sarilumab) subcutaneous (SC) injection every 2 weeks (q2w) for 16 weeks during principal treatment period (Part A) with background therapy of Prednisone (or equivalent oral corticosteroid) ≥15 mg/day and <80 mg/day as single therapy or in combination with Methotrexate (MTX) 10 to 25 mg/week and folic acid per local prescribing practice. Responders continued with the same treatment regimen up to Week 50 during extension treatment period (Part B) and non-responders were proposed to be treated with open-label Sarilumab 200 mg q2w in open-label treatment period (Part-C).
89585705|NCT01900431|Experimental|Sarilumab 200 mg q2w|Sarilumab 200 mg SC injection q2w for 16 weeks during principal treatment period (Part A) with background therapy of Prednisone (or equivalent oral corticosteroid) ≥15 mg/day and <80 mg/day as single therapy or in combination with MTX 10 to 25 mg/week and folic acid per local prescribing practice. Responders continued with the same treatment regimen up to Week 50 during extension treatment period (Part B) and non-responders were proposed to be treated with open-label Sarilumab 200 mg q2w in open-label treatment period (Part-C).
89585706|NCT01948791|Experimental|ENA713|Patients had a dose escalation from 3mg/d to 12mg/d to reach individual tolerated dosage during the titration period of 12 weeks.
89585707|NCT01899729|Experimental|IMO-8400 Regimen 1|IMO 8400 at 0.075 mg/kq q wk x 12 wks
89585708|NCT01899729|Experimental|IMO-8400 Regimen 2|IMO-8400 at 0.15 mg/kg q wk x 12 wks
89585709|NCT01899729|Experimental|IMO-8400 Regimen 3|IMO_8400 at 0.3 mg/kg q wk x 12 wks
89585710|NCT01899729|Placebo Comparator|Placebo|Saline (placebo) q wk x 12 wks
89585711|NCT01899729|Experimental|IMO-8400 Regimen 4|IMO_8400 at 0.6 mg/kg q wk x 12 wks
89585712|NCT01898091|Experimental|Neem Mouthrinse|Participants will rinse for 30 seconds with the measured 10ml dose of the assigned study mouthrinse, three times per day, for approximately 7 weeks during radiation therapy.
89585713|NCT01898091|Placebo Comparator|Placebo Mouthrinse|Participants will rinse for 30 seconds with the measured 10ml dose of the assigned study mouthrinse, three times per day, for approximately 7 weeks during radiation therapy.
89585714|NCT01947855|Experimental|Empagliflozin low dose|Empagliflozin low dose tablet once daily
89585715|NCT01947855|Experimental|Empagliflozin high dose|Empagliflozin high dose tablet once daily
89585716|NCT01947855|Placebo Comparator|Placebo|Placebo tablet once daily
89585717|NCT01888965|Experimental|Dovitinib|Dovitinib 500 mg orally daily for 5 days followed by 2 days off (7 day cycles) for up to 2 years
89585718|NCT01888497|Experimental|Arm A|
89585719|NCT01888497|Experimental|Arm B|
89585720|NCT01888497|Active Comparator|Arm C|
89585721|NCT01888497|Placebo Comparator|Arm D|
89585722|NCT01505530|Experimental|300 mg LY2495655 + chemotherapy|300 mg LY2495655 intravenous (IV) in combination with standard of care chemotherapy (investigator's choice)
89585723|NCT01505530|Experimental|100 mg LY2495655 + chemotherapy|100 mg LY2495655 intravenous (IV) in combination with standard of care chemotherapy (investigator's choice)
89585724|NCT01505530|Placebo Comparator|Placebo + chemotherapy|Placebo in combination with standard of care chemotherapy (investigator's choice)
89585725|NCT01485796|Experimental|Epoch 1 and Epoch 2|In Study Epoch 1 PIDD patients that are already on intravenous treatment or subcutaneous treatment will be enrolled and treated with IGI, 10% and rHuPH20 subcutaneously, with a short dose/interval ramp-up (Epoch 1) consisting of one 1-week dose and interval and one 2-week dose and interval. The ramp-up (Epoch 1) is followed by Epoch 2 which consists of approximately 6 months (24 weeks) of IGI, 10% and rHuPH20 treatment. For subjects pretreated intravenously (IV), this treatment will occur every 3 or 4 weeks (at a 3-week or 4-week dose, respectively), depending on the subject´s previous IV dosing schedule. For subjects pretreated subcutaneously (SC), treatment will also occur every 3 or 4 weeks (at a 3-week or 4-week dose, respectively), at the discretion of the investigator and subject.
89585726|NCT01505374|Experimental|Study Technique Left Leg, Control Technique Right Leg|
89585727|NCT01505374|Experimental|Study Technique Right Leg, Control Technique Left Leg|
89585728|NCT01897233|Experimental|Lumacaftor/Ivacaftor (LUM/IVA)|"Part A Cohort 1: Participants aged 6 through 8 years will receive LUM 200 milligram (mg) in fixed-dose combination with IVA 250 mg orally every 12 hours (q12h) for 14 days.~Part A Cohort 2: Participants aged 9 through 11 years will receive LUM 200 mg in fixed-dose combination with IVA 250 mg orally q12h for 14 days.~Part B: Participants aged 6 through 11 years will receive LUM 200 mg in fixed-dose combination with IVA 250 mg orally q12h for 24 weeks."
89585729|NCT01887717|Experimental|TheraSphere|Participants will receive TheraSphere at a dose consistent with the approved product label to the treated lobe of the liver. TheraSphere will be administered through the hepatic artery. The target dose will be 120 Gy + 10%. Dose reduction to a minimum dose of 80 Gy + 10% will be permitted to manage radiation exposure to the lungs. Re-treatment of the same participant/lobe with further cycles of TheraSphere will be permitted if a treatable progression is detected during follow-up evaluations. Any re-treatment will take place at least 28 days after the previous TheraSphere treatment administered to that lobe. Participants can receive a subsequent TheraSphere administration in the absence of radiological progression criteria at the Investigator's discretion. A maximum of 3 TheraSphere administrations will be permitted.
89585730|NCT01887717|Active Comparator|Sorafenib|Participants will receive sorafenib, oral tablets, 400 milligrams (mg) twice daily in accordance with the package insert. Treatment is to continue until the participant is no longer clinically benefiting from therapy or until unacceptable toxicity occurs. Medically appropriate dose adjustments and drug holidays due to adverse events (AEs) and toxicity will be allowed.
89585731|NCT01886781|Experimental|Lactobacillus plantarum 299v|Lactobacillus plantarum 299v capsules
89585732|NCT01886781|Placebo Comparator|Crytalline cellulose powder|Placebo capsule, filled with micro-crystalline cellulose powder
89585733|NCT01886781|No Intervention|Run in period|Run in period of one to two weeks, no treatment. At baseline randomization and treatment commenced.
89209695|NCT00808496|Experimental|MRI|Biannual disease progression monitoring with peripheral magnetic resonance imaging of the 2nd to 5th metacarpophalangeal joints of the worst-effected or dominant hand at baseline.
89209696|NCT00808496|Active Comparator|Radiography|Biannual disease progression monitoring with radiography of both hands and wrists.
89585734|NCT01886781|No Intervention|Wash out period|Wash out period of two weeks, no treatment.
89585735|NCT01463098|Experimental|Part A: E2006 1.0 mg|
89585736|NCT01463098|Experimental|Part A: E2006 2.5 mg|
89585737|NCT01463098|Experimental|Part A: E2006 5.0 mg|
89585738|NCT01463098|Experimental|Part A: E2006 10.0 mg|
89585739|NCT01463098|Experimental|Part A: E2006 25.0 mg|
89585740|NCT01463098|Experimental|Part A: E2006 50.0 mg|
89585741|NCT01463098|Experimental|Part A: E2006 100 mg|
89585742|NCT01463098|Experimental|Part A: E2006 200 mg|
89585743|NCT01463098|Experimental|Part B: Zolpidem 10 mg|
89585744|NCT01463098|Experimental|Part B: E2006 Matched Placebo or Zolpidem Matched Placebo|
89585745|NCT01463098|Experimental|Part A: E2006 Matched Placebo|
89585746|NCT01463098|Experimental|Part B: E2006 2.5 mg|
89585747|NCT01463098|Experimental|Part B: E2006 10 mg|
89585748|NCT01463098|Experimental|Part B: E2006 25 mg|
89585749|NCT01462942|Experimental|Aclidinium/Formoterol 400/6 μg|24 week, double blind treatment period
89585750|NCT01462942|Experimental|Aclidinium/Formoterol 400/12 μg|24 week, double blind treatment period
89585751|NCT01462942|Experimental|Aclidinium monotherapy 400 μg|24 week, double blind treatment period
89585752|NCT01462942|Active Comparator|Formoterol monotherapy 12 μg|24 week, double blind treatment period
89585753|NCT01462942|Placebo Comparator|Placebo|24 week, double blind treatment period
89209697|NCT00808496|Placebo Comparator|Standard of Care|Diagnostic imaging results (MRI or radiography) reported to upon requisition.
89585754|NCT01462630|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive pazopanib hydrochloride PO QD. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89209698|NCT00814736|Experimental|UK369,003 + Placebo or sildenafil|All subjects will receive 17 days daily dosing of UK-369,003 100 mg MR Subjects will receive single oral doses of the following interactant treatments in a randomized order On Day 14, a single dose of sildenafil-matching placebo or 100 mg sildenafil and on Day 17 a single dose of 100 mg sildenafil or a sildenafil matching placebo
89585755|NCT01504204|Experimental|Medication with sample and demonstration|Subjects will receive a sample tube of the Adapalene + benzoyl peroxide samples with demonstration of how to use it at the first visit.
89585756|NCT01504204|Active Comparator|Medication without samples|Subjects will receive the Adapalene + benzoyl peroxide from standard tube without a sample or demonstration of proper use of the medication.
89585757|NCT01485640|Experimental|Lurasidone|Lurasidone flexibly dosed
89585758|NCT04744987||Hypovolemic hyponatremia|Patients with any cause of hypovolemic hyponatremia were included.
89585759|NCT04744987||Euvolemic hyponatremia|Only patients with euvolemic hyponatremia secondary to Syndrome of inappropriate antidiuresis were included.
89585760|NCT04744207|Experimental|GS-248|GS-248, capsule, 120 mg, once daily for 4 weeks
89209699|NCT00814814||Cardiopulmonary arrest|
89209700|NCT00818090|Experimental|TP|paclitaxel and cisplatin every 3 weeks
89209701|NCT00642356|Experimental|Carbidopa/levodopa/entacapone|
89209702|NCT00642356|Active Comparator|Immediate release carbidopa/levodopa|
89585761|NCT04744207|Placebo Comparator|Placebo|placebo, capsule, once daily for 4 weeks
89209703|NCT00642278|Experimental|Canagliflozin 50 mg daily|Each patient will receive 50 mg of canagliflozin (JNJ-28431754) once daily (in the morning) for 12 weeks with matching placebo once daily (in the evening).
89209704|NCT00642278|Experimental|Canagliflozin 100 mg daily|Each patient will receive 100 mg of canagliflozin (JNJ-28431754) once daily (in the morning) for 12 weeks with matching placebo once daily (in the evening).
89209705|NCT00642278|Experimental|Canagliflozin 200 mg daily|Each patient will receive 200 mg of canagliflozin (JNJ-28431754) once daily (in the morning) for 12 weeks with matching placebo once daily (in the evening).
89209706|NCT00642278|Experimental|Canagliflozin 300 mg daily|Each patient will receive 300 mg of canagliflozin (JNJ-28431754) once daily (in the morning) for 12 weeks with matching placebo capsule once daily (in the evening).
89209707|NCT00642278|Experimental|Canagliflozin 300 mg twice daily|Each patient will receive 300 mg of canagliflozin (JNJ-28431754) twice daily for 12 weeks.
89209708|NCT00642278|Active Comparator|Sitagliptin 100 mg daily|Each patient will receive 100 mg of sitagliptin once daily (in the morning) for 12 weeks with matching placebo once daily (in the evening).
89209709|NCT00642278|Placebo Comparator|Placebo|Each patient will receive matching placebo twice daily for 12 weeks.
89209710|NCT00808574|Experimental|Intervention|Brief, theory-based, online assessment of OSA risk followed by risk-tailed OSA presentation.
89585762|NCT02118961|Experimental|BK1301|
89585763|NCT02118961|Active Comparator|DT toxoid|
89585764|NCT02140645||Linagliptin1|T2DM patients initiating Linagliptin (DPP-4 comparison)
89585765|NCT02140645||Other DPP4|T2DM patients initiating a non-linagliptin DPP-4 inhibitor
89585766|NCT02140645||Linagliptin2|T2DM patients initiating Linagliptin (glitizaone comparison)
89585767|NCT02140645||Glitazones|T2DM patients initiating Thiazolidinediones (glitazones)
88975068|NCT00036764|Experimental|Treatment|Patients receive BMS-247550 IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88975069|NCT00036881|Experimental|zinc sulfate|"Patients receive oral zinc sulfate 3 times daily beginning the first week of radiotherapy.~Treatment continues daily during and for 1 month after radiotherapy in the absence of unacceptable toxicity.~Quality of life is assessed at baseline, weekly during treatment, and then at 1, 2, 3, and 6 months after the completion of treatment.~Patients are followed at 1, 2, 3, and 6 months after the completion of treatment and then every 6 months for 1 year."
88975070|NCT00036881|Placebo Comparator|placebo|"Patients receive oral placebo 3 times daily beginning the first week of radiotherapy.~Treatment continues daily during and for 1 month after radiotherapy in the absence of unacceptable toxicity.~Quality of life is assessed at baseline, weekly during treatment, and then at 1, 2, 3, and 6 months after the completion of treatment.~Patients are followed at 1, 2, 3, and 6 months after the completion of treatment and then every 6 months for 1 year."
89209711|NCT00808574|No Intervention|Control|No risk assessment or presentation
89209712|NCT02551016||Primary care only|Patients with heart failure recorded in primary care and never hospitalized for heart failure
89209713|NCT02551016||Primary care and secondary care|Patients with heart failure recorded in primary care with at least one record of a heart failure related hospitalization.
89209714|NCT02551016||Secondary care only|Patients with heart failure recorded in at least one heart failure related hospitalization without a concurrent primary care record.
89585768|NCT02140645||Sulfonylurea|T2DM patients initiating any medication in the Sulfonylurea class
89585769|NCT02140645||Linagliptin3|T2DM patients initiating Linagliptin (Sulfonylurea comparison)
89585770|NCT02140567||Syncope Prediction|All enrolled patients that performed the tilt table test
89585771|NCT02140411|Experimental|Ranibizumab|Ranibizumab treatment
89585772|NCT02139943|Experimental|Canagliflozin 100 mg|Each participant will receive 100 mg of canagliflozin once daily for 18 weeks.
89585773|NCT02139943|Experimental|Canagliflozin 300 mg|Each participant will receive 300 mg of canagliflozin once daily for 18 weeks.
89585774|NCT02139943|Placebo Comparator|Placebo|Each participant will receive matching placebo once daily for 18 weeks
89585775|NCT01485172|Experimental|ropinirole|ropinirole 2, 4, 8, 12, or 24 mg/day
89585776|NCT01485172|Placebo Comparator|placebo|placebo comparator 2, 4, 8, 12, or 24 mg/day
89585777|NCT02105701|Experimental|Grazoprevir + Elbasvir 12 weeks|Participants receive grazoprevir 100 mg/elbasvir 50 mg fixed-dose combination (FDC) tablets once daily (q.d.) by mouth for 12 weeks.
89585778|NCT02105701|Experimental|Grazoprevir + Elbasvir + RBV 12 weeks|Participants receive grazoprevir 100 mg/elbasvir 50 mg FDC tablets q.d. by mouth, along with RBV capsules twice daily (b.i.d.) by mouth (weight-based dosing; 800 to 1400 mg total daily dose), for 12 weeks.
89585779|NCT02105701|Experimental|Grazoprevir + Elbasvir 16 weeks|Participants receive grazoprevir 100 mg/elbasvir 50 mg FDC tablets q.d. by mouth for 16 weeks.
89585780|NCT02105701|Experimental|Grazoprevir + Elbasvir + RBV 16 weeks|Participants receive grazoprevir 100 mg/elbasvir 50 mg FDC tablets q.d. by mouth, along with RBV capsules b.i.d. by mouth (weight-based dosing; 800 to 1400 mg total daily dose), for 16 weeks.
89585781|NCT04411225|Experimental|Cannabidiol Augmentation|The cannabidiol will be administered as an oral solution to be mixed in any fluid. The formulation is 100 mg/ml. It will be administered at 500 mg at bedtime X 1 week then 500 mg BID.
89585782|NCT04411225|Placebo Comparator|Placebo Augmentation|Placebo will appear identical to the cannabidiol solution
89585783|NCT04743349|Experimental|Experimental arm|Steam inhalations
89585784|NCT04743349|No Intervention|Control arm|No intervention
89585785|NCT04742413||A|Patients who are prescribed to switch to lurasidone (lurasidone cohort)
89585786|NCT04742413||B|Patients who are prescribed to switch to any other monotherapy SGA (other SGA cohort)
89585787|NCT01502956|Active Comparator|InterStim® device|The FSLP InterStim® device is to be done within 3 months of enrolling/consenting. The 1st stage is lead placement into the S3 foramen with best response to stimulation. The 4 electrodes will be tested and set to an amplitude that achieves comfortable stimulation in the vaginal, perineal, or rectal sensation. If =/>50% improvement, participant will then have the 2nd stage IPG implantation, 8-18 days after last FSLP. If there is a technical problem with lead on 1st FSLP, then the participant can have a 2nd FSLP and may go on to have IPG implantation with lead replacement. The 2nd FSLP must be initiated no longer than 1 month since the initiation of the 1st FSLP. If the participant is a non-responder and there is no technical problem, then the lead is removed.
89585788|NCT01502956|Active Comparator|Botox® injection|Total of 200 units of Botox A will be dissolved into 10mL of saline and injected into the bladder within 3 months of enrolling/consenting. Participants determined to have a clinical response at the 1 month visit (post 1st injection) may receive additional injections between 6-24 months.
89585789|NCT01502644|Active Comparator|Low Negative Affect (NA)|Participants with low NA (HADS score ≤5 on each subscale) received placebo or active opioid drug (immediate-release morphine 15 to 30 mg or oxycodone 5 to 10 mg) up to three times a day as needed for 1 week each in random order, followed by morphine or oxycodone titrated to a maximum allowable daily dose in morphine equivalents of 30 mg for short-acting medication and 60 mg for long-acting medication, respectively, three times a day for up to 20 weeks, followed by morphine or oxycodone tapering (individualized opioid dose was decreased by approximately 25% each week) for 4 weeks.
89585790|NCT01502644|Active Comparator|Moderate NA|Participants with moderate NA (HADS score ≥6 to ≤8 on each subscale) received placebo or active opioid drug (immediate-release morphine 15 to 30 mg or oxycodone 5 to 10 mg) up to three times a day as needed for 1 week each in random order, followed by morphine or oxycodone titrated to a maximum allowable daily dose in morphine equivalents of 30 mg for short-acting medication and 60 mg for long-acting medication, respectively, three times a day for up to 20 weeks, followed by morphine or oxycodone tapering (individualized opioid dose was decreased by approximately 25% each week) for 4 weeks.
89585791|NCT01502644|Active Comparator|High NA|Participants with high NA (HADS score ≥9 on each subscale) received placebo or active opioid drug (immediate-release morphine 15 to 30 mg or oxycodone 5 to 10 mg) up to three times a day as needed for 1 week each in random order, followed by morphine or oxycodone titrated to a maximum allowable daily dose in morphine equivalents of 30 mg for short-acting medication and 60 mg for long-acting medication, respectively, three times a day for up to 20 weeks, followed by morphine or oxycodone tapering (individualized opioid dose was decreased by approximately 25% each week) for 4 weeks.
89585792|NCT04408378||mild pneumonia|The patients who has followed in the ward
89585793|NCT04408378||severe pneumonia|The patiens who has followed in the intensive care unit
89585794|NCT04408378||control group|patients who has not covid 19 pneumonia
89585795|NCT01462318|Experimental|DAC HYP|"DAC HYP 150 mg by a subcutaneous (SC) injection using the pre-filled syringe (PFS) every 4 weeks for 24 weeks followed by a 20-week washout period. After completion of the washout period, participants may resume monthly DAC HYP 150 mg using the PFS for up to 3 additional years.~Participants in the TP-DI sub-study will receive probe-drug cocktail administration at Weeks 43 and 53. The probe-drug cocktail consists of oral midazolam 5 mg, caffeine 200 mg, S-warfarin 10 mg, vitamin K 10 mg, omeprazole 40 mg, and dextromethorphan 30 mg. The oral vitamin K is used to counteract warfarin's anticoagula nt effect prophylactically."
89585796|NCT01485094|Placebo Comparator|Matching placebo|Oral administration. Pain not sufficiently controlled may be treated with acetaminophen.
89585797|NCT01485094|Experimental|GRT6010|Oral administration. Pain not sufficiently controlled may be treated with acetaminophen.
89585798|NCT01485094|Active Comparator|Pregabalin|Oral administration. Pain not sufficiently controlled may be treated with acetaminophen.
89585799|NCT04079686|Experimental|Cephazolin|Patients will receive antibiotics (1g cephazolin) intravenously at the anesthestic induction and every 6 hours for 24 hours
88975071|NCT00063804|Experimental|1|escalating single doses of AMD070 ranging from 1/4 to 1 times the maximum tolerated dose (MTD)
88975072|NCT00063804|Experimental|2|single dose of 200 mg AMD070 after eating a standardized meal
88975073|NCT00063804|Experimental|3|single dose of 200 mg AMD070 on Days 1, 3, and 17 and single dose of 100 mg ritonavir on Days 3 through 18
88975074|NCT02967432|Experimental|Mupirocin|
88975075|NCT02967432|Placebo Comparator|Petroleum jelly|
88975076|NCT00063960|Experimental|floxuridine + irinotecan|"Within 4-8 weeks after prior resection or ablation, patients receive hepatic arterial infusion of floxuridine continuously on days 1-14 and irinotecan IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for 6 courses in the absence of unacceptable toxicity.~Patients are followed every 3 months for 2 years."
88975077|NCT04732442|Experimental|Immuno-group|The immuno-group will consist of patients who, as part of preoperative nutritional support, used immunonutrition ONS (2x Impact Oral® Nestle, Switzerland per day) for 2 weeks before surgery.
88975078|NCT04732442|Sham Comparator|Control-group|The control group will consist of patients who, as part of preoperative nutritional support, used standard ONS (3x Fortimel Compact Protein® Nutricia, United Kingdom per day) for 2 weeks before surgery.
88975079|NCT00064116|Active Comparator|Arm A: CHOP-21|Cyclophosphamide 750 mg/m² i.v. day 1 Doxorubicin 50 mg/m² i.v. day 1 Vincristine 2 mg (abs.) i.v. day 1 Prednisone 100 mg/d p.o. days 1 to 5 Recycle: day 22 Total number of cycles 6
88975080|NCT00064116|Active Comparator|Arm B: CHOP-21 + Rituximab|Rituximab 375 mg/m² i.v. day 1* Cyclophosphamide 750 mg/m² i.v. day 1 Doxorubicin 50 mg/m² i.v. day 1 Vincristine 2 mg (abs.) i.v. day 1 Prednisone 100 mg/d p.o. days 1 to 5 Recycle day 22 Total number of cycles: 6
89585800|NCT04079686|Placebo Comparator|Sterile saline|Patients will receive antibiotics (cephazolin) only at the anesthesia induction, and sterile saline intravenously every 6 hours for 24 hours
89585801|NCT01484938|Experimental|OPTI-FREE|OPTI-FREE PureMoist multi-purpose contact lens solution used for cleaning, rinsing, disinfecting/storing, and reinserting contact lenses, per protocol-specified regimen
89585802|NCT01502410|Experimental|Group 1 Relapsed/Refractory Rhabdomyosarcoma|"Patients with relapsed or refractory rhabdomyosarcoma receive sorafenib tosylate PO BID on days 1-28. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.~sorafenib tosylate: Given PO dosage 200 mg/m2/dose (max dose:400 mg/dose) given every 12 hours on days 1-28~pharmacological study: Optional correlative studies~laboratory biomarker analysis: Optional correlative studies"
89585803|NCT01502410|Experimental|Group 2 Relapsed/Refractory Wilms tumor|"Patients with relapsed or refractory Wilms tumor receive sorafenib tosylate PO BID on days 1-28. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.~sorafenib tosylate: Given PO dosage 200 mg/m2/dose (max dose:400 mg/dose) given every 12 hours on days 1-28~pharmacological study: Optional correlative studies~laboratory biomarker analysis: Optional correlative studies"
89585804|NCT01502410|Experimental|Group 3 Relapsed/Refractory hepatocellular carcinoma|"Patients with relapsed or refractory hepatocellular carcinoma receive sorafenib tosylate PO BID on days 1-28. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.~sorafenib tosylate: Given PO dosage 200 mg/m2/dose (max dose:400 mg/dose) given every 12 hours on days 1-28~pharmacological study: Optional correlative studies~laboratory biomarker analysis: Optional correlative studies"
89585805|NCT01502410|Experimental|Group 4 Papillary thyroid carcinoma|"Patients with relapsed or refractory papillary thyroid carcinoma receive sorafenib tosylate PO BID on days 1-28. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.~sorafenib tosylate: Given PO dosage 200 mg/m2/dose (max dose:400 mg/dose) given every 12 hours on days 1-28~pharmacological study: Optional correlative studies~laboratory biomarker analysis: Optional correlative studies"
89585806|NCT01462162||Rheumatoid Arthritis Participants|Participants with moderate to severe rheumatoid arthritis (RA) who have been considered and proposed by the rheumatologist to start treatment with Tocilizumab (RoActemra) according to the indications of the summary of product characteristics of the product and the standard clinical practice of each participating center will be followed-up for 6 months.
89585807|NCT01483924|Experimental|10 mg Apo805K1, or placebo|
89585808|NCT01483924|Experimental|30 mg Apo805K1, or placebo|
89585809|NCT01483924|Experimental|60 mg Apo805K1, or placebo|
89585810|NCT01483924|Experimental|100 mg Apo805K1, or placebo|
89585811|NCT01462084|Experimental|Adaptive Servo-Ventilation (ASV) then BiLevel PAP|Adaptive servo-ventilation (ASV) is a form of positive airway pressure (PAP) that is delivered based on the needs of the individual. ASV adjusts to the breathing events the individual is experiencing and provides enough PAP to resolve the breathing event. This is a crossover study, so all patients enter both treatment groups.
89585812|NCT01462084|Experimental|Bi-Level PAP then Adaptive Servo-Ventilation (ASV)|Bi-level pressure delivers two pressures, IPAP and EPAP. Both pressures are fixed and do not adjust based on the individuals breathing events. This is a crossover study, so all patients enter both treatment groups.
89585813|NCT02134028|Experimental|dupilumab treatment|"For participants coming from the DRI12544 study: dupilumab loading dose subcutaneous (SC) on Day 1, followed by 1* Dose every 2 weeks added to current controller medications.~For participants coming from other studies: dupilumab 1 * Dose SC every 2 weeks added to current controller medications."
89585814|NCT04752488|Experimental|Telerehabilitation (TR) Group|The TR group will be followed up through the video-based exercise software within the 8-week home exercise program.
89585815|NCT04752488|Active Comparator|Conventional Rehabilitation (CR) Group|The CR group will be trained face-to-face with conventional methods before the 8-week home exercise program, and an exercise program will be prescribed with a visual information form.
89585816|NCT02172950|Experimental|Previously treated patients (PTPs)|The investigator will assign subjects to either prophylaxis or on-demand treatment regimens for rVIII-SingleChain by intravenous injection. The investigator will determine the rVIII-SingleChain dose and dosing schedule for the subject based upon the subject's pharmacokinetic (PK) profile, rVIII-SingleChain PK data, previous FVIII treatment regimen, and bleeding phenotype, if available.
89585817|NCT02172950|Experimental|Previously untreated patients (PUPs)|The investigator will assign subjects to either prophylaxis or on-demand treatment regimens for rVIII-SingleChain by intravenous injection. The investigator will determine the rVIII-SingleChain dose and dosing schedule at their discretion, taking into consideration the World Federation of Hemophilia (WFH) guidelines, the type of bleeding episode, location of the bleeding, subject's age, and other disease characteristics.
89585818|NCT02151266|Experimental|Exercise and Cognitive retraining|Aerobic exercise; Computerized cognitive retraining program; Heart failure education; Home visits; telephone follow-up.
89585819|NCT02151266|Experimental|Exercise only|Each participant will be provided with an individualized target heart rate (THR)zone based on treadmill results. Under the supervision of a research nurse, participants will begin the walking sessions at 60% of THR and increase to 70% by week 5. Participants will walk a minimum of 5 times per week for a duration of 30 minutes.
89585820|NCT02151266|Sham Comparator|Stretching and Flexibility|Stretching and flexibility movements; heart failure education; home visits; telephone follow-up.
89209715|NCT00543543|Experimental|Low-dose V503|V503 (9-Valent Human Papillomavirus [HPV] Vaccine) low-dose 0.5 mL injection in a 3-dose regimen in the base study.
89209716|NCT00543543|Experimental|Mid-dose V503|V503 (9-Valent HPV Vaccine) mid-dose 0.5 mL injection in a 3-dose regimen in the base study. A subset of participants (Cohort 1) received a fourth V503 mid-dose vaccination in the extension study.
89209717|NCT00543543|Experimental|High-dose V503|V503 (9-Valent HPV Vaccine) high-dose 0.5 mL injection in a 3-dose regimen in the base study.
89209718|NCT00543543|Active Comparator|Gardasil|Gardasil (4-Valent HPV Vaccine) 0.5 mL injection in a 3-dose regimen in the base study. Participants (Cohort 2) were offered the V503 mid-dose 3-dose regimen in the extension study.
89209719|NCT00645164|Experimental|Xenaderm|Subject serves as own control
89585821|NCT02151110|Placebo Comparator|Placebo|Participants received single IV dose of placebo matching with MEDI4920 infused on Day 1.
89585822|NCT02151110|Experimental|MEDI4920 3 mg|Participants received single IV dose of MEDI4920 3 milligram (mg) infused on Day 1.
89585823|NCT02151110|Experimental|MEDI4920 10 mg|Participants received single IV dose of MEDI4920 10 mg infused on Day 1.
89585824|NCT02151110|Experimental|MEDI4920 30 mg|Participants received single IV dose of MEDI4920 30 mg infused on Day 1.
89585825|NCT02151110|Experimental|MEDI4920 100 mg|Participants received single IV dose of MEDI4920 100 mg infused on Day 1.
89585826|NCT02151110|Experimental|MEDI4920 300 mg|Participants received single IV dose of MEDI4920 300 mg infused on Day 1.
89585827|NCT02151110|Experimental|MEDI4920 1000 mg|Participants received single IV dose of MEDI4920 1000 mg infused on Day 1.
89585828|NCT02151110|Experimental|MEDI4920 3000 mg|Participants received single IV dose of MEDI4920 3000 mg infused on Day 1.
89585829|NCT04749680|Experimental|Peritoneal dialysis PD|Treatment for 2 weeks either with the comparators PD-Night or Homechoice PD cycler depending on the previous treatment (clinical phase I). At the end of these 2 treatment weeks and a subsequent training phase which up to 3 weeks, treatment with the Silencia PD cycler for 2 further weeks (clinical phase II).
89585830|NCT02132312|Experimental|OMS302|OMS302 diluted in balanced salt solution (BSS) and administered as irrigation solution
89585831|NCT02132312|Active Comparator|Phenylephrine HCl|Phenylephrine diluted in balanced salt solution (BSS) and administered as irrigation solution
89585832|NCT02131766|Experimental|USS Virginia Closed Loop Control|"The subject will be admitted to the research house/hotel and will be discharged after 5 nights. The subject will be trained on DiAs and on how to respond to the system's alerts. The DiAs will be initiated by 11:00 PM and will be discontinued before breakfast. The staff will be monitoring the subject remotely. The subject will need to remain within a 30 miles of the research house/hotel during the day and return by 6:00 PM.~A limited number of UVA and UPadova subjects will be asked to wear the DiAs at home for 5 days at the conclusion of research house admission."
89209720|NCT00815048|Active Comparator|Remifentanil|"Atropine~Remifentanil"
89209721|NCT00815048|Placebo Comparator|Fentanyl|"Atropine~Fentanyl~Succinylcholine"
89585833|NCT02131766|Placebo Comparator|Sensor Augmented Pump Therapy|The subject will wear the continuous glucose monitor with the study insulin pump for a full 7 day period (approximately 7 consecutive 24 hour periods). The subject will follow their usual regimen. The subject will be asked to use the bolus calculator function on your insulin pump and enter the carbohydrate information that you eat during the week.
89585834|NCT02150954|Active Comparator|foley bulb induction with low dose pitocin|Subjects in this arm will receive a standard infusion protocol of pitocin starting at 1 milliunit/minute (mius/min) and increasing 2 milliunits per minute every 30 minutes.
89585835|NCT02150954|Active Comparator|foley bulb with standard incremental pitocin infusion protocol|Subjects in this arm will receive a fixed low dose pitocin infusion protocol of 2 mius/min.
89585836|NCT04757012|Experimental|Calinage exposition|exposition to a maternal voice and heartbeat recording during hospital stay for preterm newborns at D2, D4 and D6
89585837|NCT04757012|No Intervention|no exposition|No exposition to a maternal voice and heartbeat recording during hospital stay for preterm newborns at D1, D3 and D5
89585838|NCT02131532|Experimental|Psychological intervention|"This is a brief psychological intervention which targets patients' mood, their beliefs about their ability to overcome fatigue, and the scheduling of daily activities, with an aim to increase physical activities in daily life and finally reduce the level of fatigue.~Each participant will meet a therapist in six face-to-face sessions. Each session will be about one hour and be two weeks apart. During the sessions, the participant will discuss with the therapist their problems related to fatigue and work through an intervention manual to learn skills to overcome these problems."
89585839|NCT04188392|Experimental|open-label treatment|pimavanserin 34mg at bedtime for 6 weeks
89585840|NCT02170688|Active Comparator|Fixed dose|50 subjects will receive contrast media based on a fixed dose. Each will receive 125 mL of Isovue 370 (370 mg of iodine/mL) administered at 4 mL/sec (1.48 gmI/sec for 31.25 sec).
89585841|NCT02170688|Active Comparator|Total body weight|25 subjects will receive contrast media dose based on the total body weight. Total body weight will be determined. Both men and women will receive contrast media at a dose of 0.7 gmI/kg (1.78 mL of Isovue 370/kg) or 0.30 gmI/lb (0.81 mL of Isovue 370/lb). The injection rate will be 0.058 mL/sec/kg (0.026 mL/sec/lb).
89209722|NCT02551796|Experimental|lenticule extraction|The patients in this group chose to receive the lenticule extraction surgery.
89209723|NCT02551796|Experimental|laser in situ keratomileusis|The patients in this group chose to receive the laser in situ keratomileusis surgery.
89209724|NCT02551796|Experimental|FS assisted laser in situ keratomileusis|The patients in this group chose to receive the FS assisted laser in situ keratomileusis surgery.
89209725|NCT02551484|Experimental|Procedure 1|Measures with 60 minutes interval during the consultation of equipment, functional testing, receuil pain.
89209726|NCT02551484|Experimental|Procedure 2|Measuring J15, J30 J 45 and after the different settings functional amputation, pain and tissue oxygenation.
89209727|NCT00723125|Experimental|Cohort 1|"Avastin 10 mg/kg IV over 90 minutes day -14~Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks with Carboplatin at AUC 6 over 30 min IV and Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10~Avastin 10 mg/kg IV over 30-60 minutes cycles 1-3 (omit dose with cycle 4) Doxorubicin 60 mg/m2* and Cyclophosphamide 600 mg/m2 IV q2weeks x 4 cycles~Definitive surgery~Avastin 10 mg/kg IV over 30-60 minutes q2weeks x 34 weeks"
89585842|NCT02170688|Active Comparator|Calculated lean body weight|"25 subjects will receive contrast media dose based on the calculated lean body weight. Total body weight and height will be determined. From this data the lean body weight will be calculated.~Men will receive a dose of 0.86 gmI / kg LBW (2.32 mL of Isovue 370/kg at 0.074 mL/sec/kg) or 0.39 gmI/lb LBW (1.05 mL of Isovue 370/lb at 0.034 mL/sec/lb). Women will receive a dose of 0.92 gmI/kg LBW (2.49 mL of Isovue 370/kg at 0.080 mL/sec/kg) or 0.42 gmI/lb LBW (1.13 mL of Isovue 370/kg at 0.036 mL/sec/kg)."
89585843|NCT02170688|Active Comparator|Measured lean body weight|"50 subjects will receive contrast media dose based on the measured lean body weight. Lean body weight will be determined using the Tanita body composition/analyzer scales. From this data the lean body weight will be calculated.~Men will receive a dose of 0.86 gmI / kg LBW (2.32 mL of Isovue 370/kg at 0.074 mL/sec/kg) or 0.39 gmI/lb LBW (1.05 mL of Isovue 370/lb at 0.034 mL/sec/lb). Women will receive a dose of 0.92 gmI/kg LBW (2.49 mL of Isovue 370/kg at 0.080 mL/sec/kg) or 0.42 gmI/lb LBW (1.13 mL of Isovue 370/kg at 0.036 mL/sec/kg)."
89585844|NCT02170688|Active Comparator|Estimated lean body (eLBW) weight|25 subjects will receive contrast media dose based on the estimated lean body (eLBW) weight. Estimated lean body weight will be determined by using a unique software program which measures the sum of the posterior to anterior attenuation from the digital scout radiograph (abbreviated as sqrt PA) obtained during the standard planning scan of the abdominal/pelvic CT. Men will receive a dose of 0.86 gmI / kg eLBW (2.32 mL of Isovue 370/kg at 0.074 mL/sec/kg) or 0.39 gmI/lb eLBW (1.05 mL of Isovue 370/lb at 0.034 mL/sec/lb). Women will receive a dose of 0.92 gmI/kg eLBW (2.49 mL of Isovue 370/kg at 0.080 mL/sec/kg) or 0.42 gmI/lb eLBW (1.13 mL of Isovue 370/kg at 0.036 mL/sec/kg).
89585845|NCT02170298|Placebo Comparator|Placebo|"Participants may be randomized into the placebo comparator arm. Participants in this group will be given a sugar pill titrated up to 70 mg daily over the course of 9 weeks.~Drug: Placebo"
89585846|NCT02170298|Experimental|Lisdexamfetamine|"Participants may be randomized into the experimental arm. Participants in this arm will be given lisdexamfetamine titrated up to 70 mg daily over the course of 9 weeks.~Drug: Lisdexamfetamine"
89585847|NCT02131064|Active Comparator|Trastuzumab (TCH) + Pertuzumab|Participants will receive pertuzumab 840 milligrams (mg) (loading dose) and 420 mg (maintenance dose) intravenous (IV) infusion followed by trastuzumab 8 milligrams per kilogram (mg/kg) (loading dose) and 6 mg/kg (maintenance dose) IV infusion followed by docetaxel 75 milligrams per square meter (mg/m^2) IV infusion and carboplatin at a dose to achieve an area under the curve (AUC) of 6 milligrams per milliliter* minute (mg/mL*min) IV infusion every 3 weeks (q3w) for 6 cycles in neoadjuvant period. Participants will receive pertuzumab 840 mg (loading dose) and 420 mg (maintenance dose) IV infusion followed by trastuzumab 8 mg/kg (loading dose) and 6 mg/kg (maintenance dose) IV infusion q3w for rest of the cycles (12 cycles) in adjuvant period (up to a total of 18 cycles).
89585848|NCT02131064|Experimental|Trastuzumab Emtansine (T-DM1) + Pertuzumab|Participants will receive pertuzumab 840 mg (loading dose) and 420 mg (maintenance dose) IV infusion followed by trastuzumab emtansine 3.6 mg/kg IV infusion q3w for a total of 18 cycles (6 cycles of neoadjuvant period and 12 cycles of adjuvant period).
89585849|NCT02130986|Experimental|Procalcitonin (PCT) group|Procalcitonin (PCT) level; Results of procalcitonin level to treating clinician; Provide procalcitonin guideline to treating clinician; Telephone Visit at Day 15 and Day 30
89585850|NCT02130986|Active Comparator|Usual Care group|Telephone Visit at Day 15 and Day 30
89585851|NCT02130284|Experimental|Predictive Low Glucose Management (PLGM)|To evaluate the safety of the Predictive Low Glucose Management feature in insulin pump algorithm with the Enlite 3 Sensor
89585852|NCT04748822|Other|Quality of life of patients with AUD.|Patients' demographic data, socioeconomic status, physical diseases, medication use, clinical features of AUD, psychiatric variables, impulsivity, autonomy, sexual functioning, sleep quality, and cognitive functioning will be measured at baseline. The Alcohol Quality of Life Scale (AQoLS) will be completed at baseline and at 6-month follow-up. Alcohol status (relapse/abstinence) will be assessed at 6 months.
89585853|NCT02147288|Experimental|Breast Recon with acellular dermal matrix (ADM) on NPWT|
89209728|NCT00723125|Experimental|Cohort 2|"Abraxane 100 mg/m2 IV over 30 minutes days -14 and -7~Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks with Carboplatin at AUC 6 over 30 min IV and Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7~Definitive surgery~Avastin 10 mg/kg IV over 30-60 minutes and Doxorubicin 60 mg/m2* and Cyclophosphamide 600 mg/m2 IV q2weeks x 4 cycles followed by Avastin 10 mg/kg IV over 30-60 minutes q2weeks x 34 weeks OR Avastin 10 mg/kg IV over 30-60 minutes q2weeks x 42 weeks"
89209729|NCT00815126|Active Comparator|Mucocutaneous symptoms from NSAIDs|
89209730|NCT00815126|Active Comparator|Respiratory symptoms from NSAIDs|
88975081|NCT02971085||Active surveillance|This is the prospective cohort study with single group of active surveillance. We define our cohort group as the patients with following criteria: Men < 80 years, pathologically proven adenocarcinoma of the prostate by transrectal prostate biopsy ≥ 10 cores, pre-biopsy PSA ≤ 10ng/ml, PSA density < 0.15 ng/ml/ml, clinical stage T1-2a, biopsy Gleason score ≤ 6, number of positive cores ≤ 2, maximum cancer involvement in any one core ≤ 20%, and no PIRADS 5 lesion on multiparametric prostate MRI (1.5T or 3T).
88975082|NCT02967237|Experimental|Insulin glargine (U300)|Type 2 diabetes mellitus patients uncontrolled with their current basal insulin therapy switched according to the physician decision, to insulin glargine (U300) administered subcutaneously and once daily using a pre-filled pen
88975083|NCT02958540|Experimental|SynGEM low dose|Group 1: 18 subjects receiving SynGEM low dose
88975084|NCT02958540|Experimental|SynGEM high dose|Group 2: 18 subjects receiving SynGEM high dose
89209731|NCT00815126|Active Comparator|NSAIDs tolerant individuals|
89209732|NCT00818402||Non-small cell lung cancer patients|
89209733|NCT02594189|Other|1|The human challenge virus will be administered intranasally to each participant using a nasal sprayer. A total volume of up to 2mL of virus will be administered.
89585854|NCT02147288|Experimental|Lipoabdominoplasty on NPWT|The Smith&Nephew Renasys*GO device connected to non-compressible drains will be applied to the lipoabdominoplasty patients enrolled in this arm.
89585855|NCT02147288|Experimental|Abdominoplasty on NPWT|The Smith&Nephew Renasys*GO device connected to non-compressible drains will be applied to the abdominoplasty patients enrolled in this arm.
89585856|NCT02147288|Experimental|Ventral Hernia Repair (VHR) on NPWT|The Smith&Nephew Renasys*GO device connected to non-compressible drains will be applied to the VHR patients enrolled in this arm.
89585857|NCT02147288|Experimental|Panniculectomy on NPWT|The Smith&Nephew Renasys*GO device connected to non-compressible drains will be applied to the panniculectomy patients enrolled in this arm.
89585858|NCT02147288|No Intervention|Breast Recon with ADM on Jackson-Pratt (JP) Drains|Standard of Care. The Jackson-Pratt (JP) drain is used following surgery to collect bodily fluids from the surgical site.
89585859|NCT02147288|No Intervention|Abdominoplasty on JP Drains|Standard of Care. The Jackson-Pratt (JP) drain is used following surgery to collect bodily fluids from the surgical site.
89585860|NCT02147288|No Intervention|Lipoabdominoplasty on JP Drains|Standard of Care. The Jackson-Pratt (JP) drain is used following surgery to collect bodily fluids from the surgical site.
89585861|NCT02147288|No Intervention|Ventral Hernia Repair (VHR) on JP Drains|Standard of Care
88975085|NCT02958540|Placebo Comparator|placebo|12 subjects receiving placebo
88975086|NCT02971124||Healthy Elderly|
88975087|NCT02971124||Mild Cognitive Impaired Elderly|
88975088|NCT00064272|Experimental|Arm I|Patients receive lower-dose oral ginger twice daily.
88975089|NCT00064272|Experimental|Arm II|Patients receive higher-dose oral ginger twice daily.
88975090|NCT00064272|Placebo Comparator|Arm III|Patients receive oral placebo twice daily.
88975091|NCT00064389|Experimental|1|levalbuterol 90 mcg MDI QID
88975092|NCT00064389|Active Comparator|2|racemic albuterol HFA MDI 180 mcg QID
88975093|NCT00064428|Experimental|Fondaparinux - UFH not indicated|Subjects with no indication for UFH therapy: 2.5mg od, sc, (1st dose IV) x 8 days or discharge
88975094|NCT00064428|Placebo Comparator|Control - UFH not indicated|Subjects with no indication for UFH therapy: Fondaparinux-placebo od, sc (1st dose IV) x 8 days or discharge
88975095|NCT00064428|Experimental|Fondaparinux - UFH indicated|Subjects indicated for UFH: 2.5mg od, sc (1st dose IV) x 8 days or discharge + UFH-placebo IV bolus + 24-48 hr infusion
88975096|NCT00064428|Active Comparator|Control - unfractionated heparin|Subjects indicated for UFH: UFH IV bolus +12 IU/kg/hr infusion x 24-48 hr + fondaparinux-placebo od, sc (1st dose IV) x 8 days or discharge
88975097|NCT02966925|Experimental|Treatment with Cellular Matrix|Patients will be treated with a combination of PRP/HA prepared with Cellular Matrix BCT-HA Kit
89585862|NCT02147288|No Intervention|Panniculectomy on JP Drains|Standard of care. The Jackson-Pratt (JP) drain is used following surgery to collect bodily fluids from the surgical site.
89585863|NCT05209178|Experimental|Self-collection of specimen|Participants allocated to this arm will perform specimen collection for the antigen tests independently using written instructions and access to a video. Sampling is performed as two individual procedures from the anterior part of the nose and the oropharynx respectively.
88975100|NCT00064974|Experimental|CC-5013|CC-5013 10 mg (two 5 mg capsules) daily on days 1-28 every 28 days (28 day cycles)
88975101|NCT00037817|Experimental|1|Dose escalation cohort
88975102|NCT00037817|Experimental|2|Molecular response cohort
88975103|NCT00037817|Experimental|3|Celecoxib combination cohort at MTD
88975104|NCT00037934|Experimental|1|Robot exercise group
88975105|NCT00037934|Active Comparator|2|Traditional exercise group
88975106|NCT00037973|Experimental|1|Ventilation-feedback plus exercise
88975107|NCT00037973|Active Comparator|2|Exercise
88975108|NCT00037973|Active Comparator|3|ventilation feedback only
89585864|NCT05209178|Active Comparator|Healthcare-collection of specimen|Participants allocated to this arm will initially have specimen collection for the antigen tests done by a healthcare personnel. Sampling is performed as two individual procedures from the anterior part of the nose and the oropharynx respectively.
89585865|NCT04737356|Experimental|Cognitive Behavior Therapy|Therapist-Guided Internet based Cognitive Behavior Therapy
89585866|NCT04737356|No Intervention|Wait-list control|Wait-list control participants will receive the same treatment at the end of the study period.
89585867|NCT04751708|Active Comparator|best medical management|Unless contra-indicated patients are treated with a standard full dose of open-label IV rt-PA (0.9mg/kg; 90mg maximum). IVT has to be initiated within 4.5 hours of estimated time of basilar artery occlusion. For the patients in whom the rtPA is contraindicated, the standard medical treatment follows the current guidelines for the early management of patients with acute ischemic stroke from the American Heart Association/American Stroke Association.
88975109|NCT00038012|Experimental|rhTPO-Derived Autologous Platelets Transfusion|
88975110|NCT00065208|Experimental|Reiki|Energy therapy
88975111|NCT00065208|Sham Comparator|Pretend Reiki|
88975112|NCT00065208|Other|Rest / Guided Imagery|Rest for pre-surgery outcomes Guided Imagery for post-surgery outcomes
88975113|NCT00038051|Experimental|HuM195/rGel|HuM195/rGel starting Dose = 3 mg/m^2 twice weekly for 2 weeks.
88975114|NCT02967198|Experimental|CT/US fusion|patients undergo routine conventional feasibility planning ultrasound, and clinical decision of percutaneous liver biopsy or RFA feasibility is made based on conventional planning ultrasound. Then additional planning ultrasound using CT/US fusion technique is immediately performed by the same operator, and clinical decision is made based on fusion imaging.
88975115|NCT00038090|Experimental|Thalidomide + Dexamethasone|
88975116|NCT00038129|Experimental|1|Participants will receive reaming of the intramedullary canal prior to insertion of an intramedullary nail.
88975117|NCT00038129|Experimental|2|Participants will receive insertion of an intramedullary nail without prior reaming of the intramedullary canal.
88975118|NCT00065325|Active Comparator|1|Exemestane
88975119|NCT00065325|Experimental|2|Fulvestrant
88975120|NCT00038168|Experimental|Estramustine + Taxol|
88975121|NCT00038207|Experimental|Liposomal Vincristine|
88975122|NCT00038246|Experimental|Thalidomide, Taxol, Estramustine|Thalidomide starting dose 200 mg by mouth every day once a week; Taxol 100 mg/m^2 by vein (IV) over 3 hours Day 3 and Day 10; Estramustine 140 mg by mouth three times a day on Days 1-5, 8-12.
89030237|NCT00516633|No Intervention|CG|The control group had regular individual information and support in connection with ordinary clinical follow-ups
89030238|NCT00516633|Experimental|IG|The intervention group had extra support and information in the form of four group discussions with parents
89030239|NCT00516672|Experimental|Arm 1|Pazopanib monotherapy or in combination with lapatinib
89030240|NCT04694625|Experimental|Structured rehabilitation program|Structured rehabilitation program & conventional physical therapy
89030241|NCT04694625|Active Comparator|conventional physical therapy|conventional physical therapy
89030242|NCT02950038|Experimental|Ibrutinib + Nivolumab|"Ibrutinib administered by mouth daily in 28 day cycles.~Nivolumab administered by vein beginning with cycle 2, and given on Days 1 and 15 of every 28 day cycle."
89030243|NCT02949960|Experimental|DMT210 Topical Gel|DMT210 Topical Gel 5% applied to target lesion twice daily
89030244|NCT02949960|Placebo Comparator|Vehicle Control|Topical Gel vehicle applied to target lesion twice daily
89030245|NCT02276183|Experimental|Arm1, Nutrition intervention, test formula and activity|
89030246|NCT02949999|Experimental|0.25mg/kg voclosporin|0.25mg/kg voclosporin BID.
89030247|NCT02949999|Experimental|0.5mg/kg voclosporin|0.5mg/kg voclosporin BID
89585868|NCT04751708|Experimental|endovascular treatment+ best medical management|Device: endovascular treatment For patients randomized to endovascular treatment arm, EVT has to be initiated within 12 hours of estimated time of basilar artery occlusion. If an appropriate thrombus or residual stenosis is identified, the choice of EVT strategy will be made by the treating neurointerventionalist. The endovascular procedures allowed by the steering committee include mechanical thrombectomy, intra-arterial thrombolysis, balloon angioplasty, stent implantation, or any combination of above procedures. We recommend applying ADAPT as the first choice of treatment. All mechanical thrombectomy devices for EVT, which are approved by CFDA for this purpose, are allowed in the trial.
89585869|NCT02147132|Experimental|Order 1|Subjects assigned to this arm will receive Placebo Nasal Spray first (Week 1), followed by Nicotine Nasal Spray (Week 2), followed by Varenicline (Weeks 3-4), followed by a washout period (Week 5) and then Placebo Varenicline (Weeks 6-7).
89585870|NCT02147132|Experimental|Order 2|Subjects assigned to this arm will receive Placebo Nasal Spray first (Week 1), followed by Nicotine Nasal Spray (Week 2), followed by Placebo Varenicline (Weeks 3-4), followed by a washout period (Week 5) and then Varenicline (Weeks 6-7).
89585871|NCT02147132|Experimental|Order 3|Subjects assigned to this arm will receive Nicotine Nasal Spray first (Week 1), followed by Placebo Nasal Spray (Week 2), followed by Varenicline (Weeks 3-4), followed by a washout period (Week 5) and then Placebo Varenicline (Weeks 6-7).
89585872|NCT02147132|Experimental|Order 4|Subjects assigned to this arm will receive Nicotine Nasal Spray first (Week 1), followed by Placebo Nasal Spray (Week 2), followed by Placebo Varenicline (Weeks 3-4), followed by a washout period (Week 5) and then Varenicline (Weeks 6-7).
89585873|NCT02146430|Experimental|DS-5565 QD|Participants take one each of placebo tablet and capsule in the morning, and one DS-5565 tablet once daily (QD) with a placebo capsule in the evening
89585874|NCT02146430|Experimental|DS-5565 BID|Participants take one DS-5565 tablet and one placebo capsule, twice daily (BID)
89585875|NCT02146430|Active Comparator|Pregabalin|Participants take one pregabalin capsule and one placebo tablet BID
89585876|NCT02146430|Placebo Comparator|Placebo|Participants take one each of placebo tablet and capsule BID
89585877|NCT02129192|Experimental|T80/A5/H12.5 mg FDC|Telmisartan 80 mg/Amlodipine 5 mg/Hydrochlorothiazide 12.5 mg fixed dose combination tablet
89585878|NCT02129192|Active Comparator|T80/H12.5 FDC + A5 mono|Telmisartan 80 mg/Hydrochlorothiazide 12.5 mg fixed dose combination tablet and Amlodipine 5 mg capsule
89585879|NCT02105948|Experimental|Arm 1|Each subject will receive 100 mg mepolizumab SC injection every 4 weeks (13 administrations during 52 week treatment period) along with optimized standard of care background therapy.
89030248|NCT02949999|Experimental|1.0mg/kg voclosporin|1.0mg/kg voclosporin BID
89585880|NCT02105948|Placebo Comparator|Arm 2|Each subject will receive placebo (0.9% sodium chloride) SC injection every 4 weeks (13 administrations during 52 week treatment period) along with optimized standard of care background therapy.
89585881|NCT02128724|Experimental|BKM120 plus radiotherapy|Three cohorts of patients will be treated with escalating doses of oral buparlisib. The doses will be 50mg, 80mg and 100mg, once daily. Patients will be treated with buparlisib for a total of fourteen days. One week after commencing buparlisib, patients will start palliative radiotherapy treatment. Radiotherapy treatment will be delivered as 20Gy in 5 fractions over a one week period. There will be an expansion cohort at the MTD. Patients in an optional fourth cohort will take buparlisib for 4 weeks at the MTD.
89030249|NCT02949999|Experimental|1.5mg/kg voclosporin|1.5mg/kg voclosporin BID
89030250|NCT02949999|Placebo Comparator|Placebo voclosporin|placebo BID
89030251|NCT04510415|Experimental|Olmutinib 600mg|HM61713 600 mg (1 x 400 mg + 1 x 200 mg tablets) once daily (QD)
89030252|NCT02949882|Experimental|Probiotic Intervention|130 Elderly participants receiving daily 65ml Yakult for 10 consecutive weeks.
89030253|NCT02949882|Active Comparator|Non-Probiotic Intervention|130 Elderly participants receiving daily 65 ml of Dairy Peach Drink (AH Basic) for 10 consecutive weeks.
89030254|NCT04517942|Experimental|EVERYbody Project: Peer facilitator version|"This dissonance-based body image program was created from focus group feedback (Ciao, Ohls, & Pringle, 2017) and piloted in an initial randomized-controlled trial. Based on the Body Project (Stice et al., 2006), it retains key dissonance activities while adapting exercises to have a more inclusive focus (e.g., expanding the gender focus, exploring diversity characteristics within appearance ideals, adjusting activities to be inclusive of diversity).~Around 10% of the original EVERYbody Project manual was modified to create the Peer Facilitator version for the current trial. Changes focused on adding individual exercises to draw out the critique of diversity in cultural ideals, refining prompts to be more suitable for peer facilitation, and flagging sections of the manual for more expert peer facilitation.~Peer facilitators received 16 hours of training on the EVERYbody Project manual and peer facilitation guidelines (e.g., group management, handling problems, etc.)."
89585882|NCT02128490|Active Comparator|Febuxostat IR 40 mg|Febuxostat Immediate Release (IR) 40 mg over-encapsulated tablet, orally, once daily, and colchicine 0.6 mg tablet, orally, every other day, or, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.
89585883|NCT02128490|Active Comparator|Febuxostat IR 80 mg|Febuxostat IR 80 mg over-encapsulated tablet, orally, once daily, and colchicine 0.6 mg tablet, orally, every other day, or, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.
89585884|NCT02128490|Experimental|Febuxostat XR 40 mg|Febuxostat Extended Release (XR) 40 mg over-encapsulated capsule, orally, once daily, and colchicine 0.6 mg tablet, orally, every other day, or, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.
89585885|NCT02128490|Experimental|Febuxostat XR 80 mg|Febuxostat XR 80 mg over-encapsulated capsule, orally, once daily, and colchicine 0.6 mg tablet, orally, every other day, or, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.
89585886|NCT02128490|Placebo Comparator|Placebo|Febuxostat placebo-matching capsule, orally, once daily, and colchicine 0.6 mg tablet, orally, every other day, or, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.
89585887|NCT02146352|Experimental|Treatment|AXIOS Stent with Electrocautery Enhanced Delivery System
89585888|NCT02146274||Ischemic Stroke Patients|Patients who have had an ischemic stroke that are hospitalized in an acute-care setting.
89585889|NCT02105636|Experimental|Arm A: Nivolumab|Nivolumab 3mg/kg intravenous (IV) Solution for Injection every 2 weeks until disease progression
89585890|NCT02105636|Active Comparator|Arm B: Cetuximab/Methotrexate/Docetaxel|"Cetuximab intravenous (IV) Solution for Injection 400 mg/m2 (first dose) then 250 mg/m2 weekly until disease progression~OR~Methotrexate intravenous (IV) Solution for Injection 40 or 60 mg/m2 weekly until disease progression~OR~Docetaxel intravenous (IV) Solution for Injection 30 or 40 mg/m2 weekly until disease progression"
89585891|NCT01626872|Experimental|MP-214 3mg|
89585892|NCT01626872|Experimental|MP-214 6mg|
89585893|NCT01626872|Experimental|MP-214 9mg|
89585894|NCT01626872|Active Comparator|Risperidone 4mg|
89585895|NCT01598090|Experimental|Part A: Peginterferon Lambda-1a + RBV + TVR|
89585896|NCT01598090|Experimental|Part B (Arm 1): Peginterferon Lambda-1a + RBV + TVR|
89585897|NCT01598090|Experimental|Part B (Arm 2): Peginterferon Lambda-2a + RBV + TVR|
89585898|NCT02105012|Experimental|BD MDI 320 µg|Budesonide metered dose inhaler (BD MDI) 320 µg (PT008) administered as 2 inhalations BID
89585899|NCT02105012|Experimental|BD MDI 160 µg|BD MDI 160 µg (PT008) administered as 2 inhalations BID
88975123|NCT05434247|Other|Reverse-bevel ProCore™|Historical comparator group of biopsies taken using Echo Tip® HD ProCore™ (Wilson-Cook Medical Inc., Winston-Salem, NC, United States) biopsy needle. Slow pull stylet technique with rapid on site evaluation in all cases.
88975124|NCT05434247|Experimental|Fork-tip SharkCore™|Experimental group of biopsies using SharkCore™ (Medtronic Inc., Sunnyvale, CA, United States) biopsy needle. Slow pull stylet technique with rapid on site evaluation in all cases.
88975125|NCT05434247|Experimental|Franseen Acquire™|Experimental group of biopsies using Acquire™ (Boston Scientific, Marlborough, MA, United States) biopsy needle. Slow pull stylet technique with rapid on site evaluation in all cases.
88975126|NCT05434208|Experimental|A RESEARCH ARM: active telephonic follow-up by specialist nurse|"Early Palliative Care cancer patients will be randomized to active telephonic follow-up program by specialist nurses until end-of-treatment (28 days)~Scheduled phone-calls each 7 days from T0 + unscheduled phone-calls (as needed)~Questionnaire: ESAS and IPOS;~Weight;~Medication intake;~ECOG-PS~Scheduled phone-calls at End of Treatment (28 days from T0):~Questionnaire: ESAS and IPOS~Questionnaire: FAMCARE-2 for CGs"
88975127|NCT05434208|No Intervention|B CONTROL GROUP: face-to-face visit at end of treatment|"Early Palliative Care cancer patients will be randomized to face-to-face visit at end of treatment (28 days)~Unscheduled phone-calls, on patients initiative:~Questionnaire: ESAS and IPOS;~Weight;~Medication intake;~ECOG-PS~Face-to-face visit at End of Treatment (28 days from T0):~Questionnaire: ESAS and IPOS~Questionnaire: FAMCARE-2 for CGs"
88975128|NCT00398814|Experimental|Perifosine + Sorafenib|
88975129|NCT05433974|Other|Radiosensitivity|Patient who agree to participate in this research study will have blood sample collected in order to perform the RadioDtect test.
88975130|NCT00065637|Experimental|1|Women will self-administer PTH injections daily for 4 weeks, then once weekly for 48 weeks
88975131|NCT00065637|Placebo Comparator|2|Women will self-administer placebo injections daily for 4 weeks, then once weekly for 48 weeks
88975132|NCT00398853|Experimental|Chromium Picolinate|Chromium
88975133|NCT00398853|Other|Placebo|Placebo
88975134|NCT05433896|Experimental|Dasatinib ASD alone|At the clinic, participants were administered a single oral dose of 90 mg Dasatinib (Amorphous Solid Dispersion Film-Coated Tablet) on Day 1 after an overnight fast of at least 9 hours. Dasatinib was given with approximately 240 mL of room temperature water. Fasting continued for at least 4 hours following drug administration, after which a standardized lunch was served.
89585900|NCT02105012|Experimental|BD MDI 80 µg|BD MDI 80 µg (PT008) administered as 2 inhalations BID
89585901|NCT02105012|Experimental|BD MDI 40 µg|BD MDI 40 µg (PT008) administered as 2 inhalations BID
89585902|NCT02105012|Placebo Comparator|Placebo MDI|Placebo MDI administered as 2 inhalations BID
89585903|NCT02145182|Experimental|Active|Eculizumab was administered by intravenous (IV) infusion over 25-45 minutes (min) for 2 doses (on the day of transplant then 18-24 hours [h] later).
89585904|NCT02145182|Placebo Comparator|Placebo|Placebo was administered by IV infusion over 25-45 min for 2 doses (on the day of transplant then 18-24 h later).
89585905|NCT02145026|Experimental|Epoetin Beta|Participants will receive epoetin beta at an initial dose of 30,000 International Units (IU) per week administered subcutaneously (SC). Response will be firstly evaluated at Week 4 and the subsequent dose will be based on the response: if hemoglobin level reaches greater than or equal to (>/=)12 grams per deciliter (g/dL) at any time, epoetin beta will be discontinued until hemoglobin levels are less than or equal to (</=) 10 g/dL; if the hemoglobin level increases less than (<) 1 g/dL from screening level and hemoglobin level ˂12 g/dL, a 60,000 IU per week epoetin beta will be administered SC until Week 12; if the hemoglobin level increases >/=1 g/dL from screening level and hemoglobin level ˂12 g/dL, a 30,000 IU per week epoetin beta will be continued until Week 12.
89030255|NCT04517942|Active Comparator|Video + Expressive Writing group|"Video + expressive writing groups were facilitated by a peer leader following a detailed script. This intervention was designed as an active but low-dissonance comparison condition. Participants viewed two separate documentary movies related to gender and/or appearance-related pressures (one during each session): (1) The Illusionists (2015 ), and (2) The Mask You Live In (2015). Participants engaged in a brief (10 minute) reflective writing exercise after each film. In order to keep dissonance low, participants were told that their reflections would not be shared with anyone and they were not turned in.~Peer facilitators received brief (1 hour) training on the video group manual."
89030256|NCT02949609|Experimental|Mirror Therapy (MT)|Standard therapy + 30 min/day of mirror therapy, 5 days/week, for 4 weeks, administered by experienced physical and occupational therapists.
89030257|NCT02949609|Active Comparator|Control Therapy (CT)|Standard therapy + 30 min/day of CT.
89585906|NCT02144012|Experimental|Arm A: Trastuzumab emtansine|Participants will be administered trastuzumab emtansine once every three weeks (Q3W). Participants may remain on study treatment until investigator assessed disease progression, unacceptable toxicity, or Sponsor study termination occurs, whichever occurs first.
89585907|NCT02144012|Active Comparator|Arm B: Trastuzumab + Docetaxel|Participants will be administered trastuzumab plus docetaxel Q3W. Participants may remain on study treatment until investigator assessed disease progression, unacceptable toxicity, or Sponsor study termination occurs, whichever occurs first.
89585908|NCT02103062|Experimental|Abraxane (nab®paclitaxel)|Abraxane (nab®paclitaxel) 125 milligrams per meter squared on days 1, 8 and 15 of a 28 day cycle
89585909|NCT02141984||Patients with Polyarticular JIA or ERA|Patients with polyarticular juvenile idiopathic arthritis (JIA) or enthesitis-related arthritis (ERA)
89585910|NCT02141672|Experimental|Voclosporin Low Dose|Voclosporin, oral, 23.7 mg BID
89585911|NCT02141672|Experimental|Voclosporin High Dose|Voclosporin, oral 23.7 mg BID until Week 2, then voclosporin, oral, 39.5 mg BID
89585912|NCT02141672|Placebo Comparator|Placebo|"Low dose: Voclosporin placebo, oral, 3 capsules BID~High dose: Voclosporin placebo, oral, 3 capsules BID until Week 2 then voclosporin placebo, oral, 5 capsules BID"
89585913|NCT02141516|Experimental|Group A|Complement deficiency
89585914|NCT02141516|Experimental|Group B|asplenia/splenic dysfunction
89585915|NCT02141516|Active Comparator|Group C|age-matched healthy controls
89585916|NCT02141360|Experimental|Experimental: Diagnostic mTBI|MRI Diagnostic of subjects with mild Tramatic Brain Injury (mTBI)
89585917|NCT02141360|Placebo Comparator|Experimental: Diagnostic Non mTBI|MRI Diagnostic of Non injured subjects that are closely matched to mTBI
89030258|NCT04510220|Experimental|Subjects diagnosed with relapsing forms of multiple sclerosis|We plan to enroll 10 subjects with relapsing MS. All enrolled subjects will receive Ofatumumab 20 mg every 4 weeks, subcutaneously for 9 months during the study. Loading doses will be administered initially at 1, 7 and 14 days. During the study period, all enrolled subjects will undergo five PET scans using [F-18] PBR06 at 0, 5, 28, 90 and 273 days after starting treatment with Ofatumumab.
89030259|NCT02949648||Electronic cigarette ever user|Youth Quitline callers who reported ever use of e-cigarette at baseline.
89030260|NCT02949648||Electronic cigarette never user|Youth Quitline callers who reported never use of e-cigarette at baseline.
89030261|NCT04510337|Active Comparator|Standard rocuronium|patients received rocuronium 0.6mg/kg
89030262|NCT04510337|Experimental|Magnesium|patients received 100 ml saline with 50mg/kg magnesium sulphate infusion over 10 minutes
89030263|NCT02949687|Experimental|ileal interposition sleeve sympathectomy|laparoscopic ileal interposition with sleeve and sympathectomy
89585918|NCT01628198|Experimental|Renal denervation group|Celcius Thermacool Catheter or Chilli II Cooled Ablation Catheter
89585919|NCT01628120|Experimental|Epoetin Hospira|Epoetin Hospira will be administered by SC bolus injection 1 to 3 times per week per each patient's dosing schedule. Other ESAs (except for long-acting) may be used as rescue therapy.
89585920|NCT01627340|Experimental|Diabetes Group|Subjects diagnosed with type 2 diabetes within the five year period before study start who received 3 doses of Engerix™-B vaccine (HBV) at 0, 1 and 6 months. The vaccine was administered intramuscularly (IM) into the deltoid region of the non-dominant arm.
89585921|NCT01627340|Active Comparator|Control Group|Subjects with no diagnosis or documented history of diabetes who received 3 doses of Engerix™-B (HBV) vaccine at 0, 1 and 6 months. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
89585922|NCT02125838|Active Comparator|Group ETT|Group endotracheal tube In the endotracheal tube group for women no. 7-7.5 tube will use. ETT:Rüschelit, Teleflex Medical Sdn. Bhd. Malaysia. Ref:112482
89585923|NCT02125838|Experimental|Group LMS|Laryngeal mask airway-supreme Group In the LMS group for <50 kg, no. 3 Between 50-70 kg, no. 4 Between 70-100 kg, no. 5 LM-S (The Laryngeal Mask Company Limited, Singapore) will insert.
89585924|NCT02125604|Experimental|Dimethyl Fumarate|Dimethyl fumarate administered orally at 120 mg twice daily (BID) for the first 7 days and 240 mg BID thereafter for a total of 12 weeks.
89585925|NCT02124746|Experimental|Cohort 1|Participants previously enrolled in Study CCL09191E will receive momelotinib for approximately 4 years.
89585926|NCT02124746|Experimental|Cohort 2|Participants previously enrolled in Study YM387-II-02 will receive momelotinib for approximately 4 years.
89585927|NCT02124746|Experimental|Cohort 3|"Participants previously enrolled in Study GS-US-354-0101 will receive momelotinib for up to 4 years.~Cohort 3 was closed and all enrolled participants were discontinued from this study because parent Study GS-US-354-0101 was terminated."
89585928|NCT02124746|Experimental|Cohort 4|Participants previously enrolled in Study GS-US-352-1672 will receive momelotinib for approximately 4 years.
89585929|NCT02123966|Experimental|Topical Sirolimus + Steroid|A four week supply of topical sirolimus will be dispensed. The treatment instructions will be to rinse and spit (NOT swallow) with one teaspoon (5 mL) of sirolimus solution 0.1mg/mL, combined with one teaspoon (5 mL) of steroid solution (dexamethasone 0.1%, clobetasol 0.05%, or budesonide 0.03%, based on the ongoing topical steroid prescription at the time of study enrollment) four times a day for 5 minutes at a time, and not to eat or drink for 15 minutes afterwards.
89585930|NCT02123576|Experimental|Treatment|Pentoxyfylline 400mg three times a day or 400mg twice a day for eGFR 10-50 and 400mg once a day for eGFR <10 for 90 days in addition to standard AMO therapy
89585931|NCT02123576|Placebo Comparator|Placebo|This is a standard placebo pill.
89585932|NCT01177397|Experimental|CC-223|All patients will receive CC-223, but serial patient groups will receive different dose levels in Phase 1. The number of groups will be determined by the number of dose levels required to establish dose-limiting toxicity.
89585933|NCT01160861|Experimental|A|
89585934|NCT01160861|Experimental|B|
89585935|NCT01160861|Experimental|C|
89585936|NCT04355975||Medical Therapy / Anticoagulation|
89585937|NCT04355975||Systemic Lysis|
89585938|NCT04355975||Interventional Therapy for PE|
89585939|NCT04355975||Surgical Embolectomy|
89585940|NCT00864227|Experimental|Umbilical Cord Blood Transplantation|Participants will receive a double unit Hematopoietic Umbilical Cord Blood Stem Cell Transplantation using a non-myeloablative preparative regimen, GVHD prophylaxis.
89585941|NCT05230511|Experimental|Intravesical Lactobacillus RhamnosusGG and Bladder Wash (Treatment Phase)|LGG® (Culturelle Probiotic LGG®) will be used. This is the product we have used in the past and for which we have demonstrated safety, tolerability, and preliminary efficacy. For the LGG® instillation in response to trigger symptoms, participants will be instructed to mix the contents of 1 LGG® capsule into 45 cc sterile 0.9% saline. After mixing, participants will draw up the 45cc liquid LGG® mixture into a 60cc syringe and instill via the intermittent catheter after the last catheterization prior to going to bed. Participants will be asked to return any remaining capsules at the end of the study. Participants will be instructed to complete the USQNB-IC at the time of symptoms (in real time) and daily during instillations for 2 days after the final instillation. Subjects will remain in this phase 6 months.
89585942|NCT05230511|Other|Intravesical Bladder Wash (Treatment Phase)|Participants will draw up the 45cc of normal saline into a 60cc syringe and instill via the intermittent catheter after the last catheterization prior to going to bed after trigger symptoms occur. Participants will be instructed to complete the USQNB-IC at the time of symptoms (in real time) and daily during instillations for 2 days after the final instillation. Subjects will remain in this phase 6 months.
89585943|NCT05230511|Experimental|Intravesical Lactobacillus RhamnosusGG and Bladder Wash (Prophylaxis Phase)|LGG® (Culturelle Probiotic LGG®) will be used. This is the product we have used in the past and for which we have demonstrated safety, tolerability, and preliminary efficacy. For the LGG® instillation in response to trigger symptoms, participants will be instructed to mix the contents of 1 LGG® capsule into 45 cc sterile 0.9% saline. After mixing, participants will draw up the 45cc liquid LGG® mixture into a 60cc syringe and instill via the intermittent catheter after the last catheterization prior to going to bed. They will then instill the LGG® mixture every 2 days for the remainder of the 6 months. Participants will be asked to return any remaining capsules at the end of the study. Participants will be instructed to complete the USQNB-IC at the time of symptoms (in real time) and biweekly post-instillation. Subjects will remain in this phase 6 months.
89585944|NCT05230511|Other|Intravesical Bladder Wash (Prophylaxis Phase)|Participants will draw up the 45cc of normal saline into a 60cc syringe and instill via the intermittent catheter after the last catheterization prior to going to bed after trigger symptoms occur. They will then instill the saline BW every 2 days for the remainder of the 6 months. Participants will be instructed to complete the USQNB-IC at the time of symptoms (in real time) and biweekly post-instillation. Subjects will remain in this phase 6 months.
89585945|NCT04810715||Patient Group|Anklyosing Spondilitis
89585946|NCT02102204|Experimental|Etelcalcetide|Participants received etelcalcetide three times a week (TIW) by bolus injection at the end of hemodialysis. The minimum etelcalcetide dose in this study was 2.5 mg and the maximum dose was 15 mg. Etelcalcetide dose was titrated to maintain parathyroid hormone levels within 2x to 9x the upper limit of normal based on the reference range of the assay used at the individual study center.
89585947|NCT02141204|Experimental|HRV Liq Group|Subjects aged 6 to 10 weeks at the time of first vaccination, who received two oral doses of Liquid Human Rotavirus Vaccine (HRV) according to a two-dose schedule, at Day 1 and Month 1.
89585948|NCT02141204|Active Comparator|HRV Lyo Group|Subjects aged 6 to 10 weeks at the time of first vaccination who received two oral doses of Lyophilized Human Rotavirus Vaccine (HRV) according to a two-dose schedule, at Day 1 and Month 1.
89585949|NCT02140970|Experimental|Liquid ibuprofen|10 mg/kg orally up to a maximum of 400 mg given once at least 15 minutes prior to ureteral stent removal
89585950|NCT02140970|Placebo Comparator|Liquid placebo|Similar-tasting and appearing liquid placebo of equal volume to be given once orally at least 15 minutes prior to ureteral stent removal
89585951|NCT02101112|Experimental|Apixaban, 10 mg (whole tablets)|Participants received a single dose of apixaban, 10 mg, given orally as 2 5-mg whole commercial tablets (reference)
89585952|NCT02101112|Experimental|Apixaban, 10 mg (crushed and suspended in water)|Participants received a single dose of apixaban, 10 mg, given by mouth as 2 5-mg whole commercial tablets crushed and suspended in 30 mL of water
89585953|NCT02101112|Experimental|Apixaban, 10 mg (crushed and mixed with applesauce)|Participants received a single dose of 10 mg, given by mouth as 2 5-mg apixaban commercial tablets crushed and mixed with 30 g of applesauce
89585954|NCT02139644|Experimental|FS MDPI 100 / 12.5 mcg|"Patients took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate 100 mcg (for a total daily dose of 200 mcg) and salmeterol 12.5 mcg (for a total daily dose of 25 mcg) for 12 weeks.~Albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
89585955|NCT02139644|Experimental|FS MDPI 50 / 12.5 mcg|"Patients took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate 50 mcg (for a total daily dose of 100 mcg) and salmeterol 12.5 mcg (for a total daily dose of 25 mcg) for 12 weeks.~Albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
89030264|NCT04510259|Experimental|Selective Brachial plexus block|Selective brachial plexus block will be done under ultrasound guidance to patients scheduled for upper extremity surgeries. Local anesthetic agents (a mixture of 2% lidocaine with 1:200,000 epinephrine and 0.5% levobupivacaine in a total of 25ml) will be injected at the superior, middle, and inferior trunks of the brachial plexus in order to anesthesize the whole upper limb.
88811285|NCT02861573|Experimental|Pembrolizumab+Lenvatinib: AC|Participants with AC mCRPC in Cohort E will receive pembrolizumab 200 mg IV on Day 1 Q3W, and lenvatinib 20 mg PO QD continuously from Day 1 of Cycle 1. Treatment with pembrolizumab will continue for a maximum of 35 cycles (up to 2 years) or until progression. Participants who must discontinue 1 of the 2 drugs due to adverse events in the combination may continue the study with the other combination drug.
88975135|NCT05433896|Other|Dasatinib ASD + Omeprazole|"At the clinic, on Day 2 to Day 6, participants were administered a single oral dose of Omeprazole 40 mg × 1 Delayed Release Capsule once before meals in the evening with approximately 150 mL of room temperature water. No food was allowed two hours before and one hour after administration of Omeprazole.~In addition, participants were administered a single oral dose of 90 mg Dasatinib (Amorphous Solid Dispersion Film-Coated Tablet) on Day 6 after an overnight fast of at least 9 hours. Dasatinib was given with approximately 240 mL of room temperature water. Fasting continued for at least 4 hours following drug administration, after which a standardized lunch was served."
88975136|NCT05433779|Experimental|Neosense Umbilical Catheter|
88975137|NCT00065715|No Intervention|A|No pills
88975138|NCT00065715|Placebo Comparator|B|Blinded placebo
88975139|NCT00065715|Experimental|C|Echinacea - Blinded
88975140|NCT00065715|Experimental|D|Echinacea - Unblinded, Open Label
88975141|NCT05433545||Adherence to specific physiotherapy exercises|
89585956|NCT02139644|Experimental|Fp MDPI 100 mcg|"Patients took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate 100 mcg for a total daily dose of 200 mcg for 12 weeks.~Albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
89585957|NCT02139644|Experimental|Fp MDPI 50 mcg|"Patients took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate 50 mcg for a total daily dose of 100 mcg for 12 weeks.~Albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
89585958|NCT02139644|Placebo Comparator|Placebo MDPI|"The placebo multidose dry powder inhaler was identical to the devices used to deliver active drug, and indistinguishable from the active treatments. Patients took one inhalation twice a day (approximately 12 hours apart).~Albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
89585959|NCT02100644|Experimental|Lamotrigine|The study objective is to examine whether the VPA dose can be reduced by additional administration of LTG in Japanese pre-menopausal female epilepsy patients, whose seizures are well controlled by VPA monotherapy. Then VPA is the standard product in this stuudy, not the investigational product.
89585960|NCT04782323|Experimental|Group A aQII-1 Investigational|
89585961|NCT04782323|Experimental|Group B aQII-3 Investigational|
89585962|NCT04782323|Experimental|Group C aQII-6 Investigational|
89585963|NCT04782323|Experimental|Group D aQII-7 Investigational|
89585964|NCT04782323|Experimental|Group E aQII-9 Investigational|
89585965|NCT04782323|Experimental|Group F aQII-10 Investigational|
89585966|NCT04782323|Experimental|Group G aQII-11 Investigational|
88975142|NCT05433428|Experimental|Cataract patients with dry eye - standard treatment|Standard pre and postop medication, preservative eye drops.
88975143|NCT05433428|Other|Cataract patients with dry eye - intensive treatment|More prolonged use of lubricant eye drops as well as the use of preservative free eye drops.
88975144|NCT05433428|Other|Cataract patients without dry eye disease / control group|Standard pre and postop medication, control group.
88975145|NCT00069927|Experimental|Arm 1- Adderall- XR®|Adderall-XR® 1 10 mg/day for 3-12 weeks depending on subject's response
89585967|NCT04782323|Active Comparator|Group H QII Active Comparator|
89585968|NCT04239521||Cases|Patients with a confirmed diagnosis of Alopecia areata within the study period will be included as cases for analysis.
89585969|NCT04239521||Controls|The control cohorts will be defined by matching cases with patients who have never been diagnosed with Alopecia areata either prior to or during the study period, by age and sex, at General Practice practice level.
89585970|NCT04168073|Experimental|High sodium diet|
89585971|NCT04168073|Experimental|Low sodium diet|
89585972|NCT02074982|Experimental|AIN457 300 mg|patients received AIN457 (secukinumab) 300 mg (two secukinumab 150 mg injections) s.c. (subcutaneously) once every week at weeks 0, 1,2,3, followed by monthly dosing starting at week 4 to week 48 inclusive
89585973|NCT02074982|Active Comparator|Ustekinumab|patients received ustekinumab 45/90 mg (weight depended, according to label) s.c. (subcutaneously) and/or placebo secukinumab injections once every week at weeks 0,1,2, and 3 followed by monthly dosing starting at week 4 to week 48 inclusive
89585974|NCT04798001|Experimental|Cohort A / Dosage Group 1 (intranasal drops) / Single Dose|Participants in this arm (18-55 years) will receive a single intranasal dose of the MV-014-212 vaccine at Dosage 1 in the form of intranasal drops on Day 1.
89585975|NCT04798001|Experimental|Cohort A / Dosage Group 2 (intranasal drops) / Single Dose|Participants in this arm (18-55 years) will receive a single intranasal dose of the MV-014-212 vaccine at Dosage 2 in the form of intranasal drops on Day 1.
89585976|NCT04798001|Experimental|Cohort A / Dosage Group 3a (intranasal drops) / Single Dose|Participants in this arm (18-55 years) will receive a single intranasal dose of the MV-014-212 vaccine at Dosage 3 in the form of intranasal drops on Day 1.
89585977|NCT04798001|Experimental|Cohort A / Dosage Group 3a (intranasal drops) / Two Doses|Participants in this arm (18-55 years) will receive an intranasal dose of the MV-014-212 vaccine at Dosage 3 in the form of intranasal drops on Day 1. These participants will receive a second, identical dose of the MV-014-212 vaccine at Dosage 3 in the form of intranasal drops on Day 36.
89585978|NCT04798001|Experimental|Cohort A / Dosage Group 3b (intranasal spray) / Single Dose|Participants in this arm (18-55 years) will receive a single intranasal dose of the MV-014-212 vaccine at Dosage 3 in the form of a nasal spray on Day 1.
88975146|NCT00069927|Experimental|Arm II Concerta®|Concerta ® 18 mg/day for 3-12 weeks depending on subject's response
88975147|NCT05433038|Active Comparator|skeletal expander with microosteoperforation in mid palatine|group1.will include ten patients undergo skeletally anchored maxillary expander with microosteoperforation in mid palatine suture
89585979|NCT04798001|Experimental|Cohort B / Dosage Group 4 (intranasal drops) / Single Dose|Participants in this arm (56-69 years) will receive a single intranasal dose of the MV-014-212 vaccine at Dosage 1 in the form of intranasal drops on Day 1.
88975148|NCT05433038|Active Comparator|skeletal expander with microosteoperforation in mid palatine and buccally|group2.will include ten patients undergo skeletally anchored maxillary expander with microosteoperforation in mid palatine suture and buccally
89585980|NCT04798001|Experimental|Cohort B / Dosage Group 5 (intranasal drops) / Single Dose|Participants in this arm (56-69 years) will receive a single intranasal dose of the MV-014-212 vaccine at Dosage 2 in the form of intranasal drops on Day 1.
89585981|NCT04798001|Experimental|Cohort B / Dosage Group 6 (intranasal drops) / Single Dose|Participants in this arm (56-69 years) will receive a single intranasal dose of the MV-014-212 vaccine at Dosage 3 in the form of intranasal drops on Day 1.
89585982|NCT02074514|Experimental|Sofosbuvir+RBV 16 weeks|Participants with HCV genotypes 1 and 3 will receive sofosbuvir plus ribavirin for 16 weeks.
89585983|NCT02074514|Experimental|Sofosbuvir+RBV 24 weeks|Participants with HCV genotypes 1 and 3 will receive sofosbuvir plus ribavirin for 24 weeks.
89585984|NCT04191161|Experimental|Brace group|patients will receive their brace 2 weeks after the first consultation (usual delay to conceive and deliver the brace), they will be asked to wear the brace all day and will be allowed to redraw it at night. Brace must be worn for 3 months. A specific eduction on how to wear the brace will also be delivered. A thermal sensor chip will be placed in the brace to assess the observance. No physiotherapy will be prescribed during this period. Patient will attend to 3 consultations, day 0, 3 months and finally at 6 months later. These three consultations are part of usual care.
89585985|NCT04191161|Placebo Comparator|Control group|patients will continue physiotherapy sessions if already prescribed but no extra sessions will be prescribed. Pain killers will be adjusted. Patients will also attend to three consultations such as described above. Main outcome will be assessed at M3. After M3, patients who did not receive the brace will have the choice to receive it for the next 3 months and secondary outcome will be assessed at 6 months.
89585986|NCT02099708||Lansoprazole 15 mg|Lansoprazole 15 mg, capsules or orally disintegrating (OD) tablets, orally, once, daily for up to 12 months.
89585987|NCT02073656|Experimental|LDV/SOF 12 Weeks|LDV/SOF for 12 weeks
89585988|NCT02073656|Experimental|Retreatment Substudy|LDV/SOF plus RBV for 24 weeks
89585989|NCT02242643|Experimental|FluLaval™ Quadrivalent Group|"Subjects in this group received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of FluLaval™ Quadrivalent vaccine.~The vaccine was administered intramuscularly into the anterolateral region of the thigh (subjects below 12 months of age) or in the deltoid muscle of the non-dominant arm (subjects ≥12 months of age)."
89585990|NCT02242643|Active Comparator|Fluzone® Quadrivalent Group|"Subjects in this group received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of Fluzone® Quadrivalent vaccine.~The vaccine was administered intramuscularly into the anterolateral region of the thigh (subjects below 12 months of age) or in the deltoid muscle of the non-dominant arm (subjects ≥12 months of age)."
89585991|NCT02097290|Experimental|CRT-D|For all subjects with the AUTOGEN CRT-D, the autothreshold algorithms will be evaluated
89585992|NCT04061213||Patients with symptomatic severe aortic stenosis|Elderly patients referred for TAVR evaluation
89585993|NCT02072174|Experimental|Anaferon for Children|On day 1, five tablets are taken in the first 2 hours (one tablet every 30 min), followed by three more tablets regularly spaced during the rest of the day. From day 2 through 5, one tablet is administered three times daily.
89585994|NCT02072174|Placebo Comparator|Placebo|On day 1, five tablets are taken in the first 2 hours (one tablet every 30 min), followed by three more tablets regularly spaced during the rest of the day. From day 2 through 5, one tablet is administered three times daily.
89585995|NCT02209181|Experimental|JNJ-10450232 250 mg|
89585996|NCT02209181|Experimental|JNJ-10450232 1000 mg|
89585997|NCT02209181|Placebo Comparator|Placebo|
88975149|NCT05432960|Experimental|RPH-104|The investigational product RPH-104 as SC injections at a dose of 160 mg on Day 0, Day 7, Day 21 and then once every 2 weeks (Q2W).
88975150|NCT05432960|Placebo Comparator|Placebo|placebo SC Q2W (equivalent to investigational product volume)
88975151|NCT00066027|Experimental|low-dose doxycycline|low-dose doxycycline (20 mg doxycycline hyclate)
88975152|NCT00066027|Placebo Comparator|Placebo|Placebo
88975153|NCT02966964|Experimental|Tenofovir 300mg qd + DWPUR001 500mg bid|Tenofovir 300mg qd + DWPUR001 500mg bid for up to 12 months
88975154|NCT02966964|Experimental|Tenofovir 300mg qd + DWPUR001 300mg bid|Tenofovir 300mg qd + DWPUR001 300mg bid for up to 12 months
88975155|NCT02966964|Placebo Comparator|Tenofovir 300mg qd + DWPUR001 Placebo bid|Tenofovir 300mg qd + DWPUR001 Placebo bid for up to 12 months
89585998|NCT02209181|Active Comparator|Acetaminophen 1000 mg|
89585999|NCT02208089|Experimental|TransPRKCXL|Simultaneous combined transepithelial photorefractive keratectomy (TransPRK) and corneal collagen cross-linking (CXL)
89586000|NCT02208089|Active Comparator|CXL only|Corneal collagen cross-linking (CXL) using the same protocol without transepithelial photorefractive keratectomy
89586001|NCT02242487|Experimental|CVT-301 Low Dose|Capsules of levodopa inhalational powder used up to 5 times/day for OFF episodes for 12 months duration
89586002|NCT02242487|Experimental|CVT-301 High Dose|Capsules of levodopa inhalational powder used up to 5 times/day for OFF episodes for 12 months duration
89586003|NCT02241785|Experimental|natalizumab|natalizumab 300 mg intravenously (IV) every 4 weeks
89586004|NCT02241551|Experimental|gemcitabine/nab-paclitaxel|three cycles of treatment in the gemcitabine/nab-paclitaxel
89586005|NCT02241551|Experimental|mFOLFIRINOX|6 cycles in the mFOLFIRINOX
89586006|NCT04769687|Experimental|Symbiotic Treatment : probiotic Vivomixx® + prebiotic Orafti®Synergy1|"The prebiotic, Orafti®Synergy1, is made from a volume-to-volume mixture of oligofructoses and Raftiline HP. Orafti®Synergy1 is a slightly sweet white powder packaged in 5 g sachets that can be administered orally. The dose used is 2 sachets per day (morning and evening) for 8 weeks (56 days).~The probiotic, Vivomixx®, consists of 4 strains of Lactobacillus (L. casei, L. plantarum, L. acidophilus and L. delbrueckii subsp. Bulgaricus) from 3 strains of Bifidobacterium (B. longum, B. breve, and B. infantis) and a strain of streptococcus (S. salivarius subsp thermophilus). Vivomixx® is in powder form packaged in sachets of 4.5.1011 bacteria which can be administered orally. The dose used is 2 sachets per day (morning and evening) for 8 weeks (56 days).~For the study, the symbiotics will be packaged by the probiotic manufacturer in the same sachet (at the same doses as mentioned above) whether for the symbiotics or for the placebo."
89586007|NCT04769687|Placebo Comparator|Placebo|
89586008|NCT02207621|Experimental|AR-13324 Ophthalmic Solution 0.02% & placebo|1 drop AR-13324 in the evening (PM) & 1 drop placebo in the morning (AM) in both eyes (OU)
89586009|NCT02207621|Active Comparator|Timolol maleate Ophthalmic Solution 0.5% BID|1 drop twice daily (BID) in the morning (AM) and evening (PM) in both eyes (OU)
89586010|NCT02207621|Experimental|AR-13324 Ophthalmic Solution 0.02% BID|1 drop AR-13324 twice daily (BID) in the morning (AM) and evening (PM) in both eyes (OU)
89586011|NCT02240693|Experimental|BI 409306 dose 1|
89586012|NCT02240693|Experimental|BI 409306 dose 2|
89586013|NCT02240693|Experimental|BI 409306 dose 3|
89586014|NCT02240693|Experimental|BI 409306 dose 4|
89586015|NCT02240693|Placebo Comparator|Placebo|
89586016|NCT02239679|Experimental|ALA X3|Cryotherapy followed by 3 aminolevulinic acid + blue light (BLU-U) treatments
89586017|NCT02239679|Placebo Comparator|VEH|Vehicle (VEH) group will be randomized (1:1) to be balanced for the two active groups; receiving cryotherapy and 2 or 3 subsequent Topical Solution Vehicle + BLU-U treatments. Subjects receiving VEH will be considered a single treatment group.
89586018|NCT02239679|Experimental|ALA X2|Cryotherapy followed by 2 aminolevulinic acid + BLU-U treatments
89586019|NCT02072096|Experimental|Strategy A (Glucose-Dependent)|Participants may receive oral and injectable (glucagon-like peptide-1 receptor agonists [GLP-1 RA]) therapies that exert a glucose-dependent mode of action. Medications allowed in this arm include: metformin, pioglitazone, acarbose, linagliptin, sitagliptin, liraglutide, exenatide once weekly (QW), and exenatide twice daily (BID). Choice of therapy is based on investigator's discretion. Treatment used in label. Treatment may last up to 72 weeks.
89586020|NCT02072096|Active Comparator|Strategy B (Reference)|Participants will receive glimepiride and may receive basal insulin glargine as a first line injectable therapy. Medications allowed in this arm include: glimepiride, metformin, pioglitazone, acarbose, linagliptin, sitagliptin and basal insulin glargine. Choice of therapy is based on investigator's discretion. Treatment used in label. Insulin glargine is titrated according treatment algorithm. Treatment may last up to 72 weeks.
89586021|NCT02071706|Other|Single-Arm PET/MRI|Single-group evaluation of PET/MRI for diagnostic quality of image
89586022|NCT05107700|Experimental|Start with: Stay at altitude 2500 m above sea level (high altitude)|Patients with precapillary pulmonary hypertension stay a sojourn of 30 h at 2500 m.
89586023|NCT05107700|Placebo Comparator|Start with: Stay at altitude 470 m above sea level (low altitude)|Patients with precapillary pulmonary hypertension stay a sojourn of 30 h at 470 m as comparator.
89586024|NCT01631825|Experimental|SPM 962|SPM 962 transdermal patch
89586025|NCT02071082|Experimental|HIV treatment-naive and HBV treatment-naive|HIV/HBV coinfected participants who are HIV treatment-naive and HBV treatment-naive will receive E/C/F/TAF for 48 weeks.
89586026|NCT02071082|Experimental|HIV-suppressed|HIV/HBV coinfected participants who are HIV-suppressed will receive E/C/F/TAF for 48 weeks.
88975156|NCT02970890|Placebo Comparator|Placebo group|Subjects received placebo therapy. The placebo Portable Pain Away™ device was identical to the active device, displayed the same settings and emitted the same sound regardless of the comparator.
88975157|NCT02970890|Active Comparator|PBMT group|Subjects received active photobiomodulation therapy (PBMT). The active Portable Pain Away™ device was identical to the placebo device, displayed the same settings and emitted the same sound.
88975158|NCT00070122|Experimental|Arm I (oxaliplatin, leucovorin calcium, fluorouracil)|Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1 and fluorouracil IV continuously over 46-48 hours beginning on day 1. Patients are further randomized to receive bevacizumab or placebo* IV over 30-90 minutes on day 1. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity. NOTE: *As of 11/15/04, placebo is no longer part of treatment plan; all patients receive bevacizumab.
88975159|NCT00070122|Experimental|Arm II (oxaliplatin, capecitabine)|Patients receive oxaliplatin IV over 2 hours on day 1and oral capecitabine on days 1-15. Patients are further randomized to receive bevacizumab or placebo* as in arm I. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity NOTE: *As of 11/15/04, placebo is no longer part of treatment plan; all patients receive bevacizumab.
88975160|NCT05432882|Experimental|bi-4SCAR-CD19/22 T Cell Therapy for CD19 and/or CD22 positive B cell malignancies|
88975161|NCT05432609||Healthy|Weight bearing CT in fully extended and flexed (20 degrees) position, loaded and unloaded, respectively.
88975162|NCT05432609||Trochlear dysplasia|Weight bearing CT in fully extended and flexed (20 degrees) position, loaded and unloaded, respectively.
88975163|NCT05432492|Experimental|Cohort 1|Subjects receive AK112 on Day 1 of every 3-week cycle (Q3W) until progression.
88975164|NCT05432492|Experimental|Cohort 2|Subjects receive AK112 on Day 1 of every 3-week cycle (Q3W) until progression.
89586027|NCT02123108|Experimental|Basiliximab|Tacrolimus with Basiliximab induction
89586028|NCT02123108|Active Comparator|Tacrolimus Group|Tacrolimus (without basiliximab induction); standard of care group
89586029|NCT02121392|Sham Comparator|Epidural Catheter without Adductor Canal Nerve Block Catheter|Patients randomized to the sham catheter will have a sham catheter placed on the skin and obscured with an opaque dressing and attached to a functional pump which will not be turned on.
89586030|NCT02121392|Experimental|Epidural Catheter with Adductor Canal Nerve Block Catheter|Patients will receive a continuous adductor canal block placed under ultrasound guidance under the supervision of an attending physician who is fellowship trained.
89586031|NCT02097056|Experimental|donepezil HCl 23 mg|Donepezil HCl 23 mg once daily, just before bed, for 24 weeks
89586032|NCT02121002|Experimental|Diclofenac Sodium Topical Gel, 1%|Diclofenac Sodium Topical Gel, 1%. 4 gm, 4 times a day for 4 weeks
89586033|NCT02121002|Active Comparator|Voltaren Topical Gel, 1%|Voltaren Topical Gel, 1%. 4 gm, 4 times a day for 4 weeks
89586034|NCT02121002|Placebo Comparator|Vehicle Diclofenac Sodium Topical Gel|Vehicle Diclofenac Sodium Topical Gel. 4 gm, 4 times a day for 4 weeks
89586035|NCT02096900|Active Comparator|zolpidem|zolpidem given orally 0.25mg/kg pre-operatively single dose
89586036|NCT02096900|Active Comparator|midazolam|midazolam will be given at 0.5mg/kg, pre-operatively single dose
89586037|NCT02120924|Active Comparator|Finacea|Finacea® (azelaic acid) Gel, 15% (Intendis)
89586038|NCT02120924|Experimental|Azelaic Acid|Azelaic Acid, 15% topical gel (Watson Laboratories, Inc.)
89586039|NCT02120924|Placebo Comparator|Vehicle Gel|Gel Vehicle of the test product (Watson Laboratories, Inc.)
89586040|NCT02096744|Experimental|Catapres-TTS-3 crossover 1|subject to receive 0.3 mg/24 hr Catapres-TTS-3 Oppanol (T1) first, followed by Catapres-TTS-3 Vistanex (R1)
88811286|NCT02861573|Experimental|Pembrolizumab+Lenvatinib:t-NE|Participants with neuroendocrine (t-NE) mCRPC in Cohort F will receive pembrolizumab 200 mg IV on Day 1 Q3W, and lenvatinib 20 mg PO QD continuously from Day 1 of Cycle 1. Treatment with pembrolizumab will continue for a maximum of 35 cycles (up to 2 years) or until progression. Participants who must discontinue 1 of the 2 drugs due to adverse events in the combination may continue the study with the other combination drug.
89586041|NCT02096744|Experimental|Catapres-TTS-3 crossover 2|subject to receive 0.3 mg/24 hr Catapres-TTS-3 Vistanex (R1) first, followed by Catapres-TTS-3 Oppanol (T1)
89586042|NCT02096744|Experimental|Catapres-TTS-1 crossover 1|subject to receive 0.1 mg/24 hr Catapres-TTS-1 with Oppanol (T2) and Vistanex (R2) simultaneously
89586043|NCT02120456|Experimental|LEO 43204|Open-label, dose-escalation, 2-day treatment
89586044|NCT02120456|Experimental|LEO 43204 Dose 0.1%|LEO 43204 dose 0.1% once daily for two consecutive days
89586045|NCT02120456|Experimental|LEO 43204 Dose 0.075%|LEO 43204 dose 0.075% once daily for two days
89586046|NCT02120456|Placebo Comparator|Placebo|Placebo once daily for two days
89586047|NCT02120300|Experimental|LDV/SOF GT 1 or 4|Participants with chronic genotypes (GT) 1 or 4 HCV infection will receive LDV/SOF for 12 or 24 weeks. Treatment-experienced cirrhotic participants with genotype 1 HCV infection will receive LDV/SOF for 24 weeks.
89586048|NCT02120300|Experimental|SOF+RBV 12 wks GT 2|Participants with chronic genotype 2 HCV infection will receive SOF+RBV for 12 weeks.
89586049|NCT02120300|Experimental|SOF+RBV 24 wks GT 3|Participants with chronic genotype 3 HCV infection will receive SOF+RBV for 24 weeks.
89586050|NCT02070380|Experimental|MultiHance 0.1 then Dotarem 0.1 mmol/kg|MultiHance 0.1 mmol/kg Then Dotarem 0.1 mmol/kg
89586051|NCT02070380|Experimental|MultiHance 0.05 then Dotarem 0.1 mmol/kg|MultiHance 0.05 mmol/kg Then Dotarem 0.1 mmol/kg
89586052|NCT02070380|Active Comparator|Dotarem 0.1 then MultiHance 0.1 mmol/kg|Dotarem 0.1 mmol/kg Then MultiHance 0.1 mmol/kg
89586053|NCT02070380|Active Comparator|Dotarem 0.1 then MultiHance 0.05 mmol/kg|Dotarem 0.1 mmol/kg Then MultiHance 0.05 mmol/kg
89586054|NCT02069366|Placebo Comparator|Placebo|"In a randomized, double-blind, placebo-controlled, between-subjects design, we will administer a one-time oral dose of dronabinol (7.5mg) or placebo (PBO) approximately two hours prior to fMRI scanning and task performance in 40 patients with PTSD, 40 trauma-exposed controls without PTSD (TEC), and 40 non-exposed healthy controls (HC).~Within each of the three groups half of the participants will receive dronabinol and the other half will received placebo to create the following 6 groups:~PTSD-dronabinol (20)~PTSD-placebo (20)~TEC-dronabinol (20)~TEC-placebo (20)~HC-dronabinol (20)~HC-placebo (20)"
89586055|NCT02069366|Active Comparator|Dronabinol|"In a randomized, double-blind, placebo-controlled, between-subjects design, we will administer a one-time oral dose of dronabinol (7.5mg) or placebo (PBO) approximately two hours prior to fMRI scanning and task performance in 40 patients with PTSD, 40 trauma-exposed controls without PTSD (TEC), and 40 non-exposed healthy controls (HC).~Within each of the three groups half of the participants will receive dronabinol and the other half will received placebo to create the following 6 groups:~PTSD-dronabinol (20)~PTSD-placebo (20)~TEC-dronabinol (20)~TEC-placebo (20)~HC-dronabinol (20)~HC-placebo (20)"
89586056|NCT04732208||Diabetic patients|
89586057|NCT02068508||Pioglitazone|Pioglitazone 15 mg to 30 mg, orally, once daily
89586058|NCT02068352|Experimental|0.3% OPA-15406|OPA-15406 0.3% ointment was applied topically twice daily (BID) to the selected treatment area(s) at approximately 12-hour intervals for 8 weeks.
89586059|NCT02068352|Experimental|1% OPA-15406|OPA-15406 1% ointment was applied topically BID to the selected treatment area(s) at approximately 12-hour intervals for 8 weeks.
89586060|NCT02068352|Placebo Comparator|Vehicle Ointment|OPA-15406 1%-matching placebo (vehicle ointment) was applied topically BID to the selected treatment area(s) at approximately 12-hour intervals for 8 weeks.
89586061|NCT02207231|Experimental|Group I|Participants received Guselkumab 100 milligram (mg) at Weeks 0, 4, and 12 and every 8 weeks (q8w) thereafter through Week 252, placebo for guselkumab at Week 16, and placebo for adalimumab (two 0.8 milliliter [mL] injections) at Week 0 followed by one 0.8 mL injection at Weeks 1, 3, and 5, and every 2 weeks (q2w) thereafter through Week 47.
89586062|NCT02207231|Placebo Comparator|Group II|Participants received Placebo for guselkumab at Weeks 0, 4, and 12, and placebo for adalimumab (two 0.8 mL injections) at Week 0, followed by one 0.8 mL injection at Weeks 1, 3, and 5, and q2w through Week 15. At Week 16, placebo participants will cross over to receive guselkumab 100 mg at Weeks 16 and 20 and q8w thereafter through Week 252, as well as placebo for adalimumab at Weeks 17, 19, 21, and 23, and q2w thereafter through Week 47.
89586063|NCT02207231|Active Comparator|Group III|Participants received Adalimumab 80 mg at Week 0 (two 40 mg [0.8 mL] injections) and 40 mg at Weeks 1, 3, 5, and q2w thereafter through Week 47, placebo for guselkumab at Weeks 0, 4, 12, 16, and 20, and q8w thereafter through Week 44 and guselkumab 100 mg at Weeks 52, 60, and q8w thereafter through Week 252.
89586064|NCT02239601|Experimental|Physical Therapy|4 Physical therapy treatment sessions provided prior to chemotherapy and a home program to continue throughout the trial.
89586065|NCT02236559|Active Comparator|Noninvasive positive pressure ventilation|"Patients will be fit with an oronasal mask using a fitting gauge that will be applied by a respiratory therapist or other clinician skilled in management of NIPPV. Initial pressures will be at low end of suggested range but can be increased as rapidly as necessary to alleviate respiratory distress. Targets should be to lower respiratory rate to the low 20s and achieve tidal volumes of 6-8 ml/kg ideal body weight. If patients find pressures uncomfortably high, they can be lowered as necessary by 1 to 2 cmH2O decrements to enhance tolerance. EPAP (PEEP) can also be adjusted upward as needed to reduce triggering effort (by counterbalancing auto-PEEP) or to improve oxygenation.~FIO2 will be 1.0 initially to assure adequate oxygenation, but should be adjusted promptly to maintain an FIO2 of no greater than 0.6 with an EPAP (PEEP) of not more than 10 cm H2O to maintain a PaO2 > 88%."
89586066|NCT02236559|Experimental|High flow therapy|"Patients will be fit with a Vapotherm adult nasal cannula that will be applied by a respiratory therapist or other clinician skilled in management of HFT. Initial flow will be set to 35 L/min but can be decreased or increased as rapidly as necessary to alleviate respiratory distress and optimize patient comfort. Targets should be to lower respiratory rate to the low 20s and with a HFT flow rate between 20 to 35 L/min. Starting temperature will be between 35 to 37 C; if patients find the gas temperature to be uncomfortable, it can be lowered as necessary down to 33 C to enhance tolerance.~FIO2 will be 1.0 initially to assure adequate oxygenation, but should be adjusted promptly to maintain an FIO2 of no greater than 0.6 to maintain a PaO2 > 88%."
89586067|NCT02206685|Active Comparator|Treatment group|The treatment group will receive 0.2 mg/kg methadone diluted to a 20 ml infusion over 10 minutes.
89586068|NCT02206685|Placebo Comparator|Control Group|The control group will receive a 20 ml normal saline placebo infusion over 10 minutes
89586069|NCT02206607|Experimental|PF-04937319 IR MST|Reference formulation
89586070|NCT02206607|Experimental|PF-04937319 MR 1|Test MR #1
89586071|NCT02206607|Experimental|PF-04937319 MR 2|Test MR #2
89586072|NCT02206607|Experimental|PF-04937319 MR 3|Test MR #3
89586073|NCT02119676|Experimental|Ruxolitinib plus regorafenib|
89586074|NCT02119676|Active Comparator|Placebo plus regorafenib|
89586075|NCT02206061|Experimental|School-Based Asthma Care for Teens (SB-ACT)|"SB-ACT consists of 2 components: Motivational Interviewing (MI) and Directly Observed Therapy (DOT) For the first 6-8 weeks, the teen will visit the school nurse to receive a daily dose of preventive asthma medication as directly observed therapy (DOT). The purpose of DOT is to establish a relationship with the nurse, learn proper medication technique, and experience potential benefits of consistent preventive therapy.~The second component, Motivational Interviewing (MI) counseling , will start 4-6 weeks after the start of DOT. A counselor will conduct 3 in-person MI sessions with the teen at school to enhance the teen's motivation to adhere to their asthma treatment plan. The 3 sessions consist of an initial 40 minute counseling session (4-6 weeks after start of DOT), and two 30 minute follow-up sessions 2 and 6 weeks later. This component consists of an evidence-based self-management program to help the teen begin to transition to independence with preventive medication use."
89586076|NCT02206061|Active Comparator|Directly Observed Therapy|For the first 6-8 weeks after enrollment, the teen will visit the school nurse once a day to receive a daily dose of preventive asthma medication as directly observed therapy (DOT).
89586077|NCT02206061|Active Comparator|Asthma Education|Asthma educators will provide an in-school asthma education program that will match the time and attention of the MI counseling portion of the primary intervention. Each teen will receive three 1-on-1 educational sessions at school, and sessions will cover 3 main topics: 1) lung physiology and asthma basics, 2) triggers, symptoms, and warning signs, and 3) medications and self-advocacy.
89586078|NCT02095106|Other|Traditional cast first|Patients in this group will first receive a traditional fiberglass cast for two weeks, after which this cast will be removed and a waterproof cast applied.
89586079|NCT02095106|Other|Waterproof cast first|Patients in this group will receive a waterproof cast for 2 weeks, after which the waterproof cast will be removed and a traditional fiberglass cast will be applied for an additional two weeks.
89586080|NCT01631747|Active Comparator|Usual Care Group|Mom and family continue their typical eating, activity and other lifestyle habits for 24 months. They are invited to attend quarterly classes addressing prenatal wellness and family topics.
89586081|NCT01631747|Experimental|Lifestyle Intervention Group|Women in the Intervention group will participate in a lifestyle program based on Moms'adopting a healthier diet and becoming more active for 24 months. Implementation is at approximately 15 weeks.Moms will meet individually with their Lifestyle Coach (LC)at least 3 times(more as needed, attend six sessions during pregnancy and one session after delivery. In addition moms will participate in monthly phone counseling sessions with Lifestyle Coach and complete daily tracking of diet & activity and use of pedometer
89586082|NCT02068118|No Intervention|Standard care|Standard follow-up, with conventional monitoring involving consultations and monitoring by their general practitioners or referring cardiologists
89586083|NCT02068118|Experimental|Tele-cardiology group|Telecardiology Program
89586084|NCT01623830|Experimental|Reactivation + VRE|Virtual reality exposure therapy (VRE) for the fear of flying (FOF) preceded by a reminder of the feared stimulus (a virtual reality clip of a virtual airplane taxiing and taking off) presented in the head mounted display 10 minutes prior to all VR exposure therapy sessions
89586085|NCT01623830|Active Comparator|Neutral Cue + VRE|VRE for the FOF preceded by a neutral cue (a virtual reality clip of a virtual living room) presented in the head mounted display 10 minutes prior to all VR exposure therapy sessions.
89586086|NCT04731896|No Intervention|Late Amniotomy|Initiating induction of labor with oxytocin infusion followed by amniotomy 4-6 hours later
89586087|NCT04731896|Active Comparator|Early Amniotomy|Early amniotomy initiating induction of labor followed by oxytocin infusion 30 minutes later
89586088|NCT01634165|Experimental|0.3 U/kg LY2963016|Single 0.3 units/kilogram (U/kg) subcutaneous dose of LY2963016
89586089|NCT01634165|Experimental|0.3 U/kg Lantus|Single 0.3 U/kg subcutaneous dose of Lantus
89586090|NCT01634165|Experimental|0.6 U/kg LY2963016|Single 0.6 U/kg subcutaneous dose of LY2963016
89586091|NCT01634165|Experimental|0.6 U/kg Lantus|Single 0.6 U/kg subcutaneous dose of Lantus
89586092|NCT02235311|Active Comparator|Pantoprazole twice daily|Pantoprazole 40mg orally twice daily x 8 weeks after acute management of UGIB
89586093|NCT02235311|Active Comparator|Pantoprazole once daily|Pantoprazole 40mg orally once daily x 8 weeks after acute management of UGIB
89586094|NCT04777955|Experimental|Group 1, core stabilization exercises group|core stabilization exercises will be performed using swissball. Program: Sitting on the ball will include (weight shifts, forward, backward and lateral sides), (pelvic bridge), (curl-up), (curlsup with diagonal reaching), (bird-dog exercise), (push-up) exercises. The application will be carried out for 6 weeks, 3 days a week for 30-45 minutes daily.
89586095|NCT04777955|Experimental|Group 2, electrical stimulation|"An adaptation of a pre-designed protocol will be used for the application of the Normocular Electrical Stimulation in the diaphragm. Current to be applied; Synchronous impulse at 30 Hz frequency, 1 sec beat increase time, 1 sec on (muscle contraction), 1 sec beat reduction time and 20 sec off (no warning) time. Two channels, each with two electrodes, will be placed in the seventh and eighth anterior intercostal space above and below the right and left sides of the xiphoid protrusion. The other two channels, each with two electrodes, will be placed on the right and left midaxillary line of the seventh and eighth anterior intercostal space. The application will be carried out for 6 weeks, 3 days a week, for 30 minutes daily."
89586096|NCT04777955|Experimental|group 3, kinesiotape|"For anterior diaphragm banding, the patient will stand with arms raised. Next, the central part of the tape will be applied to the xiphoid protrusion with a tension of 50% to 70% after the maximum inhalation. While the patient is breathing, the ends of the tape will be pulled with 10 to 15% tension towards the lower ribs. To tape the rear diaphragm, the patient's body will bend forward, and the arms will be joined crosswise over the chest. After the maximum inhalation, the central part of the tape will be applied over the T10 with a tension of 50% to 70%. As the patient exhales and stretches the trunk, the ends of the tape will be attached to the lower ribs with a tension of 10 to 15%.~The supine position will be used in the Kinesiological taping of the right and left external oblique and internal oblique muscles. The application will be carried out for 6 weeks, 3 days a week, for 30 minutes daily."
89586097|NCT02204579|Experimental|NPSP795|intravenous
89586098|NCT02235077|Active Comparator|Spironolactone|Spironolactone 25mg or 100 mg orally, once daily while in the hospital for 96 hours
89586099|NCT02235077|Placebo Comparator|Placebo|Placebo 25mg or 100mg orally, once daily while in the hospital for 96 hours
89586100|NCT02234141|Experimental|Selonsertib 2 mg|Participants will receive selonsertib 2 milligrams (mg) for 24 weeks and may continue on this dose during the long-term treatment phase.
89586101|NCT02234141|Experimental|Selonsertib 6 mg|Participants will receive selonsertib 6 mg for 24 weeks and may continue on this dose during the long-term treatment phase.
89586102|NCT02234141|Experimental|Selonsertib 18 mg|Participants will receive selonsertib 18 mg for 24 weeks and may continue on this dose during the long-term treatment phase.
89586103|NCT02234141|Experimental|Placebo|Participants will receive selonsertib placebo for 24 weeks, and may then be rerandomized 1:1:1 to selonsertib 2, 6, or 18 mg during the long-term treatment phase.
89586104|NCT02234063|Experimental|Immediate Genetic Testing|Participants randomized to intervention will receive the APOL1 genetic test upon study enrollment.
89586105|NCT02234063|No Intervention|Control- Delayed Testing|Participants randomized to control will not receive the APOL1 genetic test upon study enrollment. They will be offered the option to take the test during their final follow-up study visit (12 months post enrollment).
89586106|NCT02232893|Experimental|Daikenchuto (TU-100)|Daikenchuto (TU-100) 5g TID (15g/day)
89586107|NCT02232893|Placebo Comparator|Placebo|Placebo TID
89586108|NCT02203721|Experimental|TECNIS Symfony Extended Range of Vision IOL, Model ZXR00|Bilaterally implanted with TECNIS Symfony Extended Range of Vision Intraocular Lens, Model ZXR00
89586109|NCT02203721|Active Comparator|TECNIS Monofocal IOL, Model ZCB00|Bilaterally implanted with TECNIS Monofocal Intraocular Lens, Model ZCB00
89586110|NCT01618695|Experimental|Perampanel|
89586111|NCT01618695|Placebo Comparator|Placebo|
89586112|NCT01896531|Experimental|Ipatasertib + mFOLFOX6|Participants will receive oral ipatasertib on Days 1 to 7 of each 14-day cycle in combination with mFOLFOX6, administered on Day 1 of each cycle.
88975165|NCT00070200|Experimental|All patients|Induction Cycles 1 and 2 (CT) (21 days each), Cyclophosphamide (Days 1 thru 5) weight based dosage (> 12 kg 400 mg/m2/day, < 12 kg 13.3 mg/kg/day, < 2 years old N/A. Topotecan (Days 1 thru 5) weight based dosage (> 12 kg 1.2 mg/m2/day, < 12 kg 0.04 mg/kg/day, < 2 years old 0.04 mg/kg/day). Filgrastim (Days 6 →) weight based dosage (> 12 kg 5 micrograms/kg, < 12 kg 5 micrograms /kg, < 2 years old 5 micrograms /kg.
88975166|NCT00070239|Experimental|Treatment|"PART 1 (closed to accrual as of 8/2005): Patients receive alvocidib IV over 1 hour on days 1, 8, and 15.~Cohorts of 3-6 patients receive escalating doses of alvocidib until the MTD* is determined.~PART 2: Patients receive alvocidib IV over 1 hour at or below the MTD determined in part 1 and then receive a maintenance dose of alvocidib IV over 1-6 hours on days 1, 8, and 15. Cohorts of 3-6 patients receive escalating durations of the maintenance dose of alvocidib until the MTD* is determined. An additional cohort of 10-20 patients receives alvocidib over 1 hour on days 1 and 15 at the MTD.~NOTE: *The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.~In both parts, courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
89586113|NCT01896531|Placebo Comparator|Placebo + mFOLFOX6|Participants will receive the placebo equivalent to ipatasertib on Days 1 to 7 of each 14-day cycle in combination with mFOLFOX6, administered on Day 1 of each cycle.
88975167|NCT05432219|Experimental|Endoscopic Transoral Retropterygoid Nasopharyngectomy|a novel endoscopic approach to resect nasopharyngeal carcinoma
89586114|NCT01618305|Experimental|Arm A (Women)|Pregnant women received ZDV/3TC + EFV
89586115|NCT01618305|Experimental|Arm B (Women)|Pregnant women received ZDV/3TC + RAL
89586116|NCT01618305|No Intervention|Arm A (Infants)|Infants born to women in Arm A; infants received no study intervention.
89586117|NCT01618305|No Intervention|Arm B (Infants)|Infants born to women in Arm B; infants received no study intervention.
89586118|NCT01886313|Active Comparator|Civamide Nasal Spray|Civamide Nasal Spray 0.01% 20ug/dose (20ul), 10ul in each nostril, twice daily, for 6 weeks
89586119|NCT01886313|Placebo Comparator|Placebo Nasal Spray|Placebo Nasal Spray 10ul in each nostril, twice daily, for 6 weeks
88975168|NCT00066378|Experimental|Arimidex + Iressa® 250 mg|Arimidex + Iressa® 250 mg Treatment should be administered until documented disease progression, unacceptable toxicity as judged by the responsible physician or patient refusal
89586120|NCT01896297|Other|dabigatran etexilate|75mg BID by oral
89586121|NCT04618263|Experimental|GATE-101, 5 mg IV, Single Dose|GATE-101, 5 mg IV, Single Dose, with follow up of 28 days
89586122|NCT04618263|Experimental|GATE-101, 15 mg IV, Single Dose|GATE-101, 15 mg IV, Single Dose, with follow up of 28 days
89586123|NCT04618263|Experimental|GATE-101, 50 mg IV, Single Dose|GATE-101, 50 mg IV, Single Dose, with follow up of 28 days
89586124|NCT04618263|Experimental|GATE-101, 150 mg IV, Single Dose|GATE-101, 150 mg IV, Single Dose, with follow up of 28 days
89586125|NCT04618263|Experimental|GATE-101, 450 mg IV, Single Dose|GATE-101, 450 mg IV, Single Dose, with follow up of 28 days
89586126|NCT04618263|Experimental|GATE-101, 15 mg IV, Single Dose, Lumbar Catheter|GATE-101, 15 mg IV, Single Dose, with Lumbar Catheter for collection of cerebrospinal fluid (CSF) PK samples, with follow up of 28 days
89586127|NCT04618263|Experimental|GATE-101, 50 mg IV, Single Dose, Lumbar Catheter|GATE-101, 50 mg IV, Single Dose, with Lumbar Catheter for collection of cerebrospinal fluid (CSF) PK samples, with follow up of 28 days
89586128|NCT04618263|Experimental|GATE-101 5 mg IV, Five Daily Doses|GATE-101 5 mg IV, Five Daily Doses, with follow up for 28 days from first dose
89586129|NCT04618263|Experimental|GATE-101 15 mg IV, Five Daily Doses|GATE-101 15 mg IV, Five Daily Doses, with follow up for 28 days from first dose
89586130|NCT04618263|Experimental|GATE-101 150 mg IV, Five Daily Doses|GATE-101 150 mg IV, Five Daily Doses, with follow up for 28 days from first dose
89586131|NCT04618263|Placebo Comparator|Placebo Comparator, Single Dose|Placebo Comparator, Single Dose, with follow up for 28 days
89586132|NCT04618263|Placebo Comparator|Placebo Comparator, Five Daily Doses|Placebo Comparator, Five Daily Doses, with follow up for 28 days from first dose
89586133|NCT01884675|Experimental|Ambrisentan|Subjects in this arm will receive ambrisentan 5 mg tablet once daily during the treatment period.
89586134|NCT01884675|Placebo Comparator|Placebo|Subjects in this arm will receive ambrisentan-matching placebo tablet once daily during the treatment period.
89586135|NCT01884597|Active Comparator|Cohort 1|12 monthly, intravitreal injections of 2.0mg ranibizumab followed by 12 monthly, intravitreal injections of 1.0mg ranibizumab
89586136|NCT01884597|Active Comparator|Cohort 2|6-months of monthly, intravitreal injections of ranibizumab 2.0mg followed by 18 months of monthly, intravitreal injections of ranibizumab 1.0mg
89586137|NCT01884597|Active Comparator|Cohort 3|24 months of monthly, intravitreal injections of ranibizumab 1.0mg
89586138|NCT01895361|Experimental|High-dose SelG1 (Selg1 5.0 mg/kg)|IV Infusion, once every 4 weeks through Week 50
88975169|NCT00066378|Active Comparator|Arimidex + Placebo|Treatment should be administered until documented disease progression, unacceptable toxicity as judged by the responsible physician or patient refusal
88975170|NCT05432102||Participants having respiratory polygraphy|This label will used to describe participants having respiratory polygraphy at Royal Papworth Hospital over a 3 month period.
88975171|NCT05432102||Participants having pulse oximetry|This label will used to describe participants having pulse oximetry at Royal Papworth Hospital over a 3 month period.
88975172|NCT00066456|Experimental|Treatment (chemosensitization, radiation, docetaxel)|Patients receive docetaxel IV over 30 minutes once daily on days 1, 8, 15, 22, 29, and 35. Within 3 hours after beginning docetaxel, patients also receive low-dose abdominal radiotherapy twice daily (at least 4 hours apart) on days 1, 2, 8, 9, 15, 16, 22, 24, 29, 30, 35, and 36. Treatment continues in the absence of unacceptable toxicity.
88975173|NCT05424419||double-brace group|AIS patients with daytime and nighttime braces
89586139|NCT01895361|Experimental|Low-dose SelG1 (Selg1 2.5 mg/kg)|IV Infusion, once every 4 weeks through Week 50
88975174|NCT05424419||single-brace group|AIS patients with a single brace for day and night
88975175|NCT02967042|Other|18F-PET-TT|
88975176|NCT00070434|Experimental|Irinotecan + 5-FU + Leucovorin|Irinotecan 180mg/m2, IV for 90min on Day 1, q 2 wk x 4 cycles; 5-FU 400 mg/m2, IV bolus on Day 1, q 2 wk x 4 cycles; 5-FU 2.4 g/m2 IV for 46 hours on Day 1, q 2 wk x 4 cycles; Leucovorin 200 mg/m2 IV for 2 hours on Day 1, q 2 wk x4 cycles.
88975177|NCT00070434|Experimental|Irinotecan + Oxaliplatin|Irinotecan 175mg/m2 IV for 90 minutes on Day 1, q 2wk x4 cycles; Oxaliplatin 85mg/m2 IV for 2 hours on Day 1, q 2wk x4 cycles
88975178|NCT00070434|Experimental|Oxaliplatin + 5-FU + Leucovorin|Oxaliplatin 85mg/m2 IV for 90 minutes on Day 1, q 2wk x4 cycles; 5-FU 400mg/m2 IV bolus on Day 1, q 2wk x4 cycles; 5-FU 2.4g/m2 IV for 46 hours on Day 1, q 2wk x4 cycles; Leucovorin 200mg/m2 IV for 2 hours on Day 1, q 2wk x4 cycles.
88975179|NCT05402891|Experimental|Study population|Every patient will receive treatment: Lithiumcarbonate 300mg daily in oral tablet for six months. There will no control group included since patient represent their own control in the nontreatment-phase.
88975180|NCT00066612|Experimental|Treatment|Irinotecan
89586140|NCT01895361|Placebo Comparator|Placebo|IV Infusion, once every 4 weeks through Week 50
89586141|NCT01883895|Other|exercise treatment|"Concentric exercise: subject will utilize a dumbbell with elbow flexion exercise.~Isometric exercise: Subjects will perform 5 sets of sustained muscle contraction.~Control: Subjects will undergo a control arm where they will rest for approximately 10 minutes.~Pain testing conducted by Forgionei-Barber pressure pain-stimulator for both the control and exercise treatments."
89586142|NCT01864005|Experimental|Ticagrelor|
89586143|NCT01864005|Active Comparator|clopidogrel|
89586144|NCT01863849|Experimental|Age group 1: adults (18-59 years)|"Intervention: Vaccination with Fluval AB suspension for injection.~Dosage: A single dose (0.5 ml) vaccine, administered intramuscularly."
89586145|NCT01863849|Experimental|Age group 2: elderly (> 60 years)|"Intervention: Vaccination with Fluval AB suspension for injection.~Dosage: A single dose (0.5 ml) vaccine, administered intramuscularly."
89586146|NCT01863771|Experimental|Golimumab|
89586147|NCT01863771|Placebo Comparator|Placebo|
89586148|NCT01894581|Experimental|Obese Women|Women with a BMI of greater than or equal to 30 kg/m2 underwent all study interventions, including taking 5 g daily of LOVAZA. Women underwent 8 hours of frequent blood sampling every 10 minutes both at baseline and after LOVAZA supplementation. Each frequent blood sampling included IV administration of GnRH at 6 hours.
89586149|NCT01894581|Active Comparator|Normal Weight|Women with a BMI of between 18-25 kg/m2 underwent all study interventions, including taking 5 g daily of LOVAZA for one cycle. Women underwent 8 hours of frequent blood sampling every 10 minutes both at baseline and after LOVAZA supplementation. Each frequent blood sampling included IV administration of GnRH at 6 hours.
89586150|NCT04613973||Patients included in the PRADO program|Patients hospitalized for global heart failure or left ventricular insufficiency in the Cardiology department of the GHPSJ between January 2016 and September 2018, included in the support program for Return To Home for Heart Failure (PRADO)
89586151|NCT04613973||Patients not included in the PRADO program|Patients hospitalized for global heart failure or left ventricular insufficiency in the Cardiology department of the GHPSJ between January 2016 and September 2018, not included in the Return A DOmicile support program for Heart Failure (PRADO)
89586152|NCT04191395||Inflammatory bowel disease|
89586153|NCT04191395||Chronic inflammatory rheumatic disease|
89586154|NCT04191395||Chronic inflammatory skin diseases|
89586155|NCT01893411|Experimental|16 Units per kg body weight incobotulinumtoxinA (Xeomin)|
89586156|NCT01893411|Experimental|12 Units per kg body weight incobotulinumtoxinA (Xeomin)|
89586157|NCT01893411|Experimental|4 Units per kg body weight incobotulinumtoxinA (Xeomin)|
89586158|NCT02232425|Experimental|Drug: IX-01|Two to four 200 mg capsules administered orally, 1-6 hours prior to sexual activity
89586159|NCT02232425|Placebo Comparator|Placebo|Two to four capsules administered orally, 1-6 hours prior to sexual activity
89586160|NCT01631435|Other|bowel prep regimen|Each study subject will undergo a bowel preparation followed by a PillCam procedure.
89586161|NCT02230085||CPAP therapy|
89586162|NCT02202785|Experimental|MLN0264 1.8 mg/kg|MLN0264 1.8 mg/kg, 30-minute intravenous (IV) infusion, Day 1 of each 21-day cycle, for up to 1 year or until disease progression or unacceptable toxicity occurs (Up to 10 cycles). The dose may be decreased, delayed or discontinued in participants who develop treatment-associated nonhematologic and hematologic toxicity to MLN0264.
89586163|NCT01882647|Experimental|Active Arm|Topical lotion, applied twice daily
89586164|NCT01882647|Placebo Comparator|Vehicle Arm|Topical lotion, applied twice daily
89586165|NCT01882257|No Intervention|Normal sleep breathing|Home-based sleep studies indicate no obstructive sleep apnea or nocturnal hypoventilation. No intervention.
89586166|NCT01882257|Experimental|BiPAP -Auto for sleep apnea|Patients whose home-based sleep study detects obstructive sleep apnea, but no nocturnal hypoventilation. Noninvasive ventilatory support will be prescribed according to standard clinical criteria.
89586167|NCT01882257|Experimental|BiPAP (AVAPS) for nocturnal hypoventilation|Patients whose home-based sleep study detects nocturnal hypoventilation in the presence or absence of obstructive sleep apnea. Noninvasive ventilatory support will be prescribed according to standard clinical criteria. BiPAP/AVAPS (Phillips Respironics) is worn with a mask interface of the subject's choice. It is specifically designed to treat nocturnal hypoventilation.
89586168|NCT04415697||Responders|Those who present complete response, partial response, or stable disease, according to RECIST 1.1.
89586169|NCT04415697||Not responders|Those who present progression disease according to RECIST 1.1.
89586170|NCT02202551|Experimental|ADS-5102|amantadine HCl extended release
89586171|NCT02202317|Experimental|Y90 Based PET/CT Scan|
89586172|NCT02118337|Experimental|MEDI0680 0.1 mg/kg + Durvalumab 3 mg/kg|Participants in dose-escalation phase will receive IV infusion of MEDI0680 0.1 mg/kg and durvalumab 3 mg/kg every 2 weeks (Q2W) for up to 12 months.
89586173|NCT02118337|Experimental|MEDI0680 0.1 mg/kg + Durvalumab 10 mg|Participants in dose-escalation phase will receive IV infusion of MEDI0680 0.1 mg/kg and durvalumab 10 mg/kg Q2W for up to 12 months.
89586174|NCT02118337|Experimental|MEDI0680 0.5 mg/kg + Durvalumab 10 mg|Participants in dose-escalation phase will receive IV infusion of MEDI0680 0.5 mg/kg and durvalumab 10 mg/kg Q2W for up to 12 months.
89586175|NCT02118337|Experimental|MEDI0680 2.5 mg/kg + Durvalumab 10 mg|Participants in dose-escalation phase will receive IV infusion of MEDI0680 2.5 mg/kg and durvalumab 10 mg/kg Q2W for up to 12 months.
89586176|NCT02118337|Experimental|MEDI0680 10 mg/kg + Durvalumab 10 mg|Participants in dose-escalation phase will receive IV infusion of MEDI0680 10 mg/kg and durvalumab 10 mg/kg Q2W for up to 12 months.
89586177|NCT02118337|Experimental|MEDI0680 20 mg/kg + Durvalumab 10 mg|Participants in dose-escalation phase will receive IV infusion of MEDI0680 20 mg/kg and durvalumab 10 mg/kg Q2W for up to 12 months.
89586178|NCT02118337|Experimental|MEDI0680 20 mg/kg|Participants in dose-expansion phase will receive IV infusion of MEDI0680 20 mg/kg Q2W until unacceptable toxicity, confirmed disease progression, development of other reason for treatment discontinuation, or for a maximum of 2 years, whichever occurred first.
89586179|NCT02118337|Experimental|MEDI0680 20 mg/kg + Durvalumab 750 mg|Participants in dose-expansion phase will receive IV infusion of MEDI0680 20 mg/kg and durvalumab 750 mg/kg Q2W until unacceptable toxicity, confirmed disease progression, development of other reason for treatment discontinuation, or for a maximum of 2 years, whichever occurred first.
89586180|NCT02118337|Active Comparator|Nivolumab 240 mg|Participants in dose-expansion phase will receive IV infusion of nivolumab 240 mg Q2W until unacceptable toxicity, confirmed disease progression, development of other reason for treatment discontinuation, or for a maximum of 2 years, whichever occurred first.
89586181|NCT02117713|Experimental|LUM001 (Maralixibat)|Participant will receive LUM001 also known as Maralixibat (MRX) administered orally once per day.
89586182|NCT02105467|Experimental|Immediate Treatment Group|Participants received blinded grazoprevir 100 mg / elbasvir 50 mg fixed-dose combination (FDC) tablet orally once daily for 12 weeks followed by a 24-week follow-up period
89586183|NCT02105467|Placebo Comparator|Deferred Treatment Group|Participants received blinded placebo tablet orally once daily for 12 weeks; after a 4-week unblinding/washout period participants received open label grazoprevir 100 mg / elbasvir 50 mg FDC tablet orally once daily for 12 weeks. Follow-up was continued for an additional 24 weeks.
89586184|NCT02202161|Experimental|GSK2330672 10 mg|Subjects will receive metformin 850 mg BID for 13-15 days during the run in period followed by GSK2330672 10 mg BID for 14 days.
89586185|NCT02202161|Experimental|GSK2330672 20 mg|Subjects will receive metformin 850 mg BID for 13-15 days during the run in period followed by GSK2330672 20 mg BID for 14 days.
89586186|NCT02202161|Experimental|GSK2330672 30 mg|Subjects will receive metformin 850 mg BID for 13-15 days during the run in period followed by GSK2330672 30 mg BID for 14 days.
89586187|NCT02202161|Experimental|GSK2330672 90 mg|Subjects will receive metformin 850 mg BID for 13-15 days during the run in period followed by GSK2330672 90 mg BID for 14 days.
88975181|NCT00070551|Experimental|Stratum I (GTI-2040, cytarabine)|Patients receive GTI-2040 IV continuously on days 1-6 and high-dose cytarabine IV over 2 hours twice daily on days 2, 4, and 6.
89209734|NCT04044638|Experimental|Young Group|"Young women who underwent 8 weeks of training and had their blood pressure checked at baseline and after 4 and 8 weeks of training.~Resistance training sessions were held 3 times a week, in which each session lasted 60 minutes and was performed for a period of 8 weeks. Each session consisted of 10-minute warm-up, shortly after, starting the exercises in the form of alternating circuit by segment, as: machine bench press, extension chair, high pull (front), flexor table, direct curl, leg press, triceps pulley, adductor, abdominal, abductor and calf. In all 10 exercises, 3 sets of 8 to 12 repetitions were performed, with an interval of 60 seconds between sets and intensity of 12 arbitrary units (a.u.) to 14 a.u., measured by the rate perception effort scale."
89517585|NCT05165953||Group 3: COVID-19 negative with asthma|"data were collected from medical records including: history of COVID -19 infection, presenting symptoms and clinical examination, hospitalization either ICU or ward. For asthma patients, their full data were collected regarding asthma control in last 3 months following GINA criteria for asthma control [8], Investigations included; CBC with differential count, WBC, lymphocytes, eosinophils, HGB and platelets, Inflammatory markers as d-dimer, LDH and ferritin level, electrolytes, BUN, serum creatinine, CXR, and old spirometry reports.~Diagnosis of COVID 19 infection was made by a positive nasopharyngeal and throat swabs COVID 19 polymerase chain reaction (PCR)."
89517586|NCT02318459|Experimental|high intensity interval training-HIIT|HIIT 4 times a week, 30 minutes duration
88811287|NCT02861573|Experimental|Pembrolizumab/Vibostolimab coformulation|Participants with AC mCRPC in Cohort G will receive a coformulation fixed dose combination of 200 mg pembrolizumab and 200 mg vibostolimab (MK-7684) Q3W IV from Day 1 of Cycle 1. Treatment will continue for a maximum of 35 cycles (up to 2 years) or until progression.
88975182|NCT00070551|Experimental|Stratum II (GTI-2040, cytarabine)|Patients receive GTI-2040 IV continuously on days 1-6 and high-dose cytarabine IV over 4 hours once daily on days 2-6. In both strata, treatment continues in the absence of unacceptable toxicity.
89517587|NCT02318459|Active Comparator|Traditionnal rehabilitation|Traditionnal group rehabilitation 3 times a week, 1 hour duration.
89517588|NCT05399797|Experimental|Pharmacists in the intervention group|The pharmacist will be given an online educational training on management of acute uncomplicated urinary tract infections
88811288|NCT02861573|Experimental|Pembrolizumab/Vibostolimab coformulation:t-NE|Participants with t-NE mCRPC in Cohort H will receive a coformulation fixed dose combination of 200 mg pembrolizumab and 200 mg vibostolimab (MK-7684) Q3W IV from Day 1 of Cycle 1. Treatment will continue for a maximum of 35 cycles (up to 2 years) or until progression.
89517589|NCT05399797|No Intervention|Pharmacists in the control group|pharmacists in this group will not be trained, until after the completion of the study.
89517590|NCT04462445|Experimental|pazopanib|Pazopanib 800 mg (2x400mg ) taken orally daily as per clinical practice
89517591|NCT02318537|Experimental|Cannabidiol Oral Solution|Participants will receive cannabidiol oral solution at an appropriate dose (no higher than 40 mg/kg/day) determined by data from a previous trial. The total daily dose will be administered in twice daily doses, approximately 12 hours apart.
89517592|NCT02318537|Placebo Comparator|Placebo Solution|Participants will receive matching placebo solution administered twice daily, approximately 12 hours apart.
89517593|NCT05399719||Tumor tissue from BMT recipients|tumor tissue sections from patients received allogeneic bone marrow transplantation before
89517594|NCT05399719||Peripheral blood from healthy volunteer|peripheral blood from peripheral blood stem cell donors or healthy control
89517595|NCT02318615|Experimental|Immediate Axillary Plasty|Immediate Axillary Plasty ：After axillary lymph node dissection, a pedicled flap named Partial Latissimus Dorsi Muscle Flap is filled in the cavity of axilla, and fixed around the axillary vessels.
89517596|NCT02318615|No Intervention|Education|Education：After surgery, education on the prevention of lymphedema. In patients suffering with upper limb lymphedema during follow-up, any treatment except axillary or breast reconstruction can be used.
89517597|NCT04462211|Experimental|Management pharmacological protocol and bundle's|"The elaboration of the protocol according to the evidence-based approach, updated evidence found from both search engines such as MEDLINE, EMBASE, Cochrane Library, OVID and ScIELO will be used through the research question using the PICO method (Patient interest, Intervention, Comparation and Outcome).~the ready-made protocol will be adjusted to the pharmacological options that are available in the hospital."
89517598|NCT03500003|Experimental|Milk acute intake|14 adult and 14 elderly volunteers will consume 600mL of milk. Blood (11 sampling points) and urine samples (3 collection points) will be collected before the ingestion and during the postprandial period (6h).
89517599|NCT03500003|Experimental|Yogurt acute intake|14 adult and 14 elderly volunteers will consume 600mL of yogurt. Blood (11 sampling points) and urine samples (3 collection points) will be collected before the ingestion and during the postprandial period (6h).
89517600|NCT04454749||Stimulated cycles|Ovarian stimulation will be performed by standard protocols. Stimulation medication dosage will be individualised prior to stimulation start according to the ovarian reserve parameters and during ovarian stimulation according to the ovarian response and the measured levels of E2 and progesterone (P4), in order to avoid progesterone elevation during late follicular phase. Final oocyte maturation will be achieved by administration of either 10.000 IU of hCG, 0.3 mg of GnRH agonist (Triptorelin) or dual trigger (hCG and GnRH-analogue), as soon as ≥ 3 follicles ≥ 17 mm are present. Oocyte retrieval will be carried out 36 hours after administration of the trigger. Embryos will undergo PGT-A at blastocyst stage and be vitrified thereafter.
89532469|NCT06243692|Active Comparator|Topiramate arm|The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. All patients will receive topiramate 100 mg daily and Acetaminophen 500-1000 mg only in acute migraine attacks for 3 months. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of lacosamide was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
89586188|NCT02202161|Placebo Comparator|GSK2330672-matched placebo|Subjects will receive metformin 850 mg BID for 13-15 days during the run in period followed by matching placebo (of GSK2330672) BID for 14 days.
89586189|NCT02202161|Active Comparator|Sitagliptin 50 mg|Subjects will receive metformin 850 mg BID for 13-15 days during the run in period followed by Sitagliptin 50 mg BID for 14 days. In this study, sitagliptin 50 mg BID will be provided as open-label (unblinded) study treatment.
89586190|NCT03267563|Experimental|Enhanced implementation as usual (EIAU)|All clinics will receive enhanced implementation as usual (EIAU) that is initial clinical and operational training + tools for sustainment. This occurs once at the beginning of the trial.
89586191|NCT03267563|Experimental|Low-intensity coaching and feedback|Clinics will receive enhanced implementation as usual (EIAU) plus low-intensity (every 3 months) implementation coaching and feedback (LICF). LICF consists of quarterly clinical and operational coaching and feedback calls, as well as quarterly participation in an implementation collaborative board.
89586192|NCT03267563|Experimental|High-intensity coaching and feedback|Clinics will receive enhanced implementation as usual (EIAU) plus high-intensity (every month) implementation coaching and feedback (HICF). HICF consists of monthly clinical and operational coaching and feedback calls, monthly participation in an implementation collaborative board, and on call technical assistance.
89586193|NCT03109847|Experimental|Arm I (metformin hydrochloride)|Patients receive metformin hydrochloride PO daily for 3 days and then PO BID for up to 2 weeks after completing radioactive iodine treatment.
89586194|NCT03109847|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO daily for 3 days and then PO BID for up to 2 weeks after completing radioactive iodine treatment
89586195|NCT01461928|Other|Maintenance II Period Observation Only|Participants will receive standard chemotherapy regimen in combination with 375 mg/m^2 rituximab IV in Cycle 1 (3-4 week-cycles), followed by 1400 mg rituximab SC every 3-4 weeks for 8 cycles (induction period); 1400 mg rituximab SC every 8 weeks for 24 months (Maintenance I period); no treatment in Maintenance II period until disease progression or end of study, whichever occurs first.
89586196|NCT01461928|Experimental|Maintenance II Period Rituximab|Participants will receive standard chemotherapy regimen in combination with 375 mg/m^2 rituximab IV in Cycle 1 (3-4 week-cycles), followed by 1400 mg rituximab SC every 3-4 weeks for 8 cycles (induction period); 1400 mg rituximab SC every 8 weeks for 24 months (Maintenance I period); 1400 mg rituximab SC every 8 weeks until disease progression or end of study, whichever occurs first (Maintenance II period).
89586197|NCT03097991|Experimental|Intervention: Treatment as Usual + Focused Coparenting Consult|Receipt of Treatment As Usual/Resource and Referral supports, plus opportunity to complete six 90-minute Focused Coparenting Consultation (FCC) sessions followed by one postnatal booster session designed to strengthen the mother-father coparenting alliance
89586198|NCT03097991|No Intervention|Control: Treatment as Usual|Receipt of TAU/Resource and Referral supports
89586199|NCT02892305||PAC with LVLM|Patients with pancreatic cancer and low-volume liver metastasis
89586200|NCT02623205|Active Comparator|Escitalopram|Active Comparator: Escitalopram (Lexapro) 10mg Week 1, 20mg Weeks 2 and 3, and 30mg for Weeks 4 to 8 (or until 12 for patients close to remission)
89586201|NCT02623205|Placebo Comparator|Placebo|Lactose pill manufactured to mimic Escitalopram pill
89586202|NCT01500694|Experimental|Extended-release Guanfacine HCl|
89586203|NCT04188977|Other|Usual Practice|OTPs are able to request from state and federal health department officials to utilize interim methadone treatment to address admission delays in their OTP.
89586204|NCT04188977|Experimental|Implementation Facilitation|Implementation Facilitation (IF) will consist of educational outreach to OTP staff, identification of local champions, training, performance feedback, and learning collaborative for OTP staff and state health department officials.
89586205|NCT01500382|Experimental|Vibegron 100 mg + tolterodine ER 4 mg → placebo|During Treatment Period 1, participants will receive 7 days of once-daily vibegron 100 mg and tolterodine extended-release (ER) 4 mg. Participants will then complete a 2-week single-blind double-dummy placebo washout period prior to Treatment Period 2. During Treatment Period 2, participants will receive 7 days of once-daily placebo to match vibegron and placebo to match tolterodine ER.
89586206|NCT01500382|Experimental|Placebo → vibegron 100 mg|During Treatment Period 1, participants will receive 7 days of once-daily placebo to match vibegron and placebo to match tolterodine ER. Participants will then complete a 2-week single-blind double-dummy placebo washout period prior to Treatment Period 2. During Treatment Period 2, participants will receive 7 days of once-daily vibegron 100 mg and placebo to match tolterodine ER.
89586207|NCT01500382|Active Comparator|Placebo → tolterodine ER 4 mg|During Treatment Period 1, participants will receive 7 days of once-daily placebo to match vibegron and placebo to match tolterodine ER. Participants will then complete a 2-week single-blind double-dummy placebo washout period prior to Treatment Period 2. During Treatment Period 2, participants will receive 7 days of once-daily tolterodine 4 mg and placebo to match vibegron.
89586208|NCT01500382|Experimental|Placebo → vibegron 50 mg|During Treatment Period 1, participants will receive 7 days of once-daily placebo to match vibegron and placebo to match tolterodine ER. Participants will then complete a 2-week single-blind double-dummy placebo washout period prior to Treatment Period 2. During Treatment Period 2, participants will receive 7 days of once-daily vibegron 50 mg and placebo to match tolterodine ER.
89586209|NCT02137837|Placebo Comparator|Arm 1: fulvestrant + everolimus placebo + anastrozole placebo|Patients receive an injection of fulvestrant in each buttock on Days 1 &15 for Cycle 1 and then Day 1 only for subsequent cycles. Patients also receive an oral placebo daily for both everolimus and anastrozole. This treatment regimen will continue until disease progression or toxicity.
89586210|NCT02137837|Experimental|Arm 2: fulvestrant + everolimus + anastrozole placebo|Patients receive an injection of fulvestrant in each buttock on Days 1 &15 for Cycle 1 and then Day 1 only for subsequent cycles. Patients also receive an oral everolimus and an oral placebo for anastrozole daily. This treatment regimen will continue until disease progression or toxicity.
89586211|NCT02137837|Experimental|Arm 3: fulvestrant + everolimus + anastrozole|Patients receive an injection of fulvestrant in each buttock on Days 1 &15 for Cycle 1 and then Day 1 only for subsequent cycles. Patients also receive everolimus and anastrozole by mouth daily. This treatment regimen will continue until disease progression or toxicity.
88975183|NCT02958579||Obesity|Body mass index (BMI) score > 25.2 kg/m2 for women and > 27.3 kg/m2 for men or Waist circumference > 90 cm
89586212|NCT01483690|Experimental|Initial Dose Level|"Decitabine 15 mg/m2/day given IV over 1 hour on days 1 through 7 and days 15 through 21.~Vorinostat: 180 mg/m2/day (Max dose=400 mg daily) given orally on days 3 through 10 and days 17 through 24"
89586213|NCT01483690|Experimental|Modified Dose Level|"Decitabine 10 mg/m2/day given IV over 1 hour on days 1 through 5 and days 15 through 19.~Vorinostat: 180 mg/m2/day (Max dose=400 mg daily) given orally on days 2 through 7 and days 16 through 21"
89586214|NCT02104765|Experimental|5 mg LY2951742 Single Dose|5 mg LY2951742 given subcutaneously once
89586215|NCT02104765|Experimental|50 mg LY2951742 Single Dose|50 mg LY2951742 given subcutaneously once
89586216|NCT02104765|Experimental|120 mg LY2951742 Single Dose|120 mg LY2951742 given subcutaneously once
89586217|NCT02104765|Experimental|300 mg LY2951742 Single Dose|300 mg LY2951742 given subcutaneously once
89586218|NCT02104765|Experimental|300 mg LY2951742 Multiple Dose|300 mg LY2951742 given subcutaneously once every 4 weeks (Q4W)
89586219|NCT02104765|Placebo Comparator|Placebo Single Dose|Placebo given subcutaneously once
89586220|NCT02104765|Placebo Comparator|Placebo Multiple Dose|Placebo given subcutaneously once every 4 weeks (Q4W)
89586221|NCT01483144|Experimental|Eflornithine plus Sulindac|Eflornithine 750 mg and Sulindac 150 mg
89586222|NCT01483144|Active Comparator|Eflornithine plus Sulindac Placebo|Eflornithine 750 mg and Placebo
89586223|NCT01483144|Active Comparator|Sulindac plus Eflornithine Placebo|Sulindac 150 mg and Placebo
89586224|NCT01881789|Experimental|Oprozomib 150 mg 5/14 + Lenalidomide + Dexamethasone|Participants received oprozomib 150 mg once daily on days 1 to 5 and days 15 to 19 (5/14 schedule) of each 28-day treatment cycle, in combination with lenalidomide 25 mg on days 1 through 21 and dexamethasone 20 mg/day on days 1, 2, 8, 9, 15, 16, 22, and 23, until progression of disease, unacceptable toxicity, or for 24 cycles, whichever occurred first. After completing 24 cycles of treatment, participants with stable disease or better could have continued on oprozomib with or without dexamethasone pretreatment.
89586225|NCT01881789|Experimental|Oprozomib 180 mg 5/14 + Lenalidomide + Dexamethasone|Participants received oprozomib 180 mg once daily on days 1 to 5 and days 15 to 19 (5/14 schedule) of each 28-day treatment cycle, in combination with lenalidomide 25 mg on days 1 through 21 and dexamethasone 20 mg/day on days 1, 2, 8, 9, 15, 16, 22, and 23, until progression of disease, unacceptable toxicity, or for 24 cycles, whichever occurred first. After completing 24 cycles of treatment, participants with stable disease or better could have continued on oprozomib with or without dexamethasone pretreatment.
89586226|NCT01881789|Experimental|Oprozomib 210 mg 5/14 + Lenalidomide + Dexamethasone|Participants received oprozomib 210 mg once daily on days 1 to 5 and days 15 to 19 (5/14 schedule) of each 28-day treatment cycle, in combination with lenalidomide 25 mg on days 1 through 21 and dexamethasone 20 mg/day on days 1, 2, 8, 9, 15, 16, 22, and 23, until progression of disease, unacceptable toxicity, or for 24 cycles, whichever occurred first. After completing 24 cycles of treatment, participants with stable disease or better could have continued on oprozomib with or without dexamethasone pretreatment.
89586227|NCT01881789|Experimental|Oprozomib 210 mg 2/7 + Lenalidomide + Dexamethasone|Participants received oprozomib 210 mg once daily on days 1, 2, 8, 9, 15, 16, 22, and 23 (2/7 schedule) of each 28-day treatment cycle, in combination with lenalidomide 25 mg on days 1 through 21 and dexamethasone 20 mg/day on days 1, 2, 8, 9, 15, 16, 22, and 23, until progression of disease, unacceptable toxicity, or for 24 cycles, whichever occurred first. After completing 24 cycles of treatment, participants with stable disease or better could have continued on oprozomib with or without dexamethasone pretreatment.
89586228|NCT01881789|Experimental|Oprozomib 240 mg 2/7 + Lenalidomide + Dexamethasone|Participants received oprozomib 240 mg once daily on days 1, 2, 8, 9, 15, 16, 22, and 23 (2/7 schedule) of each 28-day treatment cycle, in combination with lenalidomide 25 mg on days 1 through 21 and dexamethasone 20 mg/day on days 1, 2, 8, 9, 15, 16, 22, and 23, until progression of disease, unacceptable toxicity, or for 24 cycles, whichever occurred first. After completing 24 cycles of treatment, participants with stable disease or better could have continued on oprozomib with or without dexamethasone pretreatment.
89586229|NCT01881789|Experimental|Oprozomib 210 mg 2/7 + Cyclophosphamide + Dexamethasone|Participants received oprozomib 210 mg once daily on days 1, 2, 8, 9, 15, 16, 22, and 23 (2/7 schedule) of each 28-day treatment cycle, in combination with oral cyclophosphamide 300 mg/m² on days 1, 8, and 15 and dexamethasone 20 mg/day on days 1, 2, 8, 9, 15, 16, 22, and 23, until progression of disease, unacceptable toxicity, or for 8 cycles, whichever occurred first. After completing 8 cycles of treatment, participants with stable disease or better were to continue on oprozomib with dexamethasone premedication for a total of 24 cycles or until progression of disease or unacceptable toxicity. After completing 24 cycles of treatment, participants without evidence of disease progression could have continued on oprozomib with or without dexamethasone pretreatment.
89586230|NCT02075203|Experimental|AERAS-404 (15 mcgH4/500 nmol IC31)|2 doses on Study Days 0 and 56
89586231|NCT02075203|Active Comparator|Bacillus Calmette-Guérin (BCG)|1 Dose on Study Day 0
89586232|NCT02075203|Placebo Comparator|Placebo|2 Doses on Study Days 0 and 56
89586233|NCT01892163|Active Comparator|Ozurdex PRN dosing|Ozurdex PRN dosing versus Ozurdex fixed dosing
89586234|NCT01892163|Experimental|Ozurdex fixed dosing|
89030265|NCT04694898|Other|Control|Households in the control arm receive standard/national nutrition specific interventions, i.e. growth monitoring, vaccination, vitamin A supplementation and deworming
89586235|NCT01881009|Experimental|Inpatient overnight|Participants in this group will have an overnight evaluation to test safety of the closed-loop system therapy device.
89586236|NCT01881009|Experimental|Summer Camp Session|Participants in this group will receive either the sensor augmented pump or the close loop controller on the first night, then alternated treatment type each night for the duration of the study.
89532470|NCT06239688|Experimental|essentiALZ|Communities randomized to this arm will receive the essentiALZ training: a web-based training taken by AL staff that contains three hours of self-paced content separated into five modules, plus a final review. Modules include: 1) Alzheimer's disease and dementia; 2) person-centered care; 3) assessment and care planning; 4) activities of daily living; and 5) behaviors and communication. Staff will be encouraged to take the training over the course of four weeks.
89586237|NCT06287151|Active Comparator|General Anesthesia with Penile Block|Penile block: prior to the start of surgery 0.5mg/kg of 0.25% bupivacaine w/o epinephrine will be administered GA : Inhalation induction with sevoflurane followed by peripheral IV access, and placement of an endotracheal tube or laryngeal mask airway. No intravenous neuromuscular blockade will be given. Sevoflurane is FDA approved for the induction and maintenance of general anesthesia in adults and pediatric patients.
89586238|NCT06287151|Active Comparator|Spinal Anesthesia with Clonidine|Spinal block: 0.5% isobaric bupivacaine with 1:200,000 epinephrine (0.2mL/kg up to 1mL), with or without 1mcg/kg clonidine Clonidine is an FDA approved medication that is commonly administered as an adjunct to SA and CA in this population.
89586239|NCT06287151|Active Comparator|Spinal Anesthesia without Clonidine|Spinal block: 0.5% isobaric bupivacaine with 1:200,000 epinephrine (0.2mL/kg up to 1mL), with or without 1mcg/kg clonidine
89586240|NCT06287151|Active Comparator|General Anesthesia with Caudal Anesthesia with Clonidine|Caudal block: single-shot caudal injection following induction of GA with 1mL/kg of 0.25% bupivacaine with 1:200,000 epinephrine, with or without clonidine 1mcg/kg Clonidine is an FDA approved medication that is commonly administered as an adjunct to SA and CA in this population.
89586241|NCT06287151|Active Comparator|General Anesthesia with Caudal Anesthesia without Clonidine|Caudal block: single-shot caudal injection following induction of GA with 1mL/kg of 0.25% bupivacaine with 1:200,000 epinephrine, with or without clonidine 1mcg/kg
89586242|NCT06287151|Active Comparator|General Anesthesia only|GA alone: Inhalation induction with sevoflurane followed by peripheral IV access, and placement of an endotracheal tube or laryngeal mask airway. No intravenous neuromuscular blockade will be given. Sevoflurane is FDA approved for the induction and maintenance of general anesthesia in adults and pediatric patients.
89586243|NCT06287138|Experimental|Experimental arm|Before the trial drug administration, included patients will receive a continuous infusion of remifentanil for analgesia, starting at 0.01 μg/kg/min and adjusting infusion rate to target a Critical-care Pain Observation Tool (CPOT) score of 0-1. The experimental drug was not to be administered until it was confirmed that the patient's baseline sedation level had reached a RASS score of ≥ -2. For sedation, the ciprofol was started at the rate of 0.3 mg/kg/h and maintained for 30 minutes. Then, the initial infusion rate was increased to 0.4, 0.5, 0.6, 0.7, and up to 0.8 mg/kg/h every 30 minutes. The infusion of ciprofol would be stopped if the RASS score ≤ -4, respiratory rate < 8 breaths/min, or Saturation of pulse oxygen (SpO2) < 90% before the maximal dose of 0.8 mg/kg/h was achieved.
89586244|NCT06287125||systemic sclerosis patients|"Adult (aged above 18 years) SSc patients who fulfilled the 2013 European League Against Rheumatism/American College of Rheumatology (EULAR / ACR) for SSC and 1980 ACR criteria.~-SSc patients will be subjected to 2017 European Scleroderma Trials and Research group (EUSTAR) activity index"
89586245|NCT06287125||systemic lupus erythematosus patients|"Adult SLE Patients who fulfilled the 2019 EULAR / ACR classification criteria for systemic lupus erythematosus.~-SLE patients will be subjected to SLE Disease Activity Score (SLE-DAS)."
89586246|NCT06287125||Healthy controls|Apparently healthy subjects
89586247|NCT06287112|Experimental|PAC-ETGBD (Prevention of Acute Cholecystitis with ETGBD)|
89586248|NCT06287060|Experimental|patients with extrinsic staining will be treated with strawberry extract.|
89586249|NCT06287060|Active Comparator|patients with extrinsic staining will be treated with Hydrogen peroxide bleaching agent.|
89586250|NCT06287034||Salvage total laryngectomy STL primary suture|Patients in both groups will then undergo salvage total laryngectomy STL surgery with primary suturing.The primary suture can be performed according to the different techniques available at the discretion of the surgeon (vertical, horizontal or T-shaped closure, with continuous suture, according to Connell or with detached stitches)31. It would be preferable for all centers to use a homogeneous pharyngeal suture technique, such as the T-shaped with Connell suture.
89586251|NCT06287034||Salvage total laryngectomy STL primary suture + onlay flap|Patients in both groups will then undergo salvage total laryngectomy STL surgery with primary suturing, but in the patients of the second group, in addition, the positioning of a free/pedunculated covering flap will also be carried out with the onlay technique. Reconstruction with the onlay technique can be performed using a pedicled pectoralis major myofascial flap or anterolateral thigh myofascial free flap at the surgeon's discretion (pharyngeal suture unchanged). The flap will be positioned with an onlay technique to reinforce the pharyngeal suture and in turn sutured to the prevertebral fascia or residual surrounding tissues.
89586252|NCT06287021|Experimental|Jump System Traser® cup|25 patients receiving unilateral primary total hip arthroplasty with the Jump System Traser® acetabular cup, a 3D-printed highly-porous titanium cup
89586253|NCT06287021|Active Comparator|Jump System HAX-Pore® cup|25 patients receiving unilateral primary total hip arthroplasty with the Jump System HAX-Pore® acetabular cup, a standard hydroxyapatite/titanium plasma-sprayed cup
89586254|NCT06286995|Active Comparator|Trunatomy file group|Using trunatomy file for chemomechanical preparation for root canal of mandibular premolars
89586255|NCT06286995|Active Comparator|Edgeendo x7 file group|Using edgeendo x7 file for chemomechanical preparation for root canal of mandibular premolars
88975184|NCT02958579||Pre-diabetics or diabetics|"if any of followings is identified the participant is regarded as diabetics and will be recruited in this arm;~Fasting Plasma glucose (FPG) level ≥ 7.0 mmol/l (126 mg/dL)~Plasma glucose ≥ 11.1 mmol/l (200 mg/dL) two hours after a 75 g oral glucose load as in a glucose tolerance test~Symptoms of hyperglycemia and casual plasma glucose ≥ 11.1 mmol/l (200 mg/dL)~Glycated hemoglobin (A1C) ≥ 6.5% if any of followings is identified the participant is regarded as pre-diabetics and will be recruited in this arm;~1- FPG levels of 100-125 mg/dl (5.6-6.9 mmol/l). 2-Two-h plasma glucose (2HPP) in the 75 g oral glucose tolerance test of 140-199 mg/dl (7.8- 11.0 mmol/l)"
88975185|NCT02958579||Hypertension|Systolic blood pressure (SBP) ≥ 130mmHgand/or diastolic blood pressure (DBP) ≥ 85mmHg or use of anti-hypertensive drugs
88975186|NCT02958579||hypertriglyceridemia|Serum triglyceride ≥150 mg/dL
88975187|NCT02958579||Low high density lipoprotein -cholesterol (HDL-c)|Serum HDL-C of <40 mg/dL for men, <50 mg/dL for women,
89586256|NCT06286969|Experimental|intensive multi-acupuncture method group|The needle entry points of the lower row are straight punctures that penetrate the muscle attachments along the medial superior margin of the posterior superior iliac spine, the medial margin of the sacroiliac joint, and a portion of the lateral iliac crest of the lumbar triangle. The entry point of the upper row of needles was made oblique, and then small lifting insertion, respectively, reached and penetrated the anterior border muscle attachments. Then subperiosteal stabbing along the bone surface was used to penetrate 1.5cm forward and downward, and the needle was retained for 15min. The needle was left in place for 15 min, and for the second puncture, the entry point was chosen to be in the middle of the two longitudinal entry points of the first puncture. The rest of the operation was unchanged. Repeat the above operation for the last 3 treatments. The treatment is performed twice a week for a total of 5 treatments.
89586257|NCT06286969|Experimental|normal needling group|"The points were selected with reference to the 2006 National Standard of the People's Republic of China (GB/T 12346-2006), Acupoint Names and Localization. The patients were placed in the prone position, the acupoints were sterilized with 75% alcohol, and the needles were inserted vertically with the conventional needling method, to the extent that there was a sensation of acidity, numbness, heaviness, distension, or radiating to the surroundings, and the needles were left in place for 15 min. The treatments were carried out twice a week for a total of five treatments."
89586258|NCT06286956|Experimental|Treated with UNI-VEC|
89586259|NCT06286943|Placebo Comparator|Placebo|Microcrystalline cellulose placebo capsules.
89586260|NCT06286943|Experimental|SCFAs|Colon-delivery Capsules of Short Chain Fatty Acids.
89586261|NCT06286930|Experimental|anodal tDCS, then cathodal tDCS|Participants receive 1, 20-minute anodal tDCS stimulation. After a washout period of 2-3 weeks, then receive 1, 20-minute cathodal tDCS stimulation.
89586262|NCT06286930|Experimental|cathodal tDCS, then andoal tDCS|Participants receive 1, 20-minute cathodal tDCS stimulation. After a washout period of 2-3 weeks, then receive 1, 20-minute anodal tDCS stimulation.
89586263|NCT06286878|Experimental|Dapagliflozin|Dapagliflozin 10 mg tablets given once daily, per oral use
89586264|NCT06286878|Placebo Comparator|Placebo group|Placebo tablets given once daily, per oral use
89586265|NCT06286865|Active Comparator|Easy-ICD interface|This arm uses our AI-based computer-assisted clinical coding (CAC) system, Easy-ICD
89586266|NCT06286865|No Intervention|Control interface|This control arm uses an interface similar to Easy-ICD, but without the AI functionality
89586267|NCT06286852||Experimental group|Subjects meeting a diagnosis of nutrition and eating disorder
89586268|NCT06286852||Control group|children - adolescents from various schools in the Florence area, chosen through statistical criteria based on age, gender, ethnicity
89586269|NCT06286839|Experimental|30 mg twice per day|The 30mg dose will be consumed in 2 capsules twice per day, for 3 days and an extra 18 capsules in case of loss of study product
89586270|NCT06286839|Experimental|120 mg twice per day|120mg dose will be consumed in 8 capsules twice per day for 3 days and an extra 12 capsules in case of loss of study product
88975188|NCT05294237|Experimental|Supported Implementation (Intervention)|"The Happy-program will be available online on a webpage and consists of 7 warm-up components and 4 resistance training components that can be completed after handball practice.~The warm-up program has three exercise variations for each of the seven components. The coaches may deliver the four resistance training components in the field or in the gym. The resistance training components in the field and the gym targets the same four body areas but differs in that the components in the gym are performed with equipment, while the components in the field can be performed without equipment. Each resistance training component has three levels.~Happy ambassadors (Health professionals with a handball player or coach background) will conduct a 3-hour train-the trainer workshop in the beginning of the season and provide coaches with the opportunity for support throughout the season. At mid-season, the ambassadors will re-visit the clubs for 1,5-hour supervision and support."
89586271|NCT06286813|Experimental|Almond oil group|On the first day of neonates' admission to the clinic, their skin condition will be evaluated using the NSCS, and the hydration of skin will be measured using a digital moisture meter with the recommended usage guide. During morning care at 09:00 a.m., almond oil (10 ml) will be applied to their entire body, except for the head. Three hours after the application, at 12:00 a.m., their skin condition will be assessed, and the hydration will be measured and recorded. This application will continue for 5 days.
89586272|NCT06286813|Experimental|Extra Virgin Olive Oil Group|On the first day of neonates' admission to the clinic, their skin condition will be evaluated using the NSCS, and the hydration of skin will be measured using a digital moisture meter with the recommended usage guide. During morning care at 09:00 a.m., extra virgin olive oil(10 ml) will be applied to their entire body, except for the head. Three hours after the application, at 12:00 a.m., their skin condition will be assessed, and the hydration will be measured and recorded. This application will continue for 5 days.
89586273|NCT06286800|Experimental|Personalized Transcranial direct current stimulation (ptDCS)|TDCS is a noninvasive form of cortical stimulation that uses a battery-powered device. [67] Weak current (0.5-2 mA) will be delivered for up to 20 minutes through surface electrodes which will be positioned using the montage identified as the best in the individual stroke patient during our initial testing session during OT targeting the affected arm.
89586274|NCT06286800|Placebo Comparator|Sham tDCS|Same OT procedure and montage as with the active stimulation but the current will be increased then decreased ramp-like and switched off after 20 seconds instead of the 20 minutes to elicit the same cutaneous sensation as the other stimulation conditions.
89586275|NCT06286787|Experimental|Intervention group|Participants in the intervention group will be invited to join the mountain craft training programme.
89586276|NCT06286787|Placebo Comparator|Placebo control group|Participants will be invited to join a control intervention that mimics the time and attention received by participants in the intervention group but will be designed to have no specific effect on the outcome variables.
89586277|NCT06286774|Experimental|CBT-I|Individual Cognitive Behavioral Therapy for Insomnia (CBT-I) delivered once a week for five (5) weeks.
89586278|NCT06286774|No Intervention|Waitlist control|Control participants will receive CBT-I at the end of the study.
89586279|NCT06286761||Single arm|"For blood assay validation and/or reproducibility testing, blood samples will be taken after an overnight fast or after oral glucose or a mixed meal and analyzed. Measurements will be made by: using different assays to determine best conditions of measurement, or repeat testing on different days. Endothelial cells will be collected from a 20-gauge intravenous catheter. One to six 0.025 J-wires will be sequentially inserted into the catheter. These measurements will allow us to determine: the reproducibility and variability of assays used, best timing of blood and endothelial cell collection and best blood volumes and endothelial cell collection wire passes to reliably perform routine assays. For imaging validation, algorithm development, and/or reproducibility testing, participants may undergo DEXA, MRI, or MRS testing to develop or improve analysis algorithms, to evaluate variability of the measurements, or testing different equipment that measure the same variable."
89586280|NCT06286748|Active Comparator|Intervention|Beetroot juice + exercise. Patients will ingest 200ml of beet juice (Beta vulgaris) containing approximately 300mg of nitrate (NO3-), and after 2 hours they will be instructed to perform an exercise protocol.
89586281|NCT06286748|Placebo Comparator|Placebo|Placebo + exercise. Patients will ingest 200ml of placebo (water, without nitrate (NO3-)), and after 2 hours they will be instructed to perform an exercise protocol.
89586282|NCT06286722|Experimental|Progressive, individualized and structured exercise program|"Individualized, progressive, structured exercise program. Participants will receive 12-weeks of either home-based and/or at a healthcare center intervention.~The at home intervention will consist of 3 visits/sessions per week (approximately 30-60 min.) for 12 weeks (maximum of 36 sessions in total) delivered in the participants own home, temporary home (e.g. 24- hour rehabilitation facility), nursing home or assisted living facilities.~The at a healthcare center intervention will be suggested to the participant when the physiotherapist and the participant feel confident that the participant can handle the transportation to/from the healthcare center, and will benefit from the higher intensity of the at a healthcare center intervention. This intervention consists of 2 visits/sessions per week (approximately 45-60 min.) for 12 weeks (total maximum of 24 sessions)."
89586283|NCT06286709|Active Comparator|Faecal Microbiota Transplant (FMT)|FMT is 50mL aliquots of filtered suspension of stool (0.6g/mL). FMT for administration via colonoscopy will be made up of 150g stool in 250mL (5 aliquots). FMT for administration via enema will be made up of 30g stool in 50mL (1 aliquot) made up to 100mL by the addition of 50mL normal saline
89586284|NCT06286709|Placebo Comparator|FMT Placebo|FMT Placebo is 50mL aliquots of 0.9% w/v saline and glycerol in a ratio of 9 parts saline: 1 part glycerol v/v.
89586285|NCT06286670|Other|Single Implant Fixation|Single implant fixation with either a precontoured lateral locking plate or an intramedullary nail.
89586286|NCT06286670|Other|Dual Implant Fixation|Dual implant fixation with either a lateral locking plate plus an intramedullary nail or a lateral locking plate plus a supplemental medial plate.
89586287|NCT06286657|Experimental|Intervention|Participants consume twice per day a study drink which contains 0,75 mg soluble Xanthohumol for 90 days
89586288|NCT06286657|Experimental|Placebo|Participants consume twice per day a study drink which contains 0 mg soluble Xanthohumol for 90 days
89586289|NCT06286644|Experimental|Xanthohumol|Participants receive a study drink supplemented with Xanthohumol (0mg = Placebo; 0,125 mg; 0,375 mg or 0,75 mg soluble Xanthohumol)
89586290|NCT06286644|Experimental|Iso-alpha-Acids|Participants receive a study drink supplemented with Xanthohumol (0 mg = Placebo; 15 mg, 45 mg or 90 mg Iso-alpha-Acids)
89586291|NCT06286644|Experimental|Xanthohumol/Iso-alpha-Acids|Participants receive a study drink supplemented with Xanthohumol + Iso-alpha-Acids (0 mg = Placebo; 0,125 mg + 15 mg, 0,375 mg + 45 mg or 0,75 mg + 90 mg soluble Xanthohumol + Iso-alpha-Acids)
89586292|NCT06286631||Past Medical Records Group|Sample size:500 Whether control group:No Name of exposure factor:papillary thyroid cancer Exposure factor type:Other Description of exposure factor:None
89586293|NCT06286631||Clinical Validation Group|Sample size:300 Whether control group:No Name of exposure factor:papillary thyroid cancer Exposure factor type:Other Description of exposure factor:None
89586294|NCT06286618|Experimental|Optimization 1|During optimization 1 phase, participants are assigned to two groups. One group will receive psychosocial support for diet only and the other will receive structural support for diet only. Each group will have three modalities.
89586295|NCT06286618|Experimental|Optimization 2|The optimization 2 phase will be used to test a combined psychosocial and structural intervention, based on the most feasible selections from optimization 1 phase.During optimization 2 phase, participants will be assigned to two groups. One group will receive referral based delivery model for a combined psychosocial and structural intervention and the other group will receive an integrated delivery model for a combined psychosocial and structural intervention.
89586296|NCT06286605|Experimental|A-oss and autogenous bone|In these group a GBR will be performed using only A-oss and autologous bone will be added and then will be covered with a membrane.
89586297|NCT06286605|Active Comparator|A-oss and LCR-A|In these subjects a GBR will be performed using only A-oss and LCR-A and then will be covered with a membrane.
89586298|NCT06286579|Experimental|Immediately implant placement|Atraumatic tooth extraction and immediately placement of implant with a new surface
89586299|NCT06286579|Active Comparator|Delayed implant placement|Atraumatic tooth extraction, after the site will be left to heal for 4 months, just grafting with A-Oss and suture, according to a socket preservation procedure. Four month later, implant will be place
89586300|NCT06286566|Experimental|Diabetics group|Group of subjects with diabetes who will be inserted implants with a new implant surface called SOI
89586301|NCT06286566|Active Comparator|Healthy Group|Group of helthy subjects who will be inserted implants with a new implant surface called SOI to compare them with the group of diabetic subjects
89586302|NCT06286514||Paper Validation|validate the paper version of the Home Food Inventory
89586303|NCT06286514||electronic validation|validate the electronic version of the Home Food Inventory
89586304|NCT06286501|Experimental|Study group|Standard, personalized oral hygiene and Lumoral Treatment home-use
89586305|NCT06286501|Active Comparator|Control group|Standard, personalized oral hygiene
89586306|NCT06286449|Other|Alcohol Use Disorder cohort and Healthy controls cohort|"Alcohol Use Disorder Cohort The intervention, which all participants from both cohorts undergo, consists of a spinal tap, in which 35 ml of cerebrospinal fluid is collected for further analysis and comparison between a cohort consisting of healthy controls. Study participants with Alcohol Use Disorder (AUD) are recruited from other previous or ongoing clinical trials performed within the research group: NordAlc (PI Andrea de Bejczy), IV-ASA (PI Bo Söderpalm), GlycinA (PI Bo Söderpalm) and COMB (PI Bo Söderpalm).~Healthy controls cohort The intervention, which all participants from both cohorts undergo, consists of a spinal tap, in which 35 ml of cerebrospinal fluid is collected for further analysis and comparison between a cohort consisting of participants with Alcohol Use Disorder. Healthy controls will be continuously recruited via advertisements in media, and onsite at the Sahlgrenska University Hospital and the University of Gothenburg"
89586307|NCT06286332|Experimental|Music Therapy|Participants received self-selected music app playback for 30 minutes every day and standard therapy. The entire study duration spans 21 days.
89586308|NCT06286332|No Intervention|Standard Care|Participants only received standard care during the entire study duration span of 21 days.
89586309|NCT06286319|Experimental|Explanted Lungs|"After the lungs are explanted from the recipient donor, they will be connected to the Angel Cooler via a tracheostomy tube or special adaptor to assess the function of this device in providing cooling oxygen and positive pressure to keep the lungs inflated while on the back table. The lungs will be hooked up to the cooling machine for 15-20 minutes. During this time, investigators will monitor the airway temperature, pressure and oxygen concentration continuously during the entire preservation time. Once these measures are obtained and synced to a corresponding computer, investigators will then disconnect the lungs from the device and continue the standard procedure of sending them to pathology where they will be discarded per usual in lung transplantation."
89586310|NCT06286267||Breast phyllodes tumor|Patients diagnosed with phyllodes tumor of breast
89586311|NCT06286254||The control group|Basic therapy of ARVI1 + Cycloferone®. Cycloferone® is administered according to the instruction for medical use: 600 mg (4 tablets) once daily on day 1, 2, 4, 6 and 8.
89586312|NCT06286254||The test group|Basic therapy of ARVI1 + Arbidol®. Arbidol® is administered according to the instruction for medical use: 200 mg (4 capsules) 4 times/day for 5 days.
89586313|NCT06286189|Placebo Comparator|Placebo|Placebo capsule 30 min before sleep
89586314|NCT06286189|Experimental|Trazodone|Trazodone capsule 30 min before sleep
89586315|NCT06286176|Experimental|Behavioral: videos|4 videos are created and distributed to subjects in the intervention group. Video 1: 10 days before delivery Video 2: the day of the delivery Video 3: 1 week postpartum Video 4: 1 month postpartum Videos content: encouraging message, information related to breastfeeding management This is arm in applied in all subjects on the intervention group
89586316|NCT06286176|Experimental|Behavioral: Whatsapp group|"4 Whatsapp groups were created. Each Whatsapp group was moderated by 1 infant feeding helper. Each whatsapp group consisted of 10-15 subjects.~Mothers asked breastfeeding related questions to infant feeding helpers and also exchange experience with the other mothers on the group.~This is arm in applied in all subjects on the intervention group. Mothers of the intervention group joined their corresponding whatsapp group 10 days before expected delivery date and the duration of the intervention involving the whatsapp group was until 6 months postpartum."
89586317|NCT06286163||Chronic Cough|"History of chronic cough of at least 8 weeks' duration and should have been followed in the Cough Clinic for at least 6 months.~Undergone a protocol with a diagnostic pathway as recommended by the ERS guidelines for management of cough.~Would have either an identifiable cause for their cough that have failed therapies targeted towards the identified cause or classed as having chronic idiopathic cough where no identifiable cause has been found."
89586318|NCT06286163||Healthy|Healthy individuals, free of significant disease No history of asthma/rhinitis, No therapies, Baseline FEV1 ≥80% predicted with FEV1/FVC ratio >70% Non-smoker for at least the past 12 months with a pack history of ≤5 pack-years
88975189|NCT05294237|Active Comparator|Unsupported implementation (control)|Access to the Happy program will be available online to the coaches. No additional education or support will be provided.
89586319|NCT06286150|Experimental|single-port robot group|
89586320|NCT06286124||Incisional Hernia patients|Patients with an Incisional Hernia, who present in the participating center
89586321|NCT06286072|Experimental|Intervention A|"Patients in this group were given training for 3 consecutive days during their stay in the hospital.~Day 1: general information about the disease, medication use Day 2: Physiology of fatigue, factors causing fatigue, and the relationship between COPD and fatigue.~Day 3 Strategies to cope with fatigue (Breathing exercises, good thinking, etc.)~Later, patients were messaged twice a week after they were discharged. Message sent for 8 weeks. Short, motivating and reminder messages were used. For example;~When I can control my shortness of breath, my fatigue level decreases significantly.~Excessive thinking and stress lead to more fatigue. That's why I stay away from negative thoughts.~At the baseline and end of 8 weeks, the patients were interviewed again and their dyspnea and fatigue levels were measured again."
88975190|NCT00070629|Experimental|1|Chemotherapy (a taxane and a platinum compound) plus CPG 7909 Injection
88975191|NCT00070629|Active Comparator|2|Chemotherapy (a taxane and a platinum compound)
88975192|NCT02958384|Experimental|Myeloid Malignancies|The trial will be conducted in a manner of simon two-stage design with Anti-LeY-CAR-transduced T cells, beginning in the first stage with the aim of over 30% reaction rate among 15 patients with myeloid malignancies. Only when the expected reaction rate is achieved the 30 patients left can be recruited.
88975193|NCT01349595|Experimental|Bortezomib|Bortezomib is a type of targeted chemotherapy
89586322|NCT06286072|Experimental|Intervention B|"Patients in this group were given training for 3 consecutive days during their stay in the hospital.~Day 1: general information about the disease, medication use Day 2: Physiology of fatigue, factors causing fatigue, and the relationship between COPD and fatigue.~Day 3 Strategies to cope with fatigue (Breathing exercises, good thinking, etc.)~No other treatment was performed on these patients.~At the baseline and end of 8 weeks, the patients were interviewed again and their dyspnea and fatigue levels were measured again."
89586323|NCT06286072|Active Comparator|Control|"These patients received routine treatment and care in the clinic. No training was given. Message not sent.~At the baseline and end of 8 weeks, the patients were interviewed again and their dyspnea and fatigue levels were measured again."
89586324|NCT06285994||HFJV|All patients who underwent bronchoscopy with the use of high frequency jet ventilation between January 1st 2019 and december 31st 2023.
89586325|NCT06285981||patients with femur fractures|adult patients with pertrochanteric, intertrochanteric and subtrochanteric fractures of the femur
89586326|NCT06285942|Experimental|Edoxaban|This arm will receive Edoxaban via PEG
89586327|NCT06285942|Active Comparator|No Edoxaban|This arm will receive other DOACs through PEG or subcutaneous heparin or LMWH
89586328|NCT06285929||Navigated patients|Student volunteer navigation support accessing barriers to care for patients, families and caregivers with a cancer diagnosis through a social determinants of health assessment and connecting with resources with an effort to eliminate barriers.
89586329|NCT06285929||non-navigated patients|Patients, families and caregivers with a cancer diagnosis without the support of student volunteer navigation and serving as the baseline and control.
89586330|NCT06285929||Student volunteers|Undergraduate or graduate students volunteering with ACS CARES program to provide navigation support to patients, families and caregivers with a cancer diagnosis.
89586331|NCT06285916|Experimental|NORA520 Dose 1|NORA520 Dose 1
89586332|NCT06285916|Experimental|NORA520 Dose 2|NORA520 Dose 2
89586333|NCT06285916|Placebo Comparator|Placebo|Placebo
89586334|NCT06285877|Active Comparator|Control Group|Control Group (CG) which received their usual sessions of conventional therapy.
88975194|NCT01349595|No Intervention|Standard Post-transplant Treatment|Mayo Clinic standard post kidney transplant follow-up.
88975195|NCT05397548||case|Gastric cancer cases from two medical centers in China
88975196|NCT05397548||control|Controls from two medical centers in China
89586335|NCT06285877|Experimental|Experimental Group|Experimental Group (EG) which received therapy with Nintendo Switch plus their usual sessions of conventional therapy.
89586336|NCT06285812||Standard of Care #1|Prospective Randomized Control Trial (RCT)
89586337|NCT06285812||OtoSight #1|Prospective Randomized Control Trial (RCT)
89586338|NCT06285812||OtoSight #2|Case and provider match
89586339|NCT06285812||Standard of Care #2|Retrospective case and provider matched controls
89586340|NCT06285799|Experimental|Low Dose IHAT|IHAT in capsule form and carob flour in capsule form - taken as 1 x 100mg IHAT capsule (equivalent to 30mg iron) in the morning with water and 1 x placebo capsule in the evening with water
89586341|NCT06285799|Experimental|High Dose IHAT|IHAT in capsule form - taken as 2 capsules (2 x 100mg IHAT, equivalent to 60mg iron total) daily with water (1 capsule in the morning and 1 capsule in the evening)
89586342|NCT06285799|Placebo Comparator|Carob flour|Carob flour in capsule form - taken as 2 capsules daily with water (1 capsule in the morning and 1 capsule in the evening)
89586343|NCT06285786|Experimental|Nursing Student|The study involves 1 single arm. A single group of participants will experience all experimental conditions. From an ergonomic standpoint, it has been recognized that providing patient-handling ergonomics training is crucial to their safety. This project will compare the same group performing patient handling tasks without training versus training while utilizing both long term care beds.
89586344|NCT06285773|Active Comparator|Group PR = RIFPB and PIFB group|Recto-intercostal fascial plane block (RIFPB) and Pecto-intercostal fascial plane block (PIFB) will be applied
89586345|NCT06285773|Other|Group Control|No block will be applied.
89586346|NCT06285747||Observational|Patients complete questionnaires and undergo chest wall and breast lymphedema measurements by clinical assessment and using the Delfin Moisture Meter D Compact and have their medical records reviewed on study.
89586347|NCT06285721|Experimental|Standardized treatment arm|Standardized tACS will be applied with 2.0 mA (peak-to-peak) intensity for 30 minutes, with a 10 Hz frequency. Two 5x5 cm saline-soaked electrodes located at the frontal and occipito-parietal part of the scalp will be utilized (corresponding to 10-20 EEG electrode locations POz-Oz and AFz), including in the stimulation field the DLPFC, precuneus and posterior cingulate cortex. At the beginning of stimulation, the intensity will ramp up for 30 seconds to 2.0 mA peak-to-peak, while at the end of stimulation, the intensity will ramp down for 30 seconds.
89586348|NCT06285721|Experimental|Personalized treatment arm|Personalized tACS will be applied with 2.0 mA (peak-to-peak) intensity for 30 minutes with a 30 second ramp up and ramp down. Treatment will be personalized based on a delirium neural mass model. After fitting the model to the individual EEG, a virtual tACS trial allows for optimization of treatment parameters for each individual patient. Treatment optimization will take place through changing stimulation location and/or frequency. After determining the optimal individual treatment strategy, settings of the personalized stimulation will remain constant during the treatment phase.
89586349|NCT06285721|Sham Comparator|Sham treatment arm|At the beginning and end of this 30-minute protocol, the tACS device will ramp up to 2.0 mA peak-to-peak intensity for 30 seconds, stimulate for 60 seconds and ramp down for 30 seconds, which mimics the sensation of actual tACS stimulation and improves blinding.
89586350|NCT06285708|Experimental|Prolonged exposure with crisis response plan|In the enhanced prolonged exposure condition, participants will complete a CRP instead of a safety plan. The CRP is another recommended standard care practice with suicidal patients that includes many of the same elements as the safety plan (i.e., warning signs, self-management strategies, sources of social support, crisis services), but is created collaboratively by the patient with active input of their clinician rather than being self-guided. The CRP also includes a section focused on the participant's reasons for living, an addition that has been shown to increase positive emotional states (e.g., hope, optimism) and lead to faster reductions in suicidal intent. The CRP will be administered during the first therapy session.
89586351|NCT06285708|Active Comparator|Prolonged exposure with safety plan|In the standard prolonged exposure condition, participants will complete a safety plan, a procedure that includes personal warning signs for a suicidal crisis, self-management strategies, sources of social support, and contact information for professional resources and crisis services within the participant's local community, as well as the National Suicide Prevention Lifeline phone number. As a recommended standard care practice with suicidal patients, the combination of PE and safety plan represents treatment as usual. The safety plan will be administered during the first therapy session.
89586352|NCT06285682|Experimental|0.5mg∙kg-1 olive derived hydroxytyrosol from OliPhenolia®.|Olive derived hydroxytyrosol will be ingested via a commercially available olive fruit wastewater (OliPhenolia®) in a dose relative to participant body mass. In this arm participants will consume and oral bolus of 0.5mg∙kg-1 olive derived hydroxytyrosol.
89586353|NCT06285682|Experimental|1.0mg∙kg-1 olive derived hydroxytyrosol from OliPhenolia®.|Olive derived hydroxytyrosol will be ingested via a commercially available olive fruit wastewater (OliPhenolia®) in a dose relative to participant body mass. In this arm participants will consume and oral bolus of 1.0mg∙kg-1 olive derived hydroxytyrosol.
89586354|NCT06285682|Experimental|1.5mg∙kg-1 olive derived hydroxytyrosol from OliPhenolia®.|Olive derived hydroxytyrosol will be ingested via a commercially available olive fruit wastewater (OliPhenolia®) in a dose relative to participant body mass. In this arm participants will consume and oral bolus of 1.5mg∙kg-1 olive derived hydroxytyrosol.
89586355|NCT06285669|Experimental|kinesiotape|Kinesio taping was applied by a single physiotherapist to support the intercostal muscles,and, the diaphragm and facilitatory method was used on the respiratory muscles
89586356|NCT06285669|No Intervention|Control|This group didn't take kinesiotape application
89586357|NCT06285656||Group 1/|Patients with postoperative hemmorhagia
89586358|NCT06285656||Grup 2|Patients without postoperative hemmorhagia
89586359|NCT06285643|Experimental|AAV2-GDNF|
89586360|NCT06285643|Sham Comparator|Control Surgery|
89586361|NCT06285630||Health infants|We aim to recruit parents of infants in an age range between 3 and 12 months. Healthy infants only, which were delivered in term, and that are not undergoing any antibiotic treatment.
89586362|NCT06285617|Experimental|Experimental group|Participants in the experimental group received 20 and 10 mg prednisone in the morning and afternoon, respectively, daily for 1 week; in the second week, these participants received 400 mg celecoxib on Day 1 and 200 mg twice daily for the remaining 6 days until celecoxib withdrawal.
89586363|NCT06285617|Active Comparator|Control group|Participants in the control group received 20 and 10 mg prednisone in the morning and afternoon, respectively, daily in the first week, and then reduced by 5 mg/week from the second week until withdrawal in the sixth week.
89586364|NCT06285604||IRBC|Anemic neonates with irradiated red blood cells transfusions.
88811289|NCT02861573|Experimental|Pembrolizumab+Carboplatin+Etoposide|Participants with neuroendocrine mCRPC in Cohort I Arm 1 will receive pembrolizumab 200 mg IV on Day 1 Q3W + carboplatin titrated to an area under the plasma drug concentration-time curve [AUC] 5 IV on Day 1 Q3W + etoposide 100 mg/m^2 IV on Days 1, 2, and 3 Q3W. Treatment with pembrolizumab will continue for a maximum of 35 cycles (up to 2 years) or until progression. Treatment with carboplatin+etoposide will continue for a maximum of 4 cycles (up to 2.8 months). Participants who must discontinue 1 or 2 of the 3 drugs due to adverse events in the combination may continue the study with the other combination drug/drugs.
89586365|NCT06285604||WRBC|Anemic neonates with washed red blood cells transfusions.
89586366|NCT06285604||LPRBC|Anemic neonates with leukocyte privative red blood cells transfusions.
89586367|NCT06285591|Placebo Comparator|Control group|Placebo-containing tablets
89586368|NCT06285591|Experimental|Experimental group|Lactobacillus Reuteri tablets
89586369|NCT06285578|Placebo Comparator|Placebo control (C)|The subjects do not perform HIIT training, but consume one placebo packet every day on a fasting status for 8 weeks.
89586370|NCT06285578|Experimental|Probiotics supplementation (P)|Each participant consume one probiotic packet every day on a fasting status for 8 weeks.
89586371|NCT06285578|Experimental|HIIT intervention (H)|HIIT training for 3 sessions per week and consume one placebo packet every day on a fasting status for 8 weeks.
89586372|NCT06285578|Experimental|HIIT with probiotics intervention (HP)|Conduct HIIT training 3 sessions per week for 8 weeks and consume one probiotic packet every day on a fasting status for 8 weeks.
89586373|NCT06285565|Experimental|Nurse-led supported group|"A supportive program consisting of the following elements will be provided:~Pre-discharge educational meeting. After the patient is deemed stable, an in-hospital educational intervention will be provided by a trained nurse not involved in the clinical pathway. Key topics of self-care management recognized by the European Society of Cardiology will be discussed.~Telephone nurse-led coaching sessions. In this phase, patients will be encouraged to focus on their values and progress towards their goals. The intervention will be customized based on the objectives identified during the initial meeting. The scheduled sessions will occur weekly during the first months and then transition to twice a month thereafter.~Patients will receive education on measuring weight, blood pressure, heart rate, and oxygen saturation at rest, every morning before breakfast. All participants will be provided with a telemonitoring system that transmits data to a web platform via Bluetooth."
89586374|NCT06285565|No Intervention|Controlled group|The controlled group will receive usual care
89586375|NCT06285552|Experimental|Parenting newborn|Program aimed at community families with children enrolled in Early Childhood Care Centers (from 0 to 2 years old).
89586376|NCT06285552|Experimental|Parenting Toddlers|Program aimed at community families with children from 2 to 5 years old.
89586377|NCT06285552|Experimental|Parenting Children|Program aimed at community families with children from 6 to 12 years old.
89586378|NCT06285552|Experimental|Parenting Adolescents|Program aimed at community families with children from 12 to 18 years old.
89586379|NCT06285552|Experimental|Active and Health Families|Program aimed at targeted families due identified needs for healthy lifestyle habits
89586380|NCT06285552|Experimental|Functional diversity Parenting|Program aimed at targeted families whose children and/or adolescents exhibit functional diversity characteristics
89586381|NCT06285552|No Intervention|Control|Families that are not participating in any program as they live in a comparable area where any of the intervention is offered
89586382|NCT06285552|Experimental|Parenting as as Father|Program aimed at fathers from the community population
89586383|NCT06285539|Experimental|Intervention|26 weeks of Filgotinib once daily, 200mg, orally,
89586384|NCT06285526||Group HIPEC|Cytoreduction surgery with hyperthermic intraperitoneal chemotherapy (HIPEC)
89586385|NCT06285526||Group CDP|Cephalic DuodenoPancreatectomy (CDP)
89586386|NCT06285500||Group 1|N-of-1 treatment with marketed drugs used on or off-label as per SOC.
89586387|NCT06285500||Group 2|N-of-1 treatment with drugs accessed from SAP.
89586388|NCT06285500||Group 3|N-of-1 treatment with non-marketed investigational agents.
89586389|NCT06285487|Experimental|Interpersonal Psychotherapy adapted for Type 2 Diabetes|Participants in the IPT-T2D will receive 1 hour weekly IPT from a licensed psychologist in a group setting for 6 weeks.
89586390|NCT06285487|Experimental|Health Education adapted for Type 2 Diabetes|Participants in the Health Education-T2D will receive 1 hour weekly Health Education lessons from a licensed psychologist in a group setting for 6 weeks.
89586391|NCT06285474|Experimental|Active Caudate|"Low Intensity Focused Ultrasound Pulsation (LIFUP) will be directed at the caudate head. To minimize the ultrasound energy's exposure to air, a gel pad will be placed between the transducer and the participant's scalp. The sonication protocol will consist of 10 ultrasound sonications in a 30 s ON, 30 s OFF fashion at 650KHz, Ispta≤720 mW/cm2, 50% duty cycle, 5ms pulse width, 1.44W/cm2 ISPPA, and 100Hz pulse repetition frequency. For active sonication, the gel pad will allow the ultrasound energy to pass through. The sham/active gel pads are identical in appearance."
89586392|NCT06285474|Sham Comparator|Sham Caudate|"Low Intensity Focused Ultrasound Pulsation (LIFUP) will be directed at the caudate head. To minimize the ultrasound energy's exposure to air, a gel pad will be placed between the transducer and the participant's scalp. The sonication protocol will consist of 10 ultrasound sonications in a 30 s ON, 30 s OFF fashion at 650KHz, Ispta≤720 mW/cm2, 50% duty cycle, 5ms pulse width, 1.44W/cm2 ISPPA, and 100Hz pulse repetition frequency. For sham sonication, the gel pad will block close to all of the ultrasound energy from the transducer from entering the brain. The sham/active gel pads are identical in appearance."
89586393|NCT06285461|Experimental|Non-palatable meal|Acute intake of a non-palatable meal, i.e., with low-hedonic reward, followed by PET/CT scans with three different radiotracers ([15O]H2O, [15O] oxygen, and [11C]-carfentanil.
89586394|NCT06285461|Experimental|Palatable|Acute intake of a palatable meal, i.e., with high-hedonic reward, followed by PET/CT scans with three different radiotracers ([15O]H2O, [15O] oxygen, and [11C]-carfentanil.
89586395|NCT06285435||pemphigus vulgaris patients|
89586396|NCT06285435||control group|
89586397|NCT06285383|Other|control group|Participants in the control group will receive classical physiotherapy 5 days a week for 4 weeks (Tens 20 min, ultrasound 5 min, hotpack 20 min).
89586398|NCT06285383|Experimental|Music group|Participants in the music group will be played Pachabel Canon D major (30 minutes) during the classical physical therapy session, free from external sounds (max 70 dB through headphones).
89586399|NCT06285370|Experimental|KW-0761|Patients will receive KW-0761 in this arm
89586400|NCT06285318||Participants with Relapsed/Refractory Multiple Myeloma (RRMM)|Participants with RRMM who received at least one dose of teclistamab outside of clinical trials on or before 31 December 2022 will be enrolled in the study. The data available from the medical records of each enrolled participant will be the collected to describe the use of teclistamab.
89586401|NCT06285292|Experimental|EMY (connected biofeedback medical device)|2 rehabilitation between M0 and M2 and pelvic-perineal exercises with the EMY device on 3 different days a week, for 15 minutes, over a period of 3 months.
89586402|NCT06285292|No Intervention|standard|15 sessions of pelvic floor rehabilitation (gold standard)
89586403|NCT06285227|Experimental|Group 1|CM313, subcutaneous injection, once
89586404|NCT06285227|Experimental|Group 2|CM313, subcutaneous injection, once
89586405|NCT06285227|Experimental|Group 3|CM313, subcutaneous injection, once
89586406|NCT06285227|Experimental|Group 4|CM313, infusion, once
89586407|NCT06285214|Experimental|V117957|
89586408|NCT06285214|Placebo Comparator|Placebo|
89586409|NCT06285201|Experimental|Group A|T-R
89586410|NCT06285201|Experimental|Group B|R-T
89586411|NCT06285188||Cohort of patients with mold invasive fungal infection|Patients >18 y, with a diagnosis of proven or probable mold invasive fungal infection (Aspergillus, Mucorales, Fusarium or Scedosporium), according to modified 2019 EORTC/MGS criteria, at diagnosis or at a refractory state after a first-line antifungal treatment
89586412|NCT06285175|Experimental|Tele-REINVENT|All participants in this study are asked to use tele-REINVENT, a 6 week home tele-rehab program with EMG biofeedback.
89586413|NCT06285162||Critically ill patients with continuous renal replacement therapy.|"The patients will be followed during the first 6 hours of the initiation of a net ultrafiltration (2-3 milliliters/kilograms/hour) with continuous monitoring (R-R interval, ANI, cardiac index, invasive arterial pressure, central venous pressure, peripheral perfusion index), and perfusion monitoring every 6 hours (arterial lactate, central venous oxygen saturation, capillary refill time, mottling score). Such a fluid removal strategy is part of an institutional protocol or an ongoing clinical trial.~In addition to the usual monitoring, the PhysioDoloris monitor will be connected to the patient's scope. The ANI and its parameters will be recorded continuously throughout the study."
89586414|NCT06285149|Experimental|80 patients with advanced HCC in Child-Pugh B who had not been systematically|Icaritin will be divided into the first dose group (200mg bid orally) using 3+3 dosage. The second dose group will be 400mg bid orally; And the third dose group, 600mg bid, taken orally. It is taken within 1 hour after a meal, and Icaritin will be administered continuously during interventional therapy.
89586415|NCT06285136|Experimental|Venetoclax in combination with Decitabine (+-sorafenib)|Venetoclax in combination with decitabine (+-sorafenib) Venetoclax (VEN) 100mg d1, 200mg d2, 400mg d3-14 Decitabine (DEC) 20mg/m2/q8h, d4-6 (infusion time >2h) Sorafenib 800mg/d, d8-14 (only for FLT3/ITD mutation positive patients)
89586416|NCT06285123||Responders|
89586417|NCT06285123||Non-Responders REP|
89586418|NCT06285123||Non-Responders REP/Facillitation|
89586419|NCT06285110||People living with HIV|People living with HIV and on a Dolutegravir-based ART regimen, and experiencing treatment failure.
89586420|NCT06285097|Experimental|Monotherapy dose escalation (Part 1A)|Participants will receive PF-07820435 orally at the prescribed dose and frequency in 28-day cycles
89586421|NCT06285097|Experimental|Combination dose escalation (Part 1B)|Participants will receive PF-07820435 orally at the prescribed dose and frequency, in combination with sasanlimab (subcutaneous injection) at a fixed dose once every 4 weeks in 28-day cycles
89586422|NCT06285097|Experimental|Expansion (Part 2) - Tumor specific Arm A|Participants will receive PF-07820435 orally at the prescribed dose and frequency in combination with sasanlimab SC once every 4 weeks in 28-day cycles
89586423|NCT06285097|Experimental|Expansion (Part 2) - Tumor specific Arm B|Participants will receive PF-07820435 orally at the prescribed dose and frequency in combination with sasanlimab SC once every 4 weeks in 28-day cycles
89586424|NCT06285097|Experimental|Expansion (Part 2) - Arm C|Participants will receive PF-07820435 orally at the prescribed dose and frequency in 28-day cycles
89586425|NCT06285084||Training Cohort|455 Athletes already evaluated for sports participation clearance, whom ECG and clinical evaluation (cleared - not cleared for competitive sports participation) will be fed into the DL model
89586426|NCT06285084||Validation Cohort|76 Athletes evaluated using standard sports eligibility clearance tests and our DL model
89586427|NCT06285071||Concizumab|Participants with haemophilia A or haemophilia B with inhibitors will be treated with commercially available Alhemo (Concizumab) according to routine clinical practice at the discretion of the treating physician. Recruitment will be completed after 4.5 years from the launch of Concizumab. The observation period for each participant is 2 years. Total duration of this study is about 6.5 years.
89586428|NCT06285019|Experimental|Combination therapy|TOMOX-HAIC combined with Sintilimab and bevacizumab biosimilar
89586429|NCT06285006|Experimental|Desmopressin|Desmopressin is a synthetic analogue of ADH released by the posterior pituitary gland that reduces urine production by increasing water reabsorption by the collecting tubules.
89586430|NCT06284993|Experimental|The more frequent acupuncture treatment group (Group M)|The more frequent acupuncture treatment group (Group M)
89586431|NCT06284993|Experimental|The less frequent acupuncture treatment group (Group L)|The less frequent acupuncture treatment group (Group L)
89586432|NCT06284941|No Intervention|0.25% ropivacaine 30ml for iliac fascia block|
89586433|NCT06284941|Experimental|0.25% ropivacaine+0.05% methylene blue 30ml for iliac fascia block|
89586434|NCT06284928||Hypertension Group|This label would be assigned to the cohort of participants who have been newly diagnosed with hypertension. They are the primary focus of the study to explore the specific patterns in their gut microbiota related to hypertension.
89586435|NCT06284928||Control Group|This label would apply to the cohort of participants who do not have hypertension and are otherwise healthy. This group serves as a baseline to compare the microbiota patterns observed in the hypertension group.
89586436|NCT06284915|Experimental|Group 1: MenACYW conjugate vaccine|Participants will receive MenACYW Conjugate Vaccine (MenQuadfi®): 2-dose schedule (1+1); dose 1 (priming dose) at 6-7 months of age and dose 2 (booster dose) at 12-13 months of age (MenQuadfi®)
89586437|NCT06284915|Active Comparator|Group 2: Nimenrix®|Participants will receive Nimenrix®: 2-dose schedule (1+1); dose 1 (priming dose) at 6-7 months of age and dose 2 (booster dose) at 12-13 months of age
89586438|NCT06284889|Experimental|Treatment|Brief Behavioral Activation
89586439|NCT06284889|Placebo Comparator|Treatment as usual (TAU)|Treatment as usual regarding depression received at their primary care centre.
89586440|NCT06284876|Experimental|Ilaprazole 10 mg|Take Ilaprazole 10 mg 1 tablet + Placebo of Lansoprazole 15 mg 1 capsule by mouth, with water, once daily.
89586441|NCT06284876|Active Comparator|Lansoprazole 15 mg|Take Lansoprazole 15 mg 1 capsule + Placebo of Ilaprazole 10 mg 1 tablet by mouth, with water, once daily.
89586442|NCT06284863|Other|nutrition|The study aims to improve the health status of chronic renal failure patients on hemodialysis using nutritional education program on quality of life anserum d electrolytes level by application of physical and clinical evaluation and some biochemical analysis before and after a specified nutritional program
89586443|NCT06284850||treatment with empagliflozin 10mg od|empagliflozin 10mg OD
89586444|NCT06284824|Experimental|MAKO group|Patients in this arm will receive the Stryker Triathlon implant and the MAKO robotic arm will be used during surgery.
89586445|NCT06284824|Experimental|VELYS group|Patients in this arm will receive the DePuy Attune implant and the VELYS robotic arm will be used during surgery.
89586446|NCT06284811|Experimental|Percussion therapy group|After exercises completed, individuals receive percussion therapy on quadriceps for 10 minutes for both sides. Afterwards individuals will be evaluated again.
89586447|NCT06284811|Active Comparator|Massage therapy group|After exercises completed, individuals receive massage therapy on quadriceps for 10 minutes for both sides. Afterwards individuals will be evaluated again.
89586448|NCT06284798|Experimental|NNC0650-0013: Subcutaneous dose|Participants will receive NNC0650-0013 subcutaneously in an ascending dose manner.
89586449|NCT06284798|Placebo Comparator|Placebo|Participants will receive matching placebo to NNC0650-0013 subcutaneously.
89586450|NCT06284798|Experimental|NNC0650-0013: Intravenous dose|Participants will receive NNC0650-0013 in an ascending dose manner intravenously.
89586451|NCT06284785||Obese patients|Obese patients with T2D and hyperfiltration that will undergo bariatric surgery
89586452|NCT06284785||Healthy controls|Healthy, lean controls with BMI 20-25
89586453|NCT06284772||FINRISK 2002 re-examination cohort|All still-living FINRISK 2002 participants (~6000) will be invited do participate in a re-examination >20 years after the initial fecal sampling.
89586454|NCT06284772||FINRISK 2002 re-examination health examination|The ~800 still-living participants from the Turku and Loimaa area will be also asked to participate in a health examination.
88975197|NCT02958501|Active Comparator|IU/Day|This is standard dose of the drug (colecalciferol), which is not calculated in relation to patient body weight
88975198|NCT02958501|Active Comparator|IU/Kg/Day|This is dose of the drug (colecalciferol), which is based or calculated in relation to patient actual body weight
89586455|NCT06284759|Experimental|Intervention|Patients in the intervention group were monitored with a tele-nursing application based on Orem's Self-Care Theory, and training and counseling were provided for 6 weeks after discharge. Post-discharge interviews were conducted by resercher via phone call and video conference (zoom, WhatsApp, etc.). The video conference method was presented to the patient's preference and the decision was made together. The interview with each patient lasted an average of 30 minutes. Patients in the intervention group were sent infographics prepared in line with the theory, including the interview content and suggestions after each interview. The study focuses on post-discharge tele-nursing practice follow-up outcomes. Baseline data were collected at the hospital on the 2nd and 3rd postoperative day. Post-discharge data were collected on the 7th-10th day, 18th-21st day and 40th-45th day.
89586456|NCT06284759|No Intervention|Control|Patients in the control group were discharged in accordance with the current hospital procedure. No intervention was made. The study focuses on post-discharge tele-nursing practice follow-up outcomes. Baseline data were collected at the hospital on the 2nd and 3rd postoperative day. Post-discharge data were collected on the 7th-10th day, 18th-21st day and 40th-45th day. It was collected by phone call or video conference (zoom, WhatsApp, etc.).
89586457|NCT06284746|Experimental|Tirelizumab combined with neoadjuvant chemotherapy|Four cycles of tirolizumab combined with SOX/XELOX neoadjuvant chemotherapy regimen before surgery, followed by laparoscopic D2 gastric cancer radical surgery, and four cycles of adjuvant chemotherapy after surgery.
89586458|NCT06284746|Active Comparator|standard chemotherapy|Four cycles of standard chemotherapy regimen (SOX/XELOX regimen) were administered before and after surgery.
89586459|NCT06284733|Experimental|Group A (WBV group)(30 HZ,4 mm ,eyes open)|This group includes 36 patients with unilateral trans-femoral traumatic amputation; they will receive WBV and conservative care.
89586460|NCT06284733|Experimental|Group B (visual feedback-deprived and WBV (VFD WBV) (30 HZ,4 mm ,eyes close)|This group includes 36 patients with unilateral trans-femoral traumatic amputation; they will receive visual feedback-deprived plus WBV (VFDWBV) and conservative care.
89586461|NCT06284733|Sham Comparator|Group C(control group (0 Hz, eyes open)|This group includes 36 patients with unilateral trans-femoral traumatic amputation; they will receive conservative care.
89586462|NCT06284694|Experimental|Repetitive Transcranial Magnetic Stimulation (rTMS)|Participants will undergo high frequency rTMS sessions 5 days a week for 4 weeks (20 treatments total). Treatment intensity will be applied at 100-120% of the participant's resting motor threshold. The neurostimulation protocol will be 10 trains of 60 pulses (600 pulses total) at a frequency of 10 Hz, with inter-train interval of 45-seconds. The rTMS will be administered to the dorsolateral prefrontal cortex (DLPFC) which will be located using Montreal Neurologic Institute (MNI) coordinates (-50, 30, 36) on a standardized brain. Participants will be seated in a comfortable chair or their wheelchair for each rTMS session.
89586463|NCT06284655|Experimental|Educational intervention|Patients randomized to the intervention group will start with peer co-led group-based psychoeducation, combined with digital video- and written information.
89586464|NCT06284655|Active Comparator|Control group|The control group will receive treatment as usual after randomization
89586465|NCT06284642|Active Comparator|lumbar drainage combined with intrathecal urokinase injection|lumbar drainage combined with intrathecal urokinase injection
89586466|NCT06284642|Placebo Comparator|lumbar drainage|lumbar drainage combined with intrathecal placebo saline injection
89586467|NCT06284629|Experimental|Intervention|The intervention consists of a wrist-worn wearable sensor that tracks motor symptoms and an app for patient-reported outcomes.
89586468|NCT06284629|Active Comparator|Standard of Care|The control group will wear the wrist-worn wearable sensor, but not be able to view the tracked data. They will report symptoms in the app, but the patient-reported outcomes won't be included in the clinical visits during the trial
89586469|NCT06284616|Experimental|JASP-1 group|Participants were recruited from August 2019 to April 2022. The JASP-1 group consisted of children 0-16 years old who were diagnosed with JIA at their first visit to the PRC and their parents
89586470|NCT06284616|No Intervention|Control group|The control group consisted of children 1-16 years old, who were diagnosed with JIA at their first visit at the PRC who were receiving standard care after the diagnosis, and their parents
89586471|NCT06284603|Active Comparator|Study Group 1: HBOT 3/week|The protocol comprises 10 Hyperbaric Oxygen Treatments (HBOT), 3 sessions per week.
89586472|NCT06284603|Active Comparator|Study Group 2: HBOT 6/week|The protocol comprises 10 Hyperbaric Oxygen Treatments (HBOT), 6 sessions per week.
89586473|NCT06284603|No Intervention|Control Group|No changes to a daily routine.
89586474|NCT06284590|Experimental|Systemic pembrolizumab in combination with intralesional L19IL2 (Arm 1)|Two-weeks screening period and a 4-weeks open-label intralesional treatment period with L19IL2. Pembrolizumab will be administered by i.v. infusion on the first day of intralesional treatment with L19IL2, and will continue every 3 weeks for approximately 2 years, 35 cycles, 2 year cap or until disease progression or unacceptable toxicity, whichever comes first.
89586475|NCT06284590|Experimental|Systemic pembrolizumab in combination with intralesional L19TNF (Arm 2)|Two-weeks screening period and a 4-weeks open-label intralesional treatment period with L19TNF. Pembrolizumab will be administered by i.v. infusion on the first day of intralesional treatment with L19TNF, and will continue every 3 weeks for approximately 2 years, 35 cycles, 2 year cap or until disease progression or unacceptable toxicity, whichever comes first.
89586476|NCT06284590|Experimental|Systemic pembrolizumab in combination with intralesional L19IL2/L19TNF (Arm 3)|Two-weeks screening period and a 4-weeks open-label intralesional treatment period with L19IL2/L19TNF. Pembrolizumab will be administered by i.v. infusion on the first day of intralesional treatment with L19IL2/L19TNF, and will continue every 3 weeks for approximately 2 years, 35 cycles, 2 year cap or until disease progression or unacceptable toxicity, whichever comes first.
89586477|NCT06284577|Experimental|Probiotics|Participants will recieve a multi-strain probiotic daily for 6 months
89586478|NCT06284577|Sham Comparator|Placebo|Participants will recieve maltodextrin daily for 6 months
89586479|NCT06284564|Experimental|Evolocumab + Nivolumab|If you are found to be eligible to take part in this study, you will receive evolocumab and nivolumab on Day 1 of each cycle (every 4 weeks). Evolocumab will be given as an injection under the skin. Nivolumab will be given by vein over about 60 minutes.
89586480|NCT06284551||Control Group|Healthy youths and adults aged 15-24 years old.
89586481|NCT06284551||Experimental Group|Youths and adults aged 15-24 years old with diagnosis of major depressive disorder, anxiety disorder, post traumatic stress disorder, or Adjustment disorder according to DSM-V.
89586482|NCT06284538|Experimental|WOUND-H|STUDY FOR THE ASSESSMENT OF THE EFFECTIVENESS OF A MEDICAL DEVICE BASED ON HYALURONIC ACID IN WOUNDS
89586483|NCT06284538|Active Comparator|Braccio controllo|NORMAL STANDARD THERAPIES FOR WOUND TREATMENT (CLEANING AND DISINFECTION)
89586484|NCT06284525|Experimental|Gait training with exoskeleton resistance|Participants will complete 20-30 minutes of ankle resistance training on each visit. This will involve walking on a treadmill with stance phase ankle resistance and biofeedback.
89586485|NCT06284512||Uveal Melanoma|Patients with uveal melanoma will undergo a routine diagnostic imaging with color fundus photography and sonography.
89586486|NCT06284499||Group 1|"Group 1 (n = 31), which contained patients fitted with 0.038 × 0.016 stainless steel wire (Ortho FlexTech® chain, Reliance Orthodontic Products, Itasca, IL, USA)"
89586487|NCT06284499||Group 2|"Group 2 (n = 23), which contained patients fitted with 0.010 × 0.026 8-braided dead soft wire (Bond-A-Braid,Reliance Orthodontic Products, Itasca, IL, USA)"
89586488|NCT06284499||Group 3|"Group 3 (n = 28), which contained patients fitted with 0.0215 5-stranded stainless steel wire (Penta-One®, Masel Orthodontics, Carlsbad, CA, USA)"
89586489|NCT06284499||Control group|Control group (n = 20), which contained individuals who had not received any orthodontic treatment
89586490|NCT06284460|Experimental|Cohort A: Single agent ASTX029|Participants will take ASTX029 daily on days 1-21 of each 28-day cycle. ASTX029 should be taken with water on an empty stomach, no food 2 hours before and 2 hours after dose.
89586491|NCT06284460|Experimental|Cohorts B and C: Combination of ASTX727 + ASTX029|Participants will take ASTX029 daily on days 1-21 of each 28-day cycle. ASTX727 daily on days 1-5 of each 28-day cycle. Both ASTX029 and ASTX727 should be taken with water on an empty stomach, no food 2 hours before and 2 hours after dose.
89586492|NCT06284447||Observational|Participants complete a survey on study.
89586493|NCT06284018|Experimental|intervention group1|Group A consisted of thirty postnatal women. They were treated by progressive muscle relaxation exercises three times per week for 4 weeks.
89586494|NCT06284018|Experimental|intervention group 2|Group B consisted of thirty postnatal women. They were treated by pilates exercises three times per week for 4 weeks.
89586495|NCT06283979|Experimental|Interventional STIMULAN VG|"Ulcer bursectomy and debridement and STIMULAN VG insertion into the ulcer cavity.~Flap closure. Peri-operative antibiotics."
89586496|NCT06283979|Active Comparator|Standard of Care (SoC)|Ulcer bursectomy, debridement and flap closure. Peri-operative antibiotics.
89586497|NCT06283550|Experimental|Abrocitinib 200 mg|Abrocitinib at dose 200 mg will be orally administered once daily for 32 weeks.
89586498|NCT06283550|Experimental|Abrocitinib 100 mg|Abrocitinib at dose 100 mg will be orally administered once daily for 32 weeks.
89586499|NCT06283550|Placebo Comparator|Placebo then abrocitinib|Placebo will be orally administered once daily for 16 weeks (Part A) then abrocitinib 200 mg will be orally administered once daily for 16 weeks (Part B).
89586500|NCT06283303|Experimental|Combination therapy with T3011 hepatic artery infusion , Regorafenib and Toripalimab|The study was divided into two dose groups, T3011 3×10^8 plaque forming unit(PFU)/time (HAI) and T3011 1×10^9 PFU/time (HAI), with a 3+3 dose escalation design. After the completion of the lead-in period, the patient entered the combination therapy period（combination therapy with T3011 hepatic artery infusion , Regorafenib and Toripalimab）,and the dosage of T3011 was determined according to the safety observation results of the lead-in period, the dose of toripalimab was 80mg intravenously, and regorafenib was 80mg orally once a day.
89586501|NCT06283134|Experimental|Combination therapy with BioTTT001 hepatic artery infusion , Regorafenib and Toripalimab|This study includes a dose escalation phase and a dose expansion phase. The dose escalation phase will adopt a 3+3 design. Subjects were first treated with BioTTT001 monotherapy (hepatic artery infusion, administered every 2 weeks, D1 and D15 for a total of two doses) after enrollment. If the subject does not develop DLT in the monotherapy stage and is judged to be safe and tolerable by the investigator, the subject will enter the treatment phase of BioTTT001 in combination with toripalimab and regorafenib( toripalimab 80mg iv. D1 and D15 , BioTTT001 5×10^7 VP/5×10^8 VP/5×10^9 VP/1×10^10 VP HAI. D2 and D16 , regorafenib 80 mg Po. D1-D21; 4 weeks per cycle), and the dose of BioTTT001 will be determined according to the safety observation results in the monotherapy phase. In the dose expansion phase, different dose groups can be expanded, and the total number of enrolled subjects is expected to be 30 for further safety, tolerability, pharmacokinetics and preliminary efficacy evaluation.
89586502|NCT06283121|Experimental|Combination therapy with BioTTT001 intraperitoneal infusion , SOX and Toripalimab|This study intends to enroll Her2-negative subjects with first-line treatment of peritoneal metastasis from gastric cancer. Subjects will be treated with BioTTT001 intraperitoneal perfusion combined with SOX and toripalimab after completing the screening period, and the subjects will first receive BioTTT001 monotherapy treatment with BioTTT001 1×10^10 VP intraperitoneal perfusion (P.I.), D1 and D3, and enter the combination therapy stage 7 days (±1d) after the first dose of BioTTT001.Subjects will be treated with the regimen as follows: BioTTT001 injection, 1×10^10 VP P.I., D1；toripalimab 160mg intravenous (i.v.), D1; Oxaliplatin 130mg/m^2 i.v. , D1 ; Tegafur 40~60mg Bis in die（b.i.d.） Peroral（p.o.）D1~D14; 3 weeks per cycle.
89586503|NCT06282809|Experimental|HistoSonics System|
89586504|NCT06282471|Experimental|Expressive Writing and Problem-Solving Therapy|Self-guided expressive writing and problem-solving therapy intervention for adult cancer survivors and adult informal caregivers thereof
89586505|NCT06281951|Experimental|Facial Nebulization|Fentanyl's facial nebulization in healthy volunteers.
89586506|NCT06281951|Experimental|Intranasal|Fentanyl's intranasal inhalation in healthy volunteers.
89586507|NCT06281600|Placebo Comparator|Placebo control arm|Maltodextrin will be given as a white powder placebo for 4 weeks.
89586508|NCT06281600|Experimental|HMO intervention arm|HMOs will be given as a white powder for 4 weeks.
89586509|NCT06281496|Experimental|Intervention group|The intervention is multi modal and multidisciplinary and consists of two main components including individual consultations based on PRO data (HM-PRO) and digital health support and education. The multidisciplinary team will consist of nurses, hematologists, physiotherapists, social workers, and dietitians.
89586510|NCT06281496|No Intervention|Control Group|Patients in the control group will receive usual care
88975199|NCT05129657|Experimental|Product usage order ABCDN|Subjects will use each of the 5 products sequentially (ABCDN) during an evaluation period, followed by a 4 hour Test Session.
88975200|NCT05129657|Experimental|Product usage order ACBND|Subjects will use each of the 5 products sequentially (ACBND) during an evaluation period, followed by a 4 hour Test Session.
88975201|NCT05129657|Experimental|Product usage order BADCN|Subjects will use each of the 5 products sequentially (BADCN) during an evaluation period, followed by a 4 hour Test Session.
88975202|NCT05129657|Experimental|Product usage order BDANC|Subjects will use each of the 5 products sequentially (BDANC) during an evaluation period, followed by a 4 hour Test Session.
88975203|NCT05129657|Experimental|Product usage order CANBD|Subjects will use each of the 5 products sequentially (CANBD) during an evaluation period, followed by a 4 hour Test Session.
88975204|NCT05129657|Experimental|Product usage order CNADB|Subjects will use each of the 5 products sequentially (CNADB) during an evaluation period, followed by a 4 hour Test Session.
88975205|NCT05129657|Experimental|Product usage order DBNAC|Subjects will use each of the 5 products sequentially (DBNAC) during an evaluation period, followed by a 4 hour Test Session.
88975206|NCT05129657|Experimental|Product usage order DNBCA|Subjects will use each of the 5 products sequentially (DNBCA) during an evaluation period, followed by a 4 hour Test Session.
88975207|NCT05129657|Experimental|Product usage order NCDAB|Subjects will use each of the 5 products sequentially (NCDAB) during an evaluation period, followed by a 4 hour Test Session.
88975208|NCT05129657|Experimental|Product usage order NDCBA|Subjects will use each of the 5 products sequentially (NDCBA) during an evaluation period, followed by a 4 hour Test Session.
88975209|NCT05084183|Experimental|PermeaDerm®|N=34 Participants will receive application of PermeaDerm® as outlined in Directions for Use
88975210|NCT05084183|Active Comparator|Mepilex Ag®|Participants will receive application of Mepilex Ag® as outlined in Directions for Use.
88975211|NCT00398892|Other|1|Crossover - placebo then active
89586511|NCT06280989|Experimental|kinesio taping|Each female will be treated by Kinesio tape which will be applied for three days (from the first day to the end of the third day of menstrual cycle) throughout 3 consecutive cycles.
89586512|NCT06280989|Experimental|myofascial release technique|Each female will be treated by myofascial relaxation technique which will be started at the third or fourth day of menstruation and continued till the onset of the next menstruation, 40 minutes, 3 times / week for 12 sessions through 3 consecutive menstrual cycle
89586513|NCT06280898||nonischemic|
89586514|NCT06280898||ischemic|
89586515|NCT06280690|Experimental|10mg SGM-101|This cohort receives 10mg
89586516|NCT06280690|Experimental|5mg SGM-101|This cohort receives 5mg
89586517|NCT06279429|Experimental|Sideral® Sucrosomial Iron|The study subjects continued to take Sucrosomial Iron 30mg supplements every day, 2 capsules a day, one 30 minutes after breakfast and dinner, for 12 consecutive weeks. During the study period, none of them used erythropoiesis stimulating agent (ESA).
89586518|NCT06279429|Active Comparator|Placebo|The study subjects continued to take Iron chewable tablet 100mg supplements every day, 2 capsules a day, one 30 minutes after breakfast and dinner, for 12 consecutive weeks. During the study period, none of them used erythropoiesis stimulating agent (ESA).
89586519|NCT06278038|Experimental|Toludesvenlafaxine hydrochloride sustained-release tablets treatment group|
89586520|NCT06278038|Active Comparator|Venlafaxine hydrochloride sustained-release tablets treatment group|
89586521|NCT06277479||AlloHSCT Rigshospitalet|All patients treated at Department of Hematology, Rigshospitalet
89586522|NCT06277479||AlloHSCT Skejby|All patients treated at Department of Hematology, Skejby
89586523|NCT06276803||Patients who have no risk factors for PDAC|In this study, LINFU® will be evaluated to help identify pancreatic intraepithelial neoplasia-2 (PanIn-2), pancreatic intraepithelial neoplasia-3 (PanIn-3), and early, asymptomatic pancreatic ductal adenocarcinoma (PDAC) in patients with no risk factors and who do not display signs or symptoms of pancreatic disease.
89586524|NCT06276738||Patients at increased risk for developing pancreatic cancer|Patients who exhibit symptoms suggestive of PDAC (i.e. jaundice, abdominal pain, weight loss, nausea and vomiting etc.) or have evidence of imaging studies suggestive of PDAC will undergo LINFU® testing.
89586525|NCT06271733|Active Comparator|Active TMS|
89586526|NCT06271733|Sham Comparator|Sham|
89586527|NCT06271668||Clinical Decision Support (CDS): Naloxone Alert|"Encounters where the naloxone clinical decision support (CDS) alert fired. CDS logic is programmed to fire alert when a provider places and order for a high-risk opioid analgesic prescription to a patient without an active naloxone prescription.~High-risk prescription logic to trigger the Naloxone CDS:~[(NOT 1 AND (2 AND AT LEAST 1 OF (3, 4, 5, 6))) AND 7 AND NOT 8]~ACTIVE OR PENDED NALOXONE PRESCRIPTION ORDER~OPIOID SCRIPT BEING PLACED CRITERIA~DAILY Milligram Morphine Equivalent (MME) >=90 UNSIGNED ORDER~DAILY MME >=90 EXISTING~DIAGNOSIS OF OPIOID USE DISORDER~DIAGNOSIS HISTORY OF OPIOID OVERDOSE~PROVIDER LOGGED INTO ELLIGIBLE DEPARTMENTS~DISCHARGE TO HOSPICE"
88975212|NCT00398892|Other|2|Crossover - active then placebo
88975213|NCT05019794|Experimental|Gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJ) with FGFR2 amplification|Infigratinib (BGJ398) 125 mg orally daily, 3 weeks on, 1 week off (every 4 weeks as one treatment cycle).
88975214|NCT05019794|Experimental|Advanced Solid tumors[Exclude GC/GEJ Arm and CHOL,UC]with FGFR1-3 fusions/rearrangements/mutations|Infigratinib (BGJ398) 125 mg orally daily, 3 weeks on, 1 week off (every 4 weeks as one treatment cycle).
88975215|NCT00066768|Experimental|Arm I|Patients receive low-dose suramin IV over 30 minutes and docetaxel IV over 1 hour on day 1.
88975216|NCT00066768|Experimental|Arm II|Patients receive low-dose suramin IV over 30 minutes and gemcitabine IV over 30 minutes on days 1 and 8.
88975217|NCT04941521|Experimental|Exenatide and Drug Counseling|Participants will receive once weekly exenatide injections and drug counseling sessions.
88975218|NCT02966457|Experimental|Selective intestinal decolonization|Drug: Decolonization with Colistimethate sodium (2 mln I.U. 4x/day PO) for 14 days
89586528|NCT06271668||Usual Care|Control group of contemporary encounters where clinical decision support (CDS) is not active. Usual care.
89586529|NCT06271538|Experimental|Skal Pro|Skal Pro in the form of 2g sachet powder contains 10 billion CFU of freeze-dried Lactobacillus plantarum 299v (LP299V) and galactooligosaccharides (GOS).
89586530|NCT06271538|Placebo Comparator|Placebo|Placebo is an oral formulation of inert powder. Placebo and Skal Pro are identical in shape, size, colour, packaging and taste.
89586531|NCT06271304|Experimental|Blue blocking glasses (BB)|Eyewear with orange-tinted lenses that block 99% of short wavelength visible light < 500 nm
88975219|NCT02966457|No Intervention|"Wait and watch strategy"|Group without decolonization interventions
88975220|NCT04732637||COVID Positive|Individuals who have recently tested positive for COVID19 by RTPCR, with active infection.
88975221|NCT04732637||COVID Negative|Individuals who have recently tested negative for COVID19 by RTPCR.
88975222|NCT04891913|Experimental|15mg SY-007/ Placebo Repeat Dose|Intravenous infusion of 15mg SY-007 or placebo twice a day for seven consecutive days.
88975223|NCT04891913|Experimental|30mg SY-007/ Placebo Repeat Dose|Intravenous infusion of 30mg SY-007 or placebo twice a day for seven consecutive days.
88975224|NCT04891913|Experimental|60mg SY-007/ Placebo Repeat Dose|Intravenous infusion of 60mg SY-007 or placebo twice a day for seven consecutive days.
88975225|NCT04732364|Placebo Comparator|Group (C) (control group):|Patient will receive 20 ml 0.25% levobupivacaine into interfascial plane below erector spinae muscle at level of T5.
88975226|NCT04732364|Active Comparator|Group (D) (Dexmetonidine group):|Patient will receive 20ml 0.25% levobupivacaine + 1μ/kg dexmedetomidine into interfascial plane below erector spinae muscle at level of T5..
88975227|NCT04732364|Active Comparator|Group (M) (magnesium slphate group):|Patient will receive 20ml 0.25% levobupivacaine + 0.7 mg/kg MgSo4 into interfascial plane below erector spinae muscle at level of T5..
89586532|NCT06271304|Sham Comparator|Low filtration glasses (LF)|Eyewear with clear lenses that block 15% of short wavelength light < 500 nm
89586533|NCT06270238|Experimental|High-Frequency1|"Confirmed responses in TMS-induced MEP: Preserved ipsilateral corticospinal tract.~High-frequency rTMS over ipsilateral primary motor cortex will be applied."
89586534|NCT06270238|Active Comparator|cTBS1|"Confirmed responses in TMS-induced MEP: Preserved ipsilateral corticospinal tract.~continous Theta Burst Stimulation (cTBS) protocol of rTMS over contralateral primary motor cortex will be applied."
89586535|NCT06270238|Experimental|High-Frequency2|"Absent responses in TMS-induced MEPs, but confirmed corticospinal tract integrity in DTI; Preserved ipsilateral alternative corticospinal tract.~High-frequency rTMS over ipsilateral premotor cortex will be applied."
89586536|NCT06270238|Active Comparator|cTBS2|"Absent responses in TMS-induced MEPs, but confirmed corticospinal tract integrity in DTI; Preserved ipsilateral alternative corticospinal tract.~continous Theta Burst Stimulation (cTBS) protocol of rTMS over contralateral primary motor cortex will be applied."
89586537|NCT06270238|Experimental|High-Frequency3|"Absent responses in all ipsilateral corticospinal tract.~High-frequency rTMS over contralateral primary motor cortex will be applied."
89586538|NCT06270238|Active Comparator|cTBS3|"Absent responses in all ipsilateral corticospinal tract.~continous Theta Burst Stimulation (cTBS) protocol of rTMS over contralateral primary motor cortex will be applied."
89586539|NCT06269965|Experimental|Regeneten® Arm|Arthroscopic shoulder repair, in double row, with complete coverage of the foot print and addition of Regeneten®
89586540|NCT06269965|No Intervention|Witness Arm|Arthroscopic shoulder repair, in double row, with complete coverage of the foot print
89586541|NCT06268366|No Intervention|Control|Participants in the control group will not receive any exercise interventions. Participants in the control group will receive their individualized corrective exercises program following completion of the research study following the 10 week follow up.
89586542|NCT06268366|Experimental|Exercise Group|Participants in the intervention will be assigned three corrective exercises based on their greatest movement pattern deficit as advised by the Symmio application. Participants in the intervention group will follow the exercise and educational guidance provided by the Symmio application including adjustment of exercises and reviewing educational materials.
89586543|NCT06265935|Experimental|Experimental Group|Breathing exercise will be explained to the pregnant woman, taught and applied for 5 minutes. When doing the diaphragmatic breathing exercise, you will be told to take chest breaths after 4-5 diaphragmatic breaths to prevent hyperventilation. Feedback will be received, questions will be answered, a training brochure will be given and the program will be completed. Pregnant women will be asked to bring the questionnaire with them to their follow-up in two weeks. The Visual Similarity Scale for Fatigue and the SF-36 Quality of Life Scale will be refilled. How he did the exercise, whether he felt any effects and his satisfaction will be questioned. Your questions will be answered. You will be notified that you need to come for a check-up again in two weeks. Visual Similarity Scale for Fatigue and SF-36 Quality of Life Scale will be completed.
89586544|NCT06265935|No Intervention|Control Group|"No treatment will be performed on the participants in the control group, and they will be asked not to engage in regular physical activity or sports for 4 weeks and not to make any changes in their living habits.~Pregnant women will be asked to bring the survey form with them at the follow-up visits two weeks later. The Visual Similarity Scale for Fatigue and the SF-36 Quality of Life Scale will be refilled. You will be notified that you need to come for a check-up again in two weeks. At the follow-up after the fourth week, the Visual Similarity Scale for Fatigue and the SF-36 Quality of Life Scale will be filled out again. At the end of thirty days, the program will be completed and the forms will be filled."
89586545|NCT06263881|Experimental|Raphamin|"Oral administration, without food. The tablet should be held in the mouth until complete dissolution.~On the first day 8 tablets are administered using the following scheme: 1 tablet every 30 minutes in the first 2 hours (5 tablets in total within 2 hours), followed by three more tablets at regular intervals during the rest of the day. From day 2 onwards, 1 tablet taken 3 times daily. The treatment period is 7 days."
89586546|NCT06263881|Placebo Comparator|Placebo|"Oral administration, without food. The tablet should be held in the mouth until complete dissolution.~Placebo is administered according to the Raphamin regimen for 7 days."
89586547|NCT06260722|Experimental|Retatrutide Dose Level 1|Participants will receive retatrutide administered subcutaneously (SC).
89586548|NCT06260722|Experimental|Retatrutide Dose Level 2|Participants will receive retatrutide administered SC.
88975228|NCT00067080|Experimental|ICL670 + deferoxamine|
89586549|NCT06260722|Active Comparator|Semaglutide|Participants will receive semaglutide administered SC.
89586550|NCT06257264|Experimental|Part 1: Dose Escalation and Safety Expansion|Sequential cohorts of increasing dose levels of BG-68501 will be evaluated as monotherapy and in combination with fulvestrant.
89586551|NCT06257264|Experimental|Part 2: Dose Expansion|The RFDE for BG-68501 (as monotherapy and in combination with fulvestrant) from Part 1 will be evaluated in selected tumor cohorts.
89586552|NCT06255821|Experimental|One week follow-up assessment|Participants will receive a pre-assessment and an exposure with a control spider (spider A). This control spider will be presented again at post-training assessments. Participants will then be assigned to the follow-up assessment one week after the exposure session, in which spider A and a novel spider (spider B) will be used to test for generalization of exposure effects.
89586553|NCT06255821|Experimental|Six weeks follow-up assessment|Participants will receive a pre-assessment and an exposure with a control spider (spider A). This control spider will be presented again at post-training assessments. Participants will then be assigned to the follow-up assessment six weeks after the exposure session, in which spider A and a novel spider (spider B) will be used to test for generalization of exposure effects.
89586554|NCT06255821|Experimental|Three months follow-up assessment|Participants will receive a pre-assessment and an exposure with a control spider (spider A). This control spider will be presented again at post-training assessments. Participants will then be assigned to the follow-up assessment three months after the exposure session, in which spider A and a novel spider (spider B) will be used to test for generalization of exposure effects.
88975229|NCT00067119|Experimental|Aggrenox|
88975230|NCT00067119|Placebo Comparator|Placebo|
88975231|NCT00070824|Experimental|B|Patients with osteoarthritis pain at rest
88975232|NCT00070824|Experimental|A|Normal Subjects without pain
88975233|NCT04750772|Experimental|68Ga-DOTA-FAPI04|Each subject receive a single intravenous injection of 18F-FDG and 68Ga-DOTA-FAPI04, and undergo PET/CT imaging within the specified time
89586555|NCT06252844|Experimental|Intervention|Progressive resistance training (PRT) of lower limb muscles. Frequency of intervention: 2-3 times per week. Duration of intervention: 24 weeks.
89586556|NCT06252844|Experimental|Active control|Flexibility training of the lower limb muscles. Frequency of intervention: 2-3 times per week. Duration of intervention: 24 weeks.
89586557|NCT06248203|Experimental|Tealeaf - Adolescent|The Tealeaf-A arm will have three randomized schools. Teachers in the Tealeaf-A arm will receive six days of training and then supervision every 2 weeks to deliver care.
89586558|NCT06248203|Active Comparator|Enhanced Usual Care (EUC)|The EUC arm will have three randomized schools and will be used as an ethical comparator for the Tealeaf-A arm. Teachers will receive two days of training, all materials, and no supervision.
89586559|NCT06247540|Experimental|Treatment (venetoclax, rituximab, nivolumab)|Patients receive venetoclax PO QD on days 1-28, nivolumab IV over 30 minutes on days 2 and 15 of cycles 1-4 and day 1 of each subsequent cycle, and rituximab IV on day 2 of cycle 1 and day 1 of cycles 2-6. Treatment repeats every 28 days up to 6 cycles in the absence of disease progression or unacceptable toxicity. After the completion of 6 cycles, rituximab is discontinued and patients receive venetoclax PO QD on days 1-28 and nivolumab IV over 30 minutes on day 1 of each cycle. Treatment repeats every 28 days for up to 2 years total therapy in the absence of disease progression or unacceptable toxicity. Patients undergo tissue biopsy during screening. Patients undergo a bone marrow biopsy and blood sample collection as well as PET/CT and CT or MRI during screening and on the trial.
89586560|NCT06237920|Experimental|Nivolumab|1 cycle of intravenous nivolumab on day 1 and 1 cycle of intraveous nivolumab on day 29. Total administration frequency is twice.
89586561|NCT06237920|Experimental|Nivolumab and relatlimab|1 cycle of intravenous nivolumab and relatlimab on day 1 and 1 cycle of intraveous nivolumab and relatlimab on day 29. Total administration frequency is twice.
89586562|NCT06230081|Active Comparator|Block|"Hip Arthroplasty: Multimodal analgesic therapy + Ultrasound guided PENG block and Iliohypogastric block or LFCN-block.~Knee arthroplasty: Multimodal analgesic therapy + Ultrasound guided iPACK block, triple Genicular blocks, Vastus intermedius block, Adductor canal block and AFCN-block."
89586563|NCT06230081|No Intervention|No block|"Hip Arthroplasty: Multimodal analgesic therapy~Knee Arthroplasty: Multimodal analgesic therapy + LIA"
89586564|NCT06222164||Residual Specimens|Residual specimen/sample collection study where peripheral blood (PB), bone marrow (BM), genomic (gDNA), and/or formalin-fixed paraffin-embedded tissue (FFPE) specimens/samples are obtained from patient samples sent to LabPMM, LLC for clinical testing.
89586565|NCT06222086|Experimental|Calisthenic exercise training with telerehabilitation|The training group will be given calisthenic exercise training via video conference accompanied by a physiotherapist for 6 weeks.
89586566|NCT06222086|Sham Comparator|Control Group|The control group will not be given any training for 6 weeks during the study period
89586567|NCT06221293||Group 1|the first group consists of patients with increased abdominal pressure, signs of multi-organ failure with a fatal outcome
89586568|NCT06221293||Group 2|the first group consists of patients with increased abdominal pressure, signs of multi-organ failure without death
89586569|NCT06220747||women aged 12-45 years old|
89586570|NCT06219408|Experimental|CIH Stepped Care|"A mindfulness-based and meaning-based stepped care approach for treating co-occurring chronic pain and PTSD that will begin with less intensive treatment (e.g., psychoeducation) and, based on patient response and preference, will be stepped up to more intensive treatment when appropriate."
89586571|NCT06219408|No Intervention|Treatment as Usual|Treatment as usual at the clinic
89586572|NCT06218914|Experimental|NT-112|Dose Escalation of NT-112.
89586573|NCT06213389|Experimental|Patients to entubate with EzVision® videolaryngoscopy|Patients will intubate with EzVision® videolaryngoscopy
89586574|NCT06213389|Other|Patients to intubate with Macintosh blade|Patients will intubate with Macintosh blade
89586575|NCT06211322|Experimental|To determine the feasibility of a patient self-management application (Urika) in patients with gout.|The intended purpose of the app is to support self-management for patients with gout that initiate urate lowering therapy.
89586576|NCT06208150|Experimental|Arm A: Talquetamab + Pomalidomide (Tal-P)|Participants will receive talquetamab as subcutaneous (SC) injections; pomalidomide will be self-administered as a single dose orally; dexamethasone may be given orally or intravenously as a pretreatment medication and study drug.
89586577|NCT06208150|Experimental|Arm B: Talquetamab + Teclistamab (Tal-Tec)|Participants will receive teclistamab in combination with talquetamab both as SC injection; dexamethasone may be given orally or intravenously as a pretreatment medication and study drug.
88975234|NCT04750772|Experimental|18F-DOTA-FAPI04|Each subject receive a single intravenous injection of 18F-FDG and 18F-DOTA-FAPI04, and undergo PET/CT imaging within the specified time
88975235|NCT00399165|Active Comparator|1|Oral Testosterone enanthate in sesame oil, 400 mg po (orally), BID (twice daily) + dutasteride 0.5 mg orally, qd (once daily) for 28 days + dutasteride load 24.5 mg po once
88975236|NCT00399165|Active Comparator|2|Oral Testosterone sesame oil, 800 mg po (orally), qd (in am daily) + placebo sesame oil (in pm daily) + dutasteride 0.5 mg orally, qd (once daily) for 28 days + dutasteride load 24.5 mg po once
88975237|NCT04476368|Experimental|yoga|Participants in yoga group will be recruited during prenatal yoga classes at two locations: Maribor and Ljubljana. Women will be instructed to attend one class per week. Classes will consist of pregnancy-adapted yoga practices according to the system Yoga in Daily Life. They will be 90 min in duration and will consist of initial relaxation (10 to 15 min), followed by yoga postures (asanas) and stretching exercises (45 to 60 min), and final breathing (pranayama), concentration (dharana), and meditation (dhyana) techniques (20 to 30 min). Two certified yoga instructors will lead yoga classes. Measurements will be performed before and after yoga session.
88975238|NCT04476368|Active Comparator|control|Control group will consist of healthy pregnant women attending regular prenatal visits at the departments of perinatology of the university medical centers Maribor and Ljubljana. Only women not attending any formal prenatal exercise program will be offered entrance in the study. Measurements in this group will be performed before and after a 20-30 minute walk.
88975239|NCT00398970|Active Comparator|Traditional flouroscopy guided sampling|
89586578|NCT06208150|Active Comparator|Arm C: Elotuzumab+ Pomalidomide+Dexamethasone (EPd) or Pomalidomide+Bortezomib+Dexamethasone (PVd)|Participants will either receive elotuzumab intravenous (IV) injection in combination with pomalidomide and dexamethasone orally; or pomalidamide orally in combination with bortezomib SC injection and dexamethasone orally as per investigator choice. Dexamethasone will be administered as a pretreatment medication.
89586579|NCT06206876|Experimental|Treatment (FL118)|Patients receive FL118 PO on days 1, 8, and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood samples and CT or MRI throughout the trial. Patients may optionally undergo biopsy at screening and on study.
89586580|NCT06206863|Experimental|Supportive Care (virtual exercise classes)|Participants participate in virtual exercise classes at least TIW over 20-60 minutes for 12 weeks. Participants are expected to work towards achieving the national physical activity exercise guidelines of 150 minutes of moderate intensity aerobic based physical activity and 2-3 strength training sessions each week.
89586581|NCT06206525|Experimental|Insulin dosing calculator|
89586582|NCT06204809|Experimental|Single Dose of PGN-EDODM1 at Dose Level 1|
89586583|NCT06204809|Experimental|Single Dose of PGN-EDODM1 at Dose Level 2|
89586584|NCT06204809|Experimental|Single Dose of PGN-EDODM1 at Dose Level 3|
89586585|NCT06204809|Placebo Comparator|Single Dose of Placebo|
89586586|NCT06204068|Experimental|Hip Spica 6 weeks, Brace 6 weeks|The experimental group will be placed in a hip spica cast for a total of 6 weeks, then will transition to a brace for 6 weeks.
89586587|NCT06204068|Active Comparator|Hip Spica 12 weeks (Control)|The control group will be placed in a hip spica cast for a total of 12 weeks with a change of spica cast, under anesthesia, at the 6-week mark. This treatment is the accepted standard of care for children who undergo closed reduction of a developmentally dysplastic and dislocated hip.
89586588|NCT06203002|Experimental|LX9211 Low Dose|LX9211 low dose, orally, once daily during a blinded treatment period.
89586589|NCT06203002|Experimental|LX9211 High Dose|LX9211 high dose, orally, once daily during a blinded treatment period.
89586590|NCT06203002|Experimental|LX9211 High Dose Followed by Low Dose|LX9211 high dose followed by LX9211 low dose, orally, once daily during a blinded treatment period.
89586591|NCT06203002|Placebo Comparator|LX9211 Placebo|LX9211 matching placebo, orally, once daily during a blinded treatment period.
89586592|NCT06198829||Clinical parameter assessment group|Various assessments will be conducted on patients with femoroacetabular cam impingement.
89586593|NCT06190236|Experimental|Experimental|This arm with utilize a stand-alone web-based cognitive behavioral therapy (CBT4CBT) for alcohol use disorder
89586594|NCT06190236|No Intervention|Control|No intervention
89586595|NCT06177340||Sacrospinofixation|patient who benefited from anterior and/or posterior sacrospinofixation using the Nanoscope system
89586596|NCT06177327||Adults with polyostotic fibrous dysplasia McCune Albright syndrome|A retrospective data collection and statistical analyses will be performed. Adults with polyostotic fibrous dysplasia McCune Albright syndrome, who underwent an hepato-bilio-pancreatic MRI since January 2002, during their follow-up
89586597|NCT06177054|Other|Rotation of sites|Each participants is first included with no instruction of rotation and then after 2 weeks instructed to avoid areas with hyperechogenicity
89586598|NCT06175364|Other|Health Professionals in the Field of Orthotics Prosthetics|Health professionals in the field of orthotics and prosthetics generally include orthotic and prosthetic specialists, physiotherapists, rehabilitation specialists, orthopedic surgeons, biomechanics experts, physiologists, and engineers. These professionals specialize in the design, production, application, and rehabilitation of orthoses and prostheses.
89586599|NCT06173648|Experimental|All Study Participants.|Single study group that requires extraction of mandibular incisors for other reasons. Teeth are accessed, subject to filing, pulp extirpation, and treated with endodontic solutions. Some teeth of the participants are then subject to study intervention consisting of an ICG solution into the root followed by laser exposure of the solution in situ. After laser exposure, the pulp chamber and roots are rinsed then mechanically extracted. Other teeth of some participants will not be subject to the ICG and laser intervention, but will proceed to the final rinse and extraction. After extraction, specimens are fixed, stained, and mounted for visual examination under a microscope. Images of tissue are captured for documentation. Samples are examined for histological and morphological condition of the periodontal ligament, cementum, and collagen attached to the external surface of the extracted tooth root.
88975240|NCT00398970|Experimental|Ultrasound guide sampling|
88975241|NCT04408469|Experimental|Online EQuIP|The online CBT treatment consists of 10 weekly modules that participants will complete over the course of 10 weeks.
88975242|NCT04408469|Placebo Comparator|Self-Monitoring|Participants will be asked to indicate their past 7-day mood; stress experiences; and mental and behavioral health on an online survey experience once per week for 10 weeks
88975243|NCT02967081||Pulp necrosis|
88975244|NCT02967081||Pulpitis (painless)|In this group the dentinal fluid will be sampled/collected twice: Firstly after the removal of the primary caries lesion. Subsequently the cavity will be temporized. Secondly, after removal of the temporary filling material (before final restoration).
88975245|NCT02967081||Irreversible pulpitis|
89586600|NCT06170723|Experimental|Part 1: BMS-986368 - Fasted|
89586601|NCT06170723|Experimental|Part 1: Itraconazole - Fasted|
89586602|NCT06170723|Experimental|Part 1: BMS-986368 with Itraconazole - Fasted|
89586603|NCT06170723|Experimental|Part 2: BMS-986368 - Fasted|
89586604|NCT06170723|Experimental|Part 2: BMS-986368 - Fed|
89586605|NCT06170723|Experimental|Part 2: Famotidine, followed by BMS-986368 - Fasted|
89586606|NCT06170385|Experimental|Intervention|"Children will participate in six PT sessions over the course of 12 weeks and will be provided with the option to choose their preferred mode of the delivery (i.e., 1:1 in-person, 1:1 virtual, group virtual, or a combination of all). The program will be tailored to the child's age, presenting symptoms, and preferred activities.~Children and parents/ caregivers will be encouraged to carry out additional tailored PT sessions through their preferred mode of delivery and to access the exercise videos provided in the additional resources section of the HEAL-ME platform."
89586607|NCT06169826|Placebo Comparator|Control|Control
88975246|NCT02967081||Normal pulp|
88975247|NCT04344002||lung cancer+COVID-19|lung cancer patients diagnosed with COVID-19
89586608|NCT06169826|Active Comparator|Treatment-Histidine|Treatment-Histidine
89586609|NCT06169644||Chemotherapy-treated GTN Patients|Patients with a diagnosis of Gestational Trophoblastic Neoplasia who completed chemotherapy treatment between 6 weeks and 24 months prior to the study. No IMP intervention to be administered, patients to be involved in a qualitative interview.
89586610|NCT06168825||Black and African American Women diagnosed with Cancer|Participants who have completed primary treatment (completed chemotherapy and/or radiation and/or surgery) are eligible to participate in the study
89586611|NCT06165328||Cohort1|Patients with aged more than 50 years and had FIT test +
89586612|NCT06161571|Experimental|EFX 50 mg|
89586613|NCT06161571|Placebo Comparator|Placebo|
89586614|NCT06161571|Experimental|EFX 50 mg (Open-Label Rollover)|
89586615|NCT06161012|Experimental|Test/Control|Eligible subjects who are habitual soft contact lens wearers will be randomized into the Test/Control sequence, to wear two different study lenses, one at a time, over two wear periods (test then control). Each wear period will be approximately 2 weeks in duration, with a washout period of approximately 1 week between wear periods. Subjects will be advised to wear the study lenses for a minimum of 8 hours per day on at least 5 days per week of each wear period.
89586616|NCT06161012|Experimental|Control/Test|Eligible subjects who are habitual soft contact lens wearers will be randomized into the Control/Test sequence, to wear two different study lenses, one at a time, over two wear periods (control then test). Each wear period will be approximately 2 weeks in duration, with a washout period of approximately 1 week between wear periods. Subjects will be advised to wear the study lenses for a minimum of 8 hours per day on at least 5 days per week of each wear period.
89586617|NCT06160882|Other|Evaluation of Powered Prosthesis for use with Transfemoral Osseointegration Recipients|Perform Osseointegration (OI)Surgery and Targeted Muscle Reinnervation (TMR) and evaluate powered prosthesis training and use. The participant will complete non-weightbearing neural control tasks along with functional, biomechanical, metabolic and qualitative patient-reported outcome measures using the OI interface and the powered leg prosthesis.
89586618|NCT06159166|Experimental|Phase 1|"For the Phase 1 portion, treatment will be administered continuously (Dose regimens 1, 2, 4) or intermittently (Dose regimen 3; 3 weeks on/1 week off) in 28-day cycles). All participants will receive study drug until:~cessation of study treatment due to death, intolerance, or withdrawal of consent from the study;~completion of 24 cycles of treatment (unless the investigator's benefit-risk assessment supports continued treatment);~participants enroll in the phase 2a portion of the study;~disease progression; or~Investigator's decision.~Treatment period ends with the administration of the last dose. The study ends 30 days after the last dose"
89586619|NCT06159166|Experimental|Phase 2|"For the Phase 2 portion, treatment will be administered based on recommended RP2D from Phase 1. All participants will receive study drug until:~cessation of study treatment due to death, intolerance, or withdrawal of consent from the study;~completion of 24 cycles of treatment (unless the investigator's benefit-risk assessment supports continued treatment;~disease progression; or~Investigator's decision.~Treatment period ends with the administration of the last dose. The study ends 30 days after the last dose."
89586620|NCT06157411|Experimental|Mindful Eating Intervention (AC group)|"Mindful eating program: Two sub-groups of 14 participants will follow the program for 8 consecutive weeks.~Follow-up group session: The two groups of 14 participants will each attend a follow-up group session.~3 visits with a doctor: The 28 participants will have a pre-intervention visit, a post-intervention visit, and a final visit 3 months after the program.~Focus groups: The two groups of 14 participants will be divided into two (N=7, x4) for a focus group session."
89586621|NCT06157411|Active Comparator|Conventional Dietetic Intervention (DC group)|"Therapeutic education program (ETP): The 28 participants will follow the ETP program Obesity: living better, balancing my weight.~Follow-up group session: The 28 participants will have an individual follow-up session in the form of a final Shared Educational Assessment.~3 visits with a doctor: The 28 participants will have a pre-intervention visit, a post-intervention visit, and a final visit 3 months after the program."
89586622|NCT06153641||Biopsy arm|Post-transplant patients undergoing standard of care liver biopsy (Biopsy arm).
89030266|NCT04694898|Experimental|SURE Intervention|"Households in the intervention group with children younger than 2 years benefit from:~Interpersonal contacts to provide counselling on infant and young child feeding practices (IYCF) and nutrition-sensitive agriculture advice to mothers and fathers of children under 24 months, inclusive of pregnant women and fathers-to-be, jointly delivered by the local health and agriculture extension workers during routine household visits~Men's and women's group dialogues targeting all men and women in a given community network, facilitated also by the local health and agriculture extension workers~Media campaign to reinforce IYCF and dietary diversity messages"
89030267|NCT00516867|Active Comparator|UVB 0.5%|
89030268|NCT00516867|No Intervention|Controls|
89030269|NCT00516867|Active Comparator|UVB 1.4%|
89030270|NCT02949765|Active Comparator|Iron sulfate 105 mg|Iron sulfate 105 mg: 1 pill/day is administered
89030271|NCT02949765|Experimental|Iron-rich diet|Iron-rich diet recommendations are given
89030272|NCT04694664||Pregnant Women|Pregnant women who are 18 years of age or older.
89030273|NCT04694664||Post-partum women|Women who have at least one child younger than 18 years of age.
89030274|NCT04518176|Experimental|study group|patients with twin pregnancy undergoing cesarean section underwent bilateral uterine artery ligation and received oxytocin.
89030275|NCT04518176|Active Comparator|control group|patients with twin pregnancy undergoing cesarean section received oxytocin only.
89030276|NCT04694859||Symptomatic Severe Aortic Valve Stenosis|Patients >18 years old with symptomatic severe aortic valve stenosis.
89586623|NCT06153641||Stable post-liver transplant arm|Stable post-liver transplantation patients without rejection (Stable post-liver transplant arm).
89586624|NCT06153641||Healthy arm|Healthy non-transplant control patients without liver disease (Healthy arm).
89586625|NCT06143566|Experimental|Polypill|Participants will take a polypill containing finerenone 10 mg, empagliflozin 12.5 mg, and losartan (50 mg or 100 mg) daily.
89586626|NCT06143566|No Intervention|Usual Care|Participants will continue to take normal medications for diabetes and high blood pressure.
89586627|NCT06140758|Active Comparator|Oral-B 1450 ppm Fluoride (1.16% sodium monofluorophosphate) Dentifrice|
89586628|NCT06140758|Active Comparator|Colgate 1450 ppm Fluoride (1.16% sodium monofluorophosphate)Dentifrice|
89586629|NCT06140758|Sham Comparator|Toms of Maine 0 ppm Fluoride Dentifrice|
89586630|NCT06140758|Active Comparator|Colgate 1450 ppm Fluoride (1.1% sodium monofluorophosphate) Dentifrice|
89586631|NCT06140758|Active Comparator|1500 ppm MFP/CaCO3 1.16% sodium monofluorophosphate) Dentifrice|
89586632|NCT06140758|Active Comparator|1100 ppm (0.454% Stannous fluoride) Dentifrice|
89586633|NCT06140147|Experimental|Protocolised reduction of non-resuscitation fluids|Participants receive non-resuscitation fluids according to a pre-defined protocol starting within two hours of randomization. The intervention is continued for the duration of the ICU admission up to a maximum of 90 days.
89586634|NCT06140147|Other|Usual Care|Participants receive non-resuscitation fluids according to local routines.
89586635|NCT06137807|Experimental|TricValve® Device (Device) Group|subjects will undergo TricValve® implantation and will continue to be managed with optimal medical therapies, per physician discretion.
89586636|NCT06137807|Placebo Comparator|Control Arm Treatment Group|subjects will continue to be managed on local standard of care (SOC) therapy for severe TR per physician discretion.
89586637|NCT06133790||HPV + Group|Patients with positive HPV diagnosis
89586638|NCT06133790||HPV - Group|Patients with negative HPV diagnosis
89586639|NCT06132737|Experimental|[90Y]Y-PTT|The study will be performed in three cohorts with different dose levels. Eligible patients will receive one cycle of 90Y-PTT, which will be administered intravenously.
89586640|NCT06130553|Experimental|AZD3470 Monotherapy|Part A dose escalation and DDI and Part B dose optimisation and expansion in varying doses of AZD3470
89586641|NCT06129864|Experimental|Study Arm|Participants in this arm will receive volrustomig.
89586642|NCT06129864|No Intervention|Observation Arm|Patients in this arm will undergo observation.
89586643|NCT06125951|Experimental|10 mg Xanamem|10 mg Xanamem tablet, to be administered orally once every morning with or without food
89586644|NCT06125951|Placebo Comparator|Placebo|Placebo tablet, to be administered orally once every morning with or without food
89586645|NCT06122714|Experimental|Part A1 (healthy participants) Cohort 1|Participants will receive one single ascending dose of AZD4144.
89586646|NCT06122714|Experimental|Part A1 (healthy participants) Cohort 2|Participants will receive one single ascending dose of AZD4144.
89586647|NCT06122714|Experimental|Part A1 (healthy participants) Cohort 3|Participants will receive one single ascending dose of AZD4144.
89586648|NCT06122714|Experimental|Part A1 (healthy participants) Cohort 4|Participants will receive one single ascending dose of AZD4144.
89586649|NCT06122714|Experimental|Part A1 (healthy participants) Cohort 5|Participants will receive one single ascending dose of AZD4144.
89586650|NCT06122714|Experimental|Part A1 (healthy participants) Cohort 6|Participants will receive one single ascending dose of AZD4144.
89586651|NCT06122714|Placebo Comparator|Part A1 (healthy participants) placebo|Participants will receive matching Placebo.
89586652|NCT06122714|Experimental|Part A2 (healthy Japanese participants) Cohort 1|Participants will receive one single ascending dose of AZD4144.
89586653|NCT06122714|Experimental|Part A2 (healthy Japanese participants) Cohort 2|Participants will receive one single ascending dose of AZD4144.
89586654|NCT06122714|Placebo Comparator|Part A2 (healthy Japanese participants) placebo|Participants will receive matching placebo.
89586655|NCT06122714|Experimental|Part A3 (healthy Chinese participants) Cohort 1|Participants will receive one single ascending dose of AZD4144.
89586656|NCT06122714|Placebo Comparator|Part A3 (healthy Chinese participants) placebo|Participants will receive matching placebo.
89586657|NCT06122714|Experimental|Part B1 (healthy participants) Cohort 1|Participants will receive one multiple ascending dose of AZD4144.
89586658|NCT06122714|Experimental|Part B1 (healthy participants) Cohort 2|Participants will receive one multiple ascending dose of AZD4144.
89586659|NCT06122714|Experimental|Part B1 (healthy participants) Cohort 3|Participants will receive one multiple ascending dose of AZD4144.
89586660|NCT06122714|Placebo Comparator|Part B1 (healthy participants) placebo|Participants will receive matching placebo.
89586661|NCT06122714|Experimental|Part B2 (healthy Japanese participants) Cohort 1|Participants will receive one multiple ascending dose of AZD4144.
89586662|NCT06122714|Placebo Comparator|Part B2 (healthy Japanese participants) placebo|Participants will receive matching placebo.
89586663|NCT06122662|Experimental|AMX0035|"AMX0035 administered by mouth for 52 weeks: once daily for first 2 weeks and then twice daily for remainder of study~For participants electing to continue into the open-label phase at Week 52; AMX0035 administered by mouth: twice daily for an additional 52 weeks"
89586664|NCT06122662|Placebo Comparator|Placebo|Placebo administered by mouth for 52 weeks: once daily for first 2 weeks and then twice daily for remainder of study
89586665|NCT06122207|Active Comparator|Probiotic|"Women will take two daily doses containing approximately 2*10E9 Colony Forming Unit (CFU) of Ligilactobacillus salivarius PS11610 (Fertibiome®). Men will take one daily dose containing approximately 1*10E9 CFU of Ligilactobacillus salivarius PS11610 (Fertibiome®).~In case of pregnancy during intervention, only women will continue taking 1 daily dose for the first 12 weeks of gestation."
89586666|NCT06122207|Placebo Comparator|Placebo|"Women will take two daily doses of Placebo supplement. Men will take one daily dose of Placebo supplement.~In case of pregnancy during intervention, only women will continue taking 1 daily dose for the first 12 weeks of gestation."
89586667|NCT06120283|Experimental|Dose Escalation|Phase 1a: Sequential cohorts of increasing dose levels of BGB-43395 will be evaluated as monotherapy and in combination with either fulvestrant or letrozole.
89586668|NCT06120283|Experimental|Dose Expansion|Phase 1b: The recommended dose for expansion (RFDE) for BGB-43395 (in combination with fulvestrant) from Phase 1a will be evaluated in HR+ breast cancer and selected tumor cohorts.
89586669|NCT06113419|Experimental|Early cholecystectomy|Early laparoscopic cholecystectomy (within 72 hours after randomization)
89586670|NCT06113419|Active Comparator|Interval cholecystectomy|Interval laparoscopic cholecystectomy (30 +/- 5 days after randomization).
89586671|NCT06112301||B-Cell Positive Lymphoproliferative Disorders|DNA Samples for subjects with B-Cell Positive Lymphoproliferative Disorders
89586672|NCT06112301||B-Cell Negative Lymphoproliferative Disorders|DNA Samples for subjects suspected of B-Cell Positive Lymphoproliferative Disorders with negative B-Cell Clonality testing
89586673|NCT06110091|Experimental|Integrated Behavioral Therapy Program|Integrated Behavioral Therapy consists of 5 weekly one-hour sessions (face-to-face either through video or in-person) + 2 telephone check-in with an interventionist. This program integrates cognitive-behavioral treatment for nocturia and insomnia. Brief telephone check-ins will be comprised of review of topics discussed during the sessions.
89586674|NCT06110091|Placebo Comparator|Health Education Program|The Health Education Program consists of 5 weekly one-hour sessions (face-to-face either through video or in-person) + 2 telephone check-in with an interventionist. The program modules focus on brain health and includes topics such physical activity, social engagement, sleep topics (e.g., changes in sleep that occur with aging, effects of poor sleep on health), medications/medical conditions, vision and hearing impairment. Brief telephone check-ins will be comprised of review of health topics discussed during the sessions.
89586675|NCT06106360||3 Cohorts|Cohort 1: Daily from day 2 through the end of treatment cycle (n=34) Cohort 2: Daily days 2-9 then every third day through end of cycle (n=33) Cohort 3: Daily days 2-9 for all symptoms, every third day thereafter regarding 'pain' only through end of cycle (n=33)
89586676|NCT06106334|Experimental|S-309309|"All participants will receive each of the following treatments:~Days 1 and 19: S-309309 once daily (QD); in the fasted state)~Day 15: Itraconazole twice daily (BID); in the fed state)~Days 16 to 24: Itraconazole QD (in the fed state, except for Day 19 [co-administration with S-309309 in the fasted state])"
89586677|NCT06104462|Experimental|Cortical hemodynamic variability of iTBS and its courses|"A group of healthy adults shall undergo repeated experimental visits with concurrent TBS/fNIRS (3≤repetition≤15). An interval of at least two days (48 hours) between the visits is required to minimize carry-over effects from the iTBS protocols.~Inter- (age, gender, personality inventory, etc.) and intra-individual factors (daily mood, daily sleep quality, physical activity levels, etc.) that are potentially moderating iTBS-induced excitability changes will be explored."
89586678|NCT06101628|Other|EXPERIMENTAL AND CONTROL GROUP|Participants who meet the inclusion criteria of the study will be informed about the research by the researchers and will be included in the study on a voluntary basis and their written permissions will be obtained. Firstly, the personal information of the participants will be recorded in the data collection form. The middle finger of the left hand of each participant will be the experimental group and the little finger will be the control group. After the gel nail is applied to the middle finger of the left hand, SpO2 and pulse values will be measured by pulse oximetry from the left hand middle finger and little finger of the participant and recorded in the data form. At the end of the study, SpO2 and pulse values before and after the gel nail application will be compared.
89586679|NCT06097169||Dex|patients using dexmedetomidine infusion
89586680|NCT06097169||Fen|patients using fentanyl for induction
89586681|NCT06096532|Other|Older Adults|
89586682|NCT06096532|Active Comparator|Younger Adults|
89586683|NCT06095297|Experimental|CICT|Constraint-Induced Cognitive Therapy uses in-lab training on everyday activities with important cognitive components and procedures designed to transfer improvements from the treatment setting to every day life. This will be combined with computer-based Speed of Processing Training.
89586684|NCT06095297|Experimental|CICT + VR|Constraint-Induced Cognitive Therapy plus Vocational Rehabilitation uses in-lab training on everyday activities with important cognitive components and procedures designed to transfer improvements from the treatment setting to every day life. This will be combined with computer-based Speed of Processing Training. This group will also receive vocational rehabilitation from the Alabama Department of Rehabilitation Services, such as career counseling and building important career skills.
89586685|NCT06095297|Active Comparator|BFT|Brain Fitness Training involves in-lab training on relaxation, healthy nutrition, and healthy sleep with procedures designed to promote integration of these lifestyles into everyday life. This will be combined with computer-based Speed of Processing Training.
89586686|NCT06095297|Active Comparator|BFT + VR|Brain Fitness Training plus Vocational Rehabilitation involves in-lab training on relaxation, healthy nutrition, and healthy sleep with procedures designed to promote integration of these lifestyles into everyday life. This group will also receive vocational rehabilitation from the Alabama Department of Rehabilitation Services, such as career counseling and building important career skills.
89586687|NCT06095102|Experimental|JNJ-77242113|Participants will receive JNJ-77242113 from Week 0 through Week 156.
89586688|NCT06095102|Placebo Comparator|Placebo|Participants will receive placebo from Week 0 through Week 16 and thereafter will receive JNJ-77242113 from Week 16 through Week 156.
89586689|NCT06092866|Experimental|Digital triage|Patients are triaged with symptom assessment by a nurse using a digital platform. They are receiving either advice for self-care, referred to other care-level or booked to a digital or physical visit on the primary health care center.
89586690|NCT06092866|Active Comparator|Telephone triage|Patients are triaged with symptom assessment by a nurse using tradition telephone. They are receiving either advice for self-care, referred to other care-level or booked to a digital or physical visit on the primary health care center.
89586691|NCT06091943|Experimental|Part 1: Dose/Injection Site Exploration|Different injection sites will be evaluated; participants will receive tislelizumab in predefined administration sequences plus histology-based chemotherapy consisting of either cisplatin/carboplatin and pemetrexed or carboplatin and paclitaxel/nab-paclitaxel depending on the cancer subtype.
89586692|NCT06091943|Experimental|Part 2: Dose Expansion|The recommended dose of tislelizumab SC determined from Part 1 plus histology-based chemotherapy consisting of either cisplatin/carboplatin and pemetrexed or carboplatin and paclitaxel/nab-paclitaxel depending on the cancer subtype will be evaluated.
89586693|NCT06088888|Experimental|TGRX-678|Subjects to be treated with the investigational drug TGRX-678
89586694|NCT06081244|Experimental|Neoadjuvant treatment: 12 weeks (4 cycles) SG i.v.|"Cohort 1a: In case of (near) cCR: end of treatment, followed by surgery~Cohort 1b: In case of cPR after 12 weeks: further 6 weeks (2 cycles) SG i.v., followed by surgery (use of core biopsy is allowed per investigator´s decision, if further NACT is planned) pCR dependent post-neoadjuvant treatment~In case of pCR: no further systemic treatment~In case of non-pCR: chemotherapy according to investigators decision, e.g., AC/EC q3w x 4, PAC/Carbo q1w x 12"
89586695|NCT06081244|Experimental|Neoadjuvant treatment: 12 weeks (4 cycles) SG+PEM i.v.|"Cohort 2a: In case of (near) cCR: end of treatment, followed by surgery~Cohort 2b: In case of cPR after 12 weeks: 6 weeks (2 cycles) SG+PEM i.v., followed by surgery (use of core biopsy is allowed per investigator´s decision, if further NACT is planned) pCR dependent post-neoadjuvant treatment~In case of pCR: no further systemic treatment~In case of non-pCR: chemotherapy according to investigators decision, e.g., AC/EC q3w x 4, PAC/Carbo q1w x 12"
89586696|NCT06081127|Experimental|Intervention|Patients assigned to the intervention arm will receive the intervention named Moving On After Breast Cancer (MOve-ABC).
89586697|NCT06081127|Experimental|Enhanced Usual Care (EUC)|All patients will receive EUC. However, participants assigned to this arm will have only EUC.
89586698|NCT06080880|Experimental|Ondansetron every 3 weeks combined with aprepitant and dexamethasone|
89586699|NCT06080880|Experimental|Ondansetron weekly combined with aprepitant and dexamethasone|
89586700|NCT06079866|Other|Mask A (Oran Park Mask) then Mask B (Evora Mask)|Participants will be randomized as to the order they will trial Mask A and Mask B. This arm will first use the Oran Park mask for 7 days and then use the Evora Mask for 7 days.
89586701|NCT06079866|Other|Mask B (Evora Mask) then Mask A (Oran Park Mask)|Participants will be randomized as to the order they will trial Mask A and Mask B. This arm will first use the Evora mask for 7 days and then use the Oran Park mask for 7 days.
89586702|NCT06079021|Active Comparator|CytoSorb hemoadsorption|Patients with acute on chronic liver failure will receive CytoSorb treatment for 72 hours. The aim is to remove the molecules that drive systemic inflammation.
89586703|NCT06079021|No Intervention|Control group|Historical group that received only standard medical care
89586704|NCT06076161|Experimental|Spirulina supplementation and calorie restriction in obese men|Respondents will be divided into 2 groups, namely the intervention group and the control group. The intervention group will be given spirulina platensis supplements at a dose of 2x2 /hr with a dose per capsule of 450 mg for 4 weeks with education about calorie restriction.
89586705|NCT06076161|Placebo Comparator|Placebo capsules and calorie restriction in obese men|The control group will be given placebo 2x2/day for 4 weeks with education on calorie restriction.
89586706|NCT06075667|Experimental|Tirzepatide|Participants will receive tirzepatide subcutaneously (SC).
89586707|NCT06075667|Placebo Comparator|Placebo|Participants will receive placebo.
89586708|NCT06074562|Experimental|LY3556050 Dose 1|Participants will receive LY3556050 orally.
89586709|NCT06074562|Experimental|LY3556050 Dose 2|Participants will receive LY3556050 orally.
89586710|NCT06074562|Experimental|LY3556050 Dose 3|Participants will receive LY3556050 orally.
89586711|NCT06074562|Placebo Comparator|Placebo|Participants will receive placebo orally.
89586712|NCT06074380|Experimental|Calfactant (Infasurf)|Neonate, 28-35 weeks gestation, less than 48 hours of age, with respiratory distress syndrome on CPAP > 30% oxygen will be given 3ml/kg of Calfacant
89586713|NCT06074380|Experimental|Poractant alfa (Curosurf)|Neonate, 28-35 weeks gestation, less than 48 hours of age, with respiratory distress syndrome on CPAP > 30% oxygen will be given 2.5ml/kg of Poractant alfa.
89586714|NCT06072911|Experimental|Intervention|Pelvic floor exercise program and general exercise programming
89586715|NCT06072911|Active Comparator|Control|Pelvic floor exercises and standard care (physical activity counseling)
89586716|NCT06069791|Experimental|Group 1|bupivacaine 0.0%, 0.01%, and 0.05% in random order, one week apart each
89586717|NCT06069791|Experimental|Group 2|bupivacaine 0.1%, 0.05%, and 0.1% in random order, one week apart each
89586718|NCT06069791|Experimental|Group 3|bupivacaine 0.0%, 0.1%, and 0.5% in random order, one week apart each
89586719|NCT06069791|Experimental|Group 4|bupivacaine [0.01% or 0.05%], [0.05% or 0.1%], and 0.05% in random order, one week apart each
89586720|NCT06066710|Experimental|Propanolol and MRI|Participants will receive propranolol via oral capsule. The drug dosage will be titrated slowly to ensure the drug is tolerated well.
89586721|NCT06066710|Placebo Comparator|Placebo and MRI|Participants will receive placebo via oral capsule.
89586722|NCT06063408|Experimental|Cognitive Functional Therapy|"Participants will received in this group four main component:~Pain education, cognitive education, explanation about their health condition, self management education~Graded exposure to painful movements or activities~Movement therapy targeted to their functional integration~Lifestyle programme."
89586723|NCT06063408|Active Comparator|Conventional Therapy|"Participants will received in this group four main component:~Tens therapy~Massage to cervical and shoulder area~Relaxation techniques~Posture exercises~Workplace education"
89586724|NCT06062199|No Intervention|Control arm|Nurses will place a peripheral venous line on these patients without having been trained in the venous status score predictive of failure.
89586725|NCT06062199|Experimental|Experimental arm|Nurses will place a peripheral venous line on these patients after being trained in the venous status score predictive of failure.
89586726|NCT06062147|Experimental|teacher training|Teacher training and support for teachers in setting up specific arrangements.
89586727|NCT06062147|No Intervention|control class|Teacher will proceed in the usual way, referring to the procedures put in place by the national education system for identifying and referring children at risk
89586728|NCT06055465|Experimental|Sacituzumab Govitecan and Pembrolizumab|"Neoadjuvant treatment with pembrolizumab and sacituzumab govitecan is given for a total for 4 cycles. Pembrolizumab is administered first on day 1 every cycle. Sacituzumab govitecan is administered second on day 1 and 8 every cycle. The next cycle should start a minimum 14 days after the Day 8 dose.~Surgery is to be performed within 4-8 weeks after day 1 of last cycle of neoadjuvant pembrolizumab/SG.~Postoperative radiotherapy is recommended for patients with R1/R2 resection.~Maintenance treatment with pembrolizumab alone is given for a total for 13 cycles. This is to be started within 4-8 weeks after surgery or within 4 weeks after postoperative radiotherapy."
89586729|NCT06047548|Experimental|Tirzepatide 5 milligram (mg)|Participants will receive tirzepatide subcutaneously (SC).
89586730|NCT06047548|Experimental|Tirzepatide Maximum Tolerated Dose|Participants will receive tirzepatide SC.
89586731|NCT06047548|Placebo Comparator|Placebo|Participants will receive placebo.
89586732|NCT06040827||Group 1 (Test)|Zimmer Persona® Personalized Knee System with Canary canturioTM (CTE) tibial extension
89586733|NCT06040827||Group 2 ( Control)|Group 2 (Control): Zimmer Persona® Personalized Knee System with 14 mm +30 mm stem extension
89586734|NCT06037252|Experimental|Tirzepatide High Dose 1|Participants will receive tirzepatide subcutaneously (SC).
89586735|NCT06037252|Experimental|Tirzepatide High Dose 2|Participants will receive tirzepatide SC.
89586736|NCT06037252|Active Comparator|Tirzepatide|Participants will receive tirzepatide SC.
89586737|NCT06037252|Placebo Comparator|Placebo|Participants will receive placebo.
89586738|NCT06036329|Experimental|Group A provided with 1 Whitsundays Nasal mask without a spare mask cushion|• Provided with 1 Whitsundays Nasal mask without a spare mask cushion (To be provided as requested)
89586739|NCT06036329|Experimental|Group B provided with 1 Whitsundays Nasal mask with 2 spare mask cushions|• Provided with 1 Whitsundays Nasal mask with 2 spare mask cushions
89586740|NCT06035783||Observational cohort|Patients undergoing PCI of a severely calcified coronary lesion in need of OA to enable proper stent placement
89586741|NCT06029621|Experimental|RATS for Thymectomy|The operator of the surgical incision and the route of entry were determined, and the endoscope and surgical instruments were inserted through the operating hole. The phrenic nerve and diaphragm began to gradually separate upward while avoiding nerve damage. Subsequently, the innominate vein was dissected to observe the branches of the thymus vessels and clamped with a 5 mm Hem-o-Lok clamp. Continue to dissect the left side of the thymus until near the phrenic nerve. After the thymus was removed entirely, it was placed in a bag and removed through an incision. After the operation, a 28 Fr chest tube was placed through the incision to the chest top. An 18 G central venous catheter was placed at the level of the posterior axillary line to the posterior costophrenic angle, and about 10 cm was inserted.
89586742|NCT06029621|Active Comparator|VATS for Thymectomy|The main operation principles and procedures of the operation are basically similar to those of the RATS and are completed under video-assisted thoracoscopic surgery.
89586743|NCT06022016|Experimental|Index case or related|
89586744|NCT06021704|Experimental|Home Health Aides with Enhanced Curriculum Training|The enhanced curriculum of 108 hours of home health aide (HHA) training will constitute the Experimental arm. This arm consists of the 100 hours of the standard curriculum plus an 8-hour enhanced curriculum that includes additional didactic content and a skills practicum on dementia and recognizing and responding to dementia-related behaviors. As with the standard curriculum, the enhanced curriculum will be delivered by the training entity, CCHERS (Center for Community Health Education, Research and Service, Inc.). The enhanced component is delivered over an additional 2 instructional days (10% increase in instructional days from the standard curriculum).
89586745|NCT06021704|No Intervention|Home Health Aides with Standard Curriculum Training|"The standard curriculum of 100 hours of home health aide (HHA) training will constitute the No Intervention arm. This 100-hour training is the standard curriculum that has been used by the training entity, CCHERS (Center for Community Health Education, Research and Service, Inc.), for many years to qualify HHAs to receive certificates from the Massachusetts Home Care Aide Council. The standard curriculum includes 75 hours of basic instruction (ABC's for Direct Care Workers) and 25 hours of additional content on mental health and dementia topics. The standard curriculum is delivered over approximately on month, or 20 instructional days."
88975248|NCT02966418|Active Comparator|Mild hypoxia preconditioning|Patients will be treated with mild hypoxia (Note: The oxygen concentration decreased from 20% to 18%, and keeping at 18%) before surgery.
89586746|NCT06018740|Experimental|Daily Balance Gummy|One Daily Balance Gummy should be taken with the last meal of the day.
89586747|NCT06017622||All subjects|There is a single group consisting of all subjects who meet the eligibility criteria
89586748|NCT06014385|Experimental|Scopolamine high dose|The target occupancy (TO) of scopolamine at M1 will be evaluated using the radiotracer [11C]EMO and positron emission tomography (PET). TO will be measured following a 15-minute IV infusion of 4.0 μg/kg scopolamine in 4-6 anticipated participants.
89586749|NCT06014385|Experimental|Scopolamine low dose|The target occupancy (TO) of scopolamine at M1 will be evaluated using the radiotracer [11C]EMO and positron emission tomography (PET). TO will be measured following a 15-minute IV infusion of 2.0 μg/kg scopolamine in 0-2 anticipated participants.
89586750|NCT06011499|Experimental|Arm I (iLIVE)|ARM I: Patients receive online access to an interactive weight loss website and participate in online group based resistance training sessions (iLIVE) on study. Patients also use a Fitbit fitness tracker and Aria smart scale while on study.
89586751|NCT06011499|Active Comparator|Arm II (Usual care)|Patients receive usual care with access to online survivorship and exercise recommendations and use a Fitbit fitness tracker and Aria (registered trademark) smart scale while on study.
88975249|NCT02966418|Sham Comparator|Sham preconditioning|Patients will be treated with sham preconditioning (oxygen concentration: 21％) before surgery.
88975250|NCT00071097|Experimental|001|TMC114/rtv 400mg TMC114/100mg rtv once daily
88975251|NCT00071097|No Intervention|005|Control Group Control Group, no intervention
88975252|NCT00071097|Experimental|004|TMC114/rtv 600mg TMC114/100mg rtv twice daily
88975253|NCT00071097|Experimental|003|TMC114/rtv 400mg TMC114/100mg rtv both twice daily
88975254|NCT00071097|Experimental|002|TMC114/rtv 800mg TMC114/100mg rtv once daily
88975255|NCT04163666|Experimental|Mirror therapy group|The mirror therapy group will receive a treatment based on this therapy, combined with task-oriented motor learning.
89586752|NCT06010953|Experimental|PK period: Cohort 1 (90 μg/kg) and Cohort 2 (270 μg/kg)|In the PK study period, subjects are divided into 2 cohorts (90 μg/kg and 270 μg/kg), which are sequentially conducted. Cohort 1 (90 μg/kg) enrollment is performed firstly, and Cohort 2 (270 μg/kg) enrollment is performed after Cohort 1 enrollment is completed. Subjects enter the PK study period as non-randomized. All screened eligible subjects will receive a single dose of comparator NovoSeven® in the absence of significant active hemorrhage, followed by PK/PD sample collection; then receive a single dose of the same dose of investigational drug SS109, followed by PK/PD sample collection.
89586753|NCT06010953|Experimental|On-demand treatment period: Group 1：90 μg/kg Group 2：180 μg/kg Group 3：270 μg/kg|After completion of the PK study period, subjects will enter a 90-day on-demand treatment period and will be randomized into 3 groups (Group 1: 90 µg/kg, Group 2: 180 µg/kg, and Group 3: 270 µg/kg) at a ratio of 1:1:1. During on-demand treatment, subjects are treated on-demand with SS109 at the time of a new hemorrhage event and their efficacy is observed.
89586754|NCT06010303|Experimental|LBL-007|LBL-007 in combination with tislelizumab plus chemotherapy doublet.
89586755|NCT06010303|Active Comparator|Tislelizumab and Chemotherapy|Tislelizumab plus chemotherapy doublet.
89586756|NCT06010004|Experimental|Orforglipron Dose 1|Participants will receive orforglipron administered orally.
89586757|NCT06010004|Experimental|Orforglipron Dose 2|Participants will receive orforglipron administered orally.
89586758|NCT06010004|Experimental|Orforglipron Dose 3|Participants will receive orforglipron administered orally.
89586759|NCT06000748|Active Comparator|Low MAP-Target|This group will be randomized to a treatment algorithm that utilizes a low MAP-target (<80 mmHg) to determine if titration of vasoconstrictors is needed.
89586760|NCT06000748|Active Comparator|High MAP-Target|This group will be randomized to a treatment algorithm that utilizes a high MAP-target (≥80 mmHg) to determine if titration of vasoconstrictors is needed.
89586761|NCT05994924|Active Comparator|Handout Only|Parents in this group receive an educational handout at the baseline visit.
88975256|NCT04163666|Experimental|Cognitive therapeutic exercise group|The cognitive therapeutic exercise group will receive a treatment based on this therapy, combined with task-oriented motor learning.
88975257|NCT04163666|No Intervention|Control Group|No additional intervention with the participants of this group will be completed.
88975258|NCT04104152|Experimental|ENDS 2.4% nicotine|Subjects will be assigned to one of four flavors variants of 2.4% ENDS products based on their preferred UB flavor.
88975259|NCT04104152|Experimental|ENDS 5.0% nicotine|Subjects will be assigned to one of four flavors variants of 5.0% ENDS products based on their preferred UB flavor.
88975260|NCT02970773|Other|rivaroxaban|Rivaroxaban Oral Tablet
88975261|NCT02970734|Experimental|Breathe|6 sessions of Internet-based cognitive behavioural therapy (CBT) with limited telephone and e-mail support
88975262|NCT02970734|Active Comparator|Resource webpage|Webpage that provides general resources on anxiety
88975263|NCT04094363|Experimental|Product usage order ABCD|Subjects will use each of the 4 products (ABCD) sequentially for 1 and 1/2 days during a 9 day confinement, followed by a 4 hour Test Session.
88975264|NCT04094363|Experimental|Product usage order BDAC|Subjects will use each of the 4 products (BDAC) sequentially for 1 and 1/2 days during a 9 day confinement, followed by a 4 hour Test Session.
89586762|NCT05994924|Active Comparator|Online-Only Video Series|Parents will be given (QR) quick-response codes to watch the videos on their own time with no discussion afterward.
89586763|NCT05994924|Active Comparator|Group Sessions|Parents will participate in 2 weekly group sessions with video viewing and group discussion.
89586764|NCT05994625|Experimental|Intervention Group|Stream™ Platform will be attached to the abdominal/pelvic drains of the patients enrolled in this group. The platform will conduct continuous pH and electrical conductivity measurements of the abdominal drain fluid. The continuous pH and electrical conductivity measurements will be used to calculate a Risk Score that will be provided to surgeons. Surgeons will employ the Risk Score produced alongside the standard of care for guiding the postoperative care of patients.
88975265|NCT04094363|Experimental|Product usage order CADB|Subjects will use each of the 4 products (CADB) sequentially for 1 and 1/2 days during a 9 day confinement, followed by a 4 hour Test Session.
88975266|NCT04094363|Experimental|Product usage order DCBA|Subjects will use each of the 4 products (DCBA) sequentially for 1 and 1/2 days during a 9 day confinement, followed by a 4 hour Test Session.
88975267|NCT02967120||p16 hydroxymethylation status|patients with p16 hydroxymethylation
88975268|NCT03752996|Experimental|ACURATE TF™ Aortic Valve System|ACURATE TF™ Aortic Valve System is intended for subjects with severe symptomatic Aortic Stenosis and considered high risk for surgical conventional Aortic Valve Replacement .
88975269|NCT03651284|Experimental|Aim2Be Live Coach|Aim2Be app with Live Coach + Fitbit + BMI tracking tools
88975270|NCT03651284|Other|Aim2Be Waitlist|Aim2Be app waitlist + Canadian Health Recommendations + Fitbit + BMI tracking tools for three months, then flip to Aim2Be app with Virtual Coach + Fitbit + BMI tracking tools
88975271|NCT01349673|Experimental|Budesonide Foam|Participants administered topical rectal budesonide foam at 2 mg/25 mL BID (morning and 12 hours later) for 2 weeks followed by 2 mg/25 mL QD (in the evenings) for 4 weeks for up to 8 cycles. After Cycle 1, participants needed to qualify to be able to participate in subsequent cycles. Participants underwent a 48-hour study drug washout period between each cycle.
88975272|NCT03445325|Experimental|LiGHT v2.1|Participants will be assigned the intervention (use of the parent or teen app for 4.5 months) and asked to use throughout the intervention period (all participants are assigned to the intervention arm and results will be analyzed pre- and post-intervention).
88975273|NCT00067587||HIV Negative|HIV negative subjects
88975274|NCT00067587||HIV Positive - NEVER had ARV therapy.|HIV Positive - NEVER had ARV therapy.
89586765|NCT05994625|Sham Comparator|Control Group|Stream™ Platform will be attached to the abdominal/pelvic drains of the patients enrolled in this group. The platform will conduct continuous pH and electrical conductivity measurements of the abdominal drain fluid. However, Stream™ Platform will not generate a Risk Score and therefore, will not impact the postoperative care of patients. All procedures will be conducted as per the standard of care or institutional policies. Stream™ Platform will only be used for observation in the Control group.
89586766|NCT05991323||Patient with prurigo nodularis|Participants aged 18 years or older who start receiving dupilumab for prurigo nodularis (according to the country-specific prescribing information) prior to and independently of their participation in the study
89586767|NCT05986318|Active Comparator|NAC + Corticosteroids|"Participants will take 600 mg of active NAC orally, three times daily, for 60 days.~Participants will also take 4 mg of active dexamethasone, orally, once daily for 10 days, then 2 mg, orally, once daily for 5 days, then 1 mg, orally, once daily for 5 days.~All participants will be treated with radical pulmonary radiation therapy."
89586768|NCT05986318|Active Comparator|Corticosteroids + NAC Placebo|"Participants will take 4 mg of active dexamethasone, orally, once daily for 10 days, then 2 mg, orally, once daily for 5 days, then 1 mg, orally, once daily for 5 days.~Participants will also take matching NAC placebo orally, three times daily, for 60 days.~All participants will be treated with radical pulmonary radiation therapy."
89586769|NCT05986318|Active Comparator|NAC + Dexamethasone Placebo|"Participants will take 600 mg of active NAC orally, three times daily, for 60 days.~Participants will also take matching dexamethasone placebo (4 mg for 10 days, then 2 mg for 5 days, then 1 mg for 5 days), orally, once daily.~All participants will be treated with radical pulmonary radiation therapy."
89586770|NCT05986318|Placebo Comparator|NAC Placebo + Dexamethasone Placebo|"Participants will take matching NAC placebo orally, three times daily, for 60 days.~Participants will also take matching dexamethasone placebo (4 mg for 10 days, then 2 mg for 5 days, then 1 mg for 5 days), orally, once daily.~All participants will be treated with radical pulmonary radiation therapy."
89586771|NCT05984927|Experimental|NG101 Gene Therapy Group 1|Single subretinal injection of 1x10^9 vector genomes of NG101 AAV gene therapy
89586772|NCT05984927|Experimental|NG101 Gene Therapy Group 2|Single subretinal injection of 3x10^9 vector genomes of NG101 AAV gene therapy
89586773|NCT05984927|Experimental|NG101 Gene Therapy Group 3|Single subretinal injection of 8x10^9 vector genomes of NG101 AAV gene therapy
89586774|NCT05979779|Experimental|Active Treatment: HU6 Planned doses of HU6|
89586775|NCT05979779|Placebo Comparator|Placebo Comparator Non-active study drug|
89586776|NCT05977998|Experimental|Paclitaxel|Participant will receive paclitaxel every 2 weeks for 6 weeks, and then participants may have a gastrectomy based on what the doctor thinks is in your best interest. You may then receive additional paclitaxel every 2 weeks for 6 weeks.
89586777|NCT05968482|Experimental|AMZ001 Low dose|AMZ001 applied once daily for 7 consecutive days
89586778|NCT05968482|Experimental|AMZ001 High dose|AMZ001 applied once daily for 7 consecutive days
89586779|NCT05968482|Active Comparator|Diclofenac Sodium 1% Gel|Reference product applied four-times daily for 7 consecutive days
89586780|NCT05967689|Experimental|"Cohort A (prior ex20ins treatment)"|"Cohort A (prior ex20ins treatment) participants will receive zipalertinib orally twice a day (BID) continuously until documentation of PD or until other withdrawal criteria are met, whichever comes first."
89586781|NCT05967689|Experimental|"Cohort B (1st line treatment)"|Cohort B participants will receive zipalertinib orally twice a day (BID) continuously until documentation of PD or until other withdrawal criteria are met, whichever comes first.
89586782|NCT05967689|Experimental|"Cohort C (active brain mets)"|Cohort C participants will receive zipalertinib orally twice a day (BID) continuously until documentation of PD or until other withdrawal criteria are met, whichever comes first.
89586783|NCT05967689|Experimental|"Cohort D (other uncommon EGFRmt)."|Cohort D participants will receive zipalertinib orally twice a day (BID) continuously until documentation of PD or until other withdrawal criteria are met, whichever comes first.
89586784|NCT05964582||Healthy children aged 6 months to < 22 months|No vaccine will be administered. All enrolled participants will have a blood sample collected at enrollment (visit 01) and a nasal swab collected each time they have an RSV-like illness visit
89586785|NCT05952557|Active Comparator|Arm A: standard endocrine therapy of investigator´s choice ± abemaciclib|standard endocrine therapy of investigator's choice (aromatase inhibitors [AI; exemestane, letrozole, anastrozole] or tamoxifen) ± abemaciclib
89586786|NCT05952557|Experimental|Arm B: camizestrant ± abemaciclib|camizestrant ± abemaciclib
89586787|NCT05952037|Experimental|Cohort 1|Participants with R/R disease to both Bruton tyrosine kinase (BTK) inhibitor and anti-CD20 antibody-based systemic therapy containing chemotherapy or proteasome inhibitor will receive BGB-11417 at a standard dose, given orally once daily.
89586788|NCT05952037|Experimental|Cohort 2|Participants with R/R disease to anti-CD20 antibody-based systemic therapy containing chemotherapy or proteasome inhibitor and were intolerant to BTK inhibitor will receive BGB-11417 at a standard dose, given orally once daily.
89586789|NCT05952037|Experimental|Cohort 3|Participants with R/R disease to a BTK inhibitor treatment and are unsuitable for chemoimmunotherapy will receive BGB-11417 at a standard dose, given orally once daily.
89586790|NCT05951205|Experimental|Exa-cel|Participants will receive a single infusion of exa-cel (autologous CD34+ hHSPCs modified with CRISPR-Cas9 at the erythroid lineage-specific enhancer of the BCL11A gene) through a central venous catheter.
89586791|NCT05950607|Experimental|TRAIN AD 2.0|Nursing homes randomized to the experimental arm will emply a multicomponent intervention among their providers designed to improve the management of suspected infections in residents with dementia. The components include: a.Orientation sessions for providers, b.On-line case based course for providers, c.Infection management algorithms for providers, d. Guidelines for providers to communicate with proxies, and e. Education booklet about infections in dementia for providers.
89586792|NCT05950607|Active Comparator|Usual Care|Nursing homes randomized to the conrol arm will employ usual care to manage nursing home residents with dementia with suspected infections.
89586793|NCT05950581|Experimental|: Modified Twin-Block Appliance with Clear Plates.|Clear plates technique A group of patients in which participants will be undergo to clear plates treatment will be applied to the upper and lower arch 17 hours daily Experimental : Modified Twin-Block Appliance with Clear Plates.
89030277|NCT04510064|Experimental|Treatment group|Patients were treated with domestic PD-1 antibody (Camrelizumab for injection) commbined with mFLOT regimen immunotherapy every two weeks, and HER-2 positive patients were added with Herceptin therapy. Camrelizumab 200mg on day 1, albumin bound paclitaxol 125mg/m² on day 1,oxaliplatin 85 mg/m² on day 1, leucovorin 200 mg/m² on day 1, and 5-FU 2600 mg/m² as 24-h infusion on day 1.Herceptin 6mg/Kg at the first time, followed by 4mg/Kg if needed.The efficacy of therapy was evaluated every 3 treatment cycles. If the tumor can be R0 resected after 6-9 cycles, then proceeded to surgery. After the operation, patients continued to receive the prior immunotherapy totally to 12 cycles or to the disease progressed or intolerable toxicity.
89030278|NCT02275520|Other|IO access|Performed intraosseus access device during simulated cardiopulmonary resuscitation
89030279|NCT04694703||Covid-19 group|Patients diagnosed with COVID-19 will be enrolled in this group.
89030280|NCT04694742||ARDS COVID-19|Patients who meet Berlin's ARDS diagnostic criteria, with confirmed SARS-CoV-2 infection, requiring invasive mechanical ventilation.
89586794|NCT05950581|Experimental|Traditional Twin-Block appliance|Traditional Twin-Block appliance A group of patients in which participants will undergo to the Traditional Twin-Block appliance Treatment, appliances will be applied to the upper and lower arch 17 hours daily
89209735|NCT04044638|Experimental|Middle-aged Group|"Middle-aged women women who underwent 8 weeks of training and had their blood pressure checked at baseline and after 4 and 8 weeks of training.~Resistance training sessions were held 3 times a week, in which each session lasted 60 minutes and was performed for a period of 8 weeks. Each session consisted of 10-minute warm-up, shortly after, starting the exercises in the form of alternating circuit by segment, as: machine bench press, extension chair, high pull (front), flexor table, direct curl, leg press, triceps pulley, adductor, abdominal, abductor and calf. In all 10 exercises, 3 sets of 8 to 12 repetitions were performed, with an interval of 60 seconds between sets and intensity of 12 arbitrary units (a.u.) to 14 a.u., measured by the rate perception effort scale."
89209736|NCT00808730|Experimental|1|fiberoptic fibroscopy
89209737|NCT00722423|Experimental|Integrated Care Model|Integrated Care
89586795|NCT05949996|Experimental|Implementation condition|Under implementation condition, a nurse-led symptom distress screening program will be implemented using 5 implementation strategies including training, audit and feedback, facilitation and adaptable workflow.
89586796|NCT05949996|No Intervention|Control condition|The control condition is the usual clinical outpatient operation without the specific implementation program (i.e. applying the five implementation strategies including training, audit and feedback, facilitation and adaptable workflow) for standardized routine symptom distress screening. Prior to the start of the first 4-month control condition, we will meet each study unit and brief the staff about the purpose of this implementation study, as well as the introduction of the symptom distress screening tool. The symptom distress screening tool and referral forms will be given to the study sites. The staff are encouraged to screened and referred all eligible patients to JCICC, a local cancer care centre. In contrast to the intervention condition, there will be no half-day skill training workshop and no weekly audit and feedback report delivered and discussed with the site facilitator. We will keep the recording of the briefing session for fidelity assessment.
89586797|NCT05949866|Experimental|Movement and Cognition Intervention group (MAC)|Movement and Cognition group is the behavioral treatment group.
89586798|NCT05949866|Placebo Comparator|Health Tracker group (Control)|Health tracker group is the control group.
89586799|NCT05946161|Experimental|testing the digital intervention|Prostate cancer survivors (n=20) randomly assigned to this arm will complete a digital psychosexual intervention and will be accompanied weekly by a certified clinical psychologist to monitor progress (synchronous or asynchronous). Pre and Post testing involve questionnaires collecting data on psychosexual variables. At post-testing a 30-minute interview will be conducted to collect information on the usability
89030281|NCT04510181|Experimental|Amino acid-based blend|The amino acid-based blend will be administered PO daily for the study duration
89030282|NCT04510103|Other|Regression Group|The Regression Group received the two test moisturizers to use split-leg (right vs. left lower leg randomized) for 6 weeks and then entered a 2-week regression period (no moisturizer usage).
89030283|NCT04510103|Other|Non-Regression Group|The Non-Regression Group received the two test moisturizers to use split-leg (right vs. left lower leg randomized) for 6 weeks and then underwent a physical insult (tape stripping) on the lower legs and continued using the moisturizer for 4 additional days.
89030284|NCT00516984|Placebo Comparator|Placebo|No-touch control condition applied while subject was at a 50-degree head-up tilt.
89030285|NCT00516984|Sham Comparator|Sham|Touch-only sham treatment applied while subject was at a 50-degree head-up tilt.
89030286|NCT00516984|Active Comparator|OMT|Cervical myofascial OMT applied while subject was at a 50-degree head-up tilt.
89030287|NCT02275598|Experimental|BV-ABVD|Treatment will consist of two three-weekly doses of Brentuximab vedotin, followed by standard treatment, ABVD (3 o 6 cycles q4w).
89030288|NCT00517023|Active Comparator|ILR + Syncope Clinic|Patients will have ILR implanted and follow-up in Syncope Clinic
89030289|NCT00517023|Active Comparator|ILR Only|Patients will have ILR implanted and routine follow up.
89030290|NCT00517023|Active Comparator|Routine Mx + Syncope Clinic|Patients will receive routine care and management plus follow up in Syncope Clinic
89209738|NCT00722423|Experimental|Usual Care Model|Usual Care
89209739|NCT02593331|Placebo Comparator|Placebo|Participants will receive placebo matching to BFKB8488A.
89586800|NCT05946161|No Intervention|waiting list|Prostate cancer survivors (n=20) randomly assigned to this arm will not be accompanied or get access to the intervention during the six week period in which the experimental group is completing the intervention. Pre and Post testing involved questionnaires collecting data on psychosexual variables. After post testing the control arm will gain access to the intervention as compensation for their participation
89586801|NCT05937776||Diagnostic (¹⁸FDG PET, MRI)|Patients receive ¹⁸FDG IV, then 60 minutes later undergo simultaneous MRI and PET scanning. During this scanning period, patients will receive gadoterate meglumine IV to obtain post-contrast MRI. Total scanning time will take 45-60 minutes.
89586802|NCT05931367|Experimental|Retatrutide Dose 1|Participants will receive retatrutide subcutaneously (SC).
89586803|NCT05931367|Experimental|Retatrutide Dose 2|Participants will receive retatrutide SC.
89586804|NCT05931367|Placebo Comparator|Placebo|Participants will receive placebo.
89586805|NCT05927389|Experimental|Experimental group: 6 months APA program|"The various assessments will be carried out during 2 visits at 6 months interval as part of the usual follow-up at the Constitutional Bone Diseases unit at the Toulouse University Hospital.~The APA program built from the initial assessment will be returned to the child and his family during a videoconference.~In addition, a regular reassessment and adjustment of this program will be made every 15 days during phone calls by the APA coach."
89586806|NCT05926921|Active Comparator|music|Brahms lullaby at 50-60dB (depending on distance to speaker), played during the intravenous line procedure.
89586807|NCT05926921|No Intervention|no music|No intervention, care as usual.
89586808|NCT05921266|Experimental|Intervention|
89586809|NCT05921266|Placebo Comparator|Control|
89586810|NCT05920512|Experimental|Patients with severe haemophilia|confirmed as hemophilia and FVIII/FIX activity <1%
89586811|NCT05914311|Active Comparator|Suture Group|secure one of the 2 trial leads with suture only-randomized to left or right
88975275|NCT00067587||HIV positive, on a NNRTI, non-PI regimen|HIV positive, currently on a NNRTI, non-PI regimen for at least 3 months. Must NEVER have received a total of more than SIX months of PI-containing regimen and at least ONE year must have passed since receipt of last PI-containing regimen.
88975276|NCT00067587||HIV positive, on a PI, non-NNRTI regimen|HIV positive, currently on a PI, non-NNRTI regimen for at least 3 months. Must NEVER have received a total of more than SIX months of NNRTI-containing regimen and at least ONE year must have passed since receipt of last NNRTIcontaining regimen.
88975277|NCT00067587||HIV positive, on a non-PI, non-NNRTI|HIV positive, currently on a non-PI, non-NNRTI containing regimen for at least 3 months. Must NEVER have received a total of more than SIX months of PI- and/or NNRTI- containing regimen and at least ONE year must have passed since receipt of last PI- and/or NNRTI-containing regimen.
88975278|NCT04732169|Active Comparator|Epidiolex (cannabidiol) (CBD)|During the first week after randomization, participants will receive 125mg of Epidiolex (CBD) or matching placebo taken twice daily (250mg/day). During the second week after randomization, the dosage will be increased to 250mg of Epidiolex or placebo taken twice daily (500mg/day) for one week. During the third week after randomization, the dosage will be increased to 500mg of Epidiolex (CBD) or matching placebo taken twice daily (1000mg/day). Participants will remain on 1000mg/day of Epidiolex (CBD) or matching placebo for four more weeks, at which point they will be stepped down to 500mg/day of Epidiolex (CBD) or placebo for one week, followed by 250mg/day of Epidiolex (CBD) or placebo for one week.
88975279|NCT04732169|Placebo Comparator|Placebo|During the first week after randomization, participants will receive 125mg of Epidiolex (CBD) or matching placebo taken twice daily (250mg/day). During the second week after randomization, the dosage will be increased to 250mg of Epidiolex or placebo taken twice daily (500mg/day) for one week. During the third week after randomization, the dosage will be increased to 500mg of Epidiolex (CBD) or matching placebo taken twice daily (1000mg/day). Participants will remain on 1000mg/day of Epidiolex (CBD) or matching placebo for four more weeks, at which point they will be stepped down to 500mg/day of Epidiolex (CBD) or placebo for one week, followed by 250mg/day of Epidiolex (CBD) or placebo for one week.
88975280|NCT03007628|Experimental|magnetic seizure therapy|10 treatment sessions of MST, three times per week in the first two weeks, two times per in the following two weeks.
88975281|NCT03007628|Active Comparator|electroconvulsive therapy|10 treatment sessions of modified-ECT, three times per week in the first two weeks, two times per in the following two weeks.
88975282|NCT00067626|Experimental|1|500/1000 mcg oral chromium taken daily or placebo (crossover)
88975283|NCT00067626|Experimental|2|500/1000 mcg oral chromium taken daily or placebo (crossover)
88975284|NCT00067665|No Intervention|1|Control group of 50 patients where dry weight is not changed.
88975285|NCT00067665|Experimental|2|All patients participating in the trial require evaluation of dry-weight at each dialysis visit for evaluation. An initial weight loss of 0.1kg/10 kg body-weight will be prescribed per dialysis. If ultrafiltration is not tolerated based on muscle cramps, need for excessive saline or symptomatic hypotension, the intensity of ultrafiltration will be reduced by 50%. If ultrafiltration is still not tolerated, the weight loss will be further reduced by 50%. If the patient cannot tolerate at least 0.2 kg incremental weight loss per dialysis, the patient will be said to be at goal dry-weight. Thus, by this protocol, all patients must experience symptoms of volume depletion to be at dry weight.
88975286|NCT02970968|Experimental|Study Drug|VLY-686 (Tradipitant) oral capsule for 4 weeks.
88975287|NCT02970968|Placebo Comparator|Placebo|Placebo oral capsule for 4 weeks.
88975288|NCT02967159|Experimental|Treatment A (Abediterol )|Treatment A: The subjects will receive Abediterol 2.5 μg via DPI
88975289|NCT02967159|Experimental|Treatment B (AZD7594)|Treatment B: The subjects will receive AZD7594 440 μg via DPI
89030291|NCT00517023|Active Comparator|Routine Mx|Patients will receive routine care and management
89586812|NCT05914311|Experimental|Dermabond|secure one of the 2 trial leads to be secured with both dermabond and suture-randomized to left or right
89586813|NCT05909995|Experimental|Dose Escalation|"Participants with RCC and MSI-H/dMMR CRC will receive 1 of two doses of INCB099280 BID with up to 4 doses of ipilimumab 1 mg/kg Q3 weeks~Participants with Melanoma and HCC will receive 1 of 2 doses of INCB099280 BID with up to 4 doses of 3 ipilimumab 3 mg/kg Q3 weeks"
89586814|NCT05909995|Experimental|Dose Expansion|"Participants with RCC will receive 1 of two doses of INCB099280 BID with up to 4 doses of ipilimumab 1 mg/kg Q3 weeks of ipilimumab~Participants with HCC will receive 1 of two doses of INCB099280 BID with up to 4 doses of ipilimumab 3 mg/kg Q3 weeks of ipilimumab"
89586815|NCT05907252|Experimental|Supervised Group-based Intervention|Supervised Group-based intervention involves a professional walking fitness coach and 2 assistant coach. The coach is expected to require the participants to engage in the intervention in a form of group. The intervention groups will receive an 18-week walking training (3 sessions per week, 1 hour per session )in accordance with the intervention.
89586816|NCT05907252|Experimental|Non-supervised Group-based Intervention|Supervised Group-based intervention involves no professional walking fitness coach; however, the research team member will ask the participants to engage in the intervention in a form of group, and complete the intervention according to goals and targets of each session. The intervention groups will receive an 18-week walking training (3 sessions per week, 1 hour per session )in accordance with the intervention.
89586817|NCT05907252|Active Comparator|Non-supervised Individual-based Intervention|Non-supervised Individual-based Intervention involves no professional walking fitness coach; and no group forming is required. The participants will engage and complete the intervention individually. The intervention groups will receive an 18-week walking training (3 sessions per week, 1 hour per session )in accordance with the intervention.
89586818|NCT05907252|No Intervention|Control Group|Participants in the control group (CG) will not be arranged to participate in any walking or physical activity intervention during the whole study period (the 18-week intervention and 12-week follow-up periods), but they will be asked to keep a daily log on their physical activity, use of medicines, illness, and other health-related activities. Besides, the CG participants will be asked to report to the research resistant (RA) if a major change has been made in the aforementioned aspects. The RA will also check the daily logs of the participants through telephone or mobile phone every two weeks. Data from those who changed their normal lifestyles (especially taking up regular physical activity) will be excluded in the subsequent data analysis.
89586819|NCT05900934|Active Comparator|Myofascial Releasing Group|The intensity of application is important for foam rollers. For intensity, the intensity of the pressure will be determined by a subjective 7/10 target numeric rating scale rating (0 representing no discomfort and 10 representing maximum discomfort) and applied at the end of each session.
89209740|NCT02593331|Experimental|BFKB8488A SC|Participants will receive single ascending SC dose of BFKB8488A in each dose escalation cohort.
89586820|NCT05900934|Sham Comparator|Sham Myofascial Releasing Group|In the sham group, similar to the literature, the intensity will be applied with foam rollers in accordance with the 0/10 numerical rating scale, to the same application areas, for the same duration and with the same rest intervals.
89586821|NCT05900050|Experimental|VS-01 on top of SOC (Active Treatment Group)|Patients randomized to Active Treatment group will receive VS-01 on top of SOC
89586822|NCT05900050|Other|SOC (Control Group)|Patients randomized to Control group will receive SOC defined as the standard medical management of patients with decompensated cirrhosis and ACLF
89586823|NCT05896423||HBH cohort|Rates of PrEP initiation among Black cis women at an FQHC, before and after the PrEP materials are used
89586824|NCT05896423||PPIL cohort|Rates of PrEP initiation among Black cis woman at a family planning clinic, before and after the PrEP materials are used
89586825|NCT05888454|Experimental|Experimental Group|Conventional treatment for T2DM + Integrative Group Program
89586826|NCT05888454|Active Comparator|Control Group|Conventional treatment for T2DM
89586827|NCT05883774|Active Comparator|rTMS|Patients are treated with repetitive transcranial magnetic stimulation (rTMS).
89586828|NCT05883774|Sham Comparator|sham-rTMS|Patients are treated with sham repetitive transcranial magnetic stimulation (sham-rTMS).
89586829|NCT05883631|Experimental|De Novo Subjects: Ablacath Mapping Catheter/Ablamap System|
89586830|NCT05883631|Experimental|Redo Subjects: Ablacath Mapping Catheter/Ablamap System|
89586831|NCT05880056|Experimental|(Nerkardou 5 mg) & (Nerkardou 10 mg)|"One ODF of bisoprolol 5 mg (Nerkardou 5 mg) Dosage form description: Bisoprolol oral dissolved film ODF: equivalent to 5 mg of bisoprolol fumarate.~One ODF of bisoprolol 10 mg (Nerkardou 10 mg) Dosage form description: Bisoprolol oral dissolved film ODF: equivalent to 10 mg of bisoprolol fumarate."
88975290|NCT02967159|Experimental|Treatment C (AZD7594/abediterol )|Treatment C: The subjects will receive AZD7594/ abediterol 440 μg/2.5 μg FDC via DPI
89586832|NCT05879744|Experimental|Part A Dose Escalation|Patients with R/R B-NHL treated with CLN-978 in dose escalation cohorts
89586833|NCT05879744|Experimental|Part B Dose Expansion|Patients with R/R DLBCL, R/R FL and other R/R B-NHL treated with CLN-978 at a dose selected from the Part A Dose Escalation arm.
88975291|NCT02967159|Experimental|Treatment D (AZD7594 and abediterol)|Treatment D: The subjects will receive AZD7594 440 μg and abediterol 2.5 μg free combination administered via 2 separate DPIs
88975292|NCT02396342|Experimental|Cohort 1|AAV5-hFIX 5 × 10E12 gc/kg intravenous single infusion
88975293|NCT02396342|Experimental|Cohort 2|AAV5-hFIX 2 × 10E13 gc/kg intravenous single infusion
88975294|NCT00067704|Experimental|Trauma writing|Four sessions of writing about traumatic experiences.
89209741|NCT02593331|Experimental|BFKB8488A IV|Participants will receive single IV dose of BFKB8488A.
89586834|NCT05877118|Active Comparator|Standard education|Written instructions and information communicated to the patient through MyChart. The following four key points are covered: (1) When someone overdoses on opiates, their breathing will get very slow and may stop (2) Naloxone is a safe life-saving medication that can reverse an opioid overdose (3) You give someone naloxone by injecting it through the nostril, (4) If a first dose of naloxone does not work after about 3 minutes, give a second dose.
89586835|NCT05877118|Experimental|Enhanced Overdose Education (EOE)|A one-page education pamphlet handed to participants and their identified support individual and a 4-minute video clip that will be viewed in the hospital and emailed or texted to both. EOE is purposefully brief and intended to increase uptake by participants and their support network who may not be motivated or willing to engage in face-to-face or extensive education. The pamphlet and video both emphasize the Why and How. That is, the significance of naloxone in decreasing the likelihood of death following an overdose while providing simple instructions on how to use the nasal kit. They also emphasize an important point missing in standard education: to tell others in the support network where it is and how to use it.
89586836|NCT05875233|Active Comparator|Group One: PCOS & Hormonal Birth Control|All participants will have a diagnosis of PCOS and be regularly taking hormonal birth control.
89586837|NCT05875233|Active Comparator|Group Two: PCOS with No Hormonal Birth Control|All participants will have a diagnosis of PCOS and must not be taking any hormonal birth control.
89209742|NCT00640562|Experimental|Quetiapine Extended Release|
89209743|NCT00640562|Active Comparator|Risperidone|
89209744|NCT00585923|Active Comparator|Usage of Fixed hole C-Tek™ Plate|Fixed Hole Plate - The fixed hole plate means that the screws do not move, restricting motion and providing additional stability
89586838|NCT05873933|Experimental|Acne and Eczema group|Participants who experience regular acne, pimples, eczema, or blemishes. Must use the test products as prescribed. In addition, must be willing to maintain the following skincare routine during the study: (1)Daily cleansing or rinsing of their face in the morning or the evening is sufficient. (2) The option to wear sunscreen if the sunscreen brand is pre-approved - a person who does not wear sunscreen is more desirable. The test product does contain some sun protection (3) Must NOT use any moisturizer besides our oil. Must use the test product in the morning and the evening daily. Must not be using retinoids and must not start using retinoids during the study. Must NOT use oral anti-acne medications/prescriptions.
89586839|NCT05873933|Experimental|Anti-Aging group|"Participants who experience early-stage wrinkles not treated by topical or oral prescription drugs/medication or over-the-counter products.~Must use the test products as prescribed. In addition, must be willing to maintain the following skincare routine during the study: (1)Daily cleansing or rinsing of their face in the morning or the evening is sufficient. (2) The option to wear sunscreen if the sunscreen brand is pre-approved - a person who does not wear sunscreen is more desirable. The test product does contain some sun protection (3) Must NOT use any moisturizer besides our oil. Must use the test product in the morning and the evening daily. Must not be using retinoids and must not start using retinoids during the study. Must NOT use oral anti-acne medications/prescriptions."
89586840|NCT05862077|Sham Comparator|Overground walking exercise without EX1|Exercise consists of 30 minutes of overground walking.
89586841|NCT05862077|Experimental|Exercise program 1 with EX1|Exercise program 1 consists of 30 minutes of overground walking.
89586842|NCT05862077|Experimental|Exercise program 2 with EX1|Exercise program 2 consists of 30 minutes of overground walking.
89586843|NCT05860296|Experimental|Dose Escalation (Phase 1b Dose Level 1)|"Dose level 1 dose will be SLC-391 100 mg PO/BID on Days 1-21 of each cycle and Pembrolizumab 200 mg IV on Day 1 of each cycle.~All dose-escalation decisions and the rationale for progressing to the next cohort will be reviewed by the Safety Review Committee (SRC).~A subject may continue treatment with SLC-391 and pembrolizumab in 21-day cycles until the treatment discontinuation criteria are met."
89586844|NCT05860296|Experimental|Dose Escalation (Phase 1b Dose Level 2)|"Dose level 2 dose will be SLC-391 150 mg PO/BID on Days 1-21 of each cycle and Pembrolizumab 200 mg IV on Day 1 of each cycle.~All dose-escalation decisions and the rationale for progressing to the next cohort will be reviewed by the Safety Review Committee (SRC)."
89586845|NCT05860296|Experimental|Dose Escalation (Phase 1b Dose Level -1)|"Dose level -1 dose will be SLC-391 50 mg PO/BID on Days 1-21 of each cycle and Pembrolizumab 200 mg IV on Day 1 of each cycle.~All dose-escalation decisions and the rationale for progressing to the next cohort will be reviewed by the Safety Review Committee (SRC)."
89586846|NCT05860296|Experimental|ICI-Naïve (Phase 2a)|"The dose of SLC-391 will be randomized between two dose levels as approved by the SRC in combination with Pembrolizumab.~Tumors must have PD-L1 expression (TPS ≥1%)~No prior systemic treatment (chemotherapy or targeted therapy) and no prior immunotherapy (SOC or investigational) in advanced or metastatic setting~Subjects with actionable genomic alterations with approved targeted therapy in first line setting are not allowed~Subjects with disease recurrence or progression following neoadjuvant or adjuvant therapy or definitive chemoradiation therapy are eligible.~Prior adjuvant, neoadjuvant immunotherapy allowed if completed more than 12 months before documented relapse~A subject may continue treatment with SLC-391 and pembrolizumab in 21-day cycles until the treatment discontinuation criteria are met."
89586847|NCT05860296|Experimental|ICI-Resistant (Phase 2a)|"The dose of SLC-391 will be randomized between two dose levels as approved by the SRC in combination with Pembrolizumab.~Up to 2 prior lines therapy in an advanced or metastatic setting allowed~Must have received at least 2 doses of an approved anti-PD(L)-1 inhibitor and disease progressed either during treatment or within 12 weeks from last dose of anti-PD(L)-1 therapy~Subjects who received treatment with a targeted therapy for an actionable genomic alteration with can participate if there is documented progressive disease or they were unable to tolerate the approved targeted therapy. Only these subjects are allowed to receive up to a maximum of 3 prior lines of cancer therapy in an advanced or metastatic setting.~A subject may continue treatment with SLC-391 and pembrolizumab in 21-day cycles until the treatment discontinuation criteria are met."
89586848|NCT05849142|Experimental|MRIdian Linac Group|All accrued participants will be enrolled onto the MRIdian Linac Group. Participants will receive adaptive radiotherapy (ART) on the MRIdian Linac. Participants will complete the duration of their radiotherapy regimen on the MRIdian Linac for approximately 7 weeks.
88975295|NCT00067704|Sham Comparator|Writing about daily events|Four sessions of writing about their daily experiences.
88975296|NCT00067743|Other|1|Open Label trial
88975297|NCT00071409|Placebo Comparator|placebo|1.5 mL SC injection
88975298|NCT00071409|Experimental|300 mg INGAP Peptide|1.5 mL SC injection, once daily for 90 days
88975299|NCT00071409|Experimental|600 mg INGAP Peptide|1.5 mL SC injection, once daily for 90 days
88975300|NCT02035085|Experimental|CS-1000|Breast cancer patients with RIF will undergo liposuction, the autologous SVF cell fraction will be isolated and labeled with CS-1000 in the operating room without entering cell culture, which will then be returned to the patient at the site of breast grafting.
88975301|NCT01547429|Experimental|Intraocular Lens Implantation for the Treatment for Aphakia|Implantation of an Artisan intraocular lens to correct aphakia in Adults. No other information is needed to describe this section
88975302|NCT00071565||1|475 families with multiple affected family members (phase I) 200 families with multiple affected family members (phase II) 1800 subjects with sporadic intracranial aneurysms
88975303|NCT01086371|Experimental|RAS walking|Subjects will walk while listening to music 20 minutes per day every day during the study period.
88975304|NCT01086371|Active Comparator|RAS no walking|Subjects will be listening to music but not performing walking exercise, for 20 minutes per day every day during the study period.
88975305|NCT01086371|Active Comparator|Walking no RAS|Subjects will be walking without listening to music for 20 minutes per day every day during the study period
88975306|NCT00067938|Other|Arm 1|Open label single arm study
89209745|NCT00585923|Active Comparator|Usage of Slotted hole C-Tek™ Plate|Slotted Hole Plate - Bone screw translates while plate is stationary, which ultimately promotes grafts settling through load sharing.
89586849|NCT05848310||Good prognosis + Poor prognosis|"Good prognosis: the serum total bilirubin level was less than 20 umol/l three months after surgery, and no liver transplantation or death occurred within a year after surgery.~Poor prognosis: the serum total bilirubin level was higher than 20 umol/l three months after surgery, and no liver transplantation or death occurred within a year after surgery."
89586850|NCT05848258|Experimental|LY3871801 Phase 2a|Participants will receive LY3871801 administered orally.
89586851|NCT05848258|Placebo Comparator|Placebo Phase 2a|Participants will receive placebo.
89586852|NCT05848258|Experimental|LY3871801 Dose 1 Phase 2b|Participants will receive LY3871801 administered orally.
89586853|NCT05848258|Experimental|LY3871801 Dose 2 Phase 2b|Participants will receive LY3871801 administered orally.
89586854|NCT05848258|Experimental|LY3871801 Dose 3 Phase 2b|Participants will receive LY3871801 administered orally.
89586855|NCT05848258|Placebo Comparator|Placebo Phase 2b|Participants will receive placebo.
89586856|NCT05845970|Experimental|Single Group|Single-group crossover trial with 100 total participants. Participants will use Pamprin Botanicals during their first period and both Pamprin Botanicals and over-the-counter Pamprin Menstrual Relief during their second period.
89586857|NCT05843240|Active Comparator|rTMS|Patients are treated with repetitive transcranial magnetic stimulation (rTMS).
89586858|NCT05843240|Placebo Comparator|sham-rTMS|Patients are treated with sham repetitive transcranial magnetic stimulation (sham-rTMS).
89586859|NCT05836324|Experimental|Part 1a - Dose Escalation|INCA33890 will be administered at a protocol defined starting regimen intravenously. Subsequent dose regimens will be determined during study conduct.
89586860|NCT05836324|Experimental|Part 1b-Dose Expansion|INCA33890 will be administered at the recommended dose(s) for expansion (RDE[s]) in participants with advanced or metastatic ICI sensitive or ICI non sensitive tumor types
89586861|NCT05833100|Experimental|Users of the Blood Glucose/b-Ketone Monitoring System|Participants are individuals who have either been diagnosed with diabetes or not and are naive users of CareSens PRO GK BT.
89586862|NCT05818826|Experimental|early cessation group|The pharmacist uses 100 ml of normal saline solution, packed out in the same format, dose, and administration of the drug were exactly the same as in the conventional cessation group. The experimental starts after required dose of vasopressor less than 0.1 mcg/kg/min. The nurse serially records capillary blood glucose and serum sodium following the doctor's order.
89586863|NCT05818826|Placebo Comparator|conventional cessation group|The pharmacist prepared hydrocortisone and normal saline solution 100 ml starts dose at least 200 mg/day according to doctor's order after patient meets the criteria of refractory septic shock then continues conventional cessation of hydrocortisone according to doctor's order after required dose of vasopressor less than 0.1 mcg/kg/min. The nurse serially records capillary blood glucose and serum sodium following the doctor's order.
89586864|NCT05818800|Other|Solution 1 - HSmartBPM (developed by a supplier consortium led by GNOMON)|Solutions consist of devices (e.g., blood pressure monitors, body composition scales) working together in an ecosystem enabled by a user-facing service and associated interfaces. Users are invited to a dedicated training session at the pilot site to officially become enrolled and begin using the solution for an extended period of time. During that time, users are instructed to use the solutions based on recommendations by their treating physicians (e.g., regular measurement of blood pressure using the solution, or scheduling of regular visits via the solution interface). Questionnaires are administered via the solution's interface at the beginning and end of the trial duration. At the end of the trial, the user is asked to return the devices to the pilot site.
89586865|NCT05818800|Other|Solution 2 - HyperHealth (developed by a supplier consortium led by TECH4CARE)|Solutions consist of devices (e.g., blood pressure monitors, body composition scales) working together in an ecosystem enabled by a user-facing service and associated interfaces. Users are invited to a dedicated training session at the pilot site to officially become enrolled and begin using the solution for an extended period of time. During that time, users are instructed to use the solutions based on recommendations by their treating physicians (e.g., regular measurement of blood pressure using the solution, or scheduling of regular visits via the solution interface). Questionnaires are administered via the solution's interface at the beginning and end of the trial duration. At the end of the trial, the user is asked to return the devices to the pilot site.
88975307|NCT02582593|Active Comparator|Cognitively Normal Group NIR|Transcranial Near Infrared Stimulation for cognitively normal participants who will attend a total of 6 treatment sessions over a two week period. During each session, stimulation via light emitting diode clusters will occur for a total of 60 minutes. Four light emitting diode (LED) clusters will be applied in 3 distinct configurations. There will be 20 minutes of stimulation at each of these 3 configurations. Each configuration will target 4 sites, for a total of 12 sites over the course of the 60 minute session. The power density used will be 500 milliwatts (mW) with a cumulative fluence (energy density) of 312 Joules/cm2 (26 J/cm2 applied at 12 sites). It is estimated that approximately 6 Joules/cm2 will reach the cortex with each daily treatment.
88975308|NCT02582593|Sham Comparator|Cognitively Normal Group - Sham|Cognitively Normal Participants in the sham control group will undergo identical procedures as the intervention group - screening, baseline testing, and LED cluster placement procedures. However, during the near infrared (NIR) session, the MedX console will not be turned on and no active stimulation will be applied.
89586866|NCT05818800|Other|control|the control group where they will be followed according to standard care
89586867|NCT05817123||OSAS patients|Patients with Obstructive Sleep Apnea Syndrome
89586868|NCT05817123||Partners|Partners of OSAS patients
89586869|NCT05796271|Experimental|R-Chop and Roflumilast|All subjects will receive R-CHOP therapy at standard doses according to the standard preparation and infusion procedures of each investigational site, which is to be repeated every 21 days (+/- 3 days) for a total of 6 cycles. All subjects will receive a fixed oral dose of one 500 microgram (μg) tablet of roflumilast per day with or without food for all 21 days of each cycle, which will amount to a total of 126 doses. Subjects will be asked to keep a drug diary to record the days and times when Roflumilast is taken. The first dose will be given on the day of the first R-CHOP treatment.
89586870|NCT05795127||Reoperated|Primary arthrodesis operations later requiring reoperation.
89586871|NCT05795127||Control|Primary arthrodesis operations with no further operations. Size of the control group is four fold.
89586872|NCT05794906|Experimental|Darolutamide+ADT|Participants will receive darolutamide plus ADT twice daily with food for a pre-specified duration of 24 months.
89586873|NCT05794906|Placebo Comparator|Placebo+ADT|Participants will receive Placebo plus ADT twice daily with food for a pre-specified duration of 24 months.
89586874|NCT05785871||Untreated Hypertension|in office SBP ≥140 at two separate occasions and currently treated with antihypertensive medications (uncontrolled), or in office SBP ≥ 140 at two different occasions and no current treatment (untreated).
89586875|NCT05785871||Normotensive|in office SBP<140 mmHg, no treatment with antihypertensive medications
89586876|NCT05785871||Controlled Hypertension|in office SBP <140 and current treatment with antihypertensive medications
89586877|NCT05785091||1|forward head posture with hamstring muscles tightness
89586878|NCT05785091||2|forward head posture with calf muscles tightness
89586879|NCT05785091||3|forward head posture and hamstring- calf muscles tightness
89586880|NCT05785091||4|forward head posture and lumber inflexibility
89586881|NCT05785091||5|forward head posture and hamstring- calf muscles tightness, lumber inflexibility
89586882|NCT05784246|Experimental|Mirikizumab Weight-Based Group 1|Experimental: Participants will receive mirikizumab weight-based dosing intravenously (IV) or subcutaneously (SC).
89586883|NCT05784246|Experimental|Mirikizumab Weight-Based Group 2|Experimental: Participants will receive mirikizumab weight-based dosing IV or SC.
89586884|NCT05784246|Experimental|Mirikizumab Weight-Based Group 3|Experimental: Mirikizumab Participants will receive mirikizumab weight-based dosing IV or SC.
89586885|NCT05782153|Active Comparator|Intervention A (hearing aid self-fitting with direct adjustment)|
89586886|NCT05782153|Active Comparator|Intervention B (hearing aid self-fitting with in-situ fitting)|
89586887|NCT05780021|No Intervention|Standard arm|The patients will have the usual care
88975309|NCT02582593|Active Comparator|Amnestic MCI Groups - Amnestic and Nonamnestic NIR|Transcranial Near Infrared Stimulation for amnestic and nonamnestic participants who will attend a total of 6 treatment sessions over a two week period. During each session, stimulation via light emitting diode clusters will occur for a total of 60 minutes. Four light emitting diode (LED) clusters will be applied in 3 distinct configurations. There will be 20 minutes of stimulation at each of these 3 configurations. Each configuration will target 4 sites, for a total of 12 sites over the course of the 60 minute session. The power density used will be 500 milliwatts (mW) with a cumulative fluence (energy density) of 312 Joules/cm2 (26 J/cm2 applied at 12 sites). It is estimated that approximately 6 Joules/cm2 will reach the cortex with each daily treatment.
88975310|NCT02582593|Sham Comparator|Amnestic MCI Groups - Amnestic and Nonamnestic - Sham|Amnestic and Nonamnestic Participants in the sham control group will undergo identical procedures as the intervention group - screening, baseline testing, and LED cluster placement procedures. However, during the near infrared (NIR) session, the MedX console will not be turned on and no active stimulation will be applied.
89030292|NCT04510025||Non-COVID|We will enrol age, gender, BMI and co-morbidity matched non-COVID control subjects ( no serological evidence of previous infection or active symptoms).
89030293|NCT04510025||COVID-19|Hospitalised patients with moderate to severe infection (admitted for at least 2 days in hospital).
89030294|NCT00517062|Active Comparator|A|Growth hormone
89030295|NCT00517062|Placebo Comparator|B|Placebo
89030296|NCT02275676||Inflammatory bowel disease|Patients with active and inactive inflammatory bowel disease
89586888|NCT05780021|Experimental|Motivational Support Program Emotiv|The patients will have the motivational support program
89586889|NCT05777564|Other|HIIT for knee OA|high intensity exercise
89030297|NCT04517981||Drug intervention|Antidepressant
89030298|NCT04517981||Psychological intervention|Cognitive behavior therapy, sand table therapy
89586890|NCT05777174|Experimental|Participants with eGFR ≥ 70 mL/min/1.73 m^2|MB-102 (130 mg) will be administered to participants with estimated glomerular filtration rate (eGFR) eGFR ≥ 70 mL/min/1.73 m^2, and fluorescence measured using the MediBeacon Transdermal GFR Measurement System. Approximately half of the participants are to be enrolled with Fitzpatrick Scale Type I, II or III, and half with Type IV, V and VI skin color type.
89586891|NCT05777174|Experimental|Participants with eGFR < 70 mL/min/1.73 m^2|MB-102 (130 mg) will be administered to participants with estimated glomerular filtration rate (eGFR) eGFR < 70 mL/min/1.73 m^2, and fluorescence measured using the MediBeacon Transdermal GFR Measurement System. Approximately half of the participants are to be enrolled with Fitzpatrick Scale Type I, II or III, and half with Type IV, V and VI skin color type.
89586892|NCT05774626||DMPA-SC|All married women of reproductive age who receive family planning counseling at a participating health facility and who choose to receive injectable contraception will be given an option of either DMPA-IM (current health worker administered standard of care) or DMPA-SC (new administration method, with option for self-injection after completing training). Those opting for DMPA-SC will receive training on self-injection procedures and an opportunity to practice injection procedures on a model (e.g. condom filled with salt) to demonstrate confidence and proficiency to inject herself under the supervision of a healthcare provider. Clients will then be shown how to use a calendar to determine when their next injection is due, and provided a calendar/reminder card, job aids that illustrate self-injection steps (including safe disposal of needles), and 3 doses of DMPA-SC to take home for future use.
89586893|NCT05774626||DMPA-IM|All married women of reproductive age who receive family planning counseling at a participating health facility and who choose to receive injectable contraception will be given an option of either DMPA-IM (current health worker administered standard of care) or DMPA-SC (new administration method, with option for self-injection after completing training).
89586894|NCT05773287|Experimental|Targeted Health Coaching Group|
89586895|NCT05773287|Placebo Comparator|Standard Care Group|
89586896|NCT05772429||Epidyolex|Participants will receive Epidyolex in accordance with their routine clinical practice as prescribed by their physician.
89586897|NCT05766709|Experimental|Group 1|Participants will receive separate injections of NNC0194-0499 B and Semaglutide B for 24 weeks. Dose escalation manner every 4 weeks for 20 weeks (30 mg NNC0194-0499 B and 0.24 mg Semaglutide B for Weeks 1-4, 30 mg NNC0194-0499 B and 0.5 mg Semaglutide B for Weeks 5-8, 30 mg NNC0194-0499 B and 1.0 mg Semaglutide B for Weeks 9-12, 30 mg NNC0194-0499 B and 1.7 mg Semaglutide B for Weeks 13-16 and 30 mg NNC0194-0499 B and 2.4 mg Semaglutide B for Weeks 17-20). Participants will receive NNC0194-0499/Semaglutide A 40/3.20 mg/mL co-formulation at the target dose of 30/2.4 mg during the weeks 21-24 (maintenance dosing period).
89586898|NCT05766709|Experimental|Group 2|Participants will receive NNC0194-0499/Semaglutide A 40/3.20 mg/mL co-formulation for 24 weeks. Dose escalation manner every 4 weeks for 20 weeks (3.1mg/0.25mg for Weeks 1-4, 6.3mg/0.5mg for Weeks 5-8, 12.5mg/1.0mg for Weeks 9-12, 21.3mg/1.7mg for Weeks 13-16 and 30mg/2.4mg for weeks 17-20). Participants will receive NNC0194-0499/Semaglutide 40/3.20 mg/mL co-formulation at the target dose of 30mg/2.4mg during the weeks 21-24 (maintenance dosing period).
89586899|NCT05766709|Experimental|Group 3|Participants will receive 4 weekly injections of NNC0194-0499/Semaglutide A 40/0.33 mg/mL co-formulation at the dose level of 30mg/0.25 mg.
89586900|NCT05764369|Experimental|Parenting Wisely Residential Treatment (PWRT)|In the PWRT condition, parents will complete a total of ten web-based modules in an online parent training program called Parenting Wisely. Each week, parents will also attend a 90-minute facilitated discussion group via Zoom. Parents will complete assessments at baseline (T1), six weeks post-baseline (T2), and six months post-baseline (T3) via REDCap. While adolescents (n=60) will not directly receive the intervention, they will complete assessments at baseline, six weeks post-baseline (T2), and six months post-baseline (T3).
89586901|NCT05764369|Placebo Comparator|Treatment as Usual (TAU)|The TAU condition is the standard of care offered to parents in RT settings. Parents in the TAU condition will receive traditional programming, including family therapy offered weekly during the RT admission. Parents will attend discharge planning meetings with caseworkers (if assigned) to discuss the adolescent's progress, continued treatment needs, safety plans, upcoming appointments, and medication needs. Following discharge, programs frequently recommend follow-up with an outpatient provider for medication management and therapy for the adolescent. Parents will complete assessments at baseline (T1), six weeks post-baseline (T2), and six months post-baseline (T3) via REDCap. While adolescents (n=60) will not directly receive the intervention, they will complete assessments at baseline, six weeks post-baseline (T2), and six months post-baseline (T3).
89586902|NCT05761119|Experimental|Early Initiated Physiotherapy Intervention|All participants will recieve the intervention (see Intervention for description) to investigate the feasibility.
89586903|NCT05757700|Experimental|Participants with Diffuse Large B-Cell Lymphoma (DLBCL) and large B cell lymphoma|Participants have histologically confirmed DLBCL and large B cell lymphoma. Participants will be treated with escalating doses of modified T cells.
89586904|NCT05756751|Other|Treatment with Impella 5.5 System|
89586905|NCT05753904|No Intervention|Reverse Total Shoulder Arthroplasty|For RTSA using a deltopectoral approach, the Perform glenoid and humeral components of Tornier Stryker Reverse Shoulder system will be used for all cases. The sizes and offsets of the components will be chosen based on each patient's local anatomy which will vary among patients. The subscapularis tendon will be repaired using three transosseous nonabsorbable sutures whenever there is a reparable subscapularis tendon. After definitive implantation of the prosthesis is completed, in the 'no interventional' group, the wound will be closed in layers, and the shoulder will be immobilized in an abduction sling.
89586906|NCT05753904|Experimental|Reverse Total Shoulder Arthroplasty with Conjoint Tendon Resection|RTSA in the experimental group will be identical, except for that after definitive implantation of the prosthesis is completed, in the 'experimental' group, the conjoint tendon will be released completely via a transverse incision made at a level 2 cm distal to the coracoid process for the patients assigned the conjoint resection group. Electrocautery will be used for the resection, and the underlying muscular portion of the conjoint tendon will be preserved. As mentioned above, the control group will not receive this conjoint tendon resection. Similarly, in the experimental group, the wound will be closed in layers, and the shoulder will be immobilized in an abduction sling.
89586907|NCT05753501|Experimental|Dose Escalation ABBV-101|Participants with relapsed or refractory (R/R) Non-Hodgkin's lymphoma (NHL) will receive escalating doses of ABBV-101, until the maximum administered dose (MAD)/Maximum tolerated dose (MTD) is determined, as part of the approximately 60 month study duration.
89586908|NCT05753501|Experimental|Dose Expansion ABBV-101 R/R Chronic Lymphocytic Lymphoma (CLL)|Participants with R/R CLL will receive ABBV-101 at the dose determined in the dose escalation arm, as part of the approximately 60 month study duration.
89586909|NCT05753501|Experimental|Dose Expansion ABBV-101 R/R non-GCB DLBCL|Participants with R/R non-germinal center B cell (GCB) diffuse large B-cell lymphoma (DLBCL) will receive ABBV-101 at the dose determined in the dose escalation arm, as part of the approximately 60 month study duration.
89586910|NCT05750667|Experimental|Penn Medicine (health system)-mediated|Probands receive automated text messages and/or emails through the Way to Health (WTH) platform containing information about FH and cascade screening from Penn Medicine, and a request to identify first-degree biological relatives. Probands choose whether to contact relatives themselves or share contact information so that automated text messages and/or emails can be sent by Penn Medicine to relatives directly via WTH. If probands opt to contact relatives themselves (self-contact), they receive tips on how to do this effectively. If probands opt for Penn Medicine to contact their relatives (direct contact), relatives receive information via WTH about FH and instructions for screening. All relatives (regardless of whether they were contacted via self-contact and direct contact) will be offered FH screening at no cost. If a proband's initial choice of outreach is not successful, they will have the option of initiating the alternate outreach approach (direct or self-contact).
89608652|NCT04149327|Active Comparator|Control group|Patients will receive full-mouth mechanical cleansing of both implants and remaining dentition using ultrasonic instruments (EMS®) and hand instruments (scalers and curettes) in one or multiple sessions (max. 4). Prior to each session patients will rinse their mouth using 0.12% chlorhexidine + 0.05% cetylpyridinium chloride without alcohol during 30 seconds. At the final session all previously cleaned areas will be re-examined and cleaned. At the end of the final treatment session, the dental hygienist will give the patients an envelop containing a recipe for 500 ml mouthrinse (0.12% chlorhexidine + 0.05% cetylpyridinium chloride without alcohol, Perio-Aid®). After the final session patients will rinse their mouth using that mouthrinse twice daily during 30 seconds for 2 weeks.
89586911|NCT05750667|Experimental|Family Heart Foundation-mediated|After using WTH to conduct an identity screen and giving probands an option to opt-out of having their information shared with Family Heart Foundation (FHF), FHF reaches out directly to probands via an FHF-employed navigator. During an initial call, the navigator introduces the proband to navigation services, conducts a social history, and initiates a plan for contacting relatives. Probands choose whether to contact relatives themselves (self-contact) or have FHF contact relatives directly (direct contact). Those who choose self-contact receive personalized coaching to address barriers and concerns. For direct contact relatives, FHF will call these relatives directly. All relatives (regardless of whether they were contacted via self-contact and direct contact) will be offered FH screening at no cost. If a proband's initial choice of outreach is not successful, they will have the option of initiating the alternate outreach approach (direct or self-contact).
89586912|NCT05750667|No Intervention|Usual Care|Probands randomized to this arm will not receive any contact from the research team or Family Heart Foundation regarding cascade screening (i.e., no intervention).
89586913|NCT05750628|Experimental|Cohort A1: Dose Level 1 INE963|Cohort A1: Dose Level 1 INE963
89586914|NCT05750628|Experimental|Cohort A1: Dose Level 2 INE963|Cohort A1: Dose Level 2 INE963
89586915|NCT05750628|Experimental|Cohort A1: Dose Level 3 INE963|Cohort A1: Dose Level 3 INE963
89586916|NCT05750628|Experimental|Cohort B1: KAE609 + INE963|Cohort B1: KAE609 + INE963
89586917|NCT05750628|Active Comparator|Cohort B1: SoC (Coartem)|Cohort B1: SoC (Coartem)
89586918|NCT05750628|Experimental|Cohort B2: KAE609 + KLU156|Cohort B2: KAE609 + KLU156
89586919|NCT05750628|Active Comparator|Cohort B2: SoC (Coartem)|Cohort B2: SoC (Coartem)
89586920|NCT05743127|Experimental|Group Conventional Expander|Conventional Laboratory Fabricated Hyrax Expander
89586921|NCT05743127|Experimental|Group 3-D Printed Expander|3D-Printed Hyrax Expander
89586922|NCT05737732|Active Comparator|Circadian Effective Lighting (CEL)|The CEL will be performed in hospital sites over a 2-month period.
89586923|NCT05737732|Sham Comparator|Circadian Ineffective Lighting (CIL)|The comparator lighting will be performed identical to Arm 1, at specified lower levels of lighting.
89586924|NCT05735483|Experimental|Lebrikizumab + Placebo|"Lebrikizumab will be given subcutaneously (SC).~Placebo will be administered to maintain the blind of parent study J2T-MC-KGBI."
89586925|NCT05733065|Other|Monozygotic Twin|we will include natural conceived twin pairs born before 2002, with known birth weight, sex and gestational age, and where both twins were live born without congenital abnormality. Twins born after pregnancies complicated by conditions such as TTTS will be excluded. MZ twins pairs will be ranked according to intra-pair birth weight difference. Next, we intend to include the 120 most discordant monozygotic twin pairs, stratified by chorionicity (1:1 ratio) and in the case of DC by fusion of the placentas (1:1 ratio). Only pairs where both twins consent to inclusion in the study will be included.
89586926|NCT05732272|Active Comparator|Standard Treatment|250 participants will be randomly assigned to the standard treatment arm and receive 7 weeks of bupropion SR following standard dosing guidelines(150 mg once daily for 3 days, then 150mg twice daily for 7 weeks). Participants in this arm will also receive 8 smoking cessation counseling sessions consistent with the Clinical Practice Guidelines.
88975311|NCT02582593|Active Comparator|Parkinson Disease Group NIR|Transcranial Near Infrared Stimulation for Parkinson Disease participants who will attend a total of 6 treatment sessions over a two week period. During each session, stimulation via light emitting diode clusters will occur for a total of 60 minutes. Four light emitting diode (LED) clusters will be applied in 3 distinct configurations. There will be 20 minutes of stimulation at each of these 3 configurations. Each configuration will target 4 sites, for a total of 12 sites over the course of the 60 minute session. The power density used will be 500 milliwatts (mW) with a cumulative fluence (energy density) of 312 Joules/cm2 (26 J/cm2 applied at 12 sites). It is estimated that approximately 6 Joules/cm2 will reach the cortex with each daily treatment.
88975312|NCT02582593|Sham Comparator|Parkinson Disease Group Sham|Parkinson Disease Participants in the sham control group will undergo identical procedures as the intervention group - screening, baseline testing, and LED cluster placement procedures. However, during the near infrared (NIR) session, the MedX console will not be turned on and no active stimulation will be applied.
88975313|NCT02358187|Experimental|HLA-A2 Restricted Glioma Antigen-Peptides with Poly-ICLC|All subjects will receive vaccine plus Poly-ICLC. Injections will be given every 3 week for a total of 8 vaccines.
88975314|NCT02290522|Experimental|tumor biopsy|Tumor biopsy for targeted treatment according to molecular profile
88975315|NCT01809808||Acromegaly Subjects|People who have a biochemical diagnosis of acromegaly, and will or have already undergone surgery for acromegaly and will be taking medications for acromegaly . Subjects will undergo blood sampling, metabolic rate measurement, adipose tissue biopsy and total body magnetic resonance imaging before and over time after either surgery or medical therapy for acromegaly.
88975316|NCT01809808||Healthy Subjects|People who are not diagnosed with acromegaly, responding to flyer or by word of mouth for participation, without medical problems, not taking medications, and with a stable weight for 3 months prior to study. Subjects will undergo blood sampling, total body MRI and adipose tissue biopsy once.
88975317|NCT01556230||Group I|The first group of subjects, Group I, will be followed in Protocol I and are a group of subjects with an apparent clinically nonfunctioning pituitary lesion who will be studied in a prospective study of conservative non-surgical management.
88975318|NCT01556230||Group II|A second group of subjects, Group II, are subjects who are undergoing surgical intervention for CNFA or radiotherapy for CNFA and these subjects will be studied in a prospectively follow up as part of Protocol II.
88975319|NCT00073892|Experimental|PI-88|Patients receive four consecutive days treatment each week in a 4-week cycle.
88975320|NCT00068055|Experimental|1|60 subjects to receive Omr-IgG-am.
88975321|NCT00068055|Active Comparator|2|20 subjects to receive Polygam® S/D (IVIG).
88975322|NCT00068055|Placebo Comparator|3|20 subjects to receive normal saline.
88975323|NCT01406197|Experimental|Vaginal progesterone|vaginal 150 mg micronized progesterone cream delivered via a vaginal applicator; dosed daily (Prochieve, Columbia Laboratories)
88975324|NCT01406197|Experimental|Topical progesterone|topical 150 mg micronized progesterone gel applied to abdomen via a novel applicator; dosed daily
88975325|NCT01406197|Experimental|Intramuscular progesterone|injected IM (upper arm or thigh via syringe) 50mg/day micronized progesterone (Watson Pharmaceuticals)
88975328|NCT02957773|Experimental|Qigong and art activities|An integrated group of Qigong and art activities for 90 minutes.
88975329|NCT02957773|Experimental|Art activities|Art activities and daily activities group for 90 minutes.
88975330|NCT02957773|Experimental|Qigong|A Qigong and daily activities group for 90 minutes
89586927|NCT05732272|Active Comparator|Extended Treatment|250 participants will be randomly assigned to the extended treatment arm and receive 24 weeks of bupropion SR following standard dosing guidelines(150 mg once daily for 3 days, then 150mg twice daily for 24 weeks). Participants in this arm will also receive 8 smoking cessation counseling sessions consistent with the Clinical Practice Guidelines.
89586928|NCT05730218|Experimental|Treatment Group A|ONL1204 Ophthalmic Solution Dose A administered by intravitreal injection
89586929|NCT05730218|Experimental|Treatment Group B|ONL1204 Ophthalmic Solution Dose B administered by intravitreal injection
89586930|NCT05730218|Sham Comparator|Treatment Group C|Sham injection is performed by touching the eye surface with a syringe without a needle
89608653|NCT04140747||non-pregnant women|Samples will be collected from 30 healthy, non-pregnant women in the reproductive age: blood, urine, stool, saliva, oral swabs, vaginal swabs
88975331|NCT02957773|Other|Daily activities|A daily activities group for 90-minutes.
88975332|NCT00144508|Experimental|1|
88975333|NCT00144508|Other|2|continue current treatment
88975334|NCT00144547|Experimental|1|
88975335|NCT00144586|Experimental|1|
89586931|NCT05723107|Experimental|Chemotherapy plus EUS-RFA|"Endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) and chemotherapy will be administered as part of standard of care treatment for PDAC in patients receiving palliative second- or third-line therapy for unresectable non-metastatic pancreatic cancer.~Study participants will undergo 3 identical EUS-RFA procedures, administered during Study Window 2 (Weeks 1-3), Window 3 (Weeks 5-7), and Window 4 (Weeks 9-11). During each EUS-RFA procedure, a tumor biopsy will also be taken for single cell RNA sequencing.~Chemotherapy will be administered during Study Window 2 (Weeks 1-3), Window 3 (Weeks 5-7), Window 4 (Weeks 9-11), and Window 5 (Weeks 13-15)."
89586932|NCT05718687|Experimental|Treatment|open-label GBT021601
89586933|NCT05718024|Experimental|Dexmedetomidine-esketamine|Dexmedetomidine-esketamine combination will be infused during night-time (8 pm to 6:30 am) for ICU patients with mechanical ventilation, for a duration of up to 5 days.
89586934|NCT05718024|Active Comparator|Propofol-remifentanil|Propofol and remifentanil will be infused during night-time (8 pm to 6:30 am) for ICU patients with mechanical ventilation, for a duration of up to 5 days.
89586935|NCT05705531||Observational (blood samples, surveys, MRI, record review)|Patients undergo collection of blood samples, complete surveys, and undergo cardiac MRI on study. Patients also have their medical records reviewed.
89586936|NCT05704790|Experimental|Intervention|The intervention will include 5 weekly sessions (60-90 minutes each) of cognitive compensatory training (CCT) delivered virtually by a pediatric neuropsychologist.
89586937|NCT05702645||Observational (biospecimen collection, clinical evaluation)|Patients undergo an optional saliva/buccal swab in part 1 and clinical assessment in part 2 of the study. Patients may then undergo blood sample collection in part 3 of the study.
88975336|NCT00144625|Experimental|1|
88975337|NCT00038402|Experimental|Herceptin + Taxol Followed by FEC|Herceptin starting 4 mg/kg intravenous (IV), then 2 mg/kg weekly for all other cycles neo-adjuvant chemotherapy and during FEC therapy for total 24 doses. Taxol 225 mg/m^2 continuous IV over 24 hours each cycle; Fluorouracil 500 mg/m^2 IV Days 1 at 3-4 week intervals; Cytoxan 500 mg/m^2 IV on Day 1; Epirubicin 75 mg/m^2 IV on Day 1. Four 21-day cycles.
88975338|NCT00144664|Experimental|1|MRA(Tocilizumab)
88975339|NCT00144898|Experimental|Sentinel Node Resection|Sentinel Node Resection
88975340|NCT00144898|Other|Conventional Axillary Dissection|Conventional Axillary Dissection
88975341|NCT00038441|Experimental|DTI-015|
88975342|NCT00071643|Experimental|1 Problem Solving Therapy|Participants will receive problem solving therapy.
88975343|NCT00071643|Experimental|2. Escitalopram|Participants will receive escitalopram.
89586938|NCT05693896|Experimental|Centering Appetite Intervention, Then Attention- Control Group|Participants randomized to the attention-control group will participate remotely via a smartphone app and online lessons. The intervention will build participants' self-efficacy to reduce binge eating and to assist them in preventing weight gain.
88975344|NCT00071643|Placebo Comparator|3 Placebo|Participants will receive placebo.
88975345|NCT04711018||Group DL (+)|Grade III or IV laryngeal view according to Cormack-Lehane classification
88975346|NCT04711018||Group DL (-)|Grade I or II laryngeal view according to Cormack-Lehane classification
88975347|NCT00202267|Active Comparator|1|Clients randomized to short-stretch bandaging application
88975348|NCT00202267|Active Comparator|2|Clients randomized to four-layer bandaging application
88975349|NCT00038558|Experimental|Filgrastim + ABVD Chemotherapy|
89586939|NCT05693896|No Intervention|Attention- Control Group, Then Centering Appetite Intervention|Participants randomized to the centering appetite intervention group will receive weekly psychoeducation emails about general wellness topics, discussion of binge eating, diet, and physical activity.
89586940|NCT05692739|Experimental|Insulin|Topical insulin 1UI/ml 4 times a day
89586941|NCT05692739|Active Comparator|Cyclosporin|Cyclosporin 0,05% every 12 hours
88975350|NCT02966496|Experimental|the test group|The patients aged 50-80 years will be randomly assigned to implantation of Acri.LISA366D multifocal aspheric IOLs in the test group.
89586942|NCT05692739|Placebo Comparator|Artificial tears|Artificial tears 4 times a day
89586943|NCT05691712|Experimental|5 mg Tirzepatide|5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.
89586944|NCT05691712|Experimental|10 mg Tirzepatide|10 mg tirzepatide administered SC once a week.
89586945|NCT05691712|Experimental|15 mg Tirzepatide|15 mg tirzepatide administered SC once a week.
88975351|NCT02966496|Experimental|the control group|The patients aged 50-80 years will be randomly assigned to implantation of TecnisZ9001 multifocal aspheric IOLs in the control group.
88975352|NCT02966808||Clinical measures|multiple sclerosis patients in treatment with fampridine
88975353|NCT00202696|Experimental|1|Nalmefene 40 mg
88975354|NCT00202696|Experimental|2|Nalmefene 80 mg
88975355|NCT00202696|Other|3|Placebo
88975356|NCT00202735|Active Comparator|Immobilization in internal rotation|"Immobilization in internal rotation:All patients in this group are immobilized with the arm in internal rotation.~The arm is immobilized with a normal collar and cuff device."
88975357|NCT00202735|Experimental|Immobilization in external rotation.|Immobilization in external rotation (ER. All patients in the ER group use a prefabricated shoulder immobilizer (Don Joy Ultrasling ER, 15˚ version.To control the position, a line at the top of the immobilizer is to be parallel with the frontal plane when the arm is correctly placed
88975358|NCT00202852|Placebo Comparator|1|
88975359|NCT00202852|Experimental|2|
88975360|NCT00202969|Experimental|1|S-1
88975361|NCT00202969|Active Comparator|2|S-1 plus CDDP
88975362|NCT00202969|Active Comparator|3|5-FU plus CDDP
88975363|NCT00203008||Observational procedure|Patients will be examined and any suspicious skin abnormalities will be biopsied
88975364|NCT00203164|Experimental|rasagiline mesylate|rasagiline mesylate 1 mg oral once daily
88975365|NCT00038792|Experimental|aGvHD|
88975366|NCT00410566|Experimental|1|
88975367|NCT00410566|Experimental|2|
88975368|NCT00410566|Experimental|3|
88975369|NCT00410566|Experimental|4|
89586946|NCT05691712|Placebo Comparator|Placebo|Participants will receive a tirzepatide matched placebo.
89586947|NCT05691634|Experimental|Patient with tatoo|
89586948|NCT05676203|Active Comparator|Arm 1|6 x Docetaxel 75 mg/m2 every 3 weeks of a 3 week cycle Co-administration of docetaxel, darolutamide and standard ADT
89586949|NCT05676203|Experimental|Arm 2|6 x Docetaxel 50 mg/ m2 every 2 weeks of a 4 week cycle Co-administration of docetaxel, darolutamide and standard ADT
89586950|NCT05673928|Experimental|Tucatinib and Adotrastuzumab Emtansine (T-DM1)|"Each study cycle is 21 days (3 weeks)~Participants will take tablets of tucatinib two (2) times a day, about 8-12 hours apart. Participants will receive T-DM1 by vein over about 30 minutes on Day 1 of each cycle"
89586951|NCT05671679|Experimental|Intervention|The intervention group will use SNAQ app for the first 3 weeks (baseline to V1) of the study.
89586952|NCT05671679|Active Comparator|Control|The control group will continue estimating the carbohydrate count using their traditional methods for the first three weeks of the study (baseline to V1).
89586953|NCT05670678||a2 growing up stage 3 formula puls lactoferrin supplement|"per 100g serving~Lactoferrin 30 mg~Galactooligosaccharides (GOS) at 3 g~DHA 0.37~Lactoferrin supplement plus: 2.68 ml per serving, 20 mg per 2 ml, 600 mg per bottle"
89586954|NCT05670678||Enfinitas growing up stage 3 formula|"per 100g serving~Lactoferrin 330 mg~Galactooligosaccharides (GOS) at 1.58 mg~β-Glucan 22 mg~DHA 0.4"
89586955|NCT05669924|Experimental|Methylphenidate|
89586956|NCT05669924|Placebo Comparator|Placebo|
89586957|NCT05659251|Experimental|Serplulimab|"Preoperative neoadjuvant therapy for 2-3 cycles. Radical surgery is performed 4-6 weeks after the last dose. Postoperative radiotherapy is determined according to the clinical situation and pathological stage of the patient.~Serplulimab can be maintained for a maximum of 1 year. During the study, patients were be followed until disease progression, withdrawal of informed consent, loss of follow-up, or death."
89586958|NCT05653648|Experimental|Potato Starch Supplement|Participants will consume a 24 grams of potato starch on Days 1-15 and 48 grams of potato starch on Days 16-30.
89586959|NCT05646706|Experimental|Semaglutide 7.2 mg|Participants will receive once-weekly injection of semaglutide subcutaneously (s.c.) in 20 week dose escalation period with dose escalation (0.25 milligram [mg], 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg, and 7.2 mg) every fourth week. Treatment was continued on the maintenance dose of 7.2 mg once-weekly for an additional 52 weeks until week 72.
89586960|NCT05646706|Experimental|Semaglutide 2.4 mg|Participants will receive once-weekly s.c. injection of semaglutide in 20 week dose escalation period with dose escalation (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg) every fourth week until maintenance dose of 2.4 mg of semaglutide was reached. Treatment was continued on the maintenance dose of 2.4 mg once-weekly for an additional 52 weeks until week 72.
89586961|NCT05646706|Placebo Comparator|Placebo|Participants will receive once-weekly s.c. injection of placebo matched to semaglutide for 72 weeks.
89586962|NCT05642533||Without a history of Type 2 diabetes|Adults with obesity
89586963|NCT05642533||With a history of Type 2 diabetes|Adults with obesity
89586964|NCT05635786||Alteplase (ALT)|Patients with distal vessel occlusion stroke treated with alteplase (from March 2016 to February 2018)
89586965|NCT05635786||Tenecteplase (TNK)|Patients with distal vessel occlusion stroke treated with tenecteplase (from March 2018 to February 2020)
89586966|NCT05635409|Experimental|Dose 1|The starting dose of this trial is selected as a dose of cells that is likely to be the minimal therapeutic dose, i.e. 100,000 surviving DA neurons per putamen, obtained by transplanting 3.54 million STEM-PD cells per putamen.
89586967|NCT05635409|Experimental|Dose 2|"To ensure that the investigators are not using a potentially suboptimal cell dose, the investigators also plan to test a higher dose, which is double the dose of dose 1, i.e., 200,000 surviving DA neurons (= 7.08 million transplanted STEM-PD cells) per putamen.~The Data and Safety Monitoring Board (DSMB) for the trial will make a recommendation for the dosing once participants 1-4 have been dosed and data is available for imaging and clinical measurements, as well as safety reports, 6 months after the last patient has been grafted. The DSMB can recommend either to: i) remain at dose 1; ii) proceed to dose 2; or, iii) wait longer to collect more data. The final decision will be made by the clinical sub-group of the Trial Management Group, after receiving confirmation of the DSMB's recommendation."
89586968|NCT05634759|Experimental|Routine Community-wide MDA followed by Two Additional Rounds of Treatment for Children|The enhanced MDA Strategy 1 consists of a routine community-wide MDA followed by two additional rounds targeted to children age 6 months to 9 years. The additional rounds of treatment will occur 2 weeks apart and will begin 1 week after the community-wide MDA.
89586969|NCT05634759|Experimental|Routine Community-wide MDA followed by a Second Community-wide MDA|The enhanced MDA Strategy 2 consist of a routine community-wide MDA followed by a second community-wide MDA approximately 6-8 months later. The timing of the second MDA will depend on local conditions and logistical concerns.
89586970|NCT05634759|Active Comparator|Standard-of-Care Annual MDA|Programmatic Control Comparator data for the standard-of-care annual MDA will come from the MDA conducted in 2022 in a random selection of 15 non-study villages.
89586971|NCT05631327|Experimental|Dose Finding Phase: JZP341|Participants who will receive JZP341 on Day 1 and Day 15 of each 28-day cycle.
89586972|NCT05631327|Experimental|Dose Expansion Phase: JZP341|Participants who will receive JZP341 at the RP2D established in the Dose Finding Phase on Day 1 and Day 15 of each 28-day cycle.
89586973|NCT05630911||High Reinvestor Group (HRG)|"Participants will be invited to complete a series of standing balance trials. The trials will involve participants standing in three different positions on a foam surface (i.e., Airex balance pad elite with a dimension of 16.1 width x 19.7 length x 2.4 height, or equivalent).The three different standing positions will be: wide-base standing on foam (WBF), narrow-base standing on foam (NBF), and tandem standing on foam (TAF) (i.e., low-level of task difficulty, moderate-level of task difficulty, and high-level of task difficulty, respectively). For each standing position, participants will be required to perform two consecutive standing balance trials, with a 1-minute rest break in between."
89608654|NCT04140747||pregnant women delivering vaginally|"From 30 healthy, pregnant women giving vaginal birth, samples will be collected shortly before, during and after birth from maternal and newborn sites:~maternal blood, urine, stool, saliva, oral swabs, vaginal swabs; cord blood, colostrum, meconium, infant oral swabs"
88975370|NCT00410566|Experimental|5|
89586974|NCT05630911||Low Reinvestor Group (LRG)|"Participants will be invited to complete a series of standing balance trials. The trials will involve participants standing in three different positions on a foam surface (i.e., Airex balance pad elite with a dimension of 16.1 width x 19.7 length x 2.4 height, or equivalent).The three different standing positions will be: wide-base standing on foam (WBF), narrow-base standing on foam (NBF), and tandem standing on foam (TAF) (i.e., low-level of task difficulty, moderate-level of task difficulty, and high-level of task difficulty, respectively). For each standing position, participants will be required to perform two consecutive standing balance trials, with a 1-minute rest break in between."
89586975|NCT05627479|Experimental|GIK Therapy|In patients randomized to the GIK Therapy Arm, a stepwise GIK infusion process will be performed. Baseline lab values that are markers of skeletal muscle injury (CPK), acute kidney injury (creatinine), and general tissue perfusion (lactate) will be obtained within the first 30 min of arrival to the ED. Subsequently, serial CPK, creatinine, myoglobin and lactate values will be obtained at regularly scheduled intervals until a minimum of 72 hours after definitive fixation or until rhabdomyolysis is resolved and/or kidney function has normalized
89030299|NCT04517981||Comprehensive intervention|Psychological intervention, community intervention combined with drug intervention
89586976|NCT05627479|Placebo Comparator|Placebo Control|Patients randomized to the control cohort will receive a normal saline infusion instead of GIK. Standard institutional ICU protocol will be used to monitor potassium and glucose levels per current standard-of-care practices and abnormal lab values will be treated accordingly per standard institutional protocols.
89586977|NCT05627453|Active Comparator|Normal gait training|"The gait training session will consist in 30 min walking side-by-side. If any, the session will take place along an indoor circuit to avoid unfavorable weather conditions. The participants will walk side by side without contact and without instructions about gait synchronisation. They will have to agree on a comfortable pace for the older participant.~The gait training session will be repeated three times a week for four weeks. The last session of each week will also include an assessement of gait quality."
89586978|NCT05627453|Experimental|Arm-in-arm gait training|"The gait training session will consist in 30 min walking side-by-side. If any, the session will take place along an indoor circuit to avoid unfavorable weather conditions. The participants will be asked to walk arm-in-arm while synchronizing their steps. They will have to agree on a comfortable pace for the older participant.~The gait training session will be repeated three times a week for four weeks. The last session of each week will also include an assessement of gait quality."
89586979|NCT05627011|Experimental|Clinical Decision Support Tool|Practices assigned to iPOP-UP intervention which involves EHR-based CDS tools refined through a formative evaluation and user-centered design.
89586980|NCT05627011|No Intervention|Control|Practices assigned to usual care that will not have access to the iPOP-UP CDS tool but will have access to many opportunities available to all pediatric clinicians nationally around the release of the new American Academy of Pediatrics guidelines for obesity management.
89586981|NCT05609370|Experimental|Phase 1b: Cohort-1: LBL-007 + tislelizumab + bevacizumab + capecitabine|LBL-007 + tislelizumab + bevacizumab + capecitabine
89586982|NCT05609370|Experimental|Phase 1b: Cohort 1a: LBL-007 + tislelizumab + bevacizumab + capecitabine|LBL-007 + tislelizumab + bevacizumab + capecitabine
89586983|NCT05609370|Experimental|Phase 1b: Cohort 2: LBL-007 + tislelizumab + bevacizumab + fluoropyrimidine|LBL-007 + tislelizumab (low dose every 3 weeks or high dose every 4 weeks) + bevacizumab (7.5 mg/kg once every 2 weeks or 5 mg/kg once every 3 weeks)+ fluoropyrimidine (5-FU or capecitabine)
89586984|NCT05609370|Experimental|Phase 2: Arm A and Arm D: LBL-007 + tislelizumab + bevacizumab + fluoropyrimidine|LBL-007 + tislelizumab (low dose every 3 weeks or high dose every 4 weeks) + bevacizumab (7.5 mg/kg once every 2 weeks or 5 mg/kg once every 3 weeks) + fluoropyrimidine (5-FU or capecitabine)
89586985|NCT05609370|Experimental|Phase 2: Arm B: LBL-007 + bevacizumab + fluoropyrimidine|LBL-007 + bevacizumab (7.5 mg/kgonce every 2 weeks or 5 mg/kg once every 3 weeks) + fluoropyrimidine (5-FU or capecitabine)
89586986|NCT05609370|Other|Phase 2: Arm C and Arm E: bevacizumab + fluoropyrimidine|bevacizumab (7.5 mg/kg once every 2 weeks or 5 mg/kg once every 3 weeks) + fluoropyrimidine (5-FU or capecitabine)
89586987|NCT05609370|Experimental|Phase 1b: Cohort 1b: LBL-007 + Tislelizumab + Bevacizumab + 5- Flurouracil (5-FU)|LBL-007 + Tislelizumab + Bevacizumab + 5- Flurouracil
89586988|NCT05607758|Experimental|App for Stress management|"Participants will:~Participate in a physical introduction to the app-based stress management program~Get access to the app-based program, and a new module every third day (total 10 modules). The app consists of stress management education, cognitive behavioral interventions and relaxation training exercises.~Receive two phone follow-up calls from study personnel (about 3 and 6 weeks after the physical introduction)"
89586989|NCT05602194|Experimental|Arm A (levocarnitine, standard of care chemotherapy)|Patients receive levocarnitine PO or IV prior to standard of care induction chemotherapy with pegaspargase or calaspargase pegol on study. Patients may also undergo blood sample collection during screening and on study.
89586990|NCT05602194|Active Comparator|Arm B (standard of care chemotherapy)|Patients receive standard of care induction chemotherapy with pegaspargase or calaspargase pegol on study. Patients may also undergo blood sample collection during screening and on study.
89586991|NCT05602194|Experimental|Arm C (rescue levocarnitine)|Patients in Arms A and B who develop conjugated hyperbilirubinemia > 3 mg/dL during induction may receive levocarnitine rescue PO or IV supplementation until resolution of conjugated hyperbilirubinemia =< 3 mg/dL (or start of consolidation or the next treatment phase, whichever occurs first).
89030300|NCT00517257|Experimental|A|Atorvastatin 80 mg orally once daily for 24 weeks
89030301|NCT00517257|Placebo Comparator|P|Placebo tablet orally once daily for 24 weeks
89030302|NCT00506246|Experimental|1|Propofol MCT/LCT
89030303|NCT00506246|Active Comparator|2|Propofol LCT
89030304|NCT00517335||1|Women who are healthy controls
89030305|NCT00517335||2|Women who have recovered from bulimia
89030306|NCT00517335||3|Women who have recovered from anorexia
89586992|NCT05601986|Other|Physiotherapy and Rehabilitation Program|Control Group
89586993|NCT05601986|Experimental|Additional Motor Imagery Training to Physiotherapy and Rehabilitation Program|Intervention Group
89586994|NCT05600907|Experimental|Single arm study|Eligible CGD patients will receive one time infusion of study product along with Alemtuzumab and TBI as part of HSCT conditioning regimen
89586995|NCT05598658|Active Comparator|RIC group|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min re-perfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mm Hg. RIC will be conducted at 6 and 18-24 hours after intravenous thrombolysis.
89586996|NCT05598658|Placebo Comparator|Sham-RIC group|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min re-perfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mm Hg. RIC will be conducted at 6 and 18-24 hours after intravenous thrombolysis.
89586997|NCT05595876|Experimental|Stent retriever|The patients will be treated to receive stent retriever (with or without contact aspiration) first line thrombectomy (experimental arm).
89586998|NCT05595876|Sham Comparator|Contact aspiration|The patients will be treated to receive direct contact aspiration first line thrombectomy (control arm)
89586999|NCT05593666|Experimental|LXE408 short regimen|LXE408 once daily for seven days (followed by 7 days of placebo).
89587000|NCT05593666|Experimental|LXE408 long regimen|LXE408 once daily for 14 days
89587001|NCT05593666|Active Comparator|Standard of care|AmBisome® 10 mg/kg IV single dose (SDA)
89030307|NCT04517708|Experimental|Intervention group|"Regarding the intervention group, patients were treated with the intervention regimen, which consisted of:~Nutritional counseling~Each patient was assigned a specific menu which were prepared by research members during the time of staying at the hospital. Before discharge, patients were instructed on preparing their diets at home with the recommended amount of energy and protein and given formula milk within two months."
89030308|NCT04517708|No Intervention|Control group|Patients had diets based on their demands
89030309|NCT00517452||Platelet Rich Plasma|Group received platelet rich plasma and observed over a period of 30 days or until wound closure
89030310|NCT00517452||Standard Wound Care|Group was treated as per standard care
89587002|NCT05583838|Experimental|Optimized rhTPO treatment|The study in a 2:1 randomization ratio (117 subjects to rhTPO group).
89587003|NCT05583838|Active Comparator|Eltrombopag treatment|The study in a 2:1 randomization ratio (58 subjects to Eltrombopag group).
89587004|NCT05577390|Experimental|Intraneural Facilitation Therapy Treatment Group|Subjects will receive nine 60-minute INF® Therapy Treatments during sessions 2 through 10. INF® Therapy is a non-invasive treatment that helps eliminate pain, tingling, numbness, and other symptoms that come with neuropathy.
89587005|NCT05577390|Experimental|Standard Physical Therapy Treatment Group|Subjects will receive nine 60-minute standard physical therapy treatments during sessions 2 through 10.
89587006|NCT05577182|Experimental|Part 1: Dose Escalation|INCA32459 will be administered at a protocol defined starting regimen intravenously. Subsequent dose regimens will be determined during study conduct.
89587007|NCT05577182|Experimental|Part 2: Dose Expansion Cohort Disease Group 1|INCA32459 will be administered at the recommended dose or doses for expansion (RDE[s]) for unresectable or metastatic melanoma.
89587008|NCT05577182|Experimental|Part 2: Dose Expansion Cohort Disease Group 2|INCA32459 will be administered at the recommended dose or doses for expansion (RDE[s]) for recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) that is PD-L1 positive.
89587009|NCT05573698|Experimental|Multiple Dose: DT-216|Participants will be administered multiple doses of DT-216
89587010|NCT05573698|Placebo Comparator|Multiple Dose: DT-216 matching placebo|Participants will be administered multiple doses of placebo
89030311|NCT01243242|Experimental|METADOXINE|Eligible subjects will be randomly assigned to receive MG01CI (1,400 mg)
89030312|NCT01243242|Placebo Comparator|Placebo|Eligible subjects will be randomly assigned to receive Placebo (1,400 mg)
89030313|NCT01242813|Experimental|Canakinumab|This was an open-label, single treatment arm, multicenter study of monthly canakinumab 150 mg (2 mg/kg for patient ≤ 40 kg) subcutaneous injections in patients with active recurrent or chronic TRAPS.
89030314|NCT00517491|Experimental|1|
89030315|NCT00517569|Experimental|1|GX-12 combined with HAART
89030316|NCT00506363|Experimental|A|pulsed dye laser and dynamic cooling device on the day of suture removal
89030317|NCT00506363|Active Comparator|B|pulsed dye laser and dynamic cooling device 2 months after suture removal
89030318|NCT00506363|Sham Comparator|C|dynamic cooling device
89030319|NCT01242111|Experimental|BMN 110|
89030320|NCT04517591|Experimental|Take a STAND for health|A newly developed personalized intervention focused on replacing sedentary time with light-(or very light-) intensity physical activity
89030321|NCT04517591|No Intervention|Control|The control group will receive all regular medical care and advice on healthy lifestyle including the promotion of recommended physical activity levels and health nutrition.
89030322|NCT04517630||Severe pneumoniae|Evaluate the progression to AKI during first 30 days of recruitment
89030323|NCT04517201|Experimental|AI group|iGMS+iNCDSS group (Artificial intelligence assisted insulin titration system group)
89587011|NCT05571449|Experimental|Experimental group|Planning of tibial plateau fracture osteosynthesis by using a three-dimensional model of the fracture.
89587012|NCT05571449|Other|Control group|Standard planning of tibial plateau fracture osteosynthesis (by plain radiography and computed tomography imaging).
89587013|NCT05569512|Experimental|Uproleselan with pre-transplant conditioning|"Participants will receive IV uproleselan on day -8 prior to stem cell transplant. Uproleselan will be administered IV twice daily from day -7 through day -2.~Participants will also receive a standard pre-transplant conditioning regimen with fludarabine, clofarabine and busulfan. Each of these 3 drugs will be administered IV once daily from day -7 through day -4."
89587014|NCT05566470||Control Group|1. Healty adults aged between 30-65 years old who do not have any pathology related to the shoulder joint and have not undergone surgery and being a volunteer to participate in the study.
89587015|NCT05566470||Patient Group|"Individuals between 30-65 years old who have been diagnosed with massive rotator cuff tear,~At least 6 months have passed after the surgery,~In the last 6 months, patients have not undergone shoulder surgery except for rotator cuff tear surgery,~Arthroscopic surgical method was performed by Prof. Dr. Gazi Huri,~The absence of another lesion involving the shoulder joint, such as SLAP (Superior Labrum Anterior Posterior), recurrent shoulder dislocation, arthroplasty, except for massive complete tear in the patient will be included in the study"
89587016|NCT05564325|Experimental|Deflectable guidewire|
89587017|NCT05564325|Active Comparator|Standard of care guidewire|
89209746|NCT04019639|Experimental|CG Paste+EasyFoam|"The subjects assigned to the test group through random assignment will receive the wound treatment by applying CG Paste and EasyFoam. CG Paste is a medical device currently marketed in CGBio.It is a free-flowing, acellular allogeneic dermis processed from human tissue skin, and then granulated and homogenized. This increases the water content and viscosity of the micronized ADM particles mixed with the gelatin sol carrier to protect the wound area and maintain the wet environment by applying to the desired wound area.It contains collagen, elastin and various growth factors in the dermis and has excellent tissue compatibility compared to the heterogeneous or synthetic material, so that the immune rejection is hardly observed in the graft site.~It also contains collagen, elastin, fibronectin, laminin, and proteoglycans, which are components of the human skin, to help the interaction between normal cells and extracellular matrix."
89209747|NCT04019639|Active Comparator|EasyFoam|"Subjects randomly assigned to the control group receive EasyFoam treatment for wound healing.~The foam has excellent moisture permeability, absorbs a large amount of exudates, and prevents scar formation to minimize scar formation."
89209748|NCT00818558|Experimental|1|stade IA [pT1 N0M0]
89209749|NCT00818558|Experimental|2|stade IB [pT2 N0M0]
89209750|NCT00818558|Experimental|3|stade IIA [pTI N1M0]
89209751|NCT00818558|Experimental|4|stade IIB [pT2 N1 et T3N0M0]
89209752|NCT00818558|Experimental|5|control groupe [tabagic subject]
88975371|NCT00071916||African American|Adult African American participants with compensated chronic hepatitis C who have not been previously been treated with interferon and/or ribavirin.
88975372|NCT00071916||Caucasian|Caucasian participants with compensated chronic hepatitis C who have not been previously been treated with interferon and/or ribavirin.
88975373|NCT00410683|Experimental|Radiotherapy|Beginning within 4-8 weeks after surgery or 2-6 weeks after chemotherapy, patients undergo adjuvant thoracic conformal radiotherapy once daily, 5 days per week, for 6 weeks.
88975374|NCT00410683|Active Comparator|No radiotherapy|Patients do not undergo adjuvant thoracic radiotherapy. After completion of study therapy, patients are followed periodically for up to 10 years.
88975375|NCT00038831|Experimental|Chemotherapy + ATG + Stem Cell Infusion|
88975376|NCT00410722|Experimental|Full-Dose Nut|Subjects will be given tree nuts (almonds, hazelnuts, pistachios, macadamia nuts, pecans, walnuts, and cashews) and peanuts (at a predetermined amount to consume based on their recommended energy intake), and advised to follow a diabetic diet.
88975377|NCT00410722|Experimental|Half-Dose Nut|Subjects will be given tree nuts (almonds, hazelnuts, pistachios, macadamia nuts, pecans, walnuts, and cashews) and peanuts as well as the control supplement (wheat bran muffin)(at a predetermined amount to consume based on their recommended energy intake), and advised to follow a diabetic diet.
88975378|NCT00410722|Active Comparator|Control|Subjects will be given a control supplement (wheat bran muffin)(at a predetermined amount to consume based on their recommended energy intake), and advised to follow a diabetic diet.
88975379|NCT00038870|Experimental|Dendritic Cell Activated Lymphocytes|
89209753|NCT00818558|Experimental|6|Control group B [intervention for a pulmonaire non tumoral pulmonary lesion]
89209754|NCT00815204||posttraumatic stress disorder|
89209755|NCT00815204||history of trauma exposure but no PTSD|
89209756|NCT00815204||healthy controls|
89209757|NCT00721955|Placebo Comparator|Inhaled Placebo|Inhaled Staccato Placebo, may repeat after 2 hours x 2
89587018|NCT05561153||Control group|It will consist of healthy individuals between the ages of 18-40 who do not have any pathology related to the knee joint and have not undergone surgery.
89587019|NCT05561153||Study group|Male and female individuals between the ages of 18-40 who were referred to Hacettepe University, Faculty of Physical Therapy and Rehabilitation, Musculoskeletal Physiotherapy and Rehabilitation Department with the diagnosis of patellofemoral pain will be included in the study.
89587020|NCT05559697|Experimental|Prospera Flex Incisional NPWT System|Sponsor incisional dressing connected to sponsor disposable negative pressure device placed on knee for seven days.
89587021|NCT05559697|Active Comparator|Prevena Incisional NPWT System|Market leader incisional NPWT system (includes the device and dressing) placed on opposite knee for seven days.
88975380|NCT00071994|Experimental|Treatment (gefitinib)|Patients receive oral gefitinib daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
88975381|NCT00203749|Experimental|1|Intervention communities will receive the community-based VCT intervention community mobilization, mobile VCT, and post-test support services), as well as standard clinic-based VCT
88975382|NCT00203749|Active Comparator|2|Comparison communities will receive standard clinic-based VCT
88975383|NCT00203788|Experimental|1|Individual Placement and Support Plus Workplace Fundamentals Module
88975384|NCT00203788|Active Comparator|2|Brokered Vocational Rehabilitation
89209758|NCT00721955|Experimental|Inhaled Loxapine 5 mg|Inhaled Staccato Loxapine 5 mg, may repeat after 2 hours x 2
89209759|NCT00721955|Experimental|Inhaled Loxapine 10 mg|Inhaled Staccato Loxapine 10 mg, may repeat after 2 hours x 2
89209760|NCT00585689|Experimental|Neoadjuvant ABI-007, Carboplatin, and Gemcitabine|Neoadjuvant ABI-007 (260 mg/m^2) on day 1, Carboplatin (Target AUC [Area under the curve] =5) on day 1, and Gemcitabine (800 mg^m2) on days 1 and 8, every 21 days.
89587022|NCT05556447|Experimental|Internet delivered pain coping|8 week online pain coping skills training program with weekly, 45-minute modules guided by an automated coach
89587023|NCT05553028|Experimental|Robot assisted surgery|Patient operated for thoracic and/or lumbar spine arthrodesis with robot assistance Mazor
89587024|NCT05553028|Active Comparator|Conventional surgery|Patient operated for thoracic and/or lumbar spine arthrodesis with conventional surgery
89209761|NCT00721799|Experimental|FLT PET scan|"Subjects receive 2 18F-Fluorothymidine PET scans~Scan 1 at baseline (within 30 days prior to the start of chemotherapy and radiation therapy)~Scan 2 between fraction 5 and 6 of radiation therapy (after 10 Gray of radiation)"
89209762|NCT00815282|Other|Patients|patients were girls aged 15 to 18 immunised with the HPV vaccine according to dutch vaccination guidelines
89209763|NCT02591693|Experimental|Caregiver Training|"Three home visits by a specialist occupational therapist, each lasting 1-2 hours. Assessment and training to confidently achieve up to three goals relating to practical activities of daily living identified by patient and caregiver.~On-going usual care from multi-professional team at hospice."
89209764|NCT02591693|No Intervention|Usual Care|On-going usual care from multi-professional team at hospice.
89209765|NCT00818636|Experimental|Expressive Writing|In addition to attending group therapy as usual, participants write about their feelings about an issue of their choosing three times during a two week period for at least 20 minutes each time.
89209766|NCT00818636|Active Comparator|Treatment as Usual|Participants attend group therapy as usual only.
89587025|NCT05548972|Other|G7 Dual Mobility with Vivacit-E polyethylene bearing in primary THA|Subjects in need of a total hip arthroplasty who meet inclusion/exclusion criteria (anticipated enrollment: 60)
89587026|NCT05548972|Other|G7 Dual Mobility with Vivacit-E polyethylene bearing in revision (total) hip arthroplasty|Subjects in need of a revision (total) hip arthroplasty who meet inclusion/exclusion criteria (anticipated enrollment: 119)
89587027|NCT05548972|Other|G7 Dual Mobility with Longevity polyethylene bearing in primary THA|Subjects in need of a total hip arthroplasty who meet inclusion/exclusion criteria(anticipated enrollment: 60)
89587028|NCT05548972|Other|G7 Dual Mobility with Vivacit-E Longevity bearing in revision (total) hip arthroplasty|Subjects in need of a revision (total) hip arthroplasty who meet inclusion/exclusion criteria (anticipated enrollment: 119)
89587029|NCT05547087|Experimental|Group 1: VN-0200 low dose|Healthy elderly subjects will be randomized to receive intramuscular injection of low dose of VAGA-9001a.
89587030|NCT05547087|Experimental|Group 2: VN-0200 low dose|Healthy elderly subjects will be randomized to receive intramuscular injection of low dose of VAGA-9001a adjuvanted with low dose of MABH-9002b.
88975385|NCT00072033|Active Comparator|Arm A|Docetaxel and Cisplatin chemo- and radiochemotherapy followed by surgery
88975386|NCT00203905|Active Comparator|A|Hydroxyurea at 500 mg PO q 12 hours x 6 days (11 total doses); Infusion of 5-FU (600 mg/m2/day x 5 days [120 hours]
89587031|NCT05547087|Experimental|Group 3: VN-0200 low dose|Healthy elderly subjects will be randomized to receive intramuscular injection of low dose of VAGA-9001a adjuvanted with medium dose of MABH-9002b.
89587032|NCT05547087|Experimental|Group 4: VN-0200 low dose|Healthy elderly subjects will be randomized to receive intramuscular injection of low dose of VAGA-9001a adjuvanted with high dose of MABH-9002b.
89587033|NCT05547087|Experimental|Group 5: VN-0200 medium dose|Healthy elderly subjects will be randomized to receive intramuscular injection of medium dose of VAGA-9001a.
88975387|NCT00203905|Experimental|B|Bevacizumab: 10 mg/kg will be given as a 90-minute infusion
88975388|NCT00203944||international adopted infants|international adoptees making their first visit to international adoption clinic
88975389|NCT00203944||Control infants|
88975390|NCT00204022|Experimental|1|Mycophenolate mofetil (target dose 2g/day)
88975391|NCT00204022|Active Comparator|2|Azathioprine (target dose 2mg/kg/day)
88975392|NCT00204061|Placebo Comparator|supportive management|needs-focused, unspecific supportive management
88975393|NCT00204061|Experimental|amisulpride|24 months amisulpride 50 to 800 mg, needs-focused, unspecific supportive management.
88975394|NCT02966652|Active Comparator|Testosterone undecanoate|Cohort 1: single dose of 120 mg (3 x 40 mg) DITEST followed by a single dose of 80 mg (2 x 40 mg) testosterone undecanoate or a single dose of 80 mg (2 x 40 mg) testosterone undecanoate followed by single dose of 120 mg (3 x 40 mg) DITEST. The two treatments are separated by a minimum of a 7-day washout period, with both treatments given in the fed state.
88975395|NCT02966652|Experimental|DITEST|Cohort 2: single dose of 200 mg (5 x 40 mg) DITEST (fed) followed by a single dose of 200 mg DITEST (fasted) or a single dose of 200 mg DITEST (fasted) followed by single dose of 200 mg (5 x 40 mg) DITEST (fed). The two treatments are separated by a minimum of a 7-day washout period.
88975396|NCT00039026|Experimental|AC2993 5 mcg (0.02 mL)|Placebo, then AC2993 5 mcg, then AC2993 5 mcg
88975397|NCT00039026|Experimental|AC2993 10mcg (0.04 mL)|Placebo, then AC2993 5 mcg, then AC2993 10 mcg
88975398|NCT00039026|Placebo Comparator|Placebo 0.02 mL|Placebo 0.02 mL, then Placebo 0.02 mL, then Placebo 0.02 mL
89587034|NCT05547087|Experimental|Group 6: VN-0200 medium dose|Healthy elderly subjects will be randomized to receive intramuscular injection of medium dose of VAGA-9001a adjuvanted with high dose of MABH-9002b.
89587035|NCT05547087|Active Comparator|Group 7: VN-0200 high dose|Healthy elderly subjects will be randomized to receive intramuscular injection of high dose of VAGA-9001a.
89587036|NCT05547087|Experimental|Group 8: VN-0200 high dose|Healthy elderly subjects will be randomized to receive intramuscular injection of high dose of VAGA-9001a adjuvanted with low dose of MABH-9002b.
89587037|NCT05547087|Experimental|Group 9: VN-0200 high dose|Healthy elderly subjects will be randomized to receive intramuscular injection of high dose of VAGA-9001a adjuvanted with medium dose of MABH-9002b.
89587038|NCT05547087|Experimental|Group 10: VN-0200 high dose|Healthy elderly subjects will be randomized to receive intramuscular injection of high dose of VAGA-9001a adjuvanted with high dose of MABH-9002b.
89587039|NCT05541159|Experimental|Group 1|Healthy control participants with normal renal function
89587040|NCT05541159|Experimental|Group 2|Mild renal impairment
89587041|NCT05541159|Experimental|Group 3|Moderate renal impairment
88975399|NCT00039026|Placebo Comparator|Placebo 0.04 mL|Placebo 0.02 mL / Placebo 0.02 mL / Placebo 0.04 mL
88975400|NCT00204412|Experimental|1|flax lignan
88975401|NCT00204412|Placebo Comparator|2|placebo
88975402|NCT00204529|Experimental|PegIFN|pegylated interferon-alpha-2a
88975403|NCT00204529|Active Comparator|IFN|interferon-alpha-2a
88975404|NCT00039104|Experimental|Arm I (rebimastat, zoledronic acid)|Patients receive zoledronate IV over at least 15 minutes on day 1 and oral BMS-275291 daily on days 1-28.
89587042|NCT05541159|Experimental|Group 4|Severe renal impairment
89587043|NCT05539937||Patient with percutaneous aortic valve replacement via the transfemoral approach|
89587044|NCT05536804|Experimental|Tirzepatide|Tirzepatide administered subcutaneously (SC)
89587045|NCT05536804|Placebo Comparator|Placebo|Placebo administered SC
89587046|NCT05534581|Active Comparator|Arctic Front Cryoballoon (Medtronic)|Pulmonary vein isolation using the Arctic Front Cryoballoon (Medtronic)
89587047|NCT05534581|Active Comparator|Pulsed Field Ablation (FARAPULSE)|Pulmonary vein isolation using the FARAPULSE PFA system (Boston Scientific)
89587048|NCT05514717|Experimental|XMT-2056|XMT-2056 alone (monotherapy)
89587049|NCT05511324|Other|Baseline Assessment|"Participants will be asked to complete a baseline assessment of questionnaires that will ask:~Demographic information (such as your age, sex, and race)~Psychological and physical health"
89587050|NCT05511324|Other|Caregiver Intervention Sessions|Caregiver will take part in 4 caregiver intervention sessions. The first 2 sessions will take place in the Simulation Center at the hospital when you are scheduled for treatment or a follow-up appointment. The remaining 2 sessions will be done remotely using a videoconference platform (such as Zoom) and will focus on discussing your caregiver's role and experiences and suggesting coping and self-care strategies.
89587051|NCT05502718|Active Comparator|Study Group|The patients in the study group will be given stretching, strengthening, breathing and rhythmic coordination exercises for the muscles involved. (Personalized exercise program)
89587052|NCT05502718|Placebo Comparator|Control Group|The patients in the control group will be given only breathing and rhythmic coordination exercises.
89587053|NCT05494736|Experimental|Panel A: MK-8527 1.0 mg|Participants receive a single oral dose of MK-8527 1.0 mg.
89587054|NCT05494736|Experimental|Panel B: MK-8527 0.5 mg|Participants receive a single oral dose of MK-8527 0.5 mg.
89587055|NCT05494736|Experimental|Panel C: MK-8527 0.25 mg|Participants receive a single oral dose of MK-8527 0.25 mg.
88975405|NCT00039104|Experimental|Arm II (zoledronic acid)|Patients receive zoledronate as in Arm I.
88975406|NCT00204568|Active Comparator|1|Adriamycin mono
88975407|NCT00204568|Experimental|2|Trofosfamide
88975408|NCT00072150|Experimental|Treatment (bortezomib)|"Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Patients with a solitary site of disease (i.e., lung or nodal metastases) and who have a partial response (PR) may be considered for surgical resection. Patients with a PR with residual disease after salvage surgery are eligible to continue study therapy. Patients who achieve a complete response, either through resection or bortezomib therapy, receive 2 additional courses of study therapy."
88975409|NCT00039182|Experimental|Treatment (erlotinib hydrochloride)|Patients receive oral erlotinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88975410|NCT04730661|No Intervention|Conventional arm|For the patients enrolled in this conventional arm, the decision of hospitalisation or discharge will be taken with usual criteria (pulsed oxygen saturation (SpO2) in room air <92% and respiratory rate> 22/min, respiratory rate> 30/min, Blood gas hypoxemia, decompensation of comorbidity, home monitoring not possible, other intercurrent pathology requiring hospitalization, several risk factors for COVID infection requiring hospitalization in intensive care (age> 65y, hypertension complicated by a cardiovascular event, chronic cardiovascular disease, unbalanced diabetes with complications, chronic respiratory disease (excluding well-controlled asthma), chronic renal failure dialysis, obesity, progressive cancer under treatment, congenital or acquired immunosuppression)
88975411|NCT04730661|Experimental|Interventional arm|For the patients enrolled in this interventional arm, the decision of hospitalisation or discharge will be taken with usual criteria and the result of Sit to Stand Test.
88975412|NCT00204763|Active Comparator|2|Solid state catheter
88975413|NCT00204763|Experimental|A|
89030324|NCT04517201|Active Comparator|Control group|iGMS+routine treatment group (Physicians decided insulin titration group)
89030325|NCT01241604|Active Comparator|Respironics BiPAP S/T|Control Arm using Respironics BiPAP S/T
89030326|NCT01241604|Active Comparator|Respironics BiPAP Auto SV3|Treatment arm using Respironics BiPAP Auto SV3
89030327|NCT01241292|Experimental|BMS-901608 (Elotuzumab) 10mg|
89587056|NCT05494736|Experimental|Panel D: MK-8527 0.25 mg|Participants receive a single oral dose of MK-8527 0.25 mg.
89587057|NCT05492773|Experimental|Micro-osteoperforations|Experimental: Micro-Osteoperforations Technique(MOPs) Experimental: Micro-Osteoperforations Technique(MOPs) Surgery will be performed to the lower anterior bony segment of the lower jaw in order to accelerate tooth movement.
89587058|NCT05492773|Experimental|Clear aligner|Traditional treatment The patients in this group will be receive treatment with the traditional clear aligners technique without any surgical procedure.
89587059|NCT05490030|Experimental|Group 1 (control)|Healthy control participants with normal hepatic function
89030328|NCT01241292|Experimental|BMS-901608 (Elotuzumab) 20mg|
89030329|NCT00517686|Experimental|1|The study will use automated databases and PHASE information systems to identify patients and incorporate feedback on a monthly basis into the ongoing reports used by program staff at facilities randomized to this intervention arm (n=4).
89030330|NCT00517686|No Intervention|2|Usual care facilities (n=4) will continue to use current PHASE reports that include information on recent risk factor levels and current use of selected medications but no treatment intensification information, and no information on medication adherence.
89030331|NCT00517725|Active Comparator|Carvedilol|
89587060|NCT05490030|Experimental|Group 2 (score 5-6)|Mild hepatic impairment: Child-Pugh A
89587061|NCT05490030|Experimental|Group 3 (score 7-9)|Moderate hepatic impairment: Child-Pugh B
89587062|NCT05490030|Experimental|Group 4 (score 10-15)|Severe hepatic impairment: Child-Pugh C. This group may be opened if allowed by the results of the interim analysis of the Groups 1 to 3.
89030332|NCT00517725|Active Comparator|Bisoprolol|
89030333|NCT00517725|Active Comparator|Nebivolol|
89030334|NCT04512248|Experimental|Quit and Stay Quit Monday Model|
89030335|NCT04512248|No Intervention|Usual Care|
89587063|NCT05481996|Experimental|App-Based Pain Education and Exercise|Patients allocated to the experimental group will receive a login and password for individual access to the smartphone app designed for the study. The app's content for this group will include three components: 1) a physical exercise program of 8 weeks; 2) weekly messages; and 3) an online booklet. The exercise component will include 8 weeks of training, with two sessions per week of core strengthening exercises. The app will provide illustrations, with animated images (GIFs), descriptions and audios of how to perform each exercise. The message component will provide eight messages (one per week), which will have their contents taken from the online booklet. Messages will include information about the benefits of exercise, motivation, and positive messages about coping with pain. The online booklet will contain general information about self-management of chronic pain, including pain education, advice on healthy lifestyle and sleeping habits and promotion of exercises.
89587064|NCT05481996|Active Comparator|Online Booklet|Patients allocated to the control group will receive a login and password for individual access to the smartphone app designed for the study. The app's content for this group will include two components: 1) an online booklet; and 2) weekly messages. The online booklet will contain general information about self-management of chronic pain, including pain education, advice on healthy lifestyle and sleeping habits and promotion of exercises. The message component will provide eight messages (one per week), which will have their contents taken from the online booklet. Messages will include information about the benefits of exercise, motivation, and positive messages about coping with pain.
89587065|NCT05481112|Experimental|XR-B Induction at Admission|"Participants will initiate extended-release buprenorphine (XR-B) treatment at the time of admission. XR-B will be continued monthly from the time of induction to the day of release (up to 6 months), and up to 3 monthly injections will be offered in the community following release.~Dosing: XR-B is available in two doses, 300mg and 100mg. Study clinicians will generally adhere to FDA-labeling on XR-B dosing, which recommends two months of 300-mg doses followed by maintenance doses of 100-mg monthly."
89587066|NCT05481112|Experimental|XR-B Induction at Pre-Release|"Participants will initiate extended-release buprenorphine (XR-B) treatment within 30 days of release. Participants will receive at least one XR-B monthly injection prior to release, and XR-B will be continued monthly from the time of induction to the day of release. Up to 3 monthly injections will be offered in the community following release.~Dosing: XR-B is available in two doses, 300mg and 100mg. Study clinicians will generally adhere to FDA-labeling on XR-B dosing, which recommends two months of 300-mg doses followed by maintenance doses of 100-mg monthly."
89587067|NCT05476614|Experimental|Social robot-instructed yoga group|A socially assistive robot will be programmed to instruct 10-14 yoga postures for a group of 20-25 older adults. The yoga session will also include meditation and centering exercises.
89587068|NCT05476614|Active Comparator|Human-instructed yoga group|A human yoga instructor will lead 10-14 yoga postures for a group of 20-25 older adults. The yoga session will also include meditation and centering exercises.
89587069|NCT05472818|Active Comparator|CUD Group|Participants will be scanned using anatomical magnetic resonance imaging (MRI) and PET. All participants will receive two PET scans, 4 weeks apart. CUD participants will be asked to abstain from cannabis for the 4 week period.
89587070|NCT05472818|Active Comparator|Healthy Controls|Participants will be scanned using anatomical magnetic resonance imaging (MRI) and PET. All participants will receive two PET scans, 4 weeks apart.
89587071|NCT05471141|Experimental|Group 1|To receive intervention during the phase 1 and will receive nothing during the phase 2, will complete the measure at the end of phase 2 as the follow-up
89587072|NCT05471141|No Intervention|Group 2|To serve as the control during phase 1 and receive intervention during the phase 2
89587073|NCT05468645|Experimental|[14C]Hemay005|
89587074|NCT05460520|Sham Comparator|Group 1: VOR readaptation with full-field OKS|This group to undergo VOR readaptation with full-field OKS. Groups 1 will be treated with stationary OKS (sham). (Group 1, n=50).
89587075|NCT05460520|Sham Comparator|Group 2: VOR readaptation with VR googles|This group to undergo VOR readaptation with VR googles. Groups 2 will be treated with stationary OKS (sham). (Group 2, n=50)
89587076|NCT05460520|Active Comparator|Group 3: Supplemental VOR habituation|This group to undergo VOR readaptation with full-field OKS combined with a habituation protocol. (Group 3, n=30)
89587077|NCT05460520|Active Comparator|Group 4: Visual desensitization treatment|This group to undergo VOR readaptation with full-field OKS combined with visual desensitization protocol. (Group 4, n=30)
89587078|NCT05460520|Active Comparator|Group 5: Treatment of gravitational pull with OKS with full-field setting|This group with phantom sensation dominated by gravity pull. This group will undergo OKS in a full-field (Group 5, n=20) .
88975414|NCT04730310||Regional Anesthesia (RA)|"RA~Includes spinal, epidural, peripheral nerve block, excludes local infiltration (unlikely that any major open revascularization can be done under local)~Defined as: NSQIP Principal (ANESTHES) or additional (ANESTHES_OTHER) anesthesia technique = regional, spinal, epidural, or MAC (in NSQIP RA/Spinal/Local + MAC are coded as MAC; while this includes local + MAC, it would be unlikely that local anesthesia would be sufficient for open revascularization)"
88975415|NCT04730310||General Anesthesia (GA)|"GA~Defined as: NSQIP Principal or additional anesthesia technique = general~Since GA is selected as the principal anesthetic technique by default when multiple techniques are present, GA + RA could potentially have been coded as GA if the optional variable of additional anesthesia technique is not filled in, leading to differential misclassification of patients with GA + RA (most likely epidural and peripheral nerve block) in the GA group."
88975416|NCT00039338|Experimental|Chemotherapy followed by surgery|neoadjuvant chemotherapy (Cisplatin) followed by surgery (radial hysterectomy)
88975417|NCT00039338|Active Comparator|Radio-chemotherapy|Concomitant radiotherapy (external radiotherapy combined with external boost or brachytherapy) and chemotherapy (cisplatin)
89587079|NCT05460520|Active Comparator|Group 6: Treatment of gravitational pull with OKS with VR setting|This group with phantom sensation dominated by gravity pull. This group will undergo OKS in a VR setting (Group 6, n=20).
89587080|NCT05452252||study group|adolescents with idiopathic scoliosis
89587081|NCT05452252||control group|healthy individuals
88975418|NCT00204997|Experimental|1|Laparoscopic Ovarian Transposition
89030336|NCT04516889|Experimental|Intervention|The intervention arm will undergo the modified sutured SFIOL technique with double Prolene sutures instead of a single Prolene suture
89030337|NCT02276261|Experimental|Vertical|Vaginal cuff closure performed in a vertical manner.
89030338|NCT02276261|Active Comparator|Horizontal|Vaginal cuff closure performed in a horizontal manner.
89030339|NCT01240863|Placebo Comparator|Placebo|Participants were administered hydrocodone ER tablets at dosages of 15, 30, 45, 60, or 90 mg every 12 hours at the dosage deemed successful for managing their pain during the titration period. During the treatment period, participants were administered placebo tablets every 12 hours that matched the dosage deemed successful for managing their pain during the titration period. A step-wise, double-blind schedule to tamper off active drug was implemented during the first 2 weeks of the 12-week, double-blind, placebo-controlled treatment period to reduce the risk of withdrawal effects in participants randomly assigned to placebo.
89587082|NCT05448365|Active Comparator|EGCG, Vit D, DCI, Vit B6|Women with uterine fibroids randomized to treatment group
89587083|NCT05448365|Placebo Comparator|Placebo|Women with uterine fibroids randomized to placebo group
89587084|NCT05443711||obesity|Patients with obesity attended in the High-Risk Obesity clinic of the Complejo ASistencial Universitario de León, 50-60 years-old
89587085|NCT05443711||control|control group of healthy people of the same age group without obesity or cardiovascular risk factors that will be selected among volunteers from the CAULE staff. and University of Leon
89587086|NCT05436366|Experimental|Soleus Loading Response Experimental|Participants in this one arm will be administered the soleus loading response protocol by applying an ankle joint rotation during treadmill walking
89587087|NCT05434312|Experimental|TGRX-678|Subjects to be treated with the investigational drug TGRX-678
89587088|NCT05427162|Experimental|Prostacyclin Receptor Agonist|Participants in Cohort 1-7 will receive multiple doses of prostacyclin receptor agonist of formulation 1 in treatment period 1, followed by a single dose of various other formulations (formulation 2, 3, and 4) in treatment period 2. Cohort 7 will be optional. Doses in Cohorts 4, 5, 6 and cohort 7 will be based on PK, safety and tolerability data of previous 3 cohorts (preceding cohorts).
89587089|NCT05418218||Migraine|Patients with migraine (including vestibular migraine), including all types of migraine as defined by ICHD-3.
89587090|NCT05418218||Other Primary Headache Disorders|Patients with other primary headache disorders (excluding migraine), including all types of other primary headache disorders (such as Tension-Type Headache, Cluster Headache) as defined by ICHD-3.
89587091|NCT05418218||Vertigo|Patients with other vertigo disorders (excluding vestibular migraine).
89587092|NCT05418218||Secondary Headache Disorders|Patients with secondary headache disorders as defined by ICHD-3.
89587093|NCT05418218||Normal control|Normal people do not have headache and vertigo.
89587094|NCT05416658|Experimental|The Antipsychotic Medication Decision Aid (APM-DA) intervention clinics|Three pairs of comparable clinics (out of 22 clinics where OnTrackNY operates) based on the same region of the state and similar numbers of patients with similar demographic composition. One of each paired clinic is assigned to the intervention group by a blinded Co-I who will generate binary random variables.
89030340|NCT01240863|Experimental|Hydrocodone ER|Participants were administered hydrocodone ER tablets at dosages of 15, 30, 45, 60, or 90 mg every 12 hours at the dosage deemed successful for managing their pain during the titration period. During the 12-week, double-blind, placebo-controlled treatment period, participants randomly assigned to hydrocodone ER were administered tablets every 12 hours at the dosage deemed successful for managing their pain during the titration period.
89030341|NCT02275715|Experimental|Parent Training Program (PT-F)|Treatment group
89030342|NCT02275715|No Intervention|Waitlist|Control group in which parents randomized to this group will be offered the PT-F at the end of the 20 week study period to address their child's feeding issues.
89030343|NCT04517045|Sham Comparator|Conventional treatment group|Control the primary disease, prevent infection, reduce gastrointestinal decompression, and actively maintain organ function.
89030344|NCT04517045|Experimental|Conventional treatment plus L92 group|Conventional treatment combined with L92
89030345|NCT04517045|Experimental|Conventional treatment plus Dachengqi decoction group|Conventional treatment combined with Dachengqi Decoction
89030346|NCT04517045|Experimental|Conventional treatment plus Dachengqi decoction plus L92 group|Conventional treatment combined with L92 and Dachengqi Decoction
89030347|NCT02955485||Patients with chronic ankle instability|All patients that develop chronic ankle instability after an ankle sprain and reporting at the emergency department. Experiencing persisting complaints of instability for more than 6 months.
89030348|NCT02955485||Patients without chronic ankle instability|All patients that do not develop chronic ankle instability after an ankle sprain and reporting at the emergency department. Complaints resolve within 6 months.
89030349|NCT01240746|Active Comparator|Group 1: Licensed 2010-2011 TIV|Participants will receive the Licensed 2010-2011 Trivalent Influenza Vaccine containing the primary B strain.
89030350|NCT01240746|Experimental|Group 2: Investigational TIV|Participants will receive the Investigational Trivalent Influenza Vaccine containing the alternate B strain
89587095|NCT05416658|No Intervention|Treatment As Usual (TAU) clinics|The other clinic of each of the three pairs will be assigned to TAU.
89587096|NCT05413746|Experimental|Antioxidant dressing (active product)|"Wound bed debridement, Antioxidant dressing (active product) application in the wound bed, covered with secondary dressing.~Device: Reoxcare®"
89608655|NCT04140747||pregnant women undergoing C-section|"From 30 healthy, pregnant women giving vaginal birth, samples will be collected shortly before, during and after birth from maternal and newborn sites:~maternal blood, urine, stool, saliva, oral swabs, vaginal swabs; amniotic fluid, cord blood, colostrum, meconium, infant oral swabs"
89608656|NCT05582733|Experimental|Cervical spine manipulation|In spinal manipulation, the velocity, magnitude and direction of the impulse are controlled to encourage relaxation and comfort of muscle and connective tissue.
89608657|NCT05582733|Experimental|traction|aimed to relieve pressure on the spine
89587097|NCT05413707|Experimental|Fixation group|"Patients are placed in a prone position on the operating table. Fixation of the posterior malleolus fracture. Posterior, and/or lateral and medial malleolus fractures will be treated with open reduction and internal fixation. ORIF of the posteromedial fragment in Mason and Molloy type 2B with one or more screws, or plate, if it is displaced more than 2 mm. Deltoid ligament injuries are repaired if incarcerated between medial malleolus and talus. The posteromedial fragment in Mason and Molloy type 2B will be fixed with one or more screws, or plate, if this fragment is displaced more than 2 mm. A Tillaux-Chaput or Wagstaffe fragment is fixed with suture anchor, plate, screw or pin if displaced >2 mm depending on size and comminution of the fragment.~The syndesmosis is tested under fluoroscopy by lateralizing and then externally rotating the talus. If unstable it is fixed with one or two 3.5 mm cortical screws or a suture button."
89587098|NCT05413707|Active Comparator|Non-fixation group|"Patients are placed in a supine position on the operating table. No fixation of the PMF. The PMF is reduced by ligamentotaxis. Lateral and/or medial malleolus fractures will be treated with ORIF if present.~ORIF of the posteromedial fragment in Mason and Molloy type 2B with one or more screws, or plate, if it is displaced more than 2 mm.~Deltoid ligament injuries are repaired if incarcerated between medial malleolus and talus.~A Tillaux-Chaput or Wagstaffe fragment is fixed with suture anchor, plate, screw or pin if displaced >2 mm depending on size and comminution of the fragment.~The syndesmosis is tested under fluoroscopy by lateralizing and then externally rotating the talus. If unstable it is fixed with one or two 3.5 mm cortical screws or a suturebutton."
89587099|NCT05413616|No Intervention|Standard care|
89587100|NCT05413616|Experimental|FITFOOD lifestyle intervention|Lifestyle intervention consisting of both a nutritional and exercise intervention.
89587101|NCT05411536||high reinvestor group (HRG)|The participants were divided into two groups, the high reinvestor group (HRG) and the low reinvestor group (LRG), using the conventional median split of their scores on the MSRS-C (Chu & Wong, 2019; Mak et al., 2020).
89587102|NCT05411536||low reinvestor group (LRG)|The participants were divided into two groups, the high reinvestor group (HRG) and the low reinvestor group (LRG), using the conventional median split of their scores on the MSRS-C (Chu & Wong, 2019; Mak et al., 2020).
89587103|NCT05407987|Experimental|Iron Therapy Arm|500 or 1000mg of IV Ferric Derisomaltose in 100mL normal saline will be administered intravenously over 1 hour. Participants with bodyweight <50kg will receive 500mg, participants with bodyweight >50kg will receive 1000mg to ensure no patient exceeds the manufacturer's recommended dose of 20mg/kg bodyweight.
89587104|NCT05407987|Placebo Comparator|Placebo Arm|100mL of normal saline will be administered intravenously over 1 hour between 21 and 90 days preceding surgical intervention.
89587105|NCT05393284|Experimental|OPL-0401 Dose 1|Participants are randomized to OPL-0401 Dose 1 twice daily for 24 weeks
89587106|NCT05393284|Placebo Comparator|Placebo|Participants are randomized to matching Placebo twice daily for 24 weeks
89587107|NCT05390814|Experimental|PET-RMI|
89587108|NCT05388812|Experimental|Individual Placement and Support|The IPS model involves the following important domains: competitive employment, eligibility based on client choice of employment, integration of IPS and treatment team personalized counseling, rapid job search, systematic job development, and time-unlimited and individualized support.
89587109|NCT05388812|Active Comparator|Treatment As Usual Vocational Rehabilitation (TAU-VR)|TAU-VR Services may include 1) Compensated Work Therapy-Transitional Work (CWT-TW) assignment in a set-aside, minimum-wage, short-term job, typically in the VA setting (approximately 50% of the Veterans randomized to TW in past studies conducted by the investigators actually engaged in TW assignment) or 2) CWT-Community-Based Employment Services (CWT-CBES) which involves a community job search, placement in a competitive job, with limited follow-along support that typically ends after the Veteran is working in his/her first job
89587110|NCT05380219|Experimental|dual task strength training|The participants of this group will perform their training following the dual task described.
89587111|NCT05380219|Active Comparator|strength training|The participants of this group will perform the work of strengthening the upper limb in a conventional way.
88975419|NCT00039416|Experimental|Treatment (imatinib mesylate)|Patients receive oral imatinib mesylate once or twice daily on days 1-28. Courses repeat every 28 days for 12 months in the absence of disease progression or unacceptable toxicity.
88975420|NCT00205075||Case|
88975421|NCT00205075||Control|
88975422|NCT00205153|Experimental|TEAM Care|Intervention pharmacies implement 6-month TEAM program.
88975423|NCT00205153|No Intervention|Usual Care|"Control pharmacies provide usual care only."
88975424|NCT00039455|Experimental|Treatment (trastuzumab and alvocidib)|Patients receive trastuzumab (Herceptin) IV over 30-90 minutes on days 1, 8, and 15 followed by flavopiridol IV continuously over 24 hours on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
88975425|NCT00205270||Pre-transplant Vaccine|Cohort consists of individuals waiting for lung transplantation. Inactivated influenza vaccine will be administered intramuscularly annually.
88975426|NCT00205270||0-6 Months Post-transplant Vaccine|Cohort consist of individuals who have received lung transplants and received inactivated influenza vaccine 0-6 months post transplant.
89030351|NCT01240746|Experimental|Group 3: Investigational QIV|Participants will receive the investigational Quadrivalent Influenza Vaccine
88975427|NCT00205270||13-60 months Post-transplant Vaccine|Cohort consist of individuals who have received lung transplants and received inactivated influenza vaccine 13-60 months post transplant.
88975428|NCT00205270||Greater than 110 months Post-transplant Vaccine|Cohort consist of individuals who have received lung transplants and received inactivated influenza vaccine greater than 110 months post transplant.
88975429|NCT00205270||Healthy Controls|Healthy controls to measure normal immune response to the influenza vaccine
88975430|NCT00072462|Active Comparator|Anastrozole|
88975431|NCT00072462|Active Comparator|Tamoxifen|
88975432|NCT00205426|Experimental|Natrecor infusion|Nesiritide
88975433|NCT00205543|Experimental|1|suture palate after resection
88975434|NCT00205543|Experimental|2|suture one side of palate afer resection
88975435|NCT00205543|Experimental|3|no sutures in palate after resection
89587112|NCT05379504|Experimental|Self Management|"The 5A's Behavior Change Mode [39] is the framework for the self-management intervention. The five As will be addressed through the integration of the self-management intervention and the sensor system. There will be a minimum of four intervention sessions with each healthcare profession (OT, RN, and SW) for 12 visits per participant."
89587113|NCT05379504|Active Comparator|Health Education|Participant's randomized to the standard health education arm will receive the intervention at Month 1 and then months 3, 6, 9 and 12.
89587114|NCT05374798|Experimental|Heart Rate Variability-Biofeedback via Smartwatch Device Intervention|Participants will wear activity trackers equipped with continuous ambulatory physiological monitoring and geolocation. Ecological momentary assessment (EMA; 4 times daily plus optional event-triggered reports) of alcohol use, couple conflict including IPV, and affect will be completed via smartphone application for 28 days. During days 21-28, participants will also be prompted to complete a 10 minute self-administered HRV-B session at least once daily. Subjective usability, feasibility, and acceptability of HRV-B will be assessed.
89587115|NCT05373654|Experimental|Patients that have at least one year of follow-up since the procedure.|
89587116|NCT05367180|No Intervention|Reference Arm|no preventive action
89587117|NCT05367180|Experimental|Vivre avec le Soleil|"Use of existing validated program vivre avec le soleil"
89587118|NCT05367180|Experimental|Vivre avec le Soleil + program of MISOLRE association|"Use of existing validated program vivre avec le soleil associated with prevention awareness program of MISOLRE association"
88975436|NCT00039494|Experimental|Treatment (erlotinib hydrochloride, radiation, temozolomide)|Patients receive oral erlotinib once daily. After 1 week of erlotinib alone, patients also receive oral temozolomide once daily for 6 weeks and undergo concurrent radiotherapy 5 days a week for 6 weeks. After completion of radiotherapy, patients continue to receive erlotinib once daily alone in the absence of disease progression or unacceptable toxicity. Beginning 4 weeks after the completion of radiotherapy, patients also receive oral temozolomide once daily for 5 days. Temozolomide treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
88975437|NCT00206011|Experimental|1|
88975438|NCT00206011|Other|2|
88975439|NCT00072657|Experimental|1|Participants will partake in cognitive behavioral therapy for 12 weeks.
88975440|NCT00072657|Experimental|2|Participants will partake in tai chi chih for 12 weeks.
88975441|NCT00072657|Active Comparator|3|Participants will act as a control and attend educational sessions for 12 weeks.
88975442|NCT00399204|Active Comparator|Control|Metformin
88975443|NCT00399204|Experimental|Experimental|Pioglitazone
88975444|NCT00068328||Group 1|"Patients participate in interviews over 30-45 minutes at baseline, at 6 months, and at 1 and 2 years.~Patients are followed annually for at least 5 years."
88975445|NCT00411190|Experimental|Session 1|Subjects will receive 500 mg acetaminophen on Day 1, 400 mg ibuprofen on Day 2, 40 mg atorvastatin on Day 3.
88975446|NCT00411190|Experimental|Session 2|Subjects will be randomized to receive relacatib 60 mg or 120 mg from Day 1-14. On Day 15 subjects will receive 500 mg acetaminophen, 400 mg ibuprofen on Day 16 and 40 mg atorvastatin on Day 17 with usual dose of relacatib.
88975447|NCT00411229|Active Comparator|1|Capecitabine + Oxalipatin
88975448|NCT00411229|No Intervention|2|
88975449|NCT00068484|Experimental|Treatment (topotecan hydrochloride, bortezomib)|Patients receive topotecan IV over 30 minutes on days 1-5. Beginning with course 2, patients also receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
88975450|NCT00206596|Experimental|Arm 1|
88975451|NCT00206596|Placebo Comparator|Arm 2|
88975452|NCT00206635||Group 1|
88975453|NCT00206674|Experimental|Arm 1|
88975454|NCT00206674|Placebo Comparator|Arm 2|
89587119|NCT05367180|Experimental|Vivre avec le Soleil + program of MISOLRE association + sun protections|"Use of existing validated program vivre avec le soleil associated with prevention awareness program of MISOLRE association and with the distribution of caps, sunscreens and sunglasses"
89587120|NCT05362032|Experimental|Diagnostic (endorectal MRI, MRI-targeted biopsy)|Patients undergo endorectal MRI and transrectal MRI-targeted biopsy using the OmnEcoil device.
88975455|NCT02966769||Chemoradiation Group|Analyze overall survival in the group of patients treatment by Concurrent Radiotherapy (>/= 60 Gy) plus Platinum-based Chemotherapy
88975456|NCT02966769||Neoadjuvant treatment plus Surgery Group|Analyze overall survival in the group of patients treatment by Neoadjuvant Platinum-based Chemotherapy or Chemoradiation (Platinum-based plus >/= 45Gy) followed by Surgery
88975457|NCT00206713|Experimental|Arm 1|
88975458|NCT00206713|Placebo Comparator|Arm 2|
88975459|NCT00206752|Experimental|unilateral radiation therapy|definitive external beam radiation in the ipsilateral neck.
88975460|NCT00206830|No Intervention|Control-Blinded from Results|
88975461|NCT00206830|Experimental|Access to Results|
88975462|NCT00206947|Active Comparator|1|
88975463|NCT00206947|Placebo Comparator|2|
88975464|NCT00206986|Experimental|1|
88975465|NCT00206986|Experimental|2|
88975466|NCT00207064|Experimental|1|
88975467|NCT00207103|Experimental|1|
88975468|NCT00207103|Experimental|2|
88975469|NCT00207103|Experimental|3|
88975470|NCT00207103|Experimental|4|
88975471|NCT00207103|Experimental|5|
88975472|NCT00207103|Experimental|6|
88975473|NCT00207220||3|subjects with heart failure and normal ejection fraction non-diabetic hypertensive controls hypertensive diabetic controls normotensive controls
88975474|NCT00207259|No Intervention|Control|Standard weekly treatments with radiation oncologist and nurse. All control patients offered intervention at end of 8-week course of radiotherapy.
89587121|NCT05361902|Experimental|Intervention Arm|All included patients will be treated according to the treatment protocol: Adaptive radiotherapy according to UPRATE
89587122|NCT05361798|Experimental|1/Arm 1|De-escalating doses of M9241 if appropriate + SBRT
89587123|NCT05361798|Experimental|2/Arm 2a|Highest tolerated dose of M941+SBRT
89587124|NCT05361798|Experimental|3/Arm 2b|SBRT
89587125|NCT05359939|Other|Head-to-head comparison of two tracers: 18F-FDGal PET/CT, 18F-choline PET/CT|Diagnostic scan
89209767|NCT03954587||Artificial (HRT) Cycles|"Commence estradiol valerate (E2) 4mg from day 2 or 3 of period for 3 days~Increase E2 to 6mg on day 4 of E2 treatment, according to clinician discretion based on endometrial thickness.~Transvaginal scan throughout the HRT cycle to not only monitor endometrial development but to also exclude the presence of a dominant follicle on the ovaries.~Serial measurements of serum LH (luteinizing hormone), estradiol and progesterone levels.~Initial progesterone dose of 100mg at 22hrs (vaginal suppository) after ≥ 7 days and ≤ 16 days of estradiol administration when the minimal endometrial thickness achieved is 6mm with a trilaminar appearance.~Subsequently increase progesterone administration to 100mg vaginally three times daily. Continue E2 administration 6mg (3 tablets daily).~Embryo transfer is scheduled on the 5th full day of progesterone administration."
89209768|NCT03954587||Spontaneous natural cycles:|"Day 2 of menses and throughout patients' natural cycle scans to monitor follicular growth.~Measurements of serum LH, estradiol and progesterone levels to determine ovulation.~The LH surge will be considered to have begun when the concentration rises by 180% above the most recent serum value and continues to rise thereafter (Irani et al. 2017, Fatemi et al., 2010).~Day 1 after the LH rise, a decrease in estradiol concentration is identified. Twenty four hours later progesterone concentrations rise with a level of greater than or equal to 1.5ng/mL confirming ovulation (day 0) (Irani et al., 2017; Speroff et al.). This is considered as day 0 with initiation of vaginal progesterone 100mg at 22hrs that night. The following day (day 1) the patient increases progesterone administration to 100mg vaginally 8 hourly and continues until 7 weeks gestation as per clinic protocol. Embryo transfer is scheduled 5 days (day 5) following confirmation of ovulation (day 0)."
89209769|NCT03864692||Hypotension group|Parturients undergoing elective C/S under spinal anesthesia whose systolic arterial pressure drop below 80 mmHg or have symptoms of hypotension such as dizziness, nausea and vomiting during the procedure.
89209770|NCT03864692||Normotension group|Parturients undergoing elective C/S under spinal anesthesia whose systolic arterial pressure does not drop below 80 mmHg or have any symptoms of hypotension during the procedure.
89209771|NCT02593019|Experimental|AZD1775|AZD1775 175 mg BID per os every 12 hours (6 doses) administered days 1-3 the first week and then days 1-3 the 2nd week of 21 day cycle.
89587126|NCT05353335|Experimental|nighttime dosing of one anti-hypertensive medication|13 participants will be randomized to nighttime dosing of one anti-hypertensive medication. After 1 week, a repeat ABPM will be obtained. At 1 month from randomization, another ABPM will be obtained. Following this, there will be a 2-week washout period, during which all subjects will be on their usual anti-hypertensive regimen. A repeat ABPM will be obtained after the washout period. Next, the subjects will crossover to the opposite arm and an ABPM will be obtained after 1 week. A final ABPM will be obtained at 1 month after crossover.
89587127|NCT05353335|Active Comparator|remain on their current regimen|13 participants will be randomized to remain on their current regimen. After 1 week, a repeat ABPM will be obtained. At 1 month from randomization, another ABPM will be obtained. Following this, there will be a 2-week washout period, during which all subjects will be on their usual anti-hypertensive regimen. A repeat ABPM will be obtained after the washout period. Next, the subjects will crossover to the opposite arm and an ABPM will be obtained after 1 week. A final ABPM will be obtained at 1 month after crossover.
89587128|NCT05341700|Experimental|Endurance and Jumping Exercises|5 days of endurance treadmill running and 5 sets of 10 jumping exercises
89587129|NCT05341700|Active Comparator|Endurance Exercise Only|5 days of endurance treadmill running
89587130|NCT05338801|Experimental|Menthol-flavored e-cigarette|All participants will complete a lab visit where they will use menthol-flavored e-cigarette ad libitum for up to 60 minutes.
89587131|NCT05338801|Experimental|Tobacco-flavored e-cigarette|All participants will complete a lab visit where they will use tobacco-flavored e-cigarette ad libitum for up to 60 minutes.
89587132|NCT05331248|Experimental|LIA Household Training|This treatment arm is an 8-session training with a tailored schedule at the household level that targets couples at risk of domestic violence. The sessions are delivered by Community Health Volunteers: 1 Facilitator and 1 Community Agent. The training aims to raise awareness of GBV and social norms around domestic violence and is delivered at the household level in a private environment. Additionally, the intervention includes sessions on soft skills and conflict resolution. The session topics are: i) gender roles, beliefs and stereotypes; ii) violence, cultural patterns and human rights; iii) healthy relationships within the family; iv) good treatment between family members and self-care; v) Assertive communication; vi) resolution and conflict management; vii) resources for domestic violence cases; and viii) leadership and women's agency.
89587133|NCT05331248|Experimental|LIA Group Training|This treatment arm is an 4-session training delivered in gender-segregated groups at the village level that targets couples at risk of domestic violence in separate spaces. The sessions are delivered by Community Health Volunteers: 1 Facilitator and 1 Community Agent. The training aims to raise awareness of GBV and social norms around domestic violence and is delivered at the household in a private environment. The sessions topics are: i) gender roles, beliefs and stereotypes; ii) violence, cultural patterns and human rights; iii) healthy relationships within the family; iv) good treatment between family members and self-care; v) Assertive communication; vi) resolution and conflict management; vii) resources for domestic violence cases; and viii) leadership and women agency.
89587134|NCT05331248|Experimental|LIA Household and Group Training|This treatment arm combines LIA Household and Group training. Villages in this arm will first receive the 8-sessions household-level intervention, then the 4-sessions of village-level gender-segregated group intervention will follow. The sessions topics for both interventions are: i) gender roles, beliefs and stereotypes; ii) violence, cultural patterns and human rights; iii) healthy relationships within the family; iv) good treatment between family members and self-care; v) Assertive communication; vi) resolution and conflict management; vii) resources for domestic violence cases; and viii) leadership and women agency.
89587135|NCT05331248|Experimental|LIA Household Training + Leader Targeting|This treatment arm is an 8-session training with a tailored schedule at the household level that targets couples at risk of domestic violence. The sessions are delivered by Community Health Volunteers: 1 Facilitator and 1 Community Agent. The training aims to raise awareness of GBV and social norms around domestic violence and is delivered at the household level in a private environment. Additionally, the intervention includes sessions on soft skills and conflict resolution. The session topics are: i) gender roles, beliefs and stereotypes; ii) violence, cultural patterns and human rights; iii) healthy relationships within the family; iv) good treatment between family members and self-care; v) Assertive communication; vi) resolution and conflict management; vii) resources for domestic violence cases; and viii) leadership and women's agency. An additional village leader (e.g. village president) would be targeted with LIA's household training.
89587136|NCT05331248|Experimental|LIA Group Training + Leader Targeting|This treatment arm is an 4-session training delivered in gender-segregated groups at the village level that targets couples at risk of domestic violence in separate spaces. The sessions are delivered by Community Health Volunteers: 1 Facilitator and 1 Community Agent. The training aims to raise awareness of GBV and social norms around domestic violence and is delivered at the household in a private environment. The sessions topics are: i) gender roles, beliefs and stereotypes; ii) violence, cultural patterns and human rights; iii) healthy relationships within the family; iv) good treatment between family members and self-care; v) Assertive communication; vi) resolution and conflict management; vii) resources for domestic violence cases; and viii) leadership and women agency. An additional village leader (e.g. village president) would be targeted with LIA's group training.
89587137|NCT05331248|Experimental|LIA Household and Group Training + Leader Targeting|"This treatment arm combines LIA Household and Group training. Villages in this arm will first receive the 8-sessions household-level intervention, then the 4-sessions of village-level gender-segregated group intervention will follow. The sessions topics for both interventions are: i) gender roles, beliefs and stereotypes; ii) violence, cultural patterns and human rights; iii) healthy relationships within the family; iv) good treatment between family members and self-care; v) Assertive communication; vi) resolution and conflict management; vii) resources for domestic violence cases; and viii) leadership and women agency.~An additional village leader (e.g. village president) would be targeted with both LIA's household and group training."
89587138|NCT05331248|No Intervention|Control group|Villages in the control group will not receive any intervention.
89587139|NCT05329441||Study Participants|All depressed participants will undergo the same study procedures
89587140|NCT05324501|Experimental|Cohort A: MTX-110|Weekly dosing of MTX110 via CED until progression/ unacceptable toxicity.
89587141|NCT05324501|Experimental|Cohort B: MTX-110 with optional catheter repositioning|Weekly dosing of MTX110 via CED until progression. At progression, optional catheter repositioning may occur, followed by continued weekly dosing of MTX110 until next progression/ unacceptable toxicity.
89587142|NCT05311176|Experimental|Arm 1: HER-Vaxx in combination with chemotherapy (ramucirumab plus paclitaxel)|Patients who have received an immune checkpoint inhibitor (ICI) previously will exclusively be enrolled in Arm 1 treated with HER-Vaxx (IM) in combination with chemotherapy (ramucirumab plus paclitaxel)
89587143|NCT05311176|Experimental|Arm 2: HER-Vaxx in combination with pembrolizumab|Arm 2 will investigate the combination of HER-Vaxx plus pembrolizumab in patients who are naïve to ICI treatment including patients who have had chemotherapy only treatment after progression on trastuzumab. As the combination treatment has not been investigated, Arm 2 is planned to initiate with a safety run-in phase.
89587144|NCT05310734|Experimental|PK and Safety|A Single 6-hour Treatment, Pharmacokinetic and Safety Study of Natroba (spinosad) Topical Suspension 0.9% w/w in Subjects 1 Month to 3 Years 11 Months of Age with an Active Scabies Infestation.
89587145|NCT05310097|Experimental|Cognitive Processing Therapy + Memory Support (CPT + MS)|CPT + MS will involve the same treatment strategies as CPT while incorporating deliberate and frequent use of memory and learning support strategies. MS strategies are designed to enhance the memory of specific treatment points, defined as any insight, skill or strategy determined to be important for the patient to remember and/or implement. MS is not designed to enhance memory functioning generally, but rather improve the encoding, consolidation and retrieval of specific components of therapeutic learning.
88975475|NCT00207259|Experimental|Relaxation Therapy|Weekly relaxation therapy with PhD psychologist and home cognitive restructering practice
88975476|NCT00207259|Experimental|Reiki|Weekly Reiki therapy with a Reiki therapist, involves laying of the therapist's hands on the patient to rechannel energy, considered pleasant and calming
88975477|NCT00207688||Infliximab 5 mg/kg|This is an observational study which includes patients from primary studies C0168T37, C0168T46, C0168T72.
88975478|NCT00207688||Infliximab 10 mg/kg|This is an observational study which includes patients from primary studies C0168T37, C0168T46, C0168T72.
88975479|NCT00207688||Placebo|This is an observational study which includes patients from primary studies C0168T37, C0168T46, C0168T72.
88975480|NCT00072930|Active Comparator|1|MEDI-522 + Docetaxel + Prednisone + Zoledronic Acid (N=55)
88975481|NCT00072930|Other|2|Docetaxel + Prednisone + Zoledronic Acid (N=55)
88975482|NCT00424450||PAD patients|30 PAD patients
88975483|NCT00424606|Experimental|1|
88975484|NCT00424606|Experimental|2|
88975485|NCT00068874|Active Comparator|1|Educational comparison group
88975486|NCT00068874|Experimental|2|Group receiving coping intervention designed to enhance coping and psychological adjustment
88975487|NCT00068874|No Intervention|3|Comparison control group with no active intervention
88975488|NCT02962921|Experimental|Diabetic patients|"Diabetic patients were treated with insulin loads, left ventricle functional parameters were compared to those of healthy persons.~Metabolic indices of insulin effect: blood insulin levels, glucose disposal rates under insulin infusion, were compared to respective group of healthy persons, studied earlier at our institution Insulin LISPRO intravenous loading"
88975489|NCT00208078|No Intervention|Usual medical therapy|Usual CF care
88975490|NCT00208078|Experimental|Non-invasive ventilation|Pressure support ventilator (SAIME,AIROX)
89030352|NCT04513028|Experimental|Treatment|"All subjects will undergo 21 days of Pembrolizumab followed by 21 days of beta-glucan.~Pembrolizumab: 200 mg/100mL IV in three week intervals~Beta-glucan: 500mg (1 capsule) by mouth twice a day for 21 days"
89030353|NCT04516382|Experimental|Intravenous|PTG-300 Intravenous
89587146|NCT05310097|Active Comparator|Cognitive Processing Therapy (CPT)|CPT is a manualized, trauma-focused therapy for PTSD. Treatment consists of psychoeducation on the cognitive model of PTSD, identification of trauma-related stuck points (i.e. dysfunctional beliefs), and cognitive challenging techniques to help participants identify more realistic and adaptive ways of viewing their trauma, themselves, and the world.
89587147|NCT05304585|Experimental|Regimen M (positive mutation)|Patients receive vincristine IV on day 1 of each cycle and days 8 and 15 of cycles 2-4, 7-8, and 11-12 and dactinomycin IV over 1-5 minutes or 10-15 minutes on day 1 of cycles 2-5 and 8-14. Patients also receive cyclophosphamide IV over 60 minutes on day 1 of each cycle. Treatment repeats every 21 days for 12-13 cycles in the absence of disease progression or unacceptable toxicity. Patients may also undergo radiation therapy at cycle 5. Patients undergo CT scan, MRI, bone scan, PET scan and tumor biopsy throughout the study.
89587148|NCT05304585|Experimental|Regimen VA (VLR RMS)|Patients with VLR RMS receive vincristine intravenously (IV) on day 1 of each cycle and days 8 and 15 of cycles 1, 3, 5, and 7 and dactinomycin IV over 1-5 minutes or over 10-15 minutes on day 1 of each cycle. Treatment repeats every 21 days for 8 cycles in the absence of disease progression or unacceptable toxicity. Patients with MYOD1 or TP53 mutated tumors transition to Regimen M at cycle 2 (if mutation status is determined to be positive at week 3) or cycle 3 (if mutation status is determined to be positive after week 3). Patients undergo CT scan, MRI, bone scan, PET scan and tumor biopsy throughout the study.
89587149|NCT05304585|Experimental|Regimen VAC/VA (VL RMS)|Patients with LR RMS receive vincristine IV on day 1 of each cycle and days 8 and 15 of cycles 1-3. Patients also receive dactinomycin IV over 1-5 minutes or 10-15 minutes and cyclophosphamide IV over 60 minutes on day 1 of each cycle. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive vincristine IV on day 1 of each cycle and days 8 and 15 of cycles 5-7 and dactinomycin IV over 1-5 minutes or over 10-15 minutes on day 1 of each cycle. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients with MYOD1 or TP53 mutated tumors transition to Regimen M at cycle 2 (if mutation status is determined to be positive at week 3) or cycle 3 (if mutation status is determined to be positive after week 3). Radiation therapy (if needed) will be administered at cycle 5.Patients undergo CT scan, MRI, bone scan, PET scan and tumor biopsy throughout the study.
89587150|NCT05303311|Active Comparator|Bupivacaine group|Patients will be anesthetized by spinal anesthesia by intrathecal injection of 3 ml hyperbaric bupivacaine 0.5% alone.
89587151|NCT05303311|Active Comparator|pethidine plus dexamethasone group|Patients will be anesthetized by spinal anesthesia by intrathecal injection of 1mg/kg preservative-free pethidine plus 4mg dexamethasone diluted to a volume of 3 ml with 0.9% sodium chloride
89587152|NCT05299528|Experimental|Direct Feedback|On approximately study day 97, surgeon participants will receive procedure-specific direct feedback through electronic and written communication, on patients' opioid consumption-to-prescription ratio. Surgeon participants who perform more than 1 of the specified procedures will receive nudging communications for each individual procedure.
89587153|NCT05299528|No Intervention|No Direct Feedback|Surgeon participants randomized to No Direct Feedback will not be contacted directly at any time in the study and will not receive feedback about patients' opioid consumption-to-prescription ratio.
89587154|NCT05296317|Experimental|Arm 1 : Dense dose epirubicin-cyclophosphamide chemotherapy with administration of G-CSF|"2 cycles of chemotherapy with administration of G-CSF (filgrastim or lenograstim) on D2, D4 to D7 or D8..~Realization of blood sampling at D1, D4, D8 and D14"
89587155|NCT05296317|Experimental|Arm 2 : Dense dose epirubicin-cyclophosphamide chemotherapy with administration of peg-G-CSF|"2 cycles of chemotherapy with administration of peg-G-CSF (pegfilgrastim) on D2.~Realization of blood sampling at D1, D4, D8 and D14"
89587156|NCT05279118|Experimental|Ketogenic diet arm|Children who have consented to the study and have been randomised to ketogenic diet arm will get ketogenic diet under supervision while starting with rapid hiking of lipid to carbohydrate ratio and primary response will be assessed at 6 weeks. Ketogenic diet ratio will be hiked quickly upto a maximum of 4:!. The duration of ketogenic diet can be extended beyond the period of study based on response and parental choice. A minimum period of 6 weeks of diet therapy will be undertaken baring any undue adverse effects when the primary outcome will be assessed
89030354|NCT04516382|Experimental|Subcutaneous Low Concentration|PTG-300 Subcutaneous Low Concentration
89030355|NCT04516382|Experimental|Subcutaneous High Concentration|PTG-300 Subcutaneous High Concentration
89030356|NCT04516382|Experimental|Intramuscular|PTG-300 Intramuscular
89030357|NCT04517123|No Intervention|Control - Usual Care|Usual Care
89030358|NCT04517123|Experimental|Intervention - Prone Positioning|Prone Positioning
89030359|NCT01240590|Experimental|Ph I Level -1: Cisplatin + Crolibulin|75mg/m(2) Cisplatin + 8 mg/m(2) Crolibulin
89030360|NCT01240590|Active Comparator|Ph I Level 1: Cisplatin + Crolibulin|75mg/m(2) Cisplatin + 13 mg/m(2) Crolibulin
89030361|NCT01240590|Active Comparator|Ph I Level 2: Cisplatin + Crolibulin|100mg/m(2) Cisplatin + 13 mg/m(2) Crolibulin
89030362|NCT01240590|Active Comparator|Ph II Level 3: Cisplatin + Crolibulin|100mg/m(2) Cisplatin + 20 mg/m(2) Crolibulin
89030363|NCT01240590|Active Comparator|Ph II Level 4: Cisplatin|100mg/m(2) Cisplatin
89030364|NCT04516187||Emergency care|Consecutive enrolment of acutely ill older adults in emergency care
89030365|NCT04516187||General practice|Consecutive enrolment of acutely ill older adults in general practice
89030366|NCT02949804||Smoker|Vasovagal tendency will be compared among smokers and non smokers
89030367|NCT02949804||Non-smokers|Vasovagal tendency will be compared among smokers and non smokers
89030368|NCT01240200|Active Comparator|Vial & Syringe (Period 1) / Pen (Period 2)|Crossover phase: patients randomized to the sequence: Insulin glargine vial and syringe in Period 1 and Insulin glargine SoloSTAR pen in Period 2.
89587157|NCT05279118|Active Comparator|ACTH arm|ACTH is the current standard therapy for children with west syndrome. Those who have been randomised to this arm will be started on high dose ACTH for 2 weeks followed by gradual tapering over remaining 4 weeks and primary response documented at 6 weeks of therapy. The high dose ACTh is 150U/m2 or 6U/kg dose administered IM daily for two weeks. After this the doses will be tapered gradually and ACTH will be stopped by 4 weeks for a total treatment duration of strictly 6 weeks.
89587158|NCT05275842|Experimental|Cognitive Processing Therapy-Lifesteps (CPT-L) [Group A]|
89587159|NCT05275842|Active Comparator|Lifesteps [Group B]|
89587160|NCT05268250|Experimental|R2D2 mHealth treatment for diabetes distress|This is a mHealth supported, cognitive behavioral treatment for parents and school-age children who were identified with clinically relevant levels of diabetes distress as part of a clinic screening program
89587161|NCT05268250|No Intervention|Standard Care Control|Parents and school-age children who were identified with clinically relevant levels of diabetes distress as part of a clinic screening program will receive local resources (print or electronic).
89587162|NCT05260021|Experimental|Tirzepatide Dose 1|"Double-Blind:~Participants receive Tirzepatide by weekly subcutaneous (SC) injection starting with a low dose then increase to a higher dose every four weeks until maintenance dose level 1 is reached.~Open-Label:~Participants will continue to receive Tirzepatide at the last dose level"
89587163|NCT05260021|Experimental|Tirzepatide Dose 2|"Double-Blind:~Participants receive Tirzepatide by weekly SC injection starting with a low dose then increase to a higher dose every four weeks until maintenance dose level 2 is reached.~Open-Label:~Participants will continue to receive Tirzepatide at the last dose level"
89587164|NCT05260021|Placebo Comparator|Placebo|"Double-Blind:~Participants receive placebo during the 30-week double-blind period.~Open-Label:~Participants will switch to Tirzepatide by weekly SC injection starting with a low dose then increase to a higher dose every four weeks until maintenance dose level 1 is reached."
89587165|NCT05235165|Experimental|Arm A (thoracotomy)|Patients undergo open thoracic surgery (thoracotomy). Patients undergo CT throughout the trial. Patients may also undergo collection of tissue on study and blood throughout the trial.
89587166|NCT05235165|Experimental|Arm B (thoracoscopy)|Patients undergo thoracoscopy (video-assisted thoracoscopic surgery or VATS). Patients undergo CT throughout the trial. Patients may also undergo collection of tissue on study and blood throughout the trial.
89587167|NCT05232929|Experimental|Risdiplam|Participants will receive risdiplam prescribed based on clinician judgment, as per the Evrysdi® USPI.
89587168|NCT05231473|No Intervention|Standard|The participants are assigned according to the implanted and functioning program of each center. In this case, without Nurse Enhanced Recovery After Surgery Coordinator. It will be the control group. ERAS program will be working without this role.
89587169|NCT05231473|Experimental|Nurse Coordinator|The participants are assigned according to the implanted and functioning program of each center. In this case, with Nurse Enhanced Recovery After Surgery Coordinator. It will be the intervention group. ERAS program will be working with this role.
88975491|NCT00208117|Active Comparator|1|Patients randomized to sertraline will receive 50 mg/d for the first 6 weeks. Based on clinical response and tolerability, the dosage will be increased to 2 tablets (100 mg/d) at the end of week 6 until the end of the study (8 weeks). If AEs occur, the dosage will be reduced by 50 mg (1 tablet) at a time, as long as a minimum daily dose of 50 mg is maintained. The psychiatry fellow will be responsible for drug administration and will see all patients weekly. All randomized patients will also be seen at the mid-treatment, post-treatment, and follow-up visits by the study psychiatrist to determine depression symptom severity (HAM-D), assess medical tolerance to the study medications, and ensure patient psychiatric safety. The study psychiatrist will be blinded to treatment allocation.
88975492|NCT00208117|Placebo Comparator|2|To ensure blinding of research assessments and the patient, all medications, including the placebo, will be reformulated into a matching number of identical-appearing pills. All randomized patients will also be seen at the mid-treatment, post-treatment, and follow-up visits by the study psychiatrist to determine depression symptom severity (HAM-D), assess the medical tolerance to the study medications (including placebo), and ensure patient psychiatric safety. The study psychiatrist will be blinded to treatment allocation.
88975493|NCT00208156|Experimental|mifepristone|
88975494|NCT02966535|Experimental|1:2, 1:1 group|Inspiratory to expiratory time ratio (I:E ratio) of 1:2 during the first one hour of laparoscopy and then switched to I:E ratio of 1:1 during the rest time of laparoscopy.
88975495|NCT02966535|Active Comparator|1:1, 1:2 group|Inspiratory to expiratory time ratio (I:E ratio) of 1:1 during the first one hour of laparoscopy and then switched to I:E ratio of 1:2 during the rest time of laparoscopy.
88975496|NCT00208234|Placebo Comparator|Control|Placebo
88975497|NCT00208234|Experimental|2|Omalizumab
88975498|NCT00208273|Experimental|A|Letrozole 2.5 mg daily for 5 years started three weeks before the first day of adjuvant radiotherapy.
89587170|NCT05214599|Experimental|Group 1|Low dose
88975499|NCT00208273|Experimental|B|Letrozole 2.5 mg daily for 5 years started three weeks after the last day of adjuvant radiotherapy.
88975500|NCT00208312|Experimental|1|Regadenoson
88975501|NCT00208312|Active Comparator|2|Adenoscan
88975502|NCT00040781|Experimental|Treatment (gefitinib)|Patients receive oral gefitinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity
89587171|NCT05214599|Experimental|Group 2|Middle dose
89587172|NCT05214599|Experimental|Group 3|High dose
89587173|NCT05214092|Experimental|Neurosurgical Patients|Patient participants with previously excised tissue within Heschl's gyrus (as dictated by clinical care)
89587174|NCT05212337|Active Comparator|Denosumab|Subcutaneous injection with 60 mg Denosumab once
89587175|NCT05212337|Placebo Comparator|Placebo|Subcutaneous injection with NaCl once
89587176|NCT05208554|Experimental|Family-Focused Facilitated Fitness program|Couple-based physical activity intervention commencing 14 (+/-7) days post-transplant (8 sessions with a health counselor). Sessions 1-4 will train couples in the use of communal coping strategies to support one another in achieving PA goals. Skill building will focus on instruction and practice in adaptive communication, with emphases on adaptive speaking, responsive listening, and joint decision-making and problem-solving around PA. Instruction and practice will focus specifically on communication about PA and working together (we versus me) to increase PA. Sessions 5-8 will afford check-in, review of PA progress, and troubleshooting any barriers to PA. All sessions will be dyad-based but will include delivery of individualized step goals for the next week using an adaptive approach and based on remotely-monitored Fitbit step data. Specifically, the 75th percentile rank of each participant's last 7 days of recorded days will serve as the step goal prescription for the next week.
89587177|NCT05207514|Experimental|Nanoxel M|AC(Doxorubicin, Cyclophosphamide) followed by Nanoxel M
89209772|NCT00818714|Experimental|1|Dose escalation study to define the maximum tolerated boost dose of stereotactic body radiation therapy (SBRT) to the residual primary tumor after definitive therapy with concurrent chemotherapy and external beam radiation.
89587178|NCT05207514|Active Comparator|Taxotere|AC(Doxorubicin, Cyclophosphamide) followed by Taxotere
89587179|NCT05204927|Active Comparator|Standard Of Care Hormone Therapy|Abiraterone with Prednisone or Enzalutamide
89587180|NCT05204927|Experimental|Investigational Drug|177Lu-PSMA-I&T
89587181|NCT05203965|Experimental|FHP; Mavoglurant-Placebo|Family History Positive (FHP) for alcoholism will be given a single dose of AFQ056 (200 mg) then placebo in two separate experimental study visits separated by 1 week. Drug and Placebo administered 2 hours prior to the MRI and other measures.
89587182|NCT05203965|Experimental|FHP; Placebo-Mavoglurant|Family History Positive (FHP) or alcoholism will be given a single dose of placebo then AFQ056 (200 mg) in two separate experimental study visits separated by 1 week. Drug and Placebo administered 2 hours prior to the MRI and other measures.
89587183|NCT05203965|Experimental|FHN; Mavoglurant-Placebo|Family History Negative (FHN) for alcoholism will be given a single dose of AFQ056 (200 mg) then placebo in two separate experimental study visits separated by 1 week. Drug and Placebo administered 2 hours prior to the MRI and other measures.
89587184|NCT05203965|Experimental|FHN; Placebo-Mavoglurant|Family History Negative (FHN) for alcoholism will be given a single dose of placebo then AFQ056 (200 mg) in two separate experimental study visits separated by 1 week. Drug and Placebo administered 2 hours prior to the MRI and other measures.
89587185|NCT05201547|Experimental|Arm A: Dostarlimab 500 mg, every 3 weeks, 4 cycles and then 1000 mg every 6 weeks|
89587186|NCT05201547|Experimental|Arm B: Carboplatin AUC 5 or 6 plus Paclitaxel 175 mg/m2, every 3 weeks, 6 cycles.|
89587187|NCT05198661|Other|Paraneoplastic neurological syndrome patients and autoimmune encephalitis patient|patients with diagnosis of paraneoplastic neurological syndrome or autoimmune encephalitis
89587188|NCT05195645|Experimental|A-10mg/kg|Patients in arm A will receive doses of 10 mg/kg of Abatacept
89587189|NCT05195645|Experimental|B-20mg/kg|Patients in arm B will receive doses of 20 mg/kg of Abatacept
89587190|NCT05195645|Experimental|C-25mg/kg|Patients in arm C will receive doses of 25 mg/kg of Abatacept
88975503|NCT00208351|Active Comparator|1) Ultima LX Collared Stem - Non-Polished/Blasted Finished|A collared non-polished blasted finished cementless femoral component for use in total hip replacement.
89209773|NCT00818792|Active Comparator|Drug-eluting stent Xience V|
89209774|NCT00818792|Active Comparator|Bare-metal stent Vision|
89587191|NCT05187832|Experimental|AND019 single dose escalation and expansion|Subjects will be administrated with AND019 capsule PO QD from 20 mg to 400 mg during Part 1, and 2 dose groups will be selected for dose expansion study
89587192|NCT05169593|Other|Endoscopy-driven postoperative biological therapy|"Endoscopic recurrence at week 30~Adalimumab: 160 mg SC at week 32, 80 mg SC at week 34, 40 mg SC at week 36 and every two weeks thereafter.~Infliximab: Induction with 5 mg/kg IV at week 32, and 5 mg/kg IV at week 34; maintenance with 5 mg/kg IV at week 38, week 42 or week 46 and every eight weeks thereafter or with 120 mg SC at week 38 and every two weeks thereafter.~Ustekinumab: 260 mg (body weight ≤55kg) or 390 mg (55-85kg) or 520 mg (>85kg) IV at week 32, 90 mg SC at week 40, and every eight weeks thereafter.~Vedolizumab: Induction with 300 mg IV at week 32, and 300 mg IV at week 34; maintenance with 300 mg IV at week 38 and every eight weeks thereafter or with 108 mg SC at week 38, week 42 or week 46 and every two weeks thereafter.~Risankizumab: Induction with 600 mg IV at week 32, week 36 and week 40; maintenance with 360 mg SC at week 44 and every eight weeks thereafter."
88975504|NCT00208351|Active Comparator|2) Ultima LX Collared Stem - Polished Finished|A collared polished finished cementless femoral component for use in total hip replacement.
88975505|NCT00208351|Active Comparator|3) Ultima LX Collarless Stem - Non-Polished/Blasted Finished|A collarless non-polished/blasted finished cementless femoral component for use in total hip replacement.
88975506|NCT00208351|Active Comparator|4) Ultima LX Collarless Stem - Polished Finished|A collarless polished finished cementless femoral component for use in total hip replacement.
88975507|NCT00208390|Other|Summit Tapered Hip System|A cementless, tapered femoral component for use in total hip replacement
88975508|NCT00208429|Other|Pinnacle Acetabular System|
88975509|NCT00208468|Other|European Hip|A cementless femoral component for use in total hip replacement
88975510|NCT00208468|Active Comparator|Zweymüller|A cementless femoral component for use in total hip replacement
88975511|NCT00208468|Active Comparator|CLS Spotorno|A cementless femoral component for use in total hip replacement
88975512|NCT00208546|Experimental|1Capecitabine + bevacizumab + oxaliplatin + cetuximab|
88975513|NCT00208546|Active Comparator|21Capecitabine + bevacizumab + oxaliplatin|
89209775|NCT00729365|Placebo Comparator|Dippers - Placebo Treated|Subjects with normal nighttime blood pressure profile that decreases at night (Dippers). This group are all given placebo.
89209776|NCT00729365|Placebo Comparator|NonDippers - Placebo Treated|Subjects with nighttime blood pressure that does not drop during the night (non-dippers). This group will be given placebo.
89587193|NCT05169593|Active Comparator|Systematic postoperative prophylaxis with a biological|"Adalimumab: 160 mg subcutaneous (SC) at day 0, 80 mg SC at week 2, 40 mg SC at week 4 and every two weeks thereafter.~Infliximab: Induction with 5 mg/kg intravenous (IV) at day 0, and 5 mg/kg IV at week 2; maintenance with 5 mg/kg IV at week 6, week 10 or week 14 and every eight weeks thereafter or with 120 mg SC at week 6 and every two weeks thereafter.~Ustekinumab: 260 mg (body weight ≤55kg), 390 mg (55-85kg) or 520 mg (>85kg) IV at day 0, 90 mg SC at week 8 and every eight weeks thereafter.~Vedolizumab: Induction with 300 mg IV at day 0, and 300 mg IV at week 2; maintenance with 300 mg IV at week 6 and every eight weeks thereafter or with 108 mg SC at week 6, week 10 or week 14 and every two weeks thereafter.~Risankizumab: Induction with 600 mg IV at day 0, week 4 and week 8; maintenance with 360 mg SC at week 12 and every eight weeks thereafter."
89587194|NCT05159206|Other|CT group|CT-scan preoperatively, postoperatively and at 3 months, 1 and 2 years. Per-operative navigation based on the CT scan.
89587195|NCT05145816|Experimental|Cohort (DL 0) for Part 1|Cohort (DL 0) for Starting Dose : 1.9 mg/kg Belantamab mafodotin intravenously every 8 weeks
88975514|NCT00068991|Experimental|1|Participants will be HIV-infected villagers and will will take part in 2-hour skills training sessions every week from study entry to Week 8. Participants will bring a family member to each training session. After training, participants complete a post-training evaluation of the training sessions. Participants will also complete questionnaires at study entry and 6 and 12 months after completion of training.
88975515|NCT00068991|Experimental|2|Participants will be villagers considered influential members of their community. In the first 2 months of the study, Participants will take part in four 2-hour training sessions focusing on anti-stigma and anti-discrimination messages. Participants will also attend additional support meetings monthly, from Months 2 to 15. They will be evaluated before and after their training sessions to determine the improvements in knowledge and attitudes about HIV among group participants.
88975516|NCT00068991|Experimental|3|Participants will be randomly selected community members and will complete a cross-sectional survey at study entry and 6 and 12 months after Group 2's completion of training to determine changing community attitudes about HIV as a result of Group 2's training. There will be no additional study visits or training for Group 3 participants.
88975517|NCT00040859|Experimental|oxaliplatin + capecitabine|"Patients receive oxaliplatin IV over 2 hours on day 1 and oral capecitabine twice daily on days 1-14. Treatment repeats every 21 days for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients with complete response (CR) receive 2 additional courses after CR.~Quality of life is assessed at baseline and then every 3 weeks (prior to each course of chemotherapy).~Patients are followed every 3 months for 1 year and then every 6 months for 2 years."
88975518|NCT00208702|Experimental|sertraline + triiodothyronine|
89587196|NCT05145816|Experimental|Cohort (DL +1) for Part 1|Cohort (DL +1) for Dose Escalation: 2.5 mg/kg Belantamab mafodotin intravenously every 8 weeks
89587197|NCT05145816|Experimental|Cohort (DL -1) for Part 1|Cohort (DL -1) for Dose De-escalation : 1.9 mg/kg Belantamab mafodotin intravenously every 12 weeks
88975519|NCT00208702|Placebo Comparator|sertraline + placebo|
88975520|NCT00208780|Experimental|Dose-response of oral BH4|Eight subjects received 100 mg of oral BH4 twice a day and 8 received 200 mg twice daily.
88975521|NCT00208780|Experimental|Onset & duration of action of oral BH4|Eight hypertensive subjects were assigned to either 5 mg kg-1 day-1 (n=4) or 10 mg kg-1 day-1 (n=4) of BH4, given in two divided doses orally for 8 weeks.
88975522|NCT04722484|Experimental|Patients with normal creatine clearance (CLCR)|Subjects with renal impairment according to their medical history and estimated glomerular filtration rate (eGFR) at screening but had normal creatinine clearance at the pre-profile day (-01day)
88975523|NCT04722484|Experimental|Normal renal function (Healthy subjects)|Subjects with creatinine clearance at pre-profile day >80 ml/min
88975524|NCT04722484|Experimental|Mildly impaired renal function|Subjects with creatinine clearance at pre-profile day in the range of 50-80 ml/min
88975525|NCT04722484|Experimental|Moderately impaired renal function|Subjects with creatinine clearance at pre-profile day in the range of 30-<50 ml/min
89587198|NCT05145816|Experimental|Cohort (DL -2) for Part 1|Cohort (DL -2) for Dose De-escalation: 1.4 mg/kg Belantamab mafodotin intravenously every 12 weeks
88975526|NCT04722484|Experimental|Severely impaired renal function|Subjects with creatinine clearance at pre-profile day <30 ml/min
88975527|NCT00041015|Active Comparator|oral topotecan plus cisplatin IV|oral topotecan once daily on days 1-5 and cisplatin IV on day 5
89587199|NCT05145816|Experimental|Cohort Dose Expansion for Part 2|Cohort Dose expansion for Part 2: Belantamab mafodotin Dose from1.0 mg/kg to 2.5mg/kg every 4 weeks, 6 weeks, 8 weeks, or 12 weeks as determined by Part 1 recommended dosage calculations.
89587200|NCT05145816|Experimental|Cohort (DL -3) for Part 1|Cohort (DL -3) for Dose De-escalation: 1.0 mg/kg Belantamab mafodotin intravenously every 12 weeks
89587201|NCT05145725||Idiopathic scoliosis in adolescents requiring surgery|
89587202|NCT05141305|Experimental|tenecteplase ( 0.25 mg/kg, Max 25 mg )|Tenecteplase (0.25 mg/kg) is given as a single, intravenous bolus (within 5-10 seconds) immediately upon randomization. Maximum dose 25mg.
89587203|NCT05141305|Active Comparator|standard medical treatment|Aspirin combined with clopidogrel, aspirin alone, or clopidogrel alone after randomization at the discretion of local investigators.
89587204|NCT05134779||Cohort 1|Patients with breast cancer (BC), any stage will be considered for this study.
89587205|NCT05111613|Active Comparator|Randomized Controlled Trial Cohort - FlowTriever Arm|Mechanical thrombectomy for pulmonary embolism using the FlowTriever System.
89587206|NCT05111613|Active Comparator|Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm|Catheter-Directed Thrombolysis for pulmonary embolism (any commercially available CDT system)
89587207|NCT05111613|Other|Non-Randomized Absolute Contraindication to Thrombolytics Cohort|Mechanical thrombectomy for pulmonary embolism using the FlowTriever System.
89587208|NCT05108948||Spinal deformity operated patients|
89587209|NCT05105360|Active Comparator|Petersen's closure group|Petersen's space closure method
89587210|NCT05105360|Experimental|Mefix group|Mesentery fixation method
89587211|NCT05101707|Experimental|CIMT + taVNS|The investigators will deliver taVNS paired with 40h of Constraint Induced Movement Therapy for unilateral weakness/hemiplegia
89587212|NCT05095532|Experimental|BM-MSCs at 20x10^6|One time infusion of islets plus BM-MSCs at 20x10^6/patient, n=14
89587213|NCT05095532|Experimental|BM-MSCs at 50x10^6|One time infusion of islets plus BM-MSCs at 50x10^6/patient, n=14
89587214|NCT05095532|Placebo Comparator|Placebo|One time infusion of islets only.
89587215|NCT05090358|Experimental|Ketogenic Diet|Postmenopausal women and men with histologically-confirmed, HR-positive, HER2-negative, PIK3CA mutant MBC who have received no more than 1 line of endocrine-based therapy in the metastatic setting will be eligible. Participants on this arm will partake in a ketogenic diet in combination with SOC endocrine therapy (fulvestrant) and PI3K inhibition (alpelisib)
89587216|NCT05090358|Experimental|Low Carbohydrate Diet|Postmenopausal women and men with histologically-confirmed, HR-positive, HER2-negative, PIK3CA mutant MBC who have received no more than 1 line of endocrine-based therapy in the metastatic setting will be eligible. Participants on this arm will be assigned to Low Carbohydrate Diet/LCD therapy each in combination with SOC endocrine therapy (fulvestrant) and PI3K inhibition (alpelisib)
89587217|NCT05090358|Experimental|SGLT2i Therapy|Postmenopausal women and men with histologically-confirmed, HR-positive, HER2-negative, PIK3CA mutant MBC who have received no more than 1 line of endocrine-based therapy in the metastatic setting will be eligible. Participants on this arm will be assigned to SGLT2i therapy each in combination with SOC endocrine therapy (fulvestrant) and PI3K inhibition (alpelisib)
89587218|NCT05088434|Active Comparator|donor FMT|Fresh stool samples were obtained immediately from close family member (donor) before being re-transplanted into the patient through a gastroscope.
89587219|NCT05088434|Active Comparator|ACHIM|One vial of ACHIM suspension (ACHIM Biotherapeutics AB, Sweden), containing 30 x 109 colony forming unit (CFU) of bacteria, was given through the work channel of a gastroscope into the lower part of duodenum.
89587220|NCT05088434|Placebo Comparator|Placebo|Fresh stool samples were obtained from the patients themselves immediately before transplantation and re-transplanted through a gastroscope.
89587221|NCT05084989|Experimental|Part1: Recombinant two-component COVID-19 vaccine (CHO cell)|Antigen: NTD-RBD-foldon protein, sodium dihydrogen phosphate, disodium hydrogen phosphate, sucrose, glycine, polysorbate 80 Adjuvant (BFA03): squalene, alpha-tocopherol, polysorbate 80, sodium chloride, potassium chloride, disodium hydrogen phosphate, potassium dihydrogen phosphate
89587222|NCT05084989|Placebo Comparator|Part1: Placebo control|Antigen: sodium dihydrogen phosphate, disodium hydrogen phosphate, sucrose, glycine, polysorbate 80 Adjuvant (BFA03): squalene, alpha-tocopherol, polysorbate 80, sodium chloride, potassium chloride, disodium hydrogen phosphate, potassium dihydrogen phosphate
89587223|NCT05084989|Experimental|Part2: Recombinant two-component COVID-19 vaccine (CHO cell)|(Lot# HA202107009 and Lot# TC202205002) Recombinant two-component COVID-19 vaccine (CHO cell) Antigen: NTD-RBD-foldon protein, sodium dihydrogen phosphate, disodium hydrogen phosphate, sucrose, glycine, polysorbate 80 Adjuvant (BFA03): squalene, alpha-tocopherol, polysorbate 80, sodium chloride, potassium chloride, disodium hydrogen phosphate, potassium dihydrogen phosphate
88975528|NCT00041015|Experimental|Cisplatin IV plus etoposide IV|Cisplatin IV on day 1 and etoposide IV over at least 30 minutes
88975529|NCT00209053|Experimental|Off Pump CABG|CABG without cardiopulmonary bypass.
88975530|NCT00209053|Active Comparator|On-Pump CABG|CABG with cardiopulmonary bypass.
88975531|NCT00041054|Experimental|carboplatin + etoposide + exisulind|"Patients receive carboplatin IV over 30 minutes on day 1 and etoposide IV over 30-60 minutes on days 1-3. Patients also receive oral exisulind twice daily on days 1-21. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~Patients are followed every 2 months for 1 year and then every 4 months for 2 years."
88975532|NCT02966106|Active Comparator|Right prefrontal low frequency rTMS.|Right prefrontal low frequency rTMS (1Hz). A treatment session each day in four weeks apart from weekends. Each session is administered with 2 pulse trains of 180 sec with a 2 min interval
88975533|NCT02966106|Placebo Comparator|Sham-rTMS|Right prefrontal rTMS sham treatment. A treatment session each day in four weeks apart from weekends. Each session is administered with 2 pulse trains of 180 sec with a 2 min interval
88975534|NCT00209209|Active Comparator|1|"randomisation: R-CHOP~randomisation: IFN maintenance"
88975535|NCT00209209|Experimental|2|"randomisation: R-FC~randomisation: Rituximab maintnenance"
88975536|NCT00041093|Experimental|Treatment (docetaxel)|Patients receive docetaxel IV over 1 hour on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
88975537|NCT00209443|Experimental|Gadodiamide Injection|All subjects received a single intravenous bolus injection via a power injector of Omniscan (Gadodiamide Injection) at a dose of 0.1 mmol/kg
88975538|NCT00399087|Experimental|Perifosine D1 + Docetaxel|
88975539|NCT00399087|Experimental|Perifosine D1+ Docexatel+Prednisone|
88975540|NCT00399087|Experimental|Perifosine+ D1,8 and 15+Docetaxel+Prednisone|
88975541|NCT00411424|Experimental|1|
89587224|NCT05084989|Active Comparator|Part2: COMIRNATY® COVID-19 Vaccine, mRNA|"Antigen: nucleoside-modified messenger RNA (mRNA) encoding the viral Spike (S) glycoprotein of SARS-CoV-2, called tozinameran.~Others: ((4-hydroxybutyl) azanediyl) bis (hexane-6,1-diyl) bis (2-hexyldecanoate), 2-[(polyethylene glycol)-2000]-N, N-ditetradecylacetamide, 1,2-distearoyl-sn-glycero-3-phosphocholine, and cholesterol, potassium chloride, potassium dihydrogen phosphate, sodium chloride, disodium phosphate dihydrate, sucrose."
88975542|NCT00411424|Placebo Comparator|2|
88975543|NCT00041171|Experimental|Arm 1: placebo + docetaxel|"Patients receive oral placebo three times daily on days 1-14 and docetaxel IV over 1 hour on day 15.~Treatment in both groups repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.~Patients are followed for new primaries and survival only."
89030369|NCT01240200|Experimental|Pen (Period 1) / Vial & Syringe (Period 2)|Crossover phase: patients randomized to the sequence: Insulin glargine SoloSTAR® pen in Period 1 and Insulin glargine vial and syringe in Period 2.
89587225|NCT05077176|Active Comparator|CoronaVac|Inactivated SARS-CoV-2 virus antigen, single intramuscular injection for boosting dose.
89587226|NCT05077176|Experimental|Turkovac|Inactivated SARS-CoV-2 virus antigen, single intramuscular injection for boosting dose.
89587227|NCT05076760|Experimental|MEM-288 Intratumoral Injection|"Part 1 MEM-288 monotherapy: Patients with accessible, subcutaneous, or superficial lymph node lesion ≥ 1 cm3 that is palpable will receive intratumoral injection of MEM-288 once every 3 week (planned 2 doses, maximum 6 doses) at one of three dose cohort levels.~Dose cohort level 1 (1 x 10^10 viral particles)~Dose cohort level 2 (3.3 x 10^10 viral particles)~Dose cohort level 3 (1 x 10^11 viral particles)"
89587228|NCT05076760|Experimental|Dose combination of MEM-288 Intratumoral Injection plus anti-PD1 (Nivolumab) Intravenous Infusion|Part 2 MEM-288 plus nivolumab combination: Patients with accessible, subcutaneous, or superficial lymph node lesion ≥ 1 cm3 that is palpable will receive intratumoral injection of MEM-288 maximum total dose of 1x10^11 viral particles once every 3 week (planned 2 doses, maximum 6 doses). MEM-288 may be injected in multiple lesions until the maximum injection dose (1x10^11 viral particles) is reached (minimum dose per lesion of 1x10^10 viral particles). Nivolumab 360 mg IV every 3 weeks.
89587229|NCT05074420|Experimental|Baricitinib|Baricitinib given orally to participants daily
89587230|NCT05068661|Active Comparator|Combined Spinal Epidural|10 mcg of preservative-free fentanyl and 2 mg of preservative-free isobaric 0.25% bupivacaine will be administered into the intrathecal space to initiate analgesia. Labor analgesia will be maintained by programmed intermittent bolus with patient-controlled epidural analgesia (PCEA) as per standard of care.
89587231|NCT05068661|Active Comparator|Dural Puncture Epidural|A 25-G Whitacre needle will be used to puncture the dura. An initiation dose of 20 mL of ropivacaine 0.1% with fentanyl (2 mcg/mL) will be administered. Labor analgesia will be maintained by programmed intermittent bolus with patient-controlled epidural analgesia (PCEA) as per standard of care.
89587232|NCT05068505|Experimental|Community health worker delivered multicomponent intervention|The study will employ a closed cohort stepped wedge cluster randomized design. There will be a sequential crossover of clusters from the control to the intervention arms and the order of the cross over will be randomly determined. This study will be conducted in 21 clusters within Nakaseke district. Each cluster will consist of 4-5 villages. We plan to rollout the intervention in three clusters per month.
89587233|NCT05068505|No Intervention|Control|All clusters will be observed under both the intervention and control arm through sequential crossover.
89587234|NCT05067790|Experimental|Higher Dose Nusinersen|All participants in the core study period, previously treated with risdiplam (nusinersen-naive participants and nusinersen-experienced participants), will receive HD nusinersen, administered as 2 loading doses of 50 milligrams (mg) each, approximately 2 weeks apart, followed by maintenance doses of 28 mg approximately every 4 months. Following the core study period, participants may be given the opportunity to receive maintenance doses of 28 mg nusinersen administered approximately every 4 months up to 2 years during the optional long-term extension (LTE) period.
88975544|NCT00041171|Experimental|Arm 2: Hypericum perforatum + docetaxel|"Patients receive oral Hypericum perforatum three times daily on days 1-14 and docetaxel as in arm 1.~Treatment in both groups repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.~Patients are followed for new primaries and survival only."
88975545|NCT00041171|Experimental|Arm 3: Hypericum perforatum + docetaxel|"Patients receive docetaxel as in arm 1 and continue to receive their chronic regimen of Hypericum perforatum except on day 15.~Treatment in both groups repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.~Patients are followed for new primaries and survival only."
88975546|NCT00209521|Experimental|fospropofol|
88975547|NCT00209521|Active Comparator|propofol|
88975548|NCT02970578|Experimental|3D printed module|The patients underwent 3D printed module-assisted lumbar pedicle screw placement using the Quandrant system, aiming to restore the stability of the spine.
88975549|NCT00209716|Experimental|1|
88975550|NCT00210418|Experimental|Preventive targeting|This arm targeted pregnant and lactating women as well as children 6-23.9 months of age to receive BCC and food assistance. A total of 27 months of enrollment in this program arm was possible.
88975551|NCT00210418|Active Comparator|Recuperative targeting|This arm targeted pregnant and lactating women as well as mothers of malnourished children (WAZ <-2 zscores) between 6 and 59 months of age. A total of 18 months of enrollment was possible in this program arm.
88975552|NCT00069069|Experimental|1|single center, Phase 1, open label, dose escalation trial assessing safety profile of four doses of intranasal recombinant human E-selectin
88975553|NCT02966613|Active Comparator|CI|TKA using conventional instrumentation (CI)
88975554|NCT02966613|Experimental|PSCG|TKA performed using Patient specific cutting guides (PSCG)
88975555|NCT02966613|Experimental|PSCG-D|TKA performed using fully disposable Patient specific cutting guides (PSCG-D)
88975556|NCT04722328||CNS infection|
88975557|NCT04722328||Non-CNS infection|
88975558|NCT00211042||Pure Red Cell Aplasia (PRCA)|This study will examine the relationship of the presence of anti-erythropoietin antibodies to the clinical course and outcome of participants currently or previously treated with recombinant human erythropoietin and who have PRCA identified from all notified reports (spontaneous postmarketing reports or from clinical trials reports).
88975559|NCT02966574|Experimental|metastatic breast cancer|
88975560|NCT00211354|Experimental|anecortave acetate|anecortave acetate 15 mg. juxtascleral injection every 6 months for 24 months
88975561|NCT00211393|Experimental|Drug: ketoconazole|"Drug: ketoconazole~Other Names:~ketoconazole~600mg. /day for 6 weeks~--------------------------------------------------------------------------------"
88975562|NCT00211432|Experimental|Title: Treatment of Pseudovitellium Detachment|Open-Label Anecortave Acetate Sterile Suspension(15mg)
88975563|NCT00211783||Autism|
88975564|NCT00211783||Control|
88975565|NCT00211822||Pathologic Gamblers|
88975566|NCT00211822||Obsessive Compulsive Disorder|
88975567|NCT00211822||Healthy Controls|
88975568|NCT00211900|Experimental|vaccine|single dose of StaphVAX in hemodialysis patients
88975569|NCT00211939|Experimental|1|PhosLo + atorvastatin
88975570|NCT00211939|Active Comparator|2|Sevelamer + atorvastatin
88975571|NCT00211978|Experimental|PhosLo|
89587235|NCT05065216|Experimental|DM199|DM199 administered by a single intravenous (IV) dose followed by a subcutaneous (SC) dose within 12 hours and then 2 times a week for three weeks (until Day 21).
89587236|NCT05065216|Placebo Comparator|Placebo|Placebo administered by a single intravenous (IV) dose followed by a subcutaneous (SC) dose within 12 hours and then 2 times a week for three weeks (until Day 21).
89587237|NCT05064579||Patients with asthma|Children and adolescents aged 8 to 17 years old with a doctor's diagnosis of asthma and controller asthma treatment
89587238|NCT05064579||Holders of parental authority|Holders of parental authority of patients with asthma described in group A
89587239|NCT05064579||Doctors|Doctors caring for patients with asthma described in group A
89587240|NCT05063344||Sexually active persons who self-select for syphilis testing|Participants must be a mixture of English and Spanish speaking, geographically diverse, gender diverse, ethnically and racially diverse, economically diverse, and with different levels of education; 18-64 years
89587241|NCT05063344||Expectant mothers|Participants must be a mixture of English and Spanish speaking, geographically diverse, gender diverse, ethnically and racially diverse, economically diverse, and with different levels of education; 18-64 years
88975572|NCT00211978|Placebo Comparator|placebo|
88975573|NCT00212017|Active Comparator|the voglibose group|Participants in the voglibose group were administered a voglibose tablet (0.2 mg) three times daily before meals.
89587242|NCT05063344||Lay users|Participants must be a mixture of English and Spanish speaking, geographically diverse, gender diverse, ethnically and racially diverse, economically diverse, and with different levels of education; 18-64 years; 1/2 high risk sexual behavior and 1/2 low risk sexual behavior
89587243|NCT05063149|Active Comparator|Broncho-Vaxom treatment|Infants in this arm will be given 3,5mg bacterial lysate (OM-85) 10 days per month from 6 weeks after birth until 12 months of age.
89587244|NCT05063149|Placebo Comparator|Placebo|Infants in this arm will be given a placebo powder from a capsule that will be indistinguishable from the active study drug.
89587245|NCT05062980|Experimental|Investigational|In Phase 1, the dose expansion portion of Phase 2 and the investigational arm of the randomized portion of Phase 2, patients will receive their assigned dose of quaratusugene ozeplasmid (via intravenous infusion) in combination with a fixed 200 mg dose of pembrolizumab (via intravenous infusion) once in every 21-day treatment cycle until disease progression or unacceptable toxicity.
89587246|NCT05062980|Active Comparator|Control|In the control arm of the randomized portion of Phase 2, patients will receive either 75 mg/m2 docetaxel (via intravenous infusion) with or without 10 mg/kg ramucirumab (via intravenous infusion) -OR- investigator's choice of treatment. The treatment regimen for patients randomized to the control arm, must begin at Cycle 1 Day 1 and continue every 21 days until disease progression or unacceptable toxicity.
89587247|NCT05053399|Experimental|TECNIS Symfony Toric IOL|Model Series ZXT
88975574|NCT00212017|Active Comparator|the control group|Participants assigned to the control group were treated only with diet and exercise therapy.
88975575|NCT00212056|Active Comparator|ANP|
89587248|NCT05052125|Active Comparator|High oxygen saturation|Peripheral oxygen saturation level >94% Intervention: Drug: Oxygen gas
89587249|NCT05052125|Active Comparator|Low oxygen saturation|Peripheral oxygen saturation level 88-92% Intervention: Drug: Oxygen gas
89587250|NCT05048836|Experimental|Food subsidy, no lifestyle support, 6 months|Participant will receive $40 healthy food subsidy for 6 months.
89587251|NCT05048836|Experimental|Food delivery, no lifestyle support, 6 months|Participant will receive twice monthly healthy food delivery for 6 months.
88975576|NCT00212056|Placebo Comparator|Control|
88975577|NCT00212095|Experimental|docetaxel and ketoconazole|
89587252|NCT05048836|Experimental|Food subsidy, with lifestyle support, 6 months|Participants will receive food subsidy and healthy lifestyle support for 6 months.
88975578|NCT00212212|Experimental|1|200 µg selenium as selenate
88975579|NCT00212212|Experimental|2|400 µg selenium as selenate
88975580|NCT00212212|Experimental|3|200 µg selenium as selenomethionine
88975581|NCT00212212|Placebo Comparator|4|placebo tablet
88975582|NCT00212251|Experimental|Lifestyle counseling|10 ActiveMoms classes, 8 Moms Time Out nutrition classes, 6 coaching calls, supportive materials
88975583|NCT00069381|Experimental|study arm|
88975584|NCT00212407|Experimental|Umbilical cord blood unit(s) transplant|Transplantation of cryopreserved umbilical cord blood unit(s)
88975585|NCT00411580|Experimental|1|CAD106
88975586|NCT00411580|Placebo Comparator|2|Placebo
88975587|NCT00411658|Experimental|Investigational Device|
88975588|NCT00411658|Active Comparator|Cryopreserved|
88975589|NCT00411697|Experimental|Group A|
88975590|NCT00411736|Experimental|A|Stratification group: Age under 8 years, no CF siblings at home.
88975591|NCT00411736|Experimental|B|Stratification group: Age >/= 8 years, no CF siblings at home.
88975592|NCT00411736|Experimental|C|Stratification group: Age >/= 8 years, CF siblings at home.
88975593|NCT00411814|Placebo Comparator|Placebo|Saline
88975594|NCT00411814|Active Comparator|Active|GSK679586
89587253|NCT05048836|Experimental|Food delivery, with lifestyle support, 6 months|Participants will receive twice monthly food box deliveries and lifestyle support for 6 months.
89587254|NCT05048836|Experimental|Food subsidy, no lifestyle support, 12 months|Participants will receive food subsidy for 12 months.
89587255|NCT05048836|Experimental|Food delivery, no lifestyle support, 12 months|Participants will receive twice monthly food box deliveries for 12 months.
89587256|NCT05048836|Experimental|Food subsidy, with lifestyle support, 12 months|Participant will receive food subsidy and lifestyle support for 12 months.
89587257|NCT05048836|Experimental|Food delivery, with lifestyle support, 12 months|Participants will receive twice monthly food box deliveries and lifestyle support for 12 months.
89587258|NCT05048732|Experimental|Cohort 1 = Healthy Volunteers|"Healthy volunteers (N=6, three male, three female) will be recruited to undergo a single 18F-FAT PET/CT imaging session for radiation dosimetry estimates.~18F-FAT administration followed by body imaging at 3 time points~0-60 min = multiple quick body scans~120 min post injection = body scan~240 min post injection = body scan"
89587259|NCT05048732|Experimental|Cohort 2a: Newly Diagnosed DLBCL patients being treated with R-CHOP|-N= 6 : 18F-FAT imaging session at baseline and Day 2-4 following Cycle 1 standard of care therapy.
89587260|NCT05048732|Experimental|Cohort 2b: Newly Diagnosed DLBCL patients being treated with R-CHOP|-N=9: 18F-FAT imaging session at baseline and best time point determined from Cohort 2a (2 days post Cycle 1 standard of care therapy)
89587261|NCT05043090|Experimental|Arm A|savolitinib 600mg plus durvalumab 1500mg
89587262|NCT05043090|Active Comparator|Arm B|sunitinib 50mg
89587263|NCT05043090|Experimental|Arm C|durvalumab 1500mg
89587264|NCT05040204|Experimental|Experimental Supplement 1|6 subjects will consume 12 grams of dietary supplement 1 daily for 4 weeks
89587265|NCT05040204|Experimental|Experimental Supplement 2|6 subjects will consume 12 grams of dietary supplement 2 daily for 4 weeks
89587266|NCT05040204|Experimental|Experimental Supplement 3|20 subjects will consume 50 grams of dietary supplement 3 daily for 4 weeks
89587267|NCT05040204|Placebo Comparator|Placebo Comparator 1|6 subjects will consume 12 grams of placebo dietary supplement daily for 4 weeks
89587268|NCT05040204|Placebo Comparator|Placebo Comparator 2|6 subjects will consume 50 grams of placebo dietary supplement daily for 4 weeks
89587269|NCT05038553||Patients with early rheumatoid arthritis|
88975595|NCT02966730|Experimental|Follicular Lymphoma|Participants will be receive Ibrutinib as an oral capsule preparation once daily for a period of 2 years. The dose will be 560mg daily. Toxicities will be recorded and graded. Response to treatment will be determined by FDG-PET imaging every 6 months, or as clinically indicated, in conjunction with clinical assessment by a physician, including physical examination, every 4 weeks from day 1 (baseline) for the first 3 months and then every 3 months until the end of treatment at 2 years.
88975596|NCT00073242|Experimental|leptin repletion|Repletion of leptin following weight loss induced by dietary modification.
88975597|NCT00073242|Experimental|T3 repletion|Repletion of T3 following weight loss induced by dietary modification.
88975598|NCT00212797|Experimental|Org 34517_1|low dose Org 34517
88975599|NCT00212797|Experimental|Org 34517_2|high dose Org 34517
88975600|NCT00212797|Placebo Comparator|Placebo|
88975601|NCT02962843|Experimental|IY TCM|Incredible Year (IY) Teacher Classroom Management (TCM) training, 6 full-day workshops (42 hours)
88975602|NCT02962843|No Intervention|Comparison|No Incredible Year (IY) Teacher Classroom Management (TCM) training.
88975603|NCT02966262||Optical Coherence Tomography registry group|Patients who had undergone optical coherence tomography within coronary intervention
88975604|NCT00213265|Active Comparator|1|
88975605|NCT00213265|Experimental|2|
88975606|NCT00213304|Experimental|varicella vaccine (VARIVAX)|varicella vaccine (VARIVAX)
88975607|NCT00213421||1|
88975608|NCT00213421||2|
88975609|NCT00213655||Daily instillation of BCG for 3 weeks then every 6 months|Effect of daily instillation of BCG (27 mg) for 3 weeks then one instillation of BCG (27 mg) every 6 months for 36 months on bladder tumor recurrence
88975610|NCT00213655||Daily instillation of BCG for 2 weeks then every 3 months|Effect of daily instillation of BCG (27 mg) for 2 weeks then one instillation of BCG (27 mg) every 3 months for 36 months on bladder tumor recurrence
88975611|NCT00213928|No Intervention|Control|
88975612|NCT00213928|Active Comparator|Horse Chestnut Seed Extract|Horse chestnut seed extract (escins, aesins)
88975613|NCT00214123|Experimental|Bin 1|bin assignment based on tumor volume
88975614|NCT00214123|Experimental|Bin 2|Bin assignment based on tumor volume
88975615|NCT00214123|Experimental|Bin 3|Bin assignment based on tumor volume
88975616|NCT00214123|Experimental|Bin 4|Bin assignment based on tumor volume
88975617|NCT00214123|Experimental|Bin 5|Bin assignment based on tumor volume
88975618|NCT00214162|Other|1|internet access and computer for 1 year
88975619|NCT00214162|Experimental|2|computer and Full CHESS
88975620|NCT00214240|Experimental|1|Cytogam in addition to standard of care (IV ganciclovir therapy)
88975621|NCT00214240|No Intervention|2|Receive standard of care therapy (IV ganciclovir)
88975622|NCT00214279|No Intervention|1|Remain on 3-drug standard of care immunosuppression including prednisone
89587270|NCT05035043|Experimental|NAFLD patients|Non-Alcoholic Fatty Liver Disease patients
89587271|NCT05034354|Experimental|Remote physiological monitoring|"Patients will be recruited from inpatient and outpatient cardiology service at the Stollery Children's Hospital will be purposively selected, with 50% of the patients living at least 100km from the Stollery into one of the following groups:~Group 1: Infants <12 months of age with single ventricle physiology or biventricular cyanotic congenital heart disease.~Group 2: Patients aged 5-17 with heart failure, listed for transplant, or within 1 year of transplant."
89587272|NCT05031767|Active Comparator|Usual care|Conventional current follow-up strategy
89587273|NCT05031767|Experimental|Remote monitoring|Remote monitoring by health professionals at the hospital
89587274|NCT05031767|Experimental|Patient-initiated care|No pre-scheduled visits or remote monitoring.
89587275|NCT05027919|Other|Within-subject design|All participants will undergo the same study design, which includes morphine stabilization (days 1-5), two naloxone challenges (scheduled during morphine stabilization), lofexidine-assisted taper (days 6-10), and transition to aftercare (day 11).
89587276|NCT05014256|Experimental|STEPS Health System Surveillance and Outreach intervention|
89587277|NCT05014256|No Intervention|Usual Kidney Care|
89587278|NCT04998422|Experimental|Part A: HG381 Monotherapy Dose Escalation Cohort|Subjects will receive HG381 IV at every one week intervals (Q1W). Escalating doses of HG381 will be evaluated by the traditional 3+3 design.
89587279|NCT04998422|Experimental|Part B: HG381 Monotherapy Dose Expansion Cohort|Subjects will be administered the recommended Phase 2 dose of HG381 IV Q1W established in Part A of the study.
89587280|NCT04998136|Experimental|Semaglutide 2.4 mg|
89587281|NCT04998136|Placebo Comparator|Placebo|
89587282|NCT04995029|Experimental|Induction Phase: Rapid Induction|Participants will receive 4 mg transmucosal buprenorphine on Day 1. Participants meeting eligibility requirements will then receive 300 mg extended-release buprenorphine by subcutaneous injection at least 1 hour later and a second dose on Day 8.
89587283|NCT04995029|Experimental|Induction Phase: Standard of Care Induction|Participants will receive transmucosal buprenorphine for a minimum of 7 days per applicable product labelling information. Participants meeting eligibility requirements will receive 300 mg extended-release buprenorphine by subcutaneous injection on Day 1 and a second dose on Day 8.
89587284|NCT04995029|Experimental|Maintenance Phase: Extended-release Buprenorphine 100 mg|Participants eligible to continue treatment will be randomized at Week 6 to receive maintenance doses of 100 mg extended-release buprenorphine by subcutaneous injection every 4 weeks for a total of up to 8 maintenance injections (Weeks 6 to 34).
89587285|NCT04995029|Experimental|Maintenance Phase: Extended-release Buprenorphine 300 mg|Participants eligible to continue treatment will be randomized at Week 6 to receive maintenance doses of 300 mg extended-release buprenorphine by subcutaneous injection every 4 weeks for a total of up to 8 maintenance injections (Weeks 6 to 34).
89587286|NCT04984850|Experimental|Intervention plus usual care|
89587287|NCT04984850|No Intervention|Usual care only|
89587288|NCT04982224|Experimental|Phase 1. Dose Escalation|Cohorts A and B: REGN5093-M114 monotherapy. Cohort C: REGN5093-M114+cemiplimab combination.
89587289|NCT04982224|Experimental|Phase 2. Dose Expansion|Cohorts A and B: REGN5093-M114 monotherapy. Cohort C: REGN5093-M114+cemiplimab combination.
89587290|NCT04977167|Experimental|Part 1:HG146 Monotherapy, Dose-escalation Cohort|Subjects will receive HG146 PO at every two days intervals (qod) for 14 consecutive days,7 days off, 21 days/ cycle. Escalating doses of HG146 will be evaluated using 3+3 approach.
89587291|NCT04977167|Experimental|Part 2A:HG146 + PD-(L)1 antibody, Dose escalation Cohort|"Subjects will receive HG146 PO at every two days intervals (qod) for 14 consecutive days,7 days off, along with PD-(L)1 antibody IV once every 3 weeks (Q3W),21 days/ cycle.~Escalating doses of HG146 in combination with PD-(L)1 antibody will be evaluated."
89587292|NCT04977167|Experimental|Part 2B-1：HG146 combination Expansion Cohort 1|Subjects who have not been treated with PD-(L)1 antibody，will receive HG146 po for 14 consecutive days,7 days off, in combination with PD-(L)1 antibody IV Q3W.
89587293|NCT04977167|Experimental|Part 2B-2：HG146 combination Expansion Cohort 2|Subjects who have progressed on PD-(L)1 antibody, will receive HG146 po for 14 consecutive days,7 days off, in combination with PD-(L)1 antibody IV Q3W.
89587294|NCT04973748|Active Comparator|Treatment as usual (TAU)|"Standard pain regimen with scheduled acetaminophen and ibuprofen, oxycodone as needed for moderate-to-severe pain, and intravenous hydromorphone as needed for breakthrough pain.~Surveys about pain levels, opioid consumption, side effects of opioids, understanding of placebo effect and symptoms of depression."
89587295|NCT04973748|Experimental|Conditioned open-label placebo (COLP)|"Standard pain regimen with scheduled acetaminophen and ibuprofen, oxycodone as needed for moderate-to-severe pain, and intravenous hydromorphone as needed for breakthrough pain.~Conditioning (i.e. exposure to clove oil scent) with each dose of oxycodone medication on post-operative day (POD) 1-5.~Scheduled placebo oxycodone medication paired with conditioning (i.e. exposure to clove oil scent) 3 times per day on POD 2-5.~Surveys about pain levels, opioid consumption, side effects of opioids, understanding of placebo effect and symptoms of depression."
89587296|NCT04968847|Experimental|FemaSeed|Investigational device and procedure
88975623|NCT00214279|Experimental|2|Corticosteroid withdrawal / prednisone taper over 14 weeks
88975624|NCT00214474|Active Comparator|ATSM Intervention|ATSM Intervention: Automated Telephone Self-Management Support
88975625|NCT00214474|Active Comparator|GMV Intervention|GMV Intervention: Group Medical Visits
88975626|NCT00214474|No Intervention|Usual Care|Usual Care: Standard care for diabetic patients
88975627|NCT00069459|Other|Extended-release Bupropion Hydrochloride|Extended-release Bupropion Hydrochloride
88975628|NCT00214669|Experimental|1|"Education for intervention specialist nurse and GPs and practice nurses from intervention practices, using our adaptation of Clarke's self-regulation education programme, designed to improve shared-decision making, goal-setting and patient-clinician partnership.~Lay-led 'expert-patient' education in small groups for patients, using an adaptation of Lorig's chronic disease self-management programme.~Improved follow-up in primary care through appointment-booking by the specialist nurse."
88975629|NCT00214669|No Intervention|2|Usual Care
88975630|NCT00397202|Active Comparator|The DivaCupTM|
89587297|NCT04966702|Active Comparator|Albendazole|"The albendazole group will receive a single dose of 400 mg, given once a month for three months.~Generic products will be used in both countries. Bendex in Mozambique and Albenza in Kenya"
89587298|NCT04966702|Experimental|Ivermectin human|The ivermectin group will receive a single dose of 400 mcg/kg, given once a month for three months. Product to be used is Stromectol (Merck) in Mozambique and Ivermectin 3mg USP (Edenbridge) in Kenya
89587299|NCT04966702|Experimental|Ivermectin human and livestock|The ivermectin group will receive a single dose of 400 mcg/kg, given once a month for three months. Product to be used is Stromectol. For livestock, locally registered veterinary injectable ivermectin at 1% will be used
89587300|NCT04960579|Experimental|P-BCMA-ALLO1 CAR-T cells (Arm S)|"Single weight-based IV administration of P-BCMA-ALLO1 following conditioning chemotherapy regimen S.~Rimiducid may be administered as indicated."
88975631|NCT00214825|Experimental|1|MR antagonist (Eplerenone) + placebo
88975632|NCT00214825|Placebo Comparator|2|Hydrochlorothiazide plus potassium
88975633|NCT00215293|Experimental|Cervical Cage|Cervical I/F Cage
88975634|NCT00215293|Active Comparator|Graft Spacer|Autograft or allograft with a plate, or autograft alone.
88975635|NCT00215332||Training- CHARITE|Non-Randomized Training (TDR with CHARITE)
88975636|NCT00215332||CHARITE|Randomized Subjects treated by Lumbar Total Disc Replacment with CHARITE
88975637|NCT00215332||Control|Randomized Subjects treated by ALIF with BAK cage
88975638|NCT00041483|Active Comparator|Anecortave and Sham PDT|
88975639|NCT00041483|Active Comparator|PDT and Sham Anecortave Acetate|
88975640|NCT00215527|Experimental|intrathecal laronidase|laronidase dose 1.74 mg, route intrathecal, frequency every 30 days, duration three months
88975641|NCT00215605|Experimental|1|
88975642|NCT00215878|Placebo Comparator|1|Adjuvant 6 weeks treatment with placebo (~2g /day)
88975643|NCT00215878|Experimental|2|Adjuvant 6 weeks treatment with D-serine (~2g /day)
88975644|NCT04722406||Low TGR group|Patients with low level of TGR determined by X-tile program
88975645|NCT04722406||High TGR group|Patients with high level of TGR determined by X-tile program
89587301|NCT04960579|Experimental|P-BCMA-ALLO1 CAR-T cells (Arm F)|"Single weight-based IV administration of P-BCMA-ALLO1 following conditioning chemotherapy regimen F.~Rimiducid may be administered as indicated."
89587302|NCT04960579|Experimental|P-BCMA-ALLO1 CAR-T cells (Arm N)|Single weight-based IV administration of P-BCMA-ALLO1. Rimiducid may be administered as indicated.
89587303|NCT04960579|Experimental|P-BCMA-ALLO1 CAR-T cells (Arm P1)|"Single weight-based IV administration of P-BCMA-ALLO1 following conditioning chemotherapy regimen P1.~Rimiducid may be administered as indicated."
89587304|NCT04960579|Experimental|P-BCMA-ALLO1 CAR-T cells (Arm P2)|"Single weight-based IV administration of P-BCMA-ALLO1 following conditioning chemotherapy regimen P2.~Rimiducid may be administered as indicated."
89587305|NCT04960579|Experimental|P-BCMA-ALLO1 CAR-T cells (Arm R)|"Single weight-based IV administration of P-BCMA-ALLO1 following conditioning chemotherapy regimen R.~Rimiducid may be administered as indicated."
89587306|NCT04960579|Experimental|P-BCMA-ALLO1 CAR-T cells (Arm RS)|"Single weight-based IV administration of P-BCMA-ALLO1 following conditioning chemotherapy regimen RS.~Rimiducid may be administered as indicated."
89587307|NCT04960579|Experimental|P-BCMA-ALLO1 CAR-T cells (Arm C)|"Cyclic weight-based IV administration of P-BCMA-ALLO1 following conditioning chemotherapy regimen C.~Rimiducid may be administered as indicated."
89587308|NCT04960579|Experimental|P-BCMA-ALLO1 CAR-T cells (Arm160)|"Single fixed dose IV administration of P-BCMA-ALLO1 following conditioning chemotherapy regimen S, P1, P1.5 or P2.~Rimiducid may be administered as indicated."
89587309|NCT04960579|Experimental|P-BCMA-ALLO1 CAR-T cells (Arm480)|"Single fixed dose IV administration of P-BCMA-ALLO1 following conditioning chemotherapy regimen S, P1, P1.5 or P2.~Rimiducid may be administered as indicated."
89587310|NCT04960579|Experimental|P-BCMA-ALLO1 CAR-T cells (Arm P1.5)|"Single weight-based IV administration of P-BCMA-ALLO1 following conditioning chemotherapy regimen P1.5.~Rimiducid may be administered as indicated."
89587311|NCT04960579|Experimental|P-BCMA-ALLO1 CAR-T cells (Arm RP1)|"Single weight-based IV administration of P-BCMA-ALLO1 following conditioning chemotherapy regimen RP1.~Rimiducid may be administered as indicated."
89587312|NCT04960579|Experimental|P-BCMA-ALLO1 CAR-T cells (Arm RP1.5)|"Single weight-based IV administration of P-BCMA-ALLO1 following conditioning chemotherapy regimen RP1.5.~Rimiducid may be administered as indicated."
89587313|NCT04960579|Experimental|P-BCMA-ALLO1 CAR-T cells (Arm RP2)|"Single weight-based IV administration of P-BCMA-ALLO1 following conditioning chemotherapy regimen RP2.~Rimiducid may be administered as indicated."
89587314|NCT04960579|Experimental|P-BCMA-ALLO1 CAR-T cells (Arm CP1)|"Cyclic weight-based IV administration of P-BCMA-ALLO1 following conditioning chemotherapy regimen CP1.~Rimiducid may be administered as indicated."
89587315|NCT04960579|Experimental|P-BCMA-ALLO1 CAR-T cells (Arm CP1.5)|"Cyclic weight-based IV administration of P-BCMA-ALLO1 following conditioning chemotherapy regimen CP1.5.~Rimiducid may be administered as indicated."
89587316|NCT04960579|Experimental|P-BCMA-ALLO1 CAR-T cells (Arm CP2)|"Cyclic weight-based IV administration of P-BCMA-ALLO1 following conditioning chemotherapy regimen CP2.~Rimiducid may be administered as indicated."
89587317|NCT04957823||Diseased|type II diabetic patients with documented coronary artery disease.
89587318|NCT04957823||Control|type II diabetic patients without coronary artery disease.
89587319|NCT04954898|Experimental|Study Lens|TECNIS Multifocal Toric 1-piece lens, Model ZMT
89587320|NCT04949230||COVID-19 Patients|Subjects who have recovered from COVID-19
89587321|NCT04948697|Experimental|Arm A: ociperlimab + tislelizumab + BAT1706|tislelizumab 200 mg intravenously once every 3 weeks followed by BAT1706 15 mg/kg intravenously once every 3 weeks followed by ociperlimab 900 mg intravenously once every 3 weeks
89587322|NCT04948697|Experimental|Arm B: tislelizumab + BAT1706|tislelizumab 200 mg intravenously once every 3 weeks followed by BAT1706 15 mg/kg intravenously once every 3 weeks
89587323|NCT04948632|Active Comparator|Complete LeoMed application|LeoMed application with integrated artificial intelligence
88975646|NCT00215956|Experimental|Dose Escalation and Radiation, Followed by Surgery|Preoperative treatment with radiation and oral topotecan for up to 5 weeks, followed by surgery.
89587324|NCT04948632|Placebo Comparator|Basic LeoMed application|LeoMed application without artificial intelligence
89587325|NCT04942405|Experimental|TURKOVAC SARS-COV-2 Vaccine|600 Subunit of SARS-CoV-2 virus antigen, intramuscular injection, two doses given 28 days apart.
89587326|NCT04942405|Active Comparator|CoronaVac|600 Subunit of SARS-CoV-2 virus antigen, intramuscular injection, two doses given 28 days apart.
88975647|NCT00215995|Experimental|Cisplatin, Irinotecan and ZD1839|As outlined in Detailed Description.
88975648|NCT00216034|Active Comparator|1|TS-1 Group: The group treated with TS-1 mono-therapy
88975649|NCT00216034|Experimental|2|TS-1+PSK Group: The group treated with combination therapy using TS-1 and PSK
88975650|NCT00216073|Active Comparator|1|Capecitabine + Oxaliplatin + trastuzumab. Patients must be HER2 positive.
88975651|NCT00216112|Experimental|Investigational Treatment|Imatinib Mesylate + Docetaxel
88975652|NCT00216151|Active Comparator|A|Patients will be randomly assigned by study number to receive 4mg of zoledronic acid every three months.
88975653|NCT00216151|No Intervention|B|Patients will be randomly assigned by study number to observation only.
88975654|NCT00216190|Experimental|Dexmedetomidine|
88975655|NCT00216190|Active Comparator|Midazolam|
88975656|NCT04722211|Experimental|PS128|Each PS128 capsule contained >1 × 10^10 colony forming units (CFU) with microcrystalline cellulose and weights 425 ± 25 mg
88975657|NCT04722211|Placebo Comparator|placebo|The placebo capsules only contained 425 ± 25 mg microcrystalline cellulose
88975658|NCT00216463|Experimental|A|Slow load with every other week maintenance
88975659|NCT00216463|Experimental|B|Slow load with every other week maintenance
88975660|NCT00216463|Experimental|C|No load; once weekly maintenance
88975661|NCT00216463|Experimental|D|No load; once weekly maintenance
88975662|NCT00216463|Experimental|E|No load; once weekly maintenance
88975663|NCT00216580|Experimental|Risperidone, long-acting injectable|
88975664|NCT00041561|Placebo Comparator|2|Nitrogen gas
88975665|NCT00041561|Experimental|1|Inhaled Nitric Oxide
89587327|NCT04941287|Experimental|Arm A (cobimetinib, atezolizumab, varlilumab)|Patients receive cobimetinib PO QD on days 1-21 of each cycle, atezolizumab IV over 30-60 minutes on days 1 and 15 of each cycle, and varlilumab IV over 90 minutes on days 1 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo a CT or MRI at baseline, every 8 weeks while on treatment, and at end of treatment or progression. Patients also undergo a tumor biopsy at baseline and on day 21 of cycle 1. Patients also undergo blood sample collection on study.
89587328|NCT04941287|Experimental|Arm B (atezolizumab, varlilumab)|Patients receive atezolizumab IV over 30-60 minutes on days 1 and 15 of each cycle and varlilumab IV over 90 minutes on days 1 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo a CT or MRI at baseline, every 8 weeks while on treatment, and at end of treatment or progression. Patients also undergo a tumor biopsy at baseline and on day 21 of cycle 1. Patients also undergo blood sample collection on study.
89587329|NCT04939597|Experimental|Arm I (memantine hydrochloride)|Patients receive memantine hydrochloride orally PO QD for week 1 and then BID for weeks 2-24 in the absence of disease progression or unacceptable toxicity. Patients also complete cognitive testing over 20-30 minutes at baseline, end of radiation therapy, and at 3, 6, 12, 24, and 48 months. Patients undergo MRI and may optionally undergo blood sample collection throughout the trial.
89587330|NCT04939597|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD for week 1 and then BID for weeks 2-24 in the absence of disease progression or unacceptable toxicity. Patients also complete cognitive testing over 20-30 minutes at baseline, end of radiation therapy, and at 3, 6, 12, 24, and 48 months. Patients undergo MRI and may optionally undergo blood sample collection throughout the trial.
89587331|NCT04936321|Active Comparator|Sleep Education + CBT for Pain|Participants will receive access to internet-delivered sleep education during Phase 1 (6 weeks) of the study followed by internet-delivered CBT for pain management during Phase 2 (6 weeks) of the study.
89587332|NCT04936321|Experimental|CBT for Insomnia + CBT for Pain|Participants will receive access to internet-delivered CBT for insomnia during Phase 1 (6 weeks) of the study followed by internet-delivered CBT for pain management during Phase 2 (6 weeks) of the study.
89587333|NCT04921241||SARS-CoV-2 Exposed Dyads|Mothers who had SARS-CoV-2 during pregnancy and their offspring
89587334|NCT04921241||SARS-CoV-2 Unexposed Dyads|Mothers who were not known to have SARS-CoV-2 during pregnancy and their offspring
89587335|NCT04909970|Experimental|Self hypnosis|Self-hypnosis program associated to usual practice of stress management
89587336|NCT04909970|Other|control group (waiting list)|Usual practice of stress management. This group will practice self-hypnosis after the intervention group has practiced self-hypnosis (waiting list).
89587337|NCT04896268|Experimental|Radiofrequency|Rafaelo's technique consists of delivering a low temperature 4 MHz radiofrequency wave current into the haemorrhoidal vascular tissue using a large single-use needle with microfibre electrodes at the end. The intracellular water in the tissue and the injection of a locally injectable Xylocaine cushion serve as resistance to the vaporisation waves without releasing water vapour, thus avoiding the damage usually encountered in electrosurgery. The delayed phenomenon is cell volatilisation. Vaporisation of the tissue allows significant haemostasis without burns. Tissue changes will depend directly on the temperature emitted and the duration of exposure to the radiofrequence current. The fibrosis process starts during the session and continues for several days to weeks, allowing the reduction of the haemorrhoidal cushions.
89587338|NCT04896268|Active Comparator|Arterial ligation then recto-anal repair with Doppler|"Arterial ligation aims to de-arterialise the haemorrhoids by selectively decreasing the arterial flow of the haemorrhoidal plexuses while avoiding obstructing the venous return. It is distinguished from mucopexy or recto anal repair (RAR®) which fixes the prolapsed hemorrhoidal plexus. Instead of excising the haemorrhoids, the principle is to reduce their size and to restore the anatomical relationships of the haemorrhoidal plexuses in the anal canal."
89587339|NCT04896034|Placebo Comparator|" control 1  fake MILTA device"|Fake device (control 1) which emits 10% red light (and no infrared) so that the difference between the two machines cannot be seen with the naked eye. The magnets present in the real device are absent in the fake machine and replaced by inert materials of the same mass.
89587340|NCT04896034|Experimental|MILTA Device|The MILTA device used for the study is composed of a panel which gathers 18 emitters composed of red, green and blue LEDs, 3 nanopulsed infrared laser diodes (cold laser), 3 infrared diodes and a permanent magnet
88975666|NCT00216619|Experimental|Open Label Phase|Topiramate treatment started with one tablet per day, taken in the evening, for the first 7 days of the OL phase. Each tablet contained 25 mg topiramate. After one week, the dose was raised to two tablets per day: one tablet was taken in the morning, the other in the evening. Until Week 26
88975667|NCT00216619|Experimental|Double Blind and Roll Out Phase|the trial medication consisted of topiramate 25 mg tablets or matching placebo tablets which were identical in appearance, taste and smell. DB randomisation phase (after the 26-weeks OL phase) were randomly allocated (1:1) to one of the two treatment groups (topiramate or placebo). The randomisation took place at Visit 6 (Week 26).
88975668|NCT00216853||Patients with Recurrent UTI|
88975669|NCT00216853||Healthy controls|
88975670|NCT00216970|No Intervention|1|"Patients will receive nutritional support in which the contents of arginine = 0, glutamate = 0 and proline = 0.~Stable isotope tracer studies will be conducted to investigate the whole body protein metabolism and the utilization of arginine in critically ill burn patients."
88975671|NCT00216970|No Intervention|2|In arm 2 patients will receive nutritional support which will provide glutamine 0.5g/kg/day. Stable isotope tracer studies will be conducted to investigate the whole body protein metabolism and the utilization of arginine in critically ill burn patients.
88975672|NCT00217009|Active Comparator|Narrowband Ultraviolet B (TL-01UVB) Therapy|treatments - 3x weekly for 15 months
88975673|NCT00217009|Active Comparator|Topical Psoralen plus ultraviolet A (PUVA)|Treatments - 3x weekly for 15 months
88975674|NCT00412048|Other|ALZHEIMER DISEASE|
88975675|NCT00412048|Other|MOLD COGNITIVE IMPAIRMENT|
88975676|NCT00412048|Other|CONTROLS|
88975677|NCT00412165|No Intervention|usual care|Usual care arm receives standard physical activity, nutrition and weight loss information from their primary care provider. The study offers and pays for a series of weight management sessions provided by Rady's Children's Hospital and Health Center's Nutrition Dept.
89587341|NCT04896034|No Intervention|" control 2  standard pain management with medication"|In first intention: PARACETAMOL: max 1 g x 4 / 24 h Second intention: IBUPROFEN: max 100 mg x 2 for 48 h Third intention: ACUPAN 20 mg in sugar 3 times per 24 h Last intention: ACTISKENAN 10 mg x 4 / 24 h
89587342|NCT04893525|Active Comparator|Buprenorphine/naloxone Microdosing|"Participants with Opioid use disorder will receive a Buprenorphine/naloxone microdosing package from the ED. This will consist of a five-day take-home packages with gradually increasing doses of 2mg/0.5mg buprenorphine/naloxone tablet employing a four times daily dosing schedule over five days.~Day 1: Buprenorphine 0.5 mg-naloxone 0.125 mg SL* QID** (One quarter tablet),~Day 2: Buprenorphine 1 mg-naloxone 0.25 mg SL QID (One half tablet),~Day 3: Buprenorphine 2 mg-naloxone 0.5 mg SL QID (1 tablet),~Day 4: Buprenorphine 3 mg-naloxone 0.75 mg SL QID (1.5 tablets)~Day 5: Buprenorphine 16 mg-naloxone 4 mg SL once daily (8 tablets).~*SL: Sublingual~** QID: four times daily"
89587343|NCT04893525|Active Comparator|Buprenorphine/naloxone Standard Dosing|"The control intervention will be provision of a buprenorphine/naloxone standard dosing package from the ED. This will consist of a five day package with a commonly accepted standard dosing regimen aiming to achieve a therapeutic buprenorphine/naloxone dose within 24 hours of initiation. Standard dosing packages are currently available in EDs in BC and Alberta as standard of care.~Day 1: Buprenorphine 2 mg-naloxone 0.5 mg SL q1h prn to a maximum of 6 tablets in the first 24 hours (1 tablet),~Day 2: Buprenorphine 12 mg-naloxone 3 mg SL once daily (6 tablets),~Day 3: Buprenorphine 16 mg-naloxone 3 mg SL once daily (8 tablets),~Day 4:Buprenorphine 16 mg-naloxone 3 mg SL once daily (8 tablets).~Day 5:Buprenorphine 16 mg-naloxone 3 mg SL once daily (8 tablets)."
89587344|NCT04886258|Active Comparator|DFV890|DFV890
89587345|NCT04886258|Placebo Comparator|Placebo|Placebo
89587346|NCT04879368|Experimental|RegoNivo|"Participants in the RegoNivo arm will;~self-administer 90mg (3x30mg) of regorafenib days 1-21 of each 28-day treatment cycle and;~receive intravenous nivolumab 240 mg day 1 of each 14 day cycle until disease progression or prohibitive adverse events as per protocol, given in hospital by infusion.~After 2 months, patients whose disease is controlled may have nivolumab administered 480 mg every 28 days."
89587347|NCT04879368|Active Comparator|Standard of Care|"Participants in the control arm will receive investigator choice chemotherapy with any of the following agents~taxane (paclitaxel or docetaxel)~irinotecan or~oral trifluridine/tipiracil (TAS102)~All treatment groups will receive Best Supportive Care (BSC)."
89587348|NCT04867837|Experimental|Octaplex Low-dose|Participants to receive 1 Octaplex infusion intravenously
89587349|NCT04867837|Experimental|Octaplex High-dose|Participants to receive 1 Octaplex infusion intravenously
89587350|NCT04867460|Experimental|Ultrasound guided venous access|Vascular access of the axillary vein will be performed using an ultrasound system (Siemens Acuson Freestyle) with a wireless vascular ultrasound probe (L8-3 or L13-5). One or more vascular punctures will be performed, as needed.
89587351|NCT04867460|No Intervention|Standard of care|Vascular access of the axillary or subclavian vein will be performed using anatomical landmarks, fluoroscopy and/or injection of X-ray contrast in the antecubital vein, at the choice of the implanter. One or more vascular punctures will be performed, as needed.
89587352|NCT04862975||Drug of Interest|Lactating moms receiving one or more antiretroviral drugs and their breastmilk fed infants per standard of care.
89587353|NCT04859660|Experimental|Tamsulosin- intervention group|
89587354|NCT04859660|Placebo Comparator|Placebo group|
89587355|NCT04852588|Experimental|Treatment Arm|Small pieces of suspicious chest lymph nodes will be removed with a procedure called endobronchial ultrasound-guided transbronchial fine needle aspiration (EBUS-TFNA) or transesophageal ultrasound-guided fine needle aspiration (EUS-FNA).
89030370|NCT04516460|Experimental|PuraStat|Interventional arm: PuraStat® applied through a catheter delivery system via the endoscope is used to prevent bleeding after endoscopic resection
89587356|NCT04843930|Experimental|AKL-T01 Intervention|Participants in the experimental group will complete 6 weeks of the AKL-T01 intervention. Participants enrolled in the intervention arm will play the game via an iPad application for 20-25 minutes daily for at least 5 days a week (but up to 7 days a week). Participants will also have weekly check-in visits via phone or a secure HIPAA compliant videoconferencing platform (Zoom) with a care manager, who will monitor mood symptoms and gameplay adherence.
89030371|NCT00504543|Active Comparator|Neoral|
89587357|NCT04843930|No Intervention|Waitlist Control|Participants in the Waitlist Control arm will not be engaging in any active control condition. Participants in the waitlist control arm will continue any ongoing self- or provider-based cognitive intervention (or no intervention) during the initial 6-week waitlist period. Participants will also have weekly check-in visits via phone or a secure HIPAA compliant videoconferencing platform (Zoom) with a care manager, who will monitor mood symptoms. The control arm will be offered the intervention at the end of 6 weeks waitlist period to ensure all participants ultimately have access to the intervention.
89587358|NCT04839406|Experimental|Intervention|"Structured follow up at the ICU~1-3 days after admittance: Map caregivers' prioritized symptoms, needs and preferences with a digital assessment tool, followed by a meeting with a nurse to address these issues.~Every 1-2 weeks: Repeat assessment of symptoms and needs with the assessment tool followed by a meeting with a nurse.~At discharge: Structured conversation focusing on information and preparation for the transition to a regular ward or to another hospital including a card with information and support.~Bereavement: Individualized support based on caregiver expressed needs, preferences and previous mapping, including a card with information and support.~Follow up: Caregivers or bereaved will be contacted after 4-6 weeks, and will be offered a follow up conversation either on phone or at the unit."
89587359|NCT04839406|No Intervention|Follow up as usual (Control)|Follow up as usual at the ICU
89587360|NCT04834414|Active Comparator|Room Temperature Platelets|Platelets stored at 20-24 degrees Celsius
89587361|NCT04834414|Experimental|Cold Stored Platelets|Platelets stored at 1-6 degree Celsius
89587362|NCT04818255|Experimental|Disclosure|Participants who demonstrated decisional capacity for and interest in disclosure (or whose care partner is able to do so) will receive the participant's personalized PET amyloid and tau biomarker status, as well as information about the meaning and clinical utility of this information and recommendations for next steps (e.g., discussing findings with his/her provider).
89587363|NCT04817956|Experimental|Atezolizumab|Atezolizumab used outside of current indication, based on biomarkers
89030372|NCT00504543|Active Comparator|AEB071 high dose with Cetican reduced dose|
89030373|NCT00504543|Active Comparator|AEB071 low dose with Cetican standard dose|
89587364|NCT04817956|Experimental|Atezilizumab combined with bevacizumab|Atezilizumab combined with bevacizumab used outside of indication, based on biomarkers
89587365|NCT04817956|Experimental|Phesgo (trastuzumab og pertuzumab)|Phesgo used outside of indication, based on biomarkers.
89587366|NCT04817956|Experimental|Alectinib|Alectinib used outside of indication, based on biomarker
89587367|NCT04817956|Experimental|vismodegib|vismodegib used outside of indication, based on biomarker
89587368|NCT04817956|Experimental|entrectinib|entrectinib used outside of indication, based on biomarker
89587369|NCT04817956|Experimental|Zelboraf + Cotellic|Zelboraf + Cotellic used outside of indication, based on biomarker
89587370|NCT04817956|Experimental|Alpelisib|Alpelisib used outside of indication, based on biomarker
89587371|NCT04817956|Experimental|Dabrafenib + trametinib|Used outside of indication, based on biomarker
89587372|NCT04817956|Experimental|Melfalan|Melfalan used outside ofcurrent indication
89587373|NCT04817956|Experimental|Pemazyre|Pemazyre used outside ofcurrent indication
89587374|NCT04817956|Experimental|Selpercatinib|used outside ofcurrent indication
89587375|NCT04817956|Experimental|Olaparib|Used outside of current indication, for patients with bi-allelic BRCA-inactication
89587376|NCT04817956|Experimental|Capmatinib|Used outside of current indication,
89587377|NCT04817956|Experimental|Imatinib|Used outside of current indication,
89587378|NCT04817956|Experimental|Bortezomib|Used outside of current indication,
89587379|NCT04817956|Experimental|Actinomycin D|Used outside of current indication,
89587380|NCT04817956|Experimental|Niraparib|Used outside of current indication,
89587381|NCT04817956|Experimental|Dostarlimab|Used outside of current indication
89587382|NCT04817956|Experimental|Ceritinib|Used outside of current indication
89030374|NCT02949570|Experimental|Treatment|
89587383|NCT04799587|Active Comparator|P6 Accupressure Group|The pressure point will be stimulated by the presence of the magnet when positioned properly on the P6 acupressure point. Additional pressure may be applied as desired by the study subject but is not necessary for P6 stimulation.
89587384|NCT04799587|Sham Comparator|Sham Pressure Point|The sham pressure point (distal to the P6 acupressure point).
89587385|NCT04791787|Active Comparator|Standard Weight Maintenance|Standard weight maintenance diet will be provided for 10 days for subjects who are not currently treated with a T2DM medication.
89587386|NCT04791787|Active Comparator|Isocaloric Diet|Isocaloric diet will be provided for 10 days for subjects who are currently treated with a T2DM medication included in the inclusion criteria
89030375|NCT02949843|Experimental|Arm I (nivolumab, pembrolizumab)|Patients receive nivolumab IV over 60 minutes every 2 weeks or pembrolizumab IV every 3 weeks in the absence of disease progression or unacceptable toxicity.
89030376|NCT02949843|Experimental|Arm II (kinase inhibitor, chemotherapy, immunotherapy)|Patients receive tyrosine kinase inhibitor therapy PO targeting the initial oncogenic driver or other treatment for about 3 weeks.
89209777|NCT00729365|Active Comparator|NonDippers - Ramipril Treated|Subjects with nighttime blood pressure that does not drop during the night (non-dippers). This group will be given ACE inhibitor (study medication).
89587387|NCT04791787|Active Comparator|Isocaloric Diet with Beta-hydroxy butyrate|Isocaloric diet with Beta-hydroxy butyrate will be provided for 10 days for subjects who are not currently treated with a T2DM medication.
89587388|NCT04788615|Experimental|ofatumumab|Oftatumumab 20mg auto injector syringes for subcutaneous injection on Day 1, Week 1 and 2, followed by subsequent monthly dosing, starting at Month 1.
89587389|NCT04788615|Active Comparator|First line DMT|"Glatiramer acetate minimum dose 20mg or maximum dose 40mg twice a day or three times a week or~Interferon minimum dose 22µg or maximum dose of 0.25mg 3 times a week or once a week or Every second week depending on preparation or~Peg-Interferon beta-1a minimum dose of 63µg or maximum dose of 125µg every 2 weeks (14 days) or~Teriflunomide 14 mg once a day or~Dimethyl fumarate minimum dose of 120mg or maximum dose of 240mg twice a day~Diroximel fumarate minimum dose of 231mg or maximum dose of 462mg twice a day"
89587390|NCT04770714|Other|Breast MRI|Patients in this arm will be randomized to receive a Breast MRI in order to delineate the extent of a known cancer and / or assess for the presence of occult secondary cancers
89587391|NCT04770714|Other|Contrast Enhanced Mammography|Patients in this arm will be randomized to receive a Contrast Enhanced Mammograph in order to delineate the extent of a known cancer and / or assess for the presence of occult secondary cancers
89587392|NCT04731519|Active Comparator|General Health Education Active Control Group|The control condition will receive General Health Education a structured manualized group health education intervention previously developed by VISN 2 MIRECC investigators as a control condition for group psychotherapy RCTs. It has 12 1.5-hour weekly group sessions focusing on health and wellness topics such as Sleep, Physical Activity, Impact of Stress, Relaxation Techniques, Substance Use, Nutrition, Managing Daily Activities, Medication Benefits and Side Effects. GHE was chosen for the AC because it aligns in many respects with CI-CT (e.g., group format, length of sessions, similar expectations) while diverging in specific topics and skills targeted allowing for control of common factors like attention without causing confounding due to overlap in concepts
89587393|NCT04731519|Experimental|CI-CT Group|The experimental group will receive CI-CT (Continuous Identity Cognitive Therapy). CI-CT is planned to be a weekly, 90-minute, 12-session group treatment and to be run by two clinicians using the final version manual and workbook. CI-CT was developed as a manualized treatment integrating components of CBT and Acceptance and Commitment Therapy (ACT) with self-continuity and future-self related interventions to help Veterans develop a better present-to-the-future life story as a framework for increasing hopefulness, a sense of life meaning, empowerment, and an ability to attain future self-goals. The CI-CT includes eight components: 1) constructing a CI narrative, 2) mindfulness training, 3) life values identification, 4) developing a self-growth perspective, 5) identifying possible future selves - timelines, 6) connecting with the desired future self, 7) CI as context for current problems, and 8) moving toward the future self.
89587394|NCT04731519|Other|CI-CT Treatment Development Group|The 3 treatment development groups will receive CI-CT (Continuous Identity Cognitive Therapy). CI-CT is planned to be a weekly, 90-minute, 12-session group treatment and to be run by two clinicians using the final version manual and workbook. CI-CT was developed as a manualized treatment integrating components of CBT and Acceptance and Commitment Therapy (ACT) with self-continuity and future-self related interventions to help Veterans develop a better present-to-the-future life story as a framework for increasing hopefulness, a sense of life meaning, empowerment, and an ability to attain future self-goals. The CI-CT includes eight components: 1) constructing a CI narrative, 2) mindfulness training, 3) life values identification, 4) developing a self-growth perspective, 5) identifying possible future selves - timelines, 6) connecting with the desired future self, 7) CI as context for current problems, and 8) moving toward the future self.
89587395|NCT04731272|Experimental|Dulaglutide|The Mixed Meal Tolerance Test as described in the primary outcome section will be performed at baseline and after 6 weeks of dulaglutide therapy in the intervention period.
89587396|NCT04731272|No Intervention|Observation|The Mixed Meal Tolerance Test as described in the primary outcome section will be performed at baseline and after 6 weeks of no intervention in the observation period.
89587397|NCT04728815|Experimental|CAMS to Maintenance|Subject assigned to CAMS for Phase 1. Subject is a Phase 1 CAMS Responder, thus placed into ongoing Maintenance/Monitoring.
89587398|NCT04728815|Experimental|CAMS to CAMS|Subject assigned to CAMS for Phase 1. Subject is a Phase 1 CAMS Insufficient Responder, then assigned to Phase 2 CAMS.
89587399|NCT04728815|Experimental|CAMS to DBT|Subject assigned to CAMS for Phase 1. Subject is a Phase 1 CAMS Insufficient Responder, then assigned to Phase 2 DBT.
88975678|NCT00412165|Experimental|Intervention - Web|This group receives access to a program internet site with weekly challenges aimed at weight loss through increased physical activity and nutrition.
88975679|NCT00412165|Experimental|Intervention - Group|This group receives access to a program internet site with weekly challenges aimed at weight loss through increased physical activity and nutrition and has access to monthly group session with other teen and parent participants.
88975680|NCT00412165|Experimental|Intervention - Cell Phone|This group receives access to a program internet site with weekly challenges aimed at weight loss through increased physical activity and nutrition and are provided with cell phones to use during the program. The cell phone allows for the transfer of text messages from the study to the participant that are tailored to their health goals. In addition, self-monitoring and uploading capabilities to the program website are included.
88975681|NCT00412204|Active Comparator|1|Tiotropium
88975682|NCT00412204|Placebo Comparator|2|Placebo
88975683|NCT00217243||Pain study Netherlands|20 healthy subjects 20 patients with a traumatic unilateral peripheral nerve injury 20 patients with CRPS I
88975684|NCT00217477|Experimental|Paricalcitol IV in combination with Gemcitabine IV|Patients receive gemcitabine hydrochloride IV over 80 minutes on days 1, 8, and 15 and paricalcitol IV over 15 minutes on days 7 and 14 in course 1. Beginning in course 2, patients receive paricalcitol IV over 15 minutes on days 1, 8, and 15 and gemcitabine hydrochloride IV over 80 minutes on days 2, 9, and 16. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
88975685|NCT00217516|Experimental|Arm I|Patients receive oral selenium for 3-6 weeks.
88975686|NCT00217516|Placebo Comparator|Arm II|Patients receive oral placebo for 3-6 weeks.
88975687|NCT00217633|Experimental|Treatment (pelvic exenteration)|Patients undergo pelvic exenteration within 14 days after study entry.
88975688|NCT00217711|Active Comparator|Arm A|Oxaliplatin, Irinotecan, and Capecitabine
88975689|NCT00041951||CAE participants|Both parents and a child with CAE of families without other affected members (trios) or whole families with many members affected with epilepsy.
88975690|NCT00041951||Controls|Healthy individuals without epilepsy and no family history of epilepsy.
89587400|NCT04728815|Experimental|TAU to Maintenance|Subject assigned to TAU for Phase 1. Subject is a Phase 1 TAU Responder, thus placed into ongoing Maintenance/Monitoring.
89587401|NCT04728815|Experimental|TAU to CAMS|Subject assigned to TAU for Phase 1. Subject is a Phase 1 TAU Insufficient Responder, then assigned to Phase 2 CAMS.
89587402|NCT04728815|Experimental|TAU to DBT|Subject assigned to TAU for Phase 1. Subject is a Phase 1 TAU Insufficient Responder, then assigned to Phase 2 DBT.
88975691|NCT04722757|Experimental|transanal IPAA|In the experimental arm, patients will undergo transanal dissection of the distal part of the rectum. After proctectomy, an ileal pouch-anal anastomosis (IPAA) will be created. A Gelpoint Path will be used to create access through the anus. Postoperative care will occur following the hospital specific protocols.
88975692|NCT04722757|Active Comparator|transabdominal IPAA|In the control group, proctectomy will occur through abdominal dissection (laparoscopy, single port laparoscopy, robotic or open). Postoperative care will occur following the hospital specific protocols.
88975693|NCT04729881|Experimental|Conventional Rehabiliation Group|"Participants 5 days a week for 4 weeks; TENS, US and neck specific exercise program will be applied.~Conventional TENS will be applied to the participants with the CefarCompex rehab400 (New Chattanooga Compex Rehab, USA) muscle rehabilitation device. It will be applied with electrodes coated with a special adhesive material for each participant for 20 minutes at a frequency of 60-120 Hz. In the study; 4 channels and 8 electrodes will be used. Electrodes will be placed paravertebrally in the cervicothoracic space, covering the painful area. The dose of the current will be increased as the patients become accustomed to the current intensity.~Continuous Ultrasound will be applied to the participants due to chronic neck pain. It will be applied at a frequency of 1MHz and a dose of 1.5 W / cm2 for 5 minutes."
89209778|NCT00818870|Active Comparator|Omeprazole 20 mg|
89587403|NCT04728815|Experimental|DBT Only|Subject Assigned to DBT for Phase 1, continuing up to 16 weeks.
89587404|NCT04728815|No Intervention|Study Counselors|Consented Study Counselors from each of the 4 sites. Data collected regarding the Counselors is minimal and is maintained completely separately from the other 7 Student Participant Arms/Groups.
89587405|NCT04726241|Experimental|Screening (biospecimen collection)|Patients undergo collection of blood and/or bone marrow samples at baseline, end of treatment cycle(s), and at relapse/refractory disease status (if applicable).
89587406|NCT04704986|Active Comparator|PVI using the Arctic Front Cryoballoon (Medtronic)|Pulmonary vein isolation using the Arctic Front Cryoballoon (Medtronic)
89587407|NCT04704986|Active Comparator|PVI using the PolarX Cryoballoon (Boston Scientific)|Pulmonary vein isolation using the PolarX Cryoballoon (Boston Scientific)
89587408|NCT04704154|Experimental|Regorafenib+Nivolumab|Parallel-cohort in adult participants with selected recurrent or metastatic tumors (HNSCC, ESCC, PDAC, BTC, and GBM/AA) who have been previously treated with one or more systemic therapy for the selected tumor indication.
89587409|NCT04696198|Experimental|Range of motion|Treatment is based on a set diagnostic and therapeutic protocol and carried out by registered health care professionals that are additionally trained in manual therapy intervention. 30 minutes of treatment will be given once a week over a period of two months
89587410|NCT04696198|Other|Standard care|Standard care
89587411|NCT04691622|Experimental|Norovirus -specific T-cell (NST) therapy for chronic norovirus infection|"This is a Phase I dose-escalation study to evaluate the safety of norovirus -specific T-cell (NST) therapy for chronic norovirus infection in participants following hematopoietic stem cell transplantation (HSCT) or with primary immunodeficiency disorders (PID) who have not undergone HSCT. There are two arms in this study:~Arm A: Participants who receive donor-derived NST therapy after HSCT~Arm B: Participants who receive partially HLA matched NSTs. The following participants apply:~Participants with PID who have not undergone HSCT~Participants who undergo HSCT but do not have available donor derived NSTs~Participants who have donors from whom NSTs cannot be generated due to norovirus seronegativity"
89587412|NCT04684368|Experimental|Plan A (chemotherapy, WVSCI, second-look surgery if needed)|See Outline in Detailed Description.
89587413|NCT04684368|Experimental|Plan B (chemotherapy, HDCSCR, second-look surgery if needed)|See Outline in Detailed Description.
89587414|NCT04675931|Experimental|IV KAE609 Dose regimen 1|Intravenous KAE609 (cipargamin) 20 mg
89587415|NCT04675931|Experimental|IV KAE609 Dose regimen 2|Intravenous KAE609 (cipargamin) 40 mg
89587416|NCT04675931|Experimental|IV KAE609 Dose regimen 3|Intravenous KAE609 (cipargamin) Dose regimen 3 (dose will be evaluated post Interim analysis from Cohort 1 and Cohort 2.
89587417|NCT04675931|Active Comparator|IV Artesunate|IV Artesunate 2.4 mg/kg (for participants weighing at least 20 kg) IV Artesunate 3 mg/kg (for participants weighing less than 20 kg)
89587418|NCT04675931|Other|Coartem|Standard of care (Coartem) will be given to all participants for 3 days as part of treatment.
89587419|NCT04671251|Experimental|AEVI-007|Open-label, dose-escalation, single-arm
89587420|NCT04665570||Treatment|The decision to prescribe Acarbose/Metformin fixed dose combination (FDC) will be solely at the discretion of the Investigator and in accordance with his/her experience. Patients can only be enrolled in the study if the decision to treat with Acarbose/Metformin fixed dose combination has been made by the treating physician in advance and independent of study inclusion.
89587421|NCT04655508|Experimental|Seretide|"For children between 6 to 11 years (< 12 years): 50 μg inhaled fluticasone propionate and 25 μg salmeterol (SERETIDE® 50/25) :two puffs twice a day from randomisation during 6 months using inhalation chamber~- For children between 12 to 17 years (> or = 12 years) : 125 μg inhaled fluticasone propionate and 25 μg salmeterol (SERETIDE® 125/25): two puffs twice a day from randomisation during 6 months using inhalation chamber"
89587422|NCT04655508|Placebo Comparator|placebo|For children between 6 to 11 years (< 12 years): placebo of SERETIDE® 50/25 :two puffs twice a day from randomisation during 6 months using inhalation chamber For children between 12 to 17 years (> or = 12 years) : placebo of SERETIDE® 125/25: two puffs twice a day from randomisation during 6 months using inhalation chamber
89587423|NCT04653181|Experimental|Iron arm|Half of patients get i.v. iron preoperatively
89030377|NCT02949843|Experimental|Arm III (kinase inhibitor, targeted therapy, other treatment)|Patients receive tyrosine kinase inhibitor therapy PO targeting initial oncogenic driver, a drug targeting the secondary mutation, or other treatment for about 3 weeks.
89030378|NCT04516343|Experimental|User testing|Two sessions of user-centric testing.
89030379|NCT04516343|Experimental|Therapist-guided training|Therapist-guided gait training with the RAAD.
89030380|NCT04516343|Experimental|Assistance training|Assistance training with the RAAD
89587424|NCT04653181|No Intervention|non-iron arm|Half of patients are treated without i.v. iron substitution
89587425|NCT04648371|Active Comparator|Cognitive Remediation and Active Transcranial Direct Current Stimulation|Cognitive Remediation (CR) is a form of group psychosocial intervention that uses a hybrid approach of restorative and strategy based methods to improve areas of cognition (ie. attention, memory, processing speed and learning) through the use of computerized exercises. Transcranial Direct Current Stimulation (tDCS): tDCS will be administered for 30 min/day, at the beginning of each group session. tDCS montage will be frontal with anode placed over Fz and the cathode over Iz. The direct current will be of 2 mA (current density = 0.57 A/m2). CR + tDCS is administered in groups consisting of 2-10 participants and one or two therapists. The groups meet 5 times per week for two hours per session over eight weeks, for a total of 40 sessions in induction phase. Afterwards 3 to 5 sessions per week on monthly boosters.
89587426|NCT04648371|Sham Comparator|Cognitive Remediation and Sham Transcranial Direct Current Stimulation|CR is identical to the one described under the Active Comparator Arm. However, sham tDCS will consist of active stimulation for only 1 min/day, at the beginning of each group session. tDCS montage and the frequency of the sessions and the boosters will be the same as for the Active Arm.
89587427|NCT04647409|Other|participants|
89587428|NCT04629196|Experimental|IV Weight-Based Induction Dose|
89587429|NCT04629196|Active Comparator|Standard Subcutaenous Dose|
89587430|NCT04593589|Experimental|Transplantation|Submandibular Gland Stem Cell Transplantation
89587431|NCT04588363||SARS-CoV-2 positive children|"Individuals less than 21 years of age who fulfill one or more of the following criteria:~SARS-CoV-2 detection from a respiratory specimen, and/or~Meets criteria for MIS-C, and/or~Meets criteria for MIS-C, except has involvement of only 1 organ system"
89587432|NCT04587401|Experimental|normotensive patients|Cerebral perfusion of normotensive patients who will have lumbar surgery at the prone position will be measured by transcranial doppler ultrasonography
89587433|NCT04587401|Experimental|patients with high blood pressure diagnosis|Cerebral perfusion of patients with high blood pressure diagnosis who will have lumbar surgery at the prone position will be measured by transcranial doppler ultrasonography
89587434|NCT04587401|Experimental|patients who do not know they are hypertensive but actual blood pressure is high|cerebral perfusion of patients who do not have high blood pressure diagnosis but actual preoperative blood pressure is higher than normal levels will be measured by transcranial doppler ultrasonography during lumbar surgery
89587435|NCT04582708|Experimental|Subjects with NERv's Inline Device Attached|This arm contains subjects which will have NERv's Inline Device attached to their peritoneal drain after abdominal surgery.
89587436|NCT04582500||patients undergoing CTC receiving iohexol|Patients will be recruited from a pool scheduled to undergo screening or diagnostic CTC for clinical purposes. They will be given 50 ml of Iohexol as a oral contrast
89587437|NCT04578756|Experimental|Cariprazine Dose 1|Participants with Schizophrenia (age 13 to 17 years and < 40 kg body weight) will receive cariprazine.
89587438|NCT04578756|Experimental|Cariprazine Dose 2|Participants with Schizophrenia (age 13 to 17 years and >= 40 kg body weight) will receive cariprazine.
89587439|NCT04578756|Experimental|Cariprazine Dose 3|Participants with Bipolar I Disorder (age 10 to 12 years and <40 kg body weight) will receive cariprazine.
89587440|NCT04578756|Experimental|Cariprazine Dose 4|Participants with Bipolar I Disorder (age 10 to 12 years and >= 40 kg body weight) will receive cariprazine.
89587441|NCT04578756|Experimental|Cariprazine Dose 5|Participants with Bipolar I Disorder (age 13 to 17 years and < 40 kg body weight) will receive cariprazine.
89587442|NCT04578756|Experimental|Cariprazine Dose 6|Participants with Bipolar I Disorder (age 13 to 17 years and >= 40 kg body weight) will receive cariprazine.
89587443|NCT04578756|Experimental|Cariprazine Dose 7|Participants with Autism Spectrum Disorder ( age 5 to 9 years) will receive cariprazine.
89587444|NCT04578756|Experimental|Cariprazine Dose 8|Participants with Autism Spectrum Disorder (age 10 to 12 years and <40 kg weight) will receive cariprazine.
89587445|NCT04578756|Experimental|Cariprazine Dose 9|Participants with Autism Spectrum Disorder (age 10 to 12 years and >=40 kg body weight) will receive cariprazine.
89587446|NCT04578756|Experimental|Cariprazine Dose 10|Participants with Autism Spectrum Disorder (age 13 to 17 years and <40 kg weight) will receive cariprazine.
89587447|NCT04578756|Experimental|Cariprazine Dose 11|Participants with Autism Spectrum Disorder (age 13 to 17 years and >= 40 kg body weight) will receive cariprazine.
89587448|NCT04568226|Experimental|ConquerFear Intervention|Participants in the ConquerFear intervention group will receive a manualized intervention, consisting of 6 therapist-led individual sessions.
89587449|NCT04568226|Active Comparator|Basic Cancer Care|Basic Cancer Care serves as an active comparator and is not developed specifically to target fear of cancer recurrence through modifying participants' cognitive beliefs. Participants in this arm will receive 6 individual sessions including 2 relaxation training sessions, 2 dietetic consultation sessions, and 2 exercise sessions, which will be led by a trained therapist, a registered dietitian, and an exercise physiologist, respectively.
89587450|NCT04555512|Active Comparator|Standard-care interval-training group|Subjects will complete a standard interval-training program that remains constant for the entire 12 weeks of cardiac rehabilitation.
89587451|NCT04555512|Experimental|Progressive interval-training group|Subjects will complete an interval-training program during which the number of intervals and the duration of each interval are changed across the 12-week cardiac rehabilitation program.
89587452|NCT04553744||Observational (survey)|Participants complete an online survey over 5-10 minutes asking how they would manage lymph node basins in the extremity sarcoma.
89587453|NCT04553692|Experimental|Ph1a: Aplitibart Single Agent Alternate Dosing Escalation|Aplitibart will be administered intravenously as a single agent on an alternate dosing schedule.
89587454|NCT04553692|Experimental|Ph1a: Aplitibart + FOLFIRI ± bevacizumab Escalation and Expansion|Aplitibart will be administered intravenously in combination with FOLFIRI± bevacizumab.
89587455|NCT04553692|Experimental|Ph1a: Aplitibart + Birinapant Escalation and Expansion|Aplitibart will be administered intravenously in combination with Birinapant which will also be administered intravenously.
89587456|NCT04553692|Experimental|Ph1a: Aplitibart + Venetoclax Escalation and Expansion|Aplitibart will be administered intravenously in combination with Venetoclax.
89587457|NCT04553692|Experimental|Ph1a: Aplitibart + Docetaxel + Gemcitabine Escalation and Expansion|Aplitibart will be administered intravenously in combination with Docetaxel and Gemcitabine.
89587458|NCT04553692|Experimental|Ph1a: Aplitibart + Venetoclax + Azacitidine Escalation and Expansion|Aplitibart will be administered intravenously in combination with Venetoclax and Azacitidine.
89030381|NCT04516343|Experimental|Therapist supervised resistance training|Resistance training with the RAAD under therapist supervision.
89587459|NCT04553692|Experimental|Ph1b: Aplitibart + FOLFIRI + Bevacizumab|Aplitibart will be administered intravenously in combination with FOLFIRI + bevacizumab
89587460|NCT04553692|Experimental|Ph1b: FOLFIRI + Bevacizumab|Standard of Care FOLFIRI + bevacizumab will be administered intravenously
89587461|NCT04550429|Active Comparator|60 mmHg MyoSure Hysteroscopic Morcellator Device|The rationale for this experimental arm is that the pressurization can result in excess fluid being absorbed by the patient without a substantial benefit to surgical outcome. Minimizing the pressure from 80 mmHg (which is standard of care) to 60 mmHg used during this procedure may optimize outcome without compromising visualization of the surgeon. The research procedure will take place in the operating room of the minimally invasive gynecologic surgery department.
89209779|NCT00818870|Experimental|Vecam 20/300|
89587462|NCT04550429|Sham Comparator|80 mmHg MyoSure Hysteroscopic Morcellator Device|This is the standard of care pressurization for this procedure at Northwestern Medicine and will be the control group for the study
89587463|NCT04529577|Experimental|His-bundle pacing first|Patients are allocated to receive His-bundle pacing for a period of 6 months. Then the patients will cross over to traditional right ventricular (RV) apical pacing for 6 months.
89587464|NCT04529577|Experimental|RV apical pacing first|Patients are allocated to receive traditional RV apical pacing for a period of 6 months. Then the patients will cross over to His-bundle pacing for 6 months.
89587465|NCT04517461||Head and neck free flap surgery patients|Patients undergoing head and neck microvascular free flap surgery at Skåne University Hospital, Lund, Sweden.
89587466|NCT04512586|Experimental|Conduction System pacing plus AV node ablation|"A His-pacing lead in combination with a backup RV pacing lead or an LBB pacing lead, and a right atrial lead (if needed) will be placed using standard technique. The His-pacing or LBB pacing lead will be Medtronic 3830, and the outer sheath will be either Medtronic C304 or C315 deflectable. If failure to implant with these tools, other leads and sheaths can be used at the discretion of the operator. A standard DDD pacemaker or CRT-P device from Medtronic will be used.~A minimum of three weeks post-implant, the device will be interrogated and His-bundle threshold will be evaluated. A threshold of ≤2.0V@1.0ms is acceptable. If the device is well-functioning and successful His-pacing is documented, AV node ablation will be performed."
89587467|NCT04512586|Active Comparator|Pulmonary vein isolation|Atrial fibrillation will be performed as a complete pulmonary vein isolation. Either Cryoballon or radio frequency ablation with irrigated tip contact force enabled catheter can be used. Pulsed field ablation can be used if available. Endpoint is complete electrical isolation of all pulmonary veins, verified by entry- and exit block using a multipolar catheter during pacing.
89587468|NCT04486833|Experimental|Investigational|In Phase 1, Phase 2a and the investigational arm of Phase 2b, patients will receive their assigned dose of quaratusugene ozeplasmid (intravenous administration once every 21 days) plus osimertinib (80 mg fixed dose oral tablet taken daily starting on Day 1 through Day 21 of every 21-day treatment cycle) until disease progression or unacceptable toxicity.
89587469|NCT04486833|Active Comparator|Control|In the control arm of Phase 2b, patients will receive platinum-based chemotherapy until disease progression or unacceptable toxicity.
89587470|NCT04477629|Experimental|Belatacept|Participants will receive Belatacept along with an upfront tacrolimus taper Participants will also receive mycophenolate mofetil and corticosteroids are part of standard of care after heart transplant and will follow dosing recommendations as per standard clinical practice.
89587471|NCT04472156|Experimental|Transfer of mosaic embryo|Women will have a mosaic embryo transferred to their uterus after in vitro fertilization (IVF) with pre implantation genetic testing completed at Colorado Center for Reproductive Medicine.
89587472|NCT04468932|Experimental|Active TMS first|After completing their baseline assessment, participants randomized to this arm will initially take part in a 2-week TMS intervention. After the midpoint assessment and subsequent a 1-month washout, these participants will then complete a 2-week sham TMS period prior to their final assessment.
89587473|NCT04468932|Experimental|Sham treatment first|After completing their baseline assessment, participants randomized to this arm will initially take part in a 2-week sham TMS period. After the midpoint assessment and subsequent a 1-month washout, these participants will then complete a 2-week TMS intervention prior to their final assessment.
89587474|NCT04465708|Other|Homework, Organization, and Planning Skills (HOPS)|"The Homework, Organization, and Planning Skills (HOPS) intervention is delivered through a series of 16 frequent but brief sessions between the HOPS provider and student. The HOPS intervention will be delivered by either a member of the school team (HOPS-ST), referred to as a school provider, or a member of the research team (HOPS-RT), referred to as a research provider. Each session is approximately 20 minutes. The three main skill areas covered as part of the program are: (1) school materials organization, (2) homework management and (3) time management and planning. A reward system is utilized in effort to change behavior patterns by making rewards available when a student engages in productive organizing and planning behaviors. The intervention also includes two parent meetings and one teacher meeting."
89587475|NCT04465708|No Intervention|Treatment-As-Usual Waitlist (WL-TAU)|The Treatment-As-Usual Waitlist (WL-TAU) will be enacted for study participants attending the enrolled schools assigned to this arm. After providing post data (and in some cases, follow-up data as well), participants will then receive the HOPS intervention.
89587476|NCT04464707|Experimental|Fremanezumab|"Participants weighing ≥ threshold will receive Dose A subcutaneously monthly for 3 months.~Participants weighing < threshold will receive Dose B subcutaneously monthly for 3 months."
89587477|NCT04464707|Placebo Comparator|Placebo|Matching placebo
89587478|NCT04445025|Experimental|Test group|Subjects will receive the medication elagolix
89587479|NCT04445025|Active Comparator|Control group|Subjects will receive leuprolide acetate
89587480|NCT04432857|Experimental|Ph1a: Urothelial carcinoma of the bladder and NSCLC|Patients will receive AN0025 orally once daily (QD); Pembrolizumab, 200mg as an intravenous infusion over 30 minutes every 3 weeks.
89587481|NCT04432857|Experimental|Phase 1b: Urothelial carcinoma of the bladder|Patients will receive AN0025 orally once daily (QD); Pembrolizumab, 200mg as an intravenous infusion over 30 minutes every 3 weeks.
89587482|NCT04432857|Experimental|Phase 1b: Non-Small Cell Lung Cancer (NSCLC)|Patients will receive AN0025 orally once daily (QD); Pembrolizumab, 200mg as an intravenous infusion over 30 minutes every 3 weeks.
89587483|NCT04432857|Experimental|Phase 1b: Triple-negative breast cancer (TNBC)|Patients will receive AN0025 orally once daily (QD); Pembrolizumab, 200mg as an intravenous infusion over 30 minutes every 3 weeks.
89587484|NCT04432857|Experimental|Phase 1b: Cervical|Patients will receive AN0025 orally once daily (QD); Pembrolizumab, 200mg as an intravenous infusion over 30 minutes every 3 weeks.
89587485|NCT04432857|Experimental|Phase 1b: Microsatellite Stable (MSS) Colorectal Cancer (CRC)|Patients will receive AN0025 orally once daily (QD); Pembrolizumab, 200mg as an intravenous infusion over 30 minutes every 3 weeks.
89587486|NCT04427956|Active Comparator|Isotonic riboflavin|CXL (UVA 9mW/cm2) treatment using isotonic riboflavin
89587487|NCT04427956|Active Comparator|Hypotonic riboflavin|CXL (UVA 9mW/cm2) using hypotonic riboflavin
89030382|NCT04516343|Experimental|Parent supervised resistance training|Resistance training under parent supervision.
89030383|NCT00517764|No Intervention|Healthy control|Healthy matched control, no intervention
89030384|NCT00517764|Active Comparator|Escitalopram|Depressed subjects receiving escitalopram
89030385|NCT00517764|No Intervention|subjects with major depression|Depressed subjects not receiving study treatment, but taking part in study measures.
89030386|NCT04516265|Active Comparator|NGT Group|A personally designed treatment program will be applied in line with the principles of neurodevelopmental treatment.
89030387|NCT04516265|Active Comparator|Video-based training group|Trunk training will be done with games developed for the use of children with cerebral palsy.
89030388|NCT04516265|Active Comparator|Video-based training group with theratogs|Video-based trunk training (45 minutes) will apply with Theratogs to the group
89587488|NCT04427956|Active Comparator|Iontophoresis|Iontophoresis with Ricrolin with following CXL (UVA 9mW/cm2).
89587489|NCT04396223|Experimental|Avelumab combined with methotrexate and folinic acid|Avelumab administration at 800 mg every 2 weeks and methotrexate administration at 1mg/kg/day during 4 months ½ (median)
89587490|NCT04395001|Experimental|behavioral intervention, nurse support plus medication|Subjects randomized to this arm will receive duloxetine, web-based Cognitive Behavioral Therapy (CBT) and nurse support.
89587491|NCT04395001|Experimental|behavioral intervention plus medication|Subjects randomized to this arm will receive duloxetine and web-based Cognitive Behavioral Therapy (CBT).
89587492|NCT04395001|Active Comparator|medication only|Subjects randomized to this arm will receive duloxetine only.
89587493|NCT04345471|Experimental|MD-120 100 mg|
89587494|NCT04345471|Experimental|MD-120 50 mg|
88975694|NCT04729881|Active Comparator|Spesific Exercise Group|Participants will be given a home exercise program consisting of exercises specifically applied to the neck. Participants will be asked to practice the exercises 5 days a week. The application status of the participants' home exercise program will be followed by the researcher over the phone. Participants who do not practice the home exercise program will be excluded from the study. The exercise program to be applied to the participants in the exercise group is listed below.Cervical stretching exercise, Craniocervical flexion exercise, Neck isometric exercises, Cervical retraction exercise, Scapular retraction exercise, Modified push-up plus exercise.
88975695|NCT04729881|Other|Control Group|
89587495|NCT04345471|Placebo Comparator|Placebo|
88975696|NCT00217867|No Intervention|1|Usual Care, defined as the usual hospital discharge process as delivered by nurses and doctors.
88975697|NCT00217867|Experimental|2|Use of animated computerized character to prepare subjects for discharge by reviewing information provided to subjects in a printed After Hospital Care Plan packet, followed by telephone system to reinforce the discharge.
88975698|NCT00217984|Experimental|Intensive intervention|Extended cognitive behavior therapy (16 sessions) plus nicotine patches and lozenges
88975699|NCT00217984|Other|Usual care|Referral to the smoking cessation clinic
88975700|NCT04722367|Experimental|Art Pedagogy and Mindfulness|Each participant will take part in four 1-hour sessions. Study activities include guided meditation, close looking, drawing, writing, and storytelling. Each session will begin with a guided meditation that is followed by an exercise inspired by two works of art, and end with an opportunity for students to reflect on the experience.
88975701|NCT00218179||Cases|Lung cancer cases diagnosed prior to 2007 among baseline smokers in the PLCO
88975702|NCT00218179||Controls|Subjects without lung cancer among smokers at baseline in the PLCO study
88975703|NCT00218218|Experimental|1|Transdermal nicotine, 42 mg
88975704|NCT00218218|Experimental|2|Transdermal nicotine, 21 mg
88975705|NCT00218218|Placebo Comparator|3|placebo patch
88975706|NCT00218413|Experimental|1|
88975707|NCT00218413|Experimental|2|
88975708|NCT00218413|Experimental|3|
89587496|NCT04334512|Experimental|Quintuple Therapy|Patients will be treated with quintuple therapy for 10 days.
89587497|NCT04334512|Placebo Comparator|Placebo|Patients will be treated with placebo.
89587498|NCT04322318|Experimental|Arm I (Regimen UH-3)|See outline in detailed description section.
89587499|NCT04322318|Experimental|Arm II (Regimen ICE/Cyclo/Topo)|"CYCLES 1, 2, 4, 5, 7, AND 9: Patients receive carboplatin IV over 15-60 minutes on day 1. Patients also receive etoposide IV over 1-2 hours and ifosfamide IV over 2-4 hours on days 1-3. Treatment repeats every 21 days during cycles 1, 2, 4, 5, 7, and 9 in the absence of disease progression or unacceptable toxicity.~CYCLES 3, 6, 8, AND 10: Patients receive cyclophosphamide IV over 15-30 minutes and topotecan IV over 30 minutes on days 1-5. Treatment repeats every 21 days during cycles 3, 6, 8, and 10 in the absence of disease progression or unacceptable toxicity.~Patients undergo surgery and/or RT during cycles 4, 7, and 10 as clinically indicated. Patients undergo a CT scan, a PET scan, a chest x-ray, MRI, an abdominal ultrasound, and/or a bone scan throughout the trial. Patients may also undergo blood specimen collection and biopsy throughout the trial."
89587500|NCT04315363|Experimental|Intervention|Brain MRI and Motivational Behavioral Intervention
89587501|NCT04315363|Active Comparator|Active control|Brain MRI and Control Behavioral Intervention
88975709|NCT00218413|Experimental|4|
88975710|NCT00218413|Experimental|5|
88975711|NCT00218452|Experimental|Lifestyle counseling|
88975712|NCT00218569|Experimental|1|Naltrexone
88975713|NCT00218569|Experimental|2|Placebo
88975714|NCT00218608|Placebo Comparator|Placebo|Placebo (microcrystalline cellulose) was suspended in the methadone during weeks 3-14.
88975715|NCT00218608|Active Comparator|Disulfiram at 62.5 mg|Disulfiram at 62.5 mg was suspended in the methadone during weeks 3-14.
88975716|NCT00218608|Active Comparator|Disulfiram at 125 mg|Disulfiram at 125 mg/day was suspended in methadone during weeks 3-14.
88975717|NCT00218608|Active Comparator|Disulfiram at 250 mg|Disulfiram at 250 mg/day was suspended in methadone during weeks 3-14.
89030389|NCT00517803|Experimental|1|
89030390|NCT00517803|Placebo Comparator|2|
89030391|NCT01243125|Experimental|NVC-422|
89030392|NCT01243125|Placebo Comparator|Saline|
89030393|NCT04516304|Placebo Comparator|Placebo|Placebo
89030394|NCT04516304|Experimental|Experimental|S-equol
89030395|NCT01242930|Experimental|Imetelstat (7.5 mg/kg)|Imetelstat (7.5 mg/kg) with or without lenalidomide standard of care
89030396|NCT01242930|Experimental|Imetelstat (9.4 mg/kg)|Imetelstat (9.4 mg/kg) with or without lenalidomide standard of care
89030397|NCT01241331|Experimental|BLI1100|BLI1100 topical cream
89587502|NCT04315233|Experimental|Treatment: all patients|Ribociclib and belinostat will be given at escalating doses and on multiple administration schedules throughout the dose escalation component of the study. The MTD identified in the dose escalation component will be used to define the dose and administration schedule used in the dose expansion.
89587503|NCT04309565|Active Comparator|Standard Primary Care|Those randomized to the standard primary care arm will be referred to primary care and community Opioid Treatment Program (OTP). Participants may receive buprenorphine or Extended-release naltrexone (XR-NTX) through primary care or with a community addiction treatment provider.
89587504|NCT04309565|Experimental|Transitions Clinic Network Primary Care|Transitions Clinic Network (TCN)- participants in this arm will be referred to a TCN program for primary care and community Opioid Treatment Program (OTP). All TCN programs have the ability to prescribe buprenorphine and Extended-release naltrexone (XR-NTX) and assist with referrals to methadone. The primary features of the TCN include (1) primary care and onsite MOUD or referral to community treatment when indicated, (2) addressing social determinants of OUD and care coordination through a Community Health Worker (CHW), and (3) addressing the discrimination and stigma that exist based on incarceration.
89587505|NCT04294030||Sexually active persons who self-select for HSV-2 testing|Participants must be a mixture of English and Spanish speaking, geographically diverse, gender diverse, ethnically and racially diverse, economically diverse, and with different levels of education; 18-64 years
89587506|NCT04294030||Expectant mothers|Participants must be a mixture of English and Spanish speaking, geographically diverse, gender diverse, ethnically and racially diverse, economically diverse, and with different levels of education; 18-64 years
89587507|NCT04294030||Low prevalence population|Participants must be a mixture of English and Spanish speaking, geographically diverse, gender diverse, ethnically and racially diverse, economically diverse, and with different levels of education; 18-64 years
89587508|NCT04294030||Lay users|Participants must be a mixture of English and Spanish speaking, geographically diverse, gender diverse, ethnically and racially diverse, economically diverse, and with different levels of education; 18-64 years; 1/2 high risk sexual behavior; 1/2 low risk sexual behavior
89587509|NCT04292288||Foreign body granuloma|men injecting paraffin oil
89587510|NCT04279028|Active Comparator|Standard CBT|Standard CBT, 12 sessions each lasting 45 minutes
89587511|NCT04279028|Experimental|Adapted CBT|Adapted CBT, 12 sessions each lasting 45 minutes
89587512|NCT04278144|Experimental|Single agent BDC-1001|Escalating doses followed by expansion targeting HER2-expressing advanced malignancies
89587513|NCT04278144|Experimental|Combination BDC-1001 plus nivolumab|Escalating doses followed by expansion targeting HER2-expressing advanced malignancies
89587514|NCT04277637|Experimental|BGB-11417 Monotherapy Dose Finding: Part 1|Participants with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) including follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), marginal zone lymphoma (MZL) or transformed NHL, mantle cell lymphoma (MCL); Waldenströms macroglobulinemia (WM); and chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) will receive oral BGB-11417 until the maximum tolerated dose (MTD) (or maximum ascending dose (MAD)) and recommended phase 2 dose can be determined
88975718|NCT00218725|Other|Cognitive Therapy|The cognitive therapy intervention for suicide attempters has been designed to provide a brief, timely, flexible intervention that can be incorporated into general and psychiatric inpatient and outpatient services and applied to the population of patients who attempt suicide. A central feature of the intervention is the adaptation of cognitive therapy to the population of patients who attempt suicide. The focus of the intervention is the identification of core beliefs and key automatic thoughts that were elicited prior to and during the most recent suicide attempt. Once these beliefs and thoughts have been articulated, the counselor and patient develop more adaptive responses during an acute suicidal crisis.
88975719|NCT00218725|Other|Enriched Care|The Enriched Care condition will be used as the treatment comparison condition for this study. The Enriched Care condition consists of the usual care that patients may obtain in the community as well as the assessment and referral services provided by the case managers. Participation in the study does not restrict patients in any way in their access to other health care, and all patients in both conditions will be allowed to receive any additional mental health and substance abuse treatment in the community.
88975720|NCT00218803|Experimental|1|
88975721|NCT00218803|Other|2|
88975722|NCT00218842|Experimental|exercise group|individualized exercise
88975723|NCT00218842|No Intervention|control group|care as usal
88975724|NCT00218920|Experimental|strength training|Over a 12-week period, 13 subjects performed three programmed exercise sessions per week; two supervised by the study investigators in the research laboratory and one performed at home or in a gym, according to instructions.
88975725|NCT00218920|Experimental|continuous moderate-intensity aerobic training|Over a 12-week period, 13 subjects performed three programmed exercise sessions per week; two supervised by the study investigators in the research laboratory and one performed at home or in a gym, according to instructions.
88975726|NCT00218920|Experimental|high-intensity interval aerobic training|Over a 12-week period, 14 subjects performed three programmed exercise sessions per week; two supervised by the study investigators in the research laboratory and one performed at home or in a gym, according to instructions.
88975727|NCT00412321|Experimental|Cohort 1 (CNTO 328)|Patients will receive 4 administrations of 3 mg/kg CNTO 328 every 2 weeks till Day 43.
88975728|NCT00412321|Experimental|Cohort 2 (CNTO 328)|Patients will receive 4 administrations of 6 mg/kg CNTO 328 every 2 weeks till Day 43.
88975729|NCT00412321|Experimental|Cohort 3 (CNTO 328)|Patients will receive 3 administrations of 12 mg/kg CNTO 328 every 2 weeks till Day 43.
88975730|NCT00412321|Experimental|Cohort 4 (CNTO 328)|Patients will receive 7 administrations of 6 mg/kg CNTO 328 every week till Day 43.
88975731|NCT00412321|Experimental|Cohort 5 (CNTO 328)|Patients will receive 4 administrations of 12 mg/kg CNTO 328 every 2 weeks till Day 43.
89030398|NCT01241331|Placebo Comparator|Vehicle cream|Vehicle topical cream
89587515|NCT04277637|Experimental|BGB-11417 Monotherapy Expansion Cohorts: Part 2|Participants with R/R indolent NHL including FL, MZL; aggressive NHL including DLBCL, transformed NHL; CLL/SLL with low tumor burden or low creatine clearance; CLL/SLL with without high tumor burden or low creatine clearance will receive oral BGB-11417 at the RP2D dose to further define the safety profile
89587516|NCT04277637|Experimental|BGB-11417 + Zanubrutinib Combination Therapy Dose Finding: Part 3|Participants with R/R indolent NHL including FL, MZL; aggressive NHL including DLBCL, transformed NHL; R/R MCL; R/R or treatment-naïve (TN) CLL/SLL will receive oral BGB-11417 until RP2D can be determined in combination with zanubrutinib
89587517|NCT04277637|Experimental|BGB-11417 + Zanubrutinib Combination Therapy Dose Expansion: Part 4|Participants with R/R indolent NHL including FL, MZL; aggressive NHL including DLBCL, transformed NHL; R/R MCL; R/R or treatment-naïve (TN) CLL/SLL will receive oral BGB-11417 at an RP2D dose to further define the safety profile in combination with zanubrutinib
89587518|NCT04277637|Experimental|: BGB-11417 + Zanubrutinib Combination Therapy Dose Escalation: Part 5|Participants with treatment naïve CLL/SLL will receive oral BGB-11417 until RP2D can be determined in combination with obinutuzumab without and with zanubrutinib.
89587519|NCT04277637|Experimental|BGB-11417 + Zanubrutinib Combination Therapy Dose Expansion: Part 6|Participants with treatment naïve CLL/SLL will receive oral BGB-11417 at an RP2D dose to further define the safety profile in combination with obinutuzumab without and with zanubrutinib
89587520|NCT04270188||anterior sacrospinofixation with autologous tissue|patients with middle and / or anterior prolapse ≥ II in the POP-Q classification and for whom an intervention by anterior sacrospinofixation by autologous tissues is planned.
89587521|NCT04268134|Experimental|Omega 3 fatty acid supplement|Omega-3 ethyl esters orally daily (containing 465 mg eicosapentaenoic acid [EPA] and 375 mg docosahexaenoic acid [DHA] per capsule,supplied as 4 x 1gm capsule)
88975732|NCT00412321|Experimental|Cohort 6 (CNTO 328)|Patients will receive 3 administrations of 12 mg/kg CNTO 328 every 3 weeks till Day 43.
88975733|NCT00412321|Experimental|Cohort 7a (CNTO 328)|Patients responding to CNTO 328 treatment will receive 9 mg/kg CNTO 328 every 3 weeks.
88975734|NCT00412321|Experimental|Cohort 7b (CNTO 328)|Patients responding to CNTO 328 treatment will receive 12 mg/kg CNTO 328 every 3 weeks as extended administration.
88975735|NCT00218959|Experimental|Narrative Exposure Therapy|carried out according to the manual as outlined by Schauer et al. (2005) (second revised edition 2011) 10 sessions of 90 min duration
88975736|NCT00218959|Active Comparator|treatment as usual|mainly help with such as sleep problems, depressive symptoms, problems related to asylum status, and other practical matters. Focus on everyday issues and the limited focus on the traumatic events, in line with reports from the National Center on Violence and Traumatic Stress.
88975737|NCT00042185|Experimental|Dissonance intervention|
88975738|NCT00042185|Active Comparator|Healthy Weight Intervention|
88975739|NCT00042185|Active Comparator|Expressive writing control intervention|
88975740|NCT00042185|No Intervention|Assessment-only control condition|
88975741|NCT00219271|Experimental|Zoledronic acid|4 mg IV infused over 15 minutes every 3 months
88975742|NCT00219427||1|
88975743|NCT04711395||Cataract Surgery Group|
88975744|NCT04711395||Non-surgical group|
89587522|NCT04243148|Experimental|Multifactorial intervention|Frail and pre-frail patients will receive multifactorial intervention consisting of home exercise, BCAA supplements and a multispecies probiotic for 12 months.
89587523|NCT04243148|Experimental|Control group|Frail and pre-frail patients will be followed but will not receive any specific intervention.
89587524|NCT04237116|Experimental|Investigational Arm - secukinumab|secukinumab 300mg s.c. weekly in first 4 weeks, followed by q4w up to Week 20; and placebo 300mg s.c. at weeks 13, 14 and 15 to maintain the blind
89587525|NCT04237116|Placebo Comparator|Control Arm - placebo|placebo 300 mg s.c. weekly in first 4 weeks, followed by q4w up to Week 8; and secukinumab 300 mg s.c. weekly for 4 weeks starting at Week 12, followed by q4w up to Week 20
89587526|NCT04232306|Experimental|Liposomal Bupivacaine + Bupivacaine HCL|Liposomal bupivacaine + bupivacaine HCl surgical-site incision infiltration following spinal anesthesia
89587527|NCT04232306|Active Comparator|Bupivacaine HCl surgical-site incision infiltration|Bupivacaine HCl surgical-site incision infiltration following spinal anesthesia
88975745|NCT00219466|Active Comparator|1|
88975746|NCT00219466|Active Comparator|2|
88975747|NCT00219739|Experimental|Imatinib mesylate 400 mg|
89030399|NCT04516031|Active Comparator|Mesh-only repair|
88975748|NCT00219739|Experimental|Imatinib mesylate 600 mg|
88975749|NCT00219739|Experimental|Imatinib mesylate 400 mg +Peg interferon|
88975750|NCT00219739|Experimental|Imatinib mesylate 400 mg +Cytarabine|
88975751|NCT00219856|Experimental|1|Anesthesic induction and maintenance with intravenous propofol.
88975752|NCT00219856|Active Comparator|2|Anesthesic induction with intravenous penthotal and maintenance with inhaled desflurane.
88975753|NCT00042458|Placebo Comparator|Placebo|Placebo injection will be supplied in the same 5-mL multidose glass vials with a rubber stopper.Ingredients: D-Mannitol 43.0 mg/mL Metacresol 2.25 mg/mL Glacial acetic acid 1.53 mg/mL Sodium acetate trihydrate 0.61 mg/mL pH 4.0 Water for injection qs to 5.0 mL
88975754|NCT00042458|Active Comparator|Pramlintide Acetate (AC137)|Pramlintide acetate (AC137) injection is a clear, colorless, sterile solution for SC injection. It consists of pramlintide in sodium acetate buffer, pH 4.0, containing 43 mg/mL mannitol as an iso-osmolality modifier and 2.25 mg/mL metacresol as a preservative. The strength of pramlintide injection is 0.6 mg/mL
88975755|NCT02962375|Experimental|Active Treatment|100% orange juice with orange pomace fiber
88975756|NCT02962375|Placebo Comparator|Control Treatment|100% orange juice
88975757|NCT00219934||Group A|acute or early in the course of HIV-1 infection, independent of decisions regarding therapy with HAART.
88975758|NCT00219934||Group B|subjects who were diagnosed with acute HIV-1 infection in the past and have been participating in an ADARC/Rockefeller University Hospital treatment protocol for acute HIV-1 infection, and currently have a viral load consistently less than 50 copies/ml on current treatment
88975759|NCT00220285|Experimental|Arm 1|
88975760|NCT00220285|Experimental|Arm 2|
88975761|NCT00077454|Experimental|Treatment (erlotinib hydrochloride, temozolomide)|Patients receive oral erlotinib once daily on days 1-28. Beginning with course 2, patients also receive oral temozolomide once daily on days 1-5. Treatment repeats every 28 days for up to 23 courses in the absence of disease progression or unacceptable toxicity.
88975762|NCT00220324|Experimental|Arm 1|
88975763|NCT00412477|Experimental|Group 1 - LFn-p24 ISOug with Alhydrogel|"HIV LFn-p24 is a combination of an Anthrax derived polypeptide Lethal factor (LFn), from which the toxin domain has been removed, and the HIV-1 gag p24 protein has been fused to LFn. Lfn-p24 is formulated in liquid form, and vialed. Product is administered IM, 1ml. Six subjects (4 vaccines and 2 placebos).~Placebo recipients will receive a saline preparation in similar volume given IM.~Immunizations given at 0, 4 and 16 weeks"
89030400|NCT04516031|Active Comparator|Transversus Abdominis Muscl|
89030401|NCT04515758|Experimental|Exercise and Cognitive Training|Each participant (in a group setting) completes 30 minutes of cognitive training and 1 hour of exercise two days/week.
89209780|NCT00818870|Experimental|Vecam 40/300|
89587528|NCT04213729|Active Comparator|Crohn's Disease (CD) Control Group|Participants will receive only the one time standard of care in-clinic diet counseling at visit 1.
89587529|NCT04213729|Experimental|Experimental CD Low Fat Diet (LFD) Group|Participants will be provided catered LFD meals for 8 consecutive weeks consisting of daily breakfast, lunch, dinner and snacks.
89587530|NCT04213729|Experimental|Experimental CD LFD + DPS Group|Participants and one family member that lives with them will be provided catered LFD meals for 8 consecutive weeks consisting of daily breakfast, lunch, dinner and snacks. In addition, the participant and their family member will receive 12 consecutive weeks of Dyadic Psychological Support (DPS).
89587531|NCT04185883|Experimental|Sotorasib + trametinib + panitumumab|"Experimental: Sotorasib + trametinib + panitumumab Dose Exploration and Dose Expansion~Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C mutant advanced solid tumors.~Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants with KRAS p.G12C mutant advanced solid tumors."
89587532|NCT04185883|Experimental|Sotorasib + RMC-4630|"Experimental: Sotorasib + RMC-4630 Dose Exploration and Dose Expansion~Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C mutant advanced solid tumors.~Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants, with KRAS p.G12C mutant advanced solid tumors."
89587533|NCT04185883|Experimental|Sotorasib + afatinib|"Experimental: Sotorasib + afatinib Dose Exploration and Dose Expansion~Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C advanced non-small cell lung cancer.~Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants with KRAS p.G12C mutant advanced non-small cell lung cancer."
89587534|NCT04185883|Experimental|Sotorasib + panitumumab +/- chemotherapy|"Experimental: Sotorasib + panitumumab +/- chemotherapy Dose Exploration and Dose Expansion~Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C mutant advanced colorectal cancer.~Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants with KRAS p.G12C mutant advanced solid tumors."
89587535|NCT04185883|Experimental|Sotorasib + atezolizumab|"Experimental: Sotorasib + atezolizumab Dose Exploration and Dose Expansion~Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C advanced non-small cell lung cancer.~Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants with KRAS p.G12C mutant advanced non-small cell lung cancer."
89587536|NCT04185883|Experimental|Sotorasib + carboplatin, pemetrexed, docetaxel, paclitaxel, pembrolizumab|"Experimental: Sotorasib + carboplatin, pemetrexed, docetaxel, paclitaxel, pembrolizumab Dose Exploration and Dose Expansion~Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C advanced non-small cell lung cancer.~Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants with KRAS p.G12C mutant advanced non-small cell lung cancer."
89587537|NCT04185883|Experimental|Sotorasib Monotherapy|"Experimental: Sotorasib only Dose Exploration and Dose Expansion~Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C advanced non-small cell lung cancer with brain metastases.~Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants with KRAS p.G12C mutant advanced non-small cell lung cancer with brain metastases."
89587538|NCT04185883|Experimental|Sotorasib + palbociclib|"Experimental: Sotorasib + palbociclib Dose Exploration and Dose Expansion~Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C advanced solid tumor.~Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants with KRAS p.G12C mutant advanced solid tumor."
89587539|NCT04185883|Experimental|Sotorasib + pembrolizumab|"Experimental: Sotorasib + pembrolizumab Dose Exploration and Dose Expansion~Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C mutant non small cell lung cancer.~Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants with KRAS P.G12C mutant non small cell lung cancer."
89587540|NCT04185883|Experimental|Sotorasib + MVASI® (bevacizumab-awwb)+ Chemotherapy|"Experimental: Sotorasib + MVASI® (bevacizumab-awwb)+ chemotherapy Dose Exploration and Dose Expansion~Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C mutant advanced colorectal cancer.~Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants with KRAS p.G12C mutant advanced colorectal cancer."
89587541|NCT04185883|Experimental|Sotorasib + TNO155|"Experimental: Sotorasib + TNO155 Dose Exploration and Dose Expansion~Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C mutant advanced solid tumors.~Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants with KRAS p.G12C mutant advanced solid tumors."
89587542|NCT04185883|Experimental|Sotorasib + BI 1701963|"Experimental: Sotorasib + BI 1701963 Dose Exploration and Dose Expansion~Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C mutant advanced solid tumors.~Upon completion of dose exploration part of the study the dose expansion cohort is for eligible participants with KRAS P.G12C mutant advanced non-small cell lung cancer and advanced colorectal cancer."
89587543|NCT04185883|Experimental|Sotorasib + AMG 404|Experimental: Sotorasib + AMG 404 Dose Exploration and Dose Expansion • Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C mutant advanced solid tumors. • Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants with KRAS p.G12C mutant advanced solid tumors
89587544|NCT04185883|Experimental|Sotorasib + everolimus|Experimental: Sotorasib + everolimus Dose Exploration and Dose Expansion • Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C advanced solid tumor. • Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants with KRAS p.G12C mutant advanced solid tumor.
89587545|NCT04184375|Experimental|TONIC|"The cognitive stimulation sessions are carried out using Liliane Israël's TRAIN YOUR MEMORY software, and are divided into two parts: the first part is essentially cognitive and the second relates to the daily life of the Bipolar patient.~This training method consists of combining two means of intervention, pedagogical action and psychotherapeutic effect. It aims to stimulate, develop and strengthen the basic mechanisms underlying memory phenomena (sensory acuity, attention, associations, structuring, executive functions, spatial and temporal landmarks, associative recruitment). It is presented in the form of exercises divided into eight modules."
89587546|NCT04184375|No Intervention|Control|The usual practice consists of interviews with the psychiatrist with the possibility of home visits by the nurse.
89587547|NCT04182815||Robotic assisted bronchoscopy|Robotic assisted bronchoscopy procedures will be performed using the Monarch platform.
89587548|NCT04169737|Active Comparator|Arm I (acalabrutinib, venetoclax, obinutuzumab)|Patients receive acalabrutinib PO BID on days 1-28. Beginning cycle 3, patients receive venetoclax PO BID on days 1-28. Patients who are BM MRD4-positive or in PR also receive obinutuzumab IV over 4-6 hours on days 1, 2, 8, and 15 of cycle 15 and day 1 of cycles 16-20. Treatment repeats every 28 days (or 42 days for cycle 14) for up to 26 cycles in the absence of disease progression or unacceptable toxicity.
89587549|NCT04169737|Experimental|Arm II (acalabrutinib, venetoclax, early obinutuzumab)|Patients receive acalabrutinib PO BID on days 1-28 beginning cycle 2 and venetoclax PO BID on days 1-28 beginning cycle 3. Patients also receive obinutuzumab IV over 4-6 hours on days 1, 2, 8, and 15 of cycle 1 and day 1 of cycles 2-6. Patients who are BM MRD4-positive or in PR receive obinutuzumab IV over 4-6 hours on day 1 cycles 15-20. Treatment repeats every 28 days (or 42 days for cycle 14) for up to 26 cycles in the absence of disease progression or unacceptable toxicity.
89587550|NCT04164199|Experimental|Tislelizumab monotherapy|
89587551|NCT04164199|Experimental|Pamiparib Monotherapy|
89587552|NCT04164199|Experimental|Tislelizumab and Pamiparib Combination Therapy|
89587553|NCT04164199|Experimental|Tislelizumab and Pemetrexed Combination Therapy|
89587554|NCT04164199|Experimental|Tislelizumab and Capecitabine Combination Therapy|
89587555|NCT04164199|Experimental|Pamiparib and temozolomide Combination Therapy|
89587556|NCT04164199|Experimental|Sitravatinib Monotherapy|
89587557|NCT04164199|Experimental|Tislelizumab and Sitravatinib Combination Therapy|
89587558|NCT04164199|Experimental|Tislelizumab and Ociperlimab Combination Therapy|
89587559|NCT04164199|Experimental|Tislelizumab and BAT1706 Combination Therapy|
89587560|NCT04164199|Experimental|Tislelizumab and Fruquintinib Combination Therapy|
89587561|NCT04160507||Healthy black adults 50 and over|Healthy black adults age 50 and over with no known history of kidney disease will be recruited as controls in this study.
89587562|NCT04160507||black adult cases with non-diabetic nephropathy|black adult cases with non-diabetic nephropathy
89587563|NCT04151550|Other|AVG LSM Procedure|Ace Vision Group LSM procedure performed on both eyes.
89587564|NCT04149301||Typically developing children|Children who do not have a problem with their walking ie children who do not have cerebral palsy
89587565|NCT04149301||Children with cerebral palsy without foot deformity|
89587566|NCT04149301||Children with cerebral palsy with mild foot deformity|
89587567|NCT04149301||Children with cerebral palsy with severe foot deformity|
88975764|NCT00412477|Experimental|Group 2 - LFn-p24 300ug with Alhydrogel|"HIV LFn-p24 is a combination of an Anthrax derived polypeptide Lethal factor (LFn), from which the toxin domain has been removed, and the HIV-1 gag p24 protein has been fused to LFn. Lfn-p24 is formulated in liquid form, and vialed. Product is administered IM, 1ml. Six subjects (4 vaccines and 2 placebos).~Placebo recipients will receive a saline preparation in similar volume given IM.~Immunizations given at 0, 4 and 16 weeks"
89030402|NCT04515758|Active Comparator|Exercise Training Only|Each participant (in a group setting) completes 1 hour of exercise two days/week (separate days than the experimental group).
89030403|NCT01241214|Experimental|Investigational drug - Dose 1|
89587568|NCT04145882|Active Comparator|No additional osteotomy|
89587569|NCT04145882|Experimental|varisation osteotomy addition|
89587570|NCT04145882|Experimental|supination osteotomy addition|
89587571|NCT04145882|Experimental|both (varisation + supination) osteotomies addition.|
89587572|NCT04137107|Experimental|Phase II, Arm I (duloxetine hydrochloride, placebo)|Patients in Phase II receive duloxetine hydrochloride 30 mg (1 duloxetine capsule) orally (PO) once daily (QD) during week 1, duloxetine hydrochloride 30 mg (1 duloxetine capsule) PO QD and placebo (1 placebo capsule) PO QD during weeks 2-16, followed by duloxetine hydrochloride 30 mg (1 duloxetine capsule) PO QD during week 17 in the absence of unacceptable toxicity.
89587573|NCT04137107|Experimental|Phase II, Arm II (duloxetine hydrochloride)|Patients in Phase II receive duloxetine hydrochloride 30 mg (1 duloxetine capsule) orally (PO) once daily (QD) during week 1, duloxetine hydrochloride 60 mg (2 duloxetine capsules) PO QD during weeks 2-16, followed by duloxetine hydrochloride 30 mg (1 duloxetine capsule) PO QD during week 17 in the absence of unacceptable toxicity.
89587574|NCT04137107|Placebo Comparator|Phase II, Arm III (placebo)|Patients in Phase II receive placebo (1 placebo capsule) orally (PO) once daily (QD) during week 1, placebo (2 placebo capsules) PO QD weeks 2-16, followed by placebo (1 placebo capsule) PO QD during week 17 in the absence of unacceptable toxicity.
89587575|NCT04137107|Experimental|Phase III, Arm I (duloxetine hydrochloride)|Patients in Phase III receive most promising dose of duloxetine hydrochloride from Phase II PO QD in the absence of unacceptable toxicity.
89587576|NCT04137107|Placebo Comparator|Phase III, Arm II (placebo)|Patients in Phase III receive placebo PO QD in the absence of unacceptable toxicity.
89587577|NCT04129658||Intervention|The patients are registered at PHCCs who agreed to participate into the study, the patients have provided an informed consent. The PHCCs (seventeen according to the power calculation) will receive an educational outreach visit by a cardiologist, discussing evidence-based treatment. The physician will decide afterwords if the treatment will be adjusted. Blood samples and electrocardiography will be collected before the intervention, data from the EMR will be collected before and after the intervention.
89587578|NCT04129658||Control|The control group will be the rest of the patients with heart failure in Southern Sweden. Data from the regional data base on medication and heath care consumption will be collected at base line and 6 and 12 months after.
89587579|NCT04114877|Experimental|attentional retraining (AR)|Cognitive bias modification (CBM) procedures are interventions aimed at changing the impulsive (automatic) processes that underlie unhealthy behaviors such as smoking. Attentional retraining (AR) is the most commonly used CBM intervention in the study of addiction-related attentional bias.
89030404|NCT01241214|Experimental|Investigational drug - Dose 2|
89030405|NCT01241214|Experimental|Investigational drug - Dose 3|
89030406|NCT01241214|Experimental|Investigational Drug - Dose 4|
89587580|NCT04114877|Active Comparator|visual probe (VP)|The visual probe (VP) task can measure attentional bias for drug-related cues.
89587581|NCT04102098|Experimental|Arm A (atezolizumab plus bevacizumab)|Participants will receive Atezolizumab + Bevacizumab until disease recurrence or unacceptable toxicity.
89587582|NCT04102098|No Intervention|Arm B (active surveillance)|Active surveillance of participants.
89587583|NCT04096170|Experimental|IV Lidocaine|100 mg Lidocaine bolus on induction, then an infusion of 1.5 mg/kg/hr to begin prior to incision, run throughout the operation and continues into PACU for 1 hour OR until one 2gm/250mL D5W bag has been infused, whichever occurs first. The Patient will be monitored by nursing staff with the aid of continuous cardiac monitoring in the PACU for at least 30 minutes after the discontinuation of the lidocaine drip.
89587584|NCT04096170|Placebo Comparator|Placebo|Patients will receive D5W solution at the same volume and rate as the IV lidocaine.
89587585|NCT04086745|Experimental|Baricitinib Low Dose|Baricitinib administered orally.
89587586|NCT04086745|Experimental|Baricitinib High Dose|Baricitinib administered orally.
89587587|NCT04086745|Active Comparator|TNF Inhibitor|Adalimumab or etanercept administered subcutaneously (SC) per standard of care.
89587588|NCT04085848|Experimental|Groupe intervention|Usual care and music therapy
89587589|NCT04085848|No Intervention|Groupe contrôle|Usual care
89587590|NCT04070703|Experimental|Cognitively enhanced Tai Ji Quan|Participants in this arm will exercise a series of Tai Ji Quan-based movements with configurations that are specifically designed for older adults to improve cognitive function, dual-task ability, strength/balance, and mobility.
88975765|NCT00412477|Experimental|Group 3 - LFn-p24 450ug with Alhydrogel|"HIV LFn-p24 is a combination of an Anthrax derived polypeptide Lethal factor (LFn), from which the toxin domain has been removed, and the HIV-1 gag p24 protein has been fused to LFn. Lfn-p24 is formulated in liquid form, and vialed. Product is administered IM, 1ml. Six subjects (4 vaccines and 2 placebos).~Placebo recipients will receive a saline preparation in similar volume given IM.~Immunizations given at 0, 4 and 16 weeks"
88975766|NCT00412555|Experimental|1|
88975767|NCT00042653|Experimental|AMG 073|AMG 073
88975768|NCT00042653|Placebo Comparator|Placebo|Placebo
88975769|NCT00073593|Experimental|bivalirudin|250mg vial given as 0.75mg/kg intravenous (IV) bolus and 1.75 mg/kg/hr IV infusion for the duration of the procedure with the option to increase or decrease the infusion in 0.25 mg/kg/hr increments or to administer additional 0.1-0.5 mg/kg boluses to maintain an ACT>300 seconds.
88975770|NCT00073593|Active Comparator|heparin/protamine|1.5-3.5 mg/kg (200-400 U/kg) intravenous (IV) bolus to target an ACT >300 seconds followed by weight-adjusted boluses as needed during the procedure to achieve/maintain the target ACT. Protamine as needed
88975771|NCT04729842|Active Comparator|Group - B , Patients who recieved Bupivacaine|30 ml of 0.5% bupivacaine was injected equally divided and injected in four nerves (musculocutaneous, median, radial and ulnar nerves)
88975772|NCT04729842|Active Comparator|Group - R , Patients who received Ropivacaine|30 ml of a solution containing 0.5% ropivacaine was equally divided and injected in the four nerves (musculocutaneous, median, radial and ulnar nerves)
88975773|NCT00042731|Active Comparator|Oral isoflavones with multivitamin|Cohorts I - III: Patients receive 1 of 3 doses of oral isoflavones twice daily and a multivitamin once daily. Treatment in all arms continues for 4-6 weeks, until prostatectomy.
89587591|NCT04070703|Active Comparator|Standard Tai Ji Quan|Serving as an active comparison arm, participants in this intervention will exercise a series of Tai Ji Quan-based movements that are specifically designed for older adults to improve strength/balance, cognitive function, and mobility.
89587592|NCT04070703|Sham Comparator|Stretching|Serving as a control arm, participants in this intervention will engage in a series of light exercise activities consisting of breathing, stretching, and body relaxation.
89587593|NCT04049331|Experimental|Testosterone|Testosterone undecanoate injection 750 MG/3 ML
89587594|NCT04049331|Placebo Comparator|Placebo|clinical grade saline 0.9% sodium chloride injection
89587595|NCT04030442|Placebo Comparator|Smoked cannabidiol 0%|
89587596|NCT04030442|Active Comparator|Smoked cannabidiol 9.7%|
88975774|NCT00042731|Active Comparator|Oral lycopene with multivitamin|Cohorts IV-VI: Patients receive 1 of 3 doses of oral lycopene twice daily and a multivitamin once daily. Treatment in all arms continues for 4-6 weeks, until prostatectomy.
89030407|NCT01241214|Other|Active Matching Reference|
89030408|NCT01241214|Placebo Comparator|Matching Placebo|
89587597|NCT04011072|Active Comparator|Infrared treatment arm|Far infrared radiation will be given for 40 minutes on the skin above the patients fistula in each dialysis session for one year
89587598|NCT04011072|No Intervention|Control arm|The control group will not receive any intervention, but will be followed with the same data as the treatment group
89587599|NCT04008121|Experimental|Adult participants with normal or diseased eyes|500 mg dose of intravenous fluorescein sodium followed by ocular angiography; after a minimum of 3 days, participants will receive a single intravenous dose of MB-102 at 4 μmol/kg followed by ocular angiography
89587600|NCT03985527|Experimental|Transvenous nerve stimulation|
89587601|NCT03983681|Experimental|Experimental|The experimental group will receive memory enhancement exercises administered twice a week for 4 weeks (8 training sessions).
89587602|NCT03983681|Placebo Comparator|Control group|The control group will receive placebo memory enhancement exercises administered twice a week for 4 weeks (8 training sessions).
89587603|NCT03980509|Experimental|Curcumin|Curcumin will be given at 500mg by mouth twice a day, immediately after each meal. Curcumin will be given from the time surgical resection is scheduled until the night before surgical resection.
89587604|NCT03978130|Experimental|mHealth-CR|
89587605|NCT03978130|No Intervention|Usual Care|
89587606|NCT03977207|Experimental|Levothyroxine|"Patients will be randomized to levothyroxine or placebo (similar in size, shape, and color to levothyroxine) via permuted blocks stratified by two TSH levels (>3.0-5.0 and 5.0-10.0mIU/L) to ensure treatment balance across TSH levels. The study medications will be prepared in pill form. In the treatment arm, initial L-T4 doses will be 25mcg vs. 50mcg among patients whose TSH is >3.0-5.0mIU/L vs. 5.0-10.0mIU/L, respectively. Patients in the placebo arm will receive an equivalent number of placebo pills daily depending upon TSH level.~The intervention period is 24 weeks. Patients will undergo up to two subsequent dose titrations after 8- and 16-weeks of treatment, based on interim TSH measurements at these time points. Patients whose TSH levels are higher or lower than the therapeutic TSH target of 0.5-3.0mIU/L will undergo a dose adjustment (+/- 25mcg), while those whose TSH levels are in target range will continue the prior dose."
89587607|NCT03977207|Placebo Comparator|Placebo|"Patients will be randomized to levothyroxine or placebo (similar in size, shape, and color to levothyroxine) via permuted blocks stratified by two TSH levels (>3.0-5.0 and 5.0-10.0mIU/L) to ensure treatment balance across TSH levels. The study medications will be prepared in pill form. In the treatment arm, initial L-T4 doses will be 25mcg vs. 50mcg among patients whose TSH is >3.0-5.0mIU/L vs. 5.0-10.0mIU/L, respectively. Patients in the placebo arm will receive an equivalent number of placebo pills daily depending upon TSH level.~The intervention period is 24 weeks. Patients in the placebo arm will undergo an equivalent titration in placebo pills (as that of the experimental arm) after 8- and 16-weeks of treatment, based on interim TSH measurements at these time points."
89587608|NCT03955198|Experimental|Patients with NSCLC metachronous oligometastatic disease|
89587609|NCT03950076|Experimental|Edoxaban 60/30mg daily|Edoxaban 60/30 mg daily (lower dose depending on clinical criteria)
89587610|NCT03950076|Active Comparator|Non-anticoagulant medical therapy|Non-anticoagulant medical therapy: no antithrombotic therapy or antiplatelet monotherapy (at discretion of local investigator)
89587611|NCT03942211|Experimental|Selexipag 200 micro gram (μg)|Study intervention will be up-titrated to allow each participant to reach their individual maximum tolerated dose (iMTD), in the range of 200 μg to1600 μg (ie, 1 to 8 tablets) twice daily/once daily. Dosing frequency will be twice daily, except for participants with moderate hepatic impairment (Child-Pugh Class B) or who are concomitantly taking (a) moderate CYP2C8 inhibitor(s), who receive study intervention once daily. The dose will be up-titrated by the investigator/delegate in 200 μg twice daily/once daily increments at weekly intervals during scheduled TCs until reaching the iMTD. If the dose regimen is not well tolerated or symptoms cannot be fully managed with symptomatic treatment, the duration of the titration step can be prolonged to 2 weeks. If needed, the dose can be reduced by 200 μg twice daily/once daily.
89587612|NCT03942211|Placebo Comparator|Placebo|The comparator will be administered similarly to the experimental intervention.
89587613|NCT03917459|Experimental|LCZ696|LCZ696 200 mg (sacubitril/valsartan 97 mg/103 mg bid)
89587614|NCT03917459|Active Comparator|Enalapril|Enalapril 10 mg
89587615|NCT03908905||Intervention|
89587616|NCT03877744|Experimental|Interactive virtual presence|Participants will engage remotely with a certified child restraint technician via interactive virtual presence. They will work together to help the participant install his or her child restraint properly into his or her vehicle. Standard Safe Kids Worldwide protocols will be followed, with the exception that the interaction will occur remotely via interactive virtual presence.
89587617|NCT03877744|Active Comparator|Live technician|Participants will engage live with a certified child restraint technician. They will work together to help the participant install his or her child restraint properly into his or her vehicle. Standard Safe Kids Worldwide protocols will be followed.
89587618|NCT03872167|Active Comparator|MANUAL|Manual titration of non-invasive mechanical ventilation using polysomnography and randomized
89587619|NCT03872167|Active Comparator|AUTOMATIC|Automatic titration of the non-invasive mechanical ventilation using the same device in an automatic mode with assured volume and pressure support.
89587620|NCT03863184|Experimental|ALR in Combination|Acalabrutinib, lenalidomide, and rituximab in combination
89587621|NCT03831334|Experimental|Minoxidil Treatment|Low dose oral minoxidil
89587622|NCT03817398|Experimental|Basic Science (stop taking TKI, biospecimen collection)|Patients stop taking TKI medication within 10 days after enrollment. Patients undergo peripheral blood collection to monitor loss of MMR every 4 weeks in year 1, every 6 weeks in year 2, and every 12 weeks in year 3. Patients who lose their molecular remission may restart TKI medication and are monitored every 4 weeks in year 1, every 6 weeks in year 2, and every 12 weeks in year 3.
89587623|NCT03800134|Experimental|Arm 1: Durvalumab with platinum-based chemotherapy|"Patients will receive durvalumab 1500 mg in combination with platinum-based chemotherapy every 3 weeks for up to 4 cycles prior to surgery, followed by durvalumab 1500 mg monotherapy every 4 weeks for up to 12 cycles after surgery unless disease is deemed unresectable, disease recurrence, or unacceptable toxicity~The platinum-based chemotherapy will be based on tumour histology and Investigator discretion:~cisplatin with pemetrexed~carboplatin with pemetrexed~carboplatin with paclitaxel~cisplatin with gemcitabine (or carboplatin with gemcitabine for patients who have comorbidities or who are unable to tolerate cisplatin per the investigator's judgment)"
88975775|NCT00042731|Active Comparator|Multiple vitamin alone|Patients receive a multivitamin once daily. Treatment in all arms continues for 4-6 weeks, until prostatectomy.
88975776|NCT00077493|Active Comparator|1|BL22 immunotoxin
88975777|NCT00077493|Active Comparator|2|antibody therapy
88975778|NCT00077493|Active Comparator|3|immunotoxin therapy
88975779|NCT00077493|Active Comparator|4|monoclonal antibody therapy
88975780|NCT00220753|Active Comparator|Active air cleaner|Two Icleen IQAir air cleaners with active filters supplied
88975781|NCT00220753|Placebo Comparator|Placebo air cleaner|Two Icleen IQAir air cleaners with placebo filters supplied
89030409|NCT01240512|Active Comparator|High Dose Arm|4000 IU/day Vitamin D3 (cholecalciferol) supplementation
89587624|NCT03800134|Placebo Comparator|Arm 2: Placebo with platinum-based chemotherapy|"Patients will receive placebo in combination with platinum-based chemotherapy every 3 weeks for up to 4 cycles prior to surgery, followed by placebo monotherapy every 4 weeks for up to 12 cycles after surgery unless disease is deemed unresectable, disease recurrence, or unacceptable toxicity~The platinum-based chemotherapy will be based on tumour histology and Investigator discretion:~cisplatin with pemetrexed~carboplatin with pemetrexed~carboplatin with paclitaxel~cisplatin with gemcitabine (or carboplatin with gemcitabine for patients who have comorbidities or who are unable to tolerate cisplatin per the investigator's judgment)"
89587625|NCT03778112|Experimental|Negative mpMRI Prostate Scan|SBRT to the whole prostate
89587626|NCT03778112|Experimental|Positive mpMRI Prostate Scan|IMRT to the prostate + seminal vesicles followed by SBRT boost to the whole prostate with SIB to MRI defined intraprostatic lesions
89587627|NCT03772899|Experimental|Study Intervention|Fecal Microbial Transplantation - all patients registered on study will receive one dose (80-100mg) of FMT. This is a single arm, unblinded study.
89587628|NCT03760263|Active Comparator|Envarsus|Once-daily extended-release tacrolimus
89587629|NCT03760263|Active Comparator|Prograf|twice-daily tacrolimus
89587630|NCT03745716|Experimental|Experimental arm: APR-246 + azacitidine|Patients will be randomized (1:1) to one of two arms: stratified by age (< 65 years versus ≥ 65):
89587631|NCT03745716|Experimental|Control arm: Azacitidine|Patients will be randomized (1:1) to one of two arms: stratified by age (< 65 years versus ≥ 65):
89587632|NCT03741335|Experimental|Strength Training|Participants wear a weighted vest while performing exercises using functional movement patterns used in everyday activities (chair rises, 90° squats, side-to-side squats, toe raises, lunges (forward, lateral, backward, walking), multi-directional step ups). Participants attend supervised, group-based moderate-intensity strength training program remotely 3 times per week for 60 minutes per session.
89587633|NCT03741335|Active Comparator|Stretching Control|Participants attend a supervised flexibility program where they will perform a series of whole body stretching exercises with a focus on developing and maintaining a healthy back. Participants attend a supervised, group-based supervised flexibility program remotely 3 times per week for 60 minutes per session.
89587634|NCT03741335|Experimental|Tai Ji Quan Training|An integrated exercise routine consisting of 8 purposeful movement forms and a set of therapeutic movements. Participants attend a supervised, group-based tai ji quan program remotely where they perform an integrated exercise routine consisting of 8 purposeful movement forms and a set of therapeutic movements 3 times per week for 60 minutes per session.
88975782|NCT00042770|Active Comparator|Arm I|Patients undergo placement of a standard pleural chest tube. Within 36 hours of chest tube placement, patients undergo pleurodesis comprising intrapleural administration of talc slurry once followed by clamping of the chest tube for 2 hours while different patient positions are used to distribute the talc. The chest tube is then unclamped to allow continuous drainage. When the chest tube drainage is less than 150 mL over 24 hours, pleurodesis is assumed and the chest tube is removed.
88975783|NCT00042770|Experimental|Arm II|Patients undergo pleurodesis comprising placement of a small (PleurX) catheter followed by pleural drainage for up to 90 minutes once daily. When the catheter drainage is less than 30 mL per day for 3 consecutive days, pleurodesis is assumed and the catheter is removed.
88975784|NCT00220987|Experimental|Intensive Insulin therapy|Intensive Insulin therapy
88975785|NCT00220987|Active Comparator|Conventional Therapy|conventional insulin therapy
88975786|NCT02966067|Experimental|Microneedle Device|Local Dental Anaesthetic Solution Delivery System: Microneedle device with an array of 2x3 pyramidal wet-etch silicone microneedles of 280µm height to inject anaesthetic solution.
88975787|NCT02966067|Active Comparator|30-gauge Short Hypodermic Needle|Local Dental Anaesthetic Solution Delivery System: Standard thirty-gauge short hypodermic needle to inject anaesthetic solution.
88975788|NCT00221026|Experimental|drug|ECP + Uvadex given for 12 weeks.
88975789|NCT00042809|Experimental|Treatment (paclitaxel, trastuzumab, erlotinib hydrochloride)|See detailed description.
88975790|NCT00221065|No Intervention|1|Control
88975791|NCT00221065|Experimental|2|CPAP
88975792|NCT02965677|Experimental|LEGFLOW OTW group|in this group subject will be treated by Paclitaxel Releasing Peripheral Balloon Dilatation Catheter (LEGFLOW) and followed up
88975793|NCT02965677|Active Comparator|Admiral Xtreme|in this group subject will be treated by Peripheral Balloon Dilatation Catheter (Admiral Xtreme) and followed up
88975794|NCT00122746|Active Comparator|Radiotherapy alone|EBRT pelvis 46 Gy, 4 field box technique + ICBT LDR 1x30 Gy/A or HDR 3x8 Gy/A
88975795|NCT00122746|Experimental|Radiotherapy plus Chemotherapy|EBRT pelvis 46 Gy, 4 field box technique + ICBT LDR 1x30 Gy/A or HDR 3x8 Gy/A + weekly cisplatin 30 mg/m2 during EBRT
89587635|NCT03741127|Other|P-BCMA-101 treated|Patients who received previous treatment with P-BCMA-101. Rimiducid may be administered as indicated.
89587636|NCT03723772|Experimental|Insulin 287 followed by insulin glargine U100|"Run-in period (2 days to 4 weeks): The basal insulin glargine dose for each subject will be established and optimised.~After run-in, participants will receive insulin 287 once a week (OW) for 8 weeks and subsequent 4 weeks of terminal pharmacokinetic sampling where subjects are treated with once daily (OD) insulin glargine.~After insulin 287 treatment, participants will receive insulin glargine U100 OD for 2 weeks."
88975796|NCT00042926|Experimental|Radiolymphoscintigraphy + surgery|"Patients undergo radiolymphoscintigraphy comprising technetium Tc 99m sulfur colloid to identify the sentinel lymph nodes (SNL). Within 18 hours after radiolymphoscintigraphy, patients undergo resection of the primary oral cavity tumor and radioguided sentinel lymphadenectomy and regional cervical lymphadenectomy. Lymph nodes are examined by hematoxylin and eosin (H&E) staining. If negative by H&E, lymph nodes are further analyzed by immunohistochemistry.~Patients are followed at 30 days."
88975797|NCT00123019|Active Comparator|1|Minimal intervention; annual weight/waist assessment, questionnaire, and advice
88975798|NCT00123019|Experimental|2|Intensive intervention. All arm 1 activities plus ongoing environmental and group interventions in worksite for two years.
89030410|NCT01240512|Active Comparator|Low Dose Arm|400 IU/day Vitamin D3 (cholecalciferol) supplementation
89030411|NCT04513769|Experimental|Study participants|This is a single-arm study so all participants receive the same intervention.
89030412|NCT04515368|Experimental|Fendrix|Fendrix (Hepatitis B surface antigen adjuvanted by AS04C containing 3¬≠O¬≠desacyl¬≠4'¬≠ monophosphoryl lipid A adsorbed on aluminium phosphate, GlaxoSmithKline; 0.5 mL. intramuscular. stat.
89030413|NCT04515368|Experimental|Bexsero|Bexsero (Meningococcal group B subunit / Outer Membrane Vesicles, GlaxoSmithKline); 0.5 mL. intramuscular. stat.
89030414|NCT04515368|Experimental|Fluad|Fluad (split virion inactivated seasonal trivalent influenza vaccine adjuvanted with MF59C, Northern Hemisphere 2016-17, Seqirus Vaccines and Diagnostics) 0.5 mL. intramuscular. stat.
89587637|NCT03723772|Experimental|Insulin glargine U100 followed by insulin 287|"Run-in period (2 days to 4 weeks): The basal insulin glargine dose for each subject will be established and optimised.~After run-in, participants will receive insulin glargine U100 OD for 2 weeks followed by 1-14 days (at least 1 day is mandatory) of continued insulin glargine treatment.~After insulin glargine treatment, participants will receive insulin 287 once a week (OW) for 8 weeks and subsequent 4 weeks of terminal pharmacokinetic sampling."
89030415|NCT04515368|Experimental|Seasonal Trivalent Influenza Vaccine|Seasonal Trivalent Influenza Vaccine ('ÄòSTIV'Äô, split virion inactivated, Northern Hemisphere 2016-17, Sanofi Pasteur); 0.5 mL. intramuscular. stat.
89587638|NCT03718533|Experimental|Eltrombopag|Patients received eltrombopag orally once daily up to 36 weeks.
89587639|NCT03711279|Experimental|SHR-1210 plus Apatinib|
89587640|NCT03711279|Active Comparator|ADM plus IFO or IFO alone|
89587641|NCT03705559|Experimental|Vaporized Marijuana|Participants will receive non-therapeutic, experimental doses of active or placebo. vaporized marijuana. Active marijuana/placebo will be administered once per session and will be administered via a vaporizer.
89587642|NCT03705559|Experimental|Opioid Agonist|Participants will receive non-therapeutic, experimental doses of an active opioid agonist or placebo. Active opioid agonist/placebo will be administered once per session and will be administered intranasally (snorting).
89587643|NCT03705559|Experimental|Opioid Agonist/Marijuana Combination|Participants will receive non-therapeutic, experimental doses of active opioid/placebo in combination with non-therapeutic, experimental doses of active vaporized marijuana/placebo. Opioid/placebo and marijuana/placebo doses will be administered once during each session. It is possible to receive both active drugs on the same day. Opioid doses will be administered intranasally; marijuana doses will be administered via vaporizer.
89587644|NCT03696797|Active Comparator|Treatment Group|Will have a Unit of blood (two cups, the same amount donated at the Red Cross) drawn. This involves having a needle inserted into a vein in your arm. Prior to taking the blood, staff will measure your blood count to be sure you are not anemic, and blood pressure to be sure no dehydration. During or after donation, a sports drink is provided to replace the fluid loss. Phlebotomy
89587645|NCT03696797|Sham Comparator|Control Group|Will not donate blood, but will have a needle inserted into a vein in your arm. Both groups will not know which group assignment they have been randomized. Sham Phlebotomy
89587646|NCT03684018|Experimental|IgPro10 (dose level 1)|
89587647|NCT03684018|Experimental|IgPro10 (dose level 2)|
89587648|NCT03670095|Experimental|Lactose-free memantine tablet|(treatment A - test) - 10 mg; orally as a single dose in fed and fasted state
89587649|NCT03670095|Experimental|Lactose-containing memantine tablet (Ebixa®)|(treatment B - reference) - 10 mg, orally as a single dose in fed and fasted state
89587650|NCT03666559|Experimental|Azacitidine|Azacitidine is administered by sub-cutaneous injection at 75 mg/m2 per day for seven consecutive days every 4 weeks until progression, intolerance or end of the study.
89587651|NCT03658304|Experimental|Mitomycin C|
89587652|NCT03653039|Experimental|Tritube|
89587653|NCT03653039|Active Comparator|Standard endotracheal tube|
89587654|NCT03649048|Active Comparator|ARM 1: High-Dose Cisplatin days 1, 22 & 43 with radiotherapy|
89587655|NCT03649048|Active Comparator|ARM 2: Low-Dose Cisplatin Q 1 wk + radiotherapy|
89587656|NCT03646760|Experimental|Hybrid Cardiac Rehabilitation (HYCR)|
89030416|NCT01240629|Experimental|Arm I|Patients receive doxorubicin-GnRH agonist conjugate AEZS-108 intravenously (IV) over 2 hours once every 21 days (21 days = 1 cycle). Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
89030417|NCT04515446|Other|TROD + PCR diagnosis|For each patient positive for flu with a rapid diagnostic test, sequential nasopharyngeal (NP) samples will be collected for quantitative PCR every day from D1 to D8 or until discharge (if before D8). Sequential quantitative PCR will quantify influenza virus load in the upper airways.
89587657|NCT03646760|Active Comparator|Center Based cardiac Rehabilitation (CBCR)|
89587658|NCT03643549|Experimental|Bortezomib and Temozolomide|Botezomib 1.3 mg/m2 administered IV on days 1, 4, 7, during each 4-week chemotherapy cycle with per oral Temozolomide at three dose levels: 150 mg/m2, 175 mg/m2 and 200mg/m2 5 days/week every 4 weeks starting on day 3.
89587659|NCT03636724|Experimental|Intervention group|Patients will receive the interventions on both PA and FVI simultaneously.
89587660|NCT03636724|No Intervention|Waiting control group|Patients will not receive any supportive interventions on PA or FVI during the intervention period but will be provided with the same intervention at follow-up six-month after the intervention.
89587661|NCT03630718|No Intervention|Control Group (CG)|Patients assigned to no intervention
89587662|NCT03630718|Active Comparator|Psychoeducational Intervention Group (EG-EDU)|Patients assigned to psychoeducational intervention
89587663|NCT03630718|Active Comparator|Hypnosis intervention Group (EG-HYP)|Patients assigned to hypnosis intervention
89587664|NCT03609346||STEMI|Arm: STEMI Intervention: PCI with 1 or more BioFreedom stents in patients presenting with a STEMI. Medication according to hospital practice.
89587665|NCT03585465|Experimental|A: Cyclophosphamide Vinblastine Nivolumab|This arm was applicable to first stage, and is closed
89587666|NCT03585465|Experimental|B: Capecitabine Nivolumab|This arm was applicable to first stage, and is closed
89587667|NCT03585465|Experimental|C: Cyclophosphamide Vinblastine Capecitabine|This arm was applicable to first stage, and is closed
88975799|NCT00123058|Experimental|Nurse administered|"Nurse Administered Intervention:~Subject received nurse administered behavioral intervention every 8 weeks via telephone for 24 months."
88975800|NCT00123058|Experimental|Nurse & BP monitor|Subjects received both a nurse administered behavioral intervention via telephone every 8 weeks for 24 months and a study provided home BP monitor. Subject recorded home BP 3 times per week for 24 months.
89587668|NCT03585465|Experimental|"Metronomic CT "|"metronomic chemotherapy selected at the end of first stage (C: Cyclophosphamide Vinblastine Capecitabine)~This arm is applicable to second stage, and 43 patients are expected"
89587669|NCT03585465|Experimental|"Metronomic CT + Nivolumab"|"metronomic chemotherapy selected at the end of first stage (C: Cyclophosphamide Vinblastine Capecitabine) + Nivolumab~This arm is applicable to second stage, and 43 patients are expected"
88975801|NCT00123058|No Intervention|Usual Care|Subjects received neither home BP monitor nor nurse phone intervention.
89209781|NCT00922376|Active Comparator|T+ Intervention|The intervention group patients will use the T+ telemedicine application whilst completing repeated measures aiming to compare them to a control group receiving standard care.
89587670|NCT03584295|Active Comparator|Conventional care|Patients with acute exacerbation of severe COPD, requiring invasive mechanical ventilation treated with Conventional care. Conventional care includes invasive mechanical ventilation and the attempt to extubate the patient and switch to NIV. If extubation fails tracheostomy can be performed according to the treating physician.
89587671|NCT03584295|Experimental|Extracorporeal carbon dioxide removal|Patients with acute exacerbation of severe COPD, requiring invasive mechanical ventilation will be treated with vv-ECCO2R (Extracorporeal carbon dioxide removal) to facilitate early extubation. ECCO2R is used in a standard configuration with either double lumen cannula (22-24Fr) or two small single vessel cannulas (15-19 Fr), allowing a blood flow rate between 1-1.75 L/min.
89587672|NCT03533582|Active Comparator|Group A1 (WDF)|Patients undergo observation.
89587673|NCT03533582|Experimental|GROUP A2 (NON-WDF)|Patients receive cisplatin IV over 6 hours on day 1 following surgery. Treatment repeats every 21 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.
89587674|NCT03533582|Experimental|GROUP B1 ARM 4-CDDP|Patients receive cisplatin IV over 6 hours on day 1. Treatment repeats every 14 days for 4 cycles (2 pre-surgery, 2 post-surgery) in the absence of disease progression or unacceptable toxicity.
89587675|NCT03533582|Experimental|GROUP B1 ARM 6-CDDP|Patients receive cisplatin IV over 6 hours on day 1. Treatment repeats every 14 days for 6 cycles (2 pre-surgery, 4 post-surgery) in the absence of disease progression or unacceptable toxicity.
89587676|NCT03533582|Experimental|GROUP B2 ARM I|Patients receive cisplatin IV over 6 hours on day 1. Treatment repeats every 14 days for up to 6 total cycles (4 pre-surgery, 2 post-surgery). After cycle 4, patients undergo surgery, then continue with 2 additional cycles of cisplatin.
89587677|NCT03533582|Experimental|GROUP B2 ARM II|Patients receive cisplatin IV over 6 hours on day 1. Treatment repeats every 14 days for up to 6 total cycles.
89587678|NCT03533582|Experimental|GROUP C ARM C5VD|Patients receive cisplatin IV over 6 hours on day 1, 5-fluorouracil IV over 1-15 minutes, vincristine sulfate IV over 1 minute on days 1, 8, and 15 and doxorubicin IV over 1-15 minutes on days 1 and 2. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo surgery after cycle 2 or 4.
89587679|NCT03533582|Experimental|GROUP C ARM CDDP|Patients receive cisplatin IV over 6 hours on day 1. Treatment repeats every 14 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo surgery after cycle 2 or 4.
89587680|NCT03533582|Experimental|GROUP D1|"SIOPEL-4 INDUCTION: Patients receive cisplatin IV over 6 hours on days 1, 8, and 15 (for cycles 1 and 2) and days 1 and 8 (for cycle 3) and doxorubicin IV over 1-15 minutes on days 8 and 9 during cycles 1 and 2 and days 1 and 2 during cycle 3. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Patients with lung complete remission (either with chemotherapy and/or surgery) receive carboplatin IV over 1 hour on day 1 and doxorubicin IV over 1-15 minutes on days 1 and 2. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity."
89587681|NCT03533582|Experimental|GROUP D2 ARM CE|"SIOPEL-4 IV INDUCTION: Patients receive cisplatin IV over 6 hours on days 1, 8, and 15 (for cycles 1 and 2) and days 1 and 8 (for cycle 3) and doxorubicin IV over 1-15 minutes on days 8 and 9. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.~Patients receive carboplatin IV over 1 hour on days 1 and 2, doxorubicin IV over 1-15 minutes on days 1 and 2 during cycles 1, 3 and 5, and carboplatin over 1 hour and etoposide IV over 2 hours on day 1 and 2 of cycles 2, 4 and 6. Treatments repeat every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity."
88975802|NCT00123058|Experimental|Home BP Monitor|Subject received study provided home BP monitor. Subject recorded home BP 3 times per week for 24 months.
88975803|NCT00123097|Experimental|Chlorinated polyethylene elastomer first|Patient receives prosthetic made from CPE then the SOC, silicon.
88975804|NCT00123097|Active Comparator|Silicon first|Patient receives prosthetic made from the SOC, silicon, followed by the CPE,Chlorinated polyethylene elastomer.
88975805|NCT02965443|Active Comparator|Verum|Dapagliflozin 10 mg + Saxagliptin 5 mg, each once daily, for 24 weeks
88975806|NCT02965443|Placebo Comparator|Placebo|Placebo 1 10 mg + Placebo 2 5 mg, each once daily, for 24 weeks
88975807|NCT00042965|Experimental|Gemcitabine + capecitabine|"Patients receive gemcitabine IV over 30 minutes on days 1, 8, and 15 and oral capecitabine twice daily on days 1-21. Treatment repeats every 28 days for a minimum of 2 courses in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive at least 2 additional courses beyond CR.~Patients are followed every 3 months for 1 year and then every 6 months for 1 year."
89209782|NCT00922376|No Intervention|Usual care|The control group will be receiving the standard care offered by the NHS to patients suffering from diabetes.
89030418|NCT03459066||Institution-Group 8 district|Group of patients belonging to institutions of district 8. Patients will be evaluated in 3 different times with different assessment instruments for tone, functionality and quality of life.
89030419|NCT03459066||Institution-Group 9 district|Group of patients belonging to institutions of district 9. Patients will be evaluated in 3 different times with different assessment instruments for tone, functionality and quality of life.
89030420|NCT03459066||Institution-Group 10 district|Group of patients belonging to institutions of district 10. Patients will be evaluated in 3 different times with different assessment instruments for tone, functionality and quality of life.
89030421|NCT00506402|Experimental|1|
89030422|NCT02949531|Active Comparator|21% oxygen|room air will be delivered via Venturi mask during cycle ergometry
89587682|NCT03533582|Experimental|GROUP D2 ARM VI|"SIOPEL-4 IV INDUCTION: Patients receive cisplatin IV over 6 hours on days 1, 8, and 15 (for cycles 1 and 2) and days 1 and 8 (for cycle 3) and doxorubicin IV over 1-15 minutes on days 8 and 9. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.~Patients receive carboplatin IV over 1 hour on days 1 and 2 and doxorubicin IV over 1-15 minutes on days 1 and 2 during cycles 1, 3 and 5. Patients also receive vincristine sulfate IV over 1 minute on days 1 and 8 and irinotecan IV over 90 minutes QD on days 1 to 5 of cycles 2, 4 and 6. Treatments repeat every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity."
89587683|NCT03533582|Active Comparator|GROUP E1|Patients undergo observation only.
89587684|NCT03533582|Experimental|GROUP E2 (PLADO)|Patients receive cisplatin IV over 6 hours on day 1 and doxorubicin IV over 1-15 minutes on days 1 and 2 following surgery. Treatments repeat every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
89587685|NCT03533582|Experimental|GROUP F ARM 1 (PLADO)|Patients receive cisplatin IV over 6 hours on day 1, doxorubicin IV over 1-15 minutes on days 1 and 2 and sorafenib PO BID on days 3-21. Treatments repeat every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients may undergo surgery, if tumors are resectable, or receive an additional 3 cycles of the treatment.
89587686|NCT03533582|Experimental|GROUP F ARM 2 (P/GEMOX)|Patients receive cisplatin IV over 6 hours on day 1, doxorubicin IV over 1-15 minutes on days 1 and 2 and sorafenib PO BID on days 3-14 of cycles 1 and 3. Patients also receive gemcitabine IV over 90 minutes on day 1, oxaliplatin IV over 2 hours on day 1 and sorafenib PO on days 1-14 of cycles 2 and 4. Patients may undergo surgery, if tumors are resectable, or receive an additional 4 cycles of the treatment.
89587687|NCT03527030||General Population|Adults living in a registered household in the Greater London area.
89587688|NCT03527030||IQOS users|Adult current IQOS users (at the time of survey) living in the Greater London area who are registered in the UK IQOS User Database and agree to be contacted for research purposes at the time of registration.
89587689|NCT03492424||Focal therapy for prostate cancer|"All men >18 years of age undergoing focal therapy for primary or salvage treatment of prostate cancer will be included. Men who had received prior focal therapy are also eligible for inclusion.~The purpose of this study is collect observational data regarding patterns of care and outcomes of focal therapies for prostate cancer, including but not limited to: high-intensity focused ultrasound (HIFU), cryotherapy, focal laser ablation, irreversible electroporation, photodynamic therapy, and brachytherapy."
89587690|NCT03490968|Other|Healthy Subjects|
89030423|NCT02949531|Active Comparator|28% oxygen|28% oxygen will be delivered via Venturi mask during cycle ergometry
89030424|NCT02949531|Active Comparator|40% oxygen|40% oxygen will be delivered via Venturi mask during cycle ergometry
89030425|NCT00517959|Experimental|1|Stereotactic conformal radiotherapy (SCRT)
89030426|NCT00517959|Other|2|Conventional radiotherapy Patients in this arm will be treated with conventional radiotherapy techniques being used at the moment in the department. This involves patient being immobilised with a customised thermoplastic mask after which they will have a contrast enhanced planning CT scan. The radiation oncologist will draw the tumour on the appropriate CT slices and a margin of 1-2 cms grown for the planning target volume. Beam arrangement will be relatively simple and typically consist of 2-3 coplanar fields using 6 MV photons. Conventional planning optimisation will be carried out by the use of wedges, beam weightage and corner shields as appropriate. Radiotherapy doses, prescription and fractionation schedules will be identical to the SCRT arm
89030427|NCT04515992|Experimental|High Intensity Body-weight Circuit (HIBC)|The at home HIBC intervention program involved the use of both bodyweight and suspension training equipment (TRX® Fit System) with modified movements. The TRX® system was used to modify squats and rows while attached to the top of a door frame.
89030428|NCT04515602|Experimental|Part 1 Arm I (low/medium tumor burden)|Primary debulking surgery with a maximal cytoreduction of complete gross resection within 3 weeks after biopsy, followed by at least 6 cycles of adjuvant chemotherapy and maintenance therapy for patients with gBRCA/sBRCA mutation, CR/PR after platinum-based therapy.
89030429|NCT04515602|Active Comparator|Part 1 Arm II (low/medium tumor burden)|Neoadjuvant chemotherapy with 3 cycles of chemotherapy, then followed by interval debulking surgery. The maximal time interval between course 3 chemotherapy and IDS is 6 weeks. And then 3 cycles of adjuvant chemotherapy and maintenance therapy for patients with gBRCA/sBRCA mutation, CR/PR after platinum-based therapy.
89587691|NCT03490968|Experimental|Peripheral Artery Disease (PAD) with Supervised Exercise|Subjects will be referred for supervised exercise therapy. Subjects will have 3 visits per week for 12 weeks. Each visit will include a minimum of 30 to 40 minutes of exercise to improve ambulation with a certified trainer.
89587692|NCT03490968|Active Comparator|PAD Subjects Who Undergo Revascularization of the Leg|This group of subjects are receiving leg revascularization as part of standard of care.
89587693|NCT03485378|Experimental|Treatment Arm: Stereotactic Ablative Radiotherapy|Stereotactic ablative radiotherapy for early non-small cell lung cancer and interstitial lung disease
89587694|NCT03483246|Experimental|Group B - fecal microbiota transplantation|Patients receiving the fecal microbiota transplantation (FMT) in 3 times after inclusion and randomisation
89587695|NCT03483246|Placebo Comparator|Group A- Sham-transplantation|Patients receiving the sham-transplantation in 3 times after inclusion and randomisation
89587696|NCT03481660|Experimental|Brolucizumab 6 mg|Brolucizumab 6 mg/0.05 mL, 5 loading doses, with subsequent doses per protocol-specified maintenance schedule
89587697|NCT03481660|Active Comparator|Aflibercept 2 mg|Aflibercept 2 mg/0.05 mL, as labeled, 5 loading doses, with subsequent doses every 8 weeks
89587698|NCT03471182|Active Comparator|Psychiatric and Cognitive Testing|All participants will complete psychiatric assessment and cognitive testing.
89587699|NCT03471182|Active Comparator|Cocaine Self-adminstration|This arm plans to assess the subjective (e.g., euphoric) and behavioral effects (e.g., self-administration) of cocaine in experienced, non-treatment seeking users of the drug in a human laboratory study of self-regulated cocaine administration.
89587700|NCT03471182|Active Comparator|Positron Emission Tomography|All participants will complete a PET scan to assess mGluR5 receptors using [18-F]FPEB
89587701|NCT03471182|Active Comparator|Magnetic Resonance Imaging|All participants will complete one MRI scan to assess brain structure and function.
89587702|NCT03465592|Experimental|Nivolumab|"Adults: 240 mg IV over 30 minutes every 2 weeks OR 480 mg IV over 30 minutes every 4 weeks. Children and Adolescents weighing 40 kg or more: 240 mg IV over 30 minutes every 2 weeks OR 480 mg IV over 30 minutes every 4 weeks.~Children and Adolescents weighing less than 40 kg: 3 mg/kg IV over 30 minutes every 2 weeks.A maximum of 24 cycles will be given on study."
89587703|NCT03428373|Experimental|Len-Dex+Rivaroxaban|Patients with MM will receive Len-Dex combination and Rivaroxaban (10 mg) daily
89587704|NCT03428373|Active Comparator|Len-Dex+ASA|Patients MM will receive Len-Dex combination and ASA 81 mg daily
89587705|NCT03427788|Experimental|Verum|Study group 1-11 of BAY2328065 (increasing dose levels for study group 2-11)
89587706|NCT03427788|Placebo Comparator|Placebo|Study group 1-11 of Placebo
89587707|NCT03414762|Experimental|PICO Dressing|PICO Negative Pressure Wound Therapy (Smith and Nephew Healthcare, Hull, United Kingdom) is a non-significant-risk, FDA Class II, medical device commercially available in the USA. The PICO unit is a single patient use, battery-powered, disposable unit that can provide continuous 80 - 125 mmHg negative pressure over a 5 to 7-day therapy period.
89587708|NCT03414762|Active Comparator|Standard Dressing|The standard-of-care is consistent with the national standard for dressing Cesarean section incisions and includes, but not limited to, coverage of the sutured incision with sterile gauze and non-penetrable barrier (e.g., Tegaderm™). The non-penetrable barrier may be left in place for a minimum of 1 day and no longer than 2 days (± 4 hours) to promote epithelialization of the surgical incision edges. After the dressing is removed, the surgical site is left exposed to air to promote further healing.
89587709|NCT03412565|Experimental|Daratumumab(D)+Bortezomib+Lenalidomide+Dexamethasone (D-VRd)|Participants will receive daratumumab 1800 milligram (mg) by subcutaneous (SC) injection on Days 1, 8 and 15 of Cycles 1 to 3 (each cycle of 21 days) and on Day 1 of Cycle 4; bortezomib 1.3 milligram per square meter (mg/m^2) SC injection on Days 1, 4, 8 and 11 of Cycles 1 to 4; lenalidomide 25 mg orally on Day 1 through Day 14 of Cycles 1 to 4 and dexamethasone 20 mg orally or intravenously on Days 1, 2 ,8, 9, 15 and 16 of Cycle 1 to 4.
88975808|NCT00123292|Experimental|1|
88975809|NCT00123292|Experimental|2|
88975810|NCT00123292|Experimental|3|
88975811|NCT00123292|Experimental|4a|
88975812|NCT00123292|Experimental|4b|
88975813|NCT00073788||Subjects with PTSD|Subjects will be American Indian, between the ages of 18-68. Approximately 66% will be female, 33% male, which conforms to the distribution of PTSD in this population. Study group subjects will be PTSD positive. Overt CVD is exclusionary.
88975814|NCT00073788||Control Group|Subjects will be American Indian, between the ages of 18-68. Approximately 66% will be female, 33% male, which conforms to the distribution of PTSD in this population. Control subjects will be PTSD negative. For both groups: overt CVD is exclusionary.
88975815|NCT02958085|Experimental|NNC0174-0833|
88975816|NCT02958085|Placebo Comparator|Placebo|
88975817|NCT00123526|Experimental|1|Worksite intervention
88975818|NCT00123526|No Intervention|2|Receive no intervention
88975819|NCT00123838|Experimental|Single Group Assignment|Calypso® 4D Localization System
88975820|NCT00043082|Experimental|carboplatin and doxorubicin|carboplatin and liposomal doxorubicin given q 4 weeks
88975821|NCT00043082|Active Comparator|carboplatin|carboplatin alone
88975822|NCT00123916|Experimental|Benznidazole|40 - 80 days (according to body weight) treatment with benznidazol
88975823|NCT00123916|Placebo Comparator|Placebo|40 - 80 days (according to body weight) treatment with matching placebo
88975824|NCT00073827|Experimental|1|levalbuterol MDI 90 mcg QID
88975825|NCT00073827|Active Comparator|2|racemic albuterol MDI 180 mcg QID
88975826|NCT00073827|Placebo Comparator|3|Placebo MDI QID
88975827|NCT02970539|Experimental|Oraxol +Ramucirumab|"Oraxol (oral HM30181 + oral paclitaxel)~HM30181 methanesulfonate monohydrate - supplied as 15-mg HM30181AK-US tablets~Paclitaxel - supplied as 30-mg capsules Ramucirumab - supplied as a solution at a concentration of 10 mg/mL"
88975828|NCT00124150|Experimental|M|Intravenous magnesium sulfate infusion for 14 days.
89587710|NCT03412565|Experimental|D + Bortezomib + Melphalan + Prednisone (D-VMP)|Participants will receive daratumumab 1800 mg by SC injection on Days 1, 8, 15, 22, 29 and 36 of Cycle 1 then on Days 1 and 22 in Cycles 2 to 9 and Day 1 of Cycle 10 and thereafter until documented progression of disease, unacceptable toxicity, or end of study; bortezomib 1.3 mg/m^2 SC injection on Day 1, 4, 8, 11, 22, 25, 29 and 32 of Cycle 1 and on Days 1, 8, 22 and 29 of Cycles 2 to 9; melphalan 9 mg/m^2 orally on Day 1 through Day 4 of Cycles 1 to 9; prednisone 60 mg/m^2 orally on Days 1 to 4 of cycles 1 to 9.
89587711|NCT03412565|Experimental|Daratumumab + Lenalidomide + Dexamethasone (D-Rd)|Participants will receive daratumumab 1800 mg by SC injection on Days 1, 8, 15 and 22 of Cycles 1 and 2 then on Day 1 and 15 of Cycles 3 to 6 and on Day 1 of Cycle 7 and thereafter until documented progression of disease, unacceptable toxicity, or end of study; lenalidomide 25 mg orally on Day 1 through Day 21 of each cycle until documented progression of disease, unacceptable toxicity, or end of study and dexamethasone 40 mg orally or intravenously weekly until documented progression of disease, unacceptable toxicity, or end of study.
89587712|NCT03412565|Experimental|Daratumumab + Carfilzomib + Dexamethasone (D-Kd)|Participants will receive daratumumab 1800 mg by SC injection on Days 1, 8, 15 and 22 of Cycles 1 and 2 (each cycle is of 28 days) then on Day 1 and 15 of Cycles 3 to 6 and on Day 1 of Cycle 7 and thereafter until documented progression of disease, unacceptable toxicity, or end of study; Carfilzomib 20 mg/m^2 intravenously (IV) on Day 1 of Cycle 1 only then 70 mg/m^2 IV on Days 8 and 15 of Cycle 1 and Days 1, 8 and 15 of Cycle 2 and thereafter until documented progression of disease, unacceptable toxicity, or end of study and dexamethasone 40 mg orally or IV weekly for Cycles 1-9 then on Days 1, 8, 15 of each cycle for Cycles 10 and thereafter until documented progression of disease, unacceptable toxicity, or end of study.
89587713|NCT03385655|Experimental|WEE-1 inhibitor - ARM CLOSED|
89587714|NCT03385655|Experimental|cMET inhibitor|
89587715|NCT03385655|Experimental|novel non-steroidal androgen receptor (AR) antagonist|
89587716|NCT03385655|Experimental|CFI400945 PLK4 inhibitor - ARM CLOSED|
89587717|NCT03385655|Experimental|Ipatasertib AKT inhibitor|
89587718|NCT03385655|Experimental|Durvalumab and Tremelimumab immunotherapy|
89587719|NCT03385655|Experimental|Carboplatin platinum based chemotherapy|
89587720|NCT03379727|Experimental|Midostaurin|"Patients went through 3 phases:~Induction phase - Day (D)8 to D28 in combination with standard of care (7+3 or 5+2 chemotherapy) up to 2 cycles; Consolidation phase - D8 to D28 in combination with cytarabine up to 4 cycles; Maintenance phase - D1 to D28 up to 12 cycles"
89587721|NCT03378271|Experimental|FGM/CGM|"each patient will have a CGM and a FGM, subcutaneous glucose sensors, the data will be compared to the time-matched reference blood glucose measurements.~Each ambulatory patient will sample capillary blood with the HemoCue meter and measure the concentration of glucose minimum 3 times per day for 14 days. The concentration of finger-stick capillary blood glucose will be measured using the self-monitoring blood glucose (SMBG) hemocue meter in their daily living. The subjects will record SMBG, in a written diary. Subjects will dose insulin according to their routine methods throughout the 14 day study"
89587722|NCT03306680|Experimental|Patients with ultra-central NSCLC T1-3 (<6cm) N0 M0|"Level-1 Dose per fraction: 4Gy Number of fractions: 15 Total Dose: 60 Gy~Level 0 Dose per fraction: 6Gy Number of fractions: 10 Total Dose: 60 Gy~Level 1 Dose per fraction: 7.5 Gy Number of fractions: 8 Total Dose: 60 Gy"
89587723|NCT03294408|Other|Imaging|multimodal imaging and clinical assessment
89587724|NCT03289923|Experimental|Active TMS+ Cognitive Therapy|active
89587725|NCT03289923|Sham Comparator|Sham TMS + Cognitive Therapy|inactive
88975829|NCT00124150|No Intervention|S|Saline infusion without additional magnesium sulfate.
88975830|NCT02958046|Experimental|Lansoprazole/Domperidone|DUOLANS 30/30 mg SR tablet per oral, one tablet daily
88975831|NCT00073905|Active Comparator|Arm A|Capecitabine plus Gemcitabine
88975832|NCT00124189|Other|open label|Sequential dose cohort, open label, escalation trial evaluating one infusion duration of 2 hours
88975833|NCT00124228|No Intervention|1|Antibiotic following hospital Protocols according the cause of the infection .
88975834|NCT00124228|Active Comparator|2|Antibiotic following hospital Protocols according the cause of infection plus albumin
88975835|NCT00043121|Experimental|Treatment (combination chemotherapy)|Patients receive oxaliplatin IV over 2 hours, leucovorin calcium IV, and fluorouracil IV on days 1 and 15. Patients also receive oral capecitabine every 8 hours on days 1-2 and 15-16. Leucovorin calcium and fluorouracil administration is held at dose level 4 and above. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88975836|NCT00402415|Experimental|1|
88975837|NCT04727476||Children with attention deficit disorders|children aged 7-13 years who have attended a specialised outpatient clinic treating children with attention deficit disorders i in the period from 1 April 2013 to 5 November 2019.
88975838|NCT00124306|Active Comparator|1|Amitryptiline
88975839|NCT00124306|Placebo Comparator|2|Placebo will be dosed exactly as active arm.
88975840|NCT00124345|Experimental|1|
88975841|NCT00124501|Active Comparator|SMT|Standard Medication Treatment
88975842|NCT00124501|Experimental|BART|Biofeedback-assisted Relaxation Training plus SMT
89587726|NCT03280056|Active Comparator|NurOwn® (MSC-NTF cells)|Three Intrathecal administrations of NurOwn® (MSC-NTF cells) at bi-monthly intervals
89587727|NCT03280056|Placebo Comparator|Placebo|Three Intrathecal administrations of Placebo at bi-monthly intervals
89587728|NCT03268382|Experimental|APR-246 + PLD|
89587729|NCT03183388|Experimental|BE-SMART|Psychobehavioral intervention with focus either on teaching emotional regulation skills or regularizing daily sleep and activity levels.
89587730|NCT03161379|Experimental|CY, Nivolumab, GVAX, and SBRT|CY, Nivolumab, GVAX, and SBRT
89587731|NCT03129646|Experimental|Arm 1 - MF/PM 14d|Paromomycin 20 mg/kg/d IM for 14 days combined with oral miltefosine allometric dosing for 14 days
89587732|NCT03129646|Experimental|Arm 2 - MF 28d/PM 14d|Paromomycin 20 mg/kg/d IM for 14 days combined with oral miltefosine allometric dosing for 28 days
89587733|NCT03129646|Active Comparator|Arm 3 - SSG/PM 17d|Sodium Stibogluconate 20 mg/kg/day IM/IV combined with Paromomycin 15 mg/kg/day IM for 17 days
89587734|NCT03126916|Experimental|Arm A (chemotherapy, HSCT, EBRT)|See Arm A in detailed description.
89587735|NCT03126916|Experimental|Arm B (Iobenguane I-131, chemotherapy, HSCT, EBRT)|See Arm B in detailed description.
89587736|NCT03126916|Experimental|Arm C (Iobenguane I-131, chemotherapy, BuMel, HSCT, EBRT)|See Arm C in detailed description. Closed to accrual as of 12/17/20.
89587737|NCT03126916|Experimental|Arm D (chemotherapy, HSCT, EBRT)|See Arm D in detailed description.
88975843|NCT00124540|Placebo Comparator|1|placebo resembling misoprostol
88975844|NCT00124540|Experimental|2|misoprostol
88975845|NCT00074022|Experimental|Treatment (GTI-2040, docetaxel)|"Phase I (closed to accrual as of 8/5/2004): Patients receive GTI-2040 IV continuously on days 1-14. Patients also receive docetaxel IV over 1 hour on day 3 during course 1 and on day 1 for all subsequent courses. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of GTI-2040 and docetaxel until the MTD is determined. The MTD is defined as the dose at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. The RP2D is defined as the dose preceding the MTD.~Phase II: Patients receive GTI-2040 and docetaxel at the RP2D as in phase I."
88975846|NCT00124852|Placebo Comparator|High Oleic Sunflower Oil|
88975847|NCT00124852|Active Comparator|400 mg EPA+DHA/day|low dose fish oil
88975848|NCT00124852|Active Comparator|1800 mg EPA+DHA/day|high dose fish oil
88975849|NCT00124969|Active Comparator|1|Amlodipine
88975850|NCT00124969|Placebo Comparator|2|Placebo
88975851|NCT00125008|Experimental|1|Typhoid Vi vaccine
88975852|NCT00125008|Active Comparator|2|Hepatitis A vaccine
88975853|NCT00125047|Experimental|1|Typhoid Vi polysaccharide vaccine
88975854|NCT00125047|Active Comparator|2|Inactivated Hepatitis A vaccine
88975855|NCT02970656|Experimental|Teens.Connect|The Teens-Connect internet-based program has two complementary components - TEENCOPE and Managing Diabetes. Managing Diabetes consists of 5 sessions on educational content related to diabetes self management targeted to adolescents. TEENCOPE consists of a series of 5 sessions designed to increase children's sense of competence and mastery by retraining inappropriate or non-constructive coping styles and forming more positive styles and patterns of behavior. Each week a new 30-45 minute session is uploaded to a password-protected website on the Yale server for youth to complete. Youth are grouped with 8-12 peers who complete the same weekly sessions in an asynchronous manner. Youth interact with each other on an online discussion board moderated by a clinical psychologist.
88975856|NCT02970656|No Intervention|Control|Wait listing will serve as the control condition. Usual care at the Yale Pediatric Diabetes Center consists of quarterly visits with physicians and nurse practitioners, accessibility to nutritional and psychological consultation, and 24/7 on call service. Following completion of the 6 month data point, youth will be offered the opportunity to participate in the internet program.
88975857|NCT04729998|Other|Sequence TR|17 subjects assigned to the sequence TR will receive a single 20 mg dose of the test product Rivaroxaban (1 x 20 mg tablet), marked as T in the sequence, in Period 1 and a single 20 mg dose of the reference product Xarelto® (1 x 20 mg tablet), marked as R in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a standardized breakfast. The tablet must be swallowed whole and must not be chewed or broken.
88975858|NCT04729998|Other|Sequence RT|17 subjects assigned to the sequence RT will receive a single 20 mg dose of the reference product Xarelto® (1 x 20 mg tablet), marked as R in the sequence, in Period 1 and a single 20 mg dose of the test product Rivaroxaban (1 x 20 mg tablet), marked as T in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a standardized breakfast. The tablet must be swallowed whole and must not be chewed or broken.
88975859|NCT00043394|Experimental|Cohort 1|0.04 mg/kg CpG 7909
88975860|NCT00043394|Experimental|Cohort 2|0.08 mg/kg CpG 7909
88975861|NCT00043394|Experimental|Cohort 3|0.12 mg/kg CpG 7909 Injection once weekly
88975862|NCT00043394|Experimental|Cohort 4|0.16 mg/kg CpG 7909
88975863|NCT00125827|Experimental|1|Single-arm, dose escalation
88975864|NCT02970617|Active Comparator|Group A (no bell after final radiation)|Patients undergo standard of care radiation therapy with or without chemotherapy.
88975865|NCT02970617|Experimental|Group B (ring bell after final radiation treatment)|On the final day of standard of care radiation therapy, patients ring a bell in the clinic.
88975866|NCT00402493|Active Comparator|Latanoprost|to determine whether commonly used OTC non-steroidal anti-inflammatory agents taken orally has any effect on the ability of either latanoprost or brimonidine to lower high eye pressure
88975867|NCT00402493|Active Comparator|Brimonidine|to determine whether commonly used OTC non-steroidal anti-inflammatory agents taken orally has any effect on the ability of either latanoprost or brimonidine to lower high eye pressure
88975868|NCT00402493|Active Comparator|ibuprofen|to determine whether commonly used OTC non-steroidal anti-inflammatory agents taken orally has any effect on the ability of either latanoprost or brimonidine to lower high eye pressure
88975869|NCT00402532|Active Comparator|Everolimus|
88975870|NCT00402532|Active Comparator|Mycophenolatmofetil|
88975871|NCT00126100|Experimental|1|Patients were randomly assigned to receive subcutaneously a daily dose of 10 microg/kg of G-CSF for 5 days.
88975872|NCT00126100|Placebo Comparator|2|Patients were randomly assigned to receive subcutaneously a daily dose of placebo for 5 days.
88975873|NCT00126217|Experimental|1|
88975874|NCT00126217|No Intervention|2|
89587738|NCT03126916|Experimental|Arm E (lorlatinib, chemotherapy, HSCT, EBRT)|See Arm E in detailed description.
89587739|NCT03118895|Experimental|Treatment Arm|Patients with coronary artery disease at high risk of bleeding receiving the BioFreedom™ BA9™ drug-coated stent
89587740|NCT03108846|Experimental|Escitalopram|Escitalopram up to 15mg/day taken as 1-3 capsules each containing 5mg escitalopram once per day in the morning
89587741|NCT03108846|Placebo Comparator|Placebo|1-3 capsules each containing placebo only once per day in the morning
89587742|NCT03098563|Experimental|Arm 1|Blinded study medication. This is a within-subject study so all session procedures will be identical. The specific medications administered that study day will be the only change each session. Study days will last approximately 8 hours and will be conducted on an outpatient basis. Participants will be asked to complete standardized pain testing procedures, do brief physical functioning testing, undergo blood draws and complete questionnaires and cognitive testing at multiple points over the course of each study visit.
89587743|NCT03098563|Experimental|Arm 2|Blinded study medication. Participants will be asked to complete standardized pain testing procedures, do brief physical functioning testing, undergo blood draws and complete questionnaires and cognitive testing at multiple points over the course of each study visit.
89587744|NCT03098563|Experimental|Arm 3|Blinded study medication. Participants will be asked to complete standardized pain testing procedures, do brief physical functioning testing, undergo blood draws and complete questionnaires and cognitive testing at multiple points over the course of each study visit.
89587745|NCT03098563|Experimental|Arm 4|Blinded study medication. Participants will be asked to complete standardized pain testing procedures, do brief physical functioning testing, undergo blood draws and complete questionnaires and cognitive testing at multiple points over the course of each study visit.
89587746|NCT03067181|Experimental|Arm I (bleomycin, carboplatin, etoposide)|Patients receive bleomycin IV over 10 minutes and carboplatin IV over 1 hour on day 1. Patients also receive etoposide IV over 1-2 hours on days 1-5. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT, MRI, and/or chest x-ray as well as blood sample collection throughout the trial. Patients may also undergo a tumor biopsy throughout the trial. Patients undergo a pulmonary function test on study.
89587747|NCT03067181|Experimental|Arm II (bleomycin, etoposide, cisplatin)|Patients receive bleomycin IV over 10 minutes on day 1. Patients also receive etoposide IV over 1-2 hours and cisplatin IV over 1-3 hours on days 1-5. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT, MRI, and/or chest x-ray as well as blood sample collection throughout the trial. Patients may also undergo a tumor biopsy throughout the trial. Patients undergo a pulmonary function test on study.
89587748|NCT03067181|Experimental|Arm III (bleomycin, etoposide, carboplatin)|Patients receive bleomycin IV over 10 minutes on days 1, 8, and 15, etoposide IV over 1-2 hours on days 1-5, and carboplatin IV over 1 hour on day 1. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT, MRI, and/or chest x-ray as well as blood sample collection throughout the trial. Patients may also undergo a tumor biopsy throughout the trial. Patients undergo a pulmonary function test on study.
88975875|NCT00126334|Active Comparator|1|Liberal transfusion threshold
88975876|NCT00126334|Experimental|2|Conservative transfusion threshold
88975877|NCT00126373|Placebo Comparator|Sugar pill|Placebo (sugar) pill with identical look to bupropion
88975878|NCT00126373|Experimental|buproprion|bupropion pill
88975879|NCT00126412|Experimental|123I-mIBG (Meta-iobenzylguanidine)|"All subjects received 123I-mIBG injection over at least 1 to 2 minutes through a cannula (or indwelling catheter in the vein). After the injection of 123I-mIBG was complete, the cannula was flushed with at least 5 mL of 0.9% sodium chloride solution over a maximum of 10 seconds.~All subjects ≥18 years of age and children with a weight of ≥70 kg were to receive an intravenous injection of 370 ±10% MBq (333 to 407 MBq [9.0 to 11 mCi] of 123I-mIBG). Doses of 123I-mIBG for children <18 years of age (with a weight of 8-70 kg) were to be calculated on the basis of a reference activity for an adult scaled to body weight according to the schedule proposed by the European Association of Nuclear Medicine (EANM) Paediatric Task Group; for children <8 kg, a scaled activity or a fixed minimum activity of 80 ±10% MBq (72 to 88 MBq [1.9 to 2.2 mCi]) was permissible."
88975880|NCT00126607|Experimental|Treatment (trastuzumab)|Patients receive trastuzumab (Herceptin) IV over 30-90 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88975881|NCT00126724|Active Comparator|1|1x10^11 DRP/mL tgAAC94
88975882|NCT00126724|Active Comparator|2|1x10^12 DRP/mL tgAAC94
88975883|NCT00126724|Active Comparator|3|1x10^13 DRP/mL tgAAC94
88975884|NCT00126724|Placebo Comparator|4|
89587749|NCT03067181|Experimental|Arm IV (bleomycin, etoposide, cisplatin)|Patients receive bleomycin IV over 10 minutes on days 1, 8, and 15, etoposide IV over 1-2 hours on days 1-5, and cisplatin IV over 1-3 hours on days 1-5. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT, MRI, and/or chest x-ray as well as blood sample collection throughout the trial. Patients may also undergo a tumor biopsy throughout the trial. Patients undergo a pulmonary function test on study.
89587750|NCT03067181|Experimental|Low-Risk (observation)|Patients with low-risk stage I grade 2, 3 ovarian immature teratoma or stage I non-seminoma or seminoma MGCTs undergo observation and can transfer to standard risk arm when eligibility criteria are met. Patients with stage I seminoma testicular MGCT undergo observation, and those with residual/recurrent disease are treated at the discretion of their physician. Patients undergo CT, MRI, and/or chest x-ray as well as blood sample collection throughout the trial. Patients may also undergo a tumor biopsy throughout the trial.
89587751|NCT03005145|Active Comparator|Short duration (7 days)|Patients in 7 day arm will receive adequate antibiotics until the end of day 7 only
88975885|NCT02970461|Placebo Comparator|Control Group|"Subjects will see in their Personal Health Record home page a simple text link pointing to their Bio page. Once in their Bio page, the site will display their personal information as usual with the only addition of a validate data button next to any non-validated field. The option to edit fields will also be present."
88975886|NCT02970461|Experimental|Gamified Group|"Subjects will see in their Personal Health Record home page a graphical representation of the percentage of completeness their Bio page has that when clicked acts as a link to their Bio page. Once in their Bio page, the site will display graphical elements such grayed out fields, graphical representations of the percentage of completeness for each data group and on mouse hover over any field a tooltip will inform of what percentage of completeness will be awarded if the data is validated. Also, an addition of a validate data button next to any non-validated field. The option to edit fields will also be present."
88975887|NCT00126763|Experimental|Matrix Transdermal Fentanyl Patch|
88975888|NCT00399438|Other|1|0 mg
88975889|NCT00399438|Other|2|25 mg
88975890|NCT00399438|Other|3|100 mg
88975891|NCT02970695|Active Comparator|Treatment arm 1|"To achieve a blinding and placebo effect of the subject, the laser device will be switched to power off mode (i.e. deactivated laser) for acupoint stimulation before the application of MAT. The subjects will be asked to wear a pair of laser protective goggles so as to blind them during treatment."
89587752|NCT03005145|Active Comparator|Long duration (14 days)|Patients in 14 day arm will receive adequate antibiotics until the end of day 14 only
89587753|NCT02989584|Experimental|Atezolizumab, Gemcitabine, Cisplatin|"This is a two phase study with a single study arm for each phase.~For Phase 1: Following enrollment participants will be treated with combination therapy on a 21 day cycle x 6 cycles. Gemcitabine (1000 mg/m2 on Day 1 and Day 8), cisplatin (70 mg/m2 on Day 1), and atezolizumab (1200 mg on Day 8) will be administered intravenously.~Phase 2: Following enrollment participants will be treated with a single dose of atezolizumab alone followed by combination therapy on a 21-day cycle x 4 cycles, followed by a single dose of atezolizumab alone. Gemcitabine 1000mg/m2, cisplatin (70 mg/m2 on Day 1), and atezolizumab (1200 mg on Day 8) will be administered intravenously."
89587754|NCT02974647|Experimental|rel/ref PTCLtumors are known to contain mutations associ|Patients will receive ruxolitinib 20mg BID orally on 28 day cycles. Ruxolitinib should be taken by mouth every 12 hours approximately the same time each day (+/- 2 hours). Treatment may continue until disease progression, unacceptable toxicity, recommended termination by the treating physician, or termination of the study.
89587755|NCT02974647|Experimental|with rel/ref PTCL with functional evidence of JAK/STAT|Patients will receive ruxolitinib 20mg BID orally on 28 day cycles. Ruxolitinib should be taken by mouth every 12 hours approximately the same time each day (+/- 2 hours). Treatment may continue until disease progression, unacceptable toxicity, recommended termination by the treating physician, or termination of the study.
89587756|NCT02974647|Experimental|with rel/ref PTCL who do not meet criteria for cohort 1 or 2.|Patients will receive ruxolitinib 20mg BID orally on 28 day cycles. Ruxolitinib should be taken by mouth every 12 hours approximately the same time each day (+/- 2 hours).Treatment may continue until disease progression, unacceptable toxicity, recommended termination by the treating physician, or termination of the study.
89587757|NCT02974647|Experimental|Rare sub-type expansion cohort: T-PLL and T-LGL & any T-Cell/NK Lymphoma with JAK fusion mutations.|Patients will receive ruxolitinib 20mg BID orally on 28 day cycles. Treatment may continue until disease progression, unacceptable toxicity, recommended termination by the treating physician, or termination of the study.
89587758|NCT02963064|Experimental|Blood Stem Cell Transplant w/ anti-CD117 conditioning|The study will enroll two groups: Group A: previously transplanted SCID patients; Group B: newly diagnosed SCID. The study plans to assess JSP191 in different dose cohorts. Patients will receive a single dose of intravenous JSP191 antibody followed by monitoring for antibody clearance. Once the antibody has cleared below a certain level, patients will receive stem cell transplant and be monitored for hematopoietic recovery.
89587759|NCT02962492|Active Comparator|Dapagliflozin Arm:|dapagliflozin 10mg (oral tablet) and exenatide (5µg acutely)/Exenatide extended release (long term) placebo (subcutaneous injection)
89587760|NCT02962492|Active Comparator|Exenatide extended release Arm:|subcutaneous injection of Exenatide (5µg acutely)/Exenatide extended release (long term) and dapagliflozin placebo
89587761|NCT02962492|Placebo Comparator|Placebo Arm:|dapagliflozin placebo (oral tablet) and exenatide (5µg acutely)/Exenatide extended release (long term) placebo (subcutaneous injection)
89587762|NCT02962492|Active Comparator|Exenatide extended release & dapagliflozin Arm:|Exenatide (5µg acutely)/Exenatide extended release (long term) and dapagliflozin 10mg
89587763|NCT02959502|Experimental|Receive tDCS + CR|Receive tDCS+CR: Over the course of 8 weeks, for 5 days a week, participants designated a 'Patient' will receive active tDCS &CR at-home. tDCS will be administered during the 2 hour CR sessions for 30 min/day. The tDCS montage will be bifrontal91 with 1 large anode placed over Fz and the cathode over Iz. The direct current will be 2 mA (current density = 0.57 A/m2). CR sessions will utilize didactic and computerized drill-based exercises which focus on practice and repetition of neurocognitive ability areas that are affected in depression such as attention, processing speed, executive function, verbal memory, and working memory. Performance feedback is given to reinforce progress and the exercises are designed to be enjoyable to complete, with titrated difficulty levels over time.
88975892|NCT02970695|Active Comparator|Treatment arm 2|Subjects will receive LAT. A laser device (Pointer Pulse™) will be used in this study.
88975893|NCT02970695|Experimental|Treatment arm 3|Subjects will receive a combined approach that includes the use of LAT plus MAT. LAT will be administered prior to MAT application on the selected auricular points, and the procedures used will be similar to the procedures described for Group 1 and Group 2.
88975894|NCT00126880|Experimental|600mg BID ATC|600mg BID ATC
88975895|NCT00126880|Experimental|800mg BID ATC|800mg BID ATC
88975896|NCT00126880|Active Comparator|150mg BID 3TC|150mg BID 3TC
88975897|NCT02965911|Active Comparator|UDCA Standard treatment|All subjects will reiceive UDCA at a dose of 13-15mg/kg/d by oral for 12 months, and UDCA will be maintained after 12 months.
88975898|NCT02965911|Experimental|Fenofibrate Combined with UDCA Treatment|All subjects will be treated with UDCA,13-15mg/kg/d, and Fenofibrate, 200mg/d by oral for 12 month,
88975899|NCT00043745|Experimental|1|Participants will receive moderate dose soy isoflavone (80 mg/day) tablets, extracted from soy protein
88975900|NCT00043745|Experimental|2|Participants will receive high dose soy isoflavone (120 mg/day) tablets, extracted from soy protein
88975901|NCT00043745|Placebo Comparator|3|Participants will receive soy extract devoid of isoflavones to serve as placebo
88975902|NCT00074295|Experimental|treatment|GVAX lung cancer vaccine
88975903|NCT00127075|Experimental|NOMA + estradiol|Oral NOMA (LUTENYL® 10 mg/day) combined with transdermal Estradiol (DERMESTRIL SEPTEM® 75 mcg, once a week),
88975904|NCT00127075|Placebo Comparator|placebo|Matching placebo treatments
89587764|NCT02959502|Experimental|Facilitate tDCS + CR|Over the course of 8 weeks, for 5 days a week, participants designated a 'facilitator' will trained to deliver tDCS &CR at-home. tDCS will be administered during the 2 hour CR sessions for 30 min/day. The tDCS montage will be bifrontal91 with 1 large anode placed over Fz and the cathode over Iz. The direct current will be 2 mA (current density = 0.57 A/m2). CR sessions will utilize didactic and computerized drill-based exercises which focus on practice and repetition of neurocognitive ability areas that are affected in depression such as attention, processing speed, executive function, verbal memory, and working memory.
89587765|NCT02927821|Experimental|ADS Plus|Families in settings assigned to intervention will receive Adult Day Services (ADS) as usual in addition to ADS Plus. ADS Plus has 5 key components: care management, referral/linkage; disease education; counseling/emotional support/stress reduction, and care skills managing daily challenges and behavioral disturbances. The intervention begins with 2 face-to-face sessions with the site interventionist to conduct a needs assessment to identify concerns and needs and develop an agreed upon care plan. The interventionist then meets with caregivers face-to-face at convenient times to implement the care plan, every other week for the first 3 months, and then for monthly reassessments for newly emerging care concerns thereafter. Contact occurs about a minimum of 1 hour per month over 12 months.
89587766|NCT02927821|No Intervention|ADS Usual Care|Caregivers in the 15 sites assigned to serve as the usual care control group will receive Adult Day Services (ADS) as usual. Near completion of the study (project year 05), control group sites will have the option of receiving training in ADS Plus for their setting.
89587767|NCT02788461|Active Comparator|Chemoradiotherapy|Patients randomized to the standard arm will receive radiotherapy (5x per week) of 60 gray (Gy) in 30 fractions with concurrent cisplatin and etoposide chemotherapy.
89587768|NCT02788461|Experimental|Chemoradiotherapy with Integrated Boost Dose|Patients randomized to the experimental arm will receive radiotherapy (5x per week) with an integrated boost dose of up to 85Gy in 30 fractions to tumor subvolumes, with concurrent cisplatin and etoposide chemotherapy.
89587769|NCT02780648|Experimental|Stereotactic Body Radiation|Patients will receive 5 fractions of 5 Gy or 6.6 Gy (dose depending upon whether or not they have received prior radiation therapy to the pancreatic region) delivered over a five-day period.
89587770|NCT02777073|Active Comparator|liraglutide 1.8 mg|single dose of Victoza ( liraglutide) 1.8 mg
89587771|NCT02777073|Placebo Comparator|Placebo|Single dose of placebo
89587772|NCT02777073|Active Comparator|Dapagliflozin|Single dose of Dapagliflozin 10 mg oral tablet
89587773|NCT02684708|Active Comparator|COPDAC-28|cyclophosphamide, vincristine, prednisone, dacarbazine; cyclophosphamide 500 mg/m2, per infusion on day 1 + 8; vincristine 1.5 mg/m2 intravenously (capping dose 2 mg) on day 1 + 8 and prednisone 40 mg/m2/day by mouth divided into 3 doses (capping dose 80 mg/day) on day 1 - 15 and dacarbazine 250 mg/m2 infusion on day 1 - 3
89587774|NCT02684708|Experimental|DECOPDAC-21|patients with intermediate and advanced stages will be randomized after the induction therapy to receive either COPDAC-28 standard consolidation or the intensified DECOPDAC-21. cyclophosphamide dose augmented to 625 mg/m2 and adminstered per infusion on day 1 and day 2; vincristine dose not changed; prednisone 40 mg/m2/day by mouth on day 1 - 8 (no capping dose prescribed), i.e. dose-reduction; dacarbazine dose not changed; etoposide infusion100 mg/m2/day on day 1 - 3 and doxorubicine 25 mg/m2 per infusion on day 1as additional drugs in comparison to active comparator; cycle is administered as 21 days instead of 28 days-cycle for intensification
89587775|NCT02667587|Experimental|Nivolumab + Temozolomide + Radiotherapy|Nivolumab: specified dose on specified days; IV (intravenous) infusion Temozolomide: 75 mg (milligram)/meter squared daily during Radiotherapy, 4 week treatment break, 150 mg/meter squared Day 1-5 for Cycle 1 and increased to 200 mg/meter squared Day 1-5 for Cycle2-Cycle 6 as tolerated; orally (additional cycles may be permitted with approval of sponsor) Radiotherapy: 2 gray units (joule of radiation energy per kilogram) 5 times per week for 6 weeks
89587776|NCT02667587|Placebo Comparator|Nivolumab placebo + Temozolomide + Radiotherapy|Nivolumab Placebo: specified dose on specified days; IV infusion Temozolomide: 75 mg/meter squared daily during Radiotherapy, 4 week treatment break, 150 mg/meter squared Day 1-5 for Cycle 1 and increased to 200 mg/meter squared Day 1-5 for Cycle2-Cycle 6 as tolerated; orally (additional cycles may be permitted with approval of sponsor) Radiotherapy: 2 gray units 5x/week x 6 weeks
89587777|NCT02598661|Experimental|Part 1: Imetelstat|Imetelstat will be administered at a starting dose of 7.5 milligram per kilogram (mg/kg) given intravenously every 4 weeks, until disease progression, unacceptable toxicity, or withdrawal of consent, or lack of response.
89587778|NCT02598661|Experimental|Part 2 (Main Study): Imetelstat|"Imetelstat will be administered at a starting dose of 7.5 mg/kg given intravenously every 4 weeks, until disease progression, unacceptable toxicity, or withdrawal of consent, or lack of response.~Subjects receiving imetelstat who continue into the extension phase will continue to receive imetelstat treatment per this same schedule."
89587779|NCT02598661|Placebo Comparator|Part 2 (Main Study): Placebo|Matching Placebo to Imetelstat will be administered.
89587780|NCT02598661|Experimental|Part 2 (Ventricular Repolarization Substudy): Imetelstat|"Imetelstat will be administered at a starting dose of 7.5 mg/kg given intravenously every 4 weeks, until disease progression, unacceptable toxicity, or withdrawal of consent, or lack of response.~Subjects receiving imetelstat who continue into the extension phase will continue to receive imetelstat treatment per this same schedule."
89587781|NCT02598661|Placebo Comparator|Part 2 (Ventricular Repolarization Substudy): Placebo|Matching Placebo to Imetelstat will be administered.
89587782|NCT02597361|Active Comparator|Irbesartan|Irbesartan: 150 or 300 mg o.d. for 2 years.The up-titration of irbesartan from 150 mg to 300 mg o.d. occurs during the first 8 weeks following randomization and will be driven by clinical, hemodynamic and biological (plasma creatinine and K) tolerability.
89587783|NCT02597361|Placebo Comparator|Placebo|Placebo once or twice per day for 2 years.
88975905|NCT00127114|Experimental|Amantadine|
88975906|NCT00127114|Placebo Comparator|Placebo|
88975907|NCT00399477|Active Comparator|Rasagiline mesylate|
89587784|NCT02579005|Experimental|Patients with a living donor|Radiation + PBMC
89587785|NCT02579005|Experimental|Patients with a UCB donor|Radiation + UCB
89587786|NCT02471352||1/ Skin disease or at risk|Subjects with a skin disease or at risk of developing a skin disease/ Family member of persons with a skin disease
89587787|NCT02471352||2/ Healthy Volunteers|Healthy Volunteers
89587788|NCT02402244||Observational (Project: Every Child)|Patients undergo medical data review to create a Childhood Cancer Registry. Patients also undergo collection of biospecimen samples (e.g., tissue, blood, bone marrow, plasma, serum, buccal swab, saliva, cerebrospinal fluid, or urine).
89587789|NCT02390752|Experimental|Phase I|take oral drug daily for a 28 day cycle
89587790|NCT02361554|Experimental|Deep Brain Stimulation Implant|Unblinded treatment arm, deep brain stimulation of the substantia nigra pars reticulata for treatment resistant schizophrenia.
89587791|NCT02346838|Experimental|Inulin|Participants will receive 10 g of inulin powder each day for 6 weeks.
89587792|NCT02346838|Placebo Comparator|Placebo|Participants will receive 10 g of maltodextrin each day for 6 weeks.
89587793|NCT02338609|Experimental|Everolimus|All patients will have been previously treated with everolimus as part of CRAD001M2301. Continued treatment with everolimus is allowed but not required for participation in this study. However, the physician may choose to place the patient on another treatment.
89587794|NCT02338609|Experimental|Physician Choice|
89587795|NCT02252432|Active Comparator|Ketamine|A bolus of intravenous (IV) ketamine during induction (0.5mg/kg), and an IV infusion of ketamine intraoperatively (5 mcg/kg/min))
89587796|NCT02252432|Active Comparator|Methadone|Will receive a single dose of IV methadone (0.2 mg/kg) preinduction
89587797|NCT02252432|Experimental|Ketamine + methadone|Methadone (0.2 mg/kg) preinduction, a bolus of IV ketamine (0.5 mg/kg) during induction and IV ketamine infusion intraoperatively (5 mcg/kg/min)
89587798|NCT02195479|Active Comparator|Treatment Arm A (VMP Alone)|Participants will receive velcade (bortezomib) 1.3 milligram per square meter (mg/m^2) as subcutaneous injection, twice weekly at Weeks 1, 2, 4 and 5 in Cycle 1 followed by once weekly at Weeks 1, 2, 4 and 5 in Cycles 2 to 9, melphalan 9 mg/m^2 , orally, once daily (on Days 1-4) and prednisone 60 mg/m^2, orally, once daily, on Days 1 to 4 of each cycle up to Cycle 9.
89587799|NCT02195479|Experimental|Treatment Arm B (D-VMP)|Participants will receive velcade 1.3 mg/m^2 as SC injection, twice weekly at Weeks 1, 2, 4 and 5 in Cycle 1 followed by once weekly at Weeks 1, 2, 4 and 5 in Cycles 2 to 9, melphalan 9 mg/m^2, orally, once daily (on Days 1-4) and prednisone 60 mg/m^2, orally, once daily, on Days 1 to 4 of each cycle up to Cycle 9. In addition participants will also receive daratumumab 16 mg/kg as IV infusion, once weekly, for 6 weeks in Cycle 1 and then every 3 weeks, in Cycle 2 to 9 and thereafter, once every 4 weeks until documented progression, unacceptable toxicity, or until the end of study. On days when daratumumab is given, dexamethasone 20 mg IV or PO is given 1 hour or less prior to daratumumab administration as pre medication and prednisone substitute, and prednisone 60 mg/m2 once daily will be given on Days 2-4. Following amendment 7, participants will have the option to switch to daratumumab subcutaneous (SC) on Day 1 of any cycle, at the discretion of the investigator.
89587800|NCT02189486||Prostate Cancer Cohort|Men with prostate cancer who have elected radical prostatectomy for their treatment of their prostate cancer within two years after prostate biopsy.
89587801|NCT02181621|Placebo Comparator|Solosite gel|Hydrogel with preservatives, used to create a moist wound environment.
89587802|NCT02181621|Active Comparator|Iodosorb|Cadexomer iodine gel
88975908|NCT00399477|Experimental|Rasagiline mesylate plus adjunct therapy|Rasagiline mesylate with one of three adjunct therapies
88975909|NCT00127270|Experimental|1|Darifenacin
88975910|NCT00127270|Other|2|Darifenacin in combination with Behavioral Modification Programme for Symptoms of Overactive Bladder
88975911|NCT00043823|Experimental|Avastin + Tarceva|Combination Therapy (Avastin + Tarceva) = Avastin IV Day 1 of each 21-day cycle + oral Tarceva daily.
88975912|NCT00399555||One|Patients with HLHS that have had surgical palliation with the Norwood procedure (Stage I palliation) at Children's Healthcare of Atlanta after January 1, 2001. These patients must be between the ages of 2.5 years and 6 years of age.
88975913|NCT00399594|Experimental|A|Targeted LV lead placement
88975914|NCT00399594|Active Comparator|B|Usual LV lead placement
88975915|NCT04726657|Active Comparator|Premixed Insulin|Premixed Human Insulin
88975916|NCT04726657|Active Comparator|Premixed insulin|Premixed Insulin Analog
88975917|NCT04726735||Patients with histologically documented normal bladder|
88975918|NCT04726735||Patients with histologically documented Non Muscle Invasive Bladder Cancer|
88975919|NCT04726735||Patients with histologically documented Muscle Invasive Bladder Cancer|
88975920|NCT00402766|Experimental|Cisplatin + Imatinib + Pemetrexed|Cisplatin 60 mg/m^2 by vein, Over 2 Hours. Imatinib 300 mg PO Daily. Pemetrexed 500 mg/m^2 by vein, Over 40 Minutes. Dexamethasone 20 mg by vein given prior to Pemetrexed therapy and 4 mg given orally on Day 2 of each cycle.
88975921|NCT00128050|Active Comparator|1|Patients treated with recombinant FVIIa
88975922|NCT00128050|Placebo Comparator|2|Patients with spontaneous supratentorial ICH included in this arm will be treated with placebo
88975923|NCT04711434|Experimental|Prevention group|Toripalimab: 240mg IV every 3 months for a year
88975924|NCT04711434|No Intervention|Follow-up group|Routine follow-up, no intervention
88975925|NCT00128245|Experimental|Pimecrolimus 0.3%|ASM981 0.3%
88975926|NCT00128245|Experimental|Pimecrolimus 1%|ASM981 1%
88975927|NCT00128245|Placebo Comparator|Vehicle with carbopol|
88975928|NCT00128245|Placebo Comparator|Vehicle without carbopol|
88975929|NCT04711629|Experimental|Smoker COPD|Patients who continue to smoke
88975930|NCT04711629|Active Comparator|Ex-smoker COPD|Patients who quit smoking.
89587803|NCT01979211|Experimental|Cetuximab and Radiation|Cetuximab 400 mg/m2 IV over 120 minutes loading dose > 4 days prior to initiation of radiation; Cetuximab 250 mg/m2 IV over 60 minutes weekly weeks 2-7 concurrent with Radiation therapy 60-66 Gy in 2 Gy daily fractions
89587804|NCT01861977|Experimental|Cognitive Behavioral Therapy|Participants in this arm will be invited to attend 8 weekly group meetings and 3 monthly follow-up meetings. In each meeting a coordinator will explore the experiences of the participants and encourage them to look for strategies to solve problems associated with changing habits. In the meetings we will use a therapeutic education approach with motivational interviewing techniques and problem solving in order to increase self-efficacy and motivation to adopt healthy habits. There will be periodic reminders and telephone contacts with patients before the meetings to assess the achievement of objectives.
89587805|NCT01861977|Active Comparator|Informational Workshop|Participants will be invited to participate in 4 weekly group meetings and an additional reinforcing meeting in the 5th month. In each meeting, workshop techniques will be used, together with educational materials as brochures, pictures, etc. The informational material will focus on the benefits of lifestyle changes in diet and physical activity.
89587806|NCT01844986|Experimental|Olaparib tablets p.o. 300mg twice daily|Olaparib/placebo tablets p.o 300mg twice daily for up to 3 years or until objective radiological disease progression as per RECIST as assessed by the Investigator. Patients with evidence of stable disease (or those who have progressed), may continue on treatment beyond 2 years, if in the patient's best interest. Dose reduction to 250mg and subsequently 200mg is permitted following confirmation of toxicity
89587807|NCT01844986|Placebo Comparator|Placebo tablets p.o. twice daily|Olaparib/placebo tablets p.o 300mg twice daily for up to 3 years or until objective radiological disease progression as per RECIST as assessed by the Investigator. Patients with evidence of stable disease (or those who have progressed), may continue on treatment beyond 2 years, if in the patient's best interest. Dose reduction to 250mg and subsequently 200mg is permitted following confirmation of toxicity
89587808|NCT01784068|Experimental|Nilotinib followed by treatment-free|Patients who received a minimum of 2 years of first line nilotinib treatment and with pre-screen PCR results in ≥ MR4.5 entered the consolidation phase of the study (52 weeks - nilotinib 300 mg BID). Patients with Minimal Residual Disease (MRD) at the end of this phase entered the Treatment-Free Remission (TFR) phase where no treatment was given. Non eligible patients will enter the continuation phase of the study. Patients with MRD at the end of the continuation phase will enter the TFR-2 phase of the study where no treatment is given. Non eligible patients will enter the prolonged continuation phase of the study. If at any time during TFR or TFR-2 the patient loses MMR, nilotinib treatment will be immediately re-initiated (nilotinib 300 mg BID).
89587809|NCT01763307|Experimental|RECONVAL CREAM|half face treated with RECONVAL CREAM
89587810|NCT01763307|Placebo Comparator|PLACEBO|half face treated with PLACEBO cream
89587811|NCT01698905|Experimental|Nilotinib|Patients with minimum 3 years of tyrosine kinase inhibitor treatment (first with imatinib and then switched to nilotinib) since initial diagnosis, at least 2 years of nilotinib treatment prior to study entry and who achieved MR4.5 (local laboratory assessment) during nilotinib treatment, and determined by a Novartis designated central PCR lab assessment at screening
88975931|NCT00128284||Normal|healthy adult subjects with no history or current gastrointestinal disorders or conditions
88975932|NCT00128284||Gastroparesis|Subjects with documented gastroparesis
88975933|NCT05562505|Active Comparator|Venovenous ECMO|Patients allocated to the ECMO strategy be initiated on VV ECMO and commenced on anticoagulation within <24 hours after being enrolled. Following VV ECMO initiation, the sweep gas will be gradually turned up to target a respiratory alkalosis (pH > 7.45; maximum 20% increase every 6 hours; PaCo2 < 35 mmHg), to reduce the patient's intrinsic respiratory drive. Following this, the patient will be de-sedated, and when clinically appropriate, extubated. The awake patient will be assessed daily to participate in physiotherapy: which includes sitting up, sitting out of bed, speech assessment and, where appropriate, mobilisation.
88975934|NCT05562505|No Intervention|Standard care|Patients allocated to the standard care arm will receive routine intensive care for hypoxic respiratory failure, including mechanical ventilation with a lung protective strategy (low tidal volumes, pressures and positive end expiratory pressure titration), weaning of sedation and assessment for extubation. Patients who continue to deteriorate will be eligible for initiation of VV ECMO if they meet the ECMO to rescue lung injury in severe ARDS (EOLIA) criteria: Partial pressures of arterial oxygen (PaO2):Fraction of inspired oxygen (FiO2)<50 for 3 hours, PaO2:FiO2<80 for 6 hours, pH<7.25 with PaCO2 >60 for >6 hours.
88975935|NCT05562232|Experimental|Intervention group|Creatine monohydrate administered once a day for seven weeks - with 5 g/day for the entire period.
88975936|NCT05562232|No Intervention|Control group|The control group will receive standard care. However, to our knowledge there is no common accepted description of a standard care in the literature. In general, these participants will be advised to keep themselves as asymptomatic as possible throughout the entire seven weeks, and besides that live as normal a life as they can.
88975937|NCT05562232|Placebo Comparator|Placebo|Powdered Sugar administered once a day for seven weeks - with 5g/day for the entire period.
88975938|NCT04730505|Experimental|Patient App + HCP Portal (Cohort 1)|Cohort 1 is to assess how patients will use the Patient App if connected in real time with the Healthcare professional (HCP) Portal
88975939|NCT04730505|Experimental|Patient App Alone (Cohort 2)|Cohort 2 is to assess how patients will use the Patient App where there is no connectivity to the Healthcare professional (HCP) Portal and thus no real-time data sharing with the HCP Portal
88975940|NCT05562154|Active Comparator|Lateral Approach|
88975941|NCT05562154|Active Comparator|Anterior Approach|
88975942|NCT05562076|Experimental|ZENFLEX ® Pinto|subjects using the spot stent(ZENFLEX ® Pinto) system
88975943|NCT05562076|Active Comparator|Everflex|subjects using the bare stent(Everflex) system
88975944|NCT05561998|Experimental|TalkingMats intervention group|Participants will use TalkingMats as a decision aid for the needs-assessment conversation as well as in conversations planning the provision of social care.
88975945|NCT05561998|Active Comparator|Usual conversation methods control group|Participants will use usual conversation methods in both the needs-assessment conversation and the provision planning conversations.
88975946|NCT00078195|Experimental|Omalizumab pre-treatment, ragweed RIT, omalizumab + ragweed IT|Participants are pre-treated with omalizumab followed by ragweed rush immunotherapy (RIT) followed by dual therapy with omalizumab plus ragweed immunotherapy (IT).
88975947|NCT00078195|Experimental|Omalizumab pre-treatment, omalizumab|Participants are pre-treated with omalizumab followed by placebo rush immunotherapy (RIT), followed by dual therapy with Omalizumab plus placebo immunotherapy (IT).
88975948|NCT00078195|Active Comparator|Ragweed RIT, ragweed IT|Participants are pre-treated with placebo omalizumab followed by ragweed rush immunotherapy (RIT), followed by dual therapy with placebo omalizumab plus ragweed immunotherapy (IT).
88975949|NCT00078195|Placebo Comparator|Placebo|Participants are pre-treated with placebo omalizumab followed by placebo rush immunotherapy (RIT), followed by dual therapy with placebo omalizumab plus placebo immunotherapy (IT).
88975950|NCT05561686||Pyrotinib-based combination therapy|Pyrotinib, 400mg po qd, 21 days/cycle
89587812|NCT01666080|Other|Reduced Intensity Conditioning|Includes patients receiving a second or greater allogeneic hematopoietic stem cell transplant (HSCT) using reduced intensity conditioning (RIC). Patients will receive busulfan, fludarabine, total body irradiation and stem cell transplant. Keppra will be given for seizure prophylaxis.
89587813|NCT01588262|Other|Stressmanagement counselling|
89587814|NCT01588262|No Intervention|Control|
89587815|NCT01545999|Active Comparator|PAS 25|In humans, paired associative stimulation (PAS-25) is a transcranial magnetic stimulation (TMS) protocol that has been shown to result in LTP-like plasticity (PAS-LTP) in the motor cortex (M1). PAS-LTP has been shown to be dependent on the NMDAR and to correlate significantly with performance on a motor learning task.
89587816|NCT01545999|Sham Comparator|PAS 100|To control for non-specific effects of PAS protocol, the investigators will use a modified PAS protocol (PAS-100) that does not result in any neurophysiologic effects. Patients with schizophrenia and healthy controls will be assessed first with the N-back task and then randomized
89587817|NCT01543763|Experimental|Panobinostat with PC124871|
89587818|NCT01542021|Experimental|Untreated patients degarelix injection occur at days 4± 1|Treatment will consist of a single 240 mg injection of degarelix 4 ± 1 day before radical prostatectomy
89587819|NCT01542021|Experimental|Untreated patients degarelix injection occur at days and 7± 1.|Treatment will consist of a single 240 mg injection of degarelix 7±1 day before radical prostatectomy
89587820|NCT01542021|Experimental|treated patients with androgen deprivation|Patients already treated with androgen deprivation are assigned to Cohort 3 and maintained on current androgen deprivation therapy until they undergo or have already undergone RP at MSKCC. Will include patients who have already undergone hormonal therapy (of any duration between 1 and 6 months) prior to prostatectomy.
89587821|NCT01542021|Experimental|Untreated patients degarelix injection occur at days 14±1|Treatment will consist of a single 240 mg injection of degarelix 14±1 day before radical prostatectomy
89587822|NCT00990483|Experimental|3D investigational imaging|patients returning with an area of interest will undergo investigational 3D imaging in 2 modes of imaging to the breast of interest and compare to the subjects standard of care imaging
89587823|NCT00775476|Active Comparator|NAC|2.4 g - 4.8 g of NAC daily starting after 3 month open label titration period.
89587824|NCT00775476|Placebo Comparator|Placebo|2.4 g - 4.8 g of placebo per day after 3 month open label titration period.
89587825|NCT00544414|Experimental|Treatment|"Patients receive neoadjuvant induction chemotherapy comprising docetaxel IV over 1 hour on day 1 and cisplatin IV, leucovorin IV, and fluorouracil IV over 24 hours on days 1-4. Induction chemotherapy repeats every 28 days for 3 courses.~Patients with partial response at the primary site may undergo radical or functional resection of the primary tumor within 3 weeks of completion of neoadjuvant therapy.~Beginning within 4 weeks of completion of neoadjuvant therapy, patients with persistent disease or complete response after chemotherapy at the primary or neck then undergo radiotherapy 5 days a week for 7 weeks and receive gemcitabine hydrochloride IV over 30 minutes and cisplatin IV over 60 minutes on day 1 of each week of radiotherapy."
89587826|NCT00235560|Experimental|Rapamycine|
89587827|NCT00090064|Experimental|MDMA-assisted therapy|Participants will receive an initial dose of 125 mg MDMA orally followed 2 to 2.5 hours later by a second dose of 62.5 mg MDMA during two 8-hour long blinded therapy sessions.
89587828|NCT00090064|Placebo Comparator|Placebo with therapy|Participants will receive an initial dose of 125 mg placebo orally followed 2 to 2.5 hours later by a second dose of 62.5 mg placebo during two 8-hour long blinded therapy sessions.
89587829|NCT01500226|Placebo Comparator|Placebo + Granisetron + Dexamethasone|Day 1: Placebo + Granisetron (2 mg PO)+ Dexamethasone (20 mg PO) Days 2-3: Granisetron (2 mg PO) will be administered orally.
89587830|NCT01500226|Experimental|Rolapitant|Day 1: Rolapitant (200 mg PO) + Granisetron (2 mg PO)+ Dexamethasone (20 mg PO) Days 2-3: Granisetron (2 mg PO) will be administered orally.
89587831|NCT02075047|Placebo Comparator|1|
89587832|NCT02075047|Experimental|ziprasidone|
89587833|NCT01859949|Experimental|Genotropin (somatropin)|
89587834|NCT01859793|Placebo Comparator|Matching Placebo|Matching Placebo for Sitagliptin
89587835|NCT01859793|Active Comparator|Sitagliptin|100mg pill, PO administered once daily.
89587836|NCT01859715|Active Comparator|Oxycodone group|Subjects given either oxycodone 5mg by ED provider decision or by triage nurse randomization.
88975951|NCT00044291|Experimental|Atamestane + toremifene|
88975952|NCT00044291|Active Comparator|Letrozole + placebo|
88975953|NCT02965872||Healthy individuals|
88975954|NCT05561569|Active Comparator|Air tamponade group|Cases with primary upper retinal detachment that will be treated with air tamponade.
89587837|NCT01859715|Active Comparator|Nausea-observational group|Patients given ondansetron 4mg by ED provider decision or by triage nurse. This is an observational cohort only.
89587838|NCT01859715|Active Comparator|Hydrocodone/Acetaminophen group|Subjects given hydrocodone/acetaminophen 5mg/500mg by ED provider decision or by triage nurse randomization.
89587839|NCT01890915||Tetraplegia|Persons with spinal cord injury, level of injury C4-T1, American Spinal Injury Association (ASIA) impairment levels A-B and duration of injury greater than 1 year. Ages 18-65 years old.
89587840|NCT01890915||Control|Age and gender-matched able-bodied controls. Ages 18-65 years old.
89587841|NCT04616235|Placebo Comparator|CON|This group will do intense aerobic exercise without concomitant IL-6R blockade
89587842|NCT04616235|Active Comparator|BLOCK|This group will do intense aerobic exercise with concomitant IL-6R blockade
89587843|NCT01615263|Active Comparator|Double lumen tube|Lung isolation with a left double lumen tube (BronchoCath, Mallinckrodt Medical, Cornamaddy, Athlone, Westmeath, Ireland.
89587844|NCT01615263|Active Comparator|Bronchial blocker|Lung isolation with a bronchial blocker with the inner channel closed (Fuji Uniblocker 9F, Fuji System Corporation, Tokyo, 113-0033, Japan) inserted via a 8.0 mm simple lumen endotracheal tube.
89587845|NCT04590495|Active Comparator|300 mg Cannabidiol (CBD) oil|
89587846|NCT04590495|Placebo Comparator|Placebo|
89587847|NCT01859403|Placebo Comparator|Usual Care|Usual care for veterans as part of the MOVE! program
89587848|NCT01859403|Active Comparator|Personalized Genomics|Personalized genomics information from the FIT Test, Pathway Genomics
88975955|NCT05561569|Active Comparator|Non expansile gas tamponade group|Cases with primary upper retinal detachment that will be treated with sulfur-hexafluoride 6 (SF-6) gas tamponade.
88975956|NCT05561296|Other|Astigmatism correction with iris registration guided corneal relaxing incisions|This sub-group will include patients who will undergo femtosecond laser-assisted cataract surgery (Catalys) and astigmatism correction using corneal relaxing incisions and implantation of EyHance IOL. The alignment would be guided by preoperatively obtained iris registration using Cassini Ambient.
88975957|NCT05561296|Other|Astigmatism correction with iris registration guided implantation of toric IOLs|This sub-group will include patients who will undergo femtosecond laser-assisted cataract surgery (Catalys) and astigmatism correction with the implantation of EyHance toric II IOLs. The alignment would be guided by preoperatively obtained iris registration using Cassini Ambient.
88975958|NCT05561023|Other|Phase Ⅰ a clinical study|"3 + 3 dose escalation scheme"
88975959|NCT05560906||Control group|Healthy patients under 18 years of age.
88975960|NCT05560906||MIS-C group|Patients with MIS-C diagnosed, based on WHO diagnostic criteria.
88975961|NCT05558488|Experimental|Meatless restrictive ketogenic diet|Diet was designed to be isoproteic (1.8 g x Kg- 1 x body weight- 1 x day-1) with three meals a day., restrictive (EER minus 500 kcal / day). The distribution of macronutrients during the very low carbohydrate ketogenic diet (KD) was: protein 1.8 g x Kg-1 x body weight- 1 x day-1 (~ 25-30%), fats (~ 65-70%, with a strong emphasis on the content of omega 3 fatty acids) and carbohydrate (< 30 g x day- 1; < 10%).
88975962|NCT00078273|No Intervention|Assessment Only Control|Completed Baseline and 6 month follow-up surveys only.
88975963|NCT00078273|Experimental|Personalized Feedback Intervention|See Intervention Description
88975964|NCT00078273|Experimental|Cognitive Behavioral Intervention|See Intervention Description
88975965|NCT05556499||HPT patients|Patients with primary hyperparathyroidism at diagnosis (HPT) treated with parathyroidectomy (HPT-PTX)
88975966|NCT04729647|Other|Axillary Lymph Node Metastasis|
88975967|NCT05530018|Experimental|BCI group|Participants will be asked to participate in a brief contact intervention and to evaluate its feasibility, including the feasibility of recruitment, intervention resources, the appropriateness of data collection, and the acceptance of the intervention.
89587849|NCT01858701|Other|AO for Astig / Biofinity Toric|Lotrafilcon B toric contact lenses worn in Period 1, followed by comfilcon A toric contact lenses in Period 2, as randomized. Each product will be worn bilaterally on a daily wear basis for 30 days, removed nightly. A minimum 1-day washout of no contact lens wear will precede each wear period.
89587850|NCT01858701|Other|Biofinity Toric / AO for Astig|Comfilcon A toric contact lenses worn in Period 1, followed by lotrafilcon B toric contact lenses in Period 2, as randomized. Each product will be worn bilaterally on a daily wear basis for 30 days, removed nightly. A minimum 1-day washout of no contact lens wear will precede each wear period.
89587851|NCT01461538|Experimental|Brentuximab vedotin 1.8 mg/kg|Brentuximab vedotin 1.8 mg/kg every 3 weeks by IV infusion
89587852|NCT01461538|Experimental|Brentuximab vedotin 2.4 mg/kg|Brentuximab vedotin 2.4 mg/kg every 3 weeks by IV infusion
89587853|NCT01461538|Experimental|Brentuximab vedotin 1.2 mg/kg|Brentuximab vedotin 1.2 mg/kg weekly, 3 out of 4 weeks, by IV infusion
89587854|NCT02117479|Experimental|Ruxolitinib plus capecitabine|
89587855|NCT02117479|Active Comparator|Placebo plus capecitabine|
89587856|NCT02229851|Experimental|NNC0195-0092 (somapacitan)|
89587857|NCT02229851|Active Comparator|Daily hGH|
89587858|NCT02229851|Placebo Comparator|Placebo|Switch to NNC0195-0092 (somapacitan) treatment in the extension period.
89587859|NCT01482910|Experimental|Aflibercept injection (EYLEA, VEGF Trap-Eye, BAY86-5321)|Participants received 2.0 mg intravitreal aflibercept injection (IAI) every 4 weeks for the first 12 weeks, followed by additional 2.0 mg IAI every 8 weeks until week 48. Additionally, sham photodynamic therapy (PDT) treatments was administered as needed.
89587860|NCT01482910|Active Comparator|PDT treatments|Participants received PDT as needed. Additionally, sham IAI injections was administered until week 28. Thereafter, participants received active IAI treatment until week 48.
89587861|NCT04077190|Experimental|adipose-derived stem cell injection|Ultrasound guided injection of 5cc adipose derived stem cells
89587862|NCT04077190|Active Comparator|cortisone injection|Ultrasound guided injection of cortisone
89587863|NCT01626391|Experimental|TRx0237|
89587864|NCT01626391|Placebo Comparator|Placebo|
89587865|NCT02103439|Experimental|Algeron|Algeron at a dose of 1.5 µg/kg of body weight subcutaneously, once a week, and Rebetol, orally, at a daily dose of 800 mg (for body weight <65 kg), 1,000 mg (for body weight 65 - 85 kg), 1,200 mg (for body weight 86 - 105 kg) or 1,400 mg (for body weight > 105 kg)
89587866|NCT02103439|Active Comparator|PegIntron|PegIntron at a dose of 1.5 µg/kg of body weight subcutaneously, once a week, and Rebetol, orally, at a daily dose of 800 mg (for body weight <65 kg), 1,000 mg (for body weight 65 - 85 kg), 1,200 mg (for body weight 86 - 105 kg) or 1,400 mg (for body weight > 105 kg).
89587867|NCT02229539|Experimental|doxepin rinse|"Patients receive 2.5 mL (25 mg) doxepin and 2.5 mL water orally. Doxepin rinse is administered in the clinic on Day 1 (Cycle 1). There is an optional continuation phase within seven days following Day 1 (Cycle 1), patients will be encouraged to continue treatment with the study agent for an additional week (Cycle 2) where the patient takes the rinse at home every 4 hours. Chemotherapy is allowed during the continuation phase. Patients randomized to doxepin or placebo, they and their caregivers will continue to be blinded to the treatment.~Patients will complete the Oral Symptoms booklet per the protocol."
89587868|NCT02229539|Active Comparator|DLA (diphenhydramine, lidocaine and antacid) rinse|"Patients receive 5.0 mL DLA orally. DLA is administered in the clinic on Day 1 (Cycle 1). There is an optional continuation phase within seven days following Day 1 (Cycle 1), patients will be encouraged to continue treatment with the study agent for an additional week (Cycle 2) where the patient takes the rinse at home every 4 hours. Chemotherapy is allowed during the continuation phase. Patients receiving DLA during the continuation phase of the study, they and/or caregivers may be aware that they are receiving DLA.~Patients will complete the Oral Symptoms booklet per the protocol."
89587869|NCT02229539|Placebo Comparator|placebo rinse|"Patients receive 2.5 mL placebo and 2.5 mL water orally. The placebo rinse is administered in the clinic on Day 1 (Cycle 1). There is an optional continuation phase within seven days following Day 1 (Cycle 1), patients will be encouraged to continue treatment with the study agent for an additional week (Cycle 2) where the patient takes the rinse at home every 4 hours. Chemotherapy is allowed during the continuation phase. Patients randomized to doxepin or placebo, they and their caregivers will continue to be blinded to the treatment.~Patients will complete the Oral Symptoms booklet per the protocol."
89587870|NCT01835223|Experimental|Treatment (tivozanib - 1 mg)|Patients receive tivozanib PO QD on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89587871|NCT01835223|Experimental|Treatment (tivozanib - 1.5 mg)|Patients receive tivozanib PO QD on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89587872|NCT01482598|Active Comparator|Optimal Remote Care|Patient follow up is performed through remote care, remote alerts on CRT-D device data are transmitted daily to the hospital, remote follow up is scheduled every 6 months, hospital in clinic follow up is scheduled at 12 months after implant.
89587873|NCT01482598|No Intervention|Optimal Standard Care|Patient standard in clinic visits are performed every 6 months.
89587874|NCT01460446|Experimental|Aviva Expert blood glucose meter|Participants used the Accu-Chek® Aviva Expert blood glucose meter with an integrated bolus advisor to determine the dose of insulin for each injection in their 24 week multiple daily injection therapy.
89587875|NCT01460446|Active Comparator|Aviva Nano blood glucose meter|Participants used the Accu-Chek® Aviva Nano blood glucose meter and manual bolus calculation to determine the dose of insulin for each injection in their 24 week multiple daily injection therapy.
89587876|NCT02229383|Experimental|Exenatide|Exenatide 2 mg 1 time per week + titrated basal insulin glargine with or without metformin
89587877|NCT02229383|Placebo Comparator|Placebo|Placebo 2 mg 1 time per week + titrated basal insulin glargine with or without metformin
89587878|NCT01499368|Experimental|Lafutidine|Lafutidine 20mg/day
89587879|NCT01499368|Active Comparator|Famotidine|Famotidine 40mg/day
89587880|NCT01499368|Other|Omeprazole|Omeprazole 20mg/day
89209783|NCT02594267|Experimental|Part 1: Dose Finding, Cohort 1|"Dose finding Phase Intervention: Folotyn (Pralatrexate Injection) CHOP: Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone~The first cohort will begin with three patients with dose A of pralatrexate plus CHOP at full dose.~The second cohort will begin with three patients with dose B of pralatrexate plus CHOP at full dose.~The third cohort will begin with three patients with dose C of pralatrexate plus CHOP at full dose.~The fourth cohort will begin with three patients with dose D of pralatrexate plus CHOP at full dose.~The fifth cohort will begin with three patients with dose E of pralatrexate plus CHOP at full dose.~Part 2: Dose Expansion, Additional ten patients will be enrolled at the MTD or MAD (if the MTD is not reached) plus CHOP at full dose in this part of the study. Blood samples for PK analysis of pralatrexate will be collected at various intervals pre and post pralatrexate injection during cycle 1, Dose 1."
89209784|NCT02594501|Experimental|COBRA PzF|Cobra PzF plus 14-day DAPT (dual antiplatelet therapy)
89209785|NCT02594501|Active Comparator|Drug Eluting Stent|standard FDA-approved DES (Xience/Promus or Resolute) plus 3 or 6-month DAPT (dual anti-platelet therapy)
89209786|NCT00254293|Placebo Comparator|Group 1 (weight < 60 kg)|
89209787|NCT00254293|Placebo Comparator|Group 2 (weight < 60 kg)|
89587881|NCT01835145|Experimental|Arm I (cabozantinib-s-malate)|Patients receive cabozantinib-s-malate PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89209788|NCT00254293|Placebo Comparator|Group 3 (weight 60-100 kg)|
89209789|NCT00254293|Placebo Comparator|Group 4 (weight > 100 kg)|
89209790|NCT00254293|Placebo Comparator|Group 5 (weight > 100 kg)|
89209791|NCT00254293|Experimental|Abatacept|Long Term
89209792|NCT00585221|Experimental|All patients|All participants enrolled in the study.
89209793|NCT02594033|Experimental|3 mm needle|
89209794|NCT02594033|Experimental|3.5 mm needle|
89209795|NCT02594033|Active Comparator|4 mm needle|
89209796|NCT00253747|Active Comparator|Osmotic-Release Methylphenidate|
89209797|NCT00253747|Placebo Comparator|Placebo|
89209798|NCT00252733|No Intervention|1|Placebo
89209799|NCT00252733|Experimental|2|candesartan cilexetil
89209800|NCT03974035|No Intervention|Control Group|Patients undergoing elective bimaxillary osteotomy who receive a preincisional infiltration of lidocaine and adrenaline.
89209801|NCT03974035|Experimental|Study Group|Patients undergoing elective bimaxillary osteotomy who receive two infiltrations (firstly pre-incision with lidocaine and adrenaline, secondly pre-extubation with ropivacaine).
89209802|NCT01071967|Experimental|Community-based nurse care management|Participants randomized to receive the intervention worked with a nurse care manager who provided them with a comprehensive set of geriatric and chronic disease preventive services.
89209803|NCT01071967|No Intervention|Usual care|Participants randomized to the control group received usual care without the involvement of a nurse care manager.
89209804|NCT00275821|Experimental|Ranibizumab 0.3 mg - 3 times monthly, then quarterly|
89209805|NCT00275821|Experimental|Ranibizumab 0.5 mg - 3 times monthly, then quarterly|
89209806|NCT00275821|Active Comparator|Ranibizumab 0.3 mg monthly|
89587882|NCT01835145|Experimental|Arm II (temozolomide or dacarbazine)|Patients receive temozolomide PO daily on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. If temozolomide is not available, patients receive dacarbazine IV over 15-60 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89587883|NCT02229227|Experimental|Albiglutide + Insulin Glargine Arm|During standardization period, subjects will transit from basal bolus regimen received during screening period to insulin glargine plus insulin lispro. During treatment period, subject will receive Albiglutide 30 milligrams (mg) weekly subcutaneous (SC) injection and insulin lispro dose will be downtitrated to half that used in the standardization period. At Week 4, Albiglutide will be uptitrated to 50 mg weekly SC injection and insulin lispro will be stopped for the remainder of the treatment Period. Insulin lispro may be re-introduced after Week 8 according to pre-defined hyperglycemia thresholds. Insulin will be adjusted according to protocol-defined insulin titration algorithms
89587884|NCT02229227|Experimental|Insulin Glargine + Insulin Lispro Arm|During standardization period, subjects will transit from basal bolus regimen received during screening period to insulin glargine plus insulin lispro. During treatment period, subject will continue with the same doses as at the end of the standardization period and doses will be adjusted according to protocol-defined insulin titration algorithms
89587885|NCT01499290|Experimental|CAZ-AVI + Metronidazole|IV treatment
89587886|NCT01499290|Active Comparator|Meropenem|IV treatment
89587887|NCT01833897|Experimental|Ketamine and DCS treatment|Standard of Care: Subjects will receive treatment with either quetiapine, olanzapine-fluoxetine, or lurasidone. If after about 2 week, subjects are symptomatic, subjects will receive infusion of ketamine hydrochloride (0.5 mg/kg). After the ketamine phase, subject who show improvement will begin an 8-week treatment of oral D-cycloserine.
89587888|NCT01481896||Metal-on-Metal Total Hip Arthroplasties|Consecutive series of patients who had metal-on-metal primary total hip arthroplasty performed with DePuy Pinnacle cups, Ultamet metal liners and 36-mm cobalt-chromium alloy femoral heads.
89587889|NCT02226653|Experimental|Evacetrapib (reference)|Single oral dose of 1 tablet of evacetrapib on Day 1 of up to three of five periods
89587890|NCT02226653|Experimental|Evacetrapib (test)|Single oral dose of 2 tablets of evacetrapib on Day 1 of up to three of five periods
89587891|NCT02201771|Active Comparator|Aspirin|aspirin 100mg tablet by mouth daily for 12 months
88975968|NCT05519917|Experimental|Afatinib|Subject meeting the inclusion criteria will take afatinib (40 mg daily) orally, 4 weeks for a cycle.
88975969|NCT00078390|Experimental|S-3304 plus chemo-irradiation|The tolerable dose of S-3304 determined in the Phase 1 part of the study will be dosed BID along with a standard of care regimen of radiation and paclitaxel/carboplatin chemotherapy
88975970|NCT00078390|Active Comparator|Chemo-irradiation|The standard of care regimen of radiation and paclitaxel/carboplatin chemotherapy will be administered
88975971|NCT05497336|Experimental|IBI351+Cetuximab|IBI351 recommended dose+Cetuximab 500mg/m2 IV Q2W
88975972|NCT05497336|Experimental|IBI351|IBI351 recommended dose
89587892|NCT02201771|Experimental|Ticagrelor plus Aspirin|ticagrelor 90mg tablet by mouth twice daily and aspirin 100mg tablet by mouth daily for 12 months
89587893|NCT02201771|Experimental|Ticagrelor|ticagrelor 90mg tablet by mouth twice daily for 12 months
89587894|NCT01460368|Experimental|Part A: LY2409021|Participants will receive 2 standard meals; one alone without LY2409021, and one along with a single dose of 300 milligrams (mg) LY2409021 administered orally. Participants enrolled in Part A will not be allowed to participate in Part B.
89587895|NCT01460368|Experimental|Part B: LY2409021|300 milligrams (mg) LY2409021 administered orally as a single dose on Day 1 of the relevant treatment period. The treatment and washout period was a total of 15 days in length.
89587896|NCT01460368|Placebo Comparator|Part B: Placebo|Administered orally as a single dose on Day 1 of the relevant treatment period. The treatment and washout period was a total of 15 days in length.
89587897|NCT01460368|Active Comparator|Part B: Moxifloxacin|400 milligrams (mg) Moxifloxacin administered orally as a single dose on Day 1 of the relevant treatment period. The treatment and washout period was a total of 15 days in length.
89587898|NCT02135705||Lomitapide|Lomitapide as prescribed by Physician.
89209807|NCT01070797|Experimental|Group A|Group A is for CMV seropositive donors.
89587899|NCT01460290|Experimental|Asenapine|12-weeks of open-label asenapine treatment
89587900|NCT01911533|Experimental|extracorporeal CO2|
89587901|NCT04408456|Active Comparator|Post Exposure Prophylaxis (PEP) Group|Standard therapy in the form of home quarantine for 2 weeks along with social distancing and personal hygiene Plus Tablet HCQ 400 mg q 12 hourly on day one followed by 400 mg once weekly for 3 weeks (total cumulative dose of 2000 mg)
88975973|NCT00044525|Experimental|Arm 1|
88975974|NCT04706143||Vaccined group by live attenuated or viral vector or mRNA vaccine|Adults between 25-65 years old
88975975|NCT05469490|Experimental|Stereotactic Body Radiotherapy (SBRT) + NLG802 and navoximod|"SBRT - Initial Starting Dose:~Lung - Peripheral - 45 Gy (3 fractions) Lung - Central OR Mediastinal/Thoracic/Axillary/Cervical Lymph Node - 50 Gy (5 fractions) Liver - 45 Gy (3 fractions) Spinal/Paraspinal OR Osseous - 30 Gy (3 fractions) Abdominal/Pelvic (including Adrenal Gland) - 45 Gy (3 fractions)~SBRT - Decreased DLT Dose:~Lung - Peripheral - 42 Gy (3 fractions) Lung - Central OR Mediastinal/Thoracic/Axillary/Cervical Lymph Node - 47.5 Gy (5 fractions) Liver - 42 Gy (3 fractions) Spinal/Paraspinal OR Osseous - 27 Gy (3 fractions) Abdominal/Pelvic (including Adrenal Gland) - 42 Gy (3 fractions)~NLG802 - 1452mg BID (no dose decrease)~navoximod - Starting dose: 1000mg BID, Dose decrease 1: 800mg BID, Dose decrease 2: 600mg BID"
88975976|NCT00397436|Experimental|1|Comparing irradiated skin to non irradiated skin.
88975977|NCT05386225||Standardized follow-up|Participants who chose to continue guideline-prescribed, standardized follow-up one year after HNC treatment.
89209808|NCT01070797|Experimental|Group B|Group B is for CMV seronegative donors.
89587902|NCT04408456|Other|Control Group|Standard therapy in the form of home quarantine for 2 weeks along with social distancing and personal hygiene
89587903|NCT03026608|Experimental|Intervention Group|Communities randomized to the intervention group receive the Veggie Van program shortly after randomization.
89587904|NCT03026608|Active Comparator|Delayed Intervention Control Group|This group will receive the Veggie Van intervention approximately 6 months after baseline data collection and randomization (after the collection of 6 months outcomes data).
89587905|NCT02200211|Experimental|Binocular Treatment|Binocular computer game play 1 hour per day, 7 days per week (minimum of 4 days per week)
89587906|NCT02200211|Active Comparator|Patching Treatment|Patching 2 hours per day, 7 days per week
89587907|NCT01459666|Experimental|Dysport (abobotulinumtoxinA)|Each patient will be able to receive up to 120 units of Dysport/placebo at the initial visit to treat the entire forehead area (the frontalis, procerus, and corrugator muscles) to insure cosmetic symmetry. Injections will be placed a minimum of 1.5cm above the orbital rim at the mid papillary line to minimize the risk of lid ptosis. The actual amount to be injected will be at the discretion of the Mohs surgeon based on his or her opinion of what amount is needed for sufficient wound paralysis and cosmetic symmetry.
89587908|NCT01459666|Placebo Comparator|Placebo|
89587909|NCT01858389|Experimental|Cohort A|Patients with NSCLC whose tumor has a documented T790M mutation in exon 20 of the Epidermal Growth Factor Receptor.
89587910|NCT01858389|Experimental|Cohort B|Patients with NSCLC. No requirement of a specific molecular signature, but excluding known T790M mutations.
89587911|NCT01645475|Experimental|Desmopressin lyophilisate (Melt)|Patients receiving Desmopressin lyophilisate (Melt).
89587912|NCT04767113|Experimental|Heparin group|Continuous infusion of heparin was used to maintain the patency of CVC.
89587913|NCT04767113|Placebo Comparator|Control group|Continuous infusion of heparin was used at the corresponding speed.
89587914|NCT01458574|Placebo Comparator|Placebo Comparator|
89587915|NCT01458574|Experimental|CP-690,550 5 mg Arm|
89587916|NCT01458574|Experimental|CP-690,550 10 mg Arm|
89587917|NCT02224703|Experimental|10 mg/kg/day GWP42003-P|GWP42003-P oral solution (100 mg/milliliter [mL] cannabidiol in sesame oil with anhydrous ethanol with added sweetener [sucralose] and strawberry flavoring). The 10 mg/kg/day dose was defined as 50% of the 20 mg/kg/day dose.
89587918|NCT02224703|Experimental|20 mg/kg/day GWP42003-P|GWP42003-P oral solution (100 mg/mL cannabidiol in sesame oil with anhydrous ethanol with added sweetener [sucralose] and strawberry flavoring). The 20 mg/kg/day dose was recommended by the DSMC after assessment of safety and pharmacokinetic data from Part A of study GWEP1332 (NCT02091206).
89587919|NCT02224703|Placebo Comparator|Placebo Control|Excipients only. Participants were pooled from 2 placebo cohorts, half receiving 10 mg/kg/day dose-volume equivalent and half receiving 20 mg/kg/day dose-volume equivalent.
89587920|NCT02198963|Experimental|Hypochlorous acid Solution 106 mg/L|Occlusive patches will be used to apply approximately 0.02 mL of the Test Product RUT058-60 to abraded and non-abraded sites on the skin in the scapular region of each subject's back.
89587921|NCT02198963|Active Comparator|0.1% (w/v) Sodium Lauryl Sulfate|Occlusive patches will be used to apply approximately 0.02 mL of the Positive Control (0.1% Sodium Lauryl Sulfate) to abraded and non-abraded sites on the skin in the scapular region of each subject's back, once daily for 21 days.
89587922|NCT02198963|Placebo Comparator|0.9% Physiological Saline, USP|Occlusive patches will be used to apply approximately 0.02 mL of the Negative Control (0.9% Physiological Saline, USP) to abraded and non-abraded sites on the skin in the scapular region of each subject's back, once daily for 21 days.
89587923|NCT02074384|Other|Continuous Glucose Monitoring|Participants will wear Continuous Glucose Monitoring for two weeks.
89587924|NCT02074384|Other|Self Monitoring Blood Glucose|Participants will self test for two weeks.
88975978|NCT05386225||Individualized follow-up|Participants who chose to switch to individualized follow-up one year after HNC treatment. Follow-up visits will only be scheduled based on clinical symptoms and questions, initiated by the patient.
88975979|NCT00074607|Experimental|Intrathecal gemcitabine administration|"Intrathecal gemcitabine will be given on a weekly schedule for the first cohort of patients at the 5 mg dose level and then a twice-weekly (i.e., every 3 to 4 days) schedule. Drug administration will be by the intraventricular (Ommaya reservoir injection) route.~Patients will be hospitalized overnight following their first dose of gemcitabine. If the first dose is well tolerated, subsequent induction doses may be administered in the outpatient setting with close observation for a minimum of 2 hours after administration.~Dose Levels and Dose Escalation:~Dose Level 1a: 5 mg~Dose Level 1b: 5 mg~Dose Level 2: 10 mg~Dose Level 3: 20 mg~Dose Level 4: 30 mg~Dose Level 5: 40 mg~Dose Level 6: 50 mg"
88975980|NCT05305885|Experimental|Group 1|Intrathecal administration, intraventricular administration or via lumbar puncture, pemetrexed plus dexamethasone, first induction intra-cerebrospinal fluid chemotherapy twice per week for 2 weeks, then once per week for 4 times, 6 weeks in total. Concurrent radiotherapy consisted of fractionated, conformal radiation given at a daily dose of 2 Gy. The planning volume consisted of sites of symptomatic disease, bulky disease observed on MRI, including the whole brain and basis cranii received 40 Gy in 20 fractions, 4 weeks in total, and/or segment of spinal canal received 40 Gy.
88975981|NCT05305885|Experimental|Group 2|Intrathecal administration, intraventricular administration or via lumbar puncture, pemetrexed plus dexamethasone, first induction intra-cerebrospinal fluid chemotherapy twice per week for 2 weeks, then once per week for 4 times, 6 weeks in total.
88975982|NCT00044564|Experimental|Arm 1|
88975983|NCT05242549|Experimental|Fitness and Nutrition Program for Seniors|"Fitness and Nutrition Program for Seniors includes physical activity training, nutrition education- nursing Information, home-based training, and telecare group care (including APP assistance)"
88975984|NCT05242549|No Intervention|wait-list|Routine care
88975985|NCT00078507|Active Comparator|Opening Exercises Only|Standard of care opening exercises following BSSO surgery to regain mouth opening
88975986|NCT00078507|Experimental|Sensory Retraining Exercises|3 sets of facial exercises performed with soft cosmetic brush 1 wk - 4 wks after surgery; 4wks to 3 mos after surgery; 3 mos to 6 mos after surgery.
89209809|NCT03973099|Experimental|Placebo|Subjects in the placebo group received the equivalent amount of starch and lactose mixture capsules and administered with the same schedule.
89587925|NCT02074384|Other|Clinicians|Clinicians completing study visits.
89587926|NCT01458106|Experimental|All participants|"PK subgroup: After a Washout Period of ≥72 hours, at the Baseline Visit (28±7 days prior to Day 1), participants receive a single IV injection of prestudy FVIII over 5 (±2) minutes at a dose of 50 IU/kg, rounded up to the nearest 250 IU increment, for a PK assessment. Following a second Washout Period of ≥72 hours, participants receive a single IV injection of rFVIIIFc over 5 (±2) minutes at a dose of 50 IU/kg for PK assessment. The first prophylactic dose of rFVIIIFc is administered at a starting dose of 25 IU/kg IV injection on Day 1 and 50 IU/kg on Day 4. Dose increases to a maximum of 80 IU/kg, and frequency of administration to a minimum interval of once every 2 days, are allowed as indicated.~Non-PK subgroup: On Day 1, a first prophylactic dose of rFVIIIFc of 25 IU/kg IV injection is given, followed by a dose of 50 IU/kg on Day 4. Dose increases to a maximum of 80 IU/kg, and frequency of administration to a minimum interval of once every 2 days, are allowed as indicated."
89587927|NCT01457950|Experimental|Arm 1|denosumab 60mg subcutaneous injection, single dose at the start of the 6-month double-blind phase
89587928|NCT01457950|Placebo Comparator|Arm 2|placebo subcutaneous injection, single dose at the start of the 6-month double-blind phase
89587929|NCT01457950|Experimental|Arm 3|open-label phase follows the double-blind phase, denosumab 60mg subcutaneous injection, single dose at the start of the 6-month open-label phase
89587930|NCT01499134|Experimental|nebivolol|nebivolol 1 to 4 capsules daily
89587931|NCT01499134|Active Comparator|metoprolol succinate|metoprolol 1 to 4 capsules daily
89587932|NCT02198651|Experimental|Adalimumab 40 mg eow|40 mg adalimumab administered subcutaneously every other week (eow) from Week 0 to Week 4 (Lead-in Period)
89587933|NCT02198651|Active Comparator|Adalimumab Tapering|40 mg adalimumab administered subcutaneously every three weeks from Week 4 to Week 40 (Double-blind Period)
89587934|NCT02198651|Placebo Comparator|Adalimumab Withdrawal Arm|Placebo administered subcutaneously every three weeks from Week 4 to Week 40 (Double-blind Period)
89587935|NCT02198651|Experimental|Adalimumab 40 mg eow Rescue Arm|40 mg adalimumab administered subcutaneously every other week from Flare Week 0 to Flare Week 16 (Open-label Rescue Period)
89587936|NCT03026920|Experimental|clinical outcome|Less invasive method was applied to pelvic or acetabular fracture of old people. Thus, the clinical outcome of Pelvic or acetabular fractures in old man was assessed.
89587937|NCT03026842|Experimental|Decitabine|Six cycles of decitabine IV over one hour at 20 mg/m2/day for 5 days, every 6 weeks
89587938|NCT03026842|Active Comparator|Conventional chemotherapy|Four cycles of conventional chemotherapy for 5 days, every 12 weeks. conventional chemotherapy includes in: DA regimen: Daunorubicin 45 mg/m2/day for 3 days, cytarabine 100 mg/m2/day for 5 days; MA regimen: Mitoxantrone 8 mg/m2/day for 3 days, cytarabine 100 mg/m2/day for 5 days; AA regimen: Aclacinomycin 20 mg/day for 5 days, cytarabine 100 mg/m2/day for 5 days.
89587939|NCT01498822|Experimental|Levetiracetam|Levetiracetam twice a day treatment group
89587940|NCT01498822|Active Comparator|Oxcarbazepine|Oxcarbazepine twice a day treatment group
89587941|NCT01421849|Experimental|Elderly with an unstable mandibular denture.|
89587942|NCT01498120|Experimental|Rotigotine|"Optimal dose after titration period~0.5 mg/24 h (2.5 cm^2)- 1 mg/24 h (5 cm^2)- 2 mg/24 h (10 cm^2)- 3 mg/24 h (15 cm^2)"
89587943|NCT01381211|Active Comparator|Yttrium-90 radioembolization (90Y-RE)|
89587944|NCT01381211|Active Comparator|Transarterial chemoembolization with drug eluting beads|Transarterial chemoembolization is performed with drug eluting beads, polyvinyl alcohol-based microspheres (DC Beads, Biocompatibles) loaded with the chemotherapeutic agent doxorubicin.
89587945|NCT01497262|Experimental|Fingolimod|Open-label fingolimod 0.5 mg, taken orally once daily for 4 months
89587946|NCT02224625|Experimental|2% CHG Cloth|Chlorhexidine Gluconate 2%
89587947|NCT02224625|Placebo Comparator|Vehicle Cloth|Excipients on cloth
89587948|NCT02224625|Active Comparator|DynaHex (2% CHG)|Chlorhexidine Gluconate 2% solution
89587949|NCT02224625|Sham Comparator|Saline|0.9% sodium chloride
89587950|NCT02224625|Active Comparator|Sodium Lauryl Sulfate (SLS)|Sodium lauryl sulfate to produce mild irritation as a positive control
89587951|NCT01195493|Experimental|test mouthrinse|
89587952|NCT01195493|Active Comparator|control group|
89587953|NCT04094038|Experimental|Intervention|Intradialytic parenteral nutrition three times weekly during 16 weeks
88975987|NCT05190328|Experimental|Muscle Energy Technique|"Experimental: Muscle Energy Technique Post isometric relaxation: Patient will perform isometrics on upper trapezius and levator scapulae one by one. Each isometric contraction will be held for 10 seconds and then participants will be asked to relax the contraction with exhalation. This will be repeated five times in one session.~Routine Physical Therapy including TENS, Hot Pack, Strengthening, and stretching exercises will also be delivered along with the Muscle energy technique."
88975988|NCT05190328|Experimental|Active Release Technique|"Experimental: Active Release Technique: The therapist will apply deep pressure on both sides of levator scapulae and upper trapezius muscles (over the area of tenderness) and the patient will be instructed to actively move the muscle from a shortened to lengthened position and thereby breaking adhesions.1 set of 5 repetitions in one session.~Routine Physical Therapy including TENS, Hot Pack, Strengthening, and stretching exercises will also be delivered along with active release technique"
89587954|NCT04094038|Placebo Comparator|Placebo|5% glucose three times weekly during 16 weeks
89587955|NCT01076855||Elderly with mild dementia|>70 years old and presence of a carer
89587956|NCT00913679|Active Comparator|Posterior approach|Posterior surgical approach in hip resurfacing arthroplasty
89587957|NCT00913679|Active Comparator|Anterolateral approach|Anterolateral surgical approach in hip resurfacing arthroplasty
89587958|NCT00752453|Experimental|1|Dialysis during 4 hours
89587959|NCT00752453|Experimental|2|Dialysis during 6 hours
89587960|NCT00752453|Experimental|3|Dialysis during 8 hours
89587961|NCT02197247|Experimental|Rifampicin and AZD9291|Sequential treatments of AZD9291 alone followed by AZD9291 +rifampicin, followed by AZD9291 alone.
89587962|NCT02224157|Experimental|"Symbicort as needed+placebo Pulmicort bid"|Symbicort (budesonide/formoterol) Turbuhaler 160/4.5 μg 'as needed' + Placebo Pulmicort Turbuhaler 200 μg bid
89587963|NCT02224157|Active Comparator|"Pulmicort bid + terbutaline as needed"|Pulmicort 200 μg Turbuhaler bid + terbutaline 0.4 mg Turbuhaler 'as needed'
89587964|NCT02196701|Experimental|Adalimumab Plus Methotrexate|Participants received 40 mg adalimumab every other week and methotrexate, between 7.5 and 25 mg/week at the discretion of the Investigator, for 24 weeks.
89209810|NCT03973099|Experimental|PM011|PM011 is a 400 mg hard gelatin capsule containing water extracts of Nelumbinis Semen. The sprayed-dry extract of the herbal medicine used was purchased from Sun Ten pharmaceutical company in Taiwan. Each participant received twelve capsules of PM011, which divided into 2.4 g treatment or 4.8 g treatment group or placebo daily for two weeks and was instructed to take six capsules after breakfast and six capsules after dinner.
89587965|NCT04763291|No Intervention|Control group|Continue habitual diet and lifestyle.
89587966|NCT04763291|Experimental|Fruit, Vegetable and Berry (FVB) group|Participants have to ingest an encapsulated juice powder concentrate, otherwise continue their habitual diet and lifestyle.
89587967|NCT04763291|Experimental|Omega group|Participants have to ingest a plant-based fatty acid supplement, otherwise continue their habitual diet and lifestyle.
89587968|NCT04763291|Experimental|Fruit, Vegetable, Berry and Omega (FVBO) group|Participants have to ingest an encapsulated juice powder concentrate along with a plant-based fatty acid supplement, otherwise continue their habitual diet and lifestyle.
89587969|NCT04773119|Active Comparator|Pulmonary vein isolation (PVI) only|
89587970|NCT04773119|Active Comparator|PVI with substrate|
89587971|NCT01481116|Experimental|TAK-875 25 mg QD|
89587972|NCT01481116|Experimental|TAK-875 50 mg QD|
89587973|NCT01481116|Active Comparator|Glimepiride 1-2 mg QD|
89587974|NCT02222207|Experimental|Regorafenib [A]|Part A: Patients will receive Regorafenib eye drops
89587975|NCT02222207|Experimental|Regorafenib [B1]|Part B: Regorafenib eye drops dose 1; plus sham IVT (Intravitreal therapy) once every 4 weeks
89587976|NCT02222207|Experimental|Regorafenib [B2]|Part B: Regorafenib eye drops dose 2; plus sham IVT (Intravitreal therapy) once every 4 weeks
89587977|NCT02222207|Experimental|Regorafenib [B3]|Part B: Regorafenib eye drops dose 3; plus sham IVT (Intravitreal therapy) once every 4 weeks
89587978|NCT02222207|Experimental|Regorafenib [B4]|Part B: Regorafenib eye drops dose 4; plus sham IVT (Intravitreal therapy) once every 4 weeks
89587979|NCT02222207|Experimental|Regorafenib [B5]|Part B: Regorafenib eye drops dose 5; plus sham IVT (Intravitreal therapy) once every 4 weeks
89587980|NCT02222207|Experimental|Regorafenib [B6]|Part B: Regorafenib eye drops dose 6; plus sham IVT (Intravitreal therapy) once every 4 weeks
89587981|NCT02222207|Active Comparator|Ranibizumab|Ranibizumab IVT once every 4 weeks; plus placebo eye drops to match the regorafenib eye drop regimens
88975989|NCT05147506|Experimental|CBT DTx|Participants randomized to active intervention will access a structured, cognitive behavioral therapy (CBT) intervention.
88975990|NCT05147506|Active Comparator|Psychoeducations DTx|Participants randomized to the comparison group will access an unstructured educational DTx.
88975991|NCT05086237|Experimental|Reminder|Participants will be sent a text message reminder of their missed well-child visit.
88975992|NCT05086237|No Intervention|Treatment as usual|This group will receive treatment as usual, which involves no text messaging follow-up.
88975993|NCT00078624|Experimental|1|Traditional exercise program supplemented with knee stability training activities
88975994|NCT00078624|Active Comparator|2|Traditional exercise program
88975995|NCT04934917||Patients with disc degenerative disease (DDD)|Patients suffering from disc degenerative disease, age 30-60 years that are on the waiting list for surgery (fusion/disc implants) at Stockholm Spine Center, Stockholm, Sweden.
88975996|NCT04934917||Healthy controls (HC)|Healthy controls matched according to age and sex, no chronic pain conditions.
88975997|NCT00402961|Active Comparator|1|Acupuncture is the insertion of needles at certain body points.
88975998|NCT00402961|Sham Comparator|2|sham acupuncture
88975999|NCT00397553|Experimental|Insulin Glulisine|
88976000|NCT00403039|Other|Open-label ranibizumab|Subjects will receive open-label intravitreal injections of ranibizumab administered every 28 ± 7 days for a total of 3 injections. Thereafter they are to be evaluated monthly for re-treatment until Month 48.
88976001|NCT02965794||Usual care|quality of care will be measured in the participating hospitals, using a retrospective patient record analysis
88976002|NCT02965794||Care Pathway|Care pathways for colorectal cancer
88976003|NCT04818073|Experimental|Group A|Participants with undergo new FINGER robotic training with no physical assistance 3 times a week for a period of 3 weeks.
88976004|NCT04818073|Experimental|Group B|Participants will undergo new FINGER robotic training with physical assistance 3 times a week for a period of 3 weeks.
88976005|NCT04818073|Experimental|Group C|Participants will undergo new FINGER robotic training with physical assistance and proprioceptive exercises 3 times a week for a period of 3 weeks.
88976006|NCT04786717|Experimental|core muscle training|Training the endurance of the core muscle.
88976007|NCT04786717|Experimental|movement control training|Based from the initial test, the subjects will receive lumbar movement control exercise. They will perform each lumbar movement control exercise in different position.
88976008|NCT04786717|Experimental|combined imagery and movement control training|The intervention of this group is mostly same as the movement control training group. The different part is that the first 3 times of the movement will be practiced through image training, and the subjects will practice the real movement in the rest of 7 times.
89030430|NCT04515602|Experimental|Part 2 Arm I (high tumor burden)|Primary debulking surgery with a maximal cytoreduction of complete gross resection within 3 weeks after biopsy, followed by at least 6 cycles of adjuvant chemotherapy and maintenance therapy for patients with gBRCA/sBRCA mutation, CR/PR after platinum-based therapy.
89587982|NCT01457014|Active Comparator|servo ventilation auto mode|Inspiratory and expiratory pressures automatically determined by the servo ventilation device.
89587983|NCT01457014|Active Comparator|Continuous positive airway pressure|Airway pressure delivered at a constant pressure level.
89587984|NCT01457014|Active Comparator|servo ventilation manual|Inspiratory and expiratory pressures automatically determined by the servo ventilation device with mandatory minimal inspiratory minus expiratory pressure difference.
89587985|NCT02254421|Experimental|Presatovir|Participants will receive presatovir on Days 1, 5, 9, 13, and 17, with follow-up visits through Day 28, and may continue in an optional extended monitoring phase with visits through Day 56.
89587986|NCT02254421|Placebo Comparator|Placebo|Participants will receive placebo to match presatovir on Days 1, 5, 9, 13, and 17, with follow-up visits through Day 28, and may continue in an optional extended monitoring phase with visits through Day 56.
88976009|NCT00074763|Experimental|Platelet Transfusion|ThromboSol-preserved autologous platelet transfusion or Standard platelet transfusion. All patients receive both platelets frozen with Thrombosol and fresh random platelets. The order in which patients receive these two types of platelets randomized in a crossover design. Patients randomly assigned to receive either the sequence FRP then Thrombosol or Thrombosol then FRP. The randomization will occur after second cycle of chemotherapy, since all patients will receive FRP with the first cycle.
88976010|NCT04731935|Experimental|tAN Therapy|tAN will be delivered at a duty cycle of for 5 minutes ON and 10 seconds OFF for a total of 120 hours (5 days) therapy duration. Stimulation intensity will be customized to the participants comfort level and within range of therapeutic effectiveness.
88976011|NCT00078858|Experimental|Treatment (prolonged MMF and truncated CSP)|"CONDITIONING: Patients receive fludarabine phosphate IV over 30 minutes on days -4 to -2, and undergo TBI on day 0.~TRANSPLANTATION: Patients undergo allogeneic PBMC transplant on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine PO BID on days -3 to 80 with taper to day 150 and mycophenolate mofetil PO or IV TID on days 0-30, BID on days 31-150, and then taper to day 180. Treatment continues in the absence of unacceptable toxicity."
88976012|NCT04686604|Experimental|Electron Health Record-based Provider Alert|Providers will receive a best practice alert for each of their eligible patients upon opening of the order entry screen in the patient's medical record. The alert will inform the provider to the presence of HFrEF and of the patient's current left ventricular ejection fraction, most recent blood pressure and heart rate, most recent potassium and estimated glomerular filtration rate, and current evidence-based medications for HFrEF. It will also provide access to an order set with recommended evidence-based HFrEF therapies as well as a link to the best available guideline-recommended information regarding the treatment of heart failure.
89517601|NCT04454749||Artificial (HRT) Cycles|"Start of estradiol valerate 4mg on day 2 of the cycle for three days. Increase E2 to 6mg on day 4 of E2 treatment. E2 dose may be increased according to clinician discretion based on endometrial thickness. Maximum time of E2 exposure will be 14 days. Transvaginally scan to monitor endometrial development and to exclude the presence of a dominant follicle. Serial measurements of serum LH, estradiol and progesterone levels. Commence the initial progesterone dose of 100mg at 22hrs (vaginal suppository) after ≥ 7 days and ≤ 16 days of estradiol administration when the minimal endometrial thickness achieved is 6mm with a trilaminar appearance. Subsequently increase progesterone administration to 100mg vaginally three times daily. Continue estradiol administration 6mg (3 tablets daily).~Blastocyst transfer is scheduled on the 5th full day of progesterone administration, following the initial initiation of progesterone."
89587987|NCT02252939|Experimental|Patients with Trapeziometacarpal (TMC) Arthrosis|Patients presenting to the Orthopaedic Hand Service not seeking care for TMC Arthrosis
89587988|NCT02196077|Experimental|BFF MDI 320/9.6 μg|Budesonide and formoterol fumarate metered dose inhaler (BFF MDI) 320/9.6 μg; PT009 administered as 2 inhalations, twice daily (BID)
89587989|NCT02196077|Experimental|BFF MDI 160/9.6 μg|Budesonide and formoterol fumarate metered dose inhaler (BFF MDI)160/9.6 μg; PT009 administered as 2 inhalations, twice daily (BID)
89587990|NCT02196077|Experimental|BFF MDI 80/9.6 μg|Budesonide and formoterol fumarate metered dose inhaler (BFF MDI) 80/9.6 μg; PT009 administered as 2 inhalations, twice daily (BID)
89587991|NCT02196077|Experimental|BD MDI 320 μg|Budesonide metered dose inhaler (BD MDI) 320 μg; PT008 administered as 2 inhalations, twice daily (BID)
89587992|NCT02196077|Experimental|FF MDI 9.6 μg|Formoterol fumarate metered dose inhaler (FF MDI) 9.6 μg; PT005 administered as 2 inhalations, twice daily (BID)
89587993|NCT02195687|Experimental|botulinum toxin type A|24U botulinum toxin Type A (BOTOX®) total dose injected into bilateral Crow's Feet Line areas on Day 1.
89587994|NCT02195687|Placebo Comparator|placebo|Placebo (Normal Saline) injected into bilateral Crow's Feet Line areas on Day 1.
89587995|NCT02195531|Active Comparator|Treatment|Participants will receive education and feedback tailored to the psychological profile of the receiving participant.
89587996|NCT02195531|Active Comparator|Control Group|Participants will receive education inconsistent with their profile.
89587997|NCT02195531|No Intervention|Standard of care|Participants will not receive education or feedback.
89587998|NCT02252081|Active Comparator|metformin|500 to 1500 mg orally per day for 16 weeks if eGFR > 45 ml/min; 500 to 1000 mg orally per day for 16 weeks if eGFR =< 45 ml/min
89587999|NCT02252081|Placebo Comparator|Placebo|placebo pill(s) orally per day for 16 weeks
89588000|NCT01623752||Patients with Rheumatoid Arthritis|
89588001|NCT01623752||Patients with Psoriasis Arthritis|
89588002|NCT01623596|Experimental|Fingolimod|
89588003|NCT01623596|Active Comparator|Disease Modifying Therapy|2 classes - Interferon Beta preparation (Exctavia, Betaseron, Rebif, Avonex) or glatiramer acetate (Copaxone)
89588004|NCT02219477|Experimental|Group 1: GT1B|ombitasvir/paritaprevir/ritonavir 25/150/100 mg once daily (QD) + dasabuvir 250 mg twice daily (BID) + ribavirin (RBV) for 12 weeks in hepatitis C virus (HCV) genotype (GT) 1b-infected participants
89588005|NCT02219477|Experimental|Group 2: GT1 Non-B|ombitasvir/paritaprevir/ritonavir 25/150/100 mg QD + dasabuvir 250 mg BID + RBV for 24 weeks in HCV GT1non-b (including GT1a)-infected participants
89588006|NCT02219477|Experimental|Group 3: GT4|ombitasvir/paritaprevir/ritonavir 25/150/100 mg QD + RBV for 24 weeks in HCV GT4-infected participants
89588007|NCT02119286|Experimental|FF/VI 100/25 mcg + UMEC (62.5mcg)|Subjects received one inhalation of FF/VI 100/25 mcg via DPI followed by one inhalation UMEC (62.5mcg) via DPI once-daily in the morning for 12 weeks.
89588008|NCT02119286|Experimental|FF/VI 100/25 mcg + UMEC (125mcg)|Subjects received one inhalation of FF/VI 100/25 mcg via DPI followed by one inhalation of UMEC (125mcg) via a DPI once-daily in the morning for 12 weeks.
89588009|NCT02119286|Experimental|FF/VI 100/25 mcg + Placebo|Subjects received one inhalation of FF/VI 100/25 mcg via DPI followed by one inhalation of matching placebo via a DPI once-daily in the morning for 12 weeks.
89588010|NCT02250443|Experimental|BYM338|BYM338 Group
89588011|NCT02093390|Experimental|TAK-385 + fluconazole|TAK-385 40 mg, tablet, orally once on Day 1 and fluconazole 400 mg, tablet, orally on Day 6 then 200 mg, tablet, orally once daily on Days 7 to 9 followed by a single dose of TAK-385 in combination with fluconazole 200 mg on Day 10 then fluconazole 200 mg, tablet, orally once daily alone on Days 11 to 14.
89588012|NCT02093390|Experimental|TAK-385 + atorvastatin|TAK-385 40 mg, tablet, orally once on Day 1 and atorvastatin 80 mg, tablet, orally once daily on Days 6 to 9 followed by a single dose of TAK-385 in combination with atorvastatin 80 mg on Day 10 then atorvastatin 80 mg, tablet, orally once daily alone on Days 11 to 14.
89588013|NCT02194985|Experimental|Migalastat HCl 150 mg|Migalastat HCl 150 milligram (mg).
89588014|NCT02219087|Experimental|Liposomal Bupivacaine|Pre-operative adductor canal nerve block (20mL of 0.5% ropivacaine). Liposomal bupivacaine (diluted to 60mL): 20mL into the posterior pocket, 20mL into the lateral, and 20mL into the medial, including all deep and superficial tissues of these areas.
89588015|NCT02219087|Active Comparator|Standard of Care|Pre-operative adductor canal nerve block (20mL of 0.5% ropivacaine). Intra-operative popliteal nerve block from the surgeon: 20mL 0.2% ropivacaine and a peri-articular injection of 10mg morphine, 30mg ketorolac and 40mg methylprednisolone.
89588016|NCT02248961|Experimental|Kanarb (Fimasartan)|88 subjects will receive Kanarb (Fimasartan), manufactured by Boryung Pharmaceutical Co., Ltd, Republic of Korea, tablets 60/120 mg for 12 weeks
89588017|NCT02248961|Active Comparator|Cozaar® (Losartan)|88 subjects will receive Cozaar® (Losartan), manufactured by MERCK SHARP & DOHME B.V., Netherlands, tablets 50/100 mg for 12 weeks
89588018|NCT02219009|Experimental|MIND1 System|
89588019|NCT02248649|Experimental|Physical Activity|Structured walking program
89588020|NCT02248649|Active Comparator|Control|Health education attention control
89588021|NCT02218541|Other|abutment margin 0.5 mm subgingival|when fabricating an abutment to support the crown, the margin will be placed 0.5 mm below the gumline
89588022|NCT02218541|Other|abutment margin 1.5 mm subgingival|when fabricating the abutment to support the crown, the margin will be placed 1.5 mm below the gumline
88976013|NCT04686604|No Intervention|Usual Care|Providers will not receive an alert and will proceed with usual care.
88976014|NCT04674202||Pharmaceutical interview|This group will benefit from a pharmaceutical interview, accordingly with the common practice in the department in which they are treated.
88976015|NCT04674202||No pharmaceutical interview|This group will not benefit from a pharmaceutical interview, accordingly with the common practice in the department in which they are treated.
88976016|NCT04665154|Experimental|MAS825 dose A|single i.v. dose
88976017|NCT04665154|Experimental|MAS825 dose B|single s.c. dose
88976018|NCT04665154|Placebo Comparator|Placebo dose A|single i.v. dose
89588023|NCT02217527|Experimental|JNJ Active Drug|200 mg (100 mg b.i.d.) Active JNJ Drug used to assess quitting for one week, as part of crossover design. This JNJ experimental compound has NO name, just a company number.
89588024|NCT02217527|Experimental|Placebo Pill|Placebo pill used for one week quit attempt, as part of crossover design.
89588025|NCT01456936|Placebo Comparator|placebo|Subjects randomized to placebo will receive placebo treatments for all three study drugs. Blinded placebo will be provided for varenicline, bupropion hydrochloride and transdermal nicotine patch (NRT). In addition, subjects will receive blinded placebo treatments for the study drugs they are not randomized to receive.
89588026|NCT01456936|Active Comparator|varenicline|
89588027|NCT01456936|Active Comparator|bupropion|
89588028|NCT01456936|Active Comparator|Nicotine Replacement Therapy Patch|
89588029|NCT01456780|Active Comparator|Zylet|Subject randomized to this arm will be treated with Zylet (Loteprednol/tobramycin), twice a day, for 4 weeks. Zylet is a combination of loteprednol and tobramycin. Loteprednol is in a class of drugs called corticosteroids. Loteprednol inhibits processes in the body that cause inflammation. Tobramycin is an antibiotic.
89588030|NCT01456780|Active Comparator|Lotemax|Subject randomized to this arm will be treated with Lotemax, twice a day, for 4 weeks. Lotemax is also known as loteprednol. Loteprednol is in a class of drugs called corticosteroids. Loteprednol inhibits processes in the body that cause inflammation.
89588031|NCT01456780|Placebo Comparator|B+L Advanced Eye Relief Lubricant Drop|Subject randomized to this arm will be treated with B+L Advanced Eye Relief Lubricant Eye Drops (Artificial Tears), twice a day, for 4 weeks.
89588032|NCT01480258|Experimental|PR5I|"Infant series: PR5I 0.5 mL injection + Prevenar 13™ 0.5 mL injection administered at 2 and 4 months of age, and rotavirus vaccine (either Rotarix™ 1.5 mL oral dose at 2 and 4 months of age [subset 1] or RotaTeq™ 2 mL oral dose at 2, 4 and 5 months of age [subset 2]).~Toddler dose: PR5I 0.5 mL injection + Prevenar 13™ 0.5 mL injection administered at 11 to 12 months of age."
89588033|NCT01480258|Active Comparator|INFANRIX™ hexa|"Infant series: INFANRIX™ hexa 0.5 mL injection + Prevenar 13™ 0.5 mL injection administered at 2 and 4 months of age, and rotavirus vaccine (either Rotarix™ 1.5 mL oral dose at 2 and 4 months of age [subset 1] or RotaTeq™ 2 mL oral dose at 2, 4 and 5 months of age [subset 2]).~Toddler dose: INFANRIX™ hexa 0.5 mL injection + Prevenar 13™ 0.5 mL injection administered at 11 to 12 months of age."
88976019|NCT04665154|Placebo Comparator|Placebo dose B|single s.c. dose
88976020|NCT04612660|Experimental|Specific Education and Dynamic Group|"Motivational group education specifically focused on cervical cancer prevention;~Dynamic group interaction and role play discussion sessions on the benefits of Self-Sample collection HPV testing and procedures;~Engaging community bilingual physicians in cervical cancer screening and referral;~Patient navigation assistance."
88976021|NCT04612660|Active Comparator|General Health Education|Comparison group participants received general health education focusing on healthy lifestyle, and prevention of disease through routine health examinations.
88976022|NCT00044798|Experimental|1|Participants will receive treatment with repetitive transcranial magnetic stimulation and citalopram.
88976023|NCT00044798|Active Comparator|2|Participants will receive treatment with sham repetitive transcranial magnetic stimulation and citalopram.
88976024|NCT04598425|Experimental|Cognitive behavioral therapy for insomnia (CBTi)|
88976025|NCT00078975|Experimental|Triapine in combination with Gemcitabine|
88976026|NCT04512274|Experimental|Test Article|The test article was applied to an open application site and to a second site of induced inflammation
89588034|NCT01479868|Experimental|TMC435 + pegylated interferon alpha-2a + ribavirin|Patients will be administered TMC435 150 mg along with pegylated interferon alpha-2a 180 microgram and ribavirin 1000 or 1200 mg for 12 weeks. Pegylated interferon alpha-2a and ribavirin will only be continued until 24 to 48 weeks.
89588035|NCT01478620|Experimental|Canephron® N|
89588036|NCT01454830|Experimental|Tailored|Tailored, or individualized, intervention addressing patient education, skills training, and cognitive perceptions
89588037|NCT01454830|Active Comparator|Usual care|The comparison group, usual care, includes the standard of care delivered to all newly-diagnosed OSA persons proceeding to CPAP treatment
89588038|NCT01454596|Experimental|1/Phase I Arm|Non-myeloablative lymphodepleting preparative regimen of cyclophosphamide and fludarabine + escalating doses of epidermal growth factor receptor (EGFRv)III Chimeric antigen receptor (CAR) transduced peripheral blood lymphocytes (PBL) + aldesleukin
89588039|NCT01454596|Experimental|2/Phase II Arm|Non-myeloablative lymphodepleting preparative regimen of cyclophosphamide and fludarabine + maximum tolerated dose (MTD) of anti-EGFRvIII CAR transduced PBL established in Phase I + aldesleukin
89588040|NCT04542850|Other|Moderate group and Severe Group|Moderate group and Severe group - . Both groups will be administered 5-aminolevulinic acid (5-ALA) is a natural delta amino acid widely present in nature that can be found in common food. 5-ALA combined with sodium ferrous citrate (SFC) produces the nutritional dietary supplement 5-ALA-Phosphate + SFC (5-ALA + SFC).
89588041|NCT02247479|Experimental|Lampalizumab Once in Every 4 Weeks (Q4W)|Participants will receive 10 milligrams (mg) dose of lampalizumab administered by intravitreal injections for approximately 96 weeks.
89588042|NCT02247479|Experimental|Lampalizumab Once in Every 6 Weeks (Q6W)|Participants will receive 10 mg dose of lampalizumab administered by intravitreal injections for approximately 96 weeks.
89588043|NCT02247479|Sham Comparator|Sham Comparator|Participants will receive sham comparator Q4W or Q6W for 96 weeks.
89588044|NCT01454284|Experimental|LY2605541 + Insulin Lispro|LY2605541 titrated based on blood glucose readings, administered subcutaneously (SC) once daily at bedtime for 52 weeks in combination with Insulin Lispro. Insulin Lispro titrated based on blood glucose readings, administered SC at meal times for 52 weeks.
89588045|NCT01454284|Active Comparator|Glargine + Insulin Lispro|Glargine dose titrated based on blood glucose readings, administered SC once daily at bedtime for 52 weeks in combination with Insulin Lispro. Insulin Lispro dose titrated based on blood glucose readings, administered SC at meal times for 52 weeks.
89588046|NCT04541290|Experimental|Treatment|Women with stage 1-2 lymphedema due to breast cancer treatment
89588047|NCT02247401|Active Comparator|Arm A|ABT-450/r/ABT-267 (paritaprevir/ritonavir/ombitasvir; 2 direct acting antiviral agent [DAA]) plus Ribavirin (RBV) for 12 weeks in treatment-naïve and treatment-experienced (with pegylated interferon and ribavirin) participants without cirrhosis.
89588048|NCT02247401|Active Comparator|Arm B|ABT-450/r/ABT-267 plus RBV for 12 weeks in treatment-naïve and treatment-experienced (with pegylated interferon and ribavirin) participants with compensated cirrhosis.
89588049|NCT02247401|Active Comparator|Arm C|ABT-450/r/ABT-267 plus RBV for 24 weeks in treatment-naïve and treatment-experienced (with pegylated interferon and ribavirin) participants with compensated cirrhosis.
89588050|NCT02247011|Other|fracture group|Fracture group included participants with new fractures during the 5 year follow-up visit. Fracture consists of non-vertebral fracture and vertebral fracture, which were investigated by questionnaire survey and lateral radiographs, respectively.
89588051|NCT02247011|Other|non-fracture group|Fracture group included participants without new fractures during the 5 year follow-up visit. Fracture consists of vertebral fracture and non-vertebral fracture, which were investigated by questionnaire survey and lateral radiographs, respectively.
89588052|NCT02246777|Experimental|Ex-PRESS|Ex-PRESS® Glaucoma Filtration Device, Model P50PL, implanted in the anterior chamber of the study eye during glaucoma surgery intended for the lifetime of the patient
89588053|NCT01495702|Experimental|Stribild|Participants will switch from their baseline treatment regimen to Stribild for up to 96 weeks, and may continue to receive Stribild in the extension phase.
89588054|NCT01495702|Active Comparator|NNRTI+FTC/TDF|Participants will stay on their baseline treatment regimen antiretroviral regimen consisting of an NNRTI plus FTC/TDF for up to 96 weeks, and may switch to Stribild in the extension phase.
89588055|NCT01630889|Experimental|Roxadustat|Participants previously randomized to roxadustat will receive roxadustat at the same dose and frequency assigned at the last dose in the previous FibroGen study. Dose adjustments will be implemented (up to a maximum roxadustat dose of 3.0 mg/kg or 400 mg, whichever is lower) every 4 weeks to maintain Hb levels at 10.0-12 grams (g)/deciliter (dL). However, if a participant, at any dose, experiences an event of excessive hematopoiesis then the participant's dose will be immediately reduced, or an event of rapidly declining Hb then the participant's dose will be immediately increased. Participants will be permitted to receive roxadustat for up to 8 years.
89588056|NCT01495000|Experimental|Arm 1|denosumab 60mg subcutaneous injection, single dose at the start of the 6-month double-blind treatment
89588057|NCT01495000|Placebo Comparator|Arm 2|placebo subcutaneous injection, single dose at the start of the 6-month double-blind treatment
89588058|NCT01494922|Experimental|Open Label|
88976027|NCT04457557|Experimental|Low concentration|Interscalene block with 0.15% ropivacaine 15 ml
88976028|NCT04457557|Active Comparator|Usual concentration|Interscalene block with 0.5% ropivacaine 15 ml
88976029|NCT00079014|Experimental|Treatment (triapine, doxorubicin hydrochloride)|"Patients receive doxorubicin IV over 15 minutes on day 1 and 3-AP (Triapine®) IV over 2 hours on days 1-4. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of 3-AP (Triapine®) until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, an additional 6 patients are treated at that dose level."
88976030|NCT04430920|Active Comparator|Intensive intraoperative blood pressure management|
89588059|NCT02192099|Experimental|Rapastinel (225 mg/450 mg IV administration) prefilled syringe|Investigators began treatment in RAP-MD-05 based on the dose level to which the patient was assigned during participation in GLYX13-C-202; patients originally assigned to rapastinel 5 mg/kg received rapastinel 225 mg, and patients originally assigned to rapastinel 10 mg/kg received rapastinel 450 mg. Investigators had the option to decrease the dose level from 450 to 225 mg if a patient experienced an adverse event(s) that the investigator believed may be associated with rapastinel
89588060|NCT01494610|Experimental|SERETIDE Rotacaps|Fluticasone propionate (250 micrograms [ug])/Salmeterol (50 ug) combination delivered in a capsule-based inhaler
89588061|NCT01494610|Active Comparator|SERETIDE Diskus|Fluticasone propionate (250 ug)/Salmeterol (50 ug) combination delivered in a multi-dose dry powder inhaler
89588062|NCT01494610|Placebo Comparator|Placebo Rotacaps|Placebo delivered in a capsule-based inhaler
89588063|NCT01494610|Placebo Comparator|Placebo Diskus|Placebo delivered in a multi-dose dry powder inhaler
89588064|NCT02116777|Experimental|Treatment (talazoparib, temozolomide): Phase 1|(Part A): Patients receive talazoparib PO QD or BID on days 1-6 and temozolomide PO QD on days 2-6. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
89588065|NCT02116777|Experimental|Treatment (talazoparib, temozolomide): Phase 2|(Part B): Relapse/Refractory EWS or PNET Patients receive MTD from Phase 1 portion of study. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
89588066|NCT01494532|Experimental|ropinirole|active treatment 4, 8, 12, 16, or 24mg/day
89588067|NCT01494532|Placebo Comparator|placebo|placebo comparator 4, 8, 12, 16, or 24mg/day
89588068|NCT02191397|Experimental|Bupropion Treatment Arm|Subject will receive bupropion in 3 dose levels along with escitalopram matching placebo to maintain the blind in acute treatment phase. At dose level 1 (Week 0 to Week 1), Subjects will receive bupropion XL 150 milligram (mg) per day for a week. At dose level 2 (Week 1 to Week 4), bupropion XL dose will be increased to 300mg/day for further 3 weeks. At dose level 3 (Week 4 to Week 8), bupropion XL dose will be maintained at 300mg/day. Subjects intolerable to dose level 3 will be allowed to down titrate to dose level 2 at anytime, and maintain the dose until the end of acute treatment phase (Week 8, Visit 7). At the end of acute treatment phase, the dose of bupropion XL will be reduced to 150mg/day for 1 week before discontinuation.
89588069|NCT02191397|Active Comparator|Escitalopram Treatment Arm|Subject will receive escitalopram in 3 dose levels along with bupropion matching placebo to maintain the blind in acute treatment phase. At dose level 1 (Week 0 to Week 1), Subjects will receive escitalopram 10mg/day for a week. At dose level 2 (Week 1 to Week 4), escitalopram dose will be maintained at 10mg/day for further 3 weeks. At dose level 3 (Week 4 to Week 8), escitalopram dose will be increased to 20mg/day. Subjects intolerable to dose level 3 will be allowed to down titrate to dose level 2 at anytime, and maintain the dose until the end of acute treatment phase (Week 8, Visit 7). At the end of acute treatment phase, the dose of escitalopram 20mg/day, the dose will be reduced to 10 mg/day for 1 week before discontinuation, while those receiving 10mg/day will discontinuation directly.
89588070|NCT01630811|Experimental|Nuedexta|Nuedexta (Dextromethorphan hydrobromide 20 mg/quinidine sulfate 10 mg), oral, once daily
89588071|NCT01630811|Placebo Comparator|Placebo|Oral, once daily
89588072|NCT01494298||T2DM|African-American men with type 2 diabetes who are not taking cholesterol-lowering medications.
89588073|NCT01494298||Control|African-American men without type 2 diabetes who are not taking cholesterol-lowering medications.
89588074|NCT03027076||Men with UCPPS|Genitourinary Specimen Collection for microbiome evaluation
89588075|NCT03027076||Asymptomatic Men|Genitourinary Specimen Collection for microbiome evaluation
89588076|NCT03027076||Women with UCPPS|Collect midstream urine samples
89588077|NCT03027076||Asymptomatic Women|Collect midstream urine samples
89588078|NCT02169791|Experimental|Haploidentical Transplant|All patients will receive a haploidentical donor transplant using a conditioning regimen of Fludarabine (Flu), cyclophosphamide (cy) and total body irradiation (TBI) followed by MLN9708.
89588079|NCT02216591|Experimental|Active Cognitive Training (ACT)|The ACT group will complete 12 individual sessions across 6-10 weeks. Sessions will utilize four commercially available memory-training programs from PSSCogRehab 2012, published by Psychological Software Service. The four programs used will be: (1) Sequence recall of digits - auditory (SRD-A), (2) Sequenced Recall Reversed Digits - Auditory (SRRD-A), (3) Sequenced Recall of Words - Visual (SRW-V), and (4) Verbal memory - categorizing (VM-C). In each training session, participants will complete each of the four memory training programs twice.
89588080|NCT02216591|Sham Comparator|Control (CON)|The CON group will also complete 12 total sessions across 6-10 weeks. The same four computer programs from PSSCogRehab 2012, published by Psychological Software Service, will be used in the control group sessions. However, the control program will identify the correct responses to participants, such that they do not need to engage their working memory to answer the questions correctly.
89588081|NCT02216357|Active Comparator|Ifetroban, Oral Capsule|Ifetroban, Oral Capsule; 200 mg per dose (four - 50 mg capsules), once per day on Study Days 1, 2, and 3.
89588082|NCT02216357|Placebo Comparator|Placebo, Oral Capsule|Placebo, Oral Capsule; matching capsules for oral ifetroban dosing, four capsules once per day on Study Days 1, 2, and 3.
88976031|NCT04430920|Placebo Comparator|Conventional intraoperative blood pressure management|
88976032|NCT00044915|Active Comparator|Arm 1|
88976033|NCT00044915|Placebo Comparator|Arm 2|
88976034|NCT04263298|Experimental|Fulvestrant Group|Fulvestrant 500mg Days 0, 14, 28, then every 28 days
88976035|NCT04263298|Active Comparator|Capecitabine Group|Capecitabine 2000mg/m2 twice daily x 14 days followed by 7 days off
88976036|NCT00079131|Experimental|Treatment (oblimersen sodium)|Patients receive oblimersen IV continuously on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
88976037|NCT00045188|Experimental|Treatment (imatinib mesylate)|Patients receive oral imatinib mesylate twice daily. Treatment continues for at least 8 weeks in the absence of disease progression or unacceptable toxicity.
88976038|NCT04107961|Experimental|Vaccine arm|Vaccine in 1 ml, single dose
89588083|NCT01492426|Experimental|Daclatasvir + Peginterferon alfa-2a + Ribavirin|
89588084|NCT01492426|Experimental|Telaprevir + Peginterferon alfa-2a + Ribavirin|
89588085|NCT01453348|Active Comparator|Group 1|This group will receive Inactivated hepatitis A and recombinant hepatitis B or 'Combined inactivated hepatitis A & recombinant hepatitis B vaccine' alone on the different visits.
89588086|NCT01453348|Active Comparator|Group 2|This group will receive Inactivated hepatitis A vaccine and recombinant hepatitis B Vaccine or 'Combined inactivated hepatitis A & recombinant hepatitis B vaccine' concomitantly with MenACWY-CRM.
89588087|NCT01453348|Active Comparator|Group 3|This group will receive only MenACWY-CRM.
89588088|NCT04076410|Experimental|5 Lenses|"The five lenses will be tested in each patient following always the same specific order, with the most protective lenses tested first (Z1).~Z1F133 (Zeiss Clarlet Z1) is a CE marked device manufactured by Carl Zeiss Vision International GmBH (Aalen, Germany).~Our lenses are CE marked devices manufactured by Cerium Optical Products (Kent, UK)."
89588089|NCT01453036|Active Comparator|Conventional AOC group|The investigators do not perform mutation test in the conventional group apply amoxicillin 1 g, bid , rabeprazole 20 mg bid, clarithromycin 500 mg bid during 1weeks
89588090|NCT01453036|Active Comparator|Mutation test group|Mutation test group is composed of two groups, clarithromycin group and metronidazole group Clarithromycin subgroup ; no point mutation at 23S rRNA apply clarithromycin 500 mg bid, amoxicillin 1 g bid, rabeprazole 20 mg bid during 1 week Metronidazole subgroup ; point mutation at 23S rRNA apply metronidazole 500 mg tid, amoxicillin 1 g bid, rabeprazole 20 mg bid during 1 week
89588091|NCT01453036|Active Comparator|Conventional AOM group|The investigators do not perform mutation test in the conventional group apply metronidazole 500 mg tid, amoxicillin 1 g bid, rabeprazole 20 mg bid during 1 week
89588092|NCT01475734|Active Comparator|albiglutide|single dose of albiglutide
89588093|NCT01475734|Placebo Comparator|placebo|single dose of placebo
89588094|NCT01452412|Experimental|Sodium bicarbonate|0.4 mEq/kg/day ideal body weight to be taken once a day
89588095|NCT01452412|Placebo Comparator|Placebo|placebo dosage/frequency equivalent to sodium bicarbonate
89588096|NCT04409392||Prothestic joint infection due to Staphylococcus lugdunensis|Patients having had a prosthetic joint infection with Staphylococcus lugdunensis
89588097|NCT01474876||Ankylosing Spondylitis|Participants with a diagnosis of ankylosing spondylitis
89588098|NCT01474876||Psoriatic Arthritis|Participants with a diagnosis of psoriatic arthritis
89588099|NCT01491802|Experimental|LAMA alone, then LAMA/LABA combination|Participants will first receive an inhaled long-acting muscarinic antagonist (LAMA) once daily for 4 weeks. After a 2 week washout period, they will then receive the fixed-dose combination product [LAMA plus long-acting beta2-agonist (LABA)] once daily for 4 weeks.
89588100|NCT01491802|Experimental|LABA/LAMA combination, then LAMA alone|Participants will first receive a long-acting muscarinic antagonist (LAMA) plus long-acting beta2-agonist (LABA) combination product once daily for 4 weeks. After a 2 week washout period, they will then receive the LAMA single product once daily for 4 weeks.
89588101|NCT02168777|Experimental|Ph1b-Refametinib/Regorafenib Cohort 0|Phase 1b part of study: Participants received different doses of Refametinib and Regorafenib combination therapy to determine recommended Phase 2 dose (RP2D) via dose-escalation. Cohort 0: Refametinib 30mg twice daily (b.i.d) + Regorafenib 80mg once daily (q.d), 3 weeks on/1 week off.
89588102|NCT02168777|Experimental|Ph1b-Refametinib/Regorafenib Cohort -1|Phase 1b part of study: Participants received different doses of Refametinib and Regorafenib combination therapy to determine recommended Phase 2 dose (RP2D) via dose-escalation. Cohort -1: Refametinib 20mg b.i.d + Regorafenib 80mg q.d, 3 weeks on/1 week off.
89588103|NCT02168777|Experimental|Ph1b-Refametinib/Regorafenib Cohort -1a|Phase 1b part of study: Participants received different doses of Refametinib and Regorafenib combination therapy to determine recommended Phase 2 dose (RP2D) via dose-escalation. Cohort -1a: Refametinib 20mg b.i.d + Regorafenib 120mg q.d, 3 weeks on/1 week off.
89588104|NCT01491178||Patients with NVAF|
89588105|NCT02189837|Placebo Comparator|Placebo|Participants received placebo subcutaneous injection once every 2 weeks on days 1, 15, 29 and 43 and placebo tablets once a day for up to 8 weeks.
89588106|NCT02189837|Active Comparator|Atorvastatin|Participants received placebo subcutaneous injection once every 2 weeks on days 1, 15, 29 and 43 and 80 mg atorvastatin orally once a day for up to 8 weeks.
88976039|NCT04107961|Placebo Comparator|Placebo|1 ml normal saline , single dose
88976040|NCT04072276||EV71 Vaccine with Adjuvant AlPO4|EV71 Vaccine Produced in Vero Cells with Adjuvant AlPO4
88976041|NCT04072276||Adjuvant AlPO4|Placebo (Adjuvant AlPO4 only)
88976042|NCT04065451|Experimental|Epinephrine|Epinephrine in the submucosal injection fluid (1:200,000)
88976043|NCT04065451|No Intervention|No epinephrine|Submucosal injection fluid without epinephrine
89209811|NCT00275509|Experimental|Thymoglobulin|Thymoglobulin was administered as 1.5 mg/kg prior to reperfusion followed by 6 post-operative doses on days 1 through 6.
89588107|NCT02189837|Experimental|Evolocumab|Participants received 420 mg evolocumab by subcutaneous injection once every 2 weeks on days 1, 15, 29 and 43 and placebo tablets once a day for up to 8 weeks.
89588108|NCT02189837|Experimental|Evolocumab and Atorvastatin|Participants received 420 mg evolocumab by subcutaneous injection once every 2 weeks on days 1, 15, 29 and 43 and 80 mg atorvastatin orally once a day for up to 8 weeks.
89588109|NCT02216123|Experimental|Tafenoquine+ Chloroquine|All subjects will receive one of two formulations of CQ from Days 1 to 3 (600 mg [2×CQ 300 mg] on Day 1, 600 mg on Day 2 and 300 mg on Day 3, each once daily [OD] orally; OR, 620 mg [4×CQ 155 mg] on Day 1, 620 mg on Day 2 and 310 mg on Day 3, each once daily [OD] orally). Tafenoquine 300mg (2×TQ 150 mg) will be given as a single oral dose on Day 1 or Day 2. Primaquine matching placebo will be given OD orally beginning on Day 1 or Day 2 and continue for 14 days total dosing. All subjects will be followed-up till 180 days.
88976044|NCT00075114|Other|1 Bladder Health Class|A two-hour bladder health class presented by two experts in urinary incontinence and followed by an individual follow-up teaching session with an incontinence nurse specialist.
88976045|NCT00075114|No Intervention|2 Control Group|Participants randomized to this arm did not receive any interventions.
88976046|NCT04057612||Pediatric participants|"Participants' temperature measured at 2 places at the same time~Esophagus~Skin near to carotid artery"
89588110|NCT02216123|Experimental|Primaquine+ Chloroquine|All subjects will receive one of two formulations of CQ from Days 1 to 3 (600 mg [2×CQ 300 mg] on Day 1, 600 mg on Day 2 and 300 mg on Day 3, each once daily [OD] orally; OR, 620 mg [4×CQ 155 mg] on Day 1, 620 mg on Day 2 and 310 mg on Day 3, each once daily [OD] orally). Primaquine 15mg will be given OD orally beginning on Day 1 or Day 2 and continue for 14 total dosing. Tafenoquine matching placebo will be given as a single oral dose on Day 1 or Day 2. All subjects will be followed-up till 180 days.
89588111|NCT02189759|Active Comparator|Continuous Kangaroo Mother Care to one hour after birth|In addition to standard WHO thermoregulation care which includes warm delivery rooms, immediate drying, Kangaroo Mother Care (KMC) whenever possible, early and exclusive breastfeeding, postponed bathing and weighing if needed, appropriate bundling and placing the infant in air incubator, radiant heater, or heat mattress if the infant develops hypothermia, the infants will receive continuous KMC most of the time possible from birth to one hour after birth.
89588112|NCT02189759|Sham Comparator|Standard Kangaroo Mother Care to one hour after birth|Infants will receive standard WHO thermoregulation care which includes warm delivery rooms, immediate drying, Kangaroo Mother Care (KMC) whenever possible, early and exclusive breastfeeding, postponed bathing and weighing if needed, appropriate bundling and placing the infant in air incubator, radiant heater, or heat mattress if the infant develops hypothermia from birth to 1 hour after birth.
89588113|NCT02189759|Active Comparator|Continuous Kangaroo Mother Care to discharge|In addition to standard WHO thermoregulation care which includes warm delivery rooms, immediate drying, Kangaroo Mother Care (KMC) whenever possible, early and exclusive breastfeeding, postponed bathing and weighing if needed, appropriate bundling and placing the infant in air incubator, radiant heater, or heat mattress if the infant develops hypothermia, the infants will receive continuous KMC most of the time possible from one hour after birth to discharge.
89588114|NCT02189759|Sham Comparator|Standard Kangaroo Mother Care to discharge|Infants will receive standard WHO thermoregulation care which includes warm delivery rooms, immediate drying, Kangaroo Mother Care (KMC) whenever possible, early and exclusive breastfeeding, postponed bathing and weighing if needed, appropriate bundling and placing the infant in air incubator, radiant heater, or heat mattress if the infant develops hypothermia from 1 hour after birth to discharge.
89588115|NCT01490866|Experimental|FOLFOX/bevacizumab and Axitinib|"Phase II trial investigating axitinib as a single-agent maintenance therapy following standard first-line FOLFOX/bevacizumab therapy for patients with mCRC. (FOLFOX is a combination of 5-Fluorouracil, Leucovorin and Oxaliplatin.)~All patients will receive FOLFOX/bevacizumab for four 28-day cycles (a total of 16 weeks). After 4 cycles, maintenance axitinib will be started."
89588116|NCT02215967|Experimental|Multiple Myeloma|Dose Escalation with 5 dose levels based on the patients actual bodyweight
89588117|NCT02168387|Active Comparator|continuous high frequency oscillator (CHFO)|Subjects randomized to receive therapy with the CHFO will receive a 20 minute treatment every 6 hours for 48 hours.
89209812|NCT00275509|Experimental|Daclizumab|Daclizumab was administered as 2 mg/kg prior to reperfusion followed by 1 mg/kg every other week for 8 weeks post-operatively (4 post-operative doses).
89209813|NCT01072045|Active Comparator|Propranolol|Oral propranolol, at a dose of 2mg/kg/day, divided in 2 doses.
89588118|NCT02168387|Active Comparator|medication|Subjects randomized to receive the medications will receive acetylcysteine and dornase alfa, two medications frequently used in the treatment of atelectasis. The medications will alternate every 6 hours for 48 hours.
89588119|NCT04418219|Experimental|Treatment (SV-BR-1GM, pembrolizumab)|Patients receive cyclophosphamide IV over 1-2 hours on day 1, SV-BR-1-GM ID on day 3, pembrolizumab IV over 30 minutes on day 5, and interferon-alpha-2b ID on days 5 and 7. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
89588120|NCT02188589|Experimental|Nasal implant group|Bilateral or unilateral INEX nasal implants
89588121|NCT02167451|Experimental|Maraviroc|Maraviroc administration will start on day -3 and will end on day +30 after stell cell transplant, making the total number of days of drug administration 34 days. Maraviroc will be administered twice daily orally or via enteral tube. Dosing of Maraviroc will be based on body surface area (starting with 100mg twice a day for BSA of 0.2 and up to 300mg twice a day for BSA greater than 1.73).
89588122|NCT02167139|Experimental|SB5 (proposed biosimilar to adalimumab)|SB5 40 mg every other week via subcutaneous injection
89588123|NCT02167139|Active Comparator|Humira (adalimumab)|Humira 40 mg every other week via subcutaneous injection
89588124|NCT02116621|Experimental|Trialist Intervention|Clinician and patient set up N-of-1 trial 4-12 weeks in length to compare two treatments for chronic pain. Patient uses Trialist smartphone app to monitor pain and associated side effects daily throughout length of N-of-1 trial. After trial ends, the patient reviews graphical displays of N-of-1 trial results with clinician.
89588125|NCT02116621|No Intervention|Control-Usual Care|Receive usual care from clinician for chronic pain, do not use Trialist smartphone app
89588126|NCT02116309|Active Comparator|Rectal Indomethacin only|Patients in this group will receive 20 ml of normal saline sprayed on the duodenal papilla and surrounding regions of edema, over a period of 1 minute using any ERCP cannulation catheter, at the end of procedure, just before the withdrawal of endoscope; followed by 100 mg of rectal indomethacin.
89588127|NCT02116309|Active Comparator|Rectal Indomethacin plus papillary spray of Epinephrine|Patients in this group will receive 20 ml of 0.02% epinephrine sprayed on the duodenal papilla and surrounding regions of edema, over a period of 1 minute using any ERCP cannulation catheter, at the end of procedure, just before the withdrawal of endoscope; followed by 100 mg of rectal indomethacin.
89588128|NCT02115607|Experimental|Definity infusion|Infusion of Definity (Perflutren Lipid Microspheres)
89588129|NCT01490632|Placebo Comparator|Placebo|Part A: Placebo administered orally (PO) once daily (QD) for 12 weeks. Part B: Placebo participants stayed on placebo or re-randomized to baricitinib 8 milligram (mg) or 10 mg PO QD for 12 weeks. Part C: Baricitinib participants re-randomized to 4 mg or placebo PO QD for 16 weeks. Part D: Retreated with Part B efficacious dose.
89209814|NCT01072045|Active Comparator|Prednisone|Oral prednisone , at a dose of 2mg/kg/day, divided in 2 doses.
89588130|NCT01490632|Experimental|Baricitinib 2 mg|Part A: Baricitinib administered PO QD for initial 12 weeks. Part B: Depending on participant's response, participant was maintained on current dose, or re-randomized to increased dose PO QD for 12 weeks. Part C: Participants re-randomized to half dose or placebo PO QD for 16 weeks. Part D: Participants retreated with Part B efficacious dose for 52 weeks.
89588131|NCT01490632|Experimental|Baricitinib 4 mg|Part A: Baricitinib administered PO QD for initial 12 weeks. Part B: Depending on participant's response, participant was maintained on current dose, or re-randomized to increased dose PO QD for 12 weeks. Part C: Participants re-randomized to half dose or placebo PO QD for 16 weeks. Part D: Participants retreated with Part B efficacious dose for 52 weeks.
89588132|NCT01490632|Experimental|Baricitinib 8 mg|Part A: Baricitinib administered PO QD for initial 12 weeks. Part B: Depending on participant's response, participant was maintained on current dose, or re-randomized to increased dose PO QD for 12 weeks. Part C: Participants re-randomized to half dose or placebo PO QD for 16 weeks. Part D: Participants retreated with Part B efficacious dose for 52 weeks.
89588133|NCT01490632|Experimental|Baricitinib 10 mg|Part A: Baricitinib administered PO QD for initial 12 weeks. Part B: Depending on participant's response, participant was maintained on current dose, or discontinued from the study for 12 weeks. Part C: Participants re-randomized to 4mg dose or placebo PO QD for 16 weeks. Part D: Participants retreated with Part B efficacious dose for 52 weeks.
89588134|NCT04726111|Other|Control patients|Control patients (negative serology and PCR)
89588135|NCT04726111|Other|asymptomatic patients|asymptomatic patients (PCR positive)
89588136|NCT04726111|Other|symptomatic patients|symptomatic patients (PCR positive)
89588137|NCT04726111|Other|Cured patients|cured patients who contracted the disease during pregnancy (positive serology in the 15 days preceding childbirth or history of positive PCR during pregnancy and negative PCR within 72 hours)
89588138|NCT01451554|Active Comparator|Portion Control Intervention|Individuals will be given a portion control plate and dietary counseling
89588139|NCT01451554|Placebo Comparator|Usual Care|Provided with self-help booklets on diet and exercise.
89588140|NCT01474486|Experimental|Micronutrients|Thiamin one tablet daily provides 50 milligrams(mg) of thiamin, Vitamin B-50 one tablet daily: provides an additional 50 mg of thiamin, riboflavin, niacin, pantothenic acid and pyridoxine, 100 microgram(mcg folic acid, and 50 mcg cyanocobalamin (B12) and biotin; Vitamin D one 50,000 International Units(IU) tablet of ergocalciferol per week for two months followed by one tablet every other week for four months, and Zinc Sulfate (Zn SO4) one tablet daily at bedtime which provides 50 mg elemental zinc (220 mg Zn SO4)
89588141|NCT04075552|Experimental|Participants|Participants are students from a specialized school for children with autism.
88976047|NCT03948568|Active Comparator|Concurrent Endocrine Therapy and Radiotherapy|Concurrent endocrine therapy and radiotherapy. Concurrent endocrine therapy will be defined as, the commencement of endocrine therapy around 2 weeks before (a minimum of 1 week before to a maximum of 4 weeks) commencement of radiotherapy and continued throughout radiotherapy.
88976048|NCT03948568|Active Comparator|Sequential Endocrine Therapy after Radiotherapy|Sequential endocrine therapy after radiotherapy. Using the pragmatic definition sequential endocrine therapy should commence around 2 weeks (minimum 1 week, maximum 4 weeks) after the last fraction of radiotherapy.
88976049|NCT03938350|Experimental|Dialectical Behavior Therapy (DBT) Skills Training|Participants in this group will receive 8 weeks of Dialectical Behavior Therapy (DBT) Skills Training.
89209815|NCT01073059|Experimental|Valproic acid|
89209816|NCT00252577||Group 1|Veterans with bipolar disorder
89209817|NCT01073137||Diabetic Subjects|
89209818|NCT01073137||Non diabetic subjects|
89209819|NCT00252499|Placebo Comparator|Placebo Arm|matching placebo for rosiglitazone, 1 po bid and placebo for fenofibrate 1 po qd
89588142|NCT01451398|Experimental|TI inhalation powder|Technosphere® Insulin powder administered via the Gen2 inhaler added to 2 or more stable OADs
89588143|NCT01451398|Placebo Comparator|Technosphere powder|Technosphere powder (with no insulin) administered via the Gen2 inhaler added to 2 or more stable OADs
89588144|NCT02073565|Experimental|Combo|The Combo Stent is composed of the OrbusNeich R stent™, with an abluminal coating of a bioabsorbable polymer matrix formulated with sirolimus for sustained release, and an anti-CD34 antibody cell capture coating on the luminal surface.
89588145|NCT02073565|Active Comparator|Everolimus Eluting Stent (EES)|Everolimus Eluting Stent (EES) (Xience V, Xience Prime, Xience Xpedition stents, Abbott Vascular/Abbott Vascular Japan). Xience Prime inherited the clinical result of Xience V and is a product that obtains efficiency essentially equal to Xience V.
89588146|NCT02072941|Experimental|PREPARE intervention|The PREPARE arm will review the PREPARE website plus the easy-to-read advance directive (AD). Participants will review PREPARE on their own for ≥20 minutes with staff present to answer questions. During PREPARE, participants answer preference questions and make an action plan (i.e., commitment to engage in advance care planning). To ensure home access to PREPARE content, participants will be given a website login and PREPARE content in digital video disc (DVD), booklet, and pamphlet format as well as the action plan and AD. One to three days before a primary care visit, the PREPARE arm will receive a reminder to come to their appointment and to bring their action plan.
89588147|NCT02072941|No Intervention|Control|The control arm will review an easy-to-read AD. Controls will review the AD for ≥15 minutes with study staff present to answer questions and will take the AD home to complete if desired. One to three days before a primary care visit, controls will receive a reminder to come to their appointment.
89588148|NCT02100631|Experimental|PXVX0200 in Older Adults|PXVX0200 Single dose; liquid suspension after reconstitution with buffer; > 2x10^8 CFU in a liquid suspension
89588149|NCT02100631|Placebo Comparator|Placebo in Older Adults|Placebo physiological saline
89588150|NCT02100631|Other|Historical Control: Adults Aged 18-45|This arm consists of historical data from subjects who received a single dose of PXVX0200 in study PXVX-VC-200-004. The data was included in study PXVX-VC-200-005 as a comparator bridging population for the Day 11 seroconversion. NCT02094586 PubMed ID:29317118
89588151|NCT01451164|Experimental|High dose|
89588152|NCT01451164|Experimental|Mid dose|
89588153|NCT01451164|Experimental|Low dose|
89588154|NCT01451164|Placebo Comparator|Placebo|
89588155|NCT02071849|Experimental|Aortic Valve Repair|Implantation of HAART 200 Aortic Valve Annuloplasty Device for bicuspid aortic valve reconstruction
89030431|NCT04515602|Active Comparator|Part 2 Arm II (high tumor burden)|Neoadjuvant chemotherapy with 3 cycles of chemotherapy, then followed by interval debulking surgery. The maximal time interval between course 3 chemotherapy and IDS is 6 weeks. And then 3 cycles of adjuvant chemotherapy and maintenance therapy for patients with gBRCA/sBRCA mutation, CR/PR after platinum-based therapy.
89030432|NCT00517998|Experimental|Group1|Treatment will be administered in two sessions.
89030433|NCT00517998|Experimental|Group2|Treatment will be administered in a single session.
89030434|NCT00505505|Experimental|A|Insulin infusion rate titrated to maintain glycemia between 80 and 100 mg/dl
89030435|NCT00505505|Active Comparator|B|Insulin infusion rate titrated to maintain glycemia between 80 and 220 mg/dl
89030436|NCT04518605|Experimental|Low protein breakfast|Subject will eat a low protein breakfast and maintain their habitual physical activity.
89030437|NCT04518605|Experimental|High protein breakfast|Subject will eat a high protein breakfast and maintain their habitual physical activity.
89030438|NCT04518605|Experimental|Low protein breakfast and exercise training|Subject will consume a low protein breakfast (bread, jam, juice) and and participate in organized exercise-training three times per week (and maintain habitual physical activity)
89030439|NCT04518605|Experimental|High protein breakfast and exercise training|Subject will consume a high protein dairy breakfast (300 g high protein yoghurt (skyr) with oats) and and participate in organized exercise-training three times per week (and maintain habitual physical activity)
89030440|NCT00518310|Placebo Comparator|0|Placebo
89030441|NCT00518310|Active Comparator|1|Azathiprine Prednisone
89030442|NCT00518388||Focus Group + Questionnaire|Participants that are self identified as Korean, Filipino, or Vietnamese.
89030443|NCT02955407||Low back pain patients|Low back pain since more than 3 months Age: 18-65 Caucasian race
89030444|NCT02955407||Controls without low back pain|no low back ain Age: 18-65 Caucasian race
89588156|NCT02071771|Other|DACP T, Then 1DAM A|Nelfilcon A toric contact lenses worn first, with etafilcon A toric contact lenses worn second. Each product worn bilaterally on a daily wear, daily disposable basis for 10 days.
89588157|NCT02071771|Other|1DAM A, Then DACP T|Etafilcon A toric contact lenses worn first, with nelfilcon A toric contact lenses worn second. Each product worn bilaterally on a daily wear, daily disposable basis for 10 days.
89588158|NCT02071225|Experimental|Obinutuzmab + Bendamustine|Participants will receive obinutuzumab and bendamustine in 28-days cycles for a maximum of 6 cycles
89588159|NCT01450696|Active Comparator|Capecitabine + Cisplatin + Herceptin (6 mg/kg)|Participants will receive Herceptin at a loading dose of 8 mg/kg on Day 1 of Cycle 1 followed by 6 mg/kg q3w as a standard of care from Day 1 of Cycle 2 until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason (cycle length = 21 days). Participants will also receive cisplatin 80 mg/m^2 intravenously q3w plus capecitabine 800 mg/m^2 orally twice daily for 14 days q3w for up to 6 treatment cycles (Cycles 1 to 6).
89588160|NCT01450696|Experimental|Capecitabine + Cisplatin + Herceptin (10 mg/kg)|Participants will receive Herceptin at a loading dose of 8 mg/kg on Day 1 of Cycle 1 followed by 10 mg/kg q3w from Day 1 of Cycle 2 until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason (cycle length = 21 days). Participants will also receive cisplatin 80 mg/m^2 intravenously q3w plus capecitabine 800 mg/m^2 orally twice daily for 14 days q3w for up to 6 treatment cycles (Cycles 1 to 6).
89588161|NCT02070991|Experimental|Macitentan|oral tablet, 10 mg once daily.
89588162|NCT02070991|Placebo Comparator|Placebo|Matching placebo, once daily.
89588163|NCT02114515|Other|Usual Care|"Hospital usual care~Hospital usual care: Written discharge instructions provided to patients prior to hospital discharge."
89588164|NCT02114515|Experimental|Usual Care + PArTNER|"Navigator intervention: (Community health worker, peer-led telephone support line, usual care)~Hospital usual care: Written discharge instructions provided to patients prior to hospital discharge.~Community health worker: The community health worker provides social support, literacy appropriate education, and acts as a conduit between the patient and the patient's medical team~Peer-led telephone support line: The peer-led telephone support line will provide social support, peer-to-peer coaching, and facilitate communication with the patient's medical care team."
89588165|NCT01490086|Experimental|15mg RP5063 daily|
89588166|NCT01490086|Experimental|30mg RP5063 daily|
89588167|NCT01490086|Experimental|50mg RP5063 daily|
89588168|NCT01490086|Placebo Comparator|Placebo|
89588169|NCT01490086|Active Comparator|aripiprazole|aripiprazole 15 mg daily
89588170|NCT02114203|Experimental|cohort 1 PF-04447943|
89588171|NCT02114203|Experimental|cohort 2 PF-04447943|
89588172|NCT02114203|Placebo Comparator|placebo comparator|
89588173|NCT02114203|Experimental|optional cohort of PF-04447943|
89588174|NCT02113579|Experimental|KOX|"After brushing for at least one-minute using at least one-inch strip of toothpaste, rinse with water and then rinse 60 seconds with 10mL of mouth rinse, twice daily.~Fluoride Toothpaste / Crest® Cavity Protection Regular and Experimental Mouth Rinse 12027-033"
89588175|NCT02113579|Placebo Comparator|PLA|"After brushing for at least one-minute using at least one-inch strip of toothpaste, rinse with water and then rinse 60 seconds with 10mL of mouth rinse, twice daily.~Fluoride Toothpaste/Crest® Cavity Protection Regular and Placebo Mouth Rinse"
89588176|NCT01474018|No Intervention|Metformin + Insulin|5 patients to continue on usual type 2 diabetic treatment consisting of 70/30 insulin, metformin and exercise and nutrition counseling.
89588177|NCT01474018|Experimental|QR-Bromocriptine +metformin+insulin|study drug add-on the usual therapy
89209820|NCT00252499|Experimental|Rosiglitazone Arm|rosiglitazone 4 mg po bid and fenofibrate placebo 1 po qd
89588178|NCT02100475|Experimental|Insulin degludec/liraglutide + Metformin|
89588179|NCT02100475|Active Comparator|Insulin degludec/liraglutide + Insulin Aspart + Metformin|
89588180|NCT04741087|Active Comparator|AMT-101 (Dose A)|Dose A: AMT-101 Tablet
89588181|NCT04741087|Active Comparator|AMT-101 (Dose B)|Dose B: AMT-101 Tablet
89588182|NCT02113189|Experimental|Walking program with ankle brace|This group will receive bilateral off-the-shelf ankle braces as well as a customized walking program.
89588183|NCT02113189|Experimental|Individualized walking program|This group will receive a customized walking program.
89588184|NCT02113189|Experimental|Walking program with custom braces|This group will receive bilateral custom-fabricated ankle braces as well as a customized walking program.
89588185|NCT01440946|Experimental|rFIXFc Prophylaxis|"At Baseline and at Day 1, participants receive a single intravenous (IV) injection of prestudy FIX and rFIXFc, respectively, over 10 (±5) minutes at a dose of 50 IU/kg. Immediately after the last PK sampling, the first prophylactic dose of approximately 50 to 60 IU/kg will be administered in clinic as an IV injection.~Dose could be increased or decreased in increments of 10 IU/kg; increases to a maximum of 100 IU/kg and frequency of administration to a maximum of twice weekly, were allowed as indicated."
89588186|NCT01450540|Active Comparator|Group 1|REMStar auto A-Flex
89588187|NCT01450540|Experimental|Group 2|modified REMstar Auto A-Flex with AGPAP
89588188|NCT02070757|Experimental|Ceftolozane/tazobactam|Participants receive 3000 mg ceftolozane/tazobactam intravenous IV (comprising 2000 mg ceftolozane and 1000 mg tazobactam) every 8 hours for 8-14 days.
89588189|NCT02070757|Active Comparator|Meropenem|Participants receive 1000 mg meropenem IV every 8 hours for 8-14 days.
89588190|NCT04417933|Experimental|Tumor Electric Fields Treatment System|Patients have a histologically confirmed diagnosis of supratentorial glioblastoma that is recurrent. All patients will receive Tumor Electric Fields Treatment System.
89588191|NCT04417855||LDH|Group of symptomatic individuals with LDH confirmed in MRI.
89588192|NCT04417855||Control|Group of asymptomatic individuals with no LDH.
89588193|NCT02100319||Azilsartan at a dose of 20 to 40 mg, orally, once daily|Azilsartan tablets
89588194|NCT01625845|Experimental|Pentoxifylline + Standard Treatment|"Pentoxifylline: Pentoxifylline is phosphodiesterase inhibitor that interferes with proinflammatory cytokine signaling and synthesis. Participants will be instructed to take pentoxifylline 400 mg p.o. t.i.d. for 12 weeks.~Standard Treatment: Beating the Blues (BtB) is a widely used, empirically supported, computer-based, CBT program for depression designed for use in primary care clinics. BtB utilizes an interactive, multimedia format to deliver and eight 50-minute, weekly therapy sessions."
89588195|NCT01625845|Placebo Comparator|Placebo + Standard Treatment|"Placebos: Placebo pills will match the study drug for color, taste, texture, size, and smell. Participants will receive the same instructions as those randomized to pentoxifylline.~Standard Treatment: Beating the Blues (BtB) is a widely used, empirically supported, computer-based, CBT program for depression designed for use in primary care clinics. BtB utilizes an interactive, multimedia format to deliver and eight 50-minute, weekly therapy sessions."
89588196|NCT01473940|Experimental|Treatment (monoclonal antibody, chemotherapy)|"INDUCTION: Patients receive ipilimumab IV over 90 minutes in weeks 1, 4, 7, and 10 and gemcitabine hydrochloride IV over 30 minutes in weeks 1-7 and 9-11.~MAINTENANCE: Beginning in week 22, patients receive ipilimumab IV over 90 minutes once every 12 weeks and gemcitabine hydrochloride IV over 30 minutes once weekly for 3 weeks. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Treatment modifications may apply according to response."
89588197|NCT04408846|Other|Minimally invasive lumbar fusion|
89588198|NCT04408846|Other|Open posterior lumbar fusion|
89588199|NCT03026374|Experimental|intervention group|The BRBC program consists of education and group discussion, and lasted for 12 months. Women in IG attended weekly meetings lasting for 120 minutes. Education took approximately 45 minute. Qualified professionals from various disciplines were invited to provide lessons to ensure the quality of the educational sessions. The group discussion followed the presentation and began with mentors sharing their experience with the topic, followed by participant discussions regarding life changes since diagnosis (e.g., physical, emotional, social, spiritual). Each group consisted of 7-9 patients and 3 leaders (2 mentors and 1 facilitator, including a clinical psychologist, nurse clinician, or social worker). The time of group discussion varied from 45-75 minutes. This was intended to foster support among group members,both in and out of sessions.
89588200|NCT03026374|No Intervention|control group|patients from both groups were provided medical, social, or psychological care if necessary, as assessed by primary oncologists. Additionally, all patients received an educational brochure about breast cancer every 1 to 2 months, and relaxation therapy was provided to both groups to prevent demoralization from random assignment.
89588201|NCT01832727|Experimental|Cohort 180 mg 5/14 Schedule (Phase 1b)|Oprozomib 180 mg treatment once daily for 5 consecutive days bimonthly (days 1, 2, 3, 4, and 5 of a 14-day cycle) with 20 mg dexamethasone once daily on days 1, 2, 8, and 9 (referred to as the 5/14 schedule). Treatment was administered in 14-day cycles until disease progression, unacceptable toxicity, or study treatment discontinuation for any reason.
89588202|NCT01832727|Experimental|Cohort 210 mg 5/14 Schedule (Phase 1b)|"Oprozomib 210 mg treatment once daily for 5 consecutive days bimonthly (days 1, 2, 3, 4, and 5 of a 14-day cycle) with 20 mg dexamethasone once daily on days 1, 2, 8, and 9 (referred to as the 5/14 schedule). Treatment was administered in 14-day cycles until disease progression, unacceptable toxicity, or study treatment discontinuation for any reason.~This was the first cohort to enroll participants into the 5/14 schedule. The Cohort Safety Review Committee (CSRC) reviewed safety data and made dose adjustments for oprozomib in 30 mg increments for all cohorts."
89030445|NCT04519814|Experimental|all eligible patients|A total of 40 eyes in 40 consecutive patients, 22 years of age or older, with primary open-angle glaucoma (HPG + NPG), who did not reach target pressure, agree to participate in the study, and will be able to complete clinical follow-up and evaluation.
89030446|NCT00518427|Experimental|1|insulin glargine
89030447|NCT04515173|Experimental|Artificial intelligence group|On the basis of conventional drug therapy combined with psychotherapy robot psychotherapy, the corresponding intelligent psychotherapy module and intensity were recommended according to the results of intelligent psychological evaluation. Each module was set once a week, 50 minutes each time, a total of 12 times.
89030448|NCT04515173|Other|General group|The subjects in this group only received routine drug therapy and routine outpatient follow-up evaluation
89030449|NCT00518466|Experimental|treatment 1|"One 7.5 mg phentermine hydrochloride IR capsule and two 25 mg topiramate MR capsules at Hour 0 on Day 1 of Period 1.~One 7.5 mg phentermine hydrochloride IR capsule and one 25 mg topiramate MR capsule at Hour 0 on Days 1, 2, and 3 of Period 2.~One 7.5 mg phentermine hydrochloride IR capsule and two 25 mg topiramate MR capsules at Hour 0 on Days 4 - 21 of Period 2."
89588203|NCT01832727|Experimental|Cohort 150/180 mg 5/14 Schedule (Phase 1b)|Oprozomib 150 mg once daily treatment for 5 consecutive days (days 1, 2, 3, 4, and 5 of a 14-day cycle) followed by a step-up in oprozomib once daily dose to 180 mg starting in cycle 2 and moving forward. Dexamethasone 20 mg once daily was administered on days 1, 2, 8, and 9 of each 14-day cycle. Treatment was administered in 14-day cycles until disease progression, unacceptable toxicity, or study treatment discontinuation for any reason.
89588204|NCT01832727|Experimental|Cohort 210 mg 2/7 Schedule (Phase 1b)|"Oprozomib 210 mg once daily on Days 1, 2, 8, and 9 of a 14-day treatment cycle in combination with 20 mg dexamethasone once daily on Days 1, 2, 8, and 9 of a 14-day cycle. Treatment was administered in 14-day cycles until disease progression, unacceptable toxicity, or study treatment discontinuation for any reason.~This was the first cohort to enroll participants into the 2/7 schedule. The Cohort Safety Review Committee (CSRC) reviewed safety data and made dose adjustments for oprozomib in 30 mg increments for all cohorts."
89588205|NCT01832727|Experimental|Cohort 240 mg 2/7 Schedule (Phase 1b)|Oprozomib 240 mg once daily on Days 1, 2, 8, and 9 of a 14-day treatment cycle in combination with 20 mg dexamethasone once daily on Days 1, 2, 8, and 9 of a 14-day cycle. Treatment was administered in 14-day cycles until disease progression, unacceptable toxicity, or study treatment discontinuation for any reason.
89588206|NCT01832727|Experimental|Cohort 270 mg 2/7 Schedule (Phase 1b)|Oprozomib 270 mg once daily on Days 1, 2, 8, and 9 of a 14-day treatment cycle in combination with 20 mg dexamethasone once daily on Days 1, 2, 8, and 9 of a 14-day cycle. Treatment was administered in 14-day cycles until disease progression, unacceptable toxicity, or study treatment discontinuation for any reason.
89588207|NCT01832727|Experimental|Cohort 300 mg 2/7 Schedule (Phase 1b)|Oprozomib 300 mg once daily on Days 1, 2, 8, and 9 of a 14-day treatment cycle in combination with 20 mg dexamethasone once daily on Days 1, 2, 8, and 9 of a 14-day cycle. Treatment was administered in 14-day cycles until disease progression, unacceptable toxicity, or study treatment discontinuation for any reason.
89588208|NCT01832727|Experimental|Cohort 330 mg 2/7 Schedule (Phase 1b)|Oprozomib 330 mg once daily on Days 1, 2, 8, and 9 of a 14-day treatment cycle in combination with 20 mg dexamethasone once daily on Days 1, 2, 8, and 9 of a 14-day cycle. Treatment was administered in 14-day cycles until disease progression, unacceptable toxicity, or study treatment discontinuation for any reason.
89588209|NCT01832727|Experimental|Phase 2 300 mg 2/7 Schedule|The Cohort Safety Review Committee (CSRC) determined this dose as the recommended phase 2 dose (RP2D). Oprozomib 300 mg once daily on Days 1, 2, 8, and 9 of a 14-day treatment cycle in combination with 20 mg dexamethasone once daily on Days 1, 2, 8, and 9 of a 14-day cycle. Treatment was administered in 14-day cycles until disease progression, unacceptable toxicity, or study treatment discontinuation for any reason.
89588210|NCT03026296|Experimental|Participators in HLCs|Adults with high risk of non-communicable diseases (musculoskeletal disease, obesity, physical distress) about to start a 3 months structural support for lifestyle change in a Healthy Life Center (HLC) in Norway
89588211|NCT04647058|Active Comparator|Cubital tunnel release|The control group will undergo cubital tunnel release in situ. In cases of preoperative or intraoperative ulnar nerve instability, anterior transposition of the ulnar nerve will be performed.
89588212|NCT04647058|Experimental|Supercharged end-to-side (SETS) nerve transfer|The SETS group will undergo the same procedure as described above, with the addition of the SETS procedure consisting of a end-to-side transfer of the anterior interosseous nerve to the ulnar nerve motor branch. Decompression of Guyon's canal during the SETS procedure is at the discretion of the treating surgeon.
89588213|NCT01473394|Placebo Comparator|Dose-matched placebo|Participants received dose-matched placebo orally once daily for 9 weeks.
89588214|NCT01473394|Experimental|Vilazodone|Participants received vilazodone orally once daily for 9 weeks, as follows: Week 1, 10 mg once a day; Week 2, 20 mg once a day; Weeks 3 to 8, 40 mg once a day; and Week 9 (down-taper period), 20 mg once a day for 4 days, then 10 mg once a day for 3 days.
89588215|NCT04408144|Experimental|StudyGroup|Patients will receive an addition of dydrogesterone (Duphaston) to the standard treatment for luteal phase support
89588216|NCT04408144|No Intervention|Control Group|Patients will receive the standard treatment for luteal phase support without Dydrogesterone
89588217|NCT01449682|Active Comparator|Ozurdex PRN|0.7 mg intravitreal DEX implant at Visit 1 then PRN for duration of trial (48 weeks) if evidence of fluid on OCT
89588218|NCT01449682|Active Comparator|Ozurdex Q16 weeks|0.7 mg intravitreal DEX implant at Visit 1 then Q16 weeks
89588219|NCT01449526|Experimental|B&L Investigational Contact Lens|The Bausch + Lomb investigational silicone hydrogel contact lens
89588220|NCT01449526|Active Comparator|B&L PureVision Contact Lens|The Bausch + Lomb PureVision silicone hydrogel contact lens
89588221|NCT01440322|Experimental|AIR OPTIX® COLORS|Lotrafilcon B contact lenses with color worn in both eyes on a daily wear, monthly replacement basis for 3 months
89588222|NCT01440322|Active Comparator|AIR OPTIX® AQUA|Lotrafilcon B contact lenses worn in both eyes on a daily wear, monthly replacement basis for 3 months
89588223|NCT02985580|Active Comparator|Blueberry|Blueberry concentrate consumed daily for 12 weeks.
89588224|NCT02985580|Placebo Comparator|Placebo|Placebo concentrate consumed daily for 12 weeks.
89588225|NCT01832493|Experimental|Cardiac Resynchronization Therapy|Patients implanted with a cardiac resynchronization therapy device
89588226|NCT01831791|Experimental|Dutasteride Arm|Subjects will receive 1 capsule of Dutasteride 0.5 mg orally once daily for 52 weeks (12 months).
89209821|NCT00252499|Experimental|Fenofibrate Arm|micronized fenofibrate 200 mg 1 po qd and rosiglitazone placebo 1 po bid
89209822|NCT00252187|Active Comparator|B-type Natriuretic Peptide (BNP)|BNP (nesiritide) administered subcutaneously twice daily for 8 weeks at 10 mcg/kg.
89588227|NCT01857531|Experimental|Ganaxolone -- Nicotine Patch|"Pre-Quit Period:~Ganaxolone -- 400mg daily for the first 3 days, 800mg daily for the next 3 days and 1200mg daily for the remainder of the first 2 wks.~Nicotine Patches -- 21mg/24h nicotine patches applied daily during wks. 3 and 4.~Post-Quit Period:~Ganaxolone -- 1200mg daily for wk. 5, 800mg daily for 3 days, and 400mg daily for 3 days.~Nicotine Patches -- 21mg/24h for 4 wks., 14mg/24h for 1 wk., and 7mg/24h for 1 wk."
89588228|NCT02166047|Placebo Comparator|Placebo 4 Weeks (Cohort A)|Placebo tablet once a week for 4 weeks
89588229|NCT02166047|Experimental|Vesatolimod 1 mg 4 Weeks (Cohort A)|Vesatolimod 1 mg tablet once a week for 4 weeks
89209823|NCT00252187|Placebo Comparator|Placebo|Placebo self-administered subcutaneously twice daily for 8 weeks.
89588230|NCT02166047|Experimental|Vesatolimod 2 mg 4 Weeks (Cohort A)|Vesatolimod 2 mg tablet once a week for 4 weeks
89588231|NCT02166047|Experimental|Vesatolimod 4 mg 4 Weeks (Cohort A)|Vesatolimod 4 mg tablet once a week for 4 weeks
89588232|NCT02166047|Placebo Comparator|Placebo 8 Weeks (Cohort B)|Placebo tablet once a week for 8 weeks
89588233|NCT02166047|Experimental|Vesatolimod 1 mg 8 Weeks (Cohort B)|Vesatolimod 1 mg tablet once a week for 8 weeks
89588234|NCT02166047|Experimental|Vesatolimod 2 mg 8 Weeks (Cohort B)|Vesatolimod 2 mg tablet once a week for 8 weeks
89588235|NCT02166047|Experimental|Vesatolimod 4 mg 8 Weeks (Cohort B)|Vesatolimod 4 mg tablet once a week for 8 weeks
89588236|NCT02166047|Placebo Comparator|Placebo 12 Weeks (Cohort C)|Placebo tablet once a week for 12 weeks
89588237|NCT02166047|Experimental|Vesatolimod 1 mg 12 Weeks (Cohort C)|Vesatolimod 1 mg tablet once a week for 12 weeks
89588238|NCT02166047|Experimental|Vesatolimod 2 mg 12 Weeks (Cohort C)|Vesatolimod 2 mg tablet once a week for 12 weeks
89588239|NCT02166047|Experimental|Vesatolimod 4 mg 12 Weeks (Cohort C)|Vesatolimod 4 mg tablet once a week for 12 weeks
89588240|NCT01493284|Experimental|Transfemoral Access|Transfemoral Access for transcatheter aortic valve implant
89588241|NCT02165735|Experimental|patient activation training|Patient activation training involves six, 90-minute, group (8-12 person) training sessions facilitated by trained peers and training staff and one (20-30 minute) pre-visit coaching session conducted by staff. The hands on group training includes: 1) HIV education; 2) use of a handheld smart device; 3) use of an HIV electronic personal health record app that runs on the smart device; 4) identification of patients' visit need priorities and skills for communicating with their HIV provider. The pre-visit coaching includes identification patient concerns and patient behavioral rehearsal for asking about these concerns.
89588242|NCT02165735|Experimental|Usual Care|Usual care for HIV
89588243|NCT02069899|Other|Enrolled-04 Cohort|"Participants enrolled in Study NI-0501-04 (NCT01818492) will be invited to participate for long-term follow-up for 1 year either after haematopoietic stem cell transplantation (HSCT) or after the last administration of emapalumab.~In Study NI-0501-04, participants received emapalumab for 4 to 8 weeks. After the treatment period, participants could have undergone HSCT.~Participants for whom an appropriate donor was not identified by Week 8, or in a case where HSCT will be delayed for reasons unrelated to the administration of emapalumab, can continue receiving treatment with emapalumab beyond the foreseen 8 weeks in the current study (NI-0501-05, NCT02069899) at the request of the investigator, providing a favorable benefit/risk assessment of treatment is established.~The dose and timing was either carried forward from the last administered emapalumab dose as part of the parent protocol or an adjusted dose was administered, if necessary."
89588244|NCT02069899|No Intervention|Enrolled-06 Cohort|"All participants who received at least 1 dose of emapalumab and were monitored for at least 4 weeks after the last drug administration in Study NI-0501-06 (NCT03311854) will be invited to participate for long-term follow-up for 1 year after the last administration of emapalumab.~Participants will not receive emapalumab in the current study (NI-0501-05, NCT02069899)."
89588245|NCT02069899|Other|Enrolled-CU Cohort|"In exceptional cases, at the spontaneous request of a treating physician, CU treatment will be granted to the participants who had exhausted all possible treatment options and who could not be enrolled in a clinical study. All participants who receive at least 1 dose of emapalumab under CU will be invited to participate for long-term follow-up for 1 year either after HSCT or after the last administration of emapalumab.~Participants can continue treatment in the context of the current Study (NI-0501-05, NCT02069899) while stem cell donor search is ongoing, or if the investigator assesses that continuation of treatment is beneficial."
89588246|NCT01831089|Experimental|Treatment|PM01183 + paclitaxel +/- bevacizumab
89588247|NCT02112877|Experimental|VICI Stent Implantation - Feasibility|Percutaneous stent placement in the common femoral vein, external iliac vein and/or common iliac vein Veniti Vici™ Venous Stent System
89588248|NCT02112877|Experimental|VICI Stent Implantation - Pivotal|Percutaneous stent placement in the common femoral vein, external iliac vein and/or common iliac vein Veniti Vici™ Venous Stent System
88976050|NCT03938350|No Intervention|Treatment as Usual|Participants in this study arm will receive treatment as usual consisting of routine prenatal care with any mental health assessment, social work involvement or mental health service provision based on clinician referral or self-referral.
89588249|NCT02098369|Other|Usual care|Written education material (basic)
89588250|NCT02098369|Experimental|Proactive|Written education material (basic) Additional education material PELICAN-Proactive [In addition to the usual care, participants will receive educational material and a proactive telephone peer coaching program (coaches call participants)]
89588251|NCT02098369|Experimental|Reactive|Written education material (basic) Additional education material PELICAN-Reactive [In addition to the usual care, participants will receive educational material and a reactive telephone peer coaching program (participants call coaches)]
89588252|NCT02111785|Active Comparator|Burr Hole Craniostomy randomized|Group receiving burr hole craniostomy and drainage of chronic subdural hematoma
88976051|NCT03928366|Experimental|Volunteers receiving propofol and remifentanil|Volunteers receive propofol to the loss of consciousness. Then they receive remifentanil during 12 min (pain stimuli in their finger also)
88976052|NCT03772249|Experimental|Cohort A1 DCR-HBVS|Single dose, Subcutaneous injection of 0.1mg/kg of DCR-HBVS (HV)
88976053|NCT03772249|Placebo Comparator|Cohort A1 Placebo|Single dose, Subcutaneous injection of 0.1mg/kg of Placebo for DCR-HBVS (HV)
88976054|NCT03772249|Experimental|Cohort A2 DCR-HBVS|Single dose, Subcutaneous injection of 1.5mg/kg of DCR-HBVS (HV)
88976055|NCT03772249|Placebo Comparator|Cohort A2 Placebo|Single dose, Subcutaneous injection of 1.5mg/kg of Placebo for DCR-HBVS (HV)
88976056|NCT03772249|Experimental|Cohort A3 DCR-HBVS|Single dose, Subcutaneous injection of 3mg/kg of DCR-HBVS (HV)
89588253|NCT02111785|Experimental|Dexamethasone randomized|Dexamethasone, tablet, initial dose 4mg q8h, total duration 15 days
88976057|NCT03772249|Placebo Comparator|Cohort A3 Placebo|Single dose, Subcutaneous injection of 3mg/kg of Placebo for DCR-HBVS (HV)
88976058|NCT03772249|Experimental|Cohort A4 DCR-HBVS|Single dose, Subcutaneous injection of 6mg/kg of DCR-HBVS (HV)
89588254|NCT02111785|Other|Burr hole craniostomy observational|Observational cohort of patients selecting burr hole craniostomy
89588255|NCT02111785|Other|Dexamethasone observational|Observational cohort of patients treated with dexamethasone protocol
88976059|NCT03772249|Placebo Comparator|Cohort A4 Placebo|Single dose, Subcutaneous injection of 6mg/kg of Placebo for DCR-HBVS (HV)
89588256|NCT02068885|Experimental|Low carbohydrate diet|Feeding study. Composition (by proportion of calories): 20% carbohydrate, 60% fat, 20% protein
89588257|NCT02068885|Experimental|Moderate carbohydrate diet|Feeding study. Composition (by proportion of calories): 40% carbohydrate, 40% fat, 20% protein
89588258|NCT02068885|Active Comparator|High carbohydrate diet|Feeding study. Composition (by proportion of calories): 60% carbohydrate, 20% fat, 20% protein
89588259|NCT02068495||Candesartan cilexetil/Amlodipine besilate|8 milligram (mg)/2.5 mg or 8 mg/5 mg, orally, once daily
89588260|NCT02097823|Experimental|Aprepitant First, Olanzapine Second|"Will receive aprepitant (weight based dose, see below) in first cycle of chemotherapy and olanzapine (weight based dose, see below) in the second cycle of chemotherapy. All doses will be given starting 30 minutes before chemotherapy on day 1.~Olanzapine dosing:~>60kg - 10mg orally daily for 4 doses 40-59.9kg - 5mg orally daily for 4 doses 20-39.9kg - 2.5mg orally daily for 4 doses <20kg - 1.25mg orally daily for 4 doses~Aprepitant dosing:~>40kg - 125mg orally on day 1, then 80mg orally daily on days 2,3 35-39.9kg - 80mg orally daily for 3 doses 20-34.9kg - 40mg orally daily for 3 doses <20kg - 1.5-2mg/kg orally daily for 3 doses"
89588261|NCT02097823|Experimental|Olanzapine First, Aprepitant Second|"Will receive olanzapine (weight based dose, see below) in first cycle of chemotherapy and aprepitant (weight based dose, see below) in the second cycle of chemotherapy. All doses will be given starting 30 minutes before chemotherapy on day 1.~Olanzapine dosing:~>60kg - 10mg orally daily for 4 doses 40-59.9kg - 5mg orally daily for 4 doses 20-39.9kg - 2.5mg orally daily for 4 doses <20kg - 1.25mg orally daily for 4 doses~Aprepitant dosing:~>40kg - 125mg orally on day 1, then 80mg orally daily on days 2,3 35-39.9kg - 80mg orally daily for 3 doses 20-34.9kg - 40mg orally daily for 3 doses <20kg - 1.5-2mg/kg orally daily for 3 doses"
89588262|NCT01830855|Experimental|rLP2086 lot 1|
89588263|NCT01830855|Experimental|rLP2086 lot 2|
89588264|NCT01830855|Experimental|rLP2086 lot 3|
89588265|NCT01830855|Active Comparator|Control|Havrix (HAV) and Saline
89588266|NCT01857063|Experimental|Montelukast/Placebo|Participants receive montelukast 5 mg chewable tablets for 7 days during Period 1 and receive placebo chewable tablets for 7 days during Period 2. There is a 7-day washout period between Periods 1 and 2.
89588267|NCT01857063|Experimental|Placebo/Montelukast|Participants receive placebo chewable tablets for 7 days during Period 1 and receive montelukast 5 mg chewable tablets for 7 days during Period 2. There is a 7-day washout period between Periods 1 and 2.
89588268|NCT01856907|Experimental|Sitagliptin-Metformin|50 mg/1000 mg twice a day (BID)
89588269|NCT01856907|Placebo Comparator|Placebo pill|1 pill/BID for 16 weeks
89588270|NCT01856907|Active Comparator|Metformin|1000 mg BID
89588271|NCT02212457|Experimental|rMenB_0_2 Group|Subjects received two injections of Bexsero vaccine at Visit Month 0 and Visit Month 2, Havrix vaccine at Visit Month 6 and Visit Month 12 and saline placebo at Visit Month 1.
89588272|NCT02212457|Experimental|ABCWY_ 0_2 Group|Subjects received MenABCWY vaccine at Visit Month 0 and Visit Month 2, Havrix vaccine at Visit Month 6 and Visit Month 12 and saline placebo at Visit Month 1.
89588273|NCT02212457|Experimental|ABCWY_0_1 Group|Subjects received MenABCWY vaccine at Visit Month 0 and Visit Month 1, Havrix vaccine at Visit Month 2 and Visit Month 12 and saline placebo at Visit Month 6.
89588274|NCT02212457|Experimental|ABCWY_0_6 Group|Subjects received MenABCWY vaccine at Visit Month 0 and Visit Month 6, Havrix vaccine at Visit Month 1 and Visit Month 12 and saline placebo at Visit Month 2.
89588275|NCT02212457|Experimental|ABCWY_0_11 Group|Subjects received MenABCWY vaccine at Visit Month 1 and Visit Month 12, Havrix vaccine at Visit Month 0 and Visit Month 6 and saline placebo at Visit Month 2.
89588276|NCT02212457|Experimental|ABCWY_0_2_6 Group|Subjects received MenABCWY vaccine at Visit Month 0, Visit Month 2 and Visit Month 6 and Havrix vaccine at Visit Month 1 and Visit Month 12.
89588277|NCT02097745|Experimental|MabThera/Rituxan|
88976060|NCT03772249|Experimental|Cohort A5 DCR-HBVS|Single dose, Subcutaneous injection of 12mg/kg of DCR-HBVS (HV)
89588278|NCT02111083|Active Comparator|Insulin Lispro A|Insulin Lispro A 20 units (U) of strength 200 units per milliliter (U/mL) (U-200)administered subcutaneously (SC) once in two of four study periods.(Two doses of test [T]).
89588279|NCT02111083|Experimental|Insulin Lispro B|Insulin Lispro B 20 units (U) of strength 100 U/mL (U-100) administered SC once in two of four study periods.(Two doses of reference [R]).
89588280|NCT01629563|Experimental|Ulipristal acetate (PGL4001) 5mg|All subjects will be asked to take a 150mg size tablet (PGL4001 5mg or matching placebo: placebo 5) orally daily for repeated periods 84 days. The first treatment course will start on the first 4 days of menstruation and will be orally administered, once daily (1 tablet of 150mg size), for 84 days. The following three treatment courses should be started in the first two days of a menstrual period.
89588281|NCT01629563|Experimental|Ulipristal acetate (PGL4001) 10mg|All subjects will be asked to take a 300mg size tablet (PGL4001 10mg or matching placebo: placebo 10 ) orally daily for repeated periods 84 days. The first treatment course will start on the first 4 days of menstruation and will be orally administered, once daily (1 tablet of 300mg size), for 84 days. The following three treatment courses should be started in the first two days of a menstrual period.
89588282|NCT02097277|Placebo Comparator|Treatment A: Placebo (Matching with BMS-986036 - Daily)|Placebo (Matching with BMS-986036) 0 mg subcutaneous injection once daily for 12 weeks
89588283|NCT02097277|Experimental|Arm 2: Treatment B: BMS-986036 (1 mg Daily)|BMS-986036 1 mg subcutaneous injection once daily for 12 weeks
89588284|NCT02097277|Experimental|Treatment C: BMS-986036 (5 mg Daily)|BMS-986036 5 mg subcutaneous injection once daily for 12 weeks
89588285|NCT02097277|Experimental|Treatment D: BMS-986036 (20 mg Daily)|BMS-986036 20 mg subcutaneous injection once daily for 12 weeks
89030450|NCT00518466|Experimental|treatment 2|"Two 7.5 mg phentermine hydrochloride IR capsules and four 25 mg topiramate MR capsules at Hour 0 on Day 1 of Period 1.~One 7.5 mg phentermine hydrochloride IR capsule and one 25 mg topiramate MR capsule at Hour 0 on Days 1, 2, and 3 of Period 2.~One 7.5 mg phentermine hydrochloride IR capsules and two 25 mg topiramate MR capsules at Hour 0 on Days 4, 5, and 6 of Period 2.~Two 7.5 mg phentermine hydrochloride IR capsules (Cardinal) and three 25 mg topiramate MR capsules at Hour 0 on Days 7, 8, and 9 of Period 2.~Two 7.5 mg phentermine hydrochloride IR capsules and four 25 mg topiramate MR capsules at Hour 0 on Days 10 - 21 of Period 2."
89588286|NCT02097277|Experimental|Treatment E: BMS-986036 (20 mg Weekly)|"BMS-986036 20 mg subcutaneous injection once weekly (on Day 1 of each week) for 12 weeks~Followed by Placebo (Matching with BMS-986036) 0 mg subcutaneous injection on Days 2-7 of each week for 12 weeks"
89588287|NCT02212379|Experimental|raltegravir and etravirine|
89588288|NCT02110693|Other|Interviewer and tablet administration|All participants were administered the TAPS Tool via interviewer and tablet computer self-administration in the same session.
89588289|NCT02212301|Active Comparator|senofilcon A / lotrafilcon B|Subjects were randomized to one of two lens wear sequences. Subjects randomized to this sequence first wore the senofilcon A contact lens and then wore the lotrafilcon B contact lens.
89588290|NCT02212301|Active Comparator|lotrafilon B/ senofilcon A|Subjects were randomized to one of two lens wear sequences. Subjects randomized to this sequence first wore the lotrafilcon B contact lens and then wore the senofilcon A contact lens
89588291|NCT02211209|Placebo Comparator|Placebo|Volanesorsen-matching placebo administered subcutaneously once-weekly for 52 weeks.
89588292|NCT02211209|Experimental|Volanesorsen|Volanesorsen 300 mg administered subcutaneously once-weekly for 52 weeks.
89588293|NCT02187809|Experimental|Clobazam|A maximum of 2.0 mg/kg/day (maximum 80 mg/day) twice daily (BID); clobazam oral suspension (2.5 mg/mL) or clobazam scored tablets (10 mg), orally
89588294|NCT04750811||Small Bowel obstruction|Patients admitted with a diagnosis of small bowel obstruction at 1 of the 6 participating centres
89588295|NCT02187029|Experimental|PF-06743649 dose level 1 (Cohort 1)|
89588296|NCT02187029|Placebo Comparator|Placebo for PF-06743649 (Cohort 1)|
89588297|NCT02187029|Experimental|PF-06743649 dose level 2 (Cohort 2)|
89588298|NCT02187029|Placebo Comparator|Placebo for PF-06743649 (Cohort 2)|
89030451|NCT00518466|Experimental|treatment 3|"Two 7.5 mg phentermine hydrochloride IR capsules and four 25 mg topiramate MR capsules at Hour 0 on Day 1 of Period 1.~One 7.5 mg phentermine hydrochloride IR capsule and one 25 mg topiramate MR capsule at Hour 0 on Days 1, 2, and 3 of Period 2.~Two 7.5 mg phentermine hydrochloride IR capsules and two 25 mg topiramate MR capsule at Hour 0 on Days 4, 5, and 6 of Period 2.~Two 7.5 mg phentermine hydrochloride IR capsules and three 25 mg topiramate MR capsules at Hour 0 on Days 7, 8, and 9 of Period 2.~Two 7.5 mg phentermine hydrochloride IR capsules and four 25 mg topiramate MR capsules at Hour 0 on Days 10 - 21 of Period 2."
89209824|NCT00572910|Experimental|V710 - Group 1|V710 (60 mcg without MAA) on Day 1 and Day 28 followed by third dose of V710 or placebo on Day 180.
89209825|NCT00572910|Experimental|V710 - Group 2|V710 (60 mcg without MAA) on Day 1 and Placebo on Day 28 followed by third dose of V710 or placebo on Day 180.
89209826|NCT00572910|Experimental|V710 - Group 3|V710 (60 mcg with MAA) on Day 1 and Day 28 followed by third dose of V710 or placebo on Day 180.
89588299|NCT04750655|Placebo Comparator|Intraoperative antibiotics (Abx) only; no postoperative topical antibiotics|intraoperative/ intracameral antibiotic (moxifloxacin) only; no postoperative topical antibiotic drops
89588300|NCT04750655|Active Comparator|Intraoperative antibiotics (Abx); Postoperative topical antibiotics four times a day for 1 week|intraoperative/ intracameral antibiotic (moxifloxacin); postoperative topical antibiotic drops four times a day for 1 week
89588301|NCT04750655|Active Comparator|Intraoperative antibiotics (Abx); Postoperative topical antibiotics once a day for 1 week|intraoperative/ intracameral antibiotic (moxifloxacin); postoperative topical antibiotic drops once a day for 1 week
89588302|NCT02162771|Experimental|CT-P10|"Patient treated with CT-P10 (375 mg/m2 IV) in combination with cyclophosphamide (750 mg/m2 IV), vincristine (1.4 mg/m2 [max 2 mg] IV), and prednisone 40 mg/m2 orally) up to 8 cycles every 3 weeks during the Core Study Period.~Patients having responses during Core Study Period treated with CT-P10 (375 mg/m2 IV) monotherapy up to 12 cycles every 2 months during the Maintenance Study Period."
89588303|NCT02162771|Active Comparator|Rituxan|"Patient treated with Rituxan (375 mg/m2 IV) in combination with cyclophosphamide (750 mg/m2 IV), vincristine (1.4 mg/m2 [max 2 mg] IV), and prednisone 40 mg/m2 orally) up to 8 cycles every 3 weeks during the Core Study Period.~Patients having responses during Core Study Period treated with Rituxan (375 mg/m2 IV) monotherapy up to 12 cycles every 2 months during the Maintenance Study Period."
89588304|NCT02161757|Experimental|Tralokinumab Dose Regimen 1|Tralokinumab subcutaneous injection
89588305|NCT02161757|Placebo Comparator|Placebo Dose Regimen 1|Placebo subcutaneous injection
89588306|NCT02161757|Experimental|Tralokinumab Dose Regimen 2|Tralokinumab subcutaneous injection
89588307|NCT02161757|Placebo Comparator|Placebo Dose Regimen 2|Placebo subcutaneous injection
89588308|NCT02160977|Experimental|QS-TKA|patients underwent minimally invasive surgery quadriceps sparing total knee arthroplasty (MIS-QS TKA)
89588309|NCT02160977|Active Comparator|MIS-TKA|patients underwent minimally invasive surgery total knee arthroplasty (MIS TKA)
89588310|NCT02160899|Placebo Comparator|Cohort A: Placebo|Participants will receive placebo (normal saline) subcutaneously on Days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78.
89588311|NCT02160899|Experimental|Cohort A: ISIS-APO(a)Rx < 2000 mg|Participants will receive ISIS-APO(a)Rx subcutaneously: 100 mg on Days 1, 8, 15, and 22; 200 mg on Days 29, 36, 43, and 50 unless down-titrated; and 300 mg on Days 57, 64, 71, and 78 unless down-titrated.
89588312|NCT02160899|Experimental|Cohort A: ISIS-APO(a)Rx >= 2000 mg|Participants will receive ISIS-APO(a)Rx subcutaneously: 100 mg on Days 1, 8, 15, and 22; 200 mg on Days 29, 36, 43, and 50 unless down-titrated; and 300 mg on Days 57, 64, 71, and 78 unless down-titrated.
89588313|NCT02160899|Placebo Comparator|Cohort B: Placebo|Participants will receive placebo (normal saline) subcutaneously on Days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78.
89588314|NCT02160899|Experimental|Cohort B: ISIS-APO(a)Rx < 2000 mg|Participants will receive ISIS-APO(a)Rx subcutaneously: 100 mg on Days 1, 8, 15, and 22; 200 mg on Days 29, 36, 43, and 50 unless down-titrated; and 300 mg on Days 57, 64, 71, and 78 unless down-titrated.
89588315|NCT02160899|Experimental|Cohort B: ISIS-APO(a)Rx >= 2000 mg|Participants will receive ISIS-APO(a)Rx subcutaneously: 100 mg on Days 1, 8, 15, and 22; 200 mg on Days 29, 36, 43, and 50 unless down-titrated; and 300 mg on Days 57, 64, 71, and 78 unless down-titrated.
89588316|NCT02160041|Experimental|BGJ398|BGJ398 was dosed on a flat scale of 125 mg (e.g., 1 x 100 mg and 1 x 25 mg capsules) once daily for the first 21 days of the 28-day cycle (3 weeks on, 1 week off in a cycle). A complete treatment cycle is defined as 28 days.
89588317|NCT02186873|Experimental|Treatment Group 1: Placebo then Golimumab|Participants will receive intravenous infusions of placebo at Weeks 0, 4 and 12. At Week 16, all participants receiving placebo will begin receiving intravenous infusions of golimumab 2 milligram per kilogram (mg/kg) at Weeks 16, 20 and thereafter every 8 weeks up to Week 52.
89588318|NCT02186873|Experimental|Treatment Group 2: Golimumab|Participants will receive intravenous infusions of golimumab 2 mg/kg at Weeks 0, 4 and thereafter every 8 weeks up to Week 52. At Week 16, participants will receive a placebo infusion to maintain the blind.
89588319|NCT02096263|Experimental|Infanrix hexa Group|Subjects between, and including, 6 and 12 weeks of age at the time of the vaccination received, in the Primary Phase of the study, 3 doses of Infanrix hexa (lot A, lot B or lot C as per the group allocation) co-administered with Prevnar13 at 2, 4 and 6 months of age and Rotarix at 2 and 4 months of age. The injectable vaccines were administered by intramuscular injection in the anterolateral thigh, while Rotarix was administered orally. Subjects received a booster dose of Infanrix and Hiberix at 15-18 months of age by intramuscular injection in the anterolateral thigh.
89588320|NCT02096263|Active Comparator|Pediarix Group|Subjects between, and including, 6 and 12 weeks of age at the time of the vaccination received, in the Primary Phase of the study, 3 doses of Pediarix and ActHIB co-administered with Prevnar13 at 2, 4 and 6 months of age and Rotarix at 2 and 4 months of age. The injectable vaccines were administered by intramuscular injection in the anterolateral thigh, while Rotarix was administered orally. Subjects received a booster dose of Infanrix and ActHIB at 15-18 months of age by intramuscular injection in the anterolateral thigh.
89588321|NCT02096263|Active Comparator|Pentacel Group|Subjects between, and including, 6 and 12 weeks of age at the time of the vaccination received, in the Primary Phase of the study, 3 doses of Pentacel and Engerix co-administered with Prevnar13 at 2, 4 and 6 months of age and Rotarix at 2 and 4 months of age. The injectable vaccines were administered by intramuscular injection in the anterolateral thigh, while Rotarix was administered orally. Subjects received a booster dose of Pentacel at 15-18 months of age by intramuscular injection in the anterolateral thigh.
89588322|NCT01830543|Experimental|rivaroxaban 2.5 mg twice daily|rivaroxaban 2.5 mg tablet twice daily plus low-dose aspirin (ASA) 75 to 100 mg once daily and clopidogrel 75 mg tablet once daily (or prasugrel 10 mg tablet once daily or ticagrelor 90 mg tablet twice daily) followed by rivaroxaban 15 mg tablet (or 10 mg for subjects with moderate renal impairment) once daily plus low-dose ASA for 12 months
89588323|NCT01830543|Experimental|vitamin K antagonist (VKA)|dose-adjusted vitamin K antagonist (VKA) once daily (target International Normalized Ratio (INR) 2.0 to 3.0) plus low-dose ASA, 75 to 100 mg per day, and clopidogrel 75 mg once daily (or prasugrel 10 mg tablet once daily or ticagrelor 90 mg tablet twice daily) followed by dose-adjusted VKA once daily (target INR 2.0 to 3.0 or 2.0 to 2.5 at the investigator discretion) plus low-dose ASA for 12 months
89588324|NCT01830543|Experimental|rivaroxaban 15 mg once daily|rivaroxaban 15 mg (or 10 mg for subjects with moderate renal impairment) once daily plus clopidogrel 75 mg tablet once daily (or prasugrel 10 mg tablet once daily or ticagrelor 90 mg tablet twice daily) for 12 months
89588325|NCT02109445|Experimental|Phase 1|PF-03084014 in combination with gemcitabine and nab-paclitaxel
89588326|NCT02109445|Experimental|Phase 2 Arm A|PF-03084014 in combination with gemcitabine and nab-paclitaxel
89588327|NCT02109445|Active Comparator|Phase 2 Arm B|Gemcitabine plus nab-Paclitaxel
89588328|NCT02109133|Experimental|Deep neuromuscular blockade|Deep neuromuscular blockade
89588329|NCT02109133|Active Comparator|moderate neuromuscular blockade|moderate neuromuscular blockade
89588330|NCT01623271|Experimental|CRPS I Pain Subjects|"This is an open label study that involves taking Gralise pills (gastic-retentive gabapentin) for 8 weeks.~Day 1-15: Titration phase- titrate Gralise from 300 mg/day to 1800 mg/day Day 16-42: Maintenance phase- maintain the dose of 1800 mg/day Day 43-56: Taper phase- taper the Gralise from 100 mg/day to 300 mg/day"
89588331|NCT01856673|Experimental|ARM 1: Component-Based Intervention|Common Elements Treatment Approach (CETA) only
89588332|NCT01856673|Experimental|ARM 2: Community Group Therapy|Narrative Community Group Therapy (NCGT) only
89588333|NCT01856673|Other|ARM 3: Standby group|Standby group without intervention, but under monthly monitoring.
89588334|NCT02095951|Experimental|Pre-emptive Ethanol Lock Therapy Group|Participants receive ethanol lock before blood cultures grow germ
89588335|NCT02095951|Active Comparator|Standard Ethanol Lock Therapy Group|Participants receive ethanol lock if and only after blood cultures grow germ
89588336|NCT02095873|Experimental|Glo1-inducer then placebo|Glyoxalase 1 Inducer (8 weeks), then washout (6 weeks), then Placebo (8 weeks).
89588337|NCT02095873|Experimental|Placebo then Glo1-inducer|Placebo (8 weeks), then washout (6 weeks), then Glyoxalase 1 Inducer (8 weeks).
89588338|NCT02094937|Experimental|Arm 1 FF/VI 100/25 mcg|Subjects will receive Fluticasone Furoate/Vilanterol 100/25 mcg once-daily via a dry powder inhaler for 8 weeks in the open-label treatment period.
89588339|NCT02094937|Experimental|Arm 2 FF 100 mcg|Subjects will receive Fluticasone Propionate matching placebo twice-daily (morning and evening) and Fluticasone Furoate 100 mcg once daily in the evening, via a dry powder inhaler for 12 weeks in the double-blind treatment period
89588340|NCT02094937|Experimental|Arm 3 FP 250 mcg|Subjects will receive Fluticasone Propionate 250 mcg twice-daily (morning and evening) and Fluticasone Furoate matching placebo once daily in the evening, via a dry powder inhaler for 12 weeks in the double-blind treatment period
89588341|NCT02094937|Experimental|Arm 4 FP 100 mcg|Subjects will receive Fluticasone Propionate 100 mcg twice-daily (morning and evening) and Fluticasone Furoate matching placebo once daily in the evening, via a dry powder inhaler for 12 weeks in the double-blind treatment period
89588342|NCT04724629|Experimental|IL-17 inhibitor (Ixekizumab)|Patients will receive study medication Ixekizumab 80 mg per week, (SC) once a week for 4 weeks or until discharge.
89588343|NCT04724629|Experimental|IL-2 (Aldesleukin)|1.5 million IU per day (SC) for 7 days or until discharge. Patients will receive study medication Aldesleukin 1.5 million IU per day (SC), for 7 days or until discharge.
89588344|NCT04724629|Experimental|Indirect IL-6 inhibitor (Colchicine)|Patients will receive study medication colchicine 0.5 mg every 8 hours for 3 days (PO), followed by 4 weeks (+/-7 days) 0.5 mg twice daily. If a dose is missed, it should not be replaced.
89209827|NCT00572910|Experimental|V710 - Group 4|V710 (60 mcg with MAA) on Day 1 and Placebo on Day 28 followed by third dose of V710 or placebo on Day 180.
89588345|NCT04724629|Active Comparator|Standard of care|Standard treatment, supplementation of O2 ventilation + standard treatment of the institution, which may include Dexamethasone according to the institutional protocol.
89588346|NCT04723537|Experimental|Part A: Upamostat 200 mg|Each day participants will receive a single 200 mg dose of upamostat along with a single matching placebo, for a total of 14 days.
89588347|NCT04723537|Experimental|Part A: Upamostat 400 mg|Each day participants will receive two 200 mg doses of upamostat, for a total of 14 days.
89588348|NCT04723537|Placebo Comparator|Part A: Placebo|Each day participants will receive two matching placebos, for a total of 14 days.
89588349|NCT04723537|Experimental|Part B: Upamostat|Based on dose selected from Part A, each day participants will receive EITHER a single 200 mg dose of upamostat OR two 200 mg doses of upamostat, for a total of 14 days.
89588350|NCT04723537|Placebo Comparator|Part B: Placebo|Based on dose selected from Part A, each day participants will receive EITHER a single matching placebo OR two matching placebos, for a total of 14 days.
89588351|NCT04183465|Active Comparator|Health Education|All patients randomized to health education during the inclusion visit are managed according to current guidelines and as follows. Quality of life, functional capacity and home physical activity are assessed by proper tools.
89588352|NCT04183465|Experimental|Multi-domain lifestyle intervention|All patients randomized to experimental arm will receive diet counselling, aggressive control of CV risk factors, smoke cessation program and exercise training. The physical activity (PA) intervention will start the program with a supervised PA session immediately after the inclusion visit. Quality of life, functional capacity and daily activities will be assessed by proper tools. The program provides 6 supervised PA sessions (30, 60, 90, 180, 270 and 360 days after hospital discharge [T0]). At the end of each supervised session, calisthenics exercises derived from Otago Exercise Program are prescribed.
89588353|NCT02093923|Experimental|DX-2930, Cohort 1|Participants will receive 30 milligram (mg) dose of DX-2930 subcutaneous (SC) injection once and followed by the second dose after 2 week into the upper arm.
89588354|NCT02093923|Experimental|DX-2930, Cohort 2|Participants will receive 100 mg dose of DX-2930 SC injection once and followed by the second dose after 2 week into the upper arm.
89588355|NCT02093923|Experimental|DX-2930, Cohort 3|Participants will receive 300 mg dose of DX-2930 SC injection once and followed by the second dose after 2 week into the upper arm.
89588356|NCT02093923|Experimental|DX-2930, Cohort 4|Participants will receive 400 mg dose of DX-2930 subcutaneous (SC) injection once and followed by the second dose after 2 week into the upper arm.
89588357|NCT02093923|Placebo Comparator|Placebo|Participants will receive placebo matched to 30, 100, 300 and 400 mg dose of DX-2930 SC injection once and followed by the second dose after 2 week into the upper arm.
89588358|NCT02186561|Experimental|Pipeline™ Embolization Device|treatment with Pipeline™ Embolization Device
89588359|NCT02066467||Heart failure patients|"Subjects with art failure who receive stable optimal pharmacologic therapy~Moderate to severe heart failure (NYHA Class III-IV) with ejection fraction (EF) ≤ 35% and QRS duration ≥ 120 ms~Left bundle branch block (LBBB) with QRS duration ≥ 130 ms, EF ≤ 30%, and mild (NYHA Class II) ischemic or non-ischemic heart failure or asymptomatic (NYHA Class I) ischemic heart failure.~The study is collecting observational data on regular CRT-D device implants with special focus on the left ventricular ACUITY X4® Lead Family' ."
89588360|NCT02186171|Experimental|Romosozumab|Participants received 210 mg romosozumab administered by subcutaneous injection once a month for 12 months.
89588361|NCT02186171|Placebo Comparator|Placebo|Participants received placebo subcutaneous injections once a month for 12 months.
89588362|NCT02186015|Experimental|Cholecalciferol|All participants will receive 50,000 IU weekly supplementation of cholecalciferol for 8 weeks.
89588363|NCT02186015|No Intervention|Vitamin D sufficient|All participants were ineligible for the intervention due to sufficient serum 25(OH)D levels at screening/baseline.
89588364|NCT02066389|Placebo Comparator|Placebo|Participants received placebo capsules twice daily for 12 weeks.
88976061|NCT03772249|Placebo Comparator|Cohort A5 Placebo|Single dose, Subcutaneous injection of 12mg/kg of Placebo for DCR-HBVS (HV)
88976062|NCT03772249|Experimental|Cohort B DCR-HBVS|Single dose, Subcutaneous injection of 3mg/kg of for DCR-HBVS (NUC naïve, CHB)
88976063|NCT03772249|Placebo Comparator|Cohort B Placebo|Single dose, Subcutaneous injection of 3mg/kg of Placebo for DCR-HBVS (NUC naïve, CHB)
88976064|NCT03772249|Experimental|Cohort C1 DCR-HBVS|4 doses- Subcutaneous injection of 1.5mg/kg of DCR-HBVS administered every 28 days (NUC experienced, CHB)
88976065|NCT03772249|Placebo Comparator|Cohort C1 Placebo|4 doses- Subcutaneous injection of 1.5mg/kg of Placebo for DCR-HBVS administered every 28 days (NUC experienced, CHB)
88976066|NCT03772249|Experimental|Cohort C2 DCR-HBVS|4 doses- Subcutaneous injection of 3mg/kg of DCR-HBVS administered every 28 days (NUC experienced, CHB)
88976067|NCT03772249|Placebo Comparator|Cohort C2 Placebo|4 doses- Subcutaneous injection of 3mg/kg of Placebo for DCR-HBVS administered every 28 days (NUC experienced, CHB)
88976068|NCT03772249|Experimental|Cohort C3 DCR-HBVS|4 doses- Subcutaneous injection of 6mg/kg of DCR-HBVS administered every 28 days (NUC experienced, CHB)
88976069|NCT03772249|Placebo Comparator|Cohort C3 Placebo|4 doses- Subcutaneous injection of 6mg/kg of Placebo for DCR-HBVS administered every 28 days (NUC experienced, CHB)
88976070|NCT03772249|Experimental|Cohort 4C DCR-HBVS|"1 dose- Subcutaneous injection of 100mg (NUC experienced, CHB)~1 dose- Subcutaneous injection of 200mg (NUC experienced, CHB)~1 dose- Subcutaneous injection of 400mg (NUC experienced, CHB)"
88976071|NCT03772249|Experimental|Cohort 5C1 DCR-HBVS|4 doses- Subcutaneous injection of 200mg administered every 4 weeks (NUC experienced, CHB)
89588365|NCT02066389|Experimental|Upadacitinib 3 mg BID|Participants received 3 mg upadacitinib twice daily (BID) for 12 weeks.
89588366|NCT02066389|Experimental|Upadacitinib 6 mg BID|Participants received 6 mg upadacitinib twice daily (BID) for 12 weeks.
89588367|NCT02066389|Experimental|Upadacitinib 12 mg BID|Participants received 12 mg upadacitinib twice daily (BID) for 12 weeks.
89588368|NCT02066389|Experimental|Upadacitinib 18 mg BID|Participants received 18 mg upadacitinib twice daily (BID) for 12 weeks.
89588369|NCT02066389|Experimental|Upadacitinib 24 mg QD|Participants received 24 mg upadacitinib once daily (QD) for 12 weeks.
89588370|NCT02106403|Experimental|Prototype disinfectant spray formulation|0.13% w/w Benzalkonium Chloride (BAC) and 1% Menthone Glycerin Acetal (MGA). After wounding, the product will be held approximately 10 cm above the wounding area, and sprayed twice towards the wound
89588371|NCT02106403|Active Comparator|Reference product|0.13% w/w BAC. After wounding, the product will be held approximately 10 cm above the wounding area, and sprayed twice towards the wound
89588372|NCT02106403|Placebo Comparator|Negative control|0.9% w/v sodium chloride solution. After wounding, the product will be held approximately 10 cm above the wounding area, and sprayed twice towards the wound
89588373|NCT02133131|Experimental|GT1:NC Grazoprevir/Elbasvir+SOF 4wk|Participants took grazoprevir/elbasvir (100mg/50mg) FDC with SOF 400mg once daily (q.d.) by mouth for 4 weeks (n=30 planned).
89588374|NCT02133131|Experimental|GT1:NC Grazoprevir/Elbasvir+SOF 6wk|Participants took grazoprevir/elbasvir (100mg/50mg) FDC + SOF 400mg q.d. by mouth for 6 weeks (n=30 planned).
89588375|NCT02133131|Experimental|GT1:C Grazoprevir/Elbasvir+SOF 6wk|Participants took grazoprevir/elbasvir (100mg/50mg) FDC + SOF 400mg q.d. by mouth for 6 weeks (n=20 planned).
89588376|NCT02133131|Experimental|GT1:C Grazoprevir/Elbasvir+SOF 8wk|Participants took grazoprevir/elbasvir (100mg/50mg) FDC + SOF 400mg q.d. by mouth for 8 weeks (n=20 planned).
89588377|NCT02133131|Experimental|GT3:NC Grazoprevir/Elbasvir+SOF 8wk|Participants took grazoprevir/elbasvir (100mg/50mg) FDC + SOF 400mg q.d. by mouth for 8 weeks (n=15 planned).
89588378|NCT02133131|Experimental|GT3:NC Grazoprevir/Elbasvir+SOF 12wk|Participants took grazoprevir/elbasvir (100mg/50mg) FDC + SOF 400mg q.d. by mouth for 12 weeks (n=15 planned).
89588379|NCT02133131|Experimental|GT3:C Grazoprevir/Elbasvir+SOF 12wk|Participants took grazoprevir/elbasvir (100mg/50mg) FDC + SOF 400mg q.d. by mouth for 12 weeks (n=10 planned).
89588380|NCT02106325|Experimental|Ketamine|IV Ketamine .25mg/kg
89588381|NCT02106325|Placebo Comparator|Diphenhydramine|25mg Diphenhydramine
89588382|NCT01625689|Experimental|SIIL LAIV|SII LAIV is a live, trivalent seasonal influenza vaccine. The viral strains in seasonal trivalent influenza vaccine (human, live attenuated) are antigenically similar to A/California/7/2009 (H1N1), A/Perth/16/2009 (H3N2) and B/Brisbane/60/2008 Type B, as per the WHO recommended strains for the Northern hemisphere 2011-12 influenza season
89588383|NCT01625689|Placebo Comparator|Placebo|Placebo identical in appearance to experimental vaccine.
89588384|NCT02184611|Experimental|Umeclidinium bromide|Subjects meeting the eligibility criteria will complete a 7 to 14 day run-in period and will be randomized to receive UMEC Inhalation Powder 62.5 mcg OD over a period of 24 weeks
89588385|NCT02184611|Placebo Comparator|Placebo|Subjects meeting the eligibility criteria will complete a 7 to 14 day run-in period and will be randomized to receive matching placebo of UMEC Inhalation Powder OD over a period of 24 weeks
89588386|NCT02066311|Experimental|nelfinavir|Nelfinavir tablets will be taken by oral administration, 750mg (three 250 mg tablets) three times a day
89588387|NCT02184455|Experimental|DermGEN Decellularized Dermal Matrix|DermGEN is a product created by a patented process that decellularizes and sterilizes donated human tissue.
89588388|NCT02184143|Experimental|CBPT intervention|CBPT program consisting of weekly phone calls.
89588389|NCT02184143|Active Comparator|Education intervention|Education program consisting of weekly phone calls.
89588390|NCT01625611|Experimental|Naltrexone|
89209828|NCT00572910|Experimental|V710 - Group 5|V710 (90 mcg with MAA) on Day 1 and Day 28 followed by third dose of V710 or placebo on Day 180.
89588391|NCT02159807|Active Comparator|1.25 mg Bupivacaine|1.25mg of bupivacaine dose with 20 mcg of fentanyl was injected in the spinal portion of the anesthetic
89588392|NCT02159807|Active Comparator|1.66 mg Bupivacaine|1.66mg of bupivacaine dose with 20 mcg of fentanyl was injected in the spinal portion of the anesthetic
89588393|NCT02159807|Active Comparator|2.5 mg Bupivacaine|2.5mg of bupivacaine dose with 20 mcg of fentanyl was injected in the spinal portion of the anesthetic
89588394|NCT02066233|Active Comparator|Subjects with Barrett's Esophagus|All subjects will receive transnasal endoscopy (EG Scan II) followed by standard endoscopy.
89588395|NCT02066233|Active Comparator|Subjects with Reflux and/or Heartburn|All subjects will receive EG Scan II (transnasal endoscopy) followed by standard endoscopy.
89588396|NCT04755491||Chloride transfer by continuous veno-venous hemofiltration|Chloride transfer over 24h of continuous veno-venous hemofiltration in mechanically ventilated ICU patients presenting with stage III AKI according to Kidney Disease: Improving Global Outcome (KDIGO) classification. Chloride concentrations will be measured in the serum, the urine, and the effluent of included patients every 4 to 6h from inclusion to H24.
89588397|NCT04755491||Chloride transfer by continuous veno-venous hemodialysis|Chloride transfer over 24h of continuous veno-venous hemodialysis in mechanically ventilated ICU patients presenting with stage III AKI according to Kidney Disease: Improving Global Outcome (KDIGO) classification. Chloride concentrations will be measured in the serum, the urine, and the effluent of included patients every 4 to 6h from inclusion to H24.
89588398|NCT04755491||Chloride transfer by continuous veno-venous hemodiafiltration|Chloride transfer over 24h of continuous veno-venous hemodiafiltration in mechanically ventilated ICU patients presenting with stage III AKI according to Kidney Disease: Improving Global Outcome (KDIGO) classification. Chloride concentrations will be measured in the serum, the urine, and the effluent of included patients every 4 to 6h from inclusion to H24.
89588399|NCT02159729|Placebo Comparator|Placebo|Participants treated with placebo in previous ATX-101 studies
88976072|NCT03772249|Experimental|Cohort 5C2 DCR-HBVS|2 doses- Subcutaneous injection of 200mg administered every 8 weeks (NUC experienced, CHB)
88976073|NCT03772249|Experimental|Cohort 5C3 DCR-HBVS|2 doses- Subcutaneous injection of 400mg administered every 12 weeks (NUC experienced, CHB)
88976074|NCT04706104||Propofol-Ketamine|2-3 mg/kg propofol and 1-2 mg/kg ketamine will be used for anesthesia induction
88976075|NCT04706104||Midazolam-Fentanyl|0.15 mg/kg midazolam and 10-15 mcg/kg fentanyl will be used for anesthesia induction
88976076|NCT03576157|Experimental|Kilkari|Pregnant and postpartum women randomized to the Kilkari arm will receive health information messages over their mobile phone during pregnancy and up to 1 year postpartum.
88976077|NCT03576157|No Intervention|Comparison|Existing standard of care; no new health messages
89209829|NCT00572910|Placebo Comparator|Group 6|Placebo on Day 1, 28 and 180.
89209830|NCT00163657|Active Comparator|tacrolimus and cyclosporine|immunosuppressant treatment regimens the intervention is antirejection treatment with the above labeled drugs tacrolimus and cyclosporine
89209831|NCT00163657|Active Comparator|MMF, tacrolimus and cyclosporine|immunosuppressant treatment regimensthe intervention is antirejection treatment with the above labeled drugs MMF tacrolimus and cyclosporine
89209832|NCT00163657|Active Comparator|daclizumub, MMFand tacrolimus|immunosuppressant treatment regimens
89209833|NCT03971149|Experimental|Behavorial intervention|
89588400|NCT02159729|Experimental|ATX-101 (1 mg/cm^2)|Participants treated with ATX-101 (1 mg/cm^2) in previous phase 2 studies
89588401|NCT02159729|Experimental|ATX-101 (2 mg/cm^2)|Participants treated with ATX-101 (2 mg/cm^2) in previous phase 2 studies
89588402|NCT02159729|Experimental|ATX-101 (4 mg/cm^2)|Participants treated with ATX-101 (4 mg/cm^2) in previous phase 2 studies
89588403|NCT04749563|Active Comparator|Active|IGC AD1
89588404|NCT04749563|Placebo Comparator|Placebo|IGC AD1 Placebo
89588405|NCT02159183|Experimental|Standard Plus ESTA STL Roxolid implant|This arm will receive the Straumann Soft Tissue Level Standard Plus Implant Ø 4.1 mm Regular Neck, SLActive® Roxolid, with a modified surface of the neck (ESTA).
89588406|NCT02159183|Active Comparator|Standard Plus STL implant|This arm will receive the Straumann Soft Tissue Level Standard Plus Implant Ø4.1mm Regular Neck,SLActive® Titanium grade IV, with a machined surface of the neck.
89588407|NCT02183675|Experimental|T/A/H|Telmisartan/Amlodipine/HCTZ fixed-dose combination
89588408|NCT02183675|Active Comparator|T/A|Telmisartan/Amlodipine fixed-dose combination
89588409|NCT02183675|Active Comparator|T/H|Telmisartan/HCTZ fixed-dose combination
89588410|NCT02183519|Experimental|Healthy older adults|All participants will receive reflex and voluntary cough testing. This will include coughing on command (voluntary cough) and coughing in response to capsaicin (reflex cough). This data will me measured to determine the strength of the cough (from both voluntary and reflex cough) and cough sensitivity (reflex cough only). Following baseline reflex and voluntary cough assessment, the participants will be cued to cough long and hard during both reflex and voluntary cough tasks. These data will help the investigators understand the baseline characteristics of voluntary and reflex cough, whether older adults can modify the magnitude of their cough response with verbal and visual cues.
89588411|NCT02183519|Experimental|Parkinson's disease|All participants will receive reflex and voluntary cough testing. This will include coughing on command (voluntary cough) and coughing in response to capsaicin (reflex cough). This data will me measured to determine the strength of the cough (from both voluntary and reflex cough) and cough sensitivity (reflex cough only). Following baseline reflex and voluntary cough assessment, the participants will be cued to cough long and hard during both reflex and voluntary cough tasks. These data will help the investigators understand the baseline characteristics of voluntary and reflex cough, whether older adults can modify the magnitude of their cough response with verbal and visual cues.
88976078|NCT02965560||HC,CHB,AD,ACLF|HC healthy controls; CHB chronic hepatitis B; AD acute decompensated cirrhosis; ACLF acute-on-chronic liver failure.
88976079|NCT03519373||PER001|HIV 1-infected pregnant women
88976080|NCT03519373||PER002|HIV 1-uninfected pregnant women
88976081|NCT03519373||PER003|HIV 1-uninfected non-pregnant women
88976082|NCT00045617|Experimental|cisplatin and etoposide followed by vaccine|standard chemotherapy with cisplatin and etoposide followed by cisplans and etoposide with an anti-idiotype monoclonal antibody vaccine
88976083|NCT03399838|Experimental|Dexmedetomidine|Application of single dose of 4mcg/kg dexmedetomidine intranasally for pediatric procedural sedation at the emergency department
88976084|NCT03399838|Active Comparator|Midazolam|0.5mg po/pr midazolam for pediatric sedation at the emergency department
89209834|NCT01073683|Experimental|larynx preservation|Decision between surgery and Chemo-rt according to response to initial induction chemotherapy
89209835|NCT00887172|Experimental|1|Wind-cold syndrome group were patients classified by Chinese Medicine practitioner of Wind-cold syndrome and took treatment of Jing Fang Bai Du san.
89209836|NCT00887172|Placebo Comparator|2|Wind-cold syndrome group were patients classified by Chinese Medicine practitioner of Wind-cold syndrome and took placebo of Jing Fang Bai Du san.
89588412|NCT02132195|Active Comparator|Adrenocorticotropic hormone (ACTH)|"Patients will receive ACTH twice weekly subcutaneously The initial dosing will be based on body surface area (BSA): 80 IU/1.73 m2~The patients will receive the initial dose for 6 months. At 6 months, the dose will be reduced by 50%. Patients who have side effects may have the dose reduced by 50% during the initial 6 months. A second dose reduction would still occur at 6 months (25% of initial dose)."
89588413|NCT02132195|No Intervention|No treatment|Patients in this treatment arm will receive no treatment to prevent relapses of nephrotic syndrome. A relapse, if it occurs, will be treated with prednisone and the patient will leave the no treatment arm of the study.
89588414|NCT02132195|Active Comparator|Rescue therapy|There is an option for the patient in no-treatment arm to elect to be placed in the active treatment arm of the trial (rescue therapy).
89588415|NCT02182973||DHM|Infants identified with neonatal abstinence syndrome requiring pharmacologic management and who will not be fed own mother's milk
89588416|NCT02182895|Experimental|Saxagliptin group|DPP4 inhibitor therapy group will receive saxagliptin 2.5 to 5 mg daily in addition to correctional sliding scale insulin therapy before each meal and bedtime.
88976085|NCT03313492|Active Comparator|E-Pamphlet|"A free non-interactive e-pamphlet (Skin Cancer Prevention and Early Detection from the American Cancer Society) will be accessible via our website."
88976086|NCT03313492|Active Comparator|Original UV4.me|Participants will view the original UV4.me web intervention, which includes educational modules, personalized responses to quizzes, information on skin type and burn risk, UV damage photo of similar individuals, avatar activity, age progression images, personal risk calculator, SPF (sun protection factor) calculator. The website content will remain the same, with the exception of updating photos, statistics, and cultural references for the current year.
88976087|NCT03313492|Experimental|Enhanced UV4.me2|Participants will view an enhanced version of the UV4.me website. Improvements to the website are based on user feedback from the original UV4.me trial, as well as reviews and models of effective e-Health interventions and implementation strategies.
88976088|NCT02988973|Experimental|rHuEPO or DA to ASP1517|Participants will receive roxadustat according to the prior randomization treatment, with starting doses of 70mg thrice weekly (TIW) to participants on <4500 IU/week of rHuEPO or <20 microgram (μg)/week of darbepoetin alfa (DA) and 100mg TIW to participants on ≥4500 IU/week rHuEPO or ≥ 20 μg/week DA. Participants roxadustat dosage will be adjusted every 4 weeks to maintain Hb level within the target range 10.0 to 12.0 g/dL. Dose adjustment steps will be as follows: 20, 40, 50, 70, 100, 150, 200, 250, 300 mg.
89209837|NCT00887172|Experimental|3|Wind-heat syndrome group were patients classified by Chinese Medicine practitioner of Wind-heat syndrome and took treatment of Ying Qiao san.
89588417|NCT02182895|No Intervention|Standard therapy group|Standard therapy group will receive basal-bolus insulin starting at a dose of 0.5 units/kg/day; given half as insulin glargine and half as insulin aspart. In addition, the standard therapy group will receive the correctional sliding scale insulin therapy before each meal and bedtime.
89588418|NCT01625377|Active Comparator|Tacrolimus|From transplantation to randomization: Basiliximab (40mg) at Day 0 and Day 4 + tacrolimus (C0 6-10 ng/ml) from Day 3-Day 5 + mycophenolic acid 1440 mg/d ± oral corticosteroids. From randomization to month 6 : tacrolimus (C0 6-10 ng/ml) + mycophenolic acid 1440 mg/d ± oral corticosteroids
89588419|NCT01625377|Experimental|Everolimus (RAD001)|"From transplantation to randomization: Basiliximab (40mg) at Day 0 and Day 4 + tacrolimus (C0 6-10 ng/ml) from Day 3-Day 5 + mycophenolic acid 1440 mg/d ± oral corticosteroids.~From randomization to month 6 : everolimus (recommended starting dose of 2 mg/day, then adjusted to achieve the target 6 ≤ C0 ≤ 10 ng/mL, until W24) + mycophenolic acid 1440 mg/d ± oral corticosteroids. The dose of tacrolimus was reduced by 50% twice: at the introduction of everolimus and at week 8 post-transplantation. Tacrolimus had to be finally discontinued in week 12 post-transplantation (by week 16 at the latest)."
89588420|NCT02158949|Experimental|mROAD|1 week of twice daily text messages modeled after SBIRT interventions
89588421|NCT02158949|No Intervention|Usual Care|Usual care in ED
89588422|NCT02132117|Experimental|Oxymetazoline HCL Cream 1.0%|Oxymetazoline HCL Cream 1.0% applied to the face once daily for 29 days.
89588423|NCT02132117|Placebo Comparator|Vehicle|Vehicle to Oxymetazoline HCL Cream applied to the face once daily for 29 days.
89588424|NCT02093689|Experimental|Part 1 OMS302|OMS302 diluted in balanced salt solution (BSS) and administered as irrigation solution
89588425|NCT02093689|Experimental|Part 2 OMS302|OMS302 diluted in balanced salt solution (BSS) and administered as irrigation solution
89588426|NCT02093689|Placebo Comparator|Part 2 Placebo|Placebo contains 20mM sodium citrate diluted in BSS and administered as irrigation solution.
89588427|NCT02047045|Experimental|Electro-acupuncture|Electro-acupuncture at bilateral ST25, SP14 ,and ST37. Patients will be treated once per day for 30 min, 5 times/week for the first 2 weeks, and 3 times/week for the next 6 weeks.
89588428|NCT02047045|Active Comparator|Prucalopride|Prucalopride Succinate taken orally, 2mg/day in the morning before breakfast
89588429|NCT02131259||Afatinib|
89588430|NCT01856595|Experimental|PF-06291874|
89588431|NCT01856595|Placebo Comparator|Placebo|
89588432|NCT02158247||Conventional group, Touch and Read group|
89588433|NCT04589559|Experimental|Intervention: Heart Rate Variability Biofeedback|Participants in this intervention group complete at-home heart rate variability biofeedback (HRVB) training using a chest-worn heart rate monitor and a smartphone app. They complete at least 10 minutes per day of HRVB training on at least 5 days per week for 3 weeks.
89588434|NCT01829295|Experimental|Methotrexate|oral methotrexate
89588435|NCT01829295|Experimental|Mycophenolate Mofetil|oral mycophenolate mofetil
89588436|NCT02157935|Active Comparator|Symbicort pMDI|Symbicort pMDI, budesonide/formoterol, 160/4.5 μg x 2 actuations BID, for oral inhalation
89588437|NCT02157935|Active Comparator|Formoterol Turbuhaler|Formoterol Turbuhaler, 4.5 μg x 2 actuations BID, for oral inhalation
89588438|NCT04589403|Placebo Comparator|0.9% Sodium Chloride Injection USP|Placebo will be 50 mL normal saline (Sodium Chloride), USP sterile solution administered by IV infusion over 30 minutes.
89588439|NCT04589403|Experimental|OPT101|The starting dose for the Phase 1a study is 0.16 mg/kg, which is 35-fold lower than the dog NOAEL (10mg/kg), on a mg/m2 basis. The dosing frequency for the MAD study was selected based on dosing performed in the supporting animal model studies. For an additional safety factor, the dose and volume infusion rates for the 0.16 mg/kg dose in humans will be 67-fold and 14-fold lower than the dogs dosed at 10mg/kg/min and mL/kg/min basis, respectively. For both Phase 1a and 1b, OPT101 will be administered by a slow IV infusion over 30 minutes.
89588440|NCT02157779|Experimental|Cognitive Behavioral Intervention (CBI)|12 weekly individual sessions consisting of psychoeducation, and cognitive and behavioral anger management strategies
89588441|NCT02157779|Active Comparator|Supportive Intervention (SI)|12 weekly individual sessions consisting of psychoeducation, problem-solving strategies, and support
89588442|NCT02093221|Experimental|Alpha1-PI 180 mg/kg/wk, 26 weeks|180 mg/kg weekly infusions of Alpha1-PI for 26 weeks.
89588443|NCT02093221|Experimental|90 mg/kg/wk Alpha1-PI, 26 weeks|90 mg/kg weekly infusions of Alpha1-PI for 26 weeks.
89588444|NCT02093221|Placebo Comparator|Placebo, 26 weeks|Weekly infusions of placebo for 26 weeks.
89588445|NCT02093221|Experimental|180 mg/kg/wk Alpha1-PI, 13 weeks|180 mg/kg weekly infusions of Alpha1-PI for 13 weeks.
89588446|NCT02093221|Experimental|90 mg/kg/wk Alpha1-PI, 13 weeks|90 mg/kg weekly infusions of Alpha1-PI for 13 weeks
89588447|NCT02093221|Placebo Comparator|Placebo, 13 weeks|Weekly infusions of placebo for 13 weeks.
89588448|NCT02092909|Experimental|IMO-8400 at escalating dose levels|IMO-8400 at escalating dose levels by subcutaneous injection
89588449|NCT01623115|Placebo Comparator|Placebo|Placebo for alirocumab every 2 weeks (Q2W) on top of stable lipid-modifying therapy (LMT) for 78 weeks.
89588450|NCT01623115|Experimental|Alirocumab 75 mg/Up to 150 mg Q2W|Alirocumab 75 mg Q2W on top of stable LMT for 78 weeks. Alirocumab dose up-titrated to 150 mg from Week 12 when low-density lipoprotein cholesterol (LDL-C) levels ≥ 70 mg/dL (1.81 mmol/L) at Week 8.
89588451|NCT02092285|Experimental|Golimumab|The first induction dose of subcutaneous (SC) golimumab 200 mg was administered at Day 0. The second induction dose of SC golimumab 100 mg was administered two weeks later at Week 2. Responders at Week 6 received a maintenance dose of golimumab (50 mg for participants with a body weight <80 kg or 100 mg for participants with a body weight ≥80 kg) every 4 weeks during the Maintenance Phase for 48 weeks, yielding a total of 54 weeks treatment.
89588452|NCT02091739|Experimental|IncobotulinumtoxinA (Xeomin) (100 Units)|"Main period (1 treatment cycle): Subjects to receive 100 Units.~Extension period (3 treatment cycles): Subjects to receive 100 Units per treatment cycle.~Mode of administration: Four injections per treatment cycle (parotid and submandibular glands, bilateral)"
89588453|NCT02091739|Experimental|IncobotulinumtoxinA (Xeomin) (75 Units)|"Main period (1 treatment cycle): Subjects to receive 75 Units.~Extension period (3 treatment cycles): Subjects to receive 75 Units per treatment cycle.~Mode of administration: Four injections per treatment cycle (parotid and submandibular glands, bilateral)"
89588454|NCT02091739|Placebo Comparator|Placebo|"Main period (1 treatment cycle): Subjects to receive placebo injection.~Extension period (3 treatment cycles): Subjects will be randomized to receive either 75 or 100 Units IncobotulinumtoxinA per treatment cycle.~Mode of administration: Four injections per treatment cycle (parotid and submandibular glands, bilateral)"
89588455|NCT02045875|Experimental|Dulera adherence monitoring|Adherence Monitoring Dulera; Identification of adherence barrier(s); Motivational Interviewing Adherence Strategies to promote adherence
89588456|NCT02045875|Active Comparator|Dulera Standard of Asthma Care|Dulera standard of asthma care
89588457|NCT01597635|Experimental|Part A|4 increasing doses of GSK2586881 given over 2 days
89030452|NCT00518466|Experimental|treatment 4|"Half of a 37.5 mg phentermine hydrochloride IR tablet and one 100 mg topiramate IR tablet at Hour 0 on Day 1 of Period 1.~One 7.5 mg phentermine hydrochloride IR capsule and one 25 mg topiramate IR tablet at Hour 0 on Days 1, 2, and 3 of Period 2.~Half of a 37.5 mg phentermine hydrochloride IR tablet and two 25 mg topiramate IR tablets at Hour 0 on Days 4, 5, and 6 of Period 2.~Half of a 37.5 mg phentermine hydrochloride IR tablet and three 25 mg topiramate IR tablets at Hour 0 on Days 7, 8, and 9 of Period 2.~Half of a 37.5 mg phentermine hydrochloride IR tablet and one 100 mg topiramate IR tablet at Hour 0 on Days 10 - 21 of Period 2."
89030453|NCT04518020|Active Comparator|Short implant|Short implant 6 mm installed
89030454|NCT04518020|Other|Conventional implant + bone augmentation|Standard length implant 13 mm in conjunction with maxillary sinus floor augmentation serves as a control group
89588458|NCT01597635|Experimental|Part B|Repeat Medium-High dose of GSK2586881 (or placebo) over 3 days
89588459|NCT01828281|Active Comparator|Therapeutic CPAP|Therapeutic CPAP
89588460|NCT01828281|Sham Comparator|control|subtherapeutic CPAP using 4 cm water
89588461|NCT01827267|Experimental|neratinib monotherapy|240 mg once daily with food, continuously in 21 day cycles
89588462|NCT01827267|Experimental|neratinib plus temsirolimus|240 mg neratinib plus 8 mg temsirolimus IV with optional dose escalation to 15 mg temsirolimus
89588463|NCT01855425|Other|Investigational CBCT|Radiation
89588464|NCT01854879|Experimental|Nucleus 6|
89588465|NCT01827111|Experimental|ABI-007 + Ipilimumab|Starting dose of ABI-007 is 150 mg/m2 administered by vein on days 1, 8, 15 every 28 days. Ipilimumab 3 mg/kg by vein over 90 minutes on day 1. Ipilimumab dose repeated every 21 days for a total of 4 doses. Every 2 months for 6 months, then every 3 months for up to 2 years, participant contacted by telephone. Each call should last about 5 minutes.
89588466|NCT02045095|Experimental|Schedule A: MLN7243 1 mg|MLN7243 1 milligram (mg), infusion, intravenously over 10-minutes, on Days 1, 4, 8, and 11 followed by 10 days of rest in a 21-day treatment cycle for a maximum of 12 months, or until symptomatic deterioration or disease progression (PD) or discontinuation of study for another reason, or until study is stopped.
89588467|NCT02045095|Experimental|Schedule A: MLN7243 2 mg|MLN7243 2 mg, infusion, intravenously over 10-minutes, on Days 1, 4, 8, and 11 followed by 10 days of rest in a 21-day treatment cycle for a maximum of 12 months, or until symptomatic deterioration or PD, or discontinuation of study for another reason, or until study is stopped.
89588468|NCT02045095|Experimental|Schedule A: MLN7243 4 mg|MLN7243 4 mg, infusion, intravenously over 10-minutes, on Days 1, 4, 8, and 11 followed by 10 days of rest in a 21-day treatment cycle for a maximum of 12 months, or until symptomatic deterioration or PD or discontinuation of study for another reason, or until study is stopped.
89588469|NCT02045095|Experimental|Schedule A: MLN7243 8 mg|MLN7243 8 mg, infusion, intravenously over 10-minutes, on Days 1, 4, 8, and 11 followed by 10 days of rest in a 21-day treatment cycle for a maximum of 12 months, or until symptomatic deterioration or PD or discontinuation of study for another reason, or until study is stopped.
89588470|NCT02045095|Experimental|Schedule A: MLN7243 12 mg|MLN7243 12 mg, infusion, intravenously over 10-minutes, on Days 1, 4, 8, and 11 followed by 10 days of rest in a 21-day treatment cycle for a maximum of 12 months, or until symptomatic deterioration or PD or discontinuation of study for another reason, or until study is stopped.
89030455|NCT00518505|Other|I|This is a single arm study. All patients will be asked to complete questionnaires and have their medical charts reviewed.
89030456|NCT04518761||Prospective group|
89030457|NCT04518761||Retrospective group|
89030458|NCT00519714|Placebo Comparator|1|three placebo capsules PO three times daily.
89030459|NCT00519714|Active Comparator|2|1-MNA 90 mg daily: one active treatment capsule and two placebo capsules PO three times daily
89588471|NCT02045095|Experimental|Schedule A: MLN7243 18 mg|MLN7243 18 mg, infusion, intravenously over 10-minutes, on Days 1, 4, 8, and 11 followed by 10 days of rest in a 21-day treatment cycle for a maximum of 12 months, or until symptomatic deterioration or PD or discontinuation of study for another reason, or until study is stopped.
89030460|NCT00519714|Active Comparator|3|1-MNA 270 mg daily: three active treatment capsules PO three times daily.
89588472|NCT02045095|Experimental|Schedule A: MLN7243 Homozygous Mutant 4 mg|MLN7243 homozygous mutant 4 mg, infusion, intravenously over 10-minutes, on Days 1, 4, 8, and 11 followed by 10 days of rest in a 21-day treatment cycle for a maximum of 12 months, or until symptomatic deterioration or PD or discontinuation of study for another reason, or until study is stopped.
88976089|NCT02988973|Experimental|rHuEPO or DA to DA|Participants will receive DA according to the prior randomization treatment, with starting doses of 15 μg/2weeks to participants on ≤ 1500 IU/week of rHuEPO or <11.25 microgram (μg)/week of DA, 30μg/2weeks to participants on >1500 to <6000 IU/week of rHuEPO or ≥ 11.25 to < 22.5 μg/week of DA, 60μg/2weeks to participants on ≥ 6000 IU/week of rHuEPO or ≥ 22.5 to < 37.5 μg/week of DA, 90μg/2weeks to participants on ≥ 37.5 to < 52.5 μg/week of DA, 120μg/2weeks to participants on ≥ 52.5 to < 75 μg/week of DA, 180μg/2weeks to participants on ≥ 75 μg/week of DA. Participant's roxadustat dosage will be adjusted every 4 weeks to maintain Hb level within the target range 10.0 to 12.0 g/dL. Dose adjustment steps will be as follows: 15, 30, 60, 90, 120, and 180 μg.
89588473|NCT04183309||Pediatric anesthetized patients|Pediatric anesthetized patients undergoing abdominal laparoscopy surgery (simple-arm study).
89588474|NCT02181803|Experimental|Part 1 Panel A & B MK-8189 Monotherapy 2-40 mg: Schizophrenic|Participants with schizophrenia will receive monotherapy of MK-8189 in escalating doses starting at 2 mg once daily (QD) up to 40 mg QD, depending on safety and tolerability
89588475|NCT02181803|Experimental|Part 2 Panel C MK-8189 Add-on Therapy 2-20 mg: Schizophrenic|Participants with schizophrenia will receive add-on therapy of MK-8189 in escalating doses starting at 2 mg QD up to 20 mg QD, depending on safety and tolerability
89588476|NCT02181803|Experimental|Part 2 Panel C MK-8189 Add-on Therapy 4-20 mg: Schizophrenic|Participants with schizophrenia will receive add-on therapy of MK-8189 in escalating doses starting at 4 mg QD up to 20 mg QD, depending on safety and tolerability
89588477|NCT02181803|Experimental|Part 3 Panel D MK-8189 Monotherapy 2-16 mg: Healthy|Healthy participants will receive monotherapy of MK-8189 in escalating doses starting at 2 mg QD up to 16 mg QD, depending on safety and tolerability
89588478|NCT02181803|Placebo Comparator|Part 1 Panel A & B Placebo Monotherapy: Schizophrenic|Participants with schizophrenia will receive dose-matched placebo to MK-8189 monotherapy
88976090|NCT02988973|Experimental|Epoetin beta pegol to ASP1517|Participants will receive roxadustat according to the prior registration treatment, with starting doses of 70mg thrice weekly (TIW) to participants on ≤100 μg/week of Epoetin beta pegol and 100mg TIW to participants on >100 μg/week of Epoetin beta pegol. Participant's roxadustat dosage will be adjusted every 4 weeks to maintain Hb level within the target range 10.0 to 12.0 g/dL. Dose adjustment steps will be as follows: 20, 40, 50, 70, 100, 150, 200, 250, 300 mg.
88976091|NCT00045773||1|
88976092|NCT00079404|Experimental|Arm I|Patients with solid tumors receive 17-N-allylamino-17-demethoxygeldanamycin (17-AAG) IV over 60-120 minutes on days 1, 4, 8, and 11. Treatment repeats every 21 days for up to 17 courses in the absence of disease progression or unacceptable toxicity.
88976093|NCT02781922|Experimental|Autologous cardiac stem cells (JRM-001)|
89588479|NCT02181803|Placebo Comparator|Part 2 Panel C Placebo Add-on Therapy: Schizophrenic|Participants with schizophrenia will receive dose-matched placebo to MK-8189 add-on therapy
89588480|NCT02181803|Placebo Comparator|Part 3 Panel D Placebo Monotherapy: Healthy|Healthy participants will receive dose-matched placebo to MK-8189 monotherapy
89588481|NCT01826487|Placebo Comparator|Placebo|Participants will receive placebo matching to ataluren orally 3 times a day (TID) at morning, midday, and evening for 48 weeks.
89588482|NCT01826487|Experimental|Ataluren|Participants will receive ataluren suspension orally TID, 10 milligrams/kilogram (mg/kg) at morning, 10 mg/kg at midday, and 20 mg/kg at evening (total daily dose 40 mg/kg) for 48 weeks.
89588483|NCT02064439|Experimental|Arm 1|Rivaroxaban 10 mg once daily for 12 months
89588484|NCT02064439|Experimental|Arm 2|Rivaroxaban 20 mg once daily for 12 months
89588485|NCT02064439|Active Comparator|Arm 3|ASA (Acetylsalicylic Acid) 100 mg once daily for 12 months
89588486|NCT02130557|Experimental|Bosutinib|Bosutinib, 400 mg, oral administration once a day
89588487|NCT02130557|Active Comparator|Imatinib|Imatinib, 400 mg, oral administration once a day
89588488|NCT01854645|Experimental|GFF MDI|Glycopyrronium Formoterol Fumarate (GFF) Metered Dose Inhaler (MDI) (PT003)
89588489|NCT01854645|Experimental|GP MDI|Glycopyrronium (GP) MDI (PT001)
89588490|NCT01854645|Experimental|FF MDI|Formoterol Fumarate (FF) MDI (PT005)
89588491|NCT01854645|Active Comparator|Open-label tiotropium bromide inhalation powder|Open-label tiotropium bromide inhalation powder (Spiriva® Handihaler®)
89588492|NCT01854645|Placebo Comparator|Placebo|Placebo MDI
89588493|NCT04418089|Experimental|Simvastatin|The group received standard treatment with the oral administration of Simvastatin
88976094|NCT02781922|No Intervention|Usual care|
88976095|NCT00079443|Experimental|Treatment|"PHASE II: Patients receive FR901228 IV over 4 hours on days 1, 8, and 15. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.~Patients who achieve a complete or partial remission receive 2 additional courses (for a total of 6 courses). Patients with stable disease after 4 courses or progressive disease at any time after 2 courses proceed to the phase I portion of the study.~PHASE I: Patients receive rituximab IV over approximately 4-8 hours on day 1; fludarabine IV over 10-30 minutes on days 2-4; and FR901228 IV over 4 hours on days 2, 9, and 16. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity."
89588494|NCT04418089|Experimental|Placebo|The group received standard treatment with the oral administration of Placebo
89588495|NCT01825941|Active Comparator|Metoclopramide + Diphenhydramine|Metoclopramide 10 milligrams + Diphenhydramine 50 milligrams, administered as an intravenous drip over 15 minutes
89588496|NCT01825941|Placebo Comparator|Metoclopramide + placebo|Metoclopramide 10mg + placebo, administered intravenously over 15 minutes
89588497|NCT02064205|Active Comparator|polydextrose or glucose syrup at breakfast|Breakfast with pre-load four hours before lunch
89588498|NCT02064205|Placebo Comparator|Pre-load with yogurt and polydextrose or glucose later|Breakfast without pre-load. Pre-load with yogurt provided 1.5h before lunch.
89588499|NCT02090959|Experimental|Ataluren|Participants will receive ataluren suspension orally 3 times a day (TID), 10 milligrams/kilogram (mg/kg) at morning, 10 mg/kg at midday, and 20 mg/kg at evening (total daily dose 40 mg/kg) for up to 144 weeks.
89588500|NCT02044159|Experimental|Hydrocortisone|Patients randomized to the hydrocortisone arm will receive a 2 mg/kg hydrocortisone IV bolus on enrolment followed by 1 mg/kg of hydrocortisone IV q6h until the patient has not had an escalation in therapy for at least 12 hours. If the patient meets these criteria their hydrocortisone will be weaned to 1 mg/kg every 8 hours which will be continued until they are off all vasoactive infusions for 12 hours. If following the initial hydrocortisone wean, the patient requires fluid boluses and/or an increase in their vasoactive infusion(s), their hydrocortisone will be increased back to 1 mg/kg of hydrocortisone IV q6h until they meet stability criteria again. Duration of treatment will range from a minimum of 20 hours to a maximum of 7 days of study drug.
89588501|NCT02044159|Placebo Comparator|Placebo|Patients randomized to the placebo arm will receive a placebo solution consisting of normal saline equivalent in volume to the appropriate dose of hydrocortisone. Hydrocortisone and placebo will be identical in appearance, volume and smell as hydrocortisone is made up in normal saline and dissolves completely with no visible precipitate. The dosing regimen will be identical to the hydrocortisone arm.
89588502|NCT02090725|Experimental|3-4 Diaminopyridine (DAP)|
89588503|NCT02180165|Experimental|Cohort 1: Posaconazole|300 mg posaconazole oral tablet (or 300 mg intravenous (IV) solution) twice on Day 1, followed by 300 mg oral tablet or IV solution once daily for up to 84 days
88976096|NCT02580838|Experimental|early OnabotulinumtoxinA group|OnabotulinumtoxinA will be injected immediately when spasticity develop in early OnabotulinumtoxinA group.
88976097|NCT02580838|Active Comparator|late OnabotulinumtoxinA group|OnabotulinumtoxinA will be injected at 6 months after emergence of spasticity in late OnabotulinumtoxinA group.
88976098|NCT02580838|No Intervention|no OnabotulinumtoxinA group|OnabotulinumtoxinA will not be injected for this group.
88976099|NCT02072356|Experimental|Treatment (yttrium Y 90 glass microspheres)|Patients receive yttrium Y 90 glass microspheres IA on day 0. Patients may receive additional treatment 4-12 weeks after initial treatment at the discretion of the study physician.
88976100|NCT00046085|Active Comparator|Patient customary care|12 months of patient customary care
88976101|NCT00046085|Experimental|Online family education|12 months of patient customary care and relative access to online education and support program
88976102|NCT00403351||ARM-CAD 1|Cross-sectional analysis using coronary angiogram results
88976103|NCT00403351||ARM-CAD 2|Prospective cohort for incident cardiovascular events and mortality
88976104|NCT00403429|Experimental|Capecitabine|
88976105|NCT00403507|No Intervention|Clean Control|Probable Alzheimer's disease in the context of no excluding medical conditions.
88976106|NCT00403507|No Intervention|CoMorbid Control|Probable Alzheimer's disease in the context of well-controlled comorbid medical conditions.
88976107|NCT00403507|Experimental|Clean Exercise|Probable Alzheimer's disease in the context no comorbid medical conditions.
88976108|NCT00403507|Experimental|CoMorbid Exercise|Probable Alzheimer's disease in the context of well-controlled comorbid medical conditions.
88976109|NCT00079599|Experimental|1|
88976110|NCT00079599|Placebo Comparator|2|
88976111|NCT00079716|Experimental|1|
88976112|NCT00130507|Active Comparator|Arm A: VX|Vinorelbine and capecitabine (VX): vinorelbine 25 mg/m2 iv, days 1 and 8 each cycle (21 days), followed of capecitabine 825 mg/m2, orally, twice a day, days 1-14 each cycle (21 days).
88976113|NCT00130507|Experimental|Arm B: VXH|Vinorelbine, capecitabine and trastuzumab (VXH): vinorelbine 25 mg/m2 iv, days 1 and 8 each cycle (21 days), followed of capecitabine 825 mg/m2, orally, twice a day, days 1-14 each cycle (21 days) and trastuzumab 4 mg/kg iv (loading dose first week), followed by 2 mg/kg weekly.
88976114|NCT00130546|Active Comparator|1|Cypher Stent
88976115|NCT00130546|Active Comparator|2|Taxus Stent
88976116|NCT00130702|Experimental|Gefitinib (Iressa)|All patients will receive Gefitinib (Iressa) at a dose of 750 mg orally (three 250 mg tabs) each day.
88976117|NCT00130819|Experimental|1|Subjects receive integrated opioid-dependence treatment with buprenorphine/naloxone at the HIV clinic
88976118|NCT00130819|Active Comparator|2|Subjects receive case management and referral to an off-site opioid treatment program for their opioid dependence
88976119|NCT00131053|Experimental|A|
88976120|NCT00079911|Experimental|Suppressive + Episodic Therapy|Valaciclovir (VAL) 500mg twice daily for 6 months, and episodic treatment with VAL 1000mg twice daily for 5 days or 10 days, when required for treatment of a genital herpes recurrence.
88976121|NCT00079911|Placebo Comparator|Episodic Therapy|Matching placebo twice daily for 6 months, and episodic treatment with VAL 1000mg twice daily for 5 or 10 days, when required for treatment of a genital herpes recurrence.
88976122|NCT00131131|Experimental|Exercise|The intervention was an exercise program of moderate to vigorous intensity. The intervention started with 30-minute sessions three times per week, with the ultimate goal to have participants exercise four to five times per week for 45 to 60 minutes per session.
88976123|NCT00131131|No Intervention|Control|Women in the control group did not attend instructional sessions with the exercise interventionist and did not receive the motivational mailings
88976124|NCT00131404|Placebo Comparator|Phase A/B: Arm 1|"Phase A: Arm 1: MK0364 Pbo capsule once daily.~Phase B: Patients who continue into Phase B will remain in the same arm they were assigned to during Phase A and will receive the following: Arm 1: MK0364 Pbo capsule once daily."
88976125|NCT00131404|Experimental|Phase A/B: Arm 2|"Phase A: Arm 2: MK0364 2 mg capsule once daily.~Phase B: Patients who continue into Phase B will remain in the same arm they were assigned to during Phase A and will receive the following: Arm 2: MK0364 2 mg capsule once daily."
88976126|NCT00131404|Experimental|Phase A/B: Arm 3|"Phase A: Arm 3: MK0364 4 mg capsule once daily.~Phase B: Patients who continue into Phase B will remain in the same arm they were assigned to during Phase A and will receive the following: Arm 3:~MK0364 4 mg capsule once daily."
88976127|NCT00131404|Experimental|Phase A/B: Arm 4|"Phase A: Arm 4: MK0364 6 mg capsule once daily.~Phase B: Patients who continue into Phase B will remain in the same arm they were assigned to during Phase A and will receive the following: Arm 4:~MK0364 6 mg capsule once daily."
89588504|NCT02180165|Active Comparator|Cohort 1: Voriconazole|300 mg voriconazole oral tablet (or 6 mg/kg IV solution) twice on Day 1, followed by 200 mg oral tablet (or 4 mg/kg IV solution) twice daily for up to 84 days
89588505|NCT02180165|Experimental|Cohort 2: Posaconazole|300 mg posaconazole oral tablet (or 300 mg intravenous (IV) solution) twice on Day 1, followed by 300 mg oral tablet or IV solution once daily for up to 84 days
89588506|NCT02180165|Active Comparator|Cohort 2: Voriconazole|300 mg voriconazole oral tablet (or 6 mg/kg IV solution) twice on Day 1, followed by 200 mg oral tablet (or 4 mg/kg IV solution) twice daily for up to 84 days
89588507|NCT04748705|Experimental|IMC-1 Oral Tablet|2X IMC-1 Tablet taken orally, each morning and evening.
89588508|NCT04748705|Placebo Comparator|Placebo|2X Placebo Tablet taken orally, each morning and evening.
89588509|NCT02155985|Active Comparator|Aspirin 300 mg + aspirin 100 mg placebo|At week 0, participants were prescribed aspirin 300 mg (one tablet) and placebo for aspirin 100 mg (one tablet) once daily. At week 12, participants were to stop both study product tablets to allow for a 4-week washout period.
89588510|NCT02155985|Active Comparator|Aspirin 100 mg + aspirin 300 mg placebo|At week 0, participants were prescribed a placebo for aspirin 300 mg (one tablet) and aspirin 100 mg (one tablet) once daily. At week 12, participants were to stop both study product tablets to allow for a 4-week washout period.
89588511|NCT02155985|Placebo Comparator|Aspirin 300 mg + aspirin 100 mg placebos|At week 0, participants were prescribed a placebo for aspirin 300 mg (one tablet) and placebo for aspirin 100 mg (one tablet) once daily. At week 12, participants were to stop both study products tablets to allow for a 4-week washout period.
89588512|NCT02155829|Experimental|Riluzole|"Weeks 1 and 2: Riluzole 50 mg tablet by mouth every 12 hours (100 mg/day) for 2-weeks~Weeks 3 to 8 (optional dose increase): 2 Riluzole 50 mg tablets by mouth every 12 hours (200 mg/day) for 6-weeks"
89588513|NCT02155829|Placebo Comparator|Placebo|"Weeks 1 and 2: Placebo 50 mg tablet by mouth every 12 hours (100 mg/day) for 2-weeks~Weeks 3 to 8 (optional dose increase): 2 Placebo 50 mg tablets by mouth every 12 hours (200 mg/day) for 6-weeks"
89588514|NCT02129777|Experimental|Blinded period: Namilumab 300 mg + namilumab 150 mg|Namilumab 300 mg (2 separate injections of 150 mg), subcutaneous injection, on Day 1, followed by namilumab 150 mg subcutaneous injection, on Days 15, 43 and 71.
89588515|NCT02129777|Experimental|Blinded period: Namilumab 160 mg + namilumab 80 mg|Namilumab 160 mg (2 separate injections of 80 mg), subcutaneous injection, on Day 1, followed by namilumab 80 mg subcutaneous injection, on Days 15, 43 and 71.
89588516|NCT02129777|Experimental|Blinded period: Namilumab 100 mg + namilumab 50 mg|Namilumab 100 mg (2 separate injections of 50 mg), subcutaneous injection, on Day 1, followed by namilumab 50 mg subcutaneous injection, on Days 15, 43 and 71.
89588517|NCT02129777|Experimental|Blinded period: Namilumab 40 mg + namilumab 20 mg|Namilumab 40 mg (2 separate injections of 20 mg), subcutaneous injection, on Day 1, followed by namilumab 20 mg subcutaneous injection, on Days 15, 43 and 71.
89588518|NCT02129777|Placebo Comparator|Blinded period: Placebo|Placebo (2 separate injections), subcutaneous injection, on Day 1, followed by placebo, subcutaneous injection, on Days 15, 43 and 71.
89588519|NCT02129777|Experimental|Open label: Namilumab 80 mg|Namilumab 80 mg subcutaneous injection, at Week 0 and every 4 weeks thereafter up to 52 weeks (active extension period) - if appropriate on the basis of treatment response.
89588520|NCT02129777|Experimental|Open label: Namilumab 150 mg|Namilumab 150 mg, subcutaneous injection, from Week 8 and then every 4 weeks thereafter up to 52 weeks (active extension period) - if appropriate on the basis of treatment response.
89588521|NCT02178995|No Intervention|Healthy Controls|"Healthy controls completed the same neurocognitive batteries and neuropsychiatric questionnaires as individuals with epilepsy, but were not exposed to study medication.~Healthy controls were included primarily for use in the open-label comparison. They did not receive blinded medication during the 'double-blind' portion and their data was not used in the 'double-blind' comparison. In order to control for test/re-test variables, they completed testing during the 'double-blind' portion, so that they completed testing an equivalent number of times to the epilepsy patients in the 'open-label' portion."
89588522|NCT02178995|Experimental|Participants With Epilepsy (Open-label)|Following the final randomized visit, interested participants were prescribed 10mg of methylphenidate twice daily, increased to 20mg of methylphenidate twice daily as tolerated. After a four week treatment trial, their scores on the batteries and questionnaires were again assessed.
88976128|NCT00131404|Experimental|Phase A/B: Arm 5|Phase A: Arm 5: MK0364 6 mg capsule once daily. 52 week treatment period. Phase B: Patients who continue into Phase B will remain in the same arm they were assigned to during Phase A and will receive the following: Arm 5: MK0364 6 mg capsule once daily.
88976129|NCT00131482|Experimental|10 micrograms|
88976130|NCT00131482|Experimental|30 micrograms|
88976131|NCT00131482|Placebo Comparator|Placebo|
88976132|NCT00131482|Experimental|3 micrograms|
88976133|NCT00131482|Experimental|1 microgram|
88976134|NCT04726774|Experimental|Hypnosis group|The intervention consisted of two hypnosis sessions by a physician trained in medical hypnosis. The hypnosis group received also the usual rehabilitation program.
88976135|NCT04726774|Active Comparator|Control group|The control group follow the usual rehabilitation program which includes intensive physiotherapy for 2 weeks (i.e., focused on walking and enhancing balance exercises in group or individual and group) and patient education on the risk of falling and on prevention of falls.
88976136|NCT00131560|Other|A|
88976137|NCT00131638|Experimental|Palifermin|Single IV dose of palifermin at 120 μg/kg, 3 days before the start of radiotherapy plus 6 once weekly palifermin doses at the same dose level during a 6-week Radiotherapy / chemotherapy course
88976138|NCT00131638|Placebo Comparator|Placebo|Single IV dose of placebo at 120 μg/kg, 3 days before the start of Radiotherapy, plus 6 once weekly placebo doses at the same dose during a 6-week radiotherapy / chemotherapy course.
88976139|NCT00080145|Active Comparator|risperidone plus parent management training|
88976140|NCT00080145|Active Comparator|risperidone only|
88976141|NCT00403780|Active Comparator|A|Active intervention with pregabalin
88976142|NCT00403780|Placebo Comparator|B|placebo arm with capsule Lyrica Placebo
88976143|NCT00080262|Experimental|1|
88976144|NCT00131989|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-14 or 1-21. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients achieving a CR may be considered for retreatment with sorafenib for up to an additional 6 courses upon disease recurrence provided the duration of CR is longer than 1 month.
88976145|NCT00132067|Experimental|Treatment (vorinostat)|Patients receive oral vorinostat twice daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
88976146|NCT00132145|Other|Intervention|Behavioural
88976147|NCT00046631||Adolescent girls|Chosen from 6 schools in 6 cities
88976148|NCT00132262|Experimental|1|Patients randomized to this arm received an intervention based in the motivational interviewing style
88976149|NCT00132262|Active Comparator|2|Patients randomized to this arm received standard hospital care
88976150|NCT00132379|Experimental|1|
88976151|NCT00132418|Placebo Comparator|Placebo|placebo
88976152|NCT00132418|Experimental|Enbrel|Enbrel
88976153|NCT00132613|Active Comparator|1|Procedure/Surgery: Observation alone after pericardial drainage
88976154|NCT00132613|Experimental|2|Drug: Pericardial instillation of bleomycin after drainage
88976155|NCT00133003|Active Comparator|1|
88976156|NCT00133003|Placebo Comparator|2|
88976157|NCT00133237|Active Comparator|A|Sirolimus-eluting stent (Cypher)
88976158|NCT00133237|Active Comparator|B|Paclitaxel-eluting stent (Taxus)
88976159|NCT00399672|Active Comparator|1|The 4 participating sites are designated either High Intensity or Low Intensity. High Intensity sites have access to: full time specialist physicians, access to full time nurses and counselors. All weekly pegylated interferon injections will be administered by clinic staff and ribavirin will be dispensed in weekly medication pack.
88976160|NCT00399672|Active Comparator|2|The 4 participating sites are designated either High Intensity or Low Intensity. In the Low intensity group, all patients will have access to: full time primary care physicians, specialist physicians and access to part time nurse or counselor by appointment. Patients will be offered the option of self or nurse administered pegylated interferon injections on an appointment basis. Ribavirin will be dispensed biweekly. The treatment medication cannot be stored at the clinic; it must be the subjects responsibility.
88976161|NCT00133276|Active Comparator|1|
88976162|NCT00133276|Placebo Comparator|2|
88976163|NCT00046865|Experimental|Acupressure|Arm I: Patients receive active acupressure plus usual nausea care during the second or third course of chemotherapy. Acupressure is applied to a specific site each morning and again whenever nausea is experienced for 3-6 minutes.
88976164|NCT00046865|Placebo Comparator|Placebo Acupressure|Arm II: Patients receive placebo acupressure plus usual nausea care during the second or third course of chemotherapy. Acupressure is applied as in arm I except at a non-specific site.
88976165|NCT00046865|Sham Comparator|Usual Care|Arm III: Patients receive usual nausea care during the second or third course of chemotherapy.
88976166|NCT02964676|Experimental|AIT group|PACG in AIT group will receive ab interno trabeculectomy with Trabectome and before AIT, Laser Peripheral Iridectomy (LPI) will be performed first.
88976167|NCT02964676|Active Comparator|Trab group|PACG in AIT group will receive trabeculectomy.
88976168|NCT00133354|Active Comparator|Arimidex and Growth Hormone|
88976169|NCT00133354|Placebo Comparator|Placebo and Growth Hormone|
88976170|NCT00403897|Experimental|1|Ages 2 - 6: Day 1= 1 sachet/day; Day 3= 1 sachet BID; Day 5= 1 sachet TID Ages 7 - 11: Day 1= 1 sachet BID; Days 3 & 5 = 2 sachets BID;
88976171|NCT00133471|Experimental|Group 1A: 3.75 mcg A/H9N2 no adjuvant|12 subjects to receive 3.75 mcg A/H9N2 with no adjuvant.
88976172|NCT00133471|Experimental|Group 2B: 7.5 mcg A/H9N2 plus MF59 adjuvant|12 subjects to receive 7.5 mcg A/H9N2 plus MF59 adjuvant.
88976173|NCT00133471|Experimental|Group 3A: 15 mcg A/H9N2 no adjuvant|12 subjects to receive 15 mcg A/H9N2 with no adjuvant.
88976174|NCT00133471|Experimental|Group 3B: 15 mcg A/H9N2 plus MF59 adjuvant|12 subjects to receive 15 mcg A/H9N2 plus MF59 adjuvant.
88976175|NCT00133471|Experimental|Group 4B: 30 mcg A/H9N2 plus MF59 adjuvant|12 subjects to receive 30 mcg A/H9N2 plus MF59 adjuvant.
88976176|NCT00133471|Experimental|Group 4A: 30 mcg A/H9N2 no adjuvant|12 subjects to receive 30 mcg A/H9N2 with no adjuvant.
88976177|NCT00133471|Experimental|Group 2A: 7.5 mcg A/H9N2 no adjuvant|12 subjects to receive 7.5 mcg A/H9N2 with no adjuvant.
88976178|NCT00133471|Experimental|Group 1B: 3.75 mcg A/H9N2 plus MF59 adjuvant|12 subjects to receive 3.75 mcg A/H9N2 plus MF59 adjuvant.
88976179|NCT00133549|Experimental|2|Vaccine dose 1: CRM-PS; Vaccine dose 2 (month 4): CRM-PS; Vaccine dose 3 (month 8): PS.
88976180|NCT00133549|Experimental|1|Vaccine dose 1: CRM-PS; Vaccine dose 2 (month 4): saline placebo; Vaccine dose 3 (month 8): PS.
88976181|NCT00133549|Active Comparator|3|Vaccine dose 1: PS; Vaccine dose 2 (month 4): saline placebo; Vaccine dose 3 (month 8): saline placebo.
88976182|NCT00133666|Experimental|1|
88976183|NCT00133666|Active Comparator|2|
88976184|NCT00133744|Active Comparator|A, 1|
88976185|NCT00133744|Experimental|A, 2|
88976186|NCT00133744|Experimental|A, 3|Multiple micronutrient supplement
88976187|NCT00080808|Active Comparator|Arm I|Patients undergo unilateral cavernous nerve-sparing radical prostatectomy with unilateral autologous interposition sural nerve grafting.
88976188|NCT00080808|Active Comparator|Arm II (No sural nerve grafting)|Patients undergo unilateral cavernous nerve-sparing radical prostatectomy (without sural nerve grafting) and erectile dysfunction rehabilitation as in arm I.
88976189|NCT00133900||Cohort|Metastatic Hormone Refractory Prostate Cancer Patients
88976190|NCT00080847|Experimental|Arm I (closed to accrual as of 9/21/04)|Patients receive rituximab IV over 6 hours, cyclophosphamide IV over 15-45 minutes, doxorubicin IV over 5-20 minutes, and vincristine IV over 5-15 minutes on day 1 and oral prednisone on days 1-5.
89588523|NCT02178995|Experimental|10mg, 20mg, Then Placebo (Double-blind)|"Participants received three single doses in randomized order of blinded medication, either a placebo, 20mg of methylphenidate, or 10mg of methylphenidate, and completed cognitive testing and neuropsychiatric questionnaires. This single-dose phase was followed by an open-label 4-week treatment trial of methylphenidate.~Methylphenidate: Participants with epilepsy first received blinded, single-dose capsules which contained either:~Placebo 20mg of methylphenidate or 10mg of methylphenidate. At each visit, they received one capsule and then completed the neurocognitive batteries and neuropsychiatric questionnaires. There was no medication administered between visits during this time."
89588524|NCT02178995|Experimental|10mg, Placebo, Then 20mg (Double-blind)|"Participants received three single doses in randomized order of blinded medication, either a placebo, 20mg of methylphenidate, or 10mg of methylphenidate, and completed cognitive testing and neuropsychiatric questionnaires. This single-dose phase was followed by an open-label 4-week treatment trial of methylphenidate.~Methylphenidate: Participants with epilepsy first received blinded, single-dose capsules which contained either:~Placebo 20mg of methylphenidate or 10mg of methylphenidate. At each visit, they received one capsule and then completed the neurocognitive batteries and neuropsychiatric questionnaires. There was no medication administered between visits during this time."
89588525|NCT02178995|Experimental|Placebo, 20mg, Then 10mg (Double-blind)|"Participants received three single doses in randomized order of blinded medication, either a placebo, 20mg of methylphenidate, or 10mg of methylphenidate, and completed cognitive testing and neuropsychiatric questionnaires. This single-dose phase was followed by an open-label 4-week treatment trial of methylphenidate.~Methylphenidate: Participants with epilepsy first received blinded, single-dose capsules which contained either:~Placebo 20mg of methylphenidate or 10mg of methylphenidate. At each visit, they received one capsule and then completed the neurocognitive batteries and neuropsychiatric questionnaires. There was no medication administered between visits during this time."
89588526|NCT02178995|Experimental|Placebo, 10mg, Then 20mg (Double-blind)|"Participants received three single doses in randomized order of blinded medication, either a placebo, 20mg of methylphenidate, or 10mg of methylphenidate, and completed cognitive testing and neuropsychiatric questionnaires. This single-dose phase was followed by an open-label 4-week treatment trial of methylphenidate.~Methylphenidate: Participants with epilepsy first received blinded, single-dose capsules which contained either:~Placebo 20mg of methylphenidate or 10mg of methylphenidate. At each visit, they received one capsule and then completed the neurocognitive batteries and neuropsychiatric questionnaires. There was no medication administered between visits during this time."
89588527|NCT02178995|Experimental|20mg, Placebo, Then 10mg (Double-blind)|"Participants received three single doses in randomized order of blinded medication, either a placebo, 20mg of methylphenidate, or 10mg of methylphenidate, and completed cognitive testing and neuropsychiatric questionnaires. This single-dose phase was followed by an open-label 4-week treatment trial of methylphenidate.~Methylphenidate: Participants with epilepsy first received blinded, single-dose capsules which contained either:~Placebo 20mg of methylphenidate or 10mg of methylphenidate. At each visit, they received one capsule and then completed the neurocognitive batteries and neuropsychiatric questionnaires. There was no medication administered between visits during this time."
89588528|NCT02178995|Experimental|20mg, 10mg, Then Placebo - Double-blind|"Participants received three single doses in randomized order of blinded medication, either a placebo, 20mg of methylphenidate, or 10mg of methylphenidate, and completed cognitive testing and neuropsychiatric questionnaires. This single-dose phase was followed by an open-label 4-week treatment trial of methylphenidate.~Methylphenidate: Participants with epilepsy first received blinded, single-dose capsules which contained either:~Placebo 20mg of methylphenidate or 10mg of methylphenidate. At each visit, they received one capsule and then completed the neurocognitive batteries and neuropsychiatric questionnaires. There was no medication administered between visits during this time."
89588529|NCT02178995|Experimental|40mg, 20mg, Then Placebo (One Participant)|This study was originally intended to use 40mg, 20mg, and placebo doses rather than 20mg, 10mg, and placebo. This individual developed tachycardia (see adverse events) on the 40mg dose, and was withdrawn from the double-blind portion as a result. We removed the 40mg doses from this study and replaced them with 10mg doses. No other participant received a 40mg dose. This participant rejoined the open-label portion after consultation with his PCP due to significant perceived benefit from the MPH dose.
89588530|NCT02128997|Experimental|Closed Incision Wound vacuum (Prevena)|Closed incision wound vacuum (Prevena)
89588531|NCT02128997|No Intervention|Routine Wound Care|This arm includes patients having a cesarean section with routine wound care
89588532|NCT02155283|Other|Treatment Continuous Passive Motion|Single-arm; 3-week treatment plan using Kyrobak compared to baseline (before treatment)
88976191|NCT00080847|Experimental|Arm II|Patients receive oblimersen IV continuously on days 1-7; rituximab IV over 6 hours, cyclophosphamide IV over 15-45 minutes, doxorubicin IV over 5-20 minutes, and vincristine IV over 5-15 minutes on day 5; and oral prednisone on days 5-10.
88976192|NCT04705831|Active Comparator|RUCONEST|IV Ruconest
88976193|NCT04705831|Placebo Comparator|Placebo|Placebo
88976194|NCT04705675|Experimental|Experimental Group|The mothers in the experimental group (152) were administered.
88976195|NCT04705675|No Intervention|Control Group|The mothers in the control group (152) were administered.
88976196|NCT00047255|Experimental|Herceptin plus docetaxel|"Cycle 1: Day 1: Herceptin (H) 4 mg/kg loading dose administered by IV infusion over 90 minutes, Day 2: Docetaxel (T) 100 mg/m2 by IV infusion over 30 minutes, Day 8: (H) 2mg/kg administered by IV infusion over 30 minutes, Day 15: 2mg/kg administered by IV infusion over 30 minutes.~Subsequent cycles: Day 1: (T) 100mg/m2 as 1 hour IV infusion given every 3 weeks, followed by (H) 2 mg/kg IV infusion over 30 minutes, Day 8: (H) 2 mg/kg administered by IV infusion over 30 minutes, Day 15: (H) 2 mg/kg administered by IV infusion over 30 minutes.~Last cycle: Day 1: (T) 100mg/m2 as 1 hour IV infusion followed by (H) 2 mg/kg IV infusion over 30 minutes, Day 8: (H) 2 mg/kg administered by IV infusion over 30 minutes, Day 15: (H) 2 mg/kg administered by IV infusion over 30 minutes, Day 22: (H) 6 mg/kg administered by IV infusion over 30 minutes."
89030461|NCT00506480|Experimental|OD|patients artificially prepared for OD will undergo a mock cycle consisting of estrogen and later by progesterone. a pipelle sample will be taken after 6 days of progesterone supplementation.
89588533|NCT02154581|Active Comparator|Type 1 implant and thin biotype|In this group, immediate implant placement (SLActive implant) is performed in patients with thin tissue biotype. In addition to implant placement bone grafting of the void between the implant and the fresh extraction socket, bone grafting the buccal aspect of the buccal plate (overcontouring) and soft tissue grafting (connective tissue) are performed.
89588534|NCT02154581|Active Comparator|Type 1 implant and thick biotype|In this group, immediate implant placement (SLActive implant) is performed including bone grafting of the void between the implant and the fresh extraction socket.
89030462|NCT00506480|Experimental|IVF|A pipelle sample will be taken on day 21 of the cycle before administration of GNRHa. Exact timing will be performed by counting 7 days from the LH surge.
89030463|NCT04694508|Experimental|Group A|Headphones (Disok, Alicante, España)
89030464|NCT04694508|No Intervention|Group B|Without music therapy
89588535|NCT02154425|Experimental|Pharmacokinetic samples|"Pharmacokinetic (PK) samples will be taken from breast milk of lactating mothers on an established dosing regimen of CZP on Day 0 of the Sampling Period, just prior to next scheduled dose of CZP, and on Days 2, 4, 6, 8, 10, 12, and 14 (pre-dose if Q2W dosing), relative to CZP administration on Day 0. In addition, in mothers on a CZP Q4W dosing regimen, the concentration of CZP in breast milk will also be evaluated on or about Day 28 (i.e., prior to and on the same day of the next scheduled administration of CZP).~Included are mothers who decided to continue on, or to start treatment with, Certolizumab Pegol (CZP) for an approved indication with their treating physician prior to participation into this study. The mother is responsible for procuring her own supply of commercial CZP. The CZP dose and administration schedule will be as per the locally approved label."
89588536|NCT02154347|Experimental|KAD-1229/KAD-1229|Patients are administered KAD-1229 for 16 weeks (double-blind period), followed by KAD-1229 for up to 52 weeks (open-label period) with insulin throughout the study.
89588537|NCT02154347|Other|Placebo/KAD-1229|Patients are administered Placebo for 16 weeks (double-blind period), followed by KAD-1229 for up to 52 weeks (open-label period) with Insulin throughout the study.
89588538|NCT01627067|Experimental|Everolimus + Exemestane + Metformin|Patients take one 25 mg tablet of exemestane once daily, everolimus 10 mg orally per day and metformin 500 mg orally per day for three days. If there are no dose limiting toxicities, dose of metformin will be increased by 500 mg orally every three days to reach the target dose of 1,000 mg orally twice daily. Drugs will be taken immediately after a meal at the same time each day.
89588539|NCT02178059|Experimental|Bricanyl Turbuhaler M3|0.4 mg terbutaline sulphate (delivered dose) per inhalation
89588540|NCT02178059|Active Comparator|Bricanyl Turbuhaler M2|0.5 mg terbutaline sulphate (metered dose) per inhalation
89588541|NCT01626989|Active Comparator|BiPAP auto SV Advanced|BiPAP auto SV Advanced
89588542|NCT01626989|Experimental|BiPAP auto SV 4|Auto Servo Ventilation Device
89588543|NCT04748237|Experimental|Coronary computed tomopraphic angiography|"Patients randomized to strategy including early CCTA will receive standard care according to responsible physician and referred to a CCTA as soon as possible, preferably within 24 hours, but not later than within 7 days. Local scanning protocols can be used on ≥64-slice multi-detector CT scanners able to perform ECG-gated coronary angiography.~The coronary angiography will be classified as normal (or near normal) or as having atherosclerosis (CAD). The report will also classify each vessel (left main, prox LAD, mid or distal LAD, LCX and RCA regarding degree of stenosis (no stenosis, 0-49%, ≥50%, or not possible to estimate because of calcification or technical reason).~The result will be presented to the responsible physician as soon as possible and who will plan further care of the patients."
89588544|NCT04748237|No Intervention|No Coronary computed tomopraphic angiography|"Patients randomized to a strategy not including early CCTA will receive further care (including examinations) according to responsible physician but not include early CCTA. These patients will often undergo a non-invasive functional test, such as Exercise-ECG, stress echocardiography or nuclear imaging according to local routines, but not always.~Regardless of diagnostic strategy, the responsible physician is encouraged to initiate secondary prevention measures if the investigations indicate signs of CAD, including medication with aspirin and statins."
89588545|NCT02128217|Experimental|Cohort 1: SOF+weight-based RBV for 12 wks|Participants in Cohort 1 were assigned Sofosbuvir (SOF)+weight-based ribavirin (RBV) for 12 weeks. Follow-up visits occurred through to 24 weeks after the end of treatment.
89588546|NCT02128217|Experimental|Cohort 2: LDV/SOF for 8 wks|Participants in Cohort 2 were assigned Ledipasvir/Sofosbuvir for 8 weeks. Follow-up visits occurred through to 24 weeks after the end of treatment.
89588547|NCT01629953|Active Comparator|Group Based Vocational Rehabilitation|Group vocational intervention
89588548|NCT01629953|Experimental|Supported Employment Condition|Group vocational intervention + supported employment
89588549|NCT02127281|Active Comparator|Prevena|Prevena NPWT system will be used immediately following surgery and continue postoperatively until hospital discharge (expected average of 4 days).
89588550|NCT02127281|No Intervention|Control|A standard of care sterile wound dressing will be placed.
89588551|NCT01628549|Experimental|P005672-HCl approximately 0.75 mg/kg/day|One P005672-HCl 50 mg capsule and one Placebo capsule, oral administration, once daily for 12 weeks
89588552|NCT01628549|Experimental|P005672-HCl approximately 1.5 mg/kg/day|Two P005672-HCl 50mg capsules, oral administration, once daily for 12 weeks
89588553|NCT01628549|Experimental|P005672-HCl approximately 3.0 mg/kg/day|Two P005672-HCl 100mg capsules, oral administration, once daily for 12 weeks
89588554|NCT01628549|Placebo Comparator|Placebo|Two Placebo capsules matching P005672-HCl, oral administration, once daily for 12 weeks
89588555|NCT02127125|Placebo Comparator|Type2 Diabetes Mellitus - Placebo|Type 2 Diabetes Mellitus subjects will receive maltodextrin (placebo)
89588556|NCT02127125|Placebo Comparator|Obese with NGT - Placebo|Obese (BMI = 30-37 kg/m2) normal glucose tolerant (NGT) subjects will receive maltodextrin (placebo)
89588557|NCT02127125|Placebo Comparator|Lean with NGT -Placebo|Lean (BMI< 26 kg/m2) normal glucose tolerant (NGT) will receive maltodextrin (placebo)
89588558|NCT02127125|Active Comparator|Type2 Diabetes Mellitus - Synbiotic|Type 2 Diabetic subjects will receive synbiotic
89030465|NCT04515056|Experimental|Papain dosage|In the 1st session, each of the middle forearms of the subject will be divided into two squared areas (4x4 cm). The two areas will be located 4 cm apart. Three areas will be exposed to 10, 50 or 100 µg of papain, while the last area will be used as control (exposed to a vehicle).
89588559|NCT02127125|Active Comparator|Type2 Diabetes Mellitus - Sevelamer|Type 2 Diabetic subjects will receive sevelamer
89588560|NCT02127125|Active Comparator|Obese with NGT - Synbiotic|Obese (BMI = 30-37 kg/m2) normal glucose tolerant subjects (NGT) will receive Synbiotic
89588561|NCT02127125|Active Comparator|Obese with NGT - Sevelamer|Obese subjects (BMI = 30-37 kg/m2) normal glucose tolerant (NGT) will receive Sevelamer
89588562|NCT02127125|Active Comparator|Lean with NGT - Synbiotic|Lean (BMI< 26 kg/m2) normal glucose tolerant (NGT) will receive Synbiotic
89588563|NCT02127125|Active Comparator|Lean with NGT - Sevelamer|Lean (BMI< 26 kg/m2) normal glucose tolerant (NGT) will receive Sevelamer
89588564|NCT04417751|Experimental|Intervention Group|Intervention group will receive 47 sessions of individual CS and participate in 3 evaluation sessions. The CS program will last 1 year and each individual CS session will last approximately 45 minutes.
89588565|NCT04417751|No Intervention|Control Group|Participants assigned to the control group will maintain their usual treatment in the institution, participating in the activities previously assigned to their individual care plan.
89588566|NCT02090413|Experimental|DMF + ASA 150 mg BID|"DMF 120 mg taken BID for the first 7 days and 240 mg BID from Week 2 through Week 48.~ASA 150 mg is taken BID from Day 1 through Week 4. (Between Weeks 5 and 8, ASA is prohibited; between Weeks 9 and 48, ASA is allowed as needed.)"
89588567|NCT02090413|Experimental|DMF + ASA 75 mg QAM|"DMF 120 mg taken BID for the first 7 days and 240 mg BID from Week 2 through Week 48.~ASA 75 mg is taken in the morning (QAM) and ASA-Placebo is taken in the evening (QPM) from Day 1 through Week 4. (Between Weeks 5 and 8, ASA is prohibited; between Weeks 9 and 48, ASA is allowed as needed.)"
89588568|NCT02090413|Experimental|DMF + ASA-Placebo BID|"DMF 120 mg taken BID for the first 7 days and 240 mg BID from Week 2 through Week 48.~ASA-Placebo is taken BID from Day 1 through Week 4. (Between Weeks 5 and 8, ASA is prohibited; between Weeks 9 and 48, ASA is allowed as needed.)"
89588569|NCT04702165|Experimental|VATS resection with J-bar|Each patient with a lung nodule meeting criteria will undergo a lung resection which could be one of three approaches: iVATS with Dyna-CT, VATS, or open. Each approach will use a the experimental device the Lung Resection Marker Locator Kit
89588570|NCT02063737|Sham Comparator|Control Group|The control group will receive text-message assessments only at the start, during, and end of shift. These queries will attempt to capture the worker's self-reported sleepiness, fatigue, and occurrence of work-related injury during shift work.
89588571|NCT02063737|Experimental|Intervention Group|The intervention group will receive the same text-message assessments as the control group. In addition, these subjects will receive text-message interventions for high level fatigue for reducing fatigue and sleepiness during shift work if they report a high-level of fatigue or sleepiness at the start or during their shift. These subjects will then receive additional text message queries at the end of their shifts to determine if they adopted a strategy for reducing perceived sleepiness or fatigue.
89588572|NCT02125877|Active Comparator|Deferasirox dispersible tablet (DFX-DT)|Iron chelation naïve participants received DFX-DT 20 mg/kg/day once daily orally from weeks 1 - 4. After week 4, the dose could be adjusted by +/- 5 to 10 mg/kg/day, with a maximum dose of 40 mg/kg/day. Iron chelation pre-treated participants were supposed to start on a dose that was equivalent to their pre-washout dose.
89588573|NCT02125877|Experimental|Deferasirox film-coated tablet (DFX-FCT)|Participants received DFX-FCT 14 mg/kg/day once daily orally from weeks 1 - 4. After week 4, the dose could be adjusted by +/- 3.5 to 7 mg/kg/day, with a maximum dose of 28 mg/kg/day. Iron chelation pre-treated participants were supposed to start on a dose that was equivalent to their pre-washout dose
89588574|NCT01598987|Experimental|Everolimus based regimen|"Conversion at Baseline from an immunosuppressive regimen which contains either cyclosporine (CsA) or tacrolimus (TAC) with or without mycophenolic acid (MPA), with or without corticosteroids in a regimen which contains everolimus combined reduced dose of either cyclosporine (CsA) or tacrolimus (TAC).~The dosing schedule was twice daily, 12 hours apart."
88976197|NCT00047255|Experimental|Docetaxel, Carboplatin, and Herceptin|"Cycle 1: Day 1: Herceptin (H) 4 mg/kg loading dose admin by IV over 90 mins, Day 2: Docetaxel (T) 75 mg/m2 by IV over 1 hour followed by carboplatin (C) at target AUC=6 mg/mL/min admin by IV over 30-60 mins, Day 8: (H) 2mg/kg admin by IV over 30 mins, Day 15: 2mg/kg admin by IV over 30 mins.~Subsequent cycles: Day 1: (T) 75mg/m2 as 1 hour IV followed by (C) at target AUC=6 mg/mL/min admin by IV 30-60 mins every 3 weeks followed by (H) 2 mg/kg IV over 30 mins, Day 8: (H) 2 mg/kg admin by IV over 30 mins, Day 15: (H) 2 mg/kg admin by IV over 30 mins.~Last cycle: Day 1: (T) 75mg/m2 as 1 hour IV followed by (C) at target AUC=6 mg/mL/min admin by IV 30-60 mins every 3 weeks followed by (H) 2 mg/kg IV over 30 mins, Day 8: (H) 2 mg/kg admin by IV over 30 mins, Day 15: (H) 2 mg/kg admin by IV over 30 mins, Day 22: (H) 6 mg/kg admin by IV over 30 mins."
88976198|NCT00134680|Experimental|Letrozole & Trastuzumab|Letrozole 2.5 mg tablets daily and Trastuzumab 2 mg/kg by IV weekly
88976199|NCT00134758|Experimental|1|"Ursodeoxycholic acid during 2 years :~between 40 and 50 kg : 500 mg/day~between 51 and 75 kg : 750 mg/day~between 76 and 100 kg : 1000 mg/day"
88976200|NCT00134758|Placebo Comparator|2|
88976201|NCT00047333|Experimental|Treatment (erlotinib hydrochloride)|Patients receive oral erlotinib once daily. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88976202|NCT00047411|Active Comparator|1|Intervention: Immediate notification of EMS by telephone and prompt initiation of CPR, in accordance with published Basic Life Support guidelines.
88976203|NCT00047411|Experimental|2|Use of the AED first, in accordance with published guidelines for AED use, followed by a call to EMS and perform CPR as in the control group.
88976204|NCT00047450|Placebo Comparator|1|Participants will take placebo
88976205|NCT00047450|Active Comparator|2|Participants will take citalopram (Celexa)
88976206|NCT00081276|Experimental|Treatment (triapine and cisplatin)|Patients receive 3-AP IV over 2 hours on days 1-4 and cisplatin IV over 1 hour on days 2 and 3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
88976207|NCT00145522|Experimental|1|
88976208|NCT00145522|Active Comparator|2|
88976209|NCT00145639|Other|1|
88976210|NCT00145678|Experimental|dynamic deconstructive psychotherapy|weekly individual psychotherapy of 50 minute duration lasting 12-18 months
89588575|NCT02063659|Experimental|250 mg Telotristat Etiprate|Following a 3 to 4-week run-in period, participants were randomized to receive one 250 mg telotristat etiprate tablet and one placebo-matching telotristat etiprate tablet administered three times daily for 12 weeks, followed by a 36 week open-label extension period.
89588576|NCT02063659|Experimental|500 mg Telotristat Etiprate|Following a 3 to 4-week run-in period, participants were randomized to receive one 250 mg telotristat etiprate tablet and one placebo-matching telotristat etiprate tablet administered three times daily for one week, followed by two 250 mg telotristat etiprate tablets administered three times daily for 11 weeks in the 12 week double-blind treatment period, followed by a 36 week open-label extension period.
89588577|NCT02063659|Placebo Comparator|Placebo|Following a 3 to 4-week run-in period, participants were randomized to receive two placebo-matching telotristat etiprate tablets administered three times daily for 12 weeks, followed by a 36 week open-label extension period.
89588578|NCT02062879|Experimental|Ketamine|Ketamine 90mg/30 mL PCA (3 mg/mL)
89588579|NCT02062879|Active Comparator|Hydromorphone|Hydromorphone 6mg/30 mL PCA (0.2 mg/mL)
89588580|NCT02062645|Experimental|amlodipine/valsartan|All patients will receive amlodipine/valsartan 5/160 mg daily in screening and up titrated to amlodipine/valsartan 10/160 mg daily at visit 2 (day 30) if their hypertension can not be controlled. The duration of treatment period is 8 weeks.
89588581|NCT04700839|Experimental|SGLT2 inhibitors group|Intervention with SGLT2 inhibitors (100mg/d) for 3 months
88976211|NCT00145678|Active Comparator|optimized community care|eclectic weekly individual and group psychotherapy, as well as drug and alcohol rehabilitation
88976212|NCT00081354||Barrett's esophagus|Barrett's esophagus
88976213|NCT00081354||Controls negative for Barrett's esophagus|Controls negative for Barrett's esophagus
88976214|NCT04706065||GROUP 1|Group 1 (patients with PD) All participants will be subjected to thorough history taking, full clinical and neurological examination. Diagnosis of PD by using Brain Bank Criteria for diagnosis of Parkinson Disease , assessment of the severity of PD by using PDRS and evaluation of cognitive functions using MMSE.
88976215|NCT04706065||Group 2|Group 2 (controls) All participants will be subjected to thorough history taking, full clinical and neurological examination.
88976216|NCT00145912|Experimental|Intrinsic Motivation|PCP motivational interview + Internet program
88976217|NCT00145912|Active Comparator|Extrinsic Motivation|PCP breif advice + Internet Program
88976218|NCT00145951||1|
88976219|NCT00145951||2|
88976220|NCT00145951||3|
88976221|NCT00081471|Experimental|1|
88976222|NCT00081471|Active Comparator|2|
88976223|NCT00146107|No Intervention|1|
88976224|NCT00146107|Experimental|2|Weight loss
89588582|NCT04700839|Active Comparator|Metformin group|Intervention with metformin (1500-2000mg/d) for 3 months
89588583|NCT02088697|Experimental|ASC-01 placebo|A single oral dose of ASC-01 Placebo (sertraline 100 mg)
89588584|NCT02088697|Active Comparator|Sertraline tablet|A single oral dose of sertraline tablets (sertraline 100 mg)
89588585|NCT01825785|Placebo Comparator|Placebo|Participants were randomized to receive matching placebo administered by subcutaneous injection once every 2 weeks (Q2W) or once every 4 weeks (Q4W) for 3 months.
89588586|NCT01825785|Experimental|Romosozumab|Participants were randomized to receive romosozumab administered by subcutaneous injection at doses of 1 mg/kg Q2W, 2 mg/kg Q4W, 2 mg/kg Q2W, or 3 mg/kg Q4W for 3 months.
89588587|NCT02043301|Active Comparator|Single 150 mg PF-04950615 dose administered to the abdomen|
89588588|NCT02043301|Experimental|Single 150 mg PF-04950615 dose administered to the upper arm|
89588589|NCT02043301|Experimental|Single 150 mg PF-04950615 dose administered to the thigh|
89588590|NCT01598753|Active Comparator|Tramadol|
89588591|NCT01598753|Placebo Comparator|Placebo|
89588592|NCT01598753|Active Comparator|Cognitive Behavior Therapy for FM|
88976225|NCT00146107|Experimental|3|Exercise
88976226|NCT00146107|Experimental|4|Weight loss and exercise
88976227|NCT00146224|Active Comparator|Epoetin alfa RB|
88976228|NCT00146224|Experimental|Epoetin alfa DT|
88976229|NCT00146263|Active Comparator|Savyon|Computerized cognitive training using the Savyon software
88976230|NCT00146263|Placebo Comparator|Control|Usual activity
88976231|NCT00081588|Experimental|001|TMC114600/100 mg tablets of TMC114/rtv BID for 144 weeks or until commercial available
88976232|NCT02957890|Experimental|Twice-annual influenza vaccination|Twice-annual influenza vaccination: administrations of inactivated influenza vaccine (Northern hemisphere formulation, NH) prior to the northern hemisphere winter, plus inactivated influenza vaccine (Southern hemisphere formulation, SH) prior to the northern hemisphere summer.
88976233|NCT02957890|Placebo Comparator|Once-annual influenza vaccination|Administrations of inactivated influenza vaccine (Northern hemisphere formulation, NH) prior to the northern hemisphere winter, plus placebo prior to the northern hemisphere summer.
88976234|NCT00146575|Experimental|1|randomized patients get sirolimus stent
88976235|NCT00146575|Experimental|2|randomized patients get paclitaxel stent
88976236|NCT00146653||Xa|An additional 20 patients will be enrolled to address the validation of heparin concentrations calculated by the Hepcon machine with laboratory-measured heparin concentrations. These patients will not be randomized and therefore will not receive an intervention. .
88976237|NCT00042978|Experimental|Arm I (oblimersen sodium, carboplatin, and etoposide)|Patients receive oblimersen sodium IV continuously on days 1-8, carboplatin IV over 30 minutes on day 6, and etoposide IV over 60 minutes on days 6-8. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
88976238|NCT00042978|Active Comparator|Arm II (carboplatin and etoposide)|Patients receive carboplatin IV over 30 minutes on day 1 and etoposide IV over 60 minutes on days 1-3. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
89588593|NCT01598753|Sham Comparator|Health Education|
89588594|NCT02177123|Experimental|InnFocus MicroShunt Surgery|InnFocus MicroShunt implantation in the anterior chamber of the eye on patients with primary open angle glaucoma after am antiproliferative treatment of mitomycin C (MMC)
89588595|NCT01824693|Experimental|Arm I (busulfan, cyclophosphamide, melphalan)|"CONDITIONING REGIMEN: Patients receive busulfan IV QD, every 12 hours, or every 6 hours over 2-3 hours on days -8 to -5, cyclophosphamide IV QD over 60 minutes on days -4 and -3, and melphalan IV over 15-30 minutes on day -1.~TRANSPLANT: Patients undergo allogeneic HCT no sooner than 24 hours after the last dose of chemotherapy.~Patients receive tacrolimus IV or PO on days -1 to 98 (related donor) or 180 (unrelated donor) and mycophenolate mofetil IV over 2 hours or PO every 8 hours on days 1-30 (related donor) or 45 (unrelated donor)."
89588596|NCT01824693|Experimental|Arm II (busulfan, fludarabine phosphate)|"CONDITIONING REGIMEN: Patients receive busulfan as in Arm I and fludarabine phosphate IV over 1 hour on days -5 to -2.~TRANSPLANT: Patients undergo allogeneic HCT as in Arm I.~Patients receive tacrolimus IV or PO on days -1 to 98 (related donor) or 180 (unrelated donor) and mycophenolate mofetil IV over 2 hours or PO every 8 hours on days 1-30 (related donor) or 45 (unrelated donor)."
89588597|NCT02176655|Active Comparator|VVD-101|One sumatriptan succinate 12.5 mg combined with acetylsalicylic acid 325 mg (VVD-101) capsule taken after the onset of a delayed alcohol induced headache.
89588598|NCT02176655|Placebo Comparator|Placebo|One placebo capsule to match taken after the onset of a delayed alcohol induced headache.
89588599|NCT02125331||PDM-SuperSTAT|PDM-SuperSTAT Arm (minimum of 55 evaluable patients): GE DINAMAP® SuperSTAT algorithm delivered by the PDM acquisition module connected to the CARESCAPE Monitor B650
89588600|NCT02125331||PSM-Datex-Ohmeda|PSM-Datex-Ohmeda Arm (minimum of 45 evaluable patients): Datex-Ohmeda delivered by the PSM acquisition module connected to the CARESCAPE Monitor B650
89588601|NCT01622569|Active Comparator|OPN-375 100 μg BID|"Double-Blind Treatment Phase: OPN-375 100 μg BID x 16 weeks~Open-Label Extension Phase: OPN-375 400 μg BID x 8 weeks"
89588602|NCT01622569|Placebo Comparator|Placebo|"Double-Blind Treatment Phase: Matching Placebo BID x 16 weeks~Open-Label Extension Phase: OPN-375 400 μg BID x 8 weeks"
89588603|NCT01622569|Active Comparator|OPN-375 200 μg BID|"Double-Blind Treatment Phase: OPN-375 200 μg BID x 16 weeks~Open-Label Extension Phase: OPN-375 400 μg BID x 8 weeks"
89588604|NCT01622569|Active Comparator|OPN-375 400 μg BID|"Double-Blind Treatment Phase: OPN-375 400 μg BID x 16 weeks~Open-Label Extension Phase: OPN-375 400 μg BID x 8 weeks"
89588605|NCT01824303|Experimental|LiRIS 400 mg|LiRIS 400 mg: investigational drug-delivery system which contains Lidocaine; the system remains in the bladder for 14 days. If eligible, participants could participate in the Open Label Extension where all participants were treated with LiRIS 400 mg.
89588606|NCT01824303|Placebo Comparator|LiRIS Placebo|LiRIS Placebo: investigational drug-delivery system which contains Lactose and no Lidocaine; the system remains in the bladder for 14 days. If eligible, participants could participate in the Open Label Extension where all participants were treated with LiRIS 400 mg.
89588607|NCT01853397|Experimental|Treatment at level 1|Single treatment with Liposonix System (Model 2) using single pass technique at level 1 (180 J/cm2)
89588608|NCT01853397|Experimental|Treatment at level 2|Single treatment with Liposonix System (Model 2)using the single pass technique at treatment level 2 (140 J/cm2)
89588609|NCT01853397|Experimental|Treatment at level 3|Single treatment with Liposonix System (Model 2)using single pass technique at level 3 (120 J/cm2)
89588610|NCT01853397|Active Comparator|Treatment with 3 passes at 60 J/cm2|Single treatment with Liposonix System (Model 2) using grid repeat technique with 3 passes at 60 J/cm2 (180 J/cm2 total fluence)
89588611|NCT02088073|Experimental|Sodium zirconium cyclosilicate 10 g three times daily|Sodium zirconium cyclosilicate 10 g three times daily for 48 hours (acute phase)
88976239|NCT00405730|Experimental|Nepafenac|One drop in the study eye 3 times daily for 23 days
88976240|NCT00405730|Active Comparator|Ketorolac Trometamol|One drop in the study eye 3 times daily for 23 days
88976241|NCT00405730|Placebo Comparator|Nepafenac Vehicle|One drop in the study eye 3 times daily for 23 days
88976242|NCT00405769|Placebo Comparator|1|placebo control
88976243|NCT00405769|Active Comparator|2|red yeast rice
88976244|NCT00043017|Experimental|MRI/MRS|MRI and MRS examinations with standard imaging, with contrast enhancement using an agent (gadopentetate dimeglumine).
88976245|NCT02957812|Experimental|Orthotics|Custom made orthotic provided for study
88976246|NCT02957812|No Intervention|Control|Wearing own footwear
88976247|NCT00147004|Experimental|1|hydrocortisone sodium succinate
88976248|NCT00147004|Placebo Comparator|2|Placebo
88976249|NCT00147121|Active Comparator|1|Rituximab+Standard CHOP
88976250|NCT00147121|Experimental|2|Rituximab+bi-Weekly CHOP
88976251|NCT04732104|Experimental|intranasal spray anesthesia|intranasal lidocaine lidocaine 4% topical
89588612|NCT02088073|Placebo Comparator|Placebo once daily|Randomized to mimic doses of experimental drug administered once daily with breakfast for 28 days.
89588613|NCT02088073|Experimental|Sodium zirconium cyclosilicate 5 g once daily|Sodium zirconium cyclosilicate (ZS) 5 g once daily for 28 days (maintenance phase)
89588614|NCT02088073|Experimental|Sodium zirconium cyclosilicate 10 g once daily|Sodium zirconium cyclosilicate (ZS) 10 g once daily for 28 days (maintenance phase)
89588615|NCT02088073|Experimental|Sodium zirconium cyclosilicate 15 g once daily|Sodium zirconium cyclosilicate (ZS) 15 g once daily for 28 days (maintenance phase)
88976252|NCT04732104|Active Comparator|injectable local anesthesia|gold standard infiltration local anesthesia (2% lidocaine with 1:100,000 epinephrine)
88976253|NCT00147355|Other|A|Ondansetron 4mg bid + Ibuprofen 200mg qds + paracetamol 1g qds days 1-6 inclusive of rIL-2 dosing cycle
88976254|NCT00147355|Other|B|Ondansetron 4mg bid + codeine phosphate 15mg tds + Ibuprofen 200mg qds + paracetamol 1g qds days 1-6 inclusive of rIL-2 dosing cycle
88976255|NCT00147355|Other|D|metoclopramide 10mg qds + codeine phosphate 15mg tds + Ibuprofen 200mg qds + paracetamol 1g qds days 1-6 inclusive of rIL-2 dosing cycle
88976256|NCT00147355|Other|C|metoclopramide 10mg qds + Ibuprofen 200mg qds + paracetamol 1g qds days 1-6 inclusive of rIL-2 dosing cycle
88976257|NCT00048152|Experimental|1|
88976258|NCT00048152|Experimental|2|
88976259|NCT00048152|Experimental|3|
88976260|NCT00147472|Other|PET|All patients receive PET scan and conventional CT imaging.
89588616|NCT01823991|Experimental|COGNUTRIN (VITABLUE and n-3 fatty acids)|Participants will be provided with two bottles containing Lovaza and VitaBlue. Participants will be asked to take 1 tablet of Lovaza two times a day and 1 tablet of VitaBlue three times a day.
89588617|NCT01823991|Placebo Comparator|Placebo Administration|Participants will be provided with two bottles containing placebo. Participants will be asked to take 1 tablet of one placebo two times a day and 1 tablet of other placebo three times a day.
89588618|NCT04729855||colorectal cancer patients|"Colorectal cancer patients( n = 74 ) from stage I-III with the following criteria:-~a. Inclusion criteria:~No sex predilection.~Age (25-65 yr).~Colorectal carcinoma confirmed by histopathological examination"
89588619|NCT04729855||Healthy controls ( n = 74)|matched as regarding age and sex as much as possible with cases.
89588620|NCT02087059|Experimental|Ruxolitinib|Ruxolitinib was administered orally twice daily at the starting dose of 5 mg, 15 mg or 20 mg bid based on Baseline platelet counts. The dosage was subsequently adjusted for safety and efficacy so that each patient was titrated to their most appropriate dose.
89588621|NCT02152163|Active Comparator|IV Ibuprofen 800 mg|IV Ibuprofen 800 mg
89588622|NCT02152163|Placebo Comparator|IV Saline|IV Saline
89588623|NCT02152007|Experimental|Split-body 1% sirolimus cream (TD201 1%)|This is a split-body design. Subjects will self-administer 1% topical sirolimus cream or placebo cream (no drug, vehicle control) on the plantar surface of each foot. At least one foot will be treated with topical sirolimus at some time during the study. Application will be one time daily for a total of 26 weeks. There will be an additional follow-up visit 3 months after the last application of study drug. The total duration of the study is 39 weeks.
89588624|NCT02151851|Experimental|Certolizumab Pegol + Methotrexate|"Subjects will receive loading doses of CZP 400 mg (200 mg / prefilled syringe [PFS], ie, 2 injections) at Baseline, and Weeks 2 and 4; then CZP 200 mg (1 injection) Q2W until Week 22.~All subjects will continue their treatment on Methotrexate (MTX), with or without folic acid, at the same dose and route of administration as at entry (unless there is a need to reduce the dose for reasons of toxicity, minimum dose permitted 10 mg per week)."
89588625|NCT02151851|Placebo Comparator|Placebo + Methotrexate|"Subjects will receive Placebo (1mL / prefilled syringe [PFS], ie, 2 injections) at Baseline, and Weeks 2 and 4; then Placebo (1 injection) Q2W until Week 22.~All subjects will continue their treatment on Methotrexate (MTX), with or without folic acid, at the same dose and route of administration as at entry (unless there is a need to reduce the dose for reasons of toxicity, minimum dose permitted 10 mg per week)."
89588626|NCT02176421|Experimental|VOLBELLA® with lidocaine|Infra-orbital skin depressions injected with VOLBELLA® with lidocaine.
89588627|NCT02042443|Experimental|Trametinib|Patients receive trametinib PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89588628|NCT02042443|Experimental|Chemotherapy|Patients receive either A) leucovorin calcium IV over 2 hours and fluorouracil IV continuously over 46-48 hours on days 1 and 15 (courses repeat every 28 days); or B) capecitabine PO BID on days 1-14 (courses repeat every 21 days). Patients treated until disease progression or unacceptable toxicity.
89588629|NCT02118896|Experimental|1: FK506E (MR4)|Single open arm of FK506E (MR4). Since this was an extension study for many studies, generally the dose given at enrollment was to be continued. The investigator was permitted to adjust the subject's dose and modify the MR4 dose regimen as deemed necessary to minimize Adverse Events (AEs) and maintain effective immunosuppression. MR4 capsules were taken orally, once daily in the morning. MR4 capsules were to be swallowed with fluid (preferably water) on an empty stomach or at least 1 hour before or 2 to 3 hours after a meal. MR4 was supplied as 0.5 mg, 1 mg and 5 mg capsules in amber glass bottles or in blister packs.
89588630|NCT02124707|Experimental|Carboplatin, Paclitaxel and Cetuximab|A 6 week course of weekly carboplatin, paclitaxel, and cetuximab will be administered to 38 patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). Once protocol therapy is complete, cetuximab may be continued if the patient and physician agree. Within 3 weeks of the end of protocol therapy, response will be assessed, and if the patient has achieved at least stable disease, the treating physician may continue to treat with weekly cetuximab at their discretion until disease progression. Patients will be followed for a maximum of 3 years after the end of the 6 week treatment phase.
89588631|NCT02067728|Active Comparator|Usual Care|Usual care is provided to patients in practice groups not undergoing intervention of FNPA tool
89588632|NCT02067728|Experimental|FNPA tool intervention|FNPA tool practice intervention comprising of two components: 1) FNPA assessment which screens for obesigenic behaviors; 2) Brief Action Planning conversation designed to assist the family develop a health behavior change goal based on obesigenic risks on the assessment tool.
89588633|NCT02118428|Experimental|Mirasol|Transfusions with Mirasol-treated whole blood
89588634|NCT02118428|Active Comparator|Control|Transfusions with untreated whole blood
89588635|NCT02067104|Placebo Comparator|Placebo|receive 150 mg of oral placebo daily for a period of 2 months
88976261|NCT04725682|Active Comparator|Sequence 1 (TRTR)|"Each subject is scheduled to receive each treatment twice by the end of the study in the order of TRTR.~Treatment T (Test): 1 × 1mg Test tacrolimus capsules (Applicant holder: Accord Healthcare, Inc.); Treatment R (Reference): 1 × 1mg RLD tacrolimus capsules"
88976262|NCT04725682|Active Comparator|Sequence 2 (RTRT)|"Each subject is scheduled to receive each treatment twice by the end of the study in the order of RTRT.~Treatment T (Test): 1 × 1mg Test tacrolimus capsules (Applicant holder: Accord Healthcare, Inc.); Treatment R (Reference): 1 × 1mg RLD capsules"
89588636|NCT02067104|Experimental|Vismodegib|receive 150 mg of vismodegib daily for a period of 2 months
88976263|NCT00147550|Experimental|1|
88976264|NCT00147901|Experimental|FCCam|After an initial subcutaneous dose escalation of alemtuzumab over 2 days, 30 mg alemtuzumab s.c., cyclophosphamide 200 mg/m2 i.v. and 25 mg/m2 fludarabine i.v. were administered on three consecutive days. Treatment was repeated after 28 days for up to six cycles
88976265|NCT02957851|Placebo Comparator|Oxygen/Nitrogen (22%/78%)|Medical Air
88976266|NCT02957851|Active Comparator|Nitrous Oxide/Oxygen (50%/50%)|EMONO
88976267|NCT00147979|Experimental|1|PTFE with bounded heparin
88976268|NCT00147979|Active Comparator|2|PTFE without bounded heparin
88976269|NCT00081822|Other|Clofarabine + Ara-C|An initial dose escalation of clofarabine with a fixed standard dose of Ara-C in phase I will be used to determine an optimal phase II dose.
89588637|NCT02092220|Experimental|Bionic Pancreas|Bionic Pancreas diabetes management, a wearable bionic pancreas system that automatically delivers insulin and glucagon using a continuous glucose monitoring (CGM) device, for 11 days.
89588638|NCT02092220|Active Comparator|Usual Care|Usual Care diabetes management, standard of care for diabetes including use of an insulin pump with or without CGM according to the participant's usual practice, for 11 days.
89588639|NCT02066402|Experimental|Tedizolid Phosphate (Sivextro, BAY119-2631)|Participants received 200 mg Tedizolid Phosphate once daily intravenous (I.V.) infusion to oral for 6 days, followed by 4 days of placebo.
89588640|NCT02066402|Active Comparator|Linezolid|Participants received 600 mg Linezolid twice daily I.V. infusion to oral for 10 days.
89588641|NCT02060383|Experimental|Incretin based therapy (randomized group)|Participants randomized to the incretin based arm started with sitagliptin once daily. If sitagliptin did not control the participant's hyperglycemia, sitagliptin was stopped and participants switched to liraglutide once daily. If despite treatment with liraglutide, hyperglycemia was not controlled then the participant was eligible for rescue therapy with addition of insulin.
89588642|NCT02060383|Experimental|Insulin (randomized group)|Participants randomized to the insulin arm started with once daily dose of basal insulin. The dose was up or down titrated at the discretion of the investigator. If blood glucose levels remained uncontrolled on basal insulin, participant switched to basal insulin plus prandial insulin.
88976270|NCT00148096|Placebo Comparator|1|Mechanical heat recovery ventilation units installed but not fully functional
88976271|NCT00148096|Active Comparator|2|Mechanical heat recovery ventilation unit installed and active
88976272|NCT00148174|Experimental|Phone calling|Phone calling to encourage improved adherence
89209838|NCT00887172|Placebo Comparator|4|Wind-heat syndrome group were patients classified by Chinese Medicine practitioner of Wind-heat syndrome and took placebo of Ying Qiao san.
89209839|NCT00609492|Experimental|Preterm I Group|Children born after a gestation period of 27-30 weeks
89209840|NCT00609492|Experimental|Preterm II Group|Children born after a gestation period of 31-36 weeks
89209841|NCT00609492|Active Comparator|Full term Group|Children born after a gestation period of more than 36 weeks
88976273|NCT00148369||Observational Group|Subjects previously administered GDNF and have discontinued the drug.
88976274|NCT00405808|Experimental|1|Administration of one tablet containing 20 mg of Rimonabant
88976275|NCT00405808|Placebo Comparator|2|Administration of one Rimonabant placebo tablet.
89209842|NCT00230971|Active Comparator|A|
89209843|NCT00230971|Active Comparator|B|
89209844|NCT02541318|Experimental|Practice-from Beginning Group|"The Practice-from Beginning Group will practice Duo-in exercise 20 minutes every day for 2 months; while there is no intervention in the Practice-2 month Later Group. Then, after 2 weeks, the participants of Practice-from Beginning Group and Practice-2 month Later Group will crossover. The Practice-from Beginning Group has no intervention, but the Practice-2 month Later Group will practice Duo-in exercise for 2 months."
89209845|NCT02541318|Other|Practice-2 month Later Group|"The Practice-from Beginning Group will practice Duo-in exercise 20 minutes every day for 2 months; while there is no intervention in the Practice-2 month Later Group. Then, after 2 weeks, the participants of Practice-from Beginning Group and Practice-2 month Later Group will crossover. The Practice-from Beginning Group has no intervention, but the Practice-2 month Later Group will practice Duo-in exercise for 2 months."
89209846|NCT02542722|Active Comparator|Control|General dietary and physical exercise recommendations
89209847|NCT02542722|Experimental|Intervention|Intensive intervention on dietary and physical exercise habits.
89209848|NCT00211081|Experimental|Open Label|
88976276|NCT00081900|Experimental|DENSPM|
88976277|NCT00148525|Experimental|social cognitive theory|This arm received an diet intervention designed to maintain changes in fruit and vegetable consumption. The intervention components were based on social cognitive theory and delivered by an automated telephone system.
88976278|NCT00148525|Experimental|Goal Systems Theory|This arm received an diet intervention designed to maintain changes in fruit and vegetable consumption. The intervention components were based on goal systems theory.
88976279|NCT00148525|No Intervention|Comparison group|comparison group
88976280|NCT00148564|Active Comparator|Olanzapine|
88976281|NCT00148564|Active Comparator|Zpirasidone|
89209849|NCT05278806|Experimental|Equity Dashboard, Population Health Coordinator and Community Health Worker Support|After the step in which the primary care providers are randomized to receiving intervention, one group of providers will receive the equity dashboard data and complete an equity huddle where they will review their list of eligible patients (Black, Indigenous and People of Color [BIPOC] patients and patients with limited English proficiency [LEP]) with a population health coordinator (PHC). The goal of the equity huddle will be to develop a plan to improve eligible patients' hypertension control. One of the options will be to refer patients to a community health worker (CHW) program focused specifically on addressing hypertension.
89209850|NCT05278806|Experimental|Equity Dashboard and Population Health Coordinator Support|After the step in which the primary care providers are randomized to receiving intervention, a second group of providers will receive the equity dashboard data and complete an equity huddle where they will review their list of eligible patients (Black, Indigenous and People of Color [BIPOC] patients and patients with limited English proficiency [LEP]) with a population health coordinator (PHC). The goal of the equity huddle will be to develop a plan to improve eligible patients' hypertension control.
89209851|NCT05278806|No Intervention|Delayed intervention|Black, Indigenous and People of Color (BIPOC) patients and patients with limited English proficiency (LEP) before their primary care providers are randomized to receiving the intervention. (By the end of the 12 steps, all BIPOC/LEP patients will be assigned to an experimental group)
89209852|NCT05278806|No Intervention|Usual Care|Patients who are not eligible for additional clinical support (i.e. White and English speaking patients).
89209853|NCT03971227|Experimental|Acuity 200 contact lens|Rigid gas permeable contact lens for daily wear, fluoroxyfocon A
89209854|NCT03971227|Active Comparator|Acuity 100 contact lens|Rigid gas permeable contact lens for daily wear, hexafocon A
89588643|NCT02060383|Other|Non-Randomized Arm|"This arm represents the non-randomized participants: Cushing's Disease (CD) or Acromegaly participants, who received pasireotide s.c. or LAR (long-acting release) respectively, but who were not randomized to the Incretin or Insulin arms.~For the purpose of analysis, this non-randomized arm is further split into 3 groups:~Baseline insulin group (BL insulin) includes participants who were receiving insulin at study entry~Oral antidiabetic drugs (OAD) group includes participants who developed hyperglycemia that was controlled by metformin and/or other background anti-diabetic treatment~No OAD group includes participants who did not receive any anti-diabetic medication during the core phase of the trial"
89588644|NCT02086591|Experimental|Doxycycline|Doxycycline 200 mg twice daily
89588645|NCT02065622|Experimental|Induction (Main Study + Japan Sub-study): I-SD|Induction Standard Dose: Double-blind adalimumab regimen of 160 mg at Week 0 followed by 80 mg at Week 2, 40 mg at Week 4, and 40 mg at Week 6.
89588646|NCT02065622|Experimental|Induction (Main Study + Japan Sub-study): I-HD|Induction Higher Dose: Double-blind adalimumab regimen of 160 mg at Weeks 0, 1, 2, and 3 followed by 40 mg at Week 4, and 40 mg at Week 6.
89588647|NCT02065622|Experimental|Maintenance (Main Study + Japan Sub-study): M-SD|Maintenance Standard Dose: Double-blind adalimumab 40 mg every other week (eow), for 44 weeks.
88976282|NCT00148642|Experimental|1|silver salts coated endotracheal tube
88976283|NCT00148642|Placebo Comparator|2|uncoated endotracheal tube
88976284|NCT00148681|Experimental|Lower Risk Regimen|
88976285|NCT00148681|Experimental|Higher Risk Regimen|
88976286|NCT00148876|Active Comparator|Capecitabine|Capecitabine 2500 mg/m² orally day 1-14 q day 22 until progression and discontinuation of Trastuzumab.
88976287|NCT00148876|Experimental|Capecitabine and Trastuzumab|Capecitabine 2500 mg/m² orally day 1-14 q day 22 until progression + Trastuzumab 6 mg/kg body weight every 3 weeks i.v. as a 90 min infusion until progression
88976288|NCT00148915|Experimental|Ibandronate|Participants will receive 150 milligrams (mg) ibandronate tablet orally once monthly for one year.
88976289|NCT00148915|Placebo Comparator|Placebo|Participants will receive ibandronate matched placebo tablet orally once monthly for one year.
88976290|NCT00149071|Active Comparator|A|rTMS
88976291|NCT00149071|Sham Comparator|B|sham rTMS
88976292|NCT00149110|Experimental|A|Sleep deprivation in combination with light and duloxetine
88976293|NCT00149110|Active Comparator|B|Exercise and duloxetine
88976294|NCT00149383|Placebo Comparator|2|
88976295|NCT00149383|Experimental|1|
88976296|NCT02965365||TTN positive group|The group which subsequently diagnosed as TTN
89209855|NCT00884676|Experimental|Schedule A|Schedule A: Ixabepilone - Weekly for 3 weeks each cycle (Days 1, 8 and 15) For both Schedules A and B, Sunitinib daily, orally, starting on Day 8 of Cycle 1
89209856|NCT00884676|Experimental|Schedule B|Ixabepilone - Day 1 of each 3-week cycle For both Schedules A and B, Sunitinib daily, orally, starting on Day 8 of Cycle 1.
89209857|NCT02542800|Experimental|Healthy participants|
89209858|NCT04036812|Experimental|Superficial cervical plexus block group|
89209859|NCT04036812|Sham Comparator|Control group|
89209860|NCT00891384|Experimental|1|25 mg lenalidomide
89209861|NCT00891384|Experimental|2|5 mg lenalidomide
89588648|NCT02065622|Experimental|Maintenance (Main Study + Japan Sub-study): M-HD|Maintenance Higher Dose: Double-blind adalimumab 40 mg every week (ew) for 44 weeks.
88976297|NCT02965365||TTN negative group|The group which is not diagnosed as TTN
88976298|NCT00149422|Active Comparator|NT-proBNP guided treatment group|In this group, management was guided by an individually set NT-proBNP, defined by the lowest level at discharge or 2 weeks thereafter. If NT-proBNP levels were elevated above the individually set NT-proBNP interventions were performed according to the ESC heart failure guidelines.
88976299|NCT00149422|Placebo Comparator|Clinically guided arm|Heart failure treatment guided by clinical assessment.
88976300|NCT00048854|Active Comparator|1|Participants will receive treatment as usual
88976301|NCT00048854|Experimental|2|Participants will take sertraline
88976302|NCT00149461|Experimental|Written Asthma Action Plan Group|Participants randomized to the written asthma action plan group received an asthma action plan form along with asthma education from their specialist physician.
88976303|NCT00149461|No Intervention|No Written Instructions Group|Participants randomized to the usual care group received no written instructions other than prescriptions from their specialist physician.
88976304|NCT00149500|Experimental|Coaching group for lifestyle changes|Patients received monthly phone calls with coaching for lifestyle changes over 2 years.
88976305|NCT00149500|No Intervention|Routine pediatric care|This group receives routine care with their pediatrician.
88976306|NCT00048971||Group 1|Patients undergo collection of blood specimens for polymerase chain reaction and restriction fragment length polymorphism analysis. Genotyping assays are performed to determine UGT1A1 promoter genotyping, UGT1A1 coding polymorphisms, TS promoter polymorphisms, and MTHFR polymorphisms.
89209862|NCT00887328|Experimental|IV tPA|intravenous tissue plasminogen activator
89209863|NCT00887328|Placebo Comparator|Placebo|
89209864|NCT00609336|Experimental|Treatment (chemotherapy, radiation, pancreaticoduodenectomy)|See Detailed Description
89209865|NCT02542566|Active Comparator|early weight bearing|early weight bearing and accelerated physiotherapy rehabilitation
89588649|NCT02065622|Experimental|Maintenance (Main Study): TDM Regimen|Double-blind adalimumab 40 mg eow at Week 8 and Week 10, with possible dose adjustments at Weeks 12, 24, and 37 based on criteria assessing blinded adalimumab serum concentration and rectal bleeding subscore (RBS) assessments.
89588650|NCT02117648|Experimental|Abemaciclib Alone Period 1|50 mg single oral dose of Abemaciclib was administered in Period 1 Day 1.
89588651|NCT02117648|Experimental|Abemaciclib + Clarithromycin Period 2|Clarithromycin 500 milligram (mg) orally twice daily for 12 days. Single oral dose of Abemaciclib 50 mg on Period 2 Day 5. Clarithromycin dosing continued for 7 days following the single dose of Abemaciclib.
89588652|NCT02117648|Experimental|Abemaciclib Safety Extension|After completing Period 2, eligible participants continued to receive 200 mg Abemaciclib every 12 hours (Q12H) on a 28-day cycle in a safety-extension phase until discontinuation criteria were met.
89588653|NCT02124161|Other|13vPnC+SIIV/Placebo|
89588654|NCT02124161|Other|Placebo+SIIV/13vPnC|
89588655|NCT02175641|Experimental|Peer-led Group Lifestyle Balance|Group-based behavioral healthy lifestyle program
88976307|NCT00149656|Placebo Comparator|1|
88976308|NCT00149656|Experimental|2|Multivitamins
88976309|NCT00149656|Experimental|3|Multivitamins with Selenium
88976310|NCT00149656|Experimental|4|Selenium
88976311|NCT02957500|Experimental|Mediclore®|adhesion barrier Mediclore 5cc, to apply medical device fully around intrauterine surgery area
88976312|NCT02957500|No Intervention|No treatment|standard treatment for surgery
88976313|NCT00049010|Experimental|Group 1|"Melastatin mRNA expression is determined by in situ hybridization using tissue from primary tumor and lymph nodes. Tissue is also examined by immunohistochemical staining using antibodies to S-100 and MART-1. Patients do not receive the results of these tests nor do the results influence individual therapy.~Patients are followed every 4 months for 3.5 years."
88976314|NCT00149773|Experimental|Cognitive Therapy + Enriched Usual Care|"The cognitive therapy intervention consists of approximately 12 (1-hour) sessions over the course of a 4-month period. The main therapy components include:~Using problem-solving and cognitive restructuring techniques to target hopelessness, reasons for living and dying, coping with loss, and perceived medical comorbidity that lead to suicidal ideation.~Improving social resources.~Improving adherence to medical regimen.~Targeting Suicidal Cognitions."
88976315|NCT00149773|No Intervention|EnrichedUsual Care Condition|"The Enriched Care (EC) condition will be used as the treatment comparison for this study. EC consists of usual care patients may obtain in the community as well as the assessment and referral services provided by the study case managers. Participation in the study does not restrict patients in any way in their access to other health care, and all patients in both conditions will be allowed to receive any additional mental health treatment in the community.~The primary role of the study case manager is to establish a strong relationship with patients in order to retain the patients in the study for the duration of the study period."
88976316|NCT00082095|Experimental|Group 1 (doxorubicin)|Pegylated liposomal doxorubicin 40 mg/m2 administered intravenously on Day 1 of each cycle. Cycle is repeated every 28 days, up to one year.
88976317|NCT00082095|Active Comparator|Group 2 (capecitabine )|Capecitabine administered orally at a dosage of 2000 mg/m2/day (1000 mg/m2 BID) for 14 consecutive days followed by a 7-day rest period. Cycle is repeated every 21 days, up to one year.
88976318|NCT00149812|Experimental|Intervention|"Intervention: Keeping Families Strong Cognitive Behavioral and Communication intervention with mothers recovering from depression and their children, 9 years and older."
88976319|NCT00049088|Experimental|Treatment (docetaxel, bevacizumab)|For course 1, patients receive docetaxel IV over 1 hour on days 1 and 8 and bortezomib IV over 3-5 seconds on days 9 and 12. Patients then receive 1 week of rest. For course 2 and all subsequent courses, patients receive docetaxel on days 1 and 8 and bortezomib on days 2, 5, 9, and 12. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 2-6 patients receive escalating doses of bortezomib and docetaxel until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which no more than 1 of 6 patients experiences dose-limiting toxicity.
88976320|NCT00149968|Experimental|Myfortic|
88976321|NCT00405886|Experimental|Neramexane 25mg/d|
88976322|NCT00405886|Experimental|Neramexane 50mg/d|
88976323|NCT00405886|Experimental|Neramexane 75mg/d|
88976324|NCT00405886|Placebo Comparator|Placebo|
89209866|NCT02542566|Active Comparator|protected weight bearing|protected weight bearing and conservative physiotherapy rehabilitation.
89209867|NCT00612066|Experimental|Rosiglitazone|
89588656|NCT02175641|Active Comparator|Usual Care Services|Usual wellness and health care services offered to clients at the two supportive housing agencies.
89588657|NCT02117570|Experimental|High dose of C. difficile vaccine|
89588658|NCT02117570|Experimental|Low dose of C. difficile vaccine|
89588659|NCT02117570|Placebo Comparator|Placebo|
89588660|NCT02123459|Experimental|Cephalexin (Reference)|Cephalexin manufactured in Mexico by Eli Lilly administered once orally in one of two study periods
89588661|NCT02123459|Active Comparator|Cephalexin (Test)|Cephalexin manufactured in Brasil by Antibioticos do Brasil Ltda administered once orally in one of two study periods
89588662|NCT01853475|Experimental|Treatment A|PQP tablets 1440mg and OZ439+TPGS 800mg co-administered as a single oral dose fasted.
89588663|NCT01853475|Experimental|Treatment B|PQP tablets 960mg and OZ439+TPGS 800mg co-administered as a single oral dose fasted.
89588664|NCT01853475|Active Comparator|Treatment C - Reference|PQP Tablets 1440 mg and OZ439 PIB 800mg + full fat cow's milk
89588665|NCT04411160||Group A|Patients of group A received inhalation of nitric oxide stared by 50 parts/billion(ppb) as starting dose titrated according to patient's saturation reaching to 90 ppb as a maximum dose.
89588666|NCT04411160||Group B|While patients of group B received 4 gram of vitamin c slowly intravenous once daily for 4 days duration.
89588667|NCT02151773||Live attenuated measles/rubella combined vaccine|Live attenuated measles/rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain) is dissolved in 0.7 milliliter (mL) of accompanying reconstitution fluid (water for injection [Japanese Pharmacopoeia]), and a 0.5-mL portion is typically administered subcutaneously as a single dose.
89588668|NCT02151461|Experimental|Low Metformin|3 capsules BID with each capsule containing 366.7 mg L-Leucine and 41.7 mg of metformin
89588669|NCT02151461|Experimental|Mid Metformin|3 capsules BID with each capsule containing 366.7 mg L-Leucine and 83.3 mg of metformin
89588670|NCT02151461|Experimental|High Metformin|3 capsules BID with each capsule containing 366.7 mg L-Leucine and 166.7 mg of metformin
89588671|NCT02151461|Experimental|Metformin Monotherapy|3 Capsules BID each containing 166.7 mg of metformin with dose escalation to 283.3 mg capsules BID (1,700 mg/Day) at Day 14.
89588672|NCT02117414|Experimental|MRI Group|Subjects randomized to the MRI group will undergo a series of MRI scans at the MRI visit (9-12 weeks post-implant).
89588673|NCT02117414|Sham Comparator|Control Group|Subjects randomized to the Control group will wait for 1 hour without having a series of MRI scans at the waiting period visit (9-12 weeks post-implant).
89588674|NCT02091986|Active Comparator|Symbicort pMDI 80/2.25 µg|Budesonide/formoterol pMDI 80/2.25 µg, 2 acuations twice daily
89588675|NCT02091986|Active Comparator|Symbicort pMDI 80/4.5µg|Budesonide/formoterol pMDI 80/4.5µg, 2 acuations twice daily
89588676|NCT02091986|Active Comparator|Budesonide pMDI|Budesonide pMDI 80µg, 2 acuations twice daily
89030466|NCT04515056|Experimental|Papain SPT|Each forearm of the subject will be divided into two squared areas (4x4 cm). The provocations of three areas will be performed with 100 µg of papain by SPT lancets. To assess the potential importance of repeated pricks, papain will be applied by 1, 5 or 25 SPT pricks thought the skin. The last area will be exposed to cowage spicules (made chemically inert by autoclaving) soaked in 5 mg/ml papain solution.
89030467|NCT04514900|Active Comparator|Video Chat +Personalized Feedback|Participants meet as a group in weekly online video chats facilitated by an experienced behavioral weight control counselor. Participants have access to a website containing interactive weekly modules pertaining to weight loss skills as well as a discussion board where they may interact with other participants in addition to class meetings. They are asked to self-monitor food and beverage intake in a digital food diary (on a smartphone app) and will receive weekly detailed, personalized feedback on self-monitoring. Participants will be asked to weigh daily on a digital scale, which will be provided.
89030468|NCT04514900|Active Comparator|Video Chat + Basic Feedback|Participants meet as a group in weekly online video chats facilitated by an experienced behavioral weight control counselor. Participants have access to a website containing interactive weekly modules pertaining to weight loss skills as well as a discussion board where they may interact with other participants in addition to class meetings. They are asked to self-monitor food and beverage intake in a digital food diary (on a smartphone app) and will receive basic feedback weekly on self-monitoring. Participants will be asked to weigh daily on a digital scale, which will be provided.
89030469|NCT04514900|Active Comparator|Discussion Board for Social Support + Basic Feedback|Participants will access a website containing 16 interactive weekly modules pertaining to weight loss skills, as well as a discussion board on which they are encouraged through prompts and posts to interact with other participants for social support. They are asked to self-monitor food and beverage intake in a digital food diary (on a smartphone app) and will receive weekly basic feedback on self-monitoring. Participants will be asked to weigh daily on a digital scale, which will be provided.
89030470|NCT04514900|Active Comparator|Discussion Board for Social Support+Personalized Feedback|Participants will access a website containing 16 interactive weekly modules pertaining to weight loss skills, as well as a discussion board on which they are encouraged through prompts and posts to interact with other participants for social support. They are asked to self-monitor food and beverage intake in a digital food diary (on a smartphone app) and will receive weekly detailed, personalized feedback on self-monitoring from a trained interventionist. Participants will be asked to weigh daily on a digital scale, which will be provided.
89588677|NCT02091752|Experimental|Ruxolitinib|All participants received ruxolitinib.
89588678|NCT02117024|Experimental|Viagenpumatucel-L Plus Metronomic Cyclophosphamide|Viagenpumatucel-L (HS-110) given as 1*10^7 cells for 12 weekly injections followed by injections every 9 weeks for up to 12 months or until discontinuation from study treatment, whichever occurs first, plus metronomic cyclophosphamide therapy for the first 12 weeks.
89588679|NCT02117024|Active Comparator|Chemotherapy Alone|Patients will be treated with a physician's choice regimen until progression.
89588680|NCT02091440|Other|HW005 Ventricular Assist System|Implant of the HW005 Ventricular Assist System.
89588681|NCT02064920|Placebo Comparator|Placebo|Placebo for donepezil hydrochloride capsule administered orally once a day for 16 weeks.
89588682|NCT02064920|Experimental|Donepezil|During the first 4 weeks, participants received placebo for donepezil. Over the following 2 weeks, participants were treated with donepezil at 5 mg per day. Then, over the remaining 10 weeks were titrated to up to 10 mg per day donepezil based on tolerability.
89588683|NCT02151149|Other|Arm A: nab-Paclitaxel and Carboplatin (Every 21 days)|nab-Paclitaxel 100 mg/m2 intravenous (IV) infusion over 30 minutes on Days 1, 8, and 15 and Carboplatin AUC = 6 mg*min/mL IV following nab-paclitaxel infusion on Day 1 of every 21-day treatment cycle
89588684|NCT02151149|Other|Arm B: nab-Paclitaxel and Carboplatin (Every 28 days)|nab-Paclitaxel 100 mg/m2 IV infusion over 30 minutes on Days 1, 8, and 15 of each 21-day treatment followed by one-week break and Carboplatin AUC = 6 mg*min/mL IV following nab-paclitaxel infusion on Day 1 of each 21-day treatment followed by one-week break
89588685|NCT04746131|Experimental|IMM0306|IMM0306 Dose escalation: 0.1mg/kg, 0.2mg/kg, 0.4mg/kg, 0.8mg/kg,1.2mg/kg and 1.6mg/kg through intravenous administration weekly up to 52 weeks.
89588686|NCT02150213|Experimental|BGG492|This was a follow-up safety study where study treatment was not administered. Patients came from BGG492 studies where patients were previously exposed to > 28 days of BGG492 50 mg, 100 mg or 150 mg given orally three times a day
89588687|NCT02091362|Placebo Comparator|Placebo|Single daily dose of placebo matching LY2409021 administered orally in 1 of 2 treatment periods.
89588688|NCT02091362|Experimental|LY2409021|Single daily dose of 20 milligrams (mg) LY2409021 administered orally in 1 of 2 treatment periods.
89588689|NCT02150057|No Intervention|Control Group|This group receives no experimental bracing intervention in the study.
89588690|NCT02150057|Active Comparator|Experimental Group|This group will receive the Breg Fusion Osteoarthritis Knee Unloading Brace to wear for a determined amount of time per study protocol for the treatment of osteoarthritis pain.
89588691|NCT02064296|No Intervention|Controls|Healthy pain free controls will be recruited for comparison with fibromyalgia patients.
89588692|NCT02064296|Active Comparator|Non-Traditional Acupuncture|40 fibromyalgia patients will be randomized to non-traditional laser acupuncture (Vita Laser 650, Lhasa OMS). They will receive 2 treatments per week for 4 weeks.
89588693|NCT02064296|Active Comparator|Traditional Acupuncture|40 fibromyalgia patients will be randomized to receive electro acupuncture (AS Super 4 digital needle stimulator, Harmony Medical Co) . They will receive 2 treatments per week for 4 weeks.
89588694|NCT02063984|Experimental|Intensive Outpatient Treatment (IOP) + Contingency Management (CM) + Working Memory Training (WMT)|IOP + CM + WMT
89588695|NCT02063984|Active Comparator|IOP + CM|IOP + CM
89588696|NCT02091284|Experimental|real tDCS|Ten sessions (every other day) of bilateral transcranial Direct Current Stimulation (tDCS: 2 milliamperes, 3 x 7 cm2, during 20 minutes) over dorsolateral Prefrontal Cortex (cathodal left / anodal right).
89588697|NCT02091284|Sham Comparator|sham-tDCS|Ten sessions (every other day) of placebo control (sham procedure) of transcranial Direct Current Stimulation (sham-tDCS) during 20 minutes with electrodes placed over the dorsolateral Prefrontal Cortex (cathodal left / anodal right). Current was delivered for 20 seconds and was turned off for the rest of the stimulation period. In this way, subjects experienced the initial itching sensation at the beginning of stimulation, but received no current for the rest of the session.
89588698|NCT02115386|Experimental|Nilotinib|Dosage was 300 mg BID daily taken orally without food.
89588699|NCT02091206|Experimental|GWP42003-P 5 mg/kg/day Dose|Participants received GWP42003-P 5 mg/kg/day administered orally, half in the morning and half in the evening. Participants titrated GWP42003-P to 5 mg/kg/day over 3 days and remained at this dose for the rest of the 21-day treatment period (19 days). The 21-day treatment period was followed by a 10-day taper (10% per day) period.
89588700|NCT02091206|Experimental|GWP42003-P 10 mg/kg/day Dose|Participants received GWP42003-P 10 mg/kg/day administered orally, half in the morning and half in the evening. Participants titrated GWP42003-P to 10 mg/kg/day over 7 days and remained at this dose for the rest of the 21-day treatment period (15 days). The 21-day treatment period was followed by a 10-day taper (10% per day) period.
89588701|NCT02091206|Experimental|GWP42003-P 20 mg/kg/day Dose|Participants received GWP42003-P 20 mg/kg/day administered orally, half in the morning and half in the evening. Participants titrated GWP42003-P to 20 mg/kg/day over 11 days and remained at this dose for the rest of the 21-day treatment period (11 days). The 21-day treatment period was followed by a 10-day taper (10% per day) period.
89588702|NCT02091206|Placebo Comparator|Placebo|Participants received placebo (0 mg/mL CBD), volume matched to one of the 3 dose levels (5, 10, or 20 mg/kg/day), administered orally, half in the morning and half in the evening for 21 days. To maintain the blinded aspect of the study, participants titrated the placebo dose over 3 to 11 days according to the matched investigational medicinal product (IMP) group (3, 7, and 11 days for the 5, 10, or 20 mg/kg/day GWP42003-P groups, respectively) and remained at this dose for the rest of the 21-day treatment period. The 21-day treatment period was followed by a 10-day taper (10% per day of the matched dose) period.
89588703|NCT04417790||Study population|Children under 12 years of age, Undergoing elective cardiac surgery for cyanotic or acyanotic congenital heart disease, Aristotle score ≤9, Giving prior written informed consent.
89588704|NCT02090426|No Intervention|Standard Care|Individuals in the standard care arm receive standard discharge planning from the hospital with no followup by Link2Care team members.
89588705|NCT02090426|Experimental|Link2Care|Participants are assigned to a multidisciplinary care team (Link2Care) comprised of a registered nurse, licensed practical nurse, social worker, intervention specialist, community health worker, and health coaches. A representative from the care team engages with the patient at bedside during the hospital admission and plans for the immediate period following discharge. The Program, as a whole, involves a series of home visits, scheduling of and accompaniment to initial primary care and specialty care visits, and support for individuals as they navigate various social service agencies to enroll in public programs including TANF, SNAP, and programs that promote housing stability.
89588706|NCT02063828|Experimental|Group A|Group A - Device Guided Breathing Low Dose
89588707|NCT02063828|Experimental|Group B|Group B - Device guided breathing high dose
89588708|NCT02063828|Sham Comparator|Group C|Group C - Usual Breathing Control Group
89588709|NCT02063672|Experimental|Lutonix DCB|Lutonix Paclitaxel Drug Coated Balloon
89588710|NCT02063672|Active Comparator|PTA Catheter|Standard Uncoated Balloon Angioplasty Catheter
89588711|NCT02062658|Experimental|Ketamine, Exposure & Response Prevention|0.5mg/kg IV Ketamine infusion followed by condensed course of Exposure and Response Prevention (EX/RP)
89588712|NCT02115308|Other|Regadenoson|Regadenoson is a single-use, pre-filled syringe containing 0.4 mg/5 mL of regadenoson.
89588713|NCT02114684|Active Comparator|Moxifloxacin|"A Moxifloxacin-containing oral regimen of Isoniazid (H), Rifampicin (R), Pyrazinamide (Z), Moxifloxacin (M), substituting Moxifloxacin for Ethambutol, daily for 24 weeks, see information below.~Intensive phase 7 days a week for 8 weeks Continuation phase - 7 days a week for 16 weeks~RH(150,75mg), Z (500mg), M (400mg) Dosage and number of tablets dispensed is dependent on participants weight band."
89209868|NCT02541084||PRN group|wAMD-patients treated with anti-VEGF therapy ´pro re nata´ (PRN)
89588714|NCT02114684|Active Comparator|Ethambutol|"An Ethambutol oral regimen of Isoniazid (H), Rifampicin(R), Pyrazinamide (Z), Ethambutol(E), daily for 24 weeks duration, substituting Ethambutol for Moxifloxacin.~Intensive phase 7 days a week for 8 weeks Continuation phase - 7 days a week for 16 weeks.See details below.~(150,75,400,275 mg) RHZE Dosage and number of tablets dispensed is dependent on participants weight band."
89588715|NCT02090114|Experimental|Cohort A:Post-enzalutamide|Men with castration-resistant prostate cancer who have progressed on enzalutamide will be enrolled to this cohort. These patients will then receive intramuscular injections with testosterone cypionate 400 mg every 28 days or testosterone enanthate 400 mg every 28 days. Upon progression on testosterone cypionate or enanthate, men will be retreated with enzalutamide 160 mg by mouth daily.
89588716|NCT02090114|Experimental|Cohort B: Post-abiraterone|Men with castration-resistant prostate cancer who have progressed on abiraterone will be enrolled to this cohort. These patients will then receive intramuscular injections with testosterone cypionate 400 mg every 28 days or testosterone enanthate 400 mg every 28 days. Upon progression on testosterone cypionate or enanthate, men will be retreated with abiraterone 1000 mg by mouth daily.
89588717|NCT02090114|Experimental|Cohort C: Castration Only|Men with metastatic prostate cancer who have only received first line hormone therapy with LHRH agonist alone or LHRH agonist plus an anti-androgen. Patients who have developed castrate resistance to first line therapy and have then received second line hormone therapy of any kind (including flutamide, bicalutamide, nilutamide, ketoconazole, abiraterone, enzalutamide, ARN-509 and investigational anti-androgens) are not eligible for enrollment in this cohort.
89588718|NCT02090114|Experimental|Cohort D: Mutation|Men with metastatic prostate cancer who have castrate resistant prostate cancer with inactivating somatic or germline mutations in the genes TP53, RB1 or PTEN identified using clinical grade sequencing of tumor tissue performed by qualified laboratory. Patients must have mutations in ≥2 of these genes to be eligible. Eligible patients must have progressed on first line hormone therapy with LHRH agonist alone and must have received at least one but not more than two second generation androgen ablative therapy (i.e. Abiraterone, Enzalutamide or Apalutamide).
89588719|NCT01623050|Experimental|SinuSys Dilation System|Maxillary Sinus Dilation
89588720|NCT02089334|Experimental|RX-0201 plus everolimus (Stage 1 & 2)|RX-0201 and everolimus will be taken together as described in the Interventions description.
89588721|NCT04742036|Experimental|capivasertib|single-dose and multiple-dose capivasertib as monotherapy (Part A) and then in combination with paclitaxel (Part B)
89588722|NCT02114606|Experimental|EoE Patients|Patients who have been diagnosed with EoE as per recent guidelines will be enrolled. Samples will be obtained using the Cytosponge™ Cell Collection Device (Cytosponge) prior to participants' routine endoscopy with biopsy.
89588723|NCT04729634|Other|Mobilization and breathing training|Usual clinical care
89588724|NCT02113436|Experimental|Fluticasone propionate (FP)/ Salmeterol xinafoate (SLM)|Subject will receive 1 or 2 inhalation of SLM 25mcg plus FP 50mcg twice daily in the first treatment period for 8 weeks and will continue to receive SLM 25mcg plus FP 50mcg one or two inhalation twice daily for 16 weeks in the second treatment period.
89588725|NCT02113436|Active Comparator|Fluticasone propionate (FP)|Subject will receive 1 or 2 inhalation of FP 50mcg twice daily in the first treatment period for 8 weeks and will receive SLM 25mcg plus FP 50mcg one or two inhalation twice daily for 16 weeks in the second treatment period.
89588726|NCT02113124||Chronic brain injury|Individuals in this group have suffered a brain injury more than 2 years prior to study. Ages range from 21 to 70.
89588727|NCT02113124||Uninjured control|This group of individuals have no history of brain injury. Ages range between 21 and 70.
89588728|NCT02087774|No Intervention|Control School|Control School received no intervention.
89588729|NCT02087774|Experimental|6 minutes activity|Implementation of 6 minutes of physical activity daily into the school day routine. Children can jog in place, do jumping jacks or dance.
89588730|NCT02111564|Experimental|Rivaroxaban|Each patient will receive either 10 mg or 7.5 mg rivaroxaban tablet once daily orally (by mouth) for 45 days. The dosing will depend on a creatinine clearance at screening.
89588731|NCT02111564|Placebo Comparator|Placebo|Each patient will receive matching placebo tablet once daily orally (by mouth) for 45 days.
89588732|NCT02087150|No Intervention|Medical management (MM)|Medical management will consist of 6 weeks of daily intranasal steroid (triamcinolone acetonide)
89588733|NCT02087150|Experimental|Eustachian tube balloon catheter (ETBC) plus MM|Eustachian tube dilation with the ETBC plus medical management
89588734|NCT02111174|Experimental|Scrambler Therapy|The device is a cutaneous electrical stimulator that uses electrodes placed on the skin similar to an electrocardiogram (EKG) machine, feeling similar to a tingling or bee-sting like sensation during the therapy. The electrodes are placed in areas thought to help relieve pain associated with chemotherapy-induced peripheral neuropathy.
89588735|NCT02111174|Sham Comparator|Sham Therapy|The device is a cutaneous electrical stimulator that uses electrodes placed on the skin similar to an electrocardiogram (EKG) machine, feeling similar to a tingling or bee-sting like sensation during the therapy. The electrodes are placed in areas not thought to help relieve pain associated with chemotherapy-induced peripheral neuropathy.
89588736|NCT02111096|Experimental|LY2409021|20 milligrams (mg) LY2409021 given orally once daily in the morning for 12 months (52 weeks). Participants remain on stable doses of metformin and sulfonylurea, as prescribed by their personal physician.
89588737|NCT02111096|Active Comparator|Sitagliptin|100 mg sitagliptin given orally once daily in the morning for 12 months (52 weeks). Participants remain on stable doses of metformin and sulfonylurea, as prescribed by their personal physician.
89588738|NCT02111096|Placebo Comparator|Placebo|Placebo matching LY2409021 and sitagliptin given orally once daily in the morning for 12 months (52 weeks). Participants remain on stable doses of metformin and sulfonylurea, as prescribed by their personal physician.
89588739|NCT02110706|Placebo Comparator|Placebo|The placebo group will receive a vehicle control infusion
89588740|NCT02110706|Experimental|Rituximab|Intervention (rituximab): The treatment group will receive a total of two cycles of rituximab separated by 6 months. Each cycle is defined as one infusion (375mg/m2 IV) per week for four consecutive weeks
89588741|NCT02110238|Active Comparator|Euflexxa|Euflexxa® (hyaluronic acid of bacterial origin)
89588742|NCT02110238|Experimental|Supartz|SUPARTZ® (hyaluronic acid of avian origin)
89588743|NCT02108912|Experimental|Traditional outpatient|Traditional outpatient physical therapy
89588744|NCT02108912|Experimental|ESTT outpatient|ESTT (early standardized task-specific training) in outpatient rehabilitation
88976325|NCT04725448|Experimental|Toripalimab Combined With Bevacizumab, Nab-paclitaxel and Carboplatin|"Drugs: Toripalimab, 240mg (6ml)/bottle, ivgtt, d1, q3w, administration until PD or death, the longest use time is two years.~Drugs: Bevacizumab, 7.5mg/kg, ivgtt, d1, q3w,the longest use time is two years.~Drugs: Nab-paclitaxel, 260mg/m2,ivgtt,d1 or 130mg/m2,ivgtt,d1,8, q3w, up to six cycles.~Drugs: Carboplatin, AUC=4～5, ivgtt, d1, q3w, up to six cycles."
89588745|NCT02108600|No Intervention|Standard of Care|Will continue usual immunosuppression and not receive any specific intervention.
89588746|NCT02108600|Experimental|Tocilizumab (TCZ) Group|Will receive tocilizumab 8 mg/kg intravenously at four-week intervals for a total of 6 doses. In addition, will continue usual immunosuppressive regimen.
89588747|NCT02107898|Placebo Comparator|Placebo Q2W|Placebo (for alirocumab) every two weeks (Q2W) added to stable lipid-modifying therapy (LMT).
89588748|NCT02107898|Experimental|Alirocumab 75 mg/Up to 150 mg Q2W|"Alirocumab 75 mg Q2W added to stable LMT for 52 weeks. Alirocumab dose up-titrated to 150 mg from Week 12 when LDL-C levels above pre-specified threshold at Week 8 as defined in Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2012 i.e.~≥100 mg/dL (2.59 mmol/L) in heFH participants or in non-familial hypercholesterolemia (non-FH) participants who had a history of documented coronary heart disease (CHD)~≥120 mg/dL (3.10 mmol/L) in non-FH participants who had a history of documented diseases or other risk factors as categorized in primary prevention category III"
89588749|NCT02059148|Experimental|LY2835219 Standard|Single oral dose of LY2835219 given with a standard meal in one of three study periods.
89588750|NCT02059148|Experimental|LY2835219 Fasted|Single oral dose of LY2835219 given with no food in one of three periods.
89588751|NCT02059148|Experimental|LY2835219 High-Fat|Single oral dose of LY2835219 given with a high fat meal in one of three periods.
89588752|NCT04721600|Experimental|treatment|
89588753|NCT04720820|Experimental|Early Supported Discharge (ESD) Group|Patients in the ESD group will be discharged to home as soon as the acute medical treatment is finished. The patients will follow a pre-planned ESD program which consists of home-based rehabilitation (at least 30 minutes of physical therapy and 30 minutes of occupational therapy per week) offered by therapists. The ESD team will also provide social/medical services as needed. The ESD program will be provided till 1 months after discharge point.
89588754|NCT04720820|Active Comparator|Conventional Rehabilitation (CR) Group|The patients in CR group will be provided with inpatient rehabilitation after the acute medical treatment is finished. The length of inpatient rehabilitation may depend on the hospital's current program. Patients will be provided with outpatient based rehabilitation program if needed after discharge.
89588755|NCT04720742|Experimental|Experimental group|The participant will perform an Analytical Treatment Interruption (ATI) of up to 18 months of duration, and during the first 8 months, a temporary immune intervention including the combination of the broadly neutralizing antibodies (bNAbs) 3BNC117 and 10-1074, which will be infused once per month.
89588756|NCT02058992||Ramelteon 8 mg administered orally once daily|
89588757|NCT04719416|Active Comparator|Active Treatment with Relaxation|This subgroup comprises of patients who are currently receiving active treatment for their cancer diagnosis. They will be completing the pre-recorded relaxation audio therapy twice weekly prior to falling asleep.
89588758|NCT04719416|Active Comparator|Remission with Relaxation|This subgroup comprises of patients who are currently in remission for their cancer diagnosis. They will be completing the pre-recorded relaxation audio therapy twice weekly prior to falling asleep.
89588759|NCT04719416|No Intervention|Active Treatment without|This subgroup comprises of patients who are currently receiving active treatment for their cancer diagnosis. They will not be asked to complete any additional relaxation therapy.
89588760|NCT04719416|No Intervention|Remission without|This subgroup comprises of patients who are currently in remission for their cancer diagnosis. They will not be asked to complete any additional relaxation therapy.
89588761|NCT02058836|Experimental|Botox Injection|The participant will be given an injection of Botox along the spermatic cord under ultrasound guidance. Before drug administration, a nerve block using bupivacaine will be completed to numb the area for treatment. This will be a 10 mL injection done one time at the initial patient visit.
89588762|NCT02058836|Placebo Comparator|Saline Injection|The patient will receive an inactive injection of normal saline along the spermatic cord under ultrasound guidance. This will be a 10 ml injection done once at the initial visit. Before the injection of saline, a spermatic cord block using bupivacaine will be completed to numb the area for treatment.
89588763|NCT02107274|Active Comparator|Azithromycin and Placebo for Azithromycin|Patients randomised to the treatment arm are to receive 1000 mg of azithromycin once a week for 12 weeks followed by placebo for azithromycin once weekly for another 12 weeks
89588764|NCT02107274|Placebo Comparator|Placebo for Azithromycin|In Part One of the study participants will be randomised to receive 12 weeks of either placebo or azithromycin in a 1:1 ratio in a double-blinded fashion. After 12 weeks, in Part Two of the study, all participants will receive placebo in a double-blinded fashion for an additional 12 weeks.
89588765|NCT02174627|Experimental|Roxadustat|
89588766|NCT02174627|Placebo Comparator|Placebo|
89588767|NCT02173769||Adults with COPD|
89588768|NCT02121509|Experimental|FDC first, fasted|Linagliptin/Metformin ER FDC followed by single tablets of linagliptin and metformin ER, fasted condition
89588769|NCT02121509|Experimental|Single tablets first, fasted|single tablets of linagliptin and metformin ER followed by Linagliptin/Metformin ER FDC, fasted condition
89588770|NCT02121509|Experimental|FDC first, fed|Linagliptin/Metformin ER FDC followed by single tablets of linagliptin and metformin ER, fed condition
89588771|NCT02121509|Experimental|Single tablets first, fed|single tablets of linagliptin and metformin ER followed by Linagliptin/Metformin ER FDC, fed condition
89588772|NCT02149199|Experimental|"Symbicort as needed+placebo Pulmicort bid"|Symbicort (budesonide/formoterol) Turbuhaler 160/4.5 μg 'as needed' + Placebo Pulmicort Turbuhaler 200 μg bid
89588773|NCT02149199|Active Comparator|"terbutaline as needed+placebo Pulmicort bid"|terbutaline Turbuhaler 0.4 mg 'as needed' + placebo Pulmicort 200 μg Turbuhaler bid
89588774|NCT02149199|Active Comparator|"Pulmicort bid + terbutaline as needed"|Pulmicort 200 μg Turbuhaler bid + terbutaline 0.4 mg Turbuhaler 'as needed'
89588775|NCT02120417|Experimental|Treatment A - Capecitabine and ruxolitinib|
89588776|NCT02120417|Active Comparator|Treatment B - Capecitabine and placebo|
89588777|NCT02148263|Experimental|Full-Time Senofilcon A Contact Lens Wear|This group will start wearing contact lenses 8 or more hours per day on the first day of wear
89588778|NCT02148263|Experimental|Graduated Senofilcon A Contact Lens Wear|This group will start wearing contact lenses on a graduated schedule (day 1 = 2 hours, day 2 = 4 hours, day 3 = 6 hours, day 4 = 8 hours, day 5 = 8 or more hours).
89588779|NCT05135585|Other|Adults vaccinated with a complete COVID-19 vaccine regimen|Adults of Melanesian, Polynesian, European, and other communities vaccinated with a complete COVID-19 vaccine regimen, residing in New Caledonia.
89588780|NCT02147561|Experimental|botulinum toxin Type A|Botulinum toxin Type A injected across specific head and neck muscles on Day 0.
89030471|NCT00519753|Experimental|DuoTrav|One drop in study eye(s) once daily in the evening (at 8:00 PM) for 12 weeks
89209869|NCT02541084||TAE group|wAMD-patients treated with anti-VEGF therapy ´treat-and-extend´ (TAE)
89209870|NCT02541084||PRN-to-TAE switcher group|wAMD patients treated with anti-VEGF therapy and switching from PRN to TAE regimens
89588781|NCT02058368|Experimental|Arm 1|Run-in phase: All subjects qualifying for the study will entered into a placebo run-in phase will receive one soft gelatin placebo capsule (swallowed whole and not chewed) and one oral disintegrating placebo tablet once daily (OD) (dissolved on the tongue then swallowed not chewed), following the first meal each day for four weeks. Randomized treatment phase: Subjects will be instructed to take 1 dutasteride 0.5 milligram (mg) capsule (swallowed whole and not chewed) and one tamsulosin 0.2mg tablet OD (dissolved on the tongue then swallowed not chewed) following the first meal each day for 104 weeks.
89588782|NCT02058368|Experimental|Arm 2|Run-in phase: All subjects qualifying for the study will entered into a placebo run-in phase will receive one soft gelatine placebo capsule (swallowed whole and not chewed) and one oral disintegrating placebo tablet OD (dissolved on the tongue then swallowed not chewed), following the first meal each day for four weeks. Randomized treatment phase: Subjects will be instructed to take 1 placebo dutasteride 0.5mg capsule (swallowed whole and not chewed) and one tamsulosin 0.2mg tablet OD (dissolved on the tongue then swallowed not chewed) following the first meal each day for 104 weeks.
89588783|NCT02107196|Experimental|Ibodutant 10 mg|Oral tablet to be given once daily for 12 weeks of treatment. Patients randomised to the ibodutant 10 mg arm will be re-randomised at week 13 in a 1:1 ratio to either ibodutant 10 mg or placebo for additional 4 weeks of treatment.
89588784|NCT02107196|Placebo Comparator|Placebo|Oral tablet to be given once daily for 12 weeks of treatment. Patients randomised to the placebo arm will be mock-re-randomised (switch in blinded conditions) to ibodutant at week 13 for additional 4 weeks of treatment.
88976326|NCT00405925|Active Comparator|combivir/kaletra|All patients started with combivir/Kaletra and were randomized if they reached undetectable viral load (2 times) within 24 weeks into continuation of the same regimen or Trizivir (2 arms)
88976327|NCT00405925|Experimental|Trizivir|patients who reach undetectable HIV-RNA within 24 weeks are randomized to switch to trizivir or continuation of combivir/kaletra
88976328|NCT00049166|Experimental|Regimen A (erlotinib hydrochloride, IMRT)|"Patients receive oral erlotinib once daily. Beginning on day 15, patients also undergo IMRT once daily 5 days a week for 7 weeks.~Patients in both regimens continue to receive erlotinib until the last day of IMRT (patients already in the maintenance phase of this study as of 5/11/04 continue to receive erlotinib once daily for up to 2 years) in the absence of disease progression or unacceptable toxicity.~In both regimens, cohorts of 3-6 patients receive escalating doses of erlotinib until the MTD is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
88976329|NCT00049166|Experimental|Regimen B (erlotinib hydrochloride, cisplatin, IMRT)|"Patients receive oral erlotinib and undergo IMRT as in regimen A. Patients also receive cisplatin IV over 20 minutes on each day of radiotherapy.~Patients in both regimens continue to receive erlotinib until the last day of IMRT (patients already in the maintenance phase of this study as of 5/11/04 continue to receive erlotinib once daily for up to 2 years) in the absence of disease progression or unacceptable toxicity.~In both regimens, cohorts of 3-6 patients receive escalating doses of erlotinib until the MTD is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
88976330|NCT00082212|Experimental|1|400 mg/m2 loading dose, 250 mg/m2 weekly X 2 Cycles
88976331|NCT00150124|Experimental|block-replacement therapy|BRT regimen until 3 months after 131I therapy
88976332|NCT00150124|Active Comparator|methimazole|methimazole stopped 8 days before 131I therapy
88976333|NCT00049283|Experimental|Treatment (erlotinib hydrochloride, docetaxel, and radiation)|Patients receive oral erlotinib alone daily on weeks 1 and 2. Patients then receive oral erlotinib daily beginning on day 1 and docetaxel IV over 1 hour on day 3 of weeks 3-9. Patients also undergo radiotherapy once daily 5 days a week on weeks 3-9. Patients continue erlotinib for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients who had N2 or greater cervical lymph node involvement at baseline or have residual neck adenopathy after chemoradiotherapy undergo neck dissection 6-8 weeks after completion of chemoradiotherapy. Erlotinib is held for 1 week before planned surgery and until healing is complete.
88976334|NCT00043368|Experimental|1|Patients will be treated with the same dosing regimen and schedule of PF-3512676 Injection with which they were treated at the end of the previous PF-3512676 Injection trial. Any proposed changes to their schedule/regimen will be at the discretion of the treating physician, following consultation with Coley.
88976335|NCT00049400|Experimental|treatment|Single-arm, dose-escalation of BMS-247550
88976336|NCT00082290|Experimental|a massage|About 45 minute massage
88976337|NCT00082290|Experimental|visit with a volunteer|45 minute visit
88976338|NCT00082290|Experimental|period of quiet time|45 minutes of quiet time
88976339|NCT00150631|Placebo Comparator|active (candesartan)|12 mo treatment with candesartan
88976340|NCT00150631|Placebo Comparator|placebo|12 mo placebo treatment
88976341|NCT00082446|Experimental|E|Subject will receive an SC dose of MVA 1x10^8 on day 0 and day 28. On day 112 subjects will receive a dose of placebo by scarification.
88976342|NCT00082446|Active Comparator|D|Subject will receive a SC dose of placebo on day 0 and day 28. On day 112 subjects will receive a dose of Dryvax® by scarification.
88976343|NCT00082446|Experimental|C|Subject will receive a SC dose of MVA 1x10^8 on day 0 and day 28. On day 112 subjects will receive a dose of Dryvax® by scarification.
88976344|NCT00082446|Experimental|B|Subjects will receive a SC dose of MVA 5x10^7 on day 0 and day 28. On day 112 subjects will receive a dose of Dryvax® by scarification.
88976345|NCT00082446|Experimental|A|Subjects will receive a SC dose of MVA 2x10^7 on day 0 and day 28. On day 112 subjects will receive a dose of Dryvax® by scarification.
88976346|NCT00082446|Experimental|F|Subject will receive an IM dose of MVA 1x10^8 on day 0 and day 28. On day 112 subjects will receive a dose of Dryvax® by scarification.
88976347|NCT00150670|Experimental|1|TS-1 and cisplatin
88976348|NCT00150670|Active Comparator|2|TS-1
89030472|NCT00519792|Experimental|1|Omega DUROS: Dose 25
89030473|NCT00519792|Experimental|2|Omega DUROS: Dose 50
89030474|NCT00519870|Active Comparator|I, II|I: nifedipine II: losartan
89030475|NCT00519909|Other|1|Diet with high content of calcium and high content of fat
89030476|NCT00519909|Other|2|Diet with low content of calcium and high content of fat
89030477|NCT00519909|Other|3|Diet with high content of calcium and normal content of fat
89030478|NCT00519909|Other|4|Diet with low content of calcium and normal content of fat
89030479|NCT00519909|Other|5|Diet with high content of calcium fra supplement and high content of fat
89030480|NCT04694937||metabolic healthy obese|Demographic, clinical laboratory and heart rate variability assesment
89209871|NCT02542488||Pregnant women with BMI >39 at booking|All women will receive routine care and in addition will complete the 8 question STOPBANG screening tool, an Epworth sleepiness scale and have overnight oximetry recorded.
89588785|NCT04185428|Experimental|Standard of care with integrative therapy|For the intervention group, an initial interview will be conducted and the Patient-Reported Outcomes Measurement Information System (PROMIS) and Memorial Symptom Assessment Scale (MSAS) questionnaires will be administered at enrollment. Integrative Therapies will then begin offering two to four sessions weekly. At 7, 14, and 21 days (+-2 days) after the start of induction chemotherapy, the PROMIS and the MSAS questionnaires will be administered again along with an acceptability questionnaire. At 21 (+-2) days after the start of induction chemotherapy, a second interview will be conducted.
89030481|NCT04694937||metabolic unhealthy obese|Demographic, clinical laboratory and heart rate variability assesment
89030482|NCT02949492|Experimental|IL-2 arm|Liver recipients <50 years old and 2-6 years after transplantation will receive IL-2 and gradually discontinue their immunosuppressive medication
89030483|NCT04512599|Experimental|Single Arm|Open-label consumption of prebiotic bar(s); 1 bar for 3 days; followed by 2 bars for 7 days
89030484|NCT04514861|Other|Tissue Oxygen Dynamics with Lumee Oxygen and TcPO2|Monitoring local subcutaneous tissue oxygen dynamics using the Wireless Lumee Oxygen Platform in correlation to TcPO2 measurements in the arm and foot
89030485|NCT04514666|Experimental|Liver/kidney transplant|The breath of patients undergoing liver or kidney transplant will be sampled and analysed
89588786|NCT04185428|No Intervention|Standard of care only|For the standard care group, an initial interview will be conducted and the PROMIS and MSAS questionnaires will be administered at enrollment. At 7, 14, and 21 days (+-2 days) after the start of induction chemotherapy, the PROMIS and the MSAS questionnaires will be administered again. At 21 days (+-2 days) after the start of induction chemotherapy, a second interview will be conducted.
89588787|NCT02058290|Active Comparator|IV Morphine Sulfate or Sponsor-approved Equivalent|Standard of Care (SOC)
89588788|NCT02058290|Experimental|EXPAREL|EXPAREL (bupivacaine liposome injectable suspension)
89588789|NCT02082158|Active Comparator|Local Respirator Model|Subjects randomized to the local respirator model will wear that model while performing study procedures.
89588790|NCT02082158|Active Comparator|Non-Local Respirator Model|Subjects randomized to the non-local respirator design will wear that model while performing study procedures.
89588791|NCT02082158|Experimental|Prototype 1 Respirator Design|Subjects randomized to the prototype 1 respirator design will wear that model while performing study procedures.
89588792|NCT02082158|Experimental|Prototype 2 Respirator Design|Subjects randomized to the prototype 2 respirator design will wear that model while performing study procedures.
89588793|NCT02082158|Experimental|Prototype 3 Respirator Design|Subjects randomized to the prototype 3 respirator design will wear that model while performing study procedures.
89588794|NCT02082158|Experimental|Prototype 4 Respirator Design|Subjects randomized to the prototype 4 respirator design will wear that model while performing study procedures.
89588795|NCT04417322||Control|Observation of serum A.actinomycetemcomitans levels and correlation of plasma A.actinomycetemcomitans levels
89588796|NCT04417322||Periodontitis|Observation of serum A.actinomycetemcomitans levels and correlation of plasma A.actinomycetemcomitans levels
89588797|NCT04718480|Placebo Comparator|Placebo|2 x 100 mg placebo daily po. (with careful dose escalation and tapered dose reduction). Overall treatment period is 74 days.
89588798|NCT04718480|Experimental|Fluvoxamine|2 x 100 mg fluvoxamine daily po. (with careful dose escalation and tapered dose reduction). Overall treatment period is 74 days.
89588799|NCT02106884|Experimental|Arm A|Nab-paclitaxel - IV - 125 mg/m2 - 3xq4wks Gemcitabine - IV - 1000 mg/m2 - 3xq4wks
89588800|NCT02106884|Active Comparator|Arm B|Gemcitabine - IV - 1000 mg/m2 - 3xq4wks
89030486|NCT02949102|Experimental|Crave Crush|Crave Crush is a plant-based tablet that alters taste perception by affecting sweet taste receptors on the tongue.
89209872|NCT00887406|Experimental|Cohort 1, Period 2|GSK961081 3mcg, Placebo, GSK961081 15mcg, GSK961081 50mcg
89209873|NCT00887406|Experimental|Cohort 1, period 1|Placebo, GSK961081 3mcg, GSK961081 15mcg, GSK961081 50mcg
89209874|NCT00887406|Experimental|Cohort 1, period 3|GSK961081 3mcg, GSK961081 15mcg, Placebo, GSK961081 50mcg
89209875|NCT00887406|Experimental|Cohort 1, period 4|GSK961081 3mcg, GSK961081 15mcg, GSK961081 50mcg, Placebo
89588801|NCT02081846|Experimental|Home Nurse Visit|Families in this arm will receive a nurse home visit within 96 hours of discharge.
89588802|NCT02081846|Active Comparator|Control|This arm will receive standard of care.
89588803|NCT02081690|Experimental|Macitentan|Macitentan tablet, dose of 10 mg, once daily
89588804|NCT02057666|Experimental|Tasquinimod|One capsule (0.25, 0.50 or 1 mg), taken orally once a day with water and food (preferably the main evening meal).
89588805|NCT02057666|Placebo Comparator|Placebo|One capsule, taken orally once a day with water and food (preferably the main evening meal).
89588806|NCT04417400|Experimental|Intervention|Patients who received MUR at visit 1
89588807|NCT04417400|No Intervention|Control|Patients received standard care and MUR after visit 2 (upon completion of the study)
89588808|NCT01625000|Experimental|MP-214 3mg|
89588809|NCT01625000|Experimental|MP-214 6mg|
89588810|NCT01625000|Experimental|MP-214 9mg|
89588811|NCT01625000|Active Comparator|Risperidone 4mg|
89588812|NCT01625000|Placebo Comparator|Placebo|
89588813|NCT02081534|Experimental|1 mg bid|1 mg AZD1722 bid
89588814|NCT02081534|Experimental|3 mg bid|3 mg AZD1722 bid
89030487|NCT02949102|Placebo Comparator|Placebo|The placebo tablet is comparable in taste and is comprised primarily of sorbitol.
89030488|NCT04514822|Other|N0 stage|patients without malignant lymph nodes
89030489|NCT04514822|Other|Non-N0 stage|patients with malignant lymph nodes
89030490|NCT04514588|Other|caffeine consumption and metabolism|Participants will take part in two trials. Each trial will last one day at least one week apart. During the first trial half of the participants will consume caffeine (5mgr/kgr) and the rest only water. During the second trial a crossover design will be applied
89030491|NCT04514588|Other|control|Control group will consume only water (not coffee) and the same parameters will be recorded as previously
89030492|NCT02276300|Experimental|HER2-Peptid-Vakzine, Cyclophosphamide|Her2-peptide vaccination, Sargramostim, Imiquimod, Cyclophosphamide
89030493|NCT02949453|Experimental|patients after suicidal episode|Patients receiving a telephone-delivered intervention after deliberate self-harm (DSH)
89030494|NCT04514939||Group A - Leg elevation|Patients will lie in their hospital bed with a moderate leg elevation (between 15 and 30 degrees)
89030495|NCT04514939||Group B- Non Leg elevation|Patients will lie in their hospital bed without leg elevation
89030496|NCT02949414|Experimental|Tracheal Replacement|Each patient will receive surgery to implant the cadaveric decellularised tracheal scaffold seeded with autologous mesenchymal cells and all follow-up procedures.
89030497|NCT02955173|Experimental|Open surgery of rectal cancer|Patients undergoing rectal cancer resection in an open approach
89030498|NCT02955173|Experimental|Laparoscopic surgery of rectal cancer|Patients undergoing rectal cancer resection in a laparoscopic approach
89030499|NCT02955173|Experimental|Open surgery of gastric cancer|Patients undergoing gastric cancer resection in an open approach
89030500|NCT02955173|Experimental|Laparoscopic surgery of gastric cancer|Patients undergoing gastric cancer resection in a laparoscopic approach
89030501|NCT00520026|Active Comparator|1|Lithium treatment
89030502|NCT00520026|Placebo Comparator|2|Placebo treatment
89030503|NCT00518856|Experimental|intervention|TBAs who receive training and supplies for the intervention
89030504|NCT00518856|Active Comparator|control|TBAs continuing with current standard of practice
89030505|NCT02955251|Experimental|Arm 1|ABBV-428 will be administered at escalating dose levels in 28-day dosing cycles (2 doses per cycle).
89030506|NCT02955251|Experimental|Arm A, B, and C|Additional participants (with ovarian cancer, NSCLC, etc.) will be enrolled in a dose expansion cohorts that will further evaluate ABBV-428.
89030507|NCT02955251|Experimental|Arm D|Additional participants with NSCLC will be enrolled in an expansion cohort that will further evaluate ABBV-428 plus nivolumab.
89030508|NCT02955251|Experimental|Arm 2|ABBV-428 plus nivolumab.
89030509|NCT00518895|Experimental|A|Dacarbazine with Genasense
89030510|NCT00518895|Active Comparator|B|Dacarbazine with placebo
89030511|NCT02275754|Experimental|PN+LCNC|Patient Navigation plus LIVESTRONG Cancer Navigation Center (PN+LCNC): Participants assigned to this group will be assisted by the patient navigator with their health-related needs. The patient navigator will call the study participant on a weekly basis for the first three months of their participation in the study, and on a monthly basis thereafter to see if study participant needs anything pertaining to their cancer care.
89030512|NCT02275754|Active Comparator|PN only|Patient Navigation ONLY. Participants assigned to this group will be assisted by the patient navigator with their health-related needs. Navigation will occur ONLY on contact with navigators initiated by the study participants.
89030513|NCT02954978|Placebo Comparator|Placebo|"Out of seventy five (75) participants that will be recruited and randomly assigned 1:1:1 to the three (3) groups (arms), 25 patients in group 1 will receive the placebo (sugar pill) one (1) capsule by mouth once daily (taken without a meal) for 12 months and 3 months follow up."
89030514|NCT02954978|Active Comparator|Nilotinib 150mg|Out of seventy five (75) participants that will be recruited and randomly assigned 1:1:1 to the three (3) groups (arms), 25 patients in group 2 will receive 150mg Nilotinib one (1) capsule once daily (taken without a meal) for 12 months and 3 months follow up.
89030515|NCT02954978|Active Comparator|Nilotinib 300mg|Out of seventy five (75) participants that will be recruited and randomly assigned 1:1:1 to the three (3) groups (arms), 25 patients in group 3 will receive 300mg Nilotinib one (1) capsule once daily (taken without a meal) for 12 months and 3 months follow up.
89030516|NCT00520065|Experimental|#1|Diabetes specific enteral product
89030517|NCT00520065|Active Comparator|#2|Standard enteral feeding
89588815|NCT02081534|Experimental|10 mg bid|10 mg AZD1722 bid
89030518|NCT00520104|Experimental|A|intranasal ketamine
89030519|NCT00520104|Experimental|B|oxymetazoline plus intranasal ketamine
89030520|NCT00520104|Experimental|C|intranasal steroid plus intranasal ketamine
89030521|NCT00519012|Active Comparator|Arm-1|Sertraline to Paroxetine
89030522|NCT00519012|Active Comparator|2|Paroxetine to Sertraline
89030523|NCT03459027|Active Comparator|Nitrate Rich Beetroot Powder (nitrate)|Dietary nitrate in the form of beetroot powder (10g) mixed in water will be administered acutely
89030524|NCT03459027|Placebo Comparator|Placebo Beetroot Powder|Beetroot powder devoid of nitrate (10g) will be mixed in water and administered acutely
89030525|NCT00520182|Active Comparator|1|ADA 2003 diet
89030526|NCT00520182|Active Comparator|2|Low Glycemic index (LGI) diet
89030527|NCT00520182|Active Comparator|3|MUFA diet
89030528|NCT00520221||2|"Minocycline group: 300 mg of minocycline hydrochloride was instilled into the pleural space through the catheter.~Control group consisted of 33 patients who had successful simple aspiration alone between January 2004 and December 2005."
89030529|NCT02954900|Other|Decision aid|50 women at high-risk for developing breast cancer will use a decision support tool, RealRisks, when discussing breast cancer risk with their providers who will have access to the BNAV provider clinical decision support tool.
89030530|NCT02949336||Group 1: Traditional UKA|Patients with a traditional Medial Unicompartmental Knee Arthroplasty, SIGMA® High Performance Partial Knee System (functional ACL and tibial posterior slope matching the native bone) will undergo observational use of fluoroscopy to analyze joint kinematics
89588816|NCT02081534|Experimental|30 mg bid|30 mg AZD1722 bid
89588817|NCT02081534|Experimental|3 mg od|3 mg AZD1722 od
88976349|NCT00150748|Experimental|Levetiracetam|Subjects received treatment up to 1764 days during the Evaluation Period. Up to 4000 mg/day (or 80 mg/kg/day for children and adolescents less than 50 kg). Oral tablets of 166, 250, or 500 mg Levetiracetam twice daily (b.i.d.).
88976350|NCT00150826|Active Comparator|Quinapril|This arm will receive quinapril which will be started at 40mg daily and titrated to 80mg daily by the end of the first week. After treatment on the maximum tolerated dose for 16 weeks, patients will be reevaluated with coronary angiogram with coronary flow reserve measurements and assessment of angina using the Seattle Angina Questionnaire.
89588818|NCT02081534|Experimental|30 mg od|30 mg AZD1722 od
89588819|NCT02081534|Placebo Comparator|Placebo|Placebo (double dummy technique)
89588820|NCT02057198|Active Comparator|Fidaxomicin|200 mg. 2 times a day for 10 days
89588821|NCT02057198|Active Comparator|Metronidazole|500 mg.orally 3 times daily for 10 days
89588822|NCT02057198|Active Comparator|Vancomycin|125 mg. orally 4 times a day for 10 days
89588823|NCT04417478|Active Comparator|Normal weight|Patients with Periodontitis and normal weight, that is BMI fluctuates between 18,50 y 24,99 kg/m2.
89588824|NCT04417478|Experimental|class I Obesity|Patients with Periodontitis and class I Obesity, that is BMI fluctuates between 30,00 a 34,99 kg/m2.
89588825|NCT04417478|Experimental|class II Obesity|Patients with Periodontitis and class II Obesity, that is BMI fluctuates between 35,00 y 39,99 kg/m2.
89588826|NCT02056652|Experimental|Pessary|Use of the Bioteque cup pessary. Pessary will be placed between 18 and 23 6/7 weeks gestation, and will be removed during the 37th week of pregnancy (or earlier, if indicated)
89588827|NCT02056652|No Intervention|No pessary|No pessary will be used. Subjects will receive standard obstetrical management
89608420|NCT01773109|Experimental|Eligible patients will receive etirinotecan pegol at a dose of|single-arm, open-label study is designed to investigate the efficacy and safety of etirinotecan pegol in patients with metastatic or recurrent NSCLC after failure of 2nd line therapy. Eligible patients will receive etirinotecan pegol at a dose of 145 mg/m2 iv every 3 weeks. One cycle will be defined as 3 weeks. Patients will be followed clinically every week for the first cycle with laboratory parameters (section 6.2.1) and physical exam. Response will be determined with RECIST version 1.1 after 2 cycles of therapy. Patients with Stable disease (SD), partial response (PR) or complete response (CR) will continue on additional therapy for up to six cycles. In the absence of disease progression in subjects completing six full cycles, further treatment beyond cycle #6 will be left to the discretion of the treating physician and his/her staff. Patients with progressive disease will be taken off study and will be followed for OS
89608421|NCT02991976|Active Comparator|35% O2|Patient receiving 35% O2 during carotid endarterectomy, Intervention - oxygen concentration
89608422|NCT02991976|Active Comparator|100% O2|Patient receiving 100% O2 during carotid endarterectomy, Intervention - oxygen concentration
89608423|NCT01772719|Experimental|Study Arm|Study Arm
89608424|NCT01798927|Other|Ankle foot orthosis fitting|All participants will receive ankle foot orthosis or orthoses. Outcomes will be compared to pre-bracing findings.
89608425|NCT00729430|Experimental|Omega-3 Fatty Acids|Participants will receive a highly purified form of omega-3 fatty acids for 6 months.
89608426|NCT00729430|Placebo Comparator|Placebo|Participants will receive placebo for 6 months.
89608427|NCT02707341||Psoriasis|Pts presenting to enrolling sites across the US are invited to enroll if eligible
89608428|NCT04144101|Experimental|Etoricoxib|Etoricoxib 60 mg QD
89608429|NCT04144101|Experimental|Aceclofenac|Aceclofenac 100 mg BID
89608430|NCT01278004|Placebo Comparator|Placebo|Placebo capsule
89608431|NCT01278004|Experimental|Drug|
89608432|NCT02700009|Experimental|Computer-assisted CBT (CCBT)|12 weeks of CCBT for depression
89608433|NCT02700009|Active Comparator|Treatment as Usual (TAU)|Treatment as usual by primary care physicians
89608434|NCT01278238|Active Comparator|Phenylephrine|
89608435|NCT01278238|Active Comparator|Lower limb compression|
89608436|NCT01278238|Placebo Comparator|Placebo|
89608437|NCT02706795|Experimental|daxibotulinumtoxinA (DAXI) for injection|DAXI for injection
89608438|NCT00722020|Experimental|Vest Arm|HFCWO treatments 2-3 times daily 15 minutes per treatment via the VEST
89608439|NCT00722020|No Intervention|Control|Historical control for PICU asthma patients
89608440|NCT04143867|Experimental|Nolix Device|Comparing use of device to non-treatment (pads only) phase
89608441|NCT01272310|Experimental|Combination therapy|
89608442|NCT01272466|Experimental|peptides from antiapoptotic proteins|
89608443|NCT04143789|Experimental|Tablets to be taken orally daily for 14 of 21 day cycle|AP-002 (4 mg and 20 mg tablets) to be taken orally daily for 14 days
89608444|NCT01272544||participation in a dental health program|Group 1 - children who participated to a dental health program Group 2 - children who did not participate to dental health program
89608445|NCT01272544||participation in a preventive program|Group 1 - children who participated to the preventive program Group 2 - children who did not participate
89608446|NCT01272700|Experimental|PCV|Peak airway pressure were set to deliver a tidal volume of 10 ml/kg of ideal body weight
89608447|NCT01272700|Active Comparator|VCV|After anesthetic induction, anesthesia maching were set to deliver a tidal volume of 10 ml/kg of ideal body weight
89608448|NCT02991742||Iodixanol|Iodixanol contrast media
89608449|NCT02991742||Ioxaglate|Ioxaglate contrast media
89608450|NCT01278316|Experimental|Cognitive training|Cognitive Intervention Tasks Participants will be asked to perform the Brain Fitness (PositScience) cognitive training tasks an hour each day, five days per week for 8-10 weeks. Six tasks manipulating auditory and verbal information will be presented, and stimuli from all tasks are presented auditorily. All tasks are designed to begin with the lowest level of difficulty required to attain 85% accuracy, and as performance improves, difficulty increases to maintain 85% accuracy, with difficulty decreasing if accuracy decreases.
89608451|NCT01278316|Active Comparator|Control|The control group will perform computerized tasks that utilize cognitive performance, but were not systematically developed to improve cognitive performance.
89588828|NCT02056340|Active Comparator|Atorvastatin|Patients will be administered study medication (atorvastatin 40 mg) orally once daily for 5 days, for a maximum of 7 days for those who remain hospitalized.
89588829|NCT02056340|Placebo Comparator|Placebo|Patients will be administered study medication (matched placebo) orally once daily for 5 days, for a maximum of 7 days for those who remain hospitalized.
88976351|NCT00150826|Placebo Comparator|Placebo|This arm will receive placebo for 16 weeks and will be reevaluated with coronary angiogram with coronary flow reserve measurements and assessment of angina using the Seattle Angina Questionnaire.
88976352|NCT00043407|Experimental|CPG 7909 Injection|
88976353|NCT02957695|Placebo Comparator|Control group|Control Intervention: Placebo-Neurofeedback, 20 sessions
88976354|NCT02957695|Active Comparator|Intervention group|Experimental Intervention: Active-Neurofeedback, 20 sessions
88976355|NCT00151060|Experimental|Estramustine, Etoposide and Paclitaxel|
88976356|NCT02970435|Experimental|Video Discharge Instructions|These videos contain the same instructions that a patient receives via the standard-of-care verbal and written discharge instructions. These instructions will be delivered by the same nursing and medical staff that also regularly provides verbal and written discharge instructions to patients. There will be no difference in the content between the standard-of-care verbal and written instructions and the video discharge instructions. Patients in this group will receive telecommunication reminders on how to access discharge videos.
88976357|NCT02970435|Active Comparator|Verbal and Written Discharge Instructions|Nursing and medical staff will provide verbal and written discharge instructions as is standard of care post surgery
88976358|NCT00151177|Experimental|A|treatment with three nights of CPAP ventilation starting the first night of admission
88976359|NCT00151177|No Intervention|B|usual Stroke Unit care
88976360|NCT00151216|Experimental|Group A-Severe Stages of LINCL|"Group A will include n= 5 children with a total disability score of 0 to 4 (the severe forms of the disease; the staging based on a modification of the scale of Steinfeld et al.~All subjects will receive 3x10^12 particle units of the AAV2CUhCLN2 vector."
88976361|NCT00151216|Experimental|Group B-Moderate Stages of LINCL|"Group B will include n=6 children with a total disability score of 5 to 6, a moderate stage of the disease.~All subjects will receive 3x10^12 particle units of the AAV2CUhCLN2 vector."
88976362|NCT00082485|Active Comparator|1|
88976363|NCT00082485|Placebo Comparator|2|
88976364|NCT00406003|Experimental|Subjects receiving treatment sequence ABC|Eligible subjects will receive treatment sequence ABC; A= paroxetine 12.5 milligrams, B= paroxetine 25 milligrams, and C= paroxetine 37.5 milligrams separated by a wash-out period of 10 days.
88976365|NCT00406003|Experimental|Subjects receiving treatment sequence BAC|Eligible subjects will receive treatment sequence BAC; B= paroxetine 25 milligrams, A= paroxetine 12.5 milligrams and C= paroxetine 37.5 milligrams separated by a wash-out period of 10 days.
88976366|NCT00406003|Experimental|Subjects receiving treatment sequence CBA|Eligible subjects will receive treatment sequence CBA; C= paroxetine 37.5 milligrams, B= paroxetine 25 milligrams and A= paroxetine 12.5 milligrams separated by a wash-out period of 10 days.
89209876|NCT00887406|Experimental|Cohort 2, period 1|Placebo, GSK961081 100mcg, GSK961081 200mcg, GSK961081 300mcg,
89588830|NCT02046122|Experimental|Idarubicin + Cytarabine + DLI|Chemotherapy combined with adoptive transfer of HLA-haploidentical donor lymphocyte infusion (DLI)
89588831|NCT04704362|Active Comparator|Training and Supervision as Usual|Non-specialists are trained in a psychological intervention under standard conditions. No feedback from competency-based evaluations is provided to modify the training or supervision curriculum.
89588832|NCT04704362|Experimental|Competency-based Training and Supervision|Non-specialists are trained and supervised in a competency-based approach in which trainers and/or supervisors are provided with the competency scores of trainees in order to modify the training and supervision content and approach as needed.
89588833|NCT02080832|Experimental|Medication (Citalopram 20mg)|Citalopram (20mg dose)
89588834|NCT02080832|Placebo Comparator|Placebo|
89588835|NCT02080832|Experimental|Medication (Citalopram 40mg)|Citalopram 40mg dose
89588836|NCT02080364|Experimental|Azeliragon 5mg|Azeliragon (TTP488) 5mg orally once daily for 18 months
89588837|NCT02080364|Placebo Comparator|Placebo|Placebo orally once daily for 18 months
89588838|NCT02079038|Active Comparator|Totalis™ Direct Decompression Procedure|Totalis
89588839|NCT02079038|Active Comparator|Comparator Procedure|Comparator Surgical Procedure
89588840|NCT02045732|Experimental|Cohort 1|
89588841|NCT02045732|Experimental|PF-06342674 1.5 mg/kg|
89588842|NCT02045732|Experimental|PF-06342674 6.0 mg/kg (q2 Weeks)|
89588843|NCT02045732|Experimental|PF-06342674 6.0 mg/kg (q1 Week)|
89588844|NCT02044874|Experimental|APD356 10 mg b.i.d.|APD356 - lorcaserin hydrochloride 10 mg tablet administered twice daily for 12 weeks
89588845|NCT02044874|Experimental|APD356 10 mg q.d.|APD356 - lorcaserin hydrochloride 10 mg tablet administered once daily and one matching placebo tablet administered once daily for 12 weeks
89588846|NCT02044874|Placebo Comparator|Placebo 10 mg b.i.d|Placebo tablet matching the APD356-lorcaserin hydrochloride 10 mg tablet administered twice daily for 12 weeks
89588847|NCT04716920|Experimental|Supportive Care (Tai Chi, Fitbit, Tai4Chijoint group)|Patients attend Tai Chi exercise classes over 1 hour BIW and wear a Fitbit device for up to 12 weeks. Patients are encouraged to complete self-practice over 30 minutes and record practice times daily in a diary log form. Patients also join a Facebook private TaiChi4joint group where they receive instructional videos matching the progress of weekly classes for at-home practices and peer support in Tai Chi engagement.
89588848|NCT04716608|Active Comparator|Group 1 INT (= intervention)|"physiotherapy program with~Myofascial Release Massage (quadriceps)~Foam Rolling lower extremity~Knee Isometrics in knee extension (sitting position)~Dynamic and static stretching (quadriceps) in half knee position~Core Stability (planks)~Strengthening (calf raises, good morning,squats, squat jump)~Balance (single leg stance)"
89588849|NCT04716608|Placebo Comparator|Group 2 USC (= usual care)|"usual care treatment with~Core Stability (prone plank)~Strengthening: (Hip extension, abduction; Calf raises)~Stretching (M. rectus femoris (static) in standing position; Hamstring in sitting position)~Balance (single leg stand)"
89030531|NCT02949336||Group 2: ACL deficient UKA|Patients with the same medial UKA implant (SIGMA® High Performance Partial Knee System) in an ACL deficient knee, where the UKA was implanted at a 50% reduced tibial posterior slope relative to the native knee will undergo observational use of fluoroscopy to analyze joint kinematics.
89588850|NCT02078960|Experimental|Omacetaxine mepesuccinate.|The study will consist of up to a 7-day screening period, and treatment for up to 12 months, in Phase 1 and Phase 2 portions, depending on response and tolerability. Patients will also have an end-of-treatment follow-up visit approximately 28 days after the last dose of omacetaxine. Each patient will be monitored for progression and survival for at least 1 year after their last dose of omacetaxine, death, or lost to follow-up, whichever comes first, regardless of patients receiving other anticancer treatment.
89588851|NCT02078102|Other|Treatment|"Meloxicam and Filgrastim will be administered in fixed doses to each patient enrolled on this study. The treatments will be administered in a staggered dose schedule for a total treatment duration of 7 days prior to apheresis.~15 mg tablets of Meloxicam will be taken orally for 5 consecutive days.~10 µg/kg of Filgrastim will be subcutaneously injected for 5 consecutive days. Filgrastim may be subcutaneously injected for an additional 3 days if patients do not meet the primary endpoint for cell collection."
89030532|NCT04514237|Experimental|Part 1: Regimens AB(CD)|Participants received 50 milligrams (mg) BOS172767 E1 tablets or matching placebo (Regimen A) in the fasted state in Period 1, followed by 50 mg BOS172767 E2 tablets or matching placebo (Regimen B) in the fasted state in Period 2. In Period 3 and 4, participants received BOS172767-Ex (selected enantiomer from Part 1 [E1 or E2]) tablets or matching placebo (Regimens C and D, respectively) from Regimen A or B in the fasted state. The Period 3 and 4 dose was selected after review of data from Periods 1 and 2. In each Period, dosing occurred on Day 1, and there was a washout period of at least 10 days or 5 half-lives of the parent (whichever is greater) between each dose of investigational medicinal product.
89588852|NCT02054702|Experimental|Brexpiprazole|Treatment (6 weeks) Up to 4 mg/day, once daily dose, tablets, orally
89588853|NCT02054702|Experimental|Aripiprazole|Aripiprazole - Up to 20 mg/day, once daily dose, tablets, orally
89588854|NCT02044094|Experimental|depot buprenorphine|Participants were treated with RBP-6000 300-mg in a single subcutaneous injection on Days 1 and 29 following a prior 14 day stabilization period (day -14 to day -1) of buprenorphine and naloxone (SUBOXONE) . Challenges consist of participants receiving on three consecutive days intramuscular (IM) injections of hydromorphone 0 mg (placebo), 6 mg and 18 mg doses during weeks 1-12 in randomized sequential order.
89588855|NCT02043938|Experimental|Healthy Volunteers|All healthy volunteers will receive four sessions of anesthesia with different common drug combinations while having SedLine EEG sensors placed on their forehead during these sessions to study the effects of these drugs on the brain. The sessions were: propofol (P), sevoflurane (S), propofol with remifentanil (PR), and sevoflurane with remifentanil (SR).
89588856|NCT04702646||Consecutive patients for outpatient colonoscopy|The researchers will offer to participate in the study to patients scheduled for a colonoscopy who meet all the inclusion criteria and none of the exclusion criteria
89588857|NCT02053610|Experimental|obinutuzumab + chlorambucil (GClb)|Participants received 1000 mg obinutuzumab intravenous (IV) infusion, on Days 1 [first infusion split 100 mg on Day 1 and 900 mg on Day 2 as per protocol amendment], 8 and 15 in Cycle 1 and Day 1 in Cycles 2-6 (28-day cycles) plus chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 Cycles).
89588858|NCT02053610|Active Comparator|rituximab + chlorambucil (RClb)|Participants received 375 mg/m^2 rituximab IV infusion on Day 1 of Cycle 1 then 500 mg/m^2 IV infusions on Day 1 of Cycles 2-6 (28-day cycles) plus chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 cycles).
89588859|NCT02053610|Active Comparator|Chlorambucil (Clb)|Participants received chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 Cycles). Participants with Progressive Disease or within 6 months of follow-up were allowed to cross over to receive obinutuzumab + chlorambucil.
89588860|NCT02075606|Experimental|Somatuline Autogel®|Somatuline Autogel® to treat Functioning Midgut NeuroEndocrine Tumours (NET)
89588861|NCT02043782|Experimental|First Coloplast Test|"The subjects are randomised 1:1:1 into six possible treatment groups to ensure random allocation of the treatments to the periods.~First subjects are allocated to Coloplast Test; Secondly to either~Own product (baseline)~Competitor soft convex"
89588862|NCT02043782|Experimental|First Competitor soft convex|"The subjects are randomised 1:1:1 into six possible treatment groups to ensure random allocation of the treatments to the periods.~First subjects are allocated to Competitor soft convex; Secondly to either~Own product (baseline)~Coloplast Test"
89588863|NCT02043782|Experimental|First Own product|"The subjects are randomised 1:1:1 into six possible treatment groups to ensure random allocation of the treatments to the periods.~First subjects are allocated to Own product; Secondly to either~Coloplast Test~Competitor soft convex"
89588864|NCT04701008||Patients with significative post-operative pain despite|Patients with significant pain despite receiving narcotics in PACU will receive a bolus dose of IV ketamine to assess its efficacy for pain score reduction. Bolus doses are given by 10mg IV increments, to reach approximate dose of 0,25mg/kg.
89588865|NCT02052596|Experimental|GSK1437173A Group|Subjects received one injection of Boostrix vaccine and one injection of the GSK1437173A vaccine during the first visit and a second injection of the GSK1437173A vaccine during the third visit, two months later.
89588866|NCT02052596|Active Comparator|Control Group|Subjects received all vaccines separately i.e. one injection of Boostrix vaccine at the first visit, one injection of the GSK1437173A vaccine at the third visit and a second injection of the GSK1437173A vaccine at the fourth visit, all two months apart.
89588867|NCT02052440|Experimental|Baclofen 10mg three times daily|Baclofen 10mg by mouth three times daily
89588868|NCT02052440|Placebo Comparator|Sugar Pill given three times daily|Placebo sugar bill
89588869|NCT02049944|Experimental|Cefazolin|All subjects undergoing elective term cesarean delivery will receive 3 grams of Cefazolin at least 30, but no more than 60 minutes prior to skin incision.
89588870|NCT02043548|Active Comparator|Group A: Tocilizumab|Tocilizumab will be given at a dose of 8mg/kg by IV infusion every 4 weeks at 6 time points (Visits 1, 2, 3, 4, 5 and 6).
89588871|NCT02043548|Placebo Comparator|Group B: Placebo|Placebo arm - no active drug
89588872|NCT01622348|Placebo Comparator|Placebo|Saline for Injection
89588873|NCT01622348|Active Comparator|IMO-3100 at 0.16 mg/kg|IMO-3100 at 0.16 mg/kg SC once weekly based on body weight at screening, not to exceed 20 mg per injection
89588874|NCT01622348|Active Comparator|IMO-3100 at 0.32 mg/kg|IMO-3100 at 0.32 mg/kg SC q wk x 4 wk based on body weight at screening, not to exceed 40 mg per injection
89588875|NCT01621880|Active Comparator|Bevacizumab|Patients receive bevacizumab 5mg/kg intravenously over 30-90 minutes on day1. Treatment repeats every 2 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
89588876|NCT01621880|Active Comparator|Corticosteroid|Patients in the corticosteroid group were treated with intravenous pulsed-steroid therapy: methylprednisolone 500 mg daily intravenously for three consecutive days followed by oral prednisone 60 mg for five days and gradually tapered 15mg every 5 days. When the prednisone dose reached 30mg per day, it was tapered down more slowly (tapered 5mg every week), until a maintenance dose of 10mg per day was reached. The entire intervention lasted two months. At 2 months, prednisone was stopped.
89588877|NCT01621802|Experimental|Inv _MMR_CO Group|Subjects received one dose of the study vaccine Priorix along with Kinrix and ProQuad vaccines at Visit 1 (Day 0).
89588878|NCT01621802|Active Comparator|Com_MMR_CO Group|Subjects received one dose of the licensed vaccine M-M-R II (also known as M-M-R Vax Pro) Lot 1 or Lot 2 along with Kinrix and ProQuad vaccines at Visit 1 (Day 0).
89588879|NCT01621802|Experimental|Inv_MMR_I Group|Subjects received one dose of Priorix at Visit 1 (Day 0).
89588880|NCT01621802|Active Comparator|Com_MMR_I Group|Subjects received one dose of M-M-R II (also known as M-M-R Vax Pro) vaccine from Lot 1 or Lot 2 at Visit 1 (Day 0).
89588881|NCT01621802|Experimental|Inv _MMR_S Group|Subjects in this safety cohort received one dose of Priorix at Visit 1 (Day 0).
89588882|NCT01621802|Active Comparator|Com_MMR_S Group|Subjects in this safety cohort received one dose of M-M-R II (also known as M-M-R Vax Pro) vaccine from Lot 1 or Lot 2 at Visit 1 (Day 0).
89588883|NCT02059291|Experimental|crFMF: 150 mg|During Epoch 2, participants received canakinumab 150mg (or 2mg/kg for participants weighing <= 40kg) q4w for 16 weeks. If participants were eligible for blinded escape, they received a single add-on dose of canakinumab (150 mg or 2mg/kg for participants weighing <= 40kg) between day 8 and day 28, and then received blinded uptitration to canakinumab 300 mg q4w from day 29 through day 112. If patients on the highest allowed canakinumab dose of 300 mg (or 4 mg/kg for patients weighing ≤ 40 kg) q4w and re-flared (PGA ≥ 2 and CRP ≥ 30 mg/L) were not eligible for further up-titration.
89588884|NCT02059291|Placebo Comparator|crCMF: placebo|"During epoch 2, participants received matching placebo to canakinumab 150 mg Participants who required blinded escape,they received a single add-on dose of canakinumab (150 mg or 2mg/kg for participants weighing <= 40kg) between day 8 and day 28, and then received blinded one dose of placebo and one dose of canakinumab q4w from day 29 through day 112. If flare or re-flare still occurred after receipt of canakinumab.~150mg, participants were uptitrated to open-label canakinumab 300 mg."
89588885|NCT02059291|Experimental|HIDS/MKD: 150 mg|During Epoch 2, participants received canakinumab 150mg (or 2mg/kg for participants weighing <= 40kg) q4w for 16 weeks. If participants were eligible for blinded escape, they received a single add-on dose of canakinumab (150 mg or 2mg/kg for participants weighing <= 40kg) between day 8 and day 28, and then received blinded uptitration to canakinumab 300 mg q4w from day 29 through day 112. If patients on the highest allowed canakinumab dose of 300 mg (or 4 mg/kg for patients weighing ≤ 40 kg) q4w and re-flared (PGA ≥ 2 and CRP ≥ 30 mg/L) were not eligible for further up-titration.
89588886|NCT02059291|Placebo Comparator|HIDS/MKD: placebo|During epoch 2, participants received matching placebo to canakinumab 150 mg qw4. Participants who required blinded escape, they received a single add-on dose of canakinumab (150 mg or 2mg/kg for participants weighing <= 40kg) between day 8 and day 28 and then received blinded one dose of placebo and one dose of canakinumab q4w from day 29 through day 112. If flare or re-flare still occurred after receipt of canakinumab 150mg, participants were uptitrated to open-label canakinumab 300 mg.
89588887|NCT02059291|Experimental|TRAPS: 150 mg|During Epoch 2, participants received canakinumab 150mg (or 2mg/kg for participants weighing <= 40kg) q4w for 16 weeks. If participants were eligible for blinded escape, they received a single add-on dose of canakinumab (150 mg or 2mg/kg for participants weighing <= 40kg) between day 8 and day 28, and then received blinded uptitration to canakinumab 300 mg q4w from day 29 through day 112. If patients on the highest allowed canakinumab dose of 300 mg (or 4 mg/kg for patients weighing ≤ 40 kg) q4w and re-flared (PGA ≥ 2 and CRP ≥ 30 mg/L) were not eligible for further up-titration
89588888|NCT02059291|Placebo Comparator|TRAPS: placebo|During epoch 2, participants received matching placebo to canakinumab 150 mg qw4. Participants who required blinded escape,they received a single add-on dose of canakinumab (150 mg or 2mg/kg for participants weighing <= 40kg) between Day 8 and 28 and then received blinded one dose of placebo and one dose of canakinumab q4w from day 29 through day 112. If flare or re-flare still occurred after receipt of canakinumab 150mg, participants were uptitrated to open-label canakinumab 300 mg.
89588889|NCT02042924|Experimental|Imaging studies|Subjects will have a FLT PET/CT and a MRI prior to starting the preparative regimen for transplant and another of each scan 100 days after transplant.
89588890|NCT02041520|Experimental|Omega 3 fatty acids|omega 3 fatty acids, 2.4 g per day, requiring intake 2 capsules (600mg each one) in the morning and two at night (Zonelabs, Marblehead MA) for 6 months.
88976367|NCT00406003|Experimental|Subjects receiving treatment sequence BCA|Eligible subjects will receive treatment sequence BCA; B= paroxetine 25 milligrams, C= paroxetine 37.5 milligrams and A= paroxetine 12.5 milligrams separated by a wash-out period of 10 days.
88976368|NCT00406003|Experimental|Subjects receiving treatment sequence CAB|Eligible subjects will receive treatment sequence CAB; C= paroxetine 37.5 milligrams, A= paroxetine 12.5 milligrams and B= paroxetine 25 milligrams separated by a wash-out period of 10 days.
88976369|NCT00406003|Experimental|Subjects receiving treatment sequence ACB|Eligible subjects will receive treatment sequence ACB; A= paroxetine 12.5 milligrams, C= paroxetine 37.5 milligrams and B= paroxetine 25 milligrams separated by a wash-out period of 10 days.
88976370|NCT00406081||Participants with AD|Children with AD who received the chicken pox vaccine 2 to 16 weeks prior to the study visit (including a group of AD subjects with eczema herpeticum)
88976371|NCT00406081||Nonatopic controls|Children without AD who received the chicken pox vaccine 2 to 16 weeks prior to the study visit
88976372|NCT00397787|Experimental|Treatment (sunitinib malate)|Patients receive oral sunitinib malate daily on days 1-28. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity.
88976373|NCT00151567|Experimental|1|Tamsulosin
88976374|NCT00151567|Placebo Comparator|2|Placebo
89588891|NCT02041520|Placebo Comparator|Placebo|Placebo (olive oil gelcaps) in similar presentation as omega 3 fatty acids, requiring intake 2 capsules in the morning and two at night (Perfect Source, Fullerton CA, product code number PER 1016, lot number 8A0019/1600-1)
89588892|NCT04699994|Experimental|FLOT therapy|
89588893|NCT04711226|Experimental|AT-1501 Single Arm|
89588894|NCT04699292||Cohort A|MLS patients managed by surgery only
89588895|NCT04699292||Cohort B|MLS patients receiving preoperative RT to a dose of 36 Gy (equivalent) followed by surgery
89588896|NCT04699292||Cohort C|MLS patients receiving preoperative RT to a dose of 50 Gy (equivalent) followed by surgery
89588897|NCT04699292||Cohort D|MLS patients receiving surgery followed by postoperative RT to a dose of 50-66 Gy (equivalent)
89588898|NCT04699292||Cohort E|MLS patients with oligometastatic and/or oligoprogressive disease receiving definitive RT to a dose of 36Gy (equivalent)
89588899|NCT02041429|Experimental|Phase I Dose Level 0: Paclitaxel + Ruxolitiniib 10 mg|"Paclitaxel 80 mg/m2 IV weekly + Ruxolitinib 10 mg orally twice daily for 4 cycles~1 cycle = 21 days~Participants with stable disease or better will have the opportunity to continue on single agent 10 mg Ruxolitinib until disease progression, unacceptable toxicity or patient withdrawal."
89588900|NCT02041429|Experimental|Phase I Dose Level 1: Paclitaxel + Ruxolitiniib 15 mg|"Paclitaxel 80 mg/m2 IV weekly + Ruxolitinib 15 mg orally twice daily for 4 cycles~1 cycle = 21 days~Participants with stable disease or better will have the opportunity to continue on single agent 15 mg Ruxolitinib until disease progression, unacceptable toxicity or patient withdrawal."
89588901|NCT02041429|Experimental|Phase I Dose Level 2: Paclitaxel + Ruxolitiniib 20 mg|"Paclitaxel 80 mg/m2 IV weekly + Ruxolitinib 20 mg orally twice daily for 4 cycles~1 cycle = 21 days~Participants with stable disease or better will have the opportunity to continue on single agent 20 mg Ruxolitinib until disease progression, unacceptable toxicity or patient withdrawal."
89588902|NCT02041429|Experimental|Phase I Dose Level 3: Paclitaxel + Ruxolitiniib 25 mg|"Paclitaxel 80 mg/m2 IV weekly + Ruxolitinib 25 mg orally twice daily for 4 cycles~1 cycle = 21 days~Participants with stable disease or better will have the opportunity to continue on single agent 20 mg Ruxolitinib until disease progression, unacceptable toxicity or patient withdrawal."
89588903|NCT02083783|Experimental|TRI102|Active, amphetamine extended-release oral suspension
89588904|NCT02083783|Placebo Comparator|Placebo|Placebo
89588905|NCT04698109||recurrent cervicovaginitis|patients with recurrent cervicovaginitis
89588906|NCT04698109||endometriosis|patients with endometriosis
89588907|NCT04698109||repeated implantation failures|patients with repeated implantation failures
89588908|NCT04698109||healthy volunteers|healthy volunteers
89588909|NCT02083081|Experimental|community intervention|Community level intervention (Social marketing campaign delivered to entire village) plus individual peer counseling sessions for enrolled pregnant women
89588910|NCT02083081|No Intervention|usual care|Usual care provided by health aides to pregnant women
89588911|NCT02040805|Experimental|Group Cognitive-Behavioral Therapy|Sixteen sessions of group therapy facilitated by a psychologist.
89588912|NCT02040805|Experimental|Peer Facilitated Support Group|Fifteen sessions of peer-facilitated group support.
89588913|NCT02040259||Mechanical thrombectomy, Trevo Retriever|Mechanical thrombectomy, Trevo Retriever
89588914|NCT02059135|Active Comparator|Recombinant Human Antithrombin (ATryn)|ATryn 250 mg loading dose over 15 minutes, immediately followed by continuous infusion of 2000 mg per 24 hours. Total daily dose is 2250 mg for the first day and 2000 mg on subsequent days
88976375|NCT00397826|Other|MK0733,simvastatin|20 patients with total cholesterol ≧ 240 mg/dL or LDL-C > 160 mg/dL for primary hypercholesterolemia; LDL-C ≧ 130 mg/dL for secondary hypercholesterolemia with identifiable risk factors will be enrolled into study to receive simvastatin 40 mg once daily for 12 weeks.
89209877|NCT00887406|Experimental|Cohort 2, period 2|GSK961081 100mcg, Placebo, GSK961081 200mcg, GSK961081 300mcg
89209878|NCT00887406|Experimental|Cohort 2, period 3|GSK961081 100mcg, GSK961081 200mcg, Placebo, GSK961081 300mcg
89588915|NCT02059135|Placebo Comparator|Normal Saline 0.9%|Placebo (Normal Saline 0.9%, matched for volume of active treatment) consisting of a loading dose over 15 minutes followed by continuous infusion.
89588916|NCT02081677|Active Comparator|etafilcon A|Marketed control soft contact lens
89588917|NCT02081677|Experimental|Prototype E1|Investigational soft contact lens
89588918|NCT02081677|Experimental|Prototype E2|Investigational soft contact lens
89588919|NCT02081677|Experimental|Prototype E3|Investigational soft contact lens
89588920|NCT04720027||Closurefast|Patients who were randomised to and underwent radiofrequency ablation using the Closurefast device in the original 3RF Study
89588921|NCT04720027||Radiofrequency Induced Thermal Therapy (RFITT)|Patients who were randomised to and underwent radiofrequency ablation using the RFITT device in the original 3RF Study
89588922|NCT04720027||EndoVenous Radiofrequency (EVRF)|Patients who were randomised to and underwent radiofrequency ablation using the EVRF device in the original 3RF Study
89588923|NCT04695769|Experimental|Group A: SOF/VEL/VOX with RBV|"Drug: Sofosbuvir/Velpatasvir/Voxilaprevir 400/100/100 mg tablets (single pill combination administered orally once daily) plus Ribavirin (weight-based dose 1000 or 1200 mg daily according to patient body weight: < or > 60 kg).~Another name: Vosevi, RBV"
89588924|NCT04695769|Active Comparator|Group B: SOF/VEL/VOX|"Drug: Sofosbuvir/Velpatasvir/Voxilaprevir 400/100/100 mg tablets (single pill combination administered orally once daily).~Another name: Vosevi"
89588925|NCT04417309|Experimental|Moderate Intensity Exercise|"Day 1 Assessment, Day 2 Fear Learning, Day 3 Fear Extinction (followed by moderate intensity exercise), Day 4 Recall of Fear Extinction~Other: Day 1 Assessments Other: Day 2 Fear Learning Other: Day 3 Fear Extinction Behavioral: Moderate Intensity Exercise Other: Day 4 Recall of Fear Extinction"
89588926|NCT04417309|Active Comparator|Control|"Day 1 Assessment, Day 2 Fear Learning, Day 3 Fear Extinction (followed by low intensity exercise), Day 4 Recall of Fear Extinction~Other: Day 1 Assessments Other: Day 2 Fear Learning Other: Day 3 Fear Extinction Behavioral: Moderate Intensity Exercise Other: Day 4 Recall of Fear Extinction"
89588927|NCT04694911||Health Services Research (focus group, interview, OOCAT)|"FOCUS GROUP: Patients participate in focus group session over 60-90 minutes.~COGNITIVE INTERVIEW: Patients complete cognitive interview on the clarity, interpretability, and ease of use of the OOCAT.~FEASIBILITY TESTING: Patients receive OOCAT at the point of care, online, or via telephone, per patients' preference."
89588928|NCT04694521|Experimental|antegrade colorectal single stapler anastomosis|open Side to end antegrade colorectal anastomosis colo rectal cancers.
89588929|NCT04694521|Experimental|open end to end colorectal stapler anastomosis|open end to end colorectal single anastomosis in non-emergent colo rectal cancers.
89588930|NCT02038933|Experimental|Nivolumab (3 mg/kg)|Nivolumab 3 mg/kg solution intravenously every 2 weeks until progression or unacceptable toxicity
89588931|NCT02081599|Experimental|Teneli (Teneligliptin) /Teneli + insulin|Teneligliptin for 16 weeks (double-blind period) followed by teneligliptin for an additional 36 weeks (open-label period) in combination with insulin.
89588932|NCT02081599|Placebo Comparator|Placebo/Teneli (Teneligliptin) + insulin|Placebo for 16 weeks (double-blind period) followed by teneligliptin for an additional 36 weeks (open-label period) in combination with insulin.
89588933|NCT02038543|Experimental|Primary hyperoxaluria patients|Subjects will be infused with 13C5-hydroxyproline and 2H3-leucine for 6 hrs in the Clinical Research and Trials Unit (CRTU). The metabolic flux of 2H3-leucine has been well characterized, and is used as a control when studying the metabolism of trace infusions of labeled amino acids 3. Blood samples will be obtained every 30 min to determine the enrichment of plasma with 13C5-hydroxyproline and 2H3-leucine. Urine collections will be obtained hourly. The fluxes of whole body hydroxyproline and leucine will be calculated
89588934|NCT02038153|Experimental|Treatment (lenalidomide)|Patients receive lenalidomide PO QD on days 1-21. Courses repeat 4 weeks in the absence of disease progression or unacceptable toxicity.
89588935|NCT02058589|Experimental|GSK1437173A Group|Subjects, aged 18 years or older, received 2 doses of the GSK 1437173A vaccine, adjuvanted with AS01B at Day 0, and Month 1, administered intramuscularly, in the deltoid muscle of an arm.
89588936|NCT02058589|Placebo Comparator|Placebo Group|Subjects, aged 18 years or older, received 2 doses of Placebo (lyophilised sucrose reconstituted with saline [NaCl] solution) at Day 0, and Month 1, administered intramuscularly, in the deltoid muscle of an arm.
88976376|NCT04725253|Experimental|Nicotinamide|Patients who meet the inclusion / exclusion criteria will be randomly assigned to the experimental group:They will continue to receive standard prevention measures: Detection of delirium, education of health care team and the patient's family, sleep hygiene plan, early mobilization, resolve sensory impairments, and delivery of information of temporal-spatial reorientation in continuously. Study medication will be managed by nurses and administered daily at 7 a.m. This regimen will be continued up to 7 days after admission. The dosage of nicotinamide will be 1,5 gr per day.
88976377|NCT04725253|Placebo Comparator|Control|Patients who meet the inclusion / exclusion criteria will be randomly assigned to the Control group: They will continue to receive the standard prevention measures: delirium detection, treatment health team education and the patient's family, sleep hygiene plan, early mobilization, resolve sensorial deterioration, and delivery of information of temporal-spatial reorientation in a continuous manner. Study medication will be managed by nurses and administered daily at 7 a.m. (in these case placebo tablets). This regimen will be continued up to 7 days after admission.
88976378|NCT00082719|Experimental|Arm I|Low-dose interferon alfa subcutaneously (SC) twice daily.
88976379|NCT00082719|Experimental|Arm II|Interferon alfa as in arm I at a higher dose.
88976380|NCT00082719|Experimental|Arm III|Interferon alfa SC once daily.
89588937|NCT02079805|Experimental|Azilsartan 20 mg|Participants will receive azilsartan 20 mg once daily in the morning before or after breakfast.
89588938|NCT02079805|Active Comparator|Telmisartan 40 mg|Participants will receive telmisartan 40 mg once daily in the morning before or after breakfast.
89588939|NCT02037295|Experimental|OF_UF Vancomycin|Healthy volunteers assigned overfeeding diet, underfeeding diet, and then vancomycin
89588940|NCT02037295|Placebo Comparator|OF_UF Placebo|Healthy volunteers assigned overfeeding diet, underfeeding diet, and then placebo
89588941|NCT02037295|Experimental|UF_OF Vancomycin|Healthy volunteers assigned underfeeding diet, overfeeding diet, and then vancomycin
89588942|NCT02037295|Placebo Comparator|UF_OF Placebo|Healthy volunteers assigned underfeeding diet, overfeeding diet, and then placebo
89588943|NCT02079649|Experimental|AL-53817|AL-53817 Ophthalmic Solution, 0.1%, 1 drop in each eye twice daily for 6-8 days followed by 1 drop in each eye once on the last day of dosing (Day 7, 8, or 9)
89588944|NCT02079649|Experimental|AL-78843|AL-78843 Ophthalmic Solution, 0.03%, 1 drop in each eye twice daily for 6-8 days followed by 1 drop in each eye once on the last day of dosing (Day 7, 8, or 9)
89588945|NCT02079649|Active Comparator|Maxidex|Dexamethasone Ophthalmic Suspension, 0.1%, 1 drop in each eye twice daily for 6-8 days followed by 1 drop in each eye once on the last day of dosing (Day 7, 8, or 9)
88976381|NCT00082719|Experimental|Arm IV|Interferon alfa as in arm III at a higher dose.
88976382|NCT00151957|Experimental|Methylphenidate transdermal system|MTS Patch 27.5mg, 41.3mg, 55mg, and 82.5mg for 7 Weeks
89588946|NCT02079649|Placebo Comparator|Vehicle|AL-53817 Vehicle, 1 drop in each eye twice daily for 6-8 days followed by 1 drop in each eye once on the last day of dosing (Day 7, 8, or 9)
89588947|NCT02036515|Experimental|Ertugliflozin 5 mg|Ertugliflozin, 5 mg, oral, once daily for 52 weeks
89588948|NCT02036515|Experimental|Ertugliflozin 15 mg|Ertugliflozin, 15 mg, oral, once daily for 52 weeks
89588949|NCT02036515|Placebo Comparator|Placebo|Matching placebo to ertuglifozin, oral, once daily for 52 weeks
89588950|NCT04417075|Experimental|Impacto|This is the mobile app to be developed and evaluated in this project.
89588951|NCT04417075|Active Comparator|Dejar de Fumar Asistente|This is the mobile app that will serve as the control condition in evaluating the efficacy of Impacto.
89588952|NCT02078713|Experimental|Contraceptive Decision Support Tool|Patients whose contraceptive counseling visits are scheduled with providers randomized to this arm will use the intervention immediately before their visit and bring the generated printout to their visit. Providers randomized to this arm will be free to integrate the tool and printout into their contraceptive counseling however they see fit.
89588953|NCT02078713|No Intervention|Usual Care (Control)|Patients in this arm will receive usual family planning care.
88976383|NCT00043602|Experimental|1|Participants will receive clinician-managed interpersonal psychotherapy
88976384|NCT00043602|Active Comparator|2|Participants will receive standard interpersonal psychotherapy
88976385|NCT04725370||CHOP (US)|Children with isolated cleft lip and/or cleft palate scheduled for surgery between 2012 to 2019 at the Children's Hospital of Philadelphia, Philadelphia, PA, USA.
88976386|NCT04725370||SFG (Guatemala)|Children with isolated cleft lip and/or cleft palate scheduled for surgery between 2017 and 2020 with Smiles for Guatemala, Guatemala City, Guatemala.
88976387|NCT00152113|Other|1|
89588954|NCT02035267|Placebo Comparator|Placebo - Grade 1|Participants received placebo administered in 0.2 mL subcutaneous (SC) injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments. Participants With CR SMFRS Grade 1 (mild).
89588955|NCT02035267|Experimental|ATX-101 deoxycholic acid injection - Grade 1|Participants received deoxycholic acid 2 mg/cm^2 administered in 0.2 mL SC injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments. Participants With Clinician-Reported Submental Fat Rating Scale (CR SMFRS) Grade 1 (mild).
89588956|NCT02035267|Placebo Comparator|Placebo - Grade 4|Participants received placebo administered in 0.2 mL SC injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments. Participants With CR SMFRS Grade 4 (extreme).
88976388|NCT00152191|Experimental|1|UFT (uracil, tegafur)
88976389|NCT00152191|Active Comparator|2|CMF(cyclophosphamide, methotrexate, and fluorouracil)
88976390|NCT00152230|Experimental|1|UFT (uracil, tegafur)
88976391|NCT00152230|Other|2|Surgery alone
88976392|NCT00152269|Experimental|1|
88976393|NCT00152269|Experimental|2|
88976394|NCT00152269|Placebo Comparator|3|
88976395|NCT00397865|Experimental|A|
88976396|NCT00152542|Experimental|Inhaled nitric oxide|
88976397|NCT00152542|Placebo Comparator|Placebo|
88976398|NCT00082875|Experimental|Arm I|"Patients receive cilengitide IV over 1 hour on days 1, 4, 8, 11*, 15, 18, 22, and 25. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~NOTE: *For the first course only, treatment is omitted on day 11"
89588957|NCT02035267|Experimental|ATX-101 deoxycholic acid injection - Grade 4|Participants received deoxycholic acid 2 mg/cm^2 administered in 0.2 mL SC injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments. Participants with CR SMFRS Grade 4 (extreme).
89588958|NCT05887596|No Intervention|Control group|The training given to the control group included preoperative preparation, operating theatre environment, breathing exercises, cough exercises, etc. to be performed after surgery. In both groups, temperature, pulse rate, blood pressure, oxygen saturation level, and pain level with a Visual/Visual Analogue Scale were measured on the morning of the operation day, before the operation, every 4 hours for 24 hours after the operation and on the day of discharge. Again, pain fear level was measured with the Fear of Pain Scale-III on the day of discharge in both groups.
89588959|NCT05887596|Experimental|Intervention group|The education given to the intervention group included preoperative preparation, operating room environment, breathing exercises, cough exercises, etc. to be performed after surgery, non-pharmacological methods related to pain management (cold application, positioning, distraction), and pharmacological methods related to pain management.
89588960|NCT05887453||Group 1: Persistent AF|
89588961|NCT05887453||Group 2 : Paroxysmal AF|
89588962|NCT05887453||Healthy controls|
89588963|NCT05887427|Experimental|Neural Mobilisation Group (NMG)|The neural mobilisation group received one session of conservative physiotherapy and neural mobilization at the end of the session. The content of the conservative program was the same in both groups. Before the neural mobilization application, a nerve stretching test was performed to provide a specific stretching position for each nerve and the patient was asked if he/she had any complaints. After adjusting the intensity of the neural mobilization tension, all participants were asked if they felt numbness, tension or tingling sensation in the nerve. When the symptoms were at a level that did not bother the patient, the nerve was held in that position for 10 seconds and then the nerve was left in the relaxation position. Each neural mobilization was performed in 10 repetitions.
89588964|NCT05887427|Active Comparator|Control Group (CG)|Control group patients received one session of conservative physiotherapy program. The conservative program consisted of 20 minutes of heat application to the cervical region, 20 minutes of Transcutaneous Electrical Stimulation (TENS) application and 5 minutes of ultrasound application.
89588965|NCT05887375|Experimental|Sugammadex 2 mg/kg|Sugammadex 2 mg/kg administered as a single intravenous (IV) dose.
89588966|NCT05887375|Active Comparator|Neostigmine + Glycopyrrolate|Neostigmine 50 μg/kg (up to 5 mg maximum dose) plus glycopyrrolate 10 μg/kg (up to 1 mg maximum dose) administered as a single IV dose.
89588967|NCT05887362|Experimental|STUDY GROUP|Each patient in the study group received 8 sessions of hand reflexology after CA in a room separating them from the patients in the control group.Using pleasant odourless almond oil to lubricate the patients' hands, the researcher used Ingham's approach to hand reflexology for 10 minutes, applying pressure for 5 minutes on the right hand and then the left.
89588968|NCT05887362|No Intervention|Group 2|The control group was selected first and received the routine care delivered by the hospital, such as assessment of vital signs, supine position, complete bed rest, and hygienic care. They didn't receive the hand reflexology intervention.
89588969|NCT05887349|Other|Control Group|The patients in the control group will be given cervical stabilization exercises consisting of 3 levels and increasing difficulty. The exercises will be taught to the patients level by level by the physiotherapist for 6 weeks. The subjects will perform the exercises for a total of 6 weeks. Before each exercise session, stretching exercises will be performed on the subjects.
89588970|NCT05887349|Experimental|Intervention group|The exercises to be applied to the control group for 6 weeks will be given to the intervention group in the same order and at weekly intervals. Additionally, Robacado exercises (jaw exercises) will be given to the individuals in this group.
88976399|NCT00082875|Experimental|Arm II|Patients receive cilengitide as in arm I at a higher dose.
89588971|NCT05887336|Active Comparator|Investigational device treament and standard treatment|After an initial demonstration of the device, study subjects will be given the device to be used for self-administration at home, 10 minutes per day in each nasal cavity, 3 days a week, for a total treatment period of six weeks.
89588972|NCT05887336|Sham Comparator|Sham device treatment and standard treatment|After an initial demonstration of the device, study subjects will be given the device to be used for self-administration at home, 10 minutes per day in each nasal cavity, 3 days a week, for a total treatment period of six weeks.
89588973|NCT05887310||Patients with drug-resistant psychiatric disorders|
89588974|NCT05887297|Experimental|Cognitive behavioural therapy for insomnia|Following randomisation, participants in the intervention group will receive the CBT-I intervention, delivered over 4 weeks.
89588975|NCT05887297|No Intervention|Waitlist control|Participants in the waitlist condition will complete all measures at the same timepoints as the intervention group. They will receive the CBT-I intervention after completing the 12-week follow-up assessment. This will then be used as a baseline measure for these participants to compare to their post-intervention and follow-up after receiving the treatment.
89588976|NCT05887271|Experimental|Low calorie meal replacement plan (MRP) arm|The MRP comprises of 3-4 meals a day (850kcal/day) supplied by Counterweight. Participants will be supported by professional research dieticians, and a study clinician. Participant health and medications will be monitored throughout the study.
88976400|NCT04725214|Experimental|Experimental|For MGMT unmethylated glioblastoma, during temozolomide adjuvant, concurrent with anti-angiogenesis targeted therapy(Anlotinib capsule,d1-14)
88976401|NCT00152776|Placebo Comparator|Group I|ovaria comp 10 Globuli 3 times per day 24 weeks - Placebo 12 weeks
88976402|NCT00152776|Placebo Comparator|Group II|Placebo 12 weeks - ovaria comp 10 globuli 3 times per day 24 weeks
88976403|NCT00152776|Placebo Comparator|Group III|ovaria comp 10 globuli 3 times per day 12 weeks - Placebo 12 weeks - ovaria comp 10 globuli 3 times per day 12 weeks
88976404|NCT00152815|Experimental|Vitamin E|alpha-tocoperol, capsules, 2 per day
88976405|NCT04725019|Experimental|Active tDCS + motor training|In this arm, participants will receive 20 minutes of active tDCS and motor training that involves a high number of repetitions while engaged in child-friendly games.
88976406|NCT04725019|Experimental|Sham tDCS + motor training|In this arm, participants will receive 20 minutes of sham tDCS and motor training that involves a high number of repetitions while engaged in child-friendly games. Children receiving sham tDCS will wear the tDCS device but not receive active stimulation.
88976407|NCT00152854|Active Comparator|A, 1, acetaminophen|acetaminophen
88976408|NCT00152854|Placebo Comparator|B placebo|placebo PO qid
88976409|NCT00152893|Experimental|Chromium|400 μg (200 μg pills, twice per day) of Cr-nicotinate
88976410|NCT00152893|Placebo Comparator|Placebo|Identical looking placebo (di-calcium phosphate)
88976411|NCT00083031|Experimental|Arm A-Bevacizumab|"Methotrexate- twice daily on predetermined days per each week per cycle~Cyclophosphamide- oral, daily, predetermined dose~Bevacizumab- Via IV on predetermined days per cycle"
88976412|NCT00083031|Experimental|Arm B- Without Bevacizumab|"Methotrexate- twice daily on predetermined days per each week per cycle~Cyclophosphamide- oral, daily, predetermined dose"
88976413|NCT00083070|Experimental|Temozolomide Therapy|
88976414|NCT00050414|Experimental|Trabectedin|Trabectedin 0.58 mg/m2 administered as a 3-hour intravenous infusion, Days 1, 8, and 15 every 28 days for up to approximately 3 years in the absence of disease progression. Dexamethasone 10 mg administered intravenously 30 minutes prior to each trabectedin infusion.
88976415|NCT00153205|Placebo Comparator|Introduction of A Clinical Pharmacist|
88976416|NCT00153205|Experimental|Technological|
88976417|NCT00083109|Experimental|Treatment (suramin and fluorouracil)|"PHASE I: Patients receive suramin IV over 30 minutes and fluorouracil IV on days 1, 8, 15, 22, 29, and 36. Cohorts of 3-6 patients receive escalating doses suramin and fluorouracil until the dose level allowing 10-50 uM of suramin into the patient's blood is determined without 2 or more of 6 patients experiencing dose-limiting toxicity.~PHASE II: Patients receive suramin and fluorouracil (at the dose level determined in phase I) as in phase I.~In both phases, courses repeat every 8 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity."
88976418|NCT00050531|Experimental|Gleevec|Gleevec 400 mg orally twice daily.
88976419|NCT00050531|Experimental|Gleevec + Peg-Intron + GM-CSF|Gleevec 400 mg orally twice daily. Peg-Intron 0.5 mcg/kg each week subcutaneously. GM-CSF 125 mcg/m^2 three times per week subcutaneously.
88976420|NCT00050570|Experimental|Intervention|An 8-week, Internet- based, structured cognitive- behavioral program combined with an online, asynchronous, moderated discussion group.
88976421|NCT00050570|No Intervention|Control|The waitlist control group was only contacted at the time of assessments and was offered the intervention at the end of the study, after the 2-year follow-up assessment was completed.
88976422|NCT00153634|Experimental|1|Antibiotic regimen assignment based on biofilm susceptibility test results
88976423|NCT00153634|Active Comparator|2|Antibiotic regimen assignment based on conventional susceptibility test results
88976424|NCT00050609|Placebo Comparator|1|
88976425|NCT00050609|Active Comparator|2|5 mg tadalafil
88976426|NCT00050609|Active Comparator|3|20 mg tadalafil
88976427|NCT00153673|Active Comparator|1|Celecoxib + Famotidine
88976428|NCT00153673|Active Comparator|2|Dologesics + Famotidine
88976429|NCT00153712||Non NSAID non-Hp|Patient of history of peptic ulcer bleeding with Hp-ve and without prior history of taking NSAID or Aspirin within 30 days
88976430|NCT00153712||Helicobacter pylori +ve|Patient with Hp+ve at peptic ulcer bleeding
88976431|NCT00153751|Experimental|Traditional Chinese Medicine|They are Common peony root, other herbs.
88976432|NCT00153751|Active Comparator|Holopon|Holopon
88976433|NCT00153751|Placebo Comparator|placebo|Placebo
88976434|NCT00050648|Active Comparator|cyclosporine|oral medication 2mg/kg/day orally from Day 0 until Day 90
89030533|NCT04514237|Experimental|Part 1: Regimens BA(CD)|Participants received 50 milligrams (mg) BOS172767 E2 tablets or matching placebo (Regimen B) in the fasted state in Period 1, followed by 50 mg BOS172767 E1 tablets or matching placebo (Regimen A) in the fasted state in Period 2. In Period 3 and 4, participants received BOS172767-Ex (selected enantiomer from Part 1 [E1 or E2]) tablets or matching placebo (Regimens C and D, respectively) from Regimen A or B in the fasted state. The Period 3 and 4 dose was selected after review of data from Periods 1 and 2. In each Period, dosing occurred on Day 1, and there was a washout period of at least 10 days or 5 half-lives of the parent (whichever is greater) between each dose of investigational medicinal product.
89030534|NCT00520260|Active Comparator|1|Active treatment arm bromfenac 0.09% BID for 6 weeks
89030535|NCT00520260|Active Comparator|2|ketorolac 0.4% BID for 6 weeks
89030536|NCT04514354|Experimental|GEST Visit|As described in the detailed study description, the GEST Visit included measures of cardiovascular health at Hartford Hospital. These measures included BMI, waist circumference, exhaled carbon monoxide (CO), vascular health (i.e., carotid intimal medial thickness and arterial stiffness), HRV, resting BP, the GEST, and blood draws pre- and post-GEST to obtain SCD and CVD biomarkers.
89030537|NCT04514354|No Intervention|CONTROL Visit|On either Visit 3 or 4, subjects performed the CONTROL Visit. Resting auscultatory blood pressure was measured according to AHA standards. At the conclusion of CONTROL, subjects were fitted for the ABP monitor. Subjects were instructed to proceed with normal activities, not to exercise, and to keep their arm still and extended at their side when each ABP measurement was being taken. Subjects carried a standard journal, recording activities performed during each measurement, any unusual physical or emotional events, and sleep and wake times. The following morning, subjects detached the monitor and returned it that day to the study investigators.
89030538|NCT00520338|Placebo Comparator|2|"placebo~celecoxib"
89030539|NCT00520338|No Intervention|1|1 placebo
89588977|NCT05887271|Active Comparator|Guideline driven care with attention control arm|Dietary advice to participants will be given in line with NICE guidelines for cardiovascular risk modification. Heart failure specific advice on exercise will be given in line with guidelines. Health advice will be reinforced at regular 4-weekly phone calls.
89588978|NCT05887258|Experimental|Opioid free anesthesia (OFA)|This arm is composed of opiate-free anesthesia, for this we will use Dexmetomidine dexdor), lidocaine, magnesium sulfate, ketamine (ketolar), Dexketoprofen (Enantyum) , dexamethasone and acethominophen.
89030540|NCT04694391||Recurrence|The period of recurrence was within 2 years after radiotherapy. Pathologic diagnosis was squamous cell carcinoma same with preradiotherapy.
89030541|NCT04694391||No recurrence|The period was more than 3 years after radiotherapy and no recurrence signs were observed.
89030542|NCT00520377|Experimental|1|MD05
89030543|NCT00520377|Active Comparator|2|Beta-TCP and autologous bone
89030544|NCT00519051|Active Comparator|control group|patients can receive pharmacotherapy and psychotherapy and specialized treatment
89030545|NCT02948946||Neuroendocrine Tumor (NET) Cohort|Participants with histologically or cytologically proven diagnosis of any grade, any stage NET of gastroenteropancreatic (GEP) or lung origin; In the first stage of the study (initial 50 patients) only potential participants with stage IV, well-differentiated tumors (G1/G2) will be enrolled.
89030546|NCT02948946||Non-NET Cohort|Participants with histologically or cytologically proven diagnosis of any grade, any stage gastrointestinal (GI) malignancies.
89588979|NCT05887258|Active Comparator|Opioid based Anesthesia (OA)|This arm of opiate-based anesthesia is composed of Remifentanil hidrochloride. Postoperative rescue analgesia will be morphine along with dexketoprofen, acethominophen, and dexamethasone.
89588980|NCT05887232|Active Comparator|Fractional Co2 laser|Patient in group A received FCL treatment's four sessions four weeks apart.
89588981|NCT05887232|Active Comparator|Platelet Rich Plasma|Group B received fractional CO2 with four Platelet Rich Plasma sessions,4 weeks apart.
89588982|NCT05887219|Active Comparator|Group A 4 % Hydroquinone Cream Topically and Oral Tranexamic Acid|Group A was managed with 4% hydroquinone cream as an adjuvant to oral tranexamic acid (250 mg twice daily)
89588983|NCT05887219|Active Comparator|Group B Azelaic Acid 20 % cream for 6 months|group B was managed with topical 20% azelaic acid (daily at night) for six months.
89588984|NCT05887206||Patients treated by Belantamab Mafodotin|"patients treated by Belantamab Mafodotin with a refractory multiple myeloma and an ophthalmologic follow-up between January 2020 and February 2022 will be included.~Data will be collected for patients coming from multiple French centers which followed patients treated by Belantamab Mafodotin between January 2020 and February 2022. They will be obtained by contacting centers through an email sent with a secure mail address."
89588985|NCT05887193||Group 1|Order of saddle testing: Joyseat saddle - Specialized Power saddle - Fizik Tundra M5 saddle
89588986|NCT05887193||Group 2|Order of saddle testing: Joyseat saddle - Fizik Tundra M5 saddle - Specialized Power saddle
89588987|NCT05887193||Group 3|Order of saddle testing: Specialized Power saddle - Fizik Tundra M5 saddle - Joyseat saddle
89588988|NCT05887193||Group 4|Order of saddle testing: Specialized Power saddle - Joyseat saddle - Fizik Tundra M5 saddle
89588989|NCT05887193||Group 5|Order of saddle testing: Fizik Tundra M5 saddle - Joyseat saddle - Specialized Power saddle
89588990|NCT05887193||Group 6|Order of saddle testing: Fizik Tundra M5 saddle - Specialized Power saddle - Joyseat saddle
89588991|NCT05887180|Experimental|PräVaNet-Intervention|Interdisciplinary Online-Board, close patient care by a specially trained nurse, E-Health-platform with physician cockpit, patient App, sensor kit (ECG-capable pulse watch, digital blood pressure monitor, digital blood glucose meter if required) and a telemonitoring/alarm system.
89588992|NCT05887180|No Intervention|Standard of Care|Standard of Care according to currently valid guidelines.
89588993|NCT05887154|Other|Microwave ablation|Each patient will undergo Microwave ablation of breast tumor before the standard clinical care (surgery)
89608452|NCT02991664|Active Comparator|Equia Forte, randomly applied|Placing glass ionomer restorations, the dentin and enamel of cavities were washed, and briefly dried. Equia Forte Fil was injected into the cavity. Isolation was maintained using cotton rolls and a saliva ejector. After the setting time of 2.5 minutes, the restoration was polished wet using high-speed fine diamonds. When the restoration was briefly dried, Equia Forte Coat was applied and photocured for 20 seconds using a photo-curing light.
89588994|NCT05887115|Active Comparator|Intervention (NFP)|In the standard NFP intervention, low-income pregnant women are recruited to voluntarily join the program through their 28th week of pregnancy. Enrolled women receive home visits from a nurse. The visits can occur in-person or via telehealth. In-person visits can occur in the client's home or in another community location agreed upon by the client and the nurse (such as a library or coffee shop). The typical schedule for visits is weekly during the first month after enrollment, every two weeks until the birth of the infant, weekly during the post-partum period, then every two to four weeks until child age two.
88976435|NCT00050648|Active Comparator|anti-TAC|1mg/kg/dose medication every other week on the odd week (week 1-13)
88976436|NCT00050648|Experimental|Cyclosporine and anti-TAC|DaclizumabTM at 1mg/kg plus low dose cyclosporine (2 mg/kg/day)
88976437|NCT00153868|Active Comparator|1|Darbepoetin alfa 200 mcg with escalation to 300 mcg after 6 weeks (week 7 dose) for non-responders subcutaneously every 2 weeks for 12 weeks (weeks 1, 3, 5, 7, 9, and 11)
88976438|NCT00153868|Active Comparator|2|darbepoetin alfa 300 mcg with escalation to 500 mcg after 6 weeks (week 7 dose) for non-responders subcutaneously every 3 weeks for 12 weeks (weeks 1, 4, 7, and 10)
88976439|NCT00153946|Active Comparator|A|The patients who are allocated to Argatroban monotherapy
88976440|NCT00153946|Active Comparator|B|The patients who are allocated to Edaravone-Argatroban combination therapy
88976441|NCT00154180|Active Comparator|Arm 1|CEE 0.45 mg w/ Prometrium 200 mg patch 0.05 mg w/ Prometrium 200 mg
88976442|NCT00154180|Placebo Comparator|Arm 2|Placebo patch, placebo CEE, placebo Prometrium
89209879|NCT00887406|Experimental|Cohort 2, period 4|GSK961081 100mcg, GSK961081 200mcg, GSK961081 300mcg, Placebo
89588995|NCT05887115|No Intervention|Control|The control group will receive usual care for pregnant people, which may include home visiting services from another source other than NFP. Participants who are randomly selected to receive other services will be given information about other services for which they may qualify and information about how to access those services.
89588996|NCT05887089||no intervention|
89588997|NCT05887089||drone transportation|
89588998|NCT05887063|Experimental|Dementia Awareness Course|Participants attended one half-day Dementia Awareness course as a part of a group, delivered online
89588999|NCT05887063|No Intervention|Treatment as Usual|Participants did not receive any active treatment but were able to access their usual supports
89589000|NCT05887024|Other|controlled|thirty patients will receive conventional physical therapy program (TENS, electric heating packs, and McKenzie back exercises).
89589001|NCT05887024|Active Comparator|shock wave therapy|thirty patients will receive radial extracorporeal shock wave therapy and conventional physical therapy program (TENS, electric heating packs, and McKenzie back exercises).
89589002|NCT05886998|Experimental|Group A (Nebulized Heparin)|Heparin is nebulized via endotracheal tube
89589003|NCT05886998|Placebo Comparator|Group B (Nebulized Saline)|Normal saline is nebulized via endotracheal tube
89589004|NCT05886959|Experimental|Session 1: How We Evolved - Threat, Impulse, and Soothing Systems|"A breath break with kindness is practiced.~Encourage them to think about how threat, impulse and sedative systems have developed in their own lives.~A safe place application is made.~Courtesy meditation is done."
89589005|NCT05886959|Experimental|Session 2: Threat and Self-Compassion|"A breath break with kindness is practiced.~Building a compassionate relationship with resilience and kindness meditation: a benevolent practices are made.~A hand on your heart and a compassionate comrade practices are made."
89589006|NCT05886959|Experimental|Session 3: Unraveling the Knots of Desire and Patterns Agenda|"Talk about homework.~A breath break with kindness is practiced.~Establishing a compassionate relationship with desire, guided meditation to discover the inner pattern, courtesy meditation: a good friend practices are made."
89589007|NCT05886959|Experimental|Session 4: Internalizing compassion|"Pretend-to-pretend practice is made for participants to observe themselves.~In addition to the previous practices, the practice of internalizing compassion is made in order to increase their expanded mindfulness.~Courtesy meditation: a neutral person, kindness towards your body, which is based on mindfulness practices and increases body awareness and mindful movement, is carried out. During the day, they will be informed that they should do the walking with kindness practice on their own"
89589008|NCT05886959|Experimental|Session 5: Me and others - Expanding the circle|"A compassionate letter application is made by asking participants to think about a situation they encountered recently or some time ago and is still causing distress. It is explained that they can gain insight with this application.~Courtesy meditation: the 'difficult' person, compassion and breathing: yourself and compassionate breathing: others practices are made"
89589009|NCT05886959|Experimental|Session 6: Growing happiness|"Revisiting the good practice is carried out to define the five sense organs for the participants.~Forgiveness, Asking for forgiveness, forgiving others, gratitude practices are carried out.~The practice is expanded as kindness meditation: groups and all beings."
89589010|NCT05886959|Experimental|Session 7: Weaving Wisdom and Compassion into Daily Life|"Participants are made to choose a day in their life and allow a few minutes to pause in a mindful way.~A breather for wise and compassionate action, calmness meditation and joy sharing meditation practices are carried out."
89589011|NCT05886959|Experimental|Session 8: Living with the Heart|"The participants are told about the applications that they can apply for, where they need help to develop compassion towards self-healing skills, and the whole training is evaluated.~The river of life application, which evaluates mindfulness in depth, is carried out.~An overall summary of the 8-session study is made and feedback is received."
89589012|NCT05886855||PerioMonitor Testing|400 Subject to be tested for Oral Inflammatory Load (OIL) with PerioMonitor. Same subjects to be tested for Oral Inflammation with the BOP method and neutrophil count.
88976443|NCT00154258|Experimental|1|
88976444|NCT00154336|Active Comparator|Imatinib 400mmg OD +MTX|
88976445|NCT00154336|Placebo Comparator|Imatinib Placebo + MTX|
88976446|NCT04724785||patients with persistant low level HBV DNA (<10 IU/ml)|No further intervention(s) to be administered except for monitoring of HBV DNA viraemia
89030547|NCT00520416||1|There is no control or experimental group. The same patients undergoing endovascular AAA repair with serve as their own control
89209880|NCT00887406|Experimental|Cohort 3|GSK961081 100mcg or Placebo
89209881|NCT00887406|Experimental|Cohort 4|GSK961081 300mcg or Placebo
89030548|NCT02948673|Placebo Comparator|Control|4 placebo tablets/day (2 in the morning and 2 in the evening)
89030549|NCT02948673|Active Comparator|Glutathione|4 oral GSH tablets/day (2 in the morning and 2 in the evening)
89589013|NCT05886829|Active Comparator|Chlorpheniramine Malate (0.4%) Nasal Spray|Chlorpheniramine Malate (0.4%) Nasal Spray
89589014|NCT05886829|Placebo Comparator|Placebo Nasal Spray|Placebo Nasal Spray
89589015|NCT05886803||Spontaneous Breathing Test|The first group will be composed only by patients admitted in intensive care/critical care for ventilation support, and who successed the spontaneous breathing test.
89589016|NCT05886803||Non Spontaneous Breathing Test|The second group will be composed only by patients admitted in intensive care/critical care for ventilation support, and who failed the spontaneous breathing test.
89589017|NCT05886790|Experimental|1. Ad5-NCO5T-IH|Vaccinated using Prototype and Omicron BA.4/5 Bivalent Recombinant COVID-19 Vaccine(Adenovirus Type 5 Vector) For Inhalation
89589018|NCT05886790|Experimental|2. mbO5|Vaccinated using Bivalent COVID-19 mRNA Vaccine
89589019|NCT05886790|Other|3. Ad5-nCoV-IH|Vaccinated using Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) For Inhalation
89589020|NCT05886751|Experimental|Video About Screening with Black Doctor|
89589021|NCT05886751|Experimental|Video About Screening with White Doctor|
89589022|NCT05886751|Experimental|Video About Screening with Black Patient|
89589023|NCT05886751|Experimental|Video About Screening with White Patient|
89589024|NCT05886751|Experimental|Video about Clinical Trials with Black Doctor|
89589025|NCT05886751|Experimental|Video about Clinical Trials with White Doctor|
89589026|NCT05886751|Experimental|Video about Clinical Trials with Black Patient|
89589027|NCT05886751|Experimental|Video about Clinical Trials with White Patient|
89589028|NCT05886738|Experimental|Obese|Individuals with obesity will be recruited. Obesity will be defined as having a body mass index >= 30 kg/m2 or a waist circumference of > 88cm (females) or >102 cm (males).
89589029|NCT05886738|Active Comparator|Lean|Lean individuals will be recruited and will act as the reference arm such that we will compare responses of individuals with obesity to the lean group. This group will be defined as having a BMI between 18.5-24.9 kg/m2 and a waist circumference of less than 88 cm (females) or 102 cm (males)
89589030|NCT05886699|Experimental|PRP combined with DFDBA|Open flap debridement, followed by placement of PRP combined with DFDBA
89589031|NCT05886699|Active Comparator|DFDBA|Open flap debridement, followed by placement of DFDBA
89589032|NCT05886660|Experimental|DPI-386 Nasal Gel|DPI-386 Nasal Gel, 0.4 mg
89589033|NCT05886660|Experimental|Placebo Comparator|Placebo Nasal Gel
89589034|NCT05886660|Experimental|DPI-386 Nasal Gel and Sensory Augmentation DPI-386 Nasal Gel, 0.4 mg|8-Channel K-Tactile Belt, Engineering Acoustics, Inc., Casselberry, FL
89589035|NCT05886660|Experimental|Placebo Comparator and Sensory Augmentation Placebo Nasal Gel|8-Channel K-Tactile Belt, Engineering Acoustics, Inc., Casselberry, FL
89589036|NCT05886647|Experimental|Group 1 experimental|"group composed by patients with respiratory disorders, which will undergo 12 sessions of neurostimulation by HD-tDCS 4x1 (tDCS 1x1, developed by Soterix Medical Inc.).~A current of 3 mA will be provided, positioning a central electrode (anode) on the left diaphragmatic primary motor cortex (4 cm lateral to the midline and 1 cm anterior to the binaural line) and the four return electrodes in a radius of 8 cm to the around. At the same time, inspiratory muscle training (IMT) will be performed by KH2; PowerBreathe International Ltd. UK with visual feedback, consisting of three series of two minutes of maximum and deep inspirations followed by two minutes of rest between them, totaling six minutes of TMI. The initial load will be through the maximum inspiratory pressure (MIP) achieved in the initial evaluation, using 40% of the total MIP in the first three weeks and 70% of the protocol will be used 40% of the MIP in the remaining three weeks and 70% in the remaining weeks."
89589037|NCT05886647|Sham Comparator|Group 2 sham comparator|The participants allocated in the control group will receive the sham HD tDCS for 20 minutes associated with the IMT, following for this training the same load guidelines, duration and load increment used in the experimental group.
89589038|NCT05886608|Other|AI500 single-dose gel|Interventional study on AI500 1.5 mL will be topically administered twice: the first at T0 and the second 24h from T0
89589039|NCT05886569|Experimental|Interventional group|This arm includes all study participants.
89030550|NCT02597075|Active Comparator|Arm A: with ST + PA|Standard therapy + structured Physical activity and pedometer
89030551|NCT02597075|Active Comparator|Arm B:|Standard therapy
89030552|NCT04694118|Experimental|15 hemiparetic cerebral palsy,walking back group|GMFM I or II degreed 6-15 age range hemiparetic cerebral palsy
89030553|NCT04694118|Experimental|15 hemiparetic cerebral palsy,rebound therapy group|GMFM I or II degreed 6-15 age range hemiparetic cerebral palsy
89589040|NCT05886543|Experimental|control group|"this group includes 30 patients who have post burn inhalation injury will receive conventional chest physiotherapy for(15-20) minutes 3times/week and medical treatment for 4 weeks as a total period of treatment.~• computerized spirometer assessment before treatment are ( The following variables were measured: forced vital capacity (PVC%) and forced ·expiratory volume in one second (FEVl %) and peak expiratory flow (PEF %)and after one month"
89589041|NCT05886543|Experimental|study group|this group includes 30 patients who have post burn inhalation injury will receive pilates exercise in addition to their conventional chest physiotherapy for(15-20) minutes 3times/week and medical treatment for 4 weeks as a total period of treatment.omputerized spirometer assessment before treatment are ( The following variables were measured: forced vital capacity (PVC%) and forced ·expiratory volume in one second (FEVl %) and peak expiratory flow (PEF %)and after one month
89589042|NCT05886530||HIV treatment survey participants|HIV treatment patients eligible to be enrolled in the patient survey
89589043|NCT05886530||Provider survey participants|HIV treatment providers eligible to be enrolled in the provider survey
89589044|NCT05886530||Time and motion observation participants|HIV treatment providers eligible to be enrolled in the time and motion observation study
89589045|NCT05886530||HIV testing survey participants|Individuals presenting for HIV testing eligible to be enrolled in the HIV testing survey
89589046|NCT05886517|Experimental|TAVI procedure|Patients will be evaluated at baseline to access their eligibility for the procedure. The day of TAVI patients will be prepared for the procedures as the institution's standard practice for an invasive percutaneous endovascular procedure. During the pre hospital discharge period, patients will be monitored and will receive standard post-procedure care as judged appropriate by PI. At 30 days from the procedure a Fu visit will be made in order to access survival and adverse clinical events.
89589047|NCT05886465|Experimental|HAIC plus A+T|
89589048|NCT05886439|Experimental|LK101 injection combined with pembrolizumab|patients with locally advanced or metastastic (stage IIIB-IV) NSCLC and received ≤3 lines systemtic therapy. eligible subjects will receive LK101 injection and pembrolizumab treatment.
89589049|NCT05886439|Experimental|LK101 injection combined with durvalumab|patients with extensive SCLC who failed with at least first-line standard therapy. eligible subjects will receive LK101 injection and durvalumab treatment.
89589050|NCT05886426||Reference study|Healthy participants (bilateral scans so 60 wrists) will be needed for the volunteer study to determine the visibility of the wrist joints (DRUJ, CMC-1 and MCP-1); acquire normal values and investigate the left right differences between the wrists
89589051|NCT05886426||Reliability study|Healthy participants (20 wrists) that underwent a 4DCT scan for the volunteer study will be needed to undergo a second unilateral scan to investigate the intra-patient test-retest reliability of the protocol
89589052|NCT05886426||DRUJ instability group|Patients with chronic unilateral wrist pain, in this study suspect for DRUJ instability, will be studied to evaluate the effect of TFCC injury on the wrist kinematics and evaluate the use of 4DCT for the diagnosis of TFCC injury
89589053|NCT05886413||Intubated patient admitted in intensive care unit at the IUCPQ-UL after cardiac surgery|
89589054|NCT05886361||ASD|Diagnosed with DSM-5 autism spectrum disorder
89589055|NCT05886361||Clinical|Patients with anxiety, depression, somatic symptoms which are non-psychotic and non-organic
89589056|NCT05886361||Control|Healthy control without psychiatric disorder or chronic somatic symptoms
89589057|NCT05886257|Experimental|Candonilimab Plus Bevacizumab|Candonilimab 10mg/kg, Bevacizumab 15mg/kg, every 3 week
89589058|NCT05886231|Experimental|music group (Group M)|"Group M patients were fitted with headphones that covered the entire ear and suppressed hearing of the sounds in the operating room. The level of the music sound was adjusted to the level where patients felt comfortable by asking them before induction.~Mean arterial pressure (MAP) greater than 20% of the initial value for one minute or longer was first evaluated in favor of superficial anesthesia, while its continuation was considered hypertension.~If the TOF value was higher than 70 for a long time, 0.1 mg/kg rocuronium iv was administered, and 50 µg fentanyl iv was administered in the need for opioids. In the last 20 minutes of the surgical period, 1 mg/kg tramadol and 20 mg/kg paracetamol IV were administered to all patients in accordance with conventional treatment for postoperative analgesia."
89589059|NCT05886205|Experimental|iPSC-exosome treatment|group1-low-dose group, 8 papatients are treated with 2 μg iPSC-Exos in 200 μL. group2-mid-dose group, 8 papatients are treated with 6 μg iPSC-Exos in 200 μL. group3-mid-dose group, 8 papatients are treated with 18 μg iPSC-Exos in 200 μL. group4-Dose expansion, 10 papatients are treated with iPSC-Exos in 200 μL. iPSC-Exos were administrated for nasal drip, bid for 12 weeks.
89589060|NCT05886192|Experimental|norepinephrine+vasopressin|norepinephrine+vasopressin
89589061|NCT05886192|Placebo Comparator|Norepinephrine|norepinephrine
89589062|NCT05886166|Experimental|robot assisted training|Rebless® (H-ROBOTICS, KOREA) is a knee or ankle robot for range of motion (ROM) and strength training that can operate in passive or active mode in knee or ankle flexion and extension. The patients underwent 30 min of robot training using Rebless® with 30 min conventional therapy, 5 days a week for 8 weeks.
89589063|NCT05886153|Other|Vitaliti CVSM Device|Examine the accuracy of the Cloud DX Vitaliti Continuous Vital Signs Monitor (Model: CVSM-1A) in an ambulatory context with healthy participants to determine the accuracy of continuous non-invasive vital signs metrics including respiration, pulse rate, oxyhemoglobin saturation (SpO2), core temperature, heart rate, and cNIBP against standard comparator devices guided by consensus standards.
89589064|NCT05886127||Patients undergoing ERCP with papilosphincterotomy or precut|All patients after ERCP papilosphincterotomy or precut will receive a novel hemostatic agent (Purastat®)
89589065|NCT05886127||Historical control|All patients who had ERCP with papilosphincterotomy or precut in the previous period, when a novel hemostatic gel (Purastat®) was not available.
89589066|NCT05886101|Active Comparator|Intervention|"Intervention factory with health education program~Health education will be provided on menstrual hygiene management and improve health literacy.~Behavior change communications program"
89589067|NCT05886101|No Intervention|Control|No health education will be provided. However, health information material will be distributed among the participants
89589068|NCT05886088|Experimental|LID104|The patient must take 1 tablet of LID104 plus 1 tablet of placebo of dapagliflozin and 1 tablet of placebo of linagliptin once a day.
89589069|NCT05886088|Active Comparator|Dapagliflozin|The patient must take 1 tablet of dapagliflozin plus 1 tablet of placebo of LID104 and 1 tablet of placebo of linagliptin once a day.
89589070|NCT05886088|Active Comparator|Linagliptin|The patient must take 1 tablet of linagliptin plus 1 tablet of placebo of LID104 and 1 tablet of placebo of dapagliflozin once a day.
89589071|NCT05886075|Experimental|R130 Treatment Group|Every 7-14 days,1-4 ml R130 （concentration of 1x10^8 plaque-forming Units/mL,PFU/mL）will be injected intratumoral or intraperitoneal in patients with advanced solid tumors
89589072|NCT05886010|Experimental|Condition 1 :prototypes 1 everyday|Application on the brown spots of the face and the hands for the prototypes 1 at D0,D1,D2,D3,D4 and D5
89589073|NCT05886010|Experimental|Condition 2 : prototypes 1 every week|Application on the brown spots of the face and the hands for the prototypes 1 at D0,D7,D14,D21,D28, D35, D42, D49, D56, D63, D70 and D77.
89589074|NCT05886010|Experimental|Condition 3 : prototypes 1 every two weeks|Application on the brown spots of the face and the hands for the prototypes 1 at D0,D14,D28, D42, D56 and D70
89589075|NCT05886010|Experimental|Condition 4 : prototypes 2 every two weeks|Application on the brown spots of the face and the hands for the prototypes 2 at D0,D14,D28, D42, D56 and D70
89589076|NCT05886010|Experimental|Condition 5 : prototypes 3 every two weeks|Application on the brown spots of the face and the hands for the prototypes 3 at D0,D14,D28, D42, D56 and D70
89589077|NCT05885984|Experimental|ACT group|Participants in the intervention group will receive ACT intervention, consisting of six online sessions via video conferencing platform (The first two sessions for patient only, the third and fourth sessions for caregiver only, and the last two sessions for patient-caregiver dyads) of 60-90 min each (once/week), in addition to health education.
89589078|NCT05885984|Other|Health eduction control group|Participants randomised to the health education control group will receive six weekly health education by a video-conferencing platform. The topics mainly include treatments and daily care during admission, medication instructions and side effects, diet and exercise advice, and retest recommendations when discharged.
89589079|NCT05885919|Experimental|Edaravone Dexborneol group|Patients in this arm will be given Edaravone Dexborneol Concentrated Solution for injection twice a day for 10 to 14 days.
89589080|NCT05885919|Placebo Comparator|Edaravone Dexborneol Placebo group|Patients in this arm will be given a placebo of Edaravone Dexborneol for injection twice a day for 10 to 14 days
89589081|NCT05885906|Active Comparator|Aloevera group|15 patients suffering from diabetes induced xerostomia that will receive aloe vera as mouthwash (20 ml of aloe vera 50%) 3 times per day for 4 weeks.
89589082|NCT05885906|Active Comparator|Thyme honey group|15 patients suffering from diabetes induced xerostomia that will receive thyme honey mouthwash (20 ml of thyme honey diluted in 100 ml of distilled water) 3 times per day for 4 weeks.
89589083|NCT05885906|Placebo Comparator|Saline group|15 patients suffering from diabetes induced xerostomia that will receive saline mouthwash as a control group (20 ml of saline) 3 times per day for 4 weeks.
89589084|NCT05885854|Experimental|XTR003; At rest|"Injection with XTR003 to investigate myocardial fatty-acid metabolism in patients with known IHD.~Adjunct injection with 18F-FDG to investigate and trace myocardial glucose metabolism in patients with known IHD.~The study population consisted of 50 participants from the following category of patients: (1) Patients with Non-ST elevation myocardial infarction (NSTEMI) (2) Patients with old myocardial infarction (3) Patients with total occlusions of coronary arteries."
89589085|NCT05885841|Experimental|XTR004|"In the resting stage, subjects will receive an IV bolus injection of XTR004 to assess myocardial perfusion and myocardial blood flow.~Under the pharmacological stress stage with adenosine, subjects will receive another IV bolus injection of XTR004 to assess myocardial perfusion and myocardial blood flow."
89589086|NCT05885802||ERAS group|Routine spine surgical patients receiving ERAS protocol that complies with current guidelines.
89589087|NCT05885776|Experimental|Targeted combined endocrine therapy|Subjects who met the inclusion criteria underwent surgery after 6 cycles of treatment with pyrrolitinib+trastuzumab+AI, and their pathological remission was evaluated after surgery
89589088|NCT05885750|Experimental|Diet 1|Unprocessed or minimally processed plant-based protein-rich food products
89589089|NCT05885750|Experimental|Diet 2|Mildly processed plant-based protein-rich food products
88976447|NCT04724785||patients with persistant HBV DNA (>10 IU/ml) but refuse to change the regimen|All patients with CHB receiving ETV or second-line NA(LAM/ADV/LdT) treatment for more than six months to one year will receive HBV-DNA detection, and patients with HBV-DNA≥10 IU/ml will be informed and recommended to adjust the treatment regimen. If those patients refuse to change the regimen which they are using , No further intervention(s) to be administered except for monitoring of HBV DNA viraemia until those patients change their idea
88976448|NCT04724785||patients with persistant HBV DNA (>10 IU/ml) and agree to change the regimen|All patients with CHB receiving ETV or second-line NA(LAM/ADV/LdT) treatment for more than six months to one year will receive HBV-DNA detection, and patients with HBV-DNA≥10 IU/ml will be informed and recommended to adjust the treatment regimen.They will change their regimen according one which they are using.
88976449|NCT04705987|Experimental|Experimental|Colchicine 0.5 mg
88976450|NCT04705987|Placebo Comparator|Placebo|Placebo
89589090|NCT05885750|Experimental|Diet 3|Heavily refined plant-based protein-rich food products
89589091|NCT05885698||Non-small Cell Lung Cancer|
89589092|NCT05885659|Other|Control group (waiting list)|T2DM in the control group will receive brief psychoeducation advice about smoking cessation as well as a general smoking cessation brochure/ booklet.
89589093|NCT05885659|Active Comparator|Experimental 1: Cognitive-behavioral treatment (CBT) for smoking cessation|CBT for smoking cessation, implemented in group-based sessions over an eight-week period. Includes three different stages: (1) Motivational interviewing to stop smoking; (2) Smoking cessation, focused on nicotine fading from the first to the fourth session; (3) Maintenance of abstinence and relapse prevention strategies from the fifth session onwards.
89589094|NCT05885659|Active Comparator|Experimental 2: CBT for smoking cessation + DiMeSALUD2 protocol|In this group, a training protocol on healthy lifestyle habits and self-management of T2DM will be carried out added to usual care (CBT for smoking cessation), including healthy lifestyle habits (dietary control and healthy nutrition, physical exercise, and glycemic control).
89589095|NCT05885633|Active Comparator|PCOS|Infertile PCOS patients (n=44)
89589096|NCT05885633|Active Comparator|Non-PCOS control|Non-PCOS control with male factor infertility
89589097|NCT05885633|Active Comparator|Phenotype A|Phenotype A: HA+OD+PCOM (classical/complete, n=17)
89589098|NCT05885633|Active Comparator|Phenotype B|phenotype B: HA+OD (classical/non-PCOM, n=10)
89589099|NCT05885633|Active Comparator|Phenotype C|phenotype C: HA+PCOM (ovulatory, n=9)
89589100|NCT05885633|Active Comparator|Phenotype D|phenotype D: OD+PCOM (non-hyperandrogenic, n=8).
89589101|NCT05885620|Active Comparator|regular|"components of interventions:~short vibration and short audio signal,~textual greeting,~textual prompt,~picture~short vibration"
89589102|NCT05885620|Active Comparator|intense|"components of interventions:~long vibration and long audio signal,~textual greeting,~textual prompt and speech output,~animation~long vibration"
89589103|NCT05885568|Active Comparator|car transportation|blood sample tube will be transported by courier (reference treatment)
89589104|NCT05885568|Experimental|drone transportation|blood sample tube will be prepared for transport by drone (departure from CHAM, 1 hour flight, arrival at CHUAP)
89589105|NCT05885451|Experimental|Arm 1: AMG 592 Dose 1|Participants will receive AMG 592 dose 1 subcutaneously
89589106|NCT05885451|Experimental|Arm 2: AMG 592 Dose 2|Participants will receive AMG 592 dose 2 subcutaneously
89589107|NCT05885451|Placebo Comparator|Arm 3: Placebo|Participants will receive placebo subcutaneously
88976451|NCT04705909|Experimental|Pitavastatin group|For the intended neoadjuvant treatment period, participants will receive -in addition to standard chemotherapy protocol - Pitavastatin tablets 2 mg once daily.
88976452|NCT04705909|Placebo Comparator|Placebo group|For the intended neoadjuvant treatment period, participants will receive -in addition to standard chemotherapy protocol - Placebo tablets matching pitavastatin orally once daily.
88976453|NCT04731428|Experimental|Progressive Relaxation Exercise|In individuals with normal daily circadian rhythms, cortisol levels peak at 8:00 AM, followed by a constantly declining daily cycle throughout the day. Therefore, it is important to collect blood samples taken for the measurement of serum cortisol levels approximately at the same time. Venous blood samples (3 ml) were obtained from the upper arm at 06:45 AM to evaluate the baseline and 45 minutes after Progressive Relaxation Exercise at 08:00. Vital signs and oxygen saturation were assessed at 6:30 AM before Progressive Relaxation Exercise and at 07:20 AM 5 minutes after Progressive Relaxation Exercise. Measurements were performed in the morning on the day of surgery and on postoperative days 1, 2, and 3.
88976454|NCT04731428|No Intervention|Standard Care|In the control group, no application made during and after the surgical intervention, and routine treatment and care applied.
89589108|NCT05885425||100 patients with stabile chronic heart failure with remote control|Group 1 is the intervention group, their health status will be monitored telemetrically for a half year by several electronic devices (for measurement of hearth frequency, blood pressure, blood saturation and periodically ECG recordings). Data will be periodically transmitted to the doctor in the ambulance. If measured data will indicated any worsening of heath (decompensation of circulation), physician will adjust the treatment remotely.
89589109|NCT05885425||Non-intervention group: 100 patients with stabile chronic heart failure without remote control|Group 2 with patients with chronic heart failure in the non-intervention group, they will not be contacted by own physician for half a year - the planned periodic control will be scheduled after half a year.
89589110|NCT05885399|Experimental|penpulimab|Penpulimab will be administered intravenously at a dose of 200 mg every 3 weeks. Treatment continued until the patient exhibited radiographic or clinical disease progression or unacceptable adverse events.
89589111|NCT05884346|Other|Heart Failure Preserved Ejection Fraction with coronary disease|
89589112|NCT05884346|Other|Heart Failure Preserved Ejection Fraction without coronary disease|
89589113|NCT05884060||group 1|patients with evidence of haemolysis without obvious cause
89589114|NCT05884060||group 2|patients with evidence of bone marrow dysfunction (AA, MDS, unexplained cytopenia)
89589115|NCT05884060||group 3|patients with thrombosis
89589116|NCT05884060||group 4|patient group that needs to be eliminated from final high risk cohort: patients with cirrhosis, patients wit septic embolisms & embolisation
89589117|NCT05881993|Experimental|CBP-4888|CBP-4888 administered once as a subcutaneous dose.
89589118|NCT05881993|Placebo Comparator|Placebo|Normal Saline administered once as a subcutaneous dose.
89589119|NCT05876260|Experimental|High-intensity interval exercise and post-exercise Greek yogurt (HIIE+GY)|Participants will consume greek yogurt following a single session of exercise
89589120|NCT05876260|Active Comparator|High-intensity interval exercise and post-exercise carbohydrate study supplement (HIIE +SS)|Participants will consume a carbohydrate-based study supplement following a single session of exercise
89589121|NCT05875870|Experimental|Experimental group|The rehabilitation program is composed of two parts: six-week bright-light exposure program and an exercise program.
89589122|NCT05875870|Active Comparator|Active control group|The active control group receives six weeks of a stretching exercise.
89589123|NCT05868772||Active Sentry Handpiece|At low IOP settings
89589124|NCT05868772||Ozil Handpiece|At high IOP settings
89589125|NCT05867719|No Intervention|Normoxic|Participants will complete three flight simulator tasks at a normoxic (baseline) altitude. During the flight simulator, participants will need to accomplish three tasks: 1) Maintaining an altitude of 5,000 ft of elevation while performing a mental math test, 2) Flying the aircraft through the center of a series of 7 targets, and 3) Taking off and flying the aircraft a short distance to land on the center of an indicated target.
89589126|NCT05867719|Experimental|Simulated 8,000 feet hypoxic|Participants will complete three flight simulator tasks at a simulated 8,000 foot altitude. During the flight simulator, participants will need to accomplish three tasks: 1) Maintaining an altitude of 5,000 ft of elevation while performing a mental math test, 2) Flying the aircraft through the center of a series of 7 targets, and 3) Taking off and flying the aircraft a short distance to land on the center of an indicated target.
89589127|NCT05867719|Experimental|Simulated 12,000 feet hypoxic|Participants will complete three flight simulator tasks at a simulated 12,000 foot altitude. During the flight simulator, participants will need to accomplish three tasks: 1) Maintaining an altitude of 5,000 ft of elevation while performing a mental math test, 2) Flying the aircraft through the center of a series of 7 targets, and 3) Taking off and flying the aircraft a short distance to land on the center of an indicated target.
89589128|NCT05867719|Experimental|Ramp hypoxic exposure|Participants will complete three flight simulator tasks in a ramp exposure breathing at simulated 8,000 feet for five minutes before ascending to simulated 12,000 feet while flying in a flight simulator. During the flight simulator, participants will need to accomplish three tasks: 1) Maintaining an altitude of 5,000 ft of elevation while performing a mental math test, 2) Flying the aircraft through the center of a series of 7 targets, and 3) Taking off and flying the aircraft a short distance to land on the center of an indicated target.
89589129|NCT05863741||control study|patients will be operated with conventional instrumentation
89589130|NCT05863741||NextAR study|patients will be operated using the NextAR guidance system
89589131|NCT05861232|Experimental|Experimental|informative animation, anxiety and fear
89589132|NCT05861232|No Intervention|No Intervention|Control not anxiety and fear
89589133|NCT05860257|Experimental|Implementation of PeerLearning.net|Teachers in implementation schools will be given access to training and resources to implement PeerLearning.net as a core component of instruction. We will not create specific requirements of teachers but will ask that they deliver lessons with PeerLearning.net at least four times per month. We will monitor all teacher usage and thus will be able to promote greater usage by (1) publicly acknowledging teachers that are using it frequently and experiencing success, and (2) targeting teachers who use it infrequently with additional resources and support to encourage more frequent use.
88976455|NCT04705792|Experimental|Physical activity|The program comprises the practice of resistance exercises for the main muscular groups, with free weights and with their own body weight against the action of gravity, the proposal consists of 3 weekly sessions, for 12 consecutive weeks.
88976456|NCT00083304|Experimental|Efaproxiral + WBRT + Supplemental Oxygen|
88976457|NCT00083304|Active Comparator|WBRT + Supplemental Oxygen|
88976458|NCT04705558|Experimental|group I|Continuous aerobic exercise with ketogenic diet for three month
88976459|NCT04705558|Experimental|group II|Ketogenic diet alone for three month
88976460|NCT00406237|Experimental|1|
88976461|NCT00406432|Experimental|Subjects receiving paroxetine|Eligible subjects will receive single dose of paroxetine 25 milligrams controlled release formulation followed by wash-out period of 5 days. Subjects will receive multiple doses of paroxetine 25 milligrams for further 14 days.
88976462|NCT00406471|Active Comparator|1|500 micrograms of ranibizumab
88976463|NCT00406471|Active Comparator|2|300 microgram ranibizumab
88976464|NCT00154687|Experimental|A|
88976465|NCT00083460|Active Comparator|1|
88976466|NCT00083460|Active Comparator|2|
88976467|NCT00154804|Experimental|A|
88976468|NCT00154843|Experimental|A|Lycopene 15 mg/day
88976469|NCT00154843|Experimental|B|Lycopene 30 mg/day
88976470|NCT00154882|Experimental|A|
88976471|NCT04724707||Myocarditis|Proven or suspected myocarditis
88976472|NCT04724707||Heart failure|Heart failure (NYHA functional class II-IV) before or during hospitalization with COVID-19
88976473|NCT04724707||ACS|Combination of COVID-19 with ACS or development of ACS during hospitalization with COVID-19 or performed percutaneous coronary intervention
89589134|NCT05860257|No Intervention|Pre-Intervention|Teachers in pre-intervention schools will continue with business as usual (i.e., typical instruction). Based upon previous experience in conducting research in school settings, we anticipate that teachers in pre-intervention schools will use CL very infrequently, and without the benefit of technology support.
89589135|NCT05858151|Active Comparator|Intervention|
89589136|NCT05858151|No Intervention|Control/No Intervention|
89589137|NCT05855122|Experimental|Tocilizumab|
89589138|NCT05855122|No Intervention|no-Tocilizumab|
89589139|NCT05824858|Experimental|LY3537982 (High-Fat Meal)|LY3537982 administered orally under fasting conditions in one study period and under fed conditions (i.e., a standard high-fat meal) in the other study period.
88976474|NCT04724707||Pulmonary embolism|Proven pulmonary embolism
88976475|NCT04724707||Arrhythmias|Hemodynamically significant arrhythmias (atrial fibrillation, high-grade ventricular premature beats, paroxysmal ventricular arrhythmias), including those associated with the QT interval prolongation
88976476|NCT00083499||Group 1|Index cases
88976477|NCT00083499||Group 2|Relatives of Index Cases
88976478|NCT00083499||Group 3|Fetal tissue
88976479|NCT00044031|Placebo Comparator|B|Placebo (immunogen vehicle) combined with gemcitabine.
88976480|NCT00044031|Experimental|A|500 µg G17DT immunogen combined with gemcitabine.
88976481|NCT00155311|Experimental|days after treatment|different days after orthodontic treament, samples will be taken.
89589140|NCT05824858|Experimental|LY3537982 (Low-Fat Meal)|LY3537982 administered orally under fasting conditions in one study period and under fed conditions (i.e., a standard low-fat meal) in the other study period.
88976482|NCT00155389|Active Comparator|H pylori eradication|All enrolled subjects received chemoprevention with Helicobacter pylori eradication
88976483|NCT00155545|No Intervention|Metformin|
88976484|NCT04724863|Experimental|Protocol|Each patient agreeing to participate in the study will be distributed in the protocol group and will receive an angioscan according to the protocol in pre-operative and at the usual post-operative check-up within 3 months after the operation. The usual procedure, foresees an angioscanner with injection of contrast product and the measurement of the images is performed during a deep breath. In order to obtain a complete respiratory cycle, the study procedure foresees in addition to the usual procedure, an image measurement during a deep exhalation.
88976485|NCT00156052|Experimental|Hypofractionated whole breast radiation|Subjects treated with 4250 cGY in 16 fractions
88976486|NCT00156052|Active Comparator|Conventional whole breast radiation|Subjects treated with 5000 cGY in 25 fractions
88976487|NCT00156130||1|Accelerated whole breast irradiation
88976488|NCT00156130||2|Conventional whole breast irradiation
88976489|NCT00156208|Experimental|1|
88976490|NCT00156208|Experimental|2|
88976491|NCT04731636|Experimental|Intervention arm|Patients with Crawford type I-V thoracoabdominal aortic aneurysms, and passed the screening and signed the informed consent form.
88976492|NCT00051350|Placebo Comparator|CARB|Diet rich in carbohydrate
88976493|NCT00051350|Active Comparator|UNSAT|Diet rich in unsaturated fat
88976494|NCT00051350|Active Comparator|PROTEIN|Diet rich in protein
88976495|NCT00156637|Other|Arm 1|
88976496|NCT00156637|Active Comparator|Arm 2|Dosing & Side Effect Monitoring
88976497|NCT00156676|Experimental|Arm 1|Cross over from body-weight support treadmill to Lokomat
88976498|NCT00156676|Experimental|Arm 2|Cross over from Lokomat to body-weight support treadmill
88976499|NCT00156949|Experimental|Epoetin alfa DT|
89030554|NCT02275793||high PH and normal PVR|Group I, diastolic heart failure with high PH and normal PVR
89030555|NCT02275793||high PH and high PVR|Group II, diastolic heart failure with high PH and High PVR
89030556|NCT02275793||normal PH and normal PVR|Group III, no heart failure, normal PH and normal PVR
89030557|NCT02275832|Experimental|Minoxidil|3% Minoxidil lotion is applied twice daily to the beard.
89589141|NCT05804201|Other|HOT Giobor|EUS-guided hepatico-gastrostomy would be performed with Niti-S HOT Giobor (Taewoong Medical, Gyeonggi-do, Korea), a novel device designed for hepatico-gastrostomy.
89589142|NCT05794984||Targeted Focus Group Discussions and Cross-sectional questionnaire|57 people for targeted Focus Group Discussions 162 people for Cross-sectional questionnaire
89589143|NCT05794477|Experimental|phase Ib：SHR-1802+Adebrelimab|
89589144|NCT05794477|Experimental|phase II cohort 1: SHR-1802+Adebrelimab|
89589145|NCT05794477|Experimental|phase II cohort 2: SHR-1802+Adebrelimab + Platinum Doublet Chemotherapy (PDCT)|
89030558|NCT02275832|Placebo Comparator|Placebo|Placebo is applied twice daily to beard.
89030559|NCT00519207|Active Comparator|1|This group will receive lidocaine and sucrose placebo (water).
89030560|NCT00519207|Active Comparator|2|This group will receive lidocaine placebo and sucrose.
89589146|NCT05794477|Experimental|phase II cohort 3: SHR-1802+Adebrelimab + PDCT|
89030561|NCT00519207|Active Comparator|3|This group will receive lidocaine and sucrose.
89030562|NCT02590094|Active Comparator|A|Study Group A: Subjects receive 2.5 mg intravitreal bevacizumab 1-3 days prior to vitrectomy.
89030563|NCT02590094|Active Comparator|B|Study Group B: Subjects receive 2.5 mg intravitreal bevacizumab 5-10 days prior to vitrectomy.
89030564|NCT02590094|Active Comparator|C|Study Group C: Subjects receive 1.25 mg intravitreal bevacizumab 1-10 days prior to vitrectomy.
89030565|NCT02590094|Active Comparator|D|Study Group D: Subjects receive 0.625 mg intravitreal bevacizumab 1-10 days prior to vitrectomy.
89030566|NCT02590094|Active Comparator|E|Study Group E: Subjects receive 2.5 mg intravitreal bevacizumab 1-10 days prior to vitrectomy.
89030567|NCT02590094|Active Comparator|F|Study Group F: Subjects receive 1.25 mg intravitreal ziv-aflibercept 1-10 days prior to vitrectomy.
89030568|NCT02590094|Active Comparator|G|Study Group G: Subjects receive 1.25 mg intravitreal ziv-aflibercept 1-3 days prior to vitrectomy.
89589147|NCT05794477|Experimental|phase II cohort 4: SHR-1802+Adebrelimab|
89589148|NCT05789381|Active Comparator|24 hours postpartum magnesium sulfate|
89589149|NCT05789381|Experimental|12 hours postpartum magnesium sulfate|
89589150|NCT05778396|Active Comparator|Active spinal manual therapy protocol|(1) Side-lying lumbar spine manipulation, (2) prone lumbar spine mobilization, and (3) prone thoracic spine manipulation.
89030569|NCT02590094|Active Comparator|H|Study Group H: Subjects receive 1.25 mg intravitreal ziv-aflibercept 5-10 days prior to vitrectomy.
89030570|NCT02590094|Active Comparator|I|Study Group I: Subjects receive 1.25 mg intravitreal ziv-aflibercept 1-10 days prior to vitrectomy, and then receive 1.25 mg intravitreal ziv-aflibercept at the completion of the vitrectomy.
89030571|NCT00520455|No Intervention|Control|Control participants were advised where they could obtain hormonal contraception on a sliding scale basis. Participants were also advised where they could obtain hormonal contraception on a sliding scale basis.
89030572|NCT00520455|Experimental|Intervention|Study subjects were prescribed levonorgestrel 0.75mg taken twice 12 hours apart (Plan B) and a package of 30 condoms provided via a commerical pharmacy at no cost to the study subject. The subject could refill this prescription as many times as they wanted for 12 months
89030573|NCT02275871|Experimental|MRI and CESM|High risk patients will get standard of care screening MRI and study CESM on the same day.
89030574|NCT02948439|Experimental|Exercise Intervention|The aerobic exercise intervention will consist of a walking program at 50-70% of individual heart rate reserve. This will begin at 16-20 weeks gestation and continue 3-4 times per week until the end of the study (34-36 weeks). The duration of exercise will increase each week up to a maximum of 40 minutes (5 min warm up, 25 minutes exercise, 5 min cool down). Women will have at least one supervised exercise session per week. The investigators will also monitor other activity using questionnaires and accelerometry. This will occur at baseline (16-20 weeks), mid-intervention (24-26 weeks) and at the end (34-36 weeks).
89030575|NCT02948439|No Intervention|Control Group|These women will continue regular daily activities. Activity will be monitored periodically with questionnaires and accelerometry. This will occur at baseline (16-20 weeks), mid-intervention (24-26 weeks) and at the end (34-36 weeks).
89589151|NCT05778396|Sham Comparator|Control spinal manual therapy protocol|(1) Control side-lying lumbar spine manipulation, (2) control prone lumbar spine mobilization, and (3) control prone thoracic spine manipulation.
89589152|NCT05752825||Acromegalic patients|Subjects with acromegaly
89589153|NCT05752825||Healthy controls|Subjects without acromegaly
89030576|NCT02590757|Active Comparator|NIV-NAVA|Noninvasive ventilation in this group is practiced with NIV-NAVA
89030577|NCT02590757|Active Comparator|N-CPAP|Patients in this group will receive nasal continuous positive airway pressure as routinely in neonatal intensive care unit.
89030578|NCT02949375|Placebo Comparator|Placebo Arm|Gel capsule containing Placebo to be taken once per day
89030579|NCT02949375|Active Comparator|4.5mg GRI-0621|4.5mg GRI-0621 gel capsule to be taken once per day
89030580|NCT02949375|Active Comparator|6mg GRI-0621|6mg GRI-0621 gel capsule to be taken once per day
89030581|NCT04514432||When music was available|3 month period during which music was available to patients experiencing agitation
89030582|NCT04514432||When music was not available|3 month period during which music was not available to patients
89030583|NCT02949180||AF|Five minutes puls wave recording will be performed in patients in atrial fibrillation at time of recruitment
89030584|NCT02949180||SR|Five minutes puls wave recording will be performed in patients in sinus rhythm at time of recruitment
89030585|NCT02598947|Experimental|Posterior shoulder tightness group|As well as receiving a strengthening program for the scapular and rotator cuff musculature, subjects allocated to the 'posterior shoulder tightness' treatment group will also receive specific manual therapy and home stretches to address stiffness of the posterior shoulder
89030586|NCT02598947|Sham Comparator|Posterior shoulder tightness sham group|The 'sham posterior shoulder tightness' group will receive the same strengthening program for the scapular and rotator cuff musculature, in addition they will receive home stretches and manual therapy of similar durations to the 'posterior shoulder tightness' group, but delivered to structures that have no known direct structural influence on the posterior shoulder
89589154|NCT05745701|Active Comparator|Period 1: PF-07081532|Participants will receive PF-07081532 as a single dose on Day 1.
89589155|NCT05745701|Experimental|Period 2: Cyclosporine + PF-07081532|Participants will receive a single dose of PF-07081532 and a single dose of cyclosporine on Day 1.
89589156|NCT05745701|Experimental|Period 3: Itraconazole + PF-07081532|Participants will receive itraconazole daily for 9 days plus a single dose of PF-07081532 on Day 4.
89589157|NCT05742594|Experimental|Intervention Sequence: ADBC|Participants will receive intervention A (lazertinib reference formulation) on Day 1 of intervention Period 1, followed by intervention D (lazertinib test formulation) on Day 1 of intervention Period 2, followed by intervention B (lazertinib test formulation) on Day 1 of intervention Period 3 followed by intervention C (lazertinib test formulation) on Day 1 of Intervention Period 4. There will be a wash-out period of at least 14 days and up to 21 days between each intervention period.
89589158|NCT05742594|Experimental|Intervention Sequence: BACD|Participants will receive intervention B (lazertinib test formulation) on Day 1 of intervention Period 1, followed by intervention A (lazertinib reference formulation) on Day 1 of intervention Period 2, followed by intervention C (lazertinib test formulation) on Day 1 of intervention Period 3 followed by intervention D (lazertinib test formulation) on Day 1 of intervention Period 4. There will be a wash-out period of at least 14 days and up to 21 days between each intervention period.
89589159|NCT05742594|Experimental|Intervention Sequence: CBDA|Participants will receive intervention C (lazertinib test formulation) on Day 1 of intervention Period 1, followed by intervention B (lazertinib test formulation) on Day 1 of intervention Period 2, followed by intervention D (lazertinib test formulation) on Day 1 of intervention Period 3 followed by intervention A (lazertinib reference formulation) on Day 1 of intervention Period 4. There will be a wash-out period of at least 14 days and up to 21 days between each intervention period.
89589160|NCT05742594|Experimental|Intervention Sequence: DCAB|Participants will receive intervention D (lazertinib test formulation) on Day 1 of intervention Period 1, followed by intervention C (lazertinib test formulation) on Day 1 of intervention Period 2, followed by intervention A (lazertinib reference formulation) on Day 1 of intervention Period 3 followed by intervention B (lazertinib test formulation) on Day 1 of intervention Period 4. There will be a wash-out period of at least 14 days and up to 21 days between each intervention period.
89589161|NCT05742334|Experimental|Robot Assisted Radical Prostatectomy with MLG-COMPLETE Allograft|Implantation of the MLG-COMPLETE allograft during your robot-assisted radical prostatectomy surgery.
89589162|NCT05741086|Experimental|Evolocumab added to statin therapy|Evolocumab (140 mg every 2 weeks for 1 year) added to statin (Atorvastatin 20-40mg). Anti-platelet aggregation and risk factor management in both arms.
89589163|NCT05741086|Active Comparator|Statin therapy|Atorvastatin 20-40mg. Anti-platelet aggregation and risk factor management in both arms.
89589164|NCT05722262|Experimental|Sequence A|Three period alternative intervention and fed/fasted sequence
89589165|NCT05722262|Experimental|Sequence B|Three period alternative intervention and fed/fasted sequence
89589166|NCT05722262|Experimental|Sequence C|Three period alternative intervention and fed/fasted sequence
89589167|NCT05722262|Experimental|Sequence D|Three period alternative intervention and fed/fasted sequence
89589168|NCT05722262|Experimental|Sequence E|Three period alternative intervention and fed/fasted sequence
89589169|NCT05722262|Experimental|Sequence F|Three period alternative intervention and fed/fasted sequence
89589170|NCT05711446|Experimental|Double Voiding|The participant will be instructed to void twice.
89589171|NCT05711446|Active Comparator|Regular Voiding|The participant will be instructed to void normally.
89589172|NCT05710887|Active Comparator|Treatment; Nitrous Oxide 50%|A single 45-minute session of inhaled 50% nitrous oxide.
89589173|NCT05710887|Placebo Comparator|Control; Oxygen-air mixture|A single 45-minute session of inhaled Oxygen-air mixture
89030587|NCT02949258|Experimental|SEEOX group|A three-cycle neoadjuvant chemotherapy will be performed in all cases. In every cycle, oxaliplatin 150 mg, etoposide 100 mg and epirubicin 50 mg will be administered from the celiac artery on day 1. Oral S-1 120 mg per day will be given for days 1-14. The second cycle will be scheduled following a 1-week rest after the first cycle.After two courses of neoadjuvant chemotherapy, patients will be reevaluated and receive curative or palliative resection or exploratory laparotomy within 14 days after completing the second course of chemotherapy.
89030588|NCT04514081|Experimental|Chidamide+Decitabine+Camrelizumab|
89030589|NCT04514081|Active Comparator|Decitabine+Camrelizumab|
89030590|NCT02948517|Experimental|Time restricted feeding|Time restricted feeding
89030591|NCT02948517|No Intervention|Control|No intervention
89030592|NCT04514120|Experimental|Stable CRS|Patients diagnosed with Chronic Rhinosinusitis including those with or without nasal polyposis and/or with Allergic Fungal Rhinosinusitis and stable condition
89589174|NCT05705947||Patients with osteoarthritis receiving radiation treatment|"Patients with osteoarthritis receiving standard of care radiation treatment at UNC Radiation Oncology clinic. Radiation dose and fractionation prescription is at the physician's discretion.~Typically, this prescription is delivered in 6 fractions, every other day, over 2 weeks."
89589175|NCT05699044||Amyloidosis Screening|Patients fulfilling eligibility criteria will screened for Cardiac Amyloidosis.
89589176|NCT05693272|Experimental|COVAC-01 10µg group|12 healthy adults ≥18 years of age receive the vaccine on Day 0.
89589177|NCT05693272|Experimental|COVAC-01 25µg group|12 healthy adults ≥18 years of age receive the vaccine on Day 0.
89589178|NCT05693272|Experimental|COVAC-01 50µg group|12 healthy adults ≥18 years of age receive the vaccine on Day 0.
89589179|NCT05693272|Placebo Comparator|Placebo Control|12 healthy adults ≥18 years of age receive a dose of normal saline (placebo) on Day 0.
89589180|NCT05657041|Experimental|Group 1: body weight <60kg|Treatment with clopidogrel 50mg once daily for a minimum of 10 days (max. 14 days), followed by a minimum of 10 days treatment with clopidogrel 25mg once daily (max 14 days).
89589181|NCT05657041|No Intervention|Group 2: body weight 60-100kg|Treatment with clopidogrel 75mg once daily
89589182|NCT05657041|Experimental|Group 3: body weight >100kg|Treatment with clopidogrel 150mg once daily for a minimum of 10 days (max. 14 days), followed by a minimum of 10 days treatment with prasugrel 10mg once daily (max 14 days).
89608453|NCT02991664|Active Comparator|G-aenial Posterior, randomly applied|After etching procedure, the enamel and dentin were conditioned with G-aenial adhesive using a microtip applicator, left undisturbed for five to 10 seconds, and then dried thoroughly for five seconds with oil-free air under air pressure, G-aenial posterior composite resin was applied with the incremental technique (2 mm thick layers) and light-cured for 20 seconds. Finally, the restoration was shaped with finishing diamonds and silicon instruments.
89589183|NCT05653362|Other|Coconut Oil followed by Commercial Ultrasound Gel|"After the patient is consented and all questions are answered, the patient's information will be entered into a RedCap and they will be randomized to either starting the scan by first obtaining the required study images with coconut oil and then proceeding to the standard ultrasound using commercial ultrasound gel (Arm 1) or to starting with the scheduled ultrasound using the commercial ultrasound gel and ending by obtaining the required study images using coconut oil (Arm 2).~Whether assigned to Arm 1 or Arm 2, prior to the collection of the study images using coconut oil, the participant will be handed a small plastic cup with a pre-measured amount of coconut oil and they will be asked to warm it in their hand for at least 2 minutes. They will then apply the coconut oil to their own abdomen with their hands prior to the ultrasound technician obtaining the required images.~The ultrasound technician will collect 3 extra images for study purposes only using the coconut oil."
89589184|NCT05653362|Other|Commercial Ultrasound Gel followed by Coconut Oil|"After the patient is consented and all questions are answered, the patient's information will be entered into a RedCap and they will be randomized to either starting the scan by first obtaining the required study images with coconut oil and then proceeding to the standard ultrasound using commercial ultrasound gel (Arm 1) or to starting with the scheduled ultrasound using the commercial ultrasound gel and ending by obtaining the required study images using coconut oil (Arm 2).~Whether assigned to Arm 1 or Arm 2, prior to the collection of the study images using coconut oil, the participant will be handed a small plastic cup with a pre-measured amount of coconut oil and they will be asked to warm it in their hand for at least 2 minutes. They will then apply the coconut oil to their own abdomen with their hands prior to the ultrasound technician obtaining the required images.~The ultrasound technician will collect 3 extra images for study purposes only using the coconut oil."
89589185|NCT05635097|Other|One group intervention|One group without comparator
89589186|NCT05632484|Experimental|Newborns with a parent with HHT disease|16 newborns with one parent suffering HHT disease and carrying a mutation in the ACVRL1, ENG or SMAD4 gene will be included in this study.
89589187|NCT05622461|Experimental|Road-to-recovery group (R2R)|Usual medical care plus the R2R-TBI intervention (self-guided web-program)
89589188|NCT05622461|Active Comparator|Internet resources comparison group (IRC)|Usual medical care plus internet resources
89589189|NCT05621889|Experimental|virtual group speech therapy intervention guided by a patient partner|
89589190|NCT05607316|Experimental|Oral Metformin|Treatment with metformin will be started at 500 mg twice daily and increased to 1000 mg twice daily only after they have tolerated the treatment.
89589191|NCT05607238|Active Comparator|Ultrasound Guided Peripheral IV|Placement of 4-5cm angiocath under ultrasound guidance
89589192|NCT05607238|Experimental|Ultrasound Guided Midline Catheter|Placement of 10-15cm midline catheter under ultrasound guidance
89589193|NCT05605587|Experimental|Leflunomide 20mg|
89589194|NCT05585515|No Intervention|Control|16/8 hours wake/sleep regime for 3 consecutive days at home and for consecutive 2 days in sleep laboratory
89589195|NCT05585515|Experimental|Sleep restriction|18/6 hours wake/sleep regime for 3 consecutive days at home and one day in sleep laboratory, followed by recovery night of 8 hours sleep
89589196|NCT05585515|Experimental|Sleep deprivation|16/8 hours wake/sleep regime for 3 consecutive days at home, one night of sleep deprivation (24/0 hours) in sleep laboratory, followed by recovery night of 8 hours sleep
89589197|NCT05584163|No Intervention|Control group|Group not using drugs used for the prevention of cardiomyopathy caused by doxorubicin, including extracorporeal shock wave
89589198|NCT05584163|Experimental|ESWT treatment group|Group receiving extracorporeal shock wave therapy
89589199|NCT05582993|Experimental|Cohort 1: Participants With Age >=12 to <18 years|Participants with age greater than or equal to (>=) 12 to less than (<) 18 years who have received on-demand (OD) therapy or prophylactic treatment with a pdVWF product will receive rVWF with an initial dose selected within the range of 40 to 60 international units per kilogram (IU/kg) rVWF, intravenous infusions, twice-weekly for 12 months. Participants may receive rVWF with or without ADVATE intravenous infusions, when indicated (as deemed necessary for breakthrough bleeding episode treatment and perioperative bleeding management).
89030593|NCT04514120|Experimental|Non-stable CRS|Patients diagnosed with Chronic Rhinosinusitis including those with or without nasal polyposis and with Allergic Fungal Rhinosinusitis who are experiencing an exacerbation
89030594|NCT02948556||Chronic fatigue syndrome|Participants with chronic fatigue syndrome
89030595|NCT00520611|Active Comparator|Lottery|Participants are entered into daily lotteries to win $10 or $100 every day their weight is at or below daily targets.
89030596|NCT00520611|Active Comparator|Deposit|Participants receive $3/day if they are at or below their daily weight goals, plus have opportunity to deposit up to $3/day of their own money, which is then matched 1:1 every day they are at or below their daily weight goals.
89030597|NCT00520611|No Intervention|Control|Participants would receive usual care from their providers and have monthly weigh ins.
89030598|NCT04514042|Active Comparator|Standard procedure|Patients with Zenker's diverticulum treated with flexible endoscopy septotomy.
89589200|NCT05582993|Experimental|Cohort 2: Participants With Age >=6 to <12 years|Participants with age >=6 to <12 years who have received OD therapy of VWF product or prophylactic treatment with a pdVWF product will receive rVWF with an initial dose selected within the range of 40 to 60 IU/kg rVWF, intravenous infusions, twice-weekly for 12 months. Participants may receive rVWF with or without ADVATE intravenous infusions, when indicated (as deemed necessary for breakthrough bleeding episode treatment and perioperative bleeding management).
89589201|NCT05582993|Experimental|Cohort 3: Participants With Age <6 years|Participants with age <6 years who have received OD therapy of VWF product or prophylactic treatment with a pdVWF product will receive rVWF with an initial dose selected within the range of 40 to 60 IU/kg rVWF, intravenous infusions, twice-weekly for 12 months. Participants may receive rVWF with or without ADVATE intravenous infusions, when indicated (as deemed necessary for breakthrough bleeding episode treatment and perioperative bleeding management).
89589202|NCT05582642|Active Comparator|Diaphragm Strength Training|
89589203|NCT05582642|Sham Comparator|Diaphragm Endurance Training|
89589204|NCT05582369|Experimental|Affective Rewards Messages|Throughout the study, each week participants will be asked to plan two exercise sessions for the upcoming week, and will be asked to report on how they did with those plans at the end of the day when they planned to exercise. At the very beginning of the time window when they planned to exercise participants will be randomized with 40% probability to receive no message, 20% probability to receive a reminder to fill out the study questionnaire at the end of the day, and 40% probability to receive one of two types of affective rewards messages (active intervention). The two types are: 1) low-reflection messages written by participants at the beginning of the study, about the affective rewards of exercise they have previously experienced; and 2) high-reflection messages that prompt participants to reflect on the affective rewards of exercise and text back a response.
89589205|NCT05581758|Experimental|Treatment Sequence AB|"Participants will be administered AMG 510 orally in the following order:~Period 1 (treatment A) - AMG 510 under fasted conditions. Period 2 (treatment B) - AMG 510 under fed conditions."
89589206|NCT05581758|Experimental|Treatment Sequence BA|"Participants will be administered AMG 510 orally in the following order:~Period 1 (treatment B) - AMG 510 under fed conditions. Period 2 (treatment A) - AMG 510 under fasted conditions."
89589207|NCT05554146|Other|Coupon for a Discounted Placebo Product|We will observe participants who were previously randomized to a coupon for discounted placebo soft-gel capsules by our collaborators, Vireo.
89589208|NCT05554146|Other|Coupon for a Discounted High THC Product|We will observe participants who were previously randomized to a coupon for discounted 4.3 mg THC/0.7 mg CBD soft-gel capsules by our collaborators, Vireo.
89589209|NCT05554146|Other|Coupon for a Discounted Equal THC and CBD Product|We will observe participants who were previously randomized to a coupon for discounted 2.5 mg THC/2.5 mg CBD soft-gel capsules by our collaborators, Vireo.
89589210|NCT05554146|Other|Coupon for a Discounted High CBD Product|We will observe participants who were previously randomized to a coupon for discounted 0.2 mg THC/4.8 mg CBD soft-gel capsules by our collaborators, Vireo.
89589211|NCT05553301|Experimental|Group 1: Quadrivalent Influenza mRNA Vaccine MRT5407 dose level 1|participants will receive a single dose of QIV mRNA vaccine (dose level 1)
89589212|NCT05553301|Experimental|Group 2: Quadrivalent Influenza mRNA Vaccine MRT5407 dose level 2|participants will receive a single dose of QIV mRNA vaccine (dose level 2)
89589213|NCT05553301|Active Comparator|Group 3: RIV4|participants will receive a single dose of RIV4 vaccine
89589214|NCT05553301|Active Comparator|Group 4: QIV-SD|participants will receive a single dose of QIV-SD vaccine
89589215|NCT05553301|Active Comparator|Group 5: QIV-HD|participants will receive a single dose of QIV -HD vaccine (for elderly only)
89589216|NCT05541315|Experimental|JNJ-88260237|Participants will be randomized into 6 cohorts to receive single oral dose of JNJ-88260237 on Day 1. The doses in each cohort (Cohorts 2 to 4 and 6) will be escalated based on the safety and pharmacokinetics (PK) data of the previous cohort. For Cohort 5, participants will receive a single-dose of JNJ-82260237 in fasted conditions and a single dose of JNJ-82260237 in fed conditions with dosing sequence determined by randomization.
89030599|NCT04514042|Experimental|Investigational procedure|Patients with Zenker's diverticulum treated with peroral endoscopic myotomy.
89030600|NCT00519246|Placebo Comparator|I|No drug was delivered.
89030601|NCT00519246|Active Comparator|II|Butorphanol tartrate 1mg was given intravenously.
89030602|NCT00519246|Active Comparator|III|Butorphanol tartrate 2 mg was given intravenously.
89589217|NCT05541315|Placebo Comparator|Placebo|Participants in Cohorts 1 to 4 and 6 will receive single oral dose of matching placebo on Day 1.
89589218|NCT05538741|Experimental|Bolus|Remimazolam bolus injection for 20 seconds
89589219|NCT05538741|Active Comparator|Continuous|Remimazolam continuous infusion
89589220|NCT05536323|Experimental|Bolus|Anesthetic induction with bolus remimazolam administration
89589221|NCT05536323|Experimental|Continuous|Anesthetic induction with continuous remimazolam administration
89589222|NCT05535738|Experimental|Baseline Contact Allergen|Individuals who will have allergic contact dermatitis induced via squaric acid dibutyl ester (SADBE) and/or known patch test allergens followed by skin and blood sampling. There is a protocol to sensitize individuals to SADBE if they have not previously been exposed to SADBE.
89589223|NCT05535738|Experimental|Contact Allergen with Immunomodulator Pre-Treatment|Individuals from Arm 1 (Baseline Contact Allergen) who have been exposed to SADBE and/or known patch test allergens followed by skin and blood sampling. These individuals will be pre-treated via administration of a single dose of 1 biologic from the following list: dupilumab, adalimumab, ustekinumab, guselkumab, canakinumab, sarilumab; or a single application of 1 topical steroid from the following list: betamethasone valerate, triamcinolone acetonide, fluticasone propionate. Allergic contact dermatitis will then be induced and the skin sampled.
89589224|NCT05518110|Experimental|PaTcH|All eligible patients will be treated with trametinib 2mg and hydroxychloroquine 1200mg daily (600mg twice a day (BID)) orally. Treatment will be continuous in treatment cycles lasting 28 days, and will continue until radiological or clinical progression of disease, unacceptable toxicity or consent withdrawal.
89589225|NCT05451589|Experimental|RESET intervention|Participants will engage in a 7-week positive psychology and self-management group telephone-based program.
89589226|NCT05451589|Active Comparator|Wellness check control|Participants will receive educational information and an individual wellness check phone call from a Community Health Worker to screen for unmet social needs.
89589227|NCT05429164|Active Comparator|Self Myofascial Release|Self Myofascial Release only
89589228|NCT05429164|Active Comparator|Myofascial Release|Myofascial Release with Physical Therapist Only
89589229|NCT05429164|Active Comparator|Instrument Assisted Soft Tissue Mobilization|Instrument Assisted Soft Tissue Mobilization Only
89030603|NCT00519246|Active Comparator|IV|Flurbiprofen Axetil 50 mg was given intravenously.
89030604|NCT00519246|Active Comparator|V|Flurbiprofen Axetil 100 mg was given intravenously.
89030605|NCT00519246|Active Comparator|VI|Tramadol Hydrochloride 10 mg was given intravenously.
89030606|NCT00519246|Active Comparator|VII|Tramadol Hydrochloride 20 mg was given intravenously.
89030607|NCT00519987|Experimental|Treatment A|intranasal ketamine
89030608|NCT00519324|Experimental|RAD001|
89030609|NCT04514471|Experimental|Unventilated Filter Cigarette|Conventional cigarette with approximately 6-7% (non-menthol) and 5-6% filter ventilation (menthol).
89030610|NCT04514471|Active Comparator|Ventilated Filter Cigarette|Conventional cigarette with approximately 22-26% (non-menthol) and 35-38% filter ventilation (menthol).
89589230|NCT05345717|Experimental|Patients treated with belatacept and proteasome inhibitor|Highly sensitized patients will be treated with belatacept and proteasome inhibitor and monitored for decreasing calculated Panel of Reactive Antibodies (cPRA) and suitable kidney donor base don negative crossmatch
89589231|NCT05332613|Experimental|TRE plus SOC|Participants will be required to fast each day for 12 weeks and will be given lifestyle recommendations with respect to diet and exercise. The registered dietitian (RD) will obtain a baseline dietary record and provide counseling on the time-restricted eating regimen. The RD will collect the participant's normal diet and exercise routine. Counseling will involve instructing the participant to choose an eight-hour eating window (e.g., 10:00am - 6:00pm) during which the participant will be able to eat. During the 16-house fasting window (e.g., 6:00pm - 10:00 am), the participant is able to drink regular water and black coffee or tea. The RD will be available to answer any questions the participants may have pertaining to the regimen and will instruct the participants regarding standard of care lifestyle recommendations. This includes education of a low-calorie diet (500-1000 kcal) and moderate-intensity exercise.
89030611|NCT04513535|Experimental|manual therapy combination 1|Cervical manipulation, Thoracic manipulation
89030612|NCT04513535|Experimental|manual therapy combination 2|Cervical manipulation, glenohumeral mobilization
89589232|NCT05332613|Active Comparator|SOC|lifestyle modifications and weight management. Participants will be given lifestyle recommendations with respect to diet and exercise. The registered dietitian (RD) will obtain a baseline dietary record and provide counseling on the time-restricted eating regimen. A baseline dietary record will be assessed prior to fasting initiation with the RD in person. The RD will also collect the subject's normal diet and exercise routine. The RD will instruct the participants regarding standard of care lifestyle recommendations. This includes education of a low-calorie diet (500-1000 kcal) and moderate-intensity exercise.
89589233|NCT05332613|Experimental|Crossover to TRE|Participants who have not lost weight or have lost less than or equal to 5% of their body weight, they will be given the option to crossover to the TRE arm. Following the initial 12-week period and end of study MRI, participants would restart another identical 12-week cycle but adhering to the exact steps of the TRE arm including another 4 visits with the registered dieticians (RDs) and an end of study visit with repeat Fibroscan, InBody 770 body composition scan, and MRI-PDFF.
89589234|NCT05332054||Patients who received a Caribou-sponsored allogeneic CAR-T therapy|in a Caribou-sponsored clinical study or special access program
89589235|NCT05319717|Active Comparator|Ready-to-use therapeutic food, no rice bran (control/comparator)|Randomized participants will receive a locally produced ready-to-use therapeutic food to be consumed daily.
89589236|NCT05319717|Experimental|Ready-to-use therapeutic food, with heat stabilized rice bran (Experimental)|Randomized participants will receive a locally produced ready-to-use therapeutic food with 5% heat stabilized rice bran to be consumed daily.
89589237|NCT05276362||Typical Sleepers|This will be a single arm study of approximately 70 typical sleepers that will wear the Study Watch(es) and Actiwatch for one night in a sleep laboratory.
89589238|NCT05276362||Sleepers with Elevated Insomnia Symptoms|This will be a single arm study of at least 15 participants with elevated insomnia symptoms that will wear the Study Watch(es) and Actiwatch for one night in a sleep laboratory.
89589239|NCT05276362||Sleepers withObstructive Sleep Apnea Sleepers|This will be a single arm study of at least 15 participants with obstructive sleep apnea that will wear the Study Watch(es) and Actiwatch for one night in a sleep laboratory.
89030613|NCT04513535|Experimental|manual therapy combination 3|cervical manipulation, sleeper stretch
89030614|NCT04513535|Experimental|manual therapy combination 4|thoracic manipulation, glenohumeral mobilization
89030615|NCT04513535|Experimental|manual therapy combination 5|thoracic manipulation, sleeper stretch
89030616|NCT04513535|Experimental|manual therapy combination 6|glenohumeral mobilization, sleeper stretch
89030617|NCT02595710||Biospecimen retention|Blood Collection Skin Punch Biopsy Collection Urine Sample Collection
89030618|NCT00519402||Partial Tonsillectomy|Patients who received a partial tonsillectomy
89030619|NCT00519402||Complete Tonsillectomy|Patients who received a complete tonsillectomy
89030620|NCT02591030|Placebo Comparator|GEMCIS|
89030621|NCT02591030|Experimental|mFOLFIRINOX|
89030622|NCT00519441|Other|I|All patients in the study will have pH studies done in order to determine the degree of reflux after laparoscopic Heller myotomies.
89589240|NCT05245968|Experimental|Dose Escalation Part|Pimitespib in combination with imatinib
89589241|NCT05245968|Experimental|Expansion Part-A|Pimitespib in combination with imatinib
89589242|NCT05245968|Experimental|Expansion Part-B|Pimitespib followed by imatinib
89589243|NCT05245968|Experimental|Expansion Part-C|Sunitinib
89589244|NCT05232682|Experimental|Probiotic Arm|Probiotic arm
89589245|NCT05225337|Experimental|Time restricted feeding (TRF)|8-h eating window Ad libitum food intake from 12-8 pm every day Fasting from 8-12 pm every day (16-h fast)
89589246|NCT05225337|Experimental|Daily calorie restriction (CR)|25% energy restriction every day Diet counseling provided
89589247|NCT05225337|No Intervention|Control|Ad libitum food intake, eating over more than 10 hours per day
89589248|NCT05220514||Non-COVID-19 Diagnosis Control Group|Subjects hospitalized and receiving intensive care for diagnosis of an acute neurological disease other than COVID-19
89589249|NCT05220514||COVID-19 Diagnosis Case Group|Subjects previously hospitalized at Mayo Clinic Hospital for treatment of PCR test confirmed COVID-19
89030623|NCT02955017|Active Comparator|Traditional follow-up|
89030624|NCT02955017|Experimental|"Distance follow-up new technologies"|
89030625|NCT00519480|Placebo Comparator|Subjects receiving treatment P|Eligible subjects will receive placebo twice daily along with metformin twice daily for 13 days.
89030626|NCT00519480|Experimental|Subjects receiving treatment A|Eligible subjects will receive GSK189075 500 milligrams twice daily along with metformin twice daily for 13 days.
89030627|NCT00519480|Experimental|Subjects receiving treatment B|Eligible subjects will receive GSK189075 750 milligrams twice daily along with metformin twice daily for 13 days.
89209882|NCT04397406|Active Comparator|Group C (Control group)|pidural analgesia with levobupivacaine alone
89589250|NCT05194969|Active Comparator|Wet-to-dry Dressings|Participants in this arm will receive standard of care wet-to-dry dressings.
89589251|NCT05194969|Experimental|Petrolatum with Non-Stick Gauze|Participants in this arm will receive petrolatum with non-stick gauze.
89589252|NCT05185440|Active Comparator|GIFTSS Training Only|Training for college health center clinicians and staff in implementation of GIFTSS Training
89589253|NCT05185440|Experimental|GIFTSS Training and Learning Collaborative|Training for college health center clinicians and staff in implementation of GIFTSS Training combined with learning collaborative to support implementation
89589254|NCT05185440|Experimental|GIFTSS Training and Provider Scripts|Training for college health center clinicians and staff in implementation of GIFTSS Training combined with provider scripts to support implementation
89589255|NCT05185440|Experimental|GIFTSS Training, Learning Collaborative, and Provider Scripts|Training for college health center clinicians and staff in implementation of GIFTSS Training combined with learning collaborative as well as provider scripts to support implementation
89589256|NCT05168826||Transcatheter Aortic Valve Implantation (TAVI)|
89589257|NCT05166239|Experimental|HAIC-Cola group|Hepatic arterial chemotherapy consisted of infusions of oxaliplatin (35 mg/m2 for 2 hours), followed by 5-fluorouracil (600 mg/m2 for 22 hours) on day1-3 every 4 weeks. 12/8 mg (weight ≥ 60kg / < 60 kg) of Lenvatinib once daily after HAIC. PD-1 inhibitors injection intravenously or percutaneously before 24h of HAIC every 4 week.
88976500|NCT00157027|Active Comparator|1|"Photopheresis (or extracorporeal photoimmunetherapy [ECP]) is a process developed by THERAKOS, Inc., a Johnson and Johnson Company. During the process of ECP, whole blood is drawn from the patient over several cycles, centrifuged and separated into the components of plasma, white cells (or buffy coat), and red blood cells. A portion of the white cells and the plasma are saved in a separate compartment. The remaining plasma and red blood cells are immediately returned to the patient.~The saved buffy coat (white blood cells) and plasma are inoculated with the photosensitizing agent UVADEX. Photoactivation begins when the suspension is exposed to a prescribed amount of ultraviolet-A light. After photoactivation is complete, the treated suspension is returned to the patient."
88976501|NCT00083772|Experimental|1|Nesiritide
88976502|NCT00157300|Experimental|Epoetin beta|
88976503|NCT00398060|Experimental|A|
88976504|NCT00406978|Experimental|MPTD|
88976505|NCT00157612|Other|Intervention|use of oral anti-microbials, portable chest radiographs, oxygen saturation monitoring, re-hydration and close monitoring by a research nurse
88976506|NCT00157612|No Intervention|Comparator|usual care
88976507|NCT00157651|Active Comparator|1|Receiving warfarin
88976508|NCT00157651|Placebo Comparator|2|Receiving matching placebo
88976509|NCT00157690|Active Comparator|1|Alendronate
89589258|NCT05166239|Active Comparator|Cola group|12/8 mg (weight ≥ 60kg / < 60 kg) of Lenvatinib once daily. PD-1 inhibitors injection intravenously or percutaneously every 4 week.
88976510|NCT00157690|Placebo Comparator|2|Placebo
88976511|NCT00157807|No Intervention|No Ablation|
88976512|NCT00157807|Other|bipolar radiofrequency ablation of persistent and permanent AF|intra operative bipolar RF ablation of persistent and permanent AF
88976513|NCT00157846|Experimental|BiV Pacing|Biventricular pacing for 3 months, subsequently right ventricular pacing for 3 months
88976514|NCT00157846|Active Comparator|RV Stimulation|Right ventricular pacing for 3 months, subsequently biventricular pacing for 3 months
88976515|NCT05568498|Experimental|Probiotic|Ecologic® BARRIER 849 (Maize starch, maltodextrin, vegetable protein, potassium chloride, +/- probiotic bacteria (B. bifidum W23, B. lactis W51, B. lactis W52, L. acidophilus W37, L. brevis W63, L. casei W56, L. salivarius W24, Lc. lactis W19, Lc. lactis W58; ≥ 2,5*10^9 colony forming unit (CFU)/g), magnesium sulphate, manganese sulphate.) sachet, two times daily dosing for a total of 2 grams (viable cell count of 2.5 × 10^9 CFU/gram) per day.
88976516|NCT05568498|Placebo Comparator|Placebo|Placebo (maize starch, maltodextrin, vegetable protein, magnesium sulphate, manganese sulphate)
88976517|NCT00158158|Placebo Comparator|1|Usual care
88976518|NCT00158158|Experimental|2|Reduction in smoking
88976519|NCT00158275|Experimental|Integrated Intervention|Participants will receive cognitive behavioral therapy for back pain and antidepressants and/or problem solving therapy for depression. Study visits will initially occur once a week and then taper to once every 2 weeks for the 6-month duration.
88976520|NCT00158275|No Intervention|Standard of Care|Participants will receive care as usual from their health care provider.
88976521|NCT00158353|Experimental|1|GirlPOWER! mentoring program
88976522|NCT00158353|Active Comparator|2|Big Brothers Big Sisters community-based mentoring program
89589259|NCT05145296|Other|Patients with cPRA ≥99%|This is a non-randomized, single arm study, combination trial designed according to the Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee. The study will enroll 12 patients with cPRA ≥99% on the deceased donor kidney transplant waiting list, who have not received a compatible donor offer for >3 year. According to inclusion and exclusion criteria patients will be screened to participate in the trial.
88976524|NCT00158431|Active Comparator|Arthroscopy plus Medical Management|Arthroscopic Surgery of the Knee plus the optimized medical management including physiotherapy, education, medication, etc
88976525|NCT00158431|No Intervention|Medical Management|Optimized Medical management including physiotherapy, education, medication, etc
88976526|NCT00051740|Active Comparator|Cognitive Adaptation Therapy|Subjects receive Cognitive adaptation therapy as part of treatment for schizophrenia
88976527|NCT00051740|Active Comparator|Minimal Environmental Support|Subjects receive minimal environmental support in schizophrenia treatment
89030628|NCT04696211|Experimental|Experimental group|The music-with-movement exercise program (MMEP) is an 8-week program. In the first 4 weeks a center-based program will be offered in the District Elderly Centers, and from week 1 to week 8 home-based and digital-based activities will be delivered via a WhatsApp group.
89589260|NCT05133180|Experimental|Oxervate|one drop of cenegermin 20 mcg/mL will be instilled in both eyes three times daily.
89589261|NCT05133180|Placebo Comparator|Vehicle|vehicle eye one drop will be instilled in both eyes three times daily.
89589262|NCT05105958|Experimental|Tideglusib|Patients receive 1000 mg Tideglusib once daily per os
89589263|NCT05105958|Placebo Comparator|Placebo|Patients receive placebo matching Tideglusib 100 mg once daily per os
89030629|NCT04696211|No Intervention|Control group|The participants in the control group will continue to receive their usual care and receive a one-page pain management pamphlet.
89030630|NCT00520689|Active Comparator|1|
89030631|NCT00520689|Active Comparator|2|
89030632|NCT00520689|Active Comparator|3|
89030633|NCT00520689|Active Comparator|4|
89589264|NCT05095922|Experimental|Heart-Protecting Musk Pill group|Heart-Protecting Musk Pill (pill, 45mg, three times a day, 3 months)+Valsartan Capsules(capsule, 80mg, once a day, 3 months）+Calcium Dobesilate Capsules (capsule, 500mg, three times a day, 3 months)
89589265|NCT05095922|Placebo Comparator|Control group|Valsartan Capsules(capsule, 80mg, once a day, 3 months), Calcium Dobesilate Capsules (capsule, 500mg, three times a day, 3 months)
89589266|NCT05046574|Experimental|Therapy dog during stroke rehabilitative therapy sessions|Participants randomized to this arm will have a therapy dog present during their stroke rehabilitative therapy sessions.
89589267|NCT05046574|No Intervention|No therapy dog during stroke rehabilitative therapy sessions|Participants randomized to this arm will have stroke rehabilitative therapy sessions per standard of care with no therapy dog present.
89589268|NCT05044598|Other|RAFT-OS|"Single-arm trial is to investigate if RAFT-OS ((Real Architecture for 3D Tissues Ocular Surface) is a safe and effective alternative treatment for patients with aniridia related keratopathy (ARK) in 21 patients.~The RAFT-OS will be transplanted into the participants worst affected eye. Following surgery, each participant will be assessed at days 1, 7, 14, 21, and 1-month for major or intermediate safety events. Participants will continue to be followed up to 12 months after transplantation and will be required to stay on the immune suppression therapy for the duration of the trial."
89589269|NCT05030961|Experimental|Pediatric Cochlear Implant Candidate Group|Participants who are in the process of receiving standard of care cochlear implant evaluation. Participants will receive a virtual team-based clinic as a part of the candidacy evaluation process for one year.
89589270|NCT05030961|Experimental|Established Cochlear Implant Recipient Group|Participants who are established cochlear implant recipients. Participants will receive a virtual team-based clinic, including remote cochlear implant programming, for one year.
89589271|NCT05014360|Experimental|JNJ-64251330|Participants will receive oral dose of JNJ-64251330 twice daily for 24 Weeks.
89030634|NCT02955056|Experimental|Teriparatide Intervention|Will be asked to self-administer Teriparatide treatment (self-injection) once a day for 12 weeks
89030635|NCT02955056|No Intervention|Usual care|No intervention, patients will be treated as per local practice but will be followed up identically to the intervention group.
89589272|NCT04954300||open|open: open ICU
89589273|NCT04954300||negative|negative: negative-pressure laminar flow ward
89030636|NCT00520728|Experimental|A|Experimental arm receives 12 week intervention along with standard care.
89030637|NCT02954939|Active Comparator|MMF-MMF|Class III/IV+V LN patients who receive prednisolone (PRED) (0.8mg/kg/d) plus mycophenolate mofetil (MMF) (1g bd) as induction-maintenance therapy
89030638|NCT02954939|Placebo Comparator|CTX-AZA|Class III/IV+V LN patients who receive prednisolone (PRED) (0.8mg/kg/d) plus Cyclophosphamide (CTX) (1.5-2mg/kg/d) followed by Azathioprine (AZA) (1-1.5mg/kg/d) as induction-maintenance therapy
89030639|NCT00519519|Active Comparator|2|regular dose versus high dose
89030640|NCT00520806|Placebo Comparator|Placebo|48 hour iv infusion of placebo
89030641|NCT00520806|Experimental|Relaxin|48 hour iv infusion of relaxin at 30 ug/kg/day
89030642|NCT00505739|Experimental|Mifepristone|
89030643|NCT00519597|Experimental|I|Asymptomatic OSA (CPAP)
89030644|NCT00519597|No Intervention|II|Asymptomatic OSA (no CPAP)
89030645|NCT00519597|Active Comparator|III|Symptomatic OSA (OSAS)
89030646|NCT00519597|No Intervention|IV|Non-OSA
89030647|NCT05149820|Active Comparator|Nudge Prompt, Liberal Magnesium Strategy|This group will be randomised to receive the Nudge design of electronic point of care randomisation prompt. The prompt will encourage the clinician to follow a liberal magnesium supplementation strategy.
89030648|NCT05149820|Active Comparator|Nudge Prompt, Restrictive Magnesium Strategy|This group will be randomised to receive the Nudge design of electronic point of care randomisation prompt. The prompt will encourage the clinician to follow a restrictive magnesium supplementation strategy.
89030649|NCT05149820|Active Comparator|Preference Prompt, Liberal Magnesium Strategy|This group will be randomised to receive the Preference design of electronic point of care randomisation prompt. The prompt will encourage the clinician to follow a liberal magnesium supplementation strategy.
89030650|NCT05149820|Active Comparator|Preference Prompt, Restrictive Magnesium Strategy|This group will be randomised to receive the Preference design of electronic point of care randomisation prompt. The prompt will encourage the clinician to follow a restrictive magnesium supplementation strategy.
89030651|NCT02948985||RAS and B-raf wild type mCRC|patients with histologically confirmed RAS and B-raf wild type mCRC treated with FOLFIRI±cetuximab
89030652|NCT04513457||Liver resection and Neoadjuvant chemotherapy|Liver resection and Neoadjuvant chemotherapy
89589274|NCT04954300||positive|positive: laminar flow ward
89589275|NCT04944147|Experimental|Anodal tDCS + cognitive training|"device: anodal transcranial direct current stimulation (tDCS), 9 sessions with 20 minutes stimulation each (2 mA) over left dorsolateral prefrontal cortex~behavioral: intensive cognitive training intensive cognitive training of letter memory updating task (20 minutes), 9 sessions"
89589276|NCT04944147|Placebo Comparator|Sham tDCS + cognitive training|"device: sham transcranial direct current stimulation (tDCS), 9 sessions with 30 seconds stimulation each (2 mA) over left dorsolateral prefrontal cortex~behavioral: intensive cognitive training intensive cognitive training of letter memory updating task (20 minutes), 9 sessions"
89589277|NCT04944147|Active Comparator|Sham tDCS + Progressive Muscle Relaxation training|"device: sham transcranial direct current stimulation (tDCS), 9 sessions with 30 seconds stimulation each (2 mA) over left dorsolateral prefrontal cortex~behavioral: progressive muscle relaxation (PMR) standardized instructed PMR (20 minutes), 9 sessions"
89589278|NCT04939558||Chronic Obstructive Pulmonary Disease|245 participants - GOLD 1, 2, 3 / A, B, C
89589279|NCT04939558||Asthma|55 participants - Mild to moderate, not labelled as severe.
89589280|NCT04939558||Congestive cardiac failure|55 participants
89589281|NCT04939558||Anaemia|55 participants - with at least 50% of participants recruited having no history of chronic cardiorespiratory conditions
89589282|NCT04939558||Bronchiectasis|55 participants - Acquired or genetic, e.g. cystic fibrosis or other primary ciliary dyskinesias
89589283|NCT04939558||Lung cancer|55 participants - including rare types e.g. mesothelioma
89589284|NCT04939558||Interstitial Lung Disease|55 participants - including pulmonary fibrosis pneumoconiosis, asbestosis, sarcoidosis, amyloidosis
89589285|NCT04939558||Long COVID|55 participants
89589286|NCT04939558||Upper airway obstruction disorder|55 participants
89589287|NCT04939558||Healthy|55 participants - with no previous or current chronic cardiorespiratory diagnoses
89589288|NCT04921449|Experimental|Embedded ED Physical Therapy (NEED-PT)|An ED physical therapist will be embedded with the primary treatment team to evaluate patients presenting with low back pain at the beginning of the overall treatment course. The physical therapist will utilize a clinical protocol (NEED-PT) that matches the patient's history and exam findings to an appropriate treatment classification consisting of directional preference exercises, manual traction, stabilization exercises, non-thrust manipulation/mobilization, and/or psychologically informed rehabilitation. The NEED-PT intervention will supplement any usual care performed by the treating physician.
89589289|NCT04921449|Other|Usual Care|Usual care consists of any ED testing or treatment not involving an ED physical therapist in accordance with the treating physician's usual and customary practice. This could include diagnostic imaging, patient education and reassurance, and administration and/or prescribing of analgesic medications.
89589290|NCT04898400|Experimental|Subjects with Obesity|Subjects will be recruited to undergo endoscopic sleeve gastroplasty. The subjects will be studied at baseline, 30, 60, 90 days after procedure
89589291|NCT04875715|Experimental|Almond oil|Almond Oil Pressed Cold
89589292|NCT04875715|Active Comparator|Hydroquinone|Hydroquinone 2% cream
89589293|NCT04874584|Experimental|CTNSM Group|Culturally Tailored Nurse Symptom Management group (CTNSM) - participants in the CTNSM group will receive one in-person or telehealth face-to-face education session followed by a weekly telephone call and/or text message during the first 12 weeks of standard of care chemotherapy. In addition, participants can receive standard of care chemotherapy education.
89589294|NCT04874584|Active Comparator|Standard of Care (control) Group|Participants in the control group will only be receiving the standard of care chemotherapy education.
89589295|NCT04861597|Experimental|Internet-based cognitive behavioral therapy|The iCBT platform selected for use in this study (Sanvello™) is an evidence-based mobile app created by clinical experts that has been shown to decrease depression, anxiety, and stress and to increase self-efficacy in a non-IBD population.15 App features include: daily mood tracking; guided journeys (e.g. psychoeducational content providing background information about cognitive behavioral therapy and instructing users on how to use app tools to maintain motivation and interest); coping tools (e.g. meditation, goal setting, and negative thought redirecting activities); weekly progress assessments; community support board.
89589296|NCT04861597|Active Comparator|Digital mood tracking|The digital mood tracking application (app) selected for this study (PixelTM) allows participants to log their mood each day by way of a facial expression emoji and a free-text box. This app is commercially available free of charge through iOS and Android app stores with English and Spanish language options.
89589297|NCT04847050|Experimental|1|100 mcg (0.5 mL) mRNA-1273 injection (IM) on days 1 and 29; with option for subsequent booster dose(s), 100 mcg (0.5 mL) mRNA-1273 injection (IM) no less than 4 weeks after day 29
89589298|NCT04847050|Experimental|2|100 micrograms (0.5 mL) mRNA-1273 injection on D1
89589299|NCT04836429|Experimental|Treatment (porfimer sodium, photodynamic therapy)|Patients receive porfimer sodium IV over 3-5 minutes 24-48 hours prior to standard of care VATS, followed by photodynamic therapy
89589300|NCT04832152|Other|Feasibility trial group|One group (arm) trial where all will receive treatment.
89589301|NCT04828954|Active Comparator|2 weeks of immobilization|Subjects randomized to this arm will be rigidly immobilized in a plaster postoperative thumb spica splint for 2 weeks following their thumb CMC arthroplasty
89589302|NCT04828954|Active Comparator|6 weeks of immobilization|Subjects randomized to this arm will be rigidly immobilized in a plaster postoperative thumb spica splint, transitioned to cast, for a total of 6 weeks following their thumb CMC arthroplasty
89589303|NCT04822467|Active Comparator|Standard Wipe|Participants will receive a supply of ethanol-based wipes for daily use
89589304|NCT04822467|Experimental|SQ53 Wipe|Participants will receive a supply of SQ53 wipes for daily use.
89589305|NCT04817566|Experimental|stimulation group|Anodal tDCS+ intensive cognitive Training
89589306|NCT04817566|Sham Comparator|sham group|Sham tDCS + intensive cognitive Training
89589307|NCT04777266|Experimental|Experimental Music therapy Group|experimental group receiving the MT programme in addition to their usual treatment (pharmacological and psychosocial) (TAU + MT)
89589308|NCT04777266|Active Comparator|Control Non music therapy group|Group with usual treatment only (TAU).
89589309|NCT04769713|Experimental|Hepatic hilar nerve block in ablation patients|15ml of 0.7% ropivacaine will be injected at the hepatic hilum anterior to the portal vein as close to the bifurcation as possible under US guidance using a 21g needle prior to the Ablation procedure.
89589310|NCT04769713|Placebo Comparator|Placebo procedure in ablation patients|15ml of sterile normal saline will be injected at the hepatic hilum anterior to the portal vein as close to the bifurcation as possible under US guidance using a 21g needle prior to the Ablation procedure.
89589311|NCT04769713|Experimental|Hepatic hilar nerve block in chemoembolization patients|15ml of 0.7% ropivacaine will be injected at the hepatic hilum anterior to the portal vein as close to the bifurcation as possible under US guidance using a 21g needle prior to the chemoembolization procedure.
89589312|NCT04769713|Placebo Comparator|Placebo procedure in chemoembolization patients|15ml of sterile normal saline will be injected at the hepatic hilum anterior to the portal vein as close to the bifurcation as possible under US guidance using a 21g needle prior to the chemoembolization procedure.
89589313|NCT04756674||Control Group|"Non-Covid -19 associated community acquired pneumonia with oxygen therapy required.~n=12"
89030653|NCT04513457||Liver resection and Adjuvant chemotherapy|Liver resection and Adjuvant chemotherapy
89589314|NCT04756674||Oxygen Therapy|"Confirmed COVID-19 infection via PCR swab, with a new oxygen therapy requirement. NB the researchers will not be involved in the clinical decision of if the participant requires oxygen, this will be the clinical-teams decision.~n=12"
89589315|NCT04756674||Non-Invasive ventilation therapy|"Confirmed COVID-19 infection via PCR Swab, with a clinical need for non-invasive ventilation.~NB the researchers will not be involved in the clinical decision if the participant requires non-invasive ventilation, this will be the clinical-teams decision.~n=12"
89589316|NCT04728581|Placebo Comparator|Placebo|use of placebo during first 2 weeks after TKA surgery
89589317|NCT04728581|Experimental|Low dose Mirtazapine|Use of Mirtazapine 3.75mg before lights-out, allowed to increase medication to 7.5mg
89589318|NCT04728581|Experimental|Low dose Quetiapine|use of Quetiapine 3.125mg before lights-out, allowed to increase medication to 6.25mg
89589319|NCT04720703|Experimental|Intervention Group|The Intervention Group will receive the Family-based Telehealth Intervention for the first three months of the study period. Once they have completed the intervention, there will be a two-week washout period. After the washout period, they will receive monthly newsletters, with similar information learned in the intervention, for three months until the end of the study period.
89589320|NCT04720703|Active Comparator|Wait-list Control Group|The Waitlist Control Group will receive monthly newsletters, with similar information learned in the intervention, for the first three months of the study period while the Intervention Group receives the intervention. Then, there will be a two-week washout period. After the washout period, they will receive the Family-based Telehealth Intervention for 3 months until the end of the study period.
89589321|NCT04677543|Active Comparator|ALIS + Background Regimen (Azithromycin + Ethambutol)|Participants will be administered 590 mg of ALIS (amikacin liposome inhalation suspension) once daily. Participants will also be administered the background regimen of azithromycin 250 mg and ethambutol 15 mg/kg tablets orally, once daily.
89589322|NCT04677543|Placebo Comparator|ELC + Background Regimen (Azithromycin + Ethambutol)|Participants will be administered ELC (empty liposome control), a matching placebo to ALIS, once daily. Participants will also be administered the background regimen of azithromycin 250 mg and ethambutol 15 mg/kg tablets orally, once daily.
89589323|NCT04671511|Experimental|Targeted Axillary Dissection|Ultrasound of the axilla preoperative. Clipped biopsy proven positive node. I125 radioactive seed before surgery. Sentinel node biopsy using Tc99 +/- blue dye. Targeted Axillary Node Dissection performed at surgery
89589324|NCT04662840|Sham Comparator|Sham procedure|"The patient will be placed on the procedural table as for the other arms. They will be blinded to what is occuring around them. A script detailing the procedure verbally will be followed by the interventionalists to waste time, but the only actual medical act that will be done is freezing of the skin around the knee (as for nerve ablation procedure) and at the groin (as for embolization procedure). Dressings will be applied at the knee and groin area."
89589325|NCT04662840|Active Comparator|Geniculate artery embolization|The patient will be placed on the procedural table as for the other arms. They will be blinded to what is occuring around them. They will undergo a similar script than everyone one else with freezing of the skin around the knee (as for the ablation procedure) and at the groin and in this group a geniculate artery embolization will be performed via an intraarterial access and use of embolization microspheres injected into the hypervascular arteries feeding the knee joint. Dressings will be applied at the knee and groin area.
89589326|NCT04662840|Active Comparator|Geniculate nerve ablation|The patient will be placed on the procedural table as for the other arms. They will be blinded to what is occuring around them. They will undergo a similar script than everyone one else with freezing of the skin around the knee and at the groin (as for the embolization procedure) and in this group a geniculate nerve ablation will be performed by advancing a radiofrequency ablation (RFA) needle at three locations alongside the tibia and femur where the nerves course and ablation performed. Dressings will be applied at the knee and groin area.
89589327|NCT04633317|Experimental|Group A Regimen|Randomized 80 subjects diagnosed with pneumonia of carbapenem-resistant gram negative bacteria will received inhaled colistimethate sodium generated by a pneumatic nebulizer or a vibrating mesh nebulizer every 12 hours for 7-10 days
89589328|NCT04633317|No Intervention|Group B Regimen|Randomized 40 subjects diagnosed with pneumonia of carbapenem-resistant gram negative bacteria will received inhaled colistimethate sodium intravenous every 12 hours for 7-10 days
89589329|NCT04630951|Experimental|Strength training based on low loads with blood flow restriction (Experimental group I)|"Squat~Single Deadlift~Back Squat"
89589330|NCT04630951|Experimental|Strenght training based on high loads (Experimental group II)|"Squat~Single Deadlift~Back Squat"
89589331|NCT04580459|Experimental|CARE Parenting Group Treatment|Participants receive the CARE mentalizing-focused group parenting intervention.
88976528|NCT05568342|Experimental|Roy Group|"The population of the research consisted of 80 patients receiving outpatient dialysis treatment in the hemodialysis unit of a university hospital. In the sample of the study, those patients who came to the dialysis session on Monday-Wednesday-Friday were randomly assigned to the Roy group (experimental) (40 patients).~Pre-test was applied to the patients in Roy and clinical groups using data collection tools. After the pre-test, the patients in the Roy group were trained 6 times in 3 months, twice a month, at home and in the clinic. Nursing interventions were performed using the Roy Adaptation Model in the trainings. At the end of the third month, the post-test data of both groups were collected. During the study, no training or intervention was given to the patients in the clinical group. The nursing education and interventions of this group were carried out by nurses working in the dialysis clinic within the scope of routine practices."
89030654|NCT04513457||Liver resection, Neoadjuvant and Adjuvant chemotherapy|Liver resection, Neoadjuvant chemotherapy and Adjuvant chemotherapy
89589332|NCT04580459|Other|Treatment as Usual (TAU)|Participants continue to receive treatment as usual in the outpatient child mental health clinic.
89589333|NCT04546568|Experimental|Servo control - Leoni plus CLAC|"Automated control of oxygen. The oxygen saturation target range will be set to 90-95% as per standard practice.~Automated oxygen control can be overridden by manual adjustment of oxygen at any time if this is considered necessary to optimise control of oxygenation according to current clinical targets."
89030655|NCT04513457||Liver resection|Liver resection
89030656|NCT02276339|Experimental|Single arm ankle exercise intervention|Chronic Ankle Instability Group assessed pre and post a 6 week eccentric - concentric exercise intervention
88976529|NCT05568342|No Intervention|Clinic Group|"The population of the research consisted of 80 patients receiving outpatient dialysis treatment in the hemodialysis unit of a university hospital. In the sample of the study, those patients who came to the dialysis session on Tuesday-Thursday-Saturday were included in the Clinical group (control) (40 patients).~Pre-test was applied to the patients in Roy and clinical groups using data collection tools. After the pre-test, the patients in the Roy group were trained 6 times in 3 months, twice a month, at home and in the clinic. Nursing interventions were performed using the Roy Adaptation Model in the trainings. At the end of the third month, the post-test data of both groups were collected. During the study, no training or intervention was given to the patients in the clinical group. The nursing education and interventions of this group were carried out by nurses working in the dialysis clinic within the scope of routine practices."
88976530|NCT00158665|Experimental|Subjects receiving vaccine|2 0.5 ml doses of '04-05 Trivalent Influenza Vaccine 4 weeks apart.
88976531|NCT00158782|Experimental|Cohort 1|Subjects will receive GW786034 500 milligrams and lapatinib 750 milligrams.
88976532|NCT00158782|Experimental|Cohort 2|Subjects will receive GW786034 250 milligrams and lapatinib 750 milligrams.
88976533|NCT00158782|Experimental|Cohort 3|Subjects will receive GW786034 250 milligrams and lapatinib 1000 milligrams.
88976534|NCT00158782|Experimental|Cohort 4|Subjects will receive GW786034 500 milligrams and lapatinib 1000 milligrams.
88976535|NCT00158782|Experimental|Cohort 5|Subjects will receive GW786034 250 milligrams and lapatinib 1250 milligrams.
88976536|NCT00158782|Experimental|Cohort 6|Subjects will receive GW786034 400 milligrams and lapatinib 1250 milligrams.
88976537|NCT00158782|Experimental|Cohort 7|Subjects will receive GW786034 200 milligrams and lapatinib 1500 milligrams.
88976538|NCT00158782|Experimental|Cohort 8|Subjects will receive GW786034 400 milligrams and lapatinib 1500 milligrams.
88976539|NCT00158782|Experimental|Cohort 9|Subjects will receive GW786034 400 milligrams and lapatinib 1000 milligrams.
88976540|NCT00158782|Experimental|Cohort 10|Subjects will receive GW786034 800 milligrams and lapatinib 1500 milligrams.
88976541|NCT05568147|Experimental|Aspirin 100 mg daily|Once enrolled, patients will receive aspirin 100mg orally once per day
88976542|NCT05568147|Placebo Comparator|Placebo|Once enrolled, patients will receive placebo orally once per day
88976543|NCT04724473|Experimental|Tretinoin Cream 0.025%|The study medication will be self-applied topically on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
88976544|NCT04724473|Active Comparator|RETIN-A® (Tretinoin) Cream 0.025%|The study medication will be self-applied topically on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
88976545|NCT04724473|Placebo Comparator|Placebo Control|The study medication will be self-applied topically on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
88976546|NCT05567991|Experimental|Treatment group|The individuals assigned to the treatment group attend the training sessions and were asked to complete all the questionnaires at both time points
88976547|NCT05567991|No Intervention|Passive Control Group|The individuals assigned to the passive control group did not attend any training session and were only asked to complete the same questionnaires as the treatment group at both time points. Participants in the control group were asked not to practice meditation during the period of the study for an unbiased comparison with the intervention group.
88976548|NCT00051935|Experimental|1|
88976549|NCT02965053|Experimental|Period 1 Arm 1|EOS789 Dose 1 in treatment sequence 1, Placebo in treatment sequence 2
88976550|NCT02965053|Experimental|Period 1 Arm 2|Placebo in treatment sequence 1, EOS789 Dose 1 in treatment sequence 2
88976551|NCT02965053|Experimental|Period 2 Arm 1|EOS789 Dose 2 in treatment sequence 1, EOS789 Dose 2 + Sevelamer carbonate in treatment sequence 2
88976552|NCT02965053|Experimental|Period 2 Arm 2|EOS789 Dose 2 + Sevelamer carbonate in treatment sequence 1, EOS789 Dose 2 in treatment sequence 2
88976553|NCT00159133|Experimental|1|Early intervention with benzodiazepines in case of prodromal symptoms of an impending relapse
88976554|NCT00159133|Active Comparator|2|Early intervention with antipsychotics in case of prodromal symptoms of an impending relapse
88976555|NCT00159211|Active Comparator|1|UMULINE NPH at bed time
88976556|NCT00159211|Experimental|2|pioglitazone 30 mg
88976557|NCT00159289|Experimental|1|Inhalation of LPS
88976558|NCT00159289|Placebo Comparator|2|PLacebo
88976559|NCT00052013|Experimental|PTK787/ZK 222584|
88976560|NCT00159484|Experimental|A|EPO906, celecoxib
88976561|NCT00159523|Experimental|probiotic|
88976562|NCT00159523|Placebo Comparator|placebo|
88976563|NCT00159562|Experimental|group education|Bipolar 1 and 2 patients in a stable euthymic phase will receive group education in 10 weekly sessions and then a session every third month for two years. Symptoms, admittances to hospital and function will be followed for two years.
88976564|NCT00159562|Active Comparator|individual education|Bipolar 1 and 2 patients in a stable euthymic phase will receive three individual sessions of education.
88976565|NCT00159601||outpatients in Child and Adolescent Mental Health Service|
88976566|NCT00159601||youth from general population|
88976567|NCT00052091|Experimental|1 Problem Solving Therapy|12 weekly sessions of problem solving therapy (PST)
88976568|NCT00052091|Experimental|2 Brief Supportive Therapy|12 weekly sessions of brief supportive therapy (BST)
88976569|NCT04729764|Experimental|GP681 Tablet 20mg|Two sentinel subjects were first enrolled in the trial (test drug: placebo=1:1). After the two sentinel subjects completed the 72h safety follow-up after the administration, it was judged that if there was no dose-limiting toxicity , Then start the trial of the remaining 6 subjects in the dose group (experimental drug: placebo = 5:1).
88976570|NCT04729764|Experimental|GP681 Tablet 40mg|10 subjects in 40mg group (including 2 placebo)
88976571|NCT04729764|Experimental|GP681 Tablet 60mg|10 subjects in 60mg group (including 2 placebo)
88976572|NCT04729764|Experimental|GP681 Tablet 80mg|10 subjects in 80mg group (including 2 placebo)
88976573|NCT04729764|Experimental|GP681 Tablet 120mg|10 subjects in 120mg group (including 2 placebo)
88976574|NCT00159952|Active Comparator|1|
89589334|NCT04546568|Active Comparator|Servo control - IntellO2 Precision Flow, Vapotherm|"Automated control of oxygen. The oxygen saturation target range will be set to 90-95% (set to maintain an integral value of 93%) as per standard practice.~Automated oxygen control can be overridden by manual adjustment of oxygen at any time if this is considered necessary to optimise control of oxygenation according to current clinical targets."
89589335|NCT04544293|Experimental|Molgramostim|Double-blind treatment with molgramostim nebulizer solution 300 µg once daily for 48 weeks, followed by open-label treatment with molgramostim nebulizer solution 300 µg once daily for 96 weeks
89589336|NCT04544293|Placebo Comparator|Placebo|Double-blind treatment with placebo nebulizer solution once daily for 48 weeks, followed by open-label treatment with molgramostim nebulizer solution 300 µg once daily for 96 weeks
89589337|NCT04513548|Experimental|Ligelizumab|test drug
89589338|NCT04513548|Placebo Comparator|Placebo|placebo
89589339|NCT04495998|Other|Motor Neurological Soft Signs|motor test and an interview for the participants
89589340|NCT04485494||Professional Rugby Athletes|These are the cohort of players that consent to the study and have a preseason baseline blood sample taken. If the participant from this cohort then receives a concussion they are assessed by the World Rugby's Head Injury Assessment (HIA) and then enter into the return to play (RTP) protocol which means they cannot play a competitive game for 6 days.
89589341|NCT04484948|Experimental|Systemic sclerosis group|Systemic sclerosis diagnosis according to 2013 American College of Rheumatology(ACR)/European League Against Rheumatism(EULAR) classification criteria
89589342|NCT04469231|Experimental|Synergy Disc|The Synergy Disc is a cervical disc prosthesis that can be inserted between C3-C7 in skeletally mature patients after anterior discectomy to provide restoration of motion to the functional spinal unit. The Synergy Disc is designed to restoring kinematics to the cervical spine. The Synergy Disc is intended for use in the cervical spine for reconstruction of the disc following a single level discectomy for intractable radiculopathy and/or myelopathy.
89589343|NCT04448951||sepsis/septic shock|target population
89589344|NCT04448951||non-septic critically ill|demographically-matched control group
89589345|NCT04448951||healthy control|control group
89589346|NCT04448080|Experimental|Topical Anesthesia|topical tetracaine eye drops (3 times, given in 1 minute intervals) followed by topical Xylocaine 2% Gel (alcohol-free formulation), given in 1 minute intervals for a total of 5 minutes
89589347|NCT04448080|Active Comparator|Analgosedation|Remifentanil 1mg i.v., and, Thiopental i.v., adapted to patients' weight, age, and hepatic and renal function; usually, a bolus of 150-250mg
89589348|NCT04421040|Experimental|Biomonitor 3|Placement of Biotronic 3 Device for a 6 month period. After the 6 month monitoring period, the patient will have the Biotronic 3 device removed.
89589349|NCT04413201|Experimental|Afatinib|Afatinib followed by osimertinib or ICT depending on T790M status
89589350|NCT04413201|Active Comparator|Osimertinib|Osimertinib followed by ICT
89589351|NCT04411251|Experimental|Outdoor|Nature-centered therapy in a near-natural area
89589352|NCT04411251|Active Comparator|Indoor|Conventional therapy in rooms mainly in a hospital building
89589353|NCT04373460|Experimental|SARS-CoV-2 convalescent plasma|SARS-CoV-2 convalescent plasma (1 cup; minimum of 175 mL collected by apheresis from a volunteer who recovered from COVID-19 disease and has SARS-CoV-2 antibody titers ≥ 1:320 and after July 2021 meets FDA criteria for high titer plasma.
89589354|NCT04373460|Active Comparator|Standard Control plasma|Plasma collected from a volunteer donor prior to January 1, 2020 will not be tested for SARS-CoV-2 antibodies. Plasma collected after December 31, 2019 will be confirmed as SARS-CoV-2 seronegative.
89589355|NCT04298658||HIV and Insomnia|Participants will test positive for HIV and Insomnia.
88976575|NCT00159991|Experimental|A|Total arterial revascularization
89589356|NCT04298658||HIV Without Insomnia|Participants will test positive for HIV and test negative for Insomnia.
89589357|NCT04298658||Non HIV with Insomnia|Participants will test negative for HIV and test positive for Insomnia.
89589358|NCT04298658||Non HIV Without Insomnia|Participants will test negative for HIV and test negative for Insomnia.
89589359|NCT04213014|Experimental|Guys/Girls Opt for Activities for Life Intervention (GOAL)|Receives the 4 month (16-wk) GOAL intervention, which has 3 components: (1) After-school GOAL Club: 26 events (2 d/wk; 120 min/event/day; 13 wks due to no club during 3 school break wks) for boys and girls to engage in physical activity and healthy eating and cooking activities; (2) Three parent-adolescent meetings (1st meeting at each school with parents and adolescents [Zoom option if needed]; 2nd and 3rd meetings delivered virtually for parents): to empower parents to assist adolescents with physical activity and healthy eating and cooking; and (3) GOAL social networking website: private website for parents to share with each other how they helped their adolescent increase physical activity and diet quality during a prior wk.
88976576|NCT00159991|Active Comparator|B|Conventional revascularization
88976577|NCT00052208|Experimental|Treatment (gefitinib, radiation therapy)|Patients receive gefitinib PO QD for 7 weeks. Beginning 1 week after initiation of gefitinib, patients undergo radiation therapy QD 5 days a week for 6 weeks. Treatment with gefitinib continues for up to 18 months in the absence of disease progression or unacceptable toxicity.
88976578|NCT00397449|Experimental|1, 2, 3|
88976579|NCT00160030|Experimental|1|
88976580|NCT00160030|Active Comparator|2|
88976581|NCT00160069|Experimental|Arm 1|
88976582|NCT00160069|Experimental|Arm 2|
88976583|NCT00160069|Experimental|Arm 3|
88976584|NCT00052286|Experimental|drug dosage 1|- Arm I: Patients receive oral high-dose modafinil twice daily.
88976585|NCT00052286|Experimental|drug dosage 2|- Arm II: Patients receive oral low-dose modafinil twice daily.
88976586|NCT00160186|Experimental|1|
88976587|NCT00160186|Placebo Comparator|2|
89589360|NCT04213014|No Intervention|Control|Received usual school activities.
89608454|NCT04386850|Experimental|Treatment|Infected patients with acute respiratory tract infection symptoms (e.g. fever, cough, dyspnea) with no other etiology that fully explains the clinical presentation accompanied by chest computed tomography (CT) scan findings compatible with Covid-19 or with a COVID-19 positive test by the polymerase chain reaction (PCR)
89589361|NCT04210583|Experimental|Vulvovaginal Treatment|"At visit 1 -(6 months post treatment in the CS0716 study):~AE assessment, VLQ, FSFI, GRAS and GAIS (optional), Vaginal pH and vaginal smear (optional),~At Visit 2 (6 months post treatment in the CS0716 study):~AE assessment, VLQ, FSFI, GRAS and GAIS (optional), Vaginal pH and vaginal smear (optional), Administer study treatment (optional: internal, mons pubis and/or labia treatment).~Discomfort/pain 10 cm VAS, immediate response assessment (applicable only if treatment provided)~Final AE follow-up 30 days post Visit 2 Treatment (if applicable): AE assessment (applicable only if treatment provided at Visit 2 in the FE1019 study)."
89589362|NCT04200690|Experimental|Interdisciplinary management|Interdisciplinary combined clinical care
89589363|NCT04200690|Active Comparator|Usual-care management|Usual-care
89589364|NCT04193904|Experimental|MRx0518 with hypofractionated preoperative radiation|Subjects will take one capsule of MRx0518 twice daily from one week prior to radiation therapy until surgical resection (6 to 9 weeks approx.) Radiation therapy will be delivered as 30Gy/10 fractions over 2 weeks.
89589365|NCT04159805|Placebo Comparator|TAK-079 Placebo-matching|TAK-079 placebo-matching injection, subcutaneously (SC), once weekly in combination with standard background therapy for 8 weeks.
89589366|NCT04159805|Experimental|TAK-079 300 mg|TAK-079 300 mg injection, SC, once weekly in combination with standard background therapy for 8 weeks.
89589367|NCT04159805|Experimental|TAK-079 600 mg|TAK-079 600 mg injection, SC, once weekly in combination with standard background therapy for 8 weeks.
89589368|NCT04139902|Experimental|Dostarlimab (TSR-042) (singly)|"Pre-Operative Phase:~Dostarlimab (TSR-042) 500mg will be administered through an IV over 30 minutes, on Cycle 1 Day 1, and then again on Cycle 2 Day 1.~Post-Operative Phase:~Dostarlimab (TSR-042) 500mg will be administered through an IV over 30 minutes for 4 doses every 3 weeks (Cycles 3-4) and then 1000mg will be administered through an IV over 30 minutes every 6 weeks for 6 doses (Cycles 5-10) for approximately 48 weeks."
89589369|NCT04139902|Experimental|Dostarlimab (TSR-042) and TSR-022 (combination)|"Pre-Operative Phase:~Dostarlimab (TSR-042) 500mg and TSR-022 300mg will be administered through an IV over 30 minutes, on Cycle 1 Day 1 and then again on Cycle 2 Day 1.~Post-Operative Phase:~Dostarlimab (TSR-042) will be administered through an IV over 30 minutes for 4 doses every 3 weeks (Cycles 3-4), and then 1000mg will be administered through an IV over 30 minutes every 6 weeks for 6 doses (Cycles 5-10) for approximately 48 weeks. TSR-022 will not be administered."
89589370|NCT04136509|Experimental|allograft|The filler used in sinus floor elevation is albumin impregnated allograft.
89589371|NCT04136509|Experimental|xenograft|The filler used in sinus floor elevation is anorganic bovine bone mineral.
89589372|NCT04136366|Experimental|ADX-2191 (intravitreal methotrexate 0.8%)|ADX-2191 (intravitreal methotrexate 0.8%) administered over 16 weeks.
89589373|NCT04136366|Active Comparator|Standard surgical care procedure|Standard procedure performed.
89589374|NCT04103450|Experimental|Vibegron|Participants will receive 75 milligrams (mg) vibegron orally once daily (QD).
89589375|NCT04098835|Experimental|ASCEND|ASCEND combines computer-based cognitive training exercises, homework exercises to enhance cognition, and coaching sessions delivered in-person and via telephone/videoconference by a neuropsychologist. ASCEND includes 24 total computer training sessions of 30 minutes each, for a total of 12 hours. ASCEND includes 8 coaching sessions of 45 minutes each. The computer exercises aim to improve attention, working memory (WM), and cognitive control through a series of engaging and interactive computer games (e.g., card games, driving simulation). The homework exercises and coaching sessions aim to assist the participant in generalizing and transferring skills from the computer exercises to daily life and to develop further strategies to compensate for attention and WM difficulties in daily life.
89589376|NCT04086511||Children with PKU|
89589377|NCT04086511||Age- and sex-matched non-PKU comparison subjects|
89589378|NCT04049591|Active Comparator|Higher Dose Unfractionated Heparin Treatment Period|A centre wide policy of administering 100 U/kg bolus of intravenous unfractionated heparin (UFH) for elective percutaneous coronary intervention (PCI) procedures will be implemented during the Higher Dose UFH treatment period.
89589379|NCT04049591|Active Comparator|Lower Dose Unfractionated Heparin Treatment Period|A centre wide policy of administering 70 U/kg bolus of intravenous UFH for elective PCI procedures will be implemented during the Lower Dose UFH treatment period.
89589380|NCT04024293|Experimental|All participants|All patients will be follow the same procedures and be placed the investigational device
89589381|NCT03993171|Experimental|7.5mg CNM-Au8|7.5mg suspension of clean-surfaced, faceted, gold nanocrystals in 120ml of sodium bicarbonate buffered water
89589382|NCT03993171|Experimental|15mg CNM-Au8|15mg suspension of clean-surfaced, faceted, gold nanocrystals in 120ml of sodium bicarbonate buffered water
89209883|NCT04397406|Experimental|Group D (Dexmedetomidine group)|Epidural analgesia with levobupivacaine and dexmedetomidine
89589383|NCT03993171|Experimental|30mg CNM-Au8|30mg suspension of clean-surfaced, faceted, gold nanocrystals in 120ml of sodium bicarbonate buffered water
89589384|NCT03993171|Experimental|60mg CNM-Au8|60mg suspension of clean-surfaced, faceted, gold nanocrystals in 120ml of sodium bicarbonate buffered water
89589385|NCT03910907||Standard of care|Men treated for mycoplasma according to standard of care
89589386|NCT03910907||Standard of care plus|Men treated for mycoplasma according to standard of care with regimen selected based on laboratory detection of resistance markers
89589387|NCT03909139||BMAC Application|"Patients age 18 or older with evidence consistent with a tear of the acetabular labrum and breakdown of the chondrolabral junction and consent to arthroscopic labral tear repair.~BMAC application at the time of arthroscopic labral repair."
89209884|NCT04397406|Experimental|Group F (Fentanyl group)|Epidural analgesia with levobupivacaine and fentanyl
89209885|NCT02542332|Active Comparator|With Data|Participants received statistical data about lung cancer screening
89209886|NCT02542332|No Intervention|Without Data|Participants had no statistical data on lung cancer screening
89209887|NCT00891540|Active Comparator|1|Local infiltration with Ropivacaine
89209888|NCT00891540|Active Comparator|2|Local infiltration with Ropivacaine
89209889|NCT00891540|Placebo Comparator|3|Local infiltration with NaCl
89589388|NCT03909139||No BMAC Application|"Patients age 18 or older with evidence consistent with a tear of the acetabular labrum and breakdown of the chondrolabral junction and consent to arthroscopic labral tear repair.~No BMAC application at the time of arthroscopic labral repair."
89589389|NCT03901456|Experimental|Phase II [Randomized]: Treatment|Participants randomized to this treatment arm will receive the Care to Plan (CtP) intervention as a part of Phase II.
89589390|NCT03901456|Active Comparator|Phase II [Randomized]: Control|"Participants randomized to a usual care control group as a part of Phase II.~Note: If eligible, participants in this control group will be asked if they are interested in enrolling in a similar, additional feature of the study to test the Care to Plan tool following the initial 6-month study."
89589391|NCT03901456|Experimental|Phase I [Non-randomized]: Treatment|Participants enrolled in Phase I of the project to receive the intervention [non-randomized; no comparison group].
89589392|NCT03866148|Active Comparator|ILR|Participants who will receive the Implantable Loop Recorder (Reveal-LINQ) inserted just after baseline. This is single intervention and lasts for 3 years after which the patient has the option to have it removed.
89589393|NCT03866148|No Intervention|No ILR|Participants who will not get the Implantable Loop Recorder (Reveal-LINQ).
89589394|NCT03858101||PKU subjects|
89589395|NCT03858101||Age and sex-matched non-PKU comparison subjects|
89589396|NCT03811847|Experimental|Sequence 1:MPH, PBO, MPH, PBO, PBO, MPH|"Over the 16-week study, each participant moved through four, 4-week treatment periods: a Placebo (PBO) lead-in, acclimation period followed by three, crossover Methylphenidate (MPH) vs PBO blocks. Each block consisted of treatment with MPH for two-weeks and treatment with PBO for two-weeks; each block order will be randomly assigned. In this group, participants first received Methylphenidate (MPH) for 2 weeks, then placebo for 2 weeks, then MPH for 2 weeks, then Placebo for 2 weeks, then Placebo for 2 weeks, then MPH for 2 weeks."
89589397|NCT03811847|Experimental|Sequence 2:MPH, PBO, PBO, MPH, MPH, PBO|"Over the 16-week study, each participant moved through four, 4-week treatment periods: a Placebo (PBO) lead-in, acclimation period followed by three, crossover Methylphenidate (MPH) vs PBO blocks. Each block consisted of treatment with MPH for two-weeks and treatment with PBO for two-weeks; each block order will be randomly assigned. In this group, participants first received Methylphenidate (MPH) for 2 weeks, then placebo for 2 weeks, then PBO for 2 weeks, then MPH for 2 weeks, then MPH for 2 weeks, then PBO for 2 weeks."
89589398|NCT03811847|Experimental|Sequence 3:MPH, PBO, PBO, MPH, PBO, MPH|"Over the 16-week study, each participant moved through four, 4-week treatment periods: a Placebo (PBO) lead-in, acclimation period followed by three, crossover Methylphenidate (MPH) vs PBO blocks. Each block consisted of treatment with MPH for two-weeks and treatment with PBO for two-weeks; each block order will be randomly assigned. In this group, participants first received Methylphenidate (MPH) for 2 weeks, then placebo for 2 weeks, then MPH for 2 weeks, then Placebo for 2 weeks, then Placebo for 2 weeks, then MPH for 2 weeks."
89589399|NCT03811847|Experimental|Sequence 4:PBO, MPH, MPH, PBO, MPH, PBO|"Over the 16-week study, each participant moved through four, 4-week treatment periods: a Placebo (PBO) lead-in, acclimation period followed by three, crossover Methylphenidate (MPH) vs PBO blocks. Each block consisted of treatment with MPH for two-weeks and treatment with PBO for two-weeks; each block order will be randomly assigned. In this group, participants first received PBO for 2 weeks, then MPH for 2 weeks, then MPH for 2 weeks, then Placebo for 2 weeks, then MPH for 2 weeks, then PBO for 2 weeks."
89589400|NCT03811847|Experimental|Sequence 5: PBO, MPH, MPH, PBO, PBO, MPH|"Over the 16-week study, each participant moved through four, 4-week treatment periods: a Placebo (PBO) lead-in, acclimation period followed by three, crossover Methylphenidate (MPH) vs PBO blocks. Each block consisted of treatment with MPH for two-weeks and treatment with PBO for two-weeks; each block order will be randomly assigned. In this group, participants first received PBO for 2 weeks, then MPH for 2 weeks, then MPH for 2 weeks, then Placebo for 2 weeks, then Placebo for 2 weeks, then MPH for 2 weeks."
89589401|NCT03811847|Experimental|Sequence 6: PBO, MPH, PBO, MPH, MPH, PBO|"Over the 16-week study, each participant moved through four, 4-week treatment periods: a Placebo (PBO) lead-in, acclimation period followed by three, crossover Methylphenidate (MPH) vs PBO blocks. Each block consisted of treatment with MPH for two-weeks and treatment with PBO for two-weeks; each block order will be randomly assigned. In this group, participants first received PBO for 2 weeks, then MPH for 2 weeks, then PBO for 2 weeks, then MPH for 2 weeks, then MPH for 2 weeks, then PBO for 2 weeks."
89589402|NCT03795454|Experimental|Singing Kangaroo|The parent is singing during the skin-to -skin sessions Musical therapeutist gives the instructions
89589403|NCT03795454|No Intervention|Silent Kangaroo|The parent is silent during the skin-to -skin sessions Musical therapeutist gives the instructions
89589404|NCT03743844|Experimental|Compassion-focused psychoeducation group|Receiving 2-hours of group-based in-person psychoeducational sessions weekly for 6-weeks.
89589405|NCT03743844|No Intervention|Control group|Weight management treatment as usual
89589406|NCT03732794|Experimental|AtriCure CryoICE & AtriClip LAA Exclusion|AtriCure CryoICE system performing the Cox-Maze III lesion set, in conjunction with LAA exclusion using the AtriClip device.
89589407|NCT03725410|Active Comparator|Venus Fiore Study Treatment|Study treatment consists of delivering radiofrequency (RF) and pulsed electromagnetic fields (PEMF) internally to the vagina (50 - 70% for up to 15 minutes), externally to the labia (10 - 35% for up to 10 minutes) and externally to the mons pubis (10 - 35% for up to 15 minutes).
88976588|NCT05567484|Active Comparator|group A pulse thearpy of itraconazole|Patients in pulse therapy group received oral itraconazole 100 mg, two capsules twice daily for seven days a month
88976589|NCT05567484|Active Comparator|Group B continous thearpy of itraconazole|Patients in continuous therapy group, received continuous oral 100 mg of itraconazole once daily for 12 weeks continuously.
88976590|NCT00160342|Active Comparator|1|
88976591|NCT00160342|Experimental|2|
88976592|NCT00160342|Experimental|3|
88976593|NCT00160342|Active Comparator|4|
88976594|NCT00160342|Experimental|5|
88976595|NCT00160342|Experimental|6|
88976596|NCT00160342|Active Comparator|7|
88976597|NCT00160342|Active Comparator|8|
88976598|NCT00160342|Placebo Comparator|9|
88976599|NCT00052364|Experimental|Treatment (oxaliplatin)|Patients receive oxaliplatin IV over 2 hours on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88976600|NCT00160381|Experimental|1|
88976601|NCT00160381|Experimental|2|
89589408|NCT03725410|Placebo Comparator|Venus Fiore Sham Treatment|Sham treatment consists of delivering radiofrequency (RF) and pulsed electromagnetic fields (PEMF) internally to the vagina (1% for up to 15 minutes), externally to the labia (1% for up to 10 minutes) and externally to the mons pubis (1% for up to 15 minutes).
89589409|NCT03709472|Experimental|Computer Assisted CIFFTA|CA CIFFTA (Computer Assisted Culturally Informed and Flexible Family Based Treatment for Adolescents) consists of a hybrid intervention utilizing office-based CIFFTA and technology-delivered material. Over 16 weeks CIFFTA participants receive 45 minutes of face-to-face sessions plus approximately 45 minutes of web-based intervention per week. During the continuing care phase participants access website resources and receive targeted messages (e.g., handling family conflicts). CA CIFFTA will: 1) deliver psycho-educational modules (e.g., depression, emotion regulation), 2) collect diary-card information, and 3) provide additional resources. During videos parents and adolescents can report symptoms and information that is automatically transmitted to therapists and used in the next session
89589410|NCT03709472|Active Comparator|Behavioral: Traditional face-to-face treatment-no technology|Participants randomized to Treatment-As-Usual (TAU) work over a 16-week period with their community agency. They may receive individual or family treatment. The team coordinates with the TAU agencies to minimize the overlap of data collected. The team will refer out to service locations that are most convenient for the participant. A great deal of thought has gone into the selection of the Treatment as Usual condition. The investigators wanted to compare CA CIFFTA's ability to retain and bring about change in participants with what is typically done in the community. Although running an in-house comparison condition gives more control of the delivery of services and tracking of clients, it is difficult to know how that compared to the services that are typically provided in the community
89589411|NCT03675477|Experimental|SHR0302 8mg QD|"Participants randomized in this arm will receive SHR0302 8mg QD for the treatment phase. All participants that had completed the 8-week treatment phase (non-responders or responders) had the option to enter a blinded 8-week extension phase to continue to receive SHR0302 8mg QD.~Those who had completed the first 8-week of the treatment phase, but decided not to enter into the extension phase were also required to attend the 2-week follow-up visit. Participants who immaturely withdrew during the first treatment phase could not enter the extension phase.~SHR0302: The study drug, SHR0302, is designed to block the activity of an enzyme protein called JAK (known as a JAK inhibitor)."
89589412|NCT03675477|Experimental|SHR0302 4mg BD|"Participants randomized in this arm will receive SHR0302 4mg BD for the treatment phase. All participants that had completed the 8-week treatment phase (non-responders or responders) had the option to enter a blinded 8-week extension phase to continue to receive SHR0302 4mg BD.~Those who had completed the first 8-week of the treatment phase, but decided not to enter into the extension phase were also required to attend the 2-week follow-up visit. Participants who immaturely withdrew during the first treatment phase could not enter the extension phase.~SHR0302: The study drug, SHR0302, is designed to block the activity of an enzyme protein called JAK (known as a JAK inhibitor)."
89589413|NCT03675477|Experimental|SHR0302 4mg QD|"Participants randomized in this arm will receive SHR0302 4mg QD for the treatment phase. All participants that had completed the 8-week treatment phase (non-responders or responders) had the option to enter a blinded 8-week extension phase to continue to receive SHR0302 4mg QD.~Those who had completed the first 8-week of the treatment phase, but decided not to enter into the extension phase were also required to attend the 2-week follow-up visit. Participants who immaturely withdrew during the first treatment phase could not enter the extension phase.~SHR0302: The study drug, SHR0302, is designed to block the activity of an enzyme protein called JAK (known as a JAK inhibitor)."
89589414|NCT03675477|Placebo Comparator|placebo|"Participants randomized in this arm will receive the placebo until week 8, and then will be re-randomized into one of the 3 active arms ( 4mg QD, 4mg BD, 8mg QD of SHR0302) in a 1:1:1 allocation ratio until the end of the study at week 16.~Those who had completed the first 8-week of the treatment phase, but decided not to enter into the extension phase were also required to attend the 2-week follow-up visit. Participants who immaturely withdrew during the first treatment phase could not enter the extension phase.~SHR0302: The study drug, SHR0302, is designed to block the activity of an enzyme protein called JAK (known as a JAK inhibitor).~Placebos: Placebo Oral Tablet"
89589415|NCT03674736|Experimental|Methionine bioavailability in Rice|Participants will be seen initially for pre-study assessment (3 hour). They will then be studied for up to 7 times. You could be expected to participate in up to 7 different sets of experiments which will take 8 weeks to 6 months. Each set of experiment consists of a 3 day period. During the first 2 days (Adaptation Days) you will be expected to consume 4 meals per day consisting of a protein liquid drink and protein freecookies and/or Rice which will be provided by the investigators
89608455|NCT04386850|Experimental|Prevention|This arm of study includes the health care providers and hospital workers with a negative test for COVID-19 and a close patient relative with a negative test for COVID-19 who lives with the infected patients.
89608456|NCT01278472|Experimental|Single Port Cholecystectomy|Laparoscopic Cholecystectomy with single port transumbilical access
88976602|NCT00160381|Placebo Comparator|3|
88976603|NCT00160420|Experimental|1|
88976604|NCT00160459|Experimental|1|
89030657|NCT00520962||1,2,3|"First degree relatives of patients with type 2 diabetes~Patients with cardiovascular disease and stroke~patients with heart valve disease"
89030658|NCT00520962||4|Healthy controls
89030659|NCT04513730|Experimental|pelvic suspension device|A device will be built with the function of keeping the user in position of pelvic suspension promoting lumbar traction that will consist of a structure of pvc pipes and connections and padded material.
89030660|NCT00521118|Experimental|Treatment (second curettage)|Patients undergo a second curettage rather than standard treatment (immediate chemotherapy) within 14 days of registration.
89209890|NCT00887718|Experimental|PET scan for lymphoma assessment|
88976605|NCT00160459|Experimental|2|
88976606|NCT00160459|Experimental|3|
88976607|NCT00160459|Placebo Comparator|4|
88976608|NCT00052481||Quality of life questionnaire|"Patients are randomized to 1 of 2 arms on ACOSOG-Z0070 (radical prostatectomy vs brachytherapy).~Patients in both arms complete a quality of life questionnaire at baseline, 2 and 6 months after treatment, and then at 1, 2, 4, 7, and 10 years after treatment as part of ACOSOG-Z0071."
89209891|NCT00573144|Placebo Comparator|Placebo|Infusion of 72 hours of saline solution (packaged to match active comparator).
89589416|NCT03674736|Experimental|Lysine bioavailability in Chickpeas|Participants will be seen initially for pre-study assessment (3 hour). They will then be studied for up to 7 times. You could be expected to participate in up to 7 different sets of experiments which will take 8 weeks to 6 months. Each set of experiment consists of a 3 day period. During the first 2 days (Adaptation Days) you will be expected to consume 4 meals per day consisting of a protein liquid drink and protein freecookies and/or Chickpeas which will be provided by the investigators
89589417|NCT03674736|Experimental|Methionine bioavailability in Wheat|Participants will be seen initially for pre-study assessment (3 hour). They will then be studied for up to 7 times. You could be expected to participate in up to 7 different sets of experiments which will take 8 weeks to 6 months. Each set of experiment consists of a 3 day period. During the first 2 days (Adaptation Days) you will be expected to consume 4 meals per day consisting of a protein liquid drink and protein freecookies and/or Wheat bread which will be provided by the investigators
89589418|NCT03674736|Experimental|Lysine bioavailability in Lentils|Participants will be seen initially for pre-study assessment (3 hour). They will then be studied for up to 7 times. You could be expected to participate in up to 7 different sets of experiments which will take 8 weeks to 6 months. Each set of experiment consists of a 3 day period. During the first 2 days (Adaptation Days) you will be expected to consume 4 meals per day consisting of a protein liquid drink and protein freecookies and/or Lentils which will be provided by the investigators
89589419|NCT03647358|Experimental|Lesion Dosimetry With Iodine-124|Patients will be administered 124I and undergo serial PET imaging consisting of up to 4 individual PET/CT scans. In order to perform a dual exponential fit, 4 scans are needed to obtain the necessary amount of data points required. Lesion dosimetry shall be performed based on the 124I PET scan data through tumor uptake and clearance pharmacokinetics. 10 patients, who sign consent for the sub-study, will be administered an additional tracer diagnostic activity of 124I (4 to 7 mCi). These patients will then undergo additional (up to a maximum of 4) PET scanning during radioiodine therapy at time points matched, if possible, to the days of the pre-therapy 124I dosimetry study.
89589420|NCT03596606|Experimental|Myofunctional Motor Control Exercises|"Both groups will be treated with Manual treatment and in one of them the myofunctional motor control treatment will be added as intervention. The experimental group will be the one that will receive the combined treatment.~The patient will receive five sessions, one session every week."
89589421|NCT03596606|Active Comparator|Manual Treatment|The control group will receive only Manual treatment (TO). The patient will receive five sessions, one session every week.
89589422|NCT03581123|Experimental|Supported-Self management (SSM)|Supported-Self management
89589423|NCT03581123|Experimental|Spinal Manipulation Therapy (SMT)|Spinal Manipulation Therapy
89589424|NCT03581123|Experimental|SMT + SSM|Spinal Manipulation Therapy + Supported Self-Management
89589425|NCT03581123|Active Comparator|Standard Medical Care (SMC)|Standard Medical Care
89589426|NCT03568097|Experimental|Avelumab + Standard 1st line Chemotherapy|Administration of cisplatin or carboplatin + etoposide every 3 weeks with phased avelumab administered every 2 weeks until disease progression.
89589427|NCT03546582|Experimental|Arm I|Patients receive Stereotactic Body Radiation Therapy (SBRT) over 2 weeks and then receive pembrolizumab every 3 weeks for up to 2 years.
89589428|NCT03546582|Other|Arm II|Patients receive Stereotactic Body Radiation Therapy (SBRT) over 2 weeks. Arm II patients who experience progressive disease within 2 years after the start of SBRT will be allowed to cross over to receive pembrolizumab for up to 2 years.
89589429|NCT03536585|Experimental|Vulvovaginal treatment|Internal vaginal treatment monthly for 3 treatments; External mons pubis treatment monthly for 3 treatments; External labia treatment monthly for 3 treatments.
89589430|NCT03536585|No Intervention|Baseline|Subject's baseline photograph to act as their own control for the one-month and four-month post-treatment photograph of the mons pubis and labia.
89589431|NCT03511352|No Intervention|Control Condition (Protocol A)|Following a one-hour sitting run-in period, participants will sit for a 5-hour period including a mid-point bathroom break.
89589432|NCT03511352|Experimental|Frequent Sit-to-Stands (Protocol B)|Following a 1-hour sitting run-in period, participants will sit for a 5-hour period including a 2-min stand every 15 min throughout the 5-hr protocol period and a mid-point bathroom break.
89589433|NCT03511352|Experimental|Stand More (Protocol C)|Following a 1-hour sitting run-in period, participants will sit for a 5-hour period including 5 8-minute standing breaks, 1 per hour, and a mid-point bathroom break.
89589434|NCT03382860||Ventriculoperitoneal dysfunction|Patients with suspected ventriculo-peritoneal (VP) shunt dysfunction are admitted to the neurosurgical department for intracranial pressure monitoring for 24 hours. The patients are approached within this time frame.
89589435|NCT03382860||Normal Pressure Hydrocephalus (NPH)|Patients with suspected NPH (triad of cognitive dysfunction, urine incontinence of urge type, abnormal gait) are admitted to the neurosurgical department for intracranial pressure monitoring for 24 hours. The following day an infusiontest is performed, where data is collected.
89589436|NCT03354377|Experimental|Vegan Diet|"Participants in this group will follow a plant-based vegan diet. The vegan group diet will be based on investigators' pilot work, which instructs participants to favor a diet built around whole grains, fruits, vegetables, and legumes. This group will be supplemented by the Oldways African Heritage and Health program, which includes a food pyramid guide. A Taste of African Heritage (ATAH) six-lesson nutrition and cooking program and an online course for health professionals and cooking instructors (all research and restaurant team members will complete this course.~Interventions include intervention meetings, physical activity, and podcasts/mailings."
89608457|NCT01278472|Active Comparator|4 Port Cholecystectomy|Laparoscopic Cholecystectomy using 4 separate conventional trocars
89030661|NCT04694235|No Intervention|Observational cohort (control group)|In the observational cohort, pregnant mothers in the 2nd trimester (n=500) will be recruited and they will be followed up until their children are 24 months old. The control group women will receive standard intervention in the form of Ante Natal Care from village midwives (Polindes) or Puskesmas (IFA tablet, calcium tablet, nutrition counselling).
89030662|NCT04694235|Experimental|Intervention group|The intervention group women (n=153) will be provided one egg three times per week from recruitment (2nd trimester) until term along with the standard Ante Natal Care.
89589437|NCT03354377|Experimental|Omnivorous (Omni) Diet|"Participants in this group will follow a low-fat omni diet. The diet intervention for the omni group will be supplemented by the Oldways African Heritage and Health program, which includes a food pyramid guide, A Taste of African Heritage (ATAH) six-lesson nutrition and cooking program and an online course for health professionals and cooking instructors (all research and restaurant team members will complete this course).~Interventions include intervention meetings, physical activity, and podcasts/mailings."
89589438|NCT03338374|Experimental|Biventricular Pacemaker|All subjects to be in a single study group experiencing all interventions.
89589439|NCT03251495|Experimental|Vaxchora Vaccination|Healthy subjects will receive a single dose of oral live cholera vaccine.
89589440|NCT03239132|Experimental|Breath-based meditation|The experimental group will receive 4 group sessions of breath-based meditation over 4 weeks, as well as meditation educational materials.
89589441|NCT03239132|Active Comparator|Control|The control will receive meditation educational materials.
89589442|NCT03234478||GBA mutation carriers without DBS|Parkinson's disease patients who have moderate to advanced disease but have not undergone deep brain stimulation. Subjects will be tested for GBA mutation status as part of this study.
89589443|NCT03234478||non-mutation carriers without DBS|Parkinson's disease patients who have moderate to advanced disease but have not undergone deep brain stimulation. Subjects will be tested for GBA mutation status as part of this study.
89589444|NCT03234478||GBA mutation carriers with DBS|Parkinson's disease patients who have moderate to advanced disease and have undergone deep brain stimulation. Subjects will be tested for GBA mutation status as part of this study.
89589445|NCT03234478||non-mutation carriers with DBS|Parkinson's disease patients who have moderate to advanced disease and have undergone deep brain stimulation. Subjects will be tested for GBA mutation status as part of this study.
89589446|NCT03226249|Experimental|Treatment (FDG-PET/CT, pembrolizumab, chemotherapy)|See Detailed Description
89589447|NCT03184155|Experimental|Intracoronary Nicardipine|200 mcg intracoronary injection of nicardipine prior to PCI, with potential for additional 100 mcg nicardipine before stent placement, balloon post-dilation, and before post-PCI IMR measurement.
89589448|NCT03184155|Placebo Comparator|Sterile Saline|Injection of sterile saline prior to PCI, with potential for additional saline injections before stent placement, balloon post-dilation, and before post-PCI IMR measurement.
89589449|NCT03172624|Experimental|R/M adenoid cystic carcinoma (ACC)|Enrolled patients will be treated with nivolumab 3 mg/kg every 2 weeks plus ipilimumab 1 mg/kg every 6 weeks (1 cycle= 6 weeks).
89589450|NCT03172624|Experimental|R/M SGC of any histology, except ACC (Non ACC)|Enrolled patients will be treated with nivolumab 3 mg/kg every 2 weeks plus ipilimumab 1 mg/kg every 6 weeks (1 cycle= 6 weeks).
89589451|NCT03100331|Experimental|Single Arm; all receive neuropsychological testing & follow-up|
89589452|NCT03063944|Experimental|Treatment (STAT inhibitor OPB-111077, venetoclax, decitabine)|"INDUCTION CYCLE 1: Patients receive STAT inhibitor OPB-111077 PO QD on days 1-28, and venetoclax PO QD on days 4-28 of cycle 1. Patients also receive decitabine IV over approximately 1 hour on days 4-8 of cycle 1. Patients who achieve complete remission (CR) after 1 cycle move on to Maintenance, and patients who do not achieve a CR move on to Cycle 2.~INDUCTION CYCLE 2: Patients receive STAT inhibitor OPB-111077, venetoclax, and decitabine as in Induction Cycle 1. Patients who achieve CR, CRi, PR, or stable disease (or clinically significant hematologic improvement as determined by the investigator) move on to Maintenance.~MAINTENANCE: Patients receive STAT inhibitor OPB-111077, venetoclax, and decitabine as in Induction Cycle 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
89589453|NCT03013309|Experimental|Intervention|Receives the Family Check-Up 4 Health
89589454|NCT03013309|Experimental|Control|Receives Treatment as Usual
89589455|NCT02971046|Experimental|Protein intake|Varying protein intakes.
89589456|NCT02901860||Traditional workers|"Individuals who work 'traditional work hours, i.e., 9a-5p."
89589457|NCT02901860||Non-traditional workers|Individuals who have work hours outside the usual daytime period
89589458|NCT02849548|Experimental|suvorexant|10 to 20 mg to be administered after an evening written trauma narrative exposure session.
89589459|NCT02849548|Placebo Comparator|Placebo pill|A pill without active ingredients
89030663|NCT04513340|Experimental|Treatment A|Treatment A will be given under fed conditions by intra-oral single dose administration
89030664|NCT04513340|Experimental|Treatment B|Treatment B will be given intra-orally and orally under fed conditions by single dose administration
89030665|NCT04513340|Experimental|Treatment C|Treatment C will be given orally under fed conditions by single dose administration
89030666|NCT04513340|Experimental|Treatment D|Treatment D will be given orally under fasting conditions by single dose administration
89030667|NCT04513379|Experimental|Trial|EFV 400mg
89589460|NCT02814253||Community Based Group|Patients who regularly present with exacerbations of COPD and have chronically-elevated CO2 levels. These patients are supported intensively in an out-patient setting (case-managed) and are potentially eligible for the community-based group.
89589461|NCT02814253||Acute Admissions Group|Patients who are admitted to hospital with an acute exacerbation of COPD. These patients are potentially eligible for the acute admission group.
89589462|NCT02791685|Experimental|Cardiac Rehabilitation - Movn Program|Participants with coronary artery disease (CAD) and chronic obstructive pulmonary disease (COPD) who are eligible for cardiac rehabilitation will undergo an in-home program.
89589463|NCT02791685|Experimental|Pulmonary Rehabilitation - Movn Program|Participants with stable chronic obstructive pulmonary disease (COPD) or hospitalized with an acute exacerbation of COPD will undergo an in-home pulmonary rehabilitation program.
89589464|NCT02791685|Active Comparator|Traditional Cardiac Rehabilitation|Participants enrolled in a facility's traditional cardiac rehabilitation program will be seen at baseline and during a 12 and 24 week follow-up visit.
89589465|NCT02780310|Experimental|Lenvatinib|All eligible patients will receive a starting lenvatinib dose of 24 mg daily taken orally for each 4-week cycle. Patients may remain on study until progression of disease or unacceptable toxicity. Alternatively, Lenvatinib may be dissolved in fluid per the Food and Drug Administration (FDA) label and administered orally or via a feeding tube.
89030668|NCT04513379|Active Comparator|Control|EFV 600mg
89030669|NCT05142839|Experimental|EUS-CD|EUS-guided choledochoduodenostomy
89030670|NCT05142839|Experimental|EUS-GEA|EUS-guided gastroenterostomy
89030671|NCT00521157|Experimental|intervention|Experimental group randomised after abstinence oriented treatment
89030672|NCT00521157|No Intervention|2|waiting list control
89030673|NCT04694352|Experimental|Jumping Exercises|Jumping in place Jump and clap Jump and reach Jump and twist Jump and turn Half jumping jack Jumping side to side
89030674|NCT04694352|Active Comparator|Conventional|"Drop and catch a ball Squeeze ball between legs, jump up and catch the ball Walking on a straight line Stand on one leg try to pick object from floor without using hands (do this on both legs) Drop the ball and catch it with both hands Jump up stair with both limbs off the floor simultaneously while holding railing.~Skipping."
89030675|NCT02948595|Experimental|Video feedback then verbal feedback|Video feedback followed by structured verbal feedback
89030676|NCT02948595|Experimental|Verbal feedback then video feedback|Structured verbal feedback followed by video feedback
89030677|NCT04513262||Video-assisted surgery|Patients undergoing video-assisted major abdominal surgery (VAS) in Trendelenburg position. The decision regarding the type of VAS was made by the attending surgeon prior to study inclusion. Twenty-five consecutive patients undergoing classic laparoscopic surgery and twenty-five patients undergoing robotic-assisted surgery will be included in the study.
89589466|NCT02772367||Breast Cancer Patients|In study participants undergoing breast reconstruction surgery prior to breast radiation therapy, we will obtain skin tissue at the time of reconstruction surgery from the surgical specimen.
89589467|NCT02763072|Experimental|Enlighten Laser|12 subjects will receive treatment the Enlighten laser.
89589468|NCT02763072|Active Comparator|Excel V Laser|12 subjects will receive treatment with the Excel V laser.
89589469|NCT02758431|Placebo Comparator|Group 1: Acyline plus placebo (No Testosterone Add-Back)|Acyline plus placebo gel and placebo tablet.
89589470|NCT02758431|Active Comparator|Group 2: Acyline plusTestosterone|Acyline plus transdermal testosterone gel plus placebo tablet.
89589471|NCT02758431|Active Comparator|Group 3: Acyline plus Testosterone plus Arimidex)|Acyline plus transdermal testosterone gel plus Aromatase inhibitor (Arimidex) oral.
89589472|NCT02756000|Experimental|complete PCI at initial hospitalization|Staged, complete revascularization of all non-culprit significant lesions in a single PCI session during initial hospitalization for ST elevation myocardial infarction
89589473|NCT02756000|Experimental|complete PCI after 30 days|Staged, complete revascularization of all non-culprit significant lesions in a single PCI session after 30 days from initial hospitalization for ST elevation myocardial infarction
89589474|NCT02756000|Active Comparator|Dobutamine stress testing|Revascularization by PCI or deferral of revascularization of non-culprit coronary artery lesions based on ischemia testing using Dobutamin stress echocardiography
89589475|NCT02601365|Experimental|Aerosolized Sargramostim|A self-controlled, open-label study to evaluate safety of Sargramostim administered by nebulization
89589476|NCT02583893|Experimental|Sirolimus, MEC chemotherapy|Patients undergo collection of bone marrow samples prior to sirolimus dosing on day 4 and within 1 week and no later than day 45 of hematologic recovery. Patients receive sirolimus PO on days 2-9 (loading dose on day 1 only), and standard MEC chemotherapy comprising mitoxantrone hydrochloride IV over 15 minutes, etoposide IV over 1 hour, and cytarabine IV over 1 hour every 24 hours on day 4-8.
89589477|NCT02538315||Surgery plus PET/CT imaging|Dopaminergic stem cell transplant and [18F]FDOPA PET/CT
89589478|NCT02350465|Experimental|Eccentric Exercise|Supervised strengthening exercise using eccentric muscle actions.
89030678|NCT00521391|Experimental|A|a tailored physical activity intervention involving moderate-intensity exercise
89030679|NCT00521391|No Intervention|B|
89030680|NCT00521196|No Intervention|Baseline- 1 month|Subjects will be asked to maintain a migraine diary in which they will record the onset of each migraine, migraine-associated symptoms, migraine-associated pain, daily average pain, and daily average anxiety.
89030681|NCT00521196|Experimental|tDCS- 1 month|"There will be 10- twenty minute sessions of the tDCS intervention over a four week period. During each tDCS session, two electrodes are placed over selected areas of the brain. 2 mA of direct current will flow through the electrodes, penetrate the scalp, and create a flow of electrical current in the brain. The subject may feel a slight itching on the scalp. The procedure will last 20 minutes. For sham tDCS, an alternate method of stimulation will be used.~During this phase, participants will continue to maintain their migraine diary. In addition, the pain threshold of patients will be measured at the first, fifth, and tenth sessions via Thermal Sensory Analysis and Von Frey Hair tests."
89030682|NCT00521196|No Intervention|Follow Up- 4 months|During the follow up phase, subjects will meet with the study investigators a total of 5 times for follow up monitoring. Participants will continue to maintain their migraine diary during this time.
89030683|NCT00521196|Other|Active tDCS- 1 month|Participants randomized to sham tDCS (placebo) will be given the opportunity to receive the active intervention if the intervention is found to be safe and efficacious.
89030684|NCT00521274|Experimental|1|"Patients randomized to Arm 1 will receive treatment cycles of Docetaxel and vaccine.~PI relocated, data not available."
89589479|NCT02350465|Active Comparator|Concentric Exercise|Supervised strengthening exercise using concentric muscle actions.
89589480|NCT02321514|Experimental|Tendyne Mitral Valve System|Patients will undergo transcatheter mitral valve replacement
89589481|NCT02266134|Experimental|Standardized Implementation, Patients|Sites in standardized condition arm will receive the standard implementation of measurement-based care intervention (PHQ-9).
89589482|NCT02266134|Experimental|Tailored Implementation, Patients|Sites in the tailored condition arm will receive the tailored implementation of measurement-based care intervention (PHQ-9).
89589483|NCT02266134|Experimental|Standardized Implementation, Therapists|Sites randomized to the standardized condition will be expected to use the measurement-based care intervention (PHQ-9) prior to each session with a depressed client and they will work as a team to maximize fidelity.
89589484|NCT02266134|Experimental|Tailored Implementation, Therapists|Sites randomized to the tailored condition will develop a site-specific protocol for use of the measurement-based care intervention (PHQ-9), and they will work as a team to maximize the fit of measurement-based care to this clinic.
89030685|NCT00521274|Active Comparator|2|"Patients randomized to Arm 2 will receive Docetaxel 75 mg/m2 on Day 1 of each cycle (1 cycle = 3 weeks). Patients who demonstrate disease progression will continue with their chemo as scheduled in Arm 2 but will also begin to receive TroVax® (cross-over).~PI relocated, data not available."
89589485|NCT02197845|Experimental|Phase I: Recruitment into Specialty Care|Participants in the Phase I Experimental Arm are enrolled into SCD specialty care. PN's will contact patient up to 3 times to assure patients have had an initial visit by 3 months time.
89589486|NCT02197845|Experimental|Phase II: Patient Navigator Arm|Participants in the Phase II Experimental Arm follow routine clinical care and are assigned a Patient Navigator. A specially trained (SCD specefic)PN will work with participants for one year. Participants will be contacted by their Navigator weekly for the first 6 months, then biweekly for the second 6 months.
89589487|NCT02197845|No Intervention|Phase II: Passenger Arm|No Intervention. Participants in the Phase II Passenger Arm follow routine clinical care.
89589488|NCT02107144|Experimental|trimetazidin|Patients, who are trimetazidine (TMZ) naïve, will be randomly assigned to receive trimetazidine plus previous medications (TMZ group) 48h before scheduled PCI- Paients that are TMZ naïve and randomized to TMZ group will be given oral loading of 70mg TMZ.
89589489|NCT02107144|No Intervention|Control|Patients, who are TMZ naïve, will be randomly assigned to receive just previous cardiac medication (Control group).
89589490|NCT01943643|Experimental|CT angiography, coronary bifurcations|
89589491|NCT01860170|Active Comparator|Cohort 1-Bortezomib (Velcade®)|Bortezomib (Velcade®) 0.7 mg/m2 rapid IV push on days 0 (at least 6 hours after transplant) and +3.
89589492|NCT01860170|Active Comparator|Cohort 2-Bortezomib (Velcade®)|Bortezomib (Velcade®) 1 mg/ m2 rapid IV push on days 0 (at least 6 hours after transplant) and +3.
89589493|NCT01860170|Active Comparator|Cohort 3-Bortezomib (Velcade®)|Bortezomib (Velcade®) 1.3 mg/m2 rapid IV push on days 0 (at least 6 hours after transplant) and +3.
89589494|NCT01847274|Active Comparator|Niraparib|2:1 Ratio administered once daily continuously during a 28 day cycle.
89589495|NCT01847274|Placebo Comparator|Placebo|Administered once daily continuously over a 28 day cycle.
89589496|NCT01802788||Cohort A|Patients implanted with a Portico valve after CE mark
89589497|NCT01802788||Cohort B|Patients implanted in previous SJM-sponsored premarket studies
89589498|NCT01611168|No Intervention|Usual Care|
89589499|NCT01611168|Experimental|Intervention Group, treatment algorithms|
89589500|NCT01560819|Experimental|Study Participants|Participants did not receive any bowel preparation before Gut Microbial Transplantation (GMT). Audio-visual aids were used to help reduce participants' anxiety about GMT.
89589501|NCT01497184|Experimental|DLI (Adults)|Arm 1: Allogeneic donor lymphocyte infusion (DLI) starting dose not to exceed 10^6/m^2 intravenously (IV) between 6 weeks - 12 weeks following date of allogeneic hematopoietic stem-cell transplantation (HSCT) as a planned DLI.
89589502|NCT01497184|Experimental|DLI any time|Arm 2: DLI will be administered at any point after disease recurrence following HSCT.
89589503|NCT01497184|Experimental|DLI Pediatrics|Arm 3: DLI administered intravenously between 6 weeks and 12 weeks following date of HSCT as a planned DLI in pediatric patients, aged 1-17 years-old.
89589504|NCT01497184|Experimental|DLI - Haplo-Identical Family Donor|Arm 4: DLI administered as planned DLI or after recurrence in adult and pediatric patients undergoing transplant with a haplo-identical family donor.
89589505|NCT01425528|Experimental|Kuvan Cohort 1|This cohort will be enrolled first. Analysis will be done to determine the optimum dosing of Kuvan to normalize BH4 levels in the Cerebral Spinal Fluid. This cohort will begin at a dose of 20mg/kg/day.
89589506|NCT01425528|Experimental|Kuvan Cohort 2|Participants in cohort 2 will be enrolled after the analysis of cohort 1 data has taken place. Dosing for cohort 2 will be based on results obtained in cohort 1, but will plan on starting at 30 mg/kg/day.
89589507|NCT01300832|Experimental|Duplex scan|Subjects undergo preoperative and post-operative duplex scanning of the lower extremities
89589508|NCT01150487|Experimental|Sensitized Renal Allograft Recipients|Patients who have antibodies against their donors in their blood.
89589509|NCT00866554|Active Comparator|LHRH agonist|Administration of a 3-month treatment with an LHRH agonist (chosen by the treating radiation oncologist) and Bicalutamide 50 mg daily for the first month of treatment with the LHRH agonist.
89589510|NCT00866554|Experimental|Dutasteride, Bicalutamide, Tamoxifen|"Administration of Dutasteride given at dose of 0.5 mg daily starting three months prior to day of implant procedure and continued for 3 months up until procedure.~Bicalutamide: given at a dose of 50 mg daily for 3 the same 3 month period as dutasteride~Tamoxifen: given at dose of 10 mg daily for 3 months that dutasteride and bicalutamide are administered."
89589511|NCT00452023|Experimental|IFN-alpha2a|Starting dose 90 microgram (mcg) injection under the skin once a week.
89589512|NCT00442104|Experimental|ganaxolone|
89589513|NCT00441896|Experimental|ganaxolone|ganaxolone
89030686|NCT05146778|Active Comparator|Opioid-free anesthesia group|OFA group will be sedated using dexmedetomidine and lidocaine during mastectomy.
89030687|NCT05146778|Active Comparator|Conventional anesthesia group with opioid|Conventional opioid anesthesia group will be sedated using remi-fentanyl during mastectomy.
89030688|NCT04694430||Severe exacerbation of COPD|N = 250
89030689|NCT04694430||Mild and moderate exacerbations of COPD|N = 250
89030690|NCT04694274||group 1|patients with temporomandibular disorders
89589514|NCT00441896|Placebo Comparator|non-active drug|placebo
89589515|NCT00194714|Experimental|Treatment (HER-2/neu peptide vaccine)|Patients receive HER-2/neu peptide vaccine ID once per month for 6 months in the absence of disease progression or unacceptable toxicity.
89589516|NCT02034877|Experimental|1|
89589517|NCT02034799|Other|Standard of Care (SoC)|Standard of Care (SoC) include any active or inactive adjunctive treatment to hemostasis methods currently used based on each surgeons surgical practice except for the use of other fibrin sealants.
89030691|NCT04694274||group 2|healthy control
89589518|NCT02034799|Experimental|Bioseal Fibrin Sealant|A porcine-derived fibrin sealant consisting of thrombin and fibrinogen
89589519|NCT02057575|Experimental|PG324 Ophthalmic Solution 0.01%|Netarsudil 0.01%, Latanoprost 0.005% fixed combination ophthalmic solution
89589520|NCT02057575|Experimental|PG324 Ophthalmic Solution 0.02%|Netarsudil 0.02%, Latanoprost 0.005% fixed combination ophthalmic solution
89589521|NCT02057575|Active Comparator|Netarsudil (AR-13324) Ophthalmic Solution 0.02%|Netarsudil 0.02% ophthalmic solution
89589522|NCT02057575|Active Comparator|Latanoprost Ophthalmic Solution 0.005%|Latanoprost 0.005% ophthalmic solution
89589523|NCT02077465|Experimental|Andecaliximab|Participants will receive andecaliximab every 2 weeks for a total of 3 infusions.
89589524|NCT02077465|Placebo Comparator|Placebo to match andecaliximab|Participants will receive placebo to match andecaliximab every 2 weeks for a total of 3 infusions.
89589525|NCT02034565|Experimental|Treatment A: Apixaban tablet|Apixaban Film coated Tablet Single dose 10 mg orally
89589526|NCT02034565|Experimental|Treatment B: Apixaban oral solution|Apixaban Solution Single dose 10 mg orally
89589527|NCT02075515|Experimental|HZ/su Lot A|Subjects will receive Lot A of the HZ/su vaccine at 0 and 2 months. The HZ/su vaccine composed of unique randomized combinations of an adjuvant lot and one gE lot.
89589528|NCT02075515|Experimental|HZ/su Lot B|Subjects will receive Lot B of the HZ/su vaccine at 0 and 2 months. The HZ/su vaccine composed of unique randomized combinations of an adjuvant lot and one gE lot.
89589529|NCT02075515|Experimental|HZ/su Lot C|Subjects will receive Lot C of the HZ/su vaccine at 0 and 2 months. The HZ/su vaccine composed of unique randomized combinations of an adjuvant lot and one gE lot.
89589530|NCT02034409|Sham Comparator|Sham|Treatment to index knee with sham device for 48 weeks
89589531|NCT02034409|Experimental|PLIUS|Treatment to index knee with PLIUS device for 48 weeks
89589532|NCT04417543|Active Comparator|Memantine hydrochloride group|included 50 patients who received memantine
89589533|NCT04417543|Placebo Comparator|Placebo group|included 50 patients who received placebo
89589534|NCT02021318|Experimental|Roxadustat|Participants received roxadustat orally according to the tiered weight-based approach, with starting dose of 70 mg (milligram) given thrice weekly (TIW) to participants weighing up to 70 kg (kilogram) and 100 mg given TIW to participants weighing more than 70 kg. Dose-titration was performed based upon regular measurement of Hb levels until participants achieved central Hb value of ≥ 11.0 g/dL (gram per deciliter) and Hb increase from baseline of ≥ 1.0 g/dL at two consecutive study visits, separated by at least 5 days. Once target Hb level was reached participants entered maintenance period during which roxadustat dosage was adjusted every 4 weeks to maintain participants Hb level within the target range of 10.0 g/dL and 12.0 g/dL. Participants received roxadustat up to a maximum of 104 weeks.
89589535|NCT02021318|Active Comparator|Darbepoetin alfa|Participants received initial dose of darbepoetin alfa based upon the weight (either 0.45 μg/kg (microgram per kilogram), as a single subcutaneous or intravenous (IV) injection once weekly or 0.75 μg/kg, as a single subcutaneous injection once every 2 weeks) as per European Summary of Product Characteristics (EU SmPC) along with IV iron supplementation according to the standard of care. Dose-adjustment was performed based upon regular measurement of Hb levels until participants achieved central Hb value of ≥ 11.0 g/dL and Hb increase from baseline of ≥ 1.0 g/dL at two consecutive study visits, separated by at least 5 days. Once target Hb level was reached participants entered maintenance period during which darbepoetin alfa dosage was adjusted every 4 weeks to maintain participants Hb level within the target range of 10.0 g/dL and 12.0 g/dL. Participants received darbepoetin alfa for up to a maximum of 104 weeks.
89589536|NCT02041286|Experimental|Intended Users of the Monitoring System|"Subjects with diabetes use the Karajishi Contour Investigational BG Monitoring System with no training. The criteria for the intended use population:~At least 60% of subjects will be younger than age 65~At least 10% of subjects will have type 1 diabetes"
89589537|NCT02020616|Experimental|LY3053102|Stage 1: Escalating dose (7 milligrams [mg] up to 200 mg) of LY3053102 administered once a week by subcutaneous (SC) injection for 12 weeks. Stage 2: LY3053102 administered once a week by SC injection for 12 weeks
89589538|NCT02020616|Placebo Comparator|Placebo|Stage 1 and Stage 2: Placebo to match LY3053102 administered by SC injection once a week for 12 weeks
89589539|NCT02020616|Active Comparator|Exenatide Extended-Release (ER)|Stage 1 and Stage 2: Exenatide ER 2 mg given by SC injection once a week for 12 weeks
89589540|NCT02020616|Experimental|LY3053102 + Exenatide ER|Stage 2: LY3053102 administered by SC injection once a week for 12 weeks and exenatide ER 2 mg administered by SC injection once a week for 12 weeks
89589541|NCT02048072|Experimental|Gilenya|Autonomic testing during first dose adminstration of Gilenya.
89589542|NCT04710446||NSTEMI Patients presenting with normal ECG|NSTEMI Patients presenting with normal ECG
89030692|NCT02948283|Experimental|Treatment (metformin hydrochloride, ritonavir)|"SINGLE AGENT STAGE : Patients receive metformin hydrochloride PO BID on days 1-7 in the absence of disease progression or unacceptable toxicity.~COMBINATION REGIMEN STAGE: Patients receive metformin hydrochloride PO BID and ritonavir orally PO BID on days 1-7. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
89589543|NCT04710446||NSTEMI Patients presenting with isolated T wave inversion|NSTEMI Patients presenting with isolated T wave inversion
89589544|NCT04710446||NSTEMI Patients presenting with transient ST-segment elevation|NSTEMI Patients presenting with transient ST-segment elevation
89589545|NCT04710446||NSTEMI Patients presenting with resting U wave inversion|NSTEMI Patients presenting with resting U wave inversion
89589546|NCT04710446||NSTEMI Patients presenting with low QRS voltage|NSTEMI Patients presenting with low QRS voltage
89589547|NCT02047604|Experimental|Cohort A - SAN-300 0.5 mg/kg QW|SAN-300 0.5 mg/kg subcutaneous once weekly for six weeks
89589548|NCT02047604|Experimental|Cohort B - SAN-300 1.0 mg/kg QW|SAN-300 1.0 mg/kg subcutaneous once weekly for six weeks
89589549|NCT02047604|Experimental|Cohort C - SAN-300 2.0 mg/kg QOW|SAN-300 2.0 mg/kg subcutaneous every other week for six weeks
89589550|NCT02047604|Experimental|Cohort D - SAN-300 4.0 mg/kg QOW|SAN-300 4.0 mg/kg subcutaneous every other week for six weeks
89589551|NCT02047604|Experimental|Cohort E - SAN-300 4.0 mg/kg QW|SAN-300 4.0 mg/kg subcutaneous every other week for six weeks
89589552|NCT02047604|Placebo Comparator|Placebo|Placebo dosing
89589553|NCT01622660|Experimental|Gemcitabine and Pazopanib|This is a phase II trial of gemcitabine and pazopanib in previously untreated patients with advanced/metastatic urothelial carcinoma (UC) who are ineligible for cisplatin-based chemotherapy.
89589554|NCT04697498|Active Comparator|The Control Group|The control group will include patients who will undergo surgery under general anesthesia.
89589555|NCT04697498|Experimental|The Study Group|The study group will include patients who will undergo surgery under general anesthesia using a bilateral bi-level Erector spine plane block.
89589556|NCT04680182|Experimental|Study group|Wound drain is kept until until a scheduled visit three weeks after the surgery unless the drain produced less than 30 ml/day for two consecutive days, in which case it could be removed earlier.
89589557|NCT04680182|Active Comparator|Control group|When the drain produces less than 100 mL over 24 hours, the self-suction bulb is removed and the drain is shortened and drained into a colostomy bag placed around the site of drain insertion. A request is filed with the community nursing system to have a visiting nurse to pull out the drain 1-2 cm per day.
89589558|NCT02019602|Experimental|Pharmacokinetic samples|"Pharmacokinetic (PK) samples will be taken from the mother at Day 0 within 24 hours before/after delivery, from the infant within 24 hours after birth, at Week 4 and Week 8 and from the umbilical cord within one hour after delivery.~Included are mothers who decided to continue on, or to start treatment with certolizumab pegol (CZP) for an approved indication with their treating physician prior to participation into this study. The mother is responsible for procuring her own supply of commercial CZP. The CZP dose and administration schedule will be as per the locally approved label."
89589559|NCT01994876|Experimental|First Coloplast Test 1|"The subjects first test their own product to collect a baseline measurement~The subjects are randomised to first test Coloplast Test 1 and thereafter Coloplast Test 2"
89589560|NCT01994876|Experimental|First Coloplast Test 2|"The subjects first test their own product to collect baseline measurements~The subjects are randomised to first test Coloplast Test 2 and thereafter Coloplast Test 1"
89589561|NCT04696718|Experimental|Traitement 1|Lactobacillus salivarius
89589562|NCT04696718|Experimental|Traitement 2|Lactobacillus Rhamnosus GG
89589563|NCT04696718|Experimental|Traitement 3|Bifidobacterium lactis
88976609|NCT00160966|Active Comparator|1|Immunosuppression with Ciclosporin and Mycophenolate-mofetil; Ciclosporin treatment being started at the latest at day 4 after transplantation with 7 mg/kg body weight daily administered every 8 hours until the target trough level of 300 µg/l was reached. Then it was administered twice daily with daily monitoring of trough levels. The target trough level was lowered to 200 µg/l 1 month after transplantation. Thereafter dosage and target trough levels were adjusted at the investigators discretion. Mycophenolate-mofetil was started previous to transplantation procedure with a starting dosage of 3 g/day administered twice daily. Once ciclosporin was entered into the therapy-scheme Mycophenolate-mofetil dosage was reduced to 2 g/daily. The therapy was controlled by measuring of trough levels with a target trough level exceeding 1 µg/ml. The dosage was adjusted at the investigators discretion.
88976610|NCT00160966|Active Comparator|2|Immunosuppression with Tacrolimus and Mycophenolate-mofetil Mycophenolate-mofetil was started previous to transplantation procedure with a starting dosage of 3 g/day administered twice daily. Once tacrolimus was entered into the therapy-scheme Mycophenolate-mofetil dosage was reduced to 2 g/daily. The therapy was controlled by measuring of trough levels with a target trough level exceeding 1 µg/ml. The dosage was adjusted to clinical signs of overimmunosuppression (infections) or intolerance (mainly gastrointestinal side effects) or rejections.
88976611|NCT00160966|Active Comparator|3|Immunosuppression with Tacrolimus and Mycophenolate-mofetil with change from Mycophenolate-mofetil to Everolimus after completion of posttransplant wound healing
88976612|NCT00052559|Experimental|Treatment (bevacizumab, fluorouracil, radiation therapy)|"Patients receive bevacizumab IV over 30-90 minutes on day 1 (courses 1-4). Beginning with course 2, patients also receive fluorouracil IV continuously on days 1-14 and undergo external beam radiotherapy on days 1-5 and 8-12. Treatment repeats every 2 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.~Patients undergo surgery 7 weeks after completion of chemoradiotherapy.~Cohorts of 6 patients receive escalating doses of bevacizumab until the MTD is determined. The MTD is defined as the dose preceding that at which at least 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, 20 additional patients are treated at the MTD."
88976613|NCT00161395|Active Comparator|1|Preconception advice.
88976614|NCT00161395|Experimental|2|Instruction in the Creighton Model Fertility Care System.
88976615|NCT00161434|Experimental|1|
88976616|NCT00161434|Placebo Comparator|2|
88976617|NCT00044694|Placebo Comparator|Placebo 0.01 mL|2 week placebo lead-in followed by Placebo 0.01 mL
88976618|NCT00044694|Placebo Comparator|Placebo 0.02 mL|2 week placebo lead-in followed by Placebo 0.02 mL
88976619|NCT00044694|Placebo Comparator|Placebo 0.03 mL|2 week placebo lead-in followed by Placebo 0.03 mL
89209892|NCT00573144|Active Comparator|Nesiritide|Infusion of 72 hours of IV nesiritide at 0.006 mcg/kg/min.
88976620|NCT00044694|Placebo Comparator|Placebo 0.04 mL|2 week placebo lead-in followed by Placebo 0.04 mL
88976621|NCT00044694|Experimental|AC2993 2.5 mcg|2 week placebo lead-in (0.01 mL) followed by AC2993 2.5 mcg; 0.01 mL
88976622|NCT00044694|Experimental|AC2993 5.0 mcg|2 week placebo lead-in followed by AC2993 5.0 mcg; 0.01 mL
88976623|NCT00044694|Experimental|AC2993 7.5 mcg|2 week placebo lead-in followed by AC2993 7.5 mcg; 0.03 mL
88976624|NCT00044694|Experimental|AC2993 10.0 mcg|2 week placebo lead-in period followed by AC2993 10.0 mcg; 0.04 mL
88976625|NCT05566977|Experimental|patients with autoimmune disease :lupus nephritis and type1 diabetes melitus|single arm of patients with autoimmune diseases : patients of the first group selected as refractory lupus nephritis. patients of the second group of autoimmune diseases are selected to have type1 diabetes Meletus.
88976626|NCT00044538|Experimental|Arm 1|
89589564|NCT02040428|Experimental|EVARREST™ Fibrin Sealant Patch|EVARREST™ Fibrin Sealant Patch is a sterile bio-absorbable combination product consisting of two constituent parts- a flexible matrix and a coating of two biological components (Human Fibrinogen and Human Thrombin).
89589565|NCT02040428|Active Comparator|Topical hemostat|Equine collagen with Human Fibrinogen and Human Thrombin
89589566|NCT02018822|Experimental|All Participants|Participants who needed at least two tooth restorations
89589567|NCT02055157|Experimental|Cohort 1|Cohort 1: 2.5 ug/kg
89589568|NCT02055157|Experimental|Cohort 2|Cohort 2: 7.5 ug/kg,
89589569|NCT02055157|Experimental|Cohort 3|Cohort 3: 15 ug/Kg
89589570|NCT02055157|Experimental|Cohort 4|Cohort 4: 30 ug/kg
89589571|NCT02022007|Active Comparator|Metformin XR|Metformin 2000 mg daily (QD) for 16 weeks
89589572|NCT02022007|Active Comparator|Saxagliptin|Saxagliptin 5 mg QD for 16 weeks
89589573|NCT02022007|Experimental|Saxagliptin-Metformin XR|"Saxagliptin-Metformin XR (combination pill)~5mg Saxagliptin/2000 mg Metformin XR QD for 16 weeks"
89589574|NCT04716595|Experimental|morning administration|K-877 ER 0.2 mg/day morning administration (once daily)
89589575|NCT04716595|Experimental|evening administration|K-877 ER 0.2 mg/day evening administration (once daily)
89589576|NCT04689919|Active Comparator|Reference Group [Xarelto 20mg (Rivaroxaban) Tablet]|Subjects will take their assigned study medication, together with 240 mL of ambient temperature water, at least 1 hour after start of the meal at their scheduled dosing time-point
89589577|NCT04689919|Experimental|Test Group [Xaroban 20mg (Rivaroxaban) Tablet]|Subjects will take their assigned study medication, together with 240 mL of ambient temperature water, at least 1 hour after start of the meal at their scheduled dosing time-point
89589578|NCT04681963||Suspected pneumonia diagnosis|Acutely admitted patients suspected having pneumonia.
89589579|NCT04680949|Placebo Comparator|Placebo|Patients receiving standard-of-care (SOC) and placebo. Placebo is injected subcutaneously once daily for 10 days
89589580|NCT04680949|Experimental|Anakinra|Patients receiving SOC and anakinra. Anakinra is injected subcutaneously as 100 mg once daily for 10 days
89589581|NCT02031679|Experimental|AZD1981|"AZD1981 for oral administration will be available in tablet form. AZD1981 tablets will be provided in 10 mg strengths.~The drug will be self-administered by the subject. Subjects will take 4 tablets in the morning, 4 tablets in the afternoon, and 4 tablets in the evening.~The tablets should be swallowed whole with a glass of water."
89589582|NCT02031679|Placebo Comparator|Placebo|"The placebo will be available in tablet form. The placebo contains the same ingredients as the AZD1981 with the exception of the active compound.~The placebo will be self-administered by the subject. Subjects will take 4 tablets in the morning, 4 tablets in the afternoon, and 4 tablets in the evening.~The tablets should be swallowed whole with a glass of water."
89589583|NCT04689139|Experimental|Thoracic aorta surgery patients|Blood samples on proadrenomedullin, presepsin, NT-proBNP, Troponin I, procalcitonin are acquired
89589584|NCT02053753|Experimental|Drug Product CP4|Participants received a single dose of 120 mg denosumab manufactured using the new CP4 process subcutaneously on day 1.
89589585|NCT02053753|Experimental|Drug Product CP2|Participants received a single dose of 120 mg denosumab manufactured using the current CP2 process subcutaneously on day 1.
89589586|NCT02019979|Experimental|metformin /carbohydrate restricted diet|metformin and carbohydrate restricted diet added to platinum based chemotherapy regimen
89589587|NCT04687501|Experimental|VR-group|"The participants randomised into this group can choose for an immersive guided relaxation VR experience or an interactive VR experience. The VR intervention is additional to the standard postoperative care management, the standard pain protocol is explained below.~The VR-intervention will be given using the Oculus Go Virtual Reality glasses with touchpad."
89589588|NCT04687501|No Intervention|Standard care-group|"The participants randomized into the standard care- group will receive the usual standard pre-and postoperative management.~Standard pain protocol:~Preoperative (arrival day-care unit) start with 1000mg paracetamol orally administered.~Postoperative Meloxicam 15mg orally administered, or when oral medication is not possible (due to nausea e.g.) than diclofenac supp 100mg or diclofenac i.v. 75mg.~On recovery ward, when necessary depending on pain score (NRS>4): dipidolor 2.5-5mg i.v. and 10-15mg i.m. after consulting the anesthesiologist.~Postoperative at home 4dd1000mg paracetamol will be continued, in combination with meloxicam 1dd15mg during 3 days. Also tramadol 50mg with a maximum of 4dd will be prescribed."
89589589|NCT02019667|Experimental|Placebo|Participants with SSADH Deficiency when on placebo for six months
89589590|NCT02019667|Experimental|Study Drug|Participants with SSADH Deficiency receiving SGS-742 when on study drug for six months
89589591|NCT02030821|Active Comparator|Tranexamic Acid (TXA)|"TXA will be administered as a 1 gm dose IV prior to the procedure then as a repeat dose of 1 gram at the time of wound closure. These doses are currently used at Duke for Total Knee Arthroplasties (TKAs) and Total Hip Arthroplasties (THAs) per standard of care by the orthopaedic team.~All data needed for this study including blood loss, need for transfusion, preoperative and lowest postoperative hematocrit and hemoglobin, and complications will be collected during the hospitalization."
88976627|NCT00052949|Experimental|Treatment (imatinib mesylate)|Patients receive oral imatinib mesylate twice daily for 28 days. Courses continue in the absence of disease progression or unacceptable toxicity.
88976628|NCT04710745||Study Group|Patients in sinus rhythm without history of AF, with high risk for ischemic stroke and AF. CHA2DS2-VASc score > 2 (for females > 3) and with more than 3 specific criteria for inclusion.
89209893|NCT00891696|Active Comparator|Exp 1: AA + Rap|Participants will receive amino acid supplementation and rapamycin.
89589592|NCT02030821|Active Comparator|Epsilon-aminocaproic acid (Amicar)|"Administered 5g in 250mL of IV normal saline over 15 minutes prior to the procedure and then an infusion of 5g at the time of wound closure. These doses are currently used at Duke for Total Knee Arthroplasties (TKAs) and Total Hip Arthroplasties (THAs) per standard of care by the orthopaedic team.~All data needed for this study including blood loss, need for transfusion, preoperative and lowest postoperative hematocrit and hemoglobin, and complications will be collected during the hospitalization."
89589593|NCT02052739|Experimental|SAGE-547 Standard Dose|Participants received SAGE-547 IV loading infusion of 286.6 micrograms per kilogram per hour (μg/kg/hr) for 1 hour on Day 1 followed by maintenance infusion of 86 μg/kg/hr for next 95 hours from Days 1 to 4 (i.e. up to Hour 96) followed by taper infusions of 64.5 μg/kg/hr, 43.0 μg/kg/hr, 21.5 μg/kg/hr at a duration of 8 hours each, on Day 5.
89589594|NCT02052739|Experimental|SAGE-547 High Dose|Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion A of SAGE-547 86 μg/kg/hr for 23 hours on Day 1 followed by maintenance infusion B of SAGE-547 156 μg/kg/hr for 72 hours from Days 2 to 4 followed by taper infusions of 125 μg/kg/hr, 94 μg/kg/hr, 62 μg/kg/hr, 31 μg/kg/hr at a duration of 6 hours each, on Day 5.
89209894|NCT00891696|Placebo Comparator|Exp 1: AA|Participants will receive amino acid supplementation and placebo rapamycin.
89209895|NCT00891696|Active Comparator|Exp 1: HEx + Rap|Participants will receive rapamycin and placebo amino acid supplementation, and they will undergo high-intensity resistance exercise.
89589595|NCT02019277|Experimental|Trastuzumab SC, Pertuzumab, and Taxane|Participants will receive pertuzumab, trastuzumab and a taxane (docetaxel, paclitaxel or nab-paclitaxel) once every 3 weeks (21-day cycles). Choice of taxane will be at the discretion of the investigator and administered per routine clinical practices and local prescribing instructions.
89589596|NCT04712773|Other|Cardiac surgery patients|Patients scheduled for elective cardiac surgery (CABG or valve surgery).
89589597|NCT02030119|Active Comparator|Control|The participant will receive either an email or text message (based on the participant's preference) stating whether the participant achieved their goal for the prior day.
89589598|NCT02030119|Experimental|Gain Framing|Participants will be told that they will earn money for each day they walk at least 7000 steps. Each participant will receive either an email or text message (based on the participant's preference) stating whether or not he/she achieved the goal for the prior day and can collect the earnings. Non-adherent participants will receive messages about how much they would have earned had they met their target step goal.
89589599|NCT02030119|Experimental|Loss Framing|The participants will be told that their account has been credited a certain amount of money for the upcoming 30 days. However, for each day they do not meet their goal of at least 7000 steps, they will lose a small portion of that money. The participant will receive either an email or text message (based on the participant's preference) stating whether the participant achieved the goal for the prior day. Non-adherent participants will receive messages about how much the participant would have kept had they met the target step goal.
89589600|NCT02030119|Experimental|Daily Lottery|Each participant will be entered into a lottery daily, but participants will only be eligible to collect their winnings if they walked at least 7000 steps the day before. Participants will receive either an email or text message (based on the participant's preference) stating whether or not they won the lottery and if they met their target step goal. If both occur, the participant will be told how much money he or she won. Non-adherent participants will receive messages about how much they would have won had they met the target step goal.
89589601|NCT04686331||Suspected CAP|All patients admitted to the emergency department with suspected community-acquired pneumonia (CAP) assessed by the receiving physician
89589602|NCT01823835|Experimental|Phase Ia - Cohort 1|100 mg GDC-0810 once daily (QD) in fasting state.
89589603|NCT01823835|Experimental|Phase Ia - Cohort 2|200 mg GDC-0810 QD in fasting state.
89589604|NCT01823835|Experimental|Phase Ia - Cohort 3|400 mg GDC-0810 QD in fasting state.
89589605|NCT01823835|Experimental|Phase Ia - Cohort 4|600 mg GDC-0810 QD in fasting state.
89589606|NCT01823835|Experimental|Phase Ia - Cohort 5|600 mg GDC-0810 QD in non-fasting state.
89589607|NCT01823835|Experimental|Phase Ia - Cohort 6|300 mg GDC-0810 twice daily (BID) in fasting state.
89589608|NCT01823835|Experimental|Phase Ia - Cohort 7|800 mg GDC-0810 QD in fasting state.
89589609|NCT01823835|Experimental|Phase Ia - Cohort 8|800 mg GDC-0810 QD in non-fasting state.
89589610|NCT01823835|Experimental|Phase Ia - Cohort 9|400 mg GDC-0810 BID in fasting state.
89589611|NCT01823835|Experimental|Phase IIa - Cohort A1|600 mg GDC-0810 QD. Additionally, participants in this arm did not receive any prior treatment with fulvestrant and had confirmed ER-a (ESR1) mutation of the ligand binding domain (LBD).
89589612|NCT01823835|Experimental|Phase IIa - Cohort A2|600 mg GDC-0810 QD. Additionally, participants in this arm had prior treatment with fulvestrant and confirmed ER-a (ESR1) mutation of the LBD.
89589613|NCT01823835|Experimental|Phase IIa - Cohort B1|600 mg GDC-0810 QD. Additionally, participants in this arm did not receive any prior treatment with fulvestrant and had progressed following ≤1 prior therapy with an aromatase inhibitor (AI).
89589614|NCT01823835|Experimental|Phase IIa - Cohort B2|600 mg GDC-0810 QD. Additionally, participants in this arm had prior treatment with fulvestrant and progressed following ≤1 prior therapy with an AI.
89589615|NCT01823835|Experimental|Phase Ib - Cohort C1|400 mg GDC-0810 + 125 mg Palbociclib QD.
89589616|NCT01823835|Experimental|Phase Ib - Cohort D1|≤600 mg GDC-0810 QD + LHRH agonist once monthly.
89589617|NCT01823679|Experimental|Capecitabine 1000 mg/m²|"Participants will receive oral capecitabine twice-a-day (BID) as 500 mg/m² doses on days 1 to 14.~Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity."
89589618|NCT04414293|Experimental|Treatment|All the patients will be treated with low dose lung radiation
89589619|NCT01823289|Experimental|Itraconazole Sequential Therapy|
89589620|NCT01822899|Experimental|Umeclidinium bromide/Vilanterol + placebo ACCUHALER/DISKUS|Subjects will receive UMEC/ VI 62.5/25 mcg, one inhalation administered once-daily in the morning via the NDPI and one placebo ACCUHALER/DISKUS administered as one inhalation each morning and evening.
89589621|NCT01822899|Active Comparator|Fluticasone propionate/Salmeterol + placebo NDPI|Subjects will receive FSC 500/50 mcg, administered as one inhalation each morning and evening via ACCUHALER/DISKUS + placebo administered once daily in the morning via NDPI.
89589622|NCT01822821|Experimental|IV Acetaminophen|Patients will receive up to four doses of IV Acetaminophen (1000mg)every six hours after surgery along with standard PCA (patient controlled) opioids.
89589623|NCT01822821|Placebo Comparator|Placebo|Patients will receive up to four doses of IV placebo every six hours after surgery along with standard PCA (patient controlled) opioids.
89589624|NCT01822665|Active Comparator|Paracetamol Tablet|Paracetamol 500 mg tablet, 2 tablets administered 4 times a day (QID) with water.
89589625|NCT01822665|Active Comparator|Ibuprofen Tablet|Ibuprofen 400 mg tablet, 2 tablets administered three times a day (TID) with water
89209896|NCT00891696|Placebo Comparator|Exp 1: HEx|Participants will receive placebo amino acid supplementation and placebo rapamycin, and they will undergo high-intensity resistance exercise.
89209897|NCT00891696|Active Comparator|Exp 1: HEx + AA + Rap|Participants will receive amino acid supplementation and rapamycin, and they will undergo high-intensity resistance exercise.
89589626|NCT01822665|Placebo Comparator|Placebo Tablet|Placebo tablets, 2 tablets QID administered with water.
89589627|NCT01822665|Active Comparator|Ibuprofen Capsule|Ibuprofen 400 mg liquid gel capsules, 2 tablets, TID administered with water
89589628|NCT02173301|Experimental|XP23829 400 mg QD (once daily)|After 4-week screening period, eligible subjects will be randomized to XP23829 400 mg QD for 12 weeks including titration period
89589629|NCT02173301|Experimental|XP23829 800 mg QD|After 4-week screening period, eligible subjects will be randomized to XP23829 800 mg QD for 12 weeks including titration period
89589630|NCT02173301|Experimental|XP23829 400 mg BID (twice daily)|After 4-week screening period, eligible subjects will be randomized to XP23829 400 mg BID for 12 weeks including titration period
89589631|NCT02173301|Placebo Comparator|Placebo|After 4-week screening period, eligible subjects will be randomized to Placebo for 12 weeks
89589632|NCT01822587|Placebo Comparator|Placebo|Administered once orally following cue exposure on each of the first two days of testing.
89589633|NCT01822587|Active Comparator|Propranolol 40mg|Administered once orally following cue exposure on each of the first two days of testing.
89589634|NCT01822587|Active Comparator|Propranolol, 80mg|Administered once orally following cue exposure on each of the first two days of testing.
89589635|NCT04595331|No Intervention|Treatment Group in pivotal study|followed for long-term safety and effectiveness with no additional treatment
89589636|NCT04595331|Experimental|Control Group in the pivotal study|receiving treatment in the extension study
89589637|NCT04587999|Experimental|bladder stimulation|
89589638|NCT04587999|Active Comparator|Quick wee|
89589639|NCT01822353|Experimental|Milk allergy|Dietary supplement, milk in increasing dosages, delivered daily and orally.
89589640|NCT01822353|Experimental|Egg allergy|Dietary supplement, egg protein given in increasing dosages, delivered daily and orally.
89589641|NCT01822353|Experimental|Nut allergy|Dietary supplement, nut cream including nut allergens, delivered in increasing dosages, daily and orally.
89589642|NCT01821963|Experimental|Pegylated Interferon Alfa 2a + Ribavirin + Telaprevir|Triple combination with Telaprevir, PegIFN alfa-2a and Ribavirin administered for 12 weeks, followed by dual therapy with PegIFN alfa-2a and Ribavirin. Dual therapy continued for 48 weeks of total duration of therapy, as standard of care treatment for cirrhotic patients, or until day of transplantation, whichever comes first. Starting doses for standard of care pegylated interferon (PegIFN) alfa-2a 180 mcg subcutaneously once weekly, for ribavirin (RBV) 1,000 mg orally daily (< 75 kg) and 1,200 mg orally daily (≥ 75 kg), and for telaprevir 750 mg taken orally 3 times a day.
88976629|NCT00053027|Experimental|rituximab + cladribine|"Patients receive rituximab IV over 4-8 hours on day 1 and cladribine IV over 2 hours on days 4-8. If 2 or more patients experience unacceptable toxicity during the first course, the study is discontinued; otherwise, the study is opened for enrollment at all NCCTG sites.~Treatment repeats every 28 days for a total of 2-6 courses in the absence of disease progression or unacceptable toxicity.~Patients are followed every 2 months for 1 year, every 4 months for 1 year, every 6 months for 1 year, and then annually for 2 years."
88976630|NCT00162214|Active Comparator|1|
88976631|NCT04731116|Experimental|CANNABIDIOL|CANNABIDIOL 5% 3 ml twice daily for 14 days.
88976632|NCT00407095|Experimental|1|
88976633|NCT04731792|Experimental|Virtual Reality group|
88976634|NCT04731792|No Intervention|control group|
88976635|NCT00405457|Other|A|
88976636|NCT04710472|Experimental|MH|Arm MH - mobile Mentora app to monitor and track treatment side-effects, vital signs, therapeutics and daily habits;
88976637|NCT04710472|No Intervention|C|SOC
88976638|NCT02965170||MS Tysabri|Patients with relapsing forms of multiple sclerosis and who are currently undergoing Tysabri® therapy at Rocky Mountain Multiple Sclerosis Research Group.
89589643|NCT01821807||26 gauge quincke|Patients (n=150) will be treated with 26 gauge quincke spinal needle for spinal anesthesia for cesarean section.
89589644|NCT01821807||26 gauge atraucan|Patients (n=110) will be treated with 26 gauge atraucan spinal needle for spinal anesthesia for cesarean section.
89589645|NCT01821729|Experimental|Experimental Arm|FOLFIRINOX, Losartan, Proton Beam Radiation Therapy
89589646|NCT01820637|Experimental|Test device arm (DES SFA)|Patients in this arm will receive the study device: the Boston Scientific DES SFA Paclitaxel-Eluting Self-Expanding Stent System (DES SFA)
89589647|NCT02172911|Experimental|Cohort I: INO-3112: Curative Intent|Cohort I included participants with biopsy-proven, stage IB-IVB inoperable, newly diagnosed invasive cervical carcinoma associated with HPV-16 and/or HPV-18 treated with standard chemoradiation therapy with curative intent. Participants received a 4-dose series of 1.1 mL IM injection of INO-3112 followed immediately by EP with CELLECTRA™-5P.
89589648|NCT02172911|Experimental|Cohort II: INO-3112: Salvage Therapy|Cohort II included participants with persistent and/or recurrent cervical carcinoma associated with HPV-16 and/or HPV-18 who had been treated with salvage therapy (chemotherapy and/or radiation therapy). Participants received a 4-dose series of 1.1 mL IM injection of INO-3112 followed immediately by EP with CELLECTRA™-5P.
88976639|NCT00162448|Experimental|A1|
88976640|NCT00162448|Placebo Comparator|A2|
88976641|NCT04724356|Experimental|Virtual Reality Group|The Kinect based rehabilitation group received virtual reality therapy using Xbox Kinect-based games, in addition to complex decongestive physiotherapy. The intervention was led once per day, five days a week, over 8 weeks. All participants wearing multilayer bandage or compression stocking during training to avoid exacerbation of the lymphedema in the affected limb.
88976642|NCT04724356|Experimental|Resistance exercise Group|The resistance exercise group received resistance training, in addition to complex decongestive physiotherapy. The intervention was led once per day, five days a week, over 8 weeks. All participants wearing multilayer bandage or compression stocking during training to avoid exacerbation of the lymphedema in the affected limb.
88976643|NCT00162565|Experimental|1|bbloquant treatment
88976644|NCT00162682|Active Comparator|1|* VL-S, the standard viral load (VL) based monitoring strategy, where switching is performed when VL is confirmed (within one month) above 400 copies per mL.
88976645|NCT00162682|Experimental|2|CD4-S, the alternative CD4 based monitoring strategy where switching is performed when a confirmed (within one month) relative decline in CD4 count of more than 30% from peak values is observed within 200 cells from baseline.
88976646|NCT00053222|Experimental|Arm A|Arsenic trioxide (0.3 mg/kg/day iv for 5 days every 28 days)
88976647|NCT00162916|Placebo Comparator|1|
88976648|NCT00162916|Experimental|2|
88976649|NCT05543811|Experimental|Product for special dietary use|Spread Enriched With 5-hydroxytryptophan, Theanine and Gamma-aminobutyric Acid will be given to the subjects enrolled to this arm, 20 gram twice daily with breakfast and supper (instead of butter)
89589649|NCT02120027|Experimental|Ibodutant 10 mg|Oral tablet to be given once daily for 24 weeks of treatment. Patients randomised to the ibodutant 10 mg arm will continue on ibodutant 10 mg for additional 28 weeks of treatment via mock-re-randomisation at week 25 .
89589650|NCT02120027|Placebo Comparator|Placebo|Oral tablet to be given once daily for 24 weeks of treatment. Patients randomised to the placebo arm will be re-randomised at week 25 in a 1:1 ratio to ibodutant or placebo for additional 28 weeks of treatment.
89589651|NCT01850823|Placebo Comparator|placebo|Placebo
89589652|NCT01850823|Active Comparator|NASONEX® Nasal Spray (Schering Corporation)|Mometasone Nasal spray
89589653|NCT01850823|Experimental|Mometasone Nasal Spray (Watson Laboratories, Inc)|Mometasone Nasal spray
89589654|NCT01820559|Active Comparator|ESL 1200 mg|eslicarbazepine acetate 1200 mg
89589655|NCT01820559|Active Comparator|ESL 800 mg|eslicarbazepine acetate 800 mg
89589656|NCT01820559|Placebo Comparator|Placebo|Placebo tablets
89589657|NCT01818765|Experimental|Procedure|"Pre-procedure speckle-tracking echocardiography assessment of latest activation~Trans-ventricular-septal placement of LV pacing lead~Acute response assessment"
89209898|NCT00891696|Placebo Comparator|Exp 1: HEx + AA|Participants will receive amino acid supplementation and placebo rapamycin, and they will undergo high-intensity resistance exercise.
89589658|NCT01850589|Other|Conservative Therapy|"Conservative therapy:~Subjects counseled by vascular attending/fellow during office appointment to stop smoking.~Counseling consists of:~Self-help materials including Smart Move: A Stop Smoking Guide from the American Cancer Society A brief educational discussion on the benefits of smoking cessation.~Patients randomized to Group 1 will be offered adjunctive treatment with nicotine replacement therapy at no cost."
89589659|NCT01850589|Other|Aggressive Therapy|"8 week comprehensive smoking cessation and pharmacotherapy program consisting of:~One hour group counseling sessions, focusing on patient education and behavior modification.~Behavior modifications including recognition; coping skills; stress management; and relapse prevention skills.~Counseling including information on nutrition, exercise, and chemical dependency.~Counseling sessions will be held 256C Mason Avenue. Pharmacotherapy adjuncts offered at no cost are as follows: Chantix (varenicline) GlaxoSmithKline, Zyban (bupropion) Pfizer,and Nicoderm/Nicorette (nicotine nasal spray, inhaler, transdermal patches and gum) GlaxoSmithKline."
89589660|NCT01818531|Experimental|Adductor canal block|Patients in this arm will receive an adductor canal block prior to undergoing a medial compartment knee arthroplasty.
89589661|NCT01818531|Active Comparator|Lumbar plexus block|Patients in this arm will receive a lumbar plexus block prior to undergoing a medial compartment knee arthroplasty.
89589662|NCT02171429|Placebo Comparator|Placebo|Participants will receive placebo matching to etrolizumab up to Week 12 and placebo matching to adalimumab up to Week 8.
89589663|NCT02171429|Active Comparator|Adalimumab|Participants will receive adalimumab up to Week 8 and placebo matching to etrolizumab up to Week 12.
89589664|NCT02171429|Experimental|Etrolizumab|Participants will receive etrolizumab up to Week 12 and placebo matching to adalimumab up to Week 8.
89589665|NCT01818297|Active Comparator|Treatment|Treatment settings of Medtronic PrimeAdvanced® neurostimulator system implant
88976650|NCT05543811|Placebo Comparator|control|This group will receive standard spread, without theanine, gamma-aminobutyric acid and 5-hydroxytryptophan, twice daily with breakfast and supper with food (instead of butter)
88976651|NCT02970786|Experimental|68Ga-NODAGA-E(c[RGDyK])2 PET|One injection of 68Ga-NODAGA-E(c[RGDyK])2 PET (app. 200 MBq) followed by 3 PET/CT scans 10 minutes, 1 hour and 2 hours post injection
88976652|NCT00163267|Placebo Comparator|ASS + Placebo|control arm
88976653|NCT00163267|Active Comparator|ASS + Plavix|active drug
88976654|NCT04731038|Experimental|Experimental|Anlotinib 12mg qd. po. d1-d14 q3w Toripalimab 240mg ivgtt. d1 q3w Paclitaxel 135mg/m2 ivgtt. d1 q3w Cisplatin 50mg/m2 ivgtt. d1 q3w Carboplatin AUC=5 ivgtt. d1 q3w
88976655|NCT00163579|Experimental|Bryophyllum|
88976656|NCT00163579|Placebo Comparator|Placebo|
88976657|NCT00053339|Experimental|trastuzumab|"Patients receive trastuzumab (Herceptin) IV over 60-90 minutes on day 1.~Treatment repeats every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity.~Patients are followed every 3 months for 5 years."
88976658|NCT00053339|Experimental|trastuzumab + tamoxifen|"Patients receive trastuzumab V over 60-90 minutes on day 1 and oral tamoxifen once daily on days 1-21.~In both arms, treatment repeats every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity.~Patients are followed every 3 months for 5 years."
88976659|NCT00407173|Experimental|1|HCV-796 1000mg single dose
88976660|NCT02970383|Experimental|10 group|Initial prescription for 10 narcotic tabs
88976661|NCT02970383|Active Comparator|30 group|Initial prescription for 30 narcotic tabs
88976662|NCT02970071||Fetal congenital heart disease cases|Gravidas with fetal congenital heart disease diagnosed by fetal echocardiography
88976663|NCT00164203|Experimental|Cognitive Behavioral Therapy|School-based, 12-session protocol, weekly
88976664|NCT00164203|Active Comparator|activity control condition|Structured games and activities, weekly for 12 weeks
89589666|NCT01818297|Other|Control|Control settings of Medtronic PrimeAdvanced® neurostimulator system implant
89589667|NCT01818141|Active Comparator|Fidaxomicin|Fidaxomicin 200mg by mouth every 12 hours for 10 days
89589668|NCT01818141|Active Comparator|Vancomycin|Vancomycin 125mg by mouth every 6 hours for 10 days
89589669|NCT01849497|Experimental|Evolocumab PFS|Participants received evolocumab 140 mg every 2 weeks for 4 weeks (Day 1, Week 2, and Week 4) subcutaneously using a prefilled syringe (PFS). Participants self-administered evolocumab in the clinic on Day 1 under supervision and then self-administered in a home setting at Weeks 2 and 4.
89589670|NCT01849497|Experimental|Evolocumab AI/pen|Participants received evolocumab 140 mg every 2 weeks for 4 weeks (Day 1, Week 2, and Week 4) subcutaneously using a prefilled autoinjector/pen (AI/pen). Participants self-administered evolocumab in the clinic on Day 1 under supervision and then self-administered in a home setting at Weeks 2 and 4.
89589671|NCT02147093|Other|Control (sphere) /Test (multi-focal)|Subjects were first fitted with Control lens (sphere) and a pair of reading glasses for one week. Subjects were then fitted with the Test lens (multi-focal) for one week.
89589672|NCT02147093|Other|Test (sphere) /Control (multi-focal)|Subjects were first fitted with the Test lens (multi-focal) for one week. Subjects were then fitted with Control lens (sphere) and a pair of reading glasses for one week.
89589673|NCT04170465|Experimental|Metformin group|Patients will receive AC-T neoadjuvant chemotherapy in addition to oral metformin HCl (850 mg tablets, twice per day, for 6 months) (n= 30)
89589674|NCT04170465|Active Comparator|Control group|Patients will receive AC-T neoadjuvant chemotherapy alone (n= 30)
89589675|NCT02119325|Experimental|Test|Fibre rich Health Food Drink packed as 30g individual sachet, administered as a single serve in 200 mL of luke warm water
89589676|NCT02119325|Placebo Comparator|Placebo|No Fibre Health Food Drink packed as 25g individual sachet, administered as single serve in 200 mL of luke warm water
89589677|NCT01816893|Sham Comparator|Euglycemic hyperinsulinemic clamp|participant undergoes a euglycemic hyperinsulinemic clamp
89589678|NCT01816893|Active Comparator|Hypoglycemic hyperinsulinemic clamp|participant undergoes a hypoglycemic hyperinsulinemic clamp
89589679|NCT01848483|Experimental|AIDS EPC Package plus MI|AIDS EPC Package plus MI: AIDS Early Palliative Care (EPC) Package and Motivational Interviewing (MI) At least one early Palliative Care visit plus four weekly MI sessions within a 3 month period of time.
89589680|NCT01848483|Other|Standard of Care (SOC)|Standard of Care (SOC): Routine Infectious Disease Program HIV-care clinic appointment
89589681|NCT05133479|Experimental|Intervention|Participants receive the Let's Know! intervention in small groups as provided by research staff
89589682|NCT05133479|No Intervention|Business-As-Usual|Participants continue to receive only their typical classroom instruction (i.e., no small groups)
89589683|NCT01610271|Experimental|Air Barrier System|The Air Barrier System will be employed throughout the surgical procedure for this group of patients.
89589684|NCT01610271|No Intervention|Control|The Air Barrier System will not be used during the surgical procedure for this group of patients.
89589685|NCT02170727|Experimental|Arm 1 : DCV/ASV/BMS-791325|DCV 30 mg (as the free base) / Asunaprevir (ASV) 200 mg / BMS-791325 75 mg FDC tablet orally twice daily for 12 weeks
89589686|NCT01847313|Active Comparator|Liraglutide|Liraglutide 0.6 mg daily
89589687|NCT01847313|No Intervention|Control|Standard diabetes care including renin angiotensin aldosterone system inhibitor or antagonist
89589688|NCT02144285|Experimental|LY3113593 IV (Part A)|Single dose of LY3113593 administered intravenous (IV) at a minimum of six dose levels
88976665|NCT00162955|Experimental|ARB administration|80mg/day from the day of the start of 1st CHOP until the completion of all the evaluations
88976666|NCT00162955|No Intervention|non-administration|ARB non-administration group
88976667|NCT00164281|Experimental|Continuous vs limited isoniazid|The placebo arm will receive 6 months of open label isoniazid before beginning placebo (as a coded medication). The treatment (experimental arm) will receive 6 months of open label isoniazid before beginning coded medication (isoniazid).
88976668|NCT00053573|Experimental|1|
88976669|NCT04723849|Experimental|Tretment group|Subjects took one tablet per day orally starting day one after the visit and continuing for the 6-month duration of the study.
88976670|NCT04723849|Placebo Comparator|Placebo group|Subjects took one tablet per day orally starting day one after the visit and continuing for the 6-month duration of the study.
88976671|NCT00044967||Group 1|"Patients undergo baseline colonoscopy before or within 6 months of initial curative resection and then surveillance colonoscopy at 1, 3, and 5 years (+/- 6 months) after resection. The number, size, location, histology, and method of removal of polyps are documented at the time of colonoscopy. Patients also undergo microsatellite instability (MSI) status testing and complete family history questionnaires at baseline.~The prognostic significance of family history and MSI status is evaluated. The individual histologic features of the tumors are compared with the MSI status to determine their predictive value. The histologic features are also correlated with outcome to determine their prognostic significance.~Patients may be referred for genetic counseling."
88976672|NCT00164515|No Intervention|Arm 1: Physical activity awareness|The awareness group received a physician-recommendation to exercise an informational brochure, and pedometer.
89589689|NCT02144285|Placebo Comparator|Placebo IV (Part A)|Single dose of placebo matching LY3113593 administered IV
89589690|NCT02144285|Experimental|LY3113593 SC (Part A)|Single dose of LY3113593 administered subcutaneous (SC)
89589691|NCT02144285|Placebo Comparator|Placebo SC (Part A)|Single dose of placebo matching LY3113593 administered SC
89589692|NCT02144285|Experimental|LY3113593 IV (Part B)|Single dose of LY3113593 administered IV
89589693|NCT02144285|Placebo Comparator|Placebo IV (Part B)|Single dose of placebo matching LY3113593 administered IV
89589694|NCT02117687|Active Comparator|OPTIVE FUSION™|1-2 drops OPTIVE FUSION™ (carboxymethylcellulose 0.5%/glycerin 0.9%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.
89589695|NCT02117687|Active Comparator|VISMED® Multi|1-2 drops VISMED® Multi (sodium hyaluronate 0.18%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.
89589696|NCT02143583||AllerT 100 μg|patients having received AllerT at a first dose of 50 μg and 4 maintenance doses of 100 μg in study AN004T
89589697|NCT02143583||AllerT 50 μg|patients having received AllerT at a first dose of 25 μg and 4 maintenance doses of 50 μg in study AN004T
89589698|NCT02143583||Placebo|Patients having received Placebo (i.e., adjuvant alone) delivered in the same manner as AllerT in study AN004T
89589699|NCT04742153|Experimental|MRG002|MRG002 will be administrated via intravenous infusion of 2.6 mg/kg once on Day 1 of every 3 weeks (21-day cycle).
89589700|NCT02105987|Experimental|ABC/DTG/3TC|Subject will take ABC 600 mg/DTG 50 mg/3TC 300 mg FDC once daily in the morning or the evening, at approximately the same time each day for 24 weeks. After Week 24, subjects will continue on this treatment arm for an additional 24 weeks.
89589701|NCT02105987|Active Comparator|Comparator|Subjects will continue on their current Combination antiretroviral therapy (cART) regimen for 24 weeks. At Week 24, subjects will switch to ABC/DTG/3TC FDC for an additional 24 weeks.
89589702|NCT04185623||Group A (immediate denudation)|Oocytes were denudated immediately after oocyte retrieval and were microinjected at 4 hours from ovum pickup. Microinjection was performed on all matured oocytes only and they were cultured to blastocyst stage.The rates of maturation, fertilization, good quality blastulation, chemical pregnancy and clinical pregnancy were analysed and compared between the two groups.
89589703|NCT04185623||Group B ( 2hs denudation after ovum pickup)|Oocytes were denudated 2 hours after retrieval and were microinjected at 4 hours from ovum pickup. Microinjection was performed on all matured oocytes only and they were cultured to blastocyst stage.The rates of maturation, fertilization, good quality blastulation, chemical pregnancy and clinical pregnancy were analysed and compared between the two groups.
88976673|NCT00164515|Experimental|Arm 2: Lower Support|The lower support group received arm 1 plus monthly newsletter, weekly personalized exercise support via telephone.
88976674|NCT00164515|Experimental|Arm 3: Higher support|The higher support group received arm 1 plus arm 2 plus a face-to-face monthly exercise support group.
88976675|NCT00164749|Placebo Comparator|Placebo|Color-matched placebo
88976676|NCT00164749|Experimental|1 gram|1 g/day curcumin
88976677|NCT00164749|Experimental|4 gram|4 g/day curcumin
88976678|NCT00164788|Active Comparator|IV Nexium|Intravenous bolus injection of esomeprazole (Astra Pharmaceutica AG, Dietikon, Switzerland) 80mg followed by continuous intravenous infusion of 8mg per hour for 24 hours
89589704|NCT02141633|Experimental|smokers|participants with smoking history ( > 10 pack/year) will be enrolled and perform airway blood flow and echocardiogram before and 15 minutes after albuterol inhalation
89589705|NCT02141633|Experimental|non-smokers|healthy life-time non smokers will be enrolled and perform airway blood flow and echocardiogram before and 15 minutes after albuterol inhalation
89589706|NCT01846611|Experimental|Arm A: trabectedin + DOXIL|Participants will receive DOXIL 30 millgram per meter square (mg/m^2) administered as an intravenous (IV) infusion over approximately 90 minutes followed by trabectedin 1.1 mg/m^2 administered as an IV infusion over approximately 3hours, every 3 weeks. Participants will be pretreated with 20 mg dexamethasone IV (or the IV equivalent) approximately 30 minutes before DOXIL study drug. As of Amendment 6, treatment with trabectedin will be discontinued for participants on treatment with trabectedin and no new participants will receive trabectedin. Participants who, in the opinion of the investigator, are deriving clinical benefit may continue treatment with single-agent DOXIL as per the local standard of care.
89589707|NCT01846611|Active Comparator|Arm B: DOXIL|Participants will receive DOXIL, 50 mg/m^2 administered as an IV infusion over approximately 90 minutes every 4 weeks.
89589708|NCT02141399|Experimental|ALKS 5461|
89589709|NCT04586673|Experimental|ChAdOx1.tHIVconsv1 low dose|3 participants will receive one dose of ChAdOx1.tHIVconsv1 at 5 x 10^9 vp
89589710|NCT04586673|Experimental|ChADOx1.tHIVconsv1 higher dose|10 participants will receive one dose of ChAdOx1.tHIVconsv1 at 5 x 10^10 vp and one dose each of MVA.tHIVconsv3 at 1 x 10^8 pfu and MVA.tHIVconsv4 at 0.9 x 10^8 pfu.
89589711|NCT01846299|Experimental|Ranibizumab|A 0.5 mg ranibizumab intravitreal injection was given to the study eye at baseline, and then as needed based on evidence of disease activity.
89589712|NCT01846299|Sham Comparator|Sham control|Sham injection was given to the study eye at baseline, and then treatment was given based on evidence of disease activity. At month 1, if treatment was needed, sham was administered. At month 2, participants switched to open-label ranibizumab on an as needed basis.
89589713|NCT01628393|Experimental|Ozanimod 0.5 mg|Participants received ozanimod 0.5 mg oral capsules daily for 24 weeks. Participants who completed the 24-week treatment period had the option to enter the blinded extension period and continue to receive ozanimod 0.5 mg weekly for another 96 weeks.
89589714|NCT01628393|Experimental|Ozanimod 1 mg|Participants received ozanimod 0.5 mg oral capsules daily for 24 weeks. Participants who completed the 24-week treatment period had the option to enter the blinded extension period and continue to receive ozanimod 1 mg weekly for another 96 weeks.
89589715|NCT01628393|Placebo Comparator|Placebo|Participants received placebo to ozanimod oral capsules daily for 24 weeks. Participants who completed the 24-week treatment period had the option to enter the blinded extension period and were randomized to receive ozanimod 0.5 mg or 1 mg weekly for 96 weeks.
89589716|NCT01846221|Experimental|Clonidine|Participants randomized to this arm of the study receive 100 micrograms clonidine with the bupivacaine in their epidural when requesting pain relief in advanced labor
89589717|NCT01846221|Experimental|Fentanyl|Participants randomized to this arm of study will receive 100 mcg fentanyl with the bupivacaine in their epidural when requesting pain relief in advanced labor
89589718|NCT01815099|Experimental|rTMS Treatment|Clinical participants will receive rTMS
89589719|NCT01845831|Experimental|Sitagliptin + glargine (Hospital)|Sitagliptin and glargine once daily + correction doses of aspart or lispro if needed
89589720|NCT01845831|Active Comparator|Basal bolus (Hospital)|Glargine once daily and rapid-acting insulin before meals + correction doses of aspart or lispro if needed
88976679|NCT00164788|Active Comparator|Oral Nexium|Oral esomeprazole (Astra Pharmaceutica AG, Dietikon, Switzerland) 40mg every 12 hours for 24 hours
88976680|NCT00053768|Active Comparator|CHOEP-21|"CHOEP-21-Schema:~Cyclophosphamid (750 mg/m2 i.v. d1), Doxorubicin (50 mg/m2 i.v. d1), Vincristin (2 mg i.v. d1), Etoposid (100 mg/m² i.v. d1-3), Prednison (100 mg p.o. d1-5)"
88976681|NCT00053768|Experimental|high CHOEP-21|"High-CHOEP-21-Schema:~Cyclophosphamid (1400 mg/m2 i.v. d1), Doxorubicin (32,5 mg/m2 i.v. d1+2), Vincristin (2 mg i.v. d1), Etoposid (175 mg/m² i.v. d1-3), Prednison (100 mg p.o. d1-5)"
88976682|NCT04724083||Fabry Disease subjects with cardiomyopathy|Patients (males and females) with confirmed Fabry disease, with clinical cardiac involvement based on results of structural imaging (cardiac echocardiography and MRI).
88976683|NCT04724083||Fabry Disease subjects without cardiomyopathy|Patients (males and females) with confirmed Fabry disease, without clinical cardiac involvement based on results of structural imaging (cardiac echocardiography and MRI).
88976684|NCT04724083||Healthy control|The control group will consist of age-and gender-matched healthy individuals.
88976685|NCT00164905|Active Comparator|Doppler ultrasound|
88976686|NCT00164905|No Intervention|No Doppler ultrasound|
88976687|NCT00164944||FDR of CRC patient|First degree relatives of patients having CRC
88976688|NCT00164944||FDR of normal colonoscopy|First degree relatives of patients having normal colonoscopy
88976689|NCT02969954|Experimental|Intervention arm|Study has one arm - who will all receive the intervention
89589721|NCT01845831|Experimental|Metformin and Sitagliptin|Patients with HbA1c ≤ 7% will be discharged on the combination of metformin and sitagliptin (Janumet ® 500/50 mg) twice daily for 6 months
89589722|NCT01845831|Experimental|Metformin and sitagliptin + glargine 50%|Patients with HbA1c between 7% and 9% will be discharged on metformin and sitagliptin (Janumet ® 500/50 mg) twice daily plus glargine insulin (50% of the inpatient glargine dose) for 6 months
89589723|NCT01845831|Experimental|Metformin and sitagliptin + glargine 80%|Patients with HbA1c > 9% will be discharged on metformin and sitagliptin (Janumet ® 500/50 mg) twice daily plus glargine insulin (80% of the inpatient glargine dose) for 6 months
89589724|NCT01627691|Experimental|Lotus Valve System|Patients enrolled will receive the Lotus Valve.
89589725|NCT01844895|Experimental|Abatacept (Autoinjector and Prefilled Syringe)|"Abatacept (prefilled syringe) 125 mg/device solution subcutaneously weekly for 3 months~Abatacept (autoinjector) 125 mg/device solution subcutaneously weekly for 1 month"
89589726|NCT02116361|Placebo Comparator|Placebo for onabotulinumtoxinA 50 U|Placebo (normal saline) for onabotulinumtoxinA 50 U injected into protocol-specified areas on Day 1.
89589727|NCT02116361|Experimental|onabotulinumtoxinA 50 U|OnabotulinumtoxinA 50 U injected into protocol-specified areas on Day 1.
89589728|NCT02116361|Placebo Comparator|Placebo for onabotulinumtoxinA 30 U|Placebo (normal saline) for onabotulinumtoxinA 30 U injected into protocol-specified areas on Day 1.
89589729|NCT02116361|Experimental|onabotulinumtoxinA 30 U|OnabotulinumtoxinA 30 U injected into protocol-specified areas on Day 1.
89589730|NCT02140775|Experimental|Behavioral Activation Counseling|Behavioral Activation counseling is a manualized intervention adapted from a behavioral activation treatment for depression (BAT-D) and provides a basic foundation for behavior change. The individual sessions last one hour and are scheduled every two weeks. The counseling offers a brief, structured approach to identifying and scheduling activities in life areas to reduce avoidant behavior and increase activity level with the goal of achieving employment or enroll in training.
89589731|NCT02140775|Active Comparator|Supportive Counseling|Supportive Counseling sessions will follow the same schedule and the Behavioral Activation Counseling, meeting for one hour every two weeks. The content of the sessions will be guided by the participant. The counselor will provide an accepting environment for the participant to explore his/her feelings about these topics.
89589732|NCT01844817|Experimental|OGX-427|Three loading doses of OGX-427 at 600mg IV will be administered Days -9 to -1. Following the loading dose period, OGX-427 will be administered at 600mg IV weekly Days 1, 8, 15, and 22 of each 28 day cycle during the Treatment Phase.
89589733|NCT01844817|Placebo Comparator|Placebo|Three loading doses of placebo will be administered Days -9 to -1. Following the loading dose period, placebo will be administered weekly Days 1, 8, 15, and 22 of each 28 day cycle.
89589734|NCT04594239|Experimental|Treatment, needle|
89589735|NCT04594239|Experimental|Treatment, cannula|
89589736|NCT04594239|Other|Untreated-control / delayed-treatment, needle|
89589737|NCT04594239|Other|Untreated-control / delayed-treatment, cannula|
89589738|NCT01814553|Experimental|Afatinib 40 mg + Loperamide (Cohort 1)|afatinib starting 40 mg daily; Cohort 1 will receive loperamide at first sign of diarrhea; Cohort 2 will receive loperamide starting C1D1.
89589739|NCT01814553|Experimental|Afatinib 40 mg + loperamide prophylactic (Cohort 2)|afatinib starting 40 mg daily; Cohort 1 will receive loperamide at first sign of diarrhea; Cohort 2 will receive loperamide starting C1D1.
89589740|NCT02116205|Experimental|Vaccine + Placebo at 1.0 mg|1.0 mg HTNV/PUUV DNA vaccine IM-EP via TriGrid™ Delivery System (TDS) on Study Day 0, 56 and 168. 1.0 mg placebo administration on Study Day 28.
89589741|NCT02116205|Experimental|Vaccine at 1.0 mg|1.0 mg HTNV/PUUV DNA vaccine IM-EP via TriGrid™ Delivery System (TDS) on Study Day 0, 28, 56 and 168.
89589742|NCT02116205|Experimental|Vaccine + Placebo at 2.0 mg|2.0 mg HTNV/PUUV DNA vaccine IM-EP via TriGrid™ Delivery System (TDS) on Study Day 0, 56 and 168. 2.0 mg placebo administration on Study Day 28.
89589743|NCT02116205|Experimental|Vaccine at 2.0 mg|2.0 mg HTNV/PUUV DNA vaccine IM-EP via TriGrid™ Delivery System (TDS) on Study Day 0, 28, 56 and 168.
89589744|NCT01844583|Experimental|Esomeprazole 40 mg + Alisertib 50 mg|"Alisertib 50 mg, tablets, orally, once on Day 1, followed by twice daily on Days 4 to 10, followed by a 14-day rest period in Cycle 1.~Esomeprazole, 40 mg, delayed-release capsules, orally, once daily on Days 1 to 10 plus alisertib, 50 mg, tablets, orally, once on Day 8, followed by twice daily on Days 11 to 17, followed by a 14-day rest period in Cycle 2.~Alisertib 50 mg, tablets, orally, twice daily on Days 1 to 7 beginning with Cycle 3 (21-day cycles) to the end of study (Up to 15 Cycles)."
89589745|NCT01844583|Experimental|Rifampin 600 mg + Alisertib 50 mg|"Alisertib 50 mg, tablets, orally, once on Day 1, followed by twice daily on Days 4 to 10, followed by a 14-day rest period in Cycle 1.~Rifampin 600 mg, capsules, orally, once daily on Days 1 to 10 in Cycle 2 plus alisertib, 50 mg, tablets, orally, once on Day 8, followed by twice daily on Days 11 to 17, followed by a 14-day rest period in Cycle 2.~Alisertib 50 mg, tablets, orally, twice daily on Days 1 to 7 beginning with Cycle 3 (21-day cycles) to the end of study (Up to 15 Cycles)."
89589746|NCT02115815|Placebo Comparator|Placebo|Sterile saline for human use from commercial source, liquid
89589747|NCT02115815|Experimental|RSV sF 20 mcg|Participants will receive single dose of 20 mcg RSV sF by intramuscular injection on Day 1.
88976690|NCT05411835|Active Comparator|Nutrition Ketogenic Supplement|The Ketone pre-exercise beverage is a nutritional supplement. The supplement will be provided by Nestle as powered sachets to mix in water. It contains a mix of D-beta-hydroxybutyrate salts, flavors and stevia.
88976691|NCT05411835|Sham Comparator|Isocaloric Placebo Supplement|The maltodextrin pre-exercise beverage is a nutritional supplement. The supplement will be provided by Nestle as powered sachets to mix in water. It contains an isocaloric amount of maltodextrin, flavors and stevia similar to the ketone beverage.
88976692|NCT00165178|Experimental|Individualized ASP dose|
88976693|NCT00165178|Active Comparator|Fixed dose ASP|
88976694|NCT00165178|Experimental|Dexamethasone|
88976695|NCT00165178|Active Comparator|Prednisone|
88976696|NCT05401968|Experimental|Intervention group|Osteoporosis patients who have participated in patient education
88976697|NCT05401968|No Intervention|Control group|Osteoporosis patients who have not participated in patient education
88976698|NCT00053885|Experimental|PTK787/ZK 222584|"Patients receive oral PTK787/ZK 222584 daily. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Patients are followed every 2 months for 1 year, every 4 months for 1 year, and then every 6 months for 1 year."
89589748|NCT02115815|Experimental|MEDI7510 (20 mcg RSV sF)|Participants will receive single dose of MEDI7510 (20 mcg RSV sF with 2.5 mcg glucopyranosyl lipid A [GLA] + 2% weight per volume stable emulsion) by intramuscular injection on Day 1.
89589749|NCT02115815|Experimental|RSV sF 50 mcg|Participants will receive single dose of 50 mcg RSV sF by intramuscular injection on Day 1.
89589750|NCT02115815|Experimental|MEDI7510 (50 mcg RSV sF)|Participants will receive single dose of MEDI7510 (50 mcg RSV sF with 2.5 mcg GLA + 2% weight per volume stable emulsion) by intramuscular injection on Day 1.
89589751|NCT02115815|Experimental|RSV sF 80 mcg|Participants will receive single dose of 80 mcg RSV sF by intramuscular injection on Day 1.
89589752|NCT02115815|Experimental|MEDI7510 (80 mcg RSV sF)|Participants will receive a single dose of MEDI7510 (80 mcg RSV sF with 2.5 mcg GLA + 2% weight per volume stable emulsion) by intramuscular injection on Day 1.
89589753|NCT02115269||primary headaches|Adults taking IndoProCaf for acute treatment of their primary headache attacks (migraine and/or episodic tension-type headache) as per routine clinical practice
89589754|NCT02115113|Experimental|Group A (Tacrolimus Elimination Arm)|At study start, participants received an Everolimus starting dose of 1.0 mg twice daily in combination with Tacrolimus. Tacrolimus was administered as per center practice. Thereafter, Everolimus doses were adjusted to achieve Everolimus C-0h blood trough levels between 3-8 ng/mL by week 1 after drug initiation until 5 months after transplant. At 5 months after transplant, Everolimus doses were adjusted to achieve C-0h blood trough level target ranges 6-10 ng/mL. Tacrolimus withdrawal was completed by 6 months after transplant.
89589755|NCT02115113|Active Comparator|Group B (Tacrolimus Minimization Arm)|At study start, participants received an Everolimus starting dose of 1.0 mg twice daily in combination with Tacrolimus. Tacrolimus was administered as per center practice. Thereafter, Everolimus doses were adjusted to achieve Everolimus C-0h blood trough levels between 3-8 ng/mL by week 1 after drug initiation until 5 months after transplant. At 5 months after transplant, Everolimus doses continued to be adjusted to achieve C-0h blood trough level target ranges 3-8 ng/mL and Tacorlimus doses were adjusted to achieve C-0h blood trough level target ranges 3-5 ng/mL.
88976699|NCT00053963|Experimental|Arm I|Patients receive FR901228 (depsipeptide) IV over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88976700|NCT00165763|Experimental|1|
88976701|NCT00165802|Experimental|1|
88976702|NCT04723693||individuals With Haemophilia A and with inhibitors on emicizumab|Qualitative interviews
88976703|NCT00165919||HCV+|No group or cohort; not a clinical trial
89589756|NCT02114879|Active Comparator|Standard of Care Rehabilitation|
89589757|NCT02114879|Experimental|Enhanced Medical Rehabilitation|
89589758|NCT02114177|Experimental|Arm 1 (Simeprevir/Sofosbuvir)|150 participants will receive 1 capsule of 150 mg simeprevir and 1 tablet of 400 mg sofosbuvir orally (by mouth) once daily for 12 weeks.
88976704|NCT00166075||Female ED patients|All eligible African American female patients were approached in the ED waiting room during study periods. Patients participated in the screening process via a computer kiosk. Questions regarding IPV and mental health symptoms were asked using validated tools
88976705|NCT00054041|Experimental|Arm I (HspE7)|Patients receive SGN-00101 subcutaneously once on weeks 1, 4, and 8 in the absence of disease progression. At week 15, all patients undergo large loop excision of the transformation zone under colposcopy.
88976706|NCT00054041|Experimental|Arm II (control)|Patients receive standard care. At week 15, all patients undergo large loop excision of the transformation zone under colposcopy.
88976707|NCT00166192|Active Comparator|Chemical Peel|Split face treatment paradigm
88976708|NCT00166231||Chest pain patients|
89589759|NCT02114177|Experimental|Arm 2 (Simeprevir/Sofosbuvir)|150 participants will receive 1 capsule of 150 mg simeprevir and 1 tablet of 400 mg sofosbuvir orally once daily for 8 weeks.
88976709|NCT00166231||Murmur group|
88976710|NCT00166270|Experimental|1|
88976711|NCT00054119|Experimental|Treatment|Patients receive karenitecin IV over 1 hour on days 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
88976712|NCT00166387||Phase I, II, III|Phase I consists of a brother pair with hemophilia, one or both of whom has a history of inhibitors, and their parents; Phase II consists of a person with hemophilia and an inhibitor, and both his parents; Phase III consists of an unrelated group of people with hemophilia.
88976713|NCT00045396|Experimental|Treatment (tipifarnib)|Patients receive oral tipifarnib twice daily on days 1-14. Treatment repeats every 21 days for up to 16 courses in the absence of disease progression or unacceptable toxicity.
88976714|NCT00054236|Experimental|non-myeloablative conditioning regimen|
88976715|NCT00166699|No Intervention|Palpation|Use of palpation to guide the the insertion site of combined spinal epidural needle in obese parturients
88976716|NCT00166699|Experimental|ultrasound|The use of ultrasound to guide the insertion of a combined spinal epidural needle
88976717|NCT04723732|Experimental|Myrrh mouthwash|1% mouthwash of Commiphora myrrha made from resin extract. Participants will use 10 ml of the mouthwash twice daily for 14 days.
88976718|NCT04723732|Active Comparator|Chlorhexidine Mouthwash|Commercial 0.2% Chlorhexidine gluconate mouthwash (Avalon Pharma, Riyadh). Participants will use 10 ml of the mouthwash twice daily for 14 days.
88976719|NCT04723732|Placebo Comparator|Normal saline|Commercial 0.9% sodium chloride solution (Pharmaceutical solutions industry, Jeddah). Participants will use 10 ml of the mouthwash twice daily for 14 days.
89589760|NCT02138825|Experimental|Riociguat (Adempas, BAY63-2521)|In the main study treatment phase participants received Riociguat titrated to optimal dose within range of 0.5 mg TID (3 times a day) to 2.5 mg TID for 10 weeks followed by maintenance period of 16 weeks. This phase was followed by a long-term extension phase, which included a blinded sham titration phase of 10 weeks followed by an open-label extension phase. During the open-label extension phase participants were to be treated with Riociguat until commercial access in the indication of pulmonary hypertension (PH) associated with idiopathic interstitial pneumonias (IIP) or until an agreed time point is defined with the individual country, local regulatory authority and the Sponsor's global team.
89589761|NCT02138825|Placebo Comparator|Placebo|In the main study treatment phase participants received sham titration within range of 0.5 mg TID to 2.5 mg TID for 10 weeks followed by maintenance period of 16 weeks. This phase was followed by a long-term extension phase, which included a blinded titration phase to optimal dose of Riociguat of 10 weeks followed by an open-label extension phase. During the open-label extension phase participants were to be treated with Riociguat until commercial access in the indication of PH associated with IIP or until an agreed time point is defined with the individual country, local regulatory authority and the Sponsor's global team.
89589762|NCT02138747|Experimental|AB: Mirabegron/Tolterodine ER|In the treatment sequence AB participants received 25 mg of mirabegron (Myrbetriq) oral controlled absorption system (OCAS) modified-release tablets and 4 mg of placebo-to-match (PTM) tolterodine ER (Detrol LA) orally once a day during period 1. In the period 2, participants received 4 mg of tolterodine ER and 25 mg of PTM mirabegron orally once a day. Four weeks after the start of each 8-week treatment period, 25 mg of mirabegron or mirabegron PTM was increased to 50 mg for the remainder of the treatment period.
89589763|NCT02138747|Experimental|BA: Tolterodine ER /Mirabegron|In the treatment sequence BA participants received 4 mg of tolterodine ER and 25 mg of PTM mirabegron (OCAS) modified-release tablets orally once a day during period 1. In the period 2, participants received 25 mg of mirabegron and 4 mg of PTM tolterodine ER orally once a day. Four weeks after the start of each 8-week treatment period, 25 mg of mirabegron or mirabegron PTM was increased to 50 mg for the remainder of the treatment period.
89589764|NCT02138747|Experimental|AA: Mirabegron/Mirabegron|In treatment sequence AA participants received 25 mg of mirabegron and PTM tolterodine ER 4 mg capsules during period 1 and 2 orally once a day. Four weeks after the start of each 8-week treatment period, 25 mg of mirabegron was increased to 50 mg for the remainder of the treatment period.
89589765|NCT02138747|Experimental|BB: Tolterodine ER /Tolterodine ER|Participants received 4 mg of tolterodine ER and PTM mirabegron 25 mg OCAS modified-release tablets orally once a day during period 1 and period 2.
89589766|NCT02105285|Experimental|OPC-1085EL ophthalmic solution|Once daily
89589767|NCT02105285|Active Comparator|Carteolol long-acting ophthalmic solution|Once daily
89589768|NCT02104895|Active Comparator|Whole breast irradiation (WBI)|Conventional whole breast irradiation (WBI)
89589769|NCT02104895|Experimental|Partial breast irradiation (APBI)|Accelerated partial breast irradiation (APBI)
89589770|NCT01621490|Experimental|Part 1-Cohort 1 and 2: Nivolumab|Nivolumab 3 mg/kg solution intravenously Every 2 weeks, Up to 2 years depending on response
89589771|NCT01621490|Experimental|Part 2-Arm A: Nivolumab + Ipilimumab|Nivolumab 1 mg/kg combined with Ipilimumab 3 mg/kg solution intravenously and then Nivolumab 3 mg/kg solution intravenously as specified
89589772|NCT01621490|Experimental|Part 3-Arm A: Nivolumab + Ipilimumab|Nivolumab 1 mg/kg combined with Ipilimumab 3 mg/kg solution intravenously and then Nivolumab 3 mg/kg solution intravenously as specified
89589773|NCT01621490|Experimental|Part 3-Arm B: Nivolumab|Nivolumab 3 mg/kg solution intravenously as specified
89589774|NCT01621490|Experimental|Part 4-Arm D: Nivolumab + Ipilimumab|Nivolumab 1 mg/kg combined with Ipilimumab 3 mg/kg solution intravenously and then Nivolumab 3 mg/kg solution intravenously as specified
89589775|NCT01621490|Experimental|Part 4-Arm E: Nivolumab|Nivolumab 3 mg/kg solution intravenously as specified
89589776|NCT02018887|Experimental|LY2969822 (Part A)|Single dose of LY2969822 administered orally in 2 of 3 study periods.
89589777|NCT02018887|Placebo Comparator|Placebo (Part A)|Single dose of placebo administered orally in 1 of 3 study periods.
89589778|NCT02018887|Experimental|LY2969822 (Part B)|LY2969822 administered orally for 14 days.
89589779|NCT02018887|Placebo Comparator|Placebo (Part B)|Placebo administered orally for 14 days.
89589780|NCT02018887|Experimental|LY2969822 (Part C)|LY2969822 administered orally for 14 days.
89589781|NCT02018887|Placebo Comparator|Placebo (Part C)|Placebo administered orally for 14 days.
89589782|NCT02030041|Experimental|Simvastatin and placebo|"Eleven participants will be vitamin D deficient with LDL-C between 100 to 130mg/dl.~This arm will receive Simvastatin 40 mg once daily and placebo once weekly, and will perform moderate intensity exercise for twelve weeks. Participants will be advised to walk a minimum of 3000 steps in 30 minutes on 5 days each week"
88976720|NCT00054431|Experimental|Treatment (imatinib mesylate, decitabine)|Patients receive oral imatinib mesylate daily and decitabine IV over 1 hour daily, 5 days per week, for 2 consecutive weeks. Courses repeat every 4-6 weeks in the absence of disease progression or unacceptable toxicity.
88976721|NCT05220852|Experimental|Dry needling and exercise|Subjects in this group will undergo one session of dry needling in their upper trapezius muscles to address any overactive trigger points, and they will subsequently continue with neck exercises for a minimum of two weeks, three times per week.
88976722|NCT05220852|Active Comparator|Exercise|subjects in this group will have neck exercise only for 2 weeks minimum 3 times a week.
88976723|NCT00167167|Experimental|BMT patients|All patients treated.
89209899|NCT00891696|Active Comparator|Exp 2: LExFR + Rap|Participants will receive rapamycin and will undergo low-intensity resistance exercise with blood flow restriction.
89589783|NCT02030041|Active Comparator|Simvastatin and vitamin D|"Eleven participants will be vitaminD deficient with LDL-C between 100 to 130mg/dl.~This arm will receive simvastatin 40 mg once daily and vitaminD 60,000 units once weekly , and will perform moderate intensity exercise for twelve weeks. Participants will be advised to walk a minimum of 3000 steps in 30 minutes on 5 days each week"
89589784|NCT02030041|Active Comparator|Vitamin D and placebo|Eleven participants will be vitamin D deficient with LDL-C between 100 to 130mg/dl This arm will receive vitamin D 60,000 units once weekly and placebo once daily, and will perform moderate intensity exercise for twelve weeks. Participants will be advised to walk a minimum of 3000 steps in 30 minutes on 5 days each week
89589785|NCT01994720|Experimental|ticagrelor|
89589786|NCT01994720|Active Comparator|Acetylsalicylic acid (ASA)|
89589787|NCT01814007|Experimental|CoolSculpting Treatment Group|CoolSculpting treatments will be performed on all subjects with 1 cooling cycle on the lower abdomen, plus simultaneous treatment of both flanks, one cooling cycle each. Two control units will be utilized at protocol-defined temperatures and durations.
89589788|NCT01844115|Placebo Comparator|Placebo|Dose-matched placebo tablets, oral administration
89589789|NCT01844115|Experimental|Vilazodone|Vilazodone tablets, oral administration
89589790|NCT02018042|Experimental|Abatacept|Patients will be treated with abatacept 125mg subcutaneous (SC) self-administered each week. Treatment will be continued for 6 months to provide adequate time to assess the short-term efficacy and safety of abatacept in patients with alopecia areata. Patients will then be followed for an additional 6 months to assess the timing and incidence of relapse.
89589791|NCT04667390|Active Comparator|total knee arthroplasty using the active robotic system|total knee arthroplasty using the active robotic surgical system TSolution One TCAT, and system for planning TPlan
89589792|NCT04667390|Active Comparator|total knee arthroplasty using computer navigation|Primary total knee arthroplasty using computer navigation and intraoperation control system
89589793|NCT04667390|Active Comparator|total knee arthroplasty using the standard manual tekhnik|Primary total knee arthroplasty using the standard recommended set of instruments
89589794|NCT01813305|Active Comparator|CSTC1|CSTC1 (vapor fraction from seeds of Glycine max (L.) Merr. and composition thereof), topical, two times daily
89589795|NCT01813305|Placebo Comparator|CSTC1 Matched vehicle|Matched vehicle, topical, two times daily
89589796|NCT01993940|Experimental|Naldemedine|Participants received 0.2 mg naldemedine orally once daily for 12 weeks.
89589797|NCT01993940|Placebo Comparator|Placebo|Participants received matching placebo orally once daily for 12 weeks.
89589798|NCT01843803|Experimental|patient inventory tool|prior to the encounter with his/her provider, the patient completes an inventory that includes information about patient contextual factors (e.g., life circumstances), resources and preferences for care delivery. This information is presented to the provider to facilitate care delivery.
89589799|NCT01843803|Active Comparator|attention control|prior to the encounter, the patient will view a brief video containing general health information.
89589800|NCT02017171|Experimental|Allopurinol|Oral allopurinol at a dose of 100 mg per day for 4 weeks and then at a dose ranging from 200 to 400 mg per day depending on kidney function
89589801|NCT02017171|Placebo Comparator|Placebo|Oral placebo tablets
89589802|NCT04686097|Experimental|experimental group (electrocoagulation)|Participants in the experimental group will receive ultrasound-guided puncture of coagulation incompetent perforator veins.
89589803|NCT04686097|Active Comparator|control group (sclerotherapy)|Participants in the control group will receive an ultrasound-guided sclerosing agent injected.
89589804|NCT02029417|Experimental|Treatment (cytarabine, omacetaxine mepesuccinate, decitabine)|"INDUCTION CHEMOTHERAPY: Patients receive cytarabine SC BID and omacetaxine mepesuccinate SC BID on days 1-14. Treatment for induction therapy repeats every 28 days for up to 4 courses or until patients achieve CR in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION THERAPY: Patients alternate courses between decitabine and OAG. Patients receive decitabine IV on days 1-5. Patients alternate with OAG courses, comprising cytarabine SC BID on days 1-7 and omacetaxine mepesuccinate SC BID on days 1-7. Treatment repeats every 28 days for up to 24 months in the absence of disease progression or unacceptable toxicity."
89589805|NCT02016716|Experimental|Romosozumab 90 mg/mL|Participants received 210 mg romosozumab monthly, administered as 2 subcutaneous (SC) 1.17 mL injections of a 90 mg/mL solution, for 6 months.
89589806|NCT02016716|Experimental|Placebo 90 mg/mL|Participants received matching placebo administered as 2 subcutaneous injections of 1.17 mL every month for 6 months.
89589807|NCT02016716|Experimental|Romosozumab 70 mg/mL|Participants received 210 mg romosozumab monthly, administered as 3 subcutaneous 1.0 mL injections of a 70 mg/mL solution, for 6 months.
89589808|NCT02016716|Placebo Comparator|Placebo 70 mg/mL|Participants received matching placebo administered as 3 subcutaneous injections of 1.0 mL every month for 6 months.
89589809|NCT02050321|Experimental|Acitretin and Vemurafenib|Vemurafenib is self-administered at a dose of 960 mg (four 240 mg tablets) twice daily. The first dose should be taken in the morning and the second dose should be taken in the evening approximately 12 hours later. Each dose can be taken with or without a meal. Acitretin will initially be dosed at 25 mg orally per day with dosing altered every two weeks with a 50 mg dose.
89030693|NCT02275910|Experimental|E7090 Arm|Oral, starting dose 1 mg once a day, dose escalation in part 1. Cycle 0 is for 7 days. For Cycle 1 and onward, each cycle is 28 days long. The Cycle 0 is set up for PK analysis of a single dose of E7090. In the following Cycle 1, subjects will be administered E7090 QD, and the PK and safety will be assessed for 28 days. One or two doses may be selected from part 1 for Part 2. E7090 will be administered continuously once a daily. Subjects can continue treatment unless they meet discontinuation criteria.
89589810|NCT02039414||Obese, Inactive|Pregnant women with a BMI≥30kg/m2 and sedentary lifestyle
89589811|NCT02039414||Obese, Active|Pregnant women with a BMI≥30kg/m2 and exercising >150min/week
89589812|NCT02017015|Experimental|nab-paclitaxel with gemcitabine|nab-paclitaxel at 125 mg/m^2, intravenous (IV) infusion over 30 to 40 minutes followed by gemcitabine at 1000 mg/ m^2 IV infusion over 30 to 40 minutes given once weekly for 3 weeks (Days 1, 8 and 15) followed by a week of rest (28 day cycle).
89589813|NCT02016625|Experimental|1 Cyclosporine + Faldaprevir|
89589814|NCT02016625|Experimental|2 Tacrolimus + Faldaprevir|
89608458|NCT01278550||Average risk cohort|Patients having no history of endoscopically confirmed ulcer bleeding, need long-term aspirin for cardiovascular or cerebrovascular prophylaxis and have H. pylori positive OR negative
88976724|NCT00054548|Experimental|Treatment (oblimersen sodium, paclitaxel)|"Patients receive oblimersen IV continuously on days 1-7 and paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 4. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of oblimersen until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.~An additional cohort of 12-15 patients receives treatment as above with oblimersen at the MTD."
88976725|NCT00167362|Experimental|1|Participants will receive cognitive enhancement therapy
88976726|NCT00167362|Placebo Comparator|2|Participants will receive enriched supportive therapy
89589815|NCT02016482|Active Comparator|Adalimumab (ADA)|Period A: ADA 40 mg subcutaneous every other week (sc eow) for 25 weeks starting 1 week after initial loading dose of 80 mg. Period B: Placebo at Week 26 followed by ADA 40 mg sc eow from Week 27 through Week 51.
89589816|NCT02016482|Placebo Comparator|Placebo|Period A: Placebo sc eow for 25 weeks. Period B: ADA 80 mg sc at Week 26 followed by ADA 40 mg sc eow from Week 27 through Week 51.
89589817|NCT02028871|Active Comparator|Intranasal Insulin First|Intranasal Insulin First, Placebo Second
89589818|NCT02028871|Placebo Comparator|Placebo First|Placebo First, Intranasal Insulin Second
89589819|NCT02028715|Placebo Comparator|Experimental (Normal Saline)|Morphine patient-controlled-anesthesia (PCA) for the initial 24 hours post-operation with a low-dose basal rate (0.5mg/hr) and patient administered boluses prn. Oral oxycodone from 24-48 hours post-operation will be used prn for pain and then patients will be transitioned to oral combined oxycodone/acetaminophen for the remainder of their hospital stay. Normal saline 100cc IV will be infused as placebo every 6 hours for a total of eight doses with the first dose being given at time of anesthesia induction.
89589820|NCT02028715|Active Comparator|Experimental (IV Acetaminophen)|Morphine PCA for the initial 24 hours post-operation with low-dose basal rate (0.5mg/hr) with patient administered boluses prn. IV acetaminophen 1,000mg will be given every six hours for a total of eight doses with the first dose being given at time of anesthesia induction. Oral oxycodone from 24-48 hours post-operation will be used prn and then patients will be transitioned to oral combined oxycodone/acetaminophen for the remainder of their hospital stay.
89589821|NCT02016170|Experimental|Ticagrelor 180mg|Patients on prasugrel will switch to ticagrelor with a 180mg loading dose
89589822|NCT02016170|Experimental|Ticagrelor 90mg|Patients on prasugrel will switch to ticagrelor with a 90mg maintenance dose
89589823|NCT02016170|Active Comparator|Prasugrel 10mg|Patients already on prasugrel, will maintain prasugrel
89589824|NCT02028169||Participants Receiving Anti-TNF for PsA|Participants who are actively working (full-time or part-time) with rheumatologist-confirmed PsA for which the physician has initiated treatment with an anti-TNF.
89589825|NCT02015546|Experimental|Vilazodone 10mg|Vilazodone 10 mg/d arm (10mg/d initiation dose, titrated to 40 mg/d in 2 weeks, continued for 8 week trial)
89589826|NCT02015546|Experimental|Vilazodone 20mg|vilazodone 20 mg arm (20mg/d initiation dose, titrated to 40 mg/d in 1 week, continued for 8-week trial)
89589827|NCT02015546|Experimental|Vilazodone 40mg|vilazodone 40 mg/d arm (40 mg/d initiation and continuation dose for 8-week trial.
89589828|NCT02027701|Experimental|IgPro20|20% liquid formulation (200 mg/mL) of human normal immunoglobulin for SC use administered SC weekly: 0.2 g/kg bw (low-dose IgPro20) for up to 48 weeks. Subjects who experience CIDP relapse on 0.2 g/kg IgPro20 will have an increase to 0.4 g/kg IgPro20 immediately and will continue on high-dose until they have completed a total of 48 weeks of IgPro20 treatment.
89589829|NCT02038790|Experimental|Suboxone sublingual film 8/2|Participants took a single dose of Suboxone sublingual film 8/2 either on Day 0 or Day 1, depending on the how each participant was randomized in this cross-over study.
89589830|NCT02038790|Active Comparator|Zubsolv sublingual tablets 5.7/1.4|Participants took a single dose of Zubsolv sublingual tablets 5.7/1.4 either on Day 0 or Day 1, depending on the how each participant was randomized in this cross-over study.
89589831|NCT04693286|Active Comparator|Vaccine candidate arm|In this arm, participants will get nOPV2 vaccine candidate 1
89589832|NCT04693286|Placebo Comparator|Placebo arm|In this arm, participants will get inactive substance like sucrose in BME media and buffer.
89589833|NCT02027623|Experimental|Motor skill training|The motor skill training condition involves supervised, massed practice of novel, challenging functional activities that are difficult or painful for the participant to perform due to his low back pain.
89589834|NCT02027623|Active Comparator|Strength and flexibility exercise|The strength and flexibility exercise condition involves performance of 1) strengthening exercises that target all trunk muscles, and 2) flexibility exercises that target all trunk and lower extremity motions.
89589835|NCT04684381|Experimental|L-glutamine|Pharmacokinetic characteristics of L-glutamine
89589836|NCT02015221|Experimental|ACTitouch|ACTitouch in sustained gradient compression mode during all waking hours (at least 10 hours per day) and intermittent pneumatic compression mode for 2 hours each day.
89589837|NCT02015221|Active Comparator|Standard Compression Garments|Standard Compression Garments of compression levels 30mmHg to 40mmHg during all waking hours each day.
88976727|NCT00054587|Active Comparator|6 FEC|Patients receive fluorouracil IV, or epirubicin IV, and cyclophosphamide IV on day 1. Treatment repeats every 3 weeks for 6 courses. Patients then undergo radiotherapy 5 days a week for 5 weeks.
89030694|NCT00521508|Other|1|Patient affected by Berger's disease confirmed by renal biopsy with increased rate of Ig A
89589838|NCT04678843|Experimental|Virtual Family-Based Treatment|Family-based treatment is the gold standard treatment for youth and adolescents with anorexia nervosa. A therapist works with the family to help parents take charge of the process of re-feeding their child, and with progress this control is gradually given back to the youth/adolescent. Other developmental issues are discussed in order to help the youth/adolescent get back to normal development.
89589839|NCT02027311|Experimental|Etomidate|This cohort would be administered etomidate with meperidine. The initial dose of etomidate is 0.1mg/kg IV and meperidine, 25mg. Additional dose of etomidate is 2mg(1cc). In old age cased, more than 65 years old, 30% of initial dose discounted.
89589840|NCT02027311|Experimental|Midazolam|This cohort would be administered midazolam with meperidine. The initial dose of midazolam is 0.06mg/kg IV and meperidine 50mg IV. Additional dose is 1mg of midazolam. In the elders, more than 65 years old, initial dose was declined to 70%.
89589841|NCT02047903||Afatinib|
89589842|NCT02015065|Experimental|Vandetanib in Children|Children with measurable localized or metastatic wt-GIST
89589843|NCT02015065|Experimental|Vandetanib in Adults|Adults with measurable localized or metastatic wt-GIST
89589844|NCT02026141|Experimental|Dexmedetomidine arm|"Standardized pre-op meds and spinal anesthetic.~Once the patient's spinal is performed, patient will receive the following:~Start with bolus of 0.5micrgram/kg over 10 minutes, and then infusion of 0.5 microgram/kg/hr~Infusion will be stopped after the last staple or suture is performed on the incision.~Both groups will have a midazolam 0.5mg prn q 5minutes to be used as a rescue to achieve moderate sedation as defined by ASA."
89589845|NCT02026141|Placebo Comparator|Saline Placebo|"Patients will receive the standardized pre-op meds and spinal anesthetic. Once the spinal anesthetic is performed,~Patient will receive the same infusion rates as in the Dexmedetomidine arm, however with Normal Saline as a Placebo.~midazolam 0.5mg prn q 5minutes to be used as a rescue to achieve moderate sedation."
89589846|NCT02026063|Experimental|250 mg Telotristat Etiprate|One telotristat etiprate (250 mg) tablet administered three times daily.
89589847|NCT02026063|Experimental|500 mg Telotristat Etiprate|Two telotristat etiprate (250 mg) tablets administered three times daily.
89589848|NCT02025907|Experimental|Canagliflozin (JNJ-28431754)|Each participant will receive canagliflozin (JNJ-28431754) 100 mg once daily during the first 6 weeks, then the dose may be increased to 300 mg once daily.
89589849|NCT02025907|Placebo Comparator|Placebo|Each participant will receive placebo (inactive medication) once daily for 28 weeks.
89589850|NCT01813071|Experimental|Part A (Adults): Cohort A1|One oral dose of ~3x10^4 cfu WRSS1(10 participants) or placebo (3 participants)
89589851|NCT01813071|Experimental|Part A (Adults): Cohort A2|Three oral doses of ~3x10^5 cfu WRSS1(10 participants) or placebo (3 participants)
89589852|NCT01813071|Experimental|Part A (Adults): Cohort A3|Three oral doses of ~3x10^6 cfu WRSS1(10 participants) or placebo (3 participants)
89589853|NCT01813071|Experimental|Part B (Children): Cohort B1|One oral dose of ~3x10^3 cfu WRSS1(12 participants) or placebo (4 participants)
89589854|NCT01813071|Experimental|Part B (Children): Cohort B2|Three oral doses of ~3x10^4 cfu WRSS1(12 participants) or placebo (4 participants)
89589855|NCT01813071|Experimental|Part B (Children): Cohort B3|Three oral doses of ~3x10^5 cfu WRSS1(12 participants) or placebo (4 participants)
89589856|NCT01813071|Experimental|Part B (Children): Cohort B4|Three oral doses of ~3x10^6 cfu WRSS1(12 participants) or placebo (4 participants)
89589857|NCT02025751|Experimental|Metoclopramide Nasal Spray|Metoclopramide Nasal Spray 10 mg, 30 minutes before meals and at bedtime (QID) for 4 weeks
89589858|NCT02025751|Placebo Comparator|Placebo Nasal Spray|Placebo Nasal Spray 30 minutes before meals and at bedtime (QID) for 4 weeks
89589859|NCT02025205|Experimental|ELVR with Endobronchial Valves|Endoscopic Lung Volume Reduction with Zephyr Endobronchial Valve
88976728|NCT00054587|Experimental|6 DE|Patients receive epirubicin IV over 10 minutes and docetaxel IV over 1 hour on day 1. Treatment repeats every 3 weeks for 6 courses. Patients then undergo radiotherapy as in arm I
88976729|NCT00167557|Experimental|Single Arm Study|
88976730|NCT00167596|Experimental|1|Early goal directed therapy based on StO2 evaluation
88976731|NCT00167596|Active Comparator|2|Early goal directed therapy
88976732|NCT00167635|Experimental|1|Face-to-Face Individualized Comprehensive Self-Management (CSM-FF) Group. Participants in the individualized CSM-FF group will be scheduled for 9 weekly sessions with the nurse therapist followed by post-intervention follow-up assessment.
89030695|NCT00521508|Other|2|Patient affected by Berger's disease with normal rate of Ig A
89030696|NCT00521508|Other|3|Healthy volunteers
89030697|NCT00506012|Experimental|1|T2000
89589860|NCT02025205|No Intervention|Standard of Care|Patients will receive optimal drug therapy and medical management according to clinical practice.
89589861|NCT01812837|Experimental|20 minutes incubation - with pretreatment|
89589862|NCT01812837|Experimental|40 minutes incubation - with pretreatment|
89589863|NCT01812837|Experimental|60 minutes incubation - with pretreatment|
89589864|NCT01812837|Sham Comparator|60 minutes incubation - no pretreatment|
89589865|NCT02024971||Pioglitazone/Metformin Hydrochloride|Pioglitazone/metformin hydrochloride combination tablets, orally, for 12 months as prescribed by the standard of care.
89589866|NCT01843023|Experimental|Extended Release Naltrexone|Participants randomly assigned to XR-NTX who do not have opioid withdrawal signs or symptoms within 4 hours of administration of the 25 mg oral dose naltrexone will be given an intramuscular injection of XR-NTX [Vivitrol®] at a dose of 4cc (380mg of naltrexone)] and will subsequently have the same dose administered to alternating sides of the buttocks every four weeks for up to 6 months. All participants will also receive psychosocial treatment.
89589867|NCT01843023|Active Comparator|Treatment as Usual|Participants randomly assigned to TAU will participate in the standard youth opioid program at the treatment center which includes either buprenorphine taper or ongoing buprenorphine treatment during the 6 months of the study for as long as they and their physicians think is appropriate. The general target dose will be 12-20 mg buprenorphine per day. All participants in TAU will receive psychosocial treatment.
89589868|NCT01812759|Experimental|Fentanyl Nasal Spray + Hydromorphone PCA|Fentanyl 100 mcg nasal spray administered plus hydromorphone PCA. All study patients receive demand dosing patient-controlled analgesia (PCA) with intravenous hydromorphone. Initial loading dose 0.2 mg with demand doses of 0.2 mg and lockout interval of 15 minutes. There will be no basal dose and the 8-hour dose limit will be 6.4 mg.
89589869|NCT01812759|Experimental|Placebo Nasal Spray + Hydromorphone PCA|Placebo nasal spray administered plus hydromorphone PCA . All study patients receive demand dosing patient-controlled analgesia (PCA) with intravenous hydromorphone. Initial loading dose 0.2 mg with demand doses of 0.2 mg and lockout interval of 15 minutes. There will be no basal dose and the 8-hour dose limit will be 6.4 mg.
89589870|NCT01812057|Experimental|Dexamethasone|Dexamethasone 8 mg IV given intraoperatively as a one-time dose.
89589871|NCT01812057|Placebo Comparator|Placebo|Sodium chloride 0.9% (5 ml) given IV intraoperatively as a one time dose.
89030698|NCT04693728|Active Comparator|Behavioral Intervention|The study intervention arm was a behavioral treatment that consisted of training resilient intrinsic self-regulation strategies to help alleviate chronic pain.
89589872|NCT01842633|Experimental|Paracetamol/ Caffeine Caplets|Two caplets of paracetamol/caffeine combination plus 2 placebo caplets to be administered
89589873|NCT01842633|Active Comparator|Ibuprofen Caplets|Two ibuprofen caplets plus two placebo caplets to be administered
89589874|NCT01842633|Placebo Comparator|Placebo Caplets|Four placebo caplets to be administered
89589875|NCT01810263|Experimental|high protein supplement|high protein supplement given
89589876|NCT01810263|No Intervention|Control|no intervention
89589877|NCT01841697|Experimental|Omarigliptin 25 mg once weekly|Participants receive omarigliptin 25 mg once a week plus placebo to sitagliptin once daily for 24 weeks. Participants continue pre-study stable dose of metformin (total daily dose ≥1500 mg) throughout the study. Participants may receive glimepiride (total daily dose of 1-6 mg) as rescue therapy.
89589878|NCT01841697|Active Comparator|Sitagliptin 100 mg once daily|Participants receive sitagliptin 100 mg once daily plus placebo to omarigliptin once a week for 24 weeks. Participants continue pre-study stable dose of metformin (total daily dose ≥1500 mg) throughout the study. Participants may receive glimepiride (total daily dose of 1-6 mg) as rescue therapy.
89589879|NCT01841073|Experimental|Inulin|Subject will take 10g inulin for 2 weeks, 20g of inulin for the next 2 weeks and then 30g for the remainder of the investigations.
89589880|NCT01841073|Placebo Comparator|Cellulose|Subjects will take 10g cellulose a day for 2 weeks, followed by 20g a day for 2 weeks, then 30g a day for the rest of the study.
89589881|NCT01809327|Experimental|Canagliflozin 100 mg|Participants will receive one 100 mg canagliflozin capsule before the morning meal and one matching placebo capsule with the evening meal plus placebo tablets with the evening meal (to match the metformin XR tablets administered in other treatment arms) for 26 weeks.
89589882|NCT01809327|Experimental|Canagliflozin 300 mg|Participants will receive one 300 mg canagliflozin capsule before the morning meal and one matching placebo capsule with the evening meal plus placebo tablets with the evening meal (to match the metformin XR tablets administered in other treatment arms) for 26 weeks.
89589883|NCT01809327|Experimental|Metformin XR|Participants will receive metformin XR tablets (in doses titrated over 9 weeks) once daily with the evening meal, plus one placebo capsule before the morning meal and one placebo capsule with the evening meal (to match the canagliflozin capsules administered in other treatment arms) for 26 weeks.
89589884|NCT01809327|Experimental|Canagliflozin 100 mg + Metformin XR|Participants will receive one 100 mg canagliflozin capsule with the evening meal and one matching placebo capsule before the morning meal plus metformin XR tablets (in doses titrated over 9 weeks) once daily with the evening meal for 26 weeks.
89589885|NCT01809327|Experimental|Canagliflozin 300 mg + Metformin XR|Participants will receive one 300 mg canagliflozin capsule with the evening meal and one matching placebo capsule before the morning meal plus metformin XR tablets (in doses titrated over 9 weeks) once daily with the evening meal for 26 weeks.
89589886|NCT03272139|Experimental|interscalene block (ISB)|The interscalene block will be done using an ultrasound-guided, in-plane approach. The anesthesiologists will target below the C5 nerve root. A 22 gauge 1.5-2 inch needle is advanced in-plane from lateral to medial through the middle scalene muscle until the needle tip is positioned in the interscalene groove between the C5 and C6 nerve roots. 15 20 ml of 0.5% bupivacaine will be injected.
89589887|NCT03272139|Experimental|superior trunk block (STB)|The superior trunk block will be performed at the point immediately distal to the roots when the c5-c6 form the superior trunk and lies anterior to the middle scalene muscle and below the deep cervical fascia, before the suprascapular nerve arises and goes into the omohyoid. A 22g 1.5-2inch needle will be advanced in-plane from lateral to medial. The needle tip will be placed lateral to the superior trunk and 15 20 ml of 0.5% bupivacaine will be injected just inferior to the deep cervical fasica. Local circumferential spread will be achieved both anterior and posterior to the superior trunk.
89589888|NCT01808313|Experimental|ambrisentan|ambrisentan 5 mg will be administered to eligible subjects for 12 weeks
89589889|NCT01840605|Experimental|TAU-284|Two TAU-284 5mg tablets and one ketotifen fumarate dry syrup 1g placebo will be taken orally twice a day, once after breakfast and once before bed.
89589890|NCT01840605|Active Comparator|ketotifen fumarate|Two TAU-284 5mg placebo tablets and one ketotifen fumarate dry syrup 1g will be taken orally twice a day, once after breakfast and once before bed.
89589891|NCT04593381|Experimental|SBRT treatment|Intervention: Radiation: SBRT
89589892|NCT02023879|Placebo Comparator|Placebo Q2W|"Period 1: Placebo (for Alirocumab) subcutaneous (SC) injection every 2 weeks (Q2W) added to stable non-statin lipid modifying therapy (LMT) or diet alone for 24 weeks.~Period 2: Alirocumab 150 mg SC injection every 4 weeks (Q4W) from Week 24 until second quarter 2017 or until the drug is commercially available in the country, whatever occurred first. Alirocumab dose could be either up-titrated to 150 mg Q2W from Week 36 or maintained according to the investigator judgement and low-density lipoprotein cholesterol (LDL-C) values. Subsequent down titration to 150 mg Q4W was allowed."
89589893|NCT02023879|Other|Alirocumab 75 mg Q2W/Up to 150 mg Q2W (Calibrator)|"Period 1: Alirocumab 75 mg SC injection Q2W added to stable non-statin LMT or diet alone for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when targeted LDL-C levels at Week 8 were not achieved i.e. LDL-C ≥70 mg/dL (1.81 mmol/L) or ≥100 mg/dL (2.59 mmol/L) depending on cardiovascular risk or <30% LDL-C reduction from baseline.~Period 2: Alirocumab 150 mg SC injection Q4W from Week 24 until second quarter 2017 or until the drug is commercially available in the country, whatever occurred first. Alirocumab dose could be either up-titrated to 150 mg Q2W from Week 36 or maintained according to the investigator judgement and LDL-C values. Subsequent down titration to 150 mg Q4W was allowed."
89608459|NCT01278550||High risk cohort|Patients have history of endoscopically confirmed ulcer bleeding, need long-term aspirin for cardiovascular or cerebrovascular prophylaxis and have successful eradication of H. pylori based on histology
89030699|NCT04693728|No Intervention|Wait-list with no treatment|The control comparison arm consisted of a wait-list condition in which participants received no treatment during a time interval comparable to the intervention arm.
89030700|NCT04512872|Experimental|CT-P41|60 mg/mL single dose administration, Solution for injection in PFS
89030701|NCT04512872|Active Comparator|EU-approved Prolia|60 mg/mL single dose administration, Solution for injection in PFS
89589894|NCT02023879|Experimental|Alirocumab 150 mg Q4W/Up to 150 mg Q2W|"Period 1: Alirocumab 150 mg SC injection Q4W alternating with placebo (for alirocumab) Q4W added to stable non-statin LMT or diet alone for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when targeted LDL-C levels at Week 8 were not achieved i.e. LDL-C ≥70 mg/dL (1.81 mmol/L) or ≥100 mg/dL (2.59 mmol/L) depending on cardiovascular risk or <30% LDL-C reduction from baseline.~Period 2: Alirocumab 150 mg SC injection Q4W from Week 24 until second quarter 2017 or until the drug is commercially available in the country, whatever occurred first. Alirocumab dose could be either up-titrated to 150 mg Q2W from Week 36 or maintained according to the investigator judgement and LDL-C values. Subsequent down titration to 150 mg Q4W was allowed."
89589895|NCT04417153||Mindfulness based intervention, Non Emergency (MBI-NE)|"4 week Mindfulness foundation course face to face (MF-NE) or~8 week Mindfulness Based stress reduction face to face (MBSR-NE)~The mindfulness-based intervention consists of either four (MF) or eight (MBSR) 2-hour sessions. Participants will be provided handouts for the information covered during these talks and discussions.~Classes are done at the Mindfulness centres providing the courses, with face to face sessions with the teacher and up to 30 participants together"
89589896|NCT04417153||Mindfulness based intervention, DORSCON Orange (MBI-Orange))|"4 week Mindfulness foundation course face to face (MF-Orange) or~8 week Mindfulness Based stress reduction face to face (MBSR-Orange)~The content of these courses are the same as in the non emergency ones, and consist of four (MF) or eight (MBSR) 2-hour sessions covering various mindfulness techniques. Participants will also be provided with the same handouts for the information covered during these talks and discussions.~Classes are done at the Mindfulness centres providing the courses, with face to face sessions with the teacher and up to 30 participants together."
89589897|NCT04417153||Mindfulness based intervention, Partial lockdown (MBI-Covid)|"4 week Mindfulness foundation course online (MF-Covid) or~8 week Mindfulness Based stress reduction online, partial lockdown situation (MBSR-Covid)~The content of these courses are the same as in the non emergency ones. Participants will also be provided with the same handouts for the information covered during these talks and discussions.~During the partial lockdown, classes can only be held online, using platform as zoom with the teacher and up to around 17 participants together."
89589898|NCT02014441|Experimental|Talimogene Laherparepvec|"Talimogene laherparepvec was administered by intralesional injection into injectable cutaneous, subcutaneous, and nodal lesions at an initial dose of 10⁶ plaque-forming units (PFU) per mL followed by a dose of 10⁸ PFU/mL 21 days after the initial dose and every 14 days thereafter.~Participants were treated with talimogene laherparepvec until they achieved a complete response (CR), all injectable tumors had disappeared, clinically relevant (resulting in clinical deterioration or requiring change of therapy) disease progression per modified World Health Organization (WHO) response criteria beyond 6 months of therapy, or intolerance of study treatment, whichever occurred first."
89589899|NCT02013817|Experimental|MabThera/Rituxan|
89589900|NCT01994863|Experimental|First Coloplast Test product; then Standard Care (see below)|"The subjects are randomised to test Coloplast Test product first and thereafter test Standard Care.~Standard Care is a collection of three different already marketed 1-piece flat ostomy appliances. These are Coloplast Sensura 1-piece; Hollister: Moderma 1-piece and B.Braun Flexima 1-piece.~The three Standard Care products were tested in a 1:1:1 randomisation."
89589901|NCT01994863|Experimental|First Standard Care (see below); Then coloplast test product|"The subjects are randomised to test Standard care first and thereafter test Coloplast test product.~Standard Care is a collection of three different already marketed 1-piece flat ostomy appliances. These are Coloplast Sensura 1-piece; Hollister: Moderma 1-piece and B.Braun Flexima 1-piece.~The three Standard Care products were tested in a 1:1:1 randomisation."
89589902|NCT02023099|Experimental|Substudy 1, Arm A: DB 2-DAA|Double-blind (DB) 150 mg ABT-450/100 mg ritonavir/25 mg ABT-267 (2 direct-acting antiviral agents [2-DAA]) once daily (QD) for 12 weeks in participants without cirrhosis
89589903|NCT02023099|Placebo Comparator|Substudy 1, Arm B: DB Placebo, Followed by OL 2-DAA|DB placebo QD for 12 weeks followed by open-label (OL) 150 mg ABT-450/100 mg ritonavir/25 mg ABT-267 (2-DAA) QD for 12 weeks in participants without cirrhosis
89589904|NCT02023099|Experimental|Substudy 2, Arm C: OL 2-DAA|OL 150 mg ABT-450/100 mg ritonavir/25 mg ABT-267 (2-DAA) QD for 12 weeks in participants with compensated cirrhosis
89589905|NCT02013037|Experimental|Eculizumab|Administration of Eculizumab to heart transplant recipients at Cedars Sinai Medical Center with a panel reactive antibody (PRA) ≥ 70%, for the prevention of antibody-mediated rejection.
89589906|NCT01967719|Active Comparator|mTHS 2.2 then mCC|"Each subject will follow the below study design:~Day 0 = Wash-out (1 day)~Day 1 = 1st intervention (single product use of mTHS 2.2)~Day 2 = wash-out~Day 3 = 2nd intervention (single product use of mCC)."
89589907|NCT01967719|Active Comparator|mCC then mTHS 2.2|"Each subject will follow the below study design:~Day 0 = Wash-out (1 day)~Day 1 = 1st intervention (single product use of mCC)~Day 2 = wash-out~Day 3 = 2nd intervention (single product use of mTHS 2.2)."
89589908|NCT01967719|Active Comparator|mTHS 2.2 then NNS|"Each subject will follow the below study design:~Day 0 = Wash-out (1 day)~Day 1 = 1st intervention (single product use of mTHS 2.2)~Day 2 = wash-out~Day 3 = 2nd intervention (single administration of NNS)"
89589909|NCT01967719|Active Comparator|NNS then mTHS 2.2|"Each subject will follow the below study design:~Day 0 = Wash-out (1 day)~Day 1 = 1st intervention (single administration of NNS)~Day 2 = wash-out~Day 3 = 2nd intervention (single product use of mTHS 2.2)."
89589910|NCT04416607|Experimental|corifollitropin alpha|Ovarian stimulation protocol is performed with a single dose of 100 μg (<60 kg) or 150 μg (≥60 kg) of corifollitropin alpha (Elonva, Schering-Plough, Brazil), plus gonadotropin-releasing hormone antagonist co-treatment (Ganirelix 25 mcg/day, Orgalutran, Schering-Plough, Brazil) in a flexible protocol (at least 1 follicle >14 mm or 3 or more follicles >12 mm).
88976733|NCT00167635|Experimental|2|Telephone Individualized Comprehensive Self-Management (CSM-TEL) Group. Participants in the individualized CSM-FTF group will initially have 2 face-to-face meetings with the nurse therapist, 6 sessions over the phone and the final session face-to-face at 9 weeks.
88976734|NCT00167635|No Intervention|3|Usual Care Control Group (UC). Following randomization the participants in the control group will receive two short phone calls to maintain contact during the comparable 9-week intervention in the treatment groups.
88976735|NCT00167674|Active Comparator|B|Combined short-course Zidovudine/Nevirapine
88976736|NCT00167674|Experimental|A|HAART during pregnancy and 6 months postpartum
89589911|NCT04416607|Active Comparator|menotropin|150-300 IU/day HMG (menotropin, Menopur, Ferring, Brazil) is administered, starting on cycle day 3, according to age, AMH level and AFC, plus gonadotropin-releasing hormone antagonist co-treatment (Ganirelix 25 mcg/day, Orgalutran, Schering-Plough, Brazil) in a flexible protocol (at least 1 follicle >14 mm or 3 or more follicles >12 mm).
89589912|NCT01967173|Experimental|Crossover sequence 1|Flovent Diskus® 250 mcg,followed by Advair Diskus® 250/50 mcg, followed by Flovent Diskus® 100 mcg, followed by Advair Diskus® 100/50 mcg
89589913|NCT01967173|Experimental|Crossover sequence 2|Advair Diskus® 250/50 mcg, followed by Advair Diskus® 100/50 mcg, followed by Flovent Diskus® 250 mcg, followed by Flovent Diskus® 100 mcg
89589914|NCT01967173|Experimental|Crossover sequence 3|Flovent Diskus® 100 mcg, followed by Flovent Diskus® 250 mcg, followed by Advair Diskus® 100/50 mcg, followed by Advair Diskus® 250/50 mcg
89589915|NCT01967173|Experimental|Crossover sequence 4|Advair Diskus® 100/50 mcg, followed by Flovent Diskus® 100 mcg, followed by Advair Diskus® 250/50 mcg, followed by Flovent Diskus® 250 mcg
89589916|NCT01967173|Experimental|Crossover sequence 5|Flovent Diskus® 500 mcg, followed by Advair Diskus® 250/50 mcg, followed by Flovent Diskus® 250 mcg, followed by Advair Diskus® 100/50 mcg
89589917|NCT01967173|Experimental|Crossover sequence 6|Advair Diskus® 250/50 mcg, followed by Advair Diskus® 100/50 mcg, followed by Flovent Diskus® 500 mcg, followed by Flovent Diskus® 250 mcg
89589918|NCT01967173|Experimental|Crossover sequence 7|Flovent Diskus® 250 mcg, followed by Flovent Diskus® 500 mcg, followed by Advair Diskus® 100/50 mcg, followed by Advair Diskus® 250/50 mcg
89589919|NCT01967173|Experimental|Crossover sequence 8|Advair Diskus® 100/50 mcg, followed by Flovent Diskus® 250 mcg, followed by Advair Diskus® 250/50 mcg, followed by Flovent Diskus® 500 mcg
89589920|NCT01994629|Experimental|MenACWY-CRM|MenACWY-CRM
89589921|NCT01994629|Active Comparator|MenACWY-TT|MenACWY-TT
89589922|NCT01994395|Experimental|Stride Management Assist (SMA) System|Participants will be randomized into either the SMA group or impairment based (IPT) group. The SMA group (task specific training) will be trained to simulate the demands of overground walking using the Stride Management Assist Device in outpatient physical therapy.
89589923|NCT01994395|Active Comparator|Impairment based therapy|Impairment based therapy will include traditional functional mobility training physical therapy. It will match the SMA group in intensity but will be focused on balance and other functional goals rather than explicitly on walking in outpatient physical therapy.
89589924|NCT01992536|Experimental|Ia: MenABCWY+OMV|Investigational
89589925|NCT01992536|Placebo Comparator|Ib: Placebo|Saline
89589926|NCT01992536|Experimental|IIa: MenABCWY+¼OMV|Investigational
89589927|NCT01992536|Placebo Comparator|IIb: Placebo|Saline
89589928|NCT01992536|Experimental|IIIa: MenABCWY+OMV|Investigational
89589929|NCT01992536|Experimental|IIIb: MenABCWY+¼OMV|Investigational
89589930|NCT01992536|Experimental|IVa: MenABCWY+OMV|Investigational
89589931|NCT01992536|Experimental|IVb: MenABCWY+¼OMV|Investigational
89589932|NCT01992536|Placebo Comparator|IVc: Placebo|Saline
89589933|NCT01993927||Voglibose 0.2 mg or OD Tablets 0.2 mg|Voglibose 0.2 mg or OD Tablets 0.2 mg will be administered orally three times daily immediately before each meal.
89589934|NCT02015390|Active Comparator|Masquelet defect reconstruction|The Masquelet defect reconstruction is a two-stage technique for the treatment of large segmental bone defects that involves the induction of a biomembrane about a poly(methylmethacrylate)(PMMA) cement spacer within the defect and, following cement removal, autogenous bone grafting (harvested using Reamer-Irrigator-Aspirator) or allogeneic bone graft is used to pack the defect while preserving the biomembrane. The typical time interval between the two stages is 6-8 weeks. The biomembrane not only assists in retaining the bone graft, but serves as a rich source of vascular supply and growth factors which constitute an excellent biological milieu for the graft to consolidate and heal the defect.
89589935|NCT02015390|Active Comparator|Titanium cage reconstruction|The cylindrical titanium mesh cage technique is a single-stage surgical procedure that immediately restores limb anatomy and alignment, and provides limb stability sufficient enough for early, unrestricted mobilization while permitting bone and soft tissue healing. It involves the implantation of a fenestrated cylindrical titanium mesh cage packed with autogenous bone graft (harvested using Reamer-Irrigator-Aspirator) or with allogeneic bone graft.
89589936|NCT02012959|Experimental|Tolvaptan Early Withdrawal|"All participants initially received tolvaptan once daily for the first 2 days. A third day of treatment was permitted if a participant had not reached the desired sodium target improvement per the investigator's judgment.~At the end of Day 2 (or Day 3), responders (participants who achieved an increase in serum sodium by ≥4 millimoles/liter [mmol/L]) were randomized to either the Early or Late Withdrawal Group. Non-responders could continue treatment with tolvaptan for an additional 2 days.~Discontinued tolvaptan treatment immediately after randomization.~All participants were observed up to 14 days post randomization."
89589937|NCT02012959|Experimental|Tolvaptan Late Withdrawal|"All participants initially received tolvaptan once daily for the first 2 days. A third day of treatment was permitted if a participant had not reached the desired sodium target improvement per the investigator's judgment.~At the end of Day 2 (or Day 3), responders (participants who achieved an increase in serum sodium by ≥4 mmol/L) were randomized to either the Early or Late Withdrawal Group in Treatment Phase B. Non-responders could continue treatment with tolvaptan for an additional 2 days.~Continued treatment for 2 additional days.~All participants were observed up to 14 days post randomization."
89589938|NCT01990742|Experimental|Palliative Care Team (PCTeam)|Palliative care teams will be established and will round with residents in the intervention homes.
89589939|NCT01990742|No Intervention|Standard care|Usual care will be provided to residents in the control homes.
89589940|NCT02012491|Active Comparator|misoprostol plus mifepristone|800 micrograms vaginal misoprostol, preceded by 200 milligrams oral mifepristone 24 hours prior
88976737|NCT05205915|Experimental|Single arm|All patients will receive active treatment which consists of stimulation (tDCS) applied using the Starstim device, with current delivered via four Starstim Pi electrodes (circular electrodes with a contact of area of 3.14 cm2) embedded in the headpiece. All study subjects will use the same fixed montage (electrode locations and currents).
88976738|NCT00045591|Experimental|Celecoxib 100 mg|
89589941|NCT02012491|Active Comparator|misoprostol|800 micrograms of vaginal misoprostol alone
88976739|NCT00045591|Experimental|Celecoxib 400 mg|
88976740|NCT00167830|Experimental|Lifestyle Intervention|Dietary modification and exercise.
88976741|NCT00167947|Active Comparator|A|
88976742|NCT00167947|Experimental|B|
88976743|NCT00168025|Experimental|IgPro10|
88976744|NCT05205876|No Intervention|Control (Dexcom app)|This group will use the Dexcom application for management of their blood glucose for the duration of the study (8 weeks).
88976745|NCT05205876|Experimental|Intervention (Eddii app)|This group will use the Dexcom application for the initial 2 weeks of the study, and switch to using the Eddii application on Day 14 of the study for the remaining 6 weeks of the study.
88976746|NCT00168220||Drug hypersensitive group|HIV positive patients with a history of a Hypersensitivity Reaction to the antiretroviral medications Nevirapine, Abacavir or Efavirenz
88976747|NCT00168220||Drug tolerant group|HIV positive patients selected based on drug exposure greater than 2 weeks and tolerance to to Abacavir or Nevirapine.
88976748|NCT00054821|Experimental|Group A|Group A participants will be treated with mechanical distraction with motion
88976749|NCT00054821|Active Comparator|Group B|Group B participants will be treated with mechanical distraction without motion
88976750|NCT00045669|Experimental|Imatinib Mesylate|Adult patients with unresectable or metastatic adenoid cystic carcinoma measurable by Response Evaluation Criteria in Solid Tumors Group criteria and expressing c-kit by immunohistochemistry were treated with imatinib 400 mg orally bid. Response was assessed every 8 weeks
88976751|NCT05180682|Experimental|Supervised|This group training was supervised by the health care provider.
88976752|NCT05180682|Active Comparator|Non-Supervised|This group was non-supervised.
89589942|NCT01990664|Experimental|senofilcon A|Contact lenses to be worn in a daily wear modality
89589943|NCT01990664|Experimental|senofilcon A for Astigmatism|Contact lenses to be worn in a daily wear modality
89589944|NCT04416139|Active Comparator|Treated group|Five patients, of any sex and age, with bilateral COVID-19 pneumonia, severe SIRA with PaO2 / FiO2 less than 150, lymphopenia less than 800 total lymphocytes, CT with bilateral pneumonia, SOFA less than 11 and that has not improved in relation to the following parameters: a) persistent PaO2 / FiO2 less than 150; b) persistent fever, c) increase in D-dimer of at least 50% of the baseline and / or ferritin greater than 1000, after 48 h of hospital stay receiving the standard management measures used at that time in the Care Center, will be included in the study. This treatment will be administered after discussing it with the relatives that it is a procedure considered as rescue and will be carried out with informed consent.
89589945|NCT04416139|No Intervention|Control Group|The results obtained in the treated group will be compared against the historical controls treated in INCMNSZ, evaluating the same variables.
89589946|NCT02038010|Experimental|Treatment (PI3K inhibitor BYL719, ado-trastuzumab emtansine)|Patients receive PI3K inhibitor BYL719 PO daily on days 1-21 and ado-trastuzumab emtansine IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89589947|NCT04416698||Youth smokers|Participants of Youth Quitline
89589948|NCT04178798|Experimental|Arm A_Acalabrutinib|Patients assigned to arm A, will receive acalabrutinib as one capsule of 100 mg orally twice daily on a continuos schedule until disease progression, unacceptable toxicity or early withdrawal.
89589949|NCT04178798|No Intervention|Arm B_Standard of care|"Patients assigned to arm B, will receive standard of care for the management of early Binet stage A patients clinical observation (watch & wait) until disease progression or early withdrawal."
89589950|NCT01989572|Experimental|Arm I (sargramostim, peptide vaccine)|Patients receive sargramostim SC on days 1-14 and peptide vaccine comprising tyrosinase, gp100 antigen, and MART-1 antigen mixed with either incomplete Freund's adjuvant or Montanide ISA-51 VG SC on days 1 and 15 (course 1) and day 1 (course 2 and subsequent courses).
89589951|NCT01989572|Experimental|Arm II (sargramostim placebo, peptide vaccine)|Patients receive sargramostim placebo SC on days 1-14 and peptide vaccine comprising tyrosinase, gp100 antigen, and MART-1 antigen mixed with either incomplete Freund's adjuvant or Montanide ISA-51 VG SC on days 1 and 15 (course 1) and day 1 (course 2 and subsequent courses).
89589952|NCT01989572|Experimental|Arm III (sargramostim, peptide placebo)|Patients receive sargramostim SC on days 1-14 and peptide placebo mixed with either incomplete Freund's adjuvant or Montanide ISA-51 VG SC on days 1 and 15 (course 1) and day 1 (course 2 and subsequent courses).
89589953|NCT01989572|Placebo Comparator|Arm IV (placebo, peptide placebo)|Patients receive placebo SC on days 1-14 and peptide placebo on days 1 and 15 (course 1) and day 1 (course 2 and subsequent courses).
89589954|NCT01989572|Experimental|Arm V (sargramostim)|Patients receive sargramostim SC on days 1-14.
89589955|NCT01989572|Placebo Comparator|Arm VI (sargramostim placebo)|Patients receive sargramostim placebo SC on days 1-14.
89589956|NCT04416776||Eligible patients for AI test|Device: strabismus diagnostic system.
89589957|NCT02036294|Other|Usual Care|Usual Care: Standard healthcare services will be received. Study participants in this arm will not receive any additional study interventions.
89589958|NCT02036294|Experimental|BREATHE program|Study participants randomized to this arm will be offered the BREATHE program an integrated multifaceted intervention that includes comprehensive biopsychosocial assessment, a tailored treatment plan, a tailored disease management program, and care management support services .
89589959|NCT02035748|Experimental|Ocriplasmin|Ocriplasmin 0.125 mg in a 0.1 mL volume administered as a single dose by intravitreal injection
89589960|NCT02014376|Experimental|SD-101 Dermal Cream (6%)|SD-101 dermal cream (6%) applied topically once daily over the entire body for 90 days.
89589961|NCT02014376|Experimental|SD-101 Dermal Cream (3%)|SD-101 dermal cream (3%) applied topically once daily over the entire body for 90 days.
89589962|NCT02014376|Placebo Comparator|Vehicle (0%)|Vehicle dermal cream (SD-101 0%) applied topically once daily over the entire body for 90 days.
89589963|NCT02035202|Experimental|CBT2go|Participants assigned to this condition will attend one session with a therapist to identify cognitive and behavioral strategies around four areas: 1) mood/psychotic symptoms, 2) medication adherence, 3) socialization, and 4) relapse prevention. Subsequently they will answer questions on a mobile device (smartphone) 3 times per day for 12 weeks, and they will receive personalized cognitive and behavioral strategies linked to their momentary responses with bi-monthly telephone support.
89589964|NCT02035202|Active Comparator|EMA-only|Participants assigned to this condition will answer questions on a mobile device (smartphone) 3 times per day for 12 weeks but will not receive personalized cognitive and behavioral strategies.
89589965|NCT02035202|No Intervention|Standard Care|Participants assigned to this condition will only participate in the assessments.
89589966|NCT01988402|Active Comparator|Allopurinol|Patients in this arm receive allopurinol, 100 mg daily for 14 days and then 200 mg daily for 14 days
89589967|NCT01988402|Placebo Comparator|Sugar pill (Placebo)|Patients in this arm receive one placebo (sugar) pill per day for 14 days then 2 placebo pills for 14 days.
89589968|NCT01988090|Experimental|High Dose Vitamin D ARM|50,000 IU Vitamin D supplement
89589969|NCT01988090|Active Comparator|800 IU Vitamin D Supplement|800 IU Vitamin D Supplement
89589970|NCT01988012|Experimental|Tocilizumab|Adults with rheumatoid arthritis will be treated with tocilizumab for 24 weeks followed by an 8 week follow-up period without treatment.
89589971|NCT02011945|Experimental|dasatinib Only|dasatinib 100 mg QD(CP) or 140 mg QD (AP)
89589972|NCT02011945|Experimental|Dose Level 1|Nivolumab 1 mg/kg q 2 weeks + dasatinib 100 mg QD (CP) or 140 mg QD (AP)
89589973|NCT02011945|Experimental|Dose Level 2|Nivolumab 3 mg/kg q 2 weeks + dasatinib 100 mg QD (CP) or 140 mg QD (AP)
89589974|NCT04666909||Hypertension Group|Participants will receive a free blood pressure screening and receive educational counseling about the importance of maintaining a healthy blood pressure. In addition, educational counseling will be administered in months 3 and 6.
89589975|NCT02013830|Experimental|Avastin + Xeloda|
89589976|NCT02010775|Active Comparator|BOTOX® 24U|Botulinum Toxin Type A (BOTOX®) 24U total dose administered intramuscularly to the bilateral masseter muscles on Day 1 and retreatment at Day 180 if applicable.
89589977|NCT02010775|Active Comparator|BOTOX® 48U|Botulinum Toxin Type A (BOTOX®) 48U total dose administered intramuscularly to the bilateral masseter muscles on Day 1 and retreatment at Day 180 if applicable.
89589978|NCT02010775|Active Comparator|BOTOX® 72U|Botulinum Toxin Type A (BOTOX®) 72U total dose administered intramuscularly to the bilateral masseter muscles on Day 1 and retreatment at Day 180 if applicable.
89589979|NCT02010775|Active Comparator|BOTOX® 96U|Botulinum Toxin Type A (BOTOX®) 96U total dose administered intramuscularly to the bilateral masseter muscles on Day 1 and retreatment at Day 180 if applicable.
89589980|NCT02010775|Placebo Comparator|Placebo|Placebo (Normal saline) administered intramuscularly to the bilateral masseter muscles on Day 1 and retreatment at Day 180 if applicable.
89589981|NCT01993615|Active Comparator|Arthroscopic Surgery|Arthroscopic surgery at the femoroacetabular joint, followed by a standardized post-operative rehabilitation protocol in physical therapy.
89589982|NCT01993615|Active Comparator|Physical Therapy|An impairment-based supervised in-clinic physical therapy program.
89589983|NCT01619059|Experimental|Arm 1: Saxagliptin+Dapagliflozin+Metformin IR|
89589984|NCT01619059|Experimental|Arm 2: Placebo+Dapagliflozin+Metformin IR|
89589985|NCT04691804|Experimental|Treatment group A|Fuzuloparib plus AA-P
89589986|NCT04691804|Placebo Comparator|Treatment group B|Fuzuloparib Placebo plus AA-P
89589987|NCT04416997||Rheumatoid arthritis patients|Blood and serum samples
89589988|NCT04176757|Experimental|ZN-c5|
89589989|NCT02013206|Experimental|Never Smokers|Never Smokers (participants who smoked ≤ 100 cigarettes in entire lifetime or had never smoked cigarettes) received erlotinib [Tarceva] 150 mg orally daily until disease progression or unacceptable toxicity.
89589990|NCT02013206|Experimental|Current/Former Smokers|Current Smokers (participants who smoked > 100 cigarettes in entire lifetime and either quit smoking < 1 year ago or were currently smoking) or Former Smokers (participants who smoked > 100 cigarettes in entire lifetime and quit smoking ≥ 1 year ago) received erlotinib [Tarceva] 150 mg orally daily, increasing to a maximum of 300 mg orally daily until disease progression or unacceptable toxicity.
89589991|NCT04690634|Experimental|PCOS group|obese female patients with Polycystic ovary syndrome. All participants underwent laparoscopic sleeve gastrectomy (LSG)
89589992|NCT04690634|Active Comparator|control group|obese female patients without Polycystic ovary syndrome. All participants underwent laparoscopic sleeve gastrectomy (LSG)
89589993|NCT04416854|Experimental|Chemotherapy plus surgery|Chemotherapy plus surgery: Four cycles of XELOX or six cycles of mFOLFOX6 combined with or without targeted therapy accroding to gene testing. After 4 cycles, the patients are randomized to surgery group. Patients receive palliative resection of Primary tumor. Then the rest four cycles XELOX or six cycles of mFOLFOX6 combined with or without targeted therapy are administrated.
89589994|NCT04416854|Active Comparator|Chemotherapy alone|Chemotherapy alone: Four cycles of XELOX or six cycles of mFOLFOX6 combined with or without targeted therapy accroding to gene testing. After 4 cycles, the patients are randomized to chemotherapy group. The rest four cycles XELOX or six cycles of mFOLFOX6 combined with or without targeted therapy are administrated.
89589995|NCT01807923|Placebo Comparator|Placebo|Placebo matched to lumacaftor (LUM, VX-809) and ivacaftor (IVA, VX-770) tablet every 12 hours (q12h), up to Week 24.
89589996|NCT01807923|Experimental|LUM 600 mg qd/IVA 250 mg q12h|LUM 600 milligram (mg) plus IVA 250 mg fixed-dose combination (FDC) tablet in the morning and IVA 250 mg film-coated tablet in the evening, up to Week 24.
89589997|NCT01807923|Experimental|LUM 400 mg q12h/ IVA 250 mg q12h|LUM 400 mg plus IVA 250 mg FDC tablet in the morning and in the evening, up to Week 24.
89589998|NCT01966003|Experimental|ABP 215|Participants received 15 mg/kg ABP 215 administered as an intravenous (IV) infusion every 3 weeks (Q3W) for 6 cycles and carboplatin and paclitaxel chemotherapy Q3W for at least 4 and not more than 6 cycles.
89589999|NCT01966003|Active Comparator|Bevacizumab|Participants received bevacizumab 15 mg/kg administered as an intravenous (IV) infusion every 3 weeks (Q3W) for 6 cycles and carboplatin and paclitaxel chemotherapy Q3W for at least 4 and not more than 6 cycles.
89590000|NCT01839279|Experimental|Tizanidine|Oral dose of 2 and 4 milligram (mg) tablets
89590001|NCT01839279|Placebo Comparator|Placebo|Placebo followed by a single dose 400 mg moxifloxacin tablets.
89590002|NCT01839279|Active Comparator|Moxifloxacin|Single dose of 400 mg moxifloxacin followed by placebo.
89590003|NCT01807299|Experimental|Physical Training|The training group will make physical exercise for three months (three times a week).
88976753|NCT00168415|Experimental|1|Botulinum Toxin Type A
89590004|NCT01807299|Other|Sedentary|The sedentary group will be oriented not to make any type of physical training for three months.
89590005|NCT01807299|Placebo Comparator|Placebo|The omega 3 group will receive 2g per day of mineral oil during 90 days treatment
89590006|NCT01807299|Experimental|Omega 3|The omega 3 group will receive 2g per day of fish oil during 90 days treatment
89590007|NCT01965535|Experimental|LDV/SOF|LDV/SOF FDC tablet plus placebo to match RBV for 24 weeks
89590008|NCT01965535|Experimental|LDV/SOF + RBV|Placebo to match SOF/LDV FDC plus placebo to match RBV for 12 weeks, followed by LDV/SOF FDC plus RBV for 12 weeks.
89590009|NCT04659577|Experimental|internet based CBT|all patients will be offered active treatment via internet based CBT
89590010|NCT01964755|Experimental|Chemotherapy + Antiviral-Based Therapy|"Combination Chemotherapy for up to six (6) 21-day cycles and Antiviral-Based Therapy:~Chemotherapy: Up to 6 cycles, 21 days each:~Doxorubicin: 20 mg/m2 intravenously (IV) on Day 1 per study protocol;~Rituximab: 375mg/m2 (optional) IV on Day 1 per study protocol;~Methotrexate: 3.5 gm/m2 IV on Day 2 per study protocol;~Leucovorin: 10 mg/m2 IV starting approximately 24 hours after start of Methotrexate infusion, and then 25 mg orally every 6 hours for at least 10 doses per study protocol;~Antiviral-Based Therapy~Zidovudine: Starting 750 mg/m2 IV on Day 2, then 1200 mg orally twice daily for 10 doses per study protocol;~Hydroxyurea: 1,000 mg orally twice daily starting Day 2 for a total of 10 doses per study protocol."
89590011|NCT01964521|Experimental|Mepilex Transfer Ag|Mepilex Transfer Ag is a transfer dressing designed for low to high exuding wounds and used to prevent microbial growth. It is worn for up to two weeks at a time.
89590012|NCT04416295|Active Comparator|Standard COPD care and a digital COPD support system|Device: LifePod The intervention group is testing LifePod on a digital communication platform between patient and healthcare provide
89590013|NCT04416295|Other|Control group Standard COPD Care|
89590014|NCT01992757||Cardiac surgery with cardiopulmary bypass|
89590015|NCT01991743|Active Comparator|Drug:Group 2.5|Administration of 2.5 mg bupivacaine
89590016|NCT01991743|Active Comparator|Group 5|Administration of 5 mg bupivacaine.
89590017|NCT01991743|Active Comparator|Group 7.5|Administration of 7.5mg bupivacaine.
89590018|NCT01991743|Active Comparator|Group 10|Administration of 10 mg bupivacaine.
89590019|NCT01991197|Experimental|Sitagliptin|"Double blind phase (week 0-16):~Sitagliptin two 50mg tablets (or one 50mg in participants with moderate kidney disease) once daily for 16 weeks.~Placebo Comparator: Gliclazide matched placebo One gliclazide matched placebo capsule daily for 4 weeks. If no severe hypoglycaemic episodes one gliclazide matched placebo capsule twice daily for 4 weeks. If no severe hypoglycaemic episodes two gliclazide matched placebo capsules twice daily for 8 weeks.~Open-label phase (week 16-32):~Sitagliptin two 50mg tablets (or one 50mg in participants with moderate kidney disease) once daily for 16 weeks."
89590020|NCT01991197|Active Comparator|Gliclazide|"Double-blind phase (week 0-16):~Gliclazide 80mg once daily for 4 weeks Then if no severe hypoglycaemic episodes increase to Gliclazide 80mg twice daily for 4 weeks.~Then if no severe hypoglycaemic episodes increase to Gliclazide 160mg twice daily for 8 weeks Placebo Comparator: Sitagliptin matched placebo Two tablets (or one tablet in participants with moderate kidney disease) once daily for 16 weeks.~Open-label phase (week 16-32):~Sitagliptin two 50mg tablets (or one 50mg in participants with moderate kidney disease) once daily for 16 weeks."
89590021|NCT01990573|Experimental|methadone HCl 0.3 mg/kg|0.3mg/kg IV methadone HCl
89590022|NCT01990573|Experimental|methadone HCl 0.4 mg/kg|0.4mg/kg IV methadon HCl
89590023|NCT01990573|Active Comparator|control group|control no methadone, standard of care opioids.
89590024|NCT01990495|Active Comparator|Exercise vs. usual care|The study involves two arms randomized to exercise and usual care groups
89590025|NCT01990495|Active Comparator|Usual care|This group will be randomized to receive usual clinical care. No other interventions will be assigned to this group.
89590026|NCT01990339||Lansoprazole|Lansoprazole (Takepron), tablets, orally, once daily for up to 8 weeks. Reflux esophagitis: the usual adult dosage is 30 mg of lansoprazole. For maintenance therapy of repeatedly recurring/relapsing reflux esophagitis, the dosage is 15 mg of lansoprazole administered orally once daily. If insufficient efficacy is observed, the dosage may be increased to 30 mg administered orally once daily. Nonerosive gastroesophageal reflux disease: the usual adult dosage is 15 mg of lansoprazole administered orally once daily for up to 4 weeks.
89590027|NCT02007577|Active Comparator|salsalate 3500mg in 2 divided doses a day|Participants will take 3, 500 mg tablets with breakfast and 4, 500 mg tablets with dinner
89590028|NCT02007577|Placebo Comparator|placebo|Participants will take 3 placebo tablets with breakfast and 4 placebo tablets with dinner
89590029|NCT01990261||Erlotinib|Participants diagnosed with locally advanced or metastatic non-small cell lung with known carcinoma epidermal growth factor receptor (EGFR) status received erlotinib at a dose determined by the investigator, guided by the recommendation in the Summary of Product Characteristics.
89590030|NCT04658095|Active Comparator|Ab-interno canaloplasty and trabeculotomy (both up to 360 degrees) using the OMNI Surgical System|
89590031|NCT04658095|Active Comparator|Ab-interno canaloplasty (360 degrees) using the OMNI Surgical System|
89590032|NCT04658095|Active Comparator|Ab-interno implantation of iStent inject (2 microstents)|
88976754|NCT00168493|Active Comparator|intervention|there is no sham or placebo control arm It is a single arm study
88976755|NCT04731948|Placebo Comparator|Folic Acid + Placebo|400µg Folic Acid per day for 16 weeks after a pre-treatment phase with 400µg FA per day for 11 weeks
88976756|NCT04731948|Active Comparator|Folic Acid + Vitamin B12 Dose 1|400µg Folic Acid + 2 µg Vitamin B12 per day for 16 weeks after a pre-treatment phase with 400µg FA per day for 11 weeks
89590033|NCT01963117|Experimental|Combined hypertermia and RT|Combined hypertermia and radiothearpy
89590034|NCT02007109||Nausea measurement by VAS and BARF|"All patients will be asked to rate their nausea on both the VAS and the BARF scales. For the nausea scales, the script would be: Have you thrown up or felt like you were going to throw up before? How did your tummy feel then? We call that feeling of being sick to the stomach as nausea.~For the BARF scale:These faces show children who feel no nausea at all, who feel a little bit nauseated, who feel even more nauseated, and these are children who have the most nausea it is possible to feel. (Point to the each face at the appropriate time). Which face is more like you feel right now? For the VAS scale: On this line the far left indicates No nausea and the far right Worst nausea ever. Can you show me on this line how much nausea you have right now?"
88976757|NCT04731948|Active Comparator|Folic Acid + Vitamin B12 Dose 2|400µg Folic Acid + 10 µg Vitamin B12 per day for 16 weeks after a pre-treatment phase with 400µg FA per day for 11 weeks
88976758|NCT04731948|Active Comparator|Folic Acid + Vitamin B12 Dose 3|400µg Folic Acid + 50 µg Vitamin B12 per day for 16 weeks after a pre-treatment phase with 400µg FA per day for 11 weeks
88976759|NCT00168688|Active Comparator|FeFol|Iron (60 mg) and folic acid (400 ug), standard of care
88976760|NCT00168688|Experimental|MN1|"1 RDA of 15 micronutrients, including iron (30 mg) and folic acid (400 ug)~Vitamin A 800 μg RE, Vitamin D 200 IU, Vitamin E 10 mg, Vitamin B1 1.4 mg, Vitamin B2 1.4 mg, Niacin 18 mg, Folic acid 400 μg, Vitamin B6 1.9 mg, Vitamin B12 2.6 μg, Vitamin C 70 mg, Zinc 15 mg, Iron 30 mg, Copper 2.0 mg, Selenium 65 μg, Iodine 150 μg"
88976761|NCT00168688|Experimental|MN2|"2 RDA of 14 micronutrients including iron (30 mg) and folic acid (800 ug)~Vitamin A 1600 μg RE, Vitamin D 400 IU, Vitamin E 20 mg, Vitamin B1 2.8 mg, Vitamin B2 2.8 mg, Niacin 36 mg, Folic acid 800 μg, Vitamin B6 3.8 mg, Vitamin B12 5.2 μg, Vitamin C 140 mg, Zinc 30 mg, Iron 30 mg, Copper 4.0 mg, Selenium 130 μg, Iodine 300 μg"
88976762|NCT00168766|Experimental|1|interferon-beta-1a in combination with methylprednisolone
89590035|NCT02006719|Experimental|Collagenase Clostridium Histolyticum|Up to 3 injections of .58 mg/1 mL of collagenase clostridium histolyticum (CCH), minimum of 21 days apart and home shoulder exercise.
89590036|NCT02006719|Placebo Comparator|Placebo|Up to 3 1-mL injections of placebo, minimum of 21 days apart and home shoulder exercise.
89590037|NCT01962493|Other|Sodium bicarbonate/ Sodium Fluoride toothpaste|Marketed Sodium bicarbonate toothpaste containing 1400 parts per million (ppm) fluoride as Sodium fluoride (NaF)
89590038|NCT01962493|Active Comparator|Sodium fluoride toothpaste|Non-sodium bicarbonate toothpaste containing 1450ppm fluoride as NaF
89590039|NCT01962493|Other|Chlorhexidine digluconate mouthwash|0.2% w/v Chlorhexidine digluconate mouthwash for rinsing post-brushing with study toothpastes
89590040|NCT01989169|Active Comparator|Midazolam|Administered as a single oral 6 mg dose on Day 1.
89590041|NCT01989169|Experimental|SSP-004184SS + Midazolam|Midazolam (6 mg) + SSP-004184SS (30 mg/kg) concomitantly administered as a single oral dose on Day 1.
89590042|NCT01988779|Active Comparator|oral placebo with nebulized intranasal levofloxacin|Placebo oral tablet by mouth daily for 14 consecutive days along with nebulized levofloxacin 125 mg twice daily for 14 consecutive days
89590043|NCT01988779|Active Comparator|oral antibiotics with nebulized intranasal placebo|Levofloxacin 500 mg by mouth once daily for 14 consecutive days, along with intranasal placebo solution twice daily for 14 consecutive days.
89590044|NCT01988233|Experimental|BAILAMOS© Dance Program|BAILAMOS© Dance Program + Maintenance Program: includes a 4-month twice-weekly adoption phase and a 4-month twice-weekly maintenance phase. Each month during adoption a new dance style is introduced by a professional dance instructor. During the 4-month maintenance phase an indigenous dance leader, trained by the professional dance instructor, will lead dance with participants twice per week
89590045|NCT01988233|Experimental|Health Education Control Group|Health Education Control Group: Sedentary older Latinos randomly assigned to the health education control group will participate in classes developed for older adults and offered by the University of Illinois Extension. All classes are conducted in Spanish by extension staff using Spanish-language materials. Classes will meet one day per week for two hours, to provide equitable social contact as the treatment group.
89590046|NCT01987765||Relestat Ophthalmic Solution 0.05%|Patients who are prescribed Relestat Ophthalmic Solution 0.05% as local standard of care in clinical practice.
89590047|NCT01987609|Experimental|Hylenex|Psoriatic plaques in this arm will be injected with Hylenex every week for 4 weeks.
89590048|NCT01987609|Placebo Comparator|Normal Saline|Psoriatic plaques in this arm will be subcutaneously injected with sterile normal saline every week for four weeks
89590049|NCT04657159||2010-2016|Patients treated 2010-2016
89590050|NCT04657159||2017-2019|Patients treated 2017-2019
89590051|NCT04174651|Experimental|Participants with AD with MRI|Participants that are diagnosed with AD will receive both the acute stress condition (TSST) and the control condition (watching a landscape video). The order when the 2 conditions will be provided is randomized per participant and completed 2 weeks apart. These subjects will be evaluated with MRI.
89590052|NCT04174651|Experimental|Healthy Participants with MRI|Healthy participants will receive both the acute stress condition (TSST) and the control condition (watching a landscape video). The order when the 2 conditions will be provided is randomized per participant and completed 2 weeks apart. These subjects will be evaluated with MRI.
89590053|NCT02013674|Experimental|Group 1: 20 million Allogeneic hMSCs|Fifteen (15) patients to be treated with Allo-hMSCs: 4 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 0.2x 10^8 (20 million) Allo-hMSCs.
89590054|NCT02013674|Experimental|Group 2: 100 million Allogeneic hMSCs|Fifteen (15) patients to be treated with Allo-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1x 10^8 (100 million) Allo-hMSCs.
89590055|NCT01987232|Experimental|Carfilzomib Combination|Participants received carfilzomib on days 2, 3, 9, and 10 of each 21-day cycle as per the dose escalation schema, carboplatin at a target area under the curve (AUC) of 5 on day 1 of each cycle, and etoposide 100 mg/m² on days 1, 2, 3 of each 21-day cycle for up to 6 cycles. Participants with stable disease or better continued to receive carfilzomib alone until progressive disease (PD), unacceptable toxicity, withdrawal of consent, study closure, or death, whichever occurred earliest.
89590056|NCT04676204||Cladribine|Participants with MS commencing cladribine disease modifying treatment as clinically prescribed.
89590057|NCT04676204||Dimethyl Fumarate|Participants with MS commencing dimethyl fumarate disease modifying treatment as clinically prescribed.
89590058|NCT04676204||Fingolimod|Participants with MS commencing fingolimod disease modifying treatment as clinically prescribed.
89590059|NCT04676204||Teriflunomide|Participants with MS commencing teriflunomide disease modifying treatment as clinically prescribed.
89590060|NCT04676204||Ozanimod|Participants with MS commencing Ozanimod disease modifying treatment as clinically prescribed.
89590061|NCT04676204||Diroximel Fumarate|Participants with MS commencing diroximel fumarate disease modifying treatment as clinically prescribed.
89590062|NCT01986920|Active Comparator|A-101 25%|Low dose group
89590063|NCT01986920|Active Comparator|A-101 32.5%|Mid Dose Group
89590064|NCT01986920|Active Comparator|A-101 40%|High Dose Group
89030702|NCT05144867|Active Comparator|Arm 1|The WBRT dosage schedule will be 30 Gy in 10 fractions over 2 weeks. For Arm 1, Treatment planning is to be done using CT simulation or conventional simulation (fluoroscopy). Simple beam arrangements, such as parallel opposed beams, will be favoured wherever possible.
89590065|NCT01986920|Placebo Comparator|A-101 Vehicle|Placebo group
89590066|NCT02010632|Experimental|Generic clopidogrel product|Apolets® 75 mg tablet
89590067|NCT02010632|Active Comparator|Original clopidogrel product|Plavix® 75mg tablet
89590068|NCT01986140|Experimental|PAXMAN Orbis Scalp Cooler|Scalp Cooling
89590069|NCT01986140|Other|Control No treatment|Control
89590070|NCT01986062|Experimental|AR11 (amphetamine sulfate) (1 week) - double blind|AR11, administered orally, BID, for one week (crossover to placebo administration week 2)
89590071|NCT01986062|Placebo Comparator|Placebo (1 week) - double blind|Placebo, administered orally, BID, for one week (crossover to AR11 administration week 2)
89590072|NCT01985360|Active Comparator|Invasive Strategy (INV)|Routine invasive strategy with cardiac catheterization followed by revascularization (Percutaneous Coronary Intervention or Coronary Artery Bypass Graft Surgery) plus optimal medical therapy.
89590073|NCT01985360|Active Comparator|Conservative Strategy (CON)|Optimal medical therapy with cardiac catheterization and revascularization reserved for patients with OMT failure.
89590074|NCT02032706|Experimental|Positional feedback|Deliver therapy when the supine position is detected
89590075|NCT02032238|Experimental|laser photocoagulation with bevacizumab|Combining laser photocoagulation and Anti-VEGF Injections in a pre-defined manner
89590076|NCT02032238|No Intervention|Bevacizumab, no laser photocoagulation|patients receive Anti-VEGF injections (Bevacizumab) only
89590077|NCT04689074||ADPKD|Patients with ADPKD
89590078|NCT04689074||advanced CKD|Patients with advanced CKD
89590079|NCT04689074||DKD|Patients with DKD
89590080|NCT04689074||IgAN|Patients with IgAN
89590081|NCT04689074||Healthy volunteers|Healthy volunteers
89590082|NCT04688450|Experimental|Intervention group|The investigational system will be evaluated for safety and user acceptance in 20 patient-subjects and associated nurse-subjects
89590083|NCT01985126|Experimental|Part 1|During Stage 1 of Part 1, participants will be randomized to receive daratumumab treatment regimens in Group A and Group B. If in Stage 1, 1 or both of the treatment groups is considered to be ineffective and/or not well tolerated, then that treatment group will be terminated. Participants in Group B will be given the option to cross over to Group A if the investigator deems it in the best interest of the participants.
89590084|NCT01985126|Experimental|Part 2|Based on the Part 1 response rate, Group A or B daratumumab treatment will be selected as the treatment regimen for participants enrolled in Part 2.
89590085|NCT01984892|Experimental|IT and IM injections Poly-ICLC|Enrolled patients will receive two cycles of Poly-ICLC treatment. Each priming (intratumoral injections - IT) and boosting (intramuscular injections - IM) treatment course will constitute one cycle.
89590086|NCT04416620|Active Comparator|The active group of Syria|"Participants in the active group received the 'pharmacist standard counseling' plus the 'pharmaceutical care service' designed by the research group. Both services were delivered by one female clinical pharmacist who has a Master's degree in pharmaceutical sciences, 5-year work experience in community pharmacies, and comprehensive knowledge of PCOS. The time it took to deliver the counseling and education to each participant in the active group was formally assessed. This time assessment excluded data collection and questionnaire filling time (which was planned to take around 15 min).~Participants in the active group received the usual care delivered at the community pharmacies plus the pharmaceutical care service designed by the research group and provided by the clinical pharmacist. The intervention was delivered via oral advice and recommendations, and written material, with a special focus on diet and exercise."
89590087|NCT04416620|No Intervention|The control group of Syria|"Participants in the control group received the usual care only which is the 'pharmacist standard counseling' involved dispensing the prescribed medication (delivered by the pharmacist in charge), counseling on how to take the dispensed medications, and a brief reply to questions if asked by the participants. The 'pharmacist standard counseling' followed what was normally delivered to females with PCOS by pharmacists working at community pharmacies in both countries. This 'pharmacist standard counseling' was established based on what was observed and reported by the project research team after viewing the usual pharmacists' interaction with females with PCOS for two weeks in each country before the start of the study.~Participants in the control group were informed that the educational intervention (the pharmaceutical care service) will be delivered to them after the end of the study (for ethical reasons)."
89590088|NCT04416620|Active Comparator|The active group of Jordan|Participants in the active group received the usual care delivered at the community pharmacies plus the pharmaceutical care service designed by the research group and provided by the clinical pharmacist. The intervention was delivered via oral advice and recommendations, and written material, with a special focus on diet and exercise.
89590089|NCT04416620|No Intervention|The control group of Jordan|"Participants in the control group received the usual care only which is the 'pharmacist standard counseling' involved dispensing the prescribed medication (delivered by the pharmacist in charge), counseling on how to take the dispensed medications, and a brief reply to questions if asked by the participants. The 'pharmacist standard counseling' followed what was normally delivered to females with PCOS by pharmacists working at community pharmacies in both countries. This 'pharmacist standard counseling' was established based on what was observed and reported by the project research team after viewing the usual pharmacists' interaction with females with PCOS for two weeks in each country before the start of the study.~Participants in the control group were informed that the educational intervention (the pharmaceutical care service) will be delivered to them after the end of the study (for ethical reasons)."
89590090|NCT01807221|Experimental|Finerenone(BAY94-8862)[2.5mg] + Placebo|Oral - 2.5mg once daily (OD) for 30 days. Potential up-titration to 5mg OD after 30 days or 60 days. Treatment duration 90 days. Placebo OD for 90 days.
89608460|NCT01272778|Experimental|Lorazepam 0.2 mg|All subjects receive lorazepam 0.2 mg in this crossover design.
89030703|NCT05144867|Experimental|Arm 2|Metastases with a maximum diameter of up to 2 cm will be treated with doses of 22 to 25 Gy and those larger than 2 cm will be treated with doses of 18 to 20 Gy.
89030704|NCT02276781||PAD Participants|PAD participants from among consecutive patients with PAD identified from Chicago area non-invasive vascular laboratories
89590091|NCT01807221|Experimental|Finerenone (BAY94-8862)[5mg] + Placebo|Oral - 5mg OD for 30 days. Potential up-titration to 10 mg OD after 30 days or 60 days. Treatment duration 90 days. Placebo OD for 90 days.
89590092|NCT01807221|Experimental|Finerenone (BAY94-8862)[7.5mg] + Placebo|Oral - 7.5mg OD for 30 days. Potential up-titration to 15 mg OD after 30 days or 60 days. Treatment duration 90 days. Placebo OD for 90 days.
89590093|NCT01807221|Experimental|Finerenone (BAY94-8862)[10mg] + Placebo|Oral - 10mg OD for 30 days. Potential up-titration to 20 mg OD after 30 days or 60 days. Treatment duration 90 days. Placebo OD for 90 days.
89590094|NCT01807221|Experimental|Finerenone (BAY94-8862)[15mg] + Placebo|Oral - 15mg OD for 30 days. Potential up-titration to 20 mg OD after 30 days or 60 days. Treatment duration 90 days. Placebo OD for 90 days.
89590095|NCT01807221|Active Comparator|Eplerenone [25 mg] + Placebo|Oral - 25mg every other day (EOD). Potential up-titration to 25mg OD after 30 days and 50mg OD after 60 days.Placebo OD for 90 days.
89590096|NCT01838499|Experimental|MEDI8968|
89590097|NCT01838499|Placebo Comparator|Saline|
89590098|NCT01807065|Experimental|Arm A (sipuleucel-T)|Patients receive sipuleucel-T IV over 60 minutes days 22, 36, and 50.
89590099|NCT01807065|Experimental|Arm B (radiation therapy, sipuleucel-T)|Patients undergo external beam radiation therapy in weeks 1-2. Patients also receive sipuleucel-T as in Arm A.
89590100|NCT04583709|Experimental|ECG Belt|ECG belt will be used to record ECG during baseline rhythm, LBBP in unipolar and bipolar configurations and / or during HOT-CRT using HBP or LBBP. These ECG belt characteristics would then be compared with baseline and existing data on RV pacing and traditional Biventricular pacing.
89590101|NCT02031458|Experimental|Atezolizumab|
89590102|NCT02009696||Pacemaker Therapy|Patients with a ProMRI Pacemaker System
89590103|NCT01806597|Experimental|secukinumab 150mg|201 subjects were randomized in a 1:1:1 ratio to secukinumab either 150 mg or 300 mg, or placebo. Subjects assigned to secukinumab 150 mg were dosed weekly for the first five weeks, then every four weeks up to and including Week 128. To maintain blinding, subjects received additional placebo injections at Weeks 17, 18 and 19. All doses of study treatment were administered by sub-cutaneous injections.
89590104|NCT01806597|Experimental|secukinumab 300 mg|201 subjects were randomized in a 1:1:1 ratio to secukinumab either 150 mg or 300 mg, or placebo. Subjects assigned to secukinumab 300 mg were dosed weekly for the first five weeks and then every four weeks up to and including Week 128. In order to maintain the blinding, subjects received additional placebo injections at Weeks 17, 18 and 19. All doses of study treatment were administered by sub-cutaneous injections.
89590105|NCT01806597|Placebo Comparator|Placebo|201 subjects were randomized in a 1:1:1 ratio to secukinumab either 150 mg or 300 mg, or placebo. Subjects on placebo were dosed weekly for 5 weeks then once every 4 weeks. At Week 16, ppIGA responders continued to receive placebo weekly for 5 weeks starting at Week 16, then every 4 weeks up to and including Week 76 while ppIGA non-responders were randomized in a 1:1 ratio to secukinumab either 150 mg or 300mg weekly for 5 weeks, starting at Week 16, then every 4 weeks up to and including Week 128. At Week 80, subjects on placebo were either terminated their participation, if ppIGA responders, or randomized in a 1:1 ratio to secukinumab either 150 mg or 300 mg once every 4 weeks until Week 128 inclusive. All doses of study treatment were administered by sub-cutaneous injections.
89590106|NCT02031302||Lotus Valve|All subjects who are candidates for Transcatheter Aortic Valve Implantation (TAVI), signed the Informed Consent Form (ICF) and are selected to receive a Lotus Valve.
89590107|NCT02031302||Lotus with Depth Guard|All subjects who are candidates for Transcatheter Aortic Valve Implantation (TAVI), signed the Informed Consent Form (ICF) and are selected to receive a Lotus with Depth Guard.
89590108|NCT01610037|Experimental|QVA149|
89590109|NCT01610037|Active Comparator|Tiotropium|
89590110|NCT01610037|Placebo Comparator|placebo|
89590111|NCT04687514|Experimental|Phase a (V1a-Ev2a): Dulaglutide first- Phase b (V1b-Ev2b) Placebo second|Dulaglutide is injected via pen s.c. once a week. The titration scale will be 1x 1.5mg in 0.5 ml in the first week and 2x 1.5 mg in 2x 0.5 ml once weekly for 3 further weeks. Dulaglutide or placebo weekly subcutaneously for 4 weeks; in random order, separated by washout period of at minimum 28 days.
89590112|NCT04687514|Experimental|Phase a (V1a-Ev2a): Placebo first- Phase b (V1b-Ev2b) Dulaglutide second|The Placebo will be injected via syringe and contains 0.5ml (only first injection) or 2x0.5ml (second to fourth injection) of 0.9% sodium chloride (0.9% NaCl). Dulaglutide or placebo weekly subcutaneously for 4 weeks; in random order, separated by washout period of at minimum 28 days.
89590113|NCT01806051|Experimental|PKU Participants (Arm 1)|"Subjects will be administered Kuvan once daily.~They will undergo several blood draws, including a 24-Hour Blood Assessment (at Study Visit #2 before the commencement of Kuvan), plasma Phe/Tyr draws (at Study Visits #3, 4, and 5), and another 24-Hour Blood Assessment (at Study Visit #6)."
89590114|NCT01806051|No Intervention|Control Group (Arm 2)|"Subjects allocated into this group will be healthy, non-PKU individuals that may be a relative (ex: sibling) of a PKU participant, but they don't have to be a blood relation.~These subjects will undergo a 24-Hour Blood Assessment (at Study Visit #2)."
89590115|NCT01837797|Placebo Comparator|Placebo|Placebo adjunct to open-label treatment with a commercially available antidepressant (ADT)
89590116|NCT01837797|Experimental|Brexpiprazole 1 mg|Brexpiprazole adjunct to open-label treatment with a commercially available ADT. Brexpiprazole dosing was 0.5 mg/day in the first 1 week followed by 1 mg/day.
89590117|NCT01837797|Experimental|Brexpiprazole 3 mg|Brexpiprazole adjunct to open-label treatment with a commercially available ADT. Brexpiprazole dosing was 0.5 mg/day in the first 1 week, 1 mg/day in the second week, followed by 3 mg/day.
89590118|NCT01984424|Other|Part A: Atorvastatin 20 mg => Placebo|Participants received atorvastatin 20 mg orally for 10 weeks (period 1) followed by placebo orally for 10 weeks (period 2), separated by a 2-week washout period.
89590119|NCT01984424|Other|Part A: Placebo => Atorvastatin 20 mg|Participants received placebo orally for 10 weeks (period 1) followed by atorvastatin 20 mg orally for 10 weeks (period 2), separated by a 2-week washout period.
89590120|NCT01984424|Active Comparator|Part B: Ezetimibe|Participants received 10 mg ezetimibe orally only a day and placebo to evolocumab by subcutaneous injection once a month for 24 weeks.
89590121|NCT01984424|Experimental|Part B: Evolocumab|Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo to ezetimibe orally once a day for 24 weeks.
89030705|NCT05144672||Patient Group|The patient group will include 60 patients with type II DM. They will be subdivided into three groups according to albumin-creatinine ratio ,normoalbuminuric group(less than 30mg/g),which will include 20 patients, microalbuminuric group (ACR =30-300 mg/), which will include 20 patients, and macroalbuminuric group (ACR more than 300mg/g),which will include 20 patients.
89030706|NCT05144672||Control Group|control group will include 30 apparently healthy age-matched and sex-matched individuals.
89030707|NCT02948166|Active Comparator|Stenting of the femoral artery|A standard endovascular treatment of the steno-occlusive lesion in femoro-popliteal arterial segment.
89030708|NCT02948166|Experimental|Open surgery|Performed open endarterectomy of the common, deep, initial of superficial femoral artery. Delamination factory complex into the lumen of the loop. After that, the translational and rotational motions loops under fluoroscopic guidance, continuing detachment of plaque in the antegrade direction to the distal end of plaque. Plastic arteriotomnyh wounds performed patches of ksenoperikard treated with epoxy compounds. Control patency of the arterial bed is performed intraoperatively by X-ray angiography.
89030709|NCT04694040||healthy adult volunteers showing no signs of temporomandibular disorders|
89030710|NCT05144594||Patients diagnosed with IBS|Patients diagnosed with IBS within primary care in Region Örebro County between 2013-2017, identified by ICD-code K.58.
89030711|NCT04694469||Group Day|operated at 07:30 AM - 06:30 PM
89030712|NCT04694469||Group Night|operated at 06:30 PM - 07:30 AM
89030713|NCT04693923|Experimental|Group A (rapid fluid challenge)|Patients will receive a rapid fluid challenge (4ml/kg of crystalloids in 5 minutes using a syringe of 60 mL and a timer in the multiparameter monitor).
89030714|NCT04693923|Active Comparator|Group B (standard fluid challenge)|Patients will receive a standard fluid challenge (500 ml of crystalloids in 30 minutes).
89030715|NCT00523185|Active Comparator|2|
89030716|NCT00523185|Active Comparator|1|
89030717|NCT04512443||1|42 women (treated with Daflon 1000 mg (study group))
89030718|NCT04512443||2|41 women (placebo (control group))
89030719|NCT04512404||hypercholesterolemia|"3-hydroxy-3-methylglutaric acid coenzyme A (HMG Co-A) reductase inhibitor Types of drug, dosage and frequency is according to the treating physician. This is an observational study.~Duration of treatment: 3-5 months"
89030720|NCT04693962||Partial Nephrectomy (PN)|Patients that will undergo PN with a transient and controlled renal ischemia injury using a renal artery clamping.
89030721|NCT04693962||Hemicolectomy (HC)|Patients who will undergo HC, as non-renal ischemia surgery controls, with similar demographic characteristics, but submitted to HC.
89030722|NCT04693962||Nephrolithotomy (NL)|Patients who undergo NL as non-renal ischemia surgery controls but with kidney physical injury
89030723|NCT05149118|Experimental|PDRN injected group|The participants in treatment group had received two consecutive injections of PDRN one day and two days after the surgery. A total 1mL of PDRN was injected along the suture line at distance of 1cm in each session.
89030724|NCT05149118|No Intervention|Control group|The participants in control group were left untreated.
89030725|NCT00521664|Active Comparator|1|Therapeutic platelet transfusion (TP) strategy versus prophylactic platelet transfusion (PP) strategy. In the TP arm platelet transfusion is only required if bleeding occurs (more than petechial)or in case of pulmonary infections with or without sepsis.
89030726|NCT00521664|Active Comparator|2|In the PP arm platelet transfusion has to be performed when platelet count is below 10.000/µL in any case and when bleeding (more than petechial) occurs.
89030727|NCT00521703|Experimental|1|group treated
89030728|NCT00521703|Placebo Comparator|2|control group
89030729|NCT05144321||All pregnant women delivering a twin pregnancy|All pregnant women delivering a twin pregnancy
89030730|NCT00523224|Experimental|single arm|open lable,single arm , intervention is Angiogenic Cell Precusors(ACPs)
89030731|NCT00521742|Experimental|Pioglitazone 15 mg to 45 mg QD|
89030732|NCT00521742|Active Comparator|Glyburide 2.5 mg to 15 mg, QD|
89030733|NCT00521742|Experimental|Pioglitazone 15 mg or 30 mg QD|
89030734|NCT00521742|Active Comparator|Glyburide 5 mg or 10 mg, QD|
89030735|NCT05144204|Experimental|Irritable Bowel Syndrome Patients|
89030736|NCT00521781|Experimental|1|Treatment will be Abraxane/hormonal therapy (LHRH Agonist) for four nine-week cycles, followed by Total androgen blockade therapy (LHRH Agonist+ Anti-androgen) for 2 years from the time the hormonal therapy was started.
89030737|NCT05144126|Experimental|i-Factor Arm|All patients undergoing spine fusion surgery will be treated with i-FACTOR
89030738|NCT00521820|Experimental|Pioglitazone QD|
89030739|NCT00521820|Active Comparator|Glyburide QD|
89030740|NCT00523263|Active Comparator|Dacron|Patients receiving polyester above-knee femoro-popliteal bypass
89030741|NCT00523263|Active Comparator|HUV|patients receiving HUV femoro-popliteal bypass
89030742|NCT04696328|Experimental|Group of subjects undergoing cell transplantation|Human (allogeneic) iPS cell derived-cardiomyocyte sheet transplantation (only once)
89030743|NCT00521859|Experimental|Cloretazine + Fludarabine|
89030744|NCT02954861||Cardiac surgery|Patients who develop delirium following cardiac surgery
89030745|NCT00521898|Experimental|DMEK|DMEK as intervention
89030746|NCT02954666|Experimental|Patients with neurally mediated syncope|Tailored radio-frequency ablation of the ARGP (CardNM).
89030747|NCT02954666|Experimental|Patients with sick sinus syndrome|Tailored radio-frequency ablation of the ARGP (CardNM).
89030748|NCT00521937|Experimental|A|Dermagen®
89030749|NCT00521937|Active Comparator|B|Conventional treatment
89030750|NCT02954705||Group AAV|Patients recruited from the Nantes University Hospital. 50 milliliter of blood and 10mL of urine are collected from these patients during levies in clinical visit.
89030751|NCT02954705||Group control|"People recruited from the Etablissement français du sang (French blood establishment ).~10 milliliter of blood are collected from these donors"
89030752|NCT04693611|Experimental|Intervention Group|"Participants who meet the inclusion criteria will be randomised to the CS intervention group or to the control group that will maintain their usual treatment.~Participants in the intervention group will participate in two CS sessions per 12 weeks besides their treatment as usual."
89608461|NCT01272778|Experimental|Lorazepam, 0.5 mg|All subjects receive lorazepam 0.5 mg in this crossover design.
89590122|NCT01984424|Experimental|Part C: Open-label Evolocumab|Participants who completed part B and were eligible to proceed to open-label extension part C and could choose quarterly between evolocumab 420 mg once a month or evolocumab 140 mg every 2 weeks for up to 2 years.
89590123|NCT01837719|Experimental|Treatment A: Atazanavir + Cobicistat coadministered|Participants received a single dose of atazanavir, 300 mg as capsule, coadministered with cobicistat,150 mg as tablet, following a light meal on Day 1 or 8
89590124|NCT01837719|Experimental|Treatment B: Atazanavir/Cobicistat FDC|Participants received a single fixed-dose combination (FDC) of atazanavir, 300 mg/cobicistat, 150 mg, following a light meal on Day 1 or 8
89590125|NCT01837719|Experimental|Treatment C: Atazanavir + Cobicistat coadministered|Participants received a single dose of atazanavir, 300 mg as capsule, coadministered with cobicistat,150 mg as tablet, in the fasted state on Day 15 or 22
89590126|NCT01837719|Experimental|Treatment D: Atazanavir/Cobicistat FDC|Participants received a single FDC dose of atazanavir, 300 mg/cobicistat, 150 mg, in the fasted state on Day 15 or 22
89590127|NCT01837719|Experimental|Treatment E: Atazanavir/Cobicistat FDC|Participants received a single FDC dose of atazanavir, 300 mg/cobicistat, 150 mg, following a high-fat meal on Day 29
89590128|NCT01984268|Experimental|Four week ACTHAR treatment|Rheumatoid arthritis subjects with inadequate response to methotrexate will be randomized to receive twice a week dosing of ACTHAR for a period of four weeks.
89590129|NCT01984268|Experimental|Twelve week ACTHAR treatment|Rheumatoid arthritis subjects with inadequate response to methotrexate will be randomized to receive twice a week dosing of ACTHAR for a period of twelve weeks.
89590130|NCT04675580|Experimental|Tele Toy Talk|Caregivers of child participants receive 1-hour of telemedicine featuring parent-mediated naturalistic developmental behavioral intervention weekly for 10 weeks.
89590131|NCT04675580|No Intervention|Multiple Baseline|Prior to receiving the intervention, participants will be randomized into one of three baseline conditions: a three-, four-, or five-week baseline period. At each weekly baseline session, caregivers will record the Tele-BOSCC (see Outcomes Measures section).
89590132|NCT04675190||Case|Cases will be patients in the department of surgery above 18 years with ultrasound findings of gall stone disease.
89590133|NCT04675190||Control|Controls will be patients in the department of surgery above 18 years with ultrasound findings showing evidence of no gallstones
89590134|NCT04674800|Experimental|Single, test arm|MYL-1701P- Subjects will receive 3 doses each of 2 mg at 8 weeks interval
89590135|NCT02031146|Other|LP|Participants undergo lumbar puncture for CSF evaluation
89590136|NCT02031146|No Intervention|No LP|Participants do not undergo lumbar puncture and CSF is not examined.
89590137|NCT02009384|Experimental|Ipilimumab|IV ipilimumab
89590138|NCT01805037|Experimental|Treatment (brentuximab vedotin, rituximab)|"INDUCTION: Patients receive brentuximab vedotin IV over 30 minutes once weekly for 3 weeks and rituximab IV once weekly for 4 weeks. Patients unable to achieve CR may receive additional optional consolidation therapy identical to induction therapy.~MAINTENANCE THERAPY: Patients receive brentuximab vedotin IV once every 3 weeks and rituximab IV once every 6 weeks. Treatment repeats every 21 days for up to 1 year in the absence of disease progression or unacceptable toxicity."
89590139|NCT01803711|Experimental|Desvenlafaxine + Omega 3 FA supplement|Desvenlafaxine 50mg/day & Omega 3 FA supplement (range 2.4 gm/day - 4.8 gm day) over a 12 week period
89590140|NCT01803711|Active Comparator|Desvenlafaxine + Placebo (for Omega 3 FA supplement)|Desvenlafaxine 50mg/day & Placebo (for Omega 3 FA supplement) over a 12 week period
89590141|NCT01836549|Experimental|Treatment (imetelstat sodium)|"Molecular Biology Phase: Patients will receive one infusion of imetelstat prior to surgery. Surgery will take place 12-24 hours after the infusion of imetelstat. Patients will continue to receive therapy on the same schedule as the Phase II patients starting 14-21 days after surgery.~Phase II: Patients receive imetelstat sodium IV over 2 hours on days 1 and 8. Treatment repeats every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity."
89590142|NCT01836471|Experimental|QAW039 450 mg qd Non-atopic|QAW039 450 mg (3 capsules of QAW039 150 mg) qd combined with background ICS (100 μg fluticasone, bid). Non-atopic patients randomized in ratio of approximately 1:1.
89590143|NCT01836471|Placebo Comparator|Placebo Non-atopic|Placebo to QAW039 (3 capsules of Placebo of QAW039 150 mg) combined with background ICS (100 μg fluticasone, bid). Non-atopic randomized in ratio of approximately 1:1.
88976763|NCT00168766|Placebo Comparator|2|interferon-beta-1a in combination with placebo
88976764|NCT04731909|Experimental|Toripalimab Combined With Anlotinib, Etoposide and Platinum|Toripalimab 240mg,d1,q3w+Anlotinib 12mg/d,d1-14,q3w+Etoposide 100mg/m2,d1-3,q3w+Cisplatin 75mg/m2 or Carboplatin AUC=5, d1, q3w,4-6 cycles in total. After the end of the first-line treatment, patients with CR, PR, and SD can continue to maintenance treatment with Toripalimab 240mg,d1,q3w+Anlotinib 12mg/d, was taken orally for 2 weeks and stopped for 1 week until the disease progressed.
89590144|NCT01836471|Experimental|QAW039 450 mg qd Atopic|QAW039 450 mg (3 capsules of QAW039 150 mg) qd combined with background ICS (100 μg fluticasone, bid). Atopic patients randomized in a ratio of approximate 1:1:1
89590145|NCT01836471|Active Comparator|Fluticasone 150 mcg bid Atopic|Placebo to QAW039 (3 capsules of Placebo of QAW039 150 mg) combined with 150 μg ICS and with background ICS (100 μg fluticasone, bid). As a consequence total ICS was 250 μg fluticasone bid. Atopic patients randomized in ratio of approximately 1:1:1
89590146|NCT01836471|Placebo Comparator|Placebo Atopic|Placebo to QAW039 (3 capsules of Placebo of QAW039 150 mg) combined with background ICS (100 μg fluticasone, bid). Atopic patients andomized in ratio of approximately 1:1:1
89590147|NCT02030600|Experimental|IDeg OD ± OADs followed by IGlar OD ± OADs|The trial includes two 32-week treatment periods in a cross-over design. Total trial duration for the individual subjects will be up to 67 weeks.
89590148|NCT02030600|Active Comparator|IGlar OD ± OADs followed by IDeg OD ± OADs|The trial includes two 32-week treatment periods in a cross-over design. Total trial duration for the individual subjects will be up to 67 weeks.
89590149|NCT01802775|Experimental|edoxaban/aspirin|Open label edoxaban will be provided. Subjects randomized to this treatment arm will receive edoxaban 60 mg once daily (QD) (two 30 mg tablets) for a total of approximately 3 months on a background of aspirin 100 mg QD.
88976765|NCT00169000|Experimental|Capecitabine and Docetaxel|Escalating doses of capecitabine days 1-14 with a fixed dose of docetaxel on Day 8 of a 21 day cycle
89590150|NCT01802775|Active Comparator|clopidogrel/aspirin|Open label clopidogrel will be provided. Subjects randomized to this treatment arm will receive clopidogrel 75 mg QD (one 75 mg tablet) for a total of approximately 3 months on a background of aspirin 100 mg QD. A loading dose of clopidogrel 300 mg (four 75mg tablets) will be given to subjects as the first dose as early as possible after adequate hemostasis (i.e., within 4 hours of hemostasis).
89590151|NCT04591041|Experimental|Training by Mixed Reality Simulation|
89590152|NCT04591041|Active Comparator|Training by Mannequin Based Simulation|
89590153|NCT01802385|No Intervention|Placebo|Standard cryptococcal meningitis therapy with amphotericin (0.7-1.0 mg/kg/day) + fluconazole (800-1200mg/day) + placebo
89590154|NCT01802385|Experimental|Sertraline 400mg|Standard cryptococcal meningitis therapy with amphotericin (0.7-1.0 mg/kg/day) + fluconazole (800-1200mg/day plus adjunctive sertraline therapy at 400mg/day for 2 weeks, then 200mg for 12 weeks, and then tapered over 3 weeks.
89590155|NCT01773993||Pregabalin|Subjects who are treated with pregabalin
89590156|NCT01802073|Experimental|Oral Vancomycin|1) For children who weight < or = 30 kg, the vancomycin dose will be 50 mg/kg/day given orally 3 times per day for the 1st month and continue with the same dose for subsequent months if the clinical laboratory studies improved and are normal. If the laboratory studies are not normal the dose will be increased to 75 mg/kg/day given orally 3 times per day for the 2nd month and 100mg/kg/day given orally 3 times per day the 3rd month. If the laboratory studies do not improve by the end of the 3rd month since starting the vancomycin, the vancomycin will be stopped and the child will not continue the study. 2) For adults and children who weigh >30 kg, the vancomycin dose will be 500 mg given orally 3 times per day for the 1st month and continue with this dose if the clinical laboratory studies improve and are normal. If the laboratory studies are not normal the dose will be increased to 750 mg 3 times per day for the 2nd month and 1000 mg 3 times per day the 3rd month.
89590157|NCT01607073|Other|open label adjunctive add on|open label adjunctive add on of verapamil to existing medications. dosing begins at 1 mg/kg/d and increases weekly to target of 4 mg/kg/d in divided doses (three times/day)
89590158|NCT01773291|Experimental|acupuncture|acupuncture on GV26 and 12 Well points
89590159|NCT01773291|Experimental|laser acupuncture|laser acupuncture on GV26 and 12 Well points
89590160|NCT01773291|Sham Comparator|control group|laser acupuncture without laser output in control group.
89590161|NCT01801917|Placebo Comparator|Placebo|5 placebo tablets daily during non-titration phase
88976766|NCT00169117|Experimental|1|Behavioural intervention: Songs/posters aimed at behaviour change to increase repair and maintenance of mosquito nets
88976767|NCT05176743|Other|Usual Care|"Referral to services~Nutrition pamphlets~One-time payment of $300 paid 4 months after baseline"
88976768|NCT05176743|Experimental|Unconditional Cash Transfer Intervention|"Three monthly payments of $100~Referral to services~Nutrition pamphlets"
88976769|NCT00169156|Experimental|Rituximab + CHOP|Rituximab + CHOP regimen Prednisone - Doxorubicine - Cyclophosphamide - Vincristine
88976770|NCT00169195|Experimental|R-GEMOX|Gemcitabine-Oxaliplatin plus Rituximab (R-GEMOX)
88976771|NCT00169234|Experimental|0.1mL Pneumococcal Conjugate Vaccine|Participants in this group were randomized at enrollment to receive 0.1mL PCV7, Prevnar® at the enrollment visit and then 0.1mL Pneumococcal Polysaccharide Vaccine 12 months later.
88976772|NCT00169234|Experimental|0.5mL Pneumococcal Conjugate Vaccine|Participants in this group were randomized at enrollment to receive 0.5mL PCV7, Prevnar® at the enrollment visit and then 0.1mL Pneumococcal Polysaccharide Vaccine 12 months later.
88976773|NCT00169234|Experimental|1.0mL Pneumococcal Conjugate Vaccine|Participants in this group were randomized at enrollment to receive 1.0mL PCV7, Prevnar® at the enrollment visit and then 0.1mL Pneumococcal Polysaccharide Vaccine 12 months later.
88976774|NCT00169234|Experimental|2.0mL Pneumococcal Conjugate Vaccine|Participants in this group were randomized at enrollment to receive 2.0mL PCV7, Prevnar® at the enrollment visit and then 0.1mL Pneumococcal Polysaccharide Vaccine 12 months later.
88976775|NCT00169234|Experimental|0.5mL Pneumococcal Polysacc Vaccine|Participants in this group were randomized at enrollment to receive 0.5mL Pneumovax 23 at the enrollment visit and then 0.1mL Pneumococcal Polysaccharide Vaccine 12 months later.
88976776|NCT00169273|Active Comparator|Weight loss only intervention|Structured group weight loss intervention
88976777|NCT00169273|Experimental|Combined intervention|Structured group program for weight loss and depression
89590162|NCT01801917|Experimental|BAF312 2mg|1 tablet of BAF312 2 mg + 4 tablets of Placebo daily during non-titration phase
88976778|NCT00398333|Experimental|Eicosapentaenoic acid enriched nutritional supplement|
88976779|NCT00398333|No Intervention|No supplementation|
88976780|NCT00169390||pregnant smokers|
88976781|NCT00169390||pregnant non smokers|
88976782|NCT00169546|Experimental|Arm 1|
88976783|NCT05015556|No Intervention|Casting|Casting of the distal radius for 6 weeks
88976784|NCT05015556|Active Comparator|Minimal invasive volar plating|Muscle sparing osteosynthesis, no casting postoperatively
88976785|NCT04723888|Experimental|alpha-ketoglutarate Group|Take alpha-ketoglutarate supplements, alpha-ketoglutarate 300mg/d mixed with food or drink, for 1 years
89590163|NCT01801917|Experimental|BAF312 10 mg|5 tablets of BAF312 2 mg daily during non-titration phase
89590164|NCT04170075|No Intervention|Usual Care (UC)|Participants randomly assigned to the UC group will serve as controls and will be tested at the same time points as the WBV group. The UC group will be asked not to change their physical activity or dietary habits across the intervention period and we will track any changes using a questionnaire.
89590165|NCT04170075|Experimental|Whole body vibration (WBV)|Participants assigned to the WBV group will participate in twice daily 10-minute WBV training sessions, 7 days a week. Each WBV session will consist of a series of timed stands on the vibration platform (Marodyne LiV). During a timed stand, participants will perform slow controlled weight shifting exercises and gentle squats. The vibration frequency will be set at 30Hz and the amplitude set at 50-200 microns, for a total body acceleration of 0.4g+/-20%.
89590166|NCT02008916|Experimental|Secukinumab 10 mg/kg i.v. / 300 mg s.c.|Three i.v. infusions: at Baseline and weeks 2 and 4, followed by one s.c. injection every four weeks until the end of the study.
89590167|NCT02008916|Experimental|Secukinumab 10 mg/kg i.v. / 150 mg s.c.|Three i.v. infusions: at Baseline and weeks 2 and 4, followed by one s.c. injection every four weeks until the end of the study.
89590168|NCT02008916|Placebo Comparator|Placebo i.v. and s.c.|Three i.v. infusions: at Baseline and weeks 2 and 4, followed by one s.c. injection at weeks 8 and 12. At week 16, patients were re-randomised to one of the active treatment arms, to receive secukinumab s.c. Q4W until the end of the study.
89590169|NCT01772823|Experimental|3MV Behavioral Intervention Group|3MV Behavioral Intervention combined with open label FTC/TDF (Truvada®) as PrEP
89590170|NCT01772823|Experimental|PCC Behavioral Intervention Group|PCC Behavioral Intervention combined with open label FTC/TDF (Truvada®) as PrEP
89590171|NCT04177082|Experimental|Pulsed 6mW/cm2|6mW/cm2, with pulsed mode, 10 seconds on, 10 second off, for 30 minute total treatment time
89590172|NCT04177082|Experimental|Pulsed 4mW/cm2|4mW/cm2, with pulsed mode, 10 seconds on, 10 second off, for 45 minute total treatment time
89590173|NCT02029976|Active Comparator|attention control condition|Child and parent participants randomized to the attention control condition will receive a Newsletter Program or mailed monthly newsletter with general family-focused health information.
89590174|NCT02029976|Experimental|after school weight management program|The 9-month after school weight management program called SNAPSHOT (Student, Nurses and Parents Seeking Healthy Options Together), with a focus on healthy food and activity practices will be directed by a school nurse and will include: 1) quarterly parent/child coaching sessions with the school nurse held in the participant's home; 2) 14 child group sessions led by the school nurse, held in a school setting 1-2 times a month; 3) 5 parent group sessions led by a school nurse held in a school setting.
89590175|NCT01983254|Experimental|Coping skills training|6 sessions of weekly telephone-based coping skills training delivered by trained interventionist
89590176|NCT01983254|Active Comparator|education program|6 week access to a web-based, critical illness-specific education program
89590177|NCT01771809|Experimental|SHP647 75 mg|Participants will receive 75 milligrams (mg) of SHP647 subcutaneous (SC) injection every 4 weeks for 72 weeks in the anterolateral right/left thigh or the deltoid area or the abdomen. During the first 72 weeks, a one time dose escalation to 225 mg of SHP647 SC injection every 4 weeks is allowed after 8 weeks of the study for participants who experience clinical deterioration or unacceptably low level of response to the investigational product. The decision to escalate will be guided by the response and relapse criteria tempered by clinical judgment. Following the first 72 weeks, participants will receive 75 mg of SHP647 SC injection every 4 weeks for an additional 72 weeks in the anterolateral right/left thigh or the deltoid area or the abdomen.
89209900|NCT00891696|Placebo Comparator|Exp 2 and 3: LExFR|Participants will receive placebo rapamycin and will undergo low-intensity resistance exercise with blood flow restriction.
89209901|NCT00891696|Active Comparator|Exp 2: SNP|Participants will receive sodium nitroprusside in a resting state.
89590178|NCT01771809|Experimental|SHP647 225 mg|Participants will receive 225 mg of SHP647 SC injection every 4 weeks for 72 weeks followed by 75 mg of SHP647 SC injection every 4 weeks for an additional 72 weeks in the anterolateral right/left thigh or the deltoid area or the abdomen.
89590179|NCT01771731|Experimental|Cannabis|Contents of 1 cannabis cigarette (4.7% THC/5.1% CBD) will be vaporized and inhaled at 12pm on Day 1; 8am, 2pm and 8pm on Days 2-4; and 8am on Day 5.
89590180|NCT01771731|Placebo Comparator|Placebo|Contents of 1 placebo cigarette (0% THC/0% CBD) will be vaporized and inhaled at 12pm on Day 1; 8am, 2pm and 8pm on Days 2-4; and 8am on Day 5.
89590181|NCT01982942|Experimental|ibudilast|Subjects will receive up to 100 mg/d ibudilast for 96 weeks.
89590182|NCT01982942|Placebo Comparator|Placebo Oral Capsule|Subjects will receive placebo for 96 weeks.
89590183|NCT01769469||Subjects Enrolled in ATN 110 or ATN 113|A subset of 100 participants who are enrolled in the ATN 110 or ATN 113 study will be recruited for participation in this study. There is no treatment or intervention for this study; however, all subjects will be on daily coformulated tenofovir/emtricitabine (TDF/FTC (Truvada®)) as part of the ATN 110 or ATN 113 study.
89590184|NCT02008526|Experimental|TXT-PHE|"Gay-specific, Theory-based Text Messages Transmitted by Peer Health Educators (TXT-PHE)~This condition is interactive and tailored to the needs of the individual participant. PHEs initiate (i.e., push) text messages to participants and also respond to participant-initiated queries and participant responses to the PHE messages (i.e., pull).~Participants receive five pre-written messages per day sent on a predetermined schedule. Participants who respond to the pre-written text messages or initiate queries or requests for support (pull) are sent additional real-time messages back from the PHE.~During the 8-week intervention, participants receive a brief weekly text-based assessment on their methamphetamine use and HIV sexual behaviors in the previous seven days."
89608462|NCT01272778|Experimental|Lorazepam, 1.0 mg|All subjects receive lorazepam 1.0 mg in this crossover design.
89608463|NCT01272778|Experimental|Lorazepam, 2.0 mg|All subjects receive lorazepam 2.0 mg in this crossover design
89608464|NCT01272778|Placebo Comparator|Sugar pill|All subjects receive a sugar pill in this crossover design.
88976786|NCT04723888|No Intervention|Normal Control Group|Don't take alpha-ketoglutarate supplements
88976787|NCT00169702|Other|Standard|standard information
88976788|NCT00169702|Active Comparator|Intervention|weight management program, 12 sessions, 2 weekly, psychoeducational program, interactive topics like healthy food, diet behavior, physical activity, stress reduction.
88976789|NCT00407641|Experimental|Tinzaparin|Patients will receive Tinzaparin as anticoagulant during the HD session.
88976790|NCT00407641|Active Comparator|Heparin|Patients will receive Heparin as an anticoagulant during the HD session
88976791|NCT00169741|Other|cohort|
88976792|NCT00169780||cohort|patients who require a CT scan prior to kidney stone surgery for diagnostic purposes
88976793|NCT00169897|Experimental|Hospital-based|This group has to go at the hospital 3 times per week to do the exercise program.
89590185|NCT02008526|Experimental|TXT-Auto|"Group 2: Gay-specific, Theory-based Text Messages Transmitted by Automation (TXT-Auto)~Participants assigned to this group receive automatic text-messages.~Following the initial welcome message, participants receive five pre-written messages per day sent on a predetermined schedule.~During the 8-week intervention, participants receive a brief weekly text-based assessment on their methamphetamine use and HIV sexual behaviors in the previous seven days."
89590186|NCT02008526|No Intervention|Assessment Only (AO)|During the 8-week intervention, participants receive a brief weekly text-based assessment on their methamphetamine use and HIV sexual behaviors in the previous seven days.
89590187|NCT04581915|Experimental|Interventional|Participants to receive Triazavirin 250mg po 8 hourly for 5 days
89590188|NCT04581915|Placebo Comparator|Control|Participants to receive placebo po 8 hourly for 5 days
89590189|NCT01769391|Experimental|Necitumumab +Paclitaxel+Carboplatin|"Necitumumab 800 milligram (mg) administered intravenously (IV) on Days 1 and 8 of every 3 week cycle.~Paclitaxel 200 milligram per square meter (mg/m²) administered IV on Day 1 of every 3 week cycle.~Carboplatin Area Under the Curve (AUC)6 (mg•min/mL) administered IV on Day 1 of every 3 week cycle.~The combination of paclitaxel-carboplatin and necitumumab may continue for a maximum of 6 cycles. Necitumumab may continue until Progressive Disease (PD), toxicity requiring cessation, protocol noncompliance, or withdrawal of consent."
89590190|NCT01769391|Active Comparator|Paclitaxel + Carboplatin|Paclitaxel 200 mg/m² administered IV on Day 1 of every 3 week cycle. Carboplatin AUC=6 administered IV on Day 1 of every 3 week cycle. The combination of paclitaxel-carboplatin may continue for a maximum of 6 cycles. After completion of chemotherapy, participants will be followed until radiographic documentation of PD.
89590191|NCT01800903|Active Comparator|Sequence 1|SpeediCath catheter then ZN-D catheter then ZN-C catheter
89590192|NCT01800903|Experimental|Sequence 2|SpeediCath catheter then ZN-C catheter then ZN-D catheter
89590193|NCT01800903|Experimental|Sequence 3|ZN-D catheter then SpeediCath catheter then ZN-C catheter
89590194|NCT01800903|Experimental|Sequence 4|ZN-D catheter then ZN-C catheter then SpeediCath catheter
89590195|NCT01800903|Experimental|Sequence 5|ZN-C catheter then SpeediCath catheter then ZN-D catheter
89590196|NCT01800903|Experimental|Sequence 6|ZN-C catheter then ZN-D catheter then SpeediCath catheter
89590197|NCT04413747|Experimental|Yoga-based breathing support|Three daily yoga pranayama breathing cycles within existing home-care provision of Covid19's patients (protocols shared dated 27 March 2020 by Italian Society of Infectious and Tropical Diseases - Italian General Practitioners Physician - Italian Society of General Medicine, Italy)
89590198|NCT01767987|Active Comparator|Ranolazine|Oral treatment Intervention: Drug: Ranolazine 1000 mg
89590199|NCT01767987|Placebo Comparator|Placebo|Oral treatment Intervention: Drug: Placebo
89590200|NCT01800201|No Intervention|Control|The control group will have their claims data analyzed for a 12 month period. We will be examining these data for hospital admissions, new vascular events (AMI, stroke, acute coronary syndrome admission), or repeat or new cardiovascular procedures.
89590201|NCT01800201|Experimental|Intervention|The intervention group (1) will use GlowCaps, a remote monitoring and reminder pill bottle; (2) assigned an engagement advisor from the study team; (3) asked to provide study team with names and contact information of up to 3 family members or friends as support partners for med adherence. The study team will contact these people in order listed until 1 agrees to this role; (4) will select a 2-digit lucky number to be used as part of the sweepstakes-based engagement incentives in which eligibility to win will be conditional on med adherence; and (5) will determine preferences for Way to Health platform communication methods.The group receiving the program intervention will also have their claims data analyzed for the 12 months post-enrollment.
89590202|NCT01767909|Experimental|Insulin (Humulin® R U-100)|120 subjects will take two daily doses of INI (20 IU bid for a total daily dose of 40 IU) approximately 30 minutes after breakfast and dinner for 12 months. A 6-month open label period will follow in which all participants will receive INI.
89590203|NCT01767909|Placebo Comparator|Placebo|120 subjects will take two daily doses of placebo approximately 30 minutes after breakfast and dinner for 12 months. A 6-month open label period will follow in which all participants will receive INI.
88976794|NCT00169897|Active Comparator|Home-Based|The group had to do the exercise program at home with indirect supervision (Polar watches and a phone call per week).
88976795|NCT02970188|No Intervention|Normal Feeding|Subjects will be instructed to eat within their normal feeding window.
88976796|NCT02970188|Experimental|Time Restricted Feeding|Subjects will be instructed to eat with an 8 hour feeding window, starting between 10:30-11:30 AM and stopping between 5:30-6:30 PM.
88976797|NCT00170209|Active Comparator|Isoniazid|The standard therapy will be daily self-administered INH, 10-15 mg/kg/day (max=300mg/day) for 9 months (9INH).
88976798|NCT00170209|Active Comparator|Rifampin|The experimental arm will be daily self-administered RIF 10-20 mg/kg/day for 4 months (4RIF).
89590204|NCT02029274|Experimental|BAF312 0.5mg|During period 1, participants were uptitrated daily from BAF312 0.25 mg to 0.5 mg over a 10 day period. After, participants continued on 0.5 mg daily for up to 24 weeks. During period 2, participants were uptitrated daily from BAF312 0.25 mg to 2.0 mg over a 10 day period. After, participants continued on 2.0 mg daily for up to 24 weeks.
89590205|NCT02029274|Experimental|BAF312 2mg|During period 1, participants were uptitrated daily from BAF312 0.25 mg to 2.0 mg over a 10 day period. After, participants continued on 2.0 mg daily for up to 24 weeks. During period 2, participants were uptitrated daily from BAF312 0.25 mg to 2.0 mg over a 10 day period. After, participants continued on 2.0 mg daily for up to 24 weeks.
89608465|NCT01272856|Experimental|Open Label Abatacept|
89608466|NCT01273090|Experimental|Treatment|
88976799|NCT00170248|No Intervention|1|Physicians in this arm will be using the standard MOXXI electronic health record.
88976800|NCT00170248|Experimental|2|In addition to the standard MOXXI electronic health record, physicians in this arm will be using the computer-based decision support for asthma management
88976801|NCT00170287|Experimental|1|ICD Therapy plus VT-Ablation
88976802|NCT00170287|Active Comparator|2|ICD Therapy only
88976803|NCT00170326|Active Comparator|Dual Chamber pacing|conventional dual-chamber pacemaker/ICD implantation with the ventricular lead in the right ventricular apex
88976804|NCT00170326|Experimental|Biventricular pacing|Biventricular pacing: dual-chamber biventricular pacemaker/ICD implantation with leads at the right ventricular apex and the left ventricle
88976805|NCT02964091|Other|Harvoni|sofosbuvir/ledipasvir once daily for 12 weeks
88976806|NCT00170677|Active Comparator|A|
88976807|NCT00170677|Experimental|B|
88976808|NCT00170716|Active Comparator|Control|
88976809|NCT00170716|Experimental|Investigational|
88976810|NCT00170755|Experimental|1|Darifenacin
88976811|NCT04994106|Experimental|Cohort A1: AZD5462 Dose 1|Randomized healthy participants will receive Dose 1 of AZD5462.
88976812|NCT04994106|Experimental|Cohort A2: AZD5462 Dose 2|Randomized healthy participants will receive Dose 2 of AZD5462.
88976813|NCT04994106|Experimental|Cohort A3: AZD5462 Dose 3|Randomized healthy participants will receive Dose 3 of AZD5462.
88976814|NCT04994106|Experimental|Cohort A4 Japanese descent: AZD5462 Dose 3|Randomized participants of Japanese descent will receive Dose 3 of AZD5462.
88976815|NCT04994106|Experimental|Cohort A5: AZD5462 Dose 4|Randomized healthy participants will receive Dose 4 of AZD5462.
88976816|NCT04994106|Experimental|Cohort A6 Japanese descent: AZD5462 Dose 4|Randomized participants of Japanese descent will receive Dose 4 of AZD5462.
88976817|NCT04994106|Experimental|Cohort A7: AZD5462 Dose 5|Randomized healthy participants will receive Dose 5 of AZD5462.
88976818|NCT04994106|Experimental|Cohort A8 Japanese descent: AZD5462 Dose 5|Randomized participants of Japanese descent will receive Dose 5 of AZD5462.
88976819|NCT04994106|Placebo Comparator|Part A: Placebo (Healthy Participants)|Randomized healthy participants will receive Placebo matched to AZD5462.
88976820|NCT04994106|Placebo Comparator|Part A: Placebo (Japanese descent participants)|Randomized participants of Japanese descent will receive Placebo matched to AZD5462.
88976821|NCT04994106|Experimental|Cohort B1: AZD5462 Dose 1|Randomized healthy participants will receive Dose 1 of AZD5462.
88976822|NCT04994106|Experimental|Cohort B2: AZD5462 Dose 2|Randomized healthy participants will receive Dose 2 of AZD5462.
88976823|NCT04994106|Experimental|Cohort B3: AZD5462 Dose 3|Randomized healthy participants will receive Dose 3 of AZD5462.
88976824|NCT04994106|Experimental|Cohort B4: AZD5462 Dose 4|Randomized healthy participants will receive Dose 4 of AZD5462.
88976825|NCT04994106|Experimental|Cohort B5 Japanese descent: AZD5462 Dose 4|Randomized participants of Japanese descent will receive Dose 4 of AZD5462.
88976826|NCT04994106|Placebo Comparator|Part B: Placebo (Healthy participants)|Randomized healthy participants will receive Placebo matched to AZD5462.
88976827|NCT04994106|Placebo Comparator|Part B: Placebo (Japanese descent participants)|Randomized participants of Japanese descent will receive Placebo matched to AZD5462.
88976828|NCT00171145|Experimental|1|Darifenacin
88976829|NCT00171145|Placebo Comparator|2|Placebo
88976830|NCT00171184|Experimental|1|Darifenacin
88976831|NCT00171184|Placebo Comparator|2|Placebo
88976832|NCT00171496|Experimental|Cyclosporine microemulsion|
88976833|NCT00171496|Active Comparator|Tacrolimus|
88976834|NCT00171808|Experimental|Letrozole|
89209902|NCT00891696|Active Comparator|Exp 2: FR|Participants will undergo blood flow restriction in a resting state.
88976835|NCT00171847|Experimental|A - HER-2 +ve patients with Femara alone|
88976836|NCT00171847|Experimental|B - HER-2 +ve patients with Femara + Herceptin|
88976837|NCT00171847|Experimental|C - HER-2 -ve patients with Femara alone|
88976838|NCT00055679|Active Comparator|6 FEC|6 cycles of CYCLOPHOSPHAMIDE + EPIRUBICINE + 5-FLUOROURACILE
88976839|NCT00055679|Experimental|4 FEC|4 cycles of CYCLOPHOSPHAMIDE + EPIRUBICINE + 5-FLUOROURACILE
88976840|NCT00171886|Experimental|octrotide|
88976841|NCT00171964|Experimental|zoledronic acid + radiotherapy|zoledronic acid every 4 weeks in combination with radiotherapy
88976842|NCT00172003|Experimental|Zoledronic acid|Zoledronic acid, dosage according to calculated creatinine clearance, administered as a 15 minute infusion every 3 weeks for 12 months. Study infusion visits should occur not earlier than the scheduled visit and no later than 3 days after the scheduled visit. The dose of zoledronic acid in patients with baseline creatinine clearance > 60 mL/min was recommended to be 4 mg infused over no less than 15 minutes.
88976843|NCT00172081|Placebo Comparator|placebo|Daily subcutaneous injection into thigh or abdomen with 700 mg Calcium and 400 IU Vitamin D daily
88976844|NCT00172081|Experimental|PTH(1-84) 100 mcg|Subcutaneous injection of PTH(1-84) with 700 mg Calcium and 400 IU Vitamin D daily
88976845|NCT04830306|Active Comparator|6MST|Six minute step test
88976846|NCT04830306|Active Comparator|6MWT|Six minute walk test
88976847|NCT04830306|Active Comparator|CPET|Cardiopulmonary exercise test
88976848|NCT00055757|Experimental|Treatment (tipifarnib, gemcitabine, cisplatin)|"Patients receive oral tipifarnib twice daily on days 1-14, gemcitabine IV over 30 minutes on days 1 and 8, and cisplatin IV over 2 hours on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~Patients with at least stable disease may continue to receive oral tipifarnib alone twice daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity."
88976849|NCT02964286|Experimental|Acupressure group|The intervention technique used is ''The electric vibrating massager'', ''SAMPO®'', and patients are taught to apply the strong mode on the 15 specific points,5 min each, 3 times a day from Monday to Friday during chemotherapy course. The intervention follows the points are used to stimulate the hematopoietic function. including Hegu (LI4), Quchi (LI11), Xuehai (SP10); Sanyin-jiao (SP6), Taixi (K3), Zusanli (ST36), Taichong (LV3), Baihui (GV20). Before the study, the trained study nurses teach patients that how to use the technique and stuck adhesive dots label on each specific acupoints.
88976850|NCT02964286|No Intervention|Control group|The patients of the control group are not admitted any acupoints press-related interventions, only take clinical treatment protocol as usual.
88976851|NCT00045786|Experimental|400 mg CC-1088|
88976852|NCT00045786|Experimental|800 mg CC-1088|
88976853|NCT00045786|Experimental|1200 mg CC-1088|
88976854|NCT00045786|Experimental|1500 mg CC-1088|
89030753|NCT04693611|No Intervention|Control Group|Participants in the control group will maintain their usual treatment: social interaction activities, stimulation of personal skills, and any prescribed dementia-specific medication.
89590206|NCT02029274|Experimental|BAF312 10 mg|During period 1, participants were uptitrated daily from BAF312 0.25 mg to 10.0 mg over a 10 day period. After, participants continued on 10.0 mg daily for up to 24 weeks. During period 2, participants were uptitrated daily from BAF312 0.25 mg to 2.0 mg over a 10 day period. After, participants continued on 2.0 mg daily for up to 24 weeks.
89590207|NCT02029274|Placebo Comparator|Placebo|During period 1, participants received matching placebo daily for up to 24 weeks. During period 2, participants were uptitrated daily from BAF312 0.25 mg to 2.0 mg over a 10 day period. After, participants continued on 2.0 mg daily for up to 24 weeks.
89590208|NCT02008370|Experimental|Exparel infiltration|Exparel infiltrated into wound and chest tube sites
89590209|NCT01981616|Experimental|Vedolizumab 750 mg|Vedolizumab 750 mg, intravenous (IV) infusion, once on Day 1. Also 3 doses of a hepatitis B vaccine series on Days 4, 32 and 60, and 2 doses of an oral cholera vaccine on Days 4 and 18.
89590210|NCT01981616|Placebo Comparator|Placebo|Vedolizumab placebo-matching, IV infusion, once on Day 1. Also 3 doses of a hepatitis B vaccine series on Days 4, 32 and 60, and 2 doses of an oral cholera vaccine on Days 4 and 18.
89590211|NCT02104817|Experimental|EPANOVA|Epanova + statin, once daily
89590212|NCT02104817|Active Comparator|Corn oil|Corn oil + Statin
89590213|NCT01962103|Experimental|nab-paclitaxel|nab-paclitaxel 100-240 mg/m2 IV on Days 1, 8 and 15 of a 28-day cycle.
89590214|NCT01962103|Experimental|Phase 1: Nab-Paclitaxel 120 mg/m^2|nab-paclitaxel 120 mg/m^2 IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity to establish the RP2D.
89590215|NCT01962103|Experimental|Phase 1: Nab-Paclitaxel 150 mg/m^2|nab-paclitaxel 150 mg/m^2 IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity to establish the RP2D.
89590216|NCT01962103|Experimental|Phase 1: Nab-Paclitaxel 180 mg/m^2|nab-paclitaxel 180 mg/m^2 IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity to establish the RP2D.
89590217|NCT01962103|Experimental|Phase 1: Nab-Paclitaxel 210 mg/m^2|nab-paclitaxel 210 mg/m^2 IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity to establish the RP2D.
89590218|NCT01962103|Experimental|Phase 1: Nab-Paclitaxel 240 mg/m^2|nab-paclitaxel 240 mg/m^2 IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity to establish the RP2D.
89590219|NCT01962103|Experimental|Phase 1: Nab-Paclitaxel 270 mg/m^2|nab-paclitaxel 270 mg/m^2 IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity to establish the RP2D.
89590220|NCT01962103|Experimental|Phase 2: Ewing's Sarcoma|Participants with Ewing's sarcoma: nab-paclitaxel at the RP2D (240 mg/m^2 in participants weighing > 10 kg and 11.5 mg/kg in participants weighing ≤ 10 kg) IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity.
89590221|NCT01962103|Experimental|Phase 2: Neuroblastoma|Participants with neuroblastoma: nab-paclitaxel at the RP2D (240 mg/m^2 in participants weighing > 10 kg and 11.5 mg/kg in participants weighing ≤ 10 kg) IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity.
89590222|NCT01962103|Experimental|Phase 2: Rhabdomyosarcoma|Participants with rhabdomyosarcoma: nab-paclitaxel at the RP2D (240 mg/m^2 in participants weighing > 10 kg and 11.5 mg/kg in participants weighing ≤ 10 kg) IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity.
89590223|NCT01961323|Experimental|Nebivolol|Nebivolol 5 mg (titrated to a maximal dose of 10mg for optimal blood pressure) for 6 months
89590224|NCT04186403|Experimental|Prior Brexpiprazole 2-3 Milligrams Per Day|Participants who received blinded brexpiprazole 2 to 3 milligrams per day (mg/day) in the previous double-blind trial (NCT04100096), received open-label brexpiprazole 2 to 3 mg/day tablets, orally for up to 12 weeks.
89590225|NCT04186403|Experimental|Prior Placebo|Participants who received blinded brexpiprazole matching placebo in the previous double-blind trial (NCT04100096), received open-label brexpiprazole 2 to 3 mg/day tablets, orally for up to 12 weeks.
89590226|NCT01960855|Placebo Comparator|Placebo BID|Placebo twice daily (BID) for 12 weeks.
89590227|NCT01960855|Experimental|ABT-494 3 mg BID|ABT-494 3 mg twice daily (BID) for 12 weeks.
89590228|NCT01960855|Experimental|ABT-494 6 mg BID|ABT-494 6 mg twice daily (BID) for 12 weeks.
89590229|NCT01960855|Experimental|ABT-494 12 mg BID|ABT-494 12 mg twice daily (BID) for 12 weeks.
89590230|NCT01960855|Experimental|ABT-494 18 mg BID|ABT-494 18 mg twice daily (BID) for 12 weeks.
89590231|NCT02007434|Experimental|Paradigm 1 / Deoxycholic Acid Injection|Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL (based on Baseline CR-SMFRS grade 2 or 3, respectively) on Day 0 and a cold compress applied to the treatment area.
88976855|NCT00055913|Experimental|Arm I|Patients receive bevacizumab IV over 30-90 minutes on day 15 and oral erlotinib on days 1-28. All subsequent courses patients receive oral erlotinib on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
88976856|NCT00055913|Experimental|Arm II|Patients receive bevacizumab IV over 30-90 minutes on day 1 and oral erlotinib on days 1-28. All subsequent courses patients receive oral erlotinib on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
88976857|NCT04723654||ICU Population|Patients admitted to one of 3 ICUs at Lurie Childrens
88976858|NCT04723654||Non-ICU Population|Healthy volunteers who are under 18 years of age, whose parents consent to their participation, and who are willing to visit CAMP for a one time study visit can participate in this study.
88976859|NCT00045903|Experimental|Exposure and Ritual Prevention|Exposure and Ritual Prevention Therapy
88976860|NCT00045903|Active Comparator|Stress Management|Stress Management Therapy
88976861|NCT00055991|Experimental|Bexarotene|Bexarotene / Targretin
88976862|NCT00055991|Placebo Comparator|Sugar Pill|Sugar pill / placebo
88976863|NCT04731194|Experimental|performance-based financial incentive program|Village doctors in villages of the intervention group will promote policy awareness, support registration, follow-up patients, and receive financial incentives based on their performance.
89590232|NCT02007434|Placebo Comparator|Paradigm 1/ Placebo|Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0 and a cold compress applied to the treatment area.
89590233|NCT02007434|Experimental|Paradigm 2 / Deoxycholic Acid Injection|Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL on Day 0, topical and injectable anesthetics (lidocaine/epinephrine) and a cold compress applied to the treatment area.
89590234|NCT02007434|Placebo Comparator|Paradigm 2 / Placebo|Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0, topical and injectable anesthetics and a cold compress applied to the treatment area.
89590235|NCT02007434|Experimental|Paradigm 3 / Deoxycholic Acid Injection|Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL on Day 0, oral antihistamine and anti-inflammatory agents (loratadine and ibuprofen), topical and injectable anesthetics and a cold compress applied to the treatment area.
89590236|NCT02007434|Placebo Comparator|Paradigm 3 / Placebo|Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0, oral antihistamine and anti-inflammatory agents, topical and injectable anesthetics and a cold compress applied to the treatment area.
89590237|NCT02007434|Experimental|Paradigm 4 / Deoxycholic Acid Injection|Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL on Day 0, a compression chin strap, oral antihistamine and anti-inflammatory agents, topical and injectable anesthetics and a cold compress applied to the treatment area.
89590238|NCT02007434|Placebo Comparator|Paradigm 4 / Placebo|Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0, a compression chin strap, oral antihistamine and anti-inflammatory agents, topical and injectable anesthetics and a cold compress applied to the treatment area.
89590239|NCT01987453|Experimental|LDV/SOF+RBV 12 weeks (Group 1)|Participants who failed a prior SOF+RBV ± pegylated interferon (Peg-IFN) regimen will receive LDV/SOF FDC plus RBV for 12 weeks.
89590240|NCT01987453|Experimental|LDV/SOF 24 weeks (Group 2)|Participants who failed a prior LDV/SOF ± RBV regimen will receive LDV/SOF FDC for 24 weeks.
89590241|NCT01987453|Experimental|LDV/SOF+RBV 24 weeks (Group 3)|Participants with advanced compensated or decompensated cirrhosis who failed a prior SOF+RBV regimen will receive LDV/SOF FDC plus RBV for 24 weeks.
89590242|NCT02006641|Placebo Comparator|Placebo|Placebo adjunct to 10 mg Donepezil
89590243|NCT02006641|Experimental|Idalopirdine 10 mg|Idalopirdine adjunct to 10 mg Donepezil
89590244|NCT02006641|Experimental|Idalopirdine 30 mg|Idalopirdine adjunct to 10 mg Donepezil
89590245|NCT04652167||Patients suspected of community-acquired pneumonia|All patients admitted to the emergency department with suspected community- acquired pneumonia by the attending physician
89590246|NCT01959919||Arm 1: Device|
89590247|NCT04176601|Experimental|Engage Coaching|Engage Coaching helps caregivers bolster motivation for increasing connectedness, teaches problem solving skills, and provides behavioral practice with social engagement. Up to 8 brief sessions (typically 30 minutes) are provided weekly over no more than three months.
89590248|NCT01986985|Other|Single arm PET MRI|single group evaluation of PET/MRI system scan for diagnostic quality of image
89590249|NCT01986907|Experimental|Ranibizumab|Administered as an Intravitreal injection
89590250|NCT01959841|Experimental|ASP2151(200 mg)|once daily
89590251|NCT01959841|Experimental|ASP2151(400mg)|once daily
89590252|NCT01959841|Experimental|valaciclovir|1000 mg three times daily
89590253|NCT02005627|Active Comparator|Grazax|The active treatment arm will receive active grass pollen immunotherapy tablet (AIT), Grazax Oral Lyophilisate 75,000 standardised quality units tablet (SQ-T) once daily.
89590254|NCT02005627|Placebo Comparator|Grazax Placebo|This arm will receive Grazax placebo once daily which contains the same composition as in the active Grazax tablet with the only difference being the exclusion of the grass pollen allergen extract.
89590255|NCT02104583|Experimental|Eleclazine 3 mg|Participants will receive a single loading dose of eleclazine 30 mg on Day 1, followed by eleclazine 3 mg daily as maintenance for up to approximately 20 months.
89590256|NCT02104583|Experimental|Eleclazine 6 mg|Participants will receive a single loading dose of eleclazine 30 mg on Day 1, followed by eleclazine 6 mg daily as maintenance for up to approximately 20 months.
89590257|NCT02104583|Placebo Comparator|Placebo|Participants will receive a single loading dose of placebo to match eleclazine on Day 1, followed by placebo to match eleclazine once daily for up to approximately 20 months.
89590258|NCT02073929|Active Comparator|Active|Liraglutide s.c. 1,8mg daily for 26 weeks
88976864|NCT04731194|No Intervention|current situation|Village doctors in villages of the control group will not be contacted. The control group would serve as a natural baseline and do not receive any intervention.
88976865|NCT00056030|Experimental|cetuximab + oxaliplatin + leucovorin + fluorouracil|"Patients receive cetuximab IV over 1 hour (over 2 hours on day 1 of course 1 only) on days 1 and 8. Patients also receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1 and fluorouracil IV continuously on days 1-2. Treatment repeats every 2 weeks in the absence of disease progression or unacceptable toxicity, for a minimum of 12 courses or until deemed to have resectable disease.~Quality of life is assessed at baseline and prior to each treatment course.~Patients are followed every 3 months for 1 year and then every 6 months for 3 years."
89590259|NCT02073929|Placebo Comparator|Placebo|Placebo s.c. daily for 26 weeks
89590260|NCT02113007|Experimental|Rituximab plus Temozolomide|Rituximab: 375 mg/m2 IV, days 1, 3, and 5 Temozolomide: 150 mg/m2 PO, days 1-5
89590261|NCT02104505|Active Comparator|700 mg Gamma Tocopherol daily x 14days|Gamma Tocopherol supplement
89590262|NCT02104505|Placebo Comparator|Placebo|Safflower oil capsules
89590263|NCT02111993|Active Comparator|Standard Defibrillation Testing|Standard Defibrillation Threshold Testing is a procedure in which a low energy shock will be delivered to the heart to induce ventricular fibrillation (VF) followed by a rescue shock to restore sinus rhythm. Process is repeated after 5 minutes.
89590264|NCT02111993|Active Comparator|Upper Limit of VulnerabilityTesting|Upper Limit of Vulnerability Testing is a procedure in which four 18J shocks will be delivered at specified intervals. If VF is induced, then a 25 J rescue shock will be delivered.
89590265|NCT01959607|Active Comparator|THS 2.2 then CC|"Each subject will follow the below study design:~Day 0 = Wash-out (1 day)~Day 1 = 1st intervention (single product use of THS 2.2)~Day 2 = wash-out~Day 3 = 2nd intervention (single product use of CC)."
88976866|NCT00173875|Experimental|A|Iressa
89209903|NCT00891696|Active Comparator|Exp 2: LEx + SNP|Participants will receive sodium nitroprusside and undergo low-intensity resistance exercise.
89590266|NCT01959607|Active Comparator|CC then THS 2.2|"Each subject will follow the below study design:~Day 0 = Wash-out (1 day)~Day 1 = 1st intervention (single product use of CC)~Day 2 = wash-out~Day 3 = 2nd intervention (single product use of THS 2.2)."
89590267|NCT01959607|Active Comparator|THS 2.2 then NRT|"Each subject will follow the below study design:~Day 0 = Wash-out (1 day)~Day 1 = 1st intervention (single product use of THS 2.2)~Day 2 = wash-out~Day 3 = 2nd intervention (single administration of NRT gum [Nicorette® 2mg])."
89590268|NCT01959607|Active Comparator|NRT then THS 2.2|"Each subject will follow the below study design:~Day 0 = Wash-out (1 day)~Day 1 = 1st intervention (single administration of NRT gum [Nicorette® 2mg])~Day 2 = wash-out~Day 3 = 2nd intervention (single product use of THS 2.2)."
89590269|NCT02111603|Other|Colesevelam|1875 mg of Colesevelam orally twice daily for 10 days
89590270|NCT04725851|Experimental|High concentration Oxygen Therapy|12-15 Litre/min O2 delivery via Non-Rebreather Mask (NRM) consecutively for 24 hours.
89590271|NCT04725851|Placebo Comparator|Room air or low concentration oxygen|Room air or low concentration oxygen (0-2 Litre/min O2 ) consecutively for 24 hours.
89590272|NCT02102399|Experimental|Vocal Warm-up|Vocal Warm-up group performed 13 minutes of vocal warm-up exercises everyday before teaching over a course of 6 weeks, with one session exercise per day.
89590273|NCT02102399|Experimental|Respiratory Muscle Training|Respiratory Muscle Training group performed 13 minutes of Respiratory Muscle Training everyday before teaching over a course of 6 weeks, with one session exercise per day.
89590274|NCT02111369|Experimental|Propranolol/Botulinum|After baseline analysis, patient will be given a prescription by the principal investigator for propranolol. This prescription will consist of a starting dose of generic immediate-release at 10 mg three times per day (30 mg each day) with an increase in dose in 5-7 days if there is no effect (60 mg each day) and if the patient had demonstrated no side effects. Dose may be increased to 240 mg each day depending on patient improvement and side effect profile. After second evaluation, patient will receive botulinum toxin injections. The risks and benefits of botulinum toxin therapy will be explained to the patient, and bilateral injections will take place.
89590275|NCT02111213|Active Comparator|Promotora for physical activity|Weekly sessions with a volunteer promotora at a community center. A promotora is a trained, lay health worker. The promotora will provide guidance, advice and support to participants to encourage them to be more physically active.
89590276|NCT02111213|Experimental|Carmen system|Weekly sessions with the virtual advisor accessed through a computer located at a community center. Carmen is the virtual advisor and will provide guidance, advice and support to participants to encourage them to be more physically active.
89590277|NCT04736303|No Intervention|POD without BIS|Assessing the incidence of POD in patients under general anethesia for elective non cardiac surgery, with CAM and Nu-DESC tools.
89590278|NCT04736303|Active Comparator|POD with BIS|Assessing the incidence of POD in patients under general anethesia for elective non cardiac surgery with the implementation of BIS monitoring, with CAM and Nu-DESC tools.
89590279|NCT02110901|Active Comparator|PRT-201|PRT-201 administered at the time of radiocephalic fistula creation
89590280|NCT02110901|Placebo Comparator|Placebo|Placebo administered at the time of radiocephalic fistula creation. The placebo is identical in appearance and composition to PRT-201 but lacks the active ingredient.
89590281|NCT02109107|Experimental|Erchonia EZ6 Laser|The Erchonia EZ6 Laser is a 6 headed scanner composed of 6 independent 17 milliWatts (mW), 635 nanometer (nm) red laser diodes mounted in scanner devices. It is a variable frequency, pulsed wave laser device.
89590282|NCT02100839|Experimental|AEM-28|"Single Ascending Dose: Single IV dose for each cohort; dose range 0.032 mg/mL to 3.54 mg/mL~Multiple Ascending Dose: Three (3) IV doses for each cohort, one (1) dose every two (2) weeks; dose range 1 mg/kg to 3.54 mg/kg."
88976867|NCT00407836|Experimental|Vaccination|One arm of open label T cell vaccination in which all participants will receive the T cell vaccine
88976868|NCT00407875|Active Comparator|Permanent interstitial prostate brachytherapy (PIPB)|patient will undergo permanent interstitial prostate brachytherapy (PIPB) using a transperineal approach to deliver 125Iodine Rapidstrand® seeds at the facilities of the British Columbia Cancer Agency (BCCA) by one or more of the certified prostate brachytherapists in the BCCA Prostate Brachytherapy Program. The minimum peripheral dose (MPD) to the prostate gland of the implant will be 144 Gy as per TG 43 protocol. A modified peripheral loading technique will be utilized in an effort to maintain the periurethral dose to < 150% of the MPD. Within 48 hours of the implant, the patient will undergo a day 0 CT scan of the pelvis to assess post implant dosimetry using the standard BCCA protocol.
88976869|NCT00407875|Experimental|Intensity modulated external beam radiation therapy (IMRT)|patient will undergo a course of intensity modulated external beam radiation therapy (IMRT) to a volume encompassing the prostate gland. The total radiation dose will be 70 Gy delivered in 28 fractions, so that the minimum dose to the PTV is 70 Gy, with CT simulation used for planning the treatment. Prior to starting the course of IMRT, fiducial markers will be placed in the prostate to assist in localization of the prostate for planning and quality assurance during treatment.
89030754|NCT02954822|Experimental|(Group A)|Evogliptin→Evogliptin+Glimepiride→Glimepiride
89030755|NCT02954822|Experimental|(Group B)|Glimepiride→Evogliptin→Evogliptin+Glimepiride
89030756|NCT00522015|Active Comparator|1|patients take 6 mg rivastigmine daily, if well tolerable increase to 12 mg rivastigmine maximum daily
89030757|NCT02954744|Experimental|Treatment arm|HIFU treatment
89030758|NCT00523380|Experimental|A|
89030759|NCT00506870|No Intervention|1|Conventional follow-up of anticoagulation
89030760|NCT00506870|Experimental|2|Self-monitoring of anticoagulation
89030761|NCT02948322|Experimental|OGTT, CMRI with gadolinium in patients|Patients with acromegaly will be investigated
89030762|NCT02948322|Active Comparator|OGTT, CMRI with gadolinium in volunteers|Age-, sex- and BMI-matched healthy volunteers will be investigated
89209904|NCT00891696|Placebo Comparator|Exp 3: LEx|Participants will undergo low-intensity resistance exercise.
89209905|NCT00891696|Active Comparator|Exp 3: HEx|Participants will undergo high-intensity resistance exercise.
89590283|NCT02100839|Placebo Comparator|Normal Saline|"Single Ascending Dose: Single IV dose for each cohort.~Multiple Ascending Dose: Three (3) IV doses for each cohort, one (1) dose every two (2) weeks."
89590284|NCT02069093|Experimental|Dexamethasone based mouthwash|Participants swished and spat 10mL of 0.5mg/5mL dexamethasone steroid mouthwash (investigational treatment) 4 times daily (qid) orally for 2 minutes each for 8 weeks. Participants remained without food or drink (NPO) for one hour after administration of the mouthwash. Also, participants received everolimus 10 mg and exemstane 25 mg (study treatments) according to local regulations.
89590285|NCT02109029|Experimental|Insulin Peglispro (LY2605541)|Part A Cohort 1: (low dose) priming dose (PD) of 2.00 units (U), 0.92 U/hour (U/h) constant infusion of insulin peglispro Part A Cohort 1: (high dose) PD of 8.00 U, 4.50 U/h constant IV infusion of insulin peglispro Part A Cohort 2: (intermediate dose 1) PD of 4.00 U, 1.84/h constant IV infusion of insulin peglispro Part A Cohort 2: (intermediate dose 2) PD of 6.0 U, 2.76 U/h constant IV infusion of insulin peglispro Part B Insulin Peglispro: PD of 6.00 U, 2.76 constant IV infusion of insulin peglispro and a constant infusion of 6 pico moles per kilogram per minute (pmol/kg/min). IV infusion of sinistrin (250 mg/mL, SOC to achieve a steady state for up to 16 hours).
89590286|NCT02109029|Active Comparator|Human Insulin|Constant IV infusion ( 6 pico moles per kilogram perminute [pmol/kg/min]) of human insulin for up to 36 hours. IV infusion of sinistrin (250 mg/mL, SOC to achieve a steady state for up to 16 hours).
89590287|NCT02069015|Experimental|Enhanced discharge|Patient education about hypertension delivered through a touch-screen kiosk at 4 time points in addition to standard discharge.
89590288|NCT02069015|No Intervention|Standard discharge|Standard discharge is patient instruction, instructions for follow-up to primary care and medication/prescription
89590289|NCT04734977|Experimental|HILT+exercise|Patients received pulsed laser treatment, using a HIRO 3 device (ASA Laser, Arcugnano, Italy), five times a week for a period of four weeks, and one session per day for a total of 20 sessions. A 3-phase treatment program was performed in each session, and the patients were then given a daily exercise program once a day by a physiotherapist.
89590290|NCT04734977|Sham Comparator|Sham HILT+exercise|Sham therapy was applied in five sessions a week for four weeks, with a total of 20 sessions a day, with no current flowing through the device. This was followed by the exercise programs described above, performed once a day with the physiotherapist.
89590291|NCT04734977|Active Comparator|Exercise only|Exercise program was applied in five sessions a week for four weeks, with a total of 20 sessions a day.
89590292|NCT01598129|Experimental|CGTG-102|CGTG-102 dose escalation
89590293|NCT02068547|Active Comparator|Group 1 - Surigical Best Practice|Group 1 will receive current best practice for posterior instrumented fusion (locally harvested autograft, demineralized bone matrix, and cadaveric allograft)
89590294|NCT02068547|Experimental|Group 2 - autograft/BMAC|Group II, will receive locally harvested autograft and 20 cc of bone marrow aspirate concentration.
89590295|NCT02108951|Experimental|Nilotinib|Nilotinib was administered orally at 300 mg BD at approximately 12 hour intervals which had to be taken without food. The capsules were to be swallowed whole with water and no food should have been consumed for at least 2 hours before and at least 1 hour after the dose was taken. Prior to the first dose of nilotinib, patients were required to have an imatinib or dasatinib washout period of at least 3 days. Therapy with nilotinib was to be continued for up to 24 months while on study.
89590296|NCT02107859|Experimental|Ataluren|Participants will receive ataluren suspension orally 3 times a day (TID), 10 milligrams/kilogram (mg/kg) at morning, 10 mg/kg at midday, and 20 mg/kg at evening (total daily dose 40 mg/kg) for 192 weeks.
89590297|NCT02007278|Active Comparator|vildagliptin and metformin|Based on basal dose of metformin, administration of vildagliptin/metformin 50 mg/850 mg twice daily (bid) or 50 mg/1000 mg bid for 12 weeks
89590298|NCT02007278|Active Comparator|glimepiride and metformin|Protocol specified dosage and frequency of glimepiride + metformin for 12 weeks based on basal dose of metformin
89590299|NCT02107313|Other|Fed Cohort|PBT2 250 mg is administered orally following a high fat breakfast
89590300|NCT02107313|Other|Fasted Cohort|PBT2 250 mg is administered orally following a 10 hour period of fasting
89590301|NCT02028338|Experimental|Dapivirine ring|dapivirine vaginal ring (25 mg)
89590302|NCT02028338|Placebo Comparator|Placebo ring|silicone vaginal ring
89590303|NCT05089487|Experimental|High altitude 2500 m above sea level|
89590304|NCT05089487|Active Comparator|Low altitude 470 m above sea level|
89030763|NCT05143580|Experimental|Cognitive Therapy Group|"The anesthesiologist will provide the patient with instructions for preoperative anesthesia.~The operating room nurses will introduce the operating room environment and surgical care instructions to the patient.~Provide a manual for disease health education.~Provide post-operative care and environmental imaging materials, explain the importance of intensive care unit routines and related equipment, indwelling pipelines, related nursing staff, post-operative care methods, and provide imaging and health education manuals for explanation.~Use gamification to evaluate: pain relief skills, lung expansion skills."
89030764|NCT05143580|Placebo Comparator|Routine Care Group|"The anesthesiologist will provide the patient with instructions for preoperative anesthesia.~The operating room nurses will introduce the operating room environment and surgical care instructions to the patient.~Provide a manual for disease health education."
89030765|NCT00522054|Other|A|Single group study
89030766|NCT00506987|Experimental|SCH 486757|
89030767|NCT00506987|Placebo Comparator|Placebo|
89590305|NCT01625897|Experimental|MP-214 1.5-9mg|
89590306|NCT01625897|Active Comparator|Risperidone 2-12mg|
89030768|NCT02276820|Experimental|Viralym-A|"Partially HLA-matched Viralym-A cells will be thawed and given by intravenous injection. Patients will receive 2 x 10^7 partially HLA-matched Viralym-A/m2 as a single infusion.~If a patient has a partial response they are eligible to receive up to 4 additional doses at biweekly intervals. These doses would come from the original infused line if sufficient vials were available but may come from another line if there are insufficient cells in the original line."
89030769|NCT00506558|Experimental|A|Ventral Decompression and Instrumented Fusion
89030770|NCT00506558|Active Comparator|B|Dorsal Decompression with or without fusion
89030771|NCT00523458|Active Comparator|1|Standard dose nevirapine (200 mg 2x daily) in combination with 2 nucleoside analogs
89030772|NCT00523458|Experimental|2|High dose nevirapine (400 mg in the morning, 200 mg in the evening) in combination with 2 nucleoside analogs
89590307|NCT02106923|Experimental|High dose, fasted|1 fixed dose combination (FDC) tablet vs 3 single tablets under fasted conditions
89590308|NCT02106923|Experimental|High dose, fed|1 fixed dose combination (FDC) tablet vs 3 single tablets under fed conditions
89590309|NCT02106923|Experimental|Low dose, fasted|2 fixed dose combination (FDC) tablets vs 4 single tablets under fasted conditions
89590310|NCT02006732|Experimental|tiotropium + olodaterol low dose|Once daily 2 puffs solution for inhalation Respimat
89590311|NCT02006732|Experimental|tiotropium + olodaterol high dose|Once daily 2 puffs solution for inhalation Respimat
89590312|NCT02006732|Active Comparator|tiotropium|Once daily 2 puffs solution for inhalation Respimat
89590313|NCT02006732|Placebo Comparator|placebo|Once daily 2 puffs solution for inhalation Respimat
89590314|NCT02098733||Pioglitazone/glimepiride|Pioglitazone/glimepiride 15 mg/1 mg or 30 mg/3 mg, orally once daily before or after breakfast
89590315|NCT02028182|Experimental|Positive reactions, Concordance with reference allergen|Subjects were patch tested with an experimental allergen panel containing ascending doses of Lyral (0.10 mg/cm2, 0.20 mg/cm2 and 0.40 mg/cm2) and a negative control. A second panel containing 20 mg of 5% Lyral in petrolatum was applied for evaluation of concordance. The panels were worn for approximately 48 hours. Skin reactions were assessed at 3, 4 and 21 days following application.
89590316|NCT04684472|Experimental|Modified anti-CD19 CAR T cell therapy|CAR T cell therapy
89590317|NCT02098109|Experimental|XM02 Filgrastim (Granix) and Plerixafor|"XM02 Filgrastim (Granix) 10 mg/kg Days 1 through 4 (Days 5 through 8 may be required if target collection goal has not be met)~Plerixafor 0.24 mg/kg Day 4 (Days 5 through 7 may be required if target collection goal has not be met)~Apheresis on Day 5 (may need to be done on Days 6-8 if target collection goal has not been met)~Patients who undergo infusion of the mobilized PBSC product within 6 months of the last apheresis procedure will be followed through Day +100 post-infusion (+/- 30 days) to assess for transplant outcomes (neutrophil and platelet engraftment, and readmission rate). Patients who successfully mobilize > 2.0 x 10^6 CD34+ cells/kg but do not undergo infusion of the mobilized PBSC product within 6 months of the last apheresis procedure will be discontinued from follow-up."
89590318|NCT02098109|Active Comparator|Filgrastim (Neupogen) and Plerixafor|"Filgrastim (Neupogen) 10 mg/kg Days 1 through 4 (Days 5 through 8 may be required if target collection goal has not be met)~Plerixafor 0.24 mg/kg Day 4 (Days 5 through 7 may be required if target collection goal has not be met)~Apheresis on Day 5 (may need to be done on Days 6-8 if target collection goal has not been met)~Patients who undergo infusion of the mobilized PBSC product within 6 months of the last apheresis procedure will be followed through Day +100 post-infusion (+/- 30 days) to assess for transplant outcomes (neutrophil and platelet engraftment, and readmission rate). Patients who successfully mobilize > 2.0 x 10^6 CD34+ cells/kg but do not undergo infusion of the mobilized PBSC product within 6 months of the last apheresis procedure will be discontinued from follow-up."
89590319|NCT02097719|Active Comparator|bimatoprost 0.01% and hypromellose 0.3%|Bimatoprost 0.01% and hypromellose 0.3% lubricant eye drops (for masking purposes) each administered to both eyes once daily for 12 weeks.
89590320|NCT02097719|Active Comparator|travoprost 0.004% and timolol 0.5%|Travoprost 0.004% and timolol 0.5% each administered to both eyes once daily for 12 weeks.
89590321|NCT01449370|Experimental|Arm A|TAK-117 administered once a day orally
89590322|NCT01449370|Experimental|Arm B|TAK-117 administered orally intermittently, once every other day (Monday, Wednesday, and Friday) each week
89590323|NCT01449370|Experimental|Arm C|TAK-117 administered orally intermittently, once a day for 3 consecutive days (Monday, Tuesday, and Wednesday) each week
89590324|NCT02067533|Experimental|flexion position|
89590325|NCT02067533|Experimental|extension position|
89590326|NCT02066129|Active Comparator|Fluticasone 44 mcg|"Fluticasone 44 mcg 2 puffs twice daily for 7 days initiated at the onset of yellow zone symptoms."
89590327|NCT02066129|Active Comparator|Fluticasone 220 mcg|"Fluticasone 220 mcg 2 puffs twice daily for 7 days initiated at the onset of yellow zone symptoms."
89590328|NCT02066051|Experimental|IPL Treatment|Subjects who had inactive chronic graft versus host disease (GVHD) after allogeneic bone marrow transplantation and severe dry eye symptoms related to ocular rosacea unresponsive to conventional management were recruited. Subjects were treated with 4 monthly sessions of intense pulsed light (IPL) and meibomian gland expression.
89030773|NCT00523458|Active Comparator|3|Standard dose efavirenz (600 mg at bedtime) in combination with 2 nucleoside analogs
89590329|NCT01980992|Active Comparator|Wheat OIT|Active treatment participants receive Vital Wheat Gluten, and have up to four oral food challenges as directed by the protocol.
89590330|NCT01980992|Placebo Comparator|Placebo|Placebo for Vital Wheat Gluten followed by crossover to open-label active therapy (Vital Wheat Gluten), and up to three oral food challenges as directed by the protocol.
89590331|NCT04085068||Study group (group A):|15 women take cranioscaral treatment
89590332|NCT04085068||control group (group B):|shame group
89590333|NCT02065895|Experimental|HIGH error, LOW error, NO error|Subjects were randomized to receive overnight and breakfast closed-loop glucose control glucose on three occasions: first with glucose-value-used-for-control higher than blood glucose (HIGH error), then second with glucose-value-used-for-control lower than blood glucose (LOW error), then third with glucose-value-used-for-control equal blood glucose (NO error).
89590334|NCT02065895|Experimental|HIGH error, NO error, LOW error|Subjects were randomized to receive overnight and breakfast closed-loop glucose control glucose on three occasions: first with glucose-value-used-for-control higher than blood glucose (HIGH error), then second with glucose-value-used-for-control equal blood glucose (NO error), then third with glucose-value-used-for-control lower than blood glucose (LOW error).
89590335|NCT02065895|Experimental|NO error, HIGH error, LOW error|Subjects were randomized to receive overnight and breakfast closed-loop glucose control glucose on three occasions: first with glucose-value-used-for-control equal blood glucose (NO error), then second with glucose-values-used-for-control higher than blood glucose (HIGH error), then third with glucose-value-used-for-control lower than blood glucose (LOW error).
89030774|NCT00523458|Experimental|4|High dose efavirenz (800 mg at bedtime) in combination with 2 nucleoside analogs
89030775|NCT00507065|Experimental|Adderall XR (10 mg)|
89030776|NCT00507065|Experimental|Adderall XR (20 mg)|
89590336|NCT02065895|Experimental|NO error, LOW error, HIGH error|Subjects were randomized to receive overnight and breakfast closed-loop glucose control glucose on three occasions: first with glucose-value-used-for-control equal blood glucose (NO error), then second with glucose-value-used-for-control lower than blood glucose (LOW error), then third with glucose-value-used-for-control higher than blood glucose (HIGH error).
89590337|NCT02065895|Experimental|LOW error, NO error, HIGH error|Subjects were randomized to receive overnight and breakfast closed-loop glucose control glucose on three occasions: first with with glucose-value-used-for-control lower than blood glucose (LOW error), then second with glucose-value-used-for-control equal blood glucose (NO error), then third with glucose-value-used-for-control higher than blood glucose (HIGH error).
89590338|NCT02065895|Experimental|LOW error, HIGH error, NO error|Subjects were randomized to receive overnight and breakfast closed-loop glucose control glucose on three occasions: first with glucose-value-used-for-control lower than blood glucose (LOW error), then second with glucose-value-used-for-control equal blood glucose (NO error), then third glucose-value-used-for-control higher than blood glucose (HIGH error),
89590339|NCT04723511|Experimental|GPR|participants in this group receive global postural reeducation technique+ Kendall exercises
89590340|NCT04723511|Active Comparator|Kendall|Kendall exercises
89590341|NCT04723355|Experimental|Holter device|In this single arm of the study, the participant will use 2 Holter systems simultaneously for 24 hours, an innovative 3-lead wireless water resistant device and a conventional device.
89590342|NCT04417985|Experimental|18F-FDG PET/CT with MRI and blood sampling|"The enrolled subjects received 18F-FDG PET/CT and MRI before, during, and after the primary definitive treatment.~The blood sample was collected on the same day of PET/CT scan."
89590343|NCT02106455||17.5 mg of sodium risedronate|17.5 mg of sodium risedronate is administered orally with a sufficient volume (approximately 180 mL) of water once daily after waking for 8 consecutive weeks.
89590344|NCT02006654|Placebo Comparator|Placebo|Placebo adjunct to base treatment with an AChEI
89590345|NCT02006654|Experimental|Idalopirdine 60 mg (or 30 mg)|Idalopirdine adjunct to base treatment with an AChEI
89590346|NCT01980056|Experimental|Vosaroxin: All Patients|All patients will receive vosaroxin according to the dose cohort in which they are enrolled.
89590347|NCT02027558|Experimental|Behavioral treatment|Manual-based cognitive behavioral treatment focusing on sleep, sleep apnea, and PAP adherence provided by allied health personnel in individual sessions.
89590348|NCT02027558|Active Comparator|Active control|Manual-based non-directive general sleep education program provided by allied health personnel in individual sessions.
89590349|NCT02027402|Experimental|Drain insertion|Laparoscopic cholecystectomy with drain insertion is performed in this arm.
89590350|NCT02027402|No Intervention|no drain insertion|In this arm, investigators perform only laparoscopic cholecystectomy, and not insert a drain
89590351|NCT01448824|Experimental|Part 1 (Cohort A): 100 mg, 1800 mg LY2484595, Placebo|"Period 1: Participants will receive either 100 milligrams (mg) LY2484595 tablets or placebo tablets once daily (QD) by mouth on Days 1 through 14 of Period 1.~Washout period lasting ≥14 days.~Period 2: Participants will receive either 1800 mg LY2484595 tablets or placebo tablets QD by mouth on Days 1 through 14 of Period 2."
89030777|NCT00507065|Experimental|Adderall XR (30 mg)|
89590352|NCT01448824|Experimental|Part 1 (Cohort B): 300 mg LY2484595, Placebo|Participants will receive either 300 milligrams (mg) LY2484595 tablets or placebo tablets once daily (QD) by mouth on Days 1 through 14.
89590353|NCT01448824|Experimental|Part 1 (Cohort C): 600 mg LY2484595, Placebo|Participants will receive either 600 milligrams (mg) LY2484595 tablets or placebo tablets once daily (QD) by mouth on Days 1 through 14.
89590354|NCT01448824|Experimental|Part 1 (Cohort D): 1200 mg LY2484595, Placebo|Participants will receive either 1200 milligrams (mg) LY2484595 tablets or placebo tablets once daily (QD) by mouth on Days 1 through 14.
89590355|NCT01448824|Experimental|Part 2 (Cohort E): 100 mg LY2484595 ± 400 mg Ketoconazole|"Period 1: Participants will receive 100 milligrams (mg) LY2484595 tablet by mouth on Day 1 of Period 1.~Washout period lasting ≥14 days.~Period 2: Participants will receive 400 mg ketoconazole tablets once daily (QD) by mouth on Days 1 through 14 of Period 2. Participants will receive 100 mg LY2484595 tablet by mouth on Day 5 of Period 2."
89590356|NCT02005562|Experimental|Mycophenolate Mofetil, Adapted Dose|Participants received 3 grams (g) mycophenolate mofetil (MMF) tablets per os (p.o.) in divided doses (every 12 hours [q12h]) adapted to mycophenolic acid (MPA) by area under the curve (AUC) beginning on the day of renal transplant, Day 0, or the day before, Day -1, and continuing through Week 52. In addition, induction by interleukin-2R (IL-2R) was administered at Day 0 per standard of care at the site at the investigator's discretion. At 72 hours post-transplantation, participants received cyclosporine 100-1500 nanograms (ng) per (/) milliliter (mL) from Day 0 to (-) Week 4, 800-1200 ng/mL from Week 4 - Week 12 and 500-800 ng/mL from Week 12 - Week 52. Solumedrol 500 mg intravenously (i.v.) was administered before or after the transplantation, and 0.5 milligrams (mg) per kilogram (kg) p.o. daily from Day 1 - Day 7.
89030778|NCT00507065|Experimental|Adderall XR (40 mg)|
89030779|NCT00507065|Placebo Comparator|placebo|
89030780|NCT00522132|Active Comparator|cohort 1|2.4 mg/kg iv artesunate at 0, 12, 24, 48and 72 hours
89030781|NCT00522132|Experimental|cohort 2|4.0 mg/kg iv Artesunate at 0, 24 and 48 h
89030782|NCT00522210|Experimental|BID insulin with LA analogue|Treatment Group: BID Insulin Regimen with Long Acting Insulin Analogue (Detemir)
89030783|NCT00522210|Active Comparator|Standard TID insulin|Active Control Group: Usual TID Insulin Regimen (intermediate insulin- Humulin N or Novolin NPH)
89030784|NCT05143151|Experimental|Treatment group|CD276 targeted chimeric antigen receptor cells treatment
89030785|NCT00523536|Experimental|1|Patient navigator-nurse disease management intervention
89030786|NCT00523536|No Intervention|2|Usual clinical care
89030787|NCT00523575|No Intervention|C|Usual nurse and dietetic care
89030788|NCT00523575|Experimental|I|Intensive nutritional support composed of oral dietary supplement combined with dietetic counselling.
89030789|NCT05143112|Experimental|Treatment group|Allogeneic CD19 CR-T cell infusion
89590357|NCT02005562|Active Comparator|Mycophenolate Mofetil, Fixed Dose|Participants received 2 g MMF tablets p.o. in divided doses q12h beginning on the day of renal transplant, Day 0, or the day before, Day -1, and continuing through Week 52. In addition, induction by IL-2R was administered at Day 0 per standard of care at the site at the investigators discretion. At 72 hours post-transplantation, participants received cyclosporine 100-1500 ng/mL from Day 0 - Week 4, 800-1200 ng/mL from Week 4 - Week 12 and 500-800 ng/mL from Week 12 - Week 52. Solumedrol 500 mg i.v. was administered before or after the transplantation, and 0.5 mg/kg p.o. daily from Day 1 - Day 7.
89590358|NCT01448044|Experimental|BMS-790052 + PegIFNα-2a + Ribavirin|"BMS-790052 60 mg Tablets, Oral, once daily for 24 weeks~PegIFNα-2a 180 μg Subcutaneous Injection, once weekly for 24 or 48 weeks depending on response~Ribavirin 400 mg (2 tablets for participants < 75 kg) or 600 mg (3 tablets for participants ≥ 75 kg) in the morning and 600 mg (3 tablets) in the evening, Oral for 24 or 48 weeks depending on response"
89590359|NCT01448044|Placebo Comparator|Placebo matching BMS-790052 + PegIFNα-2a + Ribavirin|"Placebo matching BMS-790052 0 mg Tablets, Oral, once daily for 48 weeks~PegIFNα-2a 180 μg Subcutaneous Injection, once weekly for 48 weeks~Ribavirin 400 mg (2 tablets for participants < 75 kg) or 600 mg (3 tablets for participants ≥ 75 kg) in the morning and 600 mg (3 tablets) in the evening, Oral for 48 weeks"
89590360|NCT02025530||Cases|A structured questionnaire will be administered to women who have experienced a late ≥ 28 weeks gestation stillbirth, who have a singleton pregnancy with no congenital abnormality.
89590361|NCT02025530||Controls|A structured questionnaire will be administered to controls. These are women matched to the case group by gestation and unit of birth, who have a normal ongoing singleton pregnancy with no congenital abnormality.
89590362|NCT01472380|Active Comparator|Efavirenz 600mg alone|efavirenz 600mg by mouth taken on Day 1
89590363|NCT01472380|Active Comparator|Efavirenz co-administered with fenofibric acid|co-administered oral doses of efavirenz 600 mg and fenofibric acid 105 mg taken on Day 31
88976870|NCT00056069|Experimental|Observational|Questionnaire Administration: Participants complete questionnaires regarding caregiver demands and family information over 25-30 minutes within 3-4 months of the initiation of the child's treatment and at the completion of the first year of the child's treatment.
88976871|NCT04582422|Experimental|Touch Therapy|"The main purpose is to provide Touch Therapy intervention measures, the degree of fear of dental treatment for preschool children.~Use the chip chip tool (PCT) to ask the children's degree of fear of dental treatment. The control group uses questionnaires to ask the caregiver's age, social and economic status, education, past dental experience, etc. In the intervention group, the questionnaire was used to ask the caregiver's age, socioeconomic status, education, past dental experience, etc. During the waiting process, first follow the touch flow chart and perform the touch in the waiting area for 10 minutes. When visiting the treatment chair, the companion will be asked to touch the child's unilateral hand for 5 minutes during the consultation process. A small chair is provided to accompany the child for a total of 15 minutes. The two groups will use the chip tool again after the consultation , Ask the children how scared they are after seeing a doctor,"
88976872|NCT04582422|No Intervention|dental education|The Chip Chip Tool (PCT) asked the children how scared they were about dental visits. The control group used questionnaires to ask the caregiver 's age, socioeconomic status, education, past dental experience, etc. before the visit to provide routine dental care, provide dental health education, how to use toothbrush Dental floss education,
88976873|NCT04556214|Experimental|Liver Transplant|The patients will be transplanted according to standard procedures by the institutional protocol. The transplantation procedure is initiated by an exploratory laparotomy with clinical assessment and frozen section of the lymphnodes in the hepatoduodenal ligament and along the common hepatic artery/coeliac axis. Evidence of disease dissemination to these regional lymph nodes will be an absolute contraindication to transplantation.
88976874|NCT00174499|Experimental|1|2 mg nicotine gum
88976875|NCT00174499|Experimental|2|4 mg nicotine gum
88976876|NCT00174616|Experimental|Single arm|
88976877|NCT00174655|Active Comparator|A1|
88976878|NCT00174655|Active Comparator|A2|
88976879|NCT00174655|Experimental|B|
88976880|NCT00174655|Experimental|C|
88976881|NCT00174772|Experimental|B|Concurrent chemoradiotherapy followed by consolidation chemotherapy
88976882|NCT00174772|Experimental|A|Induction chemotherapy followed by concurrent chemoradiotherapy
88976883|NCT02963779|Experimental|LY2775240 (Part A)|Escalating oral doses of LY2775240 administered in healthy participants
89590364|NCT01978262|Other|healthy woman|All women are to receive the quadrivalent influenza vaccine
89590365|NCT01447576|Experimental|OPC-34712 + ADT|Experimental: OPC-34712, Oral Tablets, 0.25 - 3 mg; Antidepressant drug treatment
89590366|NCT04084834|Experimental|Intervention group|Participants allocated to the intervention group will be familiarized with exercise intensity levels (heart rate and Borg RPE) during the assessment at Diakonhjemmet Hospital. Further, the patients will be offered to take part in a 5-hour Learning and Mastery-course at Diakonhjemmet Hospital. Thereafter, the participants will get access to a web-based exercise program and guided to choose the appropriate exercise-level. Weekly, based on the individual progression, all participants will receive an exercise program by email consisting of individually tailored exercise sessions and motivational messages. At the end of each week, the participants complete an electronic exercise diary for monitoring adherence. All participants will be offered the possibility to seek peer-support; however, if preferred they may also follow the exercise program by themselves.
89590367|NCT01447420|Experimental|Peginterferon Alfa-2a Plus Ribavirin|
89590368|NCT01446874|Experimental|Pre-operative brushing (Pilot Portion)|-Toothbrushing 3 times/day for at least 5 days preoperatively using a 0.12% chlorhexidine solution
89590369|NCT01446874|Experimental|Pre-operative & Post-Operative Brushing (Esophageal Resection)|"Toothbrushing 3 times/day for at least 5 days preoperatively using a 0.12% chlorhexidine solution~The intensive toothbrushing regimen and chlorhexidine mouthwash will be continued for the duration of the hospitalization or a minimum of 5 days postoperatively in the study group."
89590370|NCT01446874|Experimental|Pre-operative & Post-Operative Brushing (Lung Resection)|"Toothbrushing 3 times/day for at least 5 days preoperatively using a 0.12% chlorhexidine solution~The intensive toothbrushing regimen and chlorhexidine mouthwash will be continued for the duration of the hospitalization or a minimum of 5 days postoperatively in the study group."
89030790|NCT00522249|Experimental|1|One cycle of the combination therapy will be 42 days (6 weeks). All patients will receive PEG-Intron given subcutaneously on Day 1 each week. Patients will receive Sunitinib orally on Days 1-28 of each cycle. Patients will receive Tarceva orally on Days 1-42.
89590371|NCT01446796|Placebo Comparator|Native Conduction|Devices will be programmed to continuous atrial pacing at an AAI (atrial inhibited pacing) setting with base rate 90 bpm. Patients will not receive ventricular pacing.
89030791|NCT05148767|Experimental|Neoadjuvant chemoradiotherapy based on irinotecan|Locally advanced rectal cancer patients who were treated with irinotecan-based neoadjuvant chemoradiotherapy regimen can be enrolled in this group.
89030792|NCT00522288|Experimental|Contact Lens|Soft contact lenses
89030793|NCT00522288|Active Comparator|Spectacle|Spectacles
89590372|NCT01446796|Experimental|Continuous RV Pacing|Devices will be programmed to continuous dual chamber pacing at a DDD (dual chamber dual pacing) setting with base rate ≥ 90 bpm (not to exceed 100 bpm) to achieve a majority (>80%) of paced right ventricular beats
89590373|NCT01439074|Active Comparator|Mepilex Ag|Mepilex Ag consists of a Safetac(R) soft silicone wound contact layer, a grey absorbent polyurethane foam pad containing a silver compound, activated carbon, and a vapour permeable waterproof film.
89030794|NCT05142956||Smokers|Current smokers are defined as cigarettes smoking within one year before surgery.
89030795|NCT00522327|Experimental|1|remote simult med interpret
89590374|NCT01439074|Active Comparator|Silver Sulphadiazine Ag cream|SSD Ag cream is white cream, 1% SSD Ag, 40g/tube This cream is indicated for prevent and treat secondary wound infection of small area, mild burn/scald.
89590375|NCT01438996|Experimental|NVGH Vi-CRM/NVGH Vi-CRM|One 0.5 mL dose of NVGH Vi-CRM197 5.0 mcg in adults who received 1 dose of NVGH Vi-CRM197 5.0 mcg in H01_04TP study
89590376|NCT01438996|Experimental|Vi-PS/NVGH Vi-CRM|One 0.5 mL dose of NVGH Vi-CRM197 5.0 mcg in adults who received 1 dose of Vi-polysaccharide (PS) in H01_04TP study
89590377|NCT01438996|Experimental|NVGH Vi-CRM|One 0.5 mL dose of NVGH Vi-CRM197 5.0 mcg in naive adults
89590378|NCT01438840|Active Comparator|Avatrombopag (Core Study)|Avatrombopag will be administered orally as 5 mg, 10 mg, 20 mg, 30 mg, or 40 mg in a flexible dose design for 26 weeks. Participants will receive blinded therapy at a starting dose of 20 mg avatrombopag, one daily and allowed to have their dose titrated up (maximum dose of 40 mg avatrombopag) or down (minimum dose of 5 mg avatrombopag) depending on their response to study drug.
89590379|NCT01438840|Placebo Comparator|Placebo (Core Study)|Placebo will be administered as 5 mg, 10 mg, 20 mg, 30 mg or 40 mg in a flexible dose design for 26 weeks. Placebo will be administered orally at a starting dose of 20 mg, once daily. Afterwards the dose can be titrated up (maximum dose of 40 mg avatrombopag) or down (minimum dose of 5 mg avatrombopag) depending on the participant's response to the study drug; placebo titration will be used to maintain the blind.
89590380|NCT01438840|Experimental|Avatrombopag (Open-Label Extension)|Participants who meet all eligibility criteria requirements of extension phase and who discontinue the core study because of lack of treatment effect will continue into the extension phase. Avatrombopag will be administered to participants who enter extension phase, with a starting dose of 20 mg avatrombopag, once daily for 76 weeks and undergo dose titration.
89590381|NCT01471054|Experimental|Ozurdex|Patients will be followed at 1 week after Ozurdex insertion (0.7 mg) and then at 1,2, 3,4, 5, and 6 months. Following the 6-month visit, patients will be seen every 2 months. At each visit patients will be checked for side effects of treatment, measurement of best-corrected visual acuity (BCVA), complete eye examination, fundus photography, and optical coherence tomography. Fluorescein angiography will be repeated at 6 and 12 months. Each eye in the Ozurdex group can have a maximum total of three Ozurdex insertions at minimum of 4-month intervals in the first year after enrolling into the study.
89590382|NCT01471054|Active Comparator|Bevacizumab|Patients will be followed at 1 week after the initial bevacizumab injection and then at 1,2, 3,4, 5, and 6 months after implant. Following the 6-month visit, the patients will be examined every 4-8 weeks depending on the status of their macular edema. At each visit patients will be checked for side effects of treatment, measurement of BCVA, complete eye examination, fundus photography, and optical coherence tomography. Fluorescein angiography will be repeated at 6 and 12 months. Eyes in the Bevacizumab group can have a maximum total of twelve (12) bevacizumab injections at minimum of 4-week intervals in the first year after enrolling into the study.
89030796|NCT00522327|Active Comparator|2|Usual & Customary
89030797|NCT00522327|Other|3|comparison group
89030798|NCT05148728|No Intervention|Active surveillance|After a recurrence in patient with previous low grade bladder cancer tumor, strict follow up with cystoscopy and cytology, avoiding immediate surgery
89030799|NCT05148728|Active Comparator|endoscopic fulguration|After a recurrence in patient with previous low grade bladder cancer tumor, fulguration under local anesthesia and sedation will be performed using a flexible cystoscope and a monopolar electrode
89030800|NCT00523692|Experimental|1|Intensive therapy
89030801|NCT00523692|Active Comparator|2|Standard therapy
89030802|NCT05148689|Experimental|test product|Oxymetazoline Cream, 1%
89030803|NCT05148689|Active Comparator|reference|Rhofade™ (oxymetazoline) cream, 1%
89030804|NCT05148689|Placebo Comparator|placebo|Vehicle of Test product
89030805|NCT03458910|Experimental|HRV-increase group|Half of the participants will be randomly assigned to this group who will undergo daily practice to increase their heart rate variability (HRV).
89030806|NCT03458910|Experimental|HRV-decrease group|Half of the participants will be randomly assigned to this group who will undergo daily practice to decrease their HRV and heart rate.
89030807|NCT05148650|Experimental|Crystalloid infusion|Intravenous (IV) transfusions were performed of a 20ml/kg of a balanced crystalloid solution (Optilyte®, Fresenius Kabi). The infusions were performed through an intravenous cannula (18G) inserted into a vein in the antecubital fossa on the non-dominant limb at 1000 ml/h
89030808|NCT05148650|Experimental|Colloid infusion|Intravenous (IV) transfusions were performed of a 20ml/kg of gelatin 26,500 Da (Geloplasma®, Fresenius Kabi). The infusions were performed through an intravenous cannula (18G) inserted into a vein in the antecubital fossa on the non-dominant limb at 1000 ml/h
89590383|NCT01978184|Experimental|gemcitabine and abraxane|Gemcitabine and Abraxane will be administered on an outpatient basis on Days 3, 10, 17, 31, 38, and 45 as an intravenous infusion. The dose on Day 3 will be 1000 mg/m of gemcitabine followed by a 125 mg/m2 of abraxane and the infusion will take 1 hour. The second dose and infusion time may be decreased. Prior to each gemcitabine infusion, subjects will be pre-medicated with an FDA-approved anti-emetic (anti-nausea medication) in an effort to prevent nausea, at the discretion of the study physician.
89590384|NCT01978184|Experimental|gemcitabine, abraxane and hydroxychloroquine|"Gemcitabine and Abraxane will be administered on an outpatient basis on Days 3, 10, 17, 31, 38, and 45 as an intravenous infusion. The dose on Day 3 will be 1000 mg/m of gemcitabine followed by a 125 mg/m2 of abraxane and the infusion will take 1 hour. The second dose and infusion time may be decreased. Prior to each gemcitabine infusion, subjects will be pre-medicated with an FDA-approved anti-emetic (anti-nausea medication) in an effort to prevent nausea, at the discretion of the study physician.~Hydroxychloroquine is an oral drug (capsule) that subjects will take once or twice a day at home. The dose of hydroxychlorquien will be 1200mg. This is an experimental drug. Subjects will take their first dose of hydroxychloroquine on Day 1 (48 hours before the first infusion of gemcitabine/abraxane), and will continue to take it every day until the day before surgery."
89590385|NCT01445548|Experimental|Sirolimus|"Participants initially received a 20 μL (440 μg) intravitreal injection sirolimus in the study eye at baseline and every two months thereafter unless contraindicated.~As of September 2012, sirolimus intravitreal injections were no longer administered to participants."
89590386|NCT01977794|Experimental|Bisoprolol failed group|Subjects who failed monotherapy with bisoprolol 5 milligram (mg) before trial inclusion will be randomized to bisoprolol failed group to receive Bisoprolol/Amlodipine FDC tablet
89590387|NCT01977794|Experimental|Amlodipine failed group|Subjects who failed monotherapy with amlodipine 5 mg before trial inclusion will be randomized to amlodipine failed group to receive Bisoprolol/Amlodipine FDC tablet.
89590388|NCT04408768||Normal RBS|Normal RBS on ICU admission and controlled blood sugar within 24 hours
89590389|NCT04408768||High RBS|High RBS on ICU admission and uncontrolled blood sugar during first 24 hours
89590390|NCT02005484|Experimental|Trastuzumab Monotherapy|Initial dose of 4 milligrams (mg) per (/) kilogram (kg) by body weight (BW), followed by 2 mg/kg BW at each subsequent visit
89590391|NCT02005250||hyperthyroidism|61 pre- and postmenopausal women with hyperthyroidism
89590392|NCT02005250||hypothyroidism|32 pre- and postmenopausal women with hypothyroidism
89590393|NCT02024750|Experimental|Tailored Resources|Use of PRISM screening tool to identify self-management needs and to provide tailored group session resources over 1 year
89590394|NCT02024750|No Intervention|Usual Care|Patients and families obtain routine multidisciplinary diabetes care
89590395|NCT01597973|Active Comparator|colistin and meropenem|
89590396|NCT01597973|Active Comparator|colistin and placebo|
89590397|NCT04671680||Pregnant women with suspected placenta accreta|Pregnant women undergoing cesarean delivery with suspected placenta accreta spectrum.
89590398|NCT02023268|Experimental|T2762|
89590399|NCT02023268|Active Comparator|Vismed®|
89590400|NCT02047253|Experimental|Carfilzomib|Carfilzomib is administered twice-weekly on consecutive days (days 1, 2, 8, 9, 15, 16) as a 30-minute intravenous infusion for 3 weeks every 4 weeks (1 cycle) with dexamethasone given as pre-medication. The dose of carfilzomib is 20 mg/m2 on days 1 and 2 of cycle 1 and is then escalated in succeeding weeks and cycles to 56 mg/m2 if no dose limiting toxicities occur. Acyclovir is given orally at 400 mg twice daily during therapy but may be discontinued at some point. Therapy will continue until side effects become unacceptable, the disease progresses, or the doctor withdraws the patient.
89590401|NCT04707131|Experimental|LEM-S401|
89590402|NCT04707131|Placebo Comparator|Placebo|
89590403|NCT02096705|Experimental|Group 1: Dapagliflozin|Dapagliflozin 10 mg oral Tablet once daily for 24 weeks + Background Insulin
89590404|NCT02096705|Placebo Comparator|Group 2: Dapagliflozin Placebo|Dapagliflozin Placebo 0 mg oral Tablet once daily for 24 weeks + Background Insulin
89590405|NCT04705571|Experimental|MorpheusV Applicator (active)|
89590406|NCT02096471|Experimental|Agent PD-0325901|The primary aim of the study will be to assess quantitative radiographic response in a target lesion. Subjects will receive PD-0325901 by mouth on a bid dosing schedule of 2 mg/m2/dose with a maximum dose of 4 mg bid. Each course is 4 weeks duration, and subjects will receive drug on a 3 week on/1 week off schedule. Subjects may receive additional courses beyond course 8 only if there is at least 15% reduction in volume of the target tumor. Subjects who have a 20% or greater reduction in target tumor volume at the end of 12 courses can continue on therapy for up to an additional year (maximum of 24 total courses). However, subjects who do not achieve at least 15% reduction in volume of the target tumor after 8 courses (~8 months) will be considered treatment failures and taken off study.
89590407|NCT02096003|Active Comparator|Intrathecal morphine|0.25mg ( 250mcg) intrathecal morphine added to 1.5 mg 0.75% bupivicaine for single shot spinal anesthesia in primary cesarean sections
89590408|NCT02096003|Experimental|Intrathecal hydromorphone|50mcg intrathecal hydromorphone added to 1.5 mg 0.75% bupivicaine for single shot spinal anesthesia in primary cesarean sections.
88976884|NCT02963779|Experimental|LY2775240 (Part B)|Oral dose of LY2775240 in healthy participants
88976885|NCT02963779|Placebo Comparator|Placebo (Part A)|Placebo administered orally in healthy participants
88976886|NCT02963779|Active Comparator|Apremilast (Part B)|Oral dose of apremilast in healthy participants
88976887|NCT00056303|Experimental|Attachment and Biobehavioral Catch-up|Attachment and Biobehavioral Catch-up targets nurturance, synchrony, and non-frightening behavior, as well as providing caregivers with help calming toddlers.
88976888|NCT00056303|Active Comparator|Developmental Education for Families|Developmental Education for Families targets providing cognitive stimulation to their children.
88976889|NCT00174928|Experimental|Lansoprazole 0.5 mg/kg QD|
88976890|NCT00174928|Experimental|Lansoprazole 1.0 mg/kg QD|
88976891|NCT00175045|Experimental|Lansoprazole IV 30 mg QD|
88976892|NCT00175045|Active Comparator|Lansoprazole Capsule 30 mg QD|
88976893|NCT00175357|Active Comparator|1|Oral methadone
88976894|NCT00175357|Experimental|2|Injected diacetylmorphine
88976895|NCT00175396|Active Comparator|1|
88976896|NCT00175396|Experimental|2|
88976897|NCT00056459|Experimental|1|Oxaliplatin/5-FU/LV and PTK787/ZK 222584
88976898|NCT00056459|Placebo Comparator|2|Oxaliplatin/5-FU/LV and placebo
88976899|NCT00175435|Experimental|1|2 doses of HPV vaccine 0.5 mL. given IM with Topical Immune Modulator in 9-13 year-olds.
88976900|NCT00175435|Active Comparator|2|3 doses of HPV vaccine 0.5 mL given IM with Topical Immune Modulator in 9-13 year-olds.
89590409|NCT02062385|Experimental|V260 with staggered EPI|V260 administered as a 2 mL oral solution at age ~2, 3, and 4 months, and staggered China Expanded Program on Immunizations (EPI) as follows: Oral poliovirus vaccine (OPV) administered as a 1 g oral solution at age ~2.5, 3.5, and 4.5 months, and diphtheria, tetanus, acellular pertussis vaccine (DTaP) administered as a 0.5 mL intramuscular injection at age ~3.5, 4.5, and 5.5 months
89590410|NCT02062385|Placebo Comparator|Placebo with staggered EPI|Placebo administered as a 2 mL oral solution at age ~2, 3, and 4 months, and staggered EPI as follows: OPV administered as a 1 g oral solution at age ~2.5, 3.5, and 4.5 months, and DTaP administered as a 0.5 mL intramuscular injection at age ~3.5, 4.5, and 5.5 months
89590411|NCT02062385|Experimental|V260 with concomitant EPI|V260 administered as a 2 mL oral solution at age ~2, 3, and 4 months, and concomitant EPI as follows: OPV administered as a 1 g oral solution at age ~2, 3, and 4 months and DTaP administered as a 0.5 mL intramuscular injection at age ~3, 4, and 5 months
89590412|NCT02062385|Placebo Comparator|Placebo with concomitant EPI|Placebo administered as a 2 mL oral solution at age ~2, 3, and 4 months, and concomitant EPI as follows: OPV administered as a 1 g oral solution at age ~2, 3, and 4 months and DTaP administered as a 0.5 mL intramuscular injection at age ~3, 4, and 5 months
89590413|NCT02062151|Experimental|NAS babies|Acupuncture for NAS
89590414|NCT02060903|Active Comparator|Abametapir Lotion 0.74% w/w|Single topical treatment administered to hair and scalp for 10 minutes. Applied at home by a subject/caregiver.
89590415|NCT02060903|Placebo Comparator|Vehicle Lotion|Single topical treatment administered to hair and scalp for 10 minutes. Applied at home by a subject/caregiver.
89590416|NCT02095691|Experimental|Resistant Hypertension|The Celsius® ThermoCool® Renal Denervation catheter will serve to treat resistant hypertension.
89590417|NCT02095535||Study group|All study participants
89590418|NCT02095223|Experimental|Electromyographic Biofeedback Group|Participants in the electromyographic biofeedback supplemented exercise will be instructed on correct setup and use of the electromyographic biofeedback unit. Electromyographic biofeedback will be used during all exercises throughout the course of the study for this group. Participants in will be instructed on a 14 day exercise protocol on the day of enrollment. The protocol is comprised of 4 exercises focused on both non-weight bearing and weight bearing quadriceps strengthening. A compliance log will be given to each participant and will be reviewed at each supervised exercise session and at the final study visit. Participants will be instructed to discontinue exercise and contact the principle investigator if they experience knee pain due to the intervention.
89590419|NCT02095223|Active Comparator|Traditional Exercise Group|Participants in will be instructed on a 14 day exercise protocol on the day of enrollment. The protocol is comprised of 4 exercises focused on both non-weight bearing and weight bearing quadriceps strengthening. A compliance log will be given to each participant and will be reviewed at each supervised exercise session and at the final study visit. Participants will be instructed to discontinue exercise and contact the principle investigator if they experience knee pain due to the intervention.
89590420|NCT02095145|Experimental|Group I (pomegranate-extract pill)|Patients receive pomegranate-extract pill PO QD for 52 weeks (+/- 1 week).
89590421|NCT02095145|Placebo Comparator|Group II (placebo)|Patients receive placebo PO QD for 52 weeks (+/- 1 week).
89590422|NCT04722029|No Intervention|Donor|"Donors will be evaluated to determine suitability to undergo apheresis collection and their infectious disease status. Donor evaluation will include history and physical examination, laboratory tests, FDA- approved donor testing of communicable diseases (HIV, HVB, HCV, HTLV-I, II, WNV, T. pallidum, T. cruzi, and Zika virus), ABO and Rh typing, pregnancy tests, and donor serology for ADV.~Qualified donors will undergo leukapheresis. Collection will proceed for 2 hours or 2 blood volumes, whichever occurs first."
89590423|NCT04722029|Experimental|Recipient|"Recipient will undergo a screening period that will include history and physical examination, laboratory tests, performance status, HLA typing and pregnancy test (if needed).~Qualified patients will receive ADV-VSTS infusion from haploidentical donors up to a maximum of 5.0 x 104 interferon gamma-negative cells/kg. All patients will be followed for laboratory and clinical response, safety, efficacy and tolerance."
88976901|NCT00175435|Active Comparator|3|3 doses HPV vaccine 0.5 mL given IM with Topical Immune Modulator in 16-26 year-olds.
88976902|NCT00407992|Experimental|Occipital nerve stimulation ON|
88976903|NCT00407992|Other|Occipital nerve stimulation OFF|
88976904|NCT02970474|Other|All Participants|All participants will undergo the same schedule. Each participant will be fitted with a conventional and a 3D printed bolus prior to receiving radiation therapy. Each bolus will be assessed for optimal dose distribution of the radiation to the tumor through computer stimulation. The bolus, either conventional or 3D printed, that is found to be superior will be used for the actual radiation therapy treatment.
88976905|NCT00056537|Experimental|1|
88976906|NCT00408031|Experimental|1|Randomization to 2 treatment groups. One group receives adjuvant treatment with D-cycloserine, up to 1 g/day. The second group receives adjuvant treatment with placebo, up to 1 g/day.
88976907|NCT04493619|Experimental|PLX2853 Phase 2a Monotherapy|Up to 26 evaluable subjects with ARID1A mutation-positive advanced gynecological malignancies will be enrolled.
89590424|NCT02059187|Experimental|MK-1293|MK-1293 administered subcutaneously once daily in the evening.
89590425|NCT02059187|Active Comparator|Lantus™|Lantus™ administered subcutaneously once daily in the evening.
89590426|NCT02043899|Experimental|Single Arm Trial|This was a single arm trial, all patients were to undergo the same assessments and interventions.
89590427|NCT04719611|Experimental|Healthy Women|Healthy women between the ages of 18-40 years will be given a probiotic supplement to evaluate the detection and persistence of the strains in biological samples.
89590428|NCT02043509|Experimental|MiQuit|12 weeks of MiQuit text support plus a standard NHS leaflet giving information and advice on stopping smoking in addition to usual care
89590429|NCT02043509|No Intervention|Control|Usual care plus the same standard NHS leaflet giving information and advice on stopping smoking
89590430|NCT04719377|Experimental|Powerme midline catheter|Powerme midline catheter
89590431|NCT04719377|Sham Comparator|peripheral intravenous catheter|BD Pegusas peripheral intravenous catheter
89209906|NCT00891696|Active Comparator|Exp 3: HEx + AA|Participants will receive amino acid supplementation and will undergo high-intensity resistance exercise.
89209907|NCT00640328|Experimental|Cohort 1.1|100mg ofatumumab then placebo
89209908|NCT00640328|Experimental|Cohort 1.2|placebo then 100mg ofatumumab
89590432|NCT02058563|Experimental|INV_MMR Group|Subjects will receive 1 dose of GSK Biologicals' trivalent Measles, Mumps, and Rubella Virus Vaccine (Priorix®).
89590433|NCT02058563|Active Comparator|COM_MMR Group|Subjects will receive 1 dose of Merck's M-M-R®II, Measles, Mumps, and Rubella Virus Vaccine.
89590434|NCT01622231|Experimental|GW685698X|GW685698X 55mcg/day
89590435|NCT04417439||flame burns|The joint range of motion was assessed by a universal goniometer within the affected areas of burn patients. A tape measure with a width of 7 mm was used to evaluate the circumference measurement in individuals. The biochemical examination of CK (creatine kinase) was performed in the laboratories.
89590436|NCT04417439||scald burns|The joint range of motion was assessed by a universal goniometer within the affected areas of burn patients. A tape measure with a width of 7 mm was used to evaluate the circumference measurement in individuals. The biochemical examination of CK (creatine kinase) was performed in the laboratories.
89590437|NCT04417439||electrical burns|The joint range of motion was assessed by a universal goniometer within the affected areas of burn patients. A tape measure with a width of 7 mm was used to evaluate the circumference measurement in individuals. The biochemical examination of CK (creatine kinase) was performed in the laboratories.
89590438|NCT02042183|Experimental|Lubiprostone|Participants receive lubiprostone twice daily (BID) up to 12 weeks
89590439|NCT02042183|Placebo Comparator|Placebo|Participants receive placebo BID up to 12 weeks
89590440|NCT01977482|Experimental|GSK1278863 4 mg|Subjects will take GSK1278863 4 mg blinded once daily (OD) orally for 4 weeks with a glass of water. From Week 4, study medication will continue to be administered OD and the dose will be adjusted based on Hgb levels dose every 4 weeks till Week 24.
89590441|NCT01977482|Experimental|GSK1278863 6 mg|Subjects will take GSK1278863 6 mg blinded OD orally for 4 weeks with a glass of water. From Week 4, study medication will continue to be administered OD and the dose will be adjusted based on Hgb levels dose every 4 weeks till Week 24.
89590442|NCT01977482|Experimental|GSK1278863 8 mg|Subjects will take GSK1278863 8 mg blinded OD orally for 4 weeks with a glass of water. From Week 4, study medication will continue to be administered OD and the dose will be adjusted based on Hgb levels dose every 4 weeks till Week 24.
89590443|NCT01977482|Experimental|GSK1278863 10 mg|Subjects will take GSK1278863 10 mg blinded OD orally for 4 weeks with a glass of water. From Week 4, study medication will continue to be administered OD and the dose will be adjusted based on Hgb levels dose every 4 weeks till Week 24.
89590444|NCT01977482|Experimental|GSK1278863 12 mg|Subjects will take GSK1278863 12 mg blinded OD orally for 4 weeks with a glass of water. From Week 4, study medication will continue to be administered OD and the dose will be adjusted based on Hgb levels dose every 4 weeks till Week 24.
89590445|NCT01977482|Active Comparator|Control|Subjects will take GSK1278863 matching placebo blinded OD orally for 4 weeks with a glass of water. From Week 4, rhEPO will be administered and the dose will be adjusted based on Hgb levels dose every 4 weeks till Week 24.
89590446|NCT02058095|Active Comparator|Tadalafil|Subject will receive Tadalafil daily for a total of 12 weeks
89590447|NCT02058095|Placebo Comparator|Placebo|Subject will receive Placebo daily for a total of 12 weeks
89590448|NCT04718207||Patient with Alzheimer disease|Patients recruited retrospectively with the available nuclear medicine listing of patients who performed brain PET/CT scans in the nuclear medicine department from December 2017 to December 2020.
89590449|NCT04663022||Child with cochlear implant|15 childs with coclear implant but without autism spectrum disorder
89590450|NCT04663022||Child with cochlear implant and autism spectrum disorder|15 childs with coclear implant and with autism spectrum disorder
89590451|NCT02023112|Experimental|ABT-450/r/ABT-267 plus RBV for 12 weeks|ABT-450/r/ABT-267 (150/100/25 mg once daily) plus weight-based ribavirin (RBV; 400 to 1,000 mg/day, divided twice daily) for 12 weeks
88976908|NCT04493619|Experimental|PLX2853 + Carboplatin Phase 1b/2a Combination Therapy|"Phase 1b (PLX2853 + carboplatin combination): Up to 15 evaluable subjects with platinum-resistant EOC will be enrolled.~Phase 2a (PLX2853 + carboplatin combination): Up to 26 evaluable subjects with platinum-resistant EOC will be enrolled."
88976909|NCT00175903|Experimental|Levetiracetam|Daily dose of 1000 to 3000 mg film-coated oral tablets, 250-500 mg twice daily.
88976910|NCT00175903|Active Comparator|Older Antepileptic Drugs|Older AEDs consist of CBZ-CR 200 mg and 400 mg and VPA-ER 300 mg and 500 mg.
89590452|NCT02023112|Experimental|ABT-450/r/ABT-267 plus RBV for 16 weeks|ABT-450/r/ABT-267 (150/100/25 mg once daily) plus weight-based RBV (400 to 1,000 mg/day, divided twice daily) for 16 weeks
89590453|NCT01977092|Experimental|Motivational interviewing case management|MICM intervention combines aspects of motivational interviewing along with case management to influence HIV risk and recovery from alcohol and drug problems. Participants assigned to the MICM condition will be contacted to receive 3 individual sessions within the first 4 weeks of entering the study. Thereafter they will have contact with the MICM therapist monthly throughout the duration of their enrollment in the study (12 months).
88976911|NCT00056654|Experimental|1|
89590454|NCT01977092|Other|Resource referrals|Respondents will receive SLH services as usual along with a list of resources that can be used to address a variety of problems.
89590455|NCT01976624||Ganfort®|Patients who received treatment with bimatoprost/timolol (Ganfort®) for open-angle glaucoma or ocular hypertension as per local standard of care in clinical practice.
89590456|NCT02041091|Experimental|Tabalumab Auto-Injector|Tabalumab given Week 0 as a loading dose of 240 milligram (mg) given as two subcutaneous (SC) injections each of 120 mg followed by 120 mg SC injection every two weeks for 12 weeks. Participants may continue on this treatment regimen for 52 weeks.
89590457|NCT02041091|Experimental|Tabalumab Prefilled Syringe|Tabalumab given Week 0 as a loading dose of 240 mg given as two SC injections each of 120 mg followed by 120 mg SC injections every two weeks for 12 weeks. Participants may continue to on this treatment regimen for 52 weeks.
89590458|NCT04717973||patients undergo sleeve gasterectomy|
89590459|NCT04717973||patients undergo gasteric bypass|
89590460|NCT02057549|Experimental|Haloperidol plus Conventional Therapy|Intravenous dose of haloperidol 5 mg in addition to conventional therapy. Conventional Therapy includes hydration via IV fluids, pain control with analgesics (usually opiates) frequently requiring multiple doses, also antiemetics (often requires multiple doses and different agents in attempts to control nausea and vomiting within this population), in addition to electrolytes abnormalities corrections as needed.
89590461|NCT02057549|Active Comparator|Conventional Therapy alone|Conventional Therapy includes hydration via IV fluids, pain control with analgesics (usually opiates) frequently requiring multiple doses, also antiemetics (often requires multiple doses and different agents in attempts to control nausea and vomiting within this population), in addition to electrolytes abnormalities corrections as needed.
89590462|NCT02057393|Experimental|Indocyanine Green|Single arm study, each subject receives 0.9ml ICG, methylene blue and technetium 99.
89590463|NCT04698161||NSCLC|Patients with non-small-cell lung cancer (NSCLC)
89590464|NCT04698161||metastatic melanoma|patients with metastatic melanoma
89590465|NCT02040779|Experimental|BDP 80 mcg BAI|40 mcg beclomethasone dipropionate (BDP) via breath-actuated inhaler (BAI) twice daily for a total of 80 mcg/day.
89590466|NCT02040779|Experimental|BDP 160 mcg BAI|80 mcg beclomethasone dipropionate (BDP) via breath-actuated inhaler (BAI) twice daily for a total of 160 mcg/day.
89590467|NCT02040779|Placebo Comparator|Placebo BAI|Placebo breath-actuated inhaler (BAI) twice daily.
89590468|NCT02056301|Active Comparator|Patient Controlled Analgesia|One group will have a patient controlled device connected to an intravenous patient controlled analgesia (IV PCA). This device runs a basal infusion of pain medicine (morphine) intravenously with additional allowable patient controlled doses every 10 minutes.
89590469|NCT02056301|Active Comparator|epidural Catheter|The other group will have an epidural catheter inserted under sterile conditions in the thoracic epidural space after anesthesia has been induced. This will be connected to a patient controlled epidural analgesia (PCEA) device for postoperative pain control that works in a similar manner except the medication (a combination of local anesthetics and hydromorphone) will be administered in the thoracic epidural space.
89590470|NCT01967732|Active Comparator|THS 2.2 then CC|"Each subject will follow the below study design:~Day 0 = Wash-out (1 day)~Day 1 = 1st intervention (single product use of THS 2.2)~Day 2 = wash-out~Day 3 = 2nd intervention (single product use of CC)."
89590471|NCT01967732|Active Comparator|CC then THS 2.2|"Each subject will follow the below study design:~Day 0 = Wash-out (1 day)~Day 1 = 1st intervention (single product use of CC)~Day 2 = wash-out~Day 3 = 2nd intervention (single product use of THS 2.2)."
89590472|NCT01967732|Active Comparator|THS 2.2 then NNS|"Each subject will follow the below study design:~Day 0 = Wash-out (1 day)~Day 1 = 1st intervention (single product use of THS 2.2)~Day 2 = wash-out~Day 3 = 2nd intervention (single administration of NNS)"
89590473|NCT01967732|Active Comparator|NNS then THS 2.2|"Each subject will follow the below study design:~Day 0 = Wash-out (1 day)~Day 1 = 1st intervention (single administration of NNS)~Day 2 = wash-out~Day 3 = 2nd intervention (single product use of THS 2.2)."
89590474|NCT01967576|Experimental|1/Arm 1-Axitinib|Axitinib 5 mg twice a day on a 28-day cycle
89590475|NCT02039687|Experimental|1 mg per day ARA 290|1 mg ARA 290 administered subcutaneously for 28 consecutive days
89590476|NCT02039687|Experimental|4 mg per day ARA 290|4 mg ARA 290 administered subcutaneously for 28 consecutive days
89590477|NCT02039687|Experimental|8 mg per day ARA 290|8 mg ARA 290 administered subcutaneously for 28 consecutive days
89590478|NCT02039687|Placebo Comparator|placebo|1 mL placebo administered subcutaneously for 28 consecutive days
89590479|NCT02003534|Experimental|0.15% Brimonidine Tartrate|0.15% Brimonidine Tartrate (Alphagan® P) 1 drop in the affected eye 3 times daily for 3 months.
89590480|NCT02055365|Experimental|Hepatitis B vaccination|All subjects will receive the standard 3-dose course of Recombivax HB (Merck) - Hepatitis B Vaccine (Recombinant).
89590481|NCT05127473|Experimental|Dose level 1|All participants will receive a single dose of Mim8
89590482|NCT05127473|Experimental|Dose level 2|All participants will receive a single dose of Mim8
89590483|NCT05127473|Experimental|Dose level 3|All participants will receive a single dose of Mim8
88976912|NCT04420533|Active Comparator|Behavior therapy alone|Behavior therapy alone
88976913|NCT04420533|Experimental|Behavior therapy plus mirabegron 50mg|Behavior therapy plus Betmiga prolonged-release tablets (mirabegron) 50mg QDAC PO
88976914|NCT02969993|Experimental|Questionnaire|Questionnaire to previously operated patients
89590484|NCT05127473|Experimental|Dose level 4|All participants will receive a single dose of Mim8
89590485|NCT05127473|Experimental|Dose level 5|All participants will receive a single dose of Mim8
89590486|NCT05127473|Experimental|Dose level 6|All participants will receive a single dose of Mim8
89590487|NCT05127473|Experimental|Dose level 7|All participants will receive a single dose of Mim8
89590488|NCT05127473|Experimental|Dose level 8|All participants will receive a single dose of Mim8
89590489|NCT05127473|Experimental|Dose level 9|All participants will receive a single dose of Mim8
89590490|NCT05127473|Experimental|Dose level 10|All participants will receive a single dose of Mim8
89590491|NCT05127473|Experimental|Dose level 11|All participants will receive a single dose of Mim8
89590492|NCT05127473|Experimental|Dose level 12|All participants will receive a single dose of Mim8
89590493|NCT02039375|Experimental|"Hopkins post tPA monitoring protocol"|"Patients treated with IV tPA (intravenous tissue Plasminogen Activator) for acute stroke will be monitored in a non-ICU setting following the Hopkins post tPA monitoring protocol, a new schedule for vital signs and neurochecks. These patients will have vital signs and neurochecks every 15 minutes for two hours, then once upon admission to the stroke unit and after one hour, then every two hours for 8 hours and then every four hours until 24 hours post tPA."
89590494|NCT02054897|Experimental|Semaglutide 1.0 mg|
89590495|NCT02054897|Experimental|Semaglutide 0.5 mg|
89590496|NCT02054897|Placebo Comparator|Semaglutide placebo 1.0 mg|
89590497|NCT02054897|Placebo Comparator|Semaglutide placebo 0.5 mg|
89590498|NCT01976312|Experimental|Ranibizumab 0.5 mg|PRN intravitreal injection
89590499|NCT01976312|Sham Comparator|Sham injection|As of Month 3, ranibizumab 0.5 mg PRN intravitreal injections
89590500|NCT02039219|Placebo Comparator|Placebo|Placebo
89590501|NCT02039219|Experimental|10 mg Obeticholic Acid (OCA)|10 mg Obeticholic Acid (OCA) Study medication will be administered orally, once daily for 6 weeks.
89590502|NCT02053493|Active Comparator|Isosorbide Mononitrate|Isosorbide Mononitrate with dose up-titration (30 to 120 mg/day over 4 weeks)
89590503|NCT02053493|Placebo Comparator|Isosorbide Mononitate Placebo|Isosorbide Mononitrate placebo with dose up-titration (30 to 120 mg/day over 4 weeks)
89590504|NCT02003144|Experimental|Eculizumab|Eculizumab intravenous infusion every two weeks.
89590505|NCT04661540|Experimental|Auxora|"Auxora will be given as a continuous infusion:~Day 1: All 3 cohorts will receive 1.25 mL/kg over 4 hours; After initial infusion is complete, Cohort 3 will receive a continuous infusion of 1.0 mL/kg/24 hours for 96 hours Day 2: Cohort 1 will receive 1.0 mL/kg over 4 hours; Cohort 2 will receive 1.25mL/kg over 4 hours Day 3: Cohort 1 and 2 will receive 1.0 mL/kg over 4 hours Day 4: Cohort 2 will receive 1.0 mL/kg over 4 hours"
89590506|NCT04661540|Placebo Comparator|Placebo|"Placebo will be given as a continuous infusion:~Day 1: All 3 cohorts will receive 1.25 mL/kg over 4 hours. After initial infusion is complete, Cohort 3 will receive a continuous infusion of 1.0 mL/kg/24 hours for 96 hours Day 2: Cohort 1 will receive 1.0 mL/kg over 4 hours; Cohort 2 will receive 1.25mL/kg over 4 hours Day 3: Cohort 1 and 2 will receive 1.0 mL/kg over 4 hours Day 4: Cohort 2 will receive 1.0 mL/kg over 4 hours"
89590507|NCT02001194|No Intervention|Control|Participants receive either an email or text message daily (based on the participant's preference) stating whether the participant achieved the 7000 step goal during the previous day. Each participant will also be notified as to how many of their teammates reached the goal the previous day. Control Arm will receive no financial incentive.
89590508|NCT02001194|Experimental|Individual|Participants receive either an email or text message daily (based on the participant's preference) stating whether the participant achieved the 7000 step goal during the previous day. Each participant will also be notified as to how many of their teammates reached the goal the previous day. Every day one team from the arm will be chosen at random as the winning team. Each participant on the winning team receives $50 if that participant met the step goal during the prior day.
89590509|NCT02001194|Experimental|Team|Participants receive either an email or text message daily (based on the participant's preference) stating whether the participant achieved the 7000 step goal during the previous day. Each participant will also be notified as to how many of their teammates reached the goal the previous day. Every day one team from the arm will be chosen at random as the winning team. Each participant on the winning team receives $50 only if all four team members met the step goal during the prior day.
89590510|NCT02001194|Experimental|Individual Plus Team|Participants receive either an email or text message daily (based on the participant's preference) stating whether the participant achieved the 7000 step goal during the previous day. Each participant will also be notified as to how many of their teammates reached the goal the previous day. Every day one team from the arm will be chosen at random as the winning team. Each participant on the winning team receives $20 if the participant met the step goal during the prior day the participants met their own goal. Each participant will also receive an additional $10 for every one of the other three team members that also met the goal.
89590511|NCT02038907|Experimental|GI.1/GII.4 (15/15) - MPL (50)|Hepatitis A vaccine, intramuscular (IM), on Day 1, followed by norovirus bivalent virus like particle (VLP) vaccine (15 µg of GI.1 norovirus virus VLP and 15 µg GII.4 norovirus VLP) adjuvanted with 50 µg monophosphoryl lipid A (MLP) and 500 µg aluminum hydroxide, IM on Day 28.
89590512|NCT02038907|Experimental|GI.1/GII.4 (15/50) - MPL (50)|Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 50 µg MLP and 500 µg aluminum hydroxide, IM, on Day 28.
89590513|NCT02038907|Experimental|GI.1/GII.4 (50/50) - MPL (50)|Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 50 µg MLP and 500 µg aluminum hydroxide, IM, on Day 28.
89590514|NCT02038907|Experimental|GI.1/GII.4 (15/15) - MPL (15)|Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 15 µg GII.4 norovirus VLP) adjuvanted with 15 µg MLP and 500 µg aluminum hydroxide, IM, on Day 28.
89590515|NCT02038907|Experimental|GI.1/GII.4 (15/50) - MPL (15)|IM hepatitis A vaccine on Day 1, followed by IM norovirus bivalent vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 15 µg MLP and 500 µg aluminum hydroxide, on Day 28.
89590516|NCT02038907|Experimental|GI.1/GII.4 (50/50) - MPL (15)|Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 15 µg MLP and 500 µg aluminum hydroxide, IM, on Day 28.
89590517|NCT02038907|Experimental|GI.1/GII.4 (15/15)|Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 15 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminum hydroxide, IM, on Day 28.
89590518|NCT02038907|Experimental|GI.1/GII.4 (15/50)|Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminum hydroxide, IM, on Day 28.
89590519|NCT02038907|Experimental|GI.1/GII.4 (50/50)|Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminum hydroxide, IM, on Day 28.
88976915|NCT04413591|Experimental|Intervention Area|Participants are assigned to the intervention area or the control area based on the location they were recruited in.
88976916|NCT04413591|No Intervention|Control Area|Participants are assigned to the intervention area or the control area based on the location they were recruited in.
88976917|NCT00176293|Experimental|1|dexamethasone
88976918|NCT00176293|No Intervention|2|
88976919|NCT00056693|Experimental|A|
88976920|NCT00176449|Active Comparator|Bupropion SR|
89590520|NCT02038907|Experimental|GI.1/GII.4 (50/150)|Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 150 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminum hydroxide, IM, on Day 28.
89590521|NCT02038907|Experimental|GI.1/GII.4 (15/50) - Al(OH)3 (167)|Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 167 µg aluminum hydroxide, IM, on Day 28.
89590522|NCT02038907|Experimental|GI.1/GII.4 (15/50) x2|Norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminum hydroxide, IM, on Day 1 and Day 28.
89590523|NCT02038907|Experimental|GI.1/GII.4 (50/150) x2|Norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 150 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminum hydroxide, IM, on Day 1 and Day 28.
89590524|NCT02038907|Experimental|GI.1/GII.4 (15/50) - Al(OH)3 (167) x2|Norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 167 µg aluminum hydroxide, IM, on Day 1 and Day 28.
89590525|NCT02038829|Placebo Comparator|Placebo|Placebo bid
89590526|NCT02038829|Experimental|SUN-101 3 mcg|SUN-101 3 mcg bid
89590527|NCT02038829|Experimental|SUN-101 6.25 mcg|SUN-101 6.25 mcg bid
89590528|NCT02038829|Experimental|SUN-101 12.5 mcg|SUN-101 12.5 mcg bid
89590529|NCT02038829|Experimental|SUN-101 50 mcg|SUN-101 50 mcg bid
89590530|NCT02038829|Active Comparator|Aclidinium 400 mcg|Aclidinium 400 mcg bid
89590531|NCT04693247|Active Comparator|Refraction with a Hand-held Refraction Device|This is the device that will be compared to a standard device.
89590532|NCT04693247|Other|Autorefractor|Standard Device
89590533|NCT02038049|Experimental|VAY736|Intravenous infusion of VAY736
89590534|NCT02038049|Placebo Comparator|Placebo to VAY736|Matching placebo (infusion bag) administered intravenously. Placebo randomized patients were offered optional VAY736 administration after week 16
89590535|NCT02052011|Experimental|Intervention Group|Subjects will take extended release Ranolazine for 4 weeks. Subjects will take 500 mg twice daily for the first week and then 1000 mg twice daily for remaining period (Dosing will be adjusted with concomitant use of diltiazem, verapamil, erythromycin, simvastatin or metformin).
89590536|NCT02052011|Placebo Comparator|Placebo Control|Subjects will take placebo pill twice daily for 4 weeks.
89590537|NCT02036645|Experimental|MEDI1814 IV|Upto 10 cohorts of subjects are planned to be dosed by IV injection, with single and multiple ascending doses ranging from 25-1800mg.
89590538|NCT02036645|Placebo Comparator|IV Placebo|Upto 10 cohorts of subjects are planned to be dosed by IV injection, with single and multiple ascending doses ranging from 25-1800mg.
89590539|NCT02036645|Experimental|MEDI1814 Sub Cutaneous Injection|2 cohorts of subjects are planned to be dosed by sub cutaneous injection, one single ascending dose and one multiple ascending dose cohort
89590540|NCT02036645|Placebo Comparator|Subcutaneous Placebo|2 cohorts of subjects are planned to be dosed by sub cutaneous injection, one single ascending dose and one multiple ascending dose cohort
89590541|NCT02051933|Active Comparator|Botox|"Botox: At the time of definitive fixation, the hospital's investigational pharmacy will provide four syringes containing 0.5mL Botulinum toxin type A. The dose of botulinum toxin will be calculated based on the patient's weight in kilograms, such that a total dose of 200U of Botox will be used for a 70kg individual. The dosage will scale linearly in proportion to the patient's body weight, such that each kilogram change results in a 3U change in Botox (rounded to the nearest 30U interval change from 200U, with a maximum of 300U).~45-55 kg: 140U 55-65 kg: 170U 65-75 kg: 200U 75-85 kg: 230U 85-95 kg: 260U 95-105 kg: 290U 105-115 kg: 300U"
89590542|NCT02051933|Placebo Comparator|Placebo|"Placebo: At the time of definitive fixation, the hospital's investigational pharmacy will provide four syringes containing 0.5mL 0.9% sodium chloride solution . The dose of 0.9% sodium chloride will be calculated based on the patient's weight in kilograms, such that a total dose of 200U of Placebo will be used for a 70kg individual. The dosage will scale linearly in proportion to the patient's body weight, such that each kilogram change results in a 3U change in placebo(rounded to the nearest 30U interval change from 200U, with a maximum of 300U).~45-55 kg: 140U 55-65 kg: 170U 65-75 kg: 200U 75-85 kg: 230U 85-95 kg: 260U 95-105 kg: 290U 105-115 kg: 300U"
89590543|NCT02050373|Experimental|Low-Level laser|In the laser group, an indium phosphide, galium and aluminum (InGaAIP) diode laser (660nm, 40mW, 0.16 J, 4 J/cm2) was used to irradiate oral mucosa. Subjects received the LLLT from the first day of the conditioning regimen and continued until D+7. Laser therapy was applied by a single dentist expertise in laser irradiation. The tip touched the mucosa of the lips, right and left buccal mucosa, right and left lateral tongue, ventral tongue and buccal floor, giving a total of 10 points per region.
89590544|NCT02050373|No Intervention|Control|In the control group, patients receive only the preventive protocol bone marrow transplant industry, consisting of mouthwashes and sodium fluoride. For ethical reasons, individuals who present oral mucositis grade 2 (WHO) will receive LLLT.
89590545|NCT02049437|Active Comparator|Arm A: TCZ, then placebo|ARM A: TCZ, 4 mg/Kg by IV infusion over 60 minutes (not to exceed 400 mg) once at study entry, followed by TCZ, 8 mg/Kg by IV infusion over 60 minutes (not to exceed 800 mg) at weeks 4 and 8, and THEN placebo by IV infusion at weeks 20, 24, and 28.
89590546|NCT02049437|Placebo Comparator|Arm B: Placebo, then TCZ|ARM B: Placebo by IV infusion at study entry followed by placebo by IV infusion at weeks 4 and 8, and THEN TCZ, 4 mg/Kg (not to exceed 400 mg) by IV infusion over 60 minutes once at week 20, followed by TCZ, 8 mg/Kg (not to exceed 800 mg) by IV infusion over 60 minutes at weeks 24 and 28.
88976921|NCT00176449|Placebo Comparator|Placebo|
88976922|NCT00176683||All comers|capnography used for all consenting subjects
88976923|NCT00176722||surgical|males & females undergoing spine surgery in the prone position
88976924|NCT00177229|No Intervention|A|Enhanced usual care: 2 free, individual consultations with a nutritionist over first 6 months. Medical monitoring throughout study period.
88976925|NCT00177229|Experimental|B|
89209909|NCT00640328|Experimental|Cohort 2.1|300mg ofatumumab then placebo
89590547|NCT02035553|Placebo Comparator|Placebo|Placebo, two tablets, once daily by mouth
89590548|NCT02035553|Experimental|Pimavanserin 40 mg|Pimavanserin tartrate, 40 mg (two 20 mg tablets), once daily by mouth (equivalent to 34 mg free base pimavanserin)
89590549|NCT04711733||Patients 6-14 years old|Individual interview + Self-report questionnaire + long-term follow-up medical consultation + At 1 year : Assessment of prescription's adherence
89590550|NCT04711733||Parents of 6-14 years old patients|Individual interview + Self-report questionnaire
89590551|NCT04711733||Patients 15-25 years old|Individual interview + Self-report questionnaire + long-term follow-up medical consultation + At 1 year : Assessment of prescription's adherence
89590552|NCT04711733||Parents of 15-25 years old patients|Individual interview + Self-report questionnaire
89590553|NCT04711733||Patients > 25 years old|Individual interview + Self-report questionnaire + long-term follow-up medical consultation + At 1 year : Assessment of prescription's adherence
89590554|NCT04711733||Parents of > 25 years old patients|Individual interview + Self-report questionnaire
89590555|NCT01445080|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-28. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
89590556|NCT02035475|Active Comparator|Intuitive Vessel Sealer|Investigators intend to use this device unilaterally so the contralateral side can serve as an internal control.
89590557|NCT02035475|Active Comparator|Maryland Bipolar Cautery|Investigators intend to use this device unilaterally so the contralateral side can serve as an internal control.
89590558|NCT04692779||Intubated ARDS patients undergoing prone positioning|All intubated ARDS patients undergoing prone positioning will be assessed with LUS before and after prone positioning and before and after placing back in the supine position.
89590559|NCT01444456||Cohort 1: Darbepoetin alfa|Participants receiving systemic chemotherapy for solid tumors who also received darbepoetin alfa (Aranesp®) to treat symptomatic anemia according to routine institutional practice.
89590560|NCT01444456||Cohort 2: Any ESA|Participants receiving systemic chemotherapy for solid tumors who also received darbepoetin alfa (Aranesp®) or another erythropoiesis-stimulating agent (ESA) to treat symptomatic anemia according to routine institutional practice.
89590561|NCT04181177||Informed group|This group will receive the Cosmetic product RV4429A balm and targeted educational action between V1 and V2 or between V2 and V3 according to the randomization
89590562|NCT04181177||Control group|"The control group, in the first period between V1 and V2, is a group not informed about his skin condition, not receiving any emollient product and not receiving targeted educational action. It's representative of the real life called best supportive care/Supportive care: the doctor prescribes what it seems to be the best for his patient according to his opinion in view of his condition, at a given moment.~A high variability exists within this group. In order to answer the investigator's hypothesis and demonstrate the effectiveness of the RV4429A balm, the parallel group design is chosen for the first follow-up period and then a second follow-up period is chosen for the initial control group to replace the inter-individual variability by intra-individual variability."
89590563|NCT04748536|Experimental|Group 1: Dose A IRL201104 or placebo|IRL201104 IV once daily for 5 days OR Placebo IV once daily for 5 days
89590564|NCT04748536|Experimental|Group 2: Dose B IRL201104 or placebo|IRL201104 IV once daily for 7 days OR Placebo IV once daily for 7 days
89590565|NCT01438294|Active Comparator|Aerobic exercise|The aerobic training will be done on the treadmill with heart monitors with intensity required to achieve 70% of maximum heart rate reached the maximum test for thirty minutes.
89590566|NCT01438294|Experimental|Video game|The training with video game will be done with heart rate monitors with intensity required to achieve 70% of maximum heart rate reached the maximum test for thirty minutes.Will be used Kinect games ( reflex ridge- Adventure).
89590567|NCT04709471|Experimental|Switch to low nicotine e-cigarettes|Switch to e-cigarettes containing 60% of baseline e-cigarette nicotine content.
89590568|NCT04709471|Experimental|Reduce number of e-cigarette pods|Reduce e-cigarette use to 60% of baseline number of pods per week.
89590569|NCT04709471|No Intervention|Use e-cigarettes as usual|Continue using usual nicotine e-cigarettes as usual.
89590570|NCT04690985|Sham Comparator|Control group|The control group will be asked to continue their own daily routes. One research assistant, who will not be involved in other procedures of the study, will contact with the participants to talk about different issues except the SO related topic. The frequency of face-to-face meetings and telephone calls will be similar to the experimental group. The issues talked in the control group could be as follows but not limited: a) normal social communication topics such as greetings, recent living conditions, news in the past week; b) health consultations asked by the participants; c) avoid to mention dietary or exercise related information. An appointment of post-test will be made in the last time telephone call.
89590571|NCT04690985|Experimental|Experimental group|The experimental group will be required to adhere to a diet consisting of a 12% reduction in calorie and a 1.2-1.5 g/kg body weight/day intake of protein. The participants will receive 6 times face-to-face meetings (on week 1, 2, 3, 4, 8 and 12) and weekly telephone call. Each face-to-face meetings will last for around 1 hour, during which the reseacher will help to establish the participants' intention for dietary behavior change, then help transform the intention into detailed plan, and help monitor the execution of the plan continuously.
89590572|NCT02033759|Active Comparator|Traditional circumferential measurements|Traditional screening with volumetric analysis Patient Anxiety Questionnaire
89590573|NCT02033759|Experimental|Bio-Impedance Testing|Traditional Screening with Volumetric Analysis and Bio-Impedance Analysis Patient Anxiety Questionnaire
89030809|NCT00523770||Group A|Non-pneumococcal infected healthy elderly volunteers
89030810|NCT05148182||low risk|According to the China PAR equations and Chinese guidelines and consensus on cardiovascular risk assessment and management, it is considered as low-risk population.
89030811|NCT05148182||medium risk|According to the China PAR equations and Chinese guidelines and consensus on cardiovascular risk assessment and management, it is considered as medium-risk population.
89030812|NCT05148182||high risk|According to the China PAR equations and Chinese guidelines and consensus on cardiovascular risk assessment and management, it is considered as high-risk population.
89590574|NCT01959529|Experimental|Insulin degludec (IDeg)|All subjects will continue their current antidiabetic therapy except for the basal insulin component (if any) that will be replaced by the investigational product.
89590575|NCT01959529|Active Comparator|Insulin glargine (IGlar)|All subjects will continue their current antidiabetic therapy except for the basal insulin component (if any) that will be replaced by the investigational product.
89590576|NCT02033369|Experimental|Pramipexole|Six weeks of treatment with oral pramipexole, initiated at 0.25 mg/day and titrated to a maximum daily dose of 2.5 mg.
89590577|NCT02033369|No Intervention|Healthy Control|Healthy volunteers were matched to MDD group subjects by age, gender, and ethnicity, and will have no lifetime psychiatric disorders.
89590578|NCT02032901|Experimental|A1:Daclatasvir + Sofosbuvir in treatment-naive subjects|Daclatasvir 60 mg tablet and Sofosbuvir 400 mg tablet orally once daily for 12 weeks
89590579|NCT02032901|Experimental|A2:Daclatasvir + Sofosbuvir in treatment-experienced subjects|Daclatasvir 60 mg tablet and Sofosbuvir 400 mg tablet orally once daily for 12 weeks
89590580|NCT04681469|Experimental|Single Arm Treatment|"For all patient's population:~Niraparib 200 mg/day: day -49 to day -21;~Dostarlimab 500 mg iv: day -49 and day -28; At day -21, clinical evaluation will be performed and the patient will be directed to surgery with exclusion from the study in case of progressive disease. Radiological assessment will be performed according to the physician's judgement.~If no clinical evidence of disease progression:~Niraparib 200 mg/day: day -21 to day -7~Dostarlimab 500 mg iv: day -7~Radiological assessment (day -1, ± 3 days),~Surgery (original margin) at day 0 (±3 days)~Standard postoperative (chemo)radiotherapy according to pathologic report;~Maintenance Niraparib, 200 mg/day for 6 months~Maintenance Dostarlimab, 500 mg iv q3W for the first four cycles and 1000 mg iv Q6W thereafter for 3 months."
89590581|NCT04416971||mature AVF|Patients initiate HD with mature AVF.
89590582|NCT04416971||immature AVF|Patients initiate HD with immature AVF.
89590583|NCT04690127|Experimental|Plyometric Training Group|Individuals in the plyometric training group will receive plyometric training. In this training, individuals will not participate in a real plyometric training. Volunteers will watch videos to be prepared (action observation) and imagine them performing those exercises (motor imagery). Except for one session that will be applied every two weeks, all other trainings will be given on the basis of telerehabilitation via distance education tools.
89590584|NCT04690127|No Intervention|Control Group|Volunteers in this group will not participate in any training.
89590585|NCT04689659|Experimental|chimeric antigen receptor T cell treatment|
89590586|NCT02020967||Acromegaly patients|
89590587|NCT01986829|Experimental|Treatment (ablation)|"Patients undergo cryoablation, radiofrequency ablation, or microwave ablation of each lesion.~Patients complete pain survey (BPI-Short form) and quality of life questionnaires (FACT-G7)"
89590588|NCT01986751|Experimental|Clonidine and Ropivacaine|A bolus of 20 mL of 0.5% ropivacaine mixed with clonidine 1mcg/kg will be injected through the stimulating needle with gentle aspiration between divided doses (5 mL per dose).
89590589|NCT01986751|Active Comparator|Ropivacaine|Standard saphenous nerve block (adductor canal approach) will be performed using 15ml of 0.5% ropivacaine
89590590|NCT02004847|Experimental|High Intensity (HI) vs control|PSO-CT02 device: Light wavelength 453nm, high intensity, compared to contralateral untreated control plaque on the same patient.
89590591|NCT02004847|Experimental|Low Intensity (LI) vs control|PSO-CT02 device: Light wavelength 453nm, low intensity, compared to contralateral untreated control plaque on the same patient.
89590592|NCT01438060|Experimental|Aripiprazole (BMS-337039)|Double blind Acute Phase (Week 1 to Week 10), Open label Extension Phase (Week 11 to Week 140)
89590593|NCT01438060|Placebo Comparator|Placebo|Double blind Acute Phase (Week 1 to Week 10)
89590594|NCT01469182|Experimental|SCH 39641 12 Amb a 1-U|12 Units short ragweed (Ambrosia artemisiifolia) Major Allergen 1 (Amb a 1-U) extract in an AIT, sublingual, once daily.
89590595|NCT01469182|Placebo Comparator|Placebo|Matching placebo tablet, sublingual, once daily.
89590596|NCT01444378|Experimental|Absolute Pro® and Pro LL® Peripheral Stent Systems|
89590597|NCT02020889|Experimental|Mepolizumab 300 mg|Each subject will receive mepolizumab 300 mg subcutaneous (SC) injection every 4 weeks (13 administrations) along with standard care. It will be administered as 3 separate injections (100 mg each- total dose 300 mg); individual injection sites will be separated by at least 5 cm. It will be administered into any of the upper arm, thigh or anterior abdominal wall.
89590598|NCT02020889|Placebo Comparator|Placebo|Each subject will receive placebo (0.9% sodium chloride) SC injection every 4 weeks (13 administrations) along with standard care. It will be administered as 3 separate injections; individual injection sites will be separated by at least 5 cm. It will be administered into any of the upper arm, thigh or anterior abdominal wall.
89590599|NCT01444300|Experimental|Dalfampridine|
89590600|NCT01444300|Placebo Comparator|Placebo|
89590601|NCT04681001|Experimental|Coldamaris pro|One puff per nostril three puffs into mouth
89590602|NCT04681001|Placebo Comparator|Coldamaris sine|One puff per nostril three puffs into mouth
89590603|NCT01443364|Experimental|Certolizumab pegol|
89590604|NCT02020577|Experimental|combination arm|Patients to receive afatinib once daily plus weekly cetuximab infusion
89590605|NCT02020031|Experimental|Vancomycin 500mg intraosseous|Vancomycin 500mg is given via intraosseous regional administration (IORA) into a proximal tibial cannula, after tourniquet inflation and immediately prior to skin incision.
89590606|NCT02020031|Active Comparator|Vancomycin 1g IV|Vancomycin 1g is administered via forearm vein, given over a one-hour infusion, timed to finish approximately 30 minutes prior to tourniquet inflation.
89590607|NCT04179305|Experimental|Oncolo-GIST Arm - Patients|"Patients assigned to this arm will discuss scan results revealing progressive disease with an Oncolo-GIST trained physician.~Oncolo-GIST: Behavioral: Oncolo-GIST Oncolo-GIST is a brief, manualized communication intervention that guides oncologists in gist communication by itemizing 4 key steps in the process of imparting prognostic information.~Topics covered include:~Principles of introducing prognosis in the setting of worsened scan results Coupling communicating realistic prognoses with psychological support (e.g., saying average life-expectancy is months… with emphasizing that the oncology team will always provide care for you) Addressing informational needs and psychological reactions Applying proven techniques for supporting patients who are reluctant to discuss prognosis."
89590608|NCT04179305|Placebo Comparator|Usual Care Arm - Patients|"Patients assigned to this arm will will discuss scan results revealing progressive disease with a physician that was not trained with the Oncolo-GIST intervention.~Usual Care Arm: Oncologists will provide care in non-specific manner."
89590609|NCT04179305|Experimental|Oncolo-GIST Arm - Physicians|Physicians assigned to this arm will receive the Oncolo-GIST training intervention.
89590610|NCT04179305|Placebo Comparator|Usual Care Arm - Physicians|Physicians assigned to this arm will not receive the Oncolo-GIST training intervention.
89590611|NCT02019719|Experimental|GSK1278863 4 milligrams (mg)|Subjects will receive GSK1278863 4 mg once daily for 4 weeks
89590612|NCT02019719|Experimental|GSK1278863 6 mg|Subjects will receive GSK1278863 6 mg once daily for 4 weeks
89590613|NCT02019719|Experimental|GSK1278863 8 mg|Subjects will receive GSK1278863 8 mg once daily for 4 weeks
89590614|NCT02019719|Experimental|GSK1278863 10 mg|Subjects will receive GSK1278863 10 mg once daily for 4 weeks
89590615|NCT02019719|Placebo Comparator|Placebo|Subjects will receive placebo once daily for 4 weeks
89590616|NCT02030405|Experimental|Ixazomib (MLN9708)|Participants receive ixazomib PO (orally) on days 1, 4, 8, and 11. Treatment repeats every 21 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
89590617|NCT01975376|Experimental|bococizumab (PF-04950615)|150 mg, every 2 weeks, subcutaneous
89590618|NCT01975376|Placebo Comparator|Placebo|Placebo comparator, every 2 weeks, subcutaneous.
89590619|NCT01443130|Experimental|Chloroquine IPT|300 subjects to receive a therapeutic dose of chloroquine (1,500 mg given over 3 days, 2 tablets on Day 0, 2 tablets on Day 1, 1 tablet on Day 2) will be administered twice during pregnancy at 20-28 weeks and at 28-34 weeks.
89590620|NCT01443130|Experimental|Chloroquine Prophylaxis|300 subjects to receive a loading dose of chloroquine (base) 600 mg (2 tablets) at first administration followed by 300 mg of chloroquine base (1 tablet) every week.
89590621|NCT01443130|Active Comparator|SP IPT|300 subjects to receive a therapeutic dose of sulfadoxine-pyrimethamine (SP), (1500 mg sulfadoxine and 75 mg pyrimethamine (3 tablets)) administered twice during pregnancy at 20-28 weeks and at 28-34 weeks.
89590622|NCT03026686||readmit|women who were re-admitted in the post partum period for a hypertensive disorder
89590623|NCT03026686||Controls|women with similar risk factors but did not require readmission
89590624|NCT04065256|Experimental|Personalized music intervention group|Participants will receive a personalized music session for forty minutes twice a day for consecutive seven days or until discharge from ICU. A total treatment dosage of 560 minutes is required.
89590625|NCT04065256|Experimental|Personalized music plus earplug group|Participants will receive a personalized music session for forty minutes twice a day for consecutive seven days or until discharge from ICU. In addition, using earplug during night time sleep. The music intervention total treatment dosage of 560 minutes is required.
89590626|NCT04065256|No Intervention|Control group|The control group involves neither music intervention nor using earplug at night.
89590627|NCT01436500|Experimental|5 mg ifetroban, Type 1|60-minute intravenous infusion of 5 mg ifetroban given once daily for 3 days to subjects with Type 1 HRS.
89590628|NCT01436500|Placebo Comparator|Placebo, Type 1|60-minute intravenous infusion of 5% dextrose in sterile water given once daily for 3 days to subjects with Type 1 HRS.
89590629|NCT01436500|Experimental|5 mg ifetroban, Type 2|60-minute intravenous infusion of 5 mg ifetroban given once daily for 3 days to subjects with Type 1 HRS.
89590630|NCT01436500|Experimental|15 mg ifetroban, Type 1|60-minute intravenous infusion of 15 mg ifetroban given once daily for 3 days to subjects with Type 1 HRS.
89590631|NCT01436500|Experimental|15 mg ifetroban, Type 2|60-minute intravenous infusion of 15 mg ifetroban given once daily for 3 days to subjects with Type 2 HRS.
89590632|NCT01436500|Experimental|50 mg ifetroban, Type 1|60-minute intravenous infusion of 50 mg ifetroban given once daily for 3 days to subjects with Type 1 HRS.
89590633|NCT01436500|Experimental|50 mg ifetroban, Type 2|60-minute intravenous infusion of 50 mg ifetroban given once daily for 3 days to subjects with Type 2 HRS.
89590634|NCT01436500|Experimental|150 mg ifetroban, Type 2|60-minute intravenous infusion of 150 mg ifetroban given once daily for 3 days to subjects with Type 2 HRS.
89030813|NCT00522405|Active Comparator|1|Transarterial Chemoembolisation
89030814|NCT00522405|Active Comparator|2|TACE Plus oral chemotherapy
89030815|NCT00522444|Experimental|nebulized magnesium sulfate|6.3% solution of magnesium heptahydrate, which is equivalent to 3.18% anhydrous magnesium sulfate
89030816|NCT00522444|Placebo Comparator|normal saline nebulization|standard of care
89030817|NCT05148143|Experimental|RALOX|Raltitrexed combined with oxaplatin
89209910|NCT00640328|Experimental|Cohort 2.2|placebo then 300mg ofatumumab
89590635|NCT01436500|Placebo Comparator|Placebo, Type 2|60-minute intravenous infusion of 5% dextrose in sterile water given once daily for 3 days to subjects with Type 2 HRS.
89590636|NCT01958827|Experimental|Adalimumab 80 mg|All participants were to receive subcutaneous injections of open-label adalimumab 80 mg every other week from Week 0 to Week 50.
89590637|NCT01620086|Experimental|Patients|Patients with Schizophrenia who meet entry criteria for the study and first receive active repetitive transcranial magnetic stimulation for four days over a control site located at the vertex and then are randomized to receive repetitive Transcranial Magnetic Stimulation for four days over the temporal cortex at both 1 Hz and 10 Hz.
89590638|NCT01620086|Experimental|Controls|These subjects are normal controls without schizophrenia who receive sham, repetitive transcranial magnetic stimulation at 1 Hz for two days and then receive active, repetitive Transcranial Magnetic stimulation for two days. All stimulation is delivered at the control site located over the vertex.
89590639|NCT04670653|Experimental|MAGNÓLIA|Two applications in each nostril, once a day.
89590640|NCT04670653|Active Comparator|MOMETASONE FUROATE|Two applications in each nostril, once a day.
89590641|NCT01436110|Experimental|Fluticasone furoate 50 mcg|Once daily inhalation powder via Novel Dry Powder Inhaler
89590642|NCT01436110|Active Comparator|Fluticasone propionate 100mcg|Twice daily inhalation powder via DISKUS/ ACCUHALER
89590643|NCT01436110|Placebo Comparator|Placebo|Inhalation Powder via Novel Dry Powder Inhaler and DISKUS/ ACCUHALER
89590644|NCT01619852|Active Comparator|Group L|Group L will receive a 1.5 mg/kg bolus of intravenous lidocaine followed by a 2mg/kg/hr infusion that will be started at the time of surgical induction and will be discontinued one hour after the end of the surgical procedure.
89590645|NCT01619852|Placebo Comparator|.9% normal saline placebo|.9% normal saline administered as a bolus then as a maintenance infusion for the length of the surgical case.
89590646|NCT04069936|Experimental|MILs™ - NSCLC plus nivolumab with or without tadalafil|Locally advanced and unresectable and metastatic NSCLC subjects previously treated with anti-programmed cell death-1 (PD-1) will be treated with MILs™ - NSCLC plus nivolumab with or without tadalafil.
89590647|NCT02000882|Experimental|BKM120 plus Capecitabine|"BKM120 will be administered at a dose of 100 mg orally (PO) daily. Capecitabine will be administered at a dose of 1000 mg/m2 orally (PO) twice a day (rounded down to the nearest 500 mg pill) 14 days on and 7 days off.~For patients with HER2+ MBC only, standard every 3-weekly trastuzumab (6 mg/kg IV) will be added to the capecitabine/BKM120."
89590648|NCT01965938|Active Comparator|RIFL (Rigid and Flexing Laryngoscope)|Patients in the RIFL group will undergo bronchoscopy using the Rigid and Flexing Laryngoscope. Once the carina is visualized with the bronchoscope, the endotracheal tube will be advanced, and the bronchoscope removed.
89590649|NCT01965938|Other|Fiberoptic Bronchoscope|Patients in the control group will undergo bronchoscopy using the flexible fiberoptic bronchoscope. Once the carina is visualized with the bronchoscope, the endotracheal tube will be advanced, and the bronchoscope removed.
89590650|NCT01965860|Experimental|PROSPECT|the trainee will study four modules of E-learning (basic endovascular skills module, iliac artery module, superficial femoral artery module and postoperative care module). After studying each module the trainee will complete a Multiple Choice Questionnaire and perform a simple and a complex exercise on the simulator.
89590651|NCT01965860|No Intervention|CONTROL|The trainee will continue clinical education without additional curriculum, but will be allowed to study independently.
89590652|NCT01965860|Experimental|E-LEARNING|the trainee will study four modules of E-learning (basic endovascular skills module, iliac artery module, superficial femoral artery module and postoperative care module). After studying each module the trainee will complete a Multiple Choice Questionnaire, no simulation.
89590653|NCT04415827|Experimental|Athletes with community-acquired pneumonia|man and women, athletes, age 17-25, patients with community-acquired pneumonia
89590654|NCT04415827|Experimental|Untrained people with community-acquired pneumonia|man and women, untrained people, age 17-25, patients with community-acquired pneumonia
89590655|NCT04415827|Experimental|Athletes with bronchitis|man and women, athletes, age 17-25, patients with bronchitis
89590656|NCT04415827|Experimental|Untrained people with bronchitis|man and women, untrained people, age 17-25, patients with bronchitis
89590657|NCT04415827|Experimental|Athletes with chronic obstructive pulmonary disease|man and women, athletes, age 17-25, patients with with chronic obstructive pulmonary disease
89590658|NCT04415827|Experimental|Untrained people with chronic obstructive pulmonary disease|man and women, untrained people, age 17-25, patients with with chronic obstructive pulmonary disease
89590659|NCT04415827|Experimental|Athletes with acute respiratory infections|man and women, athletes, age 17-25, patients with acute respiratory infections
89590660|NCT04415827|Experimental|Untrained people with acute respiratory infections|man and women, untrained people, age 17-25, patients with acute respiratory infections
89590661|NCT04666129|Experimental|Part 1: Relugolix plus Abiraterone plus a Corticosteroid|Participants will receive relugolix in combination with abiraterone plus a corticosteroid for 12 weeks during the study treatment period.
89590662|NCT04666129|Experimental|Part 2: Relugolix plus Apalutamide|Participants will receive relugolix in combination with apalutamide for 12 weeks during the study treatment period.
89590663|NCT04666129|Experimental|Part 3: Relugolix plus Docetaxel with or without Prednisone|Participants will receive relugolix in combination with docetaxel with or without prednisone for 12 weeks during the study treatment period.
89590664|NCT04666051|Experimental|Fibrin glue|A fibrin glue was applied to the lymphadenectomy bed before wound closure and insertion of a drain.
89590665|NCT04666051|No Intervention|Control|Lymphadenctomy wound was closed after insertion of a drain,
89590666|NCT01965704|Experimental|Ondansetron|Pregnant Women: ondansetron 8mg intravenously (IV) within 4 hours of delivery. Neonates: ondansetron 0.07 mg/kg given orally every 24 hours starting 4-8 hours after delivery, for up to 5 days (if IV line available in neonate, ondansetron 0.04 mg/kg IV every 24 hours for up to 5 days).
89590667|NCT01965704|Placebo Comparator|Placebo|"Pregnant Women: placebo given intravenously prior to delivery (volume to mimic the IV volume of the ondansetron group).~Neonates: placebo given orally every 24 hours, starting 4-8 hours after delivery, for up to 5 days with volume to mimic the oral volume of the ondansetron group (if IV line available, placebo may be given IV)."
89590668|NCT02003365|Experimental|FX006 10 mg|Single 3 mL intra-articular (IA) injection
89590669|NCT02003365|Experimental|FX006 40 mg|Single 3 mL intra-articular (IA) injection
89590670|NCT02003365|Active Comparator|TCA IR 40 mg|Single 1 mL intra-articular (IA) injection
89590671|NCT01975220|Experimental|High dose, fasted|1 fixed dose combination (FDC) tablet vs. 3 single tablets under fasted conditions
89590672|NCT01975220|Experimental|High dose, fed|1 fixed dose combination (FDC) tablet vs. 3 single tablets under fed conditions
89590673|NCT01975220|Experimental|Low dose, fasted|2 fixed low dose combination (FDC) tablets vs. 4 single tablets under fed conditions
89590674|NCT04665583||Prehabilitation|All study patients will receive preoperative optimization with a standardized prehabilitation protocol prior to any intervention.
89590675|NCT01958437|Experimental|Cognitively intact older adults - ACTIVE tDCS|Group receives active brain stimulation
89590676|NCT01958437|Active Comparator|MCI ACTIVE tDCS|Group receives active brain stimulation
89590677|NCT01958437|Sham Comparator|Cognitively intact older adults - SHAM tDCS|Group receives sham brain stimulation
89590678|NCT01958437|Sham Comparator|MCI SHAM tDCS|Group receives sham brain stimulation
89590679|NCT01974752|Experimental|selumetinib 75mg twice daily|selumetinib 75mg twice daily in combination with dacarbazine.
88976926|NCT00408148|Placebo Comparator|2|Administration of one rimonabant placebo tablet once daily in the morning
89590680|NCT01974752|Placebo Comparator|placebo twice daily|placebo twice daily in combination with dacarbazine.
89590681|NCT01999946|Experimental|Extended-Release Naltrexone (XR-NTX)|Extended-Release Naltrexone (Vivitrol®), 380mg administered 1x/month by intramuscular injection.
89590682|NCT01999946|No Intervention|Enhanced Treatment As Usual (ETAU)|Enhanced Treatment As Usual arm will not receive any study medication, but will receive enhancement counseling centered on post-release treatment involvement and a patient-drug educational handout with direct referrals to re-entry community treatment, including agonist maintenance (methadone and buprenorphine programs), drug-free outpatient and 12-step resources, and residential treatment including supportive housing programs will be provided. These counseling and referral efforts are designed to exceed standard, out-of-treatment experiences, and will ensure both arms are offered tangible health benefits above and beyond that of the usual jail incarceration period in accordance with DHS prisoner research standards.
89590683|NCT01999946|No Intervention|Methadone Treatment Program (MTP)|Quasi-Experimental cohort, will be participants recruited from NYC Rikers Island jail's Key Extended Entry Program (KEEP)'s jail methadone maintenance program, they will not receive any intervention from study, but will receive enhancement counseling centered on post-release treatment involvement and a patient-drug educational handout with direct referrals to re-entry community treatment.These counseling and referral efforts are designed to exceed standard, out-of-treatment experiences, and will ensure both arms are offered tangible health benefits above and beyond that of the usual jail incarceration period in accordance with DHS prisoner research standards. MTP participants are new KEEP methadone participants not enrolled in community methadone at the time of arrest.
89590684|NCT01958281|Experimental|SOF 200 mg + RBV 200 mg (Cohort 1)|Participants with genotype 1 or 3 HCV infection will receive SOF 200 mg (2 × 100 mg tablets) plus RBV once daily for 24 weeks.
89590685|NCT01958281|Experimental|SOF 400 mg + RBV 200 mg (Cohort 2)|Participants with genotype 1 or 3 HCV infection will receive SOF 400 mg (4 × 100 mg tablets or 1 × 400 mg tablet) plus RBV once daily for 24 weeks.
89590686|NCT01958281|Experimental|LDV/SOF (Cohort 3)|Participants with genotype 1 or 4 HCV infection will receive LDV/SOF once daily for 12 weeks.
89590687|NCT04665115|Experimental|Cohort I (ibrutinib)|Patients may continue to receive ibrutinib PO daily or stop ibrutinib per provider's discretion.
89590688|NCT04665115|Experimental|Cohort II Arm 2A (ibrutinib)|Patients continue to receive ibrutinib PO daily in the absence of disease progression or unacceptable toxicity.
89590689|NCT04665115|Experimental|Cohort II Arm 2B (temporary interruption)|Patients undergo temporary interruption of ibrutinib for up to 28 days unless they are discharged home and are thought to be medically fit by the primary caregiver to resume therapy according to their primary treating oncologist.
89590690|NCT01958125|Active Comparator|gammacore|gammacore active device to be used noninvasively to the vagal nerve in the neck.
89590691|NCT01958125|Placebo Comparator|inactive gammacore|same as the active treatment, but without the therapy treatment provided
89590692|NCT02002975||Pioglitazone 15 to 30 mg|administered orally once daily before or after breakfast for 3 years.
88976927|NCT00408148|Experimental|1|Administration of one tablet containing 20 mg of active rimonabant once daily in the morning
88976928|NCT00177346|Experimental|CAS with cerebral protection|
89590693|NCT02001181|Experimental|Treatment group A|
89590694|NCT02001181|Placebo Comparator|Treatment B|
89590695|NCT04644679|Active Comparator|48-hr|48-hr electrocardiographic monitoring
89590696|NCT04644679|Experimental|7-day|7-day electrocardiographic monitoring
89590697|NCT04176055|Experimental|HALO|
88976929|NCT00177346|Active Comparator|CAS without cerebral protection|
88976930|NCT00177424|Active Comparator|1|Sertraline
88976931|NCT00177424|Placebo Comparator|2|matching placebo
88976932|NCT00397605|Experimental|Crossover|
88976933|NCT00177463|Experimental|L- Carnosine|an antioxidant and AGE inhibitor, 500 mg/day, increasing each week in titration reaching 2000 mg/day in 4 weeks and maintained for rest of trial
88976934|NCT00177463|Placebo Comparator|Placebo|Placebo
88976935|NCT00423644|Experimental|Single Arm|
88976936|NCT00177541|Experimental|Biofeedback|Biofeedback assisted pelvic floor muscle therapy (3 visits)
88976937|NCT04723342|Experimental|Blinatumomab|Consolidation therapy with Blinatumomab administration
88976938|NCT04161183|Placebo Comparator|Placebo|Placebo treatment (shock wave probe w/o energy)
88976939|NCT04161183|Experimental|Extracoporeal shock wave therapy|Extracoporeal shock wave therapy (shock wave probe w/ energy)
88976940|NCT00177853|Experimental|1|Celecoxib, Irinotecan and Concurrent Radiotherapy
88976941|NCT00177892|Experimental|1|non-OSAH/overweight individuals with the Metabolic Syndrome
88976942|NCT00177892|Experimental|2|non-OSAH/overweight individuals without Metabolic Syndrome
88976943|NCT00177892|Active Comparator|3|non-OSAH/normal weight without Metabolic Syndrome
88976944|NCT00177892|Experimental|4|OSAH patients with chronic positive airway pressure therapy
88976945|NCT00177892|Experimental|5|OSAH patients without chronic positive airway pressure therapy
88976946|NCT00177931||liver transplant patients in ICU|
89209911|NCT00640328|Experimental|Cohort 3.1|700mg ofatumumab then placebo
89209912|NCT00640328|Experimental|Cohort 3.2|placebo then 700mg ofatumumab
89209913|NCT00163189|Experimental|Somatropin|
88976947|NCT00056966|Experimental|1|recipients of HLA matched sibling transplants
88976948|NCT00056966|Experimental|2|recipients of unrelated or mismatched family donor transplants
89030818|NCT02276534|Experimental|Theatre|The participants will receive 10 sessions of peer-mediated, theatre-based intervention.
89590698|NCT01999465|Active Comparator|Standard NMES cohort|Patients who will apply standard NMES device.
89590699|NCT01999465|Sham Comparator|Sham NMES cohort|Patients who will apply sham NMES device.
89590700|NCT01982773|Experimental|Virtual Hope Box Smartphone App|Use of the smartphone app, Virtual Hope Box on their personal smartphone
89590701|NCT01982773|Active Comparator|EnhancedTreatment As Usual|Subjects will be issued printed materials guiding them in coping with suicidal thoughts, which include information about coping strategies and emergency contact information.
89030819|NCT02276534|Experimental|No Intervention then Theatre|The participants will not receive the treatment for a period of time.
89030820|NCT00522561|Other|1|healthy volunteers
89590702|NCT01974206|Experimental|ASP0113|Participants received 1 mL of 5 mg/mL of ASP0113 via injection in the deltoid muscle alternating sides with each dose on days 30, 60, 90, 120 and 180 in relation to the day of transplant (Day 0).
89590703|NCT01974206|Placebo Comparator|Placebo|Participants received 1 mL of 5 mg/mL of placebo via injection in the deltoid muscle alternating sides with each dose on days 30, 60, 90, 120 and 180 in relation to the day of transplant (Day 0).
89590704|NCT04416464||Pneumonia due to SARS-CoV-2 infection|Adult hospitalized patients with pneumonia due to proven or suspected SARS-Cov-2 infection.
89590705|NCT04659278|Placebo Comparator|Group 1 Placebo|Placebo Isolate Placebo (Hemp seed oil and peppermint flavoring)
89590706|NCT04659278|Active Comparator|Group 2 Isolate Comparator|Isolate Placebo Isolate (CBD no terpenes Hemp seed oil [slightly lower concentration of CBD ratio])
89590707|NCT04659278|Placebo Comparator|Group 3 Placebo Comparator|Placebo OMD Endourage OMD (Full flower extract with a 1:1 ratio of cannabis terpenes, Hemp seed oil and peppermint flavoring)
89590708|NCT04659278|Experimental|Group 4 Experimental Placebo|OMD Placebo Endourage OMD (Full flower extract with a 1:1 ratio of cannabis terpenes, Hemp seed oil and peppermint flavoring)
89590709|NCT01999868|Experimental|UST, ABA/UST Placebo|Participants received 2 subcutaneous injections of open-label ustekinumab (UST) (45 mg for participants weighing <=100 kg at study entry or 90 mg for those weighing >100 kg at study entry), at Weeks 0 and 4 during the lead-in phase and were then randomized to receive blinded (masked) treatment of abatacept (ABA) (125 mg) subcutaneous injections weekly from Week 12 to 39, in addition to ustekinumab placebo subcutaneous injections at Weeks 16 and 28.
89030821|NCT05145218|Experimental|TQB2450 injection + Anlotinib Hydrochloride capsules|"TQB2450 injection: once every 21 days, 1200mg each time, intravenous infusion. The longest administration time should not exceed 24 months.~Anlotinib Hydrochloride capsules: once a day, 12mg each time, oral administration on an empty stomach before breakfast for 2 weeks, withdrawal for 1 week, i.e. 3 weeks (21 days) as a course of treatment."
89030822|NCT05145218|Active Comparator|Paclitaxel injection|80mg/m2, intravenous drip, once a week (D1, D8, D15 of 21 days), 21 days as a course of treatment.
89590710|NCT01999868|Active Comparator|UST, UST/ABA Placebo|Participants received 2 subcutaneous injections of open-label ustekinumab (UST) (45 mg for participants weighing <=100 kg at study entry or 90 mg for those weighing >100 kg at study entry), at Weeks 0 and 4 during the lead-in phase and were then randomized to receive blinded (masked) treatment of ustekinumab (45 mg if <=100 kg or 90 mg if >100 kg at study entry) subcutaneous injections at Weeks 16 and 28, in addition to abatacept (ABA) placebo subcutaneous injections weekly from Week 12 to 39.
89590711|NCT01957579|Experimental|MEDI-551|
89590712|NCT03511963|Experimental|HLX04|
89590713|NCT03511963|Active Comparator|Bevacizumab|
89590714|NCT01999322|Experimental|FIAsp|The trial duration is approximately 13 weeks and consists of a 1-week screening period, a 2-week run-in period, a 6-week treatment period and 1 week plus a 30-day follow-up period
89590715|NCT01999322|Active Comparator|Insulin Aspart|The trial duration is approximately 13 weeks and consists of a 1-week screening period, a 2-week run-in period, a 6-week treatment period and 1 week plus a 30-day follow-up period
89590716|NCT01996982|Experimental|Device|CCS Device application
89590717|NCT01965158|Experimental|Naldemedine|Participants received 0.2 mg naldemedine orally once daily for 12 weeks.
89590718|NCT01965158|Placebo Comparator|Placebo|Participants received matching placebo orally once daily for 12 weeks.
89590719|NCT01964924|Experimental|Treatment (trametinib, Akt inhibitor GSK2141795)|"PART 1: Patients receive trametinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who experience disease progression continue to Part 2.~PART 2: Patients receive trametinib as in Part 1 and also receive Akt inhibitor GSK2141795 PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
89590720|NCT01964378|Experimental|Cebranopadol|Once daily oral administration. 200, 400 or 600 µg film coated tablets. Dosage 200 µg to 1000 µg per day.
89590721|NCT01964378|Active Comparator|Morphine Prolonged Release|Twice daily oral administration. 15, 30 or 45 mg morphine sulfate capsules. Dosage 30 to 150 mg per day.
89590722|NCT01442038|Experimental|Ranolazine|
89030823|NCT00522678|Experimental|Cohort A|In Cohort A, subjects will be randomized (3:1) to receive once daily doses of GW685698X 400 microgram (mcg) containing magnesium stearate or placebo via DISKUS, for 14 days.
89030824|NCT00522678|Experimental|Cohort B|In Cohort B, subjects will be randomized (3:1) to receive once daily doses of GW685698X (600 mcg) containing magnesium stearate or placebo via DISKUS, for 14 days.
89030825|NCT00522678|Experimental|Cohort C|InIn Cohort C, subjects will be randomized (3:1) to receive once daily doses of GW685698X (800 mcg) containing magnesium stearate or placebo via DISKUS, for 14 days.
89030826|NCT05140850||PRES group|PE or E with PRES
89590723|NCT01442038|Placebo Comparator|Placebo|
89030827|NCT05140850||non-PRES group|PE or E without PRES
89030828|NCT00522717|Experimental|1|
89030829|NCT00522717|Active Comparator|2|
89030830|NCT05142098|Active Comparator|Dexamethasone|Dexamethasone 4mg will be injected intramuscularly into the pterygomandibular space after achieving effective inferior dental block.
89030831|NCT05142098|Experimental|Etoricoxib|2 tablets 60mg each would be given orally one hour prior to the surgery.
89030832|NCT00523965|Experimental|A|AmBisome 5 mg/kg iv infusion over 2 h x 1 day (single dose) + oral miltefosine 50mg once daily (< 25 kg body weight) or twice daily ( > 25 kg body weight) or 2.5 mg/kg for children under 12 years, for 7 days on day 2-8
89030833|NCT00523965|Experimental|B|AmBisome 5mg/kg iv infusion over 2 h x 1 day (single dose) + paromomycin sulfate 15 mg/kg/day i.m for 10 days, on day 2-11
89030834|NCT00523965|Experimental|C|oral miltefosine 50mg once daily (< 25 kg body weight) or twice daily ( > 25 kg body weight) or 2.5 mg/kg for children under 12 years, for 10 days + Paromomycin sulfate 15 mg/kg/day im. for 10 days
89590724|NCT01998919|Experimental|Tarceva + gemcitabine/platinum|
89590725|NCT01998919|Placebo Comparator|Placebo + gemcitabine/platinum|
89590726|NCT01957111||Individuals with insomnia|
89590727|NCT01957111||Good sleepers|
89590728|NCT01964300|Experimental|Treatment (peginterferon alfa-2b)|Patients receive peginterferon alfa-2b subcutaneously (SC) weekly for 6 weeks. Treatment may repeat every 6 weeks for up to 18 courses in the absence of disease progression or unacceptable toxicity.
89590729|NCT01964222|Experimental|Decision Aid (DA)|The decision aid (DA) will be provided to patients randomized to the experimental/intervention group.
89590730|NCT01964222|No Intervention|Control|Participants randomized to the control group will receive usual care and will be shown Siteman Cancer Center website about clinical trials.
89590731|NCT04416230|Experimental|Massage|Infants randomized to the massage intervention received a 30 minute massage daily for the 7 day study.
89590732|NCT04416230|Active Comparator|Quiet Time|Infants randomized to the Quiet Time intervention experienced a 30 minute time during which non-essential clinical caregiving tasks were restricted.
89590733|NCT04416074|Experimental|Group psychotherapy group|Students will be intervened by an online 5-week professional identity group psychotherapy.
89590734|NCT04416074|Other|Controlled message push group|Students will receive online messages of self-care knowledge forward by researchers.
89590735|NCT01467700|Experimental|Ramelteon SL 0.1 mg|Ramelteon SL 0.1 mg, tablets, sublingual (SL) [dissolved under the tongue], once daily (QD), every night at bedtime for up to 8 weeks.
89590736|NCT01467700|Experimental|Ramelteon SL 0.4 mg|Ramelteon SL 0.4 mg, tablets, sublingual, once daily, every night at bedtime for up to 8 weeks.
89590737|NCT01467700|Experimental|Ramelteon SL 0.8 mg|Ramelteon SL 0.8 mg tablets, sublingual, once daily, every night at bedtime for up to 8 weeks.
89590738|NCT01467700|Placebo Comparator|Placebo|Ramelteon SL placebo-matching, tablets, sublingual, once daily, every night at bedtime for up to 8 weeks.
89590739|NCT01972724|Experimental|Pioglitazone 15 mg (Double-Blind)|Pioglitazone 15 mg tablets, orally, once daily, and metformin and sulfonylurea administered according to the prescribing information of the approved Korean label, for up to 24 weeks.
89590740|NCT01972724|Experimental|Pioglitazone 30 mg (Double-Blind)|Pioglitazone 30 mg tablets, orally, once daily, and metformin and sulfonylurea administered according to the prescribing information of the approved Korean label, for up to 24 weeks.
89590741|NCT01972724|Experimental|Pioglitazone 30 mg (Open-Label)|Pioglitazone 30 mg tablets, orally, once daily, and metformin and sulfonylurea administered according to the prescribing information of the approved Korean label, for up to 24 weeks.
89590742|NCT01441960|Experimental|Succinylcholine first, then Rocuronium|Cross-over randomized controlled, assessor blinded clinical trial.
89590743|NCT01441960|Experimental|Rocuronium first, then succinylcholine|Cross-over randomized controlled, assessor blinded clinical trial.
89590744|NCT04508062|Active Comparator|pectopexy group|this group will only have pectopexy operation
89590745|NCT04508062|Active Comparator|Pectopexy and uterosacral ligaments plication group|this group will have pectopexy operation with bilateral uterosacral ligaments plication
89590746|NCT04062838|Experimental|Prolotherapy|Injection of 20% dextrose (50 % dextrose diluted with 0.5% lidocaine) into the rotator cuff tendinous insertions as well as into the tear. All injections are performed under ultrasound.
89590747|NCT04408534|Active Comparator|continuous positive airway pressure|Patients receive continuous positive airway pressure as a mode of noninvasive ventilation
89590748|NCT04408534|Experimental|bilevel positive airway pressure|Patients receive bilevel positive airway pressure as a mode of noninvasive ventilation
89590749|NCT01955707|Experimental|natalizumab|300 mg single intravenous (IV) injection
89590750|NCT01955707|Placebo Comparator|Placebo|A single IV dose of placebo
89590751|NCT01435798|Placebo Comparator|0% MTD Dex|0% MTD Dextromethorphan
89590752|NCT01435798|Experimental|25% MTD Dex|25% MTD Dextromethorphan
88976949|NCT00178360|Experimental|Music Therapy|Subject will participate in one, individual, half-hour long music therapy session every other week and one hour-long group music therapy session each month, for a period of three months.
89590753|NCT01435798|Experimental|50% MTD Dex|50% MTD Dextromethorphan
89590754|NCT01435798|Experimental|100% MTD Dex|100% MTD Dextromethorphan
89590755|NCT01972568|Experimental|Atacicept 75 mg|
89590756|NCT01972568|Experimental|Atacicept 150 mg|
89590757|NCT01972568|Placebo Comparator|Placebo|
89590758|NCT01955161|Placebo Comparator|Placebo|Placebo adjunct to 10 mg Donepezil
89590759|NCT01955161|Experimental|Idalopirdine 30 mg|Idalopirdine adjunct to 10 mg Donepezil
89590760|NCT01955161|Experimental|Idalopirdine 60 mg|Idalopirdine adjunct to 10 mg Donepezil
89590761|NCT01441414|Experimental|ARM A|PF-04856884 in combination with AG-013736
89590762|NCT01441414|Active Comparator|ARM B|AG-013736 alone
89590763|NCT01971554|Experimental|MK-8666 50 mg|MK-8666, 50 mg, oral, once a day (QD) for Days 1 to 14.
89590764|NCT01971554|Experimental|MK-8666 150 mg|MK-8666, 150 mg, oral, QD, for Days 1 to 14
89590765|NCT01971554|Experimental|MK-8666 500 mg|MK-8666, 500 mg, oral, QD for Days 1 to 14
89590766|NCT01971554|Placebo Comparator|Placebo|Placebo, oral, QD for Days 1 to 14
89590767|NCT04411459||COVID-19 pneumonia patients|Patients needing intubation and mechanical ventilation for COVID-19 related pneumonia without other primary causes of ICU admission
89590768|NCT04664335||endometriosis cases|endometriosis laparoscopically removed / child wish
89590769|NCT04664335||controls|endometriosis laparoscopically excluded / child wish
89590770|NCT01955083|Experimental|Pillar implant|"Arm 1- Pillar implant (Study group):~15 subjects undergo pillar implant surgery of the soft palate for the treatment of snoring."
89590771|NCT01955083|Active Comparator|Radiofrequency|"Arm 2- Radiofrequency (control group):~15 subjects undergo radiofrequency of the soft palate for the treatment of snoring."
89590772|NCT01955005|Experimental|My HealtheVet Training|Participants will be asked to watch an on-line training video, review written materials, and print a document containing health information from their My HealtheVet account.
89590773|NCT01955005|Active Comparator|Internet Skills Training|Participants will review written training materials to learn how to search the Internet for health information and how to decide which Internet sites have good quality information.
89590774|NCT01954927|Active Comparator|Gabapentin|Patients will be randomized to receive one dose of gabapentin.
89590775|NCT01954927|Placebo Comparator|Placebo|Patients will be randomized to receive one dose of placebo.
89590776|NCT01954771|Active Comparator|Control Group|Patients will receive conventional care and keep on their usual SMBG(Self-monitoring of blood glucose) methods. Additionally, each patient will also wear a CGMS(continous glucose monitoring system) device for 72h in the first week and the last week, respectively.
89590777|NCT01954771|Active Comparator|SMBG-4 Group|Capillary glucose level is measured using finger stick method by 4 times (fasting plus post-meals) every other day. Additionally, each patient will also wear a CGMS device for 72h in the first week and the last week, respectively.
89590778|NCT01954771|Active Comparator|SMBG-7 Group|Capillary glucose level is measured using finger stick method by 7 times (fasting, pre-meals, post-meals and bedtime altogether) every other day. Additionally, each patient will also wear a CGMS device for 72h in the first week and the last week, respectively.
89590779|NCT01997281|Experimental|DF-cereal|"dietary fiber-enriched cereal is provided with milk, total 3 times (day 1: 6 p.m. and 10 p.m., day 2: 8 a.m.)~amount of cereal: 79 g (285.7 kcal) for dinner and breakfast, 38.5g (142.9 kcal) for night snack (10 p.m.)~one serving (40g) of steamed egg is added for dinner and breakfast"
89590780|NCT01997281|Other|conventional cereal|"conventional cereal is provided with milk, total 3 times (day 1: 6 p.m. and 10 p.m., day 2: 8 a.m.)~amount of cereal: 80g (285.7 kcal) for dinner and breakfast, 40g (142.9 kcal) for night snack (10 p.m.)~one serving (40g) of steamed egg is added for dinner and breakfast"
89590781|NCT04663087|Experimental|Treatment with XSTAT|Participants randomized to the treatment arm will be treated using the study device - XSTAT.
89590782|NCT04663087|Other|Standard Care|Participants assigned to the control group receive standard prehospital care, consisting of direct pressure/dressings.
89590783|NCT01953913|Experimental|Afatinib|Patient will receive afatinib once daily
89590784|NCT01971476|Experimental|All patients|Volasertib will be administered as intravenous infusion
89590785|NCT01996904|Experimental|arthroscopic repair|"Lateral-anterosuperior portal (Miracle Portal) was used to repair subscapularis tendon. Bursa anterior to the subscapularis tendon was usually removed for the accurate positioning of the suture-hook. Subscapularis tendon was released, pulled and sutured with suture-hook. One or two suture anchors of Modified Mason-Allen technique was used to secure the tendon."
89590786|NCT01996904|Active Comparator|arthroscopic debridement|Open and arthroscopic cuff debridement procedures have been described in the literatures for management of massive rotator cuff tears; these generally result in decreased pain and overall improvement in patient's function.
89590787|NCT01970540|Experimental|lurbinectedin (PM01183) / doxorubicin|
89590788|NCT01963676|Experimental|transcranial direct current stimulation (tDCS)|13 subjects total. 2mA stimulation for 20 minutes.
89590789|NCT01963676|Sham Comparator|Sham stimulation|13 subjects total. An initial 40sec of stimulation at 2mA followed by a small current pulse every 550msec for the remainder of the 20 minute period.
89590790|NCT01996826|Active Comparator|Avastin® (bevacizumab)|"Treatment will begin on Day 0, immediately upon the conclusion of the penetrating keratoplasty procedure with an injection of 0.1 mL (2.5 mg) bevacizumab. Starting Day 1 post-transplant surgery, subjects will begin treatment with topical bevacizumab (1% solution). Topical treatment will be self-administered 4 times a day for 4 weeks.~The study treatments are to be given in addition to standard of care treatments. Also, all patients will follow a standard post-operative follow-up visit schedule."
89590791|NCT01996826|Placebo Comparator|0.9% NaCl & Refresh Liquigel|"Treatment will begin on Day 0, immediately upon the conclusion of the penetrating keratoplasty procedure with an injection of 0.1 mL 0.9% NaCl. Starting Day 1 post-transplant surgery, subjects will begin treatment with topical Refresh Liquigel. Topical treatment will be self-administered 4 times a day for 4 weeks.~The study treatments (both topical and subconjunctival injection) are to be given in addition to standard of care treatments. Also, all patients will follow a standard post-operative follow-up visit schedule."
89590792|NCT01996748|Experimental|DF277|Two administrations daily for 7 days
89590793|NCT01996748|Placebo Comparator|Placebo|Two administrations daily for 7 days
88976950|NCT00178360|No Intervention|Standard Care|During the Standard Care time period, participants will continue to receive all of the medical care that they would normally receive for the treatment of Huntington's Disease, without the addition of music therapy services.
88976951|NCT00408187|Active Comparator|1.|
88976952|NCT00408187|Placebo Comparator|3.|
88976953|NCT00408187|Active Comparator|2.|
88976954|NCT00408226|Experimental|1|
88976955|NCT02963896|Experimental|gentamicin|intratympanic application of gentamicin 0.5 ml
88976956|NCT00178984||poor blood flow|Group with partial ischemia to the small intestine
88976957|NCT00178984||Good blood flow|Group with normal blood flow, given different conditions to effect electrical currents in normal smooth muscle
88976958|NCT00179023|Other|Part 1|Estimation of resting energy expenditure and effect of autonomic blockade with trimethaphan infusion.
88976959|NCT00179023|Other|Part 2 (closed)|Estimation of autonomic function and effect of autonomic blockade with trimethaphan infusion.
88976960|NCT00179023|Other|Part 3|Estimation of energy metabolism and effect of sympathetic stimulation with pseudoephedrine.
88976961|NCT00179023|Other|Part 4a (closed)|Isoproterenol sensitivity in adipose and muscle tissue with and without systemic autonomic blockade with trimethaphan infusion.
88976962|NCT00179023|Other|Part 4b (closed)|Metabolic and hemodynamic response to submaximal exercise in adipose and muscle tissue with and without systemic autonomic blockade with trimethaphan infusion.
88976963|NCT00057005|Experimental|1|
88976964|NCT00179062|Active Comparator|1|
88976965|NCT00179062|Active Comparator|2|
88976966|NCT00179140|No Intervention|1|control period
88976967|NCT00179140|Active Comparator|2|protein supplementation plus resistance exercise
88976968|NCT00179140|Active Comparator|3|protein supplementation only
88976969|NCT00057044|Other|Arm 1|
88976970|NCT00179179|Active Comparator|1|nutritional supplement plus resistance exercise
88976971|NCT00179179|Active Comparator|2|nutritional supplement only (resistance exercise will not be performed)
88976972|NCT00179218|Active Comparator|1|only protein supplementation
88976973|NCT00179218|Active Comparator|2|protein supplementation plus exercise
89590794|NCT01621178|Active Comparator|Insulin glargine|Insulin glargine was administered subcutaneously (SC) at bedtime per a modified forced-titration treat-to-target algorithm. Participants were instructed to administer their titrated prandial insulin lispro dose SC with the three most significant meals of the day.
89590795|NCT01621178|Experimental|0.75 mg Dulaglutide|0.75 milligram (mg) of dulaglutide was administered once weekly as a SC injection. Participants were instructed to administer their titrated prandial insulin lispro dose SC with the three most significant meals of the day.
89590796|NCT01621178|Experimental|1.5 mg Dulaglutide|1.5 mg of dulaglutide was administered once weekly as a SC injection. Participants were instructed to administer their titrated prandial insulin lispro dose SC with the three most significant meals of the day.
89590797|NCT01962974|Experimental|Golimumab 2 mg/kg IV|Study drug (golimumab 2 mg/kg IV) will be administered as an intravenous (IV) infusion at Weeks 0, 4, 12, 20 and 28.
89590798|NCT01996592||cesarean section deliveries|those subjects having an elective cesarean section will complete an informed consent form, complete the preoperative questionnaire, and then be contacted for 60 days postoperatively
89590799|NCT01962896|Experimental|Erlotinib + sirolimus|
89590800|NCT01970462|Experimental|Sitagliptin|Patients will receive Sitagliptin (renally dosed) prior to hospital discharge and 6 weeks following discharge
89590801|NCT01970462|Placebo Comparator|Placebo|Patients will receive placebo prior to discharge and 6 weeks after discharge.
88976974|NCT04723459|Active Comparator|Ivermectin mask group|Contacts who will use ivermectin masks
88976975|NCT04723459|No Intervention|ordinary mask group|Contacts who will use regular masks
88976976|NCT00057083|Other|Arm 1|
88976977|NCT00179374|Experimental|1|Tailored telephone intervention plus mailed print educational materials
88976978|NCT00179374|Active Comparator|2|print intervention with no telephone component
88976979|NCT00179452|Experimental|Intervention|Subjects invited to participate in yoga practice.
88976980|NCT00179491|Active Comparator|Group 1|604 patients received intercessory prayer after being informed they may or may not receive prayers (Group 1)
88976981|NCT00179491|No Intervention|2|597 patients did not receive prayer after being informed they may or may not receive prayer (Group 2)
88976982|NCT00179491|Experimental|Group 3|601 patients received intercessory prayer after being informed they would receive it (Group 3).
88976983|NCT00057122|Active Comparator|1|
88976984|NCT00057122|Active Comparator|2|
88976985|NCT00057122|Active Comparator|3|
88976986|NCT00057122|Active Comparator|4|
88976987|NCT04723381|Experimental|Experimental|Partivipants recieved web based genital hygiene education for seven week
88976988|NCT04723381|No Intervention|Control|No intervention was applied to the women in the control group
88976989|NCT00179764|Other|Reduced Intensity Conditioning Regimen|
88976990|NCT00057161|Other|Arm 1|
88976991|NCT00179803|Experimental|high dose chemotherapy|
88976992|NCT00057200|Other|Arm 1|
89590802|NCT01958671|Experimental|Ertugliflozin 5 mg/Ertugliflozin 5 mg|Phase A: Ertugliflozin 5 mg administered once daily for 26 weeks. Participants requiring rescue therapy will receive open-label metformin. Phase B: Ertugliflozin 5 mg administered once daily for 26 weeks. Participants not rescued with metformin in Phase A, will receive placebo to metformin. Participants rescued with metformin in Phase A will continue to receive metformin. Participants requiring rescue therapy during Phase B will receive open-label glimepiride.
88976993|NCT04063761|Experimental|Esophageal Cooling|Single arm study: Patients receive the Attune Medical Esophageal Heat Transfer Device
88976994|NCT00180232||1|Patients starting an aminobisphosphonate therapy due to medical reasons Broca-index: between -20 and +25% who are willing and capable to confirm written consent to enrolment after ample information has been provided
88976995|NCT00180310|Experimental|1|XIENCE V® Everolimus Eluting Coronary Stent System
88976996|NCT00180310|Active Comparator|2|TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent
88976997|NCT04730960||Study Group|Healthy patients between the ages of 18 and 30 without neck problems will be included in the study.
88976998|NCT04729569|Other|Tested finish line preparation|Feather edge finish line preparation (Intervention)
89590803|NCT01958671|Experimental|Ertugliflozin 15 mg/Ertugliflozin 15 mg|Phase A: Ertugliflozin 15 mg administered once daily for 26 weeks. Participants requiring rescue therapy will receive open-label metformin. Phase B: Ertugliflozin 15 mg administered once daily for 26 weeks. Participants not rescued with metformin in Phase A, will receive placebo to metformin. Participants rescued with metformin in Phase A will continue to receive metformin. Participants requiring rescue therapy during Phase B will receive open-label glimepiride.
89590804|NCT01958671|Other|Placebo/Metformin|Phase A: Placebo to ertugliflozin administered once daily for 26 weeks. Participants requiring rescue therapy will receive open-label metformin. Phase B: Participants not rescued with open-label metformin in Phase A will also receive blinded metformin up to twice daily for 26 weeks in addition to placebo. Participants rescued with metformin in Phase A will continue to receive open-label metformin. Participants requiring rescue therapy during Phase B will receive open-label glimepiride.
89590805|NCT01995266|Experimental|Asunaprevir + Daclatasvir|"Asunaprevir 100mg soft capsule by mouth twice daily for 24 weeks and~Daclatasvir 60mg tablet by mouth once daily for 24 weeks"
89590806|NCT01969058|Active Comparator|Isotretinoin Arm|Participants received Isotretinoin at approximately 0.5 mg/kg orally once daily for 4 weeks, then increased to approximately 1.0 mg/kg orally once daily for 12 weeks.
89590807|NCT01969058|No Intervention|No study treatment Arm|No Isotretinoin treatment
89590808|NCT01968980|Experimental|Bococizumab (PF-04950615;RN316)|Bococizumab (PF-04950615;RN316)
89590809|NCT01968980|Placebo Comparator|Placebo|
89590810|NCT01961882|Experimental|OCV-501 arm|
89590811|NCT01961882|Placebo Comparator|Placebo arm|
89590812|NCT01968434|Experimental|protective cough syrup|"syrup containing honey, plantago lanceolata, grindelia robusta, helichrysum italicum ina syrup form. The cough syrup is a CE marked medical device acting in a non pharmacological way to reduce cough.~Dosage: 20 ml divided in three doses per day for the duration of the study (4 nights, 3 days)"
89590813|NCT01968434|Active Comparator|carbocisteine cough syrup|Dosage 20-25 mg/kg/day three times a day (3 days/4 nights)
89590814|NCT04659902|Placebo Comparator|CON|Participants will ingest a drink containing a control protein only
89590815|NCT04659902|Active Comparator|CON-C|Participants will ingest a drink containing a control protein plus Capolac® (9547 mg to provide 2500mg of calcium)
89590816|NCT04659902|Active Comparator|PRO|Participants will ingest a drink containing an aggregate protein only
89590817|NCT04659902|Active Comparator|PRO-C|Participants will ingest a drink containing an aggregate protein plus Capolac® (9547 mg to provide 2500mg of calcium)
89590818|NCT01946438|Experimental|Adult Fluzone® Quadrivalent, Influenza Vaccine (Group 1)|Participants age 18 to < 65 years randomized to receive a dose of Fluzone® Quadrivalent, Influenza Virus Vaccine (2013-2014 formulation)
89590819|NCT01946438|Experimental|Adult Fluzone® Intradermal, Influenza Vaccine (Group 2)|Participants age 18 to < 65 years randomized to receive a dose of Fluzone® Intradermal, Influenza Virus Vaccine (2013-2014 formulation)
89590820|NCT01946438|Experimental|Elderly Fluzone® Quadrivalent, Influenza Vaccine (Group 3)|Participants age ≥ 65 years randomized to receive a dose of Fluzone® Quadrivalent, Influenza Virus Vaccine (2013-2014 formulation)
89590821|NCT01946438|Experimental|Elderly Fluzone® High-Dose, Influenza Vaccine (Group 4)|Participants age ≥ 65 years randomized to receive a dose of Fluzone® High-Dose, Influenza Virus Vaccine (2013-2014 formulation)
89590822|NCT01946282|Active Comparator|FIT Invitation Only|"Fecal Immunochemical Test (FIT) mailed to patient homes free of charge.~Intervention: Fecal Immunochemical Test (FIT) kits and an invitation letter to complete colorectal cancer screening are mailed to the homes of study eligible patients. A postage paid return mailer is included. Automated and live phone call reminders are made at the time of invitation and within one week of invitation. Up to two live phone call reminders are attempted 2 to 3 weeks post invitation.~Follow up for patients who return a normal test in Year 1 will consist of repeat screening invitations in Year 2 and Year 3 consistent with guideline recommended annual FIT for colorectal cancer screening. Follow up for patients who return an abnormal test will consist of navigation to complete colonoscopy."
89590823|NCT01946282|Active Comparator|FIT plus $5 Incentive|"Fecal Immunochemical Test (FIT) mailed to patient homes, plus an incentive to complete the test.~Intervention: FIT kits and invitation letter with a $5 gift card incentive to complete screening are mailed to the homes of 1000 randomly assigned eligible patients. A postage paid return mailer is included. Automated and live phone call reminders are made at the time of invitation and within one week of invitation. Up to two live phone call reminders are attempted 2 to 3 weeks post invitation.~Follow up for patients who return a normal test in Year 1 will consist of repeat screening invitations in Year 2 and Year 3. Follow up for patients who return an abnormal test will consist of navigation to complete colonoscopy."
89590824|NCT01946282|Active Comparator|FIT plus $10 Incentive|"Fecal Immunochemical Test (FIT) mailed to patient homes, plus an incentive to complete the test.~Intervention: FIT kits and invitation letter with a $10 gift card incentive to complete screening are mailed to the homes of 1000 randomly assigned eligible patients. A postage paid return mailer is included. Automated and live phone call reminders are made at the time of invitation and within one week of invitation. Up to two live phone call reminders are attempted 2 to 3 weeks post invitation.~Follow up for patients who return a normal test in Year 1 will consist of repeat screening invitations in Year 2 and Year 3. Follow up for patients who return an abnormal test will consist of navigation to complete colonoscopy."
89590825|NCT01945580|Active Comparator|Xenform|Prolapse Repair with Xenform Soft Tissue Repair Matrix
89590826|NCT01945580|Active Comparator|Control|Prolapse Repair with Native Tissue Only
89590827|NCT01945034|Experimental|Topical IBU twice daily|
89590828|NCT01945034|Placebo Comparator|Placebo twice daily|
89590829|NCT01945034|Experimental|Topical IBU three times daily|
89590830|NCT01945034|Placebo Comparator|Placebo three times daily|
89590831|NCT01960790||Participants who received Humira®|Humira® 40 mg (marketed product) every other week (eow) for subcutaneous injection after initial dosage of 160 mg and 2nd dosage of 80 mg in two weeks after the initial administration
89590832|NCT04655768|Active Comparator|Operative Arm|Radius fractures C1/C2 treated by palmar plate fixation
89590833|NCT04655768|No Intervention|Conservative Arm|Radius Fractures C1/C2 treated by cast fixation
89590834|NCT04638062|Experimental|Post Isometric Relaxation|"This study ARM will receive following therapies~Post isometric relaxation (Upper Trapezius and Levator Scapulae muscles)~Isometric neck strengthening exercises~Cryotherapy"
89590835|NCT04638062|Experimental|Myofascial Release Therapy|"This study ARM will receive following therapies~Myofascial release therapy (Upper Trapezius and Levator Scapulae muscles~Isometric neck strengthening exercises~Cryotherapy"
88976999|NCT04729569|Active Comparator|Comparator finish line preparation|Deep chamfer finish line preparation (Comparator)
88977000|NCT00180505|Other|1|The purpose of the ASSESS Registry is to investigate the performance of the ABSOLUTE™ .035 Peripheral Self-Expanding Stent System (ABSOLUTE™ Stent) in preventing restenosis of occluded or stenotic superficial femoral or proximal popliteal arteries.
88977001|NCT02969603|Other|Healthy volunteers- MRI|MRI scan for morphological assessment of muscle structures and anatomy
88977002|NCT02969603|Other|Healthy Volunteers- PET/MRI|The volunteers will undergo a combined [11C]acetate PET/MRI scan
88977003|NCT00180544|Other|1|Male and female patients, who meet study eligibility criteria, agree to participate in the trial, and sign an informed consent, will be enrolled in the study. A HERCULINK™ 14 Peripheral Stent will be used in the treatment of suboptimal post- procedural percutaneous transluminal angioplasty (PTA) atherosclerotic renal artery stenoses.
88977004|NCT00180583|Experimental|1|Treatment of single or multivessel long diffuse coronary stenosis with the Guidant GALILEO Intravascular Radiotherapy System
89590836|NCT04636970|No Intervention|Control group|Patients randomised to control group will get usual recommendations regarding physical activity after a discharge from inpatient cardiac rehabilitation.
89590837|NCT04636970|Experimental|Intervention group|Patients randomised to intervention group will continue home exercise training that will last 12 weeks and consists of endurance, flexibility, balance and cardiovascular resistance training performed with low to moderate intensity, in 20-60 minutes sessions, five times a week. Study participants will be asked to wear wrist and chest unobtrusive devices during active day time or at least during the training session and two hours before and after. Study participants well receive telephone calls every other week and were asked to answer questions regarding their health and physical activity.
89590838|NCT01618214|Experimental|Subject-driven titration|
89590839|NCT01618214|Active Comparator|Investigator-driven titration|
89590840|NCT01917968|Active Comparator|Uphold Lightweight Vaginal Support System|Transvaginal repair with mesh (Uphold LITE)
89590841|NCT01917968|Active Comparator|Traditional native tissue repair|Sacrospinous ligament fixation or uterosacral ligament suspension and/or colporrhaphy
89590842|NCT01917656|Experimental|Liraglutide+Metformin|Liraglutide 1.8 mg administered once daily subcutaneously, in combination with pre-trial tablet metformin of unchanged dose.
89590843|NCT01917656|Active Comparator|Sulphonylurea and Metformin|Subjects continued on pre-trial sulphonylurea tablet treatment, in combination with pre-trial tablet metformin of unchanged dose.
89590844|NCT01944722|Experimental|BD Onclarity™ HPV assay on BD Viper™ LT|The LBC specimen will be tested with the BD Onclarity™ HPV assay on the BD Viper™ LT instrument. Colposcopy will be performed on subjects who have abnormal cytology or HPV positive test results or from a random sampling of subjects with normal cytology and HPV negative test results.
89590845|NCT04415918|Experimental|Intervention group|Recruited patient according inclusion/exclusion criteria
89590846|NCT04415918|No Intervention|Historical control|Cohort of historical patients matched to study population to serve as control
89590847|NCT01917344|Other|Adults with PKU|MRI, EEG, neuropsychological testing, neurological examination, blood draw, diet diary, physical examination. These activities were performed for the study, but no drug or other interventions took place.
89590848|NCT02017535|Active Comparator|6 IPT-A Sessions|"Participants in this group will receive interpersonal psychotherapy for adolescents (IPT-A) only.~During the Continuation IPT-A sessions, the therapist will continue to emphasize the interpersonal strategies that were learned and practiced during the acute phase, and address any current interpersonal problems before they result in a recurrence of depressive symptoms. Adolescents who have responded to acute phase treatment (CGI-I = much improved or very much improved) will attend 4 biweekly IPT-A sessions followed by 2 monthly sessions."
89590849|NCT02017535|Active Comparator|6 IPT-A Sessions + Continue Current Dose of Fluoxetine|"Participants in this group will receive interpersonal psychotherapy for adolescents (IPT-A) and fluoxetine treatment.~Adolescents who have responded to acute phase treatment (CGI-I = much improved or very much improved) will attend 4 biweekly IPT-A sessions followed by 2 monthly sessions and will continue their acute phase fluoxetine dosing regimen and will meet with the psychiatrist on a monthly basis."
89030835|NCT00523965|Active Comparator|D|amphotericin B deoxycholate at 1 mg/kg every other day for 15 infusions
89030836|NCT05141669||Fingolimod|Participants who initiated fingolimod to treat multiple sclerosis (MS)
89590850|NCT02017535|Experimental|10 IPT-A Sessions + Begin Fluoxetine|"Participants in this group will receive interpersonal psychotherapy for adolescents (IPT-A) and fluoxetine treatment.~Adolescents who received only IPT-A during acute phase and who showed a partial response (CGI-I = minimally improved) will attend 8 weekly IPT-A sessions followed by 2 monthly sessions and will begin treatment with fluoxetine during the continuation phase.The dosage schedule will be 10mg per day for the first week and 20mg per day for the following 5 weeks. If no treatment response is observed by the 6th week, the dosage can be increased to 40mg per day. Pharmacotherapy sessions will be scheduled weekly for the first 4 weeks and biweekly thereafter. Pharmacotherapy sessions will include assessment of vital signs, adverse effects, safety, and symptomatic response."
89030837|NCT05141669||Non-fingolimod Disease Modifying Treatment (DMT)|All patients with ≥ 1 medical or pharmacy claim for a DMT other than fingolimod. Among patients included in the study that those with ≥ 1 pharmacy or medical claim for any MS DMT during pre-index would be excluded.
89030838|NCT00522756|Experimental|Intervention|Three ampoules of 7.5% sodium bicarbonate (89.3 mOsm/ampoule; total 150 ml for three ampoules) added to 750 ml of 5% dextrose in water, given at 1 ml/kg/hour through a dedicated intravenous line for 6 hours, and completed prior to the initiation of cardiopulmonary bypass.
89030839|NCT00522756|Active Comparator|Control|0.9% sodium chloride given at 1 ml/kg/hour through a dedicated intravenous line for 6 hours, and completed prior to the initiation of cardiopulmonary bypass.
89030840|NCT02954783|Experimental|High Intensity Interval Training|The HIIT-group will receive usual care plus a supervised aerobic High Intensity Interval Training program consisting of 4 weekly sessions of approximately 35 minutes.
89030841|NCT02954783|Active Comparator|Usual Care Observational Control|Patients randomized to usual care control will receive the standard patient care program as provided by the Department of Urology, Rigshospitalet.
89590851|NCT02017535|Experimental|10 IPT-A Sessions + Increase Dose of Fluoxetine|"Participants in this group will receive interpersonal psychotherapy for adolescents (IPT-A) and fluoxetine treatment.~Adolescents who received IPT-A and fluoxetine during the acute phase and were partial responders (CGI-I = minimally improved) will attend 8 weekly IPT-A sessions followed by 2 monthly sessions and will have their fluoxetine dose increased to 60mg. Partial responders will meet with the psychiatrist biweekly for the first 2 months and monthly for the second 2 months."
89590852|NCT01944098|Experimental|Lidocaine|Intraoperative continuous IV infusion of Lidocaine at 2mg/kg/hr
89590853|NCT01944098|Active Comparator|Placebo|Intraoperative continuous placebo infusion of dextrose at 2mg/kg/hr
89590854|NCT02017223|Experimental|Knowme Device Wear|Participants wear KNOWME devices and use mobile phone interface for three days outside of school. This is a pre-post design with no control group
89590855|NCT01944020|Experimental|Intervention - CPAP use|Active CPAP will be a therapeutic dose of positive airway pressure each night for 2 months
89590856|NCT01944020|No Intervention|Control - No CPAP use|Control will be no use of CPAP for 2 months
89590857|NCT01943552|Experimental|ipratropium|500 mcg four times a day
89590858|NCT01943552|Placebo Comparator|placebo|
89590859|NCT01915940|Experimental|13 mg Bimatoprost Ocular Insert|Washout and placebo ocular insert in each eye for at least 4 weeks, followed by 13 mg Bimatoprost Ocular Insert in each eye and placebo eye drops twice a day in each eye for 6 months.
89590860|NCT01915940|Active Comparator|Timolol 0.5% + Placebo Ocular Insert|Washout and placebo ocular insert in each eye for at least 4 weeks, followed by Timolol (timoptic ophthalmic solution 0.5%) twice a day in each eye plus placebo ocular insert for 6 months.
89590861|NCT01914926|Active Comparator|Metoprolol Study Group|Patients Receiving metoprolol administered at a dose of 0.15 mg/kg (to a maximum dose of 10 mg)
89590862|NCT01914926|Active Comparator|Diltiazem Study Group|Patients receiving diltiazem administered parenterally at a dose of 0.25 mg/kg (to a maximum dose of 30 mg)
89590863|NCT02016755|Experimental|AMG0001|Hepatocyte Growth Factor (HGF) Plasmid
89590864|NCT05119166||Canadian Healthy Infant Longitudinal Development (CHILD) Cohort Study|The CHILD Cohort Study is a prospective longitudinal birth cohort study. It is an observational study of healthy term infants in Canada (Vancouver, Edmonton, Manitoba, Toronto). The birth years were between 2009-2012, and is currently at the 8 year postnatal follow up phase. IMiC will receive 400 breast milk samples from 400 dyads (100/site) that were taken between 3-4 months postnatal.
89590865|NCT05119166||The Early Life Interventions for Childhood Growth and Development in Tanzania (ELICIT) Study|(NCT03268902). ELICIT is a randomized controlled trial (RCT) evaluating the efficacy of antimicrobials and nicotinamide in increasing growth in the setting of Rural Tanzania. It is factorial design RCT of nicotinamide (vitamin B3) to mothers and infants, and antimicrobial prophylaxis to infants. IMiC will receive 400 breast milk samples from 200 dyads, 2 samples per dyad taken at 1 & 5 months postnatal.
89590866|NCT05119166||VITAL Pakistan|Two Randomized Controlled Trials: Mumta (Nutritional support for lactating women with or without azithromycin)PW - NCT04012177 and MumtaLW - NCT03564652 VITAL is a community-based, randomized control, assessor blinded trial in peri-urban settings of Karachi, Pakistan to study the impact of Lipid-based Nutritional Supplement for Pregnant and Lactating women which is balanced energy-protein (BEP) dietary supplement, a locally produced ready-to-use nutritional product for lactating women (LW) and single prophylaxis dose of Azithromycin for infants, on growth of infants over the period of six months since birth compared to current standard of care. IMiC will receive 600 breast milk samples from 200 dyads, 3 samples per dyad taken at 0-1, 1-2 & 2-3 months.
89590867|NCT05119166||Micronutriments pour la Santé de la Mère et de l'Enfant (MISAME)-3 study (NCT03533712)|MISAME-3 is a randomized controlled clinical trial in the setting of Rural Burkina Faso. A BEP supplement provides less than 25% of protein of the total energy content, and includes different vitamins and minerals. The first part of an exploratory study will determine which type of BEP supplement (bar, drink, biscuit, soup or paste) is most accepted by pregnant women. Subsequently, two products will be tested for longer-term acceptability and at-home use (phase 1). The effect of the most suitable supplement will be tested in a controlled clinical trial (phase 2). The intervention group will receive the dietary supplement during pregnancy and/or lactation, while the control group complies with the standard iron and folic acid tablets following the national guidelines. IMiC will receive 600 breast milk samples from 200 dyads, 3 samples per dyad taken at 0-1, 1-2 & 3-4 months.
89590868|NCT01942148|Experimental|Aripiprazole|Aripiprazole (initial dose 2 mg/day, maintenance dose 6-24 mg/day, maximum dose 30 mg/day) orally administered over 52 weeks to subjects who complete the 031-09-003 study
89590869|NCT02030015|Experimental|Syner-G Therapy Regimen|The Syner-G therapy regimen includes switching the research subject to a full-time ketogenic diet, and daily treatment with orally-administered miglustat, for the duration of the 60-month study.
89590870|NCT02029235|Active Comparator|Acetaminophen/Ibuprofen (AIBU) Group|Acetaminophen 500 mg and Ibuprofen 400 mg
88977005|NCT00180700|Experimental|Self-hypnosis|A course of four weekly 2-hour training sessions coupled with daily self-hypnosis practice was given to 13 participants with diagnosed HIV
88977006|NCT00180700|Experimental|Johrei healing method|A course of four weekly 2-hour training sessions coupled with daily self-hypnosis practice was given to 9 participants with diagnosed HIV
88977007|NCT04729491|Active Comparator|Dutasteride|Dutasteride 0.5mg/day q.d. for 30 days or until COVID-19 remission (defined as full remission of symptoms plus viral clearance through rtPCR-SARS-CoV-2)
88977008|NCT04729491|Placebo Comparator|Placebo|Placebo q.d. for 30 days or until COVID-19 remission (defined as full remission of symptoms plus viral clearance through rtPCR-SARS-CoV-2)
88977009|NCT00057356|Placebo Comparator|1|
88977010|NCT00057356|Experimental|2|Low dose
89590871|NCT02029235|Active Comparator|Acetaminophen/Hydrocodone (AH) Group|Acetaminophen 325 mg and Hydrocodone 5 mg
89590872|NCT01617434|Experimental|Liraglutide|
89590873|NCT01617434|Placebo Comparator|Placebo|
89590874|NCT01940354|Experimental|Vascular access via study device|AccuCath IV Catheter System will be used for IV therapy during interventional radiology procedure. Intervention includes vascular access, fluid infusion, and blood sample removal.
89590875|NCT01940354|Active Comparator|Vascular access via control device|Conventional IV Catheter System (current catheter) will be used for IV therapy during interventional radiology procedure. Interventions include vascular access, administration of fluids, and blood sample removal.
88977011|NCT00057356|Experimental|3|Middle dose
88977012|NCT00057356|Experimental|4|High dose
88977013|NCT00181753|Experimental|1|Burn Patients receiving at least 3 days of parenteral feeding on routine formula
88977014|NCT00181753|Experimental|2|Burn patients receiving at least 3 days on parenteral feeding on glutamine enriched formula.
88977015|NCT00181753|Experimental|3|Burn patients receiving at least 3 days of enteral feeding on routine formula.
88977016|NCT00181753|Experimental|4|Burn patients receiving at least 3 days of enteral feeding on glutamine-enriched formula.
88977017|NCT00182143|Active Comparator|LMWH (Fragmin, dalteparin)|Placebo dose (normal saline) = AM dose LMWH (Fragmin, dalteparin) 5000IU daily = PM dose
88977018|NCT00182143|Active Comparator|2|Unfractionated Heparin 5000IU BID
88977019|NCT00180388|Experimental|Endoscopic vein harvesting|Harvesting of vein for coronary artery bypass grafting using endoscopy to visualize the vein
88977020|NCT00180388|Active Comparator|Open Vein harvesting|Harvesting of vein for coronary artery bypass grafting without endoscopy
89030842|NCT04693845|Active Comparator|Treatment as Usual|Community Mental Health Center Next Day Appointment clinic
89030843|NCT04693845|Experimental|Experimental|Collaborative Assessment and Management of Suicidality (CAMS)
89030844|NCT05141240||Ribociclib|Participants who initiated CDK4/6i therapy
89030845|NCT05141240||Palbociclib|Participants who initiated CDK4/6i therapy
89590876|NCT01940120|Experimental|High Risk Registry Arm|Includes patients with a predicted procedural mortality of 12% or higher. The high risk registry arm of the study is powered to show superiority of safety of treatment with the MitraClip compared to mitral valve surgery. The patients who are enrolled in this arm will undergo percutaneous mitral valve repair using MitraClip implant.
89590877|NCT01911260|Active Comparator|Growth Deficit+zinc amino acid chelate|"Children with one and a half or more standard deviations below the mean height for age and gender of the reference population (Z-score under -1.6) were included in the Growth Deficit group (GD).~During twelve weeks, children received weekly 1ml of lemon flavor caramel syrup containing zinc amino acid chelate at 3%, i.e. the equivalent to 30mg of elemental zinc per ml, disposed into an individual amber glass, containing 20ml of syrup. The supplement administration was made individually with 1ml BD Plastipak disposable syringe, directly into the child's mouth, by the principal investigator. The chosen supplementation day was Tuesday. Therefore, the following weekdays were reserved to supplement any absent student."
89590878|NCT01911260|Placebo Comparator|Growth Deficit receiving placebo|"Children with one and a half or more standard deviations below the mean height for age and gender of the reference population (Z-score under -1.6) were included in the Growth Deficit group (GD).~During twelve weeks, children received weekly 1ml of lemon flavor caramel syrup, disposed into an individual amber glass, containing 20ml of syrup. The supplement administration was made individually with 1ml BD Plastipak disposable syringe, directly into the child's mouth, by the principal investigator. The chosen supplementation day was Tuesday. Therefore, the following weekdays were reserved to supplement any absent student."
89590879|NCT01911260|Placebo Comparator|Normal Height receiving placebo|"For the Normal Stature group (NS), HAZ was set up as being between -1 and +1 standard deviations from the mean height reference for age and sex.~During twelve weeks, children received weekly 1ml of lemon flavor caramel syrup, disposed into an individual amber glass, containing 20ml of syrup. The supplement administration was made individually with 1ml BD Plastipak disposable syringe, directly into the child's mouth, by the principal investigator. The chosen supplementation day was Tuesday. Therefore, the following weekdays were reserved to supplement any absent student."
89590880|NCT01911260|Active Comparator|Normal Height+zinc amino acid chelate|"For the Normal Stature group (NS), HAZ was set up as being between -1 and +1 standard deviations from the mean height reference for age and sex.~During twelve weeks, children received weekly 1ml of lemon flavor caramel syrup containing zinc amino acid chelate at 3%, i.e. the equivalent to 30mg of elemental zinc per ml, disposed into an individual amber glass, containing 20ml of syrup. The supplement administration was made individually with 1ml BD Plastipak disposable syringe, directly into the child's mouth, by the principal investigator. The chosen supplementation day was Tuesday. Therefore, the following weekdays were reserved to supplement any absent student."
89590881|NCT02015819|Experimental|Treatment (neural stem cells, flucytosine, leucovorin)|"Patients receive CD-expressing neural stem cells intracranially on days 1 and 15. Flucytosine is taken orally every 6 hours on days 4-10 and 18-24. Depending on when a subject enters the study, they may also be given leucovorin orally every 6 hours on days 4-10 and 18-24. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Dose escalation used the following dose levels:~Dose Level 1 (NSC 5x10^7 and 5-FC 37.5 mg/kg)~Dose Level 2 (NSC 1x10^8 and 5-FC 37.5 mg/kg)~Dose Level 3 (NSC 1.5x10^8 and 5-FC 37.5 mg/kg)~Dose Level 4 (NSC 1.5x10^8 and 5-FC 37.5 mg/kg) + Leucovorin + Microdialysis"
89590882|NCT01939496|Experimental|Canagliflozin 100 mg|Each patient will receive 100 mg of canagliflozin once daily for 6 weeks.
89590883|NCT01939496|Experimental|Canagliflozin 300 mg|Each patient will receive 300 mg of canagliflozin once daily for 6 weeks.
89590884|NCT01939496|Placebo Comparator|Placebo|Each patient will receive matching placebo once daily for 6 weeks.
89590885|NCT01939028|Experimental|Diagnostic (SLN mapping, biopsy, surgery)|Patients undergo SLN mapping using isosulfan blue and/or indocyanine green solution injected directly into the cervix. Following SLN identification and biopsy, patients undergo hysterectomy, bilateral salpingo-oophorectomy, and/or complete pelvic lymphadenectomy. Patients expressing SLN positive for metastasis undergo para-aortic lymphadenectomy.
89209914|NCT04036890|Experimental|2% minocycline hydrochloride controlled-delivery system (MHS)|Mechanical ultrasonic/ hand instrumentation and subsequent administration of MHS on that day (Day 0) and on Day 4, at 3 months, 6 months and 9 months
89209915|NCT04036890|Placebo Comparator|Placebo|Mechanical ultrasonic/ hand instrumentation and subsequent administration of a placebo gel on that day (Day 0) and on Day 4, at 3 months, 6 months and 9 months
89209916|NCT00887874||A|
89030846|NCT05141240||Abemaciclib|Participants who initiated CDK4/6i therapy
89030847|NCT00522912|Experimental|A|Immediate posterior lamella tarsal rotation surgery for minor trichiasis
89030848|NCT00522912|Active Comparator|B|Regular epilation by another person
89030849|NCT02954627||Intensive dietary intervention|Supervised dietary weight loss program lasting 8 weeks
89030850|NCT00524004|Experimental|Anti-CsbD Bovine IgG|Anti CsbD Bovine Milk Immunoglobulin
89030851|NCT00524004|Experimental|Placebo|Lacto-free milk supplement
89030852|NCT00524004|Experimental|Anti-CS17 Bovin IgG|Anti-CS17 Bovin Milk Immunoglobulin
89030853|NCT05145803||College Students|"Collegiate students tested positive for SARS-CoV-2 by a molecular reference test (PCR test or antigen test) (index patients).~Collegiate students known to be contacts of the index patients."
89030854|NCT04694079|Experimental|Group 1, CMR-guided VT ablation|"Patients randomized to Group 1, will undergo CMR-guided VT ablation. LGE-CMR data obtained by 1,5 or 3 T CMR and multi-detector cardiac tomography (MDCT) data obtained using a 128 slice CT scanner will be processed with ADAS-VT software (Galgo Medical, Barcelona, Spain).~Ablation procedure will be carried out in an electrophysiology lab by using the CARTO 3 electroanatomical mapping system (Biosense Webster, Diamond Bar, CA, USA). A ThermoCool SmartTouch SF open irrigated 3,5 mm tip radiofrequency catheter (Biosense Webster, Diamond Bar, CA, USA) will be used both for mapping and ablation."
89030855|NCT04694079|Experimental|Group 2, CMR-aided VT ablation|"Patients randomized to Group 2, will undergo CMR-aided VT ablation. LGE-CMR data obtained by 1,5 or 3 T CMR and multi-detector cardiac tomography (MDCT) data obtained using a 128 slice CT scanner will be processed with ADAS-VT software (Galgo Medical, Barcelona, Spain).~Ablation procedure will be carried out in an electrophysiology lab by using the CARTO 3 electroanatomical mapping system (Biosense Webster, Diamond Bar, CA, USA). A ThermoCool SmartTouch SF open irrigated 3,5 mm tip radiofrequency catheter (Biosense Webster, Diamond Bar, CA, USA) will be used both for mapping and ablation."
89030856|NCT04694079|Active Comparator|Group 3, Electroanatomical guided ablation|Patients assigned to Group 3, will not undergo LGE-CMR. Ablation procedure will be carried out in an electrophysiology lab by using the CARTO 3 electroanatomical mapping system (Biosense Webster, Diamond Bar, CA, USA). A ThermoCool SmartTouch SF open irrigated 3,5 mm tip radiofrequency catheter (Biosense Webster, Diamond Bar, CA, USA) will be used both for mapping and ablation.
89590886|NCT01938716|Experimental|Gemcitabine Infusion|Gemcitabine administered intravenously as a dose of 500 mg/m2 at a fixed dose rate of 10 mg/m2/min for the first 5 patients (to validate hematologic safety). Next 15 subsequent patients receive 750 mg/m2 at a fixed dose rate of 10 mg/m2/min. The drug infusion started 50-75 minutes prior to complete gross tumor removal (timing dependent on dose) in order to have drug administration complete at tumor removal.
89590887|NCT01937390||LAMA/LABA Patients|
89590888|NCT04651712|No Intervention|Standard care|A treating physician must perform a clinical assessment within half an hour of patient arrival. This assessment includes the decision whether the patient is suspected of having pneumonia and if this is the case, a sputum specimen and chest x-ray will be ordered. Patients with suspected pneumonia who can deliver a sputum specimen will be randomly allocated with a 1:1 computer-generated randomization schedule with permuting blocks in relation to optimal therapeutical intervention strategy. All standard care sputum samples will be cultured and analysed according to the sites' standard procedures. Under standard care, the treating physician alone decides on the optimal therapeutical intervention.
89590889|NCT04651712|Active Comparator|POC-PCR analysis supplied with a recommended action list developed by a microbiologist|Along with standard analyses, the specimens will be analysed with POC-PCR and the treating physician will receive an action-list with the results from POC-PCR.
89590890|NCT04685681|Experimental|Hiking Challenge|This group receives access to the local hiking challenge after completion of baseline measure
89590891|NCT04685681|Active Comparator|Activity list|This group receives access to a resource sheet with activity ideas after completion of baseline measure and does not receive the main resource of interest (hiking challenge) until after the post-test (delayed intervention)
89590892|NCT04685057|Placebo Comparator|Placebo|This arm will receive placebo for 6 months then probiotic for 6 more months.
89590893|NCT04685057|Experimental|Probiotic|This arm will receive probiotic for 6 months then will keep receiving probiotic for 6 more months.
89590894|NCT02028767|Experimental|Fixed Dose Combination (FDC)|12.5 mg Empagliflozin / 500mg metformin fixed dose combination
89590895|NCT02028767|Active Comparator|Separate tablets|Empagliflozin and Metformin tablets
89590896|NCT01959932|Experimental|Tobacco Heating System (THS 2.2)|Ad libitum use of THS 2.2 for 5 days in confinement
89590897|NCT01959932|Sham Comparator|Smoking abstinence (SA)|Abstinence from smoking for 5 days in confinement
89590898|NCT01959932|Active Comparator|Conventional cigarette (CC)|Ad libitum use of subject's own preferred brand of CC for 5 days in confinement
89590899|NCT04416893||Children under 15 years of age in a community|Children under 15 years of age in a community : kindergarten, school, college, holiday center, etc.
89590900|NCT04651244||Patients with suspected acute pyelonephritis|Patients admitted in the ED with suspected infection, where the initial medical assessment raises suspicion of APN.
89590901|NCT02028065|Experimental|Sugammadex 4 mg/kg|Administration of 3 single IV doses of sugammadex 4 mg/kg, with an approximately 5-week washout between Dose 1 and Dose 2 and between Dose 2 and Dose 3
89590902|NCT02028065|Experimental|Sugammadex 16 mg/kg|Administration of 3 single IV doses of sugammadex 16 mg/kg, with an approximately 5-week washout between Dose 1 and Dose 2 and between Dose 2 and Dose 3
89590903|NCT02028065|Placebo Comparator|Placebo|Administration of 3 single IV doses of placebo, with an approximately 5-week washout between Dose 1 and Dose 2 and between Dose 2 and Dose 3
89590904|NCT04683965|Experimental|Pemetrexed + TAS-102 + Bevacizumab|Pemetrexed 500 mg/m2 d1+ TAS-102, capsule, 35mg/m2, bid,po, d1~5, d8~12 + Bevacizumab 5 mg/kg d1, d14; Repeated every 4 weeks
89590905|NCT02015195|Experimental|Acetic Acid 5%|Acetic Acid (5%) Dosage form: Liquid Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes
89590906|NCT02015195|Experimental|Sodium Bicarbonate Slurry (50%)|Sodium Bicarbonate Slurry (50%) Dosage form: Liquid slurry Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes
89590907|NCT02015195|Experimental|Papain Slurry (70%)|Papain Slurry (70%) Dosage form: Liquid slurry Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes
89590908|NCT02015195|Experimental|Household ammonia (10%)|Ammonia (10%) Dosage form: Liquid Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes
89590909|NCT02015195|Experimental|Lidocaine (4%)|Lidocaine (4%) Dosage form: Liquid Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes
89590910|NCT02015195|Experimental|Isopropyl Alcohol (70%)|Isopropyl Alcohol (70%) Dosage form: Liquid Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes
89590911|NCT02015195|Experimental|Hot Water (40 degrees Celsius)|Hot Tap Water (40 degrees Celsius) Dosage form: Liquid Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes
89590912|NCT02015039|Active Comparator|Botulinum Toxin Therapy Only|
89590913|NCT02015039|Experimental|Botulinum Toxin Therapy plus Occupational Therapy|Intervention
89590914|NCT02025725|Experimental|10 mg Metoclopramide Nasal Spray|Metoclopramide Nasal Spray 10 mg, 30 minutes before meals and at bedtime (QID) for 4 weeks
89590915|NCT02025725|Placebo Comparator|Placebo Nasal Spray|Placebo Nasal Spray 30 minutes before meals and at bedtime (QID) for 4 weeks
89030857|NCT05146076|Experimental|telemedicine supervised group|physical training supervised by telemonitoring
89030858|NCT05146076|Active Comparator|institutional training|institutional training supervised by physiotherapist
89030859|NCT04693572||Parturients undergoing repeated caesarean sectiona|
89590916|NCT02025179|Experimental|Teriparatide and vibration|"Experimental: Teriparatide and vibration~Drug: Teriparatide (Forteo) 20 ug daily Sub-Q over 12 months~Device: Vibration 10 min/day for 12 months"
89590917|NCT02013791|Other|Stage 1 Cohort 1|Vehicle administered to study eye and Sham administered to non-study eye on Day 1.
89590918|NCT02013791|Experimental|Stage 1 Cohort 2|Cyclosporine New Ophthalmic Formulation Dose A administered to study eye and Vehicle administered to non-study eye on Day 1.
89590919|NCT02013791|Experimental|Stage 1 Cohort 3|Cyclosporine New Ophthalmic Formulation Dose B administered to study eye and Vehicle administered to non-study eye on Day 1.
89590920|NCT02013791|Experimental|Stage 1 Cohort 4|Cyclosporine New Ophthalmic Formulation Dose C administered to study eye and Vehicle administered to non-study eye on Day 1.
89590921|NCT02013791|Experimental|Stage 1 Cohort 5A|Cyclosporine New Ophthalmic Formulation Dose D administered to the study eye and vehicle administered to the non-study eye on Day 1.
89590922|NCT02013791|Experimental|Stage 1 Cohort 6A|Cyclosporine New Ophthalmic Formulation Dose E administered to study eye and Vehicle administered to non-study eye on Day 1.
89590923|NCT02013791|Experimental|Stage 1 Cohort 6B|Cyclosporine New Ophthalmic Formulation Dose F administered to study eye and Vehicle administered to non-study eye on Day 1.
89590924|NCT02013791|Experimental|Stage 1 Cohort 6C|Cyclosporine New Ophthalmic Formulation Dose C administered to study eye and Vehicle administered to non-study eye on Day 1 and retreatment at Week 12 if applicable.
89590925|NCT02013791|Experimental|Stage 1 Cohort 6D|Cyclosporine New Ophthalmic Formulation Dose F administered to study eye and Vehicle administered to non-study eye on Day 1 and retreatment at Week 12 if applicable.
89590926|NCT02024867|Active Comparator|10 days of Trimethoprim-Sulfamethoxazole|Oral Trimethoprim-Sulfamethoxazole dosed at 10 mg Trimethoprim/kg/day divided twice a day, to a maximum of 640 mg Trimethoprim/day
89590927|NCT02024867|Experimental|3 days of Trimethoprim-Sulfamethoxazole|Oral Trimethoprim-Sulfamethoxazole dosed at 10 mg Trimethoprim/kg/day divided twice a day, to a maximum of 640 mg Trimethoprim/day
89590928|NCT01953601|Experimental|Arm A. Verubecestat 12 mg (Part 1); 12 mg (Part 2)|[Part 1] Verubecestat 12 mg once daily for 104 weeks in Part 1 (Base Study). [Part 2] Participants completing Part 1 and continuing to Part 2 (Extension Study) receive Verubecestat 12 mg once daily for an additional 260 weeks.
89590929|NCT01953601|Experimental|Arm B. Verubecestat 40 mg (Part 1); 40 mg (Part 2)|[Part 1] Verubecestat 40 mg once daily for 104 weeks in Part 1 (Base Study). [Part 2] Participants completing Part 1 and continuing to Part 2 (Extension Study) receive Verubecestat 40 mg once daily for an additional 260 weeks.
89590930|NCT01953601|Placebo Comparator|Arm C. Placebo (Part 1); Verubecestat 40 mg (Part 2)|[Part 1] Placebo once daily for 104 weeks in Part 1 (Base Study). [Part 2] Participants completing Part 1 and continuing to Part 2 (Extension Study) receive Verubecestat 40 mg once daily for an additional 260 weeks.
89590931|NCT01952665|Active Comparator|comfilcon A|Daily wear soft contact lens comfilcon A
89590932|NCT01952665|Active Comparator|lotrafilcon B|Daily wear soft contact lens lotrafilcon B
89590933|NCT01952041|Experimental|Device: Smartphone|Participants in the smartphone intervention arm received treatment as usual in addition to receiving a smartphone with the study application. The study application identified relapse risk and prompted the clinical team to provide enhanced services.
89590934|NCT01952041|Active Comparator|Treatment as Usual|Treatment as usual included outpatient case management, linkage to services and medication monitoring.
89030860|NCT04696367||Patients with acute intra-abdominal pathology|Patients admitted to hospital with acute intra-abdominal pathology
89030861|NCT02948127|Experimental|RSV LID cp ΔM2-2 Vaccine|Participants will receive a single dose of the RSV LID cp ΔM2-2 vaccine at study entry (Day 0).
89030862|NCT02948127|Placebo Comparator|Placebo|Participants will receive a single dose of placebo at study entry (Day 0).
89030863|NCT02948010|Active Comparator|Auto CPAP + comfort feature A|Auto CPAP with comfort feature A using Fisher & Paykel Healthcare CPAP Device
89030864|NCT02948010|Active Comparator|Auto CPAP with comfort feature B|Auto CPAP with comfort feature B using Fisher & Paykel Healthcare CPAP Device
89030865|NCT02948010|Active Comparator|Auto CPAP with no comfort feature|Auto CPAP with no comfort feature using Fisher & Paykel Healthcare CPAP Device
89030866|NCT02948010|Active Comparator|Auto CPAP with comfort feature A+B|Auto CPAP with comfort feature A+B using Fisher & Paykel Healthcare CPAP Device
89030867|NCT02948010|Active Comparator|CPAP with comfort feature A|CPAP with comfort feature A using Fisher & Paykel Healthcare CPAP Device
89590935|NCT04416529|Experimental|Intervention (tele-MBCT) group|"Tele-MBCT was an 8-week program delivered to participants online via a videoconferencing program called Zoom by a tele-MBCT instructor. Tele-MBCT was delivered in three, 8-week rounds. Each round consisted of 8 weekly, 2-hour group sessions with 4-6 participants on Wednesdays from 2:00 to 4:00 pm. Participants were trained in mindfulness concepts and techniques including mindful eating, body scan, sitting meditation, breathing awareness, mindful walking and mindful movements. Participants were given a mindfulness a book called The Mindful Way Workbook and a practice log. The book was a guide for their daily practice at home and the practice log was a simple log for self-recording daily practices (number of minutes of daily MBCT practice) and a note pad for recording the reasons/obstacles for not practicing."
89590936|NCT04416529|No Intervention|Control Group|Participants in the control group continued their usual caregiving activities.
89590937|NCT04668235|Experimental|Arm AZVUDINE|"Experimental:~AZVUDINE 1mg tablet,~Interventions:~AZVUDINE 1mg tablet, 5 tablets QD + standard treatment for up to 14 days"
89590938|NCT04668235|Placebo Comparator|Arm Placebo|"Control:~AZVUDINE placebo,~Interventions:~AZVUDINE placebo, 5 tablets QD + standard treatment for up to 14 days"
89590939|NCT01951573|Other|Delefilcon A MF, then AOAMF|Delefilcon A multifocal contact lenses first, followed by lotrafilcon B multifocal contact lenses. Each product worn bilaterally (ie, in both eyes) for 9-12 hours, with a 1-8 day washout separating the 2 wear periods.
89590940|NCT01951573|Other|AOAMF, then Delefilcon A MF|Lotrafilcon B multifocal contact lenses first, followed by delefilcon A multifocal contact lenses. Each product worn bilaterally (ie, in both eyes) for 9-12 hours, with a 1-8 day washout separating the 2 wear periods.
89590941|NCT02023697|Experimental|Radium-223 dichloride (Standard dose)|One injection to be administered every 4 weeks up to 6 injections. The dose per injection is 50 kBq/kg body weight (55 kBq/kg after implementation of NIST update).
89590942|NCT02023697|Experimental|Radium-223 dichloride (High dose)|One injection to be administered every 4 weeks up to 6 injections. The dose per injection is 80 kBq/kg body weight (88 kBq/kg after implementation of NIST update).
89590943|NCT02023697|Experimental|Radium-223 dichloride (Extended standard dose)|One injection to be administered every 4 weeks up to 12 injections. The dose per injection is 50 kBq/kg body weight (55 kBq/kg after implementation of NIST update).
89590944|NCT01951417|Experimental|Adapalene/BPO Gel/Foam Wash/Moisturizer|Adapalene BPO Gel Pump (once daily) in conjunction with a Foam Wash (twice daily) and Moisturizer SPF 30 (once daily)
89590945|NCT01951261|Active Comparator|telemonitoring and telephone control|Early discharge from hospital with telemonitoring, telephone control and three nurse scheduled visits.
89590946|NCT01951261|No Intervention|home care|Early discharge from hospital with home care provided by hospital respiratory nurses and pulmonologists (daily visits).
89590947|NCT02023151|Other|Omalizumab|Active
89590948|NCT04643743||Subjects who did receive POLYPATCH® for vascular angioplasty|Subjects who did receive POLYPATCH® at least one year ago for vascular angioplasty. 2 main sub-populations will be studied depending on location of surgery (carotid and femoral) but data will be collected for all subjects who did receive POLYPATCH.
89590949|NCT01979185|Active Comparator|Simvastatin|Administered as a single oral 20 mg dose on Day 1.
89590950|NCT01979185|Experimental|Simvastatin + SSP-004184SS|Simvastatin (20 mg) + SSP-004184SS (30 mg/kg) administered concomitantly as a single oral dose on Day 1.
89590951|NCT01946425|Experimental|Age 6 Months to <36 Months (Study Group 1)|Participants at 6 months to < 36 months of age at enrollment
89590952|NCT01946425|Experimental|Age 3 Years to <9 Years Group (Study Group 2)|Participants at 3 years to < 9 years of age at enrollment
89590953|NCT01946191|Experimental|Coaching Group|"24 months of personalized coaching through the EHR patient portal, with 24 scheduled contacts~Online self-monitoring~Real-time updates to primary care physicians"
89590954|NCT01946191|Active Comparator|Tracking Group|-Online self-monitoring
89590955|NCT01937312|Experimental|SIMBRINZA|Brinzolamide 1%/brimonidine 0.2% ophthalmic suspension, 1 drop in each eye 3 times a day (8 AM, 3 PM, 10 PM), with prostaglandin analogue, 1 drop in each eye at bedtime, for 6 weeks
89590956|NCT01937312|Placebo Comparator|Vehicle|Inactive ingredients, 1 drop in each eye 3 times a day (8 AM, 3 PM, 10 PM), with prostaglandin analogue, 1 drop in each eye at bedtime, for 6 weeks
89030868|NCT02948010|Active Comparator|CPAP with comfort feature B|CPAP with comfort feature B using Fisher & Paykel Healthcare CPAP Device
89030869|NCT02948010|Active Comparator|CPAP with no comfort feature|CPAP with no comfort feature using Fisher & Paykel Healthcare CPAP Device
89590957|NCT04632836||NIV participant (non invasive-ventilation participant)|"From patient:~demographics data (date of birth, gender, socio-professional category, education level, morphometric data)~equipment data (type, indication, parameters, observance, usage data),~medical data (EFR, blood gas, respiratory polygraphy, pulse oxymetry, medical history, smoking status)~responses of questionnaires (WHOQOL-BREF questionnaire, PSQI index, HADS scale, study specific questionnaire)~From partner:~demographics data (date of birth, gender, socio-professional category, education level, morphometric data)~responses of questionnaires (WHOQOL-BREF questionnaire, PSQI index, HADS scale, study specific questionnaire)"
89590958|NCT04632836||CPAP participant (continuous positive airway pressure participant)|"From patient:~demographics data (date of birth, gender, socio-professional category, education level, morphometric data)~equipment data (type, indication, parameters, observance, usage data),~medical data (EFR, blood gas, respiratory polygraphy, pulse oxymetry, medical history, smoking status)~responses of questionnaires (WHOQOL-BREF questionnaire, PSQI index, HADS scale, study specific questionnaire)~From partner:~demographics data (date of birth, gender, socio-professional category, education level, morphometric data)~responses of questionnaires (WHOQOL-BREF questionnaire, PSQI index, HADS scale, study specific questionnaire)"
89590959|NCT04632836||LTOT participant (long term oxygen therapy participant)|"From patient:~demographics data (date of birth, gender, socio-professional category, education level, morphometric data)~equipment data (type, indication, parameters, observance, usage data),~medical data (EFR, blood gas, respiratory polygraphy, pulse oxymetry, medical history, smoking status)~responses of questionnaires (WHOQOL-BREF questionnaire, PSQI index, HADS scale, study specific questionnaire)~From partner:~demographics data (date of birth, gender, socio-professional category, education level, morphometric data)~responses of questionnaires (WHOQOL-BREF questionnaire, PSQI index, HADS scale, study specific questionnaire)"
89590960|NCT01935128|Experimental|Arm 1 Everolimus/Reduced dose tacrolimus|In this arm, the myfortic® will be weaned off quickly and everolimus (Zortress®) initiated to achieve a target level of 3-8 ng/ml with a mean of 6 ng/ml. Once achieving a therapeutic dose of everolimus (Zortress®) the tacrolimus (Prograf® or Hecoria®) dose will be reduced a target level of 3-5 ng/ml.
89590961|NCT01934972|Experimental|CR + DCS|Subjects will receive Cognitive Remediation and active study drug.
89590962|NCT01934972|Active Comparator|CR + placebo|Cognitive Remediation and placebo
89590963|NCT01959230|Experimental|Brimonidine Tartrate|Participants will apply 1 drop of brimonidine tartrate ophthalmic solution 0.025% into each eye 4 times daily for up to 4 consecutive weeks.
89590964|NCT01959230|Placebo Comparator|Brimonidine Tartrate Vehicle|Participants will apply 1 drop of the vehicle of brimonidine tartrate ophthalmic solution into each eye 4 times daily for up to 4 consecutive weeks.
89590965|NCT01909778|Experimental|BI 201335|BI 201335 two single oral doses, separated by 14 days washout period
89590966|NCT01977937|Experimental|Gabapentin|Gabapentin 15 milligrams per kilogram will be given orally one time pre-operatively. Gabapentin will be continued at a dose of 10 milligrams per kilogram every eight hours orally starting as soon as the patient is admitted to his or her floor bed in the hospital.
89590967|NCT01977937|Placebo Comparator|Simple Syrup|Simple syrup compounded by the Oregon Health and Science University research pharmacy will be administered in the same volume as if the patient were receiving the Gabapentin both pre-operatively and every eight hours after the patient is admitted to his or her floor bed in the hospital.
89590968|NCT02015663|Experimental|Arm 1|Tobramycin Inhalation Powder (112 mg) once daily during 168 days
89590969|NCT02015663|Active Comparator|Arm 2|Tobramycin Inhalation Powder (112 mg) twice daily on days 1-28, days 57-84 and days 113-140
89030870|NCT02948010|Active Comparator|CPAP with comfort feature A + B|CPAP with comfort feature A + B using Fisher & Paykel Healthcare CPAP Device
89590970|NCT01978093|Experimental|HibCY Group|Subjects received 4 doses of Hib-MenCY-TT (MenHibrix®) vaccine at Day 0, Month 2, Month 4 and Month 10-13 , 3 doses of Pediarix® vaccine at Day 0, Month 2 and Month 4, 2 doses of Rotarix® vaccine at Day 0 and Month 2, 4 doses of Prevnar 13® vaccine at Day 0 and Month 2, Month 4 and Month 10-13 and 2 doses of Havrix® vaccine at Month 10-13 and Month 16-19.
89590971|NCT01978093|Active Comparator|PedHIB Group|Subjects received 3 doses of PedvaxHIB® vaccine at Day 0, Month 2 and Month 10-13, 3 doses of Pediarix® vaccine at Day 0, Month 2 and Month 4, 2 doses of Rotarix® vaccine at Day 0 and Month 2, 4 doses of Prevnar 13® vaccine at Day 0 and Month 2, Month 4 and Month 10-13 and 2 doses of Havrix® vaccine at Month 10-13 and Month 16-19.
89590972|NCT01951105|No Intervention|Observation|Individuals identified as having a recovering phenotype (SBPp) will be assigned to the observational arm and will be asked to continue his/her normal regime and return for the week 12 and week 24 visits for follow-up.
89590973|NCT01951105|Active Comparator|Carbidopa/Levodopa & Naproxen|"Individuals identified as having a persisting phenotype (SBPr) will be treated with Carbidopa/Levodopa on a flexible dose-titration designed intervention based on dose-response TID throughout the 12 week treatment period.~Naproxen (250mg) capsules will be administered orally, one capsule TID, throughout the 12 week treatment period."
89590974|NCT01951105|Placebo Comparator|Placebo & Naproxen|Individuals identified as having a persisting phenotype (SBPr) will be treated with placebo capsule plus 250mg naproxen tablet three times a day for 12 weeks.
89590975|NCT01958918|Experimental|Ranibizumab|1 intravitreal injection monthly until maximum stable BCVA with retreatment based on BCVA loss and/or SD-OCT signs of wet AMD disease activity
89590976|NCT01958918|Active Comparator|Aflibercept|1 intravitreal injection monthly for the first 3 months, followed by 1 intravitreal injection every 2 months
89590977|NCT01945489|Experimental|OnabotulinumtoxinA|OnabotulinumtoxinA (BOTOX®) 100U injected into the detrusor at Day 1, followed by a repeat injection of onabotulinumtoxinA 100U after a minimum of 12 weeks (if applicable).
89590978|NCT01945489|Other|Placebo/OnabotulinumtoxinA|Placebo (Normal saline) injected into the detrusor on Day 1, followed by an injection of onabotulinumtoxinA 100U after a minimum of 12 weeks (if applicable).
89590979|NCT04173559|No Intervention|Usual care|Women randomized to this group will receive no guidance regarding exercise / activity / sleep during pregnancy.
89590980|NCT04173559|Experimental|Activity Intervention|Women randomized to this group will receive detailed information and reminders about physical activity and sleep in pregnancy. .
89590981|NCT01934894|Experimental|cabazitaxel and lapatinib combination|"Cabazitaxel 1-hour IV infusion on Day 1 of each 3 week cycle (dose to be determined)~Lapatinib PO once daily (dose to be determined)~Treatment cycles will be repeated every 3 weeks."
89590982|NCT01950169|Active Comparator|Risedronate|35 mg risedronate orally administered once weekly for 12 months and orally administered Calcium 1000 mg and 800 IU vitamin D3 daily for 12 months. Group B (bisphosphonate group)
89590983|NCT01950169|Active Comparator|Nutritional supplement|Oral liquid nutritional supplement (600kcal and 40 gram protein/day) for 6 months after the hip fracture besides Risedronate and calcium and vitamin D3. Group BN (bisphosphonate and nutritional supplemented group)
89590984|NCT01950169|Active Comparator|Calcium and vitamin D3|An oral dose of 1000 mg Calcium and 800 IU vitamin D3 daily for 12 months after hip fracture. Group C (control)
89590985|NCT01934504||Tolerant AAV|Tolerant participants with AAV
89590986|NCT01934504||Non-Tolerant AAV|Non-Tolerant participants with ANCA-associated vasculitis (AAV)
89590987|NCT01934504||Healthy Controls|Healthy participants that fulfill eligibility criteria -similar in age to Tolerant and Non-Tolerant AAV participants.
89590988|NCT01934504||AAV Discontinuing Immunosuppression|Participants have been in clinical remission and on minimal maintenance therapy for at least 2 years prior to screening. Their primary physicians have planned to discontinue immunosuppression medication in the next year after screening.
89590989|NCT01950013|No Intervention|Passive Control|Hearing aid alone
89590990|NCT01950013|Experimental|Training|Auditory Training Program. Hearing aid plus auditory training
89590991|NCT01950013|Sham Comparator|Active control|Sham comparator: Active control. Hearing aid plus audio-book use
89590992|NCT04632524|Active Comparator|MgSO4|Group (Mg So4) n=30 will receive Mg So4 pre-induction as an intravenous bolus 20mg/kg over 10 minutes and maintenance dose intraoperative 5/mg/kg/h intravenous and discontinued just before the end of the surgery.
89590993|NCT04632524|Placebo Comparator|Placebo|Group (P) n=30 will receive saline in equal volume. The surgeon , anesthesiologist and the person who will collect the data will be blinded for the prepared solution. The solution will be prepared by an expert anesthesia nurse
89590994|NCT01949155|Experimental|OTO-201|"OTO-201: Single, intratympanic injection:~One injection of 6 mg OTO-201 (ciprofloxacin in poloxamer 407) into each ear during surgery."
89590995|NCT01949155|Sham Comparator|Sham|"Sham: Simulated single, intratympanic injection:~One sham injection into each ear during surgery."
89030871|NCT02948010|Active Comparator|CPAP at Sub therapeutic level|CPAP at Sub therapeutic level using Fisher & Paykel Healthcare CPAP Device
89590996|NCT01909466|Other|Gluteal Injection|
89590997|NCT01909466|Other|Deltoid Injection|
89030872|NCT05145998|Active Comparator|Control - Glucola|Glucola control beverage
89030873|NCT05145998|Experimental|Whole peas|Whole cooked peas in a 50 gram carbohydrate meal dose
89030874|NCT05145998|Experimental|Pea Flour|Pea flour in a 50 gram carbohydrate meal dose
89030875|NCT05145998|Experimental|Whole lentils|Whole cooked lentils in a 50 gram carbohydrate meal dose
89030876|NCT05145998|Experimental|Lentil flour|Lentil flour in a 50 gram carbohydrate meal dose
89590998|NCT01977625|Active Comparator|Lisdexamfetamine|Lisdexamfetamine or Vyvanse
89590999|NCT01977625|Placebo Comparator|Sugar Pill|Placebo pill, capsules
89591000|NCT01944631|Placebo Comparator|Placebo|Nasal spray 4 times a day over 4 to 10 days
89591001|NCT01944631|Experimental|Iota-Carrageenan nasal spray|Nasal spray 4 times a day over 4 to 10 days
89591002|NCT01948063|Placebo Comparator|Control|Depending on the patient's ability to swallow pills, patients in the control group will receive a placebo pill or a liquid placebo, which is 50 milliliters of Ensure (a dietary supplement). This will be given every 12 hours for 7 days or until hospital discharge.
89591003|NCT01948063|Experimental|Ubiquinol|Depending on the patient's ability to swallow pills, patients in the experimental group will receive 200mg of Ubiquinol in either a pill or a liquid. The liquid form of the study med will be mixed with 50 milliliters of Ensure (a dietary supplement) to ensure blinding. This will be given every 12 hours for 7 days or until hospital discharge.
89591004|NCT01995071|Experimental|Arm 1 Non-cirrhotic|ABT-493 Dose A (100 mg once daily [QD]) for 3 days, followed by ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
89591005|NCT01995071|Experimental|Arm 2 Non-cirrhotic|ABT-493 Dose B (400 mg QD) for 3 days, followed by ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
89591006|NCT01995071|Experimental|Arm 3 Non-cirrhotic|ABT-493 Dose C (700 mg QD) for 3 days, followed by ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
89591007|NCT01995071|Experimental|Arm 4 Non-cirrhotic|ABT-493 Dose D (200 mg QD) for 3 days, followed by ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
89591008|NCT01995071|Experimental|Arm 5 Compensated cirrhotic|ABT-493 Dose E (200 mg QD) for 3 days, followed by ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
89591009|NCT01995071|Experimental|Arm 6 Non-cirrhotic|ABT-530 Dose A (15 mg QD) for 3 days, followed by ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
89591010|NCT01995071|Experimental|Arm 7 Non-cirrhotic|ABT-530 Dose B (120 mg QD) for 3 days,followed by ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
89591011|NCT01995071|Experimental|Arm 8 Non-cirrhotic|ABT-530 Dose C (400 mg QD) for 3 days, followed by ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
89591012|NCT01995071|Experimental|Arm 9 Non-cirrhotic|ABT-530 Dose D (40 mg QD) for 3 days, followed by ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
89591013|NCT01995071|Experimental|Arm 10 Compensated cirrhotic|ABT-530 Dose E (120 mg QD) for 3 days, followed by ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
89591014|NCT01995071|Experimental|Arm 11 Non-cirrhotic|ABT-493 Dose F (300 mg QD) for 3 days, followed by ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
89591015|NCT01995071|Experimental|Arm 12 Non-cirrhotic|ABT-530 Dose F (≤ 400 mg) for 3 days, followed by ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
89591016|NCT01994837|Experimental|ABT-199|Continuous dosing of venetoclax (ABT-199) QD (once daily) beginning with dose-escalation on Week 1 Day 1. Participants received a dose of 20 mg of ABT-199 on Week 1 Day 1, 50 mg on Day 2, 100 mg on Day 3, 200 mg on Day 4, 400 mg on Day 5, 800 mg on Day 6 and QD thereafter.
89591017|NCT02010593|Experimental|Dapivirine Vaginal Ring|Safety study of a vaginal ring containing Dapivirine in a postmenopausal female population
89591018|NCT02010593|Placebo Comparator|Placebo|The placebo VR is a flexible, platinum-catalyzed-cured matrix ring, identical to Dapivirine Ring-004, containing no active-drug
89591019|NCT01994291|Active Comparator|Arm 1|Intravitreal administration of ranibizumab (either 0.3 or 0.5 mg, given monthly, as detailed in the prescribing information and label content approved for the country governing the study site) plus an oral placebo.
89591020|NCT01994291|Experimental|Arm 2|Oral PF-04634817 200 mg, once daily plus a masked sham therapy (given monthly).
89591021|NCT02094677|Active Comparator|filcon II 3 and etafilcon A|Participants were randomized to a test and control lens for each group in a contralateral design.
89591022|NCT02094677|Active Comparator|filcon II 3 and nelfilcon A|Participants were randomized to a test and control lens for each group in a contralateral design.
89591023|NCT04667195||Suspected acute pyelonephritis|Diagnosis of APN suspected at the initial clinical assessment by the receiving emergency department physician
89591024|NCT01993823|Experimental|G238|Five drops into the ear canal twice daily for 14 days
89591025|NCT01993823|Active Comparator|Clotrimazole|Five drops into the ear canal twice daily for 14 days
89591026|NCT04673123|Experimental|Core Stabilization Group|Core stabilization + Multifactorial Education Program (patient-specific upper and lower extremity stretching and strengthening exercises; application of functional electrical stimulation (FES) to upper and lower extremity muscles; balance, coordination and gait training)+ Informing about fall prevention (by verbal and written)
89591027|NCT04673123|Active Comparator|Multifactorial Education Program Group|Multifactorial Education Program (patient-specific upper and lower extremity stretching, relaxation and strengthening exercises; application of functional electrical stimulation (FES) to upper and lower extremity muscles; balance, coordination and gait training)+ Informing about fall prevention (by verbal and written)
89591028|NCT01993667|Active Comparator|Acetazolamide normal dose|Experimental : Acetazolamide 125 mg twice daily
89591029|NCT01993667|Experimental|Acetazolamide low dose|Experimental: Acetazolamide 62.5 mg twice daily
89591030|NCT01992107|Experimental|QIVc (≥4 to <18 years)|Subjects received one or two doses of QIVc-Quadrivalent Cell-based Influenza Vaccine recommended for 2013-2014 season
89591031|NCT01992107|Active Comparator|TIV1c (≥4 to <18 years)|"Subjects received one or two doses of TIV1c (Trivalent Inactivated Cell-based Influenza Vaccine containing one strain from B lineage (B1 strain) recommended for 2013-2014 season"
89591032|NCT01992107|Active Comparator|TIV2c (≥4 to <18 years)|"Subjects received one or two doses of TIV2c (Trivalent Inactivated Cell-based Influenza Vaccine containing B strain from the alternate lineage (B2 strain) recommended for 2013-2014"
89591033|NCT04673045|Active Comparator|Active neuromuscular electrical stimulation|This group will receive active NMES delivered the electrical current through electrodes inserted in saline-soaked sponges.
89591034|NCT04673045|Sham Comparator|Sham neuromuscular electrical stimulation|This group will receive sham NMES
89591035|NCT01934192|Experimental|Initial randomization: GSK962040 Arm|Subjects in the GSK962040 Arm will receive 50 mg once daily enteral dose administered through NG tube up to 7 days.
89591036|NCT01934192|Placebo Comparator|Initial randomization: Placebo Arm|Subjects in the placebo arm will receive once daily dose enteral dose administered through NG tube up to 7 days.
89591037|NCT01934192|Experimental|Treatment change due to intolerance: GSK962040 Arm|Subjects that develop intolerance and that originally received Placebo will receive 50 mg once daily enteral dose administered through NG tube + placebo IV
89591038|NCT01934192|Active Comparator|Treatment change due to intolerance: Metoclopramide Arm|Subjects that develop intolerance and that originally received GSK962040 will receive metoclopramide 10 mg IV every 6 h + placebo NG
89591039|NCT01933880|Experimental|OROS-MPH Group|Participants with ADHD will receive OROS -MPH starting at initial dosage of 18 milligram per day (mg/d) which can be increased to 36 mg/d up to a maximum dosage of 54 mg/d according to the therapeutic effect and tolerance or maintained at 36 mg or re-adjusted to 18 mg due to intolerance.
89591040|NCT01933880|Active Comparator|Normal Group|Participants did not receive any study drug in this group. Participants were assessed for changes in the cognitive functions and the efficacy was compared with ADHD children.
89591041|NCT04647578||Child with IBD|
89591042|NCT04647578||Healthy child witnesses|
89591043|NCT04620980||Cases|"Participants will be assessed for disease progression: Hoehn and Yahr stadium, MDS-UPDRS part III, MoCA test, no motor symptoms, therapy and LID occurrence.~Participants will be subjected to peripheral blood sampling for the purification of DNA, RNA, plasma and serum.~DNA of each participant will be analysed by targeted resequencing of a disease-specific gene panel including about 100 genes related to Parkinson's Disease, autophagy and levodopa induced Dyskinesia (LID)."
89591044|NCT04620980||controls|"Participants will be assessed for the presence of disease. Participants will be subjected to peripheral blood sampling for the purification of DNA, RNA, plasma and serum.~DNA of each participant will be analysed by targeted resequencing of a disease-specific gene panel including about 100 genes related to Parkinson's Disease, autophagy and levodopa induced Dyskinesia (LID)."
89591045|NCT02008877|Experimental|ganetespib / sirolimus|28-day cycles of ganetespib + sirolimus
89591046|NCT01933334|Experimental|Pirfenidone: 4-Week Titration Group|Participants will receive one 267 milligrams (mg) oral pirfenidone capsule three times daily (TID) (801 mg per day [mg/day]) for 2 weeks followed by two 267 mg oral pirfenidone capsules TID (1602 mg/day) for 2 weeks (titration period) and then three 267 mg oral pirfenidone capsules TID (2403 mg/day) for 12 weeks maintenance period).
89591047|NCT01933334|Experimental|Pirfenidone: 2-Week Titration Group|Participants will receive one 267 mg oral pirfenidone capsule TID (801 mg/day) for 1 week followed by two 267 mg oral pirfenidone capsules TID (1602 mg/day) for 1 week (titration period) and then three 267 mg oral pirfenidone capsules TID (2403 mg/day) for 14 weeks (maintenance period).
89591048|NCT01908140|Experimental|Aclidinium Bromide / Formoterol Fumarate|Aclidinium Bromide 400 μg / Formoterol Fumarate 12 μg BID for 24 Weeks
89591049|NCT01908140|Active Comparator|Salmeterol / Fluticasone propionate|Salmeterol 50 μg / Fluticasone propionate 500 μg BID for 24 Weeks
89591050|NCT02008565|Placebo Comparator|Placebo - Exercise plus Biofeedback|"Placebo and biofeedback intervention. Placebo doses range from 2mg every other day to 8mg per day. Capsules are taken by mouth once a day for 24 weeks.~Anal exercises with biofeedback intervention is a total of six sessions with trained personnel occurring every 2 weeks over a 12-week period. Sessions are held at the following study visits: baseline, 2, 4, 6, 9, and 12 week visits."
88977021|NCT00182260|Active Comparator|Proton Pump Inhibitor|Patients randomized to medical therapy received optimized treatment with PPI using a standardized management protocol based on best evidence and published guidelines.
89209917|NCT00887952|Experimental|1|Partial removal of carious dentine. Carious dentine partial removal plus restoration in one session. The group is divided according to the filling material: amalgam or resin.
88977022|NCT00182260|Active Comparator|Laparoscopic Nissen Fundoplication|Surgical patients underwent LNF using previously published technique.
88977023|NCT00408616|Experimental|1|Grazax treatment
88977024|NCT00408616|Placebo Comparator|2|Grazax Placebo
89030877|NCT02948205|Experimental|3D group|infertility patient get TU-LESS by 3D Laparoscopy
89591051|NCT02008565|Experimental|Loperamide - Exercise plus Biofeedback|"Loperamide and biofeedback intervention. Loperamide doses range from 2mg every other day to 8mg per day. Capsules are taken by mouth once a day for 24 weeks.~Anal exercises with biofeedback intervention is a total of six sessions with trained personnel occurring every 2 weeks over a 12-week period. Sessions are held at the following study visits: baseline, 2, 4, 6, 9, and 12 week visits."
89591052|NCT02008565|Placebo Comparator|Placebo - Education Only|"Placebo and education (usual care). Placebo doses range from 2mg every other day to 8mg per day. Capsules are taken by mouth once a day for 24 weeks.~Participants receive education and a NIDDK Bowel Control Educational pamphlet."
89591053|NCT02008565|Experimental|Loperamide - Education Only|"Loperamide and education (usual care). Loperamide doses range from 2mg every other day to 8mg per day. Capsules are taken by mouth once a day for 24 weeks.~Participants receive education and a NIDDK Bowel Control Educational pamphlet."
89591054|NCT01907906|Experimental|Arm 1: Mirasol-treated WB then untreated WB|Screening Period (14 days); Treatment Period 1 (49 days): Donation of WB treated with Mirasol System for Whole Blood on Day 0, LR-pRBCs manufactured & stored 21 days, radiolabeled RBCs reinfused on Day 21 and samples collected over 28 days (Days 21-49); WB Donation Deferral Period (35-49 days); Treatment Period 2 (49 days): Donation of WB, UNTREATED on Day 0, LR-pRBCs manufactured & stored 21 days, radiolabeled RBCs reinfused on Day 21 and samples collected over 28 days (Days 21-49) Study Exit on Treatment Period 2, Day 49
89591055|NCT01907906|Experimental|Arm 2: Untreated WB then Mirasol-treated WB|Screening Period (14 days); Treatment Period 1 (49 days): Donation of WB, UNTREATED on Day 0, LR-pRBCs manufactured & stored 21 days, radiolabeled RBCs reinfused on Day 21 and samples collected over 28 days (Days 21-49); WB Donation Deferral Period (35-49 days); Treatment Period 2 (49 days): Donation of WB treated with Mirasol System for Whole Blood on Day 0, LR-pRBCs manufactured & stored 21 days, radiolabeled RBCs reinfused on Day 21 and samples collected over 28 days (Days 21-49) Study Exit on Treatment Period 2, Day 49
89591056|NCT01907828|Experimental|Cardiac ablation + renal artery ablation|Renal artery ablation with the EnligHTN™ Renal Denervation System
89591057|NCT01907828|Active Comparator|Cardiac ablation|Cardiac ablation
89591058|NCT01907516|Active Comparator|Cell phone-internet first|Cell phone-internet home glucose reporting system first
89591059|NCT01907516|Placebo Comparator|Voicemail first|Voicemail home blood glucose reporting first
89591060|NCT01931462|Experimental|Certus 140™|During the operation: use of Certus 140™ microwave device for pre-coagulation of the kidney tissue adjacent to the tumor.
89591061|NCT01931150|Experimental|Dapsone LEFT, Moisturizer RIGHT|Dapsone 5% gel to LEFT side of face and chest BID (morning and evening) Moisturizer to RIGHT side of face and chest BID (morning and evening) AND oral antibiotics (doxycycline 100 mg bid OR minocycline 100 mg once daily or other antibiotic daily)
89591062|NCT01931150|Experimental|Dapsone RIGHT, Moisturizer LEFT|Moisturizer to LEFT side of face and chest BID (morning and evening) Dapsone 5% gel to RIGHT side of face and chest BID (morning and evening) AND oral antibiotics (doxycycline 100 mg bid OR minocycline 100 mg once daily or other antibiotic daily)
89591063|NCT01930214||None/mild calcification|Presence of readily apparent radiopacities within the vascular wall at the site of the stenosis.
89591064|NCT01930214||Moderate Calcification|Presence of radiopacities only during the cardiac cycle before contrast injection with calcium extended partially into the target lesion.
88977025|NCT00408655|Experimental|Arm I|"PART A: Patients receive paclitaxel IV over 3 hours followed by carboplatin IV over 30-60 minutes on day 1 and temsirolimus IV over 30 minutes on days 8 and 15. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.~PART B: Patients receive paclitaxel and carboplatin as in part A. They also receive temsirolimus IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity."
88977026|NCT00182338||Peritoneal Dialysis Patients|
88977027|NCT00182455|Experimental|1|Topiramate 25 - 400 mg/day x 12 weeks
88977028|NCT00182455|Placebo Comparator|2|Placebo
88977029|NCT00182533|Experimental|1|Sertraline
88977030|NCT00182533|Placebo Comparator|2|Placebo
88977031|NCT00408733|No Intervention|1|
88977032|NCT00408733|Experimental|2|Intervention
88977033|NCT00183079|Active Comparator|1|Brief, motivationally-focused alcohol intervention
88977034|NCT00183157|Active Comparator|1|Patients will receive an assessment, a brief motivational interview performed by a trained peer counselor, direct referrals to community-based resources for adolescents, and a 10-day follow-up phone call.
88977035|NCT00183157|Active Comparator|2|Patients will receive an assessment and a list of community resources
88977036|NCT00183157|Active Comparator|3|Patients will receive only the list of resources.
88977037|NCT00183313|Experimental|1|Participants will receive nurse case management intervention
88977038|NCT00183313|Active Comparator|2|Participants will receive usual care
88977039|NCT02963662|Experimental|Roux-en-Y gastric bypass group|The patients undergo Roux-en-Y gastric bypass (RYGB group) following a comprehensive evaluation for the surgical indication
88977040|NCT02963662|Experimental|sleeve gastrectomy group|The patients undergo sleeve gastrectomy (SG group) following a comprehensive evaluation for the surgical indication
88977041|NCT02963662|No Intervention|Normal BMI group|no intervention
88977042|NCT00183352||1|Women with bipolar disorder
88977043|NCT00183352||2|Women who are healthy controls
88977044|NCT03970083||Oxygen Levels in Tumors|-Quantitative oxygen measurements will be obtained in a single field of view using T1 sequences
88977045|NCT00183508|Experimental|1 Cognitive behavioral therapy|
88977046|NCT00183508|Experimental|2 Psychoeducation|
89591065|NCT01930214||Severe calcification|Presence of radiopacities noted without cardiac motion prior to contrast injection involving both sides of the arterial wall in at least one location, total length of calcium (including segmented) must be at least 15mm and extend partially into the target lesion.
89591066|NCT01958294|Other|MICHI Neuroprotection System|Subjects enrolled into this study will be male or female subjects who are candidates for carotid angioplasty and stenting, who, after meeting all of the eligibility criteria, undergo transcervical Carotid Artery Stenting with carotid flow reversal using the MICHI Neuroprotection System.
89591067|NCT01906346|Experimental|Low Value Alternative Reinforcer|A low value reinforcer will be made available as an alternative to cocaine and placebo.
89591068|NCT01906346|Experimental|Medium Value Reinforcer|A medium value reinforcer will be made available as an alternative to cocaine and placebo.
89591069|NCT01906346|Experimental|High Value Reinforcer|A high value reinforcer will be made available as an alternative to cocaine and placebo.
89591070|NCT01958060|Experimental|BI 1034020 intravenous part|single rising doses
89591071|NCT01958060|Experimental|BI 1034020 subcutaneous part|single rising doses
89591072|NCT04618874|Experimental|ROSE group|Ultrasound-assisted percutaneous needle aspiration with rapid on-site evaluation
89591073|NCT04618874|No Intervention|US NAB group|Ultrasound-assisted percutaneous needle aspiration without rapid on-site evaluation
89591074|NCT04645004|Other|Aspirin|81mg aspirin daily
89591075|NCT01929980|Experimental|Bortezomib|"Four doses of bortezomib, 1.3mg/m2, will be given intravenously (through a needle in a vein) or subcutaneously (under the skin) on Days 1, 4, 8, 11.~The format of receiving medications is- Therapy Dose and Route Frequency Rituximab 375 mg/m2 intravenously Once on day 1. Plasmapheresis 2 hours prior to Bortezomib Day 1,4, 8 and 11 Bortezomib 1.3 mg/m2 intravenously Day 1,4,8 and 11"
89591076|NCT01363076|Experimental|Ketorolac Tromethamine (15 mg)|Ketorolac Tromethamine - single dose (15 mg) administered intranasally (IN) for subjects weighing <50 kg.
89591077|NCT01363076|Experimental|Ketorolac Tromethamine (30 mg)|Ketorolac Tromethamine - single dose (30 mg) administered intranasally (IN) for subjects weighing ≥50 kg.
89591078|NCT01929044|Experimental|Buscopan® (hyoscine butylbromide)|1st injection of Buscopan® solution 20mg, if necessary 2nd injection after 20min of the 1st injection
89591079|NCT01929044|Active Comparator|654-II(anisodamine)|1st injection of 654-II solution 10mg, if necessary 2nd injection after 20min of the 1st injection
89591080|NCT01903460|Experimental|LUM001|LUM001 administered orally once each day
89591081|NCT01903460|Placebo Comparator|Placebo|Placebo administered orally once each day
89591082|NCT01957202|Experimental|Arm 1|Each Subject will be assigned to a sequence of three treatments (e.g ABC, BCD, ACD): A=Two, 50 microliter (mcqL) sprays per nostril of FF, total dose 100 microgram (mcg); B=Two, 50 mcqL sprays per nostril of levocabastine, total dose 200 mcg; C=Two, 50 mcql sprays per nostril of FF/levocabastine FDC, total daily dose 100 mcg FF and 200 mcg levocabastine; D=Two, 50 mcql sprays per nostril of placebo. There will be a wash out period of 14-28 days between two treatment periods
89591083|NCT01616654|Experimental|CD5789 25 mcg/g Cream|Participants randomized in stratum 1, 2 and 3 were applied with 25 mcg/g CD5789 cream, once daily for 12 weeks.
89591084|NCT01616654|Experimental|CD5789 50 mcg/g Cream|Participants randomized in stratum 1, 2 and 3 were applied with 50 mcg/g CD5789 50 once daily for 12 weeks.
89591085|NCT01616654|Active Comparator|CD5789 100 mcg/g Cream|Participants randomized in stratum 1, 2 and 3 were applied with 100 mcg/g CD5789 cream, once daily for 12 weeks.
89591086|NCT01616654|Placebo Comparator|Tazarotene 0.1% Gel|Participants randomized in stratum 1 and 2 were applied with Tazarotene 0.1% Gel, once daily for 12 weeks.
89591087|NCT01616654|Experimental|Vehicle Cream|Participants randomized in stratum 1, 2 and 3 were applied with Vehicle Cream once daily for 12 weeks.
89591088|NCT01902290|Placebo Comparator|Placebo|Participants received placebo administered by subcutaneous injection on day 1, week 1, week 2 and every 2 weeks thereafter for 24 weeks.
89591089|NCT01902290|Experimental|Brodalumab 210 mg|Participants received 210 mg brodalumab administered by subcutaneous injection on day 1, week 1, week 2, and every 2 weeks thereafter for 24 weeks.
89591090|NCT01467466|Active Comparator|Saline & oral placebo|IV isotonic saline and oral placebo drug capsule
89591091|NCT01467466|Active Comparator|Saline & oral N-acetylcysteine|IV isotonic saline and oral N-acetylcysteine drug capsule
89591092|NCT01467466|Active Comparator|Bicarbonate & oral placebo|IV isotonic bicarbonate and oral placebo drug capsule
89591093|NCT01467466|Active Comparator|Bicarbonate & oral N-acetylcysteine|IV isotonic bicarbonate and oral N-acetylcysteine drug capsule
89591094|NCT01441180|Experimental|Phase 1|Participants (N =10) will receive GS-7977 QD in combination with RBV for a total of 24 weeks. The study team will perform an interim evaluation of data and safety at the end of 12 weeks of treatment.
89591095|NCT01441180|Active Comparator|Phase 2 Arm A|(N =25) 24 weeks of GS-7977 QD in combination with weight based RBV (1000 mg for participants weighing <75 kg and 1200 mg for participants weighing ≥75kg)
89591096|NCT01441180|Active Comparator|Phase 2 Arm B|(N = 25): 24 weeks of GS-7977 QD with low dose RBV (600mg).
89591097|NCT01441102|Experimental|Dextromethorphan hydrobromide|
89591098|NCT04061980|Experimental|Arm I (encorafenib, binimetinib)|Patients receive encorafenib PO QD and binimetinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89591099|NCT04061980|Experimental|Arm II (encorafenib, binimetinib, nivolumab) - CLOSED|Patients receive encorafenib PO QD and binimetinib PO BID as in arm I. Patients also receive nivolumab IV over 30 minutes on day 1. Cycles with nivolumab repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
89591100|NCT01467076|Active Comparator|Inhaled PGE1 (150 ng/kg/min)|150 ng/kg/min Inhaled PGE1
89591101|NCT01467076|Placebo Comparator|Aerosolized Normal Saline|Eligible infants will be randomly assigned to either IPGE1 [150ng/kg/min], IPGE1 [300ng/kg/min] or control group. Infants in the control group will receive the same volume of aerosolized saline and oxygen from the respirator.
89591102|NCT01467076|Active Comparator|Inhaled PGE1 (300 ng/kg/min)|300 ng/kg/min of Inhaled PGE1
88977047|NCT02963389|Experimental|Tripegfilgrastim 60ug/kg, >=6 and <12-year-old patients|A single dose of Tripegfilgrastim 60ug/kg, S.C, 24hr after completion of chemotherapy
89591103|NCT01466062|Experimental|Palivizumab|15 mg/kg at 30-day intervals; at least 4 intramuscular injections up to a maximum of 7 intramuscular injections as appropriate for prophylaxis of severe respiratory syncytial virus (RSV) during the RSV season.
89591104|NCT04504864|Experimental|low-dose aspirin|Management policy is to use 50 mg aspirin per day as a secondary prevention strategy for patients with non-cardioembolic ischemic stroke and microbleeds. 50mg aspirin is recommended by the guideline of ASA/AHA in prevention of stroke. But this dose is rarely used clinically, especially in East Asia area.
89591105|NCT04504864|Active Comparator|conventional-does aspirin|Management policy is to use 100 mg aspirin per day as a secondary prevention strategy for patients with non-cardioembolic ischemic stroke and microbleeds. 100mg aspirin is recommended by the guideline of ASA/AHA in prevention of stroke, and this dose is widely used clinically.
89591106|NCT04060342|Experimental|Phase 1: Regimen A - GB1275 monotherapy|GB1275 Monotherapy dose escalation: Oral administration. Twice per day (BID).
89591107|NCT04060342|Experimental|Phase 1: Regimen B - GB1275 with an Anti-PD-1|"GB1275 with pembrolizumab dose escalation and expansion:~GB1275 oral administration; twice per day (BID), and pembrolizumab IV administration once every 3 weeks (Q3W)."
89591108|NCT04060342|Experimental|Phase 1: Regimen C - GB1275 with Standard of Care (SOC)|"GB1275 with SOC dose escalation:~GB1275 oral administration; twice per day (BID), and nab-paclitaxel and gemcitabine per United States Prescribing Information (USPI)"
89591109|NCT04060342|Experimental|Phase 2: Cohort 1 - GB1275 with SOC|"GB1275 with SOC Basket Cohort in patients with newly diagnosed metastatic pancreatic cancer:~GB1275 oral administration; twice per day (BID) and nab-paclitaxel and gemcitabine per USPI."
89591110|NCT04060342|Experimental|Phase 2: Cohort 2 - GB1275 with an Anti-PD-1|"GB1275 with pembrolizumab Basket Cohort in patients with MSS colorectal cancer:~GB1275 oral administration; twice per day (BID), and pembrolizumab IV administration once every 3 weeks (Q3W)."
89591111|NCT04060342|Experimental|Phase 2: Cohort 3 - GB1275 with an Anti-PD-1|"GB1275 with pembrolizumab Basket Cohort in patients with gastric/GEJ cancer, PD-L1 positive:~GB1275 oral administration; twice per day (BID), and pembrolizumab IV administration once every 3 weeks (Q3W)."
89591112|NCT01435018|Experimental|ET+ART|Etoposide (ET) plus co-formulated Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF)
89591113|NCT01435018|Experimental|BV+ART|Bleomycin and Vincristine (BV) plus co-formulated Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF)
89591114|NCT01435018|Active Comparator|PTX+ART|Paclitaxel (PTX) plus co-formulated Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF)
89591115|NCT01419184|Experimental|Daptomycin|4 milligrams per kilogram (mg/kg) daptomycin administered intravenously (IV) once a day until end of antibiotic therapy for complicated skin and skin structure infections (cSSSI) or until hospital discharge, whichever occurred first. Investigators treated participants according to their usual decision-making and discretion.
89591116|NCT01419184|Active Comparator|Vancomycin|Vancomycin was reconstituted per the manufacturer's instructions and was dosed per investigator's discretion and was administered IV until end of antibiotic therapy for cSSSI or until hospital discharge, whichever occured first. Investigators treated participants according to their usual decision-making and discretion
89591117|NCT03848962||Subjects for observational study|Various conditions & healthy subjects
89591118|NCT01417234||SNaP® Wound Care System|
89591119|NCT01417156|Experimental|All patients|
88977048|NCT02963389|Experimental|Tripegfilgrastim 60ug/kg, >=12 and <19-year-old patients|A single dose of Tripegfilgrastim 60ug/kg, S.C, 24hr after completion of chemotherapy
88977049|NCT02963389|Experimental|Tripegfilgrastim 100ug/kg, >=6 and <12-year-old patients|A single dose of Tripegfilgrastim 100ug/kg, S.C, 24hr after completion of chemotherapy
88977050|NCT02963389|Experimental|Tripegfilgrastim 100ug/kg, >=12 and <19-year-old patients|A single dose of Tripegfilgrastim 100ug/kg, S.C, 24hr after completion of chemotherapy
88977051|NCT00183547|Experimental|1|"Living in Harmony depression prevention program"
88977052|NCT00183547|Active Comparator|2|Depression-prevention education and support
88977053|NCT00057512|Experimental|Intratumoral M4N|The initial dose was 5 mg/cm3 of tumor volume on Days 1, 8, and 15. Dose escalation in cohorts on this schedule took place up to 20 mg/cm3 tumor volume. The dose per lesion was based upon the volume of tumor, and the total dose did not exceed 1197 mg M4N/m2 body surface area.
88977054|NCT00183586|Experimental|1|Participants will receive family-based treatment
88977055|NCT00183586|Active Comparator|2|Participants will receive individual adolescent focused therapy
88977056|NCT00183703||Qualitative Interview|Participants with rapid cycling bipolar disorder (RCBPD)
88977057|NCT02965248|Active Comparator|Arm A|Patients undergo radical resection of colorectal cancer (open/laparoscopic) and receive standard adjuvant systemic chemotherapy comprising mFOLFOX6/CapeOx/sLV5FU2/Cape. Systemic chemotherapy will continue for 6 months.
89030878|NCT02948205|Other|normal group|infertility patient get normal laparoscopic surgery
89030879|NCT05148377|Experimental|Sodium heparin (Heptar)|Sodium heparin (Heptar®) produced by Eurofarma Laboratory,
89030880|NCT05148377|Active Comparator|Liquemine®|Roche Lab's Liquemine®
89591120|NCT01417078|Experimental|Diazepam Nasal Spray|
89591121|NCT01954394|Experimental|Alirocumab 75 or 150 mg Q2W|Alirocumab 75 mg or 150 mg every 2 weeks (Q2W) added to stable lipid-modifying therapy (LMT) for up to 168 additional weeks (or until the product was commercially available) in participants who completed the parent studies EFC12492, R727-CL-1112, EFC12732 and LTS11717.
89591122|NCT01464424|Other|TRAVATAN, then LUMIGAN|Travoprost 0.004% ophthalmic solution (TRAVATAN), 1 drop to the study eye once daily every evening at 8:00 pm for 6 weeks, followed by bimatoprost 0.01% ophthalmic solution (LUMIGAN), same dose, same duration, as randomized, for a total duration of 12 weeks
89591123|NCT01464424|Other|LUMIGAN, then TRAVATAN|Bimatoprost 0.01% ophthalmic solution (LUMIGAN), 1 drop to the study eye once daily every evening at 8:00 pm for 6 weeks, followed by travoprost 0.004% ophthalmic solution (TRAVATAN), same dose, same duration, as randomized, for a total duration of 12 weeks
89591124|NCT01902134|Experimental|DKP/TRAM followed by DKP/TRAM|Dexketoprofen/Tramadol-single dose followed by Dexketoprofen/Tramadol-multiple doses
89591125|NCT01902134|Active Comparator|DKP followed by DKP|Dexketoprofen-single dose followed by Dexketoprofen-multiple doses
89591126|NCT01902134|Active Comparator|TRAM followed by TRAM|Tramadol-single dose followed by Tramadol-multiple doses
89591127|NCT01902134|Other|Placebo followed by DKP/TRAM|Placebo single dose followed by Dexketoprofen/Tramadol-multiple doses
89591128|NCT01902134|Other|Placebo followed by DKP|Placebo single dose followed by Dexketoprofen-multiple doses
89591129|NCT01902134|Other|Placebo followed by TRAM|Placebo single dose followed by Tramadol-multiple doses
89591130|NCT05110586|Experimental|1st group: TENS|Tens will be applied.
89591131|NCT05110586|Experimental|2nd group: Interferential current|Interferential current will be applied.
88977058|NCT02965248|Experimental|Arm B|Patients undergo radical resection of colorectal cancer (open/laparoscopic) and receive standard adjuvant systemic chemotherapy comprising mFOLFOX6/CapeOx/sLV5FU2/Cape. Systemic chemotherapy will continue for 6 months. Patients also undergo HIPEC with raltitrexed (3mg/m2) intraperitoneally for 60 minutes during surgery or within 10 days after the operation.
88977059|NCT02965248|Experimental|Arm C|Patients undergo radical resection of colorectal cancer (open/laparoscopic) and receive standard adjuvant systemic chemotherapy comprising mFOLFOX6/CapeOx/sLV5FU2/Cape. Systemic chemotherapy will continue for 6 months. Patients also undergo HIPEC comprising oxaliplatin (130mg/m2) intraperitoneally during surgery and hyperthermia for 30 minutes, following leucovorin calcium (20mg/m2 intravenously) and 5-FU (400 mg/m2 intravenously)
89591132|NCT01954082|Experimental|myo-Inositol 5% Injection|Within 12-72 hours of birth, infants will receive 80 mg myo-inositol 5% Injection per kilogram per day, administered in divided doses every 12 hours (40 mg/kg/dose). Study drug will be administered daily and continued until the earliest of 34 completed weeks PMA, 10 weeks (70 days) chronologic age, or the time of discharge. myo-Inositol 5% Injection will be administered IV until enteral feedings are established, at which time the same dose and formulation will be administered enterally every 12 hours.
89591133|NCT01954082|Placebo Comparator|5% glucose(dextrose)|Within 12-72 hours of birth, infants will receive 80 mg 5% glucose(dextrose) USP for intravenous infusion per kilogram per day, administered in divided doses every 12 hours (40 mg/kg/dose). Study drug will be administered daily and continued until the earliest of 34 completed weeks PMA, 10 weeks (70 days) chronologic age, or the time of discharge. myo-Inositol 5% Injection will be administered IV until enteral feedings are established, at which time the same dose and formulation will be administered enterally every 12 hours.
88977060|NCT00183820|Experimental|1|
88977061|NCT02969720|Experimental|Phytosterol|Daily consumption of 2 grams (8 ml) nano-phytosterols per 180 days.
89591134|NCT01417000|Experimental|Cy/GVAX + CRS-207|200 mg per square meter (mg/m^2) cyclophosphamide (Cy) administered by intravenous (IV) infusion on Day 1 of Weeks 1 and 4; GVAX pancreas vaccine (GVAX, 5 × 10e8 cells) administered by intradermal injection on Day 2 of Weeks 1 and 4; CRS-207 (1 × 10e9 colony forming units [CFU]) administered by IV infusion on Day 1 of Weeks 7, 10, 13, 16.
89591135|NCT01417000|Experimental|Cy/GVAX|200 mg/m^2 Cy administered by IV infusion on Day 1 of Weeks 1, 4, 7, 10, 13, 16; GVAX (5 × 10e8 cells) administered by intradermal injection on Day 2 of Weeks 1, 4, 7, 10, 13, 16.
89591136|NCT01416610||All Participants|Participants with chronic hepatitis C, Genotype 2, 3, 1 or 4, undergoing an opioid maintenance therapy
88977062|NCT02969720|Placebo Comparator|Placebo|Daily consumption of 8 ml of a solution with Titanium Dioxide per 180 days.
88977063|NCT00183859|Experimental|A|Intraperitoneal Irinotecan
88977064|NCT02963428|No Intervention|Standard of Care (SOC)|Participants will receive the usual standard of care which includes written educational materials as well as counseling by their obstetric care provider.
88977065|NCT02963428|Experimental|Enhanced Care (EC)|"In addition to standard of care, the study participants will also receive:~i. An initial consult with a licensed, Registered Dietician Nutritionist (RDN); ii. Regular tele-health check-ups (10-20 mins/check-up) with the RDN until delivery; iii. Exposure to personal GWG chart; iv. Letter from physician stating the recommendations for GWG over the course of the pregnancy."
88977066|NCT03898050|Experimental|A-P|Anterior - Posterior pad placement
88977067|NCT03898050|Experimental|A-L|Anterior - Lateral pad placement
88977068|NCT00183898|Experimental|Oxaliplatin and Capecitabine|Oxaliplatin given every 21 days Capecitabine given daily x 14 days every 21 days
88977069|NCT04730765||Surgical Experimental Group|Patient operated between 01/02/2021 and 30/07/2021, in elective situation of sigmoid diverticulitis
88977070|NCT04730765||Medical Control Group|Patient not operated and medically treated
88977071|NCT00183937|Experimental|Bortezomib and Docetaxel|Bortezomib 1.6 mg/m2 Docetaxel 75 mg/m2
88977072|NCT02963467|Other|Healthy Volunteers - non-smokers|control group: After baseline measurements V/Q will be measured by MIGET. After a 2 hour wash out period, the Volunteers will smoke a dummy cigarette. Then V/Q will be measured again after 15 minutes.
88977073|NCT02963467|Other|Healthy Volunteers - occasional smokers|intervention: After baseline measurements V/Q will be measured by MIGET. After a 2 hour wash out period, the Volunteers will smoke 4 conventional cigarettes. Thereafter, V/Q will be measured again after 15, 30, 45, 60 and 120 minutes.
88977074|NCT02963467|Other|Healthy Volunteers - heavy-smokers|intervention: After baseline measurements V/Q will be measured by MIGET. After a 2 hour wash out period, the Volunteers will smoke 4 conventional cigarettes. Thereafter, V/Q will be measured again after 15, 30, 45, 60 and 120 minutes.
88977075|NCT00408772|Experimental|Unresectable colorectal liver mets|
88977076|NCT00408850|Active Comparator|Pioglitazone|pioglitazone 15 mg for 6 weeks followed by 30 mg for 6 weeks
88977077|NCT00408850|Placebo Comparator|sugar pill|Placebo comparator
89591137|NCT01416142|Active Comparator|Spectacles|The subject's habitual spectacles (updated or confirmed as correct within the last 2 years)
89591138|NCT01416142|Experimental|PureVision2 HD contact lenses|Currently marketed Bausch + Lomb PureVision2 HD contact lenses
89591139|NCT01415986|Experimental|Subjects receiving Temoporfin|
89591140|NCT01415908|Active Comparator|Control Group|
89591141|NCT01415908|Experimental|Investigational Group|
89591142|NCT01415518|Other|1|budesonide/formoterol (Symbicort Turbuhaler 160/4.5µg/inhalation, 2 inhalations twice daily) added to ipratropium (AtroventTM 20 µg/inhalation, 2 inhalations four times daily) + theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)
89591143|NCT01415518|Other|2|ipratropium (AtroventTM 20 µg/inhalation, 2 inhalations four times daily) + theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)
88977078|NCT00408967|Experimental|Tucotuzumab celmoleukin (EMD 273066)|
88977079|NCT00184015|Experimental|Schedule A|
88977080|NCT00184015|Experimental|Schedule B|
89030881|NCT00523029|Experimental|1|Participants will receive a chronic disease self-management program
89591144|NCT04058392|Experimental|Camu Camu|Assessments will be done at baseline, during and after 12 weeks of Camu Camu intake.
89591145|NCT04057846|Active Comparator|Double pigtail|Plastic stent group EUS-guided drainage shall be performed as follows: a) Puncture of WON with a 19 GA Access needle (Cook Medical), b) aspiration of fluid in WON for microbiological assessment, c) insertion of guidewire (0.035 inch, 450 cm, Dreamwire (Boston Scientific), d) creation of transmural tract with needle knife over the guidewire, e) dilatation of tract to a diameter of 15 mm with dilation balloon (EZDilate, Olympus), f) insertion of two 7-Fr/6 cm double pigtail stents and a 7-Fr naso-cystic irrigation catheter.
89591146|NCT04057846|Experimental|Lumen apposing metal stent|LAMS shall be the Hot AXIOS stent with electrocautery-enhanced delivery system (Boston Scientific). The stent is a through-the-scope, fully covered, self-expandable metal stents with a diameter of 20 mm and a length of 10 mm. Before placement of the LAMS, the WON shall be punctured with a 19 GA Access needle (Cook Medical) and fluid in WON aspirated for microbiological assessment. Thereafter the LAMS shall be placed as follows: After directly puncturing the WON using the electrocautery tip (without the use of a guidewire to assist in stent insertion), the delivery catheter is advanced into the WON and the distal flange is deployed under EUS-guidance. The proximal flange is then released under EUS guidance or endoscopic view. After placement of the LAMS, a 7-Fr/4cm double pigtail and a 7-Fr nasocystic irrigation catheter shall be placed through the LAMS.
89591147|NCT04767412|Active Comparator|aerobic exercise|
89591148|NCT04767412|Active Comparator|aerobic exercise and inspiratory muscle training|
89591149|NCT01393600|Experimental|NBI-98854 12.5 mg|"During the Cross-Over Study, subjects will be randomly assigned to receive one of the following treatment sequences:~Sequence 1: Placebo once daily dose for Days 1-14 and 12.5 mg NBI-98854 once daily dose for Days 15-28.~Sequence 2: 12.5 mg NBI-98854 once daily dose for Days 1-14 and placebo once daily dose for Days 15-28."
89591150|NCT01393600|Experimental|NBI-98854 50 mg|"During the Cross-Over Study, subjects will be randomly assigned to receive one of the following treatment sequences:~Sequence 3: Placebo once daily dose for Days 1-14 and 50 mg NBI-98854 once daily dose for Days 15-28.~Sequence 4: 50 mg NBI-98854 once daily dose for Days 1-14 and placebo once daily dose for Days 15-28."
89591151|NCT01432756|No Intervention|Wait-list control|Participants in the wait-list control group will not receive the intervention until after the 3-month follow-up assessment.
89591152|NCT01432756|Experimental|Let's Talk Worskite Parenting Program|The Let's Talk Worksite Parenting Program is designed for Xhosa-speaking and Afrikaans speaking parents (separate sessions) with 11- to 15-year-old children. The 5-session program meets weekly for 2 hours. The program will include instruction on parenting skills and will cover topics relevant to promoting adolescent sexual health, such as; parental involvement; adolescent sexual behavior; HIV; violence; and alcohol/substance use. Parent participants will receive weekly exercises to help them practice their new skills at home with their child.
89591153|NCT04767178||Ibuprofen group|Infants that received oral ibuprofen were categorized into the ibuprofen group
89591154|NCT04767178||Paracetamol group|Infants that received oral paracetamol were categorized into the paracetamol group
89591155|NCT01432600|Experimental|A: Dose Escalation of Cyclophosphamide|"Phase I: Pomalidomide, high dose dexamethasone and oral cyclophosphamide:~Pomalidomide 4 mg by mouth (PO) days 1-21 of a 28 days cycle.~Dexamethasone 40* mg PO days 1- 4, 15-18 of a 28 days cycle for the first 4 cycles and subsequently 40 mg PO Days 1,8,15, 22. *Participants who were >75 years of age or those who were known to be intolerant to 40 mg weekly dexamethasone received 20 mg dexamethasone on the same schedule.~Dose Escalation of Cyclophosphamide, orallly (PO) days 1, 8, 15 as follows:~Level 1: 300 mg; Level 2: 400 mg; Level 3: 500 mg.~Aspirin 81 mg PO daily (unless the participants had contraindications or were receiving other form of anticoagulation for other indications)."
89591156|NCT01432600|Active Comparator|B: Pomalidomide and Dexamethasone|"Randomized Phase II - Pomalidomide high dose dexamethasone:~Pomalidomide 4 mg PO days 1-21 of a 28 days cycle.~Dexamethasone 40* mg PO Days 1,8,15, 22. *Participants who were >75 years of age or those who were known to be intolerant to 40 mg weekly dexamethasone received 20 mg dexamethasone on the same schedule.~Aspirin 81 mg PO daily (unless the participants had contraindications or were receiving other form of anticoagulation for other indications)."
89591157|NCT01432600|Active Comparator|C: Pomalidomide/Dexamethasone/Cyclophosphamide|"Randomized Phase II - Pomalidomide high dose dexamethasone and oral cyclophosphamide:~Pomalidomide 4 mg PO days 1-21 of a 28 days cycle.~Dexamethasone 40* mg PO days 1- 4, 15-18 of a 28 days cycle for the first 4 cycles and subsequently 40 mg PO Days 1,8,15, 22. *Participants who were >75 years of age or those who were known to be intolerant to 40 mg weekly dexamethasone received 20 mg dexamethasone on the same schedule.~Cyclophosphamide 400 mg PO days 1, 8, 15.~Aspirin 81 mg PO daily (unless the participants had contraindications or were receiving other form of anticoagulation for other indications)."
89591158|NCT01432600|Other|D: Crossover|Crossover from Arm B to Arm D. Participants who experienced progressive disease in arm B were allowed to crossover to arm D at the discretion of the treating physician, in which case oral weekly Cyclophosphamide (400 mg orally on days 1, 8, and 15) was added to their tolerated dose of pomalidomide and dexamethasone.
89591159|NCT01432444|Experimental|OPC-14597|Aripiprazole IM depot injection 300 mg or 400 mg.
89591160|NCT01432366||Rheumatoid arthritis patients treated with SC anti-TNF|
89591161|NCT01415440|Experimental|Psychostimulant|30-70 mg capsule of Lisdexamfetamine once daily for 12 weeks
89591162|NCT01415440|Placebo Comparator|Placebo|30-70 mg capsule of placebo (sugar pill) once daily for 12 weeks
89591163|NCT02076412|Experimental|Fostamatinib Disodium|Fostamatinib Disodium tablet 100 mg or 150 mg PO bid (morning and evening) over the course of 24 weeks.
89591164|NCT02076412|Other|Placebo|Placebo tablet PO bid (morning and evening) over the course of 24 weeks
89591165|NCT04048252||Focus group|
89591166|NCT04048252||Workshop|
89591167|NCT01932788|Active Comparator|Vitamin D 4000 IU|Subjects randomized into this arm will receive supplementation with 4000 IU/day vitamin D3 in gummy vitamin form, plus the standard prenatal vitamin (containing 400 IU vitamin D3.
89591168|NCT01932788|Placebo Comparator|placebo gummy vitamin|Supplementation with placebo gummy vitamin form, plus the standard prenatal vitamin (containing 400 IU vitamin D3)
89030882|NCT00524199|Placebo Comparator|Placebo|Saline IV infusion over five minutes at the beginning of dialysis.
89030883|NCT00524199|Active Comparator|Mesna|12 mg/kg mesna IV infusion over five minutes at the beginning of dialysis.
89030884|NCT00523068|Active Comparator|1|Tension Free Vaginal Tape
89030885|NCT00523068|Active Comparator|2|Tolterodine tartrate 4mg
89591169|NCT01414738|Experimental|Radiation|Whole-Brain Radiotherapy
89591170|NCT01414114|Experimental|Etelcalcetide|Participants received etelcalcetide three times a week (TIW) administered by intravenous bolus injection at the end of each hemodialysis session for 12 weeks. The starting dose was 5 mg and may have been titrated every 4 weeks based on the preceding serum parathyroid hormone (PTH) and corrected calcium (cCa) levels to a maximum dose of 20 mg per hemodialysis session in order to achieve the targeted PTH range while maintaining serum calcium within an acceptable range.
89591171|NCT01393444|Experimental|Direct Brain Interface Users|"All participants enrolled in the study will undergo Implantation of ECoG sensors on the brain surface to record neural activity. There is no control group. There are no other arms."
89591172|NCT01431976|Experimental|Lamotrigine|No comparison
89591173|NCT01392742||Cohort|
89591174|NCT01413958|Experimental|Phenylephrine|
89591175|NCT01413958|Placebo Comparator|Placebo|
89591176|NCT02985502||pancreatogenic diabetes|patients with pancreatogenic diabetes after pancreatectomy will be recruited
89591177|NCT01413178|Experimental|Busulfan + Melphalan|Busulfan test dose (32 mg/m^2) on day -9 then 130 mg/m^2 intravenous (IV) Days -7, -6, -5, and -4 + Melphalan 70 mg/m2 IV on Days -2 and -1. Stem Cell Transplant (SCT) Day 0.
89591178|NCT01413178|Experimental|Melphalan|High-dose Melphalan 200 mg/m2/day IV over 30 minutes on day -2. SCT Day 0.
89591179|NCT01799889|Experimental|CLL, Entospletinib MM/SDD|Participants with CLL, receive original formulation (mono-mesylate [MM]) of entospletinib 800 mg (4 × 200 mg tablets) (before amendment 8) or new formulation of entospletinib (spray dried dispersion [SDD]) 400 mg (2 × 200 mg tablets) (after amendment 8) orally twice daily. Treatment with entospletinib will continue until disease progression or unacceptable toxicity.
89591180|NCT01799889|Experimental|FL, Entospletinib MM/SDD|Participants with FL, receive original formulation of entospletinib 800 mg (4 × 200 mg tablets) (before amendment 8) or new formulation of entospletinib 400 mg (2 × 200 mg tablets) (after amendment 8) orally twice daily. Treatment with entospletinib will continue until disease progression or unacceptable toxicity.
89591181|NCT01799889|Experimental|DLBCL, Entospletinib MM/SDD|Participants with DLBCL, receive original formulation of entospletinib 800 mg (4 × 200 mg tablets) (before amendment 8) or new formulation of entospletinib 400 mg (2 × 200 mg tablets) (after amendment 8) orally twice daily. Treatment with entospletinib will continue until disease progression or unacceptable toxicity.
89591182|NCT01799889|Experimental|MCL, Entospletinib MM/SDD|Participants with MCL, receive original formulation of entospletinib 800 mg (4 × 200 mg tablets) (before amendment 8) or new formulation of entospletinib 400 mg (2 × 200 mg tablets) (after amendment 8) orally twice daily. Treatment with entospletinib will continue until disease progression or unacceptable toxicity.
89591183|NCT01799889|Experimental|non-FL iNHL, Entospletinib MM/SDD|Participants with non-FL iNHL (ie, participants with LPL/WM, SLL, or MZL), receive original formulation of entospletinib 800 mg (4 × 200 mg tablets) (before amendment 8) or new formulation of entospletinib 400 mg (2 × 200 mg tablets) (after amendment 8) orally twice daily. Treatment with entospletinib will continue until disease progression or unacceptable toxicity.
89591184|NCT01799889|Experimental|CLL; Prior BCR Inhibitor Naive, Entospletinib SDD 100 mg|Participants with CLL, who are prior B-cell receptor (BCR) inhibitor naive, receive new formulation of entospletinib 100 mg (1 × 100 mg tablet) orally twice daily. Treatment with entospletinib will continue until disease progression or unacceptable toxicity.
89591185|NCT01799889|Experimental|CLL; Prior BCR Inhibitor Naive, Entospletinib SDD 200 mg|Participants with CLL, who are prior BCR inhibitor naive, receive new formulation of entospletinib 200 mg (1 × 200 mg tablet) orally twice daily. Treatment with entospletinib will continue until disease progression or unacceptable toxicity.
89591186|NCT01799889|Experimental|CLL; Prior BCR Inhibitor Naive, Entospletinib SDD 400 mg|Participants with CLL, who are prior BCR inhibitor naive, receive new formulation of entospletinib 400 mg (2 × 200 mg tablets) orally twice daily. Treatment with entospletinib will continue until disease progression or unacceptable toxicity.
89591187|NCT01799889|Experimental|CLL (Non-Richters) Prior BTK Inhibitor, Entospletinib SDD|Participants with CLL and simple progression (non-Richters), who are exposed to Bruton tyrosine kinase (BTK) inhibitor, receive new formulation of entospletinib 400 mg (2 × 200 mg tablets) orally twice daily. Treatment with entospletinib will continue until disease progression or unacceptable toxicity.
89591188|NCT01799889|Experimental|CLL (Non-Richters) Prior PI3K Inhibitor, Entospletinib SDD|Participants with CLL and simple progression (non-Richters), who are exposed to phosphatidylinositol 3-kinase (PI3K) inhibitor, receive new formulation of entospletinib 400 mg (2 × 200 mg tablets) orally twice daily. Treatment with entospletinib will continue until disease progression or unacceptable toxicity.
89591189|NCT01799889|Experimental|CLL (Richters) Prior BTK Inhibitor, Entospletinib SDD|Participants with CLL, who transform to Richters or Richters-like syndrome and are exposed to BTK inhibitor, receive new formulation of entospletinib 400 mg (2 × 200 mg tablets) orally twice daily. Treatment with entospletinib will continue until disease progression or unacceptable toxicity.
89591190|NCT01799889|Experimental|CLL (Richters) Prior PI3K Inhibitor, Entospletinib SDD|Participants with CLL, who transform to Richters or Richters-like syndrome and are exposed to PI3K inhibitor, receive new formulation of entospletinib 400 mg (2 × 200 mg tablets) orally twice daily. Treatment with entospletinib will continue until disease progression or unacceptable toxicity.
89030886|NCT00524238|Other|1|11 hypothyroid patients, newly diagnosed, examined before and after treatment
89030887|NCT00524238|No Intervention|2|10 healthy controls
89030888|NCT02276378|Experimental|Telmisartan low / HCTZ fixed-dose combination, fed|
89030889|NCT02276378|Experimental|Telmisartan high / HCTZ fixed-dose combination, fed|
89030890|NCT02276378|Active Comparator|Telmisartan low /HCTZ fixed-dose combination, fasted|
89030891|NCT02276378|Active Comparator|Telmisartan high /HCTZ fixed-dose combination, fasted|
89591191|NCT01412944|Experimental|AIN457 subcutaneous (s.c.)|During the intravenous (I.V.) period, participants received two 150 mg s.c. injections of AIN457 at randomization and week 4, and AIN457 placebo I.V. at randomization, week 2 and week 4. During the maintenance period, participants received 300 mg s.c. of open-label AIN457.
89591192|NCT01412944|Experimental|AIN457 I.V.|During the I.V. period, participants received AIN457 10mg/kg I.V. at randomization, week 2 and week 4, and AIN457 placebo s.c. at randomization and week 4. During the maintenance period, participants received 300 mg s.c. of open-label AIN457.
89591193|NCT03025672||clostridium difficile|Patients that have been infected by clostridium difficile during their stay in hospital
89591194|NCT03025672||no clostridium difficile|Patients that have not been infected during their stay in hospital.
89591195|NCT03025906|Experimental|Phenobarbital|In the PB group, a loading dose of 20 mg/kg (may give an additional 10 mg/kg) begins at a rate of 50 mg/min followed by IV 100 mg q6 h.
89591196|NCT03025906|Experimental|Valproate|In the VPA group, a loading dose of 30 mg/kg (may give an additional 15 mg/kg) begins at a rate of 3 mg/kg per min followed by a continuous infusion at a rate of 1-2 mg/kg per hour.
89591197|NCT04055272|Experimental|Text messaging|Participants in the text messaging intervention arm receive mobile text messages communicating the risks of indoor tanning and motivating cessation on their mobile phones
89591198|NCT04055272|No Intervention|Control|Participants in the control arm receive no intervention
89591199|NCT04053712|Placebo Comparator|Single-hormone|FiAsp (R) - Saline
89591200|NCT04053712|Active Comparator|Dual-hormone|FiAsp(R) - GlucaGen(R)
89591201|NCT01798485|Experimental|Ganetespib and Docetaxel|Ganetespib (150 mg/m^2) and docetaxel (75 mg/m^2) were administered as separate 1-hour IV infusions on Day 1 of each 3-week treatment cycle. Administration of ganetespib preceded the administration of docetaxel. Ganetespib was administered again on Day 15 of each cycle.
89591202|NCT01798485|Active Comparator|Docetaxel|Docetaxel (75 mg/m^2) was administered on Day 1 of a 3-week treatment cycle by 1-hour IV infusion.
89591203|NCT01767597|Active Comparator|ELISA testing|HBV infection status determined by enzyme-linked immuno-assay (ELISA)
89591204|NCT01767597|Experimental|Rapid testing|HBV infection status determined initially by a rapid test, then confirmed by enzyme-linked immuno-assay (ELISA).
89591205|NCT01767519|Experimental|BOTOX®|Treatment Cycle 1: BOTOX injected at Day 1 with one solifenacin placebo capsule taken orally once daily for up to 24 weeks. After a minimum of 12 weeks, patients could request/qualify for a second BOTOX injection.
89591206|NCT01767519|Active Comparator|solifenacin|Treatment Cycle 1: Oral solifenacin taken once daily starting at Day 1 for up to 24 weeks with intradetrusor injection of BOTOX placebo on Day 1. After a minimum of 12 weeks, patients could request/qualify for a BOTOX injection.
89591207|NCT01767519|Placebo Comparator|placebo|Treatment Cycle 1: One solifenacin placebo capsule taken orally once daily starting at Day 1 for up to 24 weeks with an intradetrusor injection of BOTOX placebo at Day 1. After a minimum of 12 weeks, patients could request/qualify for a BOTOX injection.
89591208|NCT01797783|Experimental|DAILIES® AquaComfort Plus® Multifocal|Nelfilcon A multifocal contact lens with comfort additive worn for 30 days on a daily wear, daily disposable basis
89591209|NCT01797783|Active Comparator|Focus® DAILIES® Progressives|Nelfilcon A multifocal contact lens worn for 30 days on a daily wear, daily disposable basis
89591210|NCT01766817|Experimental|Arm 1: BMS 986020, 600 mg. once daily|BMS-986020, 600 mg tablets, by mouth, once daily, 26 weeks
89591211|NCT01766817|Experimental|Arm 2: BMS-986020, 600 mg twice daily|BMS-986020, 600 mg tablets, by mouth, twice daily, 26 weeks
89591212|NCT01766817|Placebo Comparator|Arm 3: Placebo matching with BMS-986020|Placebo, 0 mg tablets, by mouth, twice daily, 26 weeks
89591213|NCT01797705|Experimental|All subjects|All subjects underwent a sleep study with DeVilbiss AutoAdjust CPAP with revised algorithm simultaneously with hand-scored PSG.
89591214|NCT01797081|Experimental|Botulinum toxin Type A (24U)|24 units (U) botulinum toxin Type A (total dose) injected into bilateral Crow's Feet Line areas on Day 1. Based on retreatment criteria participants were eligible for up to 5 treatment cycles.
89591215|NCT01797081|Experimental|Botulinum toxin Type A (12U)|12U botulinum toxin Type A (total dose) injected into bilateral Crow's Feet Line areas on Day 1. Based on retreatment criteria participants were eligible for up to 5 treatment cycles.
89591216|NCT01797081|Other|Placebo/Botulinum toxin Type A (24U)|Placebo (normal saline) one treatment injected into bilateral Crow's Feet Line areas on Day 1 and subsequent treatments if applicable until day 180. Botulinum toxin Type A (24U) injected into bilateral Crow's Feet Line areas at any additional treatments from day 180 onward. Based on retreatment criteria participants were eligible for up to 5 treatment cycles (2 Placebo + 3 botulinum toxin type A).
89591217|NCT01797081|Other|Placebo/Botulinum toxin Type A (12U)|Placebo (normal saline) one treatment injected into bilateral Crow's Feet Line areas on Day 1 and subsequent treatments if applicable until day 180. Botulinum toxin Type A (12U) injected into bilateral Crow's Feet Line areas at any additional treatments from day 180 onward. Based on retreatment criteria participants were eligible for up to 5 treatment cycles (2 Placebo + 3 botulinum toxin type A).
89591218|NCT01794117|Experimental|Arm A/Anakinra 100 mg/day|An initial dose of anakinra 100 mg/day will be administered daily via self-administered subcutaneous injection. If active disease persists at this dose, anakinra dose may be escalated up to 200 mg/day injected subcutaneously daily at week 4 and 300mg at week 8.
89591219|NCT01766037|Experimental|Aspiration Therapy|Aspiration Therapy and Lifestyle Therapy
89591220|NCT01766037|Active Comparator|Lifestyle Therapy|Lifestyle Therapy only
89591221|NCT04413903|Active Comparator|Pressure controlled ventilation, Volum controlled ventilation|Undergoing laparoscopic cholecystectomy surgery according to mechanical ventilator mode; Group P (n: 30) Pressure controlled ventilation was randomly divided into Group V (n: 30) volume controlled ventilation settings were adjusted to be 50% O2- 50% air, 8ml / kg TV (tidal volume) and PEEP 5.
89591222|NCT04413903|Active Comparator|Optic Nerve Sheath Diameter|In optic nerve diameter measurements; A layer of water-soluble sterile gel was applied to the closed upper eyelid. The linear 10-5 MHz ultrasound probe was carefully placed on the upper eyelid over the gel. The entrance of the optic nerve to the orbital globe in 2D mode was displayed on the monitor without applying too much pressure. After finding the optimal contrast between the retrobulbar echogenic fat tissue and vertical hypoechoic band 23, the diameter of the optic nerve sheath was measured 3 mm behind the optic disc using an electronic caliper.
89591223|NCT01765569|Experimental|Vemurafenib + Digoxin|Single oral dose of digoxin 0.25 mg tablet on Day 1 in Period A, followed by vemurafenib 960 mg tablet orally BID from Day 8 to Day 28 in Period B, and then single oral dose of digoxin 0.25 mg on Day 29, and vemurafenib 960 mg orally BID from Day 29 to Day 35 in Period C.
89591224|NCT04414605|Experimental|Chinese herbal medicine in combination with secukinumab|Oral Chinese herbal medicine (Gu Ben Hua Yu Fang decoction) and secukinumab will be used concurrently. The treatment duration for both secukinumab and oral Chinese herbal medicine is up to 16 weeks. Secukinumab will be administered by subcutaneous injection. The required dose (300 mg) is divided into two doses of 150 mg (contained in two separate syringes), which are injected at the same time. The first five doses (each consisting of 2 injections of 150 mg) are given at weekly intervals, with subsequent treatment given monthly (2 injections of 150 mg). Chinese herbal formula (Gu Ben Hua Yu Fang) decoction will be orally administrated twice a day. One pack of Gu Ben Hua Yu Fang will be taken for each time. Chinese herbal medicine (Gu Ben Hua Yu Fang) will not be used on the day of receiving secukinumab injection.
89591225|NCT01609257|Experimental|Norovirus Bivalent VLP Vaccine|Norovirus Bivalent virus like particle (VLP) Vaccine (50 μg of GI.1 Norwalk VLP and 50 μg of GII.4 cVLP) adjuvanted with MPL and AI(OH)3, intramuscular (IM), Days 0 and 28.
89591226|NCT01609257|Placebo Comparator|Placebo|Saline Placebo (0.9% sodium chloride (NaCl) and preservative-free), intramuscular (IM), Days 0 and 28.
89591227|NCT04569357|Experimental|Prospecta|One tablet per intake 2 times a day (approximately at the same time), outside of meal (between meals or 15 minutes prior to meal or drinking). The tablet should be held in mouth until completely dissolved.
89591228|NCT04569357|Placebo Comparator|Placebo|One tablet per intake 2 times a day (approximately at the same time), outside of meal (between meals or 15 minutes prior to meal or drinking). The tablet should be held in mouth until completely dissolved.
89591229|NCT01609023||Rituximab|Participants with chronic lymphocytic leukemia treated with rituximab in combination with chemotherapy according to SPC and routine clinical practice will be observed for 24 months.
89591230|NCT01765179|Experimental|Oral testosterone undecanoate|
89591231|NCT01764945|Experimental|1 BI 201335|low dose
89591232|NCT01764945|Experimental|2 BI 201335|high dose
89591233|NCT01793883|Active Comparator|40 mg Laninamivir Octanoate DPI|40 mg Laninamivir Octanoate and matching placebo
89591234|NCT01793883|Active Comparator|80 mg Laninamivir Octanoate DPI|80 mg Laninamivir
88977081|NCT00057629|Active Comparator|1 Prolonged Exposure|Prolonged Exposure (PE) consists of 10 weekly 90-minute treatment sessions, which may be extended up to 20 sessions, depending on client response. Treatment procedures include education about common reactions to trauma, breathing retraining, prolonged (repeated) exposure to trauma memories, repeated in vivo exposure to situations the client is avoiding due to trauma-related fear, and discussion of thoughts and feelings related to exposure exercises as well as beliefs about self and the world.
88977082|NCT00057629|Active Comparator|2 Individual and group therapy|"TUGT (Treatment as usual group therapy - used in Study 1), delivered in ten weekly sessions, with 5 to 7 members and two counselors per group. There is no formal, structured format for these groups; counselors are sensitive to the participants' needs and follow their lead re content covered in discussions and exercises.~Supportive counseling (SC - study 2): individual therapy delivered in 10 weekly, 90 minute sessions. Therapist helps patient identify daily stresses that may or may not be related to traumatic events and discusses them in a supportive non-directive mode with a problem-solving orientation. The goal of this present-focused treatment is to provide support and to help the client to identify problems and stresses of daily living and to help her cope with these."
88977083|NCT00184132|Experimental|Norwegian home style ward|The walls received wainscots, colourful wallpaper and paintings; the ceilings were lowered and had multiple lighting spots, the windows tasteful curtains; we put wardrobes, chairs, flowers and personal items in the patient rooms; and Italian ceramic tile covered the entire bathroom
88977084|NCT00184132|Active Comparator|sparsely furnished ward|traditional interior design and furnishings. The rooms had sparse furniture, walls in grey colours lacking pictures, no window curtains, single lamps in the ceiling 4 m high, bathroom with grey, laminated paint all over, and patient rooms with a single bed and a chair of metal tubes
88977085|NCT00184171|Experimental|Budesonide|Budesonide 9mg
88977086|NCT00184171|Experimental|bismuth|Bismuth mixture
88977087|NCT00184171|Sham Comparator|Fiber|Fiber preparation
88977088|NCT00184249|Experimental|Bipolar radiofrequency ablation|
88977089|NCT02963584|Experimental|intervention group|Patients in this group will receive CTO Choice (decision aid).
88977090|NCT02963584|No Intervention|control group|Patients in this group will receive usual primary care.
88977091|NCT00184444|Experimental|Hypoxic Interval training|4 x 4 minutes interval training with 100% oxygenated air
88977092|NCT00184444|Experimental|Normoxic interval training|4 x 4 minutes interval training in normoxic air
89591235|NCT01793883|Placebo Comparator|Placebo|Matching Placebo
89591236|NCT01792635|No Intervention|Part A (Pilot Study)|
89591237|NCT01792635|Experimental|Monotherapy (Part B)|
88977093|NCT00184483|Experimental|Lichtenstein's operation|Patients with a primary unilateral inguinal hernia are randomized to Lichtenstein's operation to repair their groin hernia
88977094|NCT00184483|Active Comparator|Prolene Hernia System|Patients with a primary unilateral inguinal hernia are randomized to Prolene Hernia System to repair their groin hernia
88977095|NCT02969759|Other|Patients|ALS defined by El Escorial Criteria.
88977096|NCT02969759|Other|Controls|Asymptomatic subjects with normal examination.
88977097|NCT00184522|Experimental|Aflurax|pectin-containing natural product
88977098|NCT00184522|Active Comparator|esomeprazole (Nexium)|esomeprazole (Nexium)
89591238|NCT01953692|Experimental|Cohort 1: Myelodysplastic Syndrome (MDS)|Participants received pembrolizumab 10 mg/kg by intravenous (IV) infusion on Day 1 of each 14-day cycle.
89591239|NCT01953692|Experimental|Cohort 2: Relapsed Refractory/Refractory (rR/R) Multiple Myeloma (MM)|Participants received pembrolizumab 200 mg by IV infusion on Day 1 of each 21-day cycle OR 10 mg/kg by intravenous (IV) infusion on Day 1 of each 14-day cycle.
89591240|NCT01953692|Experimental|Cohort 3: Relapsed/Refractory (R/R) Hodgkin lymphoma (HL)|Participants received pembrolizumab 10 mg/kg by intravenous (IV) infusion on Day 1 of each 14-day cycle.
88977099|NCT00058097|Experimental|Treatment (tipifarnib)|"INDUCTION THERAPY: Patients receive oral tipifarnib twice daily for 3 weeks. Treatment repeats every 4 weeks for up to 3 courses.~RADIOTHERAPY: Within 14 days after the completion of induction therapy, patients undergo radiotherapy daily, 5 days a week, for 6 weeks.~MAINTENANCE THERAPY: Two weeks after the completion of radiotherapy, patients receive additional tipifarnib as in induction therapy.~Treatment continues in the absence of disease progression or unacceptable toxicity."
89591241|NCT01953692|Experimental|Cohort 4A: R/R Primary Mediastinal B-cell Lymphoma (PMBCL)|Participants received pembrolizumab 200 mg by IV infusion on Day 1 of each 21-day cycle OR 10 mg/kg by intravenous (IV) infusion on Day 1 of each 14-day cycle.
88977100|NCT00184795|Experimental|ALD 0.1|
89591242|NCT01953692|Experimental|Cohort 4B: Other Non-Hodgkin Lymphoma: Grey Zone, Splenic Marginal Zone, and Mantle Cell Lymphomas|Participants received pembrolizumab 10 mg/kg by intravenous (IV) infusion on Day 1 of each 14-day cycle.
88977101|NCT00184795|Experimental|ALD 0.25|
88977102|NCT00184795|Placebo Comparator|Placebo|
88977103|NCT00058253|Experimental|Group I|Patients receive docetaxel IV over 1 hour and 17-AAG IV over 1-2 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89591243|NCT01953692|Experimental|Cohort 4C: R/R Follicular Lymphoma (FL)|Participants received pembrolizumab 200 mg by intravenous (IV) infusion on Day 1 of each 21-day cycle.
88977104|NCT00058253|Experimental|Group II|Patients receive docetaxel IV over 30 minutes and 17-AAG as in group 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88977105|NCT00184873|Active Comparator|Lifestyle counseling|Patients receiving lifestyle counseling
88977106|NCT00184873|No Intervention|Regular care|Patients receiving regular care
88977107|NCT00058292|Experimental|Treatment Arm|
89591244|NCT01953692|Experimental|Cohort 4D: R/R Diffuse Large B-Cell Lymphoma (DLBCL)|Participants received pembrolizumab 200 mg by intravenous (IV) infusion on Day 1 of each 21-day cycle.
89591245|NCT01953692|Experimental|Cohort 5: R/R DLBCL pembrolizumab+lenalidomide 20 mg|Participants received pembrolizumab 200 mg by intravenous (IV) infusion on Day 1 of each 21-day cycle + lenalidomide 20 mg orally (PO) every day (QD) for 21 consecutive days with 7 days off within 28-day cycles.
88977108|NCT03816774|No Intervention|PEG split-dose|Group A: PEG split dose ending 3 hours before colonoscopy
88977109|NCT03816774|Active Comparator|PEG split-dose and simethicone|Group B: 250mg simethicone pill 15 minutes before PEG dose on the previous evening plus 250mg simethicone pill 15 minutes before PEG dose ending 3 hours before colonoscopy
88977110|NCT02963545|Experimental|Patients presenting cerebral infarction|no intervention of health product administration,
88977111|NCT02963545|Other|Historical controls|no intervention of health product administration, patients characteristics, history, matched with patients for age, gender, tobacco consumption and season of inclusion, free of neurologic or psychiatric disease or psychotropic medications or medications known to impact on serotonin
88977112|NCT00058331|Experimental|epoetin alfa - long term dosing|"Patients receive epoetin alfa (EPO) subcutaneously (SC) once weekly for 3 weeks. Then patients receive EPO SC once weekly for 18 weeks. Quality of life is assessed at randomization at then monthly during study treatment.~Patients are followed every 6 months for 1 year."
88977113|NCT00058331|Experimental|epoetin alfa - short term dosing|"Patients receive epoetin alfa (EPO) subcutaneously (SC) once weekly for 3 weeks. Patients receive EPO SC on day 1 of weeks 4, 7, 10, 13, 16, and 19. Quality of life is assessed at randomization at then monthly during study treatment.~Patients are followed every 6 months for 1 year."
88977114|NCT00185185|Experimental|1|olmesartan medoxomil
88977115|NCT00185185|Active Comparator|2|atenolol
88977116|NCT00185224|Experimental|Arm 1|
88977117|NCT00185224|Active Comparator|Arm 2|
88977118|NCT00185263|Experimental|1|Ad5FGF-4
88977119|NCT00185263|Experimental|2|Ad5FGF-4
88977120|NCT00185263|Placebo Comparator|3|Placebo
88977121|NCT00185302|Experimental|Histone Deacetylase Inhibitor, 3 mg|Subjects received 3 mg MS-275 orally biweekly (Days 1 and 15 of a 4 week cycle) or until disease progression or unacceptable toxicity
88977122|NCT00185302|Experimental|Histone Deacetylase Inhibitor, 7 mg|Subjects received 7 mg MS-275 orally weekly (Days 1, 8, and 15 of a 4 week cycle) until disease progression or unacceptable toxicity
88977123|NCT00185341|Experimental|CCR-1 Receptor Antagonist|Subjects received 600 mg (2 x 300 mg tablets) of CCR-1 Receptor Antagonist 3 times daily
88977124|NCT00185341|Placebo Comparator|Placebo|Subjects received placebo corresponding to verum
88977125|NCT00409084|Active Comparator|1|endoscopic variceal band ligation
88977126|NCT00409084|Active Comparator|2|subjects will receive nadolol (beta blocker) at 20mg/day with dose titration
88977127|NCT00185419|Active Comparator|Arm 1|
88977128|NCT00185419|Active Comparator|Arm 2|
88977129|NCT00058526|Experimental|Cohort 1|Six doses of dHER2 (20 µg) + AS15 administered at Weeks 0, 2, 4, 6, 10 and 14.
88977130|NCT00058526|Experimental|Cohort 2|Six doses of dHER2 (100 µg) + AS15 administered at Weeks 0, 2, 4, 6, 10 and 14.
88977131|NCT00058526|Experimental|Cohort 3|Six doses of dHER2 (500 µg) + AS15 administered at Weeks 0, 2, 4, 6, 10 and 14. Patients in this cohort can receive two booster doses at Weeks 34 and 38, respectively.
88977132|NCT00058526|Experimental|Cohort 4|Three doses of dHER2 (20 µg) + AS15 administered at Weeks 0, 4, and 14. Patients in this cohort can receive two booster doses at Weeks 34 and 38, respectively.
89591246|NCT01953692|Experimental|Cohort 5: R/R DLBCL pembrolizumab+lenalidomide 25 mg|Participants received pembrolizumab 200 mg by intravenous (IV) infusion on Day 1 of each 21-day cycle + lenalidomide 25 mg PO QD for 21 consecutive days with 7 days off within 28-day cycles.
89591247|NCT01791153|Experimental|Part 1: Tocilizumab qw + 26 weeks prednisone taper|Participants will receive tocilizumab at a dose of 162 milligrams (mg) as subcutaneous (SC) injection qw up to 52 weeks along with prednisone and/or prednisone placebo according to the protocol-defined schedule. Participants will receive prednisone tapering oral daily doses during the first 26 weeks and prednisone placebo from Week 26 up to Week 52.
89591248|NCT01791153|Experimental|Part 1: Tocilizumab q2w + 26 weeks prednisone taper|Participants will receive tocilizumab at a dose of 162 mg as SC injection q2w (and tocilizumab placebo q2w starting from Week 2) up to 52 weeks along with prednisone and/or prednisone placebo according to the protocol-defined schedule. Participants will receive prednisone tapering oral daily doses during the first 26 weeks and prednisone placebo from Week 26 up to Week 52.
89591249|NCT01791153|Placebo Comparator|Part 1: Placebo + 26 weeks prednisone taper|Participants will receive tocilizumab placebo as SC injection qw up to 52 weeks along with prednisone and/or prednisone placebo according to the protocol-defined schedule. Participants will receive prednisone tapering oral daily doses during the first 26 weeks and prednisone placebo from Week 26 up to Week 52.
89591250|NCT01791153|Placebo Comparator|Part 1: Placebo + 52 weeks prednisone taper|Participants will receive tocilizumab placebo as SC injection qw up to 52 weeks along with prednisone and/or prednisone placebo according to a protocol-defined schedule. Participants will receive prednisone tapering oral daily doses for 52 weeks.
89591251|NCT01791153|Experimental|Part 2: Open-Label Tocilizumab qw|Participants without sustained remission at Week 52 will receive open-label tocilizumab at a dose of 162 mg as SC injection qw and/or corticosteroids and/or methotrexate at the discretion of the investigator for a maximum of 104 weeks.
89591252|NCT01926782|Placebo Comparator|Placebo Q2W|Two subcutaneous (SC) injections of placebo (for alirocumab) Q2W with or without stable statin therapy for 48 weeks.
89591253|NCT01926782|Experimental|Alirocumab 75 mg/ Up 150 mg Q2W|One SC injection of each Alirocumab 75 mg and placebo Q2W with or without stable statin therapy for 48 weeks. Alirocumab dose up-titrated to 150 mg from Week 12 when LDL-C levels ≥ 70 mg/dL (1.81 mmol/L) (for very high CV risk participants) or ≥ 100 mg/dL (2.59 mmol/L) (for moderate and high CV risk participants) at Week 8.
89591254|NCT01926782|Experimental|Alirocumab 300 mg/ Up 150 mg Q4W|Two SC injections of Alirocumab 150 mg Q4W alternating with two SC injections of placebo Q4W with or without stable statin therapy for 48 weeks. Alirocumab dose up-titrated to 150 mg from Week 12 when LDL-C levels ≥ 70 mg/dL (1.81 mmol/L) (for very high CV risk participants) or ≥ 100 mg/dL (2.59 mmol/L) (for moderate and high CV risk participants) at Week 8.
89591255|NCT01926626|Experimental|Nicotine Patch+Moclobemide|After 1 week of pre-cessation nicotine patch treatment (21 mg/24 h patches), participants will receive moclobemide (400 mg/day in 2 divided doses) for 11 weeks, ending 10 weeks after the target quit date. Nicotine patch treatment will continue at 21 mg/24 h for an additional week prior to the quit date, and then for 6 weeks after the quit date, followed by 14 mg/24 h for 2 weeks and 7 mg/24 h for 2 weeks. All treatment will terminate 10 weeks after the quit date.
89591256|NCT01953224|Experimental|Game-based intervention|This arm will receive the game intervention, which will include provision of a mobile smartphone device, cellular data service, the game application loaded onto the device, credit to load approximately 40-50 songs onto the device, headphones, and an armband for wearing the device. Participants will also receive weekly counseling calls.
89591257|NCT01953224|No Intervention|Wait list control|This group will receive no intervention until after completion of the final assessment of the randomized trial. Then, they will receive the full intervention.
89591258|NCT01900730|Placebo Comparator|Placebo|Patient takes placebo capsule 3 times a day by mouth for 10 weeks. Patient contacted by phone to assess tolerance and instruction to increase dose. Questionnaires completed at baseline, weeks 2, 6, and 10. Patient given a pill diary to record the time each dose taken. Patient completes daily diary of drainage with the date and amount of fluid drained each day at home. Drained fluid from the day before brought to each clinic visit to give to the research team.
89591259|NCT01900730|Experimental|Valproic Acid (VPA)|Patients initially receive daily oral VPA 15 mg/kg/day divided in three doses. If patient tolerates the reduced dose for 10 consecutive days, then the VPA dose will increase to 30 mg/kg/day divided into three doses. Patients treated for 10 weeks. Questionnaires completed at baseline, weeks 2, 6, and 10. Patient given a pill diary to record the time each dose taken. Patient completes daily diary of drainage with the date and amount of fluid drained each day at home. Drained fluid from the day before brought to each clinic visit to give to the research team.
89591260|NCT01952834|Experimental|GoodBelly Probiotic and Vancomycin|Good Belly Probiotic 2.7 oz Daily x 6 weeks Followed by a 4 week wash out period and then, Vancomycin, a non absorbed antibiotic administered (250 mg four times daily) orally for 10 days
89591261|NCT04643912|Experimental|Injured wrist or ankle|"Child with trauma needing wrist or ankle x-ray:~Will receive vibration analysis blinded to x-ray findings."
89591262|NCT01952054|Experimental|Denosumab|Participants receive a single subcutaneous (SC) administration of Denosumab 120 mg every 4 weeks (+/- 5days). Starting week 5, in addition to receiving Denosumab every 4 weeks, participants receive a hormonal agent chosen by each physician, excluding the agent that participants received at adjuvant therapy setting.
89209918|NCT00887952|Active Comparator|2|Stepwise excavation: Carious dentine removal performed in 2 steps: partial removal of carious dentine, indirect pulp capping (calcium hydroxide cement); temporary filling with IRM; cavity re-opening after 60 days, removal of the remaining soft carious tissue and filling (amalgam or resin).
88977133|NCT03731832|Experimental|PId|Treatment of eligible patients with combination of Pomalidomide, Ixazomib, Dexamethasone for all patients until disease progression.
88977134|NCT03731832|Experimental|PICd|Treatment of patients showing an isolated biochemical relapse at disease progression with combination of Pomalidomide, Ixazomib, Dexamethasone plus Cyclophosphamide.
88977135|NCT00185848|Experimental|[18F]FHBG arm|
89209919|NCT02550860|Active Comparator|soybean oil (SO)-based IVFE (Medialipide)|
89209920|NCT02550860|Active Comparator|fish oil (FO)-containing IVFE (Lipidem)|fish oil (FO)-containing IVFE (Lipidem)
89209921|NCT00162097|Experimental|EFV600mg Participants With Mild Hepatic Impairment|
89591263|NCT01925768|Experimental|Apremilast 30 mg|30 mg Apremilast tablets administered twice daily (BID) for 24 weeks during the double-blind placebo-controlled phase; followed by 30 mg Apremilast BID for 28 weeks of active treatment phase (up to the 52 week visit); original treatment assignments remain blinded until all participants have completed their 52 week visit or have discontinued. After the Wk 52 visit, all participants in the extension phase will continue to receive treatment with apremilast 30 mg BID until the end of the study (ie, up to Week 104 visit) or until early discontinuation from the trial.
89591264|NCT01925768|Placebo Comparator|Placebo|Oral placebo BID during the placebo controlled phase weeks 0 to 24; placebo treated participants whose improvement is <10% in both swollen and tender joint counts at Week 16 are eligible for early escape (based on the measure of clinical benefit from their current treatment as evidenced by improvement (or lack of improvement) in 1) the physician (evaluator's) global assessment (EGA), 2) patients pain (pain NRS), 3) the patient global assessments (PGA), and 4) the health assessment questionnaire disability index (HAQ-DI); Placebo-treated patients who early escape are transitioned to apremilast 30 mg PO BID during the active treatment phase up to their Week 52 visit; all those who complete the 52-week treatment phase will enter an open-label extension phase for an additional 52 weeks or until early discontinuation from the trial.
89591265|NCT01431274|Experimental|tiotropium+olodaterol low dose FDC|Once daily 2 puffs solution for inhalation Respimat
89591266|NCT01431274|Experimental|tiotropium+olodaterol high dose FDC|Once daily 2 puffs solution for inhalation Respimat
89591267|NCT01431274|Active Comparator|olodaterol|Once daily 2 puffs solution for inhalation Respimat
89591268|NCT01431274|Active Comparator|tiotropium low dose|Once daily 2 puffs solution for inhalation Respimat
89591269|NCT01431274|Active Comparator|tiotropium high dose|Once daily 2 puffs solution for inhalation Respimat
89591270|NCT01991795|Experimental|Ticagrelor 60 mg|Initially ticagrelor 90 mg or corresponding placebo was the selected dose, but reduced to ticagrelor 60 mg or corresponding placebo in Clinical Study Protocol Amendment No 1.
89591271|NCT01991795|Placebo Comparator|Ticagrelor placebo|Initially ticagrelor 90 mg or corresponding placebo was the selected dose, but reduced to ticagrelor 60 mg or corresponding placebo in Clinical Study Protocol Amendment No 1.
89591272|NCT02076100|Experimental|Part I GT3 Participants|Participants receive Ruzasvir capsules, orally, starting at a dose of 60 mg once per day (QD) x 5 days with doses increasing or decreasing as clinically indicated.
89591273|NCT02076100|Experimental|Part II GT1a Participants|Participants receive Ruzasvir capsules, orally, starting at a dose of 60 mg once per day (QD) x 5 days with doses increasing or decreasing as clinically indicated.
89591274|NCT02076100|Experimental|Part III GT2b Participants|Participants receive Ruzasvir capsules, orally, starting at a dose of 60 mg once per day (QD) x 5 days with doses increasing or decreasing as clinically indicated.
89591275|NCT01411852|Experimental|0.9% Sodium Chloride 250 mL bolus|0.9% Sodium Chloride 250 mL bolus - A large bore IV will be placed and a 250cc bag of normal saline (NS) will be hung. If IV placement is difficult, NS can be given through an intraosseous line. Using small bags versus large bags will physically limit the amount of fluid given to patients in the experimental group. The requirement to change the smaller bags of fluid and recheck the pulse or blood pressure will limit the amount of fluid given. The procedure will continue until 2 hours after arrival to the hospital or until hemorrhage control is achieved whichever occurs first. Hemorrhage control will be defined as ligation of a bleeding vessel, packing of a solid organ, removal of a solid organ, and angiographic embolization of a bleeding vessel.
89591276|NCT01411852|Active Comparator|0.9% Sodium Chloride 2000 mL bolus|0.9% Sodium Chloride 2000 mL bolus - The treatment of the control group will be consistent with traditional Prehospital Trauma Life Support and Advanced Trauma Life Support guidelines which recommend early aggressive fluid resuscitation. An intravenous line (IV) will be placed and a 1000cc bag of normal saline will be hung. If IV placement is difficult, fluid can be given through an intraosseous line. This procedure will continue until either 2 hours after hospital arrival or until control of hemorrhage is achieved whichever occurs first. Hemorrhage control will be defined as ligation of a bleeding vessel, packing of a solid organ, removal of a solid organ, and angiographic embolization of a bleeding vessel.
89591277|NCT01411774|Active Comparator|Cognitive-behavioral therapy plus pill placebo|This study arm involves the subject receiving 10 sessions of cognitive behavioral therapy with pill placebo taken 1 hour before the session.
89591278|NCT01411774|Experimental|Cognitive-behavioral Therapy plus d-cycloserine|This study arm involves the subject receiving 10 sessions of cognitive behavioral therapy with d-cycloserine taken 1 hour before the session.
89209922|NCT00162097|Experimental|EFV600mg Participants With Moderate Hepatic Impairment|
89591279|NCT01411228|Experimental|60 Units/kg|
89591280|NCT01411228|Experimental|30 Units/kg|
89591281|NCT01410604|Experimental|Metformin|Tablet of 500 mg metformin, oral every 12 hours (total metformin dose of 1 g/day) for 3 months.
89591282|NCT01410604|Placebo Comparator|Placebo|Tablet of 500 mg oral placebo every 12 hours for 3 months.
89591283|NCT01991483|Experimental|LY2928057 (No ESA)|Multiple doses of LY2928057 administered intravenously (IV) either once every 2 weeks (Q2W) or once per week (QW) for 6 weeks. Participants discontinued their personal physician-prescribed erythropoiesis stimulating agent (ESA) before treatment.
88977136|NCT00185887|Active Comparator|Terbutaline|
88977137|NCT00185887|Active Comparator|Nitroglycerine|
88977138|NCT00058604|Experimental|Treatment|Each patient will receive a Biological/Vaccine Intravenous injection of EBV specific CTLs
88977139|NCT00186082|Active Comparator|Cefotetan, Cefoxitin or Clindamycin|
88977140|NCT00186082|Placebo Comparator|Normal Saline|
88977141|NCT02969642|Sham Comparator|Sham|Sham low energy laser using approximately 1/1000 th energy of treatment laser.
88977142|NCT02969642|Active Comparator|Treatment|Treatment laser.
88977143|NCT00186745|Experimental|1|All patients in this cohort receive treatment with weight-adjusted, standard-dose tinzaparin for treatment of venous thromboembolism. Trough anti-Xa level measurements done on any 2 of days 3, 5 or 7 of treatment. Patients with a trough anti-Xa level > 0.5 IU/mL receive dose adjustment of the tinzaparin.
88977144|NCT00186823|Other|1|
88977145|NCT00186862|Other|1|
88977146|NCT00186940||1|
88977147|NCT00186979|Other|1|
89591284|NCT01991483|Experimental|LY2928057 (Reduced ESA)|Multiple doses of LY2928057 administered IV either Q2W or QW for 6 weeks. Participants reduced their personal physician-prescribed ESA dose before treatment.
89591285|NCT01991483|Placebo Comparator|Placebo (No ESA)|Multiple doses of placebo administered IV either Q2W or QW for 6 weeks. Participants discontinued their personal physician-prescribed ESA dose before treatment.
89209923|NCT00162097|Experimental|EFV600mg Participants With Severe Hepatic Impairment|
89209924|NCT00162097|Active Comparator|EFV600mg Participants With Normal Hepatic Function|
89591286|NCT01991483|Placebo Comparator|Placebo (Reduced ESA)|Multiple doses of placebo administered IV either Q2W or QW for 6 weeks. Participants reduced their personal physician-prescribed ESA dose before treatment.
89591287|NCT01410448|Active Comparator|Immediate Everolimus (IE)|Everolimus was started within 48 hours after graft reperfusion at a starting dose of 0.75 mg twice daily in combination with low-dose cyclosporine and steroids for 3 months.
89591288|NCT01410448|Experimental|Delayed Everolimus|The standard dose of mycophenolate sodium was administered within 48 hours after graft reperfusion in combination with a full dose of cyclosporine and steroids. After28 +/- 4 days of treatment, mycophenolate sodium was discontinued and everolimus was introduced at a starting dose of 0.75 mg twice daily for 3 months.
89591289|NCT01943851|Experimental|Part 1: GSK525762 QD Cohort|Subject will be administered a 5 milligram (mg) starting dose of GSK525762, oral tablets, QD. Dose escalations will be performed in Part 1 and dose adjustments are allowed to address tolerability and safety issues. Thereafter, subjects will be enrolled in a standard 3+3 design. Separate dose escalation cohorts will be opened for subjects with AML, NHL, and MM for QD dosing. Dose escalation will continue until an MTD is determined or until a dose of 200 mg per day is reached.
89591290|NCT01943851|Experimental|Part 1: GSK525762 BID Cohort|Subject will be administered a starting dose of GSK525762, oral tablets, 20 mg BID (12 hours apart, total daily dose of 40 mg). Dose escalations will be performed in Part 1 and dose adjustments are allowed to address tolerability and safety issues. Thereafter, subjects will be enrolled in a standard 3+3 design. Separate dose escalation cohorts will be opened for subjects with AML, NHL, and MM, for BID dosing. Dose escalation will continue until an MTD is determined or until a dose of 200 mg per day is reached.
89591291|NCT01943851|Experimental|Part 2: GSK525762 dose expansion cohort|After the MTD has been determined in Part1, Part 2 dose expansion cohorts will be opened for AML, NHL and MM.
89591292|NCT01430104|Experimental|Teriparatide + Aspara-CA + Alfarol|Aspara-CA 600 milligrams (mg) and Alfarol 1.0 microgram (µg) administered orally once daily throughout the study. Teriparatide 20 µg administered subcutaneously once daily for 28 days during the Treatment Period.
89591293|NCT01990859|Experimental|Arm A: Ipilimumab|Ipilimumab Intravenous Injection 3 mg/kg for every 3 weeks upto 4 doses
89591294|NCT02093897|Experimental|rVIII-SingleChain|Subjects will be assigned to either an on-demand or prophylaxis regimen and will receive rVIII-SingleChain as an intravenous (IV) infusion. Subjects assigned to a prophylaxis regimen will be treated with 15 to 50 IU/kg of rVIII-SingleChain every second day or 2 to 3 times per week, or at the investigator's discretion, based on available PK data, the FVIII treatment regimen used before enrollment and/or the subject's bleeding phenotype. The dose for on-demand treatment of a bleeding episode is based on the recommendations of the World Federation of Hemophilia (WFH), with a minimum dose of 15 IU/kg. All subjects were to be treated for a minimum of 50 EDs. For the PK evaluation, the subjects will receive a single IV dose of 50 IU/kg of rVIII-SingleChain on Day 1 at the start of the PK evaluation period.
89591295|NCT01990313|Experimental|Activa PC+S|
89591296|NCT01947517||Parasol Punctal Occluder Group|Randomized to receive Brand A punctal plugs
89591297|NCT01947517||Superflex Punctal Occluder Group|Randomized to receive Group B punctal plugs
89591298|NCT02006927|Experimental|Nerve Stimulation|Placement and stimulation of implantable neurostimulation device/leads post radical robotic prostatectomy
89591299|NCT01947283|Experimental|Intervention Patients & Providers|"Participants in this arm are intervention patients who will receive the DECIDE-PA intervention.~These patients receive care from Intervention providers, who will receive the DECIDE-PC intervention.~For intervention patients, the DECIDE PA is designed to help patients identify concerns about their condition or treatment and generate questions for providers regarding these concerns. The DECIDE PA intervention consists of 3-4 brief training sessions for patients delivered by Care Managers.~For intervention providers, the DECIDE PC is designed to help providers improve therapeutic alliance, patient-provider communication, continuance in care, and satisfaction with services for patients in order to improve shared decision making."
89591300|NCT01947283|Experimental|Intervention Patients, Control Providers|"Participants in this arm are intervention patients who will receive the DECIDE-PA intervention.~These patients receive care from Control providers, who will not receive the DECIDE-PC intervention.~For intervention patients, the DECIDE PA is designed to help patients identify concerns about their condition or treatment and generate questions for providers regarding these concerns. The DECIDE PA intervention consists of 3-4 brief training sessions for patients delivered by Care Managers."
89030892|NCT04696250||Adverse Events associated with Antineoplastic and Immunomodulating Agents|Cases reported in the World Health Organization (WHO) and the French pharmacovigilance database of patients treated by anticancer drugs, with a chronology compatible with the drug toxicity
89030893|NCT05145842|Active Comparator|floroscopy|28 patients who have previously been evaluated and planned for caudal epidural injections
89030894|NCT05145842|Experimental|ultrasound+fluoroscopy|28 patients who have previously been evaluated and planned for caudal epidural injections
89030895|NCT00524433|Experimental|1|tezosentan
89030896|NCT00524433|Placebo Comparator|2|
89030897|NCT03458832||FSHD-COM|All participants will be asked to undergo FSHD-specific functional rating scale tests and procedures and Electrical Impedance Myography.
89030898|NCT05142878|Experimental|Experimental: Static air support devices (Ultracore Repose®)|"Residents will be placed on a static air foam hybrid mattress during 14 days:~• Ultracore Repose® Mattress"
89591301|NCT01947283|No Intervention|Control Patients, Intervention Providers|"Participants in this arm are control patients who will not receive the DECIDE-PA intervention.~These patients receive care from Intervention providers, who will receive the DECIDE-PC intervention.~Control patients will receive a pamphlet called Managing Your Mental Health Care. For intervention providers, the DECIDE PC is designed to help providers improve therapeutic alliance, patient-provider communication, continuance in care, and satisfaction with services for patients in order to improve shared decision making."
89591302|NCT01947283|No Intervention|Control Patients & Providers|"Participants in this arm are control patients who will not receive the DECIDE-PA intervention.~These patients receive care from Control providers, who will not receive the DECIDE-PC intervention.~Control patients will receive a pamphlet called Managing Your Mental Health Care."
89591303|NCT01947283|No Intervention|Non-Randomized Controlled Trial Patients|Participants in this arm are patients who did not participate in the Randomized Controlled Trial. One to two patients will be recruited for each enrolled provider (Control and Intervention). One clinical session per patient will be audio recorded. These clinical recordings will be used to provide feedback only for Intervention providers during part 1 of the DECIDE-PC intervention.
89591304|NCT01947283|No Intervention|Control Providers|Participants in this arm are providers who were randomized to the Control group. Control providers will not receive the DECIDE-PC intervention.
89591305|NCT01947283|Experimental|Intervention Providers|Participants in this arm are providers who were randomized to the Intervention group. Intervention providers will receive the DECIDE-PC intervention. The DECIDE PC is designed to help providers improve therapeutic alliance, patient-provider communication, continuance in care, and satisfaction with services for patients in order to improve shared decision making.
89591306|NCT02006693|Other|XEN® Gel Stent|The XEN®45 Gel Stent (XEN45 implant) was placed in the study eye as a standalone procedure.
89591307|NCT02006693|Other|XEN® Gel Stent with Cataract Surgery|The XEN® Gel Stent (XEN45 implant) with cataract surgery, occurred if the participant was diagnosed with a cataract.
89591308|NCT01947127||High lactate|Initial venous lactate level equal to or more than 2.0 mmol/L
89591309|NCT01947127||Low lactate|Initial venous lactate level less than 2.0 mmol/L
89591310|NCT01976845|Experimental|Propofol|Propofol 20 mg IV (2 ml)
89591311|NCT01976845|Active Comparator|Midazolam|Midazolam 2 mg IV (2 ml)
89591312|NCT01976845|Placebo Comparator|Saline|Saline 2 ml
89591313|NCT01989689|Experimental|Etanercept/Placebo|The subjects will receive subcutaneous etanercept therapy at 50mg twice weekly for 3 months then will be switched to placebo therapy for an additional 3 months.
89591314|NCT01989689|Active Comparator|Placebo/Etanercept|The subjects will receive placebo injections for 3 months then will be switched to etanercept therapy for an additional 3 months.
89591315|NCT01943539|Experimental|EVO Game Play|Neuro-typical controls and ADHD will receive EVO game play.
89591316|NCT04638595||Normative|50 neurotypical pediatric subjects
89591317|NCT01942993|Experimental|Vemurafenib|960 mg (four tablets of 240 mg each) of vemurafenib PO BID
89591318|NCT01989455|Experimental|Cohort 1|"Single dose of 500mg deferiprone or placebo administered via intravenous infusion.~First 2 subjects to enroll: 1 will be randomized to receive deferiprone and the other to receive placebo.~Next 14 subjects enrolled: 13 will be randomized to receive deferiprone and 1 to receive placebo."
89591319|NCT01989455|Experimental|Cohort 2|"Single dose of 1000mg deferiprone or placebo administered via intravenous infusion and oral solution.~Randomization will be done for all 16 subjects at the same time: 14 will be randomized to receive deferiprone and 2 to receive placebo.~Subjects enrolled to cohort 2 will receive an oral dose of deferiprone."
89591320|NCT01989455|Experimental|Cohort 3|"Single dose of 1500mg deferiprone or placebo administered via intravenous infusion.~Randomization will be done for all 16 subjects at the same time, 14 will be randomized to receive deferiprone and 2 to receive placebo."
89591321|NCT01989455|Experimental|Cohort 4|"Single dose of 2000mg deferiprone or placebo administered via intravenous infusion.~First 2 subjects to enroll: 1 will be randomized to receive deferiprone and the other to receive placebo.~Next 14 subjects enrolled: 13 will be randomized to receive deferiprone and 1 to receive placebo."
89591322|NCT01942837|Experimental|Enzalutamide|"Administration: 160 mg orally once daily with a 28-day cycle. Treatment will be continued until evidence of symptomatic or radiographic progression or the participant is taken off the study for another reason.~Dosing: 160 mg orally taken once daily as four 40 mg capsules."
89591323|NCT01987895|Experimental|Cadazolid|Subjects receive oral cadazolid 250 mg twice daily (bid) and oral vancomycin-matching placebo 4 times per day (qid) for 10 days
89591324|NCT01987895|Active Comparator|Vancomycin|Subjects receive oral vancomycin 125 mg qid and oral cadazolid-matching placebo bid for 10 days
89591325|NCT02005445|Experimental|Continuous Positive Airway Pressure (CPAP)|Continuous positive airway pressure
89030899|NCT05145647|Experimental|Add-on Brachytherapy|The evaluation for feasibility of surgery takes place 5-6 weeks after CCRT. Any subject whose tumor status is resectable at evaluation but declines surgical proposal will be eligible to be enrolled in the following study phase.
89591326|NCT02005445|Sham Comparator|Healthy Lifestyle and Sleep Education (HLSE)|Healthy living and sleep education
89591327|NCT01618669|Experimental|Regadenoson After Peak Exercise|On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, 3 minutes after exercise while in walk recovery and then a stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
89209925|NCT02550782|Active Comparator|perineural bupivacaine|"patient-controlled infraclavicular perineural bupivacaine~(1% bupivacaine (marcaine), 5 ml bolus dose, infusion rate of 5 ml / h, lockout time 1 hour)"
89591328|NCT01618669|Active Comparator|Regadenoson Alone|On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus (1 hour after exercise recovery), and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
89591329|NCT01390948|Experimental|Bevacizumab + TMZ Young Patient Cohort (YPC)|Participants aged greater than or equal to (>/=) 6 months and less than (<) 3 years will receive 10 milligrams per kilogram (mg/kg) Bevacizumab every 2 weeks and 150 to 200 milligrams per meter squared (mg/m^2) of TMZ daily on Days 1-5 of each cycle. TMZ will be given at a dose of 150 mg/m^2 on Days 1-5 of cycle 1 and then escalated to 200 mg/m^2 on days 1-5 from cycle 2 onwards depending on the tolerance during the 1st cycle.
89591330|NCT01390948|Experimental|Main Cohort: Chemoradiation + Bevacizumab + TMZ|Participants will receive a total dose of 54 Grey (Gy) units delivered in 30 daily fractions of 1.8 Gy over 6 weeks with 75 mg/m^2 TMZ daily for up to 49 days followed by a treatment break of approximately 4 weeks. The treatment break will be followed by an adjuvant treatment phase where participants will receive 150 to 200 mg/m^2 of TMZ daily on Days 1-5 of each cycle. TMZ will be given at a dose of 150 mg/m^2 on Days 1-5 of cycle 1 and then escalated to 200 mg/m^2 on days 1-5 from cycle 2 onwards depending on the tolerance during the 1st cycle. Bevacizumab will be given concomitantly at a dose of 10 mg/kg every 2 weeks throughout the entire treatment period.
89591331|NCT01390948|Active Comparator|Main Cohort: Chemoradiation + TMZ|Participants will receive a total dose of 54 Gy units delivered in 30 daily fractions of 1.8 Gy over 6 weeks with 75 mg/m^2 TMZ daily for up to 49 days followed by a treatment break of approximately 4 weeks. The treatment break will be followed by an adjuvant treatment phase where participants will receive 150 to 200 mg/m^2 of TMZ daily on Days 1-5 of each cycle. TMZ will be given at a dose of 150 mg/m^2 on Days 1-5 of cycle 1 and then escalated to 200 mg/m^2 on days 1-5 from cycle 2 onwards depending on the tolerance during the 1st cycle.
89591332|NCT02005211|Experimental|AZD3293|AZD3293 will be administered as single dose of an oral solution in Part 1 and single and multiple doses of an oral solution in Part 2. The ascending doses are planned to be 15, 50 and 150 mg for young subjects in Part 1 and 15 and 50 mg for elderly subjects in Part 2. Before proceeding to next dose level, safety, tolerability and pharmacokinetic data from the previous cohort(s) will be evaluated by a Safety Review Committee. Part 2 will start after confirming safety and tolerability in Part 1.
89591333|NCT02005211|Placebo Comparator|Placebo|Placebo given (2 subjects in each cohort)
89591334|NCT03842722||Critically ill septic patients|Cohort: patients admitted via the emergency department or hospital ward to the intensive care unit of Leiden University Medical Center with the diagnosis sepsis or septic shock, who receive fluid therapy (either colloid, crystalloid and/or red blood cell) in their first day of admission to the ICU.
89591335|NCT01429792|Experimental|Single Arm|
89591336|NCT04034446|Experimental|A|Single dose of CD19-CD22 CAR-T cells
89591337|NCT01409434|Other|Follow-Up Arm|All patients are recruited for inclusion in the Follow-Up Arm, which is the sole arm of the study. The Follow-Up Arm includes a one time study visit in which study interventions are performed. The Follow-Up Arm involves patients from the parent study who were enrolled in the follow-up study. The intervention in the Follow-Up Arm is the Oral Glucose Tolerance Test.
89591338|NCT01925612|Experimental|Part 1: BV(1.2 mg/kg) + RCHOP|"Brentuximab vedotin 1.2 mg/kg plus rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone~Part 1 of the study is a phase 2, randomized, open-label, multicenter study designed to evaluate the antitumor activity and safety of brentuximab vedotin when administered in combination with standard RCHOP chemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). Patients in this arm were randomized into the 1.2 mg/kg brentuximab vedotin dosing cohort, to be administered in combination with RCHOP."
89591339|NCT01925612|Experimental|Part 1: BV(1.8 mg/kg) + RCHOP|"Brentuximab vedotin 1.8 mg/kg plus rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone~Part 1 of the study is a phase 2, randomized, open-label, multicenter study designed to evaluate the antitumor activity and safety of brentuximab vedotin when administered in combination with standard RCHOP chemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). Patients in this arm were randomized into the 1.8 mg/kg brentuximab vedotin dosing cohort, to be administered in combination with RCHOP."
89591340|NCT01925612|Experimental|Part 2: BV(1.8 mg/kg) + RCHP|"Brentuximab vedotin 1.8 mg/kg plus rituximab, cyclophosphamide, doxorubicin, prednisone~Part 2 of the study is a phase 2, non-randomized, open-label, multicenter study designed to evaluate the antitumor activity and safety of brentuximab vedotin 1.8 mg/kg when administered in combination with RCHP chemotherapy (rituximab, cyclophosphamide, doxorubicin, and prednisone). Patients in this treatment arm were enrolled into a dosing cohort with 1.8 mg/kg brentuximab vedotin administered in combination with RCHP."
89591341|NCT01925612|Active Comparator|Part 3: RCHOP|"Rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone~Part 3 of the study is a phase 2, randomized, open-label, multicenter study designed to evaluate the antitumor activity and safety of brentuximab vedotin 1.8 mg/kg when administered in combination with RCHP chemotherapy compared to RCHOP chemotherapy alone. Patients in this treatment arm were randomized to receive RCHOP treatment alone."
89591342|NCT01925612|Experimental|Part 3: BV(1.8 mg/kg) + RCHP|"Brentuximab vedotin 1.8 mg/kg plus rituximab, cyclophosphamide, doxorubicin, prednisone~Part 3 of the study is a phase 2, randomized, open-label, multicenter study designed to evaluate the antitumor activity and safety of brentuximab vedotin 1.8 mg/kg when administered in combination with RCHP chemotherapy compared to RCHOP chemotherapy alone. Patients in this treatment arm were randomized to receive RCHOP treatment alone. Randomization in this part of the study is for the purpose of evaluating the safety of 1.8 mg/kg brentuximab vedotin in combination with RCHP versus standard RCHOP chemotherapy.~Part 3 of the study is a phase 2, randomized, open-label, multicenter study designed to evaluate the antitumor activity and safety of brentuximab vedotin 1.8 mg/kg when administered in combination with RCHP chemotherapy compared to RCHOP chemotherapy alone. Patients in this treatment arm were randomized to receive 1.8 mg/kg brentuximab vedotin administered in combination with RCHP."
89591343|NCT02093663|Experimental|MMX Mesalamine/Mesalazine (Low Dose)|Once daily, tablets - the amount depends on the participants weight; 900 milligram per day (mg/day) for participants weighing 18 kg to less than or equal to (<=) 23 kilograms (kg); 1200 mg/day for participants weighing greater than (>) 23 kg to <= 35 kg; 1800 mg/day for participants weighing > 35 kg to <= 50 kg; 2400 mg/day for participants weighing > 50 kg to <= 90 kg.
89591344|NCT02093663|Experimental|MMX Mesalamine/Mesalazine (High Dose)|Once daily, tablets - the amount depends on the participants weight;1800 mg/day for participants weighing 18 kg to <= 23 kg; 2400 mg/day for participants weighing > 23 kg to <= 35 kg; 3600 mg/day for participants weighing > 35 kg to <= 50 kg; 4800 mg/day for participants weighing > 50 kg to <= 90 kg.
89591345|NCT01408888|Experimental|LY2189265, Sitagliptin + LY2189265|A single 1.5-milligram (mg) dose of LY2189265 administered subcutaneously (Treatment 1). There was a washout period of at least 21 days before crossing over and receiving 100 mg of sitagliptin administered orally, once daily for 18 days in combination with two separate single 1.5-mg doses of LY2189265 administered subcutaneously, immediately prior to the sitagliptin doses on Day 5 and Day 12 (Treatment 2).
89591346|NCT01408888|Experimental|Sitagliptin + LY2189265, LY2189265|100 mg of sitagliptin administered orally, once daily for 18 days in combination with two separate single 1.5-mg doses of LY2189265 administered subcutaneously, immediately prior to the sitagliptin doses on Day 5 and Day 12 (Treatment 2). There was a washout of at least 21 days before crossing over and receiving a single 1.5 mg dose of LY2189265 administered subcutaneously (Treatment 1).
89591347|NCT01918033|Experimental|Desloratadine 5 mg|Participants receive one desloratadine 5 mg tablet and one placebo tablet orally once daily for up to 2 weeks
89591348|NCT01918033|Experimental|Desloratadine 10 mg|Participants receive two desloratadine 5 mg tablets orally once daily for up to 2 weeks
89591349|NCT01918033|Placebo Comparator|Placebo|Participants receive two placebo tablets orally once daily for up to 2 weeks
89591350|NCT01408732|Experimental|Standard Treatment then Sclerotherapy Intervention|"The standard treatment group will continue their pre-study standard treatment methods to treat epistaxis on the first 6 weeks of the study, followed by intervention with sclerotherapy on the second 6 weeks of the study, plus any additionally needed standard treatments for breakthrough epistaxis. Wash out period 2 weeks"
89591351|NCT01408732|Experimental|Sclerotherapy Intervention then Standard Treatment'|This group will receive, on the first 6 weeks of the study, sclerotherapy with STS to any visible lesions in the nose at the outset, followed by any needed standard treatments for breakthrough epistaxis. On the second 6 weeks of the study this group will continue with standard treatments that they had been receiving for epistaxis prior to the study. Wash out period of two weeks
89591352|NCT04626037|Experimental|All Participants in Group Zoom Sessions|During each session, the mother-child dyads will meet with Nurture Science program staff virtually. The entire procedure will be done on Zoom or in person depending on school opening. All mother-child pairs will then be asked to interact, with the child sitting on the mother's lap face-to-face. The rest of the session may continue with: (1) Reading Cuddle and Calm Book (2) Mutual Mother and Child Emotional Exchange Prompts (3) Mothers Support Circle to identify and engage members of the mother's family in helping the dyad with emotional connection (4) Mommy Baby Book (5) Bottle of Emotions (6) Plans for continuing the work in the family. Returning mothers will be asked how they have progressed using the Cuddle and Calm and mutual narrative over the week and what their experience with their child after the session has been.
89591353|NCT01390402|Experimental|NK Infusion + Chemotherapy|Fludarabine 40 mg/m2 intravenous (IV) daily for 4 days, immediately followed by Busulfan 130 mg/ m2 IV every 24 hours and NK cell infusion IV.
89591354|NCT01976299|Experimental|Active Treatment|Standard of Care with the AVERT system
89591355|NCT01976299|No Intervention|Standard of Care|
89591356|NCT01428076|Experimental|High Dose Polidocanol Endovenous Microfoam|
89591357|NCT01428076|Experimental|Medium Dose Polidocanol Endovenous Microfoam|
89591358|NCT01900652|Experimental|Arm A: Emibetuzumab plus Erlotinib|750 milligram (mg) Emibetuzumab flat dose given as a 1.5 hour intravenous (IV) infusion on Days 1 and 15 of a 28-day cycle and Erlotinib 150 mg given orally once daily on a 28-day cycle.
89591359|NCT01900652|Experimental|Arm B: Emibetuzumab|750 mg Emibetuzumab flat dose given as a 1.5-hour IV infusion on Days 1 and 15 of a 28-day cycle.
89591360|NCT02093351|Experimental|Cohort 1 - Tamoxifen|Olaparib-alone Steady state PK, Tamoxifen-alone steady state PK, Combined olaparib and Tamoxifen steady state PK.
89591361|NCT02093351|Experimental|Cohort 2 - Anastrozole|Olaparib-alone Steady state PK, Anastrozole-alone steady state PK, Combined olaparib and Anastrozole steady state PK.
89591362|NCT02093351|Experimental|Cohort 3 - Letrozole|Olaparib-alone Steady state PK, Letrozole-alone steady state PK, Combined olaparib and Letrozole steady state PK.
89591363|NCT02078284|Experimental|Cohort 1 with 0.5 units of CPP|A single 30 to 60 minute intravenous (IV) infusion of 0.5 unit of dimethyl sulfoxide (DMSO) cryopreserved platelets (CPP)
89591364|NCT02078284|Active Comparator|Cohort 1 with 1 unit of LSP|A single 30 to 60 minute intravenous (IV) infusion of 1 unit of liquid stored platelets (LSP)
89591365|NCT02078284|Experimental|Cohort 2 with 1 unit of CPP|A single 30 to 60 minute intravenous (IV) infusion of 1 unit of dimethyl sulfoxide (DMSO) cryopreserved platelets (CPP)
89591366|NCT02078284|Active Comparator|Cohort 2 with 1 unit of LSP|A single 30 to 60 minute intravenous (IV) infusion of 1 unit of liquid stored platelets (LSP)
89591367|NCT02078284|Experimental|Cohort 3 with 2 units of CPP|A single 30 to 60 minute intravenous (IV) infusion of 2 units of dimethyl sulfoxide (DMSO) cryopreserved platelets (CPP)
89591368|NCT02078284|Active Comparator|Cohort 3 with 1 unit of LSP|A single 30 to 60 minute intravenous (IV) infusion of 1 unit of liquid stored platelets (LSP)
88977148|NCT00058799|Experimental|Dose Level 1|Patients are treated with up to six injections of their gene-modified CD40L and IL-2 skin fibroblasts and leukemic blasts, separated by one-two weeks in an immunological treatment window.
88977149|NCT00058799|Experimental|Dose Level 2|Patients are treated with up to six injections of their gene-modified CD40L and IL-2 skin fibroblasts and leukemic blasts, separated by one-two weeks in an immunological treatment window.
88977150|NCT00058799|Experimental|Dose Level 3|Patients are treated with up to six injections of their gene-modified CD40L and IL-2 skin fibroblasts and leukemic blasts, separated by one-two weeks in an immunological treatment window.
89591369|NCT02078284|Experimental|Cohort 4 with 3 units of CPP|A single 30 to 60 minute intravenous (IV) infusion of 3 units of dimethyl sulfoxide (DMSO) cryopreserved platelets (CPP)
88977151|NCT00187057|Other|1|Acute Lymphoblastic Leukemia (ALL) Low Risk
88977152|NCT00187057|Other|2|Acute Lymphoblastic Leukemia (ALL) - High Risk
88977153|NCT00187057|Other|3A|B-Cell Non-Hodgkins Lymphoma (Group A)
88977154|NCT00187057|Other|3B|B-Cell Non-Hodgkins Lymphoma (Group B)
88977155|NCT00187057|Other|4|Hodgkins Disease
88977156|NCT00046917|Experimental|Treatment (chemotherapy)|Patients are stratified according to the number of prior treatment regimens (0 or 1 vs more than 1). Patients receive irinotecan hydrochloride IV over 30 minutes followed immediately by cisplatin IV over 30 minutes followed 7 hours later by alvocidib IV over 1-4.5 hours weekly for 2 weeks. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
88977157|NCT00187174|Experimental|Phase 1|
88977158|NCT00187252|Experimental|1|CRT + AF Suppression turned ON
88977159|NCT00187252|Active Comparator|2|CRT + AF Suppression turned OFF
89591370|NCT02078284|Active Comparator|Cohort 4 with 1 unit of LSP|A single 30 to 60 minute intravenous (IV) infusion of 1 unit of liquid stored platelets (LSP
89591371|NCT02092961|Experimental|Dosing Group A|Oral treatment and subcutaneous injection.
89591372|NCT02092961|Active Comparator|Dosing Group D|Oral treatment and subcutaneous injection.
89591373|NCT02092961|Placebo Comparator|Dosing Group E|Placebo bid for 6 weeks followed by switch to 100 mg fostamatinib bid for 24 weeks, plus placebo subcutaneous injection every 2 weeks.
89591374|NCT01898078|Experimental|Alisertib 50 mg Fed + Fasted|Alisertib 50 mg, enteric-coated tablets (ECT), orally, in fed state, once on Day 1, followed by alisertib 50 mg, ECT, orally, twice daily (BID) on Days 4 through 10, followed by a 14-day rest period in Cycle 1 (24-day cycles), followed by alisertib 50 mg, ECT, orally, in fasted state, once on Day 1, followed by alisertib 50 mg, ECT, orally, BID on Days 4 through 10, followed by a 14-day rest period in Cycle 2, followed by alisertib 50 mg, ECT, orally, BID on Days 1-7, followed by a 14-day rest period in Cycle 3 and onwards (21-day cycles) until disease progression, occurrence of an unacceptable alisertib-related toxicity.
89591375|NCT01898078|Experimental|Alisertib 50 mg Fasted + Fed|Alisertib 50 mg, ECT, orally, in fasted state, once on Day 1, followed by alisertib 50 mg, ECT, orally, BID on Days 4 through 10, followed by a 14-day rest period in Cycle 1 (24-day cycles), followed by alisertib 50 mg, ECT, orally, in fed state, once on Day 1, followed by alisertib 50 mg, ECT, orally, BID on Days 4 through 10, followed by a 14-day rest period in Cycle 2, followed by alisertib 50 mg, ECT, orally, BID on Days 1-7, followed by a 14-day rest period in Cycle 3 and onwards (21-day cycles) until disease progression, occurrence of an unacceptable alisertib-related toxicity.
89591376|NCT01987817|Experimental|AR101 powder provided in capsules|Study product provided as peanut protein in pull-apart capsules
89591377|NCT01987817|Placebo Comparator|Placebo powder provided in capsules|Placebo formulation in pull-apart capsules containing only inactive ingredients
89591378|NCT01940497|Experimental|Trastuzumab (Vial)|Participants will receive trastuzumab 600 mg SC using a vial q3w (1 cycle) for 1 year (4 cycles in combination with adjuvant or neoadjuvant chemotherapy [consisting of doxorubicin, paclitaxel or docetaxel] and 14 cycles administered alone).
89591379|NCT01940497|Experimental|Trastuzumab (SID)|Participants will receive trastuzumab 600 mg SC using SID q3w (1 cycle) for 1 year (4 cycles in combination with adjuvant or neoadjuvant chemotherapy [consisting of doxorubicin, paclitaxel or docetaxel] and 14 cycles administered alone).
89591380|NCT01924754||Standard intramuscular injection (NS-IM)|HPV vaccination regimen: Standard 3 dose (0.5mL) delivered by standard intramuscular (IM) injection using a needle and syringe (NS-IM)
89591381|NCT01924754||PharmaJet needle-free Stratis device (JI-IM)|HPV vaccination regimen: Standard 3 dose (0.5mL) delivered by IM injection using the PharmaJet needle-free Stratis device (JI-IM)
89591382|NCT01924754||PharmaJet needle-free Tropis device (JI-ID)|HPV vaccination regimen: Reduced-dose (0.1 mL) delivered by intradermal injection using the PharmaJet needle-free Tropis device (JI-ID)
88977160|NCT02969564||prostate cancer patient, with up to five metastases|prostate cancer patient, with up to five metastases (oligo-bone metastatic) based on scintigraphy 99mTc-MDP-SPECT/CT.
88977161|NCT00058955|Experimental|1|Sodium oxybate
89591383|NCT01924364|Experimental|Fat grafting with TGI|In this study, we will concentrate the adipose stromal cells (ASCs) in the fat graft material to assess whether this modification will increase fat graft retention over time. The concentrated fat to be injected into the subject from the fat grafting procedure will be processed by the Tissue Genesis Cell Isolation System™ (TGI-CIS) device. The volume retention in areas treated with ASC concentrated fat grafts will be compared with regions treated with standard fat grafts in the same patient.
88977162|NCT00058955|Active Comparator|2|triazolam
88977163|NCT00058955|Active Comparator|3|pentobarbital
88977164|NCT00058955|Placebo Comparator|4|Placebo
88977165|NCT00187798|Other|Metformin|Metformin HCl
88977166|NCT00187837|Experimental|SW intervention|Stepwise Excavation
88977167|NCT00187837|Other|DCE intervention|Control intervention Direct complete excavation. The updated terminology for completed excavation is non-selective excavation to hard dentin
88977168|NCT00187915|Other|CellCept + Prograf|Standard of Care Regime
88977169|NCT00187915|Other|CellCept + Neoral|Standard of Care Regime
88977170|NCT00047034|Experimental|Treatment (eribulin mesylate)|Patients receive E7389 IV over 1-2 minutes on days 1, 8, and 15. Treatment repeats every 4 weeks for at least 4 courses in the absence of disease progression or unacceptable toxicity.
88977171|NCT00188266|Experimental|5-Fluorouracil (5FU) and Cisplatin with Radiation|
88977172|NCT00047073|Experimental|Phase 1|See intervention description.
88977173|NCT00047073|Experimental|Phase 2|See intervention description.
88977174|NCT00188305|Experimental|1 In person|In person general health, colorectal cancer risk information and screening recommendations.
88977175|NCT00188305|Active Comparator|2 Telephone|Telephone general health counselling, colorectal cancer risk information and screening recommendations.
88977176|NCT00188305|Placebo Comparator|3 Control|Standard care for 2 months followed by summary letter with general health information, colorectal cancer risk information and screening recommendations.
88977177|NCT00188344|Active Comparator|1|pneumatic dilatation
88977178|NCT00188344|Active Comparator|2|Laparoscopic myotomy
88977179|NCT02969447|Experimental|Oxytocin administration after fetal expulsion|Administration of 10 units of intra venous oxytocin after fetal expulsion
88977180|NCT02969447|No Intervention|No additional medication after fetal expulsion|
88977181|NCT00188578|Experimental|IMRT Gynecological Cancers|
88977182|NCT00047112|Experimental|CHIMIORADIOTHERAPIE SUIVIE DE CHIRURGIE|CHIMIORADIOTHERAPIE SUIVIE DE CHIRURGIE
88977183|NCT00047112|Active Comparator|CHIRURGIE SEULE|CHIRURGIE SEULE
88977184|NCT02963038|Experimental|CD19 CAR T cells|Autologous CD19-targeting CAR T cells
88977185|NCT00409279|Experimental|1|multi-component psychosocial intervention
88977186|NCT00409279|No Intervention|2|
88977187|NCT00409318|Active Comparator|1|Etanercept
88977188|NCT00409318|Placebo Comparator|2|Placebo
88977189|NCT03492762|Experimental|Healthy Volunteer Group|The healthy volunteer group will receive the same interventions as the ILD documented diagnosed volunteer group
88977190|NCT03492762|Experimental|ILD Documented Diagnosed Volunteer Group|The ILD documented diagnosed volunteer group will receive the same interventions as the healthy volunteer group
88977191|NCT00409396|Experimental|1|Fecal calprotectin and urinary PGEm levels will be tested on all participants.
88977192|NCT03432546||ICU patients|Over 18-year old intensive care patients, non-interventional prospective observational study
88977193|NCT00188890||1|prior occupational exposure at least 20 years ago to ASBESTOS and / or documented pleural plaques on a chest x-ray Must be 30 years of age or older. NO prior cancers, except non-melanic skin cancers
88977194|NCT02963194|Experimental|Oxytocin|Oxytoxin nasal spray
88977195|NCT02963194|Placebo Comparator|Placebo|Placebo nasal spray
89591384|NCT01924364|Sham Comparator|Fat grafting without TGI - Standard of care|In this study, we will concentrate the adipose stromal cells (ASCs) in the fat graft material to assess whether this modification will increase fat graft retention over time. The concentrated fat to be injected into the subject from the fat grafting procedure will be NOT processed by the Tissue Genesis Cell Isolation System™ (TGI-CIS) device. The volume retention in areas treated with ASC concentrated fat grafts will be compared with regions treated with standard fat grafts in the same patient.
88977196|NCT00059306|Active Comparator|Antiplatelet|Participants receive aspirin + placebo OR aspirin + clopidogrel
88977197|NCT00059306|Active Comparator|Blood pressure|The goal of the blood pressure aspect of this trial is to find out if lowering blood pressure after stroke helps to prevent recurrent stroke and preserves cognition.
88977198|NCT00425542|Experimental|Outpatient treatment|
88977199|NCT00425542|No Intervention|Inpatient care|
88977200|NCT00189007|Experimental|Allopurinol|500 mg allopurinol/ 50 mL water for injection intravenously
88977201|NCT00189007|Placebo Comparator|Placebo|500 mg mannitol/50 mL water for injection intravenously
88977202|NCT00059345|Experimental|Arm 1: Acupuncture|Participants will receive acupuncture
89591385|NCT01987505|Experimental|Subcutaneous Rituximab|Participants with CD20+ non-Hodgkin's follicular lymphoma (FL) or diffuse large B-cell lymphoma (DLBCL), who had already received at least one full dose of intravenous (IV) rituximab will be treated with subcutaneous (SC) rituximab. Participants with FL will be administered 1400 mg rituximab during induction therapy (once monthly for 4-7 cycles) and maintenance therapy (once every 2 months for 6-12 cycles). Participants with DLBCL will be administered 1400 mg SC of rituximab once monthly for 4-7 cycles. Treatment duration is expected to last up to 7 months for participants with DLBCL and up to 32 months for participants with FL.
88977203|NCT00059345|Placebo Comparator|Arm 2: Shallow needling|Participants will receive shallow needling on non-mederian points
88977204|NCT00059345|Other|Arm 3: No Acupuncture or Placebo Treatment|Participants will receive usual care, no acupuncture or placebo acupuncture treatment.
88977205|NCT00189163|Active Comparator|Pioglitazone|30 mg, taken orally, once per day
88977206|NCT00189163|Placebo Comparator|Placebo|Sugar pill, taken orally, once a day
88977207|NCT00399984|Experimental|1|
88977208|NCT00399984|No Intervention|2|
88977209|NCT00189514|Experimental|1|
89591386|NCT01923896|Experimental|Behavioral Intervention & DCS|Behavioral Feeding Intervention (15 total treatment sessions over 5 days) and D-cycloserine (0.7mg/kg DCS) to be taken acutely one hour prior to the onset of the first treatment session each day
89591387|NCT01923896|Active Comparator|Behavioral Intervention & Placebo|Behavioral Feeding Intervention (15 total treatment sessions over 5 days) and placebo (lactose powder) by method of intake (bottle; formula; tube)
89591388|NCT02004353||Cochlear® Hearing Implants, hearing loss|Implanted Adolescents and Adults with permanent hearing loss
89591389|NCT01938625|Experimental|Part 1|Participants with Metavir fibrosis score F1-F2 will receive treatment with combinational regimen of simeprevir, daclatasvir, and ribavirin along with cyclosporine or tacrolimus as stable immunosuppressant therapy.
89591390|NCT01938625|Experimental|Part 2|Participants with Metavir fibrosis score F1-F4 will receive treatment with combinational regimen of simeprevir, daclatasvir, and ribavirin along with tacrolimus as stable immunosuppressant therapy.
89591391|NCT01975675|Experimental|LDV/SOF (treatment naive)|Treatment-naive participants will receive LDV/SOF for 12 weeks.
89591392|NCT01975675|Experimental|LDV/SOF+RBV (treatment naive)|Treatment-naive participants will receive LDV/SOF plus RBV for 12 weeks.
89591393|NCT01975675|Experimental|LDV/SOF (treatment experienced)|Treatment-experienced participants will receive LDV/SOF for 12 weeks.
89591394|NCT01975675|Experimental|LDV/SOF+RBV (treatment experienced)|Treatment-experienced participants will receive LDV/SOF plus RBV for 12 weeks.
89591395|NCT01975285|Active Comparator|Dexamethasone group|Dexamethasone 4mg(1 ml) per 20cc
89591396|NCT01975285|Placebo Comparator|Saline group|Saline 1 ml per 20cc
89591397|NCT01974895|Experimental|FluLaval Quadrivalent Group|Subjects received 1 or 2 doses of FluLaval® Quadrivalent vaccine at Day 0 or Days 0 and 28, depending on age and vaccine priming status.
89591398|NCT01974895|Active Comparator|Fluzone Group|Subjects received 1 or 2 doses of Fluzone® vaccine at Day 0 or Days 0 and 28, depending on age and priming status.
89591399|NCT01974817|Experimental|Vaccine|Patients will receive one dose of 0.5 ml 13-valent conjugate pneumococcal vaccine (Prevnar-13) intra-muscularly.
89591400|NCT04415749|Experimental|NasoShield One Dose in Position 1|NasoShield on Day 1 and saline placebo on Day 29 in position 1 (Group 1)
88977210|NCT00189514|Experimental|2|
88977211|NCT00189514|Experimental|3|
88977212|NCT00189514|Placebo Comparator|4|
88977213|NCT00189553|Active Comparator|Standard|Paclitaxel-Carboplatin
88977214|NCT00189553|Experimental|Experimental|Caelyx-Carboplatin
89209926|NCT02550782|Experimental|perineural dexmedetomidine|"patient-controlled infraclavicular perineural dexmedetomidine~(1% bupivacaine + 200 mic / 100cc dexmedetomidine, 5 ml bolus dose, infusion rate of 5 ml / h, lockout time 1 hour)"
89591401|NCT04415749|Placebo Comparator|Placebo in Position 1|Saline placebo on Day 1 and saline placebo on Day 29 in position 1 (Group 1)
89591402|NCT04415749|Experimental|NasoShield Two Doses in Position 2|NasoShield on Day 1 and Day 29 in position 2 (Group 2)
89591403|NCT04415749|Placebo Comparator|Placebo in Position 2|Saline placebo on Day 1 and Day 29 in position 2 (Group 2)
89591404|NCT04415749|Experimental|NasoShield Two Doses in Position 3|NasoShield on Day 1 and Day 29 in position 3 (Group 3)
89591405|NCT04415749|Placebo Comparator|Placebo in Position 3|Saline placebo on Day 1 and Day 29 in position 3 (Group 3)
89591406|NCT04624399|Experimental|Atezolizumab|Patients receive 2 x 3-weekly cycles of Atezolizumab (one infusion on the first day of each cycle) prior to cystectomy surgery.
89591407|NCT01915849|Experimental|Sequence 1: LIK066 15 mg/Placebo/LIK066 50 mg/LIK066 150 mg|Period 1- LIK066 15 mg treatment once daily (q.d.) for 4 days. Period 2- Placebo treatment once daily for 4 days Period 3 - LIK066 50 mg treatment once daily (q.d.) for 4 days. Period 4- LIK066 150 mg treatment once daily (q.d.) for 4 days. 14 days washout periods between treatment periods.
89591408|NCT01915849|Experimental|Sequence 2: LIK066 50 mg/LIK066 15 mg/LIK066 150 mg/Placebo|Period 1- LIK066 50 mg treatment once daily (q.d.) for 4 days. Period 2- LIK066 15 mg treatment once daily (q.d.) for 4 days. Period 3- LIK066 150 mg treatment once daily (q.d.) for 4 days. Period 4- Placebo treatment once daily for 4 days. 14 days washout periods between treatment periods.
89591409|NCT01915849|Experimental|Sequence 3: LIK066 150 mg/LIK066 50 mg/Placebo/LIK066 15 mg|Period 1- LIK066 150 mg treatment once daily (q.d.) for 4 days. Period 2- LIK066 50 mg treatment once daily (q.d.) for 4 days. Period 3- Placebo treatment once daily for 4 days. Period 4- LIK066 15 mg treatment once daily (q.d.) for 4 days. 14 days washout periods between treatment periods.
89591410|NCT01915849|Experimental|Sequence 3: Placebo/LIK066 150 mg/LIK066 15 mg/LIK066 50 mg|Period 1- Placebo treatment once daily (q.d.) for 4 days. Period 2- LIK066 150 mg treatment once daily (q.d.) for 4 days. Period 3- LIK066 15 mg treatment once daily (q.d.) for 4 days. Period 4- LIK066 50 mg treatment once daily (q.d.) for 4 days. 14 days washout periods between treatment periods.
89591411|NCT01915771|Experimental|lomitapide|It will comprise of 2 single oral doses with at least a 14-day washout between doses.
89591412|NCT01938391|Other|OAS + BA|Cardiovascular Systems, Inc. Orbital Atherectomy System (OAS), is used prior to adjunctive balloon angioplasty (BA)
89591413|NCT01915303|Experimental|pasireotide +/- cabergoline|pasireotide alone or with cabergoline
89591414|NCT01987427|Experimental|A|lorcaserin + phentermine placebo
89591415|NCT01987427|Experimental|B|lorcaserin + phentermine-HCl + phentermine placebo
89591416|NCT01987427|Experimental|C|lorcaserin + phentermine-HCl
89591417|NCT01937299|Experimental|SIMBRINZA|Brinzolamide 1%/brimonidine 0.2% ophthalmic suspension, 1 drop in each eye 3 times a day (8 AM, 3 PM, 10 PM), with travoprost 0.004% ophthalmic solution, 1 drop in each eye at bedtime, for 6 weeks
89591418|NCT01937299|Placebo Comparator|Vehicle|Inactive ingredients, 1 drop in each eye 3 times a day (8 AM, 3 PM, 10 PM), with travoprost 0.004% ophthalmic solution, 1 drop in each eye at bedtime, for 6 weeks
89591419|NCT01606761|Experimental|Group 1|Patients will receive placebo every 2 weeks from Week 0 through Week 22, followed by a subcutaneous (SC) sirukumab dose regimen every 2 weeks through Week 52.
89591420|NCT01606761|Experimental|Group 2|Patients will receive sirukumab 100 mg SC at Weeks 0, 2, and every 2 weeks through Week 52.
89591421|NCT01606761|Experimental|Group 3|Patients will receive sirukumab 50 mg SC at Weeks 0, 4, and every 4 weeks through Week 52. Between sirukumab injections, placebo SC administrations will be made at Weeks 2, 6, and every 4 weeks through Week 52.
89591422|NCT01790295|Experimental|Ruxolitinib Pre- Hematopoietic cell transplantation (HCT)|Ruxolitinib (INC424) tablets will be started 62 days (day -67) prior to start of conditioning chemotherapy. The starting dose of Ruxolitinib will be determined according to baseline platelet count and will be modified according to platelet count at follow-up. The drug will be given in the maximum tolerated dose as defined in the protocol for 56 days, followed by 4 days of taper, and will be stopped completely at the planned start of conditioning therapy (starting on day -5) i.e. 5 days prior to stem cell infusion. The drug will be supplied as 5 mg tablets.
89591423|NCT01597557|Active Comparator|Magnesium Sulfate|Patients in this arm are give magnesium sulfate 2 grams intravenous drip before the cardioversion procedure
89591424|NCT01597557|Placebo Comparator|Placebo|Patients in this arm receive normal saline drip intravenously before the cardioversion procedure
89591425|NCT01914757|Experimental|Benralizumab 30 mg q.4 weeks|Benralizumab administered subcutaneously every 4 weeks
89591426|NCT01914757|Experimental|Benralizumab 30 mg q.8 weeks|Benralizumab administered subcutaneously every 8 weeks
89209927|NCT04037982|Experimental|LPD|In this group, patients will undergo laparoscopic pancreaticoduodenectomy.
89591427|NCT01914757|Placebo Comparator|Placebo|Placebo administered subcutaneously
89591428|NCT02003573|Experimental|volasertib + decitabine|dose escalation and MTD (Maximum Tolerated Dose) Extension (Note: Decitabine is a Backbone Treatment and Volasertib is Investigational Medicinal Product (IMP))
89591429|NCT01914679|Experimental|Sham followed by device|4 weeks of inactive (sham) RINCE therapy involving no RINCE therapy followed by 12 weeks of RINCE therapy involving 24 total treatments
88977215|NCT00400023|Experimental|1|"During the Cross-Over Pharmacokinetic Phase, patients will be randomly assigned to receive one of the following treatment sequences:~Sequence A: Single dose of 50 mg S-1 (2 capsules of 25 mg) on Day 1 followed by a single dose of 800 mg FT (8 capsules of 100 mg) on Day 8~Sequence B: Single dose of 800 mg FT on Day 1 followed by a single dose of 50 mg S-1 on Day 8"
88977216|NCT00400023|Active Comparator|2|"During the Cross-Over Pharmacokinetic Phase, patients will be randomly assigned to receive one of the following treatment sequences:~Sequence A: Single dose of 50 mg S-1 (2 capsules of 25 mg) on Day 1 followed by a single dose of 800 mg FT (8 capsules of 100 mg) on Day 8~Sequence B: Single dose of 800 mg FT on Day 1 followed by a single dose of 50 mg S-1 on Day 8"
88977217|NCT00189592|Experimental|A|Percutaneous Fasciotomy
88977218|NCT00189592|Active Comparator|2|Standard Fasciotomy
88977219|NCT03396081|Experimental|PRADO-IC|
88977220|NCT03396081|Other|Usual care|
88977221|NCT00189709|Experimental|1|
88977222|NCT00189709|Active Comparator|2|
88977223|NCT02969330|Experimental|Glucose|Glucose ingestion
88977224|NCT02969330|Active Comparator|PES|Single session of short PES treatment before glucose ingestion.
89209928|NCT04037982|Active Comparator|OPD|In this group, patients will undergo open pancreaticoduodenectomy.
89591430|NCT01789281|Experimental|Everolimus|Participants who were receiving everolimus in a Novartis-sponsored study, were not progressing on the current study treatment and were unable to access everolimus treatment outside of a clinical trial. Participants receiving everolimus treatment in combination with Sandostatin LAR Depot on the parent protocol were allowed to continue Sandostatin LAR Depot treatment.
89591431|NCT01923740|Experimental|Absorb BVS System|Absorb BVS System: Subjects receiving Absorb BVS System
89591432|NCT01923740|Active Comparator|XIENCE V EECSS|XIENCE V EECSS: Subjects receiving XIENCE V
89591433|NCT01789203|Active Comparator|Ciprofloxacin|Ciprofloxacin will be administered as two-250 mg capsules, administered once daily for 3 months post-transplant
89591434|NCT01789203|Placebo Comparator|Placebo|Matching placebo will be administered as two-capsules given once daily for 3 months post-transplant
89591435|NCT01789047|Active Comparator|Topiramate|Topiramate as adjunct to amantadine.
89591436|NCT01789047|Placebo Comparator|Placebo (sugar pill)|Placebo
89591437|NCT01788423|Experimental|Audiologist-Based|Audiologist selects hearing aid for patient
89591438|NCT01788423|Experimental|Consumer Decides|Consumer selects hearing aid
89591439|NCT01788423|Placebo Comparator|Placebo|Patient fitted with hearing aid that is acoustically transparent.
89591440|NCT01617187|Experimental|Asenapine 2.5 mg BID|
89591441|NCT01617187|Experimental|Asenapine 5 mg BID|
89591442|NCT01617187|Active Comparator|Olanzapine 15 mg QD|
89591443|NCT01617187|Placebo Comparator|Placebo BID|
89591444|NCT01759407|Active Comparator|Femoral Nerve Block|Ropivicaine 0.2% with epinephrine 1:200,000 will be used for patients between 10kg and up to 25kg in weight; ropivicaine 0.5% with epinephrine 1:200,000 will be used for patients greater than or equal to 25kg
89591445|NCT01759407|No Intervention|Standard Anesthetic Management|
89591446|NCT01787331|Experimental|Treatment (itraconazole)|Patients receive twice/day 300mg itraconazole (oral)
89591447|NCT01757847|Active Comparator|Brief MOVE-II active control group intervention|The MOVE-II protocol was designed to reinforce the weight-loss principles that patients learn in MOVE! and to provide support in continued weight loss. This protocol includes a psycho-educational component that reinforces the key information from the medical, nutrition, and weight loss strategies modules of the MOVE! program. After review of the psycho-educational components, patients have the opportunity to share their challenges with binge eating and weight loss. Patients will then be able to receive support and feedback from other group members and the therapist. In addition, the active control group focuses on increasing self-esteem and self-efficacy by exploring patient strengths and maintaining therapeutic alliance and optimism. The brief MOVE-II active control group protocol will be delivered in four 2-hour weekly group sessions to patient with overweight or obesity who have completed the VA San Diego MOVE program.
89591448|NCT01757847|Experimental|Acceptance and Commitment Therapy (ACT)|Acceptance and Commitment Therapy (ACT), has been effective in reducing distress, increasing quality of life, and improving other indices of health in a wide range of conditions from depression to diabetes. The ACT protocol for this study focuses on reducing binge eating and distress and improving functioning in individual who are overweight or obese. The protocol focuses on a) thoughts, feelings, and bodily sensations in the context of efforts to lose weight; b) limitations of efforts to control or eliminate negative thoughts or emotions, stress, or food cravings; c) changing expectations and goals from elimination of stress or cravings to living as well as possible with such feelings; d) mindfulness exercises to increase awareness; and e) identification of personal values and goals to achieve improved quality of life. The protocol will be delivered in four 2-hour weekly group sessions to patients with overweight or obesity who have completed the VA San Diego MOVE program.
89591449|NCT01787097|Active Comparator|COPD|Participants with COPD
89591450|NCT01787097|Active Comparator|Symbicort® total dose 400ug/12ug|Symbicort® total dose 400ug/12ug: is a combination of FORM (6ug) and ICS (Budesonide, (BUD) 200ug)
89591451|NCT01787097|Active Comparator|Symbicort® total dose 800ug/24ug|Symbicort® total dose 800ug/24ug: is a combination FORM (12ug) and BUD (400ug) at a higher-dose
89591452|NCT01787097|Active Comparator|BUD total dose 800ug|BUD total dose 800ug: is an intermediate dose of ICS
89591453|NCT04414371|Experimental|Group 1 - Yoga Group|Learn online yoga practices and practice daily for 12-weeks
89591454|NCT04414371|Other|Group 2 - Control Group|waist-list control for 4-week, cross-over to yoga practice for 8-week
89591455|NCT01757691|Experimental|Fingolimod 0.5mg/daily|Oral capsule dose was given once daily for 48 weeks
89591456|NCT01757691|Placebo Comparator|Placebo|Patients received oral dose of placebo from Weeks 0-18, followed by oral dose of fingolimod 0.5/mg capsule from Weeks 18-48
89591457|NCT01786707|Experimental|Autologous SC and HOT|Autologous stem cells and hyperbaric oxygen therapy
89591458|NCT01786707|Active Comparator|Control group|Patients in a control group will continue with standard medical treatment (Insulin and Metformin)
89591459|NCT01786629|Experimental|SUPREP Bowel Prep Kit|SUPREP Bowel Prep Kit
89591460|NCT01786629|Active Comparator|FDA approved bowel preparation|FDA approved bowel preparation containing electrolytes
89591461|NCT01786551|Experimental|Eplerenone|Eplerenone 50 mg daily for 14 days
89591462|NCT01973569|Experimental|Denosumab 6 months|denosumab administered subcutaneously every 6 months
89591463|NCT01973569|Experimental|Denosumab 3 months|denosumab administered subcutaneously every 3 months
89591464|NCT01973569|Placebo Comparator|placebo|placebo administered subcutaneously to match denosumab
89591465|NCT01973491|Experimental|ATX-MS-1467|
89591466|NCT01951586|Placebo Comparator|Placebo|Participants received placebo matching to denosumab by subcutaneous injection once every 4 weeks plus one loading dose on study day 8 in addition to platinum-based standard chemotherapy. Participants with bone metastases also received 4 mg zoledronic acid administered as an IV infusion Q4W or Q3W.
89591467|NCT01951586|Experimental|Denosumab|Participants received 120 mg denosumab by subcutaneous injection once every 4 weeks plus one loading dose on study day 8 in addition to platinum-based standard chemotherapy. Participants with bone metastases also received placebo to zoledronic acid administered as an IV infusion Q4W or Q3W.
89591468|NCT04643678|Active Comparator|Anakinra Group|Anakinra + Standard of Care
89591469|NCT04643678|Other|Standard of Care Group|Standard of Care Alone
89591470|NCT04641728|Experimental|pembrolizumab plus olaparib|Until RECIST-based confirmation of progressive disease (PD), death, manifestation of intolerable toxicity, or participant withdrawal from the study, study participants will continue intravenous infusion of pembrolizumab 200 mg every three weeks (Q3W) in combination with oral olaparib 300 mg twice daily (BID) (combination therapy)
89591471|NCT01785849|Experimental|Etelcalcetide|Participants received etelcalcetide administered by intravenous bolus injection at the end of each hemodialysis session three times a week, for 26 weeks.
89591472|NCT01785849|Placebo Comparator|Placebo|Participants received placebo administered by intravenous bolus injection at the end of each hemodialysis session, three times per week (TIW) for 26 weeks.
89591473|NCT01756833|Active Comparator|Doxycycline|100 mg capsules, twice a day, for a period of two years.
89591474|NCT01756833|Placebo Comparator|Placebo|100 mg capsules, twice a day, for a period of two years.
89591475|NCT01617967|Experimental|Patisiran (ALN-TTR02)|Two administrations of patisiran will be administered once every 4 weeks [Q4W]) in 4 sequential cohorts with escalating doses followed by optional cohorts with an alternative dosing regimen (once every 3 weeks [Q3W]), and an alternative premedication regimen.
89591476|NCT01785615|Experimental|Atorvastatin|44 women randomized to 80 mg atorvastatin for 6weeks
89591477|NCT01785615|Placebo Comparator|sugar pill|44 women randomized to placebo for 6 weeks
89591478|NCT01913041||Investigation|This is an epidemiology study in which all the data from the subjects enrolled will be collected and analysis to investigate the current patient warming condition and actual perioperative hyperthermia rate in the elective operation with general anesthesia. During the whole procedure none intervention is administered.
89591479|NCT01756053|Active Comparator|ABT-089|"During both 10-day study medication periods (Days 1-10 & Days 32-41), subjects will take 4 capsules daily. Administration of study medication will be double-blind and in counter-balanced order.~Those randomized to active ABT-089 during study medication period 1 will take four 10mg capsules daily (40mg daily) during the 10-day medication period. During study medication period 2, these subjects will take four capsules of the matched placebo capsules."
89591480|NCT01756053|Placebo Comparator|Placebo|"These are matched placebo capsules manufactured by the study drug supplier.~During both 10-day study medication periods (Days 1-10 & Days 32-41), subjects will take 4 capsules daily. Administration of study medication will be double-blind and in counter-balanced order.~Those randomized to matched placebo during study medication period 1 will take four capsules daily during the 10-day medication period. During study medication period 2, these subjects will take four 10mg capsules (40mg daily) of the active ABT-089 capsules."
89591481|NCT04576299||Healthcare workers.|"Survey developed specifically for the objective of this study: Healthcare worker perception of patient safety in times of pandemic.~The application will be done through a digital questionnaire in the surveymonkey platform (Link of the instrument: https://es.surveymonkey.com/r/COVIDSP)"
89591482|NCT01785069|Experimental|Augmentation|Women who had breast augmentation with NATRELLE® 410 implants.
89591483|NCT01785069|Experimental|Reconstruction|Women who had breast reconstruction with NATRELLE® 410 implants.
89591484|NCT01785069|Experimental|Revision-Augmentation|Women who had revision of a previous breast augmentation with NATRELLE® 410 implants.
89591485|NCT01785069|Experimental|Revision-Reconstruction|Women who had revision of a previous breast reconstruction with NATRELLE® 410 implants.
88977225|NCT04722796|Experimental|TAVR with Supra-annular sizing strategy|"Experimental: Supra-annular sizing strategy (Hangzhou Solution).~Pre-dilation with balloon size (20/23/26mm Z-MED) just below the annular size.~Waist sign with less than mild contrast regurgitation: Venus A plus Valve down size and Target implant depth 0-2mm.~No waist sign and/or contrast regurgitation or unable to finish supra-annular sizing: annular sizing Venus A plus Valve with implant depth 4-6mm."
88977226|NCT04722796|Other|TAVR with Annulus based sizing strategy|"Control: Traditional sizing strategy (Annulus based sizing strategy).~Pre-dilation with balloon size (20/23/26mm Z-MED) just below the annular size.~Annular sizing Venus A plus Valve with implant depth 4-6mm."
88977227|NCT02965287||19-21 weeks' gestation|"The test validation will be performed on the 1943 serum samples of pregnant women at 19-21 weeks' gestation recruited in New Zealand for the SCOPE Study.~All the samples will be analyzed to extract and purify the whole metabolome. Metabolites will be characterized through mass spectrometric techniques. These data will be interpreted by means of a bioinformatic algorithm specifically designed for this purpose."
88977228|NCT02965287||14-16 weeks' gestation|Five hundred subjects at 14-16 weeks gestation were randomly selected from the whole cohort of patients. The serum samples collected at 14-16 weeks gestation will be used to test the diagnostic performance at this earlier gestational phase.
88977229|NCT00059462|Experimental|Arm 1|
88977230|NCT00059462|Active Comparator|Arm 2|
89209929|NCT03862742||Patients admitted to the hospital|We will recruit patient volunteers from the Scripps Green Hospital and Scripps Memorial Hospital inpatient teaching services.
89591486|NCT01784523|No Intervention|Standard treatment|patients randomized to standard treatment will not receive hydroxychloroquine.
89591487|NCT01784523|Experimental|Hydroxychloroquine|Patients will be randomized to receive standard of care or standard of care + hydroxychloroquine. Dose will be weight-adjusted: 200 mg daily for patients weighing <60kg; and 400 mg daily (200 mg twice a day)for patients weighing >60kg.
89591488|NCT01784211|Experimental|LY2605541 (Part A)|0.5 units per kilogram (U/kg) LY2605541 subcutaneously (SC) once daily for 15 days. Part A involved 3 clamp procedures on Days 8, 11, and 14. Participants remained on their regular physician-prescribed mealtime insulin.
89591489|NCT01784211|Active Comparator|Glargine (Part A)|0.5 U/kg insulin glargine SC once daily for 15 days. Part A involved 3 clamp procedures on Days 8, 11, and 14. Participants remained on their regular physician-prescribed mealtime insulin.
88977231|NCT00189826|Active Comparator|1|
88977232|NCT00189826|Experimental|2|
88977233|NCT00047190|Experimental|Arm I|Patients receive oral tipifarnib twice daily on days 1-21. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
88977234|NCT02969291|Other|Reduced Sedentary Time Intervention|Reduced Sedentary Time Intervention (RSTI)
89209930|NCT00888030||2|CKD patients with normal p-cresol
89209931|NCT00888030||3|CKD patient with normal indoxyl sulfate
89209932|NCT00888030||4|CKD patients with high indoxyl sulfate
89591490|NCT01784211|Experimental|First LY2605541 + Exercise,Then LY2605541 Alone (Part B)|0.5 U/kg LY2605541 SC once daily for an additional 6 days, beginning on Day 16. Exercise challenge on Day 17 (no exercise on Day 20).Participants remained on their regular physician-prescribed mealtime insulin.
89591491|NCT01784211|Experimental|First LY2605541 Alone, Then LY2605541 + Exercise (Part B)|0.5 U/kg LY2605541 SC once daily for an additional 6 days, beginning on Day 16. Exercise challenge on Day 20 (no exercise on Day 17). Participants remained on their regular physician-prescribed mealtime insulin.
89591492|NCT01784211|Active Comparator|First Glargine + Exercise, Then Glargine Alone (Part B)|0.5 U/kg insulin glargine SC once daily for an additional 6 days, beginning on Day 16. Exercise challenge on Day 17 (no exercise on Day 20). Participants remained on their regular physician-prescribed mealtime insulin.
89591493|NCT01784211|Active Comparator|First Glargine Alone, Then Glargine + Exercise (Part B)|0.5 U/kg insulin glargine SC once daily for an additional 6 days, beginning on Day 16. Exercise challenge on Day 20 (no exercise on Day 17).
89591494|NCT01783821|Experimental|Budesonide and Formoterol|Subjects randomized to this arm will receive combined standard aerosolized doses of budesonide (0.5 mg) and formoterol (20 mcg) twice daily, with at least 6 hours between doses, for 5 days for a total of 10 doses or until hospital discharge or death, with the first dose administered as soon as possible following randomization but not later than 4 hours.
89591495|NCT01783821|Placebo Comparator|Placebo|Subjects randomized to this arm will receive normal saline, the quantity, appearance and timing of the doses the same as the intervention arm.
89591496|NCT01783743|Experimental|Intervention arm|"Community treatment assistants (CTA ) will receive usual training, including the basic background of trachoma/trichiasis recognition, drug administration, and azithromycin dosing.~In addition to the usual training, these CTA's will also receive an additional modest half day training for TT case recognition which is called the TT training program and TT Screening Card to help them identify TT cases and refer them for surgery."
89591497|NCT01783743|No Intervention|Usual Assessment arm|Community treatment assistants will receive only usual training, including the basic background of trachoma/trichiasis recognition, drug administration, and azithromycin dosing.
89591498|NCT01608321|Experimental|rTMS|Those receiving experimental treatment will receive 20 sessions of rTMS. The treatment will be delivered by trained medical personnel.
89591499|NCT01608321|Placebo Comparator|Sham rTMS|Those receiving the sham rTMS will receive 20 sessions of sham rTMS. The treatment will be delivered by trained medical personnel.
89591500|NCT01608087|Experimental|BI 695502|Subject to receive one intravenous (i.v.) infusion of BI 695502
89591501|NCT01608087|Active Comparator|bevacizumab A|Subject to receive one i.v. infusion of bevacizumab
89591502|NCT01608087|Active Comparator|bevacizumab B|Subject to receive one i.v. infusion of bevacizumab
89591503|NCT01912963|Experimental|Phase I: Dose Level 1 (D1)|"Pertuzumab: 840 mg/cycle 1 then 420 mg/cycle IV on day 1~Trastuzumab: 8 mg/kg/cycle 1 then 6 mg/kg cycle IV on day 1~Eribulin: 1.4 mg/m2/cycle IV on days 1 and 8 (D1)~Cycle duration=21 days~The Phase I run-in potentially evaluates 2 dose levels of eribulin in combination with pertuzumab and trastuzumab. Participants first receive antibody administration then eribulin. In the treatment phase, participants receive up to 6 cycles of combination therapy unless disease progression (PD) or withdrawal for other reasons (w/d). Participants who complete 6 cycles have the option to continue with antibody therapy only until PD or w/d in the extension phase."
89591504|NCT01912963|Experimental|Phase II Cohort A: Without Prior Pertuzumab Exposure|"Pertuzumab: 840 mg/cycle 1 then 420 mg/cycle IV on day 1~Trastuzumab: 8 mg/kg/cycle 1 then 6 mg/kg cycle IV on day 1~Eribulin: 1.4 mg/m2/cycle IV on days 1 and 8 (recommended phase II dose)~Cycle duration=21 days~In the Phase II study, participants enrolled into two possible cohorts based on prior pertuzumab exposure. Participants first receive antibody administration then eribulin. In the treatment phase, participants receive up to 6 cycles of combination therapy unless disease progression (PD) or withdrawal for other reasons (w/d). Participants who complete 6 cycles have the option to continue with antibody therapy only until PD or w/d in the extension phase."
88977235|NCT03247374|Experimental|"ProComp5 Infiniti Biofeedback"|"Each participant will attend 5 sessions per week for a total duration of 5 weeks. The duration of each session will take 1 hour, including bio-feedback preparation. At the beginning of the bio-feedback session, a surface electrode will be applied to the mylohyoid muscle. The patient will be required to swallow at a given time, with food bolus if possible, and perform maneuvers that favour swallowing strength and efficacy: effortful swallow, supraglottic swallow, and Masako maneuver, the first two with bolus administration, if possible. The experimental group will perform this training for 45 minutes, plus they will receive a verbal feedback from the speech and language therapist."
88977236|NCT03247374|Active Comparator|Standard Speech and Language Therapy|"Each participant will attend 5 sessions per week for a total duration of 5 weeks. The patient will be required to swallow at a given time, with food bolus if possible, and perform maneuvers that favour swallowing strength and efficacy: effortful swallow, supraglottic swallow, and Masako maneuver, the first two with bolus administration, if possible. The control group will attend this training for 45 minutes, receiving verbal feedback from the speech and language therapist."
88977237|NCT00190060|Active Comparator|1|Transdermal testosterone gel (Testogel 1% )
88977238|NCT00190060|Placebo Comparator|2|Matched transdermal placebo gel
88977239|NCT00047229|Experimental|G3139 in combination with Doxorubicin|
88977240|NCT04722874|Active Comparator|Ortho-k|Participants will continue to use ortho-k lenses alone.
88977241|NCT04722874|Experimental|RLRL+Ortho-k|Participants will be treated with RLRL twice a day in addition to ortho-k lenses.
88977242|NCT04722640|Experimental|RISAKIZUMAB|SKYRIZI
88977243|NCT00190216|Experimental|A|
88977244|NCT00190294|Experimental|1|MIFEPRISTONE 200 mg and misoprostol 400 µg
88977245|NCT03238365|Active Comparator|Arm I (nivolumab)|Patients receive nivolumab IV over 60 minutes on days 3 and 17 and undergo surgery on day 31.
88977246|NCT03238365|Experimental|Arm II (nivolumab, tadalafil)|Patients receive nivolumab IV over 60 minutes on days 3 and 17 and tadalafil PO QD on days 3-31. Patients then undergo surgery on day 31.
88977247|NCT00059618|Experimental|Bortezomib|PS-341 (Bortezomib) 0.8-1.5 mg/m^2 IV push + Carboplatin (AUC 5) IV on Day 1 of each cycle, then Bortezomib alone on Days 4, 8 and 11 in each 28 day cycle.
88977248|NCT00190333|Active Comparator|A|
89591505|NCT01912963|Experimental|Phase II Cohort B: With Prior Pertuzumab Exposure|"Pertuzumab: 840 mg/cycle 1 then 420 mg/cycle IV on day 1~Trastuzumab: 8 mg/kg/cycle 1 then 6 mg/kg cycle IV on day 1~Eribulin: 1.4 mg/m2/cycle IV on days 1 and 8 (recommended phase II dose)~Cycle duration=21 days~In the Phase II study, participants enrolled into two possible cohorts based on prior pertuzumab exposure. Participants first receive antibody administration then eribulin. In the treatment phase, participants receive up to 6 cycles of combination therapy unless disease progression (PD) or withdrawal for other reasons (w/d). Participants who complete 6 cycles have the option to continue with antibody therapy only until PD or w/d in the extension phase."
89591506|NCT01754727||Participants with Ankylosing Spondylitis (AS)|Participants with ankylosing spondylitis treated with adalimumab in routine clinical practice.
89591507|NCT01912807|Experimental|Dextrose (D5NS)|The participants received Dexamethasone (dose 0,15 mg/Kg) as standard antiemetic prophylaxis and Dextrose 5% in 0.9 % Normal Saline (D5NS) was used as a second antiemetic, at an intravenous rate calculated based on their weight and determined for the purpose of the study.
89591508|NCT01912807|Active Comparator|Ondansetron (Control)|The control group received Dexamethasone (dose 0,15 mg/Kg) as standard antiemetic prophylaxis. Ondansetron (dose 0,05 mg/Kg) was used as a second prophylactic antiemetic.
89591509|NCT01782885|Active Comparator|Acetaminophen|Patients from this arm will receive a dosis of acetaminophen (500 mg/8 hours) while PRP treatment lasts.
89591510|NCT01782885|Experimental|Intra-articular injection of PRP|Patients from this arm will receive 3 intra-articular knee injections of autologous platelet-rich plasma, one injection every two weeks
89591511|NCT01912729|Experimental|Networked Peer Support with Peer Guide|Participants will have access to tools and lessons based on Cognitive Behavior Therapy through a mobile phone application. Additionally, participants will have access to a private social network that connects them with other participants in the study. The social network will be moderated by a trained peer coach.
89591512|NCT01912729|Experimental|Networked Peer Support with Clinician Coach|Participants will have access to tools and lessons based on Cognitive Behavior Therapy through a mobile phone application. Additionally, participants will have access to a private social network that connects them with other participants in the study. The social network will be moderated by a clinician coach.
89591513|NCT01912729|No Intervention|Wait List Control|Participants may be asked to wait for up to 8 weeks until minimum group size is met. After 4 weeks from baseline, if a group has not yet started, we will conduct another assessment. These participants will serve as the Wait List Control group.
89591514|NCT01754493|Experimental|Treatment with Duloxetine|Patients will receive open treatment with Duloxetine
89591515|NCT01972789|Experimental|Intensive retinal fluid regimen|Ranibizumab 0.5mg is given monthly for the first 3 months followed by an individualised treatment regimen as determined by disease activity defined by a loss of ≥5 letters, new retinal haemorrhage, presence of any IRF or SRF on OCT.
89591516|NCT01972789|Experimental|Relaxed retinal fluid regimen|Ranibizumab 0.5mg is given monthly for the first 3 months followed by an individualised treatment regimen as determined by disease activity defined by a loss of ≥5 letters, new retinal haemorrhage, presence of IRF or SRF >200 um on OCT.
89591517|NCT01934335|Experimental|Vandetanib|Vandetanib, 300 mg, PO, q day for 7-14 days prior to surgery
89591518|NCT01934335|Placebo Comparator|Placebo|Placebo, PO, q day for 7-14 days prior to surgery.
89591519|NCT01912339|Experimental|Treatment|Treatment: Rezūm System
89591520|NCT01912339|Other|Control|Control: Rigid Cystoscopy
89591521|NCT01911793|Experimental|Stoma tube|Stoma tube (18 French) red robinson catheter inserted into stoma at the time of surgery
89591522|NCT01911793|No Intervention|Standard Stoma|Patients will have standard stoma created without insertion of stoma tube. Stoma tube will only be inserted postoperative if the patient is felt to have postoperative ileus, nausea, vomiting, and decreased stoma output as per standard protocol.
89591523|NCT04632511|Other|Obese group|Metabolome measurements on feces and urine.
89209933|NCT00888030||1|CKD patients with high p cresol
89591524|NCT04632511|Other|Children with overweight, not yet obese|Metabolome measurements on feces and urine.
89591525|NCT04632511|Other|Normal-weight control group|Metabolome measurements on feces and urine.
89209934|NCT00884988|Active Comparator|Lymphomyosot|homeopathic remedy
89209935|NCT00884988|Placebo Comparator|Placebo remedy|identical in color, constituency and taste to true remedy
89591526|NCT01933789|Experimental|Feedback Group|Subjects will complete surveys and assessments and will be given the Communication Feedback Form for Patients with Serious Illness to use prior to and during a target outpatient visit.
89591527|NCT01933789|No Intervention|Comparison/Usual Care Group|Subjects will only complete surveys and assessments.
89591528|NCT01910389|Active Comparator|Tadalafil|Tadalafil is supplied in 20 mg tablets. Subjects will take 20 mg (one tablet) once per day and will be titrated to 40 mg (two tablets once per day) after one week. Subjects are on study drug for the duration of the trial.
89591529|NCT01910389|Placebo Comparator|Placebo|Placebo of tadalafil. Subjects will take one tablet once per day and will be titrated to two tablets once per day after one week. Subjects are on study drug for the duration of the trial.
89591530|NCT01970995|Experimental|THS 2.2 Menthol (mTHS 2.2)|Ad libitum use of THS 2.2 Menthol for 5 Days in a Confinement Setting and 85 Days in an Ambulatory Setting
88977249|NCT00190372|Other|A|
89209936|NCT00818948|Placebo Comparator|Placebo|2 subjects of each cohort (cohort 1 to 6) will receive placebo
89591531|NCT01970995|Active Comparator|Smoking abstinence (SA)|Abstinence from smoking for 5 Days in a Confinement Setting and 85 Days in an Ambulatory Setting
89591532|NCT01970995|Active Comparator|Menthol Conventional Cigarette (mCC)|Ad libitum use of subject's own preferred brand of mCC for 5 Days in a Confinement Setting and 85 Days in an Ambulatory Setting
89591533|NCT01970527|Experimental|Treatment (stereotactic body radiotherapy, ipilimumab)|Patients undergo a total of 3 fractions of stereotactic body radiotherapy between days 1-13. Patients then receive ipilimumab IV every 3 weeks. Treatment repeats every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
89591534|NCT01931995|Active Comparator|TMS to positively correlated DLPFC|High frequency TMS to a target region of dorsolateral prefrontal cortex which is positively correlated with the subgenual cingulate cortex
89591535|NCT01931995|Active Comparator|TMS to negatively correlated DLPFC|High frequency TMS to a target region of dorsolateral prefrontal cortex which is positively correlated with the subgenual cingulate cortex
89591536|NCT01408576|Experimental|Epratuzumab 600 mg per week|600 mg infusions delivered weekly for a total of 4 consecutive weeks (cumulative dose 2400 mg) over sixteen 12-week treatment cycles
89591537|NCT01408576|Experimental|Epratuzumab 1200 mg every other week|1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over sixteen 12 week treatment cycles
89591538|NCT01427920|Experimental|Subject-driven titration BIAsp 30 (BID) + metformin|The subjects performed the titration of BIAsp 30 dose.
89591539|NCT01427920|Active Comparator|Investigator-driven titration BIAsp 30 (BID) + metformin|The investigator performed the titration of BIAsp 30 dose.
89591540|NCT01427608|Active Comparator|Sertraline + Olanzapine|Randomized to continue with sertraline and olanzapine under double-blind conditions.
89591541|NCT01427608|Placebo Comparator|Sertraline + Placebo|Randomized to continue with sertraline and substitute placebo for olanzapine under double-blind conditions.
89591542|NCT01408030|Placebo Comparator|Placebo spray|sterile saline
89591543|NCT01408030|Active Comparator|Bevacizumab spray|bevacizumab 1%
88977250|NCT00190411|Experimental|Treatment|Celiprolol
88977251|NCT00190450|Experimental|1|Early Graft (Early G)
89591544|NCT01408030|Active Comparator|Estriol spray|Estriol 0.1%
89591545|NCT01408030|Active Comparator|Tranexamic acid spray|tranexamic acid 10%
89591546|NCT04407832|Active Comparator|low dose PPI|40 mg esomeprazole IV for three days followed by esomeprazole 40 mg po daily for two months
89591547|NCT04407832|Active Comparator|high dose PPI|40 mg esomeprazole IV every 6 hr for 3 days followed by 40 mg po daily for two months
89591548|NCT01897532|Experimental|Linagliptin|
89591549|NCT01897532|Placebo Comparator|Placebo|
89591550|NCT01923428|Experimental|5 mg BID|AZD1722
89591551|NCT01923428|Experimental|20 mg BID|AZD1722
89591552|NCT01923428|Experimental|50 mg BID|AZD1722
89591553|NCT01923428|Placebo Comparator|Placebo|
89591554|NCT01896986||PRD patrients|"Children/adolescent females 12-26 years with a PRD such as JIA (Juvenile Idiopathic Arthritis) or SLE (Systemic Lupus Erythematosus)~Subgroups:~receiving immunosuppressant therapy~not on immunosuppressant therapy"
89591555|NCT01896986||IBD patients|"Children/adolescent females 12-26 years diagnosed with IBD.~Subgroups:~3. receiving immunosuppressant therapy 4. not on immunosuppressant therapy"
89591556|NCT04627376|No Intervention|Control|12-weeks multimodal program includes: 4 meetings (with cancer nurse and clinical dietician). In this 4 meetings (about 30 minutes) they will have blood tests (CRP, Albumin levels), body composition measurements, questionnaires.
89591557|NCT04627376|Experimental|Intervention|12-weeks multimodal program includes: 4 meetings (with cancer nurse and clinical dietician). In this 4 meetings (about 30 minutes) they will have blood tests (CRP, Albumin levels), body composition measurements, questionnaires, education on their diet and symptom management related to anti cancer treatment.
89591558|NCT01896128|Experimental|Armodafinil|150 mg armodafinil administered 2 hours prior to start of therapeutic regimen for 10 consecutive days
88977252|NCT00190450|Experimental|2|Late Graft (Late G)
88977253|NCT00047307|Experimental|Treatment (alvocidib, gemcitabine hydrochloride, 3DRT)|"Patients receive flavopiridol IV over 1 hour twice weekly (on days 1 and 4 or days 2 and 5) for 6 weeks. Concurrently, patients undergo radiotherapy once daily 5 days a week for 5.5 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.~Four weeks after the completion of radiotherapy, patients are re-evaluated*. Beginning within 4-7 weeks after the completion of chemotherapy and radiotherapy, patients receive gemcitabine hydrochloride alone or in combination with another cytotoxic agent or gemcitabine hydrochloride combined with a targeted drug (e.g., erlotinib or bevacizumab) at the discretion of the oncologist. NOTE: *Patients whose imaging studies suggest potential curative resection are referred for a surgical evaluation before initiating gemcitabine hydrochloride therapy. Cohorts of 3-6 patients receive escalating doses of flavopiridol until the maximum tolerated dose (MTD) is determined. Continued (see detailed description)"
88977254|NCT00190528|Active Comparator|Surgery|
88977255|NCT00190528|Experimental|Chemotherapy + Surgery|
88977256|NCT02969252|Other|Open label|Single and multiple dose, open label, pharmacokinetics and safety study
88977257|NCT03169842|Experimental|Cyst fluid glucose|Single arm- cyst fluid glucose will be measured from pancreatic cyst fluid aspirate
88977258|NCT00047346|Experimental|Treatment (erlotinib hydrochloride)|"Patients receive oral erlotinib once daily. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of erlotinib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
88977259|NCT02969135|Experimental|Progressive early passive and active movement|Active exercise starts one week after surgery.
88977260|NCT02969135|Active Comparator|Limited early passive movement|Active exercise starts six weeks after surgery.
88977261|NCT03000933||Young same-sex attracted men|Same-sex attracted men aged 16 to 20
89591559|NCT01896128|Placebo Comparator|Placebo|inactive agent administered 2 hours prior to start of therapeutic regimen for 10 consecutive days
88977262|NCT02969213||Genetic|patients with Gene detection (+)
88977263|NCT02969213||Metabolism|patients with Metabolic disturbance
88977264|NCT02969213||Immune|patients with Immunological marker and Immunotherapy (+)
88977265|NCT02969213||infection|patients with the Infection of central nervous system
88977266|NCT02969213||structure|patients with abnormal image of brain
89591560|NCT01949870|Other|Selumetinib|25mg/day, 50mg/day and 75mg/day
89591561|NCT01949480|Active Comparator|Traditional approach paravertebral nerve block|After final needle placement, a hanging drop technique will be used to rule out intrapleural placement while the patient inhales and exhales deeply. After correct needle placement, 10 mL of 0.5% Ropivacaine will be injected incrementally through each needle after negative aspiration, followed by insertion of the nerve block catheter to a depth 5 cm beyond the tip of the needle. An additional 10 mL of 0.5% Ropivacaine will then be injected in 5 mL increments with negative aspiration in between, through the catheter yielding a total activation dose of 20 ml of 0.5% Ropivacaine. The catheter will be secured with Steri-strips and a transparent occlusive dressing.
89591562|NCT01949480|Experimental|Ultrasound assisted paravertebral nerve block|The 22 gauge catheter will be threaded through the needle and placed at previously found distance to paravertebral space on obtained ultrasound image. An additional 10 ml of 0.5% Ropivacaine will be administered through the catheter yielding a total activation dose of 20 ml of 0.5% Ropivacaine. The catheter will be secured with Steri-strips and a transparent occlusive dressing.
89591563|NCT01949090|Experimental|GSK2789869A F1 Group|Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 1 (F1), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
89591564|NCT01949090|Experimental|GSK2789869A F2 Group|Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 2 (F2), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
89591565|NCT01949090|Experimental|GSK2789869A F3 Group|Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 3 (F3), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
89591566|NCT01949090|Experimental|GSK2789869A F4 Group|Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 4 (F4), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
88977267|NCT02969213||unknown|patients not found any reason
88977268|NCT02922894|Experimental|Acute episodic hypoxia|To test development of ventilatory augmentation following episodic hypoxia, defined as increased Hypoxic Ventilatory Response (HVR) from early to late hypoxic exposure episodes.
89209937|NCT00818948|Other|AMG811|Six subjects in each cohort (cohort 1 to 6) will receive AMG 811
89209938|NCT04036734|Active Comparator|Transverse Ultrasound Orientation|Transverse placement of ultrasound to long axis of target lower limb vein
88977269|NCT02922894|Experimental|Supplemental oxygen|To use supplemental oxygen to decrease peripheral chemoreceptor activity in patients with SCI and central SDB. In addition, perform a repeat evaluation after treatment with supplemental oxygen or sham O2 for 6 weeks to determine if correction of chronic intermittent hypoxia, which mitigates sensory LTF, results in decreased propensity to central apnea.
88977270|NCT02922894|Experimental|Trazodone or placebo|examine the effect of trazodone on breathing during sleep
88977271|NCT02963155|Experimental|Metastatic prostate cancer blood samples|
88977272|NCT02910726|Experimental|Sentinel Lymph Node Biopsy|This is a single-center clinical trial to evaluate non-inferiority of ICG-guided SLN biopsy compared with the gold standard TcL-guided SLN biopsy in pediatric patients with solid tumors. Each patient will undergo TcL, consistent with the standard of care, but the surgeon will be blinded to the results preoperatively. Intraoperatively, ICG injection and transdermal lymphography will be used to identify the draining nodal basin and the position of the sentinel nodes. ICG transdermal lymphography will be considered successful if SLNs can be visualized on near-infrared imaging. After the transdermal lymphography results have been recorded, the surgeon will be unblinded to the TcL mapping.
88977273|NCT04723030|Experimental|carleilizumab in combination with apathy mesylate and chemoradiotherapy (paclitaxel (albumin-bound)|Carilizumab was administered every 2 weeks. The patients were orally taken apatinib after meals and evaluated by DLT(3+3) in the first 2 cycles.The drugs were stopped for 2 weeks after the start of radiotherapy.Before radiotherapy, patients received 2 cycles of karyolizumab combined with apartinib and chemotherapy. Radiotherapy was performed in the first week of cycle 3 with a total dose of 30Gy in five doses within one week.Imaging evaluation was conducted once every 6 weeks. If the patients met the indications for surgical resection, the treatment was stopped.
88977274|NCT00191698|Experimental|A|Atomoxetine is administered at 1.2 mg/kg/day, PO for 8 weeks, followed by 1.2 or 2.4 mg/kg/day, PO for 4 weeks, open label administration can continue for up to one year
88977275|NCT00191698|Placebo Comparator|B|Placebo is administered by mouth, daily for 8 weeks. After 8 weeks, those randomized to placebo may be titrated to 1.2 mg/kg/day atomoxetine for the remainder of the study up to one year
88977276|NCT02969096|Experimental|Targeted Cryoablation Therapy|liver cancer patients received targeted cryoablation therapy.
88977277|NCT00059813|Experimental|Treatment (recombinant interferon alfa, oblimersen sodium)|Patients receive oblimersen IV continuously on days 1-7 and interferon alfa subcutaneously on days 4, 6, 8, 10, and 12 of course 1 and on days 1, 3, 5, 8, 10, and 12 of all subsequent courses. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity. Patients achieving a CR receive an additional 2 courses past CR.
88977278|NCT00047502|Experimental|Gleevec + SCH 66336|"Participants in CHRONIC PHASE receive Gleevec 400 mg by mouth every day, and SCH66336 100 mg by mouth twice a day.~Participants in ACCELERATED OR BLASTIC PHASE receive Gleevec 600 mg by mouth every day, and SCH66336 100 mg by mouth twice a day."
88977279|NCT00192127|Active Comparator|1|FluMist
88977280|NCT00192127|Placebo Comparator|2|Placebo
88977281|NCT00059852|Experimental|gemcitabine + erlotinib|"Patients receive gemcitabine IV on days 1 and 8 and oral erlotinib on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Patients achieving a complete response are followed every 6 weeks for up to 5 years or until disease progression (PD). Patients discontinuing study therapy for any other reason are followed every 3 months until PD and then every 6 months for up to 5 years."
88977282|NCT00192283|Experimental|1|CAIV-T
88977283|NCT00192283|Placebo Comparator|2|Placebo
89591567|NCT01949090|Placebo Comparator|Placebo Group|Healthy male and female adults, 65 years of age and older, who received two doses of Placebo, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
88977284|NCT00192322|Experimental|CAIV-T 10^5|a single intranasal 0.2 mL dose of liquid CAIV-T 10^5 (approximately 0.1 mL into each nostril)
88977285|NCT00192322|Experimental|CAIVT 10^7|A single intranasal 0.2 mL dose of liquid CAIV-T 10^7 (approximately 0.1 mL into each nostril)
88977286|NCT00192322|Placebo Comparator|Placebo|A single intranasal 0.2 mL dose of placebo
88977287|NCT00192322|Active Comparator|Trivalent inactivated vaccine (TIV)|A single intramuscular injection of commercially available vaccine
88977288|NCT02968901|Experimental|bitherapy|Macitentan and tadalafil
88977289|NCT00192478|Active Comparator|1|MEDI-524
88977290|NCT02439255|Experimental|Arm I Black raspberry(BRB) nectar|Participants receive BRB nectar PO QD for 12 weeks.
88977291|NCT02439255|Placebo Comparator|Arm II (placebo nectar)|Participants receive placebo nectar PO QD for 12 weeks.
88977292|NCT00059891|Experimental|Anal Sphincter Prosthesis|All patients will follow a common treatment algorithm. Anorectal reconstruction with the ABS neosphincter device will be a staged surgical approach. Routine postoperative testing will then be performed at 6 months (+/- 8 weeks) and 12 months (+/- 8 weeks), following ileostomy reversal which we have designated as time zero. Postoperative testing will include completion of a series of questionnaires.
88977293|NCT00192517|Active Comparator|1|MEDI-522
88977294|NCT00192517|Placebo Comparator|2|Placebo
88977295|NCT00192595|Active Comparator|Arm 1:|Zidovudine (AZT), lamivudine (LAM), efavirenz (EFV)
88977296|NCT00192595|Experimental|Arm 2|Zidovudine (AZT), tenofovir (TDF), efavirenz (EFV)
88977297|NCT00192595|Experimental|Amr 3|Lamivudine (LAM), tenofovir (TDF), efavirenz (EFV)
88977298|NCT04730726|Experimental|Patients with thyroid nodules|Patients with thyroid nodules that underwent or will undergo an ultrasound with FNA if indicated and if indicated will be scheduled for a (hemi)thyroidectomy
88977299|NCT01760850|Experimental|Arm I (Esperanza y Vida)|Participants engage in the Esperanza y Vida educational information session for breast and cervical cancer.
88977300|NCT01760850|Active Comparator|Arm II (control)|Participants engage in an educational information session for diabetes.
88977301|NCT00192634|Active Comparator|1|Abacavir 600mg/Lamivudine 300mg
88977302|NCT00192634|Active Comparator|2|Tenofovir 300mg/emtricitabine 200mg
88977303|NCT02958644|Experimental|Synbiotics|Synbiotics - 12g / day fructo-oligosaccharide and probiotics supplemented orally for 90 days.
89591568|NCT01948076|Placebo Comparator|resident without GE vscan|baseline physical exam use
89591569|NCT01948076|Active Comparator|resident with GE vscan|residents with augmentation of physical exam by ultrasound
88977304|NCT02958644|Placebo Comparator|Placebo|"Placebo - polydextrose 12g /day supplemented orally for 90 days.~The study supplements are packed in identical envelopes containing either 12g of oral powder fructo-oligosaccharide and probiotics or placebo to be diluted in water. The powder and the solution were identical in appearance, taste, and smell."
88977305|NCT00209235|Experimental|AHO:neurocognitive and pyschosocial|Neurocognitive and psychosocial testing
88977306|NCT02958722|Active Comparator|carbon dioxide|Diagnostic hysteroscopy performed with the carbon dioxide (gas)
88977307|NCT02958722|Active Comparator|physiological solution|Diagnostic hysteroscopy performed with liquid solution (physiologic solution)
88977308|NCT00060086|Experimental|Pomegranate Juice|Subjects are given oral pomegranate juice once daily. Treatment continues for 18 months in the absence of disease progression or unacceptable toxicity.
88977309|NCT04722562|Experimental|Child Pugh A|Participants with mild hepatic impairment
88977310|NCT04722562|Experimental|Child Pugh B|Participants with moderate hepatic impairment
89209939|NCT04036734|Experimental|Longitudinal Ultrasound Orientation|Longitudinal placement of ultrasound to long axis of target lower limb vein
89209940|NCT01073215|Active Comparator|Group Condition|
89209941|NCT01073215|Experimental|Self-Guided Condition|
89591570|NCT01922258|Placebo Comparator|Placebo|Matching Placebo Once-Daily
89591571|NCT01922258|Experimental|Brexpiprazole (flexible dose range 0.5 to 2 mg)|Titrate up from 0.25 mg/day brexpiprazole to 1 mg/day brexpiprazole. After achieving 1 mg/day target dose may be increased or decreased based on efficacy and tolerability. Allowable flexible doses will be 0.5 mg/day, 1 mg/day, or 2 mg/day.
89591572|NCT01406938|Experimental|AIN457150 mg- Induction period Only(IPO)|secukinumab 150 mg (1 injection per dose) and placebo to secukinumab 150 mg (1 injection per dose). Induction period only (IPO)
89591573|NCT01406938|Experimental|AIN457 300 mg - IPO|secukinumab- 2 x 150mg injections per dose
89591574|NCT01406938|Experimental|AIN457 150 mg - Fixed Interval (FI)|1 s.c. secukinumab 150 mg injection + 1 s.c. PBO (placebo) secukinumab injection
89591575|NCT01406938|Experimental|AIN457 300 mg FI|2 s.c. secukinumab 150 mg injections
89591576|NCT01406938|Experimental|AIN457 150 mg- Start of relapse (SoR)|1 s.c. secukinumab 150 mg injection + 1 s.c. PBO secukinumab injection
89591577|NCT01406938|Experimental|AIN457 300 mg- SoR|2 s.c. secukinumab 150 mg injections
89591578|NCT01405924|Experimental|Fosaprepitant 150 mg|Women with breast cancer receiving anthracycline-cyclophosphamide (AC)-like chemotherapy and women with gynecological cancer receiving carboplatin-paclitaxel (CT) chemotherapy receive fosaprepitant 150 mg administered intravenously (IV) on Day 1 of Cycle 2 of chemotherapy
89591579|NCT01426438|Experimental|Arm A: Extended-release niacin with aspirin|
89591580|NCT01426438|Experimental|Arm B: Fenofibrate|
89591581|NCT04407910|Experimental|Air-powder polishing device|
89591582|NCT04407910|Experimental|Rubber-cup+paste|
89591583|NCT01425814|Experimental|Arm #2|Single dose, double blind treatment period
89591584|NCT01425814|Experimental|Arm #3|Single dose, double blind treatment period
89591585|NCT01425814|Experimental|Arm #4|Single dose, double blind treatment period
89591586|NCT01425814|Active Comparator|Arm #5|Single dose, double blind treatment period
89591587|NCT01425814|Placebo Comparator|Arm #6|Single dose, double blind treatment period
89591588|NCT01425814|Experimental|Arm #1|Single dose, double blind treatment period
89591589|NCT01782495|Experimental|Arm A|Liver transplant recipients with HCV genotype 1 infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 24 weeks.
88977311|NCT04722562|Experimental|Healthy participants|Participants with normal hepatic function
88977312|NCT02958488|Experimental|Preterm Neonates with Respiratory Distress Syndrome|34 to 36 Weeks Preterm Neonates with Respiratory Distress Syndrome
88977313|NCT00409552|Experimental|1|Virtual Reality with head display
88977314|NCT00409552|Active Comparator|2|Virtual Reality with flat projection display
88977315|NCT00409552|Active Comparator|3|non-interactive video with head display
88977316|NCT00409552|Active Comparator|4|non-interactive video with flat projection display
88977317|NCT00409552|No Intervention|5|No distraction
89209942|NCT05278728|Experimental|Nimotuzumab and Irinotecan|Nimotuzumab： 200, 400, 600 or 800mg weekly until progression or AEs Irinotecan：180mg/m2 d1, Q2w until progression or AEs or maximum 6 cycles
89209943|NCT01073761|Experimental|Everybody|All Subjects will receive the same intervention
89209944|NCT00819104|Experimental|1|FDC of Metoprolol XL 50mg + Amlodipine 5mg
89209945|NCT00819104|Experimental|2|FDC of Metoprolol XL 25mg + Amlodipine 2.5mg
89209946|NCT00819104|Active Comparator|3|Extended release Metoprolol succinate
89209947|NCT00819104|Active Comparator|4|Extended release Metoprolol succinate
89209948|NCT00819104|Active Comparator|5|Amlodipine 5mg in immediate release formulation
89209949|NCT02542098|Experimental|HYD 20 - 120 mg|Hydrocodone bitartrate 20 mg to 120 mg extended-release tablets administered orally every 24 hours
89591590|NCT01782495|Experimental|Arm B|Liver transplant recipients with HCV genotype 1a or genotype 1b (dependent on prior treatment experience and response) infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 24 weeks.
89591591|NCT01782495|Experimental|Arm C|Liver transplant receipts with HCV genotype 1b infection who were treatment naïve or prior responders to interferon treatment without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) for 24 weeks.
89591592|NCT01782495|Experimental|Arm D|Liver transplant recipients with HCV genotype 1a infection with Child Pugh A cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) plus weight-based ribavirin (dosed 1,000 or 1,200 mg daily divided twice a day) for 24 weeks.
89591593|NCT01782495|Experimental|Arm E|Liver transplant recipients with HCV genotype 1b infection with Child Pugh A cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 12 weeks.
89209950|NCT03617094|Experimental|Early percutaneous vertebroplasty (EPV)|Surgical procedure of percutaneous vertebroplasty.
89209951|NCT03617094|Active Comparator|Standard Conservative treatment (CT)|Thoracolumbar corset.
89209952|NCT02541162|Experimental|INFORMED|"Interventional Group (I): Couples enrolled during the diagnosis will receive written information as usual about the disease and in addition they benefit special oral interviews and written information about experiences of their sexuality during the illness.The document used for the interventional group is Sexuality and Cancer and will be given to couples. (intervention: Oral information and interviews about sexuality and self experience during the disease). Qualitative analysis will be provided by a psychologist"
89591594|NCT01782495|Experimental|Arm F|Liver transplant recipients with HCV genotype 1a infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 12 weeks.
89591595|NCT01782495|Experimental|Arm G|Liver transplant recipients with HCV genotype 1b infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) for 12 weeks.
89591596|NCT01782495|Experimental|Arm H|Renal transplant recipients with HCV genotype 1a infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 12 weeks.
89591597|NCT01782495|Experimental|Arm I|Renal transplant recipients with HCV genotype 1b infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) for 12 weeks.
89591598|NCT01782495|Experimental|Arm J|Liver transplant recipients with HCV genotype 4 infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 12 weeks.
89591599|NCT01782495|Experimental|Arm K|Liver transplant recipients with HCV genotype 4 infection with Child Pugh A cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 24 weeks.
89591600|NCT01922102|Experimental|Group I|0.5 mg ranibizumab driven by visual acuity stability criteria
89591601|NCT01922102|Experimental|Group II|0.5 mg ranibizumab driven by disease activity criteria
89591602|NCT01922102|Active Comparator|Group III|verteporfin PDT
89591603|NCT01405768|Active Comparator|Lidocaine Arm|Women in this arm will receive plain lidocaine with epinephrine injected into their cervix prior to the LEEP procedure.
89591604|NCT01405768|Experimental|Buffered Lidocaine|Women in this arm will receive sodium bicarbonate buffered lidocaine mixed with epinephrine injected into their cervix prior to the LEEP procedure.
89591605|NCT01913353|Experimental|Group 1|Two vaccinations; MVA BN ®; administered 4 weeks apart (Day 0 and Day 28) followed by a single vaccination of ACAM2000® vaccine 4 weeks after the second MVA BN® vaccination (Day 56).
89591606|NCT01913353|Active Comparator|Group 2|A single vaccination of ACAM2000® will be administered at Day 0.
89591607|NCT01754259|Experimental|Ranolazine|Subject will receive labeled bottles containing tablets with ranolazine 500 mg or a matching placebo provided by the sponsor. Each patient will receive both ranolazine and placebo for 4 weeks, but both the investigator and subject are blinded to the order.
89591608|NCT01754259|Placebo Comparator|Placebo|Subject will receive labeled bottles containing tablets with ranolazine 500 mg or a matching placebo provided by the sponsor. Each patient will receive both ranolazine and placebo for 4 weeks, but both the investigator and subject are blinded to the order.
89591609|NCT04618406|Experimental|PICO VAC|PICO14 device from Smith and Nephew. It is a Single-Use Negative Pressure Wound Therapy Device that provides an effective negative pressure of -80 mmHg for 14 days. It is an easily applied all-in-one system that ensures uniform application each time it is applied. The dressing consists of 4 distinct layers that reduce the risk of skin trauma, applies equal negative pressure to the skin and manages fluid transport away from the wound through a combination of absorption and evaporation through an airlock layer. The device is approved for the treatment of open wounds, closed surgical incisions and skin grafts. Both PICO-VAC and soft dressing are applied immediately postoperatively and removed after 12 days.
89591610|NCT04618406|Active Comparator|Standard care|Standard care (sterile surgical silicone foam dressing and soft dressing)
89591611|NCT01405456|Experimental|Eplerenone and Lifestyle|First 6 months: eplerenone 50mg daily along with lifestyle modification (counseling regarding lifestyle and diet, as well as following healthy activity guidelines) Second 6 months: same (eplerenone open label during second 6 months)
89591612|NCT01405456|Placebo Comparator|Placebo and Lifestyle|First 6 months: placebo pill daily along with lifestyle modification (counseling regarding lifestyle and diet, as well as following healthy activity guidelines) Second 6 months: eplerenone (open label) 50mg daily along with continued lifestyle modification
89591613|NCT04031794||Conventional ARDS treatment group|Patients who they or their 1st degree relative refuse to initiate ECMO. They will receive conventional ARDS treatment.
89591614|NCT04031794||ECMO group|Patients who ECMO is initiated for treat refractory hypoxemia. They will receive conventional ARDS treatment and ECMO support
89591615|NCT01404988|Experimental|Telephone-Delivered BI|Comprehensive behavioral intervention (BI) - Participants will receive the BI that is based on the transtheoretical model, which targets stage of change, decisional balance and self-efficacy, while also assessing and counseling regarding the barriers and facilitators of HF care, and to improve self-regulatory care such as self-monitoring, self-evaluation, feedback and reinforcement.
89591616|NCT01404988|Experimental|Telephone-Delivered BEI|Behavioral & Environmental Intervention (BEI) - Participants in this arm will receive the BI but will also receive environmental tailoring. Environmental Tailoring consists of Built Environment Tailoring (BET) where the intervention will incorporate aspects from the patients' environment, such as accessibility of health food stores or recreational facilities. Environmental Tailoring also consists of Human Environment Tailoring (HET) which incorporates patients' social support. Caregivers will be enrolled for patients in this arm of the study and they will also receive health education.
89209953|NCT02541162|No Intervention|ORDINARY USE|"Non-interventional Group (NI): Couples enrolled during the diagnosis will only receive written information about their experience of disease . The document used fot the non interventional group is Live during and after cancerand will be given to couples. Qualitative analysis will be provided by a psychologist"
89209954|NCT04036656|Experimental|Cohort 1:SYHA136 0.5 mg or Placebo matching SYHA136 0.5 mg|Participants will receive a single oral dose of SYHA136 0.5 mg or Placebo matching SYHA136 0.5 mg under fasted conditions.
89209955|NCT04036656|Experimental|Cohort 2:SYHA136 1 mg or Placebo matching SYHA136 1 mg|Participants will receive a single oral dose of SYHA136 1 mg or Placebo matching SYHA136 1 mg under fasted conditions.
89591617|NCT01404988|Placebo Comparator|Telephone-Delivered API|Attention Placebo Intervention (API) - patients will receive non-tailored counseling on general health topics.
89591618|NCT04043026||WP1: AF + CKD|Anticoagulated participants with atrial fibrillation and chronic kidney disease
88977318|NCT00409591|Active Comparator|1|"NVP-NVP:~In women, one NVP 200 mg tablet at onset of labor;~In neonates, NVP oral suspension 6 mg in the delivery room immediately after birth plus a second dose between 48 and 72 hours"
88977319|NCT00409591|Experimental|2|"PL-NVP:~In women, one placebo tablet at onset of labor;~In neonates, NVP oral suspension 6 mg in the delivery room immediately after birth plus a second dose between 48 and 72 hours"
88977320|NCT00409591|Experimental|3|"LPV/r:~In women, LPV/r 400/100 mg bid from 28 weeks' gestation until delivery"
88977321|NCT00060125|Experimental|Treatment (tipifarnib)|Patients receive oral tipifarnib twice daily on days 1-21. Treatment repeats every 28 days for at least 2 courses and for a maximum of 2 years in the absence of disease progression or unacceptable toxicity. Patients who achieve CR receive 2 additional courses beyond CR.
89209956|NCT04036656|Experimental|Cohort 3:SYHA136 2.5 mg or Placebo matching SYHA136 2.5 mg|Participants will receive a single oral dose of SYHA136 2.5 mg or Placebo matching SYHA136 2.5 mg under fasted conditions.
89209957|NCT04036656|Experimental|Cohort 4:SYHA136 5 mg or Placebo matching SYHA136 5 mg|Participants will receive a single oral dose of SYHA136 5 mg or Placebo matching SYHA136 5 mg under fasted conditions.
89209958|NCT04036656|Experimental|Cohort 5:SYHA136 10 mg or Placebo matching SYHA136 10 mg|Participants will receive a single oral dose of SYHA136 10 mg or Placebo matching SYHA136 10 mg under fasted conditions.
89591619|NCT04043026||WP1: AF + no CKD|Anticoagulated participants with atrial fibrillation and no chronic kidney disease
89591620|NCT04043026||WP1: no AF + CKD|Anticoagulated participants with chronic kidney disease and no atrial fibrillation
88977322|NCT00193648|Active Comparator|1|Avandia (rosiglitazone)
88977323|NCT00193648|Active Comparator|2|Humira (adalimumab)
88977324|NCT00193726|Experimental|Arm B- Experimental|Tab Premarin 0.625 mg (Ethinyl estradiol) once a day for 5 days prior to each cycle of chemotherapy
88977325|NCT00193726|Placebo Comparator|Arm A - Placebo|Tab Placebo once a day for 5 days prior to each cycle of chemotherapy
88977326|NCT00193765|Active Comparator|Wait and Watch|Therapeutic neck dissection on developing nodal relapse
88977327|NCT00193765|Experimental|Elective Neck dissection|Elective neck dissection in early oral cancer at the time of primary surgery
88977328|NCT00060203|Experimental|Brostallicin|
88977329|NCT00193804||2|Patients with histologically proven, cervical cancer FIGO Stage IIB eligible will be invited for the study. The patients will recieve either 3D conformal radiation or IMRT external radiation with concomitant cisplatin chemotherapy followed by brachytherapy.
88977330|NCT00193882|Active Comparator|A: Radiotherapy|Radiotherapy alone
88977331|NCT00193882|Experimental|B: Chemo-radiotherapy|Chemotherapy (Cisplatin + 5-Fluorouracil ) and Radiotherapy
88977332|NCT00193921|Experimental|A|Vinorelbine + cisplatin + high-dose palliative radiotherapy
88977333|NCT00193921|Active Comparator|B|Gemcitabine + high-dose palliative radiotherapy
88977334|NCT00060320|Experimental|black cohost|"Patients receive oral black cohosh twice daily for 4 weeks. All patients then cross over to the other arm and receive treatment for 4 weeks.~After completion of the crossover treatment, all patients may opt to receive open-label black cohosh for an additional 8 weeks.~Patients complete a hot flash diary daily at baseline and during the 8-week double-blind study, and then daily for 8 weeks during optional open-label treatment.~Patients who opt to receive open-label black cohosh are followed at 6 months, 1 year, and 2 years."
88977335|NCT00060320|Placebo Comparator|placebo|"Patients receive oral placebo twice daily for 4 weeks. All patients then cross over to the other arm and receive treatment for 4 weeks.~After completion of the crossover treatment, all patients may opt to receive open-label black cohosh for an additional 8 weeks.~Patients complete a hot flash diary daily at baseline and during the 8-week double-blind study, and then daily for 8 weeks during optional open-label treatment.~Patients who opt to receive open-label black cohosh are followed at 6 months, 1 year, and 2 years."
88977336|NCT00194038|Experimental|1|
88977337|NCT00194194|Active Comparator|moderate|moderate behavioral management
88977338|NCT00194194|Experimental|intensive|intensive behavioral management
88977339|NCT00060359|Experimental|Treatment (paclitaxel poliglumex, carboplatin)|"DOSE-ESCALATION PHASE: Patients receive CT-2103 IV over 10 minutes and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of CT-2103 until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity during the first course of treatment.~FEASIBILITY PHASE: Once the MTD of CT-2103 is determined, an additional 20-40 patients receive treatment at that dose level combined with carboplatin as above."
89591621|NCT04043026||WP1: no AF + no CKD|Anticoagulated participants without atrial fibrillation or chronic kidney disease
89591622|NCT04043026||WP2: AF + CKD|Anticoagulated participants with atrial fibrillation and chronic kidney disease, and are commencing statin therapy
89591623|NCT01389232|Experimental|SeriScaffold® Surgical Scaffold|Participants with breast reconstruction surgery implanted with SERI® Surgical Scaffold.
89591624|NCT01404208|Active Comparator|D-Cycloserine|
89591625|NCT01404208|Placebo Comparator|Sugar Pill|
89591626|NCT01617668|Experimental|Paclitaxel with LCL161|Patients randomized to the experimental arm received paclitaxel 80 mg/m2 weekly + LECL161 1800 mg once weekly for 12 weeks. Equal numbers of patients with gene expression signature positive and negative disease were included in each treatment arm.
89591627|NCT01617668|Active Comparator|Paclitaxel without LCL161|Patients randomized to the control arm received paclitaxel 80 mg/m2 weekly for 12 weeks. Equal numbers of patients with gene expression signature positive and negative disease were included in each treatment arm.
89591628|NCT01425268|Experimental|AeroForm Tissue Expansion|AeroForm Tissue Expansion inflation with carbon dioxide by remote control
89591629|NCT01425268|Active Comparator|Saline Tissue Expansion|Saline Tissue Expansion inflated by needle injections of saline
89591630|NCT01425190|Experimental|Cohort 1: Children 17 to ≥13 years|Participants were administered a single dose of boceprevir powder mixed in a suitable vehicle such pudding or applesauce. The first 4 participants were treated with a 11.4 mg/kg dose of boceprevir powder. The dose/weight ratio may be adjusted for the next 12 participants based on the evaluation of the PK, safety, and tolerability data from the first 4 participants.
89591631|NCT01425190|Experimental|Cohort 2: Children <13 to ≥7 years|Participants were administered a single dose of boceprevir powder mixed in a suitable vehicle such as pudding or applesauce. The first 4 participants were treated with boceprevir at a dose contingent on the PK and safety results in Cohort 1. The dose/weight ratio may be adjusted for the next 12 participants based on the evaluation of the PK, safety, and tolerability data from the first 4 participants.
89591632|NCT01425190|Experimental|Cohort 3: Children <7 to ≥3 years|Participants were administered a single dose of boceprevir powder mixed in a suitable vehicle such as pudding or applesauce. The first 4 participants were treated with boceprevir at a dose contingent on the PK and safety results in Cohort 2. The dose/weight ratio may be adjusted for the next 12 participants based on the evaluation of the PK, safety, and tolerability data from the first 4 participants.
89591633|NCT01388530|Experimental|trigeminal nerve stimulation|Open label treatment with trigeminal nerve stimulation in an 8-week trial.
89591634|NCT01895270|Experimental|Isradipine|Isradipine controlled-release formulation, 10 mg/day maintenance dose, will be administered according to the following dose procedures: Isradipine ingestion will occur under supervision 6 days per week, and a take-home dose will be given on Saturday for participants to take on Sunday. The initial dose of isradipine or placebo will be given on Day 3 of Week 1. The initial dose of isradipine will be 5 mg/day; the dose will increase to 10 mg/day on Day 3 of Week 3 and will continue through Day 2 of Week 7. On Day 3 of Week 7, isradipine will be decreased to 5 mg/day for 7 days. On Days 3-5 of Week 8, all participants will receive placebo. If ISR side effects are too severe at the 10-mg dose, isradipine will be decreased to 5 mg/day. If ISR side effects are too severe at 5 mg/day, isradipine will be discontinued and the participant will be discharged from the study and referred to local treatment agencies.
89591635|NCT01895270|Placebo Comparator|Placebo|Placebo will consist of microcrystalline cellulose. Two placebo capsules will be administered per day starting week 1 day 3 through the end of the isradipine taper.
89591636|NCT01424722|Experimental|ST Monitoring Feature|ST segment continous monitoring feature enabled and programmed ON
89591637|NCT01424644|Placebo Comparator|Placebo + Tdap + HPV|This group will receive Tdap, HPV and placebo concomitantly for the first vaccination. The second and third doses of HPV vaccine will be administered to all subjects 2 and 6 months after the first dose. All subjects will have serum samples collected at Visit 1 (baseline), Visit 2 (31 days) and Visit 5 (7 months after visit 1) for serology testing.
89591638|NCT01424644|Experimental|MenACWY-CRM + Tdap + HPV|This group will receive Tdap, HPV and MenACWY-CRM concomitantly. The second and third doses of HPV vaccine will be administered to this group 2 and 6 months after the first dose. All subjects will have serum samples collected at Visit 1 (baseline), Visit 2 (31 days) and Visit 5 (7 months after visit 1) for serology testing.
89591639|NCT01920854|Experimental|Soluble Ferric Pyrophosphate|Group/Cohort Designation: Ascending doses of SFP. Each subject will receive a defined dose of SFP IV administered under double-blind conditions. Pharmacokinetics of iron will be measured using a validated assay for iron and transferrin bound iron.
89591640|NCT01920854|Placebo Comparator|Control|Group/Cohort Designation: Each subject will receive placebo IV administered under double-blind conditions.
89591641|NCT01403194|Experimental|CPAP/Bi-PAP|Subjects will be treated with either CPAP or Bi-PAP for three months.
89591642|NCT01403116|Experimental|Oral testosterone undecanoate (TU)|"Treatment Period 1: 100 mg capsules, BID, with food~Treatment Period 2: One of the following dosages:~100 mg BID~150 mg BID~100 mg BID~100 mg and 150 mg BID~150 mg capsules BID~Safety Follow-up Phase:~Initial dose: ~84 doses Maintenance dose-Titrated dose: ~96 doses Safety follow-up at maintenance dose: ~540 doses"
88977340|NCT00194311||pregnancy complications|prospective cohort study is to determine if maternal infection with Human papillomavirus (HPV) is associated with pregnancy complications including spontaneous preterm delivery (sPTD), severe preeclampsia (PE) (as per current ACOG: American College of Obstetrics and Gynecology criteria), and intrauterine growth restriction (IUGR).
88977341|NCT00194428|Experimental|1|Almond enriched diet
88977342|NCT00194428|Active Comparator|2|Low-fat diet
88977343|NCT00194467|Experimental|1|
88977344|NCT00194467|Placebo Comparator|2|
88977345|NCT00194545|Experimental|1|Medication diary
88977346|NCT00194545|No Intervention|2|Caregivers only receive counseling which is the standard of care
88977347|NCT00194584|Experimental|1|
88977348|NCT00194584|No Intervention|0|
88977349|NCT00194740|Experimental|1|
88977350|NCT00194818|Active Comparator|1|Asacol 6 tablets BID (4.8 grams/day)
88977351|NCT00194818|Active Comparator|2|Asacol 4 tablets TID (4.8 grams/day)
88977352|NCT00084123|Experimental|Healing Touch|Healing Touch Therapy
88977353|NCT00084123|Active Comparator|Relaxation Therapy|Relaxation Therapy
88977354|NCT00084123|Placebo Comparator|Standard Care|Standard Care
88977355|NCT02963116|Experimental|Treatment A|10 mg rosuvastatin tablet alone (fasting state)
88977356|NCT02963116|Experimental|Treatment B|10 mg rosuvastatin tablet + 200 mg of AZD5718 IR tablet (2 x 100 mg tablet) (fasting state)
88977357|NCT02963116|Experimental|Treatment C|200 mg of AZD5718 IR tablet (2 x 100 mg tablet) (fasting state)
89591643|NCT01403116|Active Comparator|topical testosterone gel|"Treatment Period 1: 5 g of 1% transdermal T-gel applied QD~Treatment Period 2:~2.5 g of 1% transdermal T-gel applied QD~5 g of 1% transdermal T-gel applied QD~7.5 g of 1% transdermal T-gel applied QD~10 g of 1% transdermal T-gel applied QD~Safety Follow-up Phase:~Initial dose: ~42 doses Maintenance dose-Titrated dose: ~48 doses Safety follow-up at maintenance dose: ~270 doses"
89591644|NCT01402570|Experimental|Glutathione supplement|All subjects will be taking a glutathione supplement.Glutathione is a naturally occuring antioxidant and a nonessential amino acid.
89591645|NCT03025204|Active Comparator|GAP Surgical Access (GAP + OFD, 15 patients)|Patients diagnosed with generalized aggressive periodontitis (GAP), in which the previously selected intrabony defect will receive will receive open flap debridement.
89591646|NCT03025204|Experimental|GAP Surgical Access + EMD (GAP + OFD/EMD, 15 patients)|Patients with a diagnosis of generalized aggressive periodontitis (GAP), in which the previously selected intrabony defect will receive open flap debridement and, in addition, application of the EMD in the defect.
89591647|NCT03025204|Active Comparator|GCP Surgical Access + EMD (GCP + OFD/EMD, 15 patients)|Patients with a diagnosis of generalized chronic periodontitis (GCP), in which the previously selected intrabony defect will receive open flap debridement and, in addition, application of the EMD in the defect.
89591648|NCT01753401|Experimental|Period 2: Placebo/Acthar|Participants receive Placebo in Part 1, but after completion of Week 8 in the double-blind phase, patients who received Placebo may choose to participate in the optional open-label phase where they will receive an Acthar maintenance regimen for 44 weeks. The initial Acthar regimen will be assigned based on the study medication regimen the patient received at the completion of the double-blind phase (Visit 6, Week 8). Acthar regimen during Part 2 may be adjusted based on the Investigator's judgment with the goal of achieving a stable Acthar regimen no later than Week 28. Once the stable Acthar regimen is achieved, the Investigator should consider tapering the steroid regimen to a low daily dose or completely discontinue.
89591649|NCT01753401|Experimental|Period 2: Acthar/Acthar|After completion of Week 8 in the double-blind phase, patients who received Acthar may choose to participate in the optional open-label phase where they will receive an Acthar maintenance regimen for 44 weeks. The initial Acthar regimen will be assigned based on the study medication regimen the patient received at the completion of the double-blind phase (Visit 6, Week 8). Acthar regimen may be adjusted based on the Investigator's judgment with the goal of achieving a stable Acthar regimen no later than Week 28. Once the stable Acthar regimen is achieved, the Investigator should consider tapering the steroid regimen to a low daily dose or completely discontinue.
89591650|NCT01753401|Placebo Comparator|Period 1: Placebo|Participants receive matching placebo (in 0.5 mL daily or in 1 mL every other day) for 4 weeks. In Weeks 5-8, they will taper the study medication. Participants will continue on their stable steroid regimen during this phase of the study. After completion of Week 8 in the double-blind phase, they may choose to participate in the optional open-label phase. Participants will continue on their stable steroid regimen during this phase of the study.
89591651|NCT01753401|Experimental|Period 1: Acthar|Participants receive Acthar (40 units in 0.5 mL daily or 80 units in 1 mL every other day) for 4 weeks. In Weeks 5-8, they will taper the study medication. Participants will continue on their stable steroid regimen during this phase of the study. After completion of Week 8 in the double-blind phase, they may choose to participate in the optional open-label phase. Participants will continue on their stable steroid regimen during this phase of the study.
89591652|NCT01618916|Experimental|1.0 milligrams per kilogram (mg/kg) LY3015014 Every 2 Weeks|1.0 mg/kg LY3015014 given subcutaneously (SC) once every 2 weeks for 29 days.
89591653|NCT01618916|Experimental|1.0 mg/kg LY3015014 Every 4 Weeks|1.0 mg/kg LY3015014 given SC once every 4 weeks for 29 days.
89591654|NCT01618916|Experimental|3.0 mg/kg LY3015014 Every 2 Weeks|3.0 mg/kg LY3015014 given SC once every 2 weeks for 29 days.
89591655|NCT01618916|Experimental|3.0 mg/kg LY3015014 Every 4 Weeks|3.0 mg/kg LY3015014 given SC once every 4 weeks for 29 days.
89591656|NCT01618916|Placebo Comparator|Placebo Every 2 Weeks|Saline injection (to match LY3015014) given SC once every 2 weeks for 29 days.
88977358|NCT02963116|Experimental|Treatment D|200 mg of AZD5718 oral suspension 50 mg/mL (fasting state)
88977359|NCT02963116|Experimental|Treatment E|200 mg of AZD5718 IR tablet (2 x 100 mg tablet) (fed state)
88977360|NCT02969057|No Intervention|Breakfast only|Control breakfast providing 50g carbohydrate
88977361|NCT02969057|Active Comparator|Breakfast with rice bran oil gel|Control breakfast, plus 25g rice bran oil gel (solid)
88977362|NCT02969057|Active Comparator|Breakfast with rice bran oil|Control breakfast, plus 25g rice bran oil (liquid)
88977363|NCT02969057|Active Comparator|Breakfast with palm oil gel|Control breakfast, plus 25g palm oil gel (solid)
88977364|NCT02969057|Active Comparator|Breakfast with palm oil|Control breakfast, plus 25g palm oil (liquid)
88977365|NCT02968706|Experimental|High flow cannula arm|Patients in the experimental arm (the high flow nasal cannula group) will receive heated humidified high flow oxygen of 50L/min at FiO2 of 40% throughout the colonoscopy. A patient satisfaction survey will be administered after procedure.
88977366|NCT02968706|Active Comparator|Conventional cannula arm|Participants in control arm (the conventional nasal cannula group) will receive an oxygen flow of 2-5 L /min. A patient satisfaction survey will be administered after procedure.
88977367|NCT00195910|Active Comparator|Morphine|"single dose of intravenous (IV) morphine, 0.1 mg/kg~intervention: 0.1 mg/kg IV morphine"
88977368|NCT00195910|Experimental|Hydromorphone|"single dose of intravenous (IV) hydromorphone, 0.015 mg/kg~intervention: 0.015 mg/kg IV hydromorphone"
88977369|NCT00196144|Experimental|1|Optimization of the postventricular atrial blanking period to avoid far-field R-wave sensing.
88977370|NCT00196144|Experimental|2|Programming of the nominal setting for the post-ventricular atrial blanking period (100 ms)
88977371|NCT00196183|Experimental|1|trigger-guided ablation of paroxysmal atrial fibrillation
88977372|NCT00196183|Experimental|2|trigger-+substrate guided ablation of paroxysmal atrial fibrillation
88977373|NCT00196222|Experimental|1|RF ablation/modulation of the slow pathway in AV nodal reentrant tachycardia
88977374|NCT00196222|Experimental|2|cryo energy ablation/modulation of the slow pathway in AV nodal reentrant tachycardia
88977375|NCT00196378|Experimental|1|
89591657|NCT01618916|Placebo Comparator|Placebo Every 4 Weeks|Saline injection (to match LY3015014) given SC once every 4 weeks for 29 days.
89591658|NCT01753323|Experimental|Part 1 - Cohort 1: P. vivax: KAF156 400mg QD|Participants with Plasmodium vivax malaria received KAF156 400 mg once a day for three days.
89591659|NCT01753323|Experimental|Part 1 - Cohort 2: P. falciparum: KAF156 400mg QD|Participants with Plasmodium falciparum malaria received KAF156 400mg once a day for three days.
89591660|NCT01753323|Experimental|Part 2 - Cohort 3: P. falciparum: KAF156 800mg single dose|Participants with Plasmodium falciparum malaria received a single dose of KAF156 800mg.
89591661|NCT01894568|Experimental|Insulin Peglispro|Insulin Peglispro administered subcutaneously (SC) once daily for 26 weeks in combination with Oral Antihyperglycemic Medications (OAMs).
89591662|NCT01894568|Active Comparator|Insulin Glargine|Insulin Glargine administered SC once daily for 26 weeks in combination with OAMs.
89591663|NCT01618838|Other|CyberKnife Radiosurgery, Colonoscopy|CyberKnife radiosurgery for prostate cancer; bowel toxicity will be evaluated at 2 years by colonoscopy (lower endoscopy).
89209959|NCT04036656|Experimental|Cohort 6:SYHA136 20 mg or Placebo matching SYHA136 20 mg|Participants will receive a single oral dose of SYHA136 20 mg or Placebo matching SYHA136 20 mg under fasted conditions.
89591664|NCT01920152|Experimental|Autologous PRP Hip Injection|Patients randomized to this group of treatment will receive 3 blinded hip intra-articular injections of autologous Platelet-Rich Plasma one week apart from each other.
89591665|NCT01920152|Active Comparator|Hyaluronic Acid Hip Injection|Patients randomized to this group of treatment will receive 3 blinded hip intra-articular injections of hyaluronic acid (SUPARTZ hyaluronate/2.5ml) one week apart each other.
89591666|NCT01752933|Experimental|SGI-110|SGI-110 administered subcutaneously (SC) daily on Days 1 - 5 every 28 days
89591667|NCT01752855|Experimental|New formulation of adalimumab 40 mg every other week|New formulation adalimumab 40 mg every other week
89591668|NCT01402492|Experimental|BUP4+XR-NTX|4mg buprenorphine plus naltrexone for 8 weeks of treatment
89591669|NCT01402492|Experimental|BUP16+XR-NTX|16mg buprenorphine plus naltrexone for 8 weeks of treatment
89591670|NCT01402492|Active Comparator|PLB+XR-NTX|naltrexone for 8 weeks of treatment
89591671|NCT01402102|Experimental|Aged garlic powder|
89591672|NCT01402102|Placebo Comparator|Placebo|
89591673|NCT04029220|Experimental|Parent Peer Navigation (PPN) by Family Run Organization|In this arm, families receive PPN services from a trained provider with lived experience whose role is to effectively engage parents/caregivers in necessary treatment for their children by helping them connect with assessment, treatment and community-based resources and prepare them to independently navigate the child serving system, community-based resources, and ongoing opportunities for support once the PPN is no longer involved. PPN providers use the foundational competencies and skills to educate, inform and support families who are just entering the child-serving systems due to emerging behavioral health issues of their child.
88977376|NCT00196378|Placebo Comparator|2|
89209960|NCT04036656|Experimental|Cohort 7:SYHA136 35 mg or Placebo matching SYHA136 35 mg|Participants will receive a single oral dose of SYHA136 35 mg or Placebo matching SYHA136 35 mg under fasted conditions.
89209961|NCT04036656|Experimental|Cohort 1:SYHA136 50 mg or Placebo matching SYHA136 50 mg|Participants will receive a single oral dose of SYHA136 50 mg or Placebo matching SYHA136 50 mg under fasted conditions.
89591674|NCT04029220|Active Comparator|Resources provided by Family Support Organization|"The active comparator is service provided by Family Support Organizations (FSOs), which provide information and resources for families about disabilities, special education and other services as well as workshops and parent support groups. Unlike PPN services, FSO staff members are not veteran caregivers of a child with mental health challenges, do not provide personalized service delivery, do not provide a comprehensive assessment of family needs, and do not prepare families to make use of services through support for their initial and continued involvement in them. Finally, whereas PPNs participate in comprehensive training and coaching, training for FSO staff tends to be more general and consists primarily of being aware of local resources to which families may be referred."
89591675|NCT01423084|Experimental|MenB Lot 1|MenB vaccine Lot 1: 2 doses administered 1 month apart
89591676|NCT01423084|Active Comparator|MenB Lot 2|MenB vaccine Lot 2: 2 doses administered 1 month apart
88977377|NCT00048087|Experimental|Iressa + Docetaxel|
88977378|NCT00196573|Active Comparator|Shoulder bursectomy and acromioplasty|
88977379|NCT00048126|Experimental|1|
88977380|NCT00084396|Experimental|Letrozole/Surgery|
88977381|NCT00196807|Experimental|Information plus DA at home|
89591677|NCT04042168|Experimental|Intervention|Inappropriate use of inhalers and medication change. Pre-post intervention data will be compared.
88977382|NCT00196807|Active Comparator|UC Information at home|
88977383|NCT00196807|Experimental|Information plus decision aid at clinic|
88977384|NCT00196807|Active Comparator|UC Information at clinic|
88977385|NCT00060632|Experimental|Cohort 1: Ridaforolimus 6.25 mg|
88977386|NCT00060632|Experimental|Cohort 2: Ridaforolimus 12.5 mg|
88977387|NCT00060632|Experimental|Cohort 3: Ridaforolimus 25 mg|
88977388|NCT00060632|Experimental|Cohort 4: Ridaforolimus 50 mg|
88977389|NCT00060632|Experimental|Cohort 5: Ridaforolimus 100 mg|
88977390|NCT00060632|Experimental|Cohort 6: Ridaforolimus 75 mg|
88977391|NCT00409864|Active Comparator|PTBD|percutaneous biliary drainage
88977392|NCT00409864|Active Comparator|Endoscopic stenting|ERCP and stenting
88977393|NCT02968511|Experimental|fecal microbiota transplant|250 mL of fecal transplant material by enema as treatment
88977394|NCT00084435|Experimental|chemoRT after surgery|chemoRT with cisplatin and docetaxel after surgery
88977395|NCT02962999|Experimental|Ketamine|After induction, patients will be received 1 mg/kg ketamine bolus, then will be administered 0,5 mg/kg/hour ketamine infusion intraoperatively. Anesthesia will be maintained with %4-6 desflurane and 0,25-0,5 microgram/dk/min remifentanil.
88977396|NCT02962999|Placebo Comparator|Saline|After induction, patients will be received saline bolus, then will be administered saline infusion intraoperatively. Anesthesia will be maintained with %4-6 desflurane and 0,25-0,5 microgram/dk/min remifentanil.
88977397|NCT04710589||CTV 3mm|CTV is expanded by 3mm on the basis of GTV.
88977398|NCT04710589||CTV 6mm|CTV is expanded by 6mm on the basis of GTV.
89591678|NCT04026334|Experimental|V.A.C. VERAFLO CLEANSE CHOICE™ with Normal Saline|
89591679|NCT01894256|Other|Normal renal function|Patients with calculated serum creatinine clearance ≥81 mL/min (using Cockcroft-Gault equation).
89591680|NCT01894256|Other|Mild renal impairment|Patients with calculated serum creatinine clearance 51-80 mL/min (using Cockcroft-Gault equation).
89591681|NCT01894256|Other|Moderate renal impairment|Patients with calculated serum creatinine clearance 31-50 mL/min (using Cockcroft-Gault equation).
89591682|NCT01780935|Experimental|RBZ 0.5 mg: VA only (Group I)|RBZ 0.5 mg: Visual Acuity (VA) only (Group I) 0.5 mg intravitreal injections of ranibizumab with retreatment based on best-corrected visual acuity (BCVA) loss due to neovascular (wet) age-related macular degeneration (nAMD)
89591683|NCT01780935|Experimental|RBZ 0.5 mg: VA and/or OCT (Group II)|RBZ 0.5 mg: VA and/or OCT (Group II) 0.5 mg intravitreal injections of ranibizumab with retreatment based on best-corrected visual acuity (BCVA)loss due to neovascular (wet) age-related macular degeneration (nAMD) and/or signs of wet AMD disease activity on optical coherence tomography (OCT).
89591684|NCT01894100|Other|Delayed Intervention Group|This group will not receive shoe lifts during the first 3 months after baseline. At 3 months, they will begin the shoe lift correction for leg length inequality.
89591685|NCT01894100|Experimental|Immediate Intervention Group|At baseline, participants in this group will begin shoe lift correction for leg length inequality.
89591686|NCT02334982|Experimental|Cohort 1: TAK-137 2 mg|TAK-137 2 mg, tablets, orally, once on Day 1.
89591687|NCT02334982|Experimental|Cohort 2: TAK-137 5 mg|TAK-137 5 mg, tablets, orally, once on Day 1.
89591688|NCT02334982|Experimental|Cohort 3: TAK-137 10 mg|TAK-137 10 mg, tablets, orally, once on Day 1.
89591689|NCT02334982|Experimental|Cohort 4: TAK-137 5 mg Food Effect|TAK-137 5 mg, tablets, orally, under fasted conditions, once on Day 1 of Period 1, followed by 14 days of follow-up, followed by TAK-137 5 mg, tablets, orally, under fed conditions, once on Day 1 of Period 2.
89591690|NCT02334982|Experimental|Cohort 5: TAK-137 0.5 mg|TAK-137 0.5 mg, tablets, orally, once on Day 1.
89591691|NCT02334982|Experimental|Cohort 6: TAK-137 20 mg|TAK-137 20 mg, tablets, orally, once on Day 1.
89591692|NCT02334982|Placebo Comparator|Cohorts 1-6: Placebo|TAK-137 placebo-matching tablets, orally, once on Day 1.
89591693|NCT01401478||Stage 5 Chronic Kidney Disease|Planned for Zemplar administration due to secondary hyperparathyroidism
89591694|NCT03025516||Adults with pulmonary TB symptoms|"All patients will be tested with both the reference and index TB diagnostic tests. Index test results will not be used to inform case management.~All samples must be collected before the patient starts any form of TB treatment. Patients will be randomized to receive either the TB Breathalyser or AeonoseTM on Day 1, and will be tested with the remaining breath-test on Day 2. A follow-up evaluation will be required after 8 weeks for all patients who do not have microbiologic confirmation of TB (smear or culture). Two additional breath samples may also be collected upon follow-up."
89591695|NCT01422538|Active Comparator|Group A|Subjects will receive Ulthera® System alone.
89591696|NCT01422538|Active Comparator|Group B|Sculptra® only
89591697|NCT01422538|Active Comparator|Group C|Sculptra® treatment followed by Ultherapy™ treatment
89591698|NCT04025866|Active Comparator|Conventional rehabilitation|Conventional rehabilitation treatment for inpatients with femur fracture
89591699|NCT04025866|Active Comparator|Aerobic exercise|Addition of cycle ergometer for upper limb to conventional rehabilitation treatment for femur fracture
89591700|NCT01422382|Experimental|All Subjects|There was 1 treatment period, with each subject receiving a once-daily dose of pitavastatin 4 mg on Days 1 through 5 and on Days 11 through 15 and a once-daily dose of diltiazem 240 mg on Days 6 through 15
88977399|NCT00197548|Active Comparator|Multivitamins|Multivitamins-vitamins B-complex, C, and E
89209962|NCT02541240|Experimental|Resilience Curriculum|The intervention is exposure to an 8-hour Resilience Curriculum. It will provide education for participants about methods to increase protective factors against stress, the use of effective coping strategies, and the importance of accessing social support, with the goal of better managing stress and enhancing resilience. The curriculum will include a didactic component, skills-building training, and homework exercises to encourage the application of the skills.
89209963|NCT02541240|No Intervention|No Resilience Curriculum|The Waitlist Control group will receive no exposure to the Resilience Curriculum. After the final data is collected, this group will be offered the opportunity to attend a condensed 2-hour version of the curriculum.
89591701|NCT01401322|Experimental|Lenalidomide 50 mg/day x 28 days|Lenalidomide 50 mg daily for 28 consecutive days every 42 days (+/-7 days). Treatment to continue until evidence of disease progression or development of unexpected toxicities not reversed by dose reductions and/or interruptions.
89591702|NCT01387594|Experimental|Cohort 1|Interventions prior to treatment. Control arm
89591703|NCT01387594|Experimental|Cohort 2|Interventions prior to and after 3 monthly injections
89591704|NCT01401010|Active Comparator|Doripenem 500 mg|pharmacokinetics/pharmacodynamics
89591705|NCT01401010|Active Comparator|Doripenem 1000 mg|pharmacokinetics/pharmacodynamics
88977400|NCT00197548|Placebo Comparator|Placebo|Placebo pill
89591706|NCT01400932|Experimental|GI148512 (Benzoyl Peroxide 3% Gel)|Subjects will apply in a quantity sufficient to cover the entire face (including the forehead, nose, cheeks, and chin). Also, the dose regimen will be once daily in the evening/bedtime. Comparison of 2 arms (GI148512 vs vehicle)
89591707|NCT01400932|Placebo Comparator|vehicle gel|Subjects will apply in a quantity sufficient to cover the entire face (including the forehead, nose, cheeks, and chin). Also, the dose regimen will be once daily in the evening/bedtime.
89591708|NCT01400698|Experimental|Saizen® (Continuous or intermittent treatment)|
89591709|NCT01400698|Experimental|Saizen® (Observed and then continuous or no treatment)|
89591710|NCT01400698|Other|Observation only|
88977401|NCT00197587|Active Comparator|maternal nevirapine|
88977402|NCT00197587|Placebo Comparator|maternal placebo|
88977403|NCT00197704|Placebo Comparator|Placebo|Placebo
88977404|NCT00197704|Experimental|Multivitamins|5000 IU of retinol, 20 mg of B1, 20 mg of B2, 25 mg of B6, 100 mg of niacin, 50 mcg of B12, 500 of C, 200 mg of E, 0.8 mg of folic acid, and 100 mcg of selenium
89591711|NCT01890746|Experimental|Eltrombopag arm|Subjects received induction chemotherapy consisting of daunorubicin bolus intravenous (IV) infusion on Days 1-3 + cytarabine continuous IV infusion on Days 1-7 followed by Eltrombopag once daily orally starting on Day 4 of initial induction chemotherapy. If platelet count was not greater than 100 Gi/L after 7 days the dose was increased until a platelet count of at least 200 Gi/L was achieved/until remission was assessed/ maximum of 42 days from the start of the chemotherapy induction. Subjects who were not aplastic after first cycle of induction chemotherapy received second induction chemotherapy with a modified daunorubicin dose on Days 1-3 + cytarabine on Days 1-7.
89591712|NCT01890746|Placebo Comparator|Placebo arm|Subject received induction chemotherapy consisting of daunorubicin bolus IV infusion on Days 1-3 + cytarabine continuous IV infusion on Days 1-7 followed by matching placebo once daily oral dose starting on Day 4 of initial induction chemotherapy. If platelet count was not greater than 100 Gi/L after 7 days the matching placebo was given until a platelet count of at least 200 Gi/L was achieved/ until remission was assessed/ maximum of 42 days from the start of the chemotherapy induction. Subjects who were not aplastic after first cycle of induction chemotherapy received a second induction chemotherapy with a modified daunorubicin dose on Days 1-3 + cytarabine on Days 1-7.
89591713|NCT04614350|Experimental|A-Active|Markman Biologics microsurfaced ADM
89591714|NCT04614350|Active Comparator|B-Control|AlloDerm ADM
89591715|NCT01422304|Experimental|Sugammadex|Prior to randomization, participants will be assigned to planned active reversal or planned spontaneous recovery by the anesthesiologist according to the recovery method the anesthesiologist would have chosen if the participant were not in the study. In this treatment arm, participants assigned to planned active reversal will receive sugammadex and placebo to neostigmine, and participants assigned to planned spontaneous recovery will receive sugammadex. Study drug will be administered after the last dose of rocuronium or vecuronium and after wound closure.
89591716|NCT01422304|Experimental|Usual Care|Prior to randomization, participants will be assigned to planned active reversal or planned spontaneous recovery by the anesthesiologist according to the recovery method the anesthesiologist would have chosen if the participant were not in the study. In this treatment arm, participants assigned to planned active reversal will receive neostigmine and placebo to sugammadex, and participants assigned to planned spontaneous recovery will receive placebo to sugammadex. Study drug will be administered after the last dose of rocuronium or vecuronium and after wound closure.
89591717|NCT01387516|Experimental|Motivational Intervention|Motivational Interviewing (MI) will be a 60-90 minutes individual session.The focus is on establishing rapport and building motivation. The counselor explores youth's reasons for entering treatment, prior treatment experience, previous attempts to change use, possible goals for treatment, substance effect expectancy, and perceptions of self-efficacy. A personalized feedback report outlines assessment results, highlights any problems or concerns related to cigarette use expressed by teen, and compares tobacco use levels with national norms for same age and gender peers.
89591718|NCT01387516|Active Comparator|Relaxation Intervention|The Relaxation Therapy intervention is a 60-90 minute individual session. The session encompasses several techniques, including Progressive Muscle Relaxation and Visualization-Imagination, and as a whole is really a meditation protocol.
89591719|NCT01387516|Experimental|Cognitive Behavioral Therapy|The Cognitive Behavioral Therapy (CBT) Intervention is administered during two 90 minute group sessions. The focus is on the interrelationship between thoughts, feelings, and behaviors. It is used to address specific deficits, such as improving problem solving skills and developing social supports, and behaviors such as substance abuse and smoking.
89591720|NCT01387516|Active Comparator|Self-Help Programming|"Self Help intervention is administered during two 90 minute group sessions. The intervention modules are based on the principles of Nicotine Anonymous (NicA), to provide those who use nicotine but wants a nicotine-free life, with a community of people that has also experienced nicotine addiction and strives to be nicotine free. Elements incorporated in this intervention include the 12 Steps and the NicA tools (i.e., meetings, phone list, literature, sponsorship, and service) to facilitate and maintain abstinence from nicotine."
89591721|NCT03812146|Experimental|PC-TIME|PC-TIME consists of meeting with a behavioral health provider for 5, 30-minute sessions that will be delivered over the course of 8 weeks (spaced about 1-2 weeks apart). PC-TIME sessions integrate two effective treatments: motivational enhancement therapy approaches and brief Prolonged Exposure.
89591722|NCT03812146|Active Comparator|PC-TAU|Primary Care - treatment as usual. Participants in PC-TAU will be referred to the PCMHI mental health provider within their primary care team, and will receive whichever care or intervention is typically provided. PCMHI in VA consists of licensed, independent providers (typically psychologists or clinical social workers) providing brief assessment and interventions to veterans and consultation to other members of the PC team.
88977405|NCT00197743|Active Comparator|Vitamin A|Vitamin A + Beta Carotene
88977406|NCT00197743|Active Comparator|Multivitamins|Vitamins B, C, and E
88977407|NCT00197743|Active Comparator|Vitamin A + Multivitamins|Vitamin A + Beta Carotene, Vitamins B, C, and E
88977408|NCT00197743|Placebo Comparator|Placebo|Placebo
88977409|NCT00084630|Experimental|Treatment (imatinib mesylate)|Patients receive oral imatinib mesylate once daily on days 1-56. Treatment repeats every 56 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients with documented tumor progression and no serious side effects may continue therapy at a higher dose for another 6 courses.
88977410|NCT02963233||Non-operative Group|Patients treated within the non-operative group will be treated with gentle reduction by the orthopaedic surgery team in the emergency department under procedural sedation. Immobilization and maintenance of reduction will be obtained through either taping of the elbow in a flexed (100-110 degree) and pronated position or through long-arm casting at 90 degrees of flexion. Immobilization type and position will be noted.
88977411|NCT02963233||Operative Group|Patients treated operatively will be largely treated with closed reduction and percutaneous pinning with 2-3 laterally-based k-wires, followed by long-arm immobilization. Immobilization type and position will be noted.
88977412|NCT00198055|Experimental|Aripiprazole|Aripiprazole 5 mg per day for 2 weeks, then can be increased to 10mg per day if tolerated for 2 weeks, then can be increased to 15 mg per day for 4 weeks.
89030900|NCT05148416|Experimental|Laser group|"1. Experimental group (A) the laser group (n=20) which received~high intensity laser therapy(HILT)~knee osteoarthritis conventional exercises program in form of stretching exercises for both vastus medialis and gastrocnemius muscles , ROM exercises for knee flexion and extension , and isometric strengthening exercise of previously mentioned muscles .~all interventions were done under the supervision of physiotherapist for 30 minutes once a day for 3 days per week during a period of 4 weeks."
89030901|NCT05148416|Sham Comparator|the sham group group( B)|"the Sham group (n= 20) which received~sham HILT~knee osteoarthritis conventional exercises program previously mentioned .~all interventions were done under the supervision of physiotherapist for 30 minutes once a day for 3 days per week during a period of 4 weeks."
89030902|NCT02947932|Experimental|Pre-ERCP group Oral resveratrol in in all patients.|Oral resveratrol was administrated within 1hour before ERCP in all patients.
89591723|NCT01421134|Experimental|Lurasidone|Lurasidone 20, 40 or 60 mg
89591724|NCT01421134|Placebo Comparator|Placebo|Placebo
89591725|NCT01894022|Experimental|Ambrisentan Arm|All subjects will receive ambrisentan initially at a dose of 5 mg once daily (OD). Based on the investigator's best judgment, the subject may continue on 5 mg OD, or be up-titrated to 10 mg OD. The dose may also be adjusted back to 5 mg OD at investigator discretion.
89591726|NCT01615328|Experimental|Cervios ChronOs|The ACDF surgery will be carried out with Cervios ChronOs(TM), which is the PEEK cage filled with b-TCP.
89591727|NCT01615328|Experimental|Bonion|The ACDF surgery will be carried out with Bonion(TM), which is the PEEK cage with HA/DBM.
89591728|NCT01890512||ImageReady Pacemaker|patients previously implanted with a Boston Scientific MR Conditional pacemaker(ImageReady)
89591729|NCT01387282|Active Comparator|100 mg QD|Investigational: Anamorelin HCl; 100 mg tablets; oral administration QD for 12 weeks, at least 1 hour before the first meal of the day.
89030903|NCT02947932|Active Comparator|Post-ERCP rectal Indomethacin in high-risk patients.|Rectal Indomethacin was administrated immediately after ERCP in high-risk patients, while average risk patients did not.
89030904|NCT02947893|Placebo Comparator|Group 1 (placebo)|Out of 42 total participants with mild to moderate AD (MMSE=17-24 inclusive) and their study partners that will be recruited and 1:1 randomized, 21 (twenty-one) will be assigned to group 1 and given 1 capsule of a placebo drug by mouth every day for the first 6 months followed by 2 capsules once daily for the subsequent 6 months, every time taken without a meal, for the total duration of the study for 12 months.
89591730|NCT01387282|Placebo Comparator|Placebo|Placebo tablets identical in appearance to active tablets; oral administration once daily
89591731|NCT01386970|Active Comparator|HIV-negative|This group was used to compare intracellular ZDV- and 3TC-triphosphate concentrations to the HIV-infected group and in men versus women.
89030905|NCT02947893|Active Comparator|Group 2 (treated)|Out of 42 total participants with mild to moderate AD (MMSE=17-24 inclusive) and their study partners that will be recruited and 1:1 randomized, 21 (twenty-one) will be assigned to group 2 treated with 1 capsule (150mg Nilotinib) once a day by mouth for the first 6 months followed by dose escalation to 2 capsules (300mg Nilotinib) once daily by mouth for the subsequent 6 months, every time taken without a meal, for the total study duration of 12 months.
89030906|NCT05141747|Experimental|MRG002|MRG002 will be administrated by an IV infusion of 2.6 mg/kg on Day 1 of every 3 weeks (21-day cycle).
89591732|NCT01386970|Active Comparator|HIV-infected|This group was started on ZDV-3TC based therapy. Intracellular ZDV- and 3TC-triphosphate concentrations were compared in men versus women and the HIV-negative group.
89591733|NCT01890434|Experimental|Gadobutrol 0.1 mmol/kg body weight|Participants received gadobutrol at the total approved standard dose of 0.1 millimole per kilogram body weight (mmol/kg BW) in 2 separate bolus injections: 0.05 mmol/kg BW at peak pharmacologic stress and 0.05 mmol/kg BW at rest via a power injector.
89591734|NCT01385566|Active Comparator|Full Dose Subcutaneous|Participants will receive a full dose of ZOSTAVAX™ administered subcutaneously on Day 1 of the study. Nine participants in this group will also receive saline placebo intradermally in the alternate limb on Day 1.
89591735|NCT01385566|Experimental|1/3 Dose Subcutaneous|Participants will receive a 1/3 dose of ZOSTAVAX™ administered subcutaneously on Day 1 of the study. Six participants in this group will also receive saline placebo intradermally in the alternate limb on Day 1. Participants will have the option to receive a full subcutaneous dose of ZOSTAVAX™ after completion of the study.
89591736|NCT01385566|Experimental|Full Dose Intradermal|Participants will receive a full dose of ZOSTAVAX™ administered intradermally on Day 1 of the study. Six participants in this group will also receive saline placebo intradermally in the alternate limb on Day 1. Participants will have the option to receive a full subcutaneous dose of ZOSTAVAX™ after completion of the study.
89591737|NCT01385566|Experimental|1/3 Dose Intradermal|Participants will receive a 1/3 dose of ZOSTAVAX™ administered intradermally on Day 1 of the study. Six participants in this group will also receive saline placebo intradermally in the alternate limb on Day 1. Participants will have the option to receive a full subcutaneous dose of ZOSTAVAX™ after completion of the study.
89591738|NCT01385566|Experimental|1/10 Dose Intradermal|Participants will receive a 1/10 dose of ZOSTAVAX™ administered intradermally on Day 1 of the study. Six participants in this group will also receive saline placebo intradermally in the alternate limb on Day 1. Participants will have the option to receive a full subcutaneous dose of ZOSTAVAX™ after completion of the study.
89030907|NCT05146154|Experimental|Pharmacokinetic cohort|After at least 2 doses of study drug, serial blood samples will be collected from 12 non-infected, obese ICU patients to evaluate the pharmacokinetics of imipenem and relebactam in this population.
89030908|NCT05146154|Experimental|Safety cohort|After at least 2 doses of study drug, safety will be monitored closely during study drug dosing and through 72 hours after the last dose is administered in the same 12 non-infected, obese ICU patients from the PK arm
89030909|NCT00524667|Experimental|1|
89030910|NCT05145686|Experimental|Comparing MMP-2, -8, -9 in reversible and irreversible pulpitis|The coronal pulp samples from both reversible and irreversible groups were placed in an eppendorf tube containing TriPure Reagent transport medium. The MMP-2, -8 and -9 expression levels were determined with specific primers by real time polymerase chain reaction method (RT-PCR).
89030911|NCT05145686|Active Comparator|Comparing the clinical success of MTA and Biodientine in primary molar pulpotomy treatments|In reversible pulpitis group MTA (ProRoot MTA,white) was used in 21 teeth and Biodentine was used in the other 21 teeth for pulpotomy treatments. Final restorations were performed with stainless steel crowns in both group. At the end of 3, 6 and 9 months, all teeth were evaluated clinically and radiographically based on AAPD criteria: (1) absence of spontaneous pain and/or sensitivity to pressure; (2) absence of sinus, fistula, edema, and/or abnormal mobility; (3) absence of radiolucency at the interradicular and/or periapical regions; (4) absence of internal or external root resorption.
89030912|NCT05145179|Experimental|HER2-expressing Solid Tumors|SSGJ-705 Administered via intravenous (IV) infusion
89030913|NCT04692987|Experimental|Intervention|Participants will receive decision-aid video
89030914|NCT04692987|No Intervention|Usual care|Participants will receive usual care
89030915|NCT05147870||Irrigation group|
89030916|NCT05147870||Suction only group|
89030917|NCT02947698||Acute kidney injury patients admitted on weekday|All patients with acute kidney injury requiring dialysis admitted on week day (Monday to Friday) between 1st April 2003 and 31st March 2015
89030918|NCT02947698||Acute kidney injury patients admitted on weekend|All patients with acute kidney injury requiring dialysis admitted on weekend (Saturday or Sunday) between 1st April 2003 and 31st March 2015
89591739|NCT01385566|Experimental|1/27 Dose Intradermal|Participants will receive a 1/27 dose of ZOSTAVAX™ administered intradermally on Day 1 of the study. Six participants in this group will also receive saline placebo intradermally in the alternate limb on Day 1. Participants will have the option to receive a full subcutaneous dose of ZOSTAVAX™ after completion of the study.
89591740|NCT05365984|Experimental|innavative modeled strategy|In this arm, the risk evaluation before discharge for hyperbilirubenemia needing further intervention is based on Bhutani nomogram and end tidal carbon monoxide corrected for ambient carbon monoxide. Assessment result includes high risk, median risk, low risk and delayed discharge. Internet Plus technology is applied in follow-up management.
89591741|NCT05365984|No Intervention|traditional strategy|In this arm, the risk evaluation before discharge for hyperbilirubenemia needing further intervention is based on Bhutani nomogram and the follow-up table advised by the Chinese guideline for neonatal hyperbilirubinemia. Assessment result includes high risk, median risk and low risk. Traditional outpatient is applied in follow-up management.
89591742|NCT01780545|Experimental|Experimental Arm: Arm A|Three doses of 600 mg OGX-427 will be administered IV during the loading dose period (days -9 to -1). Following completion of the loading dose period, 600 mg OGX-427 will be given IV weekly on days 1, 8, and 15 of each 21-day cycle.
89591743|NCT01780545|Active Comparator|Control Arm: Arm B|Docetaxel (75 mg/M2) will be administered IV on day 1 of each 21 day cycle for a maximum of 10 cycles.
89591744|NCT01780389|Experimental|Milnacipran|Open-label flexibly dosed milnacipran
89591745|NCT01778985|Experimental|Premarin|Premarin cream 0.625mg/1gm. Applied to vagina by applicator as 1gm nightly for 2 weeks then 1gm 2 nights per week for 4-6 weeks or until day of surgery.
89591746|NCT01778985|Placebo Comparator|Placebo|Placebo cream, applied to vagina by applicator as 1gm nightly for 2 weeks then 1gm 2 nights per week for 4-6 weeks or until day of surgery.
89591747|NCT01778751|No Intervention|Control|Veterans will receive diabetes educational materials and management per their primary provider
89591748|NCT01778751|Experimental|Intervention|Veterans randomized to the intervention arm will be enrolled in the HT program, provided with standard telemonitoring equipment by HT nursing staff (current HT practice at DVAMC is use of the Health Buddy 3 device for patients with landline phones and the Cardiocom Interactive Voice Response System for patients with cell phones), and will receive the study intervention for 6 months. Veterans without depressive symptoms on baseline PHQ-9 assessment (PHQ-9 < 10) will not initially be entered into the depressive symptom management component of the intervention, but will be monitored for new symptoms throughout the intervention.
89591749|NCT01865084|Experimental|Placebo|Placebo taken orally once daily.
89591750|NCT01865084|Experimental|0.3 mg/kg Tadalafil|0.3 milligram per kilogram (mg/kg) tadalafil taken orally once daily.
89591751|NCT01865084|Experimental|0.6 mg/kg Tadalafil|0.6 mg/kg tadalafil taken orally once daily.
89591752|NCT01778127|Experimental|Group A: Minimal Rewards|Participants use an activity monitor and the interactive website. They will receive minimal rewards based on their physical activity levels.
89030919|NCT05142644||Early / growth restriction|Intrauterine growth restriction with onset before 32 weeks of gestation
89030920|NCT05142644||Late growth restriction|Intrauterine growth restriction with onset after 32 weeks of gestation
89030921|NCT02947542|Experimental|BLK catheter|Coronary angiography will be performed with the BLK catheter (one-catheter concept).
89030922|NCT02947542|Experimental|Tiger catheter|Coronary angiography will be performed with the Tiger catheter (one-catheter concept).
89030923|NCT02947542|Active Comparator|Judkins catheter|Coronary angiography will be performed with the Judkins catheter (standard catheter).
89030924|NCT02946762|Other|Universal Test and Treat|All incarcerated individuals with HIV infection will receive antiretroviral therapy (ART) by test and treat.
89030925|NCT00507182|Experimental|Fluorescence Spectroscopy|1-5 lesions + several normal-looking areas inside the mouth exposed to a beam of light; exposed tissues will emit very small amounts of fluorescence (light) then will be removed.
89030926|NCT00525993|Experimental|A|
89030927|NCT00525993|Active Comparator|B|
89030928|NCT00526032||Spectroscopic Oblique-Incidence Reflectometry (OIR)|
89030929|NCT02947854|Experimental|Photosensitizer and adjuvant|Run-in cohort for selection of fimaporfin starting dose in the main study. Single intradermal dosing of fimaporfin and adjuvant (Hiltonol [poly-ICLC]) followed by light application.
89030930|NCT02947854|Experimental|Photosensitizer, adjuvant and antigens|Main part: Intradermal dosing of fimaporfin, adjuvant (Hiltonol, poly-ICLC) and antigens (KLH and HPV E7) followed by light application.
89030931|NCT02947854|Experimental|Assessments of time between ID dosing and light|Optional part: Assessment of different time interval between intradermal dosing of fimaporfin, adjuvant/antigens and light application.
89030932|NCT02947815|Experimental|NABOTA|Single-dose
89591753|NCT01778127|Experimental|Group B: Immediate Incentives|"Participants use an activity monitor and the interactive website.~In addition to minimal rewards, participants will receive immediate incentives as they move from one level to the other on the website."
89591754|NCT01778127|Experimental|Group C: Control|Participants in the control group will receive an activity monitor and educational materials, but will not have access to the interactive website. No rewards will be offered for their participation.
89591755|NCT01892540|Experimental|Cohort 1: Standard positioning device|Patients undergo clinical FDG-PET/CT followed by prone breast PET/CT and/or prone breast PET/MRI with or without DTPA.
89591756|NCT01892540|Experimental|Cohort 2: New positioning device|
89591757|NCT01892540|Experimental|Cohort 3: Current positioning device until new is available|
89591758|NCT01385098|Experimental|Vitamin D3 and Calcium|Dietary supplement of vitamin D3 and calcium
89591759|NCT01398514|Experimental|Active medication|Escitalopram 10mg/day
89591760|NCT01398514|Placebo Comparator|Placebo|Matched pill placebo
89591761|NCT01398358|No Intervention|Usual Head Start Exposure|Children will attend their usual Head Start classroom and receive the usual educational interventions provided in that classroom.
89591762|NCT01398358|Experimental|Parents of Preschoolers Series (POPS)|Children attend Head Start preschool. Within the classroom, they receive a series of lessons about nutrition and obesity prevention delivered by an Extension Educator in collaboration with the classroom teacher. Parents are invited to attend a series of classes about nutrition and obesity prevention.
89591763|NCT01398358|Experimental|POPS + Incredible Years Series (IYS)|Children attend Head Start preschool. Within the classroom, they receive a series of lessons about nutrition and obesity prevention delivered by an Extension Educator in collaboration with the classroom teacher. Parents are invited to attend a series of classes about nutrition and obesity prevention. In the classroom, children also receive a series of lessons about emotional and behavioral self-regulation delivered by a trained mental health specialist. The parents also are invited to classes about child behavioral and emotional self-regulation delivered by a mental health specialist.
89591764|NCT03025282|Experimental|CD10367 3% Solution - Non-desquamated zone|
89591765|NCT03025282|Experimental|CD10367 1% Solution - Non-desquamated zone|
89591766|NCT03025282|Placebo Comparator|CD10367 solution placebo - Non-desquamated zone|CD10367 solution placebo serves as negative control.
89591767|NCT03025282|Active Comparator|Betneval ointment - Non-desquamated zone|This comparator containing Betamethasone valerate 0.1% serves as positive control.
89591768|NCT03025282|Experimental|CD10367 3% Solution - Desquamated zone|
88977413|NCT02968628||Cases: Infants of Diabetic Mothers|"Cases: Neonates born at or over 35 weeks gestation whose mother's were recommended to receive medication for diabetes during pregnancy. This includes pre-gestational and gestational diabetics.~Interventions:~Video Electroencephalogram (EEG)~Point-of Care Blood Sugar Testing~Medical Record Data Extraction~Maternal Questionnaire"
88977414|NCT02968628||Controls|"Controls: Neonates born at or over 35 weeks gestation whose mother's had normal glycemic control testing during pregnancy.~Interventions:~Video Electroencephalogram (EEG)~Point-of Care Blood Sugar Testing~Medical Record Data Extraction~Maternal Questionnaire"
88977415|NCT00198367|Experimental|Cisplatin-Gemzar|Cisplatin-Gemzar
88977416|NCT00198367|Experimental|Cisplatin-Navelbine-Radiotherapy|Cisplatin-Navelbine-Radiotherapy
88977417|NCT00198367|Experimental|Carboplatin-Taxol-Radiotherapy|Carboplatin-Taxol-Radiotherapy
89591769|NCT03025282|Placebo Comparator|CD10367 solution placebo - Desquamated zone|
89591770|NCT01778049|Experimental|Empagliflozin 10 mg dose|Empagliflozin open label treatment period
89591771|NCT01778049|Experimental|Placebo add on 10 mg dose|Empagliflozin / Linagliptin 10/5 mg Dose FDC placebo add on run-in
89591772|NCT01778049|Experimental|Empagliflozin/Linagliptin 25/5 mg Dose|Empagliflozin / Linagliptin 25/5 mg Dose FDC active
89591773|NCT01778049|Experimental|Empagliflozin/Linagliptin 10/5 mg Dose.|Empagliflozin / Linagliptin 10/5 mg Dose FDC placebo
89591774|NCT01778049|Experimental|Empagliflozin/Linagliptin 10/5 mg Dose|Empagliflozin / Linagliptin 10/5 mg Dose FDC active
89591775|NCT01778049|Experimental|Empagliflozin 25 mg dose|Empagliflozin open label treatment period
89591776|NCT01778049|Experimental|Empagliflozin/Linagliptin 25/5 mg Dose.|Empagliflozin / Linagliptin 25/5 mg Dose FDC placebo
89591777|NCT01778049|Experimental|Placebo add on 25 mg dose|Empagliflozin / Linagliptin 25/5 mg Dose FDC placebo add on run-in
89591778|NCT01777581|Experimental|milnacipran|Milnacipran, flexibly dosed
89591779|NCT01777581|Placebo Comparator|Sugar pill (placebo)|Placebo
89591780|NCT01864148|Experimental|BIIB033, 3 mg/kg|"BIIB033 3 mg/kg once every 4 weeks intravenous (IV) infusion up to Week 72.~Avonex once-weekly intramuscular (IM) injection up to Week 84."
89591781|NCT01864148|Experimental|BIIB033, 10 mg/kg|"BIIB033 10 mg/kg once every 4 weeks IV infusion up to Week 72.~Avonex once-weekly IM injection up to Week 84."
89591782|NCT01864148|Experimental|BIIB033, 30 mg/kg|"BIIB033 30 mg/kg once every 4 weeks IV infusion up to Week 72.~Avonex once-weekly IM injection up to Week 84."
89591783|NCT01864148|Experimental|BIIB033, 100 mg/kg|"BIIB033 100 mg/kg once every 4 weeks IV infusion up to Week 72.~Avonex once-weekly IM injection up to Week 84."
89591784|NCT01864148|Placebo Comparator|Placebo|"Placebo once every 4 weeks IV infusion up to Week 72.~Avonex once-weekly IM injection up to Week 84."
88977418|NCT02968589|Experimental|@ctiveHip intervention|"A training session for caregivers of patients with hip fracture on patient management.~The @ctiveHip tele-rehabilitation system. This system includes a 3-months occupational therapy and exercise-based program, recommendations for patients and their caregivers and the option of chats and videoconferences.~The program consists of 5 sessions/week of 50-60 minutes that patients will do at home. Each session includes videos with the prescribed activities and exercises that the patients will find in the private site of www.activehip.es."
88977419|NCT02968589|Active Comparator|Other training|"A training session for caregivers of patients with hip fracture on patient management.~The usual care for hip fracture patients at hospital discharge. In addition, patients and their families will receive a triptych with information on recommendations and exercises to do at home."
88977420|NCT00198445|Experimental|Bromfenac|Topical bromfenac ophthalmic solution 0.1%
89591785|NCT01751139|Other|Total Group|Subjects six months of age and older at the time of enrolment, recruited from randomly selected households originating from preselected mapped communities. Preferably the recruitment period occurred outside of the peak dengue transmission season, and continued until each site had reached its foreseen target. The expected period for recruiting the target sample size was approximately three months. Recruitment of replacement subjects was done during the low dengue transmission and the recruitment period depended on the number of subjects that need to be replaced. Enrolled subjects were subjects who either lived in households in study areas with support from the Family Health Physician Program (FHP) or the Larval Index Rapid Assay (LIRA) or with field research experience in the community (preferred) or where a similar system of mapped communities with potential for surveillance existed.
89591786|NCT04415138||Robotic-assisted Group|
89591787|NCT04415138||Video-assisted Group|
89591788|NCT01890122|Active Comparator|Metformin HCl 500 mg|Metformin hydrochloride (HCl) 500 mg, capsules, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; alogliptin and metformin HCl fixed dose combination (FDC) placebo-matching tablets, orally, twice a day for up to 26 weeks.
89591789|NCT01890122|Active Comparator|Alogliptin 12.5 mg|Alogliptin 12.5 mg, tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day; alogliptin and metformin HCl FDC placebo-matching tablets, orally, twice a day for up to 26 weeks.
89591790|NCT01890122|Experimental|Alogliptin 12.5 mg + Metformin HCl 500 mg FDC|Alogliptin 12.5 mg and metformin HCl 500 mg FDC, tablets, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day for up to 26 weeks.
89591791|NCT01890122|Placebo Comparator|Placebo|Alogliptin and metformin FDC placebo-matching tablets, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day for up to 26 weeks.
89591792|NCT01397890|Other|1|Add-on treatment
88977421|NCT00198445|Placebo Comparator|Placebo|Vehicle of bromfenac
88977422|NCT00198484|Experimental|Vitrase|ovine hyaluronidase injection 150 USP Units in 1 mL solution. Single dose of Vitrase will be administered as an adjuvant prior to ophthalmologic surgery
88977423|NCT00198523|Experimental|Prednisolone and Tobramycin|Prednisolone acetate 1.0% and tobramycin 0.3% ophthalmic suspension. One drop of test agent will be instilled in the inferior cul de sac of the operative eye prior to cataract extraction.
88977424|NCT00198523|Active Comparator|Prednisolone|Prednisolone acetate 1.0% ophthalmic suspension. One drop of test agent will be instilled in the inferior cul de sac of the operative eye prior to cataract extraction.
89591793|NCT01397890|Other|2|Add-on treatment
89591794|NCT01777269|Experimental|Duodart|Fixed dose combination of dutasteride 0.5mg and tamsulosin 0.4mg. A capsule once daily during 12 months
89591795|NCT01777269|Placebo Comparator|Sugar Pill|A capsule once daily during 12 months
88977425|NCT00198562|Active Comparator|1|target morning home blood pressure (below 130 mmHg vs 130-139 mmHg)
88977426|NCT00198562|Active Comparator|2|antihypertensive drug (amlodipine vs losartan)
88977427|NCT00409942|Experimental|1|Torasemide prolonged released
88977428|NCT00409942|Active Comparator|2|Furosemide
88977429|NCT02968667|Experimental|Intervention|Intervention group received 6 weeks of empowerment program
88977430|NCT02968667|No Intervention|Treatment as usual|Medications
88977431|NCT00084825|Experimental|Docetaxel + Imatinib Mesylate|Docetaxel intravenous (IV) over 1 hour on days 1, 8, 15, and 22 and oral imatinib mesylate once daily on days 1-42. Courses repeat every 42 days.
88977432|NCT02968550||Low shunt group|patients with shunt less than 30% in one-lung ventilation at ZEEP
88977433|NCT02968550||High shunt group|Patients with shunt equal or more than 30% in one-lung ventilation at ZEEP
88977434|NCT00198796|Experimental|H10407|H10407
88977435|NCT00198874|Active Comparator|Psychoeducation|
88977436|NCT00198874|Experimental|Conitive Behavorial Therapy|
88977437|NCT00198874|Experimental|Family Therapy|
88977438|NCT00198874|Experimental|Intergrated Family|
88977439|NCT02968472|Experimental|prophylactic 4SCAR19 cells|Patients who have relapsed and refractory B cell leukemia after chemotherapy will be treated prophylactically with CD19-specific gene-engineered T cells.
88977440|NCT00084903|Experimental|Fluorescence Spectroscopy|
88977441|NCT00199498|Experimental|Septal RV lead placement|patient randomized to Septal RV lead placement
88977442|NCT00199498|Active Comparator|Apical RV lead placement|patient randomized to Apical RV lead placement (current standard placement)
88977443|NCT02970396|Active Comparator|SMART Intervention|Participants (a total of 120 individuals) will be randomly assigned to either SMART (N=60) or the wait-list control (N= 60), in a 1:1 ratio.
88977444|NCT02970396|Active Comparator|Wait-list|Participants assigned to the wait-list will start the SMART intervention 6 months following randomization.
88977445|NCT02968394|Experimental|NEVIT|Co treatment with omalizumab during another attempt of immunotherapy introduction
88977446|NCT00084981|Experimental|Treatment (decitabine, valproic acid)|"Patients receive decitabine IV over 1 hour on days 1-10 and oral valproic acid three times daily on days 5-21. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of decitabine and valproic acid until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. After the MTD is determined, an additional 6 patients are treated at that dose."
88977447|NCT00199927|Active Comparator|standard therapy|Standard therapy
88977448|NCT00199927|Active Comparator|fluvastatin|40-80 mg/day
88977449|NCT00200005|Experimental|InterStim therapy|Patients being treated with sacral neuromodulation with InterStim therapy.
88977450|NCT00200044|Sham Comparator|Sham|This arm of the study has the procedure but does not get the Gatekeeper prostheses. The Sham arm has the option to cross-over to the Treatment arm at the 6-month visit.
88977451|NCT00200044|Active Comparator|Treatment|The treatment arm has the Gatekeeper devices implanted.
88977452|NCT00061100|Experimental|RISE intervention|Targeted RISE intervention- Behavior therapy Rise
89591796|NCT04616456|Experimental|Multiple System Atrophy (MSA)|Twenty to twenty-five subjects with probable MSA diagnosis will be recruited for this study. Each subject will undergo an [F-18]PBR06 PET and MRI scan at baseline, and will receive the experimental drug, verdiperstat (BHV-3241) under supervision of clinic staff. A follow-up [F-18]PBR06 PET and MRI scan will be performed after 6 months (26 weeks) of taking verdiperstat.
89591797|NCT05365360|Sham Comparator|Sham LaserCap|Sham device
89591798|NCT05365360|Experimental|Lasercap SD|Low fluence LLLT
89591799|NCT05365360|Experimental|Lasercap HD+|High fluence LLLT
89591800|NCT04016272|Experimental|Active tDCS|
89591801|NCT04016272|Placebo Comparator|Sham tDCS|
89591802|NCT04371250||Youth|Assessed group
89591803|NCT01751061|Experimental|Decision aid|Web-based decision aid (decision support tool) provided to surrogate decision maker
89591804|NCT01751061|Active Comparator|Usual care|usual care in an intensive care unit setting
89591805|NCT01777191|Experimental|80 mg Ixekizumab Auto-Injector|Ixekizumab administered by two 80 milligram (mg) subcutaneous (SC) injections at Week 0, then one 80 mg SC injection every 2 weeks (Q2W) at week 2, 4, 6, 8 and 10. Starting from Week 12, 80 mg Ixekizumab Prefilled Syringe was administered by one 80 mg SC injection every 4 weeks (Q4W).
89591806|NCT01777191|Experimental|80 mg Ixekizumab Prefilled Syringe|Ixekizumab administered by two 80 mg SC injections at Week 0, then one 80 mg SC injection Q2W at week 2, 4, 6, 8 and 10. Starting from Week 12, 80 mg Ixekizumab Prefilled Syringe was administered by one 80 mg SC injection Q4W.
89591807|NCT01896050||AI therapy|Subjects who started treatment with any of the three aromatase inhibitor (AI) medications
89591808|NCT01896050||Tamoxifen|Subjects who started treatment with tamoxifen
89591809|NCT01775787|Other|Tobacco Flavor/ Tobacco & Menthol Flavor|"Subjects randomized to Tobacco Flavor group 7-10 days, then crossed over to Tobacco and Menthol Flavor for 7-10 days.~Nicotine with Tobacco Flavor and Tobacco & Menthol Flavor (18mg/mL nicotine)"
89591810|NCT01775787|Other|Tobacco & Menthol Flavor/Tobacco Flavor|"Subjects randomized to Tobacco and Menthol Flavor for 7-10 days,then crossed over to Tobacco Flavor for 7-10 days.~Nicotine with Tobacco Flavor and Tobacco & Menthol Flavor (18mg/mL nicotine)"
89591811|NCT01775553|Experimental|Carfilzomib|All patients will receive Carfilzomib
89591812|NCT01775475|Active Comparator|Arm I (CHOP)|Patients receive CHOP chemotherapy comprising cyclophosphamide IV on day 1, doxorubicin hydrochloride IV on day 1, vincristine sulfate IV on day 1, and prednisone PO on days 1-5. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
89591813|NCT01775475|Experimental|Arm II (oral chemotherapy)|Patients receive lomustine PO QD on day 1 (courses 1 and 3 only), etoposide PO QD on days 1-3, cyclophosphamide PO QD on days 22-26, and procarbazine hydrochloride PO QD on days 22-26. Treatment repeats every 6 weeks for up to 3 courses in the absence of disease progression or unacceptable toxicity.
89591814|NCT01774929|Experimental|Transdermal Therapeutic System (TTS)-fentanyl|TTS-fentanyl patches releasing at the rate of 12.5 microgram per hour for 3 days. The patches will be replaced every 3 days until 30 days.
89591815|NCT01888874|Placebo Comparator|Placebo|Participants received GLPG0634 matching placebo capsules, orally, twice daily (BID) during Weeks 1 to 12. Participants who were responders (having at least 20 percent [%] improvement on TJC68 and SJC66) remained on placebo while nonresponders were re-randomized to GLPG0634 100 milligram (mg) once daily (QD) or 50 mg BID during Weeks 13 to 24.
89591816|NCT01888874|Experimental|GLPG0634 50 mg QD|Participants received GLPG0634 50 mg capsules, orally, QD during Weeks 1 to 12. Participants who were responders (having at least 20% improvement on TJC68 and SJC66) remained on 50 mg QD while nonresponders were re-randomized to 100 mg QD during Weeks 13 to 24.
89591817|NCT01888874|Experimental|GLPG0634 100 mg QD|Participants received GLPG0634 100 mg capsules, orally, QD during Weeks 1 to 24.
88977453|NCT00061100|Active Comparator|Standard Education|Education intervention. Standard prevention education
89591818|NCT01888874|Experimental|GLPG0634 200 mg QD|Participants received GLPG0634 200 mg capsules, orally, QD during Weeks 1 to 24.
89591819|NCT01888874|Experimental|GLPG0634 25 mg BID|Participants received GLPG0634 25 mg capsules, orally, BID during Weeks 1 to 12. Participants who were responders (having at least 20% improvement on TJC68 and SJC66) remained on 25 mg BID while nonresponders were re-randomized to 50 mg BID during Weeks 13 to 24.
88977454|NCT00200083|Active Comparator|A|"All subjects enrolled will be implanted with an IGS system. The active group are those randomized to on and will receive active stimulation for 12 months."
88977455|NCT00200083|Placebo Comparator|B|"All subjects enrolled will be implanted with an IGS system. The placebo group are those randomized to off and will receive no stimulation for 12 months."
88977456|NCT00410215|Active Comparator|1|sodium phosphate
88977457|NCT00410215|Active Comparator|2|picosalax
88977458|NCT00410215|Active Comparator|3|picosalax plus bisacodyl
88977459|NCT00400062||ICU survivors|The investigators will measure the independent contribution of risk factors such as delirium and exposure to sedative and analgesic medications to the incidence of long-term CI.
88977460|NCT00200239|Experimental|1|Behavioral: eating breakfast from portioned and unportioned foods
89591820|NCT01888874|Experimental|GLPG0634 50 mg BID|Participants received GLPG0634 50 mg capsules, orally, BID during Weeks 1 to 24.
89591821|NCT01888874|Experimental|GLPG0634 100 mg BID|Participants received GLPG0634 100 mg capsules, orally, BID during Weeks 1 to 24.
89591822|NCT01749735|Experimental|Armeo training with continuous tDCS|Subjects will receive 10 sessions of transcranial Direct Current Stimulation (tDCS)/Armeo training over 2 weeks. Training sessions will last for 40 minutes and will focus on repetitive tasks using the Armeo device that. To deliver the stimulation, the anode will be placed over the primary motor cortex (M1) of the affected hemisphere, while the cathode will be placed over the unaffected M1 area. Direct current will be transferred by a saline-soaked pair of surface sponge electrode (35cm2). Continuous stimulation will be delivered at an intensity of 1mA while the subject undergoes the 40-minute Armeo motor training sessions.
89591823|NCT01749735|Sham Comparator|Armeo training with sham tDCS|Subjects will receive the same number of 40-minute training sessions (i.e. 10 sessions) as the subjects in the experimental group. Training will take place over a period of two weeks as per the experimental group. Also, electrodes will be positioned on the scalp as per the experimental group. However, for sham transcranial Direct Current Stimulation (tDCS), the current will be delivered for only 30 seconds. The current intensity will be gradually increased and decreased to diminish its perception.
89591824|NCT01749033|Active Comparator|Group 1 classic|Group 1 Using the classic inserting technique and completely deflated LMA (Laryngeal Mask Airway)recommended in the LMA manual.
89591825|NCT01749033|Active Comparator|Group 2 pre inflated|Group 2 (pre-inflated): Using the recommended inserting technique with the pre-inflated volume that exists in a LMA (Laryngeal Mask Airway) from the manufacturer
88977461|NCT00200239|Experimental|2|Behavioral: eating breakfast with portioned and unportioned foods
88977462|NCT00200395|Experimental|OSI-774 (Tarceva)|Oral treatment with OSI-774 (Tarceva) will be given as a 150 mg tablets daily for 14 days. On day 15 and if there are no adverse effects the dose will be increased to 200 mg.
88977463|NCT02962804|Experimental|Nivolumab plus radiation|Nivolumab plus radiation
88977464|NCT00048555|Experimental|1|
88977465|NCT00200707|Experimental|The treatment group|Intracoronary Injection of Autologous Bone Marrow Mononuclear C
89591826|NCT01749033|Active Comparator|Group 3 ELL-PIC technique|Group 3 (ELL-PIC): Using the ELL-PIC technique.
89591827|NCT01774305|Experimental|dexmedetomidine|We administrate the dexmedetomidine single bolus (0.5ug/kg, intravenously, for 10 min) at time of muscle layer closing.
89591828|NCT01774305|Placebo Comparator|saline|We administrate the saline single bolus (0.25ml/kg,intravenously, for 10 min) at time of muscle layer closing.
89591829|NCT01737021|Experimental|Psycho-educational intervention|Psycho-education
89591830|NCT01737021|No Intervention|Treatment as usual|
89591831|NCT01397422|Placebo Comparator|Treatment A|
89591832|NCT01397422|Active Comparator|Treatment B|Low dose ADS-5102 (amantadine extended release)
89591833|NCT01397422|Active Comparator|Treatment C|A mid-dose ADS-5102 (amantadine extended release)
89591834|NCT01397422|Active Comparator|Treatment D|High dose ADS-5102 (amantadine extended release)
89591835|NCT01736553||Infants with Spinal Muscular Atrophy|Infants diagnosed Spinal Muscular Atrophy
89591836|NCT01736553||Healthy controls|Healthy control infants
88977466|NCT00200707|No Intervention|the control group|
88977467|NCT04711577|Experimental|Condition 1|Track clinician-determined symptoms
89591837|NCT01888640|Active Comparator|ActiveTENS|Active TENS for 4 weeks of the study and will add an additional 4 weeks of active TENS for the last 4 weeks of the study.
89591838|NCT01888640|Placebo Comparator|Placebo TENS|This group will receive placebo TENS for the first 4 weeks of the study and then active TENS for the last four weeks of the study.
88977468|NCT04711577|Experimental|Condition 2|Track clinician-determined and self-determined symptoms
88977469|NCT00200746|Experimental|2|Moderate Arginine
88977470|NCT00200746|Sham Comparator|3|Polycose control arm
88977471|NCT00200746|Experimental|1|High Arginine
88977472|NCT00200863|Experimental|1|420 nm light
88977473|NCT00200863|Experimental|2|480 nm
88977474|NCT00200863|Experimental|3|507 nm
88977475|NCT00200863|Experimental|4|555 nm
88977476|NCT00200863|Experimental|5|620 nm
88977477|NCT00200863|Experimental|6|460 nm
89030933|NCT02947815|Active Comparator|BOTOX|Single-dose
89030934|NCT05147285|Experimental|Stabilization group|Only stabilization exercises in patients with cystic fibrosis
89591839|NCT01888640|No Intervention|No TENS (Standard Care)|Participants will not receive TENS intervention during the first 4 weeks of the trial but will complete all testing procedures as the other two arms. This group will receive active TENS during the last 4 weeks of the study.
89591840|NCT01736475|Experimental|Prophylaxis|
89591841|NCT01736475|Experimental|On-demand|
89591842|NCT01863758|Experimental|Human-cl rhFVIII|Up to 60-80 IU/kg of intravenous Human-cl rhFVIII was administered at an individually determined dose and dose interval.
89591843|NCT01863680|Experimental|COL-1620|
89591844|NCT01747629|Placebo Comparator|Placebo MDPI|Placebo multi-dose dry powder inhaler (MDPI) administered as 2 inhalations four times a day for 12 weeks.
89591845|NCT01747629|Experimental|Albuterol MDPI|Albuterol multi-dose dry powder inhaler (MDPI) at a dose of 720 micrograms per day administered as 2 inhalations of 90 mcg /inhalation four times a day for 12 weeks.
89591846|NCT04170920|Experimental|Mobile Health Application Intervention|"LifeExtend-AI (LX-AI) will be piloted by adding Aromatase Inhibitor (AI)- specific features to LifeExtend, an already existing healthy lifestyle behavior application produced by LifeOmic. This application includes features for tracking activity, diet, sleep, and body weight, as well as creating to-do lists and participating in closed social networking for support and encouragement. LifeExtend-AI will add features to track AI adherence and patient-reported joint pain, with alerts sent to both the participant and the healthcare team in response to these parameters. In addition, the app contains educational videos and articles, to which articles addressing management of AI- related toxicities (including exercise) will be added."
89591847|NCT01863368|Experimental|Systane Ultra|Systane® ULTRA lubricant eyedrops, 1 drop in each eye 4 times a day for 35 days (Phase I), followed by 55 days additional use as needed (Phase II).
89591848|NCT01863368|Active Comparator|Optive|OPTIVE® lubricating eyedrops, 1 drop in each eye 4 times a day for 35 days (Phase I), followed by 55 days additional use as needed (Phase II).
89591849|NCT01886690|Experimental|New Eye Drop Formulation|1 to 2 drops of carboxymethylcellulose sodium based New Eye Drop Formulation in each eye as per protocol for 90 days.
89591850|NCT01886690|Active Comparator|REFRESH PLUS®|1 to 2 drops carboxymethylcellulose sodium based (REFRESH PLUS®) eye drops in each eye as per protocol for 90 days.
89591851|NCT01886378|Experimental|UX007|UX007 dosing titrated to a target dose of 25-35% of total caloric intake or maximum tolerated dose. Participants are followed to evaluate the effects of UX007 over 24 weeks (Treatment Period), then continued treatment in the Extension Period for an additional 54 weeks for a total of 78 weeks of treatment.
89591852|NCT04616378|Other|Phase 2 Prescribed Prosthesis|Participants everyday use of prosthesis
89591853|NCT04616378|Experimental|Phase 2 Robotic Prosthetic Leg|Robotic prosthetic leg with powered knee and passive ankle
89591854|NCT04616378|Other|Phase 3 Prescribed Prosthesis|Participants everyday use of prosthesis
89591855|NCT04616378|Experimental|Phase 3 Robotic Prosthetic Leg|Robotic prosthetic leg with powered knee and passive ankle
89591856|NCT04616378|Experimental|Phase 3 No Prosthesis|Participant performs tasks with no prosthetic device attached
89591857|NCT01886300||Cohort|
89591858|NCT01885208|Experimental|Semaglutide 1.0 mg|
89591859|NCT01885208|Active Comparator|Exenatide ER 2.0 mg|
89591860|NCT01859702|Experimental|VIGADEXA|Moxifloxacin 0.5%/Dexamethasone 0.1% ophthalmic solution, 1 drop instilled in the study eye 2 days before surgery, followed by 1 drop instilled 4 times a day the day before surgery. On the day of surgery, 1 drop was instilled 60 minutes prior to the procedure.
89591861|NCT04599686|Active Comparator|ADT|Evaluating men with oligometastatic prostate cancer lesions randomized to ADT.
89591862|NCT04599686|Experimental|SBRT|Evaluating men with oligometastatic prostate cancer lesions randomized to stereotactic body radiation therapy (SBRT).
89591863|NCT01835132|Experimental|Gevokizumab|Subcutaneous injection of 60 mg gevokizumab
89591864|NCT01747551|Active Comparator|mFOLFOX6 + Ziv-aflibercept|Patients received mFOLFOX6 and ziv-aflibercept every 2 weeks. Ziv-aflibercept 4mg/kg was given via intravenous (IV) infusion over 1 hour. Immediately following this was administration of mFOLFOX6: oxaliplatin 85 mg/m2 IV and leucovorin 400 mg/m2 IV were given concurrently over 120 minutes, followed by fluorouracil 400 mg/m2 IV bolus injection and then fluorouracil 2,400 mg/m2 IV infusion over 46 hours. Patients continued on treatment until radiological or clinical progression, unacceptable toxicity, or death.
89591865|NCT01747551|Active Comparator|mFOLFOX6 + Placebo|Patients received mFOLFOX6 and placebo every 2 weeks. Placebo was given via intravenous (IV) infusion over 1 hour. Immediately following this was administration of mFOLFOX6: oxaliplatin 85 mg/m2 IV and leucovorin 400 mg/m2 IV were given concurrently over 120 minutes, followed by fluorouracil 400 mg/m2 IV bolus injection and then fluorouracil 2,400 mg/m2 IV infusion over 46 hours. Patients continued on treatment until radiological or clinical progression, unacceptable toxicity, or death.
89591866|NCT01736397|Experimental|Ferric Citrate|Ferric citrate will be taken with or within one hour of meals or snacks. The starting dose of ferric citrate is 3 tablets/day and titrated by the subject's serum phosphorus results at each treatment visit.
89591867|NCT01736397|Placebo Comparator|Placebo|Placebo will be taken with or within one hour of meals or snacks. The starting dose of placebo is 3 tablets per day and titrated by the subject's serum phosphorus results at each treatment visit.
89591868|NCT01859390|Experimental|AquADEKs-2|Two control multivitamin softgel capsules will be taken orally on a once daily basis with pancreatic enzymes and a glass of milk or fat-containing meal for 4 weeks for the screening run in period. For those subjects randomized to the AquADEKs-2 arm, two AquADEKs-2 softgel capsules will be taken orally on a once daily basis with pancreatic enzymes and a glass of milk or fat-containing meal for 16 weeks.
89591869|NCT01859390|Active Comparator|Control multivitamin|Two control multivitamin softgel capsules will be taken orally on a once daily basis with pancreatic enzymes and a glass of milk or fat-containing meal for 4 weeks for the screening run in period for all participants and for 16 weeks for those randomized to this comparative therapy.
89591870|NCT01858766|Experimental|SOF+VEL 25 mg 12 Weeks (GT1)|Participants with genotype 1 HCV infection will receive SOF+VEL 25 mg for 12 weeks.
88977478|NCT00201019|Experimental|1|Active intervention participants receive a physician-pharmacist collaborative intervention.
88977479|NCT00201019|No Intervention|2|Control participants do not receive recommendations from a clinical pharmacist.
88977480|NCT00201019|No Intervention|3|Passive intervention participants receive care by the same physicians caring for participants in the active intervention arm but are not seen by a clinical pharmacist. They are not actively enrolled in the study and do not have study visits for measuring blood pressure.
88977481|NCT00201058|Experimental|1|Receives tailored web-based program
88977482|NCT00201058|Active Comparator|2|Control students receive existing web-based, generic asthma education
88977483|NCT00201136|No Intervention|MD-C/PT-C|Physician and patient control group.
88977484|NCT00201136|Experimental|MD-I/PT-C|MD CQI-type intervention; Patient control
88977485|NCT00201136|Experimental|MD-C/Pt-I|MD control; patient behavioral intervention
88977486|NCT00201136|Experimental|MD-I/Pt-I|MD CQI-type intervention; Patient behavioral intervention
88977487|NCT00048633|Experimental|Tariquidar|
88977488|NCT02968238|Active Comparator|CBT preference arm|CBT preference arm consists of participants who are randomized to the preference condition and choose to receive cognitive-behavioral therapy (CBT). CBT consists of 10 weeks of weekly treatment.
88977489|NCT02968238|Active Comparator|Yoga preference arm|Yoga preference arm consists of participants who are randomized to the preference condition and choose to receive yoga. Yoga consists of 10 weeks of bi-weekly treatment (total = 20 treatments).
88977490|NCT02968238|Active Comparator|CBT randomized arm|CBT randomized arm consists of participants who are randomized to the random condition and are randomized to receive cognitive-behavioral therapy (CBT). CBT consists of 10 weeks of weekly treatment.
88977491|NCT02968238|Active Comparator|Yoga randomized arm|Yoga randomized arm consists of participants who are randomized to the random condition and are randomized to receive yoga. Yoga consists of 10 weeks of bi-weekly treatment (total = 20 treatments).
89591871|NCT01858766|Experimental|SOF+VEL 100 mg 12 Weeks (GT1)|Participants with genotype 1 HCV infection will receive SOF+VEL 100 mg for 12 weeks.
89591872|NCT01858766|Experimental|SOF+VEL 25 mg 12 Weeks (GT2/4/5/6)|Participants with genotype 2, 4, 5, or 6 HCV infection will receive SOF+VEL 25 mg for 12 weeks.
88977492|NCT00048672|Experimental|Gleevec|Gleevec 400 mg orally daily. Dose adjustments made at discretion of treating physician within these guidelines: The highest dose acceptable is 800 mg daily. The lowest dose acceptable is 300 mg. No dose adjustment of more than 200 mg at one time is allowed. Dose adjustments to less than 300 mg may be approved after consultation with the principal investigator.
88977493|NCT00201682|Experimental|Arm I|Etanercept 25 mg administered sub-cutaneously twice weekly (Monday and Thursday) weeks 1-5 of therapy (total of 10 doses). The third dose of etanercept will be administered 1 hour prior to receiving rituximab. Rituximab: Patients will receive 375 mg/M2 of rituximab three times weekly for four weeks (a total of 12 doses of rituximab).
89591873|NCT01858766|Experimental|SOF+VEL 100 mg 12 Weeks (GT2/4/5/6)|Participants with genotype 2, 4, 5, or 6 HCV infection will receive SOF+VEL 100 mg for 12 weeks.
89591874|NCT01858766|Experimental|SOF+VEL 25 mg 12 Weeks (GT3)|Participants with genotype 3 HCV infection will receive SOF+VEL 25 mg for 12 weeks.
89591875|NCT01858766|Experimental|SOF+VEL 100 mg 12 Weeks (GT3)|Participants with genotype 3 HCV infection will receive SOF+VEL 100 mg for 12 weeks.
89591876|NCT01858766|Experimental|SOF+VEL 25 mg 8 Weeks (GT1)|Participants with genotype 1 HCV infection will receive SOF+VEL 25 mg for 8 weeks.
89591877|NCT01858766|Experimental|SOF+VEL 25 mg + RBV 8 Weeks (GT1)|Participants with genotype 1 HCV infection will receive SOF+VEL 25 mg plus RBV for 8 weeks.
89591878|NCT01858766|Experimental|SOF+VEL 100 mg 8 Weeks (GT1)|Participants with genotype 1 HCV infection will receive SOF+VEL 100 mg for 8 weeks.
89591879|NCT01858766|Experimental|SOF+VEL 100 mg + RBV 8 Weeks (GT1)|Participants with genotype 1 HCV infection will receive SOF+VEL 100 mg plus RBV for 8 weeks.
89591880|NCT01858766|Experimental|SOF+VEL 25 mg 8 Weeks (GT2)|Participants with genotype 2 HCV infection will receive SOF+VEL 25 mg for 8 weeks.
89591881|NCT01858766|Experimental|SOF+VEL 25 mg + RBV 8 Weeks (GT2)|Participants with genotype 2 HCV infection will receive SOF+VEL 25 mg plus RBV for 8 weeks.
89591882|NCT01858766|Experimental|SOF+VEL 100 mg 8 Weeks (GT2)|Participants with genotype 2 HCV infection will receive SOF+VEL 100 mg for 8 weeks.
89591883|NCT01858766|Experimental|SOF+VEL 100 mg + RBV 8 Weeks (GT2)|Participants with genotype 2 HCV infection will receive SOF+VEL 100 mg plus RBV for 8 weeks.
89591884|NCT01734993|Experimental|Tocilizumab|Moderate to severe rheumatoid arthritis participants from France, who completed the Week 97 visit of the WA22762 LTE study and considered as responders (defined as having improvement in DAS28 of >1.2 points) will continue tocilizumab treatment within this local LTE study for a maximum of 156 weeks, or until SC TCZ becomes commercially available, whichever occurs first.
89591885|NCT01745367|Active Comparator|Placebo in combination with paclitaxel|Placebo orally once daily on a 3 weeks on/1 week off schedule with 90 mg/m2 of paclitaxel administered intravenously 3 weeks on (Day 1, Day 8 and Day 15)/1 week off (4 weeks = 1 Cycle).
89591886|NCT01745367|Experimental|Tivo in combination with paclitaxel|1.5 mg tivozanib hydrochloride orally once daily on a 3 weeks on/1 week off schedule with 90 mg/m2 of paclitaxel administered intravenously 3 weeks on (Day 1, Day 8 and Day 15)/1 week off (4 weeks = 1 Cycle).
89591887|NCT01733121|Experimental|NBI-98854|Dose titration to determine a subject's optimal dose in the range of 25 to 75 mg NBI-98854. Dose titration is performed in increments of 25 mg. NBI-98854 administered as one (1) 25 mg capsule, two (2) 25 mg capsules, or one (1) 25 mg capsule and one (1) 50 mg capsule by mouth, taken every morning between 7:00am - 10:00am for 6 weeks.
89591888|NCT01733121|Placebo Comparator|Placebo|Capsule containing no active substance, manufactured to mimic NBI-98854 25 mg and 50 mg capsules.
89591889|NCT01744977|Experimental|Adherence Packaging Intervention Group|[MeadWestvaco Packaging Intervention Arm] At baseline, the intervention arm will receive instructions from the RA on obtaining medication refills and the first fill of their statin medication from the VA pharmacy. At this time, the pharmacist will provide counseling including 1) use of adherence packaging, 2) to only use statin medications from the adherence packaging 3) purpose of LDL-related medications 4) how to take the medications.
89591890|NCT01744977|No Intervention|Education Only Group|Control Arm patients will receive primary care and LDL management according to the discretion of their provider. At baseline, patients will receive similar written information on how to obtain medication refills and the importance of taking their cholesterol medications as prescribed. The 6-month interval was selected to maintain contact with patients.
89591891|NCT01383928|Experimental|Phase 1: Ixazomib 3 mg or 3.7 mg|Ixazomib (MLN9708), orally, twice-weekly in combination with lenalidomide orally and dexamethasone orally as prescribed, in 21-day treatment cycles for up to 16 cycles in the absence of disease progression or unacceptable toxicity as induction therapy during Phase 1. Participants with stable or responding disease continued receiving ixazomib (MLN9708) orally, twice weekly in 21-day treatment cycles as maintenance therapy until progressive disease or unacceptable toxicity.
89591892|NCT01383928|Experimental|Phase 2: Ixazomib 3 mg|Ixazomib (MLN9708), orally, twice-weekly in combination with lenalidomide orally and dexamethasone orally as prescribed, in 21-day treatment cycles for up to 16 cycles in the absence of disease progression or unacceptable toxicity as induction therapy during Phase 2. Participants with stable or responding disease continued receiving ixazomib (MLN9708) orally, twice weekly in 21-day treatment cycles as maintenance therapy until progressive disease or unacceptable toxicity.
89591893|NCT04023604|Active Comparator|Controlled diet with beef raised without antibiotics|Subjects will be randomized and assigned to consume the U.S. Healthy Diet Diets with beef produced in RWA (raised without antibiotics) systems for three weeks.
89591894|NCT04023604|Experimental|Controlled diet with beef produced in conventional systems|Subjects will be randomized and assigned to consume the U.S. Healthy Diet Diets with beef produced in conventional systems for three weeks.
89591895|NCT05365048|Experimental|Local Tailoring|The intervention arm will include 20 clinics randomly assigned to the intervention arm. All physicians, nurses, department administrator and other staff members from the pediatric departments randomized to this arm will be included in the study, as well as parents of HPV vaccine eligible children (9-12 years old) who had one or more visits with their pediatric provider during the data collection period.
89591896|NCT05365048|Experimental|Prescribed Strategy|The intervention arm will include 20 clinics randomly assigned to the intervention arm.. All physicians, nurses, department administrator,s and other staff members from the pediatric departments randomized to this arm will be included in the study, as well as parents of HPV vaccine eligible children (9-12 years old) who had one or more visits with their pediatric provider during the data collection period.
88977494|NCT00410332|Active Comparator|A|TRAUMEEL S
88977495|NCT00410332|Placebo Comparator|B|
88977496|NCT00410371|Experimental|GI267119|25 mg ODT tablet strength
88977497|NCT00048750|Experimental|1|
88977498|NCT00048750|Placebo Comparator|2|
88977499|NCT02968316||Pregnant women|all consecutive pregnant women presenting for prenatal care
88977500|NCT00061490|Experimental|1|16 weekly educational meetings
88977501|NCT00061490|No Intervention|2|Wait list control
88977502|NCT02968121|Experimental|Part A: Single Dose Injection: Subcutaneous|Drug: Brexpiprazole, OPDC-34712 Once, subcutaneous
89591897|NCT05365048|No Intervention|Usual Care|The intervention arm will include 20 clinics randomly assigned to the usual care arm. All physicians, nurses, department administrators,s and other staff members from the pediatric departments randomized to this arm will be included in the study, as well as parents of HPV vaccine eligible children (9-12 years old) who had one or more visits with their pediatric provider during the data collection period.
89591898|NCT05367388|Experimental|Treatment Sequence A/P|Subject will receive a single oral dose (200mg) of Treatment A on Day 1, followed by a 7-day washout period. On Day 8, the subject will begin the second treatment period by receiving a single oral dose (200 mg) of Treatment P.
89591899|NCT05367388|Experimental|Treatment Sequence P/A|Subject will receive a single oral dose (200mg) of Treatment P on Day 1, followed by a 7-day washout period. On Day 8, the subject will begin the second treatment period by receiving a single oral dose (200 mg) of Treatment A.
89591900|NCT01382602|Experimental|AMDC-USR|Subjects received 1 or 2 treatments of 150 million AMDC-USR delivered via transurethral intrasphincteric injection. After completing 12 months follow-up subjects were unblinded. Subjects were followed for 2 years after initial AMDC-USR treatment.
89591901|NCT01382602|Placebo Comparator|Placebo|Subjects received 1 or 2 treatments of placebo delivered via transurethral intrasphincteric injection. After completing 12 months follow-up subjects were unblinded and could elect to receive open-label AMDC-USR treatment. Subjects that received unblinded AMDC-USR treatment were followed for 2 years after initial placebo treatment.
89591902|NCT05893420|Experimental|Intervention Arm|Intervention Arm (experimental): eCARTv5 will monitor all adult medical-surgical (ward) patients at hospitals that implement the tool in their EHR. A pre vs. post analysis will be done to compare the impact of the tool at the intervention hospitals.
89591903|NCT05893420|Active Comparator|Control Arm|Control Arm (active comparator): hospital sites that do not implement eCARTv5 will be active comparator.
89591904|NCT05893316||Hematuria patients|Hematuria patients (≥ 3 RBCs/HPF) with treatment-naïve, pathology-confirmed urothelial carcinoma or benign genitourinary system disease or with undetermined lesion presented with hematuria.
89591905|NCT05893316||Non-hematuria patients|Patients without hematuria and diagnosed with pathology-confirmed cancer other than urothelial cancer.
89591906|NCT05893303|Experimental|PNF Technique Group|Participants in this group will receive PNF techniques and gait training 3 times per week for 8 weeks
89591907|NCT05893303|Active Comparator|Gait Training Group|Participants in this group will receive only gait training 3 times per week for 8 weeks
89591908|NCT05893290|Active Comparator|Therapeutic Exercise Group|The therapeutic exercise protocol will be taught to patients in the first session and will be done 3 times a week for 12 weeks.
89591909|NCT05893290|Experimental|Therapeutic Exercise+Basic Body Awareness (BBAT) Group|This group will receive BBAT as well as therapeutic exercises for 3 times a week for 12 week. Therapeutic exercises will include strengthening, stretching, and stabilization exercises. BBAT will include postural alignment, breathing, and cognitive exercises.
88977503|NCT02968121|Experimental|Part A: Single Dose Injection: Intramuscular|Drug: Brexpiprazole, OPDC-34712 Once, subcutaneous
88977504|NCT02968121|Experimental|Part B: Cohort 1|Drug: Brexpiprazole, OPDC-34712 Once, SC or IM
88977505|NCT02968121|Experimental|Part B: Cohort 2|Drug: Brexpiprazole, OPDC-34712 Once, SC or IM
88977506|NCT02968121|Experimental|Part B: Cohort 3|Drug: Brexpiprazole, OPDC-34712 Once, SC or IM
88977507|NCT00221767|Experimental|1|Brindley technique (bladder system)
88977508|NCT00221767|No Intervention|2|Reference group
88977509|NCT00412789|Experimental|EPO906|
88977510|NCT00048828|Active Comparator|1|
88977511|NCT00048828|Active Comparator|2|
88977512|NCT00221845|Active Comparator|Conventional BP Control|Targeted 24-hour mean arterial pressure will be the 50th-95th percentile for age.
88977513|NCT00221845|Experimental|Intensified BP Control|Targeted 24-hour mean arterial pressure will be the 5th to 50th percentile for age.
88977514|NCT02968199|Experimental|Referred women|A brief intervention based on the'5 A' model developed by the Agency for Health Care Policy and Research in the United States.
89591910|NCT05893290|No Intervention|Control Group|This group will not receive any treatment.
89591911|NCT05893212|Experimental|Nature-group|Primary care patients identified to be in the target group for health promoting activity by health or social service professionals. Participants chose to take part in the 8 week nature-group, meeting weekly in outdoor areas.
88977515|NCT00221923||Healthy individuals|They will be considered if they are above 30 years old. There is no upper age limit. Subject can be either male or female, and from African or European Descent. They must speak, read, and understand English. They can be diagnosed with other health disorders.
88977516|NCT00221923||Persons at risk for or with primary open angle glaucoma|They will be considered if they are above 30 years old. There is no upper age limit. Subject can be either male or female, and from African or European Descent. They must speak, read, and understand English. They can be diagnosed with other health disorders.
88977517|NCT00221962|Other|Open label treatment with aripiprazole|After 1-3 week screening phase, entered six week open trial of aripiprazole initiated at 2.5mg/day. DOsing was increased weekly in 2.5mg increments in order to reach maximum dose of 10mg/d.
88977518|NCT02968160|Experimental|Telmisartan+Rosuvastatin|"Duowell ® tablet (Telmisartan 40mg + Rosuvastatin 20mg) 1 tablet, once daily, Oral administration/ 8 weeks~* But, the increased Duowell ® tablet (Telmisartan 80mg + Rosuvastatin 20mg) will get administrated orally one tablet once daily to the subjects who have mean systolic blood pressure more than 140mmHg based on arm, which was determined before, at 4week visit."
88977519|NCT02968160|Active Comparator|Telmisartan/Rosuvastatin|"Telmisartan 40mg + Rosuvastatin 20mg 2 tablets, once daily, Oral administration/ 8 weeks~* But, the increased Telmisartan 80mg + Rosuvastatin 20mg will get administrated orally 2 tablets once daily to the subjects who have mean systolic blood pressure more than 140mmHg based on arm, which was determined before, at 4week visit."
88977520|NCT00222001||HMO Patients|Measurement of telephone triage outcome.
88977521|NCT00222040|Experimental|1|Levovist
88977522|NCT00222040|No Intervention|2|No specific intervention
88977523|NCT00222118|Experimental|1|intervention group
88977524|NCT00222118|Other|2|Attention control
88977525|NCT00222118|Other|3|Usual care
89591912|NCT05893212|Active Comparator|Sports-group|Primary care patients identified to be in the target group for health promoting activity by health or social service professionals. Participants chose to take part in the 8 week sports-group, meeting weekly in community sports facilities.
89591913|NCT05893199|Experimental|Telemedicine|Patients in the intervention group (Telemedicine) will be followed up using the Ti.Care App in addition to the usual primary care follow-up.
89591914|NCT05893199|Active Comparator|Primary care|Patients in the control group will be followed up exclusively in primary care.
89591915|NCT05892900|Experimental|Transcutaneous vagus nerve stimulation (tVNS)|"1 tVNS session of ca 45 minutes~The electrodes are placed at the left ear concha. The ear concha is principally innerved by the afferent branch of the vagus nerve"
89591916|NCT05892900|Sham Comparator|Sham Transcutaneous vagus nerve stimulation (tVNS)|"1 sham tVNS session of ca 45 minutes~The electrodes are attached to the center of the left ear lobe, which is known to be free of cutaneous vagal innervation"
89591917|NCT05892848||cases group|childern and adolescents with type 1 diabetes
89591918|NCT05892848||control group|age and sex matched control childern and adolsecents
89591919|NCT05892822||Amyotrophic Lateral Sclerosis|This study is an observational study without grouping.
89591920|NCT05892809|Other|With incubator cover group and without incubator cover|The incubator cover was covered while the neonate was lying in the incubator. Vital signs were measured at 0th, 15th, and 30th minutes.
89591921|NCT05892783|Experimental|experimental group|This group will receive myofascial release on the PF of both legs, namely foam rolling, plantar fascia specific stretching and soft tissue mobilization.
89591922|NCT05892783|No Intervention|control group|This group will receive advice only.
89591923|NCT05892731||age-related hearing loss with depression|According to Hamilton depression scale, age-related hearing loss patients were divided into two groups, namely age-related hearing loss with depression and age-related hearing loss without depression.
89591924|NCT05892731||age-related hearing loss without depression|According to Hamilton depression scale, age-related hearing loss patients were divided into two groups, namely age-related hearing loss with depression and age-related hearing loss without depression.
89591925|NCT05892705|Active Comparator|Study drug (dexmedetomidine intrathecal)|5 mcg dexmedetomidine intrathecally injected with 10 mg hyperbaric bupivacaine during spinal anesthesia for caesarean section.
89591926|NCT05892705|Placebo Comparator|Control (saline)|0.2 ml normal saline intrathecally injected with 10 mg hyperbaric bupivacaine during spinal anesthesia for caesarean section.
89591927|NCT05892692|No Intervention|EMA-only Condition|To examine situational precipitants of sexual assault, risky sexual behavior, and substance-use among freshman women (N=100) using EMA for 6 weeks. To examine within- and between-persons factors that may influence the relationships among these situational precipitants and adverse consequences.
89591928|NCT05892692|Other|Focus Group|To gather preliminary research about the feasibility of an EMI sexual assault intervention prior to an experimental condition. A small group of freshman women (N=20) will participate in an EMI protocol for six weeks, followed by providing feedback about their experience, including issues with phrasing, technical issues, and convenience.
89591929|NCT05892692|Experimental|EMA/EMI Condition|To examine whether an EMA/EMI condition, relative to an EMA-only and a minimal assessment-only condition, decreases incidents of sexual assault, risky sexual behavior, and alcohol use among freshman women (N=288). It is hypothesized that the 6-week EMA/EMI condition, relative to the other conditions, will be associated with lower rates of assault, risky sexual sex, and substance use from baseline to a 6-month followup.
89591930|NCT05892627|Experimental|PoZibio|PoZibio, twice daily (50 x 10^9 CFUs/ CAPSULE) for 6 weeks
89591931|NCT05892627|Placebo Comparator|Placebo|Placebo, twice daily for 6 weeks
89591932|NCT05892601|Experimental|Intervention|Mother kisses were applied to the experimental group. Kisses were delivered by the mother, free of oral ulcers, with a standard 5-second pressing of both lips on the affected body part followed by an exaggerated puckering sound.
89591933|NCT05892601|No Intervention|Control|The invasive intervention was performed with the standard method in the control group.
88977526|NCT00222274|Experimental|1|RSA Biofeedback: RSA Biofeedback Condition. The biofeedback will consist of 10 weekly sessions of training, at the same time of day for each subject. The details of the procedure for RSA biofeedback are described in Appendix A. One single practitioner, a certified biofeedback technician, will provide the biofeedback following the aforementioned protocol. In each session, 20 minutes of biofeedback will be delivered using a J&J C-2+ Physiograph. The participant will be taught to breathe at her resonant frequency, as a first step to training the individual how to produce maximal increases in amplitude of RSA.
88977527|NCT00222274|Active Comparator|2|EEG Biofeedback Condition. Participants assigned to this condition will receive 10 sessions of EEG alpha biofeedback. In each session, 20 minutes of biofeedback will be delivered using a J&J I-330-C2+ physiograph. The participant will learn how to modify specific brainwave activity known as alpha. In particular, participants will be taught to increase amplitude of alpha in the range of 8-12 Hz. Increased amplitude is this range is associated with relaxation and reduction of anxiety, but not baroreflex gain. Participants will also practice for two 20-minute periods daily using the same methods used to increase alpha found in lab sessions.
88977528|NCT00222352||central laboratory cTnI test|Control Group
88977529|NCT00222352||Point of Care cTnL testing|Experimental Group
88977530|NCT00222430|Active Comparator|A|Usual standard coronary angiographic procedure
88977531|NCT00222430|Experimental|B|Fluoroscopy-guided coronary angiography
88977532|NCT00222469|Experimental|1|3-agent treatment group
88977533|NCT02968082|Placebo Comparator|Placebo group (P group)|"The group that not existed scopolamine ingredient.~dosage form: apply~dosage: 1.5 mg~frequency: 1 times (at 9 p.m. of the day before the operation day)~duration: Until the 24hr after operation.~Patients will be applied patch that not existed scopolamine ingredient."
89591934|NCT05892575|Experimental|experimental:educt|"Training on improving the quality of life, coping with incontinence and kegel exercises will be given to obese elderly people over 65 years of age with urinary incontinence in the experimental group.~Face-to-face training will be given to the elderly in the experimental group for a total of 5 weeks, once a week day (60 minutes). In the 4th week, reminder messages will be started over the phone. The 4th week kegel exercise chart and nutrition list will be given. In the 5th week, kegel exercise dance will be watched. Sending reminder messages from the phone will continue for 3 months."
89591935|NCT05892575|No Intervention|active comparator, control group|The elderly in the control group will not be interfered with.
89591936|NCT05892562||RA combined with depression or anxiety|
89030935|NCT05147285|Experimental|combined group|stabilization exercise and aerobic exercise training in patients with cystic fibrosis
89591937|NCT05892562||RA without comorbid depression or anxiety|
89591938|NCT05892536|Experimental|blood clot regeneration|the regenerative procedures were performed by over-instrumentation the apices and irritating the apical tissues to induce bleeding into the root canal, then orifices plugged with MTA over blood clot and restored with GI.
89591939|NCT05892536|Active Comparator|photo-biomodulation regeneration|photobiomodulation therapy was carried out using diode laser with wavelenght 810 nm and output power 300 mW on the apical root areas of buccal and lingual surfaces at 48 hours intervals for 2 weeks after completion of the regenerative procedures which were performed by over-instrumentation the apices and irritating the apical tissues to induce bleeding into the root canal, then orifices plugged with MTA over blood clot and restored with GI.
89591940|NCT05892484|Experimental|Thermal Imaging|Participants will receive thermal imaging in addition to their routine x-ray for comparison.
89591941|NCT05892484|Other|X-ray|Routine x-ray is what the active comparator is being evaluated against.
89591942|NCT05892471|Experimental|ciprofol|
89591943|NCT05892471|Placebo Comparator|propofol|
89591944|NCT05892445|Experimental|Aversive Visual Health Warnings|Study subjects in this arm will be exposed to experimental aversive visual health warnings depicting risks and adverse effects of e-cigarette use. They will answer survey questions about e-cigarette perceptions before and after exposure to health warnings.
89591945|NCT05892445|No Intervention|No Warnings|Study subjects in this arm will answer the same survey questions about e-cigarette perceptions as those in the experimental arm, but they will not be shown aversive visual health warnings.
89591946|NCT05892367|Other|Control group|Application of a compression bandage following transbrachial puncture for 24 hours
89591947|NCT05892367|Active Comparator|Study group|Application of a compression bandage and a positioning splint following transbrachial puncture for 24 hours
89591948|NCT05892354|Experimental|Immunonutrition Group|"Induction chemotherapy (IC) + Concurrent chemoradiotherapy (CCRT) and enteral immunonutrition~Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 2-3 cycles before radiotherapy and then receive intensity modulated-radiotherapy (IMRT), concurrently with cisplatin (100mg/m² d1) every 3 weeks for 2-3 cycles.~Patients receive enteral immunonutrition, Oral Impact®, Nestle, 250ml/ bottle, 2 bottles per day, from 5 days before radiotherapy to the end of radiotherapy."
89591949|NCT05892354|Active Comparator|Control Group|"Induction chemotherapy+Concurrent chemoradiotherapy and standard enteral nutrition~Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 2-3 cycles before radiotherapy and then receive intensity modulated-radiotherapy (IMRT), concurrently with cisplatin(100mg/m² d1) every 3 weeks for 2-3 cycles.~Patients receive isocaloric standard enteral nutrition formula (ENSURE®), 250 mL per administration, 3 times per day, from 5 days before radiotherapy to the end of radiotherapy. Preparation of the 250 mL dose involves adding 200 mL of potable water to a cup and slowly stirring in 52.7 g of ENSURE powder (approximately 6 scoops)."
89591950|NCT05892328|Placebo Comparator|Control|Calorie-matched control beverage
89030936|NCT05147285|Experimental|control group|physical activity recommendations in patients with cystic fibrosis
89030937|NCT00507221|Experimental|1|Arm 1 will receive an intensive regimen of anti-helminthic therapy consisting of albendazole every three months for two years and praziquantel at enrollment and at one year of follow up.
89030938|NCT00507221|Active Comparator|2|Arm 2 will receive symptomatic diagnosis and treatment of helminth infection as is current standard of care in Kenya.
89591951|NCT05892328|Active Comparator|Watermelon flesh Dose 1|1 cup watermelon flesh, ~152 g
89591952|NCT05892328|Active Comparator|Watermelon flesh Dose 2|2 cups watermelon flesh, ~304 g
89591953|NCT05892315|Experimental|Repeated subgingival instrumentation|Conventional staged debridement (CSD) according to the severity of periodontitis in 2 to 4 appointments at day 0, 7, 14 and 21. Re-instrumentation at 6 weeks and 3 months after completion of step I-II.
89591954|NCT05892315|Active Comparator|Supragingival instrumentation|Conventional staged debridement (CSD) according to the severity of periodontitis in 2 to 4 appointments at day 0, 7, 14 and 21. Only supragingival instrumentation at 6 weeks and 3 months after completion of step I-II.
89591955|NCT05892289|Experimental|Robotic assisted proximal gastrectomy with double-flap technique|
89591956|NCT05892263|Experimental|Early intestinal force-feeding and drugs to promote gastrointestinal motility|
89591957|NCT05892263|Experimental|early enteral feeding|
89591958|NCT05892263|No Intervention|giving force-feeding after gas or defecation|
89591959|NCT05892224||MHO group|Metabolic healthy obesity
89591960|NCT05892224||HMO-U group|Hypermetabolic obesity-hyperuricemia
89591961|NCT05892224||HMO-I group|Hypermetabolic obesity-hyperinsulinemia
89591962|NCT05892224||LMO group|Hypometabolic obesity
89591963|NCT05892224||control group|Healthy person
89591964|NCT05892198|Active Comparator|primary closure|The group in which the pits location were in midline ,underwent excision with primary closure
89591965|NCT05892198|Active Comparator|Rhomboid flap group|in which more lateral pits and pits located <2cm from mid line natal cleft
89591966|NCT05892198|Active Comparator|Rotational flap group|in which more lateral pits and pits located >2cm from mid line natal cleft
89591967|NCT05892185|Experimental|GELA|Participants underwent at least one preoperative visit and had GELA implantation on Day 0 (The day of surgery)
89591968|NCT05892185|Active Comparator|XEN|Participants underwent at least one preoperative visit and had XEN gel stent implantation on Day 0 (The day of surgery).
89030939|NCT04693299||Study cohort|"Inclusion criteria:~Outpatient and hospitalized patients, adults, candidates for colonoscopy for any pathology, as part of the normal care process, with the need to repeat bowel preparation due to inadequate cleansing.~Exclusion criteria:~Emergency regime~Inability to obtain consent~Refusal of the patient"
89591969|NCT05892146|Experimental|Prevention therapy|Sacubitril/Valsartan (25/80) mg twice a day for 1 year
89591970|NCT05892146|No Intervention|Conventional therapy|No intervention
89591971|NCT05892146|No Intervention|Global longitudinal strain (GLS) function decreased >15%, No intervention|With the value of GLS function via echocardiography study decreased >15%, No intervention
89591972|NCT05892146|Experimental|GLS function descending >15%, Rescue therapy|Sacubitril/Valsartan (25/80) mg twice a day for 1 year
89591973|NCT05892120||control group|The control group only received usual care, the PANSS and MMSE were used to assess psychiatric symptoms and cognitive functions before (week 0) and after 8 weeks.
89591974|NCT05892120||experimental group|The experimental group use the MedAdhere app for eight weeks, the PANSS and MMSE were used to assess psychiatric symptoms and cognitive functions before (week 0) and after (week 8) intervention.
89591975|NCT05892107|Experimental|Toy Group|"Before the toy is given to the child, the child's pre-procedure pain will be assessed with the Wong-Baker Faces Pain Rating Scale.~2 minutes before the procedure, the parent will be asked to assess the child's pain with VAS (Visual Analog Scale) and their own anxiety level with State Anxiety Inventory.~Body temperature will be measured before the procedure.~Children will be given a toy 1 minute before the procedure.~The child's pain during the procedure will be assessed by the child using the Wong-Baker Faces Pain Rating Scale.~2 minutes after the procedure, the mother will re-evaluate the child's pain during the procedure using the Visual Analog Scale (VAS) and anxiety during the procedure using the State Anxiety Scale."
89591976|NCT05892107|Experimental|Mask group with cartoon characters|"The child's pain will be assessed with the Wong-Baker Faces Pain Rating Scale before the procedure.~2 minutes before the procedure, the parent will be asked to assess the child's pain with VAS (Visual Analog Scale) and their own anxiety level with State Anxiety Inventory.~Body temperature will be measured before the procedure.~1 minute before the procedure, the nurse will greet the child with a mask.~During the procedure, the child's pain will be assessed by the child using the Wong-Baker Faces Pain Rating Scale.~2 minutes after the procedure, the mother will reassess the child's pain during the procedure using the Visual Analog Scale (VAS) and anxiety during the procedure using the State Anxiety Scale."
89591977|NCT05892107|Active Comparator|Control Group|"Before the procedure, the child's pain will be assessed with the Wong-Baker Faces Pain Rating Scale.~2 minutes before the procedure, the parent will be asked to assess the child's pain with VAS (Visual Analog Scale) and their own anxiety level with State Anxiety Inventory.~Body temperature will be measured before the procedure.~1 minute before the procedure, the nurse will greet the child with a white mask on his/her face.~Children in the control group will be subjected to routine procedures (presence of the mother) during blood collection.~During the procedure, the child's pain will be assessed by the child using the Wong-Baker Faces Pain Rating Scale.~2 minutes after the procedure, the mother will reassess the child's pain during the procedure using the Visual Analog Scale (VAS) and anxiety during the procedure using the State Anxiety Scale."
89591978|NCT05892068|Experimental|Patients already on Tucatinib|Cohort A: This is a non-interventional study patients who will enter while already on Tucatinib . Patients in cohort A who are already on Tucatinib at a dose reduction (i.e., for toxicity) will continue the same dose.
89591979|NCT05892068|Experimental|Patients with documented radiological and/or clinical CNS progression with no prior tucatinib|Cohort B: Is to administer Tucatinib at standard dose of 300mg orally twice daily for 4 days prior to surgery (day -4 to 0).
89591980|NCT05892068|Experimental|HER2+ esophagogastric, lung, or colon cancer brain metastases and HER2 mutant breast cancer|Cohort C: Is to administer Tucatinib at standard dose of 300mg orally twice daily for 4 days prior to surgery (day -4 to 0).
89591981|NCT05892055||Healthy Control (HC)|Healthy controls (HC) will not have an FAPD diagnosis. The HC group receives the same procedures as the FAPD group.
89591982|NCT05892055||FAPD|Children in the FAPD group will be recruited based on the presence of an FAPD diagnosis and receive the same procedures as the HC group.
89591983|NCT05892042|Experimental|intervention|patient will receive dual antiplatelet therapy, the choose of p2Y12 inhibitor is at the discretion of the clinician. in addition the patient will receive rivaroxaban 15mg daily in addition to the dual antiplatelet therapy.
89591984|NCT05892042|No Intervention|control|patient will receive dual antiplatelet therapy, the choose of p2Y12 inhibitor is at the discretion of the clinician.
89591985|NCT05892016|No Intervention|spontaneous healing|No treatment after tooth extraction
89591986|NCT05892016|Experimental|Bone particle + subepithelial connective tissue graft|Alveolar ridge preservation grafted with bone particle and covered with a subepithelial connective tissue graft
89591987|NCT05892016|Experimental|Bone particle + Vascularized interpositional periosteal connective tissue graft|Alveolar ridge preservation grafted with bone particle and covered with vascularized interpositional periosteal connective tissue graft
89591988|NCT05892016|Experimental|Bone particle + collagen membrane|Alveolar ridge preservation grafted with bone particle and covered with a collagen membrane
89591989|NCT05892016|Experimental|Bone particle + Cytoplast|Alveolar ridge preservation grafted with bone particle and covered with a Cytoplast.
89591990|NCT05892003|Experimental|Control-High Fibre Weight Loss-High Fibre Non-Nutritive Sweetener Weight Loss: CTRL-HF WL-HF-NNS WL|"Phase 1 CTRL: Control diet with moderate fibre consumption for 14days.~Phase 2 HF WL: High Fibre Weight Loss meal consumption for 14days.~Phase 3 HF-NNS WL: High Fibre and Non-Nutritive Sweetener Weight Loss meal consumption for 14days."
89591991|NCT05891964|Experimental|Secukinumab|Injection Secukinumab 150mg subcutaneously will be administered at weeks 0, 1, 2, 3, 4, and then monthly for 5 months.
89591992|NCT05891938|Experimental|Single arm|Single group treatment
89591993|NCT05891925|Experimental|older_adults_CRC|Over 30 healthy community-dwelling older adults belonging to a Community Rehabilitation Center (CRC) at Concepcion, Chile.
89030940|NCT00507260|Experimental|Control Group|Control Group (Food Record)
89030941|NCT00507260|Experimental|Treatment Group|Treatment Group (Food Record + Nutritional Consults)
89030942|NCT03458793|Experimental|The experimental group|The experimental group will take part in the 12 week intervention after randomisation consisting of group walking and educational workshops performed once weekly for up to 90 minutes in total for each session.
89030943|NCT03458793|No Intervention|The control group|The control group will be a wait-listed arm that will be offered an intervention at 12 weeks after the randomisation (the delayed intervention).
89030944|NCT00507338|Experimental|ARC1779 low dose|0.1 mg/kg
89030945|NCT00507338|Experimental|ARC1779 mid dose|0.3 mg/kg
89591994|NCT05891912|Experimental|Technological devices intervention|"The intervention will be in individual sessions with the following technological devices and games:~Vertical screen: game of lights and vintage game.~Horizontal screen: cognitive function and activities of daily living games~Tablets: cognitive function and activities of daily living games"
89591995|NCT05891769|Experimental|18FCH PET/CT|Participant receive 18F Fluorocholine injection and approximately 45-60 minutes later receive a low dose CT scan from skull base to mid thighs, followed by a static PET emission scan over the same area.
89591996|NCT05891704|Experimental|Intervention group|The Intervention Group (IG) will receive 12-16 meetings of the standard conventional hand-therapy program according to OT intervention protocols used for clients with HI. The IG will receive one hour of 2-3 sessions a week according to patient needs and convenience. In each treatment session, the participant will receive 30 minutes of preparatory activities and therapeutic exercise, 15 min of Occupation-Based Activities, and 15 min for the culturally adjusted intervention that will be based on Focused Acceptance and Commitment Therapy (FACT) with major emphasis on values. In IG Arabic cultural values will be considered in the entire therapy process, the participant will have a companion in the therapy session. The participants in IG will be provided with a home-therapy protocol, and will complete a home program that will be based on enhancement of work values. Checklist diary will be provided to participants
89591997|NCT05891704|Active Comparator|Control group|The Control Group (CG) will follow the identical therapy protocol as the IG which will last for 45 minutes, with no culturally relevant interventions. In addition, each participant in the CG group will receive 15 minutes of free conversation with narrative feedback regarding the therapy, the challenges and opportunities in his daily life. Home-therapy protocol that will be based on conventional intervention will be provided.
89591998|NCT05891691|Experimental|Intervention Group|In addition to the training program prepared by the classroom teacher, the initiative group will receive a program that includes music activities, yoga postures accompanied by stories, breathing techniques and massage exercises, 2 days a week, 30 minutes a day for 6 weeks.
89591999|NCT05891691|No Intervention|Control Group|The teachers will continue their education within the program they have prepared.
89592000|NCT05891665|Experimental|Patients treated with the acceleration method|Patients will be treated using fixed orthodontic appliances assisted by minimally-invasive corticotomy (osteoperforations and piezocision) to accelerate impacted canines' traction after levelling and aligning the upper dental arch and opening an appropriate distance.
89592001|NCT05891665|Active Comparator|Patients treated with the traditional traction technique|Patients will be treated using the fixed orthodontic appliances to track the palatally impacted canines after levelling and aligning the upper dental arch and opening an appropriate space to receive the impacted canine.
89592002|NCT05891652|Active Comparator|Blocked|Patients had bilateral M-TAPA block with 0.25% bupivacaine (total volume of 40 ml) at the end of the surgery for postoperative pain control.
89592003|NCT05891652|No Intervention|Control|Patients did not have any block or infiltration anesthesia for their postoperative pain. They only received intravenous opioid analgesic (tramadol).
89592004|NCT05891574||healthy older adults|"Age between 65 and 90 years~No frailty indicated by Fried frailty criteria~Mini-mental state examination score equals to or more than 24, and Montreal Cognitive Assessment score equals to or more than 26~Ability to walk independently for 1 min"
89592005|NCT05891535|Experimental|Stentless FloRIN|Florence robotic Intra Corporeal Neobladder configuration was performed without the employement of Mono J ureteral catheters
89592006|NCT05891535|Active Comparator|Stented FloRIN|Florence robotic Intra Corporeal Neobladder configuration was performed with the employement of Mono J ureteral catheters
89592007|NCT05891457|Experimental|Malnourished children|"Severe Stunting (length/height-for-age Z-scores <-3SD)~Severe Acute Malnutrition (weight-for-length/height Z-scores <-3SD, and/or mid-upper-arm circumference <11.5 cm, with or without nutritional edema)~Wasting (weight-for-length/height Z-scores<-3SD)"
89592008|NCT05891444|Active Comparator|Transcranial random noise-Real|Participants will receive real tRNS once daily for two weeks
89592009|NCT05891444|Sham Comparator|Transcranial random noise-Sham|Participants will receive sham tRNS once daily for two weeks
89592010|NCT05890378||Cohort by Water Source|Using existing secondary data available on the research communities as well as qualitative inquiry, we will purposefully select 40 water sources for the water analysis across from the communities selected for the implementation research (up to 30 communities with a maximum of 5 water sources per community). The selection of water sources will be stratified by type of water sourceand near the route for long-term animal migration. For each water source, we will aim to have a water sample collected at all water sources twice a day (morning and later afternoon) once a week for four weeks, varying the day of the week. Thus, we will collect a total of 320 water samples in the course of four weeks at the end of the dry season before the rains start.
89592011|NCT05890066|No Intervention|4-port laparoscopic surgery|Patients with ectopic pregnancy will receive 4-Port laparoscopic surgery
89592012|NCT05890066|Experimental|1-port laparoscopic surgery|Patients with ectopic pregnancy will receive 1-port laparoscopic surgery
89592013|NCT05889949||TACE+MKIs|
89592014|NCT05889949||TACE|
89592015|NCT05889858||"medical secretaries of general practitioners group"|Men and women working as a secretary for a general practitioner, face-to-face in the medical practice.
89592016|NCT05888987||Before|
89592017|NCT05888987||After|
89592018|NCT05887804|Experimental|umbilical cord-derived mesenchymal stem cells (UC-MSC)|"UC-MSC was collected in 50 mL of transport medium, which contained alpha minimal essential medium (αMEM [GIBCO 12000-0221]), penicillin/streptomycin (final concentration 300u/mL [GIBCO 15140-122]) and amphotericin B (final concentration 7500ng /mL [JR Scientific 50701]), and processed in less than 8 hours after collection.~Group 1 was given UC-MSC 2 million cells/mL/cm3"
89592019|NCT05887804|Experimental|umbilical cord-derived mesenchymal stem cells conditioned medium (UC-CM)|group 2 was given UC-CM 1 mL/cm3
89592020|NCT05887804|Active Comparator|triamcinolone acetonide|group 3 was given TA 40 mg/mL/cm3
89030946|NCT00507338|Experimental|ARC1779 high dose|1.0 mg/kg
89592021|NCT05880303|Experimental|Nonsurgical periodontal therapy|Subjects in the IG will be given non-surgical periodontal treatment comprising of oral hygiene instructions, scaling and root surface debridement. Scaling will be carried out with ultrasonic scaler. For root surface debridement (for sites with PPD >4mm), local anaesthetic will be administered and ultrasonic scaler and Gracey curettes will be used. The scaling and root surface debridement will be done in 2 sittings over 2 different days within a week. Oral hygiene instructions and additional supportive scaling and root surface debridement will be repeated at 3 months and 6 months if judged necessary (presence of sites with BOP and/or PPD ≥5mm).
89592022|NCT05880303|No Intervention|Delayed treatment|Oral hygiene instructions at baseline and will be repeated at 3 months and 6 months. All subjects will receive scaling and root surface debridement at the end of the 6 month trial.
89592023|NCT05879952|Experimental|Experimental Group (EG)|"The group consists of 50 patients diagnosed with global developmental delay, randomply assigned.~The patients underwent treatment as usual (TAU) integrated with the use of BTsN pediatric modules, in a 1:1 ratio. All the exercises have been customized by the therapists according to the individual treatment needs, adapting the level of difficulty to the patient's abilities.~Overall, each patient was treated over a period of 6 months, up to a total of n. 48 sessions, twice a week, lasting 45 minutes each."
89592024|NCT05879952|Active Comparator|Control Group (CG)|"The group consists of 50 patients diagnosed with global developmental delay randomply assigned.~The patients underwent TAU, consisting in standard neuro-psychomotor training. The treatment was tailored according to each child's goals need and preferences.~Overall, each patient was treated over a period of 6 months, up to a total of n. 48 sessions, twice a week, lasting 45 minutes each."
89592025|NCT05875103|Experimental|Cognitive cortical neurodegenerative diseases and stroke PATIENTS|
89592026|NCT05874999|Experimental|Chronic Obstructive Pulmonary Disease (COPD)|People with chronic obstructive pulmonary disease (COPD) (n = 16)
89592027|NCT05874999|Active Comparator|Healthy Controls (HC)|Healthy controls matched on age, sex and objectively measured physical activity (n = 16)
89592028|NCT05873608|Other|Interview|Patients and providers undergo observation during a conversation about immunotherapy. Then participate in an interview over 20 minutes.
89592029|NCT05873608|Other|Aim 4 tests an educational video|The participants watch a video and their comprehension is tested in a pre and post methodology
89592030|NCT05873075|Experimental|Study group|Patients received intravascular laser irradiation of blood for 20 days before IVF cycles
89592031|NCT05873075|No Intervention|Control|No intervention before IVF cycles
89592032|NCT05867446|Experimental|Experimental:|pecha kucha will be practiced
89592033|NCT05867446|No Intervention|control|Routine maintenance will be applied.
89592034|NCT05842265|Experimental|Experimental:|Self acupressure
89592035|NCT05842265|No Intervention|Control|Routine maintenance will be applied.
89592036|NCT05838209|Placebo Comparator|Control|Scaling and root planing + saline solution gel (control) will be adminster at probing depth > 5mm.
89592037|NCT05838209|Active Comparator|Test|Scaling and root planing + Ozone Oil will be adminster at probing depth > 5mm.
89592038|NCT05834972||Landmark-guided percutaneous dilatational tracheostomy|All patients will be enrolled two times. First, an experienced anesthesiologist will examine the neck anatomy and mark the second or third tracheal ring using the traditional landmark-guided technique, and the duration will be recorded. Then, the same anesthesiologist will examine the neck anatomy and mark the second or third tracheal ring using the ultrasound (USG)-guided approach, and the duration will be recorded. The distance between these two aforementioned markings will be measured and recorded. The first marking determined by the landmark method will be looked at with USG and where it corresponds anatomically will be recorded. Also, the vascular and glandular structures of the area and potential complications will be noted.
89592039|NCT05834972||Ultrasound-guided percutaneous dilatational tracheostomy|All patients will be enrolled two times. First, an experienced anesthesiologist will examine the neck anatomy and mark the second or third tracheal ring using the traditional landmark-guided technique, and the duration will be recorded. Then, the same anesthesiologist will examine the neck anatomy and mark the second or third tracheal ring using the ultrasound (USG)-guided approach, and the duration will be recorded. The distance between these two aforementioned markings will be measured and recorded. The first marking determined by the landmark method will be looked at with USG and where it corresponds anatomically will be recorded. Also, the vascular and glandular structures of the area and potential complications will be noted.
89592040|NCT05820737|Placebo Comparator|Placebo|1 capsule to be consumed once a day
88977534|NCT02968082|Experimental|Scopolamine group (S group)|"'Scopolamine (1.5mg) 1 patch'~The group that existed scopolamine ingredient~dosage form: apply~dosage: 1.5 mg~frequency: 1 times (at 9 p.m. of the day before the operation day)~duration: Until the 24hr after operation.~Patients will be applied patch that existed scopolamine ingredient."
89592041|NCT05820737|Active Comparator|EF2001|1 capsule to be consumed once a day
89592042|NCT05820737|Active Comparator|beLP1|1 capsule to be consumed once a day
89592043|NCT05809505|Experimental|Multiple Sclerosis Patients|Patients with a diagnosis of multiple sclerosis.
89592044|NCT05808725|Experimental|T1 Fasting|Giving test product under fasting condition
89592045|NCT05808725|Experimental|T2 Fed|Giving test product under fed condition
89592046|NCT05808725|Active Comparator|R Fasting|Giving reference product under fasting condition
89592047|NCT05803798|Active Comparator|treatment|preventive treatment by IPL+LLLT with EYE-LIGHT, Espansione group
89592048|NCT05803798|No Intervention|standard|non preventive treatment by IPL+LLLT with EYE-LIGHT, Espansione group = standard care
89592049|NCT05792540|Active Comparator|Control Group|Control group ( fluoxetine 20 mg, n =25 ) who will receive fluoxetine (20 mg) once daily for 3 months
88977535|NCT00222742|Experimental|A|Induced moderate hypothermia (32-33 C)
88977536|NCT02968043|Active Comparator|control group|Control group will perform generalised physiotherapy exercises for a 60-min period for 2 or 3 times a week under the guidance of experienced physiotherapists in an outpatient clinic and for a 20-min period per day under the supervision of the parents at home. Generalised physiotherapy exercises consist of stretching and strengthening activities.
89030947|NCT00507338|Active Comparator|abciximab|labeled regimen for primary PCI
89592050|NCT05792540|Active Comparator|Dapagliflozin group|Patients will receive fluoxetine (20 mg) once daily plus dapagliflozin 10 mg once daily for 3 months
89592051|NCT05792540|Active Comparator|Atorvastatin group|Patients will receive fluoxetine (20 mg) once daily plus atorvastatin 80 mg once daily for 3 months
89592052|NCT05788198|Experimental|Integrated care arm|Case management in primary care setting (integration at general practitioners' practices), Depression and population management education for general practitioners, shared care guidance protocol including a medication path (drug classes, no specific drugs specified, based on available depression guidelines in Belgium).
89592053|NCT05780307|Experimental|IMM2520 in subjects with advanced solid tumors|Dose-escalation phase: the dosing schedule of IMM2520 is 0.1 mg/kg, 0.4 mg/kg, 1.0 mg/kg, 2.0 mg/kg, 4.0 mg/kg and 6.0 mg/kg sequentially.
89592054|NCT05773573|Experimental|Experimental group|Hyrax-type rapid maxillary expander anchored on the 2nd deciduous molars (V)
89592055|NCT05773573|Active Comparator|Control group|Hyrax-type rapid maxillary expander anchored on the 1st permanent molars (6)
89592056|NCT05756010|Experimental|interventional group|The program consisted of two strengthening (deep cervical flexors and shoulder retractors) and two stretchings (cervical extensors and pectoral muscles) exercises based on Harman and Mostafa et al's approach.
89592057|NCT05756010|Sham Comparator|conrol group|General exercises
89592058|NCT05743608||Moderate to severe COPD patients receiving Trimbow dry powder inhaler|Patients above the age of 35 years, who had been diagnosed with COPD for over a year by a pulmonologists specialist. Having a moderate or severe obstruction (30%≤FEV1<80%) and are uncontrolled despite fixed dual combination treatment (LABA/LAMA or ICS/LABA). Therapy was changed to Trimbow® 88/5/9 µg inhalation powder maximum 1 week prior to or on the day of study inclusion and irrespective of study entry (escalation of symptomatic patient to fixed triple combination as per treatment protocol)
89592059|NCT05742412|Experimental|Intervention Group|"Intervention group: EMS dispatcher using video-based communication in emergency calls.~In the intervention arm, the EMS Dispatchers are requested to use video in all emergency calls during the 4-month study period."
89592060|NCT05742412|Active Comparator|Control Group|"Control group: EMS dispatcher using telephone-only (audio-only) communication in emergency calls.~In the control arm, the EMS Dispatchers continue using standard telephone communication (usual care)."
89592061|NCT05740033|Active Comparator|STSG arm|"Patient demographics will be recorded during the enrollment visit. During the participant's surgery in which the radial forearm free flap (RFFF) has been used, surgeons will perform a split-thickness thigh graft to close the forearm donor site. A photograph will be taken of the participants' forearm upon the removal of the dressing and splint.~On each of the two follow-up clinic visits, another photo will be taken of the forearm scar and patient-reported outcome questionnaires will be provided for completion."
89592062|NCT05740033|Active Comparator|Hatchet flap arm|"Patient demographics will be recorded during the enrollment visit. The hatchet flap closure of the forearm donor site will be performed following the RFFF's usage. A photograph will be taken of the participants' forearm upon the removal of the dressing and splint.~On each of the two follow-up clinic visits, another photo will be taken of the forearm scar and patient-reported outcome questionnaires will be provided for completion."
89592063|NCT05729412||Compliance|Prescription is filled for specific parameters
89592064|NCT05729412||Non-compliance|Prescription is not filled for specific parameters
88977537|NCT02968043|Experimental|intervention group|Intervention group will perform physiotherapeutic scoliosis specific exercises for a 60-min period for 2 or 3 times a week under the guidance of experienced physiotherapists with expertise in scoliosis in an outpatient clinic and for a 20-min period per day under the supervision of the parents at home. Physiotherapeutic scoliosis specific exercises consist of patient and family education, 3D self-correction, stabilizing exercises, balance training, breathing exercises, and training in activities of daily living.
88977538|NCT00222937|Experimental|A|Patients are enrolled in Lessac-Madsen Resonant Voice Therapy.
88977539|NCT00222937|Experimental|B|Patients are enrolled in Casper Based Confidential Flow Therapy.
89592065|NCT05729412||Not available - NA|Data not available
89592066|NCT05721365||Pre-Infusion|Participants prior to commencing Adoptive Cell Therapy (ACT).
89592067|NCT05721365||Acute|Participants either receiving ACT or up to 30 days post treatment.
89592068|NCT05721365||Sub-acute|Up to 12 months post ACT.
89592069|NCT05721365||Long term follow up|From 12 months post ACT onwards
89592070|NCT05701826|Experimental|Treatment group A1|HRS3797 for injection
89592071|NCT05701826|Experimental|Treatment group A2|HRS3797 for injection
89592072|NCT05701826|Experimental|Treatment group B1|HRS3797 for injection
89592073|NCT05701826|Experimental|Treatment group B2|HRS3797 for injection
89592074|NCT05701826|Experimental|Treatment group C1|HRS3797 for injection
89592075|NCT05701826|Experimental|Treatment group C2|HRS3797 for injection
89592076|NCT05700214|Experimental|ESP block|Ultrasound-guided continuous ESP block with opioid PCA A high-frequency linear ultrasound transducer will be placed in a longitudinal parasagittal orientation 3 cm lateral to the T7/T8 spinous process. A Contiplex Echo ultra 360 18G needle with 20G × 55 cm Contiplex Echo catheter will be inserted using an in-plane superior-to-inferior approach to place the tip into the fascial plane on the deep (anterior) aspect of erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting erector spinae muscle off the bony shadow of the transverse process. A total of 30 mL of 0.375% ropivacaine
89592077|NCT05700214|Active Comparator|lidocaine|Before induction bolus of 1% lidocaine 1,5mg/kg IBW i.v., continuous infusion of 1% lidocaine intraoperatively rate 1 mg/kg IBW i.v.
88977540|NCT00222976|Experimental|1|A Naproxen PO + placebo PR
88977541|NCT00222976|Experimental|2|B Placebo PO + Naproxen PR
88977542|NCT00085371|Experimental|Treatment (triapene)|Patients receive triapene IV over 2 hours on days 1-4 and 15-18. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88977543|NCT00223210|Active Comparator|Quetiapine|
88977544|NCT00223210|Placebo Comparator|Placebo|Inactive ingredient matching the active medication in appearance
88977545|NCT00223249|Active Comparator|Quetiapine|Quetiapine
88977546|NCT00223249|Placebo Comparator|Placebo|Inactive ingredient matching the active medication in appearance
88977547|NCT00085449|Experimental|Regimen A + B|"Conditioning regimen A: Patients receive alemtuzumab IV over 2 hours on days -14 to -12; fludarabine IV over 30 minutes on days -7 to -3; and melphalan IV over 20-30 minutes on day -2.~Conditioning regimen B: Patients receive oral or IV cyclosporine twice daily and oral or IV mycophenolate mofetil twice daily on days -15 to 0. Patients also receive alemtuzumab, fludarabine, and melphalan as in conditioning regimen A. Patients undergo low-dose total body irradiation twice daily on days -2 and -1.~All patients undergo allogeneic, T-cell-depleted, CD34-positive peripheral blood stem cell transplantation on day 0. Patients receive sargramostim (GM-CSF) subcutaneously beginning on day 1 and continuing until blood counts recover.~Patients are followed every 3 months for 1 year and then every 6 months for 5 years."
88977548|NCT00223405||metal-ceramic (D'Sign) o|Metal ceramic crown will be placed
88977549|NCT00223405||an all-ceramic crown (IPS Empress2, Eris EXC).|All ceramic crown will be placed
88977550|NCT00223444||1|Genotype group Pro/Pro
88977551|NCT00223444||2|Genotype group Pro/Ser
88977552|NCT02965209|Experimental|motorized spiral enteroscopy|Novel Motorized Spiral Enteroscopy (NMSE) represents a new technology which offers all of the advantageous options of spiral enteroscopy with a faster and less invasive approach.
89592078|NCT05693779|Experimental|Home exercise training|Individualized exercise prescription will be provided based on the gathered cardiopulmonary exercise test data.
88977553|NCT02967770|Experimental|Molecularly Tailored Therapy|Patients will be treated according to their molecular profile and accordingly, the 29 evaluable patients enrolled may receive one of a dozen, or dozens of treatment regimens.
89592079|NCT05676918|Experimental|Positive Psychology Intervention|Ten weekly sessions. Session duration: 90 minutes.
89592080|NCT05676918|Active Comparator|Cognitive Behavior Therapy|Ten weekly sessions. Session duration: 90 minutes.
89592081|NCT05623657|Experimental|Trunk Stabilization Exercise Training Group|
89592082|NCT05623657|Experimental|Game Based Exercise Program Group|
89592083|NCT05622383|Experimental|aromatherapy|aromatherapy will be applied
89592084|NCT05622383|Experimental|music concert|music concert will be applied
89592085|NCT05622383|Experimental|aromatherapy,music concert|aromatherapy, music concert will be applied
89592086|NCT05622383|No Intervention|control|Routine maintenance will be applied.
89592087|NCT05600686|Experimental|Treatment (Lonca-R, DA-EPOCH-R)|Patients receive rituximab IV, loncastuximab tesirine IV, etoposide IV, doxorubicin IV, vincristine IV, prednisone PO, and cyclophosphamide IV on study. Patients also undergo collection of blood samples and bone marrow aspiration and biopsy at screening and CT or PET/CT at screening, throughout the study, and during follow up.
89592088|NCT05581082||Routine Clinical Care with PCP|All individuals will be seen by their primary care physician (PCP) in Geriatric Clinic. Patients previously diagnosed with frailty per their PCP. Their PCP visit will include independent assessment and physical therapy referral, and will begin a physical therapy-based strengthening intervention. Patients will be independently managed (assessment and intervention) by a Physical Therapist (PT). The PT will initiate an intervention plan (e.g., education and exercise)
89592089|NCT05564338|Experimental|Treatment Arm A: sitravatinib + tislelizumab|sitravatinib once daily and tislelizumab once every 6 weeks, for up to 17 cycles (approximately 2 years)
89592090|NCT05564338|Experimental|Treatment Arm B: Placebo + tislelizumab|sitravatinib-matching placebo once daily and tislelizumab once every 6 weeks, for up to 17 cycles (approximately 2 years)
88977554|NCT02967770|Active Comparator|Physician's Discretion Standard of Care|Patients will be treated according to physician discretion standard of care regimen.
88977555|NCT00223639|Experimental|Topiramate|
88977556|NCT00223639|Placebo Comparator|Placebo|
89592091|NCT05564338|Experimental|Treatment Arm C:Sitravatinib + Placebo|sitravatinib once daily and tislelizumab-matching placebo once every 6 weeks, for up to 17 cycles (approximately 2 years)
89592092|NCT05564338|Experimental|Treatment Arm D: Matching Placebo|sitravatinib-matching placebo once daily and tislelizumab-matching placebo once every 6 weeks, for up to 17 cycles (approximately 2 years)
89592093|NCT05550818|Experimental|High Ultra Processed Food Diet|Participants will consume a diet containing 81% total energy from UPF for 2 weeks.
88977557|NCT00223717|Experimental|1: Active drug or intervention|Clonidine, Nitroglycerin transdermal, Dipyridamole/ Aspirin (Aggrenox), Desmopressin (DDAVP), Sildenafil, Nifedipine, Hydralazine, Hydrochlorothiazide, Bosentan, Diltiazem, Eplerenone, guanfacine, L-arginine, captopril, carbidopa, losartan, metoprolol tartrate, nebivolol hydrochloride, prazosin hydrochloride, tamsulosin hydrochloride, Head-up tilt, aliskiren, local heat stress
88977558|NCT00223717|Placebo Comparator|2: Placebo|placebo pill or patch
88977559|NCT00061919|Experimental|Active arm (thalidomide)|Carboplatin IV on day 1 and etoposide IV on day 1 and 2 and, orally Day 3. Oral thalidomide daily beginning on day 1 for up to 24 months.
88977560|NCT00061919|Placebo Comparator|Placebo arm|Carboplatin IV on day 1 and etoposide IV on day 1 and 2 and, orally Day 3. Oral placebo daily beginning on day 1 for up to 24 months.
88977561|NCT00223756|Experimental|Arm 1|interdisciplinary, outpatient blind rehabilitation
88977562|NCT00223756|No Intervention|Arm 2|usual care
89592094|NCT05550818|Experimental|No Ultra Processed Food Diet|Participants will consume a diet containing 0% total energy from UPF for 2 weeks.
89592095|NCT05536284|Experimental|Acute coronary syndrome patients|Acute coronary syndrome patients that are prescribes bisoprolol
89608467|NCT04386694|Experimental|PBMT/sMF|"Active PBMT/sMF will be applied once a day, during the ICU stay, until discharge or death. The patients will receive standard physical therapy care associated with PBMT/sMF.~PBMT/sMF will be applied using MR5™ ACTIV PRO LaserShower, manufactured by Multi Radiance Medical (Solon, OH, USA). This device has 4 diodes of 905 nm (1.25 mW each diode, 0.32 cm2 each), 8 diodes of 633 nm (25 mW each diode, 0.85 cm2 - each), and 8 diodes of 850 nm (40 mW each diode, 0.56 cm2 - each). The static magnetic field is 110 mT."
88977563|NCT00085527|Experimental|depsipeptide|Depsipeptide administered on Days 1, 8, and15 of a 28-day cycle.
88977564|NCT00223834|Other|1|Single session orientation to available services
89592096|NCT05534386|Experimental|First stage intervention: Cancer survivorship care intervention (CSCI)|Patients randomized to the CSCI will attend a 120-minutes survivorship clinic in which each participant will be assessed by members a multidisciplinary team comprising a registered nurse, a dietitian, an exercise physiologist and a psychologist/counsellor. During the visit, participants will receive a personalized (1) treatment summary, (2) assessment and recommendation on managing physical and psychological symptoms, (3) assessment and recommendation on dietary advice, (4) assessment and recommendation on physical activity, and (5) advice on managing potential psychosocial issues. While this is a multidisciplinary clinic, the nurse will be the core facilitator who will give a summary of health assessment report including personalized healthy lifestyle advice and action plan to each participant at the end of the visit.
89592097|NCT05534386|Active Comparator|First stage intervention: Control intervention|Patients randomized to the control group will be given a set of pamphlets explaining symptoms and describing skill-based self-management for symptom management and lifestyle recommendations. Each pamphlet addresses one of the 7 most commonly-reported symptoms (sleep difficulties, fatigue, neuropathy, pain, anxiety, depression, and fear of cancer recurrence) observed in Hong Kong cancer survivors, plus two on lifestyle recommendations (physical activity and healthy diet). All pamphlets are developed based on the self-management framework.
89592098|NCT05534386|Experimental|Second stage intervention: Step-up targeted personalized intervention|The step-up targeted personalized intervention will adopt a multi-disciplinary approach but place more emphasis on coaching to enhance patient' skills to manage their symptom burden and weight control.
89592099|NCT05534386|Active Comparator|Second stage intervention: Control intervention|Patients randomized to the control arm at the re-assessment at 4-months post-baseline will continue in the trial as usual (i.e. those in the survivorship clinic arm will be asked to follow the advice given by the multidisciplinary team in the initial visit and for those in the control arm will be asked to follow the advices printed in the skill-based self-management pamphlets).
89592100|NCT05527756||Totally endoscopic aortic/mitral valve replacement|Study procedures include the Scar Cosmesis Assessment and Rating (SCAR) scale and numerical rating scale (NRS) questionnaire at one, 14 and 30 days after totally endoscopic aortic/mitral valve replacement. Additionally, a photo of the incisions will be taken at these time points.
89592101|NCT05527756||Totally endoscopic coronary artery bypass grafting|Study procedures include the Scar Cosmesis Assessment and Rating (SCAR) scale and numerical rating scale (NRS) questionnaire at one, 14 and 30 days after totally endoscopic coronary artery bypass grafting. Additionally, a photo of the incisions will be taken at these time points.
89592102|NCT05514210|Experimental|real-time heart team group|Patients randomized to this group will be accessed and discussed by multidisciplinary specialists during the coronary angiography process
89592103|NCT05514210|Active Comparator|conventional heart team group|Patients randomized to this group will be accessed and discussed offline and face-to-face by multidisciplinary specialists after the coronary angiography process
89592104|NCT05503446|Experimental|Oral Immunotherapy, in-hospital supervision for updosing|Active oral immunotherapy, with all updosing visits taking place in hospital
89592105|NCT05503446|Experimental|Oral Immunotherapy, virtual supervision for updosing|Active oral immunotherapy, with all updosing visits taking place with virtual supervision
89592106|NCT05503446|No Intervention|Control arm: allergen avoidance|
89592107|NCT05497921|Other|Test (device arm)|Crossover study. The subject treats 1 hand while the contralateral is the control arm. After 6 weeks the treatment/control hand are swopped.
89592108|NCT05445674|Experimental|Plasma Exchange|6 sessions of PE with human serum 5% albumin. Plasma exchange sessions will occur on days 1, 3, 8, 10, 15 and 17
89592109|NCT05445674|Sham Comparator|Sham Plasma Exchange|6 sessions of sham plasma exchange (one infusion of sterile saline solution 0.9%) on days 1, 3, 8, 10, 15 and 17.
89592110|NCT05441137|Active Comparator|A ROC with a Standing Posture for Toddlers with Mild Motor Delays (ROC-Stand(Mild))|The whole study duration will be 24 weeks, including a 12-week intervention and a 12-week follow-up. All programs will include 120 minutes/per session, 2 sessions/per week. Each week the research team will help the participant wear a wireless, head-mounted eye-tracker (46g) for recording the first 20-minute of both driving and natural play sessions in a 2-hour training session. The 2-hour training session is composed of a 70-minute driving session and a 40-to-50-minute natural play session, with a 10-mintue break if necessary according to the previous ROC-related studies. The natural play session can be divided into two 20-to-25-minute sessions depending on the participant's condition. The head-mounted cameras worn by the participants and caregivers will record the visual and manual behaviors for 40 minutes/per week during intervention. All programs will be discussed by the family, the treating therapist and the research team.
89592111|NCT05441137|Active Comparator|A ROC with a 25-minute Standing Posture for Children with Moderate Motor Delays (ROC-Stand25(Mod))|The training guidelines and time are the same as the ROC-Stand(Mild) group, except for the participant's severity level of motor delay and using a 25-minute standing and 45-mnute sitting posture for driving. The participants will also wear the head-mounted eye tracker in one training session every week.
89592112|NCT05441137|Active Comparator|A ROC with a Sitting Posture for Children with Severe Motor Delays (ROC-Sit(Sev))|The training guidelines and time are the same as the ROC-Stand(Mild) group, except for the participant's severity level of motor delay and using a sitting posture for driving. The participants will wear the head-mounted eye tracker in one training session every week.
89592113|NCT05441137|Placebo Comparator|Conventional Therapy for Children with Mild Motor Delays (Control(Mild))|The whole study duration will be 24 weeks, including a 12-week intervention and a 12-week follow-up. All programs will include 120 minutes/per session, 2 sessions/per week. Each participant will have the opportunity to walk on certain public space as the ROC training groups and interact with the therapist and caregivers depending on his/her motor abilities. The participants will also wear the head-mounted eye-tracker in one training session every week.
89030948|NCT02946723|Experimental|US group|lead implantation surgery for SNM using ultrasound guided technique
89030949|NCT02946723|Sham Comparator|X-ray group|lead implantation surgery for SNM using X-ray guided technique
89030950|NCT05140031|Active Comparator|Usual care|Participants will initially undergo 2 weeks of usual care.
89592114|NCT05441137|Placebo Comparator|Conventional Therapy for Toddlers with Moderate Motor Delays (Control(Mod))|The training guidelines and time are the same as the Control(Mild) group, except for the participant's severity level of motor delay. The participants will wear the head-mounted eye-tracker in one training session every week.
89592115|NCT05441137|Placebo Comparator|Conventional Therapy for Toddlers with Severe Motor Delays (Control(Sev))|The training guidelines and time are the same as the Control(Mild) group, except for the participant's severity level of motor delay. The participants and caregivers will also head-mounted eye-tracker in one training session every week.
89592116|NCT05440123||bronchopulmonary cancer|"The screening program includes performing a low-dose chest CT scan (STBD), spirometry, blood sampling (biobank + screening for cardiovascular risk factors) on inclusion, at 1 year and at 2 years. Subsequently, a telephone interview will be scheduled for 3 years to collect medical information, for a total follow-up period of 5 years. At each visit, a structured offer of smoking cessation will be proposed and a collection of the quality of life will be carried out. Each year, a telephone call from participants will be scheduled in order to maximize participation.~For subjects presenting with anomalies suggestive of PBC on the STBD, a consultation in pneumo-oncology will be planned with management corresponding to routine care."
89592117|NCT05437393|Experimental|Deep brain stimulation|"Deep Brain stimulation using a novel device: Bioinduction Picostim Deep Brain Stimulation system."
89592118|NCT05435612|Experimental|single-sided deafness group（SSD Group）|The single-sided group（SSD group）consists of 20 SSD patients voluntarily enrolled in the study and plan to undergo cochlear implantation.
89592119|NCT05435612|Experimental|asymmetric hearing loss group（AHL Group）|The asymmetric hearing loss group（AHL group）consists of 10 AHL patients voluntarily enrolled in the study and plan to undergo cochlear implantation.
89592120|NCT05429099|Active Comparator|Free-Hand Surgery (FHS)|In FHS, the site surgeon will proceed with the surgery as per their routine practice.
89592121|NCT05429099|Experimental|Virtual Surgical Planning (VSP)|The trial research engineer (RE), located at Vancouver General Hospital (VGH), will segment the CT data to create a 3D model for surgical planning. During the teleconference between site surgeon (SS) and RE, the RE will load the CT data and the segmented 3D model into the virtual planning environment. With the RE navigating the software, which was created in-house at VGH and used in a previous case series, the SS will determine the extent of disease and define the resection planes. After the cutting planes are created, the RE will use the software to create the reconstruction plan with either the patient-specific fibula or scapula. Once the surgeon is satisfied with the plan, the teleconference will end and the RE will create and 3D print the surgical guides for the mandible, for the fibula or scapula, as well as the 3D computed reconstruction.
89592122|NCT05424198|Active Comparator|Trident Cervical Medial Branch Radiofrequency Ablation|During this procedure a 50 mm or 100 mm long (dependent on body habitus), 18-gauge insulated cannula with a 5 mm active tip will be placed perpendicularly at targeted medial branches (the nerves carrying pain signals from the facet joints).
89592123|NCT05424198|Active Comparator|Conventional Cervical Medial Branch Radiofrequency Ablation|During this procedure a 50 mm or 100 mm long (dependent on body habitus), 18-gauge conventional cannula with a straight 5 mm active tip will be placed parallel and oblique to the targeted medial branch branches (the nerves carrying pain signals from the facet joints). At each location, one lesion will be made to accommodate anatomic variation.
89592124|NCT05409391|Experimental|AI|Insulin Titration System Based on Deep Learning
89592125|NCT05395819|Experimental|Reverse Total Shoulder Arthroplasty (RTSA)|"Patient will undergo a RTSA as per standard technique. It uses a stemmed metal humeral component attached to the glenoid and the shallow glenoid component attached to the humerus. Pre-operative CT imaging and surgical planning software based on pre-operative CT scans will be used in each case to determine the degree of eccentric (high side) anterior reaming to within < 10 degrees of neutral glenoid version. Standard instruments including a spherical burr and power reamers will be used to achieve this."
89592126|NCT05395819|Active Comparator|Total Shoulder Arthroplasty (TSA)|Patients will undergo standard glenoid preparation and implantation of a TSA. It uses a stemmed metal humeral component to replace the arthritic head of humerus and a shallow polyethylene glenoid component to replace the arthritic glenoid surface. The degree of anterior- reaming will be based on pre-operative CT scan assessment and templating software with the goal of correcting glenoid retroversion to within 10 degrees of neutral version.
89592127|NCT05395364|No Intervention|Control|No intervention will occur.
89592128|NCT05395364|Experimental|Intervention|An intervention program based on the promotion of health literacy and lifestyles, specifically on children's: 1-health literacy and infodemic resilience; 2- lifestyles (e.g. dietary intake, 24h-movement behaviour); 3-overweight and obesity; 4-blood pressure.
89592129|NCT05381454|Experimental|MitoQ|Treatment group
89592130|NCT05381454|No Intervention|Control group|Control group
89592131|NCT05368428|Experimental|Supportive Care (TENS)|Patients undergo TENS therapy daily over 1 hour for 14 days in the absence of disease progression or unacceptable toxicity.
89592132|NCT05367063|Active Comparator|Canagliflozin group|On the basis of the original metformin medication, the experimental group took canagliflozin 1 tablet (100 mg) orally once a day (qd) before the first meal of the day, and the dosing cycle lasts 6 months.
89592133|NCT05367063|Placebo Comparator|Sitagliptin group|On the basis of the original metformin medication, the experimental group took Sitagliptin 1 tablet (100 mg) orally once a day (qd) before the first meal of the day, and the dosing cycle lasts 6 months.
89592134|NCT05364242|Experimental|VLA2001|
89592135|NCT05360771|Experimental|treatment group|Percutaneously occlusion of PFO with SnowyTM PFO closure system
89592136|NCT05360771|Experimental|control group|Percutaneously occlusion of PFO with Cardi-o-fix PFO occluder
88977565|NCT00223912|Other|1|Lower-extremity functional electrical stimulation
88977566|NCT00061958|Experimental|Treatment (arsenic trioxide)|Patients receive a loading dose of arsenic trioxide IV over 2 hours on days 1-5 on week 1. Beginning on week 2, patients receive a maintenance dose of arsenic trioxide IV twice weekly thereafter. Courses repeat every 4 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients achieving a CR continue to receive therapy for at least 6 months beyond CR.
89592137|NCT05358548|Experimental|Squamous Lung Cancer|"A Cycles consist of either:~Paclitaxel Based: Carboplatin/Paclitaxel/Pembrolizumab OR~nab-Paclitaxel Based: Carboplatin/nab Paclitaxel/Pembrolizumab These A Cycles will be given for up to four cycles (standard)~B Cycles consist of Pembrolizumab alone"
89592138|NCT05358548|Experimental|Non-Squamous Lung Cancer|"A Cycles consist of Carboplatin/Pemetrexed/Pembrolizumab (up to four cycles standard)~B Cycles consist of Pembrolizumab alone~Maintenance Cycles (Cycle 5 and beyond): Pemetrexed in combination with Pembrolizumab; Alternatively, Pembrolizumab alone, for up to 2 years since enrollment (standard)"
89592139|NCT05358548|Experimental|Head and Neck Squamous Cell Carcinoma|"A Cycles consist of Carboplatin/5-Fluorouracil/Pembrolizumab (up to six cycles standard)~B Cycles consist of Pembrolizumab alone~Maintenance Cycles (Cycle 7 and beyond): Pembrolizumab alone, for up to two years since enrollment (standard)"
89592140|NCT05348564|Experimental|Direct contact|Study team contact of family members
89592141|NCT05348564|No Intervention|Indirect contact|Proband initiated contact of family members
89592142|NCT05346250||Non exercise program|Subjects receive 12 month lifestyle education alone.
89592143|NCT05346250||Moderate intensity exercise program|Subjects receive 12 month moderate exercise.
89592144|NCT05346250||Vigorous intensity exercise program|Subjects receive 6 month vigorous exercise and subsequent 6 month moderate exercise
89592145|NCT05343364|Experimental|Vonoprazan 10 mg|Participants will receive vonoprazan 10 mg once daily for 14 days.
89592146|NCT05343364|Experimental|Vonoprazan 20 mg|Participants will receive vonoprazan 20 mg once daily for 14 days.
89592147|NCT05342038|Experimental|Single Arm|T-02
88977567|NCT00085722|Experimental|Dextrose|Subjects in Group 1 receive PrT with 15% and 25% dextrose solution, as it is generally practiced in the US today.
88977568|NCT00085722|Placebo Comparator|Normal saline|Subjects in Group 2 will receive the same treatment as Group 1, except that a 0.9% 'normal' saline solution with no known benefit will be used instead of dextrose.
88977569|NCT00085722|Other|Exercise|At-home physical therapy exercises as a non-injection control
88977570|NCT00062075|Experimental|Treatment|Patients receive romidepsin IV over 4 hours on days 1, 8, and 15. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
88977571|NCT00224419|Active Comparator|1 - CBT Counseling|Participants in this arm received a tailored CBT (TCBT) intervention that included: a written self-help guide, feedback about the importance of reducing nicotine exposure to the fetus, 5 face to face and 1 telephone counseling session.
88977572|NCT00224419|Experimental|2 - Counseling + NRT|Women in this arm received the TCBT described in Arm 1, plus their choice of NRT. To minimize fetal exposure to nicotine for women in the TCBT+NRT arm, the dose of NRT are customized to the woman's current level of smoking. Women who smoke 5-10 cigarettes a day will be given the 14 mg patch or instructed to use one 2 mg lozenge or 2 mg piece of gum to replace each cigarette she usually smokes per day. Those who smoke 11 cigarettes or more per day will be given the 21 mg patch or instructed to use no more than one lozenge (2 mg) or piece of gum (2 mg) to replace each cigarette she usually smokes per day, not to exceed 15 lozenges or pieces of gum per day.
88977573|NCT00062114|Experimental|rituximab + yttrium Y 90 ibritumomab tiuxetan|"Patients receive rituximab IV followed within 4 hours by yttrium Y 90 ibritumomab tiuxetan IV (for imaging) over 10 minutes on day 1. Patients undergo 1 (or 2 if needed) imaging scan between days 2-5. In the absence of altered biodistribution, patients receive rituximab IV followed within 4 hours by yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes on day 8.~Patients are followed monthly for 3 months, every 3 months for 2 years, and then every 6 months for 2 years."
88977574|NCT00224575|Experimental|1|Diagnosis strategy and subsequent therapeutic reassessment All patients are in that arms. They all receive the diagnosis reassessment strategy.
88977575|NCT00224848|Experimental|ATP III|A novel practice-based intervention, based on the ATP III Clinical Practice Guideline, which includes the use of a personal digital assistant (PDA) based decision support tool.
88977576|NCT00224848|Active Comparator|JNC 7|A novel practice-based intervention, based on the JNC-7 blood pressure Clinical Practice Guideline, which includes the use of am automated blood pressure measurement device.
88977577|NCT00062309|Active Comparator|CIMRT|76 Gy in 38 fractions
88977578|NCT00062309|Experimental|HIMRT|70.2 Gy in 26 fractions
88977579|NCT00413101|Experimental|1|
88977580|NCT00413257|Experimental|1|nefopam infusion will start before the surgical incision, at the induction time of anesthesia and will be continued until postoperative H48
88977581|NCT00413257|Experimental|2|nefopam administration will start at the end of the surgery and will be continued until postoperative H48
88977582|NCT00413257|Placebo Comparator|3|control group that will receive a placebo from the induction time of anesthesia until H48
88977583|NCT00095316|Placebo Comparator|Placebo|Subjects receive placebo intravenously daily for 28 days
88977584|NCT00095316|Experimental|Caspofungin|Subjects receive 50mg/day caspofungin intravenously (IV) for 28 days
89030951|NCT05140031|Experimental|PNE4Adults|Participants will undergo 2 sessions (1-2 weeks) where they will be introduced to the PNE4Adult board.
89592148|NCT05329415||Diabetic Group (Cases)|"Subject aged 18 years of age or over~Written, informed consent obtained.~New diagnosis of tuberculosis and starting on anti-tuberculosis treatment~Known diagnosis of diabetes or a raised IFCC HbA1c level (>= 48 mmol/mol) at the time of TB diagnosis"
89592149|NCT05329415||Non-Diabetic Group (Controls)|"Subject aged 18 years of age or over~Written, informed consent obtained.~New diagnosis of tuberculosis and starting on anti-tuberculosis treatment~IFCC HbA1c level < 48mmol/mol and no known diagnosis of diabetes"
89592150|NCT05308238|Experimental|Occupational therapy intervention group|Participants will receive 6 telehealth coaching sessions and 8 brief email or text check-ins over the course of 4 months. Participants will also receive a Fitbit and Engage PD Workbook.
89592151|NCT05308238|Active Comparator|Disease management education group|Participants will receive online educational videos that they can watch at their own convenience over the course of 4 months. There will be up to 6 hours of content, and the links to these online videos will be provided via email. Following completion of the study, individuals in this group will receive an Engage PD Workbook and one OT coaching session, if they choose to.
89592152|NCT05299671|Experimental|Video consultation group|Patients starting a new oral anti-cancer drug (OACD) will receive help to identify and manage potential drug-drug interactions alongside patient's oncologist through a one-time video consultation.
89030952|NCT02947737|Experimental|Amniotic membrane dressing|One donor site per study participant will be covered with an amniotic membrane dressing.
89030953|NCT02947737|Active Comparator|Gentamicin and xeroform dressing|One donor site per study participant will be covered with a gentamicin and xeroform dressing.
89592153|NCT05288972|Experimental|Mattress 1|Mattress 1 group will receive Polyurethane, Bonnel spring, medium-hard mattress
89592154|NCT05288972|Active Comparator|Mattress 2|Mattress 2 group will receive Polyurethane, pocket spring, medium mattress
89592155|NCT05281666|Active Comparator|Absorbable Surgical Gut Suture|Ethicon Chromic Surgical Gut Suture Is an absorbable, sterile surgical suture composed of purified connective tissue (mostly collagen) derived from either the serosal layer of beef (bovine) or the submucosal fibrous layer of sheep (ovine) Intestines. Surgical Gut Suture is Indicated for use In general soft tissue approximation and/or ligation, including use In ophthalmic procedures, but not for use in cardiovascular and neurologic tissues.
89592156|NCT05281666|Active Comparator|Non-absorbable Nylon Suture|Ethicon ETHILON* nylon suture is a nonabsorbab\e, sterile surgical monofi\ament suture composed of the long-chain aliphatic polymers Nylon 6 and Nylon 6,6. ETHILON sutures are dyed black or green to enhance visibility in tissue. The suture is also available undyed (clear). ETHILON suture is indicated for use in general soft tissue approximation and/or ligation, including use in cardiovascular, ophthalmic and neurological procedures.
89592157|NCT05276739|Experimental|Bright light|Participants will receive a 6.5-hour 10,000 lux light pulse (4100K fluorescent light) centered within the 16-hour wake episode (start 4.75 hour after wake and end 11.25 hour after wake). Participants will receive 4 identical meals (equal calories and macronutrient content), over a 12-hour interval (meals at 2, 6, 10, and 14 hours after waking) centered within the 16-hour wake episode.
89592158|NCT05276739|Experimental|Time-restricted eating|Participants will consume 4 identical meals, as in the other groups, except that the meal window will be restricted to 6.5 hours instead of 12 hours (meals at 4.75, 6.9, 9.1, 11.25 hours after waking) centered within the 16-hour wake episode. Participants will remain in dim light (<3 lux) throughout the 16-hour wake episode.
89592159|NCT05276739|Sham Comparator|Control|Participants will receive 4 identical meals (equal calories and macronutrient content), over a 12-hour interval (meals at 2, 6, 10, and 14 hours after waking) centered within the 16-hour wake episode. Participants will remain in dim light (<3 lux) throughout the 16-hour wake episode.
89592160|NCT05275803|Experimental|Probiotics|The participants would use probiotics for 30 days
89592161|NCT05275803|Experimental|Control|The participants would use not probiotics
89592162|NCT05274477|Experimental|Fampridin SR|"Active study medication consists of 7 tablets of fampridine SR 10 mg formulated for oral administration taken in the morning and evening 12 h apart without food. Tablets must be administered whole.~There will be a washout period of at least 8 days equaling over 30 half-lives of the active substance fampridine (t½ = 6 h) between experimental and control intervention and up to 26 days depending on the individual scheduling of each subject."
89592163|NCT05274477|Placebo Comparator|Placebo|Identically looking placebo tablets consisting of widely identical additives formulated for oral administration.
89592164|NCT05274282|Experimental|Animation Therapy Group|10 sessions of Animation Therapy (1 session/week)
89592165|NCT05274282|No Intervention|Control Group|No intervention
89592166|NCT05261503|Experimental|Homeostasis-Enrichment-Plasticity|HEP group will receive an environmental enrichment-based intervention.
89592167|NCT05261503|Experimental|Traditional Physical Therapy|TPT group will receive traditional physiotherapy intervention.
89592168|NCT05244070|Experimental|BMS-986403 + Fludarabine + Cyclophosphamide|
89592169|NCT05236777||Natalizumab Cohort|The cohort will include participants with MS who are newly treated with natalizumab (administered as a standard of care/routine clinical practice) from 1st January 2019 including those participants who terminate or discontinue the treatment during the observational period.
89592170|NCT05222607||Facial treatment with incobotulinumtoxinA in treatment naïve participants|
89592171|NCT05201833||Telephone Assessment Battery|TRACK-TBI participants may complete up to three annual telephone calls to assess outcome status. These assessments will determine eligibility for the in-person study visit.
89592172|NCT05201833||Comprehensive Assessment Battery (CAB)|Participants who demonstrate decision-making capacity will be asked to complete the Comprehensive Assessment Battery (CAB). The CAB in-person is comprised of measures of cognition (i.e. attention, memory, information processing speed, executive functions), mood (i.e., depression, anxiety), social participation, subjective well-being, post-traumatic stress, interviews, global functional status measures, and a COVID-19 questionnaire.
89592173|NCT05201833||Abbreviated Assessment Battery (AAB)|Participants who do not have decision-making capacity will be asked to complete a modified assessment battery, called the Abbreviated Assessment Battery (AAB). The AAB in-person assessment will administer the Speech Intelligibility, GOAT, and CAP and/or CRS-R to study participants.
89592174|NCT05191420||Virtual topical discussion guide|Study will pilot test this virtual topical discussion guide to assess feasibility and acceptability by diverse patient populations.
89592175|NCT05177354|Experimental|Treatment|
89030954|NCT05147012||control group|
89030955|NCT05147012||focus group|
89030956|NCT04693104|Experimental|PVA Hydrogel|PVA Hydrogel (Rottapharm Biotech, Monza): 2 mL prefilled syringe for intra-articular injection
89030957|NCT04693104|Active Comparator|Synvisc-One®|Synvisc-One® (Genzyme Corporation, Ridegield, New Jersey, USA): 6 mL prefilled syringe for intra-articular injection
89030958|NCT05146934||Hormone sensitive group|Prednisone, 0.5mg/kgqd, 3-6months
89030959|NCT05146934||Hormone insensitivity group|Prednisone, 0.5mg/kgqd, 3-6months
89030960|NCT05146895|Experimental|Local Hyperthermia at 44℃ for falt warts|Local hyperthermia at 44℃ for 30 mins on one lesion region, at days of 1,2,3, 15, 16, 21 and 28.
89030961|NCT05146895|Active Comparator|Imiquimod for Flat Warts|Miquimod treatment: 3 times a week for 1 month
89030962|NCT02947776|Active Comparator|USUAL|Usual care
89030963|NCT02947776|Experimental|PEER|Usual care + peer-befriending
89030964|NCT05143073|No Intervention|No educational materials|No educational materials will be provided.
89030965|NCT05143073|Active Comparator|Alcohol use disorder and strategies to reduce risk|The information provided to participants will be related to alcohol use disorder, including a definition, prevalence, consequences, risk factors, and risk-reducing strategies. The content is based on information from National Institute of Alcohol Abuse and Alcoholism websites, Mayo Clinic websites, and the National Survey on Drug Use and Health.
89030966|NCT05143073|Active Comparator|Complex polygenic risk scores, alcohol use disorder, and strategies to reduce risk|The information provided to participants will explain polygenic risk scores by discussing genetic variation, risk variants, how polygenic scores are created, and how they can be interpreted. The participants will also receive the same information related to alcohol use disorder, including a definition, prevalence, consequences, risk factors, and risk-reducing strategies.
89592176|NCT05156164|Experimental|Kinesio-taping Group|"Conventional rehabilitative treatment (consisting in two treatments per day of 40 minutes each) plus a bi-weekly treatment focused on the joint complex of the shoulder plus Kinesio-taping (KT) treatment.~The Kinesio-taping treatment consists in 4 applications of KT on the affected shoulder to be held for 5 days a week, followed by 2 days of rest to safeguard skin integrity before a further application.~5 KT strips with graded tensions will be placed on the following muscles:~supraspinatus with a tension of 70%.~infraspinatus with a tension of 70%. 3,4,5) deltoid (3 strips, 50% of tension) A sixth application with a tension of 90% originates at the level of the anterior face of the humeral head and it ends to the lower corner of the scapula."
89592177|NCT05156164|Sham Comparator|Control Group|"Conventional rehabilitative treatment (consisting in two treatments per day of 40 minutes each), plus a bi-weekly treatment focused on the joint complex of the shoulder, plus shame KT treatment.~- The CG will undergo a KT application on the deltoid but without support function with the same frequency and duration as the experimental group (shame-application)."
89030967|NCT02946372|Experimental|ILMT|internal limiting membrane autologous transplantation (ILMT)
89592178|NCT05155761|Experimental|Osteoporotic patients|
89592179|NCT05145426|Experimental|Pain Trials|Multi visit - LIFU/Sham application, with quantitative sensory testing (using peltier device).
89592180|NCT05129891|Experimental|Part A: Oral semaglutide|Four different formulations of oral semaglutide are investigated. One formulation given for 10 days before participants receive a different formulation for 5 days
89592181|NCT05129891|Experimental|Part B: NNC0385-0434|Four different formulations of NNC0385-0434 are investigated. One formulation given for 10 days before participants receive a different formulation for 5 days
89592182|NCT05120466|Active Comparator|Usual Health Education Curriculum|Students will receive the school's usual health education curriculum.
89592183|NCT05120466|Experimental|Usual Health Education Curriculum plus Intervention|Students will receive the school's usual health education curriculum. Students will also receive the intervention. Delivery of the intervention (i.e., timing, frequency) will be determined by discussing the results of the Aim 1 focus groups with teachers and administrators.
89592184|NCT05096117|Experimental|Active Medication|
89592185|NCT05096117|Placebo Comparator|Matching Placebo|
89592186|NCT05083130|No Intervention|standard care|Standard care will consist of routine clinical care, including any advice to lie in prone position as routinely recommended by participating sites
89592187|NCT05083130|Experimental|prone position|prone position group will have a special intervention team who visits patients' rooms aiming for patients to maintain the prone position for at least 8 hours a day
89592188|NCT05072093|Experimental|All men in cohort: MSM|Prospective cohort of MSM who are followed either in-person at the PRISM Health Research Clinic and/or virtually with remote study visits. Participants will have the option to switch prevention options at any point during the study by indicating their interest during monthly surveys or contacting study staff directly.
89592189|NCT05065840|Experimental|4 Pillars Program|Patients at study clinics who consent to have their HPV vaccination history verified with the Georgia Registry of Immunization Transactions and Services (GRITS).
89592190|NCT05065840|No Intervention|Adjacent time-period Control Group|The background HPV update rate among PLWH will be obtained by using the electronic medical record (EMR) and GRITS to identify HPV vaccination uptake 18 months prior to the intervention. These data are collected retrospectively and no study participants are prospectively assigned to this study arm.
89592191|NCT05057273|Experimental|BT-11 880 mg|Oral once daily tablet
89030968|NCT05146856||Control|Residents in control group have a usual day with clinical activity before night shift
89030969|NCT05146856||Intervention|Residents in intervention group have a day off clinic before night shift (i.e day off or day with university activity)
89030970|NCT02946567|Experimental|Noisy City|Participant will play the Noisy City game developed by this project.
89592192|NCT05057273|Active Comparator|Standard of care|Biologic
89592193|NCT05049733|Experimental|Arm 1|Participants will start with ingestion of soft gel tablets high in CBD and CBD-A, but low in THC and THC-A. The total amount of cannabinoids ingested will be 1 mg/kg and then switch to other doses after washout periods.
89592194|NCT05049733|Experimental|Arm 2|Participants will start with ingestion of soft gel tablets high in CBD and CBD-A, but low in THC and THC-A. The total amount of cannabinoids ingested will be 2 mg/kg and then switch to other doses after washout periods.
89030971|NCT02946567|Placebo Comparator|Control|Participant will play a generic game.
89030972|NCT00524784|Experimental|A|Three subjects per cohort will be treated with ApoCell according to an escalating schedule of doses
89030973|NCT00524823||1|10 diagnosed men in age 60 - 90 with Prostate Cancer
89030974|NCT00524823||2|10 patients with benign growth
89030975|NCT00524823||3|10 health volunteers
89030976|NCT00524823||4|10 patients diagnosed with other cancer
89030977|NCT00524862|Other|1|
89030978|NCT00524862|Other|2|
89030979|NCT05146817|Active Comparator|Traditional oral care in long-term mechanical ventilation ICU patients|Control group - traditional protocol of oral care ( traditional tooth brushing 1 time a day + chlorhexidine rinsing
89030980|NCT05146817|Experimental|Original oral care protocol in long-term mechanical ventilation ICU patients|Treatment group - original protocol of oral care: special device for tooth brushing 3 times a day with chlorhexidine .
89030981|NCT02946450||Not applicable-observational study|Not applicable-observational study
89030982|NCT05149703|Experimental|Mezieres Group|This intervention includes a total of three postures of the Mézières therapy. Specifically, the postures maintained for 12 weeks consist of: supine dancer; in supine position with the upper extremities abducted 120 °; and dancer in a sitting position.
89592195|NCT05049733|Experimental|Arm 3|Participants will start with ingestion of soft gel tablets high in CBD and CBD-A, but low in THC and THC-A. The total amount of cannabinoids ingested will be 4 mg/kg and then switch to other doses after washout periods.
89592196|NCT05049733|Placebo Comparator|Arm 4|Participants will begin with ingestion of placebo soft gel tablets that do not contain cannabinoids and then switch to other doses after washout periods.
89592197|NCT05047718|Experimental|convalescent participants PFIZER|Participants with prior history of COVID-19 in ≥3 months, virologically confirmed and vaccinated by anti-covid19 Pfizer vaccine
89592198|NCT05047718|Experimental|Naive participants PFIZER|Participant without past history of COVID-19 and vaccinated by anti-covid19 Pfizer vaccine
89592199|NCT05047718|Experimental|convalescent participants MODERNA|Participants with prior history of COVID-19 in ≥3 months, virologically confirmed and vaccinated by anti-covid19 Moderna vaccine
89592200|NCT05047718|Experimental|Naive participants MODERNA|Participant without past history of COVID-19 and vaccinated by anti-covid19 Moderna vaccine
89592201|NCT05027633|Other|pembrolizumab, docetaxel, and cisplatin or carboplatin|IV
89592202|NCT04993183|Experimental|3-day PLUS Convention|Participants will participate in a 3-day PLUS Convention, comprising an inclusivity education workshop, service-learning seminar, disability simulation workshop, and two community contact sessions.
89592203|NCT04983108||ACLF|ACLF
89592204|NCT04975893|Other|Primary Extension Phase|CMV-seropositive and CMV-seronegative participants who completed Study mRNA-1647-P202 will be followed every 6 months for 3 years in this study after the final visit in Study mRNA-1647-P202.
89592205|NCT04975893|Experimental|Optional Booster Phase - BD Recipients|Participants who opted to enroll into the optional Booster Dose phase will receive a single mRNA-1647 vaccine dose.
89592206|NCT04975893|Other|Optional Booster Phase - Observational Group|Participants who opted to enroll into the Observational Group will be followed in the optional BP until BP Month 12.
89592207|NCT04954820|Experimental|Experimental arm|2 additional infusions of Lutathera® according to the marketing authorization schema
89592208|NCT04954820|No Intervention|Control arm|No treatment with active monitoring (clinical, biological and radiological follow-up) every 2 months.
89592209|NCT04936529|Experimental|Group 1|Group 1 participants receive oral β-glucan (40 mg/kg/day x 14 days) starting week 1. This schedule includes annual booster vaccinations, with β-glucan, administered at weeks 8, 20, 32, 52, 78, 104, and 156 (vaccinations #1 & #4-10). Participants will not receive GM-CSF.
89592210|NCT04936529|Experimental|Group 2|Group 2 participants receive oral β-glucan (40 mg/kg/day) starting week 1. Participants also receive GM-CSF (250 mcg/m2/day) x3 days with vaccinations #1-#3; x7 days with vaccinations #4-#9; and x5 days with vaccination #10. The treatment includes annual booster vaccinations, with a 2-week cycle of β-glucan, administered at weeks 8, 20, 32, 52, 78, 104, and 156 (vaccinations #1 & #4-10)
89592211|NCT04936529|Experimental|Group 3|Group 3 will include participants who cannot be randomized (e.g., due to allergy to GMCSF). It will also include participants previously treated with this vaccine and oral β-glucan on the predecessor MSK protocol IRB# 05-075 or on this protocol (participants can therefore be enrolled more than one time on this protocol). These participants will be treated as in Group 1. Participants who are registered to Group 3 and have been previously treated with vaccine (in this protocol or MSK predecessor 05-075) will not receive vaccines 4 and 6. These patients will receive a total of 8 injections. The analyses in this group will be exploratory.
89592212|NCT04920253|Experimental|debritom+|Group 1: Medaxis debritom+
89592213|NCT04920253|Active Comparator|Sharp Scalpel|Group 2: SOC (Sharp Scalpel Debridement)
89592214|NCT04907643|Experimental|Virtual Reality Program A|This arm will include software that provides immersive skills-based content for pain reduction.
89592215|NCT04907643|Experimental|Virtual Reality Program B|This arm will include software that provides immersive distraction based content for pain reduction.
89592216|NCT04907643|Sham Comparator|Virtual Reality Program C|This arm will include software that provides nonimmersive distraction based content for pain reduction.
89592217|NCT04898621|Experimental|Group A|Subjects in Group A will drink 75g fructose solution daily for 4 weeks.
89592218|NCT04898621|Experimental|Group B|Subjects in Group B will drink 150g fructose solution daily for 4 weeks.
89592219|NCT04851613|Experimental|Afuresertib and Fulvestrant Safety Run In|Safety run-in Cycle 1 (a cycle is 28 days) will be performed in the first 6 patients of the phase Ib. Combination regimens during the safety run-in period are: afuresertib 125 mg QD (once daily) or 125 mg Day1-21 Q4W + fulvestrant 500 mg or 250 mg Intra Muscular (IM) on Day 1, 15 of Cycle 1, and on Day 1 of the subsequent 28-day cycles.
89592220|NCT04851613|Experimental|Afuresertib and Fulvestrant|Combination regimens are: afuresertib 125 mg QD (once daily) or 125 mg Day1-21 Q4W + fulvestrant 500 mg or 250 mg Intra Muscular (IM) on Day 1, 15 of Cycle 1, and on Day 1 of the subsequent 28-day cycles.
89030983|NCT05149703|Active Comparator|Isostretching Group|This study aims to follow a total of 6 isostretching postures, the most similar to the Mezieres method. In each of the isostretching positions, if it is symmetric, 3, 6 or 9 repetitions will be performed and if it is asymmetric, 2, 4, or 8 repetitions.
89030984|NCT00524901|Experimental|1|25 patients undergoing CABG for three vessel disease, receiving a single dose of erythropoietin periprocedural.
89592221|NCT04835168|Experimental|BT-11 low|Oral
89030985|NCT00524901|Placebo Comparator|2|25 patients undergoing CABG for three vessel disease, receiving placebo (NaCl 0.9%) periprocedural.
89592222|NCT04835168|Experimental|BT-11 high|Oral
89592223|NCT04835168|Placebo Comparator|Placebo|Oral
89592224|NCT04801420|Experimental|Part A+B - Group 1|Part A: VLA15 at Month 0, 2 and 6 Part B: VLA15
89592225|NCT04801420|Experimental|Part A+B - Group 2|Part A: VLA15 at Month 0 and 6, placebo at Month 2 Part B: VLA15
89592226|NCT04801420|Placebo Comparator|Part A+B - Group 3|Part A: Placebo at Month 0, 2 and 6 Part B: Placebo
89592227|NCT04783272|Experimental|Treatment|Photoacoustic Computed Tomography (PACT) Imaging
89592228|NCT04746794|Experimental|Point of Care|In the point of care (POC) arm, patients will be approached at the time they come in to the clinic for a routine visit with their primary care provider. We will screen patients for familial cancer risk using electronic tablets in the waiting room or, in the case of a telehealth visit, through telephone contact before the visit. Patients identified as high risk will be offered genetic testing for a panel of hereditary cancers.
89592229|NCT04746794|Experimental|Direct Patient Engagement|"In the direct patient engagement (DPE) arm, patients will be identified by reviewing clinic records to create an active patient list (i.e., those who have had a visit in the past year). We will contact patients by postal mail and email to provide a link to the online risk screening tool. The patient outreach is not tied to a specific visit and the online screening can be completed at any time. Patients identified as high risk will be offered genetic testing for a panel of hereditary cancers."
89592230|NCT04746794|No Intervention|Stakeholder Interviews and Surveys|Samples of patients, providers, and clinic leaders will be assessed at several points throughout the study - baseline and multiple follow-ups. We will use a mixed methods approach, with both quantitative assessments (surveys) and qualitative assessments (interviews). Baseline assessments will provide initial data on the patient population and current clinic functioning and help in implementation planning. The midpoint and final assessments will provide estimates of change in patients, providers, and clinic leaders as a result of the implementation.
89592231|NCT04726462|Experimental|Functional exercise group|
89592232|NCT04726462|Experimental|Posture exercises group|
89592233|NCT04723264|Experimental|Eating behavior activities|
89592234|NCT04706676|Experimental|Integrative neuromuscular training + motivational counseling + usual care|General and specific strength and conditioning elements such as strength, power, motor skill training, dynamic stability, core-focused strength, plyometric and agility.
89592235|NCT04706676|Active Comparator|Active control group + motivational counseling + usual care|home-based training program
89592236|NCT04699968|Experimental|Treatment group A|
89592237|NCT04699968|Experimental|Treatment group B|
89592238|NCT04629521|Experimental|CyPass Micro-Stent|CyPass Micro-Stent placed in the angle of the eye at the conclusion of cataract surgery (COMPASS trial)
89592239|NCT04628026|Experimental|1|standard chemotherapy in combination with venetoclax
89592240|NCT04628026|Placebo Comparator|2|standard chemotherapy in combination with placebo
89592241|NCT04605861|Experimental|Liraglutide|Liraglutide Injection, once a day, injected subcutaneously on abdomen, thigh or upper arm.
89592242|NCT04605861|Placebo Comparator|Placebo|Placebo (Liraglutide Injection simulator), once a day, injected subcutaneously on abdomen, thigh or upper arm.
89592243|NCT04575220|Experimental|tele-exercise|Subjects will perform three sessions/week of home exercise using bicycles for 12 weeks
89592244|NCT04569266|Other|No specific exercise rehabilitation treatment|"After randomization, patients will not benefit from any specific exercise rehabilitation treatment until 6 months post-ICU. They will then be proposed to follow the treatment protocol if efficacy is demonstrated, once their follow-up in the study is completed."
89592245|NCT04569266|Experimental|specific exercise rehabilitation treatment|"Patients will receive a prescription for exercise rehabilitation, at the rate of 2 sessions of approximately 1 hour each per week for 10 weeks.~Continuous endurance training will start at 60-70% of the patient's maximum power. For patients who are unable to maintain continuous re-training, interval training sequences (30 seconds of effort followed by 30 seconds of rest) may be offered.~Initially, the effort will be 15 minutes, then gradually increase to reach an exercise duration of 40 minutes or 45-60 minutes for endurance or interval training respectively.~The power can be adjusted as the patient progresses to reach the target heart rate and dyspnea at 4-6 on the BORG scale.~All patients will be offered lower limb and upper limb strengthening exercises. Each exercise will consist of 3-4 sets of 6-12 repetitions."
88977585|NCT00062387|Experimental|Arm I|Patients receive oral perifosine 4 times daily on days 1 and 2 and once daily on days 3-28 during course 1. Patients receive oral perifosine once daily on days 1-28 for all subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88977586|NCT00225121|Experimental|1|open label single arm trial
88977587|NCT00225199|Experimental|Arm 1|
88977588|NCT00225199|Placebo Comparator|Arm 2|
88977589|NCT00225433|Active Comparator|1|Follitropin beta
88977590|NCT00225433|Active Comparator|2|Ganirelix acetate
88977591|NCT02967926|Experimental|ERCP without Fluoroscopy|Non-fluoroscopic common bile duct stone extraction
88977592|NCT02962258|Experimental|Test|Torrent's Olmesrtan Medoxomil, Amlodipine and Hydrochlorothiazide Tablets 40+10+25 mg
88977593|NCT02962258|Active Comparator|Reference|Tribenzor of Daichi Sankyo Inc., USA
88977594|NCT02967809||final diagnosis after portable echography|Experimental group: final diagnosis after portable cardiac echograph examination
88977595|NCT02967809||final diagnosis without portable echography|Group control: Final diagnosis for patient ( same medical condition and history) hospitalized in units without portable cardiac echograph examination avaible
88977596|NCT02967887|Experimental|cisplatin and 5-fluorouracil|Enrolled patients with pre-treatment tumor biopsy will receive Cisplatin (60mg/m2 for 2h on day 2) and 5-fluorouracil (500mg/m2 for 5h on days 1-3) through implanted port system. This treatment will be repeated every 4 weeks, up to 6 times.
88977597|NCT00225745||1|Pancreatic cancer patients
88977598|NCT00225745||2|Healthy controls
88977599|NCT00095667|Experimental|Treatment (lapatinib ditosylate)|Patients receive oral lapatinib once daily on days 1-28. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression.
88977600|NCT00062504|Experimental|1|Valproic: 10mg TID week 1, 25mg TID week 2, 35mg week 3
88977601|NCT00062504|Experimental|2|Non-enzyme-inducing anti-epileptic drugs: 25mg TID week 1, 35mg week 2, 50mg week 3
88977602|NCT00062504|Experimental|3|Enzyme-inducing anti-epileptic drugs: 35mg TID week 1, 505mg week 2, 75mg week 3
88977603|NCT00225979|Experimental|SMS995|
88977604|NCT00226018|Active Comparator|1|Acceleromyography with Hand Adapter on dominant arm
88977605|NCT00226018|Active Comparator|2|Acceleromyography with Hand Adapter on non-dominant arm
89592246|NCT04564443|Experimental|(Medaxis Debritom+™) micro fluid jet wound therapy|Medaxis Debritom+™ is a high-quality, micro fluid jet therapy device designed to remove fibrin, necrotic tissue, and biofilm from wound surfaces by mechanical cleaning and stimulation of the diabetic foot wound
89592247|NCT04564443|Active Comparator|Sharp Surgical Debridement|Use of a surgical scalpel or curette to remove fibrin, necrotic tissue and biofilm from wound surfaces by mechanically cleaning the wound
89592248|NCT04560140|Experimental|Intervention group|Eligible participants will be randomly assigned to receive usual care with the novel 24-week Narrative and Skills-building Intervention.
89592249|NCT04560140|No Intervention|Usual care group|Participants will receive usual stroke care.
89592250|NCT04553822|Experimental|Assisted autogenous drainage group (DAA)|The technique consists of positioning the patient in a supine position with the head slightly elevated on the supporting plane and then placing both hands around the rib cage and applying bimanual expiratory compression on both hemithoraxes.
89592251|NCT04553822|Experimental|Group prolonged slow expiration (ELPr)|This technique is applied to the baby by means of a slow thoracic-abdominal pressure that begins at the end of a spontaneous expiration and continues until the residual volume.
89592252|NCT04553822|Active Comparator|Control group (CG)|Nebulization with 4 ml Muconeb® 3% hypertonic serum, for 8 minutes in a Philips® vibrating mesh nebulizer.
89592253|NCT04549532|Experimental|T-MD Intervention Group|Participants will be prescribed 1+ interventions tailored to affected domains.Anxiety/Mood-Cog beh therapy(CBT) for maladaptive beliefs/avoidance/coping behaviors. Graded exposure/activity/relaxation exercises, cognitive restructuring. Cognitive-Accommodations for reduced work/school time/delayed deadlines, more frequent/longer cognitive rest during symptom-provoking activities. Migraine/Headache: Education, relaxation training/mindfulness based therapy. Ocular-Exercises for ocular symptoms, near point convergence, may include Brock string, pencil push-ups, fixation, saccade tracking, pursuits. Sleep-Sleep regulation/hygiene. Mindfulness-based training, morning physical activity, CBT.Vestibular-Exercises for dizziness, visual motion sensitivity, gait, imbalance that may include gaze stability, visual habituation, static and dynamic balance/gait.Autonomic-Graded aerobic exercise. Perform daily aerobic exercise, goal 80% HR max on a stationary bike/treadmill/walking/jogging.
89592254|NCT04549532|Active Comparator|Behavioral Management|Participants in control group will receive standardized behavioral management strategies including: activity, hydration, nutrition, sleep, and stress management strategies. These strategies provide general methods to manage concussion symptoms and regulate daily activities to assist in the recovery of concussion. Clinicians will discuss and review a behavioral strategies handout with each participant and answer any questions they may have about the information in the handout. Contact time between clinicians and patients will be similar to avoid effects associated with more or less contact time.
89592255|NCT04528511||Low burden of new-onset atrial fibrillation|Patients with MI who are free from a medical history of atrial fibrillation (AF) will be recognized as NOAF if they develop an atrial fibrillation (lasting for at least 30 seconds which are recorded by CEM) incident during hospitalization. Among this subset of patients, those who have a NOAF burden value<10.87% (previously established) will be divided into the low burden group.
89592256|NCT04528511||High burden of new-onset atrial fibrillation|For patients with NOAF complicating AMI, those who have a NOAF burden value≥10.87% (previously established) will be divided into the high burden group.
89592257|NCT04506606|Experimental|Afferent effect on hemodynamics|Evaluate impact of group III/IV muscle afferents on femoral blood flow
89592258|NCT04506606|Experimental|Afferent effect on fatigue|Evaluate impact of group III/IV muscle afferents on exercise-induced changes in quadriceps twitch force
88977606|NCT00226018|Placebo Comparator|3|Acceleromyography without Hand Adapter on dominant arm
88977607|NCT00226018|Placebo Comparator|4|Acceleromygraphy without Hand Adapter on non-dominant arm
88977608|NCT02967731|Experimental|480 Mometasone Furoate Sinus Drug Depot|480 Mometasone Furoate Sinus Drug Depot
88977609|NCT00095745|No Intervention|Antidepressant + Aripiprazole|
88977610|NCT00226057|Experimental|Raptiva Open Label|Raptiva administered by weekly subcutaneous injections. First dose of 0.7mg/kg. Subsequent doses will be of 1mg/kg SQ weekly.
88977611|NCT00062543|Experimental|Hepatic Artery Infusion|Donor-derived CD34+ cells administered in a total volume of 100ml via hepatic artery over 10 minutes. Cells given as a dose escalation study. First cohort of 3 patients receive 1 * 106 CD34+ cells/kg. Next 3 patients receive 2.5 * 106 CD34+cells/kg. Next 3 patients receive 5 * 106 CD34+ cells/kg. Less than 1 * 105 T cells/kg administered.
88977612|NCT00226252|Experimental|Instruction Only (IO)|IO participants will train on the dynamometer for the same length of time as the Feedback Group. They will only be instructed to follow what they learned from the video presented at the beginning of the training session.
88977613|NCT00226252|Experimental|Instruction and Feedback Group (FB)|The FB group will receive video training, and real time feedback from the SMART Wheel as they push their wheelchair. A monitor displaying a random combination and amount of biomechanical feedback variables will be placed in front of subjects. Subjects will be instructed to adjust their stroke to optimize their biomechanics with feedback from the screen.
88977614|NCT00226252|No Intervention|Control Group|Wheelchair characteristics will be noted; however, no wheelchair manipulation or changes in equipment will be performed or recommended.
88977615|NCT00400374|Experimental|Erlotinib, Celecoxib|
88977616|NCT00226291|Experimental|Synthesized evidence report|Each consultation response included a documented bibliographic search strategy with corresponding references, a targeted list of full-text articles, and a written synthesis and critique of the relevant research materials.
88977617|NCT00226291|No Intervention|No evidence report|
88977618|NCT00413296|Placebo Comparator|1|Tablets, no active ingredient, 1-6 tablets/day for 12 wks in the 2 nd phase of the trial.
88977619|NCT00413296|Active Comparator|2|Levetiracetam, 500mg (1-6 tablets /day) for 12 wks in the 2nd phase of the study.
88977620|NCT02965482|Active Comparator|Aerogen Solo|Volumetric method of methacholine challenge testing performed using the Aerogen Solo nebulizer
88977621|NCT02965482|Active Comparator|Wright|Two-minute tidal breathing method of methacholine challenge testing performed using the Wright nebulizer
88977622|NCT00413452|Experimental|50 mg|50 mg once weekly
88977623|NCT00413491|Experimental|1|Comparison of MR and mammography
89592259|NCT04506606|Experimental|Effect of cardiac rehab|Evaluate effect of chronic exercise on influence of muscle afferents on limb blood flow
89592260|NCT04469764|Experimental|Treatment (abemaciclib)|Patients receive abemaciclib PO BID on days 1-28. Patients with tumors that are hormone receptor positive also receive and anastrozole or letrozole per standard of care. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89592261|NCT04457895|Experimental|Experimental arm|"For experimental arm patients, there will be a 90-min yoga-therapeutic education session/week (during 6 weeks) given by a physical therapist trained to postural yoga (the first on site and by videoconference for the others).~Starting the first day of the yoga practice there will be one daily 15 min session at home with My Yoga Guide and the audio guide during 12 weeks."
89592262|NCT04457895|Placebo Comparator|control arm|The control arm patients will have standard care. They will be proposed to participate in the physical therapy - yoga - educational program after the end of the study.
89592263|NCT04457310|Experimental|CVL-562 (PF-06412562) 1 mg|Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Subjects will be randomized to the order of doses of CVL-562 (PF-06412562) (1 mg, 4 mg, 15 mg, or 25 mg) or placebo for the next 5 visits. The randomization will assign 75% of patients to the highest dose on the last visit and 25% would receive the highest dose on one of the other four visits. Only the highest dose (25 mg) will be subject to this pseudo-randomization strategy; all other doses will be randomly distributed.
89592264|NCT04457310|Experimental|CVL-562 (PF-06412562) 4 mg|Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Subjects will be randomized to the order of doses of CVL-562 (PF-06412562) (1 mg, 4 mg, 15 mg, or 25 mg) or placebo for the next 5 visits. The randomization will assign 75% of patients to the highest dose on the last visit and 25% would receive the highest dose on one of the other four visits. Only the highest dose (25 mg) will be subject to this pseudo-randomization strategy; all other doses will be randomly distributed.
89592265|NCT04457310|Experimental|CVL-562 (PF-06412562) 15 mg|Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Subjects will be randomized to the order of doses of CVL-562 (PF-06412562) (1 mg, 4 mg, 15 mg, or 25 mg) or placebo for the next 5 visits. The randomization will assign 75% of patients to the highest dose on the last visit and 25% would receive the highest dose on one of the other four visits. Only the highest dose (25 mg) will be subject to this pseudo-randomization strategy; all other doses will be randomly distributed.
89592266|NCT04457310|Experimental|CVL-562 (PF-06412562) 25 mg|Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Subjects will be randomized to the order of doses of CVL-562 (PF-06412562) (1 mg, 4 mg, 15 mg, or 25 mg) or placebo for the next 5 visits. The randomization will assign 75% of patients to the highest dose on the last visit and 25% would receive the highest dose on one of the other four visits. Only the highest dose (25 mg) will be subject to this pseudo-randomization strategy; all other doses will be randomly distributed.
89592267|NCT04457310|Placebo Comparator|Placebo|Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Subjects will be randomized to the order of doses of CVL-562 (PF-06412562) (1 mg, 4 mg, 15 mg, or 25 mg) or placebo for the next 5 visits. The randomization will assign 75% of patients to the highest dose on the last visit and 25% would receive the highest dose on one of the other four visits. Only the highest dose (25 mg) will be subject to this pseudo-randomization strategy; all other doses will be randomly distributed.
89592268|NCT04429984||VPRIV: All Participants|Participants with type 1 Gaucher disease who as part of standard or routine clinical practice, have already received VPRIV retrospectively and will further receive VPRIV therapy according to the investigator's judgment for approximately 12 months will be observed prospectively in this PMS study.
89592269|NCT04416737|Experimental|Upper Peritoneal, then Lower Peritoneal, then Subcutaneous|Ultra-fast acting insulin will be injected into the upper peritoneum then lower peritoneum then subcutaneous space.
88977624|NCT00226486|Experimental|1|Identification of individual risk factors for falls and specified intervention aimed diminishing these risk factors in the individual.
88977625|NCT00226486|Placebo Comparator|2|Usual care
88977626|NCT00095823|Placebo Comparator|A1|
88977627|NCT00095823|Active Comparator|A2|
88977628|NCT00095823|No Intervention|A3|
88977629|NCT02962453|Experimental|Morning walk|Rehabilitation using end-effector type gait robot for 5days.
88977630|NCT02962453|Active Comparator|Ground Walker|Rehabilitation using walker for 5days.
88977631|NCT02965521|Experimental|Intervention|Participants will be given print material on diet for cancer survivors and access to a web-based dietary intervention with text messaging for 12 weeks.
88977632|NCT02965521|No Intervention|Control|Participants randomized to the control arm will receive print materials on diet for cancer survivors. After completion of their 12-week follow-up assessments, control participants will be given access to the web-based dietary intervention with text messaging for 12 weeks.
88977633|NCT00226681|Experimental|1|
88977634|NCT00226681|Active Comparator|2|
88977635|NCT00226720|Experimental|1|at the hospital
88977636|NCT00226720|Active Comparator|2|out of the hospital
88977637|NCT00226837|Placebo Comparator|1|0% nitrous oxide
88977638|NCT00226837|Active Comparator|2|33% nitrous oxide
88977639|NCT00226837|Active Comparator|3|66% nitrous oxide
88977640|NCT00226915|Active Comparator|1|Drug: Paclitaxel 180mg/m2＋CBDCA AUC6 q21 days x 6-9cycles
88977641|NCT00226915|Experimental|2|Drug: Paclitaxel 80mg/m2 weekly ＋CBDCA AUC6 q21 days x 6-9cycles
88977642|NCT02967497|No Intervention|Blank|No intervention, just observation.
88977643|NCT02967497|Experimental|YQ1 group|Cisplatin-based chemotherapy + YQ1
88977644|NCT00226954|Experimental|Zoledronic Acid with Intermittent Hormonal Therapy|
88977645|NCT00227032|Experimental|Subjects receiving EIAEDs|Patients will be stratified according to concurrent use of enzyme inducing anti-epileptic drugs (EIAED)
88977646|NCT00227032|Experimental|Subjects NOT taking EIAEDs|Patients will be stratified according to concurrent use of enzyme inducing anti-epileptic drugs (EIAED)
89030986|NCT02954588|Active Comparator|Pyridoxamine (1)|Subjects will be asked to consume dietary supplements containing pyridoxamine (dosage 1), three times daily during 8 weeks.
89030987|NCT02954588|Active Comparator|Pyridoxamine (2)|Subjects will be asked to consume dietary supplements containing pyridoxamine (dosage 2), three times daily during 8 weeks
89030988|NCT02954588|Placebo Comparator|Placebo|Subjects will be asked to consume dietary supplements containing placebo (amylum solani), three times daily during 8 weeks
89030989|NCT04692792|Placebo Comparator|Placebo drink|
89030990|NCT04692792|Experimental|Dai Dai flower drink|
89592270|NCT04416737|Experimental|Lower Peritoneal, then Upper Peritoneal, then Subcutaneous|Ultra-fast acting insulin will be injected into the lower peritoneum then upper peritoneum then subcutaneous space.
89592271|NCT04414202||1 GROUP|"Patient with an Invasive breast cancer with a good prognosis that is accessible to breast-conserving surgery.~The treatment combines extended tumorectomy with axillary dissection (sentinel lymph node) in addition to 20 Gy of per-operative partial irradiation at the tumor Follow up after this treatment will scheduled 10 years"
89592272|NCT04381468|Experimental|pepinemab 40mg/kg|The study drug, pepinemab, will be administered via monthly intravenous infusions.
89592273|NCT04381468|Placebo Comparator|Placebo|.A placebo control will be administered via monthly intravenous infusions.
89592274|NCT04376333|Active Comparator|STD+CBT|Standard conservative dental orofacial pain care + cognitive-behavioral coping skills treatment
89592275|NCT04376333|Experimental|STD+IATP|Standard conservative dental orofacial pain care + Individualized Assessment and Treatment Program; a highly individualized coping skills training procedure.
89592276|NCT04364607|Active Comparator|Neostigmine group|After cesarean delivery, women will receive 0.5 mg IM neostigmine
89592277|NCT04364607|Placebo Comparator|Placebo group|After cesarean delivery, women will receive IM NaCl 0.9% as a placebo
89592278|NCT04348383|Experimental|Defibrotide + standard therapy|Defibrotide + standard therapy
89592279|NCT04348383|Placebo Comparator|Placebo|Placebo + standard therapy
89592280|NCT04332926|Active Comparator|Own Brand Cigarette|
89592281|NCT04332926|Experimental|ECIG 30 Watts, 0 mg/ml nicotine|
89592282|NCT04332926|Experimental|ECIG 30 Watts, 8 mg/ml nicotine|
89592283|NCT04332926|Experimental|ECIG 30 Watts, 15 mg/ml nicotine|
89592284|NCT04332926|Experimental|ECIG 30 Watts, 30 mg/ml nicotine|
89592285|NCT04316286|Experimental|Tele-multidisciplinary participants|Patients undergoing televisit
89592286|NCT04316286|Other|In-office standard participants|Patients undergoing in-office visits
89592287|NCT04294472|Experimental|Cohort 1|Cohort 1: MAU868 1350 mg IV approximately every 28 days for a total of 4 doses
89592288|NCT04294472|Experimental|Cohort 2|Cohort 2: MAU868 6750 mg IV on Study Day 1 and then 1350 mg IV approximately every 28 days for a total of 4 doses
89592289|NCT04294472|Experimental|Cohort 3|Cohort 3: MAU868 6750 mg IV approximately every 28 days for a total of 4 doses
89592290|NCT04294472|Placebo Comparator|Placebo Cohort 1, 2, 3|5% dextrose in water [D5W] IV delivered every 28 days for a total of 4 doses
89592291|NCT04285476|Experimental|Signature of microRNA|Signature of miRNA in patients with Thyroid Cytologies of undetermined type and with a Bethesda classification 3, 4 or 5
89592292|NCT04283409|Experimental|Motor Control Exercise|The primary goal of motor control exercises is to retrain optimal control and coordination of the spine. It uses principles of motor learning such as segmentation, simplification and task-specific practice to retrain control of trunk muscles activation, alignment and movement. The first stage of the treatment involves assessment of the postures, movement patterns and muscle activation associated with symptoms and a retraining program designed to improve activity of muscles assessed to have poor control (usually the deep trunk muscles). Participants are taught how to contract these muscles independently. During this stage additional exercises for breathing control, posture of spine and movement are performed. The second stage of the treatment involves the progression of the exercises towards functional activities, firstly using static then dynamic tasks. Education is also included.
89608468|NCT04386694|Placebo Comparator|Placebo PBMT/sMF|"Placebo PBMT/sMF will be applied once a day, during the ICU stay, until discharge or death. The patients will receive standard physical therapy care associated with placebo PBMT/sMF.~The placebo PBMT will be applied using MR5™ ACTIV PRO LaserShower Laser Therapy System, manufactured by Multi Radiance Medical (Solon, OH, USA). The ACTIV PRO emits 905nm, and 850nm via an electric diode energy source with outputs to 0%. The static magnetic field will be also turned off. The 660nm light via an electric diode energy source with outputs to >1% to appear like the active comparator."
89030991|NCT02954549|Active Comparator|Healthy control group|Subjects in this arm have a normal serum level of 25(OH)D, >30 ng/mL. Subjects submit to blood draws and biometric tests (DXA, body composition, BP) and questionnaires on 3 occasions. They do not receive vitamin D3 supplementation.
89030992|NCT02954549|Experimental|Low dose supplementation group|Subjects in this group have been identified as having a level of 25(OH)D of < 30 ng/mL and are randomized to receive vitamin D3 supplementation of 2000 IU daily for 3 months.
89030993|NCT02954549|Experimental|High dose supplementation group|Subjects in this group have been identified as having a level of 25(OH)D of <30 ng/mL and are randomized to receive vitamin D3 supplementation of 5000 IU daily for 3 months.
89030994|NCT02946411||Patients|The glucose of 48 patients will be measured during 5 days after cardiac surgery.
89030995|NCT05148104||Patients receiving shoulder arthroplasty|Patients receiving shoulder arthroplasty that have an intact glenoid prior to the procedure. Ideally the glenoid surface should be visible and intact during imaging.
89030996|NCT00524979||Schizophrenia|People who are diagnosed as schizophrenic by DSM-IV
89030997|NCT00524979||Mental diseases|Patients who are deagnosed as having mental disease other then schizophrenia
89030998|NCT00524979||Mentally healthy|People who have no mental disease
89030999|NCT05145608|Active Comparator|Test- Lamotrigine ER Tablets USP 50mg|Single dose of Test- Lamotrigine ER Tablets USP 50mg will be administered
89031000|NCT05145608|Active Comparator|Reference- Lamictal® XRTM ER tablet 50mg|Single dose of Reference- Lamictal® XRTM (Lamotrigine) ER tablet 50mg will be administered
89031001|NCT05143034|Experimental|TCI66207 Essence|Essence
89031002|NCT05143034|Placebo Comparator|Placebo Essence|
89592293|NCT04283409|Experimental|Graded Activity|The primary goal of graded activity is to address individual modifiable contextual factors associated with the pain experience such as self-efficacy, pain-related fear, kinesiophobia and unhelpful beliefs/behaviors about back pain while at the same time addressing physical impairments such as endurance, muscle strength and balance. A primary goal of the program is to increase activity tolerance by performing individualized and submaximal exercises in addition to ignoring illness behaviors and reinforcing well behaviors. Activities in the program are progressed in a time-contingent manner from the baseline assessed ability to a target goal set jointly by patient and therapist. Cognitive-behavioral principles are used to help patients overcome the natural anxiety associated with pain and activities.
89592294|NCT04261361|Experimental|CBCBT intervention|"Adherence counseling~Psycho-education package~The intervention program consists of three components: 1) eight weekly sessions of face-to-face interventions, 2) four weekly consolidation individual telephone calls and 3) three monthly individual follow-up phone calls."
89592295|NCT04261361|Active Comparator|enhanced treatment as usual (ETAU)|"Adherence counseling;~Psycho-education package;~To maintain some control over the contact time, we will give them 4 bi-weekly individual phone calls of about 10 minutes each while the CBCBT intervention group is having their 8 weeks of face-to-face group sessions."
89592296|NCT04233918|Experimental|Evinacumab|Part A: Single intravenous (IV) dose Part B: IV dose every 4 weeks (Q4W) until week 20 Part C: IV dose Q4W
89592297|NCT04230564||AML|Patients diagnosed with AML
89592298|NCT04230421|Experimental|Monsenso with feedback|Daily smartphone-based monitoring and treatment using the Monsenso system with a clinical feedback loop feedback.
89592299|NCT04230421|Active Comparator|Monsenso without feedback|Daily smartphone-based monitoring and treatment using the Monsenso system WITHOUT a clinical feedback loop feedback.
89592300|NCT04230421|Active Comparator|Control|CAG Bipolar treatment alone and daily mood monitoring using only the mood monitoring part of the Monsenso system.
89592301|NCT04210089|Experimental|Soft Cast with a Removable Cam Boot|Patients with a foot, ankle, or lower leg ulcer (which we expect to be mostly diabetic foot ulcers) will be provided with a total contact soft cast with removable cam boot.
89592302|NCT04210089|Experimental|Soft Cast without a Removable Cam Boot|Patients with a foot, ankle, or lower leg ulcer (which we expect to be mostly diabetic foot ulcers) will be provided with a total contact soft cast.
89592303|NCT04210089|No Intervention|Conventional|Patients with a foot, ankle, or lower leg ulcer (which we expect to be mostly diabetic foot ulcers) will use conventional offloading including total contact casting, removable cast boots (cam boots), CROW boots, bracing, AFO's, offloading shoes, insoles, padding, shoe modifications, crutches, wheelchairs, rollabout, and surgical correction.
89592304|NCT04190862|Experimental|Cell Therapy Treatment|Patients who present with simple anal fistula and elect to undergo fistulotomy for treatment will be eligible to have E-CEL UVEC injected into the fistula at the time of fistulotomy to aid in healing.
89592305|NCT04190862|Experimental|Cell Therapy Treatment Part B|Adult subjects with simple perianal fistula who meet all eligibility criteria to participate in Part B of the study will be treated in the outpatient setting with curettage and E-CEL UVEC cells without fistulotomy. E-CEL UVEC cells will be injected along the two sides (180 degrees apart from each other) of the whole length of the curetted anal fistula tract.
89592306|NCT04187040|Active Comparator|3-step hand hygiene technique|Wards assigned to this study arm will receive instructions, educational materials and tutorials about the 3-step hand hygiene technique.
89592307|NCT04187040|Active Comparator|6-step hand hygiene technique|Wards assigned to this study arm will receive instructions, educational materials and tutorials about the 6-step hand hygiene technique.
89592308|NCT04182022|Active Comparator|Contingent|The Contingent group will receive nearly immediate monetary payments over the internet each day they remotely provide negative breathalyzer samples, but will not receive the payments if they provide positive samples or fail to provide samples in a timely manner.
89592309|NCT04182022|Sham Comparator|Noncontingent|The Noncontingent group will receive payments each day they successfully provide samples independent of the alcohol content of those samples.
89592310|NCT04162678||Diagnostic (blood collection via fluid biopsy, lab analysis)|Patients undergo collection of blood samples on day 1 for analysis via HD-SCA fluid biopsy. Medical charts of patients are reviewed at 3 months post-biopsy or CT screening.
89592311|NCT04143269|Active Comparator|Active treatment|Non-invasive transcutaneous vagus nerve stimulation applied by the GammaCore device (ElectroCore LLC)
89592312|NCT04143269|Sham Comparator|Sham Treatment|Inactive sham vagus nerve stimulation applied by the GammaCore sham device (ElectroCore LLC)
89592313|NCT04104529|Experimental|Biological collection|"Biological collection~For all the patients include in the study :~samples of blood samples collected before and during treatment. In parallel to this biological collection, standardized clinical data will be entered into a database~Ancillary study :~For metastatic thyroïd cancer and neuroendocrine tumor : anapath blocks of the initial diagnosis will be archived and dosimetric data will be collected for the cycle 1 For neuroendocrine tumor : blood sample additionnal will be realized at the cycle 1 (pre and post treatment)"
89592314|NCT04085536|Other|Chronic maxillary sinusitis(for more than 12 weeks)|Patients for whom chronic maxillary sinusitis will be diagnosed in the first ENT consultation, will then be seen in a stomatology consultation to determine whether or not a dental cause is objective.
89592315|NCT04081545|Active Comparator|Control Goup A- Opioid-based regimen|"Preop - Multimodals unless contraindicated~Induction~Fentanyl (50mcg IV)~Lidocaine 1.5mg/kg IV bolus using IBW (Ideal body weight)~Propofol 2-3mg/kg IV bolus~Neuromuscular blockade per Anesthesiology team discretion~Maintenance~Sevoflurane~Neuromuscular blockade at discretion of anesthesiology team~May use fentanyl to treat SBP or HR > 20% of baseline~Emergence~Neuromuscular reversal, dosed according to Virginia Mason protocol~May titrate fentanyl per anesthesiology team throughout the case.~Patient extubated and brought to PACU~PACU opioid orders per anesthesiology team~Post-operative Nausea/Vomiting Prophylaxis~-4mg dexamethasone, 1mg haloperidol, scopolamine patch"
89608469|NCT01273246|Experimental|Children Group 1: 200U EV71 vaccine|12 children received 3 doses of 200U EV71 vaccine 28 days apart
89608470|NCT01273246|Placebo Comparator|Children Group 1: Placebo|6 children received 3 doses of placebo 28 days apart
89608471|NCT01273246|Experimental|Children Group 2: 400U EV71 vaccine|12 children received 3 doses of 400U EV71 vaccine 28 days apart
89592316|NCT04081545|Experimental|Experimental Group B- Opioid-free regimen|"Preop - Multimodals unless contraindicated~Induction~Dexmedetomidine 1mcg/kg IV bolus over 10 minutes using IBW~Lidocaine 1.5mg/kg IV bolus using IBW~Propofol 2-3mg/kg IV bolus~Neuromuscular blockade per Anesthesiology team discretion~Ketamine 0.5mg/kg IV bolus (based on IBW)~Maintenance~Sevoflurane~Dexmedetomidine 0.4 mcg/kg/hr IV infusion using IBW (may titrate based on patient response between 0.3-0.5mcg/kg/hr)~Lidocaine 2mg/kg/hr IV infusion using IBW~May use esmolol as needed to treat SBP or HR > 20% of baseline~Neuromuscular blockade at the discretion of anesthesiology team~Emergence~Dexmedetomidine infusion turned off during laparoscopic desufflation~Lidocaine infusion turned off at skin closure~Neuromuscular reversal, dosed according to VM protocol~Pt extubated and brought to PACU~PACU opioid orders per anesthesiology team~Post-operative Nausea/Vomiting Prophylaxis~-4mg dexamethasone, 1mg haloperidol, scopolamine patch"
89592317|NCT04076527||Group 1 - Incomplete Responder|"Primary Incomplete Responder: PBC patients demonstrating an insufficient response to the standard therapy with ursodeoxycholic acid (UDCA) after a minimum of 12 months of treatment (Paris II criteria).~Secondary Incomplete Responder: PBC patients demonstrating a satisfactory initial response to UDCA after a minimum of 12 months of treatment (Paris II criteria) followed by a re-increase of ALP ≥1.5 ULN, or AST ≥1.5 ULN, or bilirubin >1 mg/dl at any later time point during continuous UDCA-treatment."
89592318|NCT04076527||Group 2 - Responder|PBC patients demonstrating a satisfactory initial and contin-ued response to UDCA after a minimum of 12 months of treatment (Paris II criteria) without a re-increase of ALP ≥1.5 ULN, or AST ≥1.5 ULN, or bilirubin >1 mg/dl at any later time point during continuous UDCA-treatment.
89592319|NCT04076527||Group 3|Patients newly diagnosed for PBC receiving an approved PBC therapy for the first time. Patients are considered to be newly diagnosed if the initial diagnosis took place no later than six months prior to inclusion into the study.
89592320|NCT04064697|No Intervention|Control group|Patient will be treated by vedolizumab the standard of care alone.
89592321|NCT04064697|Experimental|Experimental group|Patient will be treated by vedolizumab the standard of care associated at valganciclovir.
89592322|NCT04063215|Experimental|HB-adMSC|HB-adMSCs will be infused three times over a six week period, spaced 14 days apart
89592323|NCT04060251|Experimental|Group 1, iGetBetter Group|Use only iGetBetter for the 3 months preceding surgery. After surgery, you will be given a new, Post-Op program to use for 2-3 months. For the first 3 weeks, you will only use iGetBetter. After those 3 weeks, you will receive outpatient physical therapy in addition to iGetBetter, approximately twice per week for the next 6-8 weeks.
89592324|NCT04060251|Experimental|Group 2, E-vive Group|You will use iGetBetter starting 3 months out from surgery. You will receive CyMedica's electrical-stimulation garment during the preoperative appointment. In addition to iGetBetter, you will wear the conductive garment two times each day for the last 3 weeks before surgery. After surgery, for the first 3 weeks you will only use the conductive garment, and will not use iGetBetter. After those 3 weeks, you will receive outpatient physical therapy in addition to wearing the brace, approximately twice per week for the next 6-8 weeks. You will not need to return the brace after this time is up, and you may keep the brace, if you so choose, at no cost.
89592325|NCT04060251|No Intervention|Group 3, Physical Therapy Group|You will receive only iGetBetter for the 3 months preceding surgery. After surgery, you will receive only home physical therapy, and will not use iGetBetter. After those three weeks, you will receive outpatient physical therapy approximately twice per week for the next 6-8 weeks.
89592326|NCT04048876|Experimental|CC-90001 400 mg once daily (QD)|CC-90001 400 mg QD
89592327|NCT04048876|Experimental|CC-90001 200 mg once daily|CC-90001 200 mg QD
89592328|NCT04048876|Experimental|CC-90001 100 mg once daily|CC-90001 100 mg QD
89592329|NCT04048876|Placebo Comparator|Placebo once daily|Placebo QD
89592330|NCT04001751|Experimental|Therapeutic educational postural yoga program|Daily 15-min yoga sessions at home during 12 weeks. One 90-min yoga-therapeutic education session/week (during 6 weeks).
89592331|NCT03976011|Experimental|Transcutaneous Laryngeal Ultrasonography|All patients operated on endocrine surgery in the three referral centers and responding to the inclusion criteria will be included after obtaining their writing consent. The gold standard NF will be performed between D1 and D15, as usually performed after these surgeries. TLU will be performed during the same time period by an investigator blind to the NF results. The subject will be his own control, NF and TLU being compared. When facing VF immobility, the subject will benefit from the usual clinical follow up: consultation with NF at 6 weeks and 6 months. TLU will be added to these appointments.
89592332|NCT03975959|Other|GLIOBLASTOMA|"One visit with collection :~demographical data clinical data QMRP questionnaire HADS questionnaire MFI questionnaire MoCA test FAB test"
89592333|NCT03975959|Other|glioma|"One visit with collection :~demographical data clinical data QMRP questionnaire HADS questionnaire MFI questionnaire MoCA test FAB test"
89592334|NCT03975959|Other|breast cancer|"One visit with collection :~demographical data clinical data QMRP questionnaire HADS questionnaire MFI questionnaire MoCA test FAB test"
89592335|NCT03975959|Other|healthy|"One visit with collection :~demographical data clinical data QMRP questionnaire HADS questionnaire MFI questionnaire MoCA test FAB test"
89592336|NCT03967990|Experimental|refined-50/50-whole|48 g/d of corn flour was delivered to participants in two daily 24 g servings as pita breads and/or muffins via (1) refined cornmeal flour, followed by (2) 50/50 mix of refined cornmeal flour plus corn bran, followed by (3) whole grain cornmeal flour
89592337|NCT03967990|Experimental|50/50-whole-refined|48 g/d of corn flour was delivered to participants in two daily 24 g servings as pita breads and/or muffins via (1) 50/50 mix of refined cornmeal flour plus corn bran, followed by (2) whole grain cornmeal flour, followed by (3) refined cornmeal flour
89608472|NCT01273246|Placebo Comparator|Children Group 2: Placebo|6 children received 3 doses of placebo 28 days apart
89608473|NCT01273246|Experimental|Infants Group 1: 100U EV71 vaccine|24 infants received 3 doses of 100U EV71 vaccine 28 days apart
88977647|NCT00062855|Experimental|Gene Modified Neuroblastoma Cells|Gene modified neuroblastoma cells given as 4 subcutaneous injections over 5 weeks
89592338|NCT03967990|Experimental|whole-refined-50/50|48 g/d of corn flour was delivered to participants in two daily 24 g servings as pita breads and/or muffins via (1) whole grain cornmeal flour, followed by (2) refined cornmeal flour, followed by (3) 50/50 mix of refined cornmeal flour plus corn bran
89592339|NCT03967990|Experimental|refined-whole-50/50|48 g/d of corn flour was delivered to participants in two daily 24 g servings as pita breads and/or muffins via (1) refined cornmeal flour, followed by (2) whole grain cornmeal flour, followed by (3) 50/50 mix of refined cornmeal flour plus corn bran
89592340|NCT03967990|Experimental|50/50-refined-whole|48 g/d of corn flour was delivered to participants in two daily 24 g servings as pita breads and/or muffins via (1) 50/50 mix of refined cornmeal flour plus corn bran, followed by (2) refined cornmeal flour, followed by (3) whole grain cornmeal flour
89592341|NCT03967990|Experimental|whole-50/50-refined|48 g/d of corn flour was delivered to participants in two daily 24 g servings as pita breads and/or muffins via (1) whole grain cornmeal flour, followed by (2) 50/50 mix of refined cornmeal flour plus corn bran, followed by (3) refined cornmeal flour
89592342|NCT03944785||Parkinson's Disease Patients|PD patients who have been newly prescribed safinamide (XADAGO) for the treatment of OFF episodes as described in the XADAGO Package Insert
89592343|NCT03921424|Experimental|V114|Participants will receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2)
89592344|NCT03921424|Active Comparator|Prevnar 13™|Participants will receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2)
89592345|NCT03915912|Experimental|Mindfulness meditation|Newly diagnosed malignant glioma patients will participate in six 1-hour mindfulness sessions over the phone, followed by one 1-hour in-person mindfulness session. Patients will complete various Quality of Life questionnaires and distress measuring tools prior to initiating the mindfulness sessions, at the clinic visit following the mindfulness intervention, and ~2 months after completing the mindfulness intervention. Additionally, patients will be provided with supplemental materials including website references and guided audiotape meditations to guide their individual practice outside of the weekly guided sessions.
89592346|NCT03896230|Active Comparator|Arm 1: 0.1 mg/kg ketamine|0.1 mg/kg in a 100 mL solution of dextrose 5% or sodium chloride 0.9% will be give after patient consent and enrollment in the study, vitals are followed (heart rate, systolic blood pressure and respiratory rate) for 2 hours following completion of ketamine infusion. Evaluated for side effects for 2 hours following completion of ketamine infusion.
89592347|NCT03896230|Active Comparator|Arm 1: 0.2 mg/kg ketamine|0.2 mg/kg in a 100 mL solution of dextrose 5% or sodium chloride 0.9% will be give after patient consent and enrollment in the study, vitals are followed (heart rate, systolic blood pressure and respiratory rate) for 2 hours following completion of ketamine infusion. Evaluated for side effects for 2 hours following completion of ketamine infusion.
89592348|NCT03896230|Active Comparator|Arm 1: 0.3 mg/kg ketamine|0.3 mg/kg in a 100 mL solution of dextrose 5% or sodium chloride 0.9% will be give after patient consent and enrollment in the study, vitals are followed (heart rate, systolic blood pressure and respiratory rate) for 2 hours following completion of ketamine infusion. Evaluated for side effects for 2 hours following completion of ketamine infusion.
89592349|NCT03878316|Active Comparator|Intranasal Oxytocin|Oxytocin, 35 IU per dose, intranasally twice-daily. One dose is defined as intranasal spray of 100 μL per each nostril x 5 sprays in alternating nostrils with a 30 second wait between sprays for a total dose volume of 500 μL. The total daily dose of oxytocin will be 70 IU/mL.
89592350|NCT03878316|Placebo Comparator|Instrasal Placebo|Identically matched placebo administered intranasally twice-daily. One dose is defined as intranasal spray of 100 μL per each nostril x 5 sprays in alternating nostrils with a 30 second wait between sprays for a total dose volume of 500 μL.
89592351|NCT03860571|Placebo Comparator|Placebo|
89592352|NCT03860571|Experimental|BT-11|
89592353|NCT03854929|Active Comparator|Ciprofloxacin|Each sachet CIPROFLOXACIN of 3g powder contains: 250mg Ciprofloxacin HCl, dissolved in water, dosed to 15mg/kg body weight /twice daily (apart 12 hours)/ 3 days.
89592354|NCT03854929|Experimental|Azithromycin|Each sachet AZICINE of 1.5 g powder contains: 250mg of Azithromycin dihydrate, dissolved in warm water, dosed to 10mg/kg body weight /daily/ 3 days
89592355|NCT03852628|Active Comparator|2mg Buprenex and 380mg Vivitrol|"2mg Buprenex and 380mg Vivitrol~Buprenex (buprenorphine) 2mg sublingual (SL) (taken every day for 12 weeks) , with Vivitrol (naltrexone) 380mg intramuscular injection (IM) (given every 4 weeks)"
89592356|NCT03852628|Placebo Comparator|Placebo|"Placebo (SL pill qd, IM injection q4weeks)~Placebo pill (taken sublingual every day for 12 weeks) and IM placebo (given intramuscular injection, every 4 weeks at baseline, week4 and week8)"
89592357|NCT03847142|Experimental|ASTHMAXcel arm|The ASTHMAXcel arm represents the study intervention, which is a patient-facing mobile application for adult patients with asthma.
89592358|NCT03847142|Active Comparator|Usual care arm|This arm represents usual care delivered in the outpatient primary care setting at the study sites.
88977648|NCT00095901|Experimental|Capecitabine|Capecitabine (Xeloda 4:14. ) 150 mg and 500 mg tablets. Capecitabine will be administered at a dose of 1000 mg/m2 twice daily, for a total daily dose of 2000 mg/m 2. Capecitabine will administered P.O. or per G-tube B.I.D. for 14 days, followed by a one-week rest period in 3-week cycles.
88977649|NCT00227110|Active Comparator|Pioglitazone|Pioglitazone 30 mg/d will be given for 8 weeks and titrated to 45 mg/d until the end of the 6-month study in a randomized, double-blind, study design.
88977650|NCT00227110|Placebo Comparator|Placebo|Placebo once daily is given following a randomized, double-blind, placebo-controlled study design.
89592359|NCT03833531|Active Comparator|PTSD-ImRS|PTSD treatment
89592360|NCT03833531|Experimental|Integrated SFT-ImRS|Integrated PTSD-PD treatment
89592361|NCT03826524|Active Comparator|Low Dose Epinephrine|Epinephrine up to 2mg total
89592362|NCT03826524|Active Comparator|Standard Dose Epinephrine|Epinephrine up to 6mg total
89592363|NCT03811769|Other|Best Medical Therapy (BMT)|Best treatment medical probably associated to the rescue endovascular treatment in case of neurological deterioration
89592364|NCT03811769|Other|Mechanical Thrombectomy (MT)|Endovascular treatment (thrombectomy) associated with the best medical treatment
89592365|NCT03741426|Experimental|Arm 1- Cediranib|Cediranib tablet oral 20mg once daily for a minimum of 2 weeks up until 36 hours before nephrectomy.
89592366|NCT03741426|Experimental|Arm 2- Olaparib|Olaparib tablet oral 300mg twice daily for a minimum of 2 weeks up until the morning of nephrectomy.
89592367|NCT03741426|Active Comparator|Arm 3- Olaparib and Cediranib|Olaparib tablet oral 300mg twice daily for a minimum of 2 weeks up until the morning of nephrectomy AND Cediranib tablet oral 20mg once daily for a minimum of 2 weeks up until 36 hours before nephrectomy.
89592368|NCT03741426|Experimental|Arm 4- Durvalumab|Durvalumab 1500mg intravenous infusion once, a maximum of 4 weeks prior to nephrectomy.
89592369|NCT03741426|Active Comparator|Arm 5- Olaparib and Durvalumab|Olaparib tablet oral 300mg twice daily for a minimum of 2 weeks up until the morning of nephrectomy. Durvalumab 1500mg intravenous infusion once, a maximum of 4 weeks prior to nephrectomy.
89592370|NCT03707158|Active Comparator|Web-based CBT|The online, multimedia suite of Cool Kids CBT web-based programs for youth anxiety is a supported, largely self-administered online digital cognitive-behavioral therapy anxiety management intervention, with adjunctive therapist phone support. Treatment content runs directly parallel to that included in the therapist-led Cool Kids face-to-face suite of interventions. The online suite of interventions is comprised of two developmentally tailored programs, depending on the age of the child.
89592371|NCT03707158|Active Comparator|Face-to-Face CBT|The Cool Kids suite of face-to-face (office-based or telehealth) CBT-based programs for youth anxiety is a well-supported therapist-led, clinic-based anxiety management intervention. The face-to-face cognitive-behavioral therapy treatment content runs directly parallel to that included in the Cool Kids online suite of interventions. The face-to-face suite of interventions is comprised of two developmentally tailored programs, depending on the age of the child.
89592372|NCT03691480|Experimental|simple exsufflation|
89592373|NCT03691480|Experimental|Fuhrman catheter and ambulatory care|
89592374|NCT03636282|Experimental|Hockey FIT Program (Immediate Delivery)|Hockey FIT Program: A gender-sensitized, weight loss and healthy lifestyle program that engages men using the power of being a sports fan.
89592375|NCT03636282|No Intervention|Wait-List Control (Delayed Delivery)|No intervention for 12 months. After 12 months, Hockey FIT program is offered.
88977651|NCT00227188||1|Children from 0-5 years of age evaluated for IPD
88977652|NCT00227461|Other|Wait control|Levitiracetam is started after a delay, with dosage and administration as described below.
88977653|NCT00227461|Experimental|Treatment first|Levitiracetam is started immediately after baseline data is collected; dosage and administration as described below.
88977654|NCT04721899||Vitamin D- recurrent implantation failure (RIF)|All women will have endometrial biopsy twice- at baseline and after 8 weeks of taking vitamin D After 8 weeks of Vitamin D, a second endometrial biopsy using a Pipelle sampler will be collected from the patients 7 days after luteinizing hormone surge (LH+7) and the endometrial receptivity will be compared.
88977655|NCT04721899||Vitamin D- recurrent pregnancy loss (RPL)|All women will have endometrial biopsy twice- at baseline and after 8 weeks of taking vitamin D After 8 weeks of Vitamin D, a second endometrial biopsy using a Pipelle sampler will be collected from the patients 7 days after luteinizing hormone surge (LH+7) and the endometrial receptivity will be compared.
88977656|NCT04721899||Vitamin D- infertility|All women will have endometrial biopsy twice- at baseline and after 8 weeks of taking vitamin D After 8 weeks of Vitamin D, a second endometrial biopsy using a Pipelle sampler will be collected from the patients 7 days after luteinizing hormone surge (LH+7) and the endometrial receptivity will be compared.
88977657|NCT00227656|Experimental|Capecitabine + PEG-interferon alfa-2a|Capecitabine 1000 mg/m2 orally twice daily during the first 14 days of each 3-week cycle (2 weeks on, 1 week rest), and PEG-interferon alfa-2a subcutaneously beginning at 180 mcg per week for 21 days.
88977658|NCT00227695|Active Comparator|Arm A: Rituximab every 2 months x4|Rituximab 375 mg/m2 every 2 months x4
88977659|NCT00227695|Active Comparator|Arm B: Rituximab (5 years)|Rituximab 375 mg/m2 every 2 months for 5 years or until PD, relapse or unacceptable toxicity
88977660|NCT00096213|Other|surgery|intralesional resection
88977661|NCT04722289|Experimental|Together on Diabetes|The intervention consists of five components: Recruitment of peers and peer supporters; training of peer supporters; matching peers and peer supporters; individual face-to-face meetings between peers and peer supporters; and ongoing supervision and network meetings for peer supporters.
88977662|NCT00227734|Active Comparator|Arm I|Patients receive oral capecitabine twice daily on days 1-15 and oxaliplatin IV over 2 hours on day 1.
89592376|NCT03623633|Active Comparator|Denosumab and Raloxifene|denosumab and raloxifene
89592377|NCT03623633|Active Comparator|Denosumab and Alendronate|denosumab and alendronate
89592378|NCT03602976|No Intervention|Observation|
89592379|NCT03602976|Experimental|UDCA at Month 6|
89592380|NCT03601247|Other|All patients|Split-face study: patients undergoing bilateral eye surgery will have the sides of their face randomized to receive either placebo or silicone gel.
89592381|NCT03595072||Stimulation|patient ECOG recordings during active VNS stimulation
89592382|NCT03595072||interstimulation|the same patient ECOG during inter-stimulation periods
89592383|NCT03582579|Experimental|Control in VR|Adults ages 18 to 35 who will be training in Virtual Reality.
89592384|NCT03582579|Experimental|Control Non-VR|Adults ages 18 to 35 who will be training on a computer screen.
89592385|NCT03582579|Experimental|College Athletes with TBI Group|Adults ages 18 to 35 with mild TBI who will be training in Virtual Reality
89592386|NCT03582579|Experimental|Older Adult Group|Older Adults over the age of 65 who will be training in Virtual Reality
89592387|NCT03581227||Participants without a diagnosis of COPD|Men and women aged 45 to 80, who have not been diagnosed with Chronic Obstructive Pulmonary Disease (COPD)
89592388|NCT03554174|Experimental|Placebo/Low Dose Psilocybin|Subjects in this arm receive placebo in the first session and low dose psilocybin in the second session.
89592389|NCT03554174|Experimental|Placebo/Medium Dose Psilocybin|Subjects in this arm receive placebo in the first session and medium dose psilocybin in the second session.
89592390|NCT03554174|Experimental|Low Dose Psilocybin/Placebo|Subjects in this arm receive low dose psilocybin in the first session and placebo in the second session.
89592391|NCT03554174|Experimental|Medium Dose Psilocybin/Placebo|Subjects in this arm receive medium dose psilocybin in the first session and placebo in the second session.
89592392|NCT03540680|Other|Term newborns (≥37GA)|Blood punction on the cordon
89592393|NCT03540680|Other|Premature newborns|Blood punction on the cordon
89592394|NCT03540680|Other|Child between 7 and 15 years old with BPD|Blood punction
89592395|NCT03540680|Other|Child between 7 and 15 years old without BPD|Blood punction
89592396|NCT03508440|Active Comparator|Standard of Care|Oral steroids (prednisone or prednisolone) 60mg per day for 10 days or 60mg/day for 5 days followed by a 5 day taper
89592397|NCT03508440|Experimental|SOC + injection|Oral steroids as described above + intratympanic injection of dexamethasone (up to 1cc of 24mg/ml) - 3 injections over three weeks.
89592398|NCT03508440|Other|Injection only|Only Intratympanic injection of dexamethasone (up to 1cc of 24mg/ml) - 3 injections over three weeks
89592399|NCT03445845|Experimental|targeting IL-23/17 axis|"The experimental group (targeting IL-23/17 axis) receiving secukinumab in compliance with the marketing authorization regimen: 150 mg per week for 5 weeks, and then every month by subcutaneous injection.~Blood specimen at each visits"
89592400|NCT03445845|Active Comparator|TNF blocker|"• The control group receiving a second TNF blocker in compliance with the marketing authorization regimen:~The TNF blocker (originator or biosimilar) will be different to the TNF used before the inclusion and will be chose by the investigator:~infliximab: 5mg/kg per IV infusion at weeks 0, 2, 6, and then every 6 weeks,~etanercept: 50mg per week in subcutaneous injection,~adalimumab: 40mg every other week in subcutaneous injection,~certolizumab: 400mg every other week 3 times, and then 200mg every other week or 400mg per month in subcutaneous injections,~golimumab: 50mg every month in subcutaneous injection, in case of overweight (>100kg) an inadequate response, 100mg every month is allow.~Blood specimen at each visits"
89592401|NCT03422861|Active Comparator|Nabilone Treatment|Patients who are chronic opioid users for chronic pain and have been exposed to cannabis or cannabinoid products, treated with IV PCA and nabilone as per protocol
89592402|NCT03422861|Placebo Comparator|Placebo Treatment|Patients who are chronic opioid users for chronic pain and have been exposed to cannabis or cannabinoid products, treated with IV PCA and placebo
89592403|NCT03421496|Experimental|CBD with Vigabatrin|Participants received up to 40 milligrams per kilogram per day (mg/kg/day) divided twice daily (BID) of CBD with food. Participants also received up to 150 mg/kg/day BID of vigabatrin with food.
89592404|NCT03421496|Placebo Comparator|Placebo with Vigabatrin|Participants received a matching placebo to CBD with food, and also received up to 150 mg/kg/day BID of vigabatrin with food.
89592405|NCT03321786||Legionnaires' Disease Volunteers|Volunteers who have been diagnosed/survivors of Legionnaire's Disease
89592406|NCT03321786||Healthy Volunteers|Volunteers who are healthy.
89592407|NCT03306992|Experimental|Personalized Exercise Program|
89592408|NCT03306992|No Intervention|Standard of Care - No Exercise|
89592409|NCT03278106|Experimental|Treatment (TAS-102)|Patients receive trifluridine/tipiracil hydrochloride combination agent TAS-102 orally PO BID on days 1-5 and 8-12. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89592410|NCT03255252|Experimental|Cisplatin|Weekly cisplatin (40 mg/m²) will be administered during radiotherapy. At least 3 cycles of cisplatin should be performed according to the hematological and renal functions but not mandatory.
88977663|NCT00227734|Active Comparator|Arm II|Patients receive capecitabine and oxaliplatin as in arm I and cetuximab IV over 1-2 hours on days 1 and 8
88977664|NCT00096291|Active Comparator|Sequence Doxorubicin followed by Paclitaxel|"Patients will be randomized into 2 groups based on sequence of neoadjuvant chemotherapy:~Doxorubicin followed by Paclitaxel versus Paclitaxel followed by Doxorubicin"
88977665|NCT00096291|Other|Sequence of neoadjuvant CT: Paclitaxel followed by Doxorubicin|"Patients will be randomized into 2 groups based on sequence of neoadjuvant chemotherapy:~Doxorubicin followed by Paclitaxel versus Paclitaxel followed by Doxorubicin"
88977666|NCT00227890|Experimental|1|Motivational Interviewing followed by Cognitive Behavior Therapy (MI/CBT)
88977667|NCT00227890|Experimental|2|Relaxation Training followed by Treatment as Usual (RT/TU)
88977668|NCT02967302|Experimental|Morphine Sulfate|Morphine 3 mg intraarticular once at baseline
88977669|NCT02967302|Active Comparator|Triamcinolone|Triamcinolone 40 mg intraarticular once at baseline
88977670|NCT02967302|Placebo Comparator|Placebo|NaCl 0,9% 5 ml intraarticular at baseline
88977671|NCT00063089|Experimental|altastaph|S. aureus Immune Globulin Intravenous (Human) 5%
88977672|NCT00063089|Placebo Comparator|Placebo|0.45% Normal Saline
88977673|NCT00096408|Active Comparator|1|Total Abdominal Hysterectomy
88977674|NCT00096408|Experimental|2|Total Laparoscopic Hysterectomy
88977675|NCT00228163|Experimental|Teriflunomide 7 mg|
88977676|NCT00228163|Experimental|Teriflunomide 14 mg|
88977677|NCT00063128|Experimental|A|
88977678|NCT00063128|Active Comparator|B|
88977679|NCT00228319|Active Comparator|Standard of Care Group|carboplatin and paclitaxel chemotherapy
88977680|NCT00228319|Experimental|Standar of Care + Ascorbic Acid Group|carboplatin and paclitaxel chemotherapy, plus intravenous sodium ascorbate. In addition, participants will take a mix of vitamins including oral ascorbic acid, oral mixed natural carotenoids with vitamin A and oral vitamin E.
88977681|NCT02967536||Mild OSA|Untreated OSA patients. Apnoea-Hypopnoea Index (AHI) >5 events/hour and <10 events/hour with Epworth Sleepiness Score (ESS)>9.
88977682|NCT02967536||Severe OSA|Untreated OSA patients. AHI >30 events/hour, with excessive sleepiness (ESS >9).
88977683|NCT02967536||Healthy control|Healthy control. AHI <5 events/hour.
88977684|NCT02962180|Experimental|single arm study|Dermabrasion with dermaroller of basal cell layer suspension obtained by soft trypsinisation in vitiligo lesion.
88977685|NCT00228358|Experimental|Group A (cellular infusions after cyclophosphamide)|Patients receive low-dose cyclophosphamide IV on day -1 and 3 escalating doses of autologous ex vivo-expanded HER2-specific T cells IV over 30 minutes on days 1, 10, and 20.
89592411|NCT03254420|Active Comparator|Image-guided radiation therapy (IGRT) with standard margins|moderate hypofractionation during 4 weeks
89592412|NCT03254420|Experimental|Calypso tracking system with margin reduction|moderate hypofractionation during 4 weeks after calypso beacon implant 10 days before
89592413|NCT03240523|Experimental|Group A1: Vilaprisan (3/1 regimen)|Orally, 2 mg, once daily, 3 months treatment followed by 1 menstrual bleeding episode
89608474|NCT01273246|Placebo Comparator|Infants Group 1: Placebo|8 infants received 3 doses of placebo 28 days apart
89592414|NCT03240523|Experimental|Group A2: Vilaprisan (6/2 regimen)|Orally, 2 mg, once daily, 6 months treatment followed by 2 menstrual bleeding episodes
89592415|NCT03240523|Experimental|Group A3/B (3/2 regimen)|"Orally, 2 mg, once daily, 3 months treatment followed by 2 menstrual bleeding episodes~With protocol version 5.0 the blinded study arms A3 and B were converted to one open-label study arm called A3/B."
89592416|NCT03230747|Experimental|TMVR|Subjects will undergo transcatheter mitral valve replacement
89592417|NCT03214198||Vonoprazan 10 mg|The usual adult dosage for oral use is 10 mg of Vonoprazan administered once daily. Participants will receive interventions as part of routine medical care.
89592418|NCT03192215|Experimental|Active agent: Apixaban|Patients with a recent embolic stroke of undetermined source (ESUS) and evidence of atrial cardiopathy will receive Apixaban
89592419|NCT03192215|Active Comparator|Active control: Aspirin|Patients with a recent embolic stroke of undetermined source (ESUS) and evidence of atrial cardiopathy will receive Aspirin
89592420|NCT03027804||Ross Operation|Patients undergone Ross Operation. Patients requiring reoperation
89592421|NCT02914639|Experimental|SF0166 low dose BID|SF0166 low dose instilled in study eye BID for 28 days of treatment.
89592422|NCT02914639|Experimental|SF0166 high dose BID|SF0166 high dose instilled in study eye BID for 28 days of treatment.
88977686|NCT00228358|Experimental|Group B (cellular infusions after ONTAK conditioning)|Patients receive denileukin diftitox IV over 1 hour on day -1 and 3 escalating doses of autologous ex vivo-expanded HER2-specific T cells IV over 30 minutes on days 1, 10, and 20.
88977687|NCT00228436|Experimental|Cohort 1|Peginesatide starting dose of 0.05 milligram per kilogram (mg/kg) administered subcutaneously (SC) once every 4 weeks (Q4W) for a total of 6 doses.
88977688|NCT00228436|Experimental|Cohort 2|Peginesatide starting dose of 0.075 mg/kg administered SC Q4W for a total of 6 doses.
88977689|NCT00228436|Experimental|Cohort 3|Peginesatide starting dose of 0.025 mg/kg administered SC Q4W for a total of 6 doses.
88977690|NCT00228436|Experimental|Cohort 4|Peginesatide starting dose of 0.05 mg/kg administered intravenously (IV) Q4W for a total of 6 doses.
88977691|NCT00228436|Experimental|Cohort 5|Peginesatide starting dose of 0.025 mg/kg administered SC once every 2 weeks (Q2W) for a total of 12 doses.
88977692|NCT00228436|Experimental|Cohort 6|Peginesatide starting dose of 0.0375 mg/kg administered SC Q2W for a total of 12 doses.
88977693|NCT00228436|Experimental|Cohort 7|Peginesatide fixed starting dose of 4 mg administered SC Q4W for a total of 6 doses.
88977694|NCT00228436|Experimental|Cohort 8|Peginesatide fixed starting dose of 3 mg administered SC Q4W for a total of 6 doses.
88977695|NCT02967575||1- or 2-level cTDR|patients suffering from intractable symptomatic cervical disc disease (SCDD) requiring 1- or 2-level reconstruction of the disc from C3-C7
88977696|NCT00075621|Other|tandem transplant|"Drug: filgrastim 16 mg/kg/day for 3 days prior to stem cell collection, through day before last collection~Drug: melphalan 200 mg/kg over 2 days~Procedure/Surgery: autologous peripheral blood stem cell transplantation~autologous peripheral blood stem cell transplantation"
88977697|NCT00228631||Sickle Cell Disease Bone Marrow Transplant|Sickle Cell Disease Bone Marrow Transplant candidates
88977698|NCT00228670||IPF-Clinic|Adult patients with idiopathic pulmonary fibrosis being followed in pulmonary clinic
88977699|NCT00228670||Controls - Clinic|Adult subjects with no underlying pulmonary disease who are the household partner of an IPF patient being followed in pulmonary clinic
88977700|NCT00228670||IPF-Transplant|IPF patient undergoing lung transplant
88977701|NCT00228670||Controls-Transplant|Lung tissue from organ donor
88977702|NCT00228865|Experimental|1|Testing performed on diabetic patients with decline in cognitive function at baseline and quarterly after the start of receiving pulsatile intravenous insulin therapy to assess continuing cognitive function ability.
88977703|NCT00228904|Placebo Comparator|1|Control patients with diagnosed diabetic neuropathy will receive baseline testing and testing every six months thereafter to compare and analyze results with patients treated with pulsatile intravenous insulin therapy.
88977704|NCT00228904|Active Comparator|2|Patients with diagnosed diabetic neuropathy have objective testing and questionnaires performed at baseline and every six months thereafter to evaluate and analyze progress of diabetic neuropathy after the start of pulsatile intravenous insulin therapy.
88977705|NCT00228982|Experimental|Ceftobiprole medocaril|Ceftobiprole medocaril 500mg q12h as 1h infusion, 7-14d
89592423|NCT02865018|Experimental|cetirizine|10mg oral each day
89592424|NCT02852538|Experimental|NEW FED TR for Anorexia|NEW FED TR
88977706|NCT00228982|Active Comparator|Vancomycin|Vancomycin 1g q12h as 1h infusion, 7-14d
88977707|NCT00229138|Experimental|reduced Tacrolimus|
88977708|NCT00229138|Active Comparator|Reference Tacrolimus|
88977709|NCT00063323|Active Comparator|Bupropion|Bupropion (brand name Zyban Sustained Release). Participants used bupropion SR 150 mg twice daily during the 16-week maintenance treatment.
88977710|NCT00063323|Active Comparator|Nicotine gum|Nicotine gum (brand name Nicorette) During the maintenance 16-week maintenance treatment phase, participants assigned to this arm received 2 mg. nicotine gum.
88977711|NCT00063323|Active Comparator|Bupropion+Nicotine Gum|Combined active treatments: Bupropion (Zyban SR) and nicotine gum (Nicorette). Participants were instructed to use the 150 mg bupropion pill twice daily and the 2 mg. gum as needed during the 16-week maintenance treatment phase.
89592425|NCT02813980||High SUDEP-7 score|Patients with epilepsy who have a high SUDEP-7 score
89592426|NCT02813980||Low SUDEP-7 score|Patients with epilepsy who have a low SUDEP-7 score
89592427|NCT02795143|Experimental|Isotretinoin|"Isotretinoin will be given at the following dosage:~Dosing will be as listed on the table below.~Weight in Kg Total Daily Dose 40-49 Kg 40mg 50-89 Kg 80mg 90-150 Kg 120mg"
89592428|NCT02795143|Placebo Comparator|Placebo|Subjects will be given placebo capsules twice a day.
89592429|NCT02790736|Experimental|Propranolol|Propranolol 40 mg capsule, given once after fear activation procedure
89592430|NCT02790736|Placebo Comparator|placebo capsule|Placebo capsule, given once after fear activation procedure
89608475|NCT01273246|Experimental|Infants Group 2: 200U EV71 vaccine|24 infants received 3 doses of 200U EV71 vaccine 28 days apart
89608476|NCT01273246|Placebo Comparator|Infants Group 2: Placebo|8 infants received 3 doses of placebo 28 days apart
89592431|NCT02736981|Active Comparator|Behavioral Weight Loss (BWL)|24 week treatment program consisting of a single, 90-minute, in-person group session in week 1, and a single 45 minute individual in-person session in week two, followed by a 6 month technology mediated program. The program includes evidenced-based behavioral weight loss content, individualized diet and physical activity goals, weekly lessons as well as reporting of key behaviors and personalized feedback to aid in goal attainment.
89592432|NCT02736981|Active Comparator|BWL + Autonomous Motivation|24 week treatment program consisting of a single, 90-minute, in-person group session in week 1, and a single 45 minute individual in-person session in week two, followed by a 6 month technology mediated program. The program includes evidenced-based behavioral weight loss content, individualized diet and physical activity goals, weekly lessons as well as reporting of key behaviors and personalized feedback to aid in goal attainment. Participants in this arm will receive coaching that places an increased emphasis on their values and personal choices, and also have the option to attend several experiential group sessions that will help those interested to apply the material and skills they are being taught (e.g., cooking demonstration, circuit training class).
89592433|NCT02736981|Active Comparator|BWL + Extrinsic Motivation|24 week treatment program consisting of a single, 90-minute, in-person group session in week 1, and a single 45 minute individual in-person session in week two, followed by a 6 month technology mediated program. The program includes evidenced-based behavioral weight loss content, individualized diet and physical activity goals, weekly lessons as well as reporting of key behaviors and personalized feedback to aid in goal attainment. Participants in this arm will have the opportunity to receive small monetary incentives in weeks 2-24 for tracking weight and calorie intake, and will be eligible for a raffle based on weight loss.
89592434|NCT02704208|Experimental|Behavioral: Thrive With Me Intervention|Participants randomized to the TWM Intervention will gain access to a website for 150 days. The TWM website includes: peer-to-peer support through a private social network and optimized gaming features; daily SMS communication for medication reminders and mood tracking; medication adherence monitoring; and tailored HIV informational content.
89592435|NCT02704208|Placebo Comparator|Behavioral: Thrive With Me Control|Participants randomized to the TWM Control group will receive HIV related content through a weekly web link. The web links will be static pages (not interactive) with information aimed at improving overall wellbeing while living with HIV, but not focused on improving ART medication adherence.
89592436|NCT02664337|Experimental|Decision tool|"A decision tool will be provided to participants who currently or previously have had one of the following 12 musculoskeletal conditions: hip arthritis, knee arthritis, ankle arthritis, hip labral tears and femoroacetabular impingement (FAI), osteochondritis dissecans, Achilles tendon rupture, patellofemoral dislocation, distal radius fracture, and fractures of the hip, ankle, tibia, and proximal humerus."
89592437|NCT02664337|Active Comparator|Standard treatment information|"Standard treatment information will be provided to participants who currently or previously have had one of the following 12 musculoskeletal conditions: hip arthritis, knee arthritis, ankle arthritis, hip labral tears and femoroacetabular impingement (FAI), osteochondritis dissecans, Achilles tendon rupture, patellofemoral dislocation, distal radius fracture, and fractures of the hip, ankle, tibia, and proximal humerus."
89592438|NCT02663739||Aortic Dissection|Treating patients with acute complicated Stanford Type B aortic dissection with the Zenith® TXD
89592439|NCT02516670|Experimental|Arm A (docetaxel, ascorbic acid)|Patients receive docetaxel IV on day 1 and ascorbic acid IV twice weekly. The first ascorbic acid treatment will be given on day 1 (same day as docetaxel). Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity.
89592440|NCT02516670|Placebo Comparator|Arm B (docetaxel, placebo)|Patients receive docetaxel IV on day 1 and placebo IV twice weekly.The first placebo treatment will be given on day 1 (same day as docetaxel). Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity.
89592441|NCT02345629|Experimental|Cordotomy Group|Radiologist performs a spinal tap to inject a contrast drug into the spinal fluid. A 20G spinal needle guided by real-time CT scan to the C1-C2 level opposite to participant's pain. A radiofrequency electrode inserted through the spinal needle into the spinal cord, to the anatomic location of the spinothalamic tract. Once ideal position of the electrode is confirmed, 1 or 2 radiofrequency ablations performed at 70C-80C for 60 seconds. The procedure will take 1-2 hours. Quantitative sensory testing on day prior to procedure, and on postoperative days number 1 and 7. Pain and symptom questionnaire completed at baseline, over the phone during the first week of study, and at each follow up visit/phone call. Participants undergo quantitative sensory testing on day prior to procedure, and on postoperative days number 1 and 7. Sensory testing to include sharpness and heat detection.
89592442|NCT02345629|Active Comparator|Comprehensive Medical Management Group|Participants receive best supportive care for 1 week. Depending on pain level after the first week, they may have a cordotomy at that time. Pain and symptom questionnaire completed at baseline, over the phone during the first week of study, and at each follow up visit/phone call.
89592443|NCT02315898|Experimental|Treatment-inhaled tPA|All patients with plastic bronchitis enrolled into the study will receive inhaled tPA.
89592444|NCT02285842||Primary Hip Resurfacings|Single study group previously implanted with CONSERVE® Press-Fit Femoral Components
89592445|NCT02280525|Experimental|Lymphodepleting Chemotherapy Option #1|"Preferred regimen for CLL and low grade lymphoma~Lenalidomide 2.5 mg by mouth once a day on Days -2 through Day +14. Fludarabine 25 mg/m2 by vein over 1 hour on Days -5 to -3. Cyclophosphamide 200 mg/m2 by vein over 3 hours on Days -5 to -3. Rituximab 375 mg/m2 by vein over 3-6 hours on Day -5 for participants with B-cell cancer.~Dose Escalation Phase Starting Dose Level of NK Cells: 1 x 10^7 NK cells/kg given by vein on Day 0.~Dose Expansion Phase Starting Dose level of NK cells: Maximum tolerated dose from Dose Escalation Phase."
89608477|NCT01273246|Experimental|Infants Group 3: 400U EV71 vaccine|24 infants received 3 doses of 400U EV71 vaccine 28 days apart
89608478|NCT01273246|Placebo Comparator|Infants Group 3: Placebo|8 infants received 3 doses of placebo 28 days apart
89608479|NCT00730522|Active Comparator|1|CPP-109 vigabatrin tablets
89608480|NCT00730522|Placebo Comparator|2|Matching Placebo Tablets
88977712|NCT00063323|Placebo Comparator|Double placebo|Placebo gum + placebo pill. Identical placebo pill was used twice daily and identical placebo gum was used as needed.
88977713|NCT00229177|Placebo Comparator|P|
88977714|NCT00229177|Experimental|E1|
88977715|NCT00229177|Experimental|E2|
89592446|NCT02280525|Experimental|Lymphodepleting Chemotherapy Option #2|"For all malignancies if able to tolerate higher dose cyclophosphamide per the discretion of the treating physician~Lenalidomide 2.5 mg by mouth once a day on Days -2 through Day +14. Fludarabine 25 mg/m2 by vein over 1 hour on Day -6 to -2. Cyclophosphamide 60 mg/kg by vein over 3 hours on Days -5 and -4.~Dose Escalation Phase Starting Dose Level of NK Cells: 1 x 10^7 NK cells/kg given by vein on Day 0.~Dose Expansion Phase Starting Dose level of NK cells: Maximum tolerated dose from Dose Escalation Phase."
89592447|NCT02280525|Experimental|Lymphodepleting Chemotherapy Option #3|"For myeloid malignancies~Lenalidomide 2.5 mg by mouth once a day on Days -2 to Day +14. Fludarabine 30 mg/m2 by vein over 1 hour on Days -6 to -2. Cytarabine 2 mg/m2 by vein on Days -6 to -2.~Dose Escalation Phase Starting Dose Level of NK Cells: 1 x 10^7 NK cells/kg given by vein on Day 0.~Dose Expansion Phase Starting Dose level of NK cells: Maximum tolerated dose from Dose Escalation Phase."
89592448|NCT02149667||Total Hip Arthroplasty|Single study group previously implanted with the following combination of components: MicroPort Orthopedics Femoral Stems, DYNASTY® BioFoam® Acetabular Components, DYNASTY® A-Class® Cross Linked Polyethylene Liners, and MicroPort Orthopedics Metal or Ceramic Femoral Heads
89592449|NCT02133898|Other|L-methyfolate|Single-arm open label administration of L-methylfolate 15mg once daily for 90 days
89592450|NCT02071290|Sham Comparator|Sham Remote Ischemic Conditioning|Sham inflation of pneumatic tourniquet pressure cuff at 0 mmHg on the thigh for 5 minutes and release for 5 minutes (repeated for 4 cycles) applied to trauma patients on arrival to hospital
89592451|NCT02071290|Experimental|Remote Ischemic Conditioning|Inflation of pneumatic tourniquet pressure cuff at 250mmHg on the thigh for 5 minutes and release for 5 minutes (repeated for 4 cycles) applied to trauma patients on arrival to hospital
89592452|NCT02066181|Experimental|Arm I (sorafenib tosylate)|Patients receive sorafenib tosylate PO QD on days 1-28.
89592453|NCT02066181|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD on days 1-28. Patients may crossover to Arm I upon disease progression.
89592454|NCT01970865|Experimental|PF-06463922|
89592455|NCT01970865|Other|Crizotinib|ALK+ NSCLC patients who are treatment naïve may be eligible to receive crizotinib following PF-06463922 as a substudy to the main study.
88977716|NCT00229255|Active Comparator|high frequency meals group|High carbohydrate diet i.e. 65% carbohydrate, 15% protein, 20% fat for 4 weeks.
88977717|NCT00229255|Active Comparator|twice-a -day meals|high carbohydrate diet i.e. 65% carbohydrate, 15% protein, 20% fat for 4 weeks
88977718|NCT02967653|Placebo Comparator|Placebo|Patients will be randomized to a placebo a day using simple 1:1 randomization using random.org, for 12 weeks.
88977719|NCT02967653|Experimental|Atorvastatin|Patients will be randomized to Atorvastatin 20mg/day for 12 weeks or pill placebo.
88977720|NCT00229450|Experimental|Treatment|0.625 mg/day of conjugated estrogen
88977721|NCT00229450|Placebo Comparator|Placebo|Daily placebo for conjugated estrogen
88977722|NCT02967419||RIF group|People who were diagnosed as repeated implantation failure after IVF-ET
88977723|NCT02967419||Control group|People who had normal pregnancy
88977724|NCT02967341|Other|Ciprofloxacin administration|Blood will be drawn, in all participants, via Port A Cath and via a peripheral draw.
88977725|NCT00413608|Experimental|1|Clopidogrel
88977726|NCT00413608|Experimental|2|Clopidogrel
88977727|NCT04730492||Renal Transplantation|Renal Transplantation
88977728|NCT04730492||Hernias reparation post renal transplantation|Hernias reparation post renal transplantation
89592456|NCT01928576|Experimental|Arm C|Nivolumab 3mg/kg every 2 weeks until progression
89592457|NCT01928576|Experimental|Arm D|"Anti-PD-1/PD-L1 treatment naïve patients only~Every 28 days for 6 cycles Azacitidine 40mg/m2 days 1-5 and 8-10 Entinostat 5mg Days 3 and 10 Nivolumab 3mg/kg Days 1 and 15~Followed by:~Nivolumab 3mg/kg every 2 weeks until progression~After a patient has completed 6 months of nivolumab, they can receive nivolumab every 4 weeks instead of every 2 weeks. The dose for Nivolumab every 4 weeks is 480mg."
89592458|NCT01928576|Experimental|Arm E|"Patients must have had refractory (Arm E=less than 24 weeks from first dose of anti-PD-1/PD-L1) disease during or after anti-PD-1 or anti-PD-L1 therapy and, in the opinion of the investigator, must be unlikely to benefit from nivolumab monotherapy.~Every 28 days for 6 cycles Azacitidine 40mg/m2 days 1-5 and 8-10 Entinostat 5mg Days 3 and 10 Nivolumab 3mg/kg Days 1 and 15~Followed by:~Nivolumab 3mg/kg every 2 weeks until progression~After a patient has completed 6 months of nivolumab, they can receive nivolumab every 4 weeks instead of every 2 weeks. The dose for Nivolumab every 4 weeks is 480mg."
89608481|NCT04345276|Experimental|Danoprevir+Ritonavir group|
89608482|NCT02991352|Experimental|Experimental|Image guided needle placement into vascular malformations based on MRI
88977729|NCT00229801|No Intervention|MRI|
88977730|NCT04730687|Placebo Comparator|Traditional non-surgical mechanical therapy|Mechanical instrumentation in all groups continued with titanium Gracey curettes (8mm in diameter, Langer ½, item code: 7103, Kohler Medizintechnik, GmbH & Co, Ltd, Stockach, Germany) until the clinician gently felt that the surface was sufficiently debrided.There is no laser application. The laser tip is placed in the peri-implant sulcus but not activated.
88977731|NCT04730687|Active Comparator|Diode laser-assisted non-surgical mechanical therapy|1 week after mechanical debridment, 940 nm diode laser (Ezlase®, Biolase Technology, Inc., San Clemente, CA) has been applied with the aid of a 300 µm diameter optical fiber tip (E3-9 mm) placed approximately 1 mm above the most apical part of the peri implant pocket, parallel to the implant surface. Pocket irrigation was performed with 3% hydrogen peroxide solution for 10 seconds before and after diode laser application.The fiber was moved in apico-coronal and mesial-distal directions for a total of 30 seconds during laser light emission.The laser tip was checked every 7-8 seconds and wiped with sterile saline in order to prevent a possible coagulation or temperature increase.The laser was used in continuous pulse mode, at a power of 0.8 Watt (W), an energy density of 3J / cm2 and a spot diameter of 1 mm. Pulse width and pulse interval were applied as 20 milliseconds.
88977732|NCT04730687|Active Comparator|Er, Cr: YSGG laser-assisted non-surgical mechanical therapy|1 week after mechanical debridment, 2780 nm Er, Cr: YSGG laser (Waterlase®, Biolase Technology, Inc., San Clemente, CA), with 500 µm diameter fiberoptic periodontal tip (RFPT5-14 mm) was applied in short pulse '' H '' mode, water cooled with a non-contact sweeping motion for 30 seconds parallel to the implant surface.The settings used are: 1.5 W power, 30 Hz frequency, 50% water, 40% air, 140 s pulse duration and 1 cm spot size.
89592459|NCT01928576|Experimental|Arm F|"Patients must have had recurrent (Arm F=more than 24 weeks from first dose of anti-PD1/PD-L1) disease during or after anti-PD-1 or anti-PD-L1 therapy and, in the opinion of the investigator, must be unlikely to benefit from nivolumab monotherapy.~Every 28 days for 6 cycles Azacitidine 40mg/m2 days 1-5 and 8-10 Entinostat 5mg Days 3 and 10 Nivolumab 3mg/kg Days 1 and 15~Followed by:~Nivolumab 3mg/kg every 2 weeks until progression~After a patient has completed 6 months of nivolumab, they can receive nivolumab every 4 weeks instead of every 2 weeks. The dose for Nivolumab every 4 weeks is 480mg."
89592460|NCT01880060|Experimental|INCENT weight loss program|INCENT: The INCENT intervention is an internet-delivered weight loss program with periodic financial incentives for weight loss. INCENT participants receive daily e-mail support with nutritional and physical activity suggestions to enhance weight loss. Monetary incentives are earned on a quarterly basis for weight loss and participants receive monthly checks that reflect the percent weight loss. A regularly calibrated scale with a built in digital camera captures an image of the participant during a weigh-in, and is used to objectively obtain weight data from participants at each quarterly weigh-in.
89592461|NCT01880060|Experimental|Livin My Weigh|Livin My Weigh: The Livin My Weigh (LMW) intervention is an internet-delivered weight loss program without daily support or financial incentives. Participants receive quarterly newsletters with tips on weight loss, increasing physical activity, and menu suggestions, and optional quarterly educational sessions. Weight is measured in the same manner as the INCENT participants.
89592462|NCT01843751|Active Comparator|Physician Office|Buprenorphine/naloxone via physician office (B-PO) x 10 months
89592463|NCT01843751|Experimental|Specialist Center|Buprenorphine/naloxone via specialist center (B-SC) x 3 months followed by B-PO x 7 months. The specialist center in this trial will be a methadone clinic.
89592464|NCT01827527||Healthy Adult|This is a protocol development study, with no interventions or treatments.
89592465|NCT01815983|Experimental|Videolaryngoscopy review.|Video review.
89592466|NCT01756248||Group 1|
89592467|NCT01744652|Experimental|Arm A - Crizotinib + Dasatinib|"Arm A: Patients receive dose of crizotinib plus an increasing dose of dasatinib. All participants take dasatinib by mouth 1 time each day. Patients take this drug alone on Day 1 of Cycle 1, before the first day they receive the study drug combination. Final dose level in both arms (dose level number 5) is identical. In the case that both arms define dose level 5 as the MTD, then the expansion cohort for safety will include 10 patients with that dose. If two different MTDs on both arms defined, then both MTDs cohorts expanded with 10 patients and 20 patients included on the safety expansion analysis.~Crizotinib dose: 250 mg by mouth twice a day in a 28 day cycle. Dasatinib starting dose: 50 mg by mouth daily in a 28 day cycle.~Crizotinib Expansion dose: 250 mg by mouth twice a day in a 28 day cycle. Dasatinib Expansion Dose: MTD from dose escalation group."
89592468|NCT01744652|Experimental|Arm B - Dasatinib + Crizotinib|"Arm B: Patients receive dasatinib plus an increasing dose of crizotinib. All participants take dasatinib by mouth 1 time each day. Patients take this drug alone on Day 1 of Cycle 1, before the first day they receive the study drug combination. Final dose level in both arms (dose level number 5) is identical. In the case that both arms define dose level 5 as the MTD, then the expansion cohort for safety will include 10 patients with that dose. If two different MTDs on both arms defined, then both MTDs cohorts expanded with 10 patients and 20 patients included on the safety expansion analysis.~Dasatinib 140 mg by mouth daily in a 28 day cycle. Crizotinib starting dose: 250 mg by mouth every other day in a 28 day cycle.~Dasatinib Expansion Dose: 140 mg by mouth daily in a 28 day cycle. Crizotinib Expansion Dose: MTD from dose escalation group."
89592469|NCT01711541|Experimental|Arm I (veliparib, combination chemotherapy)|Patients receive veliparib PO BID on days 1-7, paclitaxel IV over 60 minutes on days 1, 8, and 15, and carboplatin IV over 30 minutes on day 1. Treatment repeats every 3 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. Patients then continue on to concomitant chemoradiotherapy.
89592470|NCT01711541|Experimental|Arm II (placebo, combination chemotherapy)|Patients receive placebo PO BID on days 1-7. Patients also receive paclitaxel and carboplatin as in Phase I. Treatment repeats every 3 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. Within 10 days from completion of course 2, patients begin concomitant chemoradiotherapy.
89592471|NCT01584102|Experimental|Group 1|
89592472|NCT01584102|Active Comparator|Group 2|
89592473|NCT01370512|Active Comparator|Placebo, Then Pyridostigmine|participants first receive placebo by mouth 3 times a day, for treatment day 1. Then participants receive pyridostigmine by mouth 3 times a day for treatment day 2.
89592474|NCT01370512|Active Comparator|Pyridostigmine, Then Placebo|participants first receive pyridostigmine by mouth 3 times a day, for treatment day 1. Then participants receive placebo by mouth 3 times a day for treatment day 2.
89592475|NCT01370512|Experimental|Drioxidopa and Placebo, Then Drioxidopa and Pyridostigmine|participants first receive placebo by mouth 3 times a day, for treatment day 3. Then participants receive Droxidopa by mouth 3 times a day for treatment day 4.
88977733|NCT04722094||Patients with Psoriasis|All patients pertaining to the Unit of Dermatology and affected by psoriasis will be screened for the inclusion in the study
88977734|NCT00230035|Experimental|1|high dose immunosuppressie therapy (HDIT) followed by HSCT (hemopoietic stem cell transplantation).
88977735|NCT00230035|Active Comparator|2|Currently available immunosuppressive/immunomodulatory therapy
88977736|NCT00063401|Experimental|1|Cetuximab 400 mg/m2 IV (over 120 minutes) on Day 1 of Cycle 1, followed by weekly maintenance doses of 250 mg/m2 IV (over 60 minutes). Paclitaxel 175 mg/m2 IC (over 3 hours) and carboplatin AUC of 6 IV (over 30 minutes) on Day 1 of each cycle. For eligible subjects, maintenance therapy will consist of cetuximab 250 mg/m2/week for up to 6 months.
88977737|NCT00230113|Active Comparator|1|
88977738|NCT00230113|Placebo Comparator|2|
88977739|NCT04721509|Experimental|Smartphone-based telemedicine|
88977740|NCT04721509|No Intervention|Conventional management without telemedicine|
88977741|NCT04730414||Age, Male, Female, ethnicity,|"The aim of the study is to be inclusive of all groups as to avoid bias. Furthermore, the study aims to determine if its formulation will encompass all skin types, genders and age groups.~Full-spectrum hemp dosage is determined to begin with 40mg - 2-3X/day = topical application; for a period of 2-3 months.~Drug: Full Spectrum hemp (0.018% THC), Topical Application Placebo = cream without hemp (Double blinded) One cream will be placed on one side of the face (R/L) and the other cream on the other side of the face."
89031003|NCT02946294|Active Comparator|modified pectoral nerves block|Modified pectoral nerves block with general anesthesia. Using the ultrasound, 10 ml of bupivacaine 0.25% with epinephrine 5 ug/ml will be injected in the plane between the pectoralis major and minor muscles. And another 20 ml of bupivacaine 0.25% with epinephrine 5 ug/ml will be injected in the plane between the pectoralis minor and the serratus anterior muscles.
89031004|NCT02946294|Active Comparator|serratus plane block|Serratus plane block with general anesthesia. Using the ultrasound, 0.4 ml of bupivacaine 0.25% with epinephrine 5 ug/ml will be injected in the plane between the serratus anterior muscle and the underlying ribs.
89031005|NCT05146349|Experimental|RETAIN Programming|The experimental group receives the full set of RETAIN intervention activities.
89031006|NCT05146349|No Intervention|Control|The control group does not receive the full set of RETAIN intervention activities.
89592476|NCT01370512|Experimental|Droxidopa and Pyridostigmine, Then Droxidopa and Placebo|participants first receive Droxidopa by mouth 3 times a day, for treatment day 3. Then participants receive Placebo by mouth 3 times a day for treatment day 4.
89031007|NCT05146232|Active Comparator|Opioid free group|After induction of aesthesia, anesthesia maintained by sevoflurane and continuous unfusion of lidocaine, ketamine, dexmeditomedine and Paracetamol.
89031008|NCT05146232|Active Comparator|Opioid based group|After induction of aesthesia, anesthesia maintained by continuous remifentanyl infusion
89592477|NCT00944632|Active Comparator|Zk 245186 0.01% ointment|Active treatment, lowest dose
89592478|NCT00944632|Active Comparator|ZK 245186 0.03% ointment|Active comparator middle dose
89592479|NCT00944632|Active Comparator|ZK 245186 0.1% ointment|Active comparator highest dose
89592480|NCT00944632|Placebo Comparator|Vehicle ointment|Placebo comparator
89592481|NCT00717795||1|Arm 1 - Physical Activity intervention
89592482|NCT00717795||2|Arm 2 - Wait-list control
89592483|NCT00584883|Experimental|ABT 510|The only arm will receive the ABT 510 following standard therapy with radiation and temozolomide chemotherapy concurrent.
89592484|NCT00279318||General Population, First Degree Relative|Newborns with high risk HLA in the general population or having a first-degree relative affected with T1DM.
89592485|NCT00179465|Active Comparator|Antipsychotic plus study drug|Half of the subjects will receive the study medications in addition to their ongoing antipsychotic regimen.
89592486|NCT00179465|Placebo Comparator|Antipsychotics plus placebo|Half of the subjects will receive placebo in addition to their antipsychotic regimen.
89592487|NCT00134030|Active Comparator|Maintenance therapy group 1 arm I|Patients receive doxorubicin IV continuously over 48 hours on days 1-2 in weeks 12, 17, 22, and 26 and cisplatin IV over 4 hours on days 1 and 2 in weeks 12 and 17. Patients also receive high-dose MTX IV over 4 hours on day 1 in weeks 15, 16, 20, 21, 24, 25, 28, and 29.
89592488|NCT00134030|Experimental|Maintenance therapy group 1 arm II|Patients receive doxorubicin, cisplatin, and high-dose MTX as in arm I. Patients than receive PEG-interferon alfa-2b subcutaneously once daily on day 1 in weeks 30-104.
89592489|NCT00134030|Active Comparator|Maintenance therapy group 2 arm I|Patients receive doxorubicin, cisplatin, and high-dose MTX as in group 1 arm I.
89592490|NCT00134030|Experimental|Maintenance therapy group 2 arm II|Patients receive doxorubicin IV continuously over 48 hours on days 1-2 in weeks 12, 20, 28, and 36 and cisplatin IV over 4 hours on days 1 and 2 in weeks 12 and 28. Patients also receive high-dose MTX IV over 4 hours on day 1 in weeks 15, 19, 23, 27, 31, 35, 39, and 40. Patients receive ifosfamide IV over 4 hours on days 1-5 in weeks 16, 24, and 32 and on days 1-3 in weeks 20 and 36 and etoposide IV over 1 hour on days 1-5 in weeks 16, 24, and 32.
89592491|NCT01382446|Active Comparator|Standard Oral Care Regimen|Current oral care protocol includes the use of 1.5% H2O2-coated swabs every four hours, toothbrushing with toothpaste every 12 hours, and use of continuous subglottic suction apparatus.
89592492|NCT01382446|Experimental|Chlorhexidine Oral Care Regimen|This study will compare our current oral care practice with the use of Chlorhexidine Gluconate 0.12% (Peridex, 3M Corporation) Twice daily in addition to regularly scheduled oral care as a means to decrease the incidence of VAP utilizing evidence-based strategies.
89592493|NCT01382212|Experimental|Paricalcitol|Open-label paricalcitol (maximum dose of 16 µg), 3 times weekly (no more frequently than every other day) for 12 weeks.
89592494|NCT01381900|Experimental|Canagliflozin 100mg|Each participant will receive 100 mg of canagliflozin once daily for 18 weeks with protocol-specified doses of metformin alone or metformin plus sulphonylurea.
89031009|NCT00525096|Placebo Comparator|Placebo|Aromasin + placebo in place of Celebrex
89031010|NCT00525096|Experimental|Celebrex|Aromasin + Celebrex
89031011|NCT05142176|Placebo Comparator|control group|will receive general anesthesia with bilateral sham erector spinae plane block at the level of T6 transverse process using 0.3 ml/kg normal saline on each side.
89031012|NCT05142176|Active Comparator|Erector spinae plane block group|will receive bilateral ultrasound-guided erector spinae plane block at the level of T6 transverse process using 0.3 ml/kg bupivacaine 0.25% (on each side) with a maximum dose of 2 mg/kg.
89592495|NCT01381900|Experimental|Canagliflozin 300mg|Each participant will receive 300 mg of canagliflozin once daily for 18 weeks with protocol-specified doses of metformin alone or metformin plus sulphonylurea.
89031013|NCT00525213|Active Comparator|A|
89031014|NCT00525213|Active Comparator|B|
89031015|NCT00525213|Active Comparator|C|
89031016|NCT00525213|Placebo Comparator|D|
89592496|NCT01381900|Placebo Comparator|Placebo|Each participant will receive matching placebo once daily for 18 weeks with protocol-specified doses of metformin alone or metformin plus sulphonylurea.
89592497|NCT01744665|Experimental|Treatment Free Remission|Patients entered a monitoring phase for 2 years and received 300 mg nilotinib mg bid. Patients who achieved MR4.5 entered a Consolidation Phase and were treated with nilotinib for 2 years. If MR4.5 was sustained during the Consolidation phase, patients were eligible to stop taking niltoinib during the treatment-free remission (TFR) phase.
89592498|NCT03025126|Experimental|HEAD Rehabilitation|rehabilitation with IT multimedial devices
89592499|NCT03025126|Active Comparator|Usual care program|usual care program
89592500|NCT01744197|Experimental|Arm 1|First application: Synera (lidocaine 70mg/tetracaine 70mg) patch; Second application: Placebo patch
89592501|NCT01744197|Experimental|Arm 2|First application: Placebo patch; Second application: Synera (lidocaine 70mg/tetracaine 70mg) patch
89592502|NCT05369416|Active Comparator|Low sodium diet|-Subjects will be randomized to start a low sodium diet (1200 mg/day) for two weeks (this will be followed by a high sodium diet - crossover design)
89592503|NCT05369416|Active Comparator|high sodium diet|-Subjects will be randomized to start a high sodium diet (4200 mg/day) for two weeks (this will be followed by a low sodium diet - crossover design)
89592504|NCT04565301|Placebo Comparator|Group C|The patients in this group will be administered 2 ml isotonic saline + 20 ml bupivacaine 0.50 % in the adductor canal block (control group).
89592505|NCT04565301|Active Comparator|Group D|The patients in this group will be administered 8 mg dexamethasone (2 ml) (23) as adjuvant to 20 ml bupivacaine 0.50 % in the adductor canal block.
89592506|NCT04565301|Active Comparator|Group N|The patients in this group will be administered 500 mcg neostigmine (1 ml) + 1 ml isotonic saline (22) as adjuvant to 20 ml bupivacaine 0.50 % in the adductor canal block.
89592507|NCT01732107|Experimental|Dovitinib|Dovitinib will be administered 500mg orally in a 5 days on, 2 days off dosing schedule.
89592508|NCT01743027|Experimental|AL-4943A|AL-4943A ophthalmic solution, 1 drop per eye Day 0, followed by 1 drop per eye Day 14
89592509|NCT01743027|Active Comparator|PATADAY|Olopatadine hydrochloride ophthalmic solution, 0.2%, 1 drop per eye Day 0, followed by 1 drop per eye Day 14
89592510|NCT01743027|Active Comparator|PATANOL|Olopatadine hydrochloride ophthalmic solution, 0.1%, 1 drop per eye Day 0, followed by 1 drop per eye Day 14
89592511|NCT01743027|Placebo Comparator|Vehicle|AL-4943A ophthalmic solution vehicle, 1 drop per eye Day 0, followed by 1 drop per eye Day 14
89592512|NCT01380730|Placebo Comparator|Placebo Q2W|Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.
89592513|NCT01380730|Placebo Comparator|Placebo Q4W|Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for 12 weeks.
89592514|NCT01380730|Experimental|Evolocumab 70 mg Q2W|Participants received 70 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
89592515|NCT01380730|Experimental|Evolocumab 105 mg Q2W|Participants received 105 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
89592516|NCT01380730|Experimental|Evolocumab 140 mg Q2W|Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
89592517|NCT01380730|Experimental|Evolocumab 280 mg Q4W|Participants received 280 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
89592518|NCT01380730|Experimental|Evolocumab 350 mg Q4W|Participants received 350 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
89592519|NCT01380730|Experimental|Evolocumab 420 mg Q4W|Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
89592520|NCT05364034|Experimental|Urban Afforestation Group|Participants will perform an afforestation activity with a duration of 90 minutes.
89592521|NCT04010968|Active Comparator|FCR|"FCR :~rituximab (R): 375 mg/m² IV D1 cycle 1 and 500 mg/m² IV D1 cycles 2 to 6.~fludarabine (F): 40 mg/m² orally, D2 to D4 - cycles 1 to 6.~cyclophosphamide (C): 250 mg/m² orally, D2 to D4 - cycles 1 to 6."
89592522|NCT04010968|Experimental|venetoclax and ibrutinib (I+VEN)|"ibrutinib: 420 mg/d orally, continuously from Month 1 to the end of treatment, either Month 15 or Month 27~venetoclax: stepwise weekly dose ramp-up beginning at Month 4 from a starting dose of 20 mg/d to the final dose of 400 mg/d (20, 50, 100, 200 and then 400 mg) over a 5 weeks, and then 400 mg/d continuously from Month 5 to the end of treatment, either Month 15 or Month 27."
89592523|NCT01395784|Placebo Comparator|Placebo Maintenance Period|Participants will complete the various outcome measures following a 2-3 week maintenance period on Placebo (PCB).
89592524|NCT01395784|Experimental|PIO 15 Maintenance Period|Participants will complete the various outcome measures following a 2-3 week maintenance period on Pioglitazone (PIO) 15 mg.
89592525|NCT01395784|Experimental|PIO 45 Maintenance Period|Participants will complete the various outcome measures following a 2-3 week maintenance period on Pioglitazone (PIO) 45 mg.
89592526|NCT01380184|Experimental|Ridaforolimus 40 mg|In Part 1 (Days 1-19), participants received ridaforolimus (MK-8669) 40 mg via oral enteric-coated tablet on Day 1; followed by no study treatment on Days 2-7; followed by two weekly sequences (Days 8-19) consisting of 5 consecutive days of ridaforolimus 40 mg and 2 consecutive days off study treatment. Following Part 1, participants underwent at least a 2-day study treatment washout prior to starting Part 2. In Part 2, participants received a weekly treatment regimen consisting of 5 consecutive days (Days 1-5) of ridaforolimus 40 mg via oral enteric-coated tablet and 2 consecutive days (Days 6-7) off study treatment. This weekly treatment regimen was repeated every subsequent week for the remainder of participation in Part 2.
89592527|NCT01395394|Experimental|BH4 Non-Responders|Participants in this group have PKU and were deemed unresponsive to the drug. They will attend their first study visit, and proceed through the meal challenge without BH4. They will then take BH4 for 2 weeks. The second meal challenge will be performed with the participant's final dose of BH4.
89592528|NCT01395394|Experimental|Healthy Controls|Participants in this group match an enrolled PKU participant in terms of age, gender, and body mass index class. They will participate in a single study visit and will not be given BH4.
89592529|NCT01395394|Experimental|BH4 Responders|Participants in this group will use their already prescribed BH4 with the meal challenge and be assessed at a single study visit. They will take their prescribed BH4 with the meal.
89592530|NCT05362552|Experimental|Urban Afforestation Group|Participants will perform an afforestation activity with a duration of 90 minutes.
89592531|NCT01395316|Experimental|Alemtuzumab|Single arm, single cohort study, all subjects will be dosed with alemtuzumab.
89592532|NCT04331938|Experimental|Open Label Arm|Patients will receive a 5mL injection comprised of 4.5mL 1% bupivacaine and 0.5mL of dexamethasone (10mg/mL) directed towards the sphenopalatine ganglion. This will be performed on both sides. Patients will be asked to rate their pain pre- and 30 minutes post-procedure on a scale of 0-10. Patients will also be asked to rate their nausea and photophobia on a similar scale. Patients will be reevaluated at 24 hours and 48 hours post procedure.
89592533|NCT05362084|Active Comparator|Oblique group|medial branch block with oblique group
89592534|NCT05362084|Placebo Comparator|Anteroposterior group|medial branch block with anteroposterior group
89592535|NCT01742091|Experimental|180 mg LY2541546 SC Q4W|180 milligram (mg) LY2541546 administered subcutaneous (SC) once every 4 weeks (Q4W) for 8 weeks. Placebo administered SC at Weeks 2 and 6 to maintain the blind.
89592536|NCT01742091|Experimental|270 mg LY2541546 SC Q2W|270 mg LY2541546 administered (SC) once every 2 weeks (Q2W) for 8 weeks.
89592537|NCT01742091|Experimental|270 mg LY2541546 SC Q4W|270 mg LY2541546 administered (SC) once every 4 weeks (Q4W) for 8 weeks. Placebo administered SC at Weeks 2 and 6 to maintain the blind.
89592538|NCT01742091|Experimental|540 mg LY2541546 IV Q4W|540 mg administered intravenous (IV) once every 4 weeks (Q4W) for 8 weeks. Placebo administered IV at Weeks 2 and 6 to maintain the blind.
89592539|NCT01742091|Experimental|750 mg LY2541546 IV Q2W|750 mg administered (IV) once every 2 weeks (Q2W) for 8 weeks.
89592540|NCT01742091|Placebo Comparator|Placebo Q2W|Placebo administered IV or SC once every 2 weeks for 8 weeks.
89592541|NCT01731951|Experimental|Arm A: Imetelstat 9.4 mg/kg (Myelofibrosis [MF])|Participants with MF regardless of spliceosome mutation status or presence of ring sideroblasts received imetelstat 9.4 milligram per kilogram (mg/kg), intravenously (IV) as 2-hour infusion on Day 1 of each 21-day cycle in Core Phase up to 9 cycles. Participants could receive imetelstat beyond Cycle 9 in the Extension Phase if they did not meet any of the withdrawal criteria, did not have disease progression and were receiving clinical benefit from treatment as determined by the investigator. Following treatment discontinuation, participants entered the Event Monitoring Phase for collection of survival status, disease status, and subsequent treatment information (Up to approximately 5.7 years).
89592542|NCT01731951|Experimental|Arm B: Imetelstat 9.4 mg/kg as Induction + Maintenance (MF)|Participants with MF regardless of spliceosome mutation status or presence of ring sideroblasts received imetelstat 9.4 mg/kg, IV as 2-hour infusion on Days 1, 8, and 15 of 21-day cycle in Cycle 1 followed by 9.4 mg/kg on Day 1 of each 21-day cycle up to 9 cycles in the Core Phase. Participants could receive imetelstat beyond Cycle 9 in the Extension Phase if they did not meet any of the withdrawal criteria, did not have disease progression and were receiving clinical benefit from treatment as determined by the investigator. Following treatment discontinuation, participants entered the Event Monitoring Phase for collection of survival status, disease status, and subsequent treatment information (Up to approximately 5.7 years).
88977742|NCT00096915|Experimental|darbepoetin alfa|
88977743|NCT02962219|Experimental|Intervention|A pre-operative personalised exercise programme (my-PEP).
88977744|NCT02962219|Other|Control|Standard care
88977745|NCT00230542|Experimental|Carboplatin / Pemetrexed|Single Arm Study Carboplatin AUC 5 Pemetrexed 500 mg/m2
88977746|NCT02962336|Experimental|Test|Torrent's Olmesartan medoxomil, Amlodipine and Hydrochlorothiazide (40+10+25) mg Tablets
88977747|NCT02962336|Active Comparator|Reference|Tribenzor (40+10+25) mg Tablets of Daichi Sankyo Inc, USA
88977748|NCT02967614|Experimental|[A]→[A]+[B]|"Period 1 : At each dosing of Treatment A eye drops is administered for 8days~Period 2 : At each dosing of Treatment A + Treatment B eye drops is administered for 92days"
88977749|NCT02967614|Experimental|[B]→[A]+[B]|"Period 1 : At each dosing of Treatment B eye drops is administered for 92days~Period 2 : At each dosing of Treatment A + Treatment B eye drops is administered for 8days"
88977750|NCT00230815|Experimental|Follitropin alfa injected by Pen device|
88977751|NCT04721587|No Intervention|Standard of care|Office hysteroscopy performed as the standard of care of our Hospital
88977752|NCT04721587|Experimental|Virtual Reality|Office hysteroscopy with the use of VR environment (preprocedure and during procedure)
88977753|NCT02967380|Experimental|Diagnostic (Magnevist/Multihance, Gadavist, DCE-MRI)|Patients receive standard of care gadopentetate dimeglumine IV twice within 5 minutes or gadobenate dimeglumine IV twice within 5 minutes and then undergo DCE-MRI on day 1. Patients also receive gadobutrol IV twice within 5 minutes and then undergo DCE-MRI over approximately 30 minutes on day 3, 4, 5, 6, or 7.
88977754|NCT00230932||Group 1|outpatients selected from random visits in primary care, oncology, and cardiology clinics
88977755|NCT04721782||otherwise healthy, smoking, singleton pregnant women between 24- 36 weeks|Fetal liver circulation will be evaluated with doppler ultrasound, The degree of maternal smoking will be assessed by measuring urine cotinine and exhaled carbon monokside levels
88977756|NCT04721782||otherwise healthy, non-smoking, singleton pregnant women between 24- 36 weeks|Fetal liver circulation will be evaluated with doppler ultrasound, The degree of maternal smoking will be assessed by measuring urine cotinine and exhaled carbon monokside levels
88977757|NCT00075855|Experimental|testosterone|"Patients receive topical testosterone once daily for 4 weeks. After 4 weeks, patients cross over to the other treatment arm.~Changes in sexual functioning, mood states, and medical outcome vitality are assessed at baseline and then at the end of weeks 4 and 8.~Patients who continue or restart testosterone cream after the 8-week study period are followed at 6 months."
88977758|NCT00075855|Other|placebo|"Patients receive a topical placebo once daily for 4 weeks. After 4 weeks, patients cross over to the other treatment arm.~Changes in sexual functioning, mood states, and medical outcome vitality are assessed at baseline and then at the end of weeks 4 and 8.~Patients who continue or restart testosterone cream after the 8-week study period are followed at 6 months."
88977759|NCT00231166|Experimental|HCD122|
88977760|NCT00231244|Experimental|1|CYPHER Sirolimus-Eluting Coronary Stent
88977761|NCT04721470|Experimental|Combined therapy|Patients undergoing combined therapy
88977762|NCT04721470|Active Comparator|Transarterial chemoembolization|Patients undergoing Transarterial chemoembolization
88977763|NCT04721470|Active Comparator|Microwave ablation|Patients undergoing Microwave ablation
88977764|NCT00231673|Experimental|001|Topiramate Increasing dosing of topiramate gradually to 200 mg daily by mouth dose maintenance for 12 weeks then decreasing dose until stopped over 12 weeks
88977765|NCT00231790|Experimental|MK-0634 50 mg|All participants will receive placebo for the 1 week prior to randomization
88977766|NCT00231790|Experimental|MK-0634 125 mg|All participants will receive placebo for the 1 week prior to randomization
88977767|NCT00231790|Experimental|MK-0634 375 mg|All participants will receive placebo for the 1 week prior to randomization
88977768|NCT00231790|Placebo Comparator|Placebo|All participants will receive placebo for the 1 week prior to randomization
88977769|NCT00231907|Active Comparator|Vaccine 1: TIV. Vaccine 2: TIV.|Vaccine 1: TIV. Vaccine 2: TIV.
88977770|NCT00231907|Experimental|Vaccine 1: LAIV. Vaccine 2: TIV.|Vaccine 1: LAIV. Vaccine 2: TIV.
88977771|NCT00231907|Experimental|Vaccine 1: LAIV. Vaccine 2: LAIV.|Vaccine 1: LAIV. Vaccine 2: LAIV.
89592543|NCT01731951|Experimental|Arm D: Imetelstat 9.4 mg/kg (Blast-phase MF/Acute Myeloid Leukemia)|Participants with blast-phase myelofibrosis/acute myeloid leukemia (MF/AML) received imetelstat 9.4 mg/kg, IV as 2-hour infusion weekly on Days 1, 8, 15, 22 of a 28-day cycle up to 9 cycles in the Core Phase. Participants could receive imetelstat beyond Cycle 9 in the Extension Phase if they did not meet any of the withdrawal criteria, did not have disease progression and were receiving clinical benefit from treatment as determined by the investigator. Following treatment discontinuation, participants entered the Event Monitoring Phase for collection of survival status, disease status, and subsequent treatment information (Up to approximately 5.7 years).
89592544|NCT01731951|Experimental|Arm E: Imetelstat 7.5 - 9.4 mg/kg (MF [with Spliceosome Mutation or Ring Sideroblasts])|Participants with MF and spliceosome mutations or ring sideroblasts present received 2 cycles (Cycles 1-2) of imetelstat 7.5 mg/kg, IV as 2-hour infusion on Day 1 of a 28-day cycle followed by maintenance therapy with the same regimen or the possibility of dose escalation to imetelstat 9.4 mg/kg weekly if response to the initial dose was insufficient up to 9 cycles in the Core Phase. Participants could receive imetelstat beyond Cycle 9 in the Extension Phase if they did not meet any of the withdrawal criteria, did not have disease progression and were receiving clinical benefit from treatment as determined by the investigator. Following treatment discontinuation, participants entered the Event Monitoring Phase for collection of survival status, disease status, and subsequent treatment information (Up to approximately 5.7 years).
89592545|NCT01731951|Experimental|Arm F: Imetelstat 7.5 - 9.4 mg/kg (MF [without spliceosome mutation and ring sideroblasts])|Participants with MF without spliceosome mutations or ring sideroblasts present received 2 cycles (Cycles 1-2) of imetelstat 9.4 mg/kg, IV as 2-hour infusion on Day 1 of a 28-day cycle followed by maintenance therapy with the same regimen or imetelstat 7.5 mg/kg twice weekly on Days 1, 3 for 2 cycles of 28-day cycle (Cycles 3-4) followed by imetelstat 7.5 mg/kg 3-times-weekly on Days 1, 3, 5 of Cycles 5 and beyond of 28-day cycle up to 9 cycles in the Core Phase. Participants could receive imetelstat beyond Cycle 9 in the Extension Phase if they did not meet any of the withdrawal criteria, did not have disease progression and were receiving clinical benefit from treatment as determined by the investigator. Following treatment discontinuation, participants entered the Event Monitoring Phase for collection of survival status, disease status, and subsequent treatment information (Up to approximately 5.7 years).
89592546|NCT01731951|Experimental|Arm G: Imetelstat 7.5 - 9.4 mg/kg (MDS/MPN or MDS with Spliceosome Mutations or Ring Sideroblasts)|Participants with either myelodysplastic syndromes/ myeloproliferative neoplasm (MDS/MPN) or MDS and spliceosome mutations or ring sideroblasts present received 2 cycles of 28-day cycle (Cycles 1-2) of imetelstat 7.5 mg/kg, IV as 2-hour infusion on Day 1 of a 28-day cycle followed by maintenance therapy with the same regimen or the possibility of dose escalation to imetelstat 9.4 mg/kg weekly if response to the initial dose was insufficient up to 9 cycles in the Core Phase. Participants could receive imetelstat beyond Cycle 9 in the Extension Phase if they did not meet any of the withdrawal criteria, did not have disease progression and were receiving clinical benefit from treatment as determined by the investigator. Following treatment discontinuation, participants entered the Event Monitoring Phase for collection of survival status, disease status, and subsequent treatment information (Up to approximately 5.7 years).
89592547|NCT04560777|Experimental|experimental arm|CO-OP intervention
89592548|NCT01731171|Experimental|Probiotic Supplement|The probiotic supplement compound will consist of capsules containing approximately 10^8 colony forming units of the probiotic organisms, LactobacillusGG and Bifidobacteria lactis strain Bb12. The capsule, which will be swallowed, is a size 3 opaque, hard, hypromellose capsule. The participant will be asked to take 1 capsule of the probiotic supplement with a meal or with a snack daily for 24 weeks.
89592549|NCT01731171|Placebo Comparator|Inert Compound|The inert compound placebo looks identical to the probiotic supplement, and participants will be instructed to swallow 1 capsule with a meal or with a snack daily for 24 weeks.
89592550|NCT01741701|Experimental|Oxaloacetate (OAA)|active capsule containing 100 mg OAA and 100 mg ascorbate, taken daily
89592551|NCT01741701|Placebo Comparator|Placebo|placebo capsules that contain only 100 mg ascorbate, taken daily
89592552|NCT01741545|Experimental|Cohort A: Genotype-2,-3 (Lambda/RBV/DCV)|"Lambda 180 μg solution for subcutaneous (SC) injection, once weekly for 12 weeks~Ribavirin (RBV) 200 mg tablet by mouth (oral), twice daily for 12 weeks~Daclatasvir (DCV) 60mg tablet by mouth (oral), once daily for 12 weeks"
89592553|NCT01741545|Experimental|Cohort B: Genotype-1b,-4 (Lambda/RBV/DCV)|"Lambda 180 μg solution for subcutaneous (SC) injection, once weekly for 24 weeks~Ribavirin (RBV) 200 mg tablet by mouth (oral), twice daily for 24 weeks~Daclatasvir (DCV) 60mg tablet by mouth (oral), once daily for 12 weeks"
89592554|NCT01884350|Experimental|Arm 1: Apixaban (Primary SOC information)|Apixaban 2.5 mg or 5 mg by mouth twice daily for 48 weeks and Primary Standard of Care (SOC) information
88977772|NCT00231907|Experimental|Vaccine 1: TIV. Vaccine 2: LAIV.|Vaccine 1: TIV. Vaccine 2: LAIV.
88977773|NCT00231985|Placebo Comparator|1|Participants will receive supportive psychotherapy.
88977774|NCT00231985|Active Comparator|2|Participants will receive habit reversal therapy.
88977775|NCT00232219|No Intervention|Control|No fish oil exposure
88977776|NCT00232219|Experimental|Fish oil|Patients given 6g/day of fish oil containing 1.8g/d of EPA+DHA in a 1.5:1 ratio.
88977777|NCT00097227|Active Comparator|Arm A (3-week cycle)|"Cetuximab was administered weekly at an initial dose (Week 1) of 400 mg/m2 IV infusion and a weekly maintenance dose of 250 mg/m2 IV infusion.~Paclitaxel 225 mg/m2 infused over 180 minutes on Day 1 and subsequently every 3 weeks.~Carboplatin (AUC = 6) was infused over 30 minutes on Day 1 and subsequently every 3 weeks."
88977778|NCT00097227|Active Comparator|Arm B (4-week cycle)|"Cetuximab was administered weekly at an initial dose (Week 1) of 400 mg/m2 IV infusion and a weekly maintenance dose of 250 mg/m2 IV infusion.~Paclitaxel 100 mg/m2 infused over 180 minutes on Day 1, Day 8 and Day 15 of a 4-week cycle.~Carboplatin (AUC = 6) was infused over 30 minutes on Day 1 and subsequently every 4 weeks."
88977779|NCT00232492|Placebo Comparator|Placebo males|Saline physiological placebo males
88977780|NCT00232492|Active Comparator|Ketamine 0,1 mg/kg males|0,1 mg/kg ketamine males
88977781|NCT00232492|Active Comparator|Ketamine 0,3 mg/kg males|0,3 mg/kg ketamine males
88977782|NCT00232492|Active Comparator|Ketamine 0,5 mg/kg males|0,5 mg/kg ketamine males
88977783|NCT00232492|Placebo Comparator|Placebo females|Saline physiological as placebo females
89592555|NCT01884350|Experimental|Arm 2: Apixaban (Additional Educational Program)|Apixaban 2.5 mg or 5 mg by mouth twice daily for 48 weeks and Additional Educational Program
89592556|NCT01614795|Experimental|Treatment (cixutumumab, temsirolimus)|Patients receive cixutumumab IV over 1 hour and temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 25 courses in the absence of disease progression or unacceptable toxicity.
89592557|NCT01834586|Other|Anesthetic Topical Adhesive Synera|"Anesthetic Topical Adhesive Synera. For subjects taking interferon beta subcutaneous (Betaseron, Extavia or Rebif) apply one patch 60 minutes prior to each injection (every-other day or three times per week) for two weeks, then 30 minutes prior for two weeks.~For subjects taking glatiramer acetate subcutaneous (Copaxone) apply one patch 60 minutes prior to each injection (daily) for one week and then 30 minutes prior for one week."
89592558|NCT01614249|Placebo Comparator|Soybean oil soft gels|Participants on this arm will receive a dietary supplement of OmegaVia soybean oil soft gels as a placebo for 8 weeks with bi-weekly follow-up visits to monitor side effects and compliance.
89592559|NCT01614249|Experimental|Fish oil omega-3 EPA-rich soft gels|Participants will receive OmegaVia fish oil omega-3 EPA-rich soft gels to take orally for eight (8) weeks with bi-weekly follow-up visits for monitoring of side effects and compliance and data collection.
89592560|NCT01597778|Experimental|Haploidentical Bone Marrow Transplant|Participants will receive haploidentical bone marrow transplant using a reduced intensity conditioning regimen.
89592561|NCT01597778|Experimental|Double Umbilical Cord Blood Transplant|Participants will receive a double umbilical cord blood transplant using a reduced intensity conditioning regimen.
89592562|NCT01614093|Active Comparator|Oxytocin/Placebo|Each participant will receive intranasal oxytocin 24IU or intranasal saline 24IU in random order. All results will be reported by treatment, the sample is too small for order effects.
89592563|NCT01614093|Active Comparator|Placebo/Oxytocin|Each participant will receive intranasal oxytocin 24IU or intranasal saline 24IU in random order. All results will be reported by treatment, the sample is too small for order effects.
89592564|NCT01834274|Experimental|Fasiglifam 50 mg|Fasiglifam (TAK-875) 50 mg tablets, orally, once daily, Sitagliptin placebo-matching tablets, orally, once daily, and metformin stable dose ≥1500 mg (or maximum-tolerated dose), tablets, orally, daily for up to 24 weeks.
89608483|NCT01278628|Experimental|Lifestyle modification|
88977784|NCT00232492|Active Comparator|Ketamine 0.1 mg/kg females|0,1 mg/kg ketamine females
88977785|NCT00232492|Active Comparator|Ketamine 0,3 mg/kg females|0,3 mg/kg ketamine females
88977786|NCT00232492|Active Comparator|Ketamine 0,5 mg/kg females|0,5 mg/kg ketamine females
88977787|NCT02962531|Experimental|Treatment A|A single 1600 mg (4 x 400 caplets) oral dose of IX-01 under fasted conditions
88977788|NCT02962531|Experimental|Treatment B|A single 1600 mg (4 x 400 caplets) oral dose of IX-01 under fed conditions
88977789|NCT02962531|Experimental|Treatment C|A single 1600 mg aqueous dispersion (20 mL) oral dose of IX-01 under fasted conditions.
88977790|NCT00097266|Placebo Comparator|A|
88977791|NCT00097266|Experimental|B|
88977792|NCT00097266|Active Comparator|C|
88977793|NCT00063947|Experimental|Treatment (radiotherapy, gemcitabine, erlotinib hydrochloride)|Chemoradiotherapy: Patients undergo radiotherapy 5 days a week for 5.5 weeks. Beginning on day 1 and continuing concurrently with radiotherapy, patients receive gemcitabine IV over 30 minutes twice weekly and oral erlotinib once daily. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients with stable or responsive disease proceed to maintenance therapy. Maintenance therapy: Beginning 4-7 weeks after the completion of chemoradiotherapy, patients receive maintenance chemotherapy comprising gemcitabine IV over 30 minutes on days 1 and 8 and oral erlotinib once daily. Treatment repeats every 21 days for a total of 4 courses in the absence of disease progression or unacceptable toxicity.
88977794|NCT00232687|Active Comparator|A1|
88977795|NCT00232687|Active Comparator|A2|
88977796|NCT02967185|Experimental|Brief Behavioral Therapy for Insomnia|Treatment will consist of 4 weekly, 1 hour sessions and will be conducted by a trained graduate assistant on an individual basis.
88977797|NCT02967185|No Intervention|Waitlist Control|Participants in this group will receive no intervention, but will complete the same set of assessments as those in the Experimental Group. They will be given the option of receiving the behavioral treatment program at no charge.
88977798|NCT00232765|Experimental|1|Cypher Bx Velocity
88977799|NCT00232765|Active Comparator|2|Uncoated Bx Velocity
88977800|NCT00232804|Other|1|
88977801|NCT00232843|Experimental|1|Cordis SMART™ nitinol self-expanding stent.
88977802|NCT00232843|Active Comparator|2|balloon angioplasty
88977803|NCT02958566|Active Comparator|Narcotic|"Morphine, Dilaudid or Fentanyl patient controlled anesthesia (PCA) for the immediate postoperative period, in addition to Norco 5-325 mg 1-2 tabs Q4H PRN, or equivalent medication.~Post-operative day 1: PCA will be discontinued and the patients will have IV narcotics PRN: Morphine 1-2 mg Q2H PRN, fentanyl 50-75 mcg Q2H PRN or Dilaudid 0.5 mg Q2H PRN"
88977804|NCT02958566|Experimental|Non-Narcotic|Gabapentin 300 mg PO, orphenadrine 60 mg IV, acetaminophen 1000 mg PO or IV on Morning of surgery. Lidocaine 100 mg prior to incision, lidocaine 1mg/kg/hour during procedure, marcaine in all incisions. Ketamine and methadone per anesthesia. Acetaminophen 1000 mg PO or IV, gabapentin 300 mg PO, tramadol 50 mg PO in PACU. Acetaminophen 600 mg PO Q 6 hours, tramadol 50 mg PO Q 6 hours, gabapentin 300 mg PO Q 6 hours, orphenadrine 60 mg IV Q 12 hours, ketorolac 15 mg IV Q 6 hours for 48 hours post-operatively.
88977805|NCT00232882|Active Comparator|1|Candesartan 16 mg for 4 weeks followed by candesartan 16 mg and hydrochlorothiazide 12.5 mg for 4 weeks
88977806|NCT00232882|Active Comparator|2|Atenolol 100 mg for 4 weeks followed by atenolol 100 mg + hydrochlorothiazide 12.5 mg for 4 weeks
88977807|NCT00232882|Active Comparator|3|Thiazide 25 mg for 4 weeks then added with Candesartan 16 mg
88977808|NCT00413647|Experimental|CardioPET|
88977809|NCT00413686|Experimental|1|AZD7762 monotherapy followed by AZD7762 + gemcitabine
88977810|NCT00233077|Experimental|Behavioral: Patient Assistance|Patient assistance programs
88977811|NCT00233077|Other|Control: Information only|Control patients will be sent a pamphlet about breast cancer & its treatment. We will call all patients 2 weeks later and ask if they received the packet. If they didn't, we will send the packet again.
88977812|NCT00064103|Experimental|Treatment (Ad5CMV-p53 gene)|"Phase I: Patients receive Ad5CMV-p53 gene by intramucosal injection into the area of the lesion followed at least 2 hours later by Ad5CMV-p53 gene as an oral rinse on day 1. Patients then receive Ad5CMV-p53 gene as an oral rinse twice daily on days 2-5. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of Ad5CMV-p53 gene as an oral rinse until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.~Phase II: Patients receive treatment with intramucosal Ad5CMV-p53 gene as in phase I and Ad5CMV-p53 gene as an oral rinse at the MTD."
89592565|NCT01834274|Active Comparator|Sitagliptin 100 mg|Sitagliptin 100 mg, tablets, once daily, TAK-875 placebo-matching tablets, orally, once daily, and metformin stable dose ≥1500 mg (or maximum-tolerated dose), tablets, orally, daily for up to 24 weeks.
89592566|NCT01739595|Experimental|Androxal 12.5 mg|Androxal (enclomiphene citrate), 12.5 mg oral capsules taken once daily
89592567|NCT01739595|Experimental|Androxal 25 mg|Androxal (enclomiphene citrate), 25 mg oral capsules taken once daily
89592568|NCT01739595|Placebo Comparator|Placebo|Placebo oral capsules taken one time daily
89592569|NCT01833494|Experimental|PA21|
89592570|NCT01738971|No Intervention|control (standard care)|standard verbal and written advice on contraception from pharmacy
89592571|NCT01738971|Experimental|rapid access|rapid access to family planning service
89592572|NCT01738971|Experimental|progestogen only pill|one month progestogen only pill
89592573|NCT01738581|Experimental|rTMS + SMR, then rTMS + CTL|First phase of treatment: Repetitive transcranial magnetic stimulation (rTMS) and sensorimotor retraining (SMR). Second phase of treatment: rTMS and control treatment (CTL) (CTL therapy consisted of non-specific therapy that includes stretching, massage, range of motion).
89592574|NCT01738581|Experimental|rTMS + CTL, then rTMS + SMR|First phase of treatment: Repetitive transcranial magnetic stimulation (rTMS) with non-specific therapy that includes stretching, massage, range of motion. Second phase of treatment: rTMS and sensorimotor retraining (SMR).
89592575|NCT01738503|Experimental|(8 mg) RBP-6000: 50 mg|Participants are stabilized by day -5 on Subutex 8 mg. During the study, four subcutaneous (SC) injections containing RBP-6000 50 mg are given at 28 day intervals.
88977813|NCT00233194||Cohort 2|Children scheduled for adenotonsillectomy and healthy subjects, for comparison, not scheduled for such surgery.
88977814|NCT00064142|Experimental|Arm I (halofuginone hydrobromide)|Patients apply topical halofuginone hydrobromide ointment to each of 6 lesions twice a day for 12 weeks.
88977815|NCT00064142|Placebo Comparator|Arm II (placebo)|Patients apply topical placebo ointment to each of 6 lesions twice a day for 12 weeks.
88977816|NCT00233506|Experimental|CPG 7909 IV|Intravenous infusions will be administered with a standard infusion pump beginning at 125 cc/hr through an intravenous catheter (central or peripheral).
88977817|NCT00233506|Experimental|CPG 7909 SQ|Subcutaneous injections should be administered in the abdominal wall, upper arm, hip, or anterior thigh. If the volume of injection exceeds 1.5 ml, the volume should be divided into equal injections at a volume less than 1.5 ml and administered in different areas of the body. The maximum dose level on this trial may require 5 - 6 injections at an equal number of sites.
88977818|NCT00233818|Other|1|
88977819|NCT00076206|Experimental|A|CCI-779 1 mg dose to be taken orally daily up to 12 weeks.
88977820|NCT00076206|Experimental|B|CCI-779 2 mg dose to be taken orally daily up to 12 weeks.
88977821|NCT00076206|Experimental|C|CCI-779 4 mg dose to be taken orally daily up to 12 weeks.
88977822|NCT00076206|Placebo Comparator|D|Placebo dose to be taken orally daily up to 12 weeks.
89592576|NCT01738503|Experimental|(12 mg) RBP-6000: 100 mg|Participants are stabilized by day -5 on Subutex 12 mg. During the study, four subcutaneous (SC) injections containing RBP-6000 100 mg are given at 28 day intervals
89592577|NCT01738503|Experimental|(24 mg) RBP-6000: 200 mg|"Participants are stabilized by day -5 on Subutex 24 mg. During the study, four subcutaneous (SC) injections containing RBP-6000 200 mg are given at 28 day intervals.~Participants who receive RBP-6000 containing 200 mg buprenorphine and reach Day 112 (and have received all 4 planned SC injections) have the option to participate in the Positron Emission Tomography (PET) Pilot substudy. In the PET Pilot sub-study participants remain on 200 mg SC injections at 28 day intervals for an additional 6-9 intervals until they complete an magnetic resonance imaging (MRI) and a PET scan and pharmacokinetic samples at week 1 and week 4 post injection."
88977823|NCT02958683||Pectus excavatum|Patients with pectus excavatum (funnel chest) condition undergo chest wall motion analysis
88977824|NCT02958683||Pectus carinatum|Patients with pectus carinatum (pigeon chest) condition undergo chest wall motion analysis
88977825|NCT02958683||Chronic obstructive pulmonary disease|Patients affected by COPD undergo chest wall motion analysis
88977826|NCT02958683||Diaphragm abnormality|Patients with abnormal function or structure of the diaphragm. Including diaphragmatic hernia/rupture and diaphragmatic paralysis undergo chest wall motion analysis
88977827|NCT02958683||Healthy control|People who do not have any diagnosed thoracic condition and who do not have symptoms/signs suggestive of undiagnosed thoracic disease undergo chest wall motion analysis
88977828|NCT02958683||Lung cancer|Patients with suspected or confirmed lung malignancy of all histological subtypes undergo chest wall motion analysis
89592578|NCT01738503|Experimental|(8 mg) RBP-6000: 100 mg|Participants are stabilized by day -5 on Subutex 8 mg. During the study, four subcutaneous (SC) injections containing RBP-6000 100 mg are given at 28 day intervals.
89592579|NCT01738503|Experimental|(14 mg) RBP-6000: 200 mg|"Participants are stabilized by day -5 on Subutex 14 mg. During the study, four subcutaneous (SC) injections containing RBP-6000 200 mg are given at 28 day intervals.~Participants who receive RBP-6000 containing 200 mg buprenorphine and reach Day 112 (and have received all 4 planned SC injections) have the option to participate in the Positron Emission Tomography (PET) Pilot substudy. In the PET Pilot sub-study participants remain on 200 mg SC injections at 28 day intervals for an additional 6-9 intervals until they complete an magnetic resonance imaging (MRI) and a PET scan and pharmacokinetic samples at week 1 and week 4 post injection."
89592580|NCT01738503|Experimental|(8-24 mg) RBP-6000: 300 mg|Participants are stabilized by day -5 on a Subutex between 8-24 mg. During the study, four subcutaneous (SC) injections containing RBP-6000 300 mg are given at 28 day intervals.
89592581|NCT01738191|Active Comparator|Atomoxetine|The study drug target dose is Atomoxetine (ATM) 80 milligram (mg) per day; given as a once daily dose of an 80mg capsule. Patients will titrate up to target dose by starting on ATM 40mg capsules: 1 capsule daily for 14 days. Following study visit 3 (after 2 weeks on the titration dose), patients will increase the dose of ATM to 80mg daily.
89592582|NCT01738191|Placebo Comparator|Placebo|Patients in the placebo arm will follow the same titration schedule as those in the active arm. Patients will titrate up to target dose by starting 40mg capsules: 1 capsule daily for 14 days. Following study visit 3 (after 2 weeks on the titration dose), patients will increase the dose to 80mg daily.
89592583|NCT01737879|Experimental|Peginesatide / Epoetin Alfa|Participants were treated with peginesatide administered intravenously (IV) every 4 weeks for 24 weeks. Participants were then to be converted back to epoetin alfa administered by IV 3 times a week for 32 weeks.
89592584|NCT01879683|Experimental|LiRIS® 400 mg|LiRIS® 400 mg (Lidocaine Releasing Intravesical System 400 mg); a drug-device combination product, placed in the urinary bladder, and releases lidocaine into the bladder over a 14 day period.
89592585|NCT04415307|Experimental|Acupuncture|Acupuncture over acupoints.
89592586|NCT04415307|Experimental|Far-Infrared|Far-Infrared heat-patch attachment over acupoints.
89592587|NCT04415307|Experimental|Combination of Acupuncture and Far-Infrared|Acupuncture and Far-Infrared heat-patch attachment over acupoints.
89592588|NCT04415307|Placebo Comparator|Placebo (no Acupuncture nor Far-Infrared)|Far-Infrared heat-patch attachment over acupoints without electric current passing.
89592589|NCT01605825|Placebo Comparator|placebo/dalfampridine-ER|"Subjects will be randomized at day 1 to one of two blinded treatment sequences (A or B) in a 2:1 ratio respectively, according to a randomization created prior to the start of the study:~Period 1 = days 1, 8 and 15. Period 2 = Days 22, 29, and 36"
89592590|NCT01605825|Placebo Comparator|dalfampridine-ER/placebo|"Subjects will be randomized at day 1 to one of two blinded treatment sequences (A or B) in a 2:1 ratio respectively, according to a randomization created prior to the start of the study:~Period 1 = days 1, 8 and 15. Period 2 = Days 22, 29, and 36"
89592591|NCT04558905|Active Comparator|Usual Medical Care Model|All the patients will receive face-to-face medical visits
89592592|NCT04558905|Experimental|Hybrid Medical Care Model|The patients will receive alternating face-to-face medical visits and video medical consultations
89608484|NCT00731614|Experimental|Arm 1|Cognitive Behavior Therapy + mirror retraining
89608485|NCT00731614|Active Comparator|Arm 2|Supportive psychotherapy
88977829|NCT02958683||Pleural disease|Patients with pleural thickening and/or pleural effusion, pneumothorax, empyema undergo chest wall motion analysis
88977830|NCT02958683||Asthma|Patients diagnosed with asthma clinically or upon spirometry undergo chest wall motion analysis
88977831|NCT02958683||Cystic fibrosis|Patients diagnosed with cystic fibrosis clinically or biochemically undergo chest wall motion analysis
88977832|NCT02958683||Rib or sternal disease|Patients with an abnormality in the chest wall including fractures, osteomyelitis, malignancy of all histological subtypes, chest wall resection/reconstruction undergo chest wall motion analysis
88977833|NCT00233935|Experimental|Arm I (1 capsule)|Patients receive 1 capsule of defined green tea catechin extract PO BID for the next 6 months.
88977834|NCT00233935|Experimental|Arm II (2 capsules)|Patients receive 2 capsules of defined green tea catechin extract PO BID for the next 6 months.
88977835|NCT00233935|Experimental|Arm III (3 capsules)|Patients receive 3 capsules of defined green tea catechin extract PO BID for the next 6 months.
88977836|NCT00233935|Placebo Comparator|Arm IV (placebo)|Patients receive 1-3 capsules of placebo PO BID for the next 6 months.
88977837|NCT00233974|Experimental|PET negative|Traditional breast Surgery and full axillary dissection
88977838|NCT00233974|Experimental|PET positive|PET-probe-guided breast resection and full axillary dissection
88977839|NCT00234091|Active Comparator|1|Immediate treatment; individuals receive HAART on Day 1 of the study
88977840|NCT00234091|Active Comparator|2|Delayed treatment; individuals receive HAART if their CD4 percentage falls below 15 percentage OR if they develop a CDC category C illness
88977841|NCT04721704|Experimental|Group A|Group A will be given Amoxicillin AMO + Clarithromycin CLA + Proton pump inhibitor PPI based triple regimen
88977842|NCT04721704|Experimental|Group B|Group B will be given Amoxicillin AMO+ Metronidazole MET+ Proton pump inhibitor PPI based triple regimen
88977843|NCT02958605|Experimental|Smartphone|Smartphone application
88977844|NCT02958605|Experimental|Handbook|Resuscitation handbook who provides drug dosages for each weight for children. For example, at the page of 15 kg, it is written that the dosage of epinephrin is 1.5 cc of 1: 10 000.
88977845|NCT00234208|Experimental|Medical thoracoscopy|
89608486|NCT01273324||ADM|ADM Cup
88977846|NCT00234208|Active Comparator|Simple chest tube drainage|
88977847|NCT00064415|Experimental|1|Arformoterol tartrate 50 mcg QD
88977848|NCT00064415|Active Comparator|2|Salmeterol 42 mcg BID
88977849|NCT00234598|No Intervention|Control group, usual care|Usual care with no study interventions provided; no tooth brushing intervention and no chlorhexidine intervention. Usual care
88977850|NCT00234598|Active Comparator|Tooth brushing only|Tooth brushing by study personnel three times per 24 hours (TID) without chlorhexidine application.
88977851|NCT00234598|Active Comparator|Chlorhexidine only|Oral application of chlorhexidine 0.12% oral solution twice per 24 hours (BID) without tooth brushing.
88977852|NCT00234598|Active Comparator|Toothbrushing and chlorhexidine|Tooth brushing by study personnel three times per 24 hours (TID) and oral application of chlorhexidine 0.12% oral solution twice per 24 hours (BID)
88977853|NCT00413803|Other|1|Four-hour dialysis session, blood flow rate 300-400 ml/min
88977854|NCT00413803|Active Comparator|2|Eight-hours dialysis session, blood flow rate 200-250 ml/min
88977855|NCT00234676|Experimental|1|Premarin
88977856|NCT00234754|Active Comparator|1|Trans-vaginal tape Surgery
88977857|NCT00234754|Experimental|2|Trans-obturator tape surgery
88977858|NCT00234871|Active Comparator|1|
88977859|NCT00234871|Active Comparator|2|
88977860|NCT00234910|Experimental|A|2 drug arm
89592593|NCT04558749||Study group|The study population comprised women that will attend their routine visit to the antenatal clinic. The study population will be recruited by using simple random sampling method after verbal consent will be obtained. Resident in the Department of Obstetrics and Gynaecology who will be trained to administer the questionnaire will interview women. Face masks will be provided to the study population during the process of data collection.
89592594|NCT01727505|Active Comparator|Sequence A: Conventional-Volume Guarantee|This is a crossover study. Infants will be assigned to one of two sequences. Sequence A consists of a 24-hour period during which the infant receives conventional mechanical ventilation followed by a second 24 hour period during which the infant receives volume guarantee ventilation.
89592595|NCT01727505|Active Comparator|Sequence B: Volume Guarantee-Conventional|This is a crossover study. Infants will be assigned to one of two sequences. Sequence B consists of a 24-hour period during which the infant receives volume guarantee ventilation followed by a second 24 hour period during which the infant receives conventional mechanical ventilation.
89592596|NCT04564677||Patients eligible for laparoscopic ventral mesh rectopexy|Female patients with primary rectal prolapse, rectocele and/or enterocele eligible for laparoscopic ventral mesh rectopexy (LVMR)
89592597|NCT04564053|Experimental|LNA043|LNA043
89592598|NCT04564053|Placebo Comparator|placebo|
89592599|NCT01726803|Active Comparator|Usual Care|Usual care arm will receive management as recommended by practice guidelines and directed by the primary care provider. The recommended stepped care approach is used with initial management of advice and education only and no referral to physical therapy during the initial 4 weeks.
89592600|NCT01726803|Experimental|Early Physical Therapy with Usual Care|The Early Physical Therapy arm will receive the same advice and education intervention received by the usual care group and will be referred to receive 4 sessions of physical therapy during the first 4 weeks. The physical therapy protocol involves spinal manipulation and exercise.
89592601|NCT01726335|Experimental|Risperidone prolonged release|Risperidone will be administered as intramuscular injection as 25 milligram (mg) every two weeks, from Week 1 to 50, wherein after Week 3, dose may be adjusted up to 50 mg at physician criterion. For first two weeks, previous oral antipsychotic drug will be maintained and the dose will be gradually decreased and will cease at Week 3.
89592602|NCT01877421|Experimental|2 mg KSL-W (Phase 1, 1a)|one 2 mg KSL-W tablet at day 0 at Phase 1
89592603|NCT01877421|Experimental|4 mg KSL-W (Phase 1, 2a; Phase 2a, 1b)|one 4 mg KSL-W tablet on day 0 at both Phase 1 and Phase 2a. one 4 mg KSL-W tablet on days 1-6; two 4 mg KSL-W tablets on days 7-13 and days 14-20; and three 4 mg tablets at days 21-27 at Phase 2a.
88977861|NCT00234910|Active Comparator|B|3 drug arm, SOC
88977862|NCT00234988|Experimental|1|
88977863|NCT00235027|Experimental|Adverse Drug Event Monitoring|In this intervention arm, clinicians received medication safety alerts when they prescribed medications in the electronic medical record.
88977864|NCT00235027|No Intervention|Care as Usual|In this arm, clinicians did not receive the medication safety alerts.
88977865|NCT00400491|Experimental|1|
88977866|NCT00400491|Placebo Comparator|2|
88977867|NCT00235066|Experimental|1|Cypher Sirolimus-Eluting Stent
88977868|NCT00235144|Experimental|1|drug-eluting stent
88977869|NCT00235144|Active Comparator|2|bare-metal stent
88977870|NCT00235183|Active Comparator|Quarantined FFP|Quarantined FFP
88977871|NCT00235183|Active Comparator|Methylene blue FFP|Methylene blue FFP
88977872|NCT00235183|Active Comparator|Solvent detergent FFP|Solvent detergent FFP
89592604|NCT01877421|Experimental|6 mg KSL-W (Phase 1, 3a; Phase 2a, 2b)|One 6 mg KSL-W tablet on day 0 at both Phase 1 and Phase 2a. One 6 mg KSL-W tablet on days 1-6; two 6 mg KSL-W tablets on days 7-13 and days 14-20; and three 6 mg tablets at days 21-27 at Phase 2a.
88977873|NCT00235300|Active Comparator|1 Control|Simulect (basiliximab)
88977874|NCT00235300|Experimental|2|Thymoglobulin (anti-thymocyte globulin (rabbit))
88977875|NCT00064649|Active Comparator|2|Transurethral Needle Ablation (TUNA)
88977876|NCT00064649|Active Comparator|3|finasteride in a daily dose of 5 mg and alfuzosin in a daily dose of 10 mg
88977877|NCT00064649|Active Comparator|1|Transurethral Microwave Thermotherapy (TUMT)
88977878|NCT00097656|Experimental|Periodontal Treatment|maternal periodontal therapy
88977879|NCT00235339|Active Comparator|1|Standard exercise training rehabilitation at the hospital
88977880|NCT00235339|Experimental|2|Interval exercise training on treadmills, with high intensity
88977881|NCT00235378||1|SLE patients
88977882|NCT00235378||2|Unaffected family members of SLE patients
88977883|NCT00235378||3|Control participants
88977884|NCT04710511||Control group|Medically free children aged from 5 years to 7 years and do not practice oral habits.
89592605|NCT01877421|Experimental|10 mg KSL-W (Phase 1, 4a; Phase 2a, 3b)|One 10 mg KSL-W tablet on day 0 at both Phase 1 and Phase 2a. One 10 mg KSL-W tablet on days 1-6; two 10 mg KSL-W tablets on days 7-13 and days 14-20; and three 10 mg tablets at days 21-27 at Phase 2a.
88977885|NCT04710511||Oral habit practicing group|Medically free children aged from 5 years to 7 years and practicing oral habits.
88977886|NCT04710316|Experimental|Patients|- Hospitalized patients in one of the four centers in Bamako, with clinical signs of infection of the upper or lower respiratory tracts with fever or feeling of fever or any other signs of SARS-Cov-2 infection or who have been in close contact with a SARS-CoV-2 infected person without effective protective measures
88977887|NCT04710316|Experimental|Caregivers|"Caregivers of one of the four centers in Bamako.~Serological screening: all.~Molecular screening: with clinical signs of infection of the upper or lower respiratory tracts with fever or feeling of fever or any other signs of SARS-Cov-2 infection or who have seroconverted to SARS-CoV-2 or who have been in close contact with a SARS-CoV-2 infected person without effective protective measures"
88977888|NCT04710082|Active Comparator|Patients planned to undergo conventional 2 step trans-epithelial PTK-PRK|"Patients planned to undergo:~Epithelial removal using Phototherapeutic Keratectomy PTK as a separate step.~Laser Vision Correction using Excimer laser wavefront optimized technology."
88977889|NCT04710082|Active Comparator|Patients planned to undergo the new single step trans-epithelial (StreamLight) PRK.|"Patients planned to undergo:~Epithelial removal and Excimer wavefront optimized Laser Vision Correction in a single step using the new StreamLight Technology."
89031017|NCT04693026|Experimental|Group A: Remdesivir + Baricitinib treatment group|"Remdesivir (Injectable solution):~A loading dose of Remdesivir I/V 5mg/kg (less than 40kg) or 200mg (>40kg) on day 1, then 2.5mg/kg (less than 40kg) or 100mg (>40kg) daily following randomization.~+~Baricitinib (oral tablet form):~Baricitinib tablets 4 mg/day for 2 to 4weeks"
89031018|NCT04693026|Active Comparator|Group B: Remdesivir + Tocilizumab treatment group|"Remdesivir (Injectable solution) A loading dose of Remdesivir I/V 5mg/kg (less than 40kg) or 200mg (>40kg) on day 1, then 2.5mg/kg (less than 40kg) or 100mg (>40kg) daily following randomization.~+~Tocilizumab (Injectable solution):~Tocilizumab I/V 8mg/Kg up to 800mg highest 12 hours apart."
89592606|NCT01877421|Experimental|20 mg KSL-W (Phase 1, 5a; Phase 2a, 4b)|One 20 mg KSL-W tablet on day 0 at both Phase 1 and Phase 2a. One 20 mg KSL-W tablet on days 1-6; two 20 mg KSL-W tablets on days 7-13 and days 14-20; and three 20 mg tablets at days 21-27 at Phase 2a.
89592607|NCT01877421|Experimental|30 mg KSL-W (Phase 1, 6a; Phase 2a, 5b)|One 30 mg KSL-W tablet on day 0 at both Phase 1 and Phase 2a. One 30 mg KSL-W tablet on days 1-6; two 30 mg KSL-W tablets on days 7-13 and days 14-20; and three 30 mg tablets at days 21-27 at Phase 2a.
89592608|NCT01877421|Experimental|50 mg KSL-W (Phase 1, 7a; Phase 2a, 6b)|One 50 mg KSL-W tablet on day 0 at both Phase 1 and Phase 2a. One 50 mg KSL-W tablet on days 1-6; two 50 mg KSL-W tablets on days 7-13 and days 14-20; and three 50 mg tablets at days 21-27 at Phase 2a.
89592609|NCT01877421|Experimental|75 mg KSL-W (Phase 1, 8a; Phase 2a, 7b)|One 75 mg KSL-W tablet on day 0 at both Phase 1 and Phase 2a. One 75 mg KSL-W tablet on days 1-6; two 75 mg KSL-W tablets on days 7-13 and days 14-20; and three 75 mg tablets at days 21-27 at Phase 2a.
89592610|NCT01877421|Experimental|100 mg KSL-W (Phase 1, 9a)|one 100 mg KSL-W tablet at day 0 at Phase 1
89592611|NCT01877421|Placebo Comparator|Placebo|Placebo
89592612|NCT01726023|Experimental|Ceftazidime-Avibactam plus metronidazole|
89592613|NCT01726023|Active Comparator|Meropenem|
89592614|NCT01877265|Experimental|LY2605541 - Source 1|Each healthy participant will receive a single subcutaneous (SC) injection of 0.5 units per kilogram (U/kg) of LY2605541 on Day 1 of 1 of 3 treatment periods
89592615|NCT01877265|Experimental|LY2605541 - Source 2|Each healthy participant will receive single SC injection of 0.5 U/kg of LY2605541 on Day 1 of 1of 3 treatment periods
89592616|NCT01877265|Experimental|LY2605541 - Source 3|Each healthy participant will receive single SC injection of 0.5 U/kg of LY2605541 on Day 1 of 1 of 3 treatment periods
89592617|NCT01877187|Other|Lipiodol|Lipiodol, 10cc per TACE.
89592618|NCT04609761|Experimental|IVIG treatment|Single-arm open-label
89592619|NCT01858532|Active Comparator|Atrasentan|0.75 mg atrasentan once daily by mouth for up to 52 months
89592620|NCT01858532|Placebo Comparator|Placebo|Placebo once daily by mouth for up to 52 months
89592621|NCT01883492|Experimental|BIOLOX delta head|"Uncemented Femoral Stem is inserted into femoral medullary canal. Uncemented Acetabular Cup is inserted into acetabular cavity with or without fixation screw(s).~Acetabular Liner, which is made of E1 highly crosslinked polyethylene, is fitted into Acetabular cup.~Biolox delta head is inserted onto the taper of the Femoral stem, and is articulating against Acetabular Liner made of E1."
89592622|NCT01883492|Active Comparator|CoCr head|"Uncemented Femoral Stem is inserted into femoral medullary canal. Uncemented Acetabular Cup is inserted into acetabular cavity with or without fixation screw(s).~Acetabular Liner, which is made of E1 highly crosslinked polyethylene, is fitted into Acetabular cup.~CoCr head is inserted onto the taper of the Femoral stem, and is articulating against Acetabular Liner made of E1."
89592623|NCT01832480|Active Comparator|MTZ 2 g|Single dose MTZ
89592624|NCT01832480|Experimental|MTZ 500 mg twice daily x 7 days|Multi dose MTZ
89592625|NCT04613960|Active Comparator|Magnesium arm|patients randomized to magnesium therapy at a fixed daily dose of 64 mmol reconstituted in 0.9% saline via continuous intravenous infusion for 14 days after hemorrhage onset, or until discharge or death if it occurred.
89592626|NCT04613960|Placebo Comparator|Placebo arm|patients randomized to placebo therapy with 0.9% saline (without active component) via same protocol.
89592627|NCT04598984||Low levels of serum adipokines|
89592628|NCT04598984||High levels of serum adipokines|
89592629|NCT04598282|Placebo Comparator|Control Arm|All subjects enrolled in the study will receive the standard of care that includes epithelial debridement of all dendrites via Weck-Cel Cellulose sponge, topical prophylactic antibiotics (e.g., Ocuflox QID (four times daily) for one week) and oral acyclovir (400 mg 5x/day for 10 days for primary cases but tapered to 2x/day for 3 months for recurrent cases based on investigator's discretion).
89031019|NCT05140889||Group 1|Children with severe asthma
89031020|NCT05140889||Group 2|Children who undergo chest CT scan for other reasons than asthma
89592630|NCT04598282|Active Comparator|Treatment Arm|All subjects enrolled in the study will receive the standard of care that includes epithelial debridement of all dendrites via Weck-Cel Cellulose sponge, topical prophylactic antibiotics (e.g., Ocuflox QID for one week) and oral acyclovir (400 mg 5x/day for 10 days for primary cases but tapered to 2x/day for 3 months for recurrent cases based on investigator's discretion). The treatment arm will also receive the placement of PROKERA SLIM for 5-7 days. A second PROKERA SLIM may be applied based on investigator's discretion. For patients with bilateral involvement only the worse eye will be enrolled for the treatment arm.
89592631|NCT01858376|Other|Capros dietary supplement|Subjects will take Capros supplement (1 capsule) twice a day for 12 weeks.The subjects then will have blood drawn seven times throughout the course of the study.
89592632|NCT01831856|Experimental|F373280|
89592633|NCT01831856|Placebo Comparator|Placebo|
89592634|NCT01831544|Experimental|MVAD® Pump|Implant of HeartWare MVAD® System
89592635|NCT01857206|Experimental|TIVc|Subjects ≥4 to ≤17 years of age received one or two doses of mammalian cell-culture-derived trivalent influenza vaccine based on their previous vaccination status.
89592636|NCT01857206|Active Comparator|TIVf|Subjects ≥4 to ≤17 years of age received one or two doses of egg-derived trivalent influenza vaccine based on their previous vaccination status.
89592637|NCT01882088|Experimental|Mucofalk|Mucofalk 15 g/day i.e. 5 g TID per os, 15-20 min before meal
89592638|NCT01881776|Active Comparator|Single ISB (SISB) group|Patients in this group received single injection (SISB) interscalene brachial plexus block
89592639|NCT01881776|Active Comparator|Continuous ISB (CISB) group|Patients in this group received continuous (CISB) interscalene brachial plexus block
89592640|NCT01881776|No Intervention|General anesthesia (GA) group|Patients in this group received general anesthesia (GA)
89592641|NCT01708161|Experimental|BYL719 + AMG 479|For: Dose escalation phase/Phase II Expansion Phase. Cohorts of 3-6 patients were to be enrolled sequentially until an MTD or a recommended Phase II dose were defined. All patients were to receive the combination treatment. Sequential cohorts may receive different doses of the combination. In the Phase II expansion, all patients were to receive the same combination treatment.
89592642|NCT04557033|Experimental|Mindful Meditation|"The activity will include a guided mindfulness meditation and the creation of a digital image on an iPad.~The My Moments® application (app) is a tool used to facilitate expressive art creation in a digital photography media~Participants will be asked to complete brief surveys before and after the intervention activity."
89592643|NCT01707693|Experimental|Lifestyle Physical Activity Intervention|the women will be randomized to either the LPA Intervention or Information/Attention Comparison groups using a permuted block randomization scheme. Participants in both groups will be followed longitudinally with repeated assessments of LPA (accelerometer & LPA diary), stage of change, and self-efficacy at baseline and 3 and 6 months; and functional health and well-being (SF36) at baseline and 6 months.
89592644|NCT01707693|Active Comparator|Information/Attention Comparison|the women will be randomized to either the LPA Intervention or Information/Attention Comparison groups using a permuted block randomization scheme. Participants in both groups will be followed longitudinally with repeated assessments of LPA (accelerometer & LPA diary), stage of change, and self-efficacy at baseline and 3 and 6 months; and functional health and well-being (SF36) at baseline and 6 months.
89592645|NCT01722669|Experimental|Quercetin|Single dose of quercetin with or without ascorbic acid
89592646|NCT01722669|Active Comparator|Isoquercetin|Single dose of isoquercetin with or without ascorbic acid
89592647|NCT01707147||Patients with Type 2 Diabetes Mellitus|
89592648|NCT01876251|Experimental|PF-03084014 plus docetaxel|PF 03084014 will be administered orally, continuously, twice daily at doses from 80 to 150 mg in combination with docetaxel given every 3 weeks at doses from 75 to 100 mg/m^2
88977890|NCT00235534|Experimental|Immediate start|Initiate selected birth control method before leaving the clinic at the time of the abortion procedure.
88977891|NCT00235534|Active Comparator|Sunday start|Begin birth control the first Sunday after leaving the clinic
88977892|NCT00235690|Other|blood draws|all patients enrolled will have PK blood samples obtained around a colistin dosing
88977893|NCT00235729|Experimental|1|Lofexidine 0.8 mg QID
88977894|NCT00235729|Placebo Comparator|2|Placebo QID
88977895|NCT04721080||COPD patients with tuberculous sequelae|COPD patients with tuberculous sequelae
89592649|NCT01875471|Active Comparator|delefilcon A|Spherical daily disposable soft contact lens
89592650|NCT01875471|Experimental|narafilcon A|Spherical daily disposable soft contact lens Class 1 UV blocking
89592651|NCT01875237|Experimental|Stem Cell Transplant + Modified T-Cells + Chemotherapy|The first component is stem cell transplant. Goal is to administer more than 3 x 106 CD34+ cells/kg of peripheral blood progenitor cells (PBPC). The second component is the planned DLI infusion. iCasp9 (BPZ-1001)-Modified T-cells) of 3 X 10^6/kg in 100 ml infused over approximately a one hour period between Day + 56 to Day +64. The transplant day is referred to as day zero (D0), treatment plan activities prior or after D0 are denoted as day minus (D-) or day plus (D+). Patients receive standard reduced intensity regimen using fludarabine, melphalan, and alemtuzumab to achieve engraftment with a low risk of GVHD. At approximately 60 days post transplant patients who are alive and without GVHD, receive DLI to enhance graft-vs.-malignancy and immune reconstitution.
89592652|NCT01874535|Active Comparator|GERD Los Angeles A and B-4 week group|Patients with Los Angeles A and B esophagitis prescribed with esomeprazole (40 mg)daily- 4 week group
89592653|NCT01874535|Active Comparator|GERD Los Angeles A and B-8-week group|Patients with Los Angeles A and B esophagitis prescribed with esomeprazole (40 mg)daily- 8 week group
89592654|NCT01722045|Experimental|Open label IAI|
89592655|NCT01721109|Experimental|EVG/COBI/FTC/TDF|Participants will receive treatment for 48 weeks and then had the option to enter an Extension Phase to receive EVG/COBI/FTC/TDF until 1) the age of 18, 2) EVG/COBI/FTC/TDF becomes commercially available in the country the participant is enrolled, or 3) Gilead elects to terminate the development of EVG/COBI/FTC/TDF in that country.
89592656|NCT01874145|Active Comparator|GA 20 mg/mL every day|Glatiramer acetate (GA) 20 mg in 1 mL SC injection administered every day (QD) for the 4 months of the core study.
89592657|NCT01874145|Experimental|GA 40 mg/mL 3 times a week|"Glatiramer acetate (GA) 40 mg in 1 mL SC injection administered three times a week (TIW) for the 4 months of the core study.~During the Extension period, all participants to continue treatment with GA 40 mg/mL TIW until this dose regimen is commercially available for the treatment of RRMS patients."
88977896|NCT04721080||COPD patients without tuberculosis sequela|COPD patients with tuberculous sequelae
88977897|NCT00235807|Other|1|should contain an explanation of the nature of the study group (e.g., those with a condition and those without a condition; those with an exposure and those without an exposure).
88977898|NCT00235807|Other|2|should contain an explanation of the nature of the study group (e.g., those with a condition and those without a condition; those with an exposure and those without an exposure).
88977899|NCT00235807|Other|3|should contain an explanation of the nature of the study group (e.g., those with a condition and those without a condition; those with an exposure and those without an exposure).
88977900|NCT00235846|Active Comparator|Conventional vein harvest|Conventional open vein harvest from the lower leg
88977901|NCT00235846|Experimental|Endoscopic vein harvest|Endoscopic vein harvest from the calf
88977902|NCT00064883||Patients|Pediatric cancer patients referred to the ROB who have received or require radiation therapy
88977903|NCT00236002|Placebo Comparator|placebo|
89209964|NCT04036422|Experimental|Computer based exercise group|The fifteen patients included in this arm of the study will receive a one hourly 'one-on-one' session of conventional physical therapy five days a week to a total of twenty hours over a four week period. In addition to this, these patients will receive half an hour of conventional occupational therapy and half an hour of Rejoyce computerized exercise seven days a week to a total of twenty eight hours over a four weeks period.
88977904|NCT00236119|Experimental|CEP-701 20mg|Patient Cohort 1
89592658|NCT04415385|Experimental|Camrelizumab + Apatinib|Participants receive Camrelizumab 200mg intravenously every 2 weeks and apatinib 250mg orally once daily until disease progression or unacceptable toxicity
89592659|NCT01720797|Experimental|Micro-osteoperforation|Minimally invasive micro-osteoperforation (PROPEL™) procedure used to achieve rapid orthodontic tooth movement. Topical or local anesthetic will be delivered in the area to be treated in accordance with standard practice. Prior to intervention subject will swish 5cc of chlorhexidine for one minute, twice, will take place. Following procedure Chlorhexidine rinses are to begin twice a day for a week.
89592660|NCT01720797|Other|Non Micro-osteoperforation|Prior to intervention a swish of 5cc of chlorhexidine for one minute, twice, will take place. Chlorhexidine rinses are to begin twice a day for a week.
89592661|NCT01831466|Experimental|Treatment Group A|
89592662|NCT01831466|Experimental|Treatment Group B|
89592663|NCT01831466|Placebo Comparator|Treatment Group C|
89592664|NCT01831466|Experimental|Treatment Group D|
89592665|NCT01831466|Experimental|Treatment Group E|
89592666|NCT01831466|Placebo Comparator|Treatment Group F|
89592667|NCT01881620|Experimental|COMBI TEP : PET / enhanced CT scan|COMBI TEP : PET / enhanced CT scan
88977905|NCT00236119|Experimental|CEP-701 40mg|Patient Cohort 2
88977906|NCT00236119|Experimental|CEP-701 60mg|Patient Cohort 3
88977907|NCT00236119|Experimental|CEP-701 80mg|Patient Cohort 4
88977908|NCT04721275||Sepsis on the elderly population in ED|The elderly population is defined as patients over 65 years old of age.
88977909|NCT04721275||Sepsis on the non-elderly population in ED|The non-elderly population is defined as patients aged of 18 to 64 years old.
88977910|NCT00236158|Other|AAIR|
88977911|NCT00236158|Other|DDDR|
88977912|NCT00413881|Active Comparator|2|Conventional LASIK Enhancement
88977913|NCT00413881|Experimental|1|Wavefront guided LASIK Enhancement
88977914|NCT00414037|Experimental|eszopiclone (Lunesta) 3mg|Subchronic (1-week) administration of 3mg Lunesta (eszopiclone)
88977915|NCT00414037|Placebo Comparator|Placebo|Placebo-treated group
88977916|NCT00236275|Experimental|1|Fluoro-L-thymidine-(18F)
88977917|NCT02961907|No Intervention|Control|"The usual routine course includes :~a clinico-biological evaluation of infertility causes~a laboratory staff and decision of therapeutic strategy and decision of a therapeutic strategy~collection of blood and sperm samples"
89592668|NCT01830920|Placebo Comparator|Placebo|An identical appearing placebo will be administered.
88977918|NCT02961907|Experimental|PEPCI group|In the PEPCI group, the standardized assessment of the periconceptional profile is used to adapt the additional standardized intervention.
88977919|NCT02962141|Experimental|APERTO OTW group|in the APERTO OTW group the subject will be treated with APERTO OTW balloon (Paclitaxel Releasing Peripheral Balloon Dilatation Catheter)
88977920|NCT02962141|Active Comparator|OHICHO II group|in the OHICHO II group the subject will be treated with OHICHO II balloon (Balloon Dilatation Catheter)
88977921|NCT02961868|Experimental|Prospective cohort|3 years follow-up
88977922|NCT00237133|Experimental|Letrozole|
88977923|NCT00237172|Experimental|Imatinib Mesylate|400 mg once daily
88977924|NCT00237211|Experimental|Letrozole|
88977925|NCT00237484|Experimental|Arm A|Remicade induction dose at Day -7 prior to initiation of PEGETRON treatment for up to 48 weeks
88977926|NCT00237484|Active Comparator|Arm B|PEGETRON treatment for up to 48 weeks
89592669|NCT01830920|Experimental|THR-184 Dose 1|THR-184 initial pre-surgery low dose followed by (3) post surgery doses at the low dose.
89592670|NCT01830920|Experimental|THR-184 Dose 2|THR-184 initial pre-surgery mid-dose followed by (3) post surgery doses at the low dose.
89592671|NCT01830920|Experimental|THR-184 Dose 3|THR-184 initial pre-surgery high dose followed by (3) post surgery doses at the low dose.
89592672|NCT01830920|Experimental|THR-184 Dose 4|THR-184 initial pre-surgery high dose followed by (3) post surgery doses ~80% of the pre-surgery dose.
88977927|NCT04721743||Affected Participants|Participants with Uveitis
88977928|NCT04721431|Experimental|Normal|Body mass index must to be in range limits (18.5-24.9 kg/meter square)
88977929|NCT04721431|Experimental|Overweight|Body mass index must to be in range limits (25-29.9 kg/meter square)
88977930|NCT04721431|Experimental|Obese|Body mass index must to be in range limits (30-34.9 kg/meter square)
88977931|NCT04709887|Other|Rate of popliteal artery stenosis < 50%, W.|If the rate of popliteal artery stenosis of patients < 50%, the patients only receive the wound treatment.
88977932|NCT04709887|Other|Rate of popliteal artery stenosis < 50%, WT.|If the rate of popliteal artery stenosis of patients < 50%, the patients receive the wound treatment and tibial transverse transport surgery.
88977933|NCT04709887|Other|Rate of popliteal artery stenosis ≥ 50%, WV.|If the rate of popliteal artery stenosis of patients ≥ 50%, the patients receive the wound treatment and vascular intervention surgery.
88977934|NCT04709887|Other|Rate of popliteal artery stenosis ≥ 50%, WT.|If the rate of popliteal artery stenosis of patients ≥ 50%, the patients receive the wound treatment and tibial transverse transport surgery.
88977935|NCT04709887|Other|Rate of popliteal artery stenosis ≥ 50%, WVT.|If the rate of popliteal artery stenosis of patients ≥ 50%, the patients receive the wound treatment, vascular intervention and tibial transverse transport surgery.
88977936|NCT04710121|Experimental|Intervention Arm|"The experimental group will be asked about their anxiety states with the State and Trait Anxiety Inventory, their pain conditions with the Analog Scale (VAS), and their first life findings will be measured, and the first measurement values will be recorded in the Vital Signs Follow-up Form. Virtual reality glasses will be placed on the patient's head during colonoscopy. The duration of the colonoscopy will vary between 3-10 minutes, videos with music background, park, nature and seaside walks, underwater videos, which the patient chooses, will be watched and the Vital Signs Tracking Form Second measurement values will be recorded by making measurements. Immediately after the colonoscopy procedure is completed, Visual Analogue Scale (VAS), Vital Signs Follow-up Form (measurement will be made and 3rd measurement values will be recorded. The State Anxiety Inventory will be read and the answers will be recorded."
88977937|NCT04710121|No Intervention|Control Arm|No application will be made in the control group. during and after colonoscopy and routine treatment and care will be applied.
89592673|NCT01881230|Experimental|nab-Paclitaxel plus Gemcitabine|Treatment Arm A: nab-Paclitaxel 125 mg/m^2 by intravenous (IV) administration over 30 minutes, followed by gemcitabine 1000 mg/m^2 on Days 1 and 8 of each 21-day cycle by IV administration over 30 minutes
89592674|NCT01881230|Experimental|nab-Paclitaxel plus Carboplatin|Treatment Arm B: nab-Paclitaxel 125 mg/m^2 on Days 1 and 8 by IV administration followed by carboplatin at an Area Under the Curve (AUC) of 2 on Days 1 and 8 of each 21-day cycle by IV administration
89592675|NCT01881230|Active Comparator|Gemcitabine plus Carboplatin|Treatment Arm C: Gemcitabine 1000 mg/m^2 on Days 1 and 8 by IV administration followed by carboplatin AUC 2 on Days 1 and 8 of each 21-day cycle by IV administration
89592676|NCT01856582|Experimental|CD34+ selected stem cell infusion|An infusion of selected CD34+ stem cells will be given without any preparative regimen.
89592677|NCT01829360|Experimental|Standard then Alternative: High Dose|Children in this arm are assigned to the standard treatment for the first round of intervention (dose 6 x dose frequency 6) and then the alternative treatment that maximizes dose (dose 9 x dose frequency 4)
89592678|NCT01829360|Experimental|Alternative: High Dose then Standard|Children in this arm are assigned to the alternative treatment that maximizes dose (dose 9 x dose frequency 4) in the first round of intervention and then to the standard treatment for the second round of intervention (dose 6 x dose frequency 6)
89592679|NCT01829360|Experimental|Alternative: High Dose Frequency then Standard|Children in this arm are assigned to the alternative treatment that maximizes dose frequency (dose 4 x dose frequency 9) in the first round of intervention and then to the standard treatment for the second round of intervention (dose 6 x dose frequency 6)
89592680|NCT01829360|Experimental|Standard then Alternative: High Dose Frequency|Children in this arm are assigned to the standard treatment for the first round of intervention (dose 6 x dose frequency 6) and then the alternative treatment that maximizes dose frequency (dose 4 x dose frequency 9)
89592681|NCT01856114|Experimental|Fentanyl Buccal Tablet|After a six minute walk test, participant will sit down and rest for up to 1 hour. They will then be given a Fentanyl tablet to put in between upper gum and cheek. Study physician will determine the morphine equivalent daily dose (MEDD) in real time using standardized equianalgesic ratios. Based on clinical practice and similarly to the dose used for breakthrough pain, an FBT dose equivalent to 20-50% of the MEDD used. After 30 minutes, participant asked about any side effects they may be having, and repeat the walking test. During each walk test, participant asked 6 times how hard it is to catch their breath. The total distance walked will also be recorded. Completion of two questionnaires at beginning of study visit. It should take about 10 minutes to complete. At the end of study visit, completion of last questionnaire. It should take about 5 minutes to complete the questionnaire.
89592682|NCT01856114|Placebo Comparator|Placebo Buccal Tablet|After a six minute walk test, participant will sit down and rest for up to 1 hour. They will then be given a Placebo tablet to put in between upper gum and cheek. After 30 minutes, participant asked about any side effects they may be having, and repeat the walking test. During each walk test, participant asked 6 times how hard it is to catch their breath. The total distance walked will also be recorded. Completion of two questionnaires at beginning of study visit. It should take about 10 minutes to complete. At the end of study visit, completion of last questionnaire. It should take about 5 minutes to complete the questionnaire.
88977938|NCT04709848||Pre-screening group|Individuals undergoing bone marrow transplantation Jun 2018 - July 2020
88977939|NCT04709848||Screened group|Individuals undergoing bone marrow transplantation July 2020 - July 2021
88977940|NCT04709965|Other|Main Study|Patients attending routine genetic clinic/paediatric clinic appointments for diagnosis of a multiple anomaly syndrome where distinctive facial features form part of their presenting pattern.
88977941|NCT04709965|Other|Faces Sub Study|Patients eligible to be recruited to the Faces Sub Study will have biochemically or genetically confirmed diagnosis of inborn disorder of metabolism where no well described dysmorphic facial features are known to be associated with disorder.
88977942|NCT04710160|Active Comparator|Novel fast setting calcium silicate ( Protooth)|In the form of powder and liquid to be mixed together to form paste.
88977943|NCT04710160|Experimental|MTA|In form of powder to be mixed with saline to form paste.
88977944|NCT00065351|Experimental|1|CC-5013 - oral - 30mg daily on days 1-21 every 28 days
88977945|NCT04709809|Experimental|Experimental arm|Measurement RVA / IOP / with ECG gating
88977946|NCT04709770|Experimental|Low-volume preparation|"Low-volume preparation of 2-liters polyethylene glycol with citrate and simethicone. This formulation includes 4 large (A) and 4 small (B) sachets; the components of 2 sachets A and 2 sachets B are mixed in 1 liter of water.~Each sachet A contains:~polyethylene glycol (4000) 52.50 g;~simethicone 0.08 g;~sodium sulphate anhydrous 3.75 g.~Each sachet B contains:~sodium citrate 1.863 g;~anhydrous citric acid 0.813 g;~sodium chloride 0.73 g;~potassium chloride: 0.37 g;~acesulfame potassium 0.13 g. Participants will drink the first liter of preparation at 19.00 p.m. on the day before the colonoscopy, at a rate of 250 ml every 15 minutes, followed by 500 ml of clear liquids. The second liter of preparation will be administered at 7.00 a.m. on the day of the colonoscopy, at a rate of 250 ml every 15 minutes, followed by 500 ml of clear liquids."
88977947|NCT04709770|Active Comparator|High-volume preparation|"High-volume preparation with 4-liters polyethyleneglycol with simethicone. This formulation includes 4 sachets, each dissolved in 1 liter of water.~Each sachet contains:~polyethylene glycol (4000) 58.30 g;~simethicone 0.08 g;~sodium sulphate anhydrous 5.68 g;~sodium bicarbonate 1.68 g;~sodium chloride 1.46 g;~potassium chloride 0.74 g. Participants will drink the first 2 liters of preparation at 19.00 p.m. on the day before colonoscopy, at a rate of 250 ml every 15 minutes. The remaining 2 liters of preparation will be administered at 6.00 a.m. on the day of the endoscopic procedure, at a rate of 250 ml every 15 minutes."
88977948|NCT04709731|Experimental|Total Patients|Intolerant Group Ponatinib 15 mg tablet, taken orally once daily (QD) Resistant Group Ponatinib 30 mg tablet, taken orally once daily (QD) The dose will be reduced to 15mg once daily (QD) as soon as a Complete Cytogenetic Response will be obtained. In those patients showing Major Molecular Response or better, the dose could be further reduced to 15MG every other day (EOD), due to the prolonged half-life of the drug.
88977949|NCT00098163|Experimental|1|
88977950|NCT00098163|Placebo Comparator|2|
88977951|NCT00398645|Experimental|Arm 1|
88977952|NCT00237601||1|Women with the intention to give birth at home
88977953|NCT00237601||2|Women with the intention to give birth in a short-stay hospital setting
89031021|NCT02276859|Experimental|Normal/ Dual-wave|"On the first study day, pre-breakfast insulin was given as a normal bolus 15 minutes before a standardized high-protein meal. On the second day, pre-breakfast insulin was given as a dual-wave bolus before the same high-protein meal.~The carbo-insulin and fat-protein-insulin ratio on both study days were identical to the patient's ratio when entering trial.~Kind of study bolus insulin will be a rapid-acting insulin analog same as previously used by the participant (before entering the trial) - insulin aspart, insulin lispro or insulin glulisine"
89592683|NCT01855958|Experimental|DIMST|The investigators used acupuncture needles with guide tubes (Suzhou Huanqiu Acupuncture Medical Appliance Co. Ltd., 218, China) that were 40 mm in length and 0.25 mm in diameter. The needling in DIMST was applied using an electro acupuncture device (Cosmotron, São Paulo, Brazil) in the dermatomes corresponding to the nerve roots involved in the knee (L1, L2, L3, L4, L5, S1, and S2). DIMST using was administered maintaining a distance from the spinous process line of 2 cm. The anatomic sites of peripheral DIMST were the muscles vastus medialis, rectus femoris, vastus lateralis, tibialis anterior; and the pes anserinus bursae. All subjects received one 30min session using a frequency of 2 Hz.
89592684|NCT01855958|Sham Comparator|Placebo-sham|The investigators used the same electro acupuncture device (Cosmotron, Sao Paulo, Brazil), which was previously set to prevent the current to pass through the electrodes. Subjects were informed that it would be a stimulus of low intensity and high frequency that they probably would not have any sense of it. The electrodes were placed on the same points where the active stimulation was applied while the nerve stimulation unit was left in front of the subject, for 30 minutes. This positioning ensured that the intermittent diode simulating the electrical stimulus was visible and audible.
89592685|NCT01855412||Claudication (Rutherford 2-3)|Patients who have been diagnosed with PAD and are classified as on the Rutherford Scale as Rutherford 2-3. Patients may be treated with any FDA-cleared endovascular PAD treatment.
89592686|NCT01855412||CLI Rutherford 4-5|Patients who have been diagnosed with PAD and classified on the Rutherford Scale as Rutherford 4-5. Patients may be treated with any FDA-cleared endovascular PAD treatment.
89592687|NCT01855412||CLI Rutherford 6|Patients who have been diagnosed with PAD and classified on the Rutherford Scale as Rutherford 6. Patients may be treated with any FDA-cleared endovascular PAD treatment.
89031022|NCT02276859|Experimental|Dual-wave/Normal|"On the first study day, pre-breakfast insulin was given as a dual-wave bolus 15 minutes before a standardized high-protein meal. On the second day, pre-breakfast insulin was given as a normal bolus before the same high-protein meal.~The carbo-insulin and fat-protein-insulin ratio on both study days were identical to the patient's ratio when entering trial.~Kind of study bolus insulin will be a rapid-acting insulin analog same as previously used by the participant (before entering the trial) - insulin aspart, insulin lispro or insulin glulisine"
89031023|NCT00526266|Experimental|1|
89031024|NCT00526266|Placebo Comparator|2|
89031025|NCT00526266|No Intervention|3|No Treatment
89031026|NCT04692753||Pre-intervention|baseline data prior to training and education of health care workers. Intervention: intensive training and education of workers for maintenance of venous access devices.
89031027|NCT04692753||Post intervention|observation after training and education of health care workers
89031028|NCT02946606|Experimental|Group 1: GX-H9 + Genotropin|GX-H9 (weekly dose), Genotropin (daily)
89031029|NCT02946606|Experimental|Group 2: GX-H9 + Genotropin|GX-H9 (weekly dose), Genotropin (daily)
89031030|NCT02946606|Experimental|Group 3: GX-H9 + Genotropin|GX-H9 (weekly dose), Genotropin (daily)
89031031|NCT00525252|Placebo Comparator|2|A total of 42 alcoholic patients with liver cirrhosis treated with placebo
89031032|NCT00525252|Active Comparator|1|a total of 42 alcoholic patients with liver cirrhosis treated by baclofen
89031033|NCT05149391|Experimental|C-CAR039|Autologous C-CAR039 administered by intravenous (IV) infusion
89031034|NCT02947191|Experimental|Collagen membrane + HUC-MSCs|
89031035|NCT02947113|Experimental|chemotherapy combined with radiotherapy|Patients will be treated with two 3-weekly courses of cisplatin (Day 1: 75mg/m2) and pemetrexed (Day 1: 500mg/m2 for non-squamous) or etoposide (Day1-3 100mg/m2 for squamous), together with hypofractionated radiotherapy (24 daily fractions of 2.42 Gy to the involved mediastinal lymph nodes with an integrated boost of 2.75 Gy to the primary tumor).
89031036|NCT05149274|Active Comparator|Part1|DWP14012 Tablet A : single/multiple dose, 1 group, 2 period study
89031037|NCT05149274|Active Comparator|Part2|DWP14012 Tablet A 4T vs DWP14012 Tablet B 1T
89031038|NCT02947464|Active Comparator|Control|Standard clinical practice
89592688|NCT01614470|Experimental|Part 1: Ivacaftor First, Then Placebo|Ivacaftor 150 milligram (mg) tablet orally twice daily for 8 weeks in treatment period 1 followed by placebo matched to ivacaftor tablet orally twice daily for 8 weeks in treatment period 2. Washout out period of 4 to 8 weeks was maintained between each treatment period.
89592689|NCT01614470|Experimental|Part 1: Placebo First, Then Ivacaftor|Placebo matched to ivacaftor tablet orally twice daily for 8 weeks in treatment period 1 followed by ivacaftor 150 mg tablet orally twice daily for 8 weeks in treatment period 2. Washout out period of 4 to 8 weeks was maintained between each treatment period.
89592690|NCT01614470|Experimental|Part 2: Ivacaftor|Ivacaftor 150 mg tablet orally twice daily for 16 weeks.
89592691|NCT01880528|Experimental|Arm I (lisinopril)|Beginning within 7 days of beginning radiation therapy, patients receive lisinopril PO QD on days 1-7.
89592692|NCT01880528|Placebo Comparator|Arm II (placebo)|Beginning within 7 days of beginning radiation therapy, patients receive placebo PO QD on days 1-7.
89592693|NCT01854944|Experimental|Brexpiprazole 1mg to 4mg|"Three cohorts of subjects will be evaluated:~- Cohorts 1 and 3 will receive high doses of brexpiprazole, and Cohort 2 will receive low doses of brexpiprazole."
89592694|NCT01829048|Experimental|PF-02545920|
89592695|NCT01829048|Placebo Comparator|Placebo|
89031039|NCT02947464|Experimental|Intervention|Standard clinical practice + Rapid Maxillary Expansion
89031040|NCT00525291|Experimental|EMG-biofeedback plus EMG-triggered AM-MF-stimulation|
89031041|NCT00525291|Active Comparator|EMG-biofeedback alone|
89031042|NCT02276690|Experimental|Dosage of hepcidin|In order to assess iron deficiency, patients randomized in this arm will have dosage of hepcidin by mass spectrometry
89031043|NCT02276690|Active Comparator|Usual biomarker dosage|In order to assess iron deficiency, patients randomized in this arm will have usual biomarker dosages (ferritin and transferrin saturation)
89592696|NCT01854710|Other|Treatment sequence ABC|Treatment: A = Inhaled loxapine (2 doses of 10 mg 2 hours apart) + oral placebo, B = Inhaled placebo + oral placebo, C = Oral moxifloxacin 400 mg + Inhaled placebo
89592697|NCT01854710|Other|Treatment sequence ACB|Treatment: A = Inhaled loxapine (2 doses of 10 mg 2 hours apart) + oral placebo, B = Inhaled placebo + oral placebo, C = Oral moxifloxacin 400 mg + Inhaled placebo
89592698|NCT01854710|Other|Treatment sequence BCA|Treatment: A = Inhaled loxapine (2 doses of 10 mg 2 hours apart) + oral placebo, B = Inhaled placebo + oral placebo, C = Oral moxifloxacin 400 mg + Inhaled placebo
89592699|NCT01854710|Other|Treatment sequence BAC|Treatment: A = Inhaled loxapine (2 doses of 10 mg 2 hours apart) + oral placebo, B = Inhaled placebo + oral placebo, C = Oral moxifloxacin 400 mg + Inhaled placebo
89592700|NCT01854710|Other|Treatment sequence CAB|Treatment: A = Inhaled loxapine (2 doses of 10 mg 2 hours apart) + oral placebo, B = Inhaled placebo + oral placebo, C = Oral moxifloxacin 400 mg + Inhaled placebo
89592701|NCT01854710|Other|Treatment sequence CBA|Treatment: A = Inhaled loxapine (2 doses of 10 mg 2 hours apart) + oral placebo, B = Inhaled placebo + oral placebo, C = Oral moxifloxacin 400 mg + Inhaled placebo
89592702|NCT01828034|Experimental|Gemcitabine, Cisplatin and MEK162|Phase I component of the study, a classic 3+3 cohort dose escalation scheme will be used to identify the MTD of MEK162 when administered with gemcitabine at dose 800 mg/m2 and cisplatin given at dose 20 mg/m2 week 2 & 3 of a 3 week cycle. The final cohort will receive gemcitabine 1000mg/m2 and cisplatin 20mg/m2 week 2 and 3 of a 3 week cycle in combination with MEK162 at the MTD as determined above. In the phase II part of the study, patients will receive MEK162 at the MTD dose plus gemcitabine and cisplatin at the dose level determined acceptable in the phase I portion. In the phase II part of the study, patients will receive MEK162 at 45mg BID plus gemcitabine (800 mg/m2) and cisplatin (20 mg/m2) as determined by the phase I portion.
89592703|NCT01853696|Active Comparator|Loteprednol|Loteprednol etabonate 0.5% gel applied topically 4 times daily for 2 months, 3 times daily for 1 month, twice daily for one month and once daily for 7 months
89592704|NCT01853696|Active Comparator|Prednisolone acetate|Prednisolone acetate 1% ophthalmic solution applied 4 times daily for two months, 3 times daily for one month, twice daily for one month, and once daily for 7 months
89592705|NCT01871805|Experimental|Alectinib: Phase I (Dose Escalation)|Participants will receive escalating doses of alectinib capsules orally until disease progression, death or withdrawal for any other reasons.
89592706|NCT01871805|Experimental|Alectinib (Phase II: RP2 dose)|Participants will receive recommended Phase II dose as determined from Phase I until disease progression, death or withdrawal for any other reasons.
89592707|NCT01719861|Experimental|Desipramine HCl|Desipramine is a tricyclic antidepressant (TCA).
89592708|NCT01853618|Experimental|Pilot 1/Arm A1-Tremelimumab + RFA or TACE|Escalating doses of Tremelimumab + Radiofrequency Ablation (RFA) or Transarterial Catheter Chemoembolization (TACE)
89592709|NCT01853618|Experimental|2/Arm A2 - Tremelimumab + RFA or TACE|Tremelimumab + Radiofrequency Ablation (RFA) or Transarterial Catheter Chemoembolization (TACE)
89592710|NCT01853618|Experimental|3/Arm B - Tremelimumab + TACE|Tremelimumab + Transarterial Catheter Chemoembolization (TACE)
88977954|NCT00398684|Experimental|1|One dose maternal NVP treatment at onset of labor, and one dose of infant NVP treatment 48-72 hours after birth (NVP-NVP)
88977955|NCT00398684|Experimental|2|One dose maternal NVP treatment at onset of labor, and one dose of infant placebo 48-72 hours after birth. (NVP-Placebo)
88977956|NCT00398684|Placebo Comparator|3|One dose maternal placebo at onset of labor, and one dose of infant placebo 48-72 hours after birth. This was the reference study arm. (Placebo-Placebo)
88977957|NCT00237640|Placebo Comparator|1|
88977958|NCT00237640|Active Comparator|2|
88977959|NCT00237679|Active Comparator|Neuromuscular Electrical Stimulation|Subjects will receice Neuromuscular Electrical Stimulation (NMES)-stimulated swallowing combined with exercise therapy.
88977960|NCT00237679|Sham Comparator|Unstimulated|Subjects will receive sham (unstimulated) swallow therapy combined with exercise therapy.
88977961|NCT00237757|Experimental|Arm 1|The experimental arm consisted of a six month staff training period with an emphasis on effective team functioning to improve patient outcomes. The core of the intervention consisted of a concentrated 2.5 day workshop in Atlanta for 29 rehabilitation team leaders from 15 VA hospitals. Several weeks after the workshop, participants received a custom action plan developed on issues discussed in the workshop. The experimental arm also received a summary of results of the initial survey along with comparative data from all other sites. During the subsequent 5 months after the workshop, research staff maintained regular contact with research participants through telephone and videoconferencing
88977962|NCT00237757|Active Comparator|Arm 2|The comparison arm (staff on 16 teams) completed the identical summary of staff, hospital, and team characteristics. The local PIs at the Comparison sites received summaries of the survey findings, comparative data from other participating VA sites, and suggestions on how this information could be used to improve patient outcomes. In addition, participants in the comparison arm were invited to contact the research staff for help in interpreting data or to set-up a process improvement initiative.
88977963|NCT00237913|Active Comparator|A1|
88977964|NCT00237913|Active Comparator|B1|
88977965|NCT00398723|Experimental|Vitiligo|adult patients (age 18 or greater) with extensive vitiligo warranting treatment with whole body NB-UVB
88977966|NCT04721119|Experimental|Local Infiltration Anesthetic|This group of patients will receive the local infiltration anesthetic only.
88977967|NCT04721119|Experimental|Local Infiltration Anesthetic + Adductor Canal Block|This group of patients will receive the local infiltration anesthetic and adductor canal block combination.
88977968|NCT00238030|Active Comparator|po thyroxine|placebo is iv
88977969|NCT00238030|Active Comparator|iv thyroxine|placebo is po
88977970|NCT00065546|Active Comparator|1|Post-menopausal women randomized to receive estrogen replacement therapy.
88977971|NCT00065546|Placebo Comparator|2|Post-menopausal women randomized to receive a placebo.
88977972|NCT00065546|Experimental|3|Pre-menopausal women with specific genetic variants.
88977973|NCT00238381|Other|Arm I|Patients undergo total mesorectal excision (TME) by standard methods or laparoscopically and side-to-end anastomosis rectal reconstruction.
88977974|NCT00238381|Other|Arm II|Patients undergo TME and colon-J-pouch anastomosis rectal reconstruction.
89592711|NCT01853618|Experimental|4/Arm C (never opened)|Tremelimumab + Radiofrequency Ablation (RFA) or Transarterial Catheter Chemoembolization (TACE)
88977975|NCT00238381|Other|Arm III|Patients undergo straight coloanal anastomosis with/without temporary protective ileostomy
89592712|NCT01853618|Experimental|5/Arm D - Tremelimumab + Cryoablation|Tremelimumab + Cryoablation
89592713|NCT01853618|Experimental|6/Arm E - Tremelimumab + RFA|Tremelimumab + Radiofrequency Ablation (RFA)
89592714|NCT01853462|Experimental|Proprioceptive Neuromuscular Facilitation (PNF)|Supervised PNF training
89592715|NCT01853462|Experimental|Balance|Supervised balance training
89592716|NCT01719783|Experimental|LAIV H5N2|Two doses of live monovalent influenza vaccine A/17/turkey/Turkey/05/133 ( live monovalent (LAIV H5N2) given intranasally
89592717|NCT01719783|Placebo Comparator|Placebo|two doses of placebo solution intranasal
89592718|NCT04415619|Experimental|Intervention group|10 patients will have immediate implant placement with buccal pad of fat free tissue
89592719|NCT01853384|Experimental|HP802-247 plus compression therapy|HP802-247 (fibrinogen solution & thrombin solution containing living, irradiated, growth arrested keratinocytes and fibroblasts) 260 µL (130 µL, one spray, of each solution) containing 0.5 X 10(6th) cells per mL every 14 days. Subjects randomized to HP802-247 will receive Vehicle on alternate weeks.
89592720|NCT01853384|Placebo Comparator|HP802-247 Vehicle plus compression therapy|fibrinogen solution & thrombin solution without cells. Subjects randomized to HP802-247 Vehicle will receive Vehicle weekly.
89592721|NCT01878890|Experimental|Efavirenz: 600 mg|Cohort 1 : Participants received 600 mg of Efavirenz (oral / once a day), until progression or toxicity.
89592722|NCT01878890|Experimental|Efavirenz: 1200 mg|Cohort 2 : Participants received 1200 mg of Efavirenz (oral / once a day), until progression or toxicity.
89592723|NCT01878890|Experimental|Efavirenz: 1800 mg|Cohort 3 : Participants received 1800 mg of Efavirenz (oral / once a day), until progression or toxicity.
89592724|NCT01878890|Experimental|Efavirenz: 2200 mg|Cohort 4 : Participants received 2200 mg of Efavirenz (oral / once a day), until progression or toxicity.
89592725|NCT04415606|Experimental|QuikClot Control+|QuikClot Control+
89592726|NCT04415606|Placebo Comparator|Standard gauze|Standard gauze per standard of care
88977976|NCT00238459||Recently infected patients|Cohort 1)Patients elcted to be immediately treated with licensed drugs:21 patients Cohort 2) Or to delay treatment until clinically indicated:16 patieints
88977977|NCT00238459||A vaccine,HIV-1 immunogen was not provided for evaluation|In the intial design, acandiate HIV vaccine was to be evaluated, but in August 2007 the manufacturer refused to provide vaccine to allow this study to evaluate the effect of a vaccine on control of HIV. Therefore the study became an observational study of the effects of early versus delayed initiation of antiretrovral therapy on the preservation of anti-HIV immune responses and the ability of patients to control virus after a closely monitored discontinuation of therapy.
88977978|NCT02967146|Experimental|Mediclore|
88977979|NCT02967146|No Intervention|Not done|Standard treatment for surgery
88977980|NCT00065585|No Intervention|Usual care|
88977981|NCT00065585|Placebo Comparator|non needle control|
88977982|NCT00065585|Sham Comparator|Acupuncture - Standardized Points|
88977983|NCT00065585|Experimental|Accupunture - Experimental Points|
88977984|NCT00238888|Experimental|Asthma control awareness|Multifaceted intervention to increase the patient awareness of the leve of asthma control
88977985|NCT00238888|Active Comparator|Usual care|Usual care
88977986|NCT04720924|Experimental|AQCS-aided group|Patients in AQCS-aided group will go through white light EGD examination with assistance of AQCS.
88977987|NCT04720924|No Intervention|Control group|Patients in control group will go through white light EGD examination without AQCS.
88977988|NCT00239083|Experimental|EC-MPS|
88977989|NCT02961829|No Intervention|Antiretroviral Treated (ART) Group|Five patients will receive no further intervention this group (control group)
89592727|NCT01827332|Active Comparator|Oxytocin|intranasal administration
89592728|NCT01827332|Placebo Comparator|Saline|intranasal administration
89592729|NCT01719003|Experimental|Empagliflozin low dose qd|Empagliflozin low dose once daily
89592730|NCT01719003|Experimental|Empagliflozin high dose qd|Empagliflozin high dose once daily
89592731|NCT01719003|Experimental|OL empa high dose + met 1000 mg bid|Open label empagliflozin high dose split twice daily + metformin 1000 mg twice daily - Patients are no longer enrolled into this arm because of change in the inclusion criteria in protocol version 2.0 all patients are now enrolled into remaining double-blind arms. Patients already enrolled in the open-label arm according to protocol version 1.0 can complete the study.
89592732|NCT01719003|Experimental|Empagliflozin low dose + met 500 mg bid|Empagliflozin low dose split twice daily + metformin 500 mg twice daily
89592733|NCT01719003|Experimental|Empagliflozin low dose + met 1000 mg bid|Empagliflozin low dose split twice daily + metformin 1000 mg twice daily
89592734|NCT01719003|Experimental|Empagliflozin high dose + met 500 mg bid|Empagliflozin high dose split twice daily + metformin 500 mg twice daily
89592735|NCT01719003|Experimental|Empagliflozin high dose + met 1000mg bid|Empagliflozin high dose split twice daily + metformin 1000 mg twice daily
89592736|NCT01719003|Experimental|Metformin 500 mg bid|Metformin 500 mg twice daily
89592737|NCT01719003|Experimental|Metformin 1000 mg bid|Metformin 1000 mg twice daily
89592738|NCT01853228|Experimental|Decitabine and cytarabine|
89592739|NCT01705587|Experimental|Immediate teriparatide|Open label teriparatide given immediately following surgical repair of fracture
89592740|NCT01705587|Experimental|Delayed teriparatide|Open label teriparatide given six months following surgical repair of fracture
89592741|NCT01718535||CYP2C19 Genotyping|
89592742|NCT01717989||Cohort|Patients with end-stage renal disease (ESRD) treated at small dialysis organizations (SDOs).
89592743|NCT01705509|Other|Ranolazine Treatment Arm|All patients who meet the criteria of ischemia will receive ranolazine after enrollment. The initial CPET will serve as the control. The second CPET after 30-days of therapy will serve as the therapy arm. CPET parameters will be assessed and compared both on and off therapy.
89592744|NCT04551183|Experimental|OnlyGroup|Patients are their own witnesses
89592745|NCT01853072|Experimental|Nepafenac|With prednisolone acetate standard of care, Nepafenac Ophthalmic Suspension, 0.3%, 1 drop instilled in the operative eye 1 day prior to surgery, continuing on the day of surgery, and for 90 days following surgery. An additional 1 drop will be administered 30 to 120 minutes prior to surgery.
89592746|NCT01853072|Placebo Comparator|Vehicle|With prednisolone acetate standard of care, Nepafenac vehicle, 1 drop instilled in the operative eye 1 day prior to surgery, continuing on the day of surgery, and for 90 days following surgery. An additional 1 drop will be administered 30 to 120 minutes prior to surgery.
89592747|NCT01877720|Experimental|NAVA-PS|noninvasive NAVA first for 15 minutes and then PSV for 15 minutes
88977990|NCT02961829|Experimental|ART Intensification Group|Five patients will receive antiretroviral intensification with maraviroc and dolutegravir for 48 weeks
88977991|NCT02961829|Experimental|ART Intensification + Nicotinamide Group|Five patients will receive antiretroviral intensification with maraviroc and dolutegravir and the Sirtuin Histone deacetylase inhibitor nicotinamide for 48 weeks.
88977992|NCT02961829|Experimental|ART Intensification + Auranofin Group|Five patients will receive antiretroviral intensification with maraviroc and dolutegravir for 48 weeks and the gold salt auranofin for 24 weeks.
88977993|NCT02961829|Experimental|ART Intensification + DC vaccine Group|Five patients will receive antiretroviral intensification with dolutegravir and for 48 weeks, and dendritic cell vaccine.
88977994|NCT02961829|Experimental|Multi Interventional Group|Five patients will receive antiretroviral intensification with dolutegravir and the Sirtuin Histone deacetylase inhibitor nicotinamide for 48 weeks, and gold salt for 24 weeks and dendritic cell vaccine.
88977995|NCT00239239|Experimental|test treatment period|
88977996|NCT00414349|Experimental|1|
88977997|NCT00414349|Active Comparator|2|
88977998|NCT00414349|Experimental|3|
89592748|NCT01877720|Experimental|PS-NAVA|noninvasive PSV first for 15 minutes and then NAVA for 15 minutes
89592749|NCT01870869|Experimental|Augmentation|Women who had breast augmentation with NATRELLE® 410 implants.
89592750|NCT01870869|Experimental|Reconstruction|Women who had breast reconstruction with NATRELLE® 410 implants.
89592751|NCT01870869|Experimental|Revision-Augmentation|Women who had revision of previous breast augmentation with NATRELLE® 410 implants.
89592752|NCT01870869|Experimental|Revision-Reconstruction|Women who had revision of previous breast reconstruction with NATRELLE® 410 implants.
89592753|NCT01877408|Active Comparator|Open surgical circumcision|The open surgical technique, which is commonly used for circumcision in South Africa, requires good surgical skills and minor complications are common.
89592754|NCT01877408|Experimental|Unicirc device with tissue adhesive|Coupling removal of the foreskin using the disposable Unicirc device with wound sealing using tissue adhesive results in a procedure that can be performed by generalist doctors with minimal training.
89592755|NCT01717287|Experimental|Raltegravir Film-coated Tablet|Raltegravir film-coated tablet 400 mg administered orally twice-daily, in combination with other anti-retroviral therapy for 24 weeks
89592756|NCT01717287|Experimental|Raltegravir Chewable Tablet|Raltegravir chewable tablet weight-based dose up to 300 mg administered orally twice-daily, in combination with other anti-retroviral therapy for 24 weeks
89592757|NCT01827254||Non-Interventional Study|
89592758|NCT01824602|Experimental|Group 1|Eslicarbazepine acetate 1800 mg
89592759|NCT01824602|Experimental|Group 2|Eslicarbazepine acetate 1200 mg
89592760|NCT01824602|Experimental|Group 3|Eslicarbazepine acetate 600 mg
89592761|NCT01824602|Placebo Comparator|Group 4|Placebo pills
89592762|NCT01704651|Experimental|Alvimopan|Perioperative administration of oral alvimopan, 12mg twice daily, starting with 1 dose preoperative. Drug was continued for duration of hospital stay, but did not exceed 7 days.
89592763|NCT01704651|Placebo Comparator|Placebo|Perioperative administration of placebo, at same dosing interval as study drug.
88977999|NCT00098397|Experimental|Treatment (romidepsin)|Patients receive FR901228 (depsipeptide) IV over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88978000|NCT02966990|Other|hand orthosis patients|Patients using hand orthosis for better hand function
88978001|NCT00239551|Experimental|Prevacid|Effect of Prevacid at 8 weeks; EGD(esophagogastroduodenal endoscopy) at day 1 & EGD at 8 weeks
88978002|NCT00239707|Experimental|Infusion 1|Normal Saline
88978003|NCT00239707|Placebo Comparator|Infusion 2|GIP or modified GIP
88978004|NCT00239707|Placebo Comparator|Infusion 3|GIP or modified GIP, opposite of Infusion 2
88978005|NCT00239746|Experimental|1|
88978006|NCT00239746|Placebo Comparator|2|
88978007|NCT00239824|Experimental|1|Strength training of the pelvic floor muscles with follow up instructions by a physiotherapist
88978008|NCT00239824|Active Comparator|2|Strength training of the pelvic floor muscles without follow up instructions
89592764|NCT01876706|Experimental|UroLift® System|Single-arm of qualified subjects receiving UroLift® System intervention.
89592765|NCT01876082|Experimental|PAZOPANIB|"Pazopanib~800 mg per day~oral administration~at least 1 hour before or 2 hours after a meal,~until disease progression or for 12 months maximum"
89592766|NCT01876082|Active Comparator|Vinblastine and Methotrexate|vinblastine 5 mg / m², methotrexate 30 mg / m (J1, J8, J15, J21, 6 months and then J1, J15) 28 days per cycle until disease progression or for 12 months.
89592767|NCT01704495|Experimental|AZD5069 5 mg|AZD5069 oral capsules self-administered twice daily
89592768|NCT01704495|Experimental|AZD5069 15 mg|AZD5069 oral capsules self-administered twice daily
89592769|NCT01704495|Experimental|AZD5069 45 mg|AZD5069 oral capsules self-administered twice daily
89592770|NCT01704495|Placebo Comparator|Placebo|Placebo oral capsules self-administered twice daily
89592771|NCT01716663||Experimental: Catheter Ablation|These patients have drug refractory recurrent symptomatic paroxysmal AF, are 18 years and older, and are able and willing to provide written informed consent to participate in the study and comply with study requirements.
89592772|NCT01716585|Experimental|ABT-450/r/ABT-267 and ABT-333, plus RBV|Double-blind ABT-450/r/ABT-267 (150 mg/100 mg/25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based ribavirin (RBV; dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
89592773|NCT01716585|Experimental|Placebo Followed by ABT-450/r/ABT-267 and ABT-333, plus RBV|Double-blind placebo for 12 weeks, followed by open-label ABT-450/r/ABT-267 (150 mg/100 mg/25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (RBV; dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
89592774|NCT01852292|Experimental|Buparlisib + weekly Paclitaxel|Patients who were randomized to this arm on a 1:1 randomization, took buparlisib 100 mg daily and paclitaxel 80 mg/m^2 weekly.
89592775|NCT01852292|Placebo Comparator|Buparlisib matching placebo + Paclitaxel|Patients who were randomized to this arm on a 1:1 randomization, took buparlisib matching placebo 100 mg daily and paclitaxel 80 mg/m^2 weekly.
89592776|NCT01715805|Other|Placebo + ADT Lead-in|Antidepressant therapy (ADT) as prescribed by the investigator plus single-blind placebo for 8 weeks.
88978009|NCT00098514|Experimental|Dose Level 1a|10 mg/m2 dose of PT523 administered day 1 of a 28-day cycle as a 5 minute IV infusion (IV bolus)
88978010|NCT00098514|Experimental|Dose Level 1b|5 mg/m2 dose of PT523 administered days 1 and 8 of a 28-day cycle as a 5 minute IV infusion
88978011|NCT00098514|Experimental|Dose Level 1c|3.33 mg/m2 dose of PT523 administered days 1, 8 and 15 of a 28-day cycle as a 5 minute IV infusion
88978012|NCT00098514|Experimental|Dose Level 2|5 mg/m2 dose of PT523 administered days 1, 8 and 15 of a 28-day cycle as a 5 minute IV infusion
88978013|NCT00098514|Experimental|Dose Level 3|7.5 mg/m2 dose (or 6.7 mg/m2 depending on observed toxicity) of PT523 administered days 1, 8 and 15 of a 28-day cycle as a 5 minute IV infusion
88978014|NCT00098514|Experimental|Dose Level 4|11.25 mg/m2 dose (or 9 mg/m2 depending on observed toxicity) of PT523 administered days 1, 8 and 15 of a 28-day cycle as a 5 minute IV infusion
88978015|NCT00098514|Experimental|Dose Level 5|17 mg/m2 dose (or 12 mg/m2 depending on observed toxicity) of PT523 administered days 1, 8 and 15 of a 28-day cycle as a 5 minute IV infusion
88978016|NCT00239980|Active Comparator|A|50 IU/kg
88978017|NCT00239980|Active Comparator|B|100 IU/kg
88978018|NCT00239980|Active Comparator|C|150 IU/kg
88978019|NCT00240058|Other|phenylephrine infusion with and without nitric oxide clamp|Participants received phenylephrine infusion with saline followed by phenylephrine infusion with nitric oxide clamp
88978020|NCT00098553|Experimental|everolimus|"Patients receive oral everolimus once daily for 8 weeks. Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity.~Patients are followed every 2 months until disease progression and then every 4 months for up to 5 years after registration."
88978021|NCT00240214||1|sirolimus
88978022|NCT00240253|Active Comparator|Pramlintide|
88978023|NCT00098631|Experimental|Treatment (lapatinib ditosylate)|Patients receive oral lapatinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88978024|NCT00240565|Experimental|Arm 1|Participants underwent two phases of treatment: an initial DD, followed by a therapeutic dose. The one-day DD comprised a 1 hr IV infusion of 450 mg unlabeled TST, followed by a 20 min IV infusion of 35 mg TST labeled with 185 MBq (5.0 mCi) of I 131. After 7 to 14 days, the one-day therapeutic dose comprised a second 1 hr IV infusion of 450 mg unlabeled TST, followed by a 20 min IV infusion of 35 mg TST labeled with I 131 with an administered activity (MBq or mCi) determined from the dosimetry calculation.
88978025|NCT00066014|Active Comparator|treatment modalities changed for comparison|All subjects experienced all treatment modalities being studied.
88978026|NCT00076791|Active Comparator|1|Each participant in Cohort 1 received a single 600 mg oral dose of TDF at the start of active labor or 4 hours prior to C-section, with concurrent administration of standard intravenous zidovudine (ZDV) prophylaxis and/or other antiretrovirals prescribed by her physician. The infants from Cohort 1 received only the standard 6 weeks of oral ZDV prophylaxis postpartum.
88978027|NCT00076791|Active Comparator|2|Mothers in Cohort 2 will receive a single dose of 900 mg of TDF combined with 600 mg emtricitabine, along with standard ZDV prophylaxis and/or other antiretrovirals prescribed by her physician. Infants will receive a single dose of TDF at 4 mg/kg combined with 3 mg/kg emtricitabine as soon as possible after delivery and within 6 hours of age as well as the standard 6 weeks of oral ZDV prophylaxis after birth.
88978028|NCT00066053|Experimental|Periodontal Treatment: SRP|Comprehensive scaling & root planing and subgingival tissue removal; fluorides applied as appropriate; oral hygiene instructions.
88978029|NCT00066053|Active Comparator|Community Comparator|Referral to community dentist with copy of x-rays and letter with diagnosis and recomendations for treatment.
88978030|NCT00240682|Experimental|cetuximab|cetuximab
88978031|NCT00066092|Experimental|Pegfilgrastim 6 mg|Pegfilgrastim 6 mg given once for PBPC mobilization
88978032|NCT00066092|Experimental|Pegfilgrastim 12 mg|Pegfilgrastim 12 mg given once for PBPC mobilization
88978033|NCT00066092|Active Comparator|filgrastim|Filgrastim given daily for PBPC mobilization
89209965|NCT04036422|Active Comparator|Conventional treatment group|The fifteen patients included in this arm of the study will receive a one hourly 'one-on-one' session of conventional physical therapy five days a week, to a total of twenty hours over a four week period. In addition to this, patients in this group will receive one hourly sessions of conventional occupational therapy seven days a week to a total of twenty eight hours over a four week period.
88978034|NCT04720807|Experimental|Letrozole combined with anlotinib hydrochloride|Letrozole combined with anlotinib hydrochloride in the treatment of platinum-resistant recurrent ovarian cancer.
89209966|NCT00892164|Active Comparator|FOCUS (Group A)|Patients submitted to total thyroidectomy with the use of the FOCUS harmonic scalpel device
89592777|NCT01715805|Placebo Comparator|Placebo + ADT (Double-Blind)|Following the 8 week ADT plus single blind placebo lead-in period participants were randomized to dose-matched placebo, once per day, oral administration plus ADT for 8 weeks (up to Week 16).
89592778|NCT01715805|Experimental|Cariprazine + ADT (Double-Blind)|Following the 8 week ADT plus single blind placebo lead-in period participants were randomized to cariprazine, 1.5 to 4.5 milligrams (mg) per day, oral administration plus ADT for 8 weeks (up to Week 16).
89592779|NCT01715805|Other|Placebo + ADT (Continued Treatment)|Following the 8 week ADT plus single blind placebo lead-in period, participants who were ADT responders continued treatment with ADT plus placebo for an additional 8 weeks.
89031044|NCT02947269|Experimental|Intervention group|Patients will receive an oral capsule containing 2mg Prucalopride 2-3 hours preoperatively. Study medication (2mg oral Prucalopride daily) will continue for 6 days postoperatively or until the patient has achieved the study's primary outcome.
89592780|NCT01852214|Active Comparator|Prasugrel first, then ticagrelor|Patients randomized to prasugrel will receive prasugrel loading dose followed by maintenance dose. Randomized treatment will be maintained for 1-week (7±2 days). After completion of the 1-week treatment period, patients will discontinued the study medications for 2-4 weeks (wash-out period) and then will cross over to the alternate treatment (ticagrelor), which will be administered for 1-week.
89592781|NCT01852214|Active Comparator|Ticagrelor first, then prasugrel|Patients randomized to ticagrelor will receive prasugrel loading dose followed by maintenance dose. Randomized treatment will be maintained for 1-week (7±2 days). After completion of the 1-week treatment period, patients will discontinued the study medications for 2-4 weeks (wash-out period) and then will cross over to the alternate treatment (prasugrel), which will be administered for 1-week.
89592782|NCT01393990|Experimental|LY2228820|"The study had 4 parts, dose-escalation (Part A), 2 dose-confirmation (Parts B and C), and a tumor-specific expansion for metastatic breast cancer (Part D).~Part A: Participants received escalating doses of 10, 20, 40, 65, 90, 120, 160, 200, 300, 420 and 560 milligrams (mg) of LY2228820 every 12 hours on Days 1 through 14 of a 28-day cycle.~Part B: Participants received 420 mg of LY2228820 every 12 hours Days 1 through 14 of a 28-day cycle. Participants received midazolam orally 2 days before the first dose and again after the morning dose of study drug on Day 8 during the first cycle of treatment.~Part C: Participants received 300 mg of LY2228820 every 12 hours Days 1 through 14 of a 28-day cycle.~Part D: Participants received 200 mg and 300 mg of LY2228820 in combination with tamoxifen."
89592783|NCT00210184|Experimental|Irinotecan associated to fluorouracil and leucovorin|"On D1, as a single 90-minute intravenous infusion diluted in 250 ml of saline (sodium chloride a 9 ‰), or isotonic glucose, at a dose of 180 mg/m2. Dosage adjustments are provided in case of severe toxicity.~Then 5FU/ folinic acid: 400 mg/m2 of 5-FU as an IV bolus followed by a continuous 2400 mg/m2 infusion over 46 hours with 400 mg/m2 of folinic acid or 200 mg/m2 of l-folinic acid as a 2-hour infusion before 5-FU administration.~Doses of 5-FU are adjusted according to clinical tolerance. Resume on D15 for 6 months"
89592784|NCT00210106|Experimental|Intraoperative radiofrequency ablation (IRFA)|IRFA treatment, either with or without resection, was performed at laparotomy within 28 days of inclusion in the study. The type of IRFA current generator and probes, and whether or not resection was performed, was at the discretion of the surgeon.
89592785|NCT05361694||Participants with MGUS or SMM|Participants with either Monoclonal gammopathy of undetermined significance (MGUS) or smoldering myeloma (SMM) will be followed for disease progression to active multiple myeloma (MM) for up to 5 years.
89592786|NCT05368480|Experimental|Senior Companion|Receives a companion to socialize with them, help with daily tasks, etc.
89592787|NCT05368480|No Intervention|Control|Referred to other services available in the community
89592788|NCT05369572||Bile Reflux Group|"Gastroscopic reports of enrolled patients will be extracted and patients will be identified as having bile reflux according to Kellosalo J classification.~Grade I: small amount of yellowish reflux emerging from the pyloric orifice and/or yellowish staining of the mucus lake, which is pale yellow in colour.~Grade II: intermittent gush of reflux from the pyloric opening and/or yellowish staining of the mucus lake, which is dark yellow.~Grade III: frequent gush of yellow-green reflux from the pyloric orifice and/or yellow-green mucus covering the stomach."
89592789|NCT05369572||Non-biliary reflux group|Gastroscopic reports will be extracted from patients enrolled in the group that do not meet the Kellosalo J classification as the non-biliary reflux group.
89592790|NCT00210964|Experimental|001|ceftobiprole plus placebo ceftobiprole 500 mg every 8 hours as a 120 minute intravenous infusion and placebo administered every 12 hours as a 60-minute intravenous infusion for 7 to 14 days
89592791|NCT00210964|Active Comparator|002|linezolid plus ceftazidime linezolid 600 mg every 12 hours as a 60-minute intravenous infusion plus ceftazidime 2 g every 8 hours as a 120-minute intravenous infusion for 7 to 14 days
89592792|NCT00210652|Experimental|001|RWJ 333369: Open-Label Extension: One 250mg tablet twice daily up to a total of 1200mg/day up until RWJ-33369 is available by prescription or study is terminated by sponsor
89592793|NCT05369104|Experimental|Bacteriophages arm|1 mL (PP1493 or PP1815) or 2 mL (PP1493 and PP1815) of suspension of bacteriophages diluted in solution of NaCl 0,9% at the end of DAIR procedure.
89592794|NCT05369104|Placebo Comparator|Control Arm|One local administration of NaCl 0,9% solution is administered at the end of the DAIR procedure.
89592795|NCT05365126|Experimental|Complete Vocal Technique Voice Therapy|Up to six 45 minute sessions delivered by a CVT Practitioner using a video link within an eight week therapy period
89592796|NCT05362162|Active Comparator|Group S|Superficial cervical plexus block; After asepsis and antisepsis are achieved, it will be performed by injecting 10 ml of the local anesthetic agent into the subcutaneous area in the anterolateral neck region, from the anatomical region that fits the carotid artery bifurcation point, under the guidance of USG.
89592797|NCT05362162|Active Comparator|Group I|Intermediate cervical plexus block; After asepsis and antisepsis are achieved, it will be performed by injecting 10 ml of the local anesthetic agent under the investing fascia from the anatomical region that fits the carotid artery bifurcation point under the guidance of USG.
89031045|NCT02947269|Placebo Comparator|Placebo group|Patients will receive an oral capsule containing a placebo 2-3 hours preoperatively. Study medication (placebo) will continue for 6 days preoperatively or until the patient has achieved the study's primary outcome.
89031046|NCT04696016|Experimental|Skin conductance guided|Sufentanil is titrated by the intensive care team to maintain skin conductance in target
89031047|NCT04696016|Active Comparator|Standard care|Sufentanil is titrated at the discretion of the intensivist
89031048|NCT02276768|Experimental|GIC-1001 mid-dose|GIC-1001 , 375 mg TID during 3 consecutive days + a 10th dose in the morning of day 4 (colonoscopy day)
89031049|NCT02276768|Experimental|GIC-1001 high-dose|GIC-1001 , 500 mg TID during 3 consecutive days + a 10th dose in the morning of day 4 (colonoscopy day)
89031050|NCT02276768|Active Comparator|GIC-1002 mid-dose|GIC-1002 345 mg TID (equimolar to GIC-1001 375 mg) 345 mg TID during 3 consecutive days + a 10th dose in the morning of day 4 (colonoscopy day)
89592798|NCT02985268|Active Comparator|MitraClip/Optimal Medical Therapy (OMT) and CRT ON|Patient to be implanted with both MitraClip and CRT-D. Will also receive optimal medical therapy. CRT-D will be programmed to ON
89592799|NCT02985268|Active Comparator|MitraClip/OMT and CRT OFF|Patient to be implanted with both MitraClip and CRT-D. Will also receive optimal medical therapy. CRT-D will be programmed to OFF until the 6-month follow-up visit in which the CRT will be turned ON
89592800|NCT02985268|Active Comparator|OMT and CRT ON|"Patient to be implanted with only the CRT-D and will receive optimal medical therapy.~CRT-D will be programmed to ON"
89592801|NCT02985268|Active Comparator|OMT and CRT OFF|"Patient to be implanted with only the CRT-D and will receive optimal medical therapy.~CRT-D will be programmed to OFF until the 6-month follow-up visit in which the CRT will be turned ON"
89592802|NCT05630560||Psychologists in Danish private practice|All psychologists with a Danish university degree in psychology who have registered themselves as seeing clients in private practice (app. 1,750) have been invited to participate in the study. Thus, the sample of psychologists consists of psychologists employed in the Danish practice sector, where clients obtain a refund of 60% of the psychologist's salary, as well as psychologists working privately without any reimbursement of their salaries. Each psychologist enrolled in the study has agreed to aim to recruit no less than 10 clients each for the study. We aim to include 100 psychologists, which will yield a sample of 1,000 clients beginning therapy.
89592803|NCT04022122||Heart Failure patients|The study does not imply any specific therapeutic intervention, and will not imply any change in the management of the participating patients, who will follow the usual clinical controls and will receive the medical and invasive treatments usually provided to patients with HF in our health area; as well as the different modalities of specific health education for this disease. At the time of hospital discharge, patients will be handled according to the usual protocols of the center established for outpatient follow-up of HF patients.
89592804|NCT04019314|Experimental|Subjects with know chronic systolic heart failure|Subjects with know chronic systolic heart failure (LVEF<50%) admitted to SMH Heart Failure Medical Service for decompensated HF with clinical findings of volume overload requiring advanced diuretic therapy intervention and management will receive daily blood draws and quantitative blood volume analysis
89592805|NCT05366608||RA patients|188 patients with RA he RA activity parameters were evaluated in RA patients. BMD was measured. Serum level of 14.0- 3.0- 3.0- η protein and IL_.6 were estimated for all participants by ELISA.
89592806|NCT05366608||Control|192 matched controls were enrolled. T
89592807|NCT03995992|Active Comparator|multi sport|During 10 days, each morning, from 9 am to 12 pm, participants had sporting activities: mountain walking, mountain biking, climbing, canyoning and collective orienteering running. From 3 pm, they had individual and collective practical workshops based on PTSD psychoeducation, human resources competences and coaching, including a curriculum vitae workshop. During their free time, they could take part in collective activities like table football, pool, party games or have a rest. Relaxation exercises were proposed every day after the sporting activity and before dinner.
89592808|NCT03995992|Experimental|diving|During 10 days, each morning, from 9 am to 12 pm, participants had diving activities. From 3 pm, they had individual and collective practical workshops based on PTSD psychoeducation, human resources competences and coaching, including a curriculum vitae workshop. During their free time, they could take part in collective activities like table football, pool, party games or have a rest. Relaxation exercises were proposed every day after the sporting activity and before dinner.
89592809|NCT03995056|No Intervention|Control-group|Subjects diagnosed with NAFLD and a sedentary lifestyle will have no changes in their habits and diets.
89031051|NCT02276768|Active Comparator|GIC-1002 high-dose|GIC-1002 460 mg (equimolar to GIC-1001 500 mg) 460 mg TID during 3 consecutive days + a 10th dose in the morning of day 4 (colonoscopy day)
89031052|NCT02276768|Placebo Comparator|Placebo matching GIC-1001 and GIC-1002|"Placebo matching GIC-1001 doses Placebo matching GIC-1002 doses~Placebo, TID during 3 consecutive days, + a 10 th dose in the morning of day 4 (colonoscopy day)"
89031053|NCT05148221|Experimental|A three-week tailored, virtual exercise intervention.|A three-week tailored, virtual exercise intervention.
89031054|NCT00526344||1|Subjects with complete remission of asthma
89031055|NCT00526344||2|Subjects with symptomatic remission of asthma
89031056|NCT00526344||3|Subjects with asthma
89592810|NCT03995056|Experimental|Exercise-group|This group with diagnosed NAFLD patients will perform a high-intensity aerobic interval exercise training without changing their diets.
89592811|NCT03792958|Experimental|CM082|CM082 tablet
89031057|NCT00526344||4|Healthy controls
89031058|NCT05143268||A|In the experimental arm (arm A), a total of 11 sessions of acupuncture will be performed on a weekly basis, spanning from 2 weeks before Radiotherapy start throughout 7 weeks of treatment, to 2 weeks after its completion. Patients randomized to the experimental arm will receive acupuncture in addition to standard of care treatment, chosen by the treating multidisciplinary team in accordance with international guidelines.
89031059|NCT05143268||B|In the standard arm (arm B), patients will be treated with standard of care treatment.
89031060|NCT00526383|Experimental|A|antidepressant versus medical dispositive
89031061|NCT00526383|Placebo Comparator|B|
89031062|NCT05145257|Other|Elix Cycle Balance|Elix Cycle Balance supplement
89031063|NCT05147753|Experimental|Group|0.6 mg moxonidine daily
89031064|NCT00525408|Experimental|2|Docetaxel+Mw
89031065|NCT00525408|Active Comparator|1|Docetaxel
89031066|NCT02953925||primary health care users|Subjects with high risk of cardiovascular diseases who lived in the catchment areas of the participating PHC institutions.
89031067|NCT00508235||Quality of Friendships|Patients with Neurofibromatosis, type 1 (NF-1) between the ages of 8 and 18 years old.
89031068|NCT00525447|Experimental|1|
89031069|NCT00525486|Experimental|A|The treated group of pregnant women, after having successful treatment for PTL
89031070|NCT00525486|No Intervention|B|The no treatment arm of women treated with tocolysis for PTL.
89592812|NCT04407208|Experimental|Convalescent plasma recipient|Recipients receive 3 times of each 100 ml convalescent plasma on day 0, 3, and 6
89592813|NCT04766554|Active Comparator|Cerebral Oxymetry Monitoring|"The following procedures should be performed sequentially in the event of cerebral desaturation after 30 seconds:~The positioning of the head, the presence of facial plethora, and bad position of catheters should be corrected;~In case of arterial hypotension, the causal factors should be assessed and treated;~In the presence of arterial hypoxemia, the causal factors should be assessed and treated to maintain a PaO2 > 150 mmHg;~In the presence of hypercapnia, adjust the ventilation parameters avoiding hyperventilation;~In the presence of anemia, the causal factors should be assessed, and the decision to undergo transfusion should also take into consideration the presence of tissue hypoperfusion;~In cases of SvO2 below 70% and signs of hemodynamic instability, optimize fluid replacement and ventricular global contractility;~Assess the increase of brain consumption of O2, avoiding the superficial level of anesthesia, hyperthermia, and tremors."
89592814|NCT04766554|No Intervention|Control Group|Patients will be treated according to the attending anesthesiologist, without the monitoring of cerebral oximetry, but to maintain a heart rate between 70 - 100 bpm, lactate levels <3 mmol/L and urine output> 0.5mL/Kg/h. In case of arterial hypotension the causal factors should be assessed and treated; in case of SvO2 below 70% and signs of hemodynamic instability, optimize volume replacement and global ventricular contractility through inotropic agents (epinephrine, dobutamine or milrinone); in the presence of anemia (Hb <6 to 7g/dL during CPB or Hb <8g/dL in the pre-CPB or post-CPB period), the causal factors should be assessed and the decision to transfuse should also take into account the presence of hypoperfusion tissue (increased lactate, low SvO2, acidosis); in episodes of bradycardia with hemodynamic instability, atropine may be used.
89592815|NCT05632510|Other|EPDS Group|
89592816|NCT05632510|No Intervention|Courent practice Group|
89592817|NCT03599050|Experimental|Communication Simulation|Nurses will use simulation over 12 weeks while fidelity is monitored using the NIH Behavior Change Consortium Treatment Fidelity Guidelines.
89592818|NCT03593512|Experimental|PPN DBS|All patients will undergo bilateral PPN DBS
89592819|NCT03595462|Experimental|Snack|The study participants will be provided with a snack to consume every day of the week. The energy content of the snacks will be standardized to ~240 kcal. The snacks will have different levels of protein, fat, carbohydrates, sugar, and fiber.
89592820|NCT03595462|Placebo Comparator|No Snack|The study participants will not be provided with any snack and will be told to consume nothing from 2-4pm for a week.
89592821|NCT03990532|Experimental|treatment group|
89592822|NCT03990064|Experimental|musicotherapy|daily sessions of music listening during 2 months, associated with their standard treatment,
89592823|NCT03990064|No Intervention|waiting list|waiting list
89592824|NCT05632042|Experimental|lifestyle-modification group|erectile dysfunction (ED) psoriatic men with metabolic syndrome (group = 30 patients) will receive lifestyle changes (12 weeks of low calorie diet and moderate-intensity walking on treadmill, the walking duration will be 40 minutes, the walking will be three times per week)
89592825|NCT05632042|No Intervention|control group|erectile dysfunction (ED) psoriatic men with metabolic syndrome (number of the patients will be 30) that will receive no lifestyle changes/modifications.
89592826|NCT03595306|Experimental|Prebiotic A|
89592827|NCT03595306|Experimental|Prebiotic B|
88978035|NCT00098826|Experimental|Treatment (ispinesib)|"Induction chemotherapy: Patients receive SB-715992 IV over 1 hour on days 1-3. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.~Consolidation chemotherapy: Patients achieving CR, PR, or SD after induction chemotherapy receive up to 4 additional courses of SB-715992 beyond CR, PR, or SD.~Cohorts of 3-6 patients receive SB-715992 until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. At least 9 patients are treated at the MTD."
88978036|NCT00240799|Experimental|001|acetaminophen extended release
88978037|NCT00240799|Placebo Comparator|002|placebo
88978038|NCT00240877|Experimental|1|Monovalent vaccine prior to the release of the trivalent vaccine (FluMist).
88978039|NCT00240877|Placebo Comparator|2|Placebo
88978040|NCT02965404|Experimental|Experimental Group|"Single intramuscular injection of the investigational vaccine (0.5 ml) on Day 0;~Intervention: investigational live attenuated varicella vaccine."
88978041|NCT02965404|Active Comparator|Positive Control Group|"Single intramuscular injection of the control vaccine (0.5 ml) on Day 0;~Intervention: control live attenuated varicella vaccine."
88978042|NCT02965404|Sham Comparator|Negative Control Group|"Single intramuscular injection of the diluent of lyophilized vaccine (0.5 ml) on Day 0;~Intervention: diluent of lyophilized vaccine."
88978043|NCT00241111|Other|Zometa|
88978044|NCT00066131|Active Comparator|Scaling and root planing|Scaling and root planing delivered prior to 21 weeks of gestation.
88978045|NCT00066131|No Intervention|Placebo|Delayed treatment group. Controls monitored clinically from baseline to 29-32 weeks of gestation. Scaling and root planing provided after delivery.
88978046|NCT00066248|Experimental|Subjects that respond to Periactin|Receive 0.25mg/kg cyproheptadine hydrochloride once daily for 4 weeks. If subject responds to treatment (stable or increased weigh), go off study. If subject does not respond (loses weigh), subject will switch to10 mg/lg/day of megestrol acetate for 4 weeks.
88978047|NCT00066248|Experimental|Non-responders to Periactin- Megace Arm|Receive 0.25mg/kg cyproheptadine hydrochloride once daily for 4 weeks. If subject responds to treatment (stable or increased weigh), go off study. If subject does not respond (loses weigh), subject will switch to10 mg/lg/day of megestrol acetate for 4 weeks.
89592828|NCT03595306|Experimental|Prebiotic C|
89592829|NCT05631652|Experimental|PillSense System|All subjects were asked to swallow a PillSense Capsule, followed by the ingestion of autologous blood mixed with water, to verify the ability of the PillSense System to correctly identify blood.
89592830|NCT03594916|Experimental|Active tDCS|The anode sponge electrode will be placed on the scalp over the left primary motor cortex (M1) and the cathode sponge electrode will be positioned over the right supraorbital cortex (SO). Active stimulation consists of 2 mA current applied continuously for 20 minutes.
88978048|NCT00241189|Experimental|Rapamycin|Patients take oral rapamycin 6 mg daily (and dose adjusted to keep a serum trough level of 5-15 ng/ml) for one year
88978049|NCT00241189|Active Comparator|Methotrexate|Methotrexate 20 mg taken orally weekly for one year
88978050|NCT00241228|Experimental|High Volume|ultra filtration : High volume : 70 ml/kg/h
88978051|NCT00241228|Active Comparator|Medium Volume|Ultra filtration : conventional volume : 35 ml/kg/h
88978052|NCT00241345|Experimental|Group A|IV ganciclovir (5mg/kg every 12 hours for 7 days followed by 5mg/kg every 24 hours for 7 days. If CMV viral load <5000 copies/ml after 14 days then 5mg/kg every 24 hours for a total of 21 total days of therapy. If CMV viral load >5000/ml but less than index viral load after 14 days then 5mg/kg every 24 hours for a total of 28 total days of therapy. If CMV viral load >= index viral load after 14 days then 5mg/kg every 12 hours for 7 days. If repeat CMV viral load is <= the previous CMV viral load then 5mg/kg every 12 hours for an additional 7 days.
88978053|NCT00241345|Experimental|Group B|PO valganciclovir (900 mg every 12 hours for 7 days followed by 900 mg every 24 hours for 7 days. If CMV viral load <5000 copies/ml after 14 days then 900 mg every day until 21 total days of therapy. If CMV viral load >5000 copies/ml after 14 days but less than the index viral load then 900 mg every day until 28 total days of therapy. If CMV viral load >= the index viral load 900 mg every 12 hours for 7 days, if CMV viral load <= to previous viral load then 900 mg every 12 hours for another 7 days.
88978054|NCT00241384|Active Comparator|Pd-103 with 20Gy External Beam|Pd-103 with 20Gy External Beam
88978055|NCT00241384|Active Comparator|Pd-103 alone|Pd-103 alone
88978056|NCT00241423|Experimental|Exenatide|Exenatide and the subject's current oral antidiabetic agent regimen
88978057|NCT00241423|Placebo Comparator|Placebo|Placebo and the subject's current oral antidiabetic agent regimen
88978058|NCT04720690||Appropriately grown for age infants|40 appropriately grown for gestational age (AGA) infants. 20 will be <32 weeks, and 20 will be ≥32 weeks gestational age at birth.
88978059|NCT04720690||Small for gestational age infants|40 small for gestational age (SGA) infants. 20 will be <32 weeks, and 20 will be ≥32 weeks gestational age at birth.
88978060|NCT04720690||Fetal growth restricted infants|40 fetal growth restricted (FGR) infants. 20 will be <32 weeks, and 20 will be ≥32 weeks gestational age at birth.
89209967|NCT00892164|Active Comparator|LIGASURE (Group Β)|Patients submitted to total thyroidectomy with the use of the electrothermal bipolar vessel sealing device
89592831|NCT03594916|Sham Comparator|Sham tDCS|The anode sponge electrode will be placed on the scalp over the left primary motor cortex (M1) and the cathode sponge electrode will be positioned over the right supraorbital cortex (SO). The 2 mA current will be applied for 30 seconds at the beginning of the session.
89592832|NCT03989362|Experimental|LM1|Phase 2 study of vopratelimab by intravenous (IV) infusion administered in combination with ipilimumab by IV infusion in NSCLC
89592833|NCT03989362|Experimental|LT1|Phase 2 study of vopratelimab by IV infusion administered in combination with ipilimumab by IV infusion in NSCLC
89592834|NCT03989362|Experimental|UM1|Phase 2 study of vopratelimab by IV infusion administered in combination with ipilimumab by IV infusion in urothelial cancer
89592835|NCT03989362|Experimental|UT1|Phase 2 study of vopratelimab by IV infusion administered in combination with ipilimumab by IV infusion in urothelial cancer
89592836|NCT03989362|Experimental|LM2|Phase 2 study of vopratelimab by intravenous (IV) infusion in administered in sequence with ipilimumab by IV infusion in NSCLC
89592837|NCT03989362|Experimental|LT2|Phase 2 study of vopratelimab by intravenous (IV) infusion in administered in sequence with ipilimumab by IV infusion in NSCLC
89592838|NCT03989362|Experimental|UM2|Phase 2 study of vopratelimab by intravenous (IV) infusion in administered in sequence with ipilimumab by IV infusion in urothelial cancer
89592839|NCT03989362|Experimental|UT2|Phase 2 study of vopratelimab by intravenous (IV) infusion in administered in sequence with ipilimumab by IV infusion in urothelial cancer
89592840|NCT04009096|Experimental|Group 1|3 volunteers receiving 5 x 10^10 vp ChAd63 PvDBP and 2 x 10^8 pfu MVA PvDBP 8 weeks later, in a heterologous prime-boost regimen, followed by blood-stage CHMI 2-4 weeks later.
89592841|NCT04009096|Experimental|Group 2|Up to 10 volunteers receiving one dose of 5 x 10^10 vp ChAd63 PvDBP, 12-18 months later receiving a second dose of 5 x 10^10 vp ChAd63 PvDBP and 8 weeks later 2 x 10^8 pfu MVA PvDBP, followed by blood-stage CHMI 2-4 weeks later.
89592842|NCT04009096|Experimental|Group 3|"If fewer than 6 volunteers complete the study in Group 2, then new volunteers will be recruited into Group 3, to make up a total of 6 volunteers between Groups 2 and 3 who complete all vaccinations and CHMI.~Volunteers in Group 3 will receive 5 x 10^10 vp ChAd63 PvDBP and 2 x10^8 pfu MVA PvDBP 8 weeks later, in a heterologous prime-boost regimen, followed by blood-stage CHMI 2-4 weeks later."
89592843|NCT03594838|Experimental|Decentralized testing approach|Harm reduction site HCV viremia testing approach A. Four HRS will conduct blood draw and point-of-service (decentralized) HCV RNA testing, and results will be provided at the HRS on the same or the following day.
89592844|NCT03594838|Experimental|Centralized testing approach|Harm reduction site HCV viremia testing approach B. Two sites will collect blood samples on site and transport them to a reference (centralized) laboratory for HCV viremia testing. Results will be provided at a follow-up visit to the HRS as soon as results are available.
89592845|NCT03594838|No Intervention|Standard of Care|Current standard of care. Patients who screen anti-HCV positive at HRS will be referred to HCV treatment centers for HCV RNA testing, and results will be provided at a follow-up visit to the treatment center.
89592846|NCT05631106|Active Comparator|Stretching, Balance, Range of Motion|Participants will engage stretching, balance, and range of motion exercises 2 days per week for 12-weeks.
89592847|NCT05631106|Experimental|High Intensity Interval Resistance Training|Participants will perform resistance training exercises at high intensity intervals 2 days per week for 12-weeks.
89592848|NCT03599596|Active Comparator|Two doses of sulphadoxine-pyrimethamine|500mg of sulphadoxine and 25mg of pyrimethamine 3 tablets taken twice before delivery
89592849|NCT03599596|Active Comparator|Monthly doses of sulphadoxine-pyrimethamine|500mg of sulphadoxine and 25mg of pyrimethamine 3 tablets taken monthly delivery
89592850|NCT04407130|Active Comparator|Tab Ivermectin +Cap Doxycycline|"200 mcg/kg (12 mg tablet) ivermectin (IVERA) single dose and 200 mg stat doxycycline day-1 followed by 100mg doxycycline 12hrly for 4 day (i.e. day2-day5)~+ Placebo one tablet D2-5"
89592851|NCT04407130|Active Comparator|Tab Ivermectin|"Ivermectin - 200 mcg/kg (12 mg tablet) once per day D1-D5~+ Placebo two tablets D1 followed by Placebo one tablet D2-5"
89592852|NCT04407130|Placebo Comparator|Placebo|"Drug: Placebo~3 Placebo tablets D1 followed by 2 tablets D2-5"
89031071|NCT02946060|Sham Comparator|Usual Care|Participants in this intervention will receive the minimal standard of care provided at the Cardiac Rehabilitation and Prevention Program at Toronto Rehabilitation Institute. Participants will receive an iPod with a silent track or white noise.
89031072|NCT02946060|Active Comparator|Audiobooks|Participants in this arm will receive iPods with Audiobooks based on their preferred genres.
89031073|NCT02946060|Experimental|Tempo-pace Synchronized Playlists|Participants in this arm will receive audio playlists synchronized to their exercise pace. Rhythmic enhancements will be added to the playlists during either month 2 or month 3 of the study.
89031074|NCT00525564|Placebo Comparator|A|Placebo diskus
89592853|NCT03599440||Pulse contour disturbance|Patients with an arterial catheter and pressure line extensions.
89592854|NCT03599284|Experimental|Experimental group 1|Experimental group 1: Vicagrel 20mg loading followed by 5mg/day for 28 days
89592855|NCT03599284|Experimental|Experimental group 2|Experimental group 2: Vicagrel 24mg loading followed by 6mg/day for 28 days
89592856|NCT03599284|Experimental|Experimental group 3|Experimental group 3: Vicagrel 30mg loading followed by 7.5mg/day for 28 days
89592857|NCT03599284|Active Comparator|Control group|Control group: Clopidogrel 300mg loading followed by 75mg/day for 28 days
89592858|NCT04407052|Experimental|Double trigger|GnRH-agonist and HCG are used to trigger ovulation
89592859|NCT04407052|Active Comparator|HCG|HCG is used to trigger ovulation
89592860|NCT03024814|Experimental|acetaminophen group|Babies who took acetaminophen
89592861|NCT03024814|Experimental|Placebo group (Dextrose 5)|Babies who took placebo
89592862|NCT03024502|Experimental|EPP-AF Gel 1%|Group of patients that will be treated with EPP-AF mucoadhesive gel 1%, during 7 day, 1x/day.
89592863|NCT03024502|Experimental|Clotrimazole cream|Group of patients that will be treated with clotrimazole cream, during 7 day, 1x/day.
89592864|NCT03024502|Experimental|EPP-AF Gel 2%|Group of patients that will be treated with EPP-AF mucoadhesive gel 2%, during 7 day, 1x/day.
89592865|NCT03024580|Experimental|Megestrol acetate|Megestrol acetate 160 mg PO daily until disease progression or unacceptable toxicity Tumor biopsy and blood collection before treatment initiation and at the time of disease progression.
89592866|NCT03024580|Active Comparator|Anastrozole|Anastrozole 1 mg PO daily until disease progression or unacceptable toxicity Tumor biopsy and blood collection before treatment initiation and at the time of disease progression.
89592867|NCT03024580|Active Comparator|Letrozole|Letrozole 2.5 mg PO daily until disease progression or unacceptable toxicity Tumor biopsy and blood collection before treatment initiation and at the time of disease progression.
89592868|NCT03024580|Active Comparator|Exemestane|Exemestane 25 mg PO daily until disease progression or unacceptable toxicity Tumor biopsy and blood collection before treatment initiation and at the time of disease progression.
89592869|NCT03024580|Active Comparator|Tamoxifen|Tamoxifen 20 mg PO daily until disease progression or unacceptable toxicity Tumor biopsy and blood collection before treatment initiation and at the time of disease progression.
89592870|NCT03024580|Active Comparator|Fulvestrant|Fulvestrant 500 mg intramuscularly (IM) d1, d14, d28 and q28 days until disease progression or unacceptable toxicity Tumor biopsy and blood collection before treatment initiation and at the time of disease progression.
89592871|NCT03599128|Placebo Comparator|Placebo|Placebo
89592872|NCT03599128|Experimental|43.3 mg hydrolyzed green coffee extract|hydrolyzed green coffee extract as interventions
89592873|NCT03599128|Experimental|86.6 mg hydrolyzed green coffee extract|hydrolyzed green coffee extract as interventions
89031075|NCT00525564|Active Comparator|B|Salmeterol diskus powder
89592874|NCT03599128|Experimental|173 mg hydrolyzed green coffee extract|hydrolyzed green coffee extract as interventions
89592875|NCT03594682|Experimental|dose titration group|First of all, according to the patient's weight and ECOG score, patients were divided into three groups（the initial dose of 250 mg qd,250 mg/500 mg qd by turns, 500 mg qd）. in two weeks, if the patient who is intolerant of the initial dose,250mg qod,250mg qd ,250mg qd was selected. if the patient can tolerate the dose well,a high-dose was given,and the maximum dose does not exceeding 750mg qd.
89031076|NCT04693143|Other|Parenteral Nutrition for Critically Ill Children|Total Parenteral Nutrition for critically ill children
89031077|NCT03453125|Experimental|Spanish mSMT Experimental Treatment|Administered by computer and paper and pencil.
89031078|NCT03453125|Active Comparator|Spanish mSMT Control Treatment|Administered by computer and paper and pencil.
89031079|NCT04692909|Active Comparator|Active|Active dTMS
89031080|NCT04692909|Placebo Comparator|Placebo|Placebo dTMS
89031081|NCT02953964|Experimental|Behavioral: perceptual-based memory encoding training|Participants receive perceptual-based memory encoding training
89592876|NCT03594682|Active Comparator|non-titration group|Patients were given 750mg qd apatinib until disease progression or intolerance
89592877|NCT01851590|Experimental|Resin Lacquer|Topical 30% Resin Lacquer applied once daily for 9 months (Abicin® 30% Nail Lacquer).
89592878|NCT01851590|Active Comparator|Amorolfine|Topical 5% Amorolfine Lacquer applied once weekly for 9 months (Loceryl® 5% Nail Lacquer).
89592879|NCT01851590|Active Comparator|Terbinafine|250 mg of Terbinafine taken orally once daily for 3 months (Generics).
89592880|NCT03594370||control|Limbal image by OCT in normal subjects.
89592881|NCT03594370||Advancing wave-like epitheliopathy|Limbal image by OCT in subjects with advancing wave-like epitheliopathy.
89592882|NCT03594370||Ocular rosacea or phlyctenulosis|Limbal image by OCT in subjects with ocular rosacea or phlyctenulosis
89592883|NCT03598972||control|teeth of children of non vitamin taking mother
89592884|NCT03598972||intervention|children teeth of vitamin taking mother
89608487|NCT01273480|Experimental|002|Sequence 2 Cycle 1: Trabectedin 1.3 mg/m2 i.v. on Day 1 followed by 2 rifampin 300 mg capsules once daily on Days 24-28 followed by Cycle 2 2 rifampin capsules prior to trabectedin 1.3 mg/m2 i.v. on Day 1 of Cycle 2. Dexamethasone 20 mg i.v. administered prior to trabectedin in each cycle.
89592885|NCT03598816|Experimental|Arm 1: Durvalumab + Tremelimumab + Neoantigen DNA Vaccine|"All patients will receive durvalumab intravenous (IV) at a dose of 10 mg/kg over the course of 60 minutes given every 2 weeks (on Days 1 and 15 of each 28-day cycle) for a total of 8 doses. Durvalumab will be given thereafter as monotherapy at a dose of 209 mg/kg over the course of 60 minutes given every 4 weeks (on Day 1 of each 28-day cycle) for a total of 4 doses~All patients will receive tremelimumab at a dose of 1 mg/kg over the course of 60 minutes given every 4 weeks (on Day 1 of each 28-day cycle) for a total of 4 cycles~The first vaccination will take place two weeks after confirmed disease progression on targeted therapy. This will be Day 1 of the first 28-day cycle of treatment with durvalumab and tremelimumab~The schedule of vaccination is Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1, and Cycle 5 Day 1 (for a total of 6 doses)"
89592886|NCT03598816|Experimental|Arm 2: Durvalumab + Tremelimumab|"All patients will receive durvalumab IV at a dose of 10 mg/kg over the course of 60 minutes given every 2 weeks (on Days 1 and 15 of each 28-day cycle) for a total of 8 doses. Durvalumab will be given thereafter as monotherapy at a dose of 209 mg/kg over the course of 60 minutes given every 4 weeks (on Day 1 of each 28-day cycle) for a total of 4 doses~All patients will receive tremelimumab at a dose of 1 mg/kg over the course of 60 minutes given every 4 weeks (on Day 1 of each 28-day cycle) for a total of 4 cycles."
89592887|NCT05633758|Placebo Comparator|SOC heart failure therapy and placebo pill (Arm A)|This group will receive all standard heart failure therapy and placebo pill.
89592888|NCT05633758|Active Comparator|SOC heart failure therapy with addition of metolazone (Arm B)|This group will receive all standard heart failure therapy with addition of metolazone.
89592889|NCT03598738|Active Comparator|Esomeprazole 40mg Group|Intervention group consisted of 16 diabetic subjects that had various degrees of symptoms for functional dyspepsia, gastro-oesophageal reflux, gastritis or duodenitis. All of them were prescribed 40 mg of esomeprazole treatment for three months.
89592890|NCT03598738|No Intervention|Control Group|The control group consisted of without gastric complaints, thus who did not receive PPI drugs. This group was followed-up without any intervention for three months.
89592891|NCT03594292|Experimental|FASTFORWARDTM Bunion|The participants are treated with FASTFORWARDTM Bunion Correction system. The FASTFORWARDTM Bunion Correction system employed 3D printed titanium bone tether plate at second metatarsal. Due to the merit of 3D printing technology, the plate is designed to broadly distribute forces across bone to secure mechanical integrity of the bone. The FASTFORWARDTM Bunion Correction system has been cleared by the United States Food and Drug Administration.
89592892|NCT03594292|Active Comparator|Conventional Surgery|The participants are treated with fusion surgery. This procedures is a standard treatment for 1st metatarsal hallux valgus by cutting, realigning and fusing the 1st metatarsal or fusing the metatarsal-cuneiform joint.
89592893|NCT03594214||Single arm|pre-treatment serum vitamin d level measured by ELISA kit in patients confirmed for diagnosis with invasive breast cancer and before receiving any treatment for breast cancer
89592894|NCT04004182|Active Comparator|OGTT session|Oral Glucose Tolerance test (OGTT)
89592895|NCT04004182|Active Comparator|Fruit bar|Fruit bar Plus Oral Glucose Tolerance test (OGTT)
89592896|NCT04004182|Experimental|Fruit bar with bilberry|Fruit bar with addition of 600 mg bilberry anthocyanins Plus Oral Glucose Tolerance test (OGTT)
88978061|NCT00066482|Experimental|combination chemotherapy|"Induction therapy: bleomycin sulfate IV over 10-20 minutes on day 1, etoposide IV over 1 hour and cisplatin IV over 4 hours on days 1-5, and cyclophosphamide IV over 1 hour on day 1. MESNA & Filgrastim (G-CSF) subcutaneously once daily beginning on day 6 and continuing until blood counts recover. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. 6 patients receive escalating doses of cyclophosphamide until the maximum tolerated dose (MTD) is determined.~Evaluated after 4 courses of therapy. Partial response or stable disease undergo second-look conventional surgery & receive 2 more courses of induction therapy then re-evaluated. Those who do not achieve complete response (CR) after a total of 6 courses may undergo a third conventional surgery. Tumor that cannot be removed are removed from study therapy. Achievement of a CR at anytime are followed monthly for 1 year, every 6 months for 1 year, and then annually for 3 years."
88978062|NCT00241774||NSHS95 samples|In 1995, our study participants enrolled in the Nova Scotia Health Study (NSHS95). At the time of enrollment, epidemiologic data as well as blood samples were obtained. The participants have since been followed prospectively for a variety of health outcomes. We plan to assay stored blood samples collected in 1995 for markers of inflammation and link these results to existing epidemiologic and outcomes data, specifically the 7- year incidence of CAD events.
88978063|NCT00241813|Active Comparator|Health Education Control Program (CTL)|Health Education Control Program (CTL)
88978064|NCT00241813|Experimental|Mindfulness Meditation|Mindfulness Meditation (MM) Program
88978065|NCT00241813|Experimental|Lifeskills|Lifeskills Program (LP)
88978066|NCT00241813|Experimental|MM plus LP|Mindfulness Meditation (MM) Program plus Lifeskills Program (LP)
88978067|NCT00241852|Experimental|Behavioral Intervention: Asthma: It's a Family Affair|Separate student and parent intervention groups.
88978068|NCT00241852|Active Comparator|Behavioral Control Group|Students and parents participate in an education only control group
88978069|NCT00241891|Other|Healthy Lifestyle (Active Intervention)|Parents and children in this program which will participate in a series of consultations and activities focused on multiple healthy interventions including healthy eating, drinking, and physical activity. The children will participate in a variety of age-appropriate games, activities and exercises that are focused on healthy eating, drinking, and physical activity. In addition, your child will receive information on developing healthy interpersonal and social skills.
88978070|NCT00241891|Other|Healthy Drinks (Active Intervention)|Parents and children in this program will participate in a series of consultations and activities focused on a single intervention, the effects of beverage choices on diet, general health and teeth health. The children will participate in a variety of age-appropriate games, activities and exercises that are focused on beverages and health. In addition, your child will receive information on healthy nutrition, physical activity, and interpersonal and social skills.
89031082|NCT02953964|Experimental|Behavioral: Semantic-based memory encoding training|Participants receive semantic-based memory encoding training
89031083|NCT02953964|Active Comparator|Behavioral : control group|Participants receive cognitive stimulation intervention
89031084|NCT02954003|Experimental|Endo Bypass|Subjects implanted with the investigational ValenTx Endo Bypass System
89031085|NCT00525642|Experimental|A|six cycles of adjuvant TAC
89031086|NCT00525642|Experimental|B|four cycles of T followed by 4 cycles of AC
89031087|NCT02954042|Experimental|Pelvital probe|Probe to use for incontinence-Pevital is company name of product
89592897|NCT04004182|Experimental|Fruit bar with bilberry and apple|Fruit bar with addition of 600mg bilberry anthocyanins and 1200mg apple polyphenols Plus Oral Glucose Tolerance test (OGTT)
89031088|NCT02954042|Placebo Comparator|Placebo Probe|Placebo probe
89031089|NCT03459365|Experimental|Euflexxa|Two sets of Euflexxa injection at 0 and 6 months. Each set consists of 3 injections 1 week apart.
89592898|NCT04003948|Experimental|Fixed dose|Ibogaine Hydrochloride 100 mg on each administration.
89592899|NCT04003948|Experimental|Ascending dose|Ibogaine Hydrochloride on ascending doses (100-200-300-400-500-600).
89592900|NCT05633368||Discontinuation of C/M-ECT|Participants with major depressive disorder who are unable to continue maintenance (M-ECT) or continuation electroconvulsive therapy (C-ECT) due to hospital restrictions during Covid-19 or due to personal preference.
89592901|NCT05633368||Continuation of C/M-ECT|Participants with major depressive disorder who are able to continue maintenance (M-ECT) or continuation electroconvulsive therapy (C-ECT) during Covid-19.
89592902|NCT03598582|Other|epoetin zeta|Patients received epoetin zeta (Retacrit®) 40000UI/week subcutaneously during 12 weeks.
89592903|NCT03593980|Experimental|400ml cranberry juice|Patients will be given 400ml of cranberry juice to drink 3 hours prior to cesarean delivery.
89592904|NCT03976882|Experimental|Group A：Hetrombopag|
89592905|NCT03976882|Placebo Comparator|Group B：Placebo|
89592906|NCT04747990||Baseline (Pre-Covid19) group|All patients admitted to the participating surgical departments with a clinical and radiological diagnosis of biliary acute pancreatitis in 2019
89592907|NCT04747990||Pandemic (During Covid-19) group|All patients admitted to the participating surgical departments with a clinical and radiological diagnosis of biliary acute pancreatitis in 2020
89592908|NCT03598504|Active Comparator|Healthy Controls Group|1. A focus group to gather information about the perceptions, opinions, beliefs, and attitudes towards management of muscle spasms by vibration using our portable device, information that will drive design improvement (size, fit, weight).
89592909|NCT03598504|Active Comparator|Spinal Cord Injury Group|"1a. A focus group to gather information about the perceptions, opinions, beliefs, and attitudes towards management of muscle spasms by vibration using our portable device, information that will drive design improvement (size, fit, weight).~1b. In the lab, we will trigger spasms in paralyzed leg muscles in one of two common postures (seated, reclined), detect the contractions using electromyography (EMG), and condition alternate spasms with vibration using our custom device. We will examine the vibration parameters that reduce muscle spasms best.~2. Participants will complete 1 or 2 multi-day experiments. EMG (24-hour) data will be collected at baseline (day 1), during the vibration intervention (day 2), and post intervention (day 3) to examine the acute effects of vibration on muscle spasms"
89592910|NCT02985346|Experimental|BMSC group|Patients received Bone marrow mesenchymal stem cells (BMSC) plus standard treatment
89592911|NCT02985346|Active Comparator|Control group|Patients received standard treatment
89592912|NCT02979730|Active Comparator|Core Lab Testing Arm|For patients with clinical concern for influenza, the usual workflow in the BMC ED is that physicians order the collection of a nasopharyngeal swab (NPS) for influenza A/B testing to be performed in the core microbiology laboratory using one of two assays. The two influenza A/B-only assays available in the core lab are a) an instrumented fluorescent immunoassay rapid antigen test, the Sofia influenza A+B FIA (Quidel Corporation) and b) an automated real-time PCR test, the Xpert Flu (Cepheid, Inc.). Which test is ordered is at the discretion of the physician. Both the Sofia and Xpert assays provide a result callout to distinguish influenza type A from type B.
89592913|NCT02979730|Experimental|ED Point of Care Testing Arm|Prior to the study the Cobas Liat Influenza A/B assay will be verified for patient care at BMC. The instrument and test kits will be available in the ED for use with study subjects randomized to this study arm. The Cobas Liat assay provides a result callout to distinguish influenza type A from type B.
89592914|NCT01852058|Experimental|OnabotulinumtoxinA 50 U|Following treatment with onabotulinumtoxinA (botulinum toxin Type A) 50 U (not to exceed 6 U/kg) intramuscular injection into the detrusor wall in study 120, participants were eligible for retreatments in this study as needed with a minimum 12-week interval between doses for a maximum of 3 retreatments. Blinded dose increases (one level) were allowed based on clinical response from cycle to cycle (not to exceed 6 U/kg).
89592915|NCT01852058|Experimental|OnabotulinumtoxinA 100 U|Following treatment with onabotulinumtoxinA (botulinum toxin Type A) 100 U (not to exceed 6 U/kg) intramuscular injection into the detrusor wall in study 120, participants were eligible for retreatments in this study as needed with a minimum 12-week interval between doses for a maximum of 3 retreatments. Blinded dose increases (one level) were allowed based on clinical response from cycle to cycle (not to exceed 6 U/kg).
89592916|NCT01852058|Experimental|OnabotulinumtoxinA 200 U|Following treatment with onabotulinumtoxinA (botulinum toxin Type A) 200 U (not to exceed 6 U/kg) intramuscular injection into the detrusor wall in study 120, participants were eligible for retreatments in this study as needed with a minimum 12-week interval between doses for a maximum of 3 retreatments. Blinded dose increases (one level) were allowed based on clinical response from cycle to cycle (not to exceed 6 U/kg).
89592917|NCT05633134|Experimental|Precision preoperative embolization|60 patients with pelvic tumors will undergo arteriography and receive transcatheter arterial embolization of pelvic tumors 0-24 hours prior to surgery.
89031090|NCT00525681|Other|CsA|Investigation of systemic exposure of cyclosporine before and after 2 moths of co-adminiastration of rimonabant.
89031091|NCT00525681|Other|Tac|Investigation of systemic exposure of tacrolimus before and after 2 moths of co-adminiastration of rimonabant.
89031092|NCT03455387||sampling of serum marker Flt1 and PIGF|sampling of the serum markers sFlt1 and PlGF , every 3 days,until delivery
89031093|NCT03456635|No Intervention|usual antimicrobial prophylaxys|standard of care: perioperative antimicrobial prophylaxis without computerized decision support system
89031094|NCT03456635|Experimental|guided antimicrobial prophylaxis|perioperative antimicrobial prophylaxis guided by a computerized decision support system
89031095|NCT04692636||Total study cohort|Patients with dysfunctional hemodialysis vascular access referred for PTA or patients who received maintenance hemodialysis will be prospectively enrolled.
89592918|NCT05633134|Active Comparator|Control group|60 patients with pelvic tumors will undergo arteriography and without transcatheter arterial embolization of pelvic tumors prior to surgery.
89592919|NCT03593668|Active Comparator|Metformin|Metformin Hydrochloride Tablet 500mg po by month,three times a day for 12 weeks
89592920|NCT03593668|Active Comparator|Benaglutide|Benaglutide Injection 0.2mg, iH,po, three times a day for 3 12 weeks
89592921|NCT05632900|Experimental|NAGI BI-FLANGED METAL STENT WITH CO-AXIAL PLASTIC STENT FOR DRAINAGE OF WOPN.|Endoscopic ultrasound guided drainage -Nagi Bi Flanged metal stent--16mm diameter 2cm long with co Axial double pig tail stent used for drainage of walled of necrosis. Intra and post prodecural complications will be noted, a plane CT screening abdomen will be performed with in 48 to 72 hours to document the size of collection.
89592922|NCT05632900|Active Comparator|NAGI BI-FLANGED METAL STENT ALONE FOR DRAINAGE OF WOPN.|Endoscopic ultrasound guided drainage -Nagi Bi Flanged metal stent--16mm diameter 2cm long used for drainage of walled of necrosis. Intra and post prodecural complications will be noted, a plane CT screening abdomen will be performed with in 48 to 72 hours to document the size of collection.
89592923|NCT03598348|Experimental|Maintenance Treatment Group A|Maintenance Treatment with Capecitabine plus Apatinib after First-line XELOX chemotherapy for Patients with Advanced Gastric Cancer
89592924|NCT03598348|No Intervention|Observation Group|Observation after First-line XELOX chemotherapy for Patients with Advanced Gastric Cancer
89592925|NCT03598348|Experimental|Maintenance Treatment Group B|Maintenance Treatment with Apatinib after First-line XELOX chemotherapy for Patients with Advanced Gastric Cancer
89592926|NCT03598192|Experimental|TAP group|"The TAP block is performed under the ultrasound guidance at four points: at subcostal and lateral abdominal wall at right-side and left-side.~Drug: ropivacaine 0.375% 40 ml (maximum dose <= 3 mg/kg). Maintenance: ropivacaine 0.375% 8 ml/hour during 48 hours."
89592927|NCT03598192|Experimental|PVB group|The paravertebral block is performed under the ultrasound guidance at T7. Drug: ropivacaine 0.5% 20 ml (maximum dose <= 3 mg/kg). Maintenance: ropivacaine 0.25% 8 ml/hour during 48 hours.
89592928|NCT03597958||Hypercholesterolaemia|"Individuals attending Imperial College London Diabetes Centre (ICLDC) and with LDL-C ≥5.0 mmol/L, for children <18 years LDL-C>95th centile by age and gender for country, and possible evidence of known premature CHD.~Individuals with a high probability of disease according to the Dutch Lipid Network Criteria, score of ≥6 points, will be identified as possible probands (individual serving as our starting point for the genetic study of the family) and will be selected for further screening.~Patients will be tested for known and/or suspected FH genes, using next generation sequencing (NGS) panel, whole exome and/or whole genome sequencing (WES/WGS) in cases where FH is highly suspected despite negative results from panel testing, and transcriptomic analysis of RNA blood samples."
89592929|NCT05632822||SBT failure|The SBT was considered to be a failure if at least one the following criteria was present: (1) blood oxygen saturation (SpO2) of <90 % with a fraction of inspired oxygen (FiO2) of≥50 %; (2) acute respiratory distress (RR≥40/min, agitation, cyanosis); (3) systolic arterial blood pressure of ≥180 mmHg; (4) cardiac arrhythmias; (5) respiratory acidosis [pH<7.32 with an arterial carbon dioxide tension (PaCO2) of ≥50 mmHg].
89592930|NCT05632822||SBT success|If none of these failure criteria was present, the SBT was considered as successfully completed.
89031096|NCT02955095|Experimental|Current cigarette smoker|
89592931|NCT04003246|Experimental|Single Arm: Therapeutic Intervention|
89592932|NCT00218296|Active Comparator|Usual Care Group|Usual care for cessation with immediate quit date scheduled and two weeks of nicotine patch supplied.
89592933|NCT00218296|Experimental|Reduction Group|Reduction in nicotine exposure for 6 weeks prior to quit date using medicinal nicotine lozenge or reduced nicotine smokeless tobacco.
89592934|NCT00217672|Experimental|Bevacizumab + Docetaxel|"docetaxel: 75 mg/m2 IV q3 weeks. Subjects continue on dosing until they experience unacceptable toxicity, disease progression, or withdrawal of patient consent.~Bevacizumab: 15 mg/kg IV every 3 weeks. Subjects continue on study until disease progression, unacceptable toxicity, or withdrawal of patient consent."
89592935|NCT00217672|Active Comparator|docetaxel|docetaxel: 75 mg/m2 IV q3 weeks. Subjects continue on dosing until they experience unacceptable toxicity, disease progression, or withdrawal of patient consent.
89592936|NCT03593122|Experimental|WO 2085 Moisturising Cream|"WO2085 is a hormone-free Moisturizing Cream and is used to treat vulvovaginal dryness symptoms."
89592937|NCT03597880|Other|obese patient|BMI>30 kg/m2 and underwent bariatric surgery
89592938|NCT03592966|Placebo Comparator|Placebo|Freeze-dried placebo powder
89592939|NCT03592966|Active Comparator|Wild Blueberry powder|Freeze-dried whole fruit blueberry drink.
89592940|NCT03597802|No Intervention|Control Group|The workers will be receive orientation about manual material handling, postural and low back care (lecture and guidance).
89031097|NCT02276898|Active Comparator|Hypertonic Saline|The treatment intervention is 1 inhalation of 7% hypertonic saline (4ml)
89031098|NCT02276898|Placebo Comparator|Isotonic Saline|The placebo intervention is 1 inhalation of 0.9% isotonic saline
89031099|NCT00508313||With Lung Cancer|Patients with lung cancer.
89031100|NCT00508313||Healthy Participants|Healthy participants without cancer.
89031101|NCT02945982|Placebo Comparator|Entecavir/Carvedilol|Tablet with Entrcavir and Carvedilol
89031102|NCT02945982|Experimental|Entecavir/Carvedilol/ Fuzheng Huayu|Tablet with Entrcavir and Carvedilol+ Tablet with Fuzheng Huayu
89031103|NCT00508352|Experimental|Helical tomotherapy|Helical tomotherapy IMRT 50 Gy in 25 fractions, daily treatment
89031104|NCT02947230|Experimental|Tailored Knowledge Translation|During the 12-week KT intervention, intervention group participants will have access to the Portal and will receive mobility-focused weekly email alerts including blog posts and evidence summaries relevant to mobility and be invited to follow a Twitter and Facebook feed; a unique hashtag will be created to identify and collate relevant mobility information.
89592941|NCT03597802|Active Comparator|Intervention group 1|The workers will be receive orientation about manual material handling, postural and low back care (lecture and guidance), and will perform exercise at workplace three times per week, during 15 minutes
88978071|NCT00241891|Other|Social and Leadership Skills (Control Intervention)|Parents and children in this program will participate in a series of consultations that are designed to help your child learn strategies to make and keep friends, to express feelings appropriately, and to successfully decrease conflicts that often occur at school among children. The children will participate in a variety of age-appropriate games, activities and exercises that are focused on these friendship making strategies. In addition, your child will receive information on healthy nutrition and physical activity. There is o intervention with regards to healthy weight.
89592942|NCT03597802|Active Comparator|Intervention group 2|The workers will be receive orientation about manual material handling, postural and low back care (lecture and guidance) and and will perform exercise at workplace four times per week, during 15 minutes.
89592943|NCT03597724||Patient suffering from sarcopenia|Subjects aged 65 years or older suffering from sarcopenia (diagnosis performed with a valid definition and valid cut-off points) and they will respond to the Questionnaire composed of 13 choice questions.
89592944|NCT00216736|Placebo Comparator|1|This group received intravenous phenothiazine treatment for migraine (dosing at physician discretion) plus placebo. Patients and clinicians were blinded.
89592945|NCT00216736|Experimental|2|This group received intravenous phenothiazine migraine treatment (dosage at physician discretion) plus oral dexamethasone 8mg at time of emergency department discharge. Patients and clinicians were blinded.
89592946|NCT03592810||ECPR|All patients who received ECMO placement during cardiopulmonary resuscitation (ECPR)
89592947|NCT01850030|Experimental|Dydrogesterone 30 mg|
89592948|NCT01850030|Experimental|Micronized Progesterone 600 mg|
89592949|NCT00215644|Experimental|Epirubicin, Cisplatin, Capecitabine (ECX)+Matuzumab|
89592950|NCT00215644|Active Comparator|ECX Only|
89592951|NCT03597490||Partial thickness rotator cuff tear|Patients with symptomatic non-traumatic partial thickness rotator cuff tear treated with multimodal physical therapy with exercise
89592952|NCT04747756|Other|Study participants|No participants will be randomized. All participants will have an opportunity to participate in the study procedures.
89592953|NCT03597412|Experimental|Rosuvamibe Tab|Rosuvastatin 10mg/Ezetimibe 10mg qd for 24 weeks
88978072|NCT02958332|Experimental|video game program|Participants will play video games during 30 min , all along 5 sessions.
88978073|NCT00099177|Experimental|1|
88978074|NCT00099177|Active Comparator|2|
89209968|NCT00640016|Placebo Comparator|Placebo|Placebo matched to CAT-354 intravenous infusion over 60 minutes on Day 0, 28 and 56.
88978075|NCT02962024|Active Comparator|morphine sulphate|10mg locally morphine hydrochloride once betwwen serratus muscle and latissmus dorsi muscle
88978076|NCT02962024|Placebo Comparator|bupivacaine hydrochloride|0.25%locally bupivacaine hydrochloride once
89209969|NCT00640016|Experimental|CAT-354 1 mg/kg|CAT-354 1 milligram per kilogram (mg/kg) of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.
89209970|NCT00640016|Experimental|CAT-354 5 mg/kg|CAT-354 5 mg/kg of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.
89592954|NCT03597412|Active Comparator|Monorova Tab|Rosuvastatin 20mg qd for 24 weeks
89592955|NCT03592732||A|Patients with atrial fibrillation
89592956|NCT03592732||B|Patients without atrial fibrillation
89592957|NCT01870401|Experimental|Lutonix DCB|Lutonix Paclitaxel Drug Coated Balloon
89592958|NCT01870401|Active Comparator|PTA Catheter|Standard Uncoated PTA Catheter
89592959|NCT03597334||critical ill patients|critical ill patients who admit to ICU
89592960|NCT04414839|Active Comparator|Digital Intubation (Two-finger)|
89592961|NCT04414839|Active Comparator|Video Laryngoscopy|
89592962|NCT00213148|Active Comparator|Clomiphene Citrate 50 Milligram (mg)|
89592963|NCT00213148|Active Comparator|Clomiphene Citrate 100 mg|
89592964|NCT00213148|Experimental|Anastrozole 1 mg|
89592965|NCT00213148|Experimental|Anastrozole 5 mg|
89592966|NCT00213148|Experimental|Anastrozole 10 mg|
89592967|NCT01704261|Experimental|Omarigliptin|Omarigliptin (MK-3102) 25 mg capsule administered orally once a week for 24 weeks. Participants continue pre-study concomitant therapy of open-label glimepiride tablet(s) orally once daily (total daily dose >=4 mg per day) and metformin tablet(s) orally once or twice daily (total daily dose >=1500 mg per day).
89592968|NCT01704261|Placebo Comparator|Placebo|Matching placebo to omarigliptin capsule administered orally once a week for 24 weeks. Participants continue pre-study concomitant therapy of open-label glimepiride tablet(s) orally once daily (total daily dose >=4 mg per day) and metformin tablet(s) orally once or twice daily (total daily dose >=1500 mg per day).
89592969|NCT01715571|Experimental|Viberect treatment|Participants in this arm have documented mild to moderate ED of organic etiology and will be given the Viberect device for 4 weeks of daily home use in preparation for sexual activity. Men will be asked to use the device and attempt sexual intercourse at least 3 times weekly
89592970|NCT00212758|Active Comparator|Low- Standard GH dose|This arm will receive Low dose of growth hormone (GH) (Nutropin AQ), for 7 days in a cross over design. Low dose GH will be 0.025 mg/kg/day. This will be followed by 2 weeks of wash out, then subjects will receive and the standard dose of Nutropin AQ (GH) at 0.05 mg/kg/dose given subcutaneously for another 7 days. IGF-I levels are measured after 7 days of the Low and the Standard dose of GH. After that all subjects will be treated with the standard dose of GH therapy of 0.05 mg/kg/day for 6 months and re-evaluated. If growth is adequate then subjects will continue on standard dose of GH for another 6 months for a total of 12 months.
89608488|NCT01273480|Experimental|001|Sequence 1 Cycle 1: 2 rifampin 300 mg capsules 1x daily for 5 days followed by 2 rifampin capsules prior to trabectedin 1.3 mg/m2 i.v. on Day 1 followed 28 days later by cycle 2 trabectedin 1.3 mg/m2 i.v. on Day 1. Dexamethasone 20 mg i.v. administered prior to trabectedin in each cycle.
89031105|NCT02947230|No Intervention|Control group|Participants in the control group will have access to the Portal in a 'self-serve' fashion. These participants will be able to browse the Portal, subscribe to email alerts, follow social media, etc. but will not receive the tailored mobility intervention.
89031106|NCT02954393|Placebo Comparator|Control|Scaling and root planing + Placebos active phase thrice a day (TID) for 14 days and Placebos healing phase TID for 14 days.
89031107|NCT02954393|Active Comparator|Active phase|Scaling and root planing + Metronidazole active phase (400 mg/thrice a day,TID) + Amoxicillin active phase (500 mg/ TID) for 14 days and Placebos healing phase TID for 14 days.
89031108|NCT02954393|Active Comparator|Healing phase|Scaling and root planing + Placebos active phase thrice a day (TID) for 14 days and Metronidazole healing phase (400 mg/TID) + Amoxicillin healing phase (500 mg/TID) for 14 days.
89031109|NCT02947152|Experimental|Dose escalation part|Includes patients with serous epithelial ovarian cancer (inclusive of fallopian tubal and peritoneal cancer) and clear cell or papillary renal cell carcinoma
89031110|NCT02947152|Experimental|Dose expansion part (RCC arm)|Includes patients with clear cell or papillary renal cell carcinoma
89031111|NCT02947152|Experimental|Dose expansion part (ovarian cancer arm)|Includes patients with serous epithelial ovarian cancer (inclusive of fallopian tubal and peritoneal cancer)
89031112|NCT02954471||Participants With Breast Cancer|This study will retrospectively collect data from participants with breast cancer in Saudi Arabia.
89031113|NCT02954276|Experimental|75 mg Omexa sumatriptan sublingual tablet|
89592971|NCT00212758|Active Comparator|Standard-Low GH dose (7 Days)|This arm will receive Standard dose of growth hormone (GH) (Nutropin AQ), for 7 days in a cross over design. Standard dose GH will be 0.5 mg/kg/day. This will be followed by 2 weeks of wash out, then subjects will receive and the Low dose of Nutropin AQ (GH) at 0.025 mg/kg/dose given subcutaneously for another 7 days. IGF-I levels are measured after 7 days of the Low and the Standard dose of GH. After that all subjects will be treated with the standard dose of GH therapy of 0.05 mg/kg/day for 6 months and re-evaluated. If growth is adequate then subjects will continue on standard dose of GH for another 6 months for a total of 12 months.
89592972|NCT04549545|Active Comparator|Vivaer Procedure|"The Vivaer procedure will be performed in the study clinic using the Vivaer ARC Stylus and Aerin Console. The Vivaer ARC Stylus is a disposable handheld device capable of delivering bipolar radiofrequency energy to tissue when connected to the Aerin Console radiofrequency generating device. Participants in this study will undergo bilateral treatment of the nasal valves in a single study session. Each side of the nose will be treated with up to four (4) non-overlapping applications of RF energy at the junction of the upper and lower lateral cartilage on the lateral nasal wall. Treatment settings to be used are: temperature 60° C, power 4 watts, treatment time 18 seconds, and cooling time 12 seconds. No repeat (touch up) procedures will be permitted after the initial procedure through the end of the study (24 months)."
89592973|NCT04549545|Sham Comparator|Sham Control Procedure|The sham control procedure will be performed in the study clinic using the Vivaer ARC Stylus while audible sounds that accurately simulate the Aerin Console's active treatment are produced even though RF energy is not being generated or delivered. All other aspects of the procedure will be the same as used for the active treatment, including administration of anesthetic agent(s).
89592974|NCT03592420|Experimental|Interdisciplinary interventions|"Multicomponent interventions~On-site supervised group exercise program (11 weeks)~Educational / behavioral sessions addressing specific behavioral and environmental risk factors for falls delivered by trained health professionals (11 sessions in total)~Home visits for suggestion and implementations of safety interventions aiming at reducing environmental hazards~Home-based exercise program: Personalized multi-factorial interventions: patients will have geriatric, neurology and physiatrist outpatient referrals to assess and treat individual risk factors.~Personalized multi-factorial interventions. Patients will have geriatric, neurology and physiatrist outpatient referrals to assess and treat individual risk factors"
89592975|NCT03592420|Active Comparator|Usual care|Usual care: after pre-test assessment and randomization, participants in the control group will be given a structured booklet with detailed information about participant's own personal risk factors (fall risk profile) to be given to the family doctor, together with an information booklet on fall risk factors and their prevention.
89592976|NCT01824290|Experimental|Tadalafil|"Period 1: 20 mg or 40 mg administered orally by tablets once a day.~Period 2: 20 mg for middle weight and 40 mg for heavy weight administered orally by tablets once a day.~Final tadalafil doses for Period 1 (6-month double-blind) were assigned after the weight cohort completion from H6D-MC-LVIG (NCT01484431).Tadalafil doses would range from 5 milligram (mg) to 40 mg depending on body weight cohorts. Heavy weight cohort ≥40 kilogram (kg), Middle weight cohort ≥25 kg to <40 kg: administered orally by tablets once a day. Light weight cohort <25 kg: administered orally by suspension once a day.~Participants receiving tadalafil in Period 1 continued to receive tadalafil during Period 2 (2-year open-label extension)."
89031114|NCT02954276|Active Comparator|100 mg Imitrex oral tablet|
89031115|NCT02947074|No Intervention|Control|Waiting list
89031116|NCT02947074|Experimental|Yoga Meditation|Previously naive to yoga and meditation, subjects will receive 2 30min yoga meditation classes for 8 weeks.
89031117|NCT00526500|Experimental|P-T|
89031118|NCT00526500|Experimental|P- SAH|
89031119|NCT00526500|Experimental|P- A|
89031120|NCT00526500|Experimental|Control|
89031121|NCT00507611|Other|Single-arm|Patients will undergo preoperative lymphoscintigraphy in the nuclear medicine department to access axillary and extra-axillary sites of localization. Intraoperatively, patients will also be injected with approximately 4 to 5 mL of 1% isosulfan blue dye (by intradermal, intraparenchymal, or subareolar route). Patients will undergo intraoperative identification and biopsy of all SLN candidates. A confirmatory axillary lymph node dissection will then be performed on all patients.
89031122|NCT02953769||Arm 1|Ventral hernia repair using standard wound care.
89031123|NCT02953769||Arm 2|Ventral hernia repair, regarding wound morbidity, post-operative pain and patient comfort to ambulation, with the use of Prevena™
89031124|NCT00507650|Active Comparator|Prescribed|Fluid volume and type prescribed by MD or provider.
89031125|NCT00507650|Experimental|Supplemental|Fluid volume and type prescribed by physician or provider plus 10 ml/kg X 5 days.
89031126|NCT02946957|Experimental|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy for Insomnia is delivered by trained sleep therapists in six telephone sessions.
89592977|NCT01824290|Placebo Comparator|Placebo|"Period 1: Participants received placebo orally by tablets once a day.~Period 2: 20 mg for middle weight and 40 mg for heavy weight administered orally by tablets once a day.~Final placebo dose for Period 1 (6-month double-blind) was be assigned after the weight cohort completion from H6D-MC-LVIG (NCT01484431) to maintain blinding depending on body weight cohort.~Participants receiving placebo in Period 1 Period 2 (2-year open-label extension) would receive tadalafil in Period 2 at the corresponding tadalafil dose in that participant's weight group."
89592978|NCT03596944||Statin|History of statin use for primary prevention
89592979|NCT03596944||Non-Statin|No documented history of statin use prior to Acute Coronary Syndrome
89592980|NCT03592342|Placebo Comparator|Rivelin® plain patches|Dosing is two times per day (morning and evening) with Rivelin® plain patches (placebo).
89592981|NCT03592342|Experimental|Rivelin®-CLO patch 1µg|Dosing is two times per day (morning and evening) with Rivelin®-CLO patch 1µg Clobetasol propionate per patch.
89592982|NCT03592342|Experimental|Rivelin®-CLO patch 5µg|Dosing is two times per day (morning and evening) with Rivelin®-CLO patch 5µg Clobetasol propionate per patch.
89592983|NCT03592342|Experimental|Rivelin®-CLO patch 20µg|Dosing is two times per day (morning and evening) with Rivelin®-CLO patch 20µg Clobetasol propionate per patch.
89592984|NCT01715415|Experimental|ABT-450/r/ABT-267 and ABT-333, plus RBV|Double-blind ABT-450/r/ABT-267 (150 mg/100 mg/25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based ribavirin (RBV; dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
88978077|NCT00066638|Experimental|Treatment (romidepsin)|Patients receive FR901228 (depsipeptide) IV over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who achieve a stable plateau (stable paraprotein levels or urine protein excretion over 3 consecutive determinations at least 4 weeks apart) may receive maintenance therapy comprising FR901228 IV on days 1 and 15, with courses repeating every 28 days.
88978078|NCT00242203|Experimental|Zometa|"Zometa 4 mg IV every 3 weeks for a total of 17 doses. The first treatment will be given at the time of the first chemotherapy treatment and will continue for approximately 1 year.~Neoadjuvant therapy~Epirubicin 75 mg/m2 IV every 21 days for 4 cycles prior to surgery~Docetaxel 75 mg/m2 IV every 21 days for 4 cycles prior to surgery~Surgery - modified radical mastectomy or breast conserving surgery with axillary lymph node dissection~Adjuvant therapy~Epirubicin 75 mg/m2 IV every 21 days for 2 cycles~Docetaxel 75 mg/m2 IV every 21 days for 2 cycles~All patients who are found to be Her-2 overexpressing by 3+ by ICH for FSH will receive trastuzumab 6 mg/kg IV every 3 weeks for 1 year post surgery~Radiation therapy - 50-60 Gy in 1.8-2.0 Gy daily fractions to the breast or chest wall. Internal mammary nodes, supraclavicular fossa nodes and axillary nodal basins will receive 45-50 Gy over 5-6 weeks"
88978079|NCT00242203|Active Comparator|No Zometa|"Neoadjuvant therapy~Epirubicin 75 mg/m2 IV every 21 days for 4 cycles prior to surgery~Docetaxel 75 mg/m2 IV every 21 days for 4 cycles prior to surgery~Surgery - modified radical mastectomy or breast conserving surgery with axillary lymph node dissection~Adjuvant therapy~Epirubicin 75 mg/m2 IV every 21 days for 2 cycles~Docetaxel 75 mg/m2 IV every 21 days for 2 cycles~All patients who are found to be Her-2 overexpressing by 3+ by ICH for FSH will receive trastuzumab 6 mg/kg IV every 3 weeks for 1 year post surgery~Radiation therapy - 50-60 Gy in 1.8-2.0 Gy daily fractions to the breast or chest wall. Internal mammary nodes, supraclavicular fossa nodes and axillary nodal basins will receive 45-50 Gy over 5-6 weeks"
88978080|NCT00077025|Active Comparator|Anastrozole-placebo|Anastrozole (ZD1033, Arimidex)-Placebo
88978081|NCT00077025|Active Comparator|Anastrozole-ZD1839|Anastrozole (ZD1033, Arimidex)-ZD1839 (gefitinib, IRESSA)
88978082|NCT00242320|Active Comparator|1|Roflumilast 500 µg
88978083|NCT00242320|Placebo Comparator|2|Placebo
88978084|NCT00242359|Other|omalizumab|open-label
88978085|NCT04729920||subjects with neuromuscular disease|Adult subjects with neuromuscular disease, with an active prescription of MI-E for more than 3 months
88978086|NCT00242593|Experimental|A|oral rosiglitazone 4 mg twice daily for 18 months
88978087|NCT00242593|Placebo Comparator|B|placebo pill twice daily for 18 months
88978088|NCT04728594|No Intervention|Delayed Contact|This group will not receive an email for at least two days.
88978089|NCT04728594|Experimental|Social Proof|This group will receive an email that points out that vaccine availability for employees will soon be limited. It also emphasizes how many fellow health care workers have been vaccinated. Seeing the behaviors of other people might encourage recipients to copy that behavior.
89031127|NCT02946957|Active Comparator|Education Control|Education Only Control is delivered by trained sleep therapists in six telephone sessions.
89031128|NCT00526578||Questionnaire|Pancreatic cancer patients or family member.
89031129|NCT00508430|Experimental|1|Low dose group
89031130|NCT00508430|Experimental|2|Middle dose group
89592985|NCT01715415|Experimental|Placebo Followed by ABT-450/r/ABT-267 and ABT-333, plus RBV|Double-blind placebo for 12 weeks, followed by open-label ABT-450/r/ABT-267 (150 mg/100 mg/25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (RBV; dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
89592986|NCT00211510|Experimental|Paradigm 722 sensor augmented pump|subjects will use the Paradigm 722 sensor augmented pump for infusion of insulin and continuous glucose monitoring
89592987|NCT00211510|Active Comparator|Paradigm 715 insulin pump|subjects will use the Paradigm 715 insulin pump which does not include sensor augmentation for infusion of insulin
89592988|NCT01869777|Experimental|Diagnostic (bioelectric impedance analysis)|Patients undergo bioelectrical impedance phase angle measurement on day 1 of treatment. Patients with AML undergo a second measurement just prior to the nadir marrow. Patients also undergo bioelectrical impedance measurements prior to any invasive procedures (bone marrow biopsy, leukapheresis, PICC line placement, etc.).
89592989|NCT04199260||Papilocare|all patients gonna received papilocare treatment as per usual practice.
89592990|NCT03596710|Experimental|Diagnostic (image-guided biopsy)|Participants undergo image-guided biopsy over 45 minutes prior to first RLT course and 1-2 days after the third RLT course.
89592991|NCT01714947|Experimental|Alisertib|"Part A: [^14C]-alisertib 35 mg, oral solution containing 80 - 100 microcuries (μCi) of total radioactivity (1.19 - 1.48 mCi/mmol), orally, single dose on Day 1.~Part B: Alisertib 50 mg, enteric coated tablets, orally, twice daily for 7 days, followed by 14-day washout period in 21-day cycles until disease progression or unacceptable treatment-related toxicity (Up to 3 Cycles)."
89592992|NCT03596632|Experimental|Single Oral Solution Dose|Single 200-mg (approximately 100-µCi) oral solution dose of [14C/12C]-fenebrutinib under fasted conditions.
89592993|NCT04198636|Experimental|LY01011|LY01011 injection (120mg) by subcutaneous injection once on the first day subcutaneous injection of 120 mg (1.7 ml)only once
89592994|NCT04198636|Active Comparator|Xgeva®|Xgeva® injection (120mg) by subcutaneous injection once on the first day subcutaneous injection of 120 mg (1.7 ml)only once
89592995|NCT04414995|Experimental|Paracetamol+Ibuprofen|Patients in Group 1 will receive a combination of 1000 mg IV paracetamol and 800 mg IV ibuprofen at the end of operation following by 1000 mg IV paracetamol and 800 mg IV ibuprofen every 6 hours up to 72 hours.
89592996|NCT04414995|Experimental|Paracetamol+normal saline|Patients in Group 2 will receive 1000 mg IV paracetamol and 100 ml IV normal salines at the end of operation following by 1000 mg IV paracetamol and 100 ml IV normal salines every 6 hours up to 72 hours.
89592997|NCT04414995|Experimental|Ibuprofen+normal saline|Patients in Group 3 will receive 800 mg IV ibuprofen and 100 ml IV normal salines at the end of operation following by 800 mg IV ibuprofen and 100 ml IV normal salines every 6 hours up to 72 hours.
89592998|NCT03591718|Experimental|BI 456906|
89592999|NCT03591718|Experimental|Placebo|
89593000|NCT01869699|Placebo Comparator|Normal saline placebo|Normal saline 100 mLs intravenous, administered over 15 minutes
89593001|NCT01869699|Experimental|Acetaminophen|Acetaminophen 1 gram/100 mLs intravenous, single dose administered over 15 minutes
89593002|NCT04198480|Experimental|JMT103|Eligible subjects will receive JMT103 at a dose of 2 mg/kg subcutaneously (SC) every 4 weeks (Q4W) with a loading dose of 2 mg/kg SC on study days 8 and 15.
89593003|NCT01714635|Experimental|Tecnis Multifocal Intraocular lens #1|A low diopter add multifocal intraocular lens
89593004|NCT01714635|Experimental|Tecnis Multifocal Intraocular Lens #2|A low diopter add multifocal intraocular lens
89593005|NCT01714635|Active Comparator|Monofocal Intraocular Lens|Commercially available monofocal intraocular lens (IOL)
89593006|NCT03596398||Young stroke|Patients with acute stroke aged 20 or over, and under 56 years old (Not included 56) .
89593007|NCT01713933|Experimental|Ultherapy™ treatment|Each enrolled subject will receive a bilateral Ultherapy™ treatment of the upper arms
88978090|NCT04728594|Experimental|Reframing Side Effects and Adverse Reactions|This group will receive an email that points out that vaccine availability for employees will soon be limited. It also addresses concerns about the side effects and adverse reactions of the vaccine. Due to potentially overblown concerns about the vaccine caused by the salience of side effects in the (social) media, the email attempts to reframe the risks by explicitly noting the small possibility of being affected by serious side effects and by contrasting that to the more severe effects of COVID-19. As a result of this reframing, recipients might recalibrate their perception of risks and benefits and opt for vaccination.
88978091|NCT00242866|Experimental|Arm 1|GW274150 - 5mg or 30mg
88978092|NCT00242866|Placebo Comparator|Arm 2|Placebo to match GW274150
88978093|NCT00077142|Experimental|TAC-101|Oral TAC-101 daily Days 1-14, repeats every 21 days for 2 courses.
88978094|NCT00243100|Experimental|Arm I|"Patients receive oral vorinostat (SAHA) once daily on days 1-14 and gemcitabine IV over 1-2 hours on days 3 and 10. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of SAHA and gemcitabine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. A minimum of 6 patients are treated at the MTD"
88978095|NCT00243334|Experimental|1|Decision Support integrated with Order Entry
88978096|NCT00243334|No Intervention|2|Decision Support Only (not integrated with order entry)
88978097|NCT00067106||1: Women failing therapy|Participants will have study visits at study entry, 2 weeks after changing medications, then every 4 weeks until the amount of HIV in the blood and genital tract are undetectable. Drug levels in the blood and genital tract will also be measured at the first visit and after changing medications. Once the level of HIV is undetectable, women will be seen every 3 months for 36 months. Participants in Group 1 will be followed no more than 42 months.
89209971|NCT00640016|Experimental|CAT-354 10 mg/kg|CAT-354 5 mg/kg of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56
89593008|NCT03759106|Other|No Intervention: Usual care|All study participants in the control group will receive an 8-week written home exercise program (e.g. GRASP) , i.e. the usual care discharge home program.
89593009|NCT03759106|Experimental|Experimental: Telerehabilitation system|Participants in the experimental group will receive 8 weeks home exercise program using a virtual reality (VR) and telerehabilitation system. The intensity and choice of game for the home program will be determined by the therapist based on the patient's abilities, interests, motivation and fatigue. The patient's performance for the VR home program will be monitored asynchronously and synchronously and the program adapted to ensure it remains at an appropriate level for the patient.
89593010|NCT01868997|Placebo Comparator|Placebo|A placebo infusion (normal saline) administered q3W by IV infusion over a period of 24 weeks for a total of 8 infusions.
89593011|NCT01868997|Experimental|Teprotumumab|Teprotumumab administered q3W by IV infusion over a period of 24 weeks for a total of 8 infusions. All participants start treatment at a dose of 10 mg/kg. At Week 3, the dose is escalated to 20 mg/kg and kept constant for the remainder of the study.
89593012|NCT01875848|Experimental|buprenorphine/naloxone|induction onto buprenorphine/naloxone from opioid treatment
89593013|NCT01875848|Active Comparator|opioid dose escalation|increase of up to 25% of current opioid dose
89593014|NCT04588142|Experimental|Experimental group|Participants are randomized to receive probiotics for 6 weeks
89593015|NCT04588142|Placebo Comparator|Placebo group|Participants are randomized to receive placebo for 6 weeks
89608489|NCT02991274||T790M mutation test|genomic testing of T790M mutation
89031131|NCT00508430|Experimental|3|High dose group
89031132|NCT00508430|Placebo Comparator|4|
89031133|NCT00526617|Experimental|Open Label|Within each dose level, subjects are treated with the same regimen/doses of ABT-888 and TMZ.
89031134|NCT04693065||Ponseti|Patients treated by ponseti method
89031135|NCT02946177|Experimental|Influenza Vaccine|O.5 mL single dose influenza vaccine suspension administered intramuscularly
89031136|NCT02946177|Placebo Comparator|Saline Injection|O.5 ml of sterile Saline administered intramuscularly
89031137|NCT04693455|Experimental|Experimental: Cohort 1, Dose 1 of ZD03 or Placebo|Dose 1 of ZD03 or matching Placebo capsules by mouth
89031138|NCT04693455|Experimental|Experimental: Cohort 2, Dose 2 of ZD03 or Placebo|Dose 2 of ZD03 or matching Placebo capsules by mouth
89031139|NCT04693455|Experimental|Experimental: Cohort 3, Dose 3 of ZD03 or Placebo|Dose 3 of ZD03 or matching Placebo capsules by mouth
89593016|NCT04198402||Patient with digestive neuroendocrine tumor|naive patient with digestive neuroendocrine tumor (pancreas or small intestine), initiating Lanreotide treatment
89593017|NCT04198402||Patient without tumor|Historical control group (retrospective data) Patients, with normal endoscopic and body imaging results, having had fecal ARN16s sequencing who were assigned as control subjects for microbiota analyses.
89593018|NCT04198168||ICU patients|ICU patients who are assessed by their attending physician as having need for fluid therapy and are planned to receive IV crystalloid fluid due to oliguria and/or to improve GFR.
89593019|NCT03973294|Active Comparator|Supraglottic jet ventilation|Ventilation of the patient is performed over a steel laryngoscope or a thin catheter by means of jet ventilation (JV) using the TwinStream jet ventilator (C. Reiner Corp, Vienna, Austria). The driving pressure of the device is 1.5-3 bar and respiratory rates of 10-900 per min can be provided. In superimposed high frequency jet ventilation (SHFJV), jet ventilation of normal frequency and high frequency is conducted simultaneously and enables ventilation at two different pressure levels through the steel jet laryngoscope. It is equipped with two jet nozzles, which are placed at the distal end of the jet laryngoscope.
89593020|NCT03973294|Active Comparator|Subglottic jet ventilation|"Subglottic HFJV is performed through the LaserJet catheter. It is characterized by the delivery of small tidal volumes from a high pressure jet at very high frequencies (100-400) followed by passive expiration for a very short period before delivering the next jet, creating an auto-PEEP."
89593021|NCT03591172|Experimental|propolis|natural antibacterial, anti-inflammatory irrigation solution
89593022|NCT03591172|Experimental|Nano-propolis|natural antibacterial, anti-inflammatory irrigation solution
89593023|NCT03591172|Active Comparator|saline|sodium chloride irrigation solution
89593024|NCT04197622|Experimental|Hydrochlorothiazide|Subjects receive a single-dose treatment.Urine samples will be collected after administration (6 fractions: 0-4, 4-8, 8-12, 12-24, 24-36, 36-48 hours post-administration).
89593025|NCT03592654|Experimental|infant telehelp condition|caregiver coaching to improve infant behaviors that indicate they are at risk for autism spectrum disorder
89593026|NCT03596008|Experimental|Active1|freeze-dried strawberry powder (25 g) in active drink
89593027|NCT03596008|Placebo Comparator|Placebo|Placebo drink
89593028|NCT03595930||Subjects who received ARNUITY|This PMS will be conducted with subjects who were administered ARNUITY in accordance with the approved label.
89031140|NCT04693455|Experimental|Experimental: Cohort 4, Dose 4 of ZD03 or Placebo|Dose 4 of ZD03 or matching Placebo capsules by mouth
89031141|NCT04693455|Experimental|Experimental: Cohort 5, Dose 5 of ZD03 or Placebo|Dose 5 of ZD03 or matching Placebo capsules by mouth
89031142|NCT04693455|Experimental|Experimental: Cohort 6, Dose 6 of ZD03 or Placebo|Dose 6 of ZD03 or matching Placebo capsules by mouth
89031143|NCT04693455|Experimental|Experimental: Cohort 7, Dose 7 of ZD03 or Placebo|Dose 7 of ZD03 or matching Placebo capsules by mouth
89031144|NCT02946138|Experimental|carbon-ion radiotherapy with GM-CSF|Hypofractionated carbon-ion radiotherapy was prescribed at a dose of 40Gray(Gy) [relative biological effectiveness (RBE)] in 5 fractions for intrahepatic cases away from gastro-intestinal (GI) tract (>1cm) with concurrent GM-CSF 125ug/m2/d, subcutaneous injection d1-28;
89031145|NCT00507884||3 Tesla MRI|Patients with renal tumors scheduled to have a CT scan of the kidneys and abdomen.
89031146|NCT00507962|Experimental|Cisplatin + Liposomal Doxorubicin|Cisplatin 100 mg/m^2 Intraarterial and Liposomal Doxorubicin starting dose 20 mg/m^2 by vein on Day 1 every 4 weeks
89031147|NCT02946099|Experimental|Reciproc file|Reciproc files in reciprocating motion
89031148|NCT02946099|Active Comparator|ProTaper Next file|ProTaper Next files in continuous rotary motion
89031149|NCT02954315|Experimental|Almond arm|The almond dose will be provided as 20% of total energy (20% E) in the diet. This dose was selected based on a previous randomized trial examining lipid parameters in response to 0, 10%, and 20% E as dietary almonds and a recent meta-analysis of intervention trials.
89031150|NCT02954315|No Intervention|Western diet Snack (Granola bar + Pretzels)|The control snack will be a typical western diet snack (see Table 1). The calorie-matched control snack will be commercially available individually wrapped food products such as a small granola bar + pretzels.
89209972|NCT04036578|Other|Pelvic Floor Dysfunction With and Without POP|group 1(Pelvic Floor Dysfunction Without POP Stage I~II) and group 2(Pelvic Floor Dysfunction With POP Stage I~II)
89593029|NCT03595852|Experimental|Prophylaxis|The intervention will be a single dose of prophylactic antibiotic (cefazolin): 2 gr in adults or 3 gr for patients weighing >120Kg or 30mg/kg in children given within 30-60 minutes prior to skin incision.
89593030|NCT03595852|Placebo Comparator|No prophylaxis|The control group will receive a similarly looking prepared placebo injection (normal saline placebos for injection) 30-60 minutes prior to incision.
89593031|NCT03591016||Difficult intravenous access|Recording number of IV attempts in the operating room prior to surgery start.
89593032|NCT03595696|Experimental|Core Strengthening Exercise Intervention|All subjects will participate in the study for a total of 24 consecutive weeks. During the first 12 weeks, subjects will participate in weekly online exercise classes for Core Muscle Strength training and will be asked to perform daily homework assignments. Following completion of the 12-week intervention, subjects will be asked to continue the exercises on their own.
89031151|NCT04692948|Experimental|TAA6 cell injection|"Drug: TAA6 cell injection（Targeting CD276 autologous chimeric antigen receptor T cells）~Chimeric antigen receptor T cells (car-t) is one of the most effective therapies for malignant tumors (especially hematological tumors). Like other immunotherapies, the basic principle is to use the patient's own immune cells to clear cancer cells.Chimeric antigen receptor (car) is the core component of car-t, which endows T cells with the ability to recognize tumor antigens in an independent manner, which enables car modified T cells to recognize a wider range of targets than natural T cell surface receptors (TCR). The basic design of car includes a tumor associated antigen binding region (usually derived from scFv segment of monoclonal antibody antigen binding region), transmembrane region and intracellular signal region. The selection of target antigen is a key determinant for the specificity and effectiveness of car and the safety of genetically modified T cells."
89031152|NCT00508508|Experimental|1|Behavioral: IVR
89031153|NCT00508508|Experimental|2|Behavioral: Nurse-Led Group Visits
89031154|NCT02485938|Experimental|Allogeneic Cardiosphere-Derived Cells (CAP-1002)|CAP-1002 is an investigational product consisting of allogeneic cardiosphere-derived cells (CDCs). All subjects assigned to the active treatment arm will receive an intended total dose of 75 million (M) CAP-1002 cells infused as 25M cells into each of the three left ventricle cardiac territories (anterior, lateral, inferior/posterior). If any of the three coronary arteries are deemed by the infusing Investigator to supply less than 30% of the left ventricular myocardium, the infusing Investigator may choose to infuse only 12.5M cells into that coronary artery or arteries. Therefore the full dose of CAP-1002 delivered may range from 50M cells to 75M cells provided that all three arteries are infused.
89031155|NCT02485938|No Intervention|Usual Care|Subjects randomized to receive usual care will continue to be cared for and treated in whatever manner the investigator deems most appropriate for the subject on an ongoing basis, and will receive no infusion.
89031156|NCT00508586|Experimental|1|PTC299 with an aromatase inhibitor
89031157|NCT00508040|Experimental|A|To analyse the potential therapeutic effect of Interferon alpha2a versus Steroid therapy with a control group for a 4 months period. This short period could not expose to a worsening of the disease because of the slow pathologic processus.
89031158|NCT00508040|Active Comparator|B|
89031159|NCT02946840||Solid pancreatic masses|Consecutive patients with solid pancreatic masses, submitted to FNA with 25 G Beacon needle (Medtronic, Newton, MA, USA)
89031160|NCT00508664|Experimental|A|TP + Radiation (TPF until Feb 2009)
89031161|NCT00508664|Experimental|B|TP + Cetuximab + Radiation (TPF until Feb 2009)
89031162|NCT02946684|Placebo Comparator|Lactose Monohydrate|2 tablets of placebo are administered daily from stimulation start to day before hCG as adjunctive therapy to 150 IU of recFSH
89593033|NCT03595696|Active Comparator|Control+Core Strengthening Exercise|All subjects will participate in the study for a total of 24 weeks. During the first 12 weeks, subjects will serve as the control group, and they will be advised to continue their baseline level of exercise and lifestyle. During the subsequent 12 weeks, subjects will participate in the exact same program as Group A performed during the first 12 weeks (Core Muscle Strength Training).
89593034|NCT04197466|Experimental|Pelvic Floor Exercise Group|Pelvic floor muscle exercises will be recommended as a home program for 6 weeks every day of the week.
89593035|NCT04197466|Experimental|Kinesiotape Group|In addition to pelvic floor exercise,kinesio tape application will be performed by ligament technique to the sacral region.
89593036|NCT04197466|Experimental|Electrical Stimulation Group|In addition to pelvic floor exercise,electrical stimulation will be performed in the lying, sitting, stand up positions for 30 minutes
89593037|NCT03590860|Experimental|LY3322207 (Part A)|LY3322207 administered subcutaneously (SC)
89593038|NCT03590860|Placebo Comparator|Placebo (Part A)|Placebo matching LY3322207 administered SC
89593039|NCT03590860|Experimental|LY3322207 (Part B)|LY3322207 administered SC once weekly
89593040|NCT03590860|Placebo Comparator|Placebo (Part B)|Placebo matching LY3322207 administered SC once weekly
89593041|NCT03590860|Experimental|LY3322207 (Part C)|LY3322207 administered SC in participants with hypertension
89209973|NCT00892242|Experimental|Neoadjuvant Zoledronic Acid|"Zoledronic acid 4 mg IV prior to pancreatic resection (approximately 2 weeks prior to resection)~Pancreatic resection~Zoledronic acid 4 mg IV monthly for two additional doses"
89031163|NCT02946684|Active Comparator|Letrozole 5mg|2 tablets of 2,5mg Letrozole are administered daily from stimulation start to day before hCG as adjunctive therapy to 150 IU of recFSH
89031164|NCT02953379|Experimental|EMS Mometasone gel|The patient should administer 2 spray in each nostril, once daily.
89031165|NCT02953379|Active Comparator|Mometasone spray nasal|The patient should administer 2 spray in each nostril, once daily.
89209974|NCT00885066|Experimental|gemcitabine, capecitabine, erlotinib|
89593042|NCT04197154|Experimental|1. Control nocebo group|Conditioning and extinction of a nocebo response using moderate pain stimuli, nocebo negative suggestions, and no threat suggestions.
89593043|NCT04197154|Experimental|2. High-pain nocebo group|Conditioning and extinction of a nocebo response using higher pain stimuli, nocebo negative suggestions, and no threat suggestions.
89593044|NCT04197154|Experimental|3. High-threat nocebo|Conditioning and extinction of a nocebo response using moderate pain stimuli, nocebo negative suggestions, and threat suggestions (i.e., fear-inducing suggestions).
89209975|NCT00885222|Active Comparator|1|PD patient that were treated with STN DBS and developed depression after the surgery (n=5).
89593045|NCT04191382|Experimental|Amcenestrant 400 mg|Participants received 4 capsules of 100 milligrams (mg) of amcenestrant once daily (QD) from Day 1 to Day 14.
89593046|NCT04191382|Experimental|Amcenestrant 200 mg|Participants received 2 capsules of 100 mg of amcenestrant QD from Day 1 to Day 14.
89593047|NCT04191382|Active Comparator|Letrozole 2.5 mg|Participants received 2.5 mg of letrozole tablet QD from Day 1 to Day 14.
89593048|NCT01703091|Experimental|Ramucirumab plus Docetaxel|Ramucirumab 10 milligram per kilogram (mg/kg) on Day 1 of every 21 day cycle, administered as an intravenous (IV) infusion over approximately 60 minutes. Docetaxel 60 milligram per square meter (mg/m2) on Day 1 of every 21 day cycle, administered as an IV infusion over approximately 60 minutes.
89608490|NCT02991508|Placebo Comparator|Placebo|Vehicle (20 mM His/HCl pH 6.0)
89031166|NCT02946645|Active Comparator|Manual Physiotherapy|TMD patients will treat with orofacial physiotherapy by one expert operator according to literature
89031167|NCT02946645|Active Comparator|Neuromuscular Bite|TMD patients will receive an intraoral neuromuscular bite according to literature
89593049|NCT01703091|Placebo Comparator|Placebo plus Docetaxel|Placebo (administered at a volume equivalent to a dose of milligram per kilogram (mg/kg)) on Day 1 of every 21 day cycle, administered as an IV infusion over approximately 60 minutes. Docetaxel 60 mg/m2 on Day 1 of every 21 day cycle, administered as an IV infusion over approximately 60 minutes.
89031168|NCT02946645|Placebo Comparator|Placebo|TMD placebo group.
89031169|NCT02954120||(PCOS-CP-)|systemically and periodontally healthy participants
89031170|NCT02954120||(PCOS-CP+)|systemically healthy participants with CP
89031171|NCT02954120||(PCOS+CP-)|PCOS participants with periodontally healthy
89031172|NCT02954120||(PCOS+CP+)|PCOS participants with CP
89593050|NCT03023644|Experimental|Cogmed Working Memory Training|The group randomized to the intervention will receive Cogmed computerized training of executive function and attention skills. The standard Cogmed RM will be used for this trial arm. This is a child-friendly web-based software program. The investigators will use a version of the program that contains 12 different neurocognitive tasks. Tasks become more difficult as a function of performance on a session-by-session basis. Each training session lasts 35-40 minutes, with one session to be completed per day 5 days each week for 5 weeks, for a total of 25 sessions. The program yields individual session-by-session and task-by- task training results, including the children's responses, time spent on each task, and evolution curves.
89593051|NCT03023644|No Intervention|Standard of Care|Children randomly assigned to the control group will receive the standard of care recommended for patients with critical CHD. This includes cardiac surveillance and neurodevelopmental counseling and screening at our Cardiac Neurodevelopmental Program if needed. Once enrolled in our study, a child in the control group will not receive Cogmed intervention or any other cognitive intervention that targets executive functions or ADHD symptoms until after the 3-month follow-up neurodevelopmental evaluation is performed, i.e., 5-6 months after initial enrollment. Like children assigned to the intervention group, controls can continue on treatments that are already in place for other neurodevelopmental disabilities (e.g., speech therapy, occupational services).
89593052|NCT01712685|Experimental|Renal Cell Carcinoma|
89593053|NCT04195516|Experimental|Health Promotion Group|Experimental group will be applied Health Promotion Model Basic Health Promotion Program. Health promotion program; The Web-based Health Promotion Program includes individual counseling and reminder practices.
89593054|NCT04195516|No Intervention|Control Group|The control group will be given educational brochures to develop healthy eating and physical activity behaviors.
89593055|NCT05103267||Tauropace in high risk participants|"TauroPace™ is a CE marked (certified) medical device defined as a Disinfecting Solution to Eradicate Airborne Microbial Contamination on the Surface of Cardiac Impiantable Electronic Devices (CIED).~TauroPace™ is to eradicate environmental microbial contamination on the surface of any CIED during implantation or revision procedure.~TauroPace™ is intended to be used during CIED surgery procedure in any adult participant at high risk of CIED infections"
89593056|NCT03023800|Experimental|Buckle|Macular buckling and intraocular gas (C3F8) injection.
89593057|NCT03023800|Active Comparator|Vitrectomy|Vitrectomy, internal limiting membrane peeling, and gas tamponade (C3F8).
89593058|NCT04552821||Control|Non-sepsis and non-ARDS adults receiving mechanical ventilation
89593059|NCT04552821||Sepsis complicated with mild ARDS|Patients who meet the criteria of sepsis-3, and also meet the criteria of Berlin diagnostic for mild ARDS
89593060|NCT04552821||Sepsis complicated with moderate/severe ARDS|Patients who meet the criteria of sepsis-3, and also meet the criteria of Berlin diagnostic for moderate/severe ARDS
89593061|NCT03590548||gausher disease in children|• Inclusion criteria: All cases with confirmed diagnosis of Gaucher disease type 1 and type 3 receiving enzyme replacement therapy at Assuit University Children's Hospital.
89031173|NCT02946801|Active Comparator|Essential oils mouthwash|20 ml rinses for 30 seconds with essential oils/2 times daily (1/0/1).
89031174|NCT02946801|Experimental|essential oils without mouthwash|20 mL rinses for 30 seconds with essential oils without alcohol/2 times daily (1/0/1)
89593062|NCT04196998|Active Comparator|ETV group|50 patients would receive treatment of oral entecavir (ETV) 0.5 mg once per day from baseline to life-long.
89593063|NCT04196998|Active Comparator|TDF group|50 patients would receive treatment of oral tenofovir disoproxil fumarate (TDF) 300 mg once per day from baseline to life-long.
89593064|NCT04196998|Experimental|TAF group|50 patients would receive treatment of oral tenofovir alafenamide (TAF) 25 mg once per day from baseline to life-long.
89031175|NCT02946801|Sham Comparator|sterile water mouthwash|20 mL rinses for 30 seconds with sterile water/2 times daily (1/0/1)
89031176|NCT02953808|Experimental|Cohort 1 Group A|In dosing sessions 1, 2, and 3, subjects will receive GSK2315698 10 mg/hr, GSK2315698 20 mg/hr, and Placebo, respectively, as intravenous infusion over 1 hour.
89031177|NCT02953808|Experimental|Cohort 1 Group B|In dosing sessions 1, 2, and 3, subjects will receive GSK2315698 10 mg/hr, Placebo, and GSK2315698 40 mg/hr, respectively, as intravenous infusion over 1 hour.
89031178|NCT02953808|Experimental|Cohort 1 Group C|In dosing sessions 1, 2, and 3, subjects will receive Placebo, GSK2315698 20 mg/hr, and GSK2315698 40 mg/hr, respectively, as intravenous infusion over 1 hour.
89031179|NCT02953808|Experimental|Cohort 2 Group D|In a single dosing session, subjects will receive GSK2315698 20 mg/hr as intravenous infusion over 15 hours.
89031180|NCT02953808|Placebo Comparator|Cohort 2 Group E|In a single dosing session, subjects will receive Placebo as an intravenous infusion over 15 hours.
89209976|NCT00885222|Active Comparator|2|PD patients with depression that are candidates for STN DBS (n=5).
89593065|NCT04197232||exposed|The modality of study is a cohort study that evaluates the performance of children exposed to biologic agents during pregnancy compared to the performance of children born at the same gestational age not exposed to biologic agents.
89593066|NCT04197232||not exposed|The modality of study is a cohort study that evaluates the performance of children exposed to biologic agents during pregnancy compared to the performance of children born at the same gestational age not exposed to biologic agents.
89593067|NCT04196452||Arm A: participants 12 to under 18|
89593068|NCT04196452||Arm B: participants under 12|
89593069|NCT03590392|Experimental|Group 1|Group 1 volunteers (n= 6) will be administered ChAdOx1 Chik, 5 x 10^9 vp through intramuscular route.
89593070|NCT03590392|Experimental|Group 2|Group 2 volunteers (n= 9) will be administered ChAdOx1 Chik, 2.5 x 10^10 vp through intramuscular route.
89593071|NCT03590392|Experimental|Group 3|Group 3 volunteers (n= 9) will be administered ChAdOx1 Chik, 5 x 10^10 vp through intramuscular route.
89593072|NCT01867671|Experimental|Peanut Oral Immune Therapy (OIT)|Peanut OIT for 134 weeks followed by peanut avoidance for 26 weeks.
89593073|NCT01867671|Placebo Comparator|Peanut Placebo|Peanut placebo for 134 weeks followed by peanut avoidance for 26 weeks. The placebo extract will be derived from oat flour source material.
89593074|NCT03992950|Experimental|Cricoid pressure|Cricoid pressure is applied in the anesthetized state and during video laryngoscopy
89593075|NCT03992950|Experimental|Paratracheal pressure|Paratracheal pressure is applied in the anesthetized state and during video laryngoscopy
89593076|NCT04028206|No Intervention|Control Group|No intervention on sarcopenic subjects screened (based on the AWGS definition).
89593077|NCT04028206|Active Comparator|Exercise + HMB Group|Sarcopenic subjects on combined treatment of elastic-band exercise and HMB supplementation
89593078|NCT04028206|Active Comparator|Vibration Treatment + HMB Group|Sarcopenic subjects on combined treatment of vibration treatment and HMB supplementation
89593079|NCT04601649|Experimental|Intervention|Participants will take part in the PrEP Talk intervention sessions.
89593080|NCT04601649|No Intervention|Control|Participants will receive standard care.
89593081|NCT04548921||Participants with Friedreich's Ataxia|Participant diagnosed with Friedreich's Ataxia aged between 2 and 50 years of age
89593082|NCT03590236|Experimental|Graded exposure therapy|Patients in this group received graded exposure therapy added to physiotherapy
89593083|NCT03590236|Active Comparator|Physiotherapy|Patients included in this group received the standard treatment based on a physiotherapy approach.
89593084|NCT03590236|No Intervention|Control group|Waiting list patients
89593085|NCT01702311|Active Comparator|Bedtime supplementation|Patients in this arm will have acqhs (before meals and at bedtime) and 3 am blood glucose testing and will receive sliding scale insulin supplementation as needed.
89593086|NCT01702311|No Intervention|no bedtime supplementation|Patients in this arm will have ac (before meals), qhs (at bedtime) and 3 am blood glucose testing; however, subjects in this group will NOT receive sliding scale insulin bedtime supplementation.
89593087|NCT04196608||P. aeruginosa isolates|All isolates will be sent to the Central Laboratory, where identification will be confirmed by MALDI-TOF and susceptibility testing against ceftolozane/tazobactam, imipenem- relebactam and comparative agents will be performed
89593088|NCT04196608||Enterobacterales isolates|All isolates will be sent to the Central Laboratory, where identification will be confirmed by MALDI-TOF and susceptibility testing against ceftolozane/tazobactam, imipenem- relebactam and comparative agents will be performed
89593089|NCT04022200||Paclitaxel DCB for De Novo Coronary Lesions|we define de novo coronary artery lesions as the lesions never been treated with any interventional device, such as POBA, stent, rota ablation, laser etc.
89593090|NCT04196296|Active Comparator|Psychoeducation|
89593091|NCT04196296|Experimental|Psychoeducation plus Motivation Enhancement|
89593092|NCT04552743|Experimental|MGTA-145 and Plerixafor HSC Mobilization|Patients after screening will undergo baseline evaluation during the premobilization phase up to 30 days before mobilization. Patients will undergo sequential administration of plerixafor 0.24 mg/kg subcutaneously followed 2 hours later by MGTA-145 at 0.03 mg/kg intravenously (3 to10 minute infusion). This will be followed by apheresis. A second day of mobilization and apheresis will be pursued in patients who have not collected 6.0 x 106 CD34+ cells/kg in one session.
89593093|NCT03590158|Experimental|TRF|Participants will follow their regular diet for two weeks before 3-day lead-in food prior to the metabolic testing at visit 0. Participants will then be instructed to eat their habitual diet only within a 10-hour time frame each day for 8 weeks. Participants may self-select the precise window that best suits their lifestyles, however any food and drink must be consumed by 7:30pm.
89593094|NCT03590080||active, moderate-to-severe GO|Each participant received IVMP according to EUGOGO recommendations (cumulative dose of methylprednisolone 4.5 g, treatment duration 12 weeks in single weekly intravenous pulses, first 6 weeks 0.5g of IVMP, next 6 weeks 0.25g of IVMP).
89593095|NCT03593278|Experimental|Treatment and observation period|On Day 1, the subjects will receive a single s.c. dose of 16 mg 14C-radiolabeled ACT-246475 in the fasted state. Subjects will be followed by an observation period of 3 days (72 h) during which blood, urine, and feces samples will be collected.
89593096|NCT04028362||Neuromuscular blockade|Patients who will receive neuromuscular blockade during their ICU length stay will be follow until day 28 or their hospital discharge.
89593097|NCT03023410||Partial Revision|"A partial revision will be indicated when only the tibial liner is changed or only the tibial liner with the tibial tray or only the tibial liner with the femoral component."
89593098|NCT03023410||Total Revision|"A total revision will be indicated when all components are completely removed and replaced (tibial tray, femoral component and tibial liner)."
89593099|NCT03594058|Experimental|Solabegron modified release tablets low dose|
89593100|NCT03594058|Experimental|Solabegron modified release tablets high dose|
89593101|NCT03594058|Placebo Comparator|Placebo Comparator|
89593102|NCT01712061|Active Comparator|Arm 1 PF-04634817|
89593103|NCT01712061|Placebo Comparator|Arm 2 Placebo|
89593104|NCT03591094|Active Comparator|PTI-428 dose level 1|
89593105|NCT03591094|Active Comparator|PTI-428 dose level 2|
89593106|NCT03591094|Placebo Comparator|Placebo PTI-428|
89593107|NCT04195672||Children under 3 years-old intubated/sedated in intensive care|NIPE and CBS ware measured for each included patient
89593108|NCT03592186|Experimental|Parenting Wisely+|Parenting Wisely+ consists of access to the Parenting Wisely computer program (www.parentingwisely.com), paired with engagement strategies: up to four in-person coaching sessions, daily text messages, and access to an online networking forum.
89593109|NCT03592186|Active Comparator|Treatment as Usual|"The active comparator is defined as residential treatment services as usual.~At short-term facility, average length of stay was 6-10 days. At long-term facility, average length of stay was 30-45 days."
89593110|NCT03598114|Experimental|Program Sustainability Training|"Selected publicly funded tobacco control programs receive the intervention in the form of custom training curricula designed to identify and enable sustainable tobacco control programming at a state-organizational level. Sustainability is assessed at t=12 months and 1=24 months to capture potential impact of the training and curricula.~The intervention group will receive a follow-up survey inviting them to evaluate the training and their progress on executing their sustainability plan. The intervention group will also receive a follow-up survey inviting them to evaluate the technical assistance they have received from the research team. Responses on neither follow-up survey impact participants standing in the study"
89031181|NCT02953847|Other|sequence 1|"Rifafour e-275®, Sanofi-Aventis /Rimactazid 150/75, Sandoz/ Rimactane® 150 mg capsules, Sandoz~- 24 healthy volunteers will receive single doses of the 3 rifampicin containing products with a washout of 14 days between doses. Each volunteer will be randomised to receive the 3 doses in one of 6 sequences"
89031182|NCT02953847|Other|sequence 2|"Rifafour e-275®, Sanofi-Aventis /Rimactazid 150/75, Sandoz/ Rimactane® 150 mg capsules, Sandoz~- 24 healthy volunteers will receive single doses of the 3 rifampicin containing products with a washout of 14 days between doses. Each volunteer will be randomised to receive the 3 doses in one of 6 sequences"
89031183|NCT02953847|Other|sequence 3|"Rifafour e-275®, Sanofi-Aventis /Rimactazid 150/75, Sandoz/ Rimactane® 150 mg capsules, Sandoz~- 24 healthy volunteers will receive single doses of the 3 rifampicin containing products with a washout of 14 days between doses. Each volunteer will be randomised to receive the 3 doses in one of 6 sequences"
89593111|NCT03598114|No Intervention|Control Condition|"In this condition, publicly funded tobacco control programs do not receive the designated program sustainability training and proceed with standard operations. Sustainability is assessed at t=12 months and t=24 months to compare against tobacco control programs receiving sustainability training~The control group will receive a follow-up survey inviting them to evaluate their progress on creating their sustainability plan. Responses on the follow-up survey do not impact participants' standing in the study"
89593112|NCT03599674|Experimental|Family Bridge Program|Families receive Family Bridge Program services which include orientation to the hospital, concrete needs assessment, communication preferences assessment, communication coaching, follow-up during the hospital stay, and a follow-up phone call after discharge.
89593113|NCT04195360||Orthostatic intolerant (OI)|Patients that experience symptoms of orthostatic intolerance (dizziness, nausea, vomiting, blurry vision or syncope) or orthostatic hypotension (fall in systolic pressure > 20 mmHg and/or diastolic pressure > 10 mmHg) during mobilization
89593114|NCT04195360||Orthostatic tolerant (OT)|Patients that do not experience symptoms of orthostatic intolerance (dizziness, nausea, vomiting, blurry vision or syncope) or orthostatic hypotension (fall in systolic pressure > 20 mmHg and/or diastolic pressure > 10 mmHg) during mobilization
89593115|NCT04195282|Active Comparator|Plasma exchange group|10 patients will receive conventional treatment plus plasma exchange
89593116|NCT04195282|Experimental|RL-1 Novel Human-derived Bio-artificial Liver treatment group|10 patients will receive conventional treatment plus RL-1 Novel Human-derived Bio-artificial Liver treatment
89593117|NCT04029766|Experimental|HSK3486|0.288 mg/kg bolus (1 min)+ 1 mg/kg/h constant infusion (30 min) or 0.540 mg/kg bolus (1 min)+ 2 mg/kg/h constant infusion (30 min)
89593118|NCT04193644|Active Comparator|Walking-Group|Participants in this group walk 45 minutes 3 times a week (plus 15 minutes of warm up and cool-down) in a moderate intensity range (64-76% HRmax).
89593119|NCT04193644|Experimental|Mindfulness and Self-Compassion focussed Walking-Group|Participants in this group walk 45 minutes 3 times a week (plus 15 minutes of warm up and cool-down) in a moderate intensity range (64-76% HRmax) and additionally practice mindfulness exercises and self-compassion exercises during the 60 minutes.
89593120|NCT04193644|No Intervention|TAU-Group|Participants in this group receive no intervention.
89593121|NCT04195048||Cancer patients with acute ischemic stroke|Eighty patients previously or currently suffering from manifest cancer on or not on cancer treatment who developed stroke
89593122|NCT04195048||Control patients with acute ischemic stroke without cancer|Eighty patients with acute ischemic stroke without cancer
89593123|NCT04195126|No Intervention|Control group|Patients are treated according to most recent guidelines in burn trauma and corresponding emergency and intensive therapy. All patients included are treated with early continous veno-venal renal replacement therapy.
89593124|NCT04195126|Active Comparator|Treatment group|Besides treatment strategies of the control group, the investigators start early haemadsorption treatment right after patient admission (and inclusion).
89593125|NCT04190290|Experimental|Intervention|Mobilizations and exercises training Respiratory exercises Body image exercises
89593126|NCT04190290|Active Comparator|Control|Muscle strength evaluation and Eating behavior evaluation and Quality of life
89031184|NCT02953847|Other|sequence 4|"Rifafour e-275®, Sanofi-Aventis /Rimactazid 150/75, Sandoz/ Rimactane® 150 mg capsules, Sandoz~- 24 healthy volunteers will receive single doses of the 3 rifampicin containing products with a washout of 14 days between doses. Each volunteer will be randomised to receive the 3 doses in one of 6 sequences"
89209977|NCT00885222|Active Comparator|3|PD patients without depression that are candidates for STN DBS (n=10).
89209978|NCT00888108|Experimental|docetaxel +ABT-263|
89209979|NCT00885300|Experimental|1|cloxacillin 100 mg/ml + heparin 1000iu/ml as catheter lock at the end of hemodialysis
89209980|NCT00885300|Active Comparator|2|heparin 1000iu/ml as catheter lock at the end of hemodialysis
89209981|NCT00888186|Active Comparator|1. Duodopa optimal dose|
89209982|NCT00888186|Experimental|2. Duodopa 20% too high dose|
89593127|NCT04197544|Experimental|Intervention group|
89593128|NCT04197544|No Intervention|Control group|
89593129|NCT04194892|Experimental|Pegilodecakin Vial|Pegilodecakin administered subcutaneously (SQ) in one of two study periods.
89593130|NCT04194892|Experimental|Pegilodecakin Pre-filled syringe (PFS)|Pegilodecakin administered SQ in one of two study periods.
89593131|NCT04028752||Males and females|The investigators are interested in sampling a wide variety of individuals from varying ethnic groups, sex, and age range.
89593132|NCT04197778|Experimental|group A|
89593133|NCT04197778|Experimental|group B|
89593134|NCT04194658|Active Comparator|Case group|Case group will receive pretreatment letrozole 12.5 mg for 2 days before administration of misoprostol in a dosage according to ACOG guidelines based on gestational age.
89593135|NCT04194658|No Intervention|Control group|Control group will receive only misoprostol in a dosage according to ACOG guidelines based on gestational age.
89593136|NCT04194502|Other|Pre-operative and intra-operative TEE|All patients enrolled in the study will undergo a pre-op research TEE and a intra-op clinical transesophageal echo.
89593137|NCT04194580|Experimental|Physical activity|In the program we will perform a recreational physical activity intervention during one year that include standardized recreative and non competitive activities conducted by sports instructors
89593138|NCT04194580|No Intervention|Physical activity control|This group will not participate in the intervention
89593139|NCT04028518|Experimental|The high-dose group|"Experimental: r-PA Dose: stick 18 mg;~Mode of admin:~The high-dose group (18 mg + 18 mg) was divided into two intravenous injections. the first intravenous bolus injection of 18mg,after 30mins, the second intravenous bolus injection of 18 mg, Push slowly for more than 2mins each time.Subjects were closely monitored during the medication and within 24 hours of administration."
89593140|NCT04028518|Experimental|The low-dose group|"Experimental: r-PA Dose: stick 18 mg;~Mode of admin:~The low-dose group (12 mg + 12 mg) was divided into two intravenous injections, the first intravenous bolus injection of 12 mg, after 30mins, the second intravenous bolus injection of 12 mg, Push slowly for more than 2mins each time.Subjects were closely monitored during the medication and within 24 hours of administration."
89593141|NCT04028518|Experimental|Active Comparator: Alteplase|"Active Comparator: Alteplase Drug: Alteplase for Injection Dose:50mg;20mg~Mode of admin:~0.9 mg/kg (maximum dose of 90 mg) intravenous, 10% of which was injected intravenously within the first 1min, and the rest continued intravenous infusion for 1 h. Subjects should be closely monitored during the treatment period and within 24 hours of medication.Subjects were monitored according to the Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke in China 2018."
89593142|NCT03023956||ANF|anatomic neck fractures of proximal humerus
89593143|NCT03023956||SNF|surgical neck fractures of proximal humerus
89593144|NCT04028440|Experimental|Autologous γδT cells|Subjects will receive 3 cycles of γδT cells treatments, at four-week intervals, each cycle has 2 infusions, single infusion intravenously at a target dose of 1~2×10e9 γδT cells (constant dose).
89593145|NCT04748068|Experimental|Glidesheath Slender|The transradial procedure will be performed using the 7-Fr glidesheath slender (studied sheath)
89593146|NCT04748068|Active Comparator|Standard sheath|The transradial procedure will be performed using the standard 7- French radial sheath (comparator sheath)
89593147|NCT04190914|Active Comparator|necrotic primary molar treated with pulpectomy followed by SSC|control group treated by pulpectomy under rubber dam isolation access cavity will be prepared by a round bur then filling and irrigation will be performed and the tooth will be restored with a temporary filling. After one week all signs and symptoms will be assessed in case of absence of signs and symptoms the tooth will be restored with zin oxide and eugenol and SSC
89593148|NCT04190914|Experimental|necrotic primary molar treated with regeneration using triple|under rubber dam isolation access cavity will be prepared by a round bur then minimal filling and irrigation will be performed then triple antibiotic paste will be inserted into the canals and the tooth will be restored by a glass ionomer (GI) as a temporary filling. After2-4 weeks all signs and symptoms will be assessed in case of absence of signs and symptoms an endodontic file will be used to induce bleeding from the periapical area after hemostasis mineral trioxide aggregate will be applied followed by SSC
89593149|NCT04190914|Experimental|necrotic primary molar treated with regeneration using metape|under rubber dam isolation access cavity will be prepared by a round bur then minimal filling and irrigation will be performed then calcium hydroxide with iodoform (metapex) will be inserted into the canals and the tooth will be restored by a glass ionomer (GI) as a temporary filling. After 2-4 weeks all signs and symptoms will be assessed in case of absence of signs and symptoms an endodontic file will be used to induce bleeding from the periapical area after hemostasis mineral trioxide aggregate will be applied followed by SSC
89593150|NCT01711983|Experimental|Test Device|ASD closure with the GORE® CARDIOFORM Septal Occluder
89593151|NCT04028128|Experimental|Cocoa group|The cocoa was provided in 5 g sachets. The intervention last 10 weeks. Cocoa was provided in a single daily dose of 5 g, which provided 425 mg of flavonoids
89593152|NCT04028128|Placebo Comparator|Placebo group|Maltodextrin (5 g) was supplied as placebo in sachets identical to those provided for cocoa.
89593153|NCT04027660||Exposed Immediate Zirconia Implants|"Group Formation : patients that require a tooth extraction and have the following clinical indications to be enrolled in an immediate implant.~No Active Infection~No loss of buccal plate~ASA 1 or ASA 2 Patient~Extraction of the tooth will be performed and in the same clinical act, a zirconia dental implant will be placed toghether with a provisional or an individualized customs healing abutment. The jumping gap will be filled with a xenograft biomaterial.~Final Zirconia Crown delivered 3 month after healing.~3 STL files will be generated - Before extraction, at Final impression level 3 month after implant placement, at 3 month after final prosthesis insertion~Measure 1,2 and 3 will be at the gingival margin(measure 1), at 2mm (measure 2) and 4 mm (measure 3) apical to gingival margin. Both palatal and buccal references are joined by a line that gives a distance.Difference on the dimensions of each line with different time of evaluation represent ridge loss."
89593154|NCT04027660||Non-exposed delayed Zirconia implants|"Group Formation : patients that require a tooth extraction and have the following clinical indications not to be enrolled in an immediate implant.~Active Infection~Loss of the buccal plate.~Extraction will be performed but a classical implant approach will be made, that include a waiting period of 3 month before implant placement and 3 month after osseointegration period before place final crown.~Implant placement with Guided bone regeneration (xenograft), if needed. Final Zirconia Crown 3 month after implant placement.~4 STL files will be generated - Before extraction, before implant placement, at Final impression level 3 month after implant placement, at 3 month after final prosthesis insertion~Measure 1,2 and 3 the same has the other group"
89593155|NCT04194112|Other|NMIBC patients|Patients with primary or recurrent NMIBC for whom complete TURBT was done.
89593156|NCT04191928|Experimental|Apixaban dosing|Subjects to receive single dose of apixaban
89593157|NCT04193332|Experimental|Plus NIR optical imaging|NIR optical imaging assisted identification of parathyroid glands during thyroid surgery
89593158|NCT04193332|No Intervention|Minus NIR optical imaging|Conventional identification of parathyroid glands during thyroid surgery
89209983|NCT00888186|Experimental|3. Duodopa 10% too low dose|
89031185|NCT02953847|Other|sequence 5|"Rifafour e-275®, Sanofi-Aventis /Rimactazid 150/75, Sandoz/ Rimactane® 150 mg capsules, Sandoz~- 24 healthy volunteers will receive single doses of the 3 rifampicin containing products with a washout of 14 days between doses. Each volunteer will be randomised to receive the 3 doses in one of 6 sequences"
89031186|NCT02953847|Other|sequence 6|"Rifafour e-275®, Sanofi-Aventis /Rimactazid 150/75, Sandoz/ Rimactane® 150 mg capsules, Sandoz~- 24 healthy volunteers will receive single doses of the 3 rifampicin containing products with a washout of 14 days between doses. Each volunteer will be randomised to receive the 3 doses in one of 6 sequences"
89031187|NCT02953730|Experimental|PEG-rhG-CSF|
89031188|NCT00526929|Experimental|darbepoetin alfa|darbepoetin alfa (NESP)
89031189|NCT02953691|Experimental|Galacto-Oligosaccharides (GOS)|Clasado Biosciences Limited will provide Bimuno Pastilles for the clinical trial. Each pastille contains 0.92g GOS and will be taken 3 times per day. Following informed consent, subjects will be issued prepackaged GOS pastilles to be taken three times daily up until the evening prior to surgery. Subjects will be randomly assigned to receive GOS prebiotics. Each subject has an equal chance of receiving GOS or placebo. GOSn will be administered in the hospital when patient reinstitutes oral intake. GOS will be issued to each subject to last until the day of their scheduled follow-up for POCD (approximately 1.5 months post surgery).
89031190|NCT02953691|Placebo Comparator|Maltodextrin (Placebo)|Clasado Biosciences Limited will provide placebo (Maltodextrin) for the clinical trial. Each pastille contains maltodextrin and will be taken 3 times per day. Following informed consent, subjects will be issued prepackaged pastilles to be taken three times daily up until the evening prior to surgery. Subjects will be randomly assigned to receive GOS prebiotics or placebo. Each subject has an equal chance of receiving GOS or placebo. Placebo will be administered in the hospital when patient reinstitutes oral intake. Placebo will be issued to each subject to last until the day of their scheduled follow-up for POCD (approximately 1.5 months post surgery).
89031191|NCT02953535|Experimental|T test|Test drug (Magicbuvir)1 tablet contains 400 mg Sofosbuvir
89031192|NCT02953535|Active Comparator|B reference (first dose)|Reference drug (Sovaldi)1 tablet contains 400 mg Sofosbuvir
89031193|NCT02953535|Active Comparator|B reference (second dose)|Reference drug (Sovaldi)1 tablet contains 400 mg Sofosbuvir
89031194|NCT02953613||Cardiac Catheterization with NIRS/IVUS|Cardiac cathetirization with NIRS/IVUS assessment if with blockage of indeterminate severity (greater or equal to 20% to 70%). One day to one week after invasive catheterization a CCTA will be done to correlate result, then CCTA will be repeated at 24 months
89031195|NCT02953574|Experimental|daily sleep enhancement nursing protocol|"A 7 step nursing protocol. Each step is daily provided to the demented patient through a nurse by bedtime.~Step 1: serve a late snack Step 2: evening care (brush teeth, get pyjama on, go to toilette) Step 3: note and treat physical circumstances that restrain sleep (pain, obstipation,...) Step 4: ensure comfortable position abed Step 5: assist to eliminate stressful situation (calm, reorientating conversation) Step 6: turn off the light Step 7: care for a silent environment (turn off Television, radio and do not disturb-sign at the door)"
89031196|NCT02953574|No Intervention|usual nursing care|
89593159|NCT04199962||pneumonia without sepsis|adult patients with community acquired pneumonia change in SOFA score <2 (other than respiratory component)
89593160|NCT04199962||pneumonia with sepsis|adult patients with community acquired pneumonia change in SOFA score greater or equal to 2 (other than respiratory component)
89593161|NCT04193800||Rotational paramedic pilot group|
89593162|NCT04193800||Paramedic control group|
89593163|NCT02080312|Experimental|intratympanic injection|Magnevist (gadopentetate dimeglumine, Bayer Health Care) will be diluted eightfold with sterile saline (1:7 v/v) in a 1 ml syringe and injected intra-tympanically with a 23-25g needle up to 0.4 ml or less if contrast reflux is noted under direct visualization. Anesthesia with topical phenol is available for this procedure.
89593164|NCT04027582|Active Comparator|Low Fidelity Simulator - Wooden block|This simulator consists of a simple series of wooden panels with holes. The resident learns how to manipulate the fiberoptic bronchoscope through the holes.
89593165|NCT04027582|Active Comparator|High fidelity Simulator - ORSIM|The ORSIM® bronchoscopy is a virtual reality simulator (Airway Simulation Limited, Auckland, New Zealand). It consists of hardware and software components that interact to create a high-fidelity virtual reality simulation. A replica fiberoptic scope is advanced by the resident through a desktop sensor, which is connected to a laptop computer. The laptop software program provides a virtual airway in which the user must navigate the probe.
89031197|NCT00508703||CT Scan + IMRT Radiation Therapy|
89031198|NCT00526773|Other|1|Telephone management plus a motivational intervention
89031199|NCT00526773|Other|2|Telephone management with standard patient education
89031200|NCT02953496|Experimental|vonapanitase|
89593166|NCT04199884|Experimental|Active IU-focused Psychoeducation Intervention|
89593167|NCT04199884|Active Comparator|Health-focused Psychoeducation Intervention|
89031201|NCT00508859|Experimental|Active, 1|sertraline
89031202|NCT00508859|Placebo Comparator|Placebo|placebo
89031203|NCT00508898|Experimental|treatment group|Patients will receive calcitriol at a fixed dose of 1 mcg twice weekly.
89031204|NCT00508898|Active Comparator|control group|Patients will receive multivitamin 1 tab daily (with vitamin D2 300 IU).
89031205|NCT02944890|Experimental|RESTORE DEB|Conduct Drug Eluting Balloon Catheters(RESTORE DEB）
89209984|NCT00888186|Experimental|4. Duodopa 20% too low dose|
89593168|NCT04199806|Other|Questionnaire Review|
89593169|NCT04027504|Experimental|Fitabisc|Participants receiving fitabisc preoperatively
89593170|NCT04027738|Experimental|PRP injection|The patients received a single 3-ml injection of PRP.
89608491|NCT02991508|Active Comparator|Adrecizumab 0.5 mg/kg|To assess the safety, tolerability and pharmacokinetics/-dynamics of single escalating doses of ADRECIZUMAB (0.5 mg/kg, 2,0 mg/kg and 8,0 mg/kg administered as single infusion over 1 hour) in healthy male subjects.
89593171|NCT04193488|Active Comparator|MTP block (Group MTP)|In the MTP Group, a high frequency HFL-50 15-6 MHz linear ultrasound probe will be placed vertically approximately 3 cm laterally from the midpoint of the incision line in the midline. Using the parasaggital scan, the block needle (50 mm 22 Gauge will be advanced from the caudal to the cervical target of the paravertebral space. When the needle tip reaches the midpoint between the transverse process and the pleura, 1 ml normal saline is performed. Once the needle tip has been confirmed, 20 ml of 0.25% bupivacaine will be given to the block. The same procedure will be applied 3 cm later than the incision line.
89593172|NCT04193488|Active Comparator|ESP block (Group ESP)|In the ESP group, a high-frequency 15-6 megahertz linear ultrasound probe will be placed vertically approximately 3 cm laterally from the midpoint of the incision line in the midline. Once the erector spinae muscle and transver projections have been identified, the peripheral nerve blockage needle (50 mm 22 Gauge) will be advanced from caudal to cranial between the fascia of the erector spina muscle and the transverse process. After 1 ml normal saline injection, this plane will open. Twenty milliliters of 0.25% bupivacaine will be given for the block. The same procedure will be applied from the other 3 cm lateral of the incision line.
89593173|NCT04193488|Active Comparator|no block (Group C)|No regional plan block will be applied to the control group. Conventional analgesic methods were applied.
89593174|NCT03023098|Experimental|Drug-eluting balloon|
89593175|NCT03023098|Active Comparator|Conventional PTA|
89593176|NCT04199650||Mild ARDS|153mmHg<PaO2/FiO2≤230mmHg
89593177|NCT04199650||Moderate ARDS|76mmHg<PaO2/FiO2≤153mmHg
89593178|NCT04199650||Severe ARDS|PaO2/FiO2≤76mmHg
89593179|NCT03962686||normoglycemics|In this cohort will be enrolled 30 normoglycemics patients affected by carotid artery atherosclerotic and evidence of atherosclerotic plaque causing an endolumninal stenosis > 60%. These patients will receive a surgical intervention to remove the atherosclerotic plaque and to revascularize the obstructed coronary artery vessel.
89593180|NCT03962686||patients with diabetes mellitus (DM) treated with statin|In this cohort will be enrolled 23 DM patients affected by carotid artery atherosclerotic and evidence of atherosclerotic plaque causing an endolumninal stenosis > 60%. These patients will receive a surgical intervention to remove the atherosclerotic plaque and to revascularize the obstructed coronary artery vessel.
89593181|NCT03962686||patients with diabetes mellitus (DM) treated with statin plus PCSK9i|In this cohort will be enrolled 20 DM patients affected by carotid artery atherosclerotic and evidence of atherosclerotic plaque causing an endolumninal stenosis > 60%. These patients will receive a surgical intervention to remove the atherosclerotic plaque and to revascularize the obstructed coronary artery vessel. These patients were treated before the surgical intervention by statin therapy daily (n 20) added to PCSK9i, 140 mg twice a month (n 30).
89593182|NCT04193020||steroid only group (SG)|
89593183|NCT04193020||combined (steroid and adjuvant drug) group (CG)|
89593184|NCT04193020||bilogic therapy group (BTG)|
89593185|NCT04199338|Experimental|Randomized|Randomized
89593186|NCT04192864|Experimental|Lingually based triangular flap|
89593187|NCT04192864|Active Comparator|Buccally based triangular flap|
89593188|NCT04027270|No Intervention|Standard of Care|These individuals will receive standard of care for post operative recovery following a prostatectomy.
89593189|NCT04027270|Experimental|Physical Therapy|These individuals will receive post operative physical therapy in addition to standard of care for post operative recovery following a prostatectomy.
89031206|NCT02944890|Active Comparator|SeQuent® Please|Conduct Drug Eluting Balloon Catheters(SeQuent® Please）
89593190|NCT04027192|Experimental|Bridging part: intervention sequence ABC or BAC|10 healthy male participants will be randomly allocated to this arm. The study interventions will follow the sequence ABC or BAC: A: single dose of 50 mg BAY2328065 given as LSF in fasted state B: single dose of 50 mg BAY2328065 given as tablet in fasted state C: single dose of 50 mg BAY2328065 given as tablet in fed state (i.e. after a high caloric and high fat meal)
89593191|NCT04027192|Experimental|Multiple dose escalation part: dose 1|"10 participants will be randomly allocated to active drug or placebo (8 active drug, 2 placebo).~The study intervention will be administered with a single dose on the first dosing day followed by twice daily doses for 10 days followed by a single dose on the last dosing day"
89593192|NCT04027192|Experimental|Multiple dose escalation part: dose 2|"10 participants will be randomly allocated to active drug or placebo (8 active drug, 2 placebo).~The study intervention will be administered with a single dose on the first dosing day followed by twice daily doses for 10 days followed by a single dose on the last dosing day Midazolam is given for investigation of drug-drug interaction"
89593193|NCT04027192|Experimental|Multiple dose escalation part: dose 3|"10 participants will be randomly allocated to active drug or placebo (8 active drug, 2 placebo).~The study intervention will be administered with a single dose on the first dosing day followed by twice daily doses for 10 days followed by a single dose on the last dosing day Midazolam is given for investigation of drug-drug interaction"
89593194|NCT04027192|Experimental|Multiple dose escalation part: dose 4|"10 participants will be randomly allocated to active drug or placebo (8 active drug, 2 placebo).~The study intervention will be administered with a single dose on the first dosing day followed by twice daily doses for 10 days followed by a single dose on the last dosing day Midazolam is given for investigation of drug-drug interaction"
89031207|NCT00508937|Active Comparator|1|
89031208|NCT00508937|Experimental|2|
89031209|NCT00508937|Experimental|3|
89031210|NCT00508937|Experimental|4|
89031211|NCT00508937|Experimental|5|
89031212|NCT04692558|Experimental|HYALURONIC ACID|CAF+CTG+HA
89031213|NCT04692558|Active Comparator|WITHOUT HYALURONIC ACID|CAF+CTG
89593195|NCT04027192|Experimental|Multiple dose escalation part: dose 5|"10 participants will be randomly allocated to active drug or placebo (8 active drug, 2 placebo).~The study intervention will be administered with a single dose on the first dosing day followed by a treatment pause of 2 days followed by twice daily doses for 1 day followed by three times daily doses for 9 days followed by a single dose on the last dosing day Midazolam is given for investigation of drug-drug interaction"
89593196|NCT04406506||Group A|Group A received nasogastric feeding (NG), insure through ngt pump
89593197|NCT04406506||Group B|"receive feeding throughThe nasojejunal tube is silicone or polyurethane tube with an inner stylet that is positioned (under fluoroscopic guidance) beyond the ligament of Treitz.~Patients were placed in right lateral position"
89031214|NCT02952599||Patients treated with Edoxaban|Patients with established acute initial or recurrent VTE treated with edoxaban according to Summary of Product Characteristics (SmPC). Physician's prescribing behaviour will not be influenced, patients may only be included after the treating physician has made the clinical decision to prescribe edoxaban.
89593198|NCT04193098|Experimental|Arm: CTL plus PD-1 inhibitor|CTL , Toripalimab Toripalimab intravenous infusion 240mg d1; CTL, 1x10^9, intravenous infusion,d14; Q3W.
89593199|NCT04192942|Experimental|intensive care management|Administration of childern with major burn in intensive care to improve out comes
89593200|NCT04021186|Experimental|Intervention|Insulin treatment using standard measurements.
89593201|NCT04021186|No Intervention|Control|Standard care.
89593202|NCT04026724||Exposed group|Chinese patent medicine combined with western medicine routine treatment
89593203|NCT04026724||Non-exposed group|Western medicine routine treatment
89593204|NCT04026802|Experimental|In--Bed Resistance Training Device|The present invention provides full body resistance training devices that attach to a planar edge, such as a footboard, headboard, or sideboard of a bed. The devices employ resistance bands for resistance training in both the incursion (force applying) and excursion (force releasing) phase of exercise.
89593205|NCT04026802|Active Comparator|Standard of Care|No resistance training device
89593206|NCT04020796|Active Comparator|Beetroot juice|Randomized cross-over trial. Thirty-seven hypertension, age 40-70 years were randomized to receive a 500ml volume of beetroot juice in a single moment.
89593207|NCT04020796|Placebo Comparator|Mineral water|Randomized cross-over trial. Thirty-seven hypertension, age 40-70 years were randomized to receive a 500ml volume of mineral water in a single moment.
89593208|NCT03832348|Experimental|PET scan imaging|PET scan will be performed each of three first cycles of pembrolizumab to describe the early tumour metabolic changes during the first line of treatment.
89593209|NCT04026100|Experimental|CTA101|
89031215|NCT00526968|Experimental|1|EVT 101 8 mg capsule
89031216|NCT00526968|Experimental|2|EVT 101 15 mg capsule
89031217|NCT00526968|Placebo Comparator|3|Matching placebo capsule
89031218|NCT00527007|Experimental|A|
89031219|NCT00527007|No Intervention|B|
89031220|NCT03458715|Experimental|SGLT2 inhibitor (Empagliflozin 25 MG)|We add SGLT2 inhibitor (Empagliflozin 25 MG, oral, once daily) to type 2 diabetes patient poorly controlled with premix insulin therapy for 6 months.
89593210|NCT04192552|Active Comparator|Apixaban|Patients currently taking apixaban that have atrial fibrillation and require an elective high-bleed-risk surgery/neuraxial anesthesia.
89031221|NCT03458715|Active Comparator|DPP4 inhibitor (Linagliptin 5 MG)|We add DPP4 inhibitor (Linagliptin 5 MG, oral, once daily) to type 2 diabetes patient poorly controlled with premix insulin therapy.for 6 months.
89593211|NCT04192552|Active Comparator|Dabigatran|Patients currently taking dabigatran that have atrial fibrillation and require an elective high-bleed-risk surgery/neuraxial anesthesia.
89593212|NCT04192552|Active Comparator|Rivaroxaban|Patients currently taking rivaroxaban that have atrial fibrillation and require an elective high-bleed-risk surgery/neuraxial anesthesia.
89593213|NCT04020640||Exclusive breastfeeding (EBF)|provision of breast milk only, allowing only receiving oral rehydration salts (ORS), drops and syrups (vitamins, minerals, medicines) as necessary
89593214|NCT04020640||Predominant breastfeeding (PBF)|providing breast milk plus other liquids (water and water-based drinks, fruit juice) and ORS, drops and syrups (vitamins, minerals, medicines)
89593215|NCT04020640||Partial breastfeeding (PartBF)|provision of breast milk plus infant formula or cow milk or other solid/semi-solid complementary foods
89593216|NCT04192162|Experimental|Group of sulfur balneotherapy and mud pack therapy|Experimental group patients underwent sulfur balneotherapy and mud pack therapy. The duration of spa therapy program was 12 days.From the blood of patients, serotonin values, parameters of complete blood count, lipid status and inflammatory markers were analyzed before and after the therapy.
89593217|NCT04192162|Active Comparator|Group of sulfur balneotherapy, mud pack therapy and exercise|Control group of patients had mud pack therapy, sulfur balneotherapy and exercise in hygienic water. This group is a hydro group. From the blood of patients we analyzed parameters od complete blood count, serotonin values, lipid status and inflammatory markers before and after the therapy.
89593218|NCT03022942|Experimental|Costal mobilization & Diaphragm Release|Costal mobilization. Lying: two sets of ten deep respiratory cycles with one minute interval between sets. Sitting: two series with interval of one minute between them. Manual Diaphragm Release Technique: will be applied during two series of ten deep respiratory cycles, with one minute interval between sets.
89593219|NCT03022942|Active Comparator|Manual Diaphragm Release|Manual Diaphragm Release Technique: will be applied during two series of ten deep respiratory cycles, with one minute interval between sets.
89593220|NCT04191694|Other|Control|Patients will receive the standard dose of anti-emetic according to hospital practice (Ondansetron 4mg IV, intra-operatively)
89593221|NCT04191694|Active Comparator|Chewing Gum|Patients will receive the standard dose of anti-emetic according to hospital practice (Ondansetron 4mg IV, intra-operatively) they will also receive chewing in the recovery room and on the post-natal ward.
89031222|NCT00510575|Active Comparator|1|Subjects in this arm will receive the 5.5mm stainless steel instrumentation rod.
89031223|NCT00510575|Active Comparator|2|Subjects in this arm will receive a 6.35mm stainless steel instrumentation rod.
89031224|NCT02944812|Experimental|Chidamide|Chidamide is given to the patients, the dosage is 30mg,biw,po.
89031225|NCT00510614|Active Comparator|A|1 gram tinidazole twice weekly for 12 weeks
89031226|NCT00510614|Placebo Comparator|B|Placebo twice weekly for 12 weeks
89031227|NCT00508976|Experimental|3|
89031228|NCT00508976|Experimental|2|
89031229|NCT00508976|Experimental|4|
89031230|NCT00508976|Active Comparator|1|
89031231|NCT00509015|Active Comparator|1|Sulphadoxine-pyrimethemine (day 1) artesunate (day 1-3) primaquine (day 3)
89031232|NCT00509015|Placebo Comparator|2|Placebo: lactose tablets (Albochin)
89209985|NCT00888186|Experimental|5. Duodopa 10% too high dose|
89209986|NCT00892398|Experimental|ranibizumab|Trabeculectomy with mitomycin C associated with 2 subconjunctival injections of ranibizumab: 1 intraoperatively and 1 at 2 weeks post-operatively
89593222|NCT04191850|Active Comparator|Intercostal Nerve Block|Intercostal Nerve Block was performed just before closing the surgical incision while looking directly at the affected intercostal space. 10ml of 0.375% ropivacaine was delivered evenly at anterior and posterior intercostal spaces from the port site.
89593223|NCT04191850|Experimental|Serratus Anterior Plane Block|Serratus Anterior Plane Block was performed just before the start of surgery after anesthetic induction through ultrasound-guidance. 20ml of 0.375% ropivacaine was slowly injected between the fascia of serratus anterior and latissimus dorsi near 5th rib.
89593224|NCT04191772|Experimental|MS - training goal 1|Persons with Multiple Sclerosis (PwMS) with a 'poor VO2max', a 'fair VO2max' with no running experience and a 'good VO2max' with no running experience (VO2max values according to V.H. Heyward, Advanced Fitness Assessment and Exercise Prescription, Fifth Edition, 2006, Champaign, IL: Human Kinetics) will receive an exercise intervention existing of home-based running sessions. Participants of the first training group will be trained to run continuously for 45 minutes.
89593225|NCT04191772|Experimental|HC - training goal 1|Healthy control (HC) persons with a 'poor VO2max', a 'fair VO2max' with no running experience and a 'good VO2max' with no running experience (VO2max values according to V.H. Heyward, Advanced Fitness Assessment and Exercise Prescription, Fifth Edition, 2006, Champaign, IL: Human Kinetics) will receive an exercise intervention existing of home-based running sessions. Participants of the first training group will be trained to run continuously for 45 minutes.
89593226|NCT04191772|Experimental|MS - training goal 2|PwMS with a 'fair VO2max' and running experience, a 'good VO2max and running experience', an 'excellent VO2max' and a 'superior VO2max' (VO2max values according to V.H. Heyward, Advanced Fitness Assessment and Exercise Prescription, Fifth Edition, 2006, Champaign, IL: Human Kinetics) will receive an exercise intervention existing of home-based running sessions. Participants of the second training group will be trained to run continuously for 75 minutes.
89593227|NCT04191772|Experimental|HC - training goal 2|HC with a 'fair VO2max' and running experience, a 'good VO2max and running experience', an 'excellent VO2max' and a 'superior VO2max' (VO2max values according to V.H. Heyward, Advanced Fitness Assessment and Exercise Prescription, Fifth Edition, 2006, Champaign, IL: Human Kinetics) will receive an exercise intervention existing of home-based running sessions. Participants of the second training group will be trained to run continuously for 75 minutes.
89593228|NCT04191772|No Intervention|MS - sedentary control group|Twenty PwMS will receive no intervention, only usual care.
89593229|NCT04191772|No Intervention|HC - sedentary control group|Twenty HC will receive no intervention, only usual care.
89593230|NCT04026022|Placebo Comparator|Standard pain management|Besides the standard pain management a placebo TTS (normal wound plaster) will be administered in the Emergency Room (ER) or Post Anaesthesia Care Unit (PACU)
89593231|NCT04026022|Experimental|Modified pain management|Patients will be treated perioperatively with a new pain management, that has been modified to integrate the 2017 ESA guidelines on prevention/treatment of postoperative delirium. Moreover patients will be administered a 12µg/h Fentanyl TTS in the ER or PACU. The ER TTS will only be administered if the patients still has mild to intense pain after initial i.v. treatment as well as reposition of the fractured hip. Further aspects of the modified management are: avoiding benzodiazepines, allowing oral fluids up to 2 hours before surgery, intraoperative monitoring of anaesthesia depth and at least 1,8 ltr crystalloid infusion per day
89593232|NCT04020406||Antibacterial Activity of Urea|Activity of Urea Solution against Ocular Bacterial Isolates
89593233|NCT04020328|Experimental|leflunomide + low dose glucocorticoids therapy group|the experimental group will receive leflunomide + low dose glucocorticoids therapy on the basis of conservative treatment, while the control group receive conservative treatment
89593234|NCT04020328|No Intervention|Basic conservative treatment group|the basic conservative treatment group is the delaying the progress of renal function, including low-protein diet supplemented with ketoacid therapy, RAS inhibitor, blood pressure control, lipid-regulating therapy and antiplatelet aggregation therapy
89593235|NCT04020094|Experimental|Treatment: all patients|
89593236|NCT04025476||VKH patients|acute VKH patients
89593237|NCT04025476||control|health people age/sex match to the VKH patients
89593238|NCT04025320|Experimental|Group 1|"Intraneural facilitation treatment for 50-60 minutes. 50 minutes if ultrasound received.~9 total treatment visits, 3 visits per week~• One 50-60 minute visit on Monday, Wednesday and Friday, for 3 weeks."
89593239|NCT04025320|Sham Comparator|Group 2|"SHAM treatment for 50-60 minutes. 50 minutes if ultrasound received. 9 total treatment visits, 3 visits per week~• One 50-60 minute visit on Monday, Wednesday and Friday, for 3 weeks."
89593240|NCT01874288|Experimental|DI-Leu16-IL2 0.5 mg/m^2|Participants will receive DI-Leu16-IL2 0.5 mg/m^2 subcutaneously (SC) for 3 consecutive days every 3 weeks (21-day cycle) for a total of 4 cycles.
89593241|NCT01874288|Experimental|DI-Leu16-IL2 1.0 mg/m^2|Participants will receive DI-Leu16-IL2 1.0 mg/m^2 SC for 3 consecutive days every 3 weeks (21-day cycle) for a total of 4 cycles.
89593242|NCT01874288|Experimental|DI-Leu16-IL2 2.0 mg/m^2|Participants will receive DI-Leu16-IL2 2.0 mg/m^2 SC for 3 consecutive days every 3 weeks (21-day cycle) for a total of 4 cycles.
89593243|NCT01874288|Experimental|DI-Leu16-IL2 4.0 mg/m^2|Participants will receive DI-Leu16-IL2 4.0 mg/m^2 SC for 3 consecutive days every 3 weeks (21-day cycle) for a total of 4 cycles
89593244|NCT01874288|Experimental|DI-Leu16-IL2 6.0 mg/m^2|Participants will receive DI-Leu16-IL2 6.0 mg/m^2 SC for 3 consecutive days every 3 weeks (21-day cycle) for a total of 4 cycles.
88978098|NCT00067106||2: Women suppressed on therapy|Participants will have study visits for blood and genital tract collections at study entry and then every 4 weeks for 12 months
88978099|NCT00243529|Active Comparator|MHC Class I restricted epitopes|HLA-A2.1 patients are vaccinated with dendritic cells loaded with MHC Class I restricted epitopes of tumor antigens gp100 and tyrosinase
88978100|NCT00243529|Experimental|MHC Class I and II restricted epitopes|HLA-A2.1 and HLA-DR4 patients are vaccinated with dendritic cells loaded with MHC Class I and II restricted epitopes of tumor antigens gp100 and tyrosinase
88978101|NCT00243529|Experimental|mRNA transfected DC|HLA-A2.1 and/or HLA-DR4 patients are vaccinated with dendritic cells transfected with mRNA encoding tumor antigens gp100 and tyrosinase
88978102|NCT00243607|Experimental|immediate treatment group (SBG)|immediate start of hydrotherapy (self treatment) in immediate treatment group (SBG)
88978103|NCT00243607|No Intervention|waiting group (WG)|start of hydrotherapy (self treatment) after waiting period of 12 weeks
89593245|NCT02080468|Experimental|Arm 1: Lomitapide & EE/Norgestimate - Taken Together|Lomitapide & EE/Norgestimate - Taken Together 2 single oral doses of lomitapide (20 mg) (Day 1 & Day 22) 21 single oral doses of EE/Norgestimate(Day 8 through day 28)
89593246|NCT02080468|Experimental|Arm 2: Lomitapide & EE/Norgestimate - Taken 12 Hours Apart|Lomitapide & EE/Norgestimate - Taken 12 hours apart 2 single oral doses of lomitapide (20 mg) (Day 1 & Day 22) 21 single oral doses of EE/Norgestimate(Day 9 through day 29)
89593247|NCT04020016|Experimental|Part 1 Single Ascending Dose|Impaired liver function subjects and healthy liver subjects single ascending dosing up to 162 mg BID of Nalbuphine ER
89593248|NCT04020016|Experimental|Part 2 Multiple Ascending Dose|Impaired liver function subjects will receive multiple ascending dosing up to 162 mg BID of Nalbuphine ER
89593249|NCT02985112||Patients with FFR > 0.80|Group of patients with physiologically non-significant coronary stenoses who will not undergo coronary revascularization
89593250|NCT02985112||Patients with FFR < 0.80|Group of patients with physiologically significant coronary stenoses who will undergo coronary revascularization
89593251|NCT04025164|Experimental|Hypofractionated Radiotherapy|"40 Gy/15 fractions irradiation is delivered to the whole breast, 2.67 Gy per fraction, 5 fractions weekly.~Tumor bed is boosted to 48 Gy simultaneously, 3.2 Gy per fraction, 5 fractions weekly."
89593252|NCT04025164|Active Comparator|Conventional Irradiation|"50 Gy/25 fractions irradiation is delivered to the whole breast, 2 Gy per fraction, 5 fractions weekly.~Additional 10 Gy/5 fractions is boosted to tumor bed sequentially, 2 Gy per fraction, 5 fractions weekly."
89593253|NCT04021966|Experimental|Laser|In this arm, participants will have 3 real laser treatments first, followed by 3 consecutive sham treatments.
89593254|NCT04021966|Sham Comparator|Sham|In this arm, participants will have 3 sham treatments first, followed by 3 consecutive real laser treatments.
89593255|NCT01874054|Experimental|Brentuximab Vedotin + Bendamustine|Brentuximab vedotin 1.8 mg/kg every 3 weeks for up to 16 cycles by IV infusion and bendamustine 90 mg/m2 on Days 1 and 2 every 3 weeks by IV infusion for up to 6 cycles
89593256|NCT01873742|Experimental|The use of STIC feedback system|This will constitute the experimental condition, using of STIC feedback system.
89593257|NCT01873742|Experimental|Treatment as usual|This condition will not include the use of the STIC feedback system.
89593258|NCT04766242|Experimental|Intervention group|The intervention group will receive 10 healing session of 45-60 minutes as an adjunct to usual care, approximately once a week.The usual care will consist of the treatment plan made by their GP when they were diagnosed with moderate depression.
89593259|NCT04766242|Other|Control group|The control group will receive usual care as prescribed by their GP when they were diagnosed with moderate depression.
89593260|NCT01873586|Experimental|OsteoStrux Collagen Ceramic Scaffold|OsteoStrux Collagen Ceramic Scaffold (posterolateral gutter at the symptomatic side)
89593261|NCT01873586|Active Comparator|Local autograft|Local autograft (posterolateral gutter at the contralateral side)
89593262|NCT04029610|Active Comparator|Local anesthesia of lidocaine and arterial blockage on the arm|Local anesthesia of lidocaine and arterial blockage on the arm
89593263|NCT04029610|Experimental|Local anesthesia with lidocaine and adrenalin|Local anesthesia with lidocaine and adrenalin
89593264|NCT04024852|No Intervention|Control group|The control group did daily mild exercise (walking) outdoors for 30 minutes, for maximum 70 days.
89593265|NCT04024852|Other|Intervention group|When Air Quality Health Index is below level 5, the intervention group did daily mild exercise (walking) outdoors for 30 minutes. When Air Quality Health Index is equal to or above level 5, the group is advised to do mild exercise indoors for 30 minutes. Total study period lasted for maximum 70 days.
89593266|NCT04026880|Active Comparator|Treatment Arm|weekly IM administration of 25 mg Testosterone Enanthate for 12 weeks
89593267|NCT04026880|Placebo Comparator|Control Arm|Weekly IM administration of placebo for 12 weeks
89031233|NCT04692246|Experimental|Test Group|Patients that will receive the application of the extract in form of irrigation solutions in the periodontal pockets during regular periodontal treatment. Patients would continue at home during the follow-up period, taking the essential oils in as a rinse twice per day, and as a spray when regular toothbrush could not be performed.
89593268|NCT04190992|Experimental|Application (APP) group|After completing the questionnaires at baseline, participants in the experimental group will be asked to receive a pamphlet and an E-based & personalized breast reconstruction surgery decision aid at clinic.
89593269|NCT04190992|Other|Usual care group|After completing the questionnaires at baseline, participants in the control group will only receive a pamphlet as usual care
89593270|NCT04191070|Experimental|Class II correction using infrazygomatic crest miniscrews|class II correction by distalization using infrazygomatic crest miniscrews (G1)
89593271|NCT04191070|Experimental|Class II correction using zygomatic miniplates|class II correction by distalization using zygomatic miniplates (G2)
89031234|NCT04692246|Placebo Comparator|Control Group|Patients that will follow the same protocol, but using placebo irrigation and a placebo spray at home.
89031235|NCT02945202|Other|All Eyes|All eyes undergo the same interventions. These are the following examinations: Biometry, Refraction and Corneal Topography. The examinations take place 6 months after surgery
89031236|NCT03459560|Experimental|PolyPill|Single daily dose of PolyPill and minimal care.
89031237|NCT03459560|No Intervention|Control|Only minimal care
89593272|NCT04024384|Experimental|Daratumumab|Daratumumab as maintenance after peripheral blood stem cell transplantation from HLA-identical or haploidentical family donor in the treatment of refractory or relapsed multiple myeloma
89593273|NCT04023916|Experimental|Sintilimab-R-CHOP|Participants with previously untreated DLBCL will receive rituximab and CHOP during Cycle 1 (21-day cycle) and Sintilimab, rituximab, and CHOP during Cycles 2-6 (21-day cycle) ,Sintilimab and rituximab during Cycles 6-8 (21-day cycle) , followed by Sintilimab from Cycles 9-14 (8-week cycle) during consolidation treatment.
89031238|NCT00527085|Experimental|AMG 073|
89031239|NCT00527085|Placebo Comparator|Placebo|
89593274|NCT04023838|Placebo Comparator|Right conventional radial approach|After local anesthesia on right wrist area with lidocaine hydrochloride using a 26 gauge needle, the puncture is performed using a 20 gauge needle with the through-and-through puncture technique or a 21 gauge open needle with anterior wall puncture technique. After the successful puncture, 0.025-inch straight wire or 0.018-inch hair wire are inserted, followed by insertion of the 5Fr. radial sheath (Prelude® Radial; Merit medical, UT, USA or Radifocus® Introducer II or Glidesheath Slender®; Terumo Corporation, Tokyo, Japan).
89593275|NCT04023838|Active Comparator|Left distal radial approach|After local anesthesia on left anatomical snuffbox area with lidocaine hydrochloride using a 26 gauge needle, the puncture is performed using a 20 gauge needle with the through-and-through puncture technique or a 21 gauge open needle with anterior wall puncture technique. After the successful puncture, 0.025-inch straight wire or 0.018-inch hair wire are inserted, followed by insertion of the 5Fr. radial sheath (Prelude® Radial; Merit medical, UT, USA or Radifocus® Introducer II or Glidesheath Slender®; Terumo Corporation, Tokyo, Japan).
89031240|NCT00509327|Active Comparator|1|bisacodyl 10mg twice daily from one day preoperative to day three postoperative
89031241|NCT00509327|Placebo Comparator|2|10mg of glucosemonohydricum twice daily from one day preoperative to day three postoperative
89593276|NCT04023760|Experimental|Treatment group A: Cyclosporine in transplant recipients|A single oral dose of 10 mg apixaban will be administered to kidney or lung transplant recipients stabilized on cyclosporine as part of their immunosuppressive regimen
89593277|NCT04023760|Active Comparator|Cyclosporine in healthy subjects|"Results from Treatment group A will be compared to previously obtained data in healthy participants receiving a single dose of apixaban with a daily dose of 100 mg of cyclosporine at steady state concentration (Bashir et al. Clin Transl Sci. 2018 Jul 3. doi: 10.1111/cts.12580)~Transplant recipients require continuous immunosuppression so it will not be possible to stop the cyclosporine or tacrolimus to serve as a control. As such PK plasma time curves will be compared to data in healthy volunteers."
89593278|NCT04023760|Experimental|Treatment group B: Tacrolimus in transplant recipients|A single oral dose of 10 mg apixaban will be administered to kidney or lung transplant recipients stabilized on tacrolimus as part of their immunosuppressive regimen
89593279|NCT04023760|Active Comparator|Tacrolimus in healthy subjects|"Results from Treatment group B will be compared to previously obtained data in healthy participants receiving a single dose of apixaban with a daily dose of 100 mg of tacrolimus at steady state concentration (Bashir et al. Clin Transl Sci. 2018 Jul 3. doi: 10.1111/cts.12580)~Transplant recipients require continuous immunosuppression so it will not be possible to stop the cyclosporine or tacrolimus to serve as a control. As such PK plasma time curves will be compared to data in healthy volunteers."
89593280|NCT03022786|No Intervention|Understanding patient perspective|Patients will be interviewed who have been diagnosed with stasis dermatitis. The Principal Investigator will learn their perspective on their leg swelling, impact on quality of life, and obstacles to wearing compression stockings
89593281|NCT03022786|No Intervention|Refining tool kit|"Using in-depth interviews for our inpatients selected using the same criteria as in Phase 1 and independent focus groups of providers, The study staff will obtain feedback to refine the items in our toolkit before implementing them in January 2017.~There will be a focus group comprised of providers. This focus group will explore the perceptions of the providers and what unmet needs remain for the patients."
89593282|NCT03022786|Other|Implementation|Our patient education materials and toolkit include an order set to help providers guide patients to adhere to compression, the gold standard of care for this condition. This will also direct patients to know who to contact if itching or pain persists, what the patient can do at home, when to go to the hospital, as well as information on financial and home care assistance as it relates to managing their chronic condition.
89031242|NCT02945007|Experimental|JNJ-53718678: PART 1|Participants will receive a single dose of JNJ-53718678 500 mg under fasted conditions on day 1 for treatment A (solution) and B (novel concept formulation 1), and under fed condition for treatment C (novel concept formulation 1).
89031243|NCT02945007|Experimental|JNJ-53718678: PART 2|"Participants will receive a single dose of JNJ-53718678 500 mg under fasted conditions on day 1 for treatment A (solution) and D (novel concept formulation 2), and under fed condition for treatment E (novel concept formulation 2).~Part 2 of the study is optional and might be performed depending on the availability of concept formulations and the result of previous part."
89031244|NCT02945007|Experimental|JNJ-53718678: PART 3|"Participants will receive a single dose of JNJ-53718678 500 mg under fasted conditions on day 1 for treatment A (solution) and F (novel concept formulation 3), and under fed condition for treatment G (novel concept formulation 3).~Part 3 of the study is optional and might be performed depending on the availability of concept formulations and the result of previous part."
89031245|NCT02945007|Experimental|JNJ-53718678: PART 4|"Participants will receive a single dose of JNJ-53718678 500 mg under fasted conditions on day 1 for treatment A (solution) and H (novel concept formulation 4), and under fed condition for treatment I (novel concept formulation 4).~Part 4 of the study is optional and might be performed depending on the availability of concept formulations and the result of previous part."
89031246|NCT02945007|Experimental|JNJ-53718678: PART 5|"Participants will receive a single dose of JNJ-53718678 500 mg under fasted conditions on day 1 for treatment A (solution) and J (novel concept formulation 5), and under fed condition for treatment K (novel concept formulation 5).~Part 5 of the study is optional and might be performed depending on the availability of concept formulations and the result of previous part."
89031247|NCT02945007|Experimental|JNJ-53718678: PART 6|"Participants will receive a single dose of JNJ-53718678 500 mg under fasted conditions on day 1 for treatment A (solution) and L (novel concept formulation 6), and under fed condition for treatment M (novel concept formulation 6).~Part 6 of the study is optional and might be performed depending on the availability of concept formulations and the result of previous part."
89209987|NCT00892398|Active Comparator|standard care|Trabeculectomy with mitomycin C and standard post-operative care
89209988|NCT00892476|Experimental|1|Infants receive supplemental calcium in their 24 cal/oz formula or fortified breast milk.
89209989|NCT00892476|Active Comparator|2|Infants will receive fortified breast milk or 24 cal/oz formula
89209990|NCT00892554|Experimental|DHA supplementation|
89209991|NCT00892554|Placebo Comparator|corn/soy capsule, no DHA|
89593283|NCT04020952|Active Comparator|"st.st 0.019×0.025 wire"|
89593284|NCT04020952|Experimental|"st.st 0.016×0.022 wire"|
89593285|NCT04020952|Experimental|"st.st 0.017×0.025 wire"|
89593286|NCT04020718|Experimental|Early assessment|Patients are assessed for response to brief telephone advice plus a tailored text message program at 4 weeks post-randomization. Response is based on self-reported 7-day point prevalence abstinence. Non-responders are randomized to 4 weeks of mailed nicotine patches and/or lozenges (NRT) or 4 weeks of mailed NRT plus proactive telephone coaching.
89593287|NCT04020718|Experimental|Late assessment|Patients are assessed for response to brief telephone advice plus a tailored text message program at 8 weeks post-randomization. Response is based on self-reported 7-day point prevalence abstinence. Non-responders are randomized to 4 weeks of mailed nicotine patches and/or lozenges (NRT) or 4 weeks of mailed NRT plus proactive telephone coaching.
89593288|NCT04027348|Experimental|Treatment (octreotide, dexamethasone, metoclopramide)|IV octreotide 300 mcg TID + IV dexamethasone 4 mg BID (first dose 9am and second at 2pm) + IV metoclopramide 10 mg q6h.
89593289|NCT04195204|Experimental|Tropisetron|Patients allocated to this arm will receive intravenous Tropisetron (5mg) before anesthesia induction and once daily for 7 days after surgery.
89593290|NCT04195204|Placebo Comparator|Placebo|Patients allocated to this arm will receive an identical volume of normal saline before anesthesia and once daily for 7 days after surgery.
89593291|NCT04406350|Experimental|Study group - MRI CO2 and O2 stress test|Pilot Study of Feasibility of tight control of end-tidal respiratory gases during conduct of anesthesia
89593292|NCT04023136|Other|only one arm (resected patients)|liver resection group
89593293|NCT04023214||ADPKD|ADPKD patients
89593294|NCT04023214||Controls|Healthy volunteers
89593295|NCT04023292|Experimental|Arm I (2 weeks preoperative endocrine therapy))|Patients receive endocrine therapy before surgery for 2 weeks. Choice of endocrine therapy is according to guidelines and centre policy.
89593296|NCT04023292|Active Comparator|Arm II (4 weeks preoperative endocrine therapy)|Patients receive endocrine therapy before surgery for 4 weeks. Choice of endocrine therapy is according to guidelines and centre policy.
89593297|NCT03948958|Experimental|TIVAD evaluation|TIVAD evaluation at port removal evaluation of catheter function, visualization of catheter tip, presence of thrombus material and sleeve and any device damage during linogram (contrast injection via TIVAD), tip and chamber content microbiological culture, macroscopic catheter and port chamber evaluation PROM: patient reported outcome measurements regarding TIVAD insertion, presence and removal
89593298|NCT04198090|Other|Sexual & Gender Minority (SGM) Competence Training|Personnel will be trained using a validated, two-hour long SGM curriculum created by the Fenway Institute and tailored for Oncology.
89593299|NCT02703688|Experimental|Healthy Homes|Behavioral Intervention
89209992|NCT02541786|Active Comparator|dexlansoprazole based triple therapy|dexlansoprazole MR 60 mg once daily, clarithromycin 500 mg twice daily, and amoxicillin 1 g twice daily for 7 days
89209993|NCT02541786|Experimental|rabeprazole-based triple therapy|rabeprazole 20 mg twice daily, clarithromycin 500 mg twice daily, and amoxicillin 1 g twice daily for 7 days
89209994|NCT00888342|Active Comparator|1 supplementary oxygen|participant receives supplementary oxygen one night, polysomnography with capnography will be compared to no treatment another night
89209995|NCT00888342|Active Comparator|2 Zopiclone|participant receives 5 mg zopiclone one night, polysomnography with capnography will be compared to no treatment another night
89593300|NCT02703688|Active Comparator|Usual Care|Counseling session delivered by pediatrician
89593301|NCT04190758||Patients with rheumatoid arthritis (RA)|Patients with RA meeting the classification criteria of American College of Rheumatology (ACR) and/or European League Against Rheumatism (EULAR) från 2010.
89593302|NCT04190758||Patients with psoriatic arthritis (PsA)|Patients with PsA meeting the classification criteria of Classification for Psoriatic Arthritis (CASPAR).
89593303|NCT04190758||Patients with undifferentiated arthritis|Defined as a patients with a clear arthritis, but not meeting with established classifications criteria of any now known rheumatic disease.
89593304|NCT04190758||Patients with psoriasis|Patients with psoriasis diagnosed at a dermatology department. The patients should not have any history of joint complaints with a duration of more than 6 weeks.
89593305|NCT04190758||General population controls|General population controls retrieved from the Population Register, matched for age, sex and residence of living to the included patients.
89593306|NCT04023448|Experimental|coloplasty(CP)|After purse-string suture and ligation of the head of the stapler at the colonic end, 5cm away from the colonic end, 5cm longitudinal incision was made to the proximal end of the teniae coli in the anterior wall of the colon, transverse suture was performed, and the plasmomuscular layer was embedded, then end to end colon-rectum (or anal canal) anastomosis was performed
89593307|NCT04023448|No Intervention|straight colorectal anastomosis (SCA)|End to end colon-rectum (or anal canal) anastomosis was performed routinely
89593308|NCT02704312|Experimental|Radiotherapy techniques|Quantitative Physics: dosimetric comparison of doses in target volumes and organs at risk. The technique used is that of which the dose on the organs at risk is as low as possible, and whose dose to the target volume is the closest possible to the prescribed dose (100% of the prescribed dose)
89593309|NCT02080546|Active Comparator|Cut/Coag|
89593310|NCT02080546|Experimental|V-mode|
89593311|NCT04022824||OSA|
89593312|NCT04022824||Non-OSA|
89593313|NCT03023254|Other|hydrotherapy group|"Subjects included in the hydrotherapy group will undergo a 3-week Avène hydrotherapy in addition to their usual psoriasis and/or pruritus management (treatments and/or skin care products)."
89593314|NCT03023254|No Intervention|Control group|"Subjects included in the control group will not undergo the hydrotherapy and will keep following their usual psoriasis and/or pruritus management (treatments and/or skin care products)."
89608492|NCT02991508|Active Comparator|Adrecizumab 2.0 mg/kg|To assess the safety, tolerability and pharmacokinetics/-dynamics of single escalating doses of ADRECIZUMAB (0.5 mg/kg, 2,0 mg/kg and 8,0 mg/kg administered as single infusion over 1 hour) in healthy male subjects.
89031248|NCT02945007|Experimental|JNJ-53718678: PART 7|"Participants will receive a single dose of JNJ-53718678 500 mg under fasted conditions on day 1 for treatment A (solution) and N (novel concept formulation 7), and under fed condition for treatment O (novel concept formulation 7).~Part 7 of the study is optional and might be performed depending on the availability of concept formulations and the result of previous part."
89031249|NCT02945007|Experimental|JNJ-53718678: PART 8|"Participants will receive a single dose of JNJ-53718678, 500 mg oral solution under fasted or fed conditions on day 1 for treatment A and P (oral concept formulation 1, 2, 3, 4, 5, 6 or 7) and under fed conditions for treatment Q (oral concept formulation 1, 2, 3, 4, 5, 6 or 7).~Part 8 of the study is optional, might be performed, depending on the interim results of prior parts. One of the concept formulations might be re-evaluated under different feeding conditions."
89593315|NCT03022240|Experimental|Inhalational Technique|All patients will receive Ametop local anesthetic to the dorsum of both hands 30-45 minutes prior to induction. After inhalation induction of anesthesia with sevoflurane (in 100% O2), an IV will be obtained. Anesthesia will be maintained with sevoflurane (in a mixture of air:oxygen) with a minimum alveolar concentration of 1.0-1.3, titrated to effect. No long acting opioids or nitrous oxide will be used. Airway management will be at the discretion of the anesthesiologist. Each patient will receive the antiemetic ondansetron 0.1mg/kg IV.
89593316|NCT03022240|Experimental|Total Intravenous Anesthetic Technique|All patients will receive Ametop local anesthetic to the dorsum of both hands 30-45 minutes prior to IV insertion. Once an IV is established, patients will receive an IV bolus of propofol (2-6mg/kg). Anesthesia will be maintained with a propofol infusion starting at 250 mcg/kg/min and titrated to effect. Airway management will be at the discretion of the anesthesiologist. Each patient will receive the antiemetic ondansetron 0.1mg/kg IV.
89593317|NCT02701738|Experimental|Overeating Protocol|Subjects will ingest 30% more calories per day than their calculated daily energy requirements (~750kcals extra energy intake each day). All subjects will be instructed (and will be guided) to consume a diet containing approximately 50% carbohydrate, 35% fat, and 15% protein.
89593318|NCT04022434|Placebo Comparator|Placebo|"Psyllium powder is used as the placebo. A member of the research staff will package and dispense L-alanine and placebo in similar containers. A standard measuring spoon will be provided to the subject for preparing the placebo solution. Subjects will mix the placebo in the beverage of their choice and consume this approximately 20 minutes before meals or snacks, in according with the dosing guidelines set for them by the dietitian.~Meal Placebo Breakfast * 1-2 scoops Snack * .5 - 1 scoop Lunch * 1-2 scoops Snack * .5 - 1 scoop Dinner * 1-2 scoops"
89593319|NCT04022434|Experimental|Experimental Alanine|"L-alanine, USP (Spectrum® Chemicals and Laboratory Products, Gardena, CA) will be packaged and dispensed by one member of the research staff who will have no other role in the study. A one-month supply will be dispensed to the subjects.~Meal L-Alanine Breakfast * 1-2 scoops Snack * .5 - 1 scoop Lunch * 1-2 scoops Snack * .5 - 1 scoop Dinner * 1-2 scoops"
89593320|NCT04196374|Experimental|FHS & JHS participants with an actionable genomic finding|Framingham and Jackson Heart Study participants who have had their genomes sequenced as part of TOPMed will be notified if an actionable genetic result in an ACMG v2.0 gene is identified and will be offered the opportunity to have their research result clinically confirmed by the study.
89593321|NCT04196686|Experimental|Ice bath Control then VR/AR|Participants will be randomized with a 1:1 allocation to use their dominant or non-dominant hand with VR or control (no VR) for the cold pressor test and then crossed over. Participants will not be told of the specifics of the time limit, to avoid competitiveness and expectations and will be asked for pain scores every 30 seconds.
89593322|NCT04196686|Experimental|Ice bath with VR/AR then Control|Participants will be randomized with a 1:1 allocation to use their dominant or non-dominant hand with VR or control (no VR) for the cold pressor test and then crossed over. Participants will not be told of the specifics of the time limit, to avoid competitiveness and expectations and will be asked for pain scores every 30 seconds.
89593323|NCT03957850|Experimental|Cognitive Reappraisal Training Group|Cognitive Reappraisal Training group will perform 4 training sessions in Cognitive Reappraisal during which, behavioral responses, event-related potentials (ERPs) and eye-tracking data are collected.
89593324|NCT03957850|Active Comparator|Control Training Group|Control Training Group will perform 4 control sessions without Cognitive Reappraisal Training during which behavioral responses, ERP and eye-tracking data are collected.
89593325|NCT04192318|Experimental|Hospital-based violence prevention with community initiative|Youth who are living in communities that receive Communities that Care Prevention System (CTC) will also receive Bridging the Gap (BTG), a hospital-based violence prevention program with 6-months of community case management.
89593326|NCT04192318|Experimental|Hybrid hospital based violence prevention|Youth who do not live in a community that has CTC but will receive BTG.
89593327|NCT04192318|Active Comparator|Treatment as usual|Youth living in a community without the CTC program and will receive treatment as usual (TAU) in the hospital.
89593328|NCT04192318|Experimental|Treatment as usual with community initiative|Youth living in a community with the CTC program and will receive treatment as usual (TAU) in the hospital.
89593329|NCT02704390|Experimental|ORADUR®-Methylphenidate|ORADUR®-Methylphenidate oral capsule will be administered once daily in the morning for 24 months.
89593330|NCT03022864||Chronic pain|Follow up the patients for three months after surgery using the designed table. If the patient evaluate the pain more than 3 points according the Numerical Rating Scale, then it can be considered that the patient has chronic pain.
89593331|NCT03022864||No chronic pain|Follow up the patients for three months after surgery using the designed table. If the patient evaluate the pain no more than 3 points according the Numerical Rating Scale, then it can be considered that the patient doesn't have chronic pain.
89593332|NCT04147390|Active Comparator|usage mycophenolate mofetil|
89593333|NCT04147390|Active Comparator|usage tacrolimus|
89031250|NCT00509405|Placebo Comparator|Potassium citrate|
89031251|NCT02944851||Prospective observational|The changes of IVC diameter, SpHb and vital signs of blood donors were observed after blood donation
89031252|NCT00509444|Active Comparator|Educational materials|
89031253|NCT00509444|Experimental|Educational materials, plus patient navigation|
89031254|NCT00528138||1|Simple appendicitis
89031255|NCT00528138||2|Perforated appendicitis
89031256|NCT02945865|Experimental|ITreatment arm: Pain Assessment|Pain assessment by Doloplus-2 pain scale regularly and additional pain assessment in situations where pain is suspected.
89031257|NCT02945865|No Intervention|Control arm: No treatment|Treatment us usual
89593334|NCT02706964|Experimental|Proactive imaging|All enrolled subjects will under go a single whole-body Positron emission tomography/x-ray computed tomography (PET/CT) scan and a diagnostic-quality x-ray computed tomography (CT) scan with contrast acquired in the same imaging session; and a single brain magnetic resonance imaging (MRI) scan with contrast to be completed in separate imaging session but within 2 weeks of the PET/CT scan. Imaging will take place within 7 months after enrollment.
89593335|NCT02708758|Active Comparator|Treatment group|Medical nutrition therapy plus self monitoring capillary glucose levels and if necessary drug therapy (metformin or insulin) when goals are not met.
89593336|NCT02708758|No Intervention|Routine care group|Prenatal routine care without medical nutrition therapy and without self monitoring capillary glucose levels and drug therapy specific for GDM.
89593337|NCT02708680|Active Comparator|Entinostat plus Atezolizumab|"Participants in this arm will receive entinostat in combination with atezolizumab.~Phase 1b Dose Determination: The initial 3 to 6 participants will receive entinostat at a starting dose of 5 milligrams (mg) (Dose Group 1) on Days 1, 8, and 15 along with atezolizumab 1200 mg via intravenous (IV) infusion on Day 1 of each 21-day cycle. If the 5 mg dose exceeds the maximum tolerated dose (MTD), then a 3 mg dose of entinostat (Dose Group -1) will be evaluated in the same manner. If the -1 dose level exceeds the MTD, then a 2 mg dose of entinostat (Dose Group -2) will be evaluated.~Phase 2 Dose Expansion: Participants will receive the RP2D identified in the Dose Determination Phase."
89593338|NCT02708680|Placebo Comparator|Placebo plus Atezolizumab|Participants in this arm will receive placebo in combination with atezolizumab 1200 mg.
89593339|NCT03931642|Experimental|R-CHOP- blinatumomab|"Patients will first undergo a prior debulking therapy including 2 cycles of R-CHOP.~At Day1 (D1) : Rituximab 375 mg/m² Intravenous (IV) + Cyclophosphamide 750 mg/m² IV + Doxorubicin 50 mg/m² IV + Vincristine 1.4 mg/m² IV.~From D1 to D5 : Prednisone 60 mg/m² Per Os (PO). Patients with CR and no measurable lesion left will not be treated further in the setting of the present trial. All the remaining patients will be continuing and treating on study with a single cycle of blinatumomab induction therapy : Blinatumomab at 9 μg/d IV by continuous vein infusion from day 1-7, 28 μg/d from day 8-14 and 112 μg/d from day 15-56.~Patients who achieve an objective response after induction are eligible to receive one further optional cycle of blinatumomab consolidation : blinatumomab 9 μg/d IV by continuous vein infusion from day 1-7, 28 μg/d from day 8-14 and 112 μg/day IV from day 15-28."
89593340|NCT04147312|Experimental|Treatment group|Fufang E'Jiao Jiang, 20milliliters(mL) once, 3 times a day, continuous intervention for 21days each cycle, and use 2 cycles
89593341|NCT04147312|Placebo Comparator|control group|Placebo containing low-dose Fufang E'Jiao Jiang, 20mL once, 3 times a day, continuous intervention for 21 days each cycle, and use 2 cycles
89593342|NCT04146766|Experimental|eHealth|Provide home physiology measurement services, including automatic uploading of measured blood pressure values to the cloud, serial back-end education platform to provide numerical anomaly alarms and health care notifications, monthly measurement data reports, combined with mobile APP management system for immediate enquiry . In addition to the electric visit to the patient's health education guidance, the content includes: 1. Encourage the walking exercise to perform 2. Ask the walking exercise execution progress, please return the daily value of the case to facilitate the record 3. Answer the relevant questions asked during the intervention.
89593343|NCT04146766|Experimental|wait list control|wait list control for 3 months and then Provide home physiology measurement services, including automatic uploading of measured blood pressure values to the cloud, serial back-end education platform to provide numerical anomaly alarms and health care notifications, monthly measurement data reports, combined with mobile APP management system for immediate enquiry . In addition to the electric visit to the patient's health education guidance, the content includes: 1. Encourage the walking exercise to perform 2. Ask the walking exercise execution progress, please return the daily value of the case to facilitate the record 3. Answer the relevant questions asked during the intervention.
89593344|NCT04021342|Active Comparator|Montmorency tart cherry concentrate|Participants will consume 30 ml of Montmorency tart cherry concentrate (MC) concentrate (King Orchard farms, USA) twice daily, once in the morning and again in the evening. According to the manufacturer each 30 ml dose of MC is estimated to be equivalent to approximately 90 whole cherries (equating to ~180 cherries per day).
89593345|NCT04021342|Placebo Comparator|Isocaloric cherry flavoured placebo|The PLA is prepared by mixing by mixing unsweetened black cherry flavoured Kool-Aid (Kraft Foods, United States), dextrose, fructose with water to best match the calorie content of the MC concentrate. Additional lemon juice, for tartness, and artificial food colouring is added so the final product had a similar visual properties to the active comparator.
89593346|NCT04021888|Experimental|Exercise Group|
89593347|NCT04021888|Active Comparator|Control|
89031258|NCT02945709|Experimental|Personalized ACT|The personalized attention control training (ACT), comprised of six computerized sessions, in purpose of modulate biases in attention for personalized threat stimuli.
89031259|NCT02945709|Active Comparator|Non personalized ACT|The Non-personalized attention control training (ACT), comprised of six sessions, in purpose of modulate biases in attention for non-personalized threat stimuli.
89031260|NCT02945709|Placebo Comparator|Control training|Computerized control training, comprised of six sessions with a variation of the dot-probe task with neutral stimuli
89031261|NCT00509561|Active Comparator|Chemo-radiotherapy|
89031262|NCT00509561|Experimental|Chemo-radiotherapy plus cetuximab|
89031263|NCT02945943|Experimental|Mobilization|High Velocity Low Amplitude mobilization group. The three joints manipulated included proximal tibiofibular, the distal tibiofibular, and talocrural joints and were mobilized the first three sessions prior to the participants performing the exercise protocol.
89031264|NCT02945943|Active Comparator|Exercise Protocol|This exercise regimen is a modified version of the balance training program described by McKeon et al.
89031265|NCT00509639|Experimental|Metronidazole 10% ointment|Metronidazole 10% ointment
89031266|NCT00509639|Placebo Comparator|Placebo ointment|Placebo ointment
89031267|NCT02952716|Experimental|intervention group|Human Cord Blood Mononuclear Cell will be slowly infusion three times,at one days, 30 days,at 60days.
89593348|NCT04021420|Experimental|low intensity pulsed UltraSound|SonoCloud® is an active implantable device (implantation duration until 16 weeks at maximum after inclusion). SonoCloud® delivers low intensity pulsed UltraSound (US). Along with systemic injection of an US resonator, SonoCloud® demonstrated safe and efficient at repetitively opening the BBB.
89593349|NCT04144582|Experimental|Sintilimab Combined With Docetaxel|Sintilimab Combined With Docetaxel for Metastatic or Non-driver Gene Mutation Non-small Cell Lung Cancer
89593350|NCT01611974|Experimental|Maribavir 400 mg twice daily|
89593351|NCT01611974|Experimental|Maribavir 800 mg twice daily|
89593352|NCT01611974|Experimental|Maribavir 1200 mg twice daily|
89593353|NCT04146688|Active Comparator|Patients with neurodegenerative disease|Patients with neurodegenerative disease (AD or related disease)
89593354|NCT04146688|Active Comparator|People with no neuropathological disease|
89593355|NCT01848938|Active Comparator|Smartphone treatment|Smartphone treatment with PFMT.
89593356|NCT01848938|No Intervention|Waiting list|Waiting list for three months. They receive the smartphone application after follow-up.
89593357|NCT04146454|Experimental|Smartphone-based balance exercises|This group will complete in-home dynamic weight-shifting balance exercises (i.e., physical therapists' recommended dynamic balance exercises) with a smartphone-based wearable telerehabilitation system.
89593358|NCT04146454|No Intervention|Paper-based balance exercises|This group will complete in-home dynamic weight-shifting balance exercises (i.e., physical therapists' recommended dynamic balance exercises) with typical paper-based instructions.
89593359|NCT04149418|Experimental|Yogurt-Control|Consumption of 12 oz. of low-fat yogurt daily (2 x 6 oz. servings) for 4 weeks, followed by a washout phase for 4 weeks, then consumption of 12 oz. control food (flavored soy pudding, 2 x 6 oz. servings) for 4 weeks.
89593360|NCT04149418|Experimental|Control-Yogurt|Consumption of control food (flavored soy pudding, 2 x 6 oz. servings), followed by a washout phase for 4 weeks, then consumption of 12 oz. of low-fat yogurt daily (2 x 6 oz. servings) for 4 weeks.
89593361|NCT01871870|Experimental|Artificial Pancreas Control Software|Type 1 Diabetes Mellitus subjects who fit the inclusion/exclusion criteria will undergo artificial pancreas closed-loop study for 28 hours. For the entire study, the adaptive component of Artificial Pancreas Control Software will be used to control the subject's blood glucose.
89593362|NCT02080780|Experimental|2% Diltiazem & Clarithromycin XL|"3 parts:~- Single Dose, Diltiazem (Day 1)~- Multiple Dose, Clarithromycin XL (Days 4-9)~- Single Dose, Diltiazem (Day 8)"
89593363|NCT01871558|Active Comparator|SU+metformin + Basal Insulin|Randomized patient will remain on their previous dual therapy by SU+metformin, which will be kept unchanged, + start of Basal Insulin up-titrated as per usual algorithms primarily based on FPG
89593364|NCT01871558|Experimental|Metformin/vildagliptin + Basal Insulin|Randomized patient will receive Vildagliptin 50 mg twice daily (b.i.d) + continued therapy with Metformin, + start of Basal Insulin up-titrated as per usual algorithms primarily based on FPG
89593365|NCT01711359|Experimental|Baricitinib + MTX|Baricitinib 4 milligram (mg) administered orally once daily through Week 52. Participants received methotrexate (MTX) orally once weekly with dose ranging from 10 to 20 mg per week through Week 52. Starting at Week 24, participants who were nonresponders were rescued with baricitinib 4 mg orally once daily and MTX orally once weekly.
89593366|NCT01711359|Experimental|Baricitinib|Baricitinib 4 mg administered orally once daily through Week 52. Participants received MTX placebo orally once weekly through Week 52. Starting at Week 24, participants who were nonresponders were rescued with baricitinib 4 mg orally once daily and MTX orally once weekly.
89593367|NCT01711359|Active Comparator|MTX|MTX administered orally once weekly with dose ranging from 10 to 20 mg per week through Week 52. Participants also received baricitinib placebo orally once daily. Starting at Week 24, participants who were nonresponders were rescued with baricitinib 4 mg orally once daily and MTX orally once weekly.
89593368|NCT04149496|Experimental|All|Patients requiring IVF treatment with PCOS or a PCO pattern in their ovaries who wish to undertake IVM (as a variant of their IVF procedure)
89593369|NCT04140136|Active Comparator|Treatment group|This is a pilot randomized, double-blind, placebo-controlled, parallel-group study to evaluate the effects of 24-weeks tocotrienols (Tocovid Suprabio) supplementation in ALS patients.The investigational product is to be administered twice daily, at a dose of 400mg per day.
89593370|NCT04140136|Placebo Comparator|Placebo group|This is a pilot randomized, double-blind, placebo-controlled, parallel-group study to evaluate the effects of 24-weeks tocotrienols (Tocovid Suprabio) supplementation in ALS patients. The placebo is similar in appearance but does not contain tocotrienols and consist of palm oil.
89593371|NCT04146532|Placebo Comparator|Placebo|Single dose of a 500mg placebo tablet.
89593372|NCT04146532|Active Comparator|Aspirin 500MG|Single dose of a 500 mg aspirin tablet.
89593373|NCT03929224|Active Comparator|Bacitracin|Standard care: Bone-anchored hearing aid (BAHI) abutment incision is coated in bacitracin. A healing cap is placed over the abutment and left for a week. The healing cap is removed on postoperative day 7. Patient is instructed to apply bacitracin ointment to the area for 2 weeks.
88978104|NCT00243646|Active Comparator|no hormones|All patients will receive a 5-week course of external beam radiation therapy to the pelvis and a Pd-103 brachytherapy implant with no hormones
89593374|NCT03929224|Experimental|Medicinal honey|Medicinal honey: Medicinal honey will be applied to the abutment site immediately after surgery. The healing cap will be placed on the BAHI site. The healing cap is removed on postoperative day 7. Patient is instructed to apply medicinal honey daily to the area for 2 weeks.
89593375|NCT04146610|Experimental|Dp303c|Multiple dose grouping
88978105|NCT00243646|Active Comparator|9 months of hormone therapy|All patients will receive a 5-week course of external beam radiation therapy to the pelvis and a Pd-103 brachytherapy implant with a 9 month course of hormone therapy
88978106|NCT00099333|Experimental|Exenatide|The subjects will discontinue their insulin and substitute it with exenatide. Subjects will remain on their existing oral diabetic therapy.
88978107|NCT00099333|Active Comparator|Insulin|The subjects will remain on their current insulin therapy. Subjects will also remain on their existing oral diabetic therapy.
88978108|NCT00243685|Experimental|II and III|
89031268|NCT02952716|Placebo Comparator|control group|hyperbaric oxygen
89031269|NCT00528177|Active Comparator|O|This arm will receive intravenous oxycodone at the end of surgery and PCA oxycodone for postoperative pain relief.
89031270|NCT00528177|Active Comparator|M|This arm will receive intravenous morphine at the end of surgery and PCA morphine for postoperative pain relief.
89031271|NCT00528255|Experimental|1|
89031272|NCT02953106|Active Comparator|Azelastine-Fluticasone Nasal|137 micrograms azelastine hydrochloride / 50 micrograms fluticasone propionate per actuation. 1 squirt twice daily
89031273|NCT02953106|Placebo Comparator|Placebos|contains the same components as Dymista nasal spray with the exception of the active ingredients. 1 squirt twice daily.
89031274|NCT02944773|Experimental|facilitated tucking device (FTD)|20 infants use a FTD in the procedure of daily weight
89031275|NCT02944773|No Intervention|without FTD|20 infants use not a FTD in the procedure of daily weight
89031276|NCT02952833|Experimental|Group 1|5.0 mcg ZPIV will be administered in a homologous prime-boost regimen on Day 1 and Day 29, n=25 (2 Sentinel subjects will receive intervention prior to remaining 23 subjects), Placebo for 5 subjects
89593376|NCT03925870|Experimental|KN046 monotherapy|Eligible subjects will be enrolled and receive KN046 monotherapy treatment until progressive disease according to RECIST 1.1, unacceptable toxicity, completion of 2 years' KN046 treatment, or withdrawal of informed consent, whichever comes first.
89593377|NCT04146376||Non-Corrector|Patients with gestational week 34-38 von Willebrand factor activity, or von Willebrand factor ristocetin cofactor, or Factor VIII procoagulant activity less than 100 percent will be termed non-correctors. When laboratory monitoring can be performed, patients with an isolated von Willebrand factor collagen binding type 2 defect, von Willebrand factor collagen binding less than 100 percent can also be enrolled and determined as a non-corrector.
89593378|NCT04146376||Corrector|Patients with von Willebrand factor parameter levels greater than or equal to 100 percent self-corrected at gestational weeks 34-38 will be termed correctors.
89593379|NCT01710657|Placebo Comparator|Placebo|Matching placebo for 16 weeks.
89593380|NCT01710657|Experimental|Lacosamide 200 mg/day|Lacosamide treatment of 200 mg/day (100 mg bid (twice daily)) for 16 weeks.
89593381|NCT01710657|Experimental|Lacosamide 400 mg/day|Lacosamide treatment of 400 mg/day (200 mg bid (twice daily)) for 16 weeks.
89593382|NCT04142710|Experimental|Follow-up using telehealth solutions|Participants in this arm are followed up using a telehealth solution, as specified by the National Directorate of Health at the local centre. The actual follow-up is personalized to the individual user. All users receive a tablet, which can be used to answer questions about own health and/or transmit clinical measurements.
89593383|NCT04142710|No Intervention|Standard clinical care|Participants in this arm receive standard clinical care in accordance with their medinal needs.
89593384|NCT04142710|Experimental|Non-randomized follow-up using telehealth solutions|Participants in this arm are followed up using a telehealth solution, as specified by the National Directorate of Health at the local centre. The actual follow-up is personalized to the individual user. All users receive a tablet, which can be used to answer questions about own health and/or transmit clinical measurements. This arm is not randomized, but otherwise identical to the randomized experimental arm.
89593385|NCT04765930|Active Comparator|PRP Injection|Half of the face
89593386|NCT04765930|Placebo Comparator|Saline injection|Other half of the face
89593387|NCT05582044|Experimental|Heart Failure with Preserved Ejection Fraction (40 Participants)|Lower-body negative pressure (-15 and -25 mmHg) and neutral pressure (0 mmHg)
89593388|NCT05582044|Active Comparator|Healthy Controls (20 Participants)|Lower-body negative pressure (-15 and -25 mmHg) and neutral pressure (0 mmHg)
89593389|NCT03906682|Experimental|RAP Club program|RAP Club is a 12-session universal prevention program delivered twice per week over six weeks during the school day. The program is delivered by a trained facilitator and young adult community member.
89593390|NCT03906682|Active Comparator|Healthy Topics program|Like RAP Club, Healthy Topics is a 12-session program delivered twice per week over six weeks during the school day. The program is delivered by a trained facilitator and young adult community member.
89031277|NCT02952833|Experimental|Group 2|2.5 mcg ZPIV will be administered in a homologous prime-boost regimen on Day 1 and Day 29, n=25, Placebo for 5 subjects
89031278|NCT02952833|Experimental|Group 3|10 mcg of ZPIV will be administered in a homologous prime-boost regimen on Day 1 and Day 29, n=25, (2 Sentinel subjects will receive intervention prior to remaining 23 subjects) Placebo for 5 subjects
89031279|NCT02952989|Experimental|SGN-2FF|Dose escalation and dose expansion
89031280|NCT02952989|Experimental|SGN-2FF and Pembrolizumab|Dose escalation and dose expansion
89031281|NCT00509717|Experimental|experimental|
89031282|NCT00509717|Active Comparator|control|
89031283|NCT02952794||ESD|endoscopic submucosal dissection (ESD)for early cancer
89031284|NCT02952794||EMBL|endoscopic mucosal band ligation (EMBL) for early cancer
89031285|NCT00509756|Active Comparator|1|Drug: FXR-450
89031286|NCT00509756|Placebo Comparator|2|Placebo
89031287|NCT00509834|Experimental|hLF1-11|hLF1-11 0.5mg
89031288|NCT00509834|Placebo Comparator|Placebo|Placebo formulation is Similar to hLF1-11 iv formulation except for the active component
89031289|NCT02952560||High resolution CT Scan of the head and neck|Patients scheduled for high resolution computerized tomography (CT scan) of the head and neck as part of their medical investigation of thyroid or laryngeal disorders will be recruited for this study.
89031290|NCT03459404||Sufentanil NanoTab PCA System/15 mcg|"Drug: Sufentanil 15 mcg~Unless contraindicated patients also received around the clock regimen of NSAIDS (ketoprofen 200 mg/day) and acetaminophen (1000 mg every 8 hours)."
89031291|NCT00527202|Experimental|botulinum toxin A|active treatment arm using botulinum toxin A max 200 U injected into the painful area using SC injections 2 cm apart
89031292|NCT00527202|Placebo Comparator|placebo|saline injection with the same dosages injected using the same procedure as botulinum toxin A
89031293|NCT03459989||pregnant women|we will measure expected fetal weight by ultrasound by hadlock's formula and thigh soft tissue for each pregnant woman
89031294|NCT00527241|Experimental|1: A|
89031295|NCT00527241|No Intervention|2 B|wait-listed for intervention to begin in 6 months
89031296|NCT00527280|Experimental|1|
89532642|NCT06079164|Experimental|KITE-197|"Phase 1a (Dose Escalation): Participants with r/r large B-cell lymphoma will receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single target starting dose of KITE-197 chimeric antigen receptor (CAR) transduced autologous T cells. Based on dose limiting toxicities (DLTs) observed in the first cohort, additional participants will be enrolled and administered escalating dose of KITE-197.~Phase 1b (Dose Expansion): After completion of dose escalation, additional participants with r/r B-cell lymphoma across different disease indications will receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single dose of KITE-197 CAR-transduced autologous T cells at 1 or more dose-level deemed to be tolerable."
89532643|NCT06077487|Experimental|Group A (K-MaP)|Participants will receive 0.5mg/kg of Ketamine orally with an equivalent quantity of placebo via an intramuscular injection on Day 0/Visit 4 and receive Meaning and Purpose (MaP) therapy 4 times, twice before ketamine administration (Day 0), and twice afterward. The duration of treatment for ketamine plus MaP (K-MaP) therapy is approximately up to 28 days. Participants will be followed up to 35 days (+/-2 days) after ketamine administration.
89532644|NCT06077487|Experimental|Group B (K-Map)|Participants will receive 0.5mg/kg of Ketamine IM with a placebo oral solution on Day 0/Visit 4 and receive Meaning and Purpose (MaP) therapy 4 times, twice before ketamine administration (Day 0), and twice afterward. The duration of treatment for ketamine plus MaP (K-MaP) therapy is approximately up to 28 days. Participants will be followed up to 35 days (+/-2 days) after ketamine administration.
89532645|NCT06073119|Experimental|SAR441566 dose regimen A|Participants will receive dose regimen A of SAR441566
89593391|NCT03021772|Active Comparator|Group N|30 patients will receive intravenous 3mg/kg lidocaine 2 % (diluted with normal saline to 40 ml) + 0.5 mg neostigmine for Bier block.
89593392|NCT03021772|Active Comparator|Group D|30 patients will receive intravenous 3mg/kg lidocaine 2 % (diluted with normal saline to 40 ml) + 8 mg dexamethasone for Bier block.
89532646|NCT06073119|Experimental|SAR441566 dose regimen B|Participants will receive dose regimen B of SAR441566
88978109|NCT00243880|Experimental|lovastatin|lovastatin at escalating dosages: 1 mg/kg/day, 3 mg/kg/day, 6 mg/kg/day, 8 mg/kg/day, 10 mg/kg/day
88978110|NCT00243997|Active Comparator|1|Subjects receiving the Becoming Parents Program
88978111|NCT00243997|Placebo Comparator|2|Subjects not receiving the Becoming Parents Program
88978112|NCT00244075|Active Comparator|1|nutrition supplementation, recombinant human growth hormone, and exercise
89532647|NCT06073119|Experimental|SAR441566 dose regimen C|Participants will receive dose regimen C of SAR441566
89532648|NCT06073119|Experimental|SAR441566 dose regimen D|Participants will receive dose regimen D of SAR441566
89532649|NCT06073119|Experimental|SAR441566 dose regimen E|Participants will receive dose regimen E of SAR441566
89532650|NCT06073119|Placebo Comparator|Placebo|Participants will receive SAR441566 matching placebo
89532651|NCT06073093|Experimental|SAR441566 dose regimen A|Participant will receive dose regimen A of SAR441566 for 12 weeks
89532652|NCT06073093|Experimental|SAR441566 dose regimen B|Participant will receive dose regimen B of SAR441566 for 12 weeks
89532653|NCT06073093|Experimental|SAR441566 dose regimen C|Participant will receive dose regimen C of SAR441566 for 12 weeks
89532654|NCT06073093|Experimental|SAR441566 dose regimen D|Participant will receive dose regimen D of SAR441566 for 12 weeks
89532655|NCT06073093|Placebo Comparator|Placebo|Participant will receive SAR441566-matching placebo for 12 weeks
89532656|NCT06072781|Experimental|avutometinib + defactinib|Avutometinib 3.2 mg, PO, twice weekly (eg, Monday/Thursday, Tuesday/Friday, or Wednesday/Saturday) for 21 days on, 7 days off in a 28-day (4 weeks) cycle in combination with defactinib 200 mg, PO, twice daily for 21 days on, 7 days off in a 28-day(4 week) cycle.
88978113|NCT00244075|Active Comparator|2|nutrition supplementation only
88978114|NCT00244114||A|
88978115|NCT00244114||B|
88978116|NCT02967029|Active Comparator|b group|b group controlled hypotension with esmolol hydrochloride
88978117|NCT02967029|Active Comparator|r group|r group controlled hypotension with remifentanil hydrochloride
88978118|NCT00244270|Experimental|1|totally implantable vascular access device
88978119|NCT00077181|Experimental|Treatment (cytarabine and triapine)|Patients receive high-dose cytarabine IV over 2 hours on days 1-5 and triapine IV over 2 hours on days 2-5. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
88978120|NCT00244426|Experimental|1|
88978121|NCT00244426|Active Comparator|2|
88978122|NCT00398996|Active Comparator|1 - Early integrated-therapy group|antiretroviral therapy to be initiated within 4 weeks of starting tuberculosis treatment
88978123|NCT00398996|Active Comparator|2 - Late integrated-therapy group|antiretroviral therapy to be initiated within 4 weeks of completing the intensive phase of tuberculosis treatment
88978124|NCT00398996|Active Comparator|3 - Sequential-therapy group|Antiretroviral therapy to be initiated within 4 weeks after completing tuberculosis treatment
88978125|NCT00244504|Active Comparator|I|moxonidine group
88978126|NCT00244504|Placebo Comparator|II|placebo group
88978127|NCT00244738|Active Comparator|Intervention|Patients who received castor oil for labor induction
88978128|NCT00244738|Placebo Comparator|Control|Patients who received sunflower oil as a placebo
88978129|NCT00244972|Experimental|Treatment (sorafenib tosylate, tipifarnib)|Patients receive sorafenib tosylate PO QD or BID on days 1-28 and tipifarnib PO QD or BID on days 1-21. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity. Patients may be allowed to continue the treatment after the 12 courses if there is continued clinical response or disease stabilization, and patients do not have significant toxicities.
88978130|NCT00067340|Experimental|Intervention group|Subjects received chlorhexidine mouthwash and xylitol gum , in addition to the usual care specified under the control group
88978131|NCT00067340|Placebo Comparator|Control|Subjects received enhanced dental care, health information, toothbrushes and toothpaste. They also received placebo gum and placebo mouth rinse
88978132|NCT00245206|Experimental|1: Risperdal|Participants randomized to this arm will be prescribed risperdal. They will continue to be followed by their psychiatrist. In addition, they will take part in ongoing biological, cognitive, and psycho-social assessments with study staff.
89593393|NCT04149886|Experimental|Ablation group(Ablation+pacemaker)|"The cardioneuroablation will be performed under conscious sedation. After 3-dimensional endocardial surface of the LA and pulmonary veins have been constructed by Ensite system, the GP sites can be located in LA；High frequecy stimulation（HFS）will be used to conform if there is a positive vagal response at each GP site. The upper limits of power and temperature will be set to 30-40 W and 43-60°C, respectively. And if no vagal response been induced during ablation, radiofrequency will be delivered for 30 seconds and stopped in this site. The end point of the ablation procedure will be that no vagal response could be induced by repeat HFS.~After ablation of GPs, the participants will receive permanent pacemaker implantation(see arm of control group)."
89593394|NCT04149886|Sham Comparator|Control group(only pacemaker)|The control group only treated with permanent pacemaker without cardioneuroablation.The participants will receive permanent pacemaker implantation, the pacemaker placement will be done in accordance with standards at each center. All implanted pacemakers are provided two manufacturers (St. Jude Medical or Medtronics), His bundle pacing will be recommended in patients with a LVEF between 35%-45%. After placement of permanent pacemaker, the participants will be followed-up at 1 week, 3,6,12 months. After the permanent pacemaker implantation, the rate response function should be turned off and low pacing rate should be set at 60bpm uniformly in all the eligible participants.
89593395|NCT05584774|Placebo Comparator|PELD|
89593396|NCT05584774|Active Comparator|PELD and annuloplasty and nucleoplasty|
89593397|NCT05581654|Experimental|Junior surgeons|The surgeons will be divided into 2 arms based on their surgical experience time: less than 5 years (junior surgeons) and more than 5 years (senior surgeons). The learning curve analysis will include 30 procedures for each surgeon group in each centre. For ethical reasons, all the junior surgeons will first assist the senior surgeons in performing vNOTES salpingectomy, as first assistant in at least 15 procedures, before starting to perform them as operators.
89593398|NCT05581654|Active Comparator|Senior surgeons|The surgeons will be divided into 2 arms based on their surgical experience time: less than 5 years (junior surgeons) and more than 5 years (senior surgeons). The learning curve analysis will include 30 procedures for each surgeon group in each centre.
89593399|NCT05581576|Experimental|Pitolisant (Wakix)|Pitolisant will be titrated weekly until maximum dosage of 35.6 mg. Titration is dependent on subjects response.
88978133|NCT00245206|Experimental|3: Aripiprazole|Participants randomized to this arm will be prescribed aripiprazole. They will continue to be followed by their psychiatrist. In addition, they will take part in ongoing biological, cognitive, and psycho-social assessments with study staff.
88978134|NCT00245206|Experimental|4: Olanzapine|Participants randomized to this arm will be prescribed olanzapine. They will continue to be followed by their psychiatrist. In addition, they will take part in ongoing biological, cognitive, and psycho-social assessments with study staff.
88978135|NCT00067379|Active Comparator|1|Medicaid patients with medically necessary malocclusions treated during the mixed dentition with limited goals followed by observation
88978136|NCT00077298|Experimental|Arm A (cetuximab, bevacizumab, irinotecan)I|"Patients receive cetuximab IV over 1-2 hours on days 1, 8, 15, 22, 29, and 36; bevacizumab IV over 30-90 minutes on days 1*, 15, and 29 OR on days 1 and 22; and irinotecan IV over 30-90 minutes (at the same dose and schedule that the patient previously received) beginning on day 1.~NOTE: *Bevacizumab is given on day 2 (instead of day 1) of course 1, and is given on day 1 of subsequent courses."
88978137|NCT00077298|Experimental|Arm B (cetuximab and bevacizumab)|"Patients receive cetuximab as in Arm A and bevacizumab IV over 30-90 minutes on days 1*, 15, and 29.~NOTE: *Bevacizumab is given on day 2 (instead of day 1) of course 1, and is given on day 1 of subsequent courses."
88978138|NCT00245440|Active Comparator|1|Subjects assigned Azithromycin
88978139|NCT00245440|Active Comparator|2|Subjects assigned Telithromycin
88978140|NCT00245479|Other|1|
88978141|NCT00245752|Active Comparator|A|in points bilaterally inBL 67, LI 4, SP6, one in GV20.
89593400|NCT04149262|Active Comparator|Fiasp/Novorapid|4 weeks on Fiasp® then crossover to 4 weeks on NovoRapid® in subjects on the MiniMed 640G system equipped with SmartGuardTM technology and accompanied with EnliteTM Sensor and GuardianTM 2 Link transmitter
89593401|NCT04149262|Active Comparator|Novorapid/Fiasp|4 weeks on NovoRapid® then crossover to 4 weeks on Fiasp® in subjects on the MiniMed 640G system equipped with SmartGuardTM technology and accompanied with EnliteTM Sensor and GuardianTM 2 Link transmitter
89593402|NCT04145986||young ladies|Young ladies≤ 35 years old.
88978142|NCT00245752|Sham Comparator|2|sham acupuncture
88978143|NCT00245830|No Intervention|No Hepatic Ischemic Preconditioning|donor will act as a sham control.
88978144|NCT00245830|Experimental|Hepatic Ischemic Preconditioning|blood flow to the liver will be cut off by hilar clamping for ten minutes followed by release of the clamp prior to removal of the liver from the donor.
88978145|NCT00400647|Experimental|EC MPS|Up to 1440mg taken in two doses
88978146|NCT00400647|Active Comparator|Mycophenolate mofetil|250 mg or 500 mg in two equal doses
88978147|NCT02961556|Experimental|AJG555|After 2 weeks of the screening period, participants will be administered AJG555 starting on the day of the formal enrollment and continuing for 12 weeks.
89593403|NCT03647800|Experimental|PART 1 Dose Escalation - 10 dose cohorts|CD123 and CD3 epsilon bispecific antibody
88978148|NCT00246103|Experimental|Dose Escalation and Possible Expansion|Escalating doses of Valproic acid and one dose escalation step of epirubicin. Participants with breast cancer treated at the maximum tolerated dose, will also be treated with 5-fluorouracil and Cyclophosphamide.
88978149|NCT00424801|Experimental|Vasodilatory|Patients in this arm will receive intensive vasodilatory treatment to lower blood pressure
88978150|NCT02966951|Experimental|adipose tissue mesenchymal stem cell|Intra-articular adipose tissue derived mesenchymal stem cell injection will be given for each patient in 2 doses, 50 million of ATMSC in each dose
88978151|NCT00246532|Placebo Comparator|1: Placebo Pill|This arm contains placebo medication.
88978152|NCT00246532|Active Comparator|2: Morphine|Patients will receive oral morphine therapy.
88978153|NCT00246610|Experimental|Open-label|Non-randomized, open-label, single-arm
88978154|NCT00246688|Experimental|Sagopilone, 0.5 h infusion|Subjects received one infusion (for 0.5 h) of sagopilone every 3 weeks at a dose of 16 mg/m2 (maximum up to 32 mg) for approximately 18 weeks
89593404|NCT03647800|Experimental|PART 2 Dose expansion - 5 cohorts|90 patients, 18/cohort in 5 dose expansion cohorts, will receive the recommended dose of APVO436 determined from Part 1
89593405|NCT04145908|Active Comparator|preperitoneal mesh|patients underwent preperitoneal mesh mesh placement
89593406|NCT04145908|Active Comparator|onlay mesh|patients underwent preperitoneal mesh mesh placement
89593407|NCT05581420|Active Comparator|Oral iron|"Ferrous fumarate 200mg daily for 4 weeks.~Group A1 (Normal Hb at week 4):~Ferrous fumarate 100mg daily for 12 weeks~Group A2 (Abnormal Hb at week 4):~Ferrous fumarate 200mg daily for 8 weeks~Group A2 at week 12:~Normal Hb: ferrous fumarate 100 mg daily till week 16 Abnormal Hb: intervention failure. End of study."
89593408|NCT05581420|Active Comparator|IV Iron|Dosage based on iron formulation and instructions according to recommended guidelines (weight of patient)
89593409|NCT05581264|Experimental|Self-Management Education Program|Participants received the diabetes self-management education program. The education and counseling were maintained through follow-up via phone for the intervention group
89593410|NCT05581264|No Intervention|No Intervention/Control Group|Participants received the usual medical care prescribed by the patient's attending doctor.
89593411|NCT03022474|Experimental|Intervention group|
89593412|NCT03022474|No Intervention|Control group|
89593413|NCT03021070|Experimental|Cash transfer arm|The intervention is a conditional cash transfer payment for each health facility appointment honoured for ANC, delivery, postnatal care and childhood immunization; and referrals related to any of these visits.
89593414|NCT03021070|No Intervention|Non-cash transfer arm|The control is a mobile phone airtime transfer value of 50 Ksh. transferred through the electronic system for each health facility appointment honoured for ANC, delivery, postnatal care and childhood immunization; and referrals related to any of these visits.
89593415|NCT04149340|Other|Sufentanil sedation|3 microgram of Sufentanil IV
89593416|NCT04149340|Placebo Comparator|Placebo sedation|1 ml de NaCl 0,9%
89593417|NCT04149340|Other|Multimodal sedation|Clonidine, sufantil, midazolam, dihydrobenzperidol, ketamine
89593418|NCT03021226|Experimental|Group I: Adults|Participants in Group I will be adults ages 20 to 24 years of age, 50 hours of instruction provided over a six-week period, and address three major topic areas: Fatherhood Development, Relationship Enhancement, and Financial Literacy/Work.
89593419|NCT03021226|No Intervention|Group II: No Intervention: Adults|Participants in Group II will be adults ages 20 to 24 years of age who do not receive any hours of intervention.
89593420|NCT04148794|Experimental|Intervention group|Participants who join the class of eALS
89593421|NCT05580952|Experimental|Experimental: Treatment|Device: J-Valve® valve delivery system
89593422|NCT04405960|Experimental|Intervention group|Individuals in intervention group were given oral Vitamin D supplements (Alphacalcidol 1 µg) once daily
89593423|NCT04405960|Placebo Comparator|Control Group|Individuals in control group were given placebo once daily
89593424|NCT04405804|Experimental|Ivabradine|Eligible patients will be given treatment with ivabradine during a titration period which will last from a minimum of 3 days to a maximum of 15 days. This will be followed by a maintenance period of another 14 days. At the end of maintenance period, primary endpoint will be assessed. After maintenance period, the patient will continue ivabradine at the same dosage during a follow-up period that will last 4 months.
89593425|NCT04145206||experimental group|the experimental group is characterized by the practice of flamenco dance
89593426|NCT04145206||control group|not practice of flamenco dance
89593427|NCT04145128|Experimental|AG-881|Participants will receive AG-881 10 mg, tablet orally, once in Period 1 followed by AG-881 50 mg, tablet orally, once in Period 2. Period 1 and Period 2 will be separated by a washout period of 20 days between doses.
89593428|NCT03945604|Experimental|SHR-1210 + Apatinib +Fluzoparib|SHR-1210 will be administered as an intravenous infusion Apatinib tablets will be given orally Fluzoparib capsule will be given orally 28 days per cycle, until disease progression or unacceptable toxicity
89593429|NCT05580484||Purified starch/Control group|Patients who were willing to receive purified starch at their own expense during this first surgery were included in the purified starch group, and patients who did not re-ceive purified starch or other anti-adhesion products were included in the control group.
89593430|NCT04148716||patients|recruitement of 9 patients
89593431|NCT04148716||control|recruitement of 9 control person
89593432|NCT03582436||Prospective cohort|Kidney transplantation
89593433|NCT01701063|Experimental|Treatment-Naive or Prior Partial/Null Response|telaprevir + Peginterferon alfa-2b + Ribavirin
89593434|NCT04406116|Experimental|patients receiving microwave therapy using the HS1 Instrument|
89593435|NCT04145050|Experimental|Carbohydrate Dose: 0 grams carbohydrate|Participants will be randomly selected, in a cross-over fashion, to ingest 0 grams/hour, 30 grams/ hour, or 60 grams/ hour of carbohydrate beverage throughout each experimental trial.
89593436|NCT04145050|Experimental|Carbohydrate Dose: 30 grams carbohydrate|Participants will be randomly selected, in a cross-over fashion, to ingest 0 grams/hour, 30 grams/ hour, or 60 grams/ hour of carbohydrate beverage throughout each experimental trial.
89593437|NCT04145050|Experimental|Carbohydrate Dose: 60 grams carbohydrate|Participants will be randomly selected, in a cross-over fashion, to ingest 0 grams/hour, 30 grams/ hour, or 60 grams/ hour of carbohydrate beverage throughout each experimental trial.
89593438|NCT04144816||Passive Birth Cohort|"This will be a multicenter, prospective, observational cohort study conducted across the Lyon Public hospital maternity (HFME : Hospital for women, mother and children, Croix-Rousse, Lyon-Sud) recruited from the general population.~Infants born between October 2019 and march 2020. At birth the remains (after diagnosis use) of cord blood samples will be store. Groups of RSVh cases and control will be class at one year of age using the hospital data (RSV must be confirmed by RT-PCR). Parents will be informed of the protocol. If enrolled available hospital data will be use and RSV serology testing perform on the store blood cordon."
89593439|NCT04144660||Cardiogenic Shock Treated with ECMO|This cohort of participants required clinical intervention with ECMO for treatment of their index cardiogenic shock episode while pregnant or post delivery of their infant.
89593440|NCT01700985|Experimental|122-0551|
88978155|NCT00246688|Experimental|Sagopilone, 3 h infusion|Subjects received one infusion (for 3 h) of sagopilone every 3 weeks at a dose of 16 mg/m2 (maximum up to 32 mg) for approximately 18 weeks
89593441|NCT01700985|Placebo Comparator|Vehicle|
89593442|NCT04148404|Active Comparator|Group NT|1.Normothermic group (NT group) included patients will undergo CABG under warm bypass using warm blood cardioplegia (Normothermic CBP).
89593443|NCT04148404|Active Comparator|Group HT|2.Hypothermic group (HT group) included patients will undergo CABG under cold bypass using cold blood cardioplegia (Hypothermic CBP).
89593444|NCT04144426|Experimental|Normal diet then modified diet|Participates in the normal diet will receive 3 meals each day, breakfast at 8:00 AM,lunch at 12:30 PM and dinner at 5:45 PM. Participates in the modified diet skipped breakfast, had lunch at 12:30 PM, dinner at 5:45 PM, and a breakfast equivalent snack at 10:00 PM.
89593445|NCT04144426|Experimental|Modified diet then normal diet.|Participates in the modified diet skipped breakfast, had lunch at 12:30 PM, dinner at 5:45 PM, and a breakfast equivalent snack at 10:00 PM.Participates in the normal diet will receive 3 meals each day, breakfast at 8:00 AM,lunch at 12:30 PM and dinner at 5:45 PM.
89593446|NCT03920722|Experimental|Rituximab|Experimental regimen: One year Glucocorticoid treatment and Rituximab IV 1 gram on Day 1 and 15
89593447|NCT03920722|Placebo Comparator|Rituximab-Placebo|Standard regimen: One-year Glucocorticoid treatment and Placebo-Rituximab IV on Day 1 and 15
89593448|NCT05580094|Placebo Comparator|General anesthesia only.|the pediatric patients will receive general anesthesia only.
89593449|NCT05580094|Active Comparator|General anesthesia plus supraclavicular block.|the pediatric patients will receive combined supraclavicular block and general anesthesia.
89593450|NCT05586100|Experimental|cetuximab in combination with toripalimab|"Participants receive toripalimab administered by intravenous drip at a fixed dose of 240 mg for subjects weighing <50 kg at baseline, using 3 mg/kg. administered every 3 weeks, 2 preoperative and 6 postoperative doses.~The starting dose of cetuximab is 400 mg/m2, with a titration time of 120 min, and the titration rate should be controlled within 5 ml/min. The maintenance dose is 250 mg/m2 administered weekly for a total of 6 preoperative doses; patients with positive intraoperative pathological margins/extra lymph node envelope invasion are treated with an additional 6 cycles of postoperative cetuximab adjuvant therapy."
89593451|NCT05587270||Rock Climbers|The whole eligible population of Swedish climbers on elite- or sub-elite levels of competition will be invited to participate in the study. Participants will be both male and female, 13 years and older. There are approximately 40 climbers eligible at elite level and a minimum of 80 climbers at sub-elite level of competition.
89593452|NCT05587270||Controls|A non-athlete control group (n matched to the study group) from the general population, will be invited to participate in the study.
89593453|NCT04148248||Patients|Patients with a diagnosis of chronic constipation
89593454|NCT05585008|Active Comparator|group A|group A will receive a conventional heat-cure acrylic denture
89593455|NCT05585008|Active Comparator|group B|group B will receive a 3D printed complete denture
89593456|NCT05584852||with myosteatosis|
89593457|NCT05584852||without myosteatosis|
89593458|NCT05585086|Experimental|Experimental|Peppermint oil will be applied by diluting 1/10 in wheat oil so that it does not cause skin irritation.
89593459|NCT05585086|No Intervention|Control|Patients who underwent surgery will be monitored for the severity of nausea and vomiting after surgery. Follow-ups are 0-2, 2-6, 6-12, 12-24 and 24-48 postoperatively. hours and will be recorded without any application or intervention by the researcher.
89593460|NCT03904030|Experimental|Anti-Gravity Treadmill rehabilitation|Patients in the intervention group are participating to the Alter G exercises (n=27). The groups are randomized, so after patients have signed consent, an envelop will be opened and there can be seen in which groups patients will participate.
89593461|NCT03904030|Active Comparator|Traditional rehabilitation|Traditional exercises with instructions are given to the patients (n=27) (as a control group).
89593462|NCT03902938|Experimental|Biodesign Otologic Graft|Graft following canal wall down mastoidectomy.
89593463|NCT03902938|Active Comparator|Autograft temporalis fascia|Graft following canal wall down mastoidectomy.
88811290|NCT02861573|Experimental|Carboplatin+Etoposide|Participants with neuroendocrine mCRPC in Cohort I Arm 2 will receive carboplatin titrated to an area under the plasma drug concentration-time curve [AUC] 5 IV on Day 1 Q3W + etoposide 100 mg/m^2 IV on Days 1, 2, and 3 Q3W. Treatment will continue for a maximum of 35 cycles (up to 2 years) or until progression. Treatment with carboplatin+etoposide will continue for a maximum of 4 cycles (up to 2.8 months). Participants who must discontinue 1 of the 2 drugs due to adverse events in the combination may continue the study with the other combination drug.
88811291|NCT02861573|Experimental|Belzutifan|Participants with AC mCRPC in Cohort J will receive belzutifan 120mg QD in the initial cohort. If an efficacy signal is detected in this arm based on a totality of evidence, Cohort J may be expanded further where participants will be randomized 1:1 to receive either belzutifan 120 mg QD or belzutifan 120 mg QD and pembrolizumab 200 mg Q3W. Treatment will continue for a maximum of 35 cycles (up to 2 years) or until progression.
88978156|NCT00246727|Placebo Comparator|Study 1: Chemotherapy plus SV or Placebo|For newly diagnosed patients who will be receiving or have received less than 4 weeks of a standard chemotherapy regimen.
88978157|NCT00246727|Placebo Comparator|Study 2: SV vs Placebo without chemotherapy|For those who have stopped or refuse standard chemotherapy but will receive best supportive care.
89593464|NCT05583136|Experimental|Group DD1|tACS + visuo-attentional training
88978158|NCT04728516|Experimental|Vonoprazan-based dual eradication therapy|H. pylori eradication using a dual eradication regimen, a course of 14 days, followed up to 6 months after randomization; the treatment regimen is as follows: routine use of Vonoprazan 20mg bid + amoxicillin 1g tid, a course of 14 days .
88978159|NCT04728516|Active Comparator|Pantoprazole|To take pantoprazole 40 mg daily, followed up to 6 months after randomization.
89593465|NCT05583136|Active Comparator|Group DD2|Sham (placebo) tACS + visuo-attentional training
89593466|NCT05583136|Active Comparator|Group DD3|Sham (placebo) tACS + phonics training
89593467|NCT01710501|Experimental|Grazoprevir 25 mg + PEG-IFN + RBV|After a maximum of a 45 day screening window, randomized participants receive 25 mg grazoprevir in combination with PEG-IFN and RBV for 12 weeks followed by 24 weeks of follow-up as determined by Response Guided Therapy (RGT). Participants may receive an additional 12 weeks of PEG-IFN plus RBV depending on their Hepatitis C virus ribonucleic acid (HCV RNA) level at Treatment Week (TW) 4.
89593468|NCT01710501|Experimental|Grazoprevir 50 mg + PEG-IFN + RBV|After a maximum of a 45 day screening window, randomized participants receive 50 mg grazoprevir in combination with PEG-IFN and RBV for 12 weeks followed by 24 weeks of follow-up as determined by RGT. Participants may receive an additional 12 weeks of PEG-IFN plus RBV depending on their HCV RNA level at TW 4.
89593469|NCT01710501|Experimental|Grazoprevir 100 mg + PEG-IFN + RBV|After a maximum of a 45 day screening window, randomized participants receive 100 mg grazoprevir in combination with PEG-IFN and RBV for 12 weeks followed by 24 weeks of follow-up as determined by RGT. Participants may receive an additional 12 weeks of PEG-IFN plus RBV depending on their HCV RNA level at TW 4.
89593470|NCT05583058||Hormone Overdose and Misuse Group|Transgender and gender non-conforming individuals who have been identified as hormone overdose and misuse (HODM) at start of the cohorts according to the criteria established by the study.
89593471|NCT05583058||Non-Hormone Overdose and Misuse Group|Transgender and gender non-conforming individuals who have been identified as without hormone overdose or misuse (HODM) at start of the cohorts according to the criteria established by the study.
89593472|NCT04144270||Included patients|One-arm study. All included patients will have muscle mass and muscle function evaluated
89593473|NCT04144114|Experimental|Whey + ProHydrolase®|Subjects received 250mg of ProHydrolase® along with 25g of whey protein mixed in a drink every visit for 4 weeks
89593474|NCT04144114|Active Comparator|Whey|Subjects received 25g whey protein in a drink every visit for 4 weeks
89593475|NCT04144114|Placebo Comparator|Placebo|Subjects received 25g maltodextrin in a drink every visit for 4 weeks
89593476|NCT01700829|Active Comparator|Midazolam|0.02 mg/kg, I.V. (in the vein)
89593477|NCT01700829|Active Comparator|Ketamine|0.5 mg/kg, I.V. (in the vein)
89593478|NCT04143880|Experimental|experimental group|Progesterone
89593479|NCT04143880|Placebo Comparator|control grou|saline
89593480|NCT04144192|Experimental|Lidocaine Patch (Sequence AB)|Subjects received all study treatments: a bolus IV injection of 0.7 mg/kg lidocaine IV in the morning of study Day 1, and then lidocaine patch treatment on Day 8 and Day 15. The sequence in which they received patch treatment was determined by random assignment. For subjects in Arm 1, 3 lidocaine 1.8% patches were applied on Day 8 and 3 Lidoderm® 5% patches were applied on Day 15.
89593481|NCT04144192|Experimental|Lidocaine Patch (Sequence BA)|Subjects received all study treatments: a bolus IV injection of 0.7 mg/kg lidocaine IV in the morning of study Day 1, and then lidocaine patch treatment on Day 8 and Day 15. The sequence in which they received patch treatment was determined by random assignment. For subjects in Arm 2, 3 Lidoderm® 5% patches were applied on Day 8 and 3 lidocaine 1.8% patches were applied on Day 15.
89593482|NCT01710345|Experimental|Sufentanil NanoTab 20 mcg|Sufentanil NanoTab 20 mcg as needed every 60 minutes for 12 hours
89593483|NCT01710345|Experimental|Sufentanil NanoTab 30 mcg|Sufentanil NanoTab 30 mcg as needed every 60 minutes for 12 hours
89593484|NCT01710345|Placebo Comparator|Placebo NanoTab|Placebo NanoTab as needed every 60 minutes for 12 hours
89593485|NCT04143568||Control|Evaluation of endothelial progenitor cells level and correlation of endothelial progenitor cells level with periodontal and cardiovascular disease
89593486|NCT04143568||Periodontitis|Evaluation of endothelial progenitor cells level and correlation of endothelial progenitor cells level with periodontal and cardiovascular disease
89593487|NCT03022006|Other|Dialysis patients with genotype 1 HCV infection|elbasvir/grazoprevir
89593488|NCT04143334||RAAB survey|We will examine 3700 Chaonan County residents aged 50 years and older, selected via a clustered, randomized sampling with probability proportional to size (PPS). The cluster will be at the village level, 50 subjects aged 50 years and older will be examined in each cluster includes Visual acuity, torch light, and fundus review, the major cause of blindness or visual impairment will be determined.
89593489|NCT04143334||conventional survey|All the recruited participants underwent ophthalmic examination according to the RAAB protocol and then 60% of them were re-examined with instruments in a mobile eye clinic set up in a village center on the same day. Examination in the mobile clinic included standardized visual acuity (VA) tests using logarithm of the minimum angle resolution charts, refraction, slit-lamp biomicroscopy, and dilated fundal examination with a binocular indirect ophthalmoscope.
89593490|NCT05582824||Main group|All patients included
89593491|NCT02335216||Treated Subjects|All subjects recruited and treated with the Axium neurostimulator
89593492|NCT04148326||Patients|Patients who have been diagnosed with Parkinson's Disease
89593493|NCT04147936|Active Comparator|AXA1665 29.4g|Dietary Supplement: AXA1665 Amino acids, food study
89593494|NCT04147936|Active Comparator|AXA1665 53.9 g|Dietary Supplement: AXA1665 Amino acids, food study
89593495|NCT04147936|Placebo Comparator|Placebo 29.4 g|Dietary Supplement: Placebo
89593496|NCT04148014|Experimental|Adjunctive Emotion Regulation Skills Training|Participants will receive a 5 session once a week group emotion regulation skills training adjacent to treatment as usual provided by the eating disorder unit at the child and adolescent psychiatric clinic, Linköping, Sweden.
89031297|NCT02952521||Epithelial ovarian cancer|"Whole blood sample collection~Up to 3 fresh tumor tissue core biopsies~Tumor tissue sample taken from tumor tissue already removed from surgery (if surgery is planned)"
89593497|NCT04143022|Active Comparator|group A (acupuncture press needle)|Group A subjects first receive acupuncture press needle treatment at acupoint of Jin's 3-tongue point and EX-HN25. Then, it takes 2-week washout period. After washout period, subjects receive another course of treatment at acupoint of EX-CA1, EX-CA5 and EX-CA6. Each subject receive 2 times a week of treatment for 4 weeks (8 times in total) in each course.
89593498|NCT04143022|Active Comparator|group B (acupuncture press needle)|Group B subjects first receive acupuncture press needle treatment at acupoint of EX-CA1, EX-CA5 and EX-CA6. Then, it takes 2-week washout period. After washout period, subjects receive another course of treatment at acupoint of Jin's 3-tongue point and EX-HN25. Each subject receive 2 times a week of treatment for 4 weeks (8 times in total) in each course.
89593499|NCT04143256|Experimental|Group I|Subjects with ENDS user history may be randomized to use JUUL ENDS 5% Virginia Tobacco and 3% Virginia Tobacco
89593500|NCT04143256|Experimental|Group II|Subjects with ENDS user history may be randomized to use JUUL ENDS 5% Mint and 3% Mint
89593501|NCT04143256|Experimental|Group III|Subjects with ENDS user history may be randomized to use JUUL ENDS 5% Menthol and 3% Menthol
88978160|NCT00067613|Active Comparator|Intervention|Clinical sites randomized to intervention will receive training in the benchmarking BPD management methods identified at the Benchmark sites.
88978161|NCT00067613|Placebo Comparator|Control|Clinical sites randomized to Control will continue with their normal management practices for BPD.
88978162|NCT00400998|Placebo Comparator|Vienna Challenge Chamber in season (Phase 3)|"Phase 3 will consist of two treatment periods each lasting 8 days, with a 10 day wash-out between each treatment period.~Subjects will administer 200micrograms (μg) fluticasone propionate or fluticasone propionate matched placebo nasal spray, once daily for 8 days. Dosing will be supervised on the first and last days of each treatment period (Day 1 and Day 8).~Immediately following the last dose received on Day 8 the subject's signs and symptoms will be monitored: subjective symptom score every 15 minutes for rhinomanometry and measurement of nasal secretion every 30 minutes, and FEV1, AEs and symptoms of local irritancy."
88978163|NCT00400998|Placebo Comparator|Vienna Challenge Chamber out of season (Phase 1)|"Phase 1 will consist of two treatment periods each lasting 8 days, with a 10 day wash-out between each treatment period.~Subjects will administer 200μg fluticasone propionate or fluticasone propionate matched placebo nasal spray, once daily for 8 days. Dosing will be supervised on the first and last days of each treatment period (Day 1 and Day 8).~Immediately following the last dose received on Day 8 the subject's signs and symptoms will be monitored: subjective symptom score every 15 minutes for rhinomanometry and measurement of nasal secretion every 30 minutes, and FEV1, AEs and symptoms of local irritancy.~An intermediate study follow-up visit will take place 7-14 days after the last dose is received in treatment period 2."
89209996|NCT00888342|Active Comparator|3 Alcohol|participant receives 0,5 mg alcohol /kg body weight before sleep one night, polysomnography with capnography will be compared to no intervention another night
89209997|NCT00892632|Experimental|1|1. To compare confocal image characteristics of benign vs. malignant biliary strictures
89209998|NCT00888420||Medical Management|Patient satisfaction under current operational conditions
89209999|NCT00888420||Interventional Management|Patient satisfaction under the PSDA (Plan, do, study, act) performance improvement measures
89210000|NCT00895518|No Intervention|1|Participants will receive assessments only.
89593502|NCT04143256|Experimental|Group IV|Subjects with ENDS user history may be randomized to use JUUL ENDS 5% Mango and 3% Mango
89593503|NCT04143256|Experimental|Group V|Subjects with cigarette user history will be assigned to use US Cigarette, Non-Menthol Flavor (Marlboro Gold King Size)
89593504|NCT04143256|Experimental|Group VI|Subjects with cigarette user history will be assigned to use US Cigarette, Menthol Flavor (Newport King Size)
89593505|NCT04143412|Active Comparator|Tritace (Ramipril)|25 patients with type 2 diabetes mellitus and mild hypertension will be randomized to Tritace (Ramipril) 10 mg/ day. Full doses will be reached by forced titration after 4 weeks
89593506|NCT04143412|Active Comparator|Eraloner (Eplerenone)|25 patients with type 2 diabetes mellitus and mild hypertension will be randomized to Eraloner (Eplerenone) 50 mg/ day. Full doses will be reached by forced titration after 4 weeks
89593507|NCT04143412|Active Comparator|Tritace/Eraloner (Ramipril/Eplerenone)combination therapy|25 patients with type 2 diabetes mellitus and mild hypertension will be randomized to Tritace/Eraloner (Ramipril 10 mg / Eplerenone 50 mg ) / day. Full doses will be reached by forced titration after 4 weeks
89593508|NCT05582278|Experimental|HAIC+lenvatinib+tislelizumab|Hepatic Arterial Infusion Chemotherapy Combined With lenvatinib and tislelizumab
89593509|NCT05582278|Experimental|D-TACE+lenvatinib+tislelizumab|Transarterial chemoembolization with drug-eluting beads Combined With lenvatinib and tislelizumab
89593510|NCT05582122|No Intervention|Standard follow-up monitoring (16 visits over 5 years)|"Patients enrolled in the control arm will be monitored according to SFORL guidelines. Physical Examination (PE) will be carried out:~- every 2 months the 1st year, every 3 months the 2nd year, every 4 months the 3rd year, every 6 months at 4 and 5 years.~Annual chest CT scan will be performed for current smokers & for those who have quit smoking less than 15 years ago."
89593511|NCT05582122|Experimental|Lightened follow-up visits frequency (9 visits over 5 years), with HPV16 Ct-DNA dosing|"Physical Examinations (with HPV16 Ct-DNA dosing) planned at Months 4,8,12,18,24,30,36,48,60 post treatment.~Annual chest CT scan will be performed for current smokers & for those who have quit smoking less than 15 years ago.~Any patient with a normal PE but positive HPV16 ct-DNA test during follow-up period will require a confirmation test ~1-2 months later.~If HPV16 ct-DNA positivity is confirmed, an H&N MRI /PET-CT will be performed. Then:~If MRI and PET-CT are negative, the patient will be examined every 2 months (PE and HPV16 Ct-DNA dosing) and MRI/PET-CT will be repeated every 4-6 months, until HPV16 Ct-DNA becomes undetectable.~If MRI and/or PET-CT is positive, the patient will get a biopsy to confirm disease recurrence. Once confirmed, the patient will have the necessary care, as per local practices, but will continue to be followed up within this study up to 5 years after treatment."
89593512|NCT04147702|Experimental|Experimental Group: Balance analysis|fifty dancers will be evaluated in this study.Trunk muscle endurance, pulmonary functions and balance will be assessed.
89593513|NCT04147702|Active Comparator|Control Group:Balance Analysis|fifty healthy subjects will be evaluated in this study.Trunk muscle endurance, pulmonary functions and balance will be assessed.
89593514|NCT01710033|Placebo Comparator|Placebo|
89593515|NCT01710033|Experimental|CP-690,550 5 mg BID|
89593516|NCT01710033|Experimental|CP-690,550 15 mg BID|
89593517|NCT01710033|Experimental|CP-690,550 30 mg BID|
89593518|NCT04148170|Active Comparator|classic intubation|children suffer from congenital nasolacrimal duct obstruction will have probing with metal probe and then intubation with bicanlicular silicon tube.
89593519|NCT04148170|Active Comparator|endodiathermy probe|children suffer from congenital nasolacrimal duct obstruction will have probing with endodiathermy probe and then intubation with bicanlicular silicon tube
89593520|NCT01822496|Experimental|EGFR: Erlotinib|Induction erlotinib for 12 weeks followed by chemotherapy (either cisplatin/etoposide or paclitaxel/carboplatin) and radiation therapy. Patients who have had no response (partial or complete) after 6 weeks of induction therapy start chemoradiation therapy immediately.
89593521|NCT01822496|Active Comparator|EGFR: No Erlotinib|Chemotherapy (either cisplatin/etoposide or paclitaxel/carboplatin) and radiation therapy.
89593522|NCT01822496|Experimental|ALK: Crizotinib|Induction crizotinib for 12 weeks followed by chemotherapy (either cisplatin/etoposide or paclitaxel/carboplatin) and radiation therapy. Patients who have had no response (partial or complete) after 6 weeks of induction therapy start chemoradiation therapy immediately.
89593523|NCT01822496|Active Comparator|ALK: No Crizotinib|Chemotherapy (either cisplatin/etoposide or paclitaxel/carboplatin) and radiation therapy.
89593524|NCT03936088|Experimental|Intervention with Mindfulness App (Headspace)|Patient education regarding osteoarthritis, its natural history, and common treatments plus the mindfulness (intervention) app.
89593525|NCT03936088|Active Comparator|Control with Water App (My Water Balance)|Patient education regarding osteoarthritis, its natural history, and common treatments plus the My Water Balance (control) app and provided an in-person demonstration on how to use it.
89593526|NCT01867047|Experimental|Continuation Group|Subjects randomized to this group will continue their ACE-I through the day of surgery
89593527|NCT01867047|Experimental|Cessation Group|Subjects randomized to this group will stop their ACE-I two days prior to surgery (last dose >48 hours prior to surgery)
89593528|NCT03588988|Experimental|Dexmedetomidine group|
89593529|NCT03588988|Placebo Comparator|Control group|
89593530|NCT05581888|Other|839MP group|Patients in this group were binocularly implanted with the AT LISA tri 839MP trifocal intraocular lens.
89593531|NCT05581888|Other|TFNT00 group|Patients in this group were binocularly implanted with the AcrySof IQ PanOptix TFNT00 trifocal intraocular lens.
89593532|NCT04414137||Eosinophilic pneumonia on daptomycin|patients having an osteoarticular infection treated with daptomycin and which developped eosinophilic pneumonia
89593533|NCT05580172|Experimental|Dose Level 1|RH324
89593534|NCT05580172|Experimental|Dose Level 2|RH324
89593535|NCT05580172|Experimental|Dose Level 3|RH324
89593536|NCT05586178|No Intervention|Holdout|
89593537|NCT05586178|Experimental|Simple reminder|
89593538|NCT05586178|Experimental|Consistency reminder|
89593539|NCT05586178|Experimental|Uniqueness information reminder|
89593540|NCT05586178|Experimental|Eligibility information reminder|
89593541|NCT05586178|Experimental|Severity information reminder|
89593542|NCT05586178|Experimental|Consistency and uniqueness information reminder|
89593543|NCT01821560|Placebo Comparator|Sugar pill|Placebo-treated subjects will follow the identical schedule as Baclofen subjects.
89593544|NCT01821560|Active Comparator|Baclofen|Baclofen will be dispensed in pill form. Baclofen will be prescribed at 20 mg 4 times per day. Each baclofen pill will be 10 mg. Thus, 2 pills will be taken at each scheduled dose for a total of 8 pills a day over a period of 8 weeks. In this way, the titration schedule, taper and potential dose reductions can be managed.
89593545|NCT01871402|Experimental|Active Arm|Topical lotion, applied twice daily
89593546|NCT01871402|Placebo Comparator|Vehicle Arm|Topical lotion, applied twice daily
89593547|NCT05580328|Experimental|treatment group|"Hematoporphyrin injection is a new drug for tumor photodynamic therapy approved by the State Food and Drug Administration of China. It is a representative drug of domestic photosensitizer with independent intellectual property rights developed and produced by Chongqing Huading Modern Biological Pharmaceutical Co., Ltd.~In the third phase clinical trial, the dosage of hematoporphyrin injection (5mg/kg) should be given intravenously 48-72 hours before laser irradiation for diagnosis and treatment, and skin test should be conducted before injection. Diagnostic laser wavelength is 514.5nm, power density is 10mW/cm2, therapeutic laser wavelength is 630-690nm, average output power density is 400mW/cm, and optical dose density is 200-400J/cm2 The chemical structure formula of hematoporphyrin is: C34H38N4O6, molecular weight: 598.70"
89593548|NCT04415450|Experimental|Nutrition Education Group|The experimental group is the group who received the intervention which is the nutrition education and counseling. Phase I of the data collection from the experimental group which is the pregnant women (baseline assessment) using a questionnaire immediately before receiving nutrition counseling from their ANC providers first took place. Health professionals then started providing nutrition education to pregnant women preselected and assessed before the intervention. Immediate post education evaluation of the pregnant women was done by the same questionnaire used to assess in the pretest. Phase II or post intervention data collection of pregnant women was done after the client was appointed for 6 weeks after the counseling session.
89593549|NCT03588676|No Intervention|Normoxia|Participants will sleep in room air and receive no melatonin.
89210001|NCT00895518|Experimental|2|Participants will receive prolonged exposure therapy.
89593550|NCT03588676|Placebo Comparator|Hypoxia and Placebo|5mg placebo before sleep study
89593551|NCT03588676|Experimental|Hypoxia and Melatonin|5mg melatonin before sleep study
89593552|NCT03467542|Experimental|dAVF treatment|PHIL® Liquid Embolic System
88811292|NCT02861573|Experimental|Pembrolizumab+Belzutifan|Participants with AC mCRPC in Cohort J will receive belzutifan 120mg QD in the initial cohort. If an efficacy signal is detected in this arm based on a totality of evidence, Cohort J may be expanded further where participants will be randomized 1:1 to receive either belzutifan 120 mg QD or belzutifan 120 mg QD and pembrolizumab 200 mg Q3W. Treatment will continue for a maximum of 35 cycles (up to 2 years) or until progression.
88811293|NCT02846246|Experimental|Intervention|The experimental group will be introduced to a person-centred care model that involves shared decision making where the person with home care service and family together with contact nurse prioritise care content and make rearrangements to make sure the provided home care service maximises health.
89593553|NCT01846442|Placebo Comparator|Placebo|
89593554|NCT01846442|Experimental|0.25% DHEA|
89593555|NCT01846442|Experimental|0.5% DHEA|
89593556|NCT01846442|Experimental|1.0% DHEA|
89593557|NCT03586570|Experimental|Aprocitentan|
89593558|NCT03586570|Placebo Comparator|Placebo|
89593559|NCT03588598|Experimental|SHC014748M treatment|SHC014748M capsule， 50, 100, 150, 200, 250 mg, QD, 28 days for each cycle
89593560|NCT03588364|Experimental|Osteopathic Manipulation|Twelve weekly sessions using the techniques of osteopathy in the cranial field.
89593561|NCT03588364|No Intervention|Waitlist Control|Six-week waiting period.
89593562|NCT03588208|Experimental|Intervention Group|
89593563|NCT03588208|Active Comparator|Control Group|
89593564|NCT01709721|Experimental|Hydromorphone Hydrochloride (Randomized/Double-Blind)|Subjects on hydromorphone hydrochloride for the duration of therapy.
89593565|NCT01709721|Active Comparator|Hydromorphone Hydrochloride Titrated Downward/Control (Randomized/Double-Blind)|Subjects on hydromorphone hydrochloride titrated downward
89593566|NCT03588520|Experimental|Home BP Monitoring Group|Patients allocated to this group will receive a home blood pressure monitoring device and decisions to modify the hypertension treatment will be based on the results of the home blood pressure monitoring in accordance with the current guidelines of the European Society for Hypertension for the Treatment of Hypertension.
89593567|NCT03588520|No Intervention|Office BP Monitoring Group|Patients allocated to this group will act as controls. They will receive no home blood pressure monitoring device and decisions to modify the hypertension treatment will be based exclusively on blood pressure measurements in office visits.
89593568|NCT03588052|Experimental|VISTA using PRF|"Vestibular incision subperiosteal tunnel access combined with Platelets-Rich Fibrin~An intravenous blood will be drawn from the patient in a glass-coated plastic tubes, centrifuged at 3000 rpm for 10-12 min. A Platelets rich fibrin membrane will then be obtained"
89593569|NCT03588052|Active Comparator|VISTA using SCTG|"vestibular incision subperiosteal tunnel access combined with subepithelial connective tissue graft~Subepithelial connective tissue graft will be harvested from the palate, secured in the tunnel to cover the root dehiscence then sutured"
89593570|NCT01866657|Experimental|Intervention cohort|Open cerebral oximetry monitoring; observed desaturations will be treated with an intervention algorithm including increase FiO2, head/neck repositioning,vasoconstrictor agents, IV fluid bolus, increase ETCO2, additional anesthesia, RBC transfusion.
89593571|NCT01866657|No Intervention|Blinded cerebral oximetry monitoring|These subjects will have continous cerebral oximetry monitoring like the experimental cohort but the values will be blinded to all clinicians and research staff. There will be no cerebral desaturation interventions in this group because the clinicians will not be aware of a desaturation as the monitor's output is blinded in this group.
89593572|NCT03587350|Active Comparator|Interventional Treatment|
89593573|NCT03587350|No Intervention|Usual care|
89593574|NCT03581344|No Intervention|Control arm|Patients undergoing surgery 9-11 weeks after the end of chemoradiotherapy, whose major/complete response has to be assessed with clinical-instrumental exams to be performed 7-8 weeks after the end of chemoradiotherapy.
89593575|NCT03581344|Experimental|Experimental arm|Patients undergoing surgery 13-16 weeks after the end of chemoradiotherapy, (length of surgical interval ) showing a major/complete response at the clinical-instrumental exams to be performed 7-8 weeks after the end of chemoradiotherapy. These patients will undergo a repetition of re-staging (a second clinical and instrumental re-evaluation after 11-12 weeks and then surgery 13-16 weeks after the end of chemoradiotherapy.)
89593576|NCT03020836|Other|Hypertension patient referral|Referral to primary care physician for hypertension control: Patients with uncontrolled hypertension were referred to a primary care physician for treatment.
89593577|NCT03020836|Other|Smoking cessation patient referral|Referral to smoking quit line: Patients that were current smokers were referred to the Maryland smoking cessation quit line if they were willing.
89593578|NCT01700205|Active Comparator|Type of Formula: CMF|Infants are randomized to feed standard cow milk formula during first year of life
89593579|NCT01700205|Experimental|Type of Formula: EHF|Infants are randomized to feed extensively hydrolyzed infant formula during first year of life
89593580|NCT03589690|Experimental|Alpha Lipoic acid|Alpha lipoic acid capsules (600 mg/day)
89593581|NCT03589690|Placebo Comparator|Placebo|Starch-filled capsules (600 mg/day)
89593582|NCT03589534|Other|pregnancy test|pregnancy tests
89593583|NCT01700049|Experimental|Open Label oral vismodegib|This is a Phase 2B single-site, open-label, nonrandomized 24-week study of the efficacy and safety of vismodegib (150 mg PO daily) in subjects with high risk and/or locally advanced basal cell carcinoma (BCC). A total of 36 subjects with infiltrative/morpheaform, nodular, or superficial BCC will be enrolled in the study.
89593584|NCT03587194|Experimental|Otezla|Otezla BID
89210002|NCT00888498|Placebo Comparator|Hands-On Control|With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface, which is similar to the positioning used for the experimental groups. The treating investigator will maintain passive positioning of the ankle for the duration of 1 deep inhalation and exhalation by the subject rather than induce an iatrogenic force.
89593585|NCT01699815|Active Comparator|Preemptive group|The preemptive group will receive one dose of 1 gram of IV acetaminophen every 6 hours x 24 hours with the first dose administered within 60 minutes prior to incision. Each infusion will be administered over 15 minutes as recommended by manufacturer package insert.
89593586|NCT01699815|Active Comparator|Closure group|The closure group will receive one dose of 1 gram of IV acetaminophen every 6 hours x 24 hours with the first dose administered upon onset of skin closure.
89593587|NCT03586960|Experimental|Experimental Group|Peak tension will be measured with a calibrated force gauge (Series 3 Digital Force Gauge; Mark-10 Corporation; Copiague, NY) until the wound edges touch. A clamp will be used to secure the sutures on top of the device between measurements. At each time point (5, 10 and 30 minutes), the clamps will be loosened and the wound allowed to relax. Photographs and measurements will be taken to document the wound size after stress-reduction. The suture will be re-tensioned while measurements of peak tension (as outlined above) are recorded with the force gauge.
89608493|NCT02991508|Active Comparator|Adrecizumab 8.0 mg/kg|To assess the safety, tolerability and pharmacokinetics/-dynamics of single escalating doses of ADRECIZUMAB (0.5 mg/kg, 2,0 mg/kg and 8,0 mg/kg administered as single infusion over 1 hour) in healthy male subjects.
88811294|NCT02846246|Sham Comparator|Control|A usual care paradigm will guide the control units, i.e. a continuation with practice as usual.
88811295|NCT02807558|Experimental|R/R Non-APL AML or R/R HR-MDS: Tamibarotene Monotherapy|Participants with R/R non-APL AML or R/R HR-MDS will receive tamibarotene at 6 mg/m^2/day in 2 divided doses on Days 1-28 of a 28-day cycle.
88811296|NCT02807558|Experimental|Newly Diagnosed Non-APL AML: Tamibarotene Monotherapy|Newly diagnosed, treatment-naive participants with non-APL AML who were unlikely to tolerate standard intensive chemotherapy will receive tamibarotene at 6 mg/m^2/day in 2 divided doses on Days 1-28 of a 28-day cycle.
89593588|NCT03589222|Experimental|Selinexor, Daratumumab, Bortezomib and dexamethasone|Selinexor will be administered via oral at flat dose of 100 mg weekly in 4 out of each 4-week cycle plus dexamethasone 40 or 20 mg mg orally with each dose of selinexor in combination with daratumumab at dose of 16 mg/Kg iv weekly on days 1, 8, 15 and 22 during the first two cycles; on days 1 and 15 (Q2W) during the cycles 3 to 6; and on day 1 (Q4W) thereafter and bortezomib will be given via subcutaneous at dose of 1.3 mg/m2 on days 1, 8, 15 and 22 starting from the first cycle and on days 1 and 15 (Q2W) since cycle 9. Each cycle is of 4 weeks of duration
89593589|NCT01866423|Experimental|Treatment (orteronel)|Patients receive orteronel 300 mg PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89593590|NCT01846208|Experimental|Egg OIT Randomized|Subjects who passed a baked egg oral food challenge (OFC) at baseline were randomized to receive egg oral immunotherapy (OIT) in the form of egg white solid with up to four oral food challenges as directed by protocol.
89593591|NCT01846208|Experimental|Baked Egg Randomized|"Subjects who passed a baked egg oral food challenge (OFC) at baseline were randomized to receive baked egg in the form of home-baked goods and safe commercial products with up to four oral food challenges as directed by the protocol."
89593592|NCT01846208|Experimental|Egg OIT Assigned|Subjects who failed a baked egg oral food challenge (OFC) at baseline were assigned to receive egg oral immunotherapy (OIT) in the form of egg white solid with up to four oral food challenges as directed by protocol.
89593593|NCT04166799|Experimental|Mepitel Film Arm|Patients randomized to the Mepitel Film arm will receive the film for the entire duration of their radiation treatment and will be worn up to 2 weeks after completion of radiotherapy.
89593594|NCT04166799|No Intervention|Standard of Care Arm|Patients randomized to the Standard of Care arm will be instructed to use the institutional standard of care skin treatments for the entire duration of their radiation treatment and up to 2 weeks after completion of radiotherapy.
89593595|NCT03586804||women without dysmenorrheal syndrome|women without dysmenorrheal syndrome
89593596|NCT03586804||women with dysmenorrheal syndrome|women with dysmenorrheal syndrome
89593597|NCT03589066|Experimental|Formulation A|LY03003 28 mg intramuscular suspension, single dose, 1 day duration
89593598|NCT03589066|Experimental|Formulation B|LY03003 28 mg intramuscular suspension, single dose, 1 day duration
89593599|NCT01845974|Experimental|Low Flow Catheter|The experimental group will receive the low flow catheter (ThermoCool® SF NAV Catheter) All data will be collected pre and post procedure therefore patients will act as their own control within each therapeutic group.
89593600|NCT01845974|Active Comparator|High Flow Catheter|The control group will receive the higher flow catheter (ThermoCool® catheter). All data will be collected pre and post procedure therefore patients will act as their own control within each therapeutic group.
89593601|NCT03020368|Experimental|Leeches|"One-time topical application of 2-3 leeches (medileech, Hirudo verbana) periarticularly on the painful thumb base"
88811297|NCT02807558|Experimental|Newly Diagnosed Non-APL AML: Tamibarotene and Azacitidine|Newly diagnosed, treatment-naive participants with non-APL AML who are unlikely to tolerate standard intensive chemotherapy will receive tamibarotene at 6 mg/m^2/day in 2 divided doses on Days 8-28 of a 28-day cycle, and azacitidine at 75 mg/m^2 once daily on Days 1-7 of a 28-day cycle.
88811298|NCT02807558|Experimental|LR-MDS: Tamibarotene Monotherapy|Participants with transfusion-dependent LR-MDS without the del 5q abnormality who are refractory to erythropoietin (EPO) treatment or unlikely to respond to EPO treatment will receive tamibarotene at 6 mg/m^2/day in 2 divided doses on Days 1-28 of a 28-day cycle.
89031298|NCT00527358|Experimental|SAFER|"The intervention community will receive 4 services:~community lay workers will do family outreach and assist families in networking with other families and accessing community services, facilitating parent-youth and family-school communication and homework help for children, and help with translation of school or government/official notices;~youth leaders will provide a supportive presence, help youth navigate the system at school so that they can get help if needed, disseminate information about job training and possibilities, and provide education about avoiding violence;~school support services will offer academic support, acculturation orientation, language, conflict resolution skills training, advocacy and referrals;~Youth drop-in center: will provide youth with an adult supervised place to hang out, do homework, or participate in sports and job training."
89210003|NCT00888498|Experimental|Fast Stretching|With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface. A thrust will be delivered parallel to the long axis of the subject's lower leg after the treating therapist induces passive ankle dorsiflexion to end range.
89593602|NCT03020368|Active Comparator|Diclofenac|3 times daily topical application of Diclofenac gel (1 g with 10 mg diclofenac-Na) over 4 weeks
89593603|NCT03020290||patients with femoropopliteal lesion|patients with femoropopliteal lesion - Endovascular treatment for PAD during medical care
89593604|NCT03442582||Afluria|Afluria exposure in pregnancy
89593605|NCT03581422||NC-FET|pure natural cycle frozen-thawed embryo transfer
89593606|NCT03581422||mNC-FET|modified natural cycle frozen-thawed embryo transfer by hCG administration
89593607|NCT03581266|Experimental|Rye|A breakfast consisting of whole slices of wholemeal rye bread containing 50 g of available carbohydrates. The breakfast additionally included 250 mL water and 50 g of cucumber.
89593608|NCT03581266|Experimental|Wheat|A breakfast consisting of whole slices of refined wheat bread containing 50 g of available carbohydrates. The breakfast additionally included 250 mL water and 50 g of cucumber.
89593609|NCT05702944|Sham Comparator|Phenoxybenzamine before surgery|Phenoxybenzamine, an alpha receptor blocker, is taken at least 2 to 5 weeks before surgery
89593610|NCT05702944|Active Comparator|No phenoxybenzamine before surgery|Phenoxybenzamine, an alpha receptor blocker, is not taken before surgery
89593611|NCT05702866||Patients Suspected of Having Thoracic Outlet Syndrome|Patients who came for the diagnosis of TOS
89593612|NCT03581110||16-slice CT scanner|1426 patients that have received a noncontrast-enhanced chest CT on our 16-slice clinical routine CT scanner in inspiration only.
89593613|NCT03581110||2nd generation dual-source CT|320 patients that have received a noncontrast-enhanced chest CT on our second generation dual-source CT scanner in inspiration only.
89593614|NCT03581110||3rd generation dual-source CT|211 patients that have received a noncontrast-enhanced chest CT on our third generation dual-source CT scanner in inspiration and expiration.
89593615|NCT03586180||children and their parents|aged 4-18 children with cancer/blood disease and their parents
89593616|NCT03586180||Dr. Clowns|they will perform shows for children and parents
89593617|NCT03580876|Other|switch to anti-TNF alone|"Switch to the second anti-TNF drug alone (infliximab or adalimumab)~Loss of response under Infliximab: 10 mg/kg IV every 8 weeks Randomization to: Adalimumab: induction 160/80 mg SC and Maintenance 40 mg EOW SC OR Loss of response under Adalimumab: 40mg EW SC Randomization to: Infliximab: 5mg/kg IV at W0, W2, W6 and every 8 weeks."
89593618|NCT03580876|Other|switch to anti-TNF with addition of azathioprine|"Switch to anti-TNF (infliximab or adalimumab) with addition of azathioprine~Loss of response under Infliximab: 10 mg/kg IV every 8 weeks Randomization to: Adalimumab: induction 160/80 mg SC and Maintenance 40 mg EOW SC with azathioprine 2.5 mg/kg/day OR~Loss of response under Adalimumab: 40mg EW SC Randomization to:~Infliximab: 5mg/kg IV at W0, W2, W6 and every 8 weeks with azathioprine 2.5 mg/kg/day."
89593619|NCT03580798|Experimental|Delayed Grafting|8 weeks after extraction implant placement and simultaneous osseous grafting.
89593620|NCT03580798|Active Comparator|Simultaneous Grafting|At the time of extraction the socket will be grafted and implant placed 4 months later.
89593621|NCT03586024|Experimental|Cohort 1|cohort 1: NK/T-cell lymphoma;
89593622|NCT03586024|Experimental|Cohort 2|EBV-associated diffuse large B cell lymphomas
89593623|NCT05702632|Active Comparator|Group A|
89593624|NCT05702632|Active Comparator|Group B|
89593625|NCT03354520|Active Comparator|Tailored Videos|
89593626|NCT03354520|Active Comparator|Standard Videos|
89593627|NCT03354520|Active Comparator|OSA Treatment|
89593628|NCT03580642|Experimental|eHealth Technologies|eHealth Technologies is a messure of diferent paramenters of the patient; heart rate, blood pressure, weight, thermometer, daily activity.
89593629|NCT03580642|No Intervention|Control|Habitual treatment.
89593630|NCT03585868|Placebo Comparator|Placebo|Beverage without flavonoids
89593631|NCT03585868|Sham Comparator|No Flavonoids|Beverage with alkalinized cocoa which eliminates flavonoid content
89593632|NCT03585868|Experimental|Flavonoids|Beverage with a flavonoid rich mixture
89593633|NCT03585634|Other|Dads in Gear Program|An 8 week group program to support men's smoking cessation efforts.
89593634|NCT03163264|Experimental|PAL Intervention|"Body mass index of =30kg/m2 OR Body mass index of =25 kg/m2 with an obesity associated co-morbidity~Receiving Peer Assisted Lifestyle intervention (PAL tool, health coaching at baseline, follow-up health coaching calls, potential support of goals from primary care provider)"
89593635|NCT03163264|Active Comparator|Enhanced Usual Care (EUC)|Body mass index of =30kg/m2 OR Body mass index of =25 kg/m2 with an obesity associated co-morbidity
89593636|NCT03886324|Experimental|DCB Treatment|Stricture patients treated by DCB
89593637|NCT01865487|Placebo Comparator|2-Dose Placebo|Placebo QFT Neg and Pos, 2 Doses, days 0,56
89593638|NCT01865487|Experimental|2-Dose 5/500 H56ug/IC31nmol|5/500 H56ug/IC31nmol QFT Neg and Pos, 2 Doses, days 0,56
89593639|NCT01865487|Experimental|2-Dose 15/500 H56ug/IC31nmol|15/500 H56ug/IC31nmol QFT Negative 2 Doses, days 0,56
89593640|NCT01865487|Experimental|2-Dose 50/500 H56ug/IC31nmol|50/500 H56ug/IC31nmol QFT Negative 2 Doses, days 0,56
89593641|NCT01865487|Placebo Comparator|3-Dose, Placebo|Placebo QFT Neg and Pos, 3 doses, days 0, 56, 112
89593642|NCT01865487|Experimental|3-Dose, 5/500 H56ug/IC31nmol|5/500 H56ug/IC31nmol QFT Neg and Pos, 3 Doses, days 0, 56, 112
89593643|NCT03585556|Experimental|AAVCAGsCD59 Treated Arm|An anti-VEGF injection will be given at Day 0 followed by an intravitreal injection of AAVCAGsCD59 at Day 7. All eyes will then be treated with intravitreal anti-VEGF monthly as needed based on disease activity.
89593644|NCT05702398|Experimental|Vitamin A & Nicotinamide|1,000 μg retinyl palmitate and 500 mg NAM twice a day
89593645|NCT05702398|Placebo Comparator|Placebo|Identical placebo pills twice a day
89593646|NCT01699503|No Intervention|No Screening|Subjects who are randomized into the non-screening arm will receive the usual standard of care.
89593647|NCT01699503|Experimental|Screening Group|Subjects who are randomized into the screening arm of the study will be screened by the MIS. Subjects with MIS score of less than 5 points will be referred to the Collaborative Dementia Care Program for a subsequent diagnostic assessment, counseling and management.
89593648|NCT01709409|Experimental|Curosurf (Group 1)|Surfactant(Curosurf in this arm) is given for treatment of RDS after the diagnosis has been made by the Neonatologist. The treatment dose for Curosurf® is 2.5 ml/kg (200mg/kg) for the first dose and 1.25 ml/kg (100mg/kg) for repeat doses, given by endotracheal method. There is a maximum of 3 doses in the study.
89593649|NCT01709409|Active Comparator|BLES (Group 2)|Surfactant(BLES in this arm) is given for treatment of RDS after the diagnosis has been made by the Neonatologist. For BLES the recommended dose is 5 ml/kg. given by endotracheal method. There is a maximum of 3 doses in the study.
89593650|NCT01698879|Experimental|Single arm, three cohorts|Idarubicin, cytarabine, Mylotarg.
89593651|NCT02335294|Experimental|TRV130|
89593652|NCT02335294|Active Comparator|Morphine|
89593653|NCT02335294|Placebo Comparator|Placebo|
89210004|NCT00888498|Experimental|Slow Stretching|With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface. Traction will be delivered to the talocrural joint at the treating therapist's second perception of tissue resistance in 3 bouts of 30-second holds, separated by 10 seconds of rest.
89593654|NCT01698801|Experimental|Lenalidomide plus dexamethasone|Lenalidomide plus low-dose dexamethasone
89593655|NCT03580252||Preterm Infant Neurological Follow-Up|"Preterm infants <37 weeks' gestational age (GA) at birth admitted to the neonatal nurseries at the Abha Private Hospital in Kingdom of Saudi Arabia. This project aims to recruit 50 infants <37weeks at birth over a 1-year stating from march 2018.~A Correlation analyses for the outcomes with initial regular medical practice of MRI/Ultrasound and Hammersmith assessment."
89210005|NCT00892788|Active Comparator|A|Participants assigned to Group A will receive the LEARN (Lifestyle, Exercise, Attitudes, Relationships, Nutrition) Program weight loss manual and will be instructed to read a section of the manual each week and complete suggested activities. They will also meet with the research staff once a week for weigh-in and supportive counseling.
89593656|NCT04548297||Patients with Multiple Sclerosis|MS patients (EDSS: 0-5,5)
89593657|NCT04548297||Healthy group|Healthy individuals without chronic disease
89593658|NCT03585166||laparoscopic hepatectomy|laparoscopic hepatectomy for primary liver cancer
89593659|NCT03585166||open hepatectomy|open hepatectomy for primary liver cancer
89593660|NCT05702242|Experimental|Removal with alligator forceps|Standard of care removal with passage of an intrauterine alligator forceps under ultrasound guidance to grasp and remove the IUD. If required, multiple attempts will be performed using this technique.
89593661|NCT05702242|Experimental|Removal with manual vacuum aspiration|Intrauterine placement of an MVA under ultrasound guidance adjacent to the IUD to remove the IUD. Multiple attempts will be performed up to a maximum of 3 unsuccessful MVA attempts, after which time, the provider will switch to the alligator forceps technique, given that this is the current standard of care.
89593662|NCT01682811|Experimental|Part 1 Levulan injection|5-aminolevulinic acid uptake by control lesions after Levulan vehicle (placebo) injection and 3 hr incubation, and by Levulan treated lesions after 3 or 24 hr incubation.
89593663|NCT01682811|Experimental|Part 1 Levulan painting|5-aminolevulinic acid uptake by control lesions after Levulan vehicle (placebo) surface application and 3 hr incubation, and by Levulan treated lesions and 3 or 24 hr incubation.
89593664|NCT01682811|Experimental|Part 1 Levulan painted twice|5-aminolevulinic acid uptake by control lesions after Levulan vehicle (placebo) surface application twice or by Levulan treated lesions twice and 24 hr incubation.
89593665|NCT01682811|Experimental|Part 1 Levulan painted twice with microneedling|5-aminolevulinic acid uptake by control lesions after Levulan vehicle (placebo) surface application twice or by Levulan treated lesions twice and 24 hr incubation. All lesions prepared with microneedling.
89593666|NCT01682811|Experimental|Part 2 Dose level 1 50 J/cm^2|Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 1 - 50 J/cm^2 633 nm red light to Levulan vehicle (placebo) treated control lesions or Levulan treated lesions and 24 hr incubation. Follow-ups on day 2 for punch biopsies, 14-28 days for evaluation of cutaneous adverse events, and every 3 months up to one year for lesion measurements.
89593667|NCT01682811|Experimental|Part 2 Dose level 2 100 J/cm^2|Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 2 - 100 J/cm^2 633 nm red light to Levulan vehicle (placebo) treated control lesions or Levulan treated lesions and 24 hr incubation. Follow-ups on day 2 for punch biopsies, 14-28 days for evaluation of cutaneous adverse events, and every 3 months up to one year for lesion measurements.
89593668|NCT01682811|Experimental|Part 2 Dose level 3 200 J/cm^2|Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 3 - 200 J/cm^2 633 nm red light to Levulan vehicle (placebo) treated control lesions or Levulan treated lesions and 24 hr incubation. Follow-ups on day 2 for punch biopsies, 14-28 days for evaluation of cutaneous adverse events, and every 3 months up to one year for lesion measurements.
89593669|NCT03585088|Other|SPI Group|All patients who received the liver resection surgery will receive surgical pleth index
89593670|NCT03321760|Experimental|Run-In Dose 1|10 Gy dose delivered to the primary tumor & 10 Gy to the hilar (N1) node over 5 fractions
89593671|NCT03321760|Experimental|Run-In Dose -1|10 Gy dose delivered to the primary tumor & 9 Gy to the hilar (N1) node over 5 fractions
89593672|NCT03321760|Experimental|Run-In Dose -2|10 Gy dose delivered to the primary tumor & 8 Gy to the hilar (N1) node over 5 fractions
89593673|NCT03321760|Experimental|Phase 2|The maximum tolerated radiation dose to the hilar (N1) node from the run-in period will be used during Phase 2.
89593674|NCT03580096|Experimental|Experimental group|Patients were included in a core stability intervention. It will be done with different stages and increasing gradually.
89593675|NCT03580096|Active Comparator|Control group|Standard intervention consisting of exercises aimed at improving balance.
89593676|NCT03580018|Experimental|Tranexamic Acid group|Ten mL of TXA (100 mg/mL) was injected into the joint at the end of the index operation and the drain was clamped for 2 h.
89593677|NCT03580018|Placebo Comparator|Control Group|The control group patients only received ACLRs without TXA injections.
89593678|NCT03584854|Active Comparator|15-methyl prostaglandin F2α|IM Carboprost followed by Methylergonovine if needed.
89593679|NCT03584854|Active Comparator|Methylergonovine Maleate|IM Methylergonovine followed by Carboprost if needed.
89593680|NCT04765540|Active Comparator|T1: Business as Usual (BAU)|Handwashing station plus standard BRAC programming, i.e. in-person community WASH (water, sanitation and hygiene) demonstrations conducted in households/communal areas, and sticker signs/posters placed on walls in the 'catchment area' of the handwashing station, alerting people to the stations and roughly pointing the way.
89593681|NCT04765540|Experimental|T2: BAU + Low Intensity Nudges|"T1 plus a bundle of 'low-intensity' passive interventions, including:~Large mirrors installed above handwashing station sinks to attract more people to the station~7 to 8 large hand-shaped signposts pointing to the station and leading up to the station, placed on the ground in the vicinity of the station, starting from the nearest 'busy spot'"
89593682|NCT04765540|Experimental|T3: BAU + High Intensity Activities|"T1 plus an additional bundle of 'high-intensity' active interventions delivered for three weeks, including:~Free soap and free facemasks provided to handwashing station users in regular giveaways at key times, along with encouragement to return to the station and to spread the word.~A 'community message board' along with encouragement to make a mark on a scoreboard at the top of the board before/after use of the station to increase commitment and as an additional social cue. This will also visually show cumulative number of uses as a persistent cue of the social norm.~General encouragement to use the stations, provided by the intervention delivery team while they are at the station. Intervention team members are equipped with a loudhailer to assist this.~In addition, village handwashing station committees will be encouraged to try out their own ideas for encouraging more people to use the stations."
89593683|NCT03586336|Experimental|ReDS-Guided|Patients in the intervention arm will undergo daily measurements of lung fluid content at the bedside with the ReDS vest. The values will be shared with the treating clinicians, who can use the measurements in addition to other standard data to guide diuresis. Patients should be discharged only once their lung fluid content falls within the normal range of 20-35%.
89593684|NCT03586336|Sham Comparator|Control|Patients in the control arm will also undergo daily measurements of lung fluid content at the beside with the ReDS vest. However, the values will not be shared with the treating clinicians, who will direct management based on standard clinical tools
89593685|NCT03584698|Experimental|study group|Misoprostol + Evening primrose oil group
89593686|NCT03584698|Active Comparator|control group|Misoprostol only group
89593687|NCT03588130|Active Comparator|EscharEx (5% EX-02 formulation)|Debridement will be performed with 5% EX-02 for 24±3 hours, up to 8 applications
89593688|NCT03588130|Placebo Comparator|Gel Vehicle|Debridement will be performed with Gel vehicle for 24±3 hours, up to 8 applications
89593689|NCT03588130|Active Comparator|Non-surgical standard of care (NSSOC)|Debridement will be performed with NSSOC (Santyl or commercially approved Hydrogel) per routine procedures, until complete debridement is achieved
89593690|NCT05702008|No Intervention|Control Group|The participants in this study arm were administered no intervention.
89593691|NCT05702008|Experimental|Test Group|The participants in this arm were administered the following intervention: The test group was administered the rabies IEC material available on the National Center for Disease Control (NCDC) website (https://ncdc.gov.in/index1.php?page=1&ipp=All&lang=1&level=2&sublinkid=502&lid=428) in English and Hindi languages using a WhatsApp broadcast every 3 days for 30 days, in a cyclical manner. This material includes brochures, posters, short films, and informative documents designed to educate the general public about rabies prevention and post-exposure prophylaxis practices. Text messages, encouraging the participants to go through the material, were also a part of this intervention.
89608494|NCT01273558|No Intervention|Part 1: no Intervention|In Part 1 of the study, patients will not receive any study drug.
89593692|NCT03584620|Experimental|IMT+PR Group|Patients received a 3-month standard hospital-based Pulmonary Rehabilitation included aerobic and strength training. In addition standard pulmonary rehabilitation, patients received inspiratory muscle training.
89593693|NCT03584620|Experimental|PR group|Patients received a 3-month standard hospital-based Pulmonary Rehabilitation included aerobic and strength training.
89593694|NCT03584308|Experimental|Viusid® + Glizigen®|The experimental arm will receive nutritional supplements Viusid + Glizigen
89593695|NCT03584308|Placebo Comparator|Placebo|The control group will receive a placebo of both (Viusid and Glizigen).
89593696|NCT01682031|Placebo Comparator|Arm I (placebo, cisplatin, and radiotherapy)|Patients receive placebo PO twice daily in week 1 and then once daily in weeks 2-11. Patients also receive cisplatin IV over 3 hours once in weeks 2, 5, and 8 and undergo radiotherapy 5 days a week in weeks 2-8.
89593697|NCT01682031|Experimental|Arm II (selenomethionine, cisplatin, and radiotherapy)|Patients receive selenomethionine PO twice daily in week 1 and then once daily in weeks 2-11. Patients also receive cisplatin and undergo radiotherapy as in arm I.
89593698|NCT03584230|Experimental|Positive Condition|"Students will be assigned to a group that receives positive nonverbal teacher behaviors. At the beginning of the session participants will learn that there are three groups of students at a school, and the groups are identifiable by t-shirt color. They will be joining one of the groups and will be given a t-shirt to wear. They then view a series of interactions where a teacher directs positive nonverbal behaviors to students in the same t-shirt color and negative nonverbal behaviors to students in another t-shirt color.~Intervention: Assigned to positive group"
89593699|NCT03584230|Experimental|Negative Condition|"Students will be assigned to a group that receives negative nonverbal teacher behaviors. At the beginning of the session participants will learn that there are three groups of students at a school, and the groups are identifiable by t-shirt color. They will be joining one of the groups and will be given a t-shirt to wear. They then view a series of interactions where a teacher directs negative nonverbal behaviors to students in the same t-shirt color and positive nonverbal behaviors to students in another t-shirt color.~Intervention: Assigned to negative group"
89593700|NCT03584230|No Intervention|No Cues Condition|Students will be assigned to a group that receives no nonverbal teacher behaviors. At the beginning of the session participants will learn that there are three groups of students at a school, and the groups are identifiable by t-shirt color. They will be joining one of the groups and will be given a t-shirt to wear. They then view a series of interactions where a teacher directs positive nonverbal behaviors to students in a different t-shirt color and negative nonverbal behaviors to students in a different t-shirt color. Students wearing the same t-shirt color as the participant never interact with the teacher.
89593701|NCT03588442||Cirrhosis cohort|Patients with liver cirrhosis.
89593702|NCT03588442||HBV infection cohort|Patients with seropositivity of HBsAg.
89593703|NCT03020134|Experimental|PKGroup(Ravidasvir/Danoprevir/Ritonavir)|Ravidasvir + Danoprevir/ Ritonavir
89593704|NCT03020134|Placebo Comparator|Placebo Group|Placebo
89593705|NCT03020056|Placebo Comparator|waiting surgery|Cataract surgery will be performed at 1 year after enrollment.These participants will be provided with Phacolin eye drops(Zhongshan ophthalmic center, China).
89593706|NCT03020056|Experimental|expedited surgery|Cataract surgery will be performed within 4 weeks.
88978164|NCT00400998|Placebo Comparator|Park In Season (Phase 2)|"Phase 2 will consist of 2 treatment periods lasting either 8 to 14 days (D) (depending on out-door conditions). There will be a 10D wash-out between this treatment period in Phase 2 and that in Phase 3.~Subjects will administer 200μg fluticasone propionate (or fluticasone propionate matched placebo nasal spray, once daily up to 14D, with dosing supervised on the first and last days of each treatment period (D1 and either D8 or up to D14).~Immediately following the last dose received on either D8 or up to D14 baseline measures will be taken (time = 0). The subject is then taken by bus to the Park and the first measurement will be taken 15 minutes after the subjects leave the bus and enter the Park.~Immediately following the last dose received on D8 or up to D14 the subject's signs and symptoms will be monitored: subjective symptom score every 15 minutes for rhinomanometry and measurement of nasal secretion every 30 minutes, and FEV1, AEs and symptoms of local irritancy"
88978165|NCT00247039|Experimental|Garlic extract|Garlic extract capsules
88978166|NCT00247039|Placebo Comparator|Placebo|Placebo capsules
88978167|NCT00247078|Experimental|1|Patients with moderate or severe pain due to Black Widow envenomation
88978168|NCT00247078|Placebo Comparator|2|Patients with moderate to severe pain due to Black Widow envenomation
88978169|NCT00247195|Experimental|Culturally congruent assessment and treatment|Outreach by phone to primary care patients interested in mental health referral. Engagement and evaluation approach conducted using the DSM-IV cultural formulation model. Same treatment choices as in control arm (medication, interpersonal psychotherapy, and combination treatment).
88978170|NCT00247195|Active Comparator|Usual referral and treatment|Usual referral procedure from primary care: PC clinician gives patient information on how to access mental health care at research site. Usual engagement and evaluation approach without using cultural formulation model. Same treatment choices (medication, interpersonal psychotherapy, and combination treatment) as in experimental arm.
89210006|NCT00892788|Experimental|B|Participants assigned to Group B will receive the LEARN manual and will meet with research staff each week for weigh-in and supportive counseling. They will also receive contingency management or the opportunity to earn draws with the chance of winning prizes for losing weight and completing healthy activities.
88978171|NCT00247234|Experimental|schema therapy|
89593707|NCT05701774|Experimental|DCCR|75 - 525 mg DCCR
88978172|NCT00247234|Active Comparator|standard care|standard psychiatric out-patient care
88978173|NCT00247312|Active Comparator|125Gy prescription dose Pd-103|125Gy prescription dose Pd-103
88978174|NCT00247312|Active Comparator|110 Gy prescription dose Pd-103|110 Gy prescription dose Pd-103
88978175|NCT00401076|Experimental|1|
88978176|NCT00247390|Experimental|Ramelteon 8 mg QD|
89593708|NCT03584074|Experimental|Pregabalin and COX-2 inhibitor|Pregabalin 75mg BID + Celecoxib 200mg qd
89593709|NCT03584074|Active Comparator|COX-2 inhibitor|Celecoxib 200mg qd
89608495|NCT01273558|Experimental|Part 2: canagliflozin|In Part 2 of the study, patients will receive canagliflozin once daily on Days 1 through 8.
89608496|NCT00733096|Experimental|1|Epidural etanercept 4 mg, two doses 2 weeks apart
89031299|NCT00527358|No Intervention|2|Business as usual.
89593710|NCT03584386|Experimental|V-CAMS (aka Jaspr)|"In Phase I (formative), participants are asked to provide feedback on the V-CAMS prototype as it is being refined. Feedback will be gathered via survey measure and interview.~Phase II (summative): Patient participants enrolled in the ED RCT will be randomly assigned to this arm and will be given access to the V-CAMS tools as part of their treatment in the ED. Baseline assessment surveys will be administered in the ED, and three follow up assessments after discharge at 7 days, 30 days, and 90 days. Outpatient participants in the Telehealth RCT will be randomly assigned to receive the V-CAMS/Jaspr companion mobile app JAH in addition to their usual outpatient care. Study assessments will be administered remotely at three time points: baseline, 30- and 90-day follow ups.~Intent to treat sample for ED RCT is defined as completing post-treatment baseline assessment; telehealth study intent to treat threshold is defined as completing setup of JAH on their personal mobile phone."
89593711|NCT03584386|No Intervention|Care As Usual|"Phase II (summative): Patient participants enrolled in the ED RCT will be randomly assigned to this arm so there is an even number of participants in the experimental condition and this condition. Those assigned to this condition will be treated as usual in the ED. Same as the experimental condition, those in the Care As Usual condition will be asked to complete baseline assessment surveys while they are waiting in the ED, and then three subsequent assessments after discharge at 7 days, 30 days, and 90 days. Outpatient participants enrolled in the Telehealth RCT will be randomly assigned to CAU in addition to receiving crisis safety planning. Study assessments will be administered remotely at baseline and at 30- and 90-day follow ups.~Intent to treat sample for ED RCT is defined as completing post-treatment baseline assessment; telehealth study intent to treat threshold is defined as setting up the control condition crisis stability plan."
89593712|NCT03583996|Experimental|Open Label|All subjects receive HepQuant SHUNT Liver Diagnostic Test within 42 days of the scheduled EGD. Test includes 20mg of 13C Cholate mixed with Albumin via IV push, and 40mg of d4 Cholate mixed with juice orally, both doses given simultaneously one time.
89031300|NCT00509951|Active Comparator|1|One-session exposure treatment (OST)
89031301|NCT00509951|Experimental|2|Family-enhanced (augmented) OST
89031302|NCT03459950||Chronic Insomnia group|60 patients with chronic insomnia are included in the Chronic Insomnia group. Men and women half, the age of 18-60 years old, signature to the Information for Patient.
89031303|NCT03459950||Normal control group|60 normal people are included in the normal control group. Men and women half, the age of 18-60 years old, signature to the Information for Patient.
89031304|NCT00510965|Experimental|A|
89593713|NCT03583918|Experimental|Highthroughput Micro Coring Device|Skin excision and removal with with Highthroughput Micro Coring device
89593714|NCT03583762|Experimental|Pre-intervention group|100 participants received empiric antibiotic by ID physician, bacterial identification by Mass spectrometry technique
89593715|NCT03583762|Experimental|Post-intervention group|100 participants received empiric antibiotic therapy by ID physician, bacterial identification by Microarray assay from blood culture and confirm with Mass spectrometry technique
89593716|NCT03583294|Experimental|irradiation regimen before 9|Female who received a hematopoietic stem cell transplantation (HSCT) for AML/CML before 9 years old after conditioning regimen with total body irradation MRI pelvic will be performed
89593717|NCT03583294|Experimental|busulfan regimen before 9|Female who received a hematopoietic stem cell transplantation (HSCT) for AML/CML before 9 years old after a busulfan-based conditioning regimen MRI pelvic will be performed
89593718|NCT03583294|Experimental|irradiation regimen after 9|Female who received a hematopoietic stem cell transplantation (HSCT) for AML/CML after 9 years old after conditioning regimen with total body irradation MRI pelvic will be performed
89593719|NCT03583294|Experimental|busulfan regimen after 9|Female who received a hematopoietic stem cell transplantation (HSCT) for AML/CML after 9 years old after a busulfan-based conditioning regimen MRI pelvic will be performed
89593720|NCT05701696||Patients with fibromyalgia|Patients diagnosed with FM according to ACR 2016 criteria
89593721|NCT03153826|Other|Patients|
89593722|NCT03158818||HBV mono-infected (Standard of Care)|500 patients in Zambia
89593723|NCT03156556|Experimental|Mood Mechanic|"The Mood Mechanic Course is comprised of five online lessons completed over an 8-week period.~Lesson 1 presents information on anxiety and depression as well as on the cycle of symptoms.~Lesson 2 presents different strategies to generate helpful cognitions.~Lesson 3 describes strategies for physical de-arousal and for re-engaging in reinforcing activities.~Lesson 4 describes avoidance and safety behaviors and graded exposure.~Lesson 5 is about problem solving and relapse prevention.~For each lesson, a Do It Yourself guide is included containing homework as well as case stories. Additional material on different topics is also included such as structured problem solving."
89593724|NCT04405336|Active Comparator|giving tab block|giving patients tab block
89593725|NCT04405336|Active Comparator|giving PCA|Giving PCA to patients
89593726|NCT04405336|No Intervention|Patients who will not receive PCA or tab block|No tab block or PCA
89608497|NCT00733096|Active Comparator|2|Epidural methylprednisolone 60 mg, two doses 2 weeks apart
89031305|NCT02945826|Experimental|uPAR PET/MRI|One injection of 68Ga-NOTA-AE105 followed by PET/MRI.
89031306|NCT02945358||Prolonged ICU stay|Group 1: adult cardiac surgery with cardiopulmonary pump with prolonged ICU stay Group 2: adult cardiac surgery with cardiopulmonary pump with non-prolonged ICU stay
89031307|NCT02952209|No Intervention|No Treatment|Tooth extraction with no bone graft.
89031308|NCT02952209|Active Comparator|Alveolar Ridge Preservation Treatment|Tooth extraction followed by alveolar ridge preservation using xenograft bone graft and covered by a resorbable collagen membrane.
89031309|NCT02945397|Active Comparator|Individual activity|The individual activity consists of a 3 month membership card at a given gym. This is in addition to regular follow-up from welfare authorities.
89031310|NCT02945397|Active Comparator|Group-based activity|The group-based activity consists of a 3 month group activity with weekly gatherings, focusing on coping, goal-setting and relevant information regarding available public services. This is in addition to regular follow-up from welfare authorities.
89031311|NCT02952287|Experimental|Study Participants|4D PC MRI acquisition
89031312|NCT02945475||obese|Individuals ages 18 to 35 years of age with body mass index (BMI) 30-40 kg/m2
89031313|NCT02945475||lean|Individuals ages 18 to 35 years of age with BMI of 19-24.9 kg/m2
89593727|NCT03583138||Buprenorphine|Participants are eligible for the study if they are 18 years of age or older, HIV+, meet DSM-IV criteria for opioid dependence, have health insurance accepted at Lab Corp, are able to read and understand English, and live in Washington, DC and plan to remain in DC. The intervention is to provide buprenorphine for 12 months for those who are interested in receiving it.
89593728|NCT03583138||No buprenorphine|No buprenorphine
89593729|NCT03153514|Experimental|Obinutuzumab|"Obinutuzumab i.v.~Cycle 1: in the peri-transplant and transplantation phase~Cycle 2: if active disease and/or MRD positivity on day +60, +90, +180 or +270"
89593730|NCT03583060|Experimental|MABT|Receive 8 weekly sessions of Mindful Awareness in Body-oriented Therapy (MABT).
89593731|NCT03583060|No Intervention|Control|
89593732|NCT03020524|Experimental|Dose level 1:|Autologous CD4 T-Cells0.8-1x10^9 transduced CD4+T-cells administered IV as a single dose
89593733|NCT03020524|Active Comparator|Dose level 2|Autologous CD4 T-Cells 2.4-3x10^9 transduced CD4+ T-cells administered IV as a single dose
89593734|NCT03020524|Active Comparator|Dose level 3|Autologous CD4 T-Cells 0.8-1x10^10 transduced CD4+ T-cells administered IV as a single dose
89593735|NCT03020602|Experimental|Treatment (BPM31510)|Patients receive ubidecarenone injectable nanosuspension IV over 72 hours twice weekly. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89593736|NCT03582982|Experimental|Eccentric overload exercise|
89593737|NCT03153670|Experimental|fMRI-based programming|DBS patients will undergo fMRI scanning while on different stimulation settings. The results will be fed to the programming clinician (movement disorder neurologist) to aid the conventional programming process at the clinician's discretion.
89593738|NCT03582904|Experimental|Real tDCS|Anodal transcranial direct current stimulation (tDCS) targeting the primary motor cortex delivered via saline-soaked sponge electrodes (anode, 8 cm^2; cathode 38.4 cm^2) at an intensity of 1.5 milliamperes over < 30 minutes.
89593739|NCT03582904|Sham Comparator|Control|Anodal transcranial direct current stimulation (tDCS) targeting the primary motor cortex delivered via saline-soaked sponge electrodes (anode, 8 cm^2; cathode 38.4 cm^2) at an intensity of 1.5 milliamperes over 2 minutes.
89593740|NCT01567527|Active Comparator|1|Active Comparator: Treatment of Aripiprazole IM Depot
89593741|NCT01567527|Placebo Comparator|2|Placebo Comparator: Treatment of IM Depot Placebo
89593742|NCT03582670|Experimental|Strategy Training Intervention|Study participants receive specific memory strategy training with training games, as well as feedback on accuracy and performance.
89593743|NCT03582670|Active Comparator|Process Training|Study participants attend training sessions and complete training games, but receive no specific strategy training
89593744|NCT03582670|Other|Control Group|Study participants do not attend any strategy training sessions.
89593745|NCT03159988|Experimental|Non-randomized treatment group|12 weeks of daily does subcutaneous injection of Angiotensin-(1-7) 100 mcg/kg/day
89593746|NCT03582592|Experimental|Fluid Distribution Timetable (FDT) Group|It is the fluid distribution timetable. It is a scheduled distribution of pre-determined amounts of fluid intake on a daily basis depicted via a 5x6 table. The timetable includes three major columns. The first column has six timepoints of a day with a four-hour interval. The second column, which was further divided into four sub-columns, reflects the percentage of fluid allotment for food, activities, medication, and thirst encounters. The percentage of fluid allocation was computed based on the patient's prescribed fluid restriction, usual time of food intakes in a day, usual level of activity, time of medication intake, and common time they encounter thirst in a day. Lastly, the third column indicates the converted percentages of fluid allotment in milliliters.
89608498|NCT00733096|Placebo Comparator|3|Epidural saline, two doses 2 weeks apart
89608499|NCT02991196|Experimental|DS-8273a + nivolumab|Participants will receive their treatment dose until discontinuation for any reason, or trial completion, within two years
88978177|NCT00247390|Placebo Comparator|Placebo QD|
88978178|NCT00099606|Experimental|A1|
88978179|NCT00247663|Experimental|Letrozole|
88978180|NCT01349660|Experimental|BKM120/Bevacizumab|"Phase I:~BKM 120 orally (PO) once daily (dose is 60mg or 80mg). Bevacizumab: 10mg/kg intravenous (IV) every 2 weeks~Phase II:~BKM 120 orally (PO) once daily - dose is optimal dose determined in Phase I. Bevacizumab: 10mg/kg intravenous (IV) every 2 weeks"
88978181|NCT00247741|Active Comparator|lidocaine|
88978182|NCT00247741|Experimental|articaine|
88978183|NCT00247936|Active Comparator|1|Combined Thoracoscopic and Laparoscopic Esophagectomy
88978184|NCT00247936|Active Comparator|2|Hand-Assisted Transhiatal Esophagectomy
88978185|NCT00067730|Experimental|1|24 microgram/kg/hr for 96 hours (+ or - 1 hour)
88978186|NCT00248053|Other|Lower GI|
88978187|NCT00067769|Active Comparator|TAU|Patients received treatment as usual (TAU) as defined as continued clinical care.
89608500|NCT01278706|No Intervention|no treatment|
88978188|NCT00067769|Experimental|TAU+UCanPoopToo|Patients received treatment as usual (TAU) plus the Internet intervention (UCanPoopToo.)
88978189|NCT00248209|Placebo Comparator|Wellbutrin XL or placebo|1 arms - Wellbutrin XL or placebo
88978190|NCT00248326||1|Patients of the Cardiovascular Institute with known cardiac conditions and no history of atrial fibrillation.
88978191|NCT00248326||2|Patients of the Cardiovascular Institute with known cardiac conditions and a history of atrial fibrillation.
88978192|NCT00248365|Experimental|Low PDT intensity level|Theralux extracorporeal photochemotherapy PDT dose: TH9402 0.33μM
88978193|NCT00248365|Experimental|High PDT intensity level|Theralux extracorporeal photochemotherapy PDT dose: TH9402 1.32μM
88978194|NCT02961478|Experimental|Iohexol plasmatic clearance|
88978195|NCT00248482|Experimental|Irinotecan, Cisplatin & Gleevec™|"Cisplatin 60mg/m2 IV day 1 every 21 days x 4 cycles~Gleevec™ 400 mg po BID (800mg/day)- for patients with objective response or stable disease.~Irinotecan 65 mg/m2 IV days 1, 8 every 21 days x 4 cycles"
88978196|NCT00248677|No Intervention|No Contact Control|
88978197|NCT00248677|Experimental|Behavior Family Intervention|
88978198|NCT00248677|Experimental|Behavioral Parent-Only Intervention|
89031314|NCT02945475||overweight|Individuals ages 18 to 35 years of age with BMI of 25-29.9 kg/m2
89031315|NCT04695782|Experimental|Neo-adjuvant pencil beam proton therapy: 55 Gy(RBE)/44fx (1.25 Gy per fraction), two daily|
89593747|NCT03582592|No Intervention|Comparison Group|It is the standard of care that served as the intervention. The control group received the standard care for patients on hemodialysis. The standard care involves a 10 -15-minute face-to-face health teaching of their treatment regimen including pharmacologic management, dialysis schedule, dietary and fluid restrictions or nutritional therapy, care for vascular access, and other necessary lifestyle modifications.
89593748|NCT03582358||Verrine|Patients served verrines
89593749|NCT03582358||CNO|Patients served wrapped supplements
89593750|NCT03159598|Active Comparator|Tissue Glu with drains|This is standard of care to use Tissue Glu in addition to a drain. Pre-operatively, as well as on post-operative patients will be asked to complete a questionnaire that addresses their pain, impact of drains on activities of daily living, social and physical activities. Patients will also be asked to provide information regarding who is caring for the drains, the impact of drains on the caregiver, the amount of anxiety the patient has related to drain removal and the amount of pain associated with drain removal
89593751|NCT03159598|Experimental|Tissue Glu without drains|This group utilizes Tissue Glu without the presence of a drain. Pre-operatively, as well as on post-operative patients will be asked to complete a questionnaire that addresses their pain, impact of drains on activities of daily living, social and physical activities. Patients will also be asked to provide information regarding who is caring for the drains, the impact of drains on the caregiver, the amount of anxiety the patient has related to drain removal and the amount of pain associated with drain removal
89593752|NCT03159598|Active Comparator|Drains|This is standard of care to use traditional closed-suction drains. Pre-operatively, as well as on post-operative patients will be asked to complete a questionnaire that addresses their pain, impact of drains on activities of daily living, social and physical activities. Patients will also be asked to provide information regarding who is caring for the drains, the impact of drains on the caregiver, the amount of anxiety the patient has related to drain removal and the amount of pain associated with drain removal
89593753|NCT01818752|Experimental|Carfilzomib, Melphalan, Prednisone|Participants received carfilzomib administered in combination with melphalan and prednisone for nine 42-day cycles. Carfilzomib was administered as an intravenous (IV) infusion on days 1, 2, 8, 9, 22, 23, 29, and 30 of each 42-day cycle. The carfilzomib dose was at 20 mg/m² on cycle 1, days 1 and 2 followed by 36 mg/m² thereafter. On days 1 to 4, melphalan was administered at 9 mg/m² and prednisone was administered at 60 mg/m².
89593754|NCT01818752|Active Comparator|Bortezomib, Melphalan, Prednisone|Participants received bortezomib in combination with melphalan and prednisone for nine 42-day cycles. Bortezomib was administered either IV or subcutaneously at 1.3 mg/m² during cycles 1 to 4 on days 1, 4, 8, 11, 22, 25, 29, and 32 followed by 1.3 mg/m² during cycles 5 to 9 on days 1, 8, 22, and 29. On days 1 to 4 of each cycle, melphalan was administered at 9 mg/m² and prednisone was administered at 60 mg/m².
89593755|NCT03582202|Active Comparator|Dietetic service|Nutritional assessment and therapy by dietitian throughout the hospital stay
89593756|NCT03582202|Placebo Comparator|standard care|Nutritional handling by nurses supported by a dietician if needed
89593757|NCT03159520|Active Comparator|Advice on acupressure|Advice sheet on use of acupressure for post orthodontic pain
89593758|NCT03159520|Active Comparator|Advice on analgesics|Advice sheet on use of NSAID analgesics for post orthodontic pain
89593759|NCT03159832|Active Comparator|Normal renal function|All subjects were given SHR3824 20mg only one time.
89593760|NCT03159832|Active Comparator|Mild renal dysfunction|All subjects were given SHR3824 20mg only one time.
89593761|NCT03159832|Active Comparator|Moderate renal dysfunction|All subjects were given SHR3824 20mg only one time.
89593762|NCT03582046|No Intervention|Monitoring Group|Patients that sustain intra-abdominal pressure of < 8 mmHg for 48 hours from sepsis diagnosis. Patients will be monitored and given sepsis standard of care.
89593763|NCT03582046|Active Comparator|Mean Arterial Pressure (MAP) Group|Patients with elevated intra-abdominal pressure of ≥ 8 mmHg for 48 hours from sepsis diagnosis.
89593764|NCT03582046|Experimental|Abdominal Perfusion Pressure (APP) Group|Patients with elevated intra-abdominal pressure of ≥ 8 mmHg for 48 hours from sepsis diagnosis.
89593765|NCT01845818||Ankylosing Spondylitis and Psoriatic Arthritis|Participants with AS and PsA and in whom adalimumab treatment is initiated. All medication will be prescribed in the usual manner in accordance with the terms of the marketing authorization and in line with the Belgian reimbursement criteria.
89593766|NCT05701462|Experimental|pleural disease|
89593767|NCT04405492|Experimental|Population 1 : Patients|Hospitalized patients, positive or suspected of SARS-CoV-2 infection
89593768|NCT04405492|Experimental|Population 2 : Hospital caregivers exposed to SARS-CoV-2|Longitudinal study of a hospital caregiver cohort
89593769|NCT04405492|Experimental|Population 3 : Lay users|Suitability of rapid test in view of its intended purpose for self-testing
89593770|NCT05701384|Experimental|Lazertinib 160mg arm|
89593771|NCT04142554|Experimental|Single Arm: Parsaclisib ( Dose De-Escalation )|Prior to their scheduled standard of care surgery or research biopsy, subjects (n = 5 per dosing cohort) will be given oral doses of parsaclisib (10, 3.0 or 1.0 mg) once daily over 14 consecutive days.
89593772|NCT01362608|Experimental|Canakinumab and placebo matching to triamcinolone acetonide|ACZ885H
89593773|NCT01362608|Active Comparator|Triamcinolone acetonide 40 mg|ACZ885H
89608501|NCT01278706|Experimental|one biopsy, proliferative phase|
89608502|NCT01278706|Experimental|one biopsy, secretory phase|
89210007|NCT00900978|Experimental|7v-PCV (Prevenar)|Biological/vaccine
88978199|NCT00103272|Experimental|Treatment (17-AAG and bortezomib)|"Patients receive 17-N-allylamino-17-demethoxygeldanamycin (17-AAG) IV over 1-6 hours on days 1, 4, 8, and 11 and bortezomib IV over 3-5 seconds on days 4, 8, and 11 of course 1 and on days 1, 4, 8, and 11 of all subsequent courses.~Treatment repeats every 21 days for 3-12 courses provided patient is receiving clinical benefit. Patients achieving objective response may discontinue therapy to undergo stem cell transplantation."
88978200|NCT00248872|No Intervention|control group|This group received follow-up every 2-months for one year. Follow-up included questions about their blood pressure and how well they had been able to adhere to their medication goal.
88978201|NCT00248872|Experimental|Intervention Group|This group received follow-up every 2-months for one year. Follow-up included questions about their blood pressure and how well they had been able to engage adhere to their medication goal. The intervention included receiving an additional educational workbook about using positive affect and self affirmation, as well as participating in using positive affect and self-affirmation to motivate behavior change, which in this case was to increase their physical activity level.
88978202|NCT00248911|Experimental|Mindfulness based meditation program|Meditation and Breast Cancer: Subjects will participate in an intervention consisting of group and individual instruction in a meditation-based practice of stress-reduction and cognitive-affective-behavioral learning.
88978203|NCT00248989|Experimental|Placebo|
88978204|NCT00248989|Experimental|DHEA|
88978205|NCT00249106|Experimental|HIV vaccine|dosage escalation of ADVAX
88978206|NCT00249106|Placebo Comparator|Placebo|Sodium phosphate
88978207|NCT00414583||Observation|all adult patients (18 - 55 years of age) with an acute cerebrovascular event of any etiology
88978208|NCT00249301|Experimental|1|MLN8054
88978209|NCT02967224|Experimental|Toujeo|Toujeo will be administered once daily in addition to noninsulin antidiabetic agents
88978210|NCT02967224|Active Comparator|"Standard of care commercially available basal insulin"|Lantus, Humulin Neutral Protamine Hagedorn (NPH), Levemir or Tresiba or other basal insulin, including biosimilar insulin will be administered once or twice daily according to label in addition to noninsulin antidiabetic agents
88978211|NCT02961595|No Intervention|Inactivated Polio Vaccine (IPV)|The control group received inactivated poliovirus vaccine (IPV) at the age of 6 and 12 months according to the national immunization protocol in Finland at that time.
88978212|NCT02961595|Active Comparator|Oral Polio Vaccine (OPV)|Intervention group were given doses of oral polio vaccine OPV (Polio Sabin®) at the age of 2, 3, 6 and 12 months.
88978213|NCT04720495|Active Comparator|One stage ridge splitting|
88978214|NCT04720495|Experimental|Two-stage ridge splitting|
88978215|NCT00249457|Experimental|Therapeutic Workplace|Contingency management. Invited to work in the Therapeutic Workplace. Completed monthly assessments.
88978216|NCT00249457|No Intervention|Usual Care Control Group|No intervention. Not invited to work int the Therapeutic Workplace. Completed monthly assessments.
88978217|NCT02961673|Experimental|HU-014 Inj(Phase 1 and 2)|HU-014 Inj was given an injection to 5 glabellar lines each 4 U/0.1ml (Total 20 U/0.5ml, IM)
88978218|NCT02961673|Active Comparator|Botox Inj(Phase 2)|Botox Inj was given an injection to 5 glabellar lines each 4 U/0.1ml (Total 20 U/0.5ml, IM)
88978219|NCT00249535|Experimental|1|standard treatment plus usual magnitude prize CM
88978220|NCT00249535|Experimental|2|standard treatment plus higher magnitude prize CM
88978221|NCT00249535|Experimental|3|standard treatment plus voucher CM
88978222|NCT00249574|Experimental|pegInterferon|Open label, observational trial to determine the safety of HCV treatment in active IDUs stabilized on buprenorphine/naloxone
88978223|NCT00249652|Experimental|TAP|MI-based phone intervention.
88978224|NCT00249652|Other|TAU|Treatment As Usual
88978225|NCT00249691|Experimental|Topiramate|
88978226|NCT00249691|Placebo Comparator|Placebo|
88978227|NCT00249847|Experimental|Paroxetine|Paroxetine controlled-release (2-12.5 mg tablets, orally, every day for 4 weeks)
88978228|NCT00249847|Experimental|Conjugated equine estrogen|Conjugated equine estrogen (0.625 mg tablet, orally, every day for 4 weeks)
88978229|NCT00249964|Experimental|Combination Treatment|"Paclitaxel at 175 mg/m2 + Carboplatin at area under the curve (AUC) 5 on day 1. Then, Temozolomide at the doses described under Interventions from day 2 to day 6 (a total of 5 days).~Cycle length is 21 days."
88978230|NCT02961712|Experimental|cell therapy|NK cells and amniotic epithelial cells
88978231|NCT00068315|Experimental|Treatment (bortezomib, fludarabine, rituximab)|"Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11 and fludarabine IV over 30 minutes on days 1-3 or 1-5. Patients may also receive rituximab IV over 1 hour on day 1. Treatment repeats every 3 weeks for up to 8 courses in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of bortezomib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
88978232|NCT00250081|Active Comparator|Therapy Group|Therapy only
88978233|NCT00250081|Active Comparator|Surgery Group|surgical intervention
88978234|NCT00250081|Active Comparator|Botox Injections|botulinum toxin
88978235|NCT04720573|Active Comparator|Group N|Neostigmine was used for the reversal of neuromuscular blockade.
88978236|NCT04720573|Active Comparator|Group S|Sugammadex was used for the reversal of neuromuscular blockade.
88978237|NCT00068432|Experimental|Gemcitabine + Celecoxib|Oral celecoxib twice daily on days 1-28. Gemcitabine by vein (IV) over 65 minutes on days 1, 8 and 15. Courses repeat every 4 weeks.
88978238|NCT04720261|Other|Caplacizumab|All patients in the study are aTTP and needs to be treated by caplacizumab. The duration of this treatment will be evaluated through the ADAMTS 13 activity.
88978239|NCT00250237|Active Comparator|A|Patients receiving blinded medication (Haloperidol or Placebo)
88978240|NCT00250237|Placebo Comparator|B|Patients receiving blinded medication (Haloperidol or Placebo)
89031316|NCT04695782|Experimental|Definitive arm pencil beam proton therapy: 57.5-65Gy(RBE)/46-52 fx (1.25 per fraction) two daily|
89031317|NCT00527436|Other|Dietary Supplement|Fish oil pill
89031318|NCT00527436|Placebo Comparator|Placebo|Placebo matched corn oil pill
89608503|NCT01278706|Experimental|two biopsies|
89593774|NCT03581968|Experimental|Closed-loop therapy|Participants will undergo a closed-loop therapy where insulin delivery is determined by the MAP system. The study parameters (basal rates and ICRs) will be determined by the camp's physicians. The research staff will update the pump's settings to reflect the physician's recommendations at the beginning of the closed-loop therapy, and each time the physicians update the study parameters. The closed-loop therapy will last 2 days (48 hours).
89593775|NCT03581968|Experimental|Closed-loop therapy with learning module|participants will undergo a closed-loop therapy where insulin delivery is determined by the MAP system. The study parameters (basal rates and ICRs) will be computed by the learning algorithm and updated daily. The learning algorithm runs on a computer of the research staff members and requires patient data to calculate the optimal basal rates and ICR. Each day, the research staff members will upload patient data onto the computer, run the leaning algorithm, and update the pump parameters to reflect the recommendations computed by the learning algorithm. The closed-loop therapy with the learning module will last 8 days (192 hours).
89593776|NCT03159286|Experimental|Abstainer|Participants view social networking site profiles with alcohol content that references abstaining from alcohol use.
89593777|NCT03159286|Experimental|Abstainer + User|Participants view social networking site profiles with alcohol content that references both abstaining from alcohol use and using alcohol.
89593778|NCT03159286|Experimental|Control|Participants view social networking site profiles with no alcohol content.
89593779|NCT03581890||Danish Colorectal Cancer Group (DCCG.dk) database|The DCCG.dk database is a national population-based, clinical database with a completeness proportion of 99% of all colorectal cancer patients in Denmark. Patients are included in the database if treated for or diagnosed with colorectal cancer at a public surgical department in Denmark. No patients underwent treatment for colorectal cancer at private hospitals in Denmark. Metachronous cancers, recurrence, and tumors of other histological origin than primary adenocarcinoma, mucinous adenocarcinoma, signet ring cell carcinoma, medullary carcinoma, or undifferentiated carcinoma are not registered in the DCCG.dk database. The surgeon prospectively registers perioperative variables such as surgical priority, stent insertion and type of colectomy, and patient related variables. Information on postoperative mortality is imported to the database from the Danish Central Civil Registration Registry linking all Danish residents with a unique identification number.
89593780|NCT03159364|Experimental|Infusion of pathogen-specific CTLs|Repetitive CTL infusions to treat microbial infections
89593781|NCT01871090|Active Comparator|Interrogation with unpaired remote transmitter|Interrogation with an unpaired remote monitoring transmitter for devices that are compatible.
89593782|NCT01871090|No Intervention|Interrogation with programmer|Interrogation with programmer according to usual standard of care
89593783|NCT03159130||receiving lidocaine|Each patient will receive an OnQ pain pump intra-operatively, with attachment to two OnQ catheters inserted on the lateral sides of the abdomen. Each catheter will be infused with 15 cc of 1% lidocaine.
89593784|NCT03159130||receiving injectable saline|Each patient will receive an OnQ pain pump intra-operatively, with attachment to two OnQ catheters inserted on the lateral sides of the abdomen. Each catheter will be infused with 15 cc of injectable saline.
89593785|NCT03158974|Experimental|VIR007|Cream containing 10% East Indian Sandalwood Oil (EISO)/Albuterpenoids
89593786|NCT04142008|Experimental|Walk with Me app|
89593787|NCT05703022|Experimental|Early exercise training|Supervised aerobic interval training (uphill treadmill walking or cycling on an exercise bike 4x4 min at 65-85% of peak heart rate) 3 times weekly.
89593788|NCT03159052|Experimental|SHR3824 Placebo|once daily, 24 weeks
89593789|NCT03159052|Experimental|SHR3824 5 mg|once daily, 52 weeks
89593790|NCT03159052|Experimental|SHR3824 10 mg|once daily, 52 weeks
89593791|NCT03158584|Active Comparator|morphine 2 μg/kg|Children will receive intrathecal morphine 2 μg/kg in 2 ml volume normal saline.
89593792|NCT03158584|Active Comparator|morphine 5 μg/kg|Children will receive intrathecal morphine 5 μg/kg in 2 ml volume normal saline.
89593793|NCT03158584|Active Comparator|morphine 10 μg/kg|Children will receive intrathecal morphine 10 μg/kg in 2 ml volume normal saline.
89593794|NCT03265366|Experimental|ABPA|15 patients with ABPA
88978241|NCT02961634|Experimental|Nailner 2 in 1 + Ciclopirox 8%|"Patients should apply Nailner 2 in 1 daily in the affected nail 2X a day, morning and night for 30 days. After 30 days passed to apply only 1x daily. No need to sand the nail before the application and the product should be applied on the entire nail, including the sides and the area affected by ringworm. Avoiding wett the nail after application and expose the nail.~They should also apply ciclopirox 8% nail polish in the first month of treatment every other day (day in and day out). In the second month applied twice a week. In the third month applied once a week. Apply on the affected nails, previously sanded. On the application of two products, Ciclopirox should be applied between the investigational product applications, e.g., in the middle of the day and the investigational product at the beginning and end of the day in the sun."
88978242|NCT02961634|Active Comparator|Ciclopirox 8%|Patients should also apply ciclopirox 8% nail polish in the first month of treatment every other day (day in and day out). In the second month applied twice a week. In the third month applied once a week. Apply on the affected nails, previously sanded. On the application of two products, Ciclopirox should be applied between the investigational product applications, e.g., in the middle of the day and the investigational product at the beginning and end of the day in the sun.
88978243|NCT02966717|Active Comparator|parallel control of conventional therapy|Intervention of conventional therapy group: controlling blood pressure using amlodipine, valsartan, metoprolol and terazosin and so on , protecting the renal function using bailing capsule, alpha keto acid, low molecular weight heparin and so on.
89031319|NCT03459911|Experimental|Losartan potassium 100 mg Tablets|Losartan potassium is the test product. In period 1 and period 2, 33 of 66 subjects will be given single oral dose (1 x 100 mg) of Losartan potassium.
89593795|NCT03265366|Active Comparator|Severe asthma|12 patients with severe asthma
89593796|NCT03158506|Experimental|[C14]-labelled HMS5552|
89593797|NCT03156712|Experimental|FeSO4|Ferrou sulfate: Each participant was given a one time oral dose of the 10 mg iron as ferrous sulfate with the test meal (described in study design) and serum iron was measured every 30 min for 4 hours.
89593798|NCT03156712|Experimental|ASP Fe (10 mg)|ASP (10 mg Fe): Each participants was given a one time oral dose of ASP containing 10 mg iron. The capsule was consumed with the test meal and serum iron was measured every 30 min for 4 hours.
89031320|NCT03459911|Active Comparator|Cozaar® (Losartan potassium)100 mg Tablets|Cozaar® (Losartan potassium) is the reference product. In period 1 and period 2, 33 of 66 subjects will be given single oral dose (1 x 100 mg) of Cozaar®.
89031321|NCT02945592|Experimental|Intervention|"adaptive, therapeutic cueing during reading tasks~adaptive, therapeutic cueing during visuo spatial tasks"
89031322|NCT02945592|No Intervention|Control|- unspecific neglect treatment
89031323|NCT03459872||Acupuncture Intervention group|RU-Fit gathers measurements of fine motor control were gathered from this group before and after acupuncture treatments.
89031324|NCT03459872||Control/ Non-Intervention|This group received no intervention but still had measurements of fine motor control gathered from RU-Fit medical device.
89031325|NCT03459833|Experimental|group 1|15 patients They will receive a topical anesthetic agent for 30 minutes (Emla cream; lidocaine 25 mg, prilocaine 25 mg, Astra Xeneca, Mississauga, Canada) followed by injection of two prefilled 1 ml syringes with 30 G needle of hyaluronic acid (HA; Teosyal® PureSense Global Action, Teoxane Laboratories, Geneva, Switzerland). After 18 months from the HA injection, cross-over to placebo arm will be done.
89031326|NCT03459833|Placebo Comparator|group 2|They receive by the same method 2 ml saline as a placebo. After one month of the injection, cross-over to HA arm will be done.
89031327|NCT05648487|Experimental|Gastric Cancer With Peritoneal Metastasis, HIPEC, Anti-PD-1 Antibody|"Surgical exploration, if PCI≤20, then we perform this study.~HIPEC: HIPEC is performed after laparoscopic exploration, Mitomycin 30mg/m2, d1, Docetaxel 40mg/m2, d3, Oxaliplatin 65mg/m2, d5 within a week after surgical exploration;~Chemotherapy(SOX) and anti-PD-1 antibody Sintilimab (Tyvyt®) treatment followed (4 cycles): SOX regimen: Oxaliplatin: 130 mg/m^2, IV, d1; S-1, 40-60 mg/m^2 bid, po, day 1-14, every 3 weeks for a total of 4 cycles; Sintilimab (Tyvyt®) 200mg fixed dose every 3 weeks, for a total of 4 cycles.~Surgery: Imaging and secondary surgical exploration, assess the patient's condition and consider whether perform the cytoreductive surgery (resection of primary tumors and metastases ). After the surgery, HIPEC for three cycles, Mitomycin 30mg/m2, d1, Docetaxel 40mg/m2, d3, Oxaliplatin 65mg/m2, d5 within a week after surgery; For inoperable patients, continue to use standard chemotherapy.~After the surgery, continue to use standard adjuvant chemotherapy."
89031328|NCT04695665|Active Comparator|Cervical pain|Only patients with positive Cervical pain syndrome.
89031329|NCT04695665|Active Comparator|Thoracic pain|Only patients with positive Thoracic pain syndrome.
89031330|NCT04695665|Active Comparator|Lumbar pain|Only patients with positive Lumbar pain syndrome.
89031331|NCT00527553|Experimental|A|daily consumption of a regular egg
89031332|NCT00527553|Experimental|B|daily consumption of a lutein-enriched egg, eggs laid by chickens on a lutein-enriched feed.
89031333|NCT00527553|Experimental|C|daily consumtion of a zeaxanthin-enriched egg, eggs laid by chickens on a zeaxantin-enriched feed.
89031334|NCT00527553|Experimental|D|daily egg product from enriched eggs
89031335|NCT00527553|No Intervention|E|control subjects were not blinded as they did not receive any aditional supplementation. Only markers measured during the trial period as a control.
89031336|NCT00511082|Experimental|Treatment group|
89031337|NCT00527670||Normal Controls|Healthy patients undergoing laparoscopic surgery for cholelithiasis, appendicitis, and adrenalectomy.
89031338|NCT00527670||Recurrent Hernia|Patients presenting for laparoscopic repair of ventral or incisional hernias.
89031339|NCT00511160|Active Comparator|S|Study arm: Cardiac surgery group
89031340|NCT00511160|Active Comparator|C|Routine cardiology group
89031341|NCT00528489|Experimental|1|PENNVAX-B with 0.8 mg IL-15 administered in both deltoids at Months 0, 1, 3, and 6
89031342|NCT00528489|Experimental|2|PENNVAX-B administered alone in both deltoids at Months 0, 1, 3, and 6
89031343|NCT00528489|Experimental|3|PENNVAX-B administered alone in both deltoids at Months 0, 1, 3, and 6
89031344|NCT00528489|Experimental|4|PENNVAX-B with 2 mg IL-15 injected into both deltoids at Months 0, 1, 3, and 6
89031345|NCT02953028|Active Comparator|Continuous Positive Airway Pressure|Patients treated With an auto-CPAP-machine which is a compressor Connected to a nose- or face mask which provides increased air pressure, opening the upper Airways during an apnea or hypopnea event.
89031346|NCT02953028|Active Comparator|Mandibular Advancing Splint|Patients treated With a twin block splint (oral appliance) advancing the mandible and thereby opening the upper Airways for easier passage of air during sleep preventing apnea and hypopnea events.
89031347|NCT04692051|Experimental|Nab-paclitaxel + Cisplatin|Patients in this arm receive chemotherapy with Nab-paclitaxel plus Cisplatin
89031348|NCT04692051|Active Comparator|Gemcitabine + Cisplatin|Patients in this arm receive chemotherapy with Gemcitabine plus Cisplatin
89031349|NCT00510029|Other|GAP-134, IV and Oral|Experimental; Active Comparator; Placebo
89031350|NCT00528723|Experimental|A|BDP/salbutamol HFA pMDI
89031351|NCT00528723|Active Comparator|B|BDP/salbutamol CFC pMDI
89031352|NCT00510107|Active Comparator|1|Docetaxel 35 mg/m2 will be administered on days 1 and 8. Cisplatin 60 mg/m2 will be administered on day 1 every 3 weeks.
89031353|NCT00510107|Experimental|2|Docetaxel 35 mg/m2 will be administered on days 1 and 8. Oxaliplatin 120 mg/m2 will be administered on day 1 every 3 weeks.
89031354|NCT00528762||Focus Group|Mexican American or African American females (aged 6-12 years old) and their parents
89031355|NCT03459326||control group|men in relation
89031356|NCT03459326||FIV group|men whose couple taken care of fecundation in vitro
89031357|NCT03459326||ICSI group|men whose couple taken care of intracytoplasmic injection
89031358|NCT03459326||IUI group|men whose couple taken care of intrauterine insemination
89031359|NCT01580514|Active Comparator|Exenatide|"Drug: Exenatide~10 μg subcutaneous and 10 μg intravenously injection of exenatide BYETTA® (Amylin-Lilly) 5 min before the onset of reperfusion. And twice daily 10 μg subcutaneous injection was continued on the following 2 days."
89031360|NCT01580514|Placebo Comparator|Saline|"Drug: Saline~10 μg subcutaneous and 10 μg intravenously injection of equivalent volume of normal saline 5 min before the onset of reperfusion. And twice daily 10 μg subcutaneous injection was continued on the following 2 days."
89031361|NCT00528918|Active Comparator|Apidra|Direct 1:1 comparison of Apidra and Regular insulin.
89031362|NCT00528918|Active Comparator|Regular|Direct 1:1 comparison of Apidra and Regular insulin.
89031363|NCT00510185|Experimental|1|Coronary angiography within 72h and revascularization as clinical indicated
89593799|NCT03156712|Experimental|ASP Fe (20 mg)|ASP (20 mg Fe): Each participant was given a one time oral dose ASP containing of 20 mg iron The capsule was consumed with the test meal and serum iron was measured every 30 min for 4 hours.
89593800|NCT04765228|Experimental|Pegylated liposomal doxorubicin + Anlotinib|Pegylated liposomal doxorubicin 50mg/m2 intravenous infusion on the first day + Anlotinib 12mg/d orally, medication on days 8-21, one cycle every 21 days, 2~4 cycles
89593801|NCT04141540|Other|"Groupe Twin 1"|Twin 1 with psychotic symptoms (PANSS +) Molecular analyses 1
89593802|NCT04141540|Other|"Groupe Twin 2"|Twin 2 without psychotic symptoms (PANSS +) Molecular analyses 2
89593803|NCT04141384|Other|General rehabilitation+Modular Interactive Tiles System, MITS|Subjects were randomly assigned to the experimental or control group after completing the Berg scale test before the experiment. In the experimental group, external stimulation (MITS) was added, and the training time was 65 minutes. Before the start of the experiment and after the training every 4 weeks, each group must carry out the Berg scale and balance assessment.
89593804|NCT04141384|No Intervention|General rehabilitation|Subjects were randomly assigned to the experimental or control group after completing the Berg scale test before the experiment.In the control group, each training time was 45 minutes.Before the start of the experiment and after the training every 4 weeks, each group must carry out the Berg scale and balance assessment.
89593805|NCT04140994|Active Comparator|Intermittent theta burst stimulation|"Volunteers will be submitted to non-invasive parietal stimulation before a mirror drawing task.~A transcranial magnetic stimulator (MagPro X100, Medtronic Functional Diagnostics, Skovlunde, Denmark) will deliver interrmittent bursts of bipolar magnetic pulses exerting an excitation on the underlying brain tissue (iTBS). The stimulation coil will be placed over the parietal cortex. Stimulation consisted of a burst of three pulses administered at 50Hz, repeated at a frequency of 5Hz, delivered in 2 s trains followed by an 8 s interval for a total of 600 pulses12. Stimulation intensity was set at 70% of RMT.~Each session will consist of two spaced neuronavigated iTBS applications, separated by 15 minutes."
89593806|NCT04140994|Sham Comparator|Sham intermittent theta burst stimulation|For sham iTBS, the protocol is the same, except the sham coil produces no magnetic field.
89593807|NCT03158350|Experimental|Stationary Bristle Technique (SBT)|Instructed brushing method. Participants are asked to brush twice daily, for 2 minutes at a time, following instructions for the Stationary Bristle Technique.
89593808|NCT03158350|No Intervention|Non-Stationary Bristle Technique (NSBT)|The control group will be asked to brush twice daily, for 2 minutes at a time, following their normal toothbrushing technique.
89593809|NCT03158428|Experimental|CSD170202AA, CSD170202AB Use Group|Use of product CSD170202AA exclusively for approximately one week (seven days +1/-2 day) prior to a test visit, followed by use of product CSD170202AB exclusively for approximately one week (seven days +1/-2 day) prior to a test visit.
89593810|NCT03158428|Experimental|CSD170202AB, CSD170202AA Use Group|Use of product CSD170202AB exclusively for approximately one week (seven days +1/-2 day) prior to a test visit, followed by use of product CSD170202AA exclusively for approximately one week (seven days +1/-2 day) prior to a test visit.
89593811|NCT04140916|Experimental|Midline catheter|Insertion of a Midline catheter in patients scheduled for insertion of a catheter for intravenous fluids or medicines with an expected length of treatment between 5 and 28 days will
89593812|NCT04140916|Active Comparator|PICC-line catheter|Insertion of a Midline catheter in patients scheduled for insertion of a catheter for intravenous fluids or medicines with an expected length of treatment between 5 and 28 days will
89593813|NCT04140760|Active Comparator|Probiotic|"Thirty five Parkinson's Disease patients group will be randomly assigned to this study arm.~Participants will take the liquid probiotic (Symprove) daily following manufacturers guidelines for a period of 12 weeks."
89593814|NCT04140760|Placebo Comparator|Placebo|"Thirty five Parkinson's Disease patients group will be randomly assigned to this study arm.~Participants will take the liquid placebo daily for a period of 12 weeks following the same guidelines as for the probiotic."
89593815|NCT01818596|Experimental|E/C/F/TAF|Participants will receive E/C/F/TAF for 144 weeks. Following Week 144, in countries where E/C/F/TAF is not available (except for the United Kingdom), participants will be given the option to continue in the study and receive E/C/F/TAF for another 48 weeks, or until the product becomes available through an access program, or until Gilead Sciences elects to discontinue the study in that country, whichever comes first.
89608504|NCT00733330|Other|Conventional TKR arm|Patients to receive treatment with either a P.F.C. Sigma or L.C.S. knee using the conventional manual surgical technique
88978244|NCT02966717|Experimental|experimental group|Intervention of Rituximab combined with mesenchymal stem cells group: as follows, Rituximab, 100mg/time every one week, the infusion should be a total of 4 times; and then after at least 4 days interval after the first and the third infusion of the Rituximab , the dosage of mesenchymal stem cells tends to be 10^6/kg/time every 2 weeks, while the infusion should be a total of 2 times.
88978245|NCT00250510|No Intervention|1|
88978246|NCT00250510|Experimental|2|EatRight Program inquirers with BMI's of 30 kg/m2 or greater were told that they would have the possibility of being reimbursed 50% ($150) of their initial fee ($300) if certain conditions were met.
88978247|NCT00250549|No Intervention|HIV counselor|Patients who tested for HIV and consent to participate in the study receive a posttest educational session with an HIV counselor. Afterwards, patients complete an assessment tool concerning HIV prevention and transmission.
88978248|NCT00250549|Experimental|Post test video|Patients who tested for HIV and consent to participate in the study watch a a 15-minute HIV posttest educational video available in English/Spanish. Afterwards, patients complete an assessment tool concerning HIV prevention and transmission.
88978249|NCT02966639||LDS Patients|All patients with a diagnosis of single-level Lumbar Degenerative Spondylolisthesis who present to the DHMC Spine Center.
88978250|NCT00250744|Experimental|Arm A|
89031364|NCT00510185|Sham Comparator|2|Initially conservative treatment with coronary angiography only for recurrent ischemia
89031365|NCT00515190|Active Comparator|A|(continuous):S-1 plus oxalipatin will be continued until disease progression, unacceptable toxicity or consent withdrawal.
88978251|NCT00250744|Active Comparator|Arm B|
88978252|NCT00068510|Experimental|autologous tumor lysate-pulsed DC|
89593816|NCT03156400|Active Comparator|Parkinson's disease|"Men and women can be included in the study if they are between 50 and 85 years of age and meet the following criteria:~Have received clearance from a primary physician to perform a exercise stress test.~Will be able to walk on a motorized treadmill with supporting harness system. Individual with PD who has recently had a diagnosis of Stage 1 or 2 on the Hoehn and Yahr scale."
89593817|NCT03156400|Active Comparator|Healthy Control|"Men and women can be included in the study if they are between 50 and 85 years of age and meet the following criteria:~Have received clearance from a primary physician to perform a exercise stress test.~Will be able to walk on a motorized treadmill with supporting harness system. Healthy individual with no unresolved cardiovascular, neuromuscular, and/or musculoskeletal disease."
89593818|NCT03158194|Experimental|CBT for anxiety-related asthma|Ten to twelve weekly sessions of CBT targeting enhanced function and decreased symptoms of anxiety.
89593819|NCT03156634|Experimental|PALS|Participants will view materials about the antihypertensive, chlorthalidone on the Patient Activated Learning System (PALS).
89593820|NCT03156634|Active Comparator|WedMD|Participants will view materials about the antihypertensive, chlorthalidone on WebMD.
89593821|NCT04415216||ISR PCI with thin-DES|
89593822|NCT04415216||ISR PCI with DEB|
89593823|NCT03157570|Experimental|Exercise intervention group|The exercise group will participate in a 6-month home exercise along with demonstration videos. The exercise training program is an online 7-minute high-intensity interval training (HIIT) exercise through the integrated application of an exercise provision website and mobile Apps. The program will comprise of a broad range of exercises, applied at varying speeds and directions in order to increase heart rate, and to load a variety of muscle groups and skeletal regions in the upper and lower body. The exercise will be performed 5 days per week with the remaining 2 days as rest days.
89593824|NCT03157570|No Intervention|Control group|The control group have no intervention and receives only standard care.
89593825|NCT03157726|Active Comparator|TUKEP(enucleation of prostate)|"Patients accept TUKEP (transurethral plasmakinetic enucleation of prostate). The TUKEP procedure requires the use of a resectoscope, camera system and irrigation fluid. The system consists of a generator unit and a wire loop with an electrical current running, the beak of resectoscope was used to enucleation of prostate and the bipolar loop was used to cutting and coagulation, There are many manufacturers of Bipolar TURP systems. Any bipolar plasmakinetic system approved by the CFDA (Chinese food and drug administration) may be used for the study.~The bipolar plasmakinetic system was set at 160 W for cutting and 100 W for coagulation."
89593826|NCT03157726|Active Comparator|TURP(resection of prostate)|"Patients accept TURP (transurethral resection of prostate). The TURP procedure requires the use of a resectoscope, camera system and irrigation fluid. The system consists of a generator unit and a wire loop with an electrical current running through the loop used to cut prostate tissue and cauterize. Prostate tissue is cut away in small pieces and removed at the end of the procedure using irrigation. There are many manufacturers of TURP systems. Any monopolar and bipolar loop system approved by the CFDA (Chinese food and drug administration) may be used for the study.~The bipolar plasmakinetic system was set at 160 W for cutting and 100 W for coagulation."
89593827|NCT03156322|Active Comparator|Group 5|5 mL epidural initiation volume (bupivacaine + fentanyl)
89593828|NCT03156322|Active Comparator|Group 10|10 mL epidural initiation volume (bupivacaine + fentanyl)
89593829|NCT03156322|Active Comparator|Group 20|20 mL epidural initiation volume (bupivacaine + fentanyl)
89593830|NCT05682664|Active Comparator|Usual care|Usual care for children with preschool wheeze consist of regular visits to the outpatient clinic every three months after starting the study, while in between these visits contact with the healthcare team is by telephone as needed. At inclusion and at every outpatient clinical visits (e.g. 3, 6, 9 and 12 months), parents/caregivers will be asked to update the healthcare team on disease symptoms by completing a digital version of Test for Respiratory and Asthma Control in Kids (TRACK) questionnaire.
89593831|NCT05682664|Experimental|Luchtbrug Junior (intervention)|Online monitoring via Luchtbrug Junior will replace 50% of the outpatient visits. Children in the intervention group will be monitored online monthly by a digital version of TRACK.
89593832|NCT04140682|Experimental|PAV+ mode|Weaning with PAV+ mode
89593833|NCT04140682|Active Comparator|PSV mode|Weaning with PSV mode
89593834|NCT03156088||Overactive Bladder Patients|"Overactive bladder patients treated with sacral neuromodulator InterStim"
89593835|NCT03021382||severity of calcification|All vessels were divided into tertile groups according to the severity of coronary calcification evaluated by the Agatston score.
89593836|NCT03021382||minimal lumen diameter (MLD) ≥1.0 mm|All lesions were divided according to an MLD ≥1.0 mm, and <1.0 mm by OCT in order to isolate the lesions which an MLD below the OCT catheter size.
89593837|NCT03156166|Experimental|Ambu AuraGain|Ambu AuraGain is inserted in children undergoing general anesthesia. The size of AuraGain is as follows: size 1 for children <5 kg, size 1.5 for 5-10kg, size 2 for 10-20kg, size 2.5 for 20-30kg. Fiberoptic bronchoscope will be performed to measure the distance between the grill and vocal cord.
89593838|NCT03156166|Experimental|I-gel|I-gel is inserted in children undergoing general anesthesia. The size of I-gel is as follows: size 1 for children weighing 2-5kg, size 1.5 for 5-12kg, size 2 for 10-25kg, size 2.5 for 25-35kg. Fiberoptic bronchoscope will be performed to measure the distance between the grill and vocal cord.
89593839|NCT03156166|Experimental|Air-Q intubating laryngeal airway (ILA)|Air-Q ILA is inserted in children undergoing general anesthesia. The size of Air-Q ILA is as follows: size 1 for children between 4-7 kg, size 1.5 for 7-17kg, size 2 for 17-30kg, size 2.5 for 30-50kg. Fiberoptic bronchoscope will be performed to measure the distance between the grill and vocal cord.
89593840|NCT04140058|Active Comparator|group O4|Patients received 4mg ondansetron.
89593841|NCT04140058|Active Comparator|group O6|Patients received 6mg ondansetron.
89593842|NCT04140058|Placebo Comparator|group C|Patients received normal saline.
89593843|NCT03156244||Caucasian|This cohort will consist of 40 white patients who are receiving either radiation or surgery for treatment of their prostate or bladder cancer.
89593844|NCT03156244||African American|This cohort will consist of 40 African American patients who are receiving either radiation or surgery for treatment of their prostate or bladder cancer.
89593845|NCT03157180||Test group|general anesthesia There is allergic reaction during anesthesia Sign informed consent
88978253|NCT04720144||bIMI cases|"Adult (≥ 18 years old) patients with a hematologic malignancy receiving posaconazole prophylaxis (oral tablets or IV administration) for:~i) Induction, consolidation or re-induction chemotherapy for acute leukemia or myelodysplastic syndrome (i.e. expected duration of neutropenia post-chemotherapy of ≥ 10 days) OR ii) Allogeneic hematopoietic stem cell transplant recipients during the post-transplantation phase (100-day post-transplantation) or later in case of intensified immunosuppression for moderate to severe graft vs host disease (GVHD).~AND~iii) Being diagnosed with proven or probable bIMI according to the EORTC-MSGERC classification (10) while on continuous posaconazole prophylaxis for at least 7 days."
88978254|NCT04720144||Controls|"For each bIMI case, we will include 2 control cases fulfilling the following criteria:~i) Receiving continuous posaconazole prophylaxis for at least 7 days~ii) No diagnosis of proven, probable or possible IMI according to EORTC-MSGERC classification (10) during the entire hospital stay"
88978255|NCT00068549|Experimental|Treatment|Patients receive gemcitabine IV over 30 minutes and cisplatin IV over 1 hour on days 1, 8, 15, 22, 29, and 36 in the absence of disease progression or unacceptable toxicity. Patients also undergo external whole pelvis radiotherapy once daily on days 1-5, 8-13, 15-20, 22-27, and 29-34. After completion of external beam radiotherapy, patients undergo intracavitary radiotherapy and parametrial radiotherapy. The total elapsed time for completion of all radiotherapy is not more than 8 weeks.
88978256|NCT04720183|Experimental|Sulfasalazine + GLPG3970|
88978257|NCT00250939|Experimental|1|
88978258|NCT04719871||with posterior vitreous detachment|patient with stage 3 or more of posterior vitreous detachment on optical coherence tomography
88978259|NCT04719871||without posterior vitreous detachment|patient with stage 2 or less of posterior vitreous detachment on optical coherence tomography
89532657|NCT06072781|Active Comparator|Investigator Choice of Treatment (ICT)|"Patients will receive one of the following therapies as determined by the Investigator:~Pegylated liposomal doxorubicin: 40 mg/m2 IV on Day 1 of each 28-day (4 week) cycle.~Paclitaxel: 80 mg/m2 IV on Days 1, 8, and 15 of each 28-day (4 week) cycle.~Topotecan: 4 mg/m2 IV on Days 1, 8, and 15 of each 28-day (4 week) cycle.~Anastrozole: 1 mg, PO, once daily of each 28-day (4 week) cycle.~Letrozole: 2.5 mg, PO, once daily of each 28-day (4 week) cycle."
89532658|NCT06070649|Active Comparator|Group 1|Bolus of 0.3mg/kg/min DMT (5min) + Normal Saline infusion (60 min)
89532659|NCT06070649|Active Comparator|Group 2|Bolus of 0.2 mg/kg/min DMT (5 min) + 0.01mg/kg/min infusion (60 min)
89532660|NCT06070649|Placebo Comparator|Group 3|Bolus of 25 mg Diphenhydramine (5 min) + Normal Saline infusion (60 min)
88978260|NCT00068666|Experimental|radiation + temozolomide|"Patients receive concurrent chemoradiotherapy comprising whole brain radiotherapy daily on days 1-5, 8-13, and 16-21 and oral temozolomide daily on days 1-5. Subsequent treatment with temozolomide repeats every 4 weeks for up to 8 courses in the absence of disease progression or unacceptable toxicity.~Patients are followed every 2 months."
88978261|NCT00103701|Experimental|1|
88978262|NCT00251017|Active Comparator|Vancomycin|Effects of OCT2 genetic variation in renal elimination of Vancomycin
89532661|NCT06069375|Experimental|3.0 g/m2/day QD sodium phenylbutyrate|Up to 8 subjects (4 - ages 10-15 years old and 4 - 16 years of age and older) will be randomized to take 3.0 g/m2/day in one daily dose
89532662|NCT06069375|Experimental|3.0 g/m2/day BID sodium phenylbutyrate|Up to 8 subjects (4 - ages 10-15 years old and 4 - 16 years of age and older) will be randomized to take 3.0 g/m2/day divided into two daily doses taken 12 hours apart
89532663|NCT06069375|Experimental|4.0 g/m2/day BID sodium phenylbutyrate|Up to 8 subjects (4 - ages 10-15 years old and 4 - 16 years of age and older) will be randomized to take 4.0 g/m2/day divided into two daily doses taken 12 hours apart
89532664|NCT06067503|Experimental|Participants with ER/PR+ metastatic lobular breast cancer (LBC)|
89532665|NCT06066359|Experimental|Part A: Cell therapy with NY-ESO-1 TCR/IL-15 NK - INPATIENT|
89532666|NCT06066359|Experimental|Part A2: Cell therapy with NY-ESO-1 TCR/IL-15 NK - OUTPATIENT|
89532667|NCT06066359|Experimental|Part B: Cell therapy with NY-ESO-1 TCR/IL-15 NK - INPATIENT|
89532668|NCT06066359|Experimental|Part B2: Cell therapy with NY-ESO-1 TCR/IL-15 NK - OUTPATIENT|
89532669|NCT06066138|Experimental|Arm 1|Atezolizumab treatment course
89532670|NCT06065748|Experimental|Giredestrant + Investigator's Choice of CDK4/6i|Participants in the experimental arm will receive giredestrant plus the investigator's choice of CDK4/6 inhibitor (CDK4/6i): palbociclib, ribociclib, or abemaciclib.
89532671|NCT06065748|Active Comparator|Fulvestrant + Investigator's Choice of CDK4/6i|Participants in the control arm will receive fulvestrant plus the investigator's choice of CDK4/6 inhibitor (CDK4/6i): palbociclib, ribociclib, or abemaciclib.
89532672|NCT06065540|Experimental|CagriSema 2.4 mg/2.4 mg|Participants will receive once-weekly subcutaneous (s.c) injections of 2.4 mg cagrilintide and 2.4 mg semaglutide for 68 weeks.
89532673|NCT06065540|Experimental|CagriSema 1.0 mg/1.0 mg|Participants will receive once-weekly s.c injections of 1.0 mg cagrilintide and 1.0 mg semaglutide for 68 weeks.
89532674|NCT06065540|Active Comparator|Semaglutide 2.4 mg|Participants will receive once-weekly s.c injection of 2.4 mg semaglutide for 68 weeks.
89532675|NCT06065540|Active Comparator|Semaglutide 1.0 mg|Participants will receive once-weekly s.c injection of 1.0 mg semaglutide for 68 weeks.
89532676|NCT06065540|Active Comparator|Cagrilintide 2.4 mg|Participants will receive once-weekly s.c injection of 2.4 mg cagrilintide for 68 weeks.
89532677|NCT06065540|Placebo Comparator|Placebo 2.4 mg/2.4 mg|Participants will receive once-weekly s.c injection of placebo matched to 2.4 mg cagrilintide and 2.4 mg semaglutide for 68 weeks.
89532678|NCT06065540|Placebo Comparator|Placebo 1.0 mg/1.0 mg|Participants will receive once-weekly s.c injection of placebo matched to 1.0 mg cagrilintide and 1.0 mg semaglutide for 68 weeks.
89532679|NCT06060756||Patients with confirmed Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS) diagnosis|Patients from site's pain unit with confirmed OSAHS diagnosis. OSAHS diagnosis will be made according to standard of care practice in the investigation site, through polysomnography and Epworth Sleepiness Scale (ESS).
89532680|NCT06060067|Experimental|Cohort 1: ≥18 to ≤60 Age Group: TDV|
89532681|NCT06060067|Placebo Comparator|Cohort 1: ≥18 to ≤60 Age Group: Placebo|
89532682|NCT06060067|Experimental|Cohort 2: ≥4 to <18 Age Group: TDV|
89532683|NCT06060067|Placebo Comparator|Cohort 2: ≥4 to <18 Age Group: Placebo|
89210008|NCT04036500|Experimental|Estradiol|Subjects will take estradiol 1 mg orally after time 0 blood draw. They will get 7 blood draws at hours 0,1,2,3,4,6,8. A wash-out period of at least one week will allow for complete clearance of the exogenous oral estradiol before testing the pharmacokinetics of sublingual estradiol on the same ten patients in the same manner. On day 2 of study, subject will take estradiol 1 mg sublingually after time 0 blood draw, supervised by a research team member to ensure proper dissolution. Blood will be drawn at hours 0,1,2,3,4,6,8 as on day 1 of study.
89593846|NCT03157180||Control group|general anesthesia There is no allergic reaction during anesthesia Sign informed consent
89593847|NCT02899078|Experimental|Treatment (ibrutinib, nivolumab)|Patients receive ibrutinib PO QD on days 1-28 and nivolumab intravenously IV over 60 minutes on days 1 and 15. Courses repeat every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
89593848|NCT01670344|Other|A|Treatment with investigational method (virtual implant positioning system)
89593849|NCT01670344|Other|B|Treatment with surgical standard of care
89593850|NCT03155542||colorectal cancer patient case group|Histologically confirmed colorectal adenocarcinoma
89593851|NCT03155542||family member control group|without the diagnosis of CRC and accompanied the patient to the primary care clinic visit
89593852|NCT04747444|Other|100% body weight walking|Individuals with knee osteoarthritis will walk 45 minutes on a treadmill at 100% full body weight loading
89593853|NCT04747444|Other|50% body weight walking|Individuals with knee osteoarthritis will walk 45 minutes on a treadmill at 50% full body weight loading
89593854|NCT04764760|Other|Phase 1:Study role tissue tensile strength|The tensile strength of the orifice of Frauchad was augmented by implantation of a Accordion fold shaped prosthesis.
89593855|NCT04764760|Other|Phase 2:Curative implantation of a custom designed bio-mechanically compatible Tensiflex prosthesis|The wing shaped custom designed tensiflex prosthesis in the groin was impanted as a curative technique since it provided seamless augmenation of the tensile tissue strength.
89593856|NCT01670734|Experimental|alirocumab SAR236553 (REGN727) - mild hepatic function|Injection through subcutaneous (SC) administration in patients with mild hepatic function
89593857|NCT01670734|Experimental|alirocumab SAR236553 (REGN727) - moderate hepatic function|Injection through subcutaneous (SC) administration in patients with moderate hepatic function
89593858|NCT01670734|Experimental|alirocumab SAR236553 (REGN727) - normal hepatic function|Injection through subcutaneous (SC) administration in patients with normal hepatic function
89593859|NCT03155776||GUS_infants|Infants patient undergoing general anesthesia for abdominal surgery
89593860|NCT03155464|Other|Group 1|"Order of two elements of surgical procedure: patients in group 1 will receive sympathectomy prior to bypass during the surgical procedure.~Indocyanine Green (ICG) will be used in both groups."
89593861|NCT03155464|Other|Group 2|"Order of two elements of surgical procedure: Patients in group 2 will receive bypass prior to sympathectomy during the surgical procedure.~Indocyanine Green (ICG) will be used in both groups."
89593862|NCT01670890|Active Comparator|TMZ group|patients were treated with TMZ alone
89593863|NCT01670890|Experimental|TMZ plus CDDP group|patients were treated with TMZ plus CDDP
89593864|NCT01671046||Cohort|
89593865|NCT01676428|Experimental|Radiotherapy|"The interventional treatment will be prescribed as a 2-tiered dose scheduled dependant of target size.~For lesions <5cm, a single fraction of 26 Gy will be prescribed. For lesions ≥5cm a fractionated course of 15Gy by 3 fractions will be prescribed, delivered at least 48 hours apart."
89593866|NCT04577794|Experimental|GLPG3970|Participants received 400 milligrams (mg) GLPG3970 oral solution, once daily (QD) for a period of 6 weeks.
89593867|NCT04577794|Placebo Comparator|Placebo|Participants received GLPG3970 matching placebo oral solution, QD for a period of 6 weeks.
89593868|NCT04551196|Active Comparator|Alternating Regimen|A regimen of acetaminophen and ibuprofen alternating doses every 3 hours.
89593869|NCT04551196|Active Comparator|Combined Regimen|A regimen of acetaminophen and ibuprofen dosed together every 6 hours.
89593870|NCT03155152|Experimental|DECT Group|"The DECT session consists of four bouts of 4 min high-intensity decremental exercise with 3 min of active recovery between bouts. Load is progressively decreased throughout each exercise bout. The training period will last for a total of 4 weeks, with three weekly sessions of supervised training"
89593871|NCT03155152|Active Comparator|HIIT Group|"The HIIT session consists of four bouts of 4 min high-intensity decremental exercise with 3 min of active recovery between bouts. Load is kept constant throughout each exercise bout. The training period will last for a total of 4 weeks, with three weekly sessions of supervised training"
89593872|NCT01671124||Soline capsule|Salvia divinorum, Lycium, Chenpi and Dihuang
89593873|NCT04764838|Experimental|Intervantion|Pregnant Yoga
89593874|NCT04764838|No Intervention|Control|The clinic will receive routine care
89593875|NCT01923298|Experimental|Estradiol|ESTRING® (estradiol vaginal ring) is a slightly opaque ring with a whitish core containing a drug reservoir of 2 mg estradiol. Estradiol, silicone polymers and barium sulfate are combined to form the ring. When placed in the vagina, ESTRING releases estradiol, approximately 7.5 mcg per 24 hours, in a consistent stable manner over 90 days.
89593876|NCT03155386||Standard Angiomammography (SenoBright®)|
89593877|NCT03155386||Optimized angiomammography|
89593878|NCT01671436|Experimental|Central Meditation and Imagery Therapy|Intervention involved Central Meditation, may be characterized by a voluntary, regulated attentional set towards a specific stimulus or set of stimuli and visualization exercises utilized within CMIT, which primarily involves two types of thought experiments: 1) creating mental models of how a person fits into the larger world and universe according to evolutionary biology and modern cosmology, in order to gain a larger perspective on emotions and thought patterns, and 2) backcasting, the generation of a desirable future coupled with mental time travel back to the present to determine how to create that future with present-day actions.
88978263|NCT00251056|Active Comparator|1|
88978264|NCT00251056|Active Comparator|2|
88978265|NCT00251056|Active Comparator|3|
88978266|NCT00251056|Active Comparator|4|
88978267|NCT00251095|Active Comparator|Taxol|Taxol 80mg/m2/week
88978268|NCT00251095|Experimental|TOCOSOL|TOCOSOL Paclitaxel
88978269|NCT00251134|Active Comparator|1|omega-3-acid ethyl ester 90
88978270|NCT00251134|Placebo Comparator|2|olive oil
89210009|NCT00895596|Experimental|LB80380 30mg|LB80380 30mg
89210010|NCT00895596|Experimental|LB80380 60mg|LB80380 60mg
89593879|NCT01671514|Experimental|Sedentary|The sedentary arm will be randomly assigned to either epicatechin-enriched dark chocolate or low-epicatechin dark chocolate as a placebo. Participants will take one square of chocolate per day for 90 days.
89593880|NCT01671514|Experimental|Heart failure/diabetes|The heart failure/diabetes arm will be randomly assigned to either epicatechin-enriched dark chocolate or low-epicatechin dark chocolate as a placebo. Participants will take one square of chocolate per day for 90 days.
89593881|NCT05196022||G1|Patients with bilateral severe to profound hearing loss that would qualify for reimbursement of en cochlear implant but will not opt for a cochlear implant.
89593882|NCT05196022||G2|Patients with bilateral severe to profound hearing loss that would qualify for reimbursement of en cochlear implant and receive a cochlear implant
89593883|NCT05196022||G3|Patients with a single-sided deafness in an acute setting
89593884|NCT05196022||G4|Patients with a single-sided deafness in a chronic setting
89593885|NCT01671592|Experimental|Day 1 MRI with low dose vaccine|DC vaccine at 3 x 10e6 per course which consists of 3 daily intradermal doses per course with the MRI on day 1 of the course.
89593886|NCT01671592|Experimental|Day 3 MRI with low dose vaccine|DC vaccine at 3 x 10e6 per course which consists of 3 daily intradermal doses per course with the MRI on day 3 of the course.
89593887|NCT01671592|Experimental|Day 1 MRI with high dose vaccine|DC vaccine at 3 x 10e7 per course which consists of 3 daily intradermal doses per course with the MRI on day 1 of the course.
89593888|NCT01671592|Experimental|Day 3 MRI with high dose vaccine|DC vaccine at 3 x 10e7 per course which consists of 3 daily intradermal doses per course with the MRI on day 3 of the course.
89593889|NCT04402606|Experimental|Evaluation on skin toxicities|This evaluation consists on a clinical examination of the skin and the realization of the cutaneous measurements of reference on 4 sites frequently exposed to the cutaneous toxicities: face, neckline, palms of the hands and soles of the feet.
89593890|NCT05617768||• Cardiac anesthesiologists • Cardiac intensivists • Cardiothoracic surgeons|"Anesthesia department, Cairo university hospitals, kasr al-ainy.~Cardiothoracic thoracic surgery department, Cairo university hospitals, kasr al-ainy.~Anesthesia department, National Heart Institute.~Cardiothoracic surgery department, National Heart Institute."
89593891|NCT01671670|Experimental|acupuncture group|use traditional acupuncture to treat functional dyspepsia
89593892|NCT01671670|Sham Comparator|sham acupuncture group|use penetrating sham acupuncture to manage functional dyspepsia
89593893|NCT03154840|Experimental|Eutropin 4IU|
89593894|NCT03154840|Experimental|Eutropin AQ 12IU|
89593895|NCT03154840|Experimental|Eutropin Pen 36IU|
89593896|NCT04404790|Experimental|Anfibatide 5 IU/60kg|Ten subjects will injected with the dose of 5 IU/60kg of Anfibatide with 5 minutes.
89593897|NCT04404790|Experimental|Anfibatide 5 IU/60kg+0.002 IU/kg/h|Four or fourteen subjects will injected with the dose of 5 IU/60kg of Anfibatide with 5 minutes follow by the dose of 0.002 IU/kg/h continuous intravenous infusion with 48 hours.
89593898|NCT04404790|Experimental|Anfibatide 5 IU/60kg+0.004 IU/kg/h|Four or fourteen subjects will injected with the dose of 5 IU/60kg of Anfibatide with 5 minutes follow by the dose of 0.004 IU/kg/h continuous intravenous infusion with 48 hours.
89593899|NCT04404790|Experimental|Anfibatide 5 IU/60kg+0.008 IU/kg/h|Four or fourteen subjects will injected with the dose of 5 IU/60kg of Anfibatide with 5 minutes follow by the dose of 0.008 IU/kg/h continuous intravenous infusion with 48 hours.
89593900|NCT04404790|Experimental|Anfibatide 7 IU/60kg|Ten subjects will injected with the dose of 7 IU/60kg of Anfibatide with 5 minutes.
89593901|NCT04404790|Experimental|Anfibatide 7 IU/60kg+0.002 IU/kg/h|Four or fourteen subjects will injected with the dose of 7 IU/60kg of Anfibatide with 5 minutes follow by the dose of 0.002 IU/kg/h continuous intravenous infusion with 48 hours.
89593902|NCT04404790|Experimental|Anfibatide 7 IU/60kg+0.004 IU/kg/h|Four or fourteen subjects will injected with the dose of 7 IU/60kg of Anfibatide with 5 minutes follow by the dose of 0.004 IU/kg/h continuous intravenous infusion with 48 hours.
89593903|NCT04404790|Experimental|Anfibatide 7 IU/60kg+0.008 IU/kg/h|Four or fourteen subjects will injected with the dose of 7 IU/60kg of Anfibatide with 5 minutes follow by the dose of 0.008 IU/kg/h continuous intravenous infusion with 48 hours.
89593904|NCT03154762|Experimental|NIPPV|Patients will receive NIPPV with an S bilevel device during 4 nights, the equipment will be placed ad libitum, a 12 cmH2O inspiratory pressure and a 4 cmH2O expiratory pressure will be administered through a nasal mask. CRP, FEV1, exhaled fraction of nitric oxide, IL-4, IL-5, IL-13, IL-17, IgE, cell count will be measured before and after intervention.
89593905|NCT03154762|Sham Comparator|CPAP|Patients will receive a 4 cmH2O continuous positive airway pressure device during 4 nights; this is the minimum pressure necessary to avoid death space with no effect on minute ventilation. The equipment will be placed ad libitum. Pressure will be administered through a nasal mask. CRP, FEV1, exhaled fraction of nitric oxide, IL-4, IL-5, IL-13, IL-17, IgE, cell count will be measured before and after sham intervention.
88978271|NCT00251173|Active Comparator|Strengths Based Case Management Model (SBCM)|The Strengths Based Case Management Model (SBCM) consists of 5 case-management sessions designed to promote linkage and engagement in assessment and treatment services, while assisting with the patient's perceived needs, as well as personal strengths and barriers to linkage and engagement.
88978272|NCT00251173|Active Comparator|Motivational Enhancement Therapy (MET)|The MET therapist will conduct 2 motivational enhancement sessions to work through the content of an educational workbook targeting the participant's substance use/abuse with the goal of negotiating a 'contract' to: 1) link to services, with the eventual goal of seeking and receiving specialized substance treatment; or 2) provide a strategy to self-monitor substance use, consider consequences, and later seek assessment.
88978273|NCT00251173|Active Comparator|Brief Informational Feedback (BIF) session|Subjects will receive brief informational feedback on the results of their alcohol screening and assessment and encouragement to seek treatment.
88978274|NCT00251212|Active Comparator|1|Therapist delivered adapted motivational enhancement therapy and skills training
89210011|NCT00895596|Experimental|LB80380 90mg,|LB80380 90mg
89210012|NCT00895596|Experimental|LB80380 150mg|LB80380 150mg
89593906|NCT03154918|Experimental|GLIDE|Treated with GLIDE regiment chemotherapy for 4 cycles.
89593907|NCT01671904|Experimental|1L CLL BR+V|Participants with first-line (1L)/previously untreated CLL were administered escalating doses of venetoclax (V) in combination with fixed dose bendamustine and rituximab (BR). Participants received six 28-day cycles of BR+V. Participants with 1L CLL received 6 months of single-agent venetoclax for a total of 1-year treatment duration. Single-agent venetoclax could be extended if there was detectable minimal residual disease (MRD) in the bone marrow and/or partial response (PR) after 1 year of treatment and upon the request of the treating physician.
89593908|NCT01671904|Experimental|1L CLL BG+V|Participants with first-line (1L)/previously untreated CLL were administered escalating doses of venetoclax (V) in combination with fixed dose bendamustine and obinutuzumab (BG). Participants received six 28-day cycles of BG+V. Participants with 1L CLL received 6 months of single-agent venetoclax for a total of 1-year treatment duration. Single-agent venetoclax could be extended if there was detectable minimal residual disease (MRD) in the bone marrow and/or partial response (PR) after 1 year of treatment and upon the request of the treating physician.
89593909|NCT01671904|Experimental|R/R CLL BR+V|Participants with relapsed/refractory (R/R) CLL were administered escalating doses of venetoclax (V) in combination with fixed dose bendamustine and rituximab (BR). Participants received six 28-day cycles of BR+V. Participants with R/R CLL continued single-agent venetoclax until disease progression, death, or unacceptable toxicity.
89593910|NCT03154684|Active Comparator|STARK intervention|New care concept for hip fracture patients
89593911|NCT03154684|Other|Standard Care|Swiss standard of care for hip fracture patients
89593912|NCT03732118||Minimal hepatic encephalopathy|
89593913|NCT03732118||No hepatic encephalopathy (minimal or clinical)|
89593914|NCT01672138|Active Comparator|Control|Pulmonary Vein Antrum Isolation (PVAI) + isolation of left atrial posterior wall
89593915|NCT01672138|Active Comparator|Study I|PVAI+ scar homogenization
89593916|NCT01672138|Active Comparator|Study II|PVAI + isolation of left atrial posterior wall + non-PV triggers ablation
89593917|NCT04074850||TBI group|"A cohort of patients admitted to UZ Leuven from 1999 to 2019 due to Traumatic Brain Injury and fulfilling our inclusion and exclusion criteria will be recruited.~Inclusion criteria will be: ≥ 65 years old at the time of the accident, admitted to UZ Leuven from 1999 and 2019, all injury severities, classified by the Glasgow Coma Scale (GCS) (mild (GCS 13-15), moderate (GCS 9-12) or severe (GCS ≤8)), and having signed the informed consent to participate in the study.~Exclusion criteria will be: < 65 years old, admitted to UZ Leuven in a different period from 1999-2019, diagnosis of other neurodegenerative diseases before the TBI, cognitive and motor disturbances caused by any other pathology before the TBI, previous alcohol/drugs abuse, and not having signed the informed consent to participate in the study."
89593918|NCT03154450|Experimental|Data available to team|Encore Anywhere will be installed and available for review by the clinical team
89593919|NCT03154450|Active Comparator|No Data available to team|Encore Anywhere will be installed but the data collected will not be available to the clinical team
89593920|NCT04027894|Experimental|Rifamycin SV MMX plus ORT|Each tablet contains 200mg Rifamycin SV MMX for oral administration
89593921|NCT04027894|Placebo Comparator|Placebo tablets plus ORT|Placebo tablets identical to Rifamycin tablets with respect to size, taste and appearance.
89593922|NCT01672216|Experimental|Triple Target Treatment|In the 3T arm, patients were stimulated with a carrier wave of 25 KHz and biphasic modulations of the pulse train of 40 Hz. Anxious patients trained at first only in the biofeedback mode. The stimulation was introduced after four weeks for these patients. Patients were instructed to carry out the training at home, with an alternating combination in the morning and with EMG-triggered stimulation in the evening, each for 20-minute periods. Apart from this, the protocol of the active treatment group was identical to that of the control group.
89593923|NCT01672216|Active Comparator|EMG-biofeedback alone|In the biofeedback arm, patients were instructed to carry out EMG-biofeedback training at home, standing, mornings and evenings, for 20-minute periods. The core of the task was to pull the plug-electrode upward inside the anal channel, like a lift, and to hold it there during varying periods of tension. This can only be done successfully if the perineum rises and at the same time the puborectal muscle is activated. Just squeezing the sphincter muscles does not produce this lifting effect.
89593924|NCT03154216|Experimental|Exercise only|90 minutes of exercise
89593925|NCT03154216|Experimental|Exercise and high glycemic index drink|90 minutes of exercise followed by consumption of high-glycemic index Gatorade drink matched for calories expended during the exercise
89593926|NCT03154216|Experimental|Exercise and low glycemic index drink|90 minutes of exercise followed by consumption of low-glycemic index milk drink matched for calories expended during the exercise
89593927|NCT03154216|No Intervention|No exercise and no beverage|No exercise and no beverage
89593928|NCT03977272|Active Comparator|Chemotherapy group|Treatment with modified-FOLFIRINOX Folic acid 400mg/m^2, 5- fluorouracil 2400mg/m^2 for 46h, irinotecan 135mg/m^2 and oxaliplatin 68mg/m^2
89593929|NCT03977272|Experimental|Combination group|Treatment with modified-FOLFIRINOX and Anti-PD-1 antibody Folic acid 400mg/m^2, 5- fluorouracil 2400mg/m^2 for 46h, irinotecan 135mg/m^2 and oxaliplatin 68mg/m^2, Anti-PD-1 antibody 200mg.
89210013|NCT00895596|Experimental|LB80380 240mg|LB80380 240mg
89210014|NCT00901056|Active Comparator|Treated Group|This group will receive actual shockwave treatment
89593930|NCT03154528||healthy control group|serum level of Vitamin D is going to be checked by ELISA in 30 healthy control volunteers
89593931|NCT03154528||case study group|serum level of Vitamin D is going to be checked by ELISA in 60 Androgenetic Alopecia patients.
89593932|NCT03947398|Experimental|Treatment with BLIMP first|
89593933|NCT03947398|Active Comparator|Treatment with low-profile balloon first|
89593934|NCT01672372|Placebo Comparator|Placebo Max Stress B|oil/water emulsion with food coloring to simulate actual product
89210015|NCT00895674||Group 1|
89210016|NCT00892944|Experimental|1|AZD2516
89210017|NCT04035330|Experimental|etidronate in sodium hypochlorite|It comes in a capsule containing 0.9 g of etidronate powder, which should be mixed immediately with 10 mL of a NaOCl solution of choice directly before treatment, resulting in a combined irrigant containing both active chlorine and approximately 9% etidronate. Irrigation with a total volume of 25 ml for each case
89593935|NCT01672372|Experimental|Max Stress B|whole-nutrient natural source extract from probiotic colonies that contains vitamins B1, B2, B5, B6, B12, and folate, PABA, biotin, inositol, purified water and certified organic alcohol.
89593936|NCT03154372|Other|deliberate practice|expert supervised practice with validated metrics
89593937|NCT03154372|Other|self-guided practice|self guided practice with validated metrics
89593938|NCT03154294|Experimental|Cohort 1|Paclitaxel 60mg/m2 Day 1, Day 8, Day 15 TAK-228 2mg Days 2-4, Days 9-11, Days 16-18, Days 23-25 TAK-117 100mg Days 2-4, Days 9-11, Days 16-18, Days 23-25
89593939|NCT03154294|Experimental|Cohort 2|Paclitaxel 60mg/m2 Day 1, Day 8, Day 15 TAK-228 2mg Days 2-4, Days 9-11, Days 16-18, Days 23-25 TAK-117 200mg Days 2-4, Days 9-11, Days 16-18, Days 23-25
89031366|NCT00515190|Active Comparator|B|(intermittent arm): Treatment will be stopped after the initial 6 cycles of S-1 plus oxaliplatin, and then S-1 plus oxaliplatin will be resumed at the disease progression during follow-up, as the same dose as the last chemotherapy of initial 6 cycles.
89210018|NCT04035330|Active Comparator|sodium hypochlorite|irrigation with 2.5% NaOCl with a total volume of 25 ml for each case
89593940|NCT03154294|Experimental|Cohort 3|Paclitaxel 80mg/m2 Day 1, Day 8, Day 15 TAK-228 2mg Days 2-4, Days 9-11, Days 16-18, Days 23-25 TAK-117 200mg Days 2-4, Days 9-11, Days 16-18, Days 23-25
89593941|NCT03154294|Experimental|Cohort 4|Paclitaxel 80mg/m Day 1, Day 8, Day 15 TAK-228 3mg Days 2-4, Days 9-11, Days 16-18, Days 23-25 TAK-117 200mg Days 2-4, Days 9-11, Days 16-18, Days 23-25
89593942|NCT03154294|Experimental|Cohort 5|Paclitaxel 80mg/m2 Day 1, Day 8, Day 15 TAK-228 4mg Days 2-4, Days 9-11, Days 16-18, Days 23-25 TAK-117 200mg Days 2-4, Days 9-11, Days 16-18, Days 23-25
89593943|NCT03154606|Experimental|HP-Beverage Breakfast|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to ~250 kcal. The meals will include the same fat content but will vary in protein source. All ingredients are GRAS listed and approved. All participants will complete all 12 interventions.
89593944|NCT03154606|Active Comparator|Carbohydrate Control|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to ~250 kcal. The meals will include the same fat content but will primarily as carbohydrates as a control. All ingredients are GRAS listed and approved. All participants will complete all 12 interventions.
89593945|NCT01672450|Experimental|All patients|All participants in this study will receive the same treatment.
89593946|NCT01672528||Cardiac arrhythmia patients|Patients with cardiac arrhythmias consented to and awaiting a cardiac ablation procedure or post ablation.
89593947|NCT03154060|Experimental|Intervention|Using 3 Abbott FreeStyle Libre Flash Glucose Monitoring sensors in parallel and measure 7 times a day BG by capillary finger stick testing.
89593948|NCT01854268|Experimental|Healthy adults who receive capsaicin|Single treatment consisting of healthy adults.
89593949|NCT01672606|Experimental|Rocuronium|Intravenous infusion of rocuronium with the goal of TOF 0.70 and >0.90
89593950|NCT01594281|Experimental|Ranibizumab mono|Interventional Core Phase: One intravitreal injection of ranibizumab 0.5 mg to the study eye monthly until stability regarding morphological parameters is confirmed (ie, no further improvement of morphology or no worsening of morphology for 3 consecutive months)
89593951|NCT01594281|Active Comparator|PRP mono|Interventional Core Phase: Panretinal laser photocoagulation (PRP) treatment administered to the study eye in accordance with the modified diabetic retinopathy study (DRS) guidelines for panretinal laser photocoagulation procedures
89593952|NCT01594281|Experimental|Ranibizumab+PRP|Interventional Core Phase: Ranibizumab 0.5 mg as described for the ranibizumab mono arm and PRP treatment as described for the PRP mono arm until stability regarding morphological parameters is confirmed
89593953|NCT05025124||Method comparison|400 samples to be compared directly against the reference method. This is to get the bias estimate.
89593954|NCT05025124||Precision|30 samples will be each split into 10 individual samples to evaluate the precision of the Entia Liberty devices.
89593955|NCT04764526|Experimental|Protein-enriched ice cream|Two protein-enriched ice cream daily (afternoon and evening) in two days in addition to the normal menu
89593956|NCT04764526|No Intervention|Control|Standard menu in two days
89593957|NCT05565820|Experimental|Vamousse Spray 'n' Go|Clinical staff will apply Vamousse Spray 'n' Go during the baseline visit (Day 0) to fully coat the hair and scalp. The treatment will be left on for 8 hours, then standard at home shampoo will be used and rinsed off with warm water, followed by combing. At day 7, if live lice are still present, a repeat treatment will be administered.
89593958|NCT05565820|Active Comparator|Nix Creme Rinse Lice Treatment|During the baseline visit (Day 0) clinical staff will first shampoo the hair and scalp using regular shampoo. They will then thoroughly rinse and towel dry the hair and scalp, and allow hair to air dry for a few minutes. Staff will shake Nix Creme Rinse Lice Treatment (1% permethrin lotion) well before applying, they will then proceed to thoroughly wet the hair and scalp with the lotion, being sure to cover the areas behind the ears and on the back of the neck. After allowing the lotion to remain in place for 10 minutes, they will rinse the hair and scalp thoroughly and dry with a clean towel. At day 7, if live lice are still present, a repeat treatment will be administered.
89593959|NCT03153904|Experimental|MATCH Training plus MATCH Consultation|Therapists at local, community clinics attend a 6-day training on the Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, and Conduct Problems (MATCH; Chorpita & Weisz, 2009). After the training, therapists participate in weekly consultation meetings that are led by a MATCH Consultant from the study team. MATCH Consultants review sessions and the clinical monitoring and feedback system, provide recommendations for upcoming sessions, and review MATCH modules via role-plays and models.
89593960|NCT03153904|Active Comparator|MATCH Training only|Therapists at local, community clinics attend a 6-day training on the Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, and Conduct Problems (MATCH; Chorpita & Weisz, 2009). After the training, therapists use MATCH as they think best and receive supervision from supervisors at the clinic.
89593961|NCT01566981|Experimental|Diabetes with ICT support (E-diabetes)|The group of randomly selected patients with DM type II, who will get the software application and web- based support Intervention: Computerised support to the Diabetes type II patients
89593962|NCT01566981|No Intervention|Diabetes without support|The group of randomly selected patients with DM type II, without software application and web-based support.
89593963|NCT01672684|Experimental|Arm I (experimental arm)|Participants complete at-home group video calling sessions for 1 1/2 hours once weekly for 8 weeks.
89593964|NCT01672684|Active Comparator|Arm II (control arm)|Participants receive an educational workbook journal.
88978275|NCT00251212|Active Comparator|2|Computer delivered adapted motivational enhancement therapy and skills training
88978276|NCT00251212|No Intervention|3|3: Control brochure
89210019|NCT02540694|Active Comparator|EBUS-TBNA using 22G needle|EBUS-TBNA using 22G needle (transbronchial route)
89593965|NCT01870778|Experimental|Serelaxin (RLX030)|Participants received continuous intravenous infusion of serelaxin 30 ug/kg/day for 48 hours.
89593966|NCT01870778|Placebo Comparator|Placebo|Participants received continuous intravenous infusion of matching placebo to serelaxin for 48 hours.
89593967|NCT05496322|Experimental|cNIBP|Continuous non invasive blood pressure monitor (Volume clamp)
89593968|NCT05496322|Active Comparator|iNIBP|Intermittent Non Invasive Blood Pressure (Brachial Cuff)
89210020|NCT02540694|Active Comparator|EBUS-TBNA using 25G ProCore needle|EBUS-TBNA using 25G ProCore needle (transbronchial route)
89210021|NCT02540694|Active Comparator|EUS-B-FNA using 22G needle|EUS-B-FNA using 22G needle (transoesophageal route)
89532684|NCT06059625|Experimental|DOUBLE-ROW|rotatori cuff repair with double-row suture bridge technique
88978277|NCT00068783|Experimental|Treatment|Patients receive oral imatinib mesylate once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression, unacceptable toxicity, or symptomatic deterioration.
88978278|NCT00103779|Experimental|1|
88978279|NCT00251407|Experimental|taxotere, cisplatin, irinotecan|
88978280|NCT02966522|Experimental|Thalidomide|Patient with cardiac amyloidosis receive thalilomide with dexamethasone
88978281|NCT00251602|Experimental|1|II ACE genotype
88978282|NCT00251602|Experimental|2|ID ACE genotype
89532685|NCT06059625|Active Comparator|SINGLE-ROW|rotatori cuff repair with single-row technique
89532686|NCT06058377|Experimental|Step 1 (MammaPrint testing)|Patients without a known MP2 score undergo MammaPrint testing on a previously-collected tissue sample. Patients with MP2 score proceed to STEP 2.
89532687|NCT06058377|Active Comparator|Step 2, Arm 1 (chemotherapy)|"Patients receive paclitaxel IV over 30-60 minutes on days 1 and 8 of each cycle. Treatment repeats every 14 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive doxorubicin IV and cyclophosphamide IV over 30 minutes on day 1 of each cycle. Treatment repeats every 14 days for 4 cycles in the absence of disease progression or unacceptable toxicity.~Patients also undergo mammography during screening (STEP 1). Patients have the option to also undergo collection of tumor tissue during initial biopsy (STEP 1) and at SOC surgery, and undergo collection of blood samples prior to STEP 2 treatment, after cycle one of chemotherapy, and one month post-SOC surgery."
89210022|NCT02540694|Active Comparator|EUS-B-FNA using 25G ProCOre needle|EUS-B-FNA using 25G ProCOre needle (transoesophageal route)
89593969|NCT04964050|Experimental|Treatment sequence TRR|Participants will receive Capozide (T) in period 1 followed by ACE-Hemmer-Ratiopharm (R) in period 2 followed by ACE-Hemmer-Ratiopharm (R) in period 3.
89593970|NCT04964050|Experimental|Treatment sequence RTR|Participants will receive ACE-Hemmer-Ratiopharm (R) in period 1 followed by Capozide (T) in period 2 followed by ACE-Hemmer-Ratiopharm (R) in period 3.
89593971|NCT04964050|Experimental|Treatment sequence RRT|Participants will receive ACE-Hemmer-Ratiopharm (R) in period 1 followed by ACE-Hemmer-Ratiopharm (R) in period 2 followed Capozide (T) by in period 3.
89593972|NCT03541330|Other|siblings|Brother or sister of a child has malignant haemopathy and follow-up in the pediatric hematology department
89593973|NCT03526900|Experimental|Atezolizumab|Induction phase: atezolizumab will be given intravenously (iv) at a dose of 1200 mg for 60 minutes on day 1 of each cycle. Subsequent atezolizumab cycles may be administered for 30 minutes, if there were no perfusion-related toxicity. Pemetrexed will be administered at a dose of 500 mg/m2 IV for 15 minutes on day 1 of each cycle. In addition, folic acid, vitamin B12, and dexamethasone 4 mg will be given the day before and the day after treatment with pemetrexed. Carboplatin will be given at a dose with an area under the 5 curve for 30 minutes on day 1 of each cycle, approximately 30 minutes after the pemetrexed infusion is complete. After completing 4 to 6 cycles of Carboplatino plus pemetrexed and atezolizumab, patients will continue with pemetrexed in combination with atezolizumab (maintenance phase) until they have an unacceptable toxicity, progression of the disease, decision of the patient/physician or have Completed 2 years of treatment.
89593974|NCT03427294||Care providers involved in lumbar arthrodesis|surgeons, physiotherapists, behavioral therapists, researchers, occupational therapists
89593975|NCT03420742|Experimental|Midazolam 3 mg + Brigatinib 90 mg|Midazolam 3 mg, orally, once on Day 1, followed by brigatinib 90 mg, orally, once daily on Days 2 to 8, further followed by brigatinib 180 mg, orally, once daily on Days 9 to 28 in Part A Cycle 1 (28 days treatment cycle). Participants escalating to brigatinib 180 mg once daily will also receive midazolam 3 mg, orally, once on Day 21 of Part A Cycle 1. After completion of Part A, participants will continue into Part B. Participants in Part B will receive brigatinib up to 180 mg (or at the highest tolerated dose in Part A), orally, once daily in a 28 day treatment cycle, up to a maximum of 23 cycles or until progression of disease, unacceptable toxicity, or another discontinuation criterion is met.
89593976|NCT01672840|Experimental|5g Cocoa Consumption|Daily consumption of 10g Extra Dark cholocate and a beverage containing 2.5g of cocoa powder for 8 weeks
89593977|NCT01672840|Experimental|10g Cocoa Consumption|Daily consumption of 20g Extra Dark cholocate and two beverage containing 2.5g of cocoa powder each for 8 weeks
89593978|NCT02370706|Experimental|Dose Escalation Arm 1|
89593979|NCT02370706|Experimental|Dose Escalation Arm 2|
89593980|NCT02370706|Experimental|Dose Escalation Arm 3|
89593981|NCT02370706|Experimental|Dose Expansion Arm 1|
89593982|NCT02370706|Experimental|Dose Expansion Arm 2|
89593983|NCT02370706|Experimental|Dose Expansion Arm 3|
89593984|NCT01818284|Experimental|Filgrastim + Plerixafor|"Each donor receives Filgrastim 5 µg/kg subcutaneously in the morning daily for 4 days. The dose of Filgrastim based on the donor's actual body weight. Donors will continue Filgrastim until completion of apheresis. Each donor receives Plerixafor 240 µg/kg subcutaneously in the evening on the fourth day of Filgrastim mobilization. The dose-volume of Plerixafor based on the donor's actual body weight. Apheresis procedure to start the morning of day 5, approximately 10 to 11 hours after the administration of Plerixafor. The apheresis procedure will start in the morning of day 5, approximately 10 to 11 hours after the administration of Plerixafor.~The apheresis procedure may continue beyond day 1 until the target dose of 4x106 cluster of differentiation 34 (CD34+) cells/kg (recipient's weight) is obtained."
89593985|NCT02081014|Experimental|G-Pen Mini™ (glucagon injection) 75 ug|G-Pen Mini™ (glucagon injection), two 75 microgram subcutaneous injections given approximately 4-5 hours apart
89593986|NCT02081014|Experimental|G-Pen Mini™ (glucagon injection) 150 ug|G-Pen Mini™ (glucagon injection), two 150 microgram subcutaneous injections given approximately 4-5 hours apart
89593987|NCT02081014|Experimental|G-Pen Mini™ (glucagon injection) 300 ug|G-Pen Mini™ (glucagon injection), two 300 microgram subcutaneous injections given approximately 4-5 hours apart
89593988|NCT01673152|Placebo Comparator|Maltodextrin|
89593989|NCT01673152|Experimental|Oligofructose|Orafti P95, Beneo-Orafti, Belgium,
89593990|NCT05405842|Experimental|Gastroparesis|Patients diagnosed with Gastroparesis.
89593991|NCT05405842|Experimental|Functional Dsypepsia|Patients diagnosed with Functional Dsypepsia.
89593992|NCT05405842|Experimental|Healthy Controls|Healthy volunteers (without Functional Dsypepsia or Gastroparesis)
89593993|NCT01673230|Other|Ventricular dysfunction|cardiac surgery for ventricular dysfunction
89593994|NCT03153358|Experimental|icotinib+SBRT|icotinib 125 milligram,three times a day for 28 days oral administration,12weeks later given the SBRT treatment depended on the outcome of icotinib
88978283|NCT00251602|Experimental|3|DD ACE genotype
88978284|NCT00251602|Placebo Comparator|4|II ACE genotype
88978285|NCT00251602|Placebo Comparator|5|ID ACE genotype
88978286|NCT00251602|Placebo Comparator|6|DD ACE genotype
88978287|NCT02961166||IgM enriched Immunoglobulins|ARDS patients with septic shock requiring ECMO therapy were treated for 3 days by IgM-enriched Immunoglobulin
88978288|NCT02961166||Control|ARDS patients with septic shock requiring ECMO therapy were NOT treated by IgM-enriched Immunoglobulin
88978289|NCT02961439||Patient Participants|Patient participants are adult patients in the Epworth Richmond Intensive care Unit. They are not the focus of the research but rather represent a general population of ICU patients that require echocardiography in the management of their critical illness. They will be a mix of medical and surgical patients some of whom are receiving mechanical ventilation, have movement restrictions, high BMI or other impediments to performing echocardiography.
89593995|NCT03025594|Experimental|Gonyautoxin|Gonyautoxin 40mcg
89593996|NCT03025594|Active Comparator|Control|Mix of chirocaine 0,2%, ketorolac and epinephrine..
89593997|NCT04404946|Active Comparator|phenylephrine infusion|fixed-rate phenylephrine infusion
89593998|NCT04404946|Active Comparator|norepinephrine infusion|fixed-rate norepinephrine infusion
89593999|NCT04404946|Placebo Comparator|placebo infusion|normal saline infusion
89594000|NCT01673464||High School Athletes|
89594001|NCT01673542|Experimental|Lidocaine-Prilocaine 5%|
89594002|NCT01673542|Placebo Comparator|Dexeryl|
89594003|NCT03713710|Experimental|Pap testing|Women assigned to this arm will be scheduled a Pap testing appointment at the local health department
89594004|NCT03713710|Experimental|Choice|Women assigned to this arm will be given a choice between scheduling an appointment for a Pap testing at the health department or engage in self-sampling for HPV testing at home
89594005|NCT02634268|Active Comparator|Lifestyle intervention|Behavioral lifestyle intervention focused on healthy eating and physical activity
89594006|NCT02634268|No Intervention|Usual Care|Participants continue with usual diet and exercise activities as they desire
89594007|NCT01610492|Experimental|Cohort 1|10mg/kg belimumab intravenous (IV) administered at weeks 0 and 2, and then every 4 weeks, over a 24-week treatment period, resulting in a total of 8 doses, and will be assessed for the primary endpoint at week 28. Subjects will then enter the long term phase of the study and receive 10mg/kg belimumab every 4 weeks until week 100,or until they have been in complete remission for at least 3 months, resulting in up to 27 doses.
89594008|NCT01673776|No Intervention|K group|commonly used therapy
89594009|NCT01673776|Experimental|M group|multimodal intervention
89594010|NCT01817582|Experimental|Lotemax Gel 0.5% and Restasis 0.05%|Participants will administer lotemax gel 0.5 % BID in both eyes (OU) for 2 weeks, then administer both lotemax gel 0.5% and restasis emulsion 0.05% BID OU for 2 weeks, then administer restasis emulsion 0.05% BID OU for 8 weeks. Participants will also receive preservative-free Soothe Lubricant Eye Drops as needed (up to 4 times per day).
89594011|NCT01817582|Experimental|Lotemax Gel 0.5%|Participants will administer lotemax gel 0.5% BID OU for 12 weeks. Participants will also receive preservative-free Soothe Lubricant Eye Drops as needed (up to 4 times per day).
89594012|NCT01817582|Active Comparator|Restasis 0.05%|Participants will administer restasis emulsion 0.05% BID OU for 12 weeks. Participants will also receive preservative-free Soothe Lubricant Eye Drops as needed (up to 4 times per day).
89594013|NCT01594125|Experimental|Group I|patients with mild liver dysfunction according to their AST/ALT values and Child-Pugh score
89594014|NCT01594125|Experimental|Group II|patients with moderate liver dysfunction according to their AST/ALT values and Child-Pugh score
89594015|NCT04792684||Arm A.|Subjects that have a suspected advanced adenoma or have been newly diagnosed with CRC still not resected and scheduled for surgery
89594016|NCT04792684||Arm B|Subjects at average-risk for CRC and scheduled for CRC screening colonoscopy
89594017|NCT01673932|Experimental|Group A - UCBMC Early Treatment Group|Group A subjects will receive transplant of UCBMC isolated from HLA-matched umbilical cord blood at Day 0.
89594018|NCT01673932|Experimental|Group B - UCBMC Delayed Treatment Group|Group B subject will partipate in 6 months observation and then receive the UCBMC transplant at month 6.
89594019|NCT02986113|Experimental|Men and Providers Preventing Suicide|Tailored interactive multimedia intervention, aimed at activating suicidal middle-aged men to disclose and discuss their suicide thoughts with and be receptive to treatment offers from a primary care provider during a linked office visit
89594020|NCT02986113|Active Comparator|Sleep hygiene video|A brief (3 minute) video regarding sleep hygiene, accompanied by introductory text summarizing research linking sleep problems with increased suicide risk.
89594021|NCT04404868||Enrolled patients|"Each patient (whether hospitalized or outpatient) included in the study underwent to a baseline evaluation in which near and remote pathological history were recorded (main concomitant pathologies, drug therapy in progress, previous major surgery) and the following evaluation scales were administered: modified Ashworth scale (MAS), MI (motricity index), FMA (Fughl Meyer assessment) and Modified Rankin' scale (MRS).~Each patient will subsequently undergo to a follow-up evaluation at 4, 12 and 24 weeks after the date of inoculation through the execution of a specialist visit (physiatric/neurological) and the administration of the following evaluation scales: MAS, MI, FMA and MRS. For the duration of the study, each patient may undergo integrated rehabilitation treatment at the discretion of each of the investigators of each centre involved in the study according to the guidelines and common clinical practice."
89594022|NCT04775134||Subjects with earlier PCR-proven COVID-19 and/or serum anti-SARS-CoV-2 antibodies|Patients that require a medically indicated pulmonary resection.
89594023|NCT04775134||Subjects WITHOUT earlier PCR-proven COVID-19 and/or serum anti-SARS-CoV-2 antibodies|Patients that require a medically indicated pulmonary resection.
89594024|NCT01870076|Experimental|Healing Touch Intervention|Healing Touch performed one hour prior to bed.
89594025|NCT01870076|Sham Comparator|Healing Touch Sham|Healing Touch Sham provided one hour prior to bed.
89594026|NCT01870076|Active Comparator|Control, Presence|Control, Presence Intervention in the room one hour prior to bed.
89594027|NCT01870076|No Intervention|Control, No Presence|No Presence in the room one hour prior to bed.
89594028|NCT01592721|Experimental|EGFR Antisense DNA|EGFR AS will be administered by direct intratumoral injection using direct visualization, endoscopy, or imaging-guidance (ultrasound) as clinically determined. Patients will receive a total of up to 4 weekly intratumoral injections of EGFR antisense (or less if there is no identifiable tumor) starting 2 weeks prior to radiation. Patients will receive standard radiation 70 Gy/200 cGy/daily, 5 days/week, with concurrent cetuximab 250 mg/m2, after a loading dose of 400 mg/m2 2 weeks prior to starting radiation.
89594029|NCT01674088||Irritable Bowel Syndrome|Subjects meeting Rome III criteria will be included as the group Irritable Bowel Syndrome
89594030|NCT01674088||Healthy Controls|Subjects not meeting Rome III criteria and meeting clinical definitions of general good health will be considered as Healthy Controls
89594031|NCT02125396|Experimental|Radiotherapy|Adjuvant radiotherapy is used for postoperative curative HCC
89594032|NCT02125396|Active Comparator|Transarterial chemoembolization|Adjuvant transarterial chemoembolization [5-15 ml lipiodol 5-fluorouracil (500 mg/m2) and adriamycin (30 mg/m2)]
89594033|NCT01613378||Rheumatoid Arthritis Cohort|The cohort included participants with moderate to severe rheumatoid arthritis (RA) in whom the treating physician made the decision to initiate tocilizumab treatment.
89594034|NCT01592409|Active Comparator|Active cannabis|In this condition, participants will receive a cigarette containing 12.5% active THC.
89594035|NCT01592409|Placebo Comparator|Placebo|In this condition, participants will receive a cannabis cigarette where the active THC has been removed (contains 0% THC).
89594036|NCT02081638|Active Comparator|Elite Controller|Elite controllers not on ART
89594037|NCT02081638|Active Comparator|Treated Progressors|HIV infected on ART
89594038|NCT04603508|Experimental|Berlim 25/10|"The study is triple-dummy. The patient must take 3 tablets once a day, as follows:~1 tablet Berlim 25/10 association, oral;~1 tablet empagliflozin placebo, oral;~1 tablet rosuvastatin calcium placebo, oral."
89594039|NCT04603508|Active Comparator|Empagliflozin + rosuvastatin calcium|"The patient must take 3 tablets once a day, as follows:~1 tablet Berlim 25/10 association placebo, oral;~1 tablet empagliflozin , oral;~1 tablet rosuvastatin calcium, oral."
89594040|NCT01674166|Experimental|prucalopride|single dose 0.03 mg/kg prucalopride open label
89594041|NCT02235688|Experimental|aldoxorubicin|
89594042|NCT01676584|Placebo Comparator|Placebo|
89594043|NCT01676584|Experimental|RO6811135|
89594044|NCT03152578|Active Comparator|BetaC + Capsacian|1-3 mls BetaC + Capsacian applied to the painful areas, once upon awakening, once mid day and once before bed-time, each day for two (2) weeks.
89594045|NCT03152578|Active Comparator|BetaC Only|1-3 mls BetaC applied to the painful areas, once upon awakening, once mid day and once before bed-time, each day for two (2) weeks.
89594046|NCT03152578|Placebo Comparator|Placebo|1-3 mls Placebo applied to the painful areas, once upon awakening, once mid day and once before bed-time, each day for two (2) weeks.
89594047|NCT01065532|Active Comparator|1|SeQuent Please Drug-eluting balloon
88978290|NCT02961439||Registrar Participants|Registrar participants are doctors in training in ICU. They have completed a formal echo teaching program and completed a logbook of 30 supervised scans. They are the focus of the research and are being assessed on their diagnostic accuracy with echocardiography.
88978291|NCT02961127||group 1|no drugs were used in our study
88978292|NCT02961127||group 2|
88978293|NCT00251680|Experimental|Lapaquistat Acetate 50 mg QD|(and stable lipid-lowering therapy)
88978294|NCT00251680|Active Comparator|Stable Lipid-lowering therapy|
88978295|NCT00251836||Left-sided donor nephrectomy|Left-sided laparoscopic hand-assisted donor nephrectomy
88978296|NCT00251836||Right-sided donor nephrectomy|Right-sided laparoscopic hand-assisted donor nephrectomy
88978297|NCT00103896||HIV Infected Youth in Treatment/Care|HIV infected youth in treatment/care will be interviewed using Audio Computer-Assisted Self-Administered Interview ACASI technology to reveal possible venues where youth at high risk for acquiring the disease may be found (N = 20-30 individuals per ATN site).
88978298|NCT00103896||BVI Individuals|Additional data will be gathered on potential recruitment venues by administering a brief venue interview (BVI) to individuals who appear to be between 12 and 24 years old (N = unlimited individuals during 3-5 assessment periods per venue each lasting 5 hours).
88978299|NCT00103896||HIV Serosurvey Individuals|HIV Serosurvey Individuals Anonymous structured interview using ACASI technology and an anonymous HIV antibody assay will be administered to 20-30 young women at 2-3 targeted locations and 20-30 young men at 2-3 targeted locations whose HIV status is unknown (N = 160-360 individuals per ATN site)..
88978300|NCT00069017|Active Comparator|1|MEDI-522 - 4 mg/kg of MEDI-522 (N=200)
88978301|NCT00069017|Placebo Comparator|2|Placebo (N=100)
88978302|NCT00399074|No Intervention|chloroquine|Weekly CQ
88978303|NCT00399074|No Intervention|Sulfadoxine-pyrimethamine|Monthly SP
88978304|NCT00100308|Experimental|1|Standard treatment plus unfractioned heparin low-dose continuous infusion
88978305|NCT00100308|Placebo Comparator|2|Standard treatment plus placebo
88978306|NCT00103935|Placebo Comparator|Group A1|Placebo lead-in followed by placebo equivalent volume to 0.8 mg exenatide LAR
88978307|NCT00103935|Placebo Comparator|Group A2|Placebo lead-in followed by placebo equivalent volume to 2.0 mg exenatide LAR
88978308|NCT00103935|Experimental|Group B|Exenatide lead-in followed by exenatide LAR 0.8 mg weekly
88978309|NCT00103935|Experimental|Group C|Exenatide lead-in followed by exenatide LAR 2.0 mg weekly
88978310|NCT00399152|Experimental|Perifosine+Sunitinib malate|
88978311|NCT04719559|Other|Post-Thyroidectomy Hypertrophic Scar|Patients had all presented a persistent hypertrophic scar at the neck region for more than 1 year after their thyroidectomy.
88978312|NCT04719598|Experimental|intervention group is ( internet - based group) who will receive CBT sessions|study group ( group A)
88978313|NCT04719598|No Intervention|control group ( group B)|researchers just answer their questions
88978314|NCT00252148|Active Comparator|ADMVA|ADMVA dosage escalation
88978315|NCT00252148|Placebo Comparator|Placebo|Placebo is 10mM TRIS HCl, 140mM NaCl, ph 7.7
89594048|NCT01065532|Active Comparator|2|Xience V Drug-eluting stent
89594049|NCT01674244|Experimental|Integrative Exercise|Subjects will exercise for 12 weeks (3 times weekly, with each total workout being approximately 60 minutes in length). The exercise protocol will incorporate elements of mindfulness, cardiovascular strengthening, and controlled breathing.
89594050|NCT01674244|Active Comparator|Monitor Only Waitlist|Monitor Only Waitlist
89594051|NCT03152734||Elderly patient|Elderly patient undergoing surgical and non-surgical intervention with the use of anesthesia provided by an anesthetist
89594052|NCT01697319|Experimental|BMN 110 at 2.0 mg/kg/week|Weekly IV infusions of BMN 110 at 2.0 mg/kg/week over a period of approximately 4 hours per infusion for up to 144 weeks.
89594053|NCT03152812||free skin flaps|
89594054|NCT03152812||free muscle flaps|
89594055|NCT01674322|Experimental|Ibrutinib|All participants will receive a single oral solution dose of 50 mg to 140 mg -ibrutinib containing 1480 kBq (40 µCi) of 14C-labeled ibrutinib, with a total radiation burden of approximately 0.916 mSv.
89594056|NCT04746898|Experimental|Virtual Reality Training Group (VR group)|The students in the first group received basic life support practice training with virtual reality applications.
89594057|NCT04746898|Experimental|High Fidelity Simulation Training Group (HFS group)|The students in the second group received basic life support practice training with high fidelity simulators.
89594058|NCT04746898|Experimental|Low Fidelity Simulation Training Group (LFS group)|The students in the third group received basic life support practice training with the classical method, low-reality mannequin.
89594059|NCT03152344||COPD patients without chronic respiratory failure|"We will recruit COPD patients in stable condition (free of exacerbation of the disease for a month), 40 without chronic respiratory failure and 40 with home oxygen therapy.~The patients will be proposed to perform the following tests and to fill in questionnaires"
89594060|NCT03152344||COPD patients with home oxygen therapy|"We will recruit COPD patients in stable condition (free of exacerbation of the disease for a month), 40 without chronic respiratory failure and 40 with home oxygen therapy.~The patients will be proposed to perform the following tests and to fill in questionnaires"
89594061|NCT03152500|Experimental|FEMTIS IOL|The FEMTIS-IOL has a special haptic system that allows the lens to clamp into the capsulorrhexis.
89594062|NCT03152500|Active Comparator|Acrysof IOL|The Acrysof IOL has a flexible haptic design that keeps the IOL stable and centered in the capsular bag
89594063|NCT00831142||Prostate Cancer|Males with prostate cancer, referred for biopsy or radical prostatectomy
89594064|NCT03885310|Experimental|DCB Treatment|Stricture patients treated by DCB
89594065|NCT04764916|Experimental|Exparel/Intervention group|Will receive 10mL of standard 0.5% bupivacaine followed by 10mL of liposomal bupivacaine as adductor canal field block preoperatively
89594066|NCT04764916|Active Comparator|Standard of Care group|Will receive 20mL of standard 0.5% bupivacaine as adductor canal field block preoperatively
89594067|NCT01674790|Experimental|AEROBIC group|6-week program of one 20-min session of aerobic training and one 20-min session of ROM exercise 5 days/week.
89594068|NCT01674790|Experimental|COGNITIVE group|6-week program of one 20-min session of cognitive training and one 20-min session of ROM exercise 5 days/week.
89594069|NCT01674790|Experimental|AEROBIC + COGNITIVE group|6-week program of one 20-min session of aerobic training and one 20-min session of cognitive training 5 days/week.
89594070|NCT01674790|Experimental|CONTROL group|6-week program of one 20-min session of ROM exercise and one 20-min session of unstructured mental activity 5 days/week.
89594071|NCT01674868|Experimental|Fluoxetine|Subjects will take 20 mg fluoxetine daily for 90 days after stroke
89594072|NCT01674868|Placebo Comparator|placebo|Subjects will take one pill daily for 90 days after stroke.
89594073|NCT01674946|Placebo Comparator|ID saline|ID saline by feeding tube
89594074|NCT01674946|Active Comparator|ID saline + CDCA (5 mmol/L)|CDCA = chenodeoxycholic acid (primary bile acid)
89594075|NCT01674946|Active Comparator|ID + CDCA (15 mmol/L)|CDCA = chenodeoxycholic acid (primary bile acid)
89594076|NCT01674946|Active Comparator|ID saline + oleanolic acid (1 mmol/L)|
88978316|NCT00069134|Experimental|Sulfur Amino Acids|12 children with edematous severe malnutrition will be assigned to receive 0.65 mmol/kg/d of sulfur amino acids. Supplements will be added to the children's daily diets.
88978317|NCT00069134|Placebo Comparator|Alanine|12 children with edematous severe malnutrition are assigned to receive 0.65 mmol/kg/d of alanine as placebo. Supplements will be added to the children's daily diets.
88978318|NCT04719715||Cases with ANCA vasculitis|Indirect immunofluorescence (IIF) will be performed as well as myeloperoxidase antibody(MPO)- and anti-proteinase 3 (PR3-) ANCA immunoassays and evaluated
88978319|NCT04719715||Controls with autoimmune diseases other than ANCA vasculitis|Indirect immunofluorescence (IIF) will be performed as well as myeloperoxidase antibody(MPO)- and anti-proteinase 3 (PR3-) ANCA immunoassays and evaluated
88978320|NCT04719754||Pregnant women with abnormal vaginal discharge|
88978321|NCT04719754||Pregnant women without abnormal vaginal discharge|
88978322|NCT00252304|Experimental|Zinc|Zinc sulphate 10 or 20 mg per day
88978323|NCT00252304|Placebo Comparator|Placebo|Placebo
88978324|NCT00252421|Active Comparator|Nitroglycerin|Nitroglycerin ointment 15 mg/day daily for 24 month
88978325|NCT00252421|Placebo Comparator|Placebo|Placebo ointment daily for 24 month
88978326|NCT00252616|Experimental|1|trophic feeds
88978327|NCT00252616|Active Comparator|2|Full-calorie feeds
88978328|NCT00252928|Placebo Comparator|A|Placebo group does not receive Aquatabs.
88978329|NCT00252928|Experimental|B|Intervention arms receives Aquatabs.
89594077|NCT01674946|Active Comparator|ID saline + CDCA (5 mmol/L) + oleic acid|
89594078|NCT01674946|Placebo Comparator|ID saline + oleic acid (20 mmol/L)|
89594079|NCT01675024|Experimental|Rotigotine, Period 1|In Period 1 (Day 1 to Day 3) all 24 subjects will receive only 1 dose 2 mg / 24 hours.
89594080|NCT01675024|Experimental|Rotigotine, Period 2|In Period 2 (Day 7 to Day 14) all 24 subjects will receive 2 mg / 24 hours for 3 days then 4 mg / 24 hours for 3 days.
89594081|NCT02081950|Experimental|Enoxaparin sodium|Enoxaparin sodium (80mg) is administered subcutaneously as a single dose, in 2 periods.
89594082|NCT03878212|Experimental|mHealth+I|This group of participants will receive a proactive mHealth with interactivity program which includes two main elements: 1) mHealth application designed by the research team with the information technological support by Smartone and 2) nurse case management supported by a social service team
89594083|NCT03878212|Active Comparator|mHealth|The mHealth group will have access to the health content on the mHealth platform. This group 2018 HMRF Open Call Proposal Section 13: Proposed Research Project 5 will enjoy the same content and client-initiated help if needed. Same as the above group, the client is invited to use the mHealth application. A reminder message will pop up on the screen of smartphone when participants have not used it for more than one week. The participants are encouraged to read the self-care information that is featured in the app. There is a button for the client-imitated call if they would like to consult a nurse.
89608505|NCT00733330|Active Comparator|MiTKR CAS arm|Patients to receive treatment with either a P.F.C. or L.C.S. knees in chronological order into the CAS group which will use minimally invasive surgery and computer navigation
89608506|NCT01278784|Experimental|Healthy volunteer|
89608507|NCT04386226|Experimental|2 grams Ambrotose LIFE|2 grams daily for 8 weeks
89608508|NCT04386226|Experimental|4 grams Ambrotose LIFE|4 grams daily for 8 weeks
89608509|NCT04386226|Active Comparator|2 grams Advanced Ambrotose|2 grams daily for 8 weeks
89594084|NCT03878212|No Intervention|Control|All groups will receive usual community services. The study district provides community-based health talks and basic health checks such as measuring blood pressure and blood glucose that are accessible to all residents, and their participation is voluntary. Both health and social services are available in the community for those who need help, including referral for further help if appropriate. These services are however episodic with design for continuity of care. No mHealth application will be provided to the participants in this group but the individuals are free to do their own surfing for e-health information.
89594085|NCT04404322|Experimental|IPT A SCI|The IPT-A SCI follows the intervention protocol, which includes an intensive phase of 5 weekly 50-minute sessions and 3 follow up personal emails.
89594086|NCT04404322|Active Comparator|Treatment as usual|TAU patients receive an integrative combination of psychodynamic, supportive and cognitive behavioural therapy, usually lasting between 10-30 weeks.
89594087|NCT04404322|No Intervention|wait list|WL patients are monitored by a trained clinician during their waiting period and complete the study questionnaire battery at the parallel time intervals.
89594088|NCT01675180|Other|Information|Women randomized to the intervention will recieve information and counseling on oral health care during pregnancy
89594089|NCT01675180|No Intervention|Control|
89594090|NCT03155932|Experimental|APD334|APD334 active treatment for 24 weeks.
89594091|NCT01675258||Control|Healthy adults above the age of 18 years
89594092|NCT01675258||Study|Adult patients above the age of 18 years with gastric, colorectal (including pre-cancer polyps) or pancreatic cancer
89594093|NCT01675570|Experimental|RX-10045 active arm|RX-10045 Opththalmic Solution, 0.09%
89594094|NCT01675570|Placebo Comparator|Vehicle for RX-10045 arm|Vehicle of RX-10045 Ophthalmic Solution
89594095|NCT01675648|Experimental|Lofexidine & Diazepam Placebo|"Initial Lofexidine dosage starts from 0.8mg per day, it will be gradually increased by increments of 0.4 to 0.8mg per day up to a maximum of 2.2mg daily. After 3 peak dose days, the dosage will be gradually decreased by 0.2 to 0.6mg per day till to 0.2mg of the last lofexidine dosage in Day 10.~The Diazepam placebo will be administrated to the patients with the same frequency, time and number tablets of diazepam in the active comparator arm."
89594096|NCT01675648|Active Comparator|Diazepam & Lofexidine Placebo|"The initial dosage of Diazepam is 10 mg per day on Day 1&2, the dosage will be increased to 15 mg per day on Day 3&4, subsequently decreased to 10mg per day on Day 5, 5mg per day on Day 6&7, 2mg per day on Day 8&9&10.~The Lofexidine placebo will be administrated to the patients with the same frequency, time and number tablets of lofexidine in the experimental arm."
89594097|NCT01566435|Experimental|Arm 1-ACF Induction Therapy Followed by Chemoradiation Therapy|"ACF Induction Therapy (Cycle 1 and Cycle 2 - each cycle is every 3 weeks)~nab-Paclitaxel 100 mg/m^2 on Days 1, 8, and 15~Cisplatin 75 mg/m^2 on Day 1~5-FU 750 mg/m^2 on Days 1-3~If patient has complete or partial response, he/she will receive an additional ACF cycle (cycle 3). If patient has stable disease or progressive disease will not receive the third cycle of ACF.~Definitive Therapy~Cisplatin 100 mg/m^2 IV on Days 1, 22, and 43~Intensity modulated radiation therapy (IMRT) 7000 cGy in 35 fractions of 200 cGy each over 7 weeks. A dose of 6300 cGy in 35 fractions is optional and may be delivered to area considered to be at intermediate risk. Additional regions in the ipsilateral and contralateral neck at risk for microscopic disease in the cervical lymph nodes will receive 5600 cGy in 35 fractions.~If patient cannot receive cisplatin then he/she will receive cetuximab 250 mg/m^2 IV week for 8 weeks"
89594098|NCT03868228|Experimental|Treatment with PIPAC|Patients with colorectal cancer and peritoneal metastases being treated with pressurised intraperitoneal aerosol chemotherapy (PIPAC)
89594099|NCT01675726|Other|quality of life|
89594100|NCT01675804|Experimental|Computerized cognitive rehabilitation|-Computer-assisted cognitive rehabilitation (CACR): 20 Ninety-minute sessions of CACR.
89594101|NCT01675804|Placebo Comparator|Placebo CACR [PCACR]|-PCACR group simultaneously received 20 Ninety-minute sessions of Placebo CACR.
89594102|NCT01675804|Experimental|Ritalin|-2 to 3 doses of 10 mg Ritalin tablets per day during two months.
89594103|NCT01696929|Experimental|Tocilizumab|Following a screening evaluation, participants will receive two infusions of tocilizumab, one at baseline and another at week 4 of the study. All subjects will receive a 4 mg/kg infusion of tocilizumab, the recommended starting dose for adults with rheumatoid arthritis.
89594104|NCT04649008|Experimental|Epilepsy patient volunteers|Patients recruited for the study with intractable epilepsy who are anticipated to undergo epilepsy surgery
89594105|NCT03865654|Experimental|Surveillance Mammography Communication Tool|"Conduct 30 telephone-based patient interviews~4-6 focus groups with oncologists and primary care providers (PCs) to learn their perceptions and thoughts about when to stop surveillance mammography~Perform cognitive testing of the communication tool"
88978330|NCT00253045|Experimental|Motivational group|Group counseling using motivational interviewing
88978331|NCT00253084|Other|IPX054 - CD-LD IR|Subjects received IPX054 200 mg b.i.d and CD-LD IR Placebo q.i.d for 2 weeks and then received IPX054 Placebo b.i.d and CD-LD IR q.i.d for 2 weeks.
88978332|NCT00253084|Other|CD-LD IR - IPX054|Subjects received IPX054 Placebo b.i.d and CD-LD IR q.i.d for 2 weeks and then IPX054 200 mg b.i.d and CD-LD IR Placebo q.i.d for 2 weeks.
88978333|NCT00069407|Active Comparator|RUL|Right unilateral electroconvulsive therapy
88978334|NCT00069407|Active Comparator|BL|Bilateral electroconvulsive therapy
89594106|NCT01696773|Experimental|Tangerine tomato juice|Tangerine tomato juice will be fed
89594107|NCT01696773|Experimental|Red tomato juice|Red tomato juice will be fed
89608510|NCT04386226|Active Comparator|4 grams Advanced Ambrotose|4 grams daily for 8 weeks
88978335|NCT00069407|Active Comparator|BF|Bifrontal electroconvulsive therapy
88978336|NCT00253279||1|16 healthy subjects will be studied. Each patient will undergo one PET Scan to measure muscle protein synthesis rate.
88978337|NCT00253279||2|48 burn patients will be studied. Each patient will have a maximum of 3 PET Scans, which will be done at different times during the first 24 months after injury. A maximum of 2 of these scans will be done while they are inpatient; one after discharge.
88978338|NCT02966678||Glaucoma|Patients with a diagnosis of glaucoma will undergo color vision test
88978339|NCT00253786|Experimental|Intensive multifactorial therapy (Protocol A)|Protocol A: serum creatinine <1.2 mg/dl in male and <1.0 mg/dl in female.
89594108|NCT03158740|Active Comparator|DII-Based Counseling System|The DII-based counseling group will utilize our 12-week IMAGINE Counseling System curriculum.The DII-based counseling group will meet once a week for 12 weeks to cook, and to engage in exercise and stress-reduction activities. Along with the initial clinic, participants will meet one-on-one for a nutrition counseling session with a registered dietitian. Participants will have access to online material through our Imagine Healthy Online Portal and will be given take-home activities, referred to as IMAGINE actions. These homework assignments will focus on goal setting for nutrition, physical activity, and stress reduction. The nutrition components of this intervention will be based on the DII and will focus on anti-inflammatory foods and components.
89594109|NCT03158740|Active Comparator|general health education control|The standard of care arm will receive general health information (e.g., general guidelines of healthy eating and physical activity, stress management, cancer screening, etc.). This information will be provided through email, which will include a weekly newsletter, healthy recipes that are not focused on reducing the DII scores, links to online content, and health-related event announcements in and around Columbia, SC.
89594110|NCT01696695||Metastatic Colorectal Carcinoma (mCRC) Participants|Newly diagnosed mCRC participants, who will receive first line capecitabine based chemotherapy according to effective official Summary of Product Characteristics, will be observed. The choice of therapy is based exclusively on the medical decision of the treating physician before study enrollment. The study protocol does not enforce treatment initiation and also do not specify any treatment regimen.
89594111|NCT01676038|Active Comparator|Pinless-Navigated Total Knee Arthroplasty|The patients underwent total knee arthroplasty using a Pinless-Navigated system that is designed to restore the mechanical alignment of the lower limb.
89594112|NCT01676038|Active Comparator|Conventional Total Knee Arthroplasty|The patients underwent total knee arthroplasty using conventional technique.
89594113|NCT05261386|Placebo Comparator|Placebo Comparator: CBT-008|CBT-008 vehicle ophthalmic solution contains sodium phosphate monobasic monohydrate, sodium chloride, purified water, and sodium hydroxide to adjust pH to 7.4.
89594114|NCT05261386|Experimental|Experimental: 2.5% CBT-008|2.5% CBT-008 ophthalmic solution contains sodium phosphate monobasic monohydrate, sodium chloride, purified water, and sodium hydroxide to adjust pH to 7.4.
89594115|NCT05261386|Experimental|Experimental: 10% CBT-008|10% CBT-008 ophthalmic solution contains sodium phosphate monobasic monohydrate, sodium chloride, purified water, and sodium hydroxide to adjust pH to 7.4.
89594116|NCT04617340|No Intervention|Usual care group|No pharmacist will be actively involved in the medication review, counseling or discharge and post-discharge procedure. In both groups the best possible preadmission drug list will be compiled for inpatients within 72 hours after admission to the geriatric ward. If potentially dangerous or life-threatening drug errors are observed in the usual care group, this will be communicated to the treating physician
89594117|NCT04617340|Experimental|Intervention group|"The clinical pharmacist-collaborative service in the intervention group comprises six steps based on the clinical pharmacy intervention proposal of Van der Linden et al (Drugs Aging 2020).~The first three steps focus on optimizing the drug therapy of geriatric inpatients. The remaining steps target a safe transition from the hospital to the community."
89594118|NCT03862066||Received Nivolumab|
89594119|NCT03862066||Nivolumab Naive|
89594120|NCT03861988|Experimental|Open label ketamine|Patients will receive an intravenous ketamine infusion during surgery.
89594121|NCT03861988|Experimental|Double blind ketamine|Patients will receive an intravenous ketamine infusion during surgery.
89594122|NCT03861988|Placebo Comparator|Double blind placebo|Participants will receive placebo (normal saline infusion) during surgery.
89594123|NCT01670266|Experimental|Experimental Arm 1|Experimental Eye drops 3.0 µg/mL QD both eyes on Day 1, 5-18
89594124|NCT01670266|Experimental|Experimental Arm 2|Experimental Eye drops 10.0 µg/mL QD both eyes on Day 1, 5-18
89594125|NCT01670266|Experimental|Experimental Arm 3|Experimental Eye drop 30.0 µg/mL QD both eyes on day 1, 5-18
89594126|NCT01670266|Experimental|Experimental Arm 4|Experimental Eye drop, 2 sequence crossover Cohort [1 dose; 1-30 µg/mL]to be determined and placebo
89594127|NCT01670266|Placebo Comparator|Placebo Arm|Matched placebo eye drops dosed in same manner as ONO-9054
89594128|NCT03755440|Experimental|PD-1 antibody|SHR-1210, 200mg, ivdrip, d1, every two weeks.
89594129|NCT03753724||Group 1|On review of the scans by an expert, no further follow up or investigation is required, as the nodule(s) has been categorised as benign. As the patient was unaware the scan was being reviewed and no further investigations are required. Patient is invited to take part in the study (by telephone).
89594130|NCT03753724||Group 2|On review, the nodule is indeterminate and further scanning at a later date is required. The patient is informed of this, usually via a telephone call from either the doctor or nurse specialist working in the Lung Nodule Clinic (LNC) or site equivalent. This LNC is usually a virtual clinic - no physical interaction with the patient - and the follow up scan is reviewed and the patient contacted again via the virtual clinic. Patient is invited to take part in the study (by telephone, by post or in clinic if appropriate).
89594131|NCT03753724||Group 3|On review, the nodule is regarded as potentially malignant and further scans and a clinic appointment is made for the patient. Patient is invited to take part in the study (in clinic if appropriate).
89594132|NCT01676194|Experimental|Intra-arterial administration of DC BeadsR|Intra-arterial administration of DC BeadsR, (1 vial of 100-300 µm) as selectively as possible loaded with doxorubicin (50 mg per procedure) and mixed with an equal volume of contrast medium. The first injection will be performed within 21 days following enlisting and repeated 1-2 times until LT (only if hypervascularized vital tumor tissue is again visible on CT Scan and if liver function remains within Child A stage) or until complete response
89594133|NCT01676194|No Intervention|Control|Usual care
89594134|NCT03860974|Experimental|Serratus Plane (single injection)|A single injection serratus plane block will be administered using ropivacaine 0.5% with epinephrine 1:200,000-400,000 (20 mL for unilateral surgery; 16 mL on each side for bilateral surgery)
89031367|NCT02953184|Active Comparator|conventional Doxorubicin plus C-T|AC-T regimen 8 cycles ,60mg/M2 conventional Doxorubicin will be used as active comparator. four cycles of Doxorubicin plus 600mg/m2 Cyclophosphamide every three weeks followed 4 cycles of 100mg/m2 Taxotere, every three weeks for one cycle.Dexrazoxane (DZR)will be used for protecting cardiac toxicity.Patients will undergo Modified Radical Mastectomy or Breast Conserved Surgery or Axillary Lymph Node Dissection(ALND) or Sentinel Lymph Node Biopsy（SLNB） after 8 cycles of chemotherapy
89594135|NCT03860974|Active Comparator|Paravertebral (single injection)|Single injection paravertebral blocks will be administered using ropivacaine 0.5% with epinephrine 1:200,000-400,000 (20 mL for unilateral surgery; 16 mL each side for bilateral surgery)
89594136|NCT01565889|Experimental|Part A: SOF+EFV/FTC/TDF (Cohort 1)|Participants with a prestudy regimen of EFV/FTC/TDF will receive SOF+EFV/FTC/TDF FDC for 7 days, followed by EFV/FTC/TDF FDC (or EFV+FTC/TDF) for 7 days, coadministered once daily in the evening under fasting conditions.
89031368|NCT02953184|Experimental|PLD plus C -T|Pegylated Liposomal Doxorubicin(PLD) plus Cyclophosphamide followed Taxotere 8 cycles.35mg/M2 PLD will be used as experimental medicine. four cycles of PLD plus 600mg/m2 Cyclophosphamide every three weeks followed 4 cycles of 100mg/m2 Taxotere , every three weeks for one cycle.Vitamin B will be used for protecting hand-foot syndrome(HFS).Patients will undergo Modified Radical Mastectomy or Breast Conserved Surgery or Axillary Lymph Node Dissection(ALND) or Sentinel Lymph Node Biopsy（SLNB） after 8 cycles of chemotherapy
89031369|NCT00515229|Active Comparator|1|Verum 1: Each individual capsule has a filling volume of 25 mg amitriptyline, given once an day in the evening over 28 days
89031370|NCT00515229|Active Comparator|2|Verum 1: Each individual capsule has a filling volume of 50 mg amitriptyline, given once an day in the evening over 28 days
89031371|NCT00515229|Active Comparator|3|Verum 3: Each individual capsule has a filling volume of 75 mg amitriptyline, given once an day in the evening over 28 days
89594137|NCT01565889|Experimental|Part A: SOF+EFV+ZDV/3TC (Cohort 2)|Participants with a prestudy regimen of EFV+ZDV/3TC will receive SOF+EFV+ZDV/3TC for 7 days followed by EFV+ZDV/3TC for 7 days. Sofosbuvir and EFV will be administered once daily in the evening under fasting conditions; ZDV/3TC will be administered twice daily, in the morning without regard to food and in the evening on an empty stomach.
89594138|NCT01565889|Experimental|Part A: SOF+RTV+ATV+FTC/TDF (Cohort 3)|Participants with a prestudy regimen of RTV+ATV+FTC/TDF will receive SOF+RTV+ATV+FTC/TDF for 7 days followed by RTV+ATV+FTC/TDF for 7 days coadministered once daily in the morning with food.
89594139|NCT01565889|Experimental|Part A: SOF+RTV+DRV+FTC/TDF (Cohort 4)|Participants with a prestudy regimen of RTV+DRV+FTC/TDF will receive SOF+RTV+DRV+FTC/TDF for 7 days followed by RTV+DRV+FTC/TDF for 7 days coadministered once daily in the morning with food.
89031372|NCT00515229|Placebo Comparator|0|Placebo: Each individual capsule has a filling volume of 25 mg placebo (corn starch), given once an day in the evening over 28 days
89031373|NCT00511316|Experimental|Drug|20 mg montelukast daily for 6 months
89031374|NCT00511316|Placebo Comparator|Placebo|20 mg daily placebo
89594140|NCT01565889|Experimental|Part A: SOF+RAL+FTC/TDF (Cohort 5)|Participants with a prestudy regimen of RAL+FTC/TDF will receive SOF+RAL+FTC/TDF for 7 days followed by RAL+FTC/TDF for 7 days. Sofosbuvir and FTC/TDF will be administered once daily in the morning with food; RAL will be administered twice daily, in the morning with food and in the evening without regard to food.
89594141|NCT01565889|Experimental|Part B: SOF+PEG+RBV|Participants will receive SOF+PEG+RBV for 12 weeks.
89594142|NCT04781517||Short-segment group|Lumbar degenerative diseases' patients,whose lumbar fixed segments less than 3 was divided into Short-segment group(200).
89594143|NCT04781517||Long-segment group|Lumbar degenerative diseases' patients,whose lumbar fixed segments no less than 3 was divided into Long-segment group(200).
89594144|NCT01696071|Experimental|Treatment A|2 puffs of daily dose (5 mcg) in the evening and 2 puffs of matching placebo in the morning via Respimat inhaler
89594145|NCT01696071|Experimental|Treatment B|2 puffs of half daily dose (2.5 mcg) twice daily, in the evening and in the morning via Respimat inhaler
89594146|NCT03855280|Experimental|APVO101|APVO101: 35 - 75 IU/kg; twice weekly
89594147|NCT01591863|Experimental|fidaxomicin|
89594148|NCT03851302|Experimental|Active RIC + isometric hand exercise|Subjects will receive an active remote ischemic conditioning (200mmHg cuff pressure) before an active isometric hand exercise.
89594149|NCT03851302|Sham Comparator|Sham RIC + isometric hand exercise|Subjects will receive an sham remote ischemic conditioning (10 mmHg below the subjects' diastolic blood pressure) before an active isometric hand exercise.
89594150|NCT03850756||1: No smokers without risk factors|"A smoker is defined as: any person who habitually consumes tobacco at the time of taking the sample or who has left it in the last 12 months (WHO, 2008).~The following circumstances involved in the development of kidney damage will be considered a risk factor: Diabetes Mellitus, Hypertension and / or frequent use of NSAIDs (more than three days a week during the three months prior to sampling)~In these patients kidney function will be evaluated by:~Early kidney damage biomarkers Predisposition to kidney injury biomarkers"
89594151|NCT03850756||2: No smokers with risk factors|"A smoker is defined as: any person who habitually consumes tobacco at the time of taking the sample or who has left it in the last 12 months (WHO, 2008).~The following circumstances involved in the development of kidney damage will be considered a risk factor: Diabetes Mellitus, Hypertension and / or frequent use of NSAIDs (more than three days a week during the three months prior to sampling)~In these patients kidney function will be evaluated by:~Early kidney damage biomarkers"
89608511|NCT04386226|Placebo Comparator|Placebo|4 grams Maltodextrin daily for 8 weeks
89031375|NCT02952950|Other|Oralstimulation|Infants whose mothers is included in the cohort is randomized to receive oral stimulation when the infant's postnatal age is at least 32 + 0 weeks, as it is the time when the infant is able to coordinate sucking and swallowing reflex
89031376|NCT02952950|No Intervention|Controlgroup|Families in the control group is not seeing the oralstimulation movie, do not receive the script or the supervision of occupational therapists and these infants do not get oral stimulation. Both groups receive instructions after usual practice i.e. guidance and elements that promote breastfeeding example, skin to skin contact and compression.
89608512|NCT04386070|No Intervention|Control (normal practice)|Treatment without the trial intervention. Patients will be treated as per hospital routine practice. The control arm may change over the course of the trial and will be monitored by the TMG and DMC
89594152|NCT03850756||3: Smokers without risk factors|"A smoker is defined as: any person who habitually consumes tobacco at the time of taking the sample or who has left it in the last 12 months (WHO, 2008).~The following circumstances involved in the development of kidney damage will be considered a risk factor: Diabetes Mellitus, Hypertension and / or frequent use of NSAIDs (more than three days a week during the three months prior to sampling)~In these patients kidney function will be evaluated by:~Early kidney damage biomarkers Predisposition to kidney injury biomarkers~Also tobacco consumption will be measured"
89594153|NCT03850756||4: Smokers without risk factors|"A smoker is defined as: any person who habitually consumes tobacco at the time of taking the sample or who has left it in the last 12 months (WHO, 2008).~The following circumstances involved in the development of kidney damage will be considered a risk factor: Diabetes Mellitus, Hypertension and / or frequent use of NSAIDs (more than three days a week during the three months prior to sampling)~In these patients kidney function will be evaluated by:~Early kidney damage biomarkers~Also Tobacco consumption will be measured"
89594154|NCT01591785|Active Comparator|Retapamulin 1% ointment|Retapamulin 1% ointment for 5 days AND clobetasol propionate foam for 14 days
89594155|NCT01591785|Placebo Comparator|Placebo ointment|Placebo ointment for 5 days AND clobetasol propionate foam for 14 days
89594156|NCT04773639|Experimental|Multi-Modal Acceptance and Commitment Therapy (M-ACT)|M-ACT consists of five 2-hour group sessions (plus booster) that alternate with self-paced online modules and check-ins that participants complete on their own, between the group sessions. The intervention addresses distress associated with coping with metastatic cancer and supports engagement in advance care planning. The intervention is based on Acceptance and Commitment Therapy, an intervention model that aims to help people cope with life challenges and difficult thoughts/feelings in a manner that helps them to live fuller and more meaningful lives.
89594157|NCT04773639|Other|Control: Usual Care|Patients in the control arm will have access to usual care (UC) at the collaborating clinics, consisting of access to a clinical social worker and nurse practitioners for advance care planning and supportive visits at patient request. After completion of study procedures, including FU, the UC participants will be offered M-ACT free of cost.
89594158|NCT03658798|Experimental|FES-Garment|All participants will take part in 40 sessions of 1 hour of Functional Electrical Stimulation
89594159|NCT03654040|Experimental|arTreg|"arTreg: alloantigen-reactive T regulatory cells~The investigational product is donor alloantigen-reactive regulatory T cells (arTreg). Supportive regimen for receipt of arTregs includes everolimus, leukapheresis, cyclophosphamide, and mesna.~Note: Participants who receive at least the minimum Treg product (arTreg) dose of 30 to <90 x10^6 total cells will be included in intent-to-treat analysis."
89594160|NCT01695993|No Intervention|Arm 1 - Standard Care Only|Patients will receive standard care only
89594161|NCT01695993|Other|Arm 2 - Expectancy-neutral Arm|"Patients receive:~Expectancy-neutral handout~Expectancy-neutral MP3~Acupressure bands"
89594162|NCT01695993|Experimental|Arm 3 - Expectancy-enhancing Arm|"Patients receive:~Expectancy-enhancing handout~Expectancy-enhancing MP3~Acupressure bands"
89594163|NCT01565343|Experimental|AD Subjects|Two bolus IV injections followed by brain PET scan up to 4 weeks apart
89594164|NCT01565343|Experimental|AD Subjects: Slow vs. Fast Bolus|"Two bolus IV injections followed by a brain PET scan up to 4 weeks apart.~The first injection given as a rapid bolus (< 5 second injection, with immediate flush). The second injection given as a slow bolus (approximately 20 to 30 second injection with a flush delayed by 10 seconds after dose administration)."
89594165|NCT01565343|Experimental|Healthy controls|Healthy male or female subjects; 35-55 years old. Two bolus IV injections followed by brain PET scan up to 4 weeks apart
89594166|NCT03743116||Orthostatic intolerant (OI)|Patients that experience symptoms of orthostatic intolerance (dizziness, nausea, vomiting, blurry vision or syncope) or orthostatic hypotension (fall in systolic pressure > 20 mmHg and/or diastolic pressure > 10 mmHg) during mobilisation
89594167|NCT03743116||Orthostatic tolerant (OT)|Patients that do not experience symptoms of orthostatic intolerance (dizziness, nausea, vomiting, blurry vision or syncope) or orthostatic hypotension (fall in systolic pressure > 20 mmHg and/or diastolic pressure > 10 mmHg) during mobilisation
89594168|NCT03740932||Study group (group A):|It will consist of 30 subjects who will have cyclic pelvic pain
89594169|NCT03740932||Study group (group B):|It will consist of 30 subjects who will have non cyclic pelvic pain.
89594170|NCT03740932||Control group (group C):|It will consist of 30 subjects normal women who will not having pelvic pain.
89594171|NCT00003460|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
89594172|NCT03646786|Experimental|visually impaired patients|
89594173|NCT03646630|Active Comparator|Quadratus Lumborum Block (QL)|Patients will be placed in the lateral position,The high-frequency linear probe will be placed on the lateral abdomen, slightly cephalic to the iliac crest. Once the QL muscle will be observed, the probe will be tilted slightly to the caudal direction, to show the largest slice of the QL muscle, to confirm its posterior aspect. A 22-G block needle (Stimuplex D, Braun, Hongo, Bunkyo-ku, and Tokyo) will be inserted in-plane, ~1 cm ventral to the probe. The needle tip will be advanced until it penetrates the posterior fascia of the QL muscle. A small amount of saline will be injected to confirm the correct position of the tip, between the QL muscle and the erector spinae and latissimus dorsi muscles (Posterior or QL block type 2), then a bolus of 0.5 ml/Kg bupivacaine 0.25% will be injected.
89594174|NCT03646630|Active Comparator|Caudal block (C)|After induction of general anesthesia, a lateral position is obtained with the upper hip flexed 90⁰ and the lower one only 45⁰. A line is drawn to connect the posterior superior iliac spines bilaterally and used as one side of an equilateral triangle; then the location of the sacral hiatus should be approximated. By palpating the sacral cornua as 2 bony prominences, the sacral hiatus could be identified as a dimple in between. A 22 gauge needle is inserted at 45 degrees to the sacrum and redirected if the posterior surface of sacral bone is contacted. Children will receive caudal block with 1 ml/kg of bupivacaine 0.25%.
89594175|NCT03842956|Active Comparator|Primary wound healing|Primary woundclosure in Allgöwer suture technique
89594176|NCT03842956|No Intervention|Secondary wound healing|no closure, open wound healing
89594177|NCT04763122||Thyroid Cancer Cases|
89594178|NCT03836872|Experimental|True Acupuncture|Patients in the experimental group will receive, in addition to standard care, a standardised 30-minute acupuncture session needling specific acupoints. Bilateral acupoints will be stimulated including Waiguan (SJ5), Jianjing (GB21), Yanglingquan (GB34), Hegu (LI4), Jiexi (ST41) and Taixi (K3). In addition, joint specific acupoints will also be used, depending on where the joint symptoms are present.
89594179|NCT03836872|Sham Comparator|Sham Acupuncture|In addition to the routine methods of care, patients allocated to the sham control group will receive sham acupuncture treatment at sham acupoints with superficial needling
89594180|NCT03836872|No Intervention|Standard Control Group|The third arm will be a standard care control arm.
89594181|NCT03836326|Experimental|Sensorimotor intervention|Is a 15-minute intervention consisting of tactile (i.e., stroking the whole body) and oral input (i.e., stroking the oral structures) for 15 minutes duration. The program will start 24 hours after nasal continuous positive airway pressure (NCPAP) is discontinued and 24 hours after 80 ml/kg/day of enteral feeds are tolerated. The program will be administered once a day for 10 days, within a 14-day period. The parents will perform all the interventions in the NICU. The infants will remain in the isolette for the duration of the program. This intervention does not involve any drugs or medical procedures. It is an intervention commonly used by occupational and physical therapists in the neonatal intensive care unit.
89594182|NCT03836326|Other|Control|Infants in the control group will receive standard care only.
89594183|NCT04762420||Sugammadex dose as suggested by senior anaesthesiologists (SSD) based on clinical experience.|
89594184|NCT04762420||Dose of Sugammadex determined by quantitative monitoring (QSD).|
89594185|NCT04747132|Experimental|Intervention group|Individualized geriatric medical counseling, psychological counseling, nutritional counseling and physical activity counseling through the internet
89594186|NCT04747132|No Intervention|Control group|Health guidance through standardized audiovisual educational material through Intenert
89594187|NCT03642106|Active Comparator|Unidos Se Puede|Unidos Se Puede: consists of 5-weekly Family Workshops, 6 monthly booster sessions, 10-months success coaching, adolescent group activities and will be compared to an attention placebo control.
89594188|NCT03642106|Placebo Comparator|Attention placebo control|Placebo consists of after school club for youth.
89594189|NCT03834142|Experimental|Intervention|NSS-2-Bridge auricular therapy will be given in addition to standard of care.
89594190|NCT03834142|No Intervention|Control|No intervention, subject receives standard of care
89594191|NCT03833440|Experimental|Durvalumab + Monalizumab|
89594192|NCT03833440|Experimental|Durvalumab + MEDI9447|
89594193|NCT03833440|Experimental|Durvalumab + AZD6738|
89594194|NCT03833440|Active Comparator|Docetaxel|
89594195|NCT03833440|Experimental|durvalumab+savolitinib|
89594196|NCT01677442|Experimental|no-intubated group|Experimental: no-intubated thoracic epidural anesthesia Thoracic epidural anesthesia at the T5/T6 thoracic interspace
89594197|NCT01677442|Active Comparator|intubated group|Active Comparator:double-lumen endotracheal intubated anesthesia
89594198|NCT01695135|Experimental|Abiraterone acetate plus prednisone|
89594199|NCT01695135|Experimental|Placebo plus prednisone|
89594200|NCT01610414|Experimental|GSK1437173A Group|Subjects received 2 doses of the candidate HZ vaccine GSK 1437173A, administered intramuscularly (IM) in deltoid region of non-dominant arm, according to a 0, 1 Month schedule.
89594201|NCT01610414|Placebo Comparator|Placebo Group|Subjects received 2 doses of placebo (saline solution), administered intramuscularly (IM) in deltoid region of non-dominant arm, according to a 0, 1 Month schedule.
89594202|NCT03832114|Experimental|Cohort A - no kidney transplant|C3G patients who have not received a kidney transplant and have reduced C3 blood levels.
89594203|NCT03832114|Experimental|Cohort B - kidney transplant|C3G patients who have received a kidney transplant and have C3G recurrence.
89594204|NCT01564407|Experimental|Safety Cohort|"Stable restrictive scar contractures resulting from abdominal surgical incision, not transversing a joint. The minimum scar length of 7 cm and a maximum scar area size of 80cm². The scar is divided into five injection areas with a minimum of 0.5 cm uninjected areas between the 5 sites.Drug Dosing for Cohort 1:~Empty control no injection~Vehicle only (0.5 ml of HypoThermosol solution)~5 million cells / cm² , single administration at Day 0~5 million cells/ cm² , single administration at week 4~5 million cells/cm² , single administration at Day 0 , repeat administration of this dose @ week 4 Subjects in Cohort 1 will undergo elective surgeries, at which time the treated scars will be removed, at week 6-8 post-treatment of the first dosed subject."
89594205|NCT01564407|Active Comparator|2.5M cells/cm2|Participants receive intervention treatment of 2.5 million cells/ cm2, single administration injected into the scar.
89594206|NCT01564407|Active Comparator|5M cells/cm2|Participants receive intervention treatment of 5 million cells /cm2, single administration
89594207|NCT01564407|Active Comparator|2.5M cells/cm2 at 4 weeks|Participants receive intervention treatment of 2.5 million cells/ cm2, repeat dose administration @ 4 weeks
89594208|NCT01564407|Active Comparator|5M cells/cm2 at 4 weeks|Participants receive intervention treatment of 5 million cells / cm2 repeat dose administration @ 4 weeks
89594209|NCT03830944||G1|"Study subjects with STEMI and increased inflammatory response at 7 days after STEMI~Interventions:~Blood sampling~transthoracic echocardiography~Late Gadolinium-Enhancement Cardiac Magnetic Resonance~Coronary Angio Computed Tomography"
89594210|NCT03830944||G2|"Study subjects with STEMI and no increased inflammatory response at 7 days after STEMI~Interventions:~Blood sampling~transthoracic echocardiography~Late Gadolinium-Enhancement Cardiac Magnetic Resonance~Coronary Angio Computed Tomography"
89594211|NCT03749902|Other|Oxytocin infusion|"Oxytocin infusion will be given through an electronic infusion pump. One unit of oxytocin will be injected in 500 mL of Ringer's lactate, started at a rate of 2 mU/min, and increased every 30 min by 2 mU/min until there are three to four contractions every 10 min. The rate will be titrated to maintain that contraction frequency. The maximum dose will be 20mU/min as oxytocin summary product characteristics.~The oxytocin group will not receive misoprostol after the membranes have ruptured."
89517602|NCT04454749||Spontaneous natural cycles|"Ultrasound scans to monitor follicular growth and serial measurements of serum LH, estradiol and progesterone levels to determine the timing of ovulation. The LH surge will be considered to have begun when the concentration rises by 180% above the most recent serum value and continues to rise thereafter.~Day 1 after the LH rise, a decrease in estradiol concentration is identified. Twenty four hours later progesterone concentrations rise with a level of greater than or equal to 1.5ng/ml confirming ovulation (day 0). This is considered as day 0 with initiation of vaginal progesterone 100mg (vaginal suppository) at 2200H. The following day (day 1) increases progesterone administration to 100mg vaginally three times daily (8 hourly) and continues this regime until 7 weeks gestation as per clinic protocol.~Embryo transfer is scheduled 5 days (day 5) following confirmation of ovulation (day 0)."
88978340|NCT00253786|Active Comparator|Standard therapy (Protocol A)|Protocol A: serum creatinine <1.2 mg/dl in male and <1.0 mg/dl in female.
89517603|NCT02318927|Experimental|Deep Brain Stimulation|Deep Brain Stimulation (DBS) of Globus Pallidum plus Pedunculopontine Nucleus, including lead implant and battery placement. Magnetic Resonance Imaging and Computed Tomography (CT) scan will be obtained prior to implant. Measurement of number of Freezing of Gait (FoG) episodes during a FoG test at a lab. Other measures include freezing of gait questionnaire, gait and falls questionnaire, activities/balance confidence scale, Parkinson's disease quality of life questionnaire, Unified Parkinson's Disease Rating Scale physiology collection and sensor testing, adverse event recording, falls diaries, tracking use of assistive devices, gait and balance testing, and neuropsychological, neurosurgical, neurological, and physical exams.
89517604|NCT04955197||the histo-pathological picture|"In the present study, the exfoliated cytology of group II and III will be compared to the histo-pathological picture of the lesion reference standard. That is because the histopathology analysis is the definitive diagnosis of oral mucosal lesions"
89517605|NCT04462913||Healthy control|According to the previous clinical diagnosis, volunteers who has never suffered the lower extremity sports injuries.
89517606|NCT04462913||Patients with sports injuries|According to the previous clinical diagnosis, patients who has suffered the sports injuries(including hip, knee, and ankle joint diseases).
89517607|NCT04462913||Patients with degenerative osteoarthritis|According to the previous clinical diagnosis, patients who has suffered the degenerative osteoarthritis.
89517608|NCT04936399||Cohort 1|Participants with Squamous Cell Oesophageal Carcinoma Receiving Nivolumab
89517609|NCT02319083||Coronary artery bypass surgery|Patients undergoing coronary artery bypass surgery.
89517610|NCT02319161||Group I|Group I: the patients with systolic blood pressure above to 150 mmHg following tourniquet inflation and in which bolus dose of calcium channel blocker 10 mg was administered by intravenous route.
89517611|NCT02319161||Group II|Group II: the patients with systolic blood pressure above to 150 mmHg following tourniquet inflation and in which bolus dose of beta blocker 0.5mg/kg was administered by intravenous route
89517612|NCT02319239|Active Comparator|Conventional fractionation|During a radiotherapy period the prostate movement will be monitored by temporary implanted electromagnetic detector. Rectum fixation at 15/39 fractions. DW-MRI at baseline, 3 months and 12 months.
89517613|NCT02319239|Experimental|hypofractionated|During a radiotherapy period the prostate movement will be monitored by temporary implanted electromagnetic detector. Rectum fixation at 10/20 fractions. DW-MRI at baseline, 3 months and 12 months.
89517614|NCT02319239|Experimental|Stereotactic fractionation|During a radiotherapy period the prostate movement will be monitored by temporary implanted electromagnetic detector. Rectum fixation at 5/5 fractions. DW-MRI at baseline, 3 months and 12 months.
89517615|NCT02321579|Placebo Comparator|Negative control|Dextrins
89517616|NCT02321579|Experimental|Supplement 1|50 mg/d vitamin B-6
89517617|NCT02321579|Experimental|Supplement 2|500 mg/d Glutathione
89517618|NCT02321579|Experimental|Supplement 3|50 mg/d vitamin B-6 plus 500 mg/d Glutathione
89517619|NCT03499925|Experimental|Test Group|Telephone consultation effectiveness and cognitive behaviors
89517620|NCT03499925|No Intervention|Comparison Group|Routine product inspection
89517621|NCT02321657|Experimental|iPad app containing art, music and games|On entry to the anaesthetic room, children will be given an iPad (the intervention) with art, music and games to distract them. A nurse will help them engage with the iPad whilst the anaesthetists complete the anaesthetic. Once the child falls asleep, the iPad will be removed. This process is anticipated to last between 3 and 30 minutes depending on the time taken to anaesthetise the child.
89517622|NCT02321657|Active Comparator|Toys, books and games|On entry to the anaesthetic room, children will be given toys or games to distract them. A nurse will help them play whilst the anaesthetists complete the anaesthetic. Once the child falls asleep, the games will be removed. This process is anticipated to last between 3 and 30 minutes depending on the time taken to anaesthetise the child.
89517623|NCT01584934|Experimental|Sodium oxybate|Patient group receives sodium oxybate as treatment.
89517624|NCT01584934|Placebo Comparator|Placebo|Patient group receives placebo as treatment.
89517625|NCT03109691|Active Comparator|group 1|30 patients will receive bupivacaine
89517626|NCT03109691|Active Comparator|group 2|30 patients will receive bupivacaine and Dexamethasone. .
89517627|NCT03499847|Active Comparator|Active Intervention|subjects will be given a pamphlet about the advanced medical directive, and a standardized face-to-face counselling session will be conducted with their healthcare provider
89517628|NCT03499847|Active Comparator|Passive Intervention|subjects will be given a pamphlet about the advanced medical directive
89517629|NCT03499847|No Intervention|Control|
89517630|NCT01575730|Active Comparator|Oxaliplatin 37°C, high dose, 30 minutes|
89517631|NCT01575730|Placebo Comparator|Oxaliplatin 41 °C, high dose, 30 minutes|
89517632|NCT01575730|Active Comparator|Oxaliplatin 37°C, low dose, 90 minutes|
89517633|NCT03499769|Experimental|natural orifice|Patients who underwent laparoscopic surgery and removed the specimen from the natural orifice will be gathered. demographic data and perioperative results will be compiled
89517634|NCT03499769|No Intervention|conventional|patients who underwent laparoscopic surgery and removed specimen with conventional will be gathered. demographic data and perioperative results will be compiled. (conventional extraction is suprapubic or median incision)
89517635|NCT03497351|Experimental|Group N|the group treated with nicardipine
89517636|NCT03497351|Experimental|Group U|the group treated with Urapidil
89517637|NCT02223754|Active Comparator|lotrafilcon B / etafilcon A|Subject randomized to this sequence will first be dispensed the lotrafilcon B contact lens and then the etafilcon A contact lens.
89517638|NCT02223754|Experimental|etafilcon A / lotrafilcon B|Subject randomized to this sequence will first be dispensed the etafilcon A contact lens and then the lotrafilcon B contact lens.
89517639|NCT02321735|Other|Long-Term Ovarian Cancer survivors|Genomic, immunologic and psychosocial characterization of Long-Term survivors of ovarian cancer. This will involve a Quality of Life Questionaire.
89517640|NCT03132389||Patients attending after a sexual assault|Patients attending and examined after sexual assault at the Sexual Assault Centre in Oslo, who have given informed consent to inclusion in the study.
89517641|NCT02319395||cases|Presence of ICD in PD patients (cases) is defined as a score ≥ 2 at 1 hyperdopaminegic item, or 2 scores ≥ 2 at 1 hyperdopaminergic item of the scale for assessment of behavior and mood in PD (ECMP).
89517642|NCT02319395||controls|Absence of ICD in PD patients (controls) is defined as a score ≤ 1 at all hyperdopaminergic items of ECMP and no more than 2 items of a score = 1.
89517643|NCT02321813|Experimental|intervention group|In the quality of life pathway results of the quality of life (QoL) measure are transferred to a QoL-profile. Three experts with various professional background use the individual patient's QoL-profile and clinical and sociodemographic information in order to generate a QoL-report including therapy recommendation which is sent to the coordinating practitioner. Specific therapeutic options for the treatment of diseased QoL have been identified: pain therapy, psychotherapy, social support, nutrition counseling, stoma care, physiotherapy, fitness. To provide continuous medical education, quality circles for each therapy option haven been founded. Coordinating practitioners receive a list with addresses of all quality circle members.
89517644|NCT02321813|Placebo Comparator|control group|In control group QoL is also measured but the coordinating practitioner neither receives a QoL-profile nor a QoL-report.
89517645|NCT02223364|Active Comparator|Peripheral Nerve Block (PNB)|This group received a continuous femoral nerve block and a single injection sciatic nerve block consisting of the following: Peripheral nerve blocks with Bupivacaine.
89517646|NCT02223364|Active Comparator|Ropivacaine (PAI-R)|This group received intra articular injection with Ropivacaine, a total volume of 120 milliliters (mL) injected in the periarticular structures by the surgeon. Following the current, standardized practice for periarticular infiltration, approximately 30 - 40 mL of solution was injected into the posterior capsule just prior to cementing the implants in place and 40 - 50 mL of solution injected into the medial and lateral retinaculum while the cement was hardening and prior to deflation of the tourniquet. The remaining volume of approximately 40 mL was injected into the quadriceps tendon and subcutaneous tissue prior to skin closure.
89517647|NCT02223364|Active Comparator|Liposomal Bupivacaine (PAI-L)|This group received Intra articular injection with liposomal bupivacaine, a total volume of 120 milliliters (mL) injected in the periarticular structures by the surgeon. Following the current, standardized practice for periarticular infiltration, approximately 30 - 40 mL of solution was injected into the posterior capsule just prior to cementing the implants in place and 40 - 50 mL of solution injected into the medial and lateral retinaculum while the cement was hardening and prior to deflation of the tourniquet. The remaining volume of approximately 40 mL was injected into the quadriceps tendon and subcutaneous tissue prior to skin closure.
89517648|NCT03497273|Experimental|Itacitinib + corticosteroids|Itacitinib administered in combination with corticosteroids.
89517649|NCT01378975|Experimental|Cohort 1: Previously Untreated Participants|Participants who had not received previous treatment for brain metastases [i.e., had never received brain stereotactic radiotherapy (SRT), whole-brain radiotherapy (WBRT), surgery, or any other treatment for their brain metastases] received Vemurafenib 960 milligram (mg) tablet orally, twice daily (BID) from Day 1 until development of progressive disease within the brain or outside of the brain (whichever occurred first), unacceptable toxicity, consent withdrawal, protocol violation endangering participant's safety, death, reasons deemed by the investigator, or study termination by the Sponsor.
89517650|NCT01378975|Experimental|Cohort 2: Previously treated Participants|Participants who were previously treated with brain SRT, WBRT, or surgery for their brain metastases and have progressed following this treatment, received Vemurafenib 960 milligram (mg) tablet orally, BID from Day 1 until development of progressive disease within the brain or outside of the brain (whichever occurred first), unacceptable toxicity, consent withdrawal, protocol violation endangering participant's safety, death, reasons deemed by the investigator, or study termination by the Sponsor.
89517651|NCT03499535|Active Comparator|Study 1: Radon&Smoking Synergistic/EPA|Participants viewed radon and smoking risk information taken from the EPA's pamphlet on the dangers of radon gas exposure.
89517652|NCT03499535|Active Comparator|Study 1: Radon&Smoking Synergistic/Idaho|Participants viewed radon and smoking risk information taken from Idaho's Department of Health and Human Welfare's pamphlet on the dangers of radon gas exposure.
89517653|NCT03499535|Experimental|Study 1: Radon Only / EPA|Participants viewed only radon risk information taken from the EPA's pamphlet on the dangers of radon gas exposure.
89517654|NCT03499535|Experimental|Study 1: Radon Only / Idaho|Participants viewed only radon risk information taken from Idaho's Department of Health and Human Welfare's pamphlet on the dangers of radon gas exposure.
89517655|NCT03499535|Experimental|Study 2: Radon Only|Participants viewed a radon-only message that focused only on the effect of radon on lung-cancer risk.
89517656|NCT03499535|Other|Study 2: Radon and Smoking Isolated|Participants viewed a radon-and-smoking-isolated message that covered the individual effects of radon and of smoking on lung cancer, but without mentioning their synergistic effect.
89517657|NCT03499535|Active Comparator|Study 2: Radon & Smoking Synergistic|Participants viewed a radon-and-smoking-synergistic message that covered the individual effects of radon and of smoking but that also included information about their synergistic effect.
89517658|NCT02321891|Experimental|Treatment 1|NeuroConn DC Stimulator Plus, tDCS treatment protocol no 1
89517659|NCT02321891|Experimental|Treatment 2|NeuroConn DC Stimulator Plus, tDCS treatment protocol no 2
89517660|NCT05165719||Vaccinated|SARS-CoV-2 vaccination with 'Sputnik V' (Gam-COVID-Vac) in a period 7-14 days after the second vaccination before recruitment
89594212|NCT03749902|Other|Oral misoprostol|"An initial dose of misoprostol 25mcg will be given orally after randomisation (this must be a minimum of 2 hours after the previous misoprostol dose).~The next dose of oral misoprostol will be omitted if moderate or strong contractions are occurring at 3 in 10 minutes or more (i.e. 9 or more in the preceding 30 minutes)~If contractions subsequently reduce to less than 3 in 10 (under 9 in 30 minutes), or become irregular or mild, then the oral misoprostol 25mcg can be restarted~In the event of inadequate progress, clinicians will be advised to give further misoprostol if there are any concerns about contractions strength or frequency."
89594213|NCT01590771|Experimental|Sitagliptin|Sitagliptin 100 mg once daily for 24 weeks. Participants will continue pre-study gliclazide or glimepiride with or without metformin for ≥10 weeks before and throughout the study. All participants will receive placebo during run-in period.
89594214|NCT01590771|Placebo Comparator|Placebo|Matching placebo once daily for 24 weeks. Participants will continue pre-study gliclazide or glimepiride with or without metformin for ≥10 weeks before and throughout the study.
89594215|NCT03735940|No Intervention|Control phase|no intervention, i.e. care as usual
89594216|NCT03735940|Experimental|Intervention phase|experimental intervention: spot monitoring device, i.e. use of DeltaScan
89594217|NCT03830242|Experimental|<Sup>18<Sup>F-FDG PET/CT study group|<Sup>18<Sup>F-FDG PET/CT dynamic scan,Pathological examination and gene detection Diagnostic Test: <Sup>18<Sup>F-FDG PET/CT dynamic scan The purpose of this study is to carry out <Sup>18<Sup>F-FDG PET/CT dynamic scans and Pathological examination of metastatic central lymph nodes in newly diagnosed patients with papillary thyroid cancer, and to compare imaging findings, genomics, and pathology at the same time. The intrinsic relationship between tissue characteristics and the diagnostic value of <Sup>18<Sup>F-FDG PET/CT dynamic imaging in metastatic central lymph nodes with papillary thyroid cancer are discussed.
89594218|NCT03830242|Other|B-ultrasonography group|B-ultrasonography,Pathological examination and gene detection Diagnostic Test:B-ultrasonography The purpose of this study is to carry out <Sup>18<Sup>F-FDG PET/CT dynamic scans and Pathological examination of metastatic central lymph nodes in newly diagnosed patients with papillary thyroid cancer, and to compare imaging findings of B-ultrasonography , genomics, and pathology at the same time. The intrinsic relationship between tissue characteristics and the diagnostic value of <Sup>18<Sup>F-FDG PET/CT dynamic imaging in metastatic central lymph nodes with papillary thyroid cancer are discussed.
89594219|NCT04764058|Other|Montherapy|Thirty patients will receive IV Imipenem in doses of 15 to 25 mg/kg every 6 hours
89594220|NCT04764058|Other|Combination|Thirty patients will receive IV Colistin in dosages of 50,000-75,000 IU/kg/day in three divided doses, infused IV in 10mL normal saline over 30 minutes with IV Imipenem in doses of 15 to 25 mg/kg every 6 hours¬.21,22,24 Colistin formulation consists of 2 million IU per vial.
89594221|NCT04763824|Active Comparator|cluster-randomized controlled trial, with delayed start control arm|Control arm/Delayed Onset
89594222|NCT04763824|Experimental|cluster-randomized controlled trial, intervention|Intervention arm
89594223|NCT03638674|Active Comparator|2nd lumbar spine acquisition in same position|spine and hip STRATOS DR + 2nd lumbar spine acquisition in same position (with template)
89594224|NCT03638674|Active Comparator|2nd lumbar spine acquisition|spine and hip STRATOS DR + 2nd lumbar spine acquisition (no template)
89594225|NCT03638674|Active Comparator|2nd hip acquisition in same position|spine and hip STRATOS DR + 2nd hip acquisition in same position (with template)
89594226|NCT03638674|Active Comparator|2nd hip acquisition|spine and hip STRATOS DR + 2nd hip acquisition (without template)
89594227|NCT01563237|Experimental|MIDI Arrow|Implantation of MIDI Arrow
89594228|NCT03735316|Experimental|B12a|Subjects will receive Hydroxocobalamin marketed as Cyanokit®, 5g, IV
89594229|NCT03735316|Placebo Comparator|Placebo|Subjects will receive placebo
89594230|NCT01694433|Experimental|Calcipotriene Cream|The Calcipotriene Cream will be supplied as 1g daily use individual tubes to be used 2x/day (once in the morning and once in the evening) for 12 weeks.
89594231|NCT01694433|Placebo Comparator|Placebo|The Placebo Cream will be supplied as 1g daily use individual tubes to be used 2x/day (once in the morning and once in the evening) for 12 weeks.
89594232|NCT01694121|Experimental|MEN Count|3 session HIV intervention including a) HIV risk reduction, inclusive of gender equity and healthy relationship counseling and b) case management support for stable employment and housing.
89594233|NCT01694121|Active Comparator|Comparison|An attention comparison program similar to the MEN Count intervention in structure (3 one-on-one sessions delivered over 60-90 days) but focused on stress reduction and healthy lifestyle.
89594234|NCT01562613||Hypertensive patients|All eligible hypertensive patients treated with eprosartan
89594235|NCT01676662|Experimental|Treatment on Day 0|Subjects who are treated with the Solace Bladder Control System upon entry into the trial.
88978341|NCT00253786|Experimental|Intensive multifactorial therapy (Protocol B)|Protocol B: serum creatinine: 1.2-2.5 mg/dl in male and 1.0-2.5 mg/dl in female.
88978342|NCT00253786|Active Comparator|Standard therapy (Protocol B)|Protocol B: serum creatinine: 1.2-2.5 mg/dl in male and 1.0-2.5 mg/dl in female.
88978343|NCT04719481|Experimental|pravastatin 80mg/d|Oral administration of pravastatin at 1 h before zoledronic acid infusion, 24 h and 48 h after zoledronic acid infusion
88978344|NCT04719481|Placebo Comparator|placebo|Oral administration of placebo at 1 h before zoledronic acid infusion, 24 h and 48 h after zoledronic acid infusion
89594236|NCT01676662|Sham Comparator|Sham Treatment on Day 0|Patients who undergo a sham procedure upon entry into the trial, with treatment with the Solace Bladder Control System at 3 months after the sham procedure.
88978345|NCT00253903|Experimental|1|5 mg/day
88978346|NCT00253903|Placebo Comparator|2|
88978347|NCT00414934||metastatic bone lesion for patients with cancer|
88978348|NCT00415090|No Intervention|1|Follow with same ARV treatment
88978349|NCT00415090|Experimental|2|Switch one of ARV drugs to Nevirapine
88978350|NCT00415129|Experimental|Study Group 1|Vaccine with adjuvant
88978351|NCT00415129|Experimental|Study Group 2|Vaccine without adjuvant
88978352|NCT00254176|Active Comparator|Cysteine|Subjects that receive cysteine
88978353|NCT00254176|Placebo Comparator|No-cysteine placebo|Subjects that do not receive cysteine but an isonitrogenous placebo
88978354|NCT00100542||1|All HIV infected and uninfected participants and their caregivers.
89594237|NCT01693185|Experimental|Remifentanil|remifentanil of 0.04 mcg/kg/min with placebo (for midazolam) and placebo (for meperidine)
89594238|NCT01693185|Active Comparator|midazolam and meperidine|a bolus midazolam of 0.03 mg/kg a bolus meperidine of 1.0 mg/kg placebo (for remifentanil)
89594239|NCT01676974||Travelers|Travelers and their family members
89594240|NCT03630640|Experimental|Nivolumab Injection [Opdivo]|Intravenous Nivolumab 240 Q2W neoadjuvant Intravenous Nivolumab 480 mg Q4W- adjuvant for 12 months
89594241|NCT03629470|Active Comparator|Group 1|standard conservative treatment
89594242|NCT03629470|Experimental|Group 2|nerve gliding exercises along with the standard conservative treatment.
89594243|NCT03629080|Experimental|HB-101 vaccine preemptive|Three doses of HB-101 vaccine will be administered prior to transplantation and within proximity to the time of transplantation. However, two doses of HB-101 will be sufficient for the patients to be included in the efficacy analyses if an administration of the third dose is not feasible due to transplantation timelines. Post-transplant patients will be monitored per preemptive institutional standard.
89594244|NCT03629080|Placebo Comparator|Placebo preemptive|Three doses of placebo will be administered prior to transplantation and within proximity to the time of transplantation. However, two doses of placebo will be sufficient for the patients to be included in the efficacy analyses if an administration of the third dose is not feasible due to transplantation timelines. Post-transplant patients will be monitored per preemptive institutional standard.
89594245|NCT03629080|Experimental|HB-101 vaccine prophylactic|Three doses of HB-101 will be administered prior to transplantation and within proximity to the time of transplantation. However, two doses of HB-101 will be sufficient for the patients to be included in the efficacy analyses if an administration of the third dose is not feasible due to transplantation timelines. Post- transplant patients will receive 3-6 months anti-viral prophylaxis following institutional standard.
89594246|NCT03629080|Placebo Comparator|Placebo prophylactic|Three doses of placebo will be administered prior to transplantation and within proximity to the time of transplantation. However, two doses of placebo will be sufficient for the patients to be included in the efficacy analyses if an administration of the third dose is not feasible due to transplantation timelines. Post- transplant patients will receive 3-6 months anti-viral prophylaxis following institutional standard.
89594247|NCT03629080|Experimental|HB-101 vaccine: CMV (+) patients-Prophylactic Management|Three doses of HB-101 will be administered prior to transplantation and within proximity to the time of transplantation. However, two doses of HB-101 will be sufficient for the patients to be included in the efficacy analyses if an administration of the third dose is not feasible due to transplantation timelines. Post- transplant patients will receive 3-6 months anti-viral prophylaxis following institutional standard.
89594248|NCT03629080|Experimental|HB-101 vaccine: CMV (+) patients-Preemptive Management|Three doses of HB-101 will be administered prior to transplantation and within proximity to the time of transplantation. However, two doses of HB-101 will be sufficient for the patients to be included in the efficacy analyses if an administration of the third dose is not feasible due to transplantation timelines. Post- transplant patients will follow pre-emptive management per institutional standard.
89594249|NCT03628534|Experimental|single arm|Ablation of ventricular tachycardia with a saline-enhanced radiofrequency ablation catheter
89594250|NCT03820882|Experimental|stent retriever(Catfish)|Mechanical thrombectomy with Catfish flow restoration device
89594251|NCT03820882|Active Comparator|stent retriever(Solitaire FR)|Mechanical thrombectomy with Solitaire FR flow restoration device
89594252|NCT03815500|Experimental|Patients with open surgical wounds|Patients with open surgical wounds will undergo enhanced packing education with curriculum designed for learners with low literacy, dyslexia or associated learning disorders.
89594253|NCT03625726|Experimental|patients with cirrhosis|pathophysiology study, blood sample
89594254|NCT03625726|Placebo Comparator|healthy volunteers|pathophysiology study, blood sample
89594255|NCT03625726|Placebo Comparator|patients with hepatocellular carcinoma|pathophysiology study, blood sample
89594256|NCT04403854||ME/CFS patients|Patients diagnosed according to Canada Criteria 2003
89594257|NCT04403854||Healthy Controls|Age and sex matched healthy controls
89594258|NCT03814954|Active Comparator|Salbutamol|Patients will receive salbutamol (2 units/kg) with 3 ml normal saline by nebulizer.
89594259|NCT03814954|Experimental|Epinephrine|Patients will receive epinephrine (0.5 mg/dose) with 3 ml normal saline by nebulizer.
89594260|NCT03813160|Experimental|Lenabasum 20 mg|Subjects will receive lenabasum 20 mg twice daily
89594261|NCT03813160|Experimental|Lenabasum 5 mg|Subjects will receive lenabasum 5 mg twice daily
89594262|NCT03813160|Placebo Comparator|Placebo|Subjects will receive placebo twice daily
89594263|NCT03812848|No Intervention|Pre program implementation|All hospitalized patients on therapeutic anticoagulant medication during the pre-implementation period of the anticoagulation stewardship program.
89594264|NCT03812848|Experimental|Post program implementation|All hospitalized patients on therapeutic anticoagulant medication during the post-implementation period of the anticoagulation stewardship program.
89594265|NCT03811132||No DD or DS|No diabetes distress or depressive symptoms reported (CES-D < 22, PAID < 40)
89594266|NCT03811132||DD without DS|Diabetes distress but no depressive symptoms reported (CES-D < 22, PAID ≥ 40)
89594267|NCT03811132||DS without DD|Depressive symptoms but no diabetes distress reported (CES-D ≥ 22, PAID < 40)
89594268|NCT03811132||DD and DS|Both diabetes distress and depressive symptoms reported (CES-D ≥ 22, PAID ≥ 40)
89594269|NCT03619252|Experimental|Vaccination group|Patients receiving novel agents (Bortezomib/Lenalidomide/Ixazomib/Daratumumab) and enrolled in vaccination by pneumococcal conjugate vaccine (PCV13): 3 doses with 1 month interval, and fourth dose planned to be administered 6 months later.
89594270|NCT03619252|Active Comparator|Standard prophylaxis|Patients receiving novel agents (Bortezomib/Lenalidomide/Ixazomib/Daratumumab) and receiving standard institutional antibacterial prophylaxis by Levofloxacin 500 mg daily during the median four cycles of treatment by novel agents
89594271|NCT03717142|No Intervention|Auto-fluorescence|No LUM015 injection will be given to three (3) patients, in each indication, to measure baseline tissue fluorescence. Imaging with the LUM imaging device will be performed in vivo and ex vivo on surgical tissue.
89594272|NCT03717142|Experimental|1st Tier Dose Level|3 patients, in each indication, will be administered a single dose of LUM015 at 1.0 mg/kg.Imaging with the LUM imaging device will be performed in vivo and ex vivo on surgical tissue.
89594273|NCT03717142|Experimental|2nd Tier Dose Level|3 patients, in each indication, will be administered a single dose of LUM015 at 2.0 mg/kg. Imaging with the LUM imaging device will be performed in vivo and ex vivo on surgical tissue.
89594274|NCT03717142|Experimental|3rd Tier Dose Level|After an interim analysis, the dosing for the 3 patients, in each indication, will be administered a single dose of LUM015 of no greater than 3.0 mg/kg. Imaging with the LUM imaging device will be performed in vivo and ex vivo on surgical tissue.
89594275|NCT03807856|Active Comparator|Dabigatran Etexilate Mesylate|Dabigatran 150mg BID for 3 days
89594276|NCT03807856|Active Comparator|Standard of Care|Standard treatment for acute pancreatitis
89594277|NCT03807154|Experimental|Internet-based cognitive behavioral therapy (ICBT)|A nine-week long ICBT intervention with therapist support.
89594278|NCT03807154|Experimental|Internet-based Interpersonal Therapy (IIPT)|A nine-week long intervention based in interpersonal psychotherapy with therapist support.
89594279|NCT03807154|No Intervention|Wait-list|Wait-list control group
89594280|NCT03806530|Active Comparator|Gabapentin + Ropinirole|Gabapentin 100 mg capsule, once daily for 4 weeks. Ropinirole 0.50 mg capsule, once daily for 4 weeks.
89594281|NCT03806530|Placebo Comparator|Gabapentin + Placebo Ropinirole|Gabapentin 100 mg capsule, once daily for 4 weeks. Ropinirole placebo 0.50 mg capsule, once daily for 4 weeks.
89594282|NCT03806530|Placebo Comparator|Ropinirole + Placebo Gabapentin|Gabapentin placebo 100 mg capsule, once daily for 4 weeks. Ropinirole 0.50 mg capsule, once daily for 4 weeks.
89594283|NCT03806530|Placebo Comparator|Placebo Gabapentin + Placebo Ropinirole|Gabapentin placebo 100 mg capsule, once daily for 4 weeks. Ropinirole placebo 0.50 mg capsule, once daily for 4 weeks.
89594284|NCT03608020|Active Comparator|WBRT + BMX-001|Whole brain radiation therapy in combination with BMX-001 (subcutaneous injection of 28 mg loading dose, followed by subsequent 14 mg twice per week for 2 weeks).
89594285|NCT03608020|No Intervention|Whole Brain Radiation Therapy|Whole brain radiation therapy per standard of care.
89594286|NCT00003820|Experimental|Rituximab 375 mg/m2 per week|"375 mg/m2 rituximab by IV infusion weekly. The initial course of treatment is 4 weeks.~Subjects who achieve an objective response or stable disease after the initial course (4 weeks) were permitted to continue additional 4-week cycles of treatment, for 3 additional courses starting every 6 months (ie, at 6; 12; and 18 months)."
89594287|NCT01693029|Experimental|HX575 epoetin alfa|HX575, recombinant human epoetin alfa
89594288|NCT01693029|Active Comparator|US-licensed epoetin alfa|US-licensed recombinant human epoetin alfa
88978355|NCT00254254|Experimental|Sequence 1|Exenatide 2.5 mcg - Exenatide 5 mcg - Placebo 0.02 mL
88978356|NCT00254254|Experimental|Sequence 2|Exenatide 2.5 mcg - Placebo 0.02 mL - Exenatide 5 mcg
88978357|NCT00254254|Experimental|Sequence 3|Placebo 0.02 mL - Exenatide 2.5 mcg - Exenatide 5 mcg
88978358|NCT00254644||Dyslexia|adults from 18-35 ans.
88978359|NCT00254644||Control|adults from 18-35 ans.
88978360|NCT00254683|Experimental|PET/CT|Single arm study evaluating the use of PET/CT to assess rectal cancer response to neoadjuvant therapy
88978361|NCT00254722|Experimental|I|single arm study
88978362|NCT00254761|Experimental|1|High dose cannabis (7.5% THC by weight)
89594289|NCT01589445|Experimental|Pioglitazone (001 group)|The patients received pioglitazone hydrochloride tablet 30 mg (001 drug)once daily for first three months
89594290|NCT01589445|Experimental|Metformin (002 group)|The patients received metformin hydrochloride tablet 850 mg (002 drug)once daily for next three months.
89594291|NCT01588509|Experimental|Romosozumab 140 mg|Participants received romosozumab 140 mg administered subcutaneously once a month for 3 months.
89594292|NCT01588509|Experimental|Romosozumab 210 mg|Participants received romosozumab 210 mg administered subcutaneously once a month for 3 months.
89594293|NCT01588353|Experimental|AK160 0.58 mg|
89594294|NCT01588197|Experimental|ACC Real Time fMRI Feedback|"Each participant will undergo thermal pain threshold assessments ten times using the Medoc Pathway System with MRI-compatible ATS Thermode (30mmX30mm; Medoc Inc, Israel). Participants will be instructed to focus on the thermal stimuli for the first 5 trials, and to engage in three cognitive pain inhibition strategies (Attention/Distraction Strategy, Stimulus Quality/Severity Strategy, and the Control Strategy.~The participants will be randomly assigned to receive Real Time fMRI Feedback of inverse activation in the rACC after each pain/rest block during the last 3 fMRI scans in the form of two simple thermometer images on the in-scanner computer display."
89594295|NCT01588197|Experimental|PFC Real Time fMRI Feedback|"Each participant will undergo thermal pain threshold assessments ten times using the Medoc Pathway System with MRI-compatible ATS Thermode (30mmX30mm; Medoc Inc, Israel). Participants will be instructed to focus on the thermal stimuli for the first 5 trials, and to engage in three cognitive pain inhibition strategies (Attention/Distraction Strategy, Stimulus Quality/Severity Strategy, and the Control Strategy. The participants will be randomly assigned to receive Real Time fMRI Feedback of inverse activation in the PFC after each pain/rest block during the last 3 fMRI scans in the form of two simple thermometer images on the in-scanner computer display."
89594296|NCT01561989|Experimental|Arm I (400 IU cholecalciferol and vaccine therapy)|Patients receive low-dose cholecalciferol PO QD for 12 weeks, followed by the seasonal (2012-2013) trivalent influenza vaccine IM.
89594297|NCT01561989|Experimental|Arm II (4,000 IU cholecalciferol and vaccine therapy)|Patients receive high-dose cholecalciferol PO QD for 12 weeks, followed by the seasonal (2012-2013) trivalent influenza vaccine IM.
89594298|NCT00004054|Experimental|Hormones and RT|Androgen suppression (AS) (Luteinizing hormone releasing hormone agonist and bicalutamide [Casodex] or flutamide [Eulexin]) x 8 weeks followed by RT to 70.2 Gy with concurrent AS (LHRH agonist and bicalutamide [Casodex] or flutamide [Eulexin]). AS will continue for a total of 24 months from initiation of all treatment. Oral anti-androgen will be discontinued at the end of radiation therapy (RT).
89031377|NCT02951091|Experimental|biomarker group|400 Her-2 (-) metastatic/recurrent gastric cancer patients will be centrally screened for druggable targets [Epstein-Barr virus, Microsatellite instability, HER2, EGFR, c-MET, and PTEN] by immunohistochemistry and in situ hybridization during first line chemotherapy. At the time of second line treatment, patients will be randomized to the biomarker vs control group as 4: 1 ratio. The biomarker group will be offered for entry into a specific protocol based on their molecular cohort and treated with specific targeted agents in combination with weekly paclitaxel; 1) EGFR cohort (EGFR 2+ or EGFR 3+) for pan-ERBB inhibitor (afatinib), 2)PTEN loss cohort (PTEN score less than 100) for PIK3CB inhibitor (GSK2636771), 3) PD-L1 positive, MSI-high, or EBV positive cases for nivolumab, 4) none for weekly paclitaxel.
89031378|NCT02951091|Active Comparator|control group|Patients will be randomized to the biomarker vs control group (standard of care; paclitaxel) as 4:1 ratio.
89031379|NCT00511394|Active Comparator|I|Infusion of 100 mL of 20% Albumin
89594299|NCT00004054|Experimental|Hormones and RT plus Chemotherapy|AS (LHRH agonist and bicalutamide [Casodex] or flutamide [Eulexin]) x 8 weeks followed by RT to 70.2 Gy with concurrent AS (LHRH agonist and bicalutamide [Casodex] or flutamide [Eulexin]) and estramustine phosphate sodium, etoposide, paclitaxel, and warfarin [Coumadin®]. AS will continue for a total of 24 months from initiation all treatment. Oral antiandrogen will be discontinued at the end of RT.
89594300|NCT01587885|Experimental|Omeprazole 20 mg + Sodium Bicarbonate 1100 mg|Participants will receive omeprazole 20 mg + sodium bicarbonate 1100 mg once a day for 4 days, and then after a washout period, omeprazole 20 mg once a day for 4 days.
89031380|NCT00511394|Placebo Comparator|II|100 mL Normal Saline
89031381|NCT00529230||Chronic opioid therapy + Gonadal function|Males on chronic opioid therapy for cancer-related pain syndromes
89031382|NCT02952443||Exercise|EX group will attend multi-component exercise sessions 3 times a week at 45-60 minutes a session for 16 weeks. Each session will include aerobic, flexibility, resistance and balance training but a strong emphasis will be placed on the latter two components.
89594301|NCT01587885|Active Comparator|Omeprazole 20 mg|Participants will receive omeprazole 20 mg once a day for 4 days, and then after a washout period, omeprazole 20 mg + sodium bicarbonate 1100 mg once a day for 4 days.
89594302|NCT01587651|Experimental|Prasugrel Maintenance Dose|Prasugrel 10 mg QD MD
89594303|NCT01587651|Active Comparator|Ticagrelor Maintenance Dose|Ticagrelor 90 mg twice-daily (BID) MD
89594304|NCT01587651|Experimental|Prasugrel Loading Dose|Prasugrel 60mg Loading Dose (LD), followed by prasugrel 10mg once-daily (QD) Maintenance Dose (MD)
89594305|NCT04763434|Active Comparator|RS group|20 ml mixture of 37.5 mg ropivacaine with 5 mg dexamethasone
89594306|NCT04763434|Active Comparator|RM group|20 ml mixture of 37.5 mg ropivacaine with 1 µg/kg dexmedetomidine
89594307|NCT04763434|Experimental|RSM group|20 ml mixture of 37.5 mg ropivacaine with 1 µg/kg dexmedetomidine and 5 mg dexamethasone (RSM group)
89594308|NCT04763668||Pregnant HIV positive women on ART|Sub-Saharan women with singleton uncomplicated 11-14 week old pregnancies at recruitment, HIV positive and have been on ARTs for at least four months before pregnancy. Participants must not have type 2 diabetes, gestational diabetes, renal / cardiovascular diseases or any critical health condition.
89594309|NCT04763668||Pregnant HIV negative women|Sub-Saharan women with singleton uncomplicated 11-14 week old pregnancies at recruitment, HIV negative. Participants must not have type 2 diabetes, gestational diabetes, renal / cardiovascular diseases or any critical health condition.
89594310|NCT04763668||Babies born to HIV positive mothers on ARTs|All babies born to pregnant HIV positive women on ARTs who were in the first arm of the study
89031383|NCT02952443||Control|CON group will be asked to just maintain their normal daily living habits for the duration of the study. The same exercise program will be made available to the CON group upon completion of the study.
89594311|NCT04763668||Babies born to HIV negative mothers|All babies born to pregnant HIV negative women who were in the first arm of the study.
89594312|NCT04747210|Active Comparator|Trainig workshop and Coaching one-on-one|Ten-hour training workshop that was divided into three sessions outside working hours. Coaching one-on-one in the daily routines and natural environment.
89594313|NCT04747210|Active Comparator|Trainig workshop|Assistants receive ten-hour training workshop that was divided into three sessions outside working hours.
89594314|NCT04762966||Therapeutic|Patients with metformin blood concentration in the therapeutic ranges.
89594315|NCT04762966||Supratherapeutic|Patients with metformin blood concentration above the therapeutic ranges.
89594316|NCT03602560|Experimental|Seladelpar 5-10 mg|
89031384|NCT02952911|Experimental|A: MS Participants|MS participants will perform various active tests (daily, weekly or bi-weekly) and passive monitoring (daily) using smartphone and smartwatch over 24 weeks.
89031385|NCT02952911|Other|B: Healthy Controls|Healthy participants will perform various active tests (daily, weekly or bi-weekly) and passive monitoring (daily) using smartphone and smartwatch over 24 weeks.
89031386|NCT00515268|Experimental|Subjects receiving GSK256066|Eligible subjects will be randomized to receive GSK256066 with inhaled doses of 25 micrograms or 87.5 micrograms once daily for 7 days, administered via an ACCUHALER.
89594317|NCT03602560|Experimental|Seladelpar 10 mg|
89594318|NCT03602560|Placebo Comparator|Placebo|
89594319|NCT03597256|Experimental|Treatment Group|Single injection and optional touch-up injection with Restylane Defyne in chin
89594320|NCT03597256|No Intervention|Control Group|No treatment
89594321|NCT03596788|Experimental|Carbohydrate Beverage|A glucose-fructose beverage mixture supplying 100 grams of carbohydrate per day for 5 days
89594322|NCT03596788|Placebo Comparator|Placebo Beverage|An artificially-sweetened beverage containing aspartame
89594323|NCT01691859|Experimental|Mepolizumab|Subjects will receive 100 mg of mepolizumab (in 1ml polypropylene syringe) injected subcutaneously (SC) approximately every 4 weeks.
89594324|NCT01414192||Ezetimibe monotherapy without prior treatment|Enrolled participants who had no prior lipid-lowering therapy and were currently receiving Ezetimibe alone (Ezetrol®).
89594325|NCT01414192||Ezetimibe monotherpay with prior treatment|Enrolled participants with prior lipid-lowering therapy and were currently receiving Ezetimibe alone (Ezetrol®).
89594326|NCT01414192||Ezetimibe plus statin|Enrolled participants who were being coadministered ezetimide (Ezetrol®) and another prescription statin.
89594327|NCT01414192||Ezetimibe/simvastatin|Enrolled participants who were receiving ezetimibe and simavastatin fixed dose combination tablet (Inegy®).
89594328|NCT00779116|Active Comparator|RediTab/Zyrtec|Subjects received a single dose of desloratadine RediTab followed 8-10 minutes later by a single dose of Zyrtec chewable tablet followed thereafter by a statement of preference.
89594329|NCT00779116|Active Comparator|Zyrtec/RediTab|Subjects received a single dose of Zyrtec chewable tablet followed 8-10 minutes later by a single dose of desloratadine RediTab followed thereafter by a statement of preference.
89594330|NCT02073435||Post-Implementation Group|Living Donor Liver Transplant patients with evidence based donor pain management solution.
89594331|NCT02073435||Pre-Implementation Group|Living Donor Liver Transplant patients prior to the implementation of the evidence based donor pain management solution.
89594332|NCT01676740|Placebo Comparator|Mild anemia, normal hematinics|Mild anemia, normal iron studies, serum folate and vitamin B12 levels - will receive placebo
89594333|NCT01676740|Experimental|Anemia, normal hematinics|Mild anemia, deficient iron, folate or vitamin B12 levels Iron supplement will be given
89594334|NCT01676740|Other|Deficeicnt hematinics|Iron supplement will be provided
89594335|NCT01691781|Experimental|lisinopril|Lisinopril - open-label, 2.5-40mg daily
89594336|NCT04111731|Active Comparator|Group one|Cryoballoon pulmonary vein isolation
89594337|NCT04111731|Active Comparator|Group two|Radiofrequency pulmonary vein isolation
89594338|NCT01561755|Experimental|Intravenous Immunoglobulin|Intravenous Immunoglobulin - 2gr/kg over 2 days of Privigen®
89594339|NCT01561755|Placebo Comparator|Placebo|Saline 2gr/kg over 2 days of saline
89594340|NCT03789214|Placebo Comparator|Placebo|Placebo sleep medication (Placebo oral capsule)
89594341|NCT03789214|Active Comparator|Low Dose Suvorexant|Low dose sleep medication
89594342|NCT03789214|Active Comparator|High Dose Suvorexant|High dose sleep medication
89594343|NCT01585155|Experimental|TA-650|
89594344|NCT04124367|Active Comparator|Verum|
89594345|NCT04124367|Placebo Comparator|Control|
89594346|NCT01560507|Active Comparator|varenicline (Chantix)|This group will consist of smokers who, based on smoking behavior, DO NOT respond favorably to pre-cessation Nicotine Replacement Therapy (NRT) assessed the day before the scheduled quit day. They will receive varenicline.
89594347|NCT01560507|Active Comparator|nicotine patches|This group will consist of smokers who, based on smoking behavior, respond favorably to pre-cessation NRT (assessed the day before the scheduled quit day). They will continue to using only nicotine patches.
89594348|NCT01560507|Active Comparator|bupropion (Zyban) and nicotine patches|This group will consist of smokers who, based on smoking behavior, DO NOT respond favorably to pre-cessation NRT (assessed the day before the scheduled quit day). They will receive bupropion with nicotine patches.
89594349|NCT03785470|Experimental|Fructose and physical inactivity|Subjects will consume 6 cans of soda per day and restrict their physical activity.
89594350|NCT03591328||Culprit|Plaques which is related with acute coronary syndrome
89594351|NCT03591328||Non-culprit|Plaques which is not related with acute coronary syndrome
89594352|NCT03694600||men or women between 21-84|Multi-analyte blood test screening alone and as combination with multi-analyte Test and Ultrasound in subjects diagnosed with liver cirrhosis
89594353|NCT03690700|Active Comparator|active BFRE|14 consecutive SCI patients are block-randomized to active arm
89594354|NCT03690700|Sham Comparator|sham BFRE|14 consecutive SCI patients are block-randomized to sham arm
89594355|NCT01677520||18-30 yrs, 31-50 yrs, 51-70 yrs|No intervention
89594356|NCT03684538|Experimental|Group Probiotics|Patients in this group will be given the standard of care (initiation of hydration and early refeeding, in addition to the use of antimicrobials in case a pathogen was identified). In addition to that, the patients in this group will receive probiotics (Saccharomyces boulardii) one dose per day.
89594357|NCT03684538|Experimental|Group Zinc|Patients will be given the standard of care (initiation of hydration and early refeeding, in addition to the use of antimicrobials in case a pathogen was identified). In addition to that, the patients in this group will receive zinc (10 mg for patients less than 6 month and 20 mg for older patients) one dose per day.
89594358|NCT03684538|Active Comparator|Group Probiotics & Zinc|Patients will be given the standard of care (initiation of hydration and early refeeding, in addition to the use of antimicrobials in case a pathogen was identified). In addition to that, the patients in this group will receive a combination of probiotics (Saccharomyces boulardii) with zinc (10 mg for patients less than 6 month and 20 mg for older patients) one dose per day.
89594359|NCT03682978|Experimental|Arbaclofen|"Arbaclofen is provided as orally disintegrating tabs, round, white and beveled edges, at the following strengths: 5mg, 10mg, 15mg and 20mg.~A flexible dose titration schedule will be utilized during the first 5 weeks of the Treatment Period. Dosing regimens will be stratified by age. The total up-titration to 15 mg TID or 20 mg TID, and dose adjustment period to the optimal dose will be 35 days. If a participant does not tolerate a dose increase, he or she should return to the previous dose level and must remain at the dose level for the remainder of the Treatment Period. No changes should be made to dosing after 5 weeks, unless for safety.~5-11 years: Week 0 (BID) 5mg; Week 1 (BID) 5mg; Week 2 (TID) 10mg; Week 3 (TID) 10mg; Week 4-16 (TID) 15mg.~12-17 years: Week 0 (QD) 5mg; Week 1 (BID) 10mg; Week 2 (BID) 10mg; Week 3 (TID) 15mg; Week 4-16 (TID) 20mg."
89594360|NCT03682978|Placebo Comparator|Placebo|"Placebo tablets will have similar form, colour, smell and taste compared to the Arbaclofen tablets, and will be provided in non-distinguishable packaging.~Dosage level is n/a."
89594361|NCT03676192|Experimental|CT-P16|Drug: Bevacizumab 15mg/kg IV of CT-16 will be administered every 3 weeks up to 6 cycles during the Induction Study Period and every 3 weeks until PD or intolerable toxicity during the Maintenance Period.
89594362|NCT03676192|Active Comparator|Avastin|Drug: Bevacizumab 15mg/kg IV of EU-approved Avastin will be administered every 3 weeks up to 6 cycles during the Induction Study Period and every 3 weeks until PD or intolerable toxicity during the Maintenance Period.
89594363|NCT01584843|No Intervention|Non-treatment (10-20 PD)|Receive no treatment on Week 0
89594364|NCT01584843|Active Comparator|GSK1358820 1.25 U (10-20 PD)|Receive 1.25 U of GSK1358820 on Week 0
89594365|NCT01584843|Active Comparator|GSK1358820 2.5 U (10-20 PD)|Receive 2.5 U of GSK1358820 on Week 0
89594366|NCT01584843|No Intervention|Non-treatment (20-50 PD)|Receive no treatment on Week 0
89594367|NCT01584843|Active Comparator|GSK1358820 2.5 U (20-50 PD)|Receive 2.5 U of GSK1358820 on Week 0
89594368|NCT01584843|Active Comparator|GSK1358820 5.0 U (20-50 PD)|Receive 5.0 U of GSK1358820 on Week 0
89594369|NCT03580408|Experimental|Experimental|"Induction treatment :Nivolumab will be given alone at 240 mg flat dose every 2 weeks (i.e. one cycle) Patients will be assessed after 3 months of therapy (after 6 injections of Nivolumab)~Consolidation treatment:~It depends on the induction evaluation by PET-CT and CT-scan (Lugano 2014 criteria) :~For patients achieving CMR according to Lugano Classification : treatment by nivolumab 240 mg every 2 weeks for 9 months.~Patients who reach PMR and NMR after 3 months (according to Lugano Classification) will be treated by the Nivolumab+Vinblastin regimen every 2 weeks for 9 additional months: Vinblastin(6 mg/m2 (IV) + Nivolumab 240 mg (IV)~In case of progressive disease , patients will be considered in treatment failure."
89594370|NCT01560429|Experimental|Patient controlled epidural analgesia|An epidural catheter sited preoperatively so analgesics can be administered postoperatively. Patients were titrated on a continuous analgesic epidural infusion until stable pain scores of ≤ 3 were reached while in PACU. Once stable, they were allocated to their preoperatively determined randomization which meant they still received 2/3rd of the anesthetic as a background infusion but also had the option to self-administer the remaining 1/3rd dose as patient controlled epidural analgesia (PCEA). Rescue analgesia was available upon request.
89594371|NCT01560429|Active Comparator|continuous epidural analgesia|An epidural catheter sited preoperatively so analgesics can be administered postoperatively. Patients were titrated on a continuous analgesic epidural infusion rate until stable pain scores of ≤ 3 were reached while in PACU (as described in the PCEA group). Once stable, they were allocated to their preoperatively determined randomization assignment which for the CEA group meant they remained on the continuous background epidural infusion rate previously determined to maintain pain scores ≤ 3 while in PACU. Rescue analgesia was available as needed.
89594372|NCT01582971|Experimental|Intervention|Reflexology: 4 weekly foot reflexology sessions delivered by friend/family member
89594373|NCT01582971|No Intervention|Control|Standard medical care: no reflexology
89594374|NCT04762732|Experimental|Experimental: negative pressure wound therapy (PREVENA™ Incision Management System)|Wound of ALT donor site will be cared under PREVENA™ Incision Management System
89594375|NCT04762732|Placebo Comparator|Placebo Comparator: conventional dressing|Wound of ALT donor site will be cared by traditional dressing and care.
89594376|NCT03766750|Experimental|LIMA|
89594377|NCT03766750|Active Comparator|Tradjenta®|
89594378|NCT03766750|Active Comparator|Forxiga®|
89594379|NCT03576586|Experimental|Intervention|"Brief computerized intervention (computer game Tetris) plus usual care in the maternity department"
89594380|NCT03576586|Placebo Comparator|Control|Attention placebo control (cognitive task for same amount of time) plus usual care in the maternity department
89594381|NCT04762810|Experimental|Cyclophosphamide and Glucocorticoids|Through the selective depletion of proliferating lymphocytes, cyclophosphamide has an inhibitory effect on both humoral and cellular immunity. Cyclophosphamide 50mg per day for 6 months and decrease to 50mg Qod for 6 months.
89594382|NCT04762810|Active Comparator|Glucocorticoids monotherapy|Prednisone/prednisolone: started at 0.6-0. 8mg/kg.d for 2 to 4 weeks, tapered at 5mg per 1-2 weeks before 15mg per day, and tapered at 2.5-5mg per 2 weeks to equal to or less than 5mg per day in 6 months.
89594383|NCT03674242|Experimental|Eryaspase plus Chemotherapy|"eryaspase 100 U/kg dosed at Day 1 and Day 8 of each 3-week cycle in combination with~Gemcitabine IV infusion 1000 mg/m2, Day 1 and Day 8.~Carboplatin IV infusion at a calculated area under the curve (AUC) of 2.0 (AUC2), Day 1 and Day 8."
89594384|NCT03674242|Active Comparator|Chemotherapy alone|Gemcitabine plus carboplatin dosed at Day 1 and Day 8 of each 3-week cycle
89594385|NCT04762108||Sjögren's syndrome|Sjögren's syndrome with childhood-onset
89594386|NCT04762108||Healthy control|Age matched healthy control
89594387|NCT04761952|Experimental|n-3PUFA treatment group|On the basis of routine treatment, oral supplement of n-3PUFA was given to CD patients since 2-week-postoperative till 1-year-postoperative.
89594388|NCT04761952|Placebo Comparator|Conventional treatment group|Treatment of azathioprine (daily orally) or infliximab (intravenously, at 0, 2,6 weeks with every 8-week-interval later) was given since 2-week-postoperative till 1-year-postoperative.
89594389|NCT03760432|Experimental|Surgery|OCT-guided custom laser CXL
89594390|NCT03673072|Experimental|Arm A (gemcitabine plus cisplatin)|Patients assigned to arm A will receive treatment with gemcitabine plus cisplatin. Chemotherapy will be administered for 3 cycles preoperatively (neoadjuvant part) and for 3 cycles postoperatively (adjuvant part).
89594391|NCT03673072|Active Comparator|Arm B (standard postoperative management)|Patients assigned to arm B will receive surgery directly, without receiving perioperative chemotherapy (Standard of Care / SOC). After surgery, adjuvant chemotherapy can be administered by investigator's choice.
89594392|NCT01677208|Experimental|Danhong injection|Based on the standard medical care, 40ml of Danhong injection, added into 250ml of 0.9% saline, given by continuous IV infusion at 2.5ml/min within 2 hours.
88978363|NCT00254761|Experimental|2|Low dose cannabis (3.5% THC by weight)
88978364|NCT00254761|Placebo Comparator|3|Placebo cannabis
88978365|NCT00254800|Experimental|Sequence 1|Oral contraceptive 1 hour prior to exenatide/oral contraceptive 30 minutes after exenatide/oral contraceptive alone
88978366|NCT00254800|Experimental|Sequence 2|Oral contraceptive 30 minutes after exenatide/oral contraceptive alone/oral contraceptive 1 hour prior to exenatide
88978367|NCT00254800|Experimental|Sequence 3|Oral contraceptive alone/oral contraceptive 1 hour prior to exenatide/oral contraceptive 30 minutes after exenatide
88978368|NCT04719364||Focus Groups|10 black, 10 Latinx, and 10 white MSM will be recuited in this focus group 'cohort'
88978369|NCT04719364||Quantitative Survey Group|Cross-sectional group of 100 black, 100 Latinx, and 100 white MSM
88978370|NCT00069836|Experimental|Arm 1|
88978371|NCT00254917|Experimental|1|Concommitant recombinant hepatitis B vaccine at 0, 6 and 14 weeks of age
88978372|NCT00254917|Experimental|2|Concommitant recombinant hepatitis B vaccine at 6, 10, and 14 weeks of age.
88978373|NCT04719676|Experimental|Core strength training using unstable surface|The experimental group will use Core strength training using unstable surface
89031387|NCT00515268|Placebo Comparator|Subjects receiving placebo|Eligible subjects will be randomized to receive placebo for 7 days, administered via an ACCUHALER.
89031388|NCT00515307|Experimental|A|
89031389|NCT01356966|Experimental|Tetrahydrobiopterin + Folate|Male subjects with hypertension and chronic kidney disease stage 2 or 3 will receive Tetrahydrobiopterin (6R-BH4) 200 mg twice daily and folic acid 1 mg daily
89031390|NCT01356966|Placebo Comparator|Placebo + Folate|Male subjects with hypertension and chronic kidney disease stage 2 or 3 will receive 2 placebo pills twice daily and folic acid 1 mg daily
89031391|NCT02952677|Experimental|Experimental|"Participants receive Remind-to-move by means of vibration emitted through sensory cueing wristwatch devices, 3 consecutive hours daily, for 4 weeks, as well as usual care during the intervention period.They are also encouraged to use their arms as much as possible and the accelerometer built-in the device record the arm movement during daily activities."
89517661|NCT05165719||Convalescents|PCR (polymerase chain reaction) confirmed COVID-19 in a period 14-45 days before recruitment
89517662|NCT05165719||Healthy donors|No self-reported COVID-19 infection
89517663|NCT02321969|No Intervention|Control|Without green tea extract (GTE) supplementation
89517664|NCT02321969|Experimental|GTE group|GTE supplementation for 12 months after polypectomy for colorectal adenomatous polyps
89517665|NCT03497195|Active Comparator|Community level screening; Arm 1|use of chest X-ray plus Xpert Ultra for community level TB screening
89517666|NCT03497195|Active Comparator|Community level screening: Arm 2|use of C-reactive Protein and Xpert Ultra for community level TB screening
89517667|NCT02222896|Experimental|Chlorhexidine Gluconate Cloth|2% CHG, single application
89517668|NCT02222896|Placebo Comparator|Vehicle Cloth|Excipients on cloth
89517669|NCT02222896|Active Comparator|Active Chlorhexidine gluconate solution|Dynahex 2% CHG
89517670|NCT05165563|Experimental|Workflows|Digital and conventional workflows for treatment of implant single crowns
89517671|NCT05165563|Experimental|Materials|Materials for treatment of implant single crowns (polymer-infiltrated ceramic networks, PICNs and lithium disilicate, LS2).
89517672|NCT03499457|Experimental|treatment|penicillin chalange test, as descibed.
89517673|NCT03499379||Women initiating use of an intrauterine device|"Women obtaining a copper or hormonal intrauterine device for the purpose of contraception.~A hair sample of approximately 10 (up to 20) hairs cut close to the scalp of the posterior vertex will be taken at the time of IUD insertion, 6 months post-insertion, and 12 months post-insertion."
89517674|NCT05165407|Experimental|Sintilimab Combined With IBI310 and Surufatinib|Surufatinib at a dose of 250mg QD, with Sintilimab injected intravenously 200mg per 3 weeks and IBI310 injected intravenously 1mg/kg per 6 weeks until disease progresses or unacceptable tolerability occurs
89517675|NCT02322203|Experimental|Niacin ER in healthy participants and its effects on lipoprotein composition and function|Niacin extended release (ER) to be given as follows: 500 mg/day for 1 week, then 1000 mg/day for 1 week, then 2000 mg/day for 14 weeks in healthy participants.
89517676|NCT03499301||Chronic pain|Patients with chronic pain when arrived to emergency room.
89517677|NCT03499301||No chronic pain|Patients without chronic pain when arrived to emergency room.
89517678|NCT02222818|Other|Group A: CAFR first|Subjects randomized to Group A will receive CAFR first, then cross over to CAFRPlus.
89517679|NCT02222818|Other|Group B: CAFRPlus first|Subjects randomized to Group B will receive CAFRPlus first, then cross over to CAFR.
89517680|NCT02319629|Experimental|URSODIOL - URSODEOXYCHOLIC ACID|300 mg twice a day
89517681|NCT02319629|Placebo Comparator|placebo|placebo twice a day
89517682|NCT04455373||orthopedic surgery group|Planned tumor resection
89517683|NCT04455373||traumatic surgery group|Patients with traumatic vascular injury
89517684|NCT02322437|Experimental|Home treatment|Patients in need of acute psychiatric inpatient care are treated at their houses by mobile treatment teams instead of treatment at mental hospitals whenever home treatment is possible and appropriate.
89517685|NCT02322437|Active Comparator|Treatment as usual|Patients in need of acute psychiatric inpatient care are treated at a mental hospital.
89517686|NCT04691362|Active Comparator|Oral Tranexamic Acid|128 patients scheduled for primary total hip arthroplasty
89517687|NCT04691362|Active Comparator|Intravenous Tranexamic Acid|128 patients scheduled for primary total hip arthroplasty
89517688|NCT03499223|Experimental|Ranibizumab + THR-317|Subjects will receive intravitreal ranibizumab in combination with THR-317
89517689|NCT03499223|Active Comparator|Sham + ranibizumab|Subjects will receive a sham injection in combination with intravitreal ranibizumab
89517690|NCT01421290|Active Comparator|Conservative treatment|
89517691|NCT01421290|Active Comparator|Surgery|
89517692|NCT01416688||Observation and Questionnaires|Patients will be given questionnaires for the assessment of therapy complications, psychosocial assessment and care, and quality-of-life assessment.
89517693|NCT03497117|Other|CF pulmonary exacerbation group|"Patients with cystic fibrosis being treated for a pulmonary exacerbation will undergo Lung Clearance Index (LCI) and an MRI with PFP.~LCI testing will take place before the MRI. Each test will take 5-20 minutes and up to three tests will be performed with at least 5-minute rest periods between each test.~PFP gas will be administered using a full-face mask during the MRI. Images are acquired during 12-second breath-hold after every 3rd breath. Before and after the MRI is complete, participants will perform spirometry maneuvers in a room outside of the magnet."
89517694|NCT04454593||Lateral patellar compression syndrome|Patients diagnosed with lateral patellar compression syndrome between February 2016 and April 2019
89517695|NCT04454593||patellar dislocation|Patients diagnosed with patellar dislocation between February 2016 and April 2019
89517696|NCT04454593||meniscus tear|Patients diagnosed with meniscus tear between February 2016 and April 2019
89517697|NCT02319707|Experimental|Intramuscular treatment:IV|pregnant women, 34-41 weeks of gestation, which were treated with 10 IU of IM Oxytocin during the third stage of labor.
89517698|NCT02319707|Experimental|Combined treatment:IV+IM|pregnant women, 34-41 weeks of gestation, which were treated with 10 IU of IM Oxytocin together with 10 IU of IV Oxytocin in 100 ml NaCl 0.9% during the third stage of labor.
89517699|NCT02319707|Active Comparator|The control group|pregnant women, 34-41 weeks of gestation, which were treated with 10 IU of IV Oxytocin in 100 ml NaCl 0.9% during the third stage of labor. (this is the routine practice in our department).
88811299|NCT02807558|Experimental|R/R non-APL AML or R/R HR-MDS: Tamibarotene and Daratumumab|Participants with R/R non-APL AML or R/R HR-MDS will receive tamibarotene at 6 mg/m^2/day in 2 divided doses during a 7-day lead-in and on Days 1-28 of a 28-day cycle. Participants will also receive daratumumab at 16 mg/kg starting on Cycle 1 Day 1 once weekly for 8 weeks, followed by dosing every 2 weeks for 16 weeks, followed by dosing every 4 weeks.
88978374|NCT04719676|Active Comparator|The stable surface would be gym floor.|The control group will use stable surface.
89517700|NCT05165017|Active Comparator|Intervention Arm 1|AlloRx Stem Cells IV infusion treatment
89517701|NCT05165017|Placebo Comparator|Intervention Arm 2|IV infusion of normal saline
89517702|NCT02319785|Experimental|RAT-NMES|The combined treatment of robot-assisted therapy and neuromuscular electrical stimulation.
89517703|NCT02319785|Experimental|RAT-MT|The combined treatment of robot-assisted therapy and mirror therapy.
89517704|NCT02319785|Active Comparator|Mirror therapy|Patients practice motion in a mirror box, and look into mirror while practicing.
89517705|NCT02319785|Experimental|Unilateral RAT|Unilateral robot-assisted therapy provided by InMotion Isokinetic Testing and Evaluation System.
89517706|NCT02319785|Active Comparator|Bilateral RAT|Bilateral robot-assisted therapy provided by Bi-Manu-Track.
89517707|NCT02319785|Active Comparator|Conventional rehabilitation|Conventional rehabilitation provided by therapist.
89517708|NCT01368718|Other|Active/Sham CPAP|
89517709|NCT02322515|Experimental|Intervention Taping|The experimental group will use a rigid patellar taping (G1, n = 22) for the correction of lateralization of the patella and stabilization of the knee. The lateral stabilization will be made with self-adhesive taping positioned in the lateral border of the patella and tensioned in relation to the medial portion of the femur condyle, which allows an edge of the medial board patella and a stretching of lateral structures of the knee. All procedure will follow the recommendation from McConnell studies with regard to the patellar femoral syndrome.
89517710|NCT02322515|Placebo Comparator|Placebo Taping|The placebo group will use a rigid patellar taping (G2, n = 22), but without no correction of lateralization of the patella and/or stabilization of the knee. The taping will be placed incorrectly such as in the vertical position of knee and without any tension or traction around structures and patella.
89517711|NCT01368250||1|Patients with native aortic stenosis undergoing TAVI
89517712|NCT01368250||2|Patients with native aortic regurgitation undergoing TAVI
89517713|NCT01368250||3|Patients with degenerative surgical bioprosthesis undergoing TAV-in-SAV
89517714|NCT02319863|Active Comparator|conventional resection|Perform hepatectomy with conventional method for HCC patients.
89517715|NCT02319863|Experimental|new method|The new technique of rapid ligating the corresponding inflow and outflow vessels without hills dissection before parenchyma transection during hepatectomy.
89517716|NCT04506385|Active Comparator|A - L. delbrueckii LDD01 probiotic bacterial strain administered in sachets of 2 grams|L. delbrueckii LDD01 probiotic bacterial strain
89517717|NCT04506385|Active Comparator|B - Bifidobacterium longum DLBL probiotic bacterial strain administered in sachets of 2 grams|Bifidobacterium longum DLBL probiotic bacterial strain
89517718|NCT04506385|Active Comparator|C - LP01, LF16, LR06 and B. longum 04 administered in sachets of 2 grams|L. plantarum LP01, L.fermentum LF16, L. rhamnosus LR06 and B. longum 04: low dosage; probiotic bacterial strains blend
89517719|NCT04506385|Active Comparator|D - LP01, LF16, LR06 and B. longum 04 administered in sachets of 2 grams|L. plantarum LP01, L.fermentum LF16, L. rhamnosus LR06 and B. longum BL04: high dosage; probiotic bacterial strains blend
89517720|NCT05398861|Experimental|HER-2 Negative Advanced Breast Cancer|Utidelone Combined with Bevacizumab
89517721|NCT03499145||Eligible patients for AI test.|Device: ophthalmology diagnostic system. An artificial intelligence to make comprehensive evaluation and treatment decision of ocular diseases.
89517722|NCT04586101|Experimental|Training intervention|
89517723|NCT04586101|No Intervention|Control interverntion|
89517724|NCT05398549|Active Comparator|Conventional physical therapy|Subjects in group A was treated with conventional physical therapy i.e. grade 1 and 2 mobilization and stretching exercise.
89517725|NCT05398549|Experimental|Virtual reality group|group B was treated with virtual reality stimulation given for 30 minutes per session through kinetic Xbox with sensory accelerator model no.1414.Two traditional training activities was used to improve shoulder Range of motion i.e. badminton and American baseball activity 12 times of the training Baseline treatment protocol hot pack and ultrasound was applied to both groups. Treatment duration for both groups was 30 minutes. Each subjects were receive a total 4 week protocol with 03 treatment sessions per week.
89517726|NCT02448329|Experimental|AZD1775 in Combination With Paclitaxel|AZD1775 225 mg BID q 12 hours (x 5 doses, 2.5 days) administered days 1~3 Weekly paclitaxel 80 mg/m2 IV on 1, 8 and 15 of a four week l cycle is an widely used dose of paclitaxel given on this schedule in gastric adenocarcinoma patients as second-line therapy.
89517727|NCT03498989|Experimental|preterm formula milk neoborn|will be given preterm formula milk
89517728|NCT03498989|Experimental|exclusive breast milk|will be given exclusive breast milk
89517729|NCT03498833|Other|Test-retest reliability testing|Minimum 50 IKOA will be evaluated with the scale on two occasions within two weeks to establish test retest reliability.
89517730|NCT05398393|Other|group A|normal blood lipid level at baseline
89517731|NCT05398393|Other|group B1|baseline blood lipid is elevated and treat with lipid-lowering drugs
89517732|NCT05398393|Other|group B2|baseline blood lipid is elevated and without lipid-lowering drugs treatment
89517733|NCT03498755|Experimental|Multi-sectoral anemia behavior change|Address multiple behavioral determinants of anemia by promoting the identification, knowledge, valuation and practice of four behavioral domains: 1) consumption of micronutrient-rich animal-source foods; 2) malaria and soil-transmitted helminth infection control practices; 3) water, sanitation and hygiene (WASH) best practices; and 4) women's autonomy in decision-making and control of the use of earned income.
89517734|NCT03498755|Experimental|Strengthening market engagement of fish processors|Assist women in overcoming limited access to credit, inadequate storage facilities, and insufficient information about market prices, which constrain the timeliness and amount of market-ready product available for sale, through a three-pronged approach that includes: 1) a conditional cash transfer; 2) entrepreneurship training; and 3) enhanced access to market price information.
89517735|NCT03498755|Experimental|Improving fish smoking technology and practices|Introduce and promote a recently developed fish smoking oven known as the Ahotor, which was explicitly designed to reduce emission from biomass fuel combustion, decrease polycyclic aromatic hydrocarbon (PAH) levels of smoked fish, and increase fuel efficiency. Use of this oven will reduce workload, increase earnings, and reduce harmful occupational exposures. Introduction of this improved fish smoking oven will be combined with behavior change education focused on promoting optimal fish smoking and handling practices.
89517736|NCT01339078|Active Comparator|Plastic stenting|Patients will be randomized towards plastic stenting.
89517737|NCT01339078|Experimental|Kaffes stenting|Patients will be randomized towards Kaffes stenting.
89517738|NCT03498677|Active Comparator|Method of presentation one|
89517739|NCT03498677|Active Comparator|Method of presentation two|
89517740|NCT04190134|Experimental|Immediate Robot|One month after study entry, participants will receive the robot at home for two months, followed by a three month observation period without the robot.
89517741|NCT04190134|Active Comparator|Delayed/Waitlist Robot|Three months after study entry, participants will receive the robot at home for three months.
89517742|NCT02319941|Experimental|Low dose ticagrelor|60mg bid
89517743|NCT02319941|Active Comparator|standard dose ticagrelor|90mg bid
89517744|NCT02319941|Active Comparator|standard dose clopidogrel|75mg qd
89517745|NCT02320019|Placebo Comparator|Placebo group|Placebo
89517746|NCT02320019|Experimental|Group A|YH14618 A mg/disc
89517747|NCT02320019|Experimental|Group B|YH14618 B mg/disc
89517748|NCT02320019|Experimental|Group C|YH14618 C mg/disc
89517749|NCT02320019|Experimental|Group D|YH14618 D mg/disc
89517750|NCT02320097|Other|Foot pressure measurement|"The subject stands on the platform, with the heels and buttocks touching a vertical plane and the head held freely. The subject then moves his/her head backwards so that it touches the vertical plane. Next, he/she turns the head to the right and then towards the left. Each of these positions is maintained for 2 minutes.~The platform's sensors measure the anteroposterior foot pressure distribution during the various acquisitions."
89517751|NCT02320331|Experimental|PILI Lifestyle Program|
89517752|NCT02320409|Experimental|Sulfatinib ,after general diet|First cycle, single oral Sulfatinib after general diet intake; Second cycle, Sulfatinib before general diet intake.
89517753|NCT02320409|Experimental|Sulfatinib, before general diet|First cycle, single oral Sulfatinib before general diet intake;Second cycle,single oral Sulfatinib after general diet intake
89517754|NCT04462133|Active Comparator|Empirical therapy for H. pylori infection|The empirical group receives triple therapy of 7 or 14 days for H. pylori eradication
89517755|NCT04462133|Experimental|Tailored therapy for H. pylori infection|The tailored therapy group receives eradication regimens based on their DPO-PCR results. Triple therapy of 7 or 14 days for clarithromycin sensitive patients based on DPO-PCR and bismuth quadruple therapy of 7 or 14 days for clarithromycin resistant patients based on DPO-PCR.
89517756|NCT05164627|Active Comparator|Group A|patients will receive Dexmedetomidine infusion (0.2 mcg/kg/hr) from the start of the surgery till the end of it.
89517757|NCT05164627|Active Comparator|Group B|patients will receive Magnesium infusion (10 mg/kg/hr) from the start of the surgery till the end of it.
89517758|NCT05164627|Placebo Comparator|Group C|Patients will receive Normal Saline 0.9% infusion
89517759|NCT04461977|Experimental|A - true acupuncture|"The selection of acupuncture points is based on Traditional Chinese Medicine (Wen 2011) and on previous studies (Jeong, 2018; Bao,2018), selected as main points: bilateral baxie, SJ5, bafeng, KID3 and ST36. Modifications or additional secondary points may be indicated according to clinical judgment throughout treatment."
89517760|NCT04461977|Sham Comparator|B - sham acupuncture|"Patients will receive needling at non-acupuncture points with superficial needling without manipulation to obtain de qi, located near the real points in the hands and feet."
89517761|NCT04454359|Experimental|EXP|EXP group will ingest a supplement consisting of 1) flavored whey protein isolate with added pure leucine (3 g) diluted in water, twice daily, before breakfast and before bedtime; doses are adjusted per body weight as follows: 20 g, 25 g or 30 g per category of <65 kg, 65-75 kg and >75 kg of body weight respectively. 2) fish oil containing vitamin D, provided as 7.5 mL liquid oil providing 1500 IU vitamin D3 + 1125 mg EPA + 750 mg DHA, to be ingested once daily.
89517762|NCT04454359|Placebo Comparator|CTR|Control will ingest an isocaloric placebo consisting of 1) 30 g maltodextrin, twice daily, following the same schedule, and 2) 7.5 mL corn oil, once daily.
89517763|NCT02320565|Experimental|3D Laparoscopy|"Laparoscopic total hysterectomy with pelvic lymphadenectomy are performed with 3D Laparoscopic technology.~A 10 mm port is inserted at the umbilicus for the telescope. Once pneumoperitoneum (12 mmHg) is achieved, intra-abdominal visualization will be obtained with a 0° high-definition 3D telescope. Two additional 5 mm ports are placed under direct visualization. One more 5- mm trocar is inserted in the right mid abdomen at the level of the umbilicus. The instruments used include bipolar grasper, monopolar scissors, monopolar hook, various graspers and a suction irrigation system"
89594393|NCT01677208|Placebo Comparator|placebo|Based on the standard medical care, 40ml of 0.9% saline as the placebo, added into 250ml of 0.9% saline, given by continuous IV infusion at 2.5ml/min within 2 hours.
89594394|NCT01690299|Experimental|Apremilast 30 mg plus placebo injection|Apremilast 30 mg tablets orally twice a day (BID) plus once weekly (QW) evaluator/subject-blinded subcutaneous (SC) saline (placebo) injections
89594395|NCT01690299|Experimental|Etanercept 50 mg plus placebo tablet|Etanercept 50 mg evaluator/subject-blinded SC QW injections plus placebo tablets orally BID
89594396|NCT01690299|Placebo Comparator|Oral placebo tablets plus SC placebo injections|Identically matching placebo tablets and evaluator/subject-blinded SC injections
89594397|NCT03570814|Active Comparator|Separate Administration|Standard administration of Albendazole/Ivermectin separated from administration of azithromycin
89594398|NCT03570814|Experimental|Co-administration|Combined administration of Albendazole/Ivermectin/Azithromycin at a single time point
89594399|NCT00723736||Pediatric Patients|Those with allergic rhinitis or chronic idiopathic urticaria.
89594400|NCT00305344|Active Comparator|Cord Blood|Umbilical Cord Blood
89594401|NCT03569566||Elite endurance athletes|Cross-country skiers at high national level
89594402|NCT01690143|Experimental|Carfilzomib + high dose melphalan|Single arm.
89594403|NCT05347498|Experimental|Treatment group A|HR091506 tablets + placebo of febuxostat tablets
89594404|NCT05347498|Active Comparator|Treatment group B|febuxostat tablets + placebo of HR091506 tablets
89594405|NCT05347420||Diabetic peripheral neuropathy|Patients with diabetic peripheral neuropathy
89594406|NCT05347420||non diabetic peripheral neuropathy|Patient without diabetic peripheral neuropathy
89594407|NCT03669250|Active Comparator|CVN058, low dose|CVN058 prepared in concentrations of 10mg/mL, and are compounded by the clinical site. Subjects will receive one dose of CVN058 at 15mg or 75mg substitution of 15mg.
89594408|NCT03669250|Active Comparator|CVN058, high dose|CVN058 prepared in concentrations of 10mg/mL, and are compounded by the clinical site. Subjects will receive one dose of CVN058 at 150mg.
89594409|NCT03669250|Placebo Comparator|Placebo|Matching placebo.
89594410|NCT03553732||Active Surveillance Patients|Patients who elect to be monitored by an Active Surveillance protocol for prostate cancer
89594411|NCT03668938|Experimental|intervention|The occupational therapy intervention provides a treatment aimed at improving autonomy in the activities chosen by the patient
88978375|NCT04728672|Experimental|Experimental Group|Kinesio tape was applied and then outcome measures were noted.
88978376|NCT04728672|Placebo Comparator|Control Group|Placebo Micropore Tape was applied and then outcome measures were noted.
88978377|NCT00255112|No Intervention|1|The present study evaluates the efficacy of a family-based CBT treatment specifically tailored to children with SAD, developed at the University of Basel. The study consists of 40 participants (5-7 years old) with SAD and their families. Participants were randomly assigned to 12 weeks of SAD-specific family-based CBT treatment or to waitlist condition.
89594412|NCT03668938|Active Comparator|usual care|Usual care consists in rehabilitation treatment delivered by a multidisciplinary team
89594413|NCT03567850|Experimental|Intervention|Participants assigned to the intervention arm will receive Problem Solving Skills Training (PSST) consisting of eight one-hour individual weekly sessions.
89594414|NCT03567850|Active Comparator|Control Arm|Care As Usual Group (CAU): Participants randomized to the CAU group will be observed under naturalistic conditions. Both PSST and CAU participants and their clinicians (PCP and oncology providers) will be allowed to use any clinically appropriate medical and behavioral care without restriction (e.g., care management, rehabilitation, behavioral therapy, palliative care) or refer patients to social and community services (e.g., peer support, county cancer services program or aging services). The CAU participants will undergo the same evaluation protocol as the PSST group
89594415|NCT03668626|No Intervention|Term infants|Healthy term infants
89594416|NCT03668626|No Intervention|Usual care program (UCP)|In-hospital and after-discharge intervention (telephone calls)
89594417|NCT03668626|Experimental|Family-centered intervention program (FCIP)|In-hospital and after-discharge intervention (clinic and home visits)
89594418|NCT01677364|Active Comparator|induction of labour|drug- infusion of 30U oxytocin diluted in 500ml normal saline given at rate of 3mU/min and subsequently dose increased 3mU/min every 45 min
89594419|NCT01677364|No Intervention|Spontaneous Labour|patients were allowed to go into spontaneous labour
89594420|NCT03566524|Experimental|Citrulline|In this arm, 10 ketosis prone diabetes patients will be randomly assigned to receive 34.2 mmol/d of dietary citrulline for 20 days. Citrulline will be in the form of 2.85 mmol capsules and patients will be instructed to consume 4 capsules with each of their 3 main meals. The citrulline will be provided in a double-blind fashion by a designated unblinded investigator who will not come in direct contact with the subjects.
89594421|NCT03566524|Placebo Comparator|alanine|In this arm, 10 ketosis prone diabetes patients will be randomly assigned to receive 34.2 mmol/d of dietary alanine for 20 days. Alanine will be in the form of 2.85 mmol capsules and patients will be instructed to consume 4 capsules with each of their 3 main meals. The alanine will be provided in a double-blind fashion by a designated unblinded investigator who will not come in direct contact with the subjects.
89594422|NCT03563248|Active Comparator|FOLFIRINOX: SBRT: Surgery|"The FOLFIRINOX regimen will be administered intravenously. Treatment will be every 14 days +3/ -1 at physician discretion~SBRT should be administered 2-6 weeks after completing chemotherapy~All participants will undergo an attempt at definitive surgical resection following SBRT"
89594423|NCT03563248|Experimental|FOLFIRINOX+Losartan:SBRT+Losartan:Surgery|"The FOLFIRINOX regimen will be administered intravenously. Treatment will be every 14 days +3/ -1 at physician discretion~Losartan will be administered orally as a tablet to be taken by the patient at home every day~SBRT should be administered 2-6 weeks after completing chemotherapy~All participants will undergo an attempt at definitive surgical resection following SBRT"
88978378|NCT00255112|Active Comparator|2|The present study evaluates the efficacy of a family-based CBT treatment specifically tailored to children with SAD, developed at the University of Basel in comparison to a global CBT treatment. The study consists of 60 participants (between 8 and 13 years old), randomly assigned to one of the two treatments.
88978379|NCT00255229|Active Comparator|1|Irinotecan, 5FU, Glutamine
88978380|NCT00255229|Placebo Comparator|2|Irinotecan, 5FU, Placebo
89594424|NCT03563248|Experimental|FOLFIRINOX+Losartan:SBRT+Nivolumab+Losartan:Sur|"The FOLFIRINOX regimen will be administered intravenously. Treatment will be every 14 days +3/ -1 at physician discretion~Losartan will be administered orally as a tablet to be taken by the patient at home every day~SBRT should be administered 2-6 weeks after completing chemotherapy~Participants will receive nivolumab during SBRT~All participants will undergo an attempt at definitive surgical resection following SBRT"
89594425|NCT03563248|Experimental|FOLFIRINOX x 8 : SBRT + Nivolumab : Surgery|"The FOLFIRINOX regimen will be administered intravenously. Treatment will be every 14 days +3/ -1 at physician discretion~SBRT should be administered 2-6 weeks after completing chemotherapy~Participants will receive nivolumab during SBRT~All participants will undergo an attempt at definitive surgical resection following SBRT"
89594426|NCT03663400||Patients Treated with Tofacitinib|Microbiota profiling by 16S sequencing RNA-seq transcriptional profiling of the blood and biopsy samples Immunological profiling by multi-parameter flow cytometry
89594427|NCT04403776|Experimental|Treatment A, separated washout phase, followed Treatment B.|"Treatment A:~Single oral dose of tofacitinib MR 11mg, administered as 1xMR 11mg tablet, in a fasting state on Day 1 followed by once daily dosing (QD) on Days 3, 4, 5, 6 and 7.~washout phase: no later than 72 hours~Treatment B:~Two separate oral doses (12 hours apart) of tofacitinib IR 5mg, administered one in the morning in a fasting state and one in the evening at least 2 hours after dinner on Day 1 followed by 5 mg IR every 12 hours on Days 3, 4, 5, 6 and 7."
89594428|NCT04403776|Experimental|Treatment B, separated washout phase, followed Treatment A.|"Treatment A:~Single oral dose of tofacitinib MR 11mg, administered as 1xMR 11mg tablet, in a fasting state on Day 1 followed by once daily dosing (QD) on Days 3, 4, 5, 6 and 7.~Washout phase: no later than 72 hours~Treatment B:~Two separate oral doses (12 hours apart) of tofacitinib IR 5mg, administered one in the morning in a fasting state and one in the evening at least 2 hours after dinner on Day 1 followed by 5 mg IR every 12 hours on Days 3, 4, 5, 6 and 7."
89594429|NCT03559348|Experimental|Biweekly TS-1, Leucovorin and Gemcitabine (GSL)|Gemcitabine 800 mg/m2 , on day 1 S-1 80, 100 or 120 mg/d, orally twice daily on day 1 to 7 Leucovorin 60 mg/d, orally twice daily on day 1 to 7 Every 14 days as one cycle
89594430|NCT01679938|Experimental|primary obesity prevention|"The intervention will involve four main components:~Training of child care providers.~Curriculum sessions for children.~Family outreach activities.~Maintenance activities."
89594431|NCT01679938|No Intervention|Control group|For the control group, usual care will be provided
89594432|NCT03541018|Experimental|Posterior canalolithiasis|Type of repositional maneuvre
89594433|NCT03541018|Experimental|Lateral cupulolithiasis|Type of repositional maneuvre
89594434|NCT04762030|Experimental|Experimental Group|
89594435|NCT04761874|No Intervention|In-Person (Conventional) Stroke Care|Ischemic stroke patients admitted to a single academic, comprehensive stroke center from December 1, 2019-March 15, 2020 that were evaluated, managed, and treated by the stroke care team in person.
89594436|NCT04761874|Experimental|Telestroke Stroke Care|Ischemic stroke patients admitted to a single academic, comprehensive stroke center from March 16, 2020-June 29, 2020 that were evaluated, managed, and treated by the stroke care team remotely via telestroke.
89594437|NCT01559259|Experimental|Ibuprofen/acetaminophen (lower dose)|
89594438|NCT01559259|Experimental|Ibuprofen/acetaminophen (middle dose)|
89594439|NCT01559259|Experimental|Ibuprofen/acetaminophen (high dose)|
89594440|NCT01559259|Active Comparator|Ibuprofen|
89594441|NCT01559259|Placebo Comparator|Placebo|
89594442|NCT03538912|Other|Biomarker group|patient follow the Biomarker strategy
89594443|NCT03538912|Other|Routine group|patient follow the routine strategy
89594444|NCT03537118|Experimental|Fluoroscopic + Ultrasound Guidance|
89594445|NCT03537118|No Intervention|Fluoroscopic Guidance Alone|
89594446|NCT03088306|Active Comparator|Standard analgesia use|A strategy to manage pain in the peri-operative period that is in common clinical use.
89594447|NCT03088306|Active Comparator|Multi-modal pain management|A strategy to manage pain in the peri-operative period that is in common clinical use that is designed to reduce the need for post-operative opioid medication.
89594448|NCT01672762|Experimental|ASP1941 group|oral
89594449|NCT03088384||Combat Veterans|Eligible participants must be military veterans who have served in a combat zone as evidenced by documentation on the subject's DD214 (or equivalent if he/she served in a foreign military). Participants must have a diagnosis of post traumatic stress disorder that was as a result of their military combat experience.
89594450|NCT01677598||Patients with plaque psoriasis|Patients with plaque psoriasis using ustekinumab in Asia-Pacific countries.
89594451|NCT01676350|No Intervention|Standard of care|If you are assigned to this group, ultrasound-guided IV will be used to obtain vascular access.
89594452|NCT01676350|Experimental|IO access using EZ-IO®|If you are assigned to this group, you will receive an IO line in the humeral head of the shoulder. IO lines are placed using an FDA-approved device called an EZ-IO®.
89594453|NCT01677754|Placebo Comparator|Placebo|Participants will receive placebo as add-on to a background therapy of AChEI (donepezil, rivastigmine, or galantamine) alone or in combination with memantine.
89594454|NCT01677754|Experimental|RO4602522 1 milligram (mg)|Participants will receive RO4602522 1 mg as add-on to a background therapy of AChEI (donepezil, rivastigmine, or galantamine) alone or in combination with memantine.
89594455|NCT01677754|Experimental|RO4602522 5 mg|Participants will receive RO4602522 5 mg as add-on to a background therapy of AChEI (donepezil, rivastigmine, or galantamine) alone or in combination with memantine.
89594456|NCT03419572||Second line therapy|Data collection
89594457|NCT03419572||Third and later line therapy|Data collection
89594458|NCT01670032|Experimental|CD07223 1.5 % Topical Gel BID|Drug: 1.5% CD07223 Topical Gel applied BID for 7 days
89594459|NCT01670032|Experimental|CD07223 1.5% Topical Gel TID|Drug: 1.5% CD07223 Topical Gel applied TID for 7 days
89594460|NCT01670032|Placebo Comparator|CD07223 vehicle gel BID|Drug: CD07223 Vehicle Topical Gel applied BID for 7 days
89594461|NCT01670032|Placebo Comparator|CD07223 vehicle gel TID|Drug: CD07223 Vehicle Topical Gel applied TID for 7 days
89594462|NCT03088228||healthy pregnants|
89594463|NCT03088228||mild preeclampsia|
89594464|NCT03088228||severe preeclampsia|
89594465|NCT01670500|Active Comparator|Doxorubicin-Cyclophosphamide|Doxorubicin q 2-3 wk x 4 Cyclophosphamide q 2-3 wk x 4
89594466|NCT01670500|Active Comparator|Cisplatin|Cisplatin q 3 wk x 4
89594467|NCT01678612|No Intervention|Non copper standard surfaced objects|Rooms assigned to standard surfaced objects
89594468|NCT01678612|Experimental|Copper-alloy surfaced objects|Rooms furnished with copper surfaced objects, i.e. bed rails, bed rail levers, IV poles, nurse workstation, clipboards, sink handles.
89594469|NCT03525574|Experimental|Open-label Triple Combination|"Subjects will receive 200 mg VX-445/ 100 mg TEZ/ 150 mg IVA as FDC tablets in the morning and 150 mg IVA as mono tablet in the evening.~Parent studies are Phase 3 Vertex studies investigating VX-445 in combination with TEZ and IVA. This includes Studies VX17-445-102 and VX17-445-103."
89594470|NCT03418402|Experimental|Airseal®|Low pression laparoscopy with a 8 to 10 mmHg pneumoperitoneum.
89594471|NCT03418402|Active Comparator|Standard insufflator|laparoscopy realised with our usual insufflation system and a 12 to 15 mmHg pneumoperitoneum.
89594472|NCT03087526|Experimental|Couple at risk of transmitting a triplet-repeat disease|Expectant couple (pregnant woman between 9 and 34 weeks of gestation and her spouse) at risk of transmitting a triplet-repeat related genetic disease among Huntington disease, Myotonic Dystrophy type 1, Fragile X syndrome, Spinocerebellar Ataxia type 1, Spinocerebellar Ataxia type 2, Spinocerebellar Ataxia type 3
89594473|NCT02405260|Experimental|TTP399 400 mg|TTP399 once daily
89594474|NCT02405260|Experimental|TTP399 800 mg|TTP399 once daily
89594475|NCT02405260|Active Comparator|Sitagliptin 100 mg|Sitagliptin once daily
89594476|NCT02405260|Placebo Comparator|Placebo|Placebo once daily
89594477|NCT03519646|Experimental|Experimental Case_Eiglustat|Besides regular ERT, patients also need to take Eiglustat for 24 months.
89594478|NCT02984722|Experimental|1|PCOS women treated with 1500 mg/die of extended-release metformin
89594479|NCT02984722|Experimental|2|PCOS women treated with 1500 mg/die of immediate-release metformin
89594480|NCT02402530|Placebo Comparator|Placebo|Matching placebo administered as intravenous infusion on Day 1, Day 4, Day 7 and Day 10
89594481|NCT02402530|Experimental|125 mg Neridronic acid|Neridronic acid 62.5 mg administered as intravenous infusion on Day 1 and Day 4; matching placebo administered as intravenous infusion on Day 7 and Day 10
89594482|NCT02402530|Experimental|250 mg Neridronic acid|Neridronic acid 62.5 mg administered as intravenous infusion on Day 1, Day 4, Day 7 and Day 10
89594483|NCT03087292|Active Comparator|Resistance training group|"Patients to be randomly assigned to the resistance training group will have resistance training with vascular occlusion 2 times per week for a period of 8 weeks on unilateral leg extension machine. During each training, they will performed 3 sets of 15 repetitions at the intensity of 30% 1 RM (repetition maximum). Each training set will separated by a 30 second rest period."
89594484|NCT03087292|No Intervention|Control group|Patients to be randomly assigned to the control group (normal physical activity) will continue with their usual physical activity regime.
89594485|NCT02401750|Experimental|Oxycodone Naltrexone (a)|Double-Blind Oxycodone/Naltrexone, 1 capsule by mouth every 6 hours for 48 hours
89594486|NCT02401750|Experimental|Oxycodone Naltrexone (b)|Double-Blind Oxycodone/Naltrexone , 1 capsule by mouth every 6 hours for 48 hours
89594487|NCT02401750|Placebo Comparator|Placebo|Double-Blind Placebo to experimental Oxycodone/Naltrexone, 1 capsule every 6 hours for 48 hours
89594488|NCT02400736|Experimental|Individual Placement and Support (IPS)|"Individual Placement and Support (IPS) is supported employment and involves the following domains: 1) competitive employment: IPS assists participants to enter into competitive jobs; 2) eligibility based on client choice, i.e. zero exclusion; 3) integration of IPS and treatment team, i.e. the PACT; 4) patient-centered job match for competitive employment; 5) personalized benefits counseling: IPS specialists help Veterans obtain information about their VA, Social Security, Medicaid, and other government entitlements; 6) rapid job search: IPS specialists use a rapid job search, rather than providing lengthy pre-employment assessment, training, counseling; 7) job development: IPS specialists build an employer network based on Veterans' interests; 8) time-unlimited and individualized support: follow-along IPS supports are individualized and continue for as long as needed during the 12-month study."
89594489|NCT02400736|Active Comparator|Treatment as Usual Vocational Rehabilitation/Transitional Work (TAU-VR)|Treatment as Usual Vocational Rehabilitation includes pre-vocational counseling, Community Based Supported Employment, or most commonly Transitional Work assignments (TW) which involves 1) time-limited set-aside work experiences: short-term transitional work experiences in a brokered or set-aside work setting; 2) no strict entrance criteria other than general medical clearance; 3) limited integration of TW and clinical Services; 4) not patient-centered: TW jobs are pre-arranged, set-aside jobs are less likely to have a meaningful relationship to the Veterans' preferences; 5) personalized benefits counseling; 6) limited job search: TW specialists provide variable and limited guidance for competitive job search; 7) no job development: TW specialists do not engage in community based job development; 8) time limited: The TW specialist does not provide long-term follow-up after the first job is obtained.
89594490|NCT03086980|Active Comparator|Automatic Self Transcending Meditation|Automatic Self Transcending Meditation is a class of meditation that helps quiet the mind and induces physiological and mental relaxation whilst the eyes are shut. It utilizes a specific sound value (mantra) to draw attention inward and permit the mind to experience a restful but alert state of consciousness.Research suggests that ASTM may help reduce depression and anxiety.
89594491|NCT03086980|Placebo Comparator|Treatment as Usual (TAU)|The usual standard of care for patients with glaucoma includes starting them on first line of drugs. Participants will be initiated and maintained on appropriate dosages of such medications as part of standard of care. The usual standard of care also includes an ophthalmic examination measuring best-corrected Snellen VA and pinhole acuities and a follow-up visit once a year.
89594492|NCT03086668|Experimental|Conventional Jaw thrust Group|an assembly of video-stylet and double curve endotracheal tube with conventional jaw thrust technique to facilitate nasotracheal intubation
89594493|NCT03086668|Experimental|Fingers hook Group|an assembly of video-stylet and double curve endotracheal tube with fingers-hook technique to facilitate nasotracheal intubation
89594494|NCT01689519|Active Comparator|Placebo + Vemurafenib|Participants will receive placebo orally once daily on Days 1-21 of each 28-day cycle plus vemurafenib 960 milligrams (mg) orally twice a day on Days 1-28 of each 28-day cycle until disease progression, death, unacceptable toxicity, or withdrawal of consent, whichever occurs earliest.
89594495|NCT01689519|Experimental|Cobimetinib + Vemurafenib|Participants will receive cobimetinib 60 mg orally once daily on Days 1-21 of each 28-day cycle plus vemurafenib 960 mg orally twice a day on Days 1-28 of each 28-day cycle until disease progression, death, unacceptable toxicity, or withdrawal of consent, whichever occurs earliest.
89594496|NCT01689363|Experimental|Arm H|Intradermal injection of Amphadase (hyaluronidase 150 USP units/mL)
89594497|NCT01689363|Active Comparator|Arm P|Intradermal injection of Histatrol (histamine base 0.1 mg/mL)
89594498|NCT01689363|Placebo Comparator|Arm N|Intradermal injection of saline (0.02 mL)
89594499|NCT04410471||Liver transplant patient after having Covid19|Adult Liver transplant patient who had survived to Covid19 in the first wave of the disease in Spain (disease until june 30th), in all the liver Transplant Units in Spain (24).
89594500|NCT04410471||No immunosuppressed patient with previous Covid19|Not immunosuppressed patient who had survived to Covid19 in the first wave of the disease. These patient have been diagnosed and treated in the Hospital Gregorio Marañón (Madrid), before 30th June
89594501|NCT02072421|Other|Non-SOS|
89594502|NCT01558635|Experimental|Cardioblate CryoFlex Surgical Ablation|Subjects with longstanding persistent AF undergoing Maze III procedure using the Cardioblate CryoFlex Surgical Ablation System concomittant to Mitral valve surgery. During surgery, a Medtronic Reveal XT Insertable Cardiac Monitor was implanted to monitor future episodes of AF.
89594503|NCT03086590||Group 1|COPD mild. The individuals allocated to this group have FEV1 ≥ 80% predicted.
89594504|NCT03086590||Group 2|COPD Moderate. The individuals allocated to this group have 50% ≤ FEV1 < 80% predicted.
89594505|NCT03086590||Group 3|COPD Severe. The individuals allocated to this group have 30% ≤ FEV1 < 50% predicted.
89594506|NCT03086590||Group 4|COPD Very severe. The individuals allocated to this group have FEV1 < 30% predicted.
89594507|NCT03507946|Experimental|Test|"Subject self control; Plaque 1: Dermawrap - combined 460nm, 633nm, and 830nm LED therapyDaily treatments of 15 minutes of combined LED phototherapy, 5 days per week for 12 weeks.~Plaque 2: No Intervention"
89594508|NCT03504124|Experimental|Intervention group|Patients will receive a multicomponent intervention.
89594509|NCT03504124|No Intervention|Control group|Patients will receive the usual care.
89594510|NCT03455686|Experimental|Patients with and without lung disease|All enrolled patients will undergo pulmonary function testing, questionnaires, 1H MRI, static ventilation and/or diffusion-weighted hyperpolarized 129Xe MRI and sputum induction at one or more timepoints over five years.
89594511|NCT03086824|Experimental|MRgFUS|Patients with painful bone metastases receiving magnetic resonance-guided focused ultrasound treatment.
89031392|NCT02952677|Sham Comparator|Sham treatment|Participants wear sham wristwatch devices but without vibration cueing, 3 consecutive hours daily, for 4 weeks, as well as usual care during the intervention period. They are also encouraged to use their arms as much as possible and the accelerometer built-in the device record the arm movement during daily activities.
89594512|NCT03455140|Experimental|Group 1 - Leukaemia|PEG- BCT-100 in patients with Leukaemia Starting dose 1600U/Kg IV infusion weekly
89594513|NCT03455140|Experimental|Group 2 - Neuroblastoma|PEG- BCT-100 in patients with Neuroblastoma Starting dose 1600U/Kg IV infusion weekly
89594514|NCT03455140|Experimental|Group 3 - Sarcomas|PEG- BCT-100 in patients with Sarcomas Starting dose 1600U/Kg IV infusion weekly
89594515|NCT03455140|Experimental|Group 4 - High Grade Glioma|PEG- BCT-100 in patients with High Grade Gliomas Starting dose 1600U/Kg IV infusion weekly
89594516|NCT03086512|Active Comparator|Group I|Group I consists of 45 patients receiving a subtalar fusion with the Acutrak 2® - Fully Threaded Screw.
89594517|NCT03086512|Sham Comparator|Group II|Group II consists of 45 patients receiving a subtalar fusion with the Partially Threaded Synthes® 7.3 Cannulated Screw.
89594518|NCT03452878||Aggressive refractory patient|A pre defined group of individuals will be included in the study. This group is considered aggressive refractory patient and will be submitted to the bilateral amygdalotomy surgery.
89594519|NCT03501082|Experimental|L. reuteri PB-W1, Non-Industrialized-Type Diet Start|Participants will receive the non-industrialized-type diet for 3 weeks, followed by a crossover to 3 weeks of consuming their usual diet after a 3-week washout period. Participants will be provided with a one-time dose of L. reuteri PB-W1 strain on day 4 of each diet period. The L. reuteri PB-W1 strain will be provided as a drinkable solution (approximately 2.25x10^10 viable cells will be provided in 50 ml of water).
89594520|NCT03501082|Experimental|L. reuteri DSM20016T, Non-Industrialized-Type Diet Start|Participants will receive the non-industrialized-type diet for 3 weeks, followed by a crossover to 3 weeks of consuming their usual diet after a 3-week washout period. Participants will be provided with a one-time dose of L. reuteri DSM20016T strain on day 4 of each diet period. The L. reuteri DSM20016T strain will be provided as a drinkable solution (approximately 2.25x10^10 viable cells will be provided in 50 ml of water).
89594521|NCT03501082|Placebo Comparator|Placebo, Non-Industrialized-Type Diet Start|Participants will receive the non-industrialized-type diet for 3 weeks, followed by a crossover to 3 weeks of consuming their usual diet after a 3-week washout period. Participants will be provided with a one-time dose of a placebo solution on day 4 of each diet period. The placebo solution will be provided as a drinkable solution (2 g maltodextrin dissolved in 50 ml water in food grade conditions).
89594522|NCT03501082|Experimental|L. reuteri PB-W1, Usual Diet Start|Participants will consume their usual diet for 3 weeks, followed by a crossover to 3 weeks of consuming the provided non-industrialized-type diet after a 3-week washout period. Participants will be provided with a one-time dose of L. reuteri PB-W1 strain on day 4 of each diet period. The L. reuteri PB-W1 strain will be provided as a drinkable solution (approximately 2.25x10^10 viable cells will be provided in 50 ml of water).
89594523|NCT03501082|Experimental|L. reuteri DSM20016T, Usual Diet Start|Participants will consume their usual diet for 3 weeks, followed by a crossover to 3 weeks of consuming the provided non-industrialized-type diet after a 3-week washout period. Participants will be provided with a one-time dose of L. reuteri DSM20016T strain on day 4 of each diet period. The L. reuteri DSM20016T strain will be provided as a drinkable solution (approximately 2.25x10^10 viable cells will be provided in 50 ml of water).
89594524|NCT03501082|Placebo Comparator|Placebo, Usual Diet Start|Participants will consume their usual diet for 3 weeks, followed by a crossover to 3 weeks of consuming the provided non-industrialized-type diet after a 3-week washout period. Participants will be provided with a one-time dose of a placebo solution on day 4 of each diet period. The placebo solution will be provided as a drinkable solution (2 g maltodextrin dissolved in 50 ml water in food grade conditions).
89594525|NCT03086278|Experimental|Single Ascending Dose|
89594526|NCT03086434|Experimental|Culturally tailored intervention|The participants of the experimental condition will receive the intervention in a talking circle format. They will meet for 10 weekly 50 minute sessions.
89594527|NCT03086434|Active Comparator|Standard Substance Abuse Education|The control condition participants are assigned to the standard substance abuse education program which is delivered in a classroom format format. They will meet for 10 weekly 50 minute classroom sessions.
89594528|NCT03497806|Experimental|High Dose CP101|The active ingredient of CP101, Full-Spectrum Microbiota™, is derived from the stools of normal healthy donors who are highly screened, tested, and monitored in a clinically structured donation program.
89594529|NCT01689207|Experimental|Drug: A|Avibactam (AVI)
89594530|NCT01689207|Experimental|Drug: B|Aztreonam (ATM)
89594531|NCT01689207|Experimental|Drug: C|combination of Aztreonam-Avibactam (ATM-AVI)
89594532|NCT01689207|Placebo Comparator|Drug: D|Matching Placebo
89594533|NCT00089284|Experimental|Rituxan and 90Yttrium-Zevalin plus MGd|Patients receive motexafin gadolinium IV over 30-60 minutes on days 1-4 and 8-11. At least 1 hour after motexafin gadolinium administration, patients receive rituximab IV over 3-4 hours on days 1 and 8. After rituximab administration, patients receive indium In 111 ibritumomab tiuxetan IV over 10 minutes on day 1. Patients undergo gamma camera scanning on days 1, 2*, 4*, and 7 and dosimetry on days 2, 4, and 7. If safe biodistribution is demonstrated, patients receive yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes (after rituximab administration) on day 8.
89594534|NCT01688973|Experimental|Arm I (tivantinib)|Patients receive tivantinib PO BID on days 1-28.
89594535|NCT01688973|Experimental|Arm II (tivantinib and erlotinib hydrochloride)|Patients receive tivantinib PO BID and erlotinib hydrochloride PO QD on days 1-28.
89594536|NCT00087646|Experimental|1|
89594537|NCT00087646|Experimental|2|
89594538|NCT00087646|Experimental|3|
89594539|NCT00087646|Active Comparator|4|
89594540|NCT03492658|Experimental|Combination therapy (MTX/abatacept)|Treatment with a combination of methotrexate (10 - 25 mg once weekly) and abatacept (125 mg subcutaneously once weekly) for 6 months, followed by methotrexate monotherapy (10 - 25 mg once weekly) for another 6 months.
89594541|NCT03492658|Active Comparator|Methotrexate (MTX) monotherapy|Treatment with methotrexate monotherapy (10 - 25 mg once weekly) for 12 months.
89594542|NCT03086122|No Intervention|Obstructive Sleep Apnea (OSA)|OSA patients without erectile dysfunction (ED).
89594543|NCT03086122|No Intervention|OSA + ED|OSA patients with erectile dysfunction diagnosis who are randomly allocated to not receive continuous positive airway pressure (CPAP).
89594544|NCT03086122|Experimental|OSA + ED + CPAP|OSA patients with erectile dysfunction diagnosis who are randomly allocated to receive CPAP.
89594545|NCT03085966|Experimental|autologous immune cell therapy|Luteinizing Hormone Releasing Hormone Agonists (LHRH-a) and Autologous dendritic cells (DC) and central memory T cells (Tcm cells)
89594546|NCT03085654|Experimental|High anxiety group (single dose)|Oxytocin nasal spray or placebo nasal of one dose in subjects with high trait anxiety.
89594547|NCT03085654|Experimental|High anxiety group (3 doses)|Oxytocin nasal spray or placebo nasal spray interleaved during the 5 days( on the 1st,3rd and 5th day),24 IU per day in subjects with high trait anxiety.
89594548|NCT03085654|Experimental|High anxiety group (5 doses)|Oxytocin nasal spray or placebo nasal spray for 5 days,24 IU per day in subjects with high trait anxiety.
89594549|NCT03085654|Experimental|Low anxiety group (single dose)|Oxytocin nasal spray or placebo nasal spray of one dose in subjects with low trait anxiety.
89594550|NCT03085654|Experimental|Low anxiety group (3 doses)|Oxytocin nasal spray or placebo nasal spray interleaved during the 5 days( on the 1st,3rd and 5th day),24 IU per day in subjects with low trait anxiety.
89594551|NCT03085654|Experimental|Low anxiety group (5 doses)|Oxytocin nasal spray or placebo nasal spray for 5 days in subjects with low trait anxiety.
89594552|NCT03085732|Active Comparator|Irrigation with saline solution|during abdominal hysterectomy after vaginal cuff closure abdominal saline irrigation will be done
89594553|NCT03085732|No Intervention|control|routine abdominal hysterectomy will be performed and no abdominal saline irrigation
89594554|NCT00087568|Experimental|Non-Responders|Participants will receive Pegasys 180 micro grams (µg or mcg) subcutaneously (SC) once a week and ribavirin 1000 or 1200 milligrams per day [(mg/day), < or >=75 kilogram (Kg) body weight, respectively], orally in divided doses for 60 weeks.
89594555|NCT00087568|Experimental|Non-Tolerators|Participants will receive Pegasys 180 µg subcutaneously (SC) once a week and ribavirin 1000 or 1200 mg/day (< or >=75 kg body weight, respectively) orally in divided doses for 36 weeks.
89031393|NCT02952677|Other|Control|Participants receive usual care only during the intervention period.
89031394|NCT02952638||Healthy|BMI is between 20 and 25
89031395|NCT02952638||Overweight|BMI is between 25 and 30
89031396|NCT02952638||Obese|BMI is between 30 and 40
89031397|NCT02944734|Experimental|Candesartan Cilexetil (CC) 8mg|Candesartan Cilexetil 8mg, once a day for 8 weeks
89031398|NCT02944734|Experimental|CC 16mg|Candesartan Cilexetil 16mg, once a day for 8 weeks
89031399|NCT02944734|Experimental|Amlodipine(AML) 5mg|Amlodipine 5mg, once a day for 8 weeks
89031400|NCT02944734|Experimental|AML 10mg|Amlodipine 10mg, once a day for 8 weeks
89031401|NCT02944734|Experimental|CC 8mg / AML 5mg|Candesartan 8mg and Amlodipine 5mg, once a day for 8 weeks
89031402|NCT02944734|Experimental|CC 8mg / AML 10mg|Candesartan 8mg and Amlodipine 10mg, once a day for 8 weeks
89031403|NCT02944734|Experimental|CC 16mg / AML 5mg|Candesartan 16mg and Amlodipine 5mg, once a day for 8 weeks
89031404|NCT02944734|Experimental|CC 16mg / AML 10mg|Candesartan 16mg and Amlodipine 10mg, once a day for 8 weeks
89031405|NCT00510263|Experimental|1|
89594556|NCT04402762|Experimental|TR treatment sequence|Period 1-Test Treatment: Ovine enoxaparin sodium 60 mg SC injection, manufactured by Metiska Farma. Period 2-Reference Treatment: Porcine enoxaparin sodium 60 mg SC injection (Lovenox), manufactured by Sanofi, France.
89594557|NCT04402762|Active Comparator|RT treatment sequence|Period 2-Reference Treatment: Porcine enoxaparin sodium 60 mg SC injection (Lovenox), manufactured by Sanofi, France. Period 1-Test Treatment: Ovine enoxaparin sodium 60 mg SC injection, manufactured by Metiska Farma.
89594558|NCT03487900|Other|Clinical remission CD|
89594559|NCT00085540|Experimental|Phase 1 Dose Escalation - Romidepsin|"Patients receive FR901228 (romidepsin) IV over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Dose escalation two dose levels:~Romidepsin (depsipeptide): 13.3mg/m2 and 17.7mg/m2~Pharmacokinetics"
89594560|NCT00085540|Experimental|Phase 2 Dose from Phase 1 - Romidepsin|"Patients receive FR901228 (romidepsin) as in phase I at dose level 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity~Romidepsin (depsipeptide): 13.3mg/m2"
89594561|NCT01677676|Active Comparator|Group 2|FP-01.1 (250µg/peptide)
89594562|NCT01677676|Active Comparator|Group 3|FP-01.1-Adjuvant (150µg/peptide / 10.8mg)
89594563|NCT01677676|Active Comparator|Group 4|FP-01.1-Adjuvant (250µg/peptide / 18mg)
89594564|NCT01677676|Active Comparator|Group 1|FP-01.1 (150µg/peptide)
89594565|NCT01677832||ADHD/Taiwan|
89594566|NCT01677832||Control/Taiwan|
89594567|NCT01677832||ADHD/Germany|
89594568|NCT01677832||Control/Germany|
89594569|NCT02984488|Experimental|single visit endodontic treatment.|•single visit endodontic Treatment of necrotic teeth using Protaper next.
89594570|NCT02984488|Active Comparator|Two visits endodontic treatment|•Two visits endodontic Treatment of necrotic teeth using Protaper next.
89594571|NCT01688739|Experimental|Erenumab|Participants received a single dose of erenumab by subcutaneous injection at doses of 1 mg, 7 mg, 21 mg, 70 mg, 140 mg, and 210 mg or by IV injection at a dose of 140 mg.
89594572|NCT01688739|Placebo Comparator|Placebo|Participants received a single dose of matching placebo administered by SC or IV injection.
89594573|NCT03085264|Experimental|Community Health Worker|Patients are paired with community health workers for 30 days after hospital discharge to assist with patient care
89594574|NCT03085264|No Intervention|Usual Care|Patients are not paired with community health workers for 30 days after hospital discharge to assist with patient care
88811300|NCT02807558|Experimental|R/R non-APL AML: Tamibarotene and Azacitidine|Participants with R/R non-APL AML will receive tamibarotene at 6 mg/m^2/day in 2 divided doses on Days 8-28 of a 28-day cycle, and azacitidine at 75 mg/m^2 once daily on Days 1-7 of a 28-day cycle.
88811301|NCT02765672|Active Comparator|Control Group|Participants in this group will have the following performed: Institute of Mobility Activity and Participation's clinical battery tests and a simulated driving evaluation, a Brief Driving Behavior Interview, Propensity for Angry Driving Scale, Clinical Driving Assessment, Community Integration Questionnaire, Fitness-to-Drive Screening Measure (FTDS), and a Satisfaction with Life Questionnaire. Driving Safety Education by a traffic safety professional, three x 1 hour sessions to discuss traffic safety rules regarding person, vehicle, environmental factors.
88811302|NCT02765672|Experimental|Experimental Group|Participants in this group will have the following performed: Institute of Mobility Activity and Participation's clinical battery tests and a simulated driving tests, a Brief Driving Behavior Interview, Propensity for Angry Driving Scale, Clinical Driving Assessment, Community Integration Questionnaire, Fitness-to-Drive Screening Measure(FTDS), and a Satisfaction with Life Questionnaire. Occupational Therapy Driving Intervention (OT-DI) consisting of three x 1 hour sessions to review explicit driving errors, strategies to mitigate errors and receiving feedback from the evaluator after driving the simulator.
88811303|NCT02765672|Active Comparator|Caregiver Control Group|Caregiver control group will fill out a Fitness-to-Drive Screening Measure (FTDS) questionnaire at baseline and at the end of the study.
88811304|NCT02765672|Active Comparator|Caregiver Experimental Group|Caregivers of the experimental group will fill out a Fitness-to-Drive Screening Measure (FTDS) questionnaire at baseline and at the end of the study.
88811305|NCT02765672|Active Comparator|On-road driving Group|A subset of 30 Combat Veterans will be drawn from the control group (15 no.) and experimental group (15 no.). This group of Combat Veterans will will undergo an on-road driving test at baseline and month 5
88811306|NCT02765672|Active Comparator|Simulator-drives Evaluation Group|This group will comprise of 30 Combat Veterans who will be drawn outside of the randomized experimental and and control groups participants. This group will only perform simulator driving triggers evaluation
88811307|NCT02751710|Experimental|Whole-body FDG PET-CT alone|
88811308|NCT02751710|No Intervention|Conventional breast cancer staging|Conventional breast cancer staging consisting of a bone scan and CT imaging with contrast of the chest / abdomen & pelvis
88811309|NCT02726386|Experimental|24-hour dosing regimen|"Continuous SC infusion over 24 hours: fixed day rate of up to 0.64 mL/h for 18 hours, followed by a night rate of 0.08 mL/h for 6 hours to deliver a total daily dose of up to 720/90 mg of levodopa/carbidopa.~All patients who had been previously assigned to the 24-hour group in the prior study continued on this dosing regimen; patients who had previously been assigned to the 14-hour daytime regimen were switched to the 24-hour regimen."
88811310|NCT02726386|Experimental|16-hour dosing regimen|"Continuous SC infusion for over 16 hours: fixed rate of 0.75 mL/h to deliver a total infusion dose of 720/90 mg of levodopa/carbidopa over 16 hours.~The device is removed at night and patients in this group also receive a morning oral dose of levodopa/carbidopa upon awakening."
88811311|NCT02517554||Remote cancer genetic services by videoconference|
88811312|NCT02517554||Remote cancer genetic services by telephone|
88811313|NCT02517554||Usual Care|
88811314|NCT02296229|Experimental|Treatment (SBRT)|Patients undergo SBRT daily or every other day for a total of 5 fraction not exceeding 14 consecutive days. Patients may also receive androgen deprivation therapy for up to 9 months at the discretion of the treating physician.
88811315|NCT02270411||Healthy Subjects|Healthy subjects.
89594575|NCT00084838|Experimental|Multi-agent Intrathecal and Systemic CT with RT (mod IRS III)|"Pre-irradiation induction therapy (wks 1-6); Chemoradiation induction therapy (wks 7-12); Post-radiation induction therapy (wks 13-18); Maintenance therapy (wks 19-44); Continuation therapy (wks 45-51)~Induction Chemotherapy: CT backbone of the IRS-III regimen [vincristine, dactinomycin, cyclophosphamide (specifically, in combination), cisplatin, doxorubicin, and imidazole carboximide (DTIC)] was modified to incl temozolomide in lieu of DTIC. Pts w/ M0 dz (and initially positive CSF cytology) rcvd intrathecal (IT) CT (alt btwn intralumbar and intraventricular routes) w/ methotrexate, cytarabine, and hydrocortisone, coinciding with a cycle of CT.~Radiation Therapy: Pts w/ M0 dz OR M+ dz aged <3y received focal RT (3D conformal or intensity-modulated delivery). Pts >3y w/ M+ dz rcvd craniospinal irradiation.~Continuation Therapy: Pts treated with either non-doxorubicin or doxorubicin dose therapy if receiving CSI or mediastinal radiotherapy or not, respectively."
89594576|NCT01558089||etanercept + methotrexate|
89594577|NCT01581021|Active Comparator|Thoracic Pedicle Screws|Group treated with pedicle screws in the thoracic spine
89594578|NCT01581021|Active Comparator|Laminar Hooks|Group treated with hooks in the thoracic spine
89594579|NCT03085342|Experimental|Liver MRI|Liver MRI including noncontrast (precontrast) flow measurement, DCE, DWI using multiple b-values, MRE and MR fat quantification.
89594580|NCT04410003|Placebo Comparator|Placebo|Cellulose capsules, cloxacillin, electrolyte purgative (Peglyte)
88811316|NCT02270411||Atopic Dermatitis|Patient has a history of atopic dermatitis for at least 6 months. Subject has clinically confirmed diagnosis of active atopic dermatitis, according to Hanifin and Rajka criteria.
88811317|NCT02270411||Acne Rosacea|Patient has a history of acne rosacea for at least 6 months.
88811318|NCT02270411||Acne Vulgaris|Patient has a history of acne vulgaris for at least 6 months.
89031406|NCT00510263|Experimental|2|
89594581|NCT04410003|Active Comparator|Active|Capsules of stool from Protected donors, cloxacillin, electrolyte purgative (Peglyte)
89594582|NCT00084682|Experimental|Treatment (romidepsin)|Patients receive FR901228 (depsipeptide) IV over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89594583|NCT01556997|Experimental|XOMA 985|fixed-dose combination of perindopril arginine/amlodipine besylate(PERa/AMLb)
89594584|NCT01556997|Active Comparator|Amlodipine Besylate (AMLb)|
89594585|NCT01556997|Active Comparator|Perindopril Erbumine (PERe)|
89594586|NCT00082888|Experimental|Treatment (tipifarnib)|Patients receive tipifarnib PO BID on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89594587|NCT03482986|Experimental|Group A|Subject will be advised to follow dietary habits plan A. Since this is a single blind study, the details of the dietary interventions cannot be released during recruitment stage, but will be made public once enrollment closes.
89594588|NCT03482986|Experimental|Group B|Subject will be advised to follow dietary habits plan B. Since this is a single blind study, the details of the dietary interventions cannot be released during recruitment stage, but will be made public once enrollment closes.
89594589|NCT04403152|Experimental|Rehabilitation group|This is the study group in whom post-operative rehabilitation was provided for 5 days.
89594590|NCT04403152|Active Comparator|Mobilization group|This is the control group in whom post-operative mobilization was provided for 5 days.
89594591|NCT03084874|Experimental|Intervention group|Patients in the intervention group will receive an individualized coaching program to increase physical activity and reduce sedentary behavior during 12 weeks
89594592|NCT03084874|No Intervention|Control group|Patients in the control group will receive the standard care for patients with COPD during 12 weeks.
89594593|NCT03084952|Experimental|1 mg/day|
89594594|NCT03084952|Experimental|4 mg/day|
89594595|NCT03084952|Experimental|8 mg/day|
89594596|NCT03084952|Experimental|12 mg/day|
89594597|NCT03084952|Active Comparator|Glucantime|
89594598|NCT03084952|Experimental|Best dose 18-MC|
89594599|NCT03084952|Experimental|Minimum effective dose 18-MC|
89594600|NCT00082810|Experimental|Treatment (tipifarnib, fulvestrant)|Patients receive fulvestrant intramuscularly on day 1 and oral tipifarnib twice daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity*.
89594601|NCT04402918|Other|pregnancy patients diagnosed with SARS Cov2 during pregnancy|Delivery day biological samples from the mother and the newborn will be performed
89031407|NCT00510263|Experimental|3|
89031408|NCT00510263|Placebo Comparator|4|
89031409|NCT00515385|Experimental|1a|Cohort 1 completed
89031410|NCT00515385|Placebo Comparator|1b|Cohort 1 placebo completed
89031411|NCT00515385|Experimental|2a|Cohort 2 completed completed
89031412|NCT00515385|Placebo Comparator|2b|Cohort 2 placebo completed
89594602|NCT03085108||SIBAT, the S-STS CMCM, and the C-SSRS + CGI-SS-R|Participants randomized to Cohort A will be consented for video-recorded interviews on 3 distinct suicide assessment instruments (the Suicide Ideation and Behavior Assessment Tool [SIBAT], the Sheehan-Suicidality Tracking Scale Clinically Meaningful Change Measure [S-STS CMCM] and the Columbia-Suicide Severity Rating Scale [C-SSRS] + Clinical Global Impression of Severity of Suicidality (Revised) [CGI SS-R]). These participants will be interviewed 3 times within the single study visit by 3 different trained clinical raters, using semi-structured interviews that have been developed for each of the 3 suicide assessment instruments.
89594603|NCT03085108||SIBAT|Participants who are not videotaped for the 3 interviews will only be assessed by SIBAT.
89594604|NCT01678066||Bilateral cardiac output|This is a prospective, non-randomized study to collect data from two noninvasive FDA-approved cardiac output monitors simultaneously in pediatric patients under general anesthesia in the operating room from age 1 month old to 8 years old with all types of medical conditions. We will enroll 50 male and female pediatric patients who are having lower abdominal and lower extremity surgery in this study so that the additional 8 EKG leads placed on the patients do not interfere with the surgical site or patient positioning.
89594605|NCT03445000|Experimental|Trial treatment|"Alectinib is administered orally, 600 mg, twice per day (1200 mg per day) until progression, refusal or unacceptable toxicity.~Trial treatment may also continue beyond progression, with physician and patient agreement, for as long as the patient may still derive clinical benefit as per investigator decision."
89594606|NCT03085030|Experimental|antioxidant group|This group will take antioxidant formula tablet once daily orally for one month before IVF/ICSI cycle
89594607|NCT03085030|Placebo Comparator|control group|This group will take placebo tablet once daily orally for one month before IVF/ICSI cycle
89594608|NCT03444064|No Intervention|Control|Participants in this arm receive islet transplant only, and no PolyTregs.
89594609|NCT03444064|Experimental|Treatment|Participants in this arm receive PolyTregs infusion at week 6 post islet transplant.
89594610|NCT03443128|Experimental|Vinorelbine monotherapy treatment|Patients will be treated with Vinorelbine. Four weeks as a course. There are 20 courses in total.
89594611|NCT03084562||Dipyridamole|stress test impossible or contraindicated (first intention)
89594612|NCT03084562||Regadenoson|stress test and dipyridamole impossible or contraindicated. In particular, patients with severe COPD or asthmatic patient. (second intention)
89031413|NCT00515385|Experimental|3a|Cohort 3 active
89031414|NCT00515385|Placebo Comparator|3b|Cohort 3 placebo
89594613|NCT03479710|Experimental|FMT infusion|FMT will be performed using frozen donor stool samples obtained from the stool bank of CUHK. 100-200ml of FMT solution or sterile saline will be infused over 2-3 minutes into the distal duodenum or jejunum via OGD.
89594614|NCT03479710|No Intervention|Control|No FMT infusion.
89594615|NCT01577745|Experimental|MEDI0639 Cohort 1|Participants received MEDI0639 dose level 1 as a 60-minute intravenous (IV) infusion on Day 1 of each 21-day cycle.
89594616|NCT01577745|Experimental|MEDI0639 Cohort 2|Participants received MEDI0639 dose level 2 as a 60-minute IV infusion on Day 1 of each 21-day cycle.
88811319|NCT02270411||Psoriasis|Patient has a history of psoriasis for at least 6 months.
89031415|NCT00515385|Experimental|4a|Cohort 4 active
89031416|NCT00515385|Placebo Comparator|4b|Cohort 4 placebo
89031417|NCT00515385|Experimental|5a|Cohort 5 active
89031418|NCT00515385|Placebo Comparator|5b|Cohort 5 placebo
89031419|NCT00511628||001|Risperidone As prescribed
89031420|NCT00510302||Melanoma Risk-Reduction|Patients with melanoma, their spouses/partners, and first-degree relatives (FDRs).
89031421|NCT00529425|Active Comparator|Ropivacaine|
89031422|NCT00529425|Placebo Comparator|Saline|
89031423|NCT03459755|Experimental|Lifestyle Intervention|Patients assigned to the Physical Activity arm will undergo exercise testing protocol and have supervised physical activity interventions while on study. Patients will also complete questionnaires and have research blood drawn.
89031424|NCT03459755|No Intervention|Usual care|Patients will complete questionnaires and have research blood drawn.
89031425|NCT00515580|Experimental|A|Pilot study of 5 patients, with an additional 20 patients with conditional approval by the IRB once the initial 5 patient's data is reviewed.
89031426|NCT00510341|Active Comparator|1|CMP program
89031427|NCT00510341|No Intervention|2|Control group
89031428|NCT02950974|Active Comparator|NSS|NSS 30 ml/kg (maximum of 2 litres) intravenous load over 1 hour
89594617|NCT01577745|Experimental|MEDI0639 Cohort 3|Participants received MEDI0639 dose level 3 as a 60-minute IV infusion on Day 1 of each 21-day cycle.
89594618|NCT01577745|Experimental|MEDI0639 Cohort 4|Participants received MEDI0639 dose level 4 as a 60-minute IV infusion on Day 1 of each 21-day cycle.
89594619|NCT01577745|Experimental|MEDI0639 Cohort 5|Participants received MEDI0639 dose level 5 as a 60-minute IV infusion on Day 1 of each 21-day cycle.
89594620|NCT01577745|Experimental|MEDI0639 Cohort 6|Participants received MEDI0639 dose level 6 as a 60-minute IV infusion on Day 1 of each 21 day cycle.
89594621|NCT01678378|Experimental|SHARP Intervention|School health centers randomized to the SHARP Intervention will be trained to address adolescent relationship abuse with school health center clients.
89594622|NCT01678378|No Intervention|Control|School health centers randomized to Control will provide standard of care.
89594623|NCT03084250|Experimental|Combination|The subjects will be treated by nucleotide analogue (NA) combination with peginterferon alfa-2a
89594624|NCT03084250|Active Comparator|nucleotide analogue|The subjects will be treated by nucleotide analogue (NA) only
89594625|NCT01688037|Experimental|NBI-98854 50 mg|NBI-98854 50 mg administered as two (2) 25 mg capsules by mouth, taken every morning between 7:00am - 10:00am for 6 weeks.
89031429|NCT02950974|Experimental|Sterofundin|Sterofundin solution 30 ml/kg (maximum of 2 litres) intravenous load over 1 hour
89031430|NCT03459716||Systemic sclerosis patients w/ PH|Pulmonary hypertension will be defined as a mean pulmonary artery pressure≥25mmHg on right heart catheterization
89031431|NCT03459716||Systemic sclerosis patients w/o PH|Pulmonary hypertension will be excluded based on all of the following echocardiogram features: estimated systolic pulmonary artery pressure<35mmHg and absence of right atrial or right ventricular (RV) enlargement and lack of qualitative RV dysfunction. If a subject has any of these echo features, they will be referred for right heart catheterization (RHC) and included in the appropriate group based on their RHC results.
89031432|NCT02952755|Experimental|Study effect of DWC20162 on DWC20155/DWC20156 PK|To study effect of DWC20162 on DWC20155/DWC20156 PK
89031433|NCT02952755|Experimental|Study effect of DWC20155/DWC20156 on DWC20162 PK|To study effect of DWC20155/DWC20156 on DWC20162 PK
89594626|NCT01688037|Experimental|NBI-98854 100 mg and 50 mg|NBI-98854 100 mg administered as two (2) 50 mg capsules taken every morning between 7:00am - 10:00am for 2 weeks. After 2 weeks, NBI-98854 50 mg administered by two (2) 25 mg capsules by mouth, taken every morning between 7:00am - 10:00am for remaining 4 weeks.
89594627|NCT01688037|Placebo Comparator|Placebo|Capsule containing no active substance, manufactured to mimic NBI-98854 25 mg and 50 mg capsules.
89031434|NCT02950935|Experimental|Progesterone|25 mg of subcutaneous progesterone will be administered twice à day until the 12th week of gestation.
89031435|NCT02950935|Placebo Comparator|Placebo|placebo will be administered twice à day until the 12th week of gestation.
89031436|NCT02952404||Before workshop|October 2014 to October 2015 Cohort which is the time frame before the educational workshop
89031437|NCT02952404||After workshop|December 2015 to December 2016 Cohort which is the time after the educational workshop
89594628|NCT03084484|Experimental|Test Group|"Subjects affected by periodontitis were examined and included in the study. After 2 months subjects also received non-surgical periodontal treatment and then followed for additional 3 months.~Subjects in the test group were instructed to eat two kiwifruit per day during the whole study period."
89594629|NCT03084484|Active Comparator|Control Group|"Subjects affected by periodontitis were examined and included in the study. After 2 months subjects also received non-surgical periodontal treatment and then followed for additional 3 months.~Subjects in the control group didi not receive any dietary advice."
89031438|NCT00510380||growth-restricted Chinese pregnancies|
89031439|NCT00510380||appropriately-grown Chinese pregnancies|
89594630|NCT03084406|Experimental|Enhanced Implementation (EI)|Providers in the Free Talk EI condition will receive access to CV-ATOD. They will participate in an online training course that mirrors the training in the IAU condition. EI providers will also receive access to interactive online exercises and practice activities within the training module. They will have online access to the Free Talk: Group MI for Teens searchable manual and materials via CV-ATOD. Providers may complete an optional CE course following the completion of the training module. EI providers will have access to all EBP implementation tools provided by CV-ATOD. Student providers in the CHOICE EI condition will receive access to CV-ATOD. They will participate in an online training course that mirrors the training in the IAU condition. However, EI providers will also receive access to interactive online exercises and practice activities within the training module. They will have online access to the CHOICE: Group MI for Teens searchable manual and materials via CV-ATOD.
89608513|NCT04386070|Experimental|RESP301|RESP301 is administered quickly (8-10 minutes) via an easy-to-use, vibrating mesh nebuliser. The recommended nebulisers used to administer this intervention are available in all participating countries. The intervention will be administered using a nebuliser according to standard local practice; where permitted for patients to self-administer, a member of the clinical team will ensure that the patient has viewed the intervention administration training video, and will also oversee the patient for the first trial dose to ensure proper administration.
89031440|NCT00529620|Active Comparator|1|sulfalene pyrimethamine plus amodiaquine
89031441|NCT00529620|Active Comparator|2|dihydroartemisinin piperaquine
89031442|NCT00529620|Active Comparator|3|sulfadoxine-pyrimethamine plus piperaquine
89031443|NCT00529698|Other|A|Subjects were immunized subcutaneously with Tat, 3 dosage groups (7.5, 15 or 30 micrograms), in association with Alum as adjuvant, or with Saline + Alum, as placebo.
89031444|NCT00529698|Other|B|Subjects were immunized intradermally with Tat, 3 dosage groups (7.5, 15 or 30 micrograms), or with Saline, as placebo.
89031445|NCT02952014|Experimental|C4 Extreme|One dose of 12 grams (powder mixed with water): 1500 mg beta alanine, 1000 mg creatine nitrate, 1000 mg arginine AKG, 250 mg vitamin C, 150 mg n-acetyle tyrosine, 135 mg caffeine, 7.5 mg l-dopa, 30 mg vitamin B3, 10 mg synephrine, 0.5 mg vitamin B6, 0.25 mg vitamin B9, 0.035 mg vitamin B12.
89031446|NCT02952014|Active Comparator|C4 Extreme (without Advantra Z)|One dose of 12 grams (powder mixed with water): 1500 mg beta alanine, 1000 mg creatine nitrate, 1000 mg arginine AKG, 250 mg vitamin C, 150 mg n-acetyle tyrosine, 135 mg caffeine, 7.5 mg l-dopa, 30 mg vitamin B3, 0.5 mg vitamin B6, 0.25 mg vitamin B9, 0.035 mg vitamin B12.
89031447|NCT02952014|Placebo Comparator|Placebo|One dose of flavored placebo (powder mixed with water)
89031448|NCT00529737|Experimental|Group 1|Post Procedure Mammogram Projection View A -- (view same projection as used in the biopsy procedure), then View B (view orthogonal projection to the first view).
89031449|NCT00529737|Experimental|Group 2|Post Procedure Mammogram Projection View B than View A
89031450|NCT00512993|Active Comparator|Treatment|Patients receive zoledronic acid (4mg) for 5 years. Additionally patients receive standard endocrine, radiologic and trastuzumab treatment, respectively
89031451|NCT00512993|No Intervention|Observation|Patients will be under observation and receive standard endocrine, radiologic and trastuzumab treatment, respectively
89031452|NCT00529776|Active Comparator|1|Continuous lateral rotation therapy
89594631|NCT03084406|No Intervention|Implementation As Usual (IAU)|CMH providers in the Free Talk IAU condition will receive access to the Group MI for Teens website that provides asynchronous, self-paced training videos as well as downloadable intervention materials and resources. CMH providers in this condition are only required to watch the first two training videos before receiving access to download the Free Talk training manual and materials. Providers may also complete an optional CE course following the completion of all training videos. Student providers in the CHOICE IAU condition will receive access to the Group MI for Teens website that provides online training videos as well as downloadable intervention materials and resources. IAU providers are only required to watch the first two training videos before receiving access to download the CHOICE training manual and materials. Providers may also complete an optional EBP knowledge test following the completion of all training videos.
89594632|NCT03084328||Patients with Vitamin D level of <30ng/dL|This is a cohort of patients with fatty liver disease and also have low levels of vitamin D
89594633|NCT03084328||Patients with Vitamin D level of >30ng/dL|This is a cohort of patients with fatty liver disease and have normal levels of vitamin D
89594634|NCT03707314|Other|Group A: Immediate angiography|Immediate angiography with follow-on revascularisation if indicated
89594635|NCT03707314|Other|Group B: Standard of care angiography|Standard of care angiography with follow-on revascularisation if indicated (within 3-4 days, but will vary depending on recruiting centre)
89594636|NCT03084172||chronic kidney disease patients group|These patients were screened from 2000000 of the population. The investigator will compare the prevalence rate, awareness rate and treatment rate before and after the completion of the system. The degree of decreased glomerular filtration rate is also an important evaluation index.
89594637|NCT01678534|Placebo Comparator|Placebo|In patients randomly assigned to the placebo arm will receive a intravenous solution (containing the vehicle) with the same appearance as the drug under investigation. It will be administered as a single intravenous dose within the first two weeks after the onset of stroke symptoms.
89594638|NCT01678534|Experimental|Allogeneic stem cells from adipose tissue|The experimental drug is a solution of mesenchymal stem cells from adipose tissue. It will be administered as a single intravenous dose within the first two weeks after the onset of stroke symptoms.Dose: 1 million units/kg
89594639|NCT01678690|Experimental|Gemcitabine HCl Oral Formulation|Subjects will be treated with Gemcitabine HCl Oral Formulation according to assigned cohort (2 mg or 5 mg or 10 mg) on Day 1 of the 7-day study treatment period
89594640|NCT01679080|Experimental|Zolendronic acid, 3 yr + placebo teriparatide, 2 yr|yearly intravenous infusion of 5mg active zoledronic acid in 3 yr
89594641|NCT01679080|Experimental|teriparatide 2 yr; active zol in 3rd yr|daily injection of one dose active teriparatide for two years, active zoledronic acid in year 3.
89594642|NCT01679080|Placebo Comparator|No active treatment|Observation in three years, no treatment
89031453|NCT00529776|No Intervention|2|Standard manual positioning (Supine position)
89031454|NCT00513032||methylene blue|
89594643|NCT01679158|Experimental|Continuous Horizontal row|Use the IOP system from USGI to install suture anchors running from the distal body into the proximal antrum
89594644|NCT01679158|Experimental|"Reduction in ring opening"|"Use the IOP system from USGI to install suture anchors to reduce the ring opening to the antrum"
89594645|NCT01679158|Experimental|Control Arm|Use the IOP system from USGI to install suture anchors in the Current V shape in distal body
89594646|NCT03083782|Active Comparator|Treatment A: Apixaban alone|Oral apixaban will be administered in healthy volunteers to define baseline apixaban pharmacokinetics
89594647|NCT03083782|Experimental|Treatment B: Cyclosporine with apixaban|Oral cyclosporine will be administered to steady state in healthy volunteers followed by a single oral dose of apixaban to define apixaban pharmacokinetics in the presence of cyclosporine
89594648|NCT03083782|Experimental|Treatment C: Tacrolimus with apixaban|Oral tacrolimus will be administered to steady state in healthy volunteers followed by a single oral dose of apixaban to define apixaban pharmacokinetics in the presence of tacrolimus
89594649|NCT03083860|Other|Arm I|15-45 participants will be monitored for 4-6 weeks, using the App in a Closed version followed by 4-6 weeks, using the App in an Open version (A version of the app the generates recommendations of ADL interventions) , with feedback based on diary information and BEI; followed by 4-6 weeks using the App in an Open version, with feedback based on diary information only.
89608514|NCT04386148||laparoscopic colorectal surgery|Patients undergoing laparoscopic colorectal surgery with use of Obsidian ASG® during primary anastomosis.
88978381|NCT04719091|Experimental|HA formulation Oral Spray|The Study Examiner and staff will screen for subjects that meet the enrollment criteria. Subjects will be randomly assigned to one of two treatment groups. Oral soft and hard tissue examinations will be conducted at each visit. Following an initial 3-5 minute evaluation of resting salivary flow, subjects will wait 10 minutes and then use their assigned spray. They will then swallow, and unstimulated saliva will be collected for 3-5 minutes. They will then remain in the study center for 60 min to evaluate xerostomia relief by questionnaire at 5, 15, 30, 45 and 60 min. after the use of Experimental mouth spray. They will then be given their assigned product to use twice daily for one week
89031455|NCT00513032||C|
89031456|NCT00529815|Experimental|1CGM and SBGM|Intervention group will alternate the use of the CGM with episodic self blood glucose monitoring for four cycles of two weeks using the CGM and episodic SBGM and one week only using episodic SBGM during the 12 week study.
89031457|NCT00529815|Active Comparator|2 SBGM|The control group (SBGM) will be instructed in the use of the Accuchek Aviva glucometer.
89031458|NCT00513110|Experimental|1|Endotoxin and AMPD1 polymorphism
89031459|NCT00513110|Experimental|2|Endotoxin and intervention with caffeine
89031460|NCT00513110|Placebo Comparator|3|Endotoxin combined with placebo
89031461|NCT00529854||1|Observational evaluation of current billing and documentation practices
89031462|NCT00529854||2|Use of SIC-IR Billing Module
89031463|NCT00511745||001|
89594650|NCT03083860|Other|Arm II|15-45 participants will be monitored for 4-6 weeks, using the App in a Closed version followed by 4-6 weeks, using the App in an Open version with feedback based on diary information only followed by 4-6 weeks; followed by 4-6 weeks using the App in an Open version, with feedback based on diary information and BEI. Note the difference between Arm I and Arm II is the order of use of BEI in addition to the diary feedback.
89031464|NCT02951897|Active Comparator|IA-CTC-High-enhance|IA lung adenocarcinoma cases with high abundant CTCs prior to operation will undergo lobectomy&lymphadenectomy plus adjuvant chemotherapy. Postoperative CTC monitoring will be conducted.
89031465|NCT02951897|Placebo Comparator|IA-CTC-High-controls|IA lung adenocarcinoma cases with high abundant CTCs prior to operation will only undergo lobectomy&lymphadenectomy. Postoperative CTC monitoring will be conducted.
89594651|NCT03402334|Experimental|CVD risk factor counseling|"This arm will receive intervention 'Patient counseling for HCV associated CVD risk factors' in addition to standard of care Hepatitis C counseling.~Cardiovascular risk factor counseling will include:~Increased risk for atherosclerosis with chronic HCV infection~Increased risk of heart attack and stroke~Treatment of HCV infection and reduction of viral load reducing risk of stroke and heart attack"
89594652|NCT03402334|No Intervention|Standard of care counseling|"This arm will receive standard of care Hepatitis C counseling:~HCV infection poses an increased risk for hepatocellular carcinoma~Hepatitis C is a curable disease~Hepatitis C is transmitted through blood to blood contact, primarily through sharing needles~HCV+ individuals should be vaccinated for Hepatitis A (HAV) and Hepatitis B (HBV)~HCV+ individuals should reduce alcohol intake and shellfish consumption"
89594653|NCT03087994|Experimental|girls with obesity attending a dietary intervention|Participants in this group will attend 12 meetings of dietary interventions that will be guided by a dietician.
89594654|NCT03087994|Active Comparator|girls with obesity|participants in this group will only receive nutrition guidance once during the study
89594655|NCT03087994|Active Comparator|girls with normal weight|participants in this group will only receive nutrition guidance once during the study
89594656|NCT03083392|Experimental|Treatment|treatment of chronic maxillary sinusitis using DIVA system
89594657|NCT03471442|Active Comparator|Paravertebral|Ultrasound-guided paravertebral block performed pre-operatively with 20ml of a ropivacaine / bupivacaine mixture.
89594658|NCT03471442|Experimental|Erector spinae plane|Ultrasound-guided erector spinae plane block performed pre-operatively with 20ml of a ropivacaine / bupivacaine mixture.
89594659|NCT01679392|Experimental|Ropivacaine|Unilateral transversus abdominis plane block with 20 ml ropivacaine (7.5 mg/ml)
89594660|NCT04279912|Experimental|Patients with Multiple Sclerosis and Tremor|Participants will undergo MRgFUS thermal ablation of the ventral intermedius (Vim) thalamus contralateral to the most affected side of the body.
89594661|NCT03083158|Other|Group 1|Older adults, aged 61-80 years
89594662|NCT03083158|Other|Group 2|Younger adults, aged 40-60 years
89594663|NCT04277416||Entrada Hip System|All orthopaedic patients that are scheduled to undergo primary total hip arthroplasty using the Entrada™ Hip System within 12 weeks will be screened for the following eligibility criteria.
89594664|NCT01679704|Other|Food products|Ten food products will be given to all subjects
89594665|NCT01679782||COPD nocturnal desaturator|COPD patients who spend 30% of the nigth with a SaO2 < 90%.
89594666|NCT01679782||COPD no nocturnal desaturator|COPD patients who spend less than 30% of the night with a SaO2 < 90%
89594667|NCT01679782||control group|healthy sedentary subjects
89594668|NCT03083080|Experimental|VATS block (ropivacaine + epinephrine)|VATS block is the peripheral nerve block for video-assisted thoracic surgery, whose injection is administered at the site of chest wall incision.
89594669|NCT03080038|No Intervention|Usual Care Resuscitation Strategy|Decisions regarding the IV/IO administration of isotonic fluid boluses and/or the initiation and escalation of vasoactive medication infusions are left to the discretion of the treating physician and medical team. We ask that vasoactive medications not be initiated until at least 60 mL/kg (3 litres for children ≥ 50 kg) of isotonic fluid bolus therapy has been administered. The treating physician and medical team are advised to follow ACCM guidelines for the resuscitation of neonatal and pediatric septic shock and to target ACCM recommended therapeutic endpoints.
89594670|NCT03080038|Experimental|Fluid Sparing Resuscitation Strategy|The treating physician and medical team are advised to follow the assigned Fluid Sparing Resuscitation Strategy to guide decisions regarding the IV/IO administration of further isotonic fluid boluses, and the timing of initiation and escalation of vasoactive medication infusions to target the therapeutic endpoints recommended in the ACCM guidelines for the resuscitation of neonatal and pediatric septic shock.
89594671|NCT04761562|Active Comparator|Control group|Patients will be treated with a standard surgical procedure - tympanoplasty.
89594672|NCT04761562|Experimental|PVRP group|Patients will be treated with a standard surgical procedure - tympanoplasty combined with PVRP. PVRP will be applied to the reconstructed tympanic membrane.
89594673|NCT05346328|Experimental|Single Group Assignment|This study adopts an open research design and selects patients with refractory HER2-positive unresectable locally advanced or metastatic breast cancer who have failed previous ADC drug treatment. The patients who met the enrollment conditions were treated with injection of A166.
89594674|NCT03082690|Experimental|DuoGel|IQP-0528 1% gel administered rectally one time
89594675|NCT04403230|Experimental|Clinical behaviour on teeth prepared without finish line|Evaluate the clinical behavior of restorations placed on teeth prepared without finish line, monitoring periodontal status as well as the prostheses to assess stability and treatment predictability.
89594676|NCT03085888||Prospective Cohort|This is a prospectively enrolling cohort study with a pre-specified molecular analysis plan. A stratified case-cohort design will be employed to select cancer cases and non-cancer subjects who will be assayed. All cases of cancer (breast and non-breast cancer) will be selected. A random subset of the overall study cohort will also be selected.
89608515|NCT01276288|Active Comparator|Reference 1|administration of BI 10773 once daily for 5 days (20 patients)
89608516|NCT01276288|Active Comparator|Reference 2|administration of hydrochlorothiazide (HTC) once daily for 4 days (10 patients)
88811320|NCT02270411||Hidradenitis Suppurativa (HS)|Patient has a history of HS for at least 6 months.
89594677|NCT03082300|Experimental|Pharmacokinetic phase: ASP8273 Tablet then Capsule Sequence|Subjects will receive a single oral dose in tablet formulation on Day 1 of period 1 under fasted condition, then subjects will receive a single oral dose of ASP8273 in capsule formulation on Day 1 of period 2 under fasted condition. Each period will be for 5 days
89594678|NCT03082300|Experimental|Pharmacokinetic phase: ASP8273 Capsule then Tablet Sequence|Subjects will receive a single oral dose in capsule formulation on Day 1 of period 1 under fasted condition, then subjects will receive a single oral dose of ASP8273 in tablet formulation on Day 1 of period 2 under fasted condition. Each period will be for 5 days
89594679|NCT03082300|Experimental|Postpharmacokinetic phase: ASP8273 Capsule Formulation|All subjects will receive ASP8273 capsules in once-daily dosing for 1 cycle (28 days)
89594680|NCT03082768|Experimental|[18F]MNI-968|To evaluate [18F]MNI-968 (aka PF-06730110) as a D1 receptor targeted radiopharmaceutical
89594681|NCT03082456|Other|Three breast screening modalities|Subjects who have had mammography less than two years ago will receive MBI and breast ultrasound only. Other participants will receive three interventions including molecular breast imaging, mammography and breast ultrasound. The interval between each examination will be less than 6 months.
89594682|NCT01679860|Experimental|Clin A|Clin A. CHOP-Campath (CHOP-C) for 2 cycles , Hyper-C-Hidam for 2 cycles and auto-SCT (stem cell transplantation) or RIC allo-SCT in advanced stage PTCL pts ≥ 18 and ≤ 60 years
89594683|NCT01679860|Experimental|Clin B|Clin B: CHOP-Campath (CHOP-C) for 6 cycles . It is a combined immunochemotherapy approach in a subset of elderly pts aged > 60 ≤ 75 years
89594684|NCT05346952|Experimental|TQB2450 injection + carboplatin + pemetrexed|TQB2450 injection：1200 mg, Intravenous drip d1； carboplatin ：Area Under Curve 5mg/mL/min，Intravenous drip d1；Pemetrexed: 500mg/m2，Intravenous drip d1.The above schemes are repeated every three weeks. After 4 cycles, the regimen is changed to TQB2450 injection（1200 mg, Intravenous drip d1）+Pemetrexed（500mg/m2，Intravenous drip d1）+ Anlotinib (10mg, peros every day, d1-14) . The regimen is repeated every 3 weeks until the disease progresses.
89594685|NCT05346952|Active Comparator|TQB2450 injection + Anlotinib + Pemetrexed|Tilelizumab: 200 mg, Intravenous drip d1;carboplatin : AUC 5mg/mL/min, Intravenous drip d1；Pemetrexed: 500mg/m2, Intravenous drip d1.The above schemes are repeated every three weeks. After 4 cycles, the regimen is changed to Tilelizumab (200 mg, Intravenous drip d1)+Pemetrexed (500mg/m2，Intravenous drip d1).The regimen is repeated every 3 weeks until the disease progresses.
89594686|NCT03089788|Other|Home-based test and skin test|
89594687|NCT03089632|Experimental|Gluten-free diet|All patients will follow a strict gluten-free diet for 1 month. Measurement will be conducted at baseline and after the intervention.
89594688|NCT03081442|Active Comparator|Misoprostol group|Sixty women received 600 micrograms of misoprostol vaginally as deep as possible six hours before IUD insertion.
89594689|NCT03081442|Placebo Comparator|placebo group|Sixty women received the placebo vaginally six hours before IUD insertion. Placebo is the same in size, color and shape to misoprostol.
89594690|NCT04402450|Active Comparator|suprainguinal fascia iliaca block|Forty mL of levobupivacaine 0.25% with epinephrine 5 ug/mL will be injected cranial to the inguinal ligament between the fascia iliaca and the iliopsoas muscle.
89594691|NCT04402450|Experimental|Pericapsular nerve group block|Twenty mL of levobupivacaine 0.5% with epinephrine 5 ug/mL will be deposited in the anterior aspect of the iliac bone between its periosteum and the tendon of the iliopsoas muscle.
89594692|NCT03082222||Group 1|Participants with epilepsy, partial onset seizures with or without secondary generalization with one concomitant antiepileptic drug (AED) at baseline
89594693|NCT03082222||Group 2|Participants with epilepsy, partial onset seizures with or without secondary generalization with two or more concomitant AEDs at baseline
89594694|NCT03082222||Group 3|Participants with epilepsy, partial onset seizures with or without secondary generalization with eslicarbazepine acetate (ESL) as anticonvulsant monotherapy
89594695|NCT03089710|Experimental|Mini-Fluid Challenge arm|"Fluid challenge test will be presented after induction of anesthesia at a steady state. Fluid challenge test includes 2 components: 100 ml colloid infusion in 1 min followed by 400 ml colloid infusion in 14 mins. Hemodynamic parameter after 1 minute of the end of the 1st and 2nd colloid infusion bolus will be collected.~Applied colloid: hydroxyethyl starch"
89594696|NCT03080818|Experimental|Probiotic|Participants in this arm will receive probiotic supplementation for 12 weeks (Lactobacillus Rhamnosus GG)
89594697|NCT03080818|Placebo Comparator|Control|Participants in this arm will receive placebo that look similar to probiotics
89594698|NCT03080662|Sham Comparator|Sham valve (Placebo)|Sham Inspiratory valve (without resistance)
89594699|NCT03080662|Experimental|Intervention|Inspiratory valve with increase resistance
89594700|NCT03431194|Active Comparator|midodrine group|Patients will receive midodrine tablets
89594701|NCT03431194|Placebo Comparator|placebo group|Patients receive sugary oral tablets therapy
89594702|NCT03080740|Active Comparator|Clindamycin palmitate hydrochloride|Clindamycin palmitate hydrochloride dispersible tablet 300mg, oral after meal, twice daily, a total of 7days
89594703|NCT03080740|Active Comparator|Metronidazole|Metronidazole Tablet 400mg, oral after meal , twice daily, a total of 7days
89594704|NCT03084094|Experimental|M1|Transcranial direct current Stimulation in primary motor cortex
88978382|NCT04719091|Placebo Comparator|Placebo Oral Spray|The Study Examiner and staff will screen for subjects that meet the enrollment criteria. Subjects will be randomly assigned to one of two treatment groups. Oral soft and hard tissue examinations will be conducted at each visit. Following an initial 3-5 minute evaluation of resting salivary flow, subjects will wait 10 minutes and then use their assigned spray. They will then swallow, and unstimulated saliva will be collected for 3-5 minutes. They will then remain in the study center for 60 min to evaluate xerostomia relief by questionnaire at 5, 15, 30, 45 and 60 min. after the use of placebo mouth spray. They will then be given their assigned product to use twice daily for one week
88978383|NCT00069992|Experimental|Submyeloablative Allogeneic Stem Cell Transplant|Total Body Irradiation Fludarabine Campath 1H
89594705|NCT03084094|Experimental|DLPFC|Transcranial direct current Stimulation in the dorsolateral pre-frontal cortex
89594706|NCT03084094|Sham Comparator|Sham|sham stimulation
89594707|NCT03464500|Active Comparator|Mitopure 500mg|
89594708|NCT03464500|Active Comparator|Mitopure 1000mg|
89594709|NCT03464500|Active Comparator|Placebo|
89594710|NCT03399994|Experimental|ABLUMINUS DES+|device implantation during coronary angioplasty
89594711|NCT03399994|Active Comparator|Everolimus-eluting DES|device implantation during coronary angioplasty
89594712|NCT04279990||Functional dyspepsia patients with JHS|Patients with functional dyspepsia as defined by the Rome III criteria and joint hypermobility syndrome as defined by the Beighton Hypermobility criteria.
89594713|NCT04279990||Functional dyspepsia patients without JHS|Patients with functional dyspepsia as defined by the Rome III criteria and WITHOUT joint hypermobility syndrome as defined by the Beighton Hypermobility criteria.
89594714|NCT04279990||Healthy subjects|Healthy subjects with no gastrointestinal diseases including no functional dyspepsia
89594715|NCT03080584|Experimental|acupucture arm|all participants undergo 12 weeks of acupuncture
89594716|NCT04402372||Group 1|30 patients undergoing aortic valve replacement with minimally invasive technique prospectively randomized to receive 19 F bidirectional (BiflowTM, LivaNova, Italy) for femoral artery cannulation
89594717|NCT04402372||Group 2|30 patients undergoing aortic valve replacement with minimally invasive technique prospectively randomized to receive 19 F conventional (HLS, Maquet, Germany cannula with downstream line (6F) for femoral artery cannulation
89594718|NCT03081832|Experimental|Oxytocin|Groups of children with Prader Willi Syndrome treated by oxytocin for 7 days during their first 6 months of life.
89594719|NCT03081832|Experimental|Control|Groups of children with Prader Willi Syndrome not treated by oxytocin for 7 days during their first 6 months of life.
89594720|NCT03081754||IUGR|Fifty women with intrauterine growth restricted fetuses were included in the study. Gestational age was based on the precisely dated last menstrual period and ultra-sonographic examination of crown-rump length in the first trimester. Intrauterine growth restriction was diagnosed when fetal abdominal circumference was more than two standard deviations below the mean for gestational age and also confirmed by the serial assessment of the fetal growth parameters (Chitty and Altman, 1999). Detailed obstetric history was available for each patient. Caesarean sections were performed on clinical grounds
89594721|NCT03081754||control group|Twenty five uneventful pregnancies with appropriate for gestational age fetuses are selected as control. Obstetric history Doppler results and placenta were examined for any remarkable pathology. Caesarean sections were performed on clinical grounds. The indications for Caesarean section of the controls, which were tried to be at equivalent gestational ages with the study group, were presentation abnormalities or previous Caesarean section
88978384|NCT00255580|Experimental|1|Active cannabis (1-8% THC by weight)
88978385|NCT00255580|Placebo Comparator|2|Placebo cannabis
88978386|NCT00104091|Experimental|1|40 mL of TP-38 at a 100 nanograms/mL concentration
89031466|NCT02951897|Placebo Comparator|IA-CTC-low-controls|IA lung adenocarcinoma cases with low abundant CTCs prior to operation will only undergo segmentectomy. Postoperative CTC monitoring will be conducted.
89594722|NCT03081520|Experimental|Affective response MIT|Moderate intensity continuous training 50 min with walking or running on approximately 75% of HRmax
89594723|NCT03081520|Experimental|Affective response HAIT|High-Intensity Aerobic Interval Training 4x4 min with walking or running on 85-95% of HRmax 3 min active recovery between sets, intensity of approximately 70% of HRmax
89594724|NCT03081520|Experimental|Affective response HIIT|High-Intensity Interval Training 4-6 x 30-sec sprints on tread mill, >95% HRmax during sprints 4 min recovery between sprints, intensity of approximately 70% of HRmax
89594725|NCT03080506|Experimental|Binder|Each woman will be fitted with an elastic abdominal binder at the time of procedure completion just before leaving the operating room. The binder will be placed snuggly tight on top of the hospital gown at the infraumbilical level with the incision positioned at the middle part of the binder. The patients will be encouraged to wear binders at all time. However, periods of break from wearing the binder will be allowed at their convenience.
89594726|NCT03080506|No Intervention|No binder|The women will not be given a chance to wear abdominal binder or the likes.
89594727|NCT03394456|Experimental|Intervention|Receive diabetes group visits/diabetes program
89594728|NCT03394456|No Intervention|Control|Receive usual care in the clinic, followed by group visits (wait list control) for cohorts 1-4 case-matched comparisons via chart review for cohort 5
89594729|NCT03080350|Experimental|Fentanyl sublingual + Placebo ev|Fentanyl 100 µg sublingual in acute sever pain + NaCl 0,9% endovenous to mimic fentanyl ev
89594730|NCT03080350|Active Comparator|Fentanyl ev + Placebo sublingual|Fentanyl ev in acute sever pain + Sugar pill manufactured to mimic fentanyl sublingual
89594731|NCT03080428|Active Comparator|Endopredict®|genomic test Endopredict® realized on surgery tumour samples
89594732|NCT03080428|Active Comparator|Prosigna®|genomic test Prosigna® realized on surgery tumour samples
89594733|NCT03080428|Active Comparator|OncotypeDX®|genomic test OncotypeDX® realized on surgery tumour samples
89594734|NCT03080428|Active Comparator|Mammaprint® assay|genomic test Mammaprint® assay realized on surgery tumour samples
89594735|NCT03080194|Experimental|paliperidone palmitate group|The subjects in experimental group will be injected with 150mg eq and 100mg eq paliperidone palmitate in the deltoid at the 1st and 8th day, and afterwards a flexible dose of paliperidone palmitate from 75 to 150mg eq will be administrated monthly according to clinical judgement.
89594736|NCT03080194|Active Comparator|control group|The subjects in control group will be applied with oral antipsychotics or other conventional medication.
89594737|NCT03080116|Experimental|ARN-509 + degarelix|Treatment period of 12 weeks before RP + PLND.
89594738|NCT03080116|Active Comparator|placebo + degarelix|Treatment period of 12 weeks before RP + PLND.
89594739|NCT03081598|Placebo Comparator|Placebo|Daily dose of 6 capsules of placebo
89594740|NCT03081598|Active Comparator|PBI-4050 400 mg|Daily dose of 2 capsules of PBI-4050 and 4 capsules of placebo
89594741|NCT03081598|Active Comparator|PBI-4050 800 mg|Daily dose of 4 capsules of PBI-4050 and 2 capsules of placebo
89594742|NCT03081598|Active Comparator|PBI-4050 1200 mg|Daily dose of 6 capsules of PBI-4050
89594743|NCT04401670|Other|Triage with different options|"Self-Collection: hrHPV and Biomarkers Testing (among hrHPV+)~ThinPrep Specimen: Liquid-Based Cytology (LBC), hrHPV Testing, and Biomarker Testing (among hrHPV+)~Visual Inspection after Acetic Acid (VIA)"
89594744|NCT03088774|Experimental|New web-application|Information material developed in a participatory design together with patients.
89594745|NCT03088774|Experimental|Patient Handbook|Public available information.
89594746|NCT03089008|Experimental|Eccentric exercises|The patients were instructed to stand with straight legs on a small step, lift up on the toes, hereafter put the weight on the injured leg and slowly lower the heel as far as possible until they felt a maximal stretch of the calf muscles and/or the Achilles tendon. The exercises were repeated 15 times. Then the patients were told to repeat the exercises with semi-flexed knee. If possible the series should be repeated twice increasing to three times at each session. If pain decreased they should increase the load on the Achilles tendons by wearing a rug sack and increasing the weight of the rug sack by adding weights (5kg each). The patients were told that some pain was to be expected from the tendon during exercise, but that increasing daily pain or morning stiffness indicated that the exercises had been progressed too fast.
88978387|NCT00255658|Experimental|Treatment (sorafenib tosylate, temsirolimus)|"Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. They also receive oral sorafenib* twice daily starting on day 8 of course 1. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.~NOTE: *On the days of the temsirolimus infusion, temsirolimus should be taken concurrently with the morning dose of sorafenib.~Cohorts of 3-6 patients receive escalating doses of temsirolimus until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Up to 12 patients are treated at the MTD."
88978388|NCT00070148|Active Comparator|Arm 1 Oxandrolone 20 mg daily|Oxandrolone 20 mg (10 mg BID) for 12 weeks. 4 additional weeks of follow-up.
88978389|NCT00070148|Active Comparator|Megace 800 mg|Megestrol acetate 800 mg daily for 12 weeks. 4 additional weeks of follow-up.
88978390|NCT04719169|Experimental|Post-low pelvic colorectal anastomosis|Single armed study
88978391|NCT04719325|Experimental|Herbert screw|
88978392|NCT04719325|Active Comparator|Lag screw|
88978393|NCT00255892||Part A - Provider Interviews|The provider interviews will be comprised of participants who are clinical providers, mental health providers, and case managers with at least 1 year of experience working with HIV-positive youth; one from each category from all 15 ATN sites will be targeted for a total of 45 participants.
89594747|NCT03089008|Other|Control treatment, stretching exercises|The patients were instructed in standing stretching exercises of the gastrocnemius (straight leg) and soleus (bended knee). The stretch was slowly increased and maintained for 30s. This stretch was to be repeated five times during each session. The patients were instructed that the stretching should be pain free, although a small degree of unpleasantness was allowed.
89594748|NCT03081286|Experimental|Fat grafting|Following liposuction the fat is decanted and used for fat grafting to the area of pain after breast cancer surgery.
89594749|NCT03081286|Sham Comparator|Sham grafting|Following liposuction the fat is discarded. Instead approximately 50mL of saline is used instead of fat and injected into the area of pain after breast cancer surgery.
89594750|NCT04279678||patients undergone mitral repair|includes all patients undergone repair of mitral valve with CABG
89594751|NCT04279678||patients with no mitral repair|includes all patients where no repair done for mitral valve , only CABG
89594752|NCT04402528|Experimental|mehealth portal with integrated behavioral tools|Patients in this arm will use the mehealth for ADHD web-based software and have access to a module that allows parents and teachers/childcare providers to develop and implement behavioral interventions such as daily report cards online.
89594753|NCT01610336|Experimental|INC280 100 mg Cap QD Phase Ib|cap=capsule; QD=once daily
89594754|NCT01610336|Experimental|INC280 200 mg Cap QD Phase Ib|cap=capsule; QD=once daily
89594755|NCT01610336|Experimental|INC280 400 mg Cap QD Phase Ib|cap=capsule; QD=once daily
89594756|NCT01610336|Experimental|INC280 800 mg Cap QD Phase Ib|cap=capsule; QD=once daily
89594757|NCT01610336|Experimental|INC280 200 mg Cap BID Phase Ib|cap=capsule; BID=twice daily
89594758|NCT01610336|Experimental|INC280 400 mg Cap BID Phase Ib|cap=capsule; BID=twice daily
89594759|NCT01610336|Experimental|INC280 600 mg Cap BID Phase Ib|cap=capsule; BID=twice daily
89594760|NCT01610336|Experimental|INC280 200 mg Tab BID Phase Ib|tab=tablet; BID=twice daily
89594761|NCT01610336|Experimental|INC280 400 mg Tab BID Phase Ib|tab=tablet; BID=twice daily
89594762|NCT01610336|Experimental|INC280 400 mg Cap BID Phase II|cap=capsule; BID=twice daily
89594763|NCT01610336|Experimental|INC280 400 mg Tab BID Phase II|tab=tablet; BID=twice daily
89594764|NCT03086200|No Intervention|iTAB + SOC Control Arm|Participants will receive PrEP and standard of care (SOC) including health education, clinical assessments, laboratory safety monitoring, STI and HIV screening, HIV risk reduction counseling, assessment of psychosocial barriers, and adherence counseling. In addition to SOC, participants will receive daily text messages (iTAB) as reminders for medication adherence. Text messages will be setup during the Baseline visit in coordination with the participant's preferences.
89594765|NCT03086200|Experimental|iTAB + MI-b Intervention Arm|Participants will receive the same PrEP, SOC procedures, and iTAB support as that of the Control Arm. Participants in the Intervention Arm will also receive brief motivational interviewing counseling sessions if adherence becomes suboptimal. Adherence will be monitored by responses to the iTAB system; if Intervention Arm participants reply with 3 consecutive negative or non-responses, MI-b counselors will perform 15-minute over-the-phone motivational interviewing counseling sessions with the participant.
89594766|NCT05689138||PCA|pancreatic cancer patients
89594767|NCT05689138||NC|normal control
89594768|NCT05685550|Experimental|Treatment group|Etoposide capsules in combination with anrotinib and Emvollizumab
89594769|NCT05689060|Experimental|Group I|received mulligan straight leg raising
89594770|NCT05689060|Experimental|group II|received post facilitation stretch on hamstring muscles
89594771|NCT03088696|Active Comparator|stimulation of the acupuncture point|"a acupuncture needle and bandage will be applied at pericardium channel 6, point Neiguan"
89594772|NCT03088696|Placebo Comparator|no stimulation of the acupuncture point|"only a bandage will be applied at pericardium channel 6, point Neiguan"
89594773|NCT01613222|Experimental|Pulse oximetry monitoring|The U-TruSignal with different sensors is feasible for noninvasive and continuous SpO2 monitoring and meets the specified measurement accuracy when compared to a co-oximetry gold reference.
89594774|NCT03088462|Active Comparator|Treatment As Usual|Any treatment for bipolar disorder participant is involved in.
89594775|NCT03088462|Experimental|Treatment As Usual + LiveWell Program|Treatment as usual combined with the LiveWell program.
89594776|NCT05345860|Experimental|TNBC with high risk or MRD+|"TNBC patients with clinical high risk or post-operation 1st MRD tested positive.~It's possible that this arm will be divided into many sub-arms considering the different kinds of intensive adjuvant therapies and the adopting of MRD strategy."
89594777|NCT05345860|Experimental|HER2+ with high risk or MRD+|"HER2+ patients with clinical high risk or post-operation 1st MRD tested positive.~It's possible that this arm will be divided into many sub-arms considering the different kinds of intensive adjuvant therapies and the adopting of MRD strategy."
89594778|NCT05345860|Experimental|ER+ with high risk or MRD+|"ER+ patients with clinical high risk or post-operation 1st MRD tested positive.~It's possible that this arm will be divided into many sub-arms considering the different kinds of intensive adjuvant therapies and the adopting of MRD strategy."
89594779|NCT05345860|Experimental|TNBC with low risk and MRD-|"TNBC patients with low clinical risk and post-operation 1st MRD tested negative.~It's possible that this arm will be divided into many sub-arms considering the different kinds of standard adjuvant therapies and the adopting of MRD strategy."
89594780|NCT05345860|Experimental|HER2+ with low risk and MRD-|"HER2+ patients with low clinical risk and post-operation 1st MRD tested negative.~It's possible that this arm will be divided into many sub-arms considering the different kinds of standard adjuvant therapies and the adopting of MRD strategy."
89594781|NCT05345860|Experimental|ER+ with low risk and MRD-|"ER+ patients with low clinical risk and post-operation 1st MRD tested negative.~It's possible that this arm will be divided into many sub-arms considering the different kinds of standard adjuvant therapies and the adopting of MRD strategy."
89594782|NCT03323866|Active Comparator|Mometasone nasal spray|Mometasone nasal spray 50 mcg/dose, 2 sprays/nostril twice daily x 3 months Patients will also be taking Sinus Rinse once daily throughout the study period
89594783|NCT03323866|Experimental|Budesonide irrigation|2 cc budesonide nebule (0,5 mg/cc) incorporated to 240 of saline water (Sinus Rinse) to be taken on a daily basis x 3 months
89594784|NCT05684848|Active Comparator|Resveratrol + CMG|Medical device: nasal spray based on resveratrol associated with carboxymethylbetaglucan in isotonic solution
89594785|NCT05684848|Placebo Comparator|Isotonic solution|Medical Device with isotonic solution
89594786|NCT03322618|Experimental|SpA HLA-B27 +,|
89594787|NCT03322618|Experimental|SpA HLA-B27-|
89594788|NCT03322618|Active Comparator|healthy subject|
89594789|NCT03390244|Experimental|FCVB Implant|All subjects in this study are in the experimental treatment arm and will receive the FCVB implant
89594790|NCT04761484|Experimental|Intervention|Insertion of peripheral venous catheter on admission to the NICU
89594791|NCT04761484|No Intervention|Control|Insertion of and umbilical venous catheter on admission
89594792|NCT03320668|No Intervention|Individual OEP|"Randomized subjects (65 to 80-year-old) receiving individual Otago Exercise Program (OEP) training in a total of nine Primary Care Centers.~An OEP leader trained nurse/physiotherapist will perform in its community consult individual education to each participant in five sessions: In the 1st, 2nd, 4th and 8th week and one reinforcement session after six months. A telephone call to each participant (following a predefined telephonic interview protocol) will be carried out in the months without training session to perform the follow-up."
89031467|NCT02951897|Active Comparator|IB-CTC-High-enhance|IB lung adenocarcinoma cases with high abundant CTCs prior to operation will undergo lobectomy&lymphadenectomy plus adjuvant chemotherapy. Postoperative CTC monitoring will be conducted.
89031468|NCT02951897|Placebo Comparator|IB-CTC-High-controls|IB lung adenocarcinoma cases with high abundant CTCs prior to operation will undergo lobectomy&lymphadenectomy. Postoperative CTC monitoring will be conducted.
89594793|NCT03320668|Experimental|Group OEP|65-80 year-old randomized subjects receiving group Otago Exercise Program (OEP) training in a total of nine Primary Care Centers.
89594794|NCT03366298|Active Comparator|1|Visit 1: Emerade 300mcg then Epipen 0.3mg Visit 2: Emerade 500mcg
89594795|NCT03366298|Active Comparator|2|Visit 1: Epipen 0.3mg then Emerade 300mcg Visit 2: Emerade 500mcg
89594796|NCT03366298|Active Comparator|3|Visit 1: Emerade 500mcg Visit 2: Emerade 300mcg then Epipen 0.3mg
89594797|NCT03366298|Active Comparator|4|Visit 1: Emerade 500mcg Visit 2: Epipen 0.3mg then Emerade 300mcg
89594798|NCT03320512|Experimental|P3|Participants will use P3
89594799|NCT03320512|Experimental|P3+|Participants will use P3+
89594800|NCT03320512|Placebo Comparator|Control|Participants will receive the standard of care
89594801|NCT05683522|Experimental|Sub-omohyoidal Plane Block|Patients randomized to receive sub-omohyoid plane block.
89594802|NCT05683522|Experimental|Costoclavicular Block plus Cervical Plexus Block|Patients randomized to receive costoclavicular brachial and cervical plexus block.
89594803|NCT05688514|Experimental|Innovalve TMVR System|MV replacement with Innovalve MR system
89594804|NCT03315598|Experimental|An open-labeled, single-arm, exploratory pilot study|Electroacupunture for 2months
89594805|NCT04401124||patients treated at surgical emergency rooms|
89594806|NCT04401124||patients receiving surgeries (both elected and emergency)|
89594807|NCT03364270|Experimental|[F-18] RDG-K5|PET/CT Imaging with administration of [F-18] RGD-K5
89594808|NCT03364114|Experimental|EndoRotor Resection|For the purpose of this study the EndoRotor System is investigationally indicated for use during endoscopic procedures to resect and remove refractory Barrett's esophagus tissue in conjunction with a submucosal saline injection mix using adrenaline and dye. Subjects randomized to the EndoRotor arm will be treated up to 3 times through the 9 month follow-up period to remove gross visible Barrett's.
89594809|NCT03364114|Active Comparator|Continued Ablation (Control)|The investigator shall exercise standard of care for subjects undergoing continued ablative therapies (RFA and/or Cryotherapy). These will constitute the control devices. The investigator will choose the system in this arm. Operation of each system will be done according to the manufacturer's IFU. Subjects randomized to the control arm may be treated up to 3 time through the 9 month follow-up period to remove gross visible Barrett's.
89594810|NCT03082066||Children|Younger 18 years: Newborns, infants, small child, school child, teens
89594811|NCT03082066||Adults|Even or older 18 years
89594812|NCT04279288|Experimental|participants enrolled with epistaxis and/or nasal fractures|
89594813|NCT01612676|Experimental|Drug|FE 202158
89594814|NCT05424172|Experimental|Stage-I: Self Monitoring Exercise Using a Health App|Participants will be randomized into one of two groups: Group 1 (self monitoring using a non-interactive app), and Group 2 (self monitoring using an interactive app). Participants in both groups will be provided a customized exercise program to complete over the duration of the study. Within either app, participants will be able to view assigned exercises, log additional exercises completed, complete questionnaires as needed, and access additional resources. Participants will use their own smartphone to receive the health app. Participants will continue using their Stage-I app intervention for the entire duration of the study (weeks 1-24).
89594815|NCT05424172|Experimental|Stage-II: Strategy to Address Non-Adherence|After 12 weeks, the participants will be categorized as adherents or non-adherents based on their rates of adhering to the SCI exercise guidelines during Stage-I. Non-adherents (those who met the exercise guidelines <50% of the weeks) will be randomized to receive an augmented intervention of motivational interviewing-based e-coaching (2x per month or 4x per month) in addition to their Stage-I assigned app for 12 weeks (weeks 13-24) to further increase rates of exercise. All non-adherents who will be assigned to the e-coaching interventions will be asked to complete at least daily EMA surveys. A coach who is trained in motivational interviewing will review the EMA data and work collaboratively with participants to identify barriers and facilitators and develop individualized strategies to improve exercise adherence. Adherents (those who met the exercise guidelines >50% of the weeks) will continue with only their Stage-I assigned app intervention throughout Stage-II.
89594816|NCT01869764|Experimental|Arm I (omega-3 fatty acid)|Patients receive omega-3 fatty acid PO daily for 7-14 days.
88978394|NCT00255892||Part B - Youth Focus Groups|"The focus groups will be comprised of 6-8 participants per group who are between the ages of 16 and 24, diagnosed HIV+ and aware of their HIV diagnosis for between 12-24 months, and receive services at three selected ATN sites or their community partners for a total of 36-48 participants.~For the purposes of this study, youth who acquired HIV perinatally will be excluded from participation in this study."
88978395|NCT00070187|Experimental|Hyperfractionated Involved-Field Radiotion-immunotherapy|"Completed prior salvage induction therapy and have not received full tissue tolerance from prior radiotherapy may receive hyperfractionated involved-field radiotherapy twice daily for 7 days.~HIGH-DOSE PREPARATIVE REGIMEN: Beginning within 7 days after radiotherapy, carmustine IV over 3 hours on day -6; etoposide IV over 1 hour and cytarabine IV over 1 hour on days -5 to -2; and melphalan IV over 30 minutes on day -1.~ASCT: Autologous bone marrow or peripheral blood stem cell transplantation on day 0. Filgrastim (oral or IV) beginning on day 1 and continuing until blood counts recover.~IMMUNOTHERAPY: Cyclosporine IV twice daily beginning on day 0 and continuing until the completion of the course of recombinant interferon gamma and interleukin-2. When sufficiently recovered, Aldesleukin once daily for 18 days."
89594817|NCT01869764|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO daily for 7-14 days.
89594818|NCT01842620|Experimental|OXEMET 1000 mg coated tablets|Generic undergoing bioequivalence study against reference
89594819|NCT01842620|Active Comparator|GLAFORNIL 500 mg tablets|Reference drug for bioequivalence study
89594820|NCT04400266|Experimental|Buspirone and Melatonin|Buspirone 15mg and Melatonin 3mg
89594821|NCT04746742|Active Comparator|Tunneled femoral catheter|20 patients with end stage renal disease and exhausted upper-extremity and chest-wall vascular accesses will be randomly allocated to this group
89594822|NCT04746742|Active Comparator|Femoral artery-femoral arteriovenous graft|a straight or loop configuration 28patients with end stage renal disease and exhausted upper-extremity and chest-wall vascular accesses will be randomly allocated to this group
89594823|NCT04348162|Active Comparator|Cocoa Flavanols|Cocoa is taken every day for 10-12 weeks.
89594824|NCT04348162|Active Comparator|Berries anthocyanins|Red-berries are taken every day for 10-12 weeks.
89594825|NCT04348162|Active Comparator|Cocoa flavanols plus berries anthocyanins|Cooa and red-berries are taken every day for 10-12 weeks.
89594826|NCT04348162|No Intervention|Control|Normal diet for 10-12 weeks
89594827|NCT05658172|Active Comparator|Intensive Surveillance arm|Intensified surveillance. Prospective tumor marker (CA27.29, CA125, CEA), CTC and ctDNA testing of the blood samples. Abnormal findings of either marker (CA27.29 and/or CA125 and/or CEA and/or CTC and/or ctDNA) will be regarded as molecular relapse and trigger diagnostic imaging.
89608517|NCT01276288|Active Comparator|Reference 3|administration of torasemide (TOR) once daily for 4 days (10 patients)
89594828|NCT05658172|Placebo Comparator|Standard Surveillance arm|Surveillance according to national guidelines. Blood samples will not be analyzed immediately and will therefore not trigger imaging. A biobank will be established for retrospective and translational studies. This procedure is necessary to ensure the partially double-blinded study design.
89594829|NCT05687656|Experimental|InnovaMatrix AC porcine placental ECM therapy|Eligible subjects will be treated with a weekly application of sterilized, porcine placental ECM followed by standard of care wound therapy and offloading
89594830|NCT04746664|Other|Nutrition counselling|The intervention will be home-to-home-visit once per week lasting 30 minutes to one hour for one month period. The convenience day and time will be selected in the discussion.
89594831|NCT04746508||Unilateral Flat Foot (UniFF)|Participants with flat foot unilaterally (Only one foot's Calcaneal pitch angle ≤ 20 degree)
89594832|NCT04746508||Bilateral Flat Foot (BiFF)|Participants with flat foot bilaterally (Both feet's Calcaneal pitch angle ≤ 20 degree)
89594833|NCT03359356|Experimental|Dupilumab|An initial dupilumab dose of 600 mg (two 300 mg subcutaneous injections), followed by dupilumab 300 mg given every week
89594834|NCT03359356|Placebo Comparator|Placebo|Matching placebo in prefilled syringes identical to the dupilumab syringes
89594835|NCT05687422|Experimental|100μm laser spot diameter group|
89594836|NCT05687422|Active Comparator|200μm laser spot diameter group|
89594837|NCT04760704||Experimental group|Persons aged 65 and over, residing in an institution for dependant elderly or in a long-term care unit
89594838|NCT04760704||control group|Health and medico-social professionals between 40 and 65 years of age
89594839|NCT03383536||Phase 1|Healthy control participants will provide neuroeconomic game responses to form a pool of potential responses for participants to interact with during Phase 2.
89594840|NCT03383536||Phase 2: PTS-SA|posttraumatic spectrum-socially anhedonic
89594841|NCT03383536||Phase 2: PTS-nonSA|posttraumatic spectrum-non-socially anhedonic
89594842|NCT03383536||Phase 2: HC|healthy controls
89594843|NCT01931839|Experimental|Arm 1 Part A: LUM 600 mg qd/ IVA 250 mg q12h|Participants who received lumacaftor (LUM, VX-809) 600 milligram (mg) plus ivacaftor (IVA, VX-770) 250 mg fixed-dose combination (FDC) tablet orally in the morning and IVA 250 mg film-coated tablet orally in the evening, in the previous study VX12-809-103 or VX12-809-104, and will receive the same treatment in this study VX12-809-105 up to Week 96.
89594844|NCT01931839|Experimental|Arm 2 Part A: Placebo - LUM 600 mg qd/ IVA 250 mg q12h|Participants who received placebo matched to LUM and IVA tablet in the previous study VX12-809-103 or VX12-809-104, and will receive LUM 600 mg plus IVA 250 mg FDC tablet orally in the morning and IVA 250 mg film-coated tablet orally in the evening in this study VX12-809-105 up to Week 96.
89594845|NCT01931839|Experimental|Arm 3 Part A: LUM 400 mg q12h/ IVA 250 mg q12h|Participants who received LUM 400 mg plus IVA 250 mg FDC tablet orally in the morning and evening in the previous study VX12-809-103 or VX12-809-104, and will receive the same treatment in this study VX12-809-105 up to Week 96.
89594846|NCT01931839|Experimental|Arm 4 Part A: Placebo - LUM 400 mg q12h/ IVA 250 mg q12h|Participants who received placebo matched to LUM and IVA tablet in the previous study VX12-809-103 or VX12-809-104, and will receive LUM 400 mg plus IVA 250 mg FDC tablet orally in the morning and evening in this study VX12-809-105 up to Week 96.
89594847|NCT01931839|No Intervention|Arm 5 Part A: Observational Cohort|Participants who received either LUM 600 mg plus IVA 250 mg FDC tablet orally in the morning and IVA 250 mg film-coated tablet orally in the evening OR LUM 400 mg plus IVA 250 mg FDC tablet orally in the morning and evening OR placebo matched to LUM and IVA in the morning and evening, in the previous study VX12-809-103 or VX12-809-104, and will be observed (will not receive study drug) in this study VX12-809-105 for up to 2 years.
89594848|NCT01931839|Experimental|Arm 6 Part B: LUM 400 mg q12h/ IVA 250 mg q12h|Participants who received LUM 400 mg plus IVA 250 mg FDC tablet orally in the morning and evening in Cohort 4 of the previous study VX09-809-102, and will receive the same treatment in this study VX12-809-105 up to Week 96.
89594849|NCT01931839|Experimental|Arm 7 Part B: Placebo - LUM 400 mg q12h/ IVA 250 mg q12h|Participants who received placebo matched to LUM and IVA tablet in Cohort 4 of the previous study VX09-809-102, and will receive LUM 400 mg plus IVA 250 mg FDC tablet orally in the morning and evening in this study VX12-809-105 up to Week 96.
89031469|NCT02951897|Placebo Comparator|IB-CTC-low-controls|IB lung adenocarcinoma cases with low abundant CTCs prior to operation will undergo lobectomy&lymphadenectomy. Postoperative CTC monitoring will be conducted.
89031470|NCT02945124|Experimental|Normal children with K Tape|
89594850|NCT01842308|Experimental|Treatment|"CONDITIONING: Patients receive carfilzomib IV over 30 minutes on days -6, -5, -2, and -1. Patients also receive melphalan IV over 1 hour on days -4 and -3.~TRANSPLANT: Patients undergo autologous stem cell transplant on day 0."
89594851|NCT01931059|Experimental|Risperidone then Placebo|This group will receive 2 mg (>200lbs), 1.5mg (150-200lbs.) or 1 mg (< 150lbs. of risperidone oral solution on the first day and a placebo on the second day.
89594852|NCT01931059|Experimental|Placebo then Risperidone|This group will receive a placebo on the first day and 2mg (> 200lbs.), 1.5mg (150-200lbs), or 1 mg (<150lbs.) of risperidone oral solution on the second day
89594853|NCT01841762|Experimental|Macitentan|Macitentan tablet, dose of 10 mg, once daily
89594854|NCT03301636|Experimental|Pembrolizumab + Indoximiod|
89594855|NCT03301636|Experimental|Nivolumab + Indoximiod|
89594856|NCT01841060|Experimental|Radiofrequency ablathermy|Percutaneous radiofrequency ablation (RFA)
89594857|NCT04414592|Experimental|Human Umbilical Cord Mesenchymal Stem Cells|Injection of twenty million human umbilical cord mesenchymal stem cells into the degenerative disc
89594858|NCT04602494|Experimental|Varenicline|Participants will receive varenicline 0.5 mg once daily on days 1-3, 0.5 mg twice daily on days 4-7 and starting on day 8, 1 mg twice daily for a total of 12 weeks added to 12 weeks of group behavioral and texting support specifically designed for teen vaping cessation
89594859|NCT04602494|Placebo Comparator|Placebo|Participants will receive identical placebo 0.5 mg once daily on days 1-3, 0.5 mg twice daily on days 4-7 and starting on day 8, 1 mg twice daily for a total of 12 weeks added to 12 weeks of group behavioral and texting support specifically designed for teen vaping cessation
89594860|NCT04602494|No Intervention|Monitoring only|Participants will attend weekly and monthly sessions that will only consist of assessments. No study medication, no behavioral or texting support.
89594861|NCT03379402||Adult patients presenting with sepsis|Adult patients, both males and females, presenting with sepsis will be approached for participation in the study.
89594862|NCT04587050||Cohort 1|Women with perinatally acquired HIV aged 18 or over who are sexually active
89594863|NCT04587050||Cohort 2|Women with perinatally acquired HIV aged 18 or over who are not sexually active
89594864|NCT04414904||Case group|"Men 18-50 years of age~Already attending hospital for another reason~High risk of prior COVID-19 infection:~EITHER Prior positive COVID-19 PCR test result~OR history suggestive of COVID-19 illness"
89594865|NCT04414904||Control Group|"Men 18-50 years of age~Already attending hospital for another reason~Low risk of prior COVID-19 infection:~EITHER Negative positive COVID-19 PCR test result within last 4 weeks~OR no history suggestive of COVID-19 illness"
89594866|NCT05627518|Active Comparator|Reference formulation (Treatment A)|100 mg linaprazan glurate reference formulation, fasting conditions
89594867|NCT05627518|Experimental|Test formulation (Treatment B)|100 mg linaprazan glurate reference formulation, fasting conditions
89594868|NCT05627518|Experimental|Test Formulation (Treatment C)|100 mg linaprazan glurate test formulation, fed conditions
89594869|NCT01814696|No Intervention|Control|Subjects will continue to receive usual medical care from their doctor(s).
89594870|NCT01814696|Experimental|MedSentry System|Subjects will continue to receive usual medical care from their doctor(s). Subjects will use the MedSentry System and electronic pillbox, to manage their medications.
89594871|NCT01970371|Experimental|Plazomicin in Combination with Meropenem or Tigecycline|Cohort 1: Patients received 15 milligram per killogram (mg/kg) plazomicin therapy (plus meropenem or tigecycline) as a 30-minute intravenous (IV) infusion once daily for 7 to 14 days.
89594872|NCT01970371|Active Comparator|Colistin in Combination with Meropenem or Tigecycline|Cohort 1: Patients received a 5 mg/kg IV loading dose (300 mg maximum) colistin (plus meropenem or tigecycline) followed by a 5 mg/kg/d maintenance dose divided into every 8 hours (q8h) or every 12 hours (q12h) for 7 to 14 days.
89594873|NCT01970371|Experimental|Plazomicin in Combination with Adjunctive Antibiotic|Cohort 2: Patients received 15 mg/kg as a 30 minute IV infusion once daily. BSI, HABP or VABP patients received plazomicin and any supplemental antibiotic therapy, according to Investigator's choice, for 7 to 14 days. cUTI or AP patients received plazomicin monotherapy only for 4 to 7 days with an option to switch to oral therapy on or after Day 5.
89594874|NCT03300466|Experimental|GP0045|Treatment with GP0045
89594875|NCT03300466|Active Comparator|Comparator|Treatment with active comparator
89594876|NCT01868594|Experimental|Subetta group|Patients with poor glycemic control (HbA1c=7.0-10.0%) in basal-bolus insulin regimen with a stable basal insulin dose (permissible fluctuations are ±10%) during the previous 3 months are included
89594877|NCT01868594|Placebo Comparator|Placebo group|Patients with poor glycemic control (HbA1c=7.0-10.0%) in basal-bolus insulin regimen with a stable basal insulin dose (permissible fluctuations are ±10%) during the previous 3 months are included.
89594878|NCT03300232|Experimental|Computer-based VC-CBT|Computer-based VC-CBT: Three, one-hour computerized therapy sessions delivered on an interactive computerized platform with therapy blocks dedicated to each of three primary modules/goals: 1) psycho-education, 2) skills learning, and 3) individualized practice
89594879|NCT05686876|Experimental|68Ga-FAPI, PET/CT|Inject 68Ga-FAPI and then perform PET/CT scan.
89594880|NCT01616953|Experimental|Ixmyelocel-T|iliac bone marrow aspirates are expanded ex vivo to enrich for adult multipotent cells (ixmyelocel-T) capable of regenerating bone and blood vessels and reducing inflammation. Following cell expansion, autologous ixmyelocel-T is then packaged and can be used as an autologous graft for treatment of bone defects.
89594881|NCT01616953|Active Comparator|Autogenous Bone Grafting|Alveolar grafting will be performed. Under local anesthesia, and possibly conscious intravenous sedation (depending on patient desire for sedation due to anxiety), alveolar grafting will be performed with an autogenous bone block harvested from an intraoral or extraoral site, according to standard of care.
89594882|NCT03293524|Experimental|Treatment Arm 1|Subjects will be randomized to treatment arm 1 or treatment arm 2 in a 1:1 allocation. Subjects in treatment arm 1 will receive intravitreal GS010 in both eyes.
89594883|NCT03293524|Placebo Comparator|Treatment Arm 2|Subjects will be randomized to treatment arm 1 or treatment arm 2 in a 1:1 allocation. Subjects in treatment arm 2 will receive GS010 in one eye and placebo intravitreal injection in the other eye.
89594884|NCT01867658|Experimental|Progel® Pleural Air Leak Sealant|
89594885|NCT04401046|Experimental|Post traumatic stress and anxiety evaluation|
89594886|NCT03375892|Active Comparator|Prone Position with DIBH|For prone positioning, patients will be positioned with alpha cradle casts, and a prone breast board.
89594887|NCT03375892|Active Comparator|Supine Position with DIBH|For the supine positioning, patients will be positioned with the breast board currently in use in the Department of Radiation Oncology.
89594888|NCT03375892|Active Comparator|Prone Position with no DIBH|For prone positioning, patients will be positioned with alpha cradle casts, and a prone breast board.
89594889|NCT03375892|Active Comparator|Supine Position with no DIBH|For the supine positioning, patients will be positioned with the breast board currently in use in the Department of Radiation Oncology.
89594890|NCT01867580|Experimental|V.A.C.Ulta with Prontosan instillation|Treatment Arm
89594891|NCT01867580|Active Comparator|V.A.C.Ulta without instillation|Control Arm
88978396|NCT00070187|Experimental|Hyperfractionated Involved-Field Radiotion-no immunotherapy|"Completed prior salvage induction therapy and have not received full tissue tolerance from prior radiotherapy may receive hyperfractionated involved-field radiotherapy twice daily for 7 days.~HIGH-DOSE PREPARATIVE REGIMEN: Beginning within 7 days after radiotherapy, carmustine IV over 3 hours on day -6; etoposide IV over 1 hour and cytarabine IV over 1 hour on days -5 to -2; and melphalan IV over 30 minutes on day -1.~ASCT: Autologous bone marrow or peripheral blood stem cell transplantation on day 0. Filgrastim (oral or IV) beginning on day 1 and continuing until blood counts recover."
88978397|NCT00255931|Experimental|1|
89594892|NCT05686720|Experimental|SZ011 CAR-NK|
89594893|NCT04414982|Experimental|Intervention Values Affirmation|Compare the effects of the values-affirmation exercise with a control exercise in AI/AN patients with hypertension.
89594894|NCT04414982|Active Comparator|Control Values Affirmation|Compare the effects of the values-affirmation exercise in AI/AN patients with its effects in white patients.
89594895|NCT05604742|Experimental|Low-dose group of Belimumab|Belimumab 1mg/kg com combined with conventional therapy
89594896|NCT05604742|Experimental|High-dose group of Belimumab|Belimumab 4mg/kg com combined with conventional therapy
89594897|NCT05604742|No Intervention|Control group|conventional therapy
89594898|NCT03290326|Experimental|tACS|Transcranial alternating current stimulation (tACS) tuned at the frequency of 40Hz (gamma frequency) will be applied for 1 hour in 10 sessions on consecutive weekdays. The tACS intervention (10 sessions) will be preceded and followed by amyloid PET imaging as well as a clinical/cognitive evaluation. The assessment of adverse effects will constitute a Primary outcome measure. Changes in amyloid load in the stimulated brain region will be evaluated and constitute a secondary outcome of the study. Clinically relevant changes in cognitive and clinical scores will be also evaluated as secondary outcomes. Stimulation will be also preceded and followed by electroencephalography (EEG) recording aimed at assessing changes in spectral power in the gamma band.
89594899|NCT05300776|Experimental|M-ROSE combined with mNGS group|The bronchoalveolar lavage fluid (BALF) of patients undergoes M-ROSE analysis and decide whether the samples are qualified, whether they indicate bacterial infection and identify pathogens, and the qualified samples are sent for mNGS analysis. The individualized anti-infection treatment is comprehensively guided according to the results of M-ROSE, mNGS and clinical examinations.
89594900|NCT05300776|No Intervention|mNGS group|BALF samples were directly sent for mNGS analysis, and anti-infective treatment was guided according to clinical examinations.
89594901|NCT03351556|No Intervention|Comparison Arm|Participants in the comparison group will receive the standard HIV primary care services according to Tanzania's National Guidelines for the Management of HIV and AIDS.
89594902|NCT03351556|Experimental|Active Intervention 1|Participants will receive the standard HIV primary care services according to Tanzania's National Guidelines for the Management of HIV and AIDS plus the opportunity to earn 10,000 TZS/month (~$4.50) for up to 6 months conditional on visit attendance.
89594903|NCT03351556|Experimental|Active Intervention 2|Participants will receive the standard HIV primary care services according to Tanzania's National Guidelines for the Management of HIV and AIDS plus the opportunity to earn 22,500 TZS/month (~$10.00) for up to 6 months conditional on visit attendance.
89594904|NCT03350386|Experimental|Single dose|Single administration of FYU-981
89594905|NCT03350386|Experimental|Concomitant administration|Concomitant administration of FYU-981 with oxaprozin at steady state
89594906|NCT04761016|Active Comparator|Control|Control group participants will receive access to the same I-POP Health resources without CHW navigation until the end of 10-months (delayed CHW navigation). The current usual care model is outlined. Participants will complete study measures at baseline, 6-months, and 10-months timepoints. Upon completion of 10-months measures, these individuals will be assigned a CHW and receive delayed navigation.
89594907|NCT04761016|Experimental|I-POP CHW Intervention|I-POP+CHW participants will be paired with a CHW at baseline to assist with navigation for 10-months between health and wellness services in the selected zip codes: 75210, 75215, 75216, 75217, 75223, or 75227. Participants will receive a multi-level intervention utilizing the current I-POP Health model that includes: 1) Access to health services (including oral health), 2) Access to clinical prevention services, 3) Access to education and facilities to increase physical activity and improved nutrition choices, and 4) Scheduled visits with CHWs for education and navigation. Individuals will complete study measures at baseline, 6-months, and 10-months.
89594908|NCT04279444|Experimental|Active BKR-017|Open label study. All patients will receive 28 days of active treatment.
89594909|NCT03371056|Experimental|Woman at low risk of infection|Women with systematic vaginal sample for detection of GBS will be included.
89594910|NCT03371056|Experimental|Woman with high risk of infection > 37 SA|Women with premature rupture of membranes (> 12 hours before labor) but > 37 SA will be included.
88978398|NCT00255931|Placebo Comparator|2|
88978399|NCT00255931|No Intervention|3|Usual Care
88978400|NCT00104559|Experimental|1|Participants will receive the computer-based tutorial for VT and then the standard paper consent form for AT
88978401|NCT00104559|Experimental|2|Participants will receive the standard paper consent form for VT and then the computer-based tutorial for AT
88978402|NCT00104559|Experimental|3|Participants will receive the computer-based tutorial for AT and then the standard paper consent form for VT
88978403|NCT00104559|Experimental|4|Participants will receive the standard paper consent form for AT and then the computer-based tutorial for VT
88978404|NCT00070265|Experimental|Treatment (oxaliplatin, capecitabine, and surgery)|"Neoadjuvant chemotherapy: Patients receive oxaliplatin IV over 2 hours on day 1 and oral capecitabine twice daily on days 1-14. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.~Surgery: Four to six weeks after the completion of chemotherapy, patients undergo surgical resection of the tumor.~Adjuvant chemotherapy: Patients with satisfactory response to therapy receive 4 additional courses of oxaliplatin and capecitabine after surgery."
88978405|NCT00256048|No Intervention|Standard Care|Patients will receive enteral nutrition via a nasogastric tube as per standard feeding regime
89031471|NCT02945124|No Intervention|Normal children without K Tape|
89594911|NCT03371056|Experimental|Women with premature rupture of membranes (<37SA)|Woman with high risk of infection <37SA
89594912|NCT03371056|Experimental|Women with premature delivery or premature delivery threat|Woman with high risk of infection <37SA and Women with premature delivery or premature delivery threat
89594913|NCT05345548|Experimental|Cold Pressor test|
89594914|NCT03283462|Active Comparator|Mitopure|
89594915|NCT03283462|Placebo Comparator|Placebo|
89594916|NCT04400968|Experimental|Auricular therapy group|The auricular therapy group received an intervention based on the bilateral application of 7 adhesive tapes with vaccaria seeds. The points were located with a retractable 250 gr. pressure palpator (Sedatelec®). An experienced health professional trained on acupuncture techniques applied the vaccaria seeds.
89594917|NCT04400968|Sham Comparator|Auricular therapy Placebo group|The auricular therapy placebo group had adhesive tapes without seeds displaced from the treatment points.
89594918|NCT04400968|Experimental|Kinesio tape group|The kinesio tape group received an intervention that consisted on the standard application of three elastic bandages. An experienced kinesio tape certified physical therapist applied the taping.
89594919|NCT04400968|Sham Comparator|kinesio tape Placebo group|The kinesio tape placebo group had the application of three elastic bandages that were shorter than the used in the kinesio tape group. In addition, the tape was adhered with no tension and not place in the treatment area.
89594920|NCT04400968|No Intervention|Control group|The control group did not receive any treatment. The participants continued with their routine medical treatment. However, the controls completed all the questionnaires to collect the information regarding their symptoms in order to observe their progress with no intervention.
89594921|NCT05686330|Experimental|Interventional group (Apple watch)|These participants will wear a smartwatch (Apple Watch) for 6 months during 12 hours a day. The smartwatch will alarm the participant if an irregular heart rhythm is detected. When a participant receives an irregular heartbeat notification, they can record an ECG with the smartwatch. The ECG will automatically be sent to the Telecure team for evaluation.
89594922|NCT05686330|No Intervention|Control group|These participants will be following standard care alone. These participants are instructed to notify the investigators when atrial fibrillation is detected or when they have visited the emergency department during these six months. At the end of the study period the investigator will either call the participant, or their treating physician to check for these outcome measures.
89594923|NCT03281590||Patients with stroke|Patients with the Acute Brain injury, Transient Ischemic Attack, Acute and Chronic Ischemic and Hemorrhagic Stroke, Subarachnoid hemorrhage, and cerebral venous thrombosis from pre-hospitalization, hospitalization (in-patient) and post hospitalization (clinic) data
89594924|NCT03281590||Patients without stroke|Control subject who have the risk factors but never had stroke.
89594925|NCT03368716|Experimental|Acceptance-based Behavioral Treatment|Family acceptance-based behavioral treatment (ABBT) will be piloted with 16 child-caregiver pairs. At weeks 0 (pre-treatment), 9 (mid-treatment), and 18 (post-treatment), feedback regarding the feasibility and acceptability will be collected from participants through surveys and semi-structured group interviews to refine the family ABBT protocol.
89594926|NCT05686174|Active Comparator|MBS-217|4 ml MBS-217 twice a day for 16 weeks
89594927|NCT05686174|Placebo Comparator|Placebo|4 ml MBS-217 placebo twice a day for 16 weeks
89594928|NCT05685940|Experimental|Standard of care - risankizumab|Patients will continue to receive risankizumab according to the standard dosing schedule: subcutaneous injections at weeks 0 and 4, then every 12 weeks (2x 75mg).
89594929|NCT03344692|Experimental|Alirocumab|Alirocumab 75 mg for subcutaneous injection via a pre-filled pen. One injection every 2 weeks during a 10-weeks period (5 injections in total)
89594930|NCT03344692|Placebo Comparator|Placebo|"Placebo matching alirocumab is prepared in the same formulation as alirocumab, without the addition of protein, for subcutaneous injection via a pre-filled pen.~One injection every 2 weeks during a 10-weeks period (5 injections in total)"
89594931|NCT03343132||Subacute SCI|
89594932|NCT03343132||Chronic SCI|
89594933|NCT03343132||Controls|
89594934|NCT04278820|Experimental|Climbing group|
89594935|NCT04278820|Experimental|Titration group|
89594936|NCT04278820|Experimental|Extension group|
89594937|NCT05685862||Group 1|All patients eligible to participate in this study.
89594938|NCT05298436||Retrospective Cohort (ICD-10)|All participants with stroke according to WHO ICD-10 definition registered on the SLSR prior to the protocol change in April 2022 will be followed up by interview at 3 months, 1 year, and 5, 10 and 15 years after stroke.
89594939|NCT05298436||Prospective Cohort (ICD-11)|All participants with stroke according to WHO ICD-11 definition registered on the SLSR following the protocol change in April 2022 will be followed up by interview at 3 months and then annually up to 5 years.
89594940|NCT05556148|Experimental|Otrivine Congestion Relief|Participants will be instructed to use the product per label and leaflet instructions: 1 spray in each nostril up to 3 times per day until resolution of symptoms or up to a maximum of 7 days, whichever occurs first.
89594941|NCT05555524|Experimental|Baby oil|"A cool commercial baby oil at a temperature between 10°C and 15°C that composed of Paraffinum Liquidum, Isopropyl Palmitate, Parfumwill be applied to the affected area for a period of 15-20 min for three times a week before each hemodialysis session for 12 weeks.~the baby oil bottle will be stored at the refrigerator."
89594942|NCT05555524|Placebo Comparator|Placebo|"A cool distilled water at a temperature between 10°C and 15°C with added two drops of the baby oil to each 100 cc will be applied to the affected area for a period of 15-20 min for three times a week before each hemodialysis session for 12 weeks.~the distilled water will be put at an identical bottle as the baby oil bottle and stored at the refrigerator."
89594943|NCT03342586||Central Nervous System Lymphoma|Participants will have non-Hodgkins lymphoma involving the brain (primary or secondary)
89594944|NCT03340246|Active Comparator|Immediate phlebectomy|Mechanochemical ablation of main trunk and immediate phlebectomy of varicosities
89594945|NCT03340246|Experimental|Delayed treatment|Mechanochemical ablation of main trunk. Evaluation of varicosities at 3 months with sclerotherapy if required
89594946|NCT04279132||TOTAL INTRAVENOUS ANESTHESIA|
89594947|NCT04279132||INHALATION ANESTHESIA|
89594948|NCT05552248||Orthosis group 1|Use of LumbarBelt Soft 300 device during sport practice (for 12 weeks)
89594949|NCT05552248||Control group 1|Control group of the LumbarBelt Soft 300 group - no medical device used during sport practice (for 12 weeks)
89031472|NCT02945124|Experimental|DCD with K Tape|
89031473|NCT02945124|No Intervention|DCD without K Tape|
89594950|NCT05552248||Orthosis group 2|Use of LumbarBelt Mid 500 device during sport practice (for 12 weeks)
89594951|NCT05552248||Control group 2|Control group of the LumbarBelt Mid 500 group - no medical device used during sport practice (for 12 weeks)
88811321|NCT02203799|Experimental|Peanut Oral Immunotherapy (POIT)|The peanut OIT is taken in the form of peanut flour. It will be given in small cups containing the amount of flour that needs to be eaten for one dose. One dose should be taken per day.
89594952|NCT04400422|Experimental|Lipano MCT formula|Kanso Lipano will be consumed daily for 3 months each to assess tolerability and compliance
89594953|NCT04278430|Experimental|Real tDCS group|The tDCS applied over dorsolateral prefrontal cortex for 20 minutes with 1.5 mA intensity
89594954|NCT04278430|Sham Comparator|Sham tDCS|The tDCS applied over dorsolateral prefrontal cortex for 20 minutes with 0 mA intensity.
89608518|NCT01276288|Experimental|Test 1|administration of BI 10773 + HTC once daily for 5 days (10 patients)
89594955|NCT04278430|Active Comparator|Control|The normal heathy children age matched undergo the same activity and brain stimulation as the real tDCS group.
89594956|NCT05537974|Other|Open Suction|Endotracheal aspiration will perform after the patient disconnect from mechanical ventilation
89594957|NCT05537974|Other|Closed Suction|Endotracheal aspiration will perform without disconnection from mechanical ventilation
89594958|NCT05093374|Experimental|Cohort 1 - Quantitative|"Patients will undergo monthly follow-up visits including fluid quantification and will be retreated in case of active disease, which is defined as:~reduction of 5 EDTRS letters or more related to any (suspected) neovascular activity compared to previous visit~new sub-retinal hemorrhage~increase >50% in IRF volume in the central 1 mm compared to month 2~increase > 50 % in SRF volume in the central 1 mm compared to month 2~in case of NO intra- and/or subretinal fluid (=less than 10nl) in visits 2 or 3, retreat if fluid in central 1mm ≥ 10nl~Presence/change of sub- and intraretinal fluid will be assessed objectively by AI software and the results will be provided during the visit to the investigator. The final decision for/against retreatment is always made by the discretion of the clinical investigator."
89594959|NCT05093374|Active Comparator|Cohort 2 - Qualitative|"Patients will undergo monthly follow-up visits. Treatment will be performed in case of active disease, which is defined as:~reduction of 5 EDTRS letters or more related to any (suspected) neovascular activity~new sub-retinal hemorrhage~any fluid~In this cohort the amount of retinal fluid will not be assessed by AI software at the time of retreatment."
89594960|NCT05249374|Active Comparator|Control group|10 g/ bottle (20%, 50 mL)
89594961|NCT05249374|Experimental|test group|10 g/bottle (20%, 50 mL)
89594962|NCT04278742|Experimental|Interventional - collaborative education|Collaborative style of communication whereby the clinician and patient co-creates the treatment plan
89594963|NCT04278742|No Intervention|Control group|Traditional directive and didactic style of patient information will be provided
89594964|NCT03338218|Experimental|Volulyte 6%|Volulyte 6% solution for infusion
89594965|NCT03338218|Active Comparator|Ionolyte|Ionolyte solution for infusion
89594966|NCT04400032|Experimental|Panel 1|25 million cells/unit dose (cumulative dose: 75 million MSCs)
89594967|NCT04400032|Experimental|Panel 2|50 million cells/unit dose (cumulative dose: 150 million MSCs)
89594968|NCT04400032|Experimental|Panel 3|up to 90 million cells/unit dose (cumulative dose: up to 270 million MSCs)
89594969|NCT05262088||newborns|Assessment of the motor repertoire in children aged 0 to 5 months and its relationship with prenatal and perinatal factors and the results of neurological development in the second year of life.
89594970|NCT05226910|Experimental|tDCS and intensive therapies|Cathodal tDCS and constraint induce movement therapy
89594971|NCT05226910|Sham Comparator|Sham and intensive therapies|Sham tDCS and constraint induce movement therapy
89594972|NCT05524948|Experimental|Experimental Dentifrice|Participants will be instructed to brush twice daily (for 1 minute, morning and evening) with the experimental dentifrice (0.454% Stannous Fluoride with 0.3% Zinc Chloride) for 3 weeks.
89594973|NCT05524948|Active Comparator|Reference Dentifrice|Participants will be instructed to brush twice daily (for 1 minute, morning and evening) with the reference dentifrice (Regular Fluoride Dentifrice) for 3 weeks.
89594974|NCT01839656|Experimental|Nusinersen 6 mg|
89594975|NCT01839656|Experimental|Nusinersen 12 mg|
89594976|NCT03335332|Experimental|High intensity exercise|A training program will be developed individually for each subject with the goal of increasing duration and intensity consistent with exercise training principles. Workouts will vary with respect to mode (walk, cycle) and duration (30 - 60 minutes). Each subject will be assigned an exercise physiologist and a heart rate monitor so that each session can be tracked and recorded. The first few exercise training sessions will supervised at our hospital based fitness centre until the subject is confident to complete the training independently. All HIIT sessions will be supervised over the intervention.
89594977|NCT03335332|Active Comparator|Moderate intensity exercise|
89594978|NCT05047900|Experimental|Rapid antigen testing kit use once weekly|"Community will use rapid antigen testing kit once weekly every Monday and will be asked to conduct a weekly self-test for 3 weeks.~This research use COVID-19 Saliva Antigen Rapid Test from Tigsun COVID-19 Speichel Antigen-Schnelltest from Beijing Tigsun Diagnostics"
89594979|NCT05047900|Experimental|Rapid antigen testing kit use twice weekly|Community will use rapid antigen testing kit twice weekly every Monday and Thursday and will be asked to conduct a twice-weekly self-test for 3 weeks This research use COVID-19 Saliva Antigen Rapid Test from Tigsun COVID-19 Speichel Antigen-Schnelltest from Beijing Tigsun Diagnostics
89594980|NCT05047900|No Intervention|Control|Did not routinely use Rapid antigen testing kit
89594981|NCT01839188|Experimental|PR5I (V1); Pediacel® (V2); PR5I (V3)|[Vaccination 1]: Single doses of PR5I (V419) + NeisVac-C® + Prevenar 13® by intramuscular (IM) injection + oral RotaTeq®, given at 2 months of age. [Vaccination 2]: Single doses of Pediacel® + NeisVac-C® + Prevenar 13® by IM injection + oral RotaTeq®, given at 4 months of age. [Vaccination 3]: Single dose of PR5I (V419) by IM injection + oral RotaTeq®, given at 6 months of age.
89594982|NCT05223088|Experimental|Tislelizumab combined with apatinib and oxaliplatin plus S1|Neoadjuvant immunotherapy, PD-1, plus apatinib and oxaliplatin plus S1 will be applied to patients with Borrmann IV、large Borrmann III type and Bulky N positive advanced gastric cancer before surgery.
89594983|NCT01838876|Experimental|Cariprazine + ADT|Cariprazine, flexible dose (titrated to a dose of 3.0 milligrams (mg) adjusted to 1.5 mg or 4.5 mg based on investigator's judgment of response and tolerability), oral administration, once daily plus antidepressant drug therapy (ADT) for 26 weeks.
89594984|NCT03279250|Experimental|Arm A (LHRHa, apalutamide)|Participants receive gonadotropin-releasing hormone analog (leuprolide, goserelin, or triptorelin as determined by treating physician) IM once every 3 months and apalutamide PO QD. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Beginning no less than 48 hours after completion of therapy, participants undergo radical prostatectomy.
89594985|NCT03279250|Experimental|Arm B (LHRHa, apalutamide, abiraterone acetate)|Participants receive gonadotropin-releasing hormone analog and apalutamide as in arm A, abiraterone acetate PO QD, and prednisone PO QD. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Beginning no less than 48 hours after completion of therapy, participants undergo radical prostatectomy.
89594986|NCT01838642|Active Comparator|RET mutation positive participants|Rearranged during transfection (RET) mutation positive
89594987|NCT01838642|Active Comparator|RET mutation negative participants|Rearranged during transfection (RET) mutation negative
89594988|NCT05007418|Experimental|STI-1492|Four dosing cohorts will be evaluated: Cohort 1 (1 × 10^5 donor DAR-T cells/kg); Cohort 2 (5 × 10^5 donor DAR-T cells/kg); Cohort 3 (1 × 10^6 donor DAR-T cells/kg); Cohort 4 (3 × 10^6 donor DAR-T cells/kg) where STI-1492 will be administered intravenously once.
89594989|NCT05240170|Experimental|RIRS group|The standard RIRS will be performed using a disposable flexible ureteroscope. Holmium: YAG laser will be used for stone dusting and fragmentation. If indicated, JJ ureteral stent will be placed at the end of the procedure.
89594990|NCT05240170|Experimental|SWL group|The medical records of all patients who underwent SWL at our institution in the past five years will be reviewed. Patients with renal rotation or position anomalies, as defined by NCCT and/or IVU, will be included for possible study participation.
89594991|NCT01611194|Experimental|HBO2 at 1.5 Atomspheres Absolute (ATA)|Hyperbaric oxygen (HBO2) at 1.5 atms. Stratified by site and time from injury (less than one year versus one year or more), in which participants are randomized. Each participant will complete 40 sessions, one session per day, five sessions per week, within 12 weeks following randomization.
89594992|NCT01611194|Sham Comparator|Sham Control (1.2 Atomspheres)|Sham control 1.2 atms. Each participant will complete 40 sessions, one session per day, five sessions per week, within 12 weeks following randomization. Breathing air at a pressure of 1.2 atm abs is equivalent to inhaling 25% oxygen at sea level pressure (1.0 atm abs).
89594993|NCT05181046|Active Comparator|Standard eyedrops of 0.5% timolol maleate|Participants randomized to this arm will receive one standard drop of 0.5% timolol maleate in each eye.
89594994|NCT05181046|Experimental|Nanodropper-mediated microdrops of 0.5% timolol maleate|Participants randomized to this arm will receive one microdrop of 0.5% timolol maleate in each eye. Microdrops will be dispensed from bottles with installed Nanodropper adaptors.
89594995|NCT01813058|Placebo Comparator|Placebo|Placebo ( 0.9% Normal saline) intravenously given as a 0.5 ml/kg loading dose over 15 minutes followed by a 0.1 ml/kg/hr continuous infusion throughout the surgery.
89594996|NCT01813058|Active Comparator|Tranexamic acid|Tranexamic acid 100 mg/ml; 50 mg/kg loading dose = 0.5 ml/kg LD given over 15 minutes and 10 mg/kg/hr = 0.1 ml/kg/hr infusion for the duration of the surgery.
89594997|NCT05163262|Experimental|experimental|Addition of a sexuality questionnaire during patient follow-up within 3 months after inclusion, 6 months after and at one year
89594998|NCT01867424|Active Comparator|Participants with Advanced Disease|Advanced disease: who have failed hormone therapy and who have sufficient tissue from a soft tissue or metastatic bone lesion (measuring 1.5cm in diameter at computed tomography (CT) or magnetic resonance imaging (MRI) scan) available for organic anion-transporting polypeptide 1B3 (OATP1B3) immunohistochemistry (IHC) or must have a soft tissue or metastatic bone lesion that can be biopsied and be willing to undergo percutaneous biopsy to obtain tissue for OATP1B3 expression.
89594999|NCT01867424|Active Comparator|Participants with Localized Disease|Localized disease: must have image guided biopsy confirmed prostate cancer and sufficient tissue available for OATP1B3 IHC.
89595000|NCT04986514||Patients with systemic sclerosis|
89595001|NCT05491330|Active Comparator|R reference (first dose)|Reference drug (Paxlovid) Nirmatrelvir 150 mg + Ritonavir 100 mg tablets
89595002|NCT05491330|Experimental|T test|Test drug (Copaxid) Nirmatrelvir 150 mg + Ritonavir 100 mg tablets
89595003|NCT05491330|Active Comparator|R reference (second dose)|Reference drug (Paxlovid) Nirmatrelvir 150 mg + Ritonavir 100 mg tablets
89595004|NCT01811732|Experimental|Delafloxacin plus placebo|Delafloxacin 300 mg IV every 12 hours for a minimum of 10 and up to a maximum of 28 doses
89595005|NCT01811732|Active Comparator|Vancomycin plus Aztreonam + placebo|Vancomycin 15 mg/kg IV plus two grams Aztreonam every 12 hours for a minimum of 10 and up to a maximum of 28 doses (Aztreonam was discontinued as soon as possible if a gram-negative organism was not identified in baseline cultures)
88811322|NCT02180724|Experimental|Previously Treated|Subjects previously treated with Waldenström Macroglobulinemia N=92
88811323|NCT02180724|Experimental|Treatment Naïve|Subjects with treatment-naïve Waldenström Macroglobulinemia. N=14
88978406|NCT00256048|Active Comparator|Nasojejunal Arm|Patient will receive feeding via a nasojejunal feeding tube
89595006|NCT05146648|Active Comparator|Real AMPS|AMPS therapy consists of mechanical stimulations applied to two specific points on both feet: the tip of the big toe (hallux) and the first metatarsal joint.
88978407|NCT00256087|Placebo Comparator|Standard Care|Two capsules containing placebo will be given 12 hourly
88978408|NCT00256087|Active Comparator|First active treatment|Two capsules containing probiotic lactobacillus fermentin given 12 hourly
89595007|NCT05146648|Sham Comparator|Sham AMPS|AMPS therapy applied to two non-specific points on both feet.
89595008|NCT04400344||Survey Respondents|Respondents are members of the American Association of Diabetes Educators recruited via an introductory email sent out by the AADE on behalf of Podimetrics.
89595009|NCT04399720||BPS group|patients under Bisphosphonate therapy for at least 24 months
89595010|NCT04399720||healthy patients|healthy patients not assuming with no previous Bisphosphonate assumption
89595011|NCT01836458|Experimental|Dose 1: 30 mg|Single dose of KAE609 30 mg
89595012|NCT01836458|Experimental|Dose 2: 20 mg|Single dose of KAE609 20 mg
89595013|NCT01836458|Experimental|Dose 3: 10 mg|Single dose of KAE609 10 mg
89595014|NCT01836458|Experimental|Dose 4: 15 mg|Single dose of KAE609 15 mg
89608519|NCT01276288|Experimental|Test 2|administration of BI 10773 + TOR once daily for 5 days (10 patients)
89608520|NCT01273792||Patients with Susac syndrome|
89608521|NCT01273792||Matched healthy controls|
89595015|NCT05139004|Experimental|Treatment (90Y-basiliximab, fludarabine, melphalan, TMLI)|Patients receive cold basiliximab IV, 111In-DOTA-anti-CD25 basiliximab IV, and 90Y-DOTA-anti-CD25 basiliximab IV on day -15. Patients also receive palifermin IV on days -11 to -9, fludarabine phosphate IV on days -4 to -2, melphalan IV on day -2, and undergo TMLI on days -8 to -5 in the absence of disease progression or unacceptable toxicity. Patients then undergo AHSCT on day 0.
89595016|NCT04073992|Experimental|Cognitive behavioral treatment of insomnia (CBT-I)|Eight weeks of cognitive behavioral treatment of insomnia.
89595017|NCT01811186|Other|Group A|Start oxycodone/naloxone 10/5mg b.i.d. titration->20/10mg b.i.d.->30/15mg b.i.d->40/20mg b.i.d.
89595018|NCT01811186|Other|Group B|Start oxycodone/naloxone 5/2.5mg b.i.d titration-> 10/5mg b.i.d.->20/10mg b.i.d.->30/15mg b.i.d->40/20mg b.i.d.
89595019|NCT04414436|Experimental|GYNEA- digital coping program|Participants randomized to this arm will receive active treatment after the inclusion
89595020|NCT04414436|No Intervention|Waiting list|6 weeks waiting list before crossing over to GYNEA- digital coping program
89595021|NCT03240328|Experimental|CAR-T therapy|Transfusing CAR-T cells at least 1 million clone every time (once or twice) based on cART after attaining plasma HIV suppression (plasma HIV RNA <50 cp/ml) and CD4+ cell count more than 350 cells/ul over 1 year by cART without active HCV or HBV infection or opportunistic infections. If the candidates reach the criteria of discontinuing cART, they will stop cART and receive close observation. Once the plasma HIV viral load rebound to over 1000 cp/ml, they will restart cART immediately.
89595022|NCT04746196||45 ankylosing spondylitis patients.|Patients diagnosed with ankylosing spondylitis according to Modified New York criteria were included in the study.
89595023|NCT04746196||35 controls|Healthy controls
89595024|NCT01866098|Experimental|Naltrexone 50mg|Oral Naltrexone 50mg capsule taken once daily for 52 weeks
89595025|NCT01866098|Placebo Comparator|Placebo|Oral placebo capsule taken once daily for 52 weeks
89595026|NCT01866098|Experimental|Naltrexone 25mg|Oral Naltrexone 25mg capsule taken once daily for 52 weeks
89595027|NCT04916704||CMV seropositive|New diagnosis of AAV as evidenced by relevant biopsy and / or clinical diagnosis in the context of a positive ANCA antibody OR major relapse of previously diagnosed AAV that requires re-induction of remission treatment with intravenous rituximab or cyclophosphamide together with high dose oral corticosteroids. CMV IgG positive.
89595028|NCT04916704||CMV seronegative|New diagnosis of AAV as evidenced by relevant biopsy and / or clinical diagnosis in the context of a positive ANCA antibody OR major relapse of previously diagnosed AAV that requires re-induction of remission treatment with intravenous rituximab or cyclophosphamide together with high dose oral corticosteroids. CMV IgG positive. CMV IgG negative.
89595029|NCT04399798|Experimental|Baricitinib active treatment|Baricitinib 4 mg/day
89595030|NCT04897360|Experimental|Normocapnic SRT, Hypocapnic SRT, Recovery SRT|Sharpened Romberg Test
88978409|NCT00256087|Active Comparator|Second active reatment|Two capsules containing probiotic lactobacillus acidiphilus given 12 hourly
88978410|NCT04709536|Experimental|IBI306|IBI306 administered subcutaneously (SC)
89031474|NCT00511784||OrthoEvra(norelgestromin/ethinylestradiol contraceptive patch)|subjects in insurance claims database who used transdermal patch containing 6 milligrams norelgestromin and 0.75 milligram ethinyl estradiol worn for 1 week for 3 consecutive weeks; the fourth week was patch-free
88978411|NCT04709536|Placebo Comparator|Placebo|administered subcutaneously (SC)
88978412|NCT00104598|Active Comparator|Gain Framed Absitnence Program|Gain framed video and printed messages encouraging smoking abstinence with Bupropion.
88978413|NCT00104598|Active Comparator|Loss Framed Abstinence Program|Loss framed video and printed messages encouraging smoking abstinence with Bupropion.
88978414|NCT00256321|Experimental|Celecoxib/Oxaliplatin/Capecitabine|"Oxaliplatin 70mg/m2 IV on Days 1 and 8. Capecitabine 1000mg/m2 PO BID from Days 1 through 14. Celecoxib 400mg PO BID from Days 1 through 21.~1 Cycle = 21 days."
89031475|NCT00511784||levonorgestrel-containing oral contraceptives|subjects in insurance claims database who were first time users of triphasic levonorgestrel-containing oral contraceptives with 30 micrograms ethinyl estradiol taken for 21 consecutive days followed by no pill or an inert pill for 7 days
89595031|NCT04889326||patient hospitalized with atypical thrombosis within 4 weeks of anti-covid vaccination|
89595032|NCT04885972|Experimental|Resiniferatoxin|7.5 mcg, 10 mcg, 12.5 mcg, 15 mcg, or 20 mcg in 5 mL injected once intra-articularly
89595033|NCT04885972|Active Comparator|Zilretta|32 mg in 5 mL injected once intra-articularly
89595034|NCT04885972|Placebo Comparator|Placebo|5 mL injected once intra-articularly
89595035|NCT03985540|Experimental|memory experimental group|Experimental group will receive memory retraining exercises administered on a lab top computer twice a week for 5 weeks.
89595036|NCT03985540|Placebo Comparator|Placebo comparator memory|Placebo controlled group will receive placebo memory retraining exercises administered on a lab top computer twice a week for 5 weeks.
89595037|NCT03985540|Experimental|Processing speed|Processing speed group will receive processing speed training exercises administered on a lab top computer twice a week for 5 weeks.
89595038|NCT03985540|Placebo Comparator|Processing speed placebo|Placebo controlled group will receive placebo processing speed training exercises administered on a lab top computer twice a week for 5 weeks.
89595039|NCT04347772|Experimental|Supplements Group - SS|"The SS will be received tailored and more intensive and ongoing nutrition support and lifestyle advice as compared with the NN and will be supplemented with ONS, available in 400g/can, providing 226 kcal/serving and 9.6 g protein/serving. Participants will be encouraged to consume the ONS in small, frequent, in between meals.~All participants will receive standard post-operative care from clinical and nurse staff with commencement of free fluids and reintroduction of normal diet without interference by the researcher or protocol. The postoperative course will be carefully monitored. While complications will be noted as major or minor by using validated criteria (Buzby et al., 1988)."
89608522|NCT02702271|Experimental|WATCHMAN FLX - M|WATCHMAN FLX Main Cohort
89608523|NCT02702271|Experimental|WATCHMAN FLX - R|WATCHMAN FLX Roll-In Cohort
89608524|NCT00722566|Experimental|1|VELCADE administered by subcutaneous injection
89608525|NCT00722566|Active Comparator|2|VELCADE administered by intravenous infusion
89595040|NCT04347772|No Intervention|Control Group - NN|"While participants in NN which referred as control group will received the standard care of the clinic without supplemented with ONS. Nutritional advice will be based on a guideline specifically focused on treatment of symptoms such as nausea, vomiting, loss of appetite and diarrhoea, and how to deal with the symptoms through nutritional approaches. Basically, the advice will be given by the oncologist or nurses in the clinic.~All participants will receive standard post-operative care from clinical and nurse staff with commencement of free fluids and reintroduction of normal diet without interference by the researcher or protocol. The postoperative course will be carefully monitored. While complications will be noted as major or minor by using validated criteria (Buzby et al., 1988)."
89595041|NCT03263026|Active Comparator|R-CHOP + enzastaurin hydrochloride|Subjects in the R-CHOP + enzastaurin Arm will receive R-CHOP (Rituximab-375 mg/m2 i.v., Cyclophosphamide-750 mg/m2 i.v., Doxorubicin-50 mg/m2 i.v., Vincristine-1.4 mg/m2 i.v. (2 mg max), and Prednisone-100 mg p.o.), as directed, plus a 1125 mg loading dose of enzastaurin on Day 2 followed by 500 mg daily.
89595042|NCT03263026|Placebo Comparator|R-CHOP + placebo|Subjects in the R-CHOP + placebo Arm will receive R-CHOP (Rituximab-375 mg/m2 i.v., Cyclophosphamide-750 mg/m2 i.v., Doxorubicin-50 mg/m2 i.v., Vincristine-1.4 mg/m2 i.v. (2 mg max), and Prednisone-100 mg p.o.), as directed, plus an identical number of tablets as the subjects in the enzastaurin Arm.
89595043|NCT04858360|Experimental|Study group|
89595044|NCT01865552|Experimental|SB4 and EU sourced Enbrel in Part A|SB4 followed by EU sourced Enbrel
89595045|NCT01865552|Experimental|EU sourced Enbrel and SB4 in Part A|EU sourced Enbrel followed by SB4
89595046|NCT01865552|Experimental|SB4 and US sourced Enbrel in Part B|SB4 followed by US sourced Enbrel
89595047|NCT01865552|Experimental|US sourced Enbrel and SB4 in Part B|US sourced Enbrel followed by SB4
89595048|NCT01865552|Other|EU and US sourced Enbrel in Part C|EU sourced Enbrel followed by US sourced Enbrel
89595049|NCT01865552|Other|US and EU sourced Enbrel in Part C|US sourced Enbrel followed by EU sourced Enbrel
89595050|NCT03205072||ERCP & Spy Glass DS|Patients with cadaveric donor or live donor liver transplantation referred for ERCP in the setting of a clinical suspicion of post liver transplant bile duct strictures.
89595051|NCT01809314||NeoRecormon in Symptomatic Anemia|Participants with symptomatic anemia who are receiving epoetin beta (NeoRecormon) according to standard of care and the Summary of Product Characteristics will be observed for 4 months. Treatment must be selected at the discretion of the prescriber prior to enrollment and will not be chosen by the Sponsor in this non-interventional study.
89595052|NCT02984332|Experimental|Lower limb immobilisation|All participants will undergo 7 days of unilateral leg immobilization. Participants will wear a leg brace (Donjoy X-ACT, DJO Global, USA) on one of their legs which will fix the leg at 40 degrees of flexion for the 7 days. Participants will not be allowed to remove the brace at any stage and are prohibited from bearing weight on the immobilized leg, and will ambulate on crutches throughout the week of immobilization.
89595053|NCT01803464|Experimental|Botox plus low-magnitude vibration|Cerebral palsy and Botox + vibration
89595054|NCT01803464|Experimental|Botox|Cerebral palsy and Botox
89595055|NCT01803464|No Intervention|Cerebral palsy control|Cerebral palsy without treatment
89595056|NCT01803464|No Intervention|Typically developing control|Typically developing
89595057|NCT01808690|Experimental|Metformin|Metformin will be given at a dose of 1000 mg twice a day orally for three months to assess changes in insulin resistance compared to placebo.
89595058|NCT01808690|Placebo Comparator|Placebo|Placebo will be given at a dose of 1000 mg twice a day orally for three months to assess changes in insulin resistance compared to metformin.
89595059|NCT04583618|Experimental|SP0202-IIb|One dose at Day 1
89595060|NCT04583618|Experimental|SP0202-VI|One dose at Day 1
89595061|NCT04583618|Experimental|SP0202-VII|One dose at Day 1
89595062|NCT04583618|Active Comparator|Prevnar 13|One dose at Day 1
89595063|NCT04583618|Active Comparator|Pneumovax 23|One dose at Day 1
89595064|NCT04413734|Experimental|Triprilumab in combination with chemotherapy of GP|Triprilumab, 240 mg, every 3 weeks (Q3W), Day 1 of each 3 week cycle PLUS Gemcitabine, 1000 mg/m^2, Q3W, Day 1 and Day 8 of each cycle PLUS Cisplatin, 25 mg/m^2, Q3W, Day 1 and Day 8 of each cycle until progressive disease or unacceptable toxicity .
88978415|NCT00070304|Experimental|Treatment|Patients receive vinorelbine tartrate IV over 6-10 minutes and gemcitabine hydrochloride IV over 100 minutes on days 1 and 8. Patients also receive filgrastim (G-CSF) subcutaneously daily beginning on day 9 and continuing for at least 7 days and until blood counts recover. Treatment repeats every 21 days for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients with responding disease after 2 courses may proceed directly to stem cell transplantation off study OR receive 2 additional courses. Patients with stable disease after 2 courses receive at least 2 additional courses. Patients with continued stable or responding disease (with no disease progression) after 4 courses may continue to receive study treatment for up to 1 year or discontinue study for alternative therapy at the discretion of the treating physician.
88978416|NCT00256516|Experimental|Eco-Atkins diet|
88978417|NCT00256516|Active Comparator|NCEP diet|
89595065|NCT04413734|Active Comparator|Mono-chemotherapy of GP|Gemcitabine, 1000 mg/m^2, Q3W, Day 1 and Day 8 of each cycle PLUS Cisplatin, 25 mg/m^2, Q3W, Day 1 and Day 8 of each cycle until progressive disease or unacceptable toxicity.
88978418|NCT00256633||Group 1|enrolled in the ongoing randomized clinical trial AGlycemic Control and Complications in Diabetes Mellitus Type 2.
88978419|NCT00104715|Experimental|Hormonotherapy + chemotherapy|
88978420|NCT00104715|Active Comparator|Hormonotherapy alone|
89595066|NCT03229798|Active Comparator|Sumatriptan Succinate Oral Tablet|100 mg oral tablet commercial Imitrex sumatriptan succinate tablet
89595067|NCT03229798|Experimental|Sofusa Profile #1|Combination device for transdermal delivery of sumatriptan succinate Current approved dose (SC)
89595068|NCT03229798|Experimental|Sofusa Dose Profile #2|Combination device for transdermal delivery of sumatriptan succinate- adjust dose and flow rate to achieve PK profile based on results from Sofusa Dose Profile #1
89595069|NCT03229798|Experimental|Sofusa Dose Profile #3|Combination device for transdermal delivery of sumatriptan succinate- adjust dose and flow rate to achieve PK profile based on results from Sofusa Dose Profile #2
89595070|NCT03229798|Experimental|Sofusa Dose Profile #4|Combination device for transdermal delivery of sumatriptan succinate- adjust dose and flow rate to achieve PK profile based on results from Sofusa Dose Profile #3
89595071|NCT03229798|Experimental|Sofusa Dose Profile #5|Combination device for transdermal delivery of sumatriptan succinate- adjust dose and flow rate to achieve PK profile based on results from prior Sofusa Dose Profile #2-4
89595072|NCT04808908|Experimental|N-803|All participants will receive the intervention, N-803 treatment.
89595073|NCT03927742|Experimental|Shade and application with UV message activated|wearable device (wrist) and associated mobile application; UV sensor exposure display and messaging activated
89595074|NCT03927742|Active Comparator|Shade and application without UV messaging|wearable device (wrist) and associated mobile application; UV sensor exposure display and messaging not activated
89595075|NCT04805944||DTG treated (A)|80 HIV-infected adults treated with dolutegravir (as a component of their usual provider-prescribed antiretroviral regimen)
89595076|NCT04805944||BIC treated (B)|30 HIV-infected adults treated with bictegravir (as a component of their usual provider-prescribed antiretroviral regimen)
89595077|NCT04805944||DTG discontinued due to neuropsychiatric adverse event (C)|50 HIV-infected adults having stopped dolutegravir due to neuropsychiatric adverse effects (insomnia, depression, anxiety)
89595078|NCT04805944||Shifting to DTG (D)|20 virally controlled and immunologically functional HIV-infected adults shifting (as per standard care) from another ARV class to an antiretroviral regimen containing dolutegravir
89595079|NCT04805944||Shifting to BIC (E)|20 virally controlled and immunologically functional HIV-infected adults shifting (as per standard care) from another ARV class to an antiretroviral regimen containing bictegravir
89595080|NCT03906292|Experimental|Asciminib 60mg QD|Standard therapy of Imatinib 400 mg QD and asciminib 60 mg QD
89595081|NCT03906292|Experimental|Asciminb 20 mg BID|Standard therapy of Nilotinib 300 mg BID and asciminib 20 mg BID
89595082|NCT03906292|Experimental|Asciminib 40 mg QD|Standard therapy of Nilotinib 300 mg BID and asciminib 40 mg QD
89031476|NCT02944929|Experimental|Self-rehabilitation program|Self-rehabilitation program + standard medical care (BTI + conventional physiotherapy)
89031477|NCT02944929|No Intervention|Control arm|Arm with standard medical care ( BTI + conventional physiotherapy) without self-rehabilitation program
89595083|NCT03906292|Experimental|Asciminib 80 mg QD|Standard therapy of Dasatinib 100 mg QD and asciminib 80 mg QD
89595084|NCT03906292|Experimental|Asciminib 80 mg QD monotherapy|Asciminib 80 mg QD as a single agent
89595085|NCT04399642|Active Comparator|Standard|Patients receiving single dose of IV cefazolin (2 grams if < 120kg; 3 grams if >120kg) 10-60 minutes before incision
89595086|NCT04399642|Experimental|Vanco|Patients receiving a single dose of IV cefazolin (2 grams if < 120kg; 3 grams if >120kg) 10-60 minutes before incision + a single dose of intra-articular vancomycin powder (1 gram) before articulation (hip or knee) closure
89595087|NCT04399564|Active Comparator|temporary hemodialysis catheters|one arm-temporary hemodialysis catheter
89595088|NCT04399564|Experimental|long-term hemodialysis catheters|another arm-long term hemodialysis catheter
89595089|NCT03672526|Experimental|device compuflo|
89595090|NCT03229174|Experimental|Intervention phase|Droxidopa unforced titration dose (starting at 100mg by mouth TID) or matching placebo and titrated over 2 weeks up to maximum of 600 TID. Efficacy evaluation of given dose at week 4
89595091|NCT03229174|Other|Open label extension phase|All subjects allowed into a 4 week open label extension. Similar titration will start at 100mg Droxidopa three times a day (TID), but can be titrated up daily using the same dose escalation scale.
89595092|NCT03227926|Experimental|Screening Phase|"Patiens will be first enrolled in a Molecular Screening (MS) Phase to determine the molecular eligibility of the patients for third line panitumumab re-challenge. During MS phase, patients will be liquid biopsied (LB) at different check-points (BML which is optional, Basal Mutational Load and RML which is mandatory, Rechallenge Mutational Load) and their ctDNA tested by ddPCR to monitor the presence of RAS and EGFR ECD altered clones. Patients with no RAS and EGFR ECD mutations in the RML will be declared molecularly eligible for the Trial Phase."
89595093|NCT03227926|Experimental|Trial Phase|"Patients resulting molecularly eligible at the RML (Rechallenge Mutational Load) checkpoint, upon Informed Consent signature and having satisfied all other eligibility criteria, will be treated with panitumumab monotherapy at standard dose until documented radiological progression or unacceptable toxicity or any other reason whichever comes first."
89595094|NCT03227770|Active Comparator|regular hemodialysis|Blood purification (including low-flux hemodialysis, high-flux hemodialysis, or hemodiafiltration) treatment ≥10 hours per week
89595095|NCT03227770|Experimental|hemoperfusion combined with hemodialysis|Combination of hemodialysis and hemoperfusion treatment at least once every two week
89595096|NCT04562194|Other|Intervention|NeVa Stent Retriever
89595097|NCT04398472|Active Comparator|Challenge|"Participants in the challenge will be asked to complete four activities over the next four weeks to address loneliness and social isolation in their communities.~The activities will involve doing an activity with people in their neighbourhood. These activities have been selected based on being positive, engaging and feasible to the average individuals. An example of the type of activities is having a conversation with a neighbour on the phone or via video chat and safely checking in on someone who is elderly or living alone. All activities will adhere to the relevant country or states health department's safety recommendations and laws during COVID-19.~Hypothesis 1 (H1). There will be a reduction in the primary outcome, loneliness in participants assigned to the Nextdoor KIND Challenge groups compared to the waitlist control group post the 4-week intervention"
89595098|NCT04398472|No Intervention|Waitlist|
89595099|NCT01363297|Experimental|Inotuzumab Ozogamicin|
89595100|NCT04758598|Experimental|Direct Selective Laser Trabeculoplasty (DSLT)|Direct Selective Laser Trabeculoplasty (DSLT): employs frequency-doubled, Q-switched Nd:YAG laser with a wavelength of 532 nm. During the procedure, a laser beam targets the trabecular meshwork (TM) - to improve intraocular fluid outflow. The laser beam is delivered in short nanosecond pulses and the selective cellular effect occurs at the pigmented cells of the TM. This increases the permeability of the TM endothelial cells and thereby increases outflow, resulting in reductions in IOP. In contrast to SLT, the DSLT treatment directs the laser beam directly through the sclera around the limbus without the need for a delivery device (gonioscope lens). Laser treatment lasts for about 2 seconds with about 120 laser shots delivered to the sclera around the limbus.
89595101|NCT04758598|Active Comparator|Selective Laser Trabeculoplasty (SLT)|SLT employs frequency doubled Q switched Nd:YAG laser with a wavelength of 532 nm. It is delivered in short nano second pulses and the resulting selective effect to the pigmented cells of the TM, leaving the surrounding non-pigmented cells unaffected. This increases the permeability of the TM endothelial cells and can assist in increasing outflow and hence result in reductions in IOP. The procedure lasts approximately 10 minutes, with delivering 100 separate laser beams through a manually rotated mirrored lens (gonioscope), involving prolonged contact with the participant's eye. This treatment is applied on the cornea through a gonioscopic lens which is used to direct the laser beam to the desired location - the TM (360 degrees of treatment area).
89595102|NCT04757116|Experimental|iTind arm|The iTind is a minimally invasive temporary implant
89595103|NCT04757116|Experimental|UroLift|The UroLift is a minimally invasive permanent implant
89595104|NCT03199924|Active Comparator|Intravenous Magnesium sulfate combined to Diclofenac|Intravenous Magnesium sulfate combined to Diclofenac
89595105|NCT03199924|Active Comparator|intravenous lidocaine combined to diclofenac|intravenous lidocaine combined to diclofenac
89595106|NCT03199924|Active Comparator|diclofenac alone|diclofenac alone
89595107|NCT01908907|Active Comparator|DHA oil|DHA oil administered 50 mg/d (0.18ml)as an oil emulsion enterally with feedings or by gavage tube if the infant has one.
89595108|NCT01908907|Placebo Comparator|(MCT) control oil|MCT oil administered 0.18ml as an oil emulsion enterally with feedings or by gavage tube if the infant has one.
89595109|NCT04398940|Experimental|TQ-B3139 capsules|TQ-B3139 capsules administered orally.
89595110|NCT04632199|Experimental|111In-IPN01087 Low dose|Single intravenous injection of 220 MBq 111In-IPN01087 with a low mass dose of IPN01087
89595111|NCT04632199|Experimental|111In-IPN01087 High dose|Single intravenous injection of 220 MBq 111In-IPN01087 with a high mass dose of IPN01087
89595112|NCT03826498|Experimental|CP CB-MNC injection|CP CB-MNC injection from different donors and standard therapy.
89595113|NCT03826498|Other|Standard therapy|Patients with standard therapy as control group
89595114|NCT04399096||General population|The general public attending exhibitions of the artworks who wish to complete the on-line questionnaire and feedback
89595115|NCT04746430|Experimental|Intervention|6 mg dexamethasone prescribed during ten days and as a precaution combined with electronic monitoring of saturation and other signs and symptoms
89595116|NCT04746430|No Intervention|Control|Only remote monitoring
89595117|NCT04277650|Active Comparator|Once weekly clinical evaluation|Outpatient participants evaluated as high risk by the machine learning algorithm and provided once weekly clinical evaluations
89595118|NCT04277650|Experimental|Twice weekly clinical evaluation|Outpatient participants evaluated as high risk by the machine learning algorithm and provided twice weekly clinical evaluations
89595119|NCT03832270|Experimental|Parents InC|Group parenting support intervention based around four pillars: 1) empowerment/ownership; 2) education on ADHD and its effect on family identity/ values; 3) positive parenting in the context of ADHD; 4) making sense of ADHD in a developmental context. It is delivered over 5 weekly 2-hour sessions, a 6 week break, and a follow-up session.
89595120|NCT03832270|Active Comparator|Incredible Years|A group parenting support intervention aimed at strengthening parent-child interactions and attachment, reducing harsh discipline and fostering parents' ability to promote children's social, emotional, and academic development. The IY programme is delivered over 14 weekly 2-hour sessions. IY facilitators are videotaped during sessions to maintain intervention fidelity. IY also includes 1-4 pre-intervention preparation sessions which may involve home visits and telephone support and reminders.
89595121|NCT03258892|Experimental|Arm A (STG pre-chemotherapy)|Patients receive the STG before completing 4 courses of standard of care chemotherapy.
89595122|NCT03258892|Experimental|Arm B (STG post-chemotherapy initiation)|Patients complete 2 courses of standard of care chemotherapy and then receive the STG before completing 2 additional courses of standard of care chemotherapy.
89595123|NCT04277494|Experimental|Clorethyl cold spray® (Vapocoolant spray)|"23 volunteer athletes who are studying at the Faculty of Health Sciences of Acıbadem University, between the ages of 18-23, with a subcutaneous fold thickness of the quadriceps muscle between 5 mm and 15 mm (Shadgan et al., 2015).~From the anterior superior of the dominant legs to the spinal iliac, the upper part of the patella will be measured and the center point will be marked. Cold spray will be applied to this point and its surroundings. The ethyl chloride spray bottle will be kept approximately 30 cm from the skin. An ethyl chloride stream will be applied at a 45 ° angle for 15 seconds (Shadgan et al., 2015). Skin temperature and mechanical properties of muscle; will be measured before, immediately after, 2 minutes, 5 minutes and 15 minutes after cold application."
89595124|NCT04277572||Aortic valve replacement|using different ways of aortic valve replacement either by prosthetic valves or by ozaki technique
89595125|NCT04430842|Experimental|Dose escalation of QBS10072S|Intravenous administration of QBS10072S once every 4 weeks starting at 3mg/m2 and increasing dose levels in subsequent cohorts.
89595126|NCT04686838|Experimental|READyR II A|Continuous monitoring will be conducted and analyzed for anomaly detection. Participants in this arm will receive contact phone call when a potential change in care needs is indicated by an anomaly.
89595127|NCT04686838|Active Comparator|READyR II B (comparison)|Sensors will remain in the home but anomaly detection analysis will not be performed and contact phone calls will be at regular intervals without dynamic tailoring content. Standard educational content will instead be shared over the phone.
89595128|NCT04677010|No Intervention|Run-in period, patients with cerebral palsy or muscular dystrophy|10 weeks of no exercise
89595129|NCT04677010|Active Comparator|Exercise period, patients with cerebral palsy or muscular dystrophy|10 weeks of exercise
89517764|NCT02320565|Active Comparator|Standard Laparoscopy|Laparoscopic total hysterectomy with pelvic lymphadenectomy are performed with standard laparoscopy technology. A 10 mm port is inserted at the umbilicus for the telescope. Once pneumoperitoneum (12 mmHg) is achieved, intra-abdominal visualization will be obtained with a 0° high-definition telescope. Two additional 5 mm ports are placed under direct visualization. One more 5 mm trocar is inserted in the right mid abdomen at the level of the umbilicus. The instruments used include bipolar grasper, monopolar scissors, monopolar hook, various graspers and a suction irrigation system.
89517765|NCT02320643|Experimental|Seratom® PA mesh|Partially absorbable mesh
89031478|NCT00511823|Experimental|Subjects in Part A|Subjects will receive 100 milligrams (mg) of oral dolasetron once daily for 3 days during treatment period 1. In treatment period 2, subjects will receive 100 mg oral dolasetron once daily on days 1, 2 and 3 along with 150 mg oral casopitant on day 1 and 50 mg oral casopitant on days 2 and 3. The treatment periods will be separated by will be separated by a 5 - 14 day wash-out period.
89031479|NCT00511823|Experimental|Subjects in Part B|Subjects will receive 2 mg of oral granisetron once daily for 3 days during treatment period 1. In treatment period 2, subjects will receive 2 mg oral granisetron once daily on days 1, 2 and 3 along with 150 mg oral casopitant once daily on day 1 and 50 mg oral casopitant once daily on days 2 and 3. The treatment periods will be separated by will be separated by a 5 - 14 day wash-out period.
89031480|NCT00511823|Experimental|Subjects in Part C|Subjects will receive 4 mg of oral rosiglitazone once daily for 3 days during treatment period 1. In treatment period 2, subjects will receive 4 mg oral rosiglitazone once daily on days 1, 2 and 3 along with 150 mg oral casopitant once daily on day 1 and 50 mg oral casopitant once daily on days 2 and 3. The treatment periods will be separated by will be separated by a 5 - 14 day wash-out period.
89031481|NCT00515736|Experimental|AOX group|Treatment group - double dose (loading) for 48 hours then single dose (Se 270 mcg, Zn 30 mg, vit C 1.2 g, B1 100 mg, vit E 300 mg enteral)
89517766|NCT03496961|Experimental|Yan Nian Jiu Zhuan Fa|The kneading process will be done under the therapist guidance for 30 minutes with an average pressure of 5 Newton each time for 3 times every day.
89517767|NCT03496961|Placebo Comparator|cognitive psychology education|Psychological counseling and behavioral cognition education are conducted once a week and the rest 6 times online or by phone.
89517768|NCT03496961|No Intervention|blank control|this group will have no therapeutic exercises or cognitive education when other two groups receive therapy.
89517769|NCT05111743||Brolucizumab|Participants received brolucizumab injection during the index period
89517770|NCT02322671|Experimental|Sequence ABC|Subjects will be administered a single oral dose of treatment A, B and C in the sequence ABC, where A is Reference Treatment: 5 mg montelukast sodium reference chewable tablets (innovator product); B is Test Formulation 1: 5mg montelukast sodium (GW483100) chewable tablet and C is Test Formulation 2: 5mg montelukast sodium (GW483100) chewable tablet. The treatment periods will be separated by a washout period of 7 to 14 days
89517771|NCT02322671|Experimental|Sequence ACB|Subjects will be administered a single oral dose of treatment A, B and C in the sequence ACB, where A is Reference Treatment: 5 mg montelukast sodium reference chewable tablets (innovator product); B is Test Formulation 1: 5mg montelukast sodium (GW483100) chewable tablet and C is Test Formulation 2: 5mg montelukast sodium (GW483100) chewable tablet. The treatment periods will be separated by a washout period of 7 to 14 days
89517772|NCT02322671|Experimental|Sequence BAC|Subjects will be administered a single oral dose of treatment A, B and C in the sequence BAC, where A is Reference Treatment: 5 mg montelukast sodium reference chewable tablets (innovator product); B is Test Formulation 1: 5mg montelukast sodium (GW483100) chewable tablet and C is Test Formulation 2: 5mg montelukast sodium (GW483100) chewable tablet. The treatment periods will be separated by a washout period of 7 to 14 days
89517773|NCT02322671|Experimental|Sequence BCA|Subjects will be administered a single oral dose of treatment A, B and C in the sequence BCA, where A is Reference Treatment: 5 mg montelukast sodium reference chewable tablets (innovator product); B is Test Formulation 1: 5mg montelukast sodium (GW483100) chewable tablet and C is Test Formulation 2: 5mg montelukast sodium (GW483100) chewable tablet. The treatment periods will be separated by a washout period of 7 to 14 days
89517774|NCT02322671|Experimental|Sequence CAB|Subjects will be administered a single oral dose of treatment A, B and C in the sequence CAB, where A is Reference Treatment: 5 mg montelukast sodium reference chewable tablets (innovator product); B is Test Formulation 1: 5mg montelukast sodium (GW483100) chewable tablet and C is Test Formulation 2: 5mg montelukast sodium (GW483100) chewable tablet. The treatment periods will be separated by a washout period of 7 to 14 days
89517775|NCT02322671|Experimental|Sequence CBA|Subjects will be administered a single oral dose of treatment A, B and C in the sequence CBA, where A is Reference Treatment: 5 mg montelukast sodium reference chewable tablets (innovator product); B is Test Formulation 1: 5mg montelukast sodium (GW483100) chewable tablet and C is Test Formulation 2: 5mg montelukast sodium (GW483100) chewable tablet. The treatment periods will be separated by a washout period of 7 to 14 days
89517776|NCT05096143||Naive Sacubitril/valsartan|Participants who were prescribed with Naive Sacubitril/valsartan
89517777|NCT05096143||Naive ACEi/ARB|Participants who were prescribed with Naive Angiotensin-converting enzyme inhibitors/Angiotensin II receptor antagonists (ACEi/ARB)
89517778|NCT02322827||single tablet regimen|Subjects whose most recent antiretroviral therapy consist of a single tablet regimen
89517779|NCT02322827||multiple tablet regimen|Subjects whose most recent antiretroviral therapy consist of multi tablet regimen
89517780|NCT04248517|Experimental|mHealth intervention group|participants in the mHealth Group will download the app on to their smartphone and complete ecological momentary assessments on 3 consecutive weekdays every 2 weeks for 6 months.
89517781|NCT04248517|No Intervention|Treatment as Usual group|participants will undergo their routine treatment.
89517782|NCT02322905|Experimental|Emotion Regulation Therapy|8 sessions of Emotion Regulation Therapy.
89595130|NCT04277806|No Intervention|Standard group|No interventions would be conducted in this group and the preterm infants would be fed in the normal way.
89595131|NCT04277806|Experimental|Intervention group|The preterm infants in this group would be fed according to the new process.
89595132|NCT03771430|Experimental|Non-surgical group|Osteoarthritis education, exercise and eCBT
89595133|NCT03771430|Experimental|Combined group|Total knee arthroplasty + osteoarthritis education, exercise and eCBT
89595134|NCT03771430|Active Comparator|Surgery only (standard care)|Total knee arthroplasty + standard physiotherapy
89595135|NCT03197662|Experimental|Experimental: Intranasal Oxytocin (IN-OXT)|Syntocinon (synthetic oxytocin) will be used in this protocol. Each subject will receive a dose of 16 IU QD and will be instructed to inhale 2 puffs per nostril (4 IU each).
89595136|NCT03197662|Placebo Comparator|Placebo Comparator: Matched Placebo|Each subject will receive a dose of 16 IU QD, and will be instructed to inhale 2 puffs per nostril (4 IU each).
89595137|NCT04391062|Experimental|intraoperative PDT 400J/cm²|
89210023|NCT04035096|Experimental|The high-dose vitamin C with very low carbohydrate diet group|"Initiation of High dose IVC therapy: start with 25g IVC biweekly for one week; 50g IVC biweekly for one week; 75g biweekly for one week.~Blood vitamin C level measurement: Confirm the plasma vitamin C level above 350 mg/dl by Arkray company PocketChem VC ( Kyoto, Japan) from the 75g/dose~Once the target blood level is confirmed, the dose remains g biweekly for 12 weeks. If the target blood level is below 350mg/dl, the dose will titrate up to 100 g/dose or maximal dose of 1.5g/kg/dose to achieve the target level. The blood vitamin C level will be checked again and record. The final dose will be kept for 12 weeks.~The Riordan IVC protocol (Taiwan)~Maintenance dose: 75-100g every 2 week will be maintained for additional 12 weeks~The infusion schedule change within 2 weeks is accepted with the fixed frequency per week or month~VLCD intervention in the first 12 weeks"
89210024|NCT04035096|Active Comparator|The control group|"Selection of control group: stage IV colon cancer patients match for sex, age and chemotherapy /target therapy drugs~Usual care"
89595138|NCT04391062|Experimental|intraoperative PDT 600J/cm²|
89595139|NCT04391062|Experimental|intraoperative PDT 800J/cm²|
89595140|NCT04384276|Experimental|Prospective Weigh Easy|"Patients enrolled onto this arm of the study will use the Weigh Easy system for weight tracking in the first three months of life. Weights will be measured in home using the Weigh Easy scale and transmitted to the study team via the Weigh Easy eClipboard message. A notification scheme will be activated for weights found to have plateaued or decreased to ensure that the infant's standard of care nutritionist and provider are able to follow up and recommend additional interventions to counteract the weight change.~After three months, families will complete a satisfaction survey to determine if the Weigh Easy system was preferable or if there are any improvements that could be made.~All other aspects of the patients' care will follow the standard of care for cleft and craniofacial diagnoses and will be guided by the nutritionists specializing in cleft and craniofacial care."
89595141|NCT04384276|Other|Retrospective Control Arm|Patients enrolled onto the control arm will have retrospectively presented to the Cleft and Craniofacial Clinic from January 1, 2016 to December 31, 2018 as infants. These patients were treated with the standard of care for cleft and craniofacial diagnoses and were followed by the nutritionists specializing in cleft and craniofacial care.
89595142|NCT03247582||Edoxaban|NVAF Patients treated with Edoxaban
89595143|NCT01808612|Experimental|20 mg Fluoxetine|20 milligrams (mg) fluoxetine (capsules) administered orally, once daily, for 6 weeks
89595144|NCT01808612|Experimental|40 mg Fluoxetine|40 mg fluoxetine (capsules) administered orally, once daily, for 6 weeks
89595145|NCT01808612|Placebo Comparator|Placebo|Placebo (capsules) administered orally, once daily, for 6 weeks
89595146|NCT01908829|Experimental|Combination (solifenacin + mirabegron)|Participants received solifenacin 5 mg, mirabegron 25 mg and solifenacin 10 mg matching placebo once daily for the first 4 weeks of double-blind period. For the last 8 weeks of the double-blind treatment period, the 25 mg mirabegron tablet was replaced by a 50 mg mirabegron tablet. Placebo was given for the 2 week single-blind safety follow-up period.
89595147|NCT01908829|Active Comparator|Solifenacin 5 mg|Participants received solifenacin 5 mg, mirabegron 25 mg matching placebo and solifenacin 10 mg matching placebo once daily. For the last 8 weeks of the double-blind treatment period, the 25 mg mirabegron matching placebo tablet was replaced by a 50 mg mirabegron matching placebo tablet (to maintain the blind). Placebo was given for the 2 week single-blind safety follow-up period
89595148|NCT01908829|Active Comparator|Solifenacin 10 mg|Participants received solifenacin 5 mg matching placebo, mirabegron 25 mg matching placebo and solifenacin 10 mg once daily. For the last 8 weeks of the double-blind treatment period, the 25 mg mirabegron matching placebo tablet was replaced by a 50 mg mirabegron matching placebo tablet (to maintain the blind). Placebo was given for the 2 week single-blind safety follow-up period.
89595149|NCT04277338|Experimental|The tested injected doses of 99mTc-HE3-G3 1000 μg|"At least five (5) evaluable subjects with HER2-positive status and at least five (5) subjects with HER2-negative status have to be enrolled in the study for each tested protein dose. The tested injected dose 1000 μg.~Subjects withdrawn from the study for any reason will be replaced."
89595150|NCT04277338|Experimental|The tested injected doses of 99mTc-HE3-G3 2000 μg|"At least five (5) evaluable subjects with HER2-positive status and at least five (5) subjects with HER2-negative status have to be enrolled in the study for each tested protein dose. The tested injected dose 2000 μg.~Subjects withdrawn from the study for any reason will be replaced."
89595151|NCT04277338|Experimental|The tested injected doses of 99mTc-HE3-G3 3000 μg|"At least five (5) evaluable subjects with HER2-positive status and at least five (5) subjects with HER2-negative status have to be enrolled in the study for each tested protein dose. The tested injected dose 3000 μg.~Subjects withdrawn from the study for any reason will be replaced."
89595152|NCT01773122|Experimental|Dapsone Formulation A|Dapsone Formulation A applied once daily to the face, upper chest, upper back, and shoulders for 28 days.
89595153|NCT01773122|Experimental|Dapsone Formulation B|Dapsone Formulation B applied once daily to the face, upper chest, upper back, and shoulders for 28 days.
89595154|NCT01773122|Experimental|Dapsone Formulation C|Dapsone Formulation C applied once daily to the face, upper chest, upper back, and shoulders for 28 days.
89595155|NCT01773122|Active Comparator|Dapsone 5% Gel|Dapsone 5% gel (ACZONE®) applied twice daily to the face, upper chest, upper back, and shoulders for 28 days.
89031482|NCT00515736|Placebo Comparator|0|Group receiving vehicle solution for 5 days (double dose for 48 hours)
89595156|NCT01808534|Experimental|Treatment (palifosfamide)|Patients receive palifosfamide IV over 30 minutes on days 1-3. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
89595157|NCT01808222|Experimental|FACBC|Participants receiving a bolus of anti-[18F]FACBC injected with PET-CT detection of cancer recurrence.
89595158|NCT01772576|Experimental|Reliance 4-Front|Single arm, all patients will be implanted with the Reliance 4-Front lead
89595159|NCT03192358||Amyotrophic Lateral Sclerosis|We will be recruiting individuals with confirmed or probably ALS, who experience speech or swallowing problems, to attend one data collection session. All participants will undergo the same protocol, including a Videofluoroscopic Swallowing Examination, and Tongue Strength Measurement.
89595160|NCT03192358||Parkinson's Disease|We will be recruiting individuals with a diagnosis of Parkinson's disease, who experience speech or swallowing problems, to attend one data collection session. All participants will undergo the same protocol, including a Videofluoroscopic Swallowing Examination, and Tongue Strength Measurement.
89595161|NCT03218800|Active Comparator|Intravenous Ertapenem|Patients with urinary tract infection will be treated with ertapenem by the intravenous route.
89595162|NCT03218800|Experimental|Subcutaneous Ertapenem|Patients with urinary tract infection will be treated with ertapenem by the subcutaneous route.
89595163|NCT01802216|No Intervention|Control/Delayed Treatment|Baseline panoramic x-ray (Panorex) and complete oral examinations at every visit. Rescue scaling and root planing only to sites of periodontal disease progression (since prior examination) of greater than 3mm. Subjects will be informed of their assignment to the delayed treatment group and provided referral list of local dentists should patient not feel comfortable waiting until end of study for full intensive periodontal disease treatment. Written and verbal instruction in oral hygiene. Provision of oral hygiene supplies.
89595164|NCT01802216|Active Comparator|Intensive periodontal disease treatment|Baseline panoramic x-ray (Panorex) and complete oral examinations at every visit. Intensive periodontal disease treatment to include administration of local anesthetic to up to two quadrants for scaling and root planing with ultrasonic and hand instruments. Minocycline will be applied to any sites with probing depth >=5mm. Hopeless teeth in scaled quadrants will be extracted. Written and verbal instruction in oral hygiene. Provision of oral hygiene supplies.
89595165|NCT04760158|Experimental|Taping group|A new star taping technique and exercises were applied to participants.
89595166|NCT04760158|Sham Comparator|Sham Taping Group|Sham patellar taping and exercises were applied to participants.
89595167|NCT04760158|Other|control group|Only exercises were applied to participants.
89595168|NCT03621904||EC patients with HT|Patients with advanced stage or recurrent endometrial cancer treated with hormonal therapy
89595169|NCT01808144|Experimental|lesinurad 400 mg + febuxostat 80 mg|Patients on lesinurad 400 mg had their dose changed to lesinurad 200 mg after implementation of protocol amendment 3, dated 07 October 2015.
89595170|NCT01808144|Experimental|lesinurad 200 mg + febuxostat 80 mg|
89595171|NCT02085070|Experimental|Melanoma patients|"After establishing eligibility criteria, for patients with melanoma the investigator will determine at least one lesion that requires local therapy (surgical resection or LITT) based on size, location, and/or risk of hemorrhage; this will be considered the surgical lesion. All other eligible brain lesions will be considered clinically evaluable lesions and will be followed by modified RECIST (mRECIST) criteria to determine best response."
89595172|NCT02085070|Other|Non-small cell lung cancer patients|"NSCLC patients are not required to have a surgical lesion but must have at least one clinically evaluable lesion in the central nervous system. Patients on NSCLC are required to have formalin-fixed, paraffin-embedded tumor tissue available for biomarker analysis."
89595173|NCT01808066|Experimental|Play Groundskeeper|This study will employ design-based research models (Laurel, 2003) to the executive-functioning training game GroundsKeeper by CogCubed; we will assess the quality of digital designs for learning (Barab & Squire, 2004) using established qualitative data collection to analyze game play and player reaction over a three week period of time. We will assess the participants for their ability to stay engaged in play by observing their engagement in the game, time played, frequency of play, and the ability to complete a session over the course of three weeks while in school.
89595174|NCT01604343|Experimental|Placebo then Sirukumab 50 mg or Sirukumab 100 mg|
89595175|NCT01604343|Experimental|Sirukumab 100 mg|
89595176|NCT01604343|Experimental|Sirukumab 50 mg + Placebo|
88978421|NCT00256672|Active Comparator|1|High-dose Thoraco-Lumbar-Sacral Orthoses wear (>23hrs/day) will be compared to low-dose Thoraco-Lumbar-Sacral Orthoses wear (12hrs/day)
88978422|NCT00256672|Active Comparator|2|Low-dose Thoraco-Lumbar-Sacral-Orthoses wear (12hrs/day)
88978423|NCT00070382|Experimental|Darbepoetin alfa|darbepoetin alfa administered once every two weeks at a dose of 200 ug over a 16 week treatment period.
88978424|NCT00070382|Active Comparator|Epoetin alfa|epoetin alfa administered at 40,000 unites, once per week over a 16-week treatment period.
89031483|NCT02944422||Males|Primary school Egyptian boys from 7-10 years.
89031484|NCT02944422||Females|Primary school Egyptian girls from 7-10 years.
89031485|NCT02952482||newborns testing for ALD|newborns testing for ALD
89031486|NCT00511940|Experimental|1|acamprosate
89031487|NCT00511940|Placebo Comparator|2|sugar pill
89031488|NCT02950857|Experimental|EPEG (pegylated erythropoietin) - 0.9 µg/kg|Four weekly subcutaneous injections of 0.9 µg/kg EPEG
89031489|NCT02950857|Experimental|EPEG (pegylated erythropoietin) - 1.2 µg/kg|Four weekly subcutaneous injections of 1.2 µg/kg EPEG
89031490|NCT02950857|Experimental|EPEG (pegylated erythropoietin) - 1.5 µg/kg|Four weekly subcutaneous injections of 1.5 µg/kg EPEG
89031491|NCT00513149|Active Comparator|c6|Clopidogrel 600 mg loading
89031492|NCT00515814|Experimental|1, 2|During measurement/test periods, investigator sets implant into ON or OFF condition without subjects knowledge of when device is active.
89031493|NCT02944344|Experimental|Four Conversations Intervention|Subjects in this arm will participate in Reimagine's online Four Conversations program during the initial study period of four weeks.
89031494|NCT02944344|Other|Waitlisted Control|Subjects in this arm will continue to receive standard care from their healthcare providers during the initial study period (i.e. no intervention). After four weeks, subjects will then participate in Reimagine's online Four Conversations program.
89031495|NCT02952326|Experimental|XP Endo Finisher|
89031496|NCT02952326|Active Comparator|Conventional needle irrigation|
89595177|NCT01801436|Experimental|Bortezomib|Bortezomib 1.3 milligram (mg) per meter square (m^2) on Days 1, 4, 8, and 11 of each 3-week cycle for up to 8 cycles.
89595178|NCT01771250|Experimental|Insulin Peglispro|Stable dose of insulin peglispro (0.2 - 0.8 units per kilogram [U/kg]) administered subcutaneously (SC) once daily for at least 21 days in one of two treatment periods. Dose based on prestudy basal insulin dosing regimen.
89595179|NCT01771250|Active Comparator|Insulin Glargine|Stable dose of insulin glargine (0.2 - 0.8 U/kg) administered SC once daily for at least 21 days in one of two treatment periods. Dose based on prestudy basal insulin dosing regimen.
89595180|NCT01770860|Active Comparator|6660|Five dermabrasion wounds will be created on each subject's back by a licensed physician. Four of the wounds will be covered with four different commercially-available bandages (6660, 4314, 8336 and 4840), and one wound will be left open to the air to serve as a no treatment control (0000). Treatments and control will be randomized to application site.
89595181|NCT01770860|Active Comparator|4314|Five dermabrasion wounds will be created on each subject's back by a licensed physician. Four of the wounds will be covered with four different commercially-available bandages (6660, 4314, 8336 and 4840), and one wound will be left open to the air to serve as a no treatment control (0000). Treatments and control will be randomized to application site.
89595182|NCT01770860|Active Comparator|8336|Five dermabrasion wounds will be created on each subject's back by a licensed physician. Four of the wounds will be covered with four different commercially-available bandages (6660, 4314, 8336 and 4840), and one wound will be left open to the air to serve as a no treatment control (0000). Treatments and control will be randomized to application site.
89595183|NCT01770860|Placebo Comparator|4840|Five dermabrasion wounds will be created on each subject's back by a licensed physician. Four of the wounds will be covered with four different commercially-available bandages (6660, 4314, 8336 and 4840), and one wound will be left open to the air to serve as a no treatment control (0000). Treatments and control will be randomized to application site.
89595184|NCT01770860|No Intervention|0000|"Device: 0000~At each daily visit, designated study personnel will cut out the center pad of the bandage and apply only the adhesive tabs around the assigned wound site.~Other Names:~Sheer Strips~BAND-AID® with QuiltVent™ Pad Technology~Five dermabrasion wounds will be created on each subject's back by a licensed physician. Four of the wounds will be covered with four different commercially-available bandages (6660, 4314, 8336 and 4840), and one wound will be left open to the air to serve as a no treatment control (0000). Treatments and control will be randomized to application site."
89595185|NCT03568708|No Intervention|Control Participants|The control group will reflect a comparison group similar to the POI patient group. As bone density, body composition, and cognitive domains continue to mature throughout the teenage years, this comparison group will provide an important metric of normal growth and development.
89031497|NCT02944227|Experimental|Lucentis|Lucentis fixed treatment
89031498|NCT04695938|Other|MRI|MRI examination
89031499|NCT02950740||Center 01 (SA)|Toddlers from Santo André Early Childhood Public School
89031500|NCT02950740||Center 02 (POA)|Toddlers from Porto Alegre Early Childhood Public School
89031501|NCT02950740||Center 03 (MG)|Toddlers from Uberaba Early Childhood Public School
89031502|NCT02950740||Center 04 (RN)|Toddlers from Natal Early Childhood Public School
89031503|NCT00513383|Experimental|Part A|Determine the best dosing of panitumumab, chemotherapy and radiation.
89031504|NCT00513383|Experimental|Part B|Determine the best dosing of induction chemotherapy combined with panitumumab prior to receiving panitumumab and chemoradiotherapy.
89031505|NCT00513422|Experimental|1|Glucosamine sulfate 1500mg and chondroitin sulfate 800mg (low molecular weight, bovine)
89031506|NCT00513422|Experimental|2|Glucosamine sulfate 1500mg
89031507|NCT00513422|Experimental|3|Chondroitin sulfate 800mg
89031508|NCT00513422|Placebo Comparator|4|Matching glucosamine/chondroitin placebo capsules
89031509|NCT02944305||Patient with difficult intubation|Group 1: Patient undergoing endotracheal intubation with difficult intubation Group 2: Patient undergoing endotracheal intubation without difficult intubation
89031510|NCT04695821|Experimental|Senti Arm|"In stage 1 of this study (6 patients), the patient will apply the device and complete the initial patient survey; questions are around usability, comfort (including feelings of pressure), and acceptability. The Investigator will record the time taken to apply the device. A brief 30 seconds of chest sounds will be recorded from each of the nine sensors on the device in three different settings: standing up, lying down, walking around.~In stage 2 of this study (10 patients; 6 of whom would be re-recruited from the first stage), the participant will use the device at home over five days. The Investigator will assess the participant daily for any signs of pressure sores or complications from using the device (including topical allergic reactions). The participant will complete a daily survey. The participant is encouraged to remove the device and apply it at their discretion. The participant can opt-out of wearing the device at any stage."
89031511|NCT00513539|Active Comparator|Arm A|Biliary Stenting alone
89031512|NCT00513539|Experimental|Arm B|Photodynamic Therapy plus biliary stenting
89031513|NCT00515931|Experimental|Radiotherapy|GIST patients who have progressing metastases will be treated with radiotherapy.
89031514|NCT04695470|Experimental|Fruquintinib with Sintilimab|Patients who met the eligibility criteria took fruquintinib 5mg qd for 2 weeks on and 1 week off Q3w plus Sintilimab 200mg iv, Q3w.
89031515|NCT04691973||Access to tool|Access to the digital tool. Participants use the tool at their own in addition to usual care and do the different themes that are available. They are recommended to use it at least every other week.
89031516|NCT04691973||No access to tool|Participants are followed by their ordinary healthcare provider and are not exposed to the tool.
89031517|NCT00511979|Experimental|Technosphere insulin inhalation system, 25 units|
89595186|NCT03568708|Experimental|POI Participants|This group will be participants who have been recently diagnosed with POI. In an open-label fashion, participants with POI will receive Transdermal Estrogen(beginning at a dose of 25 μg/patch applied weekly), with the dose increased at 3, 6 12, and 18 months (to 37.5, 50, 75, and 100 µg/patch).
89595187|NCT04305106|Experimental|Bevacizumab|Bevacizumab 7.5mg/kg body weight, intravenous drip, single-dose administration, and standard of care, including prophylactic doses of low molecular weight heparin or unfractionated heparin without contraindications, and therapeutic doses of anticoagulants with the evidence of thrombosis risk or occurrence.
89595188|NCT04305106|Placebo Comparator|Placebo|Placebo (inactive excipient) 7.5mg/kg body weight, intravenous drip, single-dose administration, and standard of care, including prophylactic doses of low molecular weight heparin or unfractionated heparin without contraindications, and therapeutic doses of anticoagulants with the evidence of thrombosis risk or occurrence.
89595189|NCT01603875|Active Comparator|PrEP and Simulated PEP with PVRV by intramuscular route|
89595190|NCT01603875|Experimental|PrEP and Simulated PEP with new CPRV by intramuscular route|
89595191|NCT01603875|Experimental|PrEP and Simulated PEP with new CPRV by intradermal route|
89595192|NCT04277260||Full term delivery|In the cooperative obstetric hospital, 30 cases of full-term delivery healthy mothers and their infants are selected. Each pair of nursing mothers and infants will complete the observation for 6 months. The samples of human milk and newborn feces are the experimental objects.
89595193|NCT04277260||Preterm delivery(35-37 weeks)|In the cooperative obstetric hospital, 30 cases of preterm delivery(35-37 weeks) mothers and their infants are selected. Each pair of nursing mothers and infants will complete the observation for 6 months. The samples of human milk and newborn feces are the experimental objects.
89595194|NCT04277260||Preterm delivery(32-35 weeks)|In the cooperative obstetric hospital, 30 cases of preterm delivery(32-35 weeks) mothers and their infants are selected. Each pair of nursing mothers and infants will complete the observation for 6 months. The samples of human milk and newborn feces are the experimental objects.
89595195|NCT04277260||Preterm delivery(28-32 weeks)|In the cooperative obstetric hospital, 30 cases of preterm delivery(28-32 weeks) mothers and their infants are selected. Each pair of nursing mothers and infants will complete the observation for 6 months. The samples of human milk and newborn feces are the experimental objects.
89595196|NCT01770392|Active Comparator|Test|multiple doses of Rifampicin + single dose of Nintedanib
89595197|NCT01770392|Experimental|Reference|single dose of Nintedanib
89595198|NCT02020564|Experimental|Treatment Group|Computerized exercised will be administered on a laptop computer twice a week for 5 weeks (10 training sessions).
89595199|NCT02020564|Placebo Comparator|Placebo control group|Computerized exercises will be administered on a laptop computer twice a week for 5 weeks (10 training sessions).
89595200|NCT01603641|Experimental|BOTOX®|Participants received maximum of 5 treatments of intramuscular injections of BOTOX® (botulinum toxin Type A) into a single lower limb muscles or divided between both lower limb muscles or into the lower limb muscles and/or upper limb muscles at a minimum of 12 weeks apart. Treatment dosing was according to investigator judgment not to exceed a maximum of 8 unit per kilogram (U/kg) of body weight (not to exceed 300 U) in treatment Cycle 1. Dose could be increased to a maximum of 10 U/kg (not to exceed 340 U) in treatment Cycles 2-5. Participants received intramuscular injections of BOTOX® (botulinum toxin Type A) 4 or 8 U/kg into the lower limb in the previous study or were de novo participants who were not enrolled in the previous study.
89595201|NCT02018692|Experimental|Alga Dunaliella Bardawil 9-cis beta Carotene Rich Powder|15 patients will first receive the capsules containing the alga Dunaliella Bardawil 9-cis beta-Carotene rich powder (5mg/Kg) for 24 weeks. After 24 weeks of washout period they will receive capsule containing placebo (Starch) for 24 weeks.
89595202|NCT02018692|Placebo Comparator|Placebo (Starch)|The other 15 Patients will receive first the placebo (Starch) capsules for 24 weeks. After 24 weeks of washout period they will receive capsules containing the alga Dunaliella Bardawil 9-cis beta-Carotene rich powder .
89608526|NCT04143633|Experimental|FODMAP diet in Irritable Bowel Syndrome|Patients with IBS will be randomized to standard diet or low fodmap diet. The nutritional status (body composition and clinical parameters), gut microbiota, adherence to treatment, improvement of gastrointestinal symptoms and quality of life will be evaluated for 10 weeks.
89031518|NCT00511979|Experimental|Technosphere insulin inhalation system, 50 units|
89031519|NCT00511979|Experimental|Technosphere insulin inhalation system, 100 units|
89031520|NCT00511979|Active Comparator|Subcutaneous regular human insulin|
89031521|NCT02950662|Active Comparator|Metal housing|metal housing of ball and socket attachment the intervention will be overdenture
89031522|NCT02950662|Active Comparator|Peek housing|Peek housing of ball and socket attachment the intervention will be overdenture
89031523|NCT02952053|Experimental|Dry Needling into MTrPs.|MTrP Group: Deep Dry Needing into the medial Myofascial Trigger Point of the soleus muscle.
89031524|NCT02952053|Active Comparator|Dry Needling within Taut Band|TB Group: Deep Dry Needling distal to Myofascial Trigger Point of the soleus muscle (in the same taut band; out of MTrPs).
89031525|NCT00513656|Active Comparator|Oxycodone Hydrochloride Tablets|
89031526|NCT00513656|Experimental|Oxycodone Naloxone Tablets|
89031527|NCT00529932|Active Comparator|1|Enriched CD133+, bone marrow-derived, autologous progenitor cells for this trial will be infused in the coronary arteries
89210025|NCT00608322|Experimental|1|Subjects receive inhaled nitric oxide (40 parts per million) for six hours.
89210026|NCT00608322|Sham Comparator|2|Subjects receive sham inhaled nitric oxide for six hours.
89595203|NCT03492112|Experimental|People attending needle syringe programs in Australia|Participants will be screened for Hepatitis C using the Finger-stick whole blood HCV RNA Point of Care GeneXpert. Participants with hepatitis C will be offered treatment with a pan-genotypic DAA HCV therapy- either 12 weeks of sofosbuvir/velpatasvir or 8 weeks of glecaprevir/pibrentasvir.
89595204|NCT04397380||ED Patients|Patients Presenting in Emergency Department
89595205|NCT01556763|Placebo Comparator|Placebo|Matching placebo was administered as one capsule per day for 21 days.
89595206|NCT01556763|Experimental|EVP-6124 (1.0 mg/day)|EVP-6124 was administered as one 1.0 mg capsule per day for 21 days.
89595207|NCT01556763|Experimental|EVP-6124 (0.3 mg/day)|EVP-6124 was administered as one 0.3 mg capsule per day for 21 days.
89595208|NCT04397146|Experimental|Single-blind sensory and satiety evaluation|In total 8 different ONS products are consumed and evaluated, each product on a separate test day. The order of products is randomized between study participants.
89595209|NCT01576575|Experimental|Healthy males and non-pregnant females|"Subjects will be studied during a maximum of seven occasions.~Study drugs are intravenous buprenorphine (0.025-0.2 mg infused over 1 hr) and sublingual buprenorphine (2-4 mg), with 1-3 week washout between sessions.~Sessions 1&2: Control (no pretreatment) - intravenous and sublingual buprenorphine. Some subjects will only undergo session 1 (IV)~Sessions 3&4: Liver and gut CYP3A induction (rifampin 600 mg daily), intravenous and sublingual buprenorphine~Session 5: Gut only CYP3A inhibition (grapefruit juice the night before), sublingual buprenorphine~Sessions 6&7: Liver and gut CYP3A inhibition (ketoconazole 400 mg daily), intravenous and sublingual buprenorphine"
89595210|NCT05051566|Experimental|LY3502970 Prototype (Part A)|Multiple doses of LY3502970 prototype administered orally.
89595211|NCT05051566|Experimental|LY3502970 Reference (Part A)|Multiple doses of LY3502970 reference administered orally.
89595212|NCT05051566|Experimental|LY3502970 Prototype (Part B)|Multiple doses of LY3502970 prototype administered orally.
89595213|NCT05051566|Experimental|LY3502970 Reference (Part B)|Multiple doses of LY3502970 reference administered orally.
89595214|NCT05051566|Active Comparator|Esomeprazole (Part B)|Multiple doses of Esomeprazole (Proton Pump Inhibitor) administered orally.
89595215|NCT01555983|Active Comparator|Vaporization of Cannabis 6.7% THC|Inhaling of standardized measured puffs of Vaporized High Dose 6.7% THC. Monitored for 8 hours measuring psychoactive and analgesic effects.
89595216|NCT01555983|Active Comparator|Vaporization of Cannabis 2.9% THC|Inhaling standardized measured puffs of Vaporized Low Dose 2.9% THC. Monitored for 8 hours measuring psychoactive and analgesic effects.
89595217|NCT01555983|Placebo Comparator|Vaporization of Cannabis Placebo THC|Inhaling standardized measured puffs of Placebo THC. Monitored for 8 hours measuring psychoactive and analgesic effects.
89595218|NCT01576341|Experimental|HX575 epoetin alfa (Sandoz)|Single arm
89595219|NCT03451630|Active Comparator|High-Touch|Delivered primarily via face-to-face interactions, with telephonic interactions and information sharing that does not require access to mobile devices or the Internet. In-person support and/or telephonic interactions to occur at least four times over at least a four-month period.
89595220|NCT03451630|Active Comparator|High-Tech|Delivered via a remote care management platform and digital health tools. Remote care support interactions to occur for at least a four-month period.
89595221|NCT03451630|Active Comparator|Usual Care|Delivered via Health Plan support and resources within 14 days of an initial home or telephonic visit.
89595222|NCT04247464|No Intervention|Standard diet|The participants will follow an standard diet during the chemotherapy treatment
89595223|NCT04247464|Experimental|Fasting|The participants will follow a short-term fasting period for 44-48 hours, starting 24 hours before chemotherapy treatment
89595224|NCT04241224|Experimental|Excimer Laser Photoablation|"Device: DABRA Laser System~Patients with symptomatic peripheral vascular disease undergoing an endovascular revascularization procedure utilizing the DABRA Laser System."
89595225|NCT03411070|Experimental|Treatment (SCOUT reflector surgery)|Patients undergo image-guided placement of the SCOUT reflector prior to course 2 of standard of care neoadjuvant chemotherapy. Patients undergo standard of care surgery approximately 4-8 weeks after chemotherapy completion.
89595226|NCT03331978|Experimental|Rise - Treatment Education|Rise consists of a one-month intensive intervention (with three core 60-minute counseling sessions at weeks 1, 2, and 4) followed by two booster sessions (at weeks 12 and 20). If participants show nonadherence during booster sessions, they are offered up to four additional booster sessions (i.e., extra booster sessions if <85% of prescribed doses were taken in the past month). Thus, participants receive three core sessions in the first month, followed by 2-6 booster sessions over the next four months.
89595227|NCT03331978|No Intervention|Control - No Treatment Education|The Usual Care control group will only receive standard of care through their HIV clinics.
89595228|NCT04398004|Experimental|Clarithromycin arm|Treatment will last for seven days. Every patient will receive one tablet of 500 mg of clarithromycin every 12 hours. It is explicitly stated that all other treatment is allowed with the only exclusion the parallel intake of a) any other drug of the macrolide class of antibiotics; and/or b) hydroxychloroquine or chloroquine phosphate. Drugs contraindicated with the intake of clarithromycin are also not allowed, as they are described in the local label information.
89210027|NCT00901134||hypothermia|Patients with therapeutic hypothermia after cardiac arrest in hospitals
89595229|NCT01687413|Experimental|Radiotherapy|"Patients undergo postoperative IMRT once daily, 5 days a week, for 6 weeks. The prescribed radiotherapy dose will be 60 Gy in 2 Gy once-daily fraction size (total of 30 fractions).~Patients can consent to participate in either the randomized (physician chooses radiotherapy arm or radiotherapy & cisplatin arm) or non-randomized (patient chooses radiotherapy arm or radiotherapy & cisplatin arm) pathways"
89595230|NCT01687413|Active Comparator|Radiotherapy, cisplatin|"Patients undergo postoperative IMRT once daily, 5 days a week, for 6 weeks. The prescribed radiotherapy dose will be 60 Gy in 2 Gy once-daily fraction size (total of 30 fractions)~Patients also receive cisplatin 40 mg/m2 IV on Days 1, 8, 15, 22, 29, and 36 of radiation therapy (6 doses for a total of 240 mg/m2).~Patients can consent to participate in either the randomized (physician chooses radiotherapy arm or radiotherapy & cisplatin arm) or non-randomized (patient chooses radiotherapy arm or radiotherapy & cisplatin arm) pathways"
89595231|NCT04181320|No Intervention|Venous Leg Ulcer Standard of Care|Subjects will recieve standard of care treatment.
89031528|NCT00529932|Placebo Comparator|2|Control group patients will receive 3 injections of 0.3 mL each of buffered normal saline (the vehicle used for cell suspension) into comparable vessels. Subjects will have an identical intra-coronary injection procedure to those randomized to autologous CD133+ progenitor cell injections.
89595232|NCT04181320|Experimental|Venous Leg Ulcer Standard of Care with Granulox|Subjects will recieve standard of care treatment with Granulox added as an adjunct therapy.
89595233|NCT01555671|Active Comparator|meperidine administration group|Infusion bags were prepared and labelled as Bag A (meperidine group), containing 25 mg meperidine (Aldolan; Liba Laboratuarları, Istanbul, Turkey) .Providers and patients were blinded to the contents of the bags until the conclusion of the study. Meperidine or placebo were administered by intravenous infusion by means of injectors containing 0.5ml of solution.
89595234|NCT01555671|Placebo Comparator|plasebo group|Bag B (placebo group), containing 0.5ml of normal saline solution. Providers and patients were blinded to the contents of the bags until the conclusion of the study.Meperidine or placebo were administered by intravenous infusion by means of injectors containing 0.5ml of solution.
89595235|NCT03255616|Experimental|Healthy subjects|Spine kinematics assessment during daily activities and brain responses to thoracolumbar mechanical and vibrotactile stimulation
89595236|NCT03255616|Experimental|Low back pain patients|Spine kinematics assessment during daily activities and brain responses to thoracolumbar mechanical and vibrotactile stimulation
89595237|NCT03226756|Experimental|Nivolumab|All patients enrolled in the study will received Nivolumab injections, 3mg/kg IV, every 2 weeks, up to 12 cycles (1 cycle = 28 days).
89595238|NCT01801358|Experimental|Arm A|AEB071 and MEK162 combined
89595239|NCT01801358|Experimental|Arm B|MEK162 alone
89595240|NCT01807598|Experimental|Brentuximab vedotin|Subjects receive a 30-minute IV infusion of brentuximab vedotin once every 21 days for 8 courses, in the absence of disease progression or unacceptable toxicity.
89595241|NCT01801280|Active Comparator|Mycophenolate mofetil (C)|Mycophenolate mofetil (C) b.i.d. every 12 hours for 2 weeks.
89595242|NCT01801280|Other|Mycophenolate mofetil+Pantoprazole (C+P)|Mycophenolate mofetil b.i.d and Pantoprazole o.m. for 2 weeks.
89595243|NCT01801280|Other|Mycophenolate sodium (M)|Mycophenolate sodium (M) b.i.d. every 12 hours for 2 weeks.
89595244|NCT01801280|Other|Mycophenolate sodium+Pantoprazole (M+P)|Mycophenolate mofetil b.i.d and Pantoprazole 40mg o.m. for 2 weeks.
89595245|NCT01769456|Experimental|PCC Behavioral Intervention Group|PCC Behavioral Intervention combined with open label FTC/TDF (Truvada®) as PrEP
89595246|NCT01769378|Placebo Comparator|Placebo|Placebo administered subcutaneously (SQ) once weekly for 24 weeks added to the participant's prescribed glimepiride dose.
89595247|NCT01769378|Experimental|Dulaglutide|Dulaglutide 1.5 milligram (mg) administered SQ once weekly for 24 weeks added to the participant's prescribed glimepiride dose.
89595248|NCT01807520|Experimental|Secukinumab (AIN457) 150 mg|Participants assigned to secukinumab 150 mg were dosed weekly for five weeks, then once every four weeks up to and including Week 132. To maintain the blinding, patients received additional placebo injections at Weeks 17, 18 and 19. All doses of study treatment are administered by sub-cutaneous injections.
89595249|NCT01807520|Experimental|Secukinumab (AIN457) 300 mg|Participants assigned to secukinumab 300 mg were dosed weekly for five weeks, then once every four weeks up to and including Week 132. To maintain the blinding, patients received additional placebo injections at Weeks 17, 18 and 19. All doses of study treatment are administered by sub-cutaneous injections.
89595250|NCT01807520|Placebo Comparator|Placebo|Patients assigned to placebo were dosed weekly for five weeks, then at Week 8 and Week 12. At Week 16, placebo patients were randomized in a 1:1 ratio, to receive secukinumab either 150 mg or 300 mg and were dosed weekly for five weeks starting at Week 16, then once every four weeks up to and including Week 132. All doses of study treatment are administered by sub-cutaneous injections.
89595251|NCT01806896|Experimental|20 mg Arm Cohort A|
89031529|NCT00513734|Active Comparator|1|Geliperm Hydrogel Dressing
89031530|NCT00513734|Active Comparator|2|Lacrilube ointment
89031531|NCT00531102|Experimental|1|"Resuscitation will proceed as per standard of care and infants are only to receive respiratory support if they remain cyanotic despite 60 seconds of spontaneous regular respirations. All infants will have a pulse oximetry probe placed on the right hand (pre-ductal position) immediately after birth. Infants that meet the entry criteria will be randomized to resuscitation with one of two neonatal T-piece resuscitator circuits:~GROUP 1 - infants will receive CPAP of 6 cm H2O with 21% oxygen continuously for at least 5 minutes."
89210028|NCT04035018|Experimental|pharmacopuncture therapy|The physicians will select one or more pharmacopuncture therapy for each participants. The physicians will also decide dosage and frequency of treatment according to the participant's status.
89595252|NCT01806896|Placebo Comparator|Placebo Arm Cohort A|
89595253|NCT01806896|Experimental|5 mg Arm Cohort B|
89595254|NCT01806896|Placebo Comparator|Placebo Arm Cohort B|
89595255|NCT01768676|Experimental|avanafil|100 mg
89595256|NCT01768676|Placebo Comparator|Placebo|placebo
89595257|NCT01555125|Experimental|secukinumab 150 mg|Drug
89595258|NCT01555125|Experimental|secukinumab 300 mg|Drug
89595259|NCT01555125|Placebo Comparator|placebo|
89595260|NCT01768286|Experimental|LDV/SOF 12 Weeks|Participants will receive LDV/SOF FDC for 12 weeks.
89595261|NCT01768286|Experimental|LDV/SOF+RBV 12 Weeks|Participants will receive LDV/SOF FDC plus RBV for 12 weeks.
89595262|NCT01768286|Experimental|LDV/SOF 24 Weeks|Participants will receive LDV/SOF FDC for 24 weeks.
89595263|NCT01768286|Experimental|LDV/SOF+RBV 24 Weeks|Participants will receive LDV/SOF FDC plus RBV for 24 weeks.
89595264|NCT01800968|Active Comparator|Liraglutide|Increasing dose from 0.6mg, 1.2mg to 1.8mg SQ daily.
89595265|NCT01800968|Placebo Comparator|Placebo|Placebo dose increasing from 0.6mg, 1.2mg to 1.8 mg SQ daily.
89595266|NCT01799720|Experimental|Less oxidized oil and diet|Analyze the effect of dietary supplements Omega-3 with different levels of oxidation in the lipid profile of women who consume these supplements. For this purpose we have designed a single-blind, parallel-groups, randomized controlled trial. Participants from group 1 took 2 capsules/day of one of the less oxidized oil (containing 300 mg EPA + DHA) and diet. Follow-up 30 days
88978425|NCT00104754|Experimental|liposomal SN-38|"Patients receive SN-38 liposome IV over 90 minutes on day 1. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients achieving a complete or partial response or patients with stable disease (SD) who were previously treated before study enrollment receive up to 4 additional courses of treatment. Patients with CNS-only disease progression receive whole brain radiotherapy (WBRT). After completion of WBRT, these patients also receive up to 4 additional courses of treatment. Patients with disease progression to sites other than the CNS or patients with SD who were previously untreated before study enrollment are removed from the study.~Quality of life is assessed at baseline, before each treatment course, and then annually for 3 years.~After completion of study treatment, patients are followed every 3 months for 1 year and then every 6 months for 2 years."
88978426|NCT00100854|Active Comparator|Arm I|Patients receive oral erlotinib hydrochloride once daily on days 1-28. Courses repeat every 28 days.
88978427|NCT00100854|Experimental|Arm II|Patients receive erlotinib hydrochloride as in arm I and fulvestrant intramuscularly on days 1, 15, and 29, and then every 28 days thereafter.
88978428|NCT00255814|Other|Radiation therapy dose level II: 4.0 Gy/fx|Radiation therapy dose level II: 4.0 Gy/fraction
89210029|NCT04035018|Active Comparator|physical therapy|The physicians will select one or more physical therapy for each participants. The physicians will also decide intensity and frequency of treatment according to the participant's status.
88978429|NCT00255814|Other|Radiation therapy dose level III: 4.5 Gy/fx|Radiation therapy dose level III: 4.5 Gy/fraction
89517783|NCT02322905|No Intervention|Usual Medical Care|No planned psychotherapy.
89517784|NCT03494465|Active Comparator|MEDICAL TREATMENT GROUP|"Medical treatment will be used in a staggered manner and may also associate laser trabeculoplasty. If necessary, then surgical treatment would be indicated: trabeculectomy. or another filtering surgery.~Inadequate IOP control will be determined by the local ophthalmologist, and additional treatment will be indicated to achieve an target IOP."
89517785|NCT03494465|Experimental|INTERVENTION GROUP|"In lens extraction arm, patients will undergo lens phacoemulsification with intraocular lens implant (IOL) within 60 days after randomization.~If additional treatment is required, the same stepped sequence of therapy described for medical treatment group will be used and will be considered a therapeutic failure."
89517786|NCT04191031|Experimental|Superficial Genicular Nerves|Subjects will receive iovera° cryoneurolysis treatment of superficial genicular nerves (anterior femoral cutaneous nerve [AFCN] and infrapatellar branches of the saphenous nerve [ISN]) of the target knee
89517787|NCT04191031|Sham Comparator|Sham Comparator|Subjects will receive sham iovera° treatment of superficial genicular nerves (AFCN and ISN) of the target knee
89517788|NCT03496727||Serratus anterior plane block|Anesthesia induction was performed to all patients. At the end of the operation, patients were performed SAPB under Ultrasound guidance by the same anesthetist.For 24 hours postoperatively, tramadol was administered with patient-controlled analgesia (PCA) All patients were extubated after the operation and transferred to ICU.
89517789|NCT03496727||Patient controlled analgesia|Anesthesia induction was performed on all patients.At the end of the operation, all patients were performed with patient-controlled analgesia (PCA) All patients were extubated after the operation and transferred to ICU.
89517790|NCT03494387|Experimental|1|
89517791|NCT03494387|Experimental|2|
89517792|NCT02322983|Experimental|Cerebral Palsy Subjects|Use of conscious sedation with nitrous oxide in the control of stress during dental treatment in individuals with Cerebral Palsy
89517793|NCT03496649|Experimental|Dysport|"Dysport administration by intramuscular injection Each patient will receive one dose of Dysport at Visit 1.~At least 2 of the 4 muscles below will be injected, depending on which muscles are affected:~250 IU for the gracilis muscle 200 IU for the pectineus muscle 300 IU for the adductor longus muscle 200 IU for the adductor brevis muscle~These injections will be uni or bilateral, it will depend on clinical diagnosis.~If necessary, the 4 muscles will be injected with a maximum of 1500U Dysport. The total dose cannot exceed 1500 units."
89517794|NCT03496493||All patients|All patients enrolled in trial will have peripheral oxygen saturation simultaneously recorded with both study devices on non-adjacent (second and fourth) fingers of the same hand.
89517795|NCT03494309|Experimental|ORIF|Open Reduction & Internal Fixation
89517796|NCT03494309|Active Comparator|CREF|Closed Reduction & External Fixation
89517797|NCT02324621|Experimental|Treatment (oral ONC201)|Patients receive oral ONC201 PO on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89517798|NCT04487431|Experimental|BAY1817080 Part A|Healthy male participants will receive BAY1817080 given as an oral solution (study Part A)
89517799|NCT04487431|Experimental|[14C]BAY1817080 Part B|Healthy male participants will receive BAY1817080 blended with [14C]BAY1817080 given as an oral solution (study Part B).
89517800|NCT02324777|Experimental|CanniMed™ DPF-I Volcano® Vapourization|Using the Volcano® Medic, a dose of 100 mg of finely ground herbal cannabis drug product formulation (DPF) with a potency specification similar to CanniMed™ 22·1 product, of 21.9% w/w total THC and 0.8% w/w total CBD is vapourized and inhaled by study subjects.
89517801|NCT02324777|Experimental|CanniMed™ DPF-II Volcano® Vapourization|Using the Volcano® Medic, a dose of 100 mg of finely ground herbal cannabis drug product formulation with a potency specification the same as the CanniMed™ 15·5 product, of 15.0% w/w total THC and 5.0% w/w total CBD is vapourized and inhaled by study subjects.
89517802|NCT02324777|Experimental|CanniMed™ DPF-III Volcano® Vapourization|Using the Volcano® Medic, a dose of 100 mg of finely ground herbal cannabis drug product formulation with a potency specification the same as CanniMed™ 9·9 product, of 9.0% w/w total THC and 9.5% w/w total CBD is vapourized and inhaled by study subjects.
89595267|NCT01799720|Experimental|More oxidized oil and diet|Analyze the effect of dietary supplements Omega-3 with different levels of oxidation in the lipid profile of women who consume these supplements. For this purpose we have designed a single-blind, parallel-groups, randomized controlled trial. Participants from group 2 took 2 capsules/day of one of the most oxidized oil (containing 300 mg EPA + DHA) and diet . Follow-up 30 days
89595268|NCT01799720|Experimental|Hypercholesterolemic diet|Analyze the effect of dietary supplements Omega-3 with different levels of oxidation in the lipid profile of women who consume these supplements. For this purpose we have designed a single-blind, parallel-groups, randomized controlled trial. Participants from group 3 only took diet and no capsules. Follow-up 30 days
89595269|NCT01687257|Experimental|SOF+RBV|Participants will receive SOF+RBV for 48 weeks.
89595270|NCT01687257|Experimental|Observation, then SOF+RBV|Participants will undergo 24 weeks of observation and then receive SOF+RBV for 48 additional weeks.
89595271|NCT01806740|Experimental|Gadoterate meglumine|there is one single arm of patients (no comparative arm)
89595272|NCT01687101|Experimental|STOPAIN topical gel|STOPAIN gel which is topical menthol 6% gel applied as 2 to 4 pumps of gel applied behind the ears and to the occipital region of the neck in one or two applications within 2 hours of the onset of the migraine.
89595273|NCT01968967|Experimental|Bococizumab (PF-04950615; RN316)|
89595274|NCT01968967|Placebo Comparator|Placebo|
89595275|NCT01554579|Placebo Comparator|Sugar pill|
89595276|NCT01554579|Experimental|Gefapixant|
88978430|NCT00255814|Other|Radiation therapy dose level IV: 5.0 Gy/fx|Radiation therapy dose level IV: 5.0 Gy/fraction
88978431|NCT00257296|Experimental|Screening and Intervention|Use a computer-based screening tool for intimate partner violence and provide a multi-faceted intervention based on the needs of the woman and services should would like to utilize.
88978432|NCT00257296|Active Comparator|Usual Care|Use a computer-based screening tool for intimate partner violence and provide list of resources available. Also, all physicians were trained on intimate partner violence and were told they could help anyone regardless of randomization.
88978433|NCT00070616|Experimental|Palifermin 6 x 60 μg/kg/day|The first 3 consecutive daily doses were administered before the initiation of conditioning therapy (study days -11, -10, and -9); 3 additional consecutive daily doses were administered after administration of radiotherapy, chemotherapy and PBPC transplantation (study days 0, 1, and 2).
88978434|NCT00070616|Experimental|Palifermin 2 x 180 μg/kg/day|The first dose was administered on study day -11, 3 days before the initiation of conditioning therapy, and the second dose was given on day 0 after administration of radiotherapy, chemotherapy and the PBPC infusion
88978435|NCT04709146|Other|Recovered Covid-19 patients|Diagnostic evulation with audiometry, Tympanography, SVV, VHIT, VNG.
88978436|NCT04709146|Other|Healthy Control|Diagnostic evulation with audiometry, Tympanography, SVV, VHIT, VNG.
88978437|NCT00100893|Experimental|Dietary Supplement: grape seed proanthocyanidin extract|Administered orally.
88978438|NCT00257803|Experimental|1|In the other group, the women will receive a small injection of oxytocin directly into the vein via their intravenous (bolus) after their baby is born.
89595277|NCT01806662|Experimental|Treatment Arm (Ustekinumab first, Then Placebo)|Since there is a crossover design, each patient will be in the treatment arm for 16 weeks of the study.
89595278|NCT01806662|Placebo Comparator|Placebo Arm (Placebo first, Then Ustekinumab)|Since there is a crossover design, each patient will be in the placebo arm for 16 weeks of the study. If a patient begins in the placebo arm, they will switch over to the treatment arm at week 16.
89595279|NCT01930123|Experimental|Patients with NAFLD|70 subjects with biopsy-proven NAFLD; subjects will be challenged with a fructose infusion after a period for 12 hours fasting.
89595280|NCT01930123|Active Comparator|Health controls|15 healthy controls for comparison with NAFLD patients.The 15 subjects will be challenged with a fructose infusion after a period for 12 hours fasting.
89595281|NCT01930045|Experimental|Ralt→MAL4Ralt→Ralt4MAL→MAL6Ralt→Ralt6MAL|Part 1 was comprised of periods 1, 2 and 3; Part 2 was comprised of periods 4 and 5; with each study period separated by a washout period of at least 2 days. Part 1 was separated from Part 2 by a Pause. Each period had single oral dose treatments as follows: Raltegravir (Ralt) alone in Period 1, MAALOX (MAL) followed 4 hrs later by Ralt in Period 2, Ralt followed 4 hrs later by MAL in Period 3, MAL followed 6 hrs later by Ralt in Period 4, Ralt followed 6 hrs later by MAL in Period 5
89595282|NCT01930045|Experimental|MAL4Ralt→Ralt4MAL→Ralt→MAL6Ralt→Ralt6MAL|Part 1 was comprised of periods 1, 2 and 3; Part 2 was comprised of periods 4 and 5; with each study period separated by a washout period of at least 2 days. Part 1 was separated from Part 2 by a Pause. Each period had single oral dose treatments as follows: MAL followed 4 hrs later by Ralt in Period 1, Ralt followed 4 hrs later by MAL in Period 2, Ralt alone in Period 3, MAL followed 6 hrs later by Ralt in Period 4, Ralt followed 6 hrs later by MAL in Period 5
89595283|NCT01930045|Experimental|Ralt4MAL→Ralt→MAL4Ralt→MAL6Ralt→Ralt6MAL|Part 1 was comprised of periods 1, 2 and 3; Part 2 was comprised of periods 4 and 5; with each study period separated by a washout period of at least 2 days. Part 1 was separated from Part 2 by a Pause. Each period had single oral dose treatments as follows: Ralt followed 4 hrs later by MAL in Period 1, Ralt alone in Period 2, MAL followed 4 hrs later by Ralt in Period 3, MAL followed 6 hrs later by Ralt in Period 4, Ralt followed 6 hrs later by MAL in Period 5
89595284|NCT01930045|Experimental|Ralt→Ralt4MAL→MAL4Ralt→Ralt6MAL→MAL6Ralt|Part 1 was comprised of periods 1, 2 and 3; Part 2 was comprised of periods 4 and 5; with each study period separated by a washout period of at least 2 days. Part 1 was separated from Part 2 by a Pause. Each period had single oral dose treatments as follows: Ralt alone in Period 1, Ralt followed 4 hrs later by MAL in Period 2, MAL followed 4 hrs later by Ralt in Period 3, Ralt followed 6 hrs later by MAL in Period 4, MAL followed 6 hrs later by Ralt in Period 5
89595285|NCT01930045|Experimental|MAL4Ralt→Ralt→Ralt4MAL→Ralt6MAL→MAL6Ralt|Part 1 was comprised of periods 1, 2 and 3; Part 2 was comprised of periods 4 and 5; with each study period separated by a washout period of at least 2 days. Part 1 was separated from Part 2 by a Pause. Each period had single oral dose treatments as follows: MAL followed 4 hrs later by Ralt in Period 1, Ralt alone in Period 2, Ralt followed 4 hrs later by MAL in Period 3, Ralt followed 6 hrs later by MAL in Period 4, MAL followed 6 hrs later by Ralt in Period 5
88978439|NCT00257803|Placebo Comparator|2|In one group, women will receive a small injection of saline (salt water) directly into the vein via their intravenous (bolus) after their baby is born.
89595286|NCT01930045|Experimental|Ralt4MAL→MAL4Ralt→Ralt→Ralt6MAL→MAL6Ralt|Part 1 was comprised of periods 1, 2 and 3; Part 2 was comprised of periods 4 and 5; with each study period separated by a washout period of at least 2 days. Part 1 was separated from Part 2 by a Pause. Each period had single oral dose treatments as follows: Ralt followed 4 hrs later by MAL in Period 1, MAL followed 4 hrs later by Ralt in Period 2, Ralt alone in Period 3, Ralt followed 6 hrs later by MAL in Period 4, MAL followed 6 hrs later by Ralt in Period 5
89595287|NCT04631263|Experimental|Treatment Group|
89595288|NCT04631263|No Intervention|Control Group|
89595289|NCT01929343|Experimental|lidocaine following cue-induced craving|Lidocaine will be administered immediately following craving induction. Lidocaine will administered at a loading dose of 2mg/kg(milligrams per kilogram) initial bolus over 5 minutes lidocaine followed by continuous infusion at 2mg/kg /hour for 4 hours.
89595290|NCT01929343|Active Comparator|lidocaine following neutral stimulus|Lidocaine will be administered immediately following neutral stimulus. Lidocaine will administered at a loading dose of 2mg/kg initial bolus over 5 minutes lidocaine followed by continuous infusion at 2mg/kg /hour for 4 hours.
89595291|NCT01929343|Placebo Comparator|saline|Saline will be administered at same volume of lidocaine in active arms.
89595292|NCT01968811|Experimental|Avance foam, abdominal dressing kit|
89595293|NCT01806584|Active Comparator|SRM003|
89595294|NCT01806584|Other|Participating Site's standard practice|
89595295|NCT01798706|Experimental|Lixisenatide|Lixisenatide 10 mcg once daily (QD) for 2 weeks, then at a maintenance dose of 20 mcg QD up to Week 24. If the maintenance dose of 20 mcg was not tolerated, dose could be reduced to 10 mcg.
89595296|NCT01798706|Placebo Comparator|Placebo|Placebo (matched to lixisenatide) QD for 24 Weeks.
89595297|NCT04397926|Experimental|neoantigen vaccine|Patients received subcutaneous injection of individualized neoantigen peptides vaccine at a dose of 200ug per peptide once a week for 12 weeks
89595298|NCT01767194|Experimental|Arm I (temozolomide, irinotecan hydrochloride, temsirolimus)|CLOSED TO ACCRUAL 06/17/2016 Patients receive temozolomide PO on days 1-5, irinotecan hydrochloride IV over 90 minutes on days 1-5, and temsirolimus IV over 30 minutes on days 1 and 8.
89595299|NCT01767194|Experimental|Arm II (temozolomide, irinotecan hydrochloride, dinutuximab)|Patients receive temozolomide PO on days 1-5, irinotecan hydrochloride over 90 minutes on days 1-5, dinutuximab IV over 10-20 hours on days 2-5, and sargramostim SC or IV over 2 hours on days 6-12.
89595300|NCT04398784|Other|1-Blueberry First/Placebo First|Participants will be randomly assigned into either blueberry-first treatment or placebo-first group.
89595301|NCT04398784|Other|2-Crossover|Participants who received blueberry treatment will switch to placebo and vice versa.
89595302|NCT01575873|Experimental|Denosumab|Participants received 60 mg denosumab by subcutaneous injection on day 1 and at months 6, 12, and 18. Participants also received placebo to risedronate orally once a day for 24 months.
89595303|NCT01575873|Experimental|Risendronate|Participants received 5 mg risedronate orally once a day for 24 months and placebo to densumab by subcutaneous injection on day 1 and at months 6, 12, and 18.
89595304|NCT03216928|Experimental|Group 1|patients with good response to anti-TNF had a blood test
89595305|NCT03216928|Experimental|Group 2|patients with moderate or non-response to anti-TNF had a blood test
89595306|NCT04276636|Experimental|Caltrate|This group of patients are going to supplemented with Caltrate 0.6 g / d orally.
89595307|NCT04276636|No Intervention|Control|The other group do not interfere.
89595308|NCT04397224||CRT responder|
89595309|NCT04397224||CRT non-responder|
89595310|NCT03028545|Other|schizophrenia|Exploring and understanding, through a multidisciplinary exploration (medical, anthropological and sociological) representations and recovery strategies in schizophrenia
89595311|NCT03028545|Other|bipolar disorders|Exploring and understanding, through a multidisciplinary exploration (medical, anthropological and sociological) representations and recovery strategies in bipolar disorders
89595312|NCT03028545|Other|eating disorders|Exploring and understanding, through a multidisciplinary exploration (medical, anthropological and sociological) representations and recovery strategies in eating disorders
89595313|NCT03028545|Other|personality disorders|Exploring and understanding, through a multidisciplinary exploration (medical, anthropological and sociological) representations and recovery strategies in personality disorders
89595314|NCT00002644|Experimental|Tamoxifen citrate|Tamoxifen citrate 20 mg/day for 5 years
89595315|NCT00002644|Placebo Comparator|Placebo|Placebo 20 mg/day for 5 years
89595316|NCT01575561|Experimental|Lurasidone|Lurasidone 20, 40, 60,80 mg flexible dose
89595317|NCT03574480|Experimental|Control|Advice on healthy diet and physical activity recommendations
89595318|NCT03574480|Experimental|Intervention|"Advice on healthy diet and physical activity recommendations~Training for 3 months in use of a Smartphone application, designed to promote a healthy diet, increased physical acivity and decreased sedentary."
89595319|NCT03089086|Active Comparator|Group A|Students within schools randomised to group A will receive two doses of licensed 4CMenB vaccine after baseline oropharyngeal swab with an interval of 1 to 2 months between doses, with the first dose given at the baseline visit in 2017.
89595320|NCT03089086|No Intervention|Group B|Students within schools randomised to group B will receive the licensed 4CMenB vaccine following completion of baseline and 12 month oropharyngeal swab in 2018.
89595321|NCT04112758|Experimental|Exercise group|The group will receive twice a week for 5 week
89595322|NCT04112758|No Intervention|Control group|The group will be maintained their normal after school activities
89595323|NCT04746352|Experimental|BES-SMFR group|Using the same Vishee neuro-muscle stimulator as the sEMG assessment with a vaginal probe was inserted into the vagina and placed close to the PFMs. Three standardized programs were used in our study: (1) Tens electricity (first program): 5 min of 50-280 Hz frequency and a pulse duration of 50 µs. (b) Endorphin electricity (second program): 5 min of 1-10 Hz frequency and a pulse duration of 200 µs. (c) Spasmolysis electricity (third program): 5 min of 1-2 Hz frequency and a pulse duration of 300 µs. At the same time, patients could learn about their neuromuscular activity through the biofeedback instrument, abdominal breathing for 5 sec was necessary when PFMs were overactive.
89031532|NCT00531102|Active Comparator|2|"Resuscitation will proceed as per standard of care and infants are only to receive respiratory support if they remain cyanotic despite 60 seconds of spontaneous regular respirations. Infants that meet the entry criteria will be randomized to resuscitation with one of two neonatal T-piece resuscitator circuits:~GROUP 2 - infants will receive 50% oxygen at a rate of 6 liters per minute continuously for at least 5 minutes using a modified neonatal T-piece resuscitator circuit that does not generate pressure. Fifty percent oxygen was chosen because it reflects the actual inspired oxygen concentration when 100% oxygen is blown towards the infant's face."
89595324|NCT04746352|Active Comparator|BES group|"A standardized and structured vaginal examination was performed by digital palpation to identify pelvic floor active MTrPs, and then pain mapping was developed for the patient's use.~Patients were required to participate in intensive training regarding myofascial release techniques. (I) Pressing: press directly on a specific MTrP with gentle, slow pressures (2kg/cm2) using a flat palpation, the pressure was sustained until the participant perceived the pain decreased and taut band released, and then gradually increased to previous level of MTrPs tension and maintained until a reduction of pain again. The process was usually 3 to 5 repetitions for 90 sec. (II) Stretching: stretch in parallel to the direction of the myofascial to facilitate elongation of a contracted muscle. (III) Strumming: stroking and strumming the affected muscles region with the fingertips to aid in MTrPs tension release, the initial pressure was small and increased gradually until the patients adapted."
89595325|NCT03164122|Experimental|Intra-articular injection|
89595326|NCT04397770|Experimental|Camre+Apa+TMZ|
89595327|NCT03082846|Experimental|hypofractionated group|hypofractionated group using hypofractionated radiation with temozolomide chemotherapy: Malignant gliomas patients received concurrent postoperative radiotherapy and chemotherapy.Intensity-modulated radiotherapy is adopted, the dose at each fraction is gradually increased from 2.8 Gy/f (total of 20 times) with an escalating dose interval of 0.4 Gy in PTV1. The planning target volume (PTV2) remain unchanged with 2.5 Gy each time and a total of 50 Gy/20 f. Temozolomide is administered orally every day at 75 mg/m2 during radiotherapy and at 150-200 mg/m2 for 12 cycles following completion of chemoradiotherapy.
89595328|NCT03213418|Experimental|Contingency management|
89595329|NCT05249764|Active Comparator|Exercise|Exercise program was prepared based on WHO, American College of Sports Medicine (ACSM), Geriatrics Physiotherapists Association and Otago exercise program for the exercise group. The older adults are given individual supervised exercise training in their own homes for eight weeks, 3 days a week and 45 minutes a day, by a physiotherapist according to social distance rules. This exercise training consists of a program that includes strengthening, flexibility, aerobic and balance exercises. Each exercise is started with eight repetitions and each week will be increased by two repetitions. In case of fatigue, a rest is given. Brochures are also be prepared for the exercises. Before each session, individuals performed warm-up exercises for 5 minutes. At the end of the session, individuals performed cooling exercises.
89595330|NCT05249764|Active Comparator|Control|Individuals in the control group are performing stretching exercises for proximal extremity muscles for 15 minutes 3 times a week for eight weeks. The participants also perform breathing exercises for 5 minutes a day.
89595331|NCT04276324|Active Comparator|Control Group|Only testing sessions
89595332|NCT04276324|Experimental|Resistance training group|Ten weeks of resistance training
89595333|NCT05240482|Placebo Comparator|Conventional treatment group|Patients in the placebo group will receive bilateral ST36 injection with normal saline 1ml/point
89595334|NCT05240482|Experimental|ST36 acupoint injection group|Patients in the experimental group will receive bilateral ST36 injection with anisodamine 1ml/point
89595335|NCT04746118|No Intervention|CONTROL|During routine clinical visits the patients will receive a written standard general guidelines for diet and physical activity.
89595336|NCT04746118|Experimental|DIET CHANGE|In scheduled nutritional care the patients will receive an individual program with social media supervision. Those patients will also receive a written general guidelines for exercising without supervision.
89595337|NCT04746118|Experimental|DIET CHANGE + PHYSICAL ACTIVITY|In scheduled nutritional care the patients will receive an individual program with social media supervision. Those patients will also receive an exercise physical program prescription with fitness evaluation and close supervision.
89595338|NCT04746118|Experimental|DIET CHANGE + PHYSICAL ACTIVITY + INTEGRATIVE PRACTICES|"In scheduled nutritional care the patients will receive an individual program with social media supervision. Those patients will also receive an exercise physical program prescription with fitness evaluation and close supervision and submitted to orientated mind-fullness, auriculotherapy and laying on of hands approaches that belong to health integrative practices."
89595339|NCT02783716|Active Comparator|Cardiac Resynchronization Therapy (CRT) Group|Participants undergoing Cardiac Resynchronization Therapy Implantation (CRT) implantation for heart failure as part of standard of care will receive EndoPAT testing and collection of subcutaneous adipose tissue
89595340|NCT02783716|Active Comparator|Control Group|Participants undergoing device pacemaker or implantable cardioverter-defibrillator (ICD) implantation or pack change for sinus node dysfunction or Atrioventricular (AV) block as part of standard of care will receive EndoPAT testing and collection of subcutaneous adipose tissue
89031533|NCT02951858|Experimental|Intervention Group|The medical staffs who received the training will use the manual of brief intervention to deliver it and other materials about the harm of substance use.
89595341|NCT03145168|Experimental|High Target Mean Arterial Pressure|
89595342|NCT03145168|Active Comparator|Low target Mean Arterial Pressure|
89595343|NCT05249140|Experimental|Active Repetitive Transcranial Magnetic Stimulation|rTMS parameters are intensity 110% resting motor threshold (RMT), frequency 1Hz, duration = 30 minutes (1800 stimulations), targeting the right DLPFC. To target the dorsolateral prefrontal cortex (DLPFC) for rTMS treatment we will use the traditional method (i.e. the 5cm rule; George et al., 1995, 1996; Herwig et al., 2001, 2003; MacMaster et al., 2019), in which the TMS coil is placed 5 cm anterior to the participant's motor cortex along a line to the nasion. Treatments will occur on weekdays at the same time of day for 4 weeks (20 total).
89595344|NCT05249140|Sham Comparator|Sham Repetitive Transcranial Magnetic Stimulation|For the sham rTMS group, a sham coil is used: this sham method does not emit any magnetic field, and therefor does not affect brain activity, but it does produce auditory sensations that is indistinguishable from active rTMS in naïve subjects
89595345|NCT05241808|No Intervention|Control|No-treatment group that only participates in pre- and post-testing.
89595346|NCT05241808|Experimental|Experimental|Experimental group participants will receive the 8-week Girls Can...Move! program.
89595347|NCT01609790|Experimental|Arm I (bevacizumab and trebananib)|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15 and trebananib IV over 30-60 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89595348|NCT01609790|Active Comparator|Arm II (bevacizumab and placebo)|Patients receive bevacizumab as in Arm I and placebo IV over 30-60 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may cross over to Arm I.
89595349|NCT01767116|Experimental|ABT-450/r/ABT-267 and ABT-333, Plus RBV|ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
89595350|NCT01767116|Experimental|ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV|ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily) for 12 weeks plus placebo RBV (twice daily) for 12 weeks
89595351|NCT01574703|Experimental|placebo|
89595352|NCT01574703|Experimental|varenicline|
89595353|NCT01574703|Experimental|bupropion|
89595354|NCT01574703|Experimental|Nicotine Replacement Therapy Patch|
89595355|NCT03028623|Other|Control|Tubal sterilization will be performed by standard tubal ligation, either Parkland or Pomeroy technique, at the time of cesarean section
89595356|NCT03028623|Experimental|Experimental|Tubal sterilization will be performed by bilateral salpingectomy using a ligasure device at the time of cesarean section.
89595357|NCT01686633|Experimental|Arm1: Fluticasone Furoate/ Vilanterol 200/25 mcg|At Visit 3, eligible subjects for randomization will be stratified according to their baseline FEV1 performed at Visit 3 (<=65% or >65%) and randomized to one of the three treatment arms. Subjects in this arm will receive FF/ VI 200/25 mcg once daily in the evening for 84 days.
89595358|NCT01686633|Experimental|Arm 2: Fluticasone Furoate/ Vilanterol 100/25 mcg|At Visit 3, eligible subjects for randomization will be stratified according to their baseline FEV1 performed at Visit 3 (<=65% or >65%) and randomized to one of the three treatment arms. Subjects in this arm will receive FF/ VI 100/25 mcg once daily in the evening for 84 days
89595359|NCT01686633|Experimental|Arm 3: Fluticasone Furoate 100 mcg|At Visit 3, eligible subjects for randomization will be stratified according to their baseline FEV1 performed at Visit 3 (<=65% or >65%) and randomized to one of the three treatment arms. Subjects in this arm will receive FF 100 mcg once daily in the evening for 84 days
89595360|NCT04413669|Experimental|white light bronchoscopy and autofluorescence bronchoscopy|White light bronchoscopy and autofluorescence bronchoscopy were carried out for people at high risk for lung cancer with heavy smoking (smoking history> 400 years).Biopsy was taken for abnormal bronchial mucosa.
89595361|NCT01685697|Active Comparator|Laerdal Mask|Mask ventilation with a Laerdal face mask
89595362|NCT01685697|Experimental|F&P Mask|Mask ventilation with a F&P face mask
89595363|NCT03028233|Experimental|Healthy Lifestyles|The study will test the impact of a community health worker (CHW)-delivered intervention aimed at helping families overcome barriers to childhood obesity prevention. Barriers include social, environmental, and family issues.
89595364|NCT03028233|Active Comparator|Positive Parenting|The control condition consists of a community health worker (CHW)-delivered intervention aimed at helping families improve positive parenting skills.
89595365|NCT02395120|Active Comparator|Standard letter|Modified standard letter will be sent to caregivers.
89595366|NCT02395120|Experimental|Intervention letter|The CSM-based referral letter alone will be sent to caregivers
89595367|NCT02395120|Experimental|Reduced intervention letter|"The reduced (removing text corresponding to timeline) CSM-based referral letter alone will be sent to caregivers."
89595368|NCT02395120|Experimental|Intervention letter+DIG|The CSM-based referral letter with the dental information guide will be sent to caregivers.
89595369|NCT02395120|Experimental|Reduced intervention letter+reduced DIG|The reduced CSM-based referral letter with the reduced dental information guide will be sent to caregivers.
88978440|NCT00401115|Experimental|1|Subconjunctival injection
89595370|NCT01685229||Balloon Sinus Dilation|Subjects with chronic sinusitis electing to have a balloon sinus dilation
89595371|NCT01685229||Medical Management|Subjects with chronic sinusitis electing to continue with medical therapy
89595372|NCT03141424|No Intervention|Group A|Usual care. Unchanged asthma medication during the entire study period.
89595373|NCT03141424|Experimental|Group B|Tapering of ICS over 8 weeks. Dosis reduction of 50% in ICS treatment for 8 weeks, followed by total ICS removal. Other inhaled asthma medication remains unchanged during the entire study period.
88978441|NCT00401115|Experimental|2|Intraocular injection
88978442|NCT00401154|Experimental|Intervention Stationary Cycling|Subjects receiving the intervention performed stationary cycling 3 times a week for 30 sessions over 12 weeks.
88978443|NCT00258076|Experimental|001|EVRA transdermal contraceptive patch 6 mg NGMN and 0.75 mg EE
89595374|NCT03028389|Experimental|Limb RIPC|The limb RIPC protocol was applied after anesthetic induction and before the start of surgery. The limb RIPC was induced by placing a blood pressure cuff on the left upper arm of patient for three inflating-deflating cycles: 5 min inflating to 200 mmHg followed by a 5 min reperfusion with deflating the cuff.
89595375|NCT03028389|No Intervention|Convention|Elderly patients undergoing non-cardiac surgery received no treatment after induction of anaesthesia
89595376|NCT03614494|Active Comparator|Piroxicam|Piroxicam 40 mg (in 2 tablets) + levonorgestrel 1.5 mg single oral dose
89595377|NCT03614494|Placebo Comparator|Placebo|Placebo (2 tablets) + levonorgestrel 1.5 mg single oral dose
89595378|NCT03028155|Active Comparator|Oxaliplatin: BSA-based HIPEC|Intervention: oxaliplatin: BSA-based HIPEC HIPEC will be performed using oxaliplatin as chemotherapeutic agent at a dose of 460 mg/m2 mixed in 0.9% saline carrier solution during 30 minutes. Volume of the carrier solution: depended on the capacity of the abdominal cavity of the patient.
89595379|NCT03028155|Active Comparator|Oxaliplatin: Concentration-based HIPEC|Intervention: oxaliplatin: concentration-based HIPEC HIPEC will be performed using oxaliplatin as chemotherapeutic agent at a dose of 460 mg/m2 mixed in 0.9% saline carrier solution at 2L/m2, which equals a concentration of 230 mg/L during 30 minutes.
89595380|NCT01551693|Experimental|STA-9090 Cohort A|Patients enrolled into two possible cohorts based on tumor expression of BRAF: Cohort A - BRAF mutant disease or Cohort B - BRAF wild type. Cohort A patients received STA-9090 200 mg/m2 once weekly (d1, 8, 15 of 28 day cycle). Patients were treated until evidence of disease progression, unacceptable toxicity, intercurrent illness or withdrawal.
89595381|NCT01551693|Experimental|STA-9090 Cohort B|Patients enrolled into two possible cohorts based on tumor expression of BRAF: Cohort A - BRAF mutant disease or Cohort B - BRAF wild type. Cohort B patients received STA-9090 150 mg/m2 twice weekly (d1, 4, 8, 11, 15, 18 of 28 day cycle). Patients were treated until evidence of disease progression, unacceptable toxicity, intercurrent illness or withdrawal.
89595382|NCT01922518|Active Comparator|Septal pacing group|Put RV pacing lead around the right ventricular septum and is adjusted with normal pacing axis
89595383|NCT01922518|Active Comparator|Apex pacing group|Put RV lead around the apex
89595384|NCT04276402|Experimental|Right side of the maxilla|
89595385|NCT04276402|No Intervention|Left side of the maxilla|
89595386|NCT01574157|Active Comparator|Sodium Bicarbonate|Participants were prescribed 0.5 meq of sodium bicarbonate per 1 kilogram of lean body weight daily for six months
89595387|NCT01574157|Placebo Comparator|Placebo|Participants were prescribed an identical number of placebo tablets had they been assigned to the intervention, and took this daily for six months.
89595388|NCT04276246|Experimental|Experimental|All included participants receive each side 1 posterior implant in the edentulous areas bilaterally in Kennedy class I. Participants are provided with a conventional clasp retained removable partial denture (RPD) worn for 3 months. When implant osseointegration is ensured (3 months healing period), patients are assigned to retentive components (Group A, Test) which are connected to the implants to retain the RPD
89595389|NCT04276246|Experimental|Control|All included participants receive each side 1 posterior implant in the edentulous areas bilaterally in Kennedy class I. Participants are provided with a conventional clasp retained removable partial denture (RPD) worn for 3 months. When implant osseointegration is ensured (3 months healing period), patients are assigned to supportive components (Group B, Control), which are connected to the implants to support the RPD
89595390|NCT05247892|Active Comparator|Fluoroscopic-guided S1 Radiofrequency stimulation|
89595391|NCT05247892|Experimental|Ultrasound-guided S1 Radiofrequency stimulation|
89595392|NCT05245708|Experimental|oxytocin|a single dose of 24 international units (IU) of OT will be administered with 3 puffs of treatment to each nostril.
89595393|NCT05245708|Experimental|placebo|a single dose of 24 international units (IU) of placebo will be administered with 3 puffs of treatment to each nostril.
89595394|NCT01574079|Active Comparator|Traditional Physical Therapy|The control group will receive traditional physical therapy interventions directed at neuromuscular rehabilitation.
89595395|NCT01574079|Experimental|Physical Therapy plus Mirror Therapy|The mirror therapy will entail 15 minutes of exercises for the lower extremities focusing on ankle dorsiflexion, knee flexion, and hip flexion.
89595396|NCT05249686|Experimental|Manual Therapy + Dry Needling|
89595397|NCT05249686|Active Comparator|Manual Therapy|
89595398|NCT05249686|No Intervention|Control|The control group received only the dentist´s usual advice after endodontic surgery.
89595399|NCT01922596|Experimental|Active FNB, placebo ACB|FNB with 30 ml of ropivacaine 0,2% and ACB with 30 ml of placebo (saline). The ACB will be performed just prior to the FNB. The blockades will be performed just after obtaining the baseline values (outcome measures) at time 0.
89595400|NCT01922596|Experimental|Active ACB, placebo FNB|ACB with 30 ml of ropivacaine 0,2% and FNB with 30 ml of placebo (saline.The ACB will be performed just prior to the FNB. The blockades will be performed just after obtaining the baseline values (outcome measures) at time 0.
89595401|NCT01573767|Active Comparator|Arm 1|Vilanterol 25mcg inhalation powder inhaled once daily in the PM via the new powder inhaler
89595402|NCT01573767|Active Comparator|Arm 2|Vilanterol 12.5mcg inhalation powder inhaled once daily in the PM via the new powder inhaler
88978444|NCT00258115|Active Comparator|salsalate|4.0 g/d divided dosing
89595403|NCT01573767|Active Comparator|Arm 3|Vilanterol 6.25mcg inhalation powder inhaled once daily in the PM via the new powder inhaler
89595404|NCT01573767|Placebo Comparator|Arm 4|Placebo inhalation powder inhaled once daily in the PM via the new powder inhaler
89595405|NCT04397068|Other|macular pucker wherefore vitrectomy|one eye phaco-vitrectomy and other eye only phaco. No other involvement of drug or device. Standard of care procedure
89595406|NCT04396678|No Intervention|PrEP Standard of Care|PrEP standard of care, administered through the Baltimore City Health Department
89595407|NCT04396678|Experimental|PrEP standard of care+behavioral intervention|PrEP standard of care, administered through the Baltimore City Health Department, and the behavioral intervention.
89595408|NCT03133546|Experimental|Osimertinib plus Bevacizumab|Patients will receive treatment with osimertinib and bevacizumab until disease progression, lack of tolerability or the patient declines further treatment. Treatment may also continue beyond progression for as long as the patient may still derive benefit.
89595409|NCT03133546|Active Comparator|Osimertinib alone|Patients will receive treatment with osimertinib until disease progression, lack of tolerability or the patient declines further treatment. Treatment may also continue beyond progression for as long as the patient may still derive benefit.
89595410|NCT01551303|Placebo Comparator|Placebo|Matched nasal spray placebo.
89595411|NCT01551303|Experimental|Oxytocin|Liquid intranasal oxytocin administered in a nasal spray.
89595412|NCT04545021||Cognitive Behavioral Stress Management (CBSM) - PC Survivor|Participant receives standard cognitive behavioral stress management from the Parent study NCT03344757.
89595413|NCT04545021||CBSM - PC Survivor Partner|The survivor partner does not receive any intervention.
89595414|NCT04545021||Cultural CBSM (C-CBSM) - PC Survivor|Participant receives culturally adapted cognitive behavioral stress management from the Parent study NCT03344757.
89595415|NCT04545021||Cultural CBSM (C-CBSM) - PC Survivor Partner|The survivor partner does not receive any intervention.
89595416|NCT00638404||1|Elective Cesarean Sections-this portion completed
89595417|NCT00638404||3|Any in-patient gynecologic procedure- this portion completed
89595418|NCT01550757|No Intervention|Arm 1|Normal PACT Clinical Care
89595419|NCT01550757|Experimental|Arm 2|Normal PACT Clinical Care + Embedded Peer Mentor
89595420|NCT01550757|No Intervention|Arm 3|Normal Homeless Oriented PACT Clinical Care
89595421|NCT01550757|Experimental|Arm 4|Normal Homeless Oriented PACT Clinical Care + Embedded Peer Mentor
89595422|NCT01685073|Experimental|Zolpidem|Participants receive active zolpidem nightly in addition to psychosocial therapy during 12-week treatment of a cannabis use disorder
89595423|NCT01685073|Placebo Comparator|Placebo|Participants receive placebo medication during a 12-week psychosocial treatment for a cannabis use disorder
89595424|NCT01922674|No Intervention|Watchful Waiting|Assess pain, physical function, and other outcomes in men with asymptomatic or minimally symptomatic inguinal hernia that do not have surgery
89595425|NCT01922674|Active Comparator|Standard open tension-free inguinal hernia repair with mesh|Assess pain, physical function, and other outcomes in men with asymptomatic or minimally symptomatic inguinal hernia that undergo a standard open tension-free repair with mesh.
89595426|NCT01922908|Active Comparator|MSC infusion|Allogeneic bone marrow derived mesenchymal stem cells given in one dose 3-10 days after stroke symptom onset
89595427|NCT01922908|Placebo Comparator|SHAM infusion|Infusion of normal saline placebo
89595428|NCT05240950|Experimental|MRD or positive ctDNA patients to inject anti-CEA CAR-T cells|Patients with liver metastasis of colorectal cancer after R0 surgery and adjuvant chemotherapy could not clear MRD (including patients with MRD still positive after the intermediate and final evaluation of adjuvant chemotherapy, and patients with MRD positive again after the end of adjuvant chemotherapy), and no measurable lesions or tumor remnants were found on imaging after surgery.
89595429|NCT05241574|Experimental|radiotherapy dose escalation|Additional two fractions of endorectal high dose rate iridium brachytherapy boost, 10 Gy each.
89595430|NCT05241574|Experimental|chemotherapy dose escalation|Additional three cycles of consolidation chemotherapy consisted of 5-fluorouracil, leucovorin and oxaliplatin (FOLFOX4).
88978445|NCT00258115|Placebo Comparator|placebo|placebo for salsalate
88978446|NCT00070811||Revision|Patients with repaired cleft lip who receive lip revision surgery
89031534|NCT02951858|Active Comparator|Control Group|The participants only receive the materials about the harm of substance use.
89595431|NCT01923142|Experimental|Outer-Root-Sheath Melanocytes Suspension|This arm includes all patients sides (left or right) treated with autologous outer-root-sheath melanocytes suspension followed by targeted UVB phototherapy
89595432|NCT01923142|Placebo Comparator|Placebo|This arm includes all patients sides (left or right) treated with placebo followed by targeted UVB phototherapy
89595433|NCT05241028|Experimental|Ensartinib|Ensartinib 225mg oral daily for 3 years or until recurrence of the disease or intolerable toxicity
89595434|NCT01572909|Active Comparator|Bendavia™|Bendavia™ administered intravenously at 0.05 mg/kg/hr at least 15, but no more than 60 minutes, prior to the anticipated time of the PCI, and continued for 1 hour after re-establishment of blood flow through the culprit vessel.
89595435|NCT01572909|Placebo Comparator|Placebo|Placebo administered intravenously at 60 mL/hr at least 15, but no more than 60 minutes, prior to the anticipated time of the PCI, and continued for 1 hour after re-establishment of blood flow through the culprit vessel.
89595436|NCT01572675||Group Arcoxia®|Participants who were either previously treated with Arcoxia® or initiated on study treatment with Arcoxia®. Participant data in terms of dosage, treatment duration, and reasons for prescription was collected under actual conditions of use.
89595437|NCT01572675||Group Celebrex®|Participants who were either previously treated with Celebrex® or initiated on study treatment with Celebrex®. Participant data in terms of dosage, treatment duration, and reasons for prescription was collected under actual conditions of use.
89595438|NCT05929950||patients with PCOS|
89595439|NCT05929950||control group|
89595440|NCT05929937|Other|Minimal Opioids|Standard of care 5 tablets of Oxycodone (5mg) every 6 hours as needed for pain
89595441|NCT05929937|Other|No opioids|Standard of care
89595442|NCT05929924|No Intervention|Control|This group will not receive intervention
89595443|NCT05929924|Active Comparator|Extra-virgin olive oil|This group will receive extra-virgin olive oil (EVOO) as intervention
89595444|NCT05929872|Experimental|Experimental group|The experimental group receives strategic memory training plus non-invasive brain stimulation (ACTIVE tDCS).
89595445|NCT05929872|Sham Comparator|Control Group|The control group receives strategic memory training plus sham non-invasive brain stimulation (SHAM tDCS).
89595446|NCT05929755|Placebo Comparator|Control group (standard care)|1 cc gel foam powder mixed with thrombin
89595447|NCT05929755|Experimental|Test group (standard care + study intervention)|1 cc of gel foam powder mixed with thrombin and 80mg Depo-Medrol
89595448|NCT05929690|Experimental|Standard care plus self-acupuncture|Participants randomised to the self-acupuncture arm will be asked to attend a group workshop. All participants will be taught to safely apply acupuncture bilaterally using traditional acupuncture needles to the acupuncture point Stomach 36. If deemed to be clinically appropriate by the acupuncturists, and if patients are willing and able, they will also be taught how to safely needle the acupuncture points Spleen 6 and/or Liver 3 (maximum of six points in total). Participants will be asked to needle the points 2-3 times a week throughout their cancer treatment and for 3 months post treatment.
89595449|NCT05929690|No Intervention|Standard care|Chemotherapy patients allocated to standard care will receive no additional treatments. 'Standard care' for all patients will be consistent with current best practice.
88978447|NCT00070811||Non-Revision|Patients with repaired cleft lip who do not have lip revision surgery
88978448|NCT00070811||Non-cleft|Non-cleft 'control' subjects.
88978449|NCT00101088|Experimental|Treatment (imatinib mesylate, temsirolimus)|Patients receive temsirolimus IV over 30 minutes once on days 1, 8, 15, and 22 and oral imatinib mesylate once daily on days 1-28. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression
89595450|NCT05929638|Experimental|Experimental|Lavender oil in 15 ml opaque dark colored bottles closed with metal caps to prevent volatility to the venture group and 40 2×2 cotton pads were delivered. Patients were asked to apply lavender oil 30 minutes before going to bed. Deep breathing increases the concentration of aromatic substances in the body. The time it takes for essential oils to be absorbed into the blood circulatory system is about 30 minutes for complete absorption by the body. Information was given about dripping 3 drops of lavender oil on cotton pads and placing them 15-20 cm away from the pillow. Patients were told that they should apply lavender oil for 30 days and re-prepare the lavender oil dripped onto a new pad each night, and that the bedroom should be ventilated and free of different odors. A message was sent to the patients to remind them of the application on their phones for 30 days.
89595451|NCT05929638|No Intervention|Control|No intervention will be applied to the control group.
89595452|NCT05929625|Experimental|RF+US group|Subjects will be treated with the subject device using both, radiofrequency and ultrasound energies simultaneously with regular treatment settings.
89595453|NCT05929625|Experimental|RF only group|Subjects will be treated with the subject device using only radiofrequency energy with regular treatment settings.
89595454|NCT05929586|No Intervention|"Digital data linkage and scheduling ('C-it'): The C-it enhanced standard of care"|Linking facility to community digital data via linkage-app: Data between electronic Community Health Information System (eCHIS) and facility-based Kenya Electronic Medical Record (Kenya EMR) do not link. We do not have an existing digital data linkage module or app to track successful pregnancy referrals or allow the facility staff to view community contacts and vice versa. We will engage with national and county teams and software developers to build a digital data linkage module, linking eCHIS and Kenya EMR Maternal and Child Health (MCH) module.
89595455|NCT05929586|Experimental|"The combined C-it DU-it intervention: community data use for ANC"|"Combining C-it and work improvement teams (WITs) for community data use: We will establish and train integrated WITs in intervention sites consisting of community health members, health facility staff and community members and train them on how they will use linkage-app. The resultant combined C-it DU-it intervention has three building blocks:~We make the following assumptions about the building blocks at the bottom of figure 1.~Building block 1: We assume that high-quality digital data that can trace the entire journey through pregnancy is accessible to CHVs~Building block 2: We also assume that integrated work improvement teams (WITs) will have the right people around the table with clearly defined roles and responsibilities will use the data.~Building block 3: Community ANC contacts will be implemented."
89595456|NCT05929560|Active Comparator|Conventional impression|
89595457|NCT05929560|Experimental|Digital impression|
89595458|NCT05929521|Active Comparator|PrEP Usual Care|Sex Workers engaged in PrEP Usual Care
89595459|NCT05929521|Experimental|C-PrEP+|Sex Workers engaged in group PrEP care.
89595460|NCT05929508|Active Comparator|Ischemic Preconditioning at High Pressure|In this arm, the participant will receive ischemic preconditioning (a blood pressure cuff on the intact limb) inflated to 225mmHg for 5 minutes followed by 5 minutes of reperfusion on a cycle for a total of 50 minutes. This will be completed every other day for 7 session (14 days).
89595461|NCT05929508|Sham Comparator|Ischemic Preconditioning at Low Pressure|In this arm, the participant will receive ischemic preconditioning (a blood pressure cuff on the intact limb) inflated to 25mmHg for 5 minutes followed by 5 minutes of reperfusion on a cycle for a total of 50 minutes. This will be completed every other day for 7 session (14 days).
89595462|NCT05929456|Experimental|Glioblastoma group|This study will consist of 1 group and therefore 1 arm
89595463|NCT05929443|Experimental|END-IT intervention for nursing homes|This complex intervention, implemented at the level of the nursing home, encompasses process and goals setting, education for healthcare providers, environmental adaptations, audit and feedback on benzodiazepine use, use of an educational leaflet for residents and relatives, and multidisciplinary work.
89595464|NCT05929443|No Intervention|Control|Usual care. Nursing homes allocated to this study arm will access intervention material at the end of the study.
89595465|NCT05929417|Experimental|END-IT intervention for the community setting|The community pharmacist will distribute an educational brochure to the patient. He will also propose to the patient to communicate about a potential benzodiazepine deprescribing with his/her general practitioner through a document called pharmaceutical proposal.
89595466|NCT05929417|No Intervention|Control|The participants will receive the usual care. The community pharmacists allocated to the control group will have access to the intervention material at the end of the study.
89595467|NCT05929339|Experimental|Intravenous Oxytocin|Two 30 minute infusion of oxytocin, 17 micrograms with will be administered. The second infusion will be given 30 minutes after the completion of the first infusion.
89595468|NCT05929313|Experimental|OrbusNeich Scoreflex TRIO|OrbusNeich Scoreflex TRIO Scoring PTCA catheters
89595469|NCT05929313|Active Comparator|OrbusNeich Scoreflex NC|OrbusNeich Scoreflex NC Scoring PTCA catheters
89595470|NCT05929248|Experimental|Treatment group|conventional treatment plus Telitacicept 160 mg sc per week
89595471|NCT05929248|Placebo Comparator|Control group|Placebo plus conventional treatment
89595472|NCT05929209|Experimental|Assessment of disease biomarkers|
89595473|NCT05929144|Other|Healthy volunteers|
89595474|NCT05929118|Experimental|Aquatic Rehabilitation|Each group performed 70-90 minutes per session for a total of 6 interventions, all of which included warm-up activities, mobility training, strength training, functional exercise, and finishing activities. Each training was conducted 1-2 days apart, 2-3 times per week, and the training was completed within 2-3 weeks.
89595475|NCT05929118|Experimental|Land-based Rehabilitation|Each group performed 70-90 minutes per session for a total of 6 interventions, all of which included warm-up activities, mobility training, strength training, functional exercise, and finishing activities. Each training was conducted 1-2 days apart, 2-3 times per week, and the training was completed within 2-3 weeks.
89595476|NCT05929105||observation group|
89595477|NCT05929105||control group|
89595478|NCT05929053|Experimental|Experimental|Experiment: The Vaccine Education Program based on The Integrated Change Model will be administered to the mothers in the experimental group by the researcher. The training will take place in four sessions, one week apart, and each session will last approximately 45 minutes. The training will be carried out as group training with 4-5 people. Data collection forms will be applied before and after the program.
89595479|NCT05929053|Other|Control-waiting list|Control (waiting list): The control group of the study will be the mothers who are on the waiting list. No intervention will be made to the mothers in the control group during the education process of the experimental group. After the training process of the mothers in the experimental group is completed and the post-test data are collected, all the interventions and training will be given to the mothers in the control group.
89595480|NCT05929040|Experimental|Immediate group|"Randomized controlled waitlist study~Behavioral: Mindfulness based cognitive intervention based on the behavioural change techniques taxonomy~An online mindful cognitive intervention is used as a proposed treatment intervention for chemsex among men ho have sex with men in the United Kingdom."
89595481|NCT05929040|Other|Delayed group|"Randomized controlled waitlist study~Behavioral: Mindfulness based cognitive intervention based on the behavioural change techniques taxonomy~An online mindful cognitive intervention is used as a proposed treatment intervention for chemsex among men who have sex with men in the United Kingdom."
88978450|NCT00258661|Experimental|Osteopathic Manipulative Treatment|10-minute standardized OMT protocol + 5-minute nonstandardized component, twice daily for duration of hospitalization
88978451|NCT00258661|Sham Comparator|Light-touch Treatment|10-minute standardized light-touch protocol (designed to mimic OMT standardized protocol) + 5-minute auscultation of carotid bruits, heart, and lungs, twice daily for duration of hospitalization
88978452|NCT00258661|No Intervention|Conventional Care Only|No intervention specific to the research study provided. Only conventional treatment as per attending physician orders.
88978453|NCT00104910|Experimental|Treatment (brachytherapy, radiation, cetuximab, cisplatin)|Patients receive cetuximab IV over 1-2 hours and cisplatin IV on days 1, 8, 15, 22, 29, and 36 (weeks 1-6). Patients also undergo external beam radiotherapy to the para-aortic and pelvic lymph nodes OR whole pelvis once daily on days 1-5, 8-12, 15-19, 22-26, and 29-33 (weeks 1-5). Patients then receive either 1 or 2 applications of low-dose rate brachytherapy in weeks 6-8 OR 5 applications of high-dose rate (HDR)* brachytherapy once weekly in weeks 4-8. Treatment continues in the absence of disease progression or unacceptable toxicity.
88978454|NCT00415324|Experimental|Arm 1|Patients receive eribulin mesylate IV over 5 minutes on days 1, 8, and 15 and cisplatin IV over 30-60 minutes on day 1.
88978455|NCT00258739|Experimental|1|Concomitant radiotherapy and carboplatin-docetaxel followed by docetaxel-gemcitabine
88978456|NCT00258739|Experimental|2|docetaxel-gemcitabine followed by concomitant radiotherapy with carboplatin-docetaxel
88978457|NCT04709068||COVID19+|
88978458|NCT00258934|Experimental|1|
88978459|NCT00258934|Active Comparator|2|
88978460|NCT00259129|Experimental|Arm 1|
88978461|NCT00259207|Active Comparator|classic surgery|classic surgery
88978462|NCT00259207|Experimental|medical surgery hybride|medical surgery hybride
88978463|NCT00259324|Experimental|1|Diet and Activity
88978464|NCT00259324|Experimental|2|Diet and Activity
88978465|NCT00259324|Placebo Comparator|3|Education
88978466|NCT00104988|Experimental|Thalidomide and Temozolomide|Patients receive oral thalidomide once daily on days 1-56 and temozolomide once daily on days 1-42. Courses repeat every 56 days in the absence of disease progression or unacceptable toxicity.
88978467|NCT00415402|Placebo Comparator|placebo|non vitamin D containing sugar granules
88978468|NCT00415402|Experimental|Vitamin D3|vitamin D granules
88978469|NCT00415441|Experimental|Active physiotherapy|Manual therapy and home exercise program
88978470|NCT00415441|Placebo Comparator|Placebo physiotherapy|Manual therapy and home exercise program
88978471|NCT00259402|Experimental|Oxaliplatin|
88978472|NCT00400842|Experimental|L|
88978473|NCT00400842|Experimental|H|
88978474|NCT00400842|Placebo Comparator|P|
88978475|NCT00259519|No Intervention|1|Expectant management
88978476|NCT00259519|Active Comparator|2|Induction of delivery
88978477|NCT00259714|Active Comparator|standard dialysate sodium|In the control phase of the study, the prescribed dialysate sodium is 140 mEq/L
88978478|NCT00259714|Experimental|dialysate sodium individualization|".Dialysate sodium level prescribed matches the subject's average pre-dialysis serum sodium (individualized)."
88978479|NCT00071240|Experimental|Growth Hormone Arm|Growth hormone receipt in the first year, post-growth hormone follow-up in the second year
88978480|NCT00071240|Active Comparator|2|Observation only in the 1st year, GH receipt in the second year
88978481|NCT00259753|Experimental|1|0.2 mg/eye
88978482|NCT00259753|Experimental|2|1.5 mg/eye
88978483|NCT00259753|Experimental|3|3.0 mg/eye
88978484|NCT00105144|Experimental|1|lower dose
88978485|NCT00105144|Experimental|2|higher dose
88978486|NCT00105144|Active Comparator|3|
88978487|NCT02966405||Healthy pregnant women|A descriptive analysis involving 300 healthy pregnant women according NACB to the establish of trimester-specific reference ranges for thyroid tests in pregnant women.
88978488|NCT02966405||Normal pregnant population|According to the selection criteria, 700 cases were selected as the normal pregnant population to establish a self-sequential longitudinal reference range. The aim of this study to monitor the change of thyroid function and antibody during the course of pregnancy in those who suffer from various thyroid disorders and normal control.
88978489|NCT00259909||Subjects with COPD|Subject has a confirmed clinical diagnosis of COPD, with or without chronic bronchitis.
88978490|NCT00260143|Experimental|Testosterone enanthate|300 mg of testosterone enanthate by intramuscular injection once weekly for 16 weeks
88978491|NCT00260143|Placebo Comparator|Placebo|Placebo (sesame oil) by intramuscular injection once weekly for 16 weeks
88978492|NCT00260221|Experimental|1|Arm one uses Virtual Reality Hypnosis post hypnotic suggestions to reduce pain durng wound care procedures.
88978493|NCT00260221|Experimental|2|Arm two uses Virtual Reality distraction that is administered at times other than during burn care procedure to control for both for attention and high technology.
88978494|NCT00260221|Experimental|3|Arm three use Audio administered Hypnosis without the visual technology.
89595482|NCT05929014|Active Comparator|Active bilateral-tDCS|Participants will be received different intensities which are 1 mA, 1.5 mA and 2 mA for 20 minutes during performed serial reaction time task. The tDCS will be set with bilateral montage which applied anodal electrode over left hemisphere and cathodal electrode over right hemisphere.
89031535|NCT00529971|Experimental|1|Participants in the first arm participate in an 8-week MBSR group
89595483|NCT05929014|Sham Comparator|Sham bilateral-tDCS|Participants will be received sham of bilateral tDCS during performed serial reaction time task.
89595484|NCT05929014|Active Comparator|Active cathodal-tDCS|Participants will be received different intensities which are 1 mA, 1.5 mA and 2 mA for 20 minutes during performed serial reaction time task. The tDCS will be set with cathodal montage which applied cathodal electrode over left hemisphere and anodal over right orbit.
89595485|NCT05929014|Sham Comparator|Sham cathodal-tDCS|Participants will be received sham of cathodal tDCS during performed serial reaction time task.
89595486|NCT05929001||Lymphedema Risk Group|"Participants in this group will:~Completed questionnaires about daily function and mood,~Undergo arm circumference measurement conducted by medical staff, and~Undergo Lymphedema Index Test (L-DEX) or measurement of tissue water content, conducted standard of care.~Total expected participation is about six months."
89595487|NCT05928988|Experimental|SHR8554 and itraconazole|"SHR8554 will be provided in a solution. Participants will receive 1 mg SHR8554 by intravenous pump on Day 1 and Day 9.~Itraconazole capsules 200 mg orally after meals twice daily for 7 days from Day 4 to Day 10."
89595488|NCT05928975|Experimental|MT+ PNE with MI|Participants allocated to this group will receive 10 sessions of MT, along with 4 sessions of PNE with MI, over a period of four weeks.
89595489|NCT05928975|Experimental|MT|Participants allocated to this group will receive 10 sessions of MT (without PNE with MI), over a period of four weeks.
89595490|NCT05928975|Active Comparator|Control|Participants allocated to this group will engage in a home-based general exercise program.
89595491|NCT05928949|Active Comparator|conventional physical therapy|Group A performed flexibility, strength, and endurance exercises that focused on the lower extremity and trunk muscles, exercise for postural stability in various positions and surfaces, including flexibility exercises for the hip, knee and calf muscle. Strengthening exercises included the core muscles, hip abductors, hip extensors hamstrings and quadriceps knee extension in high sitting. Postural control involved walking in all directions, exceeding the limits of stability in various positions such as kneeling, half kneeling, standing on rough and soft surfaces, Each session started with a warming up and cooling down of 5 minutes for each period and each session lasted for 45 minutes.
89595492|NCT05928949|Experimental|pilates exercises|group B received the same program of exercises given to group A in addition to 45 minutes of Pilates exercises to improve balance and gross motor coordination. Exercises were performed on a mat, a medical ball, and from a standing position, focusing on maintaining core contraction, spinal and pelvic alignment, and respiration rhythm. Ten repetitions of Pilates exercises will be performed with a 2-minute rest period between repetitions. Both groups will attend the intervention program three times/week for 3 months
89595493|NCT05928936|Experimental|Exercise Training plus Sodium Bicarbonate|Participants with CKD will undergo exercise training for 20-45 minutes, 3 times per week, for 12 weeks. Additionally, participants take 650-1300 mg of sodium bicarbonate twice daily.
89595494|NCT05928936|Active Comparator|Exercise Training plus Placebo|Participants with CKD will undergo exercise training for 20-45 minutes, 3 times per week, for 12 weeks. Additionally, participants take placebo tablets to match 650-1300 mg of sodium bicarbonate twice daily.
89595495|NCT05928936|No Intervention|Healthy control|Baseline measurements in healthy participants without CKD will be measured and compared to participants with CKD. Healthy controls will not receive any interventions.
89595496|NCT05928819||Gastric lesion diagnostic|Every patient referred to our center for upper gastrointestinal endoscopy for investigation and/or resection of gastric neoplastic lesion can join the cohort of this study and will benefit from diagnosis and treatment by experienced endoscopists.
89595497|NCT05928780|Experimental|LAR|Coelomofacial androgen receptor
89595498|NCT05928780|Experimental|IM|Immunoregulatory type
89595499|NCT05928780|Experimental|BLIS|Basal type and immunosuppressive type
89595500|NCT05928780|Experimental|MES|Interstitial type
89595501|NCT05928754|Experimental|Uveitis Patients|"Uveitis Patients: intermediate, posterior or panuveitis noninfectious uveitis with Inflammatory activity requiring treatment with either one or more of the following:~Systemic corticosteroids or periocular or intravitreal injections of corticosteroids~Immunosuppressants: methotrexate, azathioprine, ciclosporine….~Biotherapy: infliximab, adalimumab, tocilizumab"
88978495|NCT00260338|Active Comparator|Mesenchymal stromal cell|Mesenchymal stromal cell
88978496|NCT00260494|Experimental|acupuncture|acupuncture to lower extremity postoperatively
88978497|NCT00260494|Sham Comparator|sham acupuncture|sham acupuncture at same sites.
88978498|NCT00260494|No Intervention|control|no acupuncture, otherwise the same care and measurements
88978499|NCT00260611|Experimental|Oxaliplatin and Taxotere|Patients will receive both docetaxel and oxaliplatin, IV on day 1 of each cycle. Treatment will be repeated every 21 days for up to 6 courses in the absence of disease progression, unacceptable toxicity, or >50% increase in serum PSA.
88978500|NCT00260650|Experimental|Heart PACT Program|Heart PACT Program - patient activation intervention
88978501|NCT00260650|No Intervention|Usual Care|Usual Care
88978502|NCT00260728|Experimental|Arm 1|
88978503|NCT00260806||1|Children perinatally infected with HIV with exposure to highly active anti-retroviral therapy (HAART).
88978504|NCT00260806||2|Children with perinatally acquired HIV infection enrolled on the P2C2 Study, not exposed to HAART therapy.
88978505|NCT00101205|Experimental|Arm I|Patients receive oxaliplatin IV over 2 hours on day 1 and etoposide IV over 1 hour on days 1-3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
88978506|NCT00105339||Illustration Style Preference Group|Ten participants at each site will be invited to attend a focus group to determine their comfort with and preference for one of four styles of illustration. The same two concepts will be presented in each of the four styles and ratings will be obtained from all participants. Detailed information on why participants rated each of the styles the way they did will also be obtained by reviewing comments on the rating sheets and audiotapes of the groups. Groups will be run by the study coordinator at the Florida and New York sites, and by Dannie Hoffman, protocol coordinator, in Los Angeles, using a focus group script developed by Dr. Murphy.
89595502|NCT05928754|Active Comparator|Control Patients|scheduled for cataract or vitreoretinal surgery
89595503|NCT05928715|Experimental|Experimental group|It is the group that will receive breast milk or formula by finger feeding.
89595504|NCT05928715|No Intervention|Control group|No Intervention: control group attempt will not be implemented
89595505|NCT05928702|Experimental|Armbath|"The armbath group will perform a temperature-elevating armbath developed by Hauffe and Schwenninger. A large bowl and a thermometer will be given to each participant.~Participant start with bathing their forearms up to about one third of the upper arm in a large bowl with water at approximately 37°C. Within 30min, they are advised to add hot water to the bowl for multiple times until a temperature of 42°C. After 30min, the arms can be taken out of the water, dried, and participants are recommended to rest for additional 30 min afterwards.~Prior medication should be continued throughout the whole trial."
89595506|NCT05928702|No Intervention|Waitlist|Participants will continue their treatment as usual (e.g. medication). After the end of the trial (6 months) they will be offered to get instructed on performing temperature-elevating armbaths.
89595507|NCT05928533|Active Comparator|Scotchbond Etchant gel ,Single Bond Universal adhesive , Filtek Supreme flowable composite of 3M|After cavity preparation, enamel and dentin will be etched for 15 seconds using Scotchbond Universal Etchant gel 3M. The surface will be rinsed for 10 seconds and dried with compressed air, removing all excess moisture without desiccating the dentin structure then apply two coats of Single Bond Universal adhesive 3M with a micro brush with rubbing action for 20 seconds then evaporate the solvent with gentle air stream until no movement is noticed in the adhesive then finally light cured for 10 seconds. A Filtek Supreme 3M flowable composite will be used to restore the prepared cavity after selecting the appropriate shade. The shade selection for the flowable composite will be done before the cavity preparation. The flowable composite will be applied in increments of 2mm thickness then light cured for 40 seconds using LED light curing unit.
89595508|NCT05928533|Experimental|clean and boost enamel cleanser, RE GEN universal adhesive & flowable composite of vista apex.|After cavity preparation, clean and boost enamel cleanser of vista apex will be used to clean enamel and dentin surface by three steps: 1. With the enclosed flow-thru brush tip, apply Clean & Boost to the surface to be cleansed, ensuring the surface is completely saturated. 2. Using the delivery brush tip, agitate the Clean & Boost on the surface for 10 seconds. 3. Rinse thoroughly. The RE GEN universal adhesive from vista apex will be applied with micro brush with rubbing action then air agitation. RE GEN Bio active flowable composite form vista apex will be added to the universal adhesive and then cured together for 20 seconds according to the manufacture instructions.
89595509|NCT05928507||Adult Category 1 -fresh prospective|NP swabs from the Adult population >17 years, collected prospectively from adults presenting with symptoms of respiratory illness. Tested within 72 hours of collection.
89595510|NCT05928507||Pediatric Category 1 -fresh prospective|P swabs from the pediatric population <=17 years, collected prospectively from pediatrics presenting with symptoms of respiratory illness. Tested within 72 hours of collection.
89595511|NCT05928507||Adult Category 2 -frozen prospective|NP swabs from the Adult population >17 years, were collected prospectively from adults presenting with symptoms of respiratory illness. Frozen following CLSI guidelines to be Tested at a later time point approximately 3 months.
89595512|NCT05928507||Pediatric Category 2 -frozen prospective|NP swabs from the pediatric population >17 years, were collected prospectively from pediatrics presenting with symptoms of respiratory illness. Frozen following CLSI guidelines to be tested at a later time point approximately 3 months.
89595513|NCT05928481|Experimental|İntervention group (n:39)|Postpartum hemorrhage management practices were applied to the students in the intervention group on a high-reality Gaumard Scientific brand, product code: S550.100 Noella simulator in the simulation laboratory of the Midwifery department.
89595514|NCT05928481|No Intervention|Control group (n:39)|Postpartum hemorrhage management practices were applied to the students in the control group on a standard adult patient model in the basic skills laboratory.
89595515|NCT05928468|Experimental|LYB002V14|The vaccine LYB002V14 was administered through intramuscular injection.
89595516|NCT05928468|Active Comparator|LYB002V14A|The vaccine LYB002V14A was administered through intramuscular injection.
89595517|NCT05928468|Active Comparator|LYB002CA|The vaccine LYB002CA was administered through intramuscular injection.
89595518|NCT05928455|Experimental|LYB001|Participants receiving a boost with 30ug or 60ug LYB001 after a two-or three-dose primary series of inactivated COVID-19 vaccine.
89595519|NCT05928455|Active Comparator|CoronaVac|Participants receiving a boost with vaccine CoronaVac after a two-or three-dose primary series of inactivated COVID-19 vaccine.
89595520|NCT05928442||"Endometriosis patients"|"Patient with a formal endometriosis diagnosed by clinical examination and imaging.~At least 20 patients"
89595521|NCT05928442||"Discordants patients"|"Patient with suspected endometriosis for whom the diagnosis is the source of a discrepancy between clinical examination and imaging data, AND a surgical indication.~At least 20 patients"
89595522|NCT05928442||"Surgery patients"|"Patient with a gynaecological indication for surgery of the small pelvis AND symptoms suggestive of endometriosis.~At least 20 patients"
89595523|NCT05928429|Experimental|arm A - interventional|Each patient in the experimental arm will wear glycerine-containing Elasto-Gel™ gloves and socks (Elasto-Gel™ mitts for hands: TM7008, and slippers for feet: SL3000; Southwest Technologies, Inc., North Kansas City, MO, USA) over a disposable glove and sock liner secured by Velcro at the wrist and ankle on their hands and feet from 15 minutes before paclitaxel administration to 15 minutes after the infusion is complete (90 minutes in total).
89595524|NCT05928429|No Intervention|arm B|Patients will receive planned paclitaxel chemotherapy without cryotherapy intervention.
89595525|NCT05928364|Experimental|Buccal mucosa graft for ureteral stricture|Patients with inclusion criteria of ureteral stricture will be treated with open ureteroplasty with buccal graft and omental wrapping.
89595526|NCT05928338|Experimental|Peer-supported, WhatsApp assisted lifestyle modification intervention|Study participants with BMI 23 kg/m2 and above was provided with a lifestyle modification intervention supported by peers for modifying their diet and increase physical activity to reduce weight
89595527|NCT05928299||Durable Clinical Benefit|PFS≥ 6 months
89595528|NCT05928299||Non-durable Clinical Benefit|PFS< 6 months
89595529|NCT05928286||The test group|Standard therapy + Remaxol
89595530|NCT05928286||The control group|Standard therapy
89031536|NCT00529971|Active Comparator|2|Participants assigned to the control arm do not receive the MBSR program but may or may not be receiving current psychotherapy or counselling
89031537|NCT02951741||RTHRA group|patients undergoing revision total hip replacement
89031538|NCT00530127|Placebo Comparator|A|Placebo solution
89031539|NCT00530127|Experimental|B|Deferiprone oral solution 20 mg/kg/day
89595531|NCT05928273|Experimental|Corheart 6 LVAS|Corheart 6 Left Ventricular Assist System (Corheart 6 LVAS) to be used on patients with advanced refractory heart failure.
89595532|NCT05928247|Experimental|Functional Analysis Treatment for Harmful Challenging Behavior|If challenging behavior is found to be socially maintained, we will recommend functional communication training (FCT) to teach a functional communication response (FCR) (e.g., touching a card with a picture of the participant consuming the reinforcer), but we will also offer NCR as a potential treatment option to the caregivers. During FCT, reinforcement will be discontinued for challenging behavior and only the alternative communication response will be reinforced. If the parents choose NCR over FCT for socially maintained challenging behavior, we will deliver the functional and competing reinforcers on time-based schedules. If challenging behavior is found to be automatically maintained, we will recommend using NCR with competing items and response blocking for treatment. We will use multiple and chained schedules to thin the reinforcement schedules and increase the practicality of these treatments.
89595533|NCT05928247|Experimental|Functional Analysis Treatment for Milder Challenging Behavior|Caregivers of patients with mild challenging behavior will receive training using the Research Units in Behavioral Intervention (RUBI) protocol informed by the functional analysis conducted as a part of the initial assessment (Bearss et al., 2018). The RUBI protocol includes 11 core modules and 7 optional modules on training caregivers to apply behavior-analytic techniques to help manage challenging behaviors.
89595534|NCT05928156|Experimental|Myeloma Coach or CLL Coach Mobile App|"Participants diagnosed with Multiple Myeloma will use the Myeloma Coach app and participants diagnosed with CLL (chronic lymphocytic leukemia) will use the the CLL Coach app. Pattern Health apps are built around patterns of scheduled activities. Users will encounter a list of activities to engage with for the day. There is also an option to complete activities in an ad hoc fashion."
89595535|NCT05928156|Placebo Comparator|Springboard Beyond Cancer informational website|
89595536|NCT05928143|Active Comparator|Traditional corticotomy|In this group, the acceleration procedure will be performed by elevating flaps and doing the surgical intervention directly using surgical burs.
89595537|NCT05928143|Experimental|Flapless corticotomy|In this group, the acceleration procedure will be performed without elevating flaps, and the surgical intervention will be performed using a special device.
89595538|NCT05928065||Children with low kinetic, non-deforming, non-open long bone trauma|"Children with low kinetic, non-deforming, non-open long bone trauma will be included.~Collection of datas of medical record."
89595539|NCT05928052|Experimental|ARDS cohort|Patient diagnosed with ARDS. Treated daily for 60 minutes with transcutaneous cervical and/or thoracic spinal stimulation
89595540|NCT05928052|Experimental|Surgery Cohort (Active)|Patient undergoing inpatient non-cardiac surgery admitted to the intensive care unit (ICU) after surgery. Treated daily for 60 minutes with transcutaneous cervical and/or thoracic spinal stimulation
89595541|NCT05928000||BLV-treated patients|All patients treated with daily Bulevirtide (BLV) subcutaneous injections of 2 mg, with or without concomitant use of a nucleos(t)ide analogue. Patients with concomitant use of pegylated interferon-alfa can be included.
89595542|NCT05927974||ICM Patients|Epillipsey Patients undergoing routine intracranial EEG monitoring for epilepsy.
89595543|NCT05927961||aldosterone-producing adenoma|Histopathology shows a clear boundary between adrenal adenoma and surrounding normal tissue.
89595544|NCT05927961||unilateral hyperplasia|Histopathology shows no clear boundary between adrenal hyperplasia and surrounding normal tissues.
89595545|NCT05927948|Experimental|Intervention|This is a split body study. The patients will serve as their own control. The side that receives Laight therapy will be randomized. For example, if the patient receives Laight therapy on the right, then the control will be the left.
89595546|NCT05927948|No Intervention|Control|This is a split body study. The patients will serve as their own control. The control side of the body will be randomized. For example, if the patient receives Laight therapy on the right, then the control will be the left.
89595547|NCT05927233|Experimental|Group M|IV Methylprednisolone
89595548|NCT05927233|Placebo Comparator|Group P|IV Normal Saline
89595549|NCT05925725|Active Comparator|Loxacon and Physical Therapy|physical therapy(exercise) + caps Loxacon
89595550|NCT05925725|Placebo Comparator|Physical therapy and Placebo Loxacon caps|Physical therapy + Placebo caps Loxacon
89595551|NCT05925725|Active Comparator|Pphysical therapy(alone)|Physical therapy
89031540|NCT00530127|Experimental|C|Deferiprone oral solution 40 mg/kg/day
89031541|NCT00530127|Placebo Comparator|D|Placebo solution
89031542|NCT00530127|Experimental|E|deferiprone oral solution 60 mg/kg/day
89031543|NCT02276976||cerebral white matter lesions|patients with MRI confirmed cerebral white matter lesions
89031544|NCT02276976||healthy volunteers|healthy volunteers 1:1 matched by age,sex and education years
89031545|NCT02951936|Experimental|NiCAS treated|"Measure each patient with the NiCAS once a day If Cardiac Index < 2.9 +Total Peripheral resistance Index >3000+Mean arterial pressure >70mmHG then add vasodilators.~If Heart Rate<60 consider to reduce beta blockers dose If Cardiac Index>4.2 and Mean arterial pressure 70-100mmHG and HR >100 then add Bata Blockers If patient have low Total Body Water then reduce diuretics If patient have High Total Body Water provide diuretics"
89031546|NCT02951936|Sham Comparator|Non NiCAS treated|Measure each patient with the NiCAS once a day Do note use the NiCAS parameters to direct treatment
89031547|NCT00513851|Experimental|1|Once Daily Dosing
89031548|NCT00513851|Experimental|2|Twice Daily Dosing
89031549|NCT02944266||Hypovolemia group|Those patients who are said to be positive for one or more of the following TTE criteria are grouped under this , them being i.IVC diameter of less than 1 cm , ii.Caval index of > 50%, iii.Left ventricular end diastolic area of < 10 cm2 iv. VTI variation with respiration of < 12.5%, are grouped under the hypovolaemia group .
89031550|NCT02944266||Normovolaemia group|Those patients without the above said TTE findings are hypothesised to be normovolaemic and grouped in here.
89031551|NCT00512018|Active Comparator|Isokinetic Exercise only|Individuals were asked to perform a 8-session training, twice a week, in which they trained the knee extensors muscles in an isokinetic dynamometer, 3 sets of 10 repetitions.
89595552|NCT05925595|Experimental|Experimental Arm|Arm: Medical Device Iniettabile Ginocchio
89595553|NCT05925595|Active Comparator|Comparator Arm|Arm: Medical Device Jonexa (active comparator medical device from the market )
89595554|NCT05925231||People after stroke|Czech people after stroke, aged 20 - 64 years
89595555|NCT05925231||Healthy population|Czech healthy people, aged 20 - 64 years
89595556|NCT05924906|Experimental|NB002 dose level 1|NB002 is a recombinant humanized IgG1 monoclonal antibody
89595557|NCT05924906|Experimental|NB002 dose level 2|NB002 is a recombinant humanized IgG1 monoclonal antibody
89595558|NCT05924906|Experimental|NB002 dose level 3|NB002 is a recombinant humanized IgG1 monoclonal antibody
89595559|NCT05924906|Experimental|NB002 dose level 4|NB002 is a recombinant humanized IgG1 monoclonal antibody
89595560|NCT05924906|Experimental|NB002 dose level 5|NB002 is a recombinant humanized IgG1 monoclonal antibody
89595561|NCT05924906|Experimental|NB002 dose level 6|NB002 is a recombinant humanized IgG1 monoclonal antibody
89595562|NCT05922917|Active Comparator|PVI|Pulmonary vein isolation
89595563|NCT05922917|Experimental|PVI+|Pulmonary vein isolation supplemented by the additional lesions: left atrial posterior wall isolation, mitral and cavotricuspid isthmus lines
89595564|NCT05921786|Experimental|Multiphoton microscopy|
89595565|NCT05921786|Experimental|Electrophysiological system|
89595566|NCT05906862|Experimental|AMT-253 Dose Escalation|
89595567|NCT05904548|Experimental|Vision-MR Atrial Flutter Ablation|Type 1 Atrial Flutter ablation performed in the iCMR with the Vision-MR Ablation Catheter 2.0 and associated Advantage-MR EP recorder and stimulator system.
89595568|NCT05890131|Experimental|Digital letter|The experimental group will receive a digital letter with information on the newly approved heart failure therapy option, SGLT-2 inhibitors. The letter will also invite recipients to be evaluated by a heart failure specialist for potential initiation of the therapy.
89595569|NCT05890131|No Intervention|Control|The control group will not be sent the digital letter and will therefore receive usual follow-up and care in the public healthcare system.
89595570|NCT05880537||Open Label|Open Label for subjects with End-Stage Renal Disease
89595571|NCT05873218|Experimental|Ephedrine|3 minutes after the placement of a combined spinal epidural with 25 mcg fentanyl, 7.5 mg ephedrine IV will be administered to the patient, 12 minutes later, a second dose of 7.5mg will be administered to the patient as long as the patient is not hypertensive (BP no greater than 140/90)
89595572|NCT05873218|Placebo Comparator|Placebo|3 minutes after the placement of a combined spinal epidural with 25 mcg fentanyl, 2.5cc 0.9% NS IV will be administered to the patient, 12 minutes later, a second dose of , 2.5cc 0.9% NS will be administered to the patient.
89595573|NCT05848622|Active Comparator|Real-time gait biofeedback (RTGBF)|The RTGBF regimen delivers biofeedback that cues a personalized target to normalize vertical ground reaction force (vGRF) of each limb.
89595574|NCT05848622|Sham Comparator|Sham real-time gait biofeedback (Sham RTGBF)|The Sham RTGBF regimen will receive biofeedback that cues their habitual step length determined during the accommodation period on the first session of treadmill walking.
89595575|NCT05842291|Experimental|Active rTMS with short inter-session interval|Patients in this group will receive rTMS intervention with short inter-session intervals.
89595576|NCT05842291|Sham Comparator|Sham rTMS with short inter-session interval|Patients in this group will receive sham rTMS intervention with short inter-session intervals.
89595577|NCT05842291|Active Comparator|Active rTMS with long inter-session interval|Patients in this group will receive rTMS intervention with long inter-session intervals.
89595578|NCT05841355|Other|Educate (Education + Navigation) Sessions|Session 1 BC knowledge, BC disparities, USPSTF guidelines, barriers and preferred solutions to BC screening, Community Health Workers (CHW) testimonials, empirical data, individual action plans for BC screening Session 2 &3 Health knowledge (diet and physical activity guidelines), barriers and preferred solutions to dietary and physical activity change, CHW testimonials, empirical data, individual action plans for diet
89595579|NCT05841355|Other|Empower (Empowerment + Navigation) Sessions|"Session 1 BC knowledge, BC disparities, USPSTF guidelines, barriers and preferred solutions to BC screening CHW testimonials, Empirical data, Individual action plans for BC screening Sessions 2 & 3 BC screening as leading by example, BC promotion strategies that reflect personal and network members' preferences, opportunities to volunteer/be a part of tight-knit initiatives, partnerships with navigators/CHWs to serve as bridges for network members CHW testimonials , resource guides for BC promotion, individual action plans for promoting BC, role playing activities (session 2) Participant testimonials, participant relays empirical data, group discussion and plans for promoting BC (session 3)"
89595580|NCT05839158|Experimental|HFMT treated|The experimental group will receive treatment with HFMT ointment prepared in a homogenized mixture, applied once immediately after surgery to the treatment area.
89595581|NCT05839158|Placebo Comparator|Mupirocin treated|The control group will receive treatment with Mupirocin applied once immediately after surgery to the control area.
89595582|NCT05827354||Family Members|Family members of patients admitted to the ICU between the 1st of May 2025 and the 30th of May 2023, who survived ICU stay and are still alive up to 6 months after hospital discharge.
89031552|NCT00512018|Experimental|Isokinetic exercise + NMES|In the contralateral limb, the same protocol was repeated; however, each contraction was associated with overlapped NMES (Ex+NMES).
89031553|NCT00512057|Experimental|1|
89031554|NCT00512057|Placebo Comparator|2|
89031555|NCT00531141||A|examination twice by examiner 1
89031556|NCT00531141||B|examination first by examiner 1 thereafter by examiner 2
89031557|NCT00531141||C|examination first by examiner 2 thereafter by examiner 1
89595583|NCT05783297|Active Comparator|Comparison|Clinics randomized to the comparison arm will have participants receive standard of care ART adherence support for 3 months, and will receive the TXTXT intervention for 3 months. The standard of care for ART adherence across clinic sites consists of routine follow-up from assigned case managers for appointment reminders and adherence counseling at scheduled visits .
89031558|NCT00531141||D|examination performed twice by examiner 2
89031559|NCT00513929|Experimental|X: Zinc sulphate|
89031560|NCT00531180|Experimental|4-DCT Ventilation Validation|
89031561|NCT00531219||1|Group #1 NOTES Appendectomy - Transgastric approach
89031562|NCT00531219||2|Group #2 NOTES Cholecystectomy - Transgastric approach
89031563|NCT00513968|Experimental|I|HB-110 2mg, 4mg or 8mg combined with Adefovir
89031564|NCT00513968|Active Comparator|II|Adefovir
89595584|NCT05783297|Experimental|Intervention|Clinics randomized to the intervention arm will have participants complete a 6-month intervention period. Clinics will sign up eligible participants to receive automated SMS messages from the Dimagi CommCare platform during the participant's baseline study visit. Participants will have the option to tailor the message content based on their own preferences and will be able to select to receive messages in English or in Spanish, the time the messages are delivered, and frequency of messages. Clinic staff will enter this information in the Dimagi CommCare platform, and then test receipt of text messages by the participant before they complete this baseline visit.
89595585|NCT05777772|Experimental|Educational Intervention|Educational Intervention
89595586|NCT05768763|Experimental|Precision Community Health|The Phase B precision community health intervention will consist of a three part intervention: 1) Community-enhanced reach activities 2) Person-centered care delivery; and, 3) Data-enhancement to improve precision of interventions.
89595587|NCT05768763|Active Comparator|Control|Standard of Care
89595588|NCT05761288|Experimental|Surgery days with intraoperative microbreaks and exercises|Surgery days randomized to intraoperative microbreaks and exercises will include standardized breaks lasting approximately 1.5-2 minutes. During these breaks, surgeons will perform a set of targeted stretches or exercises while remaining sterile. The exercises will be performed just before surgical time-out, at a surgically safe and convenient time 45-75 mins after the start of the case and at the end of the case. A surgically safe and convenient time means the surgeon feels that it is safe to take an approximately 1.5-2 minute break during the procedure at that time. Surgeons will skip the microbreak if there is no surgically convenient or safe time during the case. Surgeons will stop the microbreak at any point if needed to ensure patient safety.
89595589|NCT05761288|No Intervention|Surgery days without intraoperative microbreaks and exercises|Surgery days without intraoperative microbreaks and exercises will include no intervention. Surgeons will perform the surgeries as they are normally performed and surgeons will not take microbreaks or perform exercises.
89595590|NCT05739994|Experimental|Dorsolateral prefrontal cortex (DLPFC)|Theta burst transcranial magnetic stimulation (cTBS) will be applied over dorsolateral prefrontal cortex (DLPFC).
89595591|NCT05739994|Experimental|Supramarginal gyrus (SMG)|Theta burst transcranial magnetic stimulation (cTBS) will be applied over the supramarginal gyrus (SMG).
89031565|NCT00530244|Experimental|1|Infants will be fed formula supplemented with docosahexaenoic acid
89031566|NCT00530244|Placebo Comparator|2|Infants will be fed standard formula (Enfamil)
89031567|NCT00514007|Experimental|OSI-906 QD|Once per day
89031568|NCT00514007|Experimental|OSI-906 BID|Twice per day
89031569|NCT00530283||A|Patients with Squamous cell cancer of neck nodes, unknown primary
89031570|NCT00512213|Active Comparator|1|Immunonutrition containing RNA, omega-3-FAs, arginine
89031571|NCT00512213|Active Comparator|2|Standard enteral nutrition: isocaloric and isonitrogeneous but w/o active ingredients
89031572|NCT02951585|Experimental|KARTILAGE CROSS|Kartilage® Cross (2.2 mL, 16 mg/g of hyaluronic acid)
89031573|NCT02951585|Placebo Comparator|Placebo|Saline solution (2.2-2.5 mL, NaCl 9 mg/g)
89031574|NCT04691349|Experimental|Chimeric antigen receptor T cell|Chimeric antigen receptor T cells (car-t) is one of the most effective therapies for malignant tumors (especially hematological tumors). Like other immunotherapies, the basic principle is to use the patient's own immune cells to clear cancer cells. Chimeric antigen receptor (car) is the core component of car-t, which endows T cells with the ability to recognize tumor antigens in an independent manner, which enables car modified T cells to recognize a wider range of targets than natural T cell surface receptors (TCR). The basic design of car includes a tumor associated antigen binding region (usually derived from scFv segment of monoclonal antibody antigen binding region), transmembrane region and intracellular signal region. The selection of target antigen is a key determinant for the specificity and effectiveness of car and the safety of genetically modified T cells
89031575|NCT02951624|Experimental|Control|Participants will spend 8 hours sedentary. Sedentary time will be spent sitting in a chair, restricted to sedentary behaviors (working on a computer, reading, watching TV, etc.) Participants will only be allowed to stand or walk to go to the toilet.
89031576|NCT02951624|Experimental|Breaker|Participants will spend a total of 7 hours and 12 min sedentary and a total of 48 min breaking sitting time with LPA. Sedentary time will be done in bouts of 18 min with 2 min of light walking.
89031577|NCT02951624|Experimental|Intermediate|Total duration of sedentary time and LPA time will be the same as in Breaker. Sedentary time will be done in bouts of 54 min with 6 min of LPA between each bout.
89031578|NCT02951624|Experimental|Prolonger|Total duration of sedentary time and LPA time will be the same as in Breaker. Sedentary time will be done in bouts of 108 min with 12 min of LPA between each bout.
89031579|NCT00531258|Active Comparator|1|
89031580|NCT00531258|Placebo Comparator|2|
89031581|NCT02951468||Nonunion group|All patients who were treated for clavicular non- or malunion with a locking compression plate and an iliac crest bone graft between January 2010 and December 2014 were included in this retrospective study.
89595592|NCT05739994|Sham Comparator|Sham control group|Sham theta burst transcranial magnetic stimulation (cTBS) will be applied over the vertex.
89595593|NCT05721326|Experimental|Sequential Communications|This sequential arm contains three types of communication to be employed following non-response to the previous type. The initial communication will be a direct message to the patient via the MyPennMedicine. The subsequent message will be sent as a text via the Way To Health app(lication). The final communication will be a nudge to the patient's physician which will send upon opening the patient's chart and will remain as a flag thereafter.
89595594|NCT05683158||chronic stroke|The subject consisted of the physician's confirmation of chronic hemiplegia onset ≥ 6 months Mini-mental state examination≥25 Biceps ≤2, Triceps≤2 Ability to Sit on a chair alone FMA upper extremity score ≥ 21points, FMA upper extremity score ≤ 66 points The symptom is mild or moderate level (MAS≤2) and can sit alone. The subject reaches to target by affected arm in 3 directions(medial_45, forward_90 and lateral_135 degrees)
89595595|NCT05683158||Healthy|"Matching aged people, not having neurological system or orthopedic disease on Upper extremity.~The subject reaches to target by non-dominant arm in 3 directions(medial_45, forward_90 and lateral_135 degrees)"
89595596|NCT05668000|Experimental|AIDA/KT-app with devices|AIDA/KT-app with devices : with device link and with feedback
89595597|NCT05668000|Placebo Comparator|AIDA/KT-app only|AIDA/KT-app only : no device link or no feedback
89595598|NCT05632562|Experimental|PET imaging of system L amino acid transport with FET and hypoxia imaging with FMISO|The participant will have a plastic peripheral intravenous (IV) catheter placed in the arm for Positron emission tomography (PET) tracer and MR contrast administration. FET O-([2-[18F]fluoroethyl)-L-tyrosine and FMISO 1H-1-(3-[18F]fluoro-2-hydroxypropyl)-2-nitroimidazole will be produced by the UAB Cyclotron PET Production Facility. PET/MRI will be performed using a GE Signa PET/MRI system in the AIF with specific imaging protocols for FET and FMISO studies. Upon completion of imaging, the peripheral IV catheter will be removed. The participant will be asked to urinate to reduce bladder dose after completion of each PET acquisition.Patients enrolled in the study will be followed clinically and with standard of care brain MRI. PFS and OS will be monitored for up to 24 months after completion of FET and FMISO PET/MRI studies.
89595599|NCT05562830|Experimental|Zilovertamab vedotin|Participants will receive zilovertamab vedotin 2mg/kg administered on Day 1 and Day 8 of each 3 week cycle (Q3W) until documented disease progression or any other discontinuation criterion is met.
89595600|NCT05553444|Experimental|Self-management intervention|"The intervention is based on the 5 key skills for successful self-management which are;~Problem solving~Decision-making~Utilizing resources~Forming partnerships with healthcare providers~Taking action. It is important to keep in mind, that not all included patients will necessarily lack all 5 skills. As such, the intervention will be tailored to each participant based on the initial assessment and continuous clinical reasoning."
89595601|NCT05542121|Placebo Comparator|Standard of Care|60 min OT sessions; 3 sessions per week; for 4 weeks;-- augmented Standard therapy - consisting of PT, OT and SLP. Clinical Assessment (B1-pre, B2-post, B3-follow-up#1, B4-follow-up#2).
89595602|NCT05542121|Experimental|Robot-Assisted Therapy with Rehab CARES system|"60 min sessions; 3 sessions per week; for 4 weeks;----of Upper Limb therapy using 1 or more affordable robots. Robot sessions can be group play and/or single play.~Robot Assessment (B1-pre, B2-post, B3-follow-up#1, B4-follow-up#2)"
89595603|NCT05541406|Experimental|Intervention schools|Schools will be assigned to either intervention or control schools. Students in intervention schools will receive the intervention in semester 1.
89595604|NCT05541406|Active Comparator|Control schools|Students in control schools will receive no intervention
89595605|NCT05523830||Healthy Subjects|56 healhty subjects will be recruited for the current study
89595606|NCT05514184|Experimental|Plant-focused low-protein nutrition in diabetic CKD (PLAFOND)|Participants randomized to this arm will receive PLAFOND dietary intervention consisting of a flexible low-protein meal plan including 0.6-0.8 g/kg/day dietary protein with >2/3% of the protein from plant-based sources, and the meal plan will be supported by dietitian who will provide dietary education and counseling to patients assigned to this arm.
89595607|NCT05514184|Active Comparator|Standard-of-care renal diet (control group)|Participants randomized to the control group will receive standard-of-care renal diet with low-potassium content based on dietitian counseling and guidance.
89595608|NCT05511181|Experimental|BioWave|BioWaveGO is a FDA 510(k) cleared high frequency neurostimulator. Patients that are first randomized to the BioWave arm will receive a 30 minute treatment in the clinic with a BioWaveGO device followed by a 30 minute washout and ending with a final 30 minute treatment. Data will be collected before, and after the final treatment. Patients will then be instructed to take the BioWaveGO device home and perform two 30 minute treatment sessions daily at home for 2 weeks. Follow-up in the clinic will be after the 2-week treatment period and the patients will be assessed in clinic for physiologic measures of pain response. A washout period of 2 weeks will follow, the patients will return to the clinic at week 4 and the patients will crossover to receive the TENS treatment (as described in the TENS arm).
89595609|NCT05511181|Active Comparator|TENS|Patients that are first randomized to the TENS arm will receive a 30 minute treatment in the clinic with an Intensity 5000 TENS device followed by a 30 minute washout and ending with a final 30 minute treatment. Data will be collected before, and after the final treatment. Patients will then be instructed to take the TENS device home and perform two 30 minute treatment sessions daily at home for 2 weeks. Follow-up in the clinic will be after the 2-week treatment period and the patients will be assessed in clinic for physiologic measures of pain response. A washout period of 2 weeks will follow, the patients will return to the clinic at week 4 and the patients will crossover to receive the BioWaveGO treatment (as described in the BioWave arm).
89595610|NCT05449977||Patients with Schizophrenia|20 patients with schizophrenia will be conducted
89595611|NCT05449626||Alzheimer's disease group|
89595612|NCT05449626||Healthy Group|
89595613|NCT05441280|Active Comparator|Pimavanserin 34mg PO at bedtime|Pimavanserin 34mg is taken by mouth at bedtime for 8 weeks .
89595614|NCT05441280|Placebo Comparator|Placebo PO at bedtime|The active study medication listed above will be compared with a placebo, which is a pill that looks like a study medication but has no medication in it
89595615|NCT05434338|Other|Major women with HPV-related high-grade intraepithelial lesions|
89595616|NCT05425264|Experimental|Tele-exercise|Exercise training 2x/week at home. Sessions include circuit exercises of aerobic and resistive training stations which are led remotely.
89595617|NCT05416996||Shared Medical Appointments|
89595618|NCT05416996||Usual Care Appointments|
89595619|NCT05413161|Experimental|ADL-018|150 mg/mL, Solution for injection in PFS
89595620|NCT05413161|Active Comparator|US-Licensed XOLAIR|150 mg/mL, Solution for injection in PFS
89595621|NCT05413161|Active Comparator|EU-Approved XOLAIR|150 mg/mL, Solution for injection in PFS
89595622|NCT05410730|Experimental|SHR-1501|"Phase I：Phase Ia and Ib： Phase Ia include SHR-1501 dose escalation and expansion; Phase Ib ： SHR-1501 in combination with BCG dose escalation~Phase II：SHR-1501 in combination with BCG dose expansion in NMIBC Cohort 1: No previous BCG treatment (n=15); Cohort 2: CIS (with or without Ta or T1) with or without prior BCG response (n=30); Cohort 3: BCG-unresponsive Ta or T1 (without CIS) (n=30)"
89595623|NCT05386719|Other|Early stage breast cancer survivors|Patients with history of early stage breast cancer and at least 3 months from completion of local and systemic therapy at Johns Hopkins
89595624|NCT05386693||Ilioinguinal Nerve Block|
89595625|NCT05353647|Experimental|Treatment Arm|Open-label, non-randomized, single arm study of a single infusion of autologous CD34+ HSC cells transduced with the lentiviral vector containing a shRNA targeting BCL11a.
89595626|NCT05343169|Experimental|CENS Intervention|Peer outreach workers will deliver Overdose Education and Naloxone to participants and provide education, navigation, and support during the 9-month intervention
89595627|NCT05343169|Other|Control|Participants will receive Overdose Education and Naloxone and referrals to treatment
89595628|NCT05339932|Experimental|Manual wheelchair skills training|
89595629|NCT05336396|Experimental|BMI|
89595630|NCT05336396|No Intervention|Traditional Oral Hygiene Instruction|
89595631|NCT05281497|Experimental|Intervention group|Each participant was provided with a wearable device. Each participant downloaded an app (WowGoHealth app) to connect with the health management platform. All participants were taught to record a dietary diary (taking photos of meals) using a smartphone application. All collected information was uploaded to the health management platform. For the intervention group, we encouraged exercise including an 18-minutes calisthenics. We also built a LINE group to inspire the intervention group.
89595632|NCT05281497|Placebo Comparator|Control group|Each participant was provided with a wearable device. Each participant downloaded an app (WowGoHealth app) to connect with the health management platform. All participants were taught to record a dietary diary (taking photos of meals) using a smartphone application. We did not encourage exercise or build a LINE group.
89595633|NCT05244408||SCI Subjects|"Patients who suffer a traumatic spinal cord injury who meet the following inclusion criteria are eligible for admission into the study as SCI subjects:"
89595634|NCT05244408||Non-SCI Spine Trauma Control Subjects.|"Patients who suffer a fracture or dislocation of their spinal column but without neurologic injury are eligible for admission into the study as Non-SCI Spine Trauma Control Subjects"
89595635|NCT05228314|Experimental|Standard dose SCB-2020S with CpG/alum adjuvant|Day 1 and 22 standard dose of SCB-2020S with CpG/alum adjuvant
89595636|NCT05228314|Experimental|Low dose SCB-2020S with low dose squalene based adjuvant|Day 1 and 22 low dose of SCB-2020S with low dose squalene based adjuvant
89595637|NCT05228314|Experimental|Low dose SCB-2020S with standard dose squalene based adjuvant|Day 1 and 22 low dose of SCB-2020S with standard dose squalene based adjuvant
89595638|NCT05228314|Experimental|Standard dose SCB-2020S with low dose squalene based adjuvant|Day 1 and 22 standard dose of SCB-2020S with low dose squalene based adjuvant
89595639|NCT05228314|Experimental|Standard dose SCB-2020S with standard dose squalene based adjuvant|Day 1 and 22 standard dose of SCB-2020S with standard dose squalene based adjuvant
89595640|NCT05228314|Active Comparator|Standard dose SCB-2019 with CpG/alum adjuvant|Day 1 and 22 standard dose of SCB-20219 with standard CpG/alum adjuvant
89595641|NCT05227521|Experimental|AH-GRASP feedback intervention group|All study participants will receive the AH-GRASP feedback intervention.
89595642|NCT05184985|Sham Comparator|Placebo|Patients receive a placebo procedure using a sham TrueRelief device that looks and operates identically to the experimental TrueRelief device but will not emit any high frequency current.
89595643|NCT05184985|Experimental|Experimental|Patients receive an experimental procedure using a TrueRelief device.
89595644|NCT05167760|Experimental|Treatment Group|Participants will receive the study drug, apraclonidine, per its FDA-approved package labelling
89595645|NCT05135195|Experimental|First Set of Experiments|The anticipated number of participants is 336. All participants have healthy vision.
89595646|NCT05135195|Experimental|Second Set of Experiments|The anticipated number of participants is 100. Of these, 80 participants have healthy vision, and 20 have glaucoma.
89595647|NCT05134480|Active Comparator|Cornea from donor with diabetes|Participant will be assigned a cornea recovered from a donor with diabetes.
89595648|NCT05134480|Active Comparator|Cornea from donor without diabetes|Participant will be assigned a cornea recovered from a donor without diabetes.
89595649|NCT05127590|Experimental|RBN-2397 in combination with pembrolizumab|RBN-2397 orally in combination with the fixed approved dose of IV pembrolizumab
89595650|NCT05116891|Experimental|CAN04 and chemotherapy (mFOLFOX)|12 cycles for mFOLFOX/CAN04-Each cycle is 2 weeks.mFOLFOX/CAN04 treatment arm: CAN04 and mFOLFOX are administered on Day 1 with a mFOLFOX continuation of regime on Day 2. CAN04 is only administered on Day 1.
89595651|NCT05116891|Experimental|CAN04 and chemotherapy (DTX)|6 cycles for DTX/CAN04, Cycles are 3 weeks. DTX/CAN04 treatment arm: CAN04 and DTX are administered on Day 1 followed by CAN04 in monotherapy on Day 8.
89595652|NCT05116891|Experimental|CAN04 and chemotherapy (G/C)|8 cycles for G/C/CAN04, Cycles are 3 weeks. G/C/CAN04 treatment arm: CAN04 and G/C are administered on Day 1/Day 8.
89595653|NCT05100342||Low-risk|Low-risk:score 0-6
89595654|NCT05100342||Intermediate-risk|Intermediate-risk: score 7-13
89595655|NCT05100342||High-risk|High-risk:score 14-20
89595656|NCT05095038|Experimental|Appethyl®|"Participants are instructed to ingest 10 capsules daily and they are instructed to swallow the capsules in whole with a glass of water with/during lunchtime throughout the study period of 26 weeks.~Each capsule contain 0.5 g Appethyl®, and the daily intake is 5 g/day."
89595657|NCT05095038|Placebo Comparator|Placebo|"Participants are instructed to ingest 10 capsules daily and they are instructed to swallow the capsules in whole with a glass of water with/during lunchtime throughout the study period of 26 weeks.~Each capsule contain 0.5 g placebo, and the daily intake is 5 g/day."
89210030|NCT00608244|Experimental|LCP-Tacro|"Prograf was administrated BID, doses per product labeling, with an interval of 12±1 hours between the morning and evening doses. Patients continued on the same dose from Day 0 through Day 7. On Day 8, all patients were converted to LCP Tacro QD for 14 Days with one fixed dose change allowed at Day 15. LCP-Tacro was administered orally once daily in the morning, with an interval of 24 ± 1 h between doses. Trough levels were to be maintained within predefined therapeutic ranges of 5 to 15 ng/mL.~LCP-Tacro tablets were provided in 3 strengths: 1 mg, 2 mg, and 5 mg oral tablets."
89595658|NCT05069038|Experimental|Treatment|"The following drugs will be taken for six cycles:~Palbociclib at a dose of 125 mg should be taken by mouth with food on 21 days and 7 days off schedule (meaning: on Days 1-21 of each 28-day cycle).~Letrozole should be taken daily by mouth, every day of each 28-day cycle, at a dose of 2.5 mg.~Goserelin is given as subcutaneous injection every 28 days at a dose of 3.6 mg. It is to be given on Day 1 of each cycle. Goserelin will only be administered to pre-menopausal subjects."
89595659|NCT05065983|Experimental|PXVX0317 (CHIKV VLP, alum-adjuvanted) vaccine|All study participants will receive the same Investigational Product (40 µg CHIKV VLP, alum-adjuvanted according to the same single dose schedule on Day 1).
89595660|NCT05013099|Experimental|Subjects with melanoma, Merkel cell, renal cell, or NSCLC|Eligible subjects will receive up to three zirconium Zr 89 crefmirlimab berdoxam PET scans (up to 1.0 mCi ± 20% at 1.5 mg API per scan, for a total of up to 3.0 mCi ± 20% and 4.5 mg API) as an IV infusion or slow bolus injection as follows: First scan within 14 days prior to the onset of IOT, and a second scan 4 to 6 weeks after start of immunotherapy. The second zirconium Zr 89 crefmirlimab berdoxam administration and scan should be completed prior to the start of the third cycle of IOT. Subjects who are determined by the treating physician to have PD on immunotherapy can receive the optional third zirconium Zr 89 crefmirlimab berdoxam PET scan at the principal investigator's (PI's) discretion.
89595661|NCT04983030|Experimental|Ad26.Mos4.HIV, MVA-BN-HIV Vaccine Plus PGT121, PGDM1400, and VRC07-523LS bNAbs|Participants will receive Ad26.Mos4.HIV vaccine at week 0 and MVA-BN-HIV vaccine at week 12. The bNAbs PGT121, PGDM1400, and VRC07-523LS will be administered at week 24, and the bNAbs PGT121 and PGDM1400 will be administered at week 28.
89595662|NCT04983030|Active Comparator|Ad26.Mos4.HIV, MVA-BN-HIV Vaccine Plus Placebo|Participants will receive Ad26.Mos4.HIV vaccine at week 0 and MVA-BN-HIV vaccine at week 12. Placebo will be administered at week 24, and at week 28.
89595663|NCT04983030|Active Comparator|Placebo Plus PGT121, PGDM1400, and VRC07-523LS bNAbs|Participants will receive Placebo at week 0 and 12. The bNAbs PGT121, PGDM1400, and VRC07-523LS will be administered at week 24, and the bNAbs PGT121 and PGDM1400 will be administered at week 28.
89595664|NCT04981613|Experimental|Experimental group|Kunxian capsule (2# tid or 2# bid) + irbesartan tablet (150mg qd or 300mg qd) for 48 weeks
89595665|NCT04981613|No Intervention|Control group|irbesartan tablet (150mg qd or 300mg qd) for 48 weeks
89595666|NCT04973566|Experimental|Part 1: Etanercept and Nipocalimab|Participants will receive a single subcutaneous (SC) dose of etanercept on Day 1 in Period 1 followed by single intravenous (IV) infusion of nipocalimab on Day 29, SC administration of etanercept followed by an IV infusion of nipocalimab on Day 43 and then a single dose of nipocalimab IV infusion on Day 57 in Period 2 of Part 1. There will be a wash-out period of 28 days between Day 1 of Period 1 and Day 29 of Period 2 in Part 1.
89595667|NCT04973566|Experimental|Part 2 (Cohort 1): Nipocalimab|Participants will receive a single IV infusion of nipocalimab on Day 1 in Cohort 1 of Part 2.
89595668|NCT04973566|Experimental|Part 2 (Cohort 2): Nipocalimab and Hydroxychloroquine (HCQ)|Participants will receive a single oral dose of HCQ film-coated tablets once daily from Day 1 to Day 22 and a single IV infusion of nipocalimab on Day 8 in Cohort 2 of Part 2.
89595669|NCT04947579|Experimental|Administration of CC-99677 150 mg QD PO|49 participants will be randomized to CC-99677 150 mg in biologic naive main study
89595670|NCT04947579|Experimental|Administration of CC-99677 60mg QD PO|49 participants will be randomized to CC-99677 60 mg in biologic naive main study
89595671|NCT04947579|Placebo Comparator|Administration of Placebo QD PO|49 participants will be randomized to placebo in biologic naive main study
89595672|NCT04947579|Experimental|Administration of CC-99677 150 mg QD PO.|20 participants will be randomized to CC-99677 150 mg in biologic-failure substudy
89595673|NCT04947579|Experimental|Administration of CC-99677 60mg QD PO.|20 participants will be randomized to CC-99677 60 mg in biologic-failure substudy
89595674|NCT04947579|Placebo Comparator|Placebo additional dose cohort|10 participants will be randomized to placebo in biologic-failure substudy
89595675|NCT04932447|Experimental|Training Group A|Participants will perform their respiratory training (high-intensity, low-volume IMST) on a hand-held respiratory training device.
89595676|NCT04932447|Sham Comparator|Training Group B|Participants will perform their respiratory training (low-intensity, low-volume IMST) on a hand-held respiratory training device.
89595677|NCT04928014||Screening Mammogram|Individuals eligible for a screening mammogram.
89595678|NCT04906148|Experimental|Smokers|Smokers will be randomized to view an advertisement with either true or misleading and implicit or explicit harm messaging content.
89595679|NCT04906148|Experimental|Non-smokers|Non-smokers will be randomized to view an advertisement with either true or misleading and implicit or explicit harm messaging content.
89595680|NCT04863092|Experimental|Underrepresented Population|A primary emphasis is placed on those from underrepresented populations, including Hispanics, residents of outlying rural areas, and those in areas of poverty
89595681|NCT04856189|Experimental|Treatment (selinexor, pembrolizumab)|Patients receive selinexor PO on days 1, 8 and 15, and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for 24 months in the absence of disease progression or unacceptable toxicity.
89595682|NCT04855929|Experimental|ANV419 single agent|
89595683|NCT04855929|Experimental|Ipilimumab + ANV419|
89595684|NCT04848558|Experimental|Part 1: Single Dose Cohorts|Participants will receive subcutaneous (SC) injection or intravenous (IV) infusion of nipocalimab or placebo in single ascending doses on Day 1 in Cohorts 1-6 and SC administration in optional Cohorts 7-8.
89210031|NCT00893100|Experimental|Diltiazem|
89210032|NCT00895908|Experimental|Friendship Group Intervention|"Participants will receive the Friendship Groups intervention."
89595685|NCT04848558|Experimental|Part 2: Multiple Dose Cohorts|Participants will receive up to 4 weekly SC injections of nipocalimab or placebo on Days 1, 8, 15, and 22 in Cohort 1 or 4 biweekly SC injections on Days 1, 15, 29, and 43 in optional Cohort 2.
89595686|NCT04846686||preeclampsia group|"25 patients with a diagnostic of preeclampsia, having undergone a placental pathological examination and having given birth by cesarean section. A cross-referencing of data with programme for medicalization of information systems (PMSI) will be realized.~Placenta pathological examination will be performed."
89595687|NCT04846686||control group|"10 patients who had a normal pregnancy, having undergone a placental pathological examination and having given birth by cesarean section. A cross-referencing of data with PMSI will be realized.~Placenta pathological examination will be performed."
89595688|NCT04845620|Experimental|ARQ-151 Cream 0.05%|Active comparator
89595689|NCT04845620|Placebo Comparator|ARQ-151 Vehicle Cream|Placebo comparator
89595690|NCT04844411|Experimental|Arm A: JNJ-67835989 (Oral Suspension)|Participants will receive a single oral suspension dose of JNJ-67835989 on Day 1 in Part 1 and Part 2.
89595691|NCT04844411|Placebo Comparator|Arm B: Placebo|Participants will receive a single oral solution placebo on Day 1 in Part 1 only (except food effect cohorts).
89595692|NCT04844411|Experimental|Arm C: JNJ-67835989 (Oral Solid Dose)|Participants will receive a single oral solid dose (tablet) of JNJ-67835989 on Day 1 in Part 3.
89595693|NCT04843527|Active Comparator|FreeStyle Libre|Subjects will be randomized to use the FreeStyle Libre Flash Glucose Monitoring System to manage their diabetes.
89595694|NCT04843527|Active Comparator|FreeStyle Libre plus food logging|Subjects will be randomized to use the FreeStyle Libre Flash Glucose Monitoring System and a food logging smartphone application to manage their diabetes.
89595695|NCT04833361||Mothers|Mothers of children with coloboma.
89595696|NCT04816201|Experimental|Electroacupuncture|Participants in the electroacupuncture group received acupuncture at Xuanji (CV21), Danzhong (CV27), Qihai (CV06), Guanyuan (CV04), and bilateral Liangmen (ST21) and Zusanli (ST36). After skin disinfection, sterile adhesive pads were placed on these acupoints, and acupuncture needles were inserted through the adhesive pads approximately 50 to 60 mm into the skin. Paired electrodes from the electroacupuncture apparatus were attached to the needle handles of Xuanji (CV21) and Danzhong (CV27), Qihai (CV06), Guanyuan (CV04), bilateral Liangmen (ST21), and bilateral Zusanli (ST36). The electroacupuncture stimulation lasted for 30 minutes with an intermittent wave of 50 Hz and a current intensity of 1 to 5mA (preferably with the skin around the acupoints shivering mildly without pain). Participants received 1 treatment session per day until the success of ventilator weaning (up to 21 days).
89595697|NCT04816201|Sham Comparator|Sham electroacupuncture|Participants in the sham electroacupuncture group received sham electroacupuncture with a pragmatic placebo needle on sham acupoints. The sham Xuanji (CV21) point was 1 cun (≈20 mm) above to Xuanji (CV21), the sham Danzhong (CV27) point was 1 cun(≈20mm) above to Danzhong (CV27), the sham Qihai (CV06) point was 1 cun(≈20mm) above to Qihai (CV06), the sham Guanyuan (CV04) point was 1 cun(≈20mm) above to Guanyuan (CV04), the sham Liangmen (ST21) point was 1 cun(≈20mm) lateral to Liangmen (ST21), and the sham Zusanli (ST36) point was 1 cun(≈20mm) lateral to Zusanli (ST36). Procedures, electrode placements, and other treatment settings were the same as in the electroacupuncture group but with no skin penetration or electricity output.
89595698|NCT04811235|Experimental|Arm 1|NIRS monitoring of spinal cord oxygenation and hemodynamics
89595699|NCT04797650|Placebo Comparator|Placebo|Participants received CTP-543 matched placebo tablets, orally, twice daily (BID) for up to 24 weeks.
89595700|NCT04797650|Experimental|CTP-543 8 mg BID|Participants received CTP-543 8 mg tablets, orally, BID for up to 24 weeks.
89595701|NCT04797650|Experimental|CTP-543 12 mg BID|Participants received CTP-543 12 mg tablets, orally, BID for up to 24 weeks.
89595702|NCT04760496|Experimental|Experimental group|The experimental group will receive oxytocin at 4 mIU/mL
89595703|NCT04760496|Active Comparator|Control group|The control group will receive oxytocin at 2 mIU/mL
89595704|NCT04734145||Participants with an Undiagnosed Pulmonary Nodule|One hundred evaluable individuals aged 21 to 85 years with a single undiagnosed pulmonary nodule measuring <3 cm, clinically staged as cT1N0M0 (eighth edition of the TNM staging manual) by CT and PET scans, will be enrolled in this diagnostic study and will undergo e-nose testing. These patients must have a risk assessment profile that, according to institutional guidelines, identifies them as candidates for subsequent surgical resection of the pulmonary nodule, which will confirm the results of the breathprinting analysis.
89595705|NCT04722822|Experimental|Providers recommending HPV vaccine at age 9-10 years of age|Providers in this arm will routinely recommend HPV vaccine starting at 9-10 years of age.
89595706|NCT04722822|Active Comparator|Providers recommending HPV vaccine at age 11-12 years of age|Providers in this arm will routinely recommend HPV vaccine starting at 11-12 years of age.
89595707|NCT04705597|Experimental|BGE-175|BGE-175 tablet to be taken by mouth once a day for 14 days
89595708|NCT04705597|Placebo Comparator|Placebo|Placebo tablet to be taken by mouth once a day for 14 days
89595709|NCT04704830|Experimental|Standard Regime - Malaria vaccine|R21/Matrix-M x 3, n = 1600, 5-36 months olds
89031582|NCT03459248|Experimental|Dual therapy|Patients will receive 10 mg metoclopramide with 4mg ondansetron before induction of general anesthesia
89595710|NCT04704830|Placebo Comparator|Standard Regime - Rabies vaccine|Rabies vaccine x 3, n = 800, 5-36 months olds
89595711|NCT04704830|Experimental|Seasonal Regime - Malaria vaccine|R21/Matrix-M x 3, n = 1600, 5-36 month olds
89595712|NCT04704830|Placebo Comparator|Seasonal Regime - Rabies vaccine|Rabies vaccine x 3, n = 800, 5-36 month olds
89595713|NCT04649073|Experimental|OPC-415 (up to 1×10^7cells/kg)|
89595714|NCT04542603|Experimental|treatment naivete women with stage 1-4 newly diagnosed ovarian|
89595715|NCT04534114|Placebo Comparator|Pooled Placebo|Participants received subcutaneous treatment with matching placebo.
89595716|NCT04534114|Experimental|40 mg BAY2976217|Participants received subcutaneous treatment with 40 mg BAY2976217.
89595717|NCT04534114|Experimental|80 mg BAY2976217|Participants received subcutaneous treatment with 80 mg BAY2976217.
89031583|NCT03459248|Active Comparator|Monotherapy|Patients will receive 10 mg metoclopramide before induction of general anesthesia.
89031584|NCT00531297|Experimental|Treatment arm|endoscopic posterior mesorectal resection
89595718|NCT04534114|Experimental|120 mg BAY2976217|Participants received subcutaneous treatment with 120 mg BAY2976217.
89595719|NCT04517344|Experimental|Arm 1, HFNC 1 L/kg/min|The infant that is randomized to the HFNC therapy arm 1 will be placed on high flow at 1 L/kg/min (up to a maximum of 20 L/min) on fraction of inspired oxygen (FiO2) of 21 %. They will remain on FiO2 of 21% for a minimum of 10 minutes while monitoring SpO2. If oxygen saturation (SpO2) is <90%, FiO2 will be slowly increased to maintain SpO2 ≥ 90 %.
89595720|NCT04517344|Experimental|Arm 2, HFNC 1.5 L/kg/min|The infant that is randomized to the HFNC therapy arm 2 will be placed on high flow at 1.5 L/kg/min (up to a maximum of 20 L/min) on fraction of inspired oxygen (FiO2) of 21 %. They will remain on FiO2 of 21% for a minimum of 10 minutes while monitoring SpO2. If SpO2 is <90%, FiO2 will be slowly increased to maintain SpO2 ≥ 90 %.
89595721|NCT04517344|Experimental|Arm 3, HFNC 2 L/kg/min|The infant that is randomized to the HFNC therapy arm 3 will be placed on high flow at 2 L/kg/min (up to a maximum of 20 L/min) on fraction of inspired oxygen (FiO2) of 21 %. They will remain on FiO2 of 21% for a minimum of 10 minutes while monitoring SpO2. If SpO2 is <90%, FiO2 will be slowly increased to maintain SpO2 ≥ 90 %.
89595722|NCT04515641|Experimental|Moderate Hepatic Impairment|Participants receive a single dose of ISL 60 mg.
89595723|NCT04515641|Experimental|Healthy Controls|Participants receive a single dose of ISL 60 mg.
89595724|NCT04490200|Experimental|Novel chitosan semi facial respirator (VESTA)|VESTA is a semi facial respirator that follows the same technical specifications of a N95 class PFF2 respirator. However, the VESTA respirator has nanoparticles in the filtering element, which is manufactured with a product of 50 gsm melt blown polypropylene-treated with an electrostatic charge. This filtering element deposits nanoparticles of polymeric biodegradable material known as chitosan. Chitosan can act as a surface for adsorption and viral inactivation.
89595725|NCT04490200|Active Comparator|Conventional N95 semi facial respirator|The N95 PFF2 respirators are manufactured from TNT as defined in ABNT NBR 15052: 2004 and in the resolution of ANVISA RDC No. 356. The filtering element is usually formed by a layer of thin polypropylene fibers arranged at random. This configuration influences the particles (which constitute aerosols) to move along an extensive and tortuous path in relation to their size; thus, increasing the probability of them coming into contact with the fibers and being retained. A number of mechanisms influence the interception of particles by the fibers of the filter element. In addition to the mechanical interception mechanisms, the presence of charges on the surface of the filter material can enhance the association of particles with its fibers and optimize the efficiency of the respirator.
89595726|NCT04474366|Sham Comparator|Saline|Control group will receive an injection of 20ml of saline between the pectoralis minor and serratus anterior muscles bilaterally and 10ml of saline between the pectoralis minor and pectoralis major muscles bilaterally.
89595727|NCT04474366|Experimental|Ropivacaine|Intervention group will receive an injection of 20ml of 0.2% Ropivacaine between the pectoralis minor and serratus anterior muscles bilaterally and 10ml of 0.2% Ropivacaine between the pectoralis minor and pectoralis major muscles bilaterally (Not to exceed 225mg or 3.5mg/kg).
89595728|NCT04465643|Other|Immunotherapy with Nivolumab and Ipilimumab|Nivolumab 4.5 mg/kg every 3 weeks (Q3W) x 2 Ipilimumab 1 mg/kg Q3W x 2 Nivolumab monotherapy 4.5mg/kg Q3W concurrent with standard therapy Nivolumab monotherapy should be held for at least 2 weeks before and 2 weeks after surgery
89608527|NCT04143633|Experimental|FODMAP diet in Ulcerative Colitis|Patients with UC will be randomized to standard diet or low fodmap diet. The nutritional status (body composition and clinical parameters), gut microbiota, adherence to treatment, improvement of gastrointestinal symptoms and quality of life will be evaluated for 10 weeks.
89031585|NCT00512291|Experimental|Olanzapine|5 mg subcutaneous injection every 8 hours for 9 doses
89031586|NCT02944539||Gastric cancer group|300 consecutive patients were recruited, who have diagnosed with gastric cancer by biopsy
89031587|NCT02944539||Control group|The 300 healthy controls without previous cancer history were recruited from individuals who visited investigator's hospital for physical examination during the same time period as the case enrollment.
89031588|NCT02944032|Experimental|Cogmed|Cogmed RM is a computer program that consists of twelve visually-engaging and interesting exercises that target skills involving visuo-spatial and verbal Working Memory. During the intervention, children complete 25 training sessions. Children are asked to complete between 3 and 5 sessions per week, so the total treatment time to complete 25 sessions may range from 5 to 9 weeks. For children completing CogmedRM, sessions typically last between 25 and 45 minutes, depending on the child's working memory span.
89031589|NCT02944032|Active Comparator|MobyMax|"MobyMax's Reading Stories program is a program that focuses on reading comprehension skills. Participants will start their training with stories that are matched to their reading grade level. Each grade contains 30 lessons, with 3 stories in each lesson. Participants are given questions to answer at the conclusion of each story, and children advance or remain at that level depending on the progression of their reading skill. Participants randomized to this program will be asked to train 30-45 minutes per session for 25 training sessions over a 5 to 9 week period."
89031590|NCT00514163|Experimental|1|gemcitabine + S-1
89031591|NCT00514163|Active Comparator|2|S-1
89031592|NCT04691466||HIP_R|Patients undergoing hip replacement surgery
89031593|NCT04691466||KNEE_R|Patients undergoing knee replacement surgery
89595729|NCT04450706|Experimental|Treatment: all patients|"Blood will be collected, and a biopsy will be performed prior to starting the first systemic therapy (triple-negative) or first chemotherapy (hormone receptor-positive). If enough tumor is collected, the patient is eligible for the trial. Malignant tissue collected from this biopsy will be used for genomic sequencing and for the development of organoid models for drug screening. Drugs selected for sensitivity testing will be guided by the results of the genome analysis and NCCN guidelines. Following tissue acquisition, the patient will begin therapy as selected by the treating physician. This first-line of on study therapy, either standard-of-care or investigational in the context of another existing active clinical trial, will be defined as the first uninformed line of therapy.~Patient response is tracked for up to two uninformed lines of therapy. The first line of the therapy started after the biopsy will count as the first uniformed line."
89595730|NCT04450706|Experimental|Physician Questionnaire|"The results from the drug screening and mutation testing will be summarized and returned to the treating physician before the assignment of on study, second-line therapy. Before and after returning results, the treating physician will be administered a survey to assess the potential effect that the precision medicine results have on the selection of the following line of therapy. If a patient begins a therapy that was recommended by the precision medicine results, the therapy will be defined as the informed line of therapy."
89595731|NCT04430439|Experimental|Psychosocial stress|Participants will complete the Trier Social Stress Test (TSST) immediately following consumption of their assigned meal type (low or high GI).
89595732|NCT04430439|Active Comparator|Control non-stress|Participants will complete a non-stress relaxed task immediately following consumption of their assigned meal type (low or high GI).
89595733|NCT04422431|Experimental|ALXN1840|Participants will receive ALXN1840.
89595734|NCT04416451|Experimental|Rituximab and Venetoclax|Patients will be treated with an Induction phase of rituximab 375 mg/m2 weekly for 4 weeks. Patients will undergo restaging imaging after the last of 4 weekly rituximab doses and before beginning venetoclax. Based on post-rituximab restaging studies, patients will be risk-stratified for risk of Tumor Lysis Syndrome (TLS) and treated in the appropriate setting with TLS prophylaxis per institutional TLS guide lines starting at week 5. Oral venetoclax will follow a ramp-up dosing schedule and will be taken daily after 4 weeks of rituximab therapy. Following the 4-week ramped-up phase of venetoclax, patients will begin their target dose of venetoclax and continue for a maximum of 24 months. In addition, patients will receive rituximab 375 mg/m2 starting on day 1 of the maintenance phase and repeated once every 3 months for 12 months. Venetoclax may be continued after this period if patient has not achieved a complete remission
89031594|NCT04695548|Experimental|Concentric contraction exercise|After applying the dry needling technique to the upper trapezius muscle, the participant will be placed in a standing position, with the shoulders positioned in the scapular plane. A medium stiffness Theraband elastic band will be placed between the participant's ipsilateral foot on the side on which the dry needling technique was applied and the acromio-clavicular joint on the same side.The exercise will consist of raising the shoulder against the resistance of the elastic band, slowly and for 5 seconds
89031595|NCT04695548|Experimental|Isometric contraction exercise|After applying the dry needling technique to the upper trapezius muscle, the participant will be placed in a standing position, with the shoulders positioned in the scapular plane. A medium stiffness Theraband elastic band will be placed between the participant's ipsilateral foot on the side on which the dry needling technique was applied and the acromio-clavicular joint on the same side.The exercise will consist of raising the shoulder and maintaining the tension of the elastic band for 5 seconds
89031596|NCT04695548|Experimental|Eccentric contraction exercise|After applying the dry needling technique to the upper trapezius muscle, the participant will be placed in a standing position, with the shoulders positioned in the scapular plane. A medium stiffness Theraband elastic band will be placed between the participant's ipsilateral foot on the side on which the dry needling technique was applied and the acromio-clavicular joint on the same side.The exercise will consist of raising the shoulder against the resistance of the elastic band, slowly and for 5 seconds
89031597|NCT04695548|Experimental|Analytic passive stretching.|After applying the dry needling technique to the upper trapezius muscle, the patient remains supine position. The analytical passive stretch of the upper trapezius will be performed only once, bringing the muscle to the limit of elastic tension perceived by the subject. The passive stretching technique will be held for 30 seconds.
89031598|NCT04691388|Experimental|Amlotinib+Sindili|Patients will be treated with amlotinib hydrochloride combined with Sindili monoclonal antibody
89031599|NCT00530322||A|"Patients who have had previous open colorectal surgery and are referred for a further operative procedure, at which time a second-look laparoscopy can be performed."
89031600|NCT00530322||B|"Patients who have had a previous laparoscopic colorectal procedure and are having a second-look procedure"
89031601|NCT04695743|Experimental|Intervention|Attendance at online CST groups
89031602|NCT04695743|No Intervention|Control|Treatment as usual
89595735|NCT04406649|Experimental|STS101|STS101 (dihydroergotamine nasal powder)
89595736|NCT04362644|Experimental|PET/CT using PET ligands [18F]FDG and [18F]DPA-714|
89595737|NCT04316390|Experimental|Hesperidin (A)|study drink without hesperidin and without vitamin C compared to study drink with hesperidin
89595738|NCT04316390|Experimental|Hesperidin + Vitamin C (B)|study drink with vitamin C compared to study drink with hesperidin and vitamin C
89595739|NCT04308369|Other|Blood collection arm|Blood collection will be performed before the spa therapy (Day 0), at the end of the spa therapy (Week 3) and 6 months later (M6).
89031603|NCT02943486|Experimental|dac-MSCs and Fitostimoline|Intradermic application of dac-MSCs (1 mL ) in four equidistant points around the ulcer (twice: day 0 and 7) and topical application of fitostimoline every other day
89031604|NCT02943486|Active Comparator|MSCs and Fitostimoline|Intradermic application of MSCs (500,000 cells/mL) in four equidistant points around the ulcer (once: day 0 ) and topical application of fitostimoline every other day
89595740|NCT04232228||Participants with Crohn's Disease (CD)|Adult participants with moderate to severe CD who agree to be part of the study and who fit the inclusion/exclusion criteria and use Care4Today inflammatory bowel disease (C4T IBD) alongside standard of care (SOC) at participating centers will be observed. Data available per clinical practice and via the C4T IBD application will be collected within this study. Participants will also be asked to complete questionnaires that are sent directly to the patients, which are not completed as part of clinical practice or via the application. Relevant data will be collected by prospectively following participants from the index date for 12 months, and also by retrospectively collecting data for the 6-month period prior to the index date from participant's medical records. Index is the activation date of C4T IBD application in participant's smartphone.
89595741|NCT04171817|No Intervention|Control|Dog-handler teams will follow established hospital and therapy dog program guidelines for infection control with no changes for eight sessions. Participants enrolled in the session will derive their Arm assignment from the dog-handler team with which they interact.
89595742|NCT04171817|Experimental|CHX Intervention A|"Dog-handler teams will follow a modified protocol for infection control, with Treatment A first for four sessions, and cross-over to Treatment B for four sessions. Participants enrolled in the session will derive their Arm assignment from the dog-handler team with which they interact.~Treatment A consists of a pre-session shampoo with a commercial veterinary chlorhexidine-based product (2-4% chlorhexidine) within 24 hours prior to the session, and wiping with a chlorhexidine-impregnated cloth (2-4% chlorhexidine) at arrival at the session and every 20 minutes during the session, or between participants if the flow of participants is structured in a way that allows this (such as visits from one room to the next to visit individual patients)."
89595743|NCT04171817|Experimental|CHX Intervention B|"Dog-handler teams will follow a modified protocol for infection control, with Treatment B first for four sessions, and cross-over to Treatment A for four sessions. Participants enrolled in the session will derive their Arm assignment from the dog-handler team with which they interact.~Treatment B will consist of the same pre-session shampoo with a commercial veterinary chlorhexidine-based product (2-4% chlorhexidine), with a single wipe with a chlorhexidine-impregnated cloth (2-4% chlorhexidine) at arrival. This treatment will depend on the residual activity of chlorhexidine throughout the visit."
89595744|NCT04129554|Experimental|JNJ-73763989+ JNJ-56136379+ NA|Participants will receive fixed dose of JNJ-73763989 subcutaneous injection once every 4 weeks along with fixed dose of JNJ-56136379 tablet once daily and nucleos(t)ide analog (NA) treatment (either entecavir [ETV], tenofovir disoproxil fumarate [TDF], or tenofovir alafenamide [TAF]) once daily up to 48 weeks.
89595745|NCT04129554|Placebo Comparator|Placebo for JNJ-73763989+ Placebo for JNJ-56136379+ NA|Participants will receive matching placebo for JNJ-73763989 subcutaneous injection once every 4 weeks with matching placebo for JNJ-56136379 once daily and NA treatment (either ETV, TDF or TAF) once daily up to 48 weeks.
89595746|NCT04115488|Experimental|PB006|Patients with relapsing-remitting multiple sclerosis (RRMS) received intravenous (IV) infusions every 4 weeks of PB006 at a dose of 300 milligram (mg) starting at Visit 1 (Week 0) through Visit 12 (Week 44), for a total of 12 infusions.
89595747|NCT04115488|Active Comparator|Tysabri|Patients with relapsing-remitting multiple sclerosis (RRMS) received intravenous (IV) infusions every 4 weeks of Tysabri at a dose of 300 milligram (mg) starting at Visit 1 (Week 0) through Visit 12 (Week 44), for a total of 12 infusions. At Week 24, patients in the Tysabri group were re-randomized through a re-randomization step. Patients re-randomized and switched from Tysabri to PB006 at Week 24 still received a total of 12 infusions (6 infusions of Tysabri and 6 infusions of PB006).
89595748|NCT04109729|Experimental|Treatment: all patients|
89595749|NCT04080752|Experimental|JNJ-61393215 135 milligram (mg)|Participants will receive JNJ-61393215 135 mg (3*45 mg capsules) orally once daily for 6 weeks along with the prescribed standard oral antidepressants (without dose change) throughout the study.
89595750|NCT04080752|Placebo Comparator|Placebo|Participants will receive matching placebo for 6 weeks along with the prescribed standard oral antidepressants (without dose change) throughout the study.
89595751|NCT04078581|Experimental|healthy controls|Questionnaire and fecal sample collection
89595752|NCT04075162||Low charge CAC|Patients receiving CAC for Cardiovascular disease risk screening at low charge (99 USD)
89595753|NCT04075162||No charge CAC|Patients receiving CAC for Cardiovascular disease risk screening at no charge
89595754|NCT04062344||Short oral drug provocation test|Minors performing a short (1-4 days) drug provocation test
89031605|NCT02943486|Active Comparator|Fitostimoline|Topical application of fitostimoline every other day
89595755|NCT04062344||Prolonged oral drug provocation test|Minors performing a prolonged (5-8 days)drug provocation test
89595756|NCT04049513|Experimental|WZTL002-1 (1928T2z CAR T-cells)|"A starting WZTL-002 dose of 5 × 10^4 CAR T-cells/kg has been selected with four possible dose level cohorts proposed.~Escalation to a higher dose cohort will be based on assessment of dose limiting toxicities to determine safety at a given dose level."
89595757|NCT04002180||Vedolizumab 300 mg|Vedolizumab (Genetical Recombination) 300 mg, IV infusion, at Weeks 0, 2 and 6, and every 8 weeks thereafter, for up to 54 weeks. Participants will receive IV infusion as part of routine medical care.
89595758|NCT03999879||Cognitively Normal|having 30 participants with normal cognition
89595759|NCT03999879||Amnesic MCI|aMCI Group having 15 participants with a CDR of 0.5-1 and a Mini-Mental State Examination (MMSE) of 20-25.
89031606|NCT00514202|Placebo Comparator|1|Placebo plus cognitive behavioral therapy
89031607|NCT00514202|Experimental|2|Dextroamphetamine SR (60 mg/kg) plus cognitive behavioral therapy
89595760|NCT03992872|Experimental|Prior Alpha|All study participants will receive the same Investigational Product according to the same schedule. Subjects are prior recipients of experimental alphavirus vaccines.
89595761|NCT03992872|Active Comparator|Control: Naïve Alpha|All study participants will receive the same Investigational Product according to the same schedule. The alphavirus vaccine naïve subjects will serve as controls for determining the effect of pre-existing alphavirus immunity on vaccine safety and immunogenicity.
89595762|NCT03968419|Experimental|Canakinumab monotherapy|Participants received 200 mg of canakinumab once every 3 weeks for a maximum duration of 6 weeks prior to surgery
89595763|NCT03968419|Experimental|Canakinumab + pembrolizumab|Participants received 200 mg of canakinumab in combination with 200 mg of pembrolizumab once every 3 weeks for a maximum duration of 6 weeks prior to surgery
89595764|NCT03968419|Experimental|Pembrolizumab monotherapy|Participants received 200 mg of pembrolizumab every 3 weeks for a maximum duration of 6 weeks prior to surgery
89595765|NCT03924986|Experimental|Tislelizumab combined with Gemcitabine Plus Cisplatin|"Tislelizumab will be administered once every 3 weeks (Q3W)~Gemcitabine on Day 1, Day 8 of each 3 week cycle, for 4 to 6 cycles~Cisplatin on Day 1 of each 3 week cycle, for 4 to 6 cycles"
89595766|NCT03924986|Placebo Comparator|Placebo combined with Gemcitabine Plus Cisplatin|"Placebo will be administered once every 3 weeks (Q3W)~Gemcitabine on Day 1, Day 8 of 3 week each cycle, for 4 to 6 cycles~Cisplatin on Day 1 of 3 week each cycle, for 4 to 6 cycles"
89595767|NCT03915379|Experimental|Part 1: Dose Escalation|Participants will receive JNJ-67571244. The dose levels will be escalated sequentially based on the decisions of the Study Evaluation Team (SET) until the recommended Phase 2 Dose (RP2D) has been identified.
89595768|NCT03915379|Experimental|Part 2: Dose Expansion|Participants in 2 expansion cohorts of acute myeloid leukemia (AML) or either high-risk myelodysplastic syndromes (MDS) or very high-risk MDS will receive JNJ-67571244 at the RP2D determined in Part 1.
89595769|NCT03911492|Other|SCP Pressure Management|Active management of Spinal Cord Perfusion Pressure (SCPP) at or above 65 mmHg.
88978507|NCT00105339||Review of Draft Focus Group|Lori Perez will travel to each site from Westat and conduct Review of Draft Focus Groups with adolescents and young adults (n per site = approximately 10 - 15) to collect final feedback on the adolescent friendly version (present key pieces of the adolescent friendly version and obtain feedback on the wording and the illustrations). Based on the focus group feedback, the research team will finalize the adolescent friendly materials.
88978508|NCT00105339||Comprehension/Recall Assessment|The assessment will be read to the participants to preclude reading problems. Responses will be recorded by the interviewer on the assessment instrument.
88978509|NCT00261001|Experimental|Transcutaneous|
88978510|NCT00261001|Active Comparator|Intramuscular|
88978511|NCT02966600|Experimental|Progressive resistance exercise (PRE)|Progressive resistance exercise (PRE) in akinetic-rigid Parkinson's disease patients. Intervention included sixteen PRE training sessions for eight weeks: two sessions per week on non-consecutive days, sixty-seventy min each one.
88978512|NCT02966600|No Intervention|Physical Activity|The control group followed its usual weekly physical activity routine
88978513|NCT00261118|Active Comparator|1 (i)|Rituximab 1g in 500 mls of 0.9% normal saline infused into a peripheral vein
88978514|NCT00261118|Placebo Comparator|2 (ii)|500 mls of 0.9% NORMAL SALINE INFUSED INTO A PERIPHERAL VEIN
89595770|NCT03866902|Experimental|Nutrition and Physical Activity Intervention|"Classes for the intervention mothers will be run by a bilingual interventionist and will last 105 minutes weekly for 12 weeks and then monthly for 6 months.~Classes for intervention group children will be 105 minutes weekly for 12 weeks and then monthly for 6 months."
89595771|NCT03866902|Active Comparator|English for Second Language Intervention|"Mothers in the control group will receive English as a Second Language (ESL) classes taught by professional ESL teachers; they will receive the same number of contacts and time as the intervention group mothers for 105 minutes weekly for 12 weeks and 105 minutes monthly for 6 months.~Children in the control group will be read to and color with crayons 105 minutes weekly for 12 weeks and then 105 minutes monthly for 6 months."
89595772|NCT03866577|Experimental|Part A|Healthy volunteers will receive a single ascending dose of M254 or placebo
89595773|NCT03866577|Experimental|Part B|Immune thrombocytopenic purpura (ITP) patients will receive a single ascending dose of M254 followed by IVIg
89595774|NCT03866577|Experimental|Part C|ITP patients will receive a single dose of M254 or IVIg, followed by a single dose of the other drug approximately 28 days later
89595775|NCT03866577|Experimental|Part D|ITP patients will receive repeated doses of M254
89595776|NCT03859193|No Intervention|Standard care|Participants will receive standard nutrition counseling
89595777|NCT03859193|Experimental|Video|Participants will watch an Nutritional video at their first high risk visit. Participants will also receive standard nutrition counseling
89595778|NCT03835702|No Intervention|Usual care with non-sleep provider|Participant will continue the follow up for sleep apnea with the non-sleep provider
89595779|NCT03835702|Experimental|SAM Clinic Intervention|Participants will attend a sleep apnea management group based intervention to improve PAP adherence.
88978515|NCT00261196|Experimental|Collagenase|Collagenase Injection
88978516|NCT00261196|Placebo Comparator|Placebo|Placebo Injection
88978517|NCT02961049|Active Comparator|Retraction and total-etch|Gingival displacement with a gingival cord (#0, #00 or #000) prior to the restoration. Application of total-etch adhesive system: enamel and dentin etched with 35% phosphoric acid, wash, dry, two layers of primer/bond application with a brush and photoactivated for 20 seconds.
88978518|NCT02961049|Active Comparator|No retraction and total-etch|Application of total-etch adhesive system: enamel and dentin etched with 35% phosphoric acid, wash, dry, two layers of primer/bond application with a brush and photoactivated for 20 seconds.
88978519|NCT02961049|Active Comparator|Retraction and self-conditioning|Gingival displacement with a gingival cord (#0, #00 or #000) prior to the restoration. Application of self-conditioning adhesive system: selective enamel etched with 35% phosphoric acid, wash, dry, one layer of acid/pirmer on enamel and dentin with a brush, one layer of bond with a brush and photoactivated for 20 seconds.
89031608|NCT00512408||A|
89031609|NCT00512408||B|
89031610|NCT00530400|Experimental|1|intravenous 1.5g cefuroxime
89031611|NCT00530400|Placebo Comparator|2|intravenous placebo
89595780|NCT03824041|Placebo Comparator|Placebo|Formulation containing inert artificially colored maltodextrin, two capsules once a day, in a 500 mg capsule regimen (total intake 1000 mg)
89595781|NCT03824041|Experimental|Aronia full spectrum - half dose|Formulation containing 50% Aronia full spectrum and 50% placebo, two capsules once a day, in a 500 mg capsule regimen (total intake 1000 mg)
89595782|NCT03824041|Experimental|Aronia full spectrum - full dose|Formulation of 100% Aronia full spectrum, two capsules once a day, in a 500 mg capsule regimen (total intake 1000 mg)
89595783|NCT03784846|Experimental|Mindfulness-Based Resilience Training|MBRT is an 8-week program combining training in standardized mindfulness practices targeting factors that facilitate resilience, cognitive behavioral therapy (CBT), and psychoeducation. It contains experiential and didactic exercises including body scan, sitting and walking meditation, mindful movement and discussions.
89595784|NCT03784846|Active Comparator|Stress Management Education|SME was designed as an active control condition for other mindfulness-based intervention trials. SME uses a group-based didactic approach with modules on physiological and dietary effects of stress, time management, sleep physiology and insomnia, nutrition, exercise, stress hardiness, and factors mitigating impacts of stress.
89595785|NCT03784846|No Intervention|No Intervention Control|No contact control condition (other than baseline, post, and follow-up assessments)
89595786|NCT03756350|Experimental|Treatment subjects|Single group of subjects which will have the treatment of a 1060nm diode laser administered to them.
89595787|NCT03703804||Women postpartum|Women -over 18 years, ability to understand Swedish in spoken and written terms, gave birth to a child approximately 3 months ago via vaginal delivery or cesarean section will be included. Exclusion criteria will be chronic pain in the pelvis or back (defined as pain in pelvic or back in more than 3 months before pregnancy), major rupture of the pelvic floor at delivery e.g. sphincter rupture grade III/IV or other diseases or surgery that prevents examination of the pelvic floor or abdominal muscles.
89595788|NCT03703635|Experimental|Intracranial balloon angioplasty and aggressive medical management|All the participants in this group will be given Intracranial balloon angioplasty and aggressive medical management.
88978520|NCT02961049|Active Comparator|No retraction and self-conditioning|Application of self-conditioning adhesive system: selective enamel etched with 35% phosphoric acid, wash, dry, one layer of acid/pirmer on enamel and dentin with a brush, one layer of bond with a brush and photoactivated for 20 seconds.
88978521|NCT00261274|Experimental|Test Group A-ECO|
88978522|NCT00261274|Placebo Comparator|Control Group|
88978523|NCT00261313|Experimental|Aranesp|
88978524|NCT00261313|Experimental|Neulasta|
88978525|NCT00101244|Experimental|Treatment (ispinesib)|"Patients receive SB-715992 IV over 1 hour on days 1-3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of SB-715992 until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Up to 10 additional patients are treated at the MTD."
88978526|NCT00071942|Experimental|Treatment (vaccine therapy)|Patients receive vaccination comprising recombinant vaccinia-MUC-1 and recombinant vaccinia-TRICOM vaccine intradermally on days 1 and 29 (for a total of 2 doses) in the absence of disease progression or unacceptable toxicity.
88978527|NCT00261703|Experimental|1|(Docetaxel + Cisplatin + 5-FU) + Cisplatin + Radiotherapy
88978528|NCT00261703|Experimental|2|(Cisplatin + 5-FU) + Cisplatin + Radiotherapy
89595789|NCT03703635|Experimental|Aggressive Medical management|All the participants in this group will be given aggressive medical management alone.
89595790|NCT03684512|Experimental|Adolescent Only|Remote based physical activity intervention delivered to adolescents only. Adolescents will be asked to attend weekly group exercise sessions, individual support sessions, and monitor their daily physical activity.
89595791|NCT03684512|Active Comparator|Adolescent and Parent|Remote based physical activity intervention delivered to adolescents and their parent. Adolescents and a parent will be asked to attend weekly group exercise sessions, individual support sessions, and monitor their daily physical activity. Parents will have access to a Parent Facebook group.
89595792|NCT03672760|Active Comparator|IMT PowerBreath|"Participants will have PowerBreath device for IMT adjusted for 30% of maximal inspiratory pressure and will perform the exercise at home for five days/week during 10 minutes for five weeks.~An once a week meeting will provide re-adjustment of load through maximal inspiratory pressure performance"
89595793|NCT03672760|Placebo Comparator|IMT PowerBreath Placebo|"Participants will have PowerBreath device for IMT with no load and will perform the exercise at home for five days/week during 10 minutes for five weeks.~An once a week meeting will not re-adjustment the load though maximal inspiratory pressure performance will be performed"
89595794|NCT03672760|Active Comparator|CardioBreathApp|CardioBreathApp group will have the app settings of profile and spontaneous respiratory rate to determine the exercise rate of exercises, which will be performed at home for five days/week during 10 minutes for five weeks An once a week meeting will provide re-adjustment of respiratory rate to perform exercises
89595795|NCT03662022|No Intervention|No PEP|No PEP will be distributed
89595796|NCT03662022|Other|Household PEP|PEP will be given to all household contacts of an incident leprosy patient
88978529|NCT00261703|Experimental|3|Cisplatin + Radiotherapy
88978530|NCT00261781|Experimental|Treadmill training|Home-based treadmill training
88978531|NCT00261781|No Intervention|Usual care|Control group
88978532|NCT00261859|No Intervention|SCA|Standard Care with Assessment
88978533|NCT00261859|No Intervention|SCNA|Standard Care No Assessment
88978534|NCT00261859|Experimental|BNI|Brief Negotiated Interview
88978535|NCT00261859|Experimental|EBNI|Enhanced Brief Negotiated Interview
88978536|NCT00072098|Experimental|Experimental Group|Direct intratumoral injection of metastatic hepatic tumors using an adenoviral vector expressing the human recombinant interleukin-12 gene
88978537|NCT00261976||Patients in infliximab clinical studies|All patients enrolled in selected Centocor sponsored infliximab clinical studies.
88978538|NCT00072137|Experimental|Arm A (rf-GM-CSF, closed to accrual 10/2004)|Patients receive recombinant fowlpox GM-CSF vaccine adjuvant intravesically over 2 hours for 4 weekly doses (on days 1, 8, 15, and 22) with the last dose given 4-6 days prior to cystectomy.
89031612|NCT00531336|Experimental|1|Avastin first followed by retreatment of Macugen
89031613|NCT00531336|Active Comparator|2|Avastin intravitreally every 6 weeks
89595797|NCT03662022|Experimental|PEP 100m|PEP will be given to all household contacts of leprosy patients and to all other people living within a 100m radius of an incident leprosy patient.
89595798|NCT03662022|Other|PEP 100m + positive for anti-PGL-I IgM Ab|PEP will be given to all household contacts of leprosy patients and to all other people living within a 100m radius of an incident leprosy patient who test positive in the UCP-LFA detecting anti-M. leprae PGL-I IgM Ab in fingerstick blood (anti-PGL-I)
89595799|NCT03653741|Experimental|Healthy males|healthy males will undergo EEG, VEP, BAER, and SEP testing, then take a single dose of Perampanel 6 MG pill (intervention), then have blood drawn and undergo the 4 tests mentioned previously for a second time
89595800|NCT03649971|Experimental|Guselkumab Dose 1|Participants will receive guselkumab Dose 1 subcutaneous (SC), 6 doses every 4 weeks from Week 0 to Week 20. Participants who respond to guselkumab may continue treatment at the same dose level through Week 48.
89595801|NCT03649971|Experimental|Guselkumab Dose 2|Participants will receive guselkumab Dose 2 SC, 6 doses every 4 weeks from Week 0 to Week 20. Participants who respond to guselkumab may continue treatment at the same dose level through Week 48.
89595802|NCT03649971|Placebo Comparator|Placebo|Participants will receive placebo SC, 6 doses every 4 weeks from Week 0 to Week 20.
89595803|NCT03648996|Experimental|Low-fructose diet, isocaloric|Subjects assigned to this arm of the study will consume for 6 months a diet low in fructose while maintaining baseline body weight.
89595804|NCT03648996|Experimental|Allopurinol|Subjects assigned to this arm of the study will be treated for 6 months with allopurinol (max dose 300 mg)
89595805|NCT03648996|Placebo Comparator|Placebo|Subjects assigned to this arm will receive placebo
89595806|NCT03648996|Experimental|Low-fructose diet, hypocaloric|Subjects assigned to this arm of the study will consume for 6 months a diet low in fructose with a 500 Calorie energy reduction.
89595807|NCT03586050|Experimental|Microwave Ablation|All patients will receive microwave ablation using the NeuWave Microwave Ablation System and Accessories
89595808|NCT03523351|Active Comparator|Standard of care|Patients randomized to Arm 1 will undergo appropriate therapy as determined by their oncologist. These patients will either continue their current therapy or be transitioned to a new standard of care therapy at the discretion of the treating oncologist. If randomized to Arm 1, these patients may undergo palliative RT for progressive, painful lesions (a skeletal related event) at time of symptom development (not upfront palliative RT).
89595809|NCT03523351|Experimental|Selective radiation to ≤5 highest risk bone metastases|Patients on Arm 2 of the study will undergo selective RT to ≤ 5 high risk bone metastases defined as 1. bulkiest sites of osseous disease ≥ 2cm, 2. disease involving the hip (acetabulum, femoral head, femoral neck), shoulder (acromion, glenoid, humeral head), or sacroiliac joints 3. disease in long bones with1/3-2/3 cortical thickness (humerus, radius, ulna, clavicle, femur, tibia, fibula, metacarpus, phalanges) 4. disease in junctional spine (C7-T1, T12-L1, L5-S1) &/or disease with posterior element involvement.
89595810|NCT03523312|Experimental|HFA-IMRT|Eligible patients will receive HFA-IMRT to a total dose of 67.5 Gy in 15 fractions or 75Gy in 25 fractions to areas of gross tumor with concurrent capecitabine. Cross-sectional imaging will be repeated 4-6 weeks after the end of CRT to assess for resectability.
89595811|NCT03513614|Active Comparator|ALND|Tailored axillary surgery followed by axillary lymph node dissection (ALND) and regional nodal irradiation excluding the dissected axilla.
89595812|NCT03513614|Active Comparator|No ALND|Tailored axillary surgery followed by regional nodal irradiation including the full axilla.
89595813|NCT03507725|Experimental|Usual Care + Meditation|Usual care (local anaesthesia) + audio-recorded brief mind-dody intervention for 10 minutes before and for 10 minutes during the prostate biopsy procedure
89595814|NCT03507725|Active Comparator|Usual Care Group|Time-and-attention control group receiving usual care (local anesthesia) including optional background music in the biopsy procedure room
89595815|NCT03503331|Experimental|[C-11]PiB-PET/MRI|All participants in this study will undergo an amyloid-PET imaging using the tracer [C-11]PiB with a simultaneous PET/MRI system. The [C-11]PiB dosage is 300-670 MBq (8 - 18 mCi) given intravenously, and the PET/MRI imaging time is approximately 60 min.
89595816|NCT03483961|Experimental|Group 1: 20 mcg/unadjuvanted (Day 1 & 29)|20 mcg CHIKV VLP/unadjuvanted (Day 1) // Placebo (Day 15) // 20 mcg CHIKV VLP/unadjuvanted (Day 29)
89595817|NCT03483961|Experimental|Group 2: 6 mcg/adjuvanted (Day 1 & 29)|6 mcg CHIKV VLP/adjuvanted (Day 1) // Placebo (Day 15) // 6 mcg CHIKV VLP/adjuvanted (Day 29)
89595818|NCT03483961|Experimental|Group 3: 10 mcg/adjuvanted (Day 1 & 29)|10 mcg CHIKV VLP/adjuvanted (Day 1) // Placebo (Day 15) // 10 mcg CHIKV VLP/adjuvanted (Day 29)
89595819|NCT03483961|Experimental|Group 4: 20mcg/adjuvanted (Day 1 & 29);40mcg/adjuvant (Day 547)|20 mcg CHIKV VLP/adjuvanted (Day 1) // Placebo (Day 15) // 20 mcg CHIKV VLP/adjuvanted (Day 29) // 40 mcg CHIKV (Day 547)
89595820|NCT03483961|Experimental|Group 5: 6 mcg/adjuvanted (Day 15 & 29)|Placebo (Day 1) // 6 mcg CHIKV VLP/adjuvanted (Day 15) // 6 mcg CHIKV VLP/adjuvanted (Day 29)
89595821|NCT03483961|Experimental|Group 6: 10 mcg/adjuvanted (Day 15 & 29)|Placebo (Day 1) // 10 mcg CHIKV VLP/adjuvanted (Day 15) // 10 mcg CHIKV VLP/adjuvanted (Day 29)
89595822|NCT03483961|Experimental|Group 7: 20 mcg/adjuvanted (Day 15 & 29)|Placebo (Day 1) // 20 mcg CHIKV VLP/adjuvanted (Day 15) // 20 mcg CHIKV VLP/adjuvanted (Day 29)
88978539|NCT00072137|Experimental|Arm B (rf-TRICOM, closed to accrual 10/2004)|Patients receive recombinant fowlpox-TRICOM vaccine intravesically over 2 hours for 4 weekly doses (on days 1, 8, 15, and 22) with the last dose given 4-6 days prior to cystectomy.
88978540|NCT00072137|Experimental|Arm C (rfTRICOM and rf-GM-CSF)|Patients receive recombinant fowlpox-TRICOM vaccine combined with recombinant fowlpox GM-CSF vaccine adjuvant intravesically over 2 hours for 4 weekly doses (on days 1, 8, 15, and 22) with the last dose given 4-6 days prior to cystectomy.
88978541|NCT00105573|Experimental|Interpersonal Psychotherapy|Participants will receive interpersonal psychotherapy for depression.
88978542|NCT00105573|Experimental|Interpersonal psychotherapy/child-parent psychotherapy|Participants will receive interpersonal psychotherapy for depression plus 1 year of in-home, child-parent psychotherapy.
88978543|NCT00105573|Active Comparator|Enhanced community standard|Participants will be invited to attend informational meetings as well as be referred to local services available to people with depression.
89595823|NCT03483961|Experimental|Group 8: 40 mcg/adjuvanted (Day 29)|Placebo (Day 1) // Placebo (Day 15) // 40 mcg CHIKV VLP/adjuvanted (Day 29)
89595824|NCT03483961|Experimental|Group 9: 20 mcg/adjuvanted (Day 1 & 29)|20 mcg CHIKV VLP/adjuvanted (Day 1) // 20 mcg CHIKV VLP/adjuvanted (Day 29). This group will also have plasmapheresis performed on Day 57 and Leukapheresis on Day 182
89595825|NCT03483961|Experimental|Group 10: 40 mcg/adjuvanted (Day 1)|40 mcg CHIKV VLP/adjuvanted (Day 1). This group will also have plasmapheresis performed on Day 22.
89595826|NCT03481296|Active Comparator|Advanced Control|The advanced control group receives a set of standard materials regarding colorectal cancer screening.
89595827|NCT03481296|Experimental|Culturally Adapted Decision Support Navigation Intervention|The culturally adapted decision support navigation intervention group receives everything advanced group receives as well as decision support and navigation contacts.
89595828|NCT03477513|Experimental|Single Arm|Dose-escalated radiation therapy
89595829|NCT03459807|Experimental|Home systolic blood pressure (SBP) <140 mmHg|"Participants will be asked to take morning and evening blood pressures every two weeks on a non-dialysis day.~Participants will be asked to transmit these measures to the study team at minimum every 2 weeks either via Bluetooth technology, a manual log, telephone call, text message, e-mail, or verbal communication.~Assigned intervention will be dry weight adjustment and/or adjustment of standard anti-hypertensive medications."
89595830|NCT03459807|Active Comparator|Pre-dialysis SBP <140 mmHg|"Blood pressures taken in the clinical setting at prior to start of dialysis treatment will be recorded.~Assigned intervention will be dry weight adjustment and/or adjustment of standard anti-hypertensive medications."
89595831|NCT03449238|Other|Pembrolizumab and SRS|Pembrolizumab infusion will be given on Day 4 (+/-1) after SRS treatment at the standard dose of 200mg IV over 30 minutes and repeated every 3 weeks until disease progression or unacceptable toxicity.
89595832|NCT03441477|Experimental|Adults 18 years old or older|Nidek Tonoref III
89595833|NCT03439293|Experimental|Ixazomib 4 mg + Daratumumab 16 mg/kg + Dexamethasone 20 mg|Ixazomib, 4 mg, capsules, orally, on Days 1, 8 and 15 of each 28-day cycle along with daratumumab, 16 mg/kg, intravenously (IV), on Days 1, 8, 15 and 22 of Cycles 1 and 2, on Days 1 and 15 (every 2 weeks) for Cycles 3 to 6 and on Day 1 (every 4 weeks) for Cycle 7 and beyond along with dexamethasone, 20 mg, tablets, orally on Days 1, 2, 8, 9, 15, 16, 22 and 23 of each 28-day cycle until progressive disease (PD), unacceptable toxicity, or withdrawal of consent, or until the sponsor terminates the study or when the study has completed (approximately up to 4 years).
89595834|NCT03433742|Other|Preoperative Group|This is a group of 30 patients who will be undergoing a total hip replacement with a Trident II shell. This group of patients will have their bloods drawn and tested for metal ion levels at a preoperative visit.
89595835|NCT03433742|Other|1 year Postoperative Group|This is the same group of 30 patients who are now one year post op after having a total hip replacement with a Trident II shell. This group of patients will have their bloods drawn and tested for metal ion levels at their one year visit.
89595836|NCT03423979|Experimental|Optilume™ BPH Prostatic DCB Dilation Catheter|Optilume™ BPH Prostatic DCB treatment procedure
89595837|NCT03298178||all aortic stenosis|
89595838|NCT03239210|Active Comparator|Ondansetron (OND)|24 mg/day for 4 weeks
89595839|NCT03239210|Placebo Comparator|Placebo (PL)|Placebo pill
89595840|NCT03227224|Placebo Comparator|Placebo|Participants will receive 2 placebo capsules matching JNJ-42847922 once daily orally from Day 1 to Day 41 (Week 6).
89595841|NCT03227224|Experimental|JNJ-42847922|Participants will receive 2 capsules of JNJ-42847922 once daily orally from Day 1 to Day 41 (Week 6).
89595842|NCT03196466||antiepileptics titration|Titration of valproic acid, carbamazepine, phenobarbital, phenytoin, levetiracetam, lamotrigine, topiramate, oxcarbazepine, stiripentol, clobazam, brivaracétam, felbamate, lacosamide, rufinamide, gabapentine, pregabaline, sultiame, tiagabine, vigabatrine, mesuximide, primidone, perampanel, ethosuximide, zonisamide and cannabidiol
89595843|NCT03196466||antiepileptics titration and available blood samples|Titration of valproic acid, carbamazepine, phenobarbital, phenytoin, levetiracetam, lamotrigine, topiramate, oxcarbazepine, stiripentol, clobazam, brivaracétam, felbamate, lacosamide, rufinamide, gabapentine, pregabaline, sultiame, tiagabine, vigabatrine, mesuximide, primidone, perampanel, ethosuximide, zonisamide and cannabidiol
89595844|NCT03184870|Experimental|Part 1 Arm A [First-line (1L) Colorectal]: BMS-813160 followed by BMS-813160 + FOLFIRI|FOLFIRI: FOL (folinic acid [leucovorin]) F (fluorouracil [5-fluorouracil]) IRI (irinotecan [CAMPTOSAR])
89595845|NCT03184870|Experimental|Part 1 Arm B [1L Pancreatic]: BMS-813160 followed by BMS-813160 + Gemcitabine/Nab-paclitaxel|
89031614|NCT00531336|Active Comparator|3|Macugen intravitreally every 6 weeks
89595846|NCT03184870|Experimental|Part 1 Arm C [2L Pancreatic & 2/3L Colorectal MSS]: BMS-813160 followed by BMS-813160 + Nivolumab|2L: Second-line 2/3L: Second/third-line MSS: Microsatellite stable
89595847|NCT03184870|Experimental|Part 2 Arm A Cohort 1a [2L Colorectal]: BMS-813160 + FOLFIRI|
89595848|NCT03184870|Experimental|Part 2 Arm A Cohort 1b [2L Colorectal]: BMS-813160 + FOLFIRI|
89595849|NCT03184870|Experimental|Part 2 Arm A Cohort 1c [2L Colorectal]: FOLFIRI|
89595850|NCT03184870|Experimental|Part 2 Arm B Cohort 3a [1L Pancreatic]: BMS-813160 + Gemcitabine/Nab-paclitaxel|
89595851|NCT03184870|Experimental|Part 2 Arm B Cohort 3b [1L Pancreatic]: BMS-813160 + Nivolumab + Gemcitabine/Nab-paclitaxel|
89595852|NCT03184870|Experimental|Part 2 Arm B Cohort 3c [1L Pancreatic]: Gemcitabine/Nab-paclitaxel|
89595853|NCT03184870|Experimental|Part 2 Arm C Cohort 4 [2L Pancreatic]: BMS-813160 + Nivolumab|
89595854|NCT03184870|Experimental|Part 2 Arm C Cohort 5 [2/3L Colorectal MSS]: BMS-813160 + Nivolumab|
89595855|NCT03184870|Experimental|Part 2 Arm D Cohort 7 [2L Pancreatic]: BMS-813160 Monotherapy|
89031615|NCT00512486|Active Comparator|1|MEDI-563
89031616|NCT02951507|Active Comparator|Conventional partial denture|Intervention will be O T unilateral attachment
89031617|NCT02951507|Active Comparator|Conventional removal partial denture|Intervention will be new design of extra coronal attachment( O T unilateral attachment)
89031618|NCT00512525|Placebo Comparator|2|
89031619|NCT00531492|Experimental|A|
89031620|NCT00531492|Active Comparator|B|
89031621|NCT00512564||1|Patients suffering from Sickle cell disease
89595856|NCT03184870|Experimental|Part 2 Arm D Cohort 8 [2/3L Colorectal MSS]: BMS-813160 Monotherapy|
89595857|NCT03122522|Experimental|ipilimumab and nivolumab|Pts will receive 2 doses of ipilimumab 3mg/kg + nivolumab 1mg/kg every 3 weeks. Week 6, if pts have achieved a favorable antitumor effect by RECIST will begin maintenance nivolumab alone at 480mg every 4 weeks for 2 doses (week 6 & week 10) & repeat response assessments at week 12. If pts don't achieve a favorable antitumor effect at week 6, pt will get 2 additional doses of ipilimumab + nivolumab every 3 weeks & then will be assessed for response at week 12. If pts haven't achieved a favorable antitumor effect by week 12, if felt in the best interest for the pt as determined by the PI, pts may continue getting additional doses of ipilimumab + nivolumab with response reassessments after every 2 doses. Maintenance nivolumab will continued until unacceptable toxicity or confirmed disease progression. If pts have had an initial clinical benefit from therapy & subsequently experience progressive disease at any time, reinduction with combination ipilimuma+ nivolumab will be allowed.
89595858|NCT03086343|Active Comparator|Abatacept|500 mg (for body weight <60 kg); 750 mg (for body weight 60-100 kg); and 1000 mg (for body weight >100 kg) intravenous (IV) infusion at Baseline, Week 2, Week 4, Week 8, Week 12, Week 16 and Week 20
89595859|NCT03086343|Experimental|Upadacitinib 15 mg|One 15 mg tablet taken once per day by mouth for 24 weeks
89595860|NCT03074734|Other|Exposure to secondhand tobacco smoke|Exposure to secondhand tobacco smoke in outside smoking areas
89595861|NCT02904226|Experimental|Part A (JTX-2011)|Phase 1 dose escalation and expansion of JTX-2011 by intravenous (IV) infusion
89595862|NCT02904226|Experimental|Part B (JTX-2011 + nivolumab)|Phase 1 dose escalation and expansion of JTX-2011 by IV infusion in combination with nivolumab by IV infusion
89595863|NCT02904226|Experimental|Part C (JTX-2011)|Phase 2 expansion of JTX-2011 by IV infusion
89595864|NCT02904226|Experimental|Part D (JTX-2011 + nivolumab)|Phase 2 expansion of JTX-2011 by IV infusion in combination with nivolumab by IV infusion
89595865|NCT02904226|Experimental|Part E (JTX-2011 + ipilimumab)|Phase 1 dose escalation of JTX-2011 by IV infusion in combination with ipilimumab by IV infusion
89595866|NCT02904226|Experimental|Part F (JTX-2011 + ipilimumab)|Phase 2 expansion of JTX-2011 by IV infusion in combination with ipilimumab by IV infusion
89595867|NCT02904226|Experimental|Part G (JTX-2011 + pembrolizumab)|Phase 1 dose escalation of JTX-2011 by IV infusion in combination with pembrolizumab by IV infusion
89595868|NCT02904226|Experimental|Part H (JTX-2011 + pembrolizumab)|Phase 2 expansion of JTX-2011 by IV infusion in combination with pembrolizumab by IV infusion
89595869|NCT02862431|Experimental|Cohort 1 (JNJ-64565111 2.5 nmol/kg or Placebo)|Participants in ratio of 3:1 will receive 2.5 Nanomole Per Kilogram (nmol/kg) JNJ-64565111 or placebo.
89595870|NCT02862431|Experimental|Cohort 2 (JNJ-64565111 3 nmol/kg or Placebo)|Participants in ratio of 3:1 will receive 3.0 nmol/kg JNJ-64565111 or placebo. Dose may be escalated based on review by Sponsor and Principal Investigator of blinded safety, tolerability, pharmacokinetic, and (all available) pharmacodynamic data collected up to Day 29 but dose will not exceed 3.5 nmol/kg.
89595871|NCT02862431|Experimental|Cohort 3 (JNJ-64565111 3.5 nmol/kg or Placebo)|Participants in ratio of 3:1 will receive 3.5 nmol/kg JNJ-64565111 or placebo. Dose may be escalated based on review by Sponsor and Principal Investigator of blinded safety, tolerability, pharmacokinetic, and (all available) pharmacodynamic data collected up to Day 29 but dose will not exceed 3.5 nmol/kg.
89595872|NCT02862431|Experimental|Cohort 4 (JNJ-64565111 Repeat or Lower Dose or Placebo)|Participants in ratio of 3:1 will receive a dose of JNJ-64565111 or placebo that would be a repeat or lower dose level previously assessed as well-tolerated.
89595873|NCT02788045|Experimental|Group 1A: Ad26.Mos.HIV|Participants will receive Ad26.Mos.HIV vaccine at Week 0 and 12, followed by Ad26.Mos.HIV vaccine + Clade C glycoprotein 140 vaccine containing 250 micrograms (mcg) of total protein mixed with adjuvant (aluminum phosphate) at Week 24 and 48.
89595874|NCT02788045|Placebo Comparator|Group 1B: Placebo|Participants will receive placebo at Weeks 0, 12, 24 and 48.
88978544|NCT00262054|Experimental|A|bivalirudin is to be administered as an intravenous bolus of 0.75 mg/kg prior to the start of the intervention, followed by infusion of 1.75 mg/kg per hour for the duration of the procedure.
89595875|NCT02788045|Experimental|Group 2A: Ad26.Mos4.HIV|Participants will receive Ad26.Mos4.HIV vaccine at Week 0 and 12; followed by Ad26.Mos4.HIV vaccine + Clade C glycoprotein 140 vaccine containing 250 micrograms (mcg) of total protein mixed with adjuvant (aluminum phosphate) at Week 24 and 48. Participants will be included in an optional Long-term Extension (LTE) phase (3 years or 4 years Follow-up after Week 72, every 6 months visit) to assess immunogenicity and safety (serious adverse events [SAEs]).
89595876|NCT02788045|Placebo Comparator|Group 2B: Placebo|Participants will receive placebo at Weeks 0, 12, 24 and 48.
89595877|NCT02775695|Experimental|Doxycycline Administered to Patients|Patients will receive oral doxycycline and trough serum concentrations for pharmacokinetic studies will be obtained.
89595878|NCT02679040|Experimental|Immediate Mammary Reconstruction|Chemotherapy, radiation therapy, mastectomy with immediate mammary reconstruction
89595879|NCT02663232||Metastatic melanoma|Participants with metastatic melanoma who attend their physicians during the 18-month recruitment period and have valid biological samples available for BRAF mutation testing will be included in the study. There will be no intervention in this study.
89608528|NCT04143633|Active Comparator|FODMAP diet in healthy patients|Healthy patients will be randomized to standard diet or low fodmap diet. The nutritional status (body composition and clinical parameters), gut microbiota, adherence to treatment, improvement of gastrointestinal symptoms and quality of life will be evaluated for 10 weeks.
88978545|NCT00262054|Active Comparator|B|UFH given as an intravenous bolus of 140 units/kg. Double blinding will be maintained by using a double-dummy technique consisting of identical UFH and bivalirudin syringes and bivalirudin or placebo infusion bags.
89031622|NCT02943759|Experimental|Neem leaf extract|Neem leaf extract (alcoholic solution) used as an anti inflammatory , antibacterial irrigant
88978546|NCT02966366|Experimental|Cochlear implantation|Evaluation of tinnitus before and after cochlear implantation
88978547|NCT02966327|Experimental|Compression Stockings-Exercise|At T2 (4-6 weeks post-operatively), 25 study participants will be randomized to the intervention group and will be prescribed compression stockings and individualized exercise. They will also receive standard education on lymphedema risk reduction.
89595880|NCT02643498|Experimental|Stereotactic Body Radiotherapy (SBRT)|"Cohorts 1-3 After completion of induction chemotherapy, stereotactic body radiotherapy (SBRT) will be administered in 3 fractions, every other day, on an outpatient basis. Dose escalation will start with dose level 1 (9 Gy x 3 fractions) and increase by 1 Gy per fraction at each dose level, dose level 2 will be 10 Gy x 3 fractions and dose level 3 will be 11 Gy x 3 fractions.~Cohorts 4-6 For cohort 4, dose prescription will start at 7 Gy x 6 fractions (42Gy, isoeffective to 11 Gy x 3), followed by 4.8 Gy x 12 (54Gy) and 4.5Gy x 15 (67.5Gy)."
89595881|NCT02610075|Experimental|AZD1775|This is a single-arm study in which all patients will receive AZD1775 orally. Patients will continue to receive treatment with AZD1775 until disease progression, intolerable toxicity, or discontinuation criteria are met.
89595882|NCT02599454|Experimental|atezolizumab + SBRT|"DOSE ESCALATION PHASE: Patients receive atezolizumab IV over 30-60 minutes on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Within 24-48 hours after receiving atezolizumab, patients also undergo 4-5 fractions of stereotactic body radiation therapy over days 1-5 of course 3.~EXPANSION PHASE: Patients receive atezolizumab IV over 30-60 minutes on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Within 24-48 hours after receiving atezolizumab, patients also undergo 4-5 fractions of stereotactic body radiation therapy over days 1-5 of course 3."
89595883|NCT02505919|Experimental|Treatment|AQUABEAM System
89595884|NCT02505919|Active Comparator|Active Comparator|Transurethral Resection of the Prostate (TURP)
89595885|NCT02482311|Experimental|AZD1775|"Single-arm study. AZD1775 will be administered for 3 consecutive days at the start of week 1 and week 2 of each 21-day cycle.~This study will be conducted in two parts, designated Part A and Part B. Part A is a safety lead-in. Part B will commence after the safety lead-in and will investigate the safety and efficacy of AZD1775 monotherapy in expansion cohorts of specific tumour types."
89595886|NCT02344680||HIV-HBV co-infected|HIV-HBV co-infected patients receiving anti-retroviral therapy
89595887|NCT02315703|Experimental|Group 1|Participants will receive adenovirus serotype 26-Mosaic -Human Immunodeficiency Virus (Ad26.Mos.HIV) vaccine at Week 0 and 12; followed by Ad26.Mos.HIV vaccine + HIV type 1 Clade C glycoprotein 140 drug product (gp140 DP) vaccine containing 250 microgram (mcg) of total protein mixed with adjuvant (aluminum phosphate) at Week 24 and 48.
89595888|NCT02315703|Experimental|Group 2|Participants will receive Ad26.Mos.HIV vaccine at Week 0 and 12; followed by Ad26.Mos.HIV vaccine + gp140 DP vaccine containing 50 mcg of total protein mixed with adjuvant at Week 24 and 48.
89595889|NCT02315703|Experimental|Group 3|Participants will receive Ad26.Mos.HIV vaccine at Week 0 and 12; followed by Ad26.Mos.HIV vaccine + placebo injection at Week 24 and 48.
89595890|NCT02315703|Experimental|Group 4|Participants will receive Ad26.Mos.HIV vaccine at Week 0 and 12; followed by modified Vaccinia Ankara (MVA)-Mosaic vaccine + gp140 DP vaccine containing 250 mcg of total protein mixed with adjuvant at Week 24 and 48.
89595891|NCT02315703|Experimental|Group 5|Participants will receive Ad26.Mos.HIV vaccine at Week 0 and 12; followed by MVA-Mosaic vaccine + gp140 DP vaccine containing 50 mcg of total protein mixed with adjuvant at Week 24 and 48.
89595892|NCT02315703|Experimental|Group 6|Participants will receive Ad26.Mos.HIV vaccine at Week 0 and 12; followed by MVA-Mosaic vaccine + placebo injection at Week 24 and 48.
89595893|NCT02315703|Experimental|Group 7|Participants will receive Ad26.Mos.HIV vaccine at Week 0 and 12; followed by gp140 DP vaccine containing 250 mcg of total protein mixed with adjuvant + placebo injection at Week 24 and 48.
89595894|NCT02315703|Placebo Comparator|Group 8|Participants will receive 1 placebo injection at Week 0 and 12; followed by 2 placebo injections at Week 24 and 48.
89595895|NCT02188108|Experimental|Survey|Wisconsin Stone-QOL survey. Patients with kidney stones or a history thereof will complete a kidney stone-specific health-related survey at enrollment and post-enrollment at 3 months, 12 months, 24 months, and 36 months.
89595896|NCT02132858||Ancillary-Correlative (genetic mutation analysis)|Patients undergo collection of blood and tissue samples for analysis via sequencing.
89595897|NCT02049359|No Intervention|Control group|Care as usual; no bidirectional texting
89595898|NCT02049359|Experimental|Texting|Bidirectional texting weekly for 12 weeks
89595899|NCT01839695|Experimental|Valiant Mona LSA Stent Graft System|TEVAR procedure using Medtronic Stent Graft
89595900|NCT01836783|Experimental|Amnion Allograft|Atraumatic tooth extractions and amnion allograft procedures
89595901|NCT01836783|Active Comparator|Allograft|Atraumatic tooth extractions and allograft procedures
89595902|NCT01608074|Experimental|BRCA mutation carriers|"Women with BRCA1 or BRCA 2 mutation or a family history of breast/ovarian cancer.~Radical fimbriectomy. Histopathology SEE-FIM"
89595903|NCT01466686|Experimental|Temozolomide with Low Dose Fractionated Radiation Therapy|"All patients will receive temozolomide (150 to 200 mg per square meter for 5 days during each 28 day cycle) for a total of 1 year or until the time of disease progression.~All patients will receive 0.5 Gy of radiation therapy twice daily. This study will include a safety run-in component. If > 33% of patients in the initial cohort of 6 experience grade 3 or greater hematologic toxicity according to the NCI Common Toxicity Criteria version 4, then a dose reduction will occur following the schedule listed below. Otherwise, following a 1 month waiting period after the first cycle of adjuvant LDFRT plus temozolomide for the first cohort of patients, the phase 2 study will open for full accrual. Patients will receive radiation with the first six 28-day cycles of temozolomide."
89595904|NCT01093196|Active Comparator|Rd|Induction treatment with oral Lenalidomide and low dose dexamethasone followed by maintenance therapy with Lenalidomide alone or Lenalidomide and Prednisone
89595905|NCT01093196|Experimental|MPR|Induction treatment with oral Lenalidomide, Prednisone and Melphalan followed by maintenance therapy with Lenalidomide alone or Lenalidomide and Prednisone
89595906|NCT01093196|Experimental|CPR|Induction treatment with oral Lenalidomide, Cyclophosphamide and Prednisone for followed by maintenance therapy with Lenalidomide alone or Lenalidomide and Prednisone.
89595907|NCT01091831|Active Comparator|CRD|Oral therapy with Cyclophosphamide, Lenalidomide and Dexamethasone.
89595908|NCT01091831|Active Comparator|MEL200|High dose Melphalan therapy (200 mg/m2) followed by stem cell support for 2 cycles every 4 months (for 1 cycle if at least VGPR was achieved after the 1st MEL200)
89595909|NCT00481546|Experimental|Experimental|All clinical trial subjects received the same vector.
89595910|NCT01550289|Experimental|Group 1: CYD dengue vaccine|Subjects will receive a dose of CYD dengue vaccine at 0, 6, and 12 months, respectively.
89595911|NCT01550289|Placebo Comparator|Group 2: Placebo|Subjects will receive a dose of placebo at 0, 6, and 12 months, respectively
89595912|NCT04108143|Experimental|Intervention|MonitorMe device
89595913|NCT04107519|Experimental|Immediate GRIT (ImT) training intervention|
89595914|NCT04107519|No Intervention|Delayed Training (DeT) control|
89595915|NCT01968031|Experimental|Istradefylline 20 mg/day|"Istradefylline 20 mg and placebo to match istradefylline 40 mg:~A daily, oral, double-blind treatment dose of both tablets will be taken in the morning for 12 weeks."
89595916|NCT01968031|Experimental|Istradefylline 40 mg/day|"Istradefylline 40 mg and placebo to match istradefylline 20 mg:~A daily, oral, double-blind treatment dose of both tablets will be taken in the morning for 12 weeks."
89595917|NCT01968031|Placebo Comparator|Placebo|"Placebo to match istradefylline 20 mg and placebo to match istradefylline 40 mg:~A daily, oral, double-blind treatment dose of both tablets will be taken in the morning for 12 weeks."
89595918|NCT01684215|Experimental|Single-agent PD-0332991|Phase 1 Part 1
89595919|NCT01684215|Experimental|PD-0332991 in combination with letrozole|Phase 1 Part 2
89595920|NCT01684215|Experimental|PD-0332991 with letrozole|Phase 2
89595921|NCT04106973||Pleural mesothelioma|Participants with all types of histologically identified pleural mesothelioma prior to, subsequent to,or concurrent with treatment.
89595922|NCT04106973||Asbestos exposed without pleural mesothelioma|Participants with asbestos exposure radiographically confirmed by the presence of bilateral pleural plaques or bilateral pleural thickening and without presence of pleural mesothelioma.
89595923|NCT01908205|Experimental|Intranasal Oxytocin (Syntocinon)|The proposed dosing schedule is 0.4 IU/kg, taken twice daily, for a maximum of 24 IUs per dose
89595924|NCT01908205|Placebo Comparator|Placebo|The proposed dosing schedule is 0.4 IU/kg, taken twice daily, for a maximum of 24 IUs per dose
89595925|NCT01549041|Experimental|asenapine 10 mg daily in the evening|Patients will receive their entire daily dose of asenapine as a single dose in the evening
89595926|NCT01549041|Active Comparator|asenapine 5 mg twice daily|Patients will receive asenapine 5 mg daily in the morning and 5 mg daily in the evening
89595927|NCT01907815|Experimental|Treatment (trametinib, Akt inhibitor GSK2141795)|Trametinib orally once daily (PO QD) and Akt inhibitor GSK2141795 PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89595928|NCT01548573|Experimental|Tandem autologous stem cell transplant|"Induction: DPACE(dexamethasone,cisplatin,doxorubicin,cyclophosphamide,etoposide) chemotherapy plus stem cell collection. Additional stem cell collection and/or chemotherapy may be required.~After collection, participants will receive dexamethasone x 4 days every 14 days.~Transplant 1: The transplant preparative regimen will be bortezomib/thalidomide/dexamethasone/melphalan.~Once recovered, participants start thalidomide daily and dexamethasone x 4 days every 21 days.~Consolidation (if administered): VDT-PACE(bortezomib,dexamethasone,thalidomide,cisplatin,doxorubicin,cyclophosphamide, etoposide) Transplant 2: 8 weeks to 6 months after the first transplant, participants will have the second transplant Maintenance: Year 1- VTD (bortezomib, thalidomide, dexamethasone) cycles. Year 2 - VCD (bortezomib, cyclophosphamide, dexamethasone)cycles."
89595929|NCT01907737|Active Comparator|Active tDCS and active PNS|1 session of active transcranial direct current stimulation (TDCS) of the hemisphere affected by the stroke and active peripheral nerve stimulation (PNS)
89595930|NCT01907737|Other|Active tDCS and sham PNS|1 session of active transcranial direct current stimulation (TDCS) of the hemisphere affected by the stroke and sham peripheral nerve stimulation (PNS)
89595931|NCT01907737|Other|Sham tDCS and active PNS|1 session of sham transcranial direct current stimulation (TDCS) of the hemisphere affected by the stroke and active peripheral nerve stimulation (PNS)
89595932|NCT01907737|Sham Comparator|Sham tDCS and sham PNS|1 session of sham transcranial direct current stimulation (TDCS) of the hemisphere affected by the stroke and sham peripheral nerve stimulation (PNS)
89595933|NCT01570491|Active Comparator|ultrasound-guided spinal anesthesia|participants will randomly assigned to use ultrasound-guided technique for block placement by Anesthesiologist.
89595934|NCT01570491|Placebo Comparator|standard spinal anesthesia|randomized participants will be given standard spinal anesthesia insertion technique for block placement by Anesthesiologist
89595935|NCT04118517|Experimental|test meal|The study comprises one arm of 12 healthy Jamaican male and female adults with normal body mass inex, aged 20 to 45 years, receiving a test meal containing the common bean that was intrinsically labelled with deuterium .
89595936|NCT04117425|Other|Pregnant women|"40 Pregnant women and 10 Pregnant women that have a medical interruption of pregnancy who were already treated by levetiracetam.~Blood collection at each trimester of pregnancy, delivery and post partum visit or at medical interruption.~Collection of saliva at each trimester of pregnancy and post partum visit. Collection of cord blood and amniotic fluid at delivery or at medical interruption"
89595937|NCT01929109|Experimental|LY2409021 Control|Healthy participants received a single 80 mg dose of LY2409021 orally on Day 1 of the study.
89595938|NCT01929109|Experimental|LY2409021 Mild Renal Impairment|Participants received a single 80 mg dose of LY2409021 orally on Day 1 of the study.
89031623|NCT02943759|Active Comparator|Chlorhexidine gluconate|2% chlorhexidine gluconate intracanal irrigant solution used as an antibacterial chemical mean for canal irrigation
89031624|NCT00514241|Experimental|A|The arm utilizes the GPS™ II Platelet Concentrate Separation Kit.
89595939|NCT01929109|Experimental|LY2409021 Moderate Renal Impairment|Participants received a single 80 mg dose of LY2409021 orally on Day 1 of the study.
89595940|NCT01929109|Experimental|LY2409021 Severe Renal Impairment|Participants received a single 80 mg dose of LY2409021 orally on Day 1 of the study.
89595941|NCT01929109|Experimental|LY2409021 End Stage Renal Disease|Participants received a single 80 mg dose of LY2409021 orally on Day 1 of Period 1 of the study and a single 80 mg dose of LY2409021 orally on Day 1 of Period 2 of the study.
89608529|NCT05581563|Active Comparator|tourniquet use|knee replacement surgery with the aid of a tourniquet - a tight band placed around the thigh that restricts blood flow to the knee.
89608530|NCT05581563|Sham Comparator|without tourniquet use|knee replacement surgery without the aid of a tourniquet - a tight band placed around the thigh that restricts blood flow to the knee.
89595942|NCT01518153|Experimental|Low Dose Donor T-Cells|Fludarabine 40 mg/m^2 by vein on Day -6 to -3. Melphalan 140 mg/m^2 by vein on Day -2. Alemtuzumab 50 mg by vein on Day -1. Reduced intensity stem cell transplant on Day 0. Planned Donor Lymphocyte Infusion CD3+ cells: 3 * 106 CD3+ cells/kg between Day +56 and +64. Tacrolimus 0.015 mg/kg by vein as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml (target is 10 ng/ml). Tacrolimus is changed to oral dosing when tolerated. Tapering should start on approximately Day +24 with intention to be completely off drug by approximately Day +35. Methotrexate 5 mg/m2 dosed based on actual body surface area and administered intravenously on days +1, +3, +6. G-CSF 5 mcg/kg/day subcutaneously beginning on Day +7, and continuing until absolute neutrophil count (ANC) is > 500 * 10/L for 3 consecutive days.
89595943|NCT01518153|Experimental|High Dose Donor T-Cells|Fludarabine 40 mg/m^2 by vein on Day -6 to -3. Melphalan 140 mg/m^2 by vein on Day -2. Alemtuzumab 50 mg by vein on Day -1. Reduced intensity stem cell transplant on Day 0. High Dose Donor T-Cells Planned Donor Lymphocyte Infusion CD3+ cells: 1 * 107 CD3+ cells/kg between Day +56 and +64. Tacrolimus 0.015 mg/kg by vein as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml (target is 10 ng/ml). Tacrolimus is changed to oral dosing when tolerated. Tapering should start on approximately Day +24 with intention to be completely off drug by approximately Day +35. Methotrexate 5 mg/m2 dosed based on actual body surface area and administered intravenously on days +1, +3, +6. G-CSF 5 mcg/kg/day subcutaneously beginning on Day +7, and continuing until absolute neutrophil count (ANC) is > 500 * 10/L for 3 consecutive days.
89595944|NCT01906489|Experimental|AKB-6548|
89595945|NCT01906489|Placebo Comparator|Placebo|
89595946|NCT04620343|Active Comparator|Phase 1, Group 1|"Patients are provided with basic information and breathing advice with biofeedback (IBA).~This is the reference treatment against which the other methods will be measured."
89595947|NCT04620343|Experimental|Phase 1, Group 2|Patients are provided with basic information and breathing advice with biofeedback (IBA) and treated with inspiratory muscle training (IMT)
89595948|NCT04620343|Experimental|Phase 1, Group 3|Patients are provided with basic information and breathing advice with biofeedback (IBA) and treated with speech therapy
89595949|NCT04620343|Experimental|Phase 1, Group 4|Patients are provided with basic information and breathing advice with biofeedback (IBA) and treated with inspiratory muscle training (IMT) and speech therapy
89595950|NCT04620343|No Intervention|Phase 2, Group 1|Groups 2,3,4 in Phase 1 Wait for therapy effect
89595951|NCT04620343|Experimental|Phase 2, Group 2|If patients from Phase 1, Group 1 (reference treatment) have unchanged CLE-scoring, they are treated with inspiratory muscle training (IMT) and speech therapy.
89595952|NCT04620343|Experimental|Phase 3, Group 1|Treated with Surgery, supraglottoplasty - full procedure
89595953|NCT04620343|Experimental|Phase 3, Group 2|Treated with Surgery, supraglottoplasty mini-invasive procedure
89595954|NCT04620343|No Intervention|Phase3, Group 3|Non-surgery control group
89595955|NCT01517373|Placebo Comparator|Placebo|Placebo to match PF-04937319 and glimepiride
89595956|NCT01517373|Experimental|PF-04937319 10 mg|
89595957|NCT01517373|Experimental|PF-04937319 50 mg|
89595958|NCT01517373|Experimental|PF-04937319 100 mg|
89595959|NCT01517373|Active Comparator|Glimepiride|
89595960|NCT01517295|Experimental|Group 1|Blood will be drawn at 0, 1, 3, and 5 hours after taking one dose of hydrocodone/APAP. Urine will be taken at hour 0 and 3.
89595961|NCT01517295|Experimental|Group 2|Blood will be drawn at 0, 2, 4, and 6 hours after one dose of hydrocodone/APAP. Urine will be taken at hour 0 and 4.
89595962|NCT01541865|Other|Renal Denvervation|All subjects who meet the inclusion criteria and are enrolled in this trial will be treated with the Vessix Renal Denervation System.
89595963|NCT01541397|No Intervention|Non-Kuvan treated|Adults with hyperphenylalaninemia who have are not receiving Kuvan therapy.
89595964|NCT01541397|Experimental|Kuvan treated|Adults with hyperphenylalaninemia who are treated with Kuvan (sapropterin).
89031625|NCT00514241|No Intervention|B|This arm utilizes standard leg wound closure procedures.
89595965|NCT04104321|Experimental|Aramchol|Aramchol 300 mg oral tablet
89595966|NCT04104321|Placebo Comparator|Placebo|Placebo matching oral tablet
89595967|NCT04104165|Active Comparator|Intermittent catheterization|women who are catheterized intermittently every 6-8 hours up to a total time of 48 hours
89595968|NCT04104165|Active Comparator|Continous catheterization|women which will have an indwelling catheter inserted for 24 hours
89031626|NCT02944110|Active Comparator|Pancreatectomised + LY2409021|During the experimental day the patient will undergo a 75gr-OGTT. On the evening before the experimental day, the patient will ingest a dose of 300mg of LY2409021.
89031627|NCT02944110|Placebo Comparator|Pancreatectomised + placebo|During the experimental day the patient will undergo a 75gr-OGTT. On the evening before the experimental day, the patient will ingest placebo tablets.
89031628|NCT02944110|Active Comparator|Healthy + LLY2409021|During the experimental day the subject will undergo a 75gr-OGTT. On the evening before the experimental day, the subject will ingest a dose of 300mg of LY2409021.
89595969|NCT04103775|Experimental|Cognitive Remediation|Cognitive Remediation comprises of six exercises supplied by BrainHQ by Posit Science Corporation: Sound Sweeps (targets auditory processing speed): Two successive frequency-modulated tone sweeps are presented and participants indicate whether the frequency increased or decreased within each tone: Fine Tuning (targets auditory perception and processing speed): Participants indicate which one of two confusable syllables were presented; Syllable Stacks (targets auditory memory); Users report the order of presented syllables in a serial memory span task; Memory Grid (targets auditory memory); Participants match identical cards representing syllables; To do List Training (targets auditory memory): Participants see a g rid of everyday items (e.g., plant, carrots, shovel) and select the items in accordance with spoken instructions; Rhythm Recall (target auditory memory): Participants recreate auditory melodies
89595970|NCT04103775|Active Comparator|Active Control|Active Control Comprises six exercises also supplied by Post Science Corporation: A Maze Race, Reversi, Bricks Breaking Hex, Word Search II, Bricks Squasher II, and CircloO. These are all common computer games freely offered online.
89595971|NCT01548417|Active Comparator|Korlym (mifepristone)|600 mg daily taken orally for one week
89595972|NCT01548417|Placebo Comparator|Sugar Pill|placebo pill daily taken orally for one week
89595973|NCT01546857|Placebo Comparator|placebo|Placebo one dose in the evening of surgery and post op day #1.
89595974|NCT01546857|Active Comparator|Gabapentin|Gabapentin 400mg orally at 9pm on the evening of surgery and first day post operatively
89595975|NCT04767867|Experimental|Facemask oxygen (FM)|100% oxygen administered via facemask through circle system with adjustable pressure-limiting valve at 0 cmH20. Participant instructed to 'breathe normally'
89595976|NCT04767867|Active Comparator|High-flow nasal oxygen (HFNO)|100% oxygen administered via high-flow nasal cannulae at 50 L/min. Participant instructed to 'keep the mouth closed and breathe normally'
89595977|NCT04767867|Active Comparator|High-flow nasal oxygen plus mouthpiece oxygen (HFNO+MP)|100% oxygen administered via high-flow nasal cannulae at 50 L/min. Additionally, 100% oxygen administered via mouthpice through circle system with adjustable pressure-limiting valve at 0 cmH20. Participant instructed to 'keep the mouth closed and breathe normally'.
89595978|NCT01540851|Active Comparator|Care Navigator Intervention Group|Subjects randomized to the Care Navigator Intervention group will receive up to 10 telephone calls from a care navigator for 5 months post-operatively
89595979|NCT01540851|Active Comparator|Usual Care Group|Subjects in the Usual Care group receive the current standard post-operative TKA care
89595980|NCT01516749|Experimental|Anakinra|All patients in this arm will receive the investigation drug anakinra once daily subcutaneously.
89595981|NCT01516437|Experimental|HNS Group|Healthy non-smokers aged between 45-75 years
89595982|NCT01516437|Experimental|HS Group|Healthy smokers aged between 45-75 years
89595983|NCT01516437|Experimental|FeCOPD Group|COPD subjects with ≥ two exacerbations within 365 days prior to the screening visit (frequent exacerbators), aged between 45-75 years
89595984|NCT01516437|Experimental|NFeCOPD Group|COPD patients with one exacerbation within 365 days prior to the screening visit (non-frequent exacerbators), aged between 45-75 years
89210033|NCT00895908|Active Comparator|Individual Tutoring|Participants will receive individual academic tutoring.
89595985|NCT01515423|Experimental|Paliperidone palmitate 3-month (PP3M)|A formulation of paliperidone palmitate with a 3-month injection interval
89595986|NCT01515423|Active Comparator|Paliperidone palmitate 1-month (PP1M)|A formulation of paliperidone palmitate with a 1-month injection interval
89595987|NCT00637156|Experimental|PRESTIGE LP Device|
89595988|NCT00637156|Other|ATLANTIS Cervical Plate System|
89595989|NCT00637000|Experimental|Buprenorphine soluble film|"Day 1: Buprenorphine soluble film administered at a dose of 4 mg 3 times per day, plus placebo. Dosing occurred at 0900, 1100, and 2000 hours.~Days 2-5: Buprenorphine soluble film administered at a dose of 16 mg to 24 mg once per day, plus placebo. Dosing occurred at 0900 hours."
89595990|NCT00637000|Experimental|Buprenorphine/naloxone soluble film|"Day 1: Buprenorphine/naloxone soluble film administered at a dose of 4mg/1mg 3 times per day, plus placebo. Dosing occurred at 0900, 1100, and 2000 hours.~Days 2 to 5: Buprenorphine/naloxone soluble film administered at a dose of 16mg/4 mg to 24 mg/6 mg once per day, plus placebo. Dosing occurred at 0900 hours."
89595991|NCT01515189|Experimental|Arm 1: Ipilimumab (3 mg/kg)|Ipilimumab 3 mg/kg solution intravenously once every 3 weeks for 4 doses; option for Re-induction, until disease progression or unacceptable toxicity
89595992|NCT01515189|Experimental|Arm 2: Ipilimumab (10 mg/kg)|Ipilimumab 10 mg/kg solution intravenously once every 3 weeks for 4 doses; option for Re-induction, until disease progression or unacceptable toxicity
89595993|NCT04767399|Experimental|Single visit|root canal treatment will be done in one visit
89595994|NCT04767399|Experimental|multiple visit|root canal treatment will be done in multiple visit
89595995|NCT01546623|Experimental|TAP-144-SR(6M)|TAP-144-SR(6M) 22.5 mg, injection, treatment interval 24 weeks for up to 48 weeks.
89210034|NCT00895986|Experimental|1|Conversation Maps Diabetes Education
89210035|NCT00895986|Experimental|2|Heart Healthy Living Diabetes Education
89595996|NCT01546623|Active Comparator|TAP-144-SR(3M)|TAP-144-SR(3M) 11.25 mg, injection, treatment interval 12 weeks for up to 48 weeks.
89595997|NCT01546155|Experimental|healthy controls|
89595998|NCT00636610|Experimental|Vismodegib 150 mg|Patients received vismodegib 150 mg orally once daily starting on Day 3 of each 2-week treatment cycle. In addition, patients received either Modified FOLFOX (FOL=leucovorin calcium [folinic acid], F=fluorouracil, OX=oxaliplatin) + bevacizumab or FOLFIRI (FOL=leucovorin calcium [folinic acid] F=fluorouracil, IRI=irinotecan hydrochloride) + bevacizumab on Days 1-3 of each 2-week treatment cycle. The decision of which regimen (FOLFOX or FOLFIRI) to use was made by the treating physician and patient.
89595999|NCT00636610|Placebo Comparator|Placebo to vismodegib|Patients received placebo to vismodegib orally once daily starting on Day 3 of each 2-week treatment. In addition, patients received either Modified FOLFOX (FOL=leucovorin calcium [folinic acid], F=fluorouracil, OX=oxaliplatin) + bevacizumab or FOLFIRI (FOL=leucovorin calcium [folinic acid] F=fluorouracil, IRI=irinotecan hydrochloride) + bevacizumab on Days 1-3 of each 2-week treatment cycle. The decision of which regimen (FOLFOX or FOLFIRI) to use was made by the treating physician and patient.
89596000|NCT01923220|Experimental|HO/02/02|Interventions involving HO/02/02 20µg VS. Aloe Vera Jel (SOC). Treatment will be applied topically once daily
89596001|NCT01923220|Sham Comparator|Aloe Vera Jel|To be applied topically
89596002|NCT00635050|Experimental|Doxil, Paclitaxel, Cyclophosphamide + Avastin|Two stage phase II single arm trial to evaluate the pathologic complete response rate to sequential dose dense chemotherapy using Doxil 25 mg/M2 iv and Avastin 10 mg/kg iv every 2 weeks x 3, then paclitaxel 175 mg/M2 iv and Avastin 10 mg/kg iv every 2 weeks x 3, then cyclophosphamide 600 mg/M2 iv and Avastin 10 mg/kg iv every 2 weeks x 3, in patients with locally advanced invasive breast cancer.
89596003|NCT05240404|Other|Arm A|Patients with recurrent hepatocellular carcinoma would be treated with curative-intent ablation alone.
89596004|NCT05240404|Experimental|Arm B|Patients with recurrent hepatocellular carcinoma would be treated with curative-intent ablation and adjuvant immunotherapy with toripalimab.
89596005|NCT01923376|Other|Lactulose|per standard of care
89596006|NCT01923376|Active Comparator|polyethylene glycol 3350 (Golytely)|
89596007|NCT05245786|Experimental|Treatment (64Cu labeled M5A antibody and imaging)|Patients receive 64Cu labeled M5A antibody IV over 5 minutes on day 0 pre standard of care chemo/radiotherapy and on day 0 post chemo/radiotherapy. Patients also undergo 64Cu-M5A PET scan on day 1 pre chemo/radiotherapy and on day 1 post chemo/radiotherapy.
89596008|NCT00634504|Experimental|A|High-dose methotrexate, leucovorin, and Voraxaze
89596009|NCT00634504|Active Comparator|B|High-dose methotrexate and leucovorin without Voraxaze (glucarpidase)
89031629|NCT02944110|Placebo Comparator|Healthy + placebo|During the experimental day the subject will undergo a 75gr-OGTT. On the evening before the experimental day, the subject will ingest placebo tablets.
89031630|NCT02943837|Active Comparator|EUS-FNA|Device: 22G FNA needle
89031631|NCT02943837|Experimental|EUS-FNB|Device: 20G FNB needle
89031632|NCT02951975||OZURDEX®|Patients prescribed dexamethasone intravitreal implant (OZURDEX®) in clinical practice for the treatment of non-infectious uveitis affecting the posterior segment of the eye.
89517803|NCT02324777|Experimental|CanniMed™ DPF-IV Volcano® Vapourization|Using the Volcano® Medic, a dose of 100 mg of finely ground herbal cannabis drug product formulation with a potency specification similar to CanniMed™ 4·10 product, of 3.8% w/w total THC and 10.0% w/w total CBD is vapourized and inhaled by study subjects.
89031633|NCT00514358||gestational age|
89031634|NCT00512642||Patients at increased risk of lung cancer|Patients at increased risk of lung cancer
89031635|NCT00531648||1|Families with toddlers that having feeding disorders and SPD
89031636|NCT02943603|Experimental|mFOLFX6 + Pembrolizumab|Subjects will receive mFOLFOX6 every 2 weeks (on Days 1, 15, 29, 43) and Pembrolizumab every 3 weeks (on Days 1, 22, 43).
89031637|NCT00514436|No Intervention|Usual care|Usual care consisted of referral back to primary care provider after index hospitalization
89031638|NCT00514436|Experimental|Behavioral|Asthma coaching, inperson contact followed by telephone contact
89031639|NCT00531687|Other|GCT|cisplatin Paclitaxel gemcitabine
89031640|NCT00530829|Experimental|1|Mothers recieve a blister pack of zinc tablets in home every two months for use when child in home under 5 years has diarrhea. ORS satchets also given. Instructions on when and how to use zinc and ORS and when to take child in clinic are given by community health worker. Zinc will also be given in clinic if child visits clinic with diarrhea and has not yet started zinc at home.
89517804|NCT02324777|Experimental|CanniMed™ DPF-V Volcano® Vapourization|Using the Volcano® Medic, a dose of 100 mg of finely ground herbal cannabis drug product formulation with a potency specification similar to CanniMed™ 1·13 product profile of 0.6% w/w total THC and 13.0% w/w total CBD is vapourized and inhaled by study subjects.
89517805|NCT02324777|Placebo Comparator|CanniMed™ DPF-P Volcano® Vapourization|"Using the Volcano® Medic, a dose of 100 mg of ethanol extracted DPF-V, reducing the potency profile to <0.3% w/w total THC and <0.3% w/w total CBD (comparable to the threshold levels described for industrial hemp, as per the Canadian Industrial Hemp Regulations (SOR/98-156), is vapourized and inhaled by study subjects."
89517806|NCT05681845|Experimental|Arm 1 (Pilot part)|Participants will receive a single dose of Mim8 using a 32G, 4 mm pen-needle with the DV3407-C1 pen injector.
89517807|NCT05681845|Experimental|Arm 2 (Pilot part)|Participants will receive a single dose of Mim8 using a 29G, 8 mm needle and syringe with the enhanced cartridge.
89517808|NCT05681845|Experimental|Arm 3 (Bioequivalence part)|Participants will receive a single dose of Mim8 using a 29G, 4 mm pen-needle with the DV3407-C1 pen injector.
89517809|NCT05681845|Experimental|Arm 4 (Bioequivalence part)|Participants will receive a single dose of Mim8 using a 29G, 8 mm needle and syringe with the enhanced cartridge.
89517810|NCT03496415|Experimental|Remote ischemic conditioning|
89517811|NCT03496415|Sham Comparator|Sham remote ischemic conditioning|
89517812|NCT05397925|Experimental|ADSProgram|"This is the experimental arm of the study. This includes receiving the novel/experimental ADSProgram. Therapy description withheld to protect the integrity of the study.~Intervention: ADSprogram"
89517813|NCT05397925|Active Comparator|Treatment as usual|"This is the control arm of the study. This includes receiving the standard of care on nursing Consultations on a medication-based program and multidisciplinary regular care. Therapy description withheld to protect the integrity of the study.~Intervention: Nursing Consultation"
89517814|NCT02324855|No Intervention|Usual care|Subjects will receive the usual medical care in accordance with Spanish non cystic fibrosis bronchiectasis guidelines. In addition they will receive educational sessions about their disease and their pharmacology treatment.
89517815|NCT02324855|Experimental|Chest physiotherapy plus usual care|Subjects will introduce chest physiotherapy as part of their daily treatment
89517816|NCT03821545|Active Comparator|Lidocaine Group|
89517817|NCT03821545|Active Comparator|Ketamine Group|
89517818|NCT03821545|Active Comparator|Lidocaine and Ketamine Group|
89517819|NCT03821545|Placebo Comparator|Placebo (0.9% NaCl) Group|
89517820|NCT02324933|Experimental|Fentanyl Challenge Dosing|"In the operating room a fentanyl infusion will be started at 2 mcg/kg/min. The time from start of the infusion to respiratory depression(rate < 5 breaths/minute) will be used to calculate the effect-site concentration (Ce).Using the pharmacodynamic model calculated by the Stanpump PCA software, the infusion will continue intraoperatively to achieve a fentanyl Ce of 30%. In the Post Anesthesia Care Unit (PACU), the rate would be changed with the following parameters:~50% of the hourly dose is given as a basal infusion~The remainder of the hourly dose is ordered as a demand dose q 15 minutes. Post-operatively, the basal rate is adjusted according to the average demand dose use. In patients using < 1 demand dose per hour, the basal rate is decreased by 20%. In patients using > 3 demand doses per hour, the basal rate is increased by 20%. Patients whose pain cannot be managed by this protocol will be removed from the study and pain management will revert to the primary service."
89517821|NCT02324933|Active Comparator|Standard of Care (Control)|"Patients in the best practice arm would receive pre-operative sedation in the operating room comparable to the dose normally given in the Ambulatory Surgery Unit as a simulated fentanyl challenge. Best practice (control) patients will be followed by the Pain & Palliative Care team in order to make adjustments in pain management as required by the patients."
89517822|NCT01378195|Experimental|CBT-based|CBT-based program (Cognitive Behavioral Therapy) with video, workbook, and website
89517823|NCT01378195|Active Comparator|Educational/Resources Materials|Educational/Resources Materials: video, workbook, and website.
89517824|NCT02323061|Experimental|BCI-robot (I)|EEG guided training based on ipsilesional EEG signals; Training for 20 sessions
89517825|NCT02323061|Experimental|BCI-robot (IC)|EEG guided training based on both ipsilesional and contralesional EEG signals; Training for 20 sessions
89517826|NCT02323061|Placebo Comparator|robot|Training for 20 sessions
89596010|NCT03101254|Experimental|LY3022855 + Vemurafenib + Cobimetinib|LY3022855 administered intravenously every week Vemurafenib administered by mouth twice daily Cobimetinib administered by mouth once daily on days 1-21of each cycle
89596011|NCT04396054|Active Comparator|Lag Screws|Group 1: underwent open reduction and internal fixation using two lag screws.
89596012|NCT04396054|Active Comparator|Double Y-shaped plates|Group 2: underwent open reduction and internal fixation using double Y-shaped plates.
89596013|NCT00634114|Experimental|1|Esomeprazole and Omeprazole
89596014|NCT00634114|Experimental|2|Esomeprazole
89596015|NCT00634036|Active Comparator|1|
89596016|NCT00634036|Placebo Comparator|2|
89596017|NCT05241496|Experimental|Marina Ramsis|In the other group, 70 women will be randomly assigned for ibuprofen; participants will take 1 tablet (400mg) immediately & clinicians will wait at least 45 minutes before inserting the copper IUD
89596018|NCT01545375|Experimental|dPly-PhtD Group|"Healthy Native American infants between, and including, 6 and 12 weeks (42-90 days) of age at the time of the first vaccination, receiving GSK2189242A (dPly-PhtD) vaccine co-administered with Prevenar13™: 3 primary doses at 2, 4, 6 months of age and a booster dose at 12-15 months of age.~PedvaxHIB was given as study vaccine to a subset of subjects at 2, 4 and 12-15 months.~At the primary epoch, the dPly-PhtD vaccine was administered intramuscularly into the right anterolateral thigh and at the booster epoch, the dPly-PhtD vaccine was administered into the right deltoid or anterolateral thigh if the deltoid muscle size was not adequate.~At the primary epoch, the co-administered Prevenar13™ and PedvaxHIB vaccines were administered intramuscularly into the left anterolateral thigh and at the booster epoch, the Prevenar13™ and PedvaxHIB vaccines were administered into the left deltoid or anterolateral thigh if the deltoid muscle size was not adequate."
89596019|NCT01545375|Placebo Comparator|Control Group|"Healthy Native American infants between, and including, 6 and 12 weeks (42-90 days) of age at the time of the first vaccination, receiving Placebo vaccine co-administered with Prevenar13™: 3 primary doses at 2, 4, 6 months of age and a booster dose at 12-15 months of age.~PedvaxHIB was given as study vaccine to a subset of subjects at 2, 4 and 12-15 months.~At the primary epoch, the Placebo vaccine was administered intramuscularly into the right anterolateral thigh and at the booster epoch, the Placebo vaccine was administered into the right deltoid or anterolateral thigh if the deltoid muscle size was not adequate.~At the primary epoch, the co-administered Prevenar13™ and PedvaxHIB vaccines were administered intramuscularly into the left anterolateral thigh and at the booster epoch, the Prevenar13™ and PedvaxHIB vaccines were administered into the left deltoid or anterolateral thigh if the deltoid muscle size was not adequate."
89596020|NCT04396912||Control, s/p TT, without complication|Control (status/post-s/p total thyroidectomy-TT, without complication- demographics and BMI matched)
89596021|NCT04396912||Experimental, s/p TT with only VCP|Experimental (s/p TT, with only vocal cord paralysis-VCP, uni or bilateral)
89596022|NCT04396912||Experimental, s/p TT with only H|Experimental (s/p TT, with only hypocalcemia-H, transient or permanent)
89596023|NCT04396912||Experimental, s/p TT with both VCP+H|"Experimental (s/p TT, with both vocal cord paralysis-VCP and hypocalcemia-H);~Subgroups:~4.1. VCP (Permanent) + H (Permanent) 4.2. VCP (Transient) + H (Transient) 4.3. VCP (Permanent) + H (Transient) 4.4. VCP (Transient) + H (Permanent)~Please answer:~Improvement in hypocalcemia also make a positive effect on voice? (any objective sign? Ca? PTH?)~Return of voice is parallel with the improvement in hypocalcemia? (any objective sign? Ca? PTH?"
89596024|NCT03157882||Study Population|Pediatric patients presenting to the emergency department with acute painful conditions (please see inclusion and exclusion criteria)
88978548|NCT02966327|Other|Control Group|At T2 (4-6 weeks post-operatively), 25 study participants will be randomized to the control group and will receive standard education on lymphedema risk reduction.
88978549|NCT00105651|Other|Arm 1|
88978550|NCT00262288|Experimental|Recombinant Human C1INH|
88978551|NCT02966288|Experimental|Toradol injection|3-ml solution that contains 2 ml of normal saline and 1 ml of Toradol, 30 mg, will be infused into the affected joint.
88978552|NCT02966288|Active Comparator|Oral NSAID|800mg Motrin will be administered. (non-steroidal anti-inflammatory drug (NSAID))
88978553|NCT00262405|Experimental|zileuton|Zileuton
89596025|NCT01539837|Placebo Comparator|Placebo|Drug excipient
89596026|NCT01539837|Active Comparator|Deferiprone 20mg|20mg/kg/day deferiprone
88978554|NCT00262405|Active Comparator|azathioprine/prednisone|azathioprine/prednisone
88978555|NCT00262561|Active Comparator|Aspirin|All participants get Aspirin, and platelet reactivity measurements are performed.
88978556|NCT00105690|Other|Arm 1|
88978557|NCT00415675||Respiratory Tumor + Normal Tissue Motion|
88978558|NCT00072215|Experimental|Regimen A: TIP|
88978559|NCT00072215|Experimental|Regimen B: VeIP|
88978560|NCT00105729|Other|Arm 1|
88978561|NCT00262795|Experimental|F|Fludarabine
88978562|NCT00262795|Active Comparator|CLB|Chlorambucil
88978563|NCT00105768|Other|Arm 1|
88978564|NCT00263029|Experimental|1|
88978565|NCT00263068|Experimental|1|Up to 6.75 mg/day (optimal dosing)
89596027|NCT01539837|Active Comparator|Deferiprone 30mg|30mg/kg/day Deferiprone
89596028|NCT01539759|No Intervention|Interval IUD Placement|Women randomized to this arm will be scheduled for their IUD placement 4-8 weeks after their cesarean delivery
89596029|NCT01539759|Experimental|Immediate Postplacental IUD placement|Women randomized to this arm will receive on IUD at time of cesarean delivery, immediately after the delivery of the placenta
89596030|NCT04410081|Experimental|14C-lazertinib|Participants will receive a single oral dose of 14C-lazertinib on Day 1.
89596031|NCT03153124|Experimental|Respiratory muscle training|- three months of intradialytic training of a physical therapy protocol with PowerBreath.
89596032|NCT03153124|No Intervention|Control|No intervention
89596033|NCT01923610|Experimental|Main|MVA HIV-B
89596034|NCT01923766|Experimental|Cytotoxic T lymphocytes (CTLs)|Cytotoxic T lymphocytes (CTLs). CMV/AdV /EBV specific T cells will be given by slow intravenous injection over 1-2 minutes. Four dose levels will be explored. The lowest dose level will be 5x106cells/m2 and the highest will be 2.5x107/m2. During the dose escalation phase two to six patients will be entered at each dose level (depending on toxicity). If there are no toxicities and immunological efficacy is not seen at any dose, then the doses will be further escalated after additional local and federal approval.
89596035|NCT03831724|Experimental|EndoFLIP™ System|Device interventions included in this arm: HRM, EGD including biopsies, EndoFLIP and Bravo
89596036|NCT01923844|Experimental|poractantalfa|preterm infants who received poractantalfa for respiratory distress syndrome
89596037|NCT01923844|Experimental|beractant|preterm infants who received beractant for respiratory distress syndrome
89596038|NCT01923844|No Intervention|Control|Preterm infants without respiratory distress syndrome
89596039|NCT00633022|Experimental|LOSMAPIMOD 7.5 MG TWICE DAILY|Participants received 1 tablet of 7.5 mg Losmapimod orally twice daily, each morning and evening for a period of 12 weeks
89596040|NCT00633022|Placebo Comparator|Placebo|Participants received 1 tablet of placebo matching Losmapimod orally twice daily, each morning and evening for a period of 12 weeks.
89596041|NCT00633022|Experimental|LOSMAPIMOD 7.5 MG ONCE DAILY|Participants received 1 tablet of 7.5 mg Losmapimod each morning once daily and placebo tablet each evening once daily orally for a period of 12 weeks.
89596042|NCT01923922|Other|CT Perfusion|Participants with suspected Glioblastoma Multiforme undergo CT perfusion prior to surgery or biopsy.
89596043|NCT01929304||Video|Patients in this group will be shown an informational video, narrated in English.
89596044|NCT01929304||Text|Patients in this group will read a single-page printed information sheet in English.
89596045|NCT01924000|Experimental|Minoxidil lotion 1%|Minoxidil lotion 1% is applied twice daily to one eyebrow.
89596046|NCT01924000|Placebo Comparator|Placebo|Placebo is applied twice daily to the other eyebrow.
89596047|NCT01924078|Experimental|Metronomic Capecitabine and AI|Postmenopausal Hormone receptor positive breast cancer patients who wanted to conserve breast were enrolled to receive capecitabine 500mg/tid p.o plus one of the aromatase inhibitors (AIs):Anastrozole 1mg/day p.o, and who had first line or second line Letrozole therapy failure were switched to capecitabine 500mg/tid p.o plus Exemestane 25mg/day p.o；or Exemestane therapy failure were switched to capecitabine 500mg/tid p.o plus Letrozole 2.5mg/day p.o.
89596048|NCT01929616|Experimental|Regorafenib|A treatment cycle is defined as a 4 weeks period. Regorafenib will be administered once a day orally at a dose of 160 mg (4 tablets of 40 mg), for 3 weeks.
89596049|NCT01929694|Active Comparator|Berocca Boost|Guarana and vitamin and mineral complex, one tablet dissolved in 250ml water taken once.
89596050|NCT01929694|Placebo Comparator|Placebo|Matched placebo tablet, one tablet dissolved in 250ml water taken once.
89596051|NCT01924156|Experimental|adenovirus-transfected DC + CIK|adenovirus-transfected autologous DC vaccine plus CIK cells
89596052|NCT01929772||severe sepsis or septic shock|patients with severe sepsis or septic shock
89596053|NCT01929850|Active Comparator|Surgery|Sleeve gastrectomy laparoscopic surgery plus Weight Watchers for morbidly obese patients
89596054|NCT01929850|Other|Control|Weight Watchers Program for morbidly obese patients.
89596055|NCT00630838|Experimental|1|VSL#3 probiotic
89596056|NCT00630838|Placebo Comparator|2|Dosing will be based on patient weight. For those infants greater or equal to 5 kg, one gram (4 sachets) of placebo will be administered into 3 ounces of either expressed breast milk or formula daily. For patients under 5 kg, 0.5 gm (2 sachets) daily in the same amount of formula or breast milk Initiation: within one week of pullthrough Duration: 3 months
89596057|NCT03126136|Experimental|Pregnant women|
89596058|NCT01924234|Active Comparator|morphine|Volunteers are given morphine injection
89596059|NCT01924234|Active Comparator|remifentanil|Volunteers are given remifentanil infusion
88978566|NCT02966444|Experimental|MUFA-rich HF Meal|High-fat meal rich in monounsaturated fatty acids
89596060|NCT01924312|Placebo Comparator|No Intervention|A placebo cohort of 40 subjects with MCI related to vascular risk factors (MCI-CVD) will be followed longitudinally with cognitive, imaging, blood and optional spinal fluid biomarkers providing insight into the natural disease course of MCI-CVD. This natural history group will serve as the control group for the treatment arm described below.
89596061|NCT01924312|Experimental|Treatment Group|A cohort of 40 subjects with MCI-CVD will be treated with a nursing-based educational program (Heart Health Intervention) including aggressive symptom monitoring and treatment of vascular risks in a 6 visit intervention block over 12 weeks after baseline and thereafter for every 6 months for the study duration of 3 years. These subjects will be followed identically to the subjects in the natural history arm described in the control group above with cognitive testing, imaging, blood, and optional spinal fluid testing.
89596062|NCT00630058|Experimental|Group A (MP-424 High)|
89596063|NCT00630058|Experimental|Group B (MP-424 Low)|
89596064|NCT01925794|Experimental|COBRA PzF Stent|Single Arm study
89596065|NCT01927198|Experimental|RDEA3170 5 mg qd|No titration.
89596066|NCT01927198|Experimental|RDEA3170 10 mg qd|Increase from RDEA3170 5 mg to RDEA3170 10 mg qd at Week 2.
89596067|NCT01927198|Experimental|RDEA3170 12.5 mg qd|Increase from RDEA3170 10 mg to RDEA3170 12.5 mg qd at Week 4.
89596068|NCT01927198|Placebo Comparator|Placebo|Placebo group
89596069|NCT03536416|Experimental|Asthma workshop and theatre group|My Asthma in School. This group will receive the self-management workshops for asthmatic children and the theatre performance for the whole year group.
89596070|NCT03536416|Active Comparator|Theatre only group|My Asthma in School. This group will receive the theatre performance only.
89596071|NCT03536416|No Intervention|Control group|My Asthma in School. The control group will receive usual care for the duration of the intervention.
89596072|NCT01924546|Experimental|Supplementary water|This arm receives up to 3 L of supplemental water during the course of the testing day plus encouragement to drink water.
89596073|NCT01924546|No Intervention|Control|No additional water provided during the day. Additional water provided at the end of the school day.
89596074|NCT01923064|Active Comparator|NBCA-lipiodol|Patients will receive injection of a mixture of cyanoacrylate and lipiodol to treat gastric varices
89596075|NCT01923064|Experimental|NBCA-lauromacrogol|Patients will receive injection of the mixture of cyanoacrylate and lauromacrogol to treat gastric varices
89596076|NCT01924624|Experimental|Thalidomide|Thalidomide 100mg per day after the radical resection HCC
89596077|NCT01924624|Active Comparator|Control|No adjuvant Thalidomide treatment after curative hepatic resection
89596078|NCT01924702|Active Comparator|anodal tDCS|Intensive language therapy with anodal transcranial direct current stimulation
89596079|NCT01924702|Sham Comparator|sham tDCS|Intensive language therapy with Sham-tDCS
89596080|NCT01929382|Active Comparator|Actimmune (interferon gamma 1b)|Subjects > 0.5m2 BSA will receive 50 mcg/m2 BSA and subjects ≤ 0.5m2 BSA will receive 1.5mcg/kg/dose, as SC injections three times weekly, from week 1 to week 3.
89596081|NCT01929382|Experimental|Actimmune(interferon gamma 1b) titration|30% of the recommended dose as SC injections three times weekly in week 1, 60% the recommended dose as SC injections three times weekly in week 2, and at the recommended dose as SC injections three times weekly in week 3
89596082|NCT01924780|Active Comparator|NEMOS device stimulation 10 minutes|Subject will be stimulated in the cymba concha with a vibro-tactile mechanical device for 10 minutes
89596083|NCT01924780|Active Comparator|NEMOS device 60 minutes stimulation|Subjects will be stimulated in the cymba concha with a vibro-tactile mechanical device for 60 minutes
89596084|NCT01924780|Sham Comparator|Sham 10 minutes|10 minutes of t-VNS stimulation by rotating the NEMOS ear electrode 180 degrees within the pinna, which will position the electrode on the earlobe
89596085|NCT00981448|Experimental|Zinc supplement|
89596086|NCT01926184|Experimental|ARTEMIS+CM|This is a 5-session, individually delivered intervention that is designed to enhance positive affect. It is designed to boost and extend the effectiveness of contingency management (CM).
89596087|NCT01926184|Placebo Comparator|Attention-Control+CM|Attention-matched, 5-session control condition consisting of brief-self report psychological measures and neutral writing exercises. Contingency management (CM) is also administered to this arm.
89596088|NCT01924858|Experimental|GSK2647544 oral and [18F]GSK2647544 IV bolus|All subjects will receive a single oral dose of GSK2647544 100 milligram (mg) approximately 2 hours before administration of [18F] GSK2647544 and a dynamic PET scan. [18F]-GSK2647544 will be administered to the subject as an IV bolus during the PET scan, which will be conducted for up to 120 minute post the injection of [18F]GSK2647544
89596089|NCT04395820||Cystic Fibrosis|
89596090|NCT04395820||Healthy|
89596091|NCT04395742||Coffee:1,3,7-trimethylxanthine|
89596092|NCT04395742||Tea and hot chocolate with milk|
89596093|NCT00989950|Experimental|Daytrana 9 hr wear|
89596094|NCT00989950|Experimental|Daytrana 10 hr wear|
89596095|NCT00989950|Experimental|Daytrana 11 hr wear|
89596096|NCT00989950|Experimental|Daytrana 12 hr wear|
89596097|NCT01924936|Placebo Comparator|Email|Caring email (based on the caring letters literature) sent via secure email messaging. Of the interventions, it is by far the most minimal in clinical intensity and human resources needs for delivery.
89596098|NCT01924936|Experimental|DBT program|DBT online program involving three DBT skills taught across three lessons. The DBT online program will be based on a brief DBT skills intervention previously developed and pilot tested by Dr. Whiteside. This DBT online program will provide far greater clinical intensity than Intervention 1 and will be delivered with a widely-used modular software platform suitable for an R-34 project.
89596099|NCT01924936|Experimental|Email + DBT program & Coach|"Caring Email + DBT online program & Coach: in addition to the DBT online program, will include personalized outreach and support for use of the program. An intervention coach will deliver this support exclusively via secure email messaging. The intervention coach will not provide psychotherapy, but instead provide reinforcement and contingency management surrounding completion of the three lessons. This intervention will utilize significantly greater ongoing clinical resources for its maintenance and offer greater clinical intensity for patients."
88978567|NCT02966444|Experimental|PUFA-rich HF Meal|High-fat meal rich in polyunsaturated fatty acids
88978568|NCT02966444|Experimental|SFA-rich HF Meal|High-fat meal rich in saturated fatty acids
88978569|NCT00263185|Experimental|Active Treatment Group|"Patients with baseline 25OH vitamin D level of 10-19 ng/ml.~Calcium carbonate 1000 mg/day~Vitamin D 400 units daily.~Vitamin 50,000 IU/wk x 16 weeks and then once a month for a total of 6 months.~Patients with baseline 25OH vitamin D level of 20-29 ng/ml.~Calcium carbonate 1000 mg/day~Vitamin D 400 units daily.~Vitamin 50,000 IU/wk x 8 weeks and then once a month for a total of 6 months."
88978570|NCT00263185|Placebo Comparator|Control Group|"Patients with baseline 25OH vitamin D level of 10-19 ng/ml.~Calcium carbonate 1000 mg/day~Vitamin D 400 units daily.~Placebo once per week x 16 weeks and then once a month for a total of 6 months.~Patients with baseline 25OH vitamin D level of 20-29 ng/ml.~Calcium carbonate 1000 mg/day~Vitamin D 400 units daily.~Placebo once per week x 8 weeks and then once a month for a total of 6 months."
88978571|NCT00263185|Other|Observational Group|"Patients with a baseline Vitamin D level below 10 ng/ml.~Calcium carbonate 1000 mg/day~Vitamin D 400 units daily."
88978572|NCT00263458|Experimental|Integrated|Buprenorphine maintenance treatment delivered at an HIV primary care clinic
88978573|NCT00263458|Active Comparator|Non-integrated|Buprenorphine maintenance treatment delivered at a public health substance use disorder clinic
88978574|NCT00101712|Experimental|Vildagliptin|
88978575|NCT00101712|Placebo Comparator|Placebo|
88978576|NCT00072527|Experimental|Induction and consolidation chemotherapy|"Induction chemotherapy (Cycles 1 and 2): Patients receive cisplatin 30 mg/m^2 on days 1, 8, 22 and 29 and irinotecan 65 mg/m^2 on days 1, 8, 22 and 29 for cycles 1 and 2.~Consolidation chemotherapy (Cycles 3, 4 and 5 beginning on day 43, week 7): Patients receive carboplatin on days 43, 64 and 85, etoposide 100 mg/m^2 IV on days 43-45, 64-66 and 85-87 and XRT 5 fractions/week starting on day 43"
88978577|NCT00105807|Other|Arm 1|
89596100|NCT04276012|Experimental|Intervention group|The intervention group will participate in different intervention strategy depending on the individual needs (psychoeducational, recommendations of life style and diet, medication adherence and changes in pharmacological strategy)
89596101|NCT04276012|No Intervention|Control group|Usual clinical care
89596102|NCT01925092|Experimental|mifepristone|Daily doses of mifepristone over 84 days.
89596103|NCT03121378||Hip arthroplasty with bone cement|Patients undergoing hip replacement surgery with bone cement use: blood samples taken before cement use and after cement prosthesis fixation.
89596104|NCT03121378||Non cement hip arthroplasty|Patients undergoing hip replacement surgery without bone cement. Blood samples taken before bone reaming and after implantation of femoral prosthesis.
89608531|NCT00722722|Active Comparator|4 dose group|4 doses of bortezomib (1.3mg/m^2 of body surface area)
89596105|NCT01920256|Experimental|Personalized type 2 diabetes care.|Remote, personalized type 2 diabetes clinic provided by an endocrinologist using frequent remote contacts for medication adjustments.
89596106|NCT01920256|Active Comparator|Usual Endocrine Care|Usual Endocrine care will be provided by an endocrinologist.
89596107|NCT04347850||Patient with Covid-19 confirmed (middle form)|Covid-19 confirmed: middle form
89596108|NCT04347850||Patient with Covid-19 confirmed (severe form)|Covid-19 confirmed : severe form
89596109|NCT04347850||Patient with Covid-19 not confirmed|Covid-19 not confirmed
89596110|NCT01925248|Active Comparator|Whey protein group|Patients will be randomized to receive whey protein
89596111|NCT01925248|Placebo Comparator|Placebo group|Patients will be randomized to receive placebo
89596112|NCT01905943|Experimental|Obinutuzumab|Participants will receive obinutuzumab either alone as single agent or in combination with chemotherapy (Fludarabine/Cyclophosphamide [FC], Bendamustine or Chlorambucil) at the investigator's discretion. Each cycle is of 28-days duration.
89596113|NCT01905553|Experimental|SSP-004184SS (fed)|21.8 mg/kg (oral capsule form) given once on Day 1 under fed conditions
89596114|NCT01905553|Experimental|SSP-004184SS (fasted)|21.8 mg/kg (oral capsule form) given once on Day 1 under fasted conditions
89596115|NCT04629625|Experimental|End-range mobilization|End-range mobilization performed in end-position of the tibiofemoral joints' flexion and extension for 2*3 min
89596116|NCT04629625|Active Comparator|Non end-range mobilization|Non end-range mobilization performed in tibiofemoral joints' loose position
89596117|NCT04629625|Placebo Comparator|Placebo|Hands-on treatment technique performed in end-range of the tibiofemoral joints' flexion and extension for 2*3 min
89596118|NCT01929031|Other|Caffeine-Ibuprofen|Study Stage 1: One Caffeine 100 mg tablet after dental surgery; Arm Type: Active Comparator - Study Stage 2: Subsequent to Stage 1, every 6-8 hours one ibuprofen 400 mg tablet, while awake, over 5 days; Arm Type: Active Comparator
89596119|NCT01929031|Other|Placebo-Ibuprofen/Caffeine|Study Stage 1: One Placebo tablet after dental surgery Arm Type: Placebo Comparator - Study Stage 2: Subsequent to Stage 1, every 6-8 hours one Ibuprofen 400 mg/Caffeine tablet, while awake, over 5 days; Arm Type: Experimental
89596120|NCT01929031|Other|Ibuprofen/Caffeine-Ibuprofen/Caffeine|Study Stage 1: One Ibuprofen 400 mg/Caffeine 100 mg tablet after dental surgery: Arm Type Experimental - Study Stage 2: Subsequent to Stage 1, every 6-8 hours one Ibuprofen 400 mg/Caffeine 100 mg tablet, while awake, over 5 days; Arm Type Experimental
89596121|NCT01929031|Other|Ibuprofen-Ibuprofen|Study Stage 1: One Ibuprofen 400 mg tablet after dental surgery; Arm Type Active Comparator - Study Stage 2: Subsequent to stage 1, every 6-8 hours one Ibuprofen 400 mg tablet, while awake, over 5 days; Arm type; Active Comparator
89596122|NCT01929031|Other|Caffeine-Ibuprofen/Caffeine|Study Stage 1: One Caffeine 100 mg tablet after dental surgery. Arm Type; Active Comparator - Study Stage 2: Subsequent to Stage 1, every 6-8 hours one Ibuprofen 400mg/Caffeine 100 mg tablet, while awake, over 5 days; Arm Type: Experimental
89596123|NCT01929031|Other|Placebo-Ibuprofen|Study Stage 1: One Placebo tablet after dental surgery Arm Type: Placebo Comparator - Study Stage 2: Subsequent to Stage 1, every 6-8 hours one Ibuprofen 400 mg tablet, while awake over 5 days; Arm Type: Active Comparator
89596124|NCT00989092|Other|Observational Group|Participants in the observation group were evaluated once every 2 weeks for the first 12 weeks (test period). No darbepoetin alfa was administered to the observation group during this period. Darbepoetin alfa could be initiated at a dose of 3.0 μg/kg once every 2 weeks beginning with the first visit after the test period at which the participants hemoglobin concentration was less than or equal to 11.0 g/dL. The dose of darbepoetin alfa could be increased to 5.0 μg/kg once every 2 weeks after 6 weeks of darbepoetin alfa treatment in participants with a hemoglobin change from baseline of less than 1.0 g/dL.
89596125|NCT00989092|Active Comparator|21 week treatment group|Participants in the treatment group received darbepoetin alfa subcutaneously (SC) at a dose of 3.0 μg/kg once every 2 weeks for 21 weeks. The dose of darbepoetin alfa could be increased at week 7 (to 5.0 μg/kg once every 2 weeks) or at week 13 (to 9.0 μg/kg once every 2 weeks) in participants with a hemoglobin change from baseline of less than 1.0 g/dL who dose escalated at week 7.
89596126|NCT00988858|Experimental|LY2603618 and Pemetrexed|
88978578|NCT00263770|Other|Positive airway pressure (PAP)|which is air delivered by a mask worn over the nose during sleep
89596127|NCT01920334|Experimental|Zolpidem CR 12.5mg|Patients receive zolpidem CR 12.5mg at bedtime from the first night on the Cardiac Intensive Care Unit until their discharge from the hospital
89596128|NCT01920334|Placebo Comparator|Placebo|Patients receive placebo at bedtime from the first night on the Cardiac Intensive Care Unit until their discharge from the hospital
89596129|NCT04395352||Pre-ECV|Patients having undergone colonoscopy prior to the introduction of ECV (November 1 2018 to April 30 2019).
89596130|NCT04395352||ECV|Patients having undergone colonoscopy after the introduction of ECV (June 1 2019 to November 30 2019).
89596131|NCT01920490|Experimental|GUILT-INCREASE-CORRELATION|Patients in this group will receive visual feedback that reinforces increasing the correlation in fMRI signal between the right superior anterior temporal and septal-subgenual regions during the retrieval of predefined guilt-related autobiographical episodes. During the indignation condition, visual feedback will reinforce stabilization of the preceding degree of correlation.
89608532|NCT00722722|Active Comparator|16 dose group|16 doses of bortezomib (1.3mg/m^2 of body surface area)
89608533|NCT00722722|Active Comparator|32 dose group|32 doses of bortezomib (1.3mg/m^2 of body surface area)
88978579|NCT00263770|Active Comparator|outpatient surgical procedure|where small fabric rods are inserted into the soft palate (the fleshy portion of the roof of the mouth) to stiffen the tissues.
88978580|NCT00263770|Sham Comparator|Sham surgery|an outpatient surgical procedure identical to #2 except that no rods are inserted into the soft palate.
88978581|NCT00263809|Experimental|1|Treatment, Mirasol-treated platelets
88978582|NCT00263809|No Intervention|2|Reference, Untreated platelets
88978583|NCT00264043|Experimental|1|AngioGuard™ device and Bx Velocity™ stent
88978584|NCT00105846|Other|Arm 1|
88978585|NCT00264160|Experimental|AMN107|
89608534|NCT04143555||endoscopic submucosal injection of indocyanine green|
89596132|NCT01920490|Active Comparator|GUILT-STABILIZE-CORRELATION|Patients in this group will receive visual feedback that reinforces stabilization of the preceding degree of correlation in fMRI signal between the right superior anterior temporal and septal-subgenual regions during the retrieval of predefined guilt-related autobiographical episodes. During the indignation condition, visual feedback will also reinforce stabilization of the preceding degree of correlation.
89596133|NCT04275622|Experimental|Intervention|Intervention group receives lifestyle intervention for hypertriglyceridemia.
89596134|NCT04275622|No Intervention|Control|Control group receives regular surveillance.
89596135|NCT01920646|Experimental|ALV|"300 gram cooked African leafy vegetables and school meal starch as daily school meal (5 days/weeks) for 3 months.~Selected African leafy vegetables:Amaranthus cruentus (amaranth), Vigna unguiculata (cowpea), Cleome gynandra (spiderplant), and Cucurbita maxima (pumpkin)."
89596136|NCT01920646|No Intervention|Control|normal school meal as daily meal (5 days/weeks) for 3 months
89596137|NCT00986986|Experimental|Active Drug (extended release niacin)|Subjects in this arm will be given 12 weeks of extended release niacin. Intervention: extended release niacin (Niaspan) starting at 500 mg by mouth daily and titrated to a maximum dose of 1500 mg by mouth daily. Titration will depend on patient tolerability.
89596138|NCT00986986|No Intervention|Observation|Subjects in this arm will be monitored for 12 weeks and will not receive extended release niacin
89596139|NCT01925482|Other|Group 1 -- no history of otitis media|no history of otitis media
89596140|NCT01925482|Other|Group 2 --patent tympanostomy tube|at least 1 patent tympanostomy tube
89596141|NCT04275466|Experimental|necrotic cavity lavage|This arm was performed necrotic cavity lavage after debridement
89596142|NCT04275466|No Intervention|non-necrotic cavity lavage|This arm was not performed necrotic cavity lavage after debridement
89596143|NCT01904773|Placebo Comparator|Placebo|
89596144|NCT01904773|Experimental|low dose AZD5213|
89596145|NCT01904773|Experimental|high dose AZD5213|
89596146|NCT01928719|Experimental|Reduced Nicotine Content Cigarettes|the experimental group will smoke cigarettes with Gradually Reduced Nicotine Content (RNC) (11.6, 7.4, 3.3, 1.4, 0.7, and 0.2 mg per cigarette) cigarettes, each smoked for 3 weeks, except for the last period which will last 6 weeks to evaluate a longer-term adherence to the lowest nicotine content cigarette.
89596147|NCT01928719|Placebo Comparator|Same Nicotine Content Cigarettes|The Same Nicotine Control Group (SNC) will continue to smoke research cigarettes with a usual nicotine content (about 11.6 mg per cigarette)
89596148|NCT00986674|Experimental|Arm I (carboplatin, paclitaxel, cetuximab)|Patients receive carboplatin IV over 15-30 minutes and paclitaxel IV over 3 hours on days 1 and 22 and cetuximab IV over 1-2 hours on days 1, 8, 15, 22, 29, and 36. Treatment repeats every 42 days for 2 courses. Patients with stable or responding disease after 2 courses proceed to maintenance therapy with cetuximab alone on days 1, 8, 15, 22, 29, and 36. Treatment with cetuximab repeats every 42 days in the absence of disease progression or unacceptable toxicity.
89596149|NCT00986674|Experimental|Arm II (carboplatin, paclitaxel, cixutumumab)|Patients receive carboplatin and paclitaxel as in arm I. Patients also receive cixutumumab IV over 1 hour on days 1, 15, and 29. Treatment repeats every 42 days for 2 courses. Patients with stable or responding disease after 2 courses proceed to maintenance therapy with cixutumumab alone on days 1, 15, and 29. Treatment with cixutumumab repeats every 42 days in the absence of disease progression or unacceptable toxicity.
89596150|NCT00986674|Experimental|Arm III (carboplatin, paclitaxel, cetuximab, cixutumumab)|Patients receive carboplatin, paclitaxel, and cetuximab as in arm I. Patients also receive cixutumumab as in arm II. Treatment repeats every 42 days for 2 courses. Patients with stable or responding disease after 2 courses proceed to maintenance therapy with cetuximab as in arm I and cixutumumab as in arm II.
89596151|NCT00986440|Experimental|CS-7017|
89596152|NCT00986440|Placebo Comparator|Placebo|Placebo matching CS-7017
89596153|NCT01904383||Trazenta|
88978586|NCT00264199|Active Comparator|1|
88978587|NCT00264199|Placebo Comparator|2|
88978588|NCT00101790|Active Comparator|1|
88978589|NCT02966561|Experimental|Pedometer-based activity promotion|In the context of pulmonary rehabilitation (standard care), the intervention group (IG) additionally receives a pedometer-based physical activity behaviour change intervention (BCI).
88978590|NCT02966561|Active Comparator|Short patient education and exercise|In the context of pulmonary rehabilitation (standard care), the control group (CG) additionally receives a short patient education in combination with related exercise.
88978591|NCT00105885|Experimental|Arm 1|Patients randomized to receive telephone care will be scheduled to see their provider at twice the recommended clinical visit interval, and two ten-minute telephone contacts will be scheduled at a specific time at standard 0.67 and 1.3 times the multiple of the recommended interval.
88978592|NCT00105885|No Intervention|Arm 2|Patients randomized to receive routine care will be scheduled to see their psychiatric medication provider at the recommended interval.
88978593|NCT04709029|Active Comparator|intravenous dexamethazone group|Patients receive intrathecal 3 ml heavy bupivacaine 0. 5% +1 ml normal saline + intravenous 8 mg dexamethazone in 10 ml saline,to prevent postdural puncture headache. Spinal anesthesia will be done in a sitting position under complete aseptic techniques, 25 G Quincke needle was inserted intrathecally at L3-L4 or L4-L5 interspace through midline approach. The study drugs were given by an anesthesiologist not aware of the type of medications injected.
89031641|NCT00530829|Active Comparator|2|Mothers recieve ORS satchets at home every two months for use when child in home under 5 years has diarrhea. Instructions on when and how to use ORS and when to take child in clinic are given by community health worker. Zinc will be given in clinic if child visits clinic with diarrhea.
89596154|NCT01920880||ACNES patients|Patients being treated in past for anterior cutaneous nerve entrapment syndrome
89596155|NCT01920880||Healthy controls|Healthy controls
89596156|NCT01904149|Experimental|DKP/TRAM followed by DKP/TRAM|Dexketoprofen/Tramadol-single dose followed by Dexketoprofen/Tramadol-multiple doses
89596157|NCT01904149|Active Comparator|DKP followed by DKP|Dexketoprofen-single dose followed by Dexketoprofen-multiple doses
89596158|NCT01904149|Active Comparator|TRAM followed by TRAM|Tramadol-single dose followed by Tramadol-multiple doses
89596159|NCT01904149|Other|Placebo followed by DKP/TRAM|Placebo single dose followed by Dexketoprofen/Tramadol-multiple doses
89596160|NCT01904149|Other|Placebo followed by DKP|Placebo single dose followed by Dexketoprofen-multiple doses
89596161|NCT01904149|Other|Placebo followed by TRAM|Placebo single dose followed by Tramadol-multiple doses
89596162|NCT00986362|Experimental|Ocriplasmin|
89596163|NCT00986362|Placebo Comparator|Placebo|
89596164|NCT01925560|Experimental|Group A- agave inulin or placebo|Participant in this group will receive Agave Inulin dose of 5 or 7.5 grams per day or placebo.
89596165|NCT01925560|Experimental|Group B- agave inulin or placebo|Participants in this group will receive Agave Inulin dose of 5 or 7.5 grams per day or placebo
89596166|NCT01925560|Experimental|Group C-agave inulin or placebo|Participants in this group will receive Agave Inulin dose of 5 or 7.5 grams per day or placebo
89596167|NCT01890421|Experimental|Gadobutrol 0.1 mmol/kg body weight|Participants received gadobutrol at the total approved standard dose of 0.1 millimole per kilogram body weight (mmol/kg BW) in 2 separate bolus injections: 0.05 mmol/kg BW at peak pharmacologic stress and 0.05 mmol/kg BW at rest via a power injector.
89596168|NCT01925638|Experimental|BAY86-9766|The study will be conducted in two parts and study treatments will be administered as follows: •Part A: Three subjects will be enrolled and will receive 10 mg of refametinib on Day 1. Once daily dosing of ketoconazole 400 mg will be initiated on Day 5 and will continue until Day 12 with 10 mg of refametinib administered concomitantly on Day 8 •Part B: Fifteen subjects will be enrolled and will receive refametinib doses of 10 mg, 20 mg or 30 mg on Days 1 and 8 with the same dose administered on both days. Refametinib dose for Part B will be based on safety and refametinib pharmacokinetics in Part A. Ketoconazole 400 mg will be administered once daily on Days 5 to 12. Subjects will stay in the investigational site for a total period of 15 consecutive days
89596169|NCT01925716|Experimental|Corn oil/olive oil|Corn oil 56 g per day for 21 days followed by olive oil 56 g for 21 days
89596170|NCT01925716|Experimental|Olive Oil/Corn Oil|olive oil, 56g per day for 21 days followed by corn oil, 56 g for 21 days
89596171|NCT03092284|Active Comparator|Cardiology Stem Cell Centre Adipose Stem Cell (CSCC_ASC)|Allogeneic adipose derived stromal cells
89596172|NCT03092284|Placebo Comparator|Placebo|Saline
89596173|NCT00985738|Experimental|Dutasteride|The drug, Dutasteride, will be administered at 0.5 mg dose and given everyday (QD), for 3 months.
89596174|NCT00985738|Placebo Comparator|Placebo|The placebo group will receive a placebo drug for 3 months, instead of the intervention drug, Dutasteride.
89596175|NCT01928485|Active Comparator|Arm A (active surveillance)|Patients undergo active surveillance for 52 weeks.
89596176|NCT01928485|Experimental|Arm B (Sunphenon)|Patients receive Sunphenon PO QD for 52 weeks in the absence of disease progression or unacceptable toxicity.
89596177|NCT00985504|Experimental|Duloxetine|
89596178|NCT00985504|Active Comparator|Escitalopram|
89596179|NCT01921036|Experimental|combined exercise|90 minutes combined endurance and resistance exercise once a week plus 90 minutes traditional cardiac rehabilitation once a week over six months
89596180|NCT01921036|Active Comparator|traditional cardiac rehabilitation|The group-based program is offered for 90 minutes twice a week and is a combination of gymnastics, coordination and flexibility exercises, and includes educational components targeting diet and nutrition, stress and relaxation, methods for coping with CVD and behavioral and lifestyle change.
89596181|NCT01921192|Active Comparator|Folic Acid, vit B6 and B12|
89596182|NCT01921192|Placebo Comparator|Sugar pill|
89596183|NCT04275388||Xiyanping injection +other drugs|Drug: Xiyanping injection Xiyanping injection: 10-20ml daily, Qd, the maximum daily dose does not exceed 500mg (20mL) Other drugs: Lopinavir tablet or Ritonavir tablet;Alpha-interferon nebulization;Abidor Hydrochloride
89596184|NCT04275388||other drugs|Lopinavir tablet or Ritonavir tablet;Alpha-interferon nebulization;Abidor Hydrochloride
89596185|NCT01921426|Experimental|GC4419|Open label, dose escalation study of GC4419 administered in 14 doses, corresponding to the first 14 doses of radiation therapy. Each dose will be given intravenously over 60 minutes. The possible doses which may be tested are: 15mg, 30mg, 50mg, 75mg, 112mg, and 170mg.
89596186|NCT03458962||Genetic Enrollees|Enrollment of patients for whom WGS may be beneficial. Patients who are ill and for whom a genetic diagnosis is suspected but not yet established.
88978594|NCT04709029|Active Comparator|intrathecal dexamethazone group|Patients receive intrathecal 3 ml heavy bupivacaine 0.5% + 4 mg (1 ml) dexamethazone + intravenous 10 ml normal saline to prevent postdural puncture headache. Spinal anesthesia will be done in a sitting position under complete aseptic techniques, 25 G Quincke needle was inserted intrathecally at L3-L4 or L4-L5 interspace through midline approach. The study drugs were given by an anesthesiologist not aware of the type of medications injected.
88978595|NCT04708795|Experimental|Verum|AP701 single dose oromucosal application
88978596|NCT04709497|Active Comparator|viscotrabeculotomy (VT)).|
88978597|NCT04709497|Active Comparator|visco-circumferential-suture-trabeculotomy (VCST)|
88978598|NCT04709497|Active Comparator|Combined VT-Trabeculectomy with MMC (VT-Trab).|
88978599|NCT04708912||1|Mild-Moderate COVID-19
88978600|NCT04708912||2|Severe COVID-19
88978601|NCT04708912||3|Convalsent (COVID-19)
88978602|NCT04708912||4|Healthy persons
88978603|NCT04708873|Experimental|High Intensity Interval Training Group|Participants in this group will initially undergo continuous aerobic training to achieve a baseline fitness level, after which HIIT and resistance training will be employed. Warm-up period will be followed by 4 bouts of 4-minute interval treadmill running and stationary bike cycling at 80-95% of the measured HR reserve, interspersed with active recovery phase at 55-70% HRR. After this resistance exercises will be performed in a circuit fashion for strengthening the upper limbs, lower limbs and trunk. The session will be ended with a 5-7 minute cool-down period
88978604|NCT04708873|Active Comparator|Moderate Intensity Continuous Training Group|Participants in this group will also initially undergo continuous aerobic training to achieve a baseline fitness level, after which the intensity will be increased to moderate continuous training achieving 55-70% of HRR. Every session will be preceded by appropriate warm-up and end with cool down.
88978605|NCT00264394|Experimental|Updated CHD risk profiles|Provision of regularly updated CHD risk profiles
88978606|NCT00264394|Active Comparator|Guidelines|Physicians received guidelines only
89596187|NCT01926106|Experimental|nIPPV|the infants in the arm were supported by Nasal Intermittent Positive-Pressure Ventilation(nIPPV)
89596188|NCT01926106|Active Comparator|nCPAP|the infants in the arm were supported by Nasal Continuous Positive Airway Pressure(nCPAP)
89596189|NCT01921504|Experimental|Acupuncture|Participants in this group are given twice-a-week acupuncture treatment for 4 weeks.
89596190|NCT01921504|No Intervention|No treatment|The participants in this group are supposed to wait without any intervention for first 4 weeks. Then they receive the identical acupuncture treatments as in the treatment group for the following 4 weeks.
89596191|NCT01921582|Experimental|Methylphenidate|"Methylphenidate (TEVA-METHYLPHENIDATE ER-C)~Dosage: 18 mg/day at Week 1; 36 mg/day at Week 2; 54 mg/day at Week 3; 72 mg/day at Week 4. Dosage levels may be maintained or decreased to manage medication side effects.~Dosage form: tablet~Dosage frequency: daily~Duration: 12 weeks total"
89596192|NCT01921582|Active Comparator|Cognitive Behavioral Therapy|"Cognitive Behavioral Therapy~12 individual 50-minute appointments over the course of up to 14 weeks~According to Fairburn, Marcus, and Wilson (1993)"
89596193|NCT02984098|Experimental|Dextrose gel 40%|before heel lance, 2 ml oral dextrose gel 40% was administered, and pain related intensity was evaluated with premature infant pain profile scale
89596194|NCT02984098|Active Comparator|Dextrose gel 25%|before heel lance, 2ml oral dextrose gel 25% was administered, and pain related intensity was evaluated with premature infant pain profile scale
89596195|NCT03398902|Experimental|Sleep extension|Participants in the sleep extension group will keep daily sleep diaries. Sleep diaries will be reviewed with the participant and an instructor trained in Cognitive Behavioral Therapy for Insomnia (CBTI) on a weekly basis. These weekly sessions will take place by telephone or videoconferencing.
89596196|NCT03398902|Active Comparator|Habitual sleep|Participants in the habitual sleep group will be instructed to keep their habitual bedtimes and wake times. Participants will keep daily sleep diaries that will we reviewed by a study team member each week. These weekly sessions will take place by telephone or videoconferencing.
89596197|NCT00985426|Experimental|HEPLISAV-B|0.5 mL HEPLISAV-B and 0.5 mL Placebo
89596198|NCT00985426|Active Comparator|Engerix-B|2.0 mL Engerix-B
89596199|NCT00985192|Experimental|Everolimus|Patients receive oral everolimus once daily on days 1-14. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity
89596200|NCT03392662||Hemopatch Sealant Use with Hepatobiliary Surgery|
89596201|NCT03392662||Hemopatch Sealant Use with General Surgery|
89596202|NCT03392662||Hemopatch Sealant Use with Lung Surgery|
89596203|NCT03392662||Hemopatch Sealant Use with Cardiovascular Surgery|
89596204|NCT03392662||Hemopatch Sealant Use with Neurological/Spinal Surgery|
89596205|NCT03392662||Hemopatch Sealant Use with Urologic Surgery|
89596206|NCT01926340||Early maintenance treatment group|Drug (quetiapine, 400mg/d) during the 12-month randomized phase of the study
89596207|NCT01926340||Early discontinuation group|Drug (placebo) during the 12-month randomized phase of the study
89596208|NCT03390010|Active Comparator|Extra medication group|"-Procedure : Giving misoprostol plus syntocinon during CS~this group in which prevention of uterine atony is made by intrauterine misoprostol plus the usual syntocinon and using extra uterotonic drugs when needed ; methergine , carboprost"
89596209|NCT03390010|Active Comparator|Active management of labour group|"Procedure: Giving syntocinon during cesarean section~this group in which prevention of uterine atony is made by the usual active management of labour syntocinon and using extra uterotonic drugs when needed ; methergine , carboprost"
89596210|NCT00985114|Experimental|Device|EndoBarrier implanted for 6 months. Subject followed for 6 months after device was explanted.
89596211|NCT00985114|Active Comparator|Diet + Lifestyle counseling|Multidisciplinary lifestyle and nutritional counseling for 12 months
89596212|NCT00984568|Experimental|Top-Hold|Level 1: Infliximab IV 5 mg/kg at Weeks 0, 2, and 6, and every 8 weeks thereafter. Level 2: Infliximab IV 5 mg/kg every 4 weeks. Level 3: Prednisolone induction + AZA 2.0-2.5 mg/kg/day.
89596213|NCT00984568|Active Comparator|Step-Up|Level 1: Oral prednisolone (40 mg/day or 1 mg/kg/day in the case of non-response) + oral 5-aminosalicylic acid (5-ASA) 2 g/day. Level 2: Oral prednisolone (40 mg/day or 1 mg/kg/day in the case of non-response) + oral azathioprine (AZA) at a dose of 2.0-2.5 mg/kg/day. Level 3: Infliximab 5 mg/kg at Weeks 0, 2, and 6 and every 8 weeks thereafter.
89596214|NCT02984176|Active Comparator|Simethicone|Arm 1 or Group I or Simethicone 40mg. 3 tablets (one tablet after each meal) and to fast overnight the day before the operation.
88978607|NCT00106041|Other|Arm 1|Palliative Care Nurse Case Management
89596215|NCT02984176|Placebo Comparator|placebo|Arm 2 or group 2 or placebo group. 3 tablets (one tablet after each meal) and to fast overnight the day before the operation.
89596216|NCT03075280|Experimental|High carbohydrate liquid diet|No need preoperative fasting more than 6 hours. Uptake 400ml high carbohydrate liquid diet 2 hours before ERCP.
89596217|NCT03075280|No Intervention|Routine ERCP group|Preoperative fasting more than 6 hours as usual.
89596218|NCT01921738|Experimental|1% Azithromycin gel|Participants received mechanical periodontal therapy, oral hygiene instructions and placement of the in-situ gel (0.2 ml 1% Azithromycin) into the periodontal pockets in single rooted teeth; twice with an interval of 20 minutes.
89596219|NCT01921738|Experimental|Azithromycin capsule|Participants received mechanical periodontal therapy, oral hygiene instructions and antibiotic (Azithromycin 250mg x 6 capsules)
89596220|NCT01921738|Placebo Comparator|Placebo Gel|Participants received mechanical periodontal therapy, oral hygiene instructions and placebo (antibiotic) in situ gel.
89596221|NCT01921738|Placebo Comparator|placebo capsule|Participants received mechanical periodontal therapy (Scaling and Root Planing), oral hygiene instructions and placebo (antibiotic) capsules (250mg x 6), at mouth (Po), two times a day (bid) for three days.
89596222|NCT01921816|Other|Prismocitrate 18/0|citrate-containing replacement solution (Prismocitrate 18/0, Gambro) will be administered at pre-filter port during continuous hemodiafiltration, for the purpose as replacement solution and anticoagulation
88978608|NCT00101829|Experimental|Rituximab Treatment|Participants will receive rituximab at study entry and at Week 2
89596223|NCT04395976|No Intervention|Control Group|Participants randomised into the control group receive conventional standard care given by recommended guideline.
89596224|NCT04395976|Experimental|Ayurveda|Treatment includes a tailored combination of herbs based on individual constitution (based on Ayurveda) nutritional advice, specific consideration of selected food items, specific lifestyle advice, yoga advice along with standard recommendations.
89596225|NCT03092050|Active Comparator|Facilitated Discussion|Weekly facilitated discussion for 4 weeks
89596226|NCT03092050|Experimental|Guided Imagery and mindfulness|Weekly guided imagery and mindfulness for 4 weeks
89596227|NCT01926418|No Intervention|Control|The control group receives the TPB questionnaires but receives no intervention
89596228|NCT01926418|Experimental|Implementation intentions|Participants are asked to specify when, where and how they will use condoms in the future. They will be sent weekly email reminders of their implementation intentions.
89596229|NCT01926418|Experimental|Planning task|Participants will be asked to practice the Tower of Hanoi task four times per week for ten to fifteen minutes.
89596230|NCT00984256|Experimental|Drug|"5 groups, each group receiving Malarone tablet(s) (250/100mg)prior to challenge.~Group 1 - 1 tablet 1 day before challenge Group 2 - 1 tablet 4 days before challenge Group 3 - 1 tablet 7 days before challenge Group 4 - 2 tablets 7 days before challenge Group 5 - 4 tablets 7 days before challenge"
89596231|NCT00984256|Placebo Comparator|Control -no prophylaxis|
89596232|NCT00984022|Active Comparator|Iodoform dressing|Iodoform dressing for cutaneous abscess
89596233|NCT00984022|Active Comparator|Aquacel dressing|Aquacel dressing for cutaneous abscess
89596234|NCT01926574|Experimental|long rehabilitation|a 3.5-week, in-patient rehabilitation program, organized as a 7-hour workday with weekends off, simulating a close to normal summer work-week in Norway, and mainly group-based with maximum 8 participants per group. Focus on mental training (aimed at increasing motivation and self-efficacy), physical training and work-related problem solving.
89596235|NCT01926574|Experimental|short rehabilitation|4+4 full days of rehabilitation at Hysnes Rehabilitation Center, separated by 2 weeks living at home. Group-based with 8 participants per group, focus on mental training (aimed at increasing motivation and self-efficacy), physical training and work-related problem solving. A workplace visit will be included in addition to the 4 + 4 rehabilitation days, if considered relevant.
89596236|NCT01926574|Active Comparator|Acceptance and commitment therapy|6 dynamic processes (committed action, self-as-context, presence in the moment, values, defusion and acceptance) are targeted both in group-sessions and individual meetings. Only the psychological part of the experimental interventions is applied, in an outpatient setting.
89596237|NCT01926574|No Intervention|Untouched|this group will be followed in registers at group level and not be aware of their participation in the study
89596238|NCT01922128|Active Comparator|Drug, MC-1101|One eye drop of Active comparator, 0.5% MC-1101, 2 times per day, 28 days; followed by one drop of 1% MC-1101, 2 times per day, 28 days.
89596239|NCT01922128|Placebo Comparator|Placebo|One eye drop of Placebo comparator to MC-1101. Placebo contains all components of MC-1101 except for the active ingredient.
89596240|NCT01890265|Experimental|Pamrevlumab|Participants will receive pamrevlumab 30 milligram/kilogram (mg/kg) by intravenous (IV) infusion every 3 weeks for a total of 16 infusions over 45 weeks.
89596241|NCT01890265|Placebo Comparator|Placebo|Participants will receive placebo matching pamrevlumab by IV infusion every 3 weeks for a total of 16 infusions over 45 weeks.
89596242|NCT01890265|Active Comparator|Sub-Study: Pamrevlumab+Pirfenidone or Nintedanib|"Participants will receive pamrevlumab by IV infusion every 3 weeks for a total of 8 infusions over 21 weeks. Initial treatment with pamrevlumab in all active comparator participants will be administered at a dose of 15 mg/kg for the first 2 dose administrations. If these are well tolerated, all following study drug administrations will be at 30 mg/kg.~Pirfenidone or nintedanib will be dosed according to the instructions in their respective labels and the prescribing physician."
88978609|NCT00264589|Other|Study Population|"non-diabetic obese subjects and type 2 diabetic subjects~Intervention: 8 weeks individualized training program"
89596243|NCT01890265|Placebo Comparator|Sub-Study: Placebo+Pirfenidone or Nintedanib|"Participants will receive placebo matching pamrevlumab by IV infusion every 3 weeks for a total of 8 infusions over 21 weeks. Initial treatment with placebo in all active comparator participants will be administered at a dose of 15 mg/kg for the first 2 dose administrations. If these are well tolerated, all following study drug administrations will be at 30 mg/kg.~Pirfenidone or nintedanib will be dosed according to the instructions in their respective labels and the prescribing physician."
89596244|NCT01926652|Experimental|candesartan|Single administration : candesartan cilexetil 32mg, qd. Combination administration : candesartan cilexetil 32mg and amlodipine 10mg, qd
89596245|NCT01926652|Experimental|amlodipine|Single administration : amlodipine 10mg, qd. Combination administration : candesartan cilexetil 32mg and amlodipine 10mg, qd
89596246|NCT03073954|Active Comparator|Working memory training|Working memory training that increases with difficulty if participants answer two subsequent questions correctly, and standardised healthy lifestyle coaching.
89596247|NCT03073954|Sham Comparator|Sham working memory training|Working memory training that does not increase in difficulty, and standardised healthy lifestyle coaching.
89596248|NCT01926730|No Intervention|Usual diet|Patients will follow a usual diet and consume at least 16 oz of water per day
88978610|NCT00072839|Placebo Comparator|Placebo|placebo solution injected subcutaneously daily into either thigh or abdomen.
88978611|NCT00072839|Experimental|teduglutide 0.05|teduglutide 0.05 mg/kg/d injected subcutaneously daily.
88978612|NCT00072839|Experimental|teduglutide 0.1|0.1 mg/kg/d teduglutide injected subcutaneously into thigh or abdomen
88978613|NCT00072839|Experimental|teduglutide|0.2 mg/kg/d teduglutide injected subcutaneously into thigh or abdomen
88978614|NCT00264706|Other|Participant|Internal control study
88978615|NCT00264745|Experimental|1|
88978616|NCT00264745|Active Comparator|2|
88978617|NCT00264823|Experimental|1 - Experimental|
88978618|NCT00264823|No Intervention|2 - Control|
88978619|NCT00264979|Other|1|Simultaneous surgery of colorectal cancer and synchronous liver metastases
88978620|NCT00264979|Other|2|Sequential surgeries of colorectal cancer and synchronous liver metastases
88978621|NCT00265018|Active Comparator|Arm A|
88978622|NCT00265018|Experimental|Arm B|
88978623|NCT00265018|Experimental|Arm C|
88978624|NCT00265018|Experimental|Arm D|
89596249|NCT01926730|Experimental|Restriction diet|Participants will follow a diet that limits intake of selected food items. Patients will consume at least 16 oz of water per day.
89596250|NCT03070444|Experimental|Group A: CTC retainer + Essix retainer|"The CTC is bonded directly after debonding. The Essix retainer maxilla is handed out to the patient the same day after removal of fixed appliances.~Alginate impressions are taken at the follow-up visits. Questionnaires are completed at the follow-up visits."
89596251|NCT03070444|Active Comparator|Group B: Essix retainer + Essix retainer|"The Essix retainer maxilla and Essix retainer mandible are handed out to the patient the same day after removal of fixed appliances.~Alginate impressions are taken at the follow-up visits. Questionnaires are completed at the follow-up visits."
89596252|NCT01928329|Placebo Comparator|Placebo|2 mg, 1 per week via subcutaneous placebo self injection
89596253|NCT01928329|Experimental|Exenatide (Bydureon)|2 mg, of drug administration 1 per week via subcutaneous self injection
89596254|NCT01922206|No Intervention|Wait-list Control|Participants in the wait-list control condition will receive a group-based version of the TRACK intervention after their 15-month follow up appointment.
89596255|NCT01922206|Experimental|TRACK Intervention|3-session, individually administered psycho-educational intervention to promote maternal disclosure of HIV status to child
89596256|NCT01922284|Experimental|Group 1 - Combination arm|"All participants will receive DNA vaccines at 0,4 and 8 weeks. These will be administered in 2 separate injections of 1ml (CN54ENV into the muscle of the upper right arm and ZM96GPN into the muscle of upper left arm). Participants in group 1 will receive 5 immunisations (DNA, MVA and CN54rgp140 in GLA-AF vaccines) at weeks 0, 4, 8 16 and 20.~At weeks 16 and 20, individuals in group 1 will be given MVAC in a volume of 0.5mls into the upper left arm and also 100ug CN54rgp140 mixed with 5ug GLA-AF in a total volume of 0.4mls into the muscle of the upper right arm."
89596257|NCT01922284|Active Comparator|Group 2 - Non-combination arm|"All participants will receive DNA vaccines at 0,4 and 8 weeks. These will be administered in 2 separate injections of 1ml (CN54ENV into the muscle of the upper right arm and ZM96GPN into the muscle of upper left arm). Participants in group 2 will receive 7 immunisations (DNA, MVA and CN54rgp140 in GLA-AF vaccines) at weeks 0, 4, 8, 16, 20, 24 and 28.~At weeks 16 & 20 group 2 will receive only 0.5mls of MVAC into the muscle of the upper left arm. At weeks 24 and 28 they will receive injections of 100ug CN54rgp140 mixed with 5ugGLAAF in a total volume of 0.4mls into the muscle of the upper right arm."
89596258|NCT01890109|Placebo Comparator|Placebo|Participants received a single dose of placebo administered by subcutaneous injection.
89596259|NCT01890109|Experimental|Erenumab|Participants received a single dose of 70 mg erenumab administered by subcutaneous injection.
89596260|NCT03108976|Sham Comparator|Control group|Children with a typical development.
88978625|NCT02961010|Experimental|Intervention Group|The intervention group will receive the Keeping Safe programme between 2016 and 2018. This comprises a blended package of continuing professional development training and support (plus resource materials) for teachers and school staff to enable them teach sensitive preventative education concepts through the formal statutory Personal Development curriculum, and all other informal opportunities that present in the daily life of the school. Following randomisation, intervention schools will receive the package of training and support across a 3 month period and will then implement/teach in their school across 2 school years. The intervention group will collect outcome data for the evaluation between March 2016 and June 2018.
88978626|NCT02961010|No Intervention|Wait-list Control Group|The Wait List Control group will continue with standard practice of teaching the statutory Personal Development curriculum between 2016 and 2018. They will not receive the Keeping Safe intervention until Sept 2018 following completion of the evaluation. The Waitlist control intervention group will collect outcome data for the evaluation between March 2016 and June 2018.
89596261|NCT03108976|Active Comparator|Case group|Children with Autism Spectrum Disorders.
89596262|NCT01926808||Vitamin D supplementation|
89596263|NCT03069976|Experimental|1|All included patients, diagnosed with Overlap Syndrome or Primary Sclerosing Cholangitis, will receive treatment (Metronidazole x 14 days) hence single arm study.
89596264|NCT00982930|Experimental|Tobramycin Inhalation Powder (TIP)|Participants received 112 mg (four 28 mg capsules) of TIP administered by the T-326 Inhaler, twice a day (b.i.d.), given in a cycle of 28 days on treatment followed by 28 days off treatment (one cycle = 56 days) for up to 3 cycles.
89596265|NCT03069664|Active Comparator|Covered Self-expandable Metal Stent|ERCP (endoscopic retrograde cholangiopancreatography) and placement of a pancreatic duct stent
89596266|NCT03069664|No Intervention|Control group|control group
89596267|NCT05602168|Experimental|experimental:Acute leukemia/myelodysplastic or myeloproliferative disease|blood sampling, bone marrow aspirate, and buccal swab
89596268|NCT01926964||Early breast cancer patients|Patients with ER-positive, HER2 negative, pN0 or pN1a and resected primary breast cancer R0 resection.
89596269|NCT00981682|Experimental|SER120 (desmopressin)|
89596270|NCT01903993|Active Comparator|Docetaxel|Participants received docetaxel 75 milligram per meter square (mg/m^2) administered intravenously on Day 1 of each 21 day cycle until disease progression or unacceptable toxicity or death.
89596271|NCT01903993|Experimental|Atezolizumab|Participants were administered atezolizumab intravenously on Day 1 of each 21 day cycle at a fixed dose of 1200 mg. Atezolizumab treatment were to continued as long as participants were experiencing clinical benefit as assessed by the investigator.
89596272|NCT00981292|Active Comparator|135mg EGCG|
88978627|NCT00265135|Experimental|Part 1 (CNTO 328)|In Part 1 of the study, 4 intravenous infusions (IV) [injection of a substance into a vein] of CNTO 328 will be administered to patients in 4 dose levels ranging from 1, 3, 6, and 12 mg/kg on days 1, 29, 43, and 57 to determine the maximum tolerated dose for Part 2 of the study.
89596273|NCT00981292|Active Comparator|270mg EGCG|
89596274|NCT00981292|Placebo Comparator|0mg EGCG|
89596275|NCT03065140|Experimental|Healthy Volunteers|"Healthy volunteers will undergo the following:~CPEX with/without stable isotope infusion~Muscle biopsies~Magnetic Resonance Spectroscopy Followed by a period of detraining.~They will then undergo the following:~CPEX with/without stable isotope infusion~Muscle biopsies~Magnetic Resonance Spectroscopy"
89596276|NCT03065140|Experimental|Diabetic Patients|"Diabetic patients will undergo the following:~CPEX with/without stable isotope infusion~Muscle biopsies~Magnetic Resonance Spectroscopy They will then undergo a supervised training period.~They will then undergo the following:~CPEX with/without stable isotope infusion~Muscle biopsies~Magnetic Resonance Spectroscopy"
89596277|NCT01927042|Experimental|Expert Cares Helping Others plus Treatment as Usual|The experimental treatment (ECHOs plus TAU) will consist of the standard treatment consisting of group psychotherapy and skills training, nutritional counselling, and meal support, PLUS self-help unguided DVD series for carers, providing education about eating disorders and coping strategies for supporting those living with eating disorders.
89596278|NCT01927042|Active Comparator|Treatment as Usual|Treatment as usual (TAU) consists of group psychotherapy and skills training, nutritional counselling, and meal support.
89596279|NCT01927510|Experimental|early mobilisation|intervention of early mobilisation
89596280|NCT01927510|No Intervention|Control|Standard care
89596281|NCT00980044|Experimental|Tramadol 200 mg then placebo|Tramadol 200 mg daily for 1 week then placebo given for 1 week
89596282|NCT00980044|Placebo Comparator|Placebo for two weeks|Medication
89596283|NCT00980044|Experimental|Tramadol 600 mg then placebo|Tramadol 600 mg daily given for 1 week given then placebo given for 1 week
89596284|NCT05601934|Experimental|Neurophysiological Facilitation Techniques|
89596285|NCT05601934|Experimental|Respiratory exercises|
89596286|NCT01927588|Experimental|Everolimus+Tacrolimus+Prednisone|Certican 3mg/daily for 12 months TACreduced 0,15mg/Kg/daily for 12 months Steroids 1mg/Kg/daily for 12 months
89596287|NCT01927588|Active Comparator|Mycophenolate+Tacrolimus+Prednisone|Myfortic 720mg twice daily for 12 months TACreduced full dose/Kg/daily for 12 months Steroids 1mg/Kg/daily for 12 months
89596288|NCT05601466|Experimental|QN-023a|QN-023a in adult subjects with r/r AML
89596289|NCT01903837|Experimental|Low Dose|Olanzapine + low dose samidorphan tablets taken once daily
89596290|NCT01903837|Experimental|Medium Dose|Olanzapine + medium dose samidorphan tablets taken once daily
89596291|NCT01903837|Experimental|High Dose|Olanzapine + high dose samidorphan tablets taken once daily
89596292|NCT01903837|Placebo Comparator|Placebo|Olanzapine + placebo tablets taken once daily
89596293|NCT01927666|Experimental|dietary intervention|To measure the variation in extent of ITC excretion in urine from a capsule delivered dose of 100mg glucoraphanin
89596294|NCT00982696|Experimental|Single Arm|Opioid Growth Factor (OGF)
89596295|NCT00982150|Experimental|Talampanel|Talampanel 50mg tid
89596296|NCT02984254|Experimental|functional patellofemoral neoprene brace|26 Patients will use a a functional patellofemoral neoprene brace and answer WOMAC, Lequesne questionnaires, perform Timed-up-and-go (TUG), five-times-sit-to-stand-test (FTSST) and the six-minute walk test.
89596297|NCT02984254|Experimental|neoprene sleeve brace.|26 Patients will use a neoprene sleeve brace and answer WOMAC, Lequesne questionnaires, perform Timed-up-and-go (TUG), five-times-sit-to-stand-test (FTSST) and the six-minute walk test.
89596298|NCT01903525|Placebo Comparator|Placebo|The placebo capsules are supplied as 950 mg capsules consisting of 475 mg corn oil and 475 mg soy oil. Both DHA and placebo are flavored with sweet orange flavoring and masking agents. Subjects will be instructed to take 2 capsules at breakfast and 2 capsules at dinner (with food). Subjects will take their first dose in the office to assure their ability to swallow the pills. Subjects will be dosed with the placebo for 12 weeks.
89596299|NCT01903525|Experimental|Docosahexaenoic Acid (DHA)|The DHASCO capsules are supplied as 950 mg capsules with an effective dose of 500 mg DHA per capsule. Both DHA and placebo are flavored with sweet orange flavoring and masking agents. Subjects will be instructed to take 2 capsules at breakfast and 2 capsules at dinner (with food). Subjects will take their first dose in the office to assure their ability to swallow the pills. Subjects will be dosed with the DHA for 12 weeks.
89596300|NCT01927822||Pregnancy|Women who underwent termination of pregnancy at second trimester due to a variety of causes
89596301|NCT00981526|Experimental|A: Telmisartan|(existing Clozapine or Olanzapine treatment) + (Telmisartan)
89596302|NCT00981526|Placebo Comparator|B: Placebo|(existing Clozapine or Olanzapine treatment) + (Placebo)
89596303|NCT05601310||Control group|in the group, the participants exhibited negative results or <50% obstruction upon coronary artery CT or coronary angiography. The group did not have coronary heart disease and diabetes
89596304|NCT05601310||T2DM group|in the group, the participants exhibited negative results or <50% obstruction upon coronary artery CT or coronary angiography. The group did not have coronary heart disease but have type 2 diabetes mellitus.
89596305|NCT05601310||T2DM+AMI group|In the group, we eventually recruited 30 adult patients who were firstly diagnosed ST-elevation myocardial infarction (STEMI) within 12 hours of appearance chest pains or other AMI symptoms and had no previous history of coronary artery disease (CAD). Peripheral venous blood samples were drawn from subjects on admission or prior to coronary revascularization.
89596306|NCT01927900|Active Comparator|HMO1|HMO diluted in water
89210036|NCT02539914|Experimental|VR motor-cognitive task|The VR motor-cognitive task group will perform a virtual reality motor and cognitive attention/memory task customized to each user in terms of the positive content.
89596307|NCT01927900|Placebo Comparator|Glucose|Glucose diluted in water
89596308|NCT01927900|Active Comparator|HMO2|HMO diluted in water
89596309|NCT01927900|Active Comparator|HMO3|HMO diluted in water
89596310|NCT01927900|Active Comparator|HMO4|HMO diluted in water
89596311|NCT01927900|Active Comparator|HMO5|HMO diluted in water
89210037|NCT02539914|Active Comparator|Standard rehabilitation|The standard rehabilitation group will perform conventional motor and cognitive rehabilitation tasks.
89210038|NCT00896220||ICU Survivors and Their Family Caregiver|ICU Survivors who required one week or more of mechanical ventilation during their critical illness and their primary family caregiver
89596312|NCT01927900|Active Comparator|HMO6|HMO diluted in water
89596313|NCT01927900|Active Comparator|HMO7|HMO diluted in water
89596314|NCT01927900|Active Comparator|HMO8|HMO diluted in water
89596315|NCT01927900|Active Comparator|HMO9|HMO diluted in water
89210039|NCT00901212|Active Comparator|LV Pacing|left univentricular pacing
89596316|NCT04274920|Experimental|Bioactive Glass|18 teeth were capped indirectly with dental adhesive containing bioactive glass applied according to the manufacturer's instructions and cured for 20 seconds and then resin composite restoration containing bioactive glass applied by golden plated composite applicator in increments 2 mm each and cured for 40 seconds for each increment.
89596317|NCT04274920|Active Comparator|Light cured calcium hydroxide|18 teeth were capped indirectly with light cured calcium hydroxide (control group) applied according to the manufacturer's instructions by calcium hydroxide applicator and light cured for 20 seconds then resin composite restoration was applied by golden plated composite applicator in increments 2 mm each and cured for 40 seconds for each increment.
89596318|NCT04274842|Other|D-OCT image observational|Patients clinically eligible for IPL treatment of facial telangiectasia were D-OCT scanned before, after, 1-3 days after and 1 month after treatment
89596319|NCT04274608|Experimental|Intervention Arm|"Patients in the intervention arm will receive 300units of Botulinum Toxin A (Botox; Allergan Inc., Irvine, Ca, USA) diluted to 10mls of saline. Endoscopy will be performed using a single-lumen gastroscope. Injection of the solution will be done using a 23Gauge Interject needle catheter. 20 separate injections of 0.5ml each will be performed in a concentric ring 1cm apart. 10 injections will be performed into the body of the stomach, and 10 injections into the fundus, from the level of the CEJ and above~Patients will undergo a 12-week weight management program approximately 2 weeks after the injection of Botox."
89596320|NCT04274608|Active Comparator|Control Arm|Patients will undergo a 12-week weight management program.
89596321|NCT01927978||esophageal cancer, 18F-FDG PET|
89596322|NCT05601076|Experimental|The drainage tube in the experimental group was fixed with the triple-buffer system|
89596323|NCT05601076|Active Comparator|that in the control group was fixed using the conventional lifting platform method|
89596324|NCT05600998|Experimental|Camrelizumab+Anlotinib|Subjects will receive carilizumab every three weeks, with alozantinib 20 mg orally daily for 9 weeks
89596325|NCT05607940|Experimental|blood volume loss based blood transfusion|intraoperative blood transfusion begin once blood volume loss over 400ml
89596326|NCT05607940|Active Comparator|hemoglobin concentration based blood transfusion|intraoperative blood transfusion begin once hemoglobin concentration below 70g/L
89596327|NCT03831412|Active Comparator|CBT-I|5 sessions of treating insomnia
89596328|NCT03831412|Active Comparator|ERRT|5 sessions of treating post-trauma nightmares
89596329|NCT05607706|No Intervention|Control|families were not allowed to enter the NICU
89596330|NCT05607706|Active Comparator|Maternal Odor|Babies compared only to the mother's odor
89596331|NCT05607706|Active Comparator|Kangaroo care|Babies given kangaroo care
89596332|NCT05607628|Active Comparator|Low-Calorie Control Group|"The control group will receive 2x calorie-restricted balanced meals per day, each consisting of a portion of animal proteins (~20g), a portion of vegetables, and a portion of starch (rice/ noodles) per meal. The group will also receive a mid-morning beverage in the form of a malted drink (~150 kcal and ~5g protein). The third meal of the day and any additional snacks will be left to the free choice of the participants, with calorie advice provided by study dietitian. Calorie restriction aims to reduce body weight of individual participants by ~5 - 10%.~The group will also be asked to undergo a supervised mixed exercise regime three days per week, 1 hour per day. The mixed exercise regime will consist of 2 sessions of resistance training and 1 session of aerobic training."
89210040|NCT00901212|Active Comparator|BV Pacing|biventricular pacing
89596333|NCT05607628|Active Comparator|Low-Calorie Treatment Group|"The treatment group will receive 2x calorie-restricted balanced meals per day, each consisting of a portion of plant proteins (~25g), a portion of vegetables, and a portion of starch (rice/noodles) per meal. The group will also receive a mid-morning beverage, in the form of a soy-based, plant protein beverage (~120 kcal and 13g protein). The third meal of the day and any additional snacks will be left to the free choice of the participants, with calorie advice provided by study dietitian. Calorie restriction aims to reduce body weight of participants by ~5 - 10%.~The group will also be asked to undergo a supervised mixed exercise regime three days per week, 1 hour per day. The mixed exercise regime will consist of 2 sessions of resistance training and 1 session of aerobic training."
89596334|NCT04759378|Experimental|IBS patients who have upper GIT symptoms|
89596335|NCT01927861|Experimental|0.033 mg/kg/day|
89596336|NCT01927861|Experimental|0.066 mg/kg/day|
89596337|NCT05606536|Experimental|10 % hemodilution|"Recumbent surgery:~infusion rate in first 20 minutes: 15 ml/kg/h~infusion rate after 20 minutes: 2,6 ml/kg/h~Laparoscopic surgery:~infusion rate in first 20 minutes: 16 ml/kg/h~infusion rate after 20 minutes: 0,8 ml/kg/h"
88978628|NCT00265135|Experimental|Part 2 (CNTO 328)|In Part 2 of the study, 2 well tolerated dose levels of CNTO 328 from Part 1 of the study will be administered every 3 weeks as 4 IV infusions to patients.
88978629|NCT00265135|Experimental|Part 3 (CNTO 328)|In Part 3 of the study, CNTO 328 at a dose level of 6 mg/kg will be administered as IV infusion every 2 weeks for at least 6 doses.
88978630|NCT00106197|Experimental|1|Participants will receive bupropion in the sleep study
88978631|NCT00265408|Experimental|aspirin|
88978632|NCT00265408|Experimental|warfarin|
88978633|NCT00265447|Active Comparator|Strength training|3 months of strength training
88978634|NCT00265447|Active Comparator|Aerobic conditioning|3 months of aerobic conditioning
88978635|NCT00265447|Other|Delayed exercise|delayed exercise control group
88978636|NCT00265603|Experimental|1 Arm|The investigators plan to have approximately 16 persons participate in the study of transimmunization. Transimmunization uses a device, called a UVAR-XTS instrument, to remove a portion of blood, part of which is returned, and part of which is incubated overnight before being returned to the bloodstream the next day
88978637|NCT00265642|Experimental|group verum|Drug: Irbesartan
88978638|NCT00265642|Placebo Comparator|group placebo|
88978639|NCT00265720|Placebo Comparator|Control|Written materials only
88978640|NCT00265720|Experimental|Reduced out-of-pocket expense|Reimbursed up to $500 out-of-pocket expense for colorectal cancer screening
88978641|NCT00265720|Experimental|One-on-one education|Individual education with a health educator on CRC screening
88978642|NCT00265720|Experimental|Group Education|Education on CRC screening in a small group with a health educator
89596338|NCT05606536|Experimental|20 % hemodilution|"Recumbent surgery:~infusion rate in first 20 minutes: 26 ml/kg/h~infusion rate after 20 minutes: 3,4 ml/kg/h~Laparoscopic surgery:~infusion rate in first 20 minutes: 28 ml/kg/h~infusion rate after 20 minutes: 1,6 ml/kg/h"
89596339|NCT05606536|Experimental|30 % hemodilution|"Recumbent surgery:~infusion rate in first 20 minutes: 38 ml/kg/h~infusion rate after 20 minutes: 5,1 ml/kg/h~Laparoscopic surgery:~infusion rate in first 20 minutes: 44 ml/kg/h~infusion rate after 20 minutes: 2,4 ml/kg/h"
89596340|NCT05606536|No Intervention|Standart care|Infusion rate based upon the standard care.
89596341|NCT05600218||Cohort 1|Patients with pulmonary arterial hypertension on treatment with prostacyclin IP receptor agonists because they are at intermediate risk of mortality at one year
89596342|NCT05602948|Experimental|'Run, Jump & Fun' intervention|"The Run, jump & fun intervention consists of four 30 minutes sessions per week for one school year. Activities are mostly conducted as whole class activities. Head of schools and teachers/school pedagogues are involved in an initial intervention establishing process, guided by Active School personnel. The aim is to create a local plan for the intervention tailored to the particular school. Examples are movement band, structured activities during recess with older students (13-15 years olds), etc. Activities are created to be fun, motivating and with moderate to high intensity PA."
89596343|NCT05602948|Experimental|'Move & Learn' intervention|"This intervention is implemented as PA for 30 min in two Mathematics and two Danish lessons each week for one school year. Activities are conducted at whole-class level.~The physical activities in Move & Learn are closely linked to the Mathematic curriculum and the Danish curriculum. The way the body is integrated in the learning task can vary. Examples are bodily or motor-skill demanding activities or less vigorous activities, e.g. standing up miming, using hand gestures or facial expressions. An important aspect of the interventions is that movements should be task relevant. The intervention is developed based on the embodied learning theory."
89596344|NCT05602948|No Intervention|Control|Control schools will continue their usual practice.
89596345|NCT03831178|Experimental|DHA|Participants will take 11 capsules per day containing DHA-enriched triglyceride oil (1 g capsules containing at least 400 mg DHA) for a total of 5 g DHA/day divided into three times daily with meals or as tolerated.
89596346|NCT03831178|Placebo Comparator|Placebo|Participants will take 11 capsules per day containing corn/soy oil blend capsules divided into three times daily with meals or as tolerated.
89596347|NCT05602870|Experimental|Psychiatric patient|All patients having psychiatric disorders and hospitalised in a Psychiatry Unit of CHU Montpellier will have an non invasive evaluation of liver fibrosis after giving their consent
89596348|NCT01927627|Experimental|Enzalutamide|Oral therapy with enzalutamide at 160mg (4 capsules) orally once daily (QD).
89596349|NCT05602792|Experimental|T3011 Herpes Virus Injection|
89596350|NCT04394104||COVID-19 Survey Group|Group of individuals participating in the survey via self-selection. There is not intervention being administered. The group is simply answering questions on their health behaviors before COVID-19 and their health behaviors in the past 7-30 days, during the COVID-19 outbreak in the United States.
89596351|NCT01889251|Experimental|Ocriplasmin|Ocriplasmin administered as a single intravitreal injection to the study eye at baseline
89596352|NCT01889251|Sham Comparator|Sham injection|Single sham injection to the study eye at baseline
89596353|NCT05602558|Experimental|LYB001|
89596354|NCT05602558|Placebo Comparator|Placebo|
89596355|NCT04394338|Active Comparator|plastic sheath covering|plastic sheath was prepared with the standard 9 cmx15cm self-gripping mesh. Then the meshe were folded and unfolded over or under the plastic sheaths in different directions.
89596356|NCT04394338|No Intervention|mesh placement without plastic sheath|self-gripping mesh were placed without plastic sheath.
89596357|NCT01616563|Experimental|Diet and exercise|A combined diet and exercise program tailored to individuals incorporating behavioural modification support
89596358|NCT05602324|Experimental|Lauric Acid and Berberine|Participants in this arm of the trial will receive 15 ml lauric acid and 1000 mg berberine daily (via feed tube) for the duration of time that they are receiving enteral feeding, up to a maximum time of 14 days
89596359|NCT05602324|No Intervention|No-intervention|participants in this arm will receive no additional intervention, beyond standard of care
89596360|NCT05600608|Experimental|Oesophago- gastric adenocarcinoma patients|"Oesophagogastric adenocarcinoma (OG) cancer patients (who are neoadjuvant chemotherapy treatment naïve) will receive 120mls of a sterile oral stimulant drink (OSD) (manufactured by Ingenza ltd), which is an ISO accredited laboratory. The active component of the drink is iron sulphate (5g/l), pH 5-6.~Breath will be taken following an optimised methodology designed by the VOC laboratory at Imperial college London at baseline and then at 30, 60 and 90 minutes following consumption of the drink.~Participants will be nil by mouth for 6 hours prior to the breath test, they can have water up to 2 hours before the breath test."
89596361|NCT05600608|Active Comparator|Benign healthy control patients|Age, gender and demographic matched patients who have had a negative oesophagogastroscopy within 1 year which is negative for adenocarcinoma will be recuited into the comparison arm. Patients will be given the same OSD and breath will be sampled at the same time points as the experimental arm.
89596362|NCT01616173|Active Comparator|Perineural Dexamethasone|Ultrasound guided sciatic nerve block with bupivicaine 0.5% with 1:300,000 epinephrine and perineural dexamethasone 8mg/2mL, and 50mL IV normal saline infusion
89596363|NCT01616173|Active Comparator|Intravenous Dexamethasone|Ultrasound guided sciatic nerve block with bupivicaine 0.5% with 1:300,000 epinephrine with saline and IV dexamethsone 8mg in 50mL infusion
89596364|NCT01616173|Placebo Comparator|No Perioperative Steroids|Ultrasound guided sciatic nerve block with bupivicaine 0.5% with 1:300,000 epinephrine with saline and 50mL infusion
89596365|NCT05609734||Patients with an delayed traumatic intracranial hemorrhage|A total of 249 control CTs was performed, where the initial CT was normal regarding tICH. In the initial assessments 1 case of d-ICH (0,41%) was found, but after second opinion this case (case 1, Table 1) was regarded as a pictorial artefact (Table 1). Hence, no d-ICH was found.
89596366|NCT05609734||Patients without an delayed traumatic intracranial hemorrhage|A total of 249 control CTs was performed, where the initial CT was normal regarding tICH. In the initial assessments 1 case of d-ICH (0,41%) was found, but after second opinion this case (case 1, Table 1) was regarded as a pictorial artefact (Table 1). Hence, no d-ICH was found.
89210041|NCT00896376|Experimental|trastuzumab|
89596367|NCT03044314|Experimental|Iloprost and nitric oxide administration|Each patient will receive 40 ppm inhaled nitric oxide and 2.5-5 mcg inhaled iloprost in the catheterization laboratory with assessment of hemodynamic response. Patients will also receive 2.5-5 mcg iloprost during echocardiographic assessment.
89596368|NCT03040102|Experimental|Hospice Video Educational Tool|"The hospice video educational tool is a 6 minute video~Participants will watch an approximately 6-minute digital video regarding hospice on an iPad"
89596369|NCT03040102|Active Comparator|Hospice Verbal Narrative|"The RA will read a verbal narrative that is identical to the narrative of the video to participants~Standard of Care practice is used"
89596370|NCT05608720|Experimental|study group|Information Booklet prior to the dental visit
89596371|NCT05608720|No Intervention|control group|no information prior to the dental visit
89596372|NCT05608642|Active Comparator|Group given intravenous hydration|The first group consists of patients given 500 cc intravenous saline for 1 hour.
89596373|NCT05608642|Active Comparator|Group given intravenous prednisolone|Second group; consists of patients who were given 80 mg of intravenous prednisolone for the first 4 days and then given gradually decreasing doses of prednisolone in the following days.
89596374|NCT05608642|Active Comparator|Group given intravenous lidocaine|Third group; includes patients given 2 mg/kg intravenous lidocaine by 1-hour infusion.
89596375|NCT03036904|Experimental|Venetoclax plus DA-EPOCH-R|Venetoclax will be given in conjunction with 6 cycles of DA-EPOCH-R (doxorubicin hydrochloride, etoposide, vincristine sulfate, cyclophosphamide, prednisone, rituximab). The dosing schedule and regimen for DA-EPOCH-R will follow established protocols. Venetoclax will be administered days 1-10 of each 21-day cycle, with the exception of cycle 1, during which venetoclax dose will commence on day 3 and continue through day 12, so as to clarify attribution of any observed TLS and/or infusion reactions, and minimize tumor lysis syndrome (TLS) risk.
89596376|NCT02983942|Experimental|ketogenic diet group|Ketogenic diet is given in combination to standard HD-MTX chemotherapy to primary central nervous system lymphoma patients. Blood ketone is kept no less than 2mmol/L during the initial 4 cycles of chemotherapy. The adverse events is monitored and recorded. Tumor response is evaluated and recorded.
89596377|NCT02983942|Active Comparator|routine diet group|Standard HD-MTX chemotherapy is given with routine diet.Blood ketone is measured and recorded. The adverse events is monitored and recorded. Tumor response is evaluated and recorded.
89596378|NCT05608096||Hemoperfusion|ICU septic patients treated with hemoperfusion
89596379|NCT05608096||non-hemoperfusion|ICU septic patients non treated with hemoperfusion
89596380|NCT05604898|Experimental|Part 1：608 40 mg|Randomized in a 6:2 ratio to 608 40mg or placebo 2-weekly by subcutaneous injection during induction period. During the maintenance period, participants will receive 608 40mg or placebo 4-weekly.
89596381|NCT05604898|Experimental|Part 1：608 80 mg|Randomized in a 10:2 ratio to 608 80mg or placebo 2-weekly by subcutaneous injection during induction period. During the maintenance period, participants will receive 608 80mg or placebo 4-weekly.
89596382|NCT05604898|Experimental|Part 1：608 160 mg|Randomized in a 10:2 ratio to 608 160mg or placebo 2-weekly by subcutaneous injection during induction period. During the maintenance period, participants will receive 608 160mg or placebo 4-weekly.
89596383|NCT05604898|Experimental|Part 2：608 160 mg W0+80 mg Q2W+80 mg Q4W|Participants will receive starting dose of 160 mg 608 at week 0 followed by 80mg 608 once every two weeks (Q2W) by subcutaneous injection during induction period. During the maintenance period, participants will receive 80mg 608 once every four weeks (Q4W).
89596384|NCT05604898|Experimental|Part 2：608 160 mg Q2W+160 mg Q4W|Participants will receive 160mg 608 once every two weeks (Q2W) by subcutaneous injection during induction period followed by 160mg 608 once every four weeks (Q4W) during maintenance period.
88978643|NCT00265954|Experimental|1|Individuals in this arm receive a 6 month behavioral weight loss intervention delivered on-line. Groups meet via a web chat weekly for 24 weeks and monthly for the following 12 months.
88978644|NCT00265954|Experimental|2|In-person; Individuals in the in-person condition attend weekly group behavioral weight loss sessions for 24 weeks and then monthly sessions for the following 12 months.
88978645|NCT00265954|Experimental|3|In-person+internet; Individuals in this condition receive a behavioral weight loss intervention over the internet weekly for 24 weeks and monthly for the following 12 months. Every month during the first 24 weeks and every third month during the following year they have an in-person meeting.
88978646|NCT00265993|Experimental|1|enoxaparin
88978647|NCT00102141|Experimental|Arm 1|
88978648|NCT00102141|Experimental|Arm 3|
88978649|NCT00102141|Experimental|Arm 4|
88978650|NCT00102141|Placebo Comparator|Arm 5|
88978651|NCT00102141|Experimental|Arm 2|
88978652|NCT00266305|Experimental|Fish oil|
88978653|NCT00266305|Placebo Comparator|Olive oil|Control group
88978654|NCT00266305|No Intervention|High fish|Reference group
88978655|NCT00266773|No Intervention|1|Control - standard care only
88978656|NCT00266773|Experimental|2|Attention Control - standard care plus 6 months TIVR receiving minimal monthly feedback
88978657|NCT00266773|Experimental|3|Standard care plus 6 months TIVR receiving detailed monthly feedback
88978658|NCT02966132|Experimental|iMD|"Participants will receive interactive Mobile Doctor (iMD) intervention in English, Chinese, Korean or Vietnamese languages that delivers video education tailored to patient's responses on a computer tablet during the clinic visit to enhance patient-provider discussion of tobacco use. The iMD intervention implements the 5As (Ask, Advice, Assess, Assist, and Arrange) recommended by the Clinical Practice Guideline for treating tobacco dependence. A summary printout including provider recommendation options, brief summary of smoking status, quit intention and concerns are provided to patients to empower them to discuss tobacco use with their providers."
89596385|NCT05604898|Experimental|Part 2：608 160 mg Q4W+160 mg Q8W|Participants will receive 160mg 608 once every four weeks (Q4W) by subcutaneous injection during induction period followed by 160mg 608 once every eight weeks (Q8W) during maintenance period.
89596386|NCT05604898|Placebo Comparator|Part 2：Placebo|Participants will receive Placebo by subcutaneous injection.
89031642|NCT00530868|Experimental|Letrozole + Avastin|50 evaluable patients received the combination therapy of 2.5 gm daily oral Letrozole and Avastin 15 mg/kg IV every 3 weeks for 24 weeks.
89031643|NCT00530868|Experimental|Letrozole alone|25 evaluable patients received daily oral 2.5 mg letrozole as a single agent
89031644|NCT00530907|Experimental|Valproic Acid + Bevacizumab|"Valproic acid administered at a dose of 5.3 mg/Kg/day on days 1 - 28. Depending on the calculated dose, patients will take capsules once or twice a day per mouth.~Bevacizumab administered at a dose of 2.5 mg/kg by vein every 2 weeks."
89031645|NCT02951663|Experimental|Protein Supplement|Ready to drink blinded protein supplement
89031646|NCT02951663|No Intervention|Control|Control group
89031647|NCT00530985|Experimental|1|Benefits Counseling
89031648|NCT00530985|Active Comparator|2|VA Orientation
89031649|NCT00531024|Experimental|1|3 intravenous infusions of 5mg/kg bevacizumab at 2 weeks intervals
89517827|NCT02325089|Experimental|Mandibular advancement device|Mandibular advancement device titrated to reduce or eliminate snoring and sleep apnea
89031650|NCT00531024|Placebo Comparator|2|3 intravenous infusions of 100ml sodium chloride 0,9% at 2 weeks intervals
89031651|NCT00512759|No Intervention|Standard of care|Standard of care of acute decompensated heart failure will be according to the current guidelines of the European Society of Cardiology (ESC).
89031652|NCT00512759|Experimental|Intervention|Early goal-directed preload and afterload decrement using a fixed therapy schedule including sublingual or nitrospray and transdermal nitrates together with hydralazine, followed by rapid up-titration of ACE-inhibitors , AT-receptor blockers or neprilysin inhibitors/AT-receptor blockers to achieve maximal vasodilatation with a target systolic blood pressure of 90-110 mmHg. All other elements of treatment will be according to the current guidelines of the European Society of Cardiology (ESC)
89031653|NCT00531726|Sham Comparator|B|
89031654|NCT00531726|Experimental|A|
89031655|NCT00514670|Experimental|1|Intervention classrooms received alcohol-based hand sanitizer and disinfecting wipes.
89031656|NCT00514670|No Intervention|2|No hand sanitizer or disinfecting wipes were used.
89031657|NCT00512837|Active Comparator|2|
89031658|NCT02943798|Experimental|Group A|Patients will be administered with etoposide plus carboplatin as first-line treatment.
89031659|NCT02943798|Experimental|Group B|Patients will be administered with paclitaxel plus carboplatin as first-line treatment.
89031660|NCT00512915|Active Comparator|1699T (Optisense)|Implantation of the Optisense Lead 1699T, programming of the shortest possible postventricular atrial blanking period (PVAB)
89210042|NCT00901290|Experimental|1|monophasic oral contraceptive
89517828|NCT02325089|Placebo Comparator|Placebo|Oral appliance identical to the mandibular advancement device without mandibular advancement
89517829|NCT03496103|Other|Allergic Subjects|After recording baseline symptoms, subjects were exposed to ragweed pollen for three hours and symptoms were recorded
89517830|NCT03496103|Other|Healthy|After recording baseline symptoms, subjects were exposed to ragweed pollen for three hours and symptoms were recorded
89517831|NCT03496025|Experimental|Electrical stimulation|
89517832|NCT01378117|Experimental|Sitagliptin + SSI prn|Sitagliptin once daily plus supplemental doses of lispro if needed using sliding scale insulin (SSI). 100 mg/day (at any time of day) for patients with GFR 50-100 ml/min and 50 mg/day for patients with GFR 30-50 ml/min
89517833|NCT01378117|Experimental|Sitagliptin and glargine+ SSI|Sitagliptin 50-100 mg per oral once a day and SubCutaneous (SQ) glargine insulin once daily + correctional doses of lispro if needed for elevated blood glucose using sliding scale insulin (SSI). 100 mg/day (at any time of day) for patients with glomerular filtration rate (GFR) 50-100 ml/min and 50 mg/day for patients with GFR 30-50 ml/min
89517834|NCT01378117|Active Comparator|Glargine and Lispro + SSI|Glargine once daily and lispro before meals supplemental insulin lispro as needed for elevated blood glucose using sliding scale insulin (SSI)
89517835|NCT02325167|Experimental|EBT|
89517836|NCT02325167|Experimental|Treatment-as-usual|
89517837|NCT02323139|Experimental|Combination of azacitidine and LDE255|Combination of azacitidine at maximum tolerated dose and LDE255 at dose escalation, the starting dose will be 400 mg
89517838|NCT04444609||COVID -19 with chronic lung disease|"Subjects with swab confirmed COVID-19 and underlying chronic lung disease (n=60)~Severe (n=30) (defined by presence of ARDS, sepsis or severe pneumonia)~Mild/Moderate ( n =30) (absence of severe criteria)"
89517839|NCT04444609||COVID-19 without chronic lung disease|"Subjects with swab confirmed COVID-19 and no chronic lung disease (n=60)~Severe (n=30) (defined by presence of ARDS, sepsis or severe pneumonia)~Mild/Moderate ( n =30) (absence of severe criteria)"
89517840|NCT04444609||Chronic Lung disease|"Subjects with chronic lung disease (identified as requiring shielding based on severity) but no COVID-19 (n=80)~Asthma (defined as severe) - (n=20)~CF (FEV1% predicted baseline <50%) - (n=20)~COPD (FEV1% predicted baseline <50%) - (n=20)~Idiopathic Pulmonary Fibrosis (n=20)"
89517841|NCT04444609||Healthy volunteers|Healthy subjects with no COVID-19 (n=30)
89517842|NCT02325245|Experimental|Metformin|Metformin tablet 500 mg three times a day for 16 weeks.
89517843|NCT02325245|Placebo Comparator|Placebo|Placebo tablet three times a day for 16 weeks.
89517844|NCT05618899|Experimental|HIGH INTENSITY INTERVAL TRAINING|High intensity interval training basicaaly short bursts of intense exercise alternating with low intensity recovery periods. Training should be done on treadmill for 25-30 minutes.. Training proceed for 1 month once a day
89517845|NCT05618899|Experimental|MODERATE INTENSITY EXERCISE|moderate intensity exercises consist of generally 30-60 minutes of aerobic exercises at 64-76% of peak heart rate. Training should be done on treadmill for 30-60 minutes. Training proceed for 1 month once a day
89517846|NCT03494231|Experimental|HLX06, in patients with solid cancers|Each cycle of treatment consists of 4 weeks. Patients who enroll into this study will receive an infusion of assigned dose of HLX06 once per week. No intra-patient dose escalation is allowed. The proposed dose escalation sequence is 500, 750, 900, 1200, 1500 mg, starting from 500 mg/kg.
89517847|NCT05397613|Experimental|STAIR|Participants will complete 1.5 hr group sessions once per week for 12 weeks of Skills Training in Affective and Interpersonal Regulation (STAIR). Participants will complete self-report measures pre, post, and at one month intervals.
89596387|NCT01544595|Placebo Comparator|PASI 75 Responders|"PASI 75 responders participated in randomized withdrawal. Subjects who were PASI 75 responders at Week 52 visit of the core studies (e.g.CAIN457A2302 or CAIN457A2303) and have been on secukinumab s.c. 150 mg or 300 mg in core studies were randomized to continue same s.c. doses of secukinumab in PFS or receive placebo every 4 weeks up to Week 152 or until relapse. Participants on first full relapse received loading dose followed by routine dosing with secukinumab s.c. 150 mg or 300 mg regimen."
89596388|NCT01544595|Experimental|Partial responders|Partial responders were not randomized. Subjects who were partial responders at Week 52 visit in core studies (e.g.CAIN457A2302 or CAIN457A2303) and have been on secukinumab s.c. 150 mg or 300 mg in core studies did not participate in the randomized withdrawal. These subjects continued same treatment s.c. dose in PFS (secukinumab s.c. 150 mg or 300 mg) as they were receiving at the time of completing the maintenance period (Week 52) in the core studies.
89596389|NCT05600842||De-escalated radiotherapy|
89596390|NCT04759534|Experimental|Treatment group 1|Received abdominal subcutaneous injection of IBI306 150 mg Q2W
89596391|NCT04759534|Experimental|Treatment group 2|Received abdominal subcutaneous injection of IBI306 150 mg Q4W
89596392|NCT04759534|Placebo Comparator|Placebo Group 1|Received a subcutaneous injection of placebo Q2W in the abdomen
89596393|NCT04759534|Placebo Comparator|Placebo Group 2|Received a subcutaneous injection of placebo Q4W in the abdomen
89596394|NCT05606224|Experimental|iMIED+TAU: internet-based mindfulness intervention for emotional distress plus treatment as usual|The internet-based self-help version of the Mindfulness Intervention for Emotional Distress (iMIED) program integrates rationales and practices from the UP and MBIs. Formal mindfulness exercises (e.g., body scan, mindful breathing, and mindful stretching) and informal mindfulness practices (e.g., mindful tooth-brushing) were retrieved from MBIs. In addition, iMIED selected several important tasks from the UP, like practicing tolerating uncomfortable feelings by interoceptive exposure practices (e.g., rapid breathing), identifying avoidant behaviors and emotion-driven behaviors and reducing them step by step, identifying common maladaptive automatic thoughts (e.g., overestimating probability and catastrophizing), and using the above strategies in daily life by completing challenging tasks.
89596395|NCT05606224|No Intervention|TAU-only: treatment as usual|In the current study, TAU consisted of all medicinal and psychological treatments received between baseline and follow-up (about five months). Medicinal treatments included receiving Lorazepam, Olanzapine, Paroxetine Hydrochloride, Sertraline, etc. Psychological treatments included receiving cognitive behavior therapy or psychodynamic therapy.
89596396|NCT04392700|Experimental|group A|drugs：tenofovir disoproxil fumarate, dose：300mg/d
89596397|NCT04392700|Active Comparator|group B|drugs：entecavir dose： 0.5 mg/d
89596398|NCT01539525|Experimental|Motivational Interview|Motivational interview provided by a clinical research nurse or physician.
89596399|NCT01539525|Active Comparator|Motivational Interview-Electronic|Motivational Interview provided by an interactive computer program.
89596400|NCT01539525|Placebo Comparator|Treatment as Usual|No intervention- resource list provided.
88978659|NCT02966132|Active Comparator|NPA|Participants will receive a video education providing nutrition and physical activity recommendations right before before seeing their providers. A printout summarizing topics presented in the education videos will be provided to the patient
88978660|NCT00266929||Surgical|Subjects receiving surgical treatment for Type II odontoid fracture per discretion of investigator (non-randomized allocation)
88978661|NCT00266929||Non-surgical|Subjects treated with non-operative treatment options
88978662|NCT01349569|Experimental|Myeloma Vaccine, Prevnar, & Lenalidomide|Lenalidomide will be continued on the same dose as was being administered prior to the study. The allogeneic myeloma vaccine and Prevnar-13 vaccine will be given on four days over the course of the study.
88978663|NCT00073346|Experimental|cognitive behavior therapy for hoarding disorder|Cognitive behavior therapy included 26 sessions of motivational enhancements; skills training for sorting, organizing and problem solving; direct practice not acquiring new items and discarding possessions to remove clutter and organize possessions; cognitive therapy to evaluate beliefs about possessions; and relapse prevention skills.
88978664|NCT00073346|No Intervention|Wait list control|Participants waited to receive treatment for 12 weeks
88978665|NCT00267124||1|elderly people who have normal cognition
88978666|NCT00267124||2|elderly people who have mild to moderate Alzheimer's disease
88978667|NCT00267163|Experimental|1.|
89596401|NCT03827902||Intervention Group|A Telcare 2.0 BGM, which is FDA cleared, will be used to upload blood glucose measurements to a cloud server accessible by providers. Intervention group will participate in an integrated care model where they will attend Diabetic Clinic and Foot Wound appointments on the same day.
89596402|NCT03827902||Control Group|Control Group will receive usual care (a non-integrated care model where Diabetes Clinic and Foot Wound appointments are on separate days.) These patients will not receive a blood monitoring glucose device.
89596403|NCT03828058|Experimental|Envarsus XR|Envarsus XR orally administered Daily
89596404|NCT03828058|Active Comparator|Prograf|"Prograf PO administered twice daily Generic Name: tacrolimus~Dosage of prograf will be determined by trough levels and adjusted accordingly"
89596405|NCT03827590|Experimental|HLIM|HLIM+SA160021 Placebo+SA160022 Placebo
88978668|NCT00267163|Placebo Comparator|2.|
88978669|NCT00267241|Experimental|1|ALI/ARDS patients
88978670|NCT00267319|Experimental|single group|
88978671|NCT00267358|Active Comparator|RC-1291 HCl|50 mg
88978672|NCT00267358|Placebo Comparator|Placebo|
88978673|NCT00267514|Other|1|sevelamer carbonate powder x 4 weeks then, sevelamer hydrochloride x 4 weeks
88978674|NCT00267514|Other|2|sevelamer hydrochloride x 4 weeks then, sevelamer carbonate powder x 4 weeks
88978675|NCT00106548|Experimental|1|
88978676|NCT00106548|Experimental|2|
88978677|NCT00106548|Placebo Comparator|3|
88978678|NCT00267826|Experimental|1|Patients with atopic dermatitis.
88978679|NCT00425620|Experimental|Amphotericin B|
88978680|NCT00401232|Other|Arm 1|
89031661|NCT00512915|Active Comparator|Standard lead|Implantation of a standard bipolar atrial pacing lead. Optimization of the postventricular atrial blanking period (PVAB) after implantation.
89210043|NCT00901290|Experimental|2|AZD7325
89596406|NCT03827590|Active Comparator|SA160021|HLIM Placebo+SA160021+SA160022 Placebo
89596407|NCT03827590|Active Comparator|SA160022|HLIM Placebo+SA160021 Placebo+SA160022
89596408|NCT03827590|Placebo Comparator|Placebo|HLIM Placebo+SA160021 Placebo+SA160022 Placebo
89596409|NCT03827668|Experimental|Single arm|The study will have only one study group in a fixed-sequence type of design with two periods
89031662|NCT02943369|Experimental|Cangrelor|Ticagrelor will be followed by Cangrelor
89031663|NCT02943369|Active Comparator|Ticagrelor|Ticagrelor only
89596410|NCT02958280|Experimental|Brief Advice Plus the Fit&Sober App|"Phase 1 (app development & Open Pilot) will consist of: 1) development of the Fit&Sober prototype; 2) series of usability studies with patients with AUDs; and 3) An open pilot of a 12-week trial (n=20) to test the feasibility and acceptability of the Fit&Sober app with patients with AUDs in early recovery.~Phase 2: RCT of the Fit&Sober app with 160 patients with AUD"
89596411|NCT02958280|Active Comparator|Brief Advice for Physical Activity|Phase 2: Participants randomized to the BA only condition will meet for a 30-minute discussion with a research staff member. In this session, participants will receive information about the public health guidelines for physical activity, the benefits of physical activity for physical and mental health, as well as sobriety, strategies for getting started as well as instruction on gradually increasing physical activity
89596412|NCT01513551|Experimental|V114|Healthy adult participants received a single 0.5 mL intramuscular injection of aluminum adjuvanted V114 on Day 1.
89596413|NCT01513551|Active Comparator|PNEUMOVAX® 23|Healthy adult participants received a single 0.5 mL intramuscular injection of PNEUMOVAX® 23 on Day 1.
89596414|NCT01513551|Active Comparator|PREVNAR 13®|Healthy adult participants received a single 0.5 mL intramuscular injection of PREVNAR 13® on Day 1.
89596415|NCT03827122|Experimental|Group one|Botx will be injection in masster muscles 20unit Botx (onabotulinumtoxinA) and visual pain scale will be taken before and after in four intervals 2,8,16,48 weeks
89596416|NCT02956642|Experimental|Blood Glucose Monitoring System|Participants in this arm will receive the Livongo Health System to manage diabetes. 150 participants will participate in this arm.
89596417|NCT02956642|Active Comparator|Standard Blood Glucose Monitoring|Participants in this arm will receive the iHealth Glucose Meter to take blood glucose measurements that will then be compared to participants from the Livongo Health System arm. 150 participants will participate in this arm.
89596418|NCT03827356|Experimental|"High intensity group"|Intervention is administrated with an inspiratory muscle trainer (IMT). High intensity group: 15 cycles, 1 minute each one, 40% MIP with IMT. 1 minute to rest between cycles.
89596419|NCT03827356|Active Comparator|"Low intensity group"|Intervention is administrated with an inspiratory muscle trainer (IMT). Low intensity group: 15 cycles, 1 minute each one, 20% MIP with IMT. 1 minute to rest between cycles.
89596420|NCT03827200|Experimental|Ambrisentan|Ambrisentan
89596421|NCT03827278|Experimental|HIV Negative Host talaromyces using Voriconazole|Voriconazole On the first day, 6 mg/kg bid was given, and then 4 mg/kg bid was given intravenously for 6 days, and then oral voriconazole 200 mg bid was administered to maintain treatment for at least 6 months.
89596422|NCT03827278|Experimental|HIV Negative talaromyces AMB Sequential Itraconazole|Amphotericin B (AMB) sequential itraconazole group (intravenous amphotericin, dose 0.7 - 1.0 mg / kg / d, 14 days, then changed oral itraconazole 200 mg bid for 10 weeks, after which 100 mg bid maintenance Until cluster of differentiation 4 (CD4+ T) cells are greater than 100 cells/L for at least 6 months
89596423|NCT03826732|Experimental|Guided self-help based on ACT|Participants follow a self-help program and receive weekly support by trained facilitators
89596424|NCT03826732|No Intervention|Wait-list control|Participants are informed that they will receive the intervention after the 6-month follow-up assessment
89031664|NCT02943330||Hemodialysis|Hemodialysis patients
89596425|NCT01513473|Experimental|Insulin Degludec + Insulin Aspart|
89596426|NCT01513473|Experimental|Insulin Detemir +Insulin Aspart|
89596427|NCT04346368|Experimental|Bone Marrow-Derived Mesenchymal Stem Cells (BM-MSCs)|Conventional treatment plus BM-MSCs
89596428|NCT04346368|Placebo Comparator|Placebo|Conventional treatment plus placebo
89596429|NCT03826810|Experimental|aPDT + ART group|In this group, both aPDT and ART were performed.
89596430|NCT03826810|Experimental|ART group|In this group, only ART was performed.
89596431|NCT03826654|Experimental|fortified oil|daily intake of fortified sunflower oil (700IU vitamin D/ 35g)
89596432|NCT03826654|Placebo Comparator|control|daily intake of plain oil
89596433|NCT03109990|Experimental|Dexmedetomidine|Patients of dexmedetomidine group will receive a loading dose of 1ug/kg dexmedetomidine since 15 mins before induction, and receive another 1ug/kg of dexmedetomidine at a rate of 0.5ug/kg/h for 2 continuous hours during surgery.
89596434|NCT03109990|Placebo Comparator|saline|Same amount of saline will be administrated.
89596435|NCT03826420|Experimental|Secure Confinement Group|Parolees assigned to this group will be assigned sanctions that include secure confinement.
89596436|NCT03826420|Experimental|Work Release Group|Parolees assigned to this group will be assigned sanctions that include work-release.
89031665|NCT02943330||Hepatitis C|Patients receiving interferon treatment for hepatitis C
89031666|NCT00514748|Active Comparator|1|Patients who receive breast reconstruction with bilateral DIEP flap based on bilateral vessel pedicles
89596437|NCT03826420|Experimental|GPS Supervision Group|Parolees assigned to this group will be assigned sanctions that include GPS supervision.
89596438|NCT03826420|No Intervention|Control Group|
89596439|NCT03825562|Experimental|research group|Research group is attending the ACT intervention first and from before and afte measurement are compared to the control group
89596440|NCT03825562|Active Comparator|control group|Control group is offered to attend the intervention afterwards
89596441|NCT01513317|Experimental|Siltuximab|15 mg/kg of siltuximab administered as a 1-hour infusion every 4 weeks + best supportive care (BSC)
89596442|NCT01513317|Experimental|Placebo|Placebo administered as a 1-hour infusion every 4 weeks + BSC
89596443|NCT04105179|Experimental|Implant Groups|Group will receive the Smith & Nephew Journey II knee implant or the Zimmer NexGen LPS-Flex knee implant
89596444|NCT04105179|No Intervention|Healthy Control Group|Control group that will not be undergoing a total knee arthroplasty
89596445|NCT03066310||Diagnosed Urinary Bladder Cancers|Patients who are being monitored for bladder cancer will be the experimental group to test the urine-DNA by next generation sequencing for bladder cancer biomarkers
89596446|NCT03066310||Non-Urinary Bladder Cancers|Patients being treated for gross hematuria will provide a negative control to provide data from testing by next generation sequencing for biomarkers in patients being treated for other diseases.
89596447|NCT03825640|Experimental|Community treatment Adherence at Re-Entry (CARE)|"CARE will begin within the 2 months before prison release, and will continue for 6 months after re-entry. CARE will be comprised of: a) 3 individual sessions with the CARE counselor; b) 1 optional family/significant other (SO) session; and c) 11 brief (15-20 min) follow-up telephone contacts with prisoners and their SO over the first 6 months post-release.~The CARE intervention will incorporate motivational strategies from existing interventions (e.g., Acceptance and Commitment Therapy) in order to clarify values and goals to enhance motivation for community treatment engagement and behavior change. CARE will also integrate bipolar disorder psychoeducation and strategies from existing family models of intervention for BD (e.g., McMaster Model of Family Functioning) that are designed to improve family communication, social support, and problem-solving around BD illness management over this vulnerable transition period."
89596448|NCT04274452|Experimental|efgartigimod|Patients receiving an intravenous infusion of efgartigimod
89596449|NCT04274452|Placebo Comparator|placebo|Patients receiving an intravenous infusion of placebo
89596450|NCT03825328|Experimental|Chemotherapy|Albumin-binding paclitaxel+S1 / gecitabine+oxaliplatin Interchanged every 2 cycles
89596451|NCT03057184|Experimental|Intervention group|behavioral intervention program
89596452|NCT03057184|No Intervention|Usual care|Usual care
89596453|NCT03825016|Experimental|Lidocaine|Lidocaine Hydrochloride
89596454|NCT03825016|Experimental|Diclofenac|Oral Diclofenac
89596455|NCT04392466||Transtibial amputees|People who use transtibial prosthesis.
89596456|NCT04392466||Transfemoral amputees|People who use transfemoral prosthesis.
89596457|NCT04392466||Healty individuals|Healty individuals
89596458|NCT03043924|Other|PCOS women|26 PCOS women who receive consultation for hyperandrogenism needing treatment with Cyproterone Acetate + estradiol will be recruited.
89596459|NCT03043924|Other|Healthy volunteers|26 Healthy volunteers subjects who receive consultation contemplating oral contraceptives (Levonorgestrel, Ethinyl Estradiol 0.1-0.02Mg Oral Tablet ) will be recruited.
89596460|NCT03824314|Experimental|Group M|. Group M (n = 40) receive 2 ml of 0.5% isobaric levobupivacaine (10 mg) plus 0.5 ml midazolam (2 mg) ) intrathecally
89596461|NCT03824314|Experimental|group F|"group F (n = 40) receive 2 ml of 0.5% isobaric levobupivacaine (10 mg) plus 0.5 ml fentanyl (25 μg) intrathecally.~Under all aseptic precautions, spinal anaesthesia will be given in L3 and L4 space with 25 gauge Quincke spinal needle via midline approach in sitting position. On free flow of cerebrospinal fluid, study drug will be injected intrathecally . Patients will immediately turn to supine position"
89596462|NCT03824392|Placebo Comparator|Placebo|Participants will receive placebo matched to efzofitimod via intravenous (IV) infusion every 4 weeks until Week 20.
89596463|NCT03824392|Experimental|Efzofitimod 1.0 mg/kg|Participants will receive efzofitimod 1.0 milligrams/kilogram (mg/kg) via IV infusion every 4 weeks until Week 20.
89596464|NCT03824392|Experimental|Efzofitimod 3.0 mg/kg|Participants will receive efzofitimod 3.0 mg/kg via IV infusion every 4 weeks until Week 20.
89596465|NCT03824392|Experimental|Efzofitimod 5.0 mg/kg|Participants will receive efzofitimod 5.0 mg/kg via IV infusion every 4 weeks until Week 20.
89596466|NCT02976922|Active Comparator|Probiotic lozenge|Probiotic lozenge, one lozenge twice daily for 3 months. The lozenge contains Lactobacilli Reuteri (100 billions colony forming units (CFU)/tablet)
89596467|NCT02976922|Placebo Comparator|Placebo|Placebo lozenge, one lozenge twice daily for 3 months
88978681|NCT02966171|Experimental|HMPL-453|Two strengths of HMPL-453 tablets (25 mg and 100 mg based on the free base) will be used for clinical studies. The drug products are coated tablets, which are packaged in white induction sealed HDPE bottles. HMPL-453 will be administered to patients as oral tablet(s) on a daily basis, untill disease progression, intolerable toxicity, or death. Dose levels are to be potentially tested in this study include 25, 50, 100, 200, 300, 400, and 500 mg/day.
88978682|NCT00073619|Experimental|Cognitive-behavioral group therapy|School-based anxiety preventive intervention (cognitive-behavioral group therapy) originally designed for Australian children that was culturally and contextually modified for inner-city children exposed to community violence. Participants received the weekly intervention and rewards for participating in the assessments.
88978683|NCT00073619|No Intervention|Non-intervention Comparison|Provide no active intervention to the comparison group, although assess the children at the same assessment points as the experimental group. Participants in the control arm were told they were FRIENDS Program participants.They received rewards for participating in the assessments.
88978684|NCT00401310|Placebo Comparator|1|Placebo
88978685|NCT00401310|Experimental|2|MK0724
88978686|NCT00073697|Experimental|1|Interpersonal Psychotherapy
88978687|NCT00073697|Experimental|2|Escitalopram
88978688|NCT00073697|Experimental|3|Escitalopram plus IPT
88978689|NCT00268372|Active Comparator|cisplatin/RT alone|cisplatin and radiation therapy
88978690|NCT00268372|Experimental|induction chemo followed by cisplatin/RT|docetaxel, cisplatin and 5-fluorouracil induction chemotherapy followed by surgery and/or cisplatin and radiation therapy
88978691|NCT00073736|Experimental|MB07133 Dose Level 1|7-day continuous infusion in 28-day cycles
88978692|NCT00073736|Experimental|MB07133 Dose Level 2|7-day continuous infusion in 28-day cycles
88978693|NCT00073736|Experimental|MB07133 Dose Level 3|7-day continuous infusion in 28-day cycles
88978694|NCT00073736|Experimental|MB07133 Dose Level 4|7-day continuous infusion in 28-day cycles
88978695|NCT00073736|Experimental|MB07133 Dose Level 5|7-day continuous infusion in 28-day cycles
88978696|NCT00268489|Experimental|pemetrexed + bevacizumab|"Patients receive pemetrexed disodium IV over 10 minutes and bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~After completion of study treatment, patients are followed periodically for 5 years."
89210044|NCT04018014||< 30 kg/m2|patients with BMI < 30/kg/m2
89596468|NCT03824002|Experimental|patients treated with dulaglutide|Diabetes therapy with dulaglutide and various combinations of aspart insulin, glargine, metformin, repaglinide
89596469|NCT03824002|Active Comparator|patients not treated with dulaglutide|Diabetes therapy with various combinations of aspart insulin, glargine, metformin, repaglinide but without dulaglutide
89596470|NCT03823846|Experimental|Experimental Group|Patients in the experimental group were received doctor-nurse-patient cooperative analgesic linkage program.
89596471|NCT03823846|Active Comparator|control group|Patients in the control group were received routine analgesic and functional rehabilitation.
89596472|NCT02908750|Experimental|osimertinib and fexofenadine|Sequential treatments of fexofenadine alone followed by osimertinib + fexofenadine, followed by osimertinib alone, followed by osimertinib + fexofenadine
89596473|NCT03823612|Experimental|GC tooth mousse|Drug: GC tooth mousse it contains complex of Casein Phosphopeptide,Amorphous Calcium Phosphate ( CPP-ACP ) other name: Tooth Mousse (Bio-available calcium and phosphate, without fluoride)
89596474|NCT03823612|Active Comparator|clinpro tooth creme|"it contains 0.21% Sodium Fluoride, Anti-Cavity Paste is an advanced formula containing an innovative tri-calcium phosphate ingredient~other name:0.21% w/w Sodium Fluoride Anti-Cavity Paste with Tri-Calcium Phosphate"
89596475|NCT03823924||Psoriatic arthritis|
89596476|NCT03823924||Healthy volunteers|
89596477|NCT04273906|Experimental|End-range mobilization|End-range mobilization performed in end-position of the tibiofemoral joints' flexion and extension for 2*3 min
89596478|NCT04273906|Placebo Comparator|Placebo|Hands-on treatment technique performed in end-range of the tibiofemoral joints' flexion and extension for 2*3 min
89596479|NCT02834104|Experimental|Myocardial fibrosis|
89596480|NCT03823222|Experimental|Duckweed protein|20 gram of isolated protein
89596481|NCT03823222|Experimental|Whey protein|20 gram of isolated protein
89596482|NCT03823066|Experimental|Coach Pepper|Pepper is a humanoid socially assistive robot
89596483|NCT02810704|Experimental|Arm 1: Enteric Coated Aspirin|Enteric coated aspirin (162 mg po) will be administered on the day of operation, prior to surgery, with a sip of water. Thereafter, starting on postoperative day #1, all patients in the aspirin group will receive 81 mg po bid to complete the treatment period of 30 days. Patients on preoperative cardiac dose aspirin may continue their usual dosing regimen prior to the morning of surgery, and then commence the PEPPER trial aspirin dose of 81 mg po bid on the day after operation.
89596484|NCT02810704|Experimental|Arm 2: Warfarin Other Names: Coumadin|Warfarin will be administered starting on the day of operation, prior to surgery, with a sip of water. The initial dose will be empirically determined by body weight: less than 125 lbs (56.7 kg) - 2.5 mg; 125-250 lbs (56.7-113.4 kg) - 5 mg; greater than 250 lbs (113.4 kg) - 7.5mg. The initial dose will be repeated on the evening of surgery if the preoperative dose was administered prior to noon on the day of operation; no warfarin will be given on the evening of surgery if the preoperative dose was received after noon on the day of operation. Thereafter, starting on postoperative day #1, warfarin will be given each evening based on INR values to achieve a target of 2.0 (range 1.7-2.2).
89596485|NCT02810704|Experimental|Arm 3: Rivaroxaban Other Names: Xarelto|Rivaroxaban 10 mg will be first administered approximately 24 hours after completion of the index operation. Medication will then be administered in the evening on postoperative day #2 and thereafter each evening until completion.
89596486|NCT04392076||Radiofrequency Ablation (RFA) of RCC|Patients following image guided radiofrequency ablation (RFA) of renal cell carcinoma (RCC)
89596487|NCT04392076||Microwave Ablation (MWA) of RCC|Patients following image guided microwave ablation (MWA) of renal cell carcinoma (RCC)
89596488|NCT04392076||Cryoablation (CRYO) of RCC|Patients following image guided cryoablation (CRYO) of renal cell carcinoma (RCC)
89596489|NCT02790424|Experimental|Patients|Imaging devices
89596490|NCT02738398|Experimental|PET imaging|PET imaging
88978697|NCT00268528||Health service research (electronic pill monitoring system)|Patients receive an electronic pill monitoring system comprising an empty MEMS^? medication bottle with TrackCap? CR. The mercaptopurine prescription is filled using this system. Beginning on day 1 of the third or later course of maintenance therapy, patients take all doses of mercaptopurine from the MEMS^? medication bottle with TrackCap? CR for at least 169 days. The MEMS^? TrackCap? CR is mailed to the Coordinating Center at the end of study. Patients also receive methotrexate PO as indicated by their individual chemotherapy regimen.
88978698|NCT00106782|Other|1|Real TEP
88978699|NCT00106782|Other|2|Sham Stimulation
88978700|NCT00073814|Experimental|1|levalbuterol MDI 90 mcg QID
88978701|NCT00073814|Active Comparator|2|racemic albuterol MDI 190 mcg QID
88978702|NCT00073814|Placebo Comparator|3|Placebo MDI QID
88978703|NCT00102453|Experimental|Solution|All enrolled participants were give pentoxifylline in this pilot protocol.
88978704|NCT00268723|Experimental|1|levalbuterol HFA MDI 90 mcg QID
88978705|NCT00268723|Placebo Comparator|2|Placebo MDI QID
88978706|NCT00268840|Experimental|unique|Taxotère - Gemzar
88978707|NCT00268879|Placebo Comparator|1|Two capsules are taken by mouth each morning and each evening from the day of the randomization visit until the scheduled visit at the end of Week 12.
88978708|NCT00268879|Experimental|2|Renzapride 4 mg QD. Two capsules are taken by mouth each morning and each evening from the day of the randomization visit until the scheduled visit at the end of Week 12.
88978709|NCT00268879|Experimental|3|Renzapride 2 mg BID: Two capsules are taken by mouth each morning and each evening from the day of the randomization visit until the scheduled visit at the end of Week 12.
88978710|NCT00268918|Experimental|Docetaxel / PTK787|"Docetaxel: Lead In: Given intravenously on Day 1 and Day 14 Afer Lead in: Given intravenously on day 1, 8, 15, 22 of each 28-day cycle.~PTK787: Lead In: Given orally on day 4 and day 14 After Lead In: Given orally once a day."
89596491|NCT03822988||patients accepting to answer to the survey|patients with a skin lymphoma OR melanoma OR advanced skin squamous cell carcinoma OR advanced basal cell carcinoma accepting to answer to the anonymous survey
89596492|NCT03822754|Experimental|Experimental Group|sIPV-bOPV-bOPV vaccination schedule
89596493|NCT03822754|Active Comparator|Control Group|wIPV-bOPV-bOPV vaccination schedule
89596494|NCT03822676|Experimental|Stent|Prophylactic pancreatic stent before segmental pancreatic surgery
89596495|NCT03822676|No Intervention|No stent|No prophylactic stent before surgery
89596496|NCT02926222|Experimental|ARM A - Regorafenib|Patients receive REGORAFENIB 40 mg tablets once daily (160 mg/die), 3 weeks on, 1 week off, until disease progression or unacceptable toxicity.
89596497|NCT02926222|Active Comparator|ARM B - Lomustine|Patients receive LOMUSTINE 110 mg/m2 orally on day 1, every 6 weeks (q6w), until disease progression or unacceptable toxicity.
89596498|NCT04273282|Active Comparator|Dexycu Group|A total of 30 study subjects (30 eyes) will have Dexycu intracameral dexamethasone placed in their scheduled surgical eye at the time of surgery and will receive 50 micrograms of intracameral moxifloxacin at the conclusion of the procedure. They will take Prolensa qd after surgery for 4 weeks.
89596499|NCT04273282|Active Comparator|Control Group|A total of 30 study subjects (30 eyes) will receive topical moxifloxacin 0.5% qid 1 day prior to surgery and for ten days postoperatively, Prolensa qd 1 day prior to surgery and for 4 weeks postoperatively, and prednisolone acetate 1.0% qid starting at the conclusion of cataract surgery for 2 weeks and bid for 2 weeks in their scheduled surgical eye.
89596500|NCT04391530|Experimental|emotional freedom technique group|The EFT application will be implemented by the researcher who has been trained in this subject, in the most quiet and calm environment possible, in a position where the individuals are comfortable. There are basic steps to be followed in EFT application. Thought Field Therapy (TFT), developed by Callahan, based on Craig, uses different click points for specific psychological conditions, while EFT has 12 energy click points in the same specified order to treat every emotional problem, It is called 'Basic Recipe'
89596501|NCT04391530|Experimental|Breathin therapy group|Breathing therapy: the basic recipe After applying pre-test forms to students, the hall will be quiet and dim. In this study, breathing exercise application will be performed in three stages as (1) relax, (2) deep breath and (3) feel yourself.
89596502|NCT04391530|No Intervention|Control group|No intervention was made to the students in the control group.
89596503|NCT01453972|Experimental|Long distanse moderate training|40 minutes moderate treadmill running
89596504|NCT01453972|Experimental|Long interval training|4x4min interval treadmill running
89596505|NCT01453972|Experimental|Short interval training|10x1min interval treadmill running
89596506|NCT01454206|No Intervention|Treatment as Usual|
89596507|NCT01454206|Experimental|iSBIRT|Participants will receive the internet-facilitated screening, brief intervention and referral to treatment (iSBIRT intervention)
89596508|NCT01454440|Experimental|Eptifibatide|Intravenous eptifibatide (double bolus [180 microg/kg] followed by infusion [2 microg/kg per minute] for 18 to 24 hours after the procedure).
89596509|NCT01454440|Placebo Comparator|Placebo|
89596510|NCT01454518|Experimental|Infiltration of local anesthetic|30 ml of ropivacaine 0.5% infiltrated around lateral anterior and medial aspect of hip joint with ultrasound guidance.
89596511|NCT01454518|Placebo Comparator|Normal Saline Injection|injection of 30ml normal saline infiltrated around lateral anterior and medial aspect of hip joint with ultrasound guidance.
89596512|NCT01454986|Active Comparator|Cohort 1|0.06 mg/kg ALXN1007
89596513|NCT01454986|Active Comparator|Cohort 2|0.1 mg/kg ALXN1007
89596514|NCT01454986|Active Comparator|Cohort 3|0.3 mg/kg ALXN1007
89596515|NCT01454986|Active Comparator|Cohort 4|1.0 mg/kg ALXN1007
89596516|NCT01454986|Active Comparator|Cohort 5|3.0 mg/kg ALXN1007
89596517|NCT01454986|Active Comparator|Cohort 6|6.0 mg/kg ALXN1007
89596518|NCT01454986|Active Comparator|Cohort 7|10.0 mg/kg ALXN1007
89596519|NCT02983084|Experimental|Multiforce|Variable modulus version of a current orthodontic archwire
89596520|NCT02983084|Active Comparator|CuNiTi A|".016 current orthodontic archwire"
89596521|NCT02983084|Active Comparator|CuNiTi B|"0.014 and 0.018 current orthodontic archwire sequence"
89596522|NCT01455142|Experimental|Formulation 1|
89596523|NCT01455142|Experimental|Formulation 2|
89596524|NCT01455298|Other|Transient elastography and fibrotest|
89596525|NCT02983318||PET/MRI using 18[F]EPPA ligand|given experimental ligand FEPPA during MRI/PET scan to identify glutamate activity in the brain using FEPPA ligand
88978711|NCT00268957|Experimental|1|sevelamer carbonate powder
88978712|NCT00268957|Active Comparator|2|Sevelamer hydrochloride
88978713|NCT02961400|Experimental|PUSH text messages|Participants will be sent text messages containing information relevant to their treatment condition (i.e., TranS-C or PE).
88978714|NCT02961400|Experimental|PULL text messages|Participants will be sent text messages containing information relevant to their treatment condition (i.e., TranS-C or PE). Text messages will request a response from the participant.
88978715|NCT02961400|Other|No text messages|No text messages will be sent in this condition to participants in either treatment condition (i.e., TranS-C or PE).
88978716|NCT00269035|Experimental|Treatment Group 1|Subjects in group 1 will receive SB-773812 tablet once daily till still steady Cp
88978717|NCT00269035|Experimental|Treatment Group 2|Subjects in group 2 will receive SB-773812 tablets once daily over 6 weeks. Risperidone tablets 6 mg once daily from Days 1-7 two tablets of 3 mg and days 8 until stable Cp 6 mg tablets
88978718|NCT00269308|Experimental|1|Chiropractic Manual Treatment + Home Exercise
88978719|NCT00269308|Experimental|2|Supervised Rehabilitative Exercise + Home Exercise
88978720|NCT00269308|Active Comparator|3|Home Exercise
88978721|NCT00106899||1|Mild Cognitive Impairment (MCI); scans performed at screening/baseline, 6, 12, 18, 24, and 36 months
88978722|NCT00106899||2|Early Alzheimer's disease (AD); scans performed at screening/baseline, 6, 12, and 24 months
88978723|NCT00106899||3|Unaffected/normal controls; scans performed at baseline/screening, 6, 12, 24, and 36 months
88978724|NCT00074048|Experimental|1|BL22 immunotoxin
88978725|NCT00269386|Active Comparator|1 (i)|Clarithromycin S/R 1g od From April 2004, clarithromycin S/R (Klaricid XL) ceased to be available and subsequent patients will receive either standard clarithromycin 500mg bd or placebo tables of identical size, colour and taste
88978726|NCT00269386|Placebo Comparator|2 (ii)|placebo tablets of identical size, colour and taste
88978727|NCT00269425|Experimental|Mediterranean diet,|
88978728|NCT00269425|Experimental|American Heart Association Step 2 diet|
88978729|NCT00269425|No Intervention|Case controlled|
88978730|NCT00074087|Experimental|Caelyx|doxorubicin HCl liposome IV over 1 hour on days 1 and 15. Treatment repeats every 28 days for up to 6 courses.
89596526|NCT01455376|No Intervention|Hyperosmolar sodium chloride|Patients in this group received intravenous infusion of hyperosmolar Sodium Chloride 3% at 1.5 ml.KgBW-1 within 15 minutes before neurosurgery
89596527|NCT01455376|Experimental|Hyperosmolar sodium lactate|Patients in this group received intravenous infusion of hyperosmolar sodium lactate at 1.5 ml.KgBW-1 within 15 minutes before neurosurgery
89596528|NCT01455454||coronary artery disease|patients undergoing coronary artery bypass grafting using cardiopulmonary bypass
89596529|NCT01455532|Experimental|Iniparib, single agent|Iniparib will be initially administered intravenously once weekly (days 1, 8, and 15) for 3 weeks, in a 21-day cycle. Then, iniparib will be administered twice weekly (days 1, 4, 8, 11, 15, and 18) in a 21-day cycle. Cycle1 (day 1 thru day 21) will be defined as the dose limiting toxicities (DLT) observation period. Starting dose is 15 mg/kg once weekly.
89596530|NCT01455532|Experimental|Iniparib/Gemcitibine/Carboplatin|Gemcitabine/carboplatin (GC) : Gemcitabine will be administered at 1,000 mg/m² as a 30min IV infusion and carboplatin area under the curve (AUC) 2 as a 60min IV infusion. Patients will receive gemcitabine/carboplatin infusions once weekly (days 1 and 8). Iniparib will be administered for two weeks, followed by a 1week of rest in a 21-day cycle (weekly schedule: days 1 and 8; twice weekly schedule: days: 1, 4, 8 and 11).
89596531|NCT01455532|Experimental|Iniparib/Paclitaxel|Paclitaxel (P): Paclitaxel will be administered at the dose of 80 mg/m2 as a 60-minute intravenous infusion administered on days 1, 8, and 15 followed by a 1week of rest. Iniparib will be administered for three weeks, followed by 1week of rest in a 28-day cycle (weekly schedule: days 1, 8 and 15; twice weekly schedule: days 1, 4, 8, 11, 15 and 18).
89596532|NCT01455532|Experimental|Iniparib/Pegylated liposomal doxorubicin/Carboplatin|Pegylated liposomal doxorubicin (Doxil)/Carboplatin (PLD) : Doxil will be administered at 30 mg/m² as a 30min IV infusion and carboplatin AUC 4 as a 60min IV infusion on day 1 every four weeks. Iniparib will be administered for two weeks in a 28-day cycle (weekly schedule: days 1, and 8; twice weekly schedule: days 1, 4, 8, and 11).
89596533|NCT01455688|Experimental|Early antiviral therapy|
89596534|NCT01455688|Active Comparator|Conventional therapy|
89596535|NCT01455844|Experimental|CaPre 1.0g|
89596536|NCT01455844|Experimental|CaPre 2.0g|
89596537|NCT01455844|Placebo Comparator|Placebo|
88978731|NCT00269542|Experimental|1|
88978732|NCT00269542|Placebo Comparator|2|
88978733|NCT00269581|Other|1|Educational CD-Rom
88978734|NCT00269581|Experimental|2|Headstrong CD-rom
88978735|NCT00269620|Experimental|2|OrthoEvra
88978736|NCT00269620|Experimental|1|NuvaRing
88978737|NCT00424125|Experimental|Enhanced Pharmacy Care|Received enhanced community pharmacy based services.
88978738|NCT00074204|Experimental|Immediate Docetaxel|Arm I (immediate docetaxel): Patients receive immediate docetaxel IV over 1 hour on day 1.
88978739|NCT00074204|Active Comparator|Delayed Docetaxel|Arm II (delayed docetaxel): Patients are observed until first evidence of disease progression and then receive docetaxel IV over 1 hour on day 1.
88978740|NCT00106977||Family|Family members (typically parents or siblings) of probands with Muenke syndrome are alsoeligible to participate.
88978741|NCT00106977||Patient|Subjects who have had confirmation of a p. Pro250Arg mutation in FGFR3 by a CLIA-certified laboratory.
88978742|NCT00269776|Experimental|001|OROS (methylphenidate HCl) Treatment A: 1 2 or 3 OROS methylphenidate 18-mg tablets + 0 1 or 2 OROS placebo tablets (3 tablets in total) once daily + 1 placebo capsule 3x/day for 7 days. Each patient will be randomized to 1 of 9 treatment sequences each consisting of 3 7-day treatment periods of Treatment A B and C.
88978743|NCT00269776|Experimental|002|Ritalin (methylphenidate) Treatment B: 5 10 or 15-mg tablets (encapsulated/single capsule) 3 times a day + 3 OROS placebo tablets once daily for 7 days. Each patient will be randomized to 1 of 9 treatment sequences each consisting of 3 7-day treatment periods of Treatment A B and C.
88978744|NCT00269776|Experimental|003|Placebo Treatment C: Three OROS placebo tablets once daily + 1 placebo capsule 3x times/day for 7 days. Each patient will be randomized to 1 of 9 treatment sequences each consisting of 3 7-day treatment periods of Treatment A B and C.
88978745|NCT00269815|Experimental|001|methylphenidate HCl
88978746|NCT00269854|Experimental|Infliximab 5 mg/kg|
88978747|NCT00269854|Experimental|Infliximab 10 mg/kg|
88978748|NCT00269854|Experimental|Infliximab 20 mg/kg|
88978749|NCT00269854|Placebo Comparator|Placebo|
88978750|NCT00269893|Placebo Comparator|Placebo|Participants will receive matching placebo solution bolus followed by matching placebo solution infusion up to 12 hours.
88978751|NCT00269893|Experimental|Abciximab and Placebo|Participants will receive 0.25 milligram per kilogram (mg/kg) of body weight of abciximab (c7E3 Fab) bolus injection followed by followed by placebo solution infusion up to 12 hours.
88978752|NCT00269893|Experimental|Abciximab|Participants will receive 0.25 mg/kg of body weight of abciximab bolus followed by abciximab (c7E3 Fab) infusion up to 12 hours.
88978753|NCT00074321|Experimental|Arm I|Patients receive irinotecan hydrochloride IV over 90 minutes and oxaliplatin IV over 2 hours on day 1 and capecitabine PO QD on days 2-15. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
88978754|NCT00102609|Experimental|Trabectedin and doxorubicin|Doxorubicin (50 to 75 mg/m2) administered intravenously on Day 1 followed by trabectedin (0.9 to 1.3 mg/m2) administered intravenously on Day 1 every 3 weeks for up to 6 cycles. Dexamethasone 20 mg administered intravenously will be given within 1 hour before the start of doxorubicin. Patients may receive filgrastim for unmanageable neutropenia.
88978755|NCT00107016|Experimental|RAD001 + letrozole 2.5mg|
88978756|NCT00107016|Active Comparator|Letrozole 2.5mg|
88978757|NCT00074399|Experimental|1|Participants will receive nevirapine for 6 weeks
88978758|NCT00074399|Placebo Comparator|2|Participants will receive nevirapine placebo for 6 weeks
88978759|NCT00270244|Active Comparator|1|Participants will receive treatment as usual
88978760|NCT00270244|Experimental|2|Participants will receive group interpersonal psychotherapy for depressed adolescents
88978761|NCT00270361|Experimental|001|nesiritide
88978762|NCT00270361|Experimental|002|nesiritide
88978763|NCT00270361|Active Comparator|003|usual long term cardiac medications
88978764|NCT02966249|Other|Levobupivacaine intrathecally|3 ml Levobupivacaine 0,5% (15mg) given intrathecally once for anesthesia in total knee arthroplasty
89596538|NCT01455922|Experimental|ITCA 650 60 mcg/day|
89596539|NCT01455922|Active Comparator|glimepiride|
89596540|NCT01456156|Experimental|hepatectomy plus radiotherapy|
89596541|NCT04391140|Experimental|Experimental|Combination of prone position and HFNC
89596542|NCT04391140|No Intervention|Control|Standard care: HFNC set for a SpO2 90-95% if unless indication for intubation is present.
89596543|NCT01456234|Active Comparator|Patients with Oseltamivir Prescription|Patients arriving at the pharmacy with a prescription for Oseltamivir
89596544|NCT01456234|Experimental|Patients with signs, symptoms of flu|Patients arriving at the pharmacy with signs, symptoms of flu that the pharmacist diagnoses as having flu and being suitable for pharmacist prescribing of Oseltamivir according to an algorithm.
89596545|NCT01456312|Sham Comparator|HBsAg quantification>20,000 IU/ml|stop peginterferon alfa 2a if patients reach HBsAg quantification>20,000 Iu/ml at 12w
89596546|NCT01456312|Sham Comparator|HBsAg<=1500IU/ml|extend peginterferon alfa 2a until 48weeks
89596547|NCT01456312|Sham Comparator|HBsAg >1500 <=20,000 IU/ML|add Entecavir for 12w with peginterferon alfa 2a then, extend peginterferon alfa 2a until 48w
89596548|NCT01456468|Experimental|UDCA + ATRA|This is a single-arm study. All subjects will take UDCA and ATRA.
89596549|NCT01456546|Active Comparator|Period A: proguanil|Proguanil pharmacokinetics
89596550|NCT01456546|Active Comparator|Period B: clopidogrel|Clopidogrel pharmacokinetics
89596551|NCT01456624|Active Comparator|Megace / Fasting condition|800mg
89596552|NCT01456624|Experimental|DW-ES(B) / Fasting condition|625mg
89596553|NCT01456624|Active Comparator|Megace / Fed condition|800mg
89596554|NCT01456624|Experimental|DW-ES(B) / Fed condition|625mg
89596555|NCT01456702|No Intervention|control arm|volume therapy via standard operating procedure
89596556|NCT01456702|Experimental|intervention arm|goal-directed volume therapy due to svv in dependence of preoperative risk stratefication
89596557|NCT01456858|Placebo Comparator|Child UPS Largo Camp|Children 4months-36months enrolled who resided in Largo refugee camp under Untreated plastic sheeting (interior wall and ceiling lining)
89596558|NCT01456858|Experimental|Child ITPS Largo Camp|Children 4months-36months enrolled who resided in Largo refugee camp under Insecticide treated plastic sheeting (interior wall and ceiling lining)
89596559|NCT01456858|Placebo Comparator|Child UPS Tobanda Camp|Children 4months-36months enrolled who resided in Tobanda refugee camp under Untreated plastic sheeting (ceiling and interior roof lining)
89596560|NCT01456858|Experimental|Child ITPS Tobanda Camp|Children 4months-36months enrolled who resided in Tobanda refugee camp under Insecticide treated plastic sheeting (ceiling and interior roof lining)
88978765|NCT02966249|Active Comparator|Dexmetomidine intrathecally|5 μgr Dexmetomidine given intrathecally once for anesthesia in total knee arthroplasty
88978766|NCT02966249|Active Comparator|Dexmetomidine intravenously|Continuous infusion of dexdemetomidine at a rate of 0.25 μg/kg/h given intravenously starting 10 min before spinal anesthesia in total knee arthroplasty
88978767|NCT02966249|Placebo Comparator|Normal Saline intrathecally|0,5 ml Normal Saline given intrathecally given once for spinal anesthesia in total knee arthroplasty
88978768|NCT02966249|Other|Normal Saline added intrathecally|Normal Saline added intrathecally up to 0,5 ml given intrathecally for spinal anesthesia in total knee arthroplasty
88978769|NCT02966249|Other|Ringer's Lactate solution intravenously|Continuous infusion of Ringer's Lactate solution given intravenously for total knee arthroplasty will start 10 minutes before spinal anesthesia to the end of the operation
88978770|NCT00270400|Experimental|001|nesiritide
88978771|NCT00270439|Experimental|single arm|Removed omentum of patients with type 2 diabetes
88978772|NCT00074438|Experimental|1|
88978773|NCT00074438|Experimental|2|
88978774|NCT00074438|Experimental|3|
88978775|NCT00074438|Experimental|4|
88978776|NCT00074438|Experimental|5|
88978777|NCT00074438|Experimental|6|
88978778|NCT00074438|Placebo Comparator|7|
88978779|NCT00074438|Placebo Comparator|8|
88978780|NCT00074438|Placebo Comparator|9|
88978781|NCT00270712||Retrospective Cohort|537 transplant recipient records used retrospectively
88978782|NCT00270712||Prospective Cohort|3137 transplant recipients enrolled prospectively
88978783|NCT00270829|Experimental|1|Nesiritide given intrarenally
88978784|NCT00270829|No Intervention|2|No intrarenal drug administration
88978785|NCT04730375|Active Comparator|( Group A)|: Group A(N=35) dexmedetomidine is infused intraoperative after intubation at dose of (1μg/Kg LBW) bolus, followed by 0.5μg/Kg/hour continuous infusion till the end of surgery
88978786|NCT04730375|Active Comparator|(Group B)|Group B(N=35) dexmedetomidine is infused intraoperative after intubation at dose of (0.5μg/Kg LBW) bolus, followed by 0.3μg/Kg/hour continuous infusion till the end of surgery.
88978787|NCT00270907|Experimental|CT-2103 + Gemcitabine|CT-2103 135 mg/m^2 intravenous (IV) on Day 1. Gemcitabine 1000 mg/m^2 IV on Day 1 and 8.
89031667|NCT00514748|Experimental|2|Patient who receive breast reconstruction with vessel interconnected DIEP flap based on one vessel pedicle
89596561|NCT01457092|Experimental|FC Nitinol SEMS|FC Nitinol SEMS
89596562|NCT01457170|Experimental|Apelin/Saline|Apelin infusion then crossover to Saline infusion
89596563|NCT01457170|Experimental|Saline/Apelin|Saline infusion then crossover to Apelin infusion
89596564|NCT01457326||Immersion Therapy- Study|1. Patients who participate in the immersion therapy post-operative protocol and begin progressive weight bearing at 4 weeks (study)
89596565|NCT01457326||Control Group|2. Patients who undergo the traditional 10-week non-weight bearing post-operative care protocol (control)
89596566|NCT01457404|Experimental|Integrated Cognitive Behavioral Therapy|Integrated Cognitive Behavioral Therapy (ICBT) is a non-exposure based, manual-guided individual or group therapy. ICBT consists of 3 learning and skill components designed to improve PTSD symptoms and substance use: 1) Patient education about PTSD and its relation to substance use and treatment; 2) Mindful relaxation: A behavioral anxiety reduction skill including centering and breathing techniques; and 3) Cognitive restructuring/flexible thinking: A cognitive approach and functional analysis of the link among emotions, cognitives and situations.
89031668|NCT02943876|No Intervention|Control|Serves as a control group, receiving generic information about depression and self-help.
89596567|NCT01457404|Active Comparator|Treatment-as-usual|Treatment-as-usual (TAU) is the typical outpatient treatment that patients would receive ordinarily at the PVAMC Substance Abuse Treatment Program (SATP) or PTSD Clinic.
89596568|NCT01457482|Experimental|Art therapy group|Treatment in this arm consists of five Art Therapy sessions and therapeutic conversations.
89596569|NCT01457482|Active Comparator|Therapeutic conversation group|Treatment by therapeutic conversations only
89596570|NCT01457560|Experimental|Group A|
89596571|NCT04758442|Experimental|Vancomycin|Subjects with hematologic cancer who received intravenous vancomycin for a suspected or confirmed infection.
89031669|NCT02943876|Experimental|Intervention|Serves as an intervention group, receiving personalized depression risk information determined by the sex-specific risk calculators, and generic information about depression and self-help.
89031670|NCT00515957|Experimental|Patients|Patients with Nasopharyngeal Carcinoma in first or subsequent relapse or with primary refractory disease or high risk (T3 or T4, or node positive disease) in whom the EBV-genome or antigens have been demonstrated in tissue biopsies
89596572|NCT01457638|Sham Comparator|No inferior turbinate surgery|During rhinoseptoplasty there is no intervention on inferior turbinates
89596573|NCT01457638|Experimental|Inferior Turbinate surgery|During rhinoseptoplasty, inferior turbinate submucosal cauterization is performed.
89596574|NCT01457716|Experimental|Budesonide/Formoterol Easyhaler A|
89596575|NCT01457716|Experimental|Budesonide/Formoterol Easyhaler B|
89596576|NCT01457716|Experimental|Budesonide/Formoterol Easyhaler C|
89596577|NCT01457716|Active Comparator|Budesonide/Formoterol Turbohaler Forte|
89596578|NCT01457872|Experimental|Strength-based case management|Case management plus referral (vs referral-only)
89596579|NCT01457872|Active Comparator|Referral only|Referral only (no case management intervention)
89031671|NCT02943642|Experimental|A-dmDT390-bisFv(UCHT1)|A-dmDT390-bisFv(UCHT1) will be administered as Total Dose µg/kg given as 1/8 Total Dose µg/kg/injection twice a day 4-6 hours apart for four consecutive days (days 1-4) into a free flowing IV over a period of approximately 15 minutes.
89596580|NCT04391218|Experimental|Multidisciplinary Approach Group|Multidisciplinary medication review and reconciliation during hospitalization involving geriatricians, nurses, pharmacists and supported by a Clinical Decision Support System, followed by an end-user App to support patients/caregivers in the correct drug intake after discharge.
89596581|NCT04391218|No Intervention|Control Group|Medication review and reconciliation will be performed by geriatricians according to Good Clinical Practice and usual habits, that might also include digital and printed supports for medication appropriateness and drug interaction. Drug therapy will be listed and explained to the patient/caregiver at discharge. Patients/caregivers will be allowed to use any tools to support medication adherence, according to their habits and preferences (i.e. calendars, alarms, pill boxes).
89596582|NCT04391296|Experimental|I (Prepectoral)|Immediate acellular dermal matrix-assisted implant-based breast reconstruction with prepectoral implant placement.
89596583|NCT04391296|Active Comparator|II (Subpectoral)|Immediate acellular dermal matrix-assisted implant-based breast reconstruction with subpectoral implant placement.
89596584|NCT04346602||patients with COVID-2019|Patients with COVID-2019 would be observed.
89596585|NCT01458028|Experimental|Arm 1|
89596586|NCT01458028|Placebo Comparator|Arm 2|
89596587|NCT01458496|Experimental|Health Coaching|
89596588|NCT01458496|No Intervention|Usual Care -Control|Patients assigned to the control (usual care) group will be advised to seek standard lifestyle counselling from their primary care physician.
89596589|NCT01458652|Experimental|Lifestyle counseling|"Drug:Kremezin~Other Names:AST-120~Kremezin is an oral adsorbent, 9g/day in treatment arm"
89596590|NCT01458886|Experimental|BI 54903 LD b.i.d.|Patients receive 2 puffs b.i.d. via Respimat inhaler
89596591|NCT01458886|Experimental|BI 54903 MD q.d.|Patients receive 2 puffs q.d. via Respimat inhaler (p.m.) combined with 2 puffs placebo (a.m.)
89596592|NCT01458886|Placebo Comparator|Placebo|Patients receive 2 puffs b.i.d. via Respimat inhaler
89596593|NCT02880982|Active Comparator|Intervention|Softgel capsule containing 10,000 IU (250 micrograms) cholecalciferol (vitamin D3) to be taken orally once per week for 3 years
89596594|NCT02880982|Placebo Comparator|Placebo|Softgel capsule of identical taste and appearance to active comparator, but containing no cholecalciferol, to be taken orally once per week for 3 years
89596595|NCT01458964|Active Comparator|Quetiapine|Quetiapine will be administered orally, QHS at a dosage of 100 mg for 1 week increasing to a target dosage of 200 mg for 11 weeks.
89596596|NCT01458964|Placebo Comparator|Sugar pill|Sugar pill will be administered orally, QHS at a dosage of 100 mg for 1 week increasing to a target dosage of 200 mg for 11 weeks.
89031672|NCT02943642|Active Comparator|Vorinostat|Subjects in the control arm will receive oral vorinostat capsules at a dose of 400 mg daily up to 12 months in duration until disease progression or uncontrolled side effects take place. Subjects in the vorinostat arm who experience progressive disease may cross over into the experimental arm after 6 months of treatment after a 2-week vorinostat washout period.
89210045|NCT04018014||>30 kg/m2|patients with BMI > 30 kg/m2
89210046|NCT00893256|Experimental|Risperidone and citalopram|24 patients were randomized to receive add-on citalopram (20 mg/day) in a double-blind fashion to open-label risperidone (4-8 mg/day)
89210047|NCT00893256|Placebo Comparator|Risperidone and placebo|24 patients were randomized to receive add-on placebo in a double-blind fashion to open-label treatment with risperidone (4-8 mg/day)
89596597|NCT01459042||primary aldosteronism|
89596598|NCT01459042||essential hypertension|
89596599|NCT01459120|Experimental|Door-to-Door|Health care workers propose the integrated service package including VCT at the peoples' homes.
89596600|NCT01459120|Active Comparator|Pitso|"Health care workers propose the integrated service package including VCT through community gatherings (pitso)."
89608535|NCT03021603|Experimental|Intervention Group|"This is a 4-week Brief Hope Intervention~Four sessions in total:~two face-to-face sessions (1-hour) and two telephone follow up sessions (30 mins) in between.~Homework : A booklet is prepared for the participants for reviewing their planned goals and recording achieved targets."
89596601|NCT01459120|No Intervention|control|Within each cluster (catchment area of a health center), five villages are randomly chosen as comparators on cluster level. These villages get no particular intervention (VCT-campaign). However, routine services continue to be provided. These villages serve as a control for the third primary outcome that assesses the overall numbers newly enrolled into chronic HIV/AIDS care at facility-level.
89596602|NCT01459198|Experimental|Adults: Vaccine (Group 1)|Adult participants will receive one dose of the 10^6 RSV MEDI ΔM2-2 vaccine intranasally.
89596603|NCT01459198|Experimental|Seropositive Children: Vaccine (Group 2)|Seropositive children will receive one dose of the 10^6 RSV MEDI ΔM2-2 vaccine intranasally.
89596604|NCT01459198|Placebo Comparator|Seropositive Children: Placebo Vaccine (Group 2)|Seropositive children will receive one dose of the placebo vaccine intranasally.
89596605|NCT01459198|Experimental|Seronegative Infants and Children: Vaccine (Group 3)|Seronegative infants and children will receive one dose of the 10^5 RSV MEDI ΔM2-2 vaccine intranasally.
89596606|NCT01459198|Placebo Comparator|Seronegative Infants and Children: Placebo Vaccine (Group 3)|Seronegative infants and children will receive one dose of the placebo vaccine intranasally.
89596607|NCT01459198|Experimental|Seronegative Infants and Children: Vaccine (Group 4)|Seronegative infants and children will receive one dose of the 10^6 RSV MEDI ΔM2-2 vaccine intranasally.
89596608|NCT01459198|Placebo Comparator|Seronegative Infants and Children: Placebo Vaccine (Group 4)|Seronegative infants and children will receive one dose of the placebo vaccine intranasally.
89596609|NCT01459276|Experimental|FAB-6011|One 0.5 mL injection of FAB-6011 trivalent influenza vaccine containing 6μg HA of seasonal A/H1N1, A/H3N2 and B influenza antigens
89596610|NCT01459276|Active Comparator|FLUVALAB|One 0.5 mL injection of FLUVAL AB trivalent influenza vaccine containing 15μg HA of seasonal A/H1N1, A/H3N2 and B influenza antigens
89596611|NCT01459354||post, bimanual laryngoscopy, POGO score|one control, one study group
89596612|NCT02490904|Experimental|Eplerenone group|Eplerenone administration within 2 hours prior to patient departure to the operating room and for 4 days after kidney transplantation.
89596613|NCT02490904|Placebo Comparator|Placebo group|Placebo administration within 2 hours prior to patient departure to the operatingroom and for 4 days after kidney transplantation
89596614|NCT01459432||Follow-on blood sample from previous study|
89596615|NCT04390984|Experimental|1|Subjects will be administrated with 500mg apatinib on day 1 and day 12-15, and administrated with gefitinib on day 4-15.
89596616|NCT01459822||Survival Group|
89596617|NCT01459822||Death Group|
89596618|NCT02878408|Other|acute Bipolar disorder|blood sampling and data collection Following visit at end of hospitalisation (blood sampling and data collection)
89596619|NCT02878408|Other|acute Schizophrenia|blood sampling and data collection Following visit at end of hospitalisation (blood sampling and data collection)
89596620|NCT02878408|Other|stable Bipolar disorder|blood sampling and data collection (only one visit)
88978788|NCT00107445|Experimental|Treatment (EF5)|Patients receive EF5 IV over 1-2½ hours on day 1. Approximately 1-2 days later, patients undergo tumor resection or biopsy. Patients' tumor tissue samples undergo immunohistochemistry and flow cytometry to detect EF5 binding levels. Patients' blood is drawn immediately before and 30-60 minutes and 1-2 days after receiving EF5 to measure systemic EF5 binding levels.
88978789|NCT00270985|Active Comparator|nut free diet|ADA recommended diabetes diet without any nuts
88978790|NCT00270985|Experimental|almond group|calorie controlled diet with prescribed daily amount of almonds
88978791|NCT02965937|Experimental|Story-Centred Care Intervention Program|A theory-guided approach that emphasises a health-promoting potential of nurse-person dialogue about a health challenge.Participants randomised to the IG will be made to participate in a 4-week long story-centred care intervention program conducted by a trained researcher.
88978792|NCT02965937|Active Comparator|Health consultation control condition|Participants randomised to the control group will receive a health consultation from a trained researcher once a week for 4 weeks. The health consultation will be tailored to the participants' needs. Based on a previous study, the health consultation will include pain management, healthy nutrition, how to make best use of medical services and education and counselling for individual health-related concerns.
88978793|NCT00416260|Experimental|HFO-TGI|Patients with severe Acute Respiratory Distress Syndrome receiving sessions of high frequency oscillation and tracheal gas insufflation according to the study protocol
88978794|NCT00416260|No Intervention|CMV|Patients with severe Acute Respiratory Distress Syndrome receiving only conventional mechanical ventilation according to the study protocol
88978795|NCT02965859|Experimental|Metacavir Enteric-coated Capsule 80mg|"Metacavir Enteric-coated Capsules 80mg~Metacavir Enteric-coated Capsules Placebo 240mg~Adefovir Dipivoxil Capsule Placebo 10mg;"
89210048|NCT00605280|Sham Comparator|Sham Control|
89596621|NCT02878408|Other|stable Schizophrenia|blood sampling and data collection (only one visit)
89596622|NCT02878408|Other|healthy control|blood sampling and data collection (only one visit)
89596623|NCT02878408|Other|TOC|blood sampling and data collection (only one visit)
89596624|NCT01459900|Active Comparator|Renal artery ablation|By femoral access, coronary and renal angiography are performed. The patient will be sedated. In case of vessel anatomy allowing renal ablation, the patient will be randomized in the card. lab. In case of randomization to active treatment, renal artery ablation will be carried out straight away.
89596625|NCT01459900|Sham Comparator|Sham|By femoral access, coronary and renal angiography are performed. The patient will be sedated. In case of vessel anatomy allowing renal ablation, the patient will be randomized in the card. lab. In case of randomization to sham procedure, no renal artery ablation are performed.
89596626|NCT01459978||Early CUSUM result group|"Phase 1: 3 months testing and observation period. During this phase, rates of each quality indicator selected will be collected to adjust the acceptable and unacceptable rate set by practitioners of each maternity.~Phase 2: results of the CUmulative SUM (CUSUM) will be provided for a period of 12 months (Early CUSUM result group), Phase 3: maternity will continue to receive the results of the CUmulative SUM (CUSUM) for a period of 12 months,"
89608536|NCT03021603|Experimental|Control Group|"Standard care:~Clinic follow up and normal hospital care. Logistic call and social communication On completion of the 4-week standard care, the 4-session brief hope intervention will be offered"
89596627|NCT01459978||CUSUM result Delayed group|Phase 1: 3 months testing and observation period. During this phase, rates of each quality indicator selected will be collected to adjust the acceptable and unacceptable rate set by practitioners of each maternity Phase 2: the results of CUmulative SUM (CUSUM) will not be shared. Phase 3: group receive CUmulative SUM (CUSUM) result (CUSUM result Delayed group) during the same period 12 months
89596628|NCT02874898|Active Comparator|Heavy marijuana use|Heavy marijuana users with PTSD
89596629|NCT02874898|Active Comparator|No marijuana use|Non-marijuana users with PTSD
89596630|NCT02873806|Other|2 micro-bypass stents & travoprost|"Two iStent inject micro-bypass stents and topical travoprost~Intervention:~Implantation of two iStent inject micro-bypass stents~Tobramycin~Dexamethasone"
89596631|NCT01890382|Placebo Comparator|Control|alanine as placebo to leucine (same dosage); corn starch as placebo to protein and/or creatine (same dosage)
89596632|NCT01890382|Experimental|whey protein|
89596633|NCT01890382|Experimental|soy protein|
89596634|NCT01890382|Experimental|leucine supplementation|
89596635|NCT01890382|Experimental|whey plus creatine|
89596636|NCT01890382|Experimental|creatine|
89596637|NCT01890616||Motility|This arm will ingest the SmartPill.
89596638|NCT01890772|Active Comparator|VitD+telaprevir+peginterferon+ribavirin|Participants randomized to the treatment group will receive 5,000IU/day of vitamin D3 during the lead-in phase. When the serum 25(OH)D level is ≥35ng/ml the participant will begin telaprevir + vitamin D3 (15,000IU/week) + peginterferon alfa-2a (180ug/week) + weight based ribavirin treatment.
89596639|NCT01890772|Active Comparator|Telaprevir + Peginterferon + Ribavirin|Participants randomized to the control group immediately begin treatment with telaprevir + 180ug of peginterferon alfa-2a (Pegasys) per week and either weight based ribavirin.
89596640|NCT01890850||Pertussis Group|Infants less than one year of age diagnosed with pertussis/whooping cough infection within 12 months from birth (first year of life, between July 1, 2005 and September 30, 2010).
89031673|NCT02943642|Experimental|Lead-in Dosing single arm|"Dose Group 1: A-dmDT390-bisFv(UCHT1) will be administered as 5 µg/kg given as 0.625 µg/kg/injection twice a day 4-6 hours apart for four consecutive days (days 1-4) into a free flowing IV over a period of approximately 15 minutes.~Dose Group 2: A-dmDT390-bisFv(UCHT1) will be administered as 10 µg/kg given as 1.25 µg/kg/injection twice a day 4-6 hours apart for four consecutive days (days 1-4) into a free flowing IV over a period of approximately 15 minutes."
89031674|NCT02943720|Placebo Comparator|placebo|5 SC injections in 2 months
89031675|NCT02943720|Experimental|AllerT 50 ug|5 SC injections in 2 months
89596641|NCT01890850||Control Group|Infants with no evidence of pertussis/whooping cough during within 12 months from birth (first year of life, between July 1, 2005 and September 30, 2010).
89596642|NCT01890928||Critically Ill Septic Pediatric Patients|Age 5-12 years; weight ≥ 17kg and Age 13-19 years, males and females
89596643|NCT01890928||Healthy Adolescents|Age 13-19 years, males and females
89596644|NCT01891006|Experimental|Negative Pressure Wound Therapy|Negative Pressure Wound Therapy (NPWT) is an alternative method of conservative wound management, which uses negative pressure to promote wound healing in both chronic and acute wounds. The rationale for using NPWT is that it mechanically stimulates the formation of new tissue and removes wound fluid and infectious material
89596645|NCT01891006|Other|A standard wound dressing|The standard wound dressing is a hydrofiber or alginate dressing, used for open wound
89596646|NCT04272112|Active Comparator|Glass-ceramic|30 dental crowns of lithium-disilicate glass-ceramic
89596647|NCT04272112|Active Comparator|Zirconia|30 dental crowns of high translucent zirconia
89596648|NCT04272112|Active Comparator|Zirconia with mini-veneer|30 dental crowns of high translucent zirconia with a mini-veneer of porcelain
89596649|NCT04272346|Experimental|Peer helping condition|Participants in the peer helping condition will be asked to write about their cancer experience with an emphasis on using the experience to benefit a newly-diagnosed AYA cancer patient.
89031676|NCT02943720|Experimental|AllerT 10 ug|5 SC injections in 2 months
89031677|NCT04695353|Experimental|Study group|These patients will receive telemedicine by using Telecommunication Platform videoconferences/messages.
89031678|NCT04695353|No Intervention|Control group|The patients will receive in-office clinical care
89031679|NCT02944149|Active Comparator|assistant medical officer (AMO)|Assistant medical officers (AMO) are currently allowed to provide tubal ligation by minilaparotomy, however government regulations do not allow clinical officers (COs) to provide this service.
89596650|NCT04272346|Experimental|Processing + peer helping condition|Participants in the processing + peer helping condition will be asked to first write about their deepest thoughts and feelings about their cancer experience (3 writings), then share advice to a newly-diagnosed AYA cancer patient (final writing).
89596651|NCT04272346|Placebo Comparator|Facts-only writing condition|Participants in the facts-only writing condition will be asked to write about their cancer experience. Unlike the previous conditions, they will not be instructed to write for the benefit of a newly-diagnosed AYA cancer patient.
89596652|NCT01891084|Active Comparator|Paracetamol|"Paracetamol 1 tablet (500mg) four times daily. For a maximum period of 5 days if the patient is still having fever. When required, participants may take up to 2 tablets (1gm) in each dose. Precautionary statement (Do not exceed 8 tablets daily) will be printed on the dispensary label to avoid overdose.~Backup NSAID ibuprofen 200mg orally every 8 hourly will also be provided to all participants, which can be taken when necessary (PRN) if the participant finds the fever intolerable."
89596653|NCT01891084|Placebo Comparator|Placebo|"(Identical-looking) Placebo 1 tablet four times daily. For a maximum period of 5 days if the patient is still having fever. When required, participants may take up to 2 tablets in each dose. Precautionary statement (Do not exceed 8 tablets daily) will be printed on the dispensary label to avoid overdose.~Backup NSAID ibuprofen 200mg orally every 8 hourly will also be provided to all participants, which can be taken when necessary (PRN) if the participant finds the fever intolerable"
89596654|NCT01891162||Control|Assessment will be carried out general quality of life beyond the functional evaluation of the pelvic floor through the PERFECT
89596655|NCT01891162||Study|Will be held evaluate the quality of life for general and specific pelvic floor dysfunction beyond the functional assessment of the pelvic floor through the PERFECT.
89596656|NCT01891240||First time, low risk mothers|The study population will consist of first time, low risk mothers attending for antenatal care in one of the participating clinical centres.
89596657|NCT01891474|Experimental|U-health care|voice inception technique based U-healthcare service
89596658|NCT01891474|No Intervention|control|conventional treatment
89596659|NCT01891630||AA children|African-American children with moderate-to-severe asthma living in a defined geographical area whose asthma is poorly controlled, and up to 30 moderate-to-severe African-American asthmatic children living in the same defined geographical area whose asthma is well controlled.
89596660|NCT01891786|No Intervention|Usual Care|The participant's General practitioner (GP) practice and/or practice nurse will provide care as normal for their patient.
89596661|NCT01891786|Active Comparator|Group Self-Management Intervention (SMI)|Participants will be asked to attend a total of 4 SMI sessions delivered on a weekly basis.
89596662|NCT01891786|Active Comparator|SMI + Risk Results|The participant will provide a saliva sample for analysis. They will attend an appointment with their nurse to receive personalised results on their combined genetic and lifestyle risk for developing CHD in the next 10 years. They will then be asked to attend the 4 week SMI programme.
89596663|NCT01891942|Experimental|COPD patients|All of the COPD patients included in this study were stable with no episodes of exacerbation within the previous 2 months. Patients with COPD were not currently being treated with oral corticosteroids.
89596664|NCT01891942|Experimental|normal subjects|Fifteen healthy men with normal lung function
89596665|NCT01892098|Active Comparator|Zinc Sulfate|Subjects enrolled in this arm will receive 9mg elemental zinc (23mg zn sulfate)/day for 4 weeks.
89596666|NCT01892098|Placebo Comparator|Cellulose Pill|Subject enrolled in this arm will receive a placebo.
89596667|NCT01892176|Experimental|Coenzyme Q10|400mg/day, 800mg/day, 1200/day and 2400mg/day
89596668|NCT01892254|Experimental|Metformin-Placebo|Metformin, 2x 2 tablets a day, 500 mg tablets for 12 weeks, 6 weeks wash-out, 12 weeks placebo
89596669|NCT01892254|Placebo Comparator|Placebo-metformin|Placebo tablets, 2x 2 tablets per day for 12 weeks, 6 weeks wash-out, 12 weeks metformin, 2x 2 tablets per day, 500 mg per tablet
89596670|NCT01892332|Other|lidocaine with fentanyl 75ug|
89596671|NCT01892488|Placebo Comparator|lactose pill|Placebo for 5 days as supplement to standard of care for patients with AE-COPD
89031680|NCT02944149|Experimental|clinical officer (CO)|Experimental: clinical officer (CO) In Tanzania, COs are mid-level providers who offer diagnosis, treatment, and minor surgeries. They are more common in rural areas than medical officers (MOs) and assistant medical officers (AMOs) and are generally considered capable of performing minor surgery. Almost all facilities in Tanzania are understaffed, but COs vastly outnumber MOs and AMOs. COs are more prevalent in poorer and/or rural areas than other higher level cadres; thus, task-shifting to COs would increase access to tubal ligation by minilaparotomy for many women who are most in need.
89596672|NCT01892488|Experimental|Sultamicillin|Antibiotic therapy with aminopenicillin + betalactamase inhibitor (oral Sultamicillin (2 x 750mg)) for 5 days as supplement to standard of care for patients with AE-COPD
89031681|NCT04695509|Experimental|moderate sedation|patients with American Society of Anesthesiologists (ASA) I-II, Montreal cognitive assessment test ≥ 26, trauma surgery under regional anesthesia with moderate propofol sedation
89596673|NCT04390204|Experimental|Experimental|Motor control exercises are performed on foam mats. The physiotherapist instructs them, and gives a description on paper, as well as a USB key allowing to view the exercises on video. A supervised home self-rehabilitation program on foam mats is implemented.
89596674|NCT04390204|No Intervention|control|According to the recommendations of learned societies, patients are offered voluntary MPP contraction work, in strength and endurance, in increasing complexity, under manual endocavitary control and under biofeedback. A supervised program of self-rehabilitation at home by voluntary contraction of MPP is set up.
89596675|NCT01892644|Active Comparator|Deferasirox HC|10 patients with hemochromatosis treated with Deferasirox
89031682|NCT04695509|Experimental|deep sedation|Arm Description: patients with American Society of Anesthesiologists (ASA I-II), Montreal cognitive assessment test ≥ 26, trauma surgery under regional anesthesia with deep propofol sedation
89596676|NCT01892644|Active Comparator|Venesection HC|10 patients with hemochromatosis treated with venesection
89596677|NCT01892644|Active Comparator|Deferasirox MDS|20 patients with myelodysplastic syndrome treated with Deferasirox
89596678|NCT01892644|No Intervention|Controls|10 healthy control persons to assess the normal level of investigational blood tests.
89596679|NCT01892878|Other|Single Arm Study|All patients will receive treatment
89596680|NCT01892956||Healthy volunteers|
89596681|NCT01892956||Newly diagnosed T2DM|Newly diagnosed T2DM, who have not started yet medical treatment with glucose lowering medications
89596682|NCT01893034|Active Comparator|Conservative treatment|Physiotherapy and activity modification
89596683|NCT01893034|Active Comparator|Surgical treatment|Arthroscopic treatment of femoroacetabular impingement
89596684|NCT02804230|Experimental|Exablate Neuro System Treatment|MR-Guided Focused Ultrasound will be used to ablate epileptic foci up to 8 cm3 in size.
89031683|NCT02943135|Active Comparator|lidocaine in-situ|Self-administered gel 10 min before intrauterine device insertion
89596685|NCT01901653|Experimental|Rovalpituzumab tesirine|Rovalpituzumab tesirine will be administered as a single agent, at increasing dose levels as permitted based on real-time assessment of safety and tolerability, intravenously over 30 minutes. Doses will be repeated on Day 1 of each 21-day or 42-day cycle until either unacceptable toxicity or evidence of disease progression occurs.
89031684|NCT02943135|Placebo Comparator|placebo|Self-administered gel 10 min before intrauterine device insertion
89031685|NCT02951234|Experimental|IVIG only|All patients will receive IVIG (2g/kg) in 10-12 hours alone, without high-dose aspirin. After fever subsides, low-dose aspirin (3-5mg/kg/day) will be prescribed until 6-8 weeks.
89031686|NCT02951234|Active Comparator|IVIG and Aspirin|All patients will receive IVIG (2g/kg) in 10-12 hours plus high-dose aspirin (80-100mg/kg/day, divided into four doses) till fever subside. After fever subsides, low-dose aspirin (3-5mg/kg/day) will be prescribed until 6-8 weeks.
89031687|NCT00531765|Active Comparator|1|hydration with normal saline
89031688|NCT00531765|Experimental|2|hydration with sodium bicarbonate
89596686|NCT01925989|Experimental|Insulin Peglispro/Insulin Glargine|Insulin peglispro (LY2605541) administered to participants with T1DM subcutaneously (SQ) once daily (QD) for 28 to 35 days in one of two treatment periods. Dose is based on participant's prestudy basal insulin dosing regimen. Insulin glargine administered to participants with T1DM SQ QD for 28 to 35 days in one of two treatment periods. Dose is based on participant's prestudy basal insulin dosing regimen. Participants continue to use mealtime insulin.
89596687|NCT01925989|Active Comparator|Insulin Glargine/Insulin Peglispro|Insulin glargine administered to participants with T1DM SQ QD for 28 to 35 days in one of two treatment periods. Dose is based on participant's prestudy basal insulin dosing regimen. Participants continue to use mealtime insulin. Insulin peglispro (LY2605541) administered to participants with T1DM subcutaneously (SQ) once daily (QD) for 28 to 35 days in one of two treatment periods. Dose is based on participant's prestudy basal insulin dosing regimen.
89596688|NCT01925989|No Intervention|Control|Control Arm. Untreated healthy participants.
89596689|NCT01901419|Experimental|High-dose NTG|Nitroglycerin infusion 1-5 mcg/kg/min
89596690|NCT01901419|Active Comparator|Low-dose NTG|Nitroglycerin infusion 0-0.1 mcg/kg/min
89596691|NCT02798536|Experimental|A1/LMB-100 dose escalation (closed)|De-escalating doses of LMB-100 in up to 18 subjects
89596692|NCT02798536|Experimental|A2/LMB-100 dose expansion (closed)|Fixed dose of LMB-100 as determined in Arm A1 in up to 16 subjects
89596693|NCT02798536|Experimental|B1/LMB-100+ nab- paclitaxel dose escalation|De-escalating doses of LMB-100 + fixed dose of nab-paclitaxel in up to 12 subjects
89596694|NCT02798536|Experimental|B2/LMB-100+ nab- paclitaxel dose expansion|Fixed dose of LMB-100 as determined in Arm B1 + fixed dose of nab-paclitaxel in up to 16 subjects
89596695|NCT01893268||Cohort|
89031689|NCT00515996||2|paroxetine treatment group vs. normal control group
89596696|NCT01901341|Experimental|CB-5945|0.25 milligrams (mg) CB-5945 administered orally twice daily (BID) for a 12-week treatment period
89596697|NCT01901341|Placebo Comparator|Placebo|Placebo administered orally BID for a 12-week treatment period
89596698|NCT04758286|Active Comparator|Successful outcome|It will include the anesthetic and operative data and the incidence of intraoperative or postoperative complication
89596699|NCT04758286|Active Comparator|Complicated outcome|It will include the anesthetic and operative data and the incidence of intraoperative or postoperative complication
89596700|NCT04757896|Active Comparator|Costoclavicular block lateral aproach|An 80-100 mm needle will be directed from the lateral to the medial with the ultrasound guided in-plane technique and the blockage procedure will be completed by injecting
89596701|NCT04757896|Active Comparator|Costoclavicular block medial aproach|An 80-100 mm needle will be directed from the medial to the lateral with the ultrasound guided in-plane technique and the blockage procedure will be completed by injecting
89596702|NCT01615939|Active Comparator|Single Shot Sciatic Nerve Block|Single shot sciatic nerve blocks will be performed by resident trainees supervised by faculty. Bupivacaine 0.625% with epinephrine 1:300,000 will be injected incrementally in 3-ml aliquots to a total volume of 0.4 ml/kg (minimum, 20 ml; maximum, 35 ml).
89031690|NCT00531804|Experimental|1|
89031691|NCT02951390|Active Comparator|High-definition white-light endoscopy|High-definition white-light endoscopy without indigo carmine instilation
89031692|NCT02951390|No Intervention|High-definition chromoendoscopy|High-definition indigo-carmine chromoendoscopy
89596703|NCT01615939|Active Comparator|Continuous Sciatic Nerve Block|Continuous sciatic nerve block catheters will be performed using an insulated needle connected to the negative lead of a constant current nerve stimulator. The catheter will be advanced under ultrasound guidance. A test dose of 1.5% lidocaine with epinephrine will be injected to confirm catheter placement. All subjects will receive a portable pump that will infuse 0.2% ropivacaine 5 ml/hr with a 5 ml bolus/hr. The subjects will follow standard protocol discharge instructions in regards to removing the catheter themselves.
89596704|NCT02789878|Experimental|ADT and Abiraterone|"Goserelin 10.8 mg, single dose, subcutaneously.~Abiraterone 1,000 mg, once daily, orally for 3 months.~Prednisone 5 mg, once daily, orally for 3 months."
89596705|NCT02789878|Experimental|ADT, Abiraterone and Apalutamide|"Goserelin 10.8 mg, single dose, subcutaneously.~Abiraterone 1,000 mg, once daily, orally for 3 months.~Prednisone 5 mg, once daily, orally for 3 months.~Apalutamide 240 mg, once daily, orally for 3 months."
89596706|NCT01901185|Experimental|Etanercept / Autoinjector A|Participants self-injected 50 mg etanercept subcutaneously using autoinjector A at the study center on Day 1 and then once a week from Weeks 1 to 5 (total of 6 injections).
89596707|NCT01893424|Active Comparator|Sativex buccal spray|volunteers will receive a single dose of 8 actuations of Sativex® which will be administrated within 1-2 min by the study physician. The dose of THC and CBD to be administered is the following: THC 21.6 mg and CBD 20 mg. Sativex® actuations will be directed sublingually and at the buccal mucosa.
89596708|NCT01893424|Experimental|CBD-THC-Piperine-PNL capsule|12 volunteers will receive a single oral dose of THC:CBD P-PNL capsule with 200 mL of water. The dose of THC and CBD to be administered is the same as in the Sativex arm: THC 21.6 mg and CBD 20 mg.
89596709|NCT02788708|Experimental|Treatment (lenvatinib, paclitaxel)|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15 and lenvatinib mesylate PO daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89596710|NCT01888003|Active Comparator|Anemia Treatment Group (AMG)|Group of patients who are diagnosed preoperatively as being anemic (defined as a Hgb < 13.0 g/dL and MCV < 100 fL, with a hematocrit between 30% and 39%, for males and females), who will receive an ESA (PROCRIT) and iron (Venofer) preoperatively.
89031693|NCT02950610||Healthy|Healthy volunteer: self-declared healthy individual (no known illness or medications) with Normal BMI
89031694|NCT02950610||Nonalcoholic steatohepatitis|NAFLD without cirrhosis: Metabolic syndrome with known liver disease (NAFLD, excluding other coexisting liver condition) without cirrhosis
89031695|NCT02950610||NAFLD Cirrhosis|NAFLD cirrhosis: well characterised NAFLD compensated cirrhosis (Child's A-B)
89031696|NCT02943252|Experimental|Apatinib plus S1|Patients received oral apatinib 500 mg in tablet once daily. Patients also received oral S1 in capsule 40-60mg bid, days 1-14. A treatment cycle was defined as 21 days (3 weeks).
89210049|NCT00605280|Experimental|Macugen|
89596711|NCT01888003|Other|Conventional Treatment Group (CTG)|Group of patients who are diagnosed preoperatively as being anemic (defined as a Hgb < 13.0 g/dL and MCV < 100 fL, with a hematocrit between 30% and 39%, for males and females), who will receive our current, conventional perioperative standard of care, which does not involve any preoperative anemia management (other than laboratory testing). CTG patients will undergo routine perioperative laboratory testing/screening.
89596712|NCT01888003|Other|Non Anemia Group (NAG)|Group of patients who are not anemic preoperatively, who will receive our current, conventional perioperative standard of care.
89596713|NCT02783560|Experimental|Sleep First|Families in this condition will receive a behavioral sleep intervention program (The Sleep Train Program) first, prior to a parent training intervention for disruptive behavior. After the completion of the parent training program and several assessment periods, families will receive the mealtime intervention (The Family Mealtimes Program).
89596714|NCT02783560|Active Comparator|Mealtimes First|Families in this active comparison condition will receive a behavioral treatment to promote positive family mealtimes first, prior to a parent training intervention for disruptive behavior. After the completion of the parent training program and several assessment periods, families will receive a behavioral sleep intervention (The Sleep Train Program).
89596715|NCT02783248||Mitral Stenosis|"No specific protocol intervention occurs. All the cares are made as done usually.~Patients who may be included are all consecutive patients who agreed to participate in the study and having a PMC in a French medical-surgical centers that perform more than 5 year PMC.~All patients undergoing echocardiography with the realization of the score Wilkins and Cormier.~Will then be included to validate the result of late score that patients who had a good immediate result of the PMC defined by: mitral valve area ≥ 1.5 cm² and IM ≤ 2/4. Patients with a poor immediate result of the PMC will not be monitored as part of the study but their data will be collected for the description of the population and analysis of immediate results.~Patients in the study will receive an annual monitoring as recommended, independently of the study."
89596716|NCT01893502|Active Comparator|Group 1|Participants will receive weekly proactive and live telephone counselling from Quitline (run by the Health Promotion Board) for one month
89596717|NCT01893502|Active Comparator|Group 2|Participants will receive weekly proactive and live telephone counselling from Quitline (run by the Health Promotion Board) for six months
89031697|NCT00514982|Other|1/Drug #1|Oral mesalamine will be used as initial therapy in patients who are not taking any medication or have not received any prior treatment for their IBD. Dosing will begin at 2.4 g PO QD and will be increased to 4.8 g QD within 2 weeks. Topical mesalamine (enema 4 g PR HS/BID or suppository 1 g PR HS/BID) may be added for patients with inflammation that is limited to the rectum (proctitis) or who have prominent complaints of urgency, incomplete evacuation or rectal bleeding.
89031698|NCT00514982|Other|1/Drug#2|Add oral corticosteroids (prednisone) to mesalamine. The standard induction dose will be 40 mg/day. After 1 week of therapy, if the total SCCAI score has decreased by greater than or equal to 2 points the patient will continue on another week of therapy. If the SCCAI has not decreased by greater than or equal to 2 points (indicative of a reduction in symptoms) at one week, then the dose will be increased to 60 mg/day. Patients on either dosage will have another SCCAI assessment done a week later (2 weeks after beginning corticosteroids), and if they are found to be in remission (SCCAI less than or equal to 2), a steroid-tapering schedule will be initiated.
89596718|NCT02775214|No Intervention|Conventional Direct Laryngoscopy|Endotracheal intubation will be performed by conventional direct laryngoscopy.
89596719|NCT02775214|Active Comparator|Video Laryngoscopy|Endotracheal intubation will be performed by video laryngoscopy with the C-MAC.
89596720|NCT02773732|Experimental|Ciprofloxacin Dose Level 0|
89596721|NCT02773732|Experimental|Ciprofloxacin Dose Level +1|
89596722|NCT02773732|Experimental|Ciprofloxacin Dose Level -1|
89596723|NCT04390126||Register of haematological malignancies|
89596724|NCT04390126||Idiopathic Pulmonary Fibrosis and PAH Cohort|
89596725|NCT04390126||Giant Cell Arteritis Cohort|
89596726|NCT04390126||AMD and Macular Edema Cohort|
89596727|NCT04390126||Multiple Sclerosis Cohort|
89596728|NCT04390126||Myocardial Infarction Observatory RICO|
89596729|NCT04390126||Heart Failure Cohort|
89596730|NCT04390126||Hemophilia Cohort|
89596731|NCT02769520|Experimental|Pembrolizumab|Pembrolizumab 200 mg will be administered by IV infusion every 3 weeks up to 12 months or until disease progression
89596732|NCT02764528|No Intervention|Control|Women will receive standard antenatal care but will not receive any additional handwashing promotion, soap, or handwashing device during their enrollment. At the end of data collection, handwashing with soap will be recommended to participants in the control arm and their families.
89596733|NCT02764528|Experimental|Clinic|Handwashing promotion from healthcare workers at antenatal care clinic.
89596734|NCT02764528|Experimental|Clinic + home|Handwashing promotion from healthcare workers at antenatal care clinic and from community health volunteers at home visits.
89596735|NCT02764528|Experimental|Clinic + home + handwashing device|Handwashing promotion from healthcare workers at antenatal care clinic and from community health volunteers at home visits with provision of one handwashing device.
89596736|NCT02735512||Group I|Patients without cancer undergo collection of blood and urine samples for analysis via MDSC clinical assay at baseline, 1 week, and 4 months.
89596737|NCT02735512||Group II|Patients with localized bladder cancer undergo collection of blood and urine samples for analysis via MDSC clinical assay at baseline, 1 week, and within 4 weeks after cystectomy.
89596738|NCT02735512||Group III|Patients with metastatic cancer undergo collection of blood and urine samples for analysis via MDSC clinical assay at baseline, 1 week, and within 4 weeks after completion of 4 courses of systemic chemotherapy.
89596739|NCT02735122|Experimental|Test acetaminophen|acetaminophen tablet and placebo caplet and placebo liquid-filled capsule
89596740|NCT02735122|Active Comparator|Commercial acetaminophen|acetaminophen caplet and placebo tablet and placebo liquid-filled capsule
89596741|NCT02735122|Active Comparator|Commercial ibuprofen|ibuprofen liquid-filled capsule and placebo tablet and placebo caplet
89596742|NCT02735122|Placebo Comparator|Placebo|Placebo tablet and placebo caplet and placebo liquid-filled capsule
89596743|NCT02726542|Experimental|Growth hormone|Somatropin given by daily subcutaneous injection. Dose will begin at 1mg and be titrated based on insulin-like growth factor 1 (IGF-1) levels.
89596744|NCT02726542|No Intervention|No treatment|(no study treatment - observation only)
89596745|NCT02722798|Experimental|KRN23|Subjects will receive subcutaneous injections of KRN23 every 4 weeks from Week 0 through Week 224
89596746|NCT02720848|Experimental|Stiffening wire|A stiffening wire inserted into the instrument channel of the double/single balloon enteroscope will be used.
89596747|NCT02720848|Active Comparator|Standard technique|The double/single balloon enteroscope will be used without the stiffening wire as per standard technique.
89596748|NCT02718118|Experimental|1.5 mL Reconstitution|Subjects treated with Dysport reconstituted at 1.5 mL (0.05 mL/injection) following the US on-label guidelines, with each subject receiving a single treatment session (50 units [U]) at the Day 1 visit.
89596749|NCT02718118|Experimental|2.5 mL Reconstitution|Subjects treated with Dysport reconstituted at 2.5 mL (0.08 mL/injection) following the US on-label guidelines, with each subject receiving a single treatment session (50 units [U]) at the Day 1 visit.
89596750|NCT01893580|Experimental|1. Experimental|Home-based exercise pre surgery and postoperative exercise in a team initiated two weeks after surgery.
89596751|NCT01893580|Experimental|2. Experimental|Home-based exercise pre surgery and postoperative exercise in a team initiated six weeks after surgery.
89596752|NCT01893580|Experimental|3. Experimental|Exercise in a team initiated two weeks after surgery.
89596753|NCT01893580|Other|4. Usual care|Exercise in a team initiated six weeks after surgery.
89596754|NCT02718040|Experimental|Emervel Treatment Group|Eligible subjects received bilateral treatment of Nasolabial Folds (NLFs) and Marionette Lines (MLs) with Emervel Classic and/or Emervel Deep
89596755|NCT01893658|Active Comparator|Omalizumab and Prednisone|"Omalizumab in addition to prednisone. Omalizumab will be given once subcutaneously at a dose of 375 mg within 24 hours after receiving prednisone~Standard clinical therapy with prednisone.~Day 1-14: 60 mg/day 14 days (2 weeks)~Day 15-28: 40 mg/day (2 weeks)~Day 29-35: 30 mg/day (1 week)~Day 36-42: 20 mg/day (1 week)~Day 43-49: 10 mg/day (1 week)~Day 50-56: 5 mg/day (1 week)~Subjects will stop taking prednisone on day 57~If patients weigh less than 60 Kg, the dose will be adjusted accordingly (to equal 1mg/kg/day of prednisone as the starting dose)."
88978796|NCT02965859|Active Comparator|Metacavir Enteric-coated Capsules 160mg|"Metacavir Enteric-coated Capsules 160mg~Metacavir Enteric-coated Capsules Placebo 160mg~Adefovir Dipivoxil Capsule Placebo 10mg;"
88978797|NCT02965859|Placebo Comparator|Metacavir Enteric-coated Capsules 320mg|"Metacavir Enteric-coated Capsules 320mg~Adefovir Dipivoxil Capsule Placebo 10mg"
88978798|NCT02965859|Active Comparator|Adefovir Dipivoxil Capsule|"Metacavir Enteric-coated Capsules Placebo 320mg~Adefovir Dipivoxil Capsule 10mg;"
88978799|NCT02965859|Placebo Comparator|Placebo|"Metacavir Enteric-coated Capsules Placebo 320mg~Adefovir Dipivoxil Capsule Placebo 10mg;"
88978800|NCT00271336|Placebo Comparator|A|
88978801|NCT00271336|Experimental|B|
88978802|NCT00107562|Experimental|Intervention|The cohort will be comprised of up to 4 index participants and from 1-4 of their network members for a possible range of 8-16 subjects in each cohort (average of 12 per cohort). The vast majority of the intervention will be delivered to both females and males together, but it would be beneficial, and appropriate for this adolescent population, to deliver certain exercises with the two genders separated.
88978803|NCT00271492|Active Comparator|I|Qualifying patients took Atrasentan, 1 pill per day for 6 months, to determine if it had a favorable affect on patients who took it over those who were randomized to placebo.
88978804|NCT00271492|Placebo Comparator|2|placebo group to be compared to the actual medication
88978805|NCT00271531||1|150 subjects greater than 48 weeks post-conception and less than 18 years of age who are mechanically ventilated and have presumed bacterial pulmonary infection.
88978806|NCT00271960|Active Comparator|Individual Care|Participants will receive usual care for their prenatal visits
88978807|NCT00271960|Active Comparator|CenteringPregnancy|Participants will receive CenteringPregnancy(R) group prenatal care
88978808|NCT00271960|Experimental|CenteringPregnancyPlus|Participants will receive CenteringPregancy with an HIV/STD prevention component
88978809|NCT00271999|Active Comparator|1|Three times a week conventional at home hemodialysis
88978810|NCT00271999|Experimental|2|Six times a week nocturnal home hemodialysis
88978811|NCT00107640|No Intervention|Usual care|Patients not assigned to the experimental condition received usual care, which may or may not have included alcohol education.
88978812|NCT00107640|Experimental|Patient-provider education|Experimental patients received an intervention consisting of the following components: written reports and educational materials, a telephone health educator intervention (at baseline, 3 and 6 months), and a brief provider intervention.
88978813|NCT00272116|Experimental|1|10 mg/day of elemental zinc as zinc gluconate to infants and 20 mg/day to older children and Vitamin A 100,000 IU to infants and 200,000 IU to older children
88978814|NCT00272116|Placebo Comparator|2|
88978815|NCT00272272|Experimental|Balance and Music Listening|Music therapy
88978816|NCT02966054|Experimental|Intervention|"Patients will be provided with a booklet from the UCSF Dept. of Physical Therapy and Rehabilitation Science: Moving Through Cancer: A Guide to Exercise for Cancer Survivors. The intervention group will be given a Fitbit® Flex to wear throughout the study and will receive daily text messages to support increased physical activity."
88978817|NCT02966054|No Intervention|Control|"Patients in the control arm will be provided with a booklet at baseline from the UCSF Dept. of Physical Therapy and Rehabilitation Science: Moving Through Cancer: A Guide to Exercise for Cancer Survivors."
89210050|NCT00901368|Experimental|1|CHF1535 (beclometasone dipropionate plus formoterol, 400/24 µg daily)
89596756|NCT01893658|Active Comparator|Prednisone|"Standard clinical therapy with prednisone.~Day 1-14: 60 mg/day 14 days (2 weeks)~Day 15-28: 40 mg/day (2 weeks)~Day 29-35: 30 mg/day (1 week)~Day 36-42: 20 mg/day (1 week)~Day 43-49: 10 mg/day (1 week)~Day 50-56: 5 mg/day (1 week)~Subjects will stop taking prednisone on day 57~If patients weigh less than 60 Kg, the dose will be adjusted accordingly (to equal 1mg/kg/day of prednisone as the starting dose)."
89031699|NCT00514982|Other|1/Drug#3|Infliximab and 6-MP will be added to patients with a SCCAI greater than 2 at week 8. The first infusion of infliximab (5 mg/kg) will be given during that week. In addition, 6-MP will be initiated at doses of 1.0-1.5 mg/kg PO QD to reduce the incidence of infliximab antibody formation and facilitate steroid tapering (the target dose of 6-MP will be decreased accordingly if patients are found to have low TMPT levels/activity by genotypic or phenotypic testing). Also, steroids will also be rapidly tapered off at this time.
89031700|NCT00514982|Other|1/Drug#4|Infliximab and 6-MP will be added to patients with a SCCAI greater than 2 at week 8. The first infusion of infliximab (5 mg/kg) will be given during that week. In addition, 6-MP will be initiated at doses of 1.0-1.5 mg/kg PO QD to reduce the incidence of infliximab antibody formation and facilitate steroid tapering (the target dose of 6-MP will be decreased accordingly if patients are found to have low TMPT levels/activity by genotypic or phenotypic testing). Also, steroids will also be rapidly tapered off at this time.
89596757|NCT02692768|Active Comparator|Live Music Therapy|Live sedative guitar playing within a limited chord progression will be utilized. Added to this music will be vocal and verbal therapeutic suggestion for active listening, focused breathing, muscle relaxation, and guided imagery. Patients will choose from one of three nature scene options for the guided imagery in order to include patient preference of content. This treatment group will experience this music intervention live, including patient-centered interaction with the music therapist and education for repeated use of the routine on recording.
89031701|NCT00514982|Other|1/Drug#5|Subjects with a SCCAI greater than 2 after 3 doses of infliximab will continue 6-MP, discontinue infliximab infusions and start adalimumab injections approximately 2 weeks after the 3rd dose of infliximab. Induction dosing will consist of a 160 Micro/g subcutaneous injection, followed by 80 Micro/g 2 weeks after.
89031702|NCT00514982|Other|1/Drug#6|Patients who have a SCCAI greater than 2 after 2 doses of adalimumab will continue 6-MP, discontinue adalimumab, and start therapy with tacrolimus 0.01 mg/kg PO BID approximately 2 weeks after the second dose of adalimumab.
89031703|NCT00531921||Kidney transplants|patients from 5 specific sites
88978818|NCT00272467|Experimental|Rebamipide|"Dosage (1) The eradication therapy period (for all cases) Amoxicillin 2,000mg/day, clarithromycin 1,000 mg/day and omeprazole 40 mg/day. b.i.d. (morning and evening), oral administration. (2) The ulcer treatment period (on a double-blind basis) Rebamipide 100mg, t.i.d. (before breakfast, evening, before bed).~Drug period (1) The eradication therapy period: 1 week (2) The ulcer treatment period: 7 weeks"
89031704|NCT00531921||Liver transplants|patients from 5 specific sites
89031705|NCT00531921||Heart transplants|patients from 5 specific sites
89031706|NCT00531921||Lung transplants|patients from 5 specific sites
89031707|NCT02950532||Cases|Retrospective radiological evaluation in cases presenting A3 or A4 TL burst fractures (AOSpine classification) between T11 to L2 with or without suspected PLC injury
89031708|NCT00531999|Active Comparator|1|Raltegravir 400 mg twice daily for the first 14 days of the study. Lopinavir/ritonavir 400/100 mg twice daily for the last 14 days of the study
89031709|NCT00531999|Active Comparator|2|"Lopinavir/ritonavir 400/100 mg twice daily for the first 14 days of the study.~Raltegravir 400 mg twice daily for the last 14 days of the study."
89031710|NCT00516035|Experimental|1|0.50 ml (0.25 ml in each nostril) of Influenza A Vaccine H7N3 (6-2) AA ca Recombinant (A/chicken/British Columbia/CN-6/2004 x A/Ann Arbor/6/60 ca) administered by nasal spray at two timepoints (at study entry and between Weeks 4 and 8)
89031711|NCT05318118|Active Comparator|Medial Meniscus Arthroscopic Reconstruction Using the Fast Fix|
89031712|NCT05318118|Active Comparator|Medial Meniscus Arthroscopic Reconstruction Using the Fiber Stitch|
89031713|NCT05319912|Experimental|Sequence 1: ABC|"Participants received each treatment on 1 occasion:~Period 1 (Treatment A): ALXN1840 tablets following an overnight fast. Period 2 (Treatment B): ALXN1840 tablets after the start of a high-fat breakfast, preceded by an overnight fast. Period 3 (Treatment C): Omeprazole once daily in the morning of Days -5 to -1 following an overnight fast, omeprazole at Hour -1 on Day 1 following an overnight fast, and ALXN1840 non-coated capsules at Hour 0 on Day 1.~There was a washout period of at least 14 days between each ALXN1840 dosing."
89031714|NCT05319912|Experimental|Sequence 2: ACB|"Participants received each treatment on 1 occasion:~Period 1 (Treatment A): ALXN1840 tablets following an overnight fast. Period 2 (Treatment C): Omeprazole once daily in the morning of Days -5 to -1 following an overnight fast, omeprazole at Hour -1 on Day 1 following an overnight fast, and ALXN1840 non-coated capsules at Hour 0 on Day 1. Period 3 (Treatment B): ALXN1840 tablets after the start of a high-fat breakfast, preceded by an overnight fast.~There was a washout period of at least 14 days between each ALXN1840 dosing."
89031715|NCT05319912|Experimental|Sequence 3: BAC|"Participants received each treatment on 1 occasion:~Period 1 (Treatment B): ALXN1840 tablets after the start of a high-fat breakfast, preceded by an overnight fast. Period 2 (Treatment A): ALXN1840 tablets following an overnight fast. Period 3 (Treatment C): Omeprazole once daily in the morning of Days -5 to -1 following an overnight fast, omeprazole at Hour -1 on Day 1 following an overnight fast, and ALXN1840 non-coated capsules at Hour 0 on Day 1.~There was a washout period of at least 14 days between each ALXN1840 dosing."
89031716|NCT05319912|Experimental|Sequence 4: BCA|"Participants received each treatment on 1 occasion:~Period 1 (Treatment B): ALXN1840 tablets after the start of a high-fat breakfast, preceded by an overnight fast. Period 2 (Treatment C): Omeprazole once daily in the morning of Days -5 to -1 following an overnight fast, omeprazole at Hour -1 on Day 1 following an overnight fast, and ALXN1840 non-coated capsules at Hour 0 on Day 1. Period 3 (Treatment A): ALXN1840 tablets following an overnight fast.~There was a washout period of at least 14 days between each ALXN1840 dosing."
89031717|NCT05319912|Experimental|Sequence 5: CAB|"Participants received each treatment on 1 occasion:~Period 1 (Treatment C): Omeprazole once daily in the morning of Days -5 to -1 following an overnight fast, omeprazole at Hour -1 on Day 1 following an overnight fast, and ALXN1840 non-coated capsules at Hour 0 on Day 1. Period 2 (Treatment A): ALXN1840 tablets following an overnight fast. Period 3 (Treatment B): ALXN1840 tablets after the start of a high-fat breakfast, preceded by an overnight fast.~There was a washout period of at least 14 days between each ALXN1840 dosing."
89596758|NCT02692768|Active Comparator|Recorded Music Therapy|Recorded sedative guitar playing within a limited chord progression will be utilized. Added to this music will be vocal and verbal therapeutic suggestion for active listening, focused breathing, muscle relaxation, and guided imagery. Patients will choose from one of three nature scene options for the guided imagery in order to include patient preference of content. This treatment group will be given a recording of their chosen music relaxation routine for use throughout the study process.
89596759|NCT02692768|Active Comparator|Control|This group will receive standard of care with no music therapy intervention
89596760|NCT02688556|Experimental|OTX-101 0.09%|0.09% cyclosporine nanomicellar ophthalmic solution
89596761|NCT02688556|Placebo Comparator|Vehicle|vehicle of OTX-101
89596762|NCT01925209|Experimental|BYM338/bimagrumab 10 mg/kg|Participants received study medication with BYM338 at 10 mg/kg from Day 1 to Week 52 and up to Week 104, administered by intravenous (i.v.) infusion every 4 weeks.
89596763|NCT01925209|Experimental|BYM338/bimagrumab 3 mg/kg|Participants received study medication with BYM338 at 3 mg/kg from Day 1 to Week 52 and up to Week 104, administered by i.v. infusion every 4 weeks.
89596764|NCT01925209|Experimental|BYM338/bimagrumab 1 mg/kg|Participants received study medication with BYM338 at 1 mg/kg from Day 1 to Week 52 and up to Week 104, administered by i.v. infusion every 4 weeks.
89596765|NCT01925209|Placebo Comparator|Placebo|Participants received matching placebo to BYM338 from Day 1 to Week 52 and up to Week 104, administered by i.v. infusion every 4 weeks.
89596766|NCT02684032|Experimental|Letrozole Cohort|Letrozole combination cohort in dose escalation
89596767|NCT02684032|Experimental|Fulvestrant cohort|Fulvestrant combination cohort in dose escalation
89596768|NCT02684032|Experimental|ARM A|Gedatolisib + palbociclib + letrozole in dose expansion
89596769|NCT02684032|Experimental|ARM B|Gedatolisib + palbociclib + fulvestrant in dose expansion
89596770|NCT02684032|Experimental|ARM C|Gedatolisib + palbociclib + fulvestrant in dose expansion
89596771|NCT02684032|Experimental|Arm D|Gedatolisib (3:1) + palbociclib + fulvestrant in dose expansion
89596772|NCT01614925|Experimental|Emdogain|Periodontal surgery with the additional use of Straumann® Emdogain
89596773|NCT01614925|Active Comparator|Periodontal Surgery|Periodontal surgery alone
89031718|NCT05319912|Experimental|Sequence 6: CBA|"Participants received each treatment on 1 occasion:~Period 1 (Treatment C): Omeprazole once daily in the morning of Days -5 to -1 following an overnight fast, omeprazole at Hour -1 on Day 1 following an overnight fast, and ALXN1840 non-coated capsules at Hour 0 on Day 1. Period 2 (Treatment B): ALXN1840 tablets after the start of a high-fat breakfast, preceded by an overnight fast. Period 3 (Treatment A): ALXN1840 tablets following an overnight fast.~There was a washout period of at least 14 days between each ALXN1840 dosing."
89596774|NCT02388178|Placebo Comparator|Fluoride free, silica based toothpaste|Control toothpaste containing no anti-cavity ingredients
89596775|NCT02388178|Experimental|fluoride + amino acid in a silica toothpaste|Experimental toothpaste containing fluoride and amino acid (arginine)
89596776|NCT02388178|Active Comparator|1450 ppm fluoride in a silica base toothpaste|Fluoride toothpaste containing fluoride as the anti-cavity ingredient
89596777|NCT02384668|Active Comparator|Cholecalciferol|Cholecalciferol 70 mcg per day Other name: Vitamin D3.
89596778|NCT02384668|Placebo Comparator|Placebo|"Placebo tablets are identical in regards to size and appearance to the experimental intervention tablet.~The placebo regimen is identical to the vitamin D3 regimen."
89596779|NCT01886833||Mother-Infant Pair|"The study will involve consenting mother-infant pairs from Kamwala health facility in Lusaka where the Maternal Child Health (MCH). Those generally interested will be invited to the research clinic, where more detailed information about the study is offered. Motivated mothers will be recruited and taken through the written informed consent process by the study nurse.~Enrolled mother-infant pairs will undergo baseline procedures as earlier described. They will then be followed prospectively until about December 2016. They will be expected to come to the clinic for scheduled visits at baseline, 1, 3, 12, 15 and 42 months. They will be urged to come to the clinic for unscheduled visit should the infant be unwell at any time, and particularly each time the infant experiences diarrhoea."
89596780|NCT02377258||1|without previous or ongoing exposure to IS or biologics, (5ASA and Steroids are allowed)
89031719|NCT04695587||TakoTsubo|Patients hospitalized with TakoTsubo syndrome according to the INTERTAK criteria
89031720|NCT02943018||anovaginal distance variation|3 measurements
89031721|NCT00516113|Active Comparator|1|Paroxetine 20mg during the luteal phase of the menstrual cycle
89031722|NCT00516113|Placebo Comparator|2|Placebo during the luteal phase of the menstrual cycle
89031723|NCT02942940|Active Comparator|mobile app|
89031724|NCT02942940|Active Comparator|in-person|
89596781|NCT02377258||2|with on-going anti-TNF monotherapy
89596782|NCT02377258||3|with thiopurines monotherapy
89596783|NCT02377258||4|with on-going combination therapy
89596784|NCT02377258||5|patients on vedolizumab (1 on vedolizumab alone and 1 on combination therapy)
89596785|NCT02377258||6|patients on ustekinumab (alone or on combination therapy)
89596786|NCT01898923|Experimental|ON101 Cream|ON101 Cream (1.25%),15g ointment per tube. Twice daily for up to 16 weeks.
89596787|NCT01898923|Other|Aquacel® Hydrofiber® dressing|Aquacel® Hydrofiber® dressings will be changed daily, on alternate days or three times a week according to need, but not longer than 7 days.
89596788|NCT04251442|Experimental|Study Group|The study group will have soft tissue balance performed with the use of IOS.
89596789|NCT04251442|No Intervention|Control Group|Control group patients will have soft tissue balance performed manually, with final soft tissue balance values measured using IOS, while the surgeon will remain blinded to those values.
89596790|NCT04551586|Experimental|Sequence 1|"Participants will receive ACH-0145228 once each Period as a single dose under fasted or fed conditions as follows:~Period 1: ACH-0145228 as an immediate-release tablet under fasted conditions (test-fasted).~Period 2: ACH-0145228 as an immediate-release tablet under fed conditions (test-fed).~Period 3: ACH-0145228 as power-in-capsule under fasted conditions (reference).~There will be a washout period of at least 5 days between each ACH-0145228 dosing."
89596791|NCT04551586|Experimental|Sequence 2|"Participants will receive ACH-0145228 once each Period as a single dose under fasted or fed conditions as follows:~Period 1: ACH-0145228 as an immediate-release tablet under fed conditions (test-fed).~Period 2: ACH-0145228 as power-in-capsule under fasted conditions (reference).~Period 3: ACH-0145228 as an immediate-release tablet under fasted conditions (test-fasted).~There will be a washout period of at least 5 days between each ACH-0145228 dosing."
89596792|NCT04551586|Experimental|Sequence 3|"Participants will receive ACH-0145228 once each Period as a single dose under fasted or fed conditions as follows:~Period 1: ACH-0145228 as power-in-capsule under fasted conditions (reference).~Period 2: ACH-0145228 as an immediate-release tablet under fasted conditions (test-fasted).~Period 3: ACH-0145228 as an immediate-release tablet under fed conditions (test-fed).~There will be a washout period of at least 5 days between each ACH-0145228 dosing."
89596793|NCT01924429|Experimental|On Drug then off Drug|Participants receive fMRI #1 on drug, #2 off drug Escalating stepped titration: 30, 50 or 70mg
89596794|NCT01924429|Experimental|Off drug then on drug|Participants receive fMRI #1 off drug, #2 on drug Escalating stepped dose titration: 30, 50, 70mg
89596795|NCT04553848|Experimental|Augmented Reality+ Treadmill training|Participants allocated to this group will receive treadmill training with body weight support (BWS) incorporating augmented feedback games chosen to address clinically perceived deficits using the C-Mill training system.
89596796|NCT04553848|Active Comparator|Treadmill training|Participants allocated to this group will receive treadmill training with body weight support (BWS) using the C-Mill training system.
89596797|NCT04553848|Active Comparator|Over ground training/standard of care|Participants allocated to this group will receive over ground balance and mobility training that would be considered standard of care in outpatient rehabilitation.
89596798|NCT01898299|Experimental|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation (tDCS) treatments will take place for 20 minutes per day for 5 consecutive days
89596799|NCT01898299|Sham Comparator|Sham tDCS|Sham tDCS(inactive)treatment (transcranial Direct Current Stimulation) will take place for 20 minutes per day for 5 consecutive days.
88978819|NCT00272467|Active Comparator|Omeprazole|"Dosage (1) The eradication therapy period (for all cases) Amoxicillin 2,000mg/day, clarithromycin 1,000 mg/day and omeprazole 40 mg/day. b.i.d. (morning and evening), oral administration. (2) The ulcer treatment period (on a double-blind basis) omeprazole 20mg, once daily (before breakfast)~Drug period (1) The eradication therapy period: 1 week (2) The ulcer treatment period: 7 weeks"
88978820|NCT00272545|Experimental|1|Participants will receive the normalization of eating program
88978821|NCT00272545|Active Comparator|2|Participants will receive treatment as usual
88978822|NCT00272662|Experimental|Cohort 1|Peginesatide starting dose of 0.1 milligram per kilogram (mg/kg) administered subcutaneously (SC) once every 3 weeks (Q3W) for a total of 4 doses.
88978823|NCT00272662|Experimental|Cohort 2|Peginesatide starting dose of 0.15 mg/kg administered SC Q3W for a total of 4 doses.
88978824|NCT00272662|Experimental|Cohort 3|Peginesatide starting dose of 0.2 mg/kg administered SC Q3W for a total of 4 doses.
88978825|NCT00272662|Experimental|Cohort 4|Peginesatide starting dose of 0.05 mg/kg administered SC Q3W for a total of 4 doses.
88978826|NCT00074750|Experimental|DTGM|Starting dose of DTGM fusion protein 2 mcg/kg/day as a short (30 min) intravenous infusion, three times /week (M,W,F) for two consecutive weeks. In absence of defined grade 3/4 nonhematological toxicities in the first 0/3 or 1/6 patients, the dose will be escalated by 1 mcg/kg/day for the next patient cohort.
88978827|NCT00272857|Experimental|Single arm|
88978828|NCT00272935|Experimental|1|
88978829|NCT00272935|Placebo Comparator|2|
88978830|NCT02965625||open elective cardiac surgery patients|Including coronary artery bypass graft and valve replacement surgery patients
88978831|NCT00273013|Experimental|Sequence 1|Subjects will receive Placebo in period 1, Singulair 10 milligrams (mg) in period 2 and GW274150 90 mg in period 3.
88978832|NCT00273013|Experimental|Sequence 2|Subjects will receive Placebo in period 1, GW274150 90 mg in period 2 and Singulair 10 mg in period 3.
89596800|NCT04550650|No Intervention|Controll|No intervention
89596801|NCT04550650|Experimental|Training grp|Neurorehabilitation 2 years long intervention, administered daily, targeted postural instability, balance and mobility using at-limit intensity sensorimotor and visuomotor agility training
89596802|NCT04550650|Experimental|PNF|2 years long, You have only treated patients with the PNF technique.
89596803|NCT04550650|Experimental|Spinning group|Patients developed endurance for 2 years. They worked using a spinning bike.
89596804|NCT04550650|Experimental|Balance|Neurorehabilitation 2 years long intervention, administered daily, targeted postural instability, balance
89596805|NCT01886287|Experimental|Octreotide Long-acting Release (LAR)|Octreotide LAR will be administered at a dose of 60 mg intramuscularly (IM) every 4 weeks.
89596806|NCT04559386|Experimental|Overall trial|People who complete the questionnaire.
89596807|NCT04395118|No Intervention|Usual Care|Patients randomized to Group 1 will receive visit-based HCV screening, as offered by clinic providers as part of usual care. Providers must identify at-risk patients who are eligible for HCV screening, understand the benefits of screening in this population, and enter orders for HCV Ab testing. If the HCV antibody is abnormal, providers must order appropriate follow-up tests including HCV viral load to confirm HCV infection. Once HCV is confirmed, providers must refer the patients for fibrosis assessment and treatment evaluation. These efforts are augmented by an established best practice alert and health maintenance reminders.
88978833|NCT00273013|Experimental|Sequence 3|Subjects will receive Singulair 10 mg in period 1, Placebo in period 2 and GW274150 90 mg in period 3.
88978834|NCT00273013|Experimental|Sequence 4|Subjects will receive Singulair 10 mg in period 1, GW274150 90 mg in period 2 and Placebo in period 3.
88978835|NCT00273013|Experimental|Sequence 5|Subjects will receive GW274150 90 mg in period 1, Placebo in period 2 and Singulair 10 mg in period 3.
89596808|NCT04395118|Active Comparator|Mailed Outreach|Patients randomized to Group 2 will receive low literacy, written materials about HCV screening in English and Spanish. The invitation will include patient-centered educational materials that discuss the risk of HCV in patients with elevated LFTs and the benefits and risks of HCV screening. The invitation will include a phone number to schedule the HCV antibody test. Once a potential subject is identified and randomized in Group 2, an outreach invitation will be mailed out. Shortly after the letter, a bilingual patient navigator will call to this potential subject. Patients will also receive centralized patient navigation to facilitate screening completion and appropriate test follow-up. He/she will help patients schedule HCV antibody testing and will assume responsibility for tracking results. Patients referred to the Hepatitis C clinic for treatment evaluation will receive reminder calls from trained and credentialed study staff 5-7 business days for scheduled appointments.
89596809|NCT04628065|Experimental|Intervention Arm|Participants will receive a text message everyday to build behavioral skills and practice self-monitoring of three behavior goals: (1) reduce TV time to less than 2 hours per day; (2) take 10,000 steps or more every day; (3) do 20 minutes or more of structures exercise like prenatal yoga or dance videos every day. Participants will also receive two health coaching mobile phone session; an introduction session and one problem solving session.
89596810|NCT04393870|Experimental|Maryam's Flower Group|Maryam's flower was placed in a bowl of water and left in the room of the pregnant women who were at 1 cm cervical dilatation and in the first phase of the labor. It was explained to the pregnant women that the leaves of the plant would open up in the water, and they were asked to imagine that the birth canal would simultaneously open up. In effect, they were told to focus on the opening of these leaves during the course of the labor
89596811|NCT04393870|No Intervention|Control Group|All the pregnant women, those in the control group, were provided with standard midwifery care.
89596812|NCT02707588|Experimental|Pembrolizumab and radiotherapy|200 mg IV infusion every 3 weeks, i.e. on day 1, 22, 43 during the course of radiotherapy
89596813|NCT02707588|Active Comparator|Cetuximab and radiotherapy|Loading dose of 400 mg/m² IV on Day-8, followed by weekly dose of 250 mg/m² IV during the whole course of radiotherapy.
89596814|NCT05602480|Experimental|1A|Subjects received one dose of PCV13 at 18 years of age and above.
89596815|NCT05602480|Experimental|2A|Subjects received one dose of PCV13 at 6~17 years of age.
89596816|NCT05602480|Experimental|3A|Subjects received one dose of PCV13 at 2~5 years of age.
89596817|NCT05602480|Experimental|4A|Subjects received two doses of PCV13 at 12~23 months of age.
89596818|NCT05602480|Experimental|5A|Subjects received three doses of PCV13 at 7~11 months of age.
89596819|NCT05602480|Experimental|6A|Subjects received four doses of PCV13 at 3 months of age.
89596820|NCT05602480|Experimental|6B|Subjects received four doses of PCV13 at 2 months of age (At least 6 weeks old).
89596821|NCT05602480|Active Comparator|6C|Subjects received four doses of control PCV13 at 2 months of age (At least 6 weeks old).
89596822|NCT05602480|Experimental|7A|Subjects received four doses of PCV13 at 2 months of age (At least 6 weeks old).
89596823|NCT05602480|Active Comparator|7B|Subjects received four doses of control PCV13 at 2 months of age (At least 6 weeks old).
89596824|NCT05604586|Experimental|N-acetylcysteine|Intervention: Dietary Supplement: N-acetylcysteine Participants will undergo two exercise tests and daily supplementation with N-acetylcysteine orally in three doses a day for seven consecutive days.
89596825|NCT05604586|Placebo Comparator|Placebo|Supplement: Placebo Participants will undergo two exercise tests and daily supplementation with placebo orally in three doses a day for seven consecutive days.
89596826|NCT05604430||Ventilator patients|Patients being ventilated by the ZOLL 731 Series ventilator in accordance with device labeling and Agency protocols in a pre-hospital setting.
89596827|NCT05604352|Experimental|Main study|Study to investigate the safety and clinical efficacy of the DiaSole insole.
89596828|NCT05604118|Experimental|Aspirin supplemented|
89596829|NCT05604118|No Intervention|Off aspirin|
89596830|NCT03030274|Experimental|Occlutech AFR Device|Prospective, non-randomized, pilot study to assess safety and efficacy of a novel Atrial Flow Regulator in Heart Failure Patients with with reduced Ejection Fraction (HFrEF) and Heart Failure Patients with preserved Ejection Fraction (HFpEF); the AFR-Prelieve Trial
89596831|NCT04760080||Patients with a metastatic melanoma treated by dabrafenib/trametinib and hydroxychloroquine.|"Patients with a metastatic melanoma treated by dabrafenib/trametinib and hydroxychloroquine after acquired resistance to dabrafenib/trametinib.~Patients treated~for a BRAF mutated metastatic melanoma in Pr Dalle's dermatology ward at Centre Hospitalier Lyon Sud,~From January 2008 to June 2020~who received a treatment by immunotherapy before receiving a treatment by dabrafenib/trametinib~who became resistant to dabrafeib/trametinib~and received after disease progression a treatment by dabrafenib/trametinib and hydroxychloroquine"
89596832|NCT04760080||Patients with a metastatic melanoma treated by cytotoxic chemotherapy.|"Patients with a metastatic melanoma treated by cytotoxic chemotherapy after acquired resistance to dabrafenib/trametinib.~Patients treated~for a BRAF mutated metastatic melanoma in Pr Dalle's dermatology ward at Centre Hospitalier Lyon Sud,~From January 2008 to June 2020~who received a treatment by immunotherapy before receiving a treatment by dabrafenib/trametinib~who became resistant to dabrafeib/trametinib~and received after disease progression under dabrafenib/trametinib a treatment by cytotoxic chemotherapy"
89596833|NCT01885195|Experimental|MEK162|MEK162 will be dosed on a flat scale of 45 mg twice daily on a continuous dosing schedule.
89596834|NCT03337594||Control|Pediatric patients who have not been exposed to gadolinium-based contrast agent administration and who require cardiac surgery as part of their standard clinical treatment.
89596835|NCT03337594||Dotarem|Pediatric patients who have undergone routine contrast-enhanced MRI using only Dotarem contrast agent for clinical purposes and who require cardiac surgery as part of their standard clinical treatment.
89031725|NCT05317962||COVID-19 positive patients admitted to hospital|
89031726|NCT05319366||Stable angina|50 patients with stable angina will be included and tissue samples from balloon cathether and blood samples will be collected
89596836|NCT03337594||MultiHance|Pediatric patients who have undergone routine contrast-enhanced MRI using only MultiHance contrast agent for clinical purposes and who require cardiac surgery as part of their standard clinical treatment.
89596837|NCT04393792|Active Comparator|Povidone-Iodine|0.23% sinus rinse and mouthwash three times daily (tds) for days 1-3 of study
88978836|NCT00273013|Experimental|Sequence 6|Subjects will receive GW274150 90 mg in period 1, Singulair 10 mg in period 2 and Placebo in period 3.
88978837|NCT00107835|Experimental|S-Caine Peel|
88978838|NCT00074789|Experimental|1|Participants will receive home-based interpersonal depression treatment for 26 weeks
88978839|NCT00074789|Active Comparator|2|Participants will receive attention control/usual care for 26 weeks
88978840|NCT00074828|Experimental|A|
88978841|NCT00074828|Active Comparator|B|
88978842|NCT00273286|Experimental|family diabetes management intervention|A trained health advisor will be responsible for interactions with parents and patients prior to each diabetes clinic visit (Preparation Phase), at the time of the diabetes clinic visit (Consolidation Phase) and by phone, e-mail, etc. after the clinic visit (Follow-up Phase). Using educational modules developed for the study, families will be engaged in problem identification and solving activities to improve shared parent-youth responsibility for diabetes management and foster increased adolescent's independent management capabilities.
88978843|NCT00273559||1|subjects who remain on steroids after discharge
88978844|NCT00273559||2|Subjects will be off steroids at the time of discharge
88978845|NCT00273715|No Intervention|Staples|
88978846|NCT00108108|Experimental|HCD122|
88978847|NCT00108147|Experimental|1|Circuit Training
88978848|NCT00108147|Active Comparator|2|Cardiac Rehabilitation
88978849|NCT00108147|Active Comparator|3|Flexibility and toning
88978850|NCT00075101|Experimental|Study Cycle|
88978851|NCT00075140||1|All Participants hav a family member with Huntington Disease
88978852|NCT00108186|Other|Arm 1|Celecoxib is an FDA approved drug for other indications such as osteoarthritis. It is not FDA approved for non-small cell lung cancer.
88978853|NCT00075179|Experimental|Nesiritide|Nesiritide 0.01 mcg/kg/min by vein over 30 minutes during right heart catheterization procedure.
88978854|NCT00416650|Experimental|Therapeutic Intervention|Patients will receive erlotinib (OSI-774) 150 mg daily by mouth. If specified toxicities occurs, the dose may be reduced.
88978855|NCT00108225|Active Comparator|Arm 1|30% carbohydrate, 30% protein, 40% fat
88978856|NCT00108225|Placebo Comparator|Arm 2|55% carbohydrate, 15% protein, 30% fat
88978857|NCT02965430|Experimental|AL-SENSE diagnostic pantyliner|AL-SENSE diagnostic pantyliner of amniotic fluid compared with standard clinical diagnosis methods.
88978858|NCT00108381|Experimental|Arm 1|Standard and Tailored Conditions
88978859|NCT00075374|Experimental|Docetaxel|
88978860|NCT00277186|Active Comparator|Intervention|Patients entering new care continuum
88978861|NCT00277186|Active Comparator|Control|Patient enter existing conventional approach
89596838|NCT04393792|Placebo Comparator|Normal Saline|sinus rinse and mouthwash three times daily (tds) for days 1-3 of study
88978862|NCT02965664|Experimental|PresbiDrops (CSF-1)|Participants self-administer PresbiDrops (CSF-1) , with the supervision or help of the hospital staff - one drop in each eye on the day of treatment
88978863|NCT02965664|Placebo Comparator|Placebo|Participants self-administer Placebo, with the supervision or help of the hospital staff - one drop in each eye on the day of treatment
88978864|NCT00277537|Experimental|1|
88978865|NCT00277537|Other|2|
88978866|NCT00277654|Active Comparator|Risperidone|
88978867|NCT00277654|Placebo Comparator|Sugar pill|
88978868|NCT00108576|Placebo Comparator|Arm 1|Look-a-like placebo
88978869|NCT00108576|Experimental|Arm 2|Divalproex
88978870|NCT00075491|Experimental|Arm I (fenretinide, surgery)|Patients receive neoadjuvant oral fenretinide twice daily for 1 week and then undergo surgical resection.
88978871|NCT00075491|Active Comparator|Arm II (surgery)|Patients undergo surgical resection.
88978872|NCT00277888|Experimental|Femoral route|
88978873|NCT00277888|Experimental|Jugular route|
88978874|NCT00108615|Experimental|1|pioglitazone
88978875|NCT00108615|Active Comparator|2|metformin
88978876|NCT00075569|Active Comparator|1 month follow-up|3 monthly subcutaneous vaccinations with 500 microg of HspE7 followed by monthly colposcopic follow-up for 1 month; followed by LEEP or cone biopsy
88978877|NCT00075569|Active Comparator|2 month follow-up|3 monthly subcutaneous vaccinations with 500 microg of HspE7 followed by monthly colposcopic follow-up for 2 months; followed by LEEP or cone biopsy
88978878|NCT00075647|Experimental|Treatment (temsirolimus)|Patients receive CCI-779 IV over 30 minutes once weekly. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
88978879|NCT00416689||Breast or lung CA pt undergoing chemoTx|
88978880|NCT00278278|Experimental|Arm I|"Patients receive high-dose methotrexate IV over 24 hours on days 1 and 15 and leucovorin calcium IV every 6 hours on days 2-3 an 16-17. Four weeks later, patients undergo external beam radiotherapy once daily, 5 days a week, for approximately 6 weeks.~Beginning on the first day of radiotherapy, patients receive cisplatin IV over 1 hour on days 1-5, etoposide IV over 2 hours on days 1-3, and vincristine IV on days 5, 12, 19, 26, and 33. Beginning seven days prior to completion of radiotherapy, patients receive ifosfamide IV over 1 hour and cisplatin IV over 1 hour on days 1-5, etoposide IV over 2 hours on days 1-3, and vincristine IV on day 5."
88978881|NCT00278278|Active Comparator|Arm II|"Patients undergo external beam radiotherapy once daily, 5 days a week, for approximately 6 weeks.~Beginning on the first day of radiotherapy, patients receive cisplatin IV over 1 hour on days 1-5, etoposide IV over 2 hours on days 1-3, and vincristine IV on days 5, 12, 19, 26, and 33. Beginning seven days prior to completion of radiotherapy, patients receive ifosfamide IV over 1 hour and cisplatin IV over 1 hour on days 1-5, etoposide IV over 2 hours on days 1-3, and vincristine IV on day 5."
88978882|NCT00108771|Experimental|ZR-02-01 matrix fentanyl Patch|ZR-02-01 matrix fentanyl patch
88978883|NCT00108771|Placebo Comparator|Placebo Patch|
88978884|NCT00278434|Experimental|Zoledronate|"100 cc of saline with 4 mg of zoledronate intravenous (IV), over 20 minutes, for 3 doses one week apart~Treatment repeats every 21 days (one course) for up to 3 courses. In week 8, patients undergo surgical resection comprising loop excision or cone biopsy.~After completion of study treatment, patients are followed at week 10 by telephone."
89210051|NCT00901368|Active Comparator|2|Seretide® Diskus® (fluticasone plus salmeterol, 500/100 µg /daily)
89596839|NCT04129762|Experimental|Diet without NCS in irritable bowl syndrome|Participants with irritable bowl syndrome are assigned to a 5 meals divided diet. In which it does not contain any products with NCS
89596840|NCT04129762|Active Comparator|Diet with NCS in irritable bowl syndrome|Participants with irritable bowl syndrome are assigned to a 5 meals divided diet. In which it contain any products with NCS
89596841|NCT04129762|Experimental|Diet without NCS in dyspepsia|Participants with dyspepsia are assigned to a 5 meals divided diet. In which it does not contain any products with NCS
89596842|NCT04129762|Active Comparator|Diet with NCS in dyspepsia|Participants with dyspepsia are assigned to a 5 meals divided diet. In which it contain any products with NCS
89596843|NCT04129684|Experimental|Test group|SRP+BioGaia Prodentis oil drops and lozenges
89596844|NCT04129684|Placebo Comparator|Control group|SRP+subgingival delivery of placebo and placebo lozenges
89596845|NCT01896895|Experimental|IncobotulinumtoxinA (Xeomin) 25U per eye|Main Period: one injection session, 25 Units per eye. Open-Label Extension: one injection session, up to 35 Units per eye. Mode of administration: intramuscular injection.
89596846|NCT01896895|Experimental|IncobotulinumtoxinA (Xeomin) 12.5U per eye|Main Period: one injection session, 12.5 Units per eye. Open-Label Extension Period: one injection session, up to 35 Units per eye. Mode of administration: intramuscular injection.
88978885|NCT00278434|Placebo Comparator|Saline|"100 cc of saline IV, over 20 minutes, for 3 doses one week apart~Treatment repeats every 21 days (one course) for up to 3 courses. In week 8, patients undergo surgical resection comprising loop excision or cone biopsy.~After completion of study treatment, patients are followed at week 10 by telephone."
88978886|NCT00075686|Experimental|gemcitabine hydrochloride + IMC-C225|Loading dose: gemcitabine hydrochloride 1000mg/m2, IV on Day 1; Cetuxiumab 400mg/m2, IV on Day 1 (cycle 1 only) Weekly maintenance: Cetuximab 250mg/m2, IV on Days 8,15,22 of cycle 1 & days 1,8,15,22 of all subsequent cycles; gemcitabine hydrochloride 1000mg/m2, IV on Days 8,15,22 of cycle 1 and Days 1,8,15 of all subsequent cycles.
88978887|NCT00075686|Experimental|gemcitabine hydrochloride alone|gemcitabine hydrochloride 1000mg/m2, IV on Days 1,8,15,22 of cycle 1 and Days 1,8,15 of all subsequent cycles.
88978888|NCT00278551|Experimental|heatopoietic stem cell transplant|
88978889|NCT00278590|Experimental|allogeneic stem cell transplantation|allogeneic stem cell transplantation will be performed
88978890|NCT02964858|Active Comparator|Standard Arm|45 Gy in 25 fractions of 1.8 Gy per fraction over 5 weeks Involved Field radiotherapy (IFRT)/ Involved Site Radiotherapy (ISRT)
88978891|NCT02964858|Experimental|Experimental Arm|36 Gy in 20 fractions of 1.8 Gy per fraction over 4 weeks Involved Field radiotherapy (IFRT)/ Involved Site Radiotherapy (ISRT)
88978892|NCT00278746|Experimental|1|Zinc and ORS were promoted for treatment of diarrhea in underfive children
88978893|NCT00278746|Other|2|Promoted routine management of diarrhea in underfive with ORS
88978894|NCT00278824|Experimental|50 mcg/hr matrix fentanyl patch|active 50 mcg/hr ZR-02-01 matrix transdermal fentanyl patch (20 cm2)
89031727|NCT05319366||Unstable angina/non-ST-segment elevation myocardial infarction|50 patients with unstable angina/non-ST-segment elevation myocardial infarction will be included and tissue samples from balloon cathether and blood samples will be collected
89031728|NCT05319366||ST-segment elevation myocardial infarction|50 patients with ST-segment elevation myocardial infarction will be included and tissue samples from balloon cathether and blood samples will be collected
89596847|NCT01896895|Placebo Comparator|Placebo|"Main Period: Placebo to IncobotulinumtoxinA (Xeomin)(12.5 or 25U/eye), one injection session.~Open-Label Extension: IncobotulinumtoxinA (Xeomin), one injection session, up to 35 Units per eye. Mode of administration: intramuscular injection."
89596848|NCT03026764|Experimental|Outpatient|Patients in the outpatient group (same day discharge following THA) are discharged the same day following surgery. All patients are required to meet the discharge criteria to be sent home (i.e., capable of using crutches, relatively free of pain, free of nausea and vomiting, free of excess bleeding, alert and oriented, given take-home medications, and in the company of a caregiver).
89596849|NCT03026764|Active Comparator|Inpatient|Patients in the inpatient group (following day discharge following THA) stay in the hospital overnight and then are discharged home the next day. All patients are required to meet the discharge criteria to be sent home (i.e., capable of using crutches, relatively free of pain, free of nausea and vomiting, free of excess bleeding, alert and oriented, given take-home medications, and in the company of a caregiver).
89596850|NCT04129606|Other|TURBT|Transurethral resection of bladder tumour
88978895|NCT00278824|Placebo Comparator|Placebo Patch|placebo (20 cm2) will be indistinguishable in size, shape, and appearance to the active matrix fentanyl patch
88978896|NCT00278902|Experimental|ARRY-334543|
88978897|NCT00075842|Experimental|Arm I|Patients receive oral Valeriana officinalis (Valerian) once daily for 8 weeks.
88978898|NCT00075842|Placebo Comparator|Arm II|Patients receive an oral placebo once daily for 8 weeks.
88978899|NCT00279019|Experimental|Subjects receiving treatment sequence 1|Eligible subjects will receive treatment sequence 1; GSK233705 20 micrograms, GSK233705 100 micrograms, tiotropium and placebo.
88978900|NCT00279019|Experimental|Subjects receiving treatment sequence 2|Eligible subjects will receive treatment sequence 2; GSK233705 20 micrograms, Placebo, GSK233705 50 micrograms and tiotropium.
88978901|NCT00279019|Experimental|Subjects receiving treatment sequence 3|Eligible subjects will receive treatment sequence 3; GSK233705 20 micrograms, tiotropium, Placebo and GSK233705 50 micrograms.
88978902|NCT00279019|Experimental|Subjects receiving treatment sequence 4|Eligible subjects will receive treatment sequence 4; GSK233705 20 micrograms, placebo, tiotropium and GSK233705 50 micrograms.
88978903|NCT00279019|Experimental|Subjects receiving treatment sequence 5|Eligible subjects will receive treatment sequence 5; Placebo, tiotropium, GSK233705 20 micrograms and GSK233705 50 micrograms.
88978904|NCT00279019|Experimental|Subjects receiving treatment sequence 6|Eligible subjects will receive treatment sequence 6; Placebo, GSK233705 20 micrograms, GSK233705 50 micrograms and tiotropium.
88978905|NCT00279019|Experimental|Subjects receiving treatment sequence 7|Eligible subjects will receive treatment sequence 7; tiotropium, GSK233705 20 micrograms, GSK233705 50 micrograms and Placebo.
88978906|NCT00279019|Experimental|Subjects receiving treatment sequence 8|Eligible subjects will receive treatment sequence 8; tiotropium, GSK233705 20 micrograms, Placebo and GSK233705 50 micrograms.
89596851|NCT04129372|Experimental|New Foods Take Time|"Head Start classrooms will receive New Foods Take Time, a series of five interactive weekly lessons designed to promote children's willingness to try new foods, particularly fruits and vegetables. Lessons will be delivered by nutrition educations. Children will also receive three tastings per week of the new foods discussed during the lessons."
89596852|NCT02315872|Experimental|ACTH|The study drug (ACTH 40 units) will be given subcutaneously twice weekly for 2 weeks. If the patient tolerates this dosage regimen, the dose will be increased to 80 units twice weekly. If the 80 unit dosage is not tolerated, the dosage will be reduced to 40 units twice weekly for the remainder of the 24 week participation. The weekly doses will be given 3 days apart, for example, on every Monday and Thursday or every Tuesday and Friday.
89596853|NCT02315872|Placebo Comparator|Placebo|Placebo will be given subcutaneously twice weekly for 28 weeks.
89596854|NCT04128826|Experimental|Partial Range of Motion (PROM)|
89596855|NCT04128826|Experimental|Full Range of Motion (FROM)|
89596856|NCT04128826|No Intervention|Control (CON)|
89596857|NCT04128982||Videolaryngoscopy|Check the intubation conditions during laryngoscopy without external mobilization of the larynx, with Sellick manoeuvre or with low paratracheal esophagal compression in 2 groups: patient in dorsal decubitus or Rapid Airway Management Positioner.
89596858|NCT04128202|Active Comparator|Sunnyside|An online intervention to better manage mood during and after pregnancy.
89596859|NCT04128202|Experimental|Sunnyside Plus|An online intervention to better manage mood and promote and support breastfeeding during and after pregnancy.
89596860|NCT04128592|Other|Wheezing|
89596861|NCT04128592|Other|Rattling|
89596862|NCT04128280|Experimental|Test Group|Test group: Patients will receive a surgery: transurethral dilation of prostate with a columnar balloon
89596863|NCT04128280|Active Comparator|Control Group|Control group: Patients will receive a surgery: transurethral incision of bladder neck.
89596864|NCT04127812|Experimental|Savor the Flavor|"The Savor the Flavor curriculum is a series of five interactive lessons designed to teach children how to savor foods and slow down while eating by focusing on the sensory experience of eating. The intervention also teaches attention control techniques so that children are better able to delay consumption of high energy, low nutrition foods, when appropriate, as well as general mindfulness practices (e.g. breathing exercises). Lessons are delivered in the Head Start classroom by a nutrition educator."
89596865|NCT04127890|Experimental|Intervention Arm|1.5 L of ELO Water to be drunk daily for 24 weeks
89596866|NCT04127890|Placebo Comparator|Control Arm|1.5 L of placebo bottled drinking water to be drunk daily for 24 weeks
88978907|NCT00279019|Experimental|Subjects receiving treatment sequence 9|Eligible subjects will receive treatment sequence 9; GSK233705 20 micrograms, tiotropium, GSK233705 50 micrograms and Placebo.
88978908|NCT00279019|Experimental|Subjects receiving treatment sequence 10|Eligible subjects will receive treatment sequence 10; GSK233705 20 micrograms, GSK233705 100 micrograms, Placebo and tiotropium.
88978909|NCT00279019|Experimental|Subjects receiving treatment sequence 11|Eligible subjects will receive treatment sequence 11; Placebo, GSK233705 20 micrograms, tiotropium, and GSK233705 50 micrograms.
88978910|NCT00279019|Experimental|Subjects receiving treatment sequence 12|Eligible subjects will receive treatment sequence 12; Tiotropium, Placebo, GSK233705 20 micrograms and GSK233705 50 micrograms.
88978911|NCT00279019|Experimental|Subjects receiving treatment sequence 13|Eligible subjects will receive treatment sequence 13; Placebo, GSK233705 20 micrograms, GSK233705 50 micrograms and GSK233705 100 micrograms.
89596867|NCT04128046|Experimental|PRFM|Hemi-face injected with PRFM. PRFM was produced from 9 mL of blood (Healeon Medical, Inc).
89596868|NCT04128046|Placebo Comparator|Saline|Hemi-face injected with saline.
89596869|NCT04128124||self-extubation|patients receiving invasive mechanical ventilation who develops an episode of self-removal (voluntary) of the endotracheal tube. Excluding those accidentally removed.
89596870|NCT04128124||spontaneous breathing trial|patients who, according to the attending physician, are clinically ready to initiate and begin a protocolized test (acording to the institutions or unit) to evaluate the readiness to be liberated from mechanical ventilation.
89596871|NCT04127422||Study group|"Patients presenting with current symptoms related to the breast. Adult females aged 18-39 years presenting to the breast outpatient clinic with either mastalgia, nodularity and/or discharge.~A questionnaire, physical examination and bilateral breast ultrasonography will be obtained for all patients.~A- The questionnaire will contain the following items:~symptoms related to the breast.~other medical history.~menstrual history.~obstetric history.~rapid screener for beverages and fast food consumption.~rapid screener for vegetables and fruit consumption.~B- Physical examination will specifically records the following:~breast tender point(s).~breast nodularity.~nipple discharge.~weight, height, body mass index (BMI).~C- bilateral breast ultrasonography for all patients.~D- breast biopsy when clinically indicated as per hospital policy."
88978912|NCT00279019|Experimental|Subjects receiving treatment sequence 14|Eligible subjects will receive treatment sequence 14; GSK233705 20 micrograms, placebo, GSK233705 50 micrograms and GSK233705 100 micrograms.
88978913|NCT00279019|Experimental|Subjects receiving treatment sequence 15|Eligible subjects will receive treatment sequence 15; GSK233705 20 micrograms, GSK233705 100 micrograms, Placebo and GSK233705 50 micrograms.
88978914|NCT00279019|Experimental|Subjects receiving treatment sequence 16|Eligible subjects will receive treatment sequence 16; GSK233705 20 micrograms, GSK233705 100 micrograms, GSK233705 50 micrograms and Placebo.
88978915|NCT02965742|Experimental|The study population: first 25 patients|"The study population consists of patients referred to the Nuclear Medicine and Medical Biophysics Department of the Montpellier University Hospital for the performance of an osteodensitometric examination.~Intervention: Whole body and sub-regions exams using the Stratos Intervention: Whole body and sub-regions exams using the Hologic QDR 4500A Intervention: Whole body and sub-regions exams using the Hologic HORIZON A"
89596872|NCT04127422||Control group|"Age-matched healthy volunteers with no current medical conditions. Adult females aged 18-39 years with no current breast problems. These healthy volunteers will be asked to complete the same questionnaire as per the Study group and have anthropometric measure.~A- The questionnaire will contain the following items:~other medical history.~menstrual history.~obstetric history.~rapid screener for beverages and fast food consumption.~rapid screener for vegetables and fruit consumption.~B- Physical examination will specifically records the following:~1- weight, height, body mass index (BMI)."
89596873|NCT04393714|Experimental|autogenous dentin graft treated with nitric acid|
89596874|NCT04393714|Active Comparator|autogenous dentin graft treated with hydrochloric acid|
89596875|NCT04127500|Experimental|DEX group|use DEX
89596876|NCT04127500|No Intervention|control group|use placebo
89596877|NCT04127344|Experimental|Music Therapy Intervention|"Patients enrolled will be randomised between two arms: Music Therapy Intervention and Non-Music Therapy Intervention.~Patients randomised to a music therapy intervention will receive an individualised music therapy intervention."
89596878|NCT04127344|No Intervention|Non-Music Therapy Intervention|"Patients enrolled will be randomised between two arms: Music Therapy Intervention and Non-Music Therapy Intervention.~Patients allocated to Non-Music Therapy Intervention received standard treatment."
89596879|NCT03017326|Other|Group A Very Low Risk HB|Patients with well differentiated foetal histology will receive 2 cycles of Cisplatin (2x 100mg/m2). Patients will non-well differentiated histology will be followed up only (no intervention).
89596880|NCT03017326|Active Comparator|Group B Low Risk HB|Patients who are resected after 2 cycles of Cisplatin will be randomised to receive 4 or 6 cycles of Cisplatin overall (80mg/m2). Patients who are not resected will continue to receive up to 6 cycles of Cisplatin (80mg/m2) until resection.
89596881|NCT03017326|Active Comparator|Group C Intermediate Risk HB|Patients will be randomised to receive Cisplatin (80mg/m2), Carboplatin (500mg/m2) and Doxorubicin (60mg/m2) as SIOPEL-3HR (5 cycles), Cisplatin (100mg/m2), Doxorubicin (60mg/m2) 5-Fluorouracil (600mg/m2) and Vincristine (4.5mg/m2) as C5VD (6 cycles), or 6 cycles of high dose Cisplatin (100mg/m2)
89596882|NCT03017326|Active Comparator|Group D High Risk HB|Patients will receive SIOPEL-4 regimen (Cisplatin 70mg/m2, Doxorubicin 30mg/m2) then have surgery. Post surgery, patients with remaining metastases will be randomised to receive 6 cycles of either Carboplatin (500mg/m2) and Doxorubicin (40mg/m2) alternating with Carboplatin (800mg/m2) and Etoposide (400mg/m2), or Carboplatin (500mg/m2) and Doxorubicin (40mg/m2) alternating with Vincristine (3mg/m2) and Irinotecan (250mg/m2). Patients with no metastases will receive the standard treatment of 3 cycles of Carboplatin (500mg/m2) and Doxorubicin (40mg/m2).
89596883|NCT03017326|Other|Group E Resected HCC|Patients with an underlying predisposition to HCC through genetic, viral or metabolic conditions will be followed up (no intervention). De novo or fibrolamellar HCC patients will receive 4 cycles of PLADO regimen (Cisplatin (80mg/m2) and Doxorubicin (60mg/m2)) over 4 cycles.
89596884|NCT03017326|Active Comparator|Group F Unresected HCC|Patients will be randomised to receive up to 6 cycles of PLADO (Cisplatin 80mg/m2, Doxorubicin 60mg/m2) with Sorafenib (300mg/m2) or up to 8 cycles of PLADO with Sorafenib and GEMOX (Gemcitabine 1000mg/m2, Oxaliplatin 100mg/m2) with Sorafenib (300mg/m2)
89596885|NCT03014362|Active Comparator|TMS active|"Neuronetics NeuroStar XPLOR magnetic stimulator - Active;~Localization: Left prefrontal dorsolateral neocortex. Dose Delivery: Figure-8 solid core coil at 120% motor threshold, 10 Hz, 4 second train duration, 10 second interval for 30 minutes.~Treatment Dose: ~4k/session, 12-15k/day, 36-45k total pulses. Sessions: 9 in total; 3/day for 3 consecutive days over and above SOC (Standard of Care)."
89596886|NCT03014362|Sham Comparator|TMS sham|"Neuronetics NeuroStar XPLOR magnetic stimulator - Sham;~Localization: Left prefrontal dorsolateral neocortex. Sham Delivery: Figure-8 solid core coil rendered inert via blocking insert. Dose: Zero pulses. Sessions: 9 in total; 3/day for 3 consecutive days over and above SOC."
89596887|NCT04126954||Cinacalcet|Patients with primary or secondary hyperPTH resulting from phosphocalcic pathology treated by cinacalcet
89596888|NCT04126876|Experimental|Tilsotolimod (IMO-2125)|Intradermal, single injection of 1 ml (8 mg) Tilsotolimod (IMO-2125) at the primary melanoma excision site, one week prior to sentinel node biopsy (SNB).
89596889|NCT04126876|Placebo Comparator|Placebo|Intradermal, single injection of 1 ml plain saline (0.9% sodium chloride) at the primary melanoma excision site, one week prior to sentinel node biopsy (SNB).
89596890|NCT04126564|Experimental|IEO Intervention Group|The Group 1 is the active study group which receives the online mindfulness intervention first.
89596891|NCT04126564|Active Comparator|Control Group|Group 2 will be asked to read a book or journal of their choice for first 30 days, and then recieve online mindfulness intervention (IEO).
89596892|NCT04126330|Experimental|Probiotics and Omega-3/vitamin D Supplements- Elderly|
89596893|NCT04126330|Placebo Comparator|Placebo- Elderly|
89596894|NCT04126330|Experimental|Probiotics and Omega-3/vitamin D Supplements- Obese|
89596895|NCT04126330|Placebo Comparator|Placebo- Obese|
88978916|NCT02965742|Experimental|The study population: last 25 patients|"The study population consists of sportsmen patients referred to the Nuclear Medicine and Medical Biophysics Department of the Montpellier University Hospital for the performance of an osteodensitometric examination.~Intervention: Whole body and sub-regions exams using the Stratos Intervention: Whole body and sub-regions exams using the Hologic QDR 4500A Intervention: Whole body and sub-regions exams using the Hologic HORIZON A"
88978917|NCT00279175|Experimental|BMC|Intracoronary infusion of autologous bone marrow derived cells
88978918|NCT00279175|Placebo Comparator|Placebo|Intracoronary infusion of Placebo medium
88978919|NCT00279448|Experimental|A|
88978920|NCT00279448|Active Comparator|B|
88978921|NCT00279487|Active Comparator|Arm 1|Patients will receive 1200mg gabapentin 1-2 hours prior to surgery.
88978922|NCT00279487|Placebo Comparator|Arm 2|Patients will receive placebo 1-2 hours prior to surgery.
88978923|NCT00279799|Experimental|Afiya group intervention + HIV prevention phone sessions|Afiya group-based intervention plus individually tailored HIV prevention phone sessions
88978924|NCT00279799|Active Comparator|Afiya group session + nutrition phone sessions|Afiya group-based intervention plus individually tailored nutrition phone sessions
89596896|NCT04126720|Active Comparator|vitamin E|topical Corticosteroid (Kenacort A Orabase: triamcinolone acetonide 0.1% 5 gram adhesive paste - Dermapharm) four times daily and Vitamin E capsule (Vitamin E 400: 400 mg vitamin E capsules - Pharopharmaceuticles) daily.
89596897|NCT04126720|Placebo Comparator|Placebo|topical Corticosteroid (Kenacort A Orabase: triamcinolone acetonide 0.1% 5 gram adhesive paste - Dermapharm) four times daily and placebo capsule daily
89596898|NCT04126252|Experimental|Group A|This arm received pharmacotherapy for erectile dysfunction.
89596899|NCT04126252|Experimental|Group B|This arm received cognitive behavior psychotherapy for erectile dysfunction.
89596900|NCT04126252|Experimental|Group C|This arm received combined treatment approach.
89596901|NCT04126252|Placebo Comparator|Group D|This arm acted as a control group and received placebo or no intervention.
89596902|NCT04125940|Placebo Comparator|Placebo-controlled Arm|Placebo - 12oz water with food coloring
89596903|NCT04125940|Active Comparator|1 serving Resync Arm|12oz water + 7.5g Resync
89596904|NCT04125940|Active Comparator|2 servings Resync Arm|12oz water + 15g Resync
89596905|NCT04125940|Active Comparator|1 servings Resync+Collagen Arm|12oz water + 17g collagen + 2g Resync + 1g Carbohydrates
89596906|NCT04125628|Experimental|Exercise with cooling|Assigned Interventions 10 MS patients (aged 25----50 years) with Expanded Disability Status Scale between 2 to 6.5 have agreed to participate in this study. The exercise training session involved head cooling and neck wraps. The exercise training session consisted of 40 min continuous cycling where the participants performed an incremental sub-maximal exercise protocol beginning at 45 W, increasing 10 W every 10 min for a total of four stages on a semirecumbent cycle ergometer in a 20oC room. Before and after the completion of the session each participant performed a variety of functional ability tests. The evaluation of the core temperature and the assessment of the patient's quality of life also was performed.
89596907|NCT04125628|Active Comparator|Exercise without cooling|10 MS patients (aged 25----50 years) with Expanded Disability Status Scale between 2 to 6.5 have agreed to participate in this study. The exercise session performed without cooling. The exercise training session consisted of 40 min continuous cycling where the participants performed an incremental sub-maximal exercise protocol beginning at 45 W, increasing 10 W every 10 min for a total of four stages on a semirecumbent cycle ergometer in a 20oC room. Before and after the completion of the session each participant performed a variety of functional ability tests. The evaluation of the core temperature and the assessment of the patient's quality of life also was performed.
89596908|NCT04393480|Active Comparator|Robotic therapy|Robotic rehabilitation and conventional rehabilitation
89596909|NCT04393480|Sham Comparator|Conventional therapy|Conventional rehabilitation
89596910|NCT04393324||Transferred patients|A subgroup of Critically ill intubated patients with COVID-19 associated ARDS were transferred from overwhelmed ICUs to other with available free beds
89596911|NCT04393324||Matched Non-transferred patients|A subgroup from the global cohort, matched for risk factors will be compared with transferred patients for outcome variables
89596912|NCT04393402||Patients with Covid-19 and admitted in critical care unit|
89596913|NCT03007732|Experimental|Cohort 1: Prostate Only Sites (ADT, SBRT, Pembrolizumab)|"Three month androgen deprivation therapy (ADT) run-in followed by leuprolide injected intramuscularly every 3 months for 3 doses (or another FDA approved gonadotropin-releasing hormone agent for 9 months) + abiraterone by mouth daily with prednisone by mouth daily (or equivalent medication per local standard practice) for 9 months starting on Day 1.~Pembrolizumab: Given IV every 21 days for up to 13 doses~Radiotherapy: Given every other day over 10-14 days delivered to the whole prostate gland via stereotactic body radiation therapy (SBRT) starting 1-2 weeks after marker placement."
89596914|NCT03007732|Experimental|Cohort 1: Prostate Only Sites (ADT, SBRT, Pembrolizumab, SD-101)|"Three month androgen deprivation therapy (ADT) run-in followed by leuprolide injected intramuscularly every 3 months for 3 doses (or another FDA approved gonadotropin-releasing hormone agent for 9 months) + abiraterone by mouth daily with prednisone by mouth daily (or equivalent medication per local standard practice) for 9 months starting on Day 1.~TLR9 agonist SD-101: Injected into the dominant prostatic tumor lesion at time of fiducial marker placement (1-5weeks prior to Cycle 1 Day 1) and 1-3 weeks after Cycle 1 Day 1~Pembrolizumab: Given IV every 21 days for up to 13 doses~Radiotherapy: Given every other day over 10-14 days delivered to the whole prostate gland via stereotactic body radiation therapy (SBRT) starting 1-2 weeks after marker placement."
89596915|NCT03007732|Experimental|Cohort 2: Prostate and Oligometastatic sites (ADT, SBRT, Pembrolizumab)|"Three month androgen deprivation therapy (ADT) run-in followed by leuprolide injected intramuscularly every 3 months for 3 doses (or another FDA approved gonadotropin-releasing hormone agent for 9 months) + abiraterone by mouth daily with prednisone by mouth daily (or equivalent medication per local standard practice) for 9 months starting on Day 1.~Pembrolizumab: Given IV every 21 days for up to 13 doses~Radiotherapy: Given every other day over 10-14 days delivered to the whole prostate gland and oligometastatic sites via stereotactic body radiation therapy (SBRT) starting 1-2 weeks after marker placement."
89596916|NCT03007732|Experimental|Cohort 2: Prostate and Oligometastatic sites (ADT, SBRT, Pembrolizumab, SD-101)|"Three month androgen deprivation therapy (ADT) run-in followed by leuprolide injected intramuscularly every 3 months for 3 doses (or another FDA approved gonadotropin-releasing hormone agent for 9 months) + abiraterone by mouth daily with prednisone by mouth daily (or equivalent medication per local standard practice) for 9 months starting on Day 1.~TLR9 agonist SD-101: Injected into the dominant prostatic tumor lesion at time of fiducial marker placement (1-5weeks prior to Cycle 1 Day 1) and 1-3 weeks after Cycle 1 Day 1~Pembrolizumab: Given IV every 21 days for up to 13 doses~Radiotherapy: Given every other day over 10-14 days delivered to the whole prostate gland and oligometastatic sites via stereotactic body radiation therapy (SBRT) starting 1-2 weeks after marker placement."
89031729|NCT05319366||Controls|50 patients without corornary arthery-related treatment will be included and tissue samples from balloon cathether and blood samples will be collected
89210052|NCT00893334||BMD:|Patients diagnosed with Becker Muscular Dystrophy
89596917|NCT03007420|Experimental|Occipital Nerve Block|"After enrollment in the study, patients will be randomized (but not blinded) to receive either an occipital nerve block or a cervical medial branch block. These are injections of anti-inflammatory medications (steroids) and numbing medications (local anesthetics -lidocaine) in nerves located at the back of the head and neck. If patients exhibit a > or = 50% pain reduction on receiving the block evaluated after four weeks, then they may continue to receive blocks as needed, but not more than one every three months.~If patients exhibit < 50% pain reduction, the patient will be treated as per the clinician's judgment with the possibility of a cross over to the other treatment option."
89596918|NCT03007420|Experimental|Cervical Medial Branch Block|"After enrollment in the study, patients will be randomized (but not blinded) to receive either an occipital nerve block or a cervical medial branch block. These are injections of anti-inflammatory medications (steroids) and numbing medications (local anesthetics -lidocaine) in nerves located at the back of the head and neck. If patients exhibit a > or = 50% pain reduction on receiving the block evaluated after four weeks, then they may continue to receive blocks as needed, but not more than one every three months.~If patients exhibit < 50% pain reduction the patient will be treated as per the clinician's judgment with the possibility of a cross over to the other treatment option."
89596919|NCT04125706|Experimental|Mincycline hydrochloride 2% oral gel|Minocycline will be delivered locally in the periodontal pocket.
89596920|NCT04125706|Experimental|Metronidazole hylcate 0.75 % oral gel|Metronidazole gel will be delivered locally in the periodontal pocket.
89596921|NCT04125394|Experimental|NaCl 5%|Hypertonic sodium chloride (NaCl 5%) eye drops solution in single-dose, without preservatives, administered every 8 hours for 28 days.
89596922|NCT04125004|Experimental|virtual reality|Patients will use virtual reality headset during procedure
89596923|NCT04125004|No Intervention|general anesthesia|Patients will undergo general anesthesia for their procedure
89596924|NCT04125082|Other|Type 2 Diabetics|"Participants will be titrated from usual pre-meal insulin plus basal to Afrezza® inhaled insulin plus basal, and will continue on treatment for 14 weeks. Participants will attend study visits at Day 0, Weeks 1, 2, 3, 4, 8, 12 and 16, where insulin titration may be performed based on CGM readings. Participants will receive instruction in carbohydrate counting and corrective insulin dose adjustments.~Participants will wear CMG throughout the study.~At final study visit, CGM system will be collected. A1c, FEV1 and Quality of Life Questionnaires will be collected. Pregnancy test will be collected for all females of child-bearing potential. Participants will be transitioned back to Multiple Daily Injections plus basal or may choose to continue on commercial Afrezza® inhaled insulin plus basal"
89596925|NCT04125160||Type 2 diabetes and peritoneal dialysis|Case group with type 2 diabetes undergoing peritoneal dialysis for at least 3 months.
89596926|NCT04125160||Type 2 diabetes and eGFR above 60ml/min|Control group with type 2 diabetes and no nephropathy (defined as eGFR above 60ml/min and UACR below 300mg/g).
89596927|NCT04393246|Active Comparator|Standard of care|Standard of care
89596928|NCT04393246|Experimental|EDP1815|1.6 x 10^11 cells dosage-in-capsule orally twice per day for up to 7 days (with the option to extend up to 14 days), on top of standard of care
89596929|NCT04393246|Experimental|Dapagliflozin and Ambrisentan|Ambrisentan 5mg tablet orally once per day for up to a maximum of 14 days and Dapagliflozin 10mg tablet orally once per day for up to a maximum of 14 days, on top of standard of care
89596930|NCT01923181|Experimental|1:Semaglutide tablets : 2.5 mg|2.5 mg for 26 weeks. All arms include 26 weeks of treatment and a 5 week follow-up period. The trial medication will be add-on to metformin therapy or as monotherapy in the case where the subject is treated with diet and exercise alone.
89596931|NCT01923181|Experimental|2:Semaglutide tablets: 2.5 mg/5 mg|2.5 mg for 4 weeks, then 5.0 mg for 22 weeks. All arms include 26 weeks of treatment and a 5 week follow-up period. The trial medication will be add-on to metformin therapy or as monotherapy in the case where the subject is treated with diet and exercise alone.
89596932|NCT01923181|Experimental|3:Semaglutide tablets: 5.0 mg/10 mg|5.0 mg for 4 weeks, then 10 mg for 22 weeks. All arms include 26 weeks of treatment and a 5 week follow-up period. The trial medication will be add-on to metformin therapy or as monotherapy in the case where the subject is treated with diet and exercise alone.
89596933|NCT01923181|Experimental|4:Semaglutide tablets:5.0 mg/10 mg/20 mg|5.0 mg for 4 weeks, then 10 mg for 4 weeks, then 20 mg for 18 weeks. All arms include 26 weeks of treatment and a 5 week follow-up period. The trial medication will be add-on to metformin therapy or as monotherapy in the case where the subject is treated with diet and exercise alone.
89596934|NCT01923181|Experimental|5:Semaglutide tablets:5.0 mg/10 mg/20 mg/40 mg|"5.0 mg for 4 weeks, then 10 mg for 4 weeks, then 20 mg for 4 weeks, then 40 mg for 14 weeks.~All arms include 26 weeks of treatment and a 5 week follow-up period. The trial medication will be add-on to metformin therapy or as monotherapy in the case where the subject is treated with diet and exercise alone."
89596935|NCT01923181|Experimental|6:Semaglutide tablets:5.0 mg/10 mg/20 mg/40 mg|5.0 mg for 8 weeks, then 10 mg for 8 weeks, then 20 mg for 8 weeks, then 40 mg for 2 weeks All arms include 26 weeks of treatment and a 5 week follow-up period. The trial medication will be add-on to metformin therapy or as monotherapy in the case where the subject is treated with diet and exercise alone.
89596936|NCT01923181|Experimental|7:Semaglutide tablets: 5.0 mg/10 mg/20 mg/40 mg|"5.0 mg for 2 weeks, then 10 mg for 2 weeks, then 20 mg for 2 weeks, then 40 mg for 20 weeks.~All arms include 26 weeks of treatment and a 5 week follow-up period. The trial medication will be add-on to metformin therapy or as monotherapy in the case where the subject is treated with diet and exercise alone."
89596937|NCT01923181|Placebo Comparator|8:Placebo tablets|All arms include 26 weeks of treatment and a 5 week follow-up period. The trial medication will be add-on to metformin therapy or as monotherapy in the case where the subject is treated with diet and exercise alone.
89596938|NCT01923181|Active Comparator|9:Semaglutide injections :0.25 mg/0.50 mg/1.0 mg|0.25 mg for 4 weeks, then 0.50 mg for 4 weeks, then 1.0 mg for 18 weeks. All arms include 26 weeks of treatment and a 5 week follow-up period. The trial medication will be add-on to metformin therapy or as monotherapy in the case where the subject is treated with diet and exercise alone.
88978925|NCT00416767|Experimental|FOLFIRI|
88978926|NCT00280033|Placebo Comparator|9|Saline administered on days 0 and 28.
88978927|NCT00280033|Experimental|8|45 mcg alone administered on days 0 and 28.
89596939|NCT04124224||Unidos Participants|In the Unidos intervention the county/community-based CHWs will: 1) support and connect participants to health promotion resources; 2) provide individual and group-based support guided by a novel framework for understanding Latino's health advantages, the sociocultural resiliency model; and, 3) leverage community resources to help individuals address SDH-related needs.
89596940|NCT04124224||Non-Unidos Participants: Comparison Group|Using propensity score matching, the investigators will use the medical records of Unidos participants and the electronic health record comparison group to compare health outcomes.
89596941|NCT04124302|Active Comparator|IPF|Total meal bolus will consist of insulin for carbohydrates (IC) and insulin for proteins and fats (IPF) based on individual insulin-to-carbohydrate ratio (ICR). Dual bolus will be given 15 minutes before the mixed meal (toast with cheese).
89596942|NCT04124302|Experimental|30%IC|Total meal bolus will consist of insulin for carbohydrates (IC) calculated based on individual insulin-to-carbohydrate ratio (ICR) and insulin for proteins and fats (IPF) estimated as 30% of IC. Dual bolus will be given 15 minutes before the mixed meal (toast with cheese).
89596943|NCT04123990|Experimental|IBD|
89596944|NCT04124068|Experimental|GLO Science Professional Chairside Teeth Whitening|
89596945|NCT04124068|Experimental|GLO Science Professional At-Home Teeth Whitening Device|
89596946|NCT04124068|Experimental|GLO Brilliant At-Home Teeth Whitening Device|
89596947|NCT04124068|Experimental|GLO Lit At-Home Teeth Whitening Device|
89596948|NCT04124068|Experimental|GLO Lit Whitening GLO Vials|
89596949|NCT04411069|No Intervention|Patients without previous CINV|Patients who didn't have chemotherapy or that didn´t have any nausea and/or vomiting induced by chemotherapy (CINV) before surgery
89596950|NCT04411069|Other|Patients with previous CINV|Patients who had previous nausea and vomiting induced by chemoterapy.
89596951|NCT04123912|Experimental|KT-FMPT group|
89596952|NCT04123912|Placebo Comparator|Control group|
89596953|NCT04124146||Patients with Surgery more than 10 years|Patients with surgery for spinal lumbar stenosis between 2006 and 2008 will be purposed to participate to the study.
89596954|NCT01896271|Experimental|treatment|HD IL-2 (brand name Proleukin), 600,000 U/kg q8h X 14 dose, IV infusion; SABR dose varying from 8Gy-20Gy in 1-3 fractions.
89596955|NCT01884571|Experimental|Immunosuppression Regimen|Basiliximab Methylprednisolone Prednisone Tacrolimus Mycophenolate mofetil
89596956|NCT04123678||All|Patients attending a Medical Photography facility with at least 1 suspicious skin lesion will be approached to participate in the study. Participants will have an additional macro and dermoscopic image of each suspicious skin lesions suitable for photography. Photographs will be taken by a healthcare professional using an iPhone XR smart phone camera with a DL1 dermoscopic lens attachment. The images will be encrypted and electronically transmitted to Skin Analytics' cloud servers for analysis by DERM. The suspected diagnosis determined by DERM will be compared with dermatologist review and histologically confirmed diagnosis, where obtained. Healthcare resource utilization information and patient satisfaction data will also be collected
89596957|NCT04123522||anterior cervical spine surgery|The patients will be enrolled for elective anterior cervical spine surgery.
89596958|NCT04123522||posterior cervical spine surgery|The patients will be enrolled for elective postieor cervical spine surgery
89596959|NCT01884337|Experimental|Apixaban (2.5 mg)|Apixaban 2.5 mg tablets by mouth twice daily, 12 days for TKR subjects or 35 days for THR subjects
89596960|NCT02996890|Experimental|High dose - single shot|MV-ZIKA, high dose, one vaccination, day 0
89596961|NCT02996890|Experimental|Low dose|MV-ZIKA, low dose, two vaccinations, day 0 and day 28
89596962|NCT02996890|Experimental|High dose|MV-ZIKA, high dose, two vaccinations, day 0 and day 28
88978928|NCT00280033|Experimental|7|30 mcg plus aluminum hydroxide administered on days 0 and 28.
88978929|NCT00280033|Experimental|6|30 mcg alone administered on days 0 and 28.
89596963|NCT02996890|Placebo Comparator|Placebo|Physiological saline, two treatments
89596964|NCT04123288|Experimental|Test drug formulation|Test drug 60 mg single dose
89596965|NCT04123288|Active Comparator|Reference drug formulation|60 mg single dose
89596966|NCT04392934|Experimental|flat shape acromion group|a conservative physiotherapy protocol was applied for 4 weeks
89596967|NCT04392934|Experimental|curved shape acromion group|a conservative physiotherapy protocol was applied for 4 weeks
89596968|NCT04392934|Experimental|hooked shape acromion group|a conservative physiotherapy protocol was applied for 4 weeks
89596969|NCT04123210|Experimental|Vitamin A supplement|Subjects receive a vitamin A supplement containing 175 or 525 micrograms of vitamin A as retinyl palmitate daily
89596970|NCT04123210|Placebo Comparator|Placebo|Subjects receive an oil placebo containing no vitamin A
89596971|NCT02994550|Experimental|FSH/LH 2/1|dose: 300IU FSHrec and 150IU LHrec
89596972|NCT02994550|Experimental|FSH/LH 4/1|dose: 300IU FSHrec and 75IU LHrec
89596973|NCT04123132||Patients with metabolic syndrome|
89596974|NCT04123132||Healthy controls|
89596975|NCT01922089|Experimental|LCZ696 Condensed|Up-titration to LCZ696 200 mg twice daily (bid) over 3 weeks
89596976|NCT01922089|Experimental|LCZ696 Conservative|Up-titration to LCZ696 200 mg bid over 6 weeks
89596977|NCT04122664|Active Comparator|RayOne® Hydrophilic lens 600C|Patients will be randomly selected to receive the monofocal, acrylic, RayOne® Hydrophilic lens 600C
89596978|NCT04122664|Active Comparator|RayOne® Hydrophobic lens 800C|Patients will be randomly selected to receive the monofocal, acrylic, RayOne® Hydrophobic lens 800C
89596979|NCT04122430||GCT treated with first line chemotherapy|"Men with disseminated Germ Cell Tumours-GCT (AJCC Stage IS, 2, or 3) and have received first line chemotherapy with curative intent for disseminated GCT~."
89596980|NCT04122586|No Intervention|health control group|
89596981|NCT04122586|Experimental|Tongxieyaofang granule group|
89596982|NCT04122820|Other|Presence of HV-Labile|Presence of vertical heterophoria labile with proprioceptive Maddox
89596983|NCT04122820|Other|Absence of HV-Labile|Presence of stable vertical heterophoria or stable orthophoria with proprioceptive Maddox
89596984|NCT04121884|Experimental|ART Treatment|A broad patient representation of male and female adults; aged > 18 years; English speaking; and significant clinical symptoms of any of the following conditions: PTSD, Depression, ASD, Complicated Grief, and Alcohol Abuse.
89596985|NCT01884025|Experimental|Get Moving and Get Well|Walking class developed for Veterans with serious mental illness and administered as part of the PRRC
89596986|NCT01884025|Sham Comparator|Health and Humor Class|Equally engaging attention control condition
89596987|NCT04121494|Experimental|Group A|BCG-vaccinated, 1x10^9 vp, aerosol
89596988|NCT04121494|Experimental|Group B|BCG-vaccinated, 5x10^9 vp, aerosol
89596989|NCT04121494|Experimental|Group C|BCG-vaccinated, 1x10^10 vp, aerosol
89596990|NCT04121494|Experimental|Group D|BCG-vaccinated, highest tolerated dose aerosol + placebo IM; Randomized with Group E, blind
89596991|NCT04121494|Experimental|Group E|BCG-vaccinated, highest tolerated dose IM + placebo aerosol; Randomized with Group D, blind
89596992|NCT04121494|Experimental|Group F|BCG-non vaccinated, highest tolerated dose, aerosol
89596993|NCT04121416|Experimental|Oxycodone group|
89596994|NCT04121416|Experimental|Sufentanil group|
89596995|NCT02983864|Active Comparator|Alcohol and Relaxation|This arm will receive a brief (2-hour) alcohol intervention based on motivational interviewing termed BASICS and a brief (1.5 hour) relaxation intervention
89596996|NCT02983864|Active Comparator|Alcohol and Relationships|This arm will receive a brief (4-hour), two session, integrated alcohol and relationship intervention based on motivational interviewing designed to increase healthy alcohol use and sexual behavior. The interventions are based on an integrated BASICS and integrated Bystander protocols
89596997|NCT04121338|Experimental|Test group|10 patients with presumptive diagnosis of dysautonomia with chronic nausea, vomiting and food intolerance
89596998|NCT01896193|Experimental|SOF+RBV 16 Weeks|SOF+RBV for 16 weeks
89596999|NCT01896193|Experimental|SOF+RBV 24 Weeks|SOF+RBV for 24 weeks
89597000|NCT04121104|Experimental|SCS off|
89597001|NCT04121104|Experimental|SCS on|
89597002|NCT04120792|Experimental|Simultaneous exercise and cognitive training|Participants in this arm will engage in a 12-week intervention that combines physical exercise and cognitive tablet-based training. This intervention involves use of an exercise bicycle while engaging in cognitive tasks on a tablet computer three times per week.
89597003|NCT04120792|Active Comparator|Exercise training|Participants in this arm will engage in a 12-week exercise intervention that involves use of an exercise bicycle three times per week.
89597004|NCT04120792|Active Comparator|Cognitive training|Participants in this arm will engage in a 12-week intervention that involves cognitive tablet-based training three times per week.
89597005|NCT04120792|Active Comparator|Neutral Video|Participants in this arm will engage in a 12-week intervention that involves watching neutral videos on a tablet computer three times per week.
89597006|NCT04393012|Experimental|Noddle Group|Patients who received noddle to allow access to the nurse call system.
89597007|NCT01922011|Experimental|Daptomycin|Intravenous (IV) daptomycin was dosed as follows: age 12 years to <18 years (7 mg/kg); age 7 years to < 12 years (9 mg/kg); age 24 months to <7 years (12 mg/kg); age 12 months to <24 months (12 mg/kg). Drug was infused over 60 minutes ± 10 minutes once daily followed by up to 3 dummy infusions every 6 hours (q6h) infused over 60 (± 10) min to maintain the blind.
89597008|NCT01922011|Active Comparator|Vancomycin or Nafcillin|IV vancomycin (or equivalent), 10 to 15 mg/kg, was infused over 60 (± 10) minutes q6h (± 1 hour) or IV nafcillin (or β-lactam equivalent) at 100-200 mg/kg/day, in divided doses was infused over 60 (± 10) min q6h (± 1 hour)
89597009|NCT04120090|Active Comparator|Low dose|
89597010|NCT04120090|Experimental|High dose|
89597011|NCT01883635|Active Comparator|Individual Exercise Intervention|Survivor-only progressive walking and resistance exercise
89597012|NCT01883635|Experimental|Dyadic Exercise Intervention|Dyadic progressive walking and resistance exercise
89597013|NCT02983786||Non-Invasive Monitoring|"One non-invasive optode patch will be placed adjacent to the area of invasive monitoring and the second patch will be placed contralaterally. (12 hrs. daily is chosen primarily for budgetary reasons). The information for the non-invasive technology will be compared to the invasive technology.~ICG (Indocyanine Green) will be injected to derive absolute CBF and calibrate the DCS monitor to yield continuous absolute CBF. During each 12-hour monitoring session, for up to 14 days, the ICG will be injected at baseline(0.2 mg/kg,(4), every four hours (or less if signal is stable)."
89597014|NCT04127968|Experimental|intervention group|Septic children with vitamin A deficiency who will receive vitamin A supplementation.
88978930|NCT00280033|Experimental|5|15 mcg plus aluminum hydroxide administered on days 0 and 28.
88978931|NCT00280033|Experimental|4|15 mcg plus MF59 administered on days 0 and 28.
89597015|NCT04127968|Placebo Comparator|control group|Septic children with vitamin A deficiency who will receive placebo.
89597016|NCT01921387|Experimental|Treatment (90Y-BC8-DOTA, chemotherapy, PBSC)|Patients receive yttrium Y 90 anti-CD45 monoclonal antibody BC8 IV on day -14. Patients also receive carmustine IV over 3 hours on day -7, etoposide IV over 2 hours BID on days -6 to -3, cytarabine IV over 4 hours BID on days -6 to -3, and melphalan IV over 30 minutes on day -2. Patients then undergo autologous PBSC transplant on day 0.
89597017|NCT04129996|Experimental|camrelizumab in combination with nab-paclitaxel and famitinib|
89597018|NCT03179644|Experimental|Bi-pulmonary transplantation|Adult patient admitted in the Respiratory Distress and Severe Infections Intensive Care Unit in the postoperative period following a double lung transplant after written informed consent.
89597019|NCT04129216|Experimental|Tamoxifen arm|for premenopausal patients
89597020|NCT04129216|Experimental|Letrozole arm|for postmenopausal patients
89597021|NCT04129216|Experimental|Exemestane arm|for postmenopausal patients
89597022|NCT04125784||Lipid-profile|The cohort includes male and female patients diagnosed and confirmed HIV diagnosis who receive HIV related treatment in an extramural setting. All patients are adults (older than 18 years old) and have participated in the original study in 2014.
89597023|NCT04122274|Sham Comparator|Education Sheet and Sham Intervention|Participants will be asked to fill out a pre-intervention survey to assess existing concussion knowledge, perceived norms, attitudes, and behavioral intentions. Afterward, the NCAA concussion education fact sheet will be viewed along with the viewing of the sham intervention. Following the intervention, a post-intervention survey re-assessing the constructs from the pre-intervention survey will be completed. May be completed in-person or virtually.
89597024|NCT04122274|Experimental|Education Sheet and Decision-based interactive intervention|Participants will be asked to fill out a pre-intervention survey to assess existing concussion knowledge, perceived norms, attitudes, and behavioral intentions. Afterward, the NCAA concussion education fact sheet will be viewed along with the viewing of a decision- based interactive concussion education platform intervention. Following the intervention, a post-intervention survey re-assessing the constructs from the pre-intervention survey will be completed. May be completed in-person or virtually.
89597025|NCT04120558||Through knee amputees|Community dwelling individuals with through knee amputation of all mobility levels.
89597026|NCT04120558||Above knee amputees|Community dwelling individuals with above knee amputation of all mobility levels.
89597027|NCT04393168|Experimental|Patients with unilateral arm or leg lymphedema|
88978932|NCT00280033|Experimental|3|15 mcg alone administered on days 0 and 28.
88978933|NCT00280033|Experimental|2|7.5 mcg plus aluminum hydroxide administered on days 0 and 28.
88978934|NCT00280033|Experimental|1|7.5 mcg plus MF59 administered on days 0 and 28.
88978935|NCT00076154||Group 1|
88978936|NCT00280111|Experimental|1|116E AGMK
88978937|NCT00280111|Experimental|2|I321 AGMK
88978938|NCT00280111|Placebo Comparator|3|Placebo
88978939|NCT00280228|Experimental|1|Home Based Treatment
88978940|NCT00280228|Active Comparator|2|Treatment as Usual
88978941|NCT00076232|Experimental|1|Participants will receive acyclovir for the duration of the study
88978942|NCT00076232|Placebo Comparator|2|Participants will receive acyclovir placebo for the duration of the trial
88978943|NCT00280462|Active Comparator|1|Nifedipine
88978944|NCT00280462|Active Comparator|2|L-Arginin
88978945|NCT00280462|Placebo Comparator|3|Placebo
88978946|NCT00280501|Active Comparator|1|Quetiapine
88978947|NCT00280501|Active Comparator|2|Sulpiride
88978948|NCT00280501|Placebo Comparator|3|Placebo
88978949|NCT00280579||Cases|Cases would have had their blood cyanide concentration measured
88978950|NCT00076349|Experimental|1|open-label, single arm, clinical trial of bendamustine (SDX-105) plus rituximab
88978951|NCT00280696|Experimental|Lev 0.5 g|Levetiracetam 0.5 g/day as add-on therapy to ongoing treatment with 1 to 3 AED(s) administered orally twice daily (in the morning and evening).
88978952|NCT00280696|Experimental|Lev 1 g|Levetiracetam 1 g/day as add-on therapy to ongoing treatment with 1 to 3 AED(s) administered orally twice daily (in the morning and evening).
88978953|NCT00280696|Experimental|Lev 2 g|Levetiracetam 2 g/day as add-on therapy to ongoing treatment with 1 to 3 AED(s) administered orally twice daily (in the morning and evening).
88978954|NCT00280696|Experimental|Lev 3 g|Levetiracetam 3 g/day as add-on therapy to ongoing treatment with 1 to 3 AED(s) administered orally twice daily (in the morning and evening).
88978955|NCT00280696|Placebo Comparator|Placebo|Placebo tablets as add-on therapy to ongoing treatment with 1 to 3 AED(s) administered orally twice daily (in the morning and evening).
88978956|NCT00109512|Placebo Comparator|placebo|
88978957|NCT00109512|Experimental|NBI-56418 75 mg|
88978958|NCT00109512|Experimental|NBI-56418 150 mg|
88978959|NCT00280813|Active Comparator|Supportive Treatment in Alcohol Recovery (STAR)|
88978960|NCT00280969|Experimental|atazanavir arm|Patients are treated with ritonavir 100mg boosted atazanavir 300mg along with Epzicom.
88978961|NCT00280969|Active Comparator|efavirenz arm|Patients are treated with efavirenz 300mg along with Epzicom.
88978962|NCT00281008|Experimental|Cohort A|Loading doses followed by weekly maintenance doses
88978963|NCT00281008|Experimental|Cohort B|Loading doses followed by weekly maintenance doses
88978964|NCT00281008|Experimental|Cohort C|Loading doses followed by weekly maintenance doses
88978965|NCT00281008|Experimental|Cohort D|Loading doses followed by extended weekly maintenance doses
88978966|NCT00281203||healthy smokers|Must be free of serious diseases that might make it dangerous to undergo bronchoscopy.
88978967|NCT00109746|Active Comparator|Chromium Picolinate|HIV+ and control may receive 500µg of chromium picolinate or placebo twice daily for two months.
88978968|NCT00109746|No Intervention|Placebo|HIV+ and control may receive 500µg of chromium picolinate or placebo twice daily for two months.
88978969|NCT00281242||Research subjects|All participants undergo the same testing in this observational trial. There is no randomization, and no interventions other than blood drawing.
88978970|NCT00279877|Active Comparator|vertebroplasty|vertebroplasty
88978971|NCT00279877|Active Comparator|kyphoplasty|kyphoplasty
88978972|NCT04730297|Active Comparator|Paracetamol/codeine Group A|analgesic group preoperative oral dose of paracetamol 500 mg plus codeine 30 mg
88978973|NCT04730297|Active Comparator|Ibuprofen Group B|analgesic group preoperative oral dose of ibuprofen 400 mg
88978974|NCT04730297|Placebo Comparator|Placebo Group C|Placebo group preoperative placebo
89031730|NCT05319366||Vascular surgery|25 patients who undergo will be included and tissue samples and blood samples will be collected
89031731|NCT00515333|Placebo Comparator|1|Placebo: 0 milligrams; t.i.d.
89031732|NCT00515333|Active Comparator|2|Treatment group: 30 milligrams; t.i.d.
89210053|NCT00893334||LGMD2A|patient diagnosed with Limb-Girdle Muscular Dystrophy, type 2A Calpain-3 deficiency
89597028|NCT02983708|Experimental|mPBMC group|G-CSF would be administered for 5 days and then mobilized peripheral blood mononuclear cells (mPBMCs) would be collected in all included patients. One month after cryopreservation of the mPBMCs (M1), patients will be randomized to receive either mPBMCs or placebo. Six months after randomization (M7), cross-over infusion of mPBMCs or placebo will be performed and the patients are observed for another 6 months. mPBMCs group would be included all patients who received mPBMCs at M1 or M7.
89597029|NCT02983708|Placebo Comparator|Placebo group|G-CSF would be administered for 5 days and then mobilized peripheral blood mononuclear cells (mPBMCs) would be collected in all included patients. One month after cryopreservation of the mPBMCs (M1), patients will be randomized to receive either mPBMCs or placebo. Six months after randomization (M7), cross-over infusion of mPBMCs or placebo will be performed and the patients are observed for another 6 months. Placebo group would be included all patients who received placebo at M1 or M7.
89597030|NCT02979496|Other|0 g pomace (control)|16 oz of juice containing 0 g of citrus pomace will be consumed each day for 3 weeks by participants in the group receiving this assignment (group is unknown, double-blinded).
89597031|NCT02979496|Experimental|90 g pomace|16 oz of juice containing 90 g of citrus pomace will be consumed each day for 3 weeks by participants in the group receiving this assignment (group is unknown, double-blinded).
89597032|NCT02979496|Experimental|180 g pomace|16 oz of juice containing 180 g of citrus pomace will be consumed each day for 3 weeks by participants in the group receiving this assignment (group is unknown, double-blinded).
89597033|NCT02979496|Other|Flavored water (control)|16 oz of a flavored, calorie-matched water beverage will be consumed each day for 3 weeks by participants in the group receiving this assignment (group is unknown, double-blinded).
89597034|NCT03824080|Experimental|Bemcentinib|"Bemcentinib will be self-administered orally (fasted) at a dose mentioned above for a total of at least 4 cycles without a treatment-free period in between.~Responding patients (as per criteria of European LeukaemiaNet and International MDS working Group (2006)) are eligible for up to 5 additional cycles according to the maintenance daily dosing of 2 x 1 capsules of 100 mg for each 28 days cycle (up to 9 cycles in total)."
89597035|NCT01895335|Experimental|Teriflunomide|Teriflunomide 14 mg or 7 mg according to local labelling once daily (QD) orally for 48 weeks.
89597036|NCT03829696|Experimental|Non-pregnant women|"Participants will be provided Mifeprex® (oral mifepristone 200 mg) and misoprostol 800 mcg to be administered buccally (at 24-48 hours following mifepristone) or vaginally (as soon as 6 hours following mifepristone) if unintended pregnancy occurs during the study period and the participant would like to end of the pregnancy. Participants who test positive for pregnancy will consult with a study clinician over the phone prior to administering mifepristone and misoprostol, and will then attend an in-person follow-up visit.~All participants will be provided with a single dose of ella® (ulipristal acetate emergency contraception 30 mg) by a clinician at the beginning of the study, as well as 6 AccuHome® midstream urine pregnancy tests."
89597037|NCT03829774|Experimental|Primary Relief v 2.0 Device|The test product or device called Primary Relief v 2.0 device will be used for the study. The study will be conducted for a period of two to three months with the treatment period of 3 - 4 days i.e single treatment (installation). The additional time taken will be to define the characteristics of the patient population and to recruit appropriate patients. Finally, there will be a data analysis and report writing period. Overall, the study is expected to 3 months. The device will be placed onto the auricle part of the ear for percutaneous electrical nerve stimulation.
89597038|NCT03829774|Placebo Comparator|Paracetamol|A control group, receiving a standard treatment as follows: primary choice of analgesic was intravenous Paracetamol , 1 gram, and if the pain relief was inadequate, diclofenac inj. If pain persisted in spite of these measures, 50 mg tramadol was administered intravenously
89597039|NCT02974738|Experimental|Part 1A|"Drug: PART 1A: Belzutifan for the treatment of advanced solid tumors~Belzutifan inhibits HIF-2α and is a novel approach to treatment of solid tumors."
89597040|NCT02974738|Experimental|Part 1B|"Drug: PART 1B: Belzutifan for the treatment of advanced ccRCC~Belzutifan inhibits HIF-2α and is a novel approach to treatment of ccRCC."
89597041|NCT02974738|Experimental|Part 2|"Drug: Part 2: Belzutifan for the treatment of other specified solid tumors~Belzutifan inhibits HIF-2α and is a novel approach to treatment of specified solid tumors."
88978975|NCT00281359|Experimental|With heat|heat applied to contracted tissues prior to using the active stretching orthosis.
88978976|NCT00281359|Placebo Comparator|Without heat|No heat applied to the contracted tissues prior to using the stretching orthosis
88978977|NCT00109785|Experimental|PET Scans|The first group of positron emission tomography (PET) scans is performed within 2 weeks before the first dose of chemotherapy. The second group of PET scans occur no more than 7 weeks after chemotherapy and prior to local therapy, either surgery or radiation therapy. The PET scan before initiation of chemotherapy consists of 4 imaging sessions. There is one iodine I-124 iododeoxyuridine (IUdR) PET scan (3 imaging sessions) at 1, 4-8, and 24 hours after IUdR infusion, followed by one fludeoxyglucose (FDG) PET scan (1 imaging session) 45 minutes after FDG infusion.
88978978|NCT00416923|Experimental|intrathecal rituximab|3 dose levels of intrathecal rituximab, 10mg, 25mg, 50mg
88978979|NCT00109824|Experimental|Arm I|Patients receive decitabine IV over 1 hour on days 1-5 or 1-10. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
88978980|NCT00109824|Experimental|Arm II|Patients receive decitabine as in stage 1 and valproic acid PO TID on days 5-21. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
89597042|NCT02974738|Experimental|Part 2A|"Drug: Part 2A: Belzutifan for the treatment of patients with recurrent GBM who have been previously treated with radiation therapy and temozolomide~Belzutifan inhibits HIF-2α and is a novel approach to treatment of specified solid tumors."
89597043|NCT02972398|Experimental|NAC group|"Participants of NAC group receive 1000 mg NAC twice daily for 12 weeks as add-on to either a selective serotonin reuptake inhibitor (SSRI) or a serotonin and noradrenalin reuptake inhibitor (SNRI)"
89597044|NCT02972398|Placebo Comparator|Placebo group|"Participants of Placebo group receive placebo matched with NAC twice daily for 12 weeks as add-on to either a selective serotonin reuptake inhibitor (SSRI) or a serotonin and noradrenalin reuptake inhibitor (SNRI)"
89597045|NCT02971072|Experimental|Patients|Subjects with shoulder tendinopathy who will undergo both a subacromial injection and physical therapy
89597046|NCT04392778|No Intervention|Untreated|Group 1: patients that are not on a ventilator (n=10) No extra intervention will be done.
89597047|NCT04392778|Sham Comparator|Saline Control|Group 2: patients that are on a ventilator and will receive saline injections (n=10) as control for MSC transplantation group (3).
89597048|NCT04392778|Experimental|Experimental UC-MSCs|Group 3: patients that are on a ventilator and will receive MSC transplantation injections (n=10)
89597049|NCT01617655|Placebo Comparator|Placebo Q2W|Placebo for alirocumab subcutaneous (SC) injection every two weeks (Q2W) on top of stable lipid-modifying therapy (LMT) for 78 weeks.
89597050|NCT01617655|Experimental|Alirocumab 150 mg Q2W|Alirocumab 150 mg SC injection Q2W on top of stable LMT for 78 weeks.
89597051|NCT04758910|Active Comparator|High Flow Oxygen Therapy|Tracheostomized patients will undergo a spontaneous breathing trial with high flow oxygen therapy.
89597052|NCT04758910|Active Comparator|T-piece|Tracheostomized patients will undergo a spontaneous breathing trial with T-piece as a standard of care.
89597053|NCT03828916|Other|NuShield|
89597054|NCT02965768|Active Comparator|LDN arm|Naltrexone HCl 4.5mg (standard-dose) or 3.0mg (optional-dose) x24 weeks
89597055|NCT02965768|Other|Placebo/LDN arm|"Naltrexone HCl 4.5mg (standard-dose) or 3.0mg (optional-dose) Placebo~Individuals will be switched between drugs as per approved schedule during the 24 weeks."
89597056|NCT01895101|Placebo Comparator|pericardial lavage with 200 ml normothermic saline solution|"According to the anaesthetic protocol of the Amphia Hospital (Breda, the Netherlands), all patients scheduled for cardiac surgery receive intravenously 2 gr TA before sternal incision and 2 gr TA after cardiopulmonary bypass.~This arm also receives pericardial lavage with 200 ml normothermic saline solution without tranexamic acid."
89597057|NCT01895101|No Intervention|No pericardial lavage|"According to the anaesthetic protocol of the Amphia Hospital (Breda, the Netherlands), all patients scheduled for cardiac surgery receive intravenously 2 gr TA before sternal incision and 2 gr TA after cardiopulmonary bypass.~In this arm the subjects receives as in standard care no pericardial lavage."
89597058|NCT01895101|Experimental|2 gr tranexamic acid diluted in 200 ml normothermic saline|"According to the anaesthetic protocol of the Amphia Hospital (Breda, the Netherlands), all patients scheduled for cardiac surgery receive intravenously 2 gr TA before sternal incision and 2 gr TA after cardiopulmonary bypass.~This arm receives also pericardial lavage with 2 gr TA diluted in 200 ml normothermic saline solution (NaCl 0.9%)."
89597059|NCT03828682|Experimental|Prospective Arm|"De novo kidney transplant recipients receiving:~rabbit antithymocyte globulin induction (1.5mg/kg, dosage range 4-6mg/kg total dose over 5-10 days) 5-day steroid withdrawal (methylprednisolone 500mg IV on day 1 (day of transplant), 250mg IV on day 2, 125mg IV on day 3, prednisone 80mg PO on day 4, 60mg PO on day 5 and then no more steroids Once-daily tacrolimus XR 0.8mg/kg/day started when or when serum creatinine is <4mg/dL or by 48 hours of transplant to target 24-hr trough levels of 8-12ng/mL up to day 30 followed by 24-hour trough targets of 5-10ng/mL Mycophenolate mofetil (1000 mg PO BID) or mycophenolic acid (720mg PO BID) twice daily started prior to surgery"
89597060|NCT03828682|Active Comparator|Comparator arm|"Historical control arm consisting of the following~De novo kidney transplant recipients receiving:~rabbit antithymocyte globulin induction (1.5mg/kg, dosage range 4-6mg/kg total dose over 5-10 days) 5-day steroid withdrawal (methylprednisolone 500mg IV on day 1 (day of transplant), 250mg IV on day 2, 125mg IV on day 3, prednisone 80mg PO on day 4, 60mg PO on day 5 and then no more steroids Twice-daily tacrolimus 0.1mg/kg/day started when or when serum creatinine is <4mg/dL or by 48 hours of transplant to target 12-hr trough levels of 8-12ng/mL up to day 30 followed by 12-hour trough targets of 5-10ng/mL Mycophenolate mofetil (1000 mg PO BID) or mycophenolic acid (720mg PO BID) twice daily started prior to surgery"
89597061|NCT03483649|Experimental|HLX04|
89597062|NCT03483649|Active Comparator|United States (US) Avastin®|
89597063|NCT03483649|Active Comparator|European Union (EU) Avastin®|
89597064|NCT03483649|Active Comparator|China (CN) Avastin®|
89597065|NCT03822208|Active Comparator|AL003 by intravenous (IV) infusion|Single-doses of AL003 in dose-escalating cohorts Multiple doses of AL003 in single cohort
89597066|NCT03822208|Placebo Comparator|Placebo by intravenous (IV) infusion|Matching saline solution will be administered for placebo subjects
89031733|NCT00515333|Active Comparator|3|Treatment group: 60 milligrams; t.i.d.
89031734|NCT00515333|Active Comparator|4|Treatment group: 100 milligrams; t.i.d.
89031735|NCT02943174|Experimental|MIND Programme for cancer|"MIND programme for cancer is a manualized acceptance, mindfulness and compassionate-based group intervention for cancer patients. It included 8 weekly group sessions, 2h hours each, run in small groups (ranging from 6 to 12 participants).~Participants in this group also receive cancer treatment as usually performed at the Coimbra University Hospital."
89031736|NCT02943174|Other|Treatment as Usual (TAU)|Cancer treatment as usually performed at the Coimbra University Hospital.
89031737|NCT02941887||Down's Syndrome|Behavior analysis in Down's Syndrome patients
89031738|NCT00515450|Experimental|1|
89031739|NCT00515450|Active Comparator|2|
89031740|NCT02941848|Experimental|Group1|"C → A + B~A : HGP0816 B : HGP1404 C : HCP1306"
89031741|NCT02941848|Experimental|Group2|"A + B → C~A : HGP0816 B : HGP1404 C : HCP1306"
89031742|NCT00515489||001|Risperidone as prescribed
89597067|NCT03822520|Experimental|Celecoxib, Moxifloxacin, Water in order|"Intervention Celecoxib: Celecoxib 400 mg capsule and water 150ml by mouth, daily for 6days~Wash-out period (3~6 days)~Intervention Moxifloxacin: Moxifloxacin 400 mg tablet and water 150ml by mouth, once for one day~Wash-out period (3~6 days)~Intervention Pure water: Water 150ml by mouth without any drug, once for one day"
89597068|NCT03822520|Experimental|Celecoxib, Water, Moxifloxacin in order|"Intervention Celecoxib: Celecoxib 400 mg capsule and water 150ml by mouth, daily for 6days~Wash-out period (3~6 days)~Intervention Pure water: Water 150ml by mouth without any drug, once for one day~Wash-out period (3~6 days)~Intervention Moxifloxacin: Moxifloxacin 400 mg tablet and water 150ml by mouth, once for one day"
89597069|NCT03822520|Experimental|Moxifloxacin, Water, Celecoxib in order|"Intervention Moxifloxacin: Moxifloxacin 400 mg tablet and water 150ml by mouth, once for one day~Wash-out period (3~6 days)~Intervention Pure water: Water 150ml by mouth without any drug, once for one day~Wash-out period (3~6 days)~Intervention Celecoxib: Celecoxib 400 mg capsule and water 150ml by mouth, daily for 6days"
89597070|NCT03822520|Experimental|Water, Moxifloxacin, Celecoxib in order|"Intervention Pure water: Water 150ml by mouth without any drug, once for one day~Wash-out period (3~6 days)~Intervention Moxifloxacin: Moxifloxacin 400 mg tablet and water 150ml by mouth, once for one day~Wash-out period (3~6 days)~Intervention Celecoxib: Celecoxib 400 mg capsule and water 150ml by mouth, daily for 6days"
89597071|NCT03822364|Experimental|A-1 (009-1 -> active comparator)|Part A, Arm 1 (Inhaled apomorphine, Dose 1 followed by commercially available active comparator)
89597072|NCT03822364|Experimental|A-2 (active comparator -> 009-1)|Part A, Arm 2 (commercially available active comparator followed by Inhaled apomorphine, Dose 1)
89597073|NCT03822364|Experimental|B-1a (009-2)|Part B, Arm 1 (Inhaled apomorphine, Dose 2)
89597074|NCT03822364|Placebo Comparator|B-1p (009-0)|Part B, Arm 1 (Inhaled placebo)
89597075|NCT03822364|Active Comparator|B-2a (009-3)|Part B, Arm 2 (Inhaled apomorphine, Dose 3)
89597076|NCT03822364|Placebo Comparator|B-2p (009-0)|Part B, Arm 2 (Inhaled placebo)
89597077|NCT03822364|Experimental|B-3a (009-4)|Part B, Arm 3 (Inhaled apomorphine, Dose 4)
89597078|NCT03822364|Placebo Comparator|B-3p (009-0)|Part B, Arm 3 (Inhaled placebo)
89597079|NCT03822364|Experimental|C-1a (009-3)|Part C, Arm 1 (Inhaled apomorphine, Dose 3)
89597080|NCT03822364|Placebo Comparator|C-1p (009-0)|Part C, Arm 1 (Inhaled placebo)
89597081|NCT03822364|Experimental|C-2a (009-4)|Part C, Arm 2 (Inhaled apomorphine, Dose 4)
89597082|NCT03822364|Placebo Comparator|C-2p (009-0)|Part C, Arm 2 (Inhaled placebo)
89597083|NCT03822364|Experimental|C-3a (009-5)|Part C, Arm 3 (Inhaled apomorphine, Dose 5)
88978981|NCT00417040|Other|(Internet-based STAR database)|"Patients are registered into the STAR database, obtain a password, undergo STAR training, and complete a patient-STAR questionnaire after seeing their clinician (baseline self-report) on day 1 of course 2* of chemotherapy. Patients are reminded to complete online STAR questionnaire before seeing their clinician on day 1 of courses 3, 4, 5, and 6* of chemotherapy. Clinicians review these patient reports before creating their own assessment. Patients also complete a patient feedback survey on day 1 of course 4* of chemotherapy. Clinicians complete feedback survey at study completion.~NOTE: *All time points are based on scheduled therapy with clinical trial CALGB-90401, CALGB-30607, CALGB-30704, CALGB-40601, CALGB-40603, CALGB-40502, CALGB-70604, CALGB-80405, or CALGB-40503."
88978982|NCT00109863|Experimental|Hu14.18-IL2 Treatment|Hu14.18-IL2 will be given on days 1, 2, and 3 of each course of therapy as a 4 hour continuous IV infusion at a daily dose of 6 mg/m2. Treatment courses will be repeated every 28 days at the same dose.
88978983|NCT00281515|Experimental|Lonafarnib / Paclitaxel /Carboplatin|
88978984|NCT00281515|Other|Paclitaxel/Carboplatin|Standard Chemotherapy
88978985|NCT00281554|Experimental|1|
88978986|NCT00109941|Experimental|metenkephalin, OGF-opioid growth factor|DRUG All subjects treated with met-enkephalin (also called OGF) 250 ug/kg iv weekly over 45 minutes
88978987|NCT00281944|Experimental|Treatment (oxaliplatin, leucovorin calcium, fluorouracil)|Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1 followed by fluorouracil IV continuously over 46 hours on days 1-2. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
88978988|NCT00281983|Experimental|Allogeneic stem cell transplantation|"Cytoreductive therapy for inducing a state of partial remission:~FC or FC-R or alternative salvage regimens (e.g. Alemtuzumab)~Conditioning regimen:~FC +/- ATG (Arm A) or FC/Busulfan +/- ATG (Arm C: refractory patients only)~allogeneic-PBSCT (from HLA-identical donor)~GVHD prophylaxis: CSA + MTX or MMF~+/- DLI (Donor lymphocyte infusions)"
88978989|NCT00282100|Experimental|Gefitinib (Iressa)|Open label single arm study of Gefitinib (Iressa) 250mg daily as adjuvant therapy in patients with resectable Hepatocellular Carcinoma
89597084|NCT03822364|Placebo Comparator|C-3p (009-0)|Part C, Arm 3 (Inhaled placebo)
89597085|NCT03822130|Placebo Comparator|Group 1|Systemic Chemotherapy + Oral Chemotherapy Group
89597086|NCT03822130|Experimental|Group 2|Arterial catheter infusion chemotherapy plus oral chemotherapy group
88978990|NCT00110253|Experimental|S-Caine Peel|
88978991|NCT00282178|Active Comparator|1|Candesartan 16-32 mg once daily
88978992|NCT00282178|Active Comparator|2|Hydrochlorothiazide 25-50 mg once daily
88978993|NCT00282178|Placebo Comparator|3|
88978994|NCT00282646|Active Comparator|1|intraarterial application of bone marrow mononuclear cells
88978995|NCT00282646|Placebo Comparator|2|intraarterial application of placebo
89597087|NCT03822130|Experimental|Group 3|Arterial catheter infusion chemotherapy + sodium bicarbonate plus oral chemotherapy group
89597088|NCT04274062||peri partum integrated nursing care of placenta previa|"Part (1) personal data:~Part (2) baseline and characteristics of the patients participants:~Tool II- An observation checklist: This tool is develop by researcher according to guideline of Royal College of Obstetricians and Gynaecologists, 2018), and divide into three main parts: preoperative, intraoperative and postoperative.~Part (1) pre-operative: includes assessment of :~patients general condition~investigation~reserved blood~Hemoglobin level~Impact of hysterectomy option. -9-~Part (2) Intra-operative:~Includes assessment of :-~Investigation~Vital signs~Hypothermia~Blood loss~I.V fluid~Blood gases~Fetal condition and APGAR score.~Part (3) Post-operative: Includes:~maternal complication~fetal complication~psychological satisfaction"
88978996|NCT00282685|Experimental|Intra-arterial stemcell therapy|Patients were treated with intra-arterial stemcells delivered via catheter examination
88978997|NCT00282802||1|National Academy of Sciences/National Resource Council (NAS/NRC) World War II Veteran Twins Cohort
88978998|NCT00076817|Experimental|1|Participants will receive vaccine injections in the groin area or the upper arm
88978999|NCT00076817|Placebo Comparator|2|Participants will receive vaccine placebo injections in the groin area or the upper arm
88979000|NCT00283114|Experimental|1|
88979001|NCT00283153|Experimental|FAR|Facial affect recognition training (with computer assistance)
88979002|NCT00283153|Experimental|SEI|Stories of Emotional Inference
88979003|NCT02960581|Experimental|Group 1A|HIV-uninfected participants
88979004|NCT02960581|Experimental|Group 1B|HIV-uninfected participants
88979005|NCT02960581|Experimental|Group 1C|HIV-uninfected participants
88979006|NCT02960581|Experimental|Group 2A|HIV-infected on ART, (<50 cp/ml)
89517848|NCT05397613|Experimental|Waitlist control|First, participants will remain on the DBT waitlist for 12 weeks receiving no active intervention and will complete pre and post-measures. Then participants will complete 1.5 hr group sessions once per week for 12 weeks of Skills Training in Affective and Interpersonal Regulation (STAIR). Participants will complete self-report measures pre, post, and at one month intervals.
89517849|NCT02323373|Experimental|Topical group|Intervention: Tranexamic Acid - topical. Topical administration of a solution of 1.5 g of tranexamic acid (50 mg/ml, Transamin, Zydus Nikkho) diluted in 50 ml of saline (at 0.9%), sprayed over the operated area, covering it for 5 minutes, before the tourniquet release.
88979007|NCT02960581|Experimental|Group 2B|HIV-infected on ART, (<50 cp/ml)
88979008|NCT02960581|Experimental|Group 2C|HIV-infected on ART, (<50 cp/ml)
88979009|NCT02960581|Experimental|Group 3A|HIV-Infected off ART (VL 2x10^3 - 1x10^5 cp/ml)
88979010|NCT02960581|Experimental|Group 3B|HIV-Infected off ART (VL 1x10^2 - 2x10^3 cp/ml)
88979011|NCT02960581|Experimental|Arm 1D|HIV-uninfected participants
89517850|NCT02323373|Active Comparator|Intravenous group|Intervention: Tranexamic Acid - intravenous Intravenous injection of 20 mg/kg of tranexamic acid, diluted in 100 ml of saline at 0.9%, administered with anesthesia in 10 minutes.
89517851|NCT02323373|Placebo Comparator|Placebo|Intervention: intravenous injection of 100 ml of saline solution also administered with anesthesia in 10 minutes.
89517852|NCT03495635|Experimental|BBBS Community-Based Mentoring|Big Brothers Big Sisters Community-Based Mentoring Program
89517853|NCT03495635|No Intervention|Control|Not eligible to participate in a Big Brothers Big Sisters mentoring program, but may participate in other mentoring programs.
89517854|NCT02325479|Experimental|Group A|After scheduled oocyte pick up, a mock embryo transfer will be done using labotec catheter (Labotec, Gottingen Germany), and an injection of Enaoxaprin sodium (LMWH) (Clexane® Sanofi S.A Paris, France) will be given intrauterine in group A patients, 500 IU of LMWH which is 5mg, in 0.05 ml.
89517855|NCT02325479|Placebo Comparator|Group B|The control arm (group B) will be injected intrauterine with similar volume of tissue culture media (G.2 plus ref. 10132, Vitrolife)
89517856|NCT04455529||ESUS|Embolic stroke of undetermined source (ESUS) designates patients with nonlacunar cryptogenic ischemic strokes in whom embolism is the likely stroke mechanism.
89517857|NCT03495401|Experimental|fortified synbiotic milk|100 ml fortified (7,47 mg ferrous sulphate and 4,33 mg zinc acetate) synbiotic milk containing 7 billion CFU Lactobacillus plantarum Dad13 in combination with 4 g prebiotic fructooligosaccharides
89517858|NCT03495401|Placebo Comparator|non-fortified synbiotic milk|100 ml non-fortified synbiotic milk containing 7 billion CFU Lactobacillus plantarum Dad13 in combination with 4 g prebiotic fructooligosaccharides
89517859|NCT05236231|Experimental|Treatment Sequence ABC|Participants will receive single oral dose of fixed dose combination (FDC) of macitentan/tadalafil under fasting conditions in (test) (Treatment A) Treatment Period 1 followed by single oral dose of FDC of macitentan/tadalafil under fed conditions (test) (Treatment B) in Treatment Period 2 and then single oral dose of macitentan/tadalafil under fasting conditions (reference) (Treatment C) in Treatment Period 3 on Day 1 of each Treatment Period. There will be a wash-out period of at least 12 days between Day 1 of subsequent treatment period.
89517860|NCT05236231|Experimental|Treatment Sequence BCA|Participants will receive Treatment B in Treatment Period 1 followed by Treatment C in Treatment Period 2 and Treatment A in Treatment Period 3. There will be a wash-out period of at least 12 days between Day 1 of subsequent treatment period.
89517861|NCT05236231|Experimental|Treatment Sequence CAB|Participants will receive Treatment C in Treatment Period 1 followed by Treatment A in Treatment Period 2 and Treatment B in Treatment Period 3. There will be a wash-out period of at least 12 days between Day 1 of subsequent treatment period.
89517862|NCT05236231|Experimental|Treatment Sequence ACB|Participants will receive Treatment A in Treatment Period 1 followed by Treatment C in Treatment Period 2 and Treatment B in Treatment Period 3. There will be a wash-out period of at least 12 days between Day 1 of subsequent treatment period.
89517863|NCT05236231|Experimental|Treatment Sequence CBA|Participants will receive Treatment C in Treatment Period 1 followed by Treatment B in Treatment Period 2 and Treatment A in Treatment Period 3. There will be a wash-out period of at least 12 days between Day 1 of subsequent treatment period.
89517864|NCT05236231|Experimental|Treatment Sequence BAC|Participants will receive Treatment B in Treatment Period 1 followed by Treatment A in Treatment Period 2 and Treatment C in Treatment Period 3. There will be a wash-out period of at least 12 days between Day 1 of subsequent treatment period.
89517865|NCT03495323|Experimental|Prexasertib + LY3300054|"Prexasertib is administered intravenously twice per cycle~LY3300054 is administered intravenously twice per cycle"
89517866|NCT03130387|Other|Office hysteroscopy|Examinatin with Office hysteroscope for women with abnormal uterine bleeding who had a history of previous cesarean section
89517867|NCT02323451|Experimental|Medical Chitosan|Medical Chitosan, 2ml/vial (12mg/ml), intra-articular injection with a volume less than 2ml every two weeks, a total of 3 times
89517868|NCT02323451|Active Comparator|Sodium Hyaluronate Injection|Sodium Hyaluronate Injection, 2ml/vial (10mg/ml), intra-articular injection with a volume less than 2ml every one weeks, a total of 5 times.
89597089|NCT04274062||peri partum regular care of placenta previa|Routine nursing care of all cases of placenta previa (preoperative, intraoperative and postoperative)..
89597090|NCT03821974|Experimental|dry group|The sequence of the technique of the puncture is dry-wet-dry-wet.
89031743|NCT02941653|Active Comparator|Control: Potassium Nitrate 2% gel|The patient will receive the application of potassium nitrate 2% gel on vestibular surface teeth, for 10 minutes.
89031744|NCT02941653|Experimental|Intervention: Potassium Oxalate 5% gel|The patient will receive the application of potassium oxalate 5% gel on vestibular surface teeth, for 10 minutes.
89031745|NCT02941575|Active Comparator|Control|Implant superstructure crown: All ceramic, IPS Emax
89597091|NCT03821974|Experimental|wet group|The sequence of the technique of the puncture is wet-dry-wet-dry.
89597092|NCT03821662|Experimental|OT Diabetes Self-Management Intervention|The intervention is organized into five modules. Each participant receives an individually tailored combination of modules, and treatment activities within each module, as established through collaborative goal setting between the participant and OT during the initial evaluation. The five modules are: (1) Living with Diabetes-addressing gaps in the knowledge and skills necessary to effectively manage diabetes; (2) Access and Advocacy-strategies to collaborate and communicate with healthcare providers; (3) Activity and Health-analyzing daily habits and routines; (4) Social Support-strategies to address diabetes care in various social environments and to identify sources of support; (5) Emotional Well-Being-strategies to address stress, diabetes burnout, and depression.
89597093|NCT01894477|Experimental|Arm A|"Arm A: Treosulfan, Fludarabine Phosphate~Treosulfan intravenously (IV) over 2 hours on days -6 to -4 and fludarabine phosphate IV over 30 minutes on days -6 to -2."
89597094|NCT01894477|Experimental|Arm B|"Arm B: Treosulfan, Fludarabine Phosphate, TBI~Treosulfan and fludarabine phosphate as in Arm A and undergo low -dose total-body irradiation (TBI) on day 0"
89597095|NCT03821428|Experimental|Acupuncture|Needling of acupoints P6 and CV24 with indwelling permanent needles, withdrawn after TEE procedure
89597096|NCT03821428|Placebo Comparator|Control|Application of Placebo needles in the areas of P6 and CV24 acupoints
89597097|NCT03821350|No Intervention|Control Group|The control group was given verbal information
89031746|NCT02941575|Experimental|Intervention|Implant superstructure crown: Hybrid ceramic, crystal Ultra crown
89597098|NCT03821350|Experimental|Leaflet Group|The second group was given verbal information and a detailed information leaflet with written and visual content
89597099|NCT03820648|Experimental|Alexis® device|In this group, we will be used WP dual-ring Alexis® (Figure 1). The Alexis® 's size will be decided on the basis of abdominal incision (Alexis® X-Large or Alexis® XX-Large will be used for 11-17cm or 17-25 cm incision length respectively)
89031747|NCT02941731|Experimental|Sequence 1|HIP1403→HGP0919
89031748|NCT02941731|Experimental|Sequence 2|HGP0919→HIP1403
89031749|NCT05319210|Experimental|Buzzy application|It is fixed on the right upper arm area of the child one minute before the procedure. After cleaning the skin with the appropriate solution, venous catheter placement will be performed. During the procedure, the child's respiratory rate, heart rate and oxygen saturation will be observed.
89031750|NCT05319210|Experimental|Virtual Reality Glasses|A dinosaur movie suitable for the 7-12 age group will be watched 2-3 minutes before the venous catheter insertion. In this process, after cleaning the skin with the appropriate solution, a venous catheter will be inserted. During the procedure, the child's respiratory rate, heart rate and oxygen saturation will be observed.
89031751|NCT05319210|No Intervention|No intervention|The routine venous catheter placement protocol in the institution where the study is conducted will be applied. An evidence-based non-pharmacological method is not used to reduce pain during venous catheter insertion in children in the institution. A venous catheter is inserted by attaching a tourniquet to the child. During the procedure, the child's respiratory rate, heart rate and oxygen saturation will be observed.
89031752|NCT02951039||Edoxaban|Patients with established NVAF treated with edoxaban according to package information. Physician's prescribing behaviour will not be influenced; patients may only be included after the treating physician has made the clinical decision to prescribe edoxaban.
89597100|NCT03820648|Active Comparator|Standard 3M™ Steri-Drape 2|In this group, we will be used Standard 3M™ Steri-Drape 2
89597101|NCT03821194|Experimental|Gua sha group|do gua sha for the subjects
89597102|NCT03821194|Active Comparator|control group|give hot pack for the subjects
89597103|NCT03820570|Experimental|lichtenstein|hernia repair
89597104|NCT03820414|Experimental|CRV101 Group 1|Subjects receive 2 doses of the candidate CRV-101 formulation 1, administered intramuscularly (IM) in deltoid region of non-dominant arm, according to a 0, 2 Month schedule.
89597105|NCT03820414|Experimental|CRV 101 Group 2|Subjects receive 2 doses of the candidate CRV-101 formulation 2, administered intramuscularly (IM) in deltoid region of non-dominant arm, according to a 0, 2 Month schedule.
89597106|NCT03820414|Experimental|CRV 101 Group 3|Subjects receive 2 doses of the candidate CRV-101 formulation 3, administered intramuscularly (IM) in deltoid region of non-dominant arm, according to a 0, 2 Month schedule.
89597107|NCT03820414|Experimental|CRV 101 Group 4|Subjects receive 2 doses of the candidate CRV-101 formulation 4, administered intramuscularly (IM) in deltoid region of non-dominant arm, according to a 0, 2 Month schedule.
89597108|NCT03820414|Placebo Comparator|Control Group|Subjects received 2 doses of placebo (saline solution), administered intramuscularly (IM) in deltoid region of non-dominant arm, according to a 0, 2 Month schedule.
89597109|NCT03820336|Experimental|Extra Virgin Olive Oil|
89597110|NCT03820336|Placebo Comparator|Control Oil|
89597111|NCT04391998|Active Comparator|Anemia without parasitic infection|women with anemia without parasitic infection will receive iron treatment
89597112|NCT04391998|Active Comparator|parasitic infection treated with iron|women with anemia with parasitic infection will receive oral iron treatment
89597113|NCT04391998|Active Comparator|parasitic infection treated with iron and antihelmemsic|women with anemia with parasitic infection will receive oral iron treatment and antihelminsic treatment in the form of metronidazole 500mg tab twice daily for 5 days in cases with Entamoeba or Giardia or albendazol 200mg tab
89597114|NCT03828604|Experimental|Stress; Trier Social Stress Task|5 min challenging speech task, 5 min challenging math task; performed in front of evaluators
89597115|NCT03828604|Active Comparator|Placebo Trier Social Stress Task|5 min speech task, 5 min math task; performed alone
89597116|NCT03824782|No Intervention|Standard of Care|Infants in the control arm received standard examinations to screen for retinopathy of prematurity.
89597117|NCT03824782|Experimental|Standard of Care + Phototherapy Mask|Infants in the treatment arm will have a standard phototherapy mask (Biliband, Natus, Pleasanton, California, USA) applied over the eyes after instillation of mydriatic drops. The masks will be removed 4 hours after the eye examination, when the pharmacologic effect of the mydriatic agents would have subsided. Infants will then receive standard examinations to screen for retinopathy of prematurity. The mask will be removed for the examination but reapplied promptly afterward.
89597118|NCT03822598|Experimental|Intervention group|Teaching Recovery Techniques implemented 1- 3 weeks after recruitment
89597119|NCT03822598|Active Comparator|Wait-list control group|Delayed implementation of Teaching Recovery Techniques (after the experimental group has completed the program)
89597120|NCT03792880|Active Comparator|Control arm|Usual follow-up in Healthcare System for patients with obstructive sleep apnea and CPAP treatment
89597121|NCT03792880|Experimental|Intervention arm|Usual follow-up in the Healthcare System for patients with obstructive sleep apnea and CPAP treatment and a telematic control and self-management program
89597122|NCT03774160|Experimental|Generacion Actual|Generacion Actual includes Community-based and a Health Systems Components. This multi-level intervention reaches out to all MSM/trans by mobilizing them to encourage friends to reduce risk behavior and increase HIV testing, and for HIV+ friends, encourage them to link, stay in care, and take medications regularly. The community based component includes a leadership group, community space, community mobilization events, and group sessions to address a variety of psychosocial issues as well as HIV literacy. The Health Systems component includes sensitization of the HIV testing and care staff to working with MSM and trans, Navigators to help MSM/trans to navigate the complex health system; and positive prevention training of providers; all evidence-based approaches.
89597123|NCT03774160|No Intervention|Comparison|No intervention is implemented in the comparison arm.
89597124|NCT03822286|Experimental|Intervention|E-training course programs, counseling mentoring supports and support group gatherings meeting.
89597125|NCT03822286|Active Comparator|Control|Traditional classroom teaching course programs.
89597126|NCT03820180|Experimental|Test Product|Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals
89597127|NCT03820180|Active Comparator|Reference Product|ADVAIR DISKUS® 250/50
89597128|NCT01894243|Other|Normal hepatic function|"Patients with:~(i) negative result for serum hepatitis B surface antigen and hepatitis C antibody (ii) total bilirubin ≤1.5 x institutional upper limit of normal (ULN), albumin and prothrombin time within normal limits and must not have ascites (unless related to disease under study) or encephalopathy (iii) aspartate aminotransferase or serum glutamic oxaloacetic transaminase (AST), alanine aminotransferase or serum glutamic pyruvic transaminase (ALT) ≤2.5 x institutional ULN unless liver metastases are present in which case it must be ≤5 x ULN"
89597129|NCT01894243|Other|Mild hepatic impairment|As defined by the Child-Pugh Classification System.
89597130|NCT01894243|Other|Moderate hepatic impairment|As defined by the Child-Pugh Classification System.
89597131|NCT03822832|Experimental|Spesolimab|i.v.
89597132|NCT03822832|Placebo Comparator|Placebo|i.v.
88979012|NCT00110409|Experimental|1|Intervention participants will receive information focusing on asthma self-management, education, self-efficacy, and social support while in the hospital emergency room. Telephone reinforcement will occur for 8 weeks following study entry.
88979013|NCT00110409|Active Comparator|2|Participants in the control group will receive standard emergency room education about asthma.
88979014|NCT00283309|Active Comparator|Memantine|Memantine is used to determine if patients given pretreatment to corticosteroid therapy for inflammatory illnesses will show lesser declarative memory impairment than those receiving placebo. Baseline 10mg x 3 days, then 10mg BID x 4 days.
88979015|NCT00283309|Placebo Comparator|Placebo|Inactive ingredient matching the active medication in appearance
88979016|NCT00283309|Active Comparator|Riluzole|Riluzole is given to patients receiving corticosteroid therapy for inflammatory illnesses pretreatment to determine if they show lesser declarative memory impairment than those receiving placebo. Baseline 50mg x 3 days, then 50mg BID x 4 days.
88979017|NCT00401466|Experimental|1|Prolonged follow-up intervals every 12 months
89597133|NCT04613713|Experimental|Somatocognitive physiotherapy|Somatocognitive therapy is a multi-modal physiotherapy intervention utilized for women with longstanding chronic pelvic pain and provoked vestibulodynia developed at the beginning of the 2000s as a collaboration between the department of psychosomatic medicine, Oslo University Hospital (OUH) and department of physiotherapy (OsloMet)
89597134|NCT04613713|Active Comparator|Treatment as usual|The participants randomized to the treatment as usual group will follow available treatment options based on the current recommendations from Vulva clinic at Oslo University Hospital, a center that is specialized in treatment of vulvar conditions.
89597135|NCT03762694|Experimental|Electroacupuncture (EA) and Auricular Acupuncture (AA)|12 sessions acupuncture treatment (EA+AA) will be given twice a week for 6 weeks after randomization.
89597136|NCT03762694|No Intervention|Wait-list control|No treatment except routine care will be given at the first 6 weeks, followed by 12 sessions treatment as Acupuncture group.
88979018|NCT00401466|Active Comparator|2|Standard follow-up intervals of 3 months
88979019|NCT00076934|Experimental|1|Participants receive Regimen 1 for 4 months
88979020|NCT00076934|Experimental|2|Participants receive Regimen 2 for 4 months
88979021|NCT00076934|Experimental|3|Participants receive Regimen 3 for 4 months
88979022|NCT00076934|Experimental|4|Participants receive Regimen 4 for 4 months
88979023|NCT00283621|Experimental|Growth Factors + Adriamycin/Ifosfamide|Growth Factors = Aranesp (Darbepoetin Alfa) and Pegfilgrastim (Neulasta)
89597137|NCT01450150|Experimental|Active tDCS|
89210054|NCT00893334||LGMD2B|Patients diagnosed with Limb-Girdle Muscular Dystrophy, type 2B Miyoshi myopathy Dysferlin deficiency
89210055|NCT00893334||LGMD2I|Patients diagnosed with Limb-Girdle Muscular Dystrophy, type 2I FKRP-deficiency
89597138|NCT01450150|Sham Comparator|Sham tDCS|
89597139|NCT01450228|Placebo Comparator|Placebo KI1001|
89597140|NCT01450228|Experimental|KI1001|
89597141|NCT01450384|Experimental|Treatment (enzyme inhibitor therapy, antiangiogenesis)|Patients receive pemetrexed disodium IV on day 1 every 2 weeks and sorafenib tosylate PO BID for 4 weeks on days 1-5. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
89597142|NCT01450462|Experimental|Vitamin D (cholecalciferol)|
89597143|NCT01450462|Placebo Comparator|Placebo|
89597144|NCT02643238|Experimental|Group A - Blind|Subjects will be trained to ambulate through a 40-foot obstacle course by the occupational therapy colleagues at Akron Children's Hospital after which they will be scored on their performance while using the BrainPort® system.
89597145|NCT02643238|Active Comparator|Group C - Control|Subjects will be trained to ambulate through a 40-foot obstacle course by the occupational therapy colleagues at Akron Children's Hospital after which they will be scored on their performance while using the BrainPort® system.
89597146|NCT01450618||Atazanavir|HIV patients on antiretroviral therapy using Atazanavir
88979024|NCT00283660|Experimental|Active|Dietary Supplement: 10 mg zinc oxide
89597147|NCT01450618||Darunavir|HIV patients on antiretroviral therapy using Darunavir
89597148|NCT01450618||Fosamprenavir|HIV patients on antiretroviral therapy using Fosamprenavir
89597149|NCT01450618||Lopinavir|HIV patients on antiretroviral therapy using Lopinavir
89597150|NCT01450774|Experimental|CHF 1535 50/6µg|
89597151|NCT01450774|Active Comparator|beclomethasone dipropionate 50µg + formoterol fumarate 6µg|
89597152|NCT01450852|Experimental|Strength Training|The strength training group completed 12 weeks of progressive, periodized resistance training 3d/wk.
89597153|NCT01450852|No Intervention|Active Control Group|The active control group was instructed to maintain normal activity and eating habits. They participated in all pre and post intervention measures.
89597154|NCT01450930|Active Comparator|Hydrocortisone subcutaneously first|Hydrocortisone subcutaneously first
89597155|NCT01450930|Active Comparator|Hydrocortisone intramuscular first|Hydrocortisone intramuscular first
89597156|NCT01451086|Experimental|vaccine made by Beijing Minhai Biotechnology Co., Ltd|Subjects receive 0.5 mL/dose of 23-valent pneumococcal polysaccharide vaccine by intramuscular (deltoid) injection on Day 0.
89597157|NCT01451086|Active Comparator|vaccine made by Chengdu Institute of Biological Products|Subjects receive 0.5 mL/dose of 23-valent pneumococcal polysaccharide vaccine by intramuscular (deltoid) injection on Day 0.
89597158|NCT01451242||brain injury|
89210056|NCT00893334||Control|Healthy Controls
89597159|NCT01451710|Experimental|Prednisone or Prednisolone|
89597160|NCT01451788|No Intervention|Conventional group|conventional blood saving methods (use of bone wax for cancellous bony bleeding; bipolar diathermy and epidural space packing for epidural venous bleeding)
88979025|NCT00283660|Placebo Comparator|Placebo|Placebo (double blinded)
88979026|NCT00401583|Experimental|Pazopanib receivers|During Days 1 and 2 subjects will be dosed with only probe drugs, and with no drugs on Days 3-5. During Days 6 to the end of the study, subjects will receive 800 mg daily pazopanib, and on Days 23-24 subjects will receive probe drugs in addition to pazopanib
88979027|NCT00077051|Experimental|Single Arm|
88979028|NCT00283699|Active Comparator|1|"albendazole, 15 mg/kg/day for those less than 50 kg in weight. For those more than 50 kg, 800 mg was administered. All got standard symptomatic therapy~placebo plus standard symptomatic therapy"
88979029|NCT00283699|Placebo Comparator|2|
88979030|NCT00283738|Active Comparator|1|
88979031|NCT00283738|Placebo Comparator|2|Sham control
88979032|NCT00283855|No Intervention|Control Group|No intervention
88979033|NCT00283855|Active Comparator|Online Self-Management|RAHelp.org
88979034|NCT00110448|Active Comparator|1|Aspirin use
88979035|NCT00110448|Active Comparator|2|No aspirin use
88979036|NCT00284011|Active Comparator|SAMe|Two 400 mg pills.
88979037|NCT00284011|Placebo Comparator|Placebo|Two placebo pills (identical in appearance to SAMe).
88979038|NCT00110526|Experimental|Ad.hIL-12|
88979039|NCT04718701|Experimental|Experimental Group|Patients who failed first-line therapy with locally advanced or metastatic pancreatic cancer will be assigned to receive anlotinib plus toripalimab and nab-paclitaxel as second-line or maintenance treatment.
88979040|NCT00284752|Experimental|ABI-007|
89210057|NCT00607386|Other|Idursulfase|Open-label treatment with idursulfase
89210058|NCT04034940|Other|primary PCI STEMI patients|All Patients with AMI refered for primary PCI in single center
89597161|NCT01451788|Experimental|Floseal|Gelatin matrix with human derived thrombin (Floseal) used in adolescents undergoing posterior spinal deformity surgery for adolescent idiopathic scoliosis (AIS)
89597162|NCT01451866|Active Comparator|classic leg-press training|Classic resistance training on the dynamic leg press. 6 x 8 repetitions at 60% 1 RM
89597163|NCT01451866|Experimental|Complex leg-press training|Complex leg-press training with visual feed-back on a dynamic leg-press.
89597164|NCT01451944|Experimental|asthma education and case management|asthma education and case management
89597165|NCT01452022|Experimental|Inductigraft|open label non randomised to assess performance of synthetic bone graft using the product, Inductigraft, in posterolateral lumbar fusion
89597166|NCT01452100|Experimental|prednisone|• Patients enrolled into the study will be treated with prednisone, 20 mg/day (if body weight <70 kg ; or 25mg/d if body weight >70 kg) for 1 month, then tapered to 12.5 mg/d (month 2) and 7.5 mg/d (month 3) and stop. In both groups, patients will be treated according to expert advice including use of statins (according to French Health Agency recommendation), a RAS inhibitor and supportive treatment (including nutrition, treatment of heart failure, and dialysis).
89597167|NCT01452100|Placebo Comparator|placebo|Patients enrolled into the study will be treated with placebo, 20 mg/day (if body weight <70 kg ; or 25mg/d if body weight >70 kg) for 1 month, then tapered to 12.5 mg/d (month 2) and 7.5 mg/d (month 3) and stop. In both groups, patients will be treated according to expert advice including use of statins (according to French Health Agency recommendation), a RAS inhibitor and supportive treatment (including nutrition, treatment of heart failure, and dialysis).
89597168|NCT01452334|Experimental|Arm 1: BMS-936559|
89597169|NCT01452490|Experimental|Diode Laser Treatment|
89597170|NCT01452568|Experimental|Aspirin|Aspirin 150mg daily, starting day 1 after surgery, for three months.
89597171|NCT01452568|Active Comparator|Warfarin|Warfarin daily dosage to International normalized ratio(INR) value between 2,0 to 3,0.
89597172|NCT01452646|Experimental|MRD-directed therapy|
89597173|NCT01452724|Experimental|TAK-438 20 mg QD|
89597174|NCT01452724|Active Comparator|Lansoprazole 30 mg QD|
89597175|NCT01513239|Experimental|MK-6072 + SOC|Single intravenous (IV) infusion of 10 mg/kg MK-6072 + Standard of Care (SOC) for CDI
89597176|NCT01513239|Experimental|MK-3415A + SOC|Single IV infusion of 10 mg/kg MK-3415A + SOC for CDI
89597177|NCT01513239|Placebo Comparator|Placebo + SOC|Normal saline IV infusion (0.9% sodium chloride) + SOC for CDI
89597178|NCT01453114|Experimental|Psychotherapy|Cognitive Behavioral Therapy
89597179|NCT01453192|Experimental|Raltegravir|Raltegravir associated to an antiretroviral regimen without ritonavir boosted antiprotease
89597180|NCT01453270|Experimental|NICOM and PLR|A systematic approach to resuscitation started in the ED and using a step-wise approach to optimize cardiac preload, afterload, and contractility, thus optimizing oxygen delivery to the tissues will be applied to the intervention group using the Non-Invasive Cardiac Output Monitor (NICOM) and passive leg-raising (PLR) maneuver.
89597181|NCT01453270|Active Comparator|Usual care|
89597182|NCT01453426|Experimental|Chinese Subjects - Dose 1 BG00012|
89597183|NCT01453426|Experimental|Chinese Subjects - Dose 2 BG00012|
89597184|NCT01453426|Experimental|Japanese Subjects - Dose 1 BG00012|
89597185|NCT01453426|Experimental|Japanese Subjects - Dose 2 BG00012|
89597186|NCT01453426|Experimental|Caucasian Subjects - Dose 1 BG00012|
89597187|NCT01453426|Experimental|Caucasian Subjects - Dose 2 BG00012|
89597188|NCT01544127|Experimental|MI-SI+TAU|Motivational Interviewing to Address Suicidal Ideation
89597189|NCT01544127|Experimental|MI-SI-R+TAU|Motivational Interviewing to Address Suicidal Ideation Revised
89597190|NCT01544127|Other|TAU Alone|Treatment as usual
89597191|NCT01453504|Active Comparator|Ever-DHAP|Combination of Everolimus and DHAP
89597192|NCT01453504|Placebo Comparator|Placebo-DHAP|
89597193|NCT01453582|Experimental|Propolis|Total Flavonoids of Propolis dropping pill
89597194|NCT01453582|Placebo Comparator|Placebo|Simulant of total Flavonoids of Propolis dropping pill
89210059|NCT00901446||Imaging|Subjects who receive intracoronary imaging with the investigative device.
89597195|NCT01512693|Experimental|Moderate Hepatic Insufficiency Group|Single-dose administration of odanacatib 50 mg to participants with moderate hepatic insufficiency.
89597196|NCT01512693|Experimental|Healthy Matched Control Group|Single-dose administration of odanacatib 50 mg to healthy matched control participants.
89597197|NCT02588482|Experimental|electroencephalography recording|Cerebral measurements from high-density and conventional electroencephalography are recorded simultaneously
89597198|NCT01453738|Experimental|Ex- vivo cultured adult allogeneic MSCs|Single intraarticular dose of allogeneic MSCs suspended in 2-4ml Plasmalyte A followed by 2 ml of Hyaluronan
89597199|NCT01453738|Placebo Comparator|Plasmalyte-A|Single intraarticular dose of 2ml Plasmalyte
89597200|NCT01454908|Other|Partial Knee Arthroplasty|Oxford Mobile Bearing Unicompartmental Knee Arthroplasties
89597201|NCT04272892|Experimental|Digital CBT-I|6 weeks digital (online) cognitive behavioural therapy for insomnia
89597202|NCT04272892|Active Comparator|Sleep hygiene information|Leaflet of sleep hygiene information
89597203|NCT04273204|Experimental|UCP Group|
89597204|NCT04273204|Other|Control Group|
89597205|NCT01458340|Experimental|TD-9855 Dose 1|
89597206|NCT01458340|Experimental|Placebo|
89597207|NCT01458340|Experimental|TD-9855 Dose 2|
89597208|NCT04844554|Experimental|Group 1 - 3.0 mA active HD-tDCS|HD-tDCS with 3.0 milliamperes (mA) of intensitive
89597209|NCT04844554|Experimental|Group 2 - Sham HD-tDCS|Sham HD-tDCS
89597210|NCT04846270|Experimental|Investigational Device|TENA SmartCare Change Indicator
89597211|NCT04845568|No Intervention|Video|This is the control condition, which views a short video and online interactive game with psychoeducational material on healthy eating and consideration of future consequences.
89597212|NCT04845568|Experimental|Virtual Reality|This is the intervention condition, which participates in the virtual reality experience; the experience includes psychoeducational material on healthy eating and consideration of future consequences.
89597213|NCT04844008|Experimental|Nanobubble|Sports drink nanobubble drink
89597214|NCT04844008|Placebo Comparator|control|Flavoured drink- no active ingredients
89597215|NCT02868190|Other|Two micro-bypass stents (iStent inject)|Standalone implantation of two trabecular micro-bypass stents (iStent inject)
89597216|NCT02864914||Empagliflozin|Patients initiating Empagliflozin treatment within the study period
89597217|NCT02864914||DPP-4 inhibitors|Patients initiating DPP-4 inhibitor treatment within the study period
89597218|NCT04272814|Experimental|Compression therapy|compression therapy
89597219|NCT04272814|Active Comparator|Standard treatment|standard treatment
89597220|NCT04272580|Sham Comparator|Control group|No preload was given before spinal anesthesia
89597221|NCT04272580|Experimental|4 ml/kg group|4 ml/kg compound sodium chloride (0.85% NaCl, 0.03% KCl, and 0.033% CaCl2) was given before spinal anesthesia
89597222|NCT04272580|Experimental|8 ml/kg group|8 ml/kg compound sodium chloride (0.85% NaCl, 0.03% KCl, and 0.033% CaCl2) was given before spinal anesthesia.
89597223|NCT04272580|Experimental|12 ml/kg group|12 ml/kg compound sodium chloride (0.85% NaCl, 0.03% KCl, and 0.033% CaCl2) was given before spinal anesthesia.
89597224|NCT04390438|Experimental|High-Intensity short time percutaneous electrolysis|Application of a 0,66uA galvanic current in the active TrP through a needle during 10 seconds. During the 20 seconds left necessary to blind the patient and the examiner, the needle was inside but with no electrical current
89597225|NCT04390438|Experimental|Low-Intensity long time percutaneous electrolysis|Application of a 0,22uA galvanic current in the active TrP through a needle during 30 seconds
89597226|NCT04390438|Active Comparator|Dry needling|One acupuncture needle was placed in the active TrP to produce a local twitch response during 30 seconds
89597227|NCT04843852|Experimental|Intervention - vaccination|"HEPLISAV-B is available in pre-filled, single-dose 0.5 mL vials. Each dose contains 20 μg of HBsAg and 3,000 μg of 1018 adjuvant. HEPLISAV-B is administered as an intramuscular injection in the deltoid region.~Study subjects randomized to the vaccine group will receive a total of 2 injections, each administered at least 4 weeks apart - the same dosing schedule recommended for hepatitis B prevention.~Once enrolled, participants will have study visits on days 0 (first injection), 14, 28, 56, and 196 with phone call follow ups on days 7, 35, and 393. Research blood samples will be collected at days 0, 14, 28, 56, 196."
89597228|NCT04843852|No Intervention|No vaccination|Participants randomized to the control group will have study visits on days 0, 14, 28, 56, and 196 with phone call follow ups on days 7, 35, and 393. Research blood samples will be collected at days 0, 14, 28, 56, 196.
89597229|NCT04390516|Other|COViage|Machine learning intervention
89597230|NCT02849470|Active Comparator|ARM 1|Control: 1) HD-PRP + Matristem Matrix (ACell) (Current Standard of Care); 2) Intradermal injections of hair loss 3) Platelet Rich Plasma 4) Matristem Matrix (ACell)
89597231|NCT02849470|Active Comparator|ARM 2|"Experimental: HD-PRP + Emulsified AD-tSVF;~Intervention:~Platelet Rich Plasma~Adipose Derived Stem/Stromal Cells~Intradermal injections of hair loss"
89597232|NCT02849470|Experimental|ARM 3|"Experimental: HD- PRP + Emulsified AD-tSVF + Emulsified AD-cSVF; Intervention: Intradermal injections of hair loss~Platelet Rich Plasma~Adipose Derived Stem/Stromal Cells~Stem/Stromal Cell Isolation~Intradermal injections of hair loss"
89597233|NCT02846974||Calibration cohort|In this cohort, approximately 30 subjects will be put through a controlled desaturation study with controlled hypoxia until they arrive at approximately SpO2 = 70%. Measurements will be taken via arterial catheterization to resolve proper values to calibrate the device
89597234|NCT02846974||Validation cohort|In this cohort, approximately 250 patients will have a single pulse oximetry reading taken using the novel device and a gold standard device to ensure accurate validation.
89597235|NCT05025358|Experimental|LP-118|"The classic 3+3 design at dose levels of 50mg, 100mg, 200mg, 300mg, 400mg and 500mg will be implemented in this study."
89597236|NCT05026528|Experimental|Digital DSME/S|Ten-week intervention during which the participant uses a digital diabetes self management education and support system together with the diabetes nurse.
89597237|NCT05026528|No Intervention|Standard care|Control group continuing with regular standardized care.
89597238|NCT05024188|Experimental|Antibiotics + FMT|7 days of antibiotics- Ciprofloxacin, 500 mg 2/day & Metronidazole (Flagyl), 500 mg 3/day. After antibiotics administration, participants will receive 10 aFMT capsules for three consecutive days (a total of 30 capsules).
89597239|NCT05024188|Placebo Comparator|Placebo|7 days of cellules pills. After cellules pills administration, participants will receive 10 agarose capsules for three consecutive days (a total of 30 capsules).
89597240|NCT05023876|Experimental|IASTM group|
89597241|NCT05023876|Experimental|Control Group|
89597242|NCT04390594|No Intervention|Standard of Care|The Standard of Care is the treatment which is the most adapted to the patient in the clinician's opinion. It could include the combination of Hydroxychloroquine and Azithromycin in the absence of contraindication.
89597243|NCT04390594|Experimental|Standard of Care + Nafamostat mesilate|"The Standard of Care is the treatment which is the most adapted to the patient in the clinician's opinion. It could include the combination of Hydroxychloroquine and Azithromycin in the absence of contraindication.~Nafamostat mesilate"
89597244|NCT02843386|Experimental|A : Chemotherapy|Adjuvant chemotherapy by Fotemustin 100mg/m²
89597245|NCT02843386|Other|B : Surveillance|Intensive surveillance
88979041|NCT02965508|Experimental|Home-based Primary Care Arm|Participants in this arm will be assigned a Mount Sinai Visiting Doctors primary care physician who makes a home based primary care visit.
89597246|NCT05022082|Experimental|Chest Physiotherapy- Aspiration- Inhaler drugs group|The study group (n=21) will first receive chest physiotherapy (tapotement or vibration) and aspiration, followed by inhaler drug therapy.
89597247|NCT05022082|Other|Inhaler drugs- Chest Physiotherapy- Aspiration group|The control group (n=21) will be administered the inhaler drug routinely administered in the intensive care unit where the study is conducted and then receive chest physiotherapy (tapotement or vibration), then nasopharyngeal and oropharyngeal aspiration
89597248|NCT05024422|Active Comparator|Administration of Cabergoline|one dose of 1mg, up to 24 hours postpartum, or 0.25 mg twice a day for two days
88979042|NCT02965508|Active Comparator|Usual Care Arm|Participants in this arm will receive the usual care at office based visits
88979043|NCT00284830|Active Comparator|1|dual-chamber minimal ventricular pacing with the use of new pacemaker features designed to promote atrioventricular conduction, preserve ventricular conduction, and prevent ventricular desynchronization
88979044|NCT00284830|No Intervention|2|conventional dual-chamber pacing
88979045|NCT02965586|Active Comparator|intravenous dexmedetomidine group|intrathecal 2.5 ml of heavy bupivicaine 0.5% pulse 0.5 mg morphine and will receive intravenous dexmedetomidine infusion as prepared. Dexmedetomidine will be diluted to a volume of 50 ml (4 mg ml-1) and presented as coded syringes by an anesthesiologist. I.V. bolus of dexmedetomidine 1 ug kg-1 administered by a syringe pump over a 10-min period followed by an infusion of 0.4 ug kg-1h-1 dexmedetomidine during the surgery. Just after intrathecal injection, all drugs were infused intravenously. The infusions will be stopped at the end of surgery.
88979046|NCT02965586|Active Comparator|intrathecal dexmedetomidine group|intrathecal2.5 ml of heavy bupivicaine 0.5% pulse 0.5 mg morphine and dexmedetomidine (10µg) and will receive an equal volume of saline intravenously
88979047|NCT02965586|Placebo Comparator|control group|intrathecal 2.5 ml of heavy bupivicaine0.5% pulse 0.5 mg morphine and will receive an equal volume of saline intravenously
88979048|NCT00284908|Experimental|I STU-Na|Cross-over study with escalating doses
89597249|NCT05024422|Active Comparator|Administration of Vitamin B6|200 mg X 3 per day for a week
89597250|NCT04272502|Experimental|Sequence A|CKD-828, D326, D337, CKD-F1, CKD-F2
89597251|NCT04272502|Experimental|Sequence B|CKD-828, D326, D337, CKD-F1, CKD-F2
89597252|NCT04272502|Experimental|Sequence C|CKD-828, D326, D337, CKD-F1, CKD-F2
89597253|NCT04758130|Experimental|App Group|Patients in this group are provided with a link to download the application and their application usage is tracked by the clinic.
89597254|NCT04758130|Placebo Comparator|Placebo Group|Patients in this group are not provided with the clinic link to the application.
89597255|NCT01890070|Placebo Comparator|STANDARD DIET|"each patient is administered a food plan for four weeks. Every patient is required to consume per day:~Standard diet (Mediterrean reference: carbohydrates 55%-60%; protein 15% - 20% of which 50% are of vegetable derivation; total fats < 30% e 30 g of fiber)~Three weeks of washout to avoid additive effects on treatments to follow."
89597256|NCT01890070|Experimental|STANDARD DIET WITH HAZELNUTS|"Intervention type: each patient is administered a food plan for four weeks. Every patient is required to consume per day:~Standard diet (Mediterrean reference: carbohydrates 55%-60%; protein 15% - 20% of which 50% are of vegetable derivation; total fats < 30% e 30 g of fibers) with 40g Italian hazelnuts from Piedmont with Protected Geographical Indication Certification~Three weeks of washout to avoid additive effects on treatments to follow."
89597257|NCT01890070|Experimental|STANDARD DIET WITH RED WINE|"Intervention type: each patient is administered a food plan for four weeks. Every patient is required to consume per day :~Standard diet (Mediterrean reference: carbohydrates 55%-60%; protein 15% - 20% of which 50% are of vegetable derivation; total fats < 30% e 30 g of fibers) with 200 ml of Italian organic Red Wine.~Three weeks of washout to avoid additive effects on treatments to follow."
89597258|NCT01890070|Experimental|STANDARD DIET WITH CHESTNUTS|"Intervention type: each patient is administered a food plan for four weeks. Every patient is required to consume per day:~Standard diet (Mediterrean reference: carbohydrates 55%-60%; protein 15% - 20% of which 50% are of vegetable derivation; total fats < 30% e 30 g of fibers) with 100 g of Italian organic chestnuts.~Three weeks of washout to avoid additive effects on treatments to follow."
89597259|NCT01890070|Experimental|STANDARD DIET WITH CHOCOLATE|"Intervention type: each patient is administered a food plan for four weeks. Every patient is required to consume per day :~Standard diet (Mediterrean reference: carbohydrates 55%-60%; protein 15% - 20% of which 50% are of vegetable derivation; total fats < 30% e 30 g of fibers) with 100 g of Extra-dark Italian Chocolate (min. 70% of organic cocoa solids)~Three weeks of washout to avoid additive effects on treatments to follow."
89597260|NCT01890070|Experimental|STANDARD DIET WITH WILD MIXED GREEN|"Intervention type: each patient is administered a food plan for four weeks. Every patient is required to consume per day:~Standard diet (Mediterrean reference: carbohydrates 55%-60%; protein 15% - 20% of which 50% are of vegetable derivation; total fats < 30% e 30 g of fibers) with 200 g of Italian organic wild mixed green~Three weeks of washout to avoid additive effects on treatments to follow."
89597261|NCT01890070|Experimental|STANDARD DIET WITH OLIVE OIL|"Intervention type: each patient is administered a food plan for four weeks. Every patient patient is required to consume per day :~Standard diet (Mediterrean reference: carbohydrates 55%-60%; protein 15% - 20% of which 50% are of vegetable derivation; total fats < 30% e 30 g of fibers) with 100g of Italian organic Olive Oil~Three weeks of washout to avoid additive effects on treatments to follow."
89597262|NCT01890070|Placebo Comparator|HIGH FAT DIET|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:~High fat diet (carbohydrates 35%; protein 15%; total fats 50%)~Three weeks of washout to avoid additive effects on treatments to follow."
89597263|NCT01890070|Experimental|HIGH FAT WITH HAZELNUTS|"Intervention type: each patient is administered a food plan for four weeks. Every patient is required to consume per day:~High fat diet (carbohydrates 35%; protein 15%; total fats 50%) with 40g of Italian hazelnuts from Piedmont with Protected Geographical Indication Certification.~Three weeks of washout to avoid additive effects on treatments to follow."
89597264|NCT01890070|Experimental|HIGH FAT WITH RED WINE|"Intervention type: each patient is administered a food plan for four weeks. Every patient is required to consume per day:~High fat diet (carbohydrates 35%; protein 15%; total fats 50%)with 200 ml of Italian organic Red Wine~Three weeks of washout to avoid additive effects on treatments to follow."
89597265|NCT01890070|Experimental|HIGH FAT WITH CHESTNUT|"Intervention type: each patient is administered a food plan for four weeks. Every patient is required to consume per day:~High fat diet (carbohydrates 35%; protein 15%; total fats 50%) with 100 g of Italian organic chestnuts.~Three weeks of washout to avoid additive effects on treatments to follow."
89597266|NCT01890070|Experimental|HIGH FAT WITH CHOCOLATE|"Intervention type: each patient is administered a food plan for four weeks. Every patient is required to consume per day:~High fat diet (carbohydrates 35%; protein 15%; total fats 50%) with 100 g of Extra-dark Italian Chocolate (min. 70% of organic cocoa solids)~Three weeks of washout to avoid additive effects on treatments to follow."
89597267|NCT01890070|Experimental|HIGH FAT WITH WILD MIXED GREEN|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:~High fat diet (carbohydrates 35%; protein 15%; total fats 50%) with 200 g of Italian organic wild mixed green~Three weeks of washout to avoid additive effects on treatments to follow."
89031753|NCT02951117|Experimental|Arm A Venetoclax QD + ABBV-838 Q3W + Dexamethasone|ABBV-838 administered at cohort-defined doses every 3 weeks (Q3W; starting dose 4.0 mg/kg) in combination with venetoclax (400 mg or 800 mg once daily [QD]) and dexamethasone (40 mg once weekly [Q1W]); once the maximum-tolerated-dose (MTD) and recommended phase two dose (RPTD) are determined, ABBV-838 in combination with venetoclax and dexamethasone at RPTD will be administered in a dose expansion phase of the study.
89031754|NCT02951117|Experimental|Arm B Venetoclax QD + ABBV-838 Q1W or Q2W + Dexamethasone Q1W|"Dose escalation portion will investigate either the ABBV-838 weekly (Q1W) or bi-weekly (Q2W) dosing interval in combination with venetoclax (400 or 800 mg QD) and dexamethasone (40 mg Q1W).~The dose expansion portion will investigate either the ABBV-838 weekly (Q1W) or bi-weekly (Q2W) dosing interval in combination with venetoclax and dexamethasone at the RPTD combination defined from the Dose Escalation portion."
89597268|NCT01890070|Experimental|HIGH FAT WITH OLIVE OIL|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:~High fat diet (carbohydrates 35%; protein 15%; total fats 50%) with 100 of Italian organic Olive oil~Three weeks of washout to avoid additive effects on treatment following."
89597269|NCT01890070|Placebo Comparator|LOW CARBOHYDRATE DIET|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:~Low carbohydrate diet (carbohydrates 35%; protein 30%; total fats 35%)~Three weeks of washout to avoid additive effects on treatments to follow."
89597270|NCT01890070|Experimental|LOW CARBOHYDRATE DIET WITH HAZELNUT|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:~Low carbohydrate diet (carbohydrates 35%; protein 30%; total fats 35%) with 40g Italian hazelnuts from Piedmont with Protected Geographical Indication Certification~Three weeks of washout to avoid additive effects on treatments to follow."
89597271|NCT01890070|Experimental|LOW CARBOHYDRATE DIET WITH RED WINE|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:~Low carbohydrate diet (carbohydrates 35%; protein 30%; total fats 35%) with 200 ml of Italian organic Red Wine~Three weeks of washout to avoid additive effects on treatments to follow."
89597272|NCT01890070|Experimental|LOW CARBOHYDRATE DIET WITH CHESTNUT|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:~Low carbohydrate diet (carbohydrates 35%; protein 30%; total fats 35%) with 100 g of Italian organic chestnuts~Three weeks of washout to avoid additive effects on treatments to follow."
89597273|NCT01890070|Experimental|LOW CARBOHYDRATE DIET CHOCOLATE|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:~Low carbohydrate diet (carbohydrates 35%; protein 30%; total fats 35%) with 100 g of Extra-dark Italian Chocolate (min. 70% of organic cocoa solids)~Three weeks of washout to avoid additive effects on treatments to follow."
89597274|NCT01890070|Experimental|LOW CARBOHYDRATE DIET WITH WILD MIXED GREEN|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:~Low carbohydrate diet (carbohydrates 35%; protein 30%; total fats 35%) with 200 g of Italian organic wild mixed green~Three weeks of washout to avoid additive effects on treatments to follow."
89597275|NCT01890070|Experimental|LOW CARBOHYDRATE DIET WITH OLIVE OIL|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:~Low carbohydrate diet (carbohydrates 35%; protein 30%; total fats 35%) with 100 of Italian organic Olive Oil~Three weeks of washout to avoid additive effects on treatments to follow."
89597276|NCT01890070|Placebo Comparator|HIGH PROTEIN DIET|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:~High protein diet (carbohydrates 30%; protein 40%; total fats 30%)~Three weeks of washout to avoid additive effects on treatments to follow."
89597277|NCT01890070|Experimental|HIGH PROTEIN DIET WITH HAZELNUT|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:~High protein diet (carbohydrates 30%; protein 40%; total fats 30%) with 40g Italian hazelnuts from Piedmont with Protected Geographical Indication Certification"
89597278|NCT01890070|Experimental|HIGH PROTEIN DIET WITH RED WINE|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:~High protein diet (carbohydrates 30%; protein 40%; total fats 30%) with 200 ml of Italian organic Red Wine~Three weeks of washout to avoid additive effects on treatments to follow."
89597279|NCT01890070|Experimental|HIGH PROTEIN DIET WITH CHESTNUT|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:~High protein diet (carbohydrates 30%; protein 40%; total fats 30%) with 100 g of Italian organic chestnuts~Three weeks of washout to avoid additive effects on treatments to follow."
89597280|NCT01890070|Experimental|HIGH PROTEIN DIET WITH CHOCOLATE|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:~High protein diet (carbohydrates 30%; protein 40%; total fats 30%) with 100 g of Extra-dark Italian Chocolate (min. 70% of organic cocoa solids)~Three weeks of washout to avoid additive effects on treatments to follow."
89597281|NCT01890070|Experimental|HIGH PROTEIN DIET WITH ITALIAN ORGANIC WILD MIXED GREEN|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:~High protein diet (carbohydrates 30%; protein 40%; total fats 30%) with 200 g of Italian organic wild mixed green~Three weeks of washout to avoid additive effects on treatments to follow."
89597282|NCT01890070|Experimental|HIGH PROTEIN DIET WITH OLIVE OIL|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:~High protein diet (carbohydrates 30%; protein 40%; total fats 30%) with 100 of Italian organic Olive Oil~This is followed by a 3 week wash out period, to neutralize any additive effects."
89597283|NCT02819596|Experimental|Savolitinib|600 mg of Savolitinib monotherapy will administered once a day until study completion or withdrawal
89597284|NCT02819596|Experimental|MEDI4736|1500 mg MEDI4736 will be administered every 4 weeks until study completion or withdrawal
89597285|NCT02819596|Experimental|Savolitinib and MEDI4736|Savolitinib and MEDI4736 will be administered at the Recommended Phase 2 dose ascertained in the phase Ib.
89597286|NCT02819596|Experimental|Tremelimumab and MEDI4736|Subjects will receive 75 mg of Tremelimumab and 1500 mg medi4736 every 4 weeks for the first four cycles, then 750 mg MEDI4736 every 4 weeks until study completion or withdrawal.
89210060|NCT00901524|No Intervention|PegIFN- alpha 2a + RBV|
89597287|NCT02818894|Active Comparator|Lidocaine prior to THA|Participants scheduled for Total Hip Arthroplasty through anterior approach with Lidocaine spinal anesthesia and completing telephone questionnaires to see how they are feeling post-operation.
89597288|NCT02818894|Active Comparator|Bupivacaine prior to THA|Participants scheduled for Total Hip Arthroplasty through anterior approach with Bupivacaine spinal anesthesia and completing telephone questionnaires to see how they are feeling post-operation.
89210061|NCT00893412|Active Comparator|Tramadol + Metal cannula|Fast-release Orodispersible Tramadol Tablet + Metal cannula
89210062|NCT00893412|Placebo Comparator|Placebo + Metal cannula|Placebo + Metal cannula
89597289|NCT01890304|Other|Magnetic Resonance Imaging (MRI)|Athletes at risk for mild traumatic brain injury during the course of competitive play or practice. An MRI will be obtained at study entry, following any TBI occuring during sanctioned practice or play, and at study exit.
89597290|NCT01893736|No Intervention|Control|In-hospital usual care consists of routine intrapartum and postnatal obstetric care. No extra intervention will be provided by research team.
89597291|NCT01893736|Experimental|In-hospital professional support|"The participants in in-hospital professional support arm will receive three 30-minute one-to-one hands-on breastfeeding counseling sessions during postpartum hospitalization."
89597292|NCT01893736|Experimental|Postpartum telephone follow-up support|"Participants in postpartum telephone follow-up support arm will receive telephone support in the first 4 weeks postpartum."
89597293|NCT02672644|Experimental|Emervel Classic|Subjects treated with Emervel Classic (moderate NLFs; WSRS = 3/3). Subjects receiving bilateral treatment of NLFs following approved product labeling.
89597294|NCT02672644|Experimental|Emervel Deep|Subjects treated with Emervel Deep (severe NLFs; WSRS = 4/4). Subjects receiving bilateral treatment of NLFs following approved product labeling.
89597295|NCT05586646|No Intervention|control group|100 critically ill patients will be enrolled on high protein diet either enteral or parenteral but not receiving any glutamine supplementations
89597296|NCT05586646|Experimental|alanyl-glutamine group|100 critically ill patients will be enrolled on high protein diet and receiving IV alanyl Glutamine with dose 0.3 gm/kg/ day which equal 1.5 ml/kg/day of alanyl-glutamine until discharge from ICU, death (with duration of 2 weeks administration).
89597297|NCT05586568|Experimental|XZP-3621 tablet and itraconazole oral liquid|
89597298|NCT05586568|Experimental|XZP-3621 tablet and Rifampicin capsules|
89597299|NCT05586568|Experimental|XZP-3621 tablet and esomeprazole tablet|
89597300|NCT01893814|Active Comparator|Probiotics|
89597301|NCT01893814|Placebo Comparator|Control|
89597302|NCT02660320|Active Comparator|Dermabrasion|Dermabrasion using dermaroller: The dermaroller is applied on the treated areas, this dermabrasion technique is based on micro holes performed using 540 micro needles (200µm depth) which should allow the penetration of the suspension cells or hyaluronic acid alone. Twelve passages will be performed on the treated area in order to achieve 60% of coverage.
89597303|NCT02660320|Placebo Comparator|Laser|To prepare the graft recipient site, the upper layer of epidermis is removed by superficial dermabrasion using Erbium or CO2 ablative laser. The test area is ready to receive suspension cells when the dermis will appeared. The cells suspension will be applied on the wound.
89597304|NCT02655406|Active Comparator|Compression stockings|Patients randomised to group A will be asked to wear compression stockings for 1 week
88979049|NCT00284947|Experimental|Maintenance immunosuppression|"40mg Simulect i.v, once every 28 days for 24 weeks (treatment periods)~1g MMF or 720mg EC-MPS p.o twice daily~Oral corticosteroids"
89597305|NCT02655406|No Intervention|No compression|Patients randomised to group B will be provided with bandages to wear for 24 hours only, with no further compression afterwards
88979050|NCT00417235|Experimental|3-days dressing frequency/CHX sponge|"Interventions:~Device: 'Chlorhexidine Sponge (Biopatch TM)' on the insertion site"
88979051|NCT00417235|Experimental|7-days dressing frequency/CHX sponge|"Interventions:~Behavioural: 7-day catheter dressing frequency Device: 'Chlorhexidine Sponge (Biopatch TM)' on the insertion site"
88979052|NCT00417235|No Intervention|3-days dressing frequency/No CHX sponge|No intervention, classical protocol of dressing frequency every 3-days and no other device
88979053|NCT00417235|Experimental|7-days dressing change/No CHX sponge|Interventions:Behavioural: 7-day catheter dressing frequency
88979054|NCT00110760|Experimental|S-Caine Peel|
88979055|NCT00110760|Placebo Comparator|Placebo Peel|
88979056|NCT00077324||Surgery + blood and serum collection|"Patients undergo lung resection. Patients also undergo preoperative and postoperative collection of whole blood and serum for proteomic profiling using surface-enhanced laser desorption/ionization-time of flight mass spectrometry. A lung tissue biopsy taken at surgery is also analyzed.~Patients are followed at 60-90 days and then annually for 2-5 years."
88979057|NCT00285298|Experimental|Pentoxifylline|
88979058|NCT00285298|Placebo Comparator|Placebo|
88979059|NCT00285376|Experimental|1|vilazodone
88979060|NCT00285376|Placebo Comparator|2|
88979061|NCT00077363|Experimental|Treatment (tipifarnib, capecitabine)|Patients receive oral tipifarnib twice daily and oral capecitabine twice daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 4 additional courses beyond documentation of CR.
88979062|NCT00285415|Other|Doc and Car|Receiving Doc and Car
88979063|NCT00110799|Active Comparator|Arm B|SB-497115-GR 30mg administered orally daily for 12 weeks beginning 4 weeks prior to initiating 8 weeks of antiviral therapy and for 8 weeks during weekly antiviral therapy.
88979064|NCT00110799|Active Comparator|Arm C|SB-497115-GR 50mg administered orally daily for 12 weeks beginning 4 weeks prior to initiating 8 weeks of antiviral therapy and for 8 weeks during weekly antiviral therapy.
88979065|NCT00110799|Active Comparator|Arm D|SB-497115-GR 75mg administered orally daily for 12 weeks beginning 4 weeks prior to initiating 8 weeks of antiviral therapy and for 8 weeks during weekly antiviral therapy.
88979066|NCT00110799|Placebo Comparator|Arm A|Placebo administered orally daily for 12 weeks beginning 4 weeks prior to initiating 8 weeks of antiviral therapy and for 8 weeks during weekly antiviral therapy.
88979067|NCT00285532||Home test kit|
88979068|NCT00285688||1|Gastroscope positive for H. pylori and resistant to clarithromycin
88979069|NCT00285688||2|Gastroscope positive for H. pylori and not resistant to clarithromycin
88979070|NCT00285805|Other|Rosiglitazone-placebo|
89597306|NCT02624908|Active Comparator|canagliflozin|Subjects randomized to this arm will start with 100 mg tablet and increase to 300 mg tablet at Visit 4 if well tolerated.
89597307|NCT02624908|Placebo Comparator|placebo|Subjects randomized to this arm will start with 100 mg tablet and increase to 300 mg tablet at Visit 4 if well tolerated.
89597308|NCT02616406||Open repair|Repair group to be monitored with wearable activity monitors pre and post op.
89597309|NCT02616406||Laparoscopic group|Laparoscopic surgical repair group to be monitored with wearable activity monitors pre and post op.
89597310|NCT02597374|Experimental|Experimental|A 45 mn EEG for all the participants.
89597311|NCT05586412|Experimental|exercise therapy group|Exercise therapy group; joint range of motion exercises including the upper extremity, strengthening, stretching, isometric and posture exercise program will be given. These exercises are in the form of a home program and will be asked to do 2 sets a day, 5 days a week, and 10 repetitions of each movement for 4 weeks.
89597312|NCT05586412|Experimental|vagus stimulation group|To the patients in the vagus stimulation treatment group; Auricular vagus nerve stimulation in the physical therapy and rehabilitation unit, 20 sessions in total, 5 days a week, and 30 minutes each session. will be applied. Patients will be treated in the form of daily arrival and departure. Vagus nerve stimulation will be performed using a TENS device with specially designed ear-shaped surface electrodes, the size of which can be selected according to any size ear. The electrodes will be placed on the inner and outer surface of the tragus and the concha. Waveform biphasic asymmetrical, pulse duration less than 500 microseconds and frequency of 10 hertz for 30 minutes. been applied continuously throughout and the amplitude will be adjusted according to the sensory threshold level.
89597313|NCT05586412|Experimental|exercise-vagus stimulation group|Exercise and vagus stimulation treatment group; Both the applications made to the patients in the vagus stimulation group and the same exercises given to the patients in the exercise therapy group will be given as a home program. Patients in all groups will be evaluated with different parameters twice, before and after the treatment.
89597314|NCT02587000|Active Comparator|Ulipristal acetate|ESMYA® : 2 tablets of 5mg per day during 3 months, per os
89597315|NCT02587000|Placebo Comparator|Placebo|2 tablets of 5mg per day during 3 months, per os
89597316|NCT04757818|Experimental|0.07% cetylpyridinium chloride (CPC) in mouthwash|Single dose. A mouthwash and gargles with 15 ml of product for 1 minute.
89597317|NCT04757818|Placebo Comparator|Distilled water with the same colorant as the experimental product|Single dose. A mouthwash and gargles with 15 ml of product for 1 minute.
89597318|NCT04758052|Experimental|simultaneous tracheostomy with gastrostomy (TSG)|This arm include the patients assigned to placement of gastrostomy immediately after tracheostomy.
89597319|NCT04758052|No Intervention|non-simultaneous or delayed approach tracheostomy and gastrostomy (TDG)|"This arm include the patients who proceed with usual care placement of tracheostomy and gastrostomy as per Neurocritical care Unit service standard."
89597320|NCT02563678|Active Comparator|Diabetics with active, chronic infection|Adult patients with diabetes mellitus and current antibiotic use for active infection will have blood drawn before and after their first and fourth clinical hyperbaric oxygen treatments.
89597321|NCT02563678|Active Comparator|No diabetes or infection|Adult patients without diabetes and not using antibiotics will have blood drawn before and after their first and fourth clinical hyperbaric oxygen treatments.
89597322|NCT02563678|Active Comparator|Critically ill patients with infection|Adult patients with acute, life-threatening infection for which hyperbaric oxygen is clinically indicated will have blood drawn before and after their first and fourth clinical hyperbaric oxygen treatments.
89597323|NCT02563678|Active Comparator|Carbon monoxide patients|Adult patients with acute carbon monoxide poisoning will have blood drawn before and after their first clinical hyperbaric oxygen treatment.
89597324|NCT02563678|Active Comparator|Glucose tolerance test|Diabetic patients co-enrolled in a hyperbaric oxygen and glucose control study will have blood drawn before and after their glucose tolerance test and their first clinical hyperbaric oxygen treatment.
89597325|NCT02563678|Experimental|Brain injury research subjects|Research subjects co-enrolled in a study examining hyperbaric oxygen for post-concussive symptoms will have blood drawn before and after their first and fourth hyperbaric chamber sessions.
89597326|NCT02563678|Experimental|Hyperbaric chamber inside attendants|Hyperbaric chamber inside attendants will have their blood drawn before, mid-session, and after their chamber exposure during their regular duty day. The hyperbaric chamber exposure will include hyperbaric air and hyperbaric oxygen components (hyperbaric air/oxygen).
89597327|NCT02563678|Active Comparator|Volunteers, hyperbaric oxygen|Healthy adult volunteers will have blood drawn before and after a single hyperbaric chamber session.
89597328|NCT02563678|Experimental|Volunteers, normobaric pressure|Healthy volunteers will have their blood drawn before and after breathing 100% oxygen at atmospheric pressure (normobaric oxygen) for 120 minutes.
88979071|NCT00285805|Other|placebo-rosiglitazone|
88979072|NCT00285844|Experimental|pioglitazone|IR and IS subjects will be randomized to pioglitazone 45 mg daily for 16 wks for comparison with dietary weight loss intervention
88979073|NCT00285844|Experimental|Dietary Weight Loss|IR and IS subjects will be randomized to dietary weight loss for 16 wks for comparison to pioglitazone intervention
88979074|NCT00077441|Experimental|Treatment (bortezomib)|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
88979075|NCT00110877|Experimental|002|LPV/rtv One 400mg LPV tablet twice daily with 100mg RTV
88979076|NCT00110877|Experimental|001|TMC114/rtv Two 300mg TMC114 tablets twice daily with 100mg RTV
88979077|NCT00286117|Experimental|1|Anastrozole
88979078|NCT00286117|Active Comparator|2|Tamoxifen
88979079|NCT00286195|No Intervention|I|Consecutive patients, open label
88979080|NCT00110916|Experimental|Anakinra|anakinra
88979081|NCT00110916|Placebo Comparator|placebo|placebo
88979082|NCT00286273|Active Comparator|citrate|regional anticoagulation with citrate
88979083|NCT00286273|Active Comparator|nadroparin|nadroparin is a low molecular weight heparin
88979084|NCT00110955|Experimental|Darbepoetin alfa - Group A|
88979085|NCT00110955|Placebo Comparator|Placebo- Group B|
88979086|NCT04730180|Active Comparator|No neuronavigation|For this group, the stimulation location for repetitive transcranial stimulation treatment is estimated by the clinician via scalp measurements.
88979087|NCT04730180|Active Comparator|Mixed reality neuronavigation|For this group, the stimulation location for repetitive transcranial stimulation treatment is estimated by the clinician via a mixed reality neuronavigation device.
88979088|NCT00286507|Active Comparator|ILM peeling|Combined cataract surgery (phacoemulsification and intraocular lens implantation) and pars plana vitrectomy with postoperative intraocular tamponade with gas, with ILM peeling
89031755|NCT02941809|Experimental|Open-Label Placebo (OLP)|Participants who are randomly assigned to group OLP will receive placebo pills. In Phase 1 of the study (first two weeks), participants in this group are given one pill, to be taken concomitant with the methadone. In Phase 2 (3 weeks up to 3 months), OLP participants continue to take the single (morning, or AM) pill, and are given a second pill in a bottle as a take-home. OLP participants will meet with the study team at five time points: at baseline (entry into treatment), 2 weeks post-baseline, and 1-, 2- and 3-months post-baseline.
89597329|NCT02562430|Experimental|Active Treatment|12.5 % will be randomized to Welbutrin XL in phase 1 of the study.
89597330|NCT02562430|Active Comparator|Placebo Group|87.5% will be randomized to receive placebo in phase 1 of the study.
89597331|NCT02556424|Active Comparator|Reference Drug|Intravitreal implant of 700μg of dexamethasone (Ozurdex®)
89597332|NCT02556424|Experimental|Tested Drug|Subconjunctival injection of 16 mg triamcinolone (Kénacort Retard®)
89597333|NCT02549638||Tissue Collection|We plan to prospectively collect 5 bronchoscopic biopsies, 3ml blood and one tumor and adjacent normal samples from 200 qualified patients who meet the study criteria. If a patient has already had a bronchoscopy and has samples available that were previously collected and stored for research at the Mayo Clinic we will use those samples.
89597334|NCT02543944|Active Comparator|Gabapentin|"Gabapentin started on day 3 of week 1, increased up to a maximum dose of 800 mg BID by day 3 of week 2 and maintained for 2 weeks followed by 5-day taper.~Buprenorphine (BUP) stabilization up to 12 mg (day 2 of week 1) then a 10-day BUP taper by the end of week 3.~During week 4, detoxed subjects get 0.1 mg of clonidine followed by oral naltrexone (NTX) at 6.25 mg and another 6.25 mg (day 1), 25 mg (day 2) and 50 mg (day 3) then depot NTX injection (later on day 3 or day 4)."
89031756|NCT02941809|No Intervention|Treatment as Usual (TAU)|Participants assigned to TAU will not be given placebo pills, but all interactions with the study team (5 meetings total) will be matched in frequency and length.
89597335|NCT02543944|Placebo Comparator|Placebo|"Participants in this arm begin receiving placebo (microcrystalline cellulose) in twice daily capsules on day 3 of week 1 and continue to do so through the beginning of week 5.~Buprenorphine (BUP) stabilization up to 12 mg (day 2 of week 1) then a 10-day BUP taper by the end of week 3.~During week 4, detoxed subjects get 0.1 mg of clonidine followed by oral naltrexone (NTX) at 6.25 mg and another 6.25 mg (day 1), 25 mg (day 2) and 50 mg (day 3) then depot NTX injection (later on day 3 or day 4)."
89597336|NCT02531308|Experimental|R-CHOP with Metformin|"Rituximab 375 mg/m2 IV infusion Day 1 Cyclophosphamide 750 mg/m2 IV Day 1 Doxorubicin 50 mg/m2 IV Day 1 Vincristine 1.4 mg/m2 (2 mg cap) IV Day 1 Prednisone 100 mg PO Days 1-5 Pegfilgrastim 6 mg subcutaneous within 72 hours of cyclophosphomide Metformin 500 mg PO daily D 1-7, 500 mg twice daily D8-21, 850 mg twice daily D22 - 30days post study.~Cycles are 21 days. Above treatment given for 4 cycles, then restaging done. If complete response (CR) or partial response (PR), 2 more cycle given; stable disease (SD) or progressive disease (PD)- salvage therapy off study."
89597337|NCT02523976|Experimental|Arm A|Dasatinib 100 mg per day will be given orally along with combination chemotherapy starting day 8 of induction chemotherapy. Dasatinib will be given continuously (if it's tolerable) for 2 years since achievement of complete remission (CR) as part of consolidation chemotherapy and maintenance therapy.Patients can receive allogeneic hematopoietic stem cell transplantation (HSCT),or patients who keep BCR/ABL negative can receive autologous HSCT whenever possible during their first CR. Otherwise, they will finish the consolidation chemotherapy.
89597338|NCT02507986|Active Comparator|7-Day Holter monitor|This arm will receive a 7-Day Holter monitor directly after randomization.
89031757|NCT02951000|Active Comparator|platysma suture|running suture of the platysma with 3/0 polyglactin
89031758|NCT02951000|Active Comparator|no platysma suture|no platysma suture
89031759|NCT02941770|No Intervention|Control group|"Clinic standard care protocol:~Baseline evaluation session with a Pediatrician for initial screening;~Appointment with a Dietitian;~A brochure with physical activity guidelines for youth with examples of physical exercises."
89031760|NCT02941770|Experimental|Intervention group I|"Clinic standard care protocol;~Physical activity consultation (Physical activity behavior change);"
89031761|NCT02941770|Experimental|Intervention group II|"Clinic standard care protocol;~Physical activity consultation;~2 exercise sessions per week (≈60 min/session) directed by one Exercise Physiologist."
89031762|NCT02950181|Experimental|Specific Aim|Correlating the NIRS/Cerebral Oximetry readings to the various critical ill and injured pediatric patients, trends, interventions, and outcomes
89597339|NCT02507986|Experimental|Single lead ECG device|This arm will be asked to take a single lead ECG two times per day and in case of complaints with a single lead ECG device.
89597340|NCT02505958|Other|high caloric intake|Volunteers will receive 3 meals and 3 snacks over a 24 hour period which will contain ~ 6,000 calories. Main meals will consist of ~ 1,500 calories and snacks will contain ~ 500 calories.
89031763|NCT02941536|Other|Circulating Tumor Cells and Radiotherapy|Circulating tumor cells evaluation before and 4-5 weeks after focal stereotactic radiotherapy in single (SRS) or fractionated (SFRT) dose and correlate with the local and distant brain progression free survival in patients with metastatic breast cancer
89210063|NCT00893412|Active Comparator|Tramadol + Balloon|Fast-release Orodispersible Tramadol Tablet + balloon catheter
89597341|NCT02505958|Other|reduced caloric intake|On days 5 and 6 subjects will receive 3 meals only and each meal will contain ~ 333 calories for a total of 1,000/ 24 hours.
89597342|NCT01893892|Experimental|Arm I (levocarnitine start)|Patients receive levocarnitine PO BID during weeks 1-4. Washout is weeks 5-8. Patients then cross-over to placebo for weeks 9-12.
89597343|NCT01893892|Placebo Comparator|Arm II (placebo start)|Patients receive placebo PO BID during weeks 1-4. Washout is weeks 5-8. Patients then cross-over to levocarnitine for weeks 9-12.
89597344|NCT04757974|Experimental|Part 1: Treatment sequence ABC|Participants will receive FTR 3×200 mg ER tablets (Treatment A) in Period 1 followed by FTR 3×200 mg ER tablets (Treatment B) in Period 2 followed by FTR 600 mg ER tablet (Treatment C, reference) in Period 3.
89597345|NCT04757974|Experimental|Part 1: Treatment sequence BCA|Participants will receive FTR 3×200 mg ER tablets (Treatment B) in Period 1 followed by FTR 600 mg ER tablet (Treatment C, reference) in Period 2 followed by FTR 3×200 mg ER tablets (Treatment A) in Period 3.
89597346|NCT04757974|Experimental|Part 1: Treatment sequence CAB|Participants will receive FTR 600 mg ER tablet in Period 1 (Treatment C, reference) followed by FTR 3×200 mg ER tablets (Treatment A) in Period 2 followed by FTR 3×200 mg ER tablets (Treatment B) in Period 3.
89597347|NCT04757974|Experimental|Part 1: Treatment sequence ACB|Participants will receive FTR 3×200 mg ER tablets (Treatment A) in Period 1 followed by FTR 600 mg ER tablet (Treatment C, reference) in Period 2 followed by FTR 3×200 mg ER tablets (Treatment B) in Period 3.
88979089|NCT00286507|Active Comparator|No ILM peeling|combined cataract surgery (phacoemulsification and intraocular lens implantation) and pars plana vitrectomy with postoperative intraocular tamponade with gas without ILM peeling
88979090|NCT00286585|Active Comparator|Inhalational anesthetic|Sevoflurane will be used as the main anesthetic in this arm, and no propofol will be administered
88979091|NCT00286585|Active Comparator|Intravenous anesthetic, propofol|Propofol will be used as the main anesthetic in this arm, and no inhalational anesthetic will be administered
88979092|NCT00286624|Experimental|1|Allogeneic islet transplantation with anti-thymocyte globulin induction and cyclosporine and RAD maintenance immunosuppression
88979093|NCT00077597|Experimental|1|
88979094|NCT00077597|Active Comparator|2|
88979095|NCT00286780|Experimental|1|
88979096|NCT00286819|Experimental|the FEC75 regimen|"Arm A: the FEC75 regimen will be given at the following doses:~Fluorouracil 500mg/m2 by i.v. bolus or infusion. Epirubicin 75mg/m2 by 30 minutes i.v infusion and Cyclophosphamide 500mg/m2 by i.v bolus or infusion. All three drugs will be administered intravenously on Day 1 of each 14-day cycles."
88979097|NCT00286819|Experimental|FEC90 regimen|"Arm B: the FEC90 regimen will be given at the following doses:~Fluorouracil 500mg/m2 by i.v. bolus or infusion.Epirubicin 90mg/m2 by 30 minutes i.v infusion and Cyclophosphamide 500mg/m2 by i.v bolus or infusion.~All three drugs will be administered intravenously on Day 1 of each 14-day cycles.~Pegfilgrastim fixed dose of 6mg as a single subcutaneous injection will be given in both arms on Day 2 of each cycle."
88979098|NCT00417391|Experimental|1 mg RR110|1 mg RR110
88979099|NCT00417391|Experimental|4 mg RR110|4 mg RR110
88979100|NCT00417508|Experimental|Nutritional supplement|2 packages/day with nutritional supplement containing a total of 600 kcal and 40 g protein
88979101|NCT00417508|Active Comparator|Dietary advice|ordinary dietary advice with a recommendation of four meals per day or similar dietary advice
88979102|NCT00111189|Experimental|001|Paliperidone Palmitate 25, 50, 75 or 100 mg eq every 4 wk for up to 24 mo
89597348|NCT04757974|Experimental|Part 1: Treatment sequence BAC|Participants will receive FTR 3×200 mg ER tablets (Treatment B) in Period 1 followed by FTR 3×200 mg ER tablets (Treatment A) in Period 2 followed by FTR 600 mg ER tablet (Treatment C, reference) in Period 3.
89597349|NCT04757974|Experimental|Part 1: Treatment sequence CBA|Participants will receive FTR 600 mg ER tablet (Treatment C, reference) in Period 1 followed by FTR 3×200 mg ER tablets (Treatment B) in Period 2 followed by FTR 3×200 mg ER tablets (Treatment A) in Period 3.
89597350|NCT04757974|Experimental|Part 2: Treatment sequence DE|Participants will receive the selected low-dose formulation of FTR 3 × 200 mg ER tablets in a fasted state (Treatment D) in Period 1 and following a high fat high calorie meal (Treatment E) in Period 2.
89597351|NCT04757974|Experimental|Part 2: Treatment sequence ED|Participants will receive the selected low-dose formulation of FTR 3 × 200 mg ER tablets following a high fat high calorie meal (Treatment E) in Period 1 and in a fasted state (Treatment D) in Period 2.
88979103|NCT00111189|Placebo Comparator|002|Placebo Placebo every 4 wk up to 24 mo
88979104|NCT02960698|Active Comparator|TREATED PATIENT WITH TOURETTE SYNDROME|comportemental tasks included impulsivity tests will performed at V1 Resting state IRM will be performed at V2 40 patients
88979105|NCT02960698|Active Comparator|UNTREATED PATIENT WITH TOURETTE SYNDROME|comportemental tasks included impulsivity tests will performed at V1 Resting state IRM will be performed at V2 40 patients
88979106|NCT02960698|Placebo Comparator|Healthy volunteers|comportemental tasks included impulsivity tests will performed at V1 Resting state IRM will be performed at V2 80 subjects
88979107|NCT00287092|Experimental|Group 1|Participants will receive PEDIACEL vaccine
88979108|NCT00287092|Active Comparator|Group 2|Participants will receive Infanrix-IPV+Hib vaccines
88979109|NCT00287248|Experimental|Assess [123I] IMPY & SPECT Imaging|To assess [123I] IMPY & SPECT Imaging
88979110|NCT00077948|Experimental|active enoximone plus active ER metoprolol|
88979111|NCT00077948|Active Comparator|placebo enoximone plus active ER metoprolol|
88979112|NCT00077948|Placebo Comparator|placebo enoximone plus placebo ER metoprolol|
88979113|NCT00111345|Experimental|1|Daunoxome, standard risk
88979114|NCT00111345|Active Comparator|2|Idarubicin, standard risk
88979115|NCT00111345|Experimental|3|Daunoxome, high-risk, 2-CDA
88979116|NCT00111345|Active Comparator|4|Idarubicin, high-risk, nothing
88979117|NCT00287521|Experimental|AL-37807 Suspension|
88979118|NCT00287521|Active Comparator|Xalatan|
88979119|NCT00287521|Placebo Comparator|AL-37807 Vehicle|
88979120|NCT00287521|Experimental|Timolol Maleate|
89031764|NCT02951078|Experimental|Thulium Laser en Bloc Resection of bladder tumor|Thulium Laser en Bloc Resection of the Non-muscle Invasive Bladder tumor with thulium laser
89597352|NCT04757506|Placebo Comparator|Placebo|cellulose-filled capsule
89597353|NCT04757506|Experimental|Naltrexone|single 50 mg oral dose naltrexone (capsule)
89597354|NCT02484820|Experimental|Pessary|Silicone pessary is associated with standard care Silicone pessary is used between 24 weeks of pregnancy and up to 6 weeks after the date of the term (maximum 6 months)
89597355|NCT02484820|No Intervention|Control|Standard care only, No silicone pessary will be placed in the vagina.
89597356|NCT02477644|Experimental|Olaparib|Tablets per os 300 mg
89597357|NCT02477644|Placebo Comparator|Placebo|Tablets per os 300 mg
89597358|NCT02472028|Experimental|blood pressure lowering algorithm|enhanced strategy aiming to reduce systolic blood pressure to <135 mmHg
89597359|NCT02472028|Active Comparator|usual strategy|usual strategy based on the usual care of routine care
89597360|NCT02466334|Active Comparator|Active|1.5µg/min IV calcitonin-gene related peptide for 20 minutes
89597361|NCT02466334|Placebo Comparator|Placebo|IV placebo for 20 minutes
89597362|NCT02460874|Experimental|Pilot Portion|"Step 1: Patients with brain metastases requiring SRS and not taking corticosteroids 5 days prior to SRS. Treatment planning MRI may be done within 21 days prior to SRS treatment.~Step 2: Take Glyburide 1.25mg (twice a day by mouth) beginning 5 days prior to SRS. Receive glucose monitoring materials and blood glucose education- begin glucose monitoring (4 times a day).~Step 3: 1 week after SRS, return to clinic to review glucose logs- continue glyburide and blood glucose monitoring.~Step 4: 1 month after SRS, discontinue both glyburide and blood glucose monitoring, undergo MRI.~Step 5: 3 months after SRS, undergo MRI."
89597363|NCT02460874|Placebo Comparator|Randomized Portion|"Step 1: Patients with brain metastases requiring SRS and not taking corticosteroids 5 days prior to SRS.Treatment planning MRI may be done within 21 days prior to SRS treatment.~Step 2: Randomization (1:1)~Group 1: take Glyburide (1.25mg, twice a day by mouth) beginning 5 days prior to SRS. Receive glucose monitoring materials and blood glucose education. Begin glucose monitoring (once a day) {This portion will be double blinded}.~Group 2: Take Placebo (1 pill, twice a day by mouth) beginning 5 days prior to SRS. Receive glucose monitoring materials and blood glucose education. Begin glucose monitoring (once a day) {This portion will be double blinded}.~Step 3: 1 week after SRS, return to clinic to review glucose logs, continue investigation medication, but discontinue glucose monitoring.~Step 4: 1 month after SRS, discontinue investigation medication, undergo MRI.~Step 5: 3 months after SRS, undergo MRI."
89597364|NCT02451436|Active Comparator|Sleep and Media Use Intervention|The sleep intervention group will receive four sessions including cognitive behavioral training aimed at increasing sleep duration, education on the effects of media use on sleep and problem solving with the participant and parent about increasing sleep duration and decreasing nighttime media use.
88979121|NCT00287638|Active Comparator|1|CPAP
88979122|NCT00287638|Placebo Comparator|2|no CPAP
88979123|NCT00287677|Experimental|A|growth hormone + vaccination + HAART
88979124|NCT00287677|Experimental|B|growth hormone + HAART
89210064|NCT00893412|Placebo Comparator|Placebo + Balloon|Placebo + balloon catheter
89597365|NCT02451436|Active Comparator|Study Skills Control Group|The control group will receive four sessions of study skills training.
89597366|NCT02443324|Experimental|Ramucirumab + Pembrolizumab (Phase 1a Schedule 1)|Gastric-GEJ, BTC: Ramucirumab given intravenously (IV) on day 1 and 8 in combination with pembrolizumab given IV on day 1 of a 21 day cycle.
89597367|NCT02443324|Experimental|Ramucirumab + Pembrolizumab (Phase 1a Schedule 2)|Gastric, NSCLC, Urothelial: Ramucirumab given IV on day 1 in combination with pembrolizumab given IV on day 1 of a 21 day cycle.
89597368|NCT02443324|Experimental|Ramucirumab + Pembrolizumab (Phase 1b Cohort A)|Gastric-GEJ: Ramucirumab given IV on day 1 and 8 in combination with pembrolizumab given IV on day 1 of a 21 day cycle.
89597369|NCT02443324|Experimental|Ramucirumab + Pembrolizumab (Phase 1b Cohort A1)|BTC: Ramucirumab given IV on day 1 and 8 in combination with pembrolizumab given IV on day 1 of a 21 day cycle.
89597370|NCT02443324|Experimental|Ramucirumab + Pembrolizumab (Phase 1b Cohort A2)|Gastric-GEJ (first line only): Ramucirumab given IV on day 1 and 8 in combination with pembrolizumab given IV on day 1 of a 21 day cycle.
89597371|NCT02443324|Experimental|Ramucirumab + Pembrolizumab (Phase 1b Cohort B)|Gastric-GEJ: Ramucirumab given IV on day 1 in combination with pembrolizumab given IV on day 1 of a 21 day cycle.
89597372|NCT02443324|Experimental|Ramucirumab + Pembrolizumab (Phase 1b Cohort C)|NSCLC: Ramucirumab given IV on day 1 in combination with pembrolizumab given IV on day 1 of a 21 day cycle.
88979125|NCT00287677|Experimental|C|vaccination + HAART
88979126|NCT00287677|Active Comparator|D|control healthy HIV negative + vaccination
88979127|NCT00287755|Experimental|1|
88979128|NCT02960932|Experimental|hemiplegic cerebral child|Ultrasound scanner used to the SSI technical reproducibility.
88979129|NCT00111501|Experimental|Targeted Internet Intervention|Web-based self help intervention developed to include specific cultural tailoring relevant to the LGBT community
88979130|NCT00111501|Active Comparator|Standard Intervention|Standard self-help internet-based intervention with no LGBT relevant information included
88979131|NCT00287833|Experimental|Arm I (Bowman-Birk inhibitor concentrate)|Participants are sequentially assigned to 1 of 4 dose level cohorts. One participant in each dose level cohort is randomized to receive placebo. Participants receive 1 of 4 escalating doses of oral Bowman-Birk inhibitor concentrate or placebo, as an orange juice suspension, on day 1.
89031765|NCT02951078|Active Comparator|Electrical transurethral resection of bladder tumor|Electrical transurethral resection of the Non-muscle Invasive Bladder tumor
89031766|NCT02950376||Group1：amphetamine abusers|
89031767|NCT02950376||Group2: health control|
89031768|NCT02950376||Group3: norm of assessment system|
89031769|NCT00515645|Experimental|1|
89597373|NCT02443324|Experimental|Experimental: Ramucirumab + Pembrolizumab (Phase 1b Cohort D)|Urothelial: Ramucirumab given IV on day 1 in combination with pembrolizumab given IV on day 1 of a 21 day cycle.
89597374|NCT02443324|Experimental|Ramucirumab + Pembrolizumab (Phase 1b Cohort E)|NSCLC: Ramucirumab given IV on day 1 in combination with pembrolizumab given IV on day 1 of a 21 day cycle.
89597375|NCT01893970|Experimental|SWIFT: Acute Social Work Intervention in the ED and Follow Up|Participants will receive: 1) acute social work intervention for adults with mTBI, including early education, reassurance, resources and brief alcohol intervention in the ED (SWIFT-Acute) and 2) follow up telephone counseling, needs assessment and case management referral to necessary services (SWIFT).
89597376|NCT01893970|Active Comparator|SWIFT-Acute Only: Acute social work intervention in the ED|acute social work intervention for adults with mTBI, including early education, reassurance, resources and brief alcohol intervention in the ED (SWIFT-Acute)
89597377|NCT01894048|Experimental|Qvar® (beclometasone dipropionate HFA)|Participants will be converted to Qvar (HFA-beclometasone) at an equivalent therapeutic dose to their original inhaled corticosteroids. The treatment duration will for 8 weeks after a run-in period.
89031770|NCT02950220|Experimental|Arm 1|
89031771|NCT02941497|Experimental|Intensive intervention group|The intensive intervention group participates in development and implementation of the social marketing and health promotion campaign and peer-led campus activities and is assessed for their health-related behaviors. This was Wave 1 in colleges in Yr 01-02 and is being repeated as Wave 2 in colleges in Yr 03. This will also be repeated in high schools in Yr 04.
89031772|NCT02941497|Experimental|Diffuse intervention group|The diffuse intervention group receives the social marketing and health promotion campaign and participates in the peer-led campus activities and is assessed for their health related behaviors, but is not involved in the design and delivery of the intervention materials and activities. This was Wave 1 in colleges in Yr 01-02 and is being repeated as Wave 2 in colleges in Yr 03. This will also be repeated in high schools in Yr 04.
89031773|NCT05317767|Experimental|Flu-M|300 children that will be vaccinated with a single dose of the Flu-M vaccine intramuscularly at a dose of 0.5 mL (150 children aged 12 to 17 years, 150 children aged 6 to 11 years)
89031774|NCT05317767|Active Comparator|Ultrix|300 children that will be vaccinated with a single dose of the Ultrix® vaccine intramuscularly at a dose of 0.5 mL (150 children aged 12 to 17 years, 150 children aged 6 to 11 years)
89031775|NCT02950454|Experimental|Intervention|8 weeks of twice weekly high intensity interval training. Session protocol: 2 minute warm up at nominal resistance on cycle ergometer, 6 six intervals of 80-95% heart rate max interspersed with 6 intervals of 1.5 minute working rest. Then 3 minutes cool down.
89031776|NCT02950454|Active Comparator|control|8 weeks of twice weekly continuous moderate intensity exercise. Session protocol: 2 minutes warm up at nominal resistance on cycle ergometer, 20 minutes at 60-70% heart rate max. Then 3 minutes cool down.
89031777|NCT04695158||COVID-19 group (Group I)|Patients diagnosed with COVID-19 will be in this group. No additional intervention will be applied in this group except the routine COVID-19 treatment according to the Adult Patient Treatment Guide which published by the Ministry of Health, Republic of Turkey on 9 October 2020.
89031778|NCT04695158||Type II Diabetes Mellitus and COVID-19 group (Group II)|Patients diagnosed with both Type II Diabetes Mellitus and COVID-19 will be in this group. No additional intervention will be applied in this group except the routine COVID-19 treatments according to the Adult Patient Treatment Guide which published by the Ministry of Health, Republic of Turkey on 9 October 2020 and routine treatment for Type II Diabetes Mellitus.
89031779|NCT04695158||Control group (Group III)|Healthy volunteers will be in this group. No intervention will be applied in this group.
89031780|NCT05317650|No Intervention|Control group|Control group, no exercise was performed, and the measurements were repeated at the end of 4 weeks.
89597378|NCT02427178|Experimental|Open label|"Hematopoietic allogeneic stem cells will be transplanted:~HLA testing will be performed on potential stem cell donors. HLA 10/10 matched donors are eligible, however there are additional criteria that will be applied to determine an acceptable donor. Patients will receive 2 X10 6 CD34 cells/kg weight."
89597379|NCT02420314|Experimental|Ascorbate, paclitaxel, carboplatin|Paclitaxel, administered once per cycle (3 weeks) Carboplatin, administered once per cycle (3 weeks) Pharmacological ascorbate (ascorbic acid) infusions, 2 times per week for 3 weeks
89597380|NCT02404012|Active Comparator|Ferrous sulfate|Ferrous sulfate 65 mg. t.i.d is the standard of care for oral supplementation for iron deficiency
89597381|NCT02404012|Experimental|AspironTM 65 mg t.i.d.|AspironTM, an organic formulation of iron, is the experimental treatment for oral supplementation of iron deficiency
89597382|NCT01539291|Experimental|High-dose Idelalisib|Participants will receive idelalisib 300 mg twice daily (600 mg per day).
89597383|NCT01539291|Experimental|Standard-dose Idelalisib|Participants will receive idelalisib 150 mg twice daily (300 mg per day)
89597384|NCT04746040|Experimental|Test Product|Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals
89031781|NCT05317650|Experimental|M-Gravity group|Intervention group performed the exercise with the M-Gravity, 2 sessions per week, for 4 weeks, at the Outpatient Clinic of Department of Physical Therapy, Baskent University, one session for 60 minutes.
89031782|NCT02950142|Experimental|CPOE with order sets|Physicians who use CPOE including order sets for large range of indications.
89031783|NCT02950142|Active Comparator|CPOE without order sets|Physicians who use CPOE without order sets.
89597385|NCT04746040|Active Comparator|Reference Product|ADVAIR DISKUS 250/50
89597386|NCT02400814|Experimental|Arm I (concurrent cohort)|Patients receive anti-PD-L1 monoclonal antibody MPDL3280A IV over 30-60 minutes on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Beginning on day 1 of course 1, patients also undergo SAR 2-3 times per week (with a minimum of 40 hours and a maximum of 96 hours between fractions) over 1.5-2 weeks for a total of 5 fractions.
89597387|NCT02400814|Experimental|Arm II (induction cohort)|Patients receive anti-PD-L1 monoclonal antibody MPDL3280A IV over 30-60 minutes on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Beginning on day 1 of course 3, patients also undergo SAR 2-3 times per week (with a minimum of 40 hours and a maximum of 96 hours between fractions) over 1.5-2 weeks for a total of 5 fractions.
89597388|NCT02400814|Experimental|Arm III (sequential cohort)|Patients undergo SAR 2-3 times per week (with a minimum of 40 hours and a maximum of 96 hours between fractions) over 1.5-2 weeks for a total of 5 fractions beginning on day 1 of course 1. After completion of SAR (beginning on day 1 of course 2), patients receive anti-PD-L1 monoclonal antibody MPDL3280A IV over 30-60 minutes on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
89597389|NCT02398240|Experimental|Low Risk|Low Risk Patients (Stage IA, IIA; no bulky disease or extension): 3 cycles of chemotherapy
89597390|NCT02398240|Experimental|Intermediate Risk|Intermediate Risk Patients (Stage IA bulk/E, IB, IIA bulk/E, IIB, IIIA): 4 cycles of chemotherapy
89597391|NCT02398240|Experimental|High Risk|High Risk Patients (Stage IIIA bulk/ E, IIIB, IVA/B): 6 cycles of chemotherapy
89597392|NCT02022280|Experimental|Proton Pump Inhibitor|Lansoprazole (Prevacid)
89597393|NCT02022280|Placebo Comparator|Vitamin pill|
89597394|NCT02372734||Sepsis with acute kidney injury (AKI)|Prior admission for sepsis with a diagnosis of AKI as a child. Intervention: The subjects will be administered the Peds QL survey.
89597395|NCT02372734||Sepsis without acute kidney injury (AKI)|Prior admission for sepsis without a diagnosis of AKI as a child. Intervention: The subjects will be administered the Peds QL survey.
89597396|NCT02364310|Experimental|Baroreceptor stimulation on top of the best medical care|Baroreceptor stimulation with Barostim Neo TM
89597397|NCT02364310|No Intervention|Best medical care|Best medical care
89597398|NCT01538199|Experimental|TLT Treatment Group 1|The TLT group will receive 2 near-infrared radiation via Transcranial LED Therapy (TLT) treatments per week for 8 weeks
89597399|NCT01538199|Sham Comparator|TLT Treatment Group 2|The sham group will receive 2 treatments of the sham device per week for 8 weeks
89597400|NCT01511445|Active Comparator|ACDF with PEEK interbody cage|Anterior cervical discectomy and fusion (ACDF) with an interbody spacer made from polyetheretherketone (PEEK) plastic. The open space in the center of the cage is to be filled with local autologous bone harvested during the decompression phase of the procedure.
89597401|NCT01511445|Experimental|ACDF with Valeo CSC Ceramic Cage|ACDF with the Valeo CSC cage, a silicon nitride ceramic interbody cage. The center area of the cage is filled with porous silicon nitride. No autologous bone is used; the cage is soaked in patient blood.
89597402|NCT01543503||Cohort|
89597403|NCT01511055|Experimental|Folate-FITC|
89031784|NCT04691310|Active Comparator|Kinesio taping study|Kinesio tex gold tape was applied to neck localised lymphedema as stretched. Kinesio tape maintained during consecutive days and also were re applied with manual lymphatic drainage therapy as 5 times first week, and afterthat 2 times for 3 weeks (total 4 weeks)
89031785|NCT04691310|Sham Comparator|Kinesio taping sham|Kinesio tex gold tape was applied to neck localised lymphedema as no-stretched. Kinesio tape maintained during consecutive days and also were re applied with manual lymphatic drainage therapy as 5 times first week, and afterthat 2 times for 3 weeks (total 4 weeks)
89031786|NCT00515762|Experimental|1: scalp cooling|scalp cooling
89031787|NCT00515801|Experimental|A|Glibenclamide 5 mg tablets
89031788|NCT00515801|Placebo Comparator|B|placebo capsules
89031789|NCT03458364|Experimental|High flow nasal cannula|High flow nasal cannula (HFNC) is a type of oxygen device, which provides high concentration oxygen in a high flow, which exceeds patient's inspiratory flow demand, to improve oxygenation.
89210065|NCT00896610||Diabetes|Individuals who have been diagnosed with or are at risk for developing diabetes
89597404|NCT02347540||Women with a history of preeclampsia (cases)|"Cases: women with a history of preeclampsia. Measurements will be performed in a postpartum interval from 0.5 years until 30 years after the first complicated pregnancy.~This group will further be subdivided in a subgroup with Heart Failure and a group without Heart Failure."
89597405|NCT02347540||Women with a history of uncomplicated pregnancy (controls)|Controls include women with a history of uncomplicated pregnancies. The controlgroup will further be subdivided in a subgroup with Heart Failure and a group without Heart Failure.
89597406|NCT02344186|Experimental|Liraglutide|Liraglutide will be started first with 0.6 mg/d for 1 week, then increased to 1.2 mg/d from week 2 to week 12, followed by 1.8 mg/d from week 12 to week 24.
89597407|NCT02344186|Placebo Comparator|Placebo|Subjects will receive placebo for 12 weeks.
89597408|NCT04757428|Active Comparator|Lithium disilicate|The intervention will be: Prosthetic endocrown
89597409|NCT04757428|Active Comparator|Hybrid nanoceramic|The intervention will be: Prosthetic endocrown
89597410|NCT01537887|Placebo Comparator|Placebo|Administered orally once daily for 10 days during 1 of the 3 crossover periods, separated by at least a 14-day washout period.
89597411|NCT01537887|Experimental|1200 milligrams (mg) LY2484595|Administered orally once daily for 10 days during 1 of the 3 crossover periods, separated by at least a 14-day washout period.
89597412|NCT01537887|Active Comparator|400 mg Moxifloxacin|Positive control, unblinded treatment administered orally once during 1 of 3 crossover periods, separated by at least a 14-day washout period.
89597413|NCT04757350||cataract|Research subjects should meet the following criteria: Signed and dated informed consent form Commitment to abide by the research procedures and cooperate with the implementation of the whole process of research 18-90-year-old cataract patients or patients after cataract surgery
89597414|NCT02305264|Experimental|PET -18F-DPA-714 and 18F-FDG|"18F-DPA-714, dose 5mCi (185MBq), will be injected via an arm intravenous catheter.~18F-FDG , dose 5mCi(185MBq), will be injected via an arm intravenous catheter."
89597415|NCT05585944|Active Comparator|control|healthy participants
89597416|NCT05585944|Active Comparator|cases|cases of immune thrombocytopenic purpura
89597417|NCT01489527|Active Comparator|Gardasil Vaccine Administration|Gardasil Vaccine Administration. Family Health International (FHI) statisticians randomly assigned each participant an allocation number and then subsequently assigned a unique vial identification number for the vial of vaccine the participant should receive at each visit. A single participant could not be assigned more than 1 allocation number.
89597418|NCT01489527|Placebo Comparator|Placebo Administration|Placebo Administration. Family Health International (FHI) statisticians randomly assigned each participant an allocation number and then subsequently assigned a unique vial identification number for the vial of vaccine the participant should receive at each visit. A single participant could not be assigned more than 1 allocation number.
89597419|NCT02315170|Experimental|intraocular injection guide|novel intraocular injection guide is a long, tubular structure consisting of a non-moldable material with a single internal opening. There is a 2x2 square hole located at the bottom of the device where the needle exits the guide and enters the eye
89597420|NCT02315170|Active Comparator|standard lid speculum|Standard wire eyelid speculum
88979132|NCT00287833|Placebo Comparator|Arm II (placebo)|Participants are sequentially assigned to 1 of 4 dose level cohorts. One participant in each dose level cohort is randomized to receive placebo. Participants receive 1 of 4 escalating doses of oral Bowman-Birk inhibitor concentrate or placebo, as an orange juice suspension, on day 1.
88979133|NCT00287911|Experimental|Combo Chemotherapy and Radiation|"Patients undergo radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36. Some patients may also undergo brachytherapy. Patients also receive cisplatin intravenously (IV) over 1 hour on days 1, 8, 15, 22, 29, and 36 and topotecan IV continuously on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36. Treatment continues in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of topotecan until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
88979134|NCT00288028|Experimental|Bortezomib|Bortezomib is administered as a 5 second IV bolus on days 1, 4, 8,11 or 1,8 and 15 of a 21-35 days cycle (Depending on the Dosing schedule). The dosage will be calculated based on actual weight of the patient unless the actual weight is greater than 40% above the ideal body weight. In this instance the dosage will be based on the adjusted ideal body weight. The Adjusted IBW (kg) = IBW + 0.25 x (actual body weight - IBW). The dosage will be adjusted based on the safety and toxicity profile, until a MTD is determined.
88979135|NCT00111540|Experimental|Exenatide|Exenatide 5 mcg for 4 weeks (transition) then 10 mcg to study termination
88979136|NCT00288106||Long Term Follow-Up|Follow-up data collection study for men who developed prostate cancer after participation in SWOG-9217 (PCPT)
88979137|NCT02965547|Experimental|RIPC Group|RIPC was induced by 4 cycles of extremities ischemia (5-minute blood-pressure cuff inflation to 200 mm Hg, followed by 5-minute cuff deflation).All subjects will take RIPC intervention, blood collection and 7 dCA measurements.
88979138|NCT00288145|Active Comparator|T|Treatment arm comprises one worksite in a matched site pair; one site assigned to treatment, the other site assigned to comparison. Treatment site worksite-based health promotion activities such as self-directed campaigns, lectures, small group programs, online programs, environment interventions (food service and physical)--all with focus on nutrition, physical activity and/or weight management.
88979139|NCT00288184|Experimental|Allopurinol|Hypertensive children received both placebo and allopurinol in a cross over design.
88979140|NCT00288184|Placebo Comparator|Placebo|
88979141|NCT02960542|Experimental|Lifestyle Weight Loss|The Behavioral: HELP Prevent Cancer Intervention is a lifestyle intervention consisting of 24-weekly group meetings led by a community health worker and 3 individual sessions with a nutritionist/diabetes educator
88979142|NCT00288223|Experimental|1|telithromycin
88979143|NCT00111579|Active Comparator|1|CAIV-T
88979144|NCT00111579|Other|2|TIV
88979145|NCT00288301|Experimental|1|Special Intervention
88979146|NCT00288301|Experimental|2|Delayed intervention
88979147|NCT00288340|Active Comparator|1,2|
88979148|NCT00288418|Active Comparator|ARROWgard Blue® CVC|7-French x 20-cm, triple lumen, short-term CVC
88979149|NCT00288418|Experimental|Angiotech CVC|A 7-French x 20-cm, triple lumen, short-term CVC with an anti-infective polymer coating, applied to the outer surface that contains the active pharmaceutical ingredient 5-fluorouracil (5-FU). The Angiotech CVC uses a 50µg/linear cm dose of 5-FU
88979150|NCT00111696|Experimental|MEDI-522|Drug
88979151|NCT00288691|Experimental|Arm 1|
88979152|NCT00288691|Experimental|Arm 2|
88979153|NCT00288691|Experimental|Arm 3|
88979154|NCT00288691|Placebo Comparator|Arm 4|
88979155|NCT00288730|Experimental|001|nesiritide
88979156|NCT00399581|Experimental|HFOV-Lo|High Frequency Oscillatory Ventilation using lower mean airway pressures and higher FiO2s.
89597421|NCT01487577|Experimental|Mycophenolate mofetil|Pharmacokinetics-based targeting of mycophenolate mofetil
89597422|NCT02290366|Experimental|Focal Therapy|
89597423|NCT05585866||Sevoflurane|The group of patients which received sevoflurane as randomized anesthetic modality.
89597424|NCT05585866||Propofol|The group of patients which received propofol as randomized anesthetic modality.
89597425|NCT01992952|Experimental|AZD5363 plus fulvestrant|Fulvestrant 500mg and AZD5363 4 days on 3 days off at dose determined in safety run in (maximum 480mg and minimum 320mg bd)
89597426|NCT01992952|Active Comparator|Placebo plus fulvestrant|Fulvestrant 500mg D1, D15 (cycle 1) and D1 of a 28 cycle thereafter. AZD5363 placebo 4 days on 3 days off
89597427|NCT01928134|Experimental|A|Vit K2+ Vit D3+ calcium carbonate (CaCO3)
89597428|NCT01928134|Active Comparator|B|Vit K2+CaCO3
89597429|NCT01894438|No Intervention|Control Group|This arm will receive written general advice for a healthy lifestyle.
89597430|NCT01894438|Experimental|Mediterranean Diet Group|Mediterranean Diet Group participants will attend a comprehensive program,focusing on Mediterranean diet, comprising of seven 60-min group counseling sessions, conducted every two weeks for the first 2 months and every month for the following 4 months, until the 6-month evaluation.
89597431|NCT01894438|Experimental|Mediterranean Lifestyle Group|Mediterranean Lifestyle Group participants will attend a comprehensive program,focusing on Mediterranean lifestyle, comprising of seven 60-min group counseling sessions, conducted every two weeks for the first 2 months and every month for the following 4 months, until the 6-month evaluation.
89597432|NCT01928212||healthy control|Sex- and agematched healthy subjects
89597433|NCT01928212||Parkinson group|Patients with Parkinson's disease
89597434|NCT01894594|Experimental|Sodium Bicarbonate|Patients will be monitored at baseline bi-weekly intervals for 12 weeks, the first 4 weeks to establish a stable baseline, followed by 8 weeks of alkali therapy, as follows:
89597435|NCT01928368|Active Comparator|Experimental Arm|
89597436|NCT01928368|Placebo Comparator|Placebo Arm|
89597437|NCT01970254||Screening (hepatitis B screening)|Patients with unknown HBV infection status undergo 3 HBV screening tests (HBsAg, anti-HBc, and anti-HBs) before chemotherapy. Patients with known HBV infection status undergo either HBsAg or anti-HBc screening tests if there is no evidence of HBV testing in the last 3 months. All patients complete HBV risk assessment survey.
88979157|NCT00399581|Experimental|HFOV-Hi|High Frequency Oscillatory Ventilation using higher mean airway pressures
88979158|NCT00288769|Other|2|
88979159|NCT00111852|Experimental|Desmoteplase, low dose|Desmoteplase 90 mcg/kg, intravenous administration.
88979160|NCT00111852|Experimental|Desmoteplase, high dose|Desmoteplase 125 mcg/kg, intravenous administration.
88979161|NCT00111852|Placebo Comparator|Placebo|Dose-Match Placebo, intravenous administration.
88979162|NCT00289081|Active Comparator|1|Rotating Platform Cruciate Retaining Knee implant
88979163|NCT00289081|Active Comparator|2|Rotating Platform Cruciate Substituting Knee implant.
88979164|NCT00289237|Experimental|High intensity intervention group|"Lifestyle intervention consisted of 15-30 minutes of individual lifestyle counselling + offer of participation in group-based lifestyle counselling (½ year). This offer was given at baseline to all participants in the group.~Persons at high risk of IHD: offer additionally given at 1- and 3-year follow-up"
88979165|NCT00289237|Experimental|Low intensity intervention group|"Lifestyle intervention consisted of 15-30 minutes of individual lifestyle counselling. This offer was given at baseline to all participants in the group.~Persons at high risk of IHD: offer additionally given at 1- and 3-year follow-up"
88979166|NCT00289237|No Intervention|Control group|"Questionnaires regarding lifestyle and general health were sent to all participants in this group.~The importance of healthy lifestyle was not mentioned, and no intervention was offered."
89031790|NCT03458364|Active Comparator|Noninvasive ventilation|Non-invasive ventilation (NIV) refers to the provision of ventilatory support through the patient's upper airway using a mask. This technique is distinguished from those which bypass the upper airway with a tracheal tube, laryngeal mask, or tracheostomy and are therefore considered invasive.
89597438|NCT04756882|Experimental|study group|6 patients received 12.5 speywood unit/cm (SU/cm) Dysport intramuscular & intradermal injections, within the first 5 postoperative days of the trauma
89597439|NCT04756882|No Intervention|control group|of 6 patients that acted as the control group and received no treatment
89597440|NCT02271256|Experimental|Functional intimate apparel|A functional intimate apparel will be provided to patient to wear it 8 hours daily. Monitoring and observation will be provided during the 6-9 months wearing period.
89597441|NCT02271256|No Intervention|Control|Monitoring and observation will be provided during the 6-9 months wearing period.
89597442|NCT01894126|Experimental|Two-way SMS dialogue|Women will receive SMS messages with prompts to reply. They will have the ability to text back to the system and both respond to and initiate SMS dialogue
89597443|NCT01894126|Experimental|One-way SMS Messaging|Women will receive scheduled one-way SMS messages
89597444|NCT01894126|No Intervention|Control|
89597445|NCT02267512|Experimental|ATG-F single dosing group|Intravenous (IV)
89597446|NCT02267512|Experimental|ATG-F continuous dosing group|Intravenous (IV)
89597447|NCT01928602|Experimental|Expressive Aphasia Group A|"Behavioral: TherAppy Language App~Behavioral: Mind-Games"
89597448|NCT01928602|Experimental|Expressive Aphasia Group B|"Behavioral: Mind-Games~Behavioral: TherAppy Language App"
89597449|NCT01536951|Placebo Comparator|Placebo|Placebo matching LY3009104 tablets in size and appearance will be administered orally in 1 out of 3 study periods in Part A and Part B.
89597450|NCT01536951|Experimental|LY3009104|"Part A. Single escalating dose of up to 40 milligrams (mg) of LY3009104 administered orally in 2 out of 3 study periods separated by at least a 3 day wash-out period between each dose.~Part B. Single dose of LY3009104 determined in Part A administered orally in 1 out of 3 study periods separated by at least a 3 day wash-out period between each period."
89597451|NCT01536951|Active Comparator|400 mg moxifloxacin|Part B. 400 mg moxifloxacin will be administered orally in 1 out of 3 study periods separated by at least a 3 day wash-out period between each period.
89597452|NCT02259322|Active Comparator|Standard-of-Care|Standard-of-care is the continuation of any treatment or recommendations participants receive from his/her bariatric surgeon/team.
89597453|NCT02259322|Experimental|Behavioral Weight Loss Treatment|Guided self-help Behavioral Weight Loss Treatment
89597454|NCT02259322|Experimental|Cognitive Behavioral Therapy|Guided self-help Cognitive Behavioral Therapy
89597455|NCT01536795|Experimental|WR279,396 with Tegaderm dressing|24 patients will be randomly allocated to WR279,396 treatment once-a-day for 20 days with using an occlusive polyurethane Tegaderm dressing
88979167|NCT04711499|Experimental|Fatigue Group|The trial will recruit trainee anaesthetists of ST3 grade or higher who take part in a resident night-shift rota at Nottingham University Hospitals NHS Trust. Participants will undergo baseline psychometric testing to measure baseline mood. There will be a series of questions to ascertain levels of fatigue. All participants will then be asked to perform a standardised ultrasound-guided peripheral nerve blockade task using a high fidelity bench-top phantom model. Performance in this task will be independently assessed using a previously-validated scoring tool by two raters blinded to participant group allocation.
88979168|NCT04711499|Active Comparator|Non Fatigued group|The non fatigued group will be asked to perform the same series of questions and tasks after a night at home with no work duties or commitments
88979169|NCT00289432|Experimental|1|Behavioral: Psychoeducative intervention
88979170|NCT00289432|Active Comparator|2|The Hospitals standard follow-up support group
88979171|NCT00289627|Experimental|ipilimumab (MDX-010, BMS-734016)|
88979172|NCT00401661|Experimental|1|Alfuzosin for 24 weeks
88979173|NCT04711616|Experimental|physical therapy intervention|
88979174|NCT00289705|Experimental|Surgery|Laparoscopic gastric bypass
88979175|NCT00289705|No Intervention|2|Traditional treatment for obesity
88979176|NCT00289861|Active Comparator|risperdone|
89597456|NCT01536795|Experimental|WR279,396 with Gauze and Tape Dressing|24 subjects will be randomly allocated to WR279,396 treatment once a day for 20 days without an optimized polyurethane dressing (gauze and tape only).
89597457|NCT04767633|Active Comparator|group A (PMC standard-dose)|Group A (PMC standard-dose): patients will receive two oral doses of sodium picosulphate plus magnesium oxide and citric acid (Picoprep), each diluted in 150 ml of water, at 17:00 and 4 hours later in the evening prior to the colonoscopy (¼ sachet for children < 6 years, ½ sachet for children 6-12 years, and one sachet for children >12 years). Intake of at least 40-50 ml/kg (maximum 2 L) of clear fluids (cold tea, gatorade etc..) will be recommended after each dose. The age-adjusted dosage is dictated by the instructions of the manufacturing company. No solid food intake will be allowed during the 24 hours prior to the examination according to the instructions of the manufacturing company.
89597458|NCT04767633|Active Comparator|Group B (PMC split-dose)|Group B (PMC split-dose): patients will receive the first oral doses of PMC diluted in 150 ml of water (Picoprep; Ferring Italia, Milan, Italy) at 19:00 of the day before colonoscopy and the second one at 06:00 hours on the morning of the day of colonoscopy (¼ sachet for children < 6 years, ½ sachet for children 6-12 years, and one sachet for children >12 years). Intake of at least 40-50 ml/kg (maximum 2 L) of clear fluids (cold tea, gatorade etc..) will be recommended after each dose. The age-adjusted dosage is dictated by the instructions of the manufacturing company. No solid food intake will be allowed during the 24 hours prior to the examination according to the instructions of the manufacturing company.
89597459|NCT01894750|Experimental|skill bulding Intevention|group-based skill building self-care program
89597460|NCT01894750|No Intervention|usual care|
89597461|NCT01928836||Non-suspected lung cancer group|"Aged 40 to 75 years;~Male smoker (≥400 cig/year), female smoker or non-smoker;~Visible lung nodule lesion in the chest (based on local CT result);~Without the indication of biopsy (bronchoscope or percutaneous transthoracic) or surgery."
89597462|NCT01928836||Suspected lung cancer group|"Aged 40 to 75 years;~Male smoker (≥400 cig/year), female smoker or non-smoker;~Visible lung cancer lesion in the chest (based on local CT result);~With the indication of biopsy (bronchoscope or percutaneous transthoracic) or surgery."
89597463|NCT01894828|Active Comparator|Nutritional supplements|Patients are asked to drink two 200ml bottles of nutritional supplement daily
89597464|NCT01894828|No Intervention|Control|Patients are asked to keep on to their normal diet. No supplementation is introduced
89597465|NCT05585554|Experimental|Ablative MRIdian SMART|Induction Chemotherapy + MRIdian SMART 50 Gy in 5 fractions
89597466|NCT05585554|No Intervention|No ablative MRIdian SMART|Induction chemotherapy alone
89597467|NCT05583760|Experimental|Experimental: Osteopathic manipulation TUG for scaphoid bone|
89597468|NCT05583760|Sham Comparator|Sham group: Sham osteopathic manipulation TUG for scaphoid bone|
89597469|NCT01928914|Placebo Comparator|Group 1|Subjects in group 1 receive placebo for tafenoquine and placebo for moxifloxacin on three consecutive days of dosing
89597470|NCT01928914|Experimental|Group 2|Subjects in group 2 receive 400mg of tafenoquine and placebo for moxifloxacin on three consecutive days of dosing
89597471|NCT01928914|Active Comparator|Group 3|Subjects in group 1 receive placebo for tafenoquine and placebo for moxifloxacin on days 1 and 2. On day 3, subjects receive placebo for tafenoquine and 400mg moxifloxacin.
89597472|NCT01928914|Experimental|Group 4|Subjects in group 1 receive placebo for tafenoquine and placebo for moxifloxacin on days 1 and 2. On day 3, subjects receive placebo for moxifloxacin and 300mg of tafenoquine
89597473|NCT01928914|Experimental|Group 5|Subjects in group 1 receive placebo for tafenoquine and placebo for moxifloxacin on days 1 and 2. On day 3, subjects receive placebo for moxifloxacin and 600mg of tafenoquine
89597474|NCT02249104|Experimental|Acne treatment|"Adapalene/benzoyl peroxide gel, 0.1%/2.5%, once daily~Cetaphil Acne Regimen:~Cetaphil® DermaControl™ Moisturizer SPF 30, once daily and additionally 15 minutes prior to participation in outdoor sports if more than 2 hours elapsed since morning application~Cetaphil® DermaControl™ Foam Wash, at least twice daily"
89597475|NCT01928992||3D|Subjects that undergo 3D mammography
89597476|NCT01928992||2D|Subjects that undergo 2D mammography
89597477|NCT01894204|Other|HTPPE|No drug and no placebo were used in this study. For all the patients who participated at the study PADIS-EP, somme exams must be performed.
89597478|NCT01929538|Active Comparator|Covered biliary metal stent, 12 mm|ERCP and placement of a covered self-expanding biliary metal stent, 12mm in diameter
88979177|NCT00289861|Placebo Comparator|placebo|
88979178|NCT00112008|Experimental|darbepoetin alfa|
89597479|NCT01929538|Active Comparator|covered Biliary metal stent, 10 mm|ERCP and placement of a covered self-expanding biliary metal stent, 10 mm in diameter
89597480|NCT04389736|Experimental|SIT|Sitting
89597481|NCT04389736|Experimental|STAND|Standing
89597482|NCT04389736|Experimental|NMES|Self-selected maximal intensity of neuromuscular electrical stimulation
89597483|NCT04395040||Patients|Elderly patients with digestive cancer or breast cancer.
89597484|NCT01929070|Experimental|Group 1|"R1: Coadministration of Crestor 5mg 4tab and Omacor capsupe 1g 4cap in the fasting state~R2: Coadministration of Crestor 5mg 4tab and Omacor capsupe 1g 4cap on the high-fat diet~T1: Single-dose of HCP1007 1g/5mg 4 cap in the fasting state~T2: Single-dose of HCP1007 1g/5mg 4 cap on the high-fat diet~R1 -> T2 -> R2 -> T1"
89597485|NCT01929070|Experimental|Group 2|R2 -> R1 -> T1 -> T2
89597486|NCT01929070|Experimental|Group 3|T1 -> R2 -> T2 -> R1
89597487|NCT01929070|Experimental|Group 4|T2 -> T1 -> R1 -> R2
89597488|NCT01536561|Experimental|open-label, dose escalation|"Each subject will undergo two phases of study. The first phase, termed tracer Study, involves the injection of low-radioactivity doses (about 5 mCi) of 131-I anti-B1 for the purposes of determining the rate of whole body clearance of radiation so that a whole body radiation can be calculated. The calculated whole-body radiation dose per mCi administered can then be used to determined how many mCi will be required to deliver a specified whole-body radiation dose in the second phase of the study for each patient, termed radio-immunotherapy dose in a tracer-projected whole-body radiation dose will be used for dose escalation with a minimum of three subjects per dose level."
89597489|NCT02243020|Experimental|Vagus Nerve Stimulation (VNS) + Rehabilitation (1)|This group receives vagus nerve stimulation during rehabilitation. VNS and rehabilitation are the interventions.
89597490|NCT02243020|Active Comparator|Vagus Nerve Stim (VNS) + Rehabilitation (2) - Comparator|This group receives rehabilitation and VNS, but the VNS is different than given in the other group (rehabilitation is the only true intervention in this group). It may not be as effective as the other group's settings. Both groups receive the same amount of rehabilitation.
89597491|NCT01929148|Experimental|Laparoscopic myomectomy plus PBS|A Laparoscopic myomectomy plus Prophylactic bilateral salpingectomy will be performed in women which have accomplished their reproductive desire
89597492|NCT01929148|Active Comparator|Laparoscopic myomectomy without PBS|A standard laparoscopic myomectomy without any prophylactic salpingectomy will be performed
89597493|NCT02236312|Experimental|Botulinum Toxin 30 units|I.M. injection
89597494|NCT02236312|Experimental|Botulinum Toxin 45 units|I.M. injection
89597495|NCT02236312|Experimental|Botulinum Toxin 60 units|I.M. injection
89597496|NCT02236312|Placebo Comparator|Placebo|I.M. injection
89597497|NCT01916278|Experimental|Emervel Lips Lidocaine|
89597498|NCT01916278|Experimental|Juvéderm Volbella with Lidocaine|
89597499|NCT03084640|Experimental|Part 1: Dose-Escalation - CMP-001 (SC) and Pembrolizumab|Participants will receive up to 7 escalating dose levels (5 milligrams [mg], 7.5 mg, 10 mg, 12.5 mg, 15 mg, 17.5 mg, and 20 mg) of CMP-001 via SC injection once a week for 3 weeks and every 3 weeks thereafter until discontinuation of treatment in combination with pembrolizumab at its labelled dose and schedule.
89597500|NCT03084640|Experimental|Part 1: Dose-Expansion - CMP-001 (SC) and Pembrolizumab|Participants will receive RP2D (as determined in Part 1 dose-escalation phase) of CMP-001 via SC injection once a week for 3 weeks and every 3 weeks thereafter until discontinuation of treatment in combination with pembrolizumab at its labelled dose and schedule.
88979179|NCT04711421|Experimental|Experimental: Feedback|Patients in this arm will wear a pedometer following gynecology and gynecology oncology surgeries until discharge. During this period, they will recieve feedback regrding the number of steps taken by them at the end of each day
88979180|NCT04711421|No Intervention|No Intervention: Control|Patients in this arm will wear a pedometer following gynecology and gynecology oncology surgeries until discharge. During this period, they will recieve no feedback regrding the number of steps taken by them.
88979181|NCT00078260|Experimental|A|
88979182|NCT00078260|Experimental|B|
88979183|NCT02960815|Active Comparator|Intramuscular vaccine|The control intervention consists in the administration of the standard intramuscular influenza vaccine (Mutagrip®), containing 15 μg of each of the three viral strains without imiquimod.
88979184|NCT02960815|Experimental|Imiquimod and intradermal vaccine|In the imiquimod and intradermal vaccine arm, intervention consists in the topical application of a single bag of Aldara™ creme 5%, containing 12.5 mg of imiquimod, on a 16 cm2 square delimitated area on the non-dominant arm at the time of influenza vaccination. An intradermal influenza vaccine preparations containing 15 μg of each of the three viral strains (Intanza®) will be administrated in the centre of the marked area after the imiquimod cream is fully absorbed.
89597501|NCT03084640|Experimental|Part 2: CMP-001 (SC and IT) and Pembrolizumab|Participants will receive CMP-001 via SC injection once weekly for 2 weeks, then IT injection once weekly for 4 weeks, and SC injection once weekly for every 3 weeks thereafter until discontinuation of treatment in combination with pembrolizumab at its labelled dose and schedule. CMP-001 planned IT dose level in Part 2 will be up to 10 mg and the SC dose will be the RP2D determined from Part 1 dose-escalation phase of the study.
89597502|NCT01536405|Experimental|MMRV (AMP)|Participants received two 0.5 mL subcutaneous injections of Mumps, Measles, Rubella, Varicella (MMRV) vaccine made with an alternative manufacturing process (AMP)
89597503|NCT01536405|Active Comparator|MMRV (2006 process)|Participants received two 0.5 mL subcutaneous injections of MMRV vaccine made with the 2006 manufacturing process
89597504|NCT01895686||Open angle glaucoma|patients diagnosed with open angle glaucoma
89597505|NCT01895686||Narrow angle|patients diagnosed with narrow angles
88979185|NCT02960815|Experimental|Imiquimod and intramuscular vaccine|In the imiquimod and intramuscular vaccine arm, intervention consists in the topical application of a single bag of Aldara™ creme 5%, containing 12.5 mg of imiquimod, on a 16 cm2 square delimitated area on the non-dominant arm at the time of influenza vaccination. An intramuscular influenza vaccine preparations containing 15 μg of each of the three viral strains (Mutagrip®) will be administrated in the centre of the marked area after the imiquimod cream is fully absorbed.
89597506|NCT01895686||Angle Closure Glaucoma|patients diagnosed with angle closure glaucoma
89031791|NCT00515840|Sham Comparator|1|equal time with health care professional (asthma nurse)
89597507|NCT01892410|Experimental|Cetaphil Restoraderm Skin Restoring Body Wash|All subjects receive Cetaphil Daily Advance Ultra Hydrating Lotion
89597508|NCT04409691|Active Comparator|prednison group|
89597509|NCT04409691|Experimental|prednison+sirolimus group|
89597510|NCT01887808|Experimental|Cetaphil DermaControl Oil Control Moisturizer SPF 30|All subjects receive Cetaphil DermaControl Oil Control Moisturizer SPF 30
89597511|NCT04096989|No Intervention|Control group|Routine care.
89597512|NCT04096989|Experimental|Experimental group|The participants accept TCM regimen-based lifestyle mobile health application intervention.
89597513|NCT04096989|Sham Comparator|Sham comparator group|The participants accept mobile health application intervention.
89597514|NCT02219776|Active Comparator|Chlorhexidine Standard of Care Arm|Use of Chlorhexidine to cleanse pre-operative surgery site
89597515|NCT02219776|Experimental|Benzoyl Peroxide Experimental Arm|Use of Chlorhexidine scrub brush and 1.5 oz bottle of 10% benzoyl peroxide emollient
89597516|NCT01487265|Experimental|BKM120 and Erlotinib|"Cycle 1: BKM120 80 mg PO daily; Erlotinib 100mg PO daily~Cycles 2 and beyond: BKM120 100 mg PO daily; Erlotinib 100mg PO daily"
89597517|NCT01516606|Experimental|clarithromycin, oral, high dose|2 g/day clarithromycin (once a day) for 14 days followed by 7 days interval to be repeated for 4 cycles in total
89597518|NCT01485627|Experimental|Intervention|Oncologists will receive communication training. Patients will be coached to make the most of the oncologist visit.
89597519|NCT01485627|No Intervention|Control|Patients will receive usual care
89597520|NCT02209636|Experimental|Lanthanum carbonate|Eligible subjects who are randomly assigned to the experimental arm will receive lanthanum carbonate (1500-4500 mg/day in divided doses) titrated to serum phosphorus levels.
89597521|NCT02209636|Placebo Comparator|placebo|Eligible subjects who are randomly assigned to the placebo arm will receive placebo tablets (identical to the active lanthanum carbonate tablets) to be taken 3 times daily and titrated to serum phosphorus levels.
89597522|NCT01515904||Control|Approximately 50% of attendees choose not to book into the STOMP program, for reasons including difficulty attending the frequent appointments due to distance or inability to leave work early. This population will serve as the control group for the evaluation. Control participants will be recruited from the community through posters in the hospital
89597523|NCT01515904||STOMP|12-17 yrs. Patients in the program have severe complex obesity defined as children and youth who have a BMI >95th %ile for their age and gender in addition to one of the following: at least one significant obesity-related co-morbidity requiring specialty care (e.g. type 2 diabetes), other co-existing chronic illness impacted by obesity (e.g. CNS tumor, post-organ transplant), or a BMI ≥99th percentile for their age and gender
89597524|NCT01508325|Experimental|Bisoprolol|
89597525|NCT01508325|Active Comparator|Metoprolol|
89597526|NCT01514344|Experimental|intralesional rituximab|
89597527|NCT01508169|Experimental|Foot orthosis|Forty-seven women in treatment in the outpatient clinic of the Rheumatology Division of State University of Campinas(UNICAMP) who met the inclusion criteria for this study (being female with osteoporosis and aged 60 or above) were assigned, at random, to wear ethyl-vinyl-acetate insoles with medial arch supports and metatarsal pads over a four-week period. Balance, using the Berg Balance Scale (BBS) and the Timed Up and Go (TUG) indexes; pain, using a numeric pain scale (NPS); and disability of the feet, using the Manchester Foot Pain and Disability Index (MFPDI), were assessed at baseline and after four weeks.
89597528|NCT01508169|No Intervention|Control Group|Forty-seven elderly women with osteoporosis (in treatment in the outpatient clinic of the Rheumatology Division of State University of Campinas- UNICAMP) were assigned, at random, to enter the control group with no foot intervention. Balance, using the Berg Balance Scale (BBS) and the Timed Up and Go (TUG) indexes; pain, using a numeric pain scale (NPS); and disability of the feet, using the Manchester Foot Pain and Disability Index (MFPDI), were assessed at baseline and after four weeks.
89597529|NCT01536171||Shod versus Barefoot Running|two running conditions, with normal running shoes and barefoot
89597530|NCT01496014||severe open fractures of the tibia bone|
89597531|NCT01536093|Experimental|Colostrum|oropharyngeal administration of own mother's colostrum
89597532|NCT01536093|Placebo Comparator|Placebo|oropharyngeal administration of sterile water
89597533|NCT02191930|Experimental|B-CAP|Patients with ECOG of 2 or less (3 or less if caused by HL) and CIRS-G score of 6 or less (overall) and 3 or less per organ system receive 6 cycles of B-CAP (Brentuximab vedotin, cyclophosphamide, doxorubicine, predniso(lo)ne). Cycle length is 21 days
89597534|NCT02191930|Experimental|Brentoximab Vedotin only|Patients with CIRS-G score of 7 ore more receive Brentuximab Vedotin as single agent therapy for up to 16 cycles. Cycle length is 21 days
89597535|NCT01536015|Experimental|Rotigotine|Rotigotine patch titrated from 4 mg/24 h - 8 mg/24 h or until effective or maximum dose is reached.
89597536|NCT01536015|Placebo Comparator|Placebo|Placebo patch.
89597537|NCT04725825|Experimental|Dry needling|"A single dry needling session will be performed on the dominant painful trapezius muscle, with the patient lying in prone position. After palpation of a taut band, and detection of a MTrP in the upper trapezius muscle, a trained physiotherapist will penetrate the needle into skin surface, fascia, into the muscle tissue at the MTrP location, and will move the needle up and down (fast-in, fast-out technique) in three different directions.~In case local twitch responses are elicited, this will be repeated until the local twitch responses are extinct."
88979186|NCT00290875|Other|Arm 1|We randomly allocated sites to either intervention or control. At the intervention sites, active strategies were employed to implement the rule into practice, including education, policy, and real-time reminders on radiology requisitions.
89597538|NCT04725825|Sham Comparator|Sham needling|A single sham needling session will be performed with the subject lying on the non painful side. After palpation of a taut band, and detection of a MTrP in the upper trapezius muscle, a trained physiotherapist will penetrate the needle into the skin surface at the MTrP location. The fascia and muscle tissue will not be penetrated.
89597539|NCT03028077|Experimental|GS-3K8|GS-3K8 (6 cap/day, 500 mg/cap) for 12 weeks
89597540|NCT03028077|Experimental|GINst15|GINst15 (6 cap/day, 500 mg/cap) for 12 weeks
89597541|NCT03028077|Placebo Comparator|Placebo|Placebo for 12 weeks
89597542|NCT01863940|Experimental|Wound catheter|Wound catheters will be placed subcutaneously in the skin graft donor site in the lateral thigh while the patient remain intra-operative. The patients will receive a continuous infusion of procaine 0.5% at 4-5mL/hr using an elastomeric infusion device for 48 hours. Patients will be asked to asses pain on a 0-10 scale immediately prior to dressing changes, during dressing changes and 1 hour post dressing changes.
89597543|NCT01863940|No Intervention|Control|Patients will receive the standard of care pain medication regimen of Analgin/Metamizole 1 g IM and Ketorolac 3%- 30 mg IM for post-operative pain treatment. The patients will be asked to rate pain on a scale of 0-10 immediately prior to dressing changes, during dressing changes and 1 hour after dressing changes.
89597544|NCT01484691|No Intervention|Healthy non-asthmatic controls|Healthy non-asthmatic controls who will be studied at one point in time and serve as a control group for the baseline bronchoscopy and evaluation of T-cell miRNA expression.
89597545|NCT01484691|Active Comparator|Asthmatics (treatment)|Steroid-naïve asthma (randomized to 8 weeks of treatment with inhaled corticosteroids). Asthmatics not on inhaled corticosteroids, randomized to inhaled budesonide, 1 puff (180mcg) twice a day for 8-10 weeks. These subjects will undergo bronchoscopy and T-cell miRNA measurement at baseline (before corticosteroids) and again after treatment with inhaled corticosteroids.
89597546|NCT01484691|No Intervention|Asthmatics (no treatment)|Steroid-naïve asthma (randomized to 8 weeks of no inhaled corticosteroid treatment). Asthmatics not on inhaled corticosteroids, randomized to no change in treatment for 8-10 weeks. These subjects will undergo bronchoscopy and T-cell miRNA measurement at baseline and again after 8 weeks without treatment with inhaled corticosteroids.
89597547|NCT01464034|Experimental|Carfilzomib, Pomalidomide, Dexamethasone|All eligible subjects will receive the study intervention of Carfilzomib, Pomalidomide, and Dexamethasone.
89597548|NCT01860898|Other|Skin Biopsy|
89597549|NCT01535235|Active Comparator|ACE Inhibitor|Active group
89597550|NCT01535235|Placebo Comparator|Placebo|Placebo group
89597551|NCT02985723|Experimental|939MP|AT LISA tri toric 939MP intraocular lens
89597552|NCT04748211|Experimental|Infraclavicular Block|Group I received USG and neurostimulator guided infraclavicular block, 10 ml 2% lidocain and 10 ml 0.05% marcaine was administered for local anetshesia. After the block was administered MAP, HR, TAV, BAD, BAA, BF, PI and rSO 2 values were measured and recorded at the 10th, 20th, and 30th minutes.
89597553|NCT04748211|Experimental|Interscalen Block|Group II received USG and neurostimulator guided interscalen block. 10 ml 2% lidocain and 10 ml 0.05% marcaine was administered for local anetshesia. After the block was administered MAP, HR, TAV, BAD, BAA, BF, PI and rSO 2 values were measured and recorded at the 10th, 20th, and 30th minutes.
89597554|NCT04095429|Experimental|Expect Respect Support Group|"Experimental: Expect Respect Support Group Expect Respect is a program intended to create safe, trauma-informed space for young people who have been exposed to violence, to promote positive bystander intervention and healthy relationship skills, to alter norms that foster TDV/SV perpetration, and reduce violence perpetration through weekly support groups with students at elevated risk for such perpetration. Youth with prior history of exposure to violence are invited to in-school gender specific support groups that take place over 24 in-classroom sessions.~Expect Respect addresses violence perpetration prevention with youth already exposed to violence by recognizing violence as a problem that is fueled by gender norms that promote dominance and challenging the need to control and exert power in relationships especially with the use of violence, while simultaneously strengthening emotion regulation, social skills, and connectedness."
89597555|NCT04095429|Active Comparator|Enhanced Usual Care|Comparator: Enhanced Usual Care The control arm will receive enhanced usual care. Enhanced care means that the investigators will ensure each school has information, resource lists, and connection to services for individual youth who are referred to the study, including warm referrals to victim service agencies, behavioral health services, as well as resources (e.g., assistance with food insecurity, and so forth).
89597556|NCT02168686|Experimental|Part A: Dose 1|ADVM-043, at the lowest dose of three planned dose levels, of 8E13 total vg (equivalent to 1E12 vg/kg based on an 80-kg patient) administered IV
89597557|NCT02168686|Experimental|Part A: Dose 2|ADVM-043 at the intermediate dose of three planned dose levels, of 4E14 total vg (equivalent to 5E12 vg/kg based on an 80-kg patient) administered IV
88979187|NCT04729556|Experimental|Sericin and chitosan cream|A flim-forming cream containing sericin and chitosan cream. Apply sericin and chitosan cream on the back area of healthy volunteers and cover with self-adhesive nonwoven fabric in induction phase I (72 hours), induction phase II (72 hours), and challenge phase (72 hours).
88979188|NCT04729556|Active Comparator|Cavilon|"Active control is a commercial cream containing dimethicone as the substance forms a durable, thin, and transparent film. The cream is used as a moisturizer to prevent the skin against irritation, dryness, and pressure ulcers.~Apply sericin and chitosan cream on the back area of healthy volunteers and cover with self-adhesive nonwoven fabric in induction phase I (72 hours), induction phase II (72 hours), and challenge phase (72 hours)."
88979189|NCT00291031|Experimental|IRT|Patients randomly assigned to the IRT condition receive Imagery Rehearsal Therapy after 4 weeks since the entrance into the trial next to their treatment as usual.
88979190|NCT00291031|No Intervention|TAU|Patients that are randomly assigned to the waiting list control condition get treatment as usual (TAU) and complete the daily nightmare logs for a period of three months. These patients get the IRT intervention after waiting for 6 months.
88979191|NCT00112320|Active Comparator|1|Standard PVR
88979192|NCT00112320|Experimental|2|PVR plus RV remodeling
88979193|NCT00291148|Active Comparator|Paroxetine|
88979194|NCT00291148|Active Comparator|pregabalin|
88979195|NCT00078533|Experimental|CMV CTL infusion|Subjects are assigned a dose level at the time of enrollment.
88979196|NCT00112476|Experimental|Treatment (bryostatin, temsirolimus)|Patients receive bryostatin 1 IV over 1 hour on days 1, 8, 15, and 22 and temsirolimus IV over 30 minutes once on days 8, 15, and 22 during course 1. On subsequent courses patients receive bryostatin 1 and temsirolimus once on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88979197|NCT00291616|Active Comparator|1|Pegylated Interferon-alpha2a
88979198|NCT00291616|Active Comparator|2|Thymosin alpha1 & Pegylated Interferon-alpha2a
88979199|NCT00078572|Active Comparator|capecitabine alone|Capecitabine daily dose divided and given twice daily orally, for 14 days, every 21 days. The capecitabine starting dose for the monotherapy arm was 2500 mg/m2. Randomization is 1:1.
88979200|NCT00078572|Experimental|Combination|Lapatinib 1250 mg once daily plus capecitbine daily dose divided and given twice daily orally, for 14 days, every 21 days. The capecitabine starting dose for the combination arm was 2000 mg/m2.
89597558|NCT02168686|Experimental|Part A: Dose 3|ADVM-043 at the highest dose of three planned dose levels, of 1.2E15 total vg (equivalent to 1.5E13 vg/kg based on an 80-kg patient) administered IV
89597559|NCT02168686|Experimental|Part A: Dose 4|ADVM-043 administered at a dose that will be determined
89597560|NCT02168686|Experimental|Part B (optional): Intrapleural administration|ADVM-043 administered intrapleurally at a dose that will be determined
89597561|NCT04756336|Experimental|LTX-109 treatment|Patients are treated with LTX-109 gel, 3% w/w twice daily (morning- evening) by application on active hidradenitis lesions during the intervention period of 6 weeks
89597562|NCT01456390|Other|iStent and iStent supra|Implantation of two iStent devices and one iStent supra device
89597563|NCT02317744|Experimental|Naltrexone/ Bupropion combination|50 mg naltrexone and 300 mg bupropion per day for 3 months
89597564|NCT02317744|Placebo Comparator|Pill placebo|Daily placebo medication for 3 months
89597565|NCT05577442|Experimental|Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy|for the HR+/HER2+MBC will be treated with Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy. Endocrine drug be determined by physician depend on the history.
89597566|NCT01895764|Active Comparator|Adalimumab|adalimumab 40mg every 2 weeks
89597567|NCT01895764|Experimental|Adalimumab + Methotrexate|adalimumab 40mg every 2 weeks and methotrexate 10mg per week
89597568|NCT04756102||FBS lower than 80|Those pregnant patients with FBS less than 80 mg/dl
89597569|NCT04756102||FBS 80-120|Those pregnant patients with FBS between 80-120
89597570|NCT01895140|Experimental|Early renal denervation|Renal denervation takes place immediately after patient is randomized.
88979201|NCT00291733|Active Comparator|1|500mg levetiracetam for one week and 1000mg levetiracetam for one week
88979202|NCT00291733|Placebo Comparator|2|placebo
88979203|NCT00291733|Active Comparator|3|After crossover arm 3 equals arm 1
88979204|NCT00291733|Placebo Comparator|4|After crossover arm 4 equals arm 2
88979205|NCT00112554|Experimental|Induction therapy arm I|Patients receive cytarabine IV continuously on days 1-3 and VNP40101M IV over 30-60 minutes on day 2 (at least 12 hours after the start of cytarabine).
88979206|NCT00112554|Active Comparator|Induction therapy arm II|Patients receive cytarabine as in arm I and placebo IV over 30-60 minutes on day 2 (at least 12 hours after the start of cytarabine).
88979207|NCT04718311|Active Comparator|Tacrolimus treatment|Apply a small amount (about 1 teaspoon) of medication to the lesions, twice a day after brushing the teeth, with a soft bristle toothbrush or with a finger (covered with a well-fitting glove).
88979208|NCT04718311|Placebo Comparator|Anti-inflammatory mouthwash|Anti-inflammatory mouthwash In patients of the anti-inflammatory group, the mouthwash was used pure and without dilution at a dosage of 20 ml 3 times a day, immediately after normal daily oral hygiene was prescribed. It contains calcium hydroxide, hyaluronic acid, Umbelliferone and Oligomeric Proanthocyanidins. Patients were instructed to rinse for at least 5 minutes over the entire oral mucosa, with particular emphasis on the regions where the lesions are located.
88979209|NCT00291928|Placebo Comparator|Dose ranging|A double-blind, placebo controlled, dose escalation part randomized within each of 3 sequential cohorts (Part A),
88979210|NCT00291928|Placebo Comparator|Parallel Arm RCT|a parallel group part with randomization into one of 4 treatment arms (Part B).
88979211|NCT00275392|Experimental|Vestibular Rehabilitation|vestibular exercises plus standard balance and gait exercises
88979212|NCT00275392|Placebo Comparator|Placebo|placebo exercises plus standard balance and gait exercises
88979213|NCT00078845|Experimental|Amifostine|500 mg subcutaneous three times a week on Monday, Wednesday and Friday for 4 weeks.
89597571|NCT01895140|Other|Delayed renal denervation|Renal denervation takes place 6 months after the patient is randomized.
89597572|NCT02141308||Rare Chorioretinal Disease|Up to 150 patients diagnosed with a rare retinal or choroidal disease will be considered and evaluated for enrollment in this study.
89597573|NCT02138344||SCI subjects|Chronic and traumatic SCI subjects
89597574|NCT02138344||Healthy control subjects|
89597575|NCT02138344||Subjects with peripheral nerve diseases|
89597576|NCT01894360|Experimental|Belimumab 200 mg/mL, prefilled syringe|Subjects will be randomly assigned in a 1 to 1 ratio to receive a single dose of 200 mg belimumab SC (1.0 mL injection) via prefilled syringe on Day 0.
88979214|NCT00275275|Experimental|1|Conversion factor of Mirapex to Requip 24-Hour of 1:3. This was a switch study in which the conversion factor was being investigated to assist in the conversion from Mirapex to Requip PR. In this group, the dose of Requip PR was 3 times the dose of Mirapex.
88979215|NCT00275275|Experimental|2|Conversion factor of Mirapex to Requip 24-Hour of 1:4
89597577|NCT01894360|Experimental|Belimumab 200 mg/mL, Autoinjector|Subjects will be randomly assigned in a 1 to 1 ratio to receive a single dose of 200 mg belimumab SC (1.0 mL injection) via prefilled syringe contained within an autoinjector device on Day 0.
89597578|NCT01483599|Experimental|CNTO 1959 (5 mg)|CNTO 1959 5 mg at weeks 0, 4, and 16, then every 12 weeks through Week 40
89597579|NCT01483599|Experimental|CNTO 1959 (15 mg)|CNTO 1959 15 mg at weeks 0, 8, and 16, then every 8 weeks through Week 40
89597580|NCT01483599|Experimental|CNTO 1959 (50 mg)|CNTO 1959 50 mg at weeks 0, 4, and 16, then every 12 weeks through Week 40
89597581|NCT01483599|Experimental|CNTO 1959 (100 mg)|CNTO 1959 100 mg at weeks 0, 8, and 16, then every 8 weeks through Week 40
89597582|NCT01483599|Experimental|CNTO 1959 (200 mg)|CNTO 1959 200 mg at weeks 0, 4, and 16, then every 12 weeks through Week 40
89597583|NCT01483599|Active Comparator|Adalimumab (approved psoriasis dosing)|Adalimumab 80 mg at week 0 followed by 40 mg at week 1 and every second week through Week 39 (i.e., Weeks 3, 5, 7, etc.)
89597584|NCT01483599|Placebo Comparator|Placebo to CNTO 1959 (100 mg)|Placebo at weeks 0, 4, and 8; then crossover to CNTO 1959 100 mg at Week 16, then every 8 weeks through Week 40
89597585|NCT01407562|Experimental|Pazopanib with paclitaxel and carboplatin|
89597586|NCT01406548|Experimental|BPS804 dosing frequency 1|Subjects dosed 20mg/Kg BPS804 monthly
89597587|NCT01406548|Placebo Comparator|placebo dosing frequency 1|Subjects dosed with matching placebo to 20mg/Kg BPS804 monthly
89597588|NCT01406548|Experimental|BPS804 dosing frequency 2|Subjects dosed with 20mg/Kg BPS804 quarterly
89597589|NCT01406548|Placebo Comparator|placebo dosing frequency 2|Subjects dosed with matching placebo to 20mg/Kg BPS804 every 3 months
89597590|NCT01406548|Experimental|BPS804 dosing frequency 3|Subjects dosed with 20mg/Kg BPS804 weekly
89597591|NCT01406548|Placebo Comparator|Placebo dosing frequency 3|Subjects dosed with matching placebo to 20mg/Kg BPS804 weekly
89597592|NCT01798810|Experimental|Supplemental Perioperative Oxygen (80% FiO2)|After intubation, patients in the Treatment Group will receive intraoperative inspired oxygen set at 80 percent (FiO2 of 0.80). Post-extubation, patients in the treatment arm will be placed on high flow non-re-breather mask at 15L/min for up to 2 hours postoperatively and then transitioned to nasal cannula, which will be weaned as tolerated.
89597593|NCT01798810|No Intervention|Control (30% FiO2)|After intubation, patients in the control arm will receive typical standard of care intraoperative inspired oxygen of 30 percent (FiO2 of 0.30). Post-extubation, patients in the control arm of the study will be placed on a nasal cannula at 4L/min to maintain SaO2≥92% as determined by pulse oximetry. This will be maintained for up to 2 hours and then weaned as tolerated.
89597594|NCT01393522|Active Comparator|Milnacipran|Oral Milnacipran titration was Day 1-2 - 12.5mg/d; Day 3-6 - 12.5mg bid; Day 7-14 - 25mg bid; Day 15 and on - 50mg bid. After the first 30 days, patients did not continue to increase the dose beyond the dose they have achieved at 30 days. At study completion medication taper as follows: patients who at their completion visit were taking 50mg bid decreased to 25mg bid for 4 days, then decreased to 12.5mg bid for 2 days, then 12.5mg once a day for one day and then stopped. Patients on 25mg bid, decreased to 12.5mg bid for 2 days, 12.5mg once a day for one day and then stopped.
89597595|NCT01393522|Placebo Comparator|Placebo|Sugar Pill No active ingredients
89597596|NCT02086786|Experimental|Gluteus (Risperidone ISM)|Risperidone ISM (75 mg) injection in the gluteal muscle at 28-day intervals
89597597|NCT02086786|Experimental|Deltoid (Risperdione ISM)|Risperidone ISM (75 mg) injection in the deltoid muscle at 28-day intervals
89597598|NCT02120482|Experimental|Combined apheresis|Patients will be treated by semiselective immunoadsorption combined with membrane filtration
89597599|NCT02318992|Active Comparator|Fecal Microbiota_Fresh|Donor stool (greater than 150 grams) was collected <4 hours prior to the procedure and then mixed in a homogenizer with 1500 milliliters (mL) (1:10 dilution) sterilized 0.9% sodium chloride (NaCl) in a large sterilized suction canister until a smooth consistency was reached. The suspension was filtered using a coffee filter twice. The microbiota suspension (250mL) was used within 2 hours of preparation (Fresh).
89597600|NCT02318992|Active Comparator|Fecal Microbiota_Frozen|Donor stool (greater than 150 grams) was collected <4 hours prior to the procedure and then mixed in a homogenizer with 1500 milliliters (mL) (1:10 dilution) sterilized 0.9% NaCl in a large sterilized suction canister until a smooth consistency was reached. The suspension was filtered using a coffee filter twice. The microbiota suspension (250mL) was kept at -80 degrees Celsius (C) freezer labeled with identity (ID) and expiration date which was 6 months after preparation day (Frozen).
88979216|NCT00275275|Experimental|3|Conversion factor of Mirapex to Requip 24-Hour of 1:5
88979217|NCT00078923|Experimental|Placebo|Arm I (control group): Patients receive 4 placebo capsules by mouth daily for three weeks.
88979218|NCT00078923|Experimental|Soy isoflavones and placebo|Arm II: Patients receive oral soy isoflavones (PTI G-2535) 150 mg genistein capsules + 3 placebo capsules by mouth daily for 3 weeks.
89031792|NCT05317611|Active Comparator|Intraperitoneal instillation of ondansetron and bupivacaine (group A)|Patients will receive intraperitoneal instillation of (100 mg) 20 ml of bupivacaine 0.5 % and (4 mg) 2 ml ondansetron through abdominal ports by simple instillation technique before removal of trocars then clamping of abdominal drains for 1h to avoid drainage of LA.
89597601|NCT02318992|Active Comparator|Fecal Microbiota_Lyophilized|Donor stool (greater than 150 grams) was collected <4 hours prior to the procedure and then mixed in a homogenizer with 1500 milliliters (mL) (1:10 dilution) sterilized 0.9% NaCl in a large sterilized suction canister until a smooth consistency was reached. The suspension was filtered using a coffee filter twice. The microbiota suspension (250mL) was starting lyophilization process within 30 minutes after completion of stool filtration (Lyophilized). Lyophilized microbiota products were kept at 4 degrees celsius (C) and were used within 6 months after preparation day.
89597602|NCT01782820||dexamethasone late|dexamethasone during induction of anesthesia
89597603|NCT01782820||no dexamethasone|no dexamethasone during measurements
88979219|NCT00078923|Experimental|Soy Isoflavones/Placebo|Arm III: Patients receive oral soy isoflavones (PTI G-2535) 300 mg genistein capsules + 2 placebo capsules by mouth daily for 3 weeks.
88979220|NCT00078923|Experimental|Soy Isoflavones|Arm IV: Arm III: Patients receive oral soy isoflavones (PTI G-2535) 600 mg genistein capsules by mouth daily for 3 weeks.
88979221|NCT00102726|Active Comparator|Arm 1|SB-497115-GR 50mg. administered orally daily on days 2 through 11 for each 21-day cycle.
88979222|NCT00102726|Active Comparator|Arm 2|SB-497115-GR 75 mg administered orally dailey on days 2-11 of each 21-day cycle.
88979223|NCT00102726|Active Comparator|Arm 3|SB-497115 100mg administered orally daily on days 2 through 11 of each 21-day cycle.
88979224|NCT00102726|Placebo Comparator|Placebo Arm|Placebo administered orally daily on days 2 through 11 of each 21-day cycle.
88979225|NCT00275080|Experimental|Treatment (enzyme inhibitor, chemotherapy)|"Regimen 1 (sequential dosing): Patients receive oral vorinostat two or three times daily on days 6-21 or days 6-12 (patients with solid tumors or NHL only) and decitabine IV over 1 hour on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Regimen 2 (concurrent dosing): Patients receive oral vorinostat two or three times daily on days 1-21, days 1-14 (patients with hematological malignancies only), or two times daily on days 1-12 (patients with solid tumors or NHL only) and decitabine IV over 1 hour on days 1-5."
89597604|NCT01782820||dexamethasone early|dexamethasone before induction of anesthesia
89597605|NCT01374412||osteoporosis|patients with benign osteoporosis
89597606|NCT01777828||Transcatheter Aortic Valve Implantation|FRANCE TAVI registry aims to identify all patients with a change of valves implanted catheter meets the selection criteria of the technical accepting the scheduled evaluations in the context of this disease and who have agreed to participate in the study .
89597607|NCT01776736|Experimental|Posture Correction Girdle|Posture Correction Girdle applied for 8 hours per day. Clinical, radiographic, and self-report follow-up within the girdling period (6 months).
89597608|NCT02114086||breast cancer|observation of intraoperative radiotherapy
89597609|NCT02108158|Experimental|Azzalure 10 Speywood units/injection|Azzalure (botulinum toxin type A), powder for solution for injection, Total dose 50 s.U (5 x 10s.U)
89597610|NCT02108158|Active Comparator|Azzalure, 10 Speywood units/injection|Azzalure (botulinum toxin type A), powder for solution for injection, Total dose 50 s.U (5 x 10s.U)
89597611|NCT01774630|Experimental|Nilotinib|300 mg/twice a day
89597612|NCT01895920|Experimental|HIV infection|20 HIV infected subjects
89597613|NCT01895218|Experimental|Iron isomaltoside 1000 (Monofer®)|
89597614|NCT01895218|Active Comparator|Standard medical Care|
89597615|NCT02086708|Experimental|Shear Wave Sonoelastography, Fibrosis stage|Shear Wave sonoelastography is performed on patients who are scheduled for a non-focal liver biopsy.
89597616|NCT02065882|Experimental|BT524|Single intravenous infusion of a fixed dose of 70 mg BT524 per kilogram body weight (BW)
89597617|NCT01507545|Active Comparator|MORAb-004|
89597618|NCT01507545|Placebo Comparator|Placebo|
89597619|NCT04409535||Rural Living Community Member|Adult residents of a New Mexico rural county (as federally designated)
89597620|NCT04409535||Urban/Suburban Living Community Member|Comparison group: adult resident of a New Mexico urban/suburban city or town (as federally designated)
89597621|NCT01482819|Other|Sequence 1|"Five separate sessions of bilateral lens wear of 8 to 12 hours; each session separated by a minimum of 24 hours. This sequence is as follows:~Lotrafilcon A~Spectacles~Galyfilcon A Plus~Polymacon~Galyfilcon A"
89597622|NCT01482819|Other|Sequence 2|"Five separate sessions of bilateral lens wear of 8 to 12 hours; each session separated by a minimum of 24 hours. This sequence is as follows:~Galyfilcon A Plus~Galyfilcon A~Lotrafilcon A~Polymacon~Spectacles"
89597623|NCT01482819|Other|Sequence 3|"Five separate sessions of bilateral lens wear of 8 to 12 hours; each session separated by a minimum of 24 hours. This sequence is as follows:~Galyfilcon A~Polymacon~Galyfilcon A Plus~Spectacles~Lotrafilcon A"
89597624|NCT01482819|Other|Sequence 4|"Five separate sessions of bilateral lens wear of 8 to 12 hours; each session separated by a minimum of 24 hours. This sequence is as follows:~Spectacles~Lotrafilcon A~Polymacon~Galyfilcon A Plus~Galyfilcon A"
89597625|NCT01482819|Other|Sequence 5|"Five separate sessions of bilateral lens wear of 8 to 12 hours; each session separated by a minimum of 24 hours. This sequence is as follows:~Polymacon~Galyfilcon A~Spectacles~Galyfilcon A Plus~Lotrafilcon A"
89597626|NCT01482819|Other|Sequence 6|"Five separate sessions of bilateral lens wear of 8 to 12 hours; each session separated by a minimum of 24 hours. This sequence is as follows:~Galyfilcon A~Galyfilcon A Plus~Polymacon~Lotrafilcon A~Spectacles"
89597627|NCT01482819|Other|Sequence 7|"Five separate sessions of bilateral lens wear of 8 to 12 hours; each session separated by a minimum of 24 hours. This sequence is as follows:~Polymacon~Spectacles~Galyfilcon A~Lotrafilcon A~Galyfilcon A Plus"
89597628|NCT01482819|Other|Sequence 8|"Five separate sessions of bilateral lens wear of 8 to 12 hours; each session separated by a minimum of 24 hours. This sequence is as follows:~Galyfilcon A Plus~Lotrafilcon A~Galyfilcon A~Spectacles~Polymacon"
88979226|NCT00078962|Experimental|Treatment (GTI-2040, gemcitabine hydrochloride)|"Patients receive GTI-2040 IV continuously on days 2-16 of course 1 and on days 1-16 of all subsequent courses and gemcitabine IV over 30 minutes on days 1, 8, and 15 of course 1 and on days 2, 9, and 16 of all subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of GTI-2040 and gemcitabine until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, 10 additional patients are treated at that dose."
88979227|NCT00275041|Experimental|cetuximab + irinotecan|"Patients receive cetuximab IV over 1-2 hours on days 1, 8, and 15 and irinotecan hydrochloride IV over 1½ hours on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~After completion of study treatment, patients are followed periodically for up to 5 years."
89597629|NCT01482819|Other|Sequence 9|"Five separate sessions of bilateral lens wear of 8 to 12 hours; each session separated by a minimum of 24 hours. This sequence is as follows:~Lotrafilcon A~Galyfilcon A Plus~Spectacles~Galyfilcon A~Polymacon"
89597630|NCT01482819|Other|Sequence 10|"Five separate sessions of bilateral lens wear of 8 to 12 hours; each session separated by a minimum of 24 hours. This sequence is as follows:~Spectacles~Polymacon~Lotrafilcon A~Galyfilcon A~Galyfilcon A Plus"
89597631|NCT01534533|Placebo Comparator|Placebo|early atherosclerosis cases, received starch in hard shell gelatine capsules, once a day
89597632|NCT01534533|Experimental|Lutein group|early atherosclerosis cases, received 20mg lutein, once a day
89597633|NCT01534533|Experimental|Combination group|early atherosclerosis cases, received 20mg lutein plus 20mg lycopene, once a day
89597634|NCT01534533|Experimental|Normal lutein control group|20mg lutein for subjects free from atherosclerosis, once a day
89597635|NCT02986035|Experimental|Intervention|
88979228|NCT00130390|Experimental|1|One nitazoxanide 500 mg tablet twice daily for 28 days
88979229|NCT00130390|Placebo Comparator|2|One placebo tablet twice daily for 28 days
88979230|NCT00130312|Experimental|Sulodexide|Also known as KRX-101. These patients are also on ACEs and ARBs (irbesartin and/or losartan).
88979231|NCT00130312|Placebo Comparator|Placebo|These patients are also on ACEs and ARBs (irbesartin and/or losartan).
88979232|NCT00130273|Experimental|1|Participants will receive managed problem solving for 12 months
88979233|NCT00130273|Active Comparator|2|Participants will receive standard of care for 12 months
89597636|NCT01759186||None interventional|
89597637|NCT01758796|Experimental|Non-operative|Non-operative treatment with six weeks in a below-the-knee cast. Partial weight-bearing (15 to 20 kilograms) for the first four weeks and then weight-bearing as tolerated for the remaining two weeks.
89597638|NCT01758796|Active Comparator|Surgery|Open reduction and internal fixation with 1/3 semitubular plate and screws. Post-operatively, surgically treated ankles are placed in a below-the-knee cast for six weeks. They are advised to carry out partial weight-bearing (15 to 20 kilograms) for the first four weeks and then weight-bear as tolerated for the remaining two weeks.
89597639|NCT01746160|Experimental|C1 Implant|Patient having C1 implant installed.
89597640|NCT01895296|Experimental|Pasireotide|pasireotide 300 microgram s.c. t.i.d.
89597641|NCT01895296|Placebo Comparator|Placebo|saline s.c. t.i.d.
89597642|NCT04389502|Experimental|CaPtyVa app group|Those assigned to the CaPtyVa app group will receive a tutorial video describing its operation and will have to complete 10-item clinical vignette quiz according to the app recommendations based on local current CRC screening and surveillance guidelines on every question. Physicians in this group will download a free of charge application (CaPtyVa CCR APP, Digital Means, Argentina) on their iOs or Android device.
89597643|NCT04389502|Active Comparator|Control group|The ones assigned to the control group will be asked to complete the 10-item clinical vignette quiz according to their current knowledge on local current CRC screening and surveillance guidelines
89597644|NCT01895374|Experimental|amniotic membrane dressing|We compare the efficacy of amniotic membrane and hydrocolloid in same subjects to avoid confounders.
89597645|NCT01895374|Active Comparator|Hydrocolloid dressing|Same subjects received amniotic membrane and hydrocolloid dressing at the same time in different wound.
89597646|NCT01299532|Experimental|Macrolane VRF30|
89597647|NCT01276600|Experimental|Arm 1|1 tablet orally weekly
89597648|NCT01276600|Experimental|Arm 2|One tablet orally twice weekly
89597649|NCT01276600|Experimental|Arm 3|Two tablets orally twice weekly
89597650|NCT01276600|Experimental|Arm 4|One tablet orally daily
89597651|NCT04756180|Experimental|Omacor|Omacor 2gm/day for first 4 week followed by 4gms/day for 8 weeks
89597652|NCT04756180|Placebo Comparator|Placebo|Omacor Placebo 2gm/day for first 4 week followed by 4gms/day for 8 weeks
89597653|NCT04745806|Experimental|ActiGraft|Whole blood clot (WBC) gel
89597654|NCT04755868|Experimental|Maintenance therapy with talazoparib|Maintenance therapy with talazoparib (1mg once daily) (once daily 1.0 mg oral administration), 103patients
89597655|NCT04755868|Active Comparator|Maintenance therapy with placebo|Maintenance therapy with placebo (once daily 1.0 mg oral administration), 103patients
89597656|NCT05567926|Experimental|Experimental condition, receiving beetroot juice supplement|Participants will receive beetroot juice intervention in the experimental condition.
89597657|NCT05567926|Placebo Comparator|Placebo condition|Participants will receive placebo (blackcurrant juice) in the placebo condition
89597658|NCT05560204|Active Comparator|Watchman Flx|Watchman Flx device to be used for LAAO
89597659|NCT05560204|Active Comparator|Amulet|Amulet device to be used for LAAO
89597660|NCT01896076||Pediatric patients in urologic surgery|Pediatric patients undergoing caudal block for urologic surgery were included in this study.
89597661|NCT01252888|Experimental|Two iStent devices and medication|Implantation of two iStents through small temporal clear corneal incision
89597662|NCT01642342|Experimental|Weekly Treatment (sEphB4-HSA)|Patients receive recombinant albumin fusion protein sEphB4-HSA IV over 60 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89597663|NCT01642342|Experimental|Every 2 Weeks Treatment (sEphB4-HSA)|Patients receive recombinant EphB4-HSA fusion protein IV over 60 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89597664|NCT01642342|Experimental|Every 3 Weeks Treatment (sEphB4-HSA)|Patients receive recombinant EphB4-HSA fusion protein IV over 60 minutes on days 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89597665|NCT04755556|Other|Experimental group|Intensive bimanual training with routine physical therapy
89597666|NCT04755556|Other|control group|routine physical therapy
89597667|NCT01621906|Experimental|Cohort 1|Cohort 1 will include the first ten patients treated with WBRT concomitantly with sorafenib (on a separate phase I trial). We will perform a pilot study of serial FLT-PET imaging of the brain at baseline (< 4 weeks prior to initiation of WBRT), up to 7-10 days post-WBRT and 10-12 weeks after WBRT in patients with metastatic breast cancer to the brain (N=20) treated with WBRT with or without sorafenib.
89597668|NCT01621906|Experimental|Cohort 2|Cohort 2 will include patients treated with standard WBRT alone. Patients in both these cohorts will also be assessed with standard non-invasive MRI in addition to [18F] FLT PET at baseline (< 4 weeks of WBRT) and 10-12 weeks after completion of WBRT.
88979234|NCT00079118|Experimental|docetaxel + irinotecan|"Patients receive docetaxel IV over 1 hour followed by irinotecan IV over 1 hour on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients who achieve a complete response (CR) receive 2 additional courses beyond CR.~Patients are followed every 2 months until disease progression and then every 6 months thereafter."
88979235|NCT00130195|Experimental|A|
88979236|NCT00394303|Experimental|1|Intervention
88979237|NCT00394303|No Intervention|2|Control
88979238|NCT00394381|Experimental|CIK infusion|Infusion of autologous CIK cells in study group. There is only one arm to this study
88979239|NCT00130156|Experimental|1|
88979240|NCT00130156|Experimental|2|
88979241|NCT00130117|Experimental|r-metHuLeptin|r-metHuLeptin administered subcutaneously.
88979242|NCT00130117|Placebo Comparator|Oral Contraceptive Pills (OCPs)|PLACEBO
88979243|NCT00112398|Active Comparator|Standard (paramedic) prehospital care|
88979244|NCT00112398|Experimental|Physician prehospital care|
88979245|NCT00079235|Experimental|Arm I|Patients receive CCI-779 IV over 30 minutes on days 1, 8, 15, and 22.
88979246|NCT00129805|Experimental|MCI-9042|
88979247|NCT00129805|Active Comparator|Aspirin|
88979248|NCT00129727|Experimental|Phase II|Paclitaxel carboplatin bevacizumab
88979249|NCT04727814||Water exchange with computer-aided detection system|Computer-aided detection system overlaid videos with water exchange colonoscopy method
88979250|NCT04727814||Air insufflation with computer-aided detection system|Computer-aided detection system overlaid videos with air insufflation colonoscopy method
88979251|NCT00079352|Experimental|Treatment (gemcitabine, irinotecan, alvocidib)|Patients receive gemcitabine IV over 30 minutes followed by irinotecan IV over 30 minutes on days 1 and 15. Patients also receive flavopiridol IV over 60 minutes on days 2 and 16. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
88979252|NCT00119496|Active Comparator|Group 1|Inhaled beclomethasone (400mcg/day)
88979253|NCT00119496|Active Comparator|Arm 2|Rosiglitazone
88979254|NCT00119496|Active Comparator|Arm3|Oral theophylline
89597669|NCT01220752|Experimental|IMRT + carbon ion boost|(8 x 3 GyE) carbon ion therapy followed by 50 Gy IMRT (2 Gy/ Fx)corresponding to a total dose of approximately 74 GyE.
89210066|NCT00896688||Healthy Volunteers|It will involve 5 volunteers and they will undergo C arm fluoroscopic guided cervical medial branch blocks (C2-C7) on unilateral position and then followed by the 3D ultrasound machine for visualization of needle position.
89597670|NCT01615510|Experimental|Capsaicin (topical)|300 µL of 0.6% capsaicin in 45% ethanol, topically applied on the forearm intervention: tapentadol immediate release or placebo
89210067|NCT00896688||Candidates for upper and lower cervial medical branch blocks|This will involve 25 patients and they will follow the same procedures as the healthy volunteers.
89597671|NCT01615510|Experimental|Menthol (topical)|1000 µL of 40% menthol in 90% ethanol, topically applied on the forearm intervention: tapentadol immediate release or placebo
89210068|NCT00896844|Experimental|emotional disclosure|writing about emotional events from the past
89597672|NCT00530062|Experimental|Albuterol-HFA-BAI|Participants will receive single actuation of albuterol 90 micrograms (mcg), administered using BAI in treatment period 1 or 2.
89597673|NCT00530062|Active Comparator|Albuterol-HFA-MDI|Participants will receive single actuation of albuterol 90 mcg, administered using MDI in treatment period 1 or 2.
89597674|NCT01209364|Experimental|Durolane|intraarticular hyaluronic acid
89597675|NCT01209364|Active Comparator|methylprednisolone|intraarticular injection
89597676|NCT05080192||Fenofibrate recipients|Approximately 20 subjects who were randomized to the Fenofibrate arm in the FERMIN trial. This drug was administered for 10 days post-randomization.
88979255|NCT00119496|Active Comparator|Arm 4|Oral theophylline and inhaled beclomethasone
88979256|NCT00298324|Active Comparator|Myfortic|Patients in this arm will receive Myfortic + Prednisone + Cyclosporine
88979257|NCT00298324|Other|Standard Care/ Placebo|In this arm patients will receive Prednisone + Cyclosporine + Placebo or Prednisone + Cyclosporine
89597677|NCT05080192||Placebo recipients|Approximately 20 subjects who were randomized to the placebo arm in the FERMIN trial. This drug was administered for 10 days post-randomization.
89597678|NCT00474370|Experimental|Test Arm|Vicriviroc 30 mg QD
89597679|NCT00474370|Placebo Comparator|Placebo Control Arm|Placebo
89597680|NCT00472966|Other|1|Fluocinolone acetonide 0.1%/hydroquinone 4%/tretinoin 0.05% Cream in sequence with glycolic acid peels
88979258|NCT00079430|Experimental|Treatment (adjuvant, paclitaxel, carboplatin, bevacizumab)|Patients receive paclitaxel IV over 3 hours followed by intraperitoneal carboplatin over 15 minutes on day 1 in course 1. Beginning in course 2, patients also receive bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
88979259|NCT00119535|Other|Arm 1|
88979260|NCT00298675|Experimental|Iniparib|
89210069|NCT00896844|Placebo Comparator|placebo writing|writing about how they spent their time the previous day
89210070|NCT04036344|No Intervention|Control|Control participants receive treatment for a facial skin cancer with Mohs micrographic surgery (MMS), however, do not receive a peer mentor. Participants complete 3 online Skin Cancer Index (SCI) surveys at enrollment, 1 week follow-up, and 3 month follow-up.
89210071|NCT04036344|Experimental|Mentee - Preoperative Consult|Mentees are enrolled at preoperative consultation visit and paired with a peer mentor throughout their treatment of a facial cancer with MMS. Participants have regular contact with their mentor and complete 3 online SCI surveys at enrollment, 1 week follow-up, and 3 month follow-up.
89597681|NCT01896154|Experimental|NPS from yeast|Powder containing the active ingredients (500mg NPS from yeast) as well as filling substances (maltodextrins) and flavour adding up to 12.0 g altogether in sachets; consumed once daily after having been stirred in milk or filtered apple juice (ca. 200 ml/ 1 glass) for 5 weeks. 2 weeks before vaccination and 3 weeks after vaccination.
88979261|NCT00298675|Experimental|Iniparib/irinotecan|
89210072|NCT04036344|Experimental|Mentee - Same Day Surgery|Mentees are enrolled at same day surgery visit and paired with a peer mentor throughout their treatment of a facial cancer with MMS. Participants have regular contact with their mentor and complete 3 online SCI surveys at enrollment, 1 week follow-up, and 3 month follow-up.
89210073|NCT00893490|Experimental|Ahmed Glaucoma Valve (AGV) alone|
88979262|NCT00298792|Experimental|Individualized Assessment & treatment|Individualized treatment for alcohol dependent persons, based on momentary assessment of high-risk situations and recorded coping abilities.
88979263|NCT00298792|Active Comparator|Packaged Cognitive-Behavioral Treatment|Manualized cognitive-behavioral treatment for alcohol dependent persons.
88979264|NCT00298870|Experimental|PGx-treatment|NAT2 genotype-guided treatment with stratified isoniazid dose (approx. 7.5 mg/kg b.w., patients homozygous for NAT2*4: rapid acetylators; 5 mg/kg, patients heterozygous for NAT2*4: intermediate acetylators; 2.5 mg/kg, patientes without NAT2*4: slow acetylators)
88979265|NCT00298870|Active Comparator|STD-treatment|Treatment with conventional standard isoniazid dose (approx. 5 mg/kg b.w.)
88979266|NCT02960386|Other|Machine Learning Algorithm|Single group participants that will use the algorithm to be engaged in using their fitness tracker.
88979267|NCT00298909|Experimental|1|niacin
88979268|NCT00298909|Active Comparator|2|physical exercise
88979269|NCT00298909|Placebo Comparator|3|control
88979270|NCT00119574|Other|Arm 1|
88979271|NCT00079547|Active Comparator|1|Low-calorie diet
88979272|NCT00079547|Experimental|2|Low-carbohydrate diet
88979273|NCT04718623||Sepsis group (SG)|with source of infection and SOFA Score more than or equal 2
88979274|NCT04718623||Non-Sepsis Group (NSG)|with SOFA score less than 2
88979275|NCT00079586|Active Comparator|Heparin|unfractionated heparin will be administered as per institutional practice
88979276|NCT00079586|Experimental|Angiomax|1.0 mg/kg IV bolus followed by a 2.5 mg/kg/hr IV infusion
88979277|NCT00418132|Experimental|1|Participants will receive thalidomide.
88979278|NCT00418132|Placebo Comparator|2|Participants will receive placebo thalidomide.
88979279|NCT00299260|Active Comparator|vaccine|glycoprotein B plus MF59 adjuvant
88979280|NCT00299260|Placebo Comparator|placebo|normal saline
89597682|NCT01896154|Experimental|NPS from shiitake|Powder containing the active ingredient (500mg NPS from shitake) as well as filling substances (maltodextrins) and flavour adding up to 12.0 g altogether in sachets; consumed once daily after having been stirred in milk or filtered apple juice (ca. 200 ml/ 1 glass) for 5 weeks: 2 weeks before vaccination and 3 weeks after vaccination.
89597683|NCT01896154|Experimental|NPS from oat|Powder containing the active ingredient (10g NPS from oat) as well as filling substances (maltodextrins) and flavour adding up to 12.0 g altogether in sachets; consumed once daily after having been stirred in milk or filtered apple juice (ca. 200 ml/ 1 glass) for 5 weeks: 2 weeks before vaccination and 3 weeks after vaccination.
89597684|NCT01896154|Experimental|NPS from wheat|Powder containing the active ingredient (10g NPS from wheat) as well as filling substances (maltodextrins) and flavour adding up to 12.0 g altogether in sachets; consumed once daily after having been stirred in milk or filtered apple juice (ca. 200 ml/ 1 glass) for 5 weeks: 2 weeks before vaccination and 3 weeks after vaccination.
89597685|NCT01896154|Experimental|NPS from Lactobacillus mucosae|Powder containing the active ingredient (2,3g NPS from L. mucosae) as well as filling substances (maltodextrins) and flavour adding up to 12.0 g altogether in sachets; consumed once daily after having been stirred in milk or filtered apple juice (ca. 200 ml/ 1 glass) for 5 weeks: 2 weeks before vaccination and 3 weeks after vaccination.
89597686|NCT01896154|Placebo Comparator|Maltodextrin|12.0 g Maltodextrin and flavour with identical/similar appearance and taste (when mixed in drink), consumed once daily as described for the active products (NPS.
89597687|NCT01573780|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive gemcitabine hydrochloride IV over 30 minutes and smac mimetic TL32711 IV over 30 minutes once weekly for 2 weeks. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
89597688|NCT01186276|Placebo Comparator|Corn Starch|Corn starch will serve as the control arm.
89597689|NCT01186276|Experimental|Fiber|Fiber will serve as the intervention.
89597690|NCT01141426|Active Comparator|Secondary Care Treatment as Usual|At the four secondary health care sites, treatment as usual will consist of a multidisciplinary team approach including pharmacotherapy and clinical management, supportive or structured activities focused around symptom management and in some cases, individual or group psychotherapy. Pharmacotherapy treatment strategies will be individualized regimes informed by evidence-based recommendations. TAU will not be regulated in order to get a naturalistic assessment of standard secondary care treatment delivery with the exception that trial participants not be offered a psychodynamic / psychoanalytic based psychotherapy treatment during the course of the trial. Therapeutic interventions are likely to be heterogeneous therefore the trial coordinator will document in detail the dose and approaches delivered to each participant in order to account for this heterogeneity.
88979281|NCT00119613|Experimental|Group 1 - darbepoetin alfa|Darbepoetin alfa 300 mcg QW for the first 4 weeks, followed by Q3W dosing commencing on week 5 for the remainder of the treatment period.
88979282|NCT00119613|Placebo Comparator|Group 2 - Placebo|Placebo QW for the first 4 weeks, followed by Q3W dosing commencing on week 5 for the remainder of the treatment period.
88979283|NCT00299455|Experimental|1|Reconstituted amoxicillin-clavulanate at 40/5.7 mg/kg/day in 2 divided doses for 7 days.
88979284|NCT00299455|Placebo Comparator|2|Reconstituted placebo in 2 divided doses for 7 days.
88979285|NCT00299611|Active Comparator|1|Levetiracetam
88979286|NCT00299611|Placebo Comparator|2|there is no active ingredient in the pills.
88979287|NCT00299650|Placebo Comparator|A|
88979288|NCT00299650|Active Comparator|B|
88979289|NCT04727853|Experimental|irinotecan liposome injection|Patients will receive irinotecan liposome injection at 70 mg/m^2 intravenously, over 90 min on Days 1 of every 14-day cycle.
89210074|NCT00893490|Experimental|AGV plus MMC|
88979290|NCT00299884||1|Lipitor 20 mg
88979291|NCT00299884||2|Lipidil Supra 160 mg and Ezetrol 10 mg
88979292|NCT00299962|Experimental|Dose level 4|
88979293|NCT00299962|Experimental|Dose level 5|
88979294|NCT00299962|Experimental|Dose Level 1|on Days 1 and 15
88979295|NCT00299962|Experimental|Dose Level 2|On Days 1 and 15
88979296|NCT00299962|Experimental|Dose Level 3|On Days 1 and 15
88979297|NCT00119691|Experimental|Nesiritide + standard of care|Nesiritide: 1 mcg/kg bolus, followed by a continuous infusion at 0.005 mcg/kg/min which can be titrated every 3 hours by 0.005 mcg/kg/min to maximum dose of 0.03 mcg/kg/min until adequate diuresis achieved.
88979298|NCT00119691|Active Comparator|Standard of care|Standard of care until adequate diuresis achieved
88979299|NCT00300040|Experimental|1|Hemoglobin glutamer 250 - bovine
88979300|NCT00300040|Active Comparator|2|6% Hydroxyethylstarch
88979301|NCT00079820|Experimental|A|MVA3000 Smallpox vaccine (1x10-8) with Dryvax Challenge at Day 112
88979302|NCT00079820|Experimental|B|MVA3000 Smallpox vaccine (1x10-8) with no Challenge
88979303|NCT00079820|Placebo Comparator|C|Placebo
88979304|NCT00079820|Experimental|D|MVA3000 Smallpox vaccine (1x10-7) with Dryvax challenge at Day 112
88979305|NCT00079820|Experimental|E|MVA3000 Smallpox vaccine (1x10-6) with Dryvax challenge at Day 112
88979306|NCT00300118|Experimental|A|
88979307|NCT00300118|Active Comparator|B|
88979308|NCT00119730|Experimental|Fludarabine, Mitoxantrone, Rituximab, Zevalin|Drug: Fludarabine Given on days 1-3 of each 28-day cycle Drug: Mitoxantrone Given on day 1 of each 28-day cycle Drug: Rituximab Given on day 1 of each 28-day cycle Drug: Zevalin Given after two cycles if there is no disease progression.
88979309|NCT00300196|Experimental|Intravenous ancrod|Intravenous ancrod infused at a rate of 0.167 IU/kg/hr (0.6 mL/kg/hr) for 2 or 3 hours depending on the pretreatment fibrinogen level.
89210075|NCT00893490|Experimental|AGV plus amniotic membrane coverage|
89597691|NCT01141426|Experimental|Intensive Short-Term Dynamic Psychotherapy (ISTDP) Group|The ISTDP model is an emotion focused brief format of psychotherapy that helps the patients identify and address emotional factors that culminate into exacerbation of depression and perpetuation of depression. The emphasis is on awareness of emotions and how they affect the person's behavioral patterns and mood. The research protocol calls for the treatment to be delivered according to a 20-session time-limited format. The first session is an extended 2-3 hour appointment (21), then sessions are planned to occur on a weekly basis lasting 60 minutes in duration. Termination in fewer sessions is based upon agreement between therapist and patient.
89597692|NCT01895530|No Intervention|Control group|Conventional treatment with no probiotic supplementation
89597693|NCT01895530|Experimental|Probiotic group|The patients received one oral lyophilized yeast capsule, each of which contains 100 mg (0,5 x 109 cfu/g) of Saccharomyces boulardii (Merck S.A., Biocodex, Beauvais, French), once a day. The treatment started at least seven days before surgery and stopped on the operation day.
89597694|NCT01547260|Experimental|Lenalidomide|Phase I; Lenalidomide capsules will be taken orally each day on days 1-21 of each 28-day cycle. 3 subjects will be enrolled into each dose cohort for 15, 20 and 25 mg/day. Gemcitabine, 1000 mg/m2 in 0.9% sodium chloride will be administered iv over 30 minutes, at days 1, 8, 15 of each 28-day cycle. Phase II: Every other consecutive included subject in phase II part will be treated with either single lenalidomide (days 1-21 of 28) or single gemcitabine (days 1, 8, 15 of 28) during Cycle 1. The first included patient in phase II part will start with single lenalidomide. From treatment cycle number 2 and beyond, all subjects in the phase II part of the study will be treated with lenalidomide in combination with gemcitabine.
89597695|NCT01547260|Experimental|gemcitabine|Gemcitabine, 1000 mg/m2 in 0.9% sodium chloride will be administered iv over 30 minutes, at days 1, 8, 15 of each 28-day cycle in both phase I and II. Phase I:Lenalidomide capsules will be taken orally each day on days 1-21 of each 28-day cycle. 3 subjects will be enrolled into each dose cohort for 15, 20 and 25 mg/day. Phase II: Every other consecutive included subject in phase II part will be treated with either single lenalidomide (days 1-21 of 28) or single gemcitabine (days 1, 8, 15 of 28) during Cycle 1. The first included patient in phase II part will start with single lenalidomide. From treatment cycle number 2 and beyond, all subjects in the phase II part of the study will be treated with lenalidomide in combination with gemcitabine.
89597696|NCT02317042|Active Comparator|Standard ST Mode|"Participants underwent the first PSG study (Titration Night 1) on ST Mode ( prior to going on AutoEPAP iVAPS or Fixed EPAP iVAPS) whilst receiving their standard NIV therapy through the clinical trial device Juno. During this mode the participant's current NIV settings were reviewed and re-titrated to deliver optimal therapy."
89597697|NCT02317042|Experimental|AutoEPAP iVAPS|"Participants underwent a PSG study on the AutoEPAP iVAPS mode on either Night 2 or Night 3 according to their computer generated randomisation.~Participants were randomised (1:1) according to a computer-generated randomised list (Microsoft Excel 2010) to receive 'AutoEPAP iVAPS' or 'FixedEPAP iVAPS' therapy mode first."
89597698|NCT02317042|Active Comparator|Fixed EPAP iVAPS|"Participants underwent a PSG study on the Fixed EPAP iVAPS mode on either Night 2 or Night 3 according to their computer generated randomisation.~Participants were randomised (1:1) according to a computer-generated randomised list (Microsoft Excel 2010) to receive 'AutoEPAP iVAPS' or 'FixedEPAP iVAPS' therapy mode first."
88979310|NCT00300196|Placebo Comparator|Intravenous Placebo|Intravenous placebo at a rate of 0.6 mL/kg/hr for 2 or 3 hours depending on the pretreatment fibrinogen level.
88979311|NCT00119769|Placebo Comparator|1|
88979312|NCT00119769|Active Comparator|2|
88979313|NCT00300313|Active Comparator|1|
88979314|NCT00300313|Placebo Comparator|2|
88979315|NCT00086268|Experimental|Zometa®|4mg monthly for 12 months from date of first chemotherapy dose
88979316|NCT00086268|No Intervention|no further treatment|Control arm; no further treatment. Follow-up monthly for 12 months from date of first chemotherapy dose
88979317|NCT00300586|Sham Comparator|A (supervision)|medical supervision, second line chemotherapy if progression
88979318|NCT00300586|Active Comparator|B (gemcitabicine)|Maintenance treatment (gemcitabicine 1250 mg/m² J1, J8 (repeated cycles every 21 days), second line chemotherapy if progression
88979319|NCT00300586|Experimental|C (Erlotinib)|Treatment by erlotinib 150 mg/day (sequential treatment), second line chemotherapy if progression
88979320|NCT04718467|Experimental|adults group (aged 18-59 years) & vaccine|three doses of 40μg Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21, 42.
88979321|NCT04718467|Placebo Comparator|adults group (aged 18-59 years) & placebo|three doses of placebo at the schedule of day 0, 21, 42.
88979322|NCT04718467|Experimental|elderly adults group (aged 60-85 years) & vaccine|three doses of 40μg Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21, 42.
88979323|NCT04718467|Placebo Comparator|elderly adults group (aged 60-85 years) & placebo|three doses of placebo at the schedule of day 0, 21, 42.
88979324|NCT04718233|Experimental|sildenafil citrate|Sildenafil citrate at a dose of 25mg will be administered orally in patients with recurrent pregnancy loss and the blood flow indices will be measured initially and after 3 hours.
88979325|NCT04718233|Placebo Comparator|placebo|placebo will be administered orally in patients with recurrent pregnancy loss and the blood flow indices will be measured initially and after 3 hours.
88979326|NCT00080093|Experimental|1|Participants will receive individual feedback and specially-tailored manuals at study entry and at Months 2 and 4
88979327|NCT00080093|Experimental|2|Participants will receive general HIV information feedback and the best-available informational manual at study entry and at Months 2 and 4
88979328|NCT04727346||Study Group|CBCT and DISE
88979329|NCT04727346||Control Group|DISE only
88979330|NCT00300937|Experimental|A|
88979331|NCT00418210|Experimental|Accelerated partial breast irradiation|Accelerated partial breast irradiation (APBI) to region of tumour bed using 3D conformal radiation therapy (3D CRT)
88979332|NCT00119925|Active Comparator|minimal intervention|professional audit and feedback on current practice
88979333|NCT00119925|Active Comparator|maximal intervention|multi-faceted intervention consisting of professional and patient elements
88979334|NCT00300976|Experimental|Intensive therapy|
88979335|NCT00300976|Active Comparator|Conventional therapy|
88979336|NCT00301015|Experimental|1|Malaria diagnosis aided with rapid diagnostic test
89597699|NCT01896388|Active Comparator|Ifenprodil Tartrate|Oral Administration of Ifenprodil Tartrate 40mg/day (20mg After breakfast, 20mg After supper)
89597700|NCT01896388|Placebo Comparator|Placebo|Oral Administration of Placebo (After breakfast, After supper)
89597701|NCT01125436|Experimental|Cholecalciferol|Nutritional supplement
89597702|NCT01125436|Placebo Comparator|placebo|Weekly placebo plus 800 calcium daily
89597703|NCT01113658|Experimental|SNaP|SNaP disposable, mechanically powered Negative Pressure Wound Therapy System
89597704|NCT04755478||Lung lobectomy via open thoracotomy|participants scheduled for lung lobectomy via open thoracotomy
89597705|NCT04755478||Lung lobectomy via VATS|participants scheduled for lung lobectomy via video-assisted thoracoscopic surgery
89597706|NCT04755400|Active Comparator|Potassium Nitrate|4 days treatment with 24 mmol potassium nitrate capsules
89597707|NCT04755400|Placebo Comparator|Potassium Chloride|4 days treatment 24 mmol potassium chloride capsules
89597708|NCT04777942|Experimental|neo-TACE-HAIC with surgery|transartery chemoembolization with lipiodol and EADM, FOLFOX (Oxa 85mg/m2 2h+CF 400mg/m2 2h+5FU 400mg/m2 10min+5FU 1200mg/m2 23h)-based artery infusion chemotherapy, followed by hepatic resection
89597709|NCT04777942|Active Comparator|surgery alone|hepatic resection remove the liver tumors
88979337|NCT00301015|Active Comparator|2|Malaria diagnosis based on clinical judgement only
88979338|NCT04717921||Patients|Subjects with unipolar depression
88979339|NCT04717921||Healthy|Healthy Control Group
88979340|NCT00301210|Experimental|1|tramadol dose 1
89210076|NCT00901758|Placebo Comparator|2|Placebo solution was normal saline. After an initial 1mL dose, further doses could be given in 1-3mL increments until uterine relaxation was achieved, or up to a recommended maximum of 10mL.
89597710|NCT00436540|Active Comparator|1|clobetasol propionate (Clobex®) spray
89597711|NCT00436540|Active Comparator|2|clobetasol propionate (Olux®) foam
89597712|NCT01077856||Pre-Vaccine|Registry, survey, and HPV status data from 2004-2006
89597713|NCT01077856||Post-Vaccine|Registry, survey, and HPV status data from 2011-2012
89597714|NCT04778098|Experimental|SMS group|"After postoperative standard discharge education was provided to the patients in the SMS group, they were given an individualized written Postoperative Medication Reference Chart. The patient/relative, whose contact information was received, was informed that they would be reminded via text message (SMS). SMS reminders which were individualized according to the patient based on the doctor's directive, were sent to the patients in the SMS group by the researcher clinical nurse (A. Ş). SMS sending started on postoperative day 1 and ended on day seven.~SAI was applied again to all patients who came to the outpatient clinic for control on postoperative day seven. Unlike the control group, the Patient Satisfaction Form, which was prepared for the use of SMS reminders, was applied to the patients in the SMS group. Confirmation was obtained from the patients and their relatives that SMS reminders were received every day."
89597715|NCT04778098|No Intervention|Control group|the Patient Identification Form and SAI were applied to patients in the control on the day of surgery (postoperative day 0). Routine discharge education was provided to all patients by clinical nurses. During the discharge of the patients in the control group, they were informed about the change of dressing on the next day (postoperative day one) and control in the outpatient clinic on postoperative day seven. The patients were given an individualized written Postoperative Medication Reference Chart indicating the dosage and application time of eye drops they must follow for seven days at home.
88979341|NCT00301210|Experimental|2|tramadol dose 2
89597716|NCT03793738|Active Comparator|anterior component separation|The anterior component separation technique requires an extensive subcutaneous flap elevation, incision of the external oblique aponeurosis, and incision of the posterior rectus sheath.
88979342|NCT00301249||Family Investigation of Nephropathy and Diabetes (FIND)|Individuals with diabetic nephropathy, their parents, and selected siblings
88979343|NCT00301249||African American MALD|Case-control study of African American patients with nephropathy (cases) and their spouses (controls) unaffected by diabetes and nephropathy; offspring were genotyped when available to provide haplotype data.
88979344|NCT00301249||Mexican American MALD|Case-control study of unrelated individuals of Mexican American heritage in which both cases and controls had diabetes, but only the case had nephropathy
88979345|NCT00080327|Active Comparator|1|
89597717|NCT03793738|Active Comparator|posterior component separation|The posterior component separation technique utilized the retromuscular space, accessed by incising the posterior rectus sheath and dissecting the posterior sheath between the internal oblique and transversus abdominis muscles.
89597718|NCT03783052|Other|Healthy volunteers|11 Healthy volunteers
89597719|NCT03783052|Other|Obese volunteers|11 Obese Volunteers
89597720|NCT03783052|Other|Roux-en-Y Gastric Bypass patients|6 volunteers with a Roux-en-Y Gastric Bypass
89597721|NCT03783052|Other|Sleeve Gastrectomy patients|6 volunteers with a Sleeve Gastrectomy
89597722|NCT03783052|Other|Volunteers with obesity|6 obese volunteers
89597723|NCT04778254|Active Comparator|conventional obturator|conventional group received conventional clasp-retained obturators with metallic framework (Control group).
89597724|NCT04778254|Experimental|metallic attachment retained obturator|metal group received an attachment-retained obturator with metallic framework
89597725|NCT04778254|Experimental|PEEk attachment retained obturator|PEEK group received attachment-retained obturators with milled PEEK framework,
89597726|NCT01066858||Maternal/infant antepartum exposure|"HIV-infected women exposed to TDF during pregnancy~Infants of HIV-infected women exposed to TDF during pregnancy"
89597727|NCT01066858||Maternal/infant postpartum exposure|"HIV-infected women exposed to TDF while breastfeeding~Infants of HIV-infected women exposed to TDF while breastfeeding"
89597728|NCT01066858||Maternal/infant antepartum no exposure|"HIV-infected women not exposed to TDF during pregnancy~Infants of HIV-infected women not exposed to TDF during pregnancy"
89597729|NCT01066858||Maternal/infant postpartum no exposure|"HIV-infected women not exposed to TDF during breastfeeding~Infants of HIV-infected women not exposed to TDF during breastfeeding"
88979346|NCT00080327|Active Comparator|2|
88979347|NCT00080327|Active Comparator|3|
88979348|NCT00080327|Placebo Comparator|4|
88979349|NCT00301405|Active Comparator|Thalidomide|Open Label drug
88979350|NCT00301483|Experimental|1|HBOC-201 followed by standard therapy
88979351|NCT00301483|Active Comparator|2|Standard Therapy
88979352|NCT00301522|Experimental|Arm 1|
88979353|NCT00301522|Active Comparator|Arm 2|
88979354|NCT00080444|Experimental|Part 1: Aprepitant|Day 1: aprepitant 125 mg orally (PO), ondansetron 0.15 mg/kg x 3 doses intravenously (IV), dexamethasone 8 mg PO. Day 2: aprepitant 80 mg PO, ondansetron 0.15 mg/kg x 3 doses IV, dexamethasone 4 mg PO. Day 3: aprepitant 80 mg PO, dexamethasone 4 mg PO. Day 4: dexamethasone 4 mg PO. For 1 cycle and up to 9 subsequent optional cycles.
88979355|NCT00080444|Active Comparator|Part 1: Standard Therapy|Day 1: placebo to aprepitant 125 mg PO, ondansetron 0.15 mg/kg x 3 doses IV, dexamethasone 16 mg PO. Day 2: placebo to aprepitant 80 mg PO, ondansetron 0.15 mg/kg x 3 doses IV, dexamethasone 8 mg PO. Day 3: placebo for aprepitant 80 mg PO, dexamethasone 8 mg PO. Day 4: dexamethasone 8 mg PO. For 1 cycle; participants may receive open-label aprepitant for up to 9 subsequent optional cycles.
88979356|NCT00080444|Active Comparator|Part 2: Aprepitant|Day 1: aprepitant 125 mg PO, ondansetron 0.15 mg/kg x 3 doses IV, dexamethasone 8 mg PO. Day 2: aprepitant 80 mg PO, ondansetron 0.15 mg/kg x 3 doses IV, dexamethasone 4 mg PO. Day 3: aprepitant 80 mg PO, dexamethasone 4 mg PO. Day 4: dexamethasone 4 mg PO. For up to 10 cycles.
88979357|NCT00086736|Experimental|Arm I|Patients receive oral eflornithine and oral bicalutamide once daily for 28 days in the absence of unacceptable toxicity. Patients then undergo either prostatectomy or brachytherapy, as determined by the patient, on day 29.
88979358|NCT00086736|Experimental|Arm II|Patients receive oral eflornithine and oral bicalutamide placebo once daily for 28 days in the absence of unacceptable toxicity. Patients then undergo either prostatectomy or brachytherapy, as determined by the patient, on day 29.
88979359|NCT00086736|Experimental|Arm III|Patients receive oral eflornithine placebo and oral bicalutamide once daily for 28 days in the absence of unacceptable toxicity. Patients then undergo either prostatectomy or brachytherapy, as determined by the patient, on day 29.
88979360|NCT00086736|Experimental|Arm IV|Patients receive oral eflornithine placebo and oral bicalutamide placebo once daily for 28 days in the absence of unacceptable toxicity. Patients then undergo either prostatectomy or brachytherapy, as determined by the patient, on day 29.
88979361|NCT00292201|Experimental|1|Atorvastatin
88979362|NCT00292201|Placebo Comparator|2|Placebo Pill
88979363|NCT00292279|Experimental|A|
88979364|NCT00292279|Active Comparator|B|
88979365|NCT00292474|Experimental|TAXUS Express|
88979366|NCT00292474|Placebo Comparator|Express Bare|
89597730|NCT04777552||Fixed-schedule|Untill mid 2013 patients with individually determined fixed-schedule dosage of benzodiazepines in the case of alcoholdependence.
89597731|NCT04777552||CIWA-Ar|Halfway through the year 2013 the department of psychiatry changed the protocol in alcohol withdrawal treatment and changed it to a symptom-triggered therapy with the use of CIWA-Ar to assess the severity of the alcohol withdrawal syndrome.
89597732|NCT04777318|Experimental|Conventional physiotherapy|The individuals in the control group was taken in a total of 12 sessions of conventional physiotherapy program for 4 weeks, 3 days a week.
89597733|NCT04777318|Experimental|Muscle Energy Technique (MET)|In addition to the conventional physiotherapy program of 12 sessions for 4 weeks, 3 days a week, muscle energy technique was applied to the individuals in the second group.
89597734|NCT04777318|Experimental|Cervical Mobilization Techniques (CMT)|In the third group, cervical mobilization techniques was applied in addition to the conventional physiotherapy program for a total of 12 sessions for 4 weeks, 3 days a month.
89597735|NCT01506609|Experimental|Veliparib with Temozolomide|Veliparib 40 mg twice daily (BID) Days 1 through 7 plus TMZ 150 to 200 mg/m^2 QD Days 1 through 5 in each 28-day cycle.
88979367|NCT00292552||COPD subjects|Subjects with GOLD stage II-IV COPD
88979368|NCT00292552||Smoker controls|Subjects with smoking history but normal lung function
88979369|NCT00292552||Non-smoker controls|Normal healthy non-smokers
88979370|NCT00292747|Experimental|drotaverine + Ibuprofen placebo|Drotaverine 80 mg plus ibuprofen placebo orally
88979371|NCT00292747|Active Comparator|Drotaverine placebo + ibuprofen|Drotaverine placebo plus ibuprofen 400 mg orally
88979372|NCT00292747|Active Comparator|Drotaverine + ibuprofen|Drotaverine 80 mg plus ibuprofen 400 mg orally
88979373|NCT02958410|Experimental|Lymphocyte Malignancies|The trial will be conducted in a manner of simon two-stage design with Anti-CD30-CAR-transduced T cells, beginning in the first stage with the aim of over 30% reaction rate among 15 patients with B cell malignancies. Only when the expected reaction rate is achieved the 30 patients left can be recruited.
88979374|NCT00120003|Experimental|Candesartan Cilexetil|Candesartan Cilexetil
88979375|NCT00120003|Placebo Comparator|Placebo|Placebo
88979376|NCT00292903|Experimental|A|
88979377|NCT00292903|Active Comparator|B|
89597736|NCT01506609|Placebo Comparator|Placebo with Carboplatin and Paclitaxel|Placebo BID Days 1 through 7 plus carboplatin target area under the curve (mg•min/mL) (AUC) 6 administered on Day 3 of each 21-day cycle and paclitaxel 175 mg/m^2 administered on Day 3 of each 21-day cycle.
89597737|NCT01506609|Experimental|Veliparib with Carboplatin and Paclitaxel|Veliparib 80 mg BID Days 1 through 7 plus carboplatin target AUC 6 administered on Day 3 of each 21-day cycle and paclitaxel 175 mg/m^2 administered on Day 3 of each 21-day cycle.
89597738|NCT04777162|Experimental|tislelizumab+anlotinib|patients will be administrate with dual drugs, tislelizumab plus anlotinib.
88979378|NCT00201799|Experimental|Infliximab|Patients will be treated with infliximab day 1 prior to starting myeloblative chemotherapy or radiotherapy. A total of 6 doses will be administered.
88979379|NCT00080678|Experimental|Docetaxel + Imatinib Mesylate|Docetaxel 30 mg/m^2 intravenous over 60 minutes on days 1, 8, 15, and 22 in 42-day cycles, with daily oral 600 mg imatinib mesylate.
88979380|NCT00080678|Placebo Comparator|Docetaxel + Placebo|Docetaxel 30 mg/m^2 intravenous (IV) over 60 minutes on days 1, 8, 15, and 22 in 42-day cycles, with daily oral placebo.
88979381|NCT00086970|Experimental|Arm I (ifosfamide)|Patients receive high-dose ifosfamide IV continuously over 72 hours on days 1-3.
88979382|NCT00086970|Experimental|Arm II (O6-benzylguanine, ifosfamide)|Patients receive a bolus dose of O6-benzylguanine (BG) IV over 1 hour on day 1 followed by BG IV continuously and high-dose ifosfamide IV continuously over 72 hours on days 1-3.
88979383|NCT00201916|Experimental|1|5250 cGy in 20 fractions over 28 days
88979384|NCT00201916|Active Comparator|2|6600 cGy in 33 fractions over 45 days
88979385|NCT00120081|Experimental|Low dose|10 mcg Na-ASP-2/Alhydrogel
88979386|NCT00120081|Experimental|Medium dose|50 mcg Na-ASP-2/Alhydrogel
89597739|NCT02087956|Active Comparator|Personalized Support for Progress (PSP)|In Personalized Support for Progress (PSP), patients meet with a navigator to prioritize their concerns using a decision aid, develop a plan based on their identified priorities, and execute the plan.
89597740|NCT02087956|Active Comparator|Enhanced Screening and Referral (ESR)|(ESR)- participant will receive personal report of their current needs and list of resources available in the community.
89597741|NCT04776772|Placebo Comparator|Soccer player placebo|Soccer player consuming placebo sticks filled with 300 mg excipient of maltodextrin
88979387|NCT00120081|Experimental|High dose|100 mcg Na-ASP-2/Alhydrogel
89597742|NCT04776772|Experimental|Soccer player synbiotic|Soccer players consuming a mixture of probiotic strains: Bifidobacterium lactis CBP-001010, Lactobacillus rhamno-sus CNCM I-4036, Bifidobacterium longum ES1 and fructooligosaccharides (200 mg) as a prebiotic
89597743|NCT04776772|Placebo Comparator|Sedentary individuals placebo|Sedentary individuals consuming placebo sticks filled with 300 mg excipient of maltodextrin
89597744|NCT04776772|Experimental|Sedentary individuals synbiotic|Sedentary individuals consuming a mixture of probiotic strains: Bifidobacterium lactis CBP-001010, Lactobacillus rhamno-sus CNCM I-4036, Bifidobacterium longum ES1 and fructooligosaccharides (200 mg) as a prebiotic
89597745|NCT01506453|Active Comparator|Gabapentin|Active treatment arm.
89597746|NCT01506453|Placebo Comparator|Placebo|Placebo arm.
89597747|NCT00218686|Experimental|1|behavioral social network risk reduction intervention
89597748|NCT00218686|Active Comparator|2|voluntary counseling and testing (VCT
89597749|NCT04389580|Active Comparator|13 cis retinoic acid doses orally plus Tamoxifen orally|80 infected patients will receive tamoxifen 20 mg orally twice daily with a glass of water and after three days of the standard therapy the infected patients will receive 13 cis retinoic acid (0.5 mg/kg/day in 2 divided doses orally for 14 days
89597750|NCT04389580|Active Comparator|13 cis retinoic acid doses Aerosolized plus Tamoxifen orally|80 infected patients will receive tamoxifen 20 mg orally twice daily with a glass of water and after three days of tamoxifen therapy the infected patients will receive Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days
89597751|NCT04389580|No Intervention|No Intervention:|No study treatment Arm No Isotretinoin or Tamoxofien treatment
89597752|NCT01482429|Experimental|Protocol-directed|Discontinuation of ventilation was based in multidisciplinary protocol.
89597753|NCT01482429|No Intervention|Usual care|Discontinuation of ventilation was left entirely to the discretion of the physicians.
89597754|NCT00995176||1|Women residing in areas from defined geographic areas with high HIV prevalence and poverty
89597755|NCT00995176||2|Men residing in areas from defined geographic areas with high HIV prevalence and poverty
89597756|NCT04409067||TMD-pain group|The TMD-pain group consisted of 30 children aged between 7.1 and 12.3 with a pain-related TMD diagnosis. All the patients in the TMD-pain group had myogenous or arthrogenous TMD according to the RDC/TMD protocol.
88979388|NCT00120081|Placebo Comparator|Saline placebo|Saline placebo
88979389|NCT00202033|Experimental|1|self monitor blood glucose 3 times a day per usual diabetes class curriculum
88979390|NCT00202033|Experimental|2|only self monitor blood glucose when fasting
88979391|NCT00202033|Experimental|3|no self monitoring of blood glucose
88979392|NCT00120120|Experimental|1|
88979393|NCT00120120|Experimental|2|
88979394|NCT00202189|Experimental|1|Budesonide
88979395|NCT00202189|Placebo Comparator|2|Saline Solution (0.9% NaCl)
89597757|NCT04409067||pain-free TMD group|The pain-free TMD group consisted of 30 children between 7.3 and 12.6 years of age. To be included in the pain-free TMD group the participants had to meet Axis I of the RDC/TMD criteria for a pain-free diagnosis.
89597758|NCT04409067||non-TMD group|The non-TMD group comprised 30 children aged between 7.2 and 12.5 without any recognised TMD based on RDC/TMD, Axis I.
89597759|NCT00199108|Experimental|Only 1 arm|
89597760|NCT04776538|Experimental|Stem cell group|60 patients will be randomized to receive adipose-derived allogeneic stem cells
89597761|NCT04776538|Placebo Comparator|Placebo group|60 patients will receive placebo consisting of CryoStor10 (BiolifeSolutions), the freeze media for ASCs containing 10% Dimethyl sulfoxide (DMSO).
89597762|NCT01504971||Gastroesophageal reflux disease (GERD)|
89597763|NCT04776616|Sham Comparator|Exposure to white LED light|Participants will be exposed to white LED strip lights in a dark room for 2 hours a day
89597764|NCT04776616|Experimental|Exposure to green LED light|Participants will be exposed to green LED strip lights in a dark room for 2 hours a day.
89597765|NCT01479777|Experimental|FES Stepping|For the next 8 weeks, we will ask you to come to the ICSCI twice (2) time per week during which you will perform FES Stepping.
89597766|NCT03027063|Experimental|10,000 steps|"For the 10,000 steps group, participants will be asked to achieve a goal of 10,000 steps a day and to engage in 30 minutes of continuous exercise every day. Steps will be monitored with the under Armour fitness tracker which participants will receive.~For motivation, messages will be sent to study participants in this group via the messaging center in the Under Armor application three times a week. The frequency of messaging will be increased for participants who fail to meet their goals for three consecutive days. Study participants will also receive a weekly call to assess for side effects and provide additional encouragement."
89597767|NCT03027063|Active Comparator|Usual care|This will be the usual care group. Participants will also receive a fitness tracker to enable monitoring of steps and will be given a flyer that references the ACC/AHA guidelines for exercise and physical activity for the general population. Participants will not receive text messages or phone calls.
89597768|NCT04776304|Other|qEEG Art Therapy|Participants will receive art therapy while a noninvasive, mobile qEEG measures brain activity. There is no comparison as this is an exploratory pilot study.
89597769|NCT04753918|Experimental|Novel light delivery methods for photodynamic therapy|High refraction-index contrast medium: Lipiodol injected in the bronchial tree can enhance the treatment extension of the photodynamic therapy
89597770|NCT04161664|Experimental|neo adjuvant Paclitaxel and Carboplatin|6 courses of Paclitaxel 175 mg/m2 and Carboplatin AUC 5 in a 3 weekly schedule
89597771|NCT04753606|Placebo Comparator|Placebo|once-daily placebo
89597772|NCT04753606|Experimental|obicetrapib 5 mg|once-daily obicetrapib
89597773|NCT04753606|Experimental|obicetrapib 10 mg|once-daily obicetrapib
89597774|NCT04755946|Experimental|roflumilast arm|
89597775|NCT04755946|Placebo Comparator|placebo arm|
89597776|NCT01896466|Active Comparator|Young Adults - Intervention|Healthy subjects between the ages of 18-39 will participate in Cranial Nerve Non-Invasive Neuromodulation gait and balance training.
89597777|NCT01896466|Active Comparator|Healthy Older Adults - Control|Healthy subjects between age 65+ will participate in Sham Cranial Nerve Non-Invasive Neuromodulation gait and balance training.
89597778|NCT01896466|Active Comparator|Healthy Older Adults - Intervention|Healthy subjects age 65+ will participate in Cranial Nerve Non-Invasive Neuromodulation enhanced gait and balance training.
89597779|NCT01896466|Sham Comparator|Older Fallers - Control|Subjects who are age 65+ with a history of 1-3 falls in the previous six months will participate in Sham Cranial Nerve Non-Invasive Neuromodulation gait and balance training.
88979396|NCT00202228|Experimental|1|Individuals living with HIV who are naive to antiretroviral treatment, or who have been on a treatment interruption for at least six months
88979397|NCT00202228|Experimental|2|Individuals living with HIV who are on an antiretroviral regimen including one of D4T/ddI/ddC/AZT
88979398|NCT00202228|Experimental|3|Individuals living with HIV who are on an antiretroviral regimen including one of D4T/ddI/ddC/AZT and have liver disease.
88979399|NCT00202228|Experimental|4|HIV negative control group
88979400|NCT00080873|Experimental|Receive Traumeel S|
89210077|NCT00901758|Active Comparator|1|Treatment solution consisted of 100micrograms/mL of nitroglycerin. After an initial 1mL dose, further doses could be given in 1-3mL increments until uterine relaxation was achieved, or up to a recommended maximum of 10mL.
89210078|NCT00893568|Active Comparator|Healthy volunteers|Healthy volunteers without treatment
89210079|NCT00893568|Experimental|CBT|Psychotraumatized patients treated by Cognitive and Behavioral Therapies (CBT)
89597780|NCT01896466|Experimental|Older Fallers - Intervention|Subjects who are age 65+ with a history of 1-3 falls in the previous six months will participate in Cranial Nerve Non-Invasive Neuromodulation enhanced gait and balance training.
89597781|NCT01896466|Active Comparator|Young Adult - Control|Healthy subjects between the ages of 18-39 will participate in Sham Cranial Nerve Non-Invasive Neuromodulation gait and balance training.
89597782|NCT01479621|Experimental|Fp MDPI 12.5 mcg|"Fluticasone propionate (Fp) 12.5 mcg per dose twice a day (for a total daily dose of 25 mcg) using a multidose dry powder inhaler (MDPI) for 12 weeks in a double-blind manner.~During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms."
89597783|NCT01479621|Experimental|Fp MDPI 25 mcg|"Fluticasone propionate (Fp) 25 mcg per dose twice a day (for a total daily dose of 50 mcg) using a multidose dry powder inhaler (MDPI) for 12 weeks in a double-blind manner.~During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms."
88979401|NCT00080873|Placebo Comparator|Receive placebo|
88979402|NCT00087009|Experimental|Group I|Patients receive rituximab IV on days 1, 8, 15, and 22 and oral beta-glucan once daily on days 1-28 (days 8-28 of course 1). Treatment repeats every 42 days for 4 courses.
88979403|NCT00087009|Experimental|Group II|Patients receive rituximab IV on days 1, 4, 8, 15, and 22 and oral beta-glucan once daily on days 8-28. Beginning on day 42, patients with responding disease may receive monthly rituximab prophylaxis.
88979404|NCT00306397|Active Comparator|A|Rapamycin - MMF after 3 months
88979405|NCT00306397|Active Comparator|B|Low dose tacrolimus - MMF - Rapamycin after 3 months
88979406|NCT00418600|Other|1|Hectorol capsules at 1.0 times current injection dose
88979407|NCT00418600|Other|2|Hectorol capsules at 1.5 times current injection dose
88979408|NCT00418600|Other|3|Hectorol capsules at 2.0 times current injection dose
89210080|NCT00893568|Experimental|EMDR|Psychotraumatized patients treated by Eye Movement Desensitization and Reprocessing (EMDR)
89210081|NCT02539680|Experimental|normal renal function|Evaluation of the expression level of phosphate transporters at the mRNA and, if possible, on the protein level.
89210082|NCT02539680|Experimental|CKD stage 3-5 (not on dialysis)|Evaluation of the expression level of phosphate transporters at the mRNA and, if possible, on the protein level.
88979409|NCT00080951|Experimental|irinotecan + oxaliplatin + leucovorin + fluorouracil|"Patients receive irinotecan IV over 90 minutes and oxaliplatin IV over 2 hours on day 1 and leucovorin calcium IV and fluorouracil IV over 90 minutes on days 2-5. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed at baseline, before each chemotherapy course, and at the end of treatment.~Patients are followed every 3 months until 5 years after registration."
88979410|NCT00301561|Experimental|1|Simplify treatment follow-up
88979411|NCT00301561|Active Comparator|2|Standard treatment follow-up
88979412|NCT00301600|Active Comparator|Mycophenolate mofeti|
88979413|NCT04730141|Experimental|mobilization protocol|The early mobilization protocol developed by using up-to-date guidelines and expert opinions were applied to the patients in the intervention group.
88979414|NCT04730141|No Intervention|routine care|The routine mobilization follow-up approach of the intensive care unit was applied to the patients in the control group .
88979415|NCT00301795|Experimental|Treatment (oblimersen sodium and rituximab)|"Induction therapy (month 1): Patients receive oblimersen IV continuously on days 1-7 and 15-21 and rituximab IV on days 3, 10, 17, and 24 in month 1.~Extended induction therapy (months 3, 5, 7, and 9): Patients receive oblimersen IV continuously on days 22-28 and rituximab IV on day 24 in months 3, 5, 7, and 9.~Treatment continues for 9 months in the absence of disease progression or unacceptable toxicity."
88979416|NCT00080990|Experimental|Treatment (alvocidib with oxaliplatin, 5-FU, leucovorin)|"Patients receive alvocidib IV over 1 hour, oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and fluorouracil IV continuously over 48 hours on days 1, 15, and 29. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of flavopiridol until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, the cohort is expanded and an additional 10 patients are treated at that dose."
89597784|NCT01479621|Experimental|Fp MDPI 50 mcg|"Fluticasone propionate (Fp) 50 mcg per dose twice a day (for a total daily dose of 100 mcg) using a multidose dry powder inhaler (MDPI) for 12 weeks in a double-blind manner.~During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms."
88979417|NCT00301951|Experimental|cord blood transplant|
89597785|NCT01479621|Experimental|Fp MDPI 100 mcg|"Fluticasone propionate (Fp) 100 mcg per dose twice a day (for a total daily dose of 200 mcg) using a multidose dry powder inhaler (MDPI) for 12 weeks in a double-blind manner.~During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms."
89597786|NCT01479621|Experimental|Placebo MDPI|Placebo twice a day using a multidose dry powder inhaler (MDPI) for 12 weeks in a double-blind manner. During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms.
89597787|NCT01479621|Experimental|Flovent Diskus 100mcg|"Fluticasone propionate (Fp) 100 mcg per dose twice a day (for a total daily dose of 200 mcg) using a multidose dry powder inhaler (MDPI) for 12 weeks in an open-label manner.~During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms."
89597788|NCT04776226|No Intervention|Patients without depression|This group included patients without depression during enrollment of the cases.
89597789|NCT04776226|Experimental|Depressive patients with treatment|This group included patients wit depression but with treatment during enrollment of the cases.
89597790|NCT04776226|No Intervention|Depressive patients wihout treatment|This group included patients without depression but withou treatment during enrollment of the cases.
89597791|NCT02319304|Other|Pelvic Radiotherapy With Concurrent Neoadjuvant FOLFOX|"Part I:~FOLFOX: combination of drugs administered in a specific sequence as prescribed below.~Oxaliplatin: 85 mg/m2 intravenously (IV) over 2 hours~Leucovorin: 200 mg/m2 IV bolus over 2 hours~5-FU: 400 mg/m2 IV bolus over 5-15 minutes, then 2,400 mg/m2 continuous IV infusion over 46-48 hours~Part II:~Low dose fractionated radiation therapy (LDFRT) Intensity-modulated, bone marrow sparing, whole pelvic radiation therapy 40 cGy fractions twice per day delivered at least 4-6 hours apart on the first 2 days of each chemotherapy cycle for a total of 6 cycles"
89597792|NCT00910312|Experimental|Breast Fibroadenoma|
89597793|NCT00899782||Ancillary-Correlative (lung cancer tissue bank)|Grossly viable tumor and grossly normal lung tissue are identified and removed from patient surgical specimens and cryopreserved until shipment to the CALGB Lung Cancer Tissue Bank for future use in research. Blood specimens are also collected prior to surgery and at 4-12 weeks post-surgery (before the start of adjuvant therapy) and shipped immediately to the Tissue Bank.
89597794|NCT00885664|Other|Truvada/Kaletra CD4<100|All participants were treated but at baseline by design were divided based upon their CD4 count at baseline measurement. Group with CD4<100 cells/cu mm
89597795|NCT00885664|Other|Truvada/Kaletra CD4>/=100|All participants were treated but at baseline by design were divided based upon their CD4 count at baseline measurement. Group with CD4>/=100 cells/cu mm
89597796|NCT04775992||preemptive group|patients in this group will receive preoperative gabapentoids
88979418|NCT00302029||CMV positive|CMV +, N=500/167
88979419|NCT00302029||CMV negative|CMV -, N=500/167
88979420|NCT00302185|Active Comparator|Nurse-led supportive care|Visit with a Palliative Care nurse once weekly for 4 weeks
88979421|NCT00302185|Experimental|Acupuncture|Patients received acupuncture once a week for 4 weeks.
88979422|NCT00302341|Experimental|1|pafuramidine maleate, oral tablet, 100 mg bid X 14 days
88979423|NCT00302341|Active Comparator|2|TMP/SMX oral tablet, 15 mg/kg, split tid X 21 days
89210083|NCT02539680|Experimental|on dialysis|Evaluation of the expression level of phosphate transporters at the mRNA and, if possible, on the protein level.
89210084|NCT00901836|Experimental|Preoperative Proton Therapy|28 daily fractions of 1.8 cobalt gray equivalent(CGE)/fx for total of 50.4 CGE over 5.5 weeks.
89597797|NCT04775992||control group|patients in this group will not receive gabapentoids
89597798|NCT04775758|Experimental|Atypical facial pain group|Patients with clinally diagnosed G50.1 - atypical pain condition after all necessary diagnostic measures are taken to exclude a clear organic pathology (multiple diagnostic tests including MRI, CT and consultations from other specialists). Patients included in this study will undergo self-evaluating questionnaires and objective data analysis with facial expression analysis, galvanic skin response and heart rate. All tests are performed in one visit which will last up to an hour.
89597799|NCT04775758|Active Comparator|Maxillofacial fracture pain group|Patients with maxillofacial fracture (S02.3, S02.4, S02.6.) will be subjected into control group. Patients included in this study will undergo self-evaluating questionnaires and objective data analysis with facial expression analysis, galvanic skin response and heart rate. All tests are performed in one visit which will last up to an hour.
89597800|NCT04775602|Experimental|18F-PSMA PET/CT|Patients with evidence of biochemical recurrence of prostate cancer radically treated, with negative results to traditional diagnostic methods or doubtful imaging of 18F- Fluoro Methyl Choline (18F-FMC) PET/CT will perform a 18F-PSMA PET/CT as a tool for searching and location of recurrence.
89597801|NCT04784104|Experimental|Supraclaviculer block|The coronal oblique supraclavicular block will be applied to the first group with ultrasound guidance using a 22G 50 mm stimulator needle. 30 ml of bupivacaine (Bupivacaine HCl %0.5) and prilocaine (Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5 mcg adrenaline per ml. (14 ml. bupivacaine, 14 ml. prilocaine, 2 ml saline with 5 mcg adrenaline per ml.) Intermittent negative aspiration will be performed during all procedures to detect possible vascular puncture.
89597802|NCT04784104|Experimental|Infraclaviculer block|The lateral sagittal infraclavicular block will be applied to the second group with ultrasound guidance using a 22G 100 mm stimulator needle. 30 ml of bupivacaine (Bupivacaine HCl %0.5) and prilocaine (Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5 mcg adrenaline per ml. (14 ml. bupivacaine, 14 ml. prilocaine, 2 ml saline with 5 mcg adrenaline per ml.). Intermittent negative aspiration will be performed during all procedures to detect possible vascular puncture.
89597803|NCT00880594|Experimental|Open label desipramine|
89597804|NCT04783870|Experimental|Dapagliflozin|Dapagliflozin 10 mg PO QD
89597805|NCT04783870|Placebo Comparator|Control|Placebo PO QD
89597806|NCT01896310||pCLE examination|patients will be prospectively recruited and examined first with high-definition endoscopy (EG-2990i, Pentax, Japan) followed by probe-based confocal laser endomicroscopy
89597807|NCT04783636|Other|A|After a single administration of PT105R (leuprorelin acetate 3.75mg), a single administration of PT105 (leuprorelin acetate 3.75mg)
89597808|NCT04783636|Other|B|After a single administration of PT105 (leuprorelin acetate 3.75mg), a single administration of PT105R (leuprorelin acetate 3.75mg)
89597809|NCT04784026||Healthy Control Group|Healthy children who come to Afyonkarahisar Ege Youth and Sports Club Association for the purpose of sports, newly registered and between the ages of 6-18 will constitute the control group of the study.
89597810|NCT04784026||Case Group|The sample of the study will be inpatient and outpatient pediatric patients between the ages of 6-18 who have been diagnosed with cancer in the Pediatric Hematology-Oncology Clinics of Afyonkarahisar Health Sciences University Health Application and Research Center Department of Pediatrics.
89597811|NCT00820846|Experimental|Part A, Group 1|Participants will receive two injections of the pGA2/JS7 DNA vaccine and then two injections of the MVA/HIV62 vaccine
89597812|NCT00820846|Placebo Comparator|Part A, Group 2|Participants will receive four placebo injections
89597813|NCT00820846|Experimental|Part B, Group 3|Participants will receive two injections of the pGA2/JS7 DNA vaccine and then two injections of the MVA/HIV62 vaccine
89597814|NCT00820846|Experimental|Part B, Group 4|Participants will receive three injections of the MVA/HIV62 vaccine and one injection of the placebo
89597815|NCT00820846|Placebo Comparator|Part B, Group 5|Participants will receive four placebo injections
89597816|NCT03371368|Other|Gastric Bypass Diabetic and Non-diabetic|Roux-en-Y gastric bypass surgery
88979424|NCT00087204|Experimental|Treatment (becatecarin)|Patients receive rebeccamycin analogue (XL119) IV over 1 hour on days 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients achieving a CR receive 1 additional course beyond CR. Patients achieving a PR or HI receive 2 additional courses beyond PR or HI. Cohorts of 3-6 patients receive escalating doses of XL119 until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
88979425|NCT00302380||un-medicated subjects with ADHD|
88979426|NCT00302380||subjects without ADHD|
88979427|NCT00302419|Experimental|1|Following standard primary percutaneous coronary intervention for ST elevation acute myocardial infarction 250.000 U intracoronary Streptokinase will be given
88979428|NCT00302419|Active Comparator|2|Standard percutaneous coronary intervention for ST elevation myocardial infarction will be performed
88979429|NCT00400140|Experimental|A|
88979430|NCT02960425|Experimental|HI Delivra TM Livsport preworkout cream|7 mL topical creatine cream
88979431|NCT02960425|Experimental|LO Delivra TM Livsport preworkout cream|3.5 mL topical creatine + 3.5 mL placebo cream
89597817|NCT03371368|Other|Sleeve Gastrectomy Diabetic and Non-diabetic|sleeve gastrectomy surgery
89597818|NCT03371368|Active Comparator|Very Low Calorie Diet Diabetic and Non-diabetic|very low calorie diet
89597819|NCT03371368|No Intervention|Obese Control Group|Non-diabetic obese subjects
89597820|NCT03371368|No Intervention|Lean Control Group|Non-diabetic lean subjects
89597821|NCT03364348|Experimental|Cohort 1A (trastuzumab + utomilumab)|Utomilumab 20 mg IV + trastuzumab 6 mg/kg IV every 3 weeks. 3 subjects will be treated at this dose level. If no DLT events are recorded, then utomilumab dose will be increased to 100 mg (Dose Level 1B).
89597822|NCT03364348|Experimental|Cohort 1B (trastuzumab + utomilumab)|Utomilumab 100 mg IV + trastuzumab 6 mg/kg IV every 3 weeks.
89597823|NCT03364348|Experimental|Cohort 2A (ado-trastuzumab emtansine + utomilumab)|Utomilumab 20 mg IV + ado-trastuzumab emtansine 3.6 mg/kg IV every 3 weeks.
89597824|NCT03364348|Experimental|Cohort 2B (ado-trastuzumab emtansine + utomilumab)|Utomilumab 100 mg IV + ado-trastuzumab emtansine 3.6 mg/kg IV every 3 weeks.
89031793|NCT05317611|Active Comparator|Intravenous ondansetron and intraperitoneal instillation of bupivacaine (group B)|Patient will receive intravenous (4 mg) 2 ml ondansetron and intraperitoneal instillation of (100 mg) 20 ml of bupivacaine 0.5 % through abdominal ports by simple instillation technique before removal of trocars then clamping of abdominal drains for 1h to avoid drainage of LA.
89031794|NCT05317611|Sham Comparator|Intraperitoneal instillation of bupivacaine (group C)|patient will receive intraperitoneal instillation of (100 mg) 20 ml of bupivacaine 0.5 % through abdominal ports by simple instillation technique before removal of trocars then clamping of abdominal drains for 1h to avoid drainage of LA.
89031795|NCT04695314|Experimental|Glaucoma Group|Patients with glaucoma come in and get an intraocular pressure check at baseline. They get a 5 minute foot massage and then have their intraocular pressure checked every 30 minutes over 2 hour span.
89597825|NCT04775290|Experimental|Arm Yoga (YG)|Patients assigned to the YG arm participate in yoga classes
89597826|NCT04775290|No Intervention|Arm control (CG)|Patients assigned to the CG arm will follow the normal course of radiotherapy.
89597827|NCT04782622||Apatinib+Camrelizumab|treated with apatinib+camrelizumab
89597828|NCT04775212|Active Comparator|desflurane|patients to be anesthetized with desflurane
89597829|NCT04775212|Active Comparator|sevoflurane|patients to be anesthetized with sevoflurane
89597830|NCT03355066|Experimental|Part 1A: Dose Escalation|Cohorts of subjects with advanced solid tumors will receive increasing doses (10, 20, 40, 60, 80, 120, 160, or 200 mg) of SM08502, administered orally, once daily, following 28-day treatment cycles. If the maximum tolerated dose (MTD) is not determined at the 200 mg dose, dosing will continue at 50 mg/dose increments until an MTD is determined. Cohorts will include approximately 1 to 6 subjects according to an accelerated escalation design and safety requirements for expansion of subject numbers. For the purpose of dose escalation and de-escalation, the dose of SM08502 and regimen may be modified based on the type of dose limiting toxicities (DLTs) observed and following data review and discussions between the Sponsor and Investigators.
89597831|NCT03355066|Experimental|Part 1B: Dose Finding|Indications eligible for Part 1B include castration-resistant prostate cancer (CRPC), non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), colorectal cancer (CRC), endometrial cancer, or ovarian cancer for which histologic or cytologic confirmation of malignancy was obtained at diagnosis. Initially, two cohorts of 6-24 subjects will be evaluated comparing 2 different doses and schedules of SM08502 (30 mg daily and 40 mg 5 days on and 2 days off), administered orally following 28-day treatment cycles. If appropriate, alternative doses and schedules may be evaluated depending on the results.
89597832|NCT03355066|Experimental|Part 2: Expansion|"Part 2 will evaluate the recommended Part 2 dose and schedule of SM08502, as determined in Part 1B, in 3 cohorts of subjects. The indications to be evaluated include subjects with advanced and/or metastatic CRPC (two biomarker selection cohorts) and NSCLC for which histologic or cytologic confirmation of malignancy was obtained at diagnosis. Each cohort will enroll up to 20 subjects.~Approximately 10 subjects of the total enrolled in Part 2, irrespective of cohort, will be included in a food-effect substudy to assess the preliminary effect of a high-fat, high-calorie meal on the PK of SM08502."
89597833|NCT04774900||Standardised|The procedures will be observed with standardized equipment placement.
89597834|NCT04774900||Modified|The procedures will be observed with modified equipment placement - placement according to older methodology or custom.
89597835|NCT04774978|Experimental|Cardiac output measurements|Cardiac output will be measured using TTE continuously with ProbeFix
89597836|NCT04774822||Sequential Enrollment|Enrollment based on default inclusion criteria listed below
89597837|NCT04774822||Enrichment Enrollment|Enrollment based periodic statistician-activated inclusion criteria adjustment to attain statistically adequate distribution
89597838|NCT04782934|Experimental|YANG system group|
89597839|NCT04782388|Experimental|Staccato alprazolam|Study participants will receive Single dose of Staccato alprazolam on Day 1 of the Treatment Period.
89597840|NCT04782388|Placebo Comparator|Staccato placebo|Study participants will receive placebo on Day 1 of the Treatment Period.
89597841|NCT04782076|Experimental|Dabigatran + Selpercatinib|Dabigatran as single dose administered orally on Day 1 followed by a single dose of dabigatran coadministered with a single dose of selpercatinib on Day 8 orally.
89597842|NCT04782310|Experimental|Group Pregabalin|Patients will receive oral Pregabalin 75mg two hour preoperatively, 12 hours postoperative and will continue for one week twice per day.
89597843|NCT04782310|Experimental|Group Duloxetine|Patients will receive oral duloxetine 30mg two hour preoperatively …will be continued for one week once per day after breakfast .
89597844|NCT04782310|Experimental|Group Pregabalin& Duloxetine|Patients will receive single dose of Pregabalin 75mg + duloxetine 30mg two hour preoperatively, 75mg pregabalin 12 hour postoperative and then will continue pregabalin twice per day +duloxetine once after breakfast for one week.
89597845|NCT04781764||glioma patients|glioma patients with routine surgery
89597846|NCT04774432|Active Comparator|GM-CSF group|"Patients will be randomly allocated to intervention group with GM-CSF added to CAPA and maturation medium.~Following the 24h CAPA period, the evaluation of maturation (MII, GVBD, GV) will be done after 30 hrs IVM step.~Mature eggs are fertilized using Intracytoplasmic sperm injection (ICSI). Fertilized oocytes will be placed in a time-lapse incubator (ASTEC) and their development until the Day 5/6 (blastocyst formation) will be followed."
89597847|NCT04774432|Active Comparator|Control group|"Patients will be randomly allocated to control group without the addition of GM-CSF to CAPA and maturation medium.~Following the 24h CAPA period, the evaluation of maturation (MII, GVBD, GV) will be done after 30 hrs IVM step.~Mature eggs are fertilized using Intracytoplasmic sperm injection (ICSI). Fertilized oocytes will be placed in a time-lapse incubator (ASTEC) and their development until the Day 5/6 (blastocyst formation) will be followed."
89597848|NCT04774588|Other|Using VSI Streamer and Telemedicine Study|Using the real time streaming of input from video capture devices to a head mounted display during interventional radiology procedures
89597849|NCT04774588|Placebo Comparator|Not using VSI Streamer and Telemedicine Study|Not using real time streaming of input from video capture devices to a head mounted display and just using current standard imaging in the Interventional Suite.
89597850|NCT04774510|Other|Optimized C-ARM CBCT|An optimized C-arm CBCT evaluation with a different acquisition geometry and a novel software for the rapid, quality improved and less-artefacts assessment of brain parenchyma and angiogram.
89597851|NCT04774042|Placebo Comparator|Placebo|Placebo HAC two packs once daily; Placebo Infloran one pill three times per day for 8 weeks
89597852|NCT04774042|Experimental|HAC|Probiotic HAC two packs once daily; Placebo Infloran one pill three times per day for 8 weeks
88979432|NCT04717882|No Intervention|Control arm|Patients in the control arm will receive the usual treatment
88979433|NCT04717882|Experimental|Intervention arm|After crossing over to the intervention period, attending physicians will receive medication alerts from the Clinical Decision Support System (CDSS) within 1 week after inclusion of the patient. The medication alerts will be sent to the physician's email address. The physician is free to follow or ignore the advice in the alerts. If the physicians thinks these alerts are relevant for the patient, the physician will discuss these alerts with the patient and/or relatives. After this conversation, the physician will prescribe or deprescribe medications based on the alerts.
88979434|NCT00302536|Experimental|Tacrolimus|
88979435|NCT00081224|Experimental|celecoxib + capecitabine + radiation + surgery|"Neoadjuvant chemoradiotherapy: Patients receive oral celecoxib twice daily on days 1-7 and oral capecitabine twice daily on days 1-5. Patients undergo pelvic radiotherapy once daily on days 1-5. Courses repeat weekly for 5.5 weeks.~Surgery: Patients undergo surgery 4-6 weeks after completion of neoadjuvant chemoradiotherapy.~Adjuvant chemotherapy: Patients with a curative resection receive oral capecitabine twice daily on days 1-14. Treatment repeats every 21 days for up to 4 courses.~Treatment continues in the absence of disease progression or unacceptable toxicity.~Patients are followed every 3 months for 1 year and then every 6 months for 4 years."
88979436|NCT04717999|Experimental|UWN2D CAR-T|
88979437|NCT00302653|Experimental|1|Rasburicase 0,20mg/Kg/Day once a day 3-7 days
88979438|NCT00418288|Active Comparator|A|
88979439|NCT00418288|Placebo Comparator|P|
88979440|NCT00120315|No Intervention|esomeprazole|Long-term users continue antisecretory medication
88979441|NCT00120315|Placebo Comparator|placebo drug|Long-term users are treated with placebo
89517869|NCT02323529|Experimental|Nitisinone treatment group|All patients in the study will first be put on twice daily dosing of nitisinone for 4 weeks. This will then be followed by once daily dosing of nitisinone for 4 weeks.
89517870|NCT02325635|Experimental|Training of Endoscopist|A series of 1 hour classes with ongoing monitoring and feedback to endoscopist only.
89517871|NCT02325635|No Intervention|Deferred Training of Endoscopist|No intervention during the data collection period. Training will be deferred to end of study.
89517872|NCT03493997|Experimental|Radiotherapy+Ialuril®+Ialuril Soft Gels®|Radiotherapy+Ialuril®+Ialuril Soft Gels®
89517873|NCT03493997|Active Comparator|Radiotherapy only|Radiotherapy only
89517874|NCT05397301|Active Comparator|sedoanalgesia(SA group)|Sedoanalgesia was applied to the SA group
89517875|NCT05397301|Active Comparator|general anaesthesia (GA group)|General anaesthesia was applied to the GA group
89517876|NCT02323607|Experimental|Cohort A (pacritinib, cytarabine, daunorubicin hydrochloride)|INDUCTION: Patients receive pacritinib PO on days 1-21, cytarabine IV every 24 hours on days 5-11, and daunorubicin hydrochloride IV every 24 hours on days 5-7. Treatment repeats every 28 days for 1-2 courses in the absence of disease progression or unacceptable toxicity.
89517877|NCT02323607|Experimental|Cohort B (pacritinib, decitabine)|"INDUCTION: Patients receive pacritinib PO on days 1-21 and decitabine IV every 24 hours on days 5-14. Treatment repeats every 28 days for 2-4 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients achieving CR will proceed with transplant evaluation (if appropriate). Transplant-ineligible patients will receive maintenance courses of pacritinib PO on days 1-21 and decitabine IV over 1 hour daily on days 1-5. Maintenance courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
89517878|NCT02323685|Experimental|SANGUINATE™|Single infusion of SANGUINATE (pegylated carboxyhemogloblin)
89517879|NCT03495245||Opioid Usage|Patients that are currently diagnosed with fibromyalgia and taking opioids.
89517880|NCT03495245||No Opioid Usage|Patients that are currently diagnosed with fibromyalgia and are not taking opioids.
89517881|NCT02325869|Experimental|Bell Balloon Catheter|The Bell Balloon Catheter is designed to help the physician capture some of this material that may have broken off.
89517882|NCT02323763||Bipolar I or II Disorder|30 currently depressed patients with DSM-IV bipolar I and II disorder who are currently or previously suicidal will receive fMRI.
89517883|NCT02323841|Experimental|conservative treatment in cervix cancer|we performed conservative treatment cervix cancer patients with IB FIGO stage without pelvic involvement
89517884|NCT02325947|Experimental|Study group|Hand exoskeleton, brain-computer interface (BCI) 10 sessions of 45-minutes
89517885|NCT02325947|Sham Comparator|Placebo group|Hand exoskeleton, sham BCI 10 sessions of 45-minutes (BCI imitation)
89517886|NCT02323919|Active Comparator|SystemCHANGE|consists of self-efficacy enhancement and relapse prevention strategies, but is primarily anchored in a set of behavior change strategies based on System Improvement techniques.
89517887|NCT02323919|Active Comparator|CHANGE+|is based on several cognitive-behavioral theoretical frameworks: Social Problem-solving Model, Self-efficacy theory, Expectancy-value theory and Relapse Prevention theory.
89517888|NCT02323919|Placebo Comparator|Usual Care|Usual Care
89517889|NCT03493841|Experimental|Group A|Group A will receive racemic lipoic acid first and R-lipoic acid second
89517890|NCT03493841|Experimental|Group B|Group B will receive R- lipoic acid first and racemic lipoic acid second
89517891|NCT03493763||serum AFP negative HCC patients|"Patients who received liver resection within 3 months;~Hepatocellular carcinoma confirmed pathologically;~Serum alpha-fetoprotein level lower than 20ng/ml before hepatectomy."
89517892|NCT03495089|Experimental|patients with type 2 DM|"Patients with type 2 DM over 40 years of age, with or without symptoms of neuropathy, attended in Primary Care.~Intervention(s) to be administered:After verifying the inclusion criteria and receiving written informed consent to participate, during the first visit to the Primary Care centres the medical history of the patient will be obtained and a physical examination will be performed using the Monofilament testing -MFT and the Neuropathy Disability Score-NDS and Utah Early Neuropathy Scale-UENS questionnaires will be given to screen for polyneuropathy-PN. The patient will also undergo dermal electrochemical conductance- DEC quantification using the Sudoscan® device."
89597853|NCT04774042|Experimental|Infloran|Placebo HAC two packs once daily; Probiotic Infloran one pill three times per day for 8 weeks
89597854|NCT03300544|Experimental|Treatment (T-VEC, capecitabine, chemoradiation)|Patients receive talimogene laherparepvec intralesionally via endoscopy on weeks 1, 4, 6, and 8. Patients receive 5-fluorouracil IV by bolus and over 46 hours, leucovorin IV bolus, and oxaliplatin IV over 2 hours on weeks 2 and 4. Patients also receive capecitabine orally PO BID followed by radiation therapy for 28 fractions on days 1-5 of weeks 8-13. Patients undergo resection surgery on weeks 21-25.
88979442|NCT00418483|Experimental|Plasmin (Human) 25 mg|Plasmin (Human) 25 mg
88979443|NCT00418483|Experimental|Plasmin (Human) 50 mg|Plasmin (Human ) 50 mg
89597855|NCT03249844|Experimental|experimental group|Children will be treated by methylprednisolone + prednisolone and standard of care
88979444|NCT00418483|Experimental|Plasmin (Human) 75 mg|Plasmin (Human) 75 mg
88979445|NCT00418483|Experimental|Plasmin (Human) 100 mg|Plasmin (Human) 100 mg
88979446|NCT00418483|Experimental|Plasmin (Human) 125 mg|Plasmin (Human) 125 mg
88979447|NCT00418483|Experimental|Plasmin (Human) 150 mg|Plasmin (Human) 150 mg
88979448|NCT00418483|Experimental|Plasmin (Human) 175 mg|Plasmin (Human) 175 mg
88979449|NCT04718077|Experimental|IO dexamethasone injection|
88979450|NCT04718077|Active Comparator|SM dexamethasone injection.|
88979451|NCT04727268||Group 1|"Retrospective data regarding genetic information will be collected from participants' medical records.~Deep phenotyping of participants will also be completed."
88979452|NCT04727190|Experimental|TBCB group|Specimens were obtained using 1.1 mm ultrathin cryoprobe with or without guide sheath by bronchoscope.
88979453|NCT04727190|Active Comparator|TBFB group|Specimens were obtained using 1.5 mm or 1.9 mm biopsy forceps with or without guide sheath by bronchoscope.
88979454|NCT00303043||1|
88979455|NCT00087399|Experimental|gabapentin + antidepressant|"Patients continue to receive the same antidepressant (as before study entry) on weeks 1-5. During weeks 2-5, patients also receive oral gabapentin once daily on days 8-10, twice daily on days 11-13, and then three times daily on days 14-35 in the absence of unacceptable toxicity.~Patients complete a hot flash diary at baseline and then daily during study treatment."
89597856|NCT03249844|No Intervention|control group|Children will be treated by standard of care alone
88979456|NCT00087399|Experimental|gabapentin|"Patients receive gabapentin once daily on days 8-10, twice daily on days 11-13, and then three times daily on days 14-35 in the absence of unacceptable toxicity. Patients are tapered off their antidepressant over 7-10 days and remain on gabapentin alone.~Patients complete a hot flash diary at baseline and then daily during study treatment."
88979457|NCT00303199|Experimental|Single Arm|
88979458|NCT00303277|Active Comparator|1|simvastatin
88979459|NCT00303277|Active Comparator|2|pravastatin
88979460|NCT00303589|Experimental|1|
88979461|NCT00303589|Experimental|2|
88979462|NCT00303589|Active Comparator|3|
88979463|NCT00120432|Active Comparator|A|single dose vs three doses of 1%tropicamide and 10%phenylephrine
88979464|NCT00303784|Active Comparator|LHRH agonists|"Patients randomised to the control arm will receive continuous treatment with LHRH agonists as per local practice. Treatment should continue for at least 3 years. LHRH antagonists, such as degarelix, are not allowed on the trial. The recommended anti-flare medication is bicalutamide and should be prescribed according to local practice. Control arm medication should be obtained from the hospital pharmacy or GP as per local practice."
88979465|NCT00303784|Experimental|Oestrogen Patches|Patients randomised to the investigational arm will receive transcutaneous oestrogen patches (100 micrograms/24 hours). Treatment should be planned to continue for at least 3 years. For patients prescribed bicalutamide or flutamide prior to randomisation, this treatment should be discontinued before treatment with the patches can commence (no washout period is needed).
88979466|NCT00081887|Experimental|Weekly Clofarabine|
88979467|NCT00304018|Experimental|cord blood transplant|
88979468|NCT00304135|Active Comparator|Radio-chimiothérapie|Radio-chimiothérapie
88979469|NCT00304135|Experimental|GEMOX|GEMOX
88979470|NCT00304174||Subjects with bulimia nervosa|Participants with bulimia nervosa
88979471|NCT00304174||Controls between 80-120% of ideal weight|Controls without bulimia nervosa
88979472|NCT00120471|Experimental|1|Pregnant participants will receive a single dose of TDF during active labor. These participants will be hospitalized at the delivery facility through Day 3 postpartum.
89597857|NCT04755166|Experimental|100:0|100 % bone substitute, 0% autogenous bone
88979473|NCT00120471|Experimental|2|Pregnant participants will not receive TDF. Participants will be hospitalized at the delivery facility through Day 7 postpartum. Their infants will receive TDF at birth and on Days 3 and 5 after birth.
88979474|NCT00120471|Experimental|3|Pregnant participants will be hospitalized at the delivery facility through Day 7 postpartum. They will receive TDF during active labor and their infants will receive TDF at birth and on Days 3 and 5 after birth.
88979475|NCT00120471|Experimental|4|Pregnant participants will be hospitalized at the delivery facility through Day 7 postpartum. Mothers will receive TDF during active labor and their infants will receive TDF at birth and daily for 7 days after birth.
88979476|NCT00082043|Experimental|1|Dutasteride 2.5 mg by mouth daily for one month
88979477|NCT00082043|Placebo Comparator|2|Placebo oral capsule for two months
88979478|NCT02965092|Experimental|Second generation CAR-T cells|Patients receive CD19 CAR-T cells transduced with a lentiviral vector on days 0, 1, and 2 in the absence of disease progression or unacceptable toxicity.
88979479|NCT04717960|Active Comparator|study group group (1)|the group which will undergo submucosal injection of platelet rich plasma
88979480|NCT04717960|No Intervention|comparative group group (2)|patients using the usual lines of medical treatment like nasal douching and lubricants
88979481|NCT00087711|Experimental|A|
88979482|NCT00087711|Active Comparator|B|
88979483|NCT00304564|Experimental|geriatric community|Subject will stand on a computerized posturography force plate and stability scores are measured
89597858|NCT04755166|Experimental|90:10|90% bone substitute, 10% autogenous bone
89597859|NCT04781608|Experimental|Intervention group|Gains access to the digital intervention program
88979484|NCT00304603||Patients from previous topiramate obesity and diabetes studies|The patients from previous topiramate obesity and diabetes studies (PRI/TOP-INT-31 or PRI/TOP-INT-33 or a subset of patients with diabetes mellitus who were randomized within the PRI/TOP-INT-34 study at sites that also participated in the PRI/TOP-INT-31 study.
88979485|NCT00082199|Active Comparator|A1|
89597860|NCT04781608|No Intervention|Wait-list- control group|Does not gain access to the intervention (until end of study)
89597861|NCT00637624|Active Comparator|1|N-Acetylcysteine
89597862|NCT00637624|Placebo Comparator|2|Placebo
88979486|NCT00082199|Placebo Comparator|A2|
88979487|NCT00120510|Experimental|A|Randomly assigned group who will start an ART regimen of 3TC/ZDV and EFV twice daily at study entry
88979488|NCT00120510|Active Comparator|B|Randomly assigned group who will delay beginning ART regimen of 3TC/ZDV and EFC twice daily until they develop clinical AIDS or their CD4 count drops below 200 cells/mm3
88979489|NCT00304759|Experimental|1|6000 cGy / 20 fractions in 4 weeks
88979490|NCT00304759|Active Comparator|2|7800 cGy / 39 fractions in 8 weeks
88979491|NCT00304798|Experimental|Admission|Admission
88979492|NCT00304798|No Intervention|Discharge|Discharge
88979493|NCT02960269|Experimental|Telehealth team assessment|Team assessment for back pain with nurse practitioner and physical therapist via telehealth
88979494|NCT00082238|Experimental|Cystic fibrosis (CF)|
88979495|NCT00082238|Active Comparator|Healthy volunteers|
88979496|NCT00082277|Experimental|1|High-Risk Fragility Fracture-Open-Label, Non-Comparative Stratum
88979497|NCT00082277|Experimental|2|Moderate-Risk of Fragility Fracture-Randomised, Double-Blind Stratum
88979498|NCT00082277|Experimental|3|Low-Risk of Fragility Fracture - Open-Label, Non-Comparative Stratum
88979499|NCT00305032|Experimental|1|
88979500|NCT00305461|Active Comparator|1|Ciclesonide 160µg
89597863|NCT04754620|No Intervention|Standard face to face visit|This group will receive a traditional outpatient visit
89597864|NCT04754620|Experimental|Online visit|This group will receive a smartphone-based real-time video conference visit
89597865|NCT01479465|Experimental|FOLFIRI + SIM 700 mg (Part A)|Participants will receive SIM 700 mg via intravenous infusion followed by FOLFIRI via intravenous infusion on Days 1 and 15 of each 28-day treatment cycle until disease progression or unacceptable toxicity.
89597866|NCT01479465|Experimental|FOLFIRI + SIM 200 mg (Part B)|Participants will receive SIM 200 mg via intravenous infusion followed by FOLFIRI via intravenous infusion on Days 1 and 15 of each 28-day treatment cycle until disease progression or unacceptable toxicity.
89597867|NCT01479465|Experimental|FOLFIRI + SIM 700 mg (Part B)|Participants will receive SIM 700 mg via intravenous infusion followed by FOLFIRI via intravenous infusion on Days 1 and 15 of each 28-day treatment cycle until disease progression or unacceptable toxicity.
88979501|NCT00305461|Active Comparator|2|Ciclesonide 320µg
88979502|NCT00305539|Active Comparator|1|
88979503|NCT00305539|Placebo Comparator|2|placebo
88979504|NCT00305734|Experimental|Treatment (bortezomib, gemcitabine hydrochloride)|"Patients receive bortezomib IV on days 1, 4, 8, and 11. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity. Patients achieving a CR receive 2 additional courses of treatment with bortezomib.~Patients who experience disease progression on single-agent bortezomib and did not receive prior gemcitabine hydrochloride may begin combination therapy within 10-28 days of the last dose of bortezomib. Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and bortezomib IV on days 1, 4, 8, 11. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity. Patients achieving a CR receive 2 additional courses beyond the confirmed CR."
88979505|NCT00087867|Experimental|001|SCIO-469 two 30-mg capsules three times daily
88979506|NCT00087867|Other|002|SCIO-469 and bortezomib In addition to SCIO-469 patients with disease progression will receive bortesomib 1.0 mg/m2 intravenously as a bolus injection on Days 1 4 8 and 11 of a 21-day cycle followed by a 10-day rest period
88979507|NCT00305890|Experimental|1|Participants will partake in a lifestyle behavioral weight management program for 24 weeks.
88979508|NCT00305890|Experimental|2|Participants will partake in pain-coping skills training for 24 weeks.
88979509|NCT00305890|Experimental|3|Participants will partake in lifestyle behavioral weight management program plus pain-coping skills training for 24 weeks.
88979510|NCT00305890|Active Comparator|4|Participants will receive standard care for 24 weeks.
88979511|NCT00305929|Experimental|1|Treatment with Tookad VTP
88979512|NCT00306007||English prenatal|English speaking women recruited from the general OB/GYN clinic
88979513|NCT00306007||Spanish prenatal|Spanish speaking (monolingual) women recruited from the general OB/GYN clinic
88979514|NCT00306007||English abortion clinic|English speaking women recruited from the abortion clinic
88979515|NCT00306007||Spanish abortion clinic|Spanish speaking (monolingual) women recruited from the abortion clinic
88979516|NCT00306475|Active Comparator|1|
88979517|NCT00306475|Placebo Comparator|2|
88979518|NCT00306631|Experimental|1|
88979519|NCT00306709|Experimental|Teaching|
88979520|NCT00082784|Experimental|Treatment|Patients receive bortezomib IV over 3-5 seconds followed by flavopiridol IV over 1 hour on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
88979521|NCT00306904|Experimental|1|3.0 mg/eye dose group
88979522|NCT00306904|Experimental|2|1.5 mg/eye dose group
88979523|NCT00306904|Experimental|3|0.2 mg/eye dose group
88979524|NCT00307099|Experimental|Meropenem|Meropenem 1 gram intravenously every 8 hours for 3 days (9 doses), then an additional 5 days if the Clinical Pulmonary Infection Score is greater than 6.
88979525|NCT00307099|Active Comparator|Standard antibiotic therapy|Standard intravenous antibiotic therapy for a minimum of 8 days.
88979526|NCT00307177|Experimental|Arm D|25 subjects receive Recombinant rHA0 vaccine at 135 mcg per rHA0, via IM injection on Day 0
88979527|NCT00307177|Experimental|Arm C|25 subjects receive Recombinant rHA0 vaccine at 45 mcg per rHA0, via IM injection on Day 0
89031796|NCT04695314|Experimental|Ocular Hypertension Group A|"Patients with OHTN come in and get an IOP check at baseline. They get a 5 minute foot massage and then have their IOP checked every 30 minutes over 2 hour span.~2 week washout period and then patients return. Patients come in the morning to have their IOP checked. Received raised experimental shoe insert. Patients come back in the afternoon to have their IOP checked again.~2 week washout period and then patients return. Patients come in the morning to have their IOP checked. Received sham flat shoe insert. Patients come back in the afternoon to have their IOP checked again."
89031797|NCT04695314|Active Comparator|Ocular Hypertension Group B|"Patients with OHTN come in and get an IOP check at baseline. They get a 5 minute foot massage and then have their IOP checked every 30 minutes over 2 hour span.~2 week washout period and then patients return. Patients come in the morning to have their IOP checked. Received sham flat shoe insert. Patients come back in the afternoon to have their IOP checked again.~2 week washout period and then patients return. Patients come in the morning to have their IOP checked. Received raised experimental shoe insert. Patients come back in the afternoon to have their IOP checked again."
89031798|NCT05317572|Active Comparator|Group 1|Group 1: Spinal Anesthesia (10 mg hyperbaric bupivacaine + 20 mcg fentanyl+ 80 mcg intrathecal morphine) + iv Fentanyl-PCA
89031799|NCT05317572|Active Comparator|Group 2|Group 2: Spinal Anesthesia (10 mg hyperbaric bupivacaine + 20 mcg fentanyl+ 120 mcg intrathecal morphine) + iv Fentanyl-PCA
89031800|NCT05317572|Active Comparator|Group 3|Group 3: Spinal Anesthesia (10 mg hyperbaric bupivacaine + 20 mcg fentanyl+ 160 mcg intrathecal morphine) + iv Fentanyl-PCA
89031801|NCT02950805|Experimental|Placebo + AZD5634|Subjects were administered single dose of placebo in period 1 and AZD5634 in period 2.
89031802|NCT02950805|Experimental|AZD5634 + Placebo|Subjects were administered single dose of AZD5634 in period 1 and placebo in period 2.
89031803|NCT02950727|Experimental|3 bicortical screw|1st group:3 bicortical screws will be used to fix the sagittal split ramus osteotomy.
89031804|NCT02950727|Active Comparator|adjustable plate and 2 bicortical screws|adjustable plate and 2 bicortical screws will be used to fix the sagittal split ramus osteotomy.
89031805|NCT02950571|Active Comparator|Standard Care|Routine care is comprised of a high level of support from an interdisciplinary team with access to unit-specific and centralized programming
89031806|NCT02950571|Experimental|Digital Picture Frames|"Setup: Over 1-2, approximately 30 minute meetings pictures will be uploaded onto the device from picture files provided by the participant and/or their family or an open online source (e.g., Google Images) that are relevant and of interest to the participant.~Installation: The picture frames are secured to a surface in the participant's room (most typically a table) by facilities staff. Participants are instructed in its use.~Check in: At midpoint (2 weeks) an RA will check in with the participant to informally discuss whether or not it continues to work, is being used, and if they want more pictures uploaded. If the latter is requested step 1 will be repeated."
89031807|NCT02942745|Placebo Comparator|Control|Minimal interaction between participant and facilitator regarding cessation strategies. Participants will only be given a betel nut cessation booklet.
89031808|NCT02942745|Experimental|Experimental|Intensive 5-session intervention program over the span of 22 days, with an additional follow up session after 6 months. The sessions will utilize betel nut cessation social support groups, as well as interactive discussion on how to quit chewing.
89031809|NCT00515918||1|Iron deficient
89031810|NCT00515918||2|Iron sufficient
89597868|NCT01479465|Experimental|FOLFIRI + Placebo (Part B)|Participants will receive placebo to match SIM via intravenous infusion followed by FOLFIRI via intravenous infusion on Days 1 and 15 of each 28-day treatment cycle until disease progression or unacceptable toxicity.
89597869|NCT04773574|Experimental|Normal pregnant women with high myopia|Corneal topography, Optical coherence tomography (OCT) and Optical coherence tomography angiography (OCTA) were performed in each trimesters and at 6 weeks after childbirth.
89597870|NCT04773496||Balance evaluation|patient's balance is evaluated with instrumental posturography
89597871|NCT04773886|Sham Comparator|MTA GROUP|Vital Pulpotomy will be done using Mineral trioxide aggregate(MTA) as pulp capping agent.
89597872|NCT04773886|Sham Comparator|BIODENTINE GROUP|Vital Pulpotomy will be done using Biodentine as pulp capping agent.
89031811|NCT02942667||Subjects undergoing high quality MRI Scans|
89031812|NCT02950688|Experimental|Group 1: Seasonal LAIV|Participants will receive 1 dose of seasonal LAIV on Day 0. They will receive 1 dose of the wild-type A/California/2009-like influenza challenge virus on Day 56.
89031813|NCT02950688|Placebo Comparator|Group 2: Placebo|Participants will receive 1 dose of placebo on Day 0. They will receive 1 dose of the wild-type A/California/2009-like influenza challenge virus on Day 56.
89597873|NCT04773886|Active Comparator|PRF + MTA GROUP|Vital Pulpotomy will be done using PRF and Mineral trioxide aggregate (MTA) as pulp capping agent
89031814|NCT02942706|Experimental|Cet maintenance|Cetuximab maintenance treatment following induction treatment
89031815|NCT02942706|Active Comparator|Cet+chemo continuation|Cetuximab plus continuation mFOLFOX6/FOLFIRI regimens
89031816|NCT02942628|Experimental|Vegetarian - Meat|4 weeks of vegetarian diet followed by 4 weeks of 'wash out' (no intervention) and 4 weeks of meat-containing diet
89031817|NCT02942628|Active Comparator|Meat - Vegetarian|4 weeks of meat-containing diet followed by 4 weeks of 'wash out' (no intervention) and 4 weeks of vegetarian diet
89031818|NCT05305170||HF|Patients with heart failure.
89597874|NCT04773886|Active Comparator|PRF+ BIODENTINE GROUP|Vital Pulpotomy will be done using PRF and Biodentine as pulp capping agent.
89597875|NCT04781686|Experimental|First-line treatment|"First-line treatment: Apatinib plus Camrelizumab combined with Docetaxel and S1 for six cycles.~Maintenance treatment: Apatinib and Camrelizumab"
89597876|NCT04781920||Patients having undergone an Anterior Cruciate Ligament (ACL) reconstruction|Patients having undergone an ACL reconstruction will be included.
89031819|NCT05305170||Controls|Controls without heart failure.
89031820|NCT00516581||no HAART|Patients that no received HAART
89031821|NCT00516581||with HAART|Patients that received HAART
89031822|NCT05302947||Baricitinib|group included patients received Baricitinib in addition to standard of care therapy
89031823|NCT05302947||Tocilizumab|group included patients received Tocilizumab in addition to standard of care therapy
89031824|NCT05302947||Netakimab|group included patients received Netakimab in addition to standard of care therapy
89031825|NCT05302947||Control|group included patients received only standard of care therapy at the time of hospital admission according to the corresponding COVID-19 Russian guidelines 2020.
89031826|NCT04694573||POST-TX Covid-19 Serum Study Case|Kidney or liver-transplanted patients being hospitalized due to an infection with SARS-CoV-2
89031827|NCT04694573||POST-TX Covid-19 Serum Study Control|"2 matched controls without SARS-CoV-2 infection after TX; matching according to~age (18-34, 35-59, 60-75 years)~sex~type of transplantation~time after transplantation (0-180, 181-365, 366-1095, 1096-2555, >2555 days after TX)"
89031828|NCT04694573||PRE-TX Covid-19 Serum Study Case|Patients being kidney or liver-transplanted after having had an infection with SARS-CoV-2
89031829|NCT04694573||PRE-TX Covid-19 Serum Study Control|"2 matched controls without SARS-CoV-2 infection prior to TX; matching according to~age(18-34, 35-59, 60-75 years)~sex~type of transplantation"
89597877|NCT05605132|Experimental|Proprioceptive Training Group|"oculomotor exercises will be applied to the participants three times a week for four weeks.~oculomotor exercises:~head relocation gaze stability eye follow saccadic eye movement head and eye coordination"
89597878|NCT05605132|Experimental|Tactile Acuity Training|Participants will be requested to lie face down. Five points will be marked in the painful areas on the right and left sides of the neck. The distance between the points will equal the two-point discrimination value. A photograph of the neck will be taken. The patient will not see his/her own neck during the application but see the photograph of his/her neck. The points will be touched lightly with two different stimuli (a pen with a 2 mm diameter and a mushroom probe with an 11 mm diameter). Participants will be asked about the location and type of the stimuli. The interstimulus interval will be 15 seconds. If more than 90% of correct answers are obtained, the distance between the points will be reduced by 10%. The training will be performed in three separate blocks, a total of 72 stimuli (block duration = 6 minutes, rest time between blocks = 3 minutes, number of stimuli applied in each block = 24 stimuli). The treatment time will be 24 minutes.
89597879|NCT05605132|Sham Comparator|Control Group|The participants will be evaluated two times at 4-week intervals. No intervention will be applied during the time frame.
89597880|NCT04781218||Participants enrolled in the registry|Participants enrolled in the registry will include school community members including students, parents, staff, etc.
89597881|NCT04780906|Sham Comparator|Sham first (group 1)|Performs the first round of test with the sham comparator than with the experimental wrist taping
89597882|NCT04780906|Experimental|Wrist taping first (group 2)|Performs the first round of test with the experimental wrist taping than with the sham comparator
89597883|NCT03996460|Placebo Comparator|Placebo powder|Forty five (45) participants will be recruited and randomized into 3 arms (1:1:1). Fifteen (15) patients in arm 1 (group 1) will receive the matching placebo powder orally once daily for 12 weeks (90 days).
89031830|NCT02941419|Experimental|Platelet lysate injection|Injection of platelet lysate intramuscularly in the gastrocnemius muscle
89031831|NCT03458481|Experimental|SOF+DAG181 100 mg|Patients with genotype 1 HCV infection without cirrhosis will receive SOF+DAG181 100 mg for 12 weeks.
89031832|NCT03458481|Experimental|SOF+DAG181 200 mg|Patients with genotype 1 HCV infection without cirrhosis will receive SOF+DAG181 200 mg for 12 weeks.
89031833|NCT02950103|Experimental|Synthetic phosphoethalonamine|Phosphoethanolamine PO daily
89031834|NCT00516620|Active Comparator|1|Participants receive Health Canada's Food Guide and Physical Activity guide.
89031835|NCT00516620|Active Comparator|2|Participants receive a weekly sample food basket for 6 months consisting of fruits, vegetables, whole grains, and vegetable protein products.
89031836|NCT00516620|Active Comparator|3|Participants receive intensive dietary counseling for 6 months to increase intake of fruits, vegetables, whole grains, and vegetable protein products.
89031837|NCT00516620|Active Comparator|4|Participants receive intensive dietary counseling for 6 months to decrease intake of sweetened soft drink.
89031838|NCT02949752|Experimental|Aripiprazole Adjunct|Aripiprazole 5 mg as a fixed dose as adjunct to other antipsychotics
89031839|NCT05299983|Experimental|MyMenoPlan|Participants are asked to spend at least 20 minutes on the website (MyMenoPlan) assigned to them.
89031840|NCT05299983|Active Comparator|Control|"Participants are asked to spend at least 20 minutes on at least one of the following websites or other websites of their choice:~North American Menopause Society: https://www.menopause.org/for-women~National Institute on Aging: https://www.nia.nih.gov/health/topics/menopause~The Office on Women's Health-Menopause: https://www.womenshealth.gov/menopause"
89031841|NCT04694963||Subaute Cough|N=500
89031842|NCT02942550|Active Comparator|Methylnaltrexone|Methylnaltrexone bromide (Relistor®). Single intravenous injection of 8 mg (0.4 ml solution) for patients weighing 38-61 kg or 12 mg (0.6 ml solution) patients weighing 62-114 kg).
89031843|NCT02942550|Placebo Comparator|Placebo|Sodium Chloride, 9mg /mL ingle intravenous injection of 0.4 mL solution for patients weighing 38-61 kg or 0.6 mL solution patients weighing 62-114 kg).
89031844|NCT02949986|Experimental|Tablet-based Fall Prevention|The exercise program will be self-administered via a tablet-based version of the fall prevention program and the exercises performed in the home.
89031845|NCT02942589|Experimental|100% Portions|Meal portion size: 100%
89031846|NCT02942589|Experimental|125% Portions|Meal portion size: 125%
89031847|NCT02942589|Experimental|150% Portions|Meal portion size: 150%
89031848|NCT02942589|Experimental|175% Portions|Meal portion size: 175%
89031849|NCT02941302|Experimental|determine the biological boundaries|Neural navigation combined with Intraoperative ultrasound detecting the borders of gliomas, In accordance with established plan to collect multiple targets undergo pathological examination and contrast with imaging boundary to determine the biological boundaries.
89031850|NCT00516698||Group 1|"Patients undergo blood sample collection at baseline and at 1 year after initiation of aromatase inhibitor therapy (anastrozole or exemestane). Samples are analyzed for estrogen and testosterone levels and additional hormone levels and growth factors that have been previously linked with breast density and that could be altered by aromatase inhibitor use (i.e., sex hormone-binding globulin [SHBG], DHEA, DHEA sulfate, progesterone, prolactin, insulin-like growth factor-1 [IGF-1], and insulin-like growth factor binding protein 3 [IGF BP3]). Samples are also analyzed for anastrozole and exemestane levels by HPLC. Pharmacogenetic studies are also performed. Haplotype-tagged single nucleotide polymorphisms in genes in the aromatase pathway are examined.~Patients also undergo mammogram at baseline (≤ 6 months prior to study registration) and at 1 year after initiation of aromatase inhibitor therapy."
89597884|NCT03996460|Active Comparator|192 mg powder of K0706|Forty five (45) participants will be recruited and randomized into 3 arms (1:1:1) .Fifteen (15) patients in arm 2 (group 2) will receive the 192 mg powder of K0706 ( equivalent to 96 mg capsule of K0706) orally once daily for 12 weeks (90 days).
89597885|NCT03996460|Active Comparator|384 mg powder of K0706|Forty five (45) participants will be recruited and randomized into 3 arms (1:1:1) .Fifteen (15) patients in arm 3 (group 3) will receive the 384 mg powder of K0706 (equivalent to 192 mg capsule of K0706) orally once daily for 12 weeks(90 days).
89031851|NCT02941380||Ischemic heart disease|Patients admitted for coronary artery bypass grafting with the use of cardiopulmonary bypass
89031852|NCT02949557|Active Comparator|Decortication +DFDBA|After phase 1 therapy patients were assigned for decortication+ DFDBA group. Mucoperiosteal flaps were reflected. After open flap debridement, decortication was performed and DFDBA graft was placed in the treatment of intrabony defects.
89031853|NCT02949557|Active Comparator|Decortication+ Xenograft (Cerabone)TM|After phase 1 therapy patients were assigned for decortication+ xenograft (Cerabone)TM group. Mucoperiosteal flaps were reflected. After open flap debridement, decortication was performed and DFDBA graft was placed in the treatment of intrabony defects.
89031854|NCT02942433|Experimental|Radio Program|Married couple participants will be asked to interact with a radio program and participate in weekly, sex-separate listening and discussion groups (LDG) that each last for between 75 and 120 minutes over the course of 9 months.
89597886|NCT04780594||Pre-pandemic COVID-19 group (PreCOVID)|All patients who underwent surgery from 13th January until 29th February 2020, which are considered free of COVID-19 patients, therefore pre-pandemic period.
89597887|NCT04780594||Pandemic COVID-19 group (COVID)|All patients who underwent surgery from 11th March 2020 until 15th May 2020, which were done during the first wave of the pandemic crisis.
89597888|NCT04780750|Active Comparator|Arm A concurrent chemoradiotherapy with weekly docitaxel and cisplatin every 3 weeks|Arm A (tested regimen): concurrent chemoradiotherapy with weekly docitaxel (20 mg\m2) and cisplatin (80mg\m2 every 3 weeks)
89031855|NCT02942433|Other|Control|The control group participants will be exposed to the radio program only, and will not participate in the LDGs, nor will they or their family members participate in the workshops and community activities.
89031856|NCT02942316|Experimental|Pupil dilation reflex measurement|Four measurements of PDR during surgery at standardized times
89210085|NCT00901836|Active Comparator|Surgery|Standard of care surgery will be performed 4-6 weeks after the completion of radiation.
89597889|NCT04780750|Active Comparator|Arm B :concurrent chemoradiotherapy with cisplatin every 3 weeks|Arm B (standard regimen):concurrent chemoradiotherapy with cisplatin (100mg\m2 every 3 weeks)
89597890|NCT04780672|Active Comparator|Molixan|30 mg/ml solution for intravenous and intramuscular injection. Pharmacotherapeutic group: Metabolic agent. ATC code: V03AX - other medicinal products
89597891|NCT04780672|Placebo Comparator|Placebo|"Sol. of NaCl (Sodium chloride) - 0.9% Pharmacotherapeutic group: Regulators of water-electrolytic balance and acid-base balance.~ATC: B05CB01 Sodium chloride"
89597892|NCT04780984|Placebo Comparator|Placebo|Placebo, 2mL
89031857|NCT04694612|Placebo Comparator|Mild condition|"Study arm groups will receive a Favipiravir treatment of 1800 mg po BID on day 1, then 800 mg po BID from day 2 onwards and control groups will receive the same quantity of Placebo.~Duration of treatment : 5 days in each group"
89597893|NCT04780984|Experimental|Group 1 Tiotropium Bromide Inhalation Solution|"Treatment Dose (µg) Volume (mL) Concentration (µg/mL)~8 µg, 2.0 mL, 4 µg/mL"
89597894|NCT04780984|Experimental|Group 2 Tiotropium Bromide Inhalation Solution|"Treatment Dose (µg) Volume (mL) Concentration (µg/mL)~16 µg, 2.0 mL, 8 µg/mL"
89597895|NCT04780984|Experimental|Group 3 Tiotropium Bromide Inhalation Solution|"Treatment Dose (µg) Volume (mL) Concentration (µg/mL)~24 µg, 2.0 mL, 12 µg/mL"
89597896|NCT04780984|Active Comparator|Spiriva Respimat|5 ug, 2 actuations, 2.5 µg/actuation
89597897|NCT04773340||DBT intervention|Adaptation of Dialectical Behavior Therapy designed for repeat criminal offenders at high risk of reoffense.
89597898|NCT02090374|Experimental|Poly ICLC dose escalation|Poly ICLC nasal challenge dose escalation 10ug, 100ug, 500ug
89597899|NCT02090374|Experimental|Poly ICLC highest dose|Poly ICLC nasal challenge single dose of 1000ug
89597900|NCT02090374|Experimental|Poly I:C single dose|Poly I:C nasal challenge single dose 500ug
89597901|NCT02090374|Experimental|R848 high dose|R848 nasal challenge 10ug
89597902|NCT02090374|Experimental|R848 low dose|R848 nasal challenge low dose 1-2ug (0.02ug/kg)
89597903|NCT02090374|Experimental|Grass pollen|Timothy grass pollen nasal challenge
89597904|NCT02090374|Experimental|Vitamin D supplementation|Vitamin D 4000U orally daily
89597905|NCT02090374|Experimental|Tuberculin|Tuberculin PPD nasal challenge
89597906|NCT04772794|Active Comparator|hyperoxygenation group|Intraoperative administration of a mixture of 80% oxygen and 20% air
89597907|NCT04772794|Placebo Comparator|control group|intraoperative administration of 30% oxygen and 70% air
89597908|NCT04773028||PATİENT GROUP(GROUP 1)|This group is the group that underwent pulmonary thromboendarterectomy due to chronic thromboembolic pulmonary hypertension.Sample was taken from the material extracted from this group during operation.
89597909|NCT04773028||CONTROL GROUP(GROUP 2)|This group is the group that underwent lobectomy or pneumonectomy for another reason that the pulmonary artery is not affected. Patients operated for a reason other than chronic thromboembolic pulmonary hypertension and samples were taken from the intact pulmonary artery of the removed lung.
89597910|NCT04772950||Healthy adults|
89597911|NCT04772950||Patients with non-specific low back pain|
89597912|NCT04772872||Group A:Naturally conceived singleton|"Neonatal neurobehavior will be measured by Brazelton neonatal behavior assessment scale.~Neonatal maturity will be represented by the variance of estimated gestational age that determined by new Ballard score.~Apgar score will be represented by the variance of degree of scores.~Birth weight will be measured in grams."
89597913|NCT04772872||Group B: Singleton conceived from fresh embryo transfer(IVF/ICSI)|"Neonatal neurobehavior will be measured by Brazelton neonatal behavior assessment scale.~Neonatal maturity will be represented by the variance of estimated gestational age that determined by new Ballard score.~Apgar score will be represented by the variance of degree of scores.~Birth weight will be measured in grams."
89597914|NCT04772872||Group C: Singleton conceived from frozen embryo transfer (IVF/ICSI)|"Neonatal neurobehavior will be measured by Brazelton neonatal behavior assessment scale.~Neonatal maturity will be represented by the variance of estimated gestational age that determined by new Ballard score.~Apgar score will be represented by the variance of degree of scores.~Birth weight will be measured in grams."
89597915|NCT02222740|Experimental|Group 1|10 mg of Hydrocodone Bitartrate Extended Release (HC-ER) Twice per day (BID) for 7 days, followed by 20 mg BID for 7 days, followed by 30 mg BID for 7 days
89597916|NCT02222740|Experimental|Group 2|20 mg of Hydrocodone Bitartrate Extended Release (HC-ER) Twice Per Day (BID) for 7 days, followed by 30 mg BID for 7 days, followed by 40 mg BID for 7 days
89597917|NCT04752982|Active Comparator|c-SIGHT intervention|Grasp, lift and balance three wooden rods of different lengths.
89597918|NCT04752982|Sham Comparator|c-SIGHT attentional control|Grasp and lift three wooden rods of different lengths from one end only (no attempt to balance rods).
89597919|NCT04780360|Experimental|Cayanoacrylate tissue adhesives|thin layers of high viscosity blend of n-butyl and 2-octyl cayanoacrylate tissue adhesive will be applied and rinsed with saline at least three times with interval of at least 30 seconds
89210086|NCT04017780|Experimental|Single-limb circuit with turbine-driven ventilator|Non invasive ventilation delivered with a turbine-driven ventilator, single limb with intentional leaks.
89597920|NCT04780360|Active Comparator|Silk suture material|interrupted knots
89597921|NCT04780438|Active Comparator|Dapagliflozin|Patients who will be randomized to receive dapagliflozin following catheter ablation.
89210087|NCT04017780|Experimental|Double-limb circuit with Intensive Care Unit ventilator|Non invasive ventilation delivered with an intensive care unit ventilator with a double limb circuit.
89597922|NCT04780438|Placebo Comparator|Placebo|Patients who will be randomized to receive placebo following catheter ablation.
89597923|NCT04780126||COVID-19 pneumonia patients|Patients over 18 years of age who are admitted to the hospital and whose main diagnosis and reason for staying is COVID-19 pneumonia will be included.
89597924|NCT04779892|Experimental|CMAB008|
89597925|NCT04779892|Active Comparator|Remicade|
89597926|NCT02844868|Experimental|Active tDCS|During the first 20 min of training program, patient will have active tCDS (2 mA )
89597927|NCT02844868|Sham Comparator|sham tDCS|During the first 20 min of training program, patient will have sham tCDS
89597928|NCT04389268||HCV patients|Patients with uncomplicated newly diagnosed hepatitis C virus
89597929|NCT04389268||Control group|Age and sex matched with patients
89597930|NCT04771702|Experimental|Edmon arm|
89597931|NCT04771546|Experimental|Intervention (Colpofix)|Intravaginal gel with Carboxymethyl-β-glucan and Polycarbophil
89597932|NCT04771546|No Intervention|Control|No intervention (standard of care)
89597933|NCT04779346||Outpatient cancer patients|Cancer patients who are regularly treated in the Oncology Outpatient Clinic of the University Medical Center Hamburg-Eppendorf (UKE)
89597934|NCT04389424||Anastrozole|Breast cancer women with anastrozole treatment
89597935|NCT04389424||Tamoxifen|Breast cancer women with tamoxifen treatment
89597936|NCT04389424||Exemestane|Breast cancer women with exemestane treatment
89597937|NCT04389424||Basal|Breast cancer women luminal type without any endocrine treatment (at initial diagnosis)
89597938|NCT04389424||Recurrence|Breast cancer women luminal type with recurrence of disease during endocrine therapy
89597939|NCT04389346|Active Comparator|Periapical surgery with PRF group|Autologous platelet aggregate (PRF) will be placed over the denuded root surface, following apicoectomy and before flap repositioning.
89597940|NCT04389346|Placebo Comparator|Control group without PRF|Flap will be repositioned following apicoectomy without placement of any autologous platelet aggregate.
89597941|NCT04771390|Experimental|Part 1: Group A|Participants will receive 3 single doses of selitrectinib in adult tablet formulation sequentially in 3 treatment periods. The washing-out period between each dose is at least 3 days
89597942|NCT04771390|Experimental|Part 1: Group B|Participants will receive 3 single doses of selitrectinib in pediatric tablet formulation sequentially in 3 treatment periods. The washing-out period between each dose is at least 3 days
89597943|NCT04771390|Experimental|Part 2 (Group A): Dose A-B-C-D|Participants will receive dose A, B, C and D sequentially. The washing-out period between each dose is at least 3 days
89597944|NCT04771390|Experimental|Part 2 (Group A): Dose B-C-A-D|Participants will receive dose B, C, A and D sequentially. The washing-out period between each dose is at least 3 days
89597945|NCT04771390|Experimental|Part 2 (Group A): Dose C-A-B-D|Participants will receive dose C, A, B and D sequentially. The washing-out period between each dose is at least 3 days
89597946|NCT04771390|Experimental|Part 2 (Group B): Dose A-B-C-D|Participants will receive dose A, B, C and D sequentially. The washing-out period between each dose is at least 3 days
89597947|NCT04771390|Experimental|Part 2 (Group B): Dose B-D-A-C|Participants will receive dose B, D, A and C sequentially. The washing-out period between each dose is at least 3 days
89597948|NCT04771390|Experimental|Part 2 (Group B): Dose C-A-D-B|Participants will receive dose C, A, B and D sequentially. The washing-out period between each dose is at least 3 days
89597949|NCT04771390|Experimental|Part 2 (Group B): Dose D-C-B-A|Participants will receive dose D, C, B and A sequentially. The washing-out period between each dose is at least 3 days
89597950|NCT04771468||Sovratentorial ischemic stroke|
89597951|NCT04779502|Experimental|oregano|oregawash mouthwash was used twice times daily for 7 days
89597952|NCT04779502|Placebo Comparator|placebo|distilled water was used twice times daily for 7 days
89597953|NCT04779502|Active Comparator|chlorhexidine|Corsodyl with 0.2%CHX mouthwash was used twice times daily for 7 days
89597954|NCT05480956|Experimental|SIRI Checklist|A standardized checklist of clinical items to review by the attending hospitalist with participants.
89597955|NCT05480956|Experimental|Enhanced Peer Recovery Coach|Participants will receive the addiction medicine protocol plus peer recovery coaching beginning while hospitalized and continuing for up to 1 month after randomization. As part of this study, Peer recovery coaches will initiate contact with patients weekly in person during the hospitalization and at the time of hospital discharge. The enhanced part of the peer coach is the post-hospital follow-up. Following discharge, contact will continue weekly in person, by phone, and/or via text messaging based on the participant's preferences for 1 month.
89597956|NCT05480956|Experimental|SIRI Checklist + Enhanced Peer Recovery Coach|"A standardized checklist of clinical items to review by the attending hospitalist with participants.~Participants will receive the addiction medicine protocol plus peer recovery coaching beginning while hospitalized and continuing for up to 1 month after randomization. As part of this study, Peer recovery coaches will initiate contact with patients weekly in person during the hospitalization and at the time of hospital discharge. The enhanced part of the peer coach is the post-hospital follow-up. Following discharge, contact will continue weekly in person, by phone, and/or via text messaging based on the participant's preferences for 1 month."
89597957|NCT05480956|No Intervention|Standard of Care|Participants will receive the stand hospital care while in-patient.
89597958|NCT05411380|Experimental|Tucidinostat+Metronomic Capecitabine+Endocrine Therapy|This arm is divided into two groups. The main difference of this two groups lies in the selection of endocrine therapy. One is supposed to choose aromatase inhibitor, and the other is fulvestrant. The principle of making choice is based on the history of endocrine drug use.
89597959|NCT04779580|Experimental|Intervention Group (Only Group)|"Only one group in this study. 10 participants to have intervention.~Lateral femoral cutaneous nerve block and evaluation:~Routine ECG, pulse oximetry and blood pressure monitoring will be available. Using a sterile technique, the lateral femoral nerve will be approached using an in-plane ultrasound-guided technique, using a Stimuplex Ultra 360 50mm needle (B Braun, UK). Following negative aspiration, a one off STAT injection of 5mls lidocaine 1% will be administered subcutaneously.~After 10 minutes, any altered sensation will be assessed using ice to differentiate normal and altered sensation. This area will be marked on the skin using a black marker pen. Photographs will be taken and images of the procedure will be recorded.~The above will then be repeated for the subcostal nerve block.~The total area of anaesthesia will then be compared to the standard surgical incision for hip surgery to assess whether the subcostal nerve block will offer any further analgesia."
89597960|NCT04771312|Active Comparator|Information-only intervention|Participants are randomly assigned to 6-person peer networks in a mobile app. Participants in the information-only condition could respond to daily questions in a diary.
89597961|NCT04771312|Experimental|Social support network intervention|Participants are randomly assigned to 6-person peer networks in a mobile app. Participants in the social support condition could use an online chatting tool where they can send messages to their own network.
88979528|NCT00307177|Experimental|Arm B|25 subjects receive Recombinant rHA0 vaccine at 15 mcg per rHA0, via IM injection on Day 0
89597962|NCT04770688|Experimental|Osimertinib + Anlotiib|Escalating doses and expanding doses of Anlotinib administered with Osimertinib
89597963|NCT05390476|Experimental|Tucidinostat and metronomic capecitabine group|
89597964|NCT05390476|Active Comparator|metronomic capecitabine group|
89597965|NCT04770298|Experimental|Halliwick Assessment Group|8 children with GROSS MOTOR FUNCTION CLASSIFICATION SYSTEM (GMFCS) I, 13 children with GMFCS II, 7 GMFCS III children, 8 GMFCS IV children and 4 children with GMFCS V. Intervention in water environment (Halliwick Concept), 1 times/week- 1 intervention on land/week, 9 months duration.
89597966|NCT04770298|Experimental|Bobath Assessment Group|7 children with GMFCS I, 12 children with GMFCS II, 8 children with GMFCS III, 6 children with GMFCS IV and 2 children with GMFCS V. Intervention on land ( Bobath), 2 times/week, 9 months duration.
89597967|NCT04770298|No Intervention|No intervention group|1 children with GMFCS I, 1 child with GMFCS III, 1 child with GMFCS IV and 2 GMFCS V children. No intervention.
89597968|NCT05379088|Experimental|Additional Follow-up|In addition to receiving an ActiGraph activity monitor, participants will complete weekly phone/zoom calls with research staff for a more in-depth monitoring of their activity level.
89597969|NCT05379088|No Intervention|Activity Level Monitoring|Participants receive an ActiGraph activity monitor to track their activity level over a 6-week period.
89597970|NCT01503021|Other|SFP/Placebo|Soluble ferric pyrophosphate (SFP) 2 µmoles (110 µg) iron/L of dialysate in liquid bicarbonate concentrate x 2 weeks, then 1 week washout, then standard liquid bicarbonate concentrate without SFP x 2 weeks
89597971|NCT01503021|Other|Placebo/SFP|Standard liquid bicarbonate concentrate without SFP x 2 weeks, then 1 week washout, then soluble ferric pyrophosphate (SFP) 2 µmoles (110 µg) iron/L of dialysate in liquid bicarbonate concentrate x 2 weeks.
89597972|NCT04779034|Experimental|Group 1|Basketball players
89597973|NCT04778956|Experimental|Toripalimab plus salvage surgery|"Toripalimab: Toripalimab treatment before and after salvage surgery.~Salvage surgery: endoscopic nasopharyngectomy for recurrent nasopharyngeal tumor, and selective neck dissection for recurrent regional lymph node."
89597974|NCT04778956|Active Comparator|Salvage surgery alone|1. Salvage surgery: endoscopic nasopharyngectomy for recurrent nasopharyngeal tumor, and selective neck dissection for recurrent regional lymph node.
89597975|NCT04778800|Experimental|almonertinib 110mg PO once daily|
89597976|NCT04778800|Experimental|almonertinib 160mg PO once daily|
89597977|NCT04778800|Experimental|almonertinib 220mg PO once daily|
89597978|NCT01531725|Experimental|BMS implantation|Patients meeting the inclusion criteria and none of the exclusion criteria are treated by implanting the study device (the ProKinetic bare metal stent). Since it is a single arm study design, no patients are enrolled to a control arm.
89597979|NCT05324332|Experimental|68Ga-P16-093 and 68Ga-PSMA-11 PET/ CT scan|Patients of Prostate cancer PET/CT imaging: In two consecutive days, each patient underwent whole-body PET/CT scan after intravenous administration of 68Ga-P16-093 and 68Ga-PSMA-11, respectively.
89597980|NCT04769908|Experimental|Systemic Chemotherapy, Lenvatinib Plus Sintilimab|
89597981|NCT01478373|Experimental|Dovitinib (TKI258)|Patients will receive Dovitinib (TKI258) on an outpatient basis at the dose of 500 mg qd for 5 days followed by 2 days off, every week for cycle of 4 weeks (28d) until disease progression, unacceptable toxicity, or consent withdrawal.
89597982|NCT04778488|Other|NIRS diagnostics|NIRS measurement
89597983|NCT01502709|Experimental|Caloric Vestibular Neurostimulation|Subjects received caloric vestibular neurostimulation
89597984|NCT01502709|Placebo Comparator|Placebo Arm|Subjects received placebo
89597985|NCT03843268|Active Comparator|AMPS Gondola|Gondola is a portable device that runs on batteries and is fitted on both patient's feet when the patient is lying down. The device has been designed for the stimulation of two areas of both feet (first toe and metatarsal) through mechanical impulses set up for pressure, duration and sequence (Automated Mechanical Peripheral Stimulation - AMPS)
89597986|NCT03843268|Placebo Comparator|Sham Gondola|The Sham treatment consist in the stimulation of the same areas through mechanical impulses different for pressure since attached to the steel stick point is positioned a rigid plastic circle with a diameter (12mm); thanks to this the induced pressure ishence lower and the surface contact bigger.
89597987|NCT02931058|Active Comparator|Group 2|"Two knee-extension exercise sessions per week. Each exercise session comprises a single strength training exercise; knee-extension, which is performed in 3 sets with 12 RM repetitions in each set.~The knee-extension resistance training exercise is performed with an elastic exercise band."
89597988|NCT02931058|Active Comparator|Group 4|"Four knee-extension exercise sessions per week. Each exercise session comprises a single strength training exercise; knee-extension, which is performed in 3 sets with 12 RM repetitions in each set.~The knee-extension resistance training exercise is performed with an elastic exercise band."
89597989|NCT02931058|Active Comparator|Group 6|"Six knee-extension exercise sessions per week. Each exercise session comprises a single strength training exercise; knee-extension, which is performed in 3 sets with 12 RM repetitions in each set.~The knee-extension resistance training exercise is performed with an elastic exercise band."
89597990|NCT01477749|Experimental|sipuleucel-T|Each dose of sipuleucel-T contains a minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF. The recommended course of therapy for sipuleucel-T is 3 complete doses, given at approximately 2-week intervals.
89597991|NCT05606458|No Intervention|Control Group|The baby who met the inclusion and exclusion criteria underwent routine heel blood sampling at the hospital. First of all, the foot of the baby, who was taken to an open bed under a radiant heater, was warmed in the nurse's hand for one minute, the area where the baby's heel blood would be taken was determined, the baby's heel was wiped with 70% alcohol with the help of a sponge and waited for it to dry, then heel lance was performed. The procedure was completed after the relevant sections on the pre-prepared heel blood sheet were filled with blood. A light touch was provided if necessary for routine comfort of the infant for ethical reasons.
89597992|NCT05606458|Experimental|İntervention Group|"Their mothers gave a multisensory stimulus to the newborns in the mother's room.~Stimulus: Breast milk, breastfeeding (sense of taste)~Stimulus : Maternal touch (sense of touch)~Stimulus: Mother's voice (hearing sense)~Stimulus: Maternal eye contact (sense of sight)~Stimulus: Mother skin smell (sense of smell)"
89597993|NCT05606302||Piperacillin group|Blood samples for hemolytic anemia in patients treated with piperacillin were screened for the production of drug antibodies.
89597994|NCT05606302||Amoxicillin group|Blood samples for hemolytic anemia in patients treated with amoxicillin were screened for the production of drug antibodies.
89597995|NCT05606302||Cefazolin group|Blood samples for hemolytic anemia in patients treated with cefazolin were screened for the production of drug antibodies.
89597996|NCT05606302||Cefuroxime group|Blood samples for hemolytic anemia in patients treated with cefuroxime were screened for the production of drug antibodies.
89597997|NCT05606302||Ceftriaxone group|Blood samples for hemolytic anemia in patients treated with ceftriaxone were screened for the production of drug antibodies.
89597998|NCT05606302||Cefoxitin sodium group|Blood samples for hemolytic anemia in patients treated with cefoxitin sodium were screened for the production of drug antibodies.
89597999|NCT05606302||Vancomycin group|Blood samples for hemolytic anemia in patients treated with vancomycin were screened for the production of drug antibodies.
89598000|NCT00054028|Experimental|Treatment (suramin and paclitaxel)|"PHASE I: Patients receive low-dose suramin IV over 30 minutes and paclitaxel IV over 1 hour once weekly. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive adjusted doses of suramin until a target dose is determined. The suramin target dose is defined as the dose at which at least 5 of 6 patients achieve the target plasma concentration of 10-50 uM over the duration when paclitaxel levels are therapeutic.~PHASE II: Patients receive paclitaxel in combination with the target dose of suramin as above."
89598001|NCT04753060|Active Comparator|Waxing|Waxing of patients donor site who are undergoing a skingraft procedure, prior to surgery taking place.
89598002|NCT04753060|No Intervention|Standard care|Standard wound preparation
89598003|NCT05274334|Experimental|intervention group|Assessment of de novo lipogenesis non-invasively in exhaled breath in overnight-fasted humans by triggering feeding response by deuterium resolved mass spectrometry.
89598004|NCT00058240|Experimental|Arm I|Patients receive a loading dose of flavopiridol IV over 30 minutes followed by a 4-hour infusion on days 1, 8, 15, and 22. Treatment repeats every 6 weeks for up to 6 courses in the absence of unacceptable toxicity or disease progression.
89598005|NCT05606068|Experimental|Cancer patients|Cancer patients will undergo limb cryocompression based on the established optimal temperature and pressure from previous studies over multiple cycles of chemotherapy to establish safety and tolerability of repeated therapy.
89598006|NCT05605990|Experimental|Nurse group|Using an innovative tourniquet (Acusense Nonpneumatic tourniquet) for the standard of care
89598007|NCT01502631|Active Comparator|SUN13837|
89598008|NCT01502631|Placebo Comparator|Placebo|
89598009|NCT03027999|Experimental|Patient with tight nursing follow-up|Compared as usual, Patient with tight nursing follow-up will be contacted
89598010|NCT03027999|No Intervention|Patient without tight nursing follow-up|Compared as usual, Patient without tight nursing follow-up will not have interventions
88979529|NCT00307177|Active Comparator|Arm A|25 subjects receive Standard TIV at 15 mcg HA per virus, in a total volume of 0.5 mL, by deep intramuscular (IM) injection on Day 0
88979530|NCT00307216|Experimental|1|Participants will receive Graduated Recovery Intervention Program plus treatment as usual
88979531|NCT00307216|Active Comparator|2|Participants will receive treatment as usual
88979532|NCT02960152||Anorexia Nervosa|interview and periodontal full-mouth examination
88979533|NCT02960152||Bulimia Nervosa|interview and periodontal full-mouth examination
88979534|NCT02960152||Control|interview and periodontal full-mouth examination
88979535|NCT00307528|Active Comparator|Group A|
88979536|NCT00307528|Experimental|Group B|
88979537|NCT00307528|Experimental|Group C|
89598011|NCT03027921|Experimental|hepatic ultrasound|all patients will have hepatic ultrasound
89598012|NCT05262946|Active Comparator|control|control arm: usual care and foot care education.
89598013|NCT05262946|Experimental|experimental|experimental arm: sensorimotor training, foot care education and usual care
88979538|NCT00307528|Experimental|Group D|
88979539|NCT00307528|Experimental|Group E|
88979540|NCT00307528|Experimental|Group F|
88979541|NCT00307723|Experimental|Regimen Level 1|Radiation/Oxaliplatin/5-FU
89210088|NCT04017780|Experimental|Double-limb circuit with turbine-driven ventilator|Non invasive ventilation delivered with a turbine-driven ventilator with a double limb circuit.
89210089|NCT00638690|Experimental|Abiraterone acetate plus prednisone/prednisolone|
89210090|NCT00638690|Placebo Comparator|Placebo plus prednisone/prednisolone|
89598014|NCT03026907|Active Comparator|Alitretinoin|Patients with severe chronic non-hyperkeratotic hand eczema, randomized to treatment with alitretinoin.
89598015|NCT03026907|Active Comparator|Azathioprine|Patients with severe chronic non-hyperkeratotic hand eczema, randomized to treatment with azathioprine.
89598016|NCT00060424|Experimental|Treatment (enzyme inhibitor, transplant, GVHD prophylaxis)|NONMYELOABLATIVE CONDITIONING: Patients receive fludarabine phosphate IV on days -4 to -2 and TBI on day 0. TRANSPLANT: Patients undergo allogeneic peripheral blood stem cell transplant on day 0. GVHD PROPHYLAXIS: Patients receive cyclosporine PO every 12 hours on days -3 to 180 with taper on day 56 and mycophenolate mofetil PO every 12 hours on days 0-27.
89598017|NCT05253040|Experimental|Intervention group|"The experimental group will receive:~Online education modules Online group discussions facilitated by Specialist Physiotherapist"
89598018|NCT05253040|Active Comparator|Control Group|The comparator for this study is usual care pathway. Under the usual care pathway, participants will receive education booklets on exercise by Parkinson's UK.
88979542|NCT00307723|Experimental|Regimen Level 2|Radiation/Oxaliplatin/Bevacizumab/5-FU
88979543|NCT00307762|Experimental|1|Gait trainer exercise actively for 20 minutes + 55 minutes other gait-oriented physiotherapy
88979544|NCT00307762|Active Comparator|2|Overground walking exercises actively for 20 minutes + 55 minutes other gait-oriented physiotherapy
88979545|NCT00307762|No Intervention|3|Control patients with ordinary therapy
88979546|NCT00088140|Placebo Comparator|Placebo|
88979547|NCT00088140|Active Comparator|IDN-6556 5 mg twice a day (BID)|
88979548|NCT00088140|Active Comparator|IDN-6556 25mg twice a day (BID)|
88979549|NCT00088140|Active Comparator|IDN-6556 50 mg twice a day (BID)|
88979550|NCT00308152|No Intervention|Control|Observation only
88979551|NCT00308152|Active Comparator|Active|Infusion of 1 liter normal saline before sedated colonoscopy
88979552|NCT00307021|Active Comparator|Group A|
88979553|NCT00307021|Experimental|Group B|
88979554|NCT00418756|Experimental|Rifampin + nilotinib|
88979555|NCT00308269|Experimental|Vintafolide 1.2 mg IV Bolus|Vintafolide 1.2 mg administered by IV bolus on Days 1, 3, 5, 15, 17, and 19 of 4-week treatment cycles
88979556|NCT00308269|Experimental|Vintafolide 2.5 mg IV Bolus|Vintafolide 2.5 mg administered by IV bolus on Days 1, 3, 5, 15, 17, and 19 of 4-week treatment cycles
89598019|NCT05215522|Experimental|The BCI-FES Intervention|The BCI-FES device will be used by all participants.
89598020|NCT00062764|Experimental|Pioglitazone|
89598021|NCT00063622|Active Comparator|1|Pioglitazone
89598022|NCT00063622|Active Comparator|2|Vitamin E
89598023|NCT00063622|Placebo Comparator|3|Placebo Pioglitazone or Placebo Vitamin E
89598024|NCT05185726|Experimental|Mini-KIDS|Mini-KIDS is a direct treatment based on principles of stuttering modification, with pseudo-stuttering, that is, deliberate stuttering, as one of the main components. The program for 4-6-year old children consists of four stages: Stage 1 = desensitization, Stage 2 = modification, Stage 3 = identification and Stage 4 = generalization. The program for 2-4-year old children does not include stage 3. Speech therapist and parent(s) are the speech model for the child. They add normal dysfluencies to their speech. Later on in treatment and if necessary, children learn to recognise and alter their stuttering moments.
89598025|NCT05185726|Experimental|Social-Cognitive Behaviour Treatment|The social cognitive behaviour therapy contains 5 treatment phases: (1) conditioning speaking activities, (2) cognitive training focused on emotions, (3) cognitive training focused on cognitions, (4) emotional training and (5) skill training (Boey, 2010). This treatment is not directed at the speech of the children, but rather at the cognitive and emotional aspects that surround the stuttering.
89598026|NCT05185726|Active Comparator|Lidcombe Program|The Lidcombe Program (LP) is an operant program that directly provides verbal feedback to the child's stutter-free speech (mainly) and the child's stuttering (occasionally). The program comprises two stages: Stage 1 in which (near) zero levels of stuttering are achieved and Stage 2 in which the achieved (near) zero levels of stuttering are maintained for a long period of time. The LP usually takes between 11 to 23 (60-minute) treatment sessions to achieve the goals of Stage 1, i. e. (near) zero levels of stuttering.
89598027|NCT00153166|Experimental|Patients with PAD (Including diabetics)|Randomized to either atorvastatin and pioglitazone, atorvastatin/placebo, pioglitazone/placebo, or placebo/placebo.
89598028|NCT00153166|Active Comparator|PAD (Excluding Diabetics)|Randomized to either atorvastatin and pioglitazone, atorvastatin/placebo, pioglitazone/placebo, or placebo/placebo.
89598029|NCT00153166|Active Comparator|Healthy Controls|Randomized to either atorvastatin and pioglitazone, atorvastatin/placebo, pioglitazone/placebo, or placebo/placebo.
89598030|NCT00156910|Experimental|botulinum toxin Type A|Two treatment sessions in the double-blind phase and three treatment sessions in the open-label extension phase. Total minimum dose is 155 U with 31 fixed-site, fixed dose injections across seven specific head/neck muscle areas with the total maximum dose of 195 U with 39 head/neck injections.
89598031|NCT00156910|Placebo Comparator|Placebo (saline)|Two treatment sessions in the double-blind phase. Total minimum dose in 155 U with 31 fixed-site, fixed dose injections across seven specific head/neck muscle areas and the total maximum dose is 195 U with 39 head/neck injections.
89598032|NCT01475721|Experimental|ADVAIR 100/50mcg|experimental drug
89598033|NCT01475721|Experimental|ADVAIR 250/50mcg|experimental drug
89598034|NCT01475721|Experimental|ADVAIR 500/50mcg|experimental drug
89598035|NCT01475721|Active Comparator|FLOVENT 100mcg|active comparator
89210091|NCT02540928|Experimental|AMG 319 Hydrate|Up to 36 patients will be randomised into the Active Treatment arm to receive AMG 319 400 mg once daily administered orally for a minimum of 20 days and a maximum of 29 days prior to resection surgery
89598036|NCT01475721|Active Comparator|FLOVENT 250mcg|active comparator
89598037|NCT01475721|Active Comparator|FLOVENT 500mcg|active comparator
89598038|NCT00065806|Experimental|1|Patients will be treated with dietary intervention (AHA Therapeutic Lifestyle Changes [TLC] diet, [http://www.nhlbi.nih.gov/cgi-bin/chd/step2intro.cgi]), cardiovascular risk factor reduction counseling, hydroxychloroquine, low-dose aspirin, a multivitamin containing folate, plus atorvastatin at 10 mg or 20 mg depending on the patient's weight. Patients weighing more than 50 kg will receive 10 mg qd atorvastatin for the first month, which will be increased to 20 mg qd at the Day 30 visit and continue through month 36. Participants weighing less than 50kg will receive a maximum of 10 mg po qd for 36 months.
89598039|NCT00065806|Placebo Comparator|2|Patients will be treated with dietary intervention (AHA Therapeutic Lifestyle Changes [TLC] diet, [http://www.nhlbi.nih.gov/cgi-bin/chd/step2intro.cgi]), cardiovascular risk factor reduction counseling, hydroxychloroquine, low-dose aspirin, a multivitamin containing folate, plus placebo at 10 mg or 20 mg depending on the patient's weight. Patients weighing more than 50 kg will receive 10 mg qd placebo for the first month, which will be increased to 20 mg qd at the Day 30 visit and continue through month 36. Participants weighing less than 50kg will receive a maximum of 10 mg po qd for 36 months.
89598040|NCT02091466|Active Comparator|Pre-warming|The intervention is to warm patients before the anesthesia procedure in experimental groups
89598041|NCT02091466|No Intervention|Control|Patients received no active warming before the anesthesia procedure in control groups
89598042|NCT01530087|Experimental|Treatment|CASTLE Barrier
89598043|NCT00068770|Active Comparator|p450 ( +EIASD)|"on p450 inhibitor (Patients taking anttiseizure drugs that are known to induce the hepatic drug-metabolizing enzymes - including phenytoin, carbamazepine, phenobarbital, primidone and oxcarbazepine)~celecoxib and radiation therapy will be adminstered with this arm"
89598044|NCT00068770|Active Comparator|nonp450 (-EIASD)|"not on p450 inhibitor (Patients either NOT taking anti-seizure drugs or ones that are known to not significantly influence the hepatic drug-metabolizing enzymes - including gabapentin, lamotrigine, valproic acid, levetiracetam, tiagabine,topiramate, zonisamide and filbamate.~celecoxib and radiation therapy will be adminstered with this arm"
89598045|NCT01475487|Active Comparator|Cricothyrotomy using Digital Palpation|Group-1 will perform Cricothyrotomy using conventional digital palpation technique
88979557|NCT00308269|Experimental|Vintafolide 4.0 mg IV Bolus|Vintafolide 4.0 mg administered by IV bolus on Days 1, 3, 5, 15, 17, and 19 of 4-week treatment cycles
88979558|NCT00308269|Experimental|Vintafolide 2.5 mg IV Infusion|Vintafolide 2.5 mg administered by a 1-hour IV infusion on Days 1, 3, 5, 15, 17, and 19 of 4-week treatment cycles
89210092|NCT02540928|Placebo Comparator|Placebo|Up to 18 patients will be randomised into the Placebo arm to receive Placebo once daily administered orally for a minimum of 20 days and a maximum of 29 days prior to resection surgery
89210093|NCT00893646|Experimental|weight loss counseling|individual monthly counseling on diet, physical activity and sleep
89210094|NCT00893646|No Intervention|control|no lifestyle advice, yearly assessments
89210095|NCT00893724|Placebo Comparator|P (Placebo)|
89598046|NCT01475487|Experimental|Ultrasound guided cricothyrotomy group|Group-2 Ultrasound guided cricothyrotomy
89598047|NCT04102527||Patients|Patients with Terminal Chronic Kidney Disease undergoing Peritoneal Dialysis for at least three months in stable condition
89598048|NCT01475331|Active Comparator|Control Group|Cyst will be lavaged for 3-5 minutes with Ethanol (alcohol 80%). Following lavage with Ethanol (alcohol 80%), The cyst will be infused with an admixture of chemotherapy drugs (Paclitaxel/ Gemcitabine) 3mg/ml paclitaxel and 19mg/ml gemcitabine.
89598049|NCT01475331|Experimental|Study Group|Cyst will be lavaged for 3-5 minutes with Normal Saline .. Following lavage with Normal Saline, The cyst will be infused with an admixture of chemotherapy drugs (Paclitaxel/ Gemcitabine) 3mg/ml paclitaxel and 19mg/ml gemcitabine.
89598050|NCT01500213|Placebo Comparator|Placebo + Granisetron + Dexamethasone|Day 1: Placebo + Granisetron (10 mcg/kg IV)+ dexamethasone (20 mg PO) Days 2-4: Dexamethasone (8 mg PO) will be administered orally BID.
89598051|NCT01500213|Experimental|Rolapitant|Day 1: Rolapitant (200 mg PO) + Granisetron (10 mcg/kg IV)+ dexamethasone (20 mg PO) Days 2-4: Dexamethasone (8 mg PO) will be administered orally BID.
89598052|NCT00069160|Experimental|Pts who received docetaxel on day 1, 8, & tariquidar day 8,22|Patients receive 40 mg/m^2 docetaxel intravenous (IV) over 1 hour on days 1 and 8 and 150 mg tariquidar intravenous (IV) over 30 minutes on days 8 and 22. From cycle 2 and onward 75 mg/m^2 docetaxel was administered every 21 days in combination with a single 150 mg dose.
89598053|NCT00069160|Experimental|Pts who received docetaxel on days 1, 8, & tariquidar day 1,22|Patients receive docetaxel intravenous (IV) over 1 hour on days 1 and 8 and tariquidar intravenous (IV) over 30 minutes on days 1 and 22.
89598054|NCT00071890|Active Comparator|Interleukin 2 group|HAART (standard of care) and three cycles of IL-2
89598055|NCT00071890|Active Comparator|Control group|HAART alone
89598056|NCT01475253|Experimental|Lidocaine Releasing Intravesical System|Lidocaine Releasing Intravesical System (LiRIS®) is inserted into the bladder via cystoscopy on Study Day 0 and removed on Study Day 14. LiRIS releases lidocaine gradually during the 14 day indwelling period.
89598057|NCT01475253|Placebo Comparator|LiRIS containing inactive substance only|LiRIS Placebo is inserted into the bladder via cystoscopy on study Day 0 and removed via cystoscopy on study Day 14.
89598058|NCT01475253|Sham Comparator|Cystoscopy Procedure|No intervention. Cystoscopy procedure is performed on study Day 0 and study Day 14 to mimick active and placebo study arms without insertion of Investigational Product into the bladder.
89598059|NCT00072514|Experimental|Treatment|Patients receive gemcitabine hydrochloride intravenously (IV) over 30 minutes on days 1 and 8, carboplatin IV over 30-60 minutes on day 1, and dexamethasone orally (PO) on days 1-4. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients with CD20-POSITIVE LYMPHOMAS also receive rituximab IV on day 8.
89598060|NCT00074308|Experimental|Arm I|Patients receive oral imatinib mesylate once or twice daily on days 1-28 and bevacizumab IV over 30-90 minutes on days 1 and 14. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89598061|NCT00159250|Experimental|Low dose|Low dose of AVI-4658
89598062|NCT00159250|Experimental|High dose|High dose of AVI-4658
89598063|NCT00165958|Experimental|Punch excision|
89598064|NCT00165958|Active Comparator|Traditional excision|
89598065|NCT01898026|Experimental|PGX|samples of white bread, mashed potatoes, muffin, hot breakfast cereal with the addition of soluble fibre blend
89598066|NCT01898026|Other|Control|samples of white bread, mashed potatoes, muffin, hot breakfast cereal without the addition of soluble fibre blend
89598067|NCT00166036|Experimental|Atorvastatin 10MG|
89598068|NCT00166036|Experimental|Pravastatin 80mg|
89598069|NCT01500135|Experimental|TachoSil®|TachoSil® absorbable patches, applied topically, once, intraoperatively to stop bleeding. The patches were lightly compressed against the suture line for 3 minutes. The number of patches used was determined by the surgeon based on the size of the wound. If bleeding did not stop after 5 minutes treatment was repeated.
89598070|NCT01500135|Active Comparator|Surgicel® Original|Surgicel® Original absorbable patches, applied topically, once, intraoperatively to stop bleeding. The patches were lightly compressed against the suture line for 3 minutes. The number of patches used was determined by the surgeon based on the size of the wound. If bleeding did not stop after 5 minutes treatment was repeated.
89210096|NCT00893724|Active Comparator|S (Supplement)|
89598071|NCT00167206|Experimental|HSCT Patients|Patients who received total body irradiation (450 cGy [centigray]) with thymic shielding prior to chemotherapy regimen and Hematopoietic Stem Cell Transplant (HSCT)
89598072|NCT01475097|Active Comparator|Active Arm|
89210097|NCT00893724|Active Comparator|SM (Supplement with Minocycline)|
89210098|NCT00893802|Experimental|Periodontal treatment|Scaling and root planning
89210099|NCT00893802|No Intervention|Control|
89210100|NCT00819338|Active Comparator|polyunsaturated|5g per day of polyunsaturated fatty acids (3.5g EPA and DHA).
89210101|NCT00819338|Placebo Comparator|monounsaturated|5g a day of oleic enriched sunflower oil
89210102|NCT00893880|Experimental|1|(1) 30min treatment
89210103|NCT00893880|Experimental|2|(1) 60min treatment
89598073|NCT01475097|Active Comparator|Comparator Arm|
89598074|NCT04779190|Experimental|Low-level laser therapy|In the low-level laser therapy group, each patient are going to receive low-level laser therapy and cold-pack therapy and perform a home-based exercise program 5 times a week, once a day for 15 sessions.
89598075|NCT04779190|Experimental|Therapeutic ultrasound|In the therapeutic ultrasound group, each patient are going to receive therapeutic ultrasound and cold-pack therapy and perform a home-based exercise program 5 times a week, once a day for 15 sessions.
89598076|NCT04779190|Active Comparator|Control|Participants are going to perform a home-based exercise program and receive cold-pack therapy 5 times a week, once a day for 15 sessions.
89598077|NCT01529385|Experimental|Mild Compression Diabetic Sock|Diabetic socks that provide 18-25mm Hg of pressure to the lower extremities.
89598078|NCT01529385|Other|Standard Diabetic Sock|A standard diabetic sock that is designed to limit foot ulcer formation, but does not provide compression to the leg.
89598079|NCT01474551|Experimental|vemurafenib|This is a single institution phase II trial in stage III or IV melanoma patients with poor ECOG performance status (3 or 4). Patients must have melanoma with a BRAFV600E or BRAFV600K or mutation with measurable disease not curable by surgery.
89598080|NCT02094586|Experimental|PXVX0200 Lot A|PXVX0200 (Lot P700-1CA03) Single dose; liquid suspension after reconstitution with buffer; > 2x10^8 CFU in a liquid suspension
89598081|NCT02094586|Experimental|PXVX0200 Lot B|PXVX0200 (Lot P700-3CA03) Single dose; liquid suspension after reconstitution with buffer; > 2x10^8 CFU in a liquid suspension
89598082|NCT02094586|Experimental|PXVX0200 Lot C|PXVX0200 (Lot P700-6BA03) Single dose; liquid suspension after reconstitution with buffer; > 2x10^8 CFU in a liquid suspension
89598083|NCT02094586|Placebo Comparator|Placebo|Placebo physiological saline
89598084|NCT02985645|Experimental|Treatment|maxillary sinus augmentation with CGF
89598085|NCT01500057|Active Comparator|Greenlight XPS Laser|Greenlight XPS Laser of the prostate
89598086|NCT01500057|Active Comparator|BiVAP Saline Vaporization|BiVAP Saline Vaporization of the prostate
89598087|NCT02094664|No Intervention|Standard oxygen via nasal cannula|Standard therapy
89031858|NCT04694612|Active Comparator|Moderate condition|"Study arm groups will receive a Favipiravir treatment of 1800 mg po BID on day 1, then 800 mg po BID from day 2 onwards and control groups will receive Inj Remdesivir 200 mg IV on day 1, followed by 100 mg IV daily.~Duration of treatment : 10 days in Favipiravir group & 5 days in Remdesivir group"
89031859|NCT02942238|Experimental|Complete Mesocolic Excision|the group underwent laparoscopic right hemicolectomy with CME. In complete mesocolic excision group (CME), the dissecting extent includes the lymphatic and fat tissues surrounding the root of ascending mesocolon, which situated on the surface of superior mesenteric vein, and the root of right half of transverse mesocolon, which situated on the surface of pancreas neck.
89210104|NCT00893880|Experimental|3|(2) 30min treatments over two consecutive days.
89210105|NCT00893880|Experimental|4|(2) 60min treatments over two consecutive days.
89210106|NCT00815438|Experimental|Surgical Procedure|Laparoscopic transvaginal cholecystectomy with endoscopic assistance.
89598088|NCT02094664|Active Comparator|Heated and humidified oxygen|Heated and humified oxygen
89598089|NCT01499667|Experimental|8-week washout + Fingolimod (FTY720)|8-week washout (8 weeks no treatment) followed by 24 weeks of treatment with fingolimod 0.5mg once a day
89598090|NCT01499667|Experimental|12-week washout + Fingolimod (FTY720)|12-week washout (8 weeks no treatment and 4 weeks placebo) followed by 20 weeks of treatment with fingolimod 0.5mg once a day
89598091|NCT01499667|Experimental|16-week washout + Fingolimod (FTY720)|16-week washout (8 weeks no treatment and 8 weeks placebo) followed by 16 weeks of treatment with fingolimod 0.5mg once a day
89598092|NCT01499511||ASCOT participants amlodipine|It is follow up group from the ASCOT study, after treatment with amlodipine for 5.5 years. No treatment only follow up.
89598093|NCT01499511||ASCOT participants atenolol|It is follow up group from the ASCOT study, after treatment with atenolol for 5.5 years. No treatment only follow up.
89598094|NCT00168298|Experimental|700 µg Dexamethasone|700 µg dexamethasone intravitreal implant administered on Day 0 and Day 180.
89598095|NCT00168298|Experimental|350 µg Dexamethasone followed by 700 µg Dexamethasone|350 µg dexamethasone intravitreal implant administered on Day 0 and 700 µg dexamethasone intravitreal implant on Day 180.
89598096|NCT00168298|Sham Comparator|Sham Injection followed by 700 µg Dexamethasone|Sham injection on Day 0 and 700 µg dexamethasone intravitreal implant on Day 180.
89598097|NCT01474317|Experimental|Intended Users of the Monitoring System|Untrained subjects with diabetes use the G3 investigational blood glucose monitoring system.
89598098|NCT00075088|Experimental|Electrocardiogram (ECG) Intervention|Patients randomized to the experimental group had their ECGs printed out in the target ED with an audible voice alarm. Print-out of the pre-hospital ECG in the target ED was the intervention.
89598099|NCT00075088|Other|Routine Clinical Practice|Control patients had an ECG conducted after hospital arrival, as was the standard of care in the county.
89598100|NCT00076258|Experimental|SSRI+ LD|A low dose aerobic exercise (LD) augmentation intervention to SSRI
89598101|NCT00076258|Experimental|SSRI+ PHD|A public health dose of aerobic exercise (PHD) augmentation intervention to SSRI
89598102|NCT00078286|Experimental|Sertraline|Participants will take sertraline for 12 weeks
89598103|NCT00078286|Placebo Comparator|Placebo|Participants will take placebo for 12 weeks
89598104|NCT00078754|Experimental|A|Participants will to receive treatment with fluoxetine for 12 weeks
89598105|NCT00078754|Experimental|B|Participants will to receive treatment with divalproex for 12 weeks
89598106|NCT00078754|Placebo Comparator|C|Participants will to receive treatment with placebo for 12 weeks
89598107|NCT00080470|Experimental|1|Stimulation On from Initial Activation up to the 12 month post-activation. Stimulation Off from 12 months post-activation until 45 days after the 12 month visit. Stimulation On from 45 days post 12 month visit and on.
89598108|NCT00080470|Sham Comparator|2|No Stimulation until 45 days post-implant. Stimulation On from 45 days post-implant and on.
89598109|NCT00081328|Experimental|1|Metformin alone
89031860|NCT02942238|Active Comparator|D3 lymph node dissection|the group underwent laparoscopic right hemicolectomy with D3 lymph node dissection. In D3 lymph node dissection group(D3), the lymph node dissection is based on ligating the supplying vessels close to the right-side of superior mesenteric vein and clean up the surrounding lymph node and adipose tissue. No.6 lymph node should be dissected in this group.
89031861|NCT02950064|Experimental|BTP-114|Intravenous (IV) treatment n 21-day cycles
89210107|NCT00897234||Healthy Volunteers|Non-smoking healthy volunteers
89031862|NCT02941224|Experimental|SELUTION DCB|The SELUTION™ DCB (coated with sirolimus) is intended for use as a Percutaneous Transluminal Angioplasty (PTA) balloon catheter to dilate de-novo or restenotic vascular lesions, for the purpose of improving limb perfusion and decreasing the incidence of restenosis.
89031863|NCT02949791|Active Comparator|Low Intra abdominal pressure HIPEC|Cytoreductive surgery and HIPEC with low intra-abdominal pressure
89031864|NCT02949791|Experimental|High Intra abdominal pressure HIPEC|Cytoreductive surgery and HIPEC with high intra-abdominal pressure
89210108|NCT00897234||Non-Small Cell Lung Cancer|Patients with non-small cell lung cancer.
89210109|NCT00815672|No Intervention|Treatment Arm 1|Usual Care: Standard care monitoring
89598110|NCT00081328|Experimental|2|Metformin + Rosiglitazone
89598111|NCT00081328|Experimental|3|Metformin + Lifestyle Program
89598112|NCT00082342|Active Comparator|real transcranial direct current stimulation (tDCS)|
89598113|NCT00082342|Sham Comparator|sham transcranial direct current stimulation (tDCS)|
89598114|NCT01499355|Placebo Comparator|Placebo|Placebo intravenous (IV) infusion on Day 1, Week 2, Week 4, Week 8, and every 4 weeks thereafter through Week 48, plus background therapy including oral steroids (prednisone or equivalent) and mycophenolate mofetil (MMF)
89598115|NCT01499355|Experimental|BIIB023 3 mg/kg|BIIB023 3 mg/kg IV on Day 1, Week 2, Week 4, Week 8, and every 4 weeks thereafter through Week 48 plus background therapy including oral steroids (prednisone or equivalent) and MMF.
89598116|NCT01499355|Experimental|BIIB023 20 mg/kg|BIIB023 20 mg/kg IV on Day 1, Week 2, Week 4, Week 8, and every 4 weeks thereafter through Week 48 plus background therapy including oral steroids (prednisone or equivalent) and MMF.
89598117|NCT00083122|Experimental|Group 1|Patients receive cisplatin IV over 30 minutes and flavopiridol IV over 24 hours on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
89598118|NCT00083122|Experimental|Group 2|Patients receive cisplatin IV over 30 minutes and flavopiridol IV over 24 hours on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
89598119|NCT01474239|Experimental|Calibration Arm|
89598120|NCT01474239|Experimental|Investigational Arm|
89598121|NCT03026829|Experimental|CART sound therapy|
89210110|NCT00815672|Experimental|Treatment arm 2|Home-based Exercise: Progressive walking and resistance exercise treatment.
89210111|NCT02540460|Experimental|LCB01-0371 800mg|LCB01-0371 800mg
89210112|NCT02540460|Experimental|LCB01-0371 800mg BID|LCB01-0371 800mg BID
89210113|NCT02540460|Experimental|LCB01-0371 1200mg BID|LCB01-0371 1200mg BID
89210114|NCT02540460|Placebo Comparator|Placebo|LCB01-0371 800mg, LCB01-0371 800mg BID, LCB01-0371 1200mg BID
89210115|NCT00543387|Experimental|MK-5108 200 mg BID (Panel 1)|Participants receive 200 mg of MK-5108 orally twice daily (BID) the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).
89210116|NCT00543387|Experimental|MK-5108 400 mg BID (Panel 1)|Participants receive 400 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).
89210117|NCT00543387|Experimental|MK-5108 800 mg BID (Panel 1)|Participants receive 800 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).
89210118|NCT00543387|Experimental|MK-5108 1200 mg BID (Panel 1)|Participants receive 1200 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).
89210119|NCT00543387|Experimental|MK-5108 1500 mg BID (Panel 1)|Participants receive 1500 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).
89598122|NCT01473381|Placebo Comparator|Placebo|Participants received 2 placebo to vilazodone tablets, and 1 placebo to citalopram capsule orally once daily for the 11 weeks of the study.
89598123|NCT01473381|Experimental|Vilazodone 20 mg/day|Participants received 1 vilazodone tablet, 1 placebo to vilazodone tablet, and 1 placebo to citalopram capsule orally once daily for the 11 weeks of the study. Participants received vilazodone 10 mg/day during Week 1, vilazodone 20 mg/day during Weeks 2 to 10, and vilazodone 10 mg/day during Week 11.
89598124|NCT01473381|Experimental|Vilazodone 40 mg/day|Participants received 1 placebo to vilazodone tablet, 1 vilazodone tablet, and 1 placebo to citalopram capsule orally once daily during Weeks 1 and 2 of the study. Participants received 2 vilazodone tablets and 1 placebo to citalopram capsule orally once daily during Weeks 3 -10 of the study. Participants received vilazodone 10 mg/day during Week 1, vilazodone 20/day mg during Week 2, and vilazodone 40 mg/day during Weeks 3 to 10. During Week 11, participants received vilazodone 20 mg/day for 4 days and 10 mg/day for 3 days.
89598125|NCT01473381|Active Comparator|Citalopram 40 mg/day|Participants received 2 placebo vilazodone tablets, and 1 citalopram capsule once daily for the 11 weeks of the study. Participants received citalopram 20 mg/day during Weeks 1 and 2, citalopram 40 mg/day during Weeks 3 to 10, and citalopram 20 mg/day during Week 11.
89598126|NCT00168454|Placebo Comparator|Placebo|Placebo (normal saline) injected into detrusor on Day 1
89598127|NCT00168454|Experimental|BOTOX 50 U|botulinum toxin Type A 50 U injected into detrusor on Day 1
89598128|NCT00168454|Experimental|BOTOX 100 U|botulinum toxin Type A 100 U injected into detrusor on Day 1
89598129|NCT00168454|Experimental|BOTOX 150 U|botulinum toxin Type A 150 U injected into detrusor on Day 1
89598130|NCT00168454|Experimental|BOTOX 200 U|botulinum toxin Type A 200 U injected into detrusor on Day 1
89598131|NCT00168454|Experimental|BOTOX 300 U|botulinum toxin Type A 300 U injected into detrusor on Day 1
89598132|NCT00175006||Tophi Participants|
89598133|NCT04737772|Active Comparator|Standard Quitline Treatment As Usual (TAU)|State quitline treatment as usual
89598134|NCT04737772|Experimental|QL Marijuana Check-Up intervention (QL-MJCU).|Newly developed intervention for co-users of marijuana and tobacco.
89210120|NCT00543387|Experimental|MK-5108 1800 mg BID (Panel 1)|Participants receive 1800 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).
89210121|NCT00543387|Experimental|MK-5108 100 mg BID + 60 mg/m^2 Docetaxel (Panel 2)|Participants receive 100 mg of MK-5108 orally BID in combination with 60 mg/m^2 Docetaxel administered intravenously (IV) the first 2 days of a 21-day cycle.
89210122|NCT00543387|Experimental|MK-5108 150 mg BID + 60 mg/m^2 Docetaxel (Panel 2)|Participants receive 150 mg of MK-5108 orally BID in combination with 60 mg/m^2 Docetaxel administered IV the first 2 days of a 21-day cycle.
89598135|NCT01499277|Experimental|Ceftaroline fosamil|Patients will receive 600 mg of ceftaroline fosamil administered as a 120-minute intravenous infusion very 8 hours. Each dose will be infused in a volume of 250 mL over 120-minutes followed by aztreonam placebo in a volume of 100 mL infused over 30 minutes every 8 hours. In addition vancomycin placebo will be given in a volume of 250 mL infused over 120 minutes every 12 hours. Doses will be adjusted according to the patient's renal function.
89598136|NCT01499277|Active Comparator|Vancomycin plus aztreonam|Patients will receive combination of vancomycin plus aztreonam. Dose of vancomycin will be based on the patient's actual weight and will receive intravenous vancomycin every 12 hours with each dose infused over 120-minutes. Aztreonam dose will be 1 gram intravenously in a volume of 100 mL infused over 30 minutes every 8 hours. In addition, ceftaroline fosamil placebo will be given in a volume of 250 mL infused over 120 minutes every 8 hours. Doses adjusted according to patients renal function
89210123|NCT00543387|Experimental|MK-5108 225 mg BID + 60 mg/m^2 Docetaxel (Panel 2)|Participants receive 150 mg of MK-5108 orally BID in combination with 60 mg/m^2 Docetaxel administered IV the first 2 days of a 21-day cycle.
89210124|NCT00543387|Experimental|MK-5108 100 mg BID + 60 mg/m^2 Docetaxel (Crossover)|After receiving treatment in Panel 1, one participant crossed over to Panel 2 per protocol following disease progression to receive 100 mg of MK-5108 orally BID in combination with 60 mg/m^2 Docetaxel administered IV the first 2 days of a 21-day cycle.
89210125|NCT00543387|Experimental|MK-5108 150 mg BID + 60 mg/m^2 Docetaxel (Crossover)|After receiving treatment in Panel 1, participants crossed over to Panel 2 per protocol following disease progression to receive 150 mg of MK-5108 orally BID in combination with 60 mg/m^2 Docetaxel administered IV the first 2 days of a 21-day cycle.
89210126|NCT02551250||Study|Surveillance of HCC by biannual ultrasonography AND annual noncontrast MRI
89210127|NCT03455556|Experimental|Treatment (anetumab ravtansine, atezolizumab)|Participants receive anetumab ravtansine IV over 60 minutes and atezolizumab IV over 30-60 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89210128|NCT04045106|Experimental|PNF pattern|"PNF patterns were performed using Dynamic of reversals technique which is characterized as active motion alternating from one direction (agonist) to the opposite (antagonist) without relaxing. The cervical patterns consisted of~Cervical flexion with right rotation followed by extension with left rotation.~Cervical flexion with left rotation followed by extension with right rotation."
89210129|NCT04045106|Experimental|PNF stretching|PNF stretching was done using contract-relax-antagonist contract (CRAC) technique for cervical flexors, extensors, right and left lateral flexors, right rotators and left rotators.
89210130|NCT04045106|Sham Comparator|control|Participants allocated to the control group received ineffective passive ROM.
89608658|NCT05582655|Experimental|ONLINE|"This strategy will primarily include self-directed family access to the online JASPER modules developed for this project. The online modules follow a stepped hierarchy beginning with foundational concepts (e.g., engagement states) and systematically adding new concepts and strategies each week (e.g., balancing imitation and modeling, play routines). Access to the modules will be paired with a weekly brief (20 minute) check-in call provided by a community interventionist. The call is designed to create a space for the caregiver to ask questions about the week's content and to provide basic troubleshooting for implementation.~Slower responders to phase 1 ONLINE intervention will intensify to receive COACH in phase 2."
89210131|NCT04017624|Experimental|Fresh Truck with stipend|Referral to Fresh Truck mobile market
89210132|NCT04017624|Active Comparator|THRIVE-Basic|Screening-and-referral usual care model
89210133|NCT00815828|Other|1|Group that don't do the resistance exercises
89210134|NCT02540304|Experimental|TPP program|Reducing the Risk, Safer Sex Intervention, Cuidate!
89210135|NCT02540304|No Intervention|Business as Usual|Business as usual
89210136|NCT00982839|Active Comparator|Syringe Conditioning|A syringe will be used to inflate the balloon at the end of the probe which is inside of the rectum.
89210137|NCT00982839|Experimental|Barostat Conditioning|A barostat machine will be used to inflate the balloon at the end of the probe which is inside of the rectum.
89210138|NCT00897468||breast cancer patients|
89210139|NCT00809042|Experimental|1|Hydroxyurea
89210140|NCT00809042|Active Comparator|2|L-carnitine and hydroxyurea
89210141|NCT00809042|Active Comparator|4|L-carnitine , magnesium chloride and hydroxyurea
89210142|NCT00809042|Active Comparator|3|magnesium chloride and hydroxyurea
89210143|NCT02539602|Experimental|Need to Know (N2K)|The intended dosage for treatment participants is 16 lessons (25 minutes each) each year of the program (8 in the fall and 8 in the spring). The program consists of 3 years (48 lessons) of curriculum intended for 9th, 10th and 11th grade students to be delivered in a group or classroom setting of up to 32 students. There are 16 lessons in each year of the curriculum. Eight lessons are intended to be taught in the fall semester and eight in the spring. Each lesson is 25 minutes long, and can be taught in any class period that allows for 25 minutes of content instruction.
89210144|NCT02539602|No Intervention|Counterfactual|The counterfactual condition received no intervention.
89210145|NCT00988377|Experimental|10 g whey protein|
89210146|NCT00988377|Experimental|20 g whey protein|
89210147|NCT00988377|Experimental|30 g whey protein|
89210148|NCT00988377|Experimental|40 g whey protein|
89210149|NCT00988377|Experimental|water control|Iso-volumetric (300 ml) water control (Crystal Springs, Canada)
89598137|NCT00176800|Experimental|1|Paclitaxel is administered intravenously over 1 hour on Days 1, 8, 15, and 22. Cisplatin will then be administered intravenously over 1 hour on Days 1 and 22. Radiation treatments will be given twice/day, on Days 1-5, 8-12 and 15-19. The subject's esophagus will be surgically removed on approximately Day #50. Approximately 4-6 weeks after surgery, the subject will start taking Tetrathiomolybdate, for 2 years or until treatment is no longer working to control your cancer. The subject will have blood drawn weekly while he/she is receiving chemotherapy and radiation prior to their surgery. 4-6 weeks after their surgery (when the subject starts taking Tetrathiomolybdate), a blood test will be performed every other week for 2 times, and monthly thereafter. When the level of copper has been lowered sufficiently an additional blood test and a baseline chest x-ray will be obtained. Additional blood will be drawn and tested every 6 months for the first 2 years.
89598138|NCT00176878|Experimental|Bone Marrow Failure Disorders|Patients with Diamond-Blackfan Anemia, Kostmann's Neutropenia, Shwachman-Diamond Syndrome
89598139|NCT01898182|Experimental|Kinerase|Kinetin (N6-furfuryladenine) is an essential bio growth factor that regulates cell growth and is proven to delay and reverse the signs of aging. Kinerase has been found out to significantly improve the appearance of skin texture, mottled hyperpigmentation and fine wrinkles. It does not cause the cutaneous side effects that result from other commonly used anti-aging products. The Kinerase cream contains: Water, glyceryl stearate, propylene glycol, butylenes glycol, glycerin, cetyl alcohol, stearic acid, isopropyl palmitate, squalene, stearyl alcohol, glycene soja sterols, dimethicone, laureth-23, aloe barbadensis leaf juice, phenoxyethanol, carbomer, ethylhexyglycerin, sodium hydroxide, soluble collagen, kinetin, panthenol, tocopherol, citric acid, sodium citrate, hydrolysed elastin.
89598140|NCT02338336|Placebo Comparator|Placebo|Placebo
89598141|NCT02338336|Experimental|Nowarta110 3 drops|Nowarta110 3 drops administration
89210150|NCT02551328||Sevofluorane|Patients preconditioned with Sevo
89598142|NCT02338336|Experimental|Nowarta110 6 drops|Nowarta110 6 drops administration
89598143|NCT02338336|Experimental|Nowarta110 10 drops|Nowarta110 10 drops administration
89598144|NCT04672174|Other|Effect of hearing loss on dementia|Effect of hearing loss on dementia, collected with a standardized questionnaire
89598145|NCT01499199|Experimental|Dolutegravir 50mg Once Daily|All subjects will receive 50mg dolutegravir once daily in combination with background antiretroviral therapy consisting of one abacavir/lamivudine fixed dose combination tablet once daily
89598146|NCT01499043|Experimental|PLX3397|Participants will take daily oral dose of PLX3397 for 28 day cycles. Participants will continue to take PLX3397 until disease progression or toxicity.
89598147|NCT00087022|Experimental|Arm I|Patients receive monoclonal chimeric antibody cG250 (synonym names: Rencarex®, girentuximab, and WX-G250) IV over 15 minutes once weekly for 24 weeks.
89598148|NCT00087022|Placebo Comparator|Arm II|Patients receive placebo IV over 15 minutes once weekly for 24 weeks.
89598149|NCT00179998|Active Comparator|Recombinant Human DNase (Pulmozyme) then Placebo|once daily nebulized rhDNAse
89598150|NCT00179998|Placebo Comparator|Placebo (Nebulized Saline) then rhDNase|once daily nebulized vehicle
89598151|NCT02191306||HIV Positive Patients (Study Group)|
89598152|NCT02191306||Non HIV Positive Patients (Control)|
89598153|NCT02164942||Single Arm|Specimen Collection
89598154|NCT00181168|Experimental|Euthyroid Group|Euthyroid Group: Subjects received rhTSH to prepare for radioiodine therapy.
89598155|NCT00181168|No Intervention|Hypothyroid Group|Hypothyroid Group: Thyroid hormone treatment was withheld before radioiodine therapy.
88979559|NCT00308269|Experimental|Vintafolide 3.0 mg IV Infusion|Vintafolide 3.0 mg administered by a 1-hour IV infusion on Days 1, 3, 5, 15, 17, and 19 of 4-week treatment cycles
88979560|NCT00088257||Mother-child pairs|Subset of mother-child pairs enrolled in Project Viva, a cohort study of pregnant women and their offspring. 411 mother-child pairs with measures of lymphocyte proliferation in their cord blood samples make up the subset for this study.
88979561|NCT00308503|Experimental|1|5 mg/day
88979562|NCT00308503|Placebo Comparator|2|
89598156|NCT02151526|Experimental|LentiGlobin BB305 Drug Product|Following myeloablative conditioning with IV busulfan for 4 consecutive days (dose may be adjusted as per protocol) and subsequent daily monitoring of busulfan levels for confirmation of adequate washout, a single dose cluster of differentiation (CD) 34+ cells/kg LentiGlobin BB305 Drug Product was administered to participants by IV infusion.
89598157|NCT00089752|Active Comparator|Active Treatment|Continuous Positive Airway Pressure Treatment
89598158|NCT00089752|Placebo Comparator|Sham/Placebo Treatment|Ineffective sham continuous positive airway pressure device with leak in interface to <1.0 cm H2O and resistance in motor to simulate normal operating noise and no compensation for leak.
89598159|NCT00090844|Experimental|triptorelin|GnRH analogue (triptorelin) during chemotherapy
89598160|NCT00090844|No Intervention|no triptorelin|No GnRH analogue (triptorelin) during chemotherapy
89598161|NCT01897012|Experimental|Treatment (alisertib, romidepsin)|Patients receive alisertib PO BID on days 1-7 (dose levels 1-4) or days 1-3, 8-10, and 15-17 (dose levels 5-8). Patients also receive romidepsin IV over 4 hours on days 1 and 8 (dose levels 1-4) or 2, 9, and 16 (dose levels 5-8). Treatment repeats every 21 days (dose levels 1-4) or 28 days (dose levels 5-8) for up to 8 courses in the absence of disease progression or unacceptable toxicity.
89598162|NCT01948102||subjects with ALS|subjects with ALS who are undergoing a percutaneous endoscopic gastrostomy
89598163|NCT01948102||subjects without ALS|subjects without ALS who are undergoing a percutaneous endoscopic gastrostomy
89598164|NCT01498887|Experimental|Naive or de novo participants|Participants received 0.5 mg FTY720 (fingolimod) orally once daily for 12 months.
89598165|NCT01498887|Experimental|Previously treated with first-line DMTs participants|Participants received 0.5 mg FTY720 (fingolimod) orally once daily for 12 months.
89598166|NCT01498653|Experimental|FF/VI 200/25mcg once daily|ICS/LABA
89598167|NCT01498653|Active Comparator|Fluticasone propionate 500mcg twice daily|ICS
89598168|NCT01498575|Experimental|Teen Driving Plan|Access to web-based driving intervention
89598169|NCT01498575|No Intervention|Usual practice|Use of typical supervised practice driving resources
89598170|NCT01498185|Experimental|Arm 1: Dapagliflozin (1 mg)|
89598171|NCT01498185|Experimental|Arm 2: Dapagliflozin (2.5 mg)|
89598172|NCT01498185|Experimental|Arm 3: Dapagliflozin (5 mg)|
89598173|NCT01498185|Experimental|Arm 4: Dapagliflozin (10 mg)|
89598174|NCT01498185|Experimental|Arm 5: Placebo matching Dapagliflozin|
89598175|NCT01528605|Placebo Comparator|Placebo|starch in hard shell gelatine capsules
89598176|NCT01528605|Experimental|Low lutein|low lutein group
89598177|NCT01528605|Experimental|High lutein|high lutein group
89598178|NCT01528605|Experimental|Low lutein zeaxanthin|lutein plus zeaxanthin group
89598179|NCT01528605|Experimental|High zeaxanthin|zeaxanthin group
89598180|NCT01528605|Experimental|high lutein zeaxanthin|Zeaxanthin plus lutein group
89598181|NCT01528215|Experimental|OsseoSpeed EV|OsseoSpeed EV implants; Ø 3.6, 4.2, 4.8 mm in lengths of 9,11 and 13 mm
89598182|NCT01528215|Active Comparator|OsseoSpeed TX|OsseoSpeed TX implants; Ø 3.5, 4.0 and 5.0 mm in lengths of 9,11 and 13 mm
89598183|NCT01527357|Experimental|Fibrocaps + Gelatin Sponge|Single application of Fibrocaps plus gelatin sponge.
89598184|NCT01527357|Active Comparator|Gelatin Sponge|Single application of gelatin sponge alone.
89598185|NCT00093964|Experimental|Cilengitide 500 Milligram (mg)|
89598186|NCT00093964|Experimental|Cilengitide 2000 mg|
89598187|NCT01526889|Experimental|LFG316 -Intravitreal Injection|
89598188|NCT01526889|Active Comparator|Conventional Therapy|
89598189|NCT00181714|Experimental|OROS MPH|Single arm- open treatment with extended duration methylphenidate (OROS MPH)
89598190|NCT04643626|Experimental|IG|artificial intelligence dietary application, iDSA, will be introduced and installed. Explanation on the function and application of iDSA will be given. Daily energy and macro-nutrients requirement target will bed set. The daily energy and macronutrients requirement target is secured by password. Subjects will record their daily dietary intake (food with cooking method and portion size) and nutrition impact symptoms via smartphone application at least 3 times a week. Subjects able to keep track their intake at home. During follow up session, subjects show the iDSA diet intake summary records to Researcher for further assessment.
89598191|NCT04643626|No Intervention|CG|CG will receive conventional dietitian care includes nutrition care process using conventional 24 hours diet recall method for dietary assessment
89598192|NCT01472835|Experimental|Sedation|Pt will receive sedation with their procedure
89598193|NCT01472835|No Intervention|Control|Patient will not receive sedation during procedure
89598194|NCT00185692|Experimental|Transplantation of CD34+ cells|"Week #1: Total Lymphoid Inrradiation (TLI) 120 cGy + Anti-thymocyte Globulin (ATG) 1.5 mg/kg + Solumedrol 1.0 mg/kg Daily for 5 days.~Week #2: TLI 120 cGy (3 days a week, double on the 4th day) 5 days of CSP (oraly) one day after TLI was started. 3 days of MMF 4 days after TLI was started."
89598195|NCT01526733|Sham Comparator|Insulin (Aspart or Lispro)-Sham|"In Phase I or Phase II of the study, participants received 0.15 units per kilogram (U/kg) insulin (either insulin aspart or insulin lispro) as a continuous subcutaneous insulin infusion (CSII) for 16 days, with sham injections administered prior to outpatient euglycemic clamps on Days 1 and 4 and prior to outpatient meal test procedures on Days 7, 10, 13, and 16.~Each Phase was separated by a washout period of 5 to 21 days."
89598196|NCT01526733|Experimental|Insulin (Aspart or Lispro)-rHuPH20|"In Phase I or Phase II of the study, participants received 0.15 U/kg insulin (either insulin aspart or insulin lispro) as a CSII for 16 days. Prior to outpatient euglycemic clamps on Days 1 and 4 and prior to outpatient meal test procedures on Days 7, 10, 13, and 16, participants received a 1 mL (150 U) injection of recombinant human hyaluronidase (rHuPH20).~Each Phase was separated by a washout period of 5 to 21 days."
89598197|NCT00094900|Experimental|IL-1 Trap|
89598198|NCT00096460|Active Comparator|Autologous Transplant|Cyclophosphamide and Rituximab with Filgrastim conditioning and chemotherapy or radiation therapy prior to autologous Hematopoietic Stem Cell Transplant (HSCT). Rituximab maintenance therapy following HSCT.
89210151|NCT02551328||Propofol|Patients with no preconditioning
89598199|NCT00096460|Active Comparator|Allogeneic Transplant|Non-myeloablative conditioning regimen followed by allogeneic Hematopoietic Stem Cell Transplant (HSCT). Graft-versus-Host Disease (GVHD) Prophylaxis therapy following HSCT.
89598200|NCT00006178|Experimental|Sirolimus and Thymoglobulin|Thymoglobulin (Sangstat), a FDA-approved polyclonal rabbit-IgG antithymocyte preparation, will be given for ten days at the time of transplantation to achieve profound lymphocyte depletion. This will be paired with chronic therapy with Sirolimus (rapamycin, Wyeth-Ayerst), an oral immunosuppressant agent recently approved by the FDA.
89598201|NCT00098956|Experimental|Treatment (topotecan hydrochloride, UCN-01)|Patients receive topotecan IV over 30 minutes on days 1-5 and UCN-01 IV over 3 hours on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients achieving CR or PR receive 2 additional courses beyond CR or PR.
89598202|NCT01472757|Placebo Comparator|Placebo|
89598203|NCT01472757|Active Comparator|Dose 1|
89210152|NCT00982917|Experimental|teachers taught curriculum|Teachers taught Stamp-in-Safety curriculum
89598204|NCT01472757|Active Comparator|Dose 2|
89598205|NCT01472757|Active Comparator|Dose 3|
89598206|NCT02197156|Experimental|10 mg HC-ER|Hydrocodone bitartrate extended release (HC-ER) 10 mg
89598207|NCT02197156|Experimental|20 mg HC-ER|Hydrocodone bitartrate extended release (HC-ER) 20 mg
89598208|NCT02197156|Experimental|30 mg HC-ER|Hydrocodone bitartrate extended release (HC-ER) 30 mg
89598209|NCT02197156|Experimental|40 mg HC-ER|Hydrocodone bitartrate extended release (HC-ER) 40 mg
89598210|NCT02197156|Active Comparator|10 mg HC / 325 mg APAP|10 mg Hydrocodone (HC) / 325 mg acetaminophen (APAP)
89598211|NCT02197156|Placebo Comparator|Placebo|Matching placebo
89598212|NCT00187720|Experimental|OCT2-variant Group|Subjects with OCT2-variant genotype will be given a single oral dose of 850 mg of metformin.
89598213|NCT00187720|Experimental|OCT2-reference Group|Subjects with OCT2-reference genotype will be given a single oral dose of 850 mg of metformin.
89598214|NCT01472289|Experimental|BMMNC treated group|Autologous bone marrow mononuclear cell concentrate (BMMNCs) prepared using the Res-Q 60 technology (a point of care system) to be injected intramuscularly into multiple sites in the ischemic muscle tissue of the affected limb at 0.5 cc/injection for a total of 15-20 cc.
89598215|NCT00006244|Experimental|Treatment (immunotherapy)|Patients receive melphalan IV over 2-3 hours on day -2 and an infusion of IL-2-treated autologous or syngeneic peripheral blood stem cells on day 0. Beginning on day 0, patients also receive IL-2 IV continuously over 5 days followed by 2 days off. Treatment with IL-2 repeats weekly for 4 weeks. Beginning 1 month later, patients undergo maintenance therapy comprising interferon alfa SC 3 times a week in the absence of disease progression or unacceptable toxicity.
89598216|NCT00187876|Active Comparator|ACL reconstruction control|The intervention consists of the reconstruction of the ACL ligament using patellar tendon allografts.
89598217|NCT00187876|Experimental|ACL Biocleanse, surgical|The intervention consists of the surgical reconstruction of the ACL ligament using patellar tendon allografts that have undergone the BioCleanse™ process.
89598218|NCT01525875|Active Comparator|Magnesium oxide|"Part 1: 1000 mg elemental magnesium (given as one 800 mg capsule of magnesium oxide two times daily).~Part 2: 1500 mg elemental magnesium (given as two 500 mg capsules of magnesium oxide in the morning and three 500 mg capsules of magnesium oxide in the evening)."
89598219|NCT01525875|Placebo Comparator|Placebo|Part 1: 1000 mg (one 500 mg capsule two times daily) of placebo.
89598220|NCT01898260|Other|BYO Daily, then MyDay|Ultrafilcon B contact lenses, followed by stenfilcon A contact lenses. Each product worn bilaterally for 1 week in a daily wear, daily disposable modality.
89598221|NCT01898260|Other|MyDay, then BYO Daily|Stenfilcon A contact lenses, followed by ultrafilcon B contact lenses. Each product worn bilaterally for 1 week in a daily wear, daily disposable modality.
89598222|NCT04409379||acute leukemia group|300 patients were recruited, who have diagnosed with acute leukemia by bone marrow biopsy
89598223|NCT04409613|Active Comparator|Clinical pharmacist-provided services+standard care group|that receive clinical pharmacist-provided services at the Warfarin Counseling Clinic plus standard medical care
89598224|NCT04409613|No Intervention|Standard care group|that will receive standard medical care
89598225|NCT01525641||Patient with Parkinson's Disease|
89598226|NCT03026985||Observational cohort|"Ultrasound measurement of quadriceps muscle size and echogenicity will be obtained at baseline (within 48 hours of ECMO commencement), 10 days and 20 days after baseline measurement.~Measures of muscle strength and highest mobility level will be obtained at day 10 and day 20 after baseline measurement in order to determine the relationship between these volitional measures and the ultrasound parameters."
89598227|NCT00006400|Active Comparator|Hydroxyurea|Participants will receive hydroxyurea.
89598228|NCT00006400|Placebo Comparator|Placebo|Participants will receive placebo.
89598229|NCT01496469|Experimental|Febuxostat 80 mg QD|Febuxostat 80 mg, tablets, orally, once daily for up to 6 weeks.
89598230|NCT01496469|Placebo Comparator|Placebo QD|Febuxostat placebo-matching tablets, orally, once daily for up to 6 weeks.
89598231|NCT00189436|Active Comparator|Treatment with Budesonide|Subject is treated with nebulized budesonide 0.5 BID for 3 weeks
89598232|NCT00189436|Active Comparator|Usual care|Subject is treated with usual care as provided by the doctor. Usual care normally consists of treatment with albuterol with or without an oral steroid.
89598233|NCT04091607|Active Comparator|Music Therapy Intervention Group|listen to preferred choice of music during the Lumbar Medial Branch Block procedure.
89598234|NCT04091607|No Intervention|Control Group|No music will be provided but will be provided earbuds. The sound environment will be standard for procedures by closing procedure room door and minimizing extraneous sounds.
89598235|NCT01471353|Experimental|Sorafenib Plus Capecitabine (SorCape)|Sorafenib 200-400 mg PO twice daily on days 1-21 (dose escalation schema) plus Capecitabine 1000 mg/m2 PO twice daily on days 1-14 repeated every 21 days. Single arm study.
89598236|NCT01525407|Experimental|Supportive care (donor statin treatment)|Donors receive atorvastatin calcium PO beginning on day -14 and continuing until the last day of stem cell collection.
89598237|NCT01471197|Experimental|Arm 1: Ipilimumab|
89598238|NCT01471197|Active Comparator|Arm 2: Pemetrexed|
89598239|NCT04408989|Experimental|MB02-SP (Bevacizumab Biosimilar)|Sterile vial 100mg/4ml, single-dose 1mg/kg administered as 90-minute infusion on day 1.
89598240|NCT04408989|Experimental|MB02-DM (Bevacizumab Biosimilar)|Sterile vial 100mg/4ml, single-dose 1mg/kg administered as 90-minute infusion on day 1.
89598241|NCT04408989|Active Comparator|US licenced Avastin®|Sterile vial 100mg/4ml, single-dose 1mg/kg administered as 90-minute infusion on day 1.
89598242|NCT00011986|Active Comparator|Arm I|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Treatment continues every 3 weeks for 8 courses in the absence of disease progression or unacceptable toxicity.
89598243|NCT00011986|Experimental|Arm II|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1 and gemcitabine IV over 30 minutes on days 1 and 8.
89598244|NCT00011986|Experimental|Arm III|Patients receive chemotherapy as in arm I during courses 1-8 and doxorubicin HCl liposome IV over 1 hour on day 1 during courses 1, 3, 5, and 7. Treatment continues as in arm I.
89598245|NCT00011986|Experimental|Arm IV|Patients receive topotecan IV over 30 minutes on days 1-3 and carboplatin IV over 30 minutes on day 3. Treatment continues every 3 weeks for 4 courses. Patients then receive 4 courses of arm I chemotherapy.
88979563|NCT00308776|Experimental|Cholecystokinin|Participants will receive intravenous saline plus cholescystokinin.
89598246|NCT00011986|Experimental|Arm V|Patients receive gemcitabine IV over 30 minutes on days 1 and 8 and carboplatin IV over 30 minutes on day 8. Treatment continues every 3 weeks for 4 courses. Patients then receive 4 courses of arm I chemotherapy. Patients with initial unresectable or suboptimal residual disease (more than 1 cm) may undergo interval cytoreductive surgery between courses 4 and 5 of chemotherapy.
89598247|NCT01898416|Experimental|5-AminoLevulinicc Acid|consists of 60mg/kg 5-ALA prepared solution given orally, 3-5 hours before induction of anesthesia and surgical tumor resection. Red light laser given by a Dye laser system, wave length of 635nm, in s dose of 150J/cm for 2000 seconds (33 minutes) will be given to tumor bed. In the case of positive margins (for tumor presence), a second surgical intervention followed by second 60mg/kg 5-ALA administration will be performed.
89598248|NCT01524783|Experimental|Everolimus + BSC|Participants received everolimus 10 mg once daily plus best supportive care (BSC) throughout the study
89598249|NCT01524783|Placebo Comparator|Placebo + BSC|Participants received matching placebo once daily plus best supportive care (BSC) during the blinded period. Participants were allowed to crossover to treatment with everolimus 10mg once daily plus BSC during the open-label period.
89598250|NCT01494987|Experimental|Ranolazine+glimepiride|"Glimepiride stabilization period (up to 8 weeks): participants not on stable glimepiride will receive glimepiride 2 mg once daily, and if tolerated the dose will be increased on Day 8 (+ 2 days) to 4 mg once daily.~Qualifying period: participants will receive placebo to match ranolazine twice daily in addition to glimepiride for 14 days (+ 2 days) and if ≥ 80% compliant and meeting eligibility criteria will continue to the treatment period.~Treatment period: participants will be randomized to receive ranolazine 500 mg twice daily plus glimepiride 4 mg once daily on Days 1 through 7, followed by ranolazine 1000 mg twice daily plus glimepiride 4 mg once daily from Day 8 (or by Day 16 if not well tolerated) through Week 24.~Participants will be required to maintain their diet and exercise regimen."
89598251|NCT01494987|Placebo Comparator|Placebo+glimepiride|"Glimepiride stabilization period (up to 8 weeks): participants not on stable glimepiride will receive glimepiride 2 mg once daily, and if tolerated the dose will be increased on Day 8 (+ 2 days) to 4 mg once daily.~Qualifying period: participants will receive placebo to match ranolazine twice daily in addition to glimepiride for 14 days (+ 2 days) and if ≥ 80% compliant and meeting eligibility criteria will continue to the treatment period.~Treatment period: participants will be randomized to receive placebo to match ranolazine plus glimepiride 4 mg once daily for 24 weeks.~Participants will be required to maintain their diet and exercise regimen."
89598252|NCT04409769||Description of use of ceftaroline and ceftobiprole|description of patients and their PJI/BJI,conditions of use, adverse event
89598253|NCT01524627|Placebo Comparator|Control Group|Placebo will be prescribed to non-abstinent smokers at the same doses as have been demonstrated to be clinically effective for Varenicline: 0.5 mg twice a day for 3 days and then 1mg twice daily for the remainder of the treatment course of 8 weeks.
89598254|NCT01524627|Active Comparator|Varenicline|Varenicline will be prescribed to non-abstinent smokers at the same doses as have been demonstrated to be clinically effective: 0.5 mg twice a day for 3 days and then 1mg twice daily for the remainder of the treatment course of 8 weeks.
89598255|NCT01469637|Experimental|Sulfamethoxazole + MMX placebo|
89598256|NCT01469637|Experimental|Sulfamethoxazole + MMX Mesalazine/mesalamine|
89598257|NCT04748367|Experimental|Intervention group|Children wear VR headset during immunisation
89598258|NCT04748367|No Intervention|Control group|Children did not wear VR headset during immunisation( usual care)
89598259|NCT00012298|Experimental|Treatment (radiolabeled monoclonal antibody therapy)|Patients receive rituximab IV on days 1 and 8, indium In 111 ibritumomab tiuxetan IV over 10 minutes on day 1, and yttrium Y 90 ibritumomab tiuxetan (IDEC-90Y2B8) IV over 10 minutes on day 8. Patients also receive filgrastim (G-CSF) subcutaneously (SC) and interleukin-11 SC until blood counts recover.
89598260|NCT00193258|Experimental|Intervention|"In the phase I portion:~Bevacizumab 10 mg/kg slow IV infusion on days 1 and 15 of each 28-day course~Erlotinib 150 mg orally daily~Imatinib 300 mg orally daily or 400 mg orally daily~In the phase II portion:~Bevacizumab 10 mg/kg 30-60 minute IV infusion on days 1 and 15 of every 28 day cycle~Erlotinib 150 mg orally daily~Imatinib 400 mg orally daily"
89598261|NCT00029536|Experimental|Catamenial Epilepsy: Progesterone Lozenges|Subjects with catamenial epilepsy received 200 mg progesterone lozenges
89598262|NCT00029536|Placebo Comparator|Catamenial Epilepsy: Placebo Lozenges|Subjects with catamenial epilepsy received matched placebo lozenges
89598263|NCT00029536|Experimental|Noncatamenial Epilespy:Progesterone Lozenges|Subjects without catamenial epilepsy received 200 mg progesterone lozenges
89598264|NCT00029536|Placebo Comparator|Noncatamenial Epilespy: Placebo Lozenges|Subjects without catamenial epilepsy received matched placebo lozenges
89598265|NCT00193492|Active Comparator|Rituximab|All patients will receive rituximab 375mg/m2 administered by slow IV infusion weekly for 4 consecutive weeks (days 1, 8, 15, and 22). Patients who have objective response or stable disease at week 12 reevaluation will receive 4 additional doses of rituximab (375 mg/m2) administered in months 3 (week 12), 5, 7, and 9.
89598266|NCT00193492|Experimental|Rituximab/Bevacizumab|All patients will receive rituximab 375mg/m2 administered by slow IV infusion weekly for 4 consecutive weeks (days 1, 8, 15, and 22). During the 4-week course of rituximab, all patients will receive 2 doses of bevacizumab 10mg/kg IV, given on Days 3 and 15. The first dose will be given on Day 3, following rituximab on Day 1. If both drugs are well tolerated during the first dose, rituximab and bevacizumab should be given on the same day for the Day 15 dose and all subsequent doses.
89598267|NCT00194116|Experimental|Divalproex Sodium ER|
89598268|NCT00194116|Placebo Comparator|Placebo|
89598269|NCT02096458|Experimental|Dexlansoprazole 30 mg|Dexlansoprazole 30 mg delayed-release orally disintegrating tablets at Assessment 1 Day 1, Assessment 2 Day 1, and Assessment 3 Day 1.
89598270|NCT02096692||ICD System Therapy|Patients with a ProMRI ICD System
89598271|NCT00194896|Active Comparator|rosiglitazone|Rosiglitazone is an oral antidiabetic agent which acts primarily by increasing insulin sensitivity. The rosiglitazone treatment group commenced therapy with 4 mg once per day and increase to twice per day if adequate glycemic control was not achieved.
89598272|NCT00194896|Active Comparator|glyburide|Glyburide is a sulfonylurea. Glyburide therapy was initiated with 2.5 mg in the morning or the patient was maintained on the dose they had been receiving prior to starting the study. This starting dose was raised by 2.5 in the evening and further up to a maximum of 10 mg twice a day if necessary to achieve desired glycemic control.
89598273|NCT00197392|Experimental|Bactiseal TM EVD|Bactiseal External Ventricular Drainage System.
89598274|NCT00197392|Active Comparator|Standard EVD Catheter|Standard External Ventricular Device system
89598275|NCT04348474|Experimental|HCQ + AZT|All patients included in the study will receive hydroxychloroquine (HCQ) 400 mg (00 mg BID on D1 and 400 mg/day on D2 to D7) and azithromycin (AZT) (500 mg/ 5 days) on top of standard care.
88979564|NCT00308776|Placebo Comparator|Saline|Participants will receive intravenous saline only.
88979565|NCT00308854|Active Comparator|1|PD P 506 A-PDT
88979566|NCT00308854|Placebo Comparator|2|Placebo-PDT
88979567|NCT00308893|Experimental|Escitalopram|Treatment response after 3 and 6 weeks
88979568|NCT00308971|Active Comparator|1|
88979569|NCT00308971|Placebo Comparator|2|
89598276|NCT04318834|Experimental|Individuals with advanced biliary tract cancer|Following a tumour biopsy for molecular profiling, chemo-naive patients with advanced biliary tract cancer will receive first-line gemcitabine-based chemotherapy or an investigational drug on a participating clinical trial.
89598277|NCT04290286|Experimental|intervention group|TGD people (n = 82) receive 4 months of e-health intervention according to the i2TransHealth model of care (intervention group)
89598278|NCT04290286|No Intervention|waiting group|TGD people (n = 82) wait 4 months until they are offered regular care (waiting group), which can include video consultation
89598279|NCT00107536|Experimental|Arm I|Patients receive oral lapatinib ditosylate once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89598280|NCT04389190|Active Comparator|Standard Protocol|This is the fluoroscopy protocol used routinely in most catheterization labs in the region. This includes fluoroscopy and cine image acquisition at 15 frames per second (FPS) at 8-inch mode. Virtual collimation and last image hold (LIH) will be used as needed. This protocol will be implemented for 6 weeks.
89598281|NCT04389190|Experimental|Low frame rate protocol|This will have fluoroscopy and cine image acquisition at 7.5 FPS at 8-inch mode with all other settings on factory default. Virtual collimation and LIH will be used as needed. This protocol will be implemented for 6 weeks as well.
89598282|NCT04389190|Experimental|Customized Protocol|This will have varying settings based on three weight based groups. Small (<60 kg), medium (60-85 kg), large (>85 kg). The variables changed are fluoroscopy dose per frame, fluoroscopy frame rate, image acquisition frame rate, thickness of the spectral beam filters, peak tube voltage and peak cathode current. Additional features will also be utilized including live zoom (1.4 factors with 12 inch field of view, FOV), fluoro store and Spot fluoroscopy. Virtual collimation and LIH will be used as needed. This protocol will be applied for 12 weeks.
89598283|NCT00108550|Experimental|1|Gabapentin 300 mg orally three times daily up to a maximum of 1200 mg orally three times daily for 12 weeks
89598284|NCT00108550|Sham Comparator|2|Inert placebo capsules identical in size and shape to the experimental capsules, one to three capsules taken orally three times daily for 12 weeks
89598285|NCT00109876|Experimental|Treatment (RFA therapy)|A radiofrequency electrode is placed by CT guidance into the target tumor. Patients undergo RFA directly to the tumor for up to 12 minutes to obtain an intratumoral temperature > 60° C. Patients may receive 3 RFA treatments (a total of 36 minutes) to obtain the target temperature.
89598286|NCT02093962|Experimental|TH-302 and pemetrexed|TH-302 in combination with pemetrexed
89598287|NCT02093962|Active Comparator|Placebo and pemetrexed|Matching placebo in combination with pemetrexed
89598288|NCT02094118|Active Comparator|Standard of care red blood cell transfusion|Red blood cells that are administered in the normal fashion.
89598289|NCT02094118|Experimental|Point-of-Care washed red blood cell transfusion|Red blood cells that are washed at the point-of-care.
89598290|NCT01897636|Experimental|EUS-guided fine-needle injection of DCs vaccinations|
89598291|NCT00200902|Active Comparator|MED|"For medication treatment, three different types were utilized and assigned specifically to each subject depending on their condition:~MED 1: Venlafaxine XR. MED 2: Duloxetine (Cymbalta) MED 3: Escitalopram (Lexapro)"
89598292|NCT00200902|Placebo Comparator|Placebo (PBO)|Subjects enrolled will receive interpersonal clinical interaction (ICI) along with a placebo treatment (Interaction and assessment as in ICI plus double blinded treatment with placebo tablets).
89598293|NCT00200902|Other|Interpersonal Clinical Interaction (ICI)|Subjects assigned to the interpersonal clinical interaction (ICI) will undergo a one-week waiting period after the initial assessment. Visits will involve a session with a research nurse that will be approximately 20 minutes in length; visits at baseline, end of lead-in, and 1, 2, 4, and 8 weeks also will include a brief (5-10 minutes) meeting with a physician.
89598294|NCT00201448|Active Comparator|Placebo (hepatitis A)|Placebo group
89598295|NCT00201448|Experimental|Towne vaccine|Towne vaccine given at 3000 pfu/subject
89598296|NCT00201760|Experimental|Arm 1 Gemcitabine/Cisplatin/Trastuzumab|Gemcitabine 1000 mg/m2 iv over 30 minutes on days 1 and 8 Cisplatin 30 mg/m2 iv over 90 minutes on days 1 and 8 Trastuzumab 2 mg/kg iv over 30 minutes on days 1, 8 and 15 (if trastuzumab was not administered within the past 3 weeks, a loading dose of 4 mg/kg iv over 90 minutes will be given on the first day of cycle 1 only).
88979570|NCT00309049|Active Comparator|A1|
88979571|NCT00309049|Active Comparator|A2|
88979572|NCT00309049|Active Comparator|A3|
88979573|NCT00309088|Experimental|1|
88979574|NCT00309088|Placebo Comparator|2|
88979575|NCT00309283|Experimental|somatostatin|
88979576|NCT00309283|Placebo Comparator|Saline solution|
88979577|NCT04727502|Active Comparator|( Group Duloxetine )|• Dosing and administration (Group A) Duloxetine 30 mg /day oral intake at bed time
88979578|NCT04727502|Active Comparator|(Group Pregablin )|control group Pregablin 150mg /day( 75 mg /12 hours ) oral intake.
89598297|NCT00201760|Active Comparator|Arm 2 Gemcitabine / Trastuzumab|Gemcitabine 1000 mg/m2 iv over 30 minutes on days 1 and 8 Trastuzumab 2 mg/kg iv over 30 minutes on days 1, 8 and 15 (if trastuzumab was not administered within the past 3 weeks, a loading dose of 4 mg/kg iv over 90 minutes will be given on the first day of cycle 1 only).
89598298|NCT00201838|Experimental|Arm I|Patients received entanercept 25 mg subcutaneously twice weekly with gemcitabine.
89598299|NCT00201838|Active Comparator|Arm II|Patients with pancreatic cancer for which treatment with gemcitabine as a single agent is planned will be asked to participate in this trial as a control group.
89598300|NCT00040846|Experimental|Treatment (dose-escalation of alemtuzumab, HSCT)|"CONDITIONING REGIMEN: Patients receive alemtuzumab IV over 2 hours on days -8 to -5 and fludarabine phosphate IV on days -4 to -2. Patients also undergo low-dose TBI on day 0.~HSCT: Patients undergo allogeneic peripheral blood stem cell transplantation on day 0.~IMMUNOSUPPRESSION: Patients receive CSP IV or PO BID on days -3 to 180 with taper to day 365 and MMF PO TID on days 0-100, with taper to day 156."
89598301|NCT00041938|Active Comparator|aspirin|Aspirin: 325 mg per day
89598302|NCT00041938|Active Comparator|warfarin|Warfarin: International Normalized Ratio (INR) 2.5-3.0; target INR 2.75
89598303|NCT00202930|Other|Rituximab|Single Arm
89598304|NCT00044044|Experimental|Lurasidone 20 mg|Lurasidone 20 mg tablets
89598305|NCT00044044|Experimental|Lurasidone 40 mg|Lurasidone 40 mg tablets
89031865|NCT02949713|Experimental|Text messaging-motivational interviewing|Every Monday morning, a text message (SMS) will be sent to participants in the intervention group encouraging participants to continue breastfeeding, and inquire if participants have any problems breastfeeding their infants. Participants will be asked to respond within 48 hours, indicating that they either do not have a problem or they have a problem and require help. In addition to text messaging, participants will have motivational interviews post-delivery at weeks 2, 6, and 10. Motivational interviews will explore and support the participant's commitment to continue breastfeeding.
89598306|NCT00044044|Experimental|Lurasidone 80 mg|Lurasidone 2 40 mg tablets
89598307|NCT00044044|Active Comparator|Haloperidol 10mg|Haloperidol 10mg tablets
89598308|NCT00044044|Placebo Comparator|Placebo|Matching Placebo to Lurasidone and Haloperidol
89598309|NCT00112918|Active Comparator|FOLFOX4|"Weeks 1-24: Oxaliplatin was administered as an 85 mg/m^2 intravenous infusion over 2 hours concomitantly with leucovorin as a 200 mg/m^2 infusion over 2 hours, followed by 5-FU, given as a 400 mg/m^2 bolus injection, and then as a 600 mg/m^2 continuous infusion over 22 hours. Leucovorin 200 mg/m^2 (alone), followed by 5-FU 400 mg/m^2 bolus injection, and 5-FU 600 mg/m^2 continuous infusion were repeated on day 2. Cycle length was 2 weeks and cycles were repeated every second week for a total of 12 cycles (24 weeks).~Weeks 25-48: Observation only."
89598310|NCT00112918|Experimental|FOLFOX4 + Bv|"Weeks 1-24: Bevacizumab 5 mg/kg was administered as an intravenous infusion over 30 - 90 minutes followed by oxaliplatin, administered as an 85 mg/m^2 intravenous infusion over 2 hours (on day 1 only) concomitantly with leucovorin, as a 200 mg/m^2 infusion over 2 hours, followed by 5-FU, given as a 400 mg/m^2 bolus injection, and then as a 600 mg/m^2 continuous infusion over 22 hours. Leucovorin 200 mg/m^2 (alone), followed by 5-FU 400 mg/m^2 bolus injection, and 5-FU 600 mg/m^2 continuous infusion are repeated on day 2. Cycle length is 2 weeks and cycles were repeated every second week for a total of 12 cycles (24 weeks).~Weeks 25-48: Bevacizumab 7.5 mg/kg was administered as an intravenous infusion over 30 minutes. Cycle length was 3 weeks. Cycles were repeated every 3 weeks for a total of 8 cycles (24 weeks)."
89598311|NCT00112918|Experimental|XELOX+Bv|"Weeks 1-24: Bevacizumab 7.5 mg/kg was administered as an intravenous infusion over 30 - 90 minutes followed by oxaliplatin administered as a 130 mg/m^2 intravenous infusion over 2 hours (day 1 every 3 weeks) in combination with capecitabine, which was administered orally at a dose of 1000 mg/m^2 twice daily (equivalent to a total daily dose of 2000 mg/m^2), with first dose the evening of day 1 and last dose the morning of day 15, given as intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment), for a total of 8 cycles (24 weeks).~Weeks 25-48: Bevacizumab 7.5 mg/kg was administered as an intravenous infusion over 30 minutes. Cycle length was 3 weeks. Cycles were repeated every 3 weeks for a total of 8 cycles (24 weeks)."
89598312|NCT00046228|Experimental|001|Abciximab; reteplase; abciximab placebo; abciximab 0.25 mg/kg bolus; 1-2, 5 unit boluses; placebo bolus; 0.125 ¼g/kg/min, max 10 ¼g/min infusion x 12h
89598313|NCT00046228|Experimental|002|abciximab; reteplase placebo; abciximab placebo; abciximab 0.25 mg/kg bolus; 1-2 placebo boluses; placebo bolus; 0.125 ¼g/kg/min, max 10 ¼g/min infusion x 12h
89598314|NCT00046228|Experimental|003|abciximab placebo; reteplase placebo, abciximab, abciximab placebo bolus; 1-2 placebo bolus; 0.25 mg/kg bolus; 0.125 ¼g/kg/min, max 10 ¼g/min infusion x 12h
89598315|NCT00205504|Active Comparator|Obese women with metabolic syndrome|
89598316|NCT00205504|Active Comparator|Obese women without metabolic syndrome|
89598317|NCT00205504|Active Comparator|lean women without metabolic syndrome|
89598318|NCT00205660|Other|Stayers|Subjects are randomized to stay on their current antipsychotic.
89598319|NCT00205660|Other|Switchers|Subjects are randomized to switch to aripiprazole from their current antipsychotic.
89598320|NCT00113230|Experimental|Avastin|Capecitabine, Avastin (RHUMAB VEGF/Bevacizumab) And Radiotherapy
89598321|NCT00049036|Experimental|Arm I|Patients receive rituximab intravenously (IV) over 2-4 hours prior to each course of chemotherapy. Treatment repeats every 3 weeks for 4-6 courses. Patients who achieve a complete response after 4 courses of chemotherapy and rituximab receive additional rituximab alone weekly for 2 weeks.
89598322|NCT00049036|Experimental|Arm II|Patients do not receive rituximab concurrently with chemotherapy. Beginning 4 weeks after completion of chemotherapy, patients receive rituximab IV over 2-4 hours weekly for 6 weeks.
89598323|NCT00212446|Experimental|Electrical Intervention|Electrical intervention (EI) is bipolar, constant-current (1-20 mA), square-wave pulses in 20% duty cycles. Women in preterm labor have an electrode placed vaginally; tocodynamometric contraction timing and fetal heart rate are monitored continuously. Successive 20-minute periods include pre-control period (C1); the EI period, in which a 10-second current burst is delivered at expected contraction times; and a post-EI control period (C2).
89598324|NCT00049504|Experimental|Treatment (nonmyeloablative HSCT)|"NONMYELOABLATIVE CONDITIONING: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 1 hour on days -6 and -5. Patients undergo total body irradiation on day -1.~TRANSPLANTATION: Patients undergo BMT, from an HLA-haploidentical donor, on day 0.~POST-TRANSPLANT IMMUNOSUPPRESSION: Patients receive cyclophosphamide IV over 1 hour on day 3.~GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS: Patients receive tacrolimus IV over 1-2 hours and then tacrolimus PO, once tolerated, on days 4-180, with taper on day 86 in the absence of graft-versus-host disease. Patients also receive mycophenolate mofetil PO three times daily on days 4-35."
89598325|NCT00050986|Experimental|Temozolomide and R115777|
89598326|NCT00214786|Experimental|Islet Cell Transplantation|Allogenic islet cell transplantation
89598327|NCT00118144|Experimental|Arm I|Patients receive bortezomib IV over 3-5 seconds on days 1 and 8.
89598328|NCT00118378|Experimental|Modafinil|Participants will take modafinil for 4 weeks.
89598329|NCT00118378|Placebo Comparator|Placebo|Participants will take placebo for 4 weeks.
89210153|NCT00982917|Experimental|teachers do not learn curriculum|Teachers are not taught Stamp-in-Safety curriculum
89210154|NCT00901914|Placebo Comparator|1|Placebo
89210155|NCT00901914|Experimental|2|12.5 µg rBet v 1
89210156|NCT00901914|Experimental|3|25 µg rBet v 1
89210157|NCT00901914|Experimental|4|50 µg rBet v 1
89210158|NCT00815906|Experimental|SBI-087 0.15 mg IV|
89598330|NCT00217438|Experimental|Arm I (high dose melphalan, amifostine trihydrate, transplant)|"INDUCTION THERAPY:~Patients receive amifostine IV over 3-5 minutes on days -3 and -2 followed by high-dose melphalan IV over 15-30 minutes on day 2.~AUTOLOGOUS OR SYNGENEIC PBSCT: At least 20 hours after completion of melphalan, patients undergo autologous or syngeneic PBSCT on day 0.~Patients undergo restaging of the disease between days 80-90. Patients with progressive disease are removed from the study. Patients who achieve a CR or near-CR can proceed to optional maintenance therapy. Patients who do not achieve a CR or near-CR may undergo additional induction therapy as in arm I followed by a second autologous or syngeneic PBSCT.~Patients again undergo restaging of the disease 80-90 days later. Patients with progressive disease are removed from the study. Patients without progressive disease can proceed to maintenance therapy."
89598331|NCT00217438|Active Comparator|Arm II (low dose melphalan, amifostine trihydrate, transplant)|"INDUCTION THERAPY:~Patients receive amifostine as in arm I and melphalan as in arm I at a lower dose.~AUTOLOGOUS OR SYNGENEIC PBSCT: At least 20 hours after completion of melphalan, patients undergo autologous or syngeneic PBSCT on day 0.~Patients undergo restaging of the disease between days 80-90. Patients with progressive disease are removed from the study. Patients who achieve a CR or near-CR can proceed to optional maintenance therapy. Patients who do not achieve a CR or near-CR may undergo additional induction therapy as in arm I followed by a second autologous or syngeneic PBSCT.~Patients again undergo restaging of the disease 80-90 days later. Patients with progressive disease are removed from the study. Patients without progressive disease can proceed to maintenance therapy."
89598332|NCT04480450|Active Comparator|IVIg/SCIg < 3 Years Arm|Patients with CIDP successfully treated with IVIg/SCIg for under 12 months. Subjects will receive an intravenous infusion of 1,000mg Rituximab at Week 0 and Week 2.
89598333|NCT04480450|Active Comparator|IVIg/SCIg > 3 Years Arm|Patients with CIDP successfully treated with IVIg/SCIg for more than 12 months. Subjects will receive an intravenous infusion of 1,000mg Rituximab at Week 0 and Week 2.
89598334|NCT00217594|Experimental|Alemtuzumab|Patients received a 1-mg test dose of alemtuzumab, and the following day, alemtuzumab was administered at 10 mg/dose intravenously for 10 days
89598335|NCT00118534|Experimental|Arm 1|Integration of smoking cessation therapy with PTSD therapy.
89598336|NCT00118534|Active Comparator|Arm 2|Per standard of care, patients are referred to a smoking cessation clinic for their smoking cessation therapy.
89598337|NCT00052078|Active Comparator|Sertraline|Participants received sertraline for 12 weeks.
89598338|NCT00052078|Active Comparator|CBT|Participants received cognitive behavioral therapy for 12 weeks
89598339|NCT00052078|Active Comparator|SRT + CBT|Participants received both sertraline and CBT for 12 weeks.
89598340|NCT00052078|Placebo Comparator|Placebo|Participants received a placebo pill for 12 weeks.
89598341|NCT05820607||Type A atrophic gastritis|Gastroscopy and histopathology showed no significant atrophy of antrum mucosa, but significant atrophy of the body or fundus mucosa, accompanied by positive blood and/or gastric fluid anti-parietal cell antibodies and/or anti-internal factor antibodies.
89598342|NCT05820607||Type B atrophic gastritis|Gastroscopy and histopathological examination showed multifocal atrophy of gastric mucosa, mainly antrum involved.
89598343|NCT05820607||Chronic non-atrophic gastritis|Gastroscopy and histopathology showed chronic inflammation of gastric mucosa with infiltration of lymphocytes and plasma cells, and no intrinsic glandular reduction.
89598344|NCT05820542||Group M (n=42), Miller laryngoscope|The effect of direct epiglottis lifting method on the percentage of glottic patency in Miller and McGraht laryngoscopy.
89598345|NCT05820542||Group V (n= 43), McGrath MAC videolaryngoscope|The effect of direct epiglottis lifting method on the percentage of glottic patency in Miller and McGraht laryngoscopy.
89598346|NCT05820529|Other|Effect of Adenotonsillectomy in velopharyngeal valve mechanism|We do adenotonsillectomy and show its effect in velopharyngeal valve
89598347|NCT05820529|Other|Effect of Adenoidectomy in velopharyngeal valve mechanism|We do adenoidectomy and show its effect in velopharyngeal valve
89598348|NCT05820529|Other|Effect of tonsillectomy in velopharyngeal valve mechanism|We do tonsillectomy and show its effect in velopharyngeal valve
89598349|NCT05820438|Experimental|Patients requiring orthopedic treatment with Rapid Maxillary Expander|Patients will be treated with Rapid Maxillary Expander with two bands on the upper first permanent molars or upper second primary molars (depending on the eruptive stage of the patient). The screw will be activated according to clinitian's indication until a transverse overcorrection of 2 mm is achieved in the first permanent molars. When the active disjunction phase is completed, the screw will be blocked out with a metal legature and the patient will wear the cemented RME for retentions at least for six months.
89598350|NCT05820399|Experimental|Organic Guayusa Extract + High Intensity Exercise|Participants will consume an organic guayusa extract supplement that contains caffeine and antioxidants each day for 6 weeks while completing the exercise training program on 3 days/week. On days that participants exercise, they will consume the supplement 30-60 minutes before exercise training. On days they do not exercise, they will consume the capsules upon waking.
89598351|NCT05820399|Placebo Comparator|Placebo + High Intensity Exercise|Participants will consume a placebo consisting of maltodextrin each day for 6 weeks while completing the exercise training program. The placebo will be provided in capsule identical in appearance to the active supplement. On days that participants exercise, they will consume the placebo 30-60 minutes before exercise training. On days they do not exercise, they will consume the capsules upon waking.
89598352|NCT05820386|Experimental|Skin-to-skin contact during the transfer between the delivery room and the neonatal care unit|Preterm infants will be transferred using a direct skin-to-skin contact with their father from the delivery room to the intensive neonatal care.
89598353|NCT05820386|Active Comparator|Transfer in incubator between the delivery room and the neonatal care unit|Preterm infants will be transferred in an incubator set to 36°C from the delivery room to the intensive neonatal care.
89598354|NCT05820373|Experimental|Intervention group|Women being allocated to the intervention group will attend a 12-week, bi-weekly, specially designed yoga therapy course.
89598355|NCT05820373|Active Comparator|Active control group|Women being allocated to the active control group will attend a 12-week, weekly, relaxation course.
89598356|NCT05820373|Placebo Comparator|Passive control group|The passive control intervention will be the standard post-operative exercises which are currently introduced to women following surgery, for all women allocated to the control group.
89210159|NCT00815906|Experimental|SBI-087 0.5 mg IV|
89598357|NCT05820282|Active Comparator|Control|Participants in the control condition are presented with a table with two columns containing the same situations and solutions that participants in the experimental group see. Each situation and solution has a radio button (i.e. a tick box) next to it; participants in the control condition are asked to identify situations and solutions and place a tick next to each one they think would be useful to them. Therefore, participants in the control condition are not asked to form implementation intentions.
89031866|NCT02949713|No Intervention|Usual standard of care|Usual standard of care
89598358|NCT05820282|Experimental|Intervention (volitional help sheet)|Participants in the experimental condition are presented with a table with two columns and nine rows. Nine situations (barriers to delivering behaviour change interventions) are presented in the left hand column and nine solutions (or appropriate responses; processes of change) are presented in the right hand column (as separate drop down menus). Participants in this condition are asked to form implementation intentions by linking critical situations with appropriate responses by choosing an appropriate response from the drop down menu for each critical situation. Participants are told they can make as many situation-solution links as they wanted.
89598359|NCT05820165||CVOD-WS|Cerebral Venous Outflow Disturbance with symptoms such as tinnitus cerebri，somnipathy ，anxiety ，depression and cognitive decline
89598360|NCT05820165||CVOD-WOS|Cerebral Venous Outflow Disturbance without symptoms such as tinnitus cerebri，somnipathy ，anxiety ，depression and cognitive decline
89598361|NCT05820165||HC|Healthy control
89598362|NCT05820113|Experimental|Deep learning based reconstruction of T2-TSE sequence|Participants undergo multiparametric MRI of the prostate with inclusion of standard cartesian T2-TSE and non-cartesian T2-weighted sequences, as well as a newly developed deep learning enhanced T2-TSE sequence. All patients in this study undergo the same imaging protocol.
89598363|NCT05820074||Young, healthy control|"Young healthy participants below 45 years will take part in a gait protocol involving treadmill walking with pertubations and overground walking including obstacle stepping, figure-8-walk and timed-up-and-go test, as well as a seated-stepping section.~During the protocol, neural activity is recorded using EEG."
89031867|NCT00518219|Experimental|immunosuppressor|TW 120mg/d，Valsartan,160mg/d
89031868|NCT04694729|Experimental|study group|Videoconference-based
89598364|NCT05820074||Age-matched healthy control|"Age-matched healthy participants above 45 years will take part in a gait protocol involving treadmill walking with pertubations and overground walking including obstacle stepping, figure-8-walk and timed-up-and-go test, as well as a seated-stepping section.~During the protocol, neural activity is recorded using EEG."
89598365|NCT05820074||Parkinson's patients|"Parkinson's patients will take part in a gait protocol involving treadmill walking with pertubations and overground walking including obstacle stepping, figure-8-walk and timed-up-and-go test, as well as a seated-stepping section. Additionally, a neuromodulation set-up will be tested.~During the protocol, neural activity is recorded using EEG and signals from the DBS-electrodes."
89598366|NCT05820048|Active Comparator|proton pump inhibitor|"medication : Lanston~capacity : 15mg~Number of times : QD~period : 6 month~Injection path : oral"
89598367|NCT05820048|No Intervention|non-administered army|No Intervention
89598368|NCT05819996|Other|Martinsville Residents|Residents of Martinsville, Indiana, will receive educational campaign promoting participation in environmental testing
89598369|NCT05819983|Active Comparator|Oral ivermectin 3 dosages and placebo|"Twenty patients will be administered randomly oral ivermectin 200µg/kg BW on days 1, 2, and 8 and also placebo cream on days 1 and 8~Placebo cream: Cream base"
89598370|NCT05819983|Active Comparator|Oral ivermectin 2 dosages and placebo|"Twenty patients will be administered randomly oral ivermectin 200µg/kg BW on days 1 and 8 and also oral placebo on day 2, placebo cream on days 1 and 8~Placebo cream: Cream base"
89031869|NCT04694729|Experimental|control group|Video-based
89031870|NCT05318742|Active Comparator|Fewer Laser Spots|Group A patients underwent endolaser PRP with a range of 200-300 shots during PPV
89031871|NCT05318742|Active Comparator|Higher Laser Spots|Group B patients underwent endolaser PRP with a range of 500-600 shots during PPV
89031872|NCT02949869|Experimental|Infant Lumbar Punctures|Infants will all be assigned to received two sets of skin markings and sonography exam to assess lumbar puncture landmarks and anatomy.
89031873|NCT00518258||1|Patient Group
89031874|NCT00518258||2|Control Group
89031875|NCT02940990|Placebo Comparator|Group A|Participants in the Group A will receive 4-6 cycles of standard two-drug chemotherapy. After that, clinical observation or maintenance chemotherapy will be given.
89031876|NCT02940990|Experimental|Group B|Participants in the Group B will also receive 4-6 cycles of standard two-drug chemotherapy. However, they will receive an additional treatment of SBRT to primary lesions or metastatic lesions combined with GM-CSF.
89031877|NCT00518297|Active Comparator|1|
89031878|NCT00518297|Active Comparator|2|
89031879|NCT00518297|Active Comparator|3|
89031880|NCT00518414|Active Comparator|Marketed infant formula with DHA and ARA|Marketed milk-based infant formula containing docosahexaenoic acid (DHA) and arachidonic acid (ARA)
89031881|NCT00518414|Experimental|Milk-based infant formula with DHA and ARA|Experimental milk-based infant formula containing docosahexaenoic acid (DHA) and arachidonic acid (ARA)
89031882|NCT00518414|Experimental|Milk-based formula with DHA, ARA, prebiotics|Experimental milk-based infant formula containing docosahexaenoic acid (DHA) and arachidonic acid (ARA) and prebiotic blend
89210160|NCT00815906|Experimental|SBI-087 100 mg SC|
89210161|NCT00815906|Experimental|SBI-087 200 mg SC|
89598371|NCT05819983|Active Comparator|Permethrin 5% cream 2 applications and placebo|"Twenty patients will be administered randomly permethrin 5% cream on days 1 and 8 and also oral placebo on days 1, 2, and 8~Placebo: vitamin B complex"
89598372|NCT05819970|Experimental|Allium sativum oil (Experimental-Group A)|Premade Allium sativum oil (Garlic oil) (Mohammad and Baroudi, 2015b) will be used in this research (SAC group of companies-9001:2015 certified; Registration # PAK17.1724-U; NTN # 0299739-8, Karachi, Pakistan
89598373|NCT05819970|Experimental|Turmeric gel (Experimental-Group B)|Turmeric gel will be self-prepared at the Institute of Microbiology and Molecular Genetics, Punjab University, Lahore. 2kgs of Turmeric rhizomes were purchased from a local market in Lahore and verified by a taxonomist, Botany Department, Government College University, Lahore (voucher number: GC.Herb.Bot.3693). Approximately 170g powder along with 550ml distilled water will be taken in a Soxhlet extractor for 96 hours and then filtered repeatedly through Whatman No.1 filter paper. The obtained filtrate will then be mixed with 6% Sodium Carboxy-Methyl Cellulose (NaCMC) (Genevex Chem, Hyderabad, India) to form gel. Four Vitamin C grounded tablets (Wilson's Vitamin C, Wilson's Healthcare, Islamabad, Pakistan) and twelve Vitamin E capsules (Evion, Martin Dow pharmaceuticals, Ltd. Karachi, Pak) will then be added in 100g of gel as antioxidants.
89598374|NCT05819736||Rivaroxaban|Cancer patients treated with rivaroxaban
89598375|NCT05819736||Apixaban|Cancer patients treated with apixaban
89598376|NCT05819723|Active Comparator|spinal anesthesia only|The spinal anaesthesia will be done under a complete aseptic technique induced using 3ml bupivacaine 0.5% with 25μg fentanyl
89598377|NCT05819723|Active Comparator|spinal anesthesia with erector spinae block|The spinal anaesthesia will be done under a complete aseptic technique induced using 3ml bupivacaine 0.5% with 25μg fentanyl, then erector spinae block will be given The transverse process of the 4th lumbar vertebra will be identified 4-6 cm laterally to the midline. An echogenic needle will be inserted using the out-of-plane technique until it touches the transverse process. Following negative aspira¬tion, 20 ml of 0.25% bupivacaine will be injected
89031883|NCT02277015|Experimental|ETI without chest compressions|Endotracheal intubation during pediatric resuscitation without chest compressions.
89031884|NCT02277015|Experimental|ETI with chest compressions|Endotracheal intubation during pediatric resuscitation with chest compressions. Chest compression was performed using LUCAS-2 (Physio-Control).
89031885|NCT02942199|Experimental|MySafeRx Intervention|The MySafeRx platform is a combination of several key components, including daily videoconferencing check-ins with motivational interviewing-based recovery coaching, text-messaging reminders, secure storage of buprenorphine medication within a secure electronic pill dispenser, and a standardized protocol for supervising self-administration of medication via videoconferencing. This arm represents MySafeRx using the MedicaSafe 3000 electronic pill dispenser.
89031886|NCT00518453|Experimental|Arm 1: Fluvirin|
89031887|NCT05318664|Experimental|Cryotherapy|20 minutes of cryotherapy on the dominant shoulder with ice bags
89031888|NCT05318664|No Intervention|Control|20 minutes of rest
89031889|NCT02942121|Experimental|LST App|Participants will use the LifeScience Technologies application (LST app) before surgery, and post surgery. Participants will use the app as an educational tool to learn more about their surgery. Participants will also answer questions about themselves in the app.
89031890|NCT02941185|Other|Devit-3 Oral Drop 400 IU|supplemented with oral Vitamin D 400 IU/day (Devit-3 Oral Drop, 50000 IU/15 ml, Deva Company, Turkey) started when achieved 75%of total nutrition by enteral feedings and continued until 36 weeks postmenstrual age
89031891|NCT02941185|Active Comparator|Devit-3 Oral Drop 800 IU|Devit-3 Oral Drop 800 IU once daily by oral route started when achieved 75%of total nutrition by enteral feedings and continued until 36 weeks postmenstrual age
89031892|NCT02941185|Active Comparator|Devit-3 Oral Drop 1000 IU|Devit-3 Oral Drop1000 IU once daily by oral route started when achieved 75%of total nutrition by enteral feedings and continued until 36 weeks postmenstrual age
89031893|NCT00518492|Experimental|Arm 1|Includes subjects from a trial involving experimental vaccine and an active comparator vaccine. Comparator is Twinrix (not a MnB vaccine) and thus is comparator for safety but not immunogencity
89031894|NCT02942043|Experimental|Group A (low dose group)|Intrapleural injection of bevacizumab 2.5mg/kg/times, d1, d8; 21 days for a course of treatment. Subjects will received two courses of treatment if there is no termination of treatment listed in the standard.
89598378|NCT05819671||Groupe(A)|Group (A)diabetics - g
89598379|NCT05819671||group(B)|group B normal is a normal control(non-diabetics)
89598380|NCT05819645|Experimental|Early fluid intake|
89598381|NCT05819645|Other|Standard Delayed oral fluid|
89598382|NCT05819632|Experimental|curcumin gel|the denuded palatal area will be superficially covered with a continuous thin layer of curcumin gel 2% one time immediately after the surgery (curcumin gel will be prepared in 2% concentration on a carbapol base)according to (Bhatia et al., 2014)
89598383|NCT05819632|Active Comparator|gelatine sponge|"absorbable gelatin sponge will be cut to the palatal wound size and applied. Following manual compression of the wound area, both agents will be secured in place using compressive palatal sling sutures.~commercial name (CUTANPLAST)"
89031895|NCT02942043|Experimental|Group B (medium dose group)|Intrapleural injection of bevacizumab 5mg/kg/times, d1, d8; 21 days for a course of treatment. Subjects will received two courses of treatment if there is no termination of treatment listed in the standard.
89031896|NCT02942043|Experimental|Group C (high dose group)|Intrapleural injection of bevacizumab 7.5mg/kg/times, d1, d8; 21 days for a course of treatment. Subjects will received two courses of treatment if there is no termination of treatment listed in the standard.
89031897|NCT02942082|Experimental|ACP oral care geldesensitizing agent|a desensitizing agent will be applied on tooth before and /or after bleaching.
89031898|NCT02942082|Placebo Comparator|glycrin|glycrin will be applied on tooth before and /or after bleaching.
89031899|NCT00517088|Other|Other|Group Description
89031900|NCT02939664|Active Comparator|Banded Gastric Bypass|The patient will have done a laparoscopic Roux-en-Y banded (with polypropylene mesh) gastric bypass at the time of the surgical procedure.
89031901|NCT02939664|Active Comparator|Gastric Bypass.|The patient will have done a Laparoscopic Roux-en-Y gastric bypass at the time of the surgical procedure
89598384|NCT05819567|Experimental|Healthy Subjects|"Students and employees of the Vrije Universiteit Brussel as well as people from outside this institution will be recruited (via Flyer), contacted and asked if they will want to participate. No gender restrictions will be applied, the participants must be adult (18<age <60) and healthy.~Inclusion Criteria:~Healthy volunteers;~18<Age<60;~Exclusion Criteria:~Symptoms in their lower limbs in the past 6 months~History of foot and/or ankle conditions and/or surgery~Pregnancy"
89598385|NCT05819554||Acromegaly patients|
89598386|NCT05819554||Non-secreting pituitary tumors affected patients|
89598387|NCT05819554||Secreting pituitary tumors affected patients|
89598388|NCT05819554||Healthy patients|
89598389|NCT05819437|No Intervention|CONTROL|Standard of care for knee osteoarthritis
89598390|NCT05819437|Experimental|BALNEOTHERAPY PROGRAM|3-week balneotherapy program with Mineral Water of Saint Jean d'Angely in addition to standard of care for knee osteoarthritis
89598391|NCT05819411|Experimental|Intervention|This intervention includes 6 face-to-face therapy sessions with a trained clinician plus an incentivized directly observed therapy (iDOT) intervention facilitated via a mobile application.
89598392|NCT05819411|Active Comparator|incentivized Directly Observed Therapy (iDOT)|Participants in the iDOT condition will be provided a mobile application to facilitate video recording of their daily medication adherence in order to receive small, escalating monetary incentives for HIV medication adherence.
89598393|NCT05819333|Experimental|Exercise Program + Respiratory Strength Training|In addition to the Exercise Program of Flexibility, Strengthening and Cardiovascular training, subjects assigned to the Respiratory Strength Training group will use a threshold training device to resist inspiration and expiration (Orygen Dual Valve, Forumed). The respiratory ports are held closed by adjustable-tension springs, and subjects must overcome the tension to inhale or exhale air from the lung. Subjects will complete 5 sets of 5 maximal volume and speed breaths, and rest ~1 minute between sets. Inspiratory muscle training (5 sets of 5 breaths) and expiratory muscle training (5 sets of 5 breaths) will be conducted separately. Initial intensity will be 50-70% of the maximal inspiratory and expiratory pressures the subject can generate.
89598394|NCT05819333|Active Comparator|Exercise Program + Respiratory Relaxation Training|"In addition to the Exercise Program of Flexibility, Strengthening and Cardiovascular training, subjects assigned to the Respiratory Relaxation Training group will be issued the Threshold Positive Expiratory Pressure training device modified to partially inactivate the one-way valve to remove resistance. Much like the Respiratory Strength Trainng device, the RRT device was selected for its simplicity and adaptability. This device has been used in prior controlled studies as a placebo RST device. Subjects will be instructed to breathe slowly through the device, 5 sets of 5 breaths, with ~1 minute of rest between sets. These 5 sets of 5 breaths will occur twice during the intervention session, one near the beginning of the session and one near the end. While effects of relaxation breathing exercises may include a modest lowering of systolic BP in some hypertensive patients, this group primarily serves as an active control."
89598395|NCT05819281|Experimental|Probiotic blend group|Volunteers supplemented with the probiotic product (n=57) (Lactobacillus acidophilus, Lactobacillus paracasei, Bifidobacterium lactis, Bifidobacterium bifidum e Lactobacillus rhamnosus - Final concentration: 1 x 10e10 CFU/day).
89598396|NCT05819281|Placebo Comparator|Placebo group|Placebo Group (n=57): Volunteers supplemented with placebo (maltodextrin)
89598397|NCT05819229||Oral antibiotic therapy|Clinically stable (see eligibility criteria) children without any past high-risk medical history (see eligibility criteria) will initiate oral antibiotic therapy.
89598398|NCT05819216|Experimental|partial body weight support treadmill training group|A set of 24 sessions of partial body weight support treadmill training involve administration of a motorized treadmill with an attached overhead unweighting system of 30% of each participant's body weight will be decreased. The treatment session lasts for 45 min (3 sessions/ week, for 8 weeks).
89598399|NCT05819216|Experimental|loaded treadmill training group|A set of 24 sessions of loaded treadmill training includes a motorized treadmill with an additional load (sand bags) attached to the child's lower extremities. A 60% mass lower limb weight will be added.
89598400|NCT05819177||Cohort undergoing rehabilitation|This group of patients underwent standard rehabilitation programs set by national guidelines.
89598401|NCT05819164|Experimental|88% SpO2 target|During this periods , oxygen will be administered in manual titration to reach 88% of SpO2.
89598402|NCT05819164|Experimental|90% SpO2 target|During this periods , oxygen will be administered in manual titration to reach 90% of SpO2.
89598403|NCT05819164|Experimental|92% SpO2 target|During this periods , oxygen will be administered in manual titration to reach 92% of SpO2.
89598404|NCT05819164|Experimental|94% SpO2 target|During this periods , oxygen will be administered in manual titration to reach 94% of SpO2.
89598405|NCT05819164|Experimental|96% SpO2 target|During this periods , oxygen will be administered in manual titration to reach 96% of SpO2.
89598406|NCT05819151||HbA1c<6% (normal)|Subjects with HbA1c<6%, i.e, non-diabetes population
89598407|NCT05819151||HbA1c 6-6.4% (prediabetes)|Subjects with HbA1c 6-6.4%, i.e, prediabetes population
89598408|NCT05819151||HbA1c 6.5-8.9% (diabetes)|Subjects with HbA1c HbA1c 6.5-8.9%, i.e. diabetes population
89598409|NCT05819151||HbA1c≥ 9% (diabetes with high HbA1c)|Subjects with HbA1c≥ 9%, i.e. diabetes population with high HbA1c
89598410|NCT05819086|Active Comparator|"Big tobacco video message and flyer"|"Participants will view a Big tobacco video message and flyer."
89598411|NCT05819086|Active Comparator|"It's never too late video message and flyer"|"Participants will view a It's never too late video message and flyer."
89598412|NCT05819086|Placebo Comparator|Placebo Message|Participants will view a water advertisement and flyer.
89598413|NCT05819086|Active Comparator|Fear message video and flyer|Participants will view a fear message video and flyer.
89598414|NCT05819060|Experimental|Fuzuloparib Combination with Bevacizumab|Fuzuloparib 150mg/bid ; Bevacizumab 7.5mg/kg，d1，Q3W
89598415|NCT05819034|Active Comparator|Control Group|Adolescents in the control group will receive a scoliosis-specific exercise program which will be prescribed to control the progression of the scoliotic curve
89598416|NCT05819034|Experimental|Experimental Group|Adolescents in the experimental group will receive a scoliosis-specific exercise program which will be prescribed to control the progression of the scoliotic curve in addition to wearing the soft orthoses with external strapping.
89598417|NCT05818995||CKD G1|GFR ≥90 mL/(min·1.73m2)
89598418|NCT05818995||CKD G2|GFR 60~89 mL/(min·1.73m2)
89598419|NCT05818995||CKD G3|GFR 30~59 mL/(min·1.73m2)
89598420|NCT05818995||CKD G4|GFR 15~29 mL/(min·1.73m2)
89598421|NCT05818995||CKD G5|GFR <15 mL/(min·1.73m2)
89598422|NCT05818982|Experimental|Cohort A|Group A received afatinib (40 mg oral/day) every 6 weeks
89598423|NCT05818982|Active Comparator|Cohort B|Group B received irinotecan (140-180mg/m2 intravenous) every 2 weeks
89598424|NCT05818969|Experimental|Hypnosis Therapy Group|"Experimental: Hypnosis Therapy Group~Patients will receive questionnaires to establish their attitudes/beliefs toward hypnosis, baseline pain, anxiety, & knee function. 7 days prior to surgery, they will receive a pre-recorded video (-19 min) of guided hypnosis to be watched at least 1x/day, until surgery. Postoperative course will be otherwise completely standard of care, including a clinic visit at 10 days after surgery, where they will be given these same questionnaires. Patients will answer them again on postoperative day 49, constituting a study endpoint. Access to pain medication & study doctor will be the same as any total knee arthroplasty regardless of study participation."
89598425|NCT05818969|No Intervention|Control Care Group|"No Intervention: Control Care Group~Patients will receive questionnaires to establish their attitudes/beliefs toward hypnosis, baseline pain, anxiety, & knee function. 7 days prior to surgery, they will receive a pre-recorded video (-19 min) of guided information to be watched at least 1x/day, until surgery. Postoperative course will be otherwise completely standard of care, including a clinic visit at 10 days after surgery, where they will be given these same questionnaires. Patients will answer them again on postoperative day 49, constituting a study endpoint. Access to pain medication & study doctor will be the same as any total knee arthroplasty regardless of study participation."
89598426|NCT05818917|Experimental|40mg|FHND5071, 40mg, tablet, orally, once daily
89598427|NCT05818917|Experimental|80mg|FHND5071,80mg, tablet, orally, once daily
89598428|NCT05818917|Experimental|160mg|FHND5071, 160mg, tablet, orally, once daily
89598429|NCT05818917|Experimental|240mg|FHND5071, 240mg, tablet, orally, once daily
89031902|NCT00518570|Experimental|Open-Label treatment|Patients prospectively diagnosed with premenstrual dysphoric disorder.
89031903|NCT00518609||Indian Neonates|All hospitalized neonates (all live born infants <60 days of age, independent of birth weight and gestational age) brought to hospital, with the diagnosis of suspected sepsis.
89031904|NCT02939586|Active Comparator|Haemodialysis|regular convectional haemodialysis 3times/weekly
89031905|NCT02939586|Active Comparator|Haemodiafiltration|post-dilution haemodiafiltration
89031906|NCT00517127|Active Comparator|1|Arm Nr 1: If corrected flow time (fTc), measured by esophageal doppler, falls below 350 msec, 250 ml of Lactated Ringer's Solution will be administered.
89031907|NCT00517127|Active Comparator|2|Arm Nr 2: If corrected flow time (fTc), measured by esophageal doppler, falls below 350 msec, 250 ml of Hydroxyethylstarch 6% 130/0.4 will be administered.
89598430|NCT05818917|Experimental|320mg|FHND5071, 320mg, tablet, orally, once daily
89031908|NCT05174130|Experimental|Patients undergoing mechanical ventilation in stable phase|15 Patients will be changed from a basal reference ventilator to the RESPIRA ADVANCED device. The patient will be ventilated for the next 24 hours with the investigational medical device or until one withdrawal criteria is met according to clinical investigation plan. After 24 hours of ventilation with the investigational medical device, the patient will be changed to the previous conventional ventilation device.
89031909|NCT05174130|Experimental|Patients undergoing mechanical ventilation in weaning phase|15 Patients will be changed from a basal reference ventilator to the RESPIRA ADVANCED device. The patient will be ventilated for the next 24 hours with the investigational medical device or until one withdrawal criteria is met according to clinical investigation plan. After 24 hours of ventilation with the investigational medical device, the patient will be changed to the previous conventional ventilation device.
89031910|NCT00518648|Experimental|I|Multifactorial fall prevention program
89031911|NCT00518648|Other|II|Usual care
89598431|NCT05818917|Experimental|400mg|FHND5071, 400mg, tablet, orally, once daily
89598432|NCT05818839||UCP|Children diagnosed with unilateral spastic cerebral palsy
89598433|NCT05818839||TyD|Typically developing children
89598434|NCT05818748|Experimental|virtual reality distraction|watching the application by wearing virtual glasses to the child during the 1st, 2nd and 3rd days of chemotherapy treatment
89598435|NCT05818748|No Intervention|control|no virtual reality distraction
89598436|NCT05818670|Active Comparator|tamsulosin|patients with benign prostatic hyperplasia (BPH) and erectile dysfunction (ED) treated by tamsulosin with 12 months follow up
89598437|NCT05818670|Active Comparator|tadalafil|patients with benign prostatic hyperplasia (BPH) and erectile dysfunction (ED) treated by tadalafil 5 mg with 12 months follow up
89598438|NCT05818657||Group-A CKD patients|Prevalence of apical periodontitis will be checked and non-surgical root canal treatment will be given to the patients with apical periodontitis and change in PAI score, eGFR & Systemic markers will be checked
89598439|NCT05818657||Group-B Healthy individuals|Prevalence of apical periodontitis will be checked and non-surgical root canal treatment will be given to the patients with apical periodontitis and change in PAI score, eGFR & Systemic markers will be checked
89598440|NCT05818605|Experimental|Moderate Intensity Exercise arm|All patients randomized to the exercise training group will undergo a single supervised in-hospital exercise session that includes an exercise consultation with a certified exercise physiologist. Following that they will exercise at-home with video supervision 3 times a week for a period of 24 weeks.
89598441|NCT05818605|No Intervention|Usual physical activity arm|Patients randomized to the usual-activity group will be instructed to continue their current activity without initiating or intensifying any existing exercise regimens for the duration of the study
89598442|NCT05818592|Experimental|Self-Pulse Monitoring Intervention Group|Participants view an educational video instructing them on how to manually check their pulse for irregularities. Participants will be instructed to check their pulse for 30 seconds twice daily for 2 weeks.
89598443|NCT05818592|No Intervention|Control Group Standard of Care|The control group will continue with usual care.
89598444|NCT05818579|Experimental|Virtual reality|The investigators will administer a virtual reality experience programme to promote mental wellbeing of the participants
89598445|NCT05818579|No Intervention|Usual care|The investigators will not provide any interventions to the participants.
89598446|NCT05817552||CBCT|Casts STLs generated from CBCT planmeca Pro Max
89598447|NCT05817552||Intraoral Scanner|Casts STLs generated from intraoral scanner Haron from 3DISC
89598448|NCT05817552||Desktop Optical Scanner|Casts STLs generated from desktop optical scanner Medit T710
89598449|NCT05816681|Experimental|DWJ1230|
89598450|NCT05816681|Experimental|DWB2001|
89598451|NCT05816512|Experimental|Gold Nano particle from Pelargonium Graveolens Mouthwash group|Gold Nano particle from Pelargonium Graveolens Mouthwash will be applied as a mouthwash for three weeks and then follow up .
89598452|NCT05816512|Active Comparator|Chlorhexidine gluconate mouth wash group|Chlorhexidine gluconate mouth wash will be applied as a mouthwash for three weeks and then follow up .
89598453|NCT05816499|Experimental|Arm A (cadonilimab，anlotinib，docetaxel )|Patients receive anlotinib 6mg/8mg/10mg qd 2W/3W and cadonilimab IV over 90 minutes on day 1. Patients also receive docetaxel 60-75 mg/m2 IV over 60 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89598454|NCT05816486||Prospective - Longitudinal|Longitudinal follow-up cohort in which all patients who are going to receive a kidney transplant and meet the selection criteria for this study cohort will be included. This cohort will be recruited at sites that routinely perform Protocol Biopsies (PB) one year after transplant. A pre-transplant and post-transplant follow-up IMBG at 3, 6, 9 and 12 months will be performed, and additional IMBG will be carried out when an indication biopsy is required during the patients' follow-up. A protocol biopsy will be performed after one year of follow-up of the patients.
89598455|NCT05816486||Cross-sectional|Patients in whom an Indication Biopsy (IB) is to be performed due to suspicion of rejection. This cohort may be recruited in all sites participating in the study, including sites where annual protocol biopsies are not routinely performed. An IMBG will be performed coinciding with the IB. This cohort will include patients who have had their transplant for less than 3 years.
89598456|NCT05816434|Experimental|Sleep Extension|1 week of >1 hour increased time in bed
89598457|NCT05816434|No Intervention|Control|Sustained sleep behavior
89598458|NCT05816291|Placebo Comparator|Placebo|14 days of supplementation placebo (maltodextrin)
89598459|NCT05816291|Experimental|Veillonella atypica FB004|14 days of supplementation 1 x 109CFU dose Veillonella atypica FB004
89598460|NCT05816239||Patients being evaluated for bronchoscopic lung volume reduction (BLVR).|
89598461|NCT05816200|Experimental|Grupo TENS|Participants with burning mouth underwent to transcutaneous electrical nerve stimulation
89598462|NCT05816200|Active Comparator|Grupo LLLT|Participants with burning mouth underwent low-level laser therapy
89598463|NCT05816161|Experimental|Neuromuscular Inhibition Technique|
89598464|NCT05816161|Other|Myofascial Release|
89598465|NCT05816109|Experimental|Superficial cervical block|Superficial Cervical Block
88979579|NCT00309556|Active Comparator|A (experimental group)|Epirubicin/Docetaxel/Capecitabine-containing chemotherapy ± trastuzumab in HER-2 positive disease
89598466|NCT05816109|Active Comparator|without superficial cervical block|Without superficial cervical block
89598467|NCT05816096|Active Comparator|A (Hall Technique)|"31 child will be treated by one performed metal crown using Hall technique on one of HSPM affected tooth.~The correct size of SSC for tooth will be selected. Use the separating rubber if necessary. Dried the tooth and cemented the SSC by glass ionomer luting cement and used finger pressure to seat the crown and instructed the child to bite down on the SSC.~Half of the total number of children will received performed metal crown at the first by divided them randomly to the two groups using the randomization table."
89598468|NCT05816096|Experimental|B (ART)|"31 child will be treated by Bulk fill glass hybrid restorative system (Equia Forte HT®) using Atraumatic restoration treatment on one of HSPM affected tooth.~Isolate the tooth by cotton rolls, remove the carious soft tissue using hand instrument excavators then condition the cavity with a polyacrylic acid solution 11.5% for 10 seconds. After washed and dried the cavity insert the GIC and protect it by Equia forte coat.~Half of the total number of children will received ART at the first by divided them randomly to the two groups using the randomization table."
89598469|NCT05815966|Experimental|Experimental: emotion recognition and empathy focused training program|A suitable hall for children will be determined by the school administration. Education days and hours for the children in the experimental group will be determined by negotiating with the 4th grade teachers. In this study, a 50-minute training program consisting of 2 sessions per week, lasting 5 weeks, will be applied to the experimental group.
88979580|NCT00309556|Active Comparator|B (control group)|Epirubicin/Docetaxel-containing chemotherapy ± trastuzumab in HER-2 positive disease
88979581|NCT00309595|Experimental|1|Cordis SMART™ nitinol self expandable stent
88979582|NCT00309595|Active Comparator|2|balloon
88979583|NCT00083603|Experimental|1|rFPV-HIV vaccine administered as two separate 1-mL intramuscular injections, with rFPV-HIV env/gag into the left deltoid, rFPV-HIV tat/rev/nef-RT into the right deltoid at Days 0, 28, 84, 140, and 196
88979584|NCT00083603|Placebo Comparator|2|Empty TBC-FPV vector administered as two separate 1-mL intramuscular injections, one into each deltoid at Days 0, 28, 84, 140, and 196
89598470|NCT05815966|No Intervention|Control group|Standard care group
89598471|NCT05815953|Experimental|Polarstem|Polarstem uncemented femoral stem
89598472|NCT05815953|Active Comparator|Corail|Corail uncemented femoral stem
89598473|NCT05815940|Experimental|pilot study|This was followed by the second phase, during which the mobile application developed was pilot tested with 10 children. Based on the feedback received from the users, the mobile application was finalized.
89598474|NCT05815914|Experimental|Intervention group|
89598475|NCT05815914|Active Comparator|Control group|
89210162|NCT00988455|Experimental|BCC, ALA-PDT|Patients with histologically proven basal cell carcinoma who were candidates for treatment with ALA-PDT
89210163|NCT00815984||Schoolchildren with asthma.|Schoolchildren with asthma.
89598476|NCT05815901|Experimental|Epaminurad 6 mg|[Main study period] Epaminurad 6 mg and three matched placebos for 20 weeks. [Extension study period] Epaminurad 6 mg or 9 mg (open label) for 28 weeks.
89598477|NCT05815901|Experimental|Epaminurad 9 mg|[Main study period] Epaminurad 9 mg and three matched placebos for 20 weeks. [Extension study period] Epaminurad 6 mg or 9 mg (open label) for 28 weeks.
89598478|NCT05815901|Active Comparator|Febuxostat 40 mg|[Main study period] Febuxostat 40 mg and three matched placebos for 20 weeks. [Extension study period] Epaminurad 6 mg or 9 mg (open label) for 28 weeks.
89598479|NCT05815901|Active Comparator|Febuxostat 80 mg|[Main study period] Febuxostat 80 mg and three matched placebos for 20 weeks. [Extension study period] Epaminurad 6 mg or 9 mg (open label) for 28 weeks.
89598480|NCT05815862|Experimental|AL2846 capsule|orally administer AL2846 capsules monotherapy, 28 days as a treatment cycle.
89598481|NCT05815849|Active Comparator|Olive oil|In our unit, according to the recommendations to start and increase enteral feeding in preterm infants in the Turkish Neonatal Society feeding group, Total Parenteral Nutrition (TPN) and Minimal Enteral Nutrition (MEN) are started from the first day. If the infant's weight is between 1000-1500 grams, it is increased to feed the infant as 15-20 ml/kg/day (for 1-2 days) and then 30 ml/kg/day every 2-3 hours. If the infant's weight is between 1500-1800 grams, he/she is fed as 20 ml/kg for 1 day and then 30 ml/kg/day, every 3 hours. BM fortification is initiated when feeding reaches 50-100 ml/kg (recommended 80 ml/kg) [21].At this stage (approximately from the seventh day after starting to take 25-30 ml/kg/day orally), 0.5 cc/30 ml of olive oil (a brand easily available in the markets) was added to the milk at each feeding of the infants in the intervention group.
89598482|NCT05815849|No Intervention|Recommendations to start enteral feeding|In our unit, according to the recommendations to start and increase enteral feeding in preterm infants in the Turkish Neonatal Society feeding group, Total Parenteral Nutrition (TPN) and Minimal Enteral Nutrition (MEN) are started from the first day. If the infant's weight is between 1000-1500 grams, it is increased to feed the infant as 15-20 ml/kg/day (for 1-2 days) and then 30 ml/kg/day every 2-3 hours. If the infant's weight is between 1500-1800 grams, he/she is fed as 20 ml/kg for 1 day and then 30 ml/kg/day, every 3 hours. BM fortification is initiated when feeding reaches 50-100 ml/kg (recommended 80 ml/kg) [21].
89598483|NCT05815823|Experimental|conventional therapy|20 sessions of conventional therapy was applied for 5 days a week for 4 weeks, 1 hour a day
89598484|NCT05815823|Experimental|robot-assisted therapy|20 sessions of upper extremity robot-assisted therapy was applied for 4 weeks, 5 days a week, 30 minutes a day.
89598485|NCT05815784|No Intervention|Observation|No treatment.
89598486|NCT05815784|Other|Atropine|0.05% atropine. One drop per eye per day for 2 years.
89598487|NCT05815784|Other|MiSight contact lenses|MiSight contact lenses. Daily wear for 2 years.
89598488|NCT05815771|Active Comparator|Micro fragmented adipose tissue|Micro fragmented adipose tissue mixed with Bone marrow stem cells injection on healing of TMJ internal disc derangement without reduction
89598489|NCT05815771|Active Comparator|Bone marrow stem cells aspiration|Bone marrow stem cells injection on healing of TMJ internal disc derangement without reduction
89598490|NCT05815771|Placebo Comparator|hyaluronic acid gel injection|Intra and periarticular injection of 2 mm of hyaluronic acid gel on healing of TMJ internal disc derangement without reduction
89598491|NCT05815732|Experimental|Physical exercise prescription|Prescription of a personalized exercise program, which will define modalities, intensity, duration, frequency and progression of the exercise. For each subject, at baseline and after 6 months, biological samples will be collected (blood, urine, saliva and nasal swab)
89598492|NCT05815719|Experimental|Study group|Patients to carry out an experimental double ovarian stimulation and to receive 4 weekly injections of Corifollitropin alfa. Prospective group.
89598493|NCT05815719|Active Comparator|Control group|Patients to carry out a conventional double ovarian stimulation and to receive daily injections of gonadotropins. Retrospective group (data retrieved from strictly selected treatments carried out in our institution within the 24 months prior to the inclusion of the first patient in the study group and according to the standard guideline of the clinic).
89598494|NCT05815706|Experimental|Experimental|The experimental group participants were breastfed for ten minutes (five minutes for each breast) every day from the day they started oral feeding until they switched to exclusive breastfeeding. The nurse placed the warmed breast milk or formula in SNS. She then fixed it to the mother's nipples. Each experimental group participant sucked on the two breasts for 15 minutes. Breastfeeding (ten minutes), resting and SNS preparation (five minutes), and SNS feeding (15 minutes) were limited to a total of 30 minutes in light of earlier research.
89598495|NCT05815706|No Intervention|Control|Preterm infants were fed according to the clinical feeding protocol. They were not SNS-fed.
89598496|NCT05815667|Experimental|Intervention group|I-ACE. All participants are offered the I-ACE programme for the duration of 5 weeks.
89598497|NCT05815667|No Intervention|Control group|Waiting list.
89210164|NCT00986037|Experimental|IV ABT-308 in asthmatics|ABT-308 single escalating doses in mild to moderate asthmatics
89210165|NCT00986037|Experimental|SC ABT-308 in asthmatics|ABT-308 multiple SQ doses in mild to moderate asthmatics
89210166|NCT00986037|Experimental|IV ABT-308 in healthy volunteers|ABT-308 single escalating IV doses in healthy volunteers
89210167|NCT00901992|Experimental|MEDIAS 2 ICT|MEDIAS 2 ICT - education program for the initiation of intensive conventional insulin treatment (ICT) in type 2 diabetic patients
89598498|NCT05815654|Experimental|Warm Palace Analgesic Point Sticker Group|Participants in the EG group will be provided test sticker, containing Ding Xiang, Rou Gui, Gan Jiang, Huang Jie Zi, Rou Cong Rong, Xiao Hui Xiang, Hua Jiao, Ai Ye, Xiang Fu, Wu Zhu Yu, Graphene（0.01%）The acupoints for applying the sticker are Guanyuan (CV4), Zigong (EX-CA1), and Sanyinjiao (SP6). The subjects will be reminded to closely observe their skin during the process and remove the sticker in time if the subjects feel itchy or painful, and record the adverse event.
89598499|NCT05815654|Placebo Comparator|Control Group|Participants in the CG group will be provided control sticker containing flour.The acupoints for applying the sticker are the same with experimental group
89598500|NCT05815641|Experimental|food intake (breakfast)|the breakfast composition is 56 kcal% carbohydrates, 12 kcal% protein and 34 kcal% lipids and comprises yogurt, cereals and almonds
89598501|NCT05815615|Placebo Comparator|Placebo|Simulated plasma donation, same procedure as for plasmapheresis but without drawing blood.
89598502|NCT05815615|Experimental|Low-frequency|Plasma donation 1x/month for 3 months
89598503|NCT05815615|Experimental|High-frequency|Plasma donation 3x/month for 3 months
89598504|NCT05815615|Experimental|US scheme|Plasma donation 2x/week for 3 months
89598505|NCT05815589|Experimental|experimental|screw retained prosthesis group this group will received a mandibular screw retained hybrid prosthesis over four inra-foraminal implant
89598506|NCT05815589|Active Comparator|active comparator|this group received a mandibular telescopic attached overdenture.
89598507|NCT05815576|Experimental|Intrinsic foot muscle fatigue|The fatigue protocol will consist of repeated movements of doming (short foot exercise), combined with electrostimulation of the abductor hallucis muscle, while standing on both feet. Participants will be familiarized with doming and electrostimulation during five minutes. They will then have a rest period of at least 5 minutes The electrostimulation electrodes will be placed behind the head of the first metatarsal bone and in front of the medial tubercule of the calcaneus, on the most affected side of subjects with chronic ankle instability (according to CAIT questionnaire scores).
89598508|NCT05815576|No Intervention|No intrinsic foot muscle fatigue|No fatigue of the intrinsic foot muscles.
89598509|NCT05815550||PPI users|
89598510|NCT05815524|Experimental|Active|physical activity protocol
89598511|NCT05815511|Experimental|Probiotic group|Probiotic mixture in oral capsule format with selected strains in concentrations equal to or greater than 1x10^10 cfu/dose.
89598512|NCT05815511|Placebo Comparator|Placebo group|Maltodextrin in oral capsule format
89598513|NCT05815472|Experimental|Patients affected by locally advanced non-small-cell lung cancer|"Patients affected by locally advanced non-small-cell lung cancer (staged III according to 8th TNM classification), undergoing induction therapy (IT) followed by either radical surgery or immunotherapy boost and treated in Fondazione Policlinico Universitario A. Gemelli IRCCS of Rome, Italy, will be enrolled in this study."
89598514|NCT05815407||NSCLC patients|Patients were diagnosed with NSCLC at any stage, then will be subdivided into Early stage, Lympho-node involvement stage and Distant metastatic stage
89598515|NCT05815407||Control subjects|Appearantly healthy age-matched individuals
89031912|NCT03458208|Experimental|Metformin|"First aIntervention Period:~Single administered dose of Metformin (1 000 mg tablet immediate release) in a fasting condition~Third Intervention Period:~Single administered dose of Metformin (1 000 mg tablet immediate release) in a fed condition"
89598516|NCT05815394|Experimental|177Lu-Anti-PSMA mAbs|
89598517|NCT05815381||Fibromyalgia patients|Female sex, age 20-65 years and fulfilling the ACR 1990 and ACR 2016 fibromyalgia diagnostic criteria.
89598518|NCT05815381||Healthy controls|Sex and age matched healthy controls.
89031913|NCT03458208|Active Comparator|Glucophage®|"Second Intervention Period:~Single administered dose of Glucophage® ( 1 000 mg tablet immediate release) in a fasting condition~Fourth Intervention Period:~Single administered dose of Glucophage® ( 1 000 mg tablet immediate release) in a fed condition"
89598519|NCT05815329|Experimental|rehabilitation group|Outpatients undergoing neurorehabilitation through Neurotablet
89598520|NCT05815329|No Intervention|waiting list|Outpatients not undergoing rehabilitation during the study. They will have the possibility to carry on the rehabilitation at the end of the study
89598521|NCT05815316|Experimental|18F-PSMA-1007|All patients undergo the same experimental procedure
89598522|NCT05815303|Experimental|Cadonilimab + XELOX|Oxaliplatin 130 mg/m2 iv and Cadonilimab 10mg/kg iv on day 1； Capecitabine 1000mg/m2 po bid on day 1 to 14； every 21 day as a cycle, 4 cycles before surgery and 4 cycles after surgery
89598523|NCT05815303|Sham Comparator|XELOX|Oxaliplatin 130 mg/m2 iv on day 1； Capecitabine 1000mg/m2 po bid on day 1 to 14； every 21 day as a cycle, 4 cycles before surgery and 4 cycles after surgery
89598524|NCT05815290|Experimental|dMMR/MSI-H colon cancer|
89598525|NCT05815290|Experimental|dMMR/MSI-H rectal cancer|
89598526|NCT05815225||A: subjects from mental health unit|Subjects with active psychotic symptoms at the time of recruitment, attended at the Mental Health Clinical Management Unit of the Regional University Hospital of Malaga (Spain) and admitted to the Mental Health Hospitalization Unit. In turn, within this group, a cross-classification will be established according to the evolutionary staging of the disease, the concomitant presence of major affective symptoms and the consumption of substances in the weeks prior to admission.
89598527|NCT05815225||B: subjects with induced psychoses|Subjects with psychotic symptoms, diagnosed with a substance-induced psychotic episode, already recruitedand previously characterized.
89598528|NCT05815225||C: control group|Control group of volunteers extracted from the general population, without psychotic symptoms orsubstance use disorders.
89598529|NCT05815212||Patients with DME|
89598530|NCT05815134|Experimental|patients with endometriosis|
89598531|NCT05815134|Active Comparator|others infertility causes|
89598532|NCT05815121|Experimental|Acupressing group|"Patients benefit from one session of acupressing with placement of 4 vaccaria seeds covered with stickers on the ears and 2 on the wrists.~They will also be asked to regularly and gently massage the treated points"
89598533|NCT05815121|Sham Comparator|SHAM group|Patients treated according to the same scheme as the experimental group, but with stickers only on the points, and the points should not be massaged.
89598534|NCT05815108||RIS Patient|RIS patients validated by the RIS expert group
89598535|NCT05815082|Experimental|Watching and waiting group|Watch and Wait strategy is one of the treatment strategies of advanced rectal cancer, which recommends no immediate surgery with close surveillance.
89598536|NCT05815082|Active Comparator|Adjuvant chemotherapy group|Chemotherapy regimens recommended include oxaliplatin-based CapeOx or FOLFOX regimens, or single-agent 5-FU/LV, capecitabine, or combination with targeted therapy.
89598537|NCT05815056|Active Comparator|drug intervention|drug induced sedation
89598538|NCT05815056|Experimental|digital sedation|hypnosis induced by a virtual reality device
89031914|NCT00517166||A|Individuals on whom tourniquet was used.
89598539|NCT05815043|Experimental|Low- and high-sodium intake|Participants will consume two different quantities of sodium per day for 3 days each.
89598540|NCT05814978|Experimental|Experimental Scapular Therapeutic Exercise Group|Patients in this group will perform therapeutic exercises, recommended for subjects with shoulder pain and focusing the neuromuscular control, stretching and/or strengthening of the scapular muscles
89598541|NCT05814965|Experimental|Diabetic patients with Apical periodontitis|Diabetic patients with Apical periodontitis received Endodontics treatment in form of Root canal treatment and assessment of inflammatory and metabolic markers
89598542|NCT05814965|Experimental|Healthy patients with Apical periodontitis|systemically healthy participants patients with Apical periodontitis received Endodontics treatment in the form of root canal treatment and assessment of inflammatory markers
89598543|NCT05814965|Active Comparator|Diabetic patients with out Apical periodontitis|systemic inflammatory markers along with metabolic markers will be assessed
89598544|NCT05814965|Active Comparator|Healthy participants without Apical periodontitis|systemic inflammatory markers will be assessed
89598545|NCT05814952|Experimental|LX103 Injection|"Potential doses:~5E10 vg, 0.1 mL/eye/dose (low dose)~1E11 vg, 0.05 mL/eye/dose (high dose)"
89598546|NCT05814926|Experimental|Healthy Control|Each healthy participant will receive a single dose of GP681
89598547|NCT05814926|Experimental|Mild, Child-Pugh A|Each participant with Child-Pugh A will receive a single dose of GP681
89598548|NCT05814926|Experimental|Moderate; Child-Pugh B|Each participant with Child-Pugh B will receive a single dose of GP681
89598549|NCT05814874|Placebo Comparator|meat-based diet; placebo|
89598550|NCT05814874|Active Comparator|meat-based diet; selenium supplement|
89598551|NCT05814874|Active Comparator|meat-based diet; Brazil nut|
89598552|NCT05814874|Placebo Comparator|vegan diet; placebo|
89598553|NCT05814874|Active Comparator|vegan diet; selenium supplement|
89031915|NCT02939625|Active Comparator|muscle training|participants will breathing exercises for 20 min, then 40 min training with Threshold IMT therapy will be held in 7 sessions
89031916|NCT02939625|Active Comparator|bilevel positive airway pressure|participants will breathing exercises for 20 min, then 40 min bilevel (IPAP and EPAP 12 = 8 cm H2O), the therapy will be held in 7 sessions
89598554|NCT05814874|Active Comparator|vegan diet; Brazil nut|
89031917|NCT02939625|Active Comparator|Continue Positive Airway Pressure|participants will breathing exercises for 20 min, then 40 min CPAP (8 cm H2O) therapy will be held in 7 sessions
89031918|NCT02940834||patients with sodium imbalance|
89031919|NCT02940834||patients without sodium imbalance|
89031920|NCT00517244||A|Primary anxiety disorder
89031921|NCT00517244||B|Primary obsessive compulsive disorder
89031922|NCT00517244||C|Healthy children with no previous history of an anxiety disorder
89031923|NCT00517283|Experimental|Sequence 1|Exenatide 5 mcg - Exentatide 10 mcg - Placebo
89598555|NCT05814861||patients presented with GIT symptoms|Fresh Stool samples will be collected in clean sterile cups from patients suffering from gastrointestinal symptoms attending Assiut University Hospitals and examined for detection of Blastocystis hominis
89598556|NCT05814861||clinically free persons undergo routine stool analysis for any reasons other than GIT complaint|Fresh Stool samples will be collected in clean sterile cups from clinically free persons under go routine stool examination for any cause other than GIT troubles and examined for detection of Blastocystis hominis
89598557|NCT05814796||Obese patients|BMI>30
89598558|NCT05814796||Non obese|Overweight: BMI = 25-29.9 Normal weight: BMI = 18.5-24.9
89598559|NCT05814770|Experimental|Finerenone|
89598560|NCT05814770|Active Comparator|Spironolactone|
89598561|NCT05814731|Experimental|MA-BUCY2|Mitoxantrone liposome 20mg/m2，ivgtt，d-11 ；Ara-C 4g/m2.d ，ivgtt，d-10- -9； BU 0.8 mg/kg q6h，ivgtt，d-8- -6； CTX 1.8 g/m2.d ，ivgtt，d-5- -4； me-CCNU 250 mg/m2，p.o，d-3； ATG 2.5 mg/Kg.d，d-5 -2；
89598562|NCT05814731|Active Comparator|BUCY2|Ara-C 4g/m2.d ，ivgtt，d-10- -9； BU 0.8 mg/kg q6h，ivgtt，d-8- -6； CTX 1.8 g/m2.d ，ivgtt，d-5- -4； me-CCNU 250 mg/m2，p.o，d-3； ATG 2.5 mg/Kg.d，d-5 -2；
89598563|NCT05814718|Experimental|modified BEAM conditioning regimen|Mitoxantrone liposome 24 mg/m2，ivgtt，d-7；BCNU 300 mg/m2，ivgtt，d-6； Ara-C 200 mg/m2 q12h，ivgtt，d-5- -2； Vp16 200 mg/m2 ，ivgtt，d-5- -2；
89598564|NCT05814718|Active Comparator|BEAM conditioning regimen|BCNU 300 mg/m2，-7d； Vp16 200 mg/m2，-6～-3d； Ara-C 100mg/m2 q12h，-6～-3d； Mel 140mg/m2，-2d
89598565|NCT05814601|Experimental|experimental group|norepinephrine at a concentration of 5 mcg/ml is preemptively administered
89598566|NCT05814601|No Intervention|Control group|norepinephrine at a concentration of 5 mcg/ml is not preemptively administered
89031924|NCT00517283|Experimental|Sequence 2|Exenatide 10 mcg - Placebo - Exenatide 5 mcg
89031925|NCT00517283|Experimental|Sequence 3|Placebo - Exenatide 5 mcg - Exenatide 10 mcg
89031926|NCT02940912|Active Comparator|Apomorphine (5 mg/ml)|Active phase is apomorphine (from 0.5 mg (0.1 ml) to maximum 5 mg (1 ml)/hour of apomorphine), delivered with a pump (subcutaneous administration), during 22 days.
89598567|NCT05814562|Experimental|Remote Intervention|An automatic blood pressure monitor will be given to patients upon enrollment. During the three months after enrollment, patients will be administered remote intervention weekly during the first month, and biweekly during the second and third month. At the onset of those sessions the patients will be asked to measure their blood pressure and this will be recorded by the coordinator.
89598568|NCT05812391|Active Comparator|test group|Supra-gingival erythritol powerder air polishing Sub-gingival erythritol powerder air polishing Supra-gingival debridement Sub-gingival debridement
89598569|NCT05812391|Active Comparator|conventional group|Supra-gingival debridement Sub-gingival debridement Polishing with polishing paste
89598570|NCT05812235||Esophagectomy|48 patients with esophagectomy due to esophageal cancer before no more than 3 years
89598571|NCT05812235||Healthy Control|70 patients without gastrectomy , who are similar background in other group, are collected from date Pathologic analysis of primary osteoporosis: investigating age and osteoporosis related changes of bone microstructure by using HR-pQCT (UMIN000023535)
89031927|NCT02940912|Placebo Comparator|Physiologic serum|Physiological serum (from 0.1 ml to maximum 1 ml/ hour), delivered with a pump (subcutaneous administration), during 22 days.
89031928|NCT00518726|Experimental|Arm 1|
89031929|NCT02941029||Evaluate toxicity biomarkers|Investigators will determine if measurement of circulating DNA from tumor and normal tissues shortly after RT provides an early and quantitative measure of risk of radiation-related complications. It will be necessary to collect blood specimens prior to and during the first week of radiation therapy.
89031930|NCT03459053|Experimental|CBART|6 weeks participation in CBART protocol before beginning IVF treatment
89031931|NCT03459053|No Intervention|Wait control|Participants will receive treatment as usual and will be able to receive the intervention after the study is complete.
89598572|NCT05812105|Experimental|Health Buddy Program|This intergenerational program targets Spanish speaking older adults who lack reliable and/or safe transportation and are managing at least one chronic illness. The program goal is to improve older adults' awareness of existing community resources, with an emphasis on transportation and health assets. Trained college students acted as facilitators for the program and helped older adults with relevant community resources.
89598573|NCT05812014|Experimental|Study Vaccine Group|
89598574|NCT05812014|Placebo Comparator|Control Group|
89598575|NCT05812001|Experimental|Exergames-acceptance and commitment therapy (e-ACT) group|Exergame is playing of video games that require rigorous physical exercise and are intended as a work-out, such as those in which players race a virtual bicycle on-screen by pedalling a simulator resembling an exercise bike. It not only improve motivation, physical fitness and cognitive function, but it also induces antidepressant effect similar to physical exercise. Acceptance and commitment therapy (ACT) is a third-generation cognitive behavioral approach which uses acceptance and mindfulness processes, and commitment and behavior change processes to produce psychological flexibility. ACT was designed to increase adaptive coping through acceptance, cognitive defusion, mindfulness, and perspective-taking exercises while supporting depression patients in aligning behavior with their personal values. Hence, the combination of both exergame and ACT may provide additional benefit for treatment of depression patients beyond the degree of effectiveness of ACT alone.
89598576|NCT05812001|Active Comparator|Acceptance and commitment therapy (ACT) group|It is a third-generation cognitive behavioral approach which uses acceptance and mindfulness processes, and commitment and behavior change processes to produce psychological flexibility. Unlike CBT, which aims to change unhelpful thoughts and feelings, ACT was designed to increase adaptive coping through acceptance, cognitive defusion, mindfulness, and perspective-taking exercises while supporting depression patients in aligning behavior with their personal values. Hence, ACT consists of 8 sessions, one session per week to facilitate depression patients to development and maintenance of health behavioral improvements by targeting internal barriers, such as emotional discomfort and self-defeating thoughts, and by fostering connection and commitment to personal values associated with self-management of positive health behaviors.
89031932|NCT02940795|Experimental|Coke cola|Exclusively lactating mothers with infants between 4-6 weeks were investigated. Lactating mothers will be consume a 20 ounce bottle of coke cola.
89031933|NCT02940795|Experimental|Diet Rite|Exclusively lactating mothers with infants between 4-6 weeks were asked to consume a 12 ounce bottle of diet rite.
89031934|NCT00517322|Experimental|1|treatment with ramipril
89031935|NCT00517322|Experimental|2|treatment with irbesartan
89031936|NCT02939430|Active Comparator|Control|Reversal of neuromuscular blockade will be performed using classic drugs (neostigmine 80 mic/kg and atropine 40 mic/kg)
89031937|NCT02939430|Experimental|Sugammadex group|Reversal of neuromuscular blockade will be performed using Sugammadex 2mg/kg
89031938|NCT00517400|Active Comparator|Exposure-Stimulation|
89031939|NCT00517400|Active Comparator|Sham exposure - Real stimulation|
89031940|NCT00517400|Active Comparator|Exposure - Sham Stimulation|
89031941|NCT02940717|Experimental|Vita suprinity|Vita Suprinity is a recent material with glass ceramic enriched with zirconia (approx. 10 % by weight) that offer practices and laboratories a high-strength, zirconia-reinforced lithium silicate ceramic (ZLS).
89031942|NCT02940717|Active Comparator|Emax cad|lithium disilicate glass-ceramic which is etchable and proved to have good success rate if used for laminate venners
89031943|NCT00518765|Experimental|1|Various sequences of different doses of Aliskiren
89031944|NCT00518765|Experimental|2|Various sequences of different doses of Aliskiren plus placebo
89031945|NCT00518765|Experimental|3|Various sequences of different doses of Aliskiren
89031946|NCT00518765|Experimental|4|Various sequences of different doses of Aliskiren plus placebo
89031947|NCT02939469|Experimental|Experimental: Sympathetic nerve activity|Healthy volunteers will undergo microneurography, and non invasive sympathetic nerve activity by EKG analysis at baseline and in response to stress.
89031948|NCT02939391|Experimental|KW-6356 Low Dose|Oral administration
89031949|NCT02939391|Experimental|KW-6356 High Dose|Oral administration
89598577|NCT05812001|No Intervention|Treatment-as-usual control (TAU) group|The participants in the control group will receive treatment-as-usual in which non-specific ingredients of the psychotherapeutic approach will be administered, such as psychological understanding to the management of an individual patient, identifying current problems, providing opportunities for disclosure, reassurance, and deep breathing exercise. They will be given equal amount of time and attention from the professional figure compared to the intervention groups, whereby they will also attach to an 8-session program (with one session per week for 8 weeks). Each weekly TAU session will be held at the same time (± 2 hours) and at the same venue (in the psychology lab).
89210168|NCT00901992|Active Comparator|Current ICT program (ACC)|This education program consists of 10 lessons combining an insulin education program with an hypertension program
89210169|NCT00983151|Experimental|Active|
89598578|NCT05810974|Active Comparator|Concentrated beetroot juice|
89598579|NCT05810974|Active Comparator|Nitrate depleted beetroot juice + potassium nitrate (KNO3)|
89598580|NCT05810974|Placebo Comparator|Nitrate-depleted beetroot juice|
89598581|NCT05810519|Experimental|Experimental group|Participants assigned to the experimental group will receive recommendation to take an active break with the proposed lumbar and hip extension exercises for every 30 minutes of sitting.
89598582|NCT05810519|Active Comparator|Control group|Participants assigned to the control group will receive an self-care recommendations book.
89031950|NCT02939391|Placebo Comparator|Placebo|Oral administration
89031951|NCT02940873|Experimental|HARPdoc courses|Hypoglycaemia Awareness Restoration Programme for adults with type 1 diabetes and problematic hypoglycaemia persisting despite optimised self-care (HARPdoc) - a combination of structured education around hypoglycaemia recognition, avoidance and treatment combined with hypoglycaemia-focussed cognitive behavioural therapy, delivered by diabetes educators, supported by a clinical psychologist, to small groups of eligible adults.
89031952|NCT02940873|Active Comparator|BGAT courses|Blood Glucose Awareness Training is an existing psycho-educational program which coaches adults with type 1 diabetes better to predict and recognise extremes of plasma glucose - hyper- and hypo-glycaemia. It has been shown to reduce severe hypoglycaemia rates.
89031953|NCT00517517|Experimental|1|Intramuscular injection of whole virion, Vero cell-derived influenza vaccine containing 7.5 µg of H5N1 HA antigen per 0.5 mL in a non-adjuvanted formulation
89031954|NCT00517517|Experimental|2|Intramuscular injection of whole virion, Vero cell-derived influenza vaccine containing 3.75 µg of H5N1 HA antigen per 0.25 mL in a non-adjuvanted formulation
89598583|NCT05808426|No Intervention|observation with no intervention group|The control group only performed routine data collection; the research assistant asked the subjects about their usual activities by telephone every month to understand their physical activity in this half of the year.
89598584|NCT05808426|Experimental|Mahjong group|The experimental group intervened a Bonus Winner Mahjong developed by Bonus Winner Online Entertainment Co., Ltd. The participants in experimental group played three times a week, each time requiring at least lasting 30 minutes, for half of a year.
89598585|NCT05807451||Monoplanar Osteotomy group|High Tibial Osteotomy using single plane osteotomy
89598586|NCT05807451||Biplanar Osteotomy group|High Tibial Osteotomy using two plane osteotomy
89598587|NCT05804643||Breast cancer related lymphedema|Breast cancer related lymphedema cases receive observational magnetic resonance imaging before and after lymphovenous anastomosis.
89598588|NCT05804448||High-altitude group|Parturient who are native to their resident altitude, i.e. residing at the altitude above 2500 m from sea level will receive spinal anesthesia for caesarean section.
89598589|NCT05804448||Low-altitude group|Parturient who are native to their resident altitude, i.e. residing at the altitude below 500 m from sea level will receive spinal anesthesia for caesarean section.
89608537|NCT00723580|Experimental|Sleep and Activity by Treatment Condition|Actigraphic measurements were obtained by attaching an actigraphic watch device to the child's non-dominant wrist. The measurements will include three separate three week periods beginning with a baseline period and the period in which the child's pharmacological treatment was initiated. Two additional three week actigraphic measurement periods will occur at 22 months post-baseline period and at 23 months post-baseline period. The resulting five treatment conditions were: 1. Baseline no medication 2. Risperidone .25 mg at bedtime (q.h.s.) x 7 days 3. Risperidone .25 mg twice daily (b.i.d.) 4. Risperidone .25 mg three times a day (t.i.d.) and 5. Risperidone .5 mg three times a day (t.i.d.). Sleep and activity will be evaluated by treatment conditions.
89031955|NCT02939352|Experimental|Cocaine Users|Participants will receive Real continuous Theta Burst Stimulation to the left frontal pole/medial prefrontal cortex. Participants will also receive Sham continuous Theta Burst Stimulation to the left frontal pole/medial prefrontal cortex.
89031956|NCT02939352|Experimental|Alcohol Users|Participants will receive Real continuous Theta Burst Stimulation to the left frontal pole/medial prefrontal cortex. Participants will also receive Sham continuous Theta Burst Stimulation to the left frontal pole/medial prefrontal cortex.
89031957|NCT00517673|Experimental|GSK945237|Active Study Drug
89031958|NCT00517673|Placebo Comparator|Sugar Pill|Placebo
89031959|NCT02940756|Experimental|artesunate-amodiaquine|Tablets containing 25 mg of artesunate and 67.5 mg of amodiaquine: one tablet daily for three days children weighing 4.5 to 8 kg, and tablets containing 50 mg of artesunate and 135 mg of amodiaquine: one tablet daily for three days for children weighing 9 to 17 kg.
89031960|NCT02940756|Experimental|artemether-lumefantrine|"Tablets containing 20 mg of Artemether and 120 mg of Lumefantrine. Each dose to be taken with high-fat food or drinks (for example milk).~One tablet twice daily for children weighing 5 to <15 kg, two tablets twice daily for those weighing 15 to <25 kg and three tablets twice daily for those weighing 25 to < 35 kg, for three days."
89210170|NCT00983151|Placebo Comparator|Placebo|
89210171|NCT00635570|Active Comparator|Contraceptive vaginal ring|Contraceptive vaginal ring (NuvaRing)
89210172|NCT00635570|Active Comparator|Oral contraceptive pill|Oral contraceptive pill (Ortho Tri-cyclen Lo)
89598590|NCT05804136|Other|Duramesh|"Laparotomy closure is associated with the occurrence of Surgical Site Events (SSEs) such as wound dehiscence and incisional hernias. Abdominal wall closure can also cause pain and discomfort, or can lead to intestinal obstruction.~Standard sutures can cut through otherwise intact tissue due to the presence of a sharp leading edge leading to repair failure. Meshes distribute forces and allow for tissue ingrowth. Duramesh combines the desirable principles of a mesh repair with the placement precision of a suture. It is the world's first device that both approximates tissue and allows ingrowth for a strong early repair.~Consequently, the expected clinical benefit is the reduced occurrence of Surgical Site Events such as incisional hernias. Additional benefits may include reduced pain and improved quality of life due to durable closure of the abdominal wall with Duramesh. This will be evaluated in this randomized study.~Size 1 Duramesh is used in this RCT. Duramesh is CE-marked."
89598591|NCT05804136|Other|Standard suture|2-0, 0, or Number 1 polydioxanone suture (PDS) is used as comparator.
89598592|NCT05803759|Active Comparator|Allicor|Dietary Supplement: Allicor 150 mg capsule by mouth two times a day
89598593|NCT05803759|Placebo Comparator|Placebo|Placebo capsule manufactured to mimic Allicor 150 mg capsule by by mouth two times a day
89598594|NCT05801861|Experimental|Active 10-Hz rTMS|For the first TMS session, participants will receive 10-Hz repetitive TMS (rTMS) delivered at 110% of participants' resting motor threshold over the predefined parietal target for a total of 2250 pulses. For the second TMS session, participants will receive single pulse TMS during the phase target of each task trial and delivered at 110% of participants' resting motor threshold over the predefined parietal target for a total of 200 pulses.
89598595|NCT05801861|Experimental|Active single-pulse rTMS|For the first TMS session, participants will receive a single TMS pulse during the phase target of each task trial and delivered at 110% of participants' resting motor threshold over the predefined parietal target for a total of 300 pulses. For the second TMS session, participants will receive single pulse TMS during the phase target of each task trial and delivered at 110% of participants' resting motor threshold over the predefined parietal target for a total of 200 pulses.
89598596|NCT05801861|Sham Comparator|Sham 10-Hz rTMS|Identical parameters of the active 10-Hz rTMS group will be applied to the SHAM group with the exception that the TMS coil will be flipped 180º to mimic auditory stimulation.
89598597|NCT05801861|Sham Comparator|Sham single-pulse rTMS|Identical parameters of the active single-pulse rTMS group will be applied to the SHAM group with the exception that the TMS coil will be flipped 180º to mimic auditory stimulation.
89598598|NCT05795257||None-mild ARDS|
89598599|NCT05795257||Moderate-severe ARDS|
89598600|NCT05786378|Experimental|platlet rich plasma|
89598601|NCT05785845|Experimental|Computed Tomography-Guided Stereotactic Adaptive Radiotherapy (CT-STAR)|In this study, consenting and eligible patients will receive a prescription dose of 55 Gy in 5 fractions delivered on consecutive business days with adaptation based on daily anatomic changes as per clinical standard of care.
89598602|NCT05782738|Active Comparator|Reverse TAP|
89598603|NCT05782738|Active Comparator|External Minicrush|
89598604|NCT05781880|Experimental|NBO group|Normobaric hyperoxia (NBO) oxygen group will be given 100% oxgen (10L/min for 4h) via a face mask.
89598605|NCT05781880|Placebo Comparator|Control group|Control group will be given nasal oxygen (2L/min for 4h）. All other therapy measures are the same as experimental group.
89598606|NCT05778344|Experimental|Home-based pulmonary rehabilitation group|The home-based pulmonary rehabilitation group will receive breathing exercise instructions using online learning materials soon after randomization. The participants will receive a home-based exercise plan, which comprises aerobic exercise and resistance exercise with instruction sheets. The participants will also be given a smart watch (to record heart rate, step count and distance in daily life) and a portable pulse oximeter (to monitor heart pulse and oxygen saturation during exercise) for 12 weeks. Teletechnology will be incorporated into home-based pulmonary rehabilitation via videotelephony (or telephone calls if indicated). Time points for these teletechnology-assisted consultations will be at day 7, day 14 after randomization and every 2 weeks after that until the completion of the study (week 12).
89598607|NCT05778344|Active Comparator|Usual care group|The usual care group will receive breathing exercise instructions using online learning materials soon after randomization. The participants will also receive general exercise education and exercise safety principles but not any consultation about their physical activity/exercise during the study period.
88979585|NCT00083603|Experimental|3|rMVA-HIV env/gag and rMVA-HIV tat/rev/nef-RT administered as two separate 1-mL intramuscular injections, with rMVA-HIV env/gag into the left deltoid, rMVA-HIV tat/rev/nef-RT into the right deltoid at Days 0, 28; rFPV-HIV env/gag and rFPV-HIV tat/rev/nef-RT administered as two separate 1-mL intramuscular injections, with rFPV-HIV env/gag into the left deltoid, rFPV-HIV tat/rev/nef-RT into the right deltoid at Days 84, 140, and 196
89031961|NCT02940756|Experimental|Dihydroartemisinine-piperaquine|Tablets containing 20 mg of dihydroartemisinine and 160 mg of piperaquine. Half a tablet once daily for children weighing 5 to <7 kg, one tablet once daily for those weighing 7 to <13 kg, and two tablets once daily for those weighing 13 to <24 kg, for three days.
89598608|NCT05772572||Patients|Children aged 7 to 17 inclusive, and young adults operated (or re-operated) for a Moya Moya in the previous 7 years and followed at the Necker-Enfants Malades hospital, and their parents.
89598609|NCT05770596|Experimental|Vitamin C group|patients in this group will receive 2 gm vitamin C orally 1 hour before surgery and will receive 0.5 gm vitamin C per day orally for 50 days starting from the 2nd postoperative day.
89598610|NCT05770596|Placebo Comparator|Placebo group|patients in this group will receive placebo tablets with the same manner.1 hour before surgery and for 50 days starting from the 2nd postoperative day.
89598611|NCT05766358||Placebo|
89598612|NCT05766358||Tirzepatide|
89598613|NCT05762926|Experimental|Experimental|Experimental: Neuronavigation system guided halocranial application of focused sound wave pulses, using the Storz Neurolith™ equipment.
89598614|NCT05762926|Active Comparator|Active Comparator|Neuronavigation system guided halocranial application without sound waves pulses, using the Storz Neurolith™ sham equipment, prepared to block the sound waves.
88979586|NCT00083603|Placebo Comparator|4|Empty TBC-MVA vector administered in each deltoid on Days 0, 28; empty TBC-FPV vector administered in each deltoid on Days 84, 140, and 196
89598615|NCT05751317||samples containing Enterococci|"Isolates of Enterococci will be identified by Gram staining, colony morphology, catalase test, and growth on Bile Esculin agar. All isolates will be identified to species level using Vitek2 automated system Strains confirmed as Enterococci will be examined for their antibiotic susceptibility by modified Kirby Bauer's disc diffusion method on MuellerHinton Agar.~The biofilm formation activity of Enterococci isolates will be tested using the microtiter plate technique Detection of the effect of nanoparticles on the antibiotic susceptibility profile of Enterococci. Detection of the effect of nanoparticles on the biofilm producing Enterococci. Molecular identification of some virulence factors genes and antibiotic resistance genes of Enterococci using PCR"
89598616|NCT05751317||samples with bacteria other than enterococci|
89598617|NCT05748470|Experimental|Test group|
89598618|NCT05748470|Active Comparator|Control group|
89598619|NCT05746182||Participants with Pancreatic Neuroendocrine Neoplasms|
89598620|NCT05745909|Active Comparator|Loop transverse colostomy|Laparoscopic or open low-anterior resection of the rectum with total mesorectal excision and created loop transverse colostomy
89598621|NCT05745909|Experimental|Loop ileostomy|Laparoscopic or open low-anterior resection of the rectum with total mesorectal excision and created loop ileostomy
89598622|NCT05740228|Experimental|Anodal tDCS|The anode is placed over the primary motor cortex of the stroke affected hemisphere, the cathode over the contralesional supraorbital front of the patient.
89598623|NCT05740228|Experimental|Anodal High-Definition (HD) tDCS|A single HD anode is placed over the primary motor cortex of the stroke affected hemisphere, 4 HD cathodes are placed over the affected hemisphere around the anode.
89598624|NCT05740228|Sham Comparator|Sham stimulation|The electrodes are placed as in one of the active arms, but only a ramp up current is applied during 30 seconds and then switched off. This induces similar sensations for the patients, but no change in excitability.
89598625|NCT05737667|Experimental|YRI+Mobile Supervision|Youth Readiness Intervention delivered by teachers receiving mobile-based supervision
89598626|NCT05737667|Active Comparator|YRI+Standard Supervision|Youth Readiness Intervention delivered by teachers receiving standard supervision
89598627|NCT05737667|No Intervention|Control|Wait listed control
89031962|NCT02949245||Groups/Cohorts|"Surgical treatment~This observational study is examining the outcomes of standard surgical treatments for adult spinal deformity."
89031963|NCT02939547|Active Comparator|Hydroxypropyl-beta-cyclodextrin IV 1500 mg/kg|Hydroxypropyl-beta-cyclodextrin administered by slow IV infusion for 8 - 9h every 2 weeks
89031964|NCT02939547|Active Comparator|Hydroxypropyl-beta-cyclodextrin IV 2500 mg/kg|Hydroxypropyl-beta-cyclodextrin administered by slow IV infusion for 8 - 9h every 2 weeks
89031965|NCT02949167|Experimental|MyHealth intervention arm|Nurse-led follow-up
89031966|NCT02949167|No Intervention|MyHealth Control condition|Physician-led follow-up
89031967|NCT02941068|Experimental|Prophylactic group|Patients would received intravenous fluconazole (loading dose 800 mg, then 400 mg/day) or caspofungin (loading dose 70 mg, then 50 mg/day) if patients had organ failure or renal or liver dysfunction during the immediately surgery. The antifungal treatment would continue for 5 to 7 days.
89031968|NCT02941068|No Intervention|Empirical group|
89031969|NCT00517712|Active Comparator|A|Duration of maintenance therapy with single agent ATO of 12 months
89598628|NCT05737004||Prostate cancer group|Prostate cancer was confirmed by biopsy, and fMRI examination 、Zung Self Rating Anxiety Scale and Beck Depression Inventory-II were performed in these patients within 1 week before biopsy .
89031970|NCT00517712|Active Comparator|B|Duration of maintenance therapy with single agent ATO for 6 months
89031971|NCT00518843|Experimental|FBT-BN|Family-based treatment
89031972|NCT00518843|Active Comparator|SPT|Individual Supportive Psychotherapy
89031973|NCT00517907|Experimental|1|6 steroid-resistant acute GVHD patients, post-matched BMT (serial)
89031974|NCT02939274|Other|Open Label|Continuous Low-Irradiance Photodynamic Therapy (CLIPT) Using Verteporfin
89031975|NCT00518921|Experimental|Arm 1|
89598629|NCT05737004||Non-Prostate cancer group|Non-Prostate cancer was confirmed by biopsy, and fMRI examination 、 Zung Self Rating Anxiety Scale and Beck Depression Inventory-II were performed in these patients within 1 week before biopsy .
89598630|NCT05733013||Participants with refractory thyroid cancer patients|
89608538|NCT01273948|Experimental|Bavituximab 3 mg/kg|Bavituximab 3 mg/kg given by intravenous (IV) infusion once weekly, plus oral ribavirin 1000 mg (weight <75 kg) or 1200 mg (weight greater than or equal to 75 kg) divided into twice-daily doses, for 12 weeks
89031976|NCT00518921|Experimental|Arm 2|
89031977|NCT00518921|Experimental|Arm 3|
89031978|NCT00518921|Placebo Comparator|Arm 4|
89031979|NCT00516659|Active Comparator|Group 1|Group 1 subjects will receive two vaccinations via transcutaneous immunization (TCI), 14 to 21 days apart, with a patch containing 37.5µg LT
89031980|NCT00516659|Placebo Comparator|Group 2|Group 2 subjects will receive two vaccinations via transcutaneous immunization (TCI), 14 to 21 days apart, with a patch containing 0µg LT (placebo patch containing no LT)
89031981|NCT02940600|Experimental|Normothermic machine perfusion|Patients undergoing liver transplant with grafts preserved using normothermic machine perfusion
89031982|NCT02940600|Active Comparator|Static cold storage|Patients undergoing liver transplant with statically cold preserved grafts
89031983|NCT00518999||1|Schizophrenia patients who performed earlier cognitive assessment as part of routine assessment for patients in the Shalvata Mental Health Center.
89031984|NCT02949401|No Intervention|Standard of Care|"No research intervention to be administered.~Participants will have standard preparation for a procedure including discussion of the procedure with the provider the day before the procedure with all questions answered at that time."
89210173|NCT00986115|Active Comparator|Memantine|After a two-month prospective baseline during which seizure frequency and neurocognitive parameters are documented, patients will be randomized to either memantine or placebo and evaluated after twelve months on study drug. The treatment period will consist of a one month dose escalation phase, followed by an eleven month maintenance phase. The dose escalation is 5 mg in PM for days 1-7, 5 mg twice daily for days 8-14, 5 mg in AM and 10 mg in PM for days 15-21 and 10 mg twice daily from day 22 and continue.
89598631|NCT05723029|Experimental|Group A: Bowen Technique|The subjects will receive Bowen Technique. The treatment session will be 3 times per week for 4 weeks for 20 minutes. The Bowen technique is a subtle and precise mobilization called Bowen moves. The mobilization is applied by using the fingers and thumbs over muscles, tendon, nerves and fascia. Only gentle non-invasive pressure is applied. A Bowen moves challenges the muscles for several seconds by the application of a gentle lateral pressure applied by the therapist thumb, against its medial edge. The muscle fibres and its fascia are disturbed from their neutral position and they are slightly stretched. The therapist apply gentle pressure towards the muscles using the skin slack available, and then rolls the thumb across the muscles and gently compressing it, the muscle will bounce back to its original position. The therapist has a sense of tissue tension, and this enables his/her to feel where stress has built up in the tissue.
89598632|NCT05723029|Experimental|Group B: Post Isometric Relaxation Technique|The subjects will receive Post Isometric Relaxation Technique. Treatment session includes 3 times per week for 4 weeks for 20 minutes. Evaluation will be done before and after the treatment at the end of the 4th week. The outcome will be measured by the Active Knee Extension test, Numeric pain Rating Scale, and Goniometer. Post Isometric Relaxation is performed in supine position on treatment table. The therapist passively flexed the hip and knee at the 90 degrees and then passively extends the knee until the point of tissue resistance. Patient placed their leg on therapist shoulder and contracts his hamstring muscles by pushing down on the therapist shoulder for 10 seconds. After the contraction, patient is asked to relax, then therapist passively stretch to gain new range of muscles. The intervention is performed three times in a single session with 30 seconds rest intervals.
89598633|NCT05720377|Experimental|Obese, receives access to exercise phone application|obese, receives access to exercise phone application and interval contact by health provider in between clinic visits , receives continuous glucose monitor
89598634|NCT05720377|No Intervention|Obese, no intervention|obese, receives continuous glucose monitor
89598635|NCT05720377|Experimental|Prediabetes, receives access to exercise phone application|prediabetes receives access to exercise phone application and interval contact by health provider in between clinic visit, receives continuous glucose monitor
89598636|NCT05720377|No Intervention|Prediabetes, no intervention|prediabetes, receives continuous glucose monitor
89598637|NCT05720377|Experimental|Type 2 diabetes, receives access to exercise phone application|prediabetes receives access to exercise phone application and interval contact by health provider in between clinic visit, receives continuous glucose monitor
89598638|NCT05720377|No Intervention|Type 2 diabetes, no intervention|Type 2 diabetes, receives continuous glucose monitor
89598639|NCT05720299|Experimental|low-dose Akkermansia muciniphila group|They were treated with one bag of test drugs (one bag each time, twice a day, for 12 weeks)
89598640|NCT05720299|Experimental|high-dose Akkermansia muciniphila group|They were treated with one bag of test drugs (one bag each time, twice a day, for 12 weeks)
89598641|NCT05720299|Placebo Comparator|Placebo group|They were treated with one bag of test drugs (one bag each time, twice a day, for 12 weeks)
89598642|NCT05719701|Experimental|ICP-490|ICP-490 is administered continuously on Days 1-21, QD in every 28-day cycle. Patients who develop progressive disease (PD) at any timepoint during ICP-490 treatment, or who do not respond after completing 4 treatment cycles, dexamethasone can be added to the current ICP-490 dose level.
89598643|NCT05716984|Active Comparator|recombinant human brain natriuretic peptide|loading dose 1.5 μg/kg iv, followed by 0.0075 μg/kg·min with micro-pump injection for 72 hours.
89598644|NCT05716984|Placebo Comparator|placebo|loading dose 1.5 μg/kg iv, followed by 0.0075 μg/kg·min with micro-pump injection for 72 hours.
89598645|NCT05715177|Experimental|Cura kinesio-taping|consisted of 25 subjects who will receive kinesio-taping from origin to insertion on the superficial muscles of Quadriceps femoris (QF) (Vastus Medialis (VM), Vastus Lateralis (VL), Rectus Femoris (RF)
89598646|NCT05715177|Placebo Comparator|Placebo kinesio-taping|consisted of 25 subjects who will receive placebo kinesio-taping across quadriceps.
89598647|NCT05715034|Experimental|Compassionate Care|Single-session, self-guided web-based intervention (~45 minutes) hosted on Qualtrics with animated videos, audio-guided exercises, graphics, text-based material, and interactive questions. This intervention is designed to teach participants about mindfulness and self-compassion.
89031985|NCT02949401|Experimental|Virtual Reality|The VR interactive module will consist of a 360° visit to the Hospital where patients encounter the various aspects of a procedure from the front door; through the pre-operative area where patients will receive an IV; to the catheterization lab and placement of the anesthesia mask; and back to the post anesthesia care unit. Patients will be accompanied by a child who acts as a guide to the experience. The guide will help explain what the patient is seeing and what to expect along the way. Health care professionals will be enmeshed within the scenarios and will also help with the explanations along the way. Patients will be prompted to enter the relaxation scenarios at different stressful times along the tour to practice relaxation and mindfulness techniques (i.e. before IV start, or upon entering catheterization laboratory). Relaxation scenarios will include a snow scene, tropical beach or other guided imagery scenes.
89031986|NCT03458091|Active Comparator|Intubation|The patients will be intubated and ventilated
89031987|NCT03458091|Experimental|THRIVE|The patients will be oxygenated during apnea using THRIVE
89031988|NCT04690920|No Intervention|Control|
89031989|NCT04690920|Experimental|Tocilizumab|
89031990|NCT04690920|Experimental|Remdesivir|
89598648|NCT05715034|Active Comparator|Relaxing with Nature|Single-session self-guided web-based intervention (~30 to 45 minutes) hosted on Qualtrics with videos (real-life images), text-based material, and questions. Each video includes a sequence of pleasant nature photos (shown about 6 seconds each) with relaxing music in the background.
89598649|NCT05713448||Type 1 diabetes|Individuals with type 1 diabetes
89608539|NCT01273948|Experimental|Bavituximab 0.3 mg/kg|Bavituximab 0.3 mg/kg given by IV infusion once weekly, plus oral ribavirin 1000 mg (weight <75 kg) or 1200 mg (weight greater than or equal to 75 kg) divided into twice-daily doses, for 12 weeks
89598650|NCT05713305|Experimental|Intervention group|Daily members of the intervention group were thought to provide three different forms of daily sessions each day, averaging 10-20 minutes. These sessions included psycho-educational and cognitive-behavioral exercises, music therapy, sleep hygiene, stress relief methods. Weekly online lecture sessions presented by professional mental health therapists. In-depth interviews are conducted both before and after the experiment to explore the feasibility of the intervention
89598651|NCT05713305|Placebo Comparator|Control group|They will receive official mental health recommendations on how to cope mentally with the pandemic. These recommendations inform about the importance of a daily structure, social contact, acceptance of negative emotions and strengthening of positive emotions, and stimulus control to assimilate SARS-CoV-2 Omicron-related news. In-depth interviews are conducted both before and after the experiment to explore the feasibility of the intervention
89598652|NCT05698160||coagulation dysfunction group|The critically ill patients in intensive care unit showed coagulation dysfunction after treated with tigecycline.
89598653|NCT05698160||non-coagulation dysfunction group|The critically ill patients in intensive care unit showed normal coagulation function after treated with tigecycline.
89598654|NCT05689879|No Intervention|REMAIN arm|Infliximab 3 to 5 mg/kg every 4-8 weeks, methotrexate 7.5-10 mg/week (or azathioprine 1 mg/Kg/day), steroids < or = 10 mg/day
89598655|NCT05689879|Other|STOP arm|Methotrexate 0.3 mg/kg/week (or azathioprine 2 mg/kg/day (or 1 mg/kg/day if intermediary metabolism TMPT) (the dose of methotrexate will not exceed 25mg/kg/week wathever the weight of the patient), steroids < or = 10 mg/d
89598656|NCT05688904|Active Comparator|Imipramine|Topical 4% Imipramine
89598657|NCT05688904|Placebo Comparator|Vehicle|Vehicle
89598658|NCT05687357|Experimental|Arm A: Tislelizumab + Chemoradiotherapy|"Neoadjuvant: Prior to surgery, participants receive 4 cycles of Tislelizumab 200 mg via intravenous (IV) infusion on C1D1, C2D1, C2D22, C3D1 PLUS radiotherapy (TOMO or VMAT) 45Gy/1.5f PLUS S-1 initial dose depends on the body surface area, PO, bid, C1D1~D14，C2D1~C2D5, C2D8~C2D12, C2D15~C2D19, C2D22~C2D26, C2D29~C2D33, C3D1~D14 and oxaliplatin 130mg/m^2, IV, C1D1 and C3D1 OR S-1 initial dose depends on the body surface area, PO, bid, C1D1~D14，C3D1~D14 and nab-paclitaxel, IV 100~120mg/m^2，IV，C1D1，C1D8，C2D1，C2D8，C2D16，C2D22，C3D1 and C3D8.~Adjuvant: 4 to 10 weeks post-surgery, participants receive 3 cycles of SOX OR S-1 and nab-paclitaxel AND 3 cycles of S-1, AND up to 16 cycles of Tislelizumab 200 mg via IV infusion on Day 1 Q3W."
89598659|NCT05687357|Active Comparator|Arm B: Chemoradiotherapy|"Neoadjuvant: Prior to surgery, participants receive radiotherapy (TOMO or VMAT) 45Gy/1.5f PLUS S-1 initial dose depends on the body surface area, PO, bid, C1D1~D14，C2D1~C2D5, C2D8~C2D12, C2D15~C2D19, C2D22~C2D26, C2D29~C2D33, C3D1~D14 and oxaliplatin 130mg/m^2, IV, C1D1 and C3D1 OR S-1 initial dose depends on the body surface area, PO, bid, C1D1~D14，C3D1~D14 and nab-paclitaxel, IV 100~120mg/m^2，IV，C1D1，C1D8，C2D1，C2D8，C2D16，C2D22，C3D1 and C3D8.~Adjuvant: 4 to 10 weeks post-surgery, participants receive 3 cycles of SOX OR S-1 and nab-paclitaxel AND 3 cycles of S-1."
89598660|NCT05687357|Active Comparator|Arm C: Chemotherapy|"Neoadjuvant: S-1 initial dose depends on the body surface area, PO, bid, D1~D14，Q 3W for 6 cycles, and oxaliplatin 130mg/m^2, IV, D1 of each cycle for 6 cycles OR nab-paclitaxel, IV 100~120mg/m^2，IV，D1 and D8 for each cycle for 6 cycles.~Adjuvant: 4 to 10 weeks post-surgery, participants receive 3 cycles of SOX OR S-1 and nab-paclitaxel AND 3 cycles of S-1."
89598661|NCT05675943|Experimental|Anti-COVID-19 Antibody SA55 for Injection|Anti-COVID-19 Antibody SA55 for Injection
89598662|NCT05675943|Placebo Comparator|Placebo|Anti-COVID-19 Antibody SA55 for Injection administered intramuscular
89598663|NCT05673330|Active Comparator|Spinal Mobilizations|"Headache SNAG: A posteroanterior mobilization of the second cervical vertebrae is sustained for 10 to 30 s with the aim to reduce headache intensity at the time of application. (6)~Maitland's C1-C7 PA Glide: A posteroanterior (PA) mobilization of the first till seventh cervical vertebra is achieved by applying a force on to a vertebral segment in a posteroanterior direction (Back to front).~The patients will receive Spinal Mobilizations consisting of 1 set of 6 repetitions once daily thrice per week for four weeks. Pre and post intervention values will be taken on 1st day and after 4 weeks."
89608540|NCT01273948|Active Comparator|Pegylated interferon (PEG-IFN)|Pegylated interferon (PEG-IFN) alpha-2a 180 micrograms given by subcutaneous (SC) injection once weekly, plus oral ribavirin 1000 mg (weight <75 kg) or 1200 mg (weight greater than or equal to 75 kg) divided into twice-daily doses, for 12 weeks
88979587|NCT00083603|Experimental|5|rMVA-HIV env/gag and rMVA-HIV tat/rev/nef-RT administered as two separate 1-mL intramuscular injections, with rMVA-HIV env/gag into the left deltoid, rMVA-HIV tat/rev/nef-RT into the right deltoid at Days 0, 28; rFPV-HIV env/gag and rFPV-HIV tat/rev/nef-RT administered as two separate 1-mL intramuscular injections, with rFPV-HIV env/gag into the left deltoid, rFPV-HIV tat/rev/nef-RT into the right deltoid at Days 84, 140, and 196
89608541|NCT00734344|Active Comparator|Arm 1|Raltegravir plus Truvada
88979588|NCT00083603|Placebo Comparator|6|Empty TBC-MVA vector administered in each deltoid Days 0, 28; empty TBC-FPV vector administered in each deltoid Days 84, 140, and 196
88979589|NCT00083603|Experimental|7|rMVA-HIV env/gag and rMVA-HIV tat/rev/nef-RT administered as two separate 1-mL intramuscular injections, with rMVA-HIV env/gag into the left deltoid, rMVA-HIV tat/rev/nef-RT into the right deltoid at Days 0, 28; rFPV-HIV env/gag and rFPV-HIV tat/rev/nef-RT administered as two separate 1-mL intramuscular injections, with rFPV-HIV env/gag into the left deltoid, rFPV-HIV tat/rev/nef-RT into the right deltoid at Days 84, 140, and 196
88979590|NCT00083603|Placebo Comparator|8|Empty TBC-MVA vector administered in each deltoid Days 0, 28; empty TBC-FPV vector administered in each deltoid Days 84, 140, and 196
88979591|NCT00083603|Experimental|9|rMVA-HIV env/gag and rMVA-HIV tat/rev/nef-RT administered as two separate 1-mL intramuscular injections, with rMVA-HIV env/gag into the left deltoid, rMVA-HIV tat/rev/nef-RT into the right deltoid at Days 0, 28, 84, 140, 196
88979592|NCT00083603|Placebo Comparator|10|Empty TBC-MVA vector administered in each deltoid Days 0, 28, 84, 140, 196
88979593|NCT00083603|Experimental|11|rFPV-HIV vaccine administered as two separate 1-mL intramuscular injections, with rFPV-HIV env/gag into the left deltoid, rFPV-HIV tat/rev/nef-RT into the right deltoid at Days 0, 28, 84, 140, and 196
89031991|NCT04690920|Active Comparator|Standard Treatment|
89608542|NCT00734344|Active Comparator|Arm 2|Efavirenz plus Truvada
89031992|NCT00519038|Experimental|1|Patients treated according to clinical pathways
89031993|NCT00519038|Other|2|Patients treated according to usual care
89598664|NCT05673330|Active Comparator|Myofascial Release technique|"Suboccipital Inhibition Technique: While the patient will be in the supine position, the physician sitting at the top end of the table will place the fingers of both hands on the patient's suboccipital region. Flexi-perpendicular long fingers exerting an inhibitory pressure on the muscle insertions of the neck extensors in the occiput, perpendicularly to muscle fibers, while the thumbs counterbalance the head against rotation. A deep and progressive pressure would be applied perpendicular to the fibers until a decrease in muscle tone would be detected. This deep and progressive pressure would be maintained for a total of 10 min until release of suboccipital tissues is achieved.~The patients will receive myofascial release with the frequency of 1 set and 10 repetitions once a day three times per week for four weeks. Pre and post intervention values will be taken on 1st day and after 4 weeks."
89598665|NCT05657769|Experimental|Group I (Treatment)|Regular diabetes treatment with additional Medwell application and wearable device.
89598666|NCT05657769|Active Comparator|Group II (Control)|Regular diabetes treatment only with a diary card to record daily activities manually.
89598667|NCT05656924|Experimental|digital prosthetic interface technology group|Study participants randomized to this group will use the digital prosthetic interface technology developed by Bionic Skins.
89598668|NCT05656924|No Intervention|traditional socket and liner technology group|Study participants randomized to this group will use a traditional socket-liner technology (i.e., study participants will use their own liner and socket system).
89598669|NCT05653934|Experimental|Immersive reality group|patients receive care according to the usual practices of the department as well as virtual reality. Virtual reality immersion offers a visual and auditory experience during a soothing journey through visual worlds filmed in natural environments. Virtual reality headset is put on the day before the operation and in the morning just before going to the operating theatre (only on the morning of the operation for patients hospitalized the same day). The colorectal cancer surgery then proceeds as usual. In the postoperative period, virtual reality sessions are offered every day and on request without any limit in number (day and night).
89598670|NCT05653934|Active Comparator|Standard care group|patients are treated according to usual practices of the department and do not have access to virtual reality.
89598671|NCT05653570|Active Comparator|Ultrasound Guidance Only|
89598672|NCT05653570|Experimental|Electrical stimulation and Ultrasound Guidance|
89598673|NCT05648539|Experimental|The clinical response of the music therapy|To assessthe efficacy of music therapy of MT group compared to Waiting group in mental subhealth.
89598674|NCT05648539|Experimental|The alterations of acoustic features in the music therapy|To understand the possible biological mechanism underlying the efficacy of music therapy by analyzing alterations of acoustic features.
89598675|NCT05646654|Active Comparator|Erector spinae plane block group|3ml lidocaine 2% will be used to anesthetize the skin. Using a 20-gauge block needle put in-plane in a cephalad-to-caudad orientation to position the tip into the fascial plane on the deep (anterior) side of the erector spinae muscle, 20 ml bupivacaine 0.5% will be injected.
89598676|NCT05646654|Active Comparator|Interscalene group|Using a lateral-to-medial approach, the 25-gauge needle will be inserted into the middle scalene muscle, advanced, and placed immediately lateral to the nerve roots. the needle will be visualize using an ultrasound beam to avoid intraneural and intravascular injections. After confirming negative blood aspiration, we will inject 15 mL of 0.5% bupivacaine around the nerve roots
89598677|NCT05645159|Experimental|Physiotherapy students|The participants performed an 8-week heart disease blended learning program.
89598678|NCT05643482|Experimental|HBOT Arm|Pressurized at 2.0 atmospheres absolute of pressure (ATA) Breathe 100% oxygen 90 minute session, 5 days per week, for 20 sessions
89598679|NCT05643482|Sham Comparator|Control Arm|Placebo Gas Pressurized at 2.0 ATA Breathe placebo gas system of 10.5% oxygen and 89.5% nitrogen to mimic the partial pressure of oxygen breathed in regular air at sea level pressure 90 minute session, 5 days per week, for 20 sessions
89598680|NCT05636280|Experimental|schroth exercise group|In this study, Schroth exercise training applied 3 days a week for 6 weeks in people with Adolescent Idiopathic Scoliosis will be applied by a physiotherapist trained in schroth.
89598681|NCT05636280|Active Comparator|traditional scoliosis exercise group|In this study, traditional scoliosis exercise training applied 3 days a week for 6 weeks in people with Adolescent Idiopathic Scoliosis will be applied by a physiotherapist.
89598682|NCT05633693|Experimental|Counterpressure Maneuvers|"Counterpressure maneuver (CPM) trials will be performed in front of a neutral wall in silence to ensure that visual or auditory stimuli do not affect movement.~CPM:~Leg crossing and muscle tensing: Legs are crossed while upright and lower body musculature is isometrically contracted (clinical)~Crouching: Participant crouches down resting weight on the balls of their feet, pressing calves against the back surface of the thighs (clinical)~Exaggerated anterior-posterior sway: Participant sways back and forth with feet planted on ground at a pace/amplitude that is comfortable (discrete)~Gluteal clenching: Participant rhythmically tenses and relaxes the gluteal muscles at a pace/duration that is comfortable (discrete)~Participants serve as their own controls and complete both testing arms."
89608543|NCT04148937|Experimental|Cohort A LY3475070|LY3475070 administered orally.
89608544|NCT04148937|Experimental|Cohort B LY3475070 + Pembrolizumab|LY3475070 administered orally and pembrolizumab administered intravenously (IV).
89608545|NCT04148937|Experimental|Cohort C1 LY3475070 + Pembrolizumab|LY3475070 administered orally and pembrolizumab administered IV.
89608546|NCT04148937|Experimental|Cohort C2 LY3475070|LY3475070 administered orally.
89608547|NCT04148937|Experimental|Cohort D1 LY3475070 + Pembrolizumab|LY3475070 administered orally and pembrolizumab administered IV.
88979594|NCT00083603|Placebo Comparator|12|Empty TBC-FPV vector administered as two separate 1-mL intramuscular injections, one into each deltoid at Days 0, 28, 84, 140, and 196
88979595|NCT00083603|Experimental|13|rMVA-HIV env/gag and rMVA-HIV tat/rev/nef-RT administered as two separate 1-mL intramuscular injections, with rMVA-HIV env/gag into the left deltoid, rMVA-HIV tat/rev/nef-RT into the right deltoid at Days 0, 28; rFPV-HIV env/gag and rFPV-HIV tat/rev/nef-RT administered as two separate 1-mL intramuscular injections, with rFPV-HIV env/gag into the left deltoid, rFPV-HIV tat/rev/nef-RT into the right deltoid at Days 84, 140, and 196
89598683|NCT05633693|Sham Comparator|Baseline Stand|"Participants will perform a sit-stand test, followed by 5-minutes of baseline (quiet) standing trial on a force platform while cardiorespiratory responses are recorded.~Sit-stand test: following 5-minutes of supine rest, the participant will be passively moved into the seated position. They will then be asked to actively move into the standing position.~Baseline stand: immediately following the sit-stand test, the baseline trial will begin. Participants will stand quietly on the force platform for 5-minutes. This trial will be performed in front of a neutral wall in silence to ensure that visual or auditory stimuli do not affect their movement.~Participants serve as their own controls and complete both testing arms."
89598684|NCT05633446|Experimental|PepGNP-COVID19 (One vaccination)|One vaccination of PepGNP-COVID19 vaccine candidate administered on Day 0 (50 µl per dose)
89598685|NCT05633446|Placebo Comparator|Placebo (One vaccination)|One vaccination of WFI administered on Day 0 (50 µl per dose)
89598686|NCT05633446|Experimental|PepGNP-COVID19 (Two vaccinations)|Two vaccinations of PepGNP-COVID19 vaccine candidate administered on Day 0 and Day 21 (50 µl per dose)
89598687|NCT05633446|Placebo Comparator|Placebo (Two vaccinations)|Two vaccinations of WFI administered with on Day 0 & Day 21 (50 µl per dose)
89598688|NCT05618938|Experimental|Group: A Rocabado's approach|"Rest position of the tongue: The anterior 1/3 of the tongue is placed at the palate with mild pressure.~Control of TMJ rotation: The jaw is repeatedly opened and closed with the anterior 1/3 of the tongue on the palate.~Rhythmic stabilization technique: Gentle isometrics in the resting position are performed for jaw opening, closing, and lateral deviation.~Axial extension of the neck: Combined upper cervical flexion with lower cervical extension."
89598689|NCT05618938|Experimental|Group B: Kraus exercises|"Group B will be treated with Kraus exercises. Kraus exercises will be comprised of eight exercise programs.~Tongue position at rest: The patient will be instructed to maintain a resting tongue position except during function, which involves the tip of the tongue sitting on the palate with the tip resting just posterior to the upper incisors~Teeth apart: the patient will be educated to maintain the teeth apart can be therapeutic, which facilitates the resting tongue position~Nasal-diaphragmatic breathing: The patient will be instructed in nasal breathing to facilitate function of the diaphragm, which reinforces positioning of both the tongue and teeth~Tongue up and wiggle: Place the tongue to the palate, then move the jaw from side to side.~Strengthening: Resisted closing via self-manual resistance using tongue depressor between lower incisors: 5-10-second contractions."
89598690|NCT05616065|Experimental|Blinded|Interviewers will be assigned a candidate to interview. They will be asked not to review the medical school transcripts or standardized test scores (USMLE, COMLEX). They will be permitted to review personal statements, letters or recommendation, and other personal information in the application.
89598691|NCT05616065|Active Comparator|Unblinded|Interviewers will be assigned a candidate to interview. They will be given full permission to review the full application of their candidate as per their normal interview protocol.
89598692|NCT05612139||JTIN treated patients|Pediatric patients, older than 18 months, suffering from osteogenesis imperfecta treated with JTIN telescopic nail
89598693|NCT05589350|Experimental|High-fat yogurt|Daily consumption of 1-2 servings (based on daily calorie requirement) of high-fat yogurt
89598694|NCT05589350|Active Comparator|Low-fat yogurt and butter|Daily consumption of 1-2 servings of low-fat yogurt along with daily consumption of about 10 grams of animal butter
89598695|NCT05586152|Experimental|INV-102 0.1% BID|Part 1, Cohort 1: INV-102 ophthalmic solution 0.1% administered twice daily for 2 weeks
89598696|NCT05586152|Experimental|INV-102 0.25% BID|Part 1, Cohort 2: INV-102 ophthalmic solution 0.25% administered twice daily for 2 weeks
89598697|NCT05586152|Experimental|INV-102 0.7% BID|Part 1, Cohort 3: INV-102 ophthalmic solution 0.7% administered twice daily for 2 weeks
89598698|NCT05586152|Experimental|INV-102 0.7% TID|Part 1, Cohort 4: INV-102 ophthalmic solution 0.7% administered three times daily for 2 weeks
89598699|NCT05586152|Experimental|INV-102 TBD% BID|Part 2, Cohort 5: INV-102 ophthalmic solution administered for 2 weeks using a dose based on the results from Part 1, Cohorts 1 to 4
89598700|NCT05586152|Placebo Comparator|Vehicle|Part 1 (Cohorts 1-4) and Part 2 (Cohort 5): Vehicle ophthalmic solution administered two or three times daily (dependent on the cohort and the frequency of dosing of INV-102) for 2 weeks
89598701|NCT05565222|Experimental|Piperacillin/tazobactam or temocillin|Piperacillin/tazobactam, 4.5 g by intravenous route every 6 hours (adjusted in case of renal failure). Piperacillin/tazobactam will be infused over 4 hours. Duration of treatment will be adjusted according to the site of infection Temocillin, 6g/24 hours infused continuously by intravenous route after 2 g loading dose (adjusted in case of renal failure). Temocillin will be infused continuously. Duration of treatment will be adjusted according to the site of infection
89598702|NCT05565222|Active Comparator|Meropenem|2 g every 8 hours by intravenous route (adjusted in case of renal failure). Meropenem will be infused over 2 hours. Duration of treatment will be adjusted according to the site of infection
89598703|NCT05562427|Other|1|Gold-standard online behavioral weight loss treatment
89598704|NCT05552820|Experimental|Verum Electroacupuncture|Verum electroacupuncture treatment will be given 3 times a week, at least 1 day apart , for consecutive 4 weeks with a 24-week follow-up. Each session lasts for 30 min.
89598705|NCT05552820|Sham Comparator|Sham Electroacupuncture|Sham electroacupuncture on non-acupoints plus non-penetrating plus no electrical stimulation will be given 3 times a week, at least 1 day apart , for consecutive 4 weeks with a 24-week follow-up. Each session lasts for 30 min.
89598706|NCT05547932|Experimental|Block Group|After endotracheal intubation, patients will be positioned in lateral decubitus position. A linear ultrasound probe will be placed at the edge of scapula at the level of T5-T6. Under sterile conditions, the landmark points (rhomboid major muscle, 5th and 6th ribs, and intercostal muscles) will be observed and a block needle will be directed to the interfacial plane between rhomboid major muscle and intercostal muscle. RIB will be performed by injecting 20 ml of bupivacaine 0.25%. In the same position, the probe will be placed at the midaxillary line at the level of T3, and the landmark points (latissimus dorsi muscle and serratus muscle and intercostal muscles) will be observed. Under sterile conditions, a SAP block will be performed by injecting 20 ml of Bupivacaine 0.25% into the plane between serratus muscle and intercostal muscle.
89598707|NCT05547932|No Intervention|Control Group|No block procedures will be performed in this group.
89598708|NCT05546502|Experimental|COVID-19 Protein Subunit Recombinant Vaccine|2 doses of COVID-19 Protein Subunit Recombinant Vaccine administered with 28 days interval (0.5 mL per dose)
89598709|NCT05546502|Active Comparator|Active Comparator|2 doses of Covovax® - administered with 28 days interval (0.5 mL per dose)
89598710|NCT05539001||systemic lupus erythematosus group|Based on hospitalization and follow-up data, the enrolled patients were divided into severe group and mild group by BILAG score independently by specialized researchers.
89598711|NCT05532865||Adults with systemic sclerosis|It is a descriptive cohort of systemic sclerosis patients
89598712|NCT05524623|Sham Comparator|without current emission in the treatment|percutaneous microelectrolysis without current emission in the treatment of cervical pain in myofascial trigger points of the trapezius. Both will take place over 3 weeks, with one session per week.
89598713|NCT05524623|Active Comparator|wit current emission in the treatment|percutaneous microelectrolysis with current emission in the treatment of cervical pain in myofascial trigger points of the trapezius. oth will take place over 3 weeks, with one session per week.
89598714|NCT05506345|Experimental|intervention group|The intervention group carried out a series of creative drama workshops based on social interaction theory on the basis of routine nursing teaching.
89598715|NCT05506345|No Intervention|control group|The control group adopted conventional nursing teaching methods (conventional nursing teaching methods included safety education, healthy lifestyle, role positioning of nursing students, nursing etiquette, communication skills, nursing professional theory and skill training, nursing career planning, and clinical one-on-one teaching, according to plan to complete the teaching task).
89598716|NCT05497635|Experimental|A low dose of group|All subjects will be randomized to receive low dose of STSA-1002 or dose-matched placebo.
89598717|NCT05497635|Experimental|A middle dose of group|All subjects will be randomized to receive middle dose of STSA-1002 or dose-matched placebo.
89598718|NCT05497635|Experimental|A high dose of group|All subjects will be randomized to receive high dose of STSA-1002 or dose-matched placebo.
89598719|NCT05476211|Experimental|Reduction of wrinkles|
89598720|NCT05474950|Experimental|minocycline|
89598721|NCT05465096|Experimental|MF-AT injection|Patients will be treated with an intra-articular-ultrasound-guided injection of Micro-fragmented adipose tissue containing mesenchymal stromal cells.
89598722|NCT05462509|Experimental|bCPAP and blenders|"all patients admitted to the newborn care unit with respiratory failure will be evaluated for treatment with bCPAP per unit standards. All patients that meet treatment criteria will receive bCPAP. Patients for whom consent is available will be enrolled and start bCPAP therapy with the PATH kit. Patients for whom consent is not given or not available will start Kiwoko bCPAP. Patients who began bCPAP therapy with the Kiwoko kit and obtain consent within 24 hours of starting their bCPAP therapy may switch from Kiwoko to PATH bCPAP. Patients with >24 hours of Kiwoko bCPAP therapy are no longer eligible for enrolment. , oxygen blending for patients treated with PATH bCPAP will occur by the following two methods- and will be used in this order of preference:~blending via air compressor (standard of care in unit and used when available)~blending via PATH blender (when no compressor available)"
89598723|NCT05461404|Experimental|Emollient arm|Infants will receive gentle, hygienic whole-body massage by trained nurses (not parents or other family members) with 3g of SSO per kg of body weight - a dose sufficient to saturate the skin - three times daily for the first 14 days and twice daily thereafter during the duration of their stay in the hospital until death, discharge or through day 28 after birth.
89598724|NCT05461404|No Intervention|Control arm|Infants in the control group will receive the standard of care for infants in the neonatal care unit, which does not include use of topical emollients or massage (i.e., family members will not be allowed to apply skin care products to their infants), or other particular measures to prevent skin breakdown or to modulate skin barrier function.
89598725|NCT05457413||Sleeve gastrectomy|Sleeve gastrectomy for weight loss
89598726|NCT05452213|Experimental|Ribociclib|
89598727|NCT05445076|Experimental|BCD-180, low dose|Subjects in this arm will receive BCD-180 low dose infusions
88979596|NCT00083603|Placebo Comparator|14|Empty TBC-MVA vector administered in each deltoid Days 0, 28; empty TBC-FPV vector administered in each deltoid Days 84, 140, and 196
89598728|NCT05445076|Experimental|BCD-180, high dose|Subjects in this arm will receive BCD-180 high dose infusions
89598729|NCT05445076|Placebo Comparator|Placebo|Subjects in this arm will receive placebo till the assessment of the primary endpoint and then will be switched to BCD-180 low dose
89598730|NCT05436912|Experimental|Healthy participants with normal hepatic function|Selpercatinib administered orally to healthy participants.
88815028|NCT03021434|Experimental|Standard Testing|Households will participate in community and household water safety education sessions, during which they will be given generalized information on water quality and safe water handling. A water sample from these households will be collected for laboratory analysis. Household-specific water quality information will be delivered to households within 72 hours, and households will be informed whether their drinking water was found to be contaminated. A study team member will review the information from the laboratory tests with the household and review information covered in the informational materials on safe water handling, storage, and use behaviours.
88979597|NCT00083603|Experimental|15|rMVA-HIV env/gag and rMVA-HIV tat/rev/nef-RT administered as two separate 1-mL intramuscular injections, with rMVA-HIV env/gag into the left deltoid, rMVA-HIV tat/rev/nef-RT into the right deltoid at Days 0, 28, 84, 140, 196
89598731|NCT05436912|Experimental|Participants with mild hepatic impairment|Selpercatinib administered orally to participants with mild hepatic impairment per Child-Pugh [CP] classification (CP Class A, score of 5 or 6).
89598732|NCT05436912|Experimental|Participants with moderate hepatic impairment|Selpercatinib administered orally to participants with mild hepatic impairment per CP classification (CP Class C, score of 10 to 15).
88815029|NCT03021434|Experimental|Test Kits|Households will participate in community and household water safety education sessions, during which they will be given generalized information on water quality and safe water handling. Data collectors will demonstrate the use of the low-cost microbiological water test kits and test household stored drinking water. A study team member will return to the household within 72 hours and review the household-specific water quality information from the initial test with household members. Households will be given 10 water test kits to use at their discretion over the 1-2 month follow up period. They will be appropriately trained in how to both perform the test and interpret the results. Households will also review information on safe water handling, storage, and use behaviours.
89598733|NCT05436912|Experimental|Participants with severe hepatic impairment|Selpercatinib administered orally to participants with mild hepatic impairment per CP classification (CP Class B, score of 7 to 9)).
89598734|NCT05413928|Experimental|Intervention|Participants will undergo a baseline phase for 20 days, where they will follow their regular dietary intake, physical activity, and sleep. They will be wearing a CGM and an activity monitor and for a couple of nights, they will use a sleep monitor. That will be followed by 4 interventional phases where they will be asked to limit their daily eating to 10 hours or less (Time Restricted Eating, TRE), with the eating window and the caloric distribution will be shifted during each of the next 3 phases, each phase lasting 20 days. The last phase will last 8 days and participants will be asked to consume provided meals with a determined amount of protein, carbohydrates, and fat. Their body temperature will be measured using a continuous temperature device and a heart rate monitor to capture dynamic rage of the sympathetic response during and after the meal consumption (thermotyping).
89598735|NCT05408520|Experimental|Amputation with TMR|Amputation will follow standard procedure, but with the addition of the TMR procedure, which involves rerouting severed or injured nerves to new muscle targets using microsurgical techniques to provide the nerve endings with a new muscle to innervate.
89598736|NCT05408520|No Intervention|Amputation without TMR (SOC)|A traditional amputation follows the normal standard of care, with transection of peripheral nerves.
89598737|NCT05406219|Experimental|Group 1: moderately impaired renal function|Participants with moderately impaired renal function will receive a single dose of BAY2395840.
89598738|NCT05406219|Experimental|Group 2: normal renal function matched to Group 1|Participants with normal renal function matched to Group 1 will receive a single dose of BAY2395840.
89598739|NCT05406219|Experimental|Group 3: normal renal function aiming to balance out Group 2|Participants with normal renal function aiming to balance out Group 2 for the age and gender investigations will receive a single dose of BAY2395840.
89598740|NCT05393973|Experimental|Core stability exercises along with conventional physical therapy|Core stability exercises
89598741|NCT05393973|Experimental|Swiss ball exercises along with the conventional physical therapy protocol|Swiss ball exercises
89598742|NCT05389722|Experimental|Part 1|
89598743|NCT05389722|Experimental|Part 2|
89598744|NCT05389722|Experimental|Part 3|
89598745|NCT05373680|Experimental|Metformin treatment group|In this arm, patients with chronic kidney disease who meet study inclusion criteria will receive metformin 1000 mg PO daily added to their usual therapy.
89598746|NCT05373680|Experimental|Empagliflozin treatment group|In this arm, patients with chronic kidney disease who meet study inclusion criteria will receive empagliflozin 10 mg daily PO added to their usual therapy.
89598747|NCT05373680|Other|Control group|In this arm, patients with chronic kidney disease who meet study inclusion criteria will receive their usual therapy.
89598748|NCT05372718|Experimental|Recombinant non-immunogenic staphylokinase|"lyophilisate for preparation a solution, 5 mg (745,000 IU) in 20 ml over 1 minute through a perforated multihole catheter intrathrombally.~30 minutes after this injection, infusion of recombinant non-immunogenic staphylokinase will be continued at a dose of 1 mg/hour, maximum 10 mg (50 ml) for 10 hours through a perforated multihole catheter intrathrombally."
89598749|NCT05372718|Experimental|Surgical methods of treatment|endovascular intervention, open surgery and/or bypass surgery in accordance with the current National Guidelines
89598750|NCT05364970|Experimental|VR_1PP|Virtual training with an avatar observed from the first-person perspective
89598751|NCT05364970|Active Comparator|VR_3PP|Virtual training with an avatar observed from the third-person perspective
89598752|NCT05364970|No Intervention|NO_VR|No VR training administered
89598753|NCT05362682||Case|
89598754|NCT05362682||Test Negative Control|
89598755|NCT05361122|Experimental|Xylitol-exposed formerly term children|n=250 formerly term children born during the PPaX trial who were born to gravidae in the interventional arm (received xylitol chewing gum but had access to a dentist and received prenatal counseling)
89598756|NCT05361122|Active Comparator|Non xylitol-exposed formerly term children|n=250 formerly term children born during the PPaX trial who were born to gravidae in the active comparator arm (no xylitol chewing gum but had access to a dentist and received prenatal counseling)
89598757|NCT05361122|Experimental|Xylitol-exposed formerly preterm children|n=250 formerly preterm children born during the PPaX trial who were born to gravidae in the interventional arm (received xylitol chewing gum but had access to a dentist and received prenatal counseling)
88979598|NCT00083603|Placebo Comparator|16|Empty TBC-MVA vector administered in each deltoid Days 0, 28, 84, 140, 196
88979599|NCT00418873|Experimental|1. Zotepine|
88979600|NCT00418873|Active Comparator|2. Risperidone|
89598758|NCT05361122|Active Comparator|Non xylitol-exposed formerly preterm children|n=250 formerly preterm children born during the PPaX trial who were born to gravidae in the active comparator arm (no xylitol chewing gum but had access to a dentist and received prenatal counseling)
89598759|NCT05359640||quality of pain|We will recorded the pain by using a short pain questionnaire and a McGill pain questionnaire.
89598760|NCT05359640||consumption of analgesics|The consumption of analgetics, VAS score and improvement of quality of life will be monitored.
89598761|NCT05353348|Experimental|Iron treatment intervention arm|
89598762|NCT05353348|Active Comparator|control arm|
89598763|NCT05338281|Experimental|Negative Pressure Wound Therapy|This group will receive the usual care of the abdominal donor wound following DIEP flap-based breast reconstruction surgery, AND the negative pressure wound therapy. The Prevena™ Incision Management System will be placed at the abdominal flap donor site after incision is closed. The Prevena™ will remain for up to 5 days, or until patient is discharged from the hospital.
89598764|NCT05338281|Active Comparator|Standard Dressing|This group will receive the usual care of the abdominal donor wound following DIEP flap-based breast reconstruction surgery, and standard dressing which will be composed of gauze, secured with paper tape.
89598765|NCT05334836|Active Comparator|Pancreatic cystic lesion subjects|Patients with at least 1 pancreatic cystic lesion presumed to be IPMN or MCN based on CT, MRI or EUS features, with a cyst size ≥ 5mm
89598766|NCT05334836|Active Comparator|Healthy subjects|Healthy subjects
89608548|NCT04148937|Experimental|Cohort D2 LY3475070|LY3475070 administered orally.
88979601|NCT00310024|Experimental|Treatment (vorinostat, bortezomib)|"Patients receive bortezomib IV on days 1, 4, 8, and 11 followed by oral SAHA twice daily on days 4-11. Beginning in course 3, some patients may receive low-dose oral dexamethasone on days 4-8. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of SAHA until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. An additional cohort of 10 patients receive treatment at the MTD.~Patients undergo blood collection and tumor biopsies periodically during study for pharmacologic and biomarker correlative studies."
89598767|NCT05331820|No Intervention|standard care group|this group of participants will be used to compare to the intervention group. normal and professional instructions and motivation will be given to them but they will not receive weekly reminders about the importance of adherence to instructions
89598768|NCT05331820|Experimental|weekly reminder group|this group of participants will receive a weekly reminder about the importance of oral hygiene, appliance care, and adherence to recommendations from the dentist.
89598769|NCT05326256|Experimental|PSSE Group|Physiotherapy Scoliosis Specific Exercises (PSSE), 45-minute exercise session with the supervisor, twice a week for 12 weeks
89598770|NCT05326256|Experimental|Vestibular Exercise Group|Vestibular exercises to be added to PSSE exercises, 45-minute exercise session with the supervisor, twice a week for 12 weeks
89598771|NCT05320419|Active Comparator|Amniotic membrane preparation and injection (AM group)|The dehydrated AM product used in this study is derived from donated human placental tissue following healthy, live, caesarian section, full-term births which are then cleaned of blood under aseptic conditions. The product comes as a 20mg dry powder in a small vial stored at room temperature and mixed with 2 mL 0.9% sterile normal saline. Then the suspended AM will be injected to the injured tendon and the surrounding area with ultrasound-guidance via a 7cm, 23-gauge needle.
89598772|NCT05320419|Active Comparator|Physiotherapy (PT group )|Physiotherapy includes hot pack, electric therapy and therapeutic exercise, which will be supervised by a senior physical therapist. The therapeutic exercise consists of active and passive stretching, and strengthening exercise of the rotator cuff, the shoulder girdle, and the pectoral muscles, and scapular stabilization exercise, 3 times a week, and will be continued for 12 weeks.
89598773|NCT05317793||Professionals|150 knowledge workers from three Finnish companies.
89598774|NCT05314543|Experimental|Track cyclists and rowers (males and females)|All female and male rowing and track cycling athletes at the national or international national or international level, registered in a selection process and likely to represent France at the likely to represent France at the 2024 Olympics will be asked to take part to take part in this study.
89598775|NCT05313022|Experimental|ZR-202-CoV|Adult healthy subjects (60 years of age above, inclusive) receive ZR-202-CoV at Day 0 and Day 28
89598776|NCT05313022|Placebo Comparator|Placebo|Adult healthy subjects (60 years of age and above) receive 2 doses of placebo (saline) at Day 0 and Day 28
89598777|NCT05294263|Experimental|Varenicline|Varenicline will be provided at the standard recommended dose of 0.5mg daily for three days, then 0.5mg twice daily for four days, and then 1mg twice daily for the remainder of the 12-week treatment period.
89598778|NCT05294263|Placebo Comparator|Placebo|Matching placebo will be administered over the 12-week period.
89598779|NCT05294068||All subjects with cognitive impairments|
89598780|NCT05294068||All subjects with neuromotor impairments|
89598781|NCT05294068||All subjects with sensory impairments|
89598782|NCT05292625|Experimental|UC-MSC infusion via intravenous route|1.5 x 10^6 umbilical Cord Mesenchymal Stem Cells per body kg will be infusion via the intravenous at baseline, and the second transplantation will be performed 3 months after the first transplantation and combination with standard frailty treatment and supplementary medication
89598783|NCT05292625|Experimental|UC-MSC infusion via intrathecal route|1.5 x 10^6 umbilical Cord Mesenchymal Stem Cells per body kg will be infusion via the intrathecal at baseline, and the second transplantation will be performed 3 months after the first transplantation and combination with standard frailty treatment and supplementary medication
89598784|NCT05292625|Other|control arm|standard stroke treatment and rehabilitation therapy
89598785|NCT05285579||TKI+ICI|Therapeutic combination tyrosine kinase inhibitor (TKI) + immune checkpoint inhibitors (ICI)
89598786|NCT05285579||ICI+ICI|Therapeutic combination with different immune checkpoint inhibitors (ICI)
89598787|NCT05281757||Ennovate® Complex|All patients who are treated with the Ennovate® Complex system in accordance with indications given in the instructions for use (IFU)
89598788|NCT05271981||Female who underwent uterine artery embolisation for uterine pathology|
89598789|NCT05271916|Experimental|Combined treatment group|Dacomitinib+Anlotinib: Patients will be treated with combined Dacomitinib and Anlotinib.
89598790|NCT05271916|Active Comparator|Dacomitinib monotherapy group|Dacomitinib: Patients will be treated with Dacomitinib.
89598791|NCT05271656|Experimental|C-Scan System|All study participants will undergo the C-Scan System procedure, followed by a standard of care optical colonoscopy
88979602|NCT00310063|Experimental|Arm I|Sea Band elastic acupressure wristband
89598792|NCT05261594|Other|Panic disorder|Participants will be randomized to start with either the caffeine condition or placebo condition. Participants will complete session 2 with the other condition (condition not allocated to in session 1).
89598793|NCT05261594|Other|Healthy controls|Participants will be randomized to start with either the caffeine condition or placebo condition. Participants will complete session 2 with the other condition (condition not allocated to in session 1).
89598794|NCT05254431|Experimental|Exercise|The Experimental Design is a randomized trial of Moderate intensity interval training (5-minute intervals at 50% VO2peak 3 times weekly for 12 weeks) in Veterans with COPD and OSA compared with standard of care controls
88979603|NCT00310063|Sham Comparator|Arm II|Sham wristband
88979604|NCT00310141|Active Comparator|Standard Care Group|Written self-help materials, counseling, and 6-week nicotine patch supply
88979605|NCT00310141|Active Comparator|Computer Treatment Group (CDT)|Written self-help materials, counseling, 6-week nicotine patch supply and 6 weeks of computer-delivered treatment
88979606|NCT00310141|Experimental|CDT Pilot|Written self-help materials, counseling, 6-week nicotine patch supply and 6 weeks of computer-delivered treatment
89598795|NCT05254431|No Intervention|Usual Care|Participants in the control group will be instructed to maintain their routine activity level for 12 weeks
89598796|NCT05245617||JPS treated patients|This grup will include all patients with regular indication for JPS: system is intended in pediatric (excluding newborns) and small stature adult patients. Pediatric patients include infants (greater than 1 month to 1 years of age), children (greater than 1 to 12 years of age), adolescents (greater than 12 to 18 years of age) and appropriate adults (where according to investigator assessment, the JPS plates fit the treated bone anatomy).
89598797|NCT05238103|Experimental|Corrie Virtual Cardiac Rehabilitation Program|Receives Corrie Virtual Cardiac Rehabilitation Program and usual care
89598798|NCT05238103|No Intervention|Usual Care|Receives usual care. Usual care is defined as care according to the patients care team's standard practice
89598799|NCT05234515||Patients with intestinal failure or an enterocutaneous fistula undergoing elective surgery.|Adult patients with a diagnosis of intestinal failure (IF) or an enterocutaneous fistula (ECF) undergoing planned surgery in our unit.
89598800|NCT05234437|Experimental|Single arm open label|Single or multiple Intratumoural treatment of tigilanol tiglate at 3.6mg/m2 given at a minimum of 28-day intervals.
89598801|NCT05220748|Experimental|RM-1995 Photoimmunotherapy (Phase 1a Monotherapy)|Patients with locally advanced cuSCC or HNSCC or metastatic disease that has recurred or progressed, despite all available standard therapies.
89598802|NCT05220748|Experimental|RM-1995 Photoimmunotherapy + Pembrolizumab (Phased 1b Combination Therapy)|Patients with locally advanced cuSCC or HNSCC or metastatic disease that has recurred or progressed, despite all available standard therapies.
89598803|NCT05209230|Experimental|Continuous renal replacement therapy arm|Echocardiographic evaluation (with 2D speckle tracking analysis of left ventricular segmental function) 1 hour before and 3 hours after the initiation of continuous renal replacement therapy (continuous veno venous hemofiltration) initiation
89598804|NCT05209230|Other|Control arm|Two echocardiographic evaluations (with 2D speckle tracking analysis of left ventricular segmental function) at an interval of 4 hours, before the continuous renal replacement therapy initiation.
89598805|NCT05199610|Experimental|Aumolertinib|single dose oral 55mg of aumolertinib
89598806|NCT05194332|Experimental|LIFUP sonication to the amygdala|
89598807|NCT05193786|Active Comparator|Low PEEP group|In low PEEP group, the PEEP was 5 cmH2O and inspiratory pressure was 10-20 cmH2O in noninvasive ventilation.
89598808|NCT05193786|Experimental|High PEEP group|In high PEEP group, the PEEP was 10-15 cmH2O and inspiratory pressure was 15-20 cmH2O in noninvasive ventilation.
89598809|NCT05187364|Experimental|COPE Therapy Arm|Concurrent Treatment of PTSD and Substance Use Disorders using Prolonged Exposure (COPE)
89598810|NCT05180357||SEA+NP Patients on FASENRA (benralizumab)|SEA+NP Patients on FASENRA (benralizumab)
89598811|NCT05180253||Healthy Subjects|
89598812|NCT05166694|Experimental|Group 1: Prescribing Based on Information From Both Drug-Drug and Drug-Gene Profiles|"Group one consists of subjects who will participate in the Personalized Therapeutics Clinic where in which study doctors will make recommendations based on information found in both the subject's drug-drug interaction and drug-gene profiles. These recommendations will be given to participating providers. These recommendations will be communicated to healthcare providers who are directing the subject's care. These providers may work in hospitals, primary care, oncology, geriatrics, and mental and behavioral health. Each provider will have separately agreed to participate in this study. Subjects in this group will also learn about their drug-drug interaction and drug-gene profiles during educational visits with clinic staff.~Participants will randomly (like by a flip of the coin) assigned to a group."
89598813|NCT05166694|Experimental|Group 2: Prescribing Based ONLY on Information From Drug-Drug Interaction Profiles|"Group two consists of subjects who will participate in the Personalized Therapeutics Clinic where study doctors will make recommendations based on information only found in the subject's drug-drug interaction profile. Subjects in this group will also learn about their drug-drug interaction and drug-gene profiles during educational visits with clinic staff.~Participants will randomly (like by a flip of the coin) assigned to a group."
89598814|NCT05166694|Experimental|Group 3: Prescribing Not Based on ANY Profile Information (Drug-Drug or Drug-Gene Interactions)|"Group three consists of subjects who will not participate in the Personalized Therapeutics Clinic or receive recommendations. These subjects will not have any recommendations from regarding their drug-drug interaction or drug-gene profiles. Both drug-drug interaction and drug-gene profiles will be kept hidden from all of their treating providers-regardless of whether the providers directing their care have agreed to participate in this research. Subjects in this group will not learn about their drug-drug interaction or drug-gene profiles during educational visits with clinic staff.~Participants will randomly (like by a flip of the coin) assigned to a group."
89608549|NCT04148937|Experimental|Cohort E LY3475070 + Pembrolizumab|LY3475070 administered orally and pembrolizumab administered IV.
89608550|NCT03021057|Experimental|pembrolizumab|200mg i.v. once every 3 weeks Number of Cycles: until progression or unacceptable toxicity develops
89608551|NCT00734500|Experimental|Treatment|Treatment
88979607|NCT00310219|Experimental|Arm 1|Two radiation oncologists are randomly assigned to develop either a 3DCRT plan using CT only, or a 3DCRT plan using fused PET/CT
88979608|NCT00121095|Other|1|
88979609|NCT00088764|Experimental|1|Education: Either coping skills training or arthritis education interventions
88979610|NCT00088764|Experimental|2|Writing: Either emotional disclosure writing or health behavior writing
88979611|NCT05568602||GFR<30 ml/min|Patients screened for hypercortisolism and GFR<30ml/min
88979612|NCT05568602||GFR>30 ml/min|Patients screened for hypercortisolism and GFR>30ml/min
88979613|NCT00310492|Active Comparator|Subcutaneous immunotherapy|Subcutaneous injections with ALK-depot SQ mites to 100,000 SQ-U
88979614|NCT00310492|Placebo Comparator|Subcutaneous injections|placebo injections
88979615|NCT00121212|Active Comparator|Surgery - Negative PET scan|If patient is candidate for surgery with curative intent or staging lymphadenectomy, he will be enrolled in the study. If patient's PET scan is negative, the patient will receive the curative therapy and be followed for recurrence.
88979616|NCT00121212|Experimental|Surgery - Positive PET scan|If patient is candidate for surgery with curative intent or staging lymphadenectomy, he will be enrolled in the study. If patient's PET scan is positive, the patient will receive the curative therapy and be followed for recurrence or receive alternative therapy.
89598815|NCT05157477|Experimental|VR-Group|The participants who are randomized into 'CBT-based VR exposure program' (CBT+VR group) will receive the individual intervention weekly with a total of 8 sessions. The therapists, PI (Chien YL) and a clinical psychologist who is familiar with ASD psychopathology and CBT approach, will provide the CBT-based VR exposure intervention for each individual every week based on the above protocol. The participants complete the homework (i.e., relaxation and real-life exposure) between the sessions, and record 'anxiety level' before, during, and after the real-life exposure. The outcome measures will be scheduled at the end of intervention (8th week) within one week of program closure.
89598816|NCT05157477|Experimental|CBT-GROUP|The 'CBT alone' intervention applies the same protocol excluding VR exposure, which is replaced by traditional role play with the therapist.
89598817|NCT05157477|No Intervention|Control group|The participants who are randomized into control group will be regularly followed in a naturalistic outpatient clinic setting (every 2-4 week). During the clinic, sensory and socioemotional problems will be discussed face-to-face for 10 to 20 minutes, some self-help books will be recommended.
89598818|NCT05152485|Active Comparator|BIIB104 0.5 mg Reference Formulation (Fasted State)|Participants will receive BIIB104 0.5 mg, immediate-release liquid-filled hard-shell capsule, orally, on Day 1 in the fasted state.
89598819|NCT05152485|Experimental|BIIB104 0.5 mg Test Formulation (Fasted State)|Participants will receive BIIB104 0.5 mg, immediate-release softgel capsule, orally, on Day 1 in the fasted state.
89598820|NCT05152485|Experimental|BIIB104 0.5 mg Test Formulation (Fed State)|Participants will receive BIIB104 0.5 mg, immediate-release softgel capsule, orally, on Day 1 in the fed state.
89598821|NCT05149950|Experimental|Increased therapist contact.|The patient gets access to the internet treatment via a secure login to 1177 The care guide-services on 1177.se. The treatment lasts for six months and includes 12 treatment modules. The patient works with each module for two weeks. The modules have different numbers of sections, but most have 4-5 sections. The modules consist mainly of text but also films and pictures are included. It is also possible to listen to the text. The modules end with one or more exercises to be performed before the next module is activated for the patient. Participants receive feedback on the information from therapists via the email function in the treatment program. The therapist provides individual feedback on completed exercises and answers questions that the patient has.
89598822|NCT05149950|Other|Less therapist contact.|The feedback from the therapist will largely be general and not individually tailored. The general feedback is based on responses to the participants in the previous pilot study. No physical or digital meetings between patient and therapist take place during treatment.
89598823|NCT05144035|Experimental|GH treatment group|GH treatment group (n = 68): the subjects were given PEG-rhGH injection 0.2 mg / kg / week (initial dose), once a week, subcutaneously before going to bed for 104 weeks. Each follow-up, the researchers adjusted the dosage according to the IGF-1 results of the center and other individual conditions.
89598824|NCT05144035|No Intervention|Control group|Control group (n = 68): no treatment, only follow-up examination and growth and development related evaluation, and the follow-up time was 104 weeks.
89598825|NCT05141565||The Kunshan Elderly Health Study (KEHS)|Community-based observational cohort.
89598826|NCT05137925|Experimental|Mindfulness-Based Cognitive Therapy (MBCT)|MBCT will be delivered in a group based, videoconference format with 90 minute sessions 1x/week.
88979617|NCT00121212|Active Comparator|Radiation therapy Negative or Positive PET scan|If patient is candidate for radiation therapy with curative intent, he will be enrolled. If PET scan is negative he will receive curative therapy and be followed for PSA recurrence. If PET scan is positive he may receive confirmatory studies and then if negative, not indicated, or refused he will receive curative therapy be followed for PSA recurrence. If PET scan is positive and received positive confirmatory studies he will receive curative therapy and followed for recurrence.
88979618|NCT00310531|Experimental|Arm 1|
88979619|NCT00310531|Active Comparator|Arm 2|
88979620|NCT05568446|Experimental|Social VR group|Social VR (SocVR) intervention is developed to enhance the social interaction skills of children. The participants will wear a head-mounted display (HMD) for the SocVR intervention. Each session of the SocVR intervention lasts for a maximum of 20 minutes to ensure the participants focus on the intervention and prevent causing any physical effect (Yamaguchi, 1999). The intervention contains three real-life virtual scenarios, including (1) classroom and playground, (2) MTR station and compartment, and (3) street and building. One scenario will be adopted in each session. The sequences of the scenarios used in each session will be the same for all participants. During the SocVR intervention, one RA will also appear as one avatar in the scenario to guide the participants to complete a series of tasks. Each intervention session will be conducted in a classroom independently for each participant.
89031994|NCT04691895||Patients admitted to hospital for COVID19 disease (case group)|"The study cohort will be composed by consecutively enrolled COVID19 confirmed inpatients (case group)~Inclusion criteria:~Signed informed consent~Age ≥18 years and ≤85 years~Consecutive COVID19 confirmed patients (COVID +ve)~Ability to conform to study protocol~Exclusion criteria:~Patients under mechanical ventilation~Patients unable to report required data~Current diagnosis of cancer"
89598827|NCT05137925|Active Comparator|Treatment as Usual (TAU)|TAU, or the control group, provides information about the benefits of mindfulness in pregnancy, offers referrals for psychotherapy in the community, and involves monthly phone or videoconference calls to maintain engagement.
89598828|NCT05127109|Experimental|Nutrition Ecosystem pathway|"parenteral nutrition initiated within 72 hours of operative intervention~metabolic cart assessments to determine resting energy expenditure (REE) and guide registered dietitians (RDs)~expedited delivery of oral nutrition supplements and~a team-based approach on proper documentation of nutrition delivery and intake."
89598829|NCT05127109|Other|Comparator|300 historical matched control subjects not having received TPN in the first 7 hospital days will be enrolled from Duke Electronic Health Record between January 2018 and June 2020.
89598830|NCT05085808|Active Comparator|Quetiapine|"Start study medication at 25 mg daily PO ; may increase to BID or TID if RASS>=2 or rescue medication must be given; thereafter, if med is TID, dose can be increased by increment of 50 mg q12 hr if RASS>=2 and/or >1 dose of rescue medication is given within 24 hours [max dose 200 mg/day]~dose can be reduced/discontinued per discretion of ICU attending if delirium improving, patient experiences AE likely related to study drug, after 14 days of treatment, or patient is discharged from ICU~dose should be held if RASS is -3 to -5/comatose/unresponsive or sudden acute change in mental status"
89598831|NCT05085808|Experimental|Trazodone|"Start study medication at 25 mg daily PO ; may increase to BID or TID if RASS>=2 or rescue medication must be given; thereafter, if med is TID, dose can be increased by increment of 50 mg q12 hr if RASS>=2 and/or >1 dose of rescue medication is given within 24 hours [max dose 200 mg/day]~dose can be reduced/discontinued per discretion of ICU attending if delirium improving, patient experiences AE likely related to study drug, after 14 days of treatment, or patient is discharged from ICU~dose should be held if RASS is -3 to -5/comatose/unresponsive or sudden acute change in mental status"
89598832|NCT05085808|Placebo Comparator|Placebo|"Start study medication at 25 mg daily PO ; may increase to BID or TID if RASS>=2 or rescue medication must be given; thereafter, if med is TID, dose can be increased by increment of 50 mg q12 hr if RASS>=2 and/or >1 dose of rescue medication is given within 24 hours [max dose 200 mg/day]~dose can be reduced/discontinued per discretion of ICU attending if delirium improving, patient experiences AE likely related to study drug, after 14 days of treatment, or patient is discharged from ICU~dose should be held if RASS is -3 to -5/comatose/unresponsive or sudden acute change in mental status"
89598833|NCT05084625|Experimental|Arm A- access to digitized support, an app|Patients in Arm A will have access to digitized support-an app for 12 months from baseline in addition to standard follow-up.
89598834|NCT05084625|No Intervention|Arm B-standard follow-up|Patients in Arm B-will continue with standard follow-up from baseline and onwards
89598835|NCT05079750|Experimental|Group 1: Low Dose|n=6 participants vaccinated with a single dose of ChAdOx1 biEBOV 5x10^9 vp
89598836|NCT05079750|Experimental|Group 2: Mid Dose|n=6 participants vaccinated with a single dose of ChAdOx1 biEBOV 2.5x10^10 vp Note: may be increased to n=9 following interim safety reviews
89598837|NCT05079750|Experimental|Group 3: High Dose|n=14 participants vaccinated with two doses of ChAdOx1 biEBOV 5x10^10 vp, twelve weeks apart Note: will be decreased to n=11 if Group 2 is increased to n=9
89598838|NCT05078944|Experimental|Active acupuncture + Donepezil|Active acupuncture treatment is to be taken 3 sessions weekly over a period of 14 weeks. Donepezil hydrochloride (5 mg/capsule, Weicai Pharmaceutical Co., Ltd, China) is to be taken 5 mg daily over 32 weeks (including 4-week run-in) Intervention: Device: Acupuncture + Drug: Donepezil hydrochloride
89598839|NCT05078944|Sham Comparator|Sham acupuncture + Donepezil|Sham acupuncture treatment with no skin penetration and no current output on sham acupoints is to be taken 3 sessions weekly over a period of 14 weeks. Donepezil hydrochloride (5 mg/capsule, Weicai Pharmaceutical Co., Ltd, China) is to be taken 5 mg daily over 32 weeks (including 4-week run-in) Intervention: Device: Sham acupuncture + Drug: Donepezil hydrochloride
89598840|NCT05076019|Experimental|Atorvastatin 80 mg|Dosage: 80 mg Form: Tablets Frequency: 1 tabl. per day. Duration: From 7 to 14 days prior to surgery until 30 days postoperative
89598841|NCT05076019|Placebo Comparator|Placebo|Form: Tablets Frequency: 1 tabl. per day. Duration: From 7 to 14 days prior to surgery until 30 days postoperative
89598842|NCT05073913|Active Comparator|Living kidney donors|complete vascular exploration before and one year after nephrectomy
89598843|NCT05073913|Sham Comparator|potential living kidney donors|complete vascular exploration before and one year after the first exploration (for patients with medical contraindication to donation or who have declined donation after the first exploration)
89598844|NCT05069922|Active Comparator|Fresh Frozen Plasma|At 6-8 hours, Initiate FFP infusion
89598845|NCT05069922|Active Comparator|Albumin|At 7 hours, Initiate 5% Albumin infusion
89598846|NCT05065333|Experimental|Septic Shock Clinical Decision Support|Emergency Department sites in this arm will have Clinical Decision Support (CDS) alerts active in the Electronic Health Record during clinical ED care of patients with suspected sepsis, in addition to following usual institutional standard of care for sepsis. The CDS will alert providers to patients at high risk for developing septic shock.
89598847|NCT05065333|Active Comparator|Clinical Diagnosis Only|Emergency Department sites in this arm will follow the institutional standard for sepsis care without Clinical Decision Support. Standard care includes clinical diagnosis of sepsis supported by institutional sepsis education, a sepsis pathway and orderset.
89598848|NCT05063097||CCU patients|All consecutive patients over 18 years admitted to the CCU.
89598849|NCT05062239|Active Comparator|Continuance|Continuance prior statin therapy.
89598850|NCT05062239|Experimental|Discontinuance|Discontinuance prior statin therapy. Duration: From 7 to 14 days prior to surgery until 30 days postoperative
89598851|NCT05061277|Experimental|Recifercept|A 300 mg single subcutaneous (SC) dose of recifercept for the treatment phase of study
89598852|NCT05056740||MS|Patients with a definite MS diagnosis according to the 2017 McDonald criteria
89031995|NCT04691895||Patients admitted to hospital in absence of COVID19 disease (control group)|"The study cohort will be composed by consecutively enrolled COVID19 negative patients hospitalized for other reasons (controls group)~Inclusion criteria:~Signed informed consent~Age ≥18 years and ≤85 years~Consecutive hospitalized COVID19 negative patients (COVID -ve)~Ability to conform to study protocol~Exclusion criteria:~Patients under mechanical ventilation~Patients unable to report required data~Current diagnosis of cancer"
89598853|NCT05056740||Red-flag MS|Patients presenting with clinical, radiological or biological red flags for MS diagnosis who will be ultimately diagnosed as having MS
89598854|NCT05056740||Other CNS autoimmune diseases|Patients with a definite diagnostic of CNS autoimmune disease that is not MS
89598855|NCT05056740||Controls|Patients with a definite diagnostic of non-inflammatory CNS disorder
89598856|NCT05036005|Experimental|Ontruzant + Pertuzumab (optional) + Chemotherapy|"All patients will receive 6 cycles of Ontruzant® i.v. q21d in combination with standard chemotherapy with or without pertuzumab, at the discretion of investigator's decision. Initial dose of Ontruzant® i.v. will be 8 mg/kg b.w. followed by 5 cycles of Ontruzant® i.v. 6 mg/kg b.w. q21d. Clinical and bioptic tumor assessment will be performed during baseline and during surgery.~Study treatment will be applied until state of the art surgery, onset of unacceptable toxicities, progression or withdrawal of consent. A safety follow-up is planned for 30 days after the last administration of study medication."
89598857|NCT05035823|Other|Single|Implantation of the motor neuroprosthesis medical device.
89598858|NCT05033769|Experimental|Eribulin|Arm A. Eribulin 1.23 mg/m^2, administered as an injection on day 1 and 8 q 21d for a maximum of 4 therapy cycles
89598859|NCT05033769|Active Comparator|Paclitaxel|Paclitaxel 80 mg/m^2, administered as an injection on day 1, 8 and 15 q21d for a maximum of 4 therapy cycles
89608552|NCT04148391|Placebo Comparator|Placebo|Matching placebo Capsules
89598860|NCT05030142|Experimental|Mechanical thrombectomy|Mechanical thrombectomy (using a stent retriever among the following:Trevo NXT ProVue Retriever, Catchview mini, pReset Lite, Tigertriever 13) in association with the best medical treatment (usual care)
88979621|NCT05568446|Active Comparator|Traditional social skills group|An experienced special educational needs (SEN) teacher will teach the participants social interaction skills through tradidactic instructions and role-play activities. Four modules will be covered in the 4-week training: (1) how to introduce yourself and basic social skills; (2) how to listen to others; (3) how to share with others; (4) learn to know how people feel and how to empathise. These modules have been applied in many studies (Braswell & Bloomquist, 1991; Huang et al., 2015). The content of this training will be as similar as possible to the SocVR training. The training lasts 20 minutes which depends on the emotion of the participants. Each training session will be conducted in a classroom independently for each participant.
88979622|NCT05568446|No Intervention|Waitlist control group|With reference to Beck et al. (2010), the participants in this group will receive no training and they can participate in the social VR training after the intervention period. To ensure the consistency of the experiment, the participants are not allowed to initiate or change their pharmacological treatment during the 8-week intervention period.
88979623|NCT00310609|Experimental|Arm 1|
89598861|NCT05030142|Active Comparator|Active Comparator|Best medical treatment alone (usual care)
89598862|NCT05019846|Experimental|SRT+ADT|Patients in ARM A will be treated with SRT on the prostate (consecutive days or at alternate days to a total dose of 36.25 Gy administered in 5 fraction (7.25 Gy/fraction) + LHRH analogue (Triptoreline 22.5 mg). An anti-androgen drug (es. Bicalutamide 50 mg) must be administered daily starting from 7 days before LHRH analogue administration to 10 days after to prevent the flare effect
88979624|NCT00121290|Experimental|Treatment (SJG-136)|Patients receive SJG-136 IV over 20 minutes once daily on days 1-3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89598863|NCT05019846|No Intervention|SRT alone|Patients in ARM B will be treated with SRT on prostate alone at a total dose of 36.25 Gy administered daily or on alternate days in 5 fraction (7.25 Gy/fraction).
89598864|NCT05014971|Experimental|Tele-neurohub|This group will receive the tele-neurohub intervention which includes telemedicine appointments with the neurologist, speech therapist, social worker, and nutritionist at baseline, 3 months and 6 months, and PT and OT every 2 weeks for maintenance neuro-rehabilitation.
88979625|NCT05568368||Index cases|
88979626|NCT00310726|Experimental|Abrupt Weaning|Women were counseled to abruptly wean their child at 4 months of age.
88979627|NCT00310726|Active Comparator|Exclusive breastfeeding per WHO guidelines|Women were counseled to adhere to the WHO recommendations for duration of exclusive breastfeeding.
88979628|NCT00310843||All study population|
88979629|NCT05568290||Periodontitis|Individuals with Periodontitis
88979630|NCT05568290||Gingivitis|Individuals with Gingival Inflammation
88979631|NCT05568290||Healthy|Individuals with Periodontally Healthy
88979632|NCT05568212|Experimental|ARM A (experimental arm)|Investigator's choice single-agent chemotherapy plus durvalumab 1500 mg every 3 weeks.
88979633|NCT05568212|Active Comparator|ARM B (standard arm)|Investigator's choice single-agent chemotherapy.
88979634|NCT05568212|Experimental|ARM C (experimental arm)|Investigator's choice platinum doublet chemotherapy plus durvalumab 1500 mg every 3 weeks for 4 cycles followed by maintenance durvalumab 1500 mg every 3 weeks plus olaparib 300 mg twice daily.
88979635|NCT05568212|Experimental|ARM D (experimental arm)|Investigator's choice platinum doublet chemotherapy plus durvalumab 1500 mg every 3 weeks for 4 cycles followed by maintenance durvalumab 1500 mg every 3 weeks
88979636|NCT00088959|Experimental|Treatment (erlotinib hydrochloride, celecoxib)|Patients receive oral erlotinib hydrochloride once daily and oral celecoxib twice daily. Treatment continues in the absence of disease progression or unacceptable toxicity.
88979637|NCT05568017|Experimental|Y-90-DOTATOC|Patients will receive PRRT with Y-90-DOTATOC
88979638|NCT00311389|Experimental|Travoprost/Timolol|1 drop in the affected eye(s) once daily in the morning for 12 months
88979639|NCT00311389|Active Comparator|Latanoprost/Timolol|1 drop in the affected eye(s) once daily in the morning for 12 months
88979640|NCT00399776||Group A|Adolescents taking haloperidol, risperidone, or olanzapine
88979641|NCT00399776||Group B|Healthy adolescents
89598865|NCT05014971|Active Comparator|Usual care group|Receive usual care but will have study visit assessments at baseline and 6 months.
89598866|NCT05004233|Experimental|Ischemic stroke patients|Patients hospitalized for an ischemic stroke.
89598867|NCT05004025|Experimental|TTF Plus Chemotherapy|Novacure Optune with Opdivo and Yervoy
88979642|NCT00088998|Experimental|docetaxel + bevacizumab + capecitabine|"Patients receive docetaxel IV over 1 hour and bevacizumab IV over 30-90 minutes on day 1. Patients also receive oral capecitabine twice daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive at least 2 additional courses beyond CR.~Patients are followed every 3 months for 1 year, every 6 months for 1 year, and then annually for 3 years."
88979643|NCT00311467|Active Comparator|Capecitabine and Interferon|Combined Chemo-Immunotherapy Chemotherapy: Mo-Fr Immunotherapy
88979644|NCT00311467|Active Comparator|Interferon|"Patients randomized to group B will receive treatment according to the same treatment schedule and at the same dosages without capecitabine.~Efficacy evaluations will be performed every 14 weeks of treatment in both groups"
88979645|NCT00311545|Experimental|CNTO 328|CNTO 328, anti-IL-6 monoclonal antibody; 6 mg/kg, IV, q 2wks x 12 cycles (1 cycle = 2 wks)
88979646|NCT02965157|Experimental|CART20|
88979647|NCT00311662|Experimental|1|Tonabersat 40mg
88979648|NCT00311662|Placebo Comparator|2|
88979649|NCT05567939||Case|Individuals with laboratory confirmed MPXVID
88979650|NCT05567939||Control|Individuals without proctitis and without MPXVID-related symptoms
88979651|NCT00311896|Experimental|Bemiparin|
88979652|NCT00311896|Placebo Comparator|Placebo|
88979653|NCT05567666|Experimental|Treatment|Optilume Catheter System
88979654|NCT00312013|No Intervention|No Nadroparin|Patients will receive all standard anticancer treatment. Patients in this arm will not receive nadroparin
89598868|NCT04998240|Experimental|Prime BBIBP-CorV, Boost Ad26.COV2.S (A1)|The randomized study participants will receive Prime BBIBP-CorV vaccine followed by Booster dose of Ad26.COV2.S vaccine (A1).
89598869|NCT04998240|Experimental|Prime BBIBP-CorV, Boost BBIBP-CorV (A2)|The randomized study participants will receive Prime BBIBP-CorV vaccine followed by Booster dose of BBIBP-CorV vaccine (A2).
89598870|NCT04998240|Experimental|Prime Ad26.COV2.S, Boost BBIBP-CorV (B1)|The randomized study participants will receive Prime Ad26.COV2.S vaccine followed by Booster dose of BBIBP-CorV vaccine (B1).
89598871|NCT04998240|Experimental|Prime Placebo, Boost Ad26.COV2.S (B2)|The randomized study participants will receive Prime Placebo vaccine followed by Booster dose of Ad26.COV2.S (B2).
89598872|NCT04997824|Experimental|Artificial Intelligence-based atrial fibrillation catheter ablation|catheter ablation
89598873|NCT04997824|Active Comparator|Medical Therapy|catheter ablation
89598874|NCT04997200|Experimental|Intervention: One night's sleeplessness|A night without sleep. No daytime sleeping the day before the test. Participants are observed by staff at the trial unit during the night before the test.
89598875|NCT04997200|No Intervention|Control: One night's normal sleep|A normal night's sleep (at least six hours) in the patient's home.
89598876|NCT04995341|Experimental|Cohort 1: Functional and structural outcomes in children after bedside OCT imaging in infancy|80 pediatric participants who were previously enrolled in BabySTEPS1 from July 22, 2016 - December 30, 2020 will be enrolled for follow-up neurodevelopmental testing, visual acuity, visual function testing and investigational retinal imaging
89598877|NCT04995341|Experimental|Cohort 2: Test of bedside OCT imaging data to predict RW-ROP or ROP progression|250 infants at risk for retinopathy of prematurity: 132 will be enrolled and have investigational bedside OCT retinal imaging, and their data will be combined with that from 118 infants who had similar imaging in BabySTEPS1 for analysis of the total group versus the indirect ophthalmoscopic clinical exam data.
88811911|NCT02511678|Experimental|Cryoablation|All participants will have one cryoablation procedure on one painful metastatic lesion involving bone using a Galil Medical cryoablation system and needles within 14 days of screening. In the case of participants with multiple metastatic lesions involving bone, the most painful lesion is to be selected for cryoablation. If treatment could not be completed within 14 days of screening, the participant will be re-screened using the inclusion and exclusion criteria. Participant preparation, anesthesia, intra-operative monitoring, and postoperative management for the study cryoablation procedure will be identical to those for standard cryoablation treatment routinely performed at the clinical centers that participated in this study and will be at the discretion of the Investigators.
88811912|NCT01392989|Experimental|Allogeneic Cytokine-induced Killer Cells (CIK)|Target dose of ≥ 5 x 10e6 CD34+ cells/kg of recipient body weight plus an additional 2 x10e9 mononuclear cells.
88811913|NCT02511444|Other|single arm|All patients will have GBS culture and real time PCR performed.
89031996|NCT00518024|Experimental|1|Bilateral theta burst stimulation to the secondary auditory cortex
89598878|NCT04995341|Experimental|Cohort 3: Comparison of ROP imaging with investigational OCT versus retinal camera|102 infants, who are a sub-group of the 132 enrolled in Cohort 2, will also have imaging with a conventional, commercially available, retinal camera system to compare utility, stress, and prediction and documentation of referral-warranted ROP between the camera images and those from investigational OCT.
89598879|NCT04995341|Experimental|Cohort 4: Adult and pediatric participants enrolled for imaging during system development|12 awake healthy adult controls and 12 pediatric participants undergoing examination under anesthesia in the operating room will be imaged with the investigational bedside OCT for the purpose of technological development.
89598880|NCT04992611|Experimental|Circadian-Aligned Sleep Extension|A sleep extension period that roughly conforms to a given participant's circadian phase (i.e., fits the schedule of a Morning Lark vs. Night Owl).
89608553|NCT04148391|Experimental|NYX-458 30 mg|Single oral dose taken daily for 12 weeks.
89608554|NCT00734734|Experimental|1|
88811914|NCT01393457|Active Comparator|ldopa + ropinirole low dose|levodopa/carbidopa 800/200 mg/d plus ropinirole 2 mg/d
88811915|NCT01393457|Active Comparator|ldopa + ropinirole high dose|levodopa/carbidopa 800/200 mg/d plus ropinirole 4 mg/d
88811916|NCT01393457|Active Comparator|ldopa|levodopa/carbidopa 800/200 mg/d
88811917|NCT01393457|Placebo Comparator|placebo|Placebo
88811918|NCT02518464|Experimental|Ticagrelor 90 mg twice per day|Interventions include the following: All participants will have a loading dose of Ticagrelor (Brilinta) 180 mg administered in the office at the time of enrollment. Thereafter, for 28 days, Ticagrelor 90 mg tablet will be taken once in the morning and once in the evening, as close to 12 hours apart as possible. Each day, the subject will receive a text message reminder to login to the website, to record her/his headache activity.
88811919|NCT02479230|Experimental|vaccine: gemcitabine hydrochloride|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for 3 courses. Beginning 3, 7, or 10 days later, patients receive tumor blood vessel antigen peptide-pulsed alpha-type-1 polarized dendritic cell vaccine ID followed by a second vaccination 7 days later. Courses may repeat after at least 4 weeks in the absence of disease progression or unacceptable toxicity.
88811920|NCT04985448||Conbercept|In clinical treatment and research, the applied doses of Conbercept in patients with retinopathy of prematurity have been reduced compared with adults, mostly half of the adult dose. The commonly used exposure dose of intravitreal injection of Conbercept ophthalmic injection is 0.25mg/0.025ml.In addition, possible exposure doses are but not limited to 0.15mg/0.15ml, 0.1mg/ 0.1ml, 0.2mg/0.2ml, etc.
88811921|NCT04985448||Ranibizumab|In clinical treatment and research, the applied doses of Ranibizumab in patients with retinopathy of prematurity have been reduced compared with adults, mostly half of the adult dose. The commonly used exposure dose of intravitreal injection of Ranibizumab ophthalmic injection is 0.25mg/0.025ml.In addition, possible exposure doses are but not limited to 0.15mg/0.15ml, 0.1mg/ 0.1ml, 0.2mg/0.2ml, etc.
88811922|NCT04985448||Laser Treatment|In clinical and research studies, lasers are used to treat patients with retinopathy of prematurity.
88811923|NCT04985136|Experimental|camrelizumab + Rivoceranib|
88811924|NCT04985136|Active Comparator|Rivoceranib|
88811925|NCT04985136|Active Comparator|Sorafenib|
88811926|NCT04985136|Active Comparator|Regorafenib|
89598881|NCT04992611|Experimental|Circadian-Misaligned Sleep Extension|A sleep extension period that does not conform to a given participant's circadian phase. In other words, this condition asks Morning Larks to extend their sleep by sleeping in later, or asks Night Owls to extend their sleep by going to bed earlier.
89598882|NCT04991506|Experimental|Part 1 ES102 Escalation in combination with JS001|ES102 will be escalated, in combination with JS001, in patients with advanced solid tumors.
89598883|NCT04991506|Experimental|Part 2 ES102 Expansion in combination with JS001|Subjects will be treated with ES102 at the RP2D in combination with JS001.
89598884|NCT04990544|Experimental|Adult Group 2a|Adult healthy subjects (18 to 59 years of age, inclusive) receive 202-CoV low adjuvant dose at Day 0 and Day 28
89598885|NCT04990544|Experimental|Adult Group 2b|Adult healthy subjects (18 to 59 years of age, inclusive) receive 202-CoV low antigen dose at Day 0 and Day 28
89598886|NCT04990544|Experimental|Adult Group 2c|Adult healthy subjects (18 to 59 years of age, inclusive) receive 202-CoV standard dose at Day 0 and Day 28.
89598887|NCT04990544|Placebo Comparator|Adult Placebo|Adult healthy subjects (18 to 59 years of age, inclusive) receive 2 doses of placebo (saline) at Day 0 and Day 28
89598888|NCT04990544|Experimental|Elderly Group 2d|Adult healthy subjects (60 years of age and above) receive 202-CoV low adjuvant dose at Day 0 and Day 28
89598889|NCT04990544|Experimental|Elderly Group 2e|Adult healthy subjects (60 years of age and above) receive 202-CoV low antigen dose at Day 0 and Day 28
89598890|NCT04990544|Experimental|Elderly Group 2f|Adult healthy subjects (60 years of age and above) receive 202-CoV standard dose at Day 0 and Day 28
89598891|NCT04990544|Placebo Comparator|Elderly Placebo|Adult healthy subjects (60 years of age and above) receive 2 doses of placebo (saline) at Day 0 and Day 28
89598892|NCT04990427|Experimental|CLBS201|CLBS201 will be administered in an open-label fashion via intra-renal-arterial infusion in 6 subjects followed by 6 months of observation.
88979655|NCT00312013|Experimental|Nadroparin|Patients will be randomized to receive standard anticancer treatment. Nadroparin patients will be treated with therapeutic doses of subcutaneous (s.c). nadroparin for 2 weeks followed by half therapeutic doses for 4 weeks. After 4 weeks of wash-out, subsequent 2-week periods of therapeutic doses of nadroparin will be given for a total of 6 cycles each separated by a 4-week wash-out. The study treatment period ends at week 46 regardless of number of cycles achieved at that moment.
89598893|NCT04987502|Experimental|Virtual reality treatment|Virtual reality immersion with 3D audio and visual rendering (8 weekly sessions)
89598894|NCT04987502|Active Comparator|Standard treatment|Counselling Relaxation techniques Sound enrichment
89598895|NCT04982068|Experimental|Adult Group 1a|Adult healthy subjects (18 to 59 years of age, inclusive) receive 202-CoV low adjuvant dose at Day 0 and Day 28
88979656|NCT00121524|Experimental|IV yes|Intravenous needle Epinephrine q 3 min during CPR Atropine 3 mg in initial asystole Amiodarone 300 mg iv after repeated failed defibrillation attempts
88979657|NCT00121524|No Intervention|IV no|The patient will not have an intravenous needle placed or given any drugs during CPR. If patient obtains spontaneous circulation, an intravenous needle is placed and patient can receive any drugs that are appropriate during the following treatment.
89598896|NCT04982068|Experimental|Adult Group 1b|Adult healthy subjects (18 to 59 years of age, inclusive) receive 202-CoV low antigen dose at Day 0 and Day 28
89598897|NCT04982068|Experimental|Adult Group 1c|Adult healthy subjects (18 to 59 years of age, inclusive) receive 202-CoV standard dose at Day 0 and Day 28
89598898|NCT04982068|Placebo Comparator|Adult Placebo|Adult healthy subjects (18 to 59 years of age, inclusive) receive 2 doses of placebo (saline) at Day 0 and Day 28
89598899|NCT04982068|Experimental|Elderly Group 1d|Adult healthy subjects (60 years of age and above) receive 202-CoV low adjuvant dose at Day 0 and Day 28
89598900|NCT04982068|Experimental|Elderly Group 1e|Adult healthy subjects (60 years of age and above) receive 202-CoV low antigen dose at Day 0 and Day 28
88979658|NCT00312247||Boys taking steroids|Boys who are taking prednisone or deflazacort
88979659|NCT00312247||Boys who are steroid naive|Boys who are not taking steroids for a variety of reasons
88979660|NCT00312403|Other|1|Patients with primary open angle glaucoma
88979661|NCT00312403|Other|2|Age- and sex-matched control subjects
88979662|NCT05567471|Active Comparator|Group 1(BBV154 in COVAXIN recipients)|250 participants will be recruited and administered with a booster dose of BBV154 vaccine in form of drops (0.5 mL) via intranasal route, in individuals previously vaccinated with COVAXIN.
88979663|NCT05567471|Active Comparator|Group 2 (COVAXIN in COVAXIN recipients)|125 participants will be recruited and administered with a booster dose of BBV152 vaccine, in individuals previously vaccinated with COVAXIN.
89031997|NCT00518024|Experimental|2|Bilateral theta burst stimulation to the tertiary auditory cortex
89598901|NCT04982068|Experimental|Elderly Group 1f|Adult healthy subjects (60 years of age and above) receive 202-CoV standard dose at Day 0 and Day 28
89598902|NCT04982068|Placebo Comparator|Elderly Placebo|Adult healthy subjects (60 years of age and above) receive 2 doses of placebo (saline) at Day 0 and Day 28
89598903|NCT04981210||suspect LOPD|
89598904|NCT04971525||Darvadstrocel Cohort|Participants diagnosed with CD and CPAF, who administered at least one dose of darvadstrocel in fistula tract tissue under surgical environment will be observed.
89598905|NCT04971525||Matched Control Cohort: Standard of Care (SoC)|Participants diagnosed with CD and PAF with no history of administration of darvadstrocel, matched age at index date (within 3 years), time from CD diagnosis (within 1 year), and sex to individuals in the darvadstrocel cohort who received the alternative Standard of Care (SoC), which varies from country to country and according to local centre expertise will be observed.
89598906|NCT04971044|Experimental|COACH Intervention|COACH is a multi-level intervention, consisting of 1) developmentally appropriate health curriculum for 4-6 year old children; 2) family-based content that both targets parent weight loss and leverages a shared parent-child experience to improve family health behaviors; 3) community-level intervention to improve access and quality of family-based programming at local Parks and Rec centers.
89608555|NCT04143321|Experimental|empagliflozin|following a two-week washout and complete SAQ and exercise tolerance test patients gave 25 mg empagloflozin and therafter SAQ and ETT was done
89608556|NCT04143321|Placebo Comparator|No drug|following a two-week washout and complete SAQ and exercise tolerance test patients gave placebo and therafter SAQ and ETT was done
89598907|NCT04971044|Active Comparator|Educational Control|The control arm will consist of a school readiness intervention developed by education and literacy experts on our team and implemented at local libraries. It will include 1) child lessons from Puente de Cuentos, a systematic, language-based curriculum focused on dual language storytelling (narrative language), and 2) parent sessions designed to improve parents' knowledge and skills related to improving children's language production and storytelling skills, to ultimately support school readiness.
89598908|NCT04967729|Other|LUS ultrasound and standard of care|Subjects will perform a lung ultrasound in order to determine the ability of patients to take an ultrasound from their homes. The lung ultrasound will be coupled with telehealth clinical support to monitor the severity of COVID-19 patients and provide standard of care. All subjects will receive the lung ultrasound technology and daily calls for teleguidance through the ultrasound and standard of care to monitor symptoms.
89598909|NCT04956159|Active Comparator|Active iTBS rTMS|The active arm involves magnetic stimulation of the brain to the left dorsolateral prefrontal cortex (DLPFC) twice daily for two weeks (20 sessions). The active arm will be receiving intermittent Theta-Burst (iTBS) repetitive Transcranial Magnetic Stimulation (rTMS) to deliver magnetic pulses.
89598910|NCT04956159|Sham Comparator|Sham iTBS rTMS|sham rTMS treatment involves scalp stimulation with no magnetic pulse twice daily for two weeks (20 sessions). Sham rTMS involves only the click replicating the sound of the magnetic discharge, without any magnetic pulse being delivered to the brain.
89598911|NCT04952324||Pregnant women with GDM|Pregnant women with GDM
89598912|NCT04952324||Pregnant women without GDM|Pregnant women without GDM
89598913|NCT04951726|Active Comparator|IV push|2 mg slow intravenous injection over five minutes repeated q12hr until resolution for up to 24 hours. (4 mg total in 24 hours)
89598914|NCT04951726|Experimental|subcutaneous|1.0 mg subcutaneous repeated q8hr until resolution for up to 24 hours (3.0 mg total in 24 hours)
89598915|NCT04948892||Father/partner present, Kolding hospital|All father/partners, mothers and hospital staff involved in hyperacute cesarean section category 1 in general anesthesia (obstetrician, anesthesiologist, OR-nurse, midwife, anesthetic nurse, pediatrician) in Kolding Hospital, where the father is present in the OR during the cesarean section category 1
89598916|NCT04948892||Father/partner not present, Aabenraa hospital|"All father/partners and mothers involved in hyperacute cesarean section category 1 in general anesthesia in Aabenraa hospital, where the father is not present in the OR during the cesarean sectio category 1.~All relevant hospital staff, who sometimes participates in cesarean sectio category 1 (obstetrician, anesthesiologist, OR-nurse, midwife, anesthetic nurse, pediatrician) will be asked to fill in a questionnaire on their thoughts and opinions on having the father/partner present during hyperacute cesarean sectio category 1."
89598917|NCT04937478||Hemodialysis patients|Patients who undergo hemodialysis in hospital every two to three days.
89598918|NCT04936919|Experimental|Treatment Arm|Subjects in the treatment arm will receive broadband light treatment
89598919|NCT04931212|Experimental|Intervention|
89598920|NCT04926571||Dexamethasone versus non-users of corticosteroids|
89598921|NCT04926571||Dexamethasone versus non-users of dexamethasone|
89598922|NCT04926571||Dexamethasone versus methylprednisolone active comparator|
88979664|NCT05567471|Active Comparator|Group 3 (BBV154 in COVISHIELD recipients)|250 participants will be recruited and administered with a booster dose of BBV154 vaccine, in individuals previously vaccinated with COVISHIELD.
89598923|NCT04924127||Discovery cohort|Retrospective frozen tissue and paired peripheral blood samples were obtained from the Huashan Glioma Biobank between October 2010 and August 2018. A total of 753 patients diagnosed with supratentorial diffuse glioma (WHO grade 2-4) aged 18-80 years were selected for the study.
89598924|NCT04924127||Validation cohort|From January to July 2021, 223 frozen tissue samples were retrieved from the Huashan Glioma Biobank. In addition, 107 frozen tumor samples were used to assess the detection accuracy of the IDH and TERTp mutation rapid test. The accuracy of this qPCR-based rapid test was further confirmed by Sanger and targeted sequencing.
89598925|NCT04919135|Experimental|Treatment (UC-MSC trasnplatation)|1.5 x 10^6 umbilical Cord Mesenchymal Stem Cells per body kg will transplant via the intravenous at baseline, and the second transplantation will be performed 3 months after the first transplantation and combination with standard frailty treatment and supplementary medication
89598926|NCT04919135|Other|control arm|standard frailty treatment and supplementary medication
89598927|NCT04918823|Other|Single arm|All subjects will receive Restasis in this study
89598928|NCT04918459||EUS guided cyanoacrylate injection|EUS guided cyanoacrylate injection to prevent EV rebleeding.
88811927|NCT02510820|Active Comparator|Synergi / comfilcon A|Participants were randomized to wear the Synergi / comfilcon A combination for one month during the cross over study.
88811928|NCT02510820|Active Comparator|Biotrue / comfilcon A|Participants were randomized to wear the Biotrue / comfilcon A combination for one month during the cross over study.
88811929|NCT02510664|Experimental|Intervention|There is no control/comparator group for this pilot study - all participants receive the intervention
88811930|NCT01509677|Active Comparator|Roflumilast|500 μg tablet, once daily, oral administration in the morning after breakfast
88811931|NCT01509677|Placebo Comparator|Placebo|tablet, once daily, oral administration in the morning after breakfast
88811932|NCT05460936|Active Comparator|conventional physical therapy|Resistive Exercises Stretching exercise of quadriceps , hamstring adductors and abductors.
88811933|NCT05460936|Experimental|Lower Extremity Functional Training|motor learning, skill progression, and resistance training to target the balance, strength, and coordination impairments of the lower extremities. Motor learning will be based on strength and balance training using tandem walks, balance boards, and one-leg standing. Skill progression will be used to challenge the LIFT and the strength training will be achieved by performing sit-to-stand, sit-ups, stair climbs, and vertical jumps
88811934|NCT04411446|Experimental|Vitamin D|5 capsules containing 100.000 UI of vitamin D each. The intervention will be 5 capsules given in one-time oral intake.
88811935|NCT04411446|Placebo Comparator|Placebo|5 capsules containing placebo. The intervention will be 5 capsules given in one-time oral intake.
88811936|NCT01510379|Active Comparator|Reletex|Reletex plus scheduled IV ondansetron 4 mg q 6 hours for a total of 4 doses. Breakthrough nausea will be treated using IV promethazine 25 mg q 6 hours prn during the hospital stay and in elixir at the same dose and frequency after discharge.
89598929|NCT04918459||variceal band ligation|variceal band ligation to prevent EV rebleeding.
89598930|NCT04909073||Afatinib 30 mg daily|Oral afatinib 30 mg tablet once daily, continuously
89598931|NCT04894656|Experimental|Gastroparesis patients|
89598932|NCT04894656|Active Comparator|Healthy volunteers|
89598933|NCT04887519||All Participants|Participants with advanced or metastatic ALK positive NSCLC who have been prescribed with brigatinib in real-world will be observed both prospectively and/or retrospectively at the local clinical practice setting and data will be taken from medical records of the routine visit after every 12 weeks from the start of treatment up to 24 weeks of follow up or death or cancer progression or treatment discontinuation, whichever occurs first.
89598934|NCT04885166|Experimental|Web-based simulation intervention|Participants in this condition will receive psychoeducation about stimulant medication diversion, stimulant medication misuse, and will practice navigating and resisting requests for their medication with a virtual human.
89598935|NCT04885166|Placebo Comparator|Placebo condition|Participants in this condition will learn about psychological conditions that affect college students most often (e.g., depression), causes of those conditions, and pharmacological/behavioral treatments for those conditions.
89598936|NCT04884607|Experimental|Study group|Study group will receive subthreshold low-level autonomic nerve stimulation using external auditory canal electrodes.
89598937|NCT04876651|Experimental|Group A|Two single intravenous (IV) injections of 76 mCi each (equivalent to a 45 mCi/m2 dose in a standard 1.7m2 individual) of 177Lu-DOTA- rosopatamab, given 14 days apart, plus best Standard of Care
89598938|NCT04876651|Active Comparator|Group B|Participants will receive the Standard of Care
88811937|NCT01510379|Other|Control|Scheduled IV ondansetron 4 mg q 6 hours for a total of 4 doses. Breakthrough nausea will be treated using IV promethazine 25 mg q 6 hours prn during the hospital stay and in elixir at the same dose and frequency after discharge.
88811938|NCT03784716|Experimental|Ketogenic Diet|Ketogenic Diet for 28 Days
88811939|NCT03784716|Active Comparator|Standard Weight Loss Diet|Standard Weight Loss Diet for 28 Days
88811940|NCT01363986|Experimental|Trastuzumab Monotherapy|Participants received an initial loading dose of 4 milligrams per kilogram (mg/kg) trastuzumab intravenous (i.v.), followed by weekly doses of 2 mg/kg i.v. for up to 18 weeks.
88811941|NCT01510457|Placebo Comparator|Sugar Pill|BID placebo
88811942|NCT01510457|Experimental|Milnacipran|Uptitration from 10mg to 50mg BID Milnacipran
88811943|NCT01430741|Other|Implementation as Usual Case Management|"Maintaining Independence and Sobriety Through Systems Integration, Outreach, and Networking (Veterans Edition):MISSION-Vet has been developed to target mental health, substance abuse and related issues faced by homeless Veterans through assertive outreach, psychoeducation, and linkages to community-based resources.~Implementation as Usual (IU) - standard training on the MISSION model via a 1.5 hour webinar"
88811944|NCT01430741|Other|Implementation as Usual Veterans|"Maintaining Independence and Sobriety Through Systems Integration, Outreach, and Networking (Veterans Edition):MISSION-Vet has been developed to target mental health, substance abuse and related issues faced by homeless Veterans through assertive outreach, psychoeducation, and linkages to community-based resources.~Implementation as Usual (IU) - standard training on the MISSION model via a 1.5 hour webinar. Staff then deliver MISSION to Veterans."
88811945|NCT01430741|Experimental|Getting to Outcomes Case Management|Getting To Outcomes (GTO) is used to strengthens the knowledge, attitudes, and skills practitioners need to carry out evidence based programs. In GTO, staff receive ongoing technical assistance using the GTO implementation platform.
89598939|NCT04869683|Other|MDS follow up|it is a description MDS patients study
89598940|NCT04869514|Active Comparator|either lumbar manipulation (LMANIP)|LMANIP will consist of high velocity low amplitude (HVLA) SMT at the L4/L5 motion segment. LMANIP consists of two HVLA impulses, applied in side-posture on the right and left side (order pseudorandomized).
89598941|NCT04869514|Active Comparator|thoracic manipulation (TMANIP)|TMANIP will consist of high velocity low amplitude (HVLA) SMT at the T4/5 motion segment. TMANIP consists of supine SMT to the right and left (order pseudorandomized) using a thenar contact at facet joint level T4/5
89598942|NCT04869514|Sham Comparator|lumbar mobilisation (LMOB)|LMOB will be applied with the same positioning as in the LMANIP procedure, but instead of a thrust, a slow, a slow, passive mobilization without impulse will be applied
89598943|NCT04869514|No Intervention|No intervention|A natural history arm will serve to further control for potential specific and non-specific effects of TMANIP and LMOB. Subject will rest in side-lying position for the same duration as during the active interventions.
89598944|NCT04863599|Other|OMS procedure under general anesthesia or sedation|Questionnaire
89598945|NCT04861766|Experimental|Treatment group Stylage L ®|"Each subject will receive STYLAGE® L in both NLFs.~STYLAGE® L will be injected in the NLFs by the Treating Investigator with optional touch-up injections on Month 1."
89598946|NCT04861766|Active Comparator|Control group Active Comparator|"Each subject will receive the Active Comparator in both NLFs.~Active Comparator will be injected in the NLFs by the Treating Investigator with optional touch-up injections on Month 1."
89598947|NCT04857996|Experimental|UBX1325|
89598948|NCT04857996|Sham Comparator|Sham Control|
89598949|NCT04857814|Experimental|Device|All participants will wear the device to assist in determining the feasibility of wearing the device.
89598950|NCT04842747|Experimental|9mg of VERU-111 Oral daily|9mg of VERU-111
89598951|NCT04842747|No Intervention|Placebo Capsule once daily|Subjects in the Placebo treatment group will receive standard of care, plus a placebo capsule for 21 days or until released from hospital.
89598952|NCT04839458|Experimental|Dental Prescale II used|
89598953|NCT04810481|No Intervention|Standard Practice|Anesthesia will be provided at the discretion of the anesthesiologist following cardiovascular variables in accordance with usual clinical indications.
89598954|NCT04810481|Active Comparator|BIS Group|Anesthesia will be titrated to achieve a BIS value of 45-60 during maintenance of anesthesia. Additional intervention will be provided only if the subject is in distress.
89598955|NCT04806724|Experimental|Program #1|Participants attend 5 sessions (1.5 hours each) consisting of education and skills training to address cancer-related reproductive and sexual health concerns. Sessions occur via videoconference.
89608557|NCT00734968|Experimental|Treatment|Patients randomly assigned to be treated with nitrofurantoin 100mg PO BID x 3 days post-operatively
89598956|NCT04806724|Active Comparator|Program #2|Participants attend 4 sessions (1.5 hours each) consisting of education and skills training to address cancer-related concerns. Sessions occur via videoconference.
89598957|NCT04800913|Experimental|Multimodal imaging|"Preoperative 2D/3D TOE AND MDCT for appendage characterisation and sizing~Operative 2D/3D TOE and fluoroscopy/angiography for guiding and checking the procedural events and success~Postoperative 2D/3D TOE and MDCT to assess the complications (peri-device leak, thrombus)"
89598958|NCT04800913|Experimental|Standard imaging|"Preoperative MDCT for appendage characterisation and sizing~Operative 2D/3D TOE and fluoroscopy/angiography for guiding and checking the procedural events and success~Postoperative 2D/3D TOE and MDCT to assess the complications (peri-device leak, thrombus)"
89598959|NCT04785651|Experimental|Tranexamic arm|Patients in this arm will undergo to a tibial osteotomy in combination with the anti-fibrinolytic agent Tranexamic acid.
89598960|NCT04785651|Other|control arm|Patients in this arm will undergo to a tibial osteotomy without the use of Tranexamic acid
89598961|NCT04781114|Experimental|JS002|Cohort 1: 150 mg/1mL Q2W Subcutaneous(SC); Cohort 2: 300/2mL mg Q4W Subcutaneous(SC);
89598962|NCT04781114|Placebo Comparator|Placebo|Cohort 1: 1mL Q2W Subcutaneous(SC); Cohort 2: 2mL Q4W Subcutaneous(SC);
89598963|NCT04780204|Experimental|Antiviral Treatment|Tenofovir Alafenamide 25mg once daily , Oral
89598964|NCT04770480|Active Comparator|Standard Care (SC)|Standard Post-Surgical Care utilizing opioids.
89598965|NCT04770480|Active Comparator|Enriched Surgical Management Pathway (EMP)|Enriched Surgical Management Pathway utilizing Physical Therapy and Mindfulness in addition to Standard Protocol.
89598966|NCT04762719|Experimental|Diabetic Gastroparesis Subjects|Type I or II diabetes subjects who also have a diagnosis of Gastroparesis (defined by gastric retention of Tc-99m >20% at 4 hrs on scintigraphy). Subjects will receive PET/CT Scan with 11C-ER176 and a core biopsy of gastric muscle
89598967|NCT04762719|Experimental|Diabetic without gastroparesis subjects|Type I or II diabetes subjects who have not been clinically diagnosed with Gastroparesis. Subjects will receive PET/CT Scan with 11C-ER176
89598968|NCT04762719|Placebo Comparator|Healthy Subjects|Healthy subjects will be age-matched and receive a PET/CT Scan with 11C-ER176
89598969|NCT04755231|Experimental|PanOptix IOL|AcrySof IQ PanOptix Presbyopia Correcting IOL implanted in the capsular bag in the posterior chamber of the eye during cataract surgery
89598970|NCT04753853|Experimental|Stromal Vascular Fraction injection|intra- and peri-tendon ultrasound-guided injection of Stromal Vascular Fraction
89598971|NCT04748588|No Intervention|Standard of care|
89598972|NCT04748588|Experimental|Anti SARS-CoV-2 monoclonal antibody|Single IV administration of an anti-SARS-CoV-2 Monoclonal antibody
89598973|NCT04735510|Other|Single arm|This is a single arm study in which all subjects will receive study medication.
89598974|NCT04734015|Experimental|Together Overcoming Diabetes (TOD) curriculum|"A randomized waitlist control trial (RCT) design will be employed with 81 family dyads (adult caregiver and youth) randomly assigned to the Intervention group (Group A): Together Overcoming Diabetes (TOD).~Group A participant dyads will be monitored via assessment of applicable biometric, psychosocial and behavioral outcomes at baseline, 3-months into intervention delivery, 6 months after baseline (post intervention), 12 months, 18 months, and 24 months."
89598975|NCT04734015|No Intervention|Waitlist Control|"A randomized waitlist control trial (RCT) design will be employed with 81 family dyads (adult caregiver and youth) randomly assigned to the Waitlist Control group (Group B). Waitlist family dyads will not initially receive the intervention. They will be monitored via assessment of applicable biometric, psychosocial and behavioral outcomes at baseline, 3-months into intervention delivery, 6 months after baseline (post intervention), 12 months, 18 months, and 24 months.~Waitlist participant dyads will begin to receive the intervention program (TOD) approximately 24 months (2 years) after enrollment in the RCT."
89598976|NCT04696523|Active Comparator|Air/Oxygen|Control arm: air/oxygen with standard of care
89598977|NCT04696523|Experimental|xenon|Xenon arm: xenon inhalation in air/oxygen with standard of care
89598978|NCT04691102||Stroke group|"Patients will undergo electroencephalography (EEG), electromyography (EMG), electrocardiogram (EKG) and electrooculography (EOG) during resting state and the execution of motor tasks. During the records, an inertial sensors-based assessment will be performed on all patients. Three different motor tasks will be considered for postural and gait functions, commonly adopted in the clinical practice (i.e., 10-Meter-Walk, Figure-of-8-Walk, and Fukuda-Stepping tests). To assess the motor function of upper limb, three different tasks, representative of the typical ADL movements, will be considered (Reach Out, Reach and Touch, Reach and Grasp). Each task will be repeated 3 times.~The whole assessment procedure will last approximately 40 minutes."
88979665|NCT05567471|Active Comparator|Group 4(COVAXIN in COVISHIELD recipients)|125 participants will be recruited and administered with a booster dose of BBV152 (COVAXIN) vaccine, in individuals previously vaccinated with COVISHIELD.
88979666|NCT05567471|Active Comparator|Group 5 (COVISHIELD in COVISHIELD recipients)|125 participants will be recruited and administered with a booster dose of Covishield vaccine, in individuals previously vaccinated with COVISHIELD.
89608558|NCT00734968|Placebo Comparator|Placebo|Arm randomly assigned to receive placebo 1 tablet PO BID x 3 days post-operatively.The incidence of UTI in this group will be compared with group one (1)
88811946|NCT01430741|Experimental|Getting to Outcomes Veterans|Getting To Outcomes (GTO) is used to strengthens the knowledge, attitudes, and skills practitioners need to carry out evidence based programs. In GTO, staff receive ongoing technical assistance using the GTO implementation platform, that guides staff while delivering MISSION to Veterans.
88811947|NCT02478372|Active Comparator|Patient Controlled Epidural (PCEA)|A lumbar epidural was sited using a side-directed technique towards the side of surgery following establishment of the spinal blockade. Following the completion of the operation, patients received 4ml of 0.25% levobupivacaine prior to leaving the operating room. Thereafter they were connected to a PCEA pump (McKinley 545) with no background infusion. Patients could self-medicate with a bolus 2ml of 0.125% bupivacaine via the PCEA system with a lockout time of 15 minutes to control their pain until the following morning (post-operative day one) when it was stopped. Nurse-administered rescue top-ups of 4ml of 0.25% levobupivacaine were available for insufficient analgesia. The epidural catheter was removed on the morning of post-operative day two (POD2).
89598979|NCT04691102||Traumatic Brain Injury group|"Patients will undergo electroencephalography (EEG), electromyography (EMG), electrocardiogram (EKG) and electrooculography (EOG) during resting state and the execution of motor tasks. During the records, an inertial sensors-based assessment will be performed on all patients. Three different motor tasks will be considered for postural and gait functions, commonly adopted in the clinical practice (i.e., 10-Meter-Walk, Figure-of-8-Walk, and Fukuda-Stepping tests). To assess the motor function of upper limb, three different tasks, representative of the typical ADL movements, will be considered (Reach Out, Reach and Touch, Reach and Grasp). Each task will be repeated 3 times.~The whole assessment procedure will last approximately 40 minutes."
89598980|NCT04691102||Mild Cognitive Impairment group|"Patients will undergo electroencephalography (EEG), electromyography (EMG), electrocardiogram (EKG) and electrooculography (EOG) during resting state and the execution of motor tasks. During the records, an inertial sensors-based assessment will be performed on all patients. Three different motor tasks will be considered for postural and gait functions, commonly adopted in the clinical practice (i.e., 10-Meter-Walk, Figure-of-8-Walk, and Fukuda-Stepping tests). To assess the motor function of upper limb, three different tasks, representative of the typical ADL movements, will be considered (Reach Out, Reach and Touch, Reach and Grasp). Each task will be repeated 3 times.~The whole assessment procedure will last approximately 40 minutes."
89598981|NCT04691102||Parkinson Disease group|"Patients will undergo electroencephalography (EEG), electromyography (EMG), electrocardiogram (EKG) and electrooculography (EOG) during resting state and the execution of motor tasks. During the records, an inertial sensors-based assessment will be performed on all patients. Three different motor tasks will be considered for postural and gait functions, commonly adopted in the clinical practice (i.e., 10-Meter-Walk, Figure-of-8-Walk, and Fukuda-Stepping tests). To assess the motor function of upper limb, three different tasks, representative of the typical ADL movements, will be considered (Reach Out, Reach and Touch, Reach and Grasp). Each task will be repeated 3 times.~The whole assessment procedure will last approximately 40 minutes."
89598982|NCT04691102||Multiple Sclerosis group|"Patients will undergo electroencephalography (EEG), electromyography (EMG), electrocardiogram (EKG) and electrooculography (EOG) during resting state and the execution of motor tasks. During the records, an inertial sensors-based assessment will be performed on all patients. Three different motor tasks will be considered for postural and gait functions, commonly adopted in the clinical practice (i.e., 10-Meter-Walk, Figure-of-8-Walk, and Fukuda-Stepping tests). To assess the motor function of upper limb, three different tasks, representative of the typical ADL movements, will be considered (Reach Out, Reach and Touch, Reach and Grasp). Each task will be repeated 3 times.~The whole assessment procedure will last approximately 40 minutes."
89598983|NCT04691102||Healthy subjects groups|"Patients will undergo electroencephalography (EEG), electromyography (EMG), electrocardiogram (EKG) and electrooculography (EOG) during resting state and the execution of motor tasks. During the records, an inertial sensors-based assessment will be performed on all patients. Three different motor tasks will be considered for postural and gait functions, commonly adopted in the clinical practice (i.e., 10-Meter-Walk, Figure-of-8-Walk, and Fukuda-Stepping tests). To assess the motor function of upper limb, three different tasks, representative of the typical ADL movements, will be considered (Reach Out, Reach and Touch, Reach and Grasp). Each task will be repeated 3 times.~The whole assessment procedure will last approximately 40 minutes."
89598984|NCT04664400|Experimental|N-of-few Study of Pain|
89598985|NCT04657770|Experimental|Telerehabilitation|Patients will receive 36 treatment sessions over 6 weeks, consisting of 3 sessions/week that are supervised rehab therapy sessions (which begin with a 30-minute videoconference with the licensed OT or PT), alternating with 3 sessions/week of unsupervised rehab therapy sessions whereby the patient follows the instructions on the screen to engage in rehab therapy. Because patients sometimes miss a session, e.g., due to a conflict, we allow up to 8 weeks for patients to complete their 36 rehab therapy sessions.
89598986|NCT04655222||All Participants|Pregnant Multiple Sclerosis (MS) participants treated with SC interferon beta therapy or an IM interferon beta therapy in the German PSP of the MSSC.
89598987|NCT04652440|Experimental|Radiofrequency or microwave ablation combined with PD-1 monoclonal antibody|Patients who meet the inclusion criteria will receive 1 cycle of PD-1 antibody on the day before ablation, then 3 cycles of PD-1 antibody after primary radiofrequency or microwave ablation, on a schedule of per 3 weeks, then be followed until disease relapse or death.
89598988|NCT04650867||Patients with Crohn's disease|Patients diagnosed or with suspected Crohn's disease.
89598989|NCT04650867||Patients with Ulcerative colitis|Patients diagnosed or with suspected Ulcerative colitis
89598990|NCT04650867||Patients with unclassified inflammatory bowel disease (U-IBD)|Patients diagnosed or with suspected unclassified inflammatory bowel disease (U-IBD)
89598991|NCT04614389|Other|CEUS and SWE|CEUS & SWE
89598992|NCT04612192|Experimental|Active light|active blue-enriched bright light
89598993|NCT04612192|Placebo Comparator|Placebo light|dim red placebo light
88979667|NCT00089154|Experimental|Treatment (apolizumab)|Patients receive apolizumab IV over 2-4 hours on days 1, 2, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26 in the absence of disease progression or unacceptable toxicity.
88979668|NCT00312442|Experimental|WST 09|Treatment with WST09-mediated VTP
88979669|NCT00312481|Experimental|1|MOVIPREP
88979670|NCT00312481|Active Comparator|2|Picolax
88979671|NCT05567432|Active Comparator|Patients will do throidectomy using diathermy|In these patients the investigators will control bleeding and cut tissues and blood vessels using the diathermy .
88979672|NCT05567432|Active Comparator|Patients will do thyroidectomy using ligasure .|In these patients the investigators will control bleeding and cut tissues and blood vessels using the liagasure.
88979673|NCT00293137||1|Patients enrolled into the trial must have left ventricular ejection fraction of <40% by echocardiogram within 6 months of enrollment
88979674|NCT00293176|Experimental|1|
88979675|NCT00293176|Placebo Comparator|2|
88979676|NCT05567276||Group 1|Group : Non-Violent Resistance parental training (NVR)
88979677|NCT05567276||Group 2|Group 2 : Treatment as usual (TAU) = Control
88979678|NCT00121602|Active Comparator|Roller bottle|
88979679|NCT00121602|Experimental|Serum free|
88979680|NCT00293605||1|C-stem implant
88979681|NCT00293605||2|Charnley Implant
89598994|NCT04607967|No Intervention|"Conventional oxygen-therapy (study group CO)"|"Patients randomized in the Conventional Oxygen group will be treated according to the national and international recommendations with a conventional oxygen-therapy device (nasal cannula or nasal-oral mask).~Treatment failure will be evaluated after 4 hours by the need for a therapeutic escalation."
89598995|NCT04607967|Experimental|"High Flow Nasal Oxygen (study group HNFO)"|"Patients randomized in the HNFO group will be treated according to the CE Marking with the high flow nasal oxygen device.~Treatment failure will be evaluated after 4 hours by the need for a therapeutic escalation."
89598996|NCT04605159|Experimental|RSV_MAT Group|Maternal participants randomized to the RSV_MAT Group will receive a single dose of RSV MAT vaccine at day 1, via the intramuscular route; the preferred injection site will be the deltoid region of the non-dominant arm.
89598997|NCT04605159|Placebo Comparator|Control Group|Maternal participants randomized to the Control Group will receive a single dose of Placebo at day 1, via the intramuscular route; the preferred injection site will be the deltoid region of the non-dominant arm.
89598998|NCT04604067|Experimental|Arm with 4 cohorts|"Cohort A: MYD88 L265P and/or CD79A/B mutations at baseline Treatment: Acalabrutinib-R-CHOP for a total number of 6 cycles.~Cohort B, C D: Without MYD88 L265P and CD79A/B mutations at baseline:~Assignment of cohort B, C and D after 2 cycles of R-CHOP according to PET (Deauville score (DS)) and molecular response (MR) (>2log10 reduction of ctDNA) results:~Cohort B: DS 4 and No MR Treatment: 2 cycles of acalabrutinib-R-CHOP. After PET3/ctDNA3: patients with DS 1-3 and no MR OR DS4 with MR will receive 2 additional cycles of acalabrutinb-R-CHOP and 2 cycles of acalabrutinib single agent.~Cohort C: DS 1-3 and MR Treatment: 2 additional cycles of R-CHOP (4x RCHOP in total) followed by 2 cycles of rituximab single agent.~Cohort D: DS 4 and no MR OR DS 1-3 and MR Treatment: 4 additional cycles of RCHOP (6 cycles in total).~Follow up: Patients off treatment will be followed for 5 years."
89598999|NCT04594109|Active Comparator|Standard of Care|One-time standard of care in-person behavioral counseling lasting approximately one hour, plus a 30-day supply of nicotine replacement therapy consisting of nicotine patches and nicotine gum (dosage according to current smoking intensity according to manufacturers instructions). The standard of care behavioral counseling was adapted from the current U.S. clinical practice guidelines.
89599000|NCT04594109|Experimental|Tailored Counseling|Participants in the intervention arm were provided a one-time tailored cognitive-behavioral therapy in-person cessation counseling intervention lasting approximately one hour, a 30-day supply of nicotine replacement therapy (consisting of nicotine patches and nicotine gum; dosage according to current smoking intensity according to manufacturers instructions), and a tailored bi-directional text messaging program delivering two messages per day for four weeks. The TI session was adapted from the clinical practice guidelines to include behavioral elements rooted in the minority stress model. The intervention used addressed issues of stress related to HIV stigma, minority status and socioeconomic condition.
89599001|NCT04593069|Other|COVID-19 patients|Neurocognitive impairment in COVID-19 patients
89599002|NCT04586712|Experimental|Active CBD-extract high dose|High Dose (1000mg/30mL hemp extract = 62.5mg/day)
89599003|NCT04586712|Experimental|Active CBD low dose|Low Dose (500mg/30mL hemp-extract = 25mg/day)
89599004|NCT04586712|Placebo Comparator|Vehicle-Control (Placebo)|(0mg/30mL hemp extract = no hemp extract)
89599005|NCT04585711|Other|Optimal dosing|Obese children (≥ 2 year old) and adults with juvenile idiopathic arthritis (JIA) or Rheumatoid Arthritis (RA) who are starting etanercept as part of their routine medical care.
89599006|NCT04566484|Experimental|BBV87vaccine(BBV87 20 µg/ BBV87 40 µg)|"The test article, inactivated Chikungunya virus vaccine 'BBV87', is available in a 2 mL clear glass USP Type 1 vial that contains a single dose of 0.5 mL of the vaccine as singlehuman dose (SHD). Vials are stoppered and sealed with tear-down aluminum seals.~• Route: BBV87 vaccine will be given to participants intramuscularly in the deltoid region of the upper arm. 0.5 mL of the investigational vaccine (BBV87 20 µg/ BBV87 40 µg) will be administered."
89599007|NCT04566484|Placebo Comparator|Normal Saline|Each 0.5 ml vial of placebo will contain normal saline.The placebo will be given to participants intramuscularly in the deltoid region of the upper arm.0.5 mL of placebo will be administered.
89599008|NCT04551495|Experimental|Single Arm|Subjects will receive four 28-day cycles of letrozole 2.5 mg daily in combination with entrectinib 600 mg daily. Pre-menopausal women will receive goserelin 3.6 mg every 28 days.
89599009|NCT04548778||exocrine pancreatic insufficiency (PEI)|Established diagnosis of PEI based on a routine clinical diagnostic work-up including a treat-to-diagnose approach using Pancreatic Enzyme Replacement Therapy (PERT).
89599010|NCT04548778||no exocrine pancreatic insufficiency (no PEI)|No evidence of PEI according to routine clinical diagnostic work-up including a treat-to-diagnose approach using Pancreatic Enzyme Replacement Therapy (PERT).
89599011|NCT04536779|Experimental|Individuals with low mobility (Disabled and Elder)|minimum 8-10 training sessions in at least three months.
89599012|NCT04533659|Active Comparator|Control group|This group will receive 4-week diabetes nutrition education with digital self-monitoring for diet and blood glucose.
89599013|NCT04533659|Experimental|Intervention group|This group will receive 4-week personalized behavioral nutrition intervention with digital self-monitoring for diet and blood glucose and diabetes nutrition education. Participants will discuss the personalized nutrition change goals and recommendations based on metabolic profiling for assessing dietary patterns.
88979682|NCT00293605||3|Exeter Implant
88979683|NCT00293644|Experimental|Pre-emptive Treatment Group|As soon as a patient becomes aware of the pregnancy, and before the Nausea and Vomiting of Pregnancy (NVP) starts, she will begin taking Diclectin®. When NVP starts, the dose will be adjusted to match symptoms.
88979684|NCT00293644|Active Comparator|Standard Treatment Group|Women randomised to this arm will not receive any Diclectin® before symptoms appear, and will be advised to commence treatment only at first sign of nausea. The starting dose of Diclectin® will be 20mg (2 tablets) at bedtime.
89031998|NCT00518024|Sham Comparator|3|Bilateral theta burst stimulation to a non-cortical region
89031999|NCT02939508|Experimental|Colon originated|A history of colon (-innervating) nerve damage, moderate or more severe edema; and without a history of colon (-innervating) nerve damage, with mild or severe edema of colonic wall on CT.
89599014|NCT04523558|Experimental|Bilateral implantation of LuxSmart hydrophobic IOL|"Cataract surgery will be carried out using standard phacoemulsification technique with a 2.2 mm incision. Investigators will target a 5.5 mm diameter capsulorhexis to allow the optic to be fully overlapped by the anterior capsular rim.~The intended target of the post-operative refraction will be emmetropia. The patient will be implanted with LuxSmart hydrophobic IOLs in both eyes and followed up for 6 months"
89599015|NCT04520087|Experimental|allograft fixation|Patients with anteroinferior shoulder instability will be clinically treated with a mini-open arthrotomic technique involving the fixation of the corticospongeous bone graft on the glena.
89599016|NCT04515316|Experimental|healthy adults|Any adult, who is at least eighteen (18-70) years old.
89599017|NCT04515316|Experimental|Patients with intractable epilepsy|Any clinical patient referred to us via the clinical MEG program, and who is at least eighteen (18-70) years old.
89599018|NCT04513132|Active Comparator|active-CHR|Participants will be intervened with deep transcranial magnetic stimulation (dTMS).
89599019|NCT04513132|Sham Comparator|sham-CHR|Participants, as a control group, will receive sham stimulation.
89599020|NCT04513132|Active Comparator|active-FES|Patients with first-episode schizophrenia will be intervened with deep transcranial magnetic stimulation (dTMS).
89599021|NCT04513132|Sham Comparator|sham-FES|Patients with first-episode schizophrenia, as a control group, will receive sham stimulation.
89599022|NCT04508478|Experimental|Aerobic training|
89599023|NCT04508478|Active Comparator|Resistance training|
89599024|NCT04508478|Placebo Comparator|Control|
89599025|NCT04501718|Experimental|Test group|
89599026|NCT04501705|Experimental|test group|
89599027|NCT04496453|Experimental|Childhood vaccination decision support tool|Participants receive childhood vaccination decision support tool
89599028|NCT04483791|Other|DynamX Novolimus Eluting Coronary Bioadaptor System|DynamX use in de novo coronary artery lesions
89599029|NCT04463394|Experimental|Vasopressin|Participants undergoing cardiac catheterization
89599030|NCT04459104|Experimental|chronic low back patients|Participants will be given two beverages, (isomaltulose or sucrose) in a random order (one of each on each of the two test dates).
89599031|NCT04459104|Experimental|breast cancer survivors having chronic pain|Participants will be given two beverages, (isomaltulose or sucrose) in a random order (one of each on each of the two test dates).
89599032|NCT04459104|Active Comparator|healthy pain-free controls|Participants will be given two beverages, (isomaltulose or sucrose) in a random order (one of each on each of the two test dates).
89599033|NCT04454905|Experimental|Camrelizumab combination with Apatinib|Camrelizumab 200mg, every 3 weeks, intravenous infused. Apatinib 250mg, once a day, orally. Until progression or unacceptable toxicity events develop.
89599034|NCT04448106|Experimental|Phase 2 Arm 1 - OA Knee|"50 subjects receive two doses of 2.0-2.86 x 10^6 cells/kg on days 0 and 6 via intravenous infusion.~On day 3, each subject will receive a single dose of 1.0-2.86 x 10^6 cells/kg via intra-articular injection into the injured joint."
89599035|NCT04448106|Active Comparator|Phase 2 Arm 2 OA Knee|Control group- 50 subjects receive three doses of 2.0-2.86 x 10^6 cells/kg on day 0, 3, and 6 via intravenous infusion
89599036|NCT04448106|Experimental|Phase 2 Arm 3 - OA Hip|"50 subjects receive two doses of 2.0-2.86 x 10^6 cells/kg on days 0 and 6 via intravenous infusion.~On day 3, each subject will receive a single dose of 1.0-2.86 x 10^6 cells/kg via intra-articular injection into the injured joint."
89599037|NCT04448106|Active Comparator|Phase 2 Arm 4 - OA Hip|Control group- 50 subjects receive three doses of 2.0-2.86 x 10^6 cells/kg on day 0, 3, and 6 via intravenous infusion
89599038|NCT04448106|Experimental|Phase 2 Arm 5 - OA Shoulder|"50 subjects receive two doses of 2.0-2.86 x 10^6 cells/kg on days 0 and 6 via intravenous infusion.~On day 3, each subject will receive a single dose of 1.0-2.86 x 10^6 cells/kg via intra-articular injection into the injured joint."
89599039|NCT04448106|Active Comparator|Phase 2 Arm 6 - OA Shoulder|Control group- 50 subjects receive three doses of 2.0-2.86 x 10^6 cells/kg on day 0, 3, and 6 via intravenous infusion
89599040|NCT04440163|Experimental|1-Immuno Subset (ACWY Naive,MenABCWY/Saline)|ACWY Naive subjects, MenABCWY/Saline
89599041|NCT04440163|Experimental|2-Immuno Subset (ACWY Naive, Trumenba/MenACWY-CRM)|ACWY Naive subjects, Trumenba/MenACWY-CRM
89599042|NCT04440163|Experimental|3-Immuno Subset (ACWY Experienced,MenABCWY/Saline)|ACWY Experienced subjects, MenABCWY/Saline
89599043|NCT04440163|Experimental|4-Immuno Subset (ACWY Experienced,Trumenba/MenACWY-CRM)|ACWY Experienced subjects, Trumenba/MenACWY-CRM
89599044|NCT04440163|Experimental|5-Safety Subset (ACWY Naive,MenABCWY/Saline)|ACWY Naive subjects, MenABCWY/Saline
89599045|NCT04440163|Experimental|6-Safety Subset (ACWY Naive,Trumenba/MenACWY-CRM)|ACWY Naive subjects, Trumenba/MenACWY-CRM
89599046|NCT04440163|Experimental|7-Safety Subset (ACWY Experienced,MenABCWY/Saline)|ACWY Experienced subjects, MenABCWY/Saline
89599047|NCT04440163|Experimental|8-Safety Subset (ACWY Experienced,Trumenba/MenACWY-CRM)|ACWY Experienced subjects, Trumenba/MenACWY-CRM
89599048|NCT04436601|Active Comparator|Lactulose|90 ml of Lactulose dissolved in 750 ml of water administered orally by mouth or nasogastric tube (three doses within 24 hrs) continued up to 72 hours or until patient discharge, whichever comes first.
89599049|NCT04436601|Experimental|PEG: Polyethylene Glycol|Three or four sachet of Movicol(PEG) will be dissolved in 750 ml of water and will be given over 24 hrs as 3 doses orally by mouth or Nasogastric tube and will continue up to 72 hours or until patient discharge, whichever comes first
89599050|NCT04428801|Experimental|Phase 2 AdMSC group|"Each subject receives three doses of 200 million autologous adipose derived mesenchymal stem cells via intravenously infusion every three days~Other Names: Celltex-AdMSCs Celltex-AdMSCs"
89599051|NCT04428801|Placebo Comparator|Phase 2 Placebo group|The control group- receive three doses of placebo via intravenously infusion every three days.
89599052|NCT04417036|Experimental|Part A - Active Drug Dose 1|Participants will receive Active Drug Dose 1 for a maximum of 14 days in study phase Part A
89599053|NCT04417036|Experimental|Part A - Active Drug Dose 2|Participants will receive Active Drug Dose 2 for a maximum of 14 days in study phase Part A
89599054|NCT04417036|Placebo Comparator|Part A - Placebo|Participants will receive Placebo for a maximum of 14 days in study phase Part A
89599055|NCT04417036|Experimental|Part B - Active Drug Dose|Participants will receive Active Drug 1 or 2 for a maximum of 14 days in study phase Part B
89599056|NCT04417036|Placebo Comparator|Part B - Placebo|Participants will receive Placebo for a maximum of 14 days in study phase Part B
89599057|NCT04416243|Experimental|Recumbent Stepping, High-Intensity Interval Training|
89599058|NCT04373785|Experimental|NG101m and standard treatment|"Concomittant therapy:~Radiation therapy, oral temozolomide, and oral NG101m~Adjuvant therapy:~Oral temozolomide and oral NG101m"
89599059|NCT04367571|Experimental|Osteopathic Manipulative Treatment|
89599060|NCT04367571|Placebo Comparator|Manual Placebo|
89599061|NCT04366310||capillary refill index (CRI)|a waveform analysis method using a pulse oximeter to assess peripheral perfusion
89599062|NCT04362150||COVID-19 positive, recovered|Individuals with positive test for COVID-19 who have recovered from acute infection (21 days after symptom onset + improvement in symptoms + resolution of fever for 72 hours without fever reducing medicines).
89599063|NCT04359563|Experimental|Mindfulness-Based Intervention|The MBI programme adheres to a standardized protocol developed from MBSR (Kabat-Zinn, 1990) and MBCT (Segal et al., 2012) manuals and is adjusted to an adolescent population. Adjustments are based on the investigator's ample experience with mindfulness and adolescents in different contexts. Key objectives are: (1) to increase awareness of one's present moment experience; (2) to teach an attitude of openness and acceptance (non-judging) toward one's experience. This accepting attitude changes the person's relationship with the experience, being a detached and non-reactive orientation. Participants learn to recognize entanglement with one's thoughts and emotions and there is an increased understanding of one's spontaneous reactions. If adolescents adopt these skills, their negative emotions and cognitions will no longer be reinforced, creating the opportunity to deal with problematic thoughts and feelings.
88979685|NCT00293644|No Intervention|Natural Course Group|A third group will be randomly matched from Motherisk NVP callers who did not participate in our pre-emptive intervention and experienced severe Nausea and Vomiting of Pregnancy/Hyperemesis Gravidarum (NVP/HG) in their previous pregnancy. This group will serve as a control group for the potential effect of the early counselling. (These women will have called for the first time after NVP symptoms (of any degree) started in the current pregnancy).
89599064|NCT04317755|Experimental|Intervention|Comic-based body image programme
89599065|NCT04317755|No Intervention|Control|Schools lessons as usual
89599066|NCT04315545||Healthy women pregnant of singleton with a BMI ≥25 kg/m2|Healthy women pregnant of singleton with a BMI ≥25 kg/m2 will be followed from 12 weeks of gestation till 6 months postpartum. Neonates will be followed from birth up to 6 months of age.
89599067|NCT04312997|Experimental|PUL-042 Inhalation Solution|PUL-042 Inhalation Solution given by nebulization on Study Days 1, 3 and 6
89599068|NCT04312997|Placebo Comparator|Sterile saline for inhalation|Sterile saline for Inhalation given by nebulization on Study Days 1, 3 and 6
89599069|NCT04309461|Active Comparator|Stress Management Group|The Stress Management Program will utilize a smart phone app, accelerometers, telephone coaching, and behavioral incentives to target stress, relaxation, and sleep. Participants will wear accelerometers, log hours slept, enter real-time information about their relaxation exercises and stress, and monitor 3 goal thermometers (sleep, relaxation, stress) to meet behavioral targets. The Stress Management Program, including the use of the app and assessments, is identical to the Adapted MBC2 program, with the exception of the content.
89599070|NCT04309461|Experimental|Adapted MBC2 Group|The Adapted MBC2 Program will utilize a smart phone app, accelerometers, telephone coaching, and behavioral incentives to target fruit and vegetable intake, dietary fat intake, physical activity, and high sedentary leisure screen time. Participants will wear accelerometers, log hours slept, enter real-time information about their relaxation exercises and stress, and monitor goal thermometers to meet targets.
88979686|NCT00293761|Experimental|Travatan, Investigational|
88979687|NCT00293761|Active Comparator|Travatan|
88979688|NCT00293800|Experimental|Travoprost/Timolol|One drop Travoprost 0.004%/Timolol 0.5% in the study eye(s) each morning at 8 a.m. and one drop Timolol vehicle in the study eye(s) each evening at 8 p.m. for 3 months
88979689|NCT00293800|Active Comparator|Xalatan + Timolol 0.5%|One drop Timolol 0.5% in the study eye(s) each morning at 8 a.m. and one drop Xalatan in the study eye(s) each evening at 8 p.m. for 3 months
88979690|NCT04710771||Group-A|Patient performed prone lying position for three hours.
88979691|NCT04710771||Group-B|along with Prone lying position, patients also performed alternate nostril breathing for ten minutes.
89599071|NCT04304508|Experimental|BAY2433334 high dose|
89599072|NCT04304508|Experimental|BAY2433334 medium dose|
89599073|NCT04304508|Experimental|BAY2433334 low dose|
89599074|NCT04304508|Placebo Comparator|BAY2433334 matching placebo|
89599075|NCT04292145|Experimental|Relaxation Application|Participants will follow the relaxation application.
89599076|NCT04292145|Active Comparator|Relaxation Only|Participants will use any relaxation technique they normally use to relax.
89599077|NCT04291560|Experimental|Prenatal Heart Smart Intervention|This group will have usual care completed and supportive calls from a facilitator to discuss adherence to the home exercise. In addition, the group will complete a sequential static stretching exercise 5 days per week for 10 weeks. The stretching exercise consists of 20 seconds of stretching, for 3 repetitions per muscle group.
89599078|NCT04291560|No Intervention|Usual Care (Control)|This group will have usual care completed and supportive calls from a facilitator to discuss adherence to the home exercise. In addition, this group will complete moderate-intensity walking 5 days per week for 10 weeks in accordance to usual care.
89599079|NCT04291300|Experimental|Lutetium treatment|Drug: Lutetium-177-PSMA-I&T, 4 cycles of 7.4 GBq intravenously, every 6 weeks.
89599080|NCT04288856|Experimental|Cohort A: BIIB078 First Dosage|BIIB078 will be administered as 3 doses during the loading period, approximately 2 weeks apart, and maintenance doses, approximately 4 weeks apart, via IT infusion.
89599081|NCT04288856|Experimental|Cohort B: BIIB078 Second Dosage|BIIB078 will be administered as 3 doses during the loading period, approximately 2 weeks apart, and maintenance doses, approximately 4 weeks apart, via IT infusion.
89599082|NCT04288856|Experimental|Cohort C: BIIB078 Third Dosage|BIIB078 will be administered as 3 doses during the loading period, approximately 2 weeks apart, and maintenance doses, approximately 4 weeks apart, via IT infusion.
89599083|NCT04288856|Experimental|Possible Cohort D: BIIB078 Fourth Dosage|BIIB078 will be administered as 3 doses during the loading period, approximately 2 weeks apart, and maintenance doses, approximately 4 weeks apart, via IT infusion.
89599084|NCT04275180|No Intervention|control|Standard medical treatment, including routine antiplatelet, blood pressure control, statins to stabilize plaque, etc.
89599085|NCT04275180|Experimental|Argatroban group|Argatraban is used on the basis of standard medical treatment.
89599086|NCT04271332|Experimental|Arbaclofen|Arbaclofen will be dosed flexibly, with maximum permissible dose depending on age.
89599087|NCT04271332|Placebo Comparator|Placebo|The placebo tablet is manufactured to match arbaclofen in shape, size, color, and taste, and will be administered in the same manner as arbaclofen.
89599088|NCT04268875|Experimental|OCT|"Patient witch coronary artery disease who has been stented and is hospitalised for stable angina or acute coronary syndrome requiring a further coronary angiogram (regardless of time since implantation or type of the initial stent.~- Identification of intrastent restenosis during coronary angiography and realisation of an immediate or deferred OCT."
89599089|NCT04267978|Experimental|glioblastoma|
89599090|NCT04267978|Experimental|lower-grade glioma|
89599091|NCT04250233||Standard neuraxial opioids|Standard neuraxial anesthesia for cesarean delivery (heavy bupivacaine 10 mg; fentanyl 10-25 mic; and low dose intrathecal morphine
89599092|NCT04250233||Non standard neuraxial opioids|"Non standard low-dose morphine group (with heavy bupivacaine 10 mg; fentanyl 10-25 mic)~Women are offered - if they prefer not to receive low dose morphine, the option of either ultra-low dose morphine or no morphine - instead they can receive postoperative bilateral quadratus lumborum block (QLB), TAP or erector spinus block."
89599093|NCT04206332|Experimental|Part A, Group 1: CIS43LS (5 mg/kg IV)|CIS43LS (5 mg/kg) administered by intravenous (IV) infusion (Day 0)
89599094|NCT04206332|Experimental|Part A, Group 2: CIS43LS (5 mg/kg SC)|CIS43LS (5 mg/kg) administered by subcutaneous (SC) injection (Day 0)
89599095|NCT04206332|Experimental|Part A, Group 3: CIS43LS (20 mg/kg IV)|CIS43LS (20 mg/kg) administered by IV infusion (Day 0)
89599096|NCT04206332|Experimental|Part A, Group 4A: CIS43LS (40 mg/kg IV)|CIS43LS (40 mg/kg) administered by IV infusion (Day 0)
89599097|NCT04206332|Experimental|Part A, Group 4B: CIS43LS (40 mg/kg IV)|CIS43LS (40 mg/kg) administered by IV infusion (Day 0)
89599098|NCT04206332|No Intervention|Part A, Group 5: CHMI Controls|Control participants who did not receive CIS43LS and were enrolled to complete the controlled human malaria infection (CHMI); however, Group 5 did not undergo CHMI because of restrictions related to coronavirus disease 2019 (COVID-19)
89599099|NCT04206332|Experimental|Part B, Group 6: CIS43LS (5 mg/kg SC)|CIS43LS (5 mg/kg) administered by SC injection (Day 0)
89599100|NCT04206332|Experimental|Part B, Group 7: CIS43LS (20 mg/kg IV)|"CIS43LS (20 mg/kg) administered by IV infusion (Day 0)~Part B, Group 7 participants included participants previously enrolled in Part A who received either 5 mg/kg IV (1), 5 mg/kg SC (1) or 20 mg/kg IV (2) in the first part of the study and newly enrolled Part B participants"
89599101|NCT04206332|Other|Part B, Group 8: CHMI [CIS43LS (40 mg/kg IV) in Part A]|Part B, Group 8 participants included participants previously enrolled in Part A who received CIS43LS (40 mg/kg IV) in the first part of the study but did not receive CIS43LS in Part B of the study. Group 8 participants were enrolled to complete the controlled human malaria infection (CHMI).
89599102|NCT04206332|Experimental|Part B, Group 9: CIS43LS (40 mg/kg IV)|CIS43LS (40 mg/kg) administered by IV infusion (Day 0)
89599103|NCT04206332|Other|Part B, Group 10: CHMI Controls|Control participants who did not receive CIS43LS and were enrolled to complete the controlled human malaria infection (CHMI)
89599104|NCT04206332|Experimental|Part C, Group 11: CIS43LS (1 mg/kg IV)|CIS43LS (1 mg/kg) administered by IV infusion (Day 0)
89599105|NCT04206332|Experimental|Part C, Group 12: CIS43LS (5 mg/kg IV)|CIS43LS (5 mg/kg) administered by IV infusion (Day 0)
89599106|NCT04206332|Experimental|Part C, Group 13: CIS43LS (5 mg/kg SC)|CIS43LS (5 mg/kg) administered by SC injection (Day 0)
89599107|NCT04206332|Experimental|Part C, Group 14: CIS43LS (10 mg/kg IV)|CIS43LS (10 mg/kg) administered by IV infusion (Day 0)
89599108|NCT04206332|Experimental|Part C, Group 15: CIS43LS (10 mg/kg SC)|CIS43LS (10 mg/kg) administered by SC injection (Day 0)
89599109|NCT04206332|Other|Part C, Group 16: CHMI Controls|Control participants who did not receive CIS43LS and were enrolled to complete the controlled human malaria infection (CHMI)
89599110|NCT04189263|Experimental|Dietary intervention|Carbohydrate restricted dietary intervention (<20 g carbohydrates/day) + standard of care aromatase inhibitors
89599111|NCT04189263|Active Comparator|No dietary intervention|Standard of care aromatase inhibitors
89599112|NCT04174157||Prospective observational registry|This is a prospective, multi center, multinational, non-interventional observational registry.
89599113|NCT04170426|Experimental|Phase 1 ARM 0|9 subjects receive dose escalation of autologous AdMSCs via Intravenous infusion in Phase 1
89599114|NCT04170426|Active Comparator|Phase 2 ARM 1|30 subjects receive three doses of 2.0-2.86×10^6 cells/kg on day 1, 4 and 7 via Intravenous infusion in Phase 2a
89599115|NCT04170426|Placebo Comparator|Phase 2 ARM 2|15 subjects receive three doses of placebo on day 1, 4 and 7 via Intravenous infusion in Phase 2a
89599116|NCT04164602||elderly patients with newly diagnosed diabetes|"Group with exposure: patients over 60 years of age with diabetes diagnosed within six months (newly diagnosed)~Control Group: without exposure; patients over 60 years, without diabetes."
89599117|NCT04159194|Active Comparator|Normal CHO|
89599118|NCT04159194|Experimental|High CHO|
89599119|NCT04157192|Active Comparator|Patients receiving real acupuncture treatment|Treatment with needle insertion
89599120|NCT04157192|Sham Comparator|Patients receiving sham acupuncture treatment|Treatment without needle insertion
89599121|NCT04155398||Study group|Patients with radiologic features suggestive of cirrhosis on abdominal imaging studies such as transabdominal ultrasound, CT or MRI and indication for variceal screening, suspected advanced liver fibrosis as detected by Fibroscan, or with clinical evidence of hypersplenism would be invited for the study
89599122|NCT04152343|Experimental|RFA Physics Library- PGP|The RFA Physics Library will be used during during percutaneous liver RFA procedures.
89599123|NCT04152239||Study group|Study group includes consecutive patients with suspected small bowel pathology based on clinical presentation, small bowel imaging or capsule endoscopy indicated for diagnostic and/or therapeutic enteroscopy. Patients fulfilling the inclusion criteria and without exclusion criteria would undergo MSE per study protocol.
89599124|NCT04117178|Active Comparator|Standard of care|Participants allocated to this arm follow the usual routines of the out patient dementia clinic but are requested to have the serum level of the prescribed drug measured after 12 month. Also, CYP2D6, BcHE K and APOe4 status will be determined after 12 months.
89599125|NCT04117178|Experimental|Intervention arm|Participants allocated to this arm follow are requested to inform the sponsor of any side effects up to 2 months after prescription of the anti-dementia drug. If so, they will have their treatment adjusted according to the serum level. Participants in the intervention arm not experiencing side effects will have their treatment adjusted after 6 months based upon serum level of the drug in question.
89599126|NCT04115826|Placebo Comparator|Extracorporeal Shock-Wave Lithotripsy|Stone localization will first be performed by obtaining high-quality plain films of the pancreatic area in left and right oblique positions using a two-dimensional radiologic targeting system.Depending on the stone localization, ESWL will then be performed with the patient in either slight left or right lateral decubitus with shock waves entering the body from the ventral side. The shockwaves will be focused first on the most distally located stone within the main duct and then on other calculi moving from the head towards the body. If a stent has been inserted during preceding ERP then this may also serve as a guide to target main pancreatic duct stones by ESWL. A total of one hour of ESWL at a rate of 60-120 shocks/minute will be delivered in one treatment session.
89599127|NCT04115826|Active Comparator|Per-oral Pancreatoscopy-guided Lithotripsy|Standard ERP will be performed to cannulate the PD, perform pancreatic sphincterotomy, and stricture dilation as necessary. A pancreatoscope (Spyglass Digital System, Boston Scientific, Marlborough, MA) will then be inserted through the duodenoscope into the PD. For PPL, electrical pulses will be delivered through an aqueous medium by EHL or LL with the probe tip in contact with or 1-2mm away from the stone. Settings for EHL (1.9F fiber; Autolith, Northgate Technologies, Elgin, IL) are 10-20 pulses/second with a power of 50-100; and for LL (200, 272, or 365 micrometer fiber, Versa Pulse Power Suite 20-W Holmium laser, New Star, Roseville, CA) ranging from 0.8 - 2.5 Joules with a frequency of 8-15Hz and power of 9-30 W. A maximum of 1 hour of intraductal lithotripsy will be allowed to reduce performance bias.
89599128|NCT04109820|Experimental|Sickle cell patients|Sickle Cell subjects administered oral MitoQ (20mg once a day for 14 days)
89599129|NCT04109820|Active Comparator|Non Sickle cell Control subjects|Normal control subjects administered oral MitoQ (20mg once a day for 14 days)
89599130|NCT04070040|Experimental|Camrelizumab|Camrelizumab(SHR-1210) 200mg, once every 2 weeks, each 4 weeks is 1cycle.
89599131|NCT04054817|Experimental|Single Arm|
89599132|NCT04053946|Experimental|Next Science|Following amputation, SurgX™ will be applied directly to the surgical incision in the operating room under sterile conditions and covered with SOC dressing. The surgical dressing will not be removed until post-operative day 3, except if deemed necessary by the treating surgeon. At that time, direct application of the BlastX™ to the incision will be placed, then covered with a SOC dressing. BlastX™ will be applied every day and covered with SOC dressing.
89599133|NCT04053946|No Intervention|Control|Post-op SOC dressing as per treating research doctor to include dressing changes post-op day 3 and daily thereafter.
89599134|NCT04046406|Experimental|Pelvic pain syndromes|Patients with pelvic pain syndromes who will undergo MR neurography-guided cryoanalgesia
89599135|NCT04056013|Active Comparator|Absorbable|Wound repaired with Vicryl Rapide absorbable suture
89599136|NCT04056013|No Intervention|Nonabsorbable|Wound repaired with traditional nonabsorbable suture
89599137|NCT04044248||TIPS-obliteration|Patients undergoing combined transjugular intrahepatic portosystemic shunt (TIPS) creation plus transvenous obliteration for the treatment of gastric varices (GVs).
89599138|NCT04039633|Experimental|Burst spinal cord stimulation (SCS)|following implantation of a generator that sends pulses to a thin wire (lead), which delivers pulses to nerves along the spinal cord, the patients will initially undergo four six-week long periods with either burst SCS or no stimulation (sham) in a randomized order. During this period all patients will undergo two periods of SCS and sham stimulation.
89599139|NCT04039633|Sham Comparator|sham spinal cord stimulation (SCS)|following implantation of a generator that sends pulses to a thin wire (lead), which delivers pulses to nerves along the spinal cord, the patients will initially undergo four six-week long periods with either burst SCS or no stimulation (sham) in a randomized order. During this period all patients will undergo two periods of SCS and sham stimulation.
88979692|NCT05567081|Experimental|PRP group|3 cm of autologous platelet rich plasma injected once around the thickest part of ulnar nerve.
88979693|NCT05567081|Experimental|Corticosteroid group|Triamcinolone Acetonide 40mg/mL (1ml) mixed with 1ml lidocaine hydrochloride injected once around the thickest part of ulnar nerve.
88979694|NCT00293956||1|Full-term and near-term infants with respiratory distress in the first 24 hours of life
88979695|NCT05567042||drug-resistant epilepsy|No intervention
88979696|NCT05567042||Medication is effective|No intervention
88979697|NCT00294112|Experimental|High dose|High dose (8 million cells per kg of body weight)
88979698|NCT00294112|Experimental|Low dose|Low dose: 2 million cells per kg body weight
88979699|NCT00089271|Experimental|Treatment (alvespimycin hydrochloride)|Patients receive 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) IV over 1-6 hours on days 1-3 or 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
88979700|NCT00294190|Experimental|Topotecan|
88979701|NCT05565872|Experimental|Urban training Intervention + therapeutic education program with face-to-face supervision|Patients will be advised to walk in the defined urban trails with face-to-face supervision
88979702|NCT05565872|Active Comparator|Urban training Intervention + therapeutic education program with telematic supervision|Patients will be advised to walk in the defined urban trails with telematic supervision
88979703|NCT02960503|Active Comparator|Treatment arm (azithromycin)|Treatment arm: azithromycin 500 mg three times a week for 6 months
88979704|NCT02960503|Placebo Comparator|Placebo arm|Control arm: placebo three times a week for 6 months
88979705|NCT00089310|Experimental|Sentinal node mapping|
89599140|NCT04033614|Experimental|Patients with Laparostoma|"Patients needing a laparostoma will be treated with the fasciotens abdomen device. The distance between the fasciae will be measured frequently using a ruler.~12 months after the treatment an ultrasound measurement will be performed to assess hernia formation"
89599141|NCT04030676|Experimental|QuantiFERON Test|Patient with CytoMegaloVirus (CMV) infection will be included. They will have biopsies and blood samples, composite of QuantiFERON-CytoMegaloVirus (QF-CMV) assay.
89599142|NCT04014205|Experimental|Part 1 Dose Escalation|Patients with r/r B-cell malignancies including Grades 1-3a FL, MZL, MCL, and CLL/SLL
89599143|NCT04014205|Experimental|Part 2 Dose Expansion|"Arm 1: Patients with r/r MCL~Arm 2: Patients with other types of B-cell malignancies, including:~CLL/SLL with/without prior treatment~r/r FL~r/r MZL"
89599144|NCT04010422||ASD group|"Inclusion Criteria:~Having a clinical diagnosis of autism spectrum disorder~Aged over 20 years; able to read and sign an informed consent form.~Clear conscious and can follow the instruction of opening eyes and movement toward all direction.~Exclusion Criteria:~Unable to cooperate with the examinations.~Younger than 20 years old"
89599145|NCT04010422||TD Group|"Inclusion Criteria:~Aged over 20 years; able to read and sign an informed consent form.~Clear conscious and can follow the instruction of opening eyes and movement toward all direction.~Exclusion Criteria:~Unable to cooperate with the examinations.~Younger than 20 years old.~Having a clinical diagnosis of autism spectrum disorder"
89599146|NCT04010409||ASD Group|Autism spectrum disorder participants, no intervention
89599147|NCT04010409||TD Group|Typically developmental controls,no intervention
89599148|NCT04005651|Experimental|POD L GF|Approximately 50 subjects who are scheduled for multifocal IOL implantation and enrolled in the study will be randomized into the POD L GF arm. Subjects will be implanted bilaterally with the European Conformity (CE) marked POD L GF trifocal IOL and assessed according to the study visit schedule.
89599149|NCT04005651|Active Comparator|Symfony®|Approximately 50 subjects who are scheduled for multifocal IOL implantation and enrolled in the study will be randomized into the Symfony arm. Subjects will be implanted bilaterally with the CE marked TECNIS Symfony® IOL and assessed according to the study visit schedule.
89599150|NCT04005651|Active Comparator|AcrySof®|Approximately 50 subjects who are scheduled for monofocal IOL implantation and enrolled in the study will be placed in the AcrySof® arm. Subjects will be implanted bilaterally with the CE marked AcrySof® IQ monofocal IOL and assessed according to the study visit schedule.
89599151|NCT03979599|Active Comparator|magnesium sulphate& levobupivacaine|Levobupivacaine add to magnisum sulphate
89599152|NCT03979599|Placebo Comparator|levobupivacaine|levobupivacaine
89599153|NCT03974230||Patients with Fuchs Endothelial Corneal Dystrophy (FECD)|Patients with Fuchs Endothelial Corneal Dystrophy (FECD). They will have a collection of datas and a blood sample.
89599154|NCT03974230||Control group|Witness will be included in control group. They will have a blood sample and slit lamp examination.
89599155|NCT03969693||The patients with mediastinal malignant lymphoma|Patients whose radiation therapy field essentially encompasses anterior mediastinum; namely, the majority of malignant lymphoma patients with mediastinal involvement.
89599156|NCT03956784|Experimental|E-assessed follow up|Patients undergoing colorectal surgery (colectomy, sigmoidectomy, proctectomy, digestive stoma closure), bariatric or gastric, for whom an early discharge has been programmed, and followed by a connected application and a nursing logistics platform at home.
89599157|NCT03956784|Other|Standard home follow-up care|Patients undergoing surgery for colorectal surgery (colectomy, sigmoidectomy, proctectomy, digestive stoma closure), bariatric or gastric surgery, for whom an early discharge has been programmed, and followed by usual way.
89599158|NCT03946514|Experimental|losartan/hydrochlorothiazide group|
89599159|NCT03946514|Active Comparator|amlodipine/hydrochlorothiazide group|
89599160|NCT03945279|Experimental|Cohort 1: BIIB100 Dose 1|Participants will receive single oral dose of BIIB100 on Day 1.
89599161|NCT03945279|Experimental|Cohort 2: BIIB100 Dose 2|Participants will receive single oral dose of BIIB100 on Day 1.
88979706|NCT00294268|Other|1|20 weekly sessions of CBT integrated with motivational enhancement strategies
88979707|NCT00294307||Advanced Practice Nurse Care (APNC)|Hospital to Home
88979708|NCT00294307||Augmented Standard Care (ASC)|Hospital only
88979709|NCT00294307||Resource Nurse Care (RNC)|Hospital only
88979710|NCT00294385|Active Comparator|Gemcitabine, Docetaxel|Arm A (concomitant arm), Gemcitabine 1000 mglm2 will be administered intravenously on Days 1 and 8, repeated on Day 22. Docetaxel 75 mg/m2 will be given on Day 8 (before Gemcitabine), repeated on Day 22. This 3-week schedule defines a cycle of treatment for this arm. Overall 8 cycles will be administered.
88979711|NCT00294385|Active Comparator|Docetaxel|Arm B (sequential arm) four cycles of Docetaxel 100 mg/m2 an Day 1, repeated an Day 22, followed by four cycles of Gemcitabine 1250 mg/m2 an a Day 1 and 8, repeated an Day 22, will be given. Both drugs will be administered in a 3-week schedule.
89599162|NCT03945279|Experimental|Cohort 3: BIIB100 Dose 3|Participants will receive single oral dose of BIIB100 on Day 1.
89599163|NCT03945279|Experimental|Cohort 4: BIIB100 Dose 4|Participants will receive single oral dose of BIIB100 on Day 1.
89599164|NCT03945279|Experimental|Cohort 5: BIIB100 Dose 5|Participants will receive single oral dose of BIIB100 on Day 1.
89599165|NCT03945279|Experimental|Cohort 6: BIIB100 Dose 6|Participants will receive single oral dose of BIIB100 on Day 1.
89599166|NCT03945279|Placebo Comparator|Cohort 1-6: Matching Placebo|Participants will receive single oral dose of matching placebo on Day 1.
89599167|NCT03935958|Experimental|Curcumin Arm (Arm 1)|20 subjects will be randomized (1:1) to this arm and receive curcumin for a year. In addition, subjects will have four study visits at Day 0, and 3, 6 and 12 months post-transplant. These study visits also include blood samples and questionnaires.
89599168|NCT03935958|Placebo Comparator|Placebo Arm (Arm 2)|20 subjects will be randomized (1:1) to this arm and receive placebo for a year. In addition, subjects will have four study visits at Day 0, and 3, 6 and 12 months post-transplant. These study visits also include blood samples and questionnaires.
89599169|NCT03935295|Experimental|Botulinum Toxin|"The investigators plan to administer approximately 1000 U Dysport ® in the concave-sided paraspinal musculature of the major curve, based on an estimated total dose of 1000 U, the maximum allowable dose. The total dose per treatment session will not exceed 15 units/kilogram or 1000 units, whichever is lower. If two curves are equivalent within 3˚, both will be treated, however, the dosing (described above) will be divided equally across both curves.~There will be two cycles of injections. Patients will be treated at time 0 (baseline) and 4 months."
89599170|NCT03935295|Placebo Comparator|Placebo|"Control patients will receive an injection of placebo specifically prepared as a control for this study. The same volumes as indicated in the experimental arm description will be injected.~These will be administered during two cycles of injections. Patients will be treated at time 0 (baseline) and 4 months."
89599171|NCT03927651|Experimental|Administration of ICG|ICG will be injected intravenously to assess ovarian perfusion in the presence or absence (control) of pathology. Near infrared fluorescence imaging will be used to illuminate the ICG. The extent of perfusion will be determined using digital imaging software. ICG will be stored at the NM Investigational Pharmacy and administered intravenously by the anesthesiologist at the direction of the surgeon during surgical procedure.
89599172|NCT03919214|Other|QardioArm and Messaging System|Participants will self-monitor their blood pressure using the Qardio Bluetooth device and obtain 3 separate blood pressure measurements per week (2 morning, 1 evening) for 12 weeks. An automated messaging system for blood pressure management will be triggered by a weekly average systolic blood pressure >140 mm Hg or diastolic blood pressure >90 mm Hg. This automated message will be sent to the participant's primary care provider, with copies to the participant and the primary medical oncologist.
89599173|NCT03915444|Experimental|NabCG|nab-paclitaxel 125mg/m2 cisplatin 25 mg/m2 gemcitabine 1000 mg/m2, all administered intravenously (IV) on Days 1 and 8 every 21 days
89599174|NCT03895645||Study Participants|Participants on the studies' samples that are transferred to this protocol
89599175|NCT03894631|Active Comparator|Phaco/KDB|Eyes needing glaucoma and cataract extraction will receive combined KDB and phacoemulsification in one eye of a patient
89599176|NCT03894631|Active Comparator|Phaco/Trabectome|Contralateral eyes needing glaucoma and cataract extraction will receive combined Trabectome and phacoemulsification in contralateral eye of the same patient
89599177|NCT03892785|Experimental|Tocilizumab group|
89599178|NCT03892785|Active Comparator|Methotrexate group|
89599179|NCT03888287|Experimental|Retrospective Phase|Patients with Parkinson disease before completion of the Parkinson's Disease Inpatient Clinical Knowledge and Management Program.
89599180|NCT03888287|Experimental|Prospective Phase-Watch Rx system|Patients after completion of the Parkinson's Disease Inpatient Clinical Knowledge and Management Program who are also assigned to a WatchRx system
89599181|NCT03888287|Experimental|Retrospective Phase - Clinicians|Clinicians, including physician's assistant, advanced practice nurses, staff nurses, nurse educators, case managers, dietitians pharmacists physical therapist and occupational therapist before completion of the Parkinson's Disease Inpatient Clinical Knowledge and Management Program.
89599182|NCT03888287|Experimental|Prospective Phase - Clinicians|Clinicians, including physician's assistant, advanced practice nurses, staff nurses, nurse educators, case managers, dietitians pharmacists physical therapist and occupational therapist after completion of the Parkinson's Disease Inpatient Clinical Knowledge and Management Program.
89599183|NCT03880058|Active Comparator|SLI-F06|Drug Product under investigation
88979712|NCT05564156|No Intervention|Control Group|In the control group; No intervention will be made by the investigators in this group. The participant will take standard treatment. Participant's length of stay in hospital, suitability of antibiotics used, development of microbial resistance, Antibiotic related nephrotoxicity due to infection, mortality data due to infection will be recorded, hospitalization will be questioned within 30 days after the patient is discharged, and a drug consensus report will be created, drug-related problems will be determined, and a pharmacoeconomic evaluation of all possible outcomes will be made. Evaluations will be recorded, but the investigators will take no action.
89599184|NCT03880058|Placebo Comparator|Formulation Buffer|Placebo
88979713|NCT05564156|Experimental|Intervention Group|"In the intervention group; The participant will take standard treatment and the clinical pharmacist services such as drug reconciliation by the investigators, medication review (Identification of drug-related problems, detection of possible unsuitable drugs), quality of life measurement, antibiotic selection, drug suitability, dose and route of administration advice, and concomitant medications are included. Suggestions will be made by the investigators to physicians about the solution to drug-related problems.~Participants' length of hospital stay, suitability of antibiotics, development of microbial resistance, antibiotic-related nephrotoxicity due to infection, and mortality numbers due to infection will be recorded, hospitalization will be questioned within 30 days after discharge. The investigators will create a drug consensus report, drug-related problems will be determined, and a pharmacoeconomic evaluation of all possible outcomes will be accomplished by investigators."
88979714|NCT00089349|Experimental|Arm I|"Course 1: Patients receive alemtuzumab IV over 2 hours on days 1-5, 8, 10, 12, 15, 17, 19, 22, 24, and 26 in the absence of disease progression or unacceptable toxicity. Patients achieving complete remission (CR), partial remission (PR), or cytolytic PR at day 29, or patients with CNS disease that achieve a CNS 1 or CNS 2 status, proceed to course 2.~Courses 2 and 3: Patients receive alemtuzumab IV over 2 hours on days 1, 8, 15, and 22; methotrexate IV continuously over 24 hours on day 1 and then orally once daily on days 8, 15, and 22; and oral mercaptopurine once daily on days 1-28. Patients with a CR or PR at day 29 proceed to course 3. In course 3, patients receive alemtuzumab, methotrexate, and mercaptopurine as in course 2.~CNS prophylaxis*: Patients receive methotrexate intrathecally on day 1 of courses 2 and 3 on day 1 of courses 2 and 3.~NOTE: * CNS-negative patients receive methotrexate intrathecally on day 15 of course 1 and day 1 of courses 2 and 3."
88979715|NCT05562908|Active Comparator|Pedicled|Harvesting of LIMA with its surrounding tissue: fascia, veins, etc
89599185|NCT03876795|Active Comparator|Single intra-articular Bone Marrow Concentrate injection|Single intra-articular Bone Marrow Concentrate injection in the knee
89599186|NCT03876795|Experimental|combined Bone Marrow Concentrate injection|combined Bone Marrow Concentrate injection (intra-articular and intra-osseus)
89599187|NCT03869034|Experimental|A, Combination group (HAIC+PD-1)|HAIC+PD-1
89599188|NCT03869034|Experimental|B, HAIC group (HAIC only)|HAIC
89599189|NCT03861351|Experimental|Mini WELL Toric Ready intraocular lens|
89599190|NCT03858608|Experimental|Counterweight Plus|"Total Diet Replacement phase (0-12 weeks) 825-853kcal/day low energy liquid diet (LELD) for 12 weeks Food Reintroduction phase (13-18 weeks) Wk 13: 400kcal/d LELD + 1 low-fat meal/day (c. 360-400 kcal) + 2 servings of fruit, 200mls skimmed milk and free vegetables. Total intake: 1000kcal/day Wk 15: 200kcal/d LELD + 2 low-fat meals/day (c. 720-800 kcal) + 2 servings of fruit, 200mls skimmed milk and free vegetables. Total intake: 1200kcal/day.~Wk 17: 3 low-fat meals per day (c.1080-1200 kcal) + 2 servings of fruit, 200mls skimmed milk and free vegetables. Total intake: 1400kcal/day.~Weight maintenance phase (wks 19-52) Low-fat healthy eating weight loss maintenance intervention [target below 30% energy from fat, with flexibility to optimise individual compliance, to a maximum of 35%]"
89599191|NCT03858608|Active Comparator|Usual asthma care|Usual asthma management
89599192|NCT03842475||Surgical cohort|Patients with type 2 diabetes undergoing Roux-en-Y gastric bypass surgery
89599193|NCT03842475||Control|Healthy volunteers with normal body mass index
89599194|NCT03841097|Active Comparator|Extended Release Tacrolimus Tablets|Dosed once daily in the morning and started at a dose of 0.14 mg/kg/day by the first day after kidney transplant (post-operative day 1). This medication will be given with rabbit antithymocyte globulin (rATG) induction, oral mycophenolate mofetil (MMF) and oral steroids to help prevent rejection. These medications will be ordered per standard of care both inpatient and outpatient.
89599195|NCT03841097|Active Comparator|Immediate Release Tacrolimus Capsules|Dosed twice daily 12 hours apart and started at a dose of 0.1mg/kg/day by the first day after kidney transplant (post-operative day 1). This medication will be given with rabbit antithymocyte globulin (rATG) induction, oral mycophenolate mofetil (MMF) and oral steroids to help prevent rejection. These medications will be ordered per standard of care both inpatient and outpatient.
89599196|NCT03831776|Experimental|Bosutinib-Ropeginterferon combination|
89599197|NCT03831776|Active Comparator|Bosutinib monotherapy|
89599198|NCT03831425|Experimental|Coenzyme Q|Each patient will be asked to take part in a 6 wk trial of pharmaceutical grade CoQ10 and will be randomly assigned to a start time. There will be a 6 wk washout period between treatment and placebo arms. At baseline, if this is the first arm, testing will include determination of muscle function based on our 3 min step test, muscle power (maximal jump, handgrip), strength (Queens' Square), endurance (6MWT), fatigue (PedsQL fatigue scale), physical activity level (3DPAR), attention (ADHDT scale), cognition (MoCA), physical function (CHAQ).and quality of life (PedQL). Following the 6 wk CoQ10 trial, testing will include repeat determination of all of the above as well as determination of total aerobic capacity (maximum cycle ergometry) and muscle metabolism (31P-MRS ergometry).
89599199|NCT03831425|Placebo Comparator|Placebo|Each patient will be asked to take part in a 6 wk trial of placebo and will be randomly assigned to a start time. There will be a 6 wk washout period between treatment and placebo arms. At baseline, if this is the first arm, testing will include determination of muscle function based on our 3 min step test, muscle power (maximal jump, handgrip), strength (Queens' Square), endurance (6MWT), fatigue (PedsQL fatigue scale), physical activity level (3DPAR), attention (ADHDT scale), cognition (MoCA), physical function (CHAQ).and quality of life (PedQL). Following the 6 wk placebo trial, testing will include repeat determination of all of the above as well as determination of total aerobic capacity (maximum cycle ergometry) and muscle metabolism (31P-MRS ergometry).
89599200|NCT03790111|Experimental|Xermelo 250mg plus first line therapy for a week, then Xermelo 500mg|Xermelo 250 milligram (mg) plus first line therapy for a week, then Xermelo 500mg plus first line therapy for the duration of the study
89599201|NCT03780543|Active Comparator|HBeAg-negative Subjects from Parent Study ABI-H0731-201|Subjects who on Day 1 of parent study ABI-H0731-201 (NCT03576066) were standard of care (SOC) nucleos(t)ide (NrtI)-suppressed and HBeAg-negative will receive both ABI-H0731 + SOC NrtI for at least 52 weeks, after which time they will discontinue both ABI-H0731 and SOC NrtI and enter long-term off-treatment follow-up (FU) for up to 3 years.
89599202|NCT03780543|Active Comparator|HBeAg-positive Subjects from Parent Study ABI-H0731-201|"Subjects who on Day 1 of parent study ABI-H0731-201 (NCT03576066) were SOC NrtI-suppressed and HBeAg-positive will receive ABI-H0731 + SOC NrtI for at least 52 weeks, after which time their viral response will be evaluated.~Subjects who meet the virologic response criteria will discontinue both ABI-H0731 and SOC NrtI and enter long-term off-treatment follow-up (FU) for up to 3 years.~Subjects with insufficient virologic response will discontinue ABI-H0731 only and continue on SOC NrtI alone and followed-up for 12 weeks."
88979716|NCT05562908|Active Comparator|Surgical skeletonised|"Harvesting of LIMA in a naked fashion where you dissect the artery free of the surrounding tissue."
88979717|NCT05562908|Active Comparator|Skeletonised with Thunderbeat|Same as Surgical skeletonised but instead of closing the side branches with clips a surgical tool is used for coagulation of the side-branches.
88979718|NCT00294619|Experimental|LB03002|
88979719|NCT00294619|Placebo Comparator|Placebo|
88979720|NCT00089388|Experimental|Arm I (low dose cilengitide)|Patients receive cilengitide IV at a lower dose over 1 hour twice weekly for 4 weeks.
88979721|NCT00089388|Experimental|Arm II (higher dose cilengitide)|Patients receive cilengitide IV at a higher dose over 1 hour twice weekly for 4 weeks.
88979722|NCT05562479||Non exposed to Sars Cov 2 egg donors|Evaluate the results within oocyte retrieval, oocyte fertilisation and blastocyst formation.
88979723|NCT05562479||Exposed to Sars Cov 2 Infection|Evaluate the results within oocyte retrieval, oocyte fertilisation and blastocyst formation, after being exposed to the infection.
88979724|NCT05562479||Exposed to Sars Cov 2 Vaccines|Evaluate the results within oocyte retrieval, oocyte fertilisation and blastocyst formation, after being exposed to vaccination.
88979725|NCT00294736|Experimental|Arm A|Arm A (Tarceva MTD established in Part I)
88979726|NCT00294736|Experimental|Arm B|Arm B (150 mg Tarceva daily).
88979727|NCT00121680|Experimental|1|
89599203|NCT03780543|Active Comparator|Subjects from Parent Study ABI-H0731-202|"Subjects who on Day 1 of parent study ABI-H0731-202 (NCT03577171) were treatment-naive and HBeAg-positive will receive ABI-H0731 + SOC NrtI for at least 52 weeks, after which time their viral response will be evaluated.~Subjects who meet the virologic response criteria at Week 52 will continue to receive ABI-H0731 + SOC NrtI for an additional 96 weeks, after which time their viral response will be evaluated at Week 148.~Subjects who meet the virologic response criteria at Week 148 will discontinue both ABI-H0731 and SOC NrtI and enter long-term off-treatment follow-up for up to 3 years. Subjects with insufficient virologic response at Week 148, will discontinue ABI-H0731 only and continue on SOC NrtI alone for up to 12 weeks.~Subjects with insufficient virologic response at Week 52 will discontinue from ABI-H0731only and continue on SOC NrtI alone and enter follow-up for up to 12 weeks."
89599204|NCT03772314|Active Comparator|Modafinil|Participants in this study arm will take modafinil.
89599205|NCT03772314|Experimental|Amphetamine-dextroamphetamine|Participants in this study arm will take amphetamine-dextroamphetamine (amphetamine salts).
89599206|NCT03760575|Experimental|Pembrolizumab with image-guided surgery and chemotherapy|
89599207|NCT03750981|Other|A 12-week pilot intervention study introducing a high-intensi|
89599208|NCT03747393|Active Comparator|DoD/VA CPG Core Set|The standard core set of interventions recommended by the DoD/VA clinical practice guidelines for non-surgical management of knee OA.
89599209|NCT03747393|Experimental|DoD/VA CPG Core Set + PT|In addition to DoD/VA clinical practice guidelines, patients will be referred to physical therapy (PT). Physical therapy will consist of evidence-based interventions that can be provided by a PT (exercise, manual therapy, education).
89599210|NCT03745820|Experimental|BIIB104 0.5 mg|Participants will receive 0.5 mg of BIIB104 twice a day, orally, for 12 weeks.
89599211|NCT03745820|Experimental|BIIB104 0.15 mg|Participants will receive 0.15 mg of BIIB104 twice a day, orally, for 12 weeks.
89599212|NCT03745820|Placebo Comparator|Matching Placebo|Participants will receive matching placebo twice a day, orally, for 12 weeks.
89599213|NCT03720522||Group 1: Patients suffering from acute myocardial infarction|Patients with positive gadolinium late enhancement and positive intramyocardial oedema in the short CMR have an acute myocardial infarction and will be allocated to group 1.
89599214|NCT03720522||Group 2: Patients suffering from chronic myocardial infarction|Patients with elevated (≥ 0.015 mg/L) high sensitive troponin T (hsTnT) levels, positive gadolinium late enhancement and/or positive myocardial infarction suffer from chronic myocardial infarction or significant coronary stenosis. They will be allocated to group 2 and receive coronary angiography in a timely manner according to clinical routine and current guidelines.
89599215|NCT03720522||Group 3: Patients suffering from stunned neurogenic myocardium|"Patients with elevated (≥ 0.015 mg/L) high sensitive troponin T (hsTnT) levels and presence of wall motion abnormalities (WMA) have potential WMA due to neurogenic myocardial stunning. They will be allocated to group 3.~These patients will undergo a follow-up CMR without adenosine-perfusion after 3 months to confirm improvement/normalization of WMA.~Patients with normal (< 0.015mg/L) hsTnT levels and presence of WMA will also be allocated to group 3."
89599216|NCT03720522||Group 4: Control|Patients with normal (< 0.015mg/L) high sensitive troponin T (hsTnT) levels without late enhancement, without myocardial infarction and without wall motion abnormalities will serve as control group and will be classified to group 4.
89599217|NCT03704922|Experimental|≤10 day Blood|Subjects in this group will receive only blood stored ≤10 days for 3 consecutive transfusion events.
89599218|NCT03704922|Experimental|≥30 day Blood|Subjects in this group will receive only blood stored ≥30 days for 3 consecutive transfusion events.
89599219|NCT03699631|Experimental|Tacrolimus/Methotrexate/Tocilizumab|"Patients enrolled on the clinical trial will receive tacrolimus initiating at Day -1 at doses to maintain therapeutic levels per institutional preference and continued until at least Day +90 post-transplant.~Methotrexate will be administered intravenously and dosed at 15 mg/m2 Day +1 and 10 mg/m2 Days +3, +6 and +11.~Tocilizumab will be administered intravenously at a dose of 8 mg/kg on Day -1 and at day +100 (+/- 14 days)."
89599220|NCT03686150|Experimental|Part 1, Cohort 1 Vitamin D3 oral regimen|Intervention: Vitamin D: Single 50,000 IU loading dose + 6000 IU daily dose
89599221|NCT03686150|Experimental|Part 1, Cohort 2 Vitamin D3 oral regimen|Vitamin D: Single 50,000 IU loading dose + 10,000 IU daily dose
89599222|NCT03686150|Experimental|Part 1, Cohort 3 Vitamin D3 oral regimen|Vitamin D: 6000 IU daily dose
89599223|NCT03686150|Active Comparator|Part 1, Cohort 4 Vitamin D3 oral regimen|Vitamin D: 600 IU daily dose
89599224|NCT03686150|Experimental|Part 2, Cohort A Vitamin D3 oral regimen|Vitamin D: Single 50,000 IU loading dose + 8,000 IU daily doseD
89599225|NCT03686150|Active Comparator|Part 2, Cohort B Vitamin D oral regimen|Vitamin D: 600 IU daily dose
89599226|NCT03680781|Experimental|Accelerated theta burst treatment|All participants will receive theta-burst TMS.
89599227|NCT03678233|Active Comparator|Intervention|AndroGel® AndroGel 16.2 mg/L will be applied to upper arms or shoulders once a day at 9:00 am to dry and intact skin for a period of 28 days or until ICU discharge. The daily dose 101.25 mg in men and 20.25 mg in women
89599228|NCT03678233|No Intervention|Control|In the control group, AndroGel will not be administered.
89599229|NCT03650478|Experimental|Premature infants group|NeuroPAP ventilation (2h) and NeuroBox monitoring (23h)
89599230|NCT03650478|Experimental|Bronchiolitis group|NeuroPAP ventilation (4h) and NeuroBox monitoring (25h)
89599231|NCT03606642|Experimental|PCI with 30 day DAPT Therapy|Single group of patients undergoing IVUS stent placement for PCI with 30 day DAPT therapy regimen. DAPT therapy consists of Aspirin (325 mg loading dose [if applicable] and 81 mg for maintenance dose) and P2Y12 Inhibitor (INFO ABOUT THE DRUGS)
89599232|NCT03604172|Experimental|Cognitive behavioral therapy|16-week cognitive behavioral therapy intervention for binge eating disorder
89599233|NCT03604172|Other|Waitlist control|16-weeks on waitlist then participants will be provided with 16-weeks of cognitive behavioral therapy
89599234|NCT03591263||Chronic obstructive pulmonary disease|Subjects with the diagnosis of chronic respiratory disease, such as chronic obstructive pulmonary disease, bronchiectasis, idiopathic pulmonary fibrosis that referred for evaluation as routine care at Physical Therapy Center (National Taiwan University)
89599235|NCT03572322||Doctors|
89599236|NCT03572322||Patients|
89599237|NCT03561012|Experimental|Intervention arm|
89599238|NCT03561012|Active Comparator|Control Arm|
89599239|NCT03503032||Fenestrated|Standard extracardiac fontan undergoing Fontan fenestration creation
89599240|NCT03503032||Non fenestrated|Standard extracardiac fontan without fenestration
89599241|NCT03496207|Placebo Comparator|Placebo|Participants will receive placebo plus SOC by SC injection during the 24-week treatment period. Dosing will occur once every 3 weeks.
89599242|NCT03496207|Experimental|Sotatercept 0.3 mg/kg|Participants will receive sotatercept 0.3 mg/kg plus SOC by SC injection during the 24-week treatment period. Per protocol, participants may have their doses titrated. Dosing will occur once every 3 weeks.
89599243|NCT03496207|Experimental|Sotatercept 0.7 mg/kg|Participants will receive sotatercept 0.7 mg/kg plus SOC by SC injection during the 24-week treatment period. Per protocol, participants may have their doses titrated. Dosing will occur once every 3 weeks.
89599244|NCT03494868|No Intervention|Fasting|Fasting prior to elective cesarean section delivery (standard of care)
89599245|NCT03494868|Experimental|Carbohydrate Drink|Subjects will drink 2 carbohydrate drinks prior to elective cesarean section delivery
89599246|NCT03470428||Pediatric Fontan Patients|Participants ages 10 to 18 who have had Lateral Tunnel or Extracardiac Fontan procedures.
89599247|NCT03470428||Adult Fontan Patients|Participants ages 18 to 60 who have had Lateral Tunnel or Extracardiac Fontan procedures.
88979728|NCT00294892|Active Comparator|Carbamazepine|An oral dose of 400mg Carbamazepine is added to the 200mg oral dose Nevirapine intake prior delivery
89599248|NCT03458221|Experimental|A - ER active tumors|In case of an aberrantly active Estrogen Receptor (ER) pathway, patients will be treated with Letrozole 2.5mg daily orally until progression of disease.
88979729|NCT00294892|Placebo Comparator|Nevirapine|Standard therapy of 200mg Nevirapine oral prior to delivery
88979730|NCT00294970||PTSD|Patients with diagnosis of PTSD
88979731|NCT00294970||OCD|Patients with diagnosis of OCD
88979732|NCT00294970||PTSD/OCD|Patients with diagnosis of comorbid PTSD and OCD
88979733|NCT02958423|Experimental|Transcranial DCS Healthy Volunteers|5 HV will be treated once with transcranial direct current stimulation (2mA, anodal, 20 minutes) over right primary motor cortex with the Direct Current (DC) Stimulator (NeuroConn. Germany)
88979734|NCT02958423|Experimental|Transspinal DCS Healthy Volunteers|5 HV will be treated once with transspinal direct current stimulation (2mA, anodal, 20 minutes) over the D10 spinal process with the Direct Current (DC) Stimulator (NeuroConn. Germany)
88979735|NCT02958423|Experimental|Transcranial DCS CPP patients|5 chronic pelvic pain patients will be treated with transcranial direct current stimulation (2mA, anodal, 20 minutes) over right primary motor cortex 5 days/week for 4 weeks with the Direct Current (DC) Stimulator (NeuroConn. Germany)
88979736|NCT02958423|Experimental|Transspinal DCS CPP patients|5 chronic pelvic pain patients will be treated with transspinal direct current stimulation (2mA, anodal, 20 minutes) over the D10 spinal process 5 days/week for 4 weeks with the Direct Current (DC) Stimulator (NeuroConn. Germany)
88979737|NCT00295165|Experimental|Arm 1|
88979738|NCT00295165|Placebo Comparator|Arm 2|
88979739|NCT02958618|Experimental|"Duration for 30 group"|A limited sphincterotomy measuring up to one-third of the size of the papilla was first performed. Dilation with a controlled radial expansion (CRE) balloon (diameter 10, 12, 15, 18 ) was performed after the sphincterotomy. The balloon was centered at the sphincter and gradually filled with diluted contrast under endoscopic and fluoroscopic guidance until waisting was abolished. Once the waist had disappeared, the balloon was kept in position for 30 seconds. The stones were then removed by a basket or retrieval balloon. An ENBD catheter (.) was routinely placed into the CBD after stone removal.
88979740|NCT02958618|Experimental|"Duration for 60 group"|A limited sphincterotomy measuring up to one-third of the size of the papilla was first performed. Dilation with a controlled radial expansion (CRE) balloon (diameter 10, 12, 15, 18 ) was performed after the sphincterotomy. The balloon was centered at the sphincter and gradually filled with diluted contrast under endoscopic and fluoroscopic guidance until waisting was abolished. Once the waist had disappeared, the balloon was kept in position for 60 seconds. The stones were then removed by a basket or retrieval balloon. An ENBD catheter (.) was routinely placed into the CBD after stone removal.
88979741|NCT02958618|Experimental|"Duration for 180 group"|A limited sphincterotomy measuring up to one-third of the size of the papilla was first performed. Dilation with a controlled radial expansion (CRE) balloon (diameter 10, 12, 15, 18 ) was performed after the sphincterotomy. The balloon was centered at the sphincter and gradually filled with diluted contrast under endoscopic and fluoroscopic guidance until waisting was abolished. Once the waist had disappeared, the balloon was kept in position for 180 seconds. The stones were then removed by a basket or retrieval balloon. An ENBD catheter (.) was routinely placed into the CBD after stone removal.
88979742|NCT02960464|Active Comparator|Active Arm|Active sessions will involve the placement of the anode over the scalp corresponding to the F3 (10-20 EEG system), and cathode over F4. Current intensity will be 2mA, and the stimulation will last for 20 minutes.
88979743|NCT02960464|Sham Comparator|Sham Arm|Sham stimulation will follow the same procedure as the Active, however after 30 seconds of stimulation, the current is turned off, mimicking the initial sensation of the tDCS session but providing no clinical or physiological effect.
88979744|NCT00295282|Experimental|1|patients will receive active MDX-1100
88979745|NCT00295438|Experimental|Robot-Based Tele-Echography (TER)|ultrasound performed according to the method Tele-Echography
88979746|NCT00295438|Active Comparator|ultrasound method FAST|ultrasound performed according to the method FAST (Focused Assessment Sonography for Trauma)
88979747|NCT00295594|Active Comparator|1|
88979748|NCT00295594|Experimental|2|
89599249|NCT03458221|Experimental|B - AR active tumors|In case of an aberrantly active androgen receptor (AR) pathway, patients will be treated with Bicalutamide 150mg daily orally until progression of disease.
89599250|NCT03458221|Experimental|C - PI3K active tumors|In case of an aberrantly active phosphoinositide 3-kinase (PI3K) pathway, patients will be treated with Everolimus 10mg daily orally until progression of disease.
89599251|NCT03458221|Experimental|D - HH and/or PI3K active tumors|In case of an aberrantly active Hedgehog (HH) or PI3K pathway, patients will be treated with Itraconazole 300mg twice daily orally until progression of disease.
89599252|NCT03451487|Placebo Comparator|Reference drug (1000mg)|"Eligible subjects were randomly assigned to either of the two treatment sequence.The evaluable subjects were those who had completed both period I and II. The study was completed when there were at least 12 evaluable subjects.~Panadol® oral dosage form (500 mg*2 tablets = 1000 mg) was orally administered with 240 ml of water once daily in the morning in each of the single-dose study period."
89599253|NCT03451487|Experimental|Test drug (1000mg)|"Eligible subjects were randomly assigned to either of the two treatment sequence.The evaluable subjects were those who had completed both period I and II. The study was completed when there were at least 12 evaluable subjects.~SafeTynadol® oral dosage form (500 mg*2 tablets = 1000 mg) was orally administered with 240 ml of water once daily in the morning in each of the single-dose study period."
89599254|NCT03451487|Placebo Comparator|Reference drug (4000mg)|"Eligible subjects were randomly assigned to either of the two treatment sequence.The evaluable subjects were those who had completed both period III and IV. The study was completed when there were at least 12 evaluable subjects.~Panadol® oral dosage form (500 mg*8 tablets = 4000 mg) was orally administered with 240 ml of water once daily in the morning in each of the single-dose study period."
89599255|NCT03451487|Experimental|Test drug (4000mg)|"Eligible subjects were randomly assigned to either of the two treatment sequence.The evaluable subjects were those who had completed both period III and IV. The study was completed when there were at least 12 evaluable subjects.~SafeTynadol® oral dosage form (500 mg*8 tablets = 4000 mg) was orally administered with 240 ml of water once daily in the morning in each of the single-dose study"
89599256|NCT03451487|Placebo Comparator|Reference drug 2 tablets Q6H (28,000mg)|"Eligible subjects were randomly assigned to either of the two treatment stage.Each treatment will be completed when there are at least 7 evaluable subjects. The evaluable subjects are randomized into period V.~Panadol® oral dosage form (500mg*2 tablets =1000mg) will be orally administered with 240 ml of water every 6 hours daily in each of the multiple-dose study period (Q6H, total 28 dosages, 56 tablets)."
89599257|NCT03451487|Experimental|Test drug 2 tablets Q6H (28,000mg)|"Eligible subjects were randomly assigned to either of the two treatment stage.Each treatment will be completed when there are at least 7 evaluable subjects. The evaluable subjects are randomized into period V.~SafeTynadol® oral dosage form (500mg*2 tablets =1000mg) will be orally administered with 240 ml of water every 6 hours daily in each of the multiple-dose study period (Q6H, total 28 dosages, 56 tablets)."
89599258|NCT03444870|Experimental|Gantenerumab|Gantenerumab will be administered as SC injections with gradual uptitration.
89599259|NCT03444870|Placebo Comparator|Placebo|Placebo will be administered as SC injections with gradual uptitration.
89599260|NCT03429322|Experimental|Medical Care and Resource Facilitation|All intervention components will be delivered remotely: there will be no face-to-face interaction with the participants. The intervention is comprised of the clinical, educational, and supportive services of Mayo's Brain Rehabilitation Clinic integrated with the MN BIA RF program.
89599261|NCT03429322|Active Comparator|Usual care|Individuals with TBI, their family members and PCPs assigned to the usual care group will receive care and provide services as usual in their communities. Individuals with TBI assigned to the usual care group will receive RF as routinely provided by MN BIA.
89599262|NCT03410030|Experimental|Ascorbic Acid|Some human studies of high-dose IV vitamin C in patients with cancer have shown improved quality of life, as well as improvements in physical, mental, and emotional functions, symptoms of fatigue, nausea and vomiting, pain, and appetite loss. Intravenous high-dose ascorbic acid has caused very few side effects in clinical trials
89599263|NCT03406221|Experimental|Intervention arm|
89599264|NCT03406221|Active Comparator|Control Arm|
89599265|NCT03400553|Experimental|non-traumatic thoracic pain|Patients with out-of-hospital non-traumatic thoracic pain admitted to the emergency unit via ambulance or MUG will be screened for enrolment. Blood analysis for troponin-T will be performed by 3 different devices as explained earlier.
89599266|NCT03382301|Experimental|Ciclosporin A preconditioning|Ciclosporin A preconditioning before renal artery stenosis dilation
89599267|NCT03382301|Placebo Comparator|NaCl preconditioning|
89599268|NCT03379870|Experimental|Arm 1|"Subjects who receive a CI and present with a post-operative LFPTA of ≤ 75 dB HL.~Electric Acoustic Speech Processor: EAS fitting. They will be evaluated in the EAS condition and the hearing aid (HA) alone condition."
89599269|NCT03379870|Experimental|Arm 2|"Subjects with pre-operative low frequency hearing who receive a CI and present with a post-operative LFPTA of > 75 dB HL.~Electric Acoustic Speech Processor: Electric only fitting They will be evaluated in the traditional fully electric condition only."
89599270|NCT03355690||Stroke patients|Stroke patients are treated according to the clinical practice which can be divided into: anti-aggregation, thrombectomy and/or thrombolysis
88979749|NCT00121875||Turner syndrome|Girls, aged 7-14, with short stature due to Turner syndrome and eligible for growth hormone therapy
88979750|NCT00121875||Control / idiopathic short stature|Girls, aged 7-14, with idiopathic short stature and eligible for growth hormone therapy
88979751|NCT00295789|Active Comparator|1|Drug: chemotherapy: Paclitaxel/Cisplatin
88979752|NCT00295789|Experimental|2|Drug: chemotherapy: Paclitaxel/Carboplatin
88979753|NCT04718584|Experimental|Experimental Arms|All participants will receive treatment with LDP 10mg/kg once every two weeks, every 2 weeks will be a cycle. In Cort 1, surgical treatment will be performed within 2 weeks after the end of 3 cycles of treatment.
88979754|NCT00417937|Active Comparator|1|Azelaic acid 15 % gel once daily
88979755|NCT00417937|Active Comparator|2|Azelaic acid 15 gel twice daily
88979756|NCT00295828|Active Comparator|1|Panretinal Photocoagulation (PRP)
88979757|NCT00295828|Active Comparator|2|Panretinal Photocoagulation and Macugen Intravitreal Injection
88979758|NCT00295945||PCA|Patient-controlled intravenous analgesia
88979759|NCT00295945||PCEA|Perioperative patient-controlled epidural analgesia
88979760|NCT00296023|Experimental|stem cell transplant|
88979761|NCT00089856|Other|2|Standard of care - chemotherapy
88979762|NCT00089856|Experimental|1|Immunotherapy
88979763|NCT04718428||psoriatic arthritis|Patients with psoriatic arthritis who met the CASPAR criteria and were 18-70 years old were included. Participants with infection of the nails to be examined, loss of nails, trauma history of the nails, having the habit of nail biting, peripheral neuropathy, peripheral vascular disease, another rheumatological disease, systemic infection, and pregnancy were excluded.
89599271|NCT03290391|Experimental|LINC-II|LINC-II is a multi-faceted intervention combining pharmacological therapy (i.e., ART and naltrexone for opioid use disorder) and 12 months of strengths-based case management delivered to coordinate care across the narcology and HIV health care systems.
89599272|NCT03290391|No Intervention|Standard of Care|Participants randomized to the control group will receive the narcology hospital's standard of care, which is detoxification with or without stabilization. Prior to discharge, those identified as HIV-infected are given contact details for an HIV clinic, not an appointment. Upon discharge, patients are encouraged to receive outpatient narcology treatment, monthly, for 1 year. For this study, with regard to linkage to HIV medical care, patients will be given printed information about where to obtain HIV medical care and a resource card containing harm reduction information.
89599273|NCT03280030|Experimental|Midostaurin|Patients will take study drug on day 8-21 during induction and consolidation phase; then continuously during continuation phase.
89599274|NCT03280030|Placebo Comparator|Placebo|Patients will take placebo on day 8-21 during induction and consolidation phase; then continuously during continuation phase.
89599275|NCT03260842||Pancreatic Cysts|Patients with pancreatic cyst undergoing endoscopic ultrasound and/or surgery who will have bio-specimens collected
89599276|NCT03260842||High Risk Individuals|Patients with established family history and/or genetic mutations for Pancreas cancer who will have bio-specimens collected
89599277|NCT03235219|Experimental|Cohort 1 to 4: JNJ-64565111 or Placebo|Participants in cohort 1 to 4 in a ratio of 4:1 will receive a dose of JNJ-64565111 or placebo subcutaneously on Days 1, 8, 15 and 22. Cohort 1, 2 and 3 will be dosed in parallel. Dosing for subsequent cohort 4 will be escalated based on review by the Sponsor and Principal Investigator of blinded safety, tolerability, pharmacokinetic, and (all available) pharmacodynamic data collected up to Day 29, but will not exceed from well-tolerated dose.
89599278|NCT03235219|Experimental|Cohort 5: JNJ-64565111 (Repeat or Lower Dose) or Placebo|Participants in ratio of 4:1 will receive a dose of JNJ-64565111 or placebo subcutaneously on Days 1, 8, 15 and 22, and may be modified. The dose can be repeated or lower than a dose previously assessed as well tolerated.
89599279|NCT03224624|Experimental|self-management|Participants will be taught to monitor blood pressure and make limited adjustments to their medications
89599280|NCT03224624|No Intervention|usual care|Participants will be enrolled in the study and undergo a baseline, 6 month, and 1 year visit but their hypertension care will be per usual care.
89599281|NCT03194867|Experimental|Isatuximab/cemiplimab (Regimen 1)|"Isatuximab on Days 1, 8, 15, and 22, then Days 1 and 15 in 28-day cycles up to disease progression.~Cemiplimab on Days 1 and 15 in 28-day cycle up to disease progression."
89599282|NCT03194867|Experimental|Isatuximab/cemiplimab (Regimen 2)|"Isatuximab on Days 1, 8, 15, and 22, then Days 1 and 15 in 28-day cycles up to disease progression.~Cemiplimab on Day 1 in 28-day cycle up to disease progression."
89599283|NCT03194867|Active Comparator|Isatuximab|Isatuximab on Days 1, 8, 15 and 22, then Day 1 and 15 in 28-day cycles up to disease progression.
89599284|NCT03143647||Control|"Female~Over 18 years of age~American Society of Anesthesiologists physical fitness scale 1~Not pregnant"
89599285|NCT03143647||Case|"Female~Pregnant with possible pre-eclampsia~Over 18 years of age~American Society of Anesthesiologists physical fitness scale 1"
89599286|NCT03143504||Single arm.|All participants in the same arm.
88979764|NCT04718428||healthy controls|A gender- and age-matched healthy controls were included. They were recruited from the healthy relatives of the hospital staff. Participants with infection of the nails to be examined, loss of nails, trauma history of the nails, having the habit of nail biting, peripheral neuropathy, peripheral vascular disease, any rheumatological disease, systemic infection, and pregnancy were excluded.
88979765|NCT00296413||1|Valproate monotherapy
88979766|NCT00296413||2|Valproate monotherapy with combined oral contraceptive
88979767|NCT00296413||3|Lamotrigine monotherapy
88979768|NCT00296413||4|Lamotrigine monotherapy with combined oral contraceptive
88979769|NCT00122031|Experimental|DBS|
88979770|NCT05428436|Experimental|BI 1015550 TF2 fasted/BI 1015550 iCF fasted/BI 1015550 iCF fed|
88979771|NCT05428436|Experimental|T1 BI 1015550 iCF fasted/BI 1015550 iCF fed/BI 1015550 TF2 fasted|
88979772|NCT05428436|Experimental|BI 1015550 iCF fed/BI 1015550 TF2 fasted/BI 1015550 iCF fasted|
88979773|NCT00296608|Active Comparator|Radiotherapy|RT was delivered with photons from a linear accelerator with an energy level of 8MVor above.
88979774|NCT00296608|Experimental|Chemotherapy and radiotherapy|The first CT cycle was administered from days 1 to 5 of the RT treatment. LV 20 mg/m2/d was delivered intravenously immediately before administration of FU. FU 350 mg/m2/d was delivered during 20 minutes in 100 mL of saline infusion, 1 hour before RT. The second cycle was administered from days 29 to 33 of the RT treatment using the same schedule.
89599287|NCT03138720|Experimental|Open Label|All patients will receive open label medication at set dosages unless the dosage needs to be adjusted to treat an adverse event or dose toxicity.
89599288|NCT03131726|Experimental|Simvastatin|simvastatin 40 mg daily for 6 months
89599289|NCT03131726|No Intervention|No treatment|No treatment
89599290|NCT03112590|Experimental|Combination Therapy|"Phase 1: Participants with HER-2 positive metastatic breast cancer enrolled in groups of 3-6 or more; each group participant to be given the same dose and schedule of Interferon-gamma plus paclitaxel, trastuzumab, and pertuzumab. If group participants do not have bad side effects, the next group will be given a higher dose of Interferon-gamma. This will continue until the highest safe dose of Interferon-gamma is found. Once highest safe dose of Interferon-gamma is found, participants may be enrolled in Phase II.~Phase 2: Approximately 31 participants with Stage 2-3 HER2 positive early stage breast cancer enrolled to receive therapy with Interferon-gamma plus paclitaxel, trastuzumab, and pertuzumab. Interferon-gamma given at dose found in the Phase 1.~Phase 2: Post therapy surgery."
89599291|NCT03085394|Active Comparator|Treatment arm|Preoperative intravenous administration of 2g tranexamic acid in 10ml fluid.
89599292|NCT03085394|Placebo Comparator|Control Arm|Preoperative intravenous administration of 10ml normal saline.
89032000|NCT02939508|Active Comparator|Non-colon originated|"NCOG met one of the two following criteria:~History of nerve damage that could affect colon movement (colon [-innervating] nerve damage), such as pelvic or retroperitoneal operation, spine injury, or cerebral lesion; and non-existing or mild edema of colonic wall on abdominal CT;~Absence of history of colon(-innervating) nerve damage, with no obvious change in the colonic wall visible on the CT scan."
89599293|NCT03065621|Experimental|Palbociclib with Endocrine Therapy|All subjects will receive palbociclib 125 mg for 4 cycles, orally, once a day, for 21 days followed by 7 days of rest (4 cycles of 28 day long). After the final rest week (therefore post cycle 4), subjects will receive 3 to 7 additional days of palbociclib, as necessary, at the same dose and posology, until the day before curative intent surgery. Depending upon the menopausal status, the patient will receive either letrozole or tamoxifen continuously during the palbociclib treatment (which consists of 4 cycles of 28 days).
89599294|NCT03060629|Experimental|Group 1|Participants will receive Ad26.Mos4.HIV 5*10^10 virus particles (vp) as 0.5 milliliter (mL) via Intramuscular (IM) injection into the left deltoid on Months 0, 3, 6, and 12 and Clade C gp140 (250 [microgram] mcg) mixed with Aluminum phosphate adjuvant as 0.5 mL IM into the right deltoid on Months 6 and 12.
89599295|NCT03060629|Placebo Comparator|Group 2|Participants will receive Placebo for Ad26.Mos4.HIV as 0.5 mL into the left deltoid on Months 0, 3, 6, and 12 and Placebo for Clade C gp140 / Aluminum phosphate adjuvant as 0.5 mL IM into the right deltoid on Months 6 and 12.
89599296|NCT03060434|Active Comparator|Control|Ibuprofen
89599297|NCT03060434|Experimental|Pentoxifylline|Pentoxifylline oral tablets
89599298|NCT03617354||Trainee Gynaecologists|"RANZCOG accredited O&G specialists who are proficient in RANZCOG laparoscopic skills level 3 or higher;~Surgical capabilities will be assessed using The Global Operative Assessment of Laparoscopic Skills (GOALS) Tool which is an adapted GOALS tool for hysterectomy. GOALS measures depth perception, bimanual dexterity, efficiency, tissue handling and surgeon autonomy each on a 5 point Likert scale. An experienced mentor will assess each surgeon using this scale and skills will be validated against objective outcomes (surgical adverse events recorded in the baseline period).~Will be able to attend each of the 10 training days."
89599299|NCT03021486|Experimental|Group I (haloperidol)|Patients receive haloperidol IV over 3-15 minutes every 4 hours in the absence of unacceptable toxicity.
89599300|NCT03021486|Experimental|Group II (chlorpromazine)|Patients receive chlorpromazine IV over 3-15 minutes every 4 hours in the absence of unacceptable toxicity.
89599301|NCT03021486|Experimental|Group III (haloperidol, chlorpromazine)|Patients receive haloperidol and chlorpromazine IV over 3-15 minutes every 4 hours in the absence of unacceptable toxicity.
89599302|NCT02999789|Active Comparator|Intervention: Reminder System|After an initial six week run-in period, participants will be randomized to either the intervention group or placebo group. The intervention group will have SMS reminder and audiovisual reminder functions turned on. SMS reminders will be sent twice daily to child's caregiver's cell phone reminding them to administer daily asthma medication. SmartInhaler with reminder function turned on that is attached to Inhaler medication will remind child's caregiver twice daily to administer daily asthma medication.
89599303|NCT02999789|Placebo Comparator|Placebo: Delayed Reminder System|After an initial six week run-in period, participants will be randomized to either the intervention group or placebo group. The placebo group will have SMS reminder and audiovisual reminder functions turned off. The SmartInhaler will only function to measure daily adherence. Once intervention group has finished their 6 week period, this group will have intervention turned on.
89599304|NCT02970331|Experimental|pefcalcitol|pefcalcitol 0.005% BID for 8 weeks
89599305|NCT02923115|Experimental|DS-1040b|Participants who are randomized to receive DS-1040b as a single, continuous intravenous infusion (initial loading dose 3-6 mg). All participants will also receive standard of care anticoagulation enoxaparin therapy during the study drug infusion.
89599306|NCT02923115|Placebo Comparator|Placebo|Participants who are randomized to receive placebo as a single, continuous intravenous infusion. All participants will also receive standard of care anticoagulation enoxaparin therapy during the study drug infusion.
89599307|NCT02910583|Experimental|Fixed Duration (FD) Cohort: Open Label Ibrutinib + Venetoclax|Participants receive 420 mg of single-agent ibrutinib for first 3 cycles followed by ibrutinib plus venetoclax combination treatment (ibrutinib 420 mg and venetoclax 400 mg orally once daily on a continuous schedule) for 12 cycles (a cycle is defined by 28 days) or until disease progression or unacceptable toxicity.
89599308|NCT02910583|Experimental|MRD Cohort/Confirmed Undetectable MRD (uMRD): Randomized to Ibrutinib (Blinded)|"Participants receive 420 mg of single-agent ibrutinib for the first 3 cycles followed by ibrutinib plus venetoclax combination treatment for at least 12 cycles (a cycle is defined as 28 days) prior to randomization (pre-randomization phase).~Participants with confirmed uMRD are randomized to receive ibrutinib 420 mg orally once daily on a continuous schedule until MRD-positive relapse, disease progression (PD), or unacceptable toxicity.~After MRD-positive relapse or disease progression (PD) by iwCLL criteria, participants can reintroduce 400 mg venetoclax with a 5-week ramp up. If venetoclax is to be reintroduced, venetoclax treatment is to continue at the dose of 400 mg/day for up to approximately 2 years (cumulative) until PD or unacceptable toxicity."
88979775|NCT00296686|Experimental|tranylcypromine|sequential tranylcypromine (TC) followed by TC + dextroamphetamine followed by TC + T3
88979776|NCT00122070|Experimental|A|Quetiapine at dosage of 50 to 150 mg
88979777|NCT05418140||Women with diagnosis of adenomyosis on ultrasound scan|"The cohort group (375 participants) will comprise of women diagnosed with adenomyosis on pre-treatment baseline ultrasound scan before ART treatment who satisfy the eligibility criteria and consent to participate in the study.~September 2022: Amendments to the protocol: Some of the methodological aspects of the AdAPT-ART study have been revisited to ensure timely delivery of the study to a full sample size. These amendments have been approved by the local ethics committee.~Amendment sample size:~Sample size of 276 women with adenomyosis and 552 women with normal uterus with 2:1 control: cohort design. Power remains 80%"
89599309|NCT02910583|Placebo Comparator|MRD Cohort/Confirmed uMRD: Randomized Placebo (Blinded)|"Participants receive 420 mg of single-agent ibrutinib for the first 3 cycles followed by ibrutinib plus venetoclax combination treatment for at least 12 cycles (a cycle is defined as 28 days) prior to randomization (pre-randomization phase).~Participants with confirmed uMRD are randomized to receive placebo orally once daily on a continuous schedule until MRD-positive relapse, PD or unacceptable toxicity.~If MRD-positive relapse or PD is confirmed after restaging per iwCLL criteria, participants can first reintroduce oral daily ibrutinib with the option of subsequently reintroducing 400 mg venetoclax with a 5-week ramp up, if subsequent disease relapse per iwCLL criteria occurs after ibrutinib reintroduction. If venetoclax is to be reintroduced, venetoclax treatment is to continue at the dose of 400 mg/day for up to approximately 2 years (cumulative) until PD or unacceptable toxicity."
89599310|NCT02910583|Experimental|MRD Cohort/uMRD Not Confirmed: Randomized to Ibrutinib (Open-Label)|"Participants receive 420 mg of single-agent ibrutinib for the first 3 cycles followed by ibrutinib plus venetoclax combination treatment for at least 12 cycles (a cycle is defined as 28 days) prior to randomization (pre randomization phase).~Participants with uMRD not confirmed are randomized to receive open-label ibrutinib 420 mg orally once daily on a continuous schedule until PD or unacceptable toxicity.~In case of confirmed PD after restaging per iwCLL criteria, participants can continue ibrutinib and reintroduce venetoclax treatment. If venetoclax is to be reintroduced, venetoclax treatment is to continue at the dose of 400 mg/day for up to approximately 2 years (cumulative) until PD or unacceptable toxicity."
89599311|NCT02910583|Experimental|MRD Cohort/uMRD Not Confirmed: Randomized Ibrutinib + Venetoclax (Open-Label)|"Participants receive 420 mg of single-agent ibrutinib for the first 3 cycles followed by ibrutinib plus venetoclax combination treatment for at least 12 cycles (a cycle is defined as 28 days) prior to randomization (pre randomization phase).~Participants with uMRD not confirmed are randomized to receive open-label ibrutinib 420 mg and venetoclax 400 mg orally once daily on a continuous schedule until PD or unacceptable toxicity. Venetoclax was allowed for administration up to 2 years cumulatively from first dose started in the pre-randomization phase to last dose in the randomization phase."
89599312|NCT02896348|Experimental|SynPhNe therapy|"Subjects will be asked to participate in a program of 18 upper-extremity rehabilitation sessions of 60 minutes with SynPhNe platform, over 6 weeks. The sessions will emphasize on the wrist and fingers movements, including functional activities.~During week the two first weeks, 6 sessions will be done under therapist supervision at the Motion Analysis Laboratory at Spaulding Rehabilitation Hospital. Over the next 4 to 5 weeks, 10 sessions following exercises prompted by the SynPhNe system will be done unsupervised at home (or under limited supervision at the hospital), 2 sessions will be done at Spaulding Rehabilitation Hospital to review exercises with the SynPhNe system."
89599313|NCT02896348|Active Comparator|Conventional therapy|"Subjects will be asked to participate in a program of 18 upper-extremity rehabilitation sessions of 60 minutes under therapist supervision over two weeks at the Motion Analysis Laboratory at Spaulding Rehabilitation Hospital. The sessions will emphasize on the wrist and fingers movements, including functional activities.~During week the two first weeks, 6 sessions will be done under therapist supervision at the Motion Analysis Laboratory at Spaulding Rehabilitation Hospital. The remaining 10 sessions will be done unsupervised at home, over approximately 4 weeks, and following the therapist home treatment plan. Over that time, 2 visits to Spaulding Rehabilitation will be made to review home treatment plan. Over the course of the study, participants will wear GeneActiv sensors to gather information about upper-extremity usage."
89599314|NCT02866461||Fibromyalgia|No treatment
89599315|NCT02863172||Consenting Proband Group|Questionnaires completed at baseline. Blood sample taken at baseline. Follow-up questionnaire completed at least 1 time in 5 years.
89599316|NCT02863172||Family Members (MDA Registered Patients) Group|Health questionnaire completed at baseline. Blood sample taken at baseline. Follow-up questionnaire completed at least 1 time in 5 years.
89599317|NCT02863172||Family Members (Not MDA Registered Patients) Group|Health questionnaire completed at baseline. Blood sample taken at baseline. Follow-up questionnaire completed at least 1 time in 5 years.
89599318|NCT02821299|Experimental|Laryngeal transplantation|Laryngeal transplantation
89599319|NCT02820857|Experimental|Folfiri-bevacizumab|Patient treated with a combination Folfiri-bevacizumab. Treatment every 2 weeks (D1 = D15)
89599320|NCT02820857|Active Comparator|Folfiri|Patient treated with Folfiri only. Treatment every 2 weeks (D1 = D15)
89599321|NCT02810821||female, premenopause|Women with regular menstrual cycles in normal range (22-35 days) for the previous three cycles.
89599322|NCT02810821||female, perimenopause|Peri-menopause was defined as the presence of menses within the past 3 months with a decrease in cycle predictability in the year preceding examination or 3-11 months of amenorrhea. To investigate the association between serum FSH and cholesterol levels independent of E2, we further selected peri-menopausal subjects with the presence of menses within the past 3 months with a decrease in cycle predictability in the year preceding examination because their E2 levels have been reported to be similar to those in pre-menopause.
89599323|NCT02810821||Serum FSH level Quartile 1|Serum FSH level: <6.95 mIU/mL
89599324|NCT02810821||Serum FSH level Quartile 2|Serum FSH level: 6.95-10.87 mIU/mL
89599325|NCT02810821||Serum FSH level Quartile 3|Serum FSH level: 10.88-25.45 mIU/mL
89599326|NCT02810821||Serum FSH level Quartile 4|Serum FSH level: >25.45 mIU/mL
89599327|NCT02797457|Other|Allograft|Bilateral allograft of the hands and forearms.
89599328|NCT02797457|Other|Prostheses|Prosthetic forehands
89599329|NCT02797314|Other|Type 2 diabetic population|Bone biopsies
89032001|NCT00518102||001|REGRANEX (becaplermin) A cohort of REGRANEX (becaplermin) users (ie patients treated with REGRANEX (becaplermin) a topical medication used to treat non-healing neuropathic foot ulcers in patients with diabetes).
89599330|NCT02797314|Other|Non-diabetic control population|Bone biopsies
89599331|NCT02790710|Experimental|Propanolol|Propranolol 40 mg capsule, given once after fear reactivation procedure
89599332|NCT02790710|Placebo Comparator|Placebo capsule|Placebo capsule, given once after fear reactivation procedure
89599333|NCT02680015|Experimental|Experimental Group|Immediate enrollment in the PEERS group.
89599334|NCT02680015|No Intervention|Waitlist Group|Research measures while waiting for PEERS; will receive PEERS within one year.
89599335|NCT02650843||Patients with parkinsonism|Patients with parkinsonism that are referred for DAT SPECT imaging in Turku University Hospital, Finland or Helsinki University Hospital, Finland
89032002|NCT00518102||002|REGRANEX (becaplermin) comparators A cohort of REGRANEX (becaplermin) nonusers (ie patients who are not treated with REGRANEX [becaplermin]) but are similar in characteristics to patients in the REGRANEX [becaplermin] user cohort)
89599336|NCT02613377||Transfused critically ill children|Any infusion of RBC, plasma or platelets will be considered a transfusion.
89599337|NCT02613377||Non-transfused critically ill children|For each transfused patient (index patient), one matched non-transfused control will be identified and included in the control group. The matching will be conducted using four criteria in hierarchical order: gender; age ± 10%; baseline Hemoglobin level (± 15 g/L); and Pediatric Risk of Mortality III score (PRISM III score ± 10%).
89599338|NCT02604732|Active Comparator|Patients who stop Aspirin perioperatively|Patients undergoing laparoscopic inguinal hernia repair will stop Aspirin 5-7 days before the surgery
89599339|NCT02604732|Experimental|Patients who continue Aspirin perioperatively|Patients undergoing laparoscopic inguinal hernia repair will continue on Aspirin perioperatively
89599340|NCT02603640|Experimental|epileptic patient|
89599341|NCT02498847|Experimental|ENGAGE intervention|8 in-person weekly treatment sessions with an occupational therapist of 30 minutes - 1 hour duration intervention content provided on website, homework assigned each week after intervention period, monthly calls conducted to check on health status
89599342|NCT02498847|No Intervention|Usual Care|participated in usual care and received monthly calls to check on health status
89599343|NCT02487394||COPD Smoker Subjects|Smokers Active smoking will be defined as daily use of cigarettes, pipes, cigarillos or cigars at time of entry into the study and through duration of study.
89599344|NCT02487394||Asthma Non-Smoker Subjects|Non-Smokers Subjects with no active smoking. No active smoking defined as never smoking or having stopped smoking for 5 years or greater.
89599345|NCT06297083|Experimental|High-dose peanut OIT combined with probiotic (HD PPOIT)|High-dose rapid escalation peanut OIT combined with probiotic (HD PPOIT) taken daily for 18 months.
89599346|NCT06297083|Experimental|High-dose peanut OIT combined with probiotic placebo (HD OIT)|High-dose rapid escalation peanut OIT combined with probiotic placebo (HD OIT) taken daily for 18 months
89599347|NCT06297083|Active Comparator|Low-dose peanut OIT combined with probiotic placebo (LD OIT)|Low-dose slow escalation peanut OIT combined with probiotic placebo (LD OIT) taken daily for 18 months.
89599348|NCT06297057|Experimental|Neurophysiological Recordings|"Participants suitable for hdEEG, MEG, and MUSE recordings will first undergo a neuronavigation session, and then three identical neurophysiological data acquisition sessions, one for hdEEG, one for MEG, and one for MUSE.~The sessions will take place in three consecutive weeks, once a week, taking care that they are made at the same time of day for each participant. Finally, a structural magnetic resonance imaging (MRI) recording will be obtained for each participant.~Each neurophysiological data acquisition session will consist of 5 blocks: 4 eyes-open and eyes-closed resting-state blocks, and one passive auditory stimulation block.~The four blocks in the resting condition will be performed first, to avoid interference due to the passive acoustic task. The order of blocks 1 and 2, and consequently also blocks 3 and 4, representing the open-eye and closed-eye conditions will be counterbalanced between subjects and between different sessions for the same subject."
89599349|NCT06297044||Right Hemispheric Stroke|"Specific inclusion criteria for this participants' group are:~- unilateral right hemispheric lesion after an ischemic or hemorrhagic stroke.~There are no specific exclusion criteria for this participants' group (see general exclusion criteria).~Participants will undergo a detailed neuropsychological assessment as detailed in the study's detailed description and outcome measures sections."
89599350|NCT06297044||Left Hemispheric Stroke|"Specific inclusion criteria for this participants' group are:~- unilateral left hemispheric lesion after an ischemic or hemorrhagic stroke.~There are no specific exclusion criteria for this participants' group (see general exclusion criteria).~Participants will undergo a detailed neuropsychological assessment as detailed in the study's detailed description and outcome measures sections."
89032003|NCT02939235|Active Comparator|Crushed ticagrelor followed by morphine|crushed ticagrelor 180 mg administered orally followed by morphine 5 mg intravenously
89032004|NCT02939235|Active Comparator|Crushed ticagrelor, morphine,metoclopramide|crushed ticagrelor 180 mg administered orally followed by morphine 5 mg and metoclopramide 10 mg intravenously
89032005|NCT00518141|Experimental|1|FER
89032006|NCT00518141|No Intervention|2|FER
89032007|NCT00518141|Experimental|3|SET
89032008|NCT00518141|No Intervention|4|SET
89032009|NCT00518141|Experimental|5|DET
89599351|NCT06297044||Traumatic Brain Injury|"Specific inclusion criteria for this participants' group are:~presence of a traumatic brain injury episode~absence of previous neurological and psychiatric conditions.~There are no specific exclusion criteria for this participants' group (see general exclusion criteria).~Participants will undergo a detailed neuropsychological assessment as detailed in the study's detailed description and outcome measures sections."
89032010|NCT00518141|No Intervention|6|DET
89032011|NCT02938962|Active Comparator|Intravenous TXA|The IV administration group will receive a single 20mg/kg dose of TXA prior to the skin incision.
89032012|NCT02938962|Active Comparator|Topical TXA|The topical administration group will have a 100mL solution (3g TXA in 100cc of normal saline) instilled into the surgical field throughout the operative procedure; 50mL of the solution will be instilled after bony preparation of the acetabulum and/or femur and 50mL of the solution will be instilled prior to closure. The topical TXA solution will be allowed to bathe the wound for 5 minutes at each administration.
89032013|NCT00519701|Experimental|1|hydroxyurea
89032014|NCT02939040|Experimental|Positive Activities Intervention|Patients will note at least one positive event each day, write it down on a slip of paper and then deposit this piece of paper in a piggy bank. After approximately 21 days, the participant reads each one the night before surgery.
89032015|NCT02939040|No Intervention|Usual Care Group|The control group will serve to show the relative benefits of the Positive Piggy Bank intervention. These participants will follow the same questionnaire completion procedures.
89032016|NCT00519155|Experimental|1|Open flap debridement + MD05
89032017|NCT00519155|Active Comparator|2|Open flap debridement
89032018|NCT02939196||Group(A)|2.7 mm rigid hysteroscopy.
89032019|NCT02939196||Group(B)|2.9 mm rigid hysteroscopy.
89599352|NCT06297044||Right Hemispheric Brain Tumor|"Specific inclusion criteria for this participants' group are:~- unilateral right hemispheric brain tumor.~There are no specific exclusion criteria for this participants' group (see general exclusion criteria).~Participants will undergo a detailed neuropsychological assessment as detailed in the study's detailed description and outcome measures sections."
88979778|NCT05418140||Control group: Women with normal uterus on baseline ultrasound scan|"Women with normal uterus on baseline ultrasound scan during the study duration will be used as control (375 participants) and will be matched for the following variables: age, embryo quality, type of ART cycle (donor or self and IVF or ICSI) and number of embryos transferred. The eligibility criteria will be applicable to the controls as well.~September 2022: Amendments to the protocol: Some of the methodological aspects of the AdAPT-ART study have been revisited to ensure timely delivery of the study to a full sample size. These amendments have been approved by the local ethics committee.~Amendment sample size:~Sample size of 276 women with adenomyosis and 552 women with normal uterus with 2:1 control: cohort design. Power remains 80%"
89599353|NCT06297044||Left Hemispheric Brain Tumor|"Specific inclusion criteria for this participants' group are:~- unilateral left hemispheric brain tumor.~There are no specific exclusion criteria for this participants' group (see general exclusion criteria).~Participants will undergo a detailed neuropsychological assessment as detailed in the study's detailed description and outcome measures sections."
89599354|NCT06297044||Mild Cognitive Impairment|"Specific inclusion criteria for this participants' group are:~MCI diagnosis according to Petersen et al., 2006 criteria~absence of previous neurological and psychiatric conditions.~There are no specific exclusion criteria for this participants' group (see general exclusion criteria).~Participants will undergo a detailed neuropsychological assessment as detailed in the study's detailed description and outcome measures sections."
89599355|NCT06297044||Healthy Individuals|"Specific inclusion criteria for this participants' group are:~- absence of neurological and psychiatric conditions.~There are no specific exclusion criteria for this participants' group (see general exclusion criteria).~Participants will undergo a detailed neuropsychological assessment as detailed in the study's detailed description and outcome measures sections."
89599356|NCT06297031|Experimental|heat application|women in the intervention group were treated with hot water application to the sacral region during the first stage of labor. When the cervical dilatation was 3-4 cm, 5-6 cm and 7-8 cm, heat application was applied a total of 3 times.
89599357|NCT06297031|No Intervention|no heat application|No treatment was performed on women in the control group during the study. In the clinic, women's cervical dilatation is routinely checked by the midwife every 2-3 hours, and the progress of labor is monitored by fetal heart rate and fetal monitoring
89599358|NCT06297018|No Intervention|1|No intervention: This group includes liver transplant recipients and no intervention is applied to this group. Depression, anxiety and stress levels are measured in the pre-test. No intervention is implemented. As a post-test, depression, anxiety and stress levels are measured again.
89599359|NCT06297018|Experimental|2|Bioenergy group: This group includes liver transplant recipients and recipients who underwent intervention. Depression, anxiety and stress levels are measured in the pre-test. Bioenergy is then applied. As a post-test, depression, anxiety and stress levels are measured again.
89599360|NCT06297005||Vapers|Women who vape during pregnancy
89599361|NCT06297005||Smokers|Women who smoke tobacco during pregnancy
89599362|NCT06297005||Controls|Women who neither smoke tobacco or vape during pregnany
89599363|NCT06296992|Experimental|12-week TEAM peer mentor program|A 12-week peer-led behavioural intervention that supports increased physical activity. It will consist of 3 weekly contacts between participants and peer mentors that will be a mix of in-person, virtual, and texting. The intervention components and communication between adolescents and peer mentors with T1D will be guided by SDT, and designed to overcome the key psychosocial barriers to PA. The peer mentors that complete the training will deliver a 12-week intervention to increase behavioural skills that foster autonomy for goal setting and overcoming barriers to PA.
89599364|NCT06296992|No Intervention|12-week waitlist control|A 12-week waitlist control group that receives usual care, including standard educational resources developed by the Canadian Society of Exercise Physiology and the American Heart Association for adopting and sustaining daily PA. Adolescents randomized to the control arm will receive the 12 week intervention following the 24 week follow-up time point.
89599365|NCT06296979|Active Comparator|USUAL PHYSIOTHERAPY|the usual treatment of the center consisting of manual therapy, exercise and thermotherapy will be performed.
88979779|NCT00297154|No Intervention|Control|Patients continue receive a single educational session and continue medical managment of heart failure as per their physician
88979780|NCT00297154|Experimental|Lifestyle modification|Patients recieve weekly sessions with dietician, replace 2 meals/day with meal replacement beverage, and initiate a walking program.
88979781|NCT05391620|Experimental|CAD group|Coronary artery diseases
88979782|NCT05391620|Experimental|HFrEF group|Heart Failure with reduced Ejection Fraction
88979783|NCT00297193|Experimental|Transplant Arm|Hematopoietic stem cell mobilisation followed, within 4 weeks, by high dose immunoablation and autologous stem cell transplantation
88979784|NCT00297193|Experimental|Delayed Transplant|Hematopoietic stem cell mobilisation followed, after 59 weeks, by high dose immunoablation and autologous hematopoietic stem cell transplantation
88979785|NCT00297271||Mild cognitive impairment or dementia|Patients with mild cognitive impairment or dementia.
88979786|NCT00122148|Other|1|
88979787|NCT00297349||001|
88979788|NCT05377307||Group A|After completion or early withdraw from the treatment protocol, patients will be enrolled into this long-term follow-up study. If patients do not enter this study right after leaving the treatment protocol, they may have the option to enter this study at any time within 15 years after the last lentiviral-based gene-edited immune cell infusion.
88979789|NCT05377307||Group B|Some patients may require joining other Pell's gene-edited immune cell therapy study during participating in this long-term follow-up study. For such case, the patient could be enrolled into the new treatment protocol. Meanwhile, the patient can be remaining in this long-term follow-up protocol as an inactive participant.
88979790|NCT00090129|Experimental|Onercept|
88979791|NCT00090129|Placebo Comparator|Placebo|
89599366|NCT06296979|Experimental|Transcutaneous electrical nerve stimulation|The intervention group will receive the usual physiotherapy treatment at the health center and will also receive neuromodulation on the phrenic nerve at its exit through the anterior cervical region. The neuromodulation technique will be applied for 10 minutes.
89599367|NCT06296966|Experimental|VSJ-110 Solution|
89599368|NCT06296966|Placebo Comparator|Placebo Solution|
89599369|NCT06296953|Experimental|Patient Group|Patient will be examined with the new device, PERIsign.
89599370|NCT06296953|Active Comparator|Healthy Volunteers|The group will also be examined with the device, PERIsign
89599371|NCT06296940|Active Comparator|Treatment as Usual (TAU)|Participants randomized to the TAU condition, which involves the standard clinical services available in a short term residential SUD treatment context. Examples of these services are: Individual counseling/case management; Group psychoeducation; Group counseling; Assessment and addiction related medical treatment from a physician; Pharmacotherapy for substance use disorders; 12-step groups. However, participants in this group do not receive treatment that is targeted at decreasing PTSD symptoms.
89599372|NCT06296940|Experimental|TAU + Written Exposure Therapy (WET)|Participants in this condition receive everything included in TAU plus 5 individual sessions of WET delivered by a therapist. Sessions average less than 60 minutes and primarily involve writing about the traumatic experience that is guided by the therapist.
89599373|NCT06296927|Experimental|Intervention Group|Emotional Freedom Technique will be applied to women in the intervention group applying for mammography screening 30-40 minutes before the procedure.
89599374|NCT06296927|No Intervention|Control Group|Women in the control group applying for mammography screening will not receive any intervention other than routine mammography screening.
89599375|NCT06296914|Experimental|POTSapp|Participants will receive a smart watch and Bluetooth blood pressure monitor and attend a virtual Zoom meeting to learn how to install and use the app with devices.
89599376|NCT06296914|Active Comparator|Waitlist Control|Participants will receive an emailed information sheet containing online support information on POTS. After the initial 4- month period is over, participants will receive a smart watch and Bluetooth blood pressure monitor and attend a virtual Zoom meeting to learn how to install and use the app with devices.
89599377|NCT06296901|Experimental|Perineal Wipe|Patient will use wipe before collecting mid-stream clean catch culture
89599378|NCT06296901|No Intervention|No Wipe|Patient will not use wipe before collecting mid-stream clean catch culture
89599379|NCT06296888|Experimental|Radiofrequency balloon catheter ablation|Enrolled patients will undergo PVI by radiofrequency balloon ablation.
89599380|NCT06296862|Experimental|Dietary Approaches to Stop Hypertension Diet|
89599381|NCT06296862|No Intervention|Usual Diet|
89599382|NCT06296849|No Intervention|No-FIT Treatment-as-Usual (TAU) Condition|Participants in the no-FIT control condition will not receive incentives.
89599383|NCT06296849|Experimental|Single-Target FIT (SFIT)|One couple member offered incentives. Targets in the SFIT condition will be offered financial incentives for biochemically verified abstinence ($200 at each of three follow-ups [1, 3, and 6 Month]).
89599384|NCT06296849|Experimental|Dyadic-FIT condition (DFIT)|Both couple members offered incentives and tracked across 12 months. Both targets and partners will be offered financial incentives for abstinence. Thus, in this condition, the total financial incentives offered to the dyad are twice the amount as offered to participants in the SFIT condition.
89599385|NCT06296836|Active Comparator|Metformin continuation|Continuation of home metformin regimen during hospitalization to an internal medicine service
88811948|NCT02478372|Experimental|Local Infiltration Analgesia (LIA)|Subcutaneous infiltration during surgery using 200ml of 0.2% plain ropivacaine. 50ml injected following bone preparation prior to implant cementation perpendicular to the posterior femur through the posterior joint capsule in 10ml aliquots. 30ml proximal to the suprapatellar pouch down to the femur.100ml spread into subcutaneous tissues including; collateral and cruciate ligaments, fatty and connective tissue on the anterior aspect of the incision. A 16 gauge epidural catheter inserted via a medial portal, 20ml was injected via the catheter following closure of wound. Post-operatively, patients received boluses of 40ml ropivacaine 0.2% via the catheter using a mechanical McKinley 595 pump 4 hours after leaving theatre, at 22:00 and 08:00 on post-operative day one.
89032020|NCT04691076|Experimental|Propofol/Esketamine sedation|Propofol target-controlled infusion is performed first,when the infusion concentration reaches 1.5μg/ml,esketamine 0.15mg/kg is injected intravenously;then the dose is adjusted according to the depth of anesthesia and the modified observer's assessment of alert /sedation scale, and propofol target-controlled infusion for every increase of 5μg/ml in concentration, the corresponding increase of esketamine is 0.05mg/kg; the total dose of esketamine used in surgery shall not exceed 0.5mg/kg.
89599386|NCT06296836|No Intervention|Metformin discontinuation|Holding home metformin regimen during hospitalization to an internal medicine service
89599387|NCT06296823|Experimental|Meal timing|Three days of meals, bedtimes and wake times scheduled to occur 5h earlier.
89599388|NCT06296823|Experimental|Bright light|Three days of exposure to bright light of ~3,000 lux, which is less than one-third the brightness of a sunrise or sunset (timed to start earlier by 1h each day) with scheduled bed and wake times timed 5h earlier.
89599389|NCT06296810||PD|Subjects with PD who have an implanted Medtronic DBS system with a Percept IPG.
89599390|NCT06296797|Experimental|Comparative information on tubal sterilization and other long-acting contraceptives|A new website comparing tubal sterilization to vasectomy and long-acting reversible contraceptives
89599391|NCT06296797|Active Comparator|Information on tubal sterilization|Participants will be shown an existing web page developed by Planned Parenthood for people considering tubal sterilization
89599392|NCT06296784|Experimental|e-health psychoeducation|
89599393|NCT06296784|No Intervention|waiting list|
89599394|NCT06296771|Experimental|Dietary energy restriction and exercise group (D+E)|
89599395|NCT06296771|Active Comparator|Dietary energy restriction group (D)|
89599396|NCT06296758|Experimental|SIFI local anesthesia|Subjects randomized to the SiFi arm will have an ultrasound-guided suprainguinal fascia iliaca block performed preoperatively in the anesthesia block room with 40ml of ropivacaine local anesthetic.
89599397|NCT06296758|Active Comparator|FNB local anesthesia|Subjects randomized to the FNB arm will have an ultrasound-guided femoral nerve block performed preoperatively in the anesthesia block room with 20ml of ropivacaine local anesthetic.
89599398|NCT06296745|Experimental|Group|Intra-pemetrexed
89599399|NCT06296719|Experimental|Chit-Chat|The Chit-Chat intervention, covering five areas, including (1) Serious illness in older adults, (2) Realities of caring and dying from a carer's perspective, (3) Introduction to the importance of advance care planning for individuals and communities, (4) Effective communication between older adults, family members, and healthcare professionals in ACP conversations (i.e. listening to the wishes and preferences of older adults regarding their needs), and (5) audience participation and clarification including questions, answers and concerns.
89599400|NCT06296719|No Intervention|Waitlist Control|No intervention
89599401|NCT06296706|Experimental|Docetaxel for Injection (Albumin-bound)|Docetaxel for Injection (Albumin-bound) will be administrated by intravenous infusion once every 3 weeks.
89599402|NCT06296706|Active Comparator|Taxotere (Docetaxel)|Taxotere will be administrated by intravenous infusion once every 3 weeks.
89599403|NCT06296693|Experimental|POCUS-L|The investigators will study the diagnostic accuracy of a pocket-size POCUS device vs. CXR for the etiological diagnosis of CAP, in paediatric age. During 1 year, all children aged >12 months and <18 years admitted to the Paediatric Department with the diagnosis of CAP on admission will be included. At least 76 participants will be required. Two investigators will perform, independently, a POCUS at admission, daily during hospitalization, 15 days and 1 month after discharge. All children will also undergo a CXR upon admission and whenever necessary. A third investigator will classify the CXR independently. It will be used the General Electrics Vscan AirTM®, with Bluetooth connection to smartphone/tablet. It will be collected the systematized description of POCUS and CXR, sociodemographic, clinical and therapeutic variables.
89599404|NCT06296680|Experimental|Reiki|In the intervention group, patients received an energy therapy called Reiki. Reiki was administered to cancer patients for four consecutive days at specified times. During this procedure, while the patient was in the supine position, the researcher's hands were placed approximately two to three centimeters above the chakra regions of the patient, covering the seven chakra areas as well as the areas experiencing pain. The application lasted a total of 25-30 minutes. Silence was maintained in the patient's room during the intervention.
89599405|NCT06296680|Sham Comparator|Sham Reiki|In the placebo group, patients received Sham Reiki. Sham Reiki was administered to cancer patients for four consecutive days at specified times. During this procedure, while the patient was in the supine position, Sham Reiki practitioner's hands were placed approximately two to three centimeters above the chakra regions of the patient, covering the seven chakra areas as well as the areas experiencing pain. The application lasted a total of 25-30 minutes. Silence was maintained in the patient's room during the intervention.
89599406|NCT06296680|Active Comparator|Progressive Relaxation Exercise|Silence was maintained in the patient's room during the intervention. At the beginning of the session, the patient is asked to assume the most comfortable seated or supine position. Then, they are instructed to close their eyes, take deep breaths, direct their thoughts to their own body and the muscle groups being treated, notice the tension and relaxation in the muscle groups during the exercise, and continue to breathe regularly. This practice was conducted in four parts of the body: hands and arms; face and shoulders; chest, abdomen, hips; legs and feet.
89599407|NCT06296667|Experimental|group1: vertical/ vertical|participant posture: The thoracic block is vertically aligned over the pelvic block.The angle of the thoracic block is vertical in the sagittal plane allowing for the dome of the diaphragm to rest on top of the abdomen.Vertical force transfers through the musculoskeletal system through the mid-foot and into the standing surface causing no shifts in postural alignment.
89599408|NCT06296667|Experimental|group 2: vertical/ posterior|participant posture: The thoracic block is vertically aligned over the pelvic block but is posteriorly tipped in the sagittal plane.Vertical force leads to an accentuated extension in the thoracolumbar and lumbar regions with decreased ability to sustain vertical forces.
89599409|NCT06296667|Experimental|group 3: posterior/ posterior|participant posture: The thoracic block is aligned posterior to the pelvic block and is posteriorly tipped in the sagittal plane. Vertical force leads to an accentuated extension in the lower lumbar region with a forward shear of the pelvis and decreased ability to sustain vertical forces.
89599410|NCT06296667|Experimental|group 4: posterior/ anterior|participant posture: The thoracic block is aligned posterior to the pelvic block and is anteriorly tipped in the sagittal plane. Vertical force leads to a slight flexion in the thoracic and lumbar regions with a forward shear of the pelvis and decreased ability to sustain vertical force.
88811324|NCT02135419|Experimental|Arm I (treatment)|Patients are directed to receive either topical or ablative treatment at the discretion of the clinician. Patients receiving topical treatment apply imiquimod intra-anally, peri-anally or both thrice weekly for up to 16 weeks, fluorouracil twice daily for 5 days every 2 weeks for up to 16 weeks, or trichloroacetic acid every 3 weeks up to 12 weeks. Patients receiving ablative treatment using infrared photocoagulation therapy, hyfrecation/electrocautery (thermal ablation therapy), or laser therapy. Patients may undergo excision under anesthesia if the clinician believes none of the other treatment approaches will be effective. The number and timing of such treatments will be at the discretion of the investigator. Patients with persistent HSIL should continue a protocol-approved treatment or a new protocol treatment should be considered. All participants will have samples collected for laboratory biomarker analysis.
89032021|NCT04691076|Active Comparator|Propofol/Fentanyl sedation|Propofol target-controlled infusion is performed first.When the infusion concentration reaches 1.5μg/ml, fentanyl 0.6μg/kg is injected intravenously; then the dose is adjusted according to the depth of anesthesia and the modified observer's assessment of alert /sedation scale, and propofol target-controlled infusion for every increase of 5μg/ml in concentration,the corresponding increase of fentanyl is 0.2ug/kg; the total dose of fentanyl used in surgery shall not exceed 1.2ug/kg.
89032022|NCT00519935|Experimental|Multisystemic Therapy|In-home, intensive family therapy
89032023|NCT00519935|No Intervention|Standard Medical Care (TAU)|Standard medical care is provided at Children's Hospital of Michigan consistent with the standards for the care of children with T1D outlined by the American Diabetes Association.
89032024|NCT02949323||children with urinary stones|children with urinary stones
89032025|NCT02949323||children without urinary stones|children without urinary stones
88979792|NCT05365685|Experimental|adolescents with obesity|There is only one arm as this is an acute randomized study comparing three different conditions within the same sample of participants.
88979793|NCT04718272|Experimental|Puncture tube group|After the operation, the traditional traditional silicone tube which placed through the surgical incision was removed in the operating room, and the small puncture tube was retained for thoracic drainage.
89599411|NCT06296667|Experimental|group 5:anterior/ posterior|participant posture: The thoracic block is aligned anterior to the pelvic block and is posteriorly tipped in the sagittal plane. Vertical force leads to extension in the mid and lower lumbar regions with a posterior shear of the pelvis and decreased ability to sustain vertical forces.
89599412|NCT06296667|Experimental|group 6: anterior/ anterior|participant posture: The thoracic block is aligned anterior to the pelvic block and is anteriorly tipped in the sagittal plane. Vertical force leads to an overall flexion of the trunk and decreased ability to sustain vertical forces
89599413|NCT06296654|Experimental|Empowerment-Based Interventions (EBI)|The EBI was used for the study group. It is an integrative educational program under the patient-centered care approach emphasizing collaborative patient interaction. The EBI was implemented through structured (a) small-group discussion sessions, (b) individualized consultations, and (c) follow-up sessions.
89599414|NCT06296654|Active Comparator|standard health education|Patients in the control group received standard health education from SCD clinics in the HC. The clinic employs a multidisciplinary team, including a nurse, a physician, a health record clerk, a laboratory technician, a social worker, and a health promotion specialist, to provide integrated patient health services. It consists of both preventative and curative services. The nurses at the health center provide patients with information regarding factors that may cause vaso-occlusion and precipitate VOCs when to seek emergency care and educate patients on the significance of regular medical examinations and screening using different standardized audiovisual aids.
89599415|NCT06296641|Experimental|Needs Navigation Intervention|Individuals who screen positive will all move forward to receive this intervention. This includes connection to community partners with financial education and easily accessible resources, and a vocational navigation and support consultation for caregivers for 6-months.
89599416|NCT06296628|Active Comparator|Conventional Therapy Group|Participants in this group with train using Mirror Therapy (MT), the current standard of care.
89599417|NCT06296628|Experimental|Miraπ Group|Participants in this group will train with the Miraπ device.
89599418|NCT06296589|Experimental|trauma Informed Guilt Reduction Therapy|6 session behavioral intervention focused on trauma-related guilt, shame, and moral injury
89210174|NCT00986115|Placebo Comparator|Placebo|After a two-month prospective baseline during which seizure frequency and neurocognitive parameters are documented, patients will be randomized to either memantine or placebo and evaluated after twelve months on study drug. The treatment period will consist of a one month dose escalation phase, followed by an eleven month maintenance phase. The dose escalation is 5 mg in PM for days 1-7, 5 mg twice daily for days 8-14, 5 mg in AM and 10 mg in PM for days 15-21 and 10 mg twice daily from day 22 and continue.
89599419|NCT06296589|Active Comparator|Prolonged Exposure Therapy|12 session behavioral intervention focused on PTSD symptoms
89599420|NCT06296563|Experimental|HAIC+Adebrelimab+apatinib|Neoadjuvant therapy with Adebrelimab combined with apatinib and FOLFOX-HAIC for 2 cycles (1 treatment cycle every 21 days, apatinib only used for the first cycle), and surgery was performed 14-28 days after the end of treatment. After 28 days of surgery, patients will continue to receive adjuvant treatment with Adebrelimab combined with apatinib.
89599421|NCT06296550|Experimental|CGM Group|Participants will be provided continuous glucose monitors (Dexcom G7) to monitor blood glucose for the entire duration of this study (i.e., one new device every 10 days for a total of 18 devices to last up to 6 months).
89599422|NCT06296550|Other|Usual Care Blood Glucose Monitoring Group|Participants will use standard blood glucose monitoring devices that are covered by health insurance.
89599423|NCT06296537|Experimental|Dynamic Neuromuscular Stabilization Training Group|A dynamic neuromuscular stabilization training program consisting of a series of special exercises based on the developmental kinesiology steps of a healthy baby will be prepared and applied for athletes in the DNS group. As the sessions progress, elastic bands will be used to create resistance in the exercises as the participants gain stabilization. All exercises will start with 1 set of 3 repetitions and increase to 1 set of 20 repetitions. All exercises will be performed barefoot.
89599424|NCT06296537|Experimental|Balance Training Group|An intervention program will be prepared for balance training group in which balance training is added to an effective postural stability program. As the sessions progress, hand and ankle sandbags will be used together with the exercises. All exercises will start with 1 set of 10 repetitions and increase to 3 sets of 15 repetitions. Exercises will be performed barefoot.
89599425|NCT06296537|Active Comparator|Conventional Training Group|A program including stretching, joint range of motion, strengthening and postural control exercises will be prepared for athletes in the conventional group. As the sessions progress, hand and ankle sandbags will be used together with the exercises. All exercises will start with 1 set of 10 repetitions and increase to 3 sets of 15 repetitions. Exercises will be performed barefoot.
88979794|NCT04718272|No Intervention|Traditional tubes group|Routine thoracic drainage management measures were adopted, that is, both of the small puncture tube and traditional silicone tube were retained after surgery.
88979795|NCT00297817|Experimental|Arm 1: rMenB|
88979796|NCT00297817|Experimental|Arm 2: rMenB + OMV|
88979797|NCT00297817|Placebo Comparator|Arm 3: Placebo|
88979798|NCT00297856||Boostrix cohort|
88979799|NCT00297856||Historical Td cohort|
88979800|NCT00297895|Active Comparator|Ultrasound observation + delayed CLND if recurrence detected|
88979801|NCT00297895|Active Comparator|CLND|
88979802|NCT05198648||Postoperative myocardial injury|
88979803|NCT05198648||Non postoperative myocardial injury|
88979804|NCT00298051|No Intervention|Early umbilical cord clamping (control)|"Umbilical cord was clamped immediately, or as close as possible, after delivery of the infant's shoulders. (This was standard practice in the study hospital, thus it served as the control group)."
89599426|NCT06296511|Experimental|Exercise|Participants were asked to arrive at the lab at 8.30 am, having fasted overnight for 10 hours. After resting in the lab for 30 minutes, participants were asked to exercise at an intensity of 70 percent of their peak oxygen uptake for an hour before resting in the lab for a further 2.5 hours. Ad libitum energy intake was assessed 1 h after exercise completion.
89599427|NCT06296511|No Intervention|Control|Participants replicated all the procedures of the exercise trial except they rested for 1 h as the exercise counterpart.
89599428|NCT06296498|Active Comparator|Group OFD + L-PRF|Open flap debridement (OFD) with L-PRF is used during periodontal surgical procedure that is used to improve periodontal health by providing access to the tooth roots and alveolar bone.
89599429|NCT06296498|Other|Group OFD|Open flap debridement (OFD) is one periodontal surgical procedure that is used to improve periodontal health by providing access to the tooth roots and alveolar bone.
89599430|NCT06296485|Experimental|Group Education Sessions|Participants will participate in 3 educational sessions designed to teach about applying and using continuous glucose monitors [CGMs] (Session 1) and how to prevent hypoglycemia episodes based on CGM readings and hypoglycemia journal entries (Sessions 2 & 3).
89599431|NCT06296485|Experimental|Group Education Sessions + Individual Meeting with Diabetes Pharmacist|Participants will participate in 3 educational sessions designed to teach about applying and using continuous glucose monitors [CGMs] (Session 1) and how to prevent hypoglycemia episodes based on CGM readings and hypoglycemia journal entries (Sessions 2 & 3). Participants will also have the opportunity to meet 1:1 with a Diabetes Pharmacist.
89599432|NCT06296485|Active Comparator|Usual Care|Participants allocated to the control arm will continue with usual care.
89599433|NCT06296472|Active Comparator|Standard|
89599434|NCT06296472|Experimental|Experimental|
89599435|NCT06296459|Active Comparator|Low volume CBCT|Radiographic low volume cone beam computed tomography used to plan implant placement
89599436|NCT06296459|Placebo Comparator|Standard periapical radiographs|Standard radiography used to plan implant placement
89599437|NCT06296407|Experimental|Respiratory exercises|Males and females with obesity on standard metabolic integrated rehabilitation protocol + respiratory exercises
89599438|NCT06296407|Active Comparator|Control|Males and females with obesity on standard metabolic integrated rehabilitation protocol
89599439|NCT06296368|No Intervention|Usual Care|Receive usual care.
89599440|NCT06296368|Experimental|PRIME intervention|Receive the PRIME intervention.
89599441|NCT06296355|Experimental|Health Warning Label|Participants will view four products (a fruit-flavored drink, pretzels, a yogurt, and a breakfast cereal) each with a health warning label displayed on the front of package.
88979805|NCT00298051|Experimental|Delayed umbilical cord clamping|Umbilical cord was clamped at 2 minutes after delivery of the infant's shoulder's with the infant held at the level of the mother's uterus.
88979806|NCT00298168|Experimental|1|
88979807|NCT00298168|Experimental|2|
88979808|NCT00298168|Placebo Comparator|3|
88979809|NCT00322543|Experimental|Drug eluting stent|Corio™ Pimecrolimus-eluting stent
88979810|NCT00313963|Experimental|1|
88979811|NCT00313963|Placebo Comparator|2|
88979812|NCT00122343|Experimental|1|AP23573 will be administered intravenously (IV) at a fixed dose of 12.5 mg over 30 minutes once daily for 5 days (QDx5) every 2 weeks. A 4-week period comprised of 2 courses of AP23573 is defined as a cycle of treatment.
88979813|NCT00314158|Experimental|Brinzolamide +Timolol|
88979814|NCT00314158|Active Comparator|Brinzolamide|
88979815|NCT00314158|Active Comparator|Timolol|
88979816|NCT05147051|Experimental|Reamberin group|Patients receive the investigational treatment (meglumine sodium succinate), 500 ml intravenously every 8 hours (up to 6 infusions).
88979817|NCT05147051|Placebo Comparator|Placebo|Patients receive a Placebo (Ringer's solution), 500 ml intravenously every 8 hours (up to 6 infusions).
88979818|NCT00090480|Experimental|Vaccine group|
88979819|NCT00314275|Experimental|ENDEAVOR|Drug Eluting Stent
88979820|NCT00322699|Experimental|A single arm, non-randomized Phase II Study|Non-Randomized Phase II,Single Arm Study evaluating the efficacy of whole bladder photodynamic therapy as an alternative to radical cystectomy.
88979821|NCT00122421|Active Comparator|pharmacist recommendation|recommendations based on chart review by pharmacist, given to pcp at time of visit
88979822|NCT00122421|No Intervention|usual care|usual care
89599442|NCT06296355|Experimental|Identity Warning Label|Participants will view four products (a fruit-flavored drink, pretzels, a yogurt, and a breakfast cereal) each with an identity warning label displayed on the front of package.
89599443|NCT06296355|Other|Barcode Label|Participants will view four products (a fruit-flavored drink, pretzels, a yogurt, and a breakfast cereal) each with a barcode control label displayed on the front of package.
89599444|NCT06296342|No Intervention|Control (No framing)|Participants will view one message about the front-of-package labeling policy. The message will display the same introductory sentence as all experimental arms, but it will not include a framed message about the objective of the front-of-package labeling policy.
89599445|NCT06296342|Experimental|Information framing|Participants will view one message that frames the objective of the front-of-package labeling policy as providing nutritional information.
89599446|NCT06296342|Experimental|Healthier choices framing|Participants will view one message that frames the objective of the front-of-package labeling policy as encouraging consumers to make healthier choices.
89599447|NCT06296342|Experimental|Industry framing|Participants will view one message that frames the objective of the front-of-package labeling policy as encouraging the food industry to make healthier products.
89599448|NCT06296303|Experimental|Pulsed electromagnetic therapy group|Patients in this group will receive Pulsed electromagnetic therapy + Conventional physical therapy
89599449|NCT06296303|Experimental|Ultrasound phonophoresis group|Patients in this group will receive Ultrasound phonophoresis + Conventional physical therapy
89599450|NCT06296303|Active Comparator|Control group|Patients in this group will receive Conventional physical therapy
89599451|NCT06296290||All participants|The participants are the swimmers engaged in the 6-hour cold water swim during the Channel Swim Camp who volunteered to participate in the study.
89599452|NCT06296264|Other|Standard ultrasound|Comparator
89599453|NCT06296264|Experimental|Ultra-portable ultrasound|
89599454|NCT06296251|Placebo Comparator|Placebo treatment|Placebo treatment (Microcrystaline cellulose): 1 capsule/day
89599455|NCT06296251|Active Comparator|Active low dose of plant derived phenolics|Active low dose of plant derived phenolics via 1 capsule/day
89599456|NCT06296251|Active Comparator|Active high dose of plant derived phenolics|Active high dose of plant derived phenolics via 1 capsule/day
89599457|NCT06296238||Enhanced Nutrition Package (ENP) health center + Enhanced Infection Management Package (EIMP)|ENP: Health centers were strengthened to provide WHO/FMOH-recommended nutrition interventions in pregnancy. Pregnant women received a supply of adequately iodized salt for household use and iron-folate tablets from enrollment to birth. Women with undernutrition (MUAC <23 cm), also received a daily balanced energy protein supplement. EIMP: Pregnant women were screened at enrollment for bacteriuria with urine culture and antimicrobial susceptibility testing and presumptive deworming with mebendazole 500mg. Some women also received screening for chlamydia and gonorrhea and symptomatic women were tested for bacterial vaginosis and trichomonas. For women with chlamydia or gonorrhea, the participant was treated per FMOH guidelines with recommended antibiotics. STI/RTI screening was eventually discontinued due to supply shortage and the low prevalence of STI. At ANC follow-up visits, infected women were treated with antibiotics and persistent infection was retreated.
89599458|NCT06296238||ENP health center, routine care infection management participant|ENP: The health centers were strengthened to provide WHO/FMOH-recommended nutrition interventions in pregnancy. Pregnant women received a supply of adequately iodized salt for household use and iron-folate tablets from enrollment to birth. Women with undernutrition (MUAC <23 cm), also received a daily balanced energy protein supplement. Standard infection care: Maternal genitourinary tract infections is managed as per standard FMOH health center guidelines that utilize a syndromic management approach.
89599459|NCT06296238||Routine nutrition care health center, EIMP participant|"Routine nutrition care: Maternal nutrition was managed as per standard FMOH health center guidelines.~EIMP: Pregnant women were screened at enrollment for bacteriuria with urine culture and antimicrobial susceptibility testing and presumptive deworming with mebendazole 500mg. Some women also received screening for chlamydia and gonorrhea and symptomatic women were tested for bacterial vaginosis and trichomonas. For women with chlamydia or gonorrhea, the participant (and partner) was treated per FMOH guidelines with recommended antibiotics. STI/RTI screening was eventually discontinued due to supply shortage and the low prevalence of STI. At ANC follow-up visits, infected women were treated with antibiotics and persistent infection was retreated."
89599460|NCT06296238||Routine of care nutrition and infection management|Pregnant women received routine strengthened antenatal care services at the health center per FMOH guidelines. Maternal genitourinary tract infections were managed as per standard FMOH health center guidelines that utilize a syndromic management approach.
89599461|NCT06296212|Experimental|TAD® 600 mg/4 mL Solution for Injection|TAD® 600 mg/4 mL powder and solvent for solution for injection, 1 vial powder (glutathione sodium salt 646 mg) + 1 solvent ampoule (4 mL water for injection) reconstituted solution in 50 mL of 0.9% sodium chloride solution) administered intravenously (with an infusion rate of 10 mL/min), 2 times a day (with a dosing interval of 8 hours ± 30 minutes) for 5 consecutive days (Day 1, Day 2, Day 3, Day 4 and Day 5). Doses will be administered at the same time of the day (every 24 hours ± 30 minutes).
89599462|NCT06296212|Placebo Comparator|Saline solution of 0.9% sodium chloride|Placebo (50 mL of 0.9% sodium chloride solution) administered intravenously (with an infusion rate of 10 mL/min), 2 times a day (with a dosing interval of 8 hours ± 30 minutes) for 5 consecutive days (Day 1, Day 2, Day 3, Day 4 and Day 5). Doses will be administered at the same time of the day (every 24 hours ± 30 minutes).
89599463|NCT06296199|Experimental|Intervention|participants will listen to and watch a concert of musicians playing classical music through a VR headset
89599464|NCT06296199|Active Comparator|Control|participants will simply listen to the concert through headphones
89599465|NCT06296186|Experimental|Massed PE|Prolonged Exposure delivered in a massed format - sessions multiple times per week
89599466|NCT06296186|Active Comparator|Weekly PE|Prolonged Exposure delivered with weekly sessions
89599467|NCT06296173|Experimental|Open lung extubation|Before emergence from anesthesia, the patient will be positioned at 30 degrees, and oropharyngeal secretions will be suctioned. Anesthetic gas or intravenous agents will be stopped. Oxygen levels will be set to 50% with a fresh gas flow of at least 10 L/min. Ventilation mode will switch to pressure support adjusted to achieve similar volumes as controlled ventilation. PEEP levels will remain unchanged, while the minimum respiratory rate will decrease by 4 breaths/min. The inspiratory flow for triggering will be set at 2 L/min.
89599468|NCT06296173|Active Comparator|Conventional extubation|Before emergence from anesthesia, the patient will be kept supine and oropharyngeal secretions will be suctioned. Anesthetic gas or IV agents will be stopped. Oxygen concentration will be inscreased to 100% with a fresh gas flow ≥10 L/min. The ventilator will be halted, APL valve opened to atmosphere, and the patient manually ventilated with the reservoir bag until spontaneous breathing resumes, followed by manual assistance as deemed necessary by the anesthesiologist.
89032026|NCT04690959|Experimental|Neural gliding mobilization|Initial participant positioning for gliding will be : lying in supine, shoulder at approximately 90 of abduction, wrist in neutral, elbow at 90 flexion and head/neck neutral. From this starting position, participants actively and simultaneously will perform extension of the elbow (to 45) and ipsilateral neck flexion (to approximately 45) and then returned to 90 of elbow flexion and 45 of contralateral neck flexion while maintaining the shoulder at 90 abduction. According to Silva et al., (2014) this combination of movements was the one that promoted the greatest excursion of the median nerve (10.2 mm) . For gliding, four series of 10 movements at a rhythm of approximately 6 s per cycle and 1-min rest between series was performed.
89599469|NCT06296160|Experimental|Interventional Arm|"Based on the Ultrasound result, Dry Weight Modification:~Duration: 2 months. Number of visits: 5 visits.~A- Intervention Phase (Dry weight modification)= [Day-1 and Day-15]~B- Observational Phase (No Dry weight modification on Day 30, Day 45, and Day 60)."
89599470|NCT06296160|No Intervention|Control Arm|"Includes patients who will receive usual ambulatory and at-discharge care.~No dry-weight modification (The study investigators will not modify the dry weight).~All subjects in the Control group will be under follow-up close observation for two months [5 visits].~The participant will follow the standard of care practice (Dry Weight evaluation according to clinical judgment by the assigned physician and biological data.~Study procedures:~Obtain a lung ultrasound after the midweek dialysis session.~The 8-zone lung ultrasound method calculates the number of B-line scores.~Check the Blood Pressure 3 times/day on non-Dialysis days.~Check the ambulatory blood pressure for 48 hours (Baseline on Day 1 and Follow-up on Day 60)."
89599471|NCT06296147|Experimental|Virtual Reality Device|The VR device used is the Flowly biofeedback virtual headset. This device uses calming immersive virtual worlds along with breathing exercises and a heart rate monitor to guide patients through meditated breathing exercises. The Flowly app is based on a smartphone which will be purchased through the department and used by all participants. The account used is a generic account for our department. No patient information or individualized accounts will be needed. No patient information or data will be collected.
89599472|NCT06296147|Experimental|Aromatherapy|The aromatherapy arm will utilize one standardized patch with a peppermint/lavender scent based on prior research and experience.
89599473|NCT06296147|Experimental|Virtual Reality and Aromatherapy|This arm will combine both the Virtual Reality arm and the aromatherapy arm procedure.
89599474|NCT06296147|Active Comparator|Standard of Care|Participant will undergo transperineal prostate biopsy as standard of care.
89599475|NCT06296134|Experimental|perineal massage|participants randomized to this arm are asked to perform themselves the perineal massage once daily from 34 gestational weeks until delivery.
89599476|NCT06296134|No Intervention|standard care|participants randomized to this arm are asked to care for their pelvic floor according to the standard practice, which includes healthy diet, weight gain control, physical activity and voiding training therapy.
89599477|NCT06296121|Experimental|BCD-264|"Blinded period: BCD-264 (daratumumab) will be administered intravenously once weekly for the first 8 weeks (Cycles 1 and 2), then once every two weeks for 16 weeks (Cycles 3, 4, 5 and 6). The total duration of the blinded treatment period is 6 cycles.~Open-label period: starting from Day 1 of Cycle 7, the subjects will receive open-label BCD-264 once every 4 weeks"
89599478|NCT06296121|Active Comparator|Darzalex|"Blinded period: Darzalex (daratumumab) will be administered intravenously once weekly for the first 8 weeks (Cycles 1 and 2), then once every two weeks for 16 weeks (Cycles 3, 4, 5 and 6). The total duration of the blinded treatment period is 6 cycles.~Open-label period: starting from Day 1 of Cycle 7, the subjects will receive open-label BCD-264 once every 4 weeks"
89599479|NCT06296095|Experimental|Single arm|cell therapy
89599480|NCT06296082|Active Comparator|Botox Intervention|Intramuscular approach with guidance of EMG or Ultrasound. Reconstitute with: 1 vial of 100 BOTOX Units with 1 ml of sterile unpreserved normal saline (which means 10 BOTOX units per 0.1 ml normal saline). The normal saline indicates 0.9% sodium chloride solution for injection. Recommended needle: preferred caliber 30 gauge
88979823|NCT00322972|Other|A|Annual mass treatment
88979824|NCT00322972|Other|B|Biannual mass treatment
88811949|NCT01511315|Experimental|Ustekinumab|
88811950|NCT01654536|Experimental|ciclesonide nasal aerosol|ciclesonide nasal aerosol 74 mcg
88811951|NCT01654536|Active Comparator|ciclesonide nasal spray|ciclesonide nasal spray 200 mcg
88811952|NCT01654380|Experimental|Part A, Cohort A; LY2605541|Healthy participants received 5.1 milliunits/minute (mU/min) in Period 1, 10.2 mU/min in Period 2, and 15.3 mU/min in Period 3, administered intravenously (IV) over 8 hours. All periods were separated by a minimum 6-day washout period
88811953|NCT01654380|Active Comparator|Part A, Cohort A; Insulin Glargine|Healthy participants received insulin glargine (30 milliunits/meter squared/minute [mU/m^2/min]) administered IV over 8 hours in Period 4. All periods were separated by a minimum 6-day washout period
88811954|NCT01654380|Experimental|Part A, Cohort B; LY2605541|Healthy participants received 15.3 mU/min in Period 1, 37.0 mU/min in Period 2, and 74.1 mU/min in Period 3, administered IV over 8 hours. All periods were separated by a minimum 6-day washout period.
88811955|NCT01654380|Active Comparator|Part A, Cohort B; Insulin Glargine|Healthy participants received insulin glargine (60 mU/m^2/min) administered IV over 8 hours in Period 4. All periods were separated by a minimum 6-day washout period.
88811956|NCT01654380|Experimental|Part B; LY2605541|Participants with T1DM received 15.3 mU/min in 1 of 4 study periods, administered IV up to 8 hours and received 74.1 mU/min in 1 of 4 Periods, administered IV up to 10 hours. Each dose was separated by a minimum 6-day washout period.
88811957|NCT01654380|Active Comparator|Part B; Insulin Glargine|Participants with T1DM received 1 insulin glargine dose per study period (10 and 20 mU/m^2/min) administered IV over 8 hours in 2 of 4 study periods. Each dose was separated by a minimum 6-day washout period.
88811958|NCT02477670|Placebo Comparator|Placebo|Placebo capsules administered twice a day over a 12-week period
88811959|NCT02477670|Experimental|AVP-786|AVP-786 dose 2 capsules administered twice a day over a 12-week period
88811960|NCT02509026|Experimental|Etanercept|etanercept 50 mg QW
88811961|NCT03439280|Experimental|Phase 1 Dose Escalation Cohort: Mezagitamab 45 mg|Mezagitamab 45 mg, subcutaneously (SC), once weekly for 8 weeks, then once every 2 weeks for 16 weeks, and then once every 4 weeks thereafter in a 28-day treatment cycle until progressive disease (PD), unacceptable toxicities or withdrawal due to other reasons.
88811962|NCT03439280|Experimental|Phase 1 Dose Escalation Cohort: Mezagitamab 135 mg|Mezagitamab 135 mg, SC, once weekly for 8 weeks, then once every 2 weeks for 16 weeks, and then once every 4 weeks thereafter in a 28-day treatment cycle until PD, unacceptable toxicities or withdrawal due to other reasons.
88811963|NCT03439280|Experimental|Phase 1 Dose Escalation Cohort: Mezagitamab 300 mg|Mezagitamab 300 mg, SC, once weekly for 8 weeks, then once every 2 weeks for 16 weeks, and then once every 4 weeks thereafter in a 28-day treatment cycle until PD, unacceptable toxicities or withdrawal due to other reasons.
89599481|NCT06296082|Active Comparator|Dry Needling Intervention|The puncture is intramuscular and is performed with a non-beveled needle of 0.3 mm caliber, filiform, solid, similar to those used in acupuncture, which has been shown to produce less damage at the muscle level. It does not inject any substance. The same muscles as in BTX A will be stimulated with repeated insertions to try to provoke at least one Local Twitch Response (LTR) at each muscle location. If no LTR is found, the therapist will continue trying to find an LTR in another location. The intervention is performed under ultrasound guidance (Butterfly portable US), although the physiotherapist may provoke an electric stimulation of the Myofascial Trigger Point (MTrP) to confirm the area of the end plate (motor unit), similarly to the EMG procedure that uses motor stimulation to confirm the injection area of the BTX A.
89599482|NCT06296069|Experimental|Intervention group|"The intervention group will conduct an exergame-based cognitive-motor intervention on a unstable surface (on top of their standard inpatient treatment).~Intervention duration will be tailored to the stay in the inpatient rehabilitation clinic (3-4 weeks). Training sessions will last 20-28 minutes (progressive increase)."
89599483|NCT06296069|Active Comparator|Control group|"The intervention group will conduct an exergame-based cognitive-motor intervention on a stable surface (on top of their standard inpatient treatment).~Intervention duration will be tailored to the stay in the inpatient rehabilitation clinic (3-4 weeks). Training sessions will last 20-28 minutes (progressive increase)."
89599484|NCT06296056|Experimental|Combi|Dendritic cell+NK cell+Cytotoxic T cell
89599485|NCT06296030|Experimental|Classic ACT program|Participants will engage in pre-test measures (anxiety, race-based stress, and psychological flexibility). Subjects will then participate in a 12-week telehealth group (once a week, 2 hours a week) with other group members where a classic Acceptance and Commitment Therapy protocol will be administered. After this, participants will engage in post-test measures.
89599486|NCT06296030|Experimental|POOF ACT program|Participants will engage in pre-test measures (anxiety, race-based stress, and psychological flexibility). Subjects will then participate in a 12-week telehealth group (once a week, 2 hours a week) with other group members where an Acceptance and Commitment Therapy protocol will be administered that has been culturally tailored to address African American racial trauma. After this, participants will engage in post-test measures.
89599487|NCT06296017|Experimental|Extracorporeal Shock Wave Therapy|Extracorporeal Shock Wave Therapy (ESWT for short) application will be performed on A1 pulley at 15 Hz, 1000 beats, and 2.0 bar level, for a total of 5 sessions, one week apart.
89599488|NCT06296017|Experimental|Trigger Finger Splint|A trigger finger splint that immobilizes the MCF joint will be recommended for the splint treatment group. The patient will be asked to use this splint throughout the day for 8 weeks.
89599489|NCT06296017|Experimental|Extracorporeal Shock Wave Therapy+Trigger Finger Splint|Splint treatment will be applied together with ESWT. ESWT application will be performed on A1 pulley at 15 Hz, 1000 beats, and 2.0 bar level, in a total of 5 sessions, one week apart. A trigger finger splint that immobilizes the MCF joint will be recommended for the splint treatment group. The patient will be asked to use this splint throughout the day for 8 weeks.
88979825|NCT00322972|Experimental|C|Mass administration of antibiotic; treatment of children (1-10 years of age) only
88979826|NCT00322972|No Intervention|D|Delayed initiation of mass administration of antibiotic
88979827|NCT00322972|Other|F|One-time mass administration only
88979828|NCT00322972|Experimental|G|One-time mass administration of antibiotics, plus intensive latrine construction
88979829|NCT00323011|Active Comparator|Arm A: 5-FU/LV/CPT-11/Bevacizumab|5-FU 400 mg/m2, days 1, 15, & 29 Leucovorin Calcium 200 mg/m2, days 1, 15, & 29 CPT-11 180 mg/m2, days 1, 15 & 29 Bevacizumab 5mg/kg, days 1, 15, & 29
88979830|NCT00323011|Experimental|Arm B: 5-FU/LV/CPT-11/Bevacizumab + Dalteparin|5-FU 400 mg/m2, days 1, 15, & 29 5-FU 2400 continuous infusion days 1-2, 15-16, 29-30. Leucovorin Calcium 200 mg/m2, days 1, 15, & 29 CPT-11 180 mg/m2, days 1, 15 & 29 Bevacizumab 5mg/kg, days 1, 15, & 29 Dalteparin 5000 IU subcutaneous starting cycle 2, days 1, 15, & 29
88979831|NCT00323011|Experimental|5-FU/LV/CPT-11/Bevacizumab+Dalteparin daily|5-FU 400 mg/m2, days 1, 15, & 29 5-FU 2400 continuous infusion days 1-2, 15-16, 29-30. Leucovorin Calcium 200 mg/m2, days 1, 15, & 29 CPT-11 180 mg/m2, days 1, 15 & 29 Bevacizumab 5mg/kg, days 1, 15, & 29 Dalteparin 5000 IU subcutaneous starting cycle 2, daily
88979832|NCT02965235||non-POCD|Patients who don't develop POCD after surgery.
88979833|NCT02965235||POCD|Patients who develop POCD after surgery.
88979834|NCT00323089|Experimental|Surgical Arm|Preoperative CT-Guided Microcoil Localization (CTML) and Fluoroscopic-Guided Video-Assisted Thoracoscopic (VATS) Wedge Resection of Small Peripheral Pulmonary Nodules (SPPN)
88979835|NCT00323206|Experimental|Intra-tumoral Electroporation of pIL-12|Participants will receive intra-tumoral injection of pIL-12 followed immediately by electrical discharge around the tumor site resulting in electroporation of plasmid DNA into tumor cells. For each lesion selected for therapy, a total of three electroporation treatments will be performed.
88979836|NCT04730102||Patients undergoing rectal washout in transanal mesorectal excision|Patients undergoing rectal washout in transanal mesorectal excision for rectal cancer.
88979837|NCT04717531|Experimental|Cohort A|"2 cycles of pyrotinib and trastuzumab with docetaxel followed by 4 cycles of pyrotinib, epirubicin, and cyclophosphamide (THB*2-ECB*4). The cycles repeated every 21 days.~Pyrotinib: 400mg, qd, po, day 1-21; Trastuzumab: 6 mg/kg, day 1; Docetaxel: 100 mg/m2, day 1; Epirubicin: 90 mg/m2, day 1; Cyclophosphamide: 600 mg/m2, day 1."
88979838|NCT04717531|Active Comparator|Cohort B|"2 cycles of trastuzumab and pertuzumab with docetaxel followed by 4 cycles of epirubicin and cyclophosphamide (THP*2-EC*4). The cycles repeated every 21 days.~Trastuzumab: 6 mg/kg, day 1; Pertuzumab: 420 mg, day 1; Docetaxel: 100 mg/m2, day 1; Epirubicin: 90mg/m2, day 1; Cyclophosphamide: 600 mg/m2, day 1."
88979839|NCT04728789|Experimental|Avatrombopag treatment group|Avatrombopag would be started with 20mg/day. The dosage would be increased by 20 mg/day every 2 weeks if the platelet count remains less than 20×10e9/L and reduced if the platelet count reaches over than 150×10e9/L. The dosage could range from 20mg/week to 60mg/day.
88979840|NCT05085158||Group 1|HIV-infected children with non-malarial febrile illnesses (NMFIs) less than 5 years old
89599490|NCT06296004||adult patient with Behçet's Disease|. Adult BD patients who fulfilling the criteria for the diagnosis by International Team for the Revision of the International Criteria for Bechet's Disease .
88979841|NCT05085158||Group 2|HIV-infected children and adolescents with non-malarial febrile illnesses (NMFIs) but less than 15 years old
89599491|NCT06296004||healthy subjects|apparently healthy subjects
89599492|NCT06295991|Experimental|study group|wearing lycra garment
89599493|NCT06295991|Placebo Comparator|control group|wearing non-lycra garment
89599494|NCT06295952|Experimental|Pasireotide|All patients will initiate open-label treatment with pasireotide LAR on week 1 in the outpatient setting. Pasireotide will be initiated at 40 mg IM one time dose and if tolerated dose will be increased to 60 mg IM every 4 weeks +/-7 days. Administration of pasireotide will align with package inset. Patients must return to the study center every 28 days (+/- 7 days) to receive study medication and for evaluation.
89599495|NCT06295926|Experimental|Study arm|Concurrent radiotherapy with chemotherapy (Etoposide+Cisplatin/Carboplatin) with Serplulimab, and followed by consolidation Serplulimab
89599496|NCT06295913|Experimental|Capsule of an olive extract with a high content of hydroxytytorosol (Hytolive®). Group 1|Intake of one capsule (Hytolive®)/day containing 15 mg of hydroxytyrosol before breakfast for 16 weeks.
89599497|NCT06295913|Active Comparator|Capsule of placebo. Group 2|Intake of one capsule placebo/day without hydroxytyrosol before breakfast for 16 weeks.
89599498|NCT06295900|Active Comparator|Intervention 1 Group|In this group, application is made with chamomile, lavender and neroli oil.
89599499|NCT06295900|Sham Comparator|Intervention 2 Group|In this group, application is made with lavender oil.
89599500|NCT06295900|Placebo Comparator|Placebo Control Group|In this group, application is made only with almond oil.
89599501|NCT06295874|Active Comparator|Intervention Group|After obtaining written and verbal permission from the families of the patients in the intervention group by signing the Informed Volunteer Consent Form, the patients were filled out the Patient Introduction Form, Patient Monitoring Form and Medication Monitoring Form by the nurses. The massage process, which was performed according to the application protocol of the aroma oil prepared for the patients (5 drops of lavender oil, 4 drops of thyme oil, 3 drops of eucalyptus oil and 20 ml of almond oil in 20 ml), was performed by the researcher by stroking the patient's back and chest, effleurage, re-effleurage, back massage. Deep caressing and stroking on the dorsal surface were performed in 6 consecutive steps.
89599502|NCT06295874|Placebo Comparator|Placebo Control Group|After obtaining written and verbal approval from the families of the patients included in the placebo control group by signing the Informed Volunteer Consent Form, the patients were filled out the Patient Introduction Form, Patient Monitoring Form and Medication Monitoring Form by the nurses. According to the oil application protocol, the massage with almond oil was performed by the researcher in 6 consecutive steps by stroking the patient's back and chest, effleurage, re-effleurage, deep stroking of the back and stroking the back surface.
89599503|NCT06295861||ASCVD cohort|The patient had atherosclerosis in 2 or more vessels
89599504|NCT06295861||healthy cohort|The patient had no atherosclerosis in vessels
89599505|NCT06295822|Experimental|Nuan-gong-ye|
89599506|NCT06295822|Placebo Comparator|Placebo|
89599507|NCT06295783||Head and Neck Cancer (HNC) Questionnaire|"Participants will be asked to fill out three head and neck cancer (HNC) questionnaires during your visits to the clinic:~The MDASI-HN questionnaire (standard-of-care) has 28 questions.~The EORTC QLQ-HN35 questionnaire has 35 questions.~The EORTC QLQ-30 questionnaire has 30 questions."
89599508|NCT06295770|Experimental|Obinutuzumab in Treatment of Fibrillary Glomerulonephritis|Patients with biopsy proven fibrillary GN who have >1 gram/24 hour of proteinuria and eGFR ≥ 20 ml/min/BSA will be treated with Obinutuzumab.
89599509|NCT06295757|Other|Continuous Smoking|"During the study visits, measures will be taken before and after participants smoke their own usual brand cigarette one continuously. Participants will be randomly assigned to continuous smoking or relight smoking conditions. Participants randomized to the continuous smoking condition will crossover to the relight smoking condition after 60 minutes on their first visit.~Visits will be separated by 7-10 days, to ensure there are 2 weekdays and 1 weekend day falling in that period for cigarette butt collection.~On the second visit, participants will begin with the second smoking condition they were assigned on their first visit. They will crossover to the remaining condition after 60 minutes. Participants initially assigned to the continuous smoking condition will begin their second visit with the relighting smoking condition and cross over to the continuous smoking condition after the 60 minutes."
89599510|NCT06295757|Other|Relight Smoking|"During the study visits, measures will be taken before and after participants smoke their own usual brand cigarette one continuously. Participants will be randomly assigned to continuous smoking or relight smoking conditions. Participants randomized to the relight smoking condition will crossover to the continuous smoking condition after 60 minutes on their first visit.~Visits will be separated by 7-10 days, to ensure there are 2 weekdays and 1 weekend day falling in that period for cigarette butt collection.~On the second visit, participants will begin with the second smoking condition they were assigned on their first visit. They will crossover to the remaining condition after 60 minutes. Participants initially assigned to the relighting smoking condition will begin their second visit with the continuous smoking condition and cross over to the relighting smoking condition after the 60 minutes."
89599511|NCT06295731|Experimental|INBRX-106 plus pembrolizumab|Participants will receive INBRX-106 plus pembrolizumab, both given by intravenous (IV) infusion every 3 weeks (QW3)
89210175|NCT00983229|Active Comparator|CTrach|"Induction to GA with 1mcg/kg fentanyl, and 1-3 mg/kg of propofol to loss of verbal contact and neuromuscular relaxation with 0.5 mg/kg of atracurium.~Direct laryngoscopy, evaluation of laryngeal view grade according to Cormack-Lehane classification.~Insertion of CTrach (sizes 3,4 or 5), establishment of ventilation.~Direct evaluation of laryngeal view through CTrach~Tracheal intubation through CTrach LMA~Maintenance of anaesthesia with 02, air and sevoflurane 1-2 MAC and positive pressure ventilation~At the end of surgery patient will be awoken as normal. Any sign of trauma to the oral cavity and airways and gastric fluid in trachea will be noted."
89210176|NCT00983229|Active Comparator|Intubating Laryngeal Mask Airway (ILMA)|"Induction to GA with 1mcg/kg fentanyl, and 1-3 mg/kg of propofol to loss of verbal contact and neuromuscular relaxation with 0.5 mg/kg of atracurium.~Direct laryngoscopy, evaluation of laryngeal view grade according to Cormack-Lehane classification.~Insertion of ILMA (sizes 3,4 or 5), establishment of ventilation.~Evaluation of laryngeal view through ILMA using fibrescope~Tracheal intubation through ILMA using fibrescope.~Maintenance of anaesthesia with 02, air and sevoflurane 1-2 MAC and positive pressure ventilation~At the end of surgery patient will be awoken as normal. Any sign of trauma to the oral cavity and airways and gastric fluid in trachea will be noted."
89599512|NCT06295731|Active Comparator|pembrolizumab monotherapy (+ placebo in phase 3 part)|Participants will receive pembrolizumab (plus placebo in Phase 3), given by intravenous (IV) infusion every 3 weeks (QW3)
89599513|NCT06295718||Ambulatory Children with Duchenne Muscular Dystrophy|"Participants who meet the inclusion criteria will be evaluated synchronously online using the Zoom platform in terms of the functional performance and quality of life parameters specified below, after ensuring the presence of a suitable environment and a stable internet connection. During the online evaluation, patients will be asked to perform the specified functions in front of the camera. In addition, the survey questions necessary to evaluate the quality of life will be expressed verbally to the participants. Inter-rater reliability will be examined by comparing the scores after being performed separately by two different physiotherapists. The reliability and validity of the online assessment will be investigated by repeating the same assessments online and face-to-face.~Timed Performance Tests~Upper Extremity Functions~Lower Extremity Functions~Quality of Life"
89599514|NCT06295666||Healty|Periodontal healty group
88979842|NCT00323323|Experimental|Alemtuzumab/CHOP|For all patients enrolled, the study will begin with a stepped-up schedule of single agent Alemtuzumab given subcutaneously (SQ) on week #1. Dose escalation will occur during the first week of therapy, starting with 3 mg of Alemtuzumab administered SQ on day 1. If well tolerated, this will be followed by 10 mg SQ on day 3 and 30 mg (split into 2 injection sites) on day 5. Plasma samples will be obtained for Alemtuzumab pharmacokinetics (PK) during the first week of single agent Alemtuzumab stepped up dosing and subsequently before and after the 5th and the 8th Alemtuzumab/CHOP dose
89599515|NCT06295666||Periodontitis|Periodontitis group
89599516|NCT06295653|Active Comparator|Autogenous Subepithelial Connective Tissue Graft plus dental implants|implant placement and augment Subepithelial Connective Tissue Graft and suture implant site
89599517|NCT06295653|Active Comparator|Amniotic Chorion Membrane plus dental implant|implant placement and augment Amniotic Chorion Membrane and suture implant site
89599518|NCT06295627||Infected group|The infection group consisted of patients with urinary tract infection (13 cases)
89599519|NCT06295627||Non-infected group|Non-infection group The first group consisted of patients without urinary tract infection (278 cases)
89599520|NCT06295601|Experimental|Experimental group|Individuals will receive standard rehabilitation and telerehabilitation-based motor imagery and action observation therapy.
89599521|NCT06295601|Experimental|Control group|Individuals will receive standard rehabilitation.
89599522|NCT06295588|Experimental|Fucoidan|They will receive 4 grams daily of fucoidan extracted from F. Vesiculosus for 8 weeks.
89599523|NCT06295588|Active Comparator|Usual Care|They will receive usual care for 8 weeks followed by 4 grams daily of fucoidan extracted from U. Pinnatifida for 8 weeks.
89599524|NCT06295575|Active Comparator|Treatment group|In treatment group, patients received 1×109 colony forming units (CFU) /day of probiotic, which was provided by Hangzhou Grand Biologic Pharmaceutical INC (Zhejiang, China) in the form of freeze-dried powder containing Bifidobacterium infantis and Lactobacillus with a density of 109 CFU/g. The probiotic powder was mixed with lactose and portioned into sachets with the help of Nanjing Medical University Central Pharmacy.
89599525|NCT06295575|Placebo Comparator|Control group|Patients in the control group received lactose as placebo. The placebo was packed in sachets and provided in the same way as treatment group.
89599526|NCT06295549|Experimental|Experimental: LUCAR-G39P cells product|Each subject will be given a single-dose LUCAR-G39P cells infusion at each dose level.
89599527|NCT06295536|Experimental|Photorefraction prototype device|- Photoretinoscopic images without cycloplegia
89599528|NCT06295523|Experimental|Experimental: Very hot and dry|Subjects will be exposed to 3 hours in a climate chamber set to approximately 47 deg C and 15% relative humidity, which reflects a very hot and dry heat wave condition similar to the 2018 Los Angeles heat wave. Two visits will be required to complete this arm, with one visit including water spray for cooling.
89599529|NCT06295523|Experimental|Experimental: Hot and humid|Subjects will be exposed to 3 hours in a climate chamber set to approximately 41 deg C and 40% relative humidity, which reflects hot and humid heat wave similar to the 1995 Chicago heat wave. Two visits will be required to complete this arm, with one visit including water spray for cooling.
88979843|NCT00323401|Experimental|Interventon|Antenatal classes for the parents
89599530|NCT06295510||healthy group (HG)|"Participants were grouped according to their basic conditions without any intervention.~no intervention It's only observational study. No interventions."
88979844|NCT00323401|No Intervention|Control|No programme are offered
88979845|NCT00323440||Group 1|FMF patients in remission
88979846|NCT00323440||Group 2|FMF patients during attack
88979847|NCT00323440||Group 3|FMF patients without colchicine in remission
88979848|NCT00323440||Group 4|FMF patients without colchicine in attack
88979849|NCT00312598||aripiprazole|observational measures of metabolic parameters of subjects who are making clinically determined medication switch to aripiprazole
89599531|NCT06295510||case group（PG）|"Participants were grouped according to their basic conditions without any intervention.~no intervention It's only observational study. No interventions."
89599532|NCT06295497|Other|Artificial intelligence-based programme (Lung-SIGHT)|Artificial intelligence (AI) algorithms have been demonstrated to function well and complement radiologists as second or concurrent readers in pulmonary nodule detection. AI Lung nodule detection and quantification solution are now widely used in the hospitals in the United Kingdom and at least eight other European countries. The sensitivity of nodule detection by radiologists increased from 72% to 80% with the aid of the AI programme. A clinical trial in Taiwan showed that using AI programme alone achieved an overall sensitivity of 95.6% in nodule detection, and superior performance in detecting nodule sized 4-5 mm comparing to radiologists. Overall, application of AI in CT analysis and lung nodule detection may significantly reduce the cost and workload of radiologist.
89599533|NCT06295484|Other|Traditional CPAP, then NIPPV, then high CPAP.|The participant will stay for 2 hours on Traditional CPAP, then 2 hours on NIPPV, then 2 hours on high CPAP. The investigators will continue to record the Edi signals during the 3 methods.
89599534|NCT06295484|Other|Traditional CPAP, then high CPAP, then NIPPV|The participant will stay for 2 hours on Traditional CPAP, then 2 hours on high CPAP, then 2 hours on NIPPV. The investigators will continue to record the Edi signals during the 3 methods.
89599535|NCT06295484|Other|NIPPV, then traditional CPAP, then high CPAP|The participant will stay for 2 hours on NIPPV, then 2 hours on traditional CPAP, then 2 hours on high CPAP. The investigators will continue to record the Edi signals during the 3 methods.
89599536|NCT06295484|Other|NIPPV, then high CPAP, then traditional CPAP.|The participant will stay for 2 hours on NIPPV, then 2 hours on high CPAP, then 2 hours on traditional CPAP. The investigators will continue to record the Edi signals during the 3 methods.
89599537|NCT06295484|Other|High CPAP, then traditional CPAP, then NIPPV.|The participant will stay for 2 hours on High CPAP, then 2 hours on traditional CPAP, then 2 hours on NIPPV. The investigators will continue to record the Edi signals during the 3 methods.
89599538|NCT06295484|Other|High CPAP, then NIPPV, then traditional CPAP.|The participant will stay for 2 hours on High CPAP, then 2 hours on NIPPV, then 2 hours on traditional CPAP. The investigators will continue to record the Edi signals during the 3 methods.
89599539|NCT06295471|Experimental|Treatment|23 healthy subjects with treatment of the DFG and CO2 laser
89210177|NCT00983229|Active Comparator|I-gel|"Induction to GA with 1mcg/kg fentanyl, and 1-3 mg/kg of propofol to loss of verbal contact and neuromuscular relaxation with 0.5 mg/kg of atracurium.~Direct laryngoscopy, evaluation of laryngeal view grade according to Cormack-Lehane classification.~Insertion of I-gel (sizes 3,4 or 5), establishment of ventilation.~Evaluation of laryngeal view through I-gel using fibrescope~Tracheal intubation through I-gel using fibrescope~Maintenance of anaesthesia with 02, air and sevoflurane 1-2 MAC and positive pressure ventilation~At the end of surgery patient will be awoken as normal. Any sign of trauma to the oral cavity and airways and gastric fluid in trachea will be noted."
89599540|NCT06295458|Experimental|Treatment Group|Participants will receive flicker exposure (via a light and sound device-based stimulation)
89599541|NCT06295458|Sham Comparator|Control Group|Participants will receive sham stimulation
89599542|NCT06295393||Pediatric Septic|1 day -18 year olds admitted to the ICU meeting criteria for sepsis define as pSOFA >/= 2 and/or Phoenix score.
89599543|NCT06295393||Healthy|1 day - 18 year old; healthy outpatient
89599544|NCT06295380|Experimental|Virtual environment practiced on the Caren|Caren virtual training phase plus conventional physiotherapy phase
89599545|NCT06295380|Active Comparator|Conventional physiotherapy|Conventional physiotherapy phase plus Caren virtual training phase
89599546|NCT06295354||20-30 years old|The target population consists of 1000 participants, equally distributed over different age groups (20-30, 30-40, 40-50, and 50-60 years old) and sex. Main exclusion criteria are any systemic condition or medication apart from cardiometabolic disorders, pregnancy at inclusion or recent vaccinations. Individuals will be compared over time, and age groups will be compared over time and per time point. None of the age groups will get an intervention, the goal is to observationally study them.
89599547|NCT06295354||3-40 years old|The target population consists of 1000 participants, equally distributed over different age groups (20-30, 30-40, 40-50, and 50-60 years old) and sex. Main exclusion criteria are any systemic condition or medication apart from cardiometabolic disorders, pregnancy at inclusion or recent vaccinations. Individuals will be compared over time, and age groups will be compared over time and per time point. None of the age groups will get an intervention, the goal is to observationally study them.
88979850|NCT00312949|Experimental|1|Participants will use the interactive website
89599548|NCT06295354||40-50 years old|The target population consists of 1000 participants, equally distributed over different age groups (20-30, 30-40, 40-50, and 50-60 years old) and sex. Main exclusion criteria are any systemic condition or medication apart from cardiometabolic disorders, pregnancy at inclusion or recent vaccinations. Individuals will be compared over time, and age groups will be compared over time and per time point. None of the age groups will get an intervention, the goal is to observationally study them.
89599549|NCT06295354||50-60 years old|The target population consists of 1000 participants, equally distributed over different age groups (20-30, 30-40, 40-50, and 50-60 years old) and sex. Main exclusion criteria are any systemic condition or medication apart from cardiometabolic disorders, pregnancy at inclusion or recent vaccinations. Individuals will be compared over time, and age groups will be compared over time and per time point. None of the age groups will get an intervention, the goal is to observationally study them.
89599550|NCT06295341||cases - children with familial short stature|- 35 children, aged between 6 and 14 years, of both sexes, with familial short stature (height < 3rd centile according to the Italian reference standards) and their caregivers of reference. Children with familial short stature will be characterized by: short stature in other members of the family group, not necessarily the parents, harmonious appearance, without particular clinical signs and normal pubertal development, parallel growth curve below the 3rd centile, bone age corresponding to chronological age. Children and teenagers with obesity (BMI > 97th centile) will be excluded
89599551|NCT06295341||cases - children with normal height|35 children, aged between 6 and 14 years, of both sexes, with normal height (height > 25th centile) and weight.
88979851|NCT00312949|Active Comparator|2|Participants will read written materials and watch a video
88979852|NCT00313105|Experimental|Smokeless Tobacco|Smokeless Tobacco and individual visits
89210178|NCT04035876|Experimental|Camrelizumab plus apatinib|
88979853|NCT00313105|Active Comparator|Nicotine tablets|Nicotine tablets
88979854|NCT00313105|Placebo Comparator|3|7-mg nicotine patch acts as placebo
88979855|NCT04994756||Stroke|
88979856|NCT04994756||Thrombectomy|
88979857|NCT04994756||Aneurysm|
88979858|NCT00313183|Experimental|1|single doses of pramlintide acetate or placebo, given in three different sequences to three cohorts of subjects
88979859|NCT06003335|Experimental|IG|The intervention group will receive personalised motivational messages (according to their physical activity levels and preferences screened during the baseline measurement) using instant messaging applications (e.g., WhatsApp). They will be equipped with a wearable activity tracker for 3 months to monitor their physical activity level. In accordance with the guidelines for mobile instant messageing development, we will develop a message content library and protocol for intervention delivery.
89599552|NCT06295341||cases - children with growth hormone deficiency|"10 children, aged between 6 and 14 years, of both sexes, affected by isolated GH deficiency according to the criteria established by AIFA note 39 for this pathology (short stature: ≤ -3 SD or ≤ -2 SD and growth velocity/year ≤ -1.0 SD for age and sex evaluated at least 6 months apart and peak GH at two different pharmacological stimulus tests < 8 ng/ml). The exclusion criterion from the present study (and from treatment with rhGH) will be the presence of organic pathologies at the hypothalamic-pituitary level (assessed by performing brain MRI).~Children with GH deficiency are evaluated in baseline conditions and after 6 months of therapy with recombinant DNA GH (at a dose of 0.025-0.035 mg/kg of body weight per day (or 0.7-1.0 mg/m2 of body surface area per day)."
89599553|NCT06295328|Active Comparator|NUC + Study drug|Tenofovir + Terbinafine
89599554|NCT06295328|Placebo Comparator|NUC + Placebo|Tenofovir + Placebo
89599555|NCT06295328|Active Comparator|Study drug|Terbinafine
89599556|NCT06295328|Placebo Comparator|Placebo|Placebo
89599557|NCT06295289|Experimental|Hybrid closed-loop insulin delivery system group|After patients signed the informed consent form in the ward, the nurse installed the insulin pump and the subcutaneous, real-time, continuous glucose monitor (CGM). The insulin pump was installed in the abdomen or upper arm, and the CGM was installed in the upper arm. A Hybrid closed-loop insulin delivery system with an open-source algorithm was set up for participants by the clinical trial investigators. The algorithm was initialised with participant's weight and basal insulin requirements. The control algorithm modulated insulin delivery every 5 min based on the CGM glucose level, anticipated glucose trends, and patient-specific information such as the basal rate profile to guarantee blood glucose control within the target range. The perioperative patients in the hybrid closed-loop insulin delivery group who were admitted to the hospital received about 7 days of glucose-lowering therapy.
89599558|NCT06295289|Placebo Comparator|Insulin pump therapy group (Control group)|The insulin treatment with a pump and CGM was applied according to the local clinical guidelines. The insulin pump was installed in the abdomen or upper arm, and the CGM was inserted in the upper arm by the investigator. Doctors adjust the insulin dose according to the patient's glucose level.
89599559|NCT06295276|Experimental|Intervention|a six-week muscle training program with 5 exercises 3 times a week as video-guided exercises for homework alone and the same exercises once a week guided by Zoom. The program lasts 6 weeks
89599560|NCT06295276|Other|waiting list|After the 6 weeks, participants are offered the opportunity to take part in the intervention program (see above)
89599561|NCT06295250|Active Comparator|Depression Treatment (DT)|Participants in the control group will receive a 6 month manualized group based psychotherapy treatment..
89599562|NCT06295250|Experimental|Integrated Intervention|"The experimental arm includes 2 elements:~A poverty alleviation intervention~The psychotherapy intervention described above."
89599563|NCT06295224||Anterior Iliac Block|Patients who were performed anterior iliac block with ultrasound guidance with 10-20 mL 0.25% bupivacaine.
89599564|NCT06295185|Experimental|mental health treated with digital intervention app 'Maro'|"Intervention group will use 'Maro app' which was developed to improve mental health for 8weeks.~Through 8weeks intervention group will record their status more than once a day and utilize specific functions in the app.~They will also have meetings once a week in the online chat in order to share their own experience about Maro application use with other employees in the same branch."
89599565|NCT06295185|Sham Comparator|Digital Sham App|Control group will use Sham app for 8weeks.
89599566|NCT06295172|Experimental|Lafullen15|PCL
89599567|NCT06295172|Active Comparator|Lafullen|PCL
89599568|NCT06295146|Experimental|Active intervention (intervention A)|Active intervention (intervention A) which will include training through peer coaching
89599569|NCT06295146|Active Comparator|Waitlist control group|Waitlist control group that will receive the same intervention A but at 6 months
89599570|NCT06295146|Active Comparator|Self-study intervention|Self-study intervention with review of educational materials
88979860|NCT06003335|Active Comparator|CG 1|Control group 1 will receive regular message delivery (as mentioned in the intervention) without personalised motivational messaging for better evaluation of the effect of personalized motivational messaging.
88979861|NCT06003335|No Intervention|CG 2|Control group 2 (self-management) will only receive a leaflet containing basic information about CRCI distributed during the recruitment process and text message reminders for follow-up surveys. Regular and real-time support (i.e., chat-type) messages will not be made available to the control group.
88979862|NCT06003322|Experimental|non - Incised Papilla surgical approach NIPSA for intrabony defect|Group I will be allocated to non - Incised Papilla surgical approach NIPSA for intrabony defect with DBBM and PRF
88979863|NCT06003322|Active Comparator|single-flap approach|group II will be allocated to single-flap approach SFA for intrabony defect with DBBM and PRF
88979864|NCT06003296|Other|Screw fixation|Calcaneocuboid arthrodesis in triple arthrodesis by Screw fixation
89599571|NCT06295133|Experimental|Stress intervention|One arm : all volunteers will receive a stress management intervention.
89599572|NCT06295107||Spastic leg|Children with spastic hemiplegic cerebral palsy.
89599573|NCT06295107||Non spastic leg|Children with spastic hemiplegic cerebral palsy.
89599574|NCT06295094|Experimental|Pressurized intraperitoneal chemotherapy (PIPAC)|"In the intervention arm, conventional pressurized intraperitoneal chemotherapy (PIPAC) with cisplatin (10.5 mg/m2 body surface in 150ml saline) and doxorubicin (2.1 mg/m2 body surface in 50ml saline) is performed through Medical Device Regulation (MDR) class IIb the CE-certified nebuliser by certified PIPAC surgeons directly after the completion of the minimally invasive gastric resection and reconstruction using the remaining relevant ports. Chemotherapy is administered through a CE-certified nebulizer according to the manufacturer's manual and followed by 30 minutes of simple diffusion. The carbondioxide is evacuated through a closed system, and the abdominal wall is closed according to local surgical standards.~The same procedure is repeated, incorporating the same compounds and dose regimens six to eight weeks postoperatively and before the start of the adjuvant part of the perioperative systemic chemotherapy."
88979865|NCT06003270|Active Comparator|Quercetin 1000 mg/day|Quercetin 1000 mg/day Quercetin is provided as caplet and each caplet will have 500 mg of quercetin Quercetin will be administered orally twice daily, one half dose (1 caplet) in the morning after breakfast and one half dose (1 caplet) in the evening after dinner for six months.
89599575|NCT06295094|No Intervention|Standard|In the control arm, patients will undergo minimally invasive D2 gastrectomy
89599576|NCT06295081||Walkers|Amateur athletes who perform a walking exercise with a minimum distance of 20 km
89599577|NCT06295081||Runners|Amateur athletes who perform a running exercise with a minimum distance of 15 km
89599578|NCT06295081||Cyclists|Amateur athletes who perform a cycling exercise with a minimum distance of 100 km
89599579|NCT06295055|Experimental|semi-rigid shell barrier system|"The semi-rigid shell barrier system is based on polycaprolactone (PCL) and biphasic calcium phosphate (BCP) in a 70:30 ratio.~In vitro study, Tunthasen Pripatnanont et al. demonstrated that the semi-rigid shell barrier system exhibits suitable physical characteristics and mechanical properties, including appropriate morphology, hydrophilicity, adequate porosity, and a small pore size of less than 40 µm, facilitating angiogenesis and vascular penetration into the defect area. The semi-rigid shell demonstrates high resistance to compressive force, while the semi-resorbable covering membrane exhibits high elastic strength.~In vivo studies have confirmed the effectiveness of the semi-rigid shell barrier system, showing bone and tissue integration after function, good stability, biocompatibility, and property as a barrier due to space-making and maintenance. The system also exhibits limited susceptibility to complications and ease of clinical handling during surgery."
89599580|NCT06295042||Autologous Breast Reconstruction|Patients undergoing autologous breast reconstruction with free flaps
89599581|NCT06295042||Alloplastic Breast Reconstruction|Patients undergoing alloplastic breast reconstruction with implants or expander prosthesis
89599582|NCT06295016|No Intervention|Regular training|Participants maintain their regular training habits for 3 weeks.
89599583|NCT06295016|Experimental|High-intensity intensive training|Participants increase their regular regular training volume by 10% each week for 3 weeks.
89599584|NCT06295016|Experimental|Taper|Participants gradually reduced to 55% of their regular training volume for 1 week.
89599585|NCT06294990|Active Comparator|Testosterone|Testosterone gel applied to the skin
89599586|NCT06294990|Placebo Comparator|Placebo|Placebo gel applied to the skin
89599587|NCT06294964|Experimental|sleep education group|
89599588|NCT06294964|No Intervention|routine management group|
89599589|NCT06294951||BPS group|Patients with BPS (subject to current diagnostic criteria and clinical guidelines).
89599590|NCT06294951||Control group|Patients with symptoms of bladder pain and evidence of current urinary tract infection.
89599591|NCT06294938|Active Comparator|Dextrose|Dextrose matched for available carbohydrate
89599592|NCT06294938|Experimental|Cacao fruit pulp|Cacao fruit pulp matched for available carbohydrate
89599593|NCT06294925||Patients receiving etrasimod for ulcerative colitis|
89599594|NCT06294912|Experimental|Panel A: MK-7602 Single dose Part 1|Participants are inoculated with Plasmodium falciparum (P. falciparum). Panel A participants receive MK-7602 as a single oral dose. Participants will receive artemether/lumefantrine oral tablets as definitive antimalarial treatment. Additional definitive antimalarial treatment may be administered at the investigator's discretion.
89599595|NCT06294912|Experimental|Panel B: MK-7602 Single dose Part 1|Participants are inoculated with P. falciparum. Panel B participants receive MK-7602 as a single oral dose. Participants will receive artemether/lumefantrine oral tablets as definitive antimalarial treatment. Additional definitive antimalarial treatment may be administered at the investigator's discretion.
89599596|NCT06294912|Experimental|Panel C: MK-7602 Single dose Part 1|Participants are inoculated with P. falciparum. Panel C participants receive MK-7602 as a single oral dose. Participants will receive artemether/lumefantrine oral tablets as definitive antimalarial treatment. Additional definitive antimalarial treatment may be administered at the investigator's discretion.
89599597|NCT06294912|Experimental|Panel D: MK-7602 Single dose Part 1|Participants are inoculated with P. falciparum. Panel D participants receive MK-7602 as a single oral dose. Participants will receive artemether/lumefantrine oral tablets as definitive antimalarial treatment. Additional definitive antimalarial treatment may be administered at the investigator's discretion.
89599598|NCT06294912|Experimental|Panel E: MK-7602 Single dose Part 1|Participants are inoculated with P. falciparum. Panel E participants receive MK-7602 as a single oral dose. Participants will receive artemether/lumefantrine oral tablets as definitive antimalarial treatment. Additional definitive antimalarial treatment may be administered at the investigator's discretion.
89599599|NCT06294912|Experimental|Panel F: MK-7602 Multiple dose Part 2|Participants are inoculated with P. falciparum. Panel F participants receive MK-7602 at multiple oral doses. Participants will receive artemether/lumefantrine oral tablets as definitive antimalarial treatment. Additional definitive antimalarial treatment may be administered at the investigator's discretion.
89599600|NCT06294912|Experimental|Panel G: MK-7602 Multiple dose Part 2|Participants are inoculated with P. falciparum. Panel G participants receive MK-7602 at multiple oral doses. Participants will receive artemether/lumefantrine oral tablets as definitive antimalarial treatment. Additional definitive antimalarial treatment may be administered at the investigator's discretion.
88979866|NCT06003270|Active Comparator|Quercetin 500mg/day|"Quercetin 500 mg/day Quercetin is provided as caplet and each caplet will have 500 mg of quercetin Quercetin will be administered orally once daily, (1 caplet) in the morning after breakfast and matching placebo in the evening after dinner for six months.~The placebo is added to match the number of caplets with 1000 mg/day arm"
89599601|NCT06294912|Experimental|Panel H: MK-7602 Multiple dose Part 2|Participants are inoculated with P. falciparum. Panel H participants receive MK-7602 at multiple oral doses. Participants will receive artemether/lumefantrine oral tablets as definitive antimalarial treatment. Additional definitive antimalarial treatment may be administered at the investigator's discretion.
89599602|NCT06294847|Experimental|Experimental arm: 'UDCA'|Experimental arm: 'UDCA': Patients will be treated with ursodeoxycholic acid (UDCA), receiving a single dose of Ursolvan® (10mg/kg) orally within 24 hours before the surgical intervention, followed by a daily dose of 10mg/kg in two divided doses for 30 days.
89599603|NCT06294847|Placebo Comparator|Control arm: 'Placebo'|Control arm: 'Placebo': Patients will receive a single dose of placebo orally within 24 hours before the surgical intervention, followed by two doses per day for 30 days.
89599604|NCT06294834|Other|Group 1: therapists|Group 1 will receive the active intervention (intervention A) of remote wheelchair skills training. They will cross-over to receive the control intervention (intervention B) of education on wheelchair provision at 6 months.
89599605|NCT06294834|Other|Group 2|Group 2 will complete the control intervention (intervention B) of education on wheelchair provision. They will cross-over to receive the active intervention (intervention A) of remote wheelchair skills training at 6 months.
89599606|NCT06294834|Other|Group 3|Groups 3 will mirror Group 1 but for intervention A will only complete Part 1 of the training and then be cued weekly to practice.
89599607|NCT06294834|Other|Group 4: rehab professionals, not therapists|Group 4 will mirror Group 3 but receive access to both interventions at the same time.
89599608|NCT06294782|Experimental|STereotactic Arhythmia Radioablation (STAR)|Patients fulfilling the inclusion and exclusion criteria will undergo (or already underwent) a single-session 25 Gy STAR for the treatment of refractory monomorphic VT.
89599609|NCT06294769|Experimental|Group 1|Group will receive application of aromatherapy with 2% lavender essential oil dermal and inhalation via by a nurse, associated with usual care, in the immediate postoperative period.
89599610|NCT06294769|Placebo Comparator|Group 2|Placebo group will only receive the application of grape seed vegetable oil associated with usual care in the post anesthetic recovery room.
89599611|NCT06294756|Active Comparator|Long covid patients undergoing inhalations with sulfurous thermal water (STW)|"Adult Outpatients aged 18-75, presenting to the spa facility with an independent prescription of inhalation therapy with sulfurous water for post-COVID respiratory issues.~Active arm treatment consisted of 12 consecutive sessions of sulfurous thermal water (STW) from Visit 1 for 12 days.~Re-assessment of study analyses was performed on Visit 2 after, 14 days from Visit 1. The follow-up (Visit 3) was 90 days after Visit 1."
89599612|NCT06294756|Placebo Comparator|Long covid patients undergoing inhalations with Sterile Distilled non-pyrogenic Water (SDW)|"Adult Outpatients aged 18-75, presenting to the spa facility with an independent prescription of inhalation therapy with sulfurous water for post-COVID respiratory issues. Placebo arm treatment consisted of 12 consecutive sessions of Sterile Distilled non-pyrogenic Water (SDW) from Visit 1 for 12 days.~Re-assessment of study analyses was performed on Visit 2 after, 14 days from Visit 1. The follow-up (Visit 3) was 90 days after Visit 1."
89599613|NCT06294743|Experimental|Group-1|Posterior tibial nerve neuroprolotherapy will be administered during the first two menstrual cycles, followed by oral acetaminophen (500mg) for the subsequent two menstrual cycles
89599614|NCT06294743|Experimental|Group-2|Oral acetaminophen (500mg) will be given during the initial two menstrual cycles, followed by a transition to posterior tibial nerve neuroprolotherapy for the last two menstrual cycles.
89599615|NCT06294353|Experimental|WELT-ED (CBT based DTx)|"Participants in this group will receive a shortened version of the standard treatment plus access to the DTx app for 8 weeks.~The DTx app is designed to provide therapeutic interventions based on CBT principles, aiming to help participants manage and reduce their eating disorder symptoms.~Participants are expected to engage with the app, completing tasks such as self-monitoring food diaries. The app will collect data on adherence, including diary completion rates and app login frequency.~Additional Support: Aside from app usage, participants will receive counseling and support therapy during visits at baseline, the 4-week mark, and the 8-week mark.~They will continue any pre-existing medication for eating disorders."
89599616|NCT06294353|Other|Standard Treatment|"Participants will receive the standard treatment protocol for eating disorders, which includes regular counseling and support therapy at all scheduled visits.~This treatment is comprehensive and follows the conventional approach to managing eating disorders, without the use of the DTx app.~Participants will continue any pre-existing medication for eating disorders."
89599617|NCT06294054||Patients enrolled in VESPER study|Tumors from patient having muscle invasive bladder cancer who benefit from neoadjuvant chemotherapy with cisplatine included in VESPER cohort
89599618|NCT06294054||Patients from St Louis cohort not enrolled in VESPER study|Tumors from patient having muscle invasive bladder cancer who benefit from neoadjuvant chemotherapy with cisplatine included in Saint-Louis cohort
89599619|NCT06294054||Patients from COBLAnCE cohort not enrolled in VESPER study|Tumors from patient having muscle invasive bladder cancer who benefit from neoadjuvant chemotherapy with cisplatine included in COBLAnCE cohort
89599620|NCT06294002|Experimental|Dynamic neuromuscular stabilization group (DNS)|DNS - Dynamic neuromuscular stabilization intervention
89599621|NCT06294002|Experimental|Whole body vibration group (VIBRO)|VIBRO - Whole body vibration intervention
89599622|NCT06294002|Experimental|Dynamic neuromuscular stabilisation with whole body vibration group (MIX)|MIX group - neuromuscular and whole body vibration intervention
88979867|NCT06003270|Placebo Comparator|Placebo|"Placebo is also provided as caplets that is similar to quercetin in color, taste and texture and will contain all the stabilizers and the inactive ingredients that is present in the quercetin chews.~Placebo will be administered orally twice daily, one half dose (1caplet) in the morning after breakfast and one half dose (1 caplet) in the evening after dinner for six months."
88979868|NCT06003257|Active Comparator|primary molars will be restored by stainless steel crowns|
88979869|NCT06003257|Active Comparator|primary molars will be restored by zirconia crowns|
89599623|NCT06294002|No Intervention|Control group (CONTROL)|Control group - no intervention
88979870|NCT06003257|Active Comparator|primary molars will be restored by fiberglass crowns.|
88979871|NCT06003062||Standard Topical NIghtly Dose|Treatment group
89599624|NCT06293690|Experimental|SBRT combined with immunochemotherapy|Patients received preoperative neoadjuvant therapy: SBRT 12Gy on the first day, and Toripalimab (IV 240mg, q3W) combined with platinum-containing dual drugs on the second day. Two cycles in total.
89599625|NCT06293690|Other|SBRT combined with immunotherapy|Patients received preoperative neoadjuvant therapy: SBRT 12Gy on the first day, and Toripalimab (IV 240mg, q3) on the second day. Two cycles in total.
89599626|NCT06292624|Experimental|Intermittent vacuum therapy + Cycling exercise|Participants received 12 IVT sessions of 30 minutes combined with 20 minutes of cycling exercise during the 6-week period.
89599627|NCT06292091|Active Comparator|Captopril|Single dose of captopril 12.5 mg
89599628|NCT06292091|Experimental|Sodium bicarbonate+captopril|Single dose of captopril 12.5 mg during multiple doses of sodium bicarbonate 1 g every 4-6 hours
89599629|NCT06292091|Experimental|Torsemide+captopril|Single dose of captopril 12.5 mg during multiple doses of torsemide 20 mg every 6-12 hours
89599630|NCT06292065|Experimental|Gastric Ultrasound|Gastric ultrasound will be performed shortly before induction; i.e. in the preoperative room. The exam will be performed by the treating anaesthetist experienced with gastric ultrasound. The gastric antrum will be visualised in supine position followed by a second visualisation of the antrum in right lateral decubitus. In the latter position the cross-sectional area of the antrum (RIGHT-LAT CSA) will be measured and used to calculate the gastric volume using the [VOLUME (ML) = 27.0 + 14.6 X RIGHT-LAT CSA - 1.28 X AGE] formula. The patient will be considered to have a full stomach or positive gastric ultrasound if solid gastric content is visible in any visualisation of the antrum or if calculated liquid gastric content exceeds 1.5 ml/kg of total body weight.
89599631|NCT06292039|Experimental|Injury Thrivorship Pathway|Enrollment in the human-centered injury thrivorship pathway.
89599632|NCT06291987|Experimental|Dose Level -1|Ivosidenib 500mg daily + Ruxolitinib 5mg twice a day
89599633|NCT06291987|Experimental|Dose Level 1|Ivosidenib 500mg daily + Ruxolitinib 10mg twice a day
89599634|NCT06291987|Experimental|Dose Level 2|Ivosidenib 500mg daily + Ruxolitinib 20mg twice a day
89599635|NCT06291961|Experimental|CS-101 injection|Autologous CD34+ hematopoietic stem cell suspension modified by in vitro base editing technique
89599636|NCT06291883|Experimental|Treat|four packets of concentrated powder per day.
89599637|NCT06291883|Placebo Comparator|Control|four packets of concentrated powder per day.
89599638|NCT06291415|Experimental|Dose escalation|Part 1 will consist of the following 3 dose levels: 300, 400, and 500 mg once daily (QD).
89599639|NCT06291415|Experimental|Dose optimization stage|In part 2 subjects will be randomized in a 1:1 ratio between the 2 dose levels selected at the end of part 1.
89599640|NCT06291207|Experimental|AD-224A|AD-224A+Placebo of AD-224B+Placebo of AD-224C
89599641|NCT06291207|Experimental|AD-224B|Placebo of AD-224A+AD-224B+Placebo of AD-224C
89599642|NCT06291207|Active Comparator|AD-224C|Placebo of AD-224A+Placebo of AD-224B+AD-224C
89599643|NCT06290869|Experimental|MedStar Health System|Phone-based Tobacco Treatment, Nicotine Replacement, and Stepped Care Intervention
89599644|NCT06290869|Active Comparator|E-Referral to the Tobacco Quitline|Standard tobacco quitline protocol, including coaching, nicotine replacement, and web-, and text-based resources.
89599645|NCT06290687|Experimental|Cisplatin Eligible Participants|"Participants who are deemed eligible for cisplatin-based NAC will undergo:~Standard of care neoadjuvant systemic therapy (currently cisplatin-based chemotherapy in cisplatin-eligible participants)~Partial cystectomy with extended pelvic lymph node dissection~Standard of care adjuvant systemic therapy in eligible patients"
89599646|NCT06290687|Experimental|Cisplatin Ineligible Participants|"Participants who are deemed ineligible for cisplatin-based NAC will undergo:~Partial cystectomy with extended pelvic lymph node dissection~Standard of care adjuvant systemic therapy in eligible participants"
89599647|NCT06290596|Experimental|Vasopressin group|patients in this group will be injected with a 10-ml syringe containing 10 units of vasopressin (5 mL bilaterally)
89599648|NCT06290596|Experimental|Tranexamic acid group|patients in this group will be injected with a 10-ml syringe containing 10 ml of tranexamic acid (5 mL bilaterally).
89210179|NCT00902070||1|Patients to whom Eslax has been administered to relax muscles at the time of anesthesia or tracheal intubation
89599649|NCT06290596|Placebo Comparator|Control group|patients in this group will be injected with a 10-ml syringe containing 10 ml of normal saline (5 mL bilaterally).
89599650|NCT06290440|Active Comparator|Pharmacist-led counselling|
89599651|NCT06290440|Experimental|Telepharmacy-led counselling|
89599652|NCT06289374||The LABS study (Bioresource 2: Longitudinal)|200 patients following oesophagogastric cancer resection recruited into BIORESOURCE 1. Following surgery at 3 months, 6 months, 1 year and 2 years: saliva, urine, blood, breath and quality of life questionnaires will be collected.
89599653|NCT06288607||Patients|Patients with solar lentigo
89210180|NCT00635492||1|exenatide
89210181|NCT00635492||2|insulin
89599654|NCT06288594|Experimental|Application Plus Online Therapist Support Group|"Participants in this arm will engage with the TraumaRelief mobile application while also receiving weekly online therapy sessions lasting 20 to 30 minutes for the duration of five weeks."
89599655|NCT06288594|Experimental|Application Only Group|"Participants in this arm will utilize the TraumaRelief mobile application as the sole intervention over a period of five weeks. This group will not receive any therapist-led sessions or additional support outside of the application's features."
89599656|NCT06288594|No Intervention|Waitlist Control Group|"Participants in this control group are placed on a waitlist and will not receive any intervention during the initial five-week active phase of the trial. They serve as a comparative benchmark against the experimental groups to assess the effectiveness of the interventions. Following the three-month follow-up period, participants in this group will be granted access to the TraumaRelief mobile application, allowing them to benefit from the application."
89599657|NCT06288438|Experimental|Multicomponent Telerehabilitation Intervention (Group 1)|Veterans randomized to the MCTR group will complete the 24-week study intervention consisting of the Active (weeks 1-6), Transition (weeks 7-12), and Sustainability (weeks 13-24) phases. Participants will receive a total of 16 individual sessions (6 integrated, 4 high-intensity rehabilitation, and 6 self-management intervention sessions).
89599658|NCT06288438|Other|Education Control (Group 2)|This group will not receive any exercise intervention but will complete 16 sessions with research staff through videoconferencing. These visits will consist of standardized Health Status Update and education sessions on general health topics.
89599659|NCT06288113|Experimental|Treatment (177Lu-PSMA-617)|Patients receive 177Lu-PSMA-617 IV on day 1 of each cycle. Treatment repeats every 6 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive gallium Ga 68 gozetotide IV and undergo PET/CT at screening and on study, undergo SPECT/CT on study, and undergo collection of blood samples throughout the trial.
89599660|NCT06287892||HCM group|Patients diagnosed with HCM
89599661|NCT06287892||Control group|Subjects without HCM
89599662|NCT06287840||Children with Type-1 Diabetes|"Females: 10-11 years old~Males: 11-12 years old~Diagnosed with type-1 diabetes for at least 6 months"
89599663|NCT06287840||Control|"Females: 10-11 years old~Males: 11-12 years old"
89599664|NCT06286137|Active Comparator|Control group|The control group will be seated for 20 minutes without doing anything else, and not listen to music.
89599665|NCT06286137|Experimental|1 minute music group|The 1 minute music group will be seated for 19 minutes without doing anything else, and listen to music for 1 minute.
89599666|NCT06286137|Experimental|5 minutes music group|The 5 minutes music group will be seated for 15 minutes without doing anything else, and listen to music for 5 minutes.
89599667|NCT06286137|Experimental|20 minutes music group|The 20 minutes music group will listen to music for 20 minutes.
89599668|NCT06286020|Experimental|The experimental group|conventional dysphagia treatment and Virtual Reality Therapy are provided
89599669|NCT06286020|Active Comparator|The control group|conventional dysphagia treatment is provided
89599670|NCT06284057||Culotte Group|Data regarding patient with performed PCI- bifurcation with subsequent implantation of two stents using the Culotte technique
89599671|NCT06284057||Double Kiss (DK) Culotte Group|"Data regarding patient with performed PCI- bifurcation with subsequent implantation of two stents using the Double Kiss- Culotte technique. DK-Culotte technique is a variety of classical Culotte techniques in which one additional kissing balloon dilation is performed just after SB stenting, and prior to MB stent implantation."
89599672|NCT06283810|Experimental|psychotherapy of interpersonal relationships|"Informed Consent Form and Voluntary Consent Form will be presented to the students assigned to Group 1 in the first interview and their consent will be obtained, Student Information Form (ANNEX-1), CIBS (ANNEX-3), PCI (ANNEX-4), CPI (ANNEX-5) and SB3S (ANNEX-6) will be applied.~After the initial data are collected, 2-3 sessions of individual interviews will be conducted to assess the student's suitability for Group CIPT."
89599673|NCT06283810|Experimental|laughter therapy|"In the first interview, Informed Consent Form and Voluntary Consent Form will be presented to the students assigned to Group 2 and their consent will be obtained, and Student Information Form (ANNEX-1), CIBS (ANNEX-3), PCI (ANNEX-4), CPI (ANNEX-5) and SB3S (ANNEX-6) will be applied.~After the initial data were collected, the students in Experiment 2 will be informed about Laughter Therapy and Group IPT. An agreement will be made with the students about the points to be considered regarding laughter therapy"
89599674|NCT06283810|Placebo Comparator|Plasebo group|"Informed Consent Form and Voluntary Consent Form were presented to the students in the placebo group in the first interview and their consent was obtained, Student Information Form (ANNEX-1), CIBS (ANNEX-3), PCI (ANNEX-4), CPI (ANNEX-5) and SB3S (ANNEX-6) were applied."
89599675|NCT06283810|No Intervention|control group|The students assigned to G4 will be informed that they are in the control group and that no application will be made. After the completion of the study data (by giving information about Group CIPT and laughter therapy), it will be stated that they can receive Group CIPT or laughter therapy if they wish.
88979872|NCT06002893|Experimental|Cholesfytol NG®) supplement|Patients will receive a single oral dose of 2 tablets a day of Cholesfytol NG®) supplement for 2-months.
89599676|NCT06282978|Experimental|Elranatamab|Elranatamab will be administered by subcutaneous (SC) injection
89599677|NCT06282562|Experimental|HIIT|"The intervention group will perform High-Intensity Interval Training (HIIT), consisting of two supervised exercise sessions per week on a stationary bike, for 12 weeks.~In addition, participants will receive information on general guidelines for weekly physical activity levels and will be asked to keep an exercise diary."
89599678|NCT06282562|No Intervention|Waiting-list|"The control group on the waiting list will be given the option to perform High-Intensity Interval Training (HIIT) after their participation in the study.~In addition, also participants from the waiting-list control group will receive information on general guidelines for weekly physical activity levels and will be asked to keep an exercise diary."
89599679|NCT06282289|Other|6-month-old infants|
89599680|NCT06282289|Other|10-month-old infants|
89599681|NCT06282016||Cases|Patients with a neuroendocrine neoplasm of the bronchopulmonary or gastroenteropancreatic system diagnosed in the years 2020 or 2021
89599682|NCT06282016||Controls|Patients without a neuroendocrine neoplasm of the bronchopulmonary or gastroenteropancreatic system diagnosed in the years 2020 or 2021 (=no documented diagnosis of neuroendocrine neoplasm of the bronchopulmonary or gastroenteropancreatic system in the Bavarian Cancer Registry)
89599683|NCT06281769|Other|Diagnostic evaluation of prostate cancer|
89599684|NCT06281574||Patients with shoulder arthroplasty|Including all surgical interventions (anatomic total shoulder arthroplasty, humeral head hemi arthroplasty or reversed shoulder arthroplasty) for patients with shoulder arthroplasty
89599685|NCT06281548|Experimental|Intervention arm|Participants in the intervention arm will receive 56 text messages over 4-weeks.
88979873|NCT06002854|Experimental|GROUP A Microneedling with PRP(platelete rich plasma)|
88979874|NCT06002854|Experimental|GROUP B Microneedling with topical INSULIN|
88979875|NCT06002841|Experimental|EV group|will consist of 10 participants who will receive two infusions of 25 mL of the investigational product (Plasma-Lyte A solution containing EVs obtained from MSCs), intravenously, at intervals of 48 h.
89599686|NCT06281002|Active Comparator|conventional physical impressions|"Nine physical open tray impressions will be poured into a hard dental stone to obtain nine definitive implant casts with conventional implant analogs.~The impressions will be scanned to provide a gold standard reference STL files."
89599687|NCT06281002|Experimental|optical impressions with additional geometric scanning aids coupled with the scan bodies|Nine optical impressions will be obtained while additional geometric scanning aids are coupled with the scan bodies to get nine CAD/CAM 3D-printed polymer casts with digital implant analogs.
89599688|NCT06280703|Experimental|Part A: LY3938577|Single dose of LY3938577 administered intravenously (IV) in healthy participants.
89599689|NCT06280703|Placebo Comparator|Part A: Placebo|Single dose of Placebo administered intravenously (IV) in healthy participants.
89599690|NCT06280703|Experimental|Part B: LY3938577|For each euglycemic and hyperglycemic clamps participants with T1DM will receive single doses of LY3938577 administered intravenously (IV) with Insulin Lispro administered at a constant low rate to cover individual participant's basal (fasting) insulin demand to maintain a stable glucose level.
89599691|NCT06280703|Active Comparator|Part B : Insulin Degludec|For each euglycemic and hyperglycemic clamps participants with T1DM will receive single doses of Insulin Degludec administered intravenously (IV) with Insulin Lispro administered at a constant low rate to cover individual participant's basal (fasting) insulin demand to maintain a stable glucose level.
89599692|NCT06280703|Experimental|Part C: LY3938577|During 3-step clamp and a hyperglycemic clamp with hypoglycemia provocation participants with T1DM will receive LY3938577 by continuous infusion. Insulin Lispro will be administered intravenously to maintain a stable glucose level before administration of LY3938577.
89599693|NCT06280703|Active Comparator|Part C: Insulin Degludec|During 3-step clamp and a hyperglycemic clamp with hypoglycemia provocation participants with T1DM will receive Insulin Degludec by continuous infusion. Insulin Lispro will be administered intravenously to maintain a stable glucose level before administration of Insulin Degludec.
89599694|NCT06280040||Uveal Melanoma|Patients with newly diagnosed uveal melanoma, which will be treated with hypofractionated stereotactic photon radiotherapy as clinical routine.
88979876|NCT06002841|Placebo Comparator|Placebo group|will consist of 5 participants who will receive an equal volume of Plasma-Lyte A, intravenously, following the same schedule as the IV group: two infusions with an interval of 48 hours.
88979877|NCT06002828||Observational (questionnaires, biospecimen collection)|Participants complete questionnaires about health-related quality of life and undergo collection of blood samples at baseline and 6, 12, 18, and 24 months.
88979878|NCT06002776||preoperative and perioperative anaesthetic management|We have planned to retrospectively review data for patients aged 18 and above who underwent major abdominal surgery at our center between October 2017 and February 2022. The study aims to record data regarding the administration of thromboprophylaxis, preoperative hemoglobin values, and Revised Cardiac Risk Index scores and their impact on one-year postoperative mortality. Additionally, we intend to examine the effects of the amount of fluid administered during the perioperative period, the application of epidural analgesia, and the use of blood products on hospital stay duration and one-year postoperative mortality.
88979879|NCT06002711||retrospective study cohort|In the retrospective study, patient cases will be gathered from multi-center repositories, where surgical cases will be confirmed to be high-grade gliomas and will undergo preoperative contrast-enhanced MRI examinations. These patients will possess comprehensive clinical, pathological, and genetic data.
88979880|NCT06002711||Prospective study cohort|The prospective study will encompass a cohort of individuals who are clinically suspected to have high-grade gliomas and will undergo multimodal MRI imaging. Subsequent to surgery, their postoperative pathology will confirm the diagnosis of high-grade gliomas. Following the surgical intervention, these patients will undergo standard procedures for radiotherapy and chemotherapy, as well as regular follow-up assessments.
89210182|NCT00543309|Experimental|I- nesiritide|Patients assigned to the nesiritide group will receive an intravenous loading dose of 2 mcg/kg followed by an infusion of 0.015 mcg/kg/min, administered for at least 12 hours after CICU admission and up to five days unless prespecified lack of efficacy criteria are met.
89210183|NCT00543309|Active Comparator|II- Milrinone|Patients assigned to the milrinone group will receive a bolus of 50 mcg/kg followed by an infusion of 0.5 mcg/kg/min, administered for at least 12 hours after CICU admission and up to five days unless prespecified lack of efficacy criteria are met.
89599695|NCT06279156|Experimental|the first group (every-1-month BIA and then every-2-month BIA)|measure Bioelectrical Impedance analysis (BIA) for patients' dry weight every 1 month for 4 months, and then every 2 months for 4 months
89599696|NCT06279156|Experimental|the second group (every-2-month BIA and then every-1-month BIA)|measure Bioelectrical Impedance analysis (BIA) for patients' dry weight every 2 months for 4 months, and then every 1 month for 4 months
89599697|NCT06276660|Active Comparator|Buffalo Concussion Treadmill Test (BCTT)|"Participants in this group will complete the Buffalo Concussion Treadmill Test (BCTT). This involves individuals walking at 5.8 km/hr. (3.6 mph) at a 0.0% incline (5.1 km/hr. [3.2 mph] if below 5' 10 tall), the treadmill incline is increased 1 degree each minute for the first 15 minutes, then speed increased 0.64 km/hr. (0.4 mph) each minute thereafter."
89599698|NCT06276660|Experimental|Modified EXiT Test (mEXiT)|Participants in this group will complete the modified EXiT test (mEXiT). Participants will complete a 12 minute treadmill interval program followed by a dynamic circuit (10 squat jumps, 10 side to side push ups and 10 medicine ball rotations), jump ball toss, zig zag agility and arrow agility. Parameters will be recorded the same as the established dynamic EXiT test; heart rate and RPE will be recorded at 0, 2, 6:30 and 12 minutes of the treadmill program as well as after the second trial of each activity. The time to complete two trials of the zig zag agility and arrow agility will also be recorded.
89599699|NCT06275191|Experimental|Intervention condition|"Academic detailing (45 to 60-minute session), plus~Provision of standardized patient post-extraction instructions for distribution, plus~Provision of blister-packaged acetaminophen and ibuprofen at recommended standard doses for distribution to to adolescent/young adult patients after tooth extraction in the course of clinical practice"
89599700|NCT06275191|Active Comparator|Control condition|Usual practice
89599701|NCT06269835|Experimental|The observation group|All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy, to promote the development of motor and cognitive function, as well as to improve intellectual development. Besides, swallowing function training was also provided, including direct training, indirect training, and compensatory training.Within 4 hours of admission, the observation group were required to undergo nasogastric tube removal and initiated Intermittent Oro-Esophageal Tube Feeding for nutrition support.
89599702|NCT06269835|Active Comparator|The control group|All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy, to promote the development of motor and cognitive function, as well as to improve intellectual development. Besides, swallowing function training was also provided, including direct training, indirect training, and compensatory training.The control group was given nutrition support with persistent nasogastric tube feeding , of which the tube passed through the nasal cavity into the stomach.
89599703|NCT06267950|Experimental|IOE group|IOE groups were given systematic therapy according to the routine treatment plan for PRS for 4 weeks. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
89599704|NCT06267950|Active Comparator|PNG group|PNG groups were given systematic therapy according to the routine treatment plan for PRS for 4 weeks. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
89599705|NCT06265857|Active Comparator|The control group|"Assigned by the random number table. During the treatment, all patients were provided with comprehensive rehabilitation therapy.~Besides, the control group was given enteral nutritional support with nasogastric tube according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation."
89599706|NCT06265857|Experimental|The observation group|"Assigned by the random number table. During the treatment, all patients were provided with comprehensive rehabilitation therapy.~Besides, the observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube Feeding according to the relevant guidelines."
89599707|NCT06265844|Experimental|The observation group|During the 15-day treatment, both groups of patients are hospitalized, while conventional care and enteral nutrition support are provided to the two groups. Specifically, conventional care includes health education, dietary adjustments, nasopharyngeal hygiene, management of risk factors (blood pressure and lipid control, etc.), exercise rehabilitation, and psychological support. The frequency and content of these interventions are arranged based on the patients; health condition. The observation group receives Intermittent Oro-esophageal Tube Feeding for enteral nutrition support
89599708|NCT06265844|Active Comparator|The control group|During the 15-day treatment, both groups of patients are hospitalized, while conventional care and enteral nutrition support are provided to the two groups. Specifically, conventional care includes health education, dietary adjustments, nasopharyngeal hygiene, management of risk factors (blood pressure and lipid control, etc.), exercise rehabilitation, and psychological support. The frequency and content of these interventions are arranged based on the patients; health condition.The control group receives nasogastric tube for enteral nutrition support
89599709|NCT06265818|Experimental|The experimental group|"Assigned by the random number table. During the treatment, all patients were provided with comprehensive rehabilitation therapy as follows:~Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Based on this, this group was given Active Breathing Exercises"
89599710|NCT06265818|Active Comparator|The control group|"Assigned by the random number table. During the treatment, all patients were provided with comprehensive rehabilitation therapy as follows:~Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training."
88979881|NCT06002698|Other|Root canal treatment (Control)|The procedure can be carried out in single or two visits. Variations in root canal treatment protocols however will make it difficult to compare with pulpotomy so the aim is to standardize the protocols for the following variables including use of rubber dam, Irrigation protocol with 2-2.5% sodium hypochlorite; working length with combined radiographs and apex locators, automated instrumentation to accompany hand instrumentation and preparation to apical size 2-3 larger than the initial binding file. Canal to be medicated with non-setting calcium hydroxide if done in two visits and root canal filling with gutta percha and traditional sealers (warm or cold lateral condensation) and good coronal seal.
89210184|NCT00543309|Placebo Comparator|III- placebo|Patients assigned to the placebo group will receive a 0.33 mL/kg bolus of 5% dextrose in water (D5W), followed by an infusion of D5W, administered for at least 12 hours after CICU admission and up to five days, unless prespecified lack of efficacy criteria are met.
89210185|NCT00902148|No Intervention|Control Group|Colorectal Surgery without use of SurgiWrapTM
89210186|NCT00902148|Active Comparator|Test Group|Colorectal Surgery with use of SurgiWrapTM film secured directly below the abdominal incision
89210187|NCT00894114|Other|Stratum 1|Placebo recipients in the parent protocol (Merck V520 Protocols 007 or 012) will receive ALVAC-HIV Vaccine
89599711|NCT06265805|Experimental|the observation group|"Assigned randomly before the treatment, all patients were provided with comprehensive rehabilitation therapy as follows:~Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training.~The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure. The feeding content was formulated by the nutritionists based on the condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups"
89599712|NCT06265805|Active Comparator|the control group|"Assigned randomly before the treatment, all patients were provided with comprehensive rehabilitation therapy as follows:~Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training.~Besides, the control group was given enteral nutritional support with Nasogastric Tube according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements."
89599713|NCT06265792|Experimental|The experimental group|All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy.The experimental group was given Stellate Ganglion Block.
89599714|NCT06265792|Active Comparator|The control group|All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy.
89599715|NCT06265779|Experimental|The experimental group|The patients are randomly assigned to either the experimental group or the placebo group. All patients receive routine rehabilitation therapy and swallowing rehabilitation training, along with enteral nutrition support using Intermittent Oro-esophageal Tube. In addition to these interventions, patients in the experimental group receive transcranial direct current stimulation, while the instruments used for patients in the placebo group only illuminate an indicator light without any actual effect.
89599716|NCT06265779|Placebo Comparator|The placebo group|The patients are randomly assigned to either the experimental group or the placebo group. All patients receive routine rehabilitation therapy and swallowing rehabilitation training, along with enteral nutrition support using Intermittent Oro-esophageal Tube. In addition to these interventions, patients in the experimental group receive transcranial direct current stimulation, while the instruments used for patients in the placebo group only illuminate an indicator light without any actual effect.
89599717|NCT06265259|Experimental|Vasopresin Group|Initiation of vasopressin as the first vasoactive agent (1 amp in 50 mlN/S) up to a maximum dose of 0.03 IU/min (2.3 ml/h). If the patient has MAP <65 mmHg then noradrenaline will be started.
89599718|NCT06265259|Active Comparator|Noradrenaline group|Initiation of noradrenaline first, up to 0,5 mcg/kg/min. If the patient has MAP <65 mmHg vasopressin will be started (maximum dose of 0.03 IU/min (2.3ml/h)]. If If the patient has MAP <65 mmHg, noradrenaline will be further escalated.
89599719|NCT06264245||High exposure to compressed sound|
89599720|NCT06264245||Moderate or limited exposure to compressed sound|
88979882|NCT06002698|Experimental|Full pulpotomy|The clinical procedure will be completed over one or two visits. Following adequate anesthesia and isolation with rubber dam, access to the pulp will be gained following caries removal to de-roof the pulp chamber and excision of the entire coronal pulp. The pulp chamber is irrigated with 2% sodium hypochlorite solution and the resultant bleeding from the remaining pulp will be controlled with a cotton pellet soaked in 2% sodium hypochlorite solution. Following complete haemostasis, the pulp stump will then be covered with Biodentine (Septodont Ltd., Saint Maur des Fausse ́s, France) and the tooth permanently restored with a restoration if treatment is completed in single visit or temporized with glass ionomer cement for the final restoration to be placed in the 2nd visit if operator opted for 2-visit treatment.
88979883|NCT06002672|Placebo Comparator|Control|group that consumed control lettuce
88979884|NCT06002672|Active Comparator|Intervention|group that consumed eustress lettuce
88979885|NCT06002659|Experimental|Treatment|CAR20(NAP)-T treatment
88979886|NCT06002646|Active Comparator|first group (Group A)|using a 1:5 dilution of Buckley's FC (SSA, Produits Dentaires, Switzerland). A sterile cotton pellet will be moistened with a 1:5 concentration formocresol and it will be placed on the pulp stumps for 5 minutes for achieving hemostasis before being covered with MTA. If hemostasis will not be achieved after 5 minutes, it will presume that the pulp tissue in the canal was infected, and the tooth will be removed from the research
88979887|NCT06002646|Experimental|second group (Group B)|using 3% NaOCl(Tahno-dent, Greece) A sterile cotton pellet will be moistened with a 3% NaOCl and it will be placed on the pulp chamber for 5 minutes for achieving hemostasis before being covered with MTA
88979888|NCT06002646|Experimental|third group (Group C)|In this group hemostasis will be achieved by exposure to diode laser (Biolase, epic X) of 940 nm. The laser energy will be introduced into the canal orifice through a 300 µm optical fiber at 2 W, in a contact mode with continuous mode CW(According to the user manual('EpicX_CAN_UM.pdf', no date) for 1 second at each orifice for three times to achieve complete hemostasis. During laser application patients, operator and assistant will use protective eye shields according to the safety measures of the device user manual.
89210188|NCT00894114|Experimental|Stratum 2|Nonresponders who received active vaccine in parent protocol will be randomized to receive ALVAC-HIV vaccine or MRKAd5 HIV-1 gag vaccine
89599721|NCT06263608|Other|Symptomatic AF patients|Eligible participants will use the NOX T3s polygraphy device for one night at home. If they have a positive obstructive sleep apnea diagnosis, they will be referred to a polysomnography examination, and subsequently treatment. Participants will also receive 3 to 6 months of semi-continuous heart rhythm monitoring with the Fitbit smartwatch (depending on whether they get treatment after obstructive sleep apnea diagnosis via polysomnography).
89599722|NCT06263452|Experimental|Propranolol|Propranolol tablet, 40mg, one-time, orally
89599723|NCT06263452|Placebo Comparator|Placebo|Encapsulated placebo tablet
89599724|NCT06261281|Experimental|The observation group|Both groups of patients were provided with routine treatments, including pharmacological treatment, rehabilitation therapy.Based on this, the patients in the observation group were given enteral nutrition support with Intermittent Oro-esophageal Tube Feeding (Medical Device No. 20010234, developed by the Swallowing Disorders Research Institute of Zhengzhou University).
89599725|NCT06261281|Active Comparator|The control group|Both groups of patients were provided with routine treatments, including pharmacological treatment, rehabilitation therapy. The patients in the control group were provided nutrition support with Nasogastric tube feeding , while the feeding process strictly followed the relevant guideline
89599726|NCT06261021|Experimental|ruxolitinib 1.5% cream (Sequence 1)|ruxolitinib 1.5% cream without occlusion for Area 1 and ruxolitinib 1.5% cream under occlusion at night for Area 2
89599727|NCT06261021|Experimental|ruxolitinib 1.5% cream ( Sequence 2)|ruxolitinib 1.5% cream under occlusion at night for Area 1 and ruxolitinib 1.5% cream without occlusion for Area 2
89599728|NCT06259435|Experimental|Low energy dense diet|Subjects will be required to follow time-restricted eating and receive a diet low in energy density
89599729|NCT06259435|Active Comparator|Usual diet|Subjects will be required to follow time-restricted eating and receive the usual diet.
89599730|NCT06259006|Experimental|Dexamethasone|Participants will receive oral dexamethasone 20mg/m2/day in three divided doses, (maximum dose 24mg/day), for 3 days
88979889|NCT06002646|Experimental|fourth group (Group D)|Irradiation of the floor of the pulp chamber with Er,Cr:YSGG laser 2790 nm (Waterlase MD, Biolase) at a Power of 1.5 w, Frequency of 50 Hz, mode S (soft tissue mode) , 20%air and no water with a gold handpiece and Tip type MZ6, for 10 sec.(According to the manufacturer manual iPlus™ software copyright ©2016 BIOLASE, Inc.)('WaterLase-iPlus-UM.pdf', no date). In which a fixed char layer should be formed over the pulpal tissue of the canals orifices. During laser application patients, operator and assistant will use protective eye shields according to the safety measures of the device user manual.
89210189|NCT00894114|Experimental|Stratum 3|Low responders who received active vaccine in the parent protocol will be randomized to receive ALVAC-HIV vaccine or MRKAd5 HIV-1 gag vaccine
89210190|NCT00894114|Experimental|Stratum 4|High responders who received active vaccine in the parent protocol will be randomized to receive ALVAC-HIV vaccine or MRKAd5 HIV-1 gag vaccine
89210191|NCT00986193|Active Comparator|Conventional Aortic Valve Surgery|Insertion of a biological valve
89210192|NCT00986193|Experimental|Transapical Aortic Valve Implantation|Transapical implantation of an Edwards SAPIENtm valve
89599731|NCT06259006|Placebo Comparator|Placebo control|Participants will receive oral placebo tablet three times a day for 3 days
89599732|NCT06257576|Experimental|Tamusolin|Participants will receive tamsulosin postoperatively for two days.
89599733|NCT06257576|Other|Control Group|Participants will be randomized to the standard of care, with no medication given.
89599734|NCT06256874|Experimental|the observation group|The observation group is the only group of the participants.The elderly individuals will be arranged to undergo a continuous three-week (21 days) duration of Myofascial Release Training, with weekends off and training conducted only on weekdays, two sessions per day, each lasting 15-30 minutes. Each training session will be conducted approximately one hour prior to meals. Apart from this,we require participants to only engage in daily activities and avoid strenuous and dangerous behaviors
89599735|NCT06256861|Experimental|The experimental group|Study lasts 21 days for each patient. All patients are given rehabilitation treatment.The experimental group was given the Myofascial Release Therapy, five days a week, once a day, for 30-60 minutes each time.
89599736|NCT06256861|Active Comparator|The control group|Study lasts 21 days for each patient. All patients are given rehabilitation treatment, five days a week, once a day, for 30-60 minutes each time.
89599737|NCT06255756|Experimental|routine treatment+swallowing rehabilitation training+acupuncture therapy|The experimental group was given routine treatment and swallowing rehabilitation training. Moreover, the experimental group was given acupuncture therapy.
89599738|NCT06255756|Active Comparator|routine treatment+swallowing rehabilitation training|The control group was given routine treatment and swallowing rehabilitation training.
89599739|NCT06255730|Experimental|Stellate Ganglion Block Group|Stellate Ganglion Block Group will be given Stellate Ganglion Block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g), once a day
89599740|NCT06255717|Experimental|The observation group|"Assigned by the random number table. During the treatment, all patients were provided with comprehensive rehabilitation therapy as follows:~Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
89599741|NCT06255717|Active Comparator|The control group|"Assigned by the random number table. During the treatment, all patients were provided with comprehensive rehabilitation therapy as follows:~Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
89599742|NCT06255613|Experimental|UH-Participant|Potential participants will be identified from patients scheduled for in-lab PSG at the two medical centers of University Hospitals
89599743|NCT06255353|Experimental|The observation group|"The patients were provided with 1) basic treatment including intracranial pressure reduction, anti-infection therapy, blood pressure and blood glucose control, and 2) comprehensive rehabilitation therapy including respiratory tract management, care for tracheotomy tube, comprehensive training for hemiplegic limbs, swallowing function training, pulmonary function training, and acupuncture.~For the observation group, the nasogastric tube was removed, and Intermittent oro-esophageal tube feeding was initiated for nutrition support within 4 hours after completing the admission assessment, following the standard Intermittent oro-esophageal tube feeding procedure."
89599744|NCT06255353|Active Comparator|The control group|"The patients were provided with 1) basic treatment including intracranial pressure reduction, anti-infection therapy, blood pressure and blood glucose control, and 2) comprehensive rehabilitation therapy including respiratory tract management, care for tracheotomy tube, comprehensive training for hemiplegic limbs, swallowing function training, pulmonary function training, and acupuncture.~Patients in the control group were provided with nutrition support by the indwelling nasogastric tube. The entire feeding process strictly followed the standardized procedure for nasogastric feeding."
88979890|NCT06002620|Experimental|Control arm (CA)|A positive control group using an existing nutritional intervention with the known effect will be adopted, so as to meet ethical practice and be able to determine the effect of our new intervention response on the experimental group. The study will use double blinded approach with the control group receiving standard known flour of the supercereal CSB+ adjusted for ages as follows:6-8 months infants receiving 31g daily,9-11 months receiving 47g and 12-24 months receiving 86g to supply 200,300 and 550KCal daily respectively, with both the caregiver and person administering the food will be blinded from the content of the flour.
88979891|NCT06002620|Experimental|Enriched nutrition arm (ENA)|The study will use a Cricket Enriched flour(CEF) - with 20% cricket (, maize, millet, mineral and vitamin premix with amounts served adjusted to ages as:6-8 months infants receiving 29g daily,9-11 months receiving 44g and 12-24 months receiving 80g to supply 200,300 and 550KCal daily respectively, with both the caregiver and person administering the food will be blinded from the content of the flour.
88979892|NCT06002620|Experimental|Nutrition education arm (NEdA)|Combines the control and nutrition education where nutrition education comprises of a video, face to face session and SMS reminder in predetermined regular sessions
88979893|NCT06002620|Experimental|Combined Nutrition Education and enriched nutrition (CEdNA)|Combines the Cricket Enriched flour(CEF) and Nutrition education
88979894|NCT06002594|Experimental|group low-volume irrigation|Nasal irrigation was performed using low-volume saline solution
88979895|NCT06002594|Experimental|group high-volume irrigation|Nasal irrigation was performed using high-volume saline solution
88979896|NCT06002568|Placebo Comparator|Control|In the control group, a silent state (a wave file made without sound) is applied via the sound generator and a headset, at the starting of general anesthesia induction. The sound generator volume is set to 60 dB. The sound generator and the headset is assigned after the randomization, and is blinded to the patient and the investigator. This sound is applied during the operation, and at the time of the final skin suture, the sound generator and the headset will be removed from the patient.
88979897|NCT06002568|Experimental|Binaural Beat|In the experimental group, the binaural beat which is produced by the beat of 1Hz difference is applied via the sound generator and a headset, at the starting of general anesthesia induction. The sound generator volume is set to 60 dB. The sound generator and the headset is assigned after the randomization, and is blinded to the patient and the investigator. This sound is applied during the operation, and at the time of the final skin suture, the sound generator and the headset will be removed from the patient.
88979898|NCT06002542|Experimental|Information provided|Participants are invited to the chat room and receive messages, which include the stages of their medical care, information about tests and medications, and non-medical information such as directions to pharmacy and parking information.
88979899|NCT06002542|Experimental|Control|Participants are invited to the chat room and they can get information when they request it.
88979900|NCT06002529|Other|HFR treatment|patient received HFR treatment
88979901|NCT06002516|Experimental|RELIEF pathway|Patients in the intervention group (RELIEF-pathway) will receive access to the web-based education tool before visit of the outpatient clinic of Surgery or Gastroenterology.
88979902|NCT06002516|No Intervention|Usual care|Patients assigned to the control group will receive the usual care given at participating centers. During the first visit at the surgery or gastroenterology outpatient clinic subjects are seen by a random medical specialist, who will assess history, examine the patient, and review investigations. Diagnostic and treatment decisions will be based on the physician's preference and experience and on the patients' preferred choice of treatment.
88979903|NCT06002360|Experimental|Reach Out and Read|Families assigned to this group will receive Reach Out and Read education every two weeks between enrollment and when their infant reaches 36 weeks gestation.
88979904|NCT06002360|No Intervention|Control|Standard neonatal care
89599745|NCT06253845|Experimental|CG0070|CG0070 is a conditionally replicating oncolytic adenovirus (serotype 5) designed to preferentially replicate in and kill cancer cells.
89599746|NCT06252818|Experimental|ReHub|ReHub is a medical device designed to assist rehabilitation professionals by providing information for the design, monitoring, and analysis of therapeutic exercise programs for respiratory functional rehabilitation. Patients use the platform to follow the exercise program designed by their therapist from the location that suits them best.
88979905|NCT06002321||HFpEF|The HFpEF group includes patients with signs and/or symptoms of heart failure and LVEF > 50% and objective evidence of structural and/or functional cardiac abnormalities consistent with the presence of LV diastolic dysfunction/raised LV filling pressures, including raised natriuretic peptides.
88979906|NCT06002321||HFmrEF|The HFmrEF group includes patients with signs and/or symptoms of heart failure and LVEF 41-49%.
88979907|NCT06002321||HFrEF|The HFrEF group includes patients with signs and/or symptoms of heart failure and LVEF < 40%.
89599747|NCT06251765||Patients|Patients who underwent Judet arthromyilisis for treatment of post-traumatic knee stiffness
89599748|NCT06251310|Experimental|Phase 1 Dose Escalation Cohorts Ranging in Dose|Participants with advanced solid tumors with or without Hippo pathway mutations will receive SW-682 tablets administered orally in continuous 28-day cycles. SW-682 dosage and frequency of administration will vary by cohort.
89599749|NCT06251310|Experimental|Part 2 Dose Expansion Cohort 1|Participants with mesothelioma with or without NF2 mutations will receive SW-682 tablets administered orally in continuous 28-day cycles at the recommended dose for expansion, based on Part 1 data.
89599750|NCT06251310|Experimental|Part 2 Dose Expansion Cohort 2|Participants with advanced solid tumors with NF2 mutations will receive SW-682 tablets administered orally in continuous 28-day cycles at the recommended dose for expansion, based on Part 1 data.
89599751|NCT06251310|Experimental|Part 2 Dose Expansion Cohort 3|Participants with advanced solid tumors with other Hippo pathway mutations identified during Part 1 (Phase 1a) dose escalation will receive SW-682 tablets administered orally in continuous 28-day cycles at the recommended dose for expansion, based on Part 1 data.
89599752|NCT06251310|Experimental|Part 2 Dose Expansion Cohort 4|Participants will receive SW-682 tablets administered orally in continuous 28-day cycles at the recommended dose for expansion, based on Part 1 data, with appropriate combination therapy, identified based on Part 1 data.
89599753|NCT06250660|No Intervention|Control group|Participants in the comparison group will not have intervention and will not receive strawberry supplements, they will follow their conventional treatment and their usual diet. They will be evaluated before the start of the intervention, one month, two months and three months after the intervention.
89599754|NCT06250660|Experimental|Strawberry intervention with Fortuna variety|"This group will receive an intake of strawberries of the Fortuna variety. The participants of this group will have to eat 250 g of this strawberry variety per day for 2 months.~All participants in the intervention group will be invited to participate in focus groups once the intervention has ended, in order to learn about their experiences during it.~They will be evaluated before the start of the intervention, one month, two months and three months after the intervention."
89599755|NCT06250660|Experimental|Strawberry intervention with Marisma or Rociera variety|"This group will receive an intake of strawberries of the Marisma or Rociera variety. The choice of the variety between Marisma or Rociera will depend on availability at the time of the intervention. The participants of this group will have to eat 250 g of this strawberry variety per day for 2 months.~All participants in the intervention group will be invited to participate in focus groups once the intervention has ended, in order to learn about their experiences during it.~They will be evaluated before the start of the intervention, one month, two months and three months after the intervention."
89599756|NCT06250335|Experimental|Arm 1|Participants found to be eligible to take part in this study, participants will be provided with the PreFED diet during the 12-week PreFED Intervention Phase. The PreFED diet from the MD Anderson Bionutrition Research Core's (BCR) kitchen (led by co-PI) will provide 2 fully prepared snacks for each day of the intervention phase as part of the bi-weekly food pack-out. The snacks will be shipped to participants, or participants may pick them up in person.
89599757|NCT06249841|Experimental|Forceps biopsy against Cryoprobe biopsy|A total of 6 forceps biopsies and 3 cryobiopsies will be taken for each patient, corresponding to a 2:1 ratio. The biopsies are divided into blocks of two (6 forceps, 3 cryo). The biopsy technique blocks are randomized, resulting in a sequence of 6 forceps biopsies followed by 3 cryobiopsies
89599758|NCT06249841|Active Comparator|Cryoprobe biopsy against Forceps biopsy|A total of 6 forceps biopsies and 3 cryobiopsies will be taken for each patient, corresponding to a 2:1 ratio. The biopsies are divided into blocks of two (6 forceps, 3 cryo). The biopsy technique blocks are randomized, resulting in a sequence of 3 cryobiopsies followed by 6 forceps biopsies.
89599759|NCT06249516|Experimental|The experimental group|"Assigned by the random number table. During the treatment, all patients were provided with comprehensive rehabilitation therapy as follows:~Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Based on this, this group was given Active Breathing Exercises"
89599760|NCT06249516|Active Comparator|The control group|"Assigned by the random number table. During the treatment, all patients were provided with comprehensive rehabilitation therapy as follows:~Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training."
89599761|NCT06249490|Experimental|The experimental group|All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy.The experimental group was given Stellate Ganglion Block.
89599762|NCT06249490|Active Comparator|The control group|All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy.
89599763|NCT06249464|Experimental|Stellate Ganglion Block group|Patients enrolled were firstly numbered for privacy with software and divided into the observation group (n=33) and the control group (n=33) with a random number table. Additionally, the staffs involved in assessment would not participate in the intervention of the study. The treatment lasted 20 days.
88979908|NCT06002282|Experimental|Tailored Messaging|Tailored text messages based on parents' HPV vaccine hesitancy and perceived barriers to vaccination.
88979909|NCT06002282|Active Comparator|Standard Messaging|Standard (untailored) text messages about HPV vaccination reminder/recall.
89599764|NCT06249464|Active Comparator|Routine treatment group|Patients enrolled were firstly numbered for privacy with software and divided into the observation group (n=33) and the control group (n=33) with a random number table. Additionally, the staffs involved in assessment would not participate in the intervention of the study. The treatment lasted 20 days.
89032027|NCT04690959|Experimental|Neural tensioning mobilization|Tensioning will be performed with the subject lying supine. The investigator will perform the upper limb neurodynamic test as reported by Butler (2000): shoulder depression; 110 of shoulder abduction; external shoulder rotation; wrist and fingers extension; forearm supination and then elbow extension. The final test position will be defined as either i) end of joint amplitude or ii) the joint amplitude that provokes pain, paresthesia or numbness. In this case, a decrease of 5 to 10 of range of motion (elbow extension) will be allowed for symptoms to disappear and from this end position the investigator will perform repetitive movements of approximately 10 of elbow flexion/extension while maintaining the test end position for all the other joints. For tensioning, four series of 10 movements at a rhythm of approximately 6 s per cycle and 1-min rest between series will be performed. After each cycle of 10 repetitions, the position will be held for 10 seconds.
89032028|NCT04690959|Sham Comparator|Control|Participants in the sham group will receive a treatment consisting of maneuvers that mimic the neural mobilization treatment but not to stress the neural tissues in the upper extremity. The sham mobilization consists of passively positioning the participants in the following consecutive positions: (1) a neutral cervical spine (0° of lateral flexion), (2) 45°of shoulder abduction without scapula depression, and (3) 45° of shoulder external rotation combined with 45° of elbow flexion with forearm pronation. This will be immediately followed by 10 cycles of passive wrist flexion/extension at a rate of approximately 6 seconds per cycle (3 seconds into extension and 3 seconds into flexion) . Upon moving from wrist flexion to extension, an initial sense of resistance will be used as a sign to alternate directions. Following the 10th cycle, a static hold will be maintained while in wrist flexion for 10 seconds.
89599765|NCT06248879|Experimental|The observation group|During the 15-day treatment, both groups of patients are hospitalized, while conventional care and enteral nutrition support are provided to the two groups. Specifically, conventional care includes health education, dietary adjustments, nasopharyngeal hygiene, management of risk factors (blood pressure and lipid control, etc.), exercise rehabilitation, and psychological support. The frequency and content of these interventions are arranged based on the patients; health condition. The observation group receives Intermittent Oro-esophageal Tube Feeding for enteral nutrition support
89599766|NCT06248879|Active Comparator|The control group|During the 15-day treatment, both groups of patients are hospitalized, while conventional care and enteral nutrition support are provided to the two groups. Specifically, conventional care includes health education, dietary adjustments, nasopharyngeal hygiene, management of risk factors (blood pressure and lipid control, etc.), exercise rehabilitation, and psychological support. The frequency and content of these interventions are arranged based on the patients; health condition.The control group receives nasogastric tube for enteral nutrition support
89599767|NCT06248632||Patients with genetically confirmed XLH diagnosis treated with bursosumab|Blood sampling at D0 and D7 for monocytic cell extraction in vitro
89599768|NCT06246175|Experimental|A group (Healthy Control)|
89599769|NCT06246175|Experimental|B group (Mild Renal Impairment)|
89599770|NCT06246175|Experimental|C group (Moderate Renal Impairment)|
89599771|NCT06246175|Experimental|D group (Severe Renal Impairment)|
89599772|NCT06244511|Active Comparator|Early Bipedal Exercise|Individuals with a diagnosis of chronic ankle instability who underwent supervised exercise under the guidance of a physiotherapist for 8 weeks, 2 days a week.
89599773|NCT06244511|Active Comparator|Late Bipedal Exercise|Individuals with a diagnosis of chronic ankle instability who underwent supervised exercise under the guidance of a physiotherapist for 8 weeks, 2 days a week.
89599774|NCT06242249|Experimental|Relapsed or Refractory Multiple Myeloma|
89599775|NCT06240312|Other|All subjects|Each subject will be imaged at two different times and eye pressures
89599776|NCT06237608|Experimental|Intervention|Attend DBT-informed skills group intervention
89599777|NCT06237413|Experimental|Phase 1 Dose Escalation|"This Phase adopts an open-label design, with an Accelerated Titration(AT) design for the low-dose group (50 mg Bid) and the standard 3+3 design for the high-dose groups（100 mg Bid、50 mg Qd、100 mg Qd、200 mg Qd）."
89032029|NCT02949206|Experimental|Part 1: Cohort 1 (0.03 mg/kg of JNJ-64179375 or Placebo)|Participants in a ratio of 3:1 will receive a single 0.03 milligram per kilogram (mg/kg) intravenous (IV) dose of JNJ-64179375 or matching placebo on Day 1.
89599778|NCT06237413|Experimental|Phase 2 Dose Expansion|After the completion of the dose escalation study, RP2D will be selected for dose expansion in advanced solid tumors (such as non-small cell lung cancer, colorectal cancer, pancreatic cancer, etc.) with KRAS mutations that have failed at least the first-line standard treatment
89599779|NCT06236009|Experimental|Part 1: TAK-004 or Placebo (Single Ascending Dose Cohorts)|Participants will receive TAK-004 or matching-placebo subcutaneous injection on Day 1 in Cohort S1 using a sentinel dosing scheme in a double-blind manner. After dosing the first two participants in Cohort S1, the investigator will review all available safety and tolerability data up to 24 hours post-dose before dosing the remaining participants in the Cohort S2-S10. Single ascending doses are nominal and may be modified based on emerging safety and available PK data during the study but will have a corresponding dose that does not exceed the maximal defined exposure.
89599780|NCT06236009|Experimental|Part 2: TAK-004 or Placebo (Multiple Ascending Dose Cohorts)|Participants will receive TAK-004 (dose to be decided [TBD]) or matching-placebo subcutaneous injection, once daily for 5 days (i.e., Day 1 to 5) in each 5 multi-ascending dose cohorts (M1-M5). The dose in Part 2 will be determined at the dose escalation meeting based upon emerging safety, tolerability, and available PK data from Part 1.
89599781|NCT06236009|Experimental|Part 3: TAK-004 or Placebo (Expansion Cohorts)|Participants will receive TAK-004 (TBD) or matching-placebo subcutaneous injection on Day 1 in each single ascending dose expansion cohorts (E1 and E2). Doses will be determined at the dose escalation meeting based on safety, tolerability and available PK data from Parts 1 and 2. Expansion cohort 2 (optional) may be conducted at the sponsor's discretion after reviewing expansion cohort 1 data.
89032030|NCT02949206|Experimental|Part 1: Cohort 2 (0.1 mg/kg of JNJ-64179375 or Placebo)|Participants in a ratio of 3:1 will receive a single 0.1 mg/kg IV dose of JNJ-64179375 or matching placebo on Day 1.
89599782|NCT06234111||Patients with severe obesity and multimorbidity|Patients with morbid obesity (mainly class II and III) with multiple chronic conditions. Most patients are initially referred for bariatric surgery, but are deemed ineligible for various reasons (typically inability to independently induce weight loss, severe mental disease, eating disorder, and serious comorbidity).
89599783|NCT06232031|Experimental|The observation group|The observation group is the only group of the participants.The elderly individuals will be arranged to undergo a continuous three-week (21 days) duration of Active Breathing Exercises, with weekends off and training conducted only on weekdays. Apart from this,we require participants to only engage in daily activities and avoid strenuous and dangerous behaviors.
89599784|NCT06231771|Experimental|Allogeneic mesenchymal stem cells (MSCs)|Peri-ulcer injection of Umbilical cord MSC (1.0 million cells/cm2 of the ulcer) will be administered at multiple sites (maximum of 30 sites) with intervals of 3 cm x 3 cm around the ulcer with total volume of 0.1 to 0.2 ml per injection. Whatever IMP is drawn into the syringe for administration to the wound must be completely dispensed and nothing should be left in the syringe. Number of injections and volume of each injection can be as per Investigator's discretion. The same to be recorded in the source notes and CRF.The injection will be done approximately using a 24G needle and 1 ml/3ml syringe approximately within 0.75 cm from the edge of the ulcer. The needle should enter the base of the ulcer from the edge. After injection, patients must be in a lying down position for at least one hour in daycare center at the site and monitoring of oxygen saturation will be done up to 2 hours ± 10 minutes after the administration of the product.
89599785|NCT06231771|Placebo Comparator|Normal Saline|The blinded placebo group will be injected with normal saline (NSand the volume to be injected is similar to the area of ulcer (2 mL of normal saline per 1 cm2 of ulcer). each injection will be o.1 to 0.2 ml normal saline (maximum injection will be 30 injection peri ulcer)
89599786|NCT06228170|Experimental|The observation group|"The study lasted 20d for each patient. During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.~Based on the invention above, the patients in the observation group were provided with stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g)"
89599787|NCT06228170|Active Comparator|The control group|The study lasted 20d for each patient. During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.
89599788|NCT06228157|Experimental|the experimental group|"The study lasts 20d for each patient. During the treatment, All the participants are provided with the routine rehabilitation therapy.~Based on the invention above, the patients in the experimental group were provided with stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g)"
89599789|NCT06228157|Active Comparator|the control group|The study lasts 20d for each patient. During the treatment, All the participants are provided with the routine rehabilitation therapy.
89599790|NCT06226415|Active Comparator|The comparison group|The study lasted 20d for each patient. During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.
89599791|NCT06226415|Experimental|The observation group|"The study lasted 20d for each patient. During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.~Based on the invention above, the patients in the observation group were provided with SGB, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g)."
89599792|NCT06226194||Lleida|Saliva sample collection and questionnaire
89599793|NCT06226194||Barcelona|Saliva sample collection and questionnaire
89599794|NCT06226194||Madrid|Saliva sample collection and questionnaire
89599795|NCT06226194||Málaga|Saliva sample collection and questionnaire
89599796|NCT06226194||Santiago de Compostela|Saliva sample collection and questionnaire
89599797|NCT06226194||Pamplona|Saliva sample collection and questionnaire
89599798|NCT06226194||León|Saliva sample collection and questionnaire
89599799|NCT06226194||A Coruña|Saliva sample collection and questionnaire
89599800|NCT06226194||Mallorca|Saliva sample collection and questionnaire
89599801|NCT06226194||Tenerife|Saliva sample collection and questionnaire
89599802|NCT06226194||Las Palmas|Saliva sample collection and questionnaire
89599803|NCT06225921|Experimental|Adebrelimab+Dalpiciclib(100mg)|"Adebrelimab will be given at a dose of 20 mg per kilogram of body weight every three weeks on day 23 of a planned 28-day cycle, and two doses before surgery.~Dalpiciclib will be given at a dose of 100 mg every day orally with three weeks on and one week off. Four weeks is a cycle and it will be given for two cycles.~For dalpiciclib, there is 2 dose levels, 100mg qd and 150 mg qd, and if no patients experience DLT on 100mg level, 150mg level will be administered."
88811964|NCT03439280|Experimental|Phase 1 Dose Escalation Cohort: Mezagitamab 600 mg|Mezagitamab 600 mg, SC, once weekly for 8 weeks, then once every 2 weeks for 16 weeks, and then once every 4 weeks thereafter in a 28-day treatment cycle until PD, unacceptable toxicities or withdrawal due to other reasons.
89032031|NCT02949206|Experimental|Part 1: Cohort 3 (0.3 mg/kg of JNJ-64179375 or Placebo)|Participants in a ratio of 3:1 will receive a single 0.3 mg/kg IV dose of JNJ-64179375 or matching placebo on Day 1.
88979910|NCT06002126|Experimental|Cervical cancer screening (single arm)|Women will be screened for cervical cancer with HPV testing that provides extended genotyping and DNA quantification. Women will also provide other samples for cervical cancer screening tests. Women will under cervical biopsies.
88979911|NCT06002113|Experimental|GOCD Tool|Intensive care unit-facilitated goals-of-care discussion using web-based shared-decision making software tool
88979912|NCT06002113|Active Comparator|usual care|Usual discussions conducted by attending physician with patient
88979913|NCT06002048||Healthy|Participants who do not have Type 1 or Type 2 Diabetes
88979914|NCT06002048||Pre-diabetes/Diet Controlled|Participants with pre-Type 2 Diabetes and those with Type 2 Diabetes whose blood sugar is controlled by diet
88979915|NCT06002048||Oral Medication and/or Non-insulin-injectable Medication Controlled|Participants with Type 2 Diabetes whose blood sugar is controlled by oral or injectable medications other than insulin
88979916|NCT06002048||Insulin Dependent|Participants with Type 2 Diabetes whose blood sugar is controlled by insulin
88979917|NCT06002035||patients without spontaneous abortion(SA0)|The patients with VD deficiency or insufficiency take 30 drops (relative to 1ml) once a day, directly into the mouth or with complementary foods added.
88979918|NCT06002035||patients with a spontaneous abortion(SA1)|The patients with VD deficiency or insufficiency take 30 drops (relative to 1ml) once a day, directly into the mouth or with complementary foods added.
88979919|NCT06002035||patients with RSA (SA2 and above)|The patients with VD deficiency or insufficiency take 30 drops (relative to 1ml) once a day, directly into the mouth or with complementary foods added.
89517893|NCT03495089|Experimental|prediabetes|"Patients with intermediate alterations of glucose metabolism defined as impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT) determined by OGTT after 2-hour 75 g oral glucose administration.~Intervention(s) to be administered:After verifying the inclusion criteria and receiving written informed consent to participate, during the first visit to the Primary Care centres the medical history of the patient will be obtained and a physical examination will be performed using the Monofilament testing -MFT and the Neuropathy Disability Score-NDS and Utah Early Neuropathy Scale-UENS questionnaires will be given to screen for polyneuropathy-PN. The patient will also undergo dermal electrochemical conductance-DEC quantification using the Sudoscan® device."
88979920|NCT06002022|No Intervention|Standard treatment|"Patients in the control arm will be treated as usual after the first-line breast cancer treatment. Specifically, in Valencia, this process entails biannual medical evaluation control visits for the first port-treatment year at the Oncology Department, including standardised blood examinations.~On top of that, patients of this group will be offered 3 supportive consultation sessions, over the phone, with generic advice on desired lifestyle choices (physical activity, dietary habits, sleep habits and social mobility) that will be helpful for managing the ongoing treatment"
89032032|NCT02949206|Experimental|Part 1: Cohort 4 (1.0 mg/kg of JNJ-64179375 or Placebo)|Participants in a ratio of 3:1 will receive a single 1.0 mg/kg IV dose of JNJ-64179375 or matching placebo on Day 1.
89210193|NCT02540382|Experimental|covered stent|"Procedure/Surgery: Jugular vein puncture and catheterization. Device: RUPS-100 (COOK Company) sheath, 8 mm balloon, Pigtail catheter, 8 mm covered stents (Bard, Fluency).~Drug (including placebo): No Biological/Vaccine: No Radiation: No Behavioral (e.g., Psychotherapy, Lifestyle Counseling): No Genetic (including gene transfer, stem cell and recombinant DNA): No Dietary Supplement (e.g., vitamins, minerals): No."
89599804|NCT06225921|Experimental|Adebrelimab+Dalpiciclib(150mg)|"Adebrelimab will be given at a dose of 20 mg per kilogram of body weight every three weeks on day 23 of a planned 28-day cycle, and two doses before surgery.~Dalpiciclib will be given at a dose of 100 mg every day orally with three weeks on and one week off. Four weeks is a cycle and it will be given for two cycles.~For dalpiciclib, there is 2 dose levels, 100mg qd and 150 mg qd, and if no patients experience DLT on 100mg level, 150mg level will be administered."
89599805|NCT06225843|Experimental|Sotevtamab and FOLFOX|Sotevtamab at 800 mg IV infusion once weekly on Days 1 and 8 for 6 cycles combined with FOLFOX (oxaliplatin 85 mg/m² IV infusion + leucovorin 400 mg/m² IV infusion + 5-Fluorouracil (5-FU) 400 mg/m² IV bolus + 5-FU 2400 mg/m² continuous IV infusion over 46 hours) once every 2 weeks on Day 1 for the first 4 cycles.
89599806|NCT06225115|Experimental|SAD Cohort 1|Single-Ascending Dose Cohort 1. Intervention: KYN-5356 A mg or placebo, single dose, oral tablet
89599807|NCT06225115|Experimental|SAD Cohort 2|Single-Ascending Dose Cohort 2. Intervention: KYN-5356 B mg or placebo, single dose, oral tablet
89599808|NCT06225115|Experimental|SAD Cohort 3|Single-Ascending Dose Cohort 3. Intervention: KYN-5356 C mg or placebo, single dose, oral tablet
89599809|NCT06225115|Experimental|SAD Cohort 4|Single-Ascending Dose Cohort 4. Intervention: KYN-5356 D mg or placebo, single dose, oral tablet
89599810|NCT06225115|Experimental|SAD Cohort 5|Single-Ascending Dose Cohort 5. Intervention: KYN-5356 E mg or placebo, single dose, oral tablet
89599811|NCT06225115|Experimental|SAD Cohort 6|Single-Ascending Dose Cohort 6. Intervention: KYN-5356 F mg or placebo, single dose, oral tablet
89599812|NCT06225115|Experimental|MAD Cohort 1|Multiple-Ascending Dose Cohort 1. Intervention: KYN-5356 G mg or placebo, oral tablets for 7 days
89599813|NCT06225115|Experimental|MAD Cohort 2|Multiple-Ascending Dose Cohort 2. Intervention: KYN-5356 H mg or placebo, oral tablets for 7 days
89599814|NCT06225115|Experimental|MAD Cohort 3|Multiple-Ascending Dose Cohort 3. Intervention: KYN-5356 I mg or placebo, oral tablets for 7 days
89599815|NCT06225115|Experimental|Food Effect Cohort|Intervention: KYN-5356 J mg, single dose, oral tablets in fasted or fed state.
89599816|NCT06223542|Experimental|Arm A (twice weekly UAE inhibitor TAK-243)|Patients receive TAK-243 IV BIW on study. Patients also undergo biopsy on study, and undergo CT, MRI, and collection of blood throughout the study.
89599817|NCT06223542|Experimental|Arm B (once weekly UAE inhibitor TAK-243)|Patients receive TAK-243 IV QW on study. Patients also undergo biopsy on study, and undergo CT, MRI, and collection of blood throughout the study.
89599818|NCT06222554|Experimental|Patients Hospitalized following Kidney or Liver Transplant|Patients in the study will be introduced to the exercise software program and provided with a demonstration. Measurements will be taken at baseline (post-operation) and at the final study visit. Participants will remain in the study until the end of their hospital stay, typically no longer than 6 months post-operation.
89599819|NCT06218823|Active Comparator|Low-Intensity Standard Smoking Cessation Treatment|2 weeks of nicotine patch therapy, 3 telephone counseling sessions, and information about quitline and National Cancer Institute text messaging support services (SmokefreeTXT)
89599820|NCT06218823|Experimental|High-Intensity, Cancer-Targeted Smoking Cessation Treatment|12 weeks of varenicline therapy, 7 counseling sessions targeted to cancer patients, and information about quitline and SmokefreeTXT services
89599821|NCT06215469|Experimental|Portable Scalp Cooling System (PSCS)|Participants will participate in training in AMMA use and will be asked to bring the device for use during each non-investigational, chemotherapy treatment visit. The device will be used for 30 minutes prior to the start of chemotherapy, during chemotherapy, and for at least 2.5 hours after chemotherapy. Scalp photos will be obtained at baseline and 3 weeks after the last chemotherapy treatment. Questionnaires will be given throughout the study and 3 weeks after the last after the last chemotherapy treatment.
89599822|NCT06213194|Experimental|Experimental Group|It combines social cognitive and executive functions skills and it will be present on the designed website and they will participate in the intervention online. After participants are assigned the experimental group the 6-week training program will start and they cannot access the next week before completing the previous week. Each week's will last about 75 minutes. The training includes social cognitive skills including cognitive and affective empathy and executive functions.
89599823|NCT06213194|No Intervention|Control Group|This group will not take the training until the follow-up test. After the study will be done, the training program will be offered to the control group as well.
89599824|NCT06205043|Active Comparator|Standard of care (SoC) based programming in Parkinson's disease patients|Patients will be programmed in a routine (Standard of Care) program. Based on the randomization the patient may receive this at the beginning or after the Stim search program (crossover)
89599825|NCT06205043|Experimental|StimSearchTM software based programing in Parkinson's disease patients|Patients will be programmed using StimSearch algorithm. Based on the randomization the patient may receive this at the beginning or after the Standard of Care program (crossover)
89599826|NCT06204861|Experimental|Capacitive and Resistive Electric Transfer Therapy Group|Participants underwent 30 minutes of treatment per session, three times per week for four weeks during the experiment.
89599827|NCT06204861|Experimental|Balance Training Group|Participants underwent 30 minutes of training per session, three times per week for four weeks during the experiment.
89599828|NCT06204861|Experimental|Balance Training Combined with Capacitive and Resistive Electric Transfer Therapy Group|Participants underwent 30 minutes of training and treatment per session, three times per week for four weeks during the experiment.
89599829|NCT06203600|Experimental|Arm 1 (nivolumab, ramucirumab, paclitaxel)|Patients receive nivolumab IV over 30 minutes on day 1, ramucirumab IV over 30-60 minutes on days 1 and 15 of each cycle, and paclitaxel IV over 30 minutes on days 1, 8 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan and MRI throughout the study. Patients may also optionally undergo blood sample collection on study.
89599830|NCT06203600|Active Comparator|Arm 2 (ramucirumab, paclitaxel)|Patients receive ramucirumab IV over 30-60 minutes on days 1 and 15 of each cycle and paclitaxel IV over 30 minutes on days 1, 8 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan and MRI throughout the study. Patients may also optionally undergo blood sample collection on study.
89599831|NCT06202846|Experimental|Turner syndrome patients|Patients with a Turner syndrome confirmed by karyotype.
89599832|NCT06201910||Controll|Pregnant women without uterine dilation due to a twin pregnancy or a macrosomic singleton
89599833|NCT06201910||Gemini|Pregnant women with uterine dilation due to a twin pregnancy
89599834|NCT06201910||Makrosome|Pregnant women with uterine dilation due to a macrosomic singleton
88979921|NCT06002022|Experimental|Standard treatment + REBECCA|"Patients will be trained in the use of the complementary monitoring modules of the REBECCA mobile and online monitoring platform, which will be used longitudinally, facilitating the collection of real world data within the REBECCA framework. Their supervising health personnel will be given access to the REBECCA patient dashboard, that provides in-depth information about their lifestyle, as well as continuous REBECCA measurements for their online behaviour and self- or companion-reported measures of emotional state and quality of life.~Unlike those in the Standard care study-arm, 3 phone-based consultation sessions in the first 12 months of treatment visits will be scheduled based on system-predicted eminent life functionality and emotional state deteriorations (and potential decrease in treatment compliance), targeting the just-in-time patient support, aiming at improving treatment acceptance and efficacy"
88979922|NCT06001983|Experimental|Imaginary resisted exercises|• Handgrip exercises with the imagination of resistance in hand by getting feedback in VR Box will be given as an intervention. Stretching will be given at the beginning and the end of each session. This will include imaginary resistance exercises for handgrip by using Virtual Reality Box. Five types of different resistances will be imagined by patients by watching their own videos in VR box, which will be recorded on day one to make them familiar with the resistive objects and the resistance experienced from them by asking patients to perform 15-15 repetitions of each object. Every imaginary resistance exercise will have 15 repetitions. After performing exercises, the participants will ask to perform Finger-to-Nose Test and Purdue Pegboard Test.
89032033|NCT02949206|Experimental|Part 1: Cohort 5 (2.5 mg/kg of JNJ-64179375 or Placebo)|Participants in a ratio of 3:1 will receive a single 2.5 mg/kg IV dose of JNJ-64179375 or matching placebo on Day 1.
89032034|NCT02949206|Experimental|Part 1: Cohort 6 (5.0 mg/kg of JNJ-64179375 or Placebo)|Participants in a ratio of 3:1 will receive a single 5.0 mg/kg IV dose of JNJ-64179375 or matching placebo on Day 1.
89599835|NCT06200116||Observational|Participants create and review output auto-segmentations of CT images using the AI algorithm and complete a survey about the performance/functionality of the auto segmentation algorithm on study.
89599836|NCT06199713||Advanced Melanoma Patients with Immune Checkpoint Inhibitors|
89599837|NCT06197672|Experimental|Treatment|"Redirected autologous T cells transduced with the anti-CD4 lentiviral vector (referred to as CD4CAR cells)"
89599838|NCT06196580|Experimental|SHR4640 group A|
89599839|NCT06196580|Experimental|SHR4640 group B|
89599840|NCT06196580|Placebo Comparator|SHR4640 Placebo|
89599841|NCT06195241|Experimental|Benign Essential Blepharospasm or Hemifacial Spasm|Patients with either Benign Essential Blepharospasms or Hemifacial Spasms
89599842|NCT06185595|Placebo Comparator|Control|No sodium, No glycerol
89599843|NCT06185595|Experimental|Sodium only group 1|55 mmol/L sodium
89599844|NCT06185595|Experimental|Glycerol only|4.6% glycerol
89599845|NCT06185595|Experimental|Sodium and Glycerol group 1|55 mmol/L sodium and 4.6% glycerol
89599846|NCT06185595|Experimental|Sodium only group 2|27.5 mmol/L sodium
89599847|NCT06185595|Experimental|Sodium and Glycerol group 2|27.5 mmol/L sodium and 2.3% glycerol
89599848|NCT06184919||Patients and caregivers|Patients attending the Perioperative Optimization of Senior Health (POSH) clinic
89599849|NCT06184919||Healthcare providers|Healthcare providers referring to or working in the Perioperative Optimization of Senior Health (POSH) clinic
89599850|NCT06183840|Active Comparator|Conventional|Patients with a traumatic fixation of the mesh
89599851|NCT06183840|Experimental|Glutack|Patient with Glutack mesh fixation
89599852|NCT06182579|Experimental|RiMO-401|• Single intratumoral injection followed by radiation
89599853|NCT06181370|Experimental|AGMB-447|Participants will receive a single dose of AGMB-447 (part A), multiple doses of AGMB-447 over 7 days (part B) or multiple doses of AGMB-447 over 14 days (part C)
89599854|NCT06181370|Placebo Comparator|placebo|Participants will receive a single dose of placebo (part A), multiple doses of placebo over 7 days (part B) or multiple doses of placebo over 14 days (part C)
89599855|NCT06181058|Experimental|escape room game|"The participant list will be uploaded to a program and teams of 6-8 people will be formed with random names. The participant list will be uploaded to a program and teams of 6-8 people will be formed with random names. Each team will play the escape game.~Participants will be informed about the game. He/she will be asked to solve puzzles within the framework of an oncology patient scenario. There will be a debriefing session at the end of the escape game.~Participants will be informed with a scenario containing the story of an oncology patient, and puzzles-riddles related to the case will be given within the game. They will get a letter when they solve each riddle and complete the game by solving the password."
89599856|NCT06180395||Group 1 (Ambulant )|"consisted of 37 children with CP classified to level I, II and III according to GMFCS., then:~Dual-energy X-ray absorptiometry (DXA) scans will be used to assess bone mineral density (BMD).~Gross motor function measurement scale (GMFM) will be used to assess gross motor function.~Quality of Life Questionnaire for Children (CP QOL-Child) will be used to assess quality of life (QOL)."
89599857|NCT06180395||Group 2 (Non-Ambulant )|"consisted of 38 children with CP classified to level IV and V according to GMFCS.then:~Dual-energy X-ray absorptiometry (DXA) scans will be used to assess bone mineral density (BMD).~Gross motor function measurement scale (GMFM) will be used to assess gross motor function.~Quality of Life Questionnaire for Children (CP QOL-Child) will be used to assess quality of life (QOL)."
89599858|NCT06179888|Active Comparator|Group 1 (monitoring)|Patients undergo disease monitoring at monthly clinic visits until disease progression. Patients also undergo bone marrow aspiration and biopsy throughout the trial, undergo collection of blood samples at screening and on study, and undergo PET/CT and/or skeletal survey x-ray, CT, or MRI at screening and then as clinically indicated.
89599859|NCT06179888|Experimental|Group II (iberdomide)|Patients receive iberdomide PO QD on days 1-21 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspiration and biopsy throughout the trial, undergo collection of blood samples at screening and on study, and undergo PET/CT and/or skeletal survey x-ray, CT, or MRI at screening and then as clinically indicated.
89599860|NCT06173596|Experimental|Part 1|During Part 1, Period 1, participants will receive a single dose of ALXN2080 on the morning of Day 1. In Part 1, Period 2, participants will receive a dose of itraconazole orally once daily on the morning of Day 1 to Day 13. On the morning of Day 5, participants will be given a single dose of ALXN2080 co-administered with itraconazole.
89599861|NCT06173596|Experimental|Part 2 (Optional)|During Part 2, Period 1, participants will receive a single dose of ALXN2080 on the morning of Day 1. In Part 2, Period 2, participants will receive a single loading dose of fluconazole, followed by a dose of fluconazole qd on the morning of Day 2 to Day 10. On the morning of Day 4, participants will be given a single dose of ALXN2080 co-administered with fluconazole.
89599862|NCT06173596|Experimental|Part 3|During Part 3, Period 1 participants will receive a single dose of ALXN2080 on the morning of Day 1. In Part 3, Period 2, participants will receive a dose of carbamazepine bid on the morning and evening of Day 1 to Day 3, followed by a dose of carbamazepine bid on the morning and evening of Day 4 to Day 6 and a dose of carbamazepine bid on the morning and evening of Day 7 to Day 23. On the morning of Day 19, participants will be given a single dose of ALXN2080 co-administered with carbamazepine.
89599863|NCT06173544|Active Comparator|Standard of Care (SOC)|35 adolescents living with HIV seeking HIV care at participating clinics in Lilongwe, Malawi will be enrolled in this study arm during study recruitment. Enhanced usual care will include general training of the HIV providers and clinics about common mental disorder (CMD) identification and management, and feedback to the HIV provider of the status of their enrolled patient to allow follow-up per the clinic's standard care. Enhanced usual care will included a mental health evaluation provided by a rained study nurse; brief supportive counseling; information, education, and support on depression; and (if indicated) facilitation of referral to the clinic's psychiatric nurse or mental health clinic or to the tertiary care hospital.
89599864|NCT06173544|Experimental|Adapted Friendship Bench (AFB)|35 adolescents living with HIV seeking HIV care at participating clinics in Lilongwe, Malawi will be enrolled in this study arm during study recruitment. Individuals enrolled in this arm will receive 6 weekly counseling sessions per the AFB protocol.
89599865|NCT06173544|Experimental|Enhanced Friendship Bench (EFB)|35 adolescents living with HIV seeking HIV care at participating clinics in Lilongwe, Malawi will be enrolled in this study arm during study recruitment. Individuals enrolled in this arm will receive 6 weekly counseling sessions and peer support per the EFB protocol.
89599866|NCT06170905|Experimental|Oral glucose tolerance test with whey protein pre-load|30 minutes prior to the 75 g OGTT, a whey protein solution is given.
89599867|NCT06170905|No Intervention|Control oral glucose tolerance|75 g OGTT without whey protein pre-load.
89599868|NCT06170801|Experimental|Kiesler Circle Training (KCT) + Cognitive Behavioral Therapy (CBT)|The Kiesler Circle Training (KCT) consists of 12 weekly group sessions of 100 minutes each (in a group of max. 10 patients). In addition, all patients receive weekly individual state-of-the-art CBT sessions (50 minutes each).
88979923|NCT06001983|Experimental|Physical resisted exercises|Handgrip exercises with physical resistance in hand will be given as an intervention. Stretching will be given at the beginning and the end of the session. 5 different types of resistances will be given to patients for making themselves familiarize themselves with the type of resistance applied by each object, that they will experience in further sessions, by asking them to perform 15-15 repetitions of each object. Every physical resistance exercise will have 15 repetitions. After performing exercises, the participants will ask to perform Finger-to-Nose Test and Purdue Pegboard Test. In physical resistance exercises, resistive force is applied to the targeted region by using different and appropriate resistive objects
88979924|NCT06001970||Adults who experience fatigue and have been through an activity pacing program|Adults with chronic conditions who experience fatigue recruited from Cresta Fatigue Clinic, Newcastle, UK
88979925|NCT06001970||Adults who experience fatigue and have not been through an activity pacing program|Adults with chronic conditions who experience fatigue recruited from the waiting list of Cresta Fatigue Clinic, Newcastle, UK
88979926|NCT06001970||Health professionals working on activity pacing|Health professionals who are working on Cresta Fatigue Clinic, Newcastle, UK
88979927|NCT06001957||Proband|Patient with extremely giant coronary artery ectasia (CAE) and positive family history
88979928|NCT06001944|Active Comparator|Control group|8 weeks, 2 days a week, a multi-model rehabilitation program is implemented.
88979929|NCT06001944|Experimental|Experimental group|8 weeks, 2 days a week, blood flow restriction during exercise will be applied in addition to the multi-model rehabilitation program. The elbow will be placed near the elbow and the patient's systolic pressure will be used to restrict the blood flow with the recommended 40%-50% occlusion for the upper extremity, and the exercise intensity will be performed 75 times at 20-30% of 1 maximum repetition, 30-15-15-15 repetition and 30 seconds rest between sets.
89599869|NCT06170801|Active Comparator|Cognitive Behavioral Therapy (CBT)|The patients receive weekly individual state-of-the-art CBT sessions (50 minutes each).
89599870|NCT06170606|Experimental|Cryoablation|Subjects undergoing cardiac ablation procedure with the Boston Scientific Cardiac Cryoablation System.
89599871|NCT06169397|Experimental|XTMAB-16 Treatment|Dose to be established in the XTMAB-16-201 Study.
89599872|NCT06165302|Experimental|Exercise Intervention|Participants will be prescribed an exercise program after completing assessments at baseline. Participants will adhere to the prescribed exercise intervention for 12 weeks and log activity in a physical activity diary. Participants will return to clinic on Week 5 and Week 9 for assessments and adjustment to their exercise prescription as needed.
89599873|NCT06164587|Experimental|Patients with geographic atrophy associated with age-related macular degeneration|Kamuvudine-8 treatment (0.3 mg) at baseline visit and week 13 visit, in one eye of each subject, for a total of 5 subjects. Patients will be followed for 26 weeks after baseline visit injection.
89599874|NCT06164145||patients with hemiplegia|The intervention program will be based on usual care physiotherapy treatment in a hospital setting. It will be given 3 times per day, 5 days per week for 4 weeks duration.
89599875|NCT06163404|Experimental|Investigational Device|Treatment with the Spirair Septal correction device and delivery system for correction of cartilaginous nasal septal deviation.
89599876|NCT06160414|Experimental|Cohort 1|On Day 1, all participants will receive a single oral dose (fasted) of Metformin followed by a single oral dose (fasted) of Rosuvastatin on Day 3.
89599877|NCT06160414|Experimental|Cohort 2|All participants will receive ALXN2080 twice daily (BID) on Day 1 to Day 11. On the morning of Day 6, participants will be given a single dose of Metformin co-administered with the morning dose of ALXN2080. On the morning of Day 8, participants will be given a single dose of Rosuvastatin co-administered with the morning dose of ALXN2080.
89599878|NCT06160284|Experimental|Current OUD diagnosis + psilocybin|All participants will receive a [11C]-UCB-J PET scan and fMRI with in 1-2 weeks pre and post treatment with one dose of Psilocybin. Intravenous lines will be used for phlebotomy and administration of the [11C]-UCB-J radiotracer. On the PET scanning day, a radial arterial catheter may be inserted.
89599879|NCT06159556|Active Comparator|Peanut group|Participants will be consuming 2 ounces of peanuts /peanut butter everyday for 12 weeks
89599880|NCT06159556|No Intervention|control group|Participants will continue with habitual diet and abstain from eating peanuts
89599881|NCT06158542||The women meeting the inclusion criteria, undergoing cesarean section|Women who meet the inclusion criteria and have undergone spinal anesthesia for cesarean section between November 2023 and March 2024
89599882|NCT06157671||Patients at increased risk for developing pancreatic cancer|Patients being screened for pancreatic cancer because they have known risk factors (i.e. smoking, diabetes, chronic pancreatitis, family history of pancreatic cancer, or certain genetic syndromes) and are undergoing other imaging diagnostic tests to determine if they have pancreatic cancer
89599883|NCT06151561|Experimental|Dose 1|Participants will receive 5 intramuscular injections of AGN-151586 in the glabellar complex on Day 1.
89599884|NCT06151561|Experimental|Dose 2|Participants will receive 5 intramuscular injections of AGN-151586 in the glabellar complex on Day 1.
89599885|NCT06151561|Experimental|Dose 3|Participants will receive 5 intramuscular injections of AGN-151586 in the glabellar complex on Day 1.
89599886|NCT06151561|Placebo Comparator|Placebo|Participants will receive 5 intramuscular injections of Placebo in the glabellar complex on Day 1.
89599887|NCT06150742|Experimental|Niyad|1 mg/mL infusion of nafamostat mesylate
89599888|NCT06150742|Placebo Comparator|Placebo|0.9% saline infusion
89599889|NCT06150404|Experimental|Intervention Group|Those in the intervention group will receive the administration of white noises and maternal and/or paternal voice recording.
89599890|NCT06150404|No Intervention|Control Group|Those enrolled in the control group will receive standard care and will be subjected to the usual level of ambient noise.
89599891|NCT06147531|Experimental|Intervention Group|Patients randomized to the Delayed Cold-Stored Platelet Group will receive ABO-identical buffy-coat platelets (pathogen reduced products) maintained at 22°C for up to 4 days then placed at 4°C for a minimum of 1 day (24 hours), with expiration at 14 days after collection.
89599892|NCT06147531|Active Comparator|Control Group|Those randomized to the Room Temperature Platelet Group will receive ABO-identical buffy-coat platelets (pathogen reduced products) maintained at 22°C for up to 7 days (as per current standard of care).
89599893|NCT06146179||Group 1|Group 1: Combined Anterior Suprascapular Nerve Block and Superficial Cervical Plexus Block
89599894|NCT06143839||Acute Myeloid Leukemia (AML)|Participants with newly diagnosed AML-MRC (Acute myeloid leukemia with myelodysplasia-related changes) or t-related AML (Therapy related Acute myeloid leukemia) receiving Vyxeos liposomal as part of their standard of care treatment.
89599895|NCT06143020|Experimental|Erector spinae plane block group|"Before surgery, an ultrasound-guided ESPB was performed. 30 mL of 0.375% ropivacaine and 0.5μ g/kg dexmedetomidine mixture was injected in the interfascial plane between rhomboideus major and erector spinae muscle.~Ropivacaine is produced by AstraZeneca AB under the trade name of Naropin, and the specifications are 75 mg / 10 ml. Dexmedetomidine is produced by HengRui medical China and the specifications are 100μg / 1 ml。"
89599896|NCT06143020|No Intervention|Control group|Control groups do not receive additional analgesia.
89599897|NCT06142045||Children (7-10 years)|All groups of the experiment will be exposed to the same intervention. The intervention the participants are exposed to is the use of the computer controlled gas blender system for manipulation of end-tidal and arterial blood gases. This will be used for the following protocols, to either clamp end-tidal concentrations at resting levels or administer a hypercapnia challenge. The protocol includes assessment of cerebral blood flow responses (measured using ultrasound) to carbon dioxide; including a hypercapnia ramp protocol followed by a transient protocol. Following at least 30 minute wash out, participants will then perform isometric exercise at 30% of their maximal voluntary contraction for 2 minutes. Participants will perform the isometric handgrip exercise under 2 different conditions (hypercapnia (+9 mmHg) and clamped breathing; to maintain baseline end-tidal carbon dioxide and oxygen concentrations) with a 20-minute recovery period between each bout.
89599898|NCT06142045||Adolescents (12-16 years)|All groups of the experiment will be exposed to the same intervention. The intervention the participants are exposed to is the use of the computer controlled gas blender system for manipulation of end-tidal and arterial blood gases. This will be used for the following protocols, to either clamp end-tidal at resting levels or administer a hypercapnia challenge. The protocol includes assessment of cerebral blood flow responses (measured using ultrasound) to carbon dioxide; including a hypercapnia ramp protocol followed by a transient protocol. Following at least 30 minute wash out, participants will then perform isometric exercise at 30% of their maximal voluntary contraction for 2 minutes. Participants will perform the isometric handgrip exercise under 2 different conditions (hypercapnia (+9 mmHg) and clamped breathing; to maintain baseline end-tidal carbon dioxide and oxygen concentrations) with a 20-minute recovery period between each bout.
89599899|NCT06142045||Adults (18-35 years)|All groups of the experiment will be exposed to the same intervention. The intervention the participants are exposed to is the use of the computer controlled gas blender system for manipulation of end-tidal and arterial blood gases. This will be used for the following protocols, to either clamp end-tidal at resting levels or administer a hypercapnia challenge. The protocol includes assessment of cerebral blood flow responses (measured using ultrasound) to carbon dioxide; including a hypercapnia ramp protocol followed by a transient protocol. Following at least 30 minute wash out, participants will then perform isometric exercise at 30% of their maximal voluntary contraction for 2 minutes. Participants will perform the isometric handgrip exercise under 2 different conditions (hypercapnia (+9 mmHg) and clamped breathing; to maintain baseline end-tidal carbon dioxide and oxygen concentrations) with a 20-minute recovery period between each bout.
89599900|NCT06141486|Experimental|Frexalimab|Frexalimab IV administration
89599901|NCT06141486|Placebo Comparator|Placebo|Matching placebo
89599902|NCT06138236|Experimental|Infiltration|1. Infiltration of collagen hydrolyzed peptides
89599903|NCT06138236|Experimental|ESWT(Extracorporeal Shockwave Therapy)|ESWT (Extracorporeal Shockwave Therapy)
89599904|NCT06138236|Experimental|Combination|Combination of both treatments
89599905|NCT06137040|Experimental|Magnesium Sulfate in the first hour|These patients will receive 40-50 mg/kg IV magnesium sulfate within the first hour of treatment alongside all first line asthma exacerbation therapies (ie inhaled beta agonists, IV steroids).
89599906|NCT06137040|Placebo Comparator|No Magnesium Sulfate|These patients will not receive IV magnesium sulfate within the first hour of treatment but may receive it later if the provider feels it is clinically necessary.
89599907|NCT06136481|Experimental|Intervention group|CPT intervention: participants will attend the 12 consecutive sessions administered by a psychologist in twice a week.
89599908|NCT06136481|No Intervention|Control group|The control (enhanced care as usual) group will receive the information about freely available psychological support options. E-CAU ranges from standard community care which may include any existing mental health support services available to earthquake survivors in container cities. The participants will be given flyers which include information about the services provided by the government and by non-governmental organizations. After completion of the post and follow-up assessment of experimental group, those in the E-CAU condition will be offered with CPT
89599909|NCT06135545|Experimental|T Group|The T group used liposomal bupivacaine for ultrasound-guided serratus anterior plane block.
89599910|NCT06135545|Active Comparator|C Group|The C group used traditional ropivacaine for ultrasound-guided paravertebral nerve block.
89599911|NCT06131307|Experimental|Experimental group|Managers of this group will be given paternalistic leadership training. Before the training, paternalistic leadership perception, motivation, organizational commitment, and performance levels will be measured. Two months after the paternalistic leadership training given to managers, the paternalistic leadership perception, motivation, organizational commitment and performance levels of the same participants will be measured again.
89599912|NCT06131307|No Intervention|Control group|Managers of this group will not be given paternalistic leadership training. At the same time as the first group, paternalistic leadership perception, motivation, organizational commitment, and performance levels will be measured.
89032035|NCT02949206|Experimental|Part 1: Cohort 7 (Escalation Dose of JNJ-64179375 or Placebo)|Dose escalation will proceed until the toxicology study exposure limits or a highest tolerable dose will be reached.
89032036|NCT02949206|Experimental|Part 1: Cohort 8 (Escalation Dose of JNJ-64179375 or Placebo)|Dose escalation will proceed until the toxicology study exposure limits or a highest tolerable dose will be reached.
89599913|NCT06131203||Emergency Department Burn Subjects|Subjects with Thermal Burn Injury enrolled through the emergency department
89599914|NCT06131203||Burn Center Burn Subjects|Subjects with Thermal Burn Injury enrolled through the burn center
89599915|NCT06129747|Experimental|Radiation Therapy(RT)|There will be one treatment cohort. Radiation therapy will be delivered daily for 15 daily fractions, 2.67Gy per fraction, delivered using a 3-D or IMRT(Intensity Modulate Radiation Therapy) plan. For participants with high-risk features deemed by the radiation oncologist who would otherwise be a candidate for a boost (age <50, high grade, poor biology, close margins), 48 Gy delivered in fifteen fractions of 3.2 Gy is allowed.
89599916|NCT06128564|Experimental|Delandistrogene Moxeparvovec|Participants will receive a single intravenous (IV) infusion of delandistrogene moxeparvovec on Day 1.
89599917|NCT06127524||Nursing Home Residents|All Nursing Home residents in the facility
89599918|NCT06126003||Arm 1: Advanced ER-positive and HER2-negative Breast Cancer|Advanced ER+ and HER2- breast cancer participants due to receive standard of care CDK4/6 inhibitors (palbociclib, ribociclib, or abemaciclib) in combination with endocrine therapy.
89599919|NCT06126003||Arm 2: Advanced Melanoma|Unresectable Stage III or unresectable Stage IV melanoma participants due to receive first-line systemic treatment with PD-1 checkpoint inhibitor therapy.
89599920|NCT06124625|Active Comparator|Rehabilitation maintenance program|
89599921|NCT06124625|Placebo Comparator|No Rehabilitation maintenance program|
89599922|NCT06116968|Experimental|Aficamten|Patients in this arm take daily dose of Aficamten. Each patient will start at the lowest dose (5 mg) in the pre-specified dose range and undergo dose titration up to a maximum of 20 mg.
89599923|NCT06112379|Experimental|Dato-DXd plus durvalumab|"Participants receive durvalumab every 3 weeks (Q3W) + Dato-DXd Q3W as neoadjuvant therapy prior to surgery; followed by 9 cycles of durvaluamb Q3W as adjuvant therapy post-surgery. Adjuvant chemotherapy may be given in combination with durvalumab only if participants have residual disease.~Olaparib may be given for participants with gBRCA-positive tumours and residual disease~Adjuvant chemotherapy may be one of these:~Doxorubicin (Q3W) or epirubicin (Q3W) + cyclophosphamide (Q3W) for 4 cycles (12 weeks) followed by paclitaxel (weekly) and carboplatin (weekly or Q3W) for 4 cycles (12 weeks);~Doxorubicin (Q3W) or epirubicin (Q3W) + cyclophosphamide (Q3W) for 4 cycles (12 weeks) followed by paclitaxel (weekly) for 4 cycles (12 weeks);~Carboplatin (weekly or Q3W) + paclitaxel (weekly) for 4 cycles (12 weeks);~Capecitabine (Q3W) for 8 cycles."
89599924|NCT06112379|Active Comparator|Pembrolizumab plus chemotherapy|Participants receive pembrolizumab every 3 weeks (Q3W) + paclitaxel weekly + carboplatin (weekly or Q3W) x 4 cycles, followed by pembrolizumab Q3W + (doxorubicin OR epirubicin) + cyclophosphamide Q3W x 4 cycles as neoadjuvant therapy prior to surgery; followed by 9 cycles of pembrolizumab Q3W as adjuvant therapy post-surgery. Adjuvant capecitabine (Q3W) for 8 cycles may be given in combination with pembrolizumab only if participants have residual disease. Olaparib may be given for participants with gBRCA-positive tumours and residual disease.
89599925|NCT06111235|Experimental|Cretostimogene after TURBT|Following screening confirmation of IR-NMIBC and complete resection of the tumor, participants will be treated with adjuvant cretostimogene.
89599926|NCT06111235|No Intervention|Observation after TURBT|"Following screening confirmation of IR-NMIBC and complete resection of tumor, participants will enter observation.~Participants who recur with IR-NMIBC after TURBT and observation will be offered treatment with cretostimogene as per the treatment schedule in Arm A. This arm will be called the Extension Arm."
89599927|NCT06106022|Experimental|Vonoprazan 10mg|Participants will receive vonoprazan 10mg QD for 14 days.
89599928|NCT06106022|Experimental|Vonoprazan 20mg|Participants will receive vonoprazan 20mg QD for 14 days.
89032037|NCT02949206|Experimental|Part 2: Reversal Cohort :(50 IU/kg of 4-factor PCC)|Participants will receive a 2.5 mg/kg of JNJ-64179375 or highest tolerable dose if lower than 2.5 mg/kg followed by administration of a single IV 50 International Unit per kilogram (IU/Kg) dose of a 4 factor prothrombin complex concentrate (PCC) or matching placebo on Day 1.
89032038|NCT02949206|Experimental|Part 3: Subcutaneous Cohort (1.0 mg/kg of JNJ-64179375)|Participants will receive a Single Subcutaneous (SC) dose of 1.0 mg.kg or highest tolerable dose if less than 1.0 mg/kg of JNJ-64179375 or matching placebo on Day 1.
89599929|NCT06104878||ABVD: Doxorubicin 25 mg/m^2 + Bleomycin 15 mg + Vinblastine 6 mg/m^2 + Dacarbazine 375 mg/m^2|Participants treated with doxorubicin 25 mg/m^2, bleomycin 15 mg, vinblastine 6 mg/m^2, and dacarbazine 375 mg/m^2 as first line therapy in each 28-day cycle for up to 6 cycles from July 1st, 2017, to December 31st, 2020, will be observed retrospectively.
89599930|NCT06104878||A+AVD: Brentuximab Vedotin 1.2mg/kg+Doxorubicin 25mg/m^2 +Vinblastine 6mg/m^2 +Dacarbazine 375mg/m^2|Participants treated with brentuximab vedotin 1.2 mg/kg, doxorubicin 25 mg/m^2, vinblastine 6 mg/m^2, and dacarbazine 375 mg/m^2 as first line therapy in each 28-day cycle for up to 6 cycles from July 1st, 2017, to December 31st, 2020, will be observed retrospectively.
89599931|NCT06104722|Experimental|high intensity copenhagen adduction exercise group|Athletes in the high-intensity copenhagen adduction exercise group will perform classic copenhagen adduction exercise protocol.
89599932|NCT06104722|Experimental|low intensity copenhagen adduction exercise group|Athletes in the low-intensity copenhagen adduction exercise group will perform a modified copenhagen adduction exercise protocol.
89599933|NCT06104397|No Intervention|Standard Care|Standard care patient's with Parkinson's Disease are receiving at each site.
89599934|NCT06104397|Active Comparator|Written exercise guidance by neurologist|Neurologists will provide written exercise education and guidance to their patients with Parkinson's Disease.
89599935|NCT06104397|Experimental|Physical therapy|A consultative model of physical therapy will be implemented at each site for patient's with Parkinson's Disease.
89599936|NCT06104020|Active Comparator|Restrictive fluid group (RG)|The restrictive fluid group (RG) aims to achieve a net zero fluid balance and involves a 2 mL/kg bolus at anesthesia induction, followed by an intraoperative crystalloid infusion at a rate of 4 mL/kg/hr.
89032039|NCT02939001|Experimental|Ophthalmic surgery group|Ophthalmic surgery group (refractive surgery, phakic Intraocular Lens implantation, and cataract surgery)
89599937|NCT06104020|Active Comparator|liberal group (LG)|The liberal group (LG) will receive a 10 mL/kg bolus at anesthesia induction, followed by an intraoperative crystalloid infusion at a rate of 8 mL/kg/hr [12, 13].
89599938|NCT06103318|Active Comparator|ICOnnectat|"ICOnnecta't is a stepped-care digital intervention tailored to breast cancer patients' psychosocial needs. It consists of four levels:~rst level. Psychosocial Screening and Monitoring: Patients assess their emotional distress and symptoms; consultations with a health psychologist are scheduled if distress is high.~nd level. Campus (Psychoeducation and Health Education): Patients access educational resources covering medical information, emotional well-being, relationships, and healthy habits.~r level. Community Psychosocial Support: Patients engage in an online community to share experiences and concerns under supervision.~th level. Online Group Psychotherapy: Patients participate in online group psychotherapy sessions led by a psycho-oncology specialist."
89599939|NCT06103318|Experimental|ICOgnition|"ICOgnition enhances ICOnnecta't with a Cognitive Module, following the same stepped-structure and specifically addressing cognitive deficits in breast cancer patients. It includes:~rst level. Cognitive Screening and Monitoring: Patients complete monthly cognitive assessments and online objective cognitive tests. If scores indicate impairment, they advance to the next level.~nd level. Cognitive Psychoeducational Campus: Patients undergo psychoeducation focusing on cognitive impairment understanding, behavioural strategies to enhance cognitive functioning, and acceptance strategies through mindfulness and metaphors.~rd level. Online Cognitive Training: Individual 30-minute online cognitive training sessions are conducted twice a week for 12 weeks, targeting specific cognitive skills. Sessions are facilitated through the CogniFit program, integrated with the ICOnnecta't App."
89599940|NCT06101082|Experimental|Anti-HER2-CAR-T cell infusion|Anti-HER2-CAR-T cell is administered as a single intravenous infusion. Follow-up infusions are based on the investigator's decision.The dose group to be infusion was 1×10^6 CAR-T cells/kg, 3×10^6 CAR-T cells/kg, and 1×10^7 CAR-T cells/kg based on the 3+3 dose escalation principle. The infusion dose refers to the number of CAR-positive cells.The patients will receive lymphocyte clearance therapy with cyclophosphamide and fludarabine before the infusion.
88979930|NCT06001892|Experimental|Be in Charge|The 7 units of curriculum fit in with the theory of planned behavior where the educational components of the BiC intervention are designed to impact knowledge, attitudes, norms, and perceived control over sexual health related outcomes (i.e., sexual intercourse and contraception usage), ultimately influencing intention and behavior. The curricula is trauma-informed and integrate a PYD approach through creation of safe environments, engagement of youth through creative activities, and facilitation of progressive skill-building.
88979931|NCT06001892|Active Comparator|Adolescent Health Curricula|Adolescent Health Curriculum which is designed to navigate youth through the emotional components of adolescence in preparation for adulthood.
88979932|NCT06001879|Experimental|SBLST Group|Treatment (B): Simulation in basic life support training The interventional tools, simulation in basic life support training (SBLST), were prepared in English. The researcher will use an already established BLS training from the American Guidelines 2020, a simplified two-part; PowerPoint presentation and clinical simulation training.
88979933|NCT06001879|Active Comparator|Standard Group|The investigator will give the participants in the control group; the standard treatment by using an AHA-BLS 2020 brochure. The participants will read and understand this brochure over 30 minutes, including a brief guideline about basic life support guidelines, and after these 30 minutes, the participants will move to the post-test.
89599941|NCT06097052||FloTrac|Subject received standard advanced hemodynamic monitoring. Hypotensive episodes were treated using a reactive approach.
89599942|NCT06097052||HPI|Subject were monitored using the hypotension predictive index coupled with standard advanced hemodynamic monitoring. Hypotensive episodes were treated using a proactive approach.
89599943|NCT06096714|Active Comparator|Nicotine|Adaptation Session followed by 4 Test Days. The Adaptation Session will familiarize the participants with study procedures. In each Test Day, a different nicotine dose (0.1, 0.05, 0.025, and 0.0125 mg nicotine/pulse) will be compared to saline for nicotine discrimination, subjective effects, and reinforcement. Participants will first sample the assigned nicotine dose and saline, followed by 4 trials to test their ability to discriminate it from saline. This will be followed by 4 Choice trials where participants will be able to choose between nicotine (at the session-assigned dose) or saline (A or B).
89599944|NCT06096714|Placebo Comparator|saline|Subjects will have sample A and B, one being nicotine and one being saline. The doses will be blinded from PI, subject and staff. The subject must choose A or B for the next ten choices.
89599945|NCT06094842|Experimental|Treatment (autologous L1CAM-specific CAR+EGFRt+ T cells)|Patients undergo leukapheresis to obtain PBMCs for T cell product manufacturing and may undergo bridging therapy at the discretion of the treating clinician on study. Patients then undergo lymphodepleting chemotherapy with cyclophosphamide IV and fludarabine IV on days -5, -4 and -33 or single agent bendamustine on days -4 and -3 at the discretion of the treating clinician and/or PI. Patients receive an autologous L1CAM-specific CAR+EGFRt+ T cells infusion on day 0. Based on disease response and persistence of CAR T cells, patients may receive additional lymphodepletion chemotherapy and an autologous L1CAM-specific CAR+EGFRt+ T cell infusion as soon as 6 weeks and no later than 24 weeks after the first infusion, or at the discretion of the PI. Patients also undergo ECHO or MUGA during screening. Patients undergo x-ray imaging, CT, bone scan, and blood sample collection throughout the trial. Additionally, patients may undergo tissue biopsy on the trial.
89599946|NCT06094296|Experimental|Part 1: BMS-986315 Dose Level (DL) 1 + Nivolumab + Histology-based PDCT|
89599947|NCT06094296|Experimental|Part 1: BMS-986315 DL 2 + Nivolumab + Histology-based PDCT|
89599948|NCT06094296|Active Comparator|Part 2: Nivolumab + Histology-based PDCT|
89599949|NCT06094296|Experimental|Part 2: BMS-986315 DL 2 + Nivolumab + Histology-based PDCT|
89599950|NCT06094296|Experimental|Part 2: BMS-986315 DL 1 + Nivolumab + Histology-based PDCT|
89599951|NCT06091774||"Group with the medical device iATROS"|"Patients are subsequently assigned to one of the two groups in a 1:1 randomization.~The treatment to be carried out in the intervention group is the use of the therapy control for the treatment of CHD, which is played out via the iATROS medical device. At the start of the digital treatment, the patients receive suitable measuring devices for recording their vital parameters in the home environment. With the completion of the visit in month 9, the active phase of the study has ended. Patients will now use the iATROS medical device for another 9 months, after which the stability of the intervention effects will be determined."
89599952|NCT06091774||"Group without the medical device iATROS"|"All patients in the control group will receive standard-of-care treatment in the 9 months after randomization. There will be no further intervention during this phase. Similarly, treatment is not influenced or restricted in terms of free choice of medical care or medical treatment.~Subsequently, they also receive access to the iATROS medical device. Patients will receive suitable measuring devices for recording their vital parameters in the home environment. The effects of the intervention will be recorded after 9 months."
89599953|NCT06087341|Experimental|NKG2D-CAR memory T cells infusion|If the primary tumor and/or metastases are not accessible, the patient will be included in Arm A.This group will receive an intravenous infusion of NKG2D-CAR memory T cells.
89599954|NCT06087341|Experimental|Systemic and locally transduced NKG2D-CAR memory T cells infusion|If the primary tumor and/or metastases are accessible, the patient will be included in Arm B. This group will receive an intravenous infusion of NKG2D-CAR memory T cells and an intratumoral dose of NKG2D-CAR memory T cells.
89599955|NCT06084429|Experimental|pre and post test|School adolescents studying in 8th grade.
89599956|NCT06083363||post-ICU with ARDS|Patients admitted to the ICU who have developed Acute Respiratory Distress Syndrome (ARDS), as defined according the new 2023 guidelines (Matthay et.al, 2023)
89599957|NCT06083363||post-ICU without ARDS|Patients admitted to the ICU who have suffered a severe pneumonia, needing advanced respiratory support, but without developing ARDS according to the new 2023 guidelines.
89599958|NCT06083051|Active Comparator|6Fr Percuflex ureteral stents|
89599959|NCT06083051|Active Comparator|6Fr Tria ureteral stents|
89599960|NCT06083051|Active Comparator|4.8Fr Tria ureteral stents|
89599961|NCT06078527|Experimental|Cancer Survivors|Participants will attend a single 15-30 minute study session during which they will answer questionnaires (5-10 minutes) and undergo laryngopharyngeal sensory testing (10-20 minutes). There will be up to 2 years of medical record follow up after completing the main study.
89599962|NCT06074666|Experimental|CareMeds Intervention|Participants complete the CareMeds parent training sessions during weeks 2, 3 and 4.
89599963|NCT06074666|Active Comparator|Usual Care|Usual care consists of medical consultations and supportive care, The usual care group will serve as a delayed intervention/wait list group for which 3 parent training sessions will be offered during weeks 13 through 15.
89599964|NCT06070493|Experimental|Control group|classical physiotherapy
89599965|NCT06070493|Experimental|Treatment group|classical physiotherapy and myofascial release
89599966|NCT06069778|Experimental|Phase 1 - BNT321 Dose Level 1 + mFOLFIRINOX|BNT321 in combination with mFOLFIRINOX chemotherapy (24 weeks) followed by BNT321 monotherapy (24 weeks)
88979934|NCT06001866|Experimental|Spaced Retrieval practice during verb learning|"Each child will learn 8 novel verbs referring to unfamiliar transitive actions (mape). Four verbs will be learned in a condition requiring spaced retrieval practice; four verbs will be learned in a standard study-only (no retrieval practice) condition. In the spaced retrieval condition, the number of other words intervening between hearing the target and an attempt to retrieve it will increase from 0 to 3 words. In the study-only condition, children will simply hear the verb used to describe the action."
88979935|NCT06001749|Experimental|Psilocybin|"Participants will complete study procedures as follows:~2, in-clinic or remote, preparation sessions with therapists.~In-clinic treatment session with therapists at Dana-Farber Cancer Institute. Participants will take a predetermined amount of psilocybin once. Participants will be transported home by a friend or family member.~In-clinic integration session the day after psilocybin administration with therapists.~In-clinic or remote, integration session with therapists 1 week after psilocybin administration.~In-clinic or remote follow visits with therapists at week 2, 3, 5, 8, and 12 after psilocybin administration."
88979936|NCT06001710|Active Comparator|classic inferior alveolar nerve block anesthesia|Inferior alveolar nerve block (IANB) is a technique of dental anesthesia, used to produce anesthesia of the mandibular teeth, gingivae of the mandible and lower lip. The conventional IANB is the most commonly used the nerve block technique for achieving local anesthesia for mandibular surgical procedures using long needle
88979937|NCT06001710|Experimental|needleless jet injector anesthesia|Jet injection technology uses mechanical energy to force a liquid drug into subcutaneous tissues without a needle using infiltration technique
89210194|NCT02540382|Other|bare stent|"Surgery: Jugular vein puncture and catheterization. Device: RUPS-100 (COOK Company) sheath, 8 mm balloon, Pigtail catheter, 8 mm bare stents (EV3, protégé; Cordis, Smart).~Drug (including placebo): No Biological/Vaccine: No Radiation: No Behavioral (e.g., Psychotherapy, Lifestyle Counseling): No Genetic (including gene transfer, stem cell and recombinant DNA): No Dietary Supplement (e.g., vitamins, minerals): No."
88979938|NCT06001684|Experimental|IBR854 Cell Injection|The minimum initial dose is 3.0×10^9 cells and then escalate to 5.0×10^9 cells and 7.0×10^9 cells. Every 21 days is one cycle, and intravenous infusion is performed on day 1 and day 8 of each cycle.
89210195|NCT00986271|Other|With and without MODS developement|EVLI was determinated by PiCCO plus system.
89210196|NCT00897858||Pediatric CNS tumor patients|Newly diagnosed pediatric patients with CNS tumor and no prior irradiation or chemotherapy
89210197|NCT00988689|Experimental|Soup with no added starch|
89210198|NCT00988689|Experimental|Soup + 50 g of whole grain starch|
89210199|NCT00988689|Experimental|Soup + 50 g of high amylose corn starch|
89599967|NCT06069778|Experimental|Phase 1- BNT321 Dose Level 2 + mFOLFIRINOX|BNT321 in combination with mFOLFIRINOX chemotherapy (24 weeks) followed by BNT321 monotherapy (24 weeks)
89599968|NCT06069778|Experimental|Phase 2 - BNT321 RP2D + mFOLFIRINOX|BNT321 in combination with mFOLFIRINOX chemotherapy (24 weeks) followed by BNT321 monotherapy (24 weeks)
89599969|NCT06069778|Active Comparator|Phase 2 - mFOLFIRINOX|mFOLFIRINOX chemotherapy (24 weeks) as monotherapy
89599970|NCT06064097|Experimental|Treatment (nivolumab, gemcitabine, cisplatin, radiattion)|See Detailed Description
89599971|NCT06060977|Experimental|IMG-007 Dose 1|IMG-007 Dose 1 will be administered intravenously 3 times over 4 weeks
89599972|NCT06060977|Experimental|IMG-007 Dose 2|IMG-007 Dose 2 will be administered intravenously 3 times over 4 weeks
89599973|NCT06057155||acute brain injury|Intra Cerebral Hemorrhage Subarachnoid Hemorrhage, Aneurysmal Trauma, Brain Stroke, Ischemic
89599974|NCT06056297|Experimental|Mavorixafor|Participants will receive mavorixafor orally once daily starting from Day 1 through Week 52.
89599975|NCT06056297|Placebo Comparator|Placebo|Participants will receive placebo matching to mavorixafor orally once daily starting from Day 1 through Week 52.
89599976|NCT06054815|Experimental|Part 1 Group 1|"DA-1241 Dose 1~In Part 1: Participants will be randomized into 3 treatment groups and will be dosed with: DA-1241 or placebo in a 1:2:1 ratio."
89599977|NCT06054815|Experimental|Part 1 Group 2|"DA-1241 Dose 2~In Part 1: Participants will be randomized into 3 treatment groups and will be dosed with: DA-1241 or placebo in a 1:2:1 ratio."
89599978|NCT06054815|Placebo Comparator|Part 1 Group 3.1|"DA-1241 Placebo and Sitagliptin Placebo~In Part 1: Participants will be randomized into 3 treatment groups and will be dosed with: DA-1241 or placebo in a 1:2:1 ratio."
89599979|NCT06054815|Placebo Comparator|Part 2 Group 3.2|"DA-1241 Placebo and Sitagliptin Placebo~In Part 2: Participants will be randomized into 2 treatment groups and will be dosed with: DA-1241 in combination with sitagliptin (DA-1241/sitagliptin) or DA-1241/ sitagliptin placebo in a 2:1 ratio."
89599980|NCT06054815|Experimental|Part 2 Group 4|"DA-1241 and Sitagliptin~In Part 2: Participants will be randomized into 2 treatment groups and will be dosed with: DA-1241 in combination with sitagliptin (DA-1241/sitagliptin) or DA-1241/ sitagliptin placebo in a 2:1 ratio."
89599981|NCT06054659|Experimental|Real time - Continuous glucose monitoring|Participants will wear a CGM sensor in the abdomen or arm placed by a study team prior to hospital discharge. Participants will have instructions on how to monitor BG with the CGM device and will use their own glucometer and do fingersticks as needed including for CGM calibration.
89599982|NCT06054659|Active Comparator|Fingerstick blood glucose (FBG) monitoring|Participants randomized to this group will monitor blood glucose by performing fingersticks, they will also have the application of CGM but will not be given the receiver to allow for self-monitoring. CGM will only be applied by the research team for monitoring over a 14-day interval at baseline, week 4, week 8, and week 12. Blinding will continue throughout the study. This group will receive training only in home BG monitoring with FBG.
89599983|NCT06052202|Experimental|CRC mHealth intervention|Experimental group participants will have access to the CRC mHealth intervention.
89599984|NCT06052202|Active Comparator|Control Education|Control condition participants will receive information about colorectal cancer and screening developed by the Centers for Disease Control.
89599985|NCT06051474|Experimental|Caregivers of hospitalized children|
89599986|NCT06051383|Experimental|single group|"Research design:~Quasi-experimental, single group pre- posttest design was utilized in the study. all patients will be assessed for LUTS at base line then will be reassessed after three months.~Study variables:~The independent variable is self management intervention while the dependent variable is the severity of lower urinary tract symptoms."
89599987|NCT06046820|Experimental|INZ-701|Subjects randomized to the INZ-701 arm will be administered a 2.4 mg/kg once weekly dose by subcutaneous (SC) injection for the duration of the 52-week Randomized Treatment Period and the Open-label Extension Period.
89599988|NCT06046820|Active Comparator|Control Arm (Conventional Therapy)|Subjects randomized to the control arm will continue taking their conventional therapy as clinically indicated by their treating physician for the duration of the 52-week Randomized Treatment Period.
89599989|NCT06043531|Experimental|EVOO supplementation|50g/day, dietary supplementation Extra Virgin Olive Oil (EVOO)
89599990|NCT06043531|No Intervention|Standard of Care|Standard of care control
89599991|NCT06043323|Experimental|Axicabtagene Ciloleuce|Participants will first have a procedure to collect your white blood cells that will be used to make axicabtagene ciloleucel. Then participatns will receive radiation therapy, followed by conditioning chemotherapy and 1 infusion of axicabtagene ciloleucel.
89599992|NCT06041828|Experimental|Study group|Standard oral hygiene and Lumoral Treatment home-use
89599993|NCT06041828|Active Comparator|Control group|Standard oral hygiene only
89599994|NCT06035887||Normative Controls|Age- and sex- matched normal controls
89599995|NCT06035887||On Hydroxychloroquine, NO retinopathy|Participants over 18 years on hydroxychloroquine without hydroxychloroquine-related retinopathy
89599996|NCT06035887||On Hydroxychloroquine, POSSIBLE retinopathy|Participants over 18 years on hydroxychloroquine with possible (indeterminate) hydroxychloroquine-related retinopathy
89599997|NCT06035887||On Hydroxychloroquine, DEFINITE retinopathy|Participants over 18 years on hydroxychloroquine with definite hydroxychloroquine-related retinopathy
89599998|NCT06035861|Experimental|XBD173|8 weeks exposure to XBD173
89599999|NCT06034600|Experimental|exercise and taping|Individuals in this group are planned to practice exercise together with taping therapy for eight weeks.
89600000|NCT06034600|Experimental|exercise|Individuals in this group are planned to receive only exercise practice for eight weeks.
89600001|NCT06031415|Experimental|Part A: Rheumatoid Arthritis (RA) Cohorts: GS-0272 or Placebo|"Part A will include participants with RA. Part A will have 3 cohorts. Each cohort in Part A will be randomized in a 3:1 ratio to receive either ascending doses of GS-0272 or placebo for 12 weeks.~Dosing will begin in Cohort 1. Cohorts 2 and 3 will be initiated upon review of blinded safety data from the preceding cohort."
89600002|NCT06031415|Experimental|Part B: Systemic Lupus Erythematosus (SLE) Cohort: GS-0272 or Placebo|Part B will include participants with SLE. Part B will have only 1 cohort (Cohort 4). Participants in Cohort 4 will be randomized in a 3:1 ratio to receive either GS-0272 or placebo for 12 weeks.
89600003|NCT06030609|Experimental|Ringer lactate arm|The patient will receive RLS as a replacement fluid for urine output (mL per mL) until the patient have sufficient oral intake and fluid can be removed.
89600004|NCT06030609|Active Comparator|Normal saline arm|The patient will receive NSS as a replacement fluid for urine output (mL per mL) until the patient have sufficient oral intake and fluid can be removed.
89600005|NCT06024681|Experimental|NAFLD patients|Patients receiving capsulised FMT
89210200|NCT00988689|Experimental|Soup + 50 g of regular corn starch|
89600006|NCT06022055|Experimental|epileptic patients|All patients will be enrolled in the same arm. Patients can be enrolled during the pre-surgical evaluation (group 1) or in the days preceding the surgery (group 2).
89600007|NCT06019728|Experimental|agalsidase beta|agalsidase beta 1 mg/kg infusion once every other week
89600008|NCT06017505||Subject population|Males and females 50 years of age and over who complete the eSAGE as part of their office visit at the Center for Cognitive and Memory Disorders.
89600009|NCT06017401|Active Comparator|Group OSTAP|The investigator will perform oblique subcostal transversus abdominis plane block to that patient group for postoperative analgesia
89600010|NCT06017401|Active Comparator|Group TQLB|The investigator will perform transmuscular quadratus lumborum block to that patient group for postoperative analgesia
89600011|NCT06014554|Experimental|Stratify|Patients randomised to the 'Stratify' intervention will receive usual care and an intervention based on their subgroup assignment. The intervention will start before the third postoperative day and be delivered during the inpatient stay. Intervention components will be delivered by a physiotherapist, occupational therapist, or therapy assistant depending on staffing availability.
89600012|NCT06014554|Placebo Comparator|Usual care|Patients randomised to the control arm will receive usual physiotherapy and occupational therapy care.
89600013|NCT06014138|Active Comparator|Conventional intravenous sedation|Conventional intravenous sedation (e.g. propofol) with short acting opioid, titrated to a clinically prescribed sedation score. Period of observation will be 2 hours pre-cross over and 2 hours post cross over.
89600014|NCT06014138|Active Comparator|Inhaled volatile sedation|Inhaled volatile sedation (Isoflurane) delivered via the AnaConDa device for a 6 hour period (2 hours washout of intravenous sedation / wash-in of volatile to achieve stable baseline, followed by 4 hours of observations at steady state) titrated to an equivalent sedation score. During this period opioid infusion should be maintained at baseline level unless clinical indication for titration of dose.
89210201|NCT00988689|Experimental|Soup + 50 g maltodextrin starch|
89210202|NCT00902382||1|Infertile women who conceive spontaneously
89210203|NCT00902382||2|Infertile women who conceive on various ovulation stimulation medications
89210204|NCT04006977|Placebo Comparator|Arm 1: placebo plus standard therapy|placebo plus standard therapy
89210205|NCT04006977|Experimental|Arm 2: DSF plus standard therapy|DSF (4 sachets/day) plus standard therapy
89210206|NCT04332432|Experimental|belapectin|"Single dose of 4 mg/kg of lean body mass (LBM) belapectin solution for injection administered intravenously (infused over approximately 60 minutes).~Group 1: 16 matched healthy subjects with normal hepatic function~Group 2: 8 subjects with mild hepatic impairment (Child-Pugh Class A [4 x subjects with a score of 5 and 4 x subjects with a score of 6])~Group 3: 8 subjects with moderate hepatic impairment (Child-Pugh Class B [score of 7 to 9])~Group 4: 8 subjects with severe hepatic impairment (Child-Pugh Class C [score of 10 to 14])."
89210207|NCT00988767|Experimental|intramuscular injections|Patients received 4 injections of DNA vaccine at M0, M2, M4 and M10
89600015|NCT06011148||Subject implanted with Perceval S sutureless prosthetic heart valve|Subjects who have been implanted with Perceval S sutureless prosthetic heart valve from 2022 onward and subjects that will be implanted up to study closure.
88979939|NCT06001632|Experimental|Krill oil capsules (LC n-3 PUFAs)|4 g/day krill oil (SuperbaBoostTM), with each 1g capsule containing 191mg EPA, 94mg DHA and 78mg choline.
88979940|NCT06001632|Placebo Comparator|Vegetable oil capsules|4g/day of mixed vegetable oil (a mixture of olive oil (extra virgin, cold-pressed), maize oil (refined), palm kernel oil (refined) and medium-chain triglycerides, in the ratio 4:4:3:2).
88979941|NCT06001619|Experimental|Prostatic hyperplasia|Inclusion criteria for the BPH cohort includes clinical decision to initiate treatment of benign prostate hyperplasia (BPH) with 5-alpha-reductase inhibitors (finasteride, dutasteride, or combination of dutasteride and tamsulosin). Before starting the medication, size of the prostate has been measured with TRUS (transrectal ultrasound). The BPH cohort will include a total of 50 subjects and the study samples (gut microbiota, metabolite sampling) will be collected prior the start of the 5-alpha- reductase inhibitors and after 2 months of medical therapy. At this stage, PSA is determined from blood sample and the size of the prostate is measured with transrectal ultrasound (TRUS). In addition, after 6 months, PSA and prostate size measurements are repeated.
88979942|NCT06001619|Experimental|Prostatic cancer|Inclusion criteria for the cancer cohort include a clinical decision to initiate PCa treatment with androgen deprivation therapy (ADT) with LHRH antagonist (degarelix). This may include either treatment of a metastatic disease with definite ADT or adjuvant ADT to external beam radiation of the prostate. The cancer cohort will include a total of 50 subjects and the study samples (gut microbiota, metabolite sampling) will be collected prior the start of the ADT and after 2 months of medical therapy. In addition, after 2 and 6 months, PSA measurement is repeated.
88979943|NCT06001606|Experimental|Shingrix|
89600016|NCT06004011|Experimental|ARROW strategies|The ARROW strategies which use peer-peer support at the patient level (through peer counselors), at the provider level (through peer lead education sessions) and at the health system level (through a health collaborative forum) to deliver high quality screenings and ensure cancer treatment completion.
89600017|NCT06004011|Active Comparator|One-time education|The comparator arm participants will receive one-time education and usual care services.
89600018|NCT06003777|Experimental|Cohort 1|Single dose administration of PF-06954522 and placebo. Participants will receive up to 5 dose levels of PF-06954522 and up to 2 dose levels of matching placebo.
89600019|NCT06003777|Experimental|Cohort 2|Single dose administration of PF-06954522 and placebo. Participants will receive up to 4 dose levels of PF-06954522 and up to 2 dose levels of matching placebo.
88979944|NCT06001606|Placebo Comparator|Placebo|
88979945|NCT06001593|Experimental|electircal stimulation + betahistine|
88979946|NCT06001593|Sham Comparator|sham electircal stimulation + betahistine|
88979947|NCT06001593|Other|betahistine|control group
88979948|NCT06001580|Experimental|BR101|
89210208|NCT00569582|Experimental|1|
89210209|NCT00894192|Active Comparator|Wavefront guided lenses|
89210210|NCT00894192|Placebo Comparator|Conventional lenses|
89210211|NCT00988845|Experimental|Indole-3-carbinol|
89210212|NCT00819416|Experimental|1|5% albumin
89210213|NCT00819416|Other|2|Normal saline
89210214|NCT04005807|Experimental|Cohort 1 (fasted condition)|10 mg BPN-14967 or placebo
89210215|NCT04005807|Experimental|Cohort 2 (fasted condition)|25 mg BPN-14967 or placebo
89210216|NCT04005807|Experimental|Cohort 3 (fasted condition)|50 mg BPN-14967 or placebo
89210217|NCT04005807|Experimental|Cohort 4 (fed condition)|10 mg BPN-14967 or placebo
89210218|NCT04005807|Experimental|Cohort 5 (high-fat fed condition)|10 mg BPN-14967 or placebo
89600020|NCT06003777|Experimental|Cohort 3|Single dose administration of PF-06954522 and placebo. Participants will receive up to 2 dose levels of PF-06954522 and up to 1 dose level of matching placebo.
89600021|NCT06000761|Active Comparator|Group 1|Standardized oral care performed every 3-4 hours using human milk, donor or breast milk.
89600022|NCT06000761|Active Comparator|Group 2|Standardized oral care performed every 3-4 hours using sterile water.
89600023|NCT06000761|Active Comparator|Group 3|Standardized oral care performed every 12 hours using sterile water.
89600024|NCT05994157|Experimental|CD38-SADA:177Lu-DOTA Complex|
89600025|NCT05986188||Implementing Schools|Implementing schools are public K-12 schools in the State of Michigan that participated in the Pathways to Potential program in a given year (from 2012 to 2024).
89600026|NCT05986188||Non-implementing schools|Non-implementing schools are public K-12 schools in the State of Michigan that DID NOT participate in the Pathways to Potential program in a given year (from 2012 to 2024).
89600027|NCT05986032||no bronchopulmonary dysplasia|Group of patients who do not receive the diagnosis of bronchopulmonary dysplasia defined as the need for respiratory support at 36 weeks post-mentrual age
89600028|NCT05986032||bronchopulmonary dysplasia|Group of patients developing bronchopulmonary dysplasia defined as the need for respiratory support at 36 weeks post-menstrual age.
89600029|NCT05980416|Experimental|Part A: Escalation|Adult patients with select advanced unresectable or metastatic solid tumors likely to express CLDN18.2 will receive EO-3021 IV infusion at various doses every 3 weeks to determine MTD/RP2D(s).
89600030|NCT05980416|Experimental|Part B Expansion|Patients with select advanced unresectable or metastatic solid tumors will receive EO-3021 IV infusion every 3 weeks to confirm the RP2D.
89600031|NCT05979545|Active Comparator|Intervention|Samples from patients randomised to the intervention arm will undergo the BioFire FilmArray systems. Patients will be then administered with the study drug, ceftazidime-avibactam when Pseudomonas aeruginosa or carbapenemase producing Enterobacterales detected.
89600032|NCT05979545|No Intervention|Control|Patients randomised to the control arm, will have samples analysed by clinical microbiology laboratories using standard of care diagnostics. Antibiotics treatment will be administered as per usual institutional practice from hospital supplies.
89600033|NCT05974891|Experimental|Experimental: Simulated group|"Pilot application will be carried out with at least 10 students. A pre-test will be applied to the experimental group. After the scales are applied, the experiment will be applied to the experimental group with the Geriatric Medication Game simulation.~Students simulating the elderly patient role during this simulation will gain a better understanding of age-related health problems and how older adults feel when confronting them. After the application, debriefing, which is the last stage of the simulation training, will be done to evaluate the application. After the application and analysis session is completed, the post-test will be applied to the experimental group. A 3-week clinical practice will be planned for the students in the experimental groups in order to evaluate the continuation of the acquired skills and acquired awareness. In this application, students will be asked to care for the elderly patient and the pre-test will be repeated at the end of the application."
89600034|NCT05974891|No Intervention|No Intervention: Control group|The control group will be pre-tested. After the scales are applied, no intervention will be made to the control group. A 3-week clinical practice will be planned for the students in the control group. In this application, students in the control group will be asked to care for the elderly patient and the scales will be repeated at the end of the application.
89600035|NCT05972772|Active Comparator|Doxycycline|Doxycycline (Vibramycin, 100-mg film-coated tablets; Pfizer)) 200-mg loading dose, followed by 100 mg every 12 hours for 3 days.
89600036|NCT05972772|Active Comparator|Azithromycin|Azithromycin (Zithromax, 250-mg capsules; Pfizer) with a 500-mg loading dose, followed by 250 mg every 24 hours for 2 days. This will be followed by three days of doxycycline at the dose in A.
89600037|NCT05971940|Experimental|Orforglipron Dose 1|Participants will receive orforglipron orally.
89600038|NCT05971940|Experimental|Orforglipron Dose 2|Participants will receive orforglipron orally.
89600039|NCT05971940|Experimental|Orforglipron Dose 3|Participants will receive orforglipron orally.
89600040|NCT05971940|Placebo Comparator|Placebo|Participants will receive placebo orally.
89600041|NCT05962320|Experimental|mERAS Group|"Education and counselling of patients and their parents~Avoiding the use of nasogastric catheters, drains and urinary catheters or/and removing them as early as possible~Stimulation of intestinal motility in the postoperative period~Initiation of oral intake in the early postoperative period~Early removal of the patient by reducing postoperative IV fluid infusion~Initiation of early mobilization of the patient in the postoperative period~Reducing opioid use and ensuring pain management~Implement nausea and vomiting prophylaxis~Management of thirsty~Management of fear and stress"
89600042|NCT05962320|No Intervention|Standart Care Group|Patients in this group will receive standard care according to the practices of the clinic where the study will be conducted.
89600043|NCT05961839|Experimental|Dose Escalation in the Absence of Specific Azole Antifungal Treatments|Up to 9 dose levels will be evaluated in subjects not receiving specific azole antifungal treatment.
89600044|NCT05961839|Experimental|Dose Escalation in the Presence of Specific Azole Antifungal Treatments|Up to 9 dose levels will be evaluated in subjects receiving specific azole antifungal treatment.
89600045|NCT05961488|Experimental|Patients|
88979949|NCT06001502|Experimental|Virtual Reality group|Virtual Reality distraction therapy on post-operative days 1,2 and 3.
89210219|NCT00898092||Group 1|Peripheral blood and bone marrow samples are analyzed to assess gene expression using polymerase chain reaction (PCR) or reverse transcriptase-PCR assays and microarray assays. Genes to be studied include BAALC, ERB, EVI1, MLL, FLT3, NPM1, and CEBPA.
89600046|NCT05960578|Experimental|Treatment (golimumab, apalutamide)|Patients receive golimumab SC every 4 weeks for 6 doses and apalutamide PO daily. Treatment with apalutaminde continues in the absence of disease progression or unacceptable toxicity. Patients undergo tumor biopsy at baseline and during cycle 4. Patients also undergo CT scans or MRI, PSMA PET, and collection of blood samples at baseline, during cycle 4, and at end of treatment.
89600047|NCT05955534|Placebo Comparator|Control Group|The control group will receive percutaneous bedside tracheostomy along with gastrostomy methods other than PUG, including but not limited to Percutaneous Endoscopic or Radiologic Gastrostomy (PEG or PRG, respectively), or surgical gastrostomy.
89600048|NCT05955534|Experimental|Intervention Group (TPUG)|The intervention group will receive concomitant percutaneous bedside tracheostomy and PUG.
89600049|NCT05954871|Experimental|Dose-Finding Stage: Non-Small Cell Lung Cancer (NSCLC)|Participants with unresectable, locally advanced or metastatic NSCLC will receive GDC-1971 at an assigned dose, orally, once daily (QD), on Days 1 to 28 of each 28-day cycle in combination with osimertinib, 80 milligrams (mg), orally, QD, on Days 1 to 28 of each cycle until disease progression or unacceptable toxicity.
89600050|NCT05954871|Experimental|Dose-Finding Stage: Colorectal Cancer (CRC)|Participants with metastatic CRC will receive GDC-1971, at an assigned dose, orally, QD, on Days 1 to 28 days of each 28-day cycle in combination with cetuximab, 500 milligrams per square meter (mg/m^2), given by IV infusion on Days 1 and 15 of each cycle, until disease progression or unacceptable toxicity.
89600051|NCT05954871|Experimental|Dose Expansion Stage: NSCLC|Participants with unresectable, locally advanced or metastatic NSCLC will receive GDC-1971 at a dose determined in the dose finding stage, orally, QD, on Days 1 to 28 of each 28-day cycle in combination with osimertinib, 80 mg, orally, QD, on Days 1 to 28 of each cycle until disease progression or unacceptable toxicity.
89600052|NCT05954871|Experimental|Dose Expansion Stage: CRC|Participants with metastatic CRC will receive GDC-1971 at a dose determined in the dose finding stage, orally, QD, on Days 1 to 28 of each 28-day cycle in combination with cetuximab, 500 mg/m^2, given by IV infusion on Days 1 and 15 of each cycle until disease progression or unacceptable toxicity.
89600053|NCT05952453|Experimental|Carbo/taxol/pembro followed by maintenance of olaparib/pembro post-surgery|neoadjuvant carbo/taxol/pembro followed by maintenance olaparib/pembro post- surgery
89600054|NCT05951959|Experimental|Acalabrutinib + Venetoclax + Rituximab|Acalabrutinib + Venetoclax + Rituximab (AVR)
89600055|NCT05948592|Experimental|TP-102|Patients will be randomly assigned in a 1:1 ratio to one of two treatment arms at Day 1. The wound standard of care (SoC) procedures shall be in accordance to each sites normal DFI routine.
89600056|NCT05948592|Placebo Comparator|Placebo|Patients will be randomly assigned in a 1:1 ratio to one of two treatment arms at Day 1. The wound standard of care (SoC) procedures shall be in accordance to each sites normal DFI routine.
89600057|NCT05944796|Experimental|Diathermy|The experimental group will receive 10 diathermy sessions.
89600058|NCT05944796|Placebo Comparator|Placebo|The placebo comparator, will receive 10 placebo sessions.
89600059|NCT05942937|Experimental|Whole-of-prison education intervention|The HepPEd Program will saturate the entire prison during a 3-month intervention phase.
89600060|NCT05936229|Experimental|Prevention (interferon beta-1A [FP-1201])|Patients undergo leukapheresis prior to treatment and receive FP-1201 IV for 3 days every 24 hours from day -3 through day -1 or for 5 days every 24 hours from day -5 through day -1 or on day -5, day -3, and day -1. Patients may receive lymphodepletion chemotherapy with either cyclophosphamide IV and fludarabine IV on days -5, -4, -3 followed by axi-cel IV or brexu-cel IV on day 0 or fludarabine IV over 30 minutes on days -4, -3, and -2 and cyclophosphamide IV over 60 minutes on day -2 followed by brexu-cel IV on day 0. Patients undergo x-ray imaging and ECHO or MUGA during screening. Patients also undergo CT or PET/CT as well as LP for CSF collection and/or bone marrow aspiration and biopsy as clinically indicated during screening and follow-up. Patients undergo blood sample collection on study and during follow-up as well as a tissue biopsy during screening and follow-up.
89600061|NCT05935306|Active Comparator|G1- Control group|Conventional treatment + FBM simulation (n = 17 patients): All participants will undergo the same conventional surgical procedure. Patients will receive the FBM simulation and will be treated identically to the G2 group. The person responsible for applying the FBM will simulate the radiation by placing the devices in the same places described for the FBM group, however, the equipment will remain turned off. Thus for the participant does not identify the group to which he belongs, the device activation sound (beep) will be recorded and it will turn on at the time of application.
89600062|NCT05935306|Experimental|G2- Intervention group|"Conventional treatment with placebo ibuprofen + FBM (n = 17) All participants will undergo the same surgical procedure. Patients will receive FBM (Table 1) and will be treated identically to the G2 group.~The irradiated region will be on the lesion at 4 equidistant points on the vertex of a flat square 1 cm away. A dot will be irradiated in the middle of the square (Figure 1). Placebo ibuprofen will be manipulated."
89600063|NCT05932810|Other|Treatment as Usual|Participants in the treatment as usual group will be provided educational material about mood management available via the EHR with the suggestion to discuss questions with their oncology provider. Participants will be asked to complete questionnaire measures weekly for 4 weeks following study enrollment.
89600064|NCT05932810|Experimental|Moodivate|Participants randomized to the Moodivate condition will be instructed to utilize Moodivate regularly, at least once per day, for the treatment of depressed mood among cancer survivors. Participants in the Moodivate group will receive a download code to download the Moodivate mobile application. Moodivate is a mobile app for individuals with elevated symptoms of depression. Within the app, users identify values, create activities, schedule activities, and rate mood daily. Participants will be asked to complete questionnaire measures weekly for 4 weeks following study enrollment.
89600065|NCT05931003|Experimental|Carotid artery stenting|Carotid artery stenting
89600066|NCT05931003|Active Comparator|Carotid endarterectomy|Carotid endarterectomy
89600067|NCT05929677|Experimental|Alcohol, Then Placebo, then Free-access session|participants will complete two intravenous administration sessions in the lab during which they will receive alcohol then placebo (saline), followed by a third lab session in which they will have free-access to self-administer alcohol (up to 120mg% BrAC) and placebo intravenously for 60 min
89600068|NCT05929677|Experimental|Placebo, Then Alcohol, then Free-access session|participants will complete two intravenous administration sessions in the lab during which they will receive placebo (saline) then alcohol, followed by a third lab session in which they will have free-access to self-administer alcohol (up to 120mg% BrAC) and placebo intravenously for 60 min
89600069|NCT05929079|Experimental|Retatrutide Dose 1|Participants will receive retatrutide subcutaneously (SC).
89600070|NCT05929079|Experimental|Retatrutide Dose 2|Participants will receive retatrutide SC.
89600071|NCT05929079|Experimental|Retatrutide Dose 3|Participants will receive retatrutide SC.
89600072|NCT05929079|Placebo Comparator|Placebo|Participants will receive placebo.
89600073|NCT05927571|Experimental|Safety Lead-In Cohort|Participants will receive cevostamab, intravenously (IV), in combination with elranatamab, subcutaneously (SC), with step-up dosing of each drug in pre-phase following which they will receive elranatamab, at the assigned dose as a SC injection until disease progression or unacceptable toxicity. Participants will also receive cevostamab at the assigned dose as IV infusion until disease progression or unacceptable toxicity or up to 1 year on treatment, whichever occurs first.
89600074|NCT05927571|Experimental|Dose Expansion Cohort|Participants will receive cevostamab, IV, in combination with elranatamab, SC, with step-up dosing of each drug in pre-phase following which they will receive elranatamab, at the assigned dose as a SC injection until disease progression or unacceptable toxicity. Participants will also receive cevostamab at the assigned dose as IV infusion until disease progression or unacceptable toxicity or up to 1 year on treatment, whichever occurs first.
89600075|NCT05924880|Experimental|durvalumab in combination with gemcitabine-based chemotherapy|single-arm
89600076|NCT05922202||COPD outpatients|Outpatients with COPD. COPD diagnosis confirmed by spirometry and according to Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD) guidelines.
89600077|NCT05920590|Experimental|PNF Group|Participants allocated to this group will receive 18 sessions of therapeutic exercise program based on the PNF concept (Bello et al. 2011).
89600078|NCT05920590|Experimental|PNF and Tendon Vibration Group|Participants allocated to this group will receive the same PNF protocol with Group 1 in combination with the application of tendon vibration.
89600079|NCT05920590|Active Comparator|Control|Participants in this group will follow a conventional six-week home-based physical therapy program
89600080|NCT05919082|Experimental|LEO 90100|The subjects will receive LEO 90100 foam once daily for 4 weeks.
89600081|NCT05919082|Active Comparator|Daivobet® ointment|The subjects will receive Daivobet® ointment once daily for 4 weeks.
89600082|NCT05912244|Experimental|IO102/IO103, Nivolumab, and Relatlimab|All patients will be treated with nivolumab-relatlimab FDC on Day 1 of every 28-day cycle for up to two years. Patients will be treated with IO102/IO103 on Days 1 and 15 of the first two 28-day cycles, then on Day 1 of subsequent cycles for up to two total years of treatment.
89600083|NCT05911295|Experimental|Disitamab vedotin arm|disitamab vedotin + pembrolizumab
89600084|NCT05911295|Active Comparator|Standard of care arm|gemcitabine + cisplatin OR carboplatin
89600085|NCT05911009|Experimental|1350mg BC 007 solution for infusion for 75-minutes intravenous infusion|
89600086|NCT05911009|Placebo Comparator|0.9% NaCl solution for infusion for 75-minutes intravenous infusion|
89600087|NCT05911009|Experimental|1900mg BC 007 solution for infusion for 105-minutes intravenous infusion|
89600088|NCT05911009|Placebo Comparator|0.9% NaCl solution for infusion for 105-minutes intravenous infusion|
89600089|NCT05910996||Conversion from vv-ECMO to va-ECMO Positive|
89600090|NCT05910996||Conversion from vv-ECMO to va-ECMO Negative|
89600091|NCT05910177|Experimental|Karelizumab combined with etoposide and cisplatin group|The cycle dose should be strictly controlled according to the experimental design. The order of administration is as follows: Karelizumab → Cisplatin → Etoposide (with an interval of at least 30 minutes)
89210220|NCT00983697|Experimental|FDG PET/CT|Planning for Therapeutic conventional surgery of the N0 neck is documented prior to and immediately after review of the fludeoxyglucose F 18 (FDG)-PET/CT scan completed per protocol.
89600092|NCT05907629||CAPTIVA-MRI Group|CAPTIVA patients with stroke attributed to 70-99% intracranial atherosclerotic stenosis (ICAS) to aspirin plus ticagrelor, clopidogrel, or rivaroxaban.
89600093|NCT05907096|Experimental|ARGX-117|Patients receiving ARGX-117 intravenous infusions
89600094|NCT05907096|Placebo Comparator|Placebo|Patients receiving placebo intravenous infusions
89600095|NCT05904379|Experimental|AK112, AK104 dose 1 plus carboplatin and paclitaxel|
89600096|NCT05904379|Experimental|AK112, AK104 dose 1 plus carboplatin and pemetrexed|
89600097|NCT05904379|Experimental|AK112, AK104 dose 2 plus carboplatin and paclitaxel|
89600098|NCT05904379|Experimental|AK112, AK104 dose 2 plus carboplatin and pemetrexed|
89600099|NCT05904379|Experimental|AK112 plus AK104|
89600100|NCT05904379|Experimental|AK112, AK104 plus docetaxel|
89600101|NCT05904379|Active Comparator|docetaxel|
89600102|NCT05903092|Experimental|Durvalumab + Monalizumab + Chemotherapy|"On Day 1 of every Cycle for the first 4 Cycles (Cycle = 21 Days):~Durvalumab 1500mg IV, Monalizumab 1500mg IV, Either Carboplatin AUC 5-6 OR Cisplatin 75-80mg/m^2~On Days 1-3 of every Cycle for the first 4 Cycles:~Etoposide 80-100mg/m^2~On Day 1 of Cycles 5+ (Cycle = 28 Days):~Durvalumab 1500mg IV Monalizumab 1500mg IV"
89210221|NCT00902460|Experimental|Treatment Sequence 1|
89210222|NCT00902460|Experimental|Treatment Sequence 2|
89600103|NCT05900271|Experimental|intermittent theta burst transcranial magnetic stimulation (iTBS)|5-day multi daily neuronavigated intermittent theta burst sessions (developed by Stanford University) and coined, SNT, i.e., Stanford NeuromdulaTion protocol
89600104|NCT05900271|Active Comparator|10 Hz repetitive-transcranial-magnetic-stimulation (rTMS)|6-weeks standard 10 Hz rTMS
89600105|NCT05897801||Patients with a respiratory tract infection|Patients entering the emergency department of the sites, presenting with symptoms compatible with the diagnosis of respiratory tract infection.
89600106|NCT05894187|No Intervention|Control group (no video)|Children in this group will not receive a link to view an informational animated prior to their surgery date
89600107|NCT05894187|Experimental|Intervention group ( video)|Children in this group will receive a link to view an informational animated video 3 nights prior to their surgery date.
89600108|NCT05889494|Experimental|Autologous Whole Blood Management|Intraoperative high volume autologous whole blood withdrawal prior to cardiopulmonary bypass (CPB) with re-transfusion following weaning from CPB.
89600109|NCT05889494|Active Comparator|Allogenic and Derivative Transfusion|Control arm participants will receive standard care involving transfusion of plasma, platelets, cryoprecipitate, and/or lyophilized concentrates following weaning from CPB.
89600110|NCT05889182|Experimental|Period 1: Upadacitinib Dose A|Participants will receive Upadicitinib Dose A once daily for 16 weeks.
89600111|NCT05889182|Placebo Comparator|Period 1: Placebo|Participants will receive Placebo once daily for 16 weeks.
89600112|NCT05889182|Experimental|Period 2: Group 1 - Upadacitinib Dose A|Participants who were randomized to placebo in Period 1 who did not achieve HiSCR 50 (clinical non-responder, CNR) at Week 16 will receive Upadacitinib Dose A once daily for 20 weeks.
89600113|NCT05889182|Placebo Comparator|Period 2: Group 2 - Placebo|Participants who were randomized to placebo in Period 1 who achieve HiSCR 50 (clinical responder, CR) at Week 16 will continue to receive placebo once daily for 20 weeks.
89600114|NCT05889182|Experimental|Period 2: Group 3 - Upadacitinib Dose A|Participants who were randomized to upadacitinib Dose A in Period 1 who did not achieve HiSCR 50 (CNR) at Week 16 will continue to receive upadacitinib Dose A once daily for 20 weeks.
89600115|NCT05889182|Experimental|Period 2: Group 4 - Upadacitinib Dose A|Participants who were randomized to upadacitinib Dose A in Period 1 who achieve HiSCR 50 (CR) at Week 16 will receive upadacitinib Dose A once daily for 20 weeks.
89600116|NCT05889182|Experimental|Period 2: Group 5 - Upadacitinib Dose B|Participants who were randomized to upadacitinib Dose A in Period 1 who achieve HiSCR 50 (CR) at Week 16 will receive upadacitinib Dose B once daily for 20 weeks.
89600117|NCT05889182|Experimental|Period 2: Group 6 - Placebo|Participants who were randomized to upadacitinib Dose A in Period 1 who achieve HiSCR 50 (CR) at Week 16 will receive placebo once daily for 20 weeks.
89600118|NCT05889182|Experimental|Period 3: Long-Term Extension|Eligible participants will continue to receive upadacitinib or placebo for 68 weeks. Participants will be followed-up for approximately 30 days.
89600119|NCT05887167|Experimental|CAR T Therapy with Autologous Hematopoietic Stem Cells (aHSCs)|
89600120|NCT05886478||Brentuximab Vedotin|Participants with CTCL who were retreated with BV after relapse will be observed retrospectively and the outcomes will be observed from June 2023 to September 2023.
88979950|NCT06001502|No Intervention|Control Group|Conventional post-operative pain and anxiety management
88979951|NCT06001489|Active Comparator|Control group|"This patient group received A standard form of patient education, consisting of oral information and an informative flyer during their outpatient clinic visit. After this visit, patients were asked to fill out 2 validated questionnaires: Spielberger's State-Trait Anxiety Inventory (STAI) and the Amsterdam Preoperative Anxiety and Information Scale (APAIS).~1 day prior to surgery, during admission to the hospital, patients were asked to fill out the STAI and APAIS again."
88979952|NCT06001489|Experimental|Intervention group - VR|"This patient group first received a standard form of patient education, consisting of oral information and an informative flyer. Additionally, patients watched a 360-degree VR Tour using a Pico G2 4K VR headset, describing their entire clinical pathway in more detail.~After this visit, patients were asked to fill out 2 validated questionnaires: Spielberger's State-Trait Anxiety Inventory (STAI) and the Amsterdam Preoperative Anxiety and Information Scale (APAIS).~1 day prior to surgery, during admission to the hospital, patients were asked to fill out the STAI and APAIS again."
88979953|NCT06001476|Experimental|Cold snare polypectomy group|
88979954|NCT06001450||Pregnant people with Crohns disease (Case)|Arm 1 is pregnant people with Crohns disease who enroll with the infant that they are pregnant with at the time.
88979955|NCT06001450||Pregnant people without Crohns disease (Control)|Arm 2 is the control arm of pregnant people without Crohns disease and other inflammatory bowel diseases who enroll with the infant that they are pregnant with at the time.
88979956|NCT06001424|Experimental|study group|will receive physical therapy program of in addition to life kinetik training.
88979957|NCT06001424|Active Comparator|control|will receive physical therapy program
88979958|NCT06001411|Experimental|Prone Position Training group (PPT group)|All patients were admitted to our hospital at least 3 days before surgery. Patients in the intervention group (PPT group) received the prone position training daily in the hospital, three times a day, and about 1 hours every times, for at least 3 days before surgery. On the day of admission to the hospital, the patients in the PPT group were instructed to perform prone position training by nurses who were previously trained by prone position training.
88979959|NCT06001411|Placebo Comparator|Control group (C group)|Patients in the control group (C group) received standard perioperative care without any prone position training.
88979960|NCT06001203|Experimental|intervention group|The intervention group is received two reflexology sessions.
88979961|NCT06001203|No Intervention|control group|The control group is given routine care and no intervention will be performed.
88979962|NCT06001190|Active Comparator|probiotic intervention|probiotic group with daily treatment
88979963|NCT06001190|Placebo Comparator|placebo|placebo-controlled with daily treatment
88979964|NCT06001164|Active Comparator|Double-bundle|
88979965|NCT06001164|Active Comparator|Single-bundle|
88979966|NCT06001151|Experimental|Experimental Arm|Patients will receive cadonilimab (10mg/kg) plus pemetrexed(500mg/m2) and carboplatin (AUC=5) every 3 weeks for 4 cycles, follwed with cadonilimab (10mg/kg) plus pemetrexed (500mg/m2) every 3 weeks as maintenance therapy.
88979967|NCT06001086|Experimental|Disitamb Vedotin combined with pyrotinib|Disitamb Vedotin: 2 mg/kg，ivgtt，d1,14/28day/cycle pyrotinib:320mg, oral, every day.
88979968|NCT06001073||Coronary artery disease group|Diagnosis of coronary artery disease by clinical guidelines.
88979969|NCT06001073||Arrhythmia group|Diagnosis of arrhythmia by clinical guidelines. by clinical guidelines.
88979970|NCT06001073||Heart valve disease group|Diagnosis of heart valve disease by clinical guidelines.
88979971|NCT06001073||aortic dissection group|Diagnosis of aortic dissection by clinical guidelines.
89600121|NCT05878860|Experimental|Cohort 1|ATSN-201 at Low Dose
89600122|NCT05878860|Experimental|Cohort 2|ATSN-201 at High Dose
89600123|NCT05878860|Experimental|Cohort 3, High Dose|ATSN-201 at High Volume
89600124|NCT05878860|Experimental|Cohort 3, Low Dose|ATSN-201 at Low Volume
89600125|NCT05878860|No Intervention|Cohort 3, Control|
89600126|NCT05878860|Experimental|Cohort 4, Pediatric|ATSN-201 at High Dose
89600127|NCT05877664|Experimental|Part1：Dose Escalation|"During the dose-escalation stage, an accelerated titration design (ATD) will be utilized for the first three lower dose groups (0.06, 0.12 and 0.18 mg/m^2). The conventional 3+3 dose escalation method will be used for the subsequent dose groups. The entire duration of 21 days after the first dose of ZG0895.HCl is defined as the dose-limiting toxicity (DLT) observation period."
89600128|NCT05871385|Experimental|Group A (r TMS group)|"Twenty five randomly assigned patients with peripheral vestibular disorders will undergo 10 Hz rTMS to the dorsolateral prefrontal cortex of their dominant hemisphere; in addition to designed vestibular rehabilitation exercises.~Device: repetitive transcranial magnetic stimulation high frequency (10 HZ) rTMS pulses are applied to the dorsolateral prefrontal cortex of the dominant hemisphere."
89600129|NCT05871385|Placebo Comparator|Control (Group B) (placebo rTMS)|Twenty five randomly assigned patients with peripheral vestibular disorders will undergo placebo rTMS plus designed vestibular rehabilitation exercises.
89600130|NCT05870488|Other|Use of iFuse TORQ for SI Joint Fusion|Participants with SI joint dysfunction are treated with iFuse TORQ.
89600131|NCT05870332||All patients|Patient ≥18 years old, with capacity to consent, scheduled for diagnostic colonoscopy
89600132|NCT05868005|Experimental|Primary care centres with the ISMiHealth software tool.|Primary care centres implementing the screening programme through the ISMiHealth software (tool-based arm).
89600133|NCT05868005|No Intervention|Primary care centres that follow current routine care.|Primary care centres that follow the current practices in routine care (non tool-based arm).
89600134|NCT05866549|Experimental|Intervention Group|
89600135|NCT05866549|No Intervention|Control Group|
89600136|NCT05863624|Experimental|Open hernioplasty|Open Lichtenstein hernia repair
89600137|NCT05863624|Active Comparator|TEP hernioplasty|totally endoscopic hernia repair (TEP)
89600138|NCT05858437|Experimental|PA Intervention|The group which receives the PA as a dietary food supplement. A single capsule contains 500mg of sodiumpropionate, which is taken twice daily for 28 days.
89600139|NCT05858437|Placebo Comparator|Placebo Intervention|The control-group receives a placebo instead of propionate. The placebo contains maltodextrin and the same amount of sodium chloride as compared to the PA intervention. The placebo is taken twice per day for 28 days.
89600140|NCT05844618|Active Comparator|Triamcinolone Acetonide (Aristocort® C)|
89600141|NCT05844618|Placebo Comparator|Vehicle|
89600142|NCT05841758|Experimental|Hydroxychloroquine|prednisone (scheduled protocol) + hydroxychloroquine (200-400 mg /day during a 12 months double blind placebo-controlled period, then according to the treating the physician for an additional open period of 12 months)
89600143|NCT05841758|Placebo Comparator|Placebo arm|prednisone (scheduled protocol) + placebo (1-2 tablets/day during a 12 months double blind placebocontrolled period, then the treatment is left to the physician's discretion until M24)
89210223|NCT00988923|Experimental|group a: Hyperthermia (HT)|HT were treated for 20 minutes per session, a total of 8 sessions with device;
89210224|NCT00988923|No Intervention|group b: No intervention|device was switched in off, only bolus was active
89210225|NCT02539446|Other|stable condition & attentional focus|for measure the relationships between task difficulty and attentional focus on supraposture
89210226|NCT02539446|Other|unstable condition & attentional focus|for measure the relationships between task difficulty and attentional focus on supraposture
89600144|NCT05841719|Other|Population from Cantalupo, locality of the Municipality of Cerro Maggiore (MI).|capillary sampling and questionnaires to test feasibility and acceptability
89600145|NCT05838911|Active Comparator|Control Group|The patients in this group were received the chest physiotherapy program for 20 min each day, for five days a week for three consecutive weeks.
89600146|NCT05838911|Experimental|Study Group|The patients in this group were received the same chest physiotherapy program combined with neuromuscular electrical stimulation (NMES) of gluteus max., quadriceps, and calf muscles performed for 30 min /day for five days a week for three consecutive weeks.
89600147|NCT05835765|Experimental|Dynamic Elastometric Body and neurological evaluation|Use of dynamic elastometric body for one week and neurological evaluation before use of body, at 30 minutes after application, at one week after using the device and at 1th months since discharge
89600148|NCT05835765|No Intervention|Neurological evaluation|Neurological evaluation at enrollment, at one week after enrollment and at 1th months since discharge
89600149|NCT05830955|Experimental|Lullaby Group|The preterm newborns who are going to listen a live lullaby from their mothers' voice will be the first group (Lullaby group).
89600150|NCT05830955|Experimental|Breast milk Group|The preterms in the second group (Breast milk group) are going to smell their mothers' breast milk.
89600151|NCT05830955|Other|Control Group|The preterms in the third group (Control group) are going to recieve rutin nursing care interventions.
89600152|NCT05826496|Experimental|Exercise|HLA-A2 positive participants will perform one bout of high-intensity interval training.
89600153|NCT05817812|Experimental|Efanesoctocog alfa|All patients will be treated intravenously once weekly with 50 IU/kg efanesoctocog alfa
89600154|NCT05817110||Computed tomography Cohort|In case of any nodule detection by qXR, it will be classified either as low-risk LNMS(lung nodule malignancy score ) or high-risk LNMS confirmed by radiologist. The patient will be requested to get a CT scan after enrolment in the study.
89600155|NCT05816343|Active Comparator|Orlistat Drug|Drug will be given orally.
89600156|NCT05816343|Placebo Comparator|Placebo|Placebo will be given orally.
89210227|NCT00989079|Experimental|Cohort 1 Sequence 1|Period 1 (fasted) Placebo → Period 2 (fasted) ertugliflozin (E) 10 mg → Period 3 (fasted) E 100 mg → Period 4 (fed) E 100 mg. Each dose of study drug will be separated by a minimum of 7 days.
89600157|NCT05810220|Experimental|Hearing-Impaired Individuals who use Cochlear Implants or Auditory Brainstem Implant (ABI) Devices|"Two types of measurements will be obtained:~Perceptual: one or more sounds are presented and a behavioral response is collected (e.g., judgements of loudness, pitch or other differences between the sounds, or identifying the word or sentence that was said).~Physiological: noninvasive electrophysiological recordings of nervous system activity."
89600158|NCT05807126|Experimental|Treatment (magrolimab, olaparib)|Patients receive magrolimab IV on days 1, 8, 15 and 22 of cycle 1 and days 1 and 15 of subsequent cycles. Patients also receive olaparib PO BID during each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood samples and CT and/or MRI throughout the trial. Patients in the dose-expansion portion of the study also undergo tumor biopsies during screening and on study.
89600159|NCT05805371|Experimental|Treatment plan I (PSCA CAR T-cells)|Patients undergo leukapheresis and lymphodepletion and receive PSCA-CAR T cells IV up to 3 times on study. Patients undergo bone scan, CT scan, tumor biopsy, and collection of blood, stool, and urine samples throughout the trial.
89600160|NCT05805371|Experimental|Treatment plan II (PSCA CAR T-cells, radiation)|Patients undergo leukapheresis, radiation in 2 doses, and lymphodepletion, and receive PSCA-CAR T cells IV up to 3 times on study. Patients undergo bone scan, CT scan, tumor biopsy, and collection of blood, stool, and urine samples throughout the trial.
89600161|NCT05802173|Experimental|TDM-105795 topical solution, 0.0025%|Daily dose of 0.0025% of TDM-105795 topical solution
89600162|NCT05802173|Experimental|TDM-105795 topical solution, 0.02%|Daily dose of 0.02% of TDM-105795 topical solution
89600163|NCT05802173|Placebo Comparator|TDM-105795 topical vehicle solution|Daily dose of placebo for TDM-105795 topical solution
89600164|NCT05798260||Healthy Volunteers|Healthy Volunteers
89600165|NCT05798260||COVID-19 positive admitted to the ICU and on the ventilator|COVID-19 positive admitted to the ICU and on the ventilator
89600166|NCT05797831|Experimental|Part 1 Arm 1|Navtemadlin administered orally at 180 mg, once daily (QD) on Days 1-7 in a 28-day treatment cycles.
89600167|NCT05797831|Experimental|Part 1 Arm 2|Navtemadlin administered orally at 240 mg, once daily (QD) on Days 1-7 in a 28-day treatment cycles.
89600168|NCT05797831|No Intervention|Part 1 Arm 3|"Observational control (watch and wait) on a 28-day cycle."
89600169|NCT05797831|Experimental|Part 2 Arm A|Navtemadlin administered orally at 180 mg once daily (QD) on Days 1-7 in a 28-day treatment cycles.
89600170|NCT05797831|Experimental|Part 2 Arm B|Navtemadlin administered orally at 240 mg once daily (QD) on Days 1-7 in a 28-day treatment cycles.
89600171|NCT05797831|Placebo Comparator|Part 2 Arm C|Placebo administered orally at 180 mg once daily (QD) on Days 1-7 in a 28-day administration cycle.
89600172|NCT05797831|Placebo Comparator|Part 2 Arm D|Placebo administered orally at 240 mg once daily (QD) on Days 1-7 in a 28-day administration cycle.
89600173|NCT05789901|Other|MARVIN: a Chatbot for HIV patients|Co-construction of the chatbot, Usability study, Implementation, Evaluation of outcomes and Continuous improvements
89600174|NCT05789901|Other|MARVIN: a Chatbot for Community Pharmacists|Co-construction of the chatbots, Usability study, Implementation, Evaluation of outcomes and Continuous improvements
89600175|NCT05789901|Other|MARVINA: a Chatbot for Breast Cancer Patients|Co-construction of the chatbots, Usability study, Implementation, Evaluation of outcomes and Continuous improvements
89600176|NCT05789901|Other|MARVIN CHAMP: a Chatbot for Pediatric Infectious Conditions|Co-construction of the chatbots, Usability study, Implementation, Evaluation of outcomes and Continuous improvements
89600177|NCT05788094|Experimental|Dihydroartemisinin-piperaquine plus tafenoquine (450 mg adult dose)|"Dihydroartemisinin-Piperaquine will be purchased as Duo-Cotecxin® Beijing Holley-Cotec Pharmaceuticals Co., Ltd, China). One tablet contains 40 mg of dihydroartemisinin and 320 mg piperaquine (i.e. a 1:8 ratio). A weight-based regimen containing a total dose of approximately 7 mg/kg DHA and 55 mg/kg piperaquine given in 3 divided doses once daily.~Tafenoquine KOZENIS® 100 mg film-coated tablets will be purchased from Biocelect (Suite 5.02, Level 5, 139 Macquarie Street, Sydney NSW, 2000 Australia), 450 mg (4 1/2 tablets) will be given."
89600178|NCT05788094|Experimental|Chloroquine plus Tafenoquine (450 mg adult dose)|"Chloroquine will be dosed as a 25 mg/kg base given in divided doses of 10 mg/kg orally on days 0 and 1, and in 5 mg/kg dose on day 2. Tablets will be obtained from Government Pharmaceutical Organization (GPO) in Bangkok, Thailand and supplied as 250 mg tablets (155.3 mg base).~Tafenoquine KOZENIS® 100 mg film-coated tablets will be purchased from Biocelect (Suite 5.02, Level 5, 139 Macquarie Street, Sydney NSW, 2000 Australia), 450 mg (4 1/2 tablets) will be given."
89600179|NCT05788094|Experimental|Artemether-Lumefantrine plus Tafenoquine (450 mg adult dose)|"Artemether-Lumefantrine will be given at a standard dose of 20/120 mg twice daily for three days. (AL will be purchase from Novartis Pharma Services AG- Lichtstrasse 35, CH-4056 Basel, Switzerland.~Tafenoquine KOZENIS® 100 mg film-coated tablets will be purchased from Biocelect (Suite 5.02, Level 5, 139 Macquarie Street, Sydney NSW, 2000 Australia), 450 mg (4 1/2 tablets) will be given."
88979972|NCT06001073||Cardiac masses group|Diagnosis of cardiac messes by clinical guidelines.
88979973|NCT06001073||Myocarditis group|Diagnosis of myocarditis by clinical guidelines.
88979974|NCT06001073||Hypertension group|Diagnosis of hypertension by clinical guidelines.
88979975|NCT06001073||Cardiomyopathy group|Diagnosis of cardiomyopathy by clinical guidelines.
89210228|NCT00989079|Experimental|Cohort 1 Sequence 2|Period 1 (fasted) E 0.5 mg → Period 2 (fasted) Placebo → Period 3 (fasted) E 100 mg → Period 4 (fed) E 100 mg. Each dose of study drug will be separated by a minimum of 7 days.
88979976|NCT06001073||Structural heart disease group|Diagnosis of structural heart disease by clinical guidelines.
88979977|NCT06001073||Ischemic cerebrovascular disease group|Diagnosis of ischemic cerebrovascular disease by clinical guidelines.
88979978|NCT06001073||Hemorrhagic cerebrovascular disease group|Diagnosis of hemorrhagic cerebrovascular disease by clinical guidelines.
88979979|NCT06001073||Intracranial space occupying lesion group|Diagnosis of intracranial space occupying by clinical guidelines.
88979980|NCT06001060||women of reproductive age with elevated homocysteine levels|
88979981|NCT06001034|Experimental|Group 1: Aerobic exercise plus occlusive tool.|Performing low-impact aerobic exercise with an occlusive tool 2 days per week.
89600180|NCT05785104|Experimental|Myofascial release|The patients will receive myofascial release technique on cervical and lumbar regions three times per week for four weeks
89600181|NCT05785104|Experimental|Muscle energy technique|The patients will receive muscle energy technique for cervical and lumbar regions three times per week for four weeks
89600182|NCT05783661|Active Comparator|Conventional antibiotic strategies|The control group will receive treatment according to the local guidelines of the Hospital Clinic de Barcelona.
89600183|NCT05783661|Experimental|Regimens guided by epidemiological surveillance|The experimental group will receive treatment to the local guidelines of the Hospital Clinic de Barcelona guided by colonization/epidemiological surveillance.
89600184|NCT05775510||Pilot Phase Cohort|
89600185|NCT05775510||Data at Scale Phase Cohort|
89600186|NCT05774041||SIS Group|Standard of care DBS surgery + use of (FDA-cleared) SIS System for preoperative target planning
89600187|NCT05774041||Control Group|Standard of care DBS surgery and preoperative target planning
89600188|NCT05770375|Experimental|MDMA|Each subject will receive 3 doses of MDMA in ascending order: 40mg, 80mg, 120mg.
89600189|NCT05766839|Experimental|Patiromer|"4-week pharmacodynamic (PD)/dose-ranging period~Cohort 1: 6 to <12 years of age~Cohort 2: 2 to <6 years of age~Cohort 3: 0 to <2 years of age); In Cohort 3, a minimum of 3 study participants will be assessed in the sub-group of 0 to <6 months and another 3 study participants in the sub-group 6 to <24 months of age."
89600190|NCT05766228|Experimental|Experimental|Web-Based Intercultural Midwifery Training
89600191|NCT05766228|No Intervention|Control|without any intervention
89600192|NCT05761106|Experimental|Oculomotor Therapy|The procedures for oculomotor therapy will be arranged sequentially, from easiest to most difficult. It will consist of a convergence technique (Brock Cord and Barrille Cartouche) and an accommodative technique (Eccentric circles or lifesaving cards) and Eye Relaxation.
89600193|NCT05761106|Active Comparator|Therapy for Temporomandibular Disorder|"Extra-oral and intra-oral massage: The main objective is to reduce pain as well as re-establish proper muscle length and flexibility. The patient will be instructed to use diaphragmatic breathing to promote relaxation during these massage procedures.~Myofascial release of the masseter, temporalis and sternocleidomastoid muscles, release of neck soft tissues, cervical pomp, suboccipital inhibition, passive anteroposterior mobilization of the upper cervical, cervical exercises, Temporomandibular Joint exercises (mouth opening exercise with tongue on palate) , Proprioceptive exercises)."
89600194|NCT05758506||Pediatric PID patients (prospective)|Prospective, age-matched, healthy patients
89600195|NCT05758506||Pediatric PID patients (recontacted from registry)|
89600196|NCT05758506||Prospective, age-matched, healthy patients|
89600197|NCT05757141|Experimental|ABBV-CLS-7262 - Cohort 1|Cohort 1: VWM adults ≥18 years
89600198|NCT05757141|Experimental|ABBV-CLS-7262 - Cohort 2|Cohort 2: VWM children ≥12 y and <18 years
89600199|NCT05757141|Experimental|ABBV-CLS-7262 - Cohort 3|Cohort 3: VWM children ≥6 y and <12 years
89600200|NCT05750147||Cardiomyopathies|"Approximately 1000 participants recruited prospectively from participating sites with a diagnosis of cardiomyopathy~Participants will provide biosamples and allow access to medical scans and records for health data collection"
89600201|NCT05749432|Experimental|Hemay181|"Part one: Dose Escalation Group Hemay181 will be injected in doses of 4.5 mg/m^2, 9.0 mg/m^2, and 18 mg/m^2 until any drug-related toxicity of grade 2 or higher is observed in any dose group. Next, Hemay181 will be injected in doses of 36mg/m^2, 60mg/m^2, 90mg/m^2, 120mg/m^2, 150mg/m^2, 180mg/m^2, 210mg/m^2 until there are two cases of dose-limiting toxicity in a dose group.~Part two: Extension Group Hemay181 will be injected in the highest three dose groups that had been assessed until disease progression."
89600202|NCT05748028||Parkinson Disease|Patients affected by Parkinson's disease admitted for rehabilitation in Maugeri Clinical Scientific Institutes
89600203|NCT05748028||Multiple System Atrophy|Patients affected by Multiple System Atrophy admitted for rehabilitation in Maugeri Clinical Scientific Institutes
88979982|NCT06001034|No Intervention|Group 2: Aerobic exercise without occlusive tool.|Performing low-impact aerobic exercise without an occlusive tool 2 days per week.
88979983|NCT06001021|Experimental|Psychopharmacological Intervention|This group will receive psychopharmacological intervention with perinatal safe light doses of antidepressants (see Langan et al., 2016; Schoretsanitis et al., 2021) and/or anxiolytic medications (see Nishimura et al, 2021; Saito et al, 2022) by a gynecologist. Selective Serotonin Reuptake Inhibitor (Escitalopram, 5-10 mg in pregnancy and Sertraline, 12.5-25 mg in postpartum) and/or Benzodiazepine (Alprazolam, 0.25-0.5 mg) will be prescribed in tablet form per day.
88979984|NCT06001021|Experimental|Cognitive Behavioral Couple Therapy (CBCT) Intervention|This group will receive CBCT intervention from a trained psychologist in CBT. There are two conditions of CBCT, i) with Zikr, and ii) without Zikr.
89600204|NCT05748015|Active Comparator|relapsing-remitting multiple sclerosis|Patients with relapsing-remitting multiple sclerosis will be hospitalized in Maugeri Clinical Institute of Telese Terme for a rehabilitation treatment and will perform a functional and morphological study of sensory and autonomic nervous system, evaluation of peripheral sensory and autonomic nerve fibers performed by skin biopsy.
89600205|NCT05748015|Active Comparator|primary progressive multiple sclerosis|Patients with primary progressive multiple sclerosis will be hospitalized in Maugeri Clinical Institute of Telese Terme for a rehabilitation treatment and will perform a functional and morphological study of sensory and autonomic nervous system, evaluation of peripheral sensory and autonomic nerve fibers performed by skin biopsy.
89600206|NCT05747937|Experimental|Amyotrophic Lateral Sclerosis patients|Amyotrophic Lateral Sclerosis (ALS) patients within 18 months from symptoms onset will be recruited
89600207|NCT05747937|Active Comparator|Healthy controls|A population of healthy controls matched for sex and age will be enrolled
89600208|NCT05746923||LECRA-HF patients|The study population consists of hospitalized patients with acute heart failure who are over 18 years of age, both women and men. Patients will be initially categorized into one of three groups based on the current European Society of Cardiology (ESC) heart failure guidelines based on left ventricular ejection fraction (LVEF) values: patients with reduced (LVEF ≤40%), mildly reduced (LVEF 41-49%) and preserved (LVEF ≥50%) ejection fraction.
89600209|NCT05736354||BII Subjects|Subjects with breast implants having BII manifestations.
89600210|NCT05736354||Non-BII Subjects|Subjects with breast implants with no reported BII symptoms.
89600211|NCT05736354||Subjects without Breast Implants|Subjects without breast implants.
88979985|NCT06001021|Experimental|Combined Intervention|This group will receive Medicine (prescribed by a consultant gynecologist) and CBCT intervention (with or without Zikr) from a trained psychologist in CBT.
89600212|NCT05735015|Experimental|Treatment|All participants given 5 days of encaleret twice daily
89600213|NCT05733494||Patients with neurodegenerative disease|Patients with neurodegenerative disease
89600214|NCT05732350||Group 1|Patients in group 1 already receive a DOAC and will start treatement with an SMI. Blood samples will be drawn before start of the SMI and during concomittant use with the SMI.
89600215|NCT05732350||Group 2|Patients in group 2 already use a potentially relevant DOAC-SMI combination or already use an SMI and start with a DOAC. In this group, blood samples are taken after the start of concomittant use of the DOAC-SMI combination.
89600216|NCT05731765||Patients aged ≥18 years with presumed normal intracranial pressure|
89600217|NCT05731765||Patients aged ≥18 years with suspected raised intracranial pressure|
89600218|NCT05728476|Experimental|Vitrectomy group|Standard 25-gauge PPV will be performed by an experienced surgeon under retrobulbar anesthesia. After clearing the central vitreous, a complete posterior vitreous detachment (PVD) will be achieved with aspiration to remove the tightly attached posterior hyaloid. The vitreous will be removed by a high-speed vitrectomy surgical system (Constellation Vision System, Alcon Laboratories, Fort Worth, Texas, USA). The ILM stained with indocyanine green (ICG) will be peeled up to the vascular arcades. In case of need, panretinal photocoagulation (PRP) can be performed during surgery. The vitreous cavity will be filled with balanced salt solution (BSS) at the end of the procedure.
89600219|NCT05728476|Active Comparator|Anti-VEGF group|Patients will receive three monthly intravitreal injections of 0.5 mg Conbercept (Chengdu Kanghong Biotech Co.) with a 30-gauge syringe needle approximately 3.5-4 mm posterior to the corneal limbus under topical anesthesia.
89600220|NCT05724108|Experimental|Arm 1 (triapine, lutetium Lu 177 dotatate)|Patients receive triapine PO on days 1-14 of each cycle and lutetium Lu 177 dotatate IV over 30 minutes on day 1 of each cycle. Cycles repeat every 8 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and/or MRI and collection of blood samples throughout the trial.
89600221|NCT05724108|Active Comparator|Arm 2 (lutetium Lu 177 dotatate)|Patients receive lutetium Lu 177 dotatate IV over 30 minutes on day 1 of each cycle. Cycles repeat every 8 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and/or MRI and collection of blood samples throughout the trial.
89600222|NCT05720962|Experimental|experimental group|The experimental group will be provided with routine midwife support and uninterrupted accompanying support.
89600223|NCT05720962|No Intervention|control group|Only routine midwife support will be provided to the control group.
89600224|NCT05717842||People with ESLD and eGFR between >=25 and <=40ml/min|"> 18 years old~Listed for Liver Transplant for ESLD and Kidney Transplant (not on dialysis)~Candidates with two native kidneys.~Willing to participate and sign informed consent"
88979986|NCT06001021|Placebo Comparator|Control (Placebo and No Intervention)|This group will receive a placebo from a gynecologist or no intervention from a trained psychologist.
88979987|NCT06001021|No Intervention|Other|This group will receive no intervention from a trained psychologist.
89600225|NCT05716295|Experimental|MDK-703 Monotherapy|MDK-703 will be administered in sequential ascending doses as a monotherapy until unacceptable toxicity, disease progression, or withdrawal of consent.
89600226|NCT05716295|Experimental|MDK-703 in combination with a checkpoint inhibitor|MDK-703 will be administered in sequential ascending doses in combination with a checkpoint inhibitor until unacceptable toxicity, disease progression, or withdrawal of consent.
89600227|NCT05715281|Experimental|Treatment (atezolizumab, tiragolumab)|Patients receive atezolizumab and tiragolumab intravenously (IV) on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo ECHO during screening, and CT scans during screening, at the end of cycle 3 and every 2 cycles thereafter. Patients undergo tumor biopsy at baseline, on cycle 3 day 1 and optionally at response or disease progression, and blood sample collection at baseline, on day 1 of every subsequent cycle, and at time of response/disease progression on study.
89600228|NCT05715021|Experimental|Bankart repair + Remplissage|Arthroscopic repair of anterior capsulo-labral structures
88979988|NCT06001008||General or regional anesthesia|Patients who have undergone inguinal or umbilical hernia surgery
88979989|NCT06000995||Pulmonologists|pulmonologists actively performing fiberoptic bronchoscopy
88979990|NCT06000982|Experimental|PTCy-40|Patients receive 40mg/kg PTCY (day+3 and +4) with tacrolimus from day+5 and low-dose ATG of 2,5mg/kg 72 hours after documentation neutrophil engraftment.
88979991|NCT06000982|Active Comparator|PTCy-50|Patients receive 50mg/kg PTCY (day+3 and +4) with tacrolimus from day+5 and low-dose ATG of 2,5mg/kg 72 hours after documentation neutrophil engraftment.
88979992|NCT06000969|Experimental|Conventional group (group C)|Patients will be shifted to 100% Oxygen then; the recruitment maneuver will be performed by manual inflation with a pressure of 30 cmH2O for 30 seconds.
88979993|NCT06000969|Experimental|Ultrasound-guided group (group US)|Patients will be shifted to 100% Oxygen then; the recruitment maneuver will be performed under the direct real-time guidance of ultrasound if atelectasis (defined as LUS of ≥ 2 for any of the 12 regions) is present. This will be done by manual inflation with a pressure of 10 cmH2O for 10 seconds, increased 10 cmH2O every 10 seconds until no collapsed areas are visible on the ultrasound, the maximum airway pressure will be limited to 40 cmH2O. This could be repeated if needed.
88979994|NCT06000956|Experimental|Jitongning tablets|
88979995|NCT06000956|Placebo Comparator|a simulated agent of Jitongning tablets|
88979996|NCT06000930||marathon runners|Marathon runners
88979997|NCT06000930||myocardial infarction|Patients with Type 1 myocardial infarction
89600229|NCT05715021|No Intervention|Conservative treatment|Non surgical intervention
89600230|NCT05714501|Experimental|Single Arm|Millipede System
89600231|NCT05707234|Active Comparator|Control Group|"During the procedure, the patient in the control group receives pharmacological sedation, which is the standard of care currently practiced. Such sedation allows intraoperative anxiolysis, which is constantly required by patients in order to dissociate from their surroundings. Recall that total knee replacement surgery is extremely noisy, and the surrounding environment is itself an anxiety-provoking factor for the patient. Light to moderate, intraoperative sedation is carried out by intermittent boluses of midazolam 1 mg IV. Boluses are given every 5 minutes until a sedation level of -2 or -3 on the RASS (Richmond Agitation-Sedation Scale) scale is reached.~Patients randomized to the control group will undergo perioperative anesthesia according to the current standards of care, without the addition of the VR headset or headphones."
89600232|NCT05707234|Experimental|VRH Group|"They will experience an underwater experience while listening to hypnotic script designed to induce a change in state of consciousness, increasing parasympathetic system tone and relaxation response, and reducing the perception of painful stimuli.~During the whole procedure, an anesthesiologist will perform the usual cares, including closely monitoring, and will administrate intravenous sedation (midazolam) when necessary (see sedation protocol in the previous section)."
89600233|NCT05697302|Experimental|Relactation|
89600234|NCT05697302|Active Comparator|Control|
89600235|NCT05691517|Experimental|Treatment (CBX-12)|Patients receive CBX-12 IV on study. Patients undergo tumor biopsy and CT scans on study and undergo blood sample collection throughout the trial.
89600236|NCT05691491|Experimental|Treatment (tuvusertib, temozolomide)|Patients receive tuvusertib PO QD) on days 1-7 and temozolomide PO QD on days 1-5 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan and MRI as well as collection of blood samples throughout the trial. Patients also undergo a biopsy at baseline and may undergo one on study and/or at time of progression.
89600237|NCT05689970||STE patients|Patients with ST segment elevation (STE) and coronary arteries without significant lesions and without a serum troponin curve suggestive of acute necrosis (group without acute myocardial necrosis).
89600238|NCT05689970||STEMI patients|Patients with ST segment elevation with acute occlusion of at least one epicardial coronary artery and TIMI flow 0 or I (group with acute myocardial necrosis of ischemic origin), that meet the definition of myocardial infarction (STEMI) with an acute cardiac necrosis curve verified by measurement of troponin I or troponin T.
89600239|NCT05687123|Experimental|Treatment (sunitinib malate, lutetium Lu 177 dotatate)|Patients receive sunitinib malate PO QD from day 1 of lutetium 177 dotatate therapy to 28 days after the last dose of lutetium 177 dotatate in the absence of unacceptable toxicity. Patients also receive lutetium Lu 177 dotatate IV over 30 minutes on day 1 of each cycle. Cycles repeat Q8W for 4 cycles in the absence of unacceptable toxicity. Patients undergo a CT scan and/or MRI throughout the trial. Patients also undergo a SSR PET/CT scan during screening and blood sample collection on study.
89600240|NCT05682066|Experimental|Innovalve TMVR System|MV replacement with Innovalve MR system
89600241|NCT05678374||Graves' patients with mental fatigue|Women diagnosed with Graves 15 moths to 60 months ago with Mental Fatigue Scale score of more than 13 (maximum 42, cut of 10,5 for mental fatigue)
89600242|NCT05678374||Graves' patients without mental fatigue|Women diagnosed with Graves 15 moths to 60 months ago with Mental Fatigue Scale score of less than 8 (maximum 42, cut of 10,5 for mental fatigue)
89600243|NCT05678374||Thyroid healthy controls without mental fatigue|Women without current or previous thyroid disease and with Mental Fatigue Scale scores of less than 8
89600244|NCT05678101|Active Comparator|TENS|The Chattanooga Physio TENS (DJO Global, Vista, CA) will be applied with mixed burst / TENS alternated, which is a 30-minutes programmed. The stimulation frequencies of this alternative vary every 3 seconds, producing a combined stimulation of 80 Hz and 2 Hz. The energy intensity level will firstly be adjusted for 80 Hz (TENS) until a tingling sensation is felt, and then the procedure will be repeat for 2 Hz to produce visible, but not painful, muscle twitches. The patient will use a pair of pants with integrated stimulation electrodes, to which the CE-marked TENS device (Chattanooga Physio, DJO Nordic, Malmö, Sweden) will be connected and used to provide pain relief, in addition to usual postoperative care. The TENS device will be connected to the textile electrodes of the pants, which are located just 5cm in front, respectively behind the hip incision dressing.
89600245|NCT05678101|Sham Comparator|Control|The control group will also receive the TENS-pants described above with integrated stimulation electrodes, connected to TENS treatment. However, the TENS treatment to the control group will be set so that no electricity will reach the patient. In all other regards, the control group will follow the same protocol as the intervention group.
89600246|NCT05676242|Experimental|Jaktinib 100mg BID|Drug: Jaktinib Hydrochloride Tablet 100mg dosage, orally administered, twice a day
89600247|NCT05676242|Experimental|Jaktinib 75mg BID|Drug: Jaktinib Hydrochloride Tablet 75mg dosage, orally administered, twice a day
89600248|NCT05676242|Placebo Comparator|Placebo|Drug: Placebo Orally administered, twice a day
89600249|NCT05671770||Cohort 1|Patients with chronic kidney disease
89600250|NCT05671770||Cohort 2|Patients with hypertrophic cardiomyopathy
89600251|NCT05669677||Standard|Chronic liver disease
89600252|NCT05668286|Active Comparator|posterior intra-articular steroid injection under USG guidance|Intra-articular steroid injection will be performed to the glenohumeral joint from the posterior, 2cm inferior and 2cm medial of the acromion posterolateral corner, under the guidance of USG.
89600253|NCT05668286|Active Comparator|anterior extra-articular steroid injection under USG guidance|Steroid injection will be performed from the anterior, immediately lateral to the coracoid process, to the CHL localization, to the extra-articular area under the guidance of USG.
89210229|NCT00989079|Experimental|Cohort 1 Sequence 3|Period 1 (fasted) E 0.5 mg → Period 2 (fasted) E 10 mg → Period 3 (fasted) Placebo → Period 4 (fed) E 100 mg. Each dose of study drug will be separated by a minimum of 7 days.
89600254|NCT05660850|Experimental|Part A: CRC Asthma atopic|Patients with CRC atopic asthma will be randomized in a 1:1 ratio to receive GDC-6599 or placebo for 14 days during the first study period (Treatment Period 1, Study Visits 2-4). Following a 14-day washout period, patients will cross over to the second study period (Treatment Period 2, Study Visits 5-7) and will receive the alternate treatment (GDC-6599 or placebo) for 14 days starting at Study Visit 5
89600255|NCT05660850|Experimental|Part A: CRC Asthma non-atopic|Patients with CRC non-atopic asthma will be randomized in a 1:1 ratio to receive GDC-6599 or placebo for 14 days during the first study period (Treatment Period 1, Study Visits 2-4). Following a 14-day washout period, patients will cross over to the second study period (Treatment Period 2, Study Visits 5-7) and will receive the alternate treatment (GDC-6599 or placebo) for 14 days starting at Study Visit 5
89600256|NCT05660850|Experimental|Part A: Unexplained Chronic Cough|Patients with Unexplained Chronic Cough will be randomized in a 1:1 ratio to receive GDC-6599 or placebo for 14 days during the first study period (Treatment Period 1, Study Visits 2-4). Following a 14-day washout period, patients will cross over to the second study period (Treatment Period 2, Study Visits 5-7) and will receive the alternate treatment (GDC-6599 or placebo) for 14 days starting at Study Visit 5
89600257|NCT05660850|Experimental|Part B: Chronic Refractory Cough with Chronic Obstructive Pulmonary Disease|Patients with Chronic Obstructive Pulmonary Disease will be randomized in a 1:1 ratio to receive GDC-6599 or placebo for 14 days during the first study period (Treatment Period 1, Study Visits 2-4). Following a 14-day washout period, patients will cross over to the second study period (Treatment Period 2, Study Visits 5-7) and will receive the alternate treatment (GDC-6599 or placebo) for 14 days starting at Study Visit 5.
89600258|NCT05660850|Experimental|Part B: Chronic Refractory Cough with Chronic Obstructive Pulmonary Disease with Chronic Bronchitis|Patients with Chronic Obstructive Pulmonary Disease with Chronic Bronchitis will be randomized in a 1:1 ratio to receive GDC-6599 or placebo for 14 days during the first study period (Treatment Period 1, Study Visits 2-4). Following a 14-day washout period, patients will cross over to the second study period (Treatment Period 2, Study Visits 5-7) and will receive the alternate treatment (GDC-6599 or placebo) for 14 days starting at Study Visit 5.
89600259|NCT05649982|Experimental|Digital Tool for Problematic Alcohol Use|This is the base version of the intervention with no added guidance.
89600260|NCT05649982|Experimental|Digital Tool for Problematic Alcohol Use + Extra Telephone Interview|This is the same intervention as the base version, with an added mid-treatment telephone interview.
89600261|NCT05649982|Experimental|Digital Tool for Problematic Alcohol Use + Written Guidance|This is the same intervention as the base version, with added weekly written guidance.
89600262|NCT05649982|Experimental|Digital Tool for Problematic Alcohol Use + Extra Telephone Interview and Written Guidance|This is the same intervention as the base version, with added weekly written guidance and an added mid-treatment telephone interview.
89600263|NCT05644964||Group 1:|Anemic pregnancies under the age of 18 (study group),
88979998|NCT06000917|Experimental|pyrotinib,Trastuzumab，carboplatin，Albumin paclitaxel|"Pyrotinib tablets: 320mg qd, 21 days for 1 cycle, continuous administration of 6 cycles.~Trastuzumab: The first cycle was 8mg/kg, the second to sixth cycle was 6mg/kg, 21 days was 1 cycle, continuous administration of 6 cycles.~Albuminpaclitaxel: On the first day of cycle 1, 260mg/m2 was given intravenously, 21 days for 1 cycle, and 6 consecutive cycles were given.~Carboplatin: Endogenous creatinine clearance was calculated using the Cockcroft formula, with AUC 5 for the 1st to 6th cycle and 1 cycle for the 21st day and 6 consecutive cycles of administration"
88979999|NCT06000904|Experimental|Exergame-based balance training group|
88980000|NCT06000904|Active Comparator|Upper limb and trunk training group|
88980001|NCT06000878|Experimental|experimental group|The experimental group received a one-hour e-book course plus one month of first aid e-book intervention and regular training
88980002|NCT06000878|No Intervention|control group|The control group only received one month of regular training.
88980003|NCT06000839|Experimental|CELLBOOSTER® Lift|
88980004|NCT06000800|Experimental|Group (clamping at 30 seconds)|Umbilical cord clamping at 30 seconds
88980005|NCT06000800|Experimental|Group clamping at 60 seconds|Umbilical cord clamping at 60 seconds
88980006|NCT06000800|Experimental|Group clamping at 90 seconds|Umbilical cord clamping at 90 seconds
88980007|NCT06000800|Active Comparator|Group clamping immediately|Umbilical cord clamping immediately after birth (5 second)
88980008|NCT06000735|Experimental|7-Day Continuous Glucose Monitoring with Abbott Freestyle Libre 2|All participants will go through the same intervention described above.
88980009|NCT06000644|Experimental|combined group|The combined group will undertake progressive treadmill walking speed while performing a cognitive task with rhythmic auditory cueing.
88980010|NCT06000644|Active Comparator|cognitive group|The cognitive group will receive cognitive training while walking on the treadmill.
88980011|NCT06000644|Active Comparator|rhythmic group|The rhythmic group will hear rhythmic auditory stimulation while treadmill walking.
88980012|NCT06000644|Active Comparator|treadmill group|The treadmill group will train only in progressive treadmill walking.
88980013|NCT06000618|Experimental|experimental group|The experimental group will undergo intrapulmonary percussive therapy
88980014|NCT06000553|Other|collection of blood and tumor samples|
88980015|NCT06000514|Experimental|Topical Sm29 and Sbv|Use of topical Sm29 twice a day during 20 days and systemic Sbv during 20 days
88980016|NCT06000514|Placebo Comparator|Topical Placebo and Sbv|Use of topical placebo twice a day during 20 days and systemic Sbv during 20 days
88980017|NCT06000449|Experimental|Center M|This intervention will include digital PD screening as well as four weekly one-hour group telehealth Mindfulness Cognitive Behavioral Therapy sessions and digitally delivered home practice materials for skill building between online group sessions.
88980018|NCT06000449|Active Comparator|Treatment as Usual (TAU)|This arm will receive the current standard of care, which includes a paper-based PD screening and a PD educational handout.
88980019|NCT06000358|Active Comparator|Cryotherapy and Pembrolizumab monotherapy;|Patients with metastatic non-small cell lung cancer, who are eligible for first-line pembrolizumab monotherapy (PD-L1 expression equal to or greater than 50%, no EGFR mutations or ALK translocations). Bronchoscopic cryotherapy procedure is performed before the start of systemic treatment.
89600264|NCT05644964||Group 2:|Anemic pregnancies over the age of 35 (study group)
89600265|NCT05644964||Group 3:|Pregnant women under the age of 18 are not anemic (control group)
89600266|NCT05644964||Group 4:|Non-anemic pregnant women over the age of 35 (control group)
89600267|NCT05643638|Experimental|CYP-001 plus corticosteroids|
89600268|NCT05643638|Placebo Comparator|Placebo plus corticosteroids|
89600269|NCT05630053|Active Comparator|Cementless Persona Keel Knee System|Persona PPS CoCr Cementless Femur and Persona OsseoTi Keel Cementless Tibia
89600270|NCT05630053|Active Comparator|Cemented Persona Keel Knee System|Persona Keel Cemented Tibia
89600271|NCT05627375|Experimental|strategy of full-dose anticoagulant therapy alone (AC)|"The experimental group receiving full-dose anticoagulant therapy alone (AC).~Anticoagulant (AC) therapy :at the investigator's discretion in accordance with international recommendations for the management of DVT/PE Antiplatelet therapy will be stopped."
89600272|NCT05627375|Active Comparator|strategy of combined full-dose anticoagulant and antiplatelet therapies (AC+AP)|"The control group receiving the standard of care: Antiplatelet therapy will be combined to full-dose anticoagulant therapy.~Anticoagulant (AC) therapy :at the investigator's discretion in accordance with international recommendations for the management of DVT/PE~Antiplatelet (AP) therapy : Aspirin or Clopidogrel"
89600273|NCT05621798|Active Comparator|Hearing Aid Manufacturer's Software Group|Participants' hearing aids are fitted by using manufacturer's software.
88980020|NCT06000358|Active Comparator|Cryotherapy and Pembrolizumab with platinum-based chemotherapy;|Patients with metastatic non-small cell lung cancer, who are eligible for first-line pembrolizumab and platinum-based chemotherapy (PD-L1 expression less than 50%, no EGFR mutations or ALK translocations). Bronchoscopic cryotherapy procedure is performed before the start of systemic treatment.
88980021|NCT06000358|Active Comparator|Pembrolizumab monotherapy;|Patients with metastatic non-small cell lung cancer, who are eligible for first-line pembrolizumab monotherapy (PD-L1 expression equal to or greater than 50%, no EGFR mutations or ALK translocations).
88980022|NCT06000358|Active Comparator|Pembrolizumab with platinum-based chemotherapy;|Patients with metastatic non-small cell lung cancer, who are eligible for first-line pembrolizumab and platinum-based chemotherapy (PD-L1 expression less than 50%, no EGFR mutations or ALK translocations).
88980023|NCT06000345|Experimental|AOT + MI group|The AOT + MI group was shown a video (4 minutes) in which a subject (matched for age, sex, and limb affected) performed, in third person view, quadriceps concentric contractions for 2 minutes and isometric contractions for 2 minutes. The video contained visual elements indicating the maximality of the effort. After both concentric and isometric movement video the subjects performed a MI session (1 minute in length each), in which they were asked to imagine in first person the action previously observed in the video.
88980024|NCT06000345|Sham Comparator|Control group|The control group was shown a video of landscapes (4 minutes in length). Halfway through and at the end of the video they were asked to imagine what they had just seen for 1 minute.
88980025|NCT06000319||Lumbar Interbody Fusion with NMP|Subject has undergone lumbar interbody spine fusion at no more than 3 adjacent levels between L1 and S1 where NMP fibers have been used as a bone void filler
89600274|NCT05621798|Active Comparator|REM Group|Participants' hearing aids are fitted by REM (Real Ear Measurements) method.
89600275|NCT05610319|Experimental|Treat and Extend|Participants randomized to the T&E Arm will initially receive 6 milligrams (mg) faricimab intravitreal (IVT) injections monthly (28d +/-7 days), with treatment intervals increased/extended, reduced, or maintained based on CST assessments, until week 100.
89600276|NCT05610319|Other|Control/Usual Care Arm|Participants in the control arm will receive 6 milligrams (mg) faricimab intravitreal (IVT) injections monthly (28d +/-7 days), for 6 treatments. Afterwards, participants will continue to receive 6mg faricimab IVT every 8 weeks until week 100.
89600277|NCT05604547|Other|1|Single-arm study
89600278|NCT05602597|Experimental|Part A - Itraconazole|"Period 1 -- Participants to receive 10mg dose of HMPL-689 by mouth as a single agent treatment on Day 1~Period 2 -- Participants to receive 200mg Itraconazole by mouth twice daily beginning on Day 3 through Day 10. On Day 7 200 mg Itraconazole and 10 mg HMPL-689 will be simultaneously administered."
89600279|NCT05602597|Experimental|Part B - Fluconazole|"Period 1 -- Participants to receive 10mg dose of HMPL-689 by mouth as a single agent treatment on Day 1~Period 2 -- Participants to receive 400mg Fluconazole by mouth daily on Day 3, then 200 mg Fluconazole by mouth daily Day 4 through Day 10. On Day 7 200 mg Fluconazole and 10 mg HMPL-689 will be simultaneously administered."
89600280|NCT05602597|Experimental|Part C - Rimfampin|"Period 1 -- Participants to receive 30mg dose of HMPL-689 by mouth as a single agent treatment on Day 1~Period 2 -- Participants to receive 600mg Rifampin by mouth daily beginning on Day 3 through Day 11. On Day 10 600mg Rifampin will be administered by mouth approximately 1 hour before the start of breakfast and 30mg HMPL-689 will be administered by mouth approximately 30 minutes after the start of breakfast."
89600281|NCT05602597|Experimental|Part D - Rabeprazole|"Period 1 -- Participants to receive 30mg dose of HMPL-689 by mouth as a single agent treatment on Day 1~Period 2 -- Participants to receive 40mg Rabeprazole by mouth daily beginning on Day 3 through Day 9. On Day 9 40mb Rabeprazole will be administered by mouth approximately 1 hour before the start of breakfast and 30mg HMPL-689 will be administered by mouth approximately 30 minutes after the start of breakfast."
89600282|NCT05601999|Experimental|GNR-060|Main group (122 patients) - GNR-060
89600283|NCT05601999|Active Comparator|Metalyse|Control group (122 patients) - Metalyse
89600284|NCT05599672|Experimental|Alcohol-targeted Brief Intervention-Medication Therapy Management|Alcohol-targeted Brief Intervention-Medication Therapy Management (ABI-MTM) intervention is a pharmacy-based medication management intervention, combined with Screening, Brief Intervention, and Referral to Treatment
88980026|NCT06000319||Cervical Interbody Fusion with NMP|Subject has undergone cervical interbody spine fusion at no more than 3 adjacent levels between C2 and T1 where NMP fibers have been used as a bone void filler
89600285|NCT05599672|Active Comparator|Standard medication counseling|Standard Medication Counseling (SMC) (1) will offer counseling, (2) document counseling was offered, (3) offer a counseling process for patients not present, and (4) discuss generic substitution. Following this session, in the second SMC component, participants will be emailed/mailed (according to participant preference) safety information about co-use of alcohol and opioids
89600286|NCT05598385|Active Comparator|Percutaneous cannulation|Percutaneous peripheral cannulation will be applied. An ultrasound is performed preoperative, at discharge and during the follow-up consultation.
89032040|NCT02949440|Experimental|the caudal-to-cranial approach|Cutting the peritoneum along the line between the right mesocolon and retroperitoneum, enter the Toldt's space to dissect the posterior of Superior mesenteric vein（SMV）and Superior mesenteric artery（SMA）and their branches, and then finished the D3 dissection from caudal to cranial on both sides of the mesentery along the Superior mesenteric vein（SMV）. In the end, cut the lateral ligament to mobilize the posterior space of ascending colon. This approach is called caudal-to-cranial approach.
89032041|NCT02949440|Active Comparator|the medial-to-lateral approach|First, the pedicle of ileocolic vessels is identified and the mesocolon is dissected between the pedicle and the periphery of the Superior mesenteric vein（SMV）to expose the second portion of the duodenum. The ileocolic vessels are then cut at their roots. The ascending mesocolon is separated from the retroperitoneal tissues, duodenum, and pancreatic head up to the hepatocolic ligament cranially. The important detail in this procedure is the wide separation between the pancreatic head and the transverse mesocolon.This approach is the medial-to-lateral(MtL) approach
89032042|NCT02938884|Active Comparator|HidrateSpark Water Bottle|"Patients meeting the eligibility criteria who are interested in participating in the study and randomized to receive the HidrateSpark water bottle be given one at no cost. They will download the associated free software application to their smartphone and be given education in the outpatient setting regarding how to use the system.~All subjects in both cohorts will be provided the same questionnaire on two occasions, at the beginning and end of the trial, to determine their attitudes about fluids and potentially identify barriers to maintaining adequate hydration status (Appendix A). Additionally, standard information from the medical record including demographics, occupation, medical history and medications will be recorded."
89210230|NCT00989079|Experimental|Cohort 2 Sequence 1|Period 1 (fasted) Placebo → Period 2 (fasted) E 30 mg → Period 3 (fasted) E 300 mg. Each dose of study drug will be separated by a minimum of 7 days.
89600287|NCT05598385|Active Comparator|Open cannulation|Open peripheral cannulation will be applied. An ultrasound is performed preoperative, at discharge and during the follow-up consultation.
89600288|NCT05594563|Active Comparator|Treatment Arm|Difluoromethylornithine (DFMO) pill ,1000mg/m2/day, for 6 months
89600289|NCT05594563|Placebo Comparator|Placebo Arm|Placebo pill taken twice a day orally for 6 months
89600290|NCT05594277||surgical elderly patients|Patients ≥ 70 years old, undergoing a major surgery in general and vascular surgery, urology, orthopedics at Maggiore della Carità University Hospital, Novara, Italy, having a General Practitioner listed in the Local Health Authority of Novara.
89600291|NCT05593237|Experimental|High Frequency rTMS|High frequency 10 Hz stimulation of motor cortex (M1)
89600292|NCT05593237|Active Comparator|Low Frequency rTMS|Low frequency 1 Hz stimulation of motor cortex (M1)
89600293|NCT05593146|Experimental|modified anteversion angle placement (( α-15°)±10°) of the acetabular component|α refers to the anatomical preoperative anteversion angle of the affected hip. α equals to the anteversion angle of the contralateral limb if it cannot be accurately measured on the affected limb. A standard error within 10° is accepted
89600294|NCT05593146|Placebo Comparator|conventional anteversion angle placement ( α±10°) of the acetabular component|α refers to the anatomical preoperative anteversion angle of the affected hip. α equals to the anteversion angle of the contralateral limb if it cannot be accurately measured on the affected limb. A standard error within 10° is accepted
89600295|NCT05592392|Experimental|Therapy|SDS system implanted and Therapy On for 6 months post randomization
89600296|NCT05592392|Sham Comparator|Control|SDS system implanted and Therapy Off for 6 months post randomization
89600297|NCT05587764||Standard of Care|Standard of Care for emergency care
89600298|NCT05586022||Patients with lower extremity arterial occlusion undergoing endovascular revascularization|We will enroll the patients with lower extremity arterial occlusive disease admitted to the Department of Vascular Surgery of The First Affiliated Hospital of Xi 'an Jiaotong University. These patients undergo successful endovascular revascularization of the diseased vessel.
89600299|NCT05585840|Experimental|Biofeedback-based virtual reality group/Intervention|When approaching the moment of the procedure (2 minutes before), children will be asked to put on the virtual reality glasses, saturation probe and respiratory sensor in addition to routine care. At this stage, the child will be assisted by the researcher. The launch of the mobile application on the researcher's phone will be provided just before the port needle placement (1 minute before). In this process, the child will provide biofeedback to the game with regular and deep breathing behavior. The game will end when the port pin placement is complete.
89600300|NCT05585840|No Intervention|Control group|In the pediatric oncology unit where the study will conduct, there is no standard pharmacological and non-pharmacological application use to reduce pain, anxiety, and fear during intervention. Family presence and positive encouragement are used in routine care. For children in this group, port catheter needle insertion will be performed in accordance with their clinical routines.
89600301|NCT05583617|Experimental|Substudy 2: Dose Escalation and Expansion|"In the pre-phase, participants will receive 2 step-up doses and a target dose of cevostamab. The step-up dose will be given on Day(D)1 and D4. The target dose will be given on D8. Subsequently the target dose will be administered on D1 and D15 for cycles 1-6 and D1 of cycle 7 onwards. Each cycle is 28 days. Lenalidomide will be administered by mouth (PO) on a 28-day cycle.~During the dose expansion phase, cevostamab will be administered following the same dosing schedule as the dose escalation phase. The target dose will be determined after the escalation phase. Lenalidomide will be administered PO on a 28-day cycle."
89600302|NCT05583617|Experimental|Substudy 4: Dose Escalation and Expansion|"In the pre-phase, participants will receive 2 step-up doses and a target dose of cevostamab. The step-up dose will be given on D1 and D4. The target dose will be given on D8. Subsequently the target dose will be administered on D1 of each cycle, every 3 weeks (Q3W). Each cycle is 21 days. Iberdomide will be administered PO on a 21-day cycle.~During the dose expansion phase, cevostamab will be administered following the same dosing schedule as the dose escalation phase. The target dose will be determined after the escalation phase. Iberdomide will be administered PO on a 21-day cycle."
89600303|NCT05582499|Experimental|L1-1|If patients were hormone receptor-positive (HR+) and HER2-negative (HER2-) defined as similarity network fusion 1(SNF1) subtype
89600304|NCT05582499|Active Comparator|L1-2|If patients were HR+HER2- with SNF1 subtype
89600305|NCT05582499|Experimental|L2-1|If patients were HR+HER2- with similarity network fusion 2 (SNF2) subtype
89600306|NCT05582499|Active Comparator|L2-2|If patients were HR+HER2- with SNF2 subtype
89600307|NCT05582499|Experimental|L3-1|If patients were HR+HER2- with similarity network fusion 3 (SNF3) subtype
89600308|NCT05582499|Active Comparator|L3-2|If patients were HR+HER2- with SNF3 subtype
89600309|NCT05582499|Experimental|L4-1|If patients were HR+HER2- with similarity network fusion 4 (SNF4) subtype
89600310|NCT05582499|Active Comparator|L4-2|If patients were HR+HER2- with SNF4 subtype
89600311|NCT05582499|Experimental|L4-low-1|If patients were HR+HER2-low with SNF4 subtype
89600312|NCT05582499|Active Comparator|L4-low-2|If patients were HR+HER2-low with SNF4 subtype
89600313|NCT05582499|Experimental|TN1-1|If patients were triple-negative breast cancer with immunomodulatory (IM) subtype
89600314|NCT05582499|Active Comparator|TN1-2|If patients were triple-negative breast cancer with IM subtype
89600315|NCT05582499|Experimental|TN2-1|If patients were triple-negative breast cancer with basal-like immune suppressed (BLIS) subtype
89600316|NCT05582499|Active Comparator|TN2-2|If patients were triple-negative breast cancer with BLIS subtype
89600317|NCT05582499|Experimental|TN3-1|If patients were triple-negative breast cancer with androgen receptor positive HER2 activated (AR HER2) subtype
89600318|NCT05582499|Active Comparator|TN3-2|If patients were triple-negative breast cancer with AR HER2 subtype
89600319|NCT05582499|Experimental|TN4-1|If patients were HR-HER2-low
89600320|NCT05582499|Active Comparator|TN4-2|If patients were HR-HER2-low
88980027|NCT06000189||Participants who received phototherapy for various dermatological indications|A case-control study will be conducted participants who received narrow-band ultraviolet B (NBUVB) or ultraviolet A-1 (UVA-1) therapy for various dermatological indications. Standardized skin surface biopsies (SSSB) were performed before and after phototherapy to assess Demodex density. Demographic data, medical information, and the presence of demodex-related skin conditions were recorded using a standardized form. Statistical analysis will be performed to compare the demodex densities and prevalence of demodicosis between baseline and 20th session of phototherapy.
88980028|NCT06000176||interventional details : diagnostic test OCTA macula and ONH|interventional details : diagnostic test OCTA macula and ONH in the 3 groups
88980029|NCT06000137|Experimental|group S|sufentanil 2μg/kg + flurbiprofen 250mg+granisetron 6mg
88980030|NCT06000137|Active Comparator|group D1|dezocine 0.5mg/kg + flurbiprofen 250mg+granisetron 6mg
88980031|NCT06000137|Active Comparator|group D2|dezocine 0.6mg/kg + flurbiprofen 250mg+granisetron 6mg
88980032|NCT06000033|Experimental|RC48+Anlotinib|Disitamab Vedotin : 2 mg/kg，ivgtt，d1-14/28day/cycle Anlotinib: 12mg once daily (taken before meals) orally, continuously for 2 weeks followed by a 1-week break. Each cycle consists of 21 days.
88980033|NCT06000020||Diagnostic laparoscopy|Diagnostic laparoscopy on suspicion of acute appendicitis with normal intraoperative findings (including mesenteric adenitis).
88980034|NCT06000020||Laparoscopic appendectomy|Laparoscopic appendectomy despite normal intraoperative findings (including mesenteric adenitis) and histopathology showing a normal appendix.
88980035|NCT05999942|Experimental|Amikacin Liposome Inhalation|Participants will receive a single dose of radiolabelled amikacin loaded liposomes by inhalation on Day 1.
88980036|NCT05999929|Experimental|Memory Support System participants|
88980037|NCT05999890|Experimental|Tapentadol|Tapentadol is a novel, centrally acting analgesic with dual mechanism of action, combining mu-opioid receptor agonism with norepinephrine reuptake inhibition.this dual mode of action is responsible for its opioid sparing effect, which contributes to reduction in some of the typical opioid related adverse effects
89600321|NCT05582499|Experimental|TN5-1|If patients were triple-negative breast cancer with other subtypes
89600322|NCT05582499|Active Comparator|TN5-2|If patients were triple-negative breast cancer with other subtypes
89600323|NCT05582499|Experimental|H1-1|If patients were HR+HER2+
89600324|NCT05582499|Active Comparator|H1-2|If patients were HR+HER2+
89600325|NCT05582499|Experimental|H2-1|If patients were HR-HER2+
89600326|NCT05582499|Active Comparator|H2-2|If patients were HR-HER2+
89600327|NCT05580068|Experimental|Intervention Group|The intervention to be carried out in the treatment group is the use of the therapy measures for the treatment of arterial hypertension, which is delivered through the iATROS medical device. The therapy by means of the medical device takes place over 90 days.
89600328|NCT05580068|No Intervention|Control Group|For the duration of the in-life phase, the treatment of the control group will follow the standard-of-care except for the measures necessary for the conduct of the study.
89600329|NCT05579704|Active Comparator|Web-based wellness platform|Participants will receive access to a web-based wellness platform focused on nutrition, physical activity, and mindfulness. Interactions with the platform will be fully self-guided (without weekly group video conferencing sessions healthcare professionals and peers).
89600330|NCT05579704|Experimental|Web-based wellness platform with healthcare professional-facilitated online support|Participants will receive access to a web-based wellness platform focused on nutrition, physical activity, and mindfulness. In addition to the platform access, participants will take part in weekly group video conferencing sessions with various healthcare professionals (registered dietitian, mental health therapist, and exercise professional). The sessions will occur once per week for 1 hour each. The group sessions will contain cohorts of approximately 10 individuals.
89600331|NCT05575843|Other|Group A|First neurologist, second nurse
89210231|NCT00989079|Experimental|Cohort 2 Sequence 2|Period 1 (fasted) E 2.5 mg → Period 2 (fasted) Placebo → Period 3 (fasted) E 300 mg. Each dose of study drug will be separated by a minimum of 7 days.
89600332|NCT05575843|Other|Group B|First nurse, second neurologist
89600333|NCT05573906|Experimental|Cognitive behavioral therapy for anxiety plus benzodiazepine taper|11 sessions of individual therapy consisting of exposure-based cognitive behavioral therapy that is designed specifically for assisting with benzodiazepine taper. This will be added to a gentle, 12-week benzodiazepine taper. CBT will be initiated for two sessions prior to the benzodiazepine taper initiation.
89600334|NCT05573906|Active Comparator|Health education control plus benzodiazepine taper|11 sessions of individual therapy control consisting of psychoeducational topics related to health and well-being, along with the gentle, 12-week benzodiazepine taper.
89600335|NCT05572853||Classification of oxygenation status stratification|Patients were classified into 3 groups with stratification of oxygenation status based on the relationship between blood oxygen saturation (SpO2) and fraction of inspired oxygen (FiO2) SpO2/FiO2, divided into three categories: normal (> 315), mild to moderate (314 - 235) and severe (< 234).
89600336|NCT05568888|Experimental|BE1116|Administration by IV infusion
89600337|NCT05568888|Placebo Comparator|Placebo|Administration by IV infusion
89600338|NCT05568134||OGTT Cohort|All enrolled participants will complete an OGTT.
89600339|NCT05564468|Experimental|Group I (Peacefully's)|Patients receive Peacefully's web-based tool to help with end-of-life planning on day 7.
89600340|NCT05564468|Active Comparator|Group II (standard of care)|Patients receive standard care.
89600341|NCT05564403|Active Comparator|Arm 1 (mFOLFOX6)|Patients receive leucovorin IV over 30 minutes on day 1, oxaliplatin IV over 30 minutes on day 1, and fluorouracil IV over 46-48 hours on days 1-2. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO and MUGA during screening and on study, a CT with contrast, MRI, or a FDG-PET during screening, collection of blood during screening and on study, and a biopsy during screening. Patients may also undergo brain MRI or CT during screening and on study, bone scans on study, and biopsy on study if clinically indicated.
89600342|NCT05564403|Experimental|Arm 2 (binimetinib, mFOLFOX6)|Patients receive binimetinib orally (PO) on days 1-14, and leucovorin IV, oxaliplatin IV, and fluorouracil IV as in Arm 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO and MUGA during screening and on study, a CT with contrast, MRI, or an FDG-PET during screening, collection of blood during screening and on study, and a biopsy during screening. Patients may also undergo brain MRI or CT during screening and on study, bone scans on study, and biopsy on study if clinically indicated.
89600343|NCT05563051|Other|Interventional treatment|Open label
89600344|NCT05558449|Active Comparator|VR|"Patients in the VR group (19 patients) will receive VR alone without hypnosedation. The VR headset will be used on these patients without an external voice or device allowing hypnosis. The VR module used will be Silva, i.e. a scenario of a walk in the forest through the 4 seasons."
89600345|NCT05558449|Experimental|VRH|"The patients in the VRH group (19 patients) will benefit from a hypnosedation session with a VRH headset during the local anesthesia technique and during the surgery (approximately 60 minutes). The VRH module used will be Silva, i.e. the same scenario of a walk in the forest through the 4 seasons with a voice accompanying the hypnosis session."
89600346|NCT05558449|Active Comparator|C|Patients in group C (control group, 19 patients) will receive only midazolam-based pharmacological sedation. This will be administered with intermittent boluses of 1 mg until patient comfort and sedation on the Richmond analgo-sedation scale (RASS) of -3 (response to verbal stimulus) is achieved.
89600347|NCT05554341|Experimental|Treatment (nilotinib hydrochloride monohydrate, paclitaxel)|Patients receive nilotinib hydrochloride monohydrate PO BID on days 1-28 and paclitaxel IV over 1 hour on days 1, 8, and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT or MRI throughout the study. Patients also undergo collection of blood samples and tumor biopsy on study.
89600348|NCT05551156|Experimental|Animal-assisted interaction|A dog-handler team will visit participants in their hospital room
89600349|NCT05551156|Experimental|Conversational interaction|Conversational interaction with the participants and the dog-handler
89600350|NCT05551156|No Intervention|Treatment as usual|Participants will received the regular services currently being received in the hospital
89600351|NCT05551104|Active Comparator|Oral Nifedipine|Participants will receive oral nifedipine for blood pressure control. Dosage may initially start at one 10mg capsule by mouth three times per 24 hours (total of 30mg a day), however dosage may be increased by 30mg increments (i.e. 20mg capsule three times a day for a total of 60mg a day). Maximum dosage for oral Nifedipine will be 120mg per day.
89600352|NCT05551104|Active Comparator|Oral Labetalol|Participants will receive oral labetalol for blood pressure control. Dosage may initially start at one 200mg tablet by mouth two times per 12 hours (total of 400mg every a day), however dosage may be increased by 100-200mg increments at a time. Maximum dosage for oral labetalol will be 2400mg per day.
89600353|NCT05541861|Experimental|BNT162b2 Bivalent 30 µg + BNT162b4 5 µg - participants aged 18-55 years|Intramuscular injection. BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 µg + BNT162b4 5 µg. Cohort 1. Two doses (At Day 1 and 6 to 7 months post-Dose 1, if the participant consents to a second dose of IMP, otherwise only one dose at Visit V1).
89600354|NCT05541861|Experimental|BNT162b2 Bivalent 30 µg + BNT162b4 10 µg - participants aged 18-55 years|Intramuscular injection. BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 µg + BNT162b4 10 µg. Cohort 2. Two doses (At Day 1 and 6 to 7 months post-Dose 1, if the participant consents to a second dose of IMP, otherwise only one dose at Visit V1)
89600355|NCT05541861|Experimental|BNT162b2 Bivalent/Monovalent 30 µg + BNT162b4 15 µg - participants aged 18-55 years|"Intramuscular injection. BNT162b2 Bivalent (original/Omicron BA.4/BA.5)/Monovalent (OMI XBB.1.5) 30 µg + BNT162b4 15 µg.~Cohort 3a. Two doses (At Day 1 and 6 to 7 months post-Dose 1, if the participant consents to a second dose of IMP, otherwise only one dose at Visit V1).~Dose 1: BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 µg + BNT162b4 15 µg, Dose 2: BNT162b2 Monovalent (OMI XBB.1.5) 30 µg + BNT162b4 15 µg"
88980038|NCT05999890|Active Comparator|Paracetamol|Paracetamol is one of the most frequently used analgesic and antipyretic agent, interferes neither with platelet nor kidney functions nor does it present the unwanted side effects of NSAIDS.
89600356|NCT05541861|Experimental|BNT162b2 Bivalent/Monovalent 30 µg + BNT162b4 15 µg - participants aged >55 years|"Intramuscular injection. BNT162b2 Bivalent (original/Omicron BA.4/BA.5)/Monovalent (OMI XBB.1.5) 30 µg + BNT162b4 15 µg.~Cohort 3b. Two doses (At Day 1 and 6 to 7 months post-Dose 1, if the participant consents to a second dose of IMP, otherwise only one dose at Visit V1).~Dose 1: BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 µg + BNT162b4 15 µg, Dose 2: BNT162b2 Monovalent (OMI XBB.1.5) 30 µg + BNT162b4 15 µg"
89600357|NCT05541861|Experimental|BNT162b2 Bivalent/Monovalent 30 µg + BNT162b4 30 µg - participants aged 18-55 years|"Intramuscular injection. BNT162b2 Bivalent (original/Omicron BA.4/BA.5)/Monovalent (OMI XBB.1.5) 30 µg + BNT162b4 30 µg.~Cohort 4a. Two doses (At Day 1 and 6 to 7 months post-Dose 1, if the participant consents to a second dose of IMP, otherwise only one dose at Visit V1).~Dose 1: BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 µg + BNT162b4 30 µg, Dose 2: BNT162b2 Monovalent (OMI XBB.1.5) 30 µg + BNT162b4 30 µg"
89600358|NCT05541861|Experimental|BNT162b2 Bivalent/Monovalent 30 µg + BNT162b4 30 µg - participants aged >55 years|"Intramuscular injection. BNT162b2 Bivalent (original/Omicron BA.4/BA.5)/Monovalent (OMI XBB.1.5) 30 µg + BNT162b4 30 µg.~Cohort 4b. Two doses (At Day 1 and 6 to 7 months post-Dose 1, if the participant consents to a second dose of IMP, otherwise only one dose at Visit V1).~Dose 1: BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 µg + BNT162b4 30 µg, Dose 2: BNT162b2 Monovalent (OMI XBB.1.5) 30 µg + BNT162b4 30 µg"
89600359|NCT05541861|Active Comparator|BNT612b2 Bivalent 30 µg - participants aged 18-55 years|Intramuscular injection at Day 1. Cohorts 1, 2 and 3a. BNT612b2 Bivalent (original/Omicron BA.4/BA.5) 30 µg.
89600360|NCT05541861|Active Comparator|BNT612b2 Bivalent 30 µg - participants aged >55 years|Intramuscular injection at Day 1. Cohort 3b. BNT612b2 Bivalent (original/Omicron BA.4/BA.5) 30 µg.
89600361|NCT05538000|Experimental|Personalized support program|
89600362|NCT05536882|Experimental|Benzoyl peroxide|topical benzoyl peroxide 10% (vehicle choice per patient preference) applied 1-2x daily as tolerated until complete clearance or 12 week follow up
89600363|NCT05536882|Active Comparator|Adapalene|adapalene 0.1% gel applied 1-2x daily as tolerated until complete clearance or 12 week follow up
89600364|NCT05535244|Experimental|Cohort A1: Prior BCMA antibody-drug conjugate (ADC) or chimeric antigen receptor T (CAR-T)|Participants in Cohort A1 will be treated at the double step-up split dosing regimen.
89600365|NCT05535244|Experimental|Cohort A2: Prior BCMA Bispecific|Participants enrolled into exploratory Cohort A2 will receive the same dosing regimen as Cohort A1.
89600366|NCT05535244|Experimental|Cohort B1: Prior BCMA CAR-T|Participants enrolled in expansion Cohort B1, will be given cevostamab at the selected dosing regimen.
89600367|NCT05535244|Experimental|Cohort B2: Prior BCMA Bispecific|Expansion Cohort B2 will be opened, after the initial results from Cohort A2, at the same dose as per Cohort B1.
89600368|NCT05528094|Experimental|GeniusDrops|"Once participants have signed the consent and assent, they will take the baseline survey to gather information about their ability to focus and concentration.~Once in the study, participants will be asked to take two dropperfuls of the test product (Genius Drops) twice daily. The participants can take the dropperful directly or add it to drinks/snacks. Participants will need to be in school during the entirety of the study.~Participants will take a subsequent survey after two weeks in the trial and then another survey at the end of the trial."
89600369|NCT05527418|Experimental|Dasatinib|Dasatinib monotherapy (70 mg/day) will be given for 4 weeks. Antiretroviral therapy (ART) based on unboosted integrase inhibitors will be initiated at week 4 (S4) and dasatinib will be continued with ART until week 12.
89600370|NCT05527418|Placebo Comparator|Placebo|Placebo monotherapy will be given for 4 weeks. Antiretroviral therapy (ART) based on unboosted integrase inhibitors will be initiated at week 4 (S4) and placebo will be continued with ART until week 12.
89600371|NCT05520736|Experimental|Intervention|Prospectively received appointment reminders, motivational interviews and targeted vaccine drives.
89600372|NCT05519436||Morbid obesity individuals|
89600373|NCT05519436||Healthy individuals|
89600374|NCT05519423|Experimental|Morbid obesity individuals|"All subjects participating in the study will be given physical activity incentive program (PAI) individually. After evaluating it is aimed to provide information transfer and motivation support to increase physical activity levels before bariatric surgery within the scope of PAI.~For this purpose, individual face-to-face interviews will conduct with all cases; verbal information will be given about the importance of physical activity, its effects and different levels of severity. The progress of the program will be made with the whats app application.~8-week follow-up chart will be given to the individuals, about the completion of the physical activity follow-up chart prepared in order to raise awareness about the activity levels of individuals in daily life and to increase their physical activity levels.~All subjects will record daily step counts, low, moderate, and vigorous activities on the chart at the end of the day, every day for 8 weeks."
89600375|NCT05518032|Experimental|Treatment (pembrolizumab, autologous dendritic cells)|Patients receive pembrolizumab IV on days 8, 29, 50, and 71, and autologous dendritic cells intratumorally on days 1 and 8 in the absence of disease progression or unacceptable toxicity. Patients may also receive an autologous dendritic cells intratumorally on day 50.
89600376|NCT05508399||PD-1 group|Patients who are qualified for receiving anti-PD-1 antibody combined with chemotherapy neoadjuvant therapy
89600377|NCT05505643|Experimental|Cryoablation|Patients will be treated with cryoablation using the Endocare SlimLine Cyroprobe under real time ultrasound guidance and local anesthesia. The cryoablation consists of a 10 minute freeze phase followed by a 10 minute passive thaw, and ends with a second 10 minute freeze cycle. The freeze-thaw-freeze times may be adjusted at the physician's discretion depending on tumor size.
89210232|NCT00989079|Experimental|Cohort 2 Sequence 3|Period 1 (fasted) E 2.5 mg → Period 2 (fasted) E 30 mg → Period 3 (fasted) Placebo. Each dose of study drug will be separated by a minimum of 7 days.
89210233|NCT00809198|Experimental|Sodium Hyaluronate|Sodium Hyaluronate (Kynex)
88980041|NCT05999851|Experimental|Principal arm|The entire cohort of participants will undergo all experimental procedures. Participants who will develop hypertensive disorders of pregnancy and matched participants with healthy pregnancies will also undergo serum endothelial and angiogenic markers assessment.
89210234|NCT00809198|Active Comparator|Carboxymethylcellulose sodium|Carboxymethylcellulose sodium (Refresh Plus)
89210235|NCT00898170|Experimental|myoma, with or without hypertension|those with myoma with or without hypertension in holter monitoring
89600378|NCT05505643|Active Comparator|Lumpectomy|Lumpectomy will be performed under general anesthesia as per standard operative procedures at Washington University and Siteman Cancer Center.
89600379|NCT05505643|Other|Rescue Arm: Lumpectomy|If there is evidence of residual or recurrent tumor on follow-up imaging evaluation (6 month MRI and yearly MRI/mammography), patients in the cryoablation safety lead-in and who were randomized to receive cryoablation only will be crossed over to receive a rescue lumpectomy followed by adjuvant treatment based on standard of care.
89600380|NCT05505643|Experimental|Cryoablation - Safety Lead In|Patients will be treated with cryoablation (Day 1) using the Endocare SlimLine Cyroprobe followed by adjuvant treatment.
89600381|NCT05497089|Experimental|Temelimab 54mg/kg|Monthly IV repeated dose in addition to standard of care
89600382|NCT05497089|Placebo Comparator|Placebo|Monthly IV repeated dose in addition to standard of care
89600383|NCT05496595|Experimental|Part 1: Dose Escalation|Dose escalation to investigate safety, tolerability, and determine recommended phase 2 dose (RP2D) for DCBY02.
89600384|NCT05496595|Experimental|Part 2: Dose Expansion|Dose expansion to further investigate safety, tolerability, and preliminary evidence of antitumor activity and characterize PK and PD of DCBY02.
89600385|NCT05495906|Active Comparator|Routine schedule|Three doses of 9vHPV vaccine at the routine dosing schedule of 0/2/6 months
89600386|NCT05495906|Experimental|Extended schedule|Two doses of 9vHPV vaccine at an expanded dosing schedule of 0/6 months with a third dose given at month 12
89600387|NCT05492409|Experimental|GNR-069|Weekly subcutaneous injections of GNR-069 in the individually titrated dose.
89600388|NCT05489588|Experimental|GORE® VIAFORT Vascular Stent|GORE® VIAFORT Vascular Stent
89600389|NCT05488782|Experimental|TEAM-Red|Five 60-minute group sessions with 6-10 patients. These sessions will be held weekly and delivered remotely via videoconference
89600390|NCT05488782|Other|Enhanced Waitlist (eWL)|After the week 12 follow up visit, subjects in the Waitlist group will receive the TEAM Red intervention
89600391|NCT05478499|Experimental|Deucravacitinib|
89600392|NCT05478499|Placebo Comparator|Placebo then Deucravacitinib|
89600393|NCT05475106|Experimental|Treatment|Patients will receive intradermal injection of individualized neoantigen peptides vaccine at a dose of ~500ug per peptide once a week for 4 weeks and once every month after that for 5 months.
89600394|NCT05467995|Experimental|AK111 75mg|AK111 75mg will be administered by subcutaneous injection at Week 0, 1 and 4 , followed by dosing every 4 weeks until Week12.
89600395|NCT05467995|Experimental|AK111 150mg|AK111 150mg will be administered by subcutaneous injection at Week 0, 1 and 4 , followed by dosing every 4 weeks until Week12.
89600396|NCT05467995|Experimental|AK111 300mg|AK111 300mg will be administered by subcutaneous injection at Week 0, 1 and 4 , followed by dosing every 4 weeks until Week12.
89600397|NCT05467995|Placebo Comparator|Placebo|Placebo will be administered by subcutaneous injection at Week 0, 1 and 4 , followed by dosing every 4 weeks until Week12.
89600398|NCT05462574||Participants with Pulmonary Arterial Hypertension (PAH)|Participants with heritable, idiopathic, and scleroderma associated PAH.
89600399|NCT05461157|Experimental|Preoperative silicone ointment|Participants will apply silicone ointment to the area where the surgical incision will be made, twice daily for 2-6 weeks prior to their scheduled surgery.
89600400|NCT05461157|Placebo Comparator|Preoperative placebo ointment|Participants will apply placebo ointment to the area where the surgical incision will be made, twice daily for 2-6 weeks prior to their scheduled surgery.
89600401|NCT05454696|Experimental|Exercise Group|The exercise group will follow the online clinical mat pilates exercises (via Zoom application) accompanied by a physiotherapist.
89600402|NCT05454696|Active Comparator|Control Group|The control group will receive online (via Zoom application) physical activity counselling by the physiotherapist only once.
89600403|NCT05454566|Experimental|Group 1: ICM-203 (Low dose)|3 to 6 subjects will receive a single intra-articular injection of ICM-203 at 6x10e12 vg into the target knee at Day 1
88980042|NCT05999825|Experimental|Vaccine group|The vaccine group will be immunised three times with 30 μg Sm-p80 + 5 μg GLA-SE i.m. at weeks 0,4, and 8. Participants will be exposed to 20 male Schistosoma mansoni cercariae at week 12.
89600404|NCT05454566|Experimental|Group 2: ICM-203 (Medium dose)|3 to 6 subjects will receive a single intra-articular injection of ICM-203 at 2x10e13 vg into the target knee at Day 1
89600405|NCT05454566|Experimental|Group 3: ICM-203 (High dose)|3 to 6 subjects will receive a single intra-articular injection of ICM-203 at 6x10e13 vg into the target knee at Day 1
89600406|NCT05451849|Experimental|Lymphodepletion followed by TC-510|Lymphodepletion (fludarabine and cyclophosphamide) followed by TC-510 T cells
89600407|NCT05445830|Experimental|Post-covid patients|
89600408|NCT05445830|Experimental|Control|
89600409|NCT05443906|Experimental|Home exercise|Individually designed home exercise program
89600410|NCT05443594|Experimental|Pulsed Field Ablation (Phase 1)|PHASE 1 only
89600411|NCT05443594|Experimental|Pulsed Field Ablation (Phase 2)|PHASE 2 only
89600412|NCT05442814|Active Comparator|Posterior suprascapular block|Suprascapular block performed by posterior approach
88980043|NCT05999825|Placebo Comparator|Placebo control group|The placebo control group will be immunised three times with saline i.m. at weeks 0,4, and 8. Participants will be exposed to 20 male Schistosoma mansoni cercariae at week 12.
88980044|NCT05999786|Active Comparator|patients receiving early rehabiliation swallowing program|the early rehabilitation program beginning from before to after surgery
89600413|NCT05442814|Active Comparator|Anterior suprascapular block|Suprascapular block performed by anterior approach
89608559|NCT03753945|Experimental|DBS electrode placement|"Participants in this study will be patients who have already undergone surgery for implantation of DBS electrodes.~Patients who have already undergone surgery for implantation of DBS electrodes and patients for whom the treating physicians recommends (based on clinical grounds) a spine MRI (cervical, thoracic or lumbar) shall be recruited for the study.This eligible patient population is broad but unified by the fact that they have undergone DBS to treat specific circuit dysfunctions. Patients with internalized leads and IPG may be included. Patients will undergo routine clinical MRI sequences used for the spine (structural in axial and sagittal planes). The choice of imaging the cervical, thoracic or lumbar will depend on the requisition from the treating physician."
89600414|NCT05442671|Other|Home exercise intervention|"Personalized 16 week home exercise program - aerobic exercise for 20 minutes per day/4 days per week and light resistance exercise using resistance bands 3 days per week.~Aerobic sessions will include walking, biking, or light jogging, depending on access to facilities/equipment and weather.~Smartwatch for the length of the intervention and a heart rate monitor during exercise sessions.~Max heart rate prescribed will be 80% of that on recent cardiopulmonary exercise test (at most 150 beats/min).~Heart rate monitor will sync with the smartwatch.~Activity and heart rate data will be transmitted to the study team via a data hub connected to the participant's home internet modem several times per week.~Periodic text messaging to remind participants to wear the watch, sync the data, or adhere to heart rate goals, to ask about symptoms, or to support activity progress.~Multiple ways to contact the study team with questions or concerns."
89600415|NCT05442567|Experimental|Treatment Cohort: Participants 10 to ≤15 kg, Vedolizumab 150 mg|Eligible participants from studies MLN0002-3024 or MLN0002-3025 weighing 10 to ≤15 kg will receive vedolizumab 150 mg, IV infusion, Q8W, (same as their Week 46 dose in parent study) in this study for up to approximately 5 years.
89600416|NCT05442567|Experimental|Treatment Cohort: Participants 10 to ≤15 kg, Vedolizumab 100 mg|Eligible participants from studies MLN0002-3024 or MLN0002-3025 weighing 10 to ≤15 kg will receive vedolizumab 100 mg, IV infusion, Q8W, (same as their Week 46 dose in parent study) in this study for up to approximately 5 years.
89600417|NCT05442567|Experimental|Treatment Cohort: Participants >15 to <30 kg, Vedolizumab 200 mg|Eligible participants from studies MLN0002-3024 or MLN0002-3025 weighing >15 to <30 kg will receive vedolizumab 200 mg, IV infusion, Q8W, (same as their Week 46 dose in parent study) in this study for up to approximately 5 years.
89600418|NCT05442567|Experimental|Treatment Cohort: Participants >15 to <30 kg, Vedolizumab 100 mg|Eligible participants from studies MLN0002-3024 or MLN0002-3025 weighing >15 to <30 kg will receive vedolizumab 100 mg, IV infusion, Q8W, (same as their Week 46 dose in parent study) in this study for up to approximately 5 years.
89600419|NCT05442567|Experimental|Treatment Cohort: Participants ≥30 kg, Vedolizumab 300 mg|Eligible participants from studies MLN0002-3024 or MLN0002-3025 weighing ≥30 kg will receive vedolizumab 300 mg, IV infusion, Q8W, (same as their Week 46 dose in parent study) in this study for up to approximately 5 years.
89600420|NCT05442567|Experimental|Treatment Cohort: Participants ≥30 kg, Vedolizumab 150 mg|Eligible participants from studies MLN0002-3024 or MLN0002-3025 weighing ≥30 kg will receive vedolizumab 150 mg, IV infusion, Q8W, (same as their Week 46 dose in parent study) in this study for up to approximately 5 years.
89600421|NCT05442567|Other|Observational Cohort: Early Terminated Participants From Parent Studies|Participants will have assessment visits at Day 1 and Weeks 8, 34, 60, and 86 as part of a long-term follow-up period to assess prespecified safety events of interest and to monitor growth and pubertal development for approximately 2 years after their last dose of study drug in parent study.
89600422|NCT05430178|Experimental|NAFLD|Participants in the pediatric NAFLD clinic
89600423|NCT05430178|Experimental|Ob control|Participants with obesity, without NAFLD
89600424|NCT05430178|Experimental|NW control|Participants in the normal range for body weight, without NAFLD
89600425|NCT05430178|Experimental|Liver control|Participants undergoing liver biopsy or liver surgery, without NAFLD
89600426|NCT05429008|Other|HMPL-A83|Drug: HMPL-A83 The starting dose of HMPL-A83 is 0.3 mg/kg IV QW with escalating dose levels of 1, 3, 10, 20, and 30 mg/kg IV QW, in 28-day treatment cycles.
89600427|NCT05427630|Experimental|THC ~2.5%|Inhalation of cannabis flower containing THC ~2.5%
89600428|NCT05427630|Experimental|THC ~5%|Inhalation of cannabis flower containing THC ~5%
89600429|NCT05427630|Experimental|THC ~10%|Inhalation of cannabis flower containing THC ~10%
89600430|NCT05427630|Sham Comparator|Sham Cannabis|Inhalation of cannabis flower from which the THC and CBD have been extracted
89600431|NCT05422794|Experimental|Dose Escalation (ZEN003694, nab-paclitaxel, pembrolizumab)|Patients receive ZEN003694 PO QD on days 1-21, nab-paclitaxel IV over 30 minutes on day 1, 8, and 15, and pembrolizumab IV over 30 minutes every 21 days of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity with a maximum of 35 doses of pembrolizumab administered. Patients also undergo CT or MRI scan and collection of blood samples throughout the trial.
89600432|NCT05422794|Experimental|Dose Expansion (ZEN003694, nab-paclitaxel, pembrolizumab)|Patients receive ZEN003694 PO QD on days 1-7 prior to combination therapy. Patients then receive ZEN003694 PO QD on days 1-21, nab-paclitaxel IV over 30 minutes on days 1, 8, and 15, and pembrolizumab IV over 30 minutes every 21 days of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity with a maximum of 35 doses of pembrolizumab administered. Patients also undergo biopsies on study, and CT or MRI scans and collection of blood samples throughout the trial.
89032043|NCT02938884|No Intervention|No Smart water bottle|All subjects in both cohorts will be provided the same questionnaire on two occasions, at the beginning and end of the trial, to determine their attitudes about fluids and potentially identify barriers to maintaining adequate hydration status (Appendix A). Additionally, standard information from the medical record including demographics, occupation, medical history and medications will be recorded.
89600433|NCT05416021|Active Comparator|25 mg dapivirine ring|25 mg dapivirine vaginal ring (Ring-004) for 90 days (replaced every 30 days) (Treatment A), followed by the 100 mg dapivirine ring (Ring-008) used continuously for 90 days (Treatment B)
89032044|NCT05135052|Experimental|Treatment arm|Treatment with Rhenium-SCT, Single treatment.
89032045|NCT02948972|Experimental|complete surgery|Prior surgery 3 months before IVF followup 1, 6 12 and 24 month after surgery
88811325|NCT02135419|Active Comparator|Arm II (active monitoring) (closed since SEP2021)|Patients undergo active monitoring with examinations for clinical observation every 6 months. Every 12 months, patients undergo biopsies of visible lesions. Patients have cytology sampling performed at every visit. All participants will have samples collected for laboratory biomarker analysis.
89032046|NCT02948972|Active Comparator|In vitro fertilization without surgery|IVF without endometriosis surgery follow up 6, 12 and 24 month after inclusion.
89032047|NCT05108454||Intervention group|Pregnant women who received MMS from the SMC program
89032048|NCT05108454||Comparison|Pregnant women who did not receive MMS
89600434|NCT05416021|Active Comparator|100 mg dapivirine ring|100 mg dapivirine vaginal ring (Ring-008) used continuously for 90 days (Treatment B), followed by the 25 mg dapivirine ring (Ring-004) for 90 days (replaced every 30 days) (Treatment A)
89600435|NCT05409131|Active Comparator|Intervention Arm|Omnipod 5 System with Dexcom G6 continuous glucose monitoring system
89600436|NCT05409131|No Intervention|Control Arm|Participant's current insulin pump with Dexcom G6 continuous glucose monitoring system
89600437|NCT05405166|Experimental|Isatuximab Subcutaneous (SC)|Isatuximab dose will be administered SC weekly for 4 weeks during Cycle 1 (Days 1, 8, 15, and 22) and Day 1 and 15 of subsequent cycles. Each cycle will be 28 days in duration. Pomalidomide dose will be taken orally on Day 1 to Day 21 of each cycle at the time that is the most convenient for the participants prior to or after isatuximab administration, preferably at the same time every day. Dexamethasone will be taken orally on Day 1, 8, 15 and 22 (to be repeated every 28 days).
89600438|NCT05405166|Active Comparator|Isatuximab Intravenous (IV)|Isatuximab dose will be administered via IV infusion weekly for 4 weeks during Cycle 1 (Days 1, 8, 15, and 22) and Day 1 and 15 of subsequent cycles. Each cycle will be 28 days. Pomalidomide dose will be taken orally on Day 1 to Day 21 of each cycle at the time that is the most convenient for the participants prior to or after isatuximab administration, preferably at the same time every day. Dexamethasone will be taken orally on Day 1, 8, 15 and 22 (to be repeated every 28 days).
89600439|NCT05394831|Experimental|Phase 1 dose-escalation, Phase 1 dose-exploratory, Phase 2 dose-expansion|Single arm
89600440|NCT05394272|Experimental|Efficacy of Energy Therapy - Pranic Healing with chronic pain|Energy therapy - Pranic Healing to be applied for 8 weeks weekly and 3 times 4 weeks apart for relief of chronic pain
89600441|NCT05394272|Experimental|Efficacy of Energy Therapy - Pranic Healing - with linked medical condition|Energy Therapy - Pranic Healing protocol for linked medical condition applied for 8 weeks weekly and 3 times 4 weeks apart , relevant BT/Urine sample /stool sample 4 weeks apart to evaluate changes.
89600442|NCT05393674|Experimental|Experimental|"Fedratinib (Cycle 1: Run-in-Phase with 400 mg QD for 4 weeks, Cycle 2-12: 400 mg QD, Dose modifications will be allowed based on observed toxicity to a 300 mg or a 200 mg daily dose) + Nivolumab (Cycle 2-12: 240 mg, i.v., q2w)~Patients will receive study treatment until loss of response, death or study discontinuation for other reasons."
89600443|NCT05389527|Experimental|experimental arm|Pembrolizumab+Lenvatinib
89600444|NCT05388214|Experimental|E-Co|The E-Co intervention will integrate active components of a mobile health exercise intervention (GO-EXCAP) into a cognitive rehabilitation intervention (MAAT-G).
89600445|NCT05386563|Experimental|Transcutaneous Auricular Vagal Nerve Stimulation (taVNS)|
89600446|NCT05386563|Sham Comparator|Sham|
89600447|NCT05386563|No Intervention|No Intervention (Control)|
89600448|NCT05386550|Experimental|Arm A: Xevinapant (Debio 1143) + IMRT|
89600449|NCT05386550|Placebo Comparator|Arm B: Placebo + IMRT|
89600450|NCT05383742|Experimental|Arm A|RIF 35 mg/kg + INH 15 mg/kg + LZD 1200 mg + PZA 25 mg/kg for 2 weeks, followed by RIF 35 mg/kg + INH 10 mg/kg + LZD 1200 mg + PZA 25 mg/kg for 6 weeks, and then RIF 35 mg/kg and INH 10 mg/kg for 16 weeks, for a total of 24 weeks of study treatment.
89600451|NCT05383742|Active Comparator|Arm B|WHO SOC: RIF 10 mg/kg + INH 5 mg/kg + ethambutol (EMB) 20 mg/kg + PZA 25 mg/kg for 8 weeks, followed by RIF 10 mg/kg and INH 5 mg/kg for 28 weeks, for a total of 36 weeks of study treatment. Up to 15 mg/kg or a maximum of 900 mg daily of oral RIF will be permitted in this arm at clinician's discretion.
89600452|NCT05380466|Experimental|Quantum Touch|Those who are planned to be hospitalized from the emergency department and applied quantum touch
89600453|NCT05380466|No Intervention|Control|Those who are planned to be hospitalized from the emergency department and who have not intervention
89600454|NCT05372276||Inactive|"The score obtained by multiplying the duration, frequency and MET values of the physical activities in which the participants participated in 7 days and for at least 10 minutes is <600 MET - min/week.~After the participants are divided into groups according to their physical activity levels, mental toughness and mental imagery skills will be evaluated with the Mental Toughness Scale and the Sports Imagery Questionnaire."
89600455|NCT05372276||Low Level Physical Activity (PA)|"The score obtained by multiplying the duration, frequency and MET values of the physical activities in which the participants participated in 7 days and for at least 10 minutes is 600 - 3000 MET - min/week.~After the participants are divided into groups according to their physical activity levels, mental toughness and mental imagery skills will be evaluated with the Mental Toughness Scale and the Sports Imagery Questionnaire."
88811326|NCT01853748|Active Comparator|Trastuzumab emtansine (T-DM1)|T-DM1 3.6mg/kg every three weeks by IV for 17 doses for a total of 51 weeks
88811327|NCT01853748|Active Comparator|Paclitaxel + Trastuzumab|paclitaxel 80 mg/m2 IV weekly and trastuzumab 4 mg/kg IV load, followed by 2 mg/kg IV weekly for 12 weeks, followed by trastuzumab 6 mg/kg IV every 3 weeks for 13 treatments
88811328|NCT01843374|Experimental|Tremelimumab|Tremelimumab
88811329|NCT01843374|Placebo Comparator|Placebo|Placebo
88811330|NCT01773733||Obese|Patients 18-65 y.o.with alimentary obesity, BMI (Body Mass Index) ≥ 30 kg/m2)
88811331|NCT01773733||Overweight & risk factors|Patients 18-65 y.o., overweight, BMI ≥ 27 kg/m 2 plus T2DM ( type 2 diabetes mellitus) or dyslipidemia
88811332|NCT01757535|Experimental|Oral Azacitidine|300 mg oral azacitidine on days 1 to 14 of each 28-day treatment cycle.
88811333|NCT01757535|Placebo Comparator|Placebo|Identically matching placebo tablets on days 1 to 14 of each 28-day treatment cycle.
88811334|NCT01680770||Hypotensive patients in shock|
88811335|NCT01584258|Active Comparator|PACE-A: Prostatectomy vs prostate SBRT|Low and intermediate risk patients, for whom surgery is considered, will be randomised to prostatectomy vs prostate SBRT delivered with 36.25 Gy in 5 fractions.
88811336|NCT01584258|Active Comparator|PACE-B: Conventionally Fractionated RT vs Prostate SBRT|Low and intermediate risk patients, for whom surgery is not considered or who refuse surgery, will be randomised to either conventionally fractionated radiotherapy delivered to a dose of 78 Gy in 39 fractions or 62 Gy in 20 fractions vs SBRT delivered with 36.25 Gy in 5 fractions.
89600456|NCT05372276||Adequate Level Physical Activity (PA)|"The score obtained by multiplying the duration, frequency and MET values of the physical activities in which the participants participated in 7 days and for at least 10 minutes is >3000 MET - min/week.~After the participants are divided into groups according to their physical activity levels, mental toughness and mental imagery skills will be evaluated with the Mental Toughness Scale and the Sports Imagery Questionnaire."
89600457|NCT05370547|Experimental|high NOXA expression|NOXA IHC score > 4; Bridging therapy was allowed but not containing chidamide; n=60.
89600458|NCT05370547|Experimental|low NOXA expression and no chidamide intervention|NOXA IHC score < 4; Bridging therapy was allowed but not containing chidamide; n=30.
88980045|NCT05999786|Placebo Comparator|patients not receiving early rehabilitation swallowing program|the Taiwan Dysphagia Society's publicly shared swallowing exercises for dysphagia, which is started from before to after surgery
88980046|NCT05999760|Active Comparator|Group I (patients received Versacryle removable partial denture)|patients having Kennedy class I received maxillary Versacryle removable partial denture
88980047|NCT05999760|Active Comparator|Group II (patients received CAD/CAM fabricated removable partial denture)|patients having Kennedy class I received maxillary CAD/CAM fabricated removable partial denture
88980048|NCT05999656|Experimental|human cord blood-derived mononuclear cells (HCB-MNCs)|About 1×10^8 of HCB-MNCs were injected 3 times at a week interval for each participant.
88980049|NCT05999643|Experimental|Inject 68Ga-FAPI and then perform PET/CT scan.|Inject 68Ga-FAPI and then perform PET/CT scan
88980050|NCT05999617|Experimental|Intervention Group|Conventional rehabilitation (stretching, strengthening, balance) plus dual task exercise training (simple math during active stretching, carrying the ball without dropping child while on the balance pad) will be applied 3 days a week for 12 weeks. Interventions will be implemented individually. Patients will be evaluated before and 12 weeks after the interventions.
88980051|NCT05999617|Active Comparator|Control Group|Conventional rehabilitation program (stretching, strengthening, balance) will be employed.
88980052|NCT05999591||Intrauterine insemination|Patients undergoing intrauterine insemination
88980053|NCT05999578|Experimental|Anxious patients with hypnosis|Hypnosis support before, during and at the end of cardiac MRI exam
88980054|NCT05999578|No Intervention|Anxious patients without hypnosis|Cardiac MRI exam accordingly to usual care
88980055|NCT05999578|No Intervention|Non anxious patients|Cardiac MRI exam accordingly to usual care
88980056|NCT05999552|No Intervention|Control Group|any exercise program will not be applied and will only be followed.
88980057|NCT05999552|Experimental|Experimental Group|eye exercise program will be applied.
88980058|NCT05999500||Irritable bowel syndrome patients participating in temple stay|We plan to observe a group of patients aged 20-69 with diarrhea-predominant irritable bowel syndrome who have voluntarily agreed to participate in a temple stay for up to 8 days. Observations will be made before the temple stay, immediately after, and then followed up for 4 weeks after the experience.
88980059|NCT05999487|Active Comparator|patients who will recieve dobutrex|patient presenting with acute heart failure , who will recieve dobutrex as a result of their randomixation , startng dose will be 5 mic , assesing their need for tittration of dose , the need for addition of another inotrope , the prescence of any side effects and the duration of inotropic use for reaching hemodynamically stable state
88980060|NCT05999487|Experimental|patients who will recieve milirinone|patient presenting with acute heart failure , who will recieve milirinone as a result of their randomixation , startng dose will be 0.25 mic , assesing their need for tittration of dose , the need for addition of another inotrope , the prescence of any side effects and the duration of inotropic use for reaching hemodynamically stable state
88980061|NCT05999474|Experimental|Fractional CO2 laser combined with topical tioconazole|"Fractional CO2 laser (10,600 nm) will be done. The sessions will be done every 2 weeks.~Topical tioconazole 28% nail solution will be applied in between the sessions twice daily"
88980062|NCT05999474|Active Comparator|Q switched ND-Yag|Laser protocol with a specific parameters will be applied on the affected nails. In one session two passes across each nail plate will be performed with two minutes pauses between each pass. Sessions will be done every 2 weeks
88980063|NCT05999448|Experimental|No Algorithm + Participation Enhancement Intervention|Participants are randomly assigned to support program without use of a personalized health algorithm AND receive the participation enhancement intervention.
88980064|NCT05999448|Experimental|No Algorithm + No Participation Enhancement Intervention|Participants are randomly assigned to support program without use of a personalized health algorithm AND do not receive the participation enhancement intervention.
88980065|NCT05999448|Experimental|Algorithm 1 + Participation Enhancement Intervention|Participants are assigned to support programs using Algorithm 1 AND receive the participation enhancement intervention.
88980066|NCT05999448|Experimental|Algorithm 1 + No Participation Enhancement Intervention|Participants are assigned to support programs using Algorithm 1 AND do not receive the participation enhancement intervention.
88980067|NCT05999448|Experimental|Algorithm 2 + Participation Enhancement Intervention|Participants are assigned to support programs using Algorithm 2 AND receive the participation enhancement intervention.
88980068|NCT05999448|Experimental|Algorithm 2 + No Participation Enhancement Intervention|Participants are assigned to support programs using Algorithm 2 AND do not receive the participation enhancement intervention.
88980069|NCT05999448|Experimental|Algorithm 3 + Participation Enhancement Intervention|Participants are assigned to support programs using Algorithm 3 AND receive the participation enhancement intervention.
88980070|NCT05999448|Experimental|Algorithm 3 + No Participation Enhancement Intervention|Participants are assigned to support programs using Algorithm 3 AND do not receive the participation enhancement intervention.
89600459|NCT05370547|Experimental|low NOXA expression and chidamide intervention|NOXA IHC score < 4; Bridging therapy containing chidamide alone or combination; n=30.
89600460|NCT05370300||Controls: Patients with negative screening MMG|Patients presenting to Duke Radiology for routine screening mammogram will be screened for eligibility as negative controls. Study enrollment for negative controls presumes that patients do not receive their screening mammography results immediately. Patients will be approached on the day of their first new patient visit to the Duke Cancer Center. If they are willing, they will be consented in clinic, and directed down to the lab for their first blood draw.
89600461|NCT05370300||Cases: Patients with known cancer diagnosis|Patients presenting to the Duke Cancer Center for evaluation by Medical or Surgical Oncology of a newly diagnosed breast cancer will be screened for study eligibility and approached, enrolled, and consented accordingly. Patients will be approached on the day of their first new patient visit to the Duke Cancer Center. If they are willing, they will be consented in clinic, and directed down to the lab for their first blood draw.
89600462|NCT05367440|Experimental|Arm 1 (AZD5305 in combination with enzalutamide)|Patients will receive an oral dose of AZD5305 and Enzalutamide once daily until disease progression, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue study treatment occur.
89600463|NCT05367440|Experimental|Arm 2 (AZD5305 in combination with abiraterone acetate)|Patients will receive an oral dose of AZD5305 and Abiraterone Acetate once daily until disease progression, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue study treatment occur.
89600464|NCT05367440|Experimental|Arm 3 (AZD5305 in combination with darolutamide)|Patients will receive an oral dose of AZD5305 once daily and Darolutamide twice daily until disease progression, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue study treatment occur.
89600465|NCT05359822|No Intervention|Clinical Standard Report Only|Participants referred for Coronary Artery Calcium Score Test that receive clinical standard CAC risk report only.
89600466|NCT05359822|Experimental|Clinical Standard Report plus Image-Based Report|Participants referred for Coronary Artery Calcium Score Test that receive clinical standard CAC risk report plus additional image-based report.
89600467|NCT05355298|Experimental|AMP945|Part A: AMP945 administered in dose escalating cohorts Part B: AMP945 recommended phase 2 dose
89600468|NCT05337787|Experimental|Experimental|The students in the experimental group were trained using the flipped learning model.
89600469|NCT05337787|No Intervention|Control|The students in the control group were trained using only a traditional education method.
89600470|NCT05331638|Experimental|Prostate Cancer Genius app|The Prostate Cancer Genius app includes the following components: (1) educational content that is consistent with existing evidence and recommendations for prostate cancer and prostate cancer screening but has been adapted for the African American male population and for adults who read at or below the 8th-grade level; (2) real-time messages about the risks of prostate cancer and the benefits of completing a PSA test, placing a special emphasis on screening considerations for individuals with a family history of prostate cancer and/or lower urinary tract symptoms (measured via the American Urological Association Symptom Score); (3) general trivia that also incorporates quiz questions about prostate cancer and the PSA test; (4) African American-specific testimonials and educational videos; (5) optional counseling by African American prostate cancer survivors; and (6) on-demand, automated ordering of a home-based PSA test.
89600471|NCT05331638|Active Comparator|Prevention Taskforce app|The Prevention Taskforce app provides on-demand access to evidence-based recommendations for prostate cancer for men between 55 and 69 (i.e., it can be accessed as needed).
89600472|NCT05326126|Experimental|Coronary physiology evaluation|Patient will undergo TAVI and then Myocardial fibrosis will be evaluated on images acquired at the time of the cardiac CT obtained for TAVI planning. Briefly, an extra late post-contrast acquisition image will be acquired. The delayed post-contrast scan will be reconstructed with a soft convolution kernel and will be reformatted in the short- and long-axis planes (slice thickness 8 mm; gap 0 mm) in average mode.
88980071|NCT05999448|No Intervention|Waitlist Control|Participants are enrolled in the waitlist control condition, which includes identical data collection procedures to participants enrolled in support programs. Waitlist controls are offered the opportunity to enroll in future cycles.
88980072|NCT05999422||Patients with primary immunodeficiency|"Maximal exercise capacity measured with Cardiopulmonary exercise testing, functional exercise capacity with six minute walk test, pulmonary function using spirometry, respiratory muscle strength using mouth pressure device, peripheral muscle strength using hand held dynamometer, muscle oxygenation using Moxy monitor, respiratory muscle endurance using incremental threshold loading test, life quality using Pediatric Quality of Life Inventory™ 4.0 (PedsQL™ 4.0) (Turkish version)."
88980073|NCT05999422||Healthy control|"Maximal exercise capacity measured with Cardiopulmonary exercise testing, functional exercise capacity with six minute walk test, pulmonary function using spirometry, respiratory muscle strength using mouth pressure device, peripheral muscle strength using hand held dynamometer, muscle oxygenation using Moxy monitor, respiratory muscle endurance using incremental threshold loading test, life quality using Pediatric Quality of Life Inventory™ 4.0 (PedsQL™ 4.0) (Turkish version)."
88980074|NCT05999383|Experimental|Placebo marijuana and regular cigarette|Participants will vape a 50/50 mixture of placebo marijuana (0% THC) and regular cigarette (25.94 mg/g nicotine content)
88980075|NCT05999383|Experimental|Placebo marijuana and Very Low Nicotine Content cigarette|Participants will vape a 50/50 mixture of placebo marijuana (0% THC) and Very Low Nicotine Content cigarette (0.42 mg/g nicotine content)
88980076|NCT05999383|Experimental|Medium marijuana and regular cigarette|Participants will vape a 50/50 mixture of medium marijuana (<5% THC) and regular cigarette (25.94 mg/g nicotine content)
89032049|NCT04694222|Other|Control Group|scaling and root planning (SRP) was applied.
89600473|NCT05324852|Experimental|Intranasal midazolam|Midazolam, 5 mg, injectable solution in 5mg/ml, if weight < 50 kg : 5mg; if weight ≥50kg : 10mg, intranasal administration, atomize into nose with Mucosal Atomizer Device (MAD) 5mg(1ml) up each nostril , one time
89600474|NCT05324852|Active Comparator|Intramuscular loxapine|Loxapine, 100mg, injectable solution in 50mg/2ml intramuscular, intra muscular administration, one time
89600475|NCT05324683||Study population (cohort)|No study arms; one patient population will be observed.
88980077|NCT05999383|Experimental|Medium marijuana and Very Low Nicotine Content cigarette|Participants will vape a 50/50 mixture of medium marijuana (<5% THC) and Very Low Nicotine Content cigarette (0.42 mg/g nicotine content)
88980078|NCT05999383|Experimental|High marijuana and regular cigarette|Participants will vape a 50/50 mixture of high marijuana (>10% THC) and regular cigarette (25.94 mg/g nicotine content)
89032050|NCT04694222|Active Comparator|LANAP Group|After scaling and polishing, three LANAP stages were performed : In the first stage, Nd:YAG laser was applied. In the second stage, full mouth SRP procedure was performed. In the third stage, Nd:YAG laser was applied again.
89600476|NCT05321433||The Swedish Cohort|Swedish data comes from a historical cohort of 424,386 clients of public dental clinics aged 23 and older in the Stockholm region with inception between October 2015 and January 2020, with follow-up from February 2020 to December 2020. In Sweden, the public dental clinics (Folktandvården, FTV) provide routine preventive visits (oral check-ups) to all residents who choose to receive care in these clinics. At each health check-up smoking and snus use are ascertained as past use, current use, and amount of current use. The national personal numbers assigned to every resident in Sweden at birth or at immigration will be used to obtain information on diagnoses of COVID-19 and of other diseases through record-linkage with regional health care registers. Demographic information will be extracted through record-linkage with the register of the total population of the Stockholm region held by Statistics Sweden.
89600477|NCT05321433||The Finnish Cohort|The Finnish data will come from three pooled cross-sectional national health surveys in Finland (FinSote 2018-2020) of 44,199 participants aged 20 and older. The study samples included permanent residents in Finland from the FinSote surveys 2018, 2019, and 2020. The unique personal identifier assigned to all Finnish residents will be linked to the Communicable Diseases Registry to obtain information on diagnoses of COVID-19, to the Care Register for Health Care (HILMO) to obtain information on hospital admissions due to COVID-19, and to Statistics Finland Mortality Data to obtain information on deaths. Data on some sociodemographic characteristics will be also obtained from the Digital and Population Data Services Agency.
89600478|NCT05321433||The Norwegian Cohort|The Norwegian data will be based on the Norwegian Mother, Father and Child Cohort Study (MoBa) (Magnus et al., 2016), and the Norwegian Influenza Pregnancy Cohort (NorFlu) (Laake, 2018), with linkages to the Norwegian Surveillance System for Communicable Diseases (MSIS), the Norwegian Immunisation Registry (SYSVAK), and the Norwegian Population Registry. MoBa is a nation-wide population-based cohort consisting of 280 000 participants, where parents were recruited during pregnancy from 1999 to 2008, while NorFlu is a pregnancy cohort consisting of 9 000 participants recruited in Oslo and Bergen during the swine flu pandemic in 2009-2010. Demographic information is extracted from the registries via linkage to the existing cohort databases. For the purpose of this study, all subjects who died before the onset of the pandemic (February 2020) in the three countries will be excluded from the analysis.
89600479|NCT05316688|Experimental|Diagnostic (tozuleristide, surgery, NIR imaging)|Beginning 1 hour before surgery, patients receive tozuleristide intravenously (IV) over 1-5 minutes. Patients then surgical resection per standard of care and undergo near infrared (NIR) imaging with standard of care device.
89600480|NCT05313581|Active Comparator|START NOW as web-based group training guided by a facilitator|"In condition 1, participants will be required to attend weekly sessions of the group training (period of 9 weeks; 3 double sessions;4 to12 participants) guided by a facilitator, either face-to-face or via videoconferencing. Facilitation will be provided either by a staff member (caretaker) of the institution who has received a 1.5 days training in START NOW (face-to-face setting), or by a member of the START NOW facilitator team of Universitäre Psychiatrische Kliniken (UPK) Basel (videoconference setting). All participants will have access to the START NOW Web application (WebApp) during the entire intervention and follow-up phase to complete additional exercises or review content.~Institutions randomized to group training guided by a facilitator condition will receive the complete pretraining (12 hours à 3 blocks: Theoretical Background; WebApp and Facilitator Material; Running Sessions) with individual coaching. Supervision will be provided twice during the intervention phase."
89600481|NCT05313581|Active Comparator|START NOW as web-based pure self-help training|Participants in condition 2 will use the START NOW web-based pure self-help training. Using the same session contents as in the group training guided by a facilitator, sessions have been adjusted so that participants can complete them individually and participants receive one session each week (session 1+2, 9+10 and 11+12 as double sessions). Institutions randomized to pure self-help training will receive the first block of the pretraining and the material from the second block (facilitator training material) prior to interventions start.
89600482|NCT05313581|No Intervention|Treatment as usual (TAU)|Participants in condition 3 will not receive any health promotion services during the skills training or follow-up period beyond what is offered at their respective institution. They will also be excluded from any group trainings similar to START NOW. For ethical reasons and to increase study-related commitment, they will be provided with the web-based pure self-help training after completion of the study. Institution staff will receive the first block of the pretraining and material from the second block after the end of the intervention. Supervision for participating caretakers and facilitators will not be provided during the intervention phase.
89600483|NCT05311371|Experimental|Breathing exercise group|"The researcher will collect the data using Patient Information Form, Rhodes Index of Nausea, Vomiting and Retching Scale, Patient Diary for determining the number of nausea, vomiting, and retching episodes and the hours of breathing exercise of the patient, and Daily Nutritional Consumption Amount Form through face-to-face interview technique on the first day and for 14 days.~During chemotherapy and stem cell transplantation, antiemetic treatment included in the treatment protocol will be applied to the patients.~The patients will train about the application of breathing exercise by the researcher. They will be asked to do this breathing exercise with the guideline for at least 5 min in case of sensation of nausea and vomiting for 14 days."
89600484|NCT05311371|Other|Control group|"The researcher will collect the data using Patient Information Form, Rhodes Index of Nausea, Vomiting and Retching Scale, Patient Diary for determining the number of nausea, vomiting, and retching episodes and the hours of breathing exercise of the patient, and Daily Nutritional Consumption Amount Form through face-to-face interview technique on the first day. The researcher will continue to fill out Rhodes Index of Nausea, Vomiting and Retching Scale, Patient Diary for determining the number of nausea, vomiting, and retching episodes and the hours of breathing exercise of the patient, and Daily Nutritional Consumption Amount Form for 14 days.~During chemotherapy and stem cell transplantation, antiemetic treatment included in the treatment protocol will be applied to the patients."
89600485|NCT05307562|Active Comparator|Training program|Global intervallic exercise using cyclometer and analytical strength exercises
89032051|NCT04694222|Active Comparator|LLLT Group|after SRP Low Level Laser Therapy was performed using Nd:YAG laser.
89032052|NCT04694222|Active Comparator|LANAP+LLLT Group|after scaling both LANAP and LLLT were applied.
89032053|NCT02948855||Tm group|Simple thymoma group：The patients have suffered thymoma only and have no other complications.
89032054|NCT02948855||Tm+MG group|Thymoma complicated with myasthenia gravis (MG) group: The patients have suffered thymoma and myasthenia gravis in the mean time.
89600486|NCT05307562|Experimental|Training program + Inspiratory muscle traioning (IMT)|Global intervallic exercise using cyclometer and analytical strength exercises + inspiratory muscles training
89600487|NCT05304520||On Natalizumab: Switcher IV to SC Cohort|Participants who are already on natalizumab treatment, 300 milligrams (mg) IV infusion and who decide to switch to 2x150 mg SC injection administered as standard of care/routine clinical practice will be observed for up to 12 months.
89600488|NCT05304520||Natalizumab-Naive IV Cohort|Participants who initiate natalizumab, 300 mg, IV infusion injection administered as standard of care/routine clinical practice will be observed for up to 12 months
89600489|NCT05304520||Natalizumab-Naive SC Cohort|Participants who initiate natalizumab, 2x150 mg, SC injection administered as standard of care/routine clinical practice will be observed for up to 12 months.
89600490|NCT05303467|Experimental|Treatment|The projected radiation absorbed dose to the treatment volume is 40 Gy ±10%.
89600491|NCT05296538|Experimental|Broad-Minded Affective Coping Intervention + Risk assessment and signposting|Participants will first receive one to two 50 minute sessions focused on risk assessment and management, including signposting to further support. They will then be offered six sessions of the Broad-Minded Affective Coping (BMAC) Intervention. Sessions will take place weekly where possible and the intervention window will be eight weeks. A booster session will be offered in the 8 weeks following the end of therapy.
89600492|NCT05296538|Other|Risk assessment and signposting + Treatment As Usual|Participants will first receive one to two 50 minute sessions focused on risk assessment and management, including signposting to further support. In addition they will be able to access usual care from their University counselling service or other health services.
89600493|NCT05295563||Group 1|Children who had been injected once or twice before were included in Group 1.
89600494|NCT05295563||Group 2|Children who received 3 or more injections were included in Group 2.
89600495|NCT05288387|Experimental|Spinal cord stimulation in heart failure patients with hypotension|"Adhesive patches are applied to subjects' back skin. Single stimuli are delivered in order to define the stimulation threshold under the guidance of neuromyography. Vascular access is performed (jugular or subclavian) according to conventional preparation to right heart catheterization. Invasive hemodynamic measures are performed as usual.~High-frequency spinal cord stimulation at T5 level is initiated, and repeated hemodynamic measures performed within 2 minutes. Stimulation lasts for 5-10 minutes, and then ceased. Following a 5-minutes waiting period, repeat hemodynamic measures are performed. The same sequence of steps applies for stimulation levels T7-8 and a combination of T5 and T7-8.~Then the procedure is completed and data are analysed."
89600496|NCT05287724|Experimental|N-acetyl Cysteine then Placebo|Subjects will be treated with N-acetyl cysteine twice daily for seven days. Subject will complete a minimum of 30-day washout period before crossing over to take the placebo.
89600497|NCT05287724|Experimental|Placebo then N-acetyl Cysteine|Subjects will be treated with placebo twice daily for seven days. Subject will complete a minimum of 30-day washout period before crossing over to take N-acetyl cysteine.
89600498|NCT05284266|Active Comparator|Standard conservative treatment|"Standard conservative treatment consisting of:~Physical therapy, including compression garment and exercise program~Self-care program~Individual counseling from a clinical dietician"
89600499|NCT05284266|Experimental|Standard treatment plus additional lymphedema treatment|"Standard conservative treatment consisting of:~Physical therapy, including compression garment and exercise program~Self-care program~Individual counseling from a clinical dietician Additional lymphedema treatment consisting of intermittent pneumatic compression (IPC)"
89600500|NCT05284266|Experimental|Surgical group: Liposuction|Early liposuction, 6-9 months after inclusion in study.
89600501|NCT05284266|Active Comparator|Surgical group: Control|Late liposuction, 18-21 months after inclusion. This group functions as a control group for 1 year before enrolment in the Liposuction group.
89032055|NCT02948855||Tm+MG+AD group|"Thymoma complicated with myasthenia gravis and other autoimmune diseases (AD) group:~The patients have suffered thymoma, myasthenia gravis and other autoimmune diseases in the mean time."
89033274|NCT02942459|Experimental|Music Therapy|"25 Weekly Hours of Music Therapy adapted to the Needs of the Participants. Interventions can be Active (playing Music, singing, improvising, Song-writing) or Receptive (Listening to selected Play-lists, or to the Participants´ favored Music).~A Manual is created and trained with the Music Therapists, which distinguishes between~Unique and Essential Principles for Music Therapy with people suffering from Schizophrenia with negative Symptoms,~Essential but not Unique Principles,~Acceptable but not necessary Principles,~Not acceptable and Proscribed Principles. These Principles concern Attitude and Listening Perspectives by the Music Therapist, how to conduct the Musical Interventions and Questions of Frames for the Music Therapy Work."
89600502|NCT05274347|Experimental|Multi-faceted virtual, remote intervention|"The intervention will use the Aetonix - aTouchAwayTM software platform (AETONIX Systems Inc). Each study participant will receive a tablet with Aetonix software. Interventions Components:~Cognitive behavioral therapy (CBT): After discharge, patients will receive weekly group CBT sessions delivered virtually by a psychologist. Throughout the series of CBT sessions, patients will learn strategies for problem-solving, assertive communication, relaxation, behavioural activation, time-based pacing, challenging unhelpful thinking, building motivation, and goal setting.~Remote monitoring of vital signs and symptoms: Messages will be sent to patients asking them to measure their vitals, to report symptoms, and answer questions about medications. Concerning responses will be flagged for review by the patient's healthcare team."
89210236|NCT04006743|No Intervention|The routine care group|In the routine care group, while a neonatal nurse performed the OGT insertion procedure, physiological measurements of the highest value of heart rate and the lowest value of oxygen saturation were recorded by one researcher (the first author) 1 min before the procedure, during the process and after the process in 1st and 2nd minutes acquired for each infant in the unit with an individual monitor.
89210237|NCT04006743|Experimental|The swaddling group|In this group, preterm infants were given swaddling method.
89210238|NCT04006743|Experimental|The expressed breast milk group|In this group, preterm infants were given expressed breast milk method.
89210239|NCT04006743|Experimental|The facilitated tucking group|In this group, preterm infants were given facilitated tucking method.
89600503|NCT05272384|Experimental|Treatment (nivolumab, decitabine and cedazuridine)|Patients receive decitabine and cedazuridine PO QD on days 1-3 or 1-5 of each cycle and nivolumab IV over 30 minutes on day 15 of each cycle. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo PET/CT and collection of blood samples throughout the trial.
89600504|NCT05271409|Experimental|Group A: Satralizumab|In the double-blind treatment period, participants will receive satralizumab at Weeks 0, 2, 4 (loading doses) and maintenance doses every 4 weeks (Q4W) thereafter. In the OLE period, all participants will receive open label treatment with satralizumab.
89600505|NCT05271409|Placebo Comparator|Group B: Placebo|In the double-blind treatment period, participants will receive satralizumab matching placebo at Weeks 0, 2, 4 (loading doses) and maintenance doses every 4 weeks (Q4W) thereafter. In the OLE period, all participants will receive open label treatment with satralizumab.
89600506|NCT05264415|Experimental|Families Over-Coming Under Stress-Early Childhood Program (FOCUS-EC)|"FOCUS-EC is a trauma-informed, family-level, skill building program that provides developmental guidance, parent education, and key resilience skills that promote positive individual and family coping (including emotional regulation, problem solving, goal setting, communication, and management of trauma & loss reminders), which foster parent-child and family cohesion. It is delivered in approximately 8 weekly sessions (including approximately six 60-minute sessions with parent/caregivers only, and two 30-60 minute sessions with children and parent/caregivers together). Each session is structured with a check-in, review of the previous week's home activity, new skills-based activity and discussion, selection of a new home activity, and a closing check-out. FOCUS-EC promotes parenting skills and more cohesive family relationships in two key phases: 1) creating a family timeline and 2) enhancing parent-child interactions."
89600507|NCT05264415|Active Comparator|Parenting Education Website|The Parenting Education Website includes information and high-quality parenting resources covering topics such as typical child development, common child reactions to family stress and transitions, play, positive parenting strategies, and the importance of self-care.
89600508|NCT05263297|Other|video group|During the bloodletting process, children in the video game group will be played with audio and visual video games that they can play with one hand. Thus, children will be provided with both visual and auditory stimuli. It will be preferred that children play the video game that they have knowledge about and know how to play the game. For this reason, children in the video game group will be given the chance to choose video games suitable for their age and development level on their parents' smartphones. These video games within the scope of the research will not be named and will not be promoted/advertised.
89600509|NCT05263297|Other|kaleidoscope group|In this study, a kaleidoscope with colorful patterns that can be used by children with one hand will be used. In the research, the kaleidoscope will be introduced to children and how to use it will be explained. After the procedure, the kaleidoscope will be disinfected using appropriate disinfectant materials.
89600510|NCT05257083|Active Comparator|Arm A: DVRd + ASCT+DVRd (Standard Therapy)|"Participants will receive daratumumab, bortezomib, lenalidomide and dexamethasone (DVRd) for 4 induction cycles. Followed by ASCT and 2 cycles of DVRd consolidation, and lenalidomide maintenance therapy for 2 years~Daratumumab subcutaneously (SC), 1800 mg on days 1, 8, 15 and 22 of cycle 1 and 2, on days 1 and 15 of cycle 3-6.~Bortezomib SC 1.3 mg/m^2 on days 1, 4, 8, and 11 of each cycle 1-6. Lenalidomide orally, 25 mg on days 1 to 21 of each cycle 1-6. Dexamethasone orally, 40 mg once a week on days 1, 8, 15 and 22 of each cycle 1-6.~Each cycle will consist 28 days.~Lenalidomide maintenance orally 10 to 15 mg on days 1 to 28 (continuously) until confirmed progressive disease or unacceptable toxicity or for a maximum of 2 years"
89608560|NCT03918837|Sham Comparator|Sham rTMS|"The investigators will perform sham rTMS at 30% of the Motor Threshold, with a 1Hz frequency and 1200 pulses during one session. The target will be the right Orbito Frontal Cortex, localized using Neuronavigation. Sessions will last fifteen minutes; subjects will perform two sessions a day during five days. The coil will have a 180° rotation compared to the active coil position, thus making the magnetic field ineffective on the patient's cortex.~Participants will undergo a MRI with anatomical and ASL sequences one week before and four weeks after treatment.~All participants of this group will have the opportunity to undergo an active rTMS treatment right after the end of each one's participation in the study."
88980079|NCT05999383|Experimental|High marijuana and Very Low Nicotine Content cigarette|Participants will vape a 50/50 mixture of high marijuana (>10% THC) and Very Low Nicotine Content cigarette (0.42 mg/g nicotine content)
88980080|NCT05999383|Experimental|High marijuana only|Participants will vape high marijuana (>10% THC)
88980081|NCT05999383|Experimental|Regular cigarette only|Participants will vape a regular cigarette (25.94 mg/g nicotine content)
88980082|NCT05999370|Other|Nutrition and exercise|"The nutrition intervention will be based on a comprehensive nutrition assessment by a dietitian at baseline, enabling individualized caloric and protein targets.~The exercise intervention will be personalized based on a comprehensive assessment to include both a resistance and an aerobic component in the form of a snack."
88980083|NCT05999370|Other|Nutrition only|The nutrition intervention will be based on a comprehensive nutrition assessment by a dietitian at baseline, enabling individualized caloric and protein targets.
88980084|NCT05999331||Non-SALD group|SALD did not occur in adult patients with sepsis during ICU stay.SALD was diagnosed by the following criteria: (1) ALT or AST≥20 folds upper limit of normal level; or (2) TBIL≥2.0 mg/dL.
89210240|NCT04006743|Experimental|The swaddling and expressed breast milk group|In this group, preterm infants were given combined swaddling and expressed breast milk method.
89210241|NCT04006743|Experimental|The facilitated tucking and expressed breast milk group|In this group, preterm infants were given combined facilitated tucking and expressed breast milk method.
89210242|NCT00986505|Experimental|Lidocaine|Comparison between intravenous lidocaine and saline infusion
89210243|NCT00894426||1|Morning Symptoms (+)
89210244|NCT00894426||2|Morning Symptoms (-)
89210245|NCT00983775|Experimental|healthy low dose insulin|16 healthy non-diabetic volunteers. The type of insulin tested will be the rapid-acting insulin analogue insulin aspart (Novorapid®), at a dose of 0.2 units per kg body weight.
89600511|NCT05257083|Experimental|Arm B: DVRd followed by Ciltacabtagene Autoleucel|"Participants will receive daratumumab, bortezomib, lenalidomide and dexamethasone (DVRd) for 6 induction cycles.~Participants will receive a conditioning regimen (cyclophosphamide 300 mg/m^2 intravenous [IV] and fludarabine 30 mg/m^2 IV daily for 3 days) and Cilta-cel infusion 0.75*10^6 chimeric antigen receptor (CAR)-positive viable T cells/kilogram (kg), followed by lenalidomide post CAR-T cell therapy for 2 years~Daratumumab subcutaneously (SC), 1800 mg on days 1, 8, 15 and 22 of cycle 1 and 2, on days 1 and 15 of cycle 3-6.~Bortezomib SC 1.3 mg/m^2 on days 1, 4, 8, and 11 of each cycle 1-6.~Lenalidomide orally, 25 mg on days 1 to 21 of each cycle 1-6.~Dexamethasone orally, 40 mg once a week on days 1, 8, 15 and 22 of each cycle 1-6.~Each cycle will consist of 28 days.~Lenalidomide maintenance orally 10 to 15 mg on days 1 to 28 (continuously) until confirmed progressive disease or unacceptable toxicity or for a maximum of 2 years"
89600512|NCT05256303|Experimental|Home Hospital care|Patients receive hospital-level care in their home, as a substitute to traditional hospital care.
89600513|NCT05256303|Active Comparator|Traditional Hospital care|Patients receive hospital-level care in the hospital.
89600514|NCT05256290|Experimental|Phase 1 Dose Escalation - Monotherapy (Recruitment Closed)|"Advanced/metastatic NSCLC with acquired resistance EGFR mutation (eg, C797S), following a 3rd generation EGFR inhibitor in the 1st line setting (in the absence of concurrent T790M).~Advanced/metastatic NSCLC with non-classical EGFR mutation (eg, G719X) following standard-of-care therapy with an EGFR inhibitor~Recurrent GBM with confirmed EGFR alterations (including amplification, mutation, and/or variant)"
89600515|NCT05256290|Experimental|Phase 2 Cohort 1: NSCLC EGFR Non-Classical Driver Mutations|Advanced/metastatic NSCLC with a non-classical driver EGFR mutation following up to 2 lines of therapy with only 1 prior EGFR targeted regimen (third-generation preferred; other approved EGFR inhibitors acceptable)
89600516|NCT05256290|Experimental|Phase 2 Cohort 2: NSCLC EGFR Acquired Resistance (C797S) Mutation|Advanced/metastatic NSCLC with the acquired resistance C797S EGFR mutation following up to 2 lines of therapy, including only 1 EGFR targeted regimen, which must be a third generation EGFR TKI (eg, osimertinib)
89600517|NCT05256290|Experimental|Phase 2 Cohort 3: Treatment Naive NSCLC EGFR Non-Classical Driver Mutations|Treatment-naïve (first-line) advanced/metastatic NSCLC with a non-classical driver EGFR mutation (1 cycle of chemotherapy or immune checkpoint inhibitor are permitted)
89600518|NCT05253846|Experimental|SCRT--> FOLFOXIRI--> SURGERY|"SHORT-COURSE RT~FOLFOXIRI~IRINOTECAN 165 mg/sqm iv over 60 minutes, day 1 followed by~OXALIPLATIN 85 mg/sqm iv over 2 hours, day 1 in two-way with~LEDERFOLIN 200 mg/sqm iv over 2 hours, day 1 followed by~5-FLUOROURACIL 3200 mg/sqm 48 h-continuous infusion, starting on day 1. The chemotherapy treatment will be repeated every 2 weeks up to 8 cycles.~Surgery with TME should be performed after 4 weeks after the last cycle of chemotherapy"
89600519|NCT05245318|Active Comparator|Standard clinical care control group|Standard physiotherapy program of 12 weeks (1 treatment session /week)
89600520|NCT05245318|Experimental|Experimental blended physiotherapy program group|Blended physiotherapy program of 12 weeks with exercises and counselling provided through a smartphone application and 6 face-to-face treatment sessions (1 physiotherapy treatment session every 2 weeks)
89600521|NCT05242497|Experimental|pharmacopuncture group|The physicians will choose the type and volume of pharmacopuncture according to participants' conditions.
89600522|NCT05242497|Active Comparator|conservative treatment group|The physicians will choose the type and time of physical therapy and if needed, pharmacological treatment according to participants' conditions.
89600523|NCT05221125|Experimental|Psychologically-Informed Physical Therapy (PIPT)|CBT-trained physical therapist evaluation and treatment with recommendation for Spine Health follow up after ED discharge
89600524|NCT05221125|No Intervention|Control|Usual care only
89600525|NCT05220878|Experimental|GNR-069|Main group (80 patients) - multiple weekly subcutaneous injections of GNR-069, doses are calculated individually.
89600526|NCT05220878|Active Comparator|Nplate|Control group (80 patients) - multiple weekly subcutaneous injections of Nplate, doses are calculated individually.
89600527|NCT05218213||Healthy young|Healthy young adults
89600528|NCT05218213||Healthy elderly|Healthy elderly adults
89600529|NCT05218213||Parkinson's disease|Elderly with Parkinson's disease
89600530|NCT05213026||Apexification|"Apexification treatment was applied by a single operator (GK) in Istanbul University Faculty of Dentistry, Department of Pedodontics,~Having no systemic or periodontal problems,~Asymptomatic or diagnosed with apical periodontitis with fistula tract,~Not having external/internal resorption, fracture, more than one root/canal,~Root canal filling is sufficient for the MTA,~Root canal filling and coronal restorations were completed in Istanbul University Faculty of Dentistry Department of Pedodontics,~Cases with periapical radiographs taken before the procedure and at least one year after the procedure was included."
89600531|NCT05213026||Regenerative|"Apexification treatment was applied by a single operator (GK) in Istanbul University Faculty of Dentistry, Department of Pedodontics,~Having no systemic or periodontal problems,~Asymptomatic or diagnosed with apical periodontitis with fistula tract,~Not having external/internal resorption, fracture, more than one root/canal,~Root canal filling and coronal restorations were completed in Istanbul University Faculty of Dentistry Department of Pedodontics,~Cases with periapical radiographs taken before the procedure and at least one year after the procedure was included."
89600532|NCT05210387|Experimental|7-day adequate antibiotic therapy|Adequate antibiotic therapy is defined as antimicrobial treatment with at least one agent with in vitro susceptibility.
89210246|NCT00983775|Experimental|healthy high dose insulin|16 healthy non-diabetic volunteers. The type of insulin tested will be the rapid-acting insulin analogue insulin aspart (Novorapid®), at a dose of 0.4 units per kg body weight.
89210247|NCT00983775|Experimental|type 1 diabetes mellitus|16 people with type 1 diabetes mellitus. The type of insulin tested will be the rapid-acting insulin analogue insulin aspart (Novorapid®), at a dose of 0.4 units per kg body weight.
89210248|NCT04017858|Experimental|Experimental|Multiprofessional and educational Program prior to Total knee replacement TKA. (PARQVE TKA).
89210249|NCT04017858|Active Comparator|Control|Patients will be submitted to total knee replacement.
89210250|NCT03687333|Experimental|Alglucosidase Alfa therapy|Alglucosidase Alfa dose is calculated per kg body weight and administered once every 2 weeks for up to 52 weeks.
89210251|NCT00902616|Active Comparator|1. L-arginine|3 gm TDS for 3 months
89210252|NCT00902616|Placebo Comparator|2. Placebo - Lactose powder|3 gm TDS for 3 months
89600533|NCT05210387|Active Comparator|14-day adequate antibiotic therapy|Adequate antibiotic therapy is defined as antimicrobial treatment with at least one agent with in vitro susceptibility.
89600534|NCT05208281|Experimental|Adult: GNR-055|GNR-055: 1.0-2.0-3.0 mg/kg
89600535|NCT05208281|Experimental|Paediatric: GNR-055 2.0 mg/kg|GNR-055 2.0 mg/kg
89600536|NCT05208281|Experimental|Paediatric: GNR-055 3.0 mg/kg|GNR-055 3.0 mg/kg
89600537|NCT05206942|Experimental|Ultrasound|Patients receiving standard of care immune checkpoint inhibitor are followed with the ultrasound studies at treatment baseline, 3 weeks and 6 weeks.
89600538|NCT05204147|Experimental|Treatment (Ac225-DOTA-M5A)|Patients receive Ac225-DOTA-M5A IV over 25 minutes on day 1.
89600539|NCT05202262|Experimental|BFF MDI 320/9.6 μg|Budesonide/ Formoterol Fumarate (BFF) metered-dose inhaler (MDI), 320/9.6 μg
89600540|NCT05202262|Experimental|BFF MDI 160/9.6 μg|Budesonide/ Formoterol Fumarate (BFF) metered-dose inhaler (MDI), 160/9.6 μg
89600541|NCT05202262|Experimental|BD MDI 320 μg|Budesonide MDI (BD MDI), 320 μg
89600542|NCT05202262|Active Comparator|Open-label Symbicort TBH 320/9 μg|Open-Label Comparator Symbicort Turbuhaler 320/9 μg
89600543|NCT05198830|Experimental|Arm I (methoxyamine, usual care)|Patients receive methoxyamine PO on day 1 of each cycle, pemetrexed IV over 10 minutes on day 1 of each cycle, and cisplatin IV over 60 minutes on day 3 of each cycle. Beginning day 3, patients also undergo radiation therapy daily Monday-Friday. Treatment repeats every 21 days for 2 cycles in the absence of disease progression or unacceptable toxicity. Beginning 2-6 weeks after cycle 2, patients receive durvalumab IV over 60 minutes every 2 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients also undergo CT scan or MRI throughout the trial and PET/CT scan during screening and on study.
89600544|NCT05198830|Active Comparator|Arm II (usual care)|Patients receive pemetrexed IV over 10 minutes and cisplatin IV over 60 minutes on day 1 of each cycle. Beginning day 1 of each cycle, patients also undergo radiation therapy daily Monday-Friday. Treatment repeats every 21 days for 2 cycles in the absence of disease progression or unacceptable toxicity. Beginning 2-6 weeks after cycle 2, patients receive durvalumab IV over 60 minutes every 2 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients also undergo CT scan or MRI throughout the trial and PET/CT scan during screening and on study.
89600545|NCT05197634||Children with Autism Spectrum Disorder|The orofacial trauma history, dietary habits and lifestyle changes of children aged 3-14 years diagnosed with autism in Istanbul University Department of Child Psychiatry evaluated through a questionnaire to be applied to their families.
89600546|NCT05197634||Healthy children|The orofacial trauma history, dietary habits and lifestyle changes of healthy children aged 3-14 years applying to Istanbul University Faculty of Dentistry Department of Pediatric Dentistry will be evaluated through a questionnaire to be applied to their families.
89600547|NCT05190770|Experimental|Triamcinolone + Oleogel-S10|25 participants will be randomized to triamcinolone 0.1% cream once every morning and topical Oleogel-S10 gel once prior to bedtime for a 3 week period.
89600548|NCT05190770|Placebo Comparator|Triamcinolone + Placebo|25 patients with breast cancer will be randomized to triamcinolone 0.1% cream once every morning (QAM) and vehicle gel once prior to bedtime for a 3 week period.
89600549|NCT05190718||Dysphagia rehabilitation|All interventions are part of routine treatment of dysphagia.
89600550|NCT05184582|No Intervention|Standard|Routine information on the benefit of physical activity
89600551|NCT05184582|Experimental|Intervention|High-intensity interval and strength training during neoadjuvant chemotherapy
89600552|NCT05176483|Experimental|XL092 + Nivolumab Dose-Escalation Cohorts|"Approximately 12 subjects will accrue across 1-2 dose levels of XL092 following the rolling 6 design."
89600553|NCT05176483|Experimental|XL092 + Nivolumab + Ipilimumab Dose-Escalation Cohorts|"Approximately 12 subjects will accrue across 1-2 dose levels of XL092 following the rolling 6 design."
89600554|NCT05176483|Experimental|XL092 + Nivolumab Expansion Cohorts|The recommended dose from the dose-escalation stage may be further explored in tumor-specific cohorts.
89600555|NCT05176483|Experimental|XL092 + Nivolumab + Ipilimumab Expansion Cohorts|The recommended dose from the dose-escalation stage may be further explored in tumor-specific cohorts.
89600556|NCT05176483|Experimental|XL092 Single-Agent Expansion Cohorts|
89210253|NCT00984087|Experimental|Active rTMS treatment|
89210254|NCT00898326||Biopsy 36 month after breacchytherapy|Biopsy 36 month after breacchytherapy on protocol JUSMH-BRI-GU05-01.
89600557|NCT05176483|Experimental|XL092 + Nivolumab + Relatlimab Dose-Escalation Cohorts|"Approximately 12 subjects will accrue across 1-2 dose levels of XL092 following the rolling 6 design."
89600558|NCT05176483|Experimental|XL092 + Nivolumab + Relatlimab Expansion Cohorts|The recommended dose from the dose-escalation stage may be further explored in tumor-specific cohorts.
89600559|NCT05173961|Experimental|Supportive Care (oncpatient application, survey)|Patients use the oncpatient mobile application over the course of radiation therapy. Patients also complete a survey on the final day of radiation treatment.
89600560|NCT05173051|Experimental|Ability of Swallowing solid placebos vs. a crushed placebo|During routine FEES examination, patients are sequentially being given 3 different solid placebos pills and one crushed placebo mixed with semisolid texture.
89210255|NCT00989313||1|
89600561|NCT05172765|Active Comparator|Active TENS Stimulation|
89600562|NCT05172765|Sham Comparator|Inactive TENS Stimulation|
89600563|NCT05172297|Experimental|Immediate Intervention Group|The immediate intervention group will take part in the online parent training program called the Parent Web (PW). This immediate intervention group are parents of PATHS children who took part in a social emotional curriculum (PATHS) at age 4 to 5 years old and during the PW trial will be 11 to 13 years old. Parents are participating in the Parent Web.
89600564|NCT05172297|Other|Wait-List Control Group|This is a group of parents who are in a wait-list control group and will receive the Parent Web, after pre and post testing.
89600565|NCT05167591|Experimental|Study group|Measurements of paracetamol concentration
89600566|NCT05165628|Experimental|Group 1 - CYP-006TK|Participants will receive CYP-006TK dressings
89600567|NCT05165628|No Intervention|Group 2 - Standard of Care|Participants will continue to be treated as per local standard of care
89600568|NCT05164640|Other|assessment of coronary physiology|"This is a prospective, multicentric, non-randomized , single-arm , open label clinical study.~Included patients will be studied with invasive functional tests performed during index coronary angiography. These will include FFR, instantaneous Wave-Free Ratio (iFR), Resting Ful-Cycle Ra-tio (RFR), CFR, IMR and provocative Acetylcholine test.~After the diagnosis of vasospastic angina (VSA) or coronary microvascular dysfunction (CMD) is made, a stratified medical therapy will then be initiated according to the results of physiological assessment according to ESC guidelines and recent EAPCI expert consensus document ."
89600569|NCT05162586|Placebo Comparator|Cohort A: Placebo|Participants with CLE (active SCLE and/or DLE) or SLE with predominantly active lupus rash (Cutaneous Lupus Erythematosus Disease Area and Severity Index [CLASI-A] greater than or equal to [>=] 8) will be enrolled in Cohort A to receive placebo matched to Enpatoran.
89600570|NCT05162586|Experimental|Cohort A: Enpatoran low dose|Participants with CLE (active SCLE and/or DLE) or SLE with predominantly active lupus rash (CLASI-A >= 8) will be enrolled in Cohort A to receive low dose of Enpatoran.
89600571|NCT05162586|Experimental|Cohort A: Enpatoran medium dose|Participants with CLE (active SCLE and/or DLE) or SLE with predominantly active lupus rash (CLASI-A >= 8) will be enrolled in Cohort A to receive medium dose of Enpatoran.
89600572|NCT05162586|Experimental|Cohort A: Enpatoran high dose|Participants with CLE (active SCLE and/or DLE) or SLE with predominantly active lupus rash (CLASI-A >= 8) will be enrolled in Cohort A to receive high dose of Enpatoran.
89600573|NCT05162586|Placebo Comparator|Cohort B (Part 1 + Part 2): Placebo|Participants with active SLE who have moderate to high systemic disease activity (British Isles Lupus Assessment Group [BILAG A/2B]) with 1 or 2 of the following: CLASI-A >= 8 and/or Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) >= 6 will be enrolled in Cohort B to receive placebo matched to Enpatoran .
89600574|NCT05162586|Experimental|Cohort B (Part 1 + Part 2): Enpatoran high dose|Participants with active SLE who have moderate to high systemic disease activity (BILAG A/2B) with 1 or 2 of the following: CLASI-A >= 8 and/or SLEDAI >= 6 will be enrolled in Cohort B to receive high dose of Enpatoran.
89600575|NCT05162586|Experimental|Cohort B (Part 2): Enpatoran low dose|Participants with active SLE who have moderate to high systemic disease activity (BILAG A/2B) with 1 or 2 of the following: CLASI-A >= 8 and/or SLEDAI >= 6 will be enrolled in Cohort B to receive low dose of M5049.
89600576|NCT05162586|Experimental|Cohort B (Part 2): Enpatoran medium dose|Participants with active SLE who have moderate to high systemic disease activity (BILAG A/2B) with 1 or 2 of the following: CLASI-A >= 8 and/or SLEDAI >= 6 will be enrolled in Cohort B to receive medium dose of Enpatoran.
89600577|NCT05159791|Experimental|Anomalous coronary blood flow|Subjects suspected to have AAOCA will be submitted to angiographic coronary CT imaging to confirm the diagnosis. If the diagnosis of AAOCA will be confirmed, subjects will undergo to invasive coronary blood flow evaluation (intervention).
89600578|NCT05155631|Experimental|Cognitive Behavioral Treatment Arm|"Subjects in the Cognitive Behavioral Treatment Arm will undergo 8-10 weeks of remote cognitive behavioral therapy. Subjects will complete modules on their phones and will be monitored by study coordinators for support and treatment completion."
89600579|NCT05155631|No Intervention|Usual Care Arm|"Subjects in the Usual Care Arm will undergo 8-10 weeks of continued lifestyle. Subjects will be asked to report any new medications or lifestyle changes to study coordinators throughout the 8-10 weeks."
89600580|NCT05149755|Experimental|Medtronic Evolut PRO+, or Evolut FX,TAVR System, & guideline-directed management & therapy (GDMT)|Medtronic Evolut PRO+ TAVR or Evolut FX TAVR Systems, & guideline-directed management & therapy
89600581|NCT05149755|No Intervention|Clinical site determined guideline-directed management and therapy (GDMT) alone|Clinical site determined guideline-directed management and therapy (GDMT) alone
89600582|NCT05142241|Experimental|Treatment (talazoparib, temozolomide)|Patients receive talazoparib PO QD on days 1-28 and temozolomide PO QD on days 2-6 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT scans and may optionally undergo biopsy and/or blood sample collection at baseline and on the trial.
89600583|NCT05142189|Experimental|Cohort 1A - BNT116 monotherapy|
89600584|NCT05142189|Experimental|Cohort 1B - BNT116 monotherapy|
89600585|NCT05142189|Experimental|Cohort 2 - BNT116 + cemiplimab (PD-1/PD-L1 inhibitor refractory/relapsed patients)|
89600586|NCT05142189|Experimental|Cohort 3 - BNT116 + docetaxel|
89600587|NCT05142189|Experimental|Cohort 4 - BNT116 + cemiplimab (frail patients)|
89600588|NCT05142189|Experimental|Cohort 5 - BNT116 + cemiplimab (after concurrent chemoradiotherapy [CRT])|
89033275|NCT02942459|Active Comparator|Music Listening|"25 Weekly Hours of Being together with an unknown Care Staff Member listening to Music from selected Play-Lists. Music Therapists at the Music Therapy Research Clinic at Aalborg University Hospital, Psychiatry have developed Play-Lists in a Taxonomy from very Supportive to less Supportive Music including around 100 Hours of Music all together on the Lists.~A Manual is created and trained with the Care Staff Members. Here the Activities are much more limited (only Music Listening to the Play-Lists are allowed). No Therapeutical Conversation is allowed."
89600589|NCT05142189|Experimental|Cohort 6 - BNT116 + cemiplimab + carboplatin + paclitaxel|BNT116 + cemiplimab + carboplatin + paclitaxel as neo-adjuvant treatment followed by surgery, thereafter adjuvant treatment with BNT116 + cemiplimab
89600590|NCT05138133|Experimental|Anifrolumab|Solution for intravenous infusion
89600591|NCT05138133|Placebo Comparator|Placebo|Solution for intravenous infusion
89600592|NCT05127850|Experimental|Consultation audio recording|"Instructions on installation and detailed use of chosen application will be provided before an upcoming oncology visit. Research staff will contact the participant and encourage a practice recording session. 15-30 minutes prior to the consultation, research staff will send an anonymous text message to the participants' mobile device with a reminder to record the visit. Three days after the consultation, research staff will send an anonymous text reminder message to the participants' mobile device to listen to the recording."
89600593|NCT05123664|Experimental|Bacillus coagulans|2 billion CFU Bacillus coagulans Unique IS2 per capsule
89600594|NCT05123664|Placebo Comparator|Placebo|Appearance-matched capsule
89033276|NCT02920437|Experimental|Intervention group|Four-week weekly intervention to reduce salt intake.
89033277|NCT02920437|Other|Control group|Usual government pamphlets.
89033278|NCT02942420|Experimental|Dose Group A|Bucillamine 300 mg/day
89600595|NCT05121961|Experimental|Platelet-rich Plasma|Patients will receive an intra-articular injection 3 mL of autologous platelet-rich plasma in the sacroiliac joint.
89600596|NCT05121961|Active Comparator|Steroid/Anesthetic|Patients will receive an intra-articular injection 40 mg Depo-medrol mixed with 2 mL 0.25% bupivicaine in the sacroiliac joint.
88980085|NCT05999331||SALD group|SALD was occured in adult patients with sepsis during ICU stay.SALD was diagnosed by the following criteria: (1) ALT or AST≥20 folds upper limit of normal level; or (2) TBIL≥2.0 mg/dL. SALD is further divided into hypoxic hepatitis and sepsis induced cholestasis (SIC), based on the presence or absence of elevated TBIL. Hypoxic hepatitis is diagnosed when elevated transaminase (>800 IU/L) is present only; and SIC is diagnosed when TBIL is elevated (≥2.0 mg/dL).
89600597|NCT05117931|Experimental|Amivantamab|Patients will receive amivantamab intravenously weekly for the first cycle, and biweekly subsequently at a dose of 1050mg (patients <80kg) or 1400mg (patients ≥80kg). The initial dose will be administered over 2 days in split doses in order to mitigate the risk of infusion reactions. Therapy will continue for up to 2 years or until progression of disease, initiation of alternative cancer therapy, unacceptable toxicity, or other reason to discontinue treatment occurs-whichever comes first.
89600598|NCT05100381|Experimental|Experimental group|The experimental group will comprise 20 participants with chronic non-specific low back pain. The treatment will include dry needling of the lumbar multifidus muscle and routine physical therapy. The needles will be inserted to obtain local twitch response, and this process will continue until no more local twitch response occurs in each session. Then the needles will be left in place for 20 minutes. Routine physical therapy will include low level laser therapy and motor control training. The treatment will last 3 weeks, 6 sessions, twice a week.
89600599|NCT05100381|Placebo Comparator|Control group|"The control group will comprise 20 participants with chronic non-specific low back pain. The treatment will include sham dry needling of the lumbar multifidus muscle and routine physical therapy. The sham dry needling method consists of the insertion of the needles subcutaneously and no local twitch response will be obtained. The needles will be left in the place for 20 minutes. Routine physical therapy will include low level laser therapy and motor control training. The treatment will last 3 weeks, 6 sessions, twice a week."
89600600|NCT05099276|Experimental|Oral TXA|1,950 mg oral tranexmic acid (three capsules of 650 mg) administered in post-anesthesia care, postop day one and postop day two. Compounded by registered pharmacist and labeled with subject name and instructions for use.
89600601|NCT05099276|Placebo Comparator|Oral placebo|Three capsules of cellulose administered in post-anesthesia care, postop day one and postop day two. Compounded by registered pharmacist and labeled with subject name and instructions for use.
89600602|NCT05086744|Experimental|Iptacopan 200 mg BID|Iptacopan 200 mg BID
89600603|NCT05086120|Experimental|Remote Electronically Delivered Integrated Care Pathway (ICP)|The remote electronically-delivered ICP (also known as eCARIBOU) will consist of psychiatry appointments through telemedicine every 4 weeks over 16 weeks, where the youth is at home. Prior to these appointments, measures (i.e., Mood and Feelings Questionnaire - MFQ) will be sent to the youth to be completed. Change in measure scores will be reviewed collaboratively between the psychiatrist and the youth to assist in making treatment decisions. The medication algorithm in the in-person ICP will be used to guide these decisions. The psychiatrist will also administer the Columbia Suicide Severity Rating Scale (C-SSRS) at each telepsychiatry appointment to monitor risk. Concurrently, youth will be offered internet-based Cognitive Behavioural Therapy (iCBT) and health-coaching via text.
88980086|NCT05999318|Active Comparator|active cTBS group|active cTBS combined with speech language therapy
88980087|NCT05999318|Sham Comparator|sham cTBS group|sham cTBS combined with speech language therapy
88980088|NCT05999227|Experimental|Immunotherapy|"Patients with rectal cancer will receive short-course radiotherapy and neoadjuvant chemotherapy plus immunotherapy.~68Ga-FAPI-04 and 18F-FDG PET will be performed at baseline and after short-course radiotherapy and 2 cycles of neoadjuvant chemotherapy plus immunotherapy. The two imaging intervals will be completed two days apart."
88980089|NCT05999201|Experimental|craniocervical neural mobilization|the patients will receive craniocervical neural mobilization and a selected physiotherapy program twice a week for four weeks
88980090|NCT05999201|Active Comparator|selected physiotherapy program|the patients will receive a selected physiotherapy program twice a week for four weeks
88980091|NCT05999188||Aortic dissection group|Patients diagnosed with aortic dissection at any of the centres and regularly consulted and followed up.
88980092|NCT05999162||Minimally invasive surgery (MIS)|The patients underwent minimally invasive surgery for the treatment of colorectal cancer.
88980093|NCT05999162||Traditional open surgery (TOS)|The patients underwent traditional open surgery for the treatment of colorectal cancer.
88980094|NCT05999071|Experimental|Coriandrum sativum group|500 mg of C. sativum (capsules) were administered twice daily
88980095|NCT05999071|Placebo Comparator|control group|500 mg of starch (capsules) were administered twice daily
88980096|NCT05998993|Experimental|Radiation|A total of 35 patients diagnosed and treated at CTIC Centro de Tratamiento e Investigación Sobre Cáncer Luis Carlos Sarmiento Angulo.
88980097|NCT05998980|Active Comparator|Componeer Prefabricated Veneers|Componeer veneers (device 1) were randomly applied to patients. The teeth were evaluated in terms of color and size matching in order to select the correct veneers. Componeer sizing guide was used for size selection. Prefabricated veneers were adapted to the teeth' surfaces. Then, the inner surfaces of the prefabricated veneers were roughened to obtain better mechanical retention. Then the labial surfaces of the teeth were etched using 36% phosphoric acid. The etched surfaces were rinsed and dried. An adhesive system was applied to the teeth. Prefabricated veneers' inner surfaces were cleaned with alcohol, and One Coat dental adhesive was applied. Synergy D6 nanohybrid resin composite was placed on the inner surfaces of the veneers and transferred to the teeth. The restorations were light-cured for 40 s Gingival borders were adapted with contouring and polishing discs (intervention 1).
89033279|NCT02942420|Experimental|Dose Group B|Bucillamine 600 mg/day
89033280|NCT02920359|Experimental|LEUPRORELIN ACETATE|
89600604|NCT05083832|Active Comparator|Continuous erector spinae plane block|Following the visualization of the anatomical structures, the nerve block needle was advanced via the in-plane technique beneath the erector spinae muscles until the interfascial space was reached. After hydrodissection with 2 ml normal saline, 20 ml 0.25% bupivacaine was injected into the area. A catheter will be placed in this area. Then, 5 ml/hour 0.125% bupivacaine will be infused via erector spinae plane block catheter.
89600605|NCT05083832|Active Comparator|Continuous serratus anterior plane block|Following the visualization of the anatomical structures, the nerve block needle was advanced via the in-plane technique beneath the serratus anterior muscles until the fourth rib area. After hydrodissection with 2 ml normal saline, 20 ml 0.25% bupivacaine was injected into the area. A catheter will be placed in this area. Then, 5 ml/hour 0.125% bupivacaine will be infused via serratus anterior plane block catheter.
89600606|NCT05080946|Experimental|Participants Randomized to Aspirin|Participants randomized to this arm will receive 325mg daily dose aspirin
89600607|NCT05080946|Placebo Comparator|Participants Randomized to Placebo|Participants randomized to this arm will receive a daily dose of a placebo (inactive substance)
89600608|NCT05076708|Other|IQOS|
89600609|NCT05076370|Active Comparator|CBD 400mg|CBD 400mg
89600610|NCT05076370|Active Comparator|CBD 800mg|CBD 800mg
89600611|NCT05076370|Active Comparator|CBD 1200mg|CBD 1200mg
89600612|NCT05075837|Experimental|Virus-specific T cells for the treatment of active viral infections following allogeneic HSCT.|Virus specific T lymphocytes selected in vitro from a family donor to treat some refractory viral infections as Adenovirus (ADV), Ebstein Barr virus (EBV), Cytomegalovirus (CMV) that developed in young patients (age between 0 and 21 years) after allogeneic hematopoietic cell transplantation (allo-HSCT)
89600613|NCT05074264|Experimental|Imaging, biospecimen collection, anoscopy and/or colposcopy|Patients undergo collection of cervical images (if applicable), 3 cervical anal swabs (if applicable) and 3 anal swabs for real-time testing of HPV or hrHPV over 90 minutes. Patients with a positive HPV or hrHPV test on undergo biopsies of visible lesions. Patients with a negative hrHPV test on their cervical swab may undergo a colposcopy. Patients with a positive hrHPV test on their anal swab undergo high-resolution anoscopy at a later visit within 1 month. Patients with a negative hrHPV on their anal swabs may undergo a high-resolution anoscopy and biopsies of visible lesions, and those with a positive anal cytology for LSIL or worse undergo a high-resolution anoscopy and biopsies within 1 month. Patients may be given a diagnosis and treatment at the second visit. Patients diagnosed with HSIL may undergo SOC treatment or enroll in additional studies when they are open to accrual
89600614|NCT05070351|Experimental|PPI deprescribing arm|Patients taking a PPI (at least 20 mg omeprazole equivalent daily) will be instructed to stop taking their PPI.
89600615|NCT05070351|No Intervention|PPI continuation arm|Patients will be instructed to continue taking their PPI (at least 20 mg omeprazole equivalent daily) as usual.
88811337|NCT01584258|Active Comparator|PACE-C: Conventionally Fractionated RT vs Prostate SBRT|Intermediate and high risk patients, indicated for 6 months ADT, will be randomised to either conventionally fractionated radiotherapy delivered to a dose of 60 Gy in 20 fractions vs SBRT delivered with 36.25 Gy in 5 fractions.
89210256|NCT04035954|Active Comparator|Interventional|The control group will continue the routine physiotherapy program based on NDT: Neurodevelopmental Therapy twice a week, 2 days / 1 hour / day during 8 weeks.
88811338|NCT01520597||Case|Patient with culture-proven listeriosis
88811339|NCT01520597||Control|Patient above the age of 18 years with medical background and clinical features compatible with one of the 3 forms of systemic listeriosis: febrile pregnant women (temp > 38°C), febrile patient with co-morbidity for septicaemic listeriosis, and any febrile symptom leading to empiric amoxicillin prescription.
88811340|NCT01447329|Experimental|Standard treatment plus ear acupuncture|Standard treatment plus ear acupuncture
88811341|NCT01447329|Placebo Comparator|standard|placebo
88811342|NCT01117779||Kidney lesions amenable to cryoablation|Kidney lesions treated with cryoablation.
88811343|NCT01110005|Active Comparator|D5 Lactated Ringer's solution (D5LR)|IV fluid containing glucose administered throughout labor at an average infusion rate of 125 ml/hr.
88811344|NCT01110005|Active Comparator|Lactated Ringer's solution (LR)|Non-glucose IV fluid administered throughout labor at an average infusion rate of 125 ml/hr.
88811345|NCT01013714|Active Comparator|Routine Care + Cardiac Sympathetic Denervation (CSD)|"Patients in this arm receive routine care and undergo cardiac sympathetic denervation. The procedure must be scheduled to occur within one month of randomization.~Follow-up Visits~Follow up at 4 weeks after optimization of medical therapy and surgery~All patients are followed at the ICD clinic at 7 months or as needed.~Information regarding ICD therapy and arrhythmias will be obtained from ICD interrogations at the follow up visits.~Monthly phone calls will be used to determine for interval events, including presence of side-effects.~VT Ablation is permitted in both arms for ICD shock after optimization."
88811346|NCT01013714|Placebo Comparator|Routine Care|"Patients in this arm remain on prescribed drug regimen and will not undergo CSD.~Follow-up Visits~Medical follow up at 4 weeks after optimization of medical therapy.~All patients are followed at the ICD clinic at 7 months or as needed.~Information regarding ICD therapy and arrhythmias will be obtained from ICD interrogations at the follow up visits.~Monthly phone calls will be used to determine for interval events, including presence of side-effects.~VT Ablation is permitted in both arms for ICD shock after optimization."
88811347|NCT00840801|Experimental|1|Subjects receive three vaccinations with a paediatric TBE vaccine according to the conventional vaccination schedule.
88811348|NCT00840801|Experimental|2|Subjects receive three vaccinations with a paediatric TBE vaccine according to the conventional vaccination schedule.
88811349|NCT00804128||Breast Cancer patients|Adult, breast cancer patients with confirmed Ductal Carcinoma in Situ (DCIS) or atypical ductal hyperplasia (ADH)
88811350|NCT00533780|Experimental|MRI high resolution 3D diffusion|Total duration is about 8 minutes.
88811351|NCT00515359|Active Comparator|Continuous Dosing|continuous dosing
88811352|NCT00515359|Active Comparator|Intermittent Dosing|Intermittent Dosing
89600616|NCT05066607|Experimental|Single-stage|"Patient eligible to enter the study will receive 9 to 12 cycles (according to response) of intravenous Isatuximab (10 mg/kg) and oral Pomalidomide 4 mg from day 1 to day 21 and Dexamethasone 10-20 mg weekly on days 1, 8, 15 and 22.~Each cycle will be of 28 days duration. During cycle 1, Isatuximab will be administered weekly on days 1, 8, 15, and 22 then days 1 and 15 in subsequent cycles from cycle 2 to 9 or 12.~For each individual patient, the treatment period will be 12 months, unless CR at the completion of 9 cycles, disease progression or unacceptable toxicity occurs. The duration of follow-up for overall survival will be 1 year after the last patient enters overall survival follow-up."
89600617|NCT05065957|Experimental|Phase IIa:Dose-Finding Stage|"Level -5: 20 mg D07001-softgel capsules plus 625 mg/m^2 Xeloda (or 20/30/40 mg TS-1).~Level -4: 40 mg D07001-softgel capsules plus 625 mg/m^2 Xeloda (or 20/30/40 mg TS-1).~Level -3: 60 mg D07001-softgel capsules plus 625 mg/m^2 Xeloda (or 20/30/40 mg TS-1).~Level -2: 80 mg D07001-softgel capsules plus 625 mg/m^2 Xeloda (or 20/30/40 mg TS-1).~Level -1 (starting dose): 100 mg D07001-softgel capsules plus 625 mg/m^2 Xeloda (or 20/30/40 mg TS-1).~Level 1: 100 mg D07001-softgel capsules plus 800 mg/m^2 Xeloda (or 30/40/50 mg TS-1).~Level 2: 100 mg D07001-softgel capsules plus 1000 mg/m^2 Xeloda (or 40/50/60 mg TS-1)."
89600618|NCT05065957|Active Comparator|Phase IIb/III: Dose Expansion Stage|"ASC+ D07001-softgel capsules plus Xeloda (or TS-1)~ASC+mFOLFOX (5-FU+Oxalipatin+folinic acid)"
89600619|NCT05064813|Experimental|Mindfulness Based Stress Reduction Group|8 weeks of Mindfulness Based Stress Reduction Group (MBSR).
89600620|NCT05064813|Active Comparator|Stress Education Group|8 weeks of Stress Education Group (SE).
89600621|NCT05051761|Experimental|Jaktinib 50mg BID|Participants received Jaktinib 50mg tablets, orally, twice daily (BID) for up to 24 weeks.
89600622|NCT05051761|Experimental|Jaktinib 75mg BID|Participants received Jaktinib 75mg tablets, orally, twice daily (BID) for up to 24 weeks.
89600623|NCT05051761|Placebo Comparator|placebo|Participants received Jaktinib matched placebo tablets, orally, twice daily (BID) for up to 24 weeks.
89600624|NCT05050214|Experimental|Experimental: GAZYVA, GAZYVARO(Obinutuzumab)|Participants will receive Obinutuzumab 1000 mg solution for infusion (total dose of 3000 mg in 30 days).
89600625|NCT05050136|Experimental|Volixibat 20mg|Participants randomized to this arm will receive volixibat 20mg twice daily.
89600626|NCT05050136|Experimental|Volixibat 80mg|Participants randomized to this arm will receive volixibat 80mg twice daily.
88980098|NCT05998980|Active Comparator|Essentia resin composite venners|Direct resin composite restorations were randomly applied to patients. Essentia resin composite (device 2) shade guide was used for color selection. After the preparation, the labial surfaces of the teeth were etched using 36% phosphoric acid. The etched surfaces were then rinsed and dried. An adhesive system G-Premio Bond was applied to the teeth. Then Essentia micro-hybrid resin composite with dentin shade was placed on labial surfaces of teeth and was light-cured. Then enamel shade was placed on the tooth. After that, the resin composite veneer was light-cured for 20 s from each surface. Proximal surfaces were polished using proximal sandpaper strips (intervention 2).
88980099|NCT05998876||3-6 HRS|Microneedle electrode array placed into dermis for up to 6 hours. DPV Scans performed at a frequency of 1-20 per hour.
88980100|NCT05998876||12 HRS|Microneedle electrode array placed into dermis for up to 12 hrs. DPV Scans performed at a frequency of 1-20 per hour.
88980101|NCT05998876||3 Days|Microneedle electrode array placed into dermis for up to 3 days. DPV Scans performed at a frequency of 1-20 per hour.
89210257|NCT04035954|Experimental|Experimental|The treatment group will participate in clinical pilates exercises 2 days / 1 hour / day during 8 weeks.They will also continue their weekly routine physiotherapy programs.
89600627|NCT05050136|Placebo Comparator|Placebo|Participants in this arm will receive capsules matched to the study drug minus the active volixibat substance, twice daily.
89600628|NCT05041816|Experimental|Focal vibration group|The Myovolt device used in our previous study will be used for focal vibration delivery during week three to six. Participants will wear Myovolt secured by an elastic band, at a location based on therapist and participants preference. During the four weeks of the FV therapy, participants will be asked to use the Myovolt device for up to 0.5-hour per session (each site 10 minutes per session, with one-minute intersession between sites), once in the morning and once in the evening each day, for five days a week. The dosing paradigm was chosen based on the safety and potential effectiveness of the FV therapy, and our preliminary study.
89600629|NCT05037682|Other|Primary Care Practices|Dissemination and Implementation Research
89600630|NCT05034419|Experimental|Active stimulation|Patients undergoing cardiac surgery will be randomized to active low level tragus stimulation for 30 min (pulse width of 200 μs, amplitude of 20 mA and a pulse frequency of 20 Hz). Stimulation will be provided using the Parasym device.
89600631|NCT05034419|Sham Comparator|Sham stimulation|Patients undergoing cardiac surgery will be randomized to sham stimulation for 30 min. The Parasym device will be placed on the patient's tragus, but no current will be delivered.
89600632|NCT05033522|Experimental|AlloStim®|AlloStim® is a formulation of living allogeneic Th1-like cells with anti-CD3/CD28 microbeads attached derived from precursors purified from healthy screened blood donors that are differentiated and expanded ex-vivo. AlloStim® is formulated at 10-7 cells/ml in 0.5ml for ID administration and 3ml for IV administration
89600633|NCT05033522|Active Comparator|Physician's Choice|Physician's Choice is sorafenib or levantinib or FOLFOX4 monotherapy
89600634|NCT05025800|Experimental|Treatment (ALX148, rituximab, lenalidomide)|Patients receive ALX148 IV over 1 hour once on days 1, 8, 15 and 22, or days 1 and 15, or day 1 depending on dose level. Patients also receive rituximab IV over 4-6 hours on days 1, 8, 15 and 22 of cycle 1, then on day 1 of cycles 2-6, and lenalidomide PO QD on days 1-21 of cycles 1-6. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89600635|NCT05023135||Subjects with Thermal Burn Injury|An initial imaging with the DV-SSP would be completed at the Study Site within 72 hours of suffering a thermal burn injury.
89608561|NCT03918837|Active Comparator|Active rTMS|"The investigators will perform active rTMS at 120% of the Motor Threshold, with a 1Hz frequency and 1200 pulses during one session. The target will be the right Orbito Frontal Cortex, localized using Neuronavigation. Sessions will last fifteen minutes; subjects will perform two sessions a day during five days.~Participants will undergo a MRI with anatomical and ASL sequences one week before and four weeks after treatment"
89608562|NCT04143399|Active Comparator|holmium laser enucleation of the prostate|holmium laser enucleation of the prostate (HoLEP)
89600636|NCT05019716|Experimental|Treatment (ZEN-3694, etoposide, cisplatin)|Patients receive ZEN003694 orally (PO) once or twice daily on days 1-14 or days 1-21 of each cycle depending upon dosage assignment. Patients also receive etoposide IV over 60 minutes on days 1-3 for cycles 1-4 or up to 8 cycles, and cisplatin IV over 60 minutes on day 1 of cycles 1-4 or up to 8 cycles. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients may undergo radiologic evaluation (chest x-ray, CT, PET-CT, MRI, and/or FDG-PET) at the completion of every 2 cycles or 6 weeks, and then at the end of every 3 or 4 cycles after the completion of cycle 10. Patients may also undergo biopsy between cycle 1 day 4 and cycle 1 day 14.
89600637|NCT05019274|Experimental|Culinary Medicine|Series of 6 virtual group Culinary Medicine sessions delivered monthly for 6 months
89600638|NCT05019274|Active Comparator|Nutrition Education|Series of 6 standard of care nutrition visits delivered by clinic dieticians. These are a mix of individual and group sessions.
89600639|NCT05016531|Experimental|Low Intensity Focused Ultrasonic Stimulation|There are different combinations of intensity and frequency with LIFUS
89600640|NCT05014672|Experimental|Setanaxib 1200 mg/day|Participants will be administered setanaxib at a dose of 1200 mg/day for the 24-week double-blind treatment period.
89600641|NCT05014672|Experimental|Setanaxib 1600 mg/day|Participants will be administered setanaxib at a dose of 1600 mg/day for the 24-week double-blind treatment period.
89600642|NCT05014672|Placebo Comparator|Placebo|Participants will be administered a placebo for the 24-week double-blind treatment period.
89600643|NCT05014074|Experimental|Theater/Pilot Testing|Participants will take part in a theater/pilot testing in order to receive adequate feedback and make substantive change in the intervention
89600644|NCT05007821|Experimental|Arm A|"Everyone in the study will take bedaquiline (BDQ), delamanid (DLM), and clofazimine (CFZ) once a day for the entire treatment period. Arm A participants will take linezolid (LZD) once a day for the entire treatment period.~Weeks 1-26: LZD 600 mg once daily (QD)~Weeks 1-2: BDQ 200 mg QD + DLM 300 mg QD + CFZ 300 mg QD~Weeks 3-8: BDQ 200 mg QD + DLM 300 mg QD + CFZ 100 mg QD~Weeks 9-26: BDQ 100 mg QD + DLM 300 mg QD + CFZ 100 mg QD"
89600645|NCT05007821|Experimental|Arm B|"Everyone in the study will take bedaquiline (BDQ), delamanid (DLM), and clofazimine (CFZ) once a day for the entire treatment period. Arm B participants will take a higher dose of linezolid (LZD) once a day for 4 weeks and then continue taking that higher dose of LZD just three times a week for the rest of the treatment period.~Weeks 1-4: LZD 1200 mg once daily (QD)~Weeks 5-26: LZD 1200 mg three times per week (TIW)~Weeks 1-2: BDQ 200 mg QD + DLM 300 mg QD + CFZ 300 mg QD~Weeks 3-8: BDQ 200 mg QD + DLM 300 mg QD + CFZ 100 mg QD~Weeks 9-26: BDQ 100 mg QD + DLM 300 mg QD + CFZ 100 mg QD"
89600646|NCT05006963|Experimental|face-to-face group|The patient will be submitted to multimodal treatment, twice a week, for twelve weeks, totaling 24 face-to-face consultations lasting 40 minutes each. In the first session, the patient will be explained what is TMD, what is the correct placement of the tongue and teeth, influence of parafunctional and sleep habits in TMD signs and symptoms.Techniques of manual therapy and therapy by exercise. In general, extra-oral and intraoral massage, myofascial release in the cranio-cervical musculature, mobilization of the hyoid bone and may also receive unspecific joint mobilization. Will be mouth opening exercise will be also performed with the tongue on the palate, proprioceptive exercises with hyperboloid. In addition to these, additional exercises may be performed, according to the patient's need. The conducts will be adapted according to the needs of each patient. The use of post its may be indicated to help maintain the correct posture of the tongue and jaw, as well as sleep hygiene.
89600647|NCT05006963|Active Comparator|telerehabilitation|The patient will be submitted to multimodal treatment, twice a week, for twelve weeks, by telerehabilitation lasting 40 minutes each.A physiotherapist through video call via WhatsApp application. In the first session, the patient will be explained what is TMD, what is the correct placement of the tongue and teeth, influence of parafunctional and sleep habits in TMD signs and symptoms. Patients will be instructed to perform extra-oral and intra-oral self-massage and in the cranio-cervical musculature, bone mobilization hyoid, which would replace the mobilization unspecific articulation performed in person.Exercise will also be carried out mouth opening with tongue on the palate, exercises proprioceptives with hyperboloid. The conducts will be adapted according to the needs of each patient.The conducts will be adapted according to the needs of each patient.The use of post its may be indicated to help maintain the correct posture of the tongue and jaw, as well as sleep hygiene
89600648|NCT05005507|Experimental|Arm 1: JNJ-73763989 + nucleos(t)ide analog (NA) + pegylated interferon alpha-2a (PegIFN-alpha-2a)|Participants will receive JNJ-73763989 subcutaneous (SC) injection once every 4 weeks for 24 weeks plus NA treatment (either entecavir [ETV], tenofovir disoproxil or tenofovir alafenamide [TAF] tablets orally) once daily for 24 weeks plus PegIFN-alpha-2a SC injection once weekly for 24 weeks.
89600649|NCT05005507|Experimental|Arm 2: JNJ-73763989 + NA + PegIFN-alpha-2a|Participants will receive JNJ-73763989 SC injection once every 4 weeks for 24 weeks plus NA treatment (either ETV, tenofovir disoproxil, or TAF tablets orally) once daily for 24 weeks plus PegIFN-alpha-2a SC injection once weekly from Week 12 till Week 24.
89600650|NCT05005507|Experimental|Arm 3: JNJ-73763989 + NA + PegIFN-alpha-2a|Participants will receive JNJ-73763989 SC injection once every 4 weeks for 24 weeks plus NA treatment (either ETV, tenofovir disoproxil or TAF tablets orally) once daily for 24 weeks plus PegIFN-alpha-2a SC injection once weekly from baseline till Week 12.
89600651|NCT05002868|Experimental|RP12146|RP12146 will be administered orally daily (QD or BID)
89600652|NCT05002543||MANTRA Aortic Sub-study|"Subjects diagnosed with aortic valve disease who are considered suitable to undergo aortic valve replacement with a CORCYM device can be included in this study.~The following devices can be entered in the study:~Tissue Valve:~Perceval® PLUS SUTURELESS AORTIC HEART VALVE~Perceval® S SUTURELESS AORTIC HEART VALVE~Mechanical Valves:~Bicarbon™ Bileaflet Heart Valve Prostheses Models:~Bicarbon Fitline Aortic (LFA)~Bicarbon Slimline Aortic (LSA)~Bicarbon Overline Aortic (LOV)~Carbomedics Prosthetic Heart Valve Models:~Standard Aortic Valve~Reduced Aortic Valve~Supra-Annular Aortic Valve (Top Hat)~Orbis™ Aortic Valve~Ascending Aorta Prostheses~CARBOMEDICS-CARBO-SEAL™~CARBOMEDICS CARBO-SEAL™ VALSALVA"
89608563|NCT04143399|Active Comparator|bipolar resection of the prostate|bipolar resection of the prostate (BPEP)
89608564|NCT00735436|Other|Gliadel/Avastin/CPT-11|Gliadel/Avastin/CPT-11
89210258|NCT02539524|Active Comparator|Pulmonary Rehabilitation Group|Pulmonary Rehabilitation Group Intervention consisted of 12-week pulmonary rehabilitation. Two 1 hour sessions a week, consisting of: 30 min of aerobic training followed by resistance exercises for upper and lower limbs.
89600653|NCT05002543||MANTRA Mitral/Tricuspid Sub-study|"Subjects diagnosed with mitral and/or tricuspid valve disease who are considered suitable to undergo mitral valve repair/replacement and/or tricuspid valve repair with a CORCYM device can be included in this study.~The following devices can be entered in the study:~Annuloplasty Rings:~SOVERING™ ANNULOPLASTY DEVICE models~annuloplasty ring, mitral model~annuloplasty band, mitral and tricuspid models~Carbomedics Annuloplasty Ring models:~CARBOMEDICS ANNULOFLO®~CARBOMEDICS ANNULOFLEX®~Memo Annuloplasty Ring o MEMO 3D™ SEMIRIGID ANNULOPLASTY RING~Mitral Valves:~Bicarbon™ Bileaflet Heart Valve Prostheses Models:~o Bicarbon Fitline Mitral (LFM)~Carbomedics Prosthetic Heart Valve Models:~Standard Mitral Valve~Orbis™ Mitral Valve~OptiForm® Mitral Valve"
89600654|NCT05002543||MANTRA Memo 4D Sub-study|Subjects diagnosed with mitral valve disease who are considered suitable to undergo mitral valve repair with a CORCYM Memo 4D annuloplasty ring can be included in this study.
89600655|NCT04983667|Experimental|Orange|Zinc-AA, Tablet, 30 mg. PO, Once Daily for up to one year
89600656|NCT04983667|Placebo Comparator|Green|Placebo, Tablet, 30 mg. PO, Once Daily for up to one year.
89600657|NCT04981509|Experimental|Treatment (bevacizumab, atezolizumab, erlotinib)|Patients receive bevacizumab IV over 30-90 minutes and atezolizumab IV over 30-60 minutes on day 1 of each cycle. Patients also receive erlotinib PO QD on days 1-21 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT with or without contrast and MRI throughout the trial. Patients undergo collection of blood throughout the trial, and may undergo a biopsy during screening, as well as a brain MRI/CT scan with contrast, bone scan, and/or F-18 sodium fluoride PET scan as clinically indicated.
89600658|NCT04971551|Experimental|Jaktinib treatment|Participants began oral administration of Jaktinib at 75mg twice daily (BID); if stable after the first 3 days of treatment, the dose could be increased to 100mg BID Or continue 75mg BID treatment .
89600659|NCT04963153|Experimental|Treatment (erdafitinib, enfortumab vedotin)|Patients receive erdafitinib PO QD on days 1-28 of each cycle and enfortumab vedotin IV over 30 minutes on days 1, 8, and 15 of each cycle. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and blood sample collection throughout the trial.
89600660|NCT04959929|Experimental|Focal vibration therapy|Myovolt delivers vibration with a frequency between 50-80 Hz. Myovolt intensity will be set to ~up to 2X the participant's initial Myovolt perception threshold. If the stimulation does not feel strong, the participant will be asked to manually increase the intensity until it feels strong but comfortable.
89600661|NCT04949620|Experimental|REThink game, then responder monitoring|Participants in this group will have access to the REThink game for four weeks; based on their response to the intervention, they will be monitored for an additional period of four weeks.
89600662|NCT04949620|Experimental|REThink game, then online parent intervention for non-responders|Participants who are allocated to the REThink game and do not respond to the four-week intervention will be allocated to the online
89600663|NCT04949620|No Intervention|Monitoring|Participants in this arm will be monitored for a total of eight weeks, for comparison with the REThink game intervention (after four weeks) and the online parenting program (after an additional four weeks).
89600664|NCT04947020||Rectal cancer|Patients with primary rectal cancer operated on between 2013 and 2019.
89600665|NCT04944420|Experimental|Intervention|"Intervention group will have access to Health enSuite Caregivers, an e-health program designed to meet some of the most common needs of caregivers of persons with dementia, including information about dementia and dementia care, caregivers' emotional health, formal or informal help received from others. It also recommends specific strategies to promote well-being and provides tools to help caregivers implement these strategies in their everyday lives.~Health enSuite Caregivers is designed to offer advice to caregivers of persons with dementia based on an assessment of their specific needs. Topics are divided into five main content areas, which are recommended based on an assessment of the caregivers current challenges and sources of stress."
89600666|NCT04944420|No Intervention|Waitlist Control|Participants in the control group will be wait-listed and receive only treatment as usual from their healthcare providers during the study. After their participation is the study has ended, participants in the control group will be given access to the full Health enSuite Caregivers program.
89600667|NCT04937153|Experimental|acasunlimab monotherapy|
88980102|NCT05998850|Experimental|CHW Dialysis Implementation|A single-arm 6-month pilot study testing the feasibility of tailored implementation, by using IMPaCT model with a Community Health Worker to help low-income dialysis patient to navigate the health system and community resources to eliminate or minimize health-related social needs among dialysis patients so that they adhere to the treatment, improve their health and may be candidates for transplantation.
88980103|NCT05998772||PD patients with craving for sweets|
88980104|NCT05998772||PD patients without craving for sweets|
89600668|NCT04937153|Experimental|acasunlimab + pembrolizumab combination therapy|
89600669|NCT04935229|Experimental|SD-101|3 weekly doses of SD-101 given via hepatic artery infusion over 2 cycles
89600670|NCT04933474|Experimental|painTRAINER (2D mHealth intervention)|Participants will use one of the most widely-validated mHealth interventions for pain management called painTRAINER®, which is a standardized, 56-day program delivering skills training and Cognitive behavioral therapy (CBT)-related treatments through daily virtual experiences.
88980105|NCT05998733||sepsis group|diagnostic sepsis；age>18；Time from clinical symptoms to admission ≤ 7 days； It also meets the following two criteria: ① clinical infection② Sequential Organ Failure Assessment (SOFA) score ≥ 2 points at admission
88980106|NCT05998733||non-sepsis group|diagnostic sepsis；age>18；Time from clinical symptoms to admission ≤ 7 days； It also meets the following two criteria: ① clinical infection②Systemic inflammatory response syndrome(SIRS)，SIRS was defined as the presence of 2 or more of the following: (1) temperature <36℃or >38℃, (2) heart rate >90 beats per minute, (3) respiratory rate >20 breaths per minute or PaCO2 < 32 mm Hg, or (4) white blood cell count ≥12 000 cells/mm3 or≤4000 cells/mm
88980107|NCT05998720||normal group|There are no lesions on the hip.
88980108|NCT05998720||abnormal group|There are some lesions on the hip.
88980109|NCT05998707||benign group|benign lesions in the lung
88980110|NCT05998707||malignant group|malignant tumor in the lung
89600671|NCT04933474|Experimental|Skills-based VR Therapy|Participants will use the Pico G2 4K VR audio and visual head-mounted device. The Pico G2 4K is a standalone VR headset that comes with an orientation-tracked controller. It does not require a smartphone or personal computer to operate. The device supports 3 degrees of freedom (3DOF) head tracking, has best-in-class optics, and a wide field-of-view.
89600672|NCT04930328||Retrospective Data Collection|Retrospective Data Collection
89032056|NCT04690881|Experimental|Psychodrama group psychoteraphy|Psychodrama is not just a training but also a treatment technique where an individual is offered a potential cure, as well as improvement and awareness for his or her ongoing relationships within the group. In psychodrama, the participant is given an opportunity to re-experience of earlier incidents for a second time so that the person could be free from the impacts of that earlier experience. All of this happens simultaneously with joy, tears, laughter, and depth of feeling.Prenatal psychodrama is held by psychodrama psychotherapists in individual and group therapy sessions. In these sessions the pregnant mother encounters herself, her baby, her partner, her mother, her fear of childbirth and the moment of birth; she may act as protagonist in some scenes and in this way she closes any unfinished business from the past and rehearses the future in a safe therapeutic environment. In this study, 90-minute psychodrama practice was conducted in addition to pregnancy training for 6 weeks.
89032057|NCT04690881|No Intervention|Childbirth-antenatal education|Childbirth is one of the most significant events in a parent's life and has the potential to be an exhilarating and fulfilling experience for some or a frightening anxiety provoking experience for others. Structured antenatal classes have developed worldwide as traditional methods of information sharing have declined and expectant parents look for strategies to prepare for childbirth. In this study, routine pregnancy training was conducted for 6 weeks.
89032058|NCT00519233|Experimental|1.AGS-1C4D4|
89032059|NCT02940561|Experimental|Methotrexate - Amneal|Methotrexate Tablets USP, 2.5 mg, single-dose in each period
89032060|NCT02940561|Active Comparator|Methotrexate - DAVA|Methotrexate Tablets USP, 2.5 mg, single-dose in each period
89600673|NCT04928326||Patients with heart failure undergoing right heart catheterization|Subjects with a diagnosis of NYHA class II-IV heart failure who meet the inclusion and exclusion criteria will be eligible for participation in this study.
89600674|NCT04924920|Experimental|Intervention EEO_SIGH|Single arm intervention. All the patients will receive the two tests (SIGH and EEOT) in 1:1 random sequence order (6 patient-block)
89600675|NCT04922229|Active Comparator|Root canal treatment (RCT)|For cases with this diagnosis RCT is the standard of care and will be done according to clinically approved protocols
89600676|NCT04922229|Experimental|Pulpotomy|Pulpotomy with tricalcium silicates has shown high clinical success in these cases. However, it is not known how this success compares to RCT under similar conditions and with an intent-to-treat study design, which will be employed here.
89600677|NCT04915612|Experimental|Treatment (CPX-351, GO)|"INDUCTION 1 (28 days): Patients receive CPX-351 IV over 90 minutes on days 1, 3, and 5 and GO IV over 2 hours on day 1 in the absence of disease progression or unacceptable toxicity.~INDUCTION 2: Patients who do not attain a defined clinical response after cycle Induction 1 receive CPX-351 IV on days 1 and 3 and GO IV over 2 hours on day 1 in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Beginning 4 weeks after last induction, patients receive CPX-351 IV over 90 minutes on days 1 and 3 and GO IV over 2 hours on day 1 in the absence of disease progression or unacceptable toxicity."
89600678|NCT04912674||Operative|"Inclusion Criteria:~≥18 years old at time of treatment~Patient undergoing a posterior cervical instrumented fusion using the DePuy Synthes SymphonyTM OCT System for the treatment of adult cervical deformity, defined as any of below criteria:~Loss of cervical lordosis (≤ 0° cervical lordosis C2-7)~≥ 5° of kyphosis across any 1 or 2 cervical segments~≥ 10° of cervical scoliosis~C2-C7 SVA ≥ 4cm~T1 Slope minus Cervical Lordosis ≥ 20°~Grade I or greater Spondylolisthesis at any segment C1-T1~Horizontal Gaze ≤ 0 or ≥ 11~Plan for surgical correction of cervical deformity in the next 6 months~Willing to provide consent and complete study forms at baseline and follow-up intervals~Exclusion Criteria:~Active spine tumor or infection~Deformity due to acute trauma~Unwilling to provide consent or to complete study forms~Prisoner~Pregnant or immediate plans to get pregnant"
89600679|NCT04910568|Experimental|Single-Agent Cevostamab (Arm A)|"Cohort A1S is a safety run-in arm evaluating cevostamab administered in 28-day cycles on a modified weekly schedule.~Cohort A1E, an expansion cohort, has been opened and finished enrolling participants. Participants will be treated with single-agent cevostamab administered in 28-day cycles on a modified weekly schedule."
89600680|NCT04910568|Experimental|Cevostamab plus Pomalidomide and Dexamethasone (Pd) (Arm B)|"Participants will be treated with cevostamab monotherapy during a 21-day period prior to the start of pomalidomide treatment (cevostamab pre-phase).~Cohort B1S is a safety run-in arm evaluating cevostamab and Pd administered in 28-day cycles every 2 weeks (Q2W) followed by every 4 weeks (Q4W) schedule. Additional safety run-in cohort(s) with lower target dose levels of cevostamab may be opened prior to opening the expansion cohorts.~Two target dose levels of target dose level 1 (DL1) and lower dose level -1 (DL-1) of cevostamab will be selected for randomization in two expansion cohorts. Expansion cohorts will follow the same Q2W/Q4W dosing schedule as Cohort B1S."
89608565|NCT04143165|Active Comparator|Epidural block|Group I patients received caudal epidural injections with 1% lidocaine hydrochloride (xylocaine Astra Zeneca) 9 mL mixed with 1 mL of triamcinolone 40 milligrams (Kenacort Bristol Myers Squip)
89608566|NCT04143165|No Intervention|control group|patients did not receive injection
89032061|NCT02940366|Experimental|Pitavastatin 4 mg orally daily|
89032062|NCT02940366|Placebo Comparator|Atorvastatin 20 mg orally daily|
89032063|NCT00519272||Cervical Cancer Care Questionnaires|New cervical cancer patients through stage IVB presenting to the LBJ Gyn-Onc Clinic.
89032064|NCT02940405|Experimental|ketorolac tromethamine|One tablet of Ketorolac tromethamine 10-mg one hour before endodontic treatment
89032065|NCT02940405|Placebo Comparator|placebo tablet|One tablet of a placebo one hour before endodontic treatment
89032066|NCT02940444|Experimental|case group|start heparin sodium (5000IU, BID) upon admission, and continue until discharge
89032067|NCT02940444|Active Comparator|control group|start heparin sodium (5000 IU,BID) from postoperative day 1, and continue until discharge
89032068|NCT00520052|Active Comparator|LHRH Group|Patients on LHRH agonists and zoledronic acid
89032069|NCT00520052|Active Comparator|Bicalutamide Group|Patients on Bicalutamide and zoledronic acid
88980111|NCT05998681|Experimental|Breastfeeding and Basic Maternal-Neonatal Care and mobile messages group|"In the study, education on Breastfeeding and Basic Maternal-Neonatal Care was given to the women in the experimental group within the first 24 hours after the birth, and the training topics were sent as a mobile message for 6 weeks after the birth.~Education on Breastfeeding and Basic Maternal-Neonatal Care was given in 2 postpartum sessions. In the first session, breastfeeding education was given to women in practice, together with the first postpartum breastfeeding. At the beginning of the second session, breastfeeding training was repeated and then Basic Maternal-Neonatal Care training was given. The first session was given at the first breastfeeding time, and the second session was given between 20-24 hours after birth. Each session lasted approximately 20-25 minutes. In order to solve the problems of the mothers, questions, and answers were made before discharge, and breastfeeding of the mothers was observed."
89032070|NCT04690647|Placebo Comparator|Opioid and non opioid postoperative analgesia.|Group of patients with opioid and non opioid based postoperative analgesia without preoperative regional anaesthesia and dexamethasone.
89032071|NCT04690647|Experimental|Regional anaesthesia, opioid and non opioid postoperative analgesia.|Group of patients with opioid and non opioid based postoperative analgesia with preoperative regional anaesthesia and without preoperative dexamethasone.
89600681|NCT04910568|Experimental|Cevostamab plus Daratumumab and Dexamethasone (Dd) (Arm C)|"Cohort C1S is a safety run-in arm evaluating cevostamab and Dd administered in 21 day cycles from Cycle(C)1 - C8 every 3 weeks (Q3W) and 28-day cycles from C9 onwards Q4W. Additional safety run-in cohort(s) with lower target dose levels of cevostamab may be opened prior to opening the expansion cohorts.~Two target dose levels of DL1 and DL-1 of cevostamab will be selected for randomization in two expansion cohorts. Expansion cohorts will follow the same Q3W/Q4W dosing schedule as Cohort C1S."
89600682|NCT04900090|Experimental|Case group : gout patients|Epidemiological study
89600683|NCT04900090|Experimental|Control group|Epidemiological study
89600684|NCT04898855|Experimental|OncoSleep intervention (internet-delivered cognitive-behavioral treatment for insomnia)|Participants assigned to the experimental group receive immediate access to the OncoSleep program, a web-based self-guided cognitive-behavioral intervention for insomnia consisting of 6 weekly sessions. A certified psychologist will monitor the participant's progress and provide feedback.
89600685|NCT04898855|No Intervention|waitlist control|Participants assigned to the waitlist control group receive access to the OncoSleep program after 8 weeks.
89600686|NCT04896918||Cohort of adult client of public dental clinics in Region Stockholm|Tobacco use (cigarette smoking and/or snus use) will be considered as exposure. Information on tobacco use will be extracted by public dental clinic records in Stockholm Region (October 2015-January 2020). Any diagnosis of COVID-19, hospitalization, receiving intensive care, and death because of COVID-19 will be examined as outcomes. Diagnoses of COVID-19 will be obtained through record linkage with health care registers of inpatient and outpatient care (February 2020-August 2021).
89600687|NCT04896086|Experimental|Group 1A-1B|20 mcg of FluMos-v1
89600688|NCT04896086|Experimental|Group 2A-2B|60 mcg of FluMos-v1
89600689|NCT04896086|Active Comparator|Group 3A-3B|standard dose of 60 mcg of the licensed QIV Flucelvax
89600690|NCT04896086|Experimental|Group 4A-4B|100 mcg of FluMos-v1
89600691|NCT04896086|Experimental|Group 5A-5B|100 mcg of FluMos-v1 plus Adjuplex
89600692|NCT04896086|Experimental|Group 6A-6B|Optional: 60 mcg of FluMos-v1 plus Adjuplex
89600693|NCT04896086|Experimental|Group 7A-7B|Optional: TBD mcg of FluMos-v1
89600694|NCT04896086|Experimental|Group 8A-8B|Optional: TBD of FluMos-v1 plus Adjuplex
89600695|NCT04896060||Ecological Momentary Assessment (EMA) volunteers|Volunteers with access to mobile device with Wi-Fi and data recruited for an additional 1-week daily assessment study utilizing EMA to examine COVID-19 related stress and eating behavior in real-time
89600696|NCT04896060||General global population volunteers|Newly recruited volunteers 18 and above from the general global population that agree to participate in the COVID study
89600697|NCT04896060||NIDDK-Phoenix study volunteers|Previous research participants, who signed consents that allow data sharing that agree to participate in the COVID study
89600698|NCT04889872|Experimental|TAVR|Transcatheter Aortic Valve Replacement (TAVR)
89600699|NCT04889872|No Intervention|CS|Clinical Surveillance (CS)
89600700|NCT04882241|Experimental|Pembrolizumab+Chemotherapy|"Neoadjuvant: Prior to surgery, participants receive 3 cycles of pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle (Q3W) PLUS cisplatin 80 mg/m^2 via IV infusion on Day 1 Q3W and capecitabine 1000 mg/m^2 via oral tablets twice each day (BID) on Days 1 to 14 of each 3-week cycle OR cisplatin 80 mg/m^2 via IV infusion on Day 1 Q3W and 5-fluorouracil (5FU) via continuous IV infusion on Days 1 to 5 of each 3-week cycle.~Adjuvant: 4 to 10 weeks post-surgery, participants receive pembrolizumab 200 mg via IV infusion on Day 1 Q3W PLUS cisplatin 80 mg/m^2 via IV infusion on Day 1 Q3W and capecitabine 1000 mg/m^2 via oral tablets BID on Days 1 to 14 of each 3-week cycle OR cisplatin 80 mg/m^2 via IV infusion on Day 1 Q3W and 5FU via continuous IV infusion on Days 1 to 5 of each 3-week cycle for up to 3 cycles."
89600701|NCT04882241|Placebo Comparator|Placebo+Chemotherapy|"Neoadjuvant: Prior to surgery, participants receive 3 cycles of placebo (normal saline solution) via IV infusion on Day 1 Q3W PLUS cisplatin 80 mg/m^2 via IV infusion on Day 1 Q3W and capecitabine 1000 mg/m^2 via oral tablets BID on Days 1 to 14 of each 3-week cycle OR cisplatin 80 mg/m^2 via IV infusion on Day 1 Q3W and 5FU via continuous IV infusion on Days 1 to 5 of each 3-week cycle.~Adjuvant: 4 to 10 weeks post-surgery, participants receive placebo via IV infusion on Day 1 Q3W PLUS cisplatin 80 mg/m^2 via IV infusion on Day 1 Q3W and capecitabine 1000 mg/m^2 via oral tablets BID on Days 1 to 14 of each 3-week cycle OR cisplatin 80 mg/m^2 via IV infusion on Day 1 Q3W and 5FU via continuous IV infusion on Days 1 to 5 of each 3-week cycle for up to 3 cycles."
89600702|NCT04882241|Experimental|Pembrolizumab+FLOT Cohort|"FLOT=docetaxel+oxaliplatin+5FU+leucovorin (calcium folinate). Neoadjuvant: Prior to surgery, participants receive 3 cycles of pembrolizumab 200 mg via IV infusion on Day 1 Q3W PLUS docetaxel 50 mg/m^2 via IV infusion, oxaliplatin 85 mg/m^2 via IV infusion, 5FU 2600 mg/m^2 via IV infusion, and leucovorin (calcium folinate) 200 mg/m^2 via IV infusion Q2W (on Days 1 and 15 of Cycle 1; Day 8 of Cycle 2, and Day 1 of Cycle 3) for 4 administrations.~Adjuvant: 4 to 10 weeks postsurgery, participants receive pembrolizumab 200 mg via IV infusion Day 1 Q3W for up to 11 cycles PLUS docetaxel 50 mg/m^2, oxaliplatin 85 mg/m^2, 5FU 2600 mg/m^2, and leucovorin 200 mg/m^2 Q2W (on Days 1 and 15 of Cycle 1; Day 8 of Cycle 2, and Day 1 of Cycle 3) for 4 administrations."
89608567|NCT04143087||Withdrawal TKIs|
89600703|NCT04882241|Placebo Comparator|Placebo+FLOT Cohort|"Neoadjuvant: Prior to surgery, participants receive 3 cycles of placebo (normal saline solution) via IV infusion on Day 1 Q3W PLUS docetaxel 50 mg/m^2 via IV infusion, oxaliplatin 85 mg/m^2 via IV infusion, 5FU 2600 mg/m^2 via IV infusion, and leucovorin 200 mg/m^2 via IV infusion Q2W (on Days 1 and 15 of Cycle 1; Day 8 of Cycle 2, and Day 1 of Cycle 3) for 4 administrations.~Adjuvant: 4 to 10 weeks postsurgery, participants receive placebo via IV infusion on Day 1 Q3W PLUS docetaxel 50 mg/m^2 via IV infusion, oxaliplatin 85 mg/m^2 via IV infusion, 5FU 2600 mg/m^2 via IV infusion, and leucovorin 200 mg/m^2 via IV infusion Q2W (on Days 1 and 15 of Cycle 1; Day 8 of Cycle 2, and Day 1 of Cycle 3) for 4 administrations."
89600704|NCT04881240|Experimental|Group A|Participants in group A have received a prior stem cell transplant from their CAR T-cell donor.
89600705|NCT04881240|Experimental|Group B|Participants in group B have not received a prior stem cell transplant from their CAR T-cell donor.
89600706|NCT04881071|Experimental|Scarf|"Two hours after delivery, mothers will be informed of the benefits of the skin-to-skin method, and the towel with which mother and newborn are covered from the moment of delivery will be replaced by a NeoBulleⓇ scarf. This scarf, which can be used by the mother and/or her partner, is specific for practicing the skin-to-skin technique. It facilitates breastfeeding posture, keeps the newborn well covered and supported on the back. The NeoBulleⓇ scarf is not a baby carrier device that allows standing or walking without holding the baby with the arms. Nursing staff will ensure the proper understanding of scarf usage instructions by parents and provide them with written instructions. Mother and newborn will remain with the NeoBulleⓇ scarf placed in the delivery area until they are transferred to the hospitalization unit. Once in the hospitalization unit, mothers will have the option to continue contact with the baby using the scarf or dress the newborn."
89600707|NCT04881071|Active Comparator|Usual clinical practice|Two hours after delivery, mothers will be informed about the benefits of the skin-to-skin method, and the traditional practice in the study centers will be followed, whereby the newborn remains in contact with the mother, covered by a towel, from the moment of birth until both are transferred to the hospitalization unit. In the hospitalization unit, they will have the option to continue in this manner or dress the newborn.
89600708|NCT04879329|Experimental|Cohort A - DV monotherapy for HER2-positive tumor types|Disitamab vedotin monotherapy
89600709|NCT04879329|Experimental|Cohort B - DV monotherapy for HER2-low tumor types|Disitamab vedotin monotherapy
89600710|NCT04879329|Experimental|Cohort C - Non-randomized combination therapy|Disitamab vedotin + pembrolizumab
89600711|NCT04879329|Experimental|Cohort C - Randomized combination therapy|Disitamab vedotin + pembrolizumab
89600712|NCT04879329|Experimental|Cohort C - Randomized monotherapy|Disitamab vedotin monotherapy
88980112|NCT05998681|No Intervention|Routine checks|The researchers applied no initiative to the control group, and the women in the control group solely had the routine checks. The women in the control group filled out all pretest forms(A sociodemographic questionnaire including questions about age, educational level, employment, income level, whether the pregnancy was planned and the gender of the baby, as well as the personal phone numbers of the women, Breastfeeding Self-Efficacy Scale (BSES), IOWA-Infant Feeding Attitude Scale (IIFAS), and Being a Mother Scale (BaM-13) . The BSES, IIFAS, and BaM-13 were re-administered to all participants at postpartum 6 weeks as post-tests. In addition, the method by which the participants continued to feed their babies, their use of bottles or pacifiers, and their nipple problems were recorded in the form created by the researchers. Post-test data were collected by the researchers by contacting the participants by phone.
88980113|NCT05998668|Experimental|genital hygiene training|"Following the pretest, genital hygiene behaviors training was provided to the women in the intervention group by E.S.B., one the researchers. In addition, a genital hygiene brochure prepared by the researchers which included the same content as the training was given to each participant. The training program was carried out as oral instruction as well as using the demonstration method which is called as tell-show-do. Individual questions of the women were answered at the end of the training. In the first meeting with the women, 2 sessions of 45 minutes with a 10-minute break were held in the counselling rooms of the relevant family health centers. Four weeks after these sessions, a 45-minute session was held in order to reinforce the training with the same method. Four weeks after the data collection tools used in the research were filled in as a pre-test, post-test data were obtained with the same measurement tools."
88980114|NCT05998668|No Intervention|Routine checks|The researchers applied no initiative to the control group, and the women in the control group solely had the routine checks. The women in the control group filled out all pretest forms (A sociodemographic questionnaire, Genital Hygiene Behavior Inventory (GHBI), and Self-Care Agency Scale (SCAS). The post-test forms (GHBI, SCAS) were re-administered 4 weeks later to women who did not receive any intervention.
88980115|NCT05998590|Experimental|High protein intake supplementation|A daily 60g dose of whey protein supplementation received between 8-9pm during BT.
88980116|NCT05998590|Experimental|Moderate protein intake supplementation|A daily 20g dose of whey protein supplementation received between 8-9pm during BT.
88980117|NCT05998590|Placebo Comparator|Carbohydrate placebo supplementation|A daily isocaloric carbohydrate (maltodextrin) placebo received between 8-9pm during BT.
88980118|NCT05998590|Other|Control group|Control group, no daily supplement received, only participating in BT.
88980119|NCT05998564||Patients aged 1 to 4 years of age|Patients will be connected to the NOL monitor and the SCA monitor during surgery with general anaesthesia.
88980120|NCT05998564||Patients aged 5 to 12 years of age|Patients will be connected to the NOL monitor and the SCA monitor during surgery with general anaesthesia.
88980121|NCT05998551|Active Comparator|Dexmedetomidine Group|participants will receive intrathecal injection of 5mg (1ml) of 0.5% hyperbaric bupivacaine + 1 ml contain 5μg dexmedetomidine(0.05ml dexmedetomidine in insulin syringe+ 0.95ml normal saline).
88980122|NCT05998551|Active Comparator|Fentanyl group|participants will receive intrathecal injection of 5 mg (1ml) of 0.5% hyperbaric bupivacaine + 1 ml contain 12.5μg fentanyl(0.25ml fentanyl in insulin syringe+ 0.75ml normal saline).
88980123|NCT05998551|Active Comparator|Control group|participants will receive intrathecal injection of 5mg (1ml) of 0.5% hyperbaric bupivacaine + 1 ml normal saline
88980124|NCT05998538||TKA (Total Knee Arthroplasty) procedure|Total Knee Arthroplasty
88980125|NCT05998538||UKA (Uni Knee Arthroplasty) procedure|Uni Knee Arthroplasty
88980126|NCT05998525|Experimental|Dapagliflozin|Dapagliflozin 10 mg orally every 24 hours for 12 months
88980127|NCT05998525|Placebo Comparator|Placebo|Placebo orally every 24 hours for 12 months
88980128|NCT05998499||EuroLatin HIV Cohort (ELHC)|Cohort of Latin American migrants living with HIV who were seeking international protection in Spain (Europe)
88980129|NCT05998486||Tremor of rest|Patient with a diagnosis of Parkinson's disease and who performed surface EMG recordings of wrist flexor-pronators and extensor-supinators analysis in Laboratories
88980130|NCT05998486||Cerebellar tremor|Patient with a diagnosis of cerebellar tremor and who performed surface EMG recordings of wrist flexor-pronators and extensor-supinators analysis in Laboratories
88980131|NCT05998473||Normal pressure hydrocephalus|Patients with a diagnosis of normal pressure hydrocephalus and who performed a gait analysis in laboratories
88980132|NCT05998473||Parkinson's disease|Patients with a diagnosis of Parkinson's disease and who performed a gait analysis in laboratories
88980133|NCT05998434|Experimental|the digital therapy|The participants randomly assigned to the intervention group will receive home-based exercise training with human key-point detection.They will be instructed to complete a minimum of three sports training sessions per week at their preferred time and location.The exercise prescription will be formulated based on previous comprehensive studies, encompassing exercises targeting strength, balance, flexibility, and mobility.Human key point detection technology accurately estimates 25 key points of the human body in pictures or videos using visual detection.
88980134|NCT05998434|Active Comparator|traditional exercise therapy|The participants randomly assigned to the control group will receive traditional face-to-face exercise instruction. An experienced therapist( 10 years of experience) will be arranged to provide the subjects with 20-30 minutes of exercise instruction three times a week for four weeks. The training sessions were scheduled to start at 4 p.m. on Monday, Wednesday, and Friday of each week. The exercise training content selected for the control group will be consistent with that of the intervention group.
88980135|NCT05998421|Active Comparator|the drug group (control group)|The patients in the control group accepted routine aspirin and heparin treatment. Two months before pregnancy, 50 mg of aspirin (Chenxin Pharmaceutical, China) was taken orally once a day.
88980136|NCT05998421|Experimental|the drug-accompanied-by-acupuncture group (acupuncture group)|The patients in the acupuncture group accepted acupuncture treatment weekly from the second day of menstruation and three times in one cycle.
88980137|NCT05998356|Experimental|Intervention group (BET procedure)|Subjects randomly assigned to the intervention group will benefit from BET procedure
88980138|NCT05998356|Placebo Comparator|Control group|Subjects from control group will undergo insertion of catheter for probing and flushing the Eustachian tube, the catheter won't be dilated
88980139|NCT05998343|Experimental|HOW R U? intervention delivered by same-generation peer volunteer|HOW R U?
88980140|NCT05998343|Experimental|HOW R U? intervention delivered by intergenerational volunteer|
88980141|NCT05998343|No Intervention|Waitlist control group|After the primary outcome assessment at 12 weeks, control group participants will be offered HOW R U? intervention support outside of the main trial. They will be allowed to choose either intergenerational or same-generation versions.
88980142|NCT05998265|Experimental|FeetMe Rehabilitation arm|
88980143|NCT05998265|Active Comparator|Conventional physiotherapy arm|
88980144|NCT05998226|No Intervention|Standard care (control group)|The clinicians from the control arm do not participate in VAT meetings. The antibiotic prescriptions prescribed by clinicians in the control group are extracted from the prescription system after the study period. Two researchers independently extract the data from patient files, including any culture results, and assess the antibiotic use based on the algorithm from the current guidelines that are used in NHs.
88980145|NCT05998226|Experimental|Virtual Antimicrobial stewardship Team (VAT) (intervention group)|The VAT consists at least of a medical microbiologist and a clinician from the NH. Depending on the NH organization concerned and cooperation agreements, a pharmacist will or will not be involved. They conduct weekly consultations during 9 months to evaluate the antibiotic prescriptions of the clinician based on algorithms from current guidelines in use in the NH. This is an evaluation of standard care .
88980146|NCT05998213|Experimental|Donor fecal microbiota transplant|
88980147|NCT05998213|Placebo Comparator|Autologous fecal microbiota transplant|
88980148|NCT05998200|Other|Serum with low concentration AHA (1% Glycolic acid and Lactic acid) and PGA|This serum containing low concentration AHA (1% Glycolic acid and Lactic acid) and PGA.
88980149|NCT05998187|Experimental|intra-rectal botulinum toxin injections|Patients with fecal incontinence who have failed conservative treatments and are candidates for intra-rectal botulinum toxin injections.
88980150|NCT05998148|No Intervention|standard in-person appointment visits|Randomly selected participants will receive standard in-person post-operative appointment visits at 6 week, 12 week, and 6 months after surgery.
88980151|NCT05998148|Experimental|virtual phone appointment visits|Randomly selected participants will receive virtual telemedicine post-operative appointment visits at 6 week, 12 week, and 6 months after surgery.
88980152|NCT05998122|Experimental|Experimental|"Radiation: Long-course chemoradiotherapy is delivered in 50 Gy/25 fractions with concurrent Capecitabine (825mg/m2, P.O. Bid, 5d/w).~Drug: CapeOX (Capecitabine 1000mg/m2, P.O. Bid, d1-d14, q3w; Oxaliplatin 130mg/m2, i.v., d1, q3w), and Sintilimab (200mg, i.v. , d1).~Surgical Approach: TME surgery, The surgical approach can be open, laparoscopic or robotic depending on the patient."
88980153|NCT05998096|Placebo Comparator|Placebo|Placebo (void of all actives)
88980154|NCT05998096|Active Comparator|Caffeine-Based Energy Drink|Caffeine-based energy drink containing 200 mg caffeine
88980155|NCT05998083|Active Comparator|control group|continued their normal education and physiotherapy
88980156|NCT05998083|Experimental|experimental group|they continued their normal training and physiotherapy, in addition, purposeful balance and coordination exercises were given for 40 minutes a day, 2 days a week for 8 weeks.
88980157|NCT05997992|Experimental|Electroacupuncture group|"The Electroacupuncture group received electroacupuncture at Baihui(GV20), bilateral Sanyinjiao(SP-6) and Fuliu points(KP-7).20 minutes of acupuncture.~Twice a week."
88980158|NCT05997992|Placebo Comparator|Sham acupuncture group|The control group received placebo acupuncture.Except for placebo acupuncture, which won't penetrate the skin, the rest is the same as the Electroacupuncture group.
89600713|NCT04879329|Experimental|Cohort D - DV monotherapy (Japan only)|Disitamab vedotin monotherapy
89608568|NCT04143087||halve TKIs|
88980159|NCT05997966|Active Comparator|Progressive Resistance Exercises Group|In the exercise group, a home-based exercise program will be applied in addition to a 30-minute walking request twice a week, and will consist of stretching exercises for the lower extremities, isometric exercises and progressive resistance strengthening exercises (IDE) of the hip, knee and ankle. The 12-week home-based IDE program will be applied 2 sets/day for 3 days/week (on non-consecutive days). Resistance bands will be used for resistance in the IDE program. In addition, the exercise intensity in the IDE program will be questioned with the perceived difficulty level (AZD). The AZD scale shows the perceived intensity and pulse rate change during exercise between 6-20. All exercises will be performed without resistance for the first 4 weeks, with AZD levels at 40% of 1 maximum repetition at week 5 to 8, AZD 13-15 (somewhat difficult), and after week 8 to AZD 15-16 (difficult). Progress will be achieved by increasing the number of repetitions.
88980160|NCT05997966|Sham Comparator|Control Group|In the control group, 30 minutes of walking will be requested twice a week, and no other intervention will be made. Individuals in the control group will be called every week by phone for gait follow-up.
88980161|NCT05997940|Active Comparator|PENG|PENG block performed before spinal anesthesia
88980162|NCT05997940|No Intervention|Control|
88980163|NCT05997927|Experimental|VC005 Tablets Low Dose groups|
88980164|NCT05997927|Experimental|VC005 Tablets Medium Dose groups|
88980165|NCT05997927|Experimental|VC005 Tablets High Dose groups|
88980166|NCT05997927|Placebo Comparator|VC005 Tablets Placebo groups|
88980167|NCT05997862|Experimental|Intervention|This group will do a 12-week high intensity exercise program. The subjects will exercise by increasing how much they lift their knees while walking on treadmill. The exercise will also involve controlling the impact of the feet on the treadmill. A TV placed in front of the treadmill shows how high individuals need to lift their knees. How much participants need to lift their knees is calculated based on real-time heart rate readings.
88980168|NCT05997862|No Intervention|Control|This group will do initially a 12-week period of no intervention. After these 12 weeks, participants will do a 12-week high intensity exercise program. The subjects will exercise by increasing how much they lift their knees while walking on treadmill. The exercise will also involve controlling the impact of the feet on the treadmill. A TV placed in front of the treadmill shows how high individuals need to lift their knees. How much participants need to lift their knees is calculated based on real-time heart rate readings.
88980169|NCT05997836|Other|Wave 1|Study design is a stepped wedge; Wave 1 begins by receiving Implementation Facilitation
88980170|NCT05997836|Other|Wave 2|Study design is a stepped wedge; Wave 2 begins by receiving Centralized Technical Assistance before crossing over to Implementation Facilitation
88980171|NCT05997836|Other|Wave 3|Study design is a stepped wedge; Wave 3 begins by receiving Centralized Technical Assistance before crossing over to Implementation Facilitation
88980172|NCT05997836|Other|Wave 4|Study design is a stepped wedge; Wave 4 begins by receiving Centralized Technical Assistance before crossing over to Implementation Facilitation
88980173|NCT05997797||Single Group|A total of 175 patients with a range of foot or ankle problems were included for the review. Informed consent was taken from the review members in written form. They all finished the Urdu version of FAAM in the test session. With a time, span of 3 days after the primary recording, a total of the 175 patients whose conditions were relied upon to stay stable were approached to complete the forms again in the retest meeting; no treatment was given during this time-frame. The FAAM is made out of two subscales including ADL and Sports subscales that have a complete score of 84 and 32, individually. Also, toward the finish of the structure, patients were approached to rate the current degree of function with a 4-point Likert scale. Patients evaluated everything as indicated by the trouble they go over with each undertaking on account of their foot or ankle condition. After assortment, information was saved in a safe spot to keep away from any dispositions.
88980174|NCT05997745|Experimental|study group|an intervention arm consisting of patients who will receive the locally manufactured protein-energy ration after a laparotomy indicated for generalized acute peritonitis
88980175|NCT05997745|Active Comparator|control group|patients who will receive the commercially available protein-energy ration after a laparotomy indicated for generalized acute peritonitis
88980176|NCT05997706|Experimental|Infertile patients|Infertile patients going to surgery for fertility preservation or infertility treatment at University Clinic Saint-Luc Brussels
88980177|NCT05997667|Experimental|experimental group|Subjects in this arm will receive stimulation of DBS system within 1 month after surgery.
88980178|NCT05997667|Other|control group|Subjects in this arm will receive stimulation of DBS system at 3 months after surgery.
88980179|NCT05997654|Experimental|Instrumental procedures and safety and efficacy assessments|"Group I: 23 participants who will undergo instrumental procedures, perceived efficacy questionnaires and clinical assessments of safety and efficacy.~Group II: 10 participants who will only perform perceived efficacy questionnaires and clinical assessments of safety and efficacy."
88980180|NCT05997628||18-40 years|Each group has 20 subjects, and the sex ratio of 18-40 years group is 1:1. After each participant is enrolled, peripheral blood samples are taken before breakfast and before lunch to detect NAD+/NADH levels in peripheral blood and determine the physiological baseline levels of NAD+/NADH in different age groups
88980181|NCT05997628||41-60 years|Each group has 20 subjects, and the sex ratio of 41-60 years group is 1:1. After each participant is enrolled, peripheral blood samples are taken before breakfast and before lunch to detect NAD+/NADH levels in peripheral blood and determine the physiological baseline levels of NAD+/NADH in different age groups
88980182|NCT05997628||61-80 years|Each group has 20 subjects, and the sex ratio of 61-80 years group is 1:1. After each participant is enrolled, peripheral blood samples are taken before breakfast and before lunch to detect NAD+/NADH levels in peripheral blood and determine the physiological baseline levels of NAD+/NADH in different age groups
88980183|NCT05997589|Experimental|Health Services Research (educational program)|Participants attend financial health educational program over 60 minutes. Patients also receive educational materials on study.
88980184|NCT05997576|Experimental|TG103 22.5 mg|Administered subcutaneously once every week for 52 weeks. Doses gradually increased to 22.5 mg.
88980185|NCT05997576|Placebo Comparator|Placebo|Administered subcutaneously once every week for 52 weeks.
88980186|NCT05997524|Experimental|Tras-Capox|
88980187|NCT05997511|Other|COVID-19|Behavioral (SMS) Intervention
88980188|NCT05997511|Other|Mental Health|Behavorial (SMS) Intervention
88980189|NCT05997498|Experimental|dilation group|mechanical cervical dilatation will be done.
88980190|NCT05997498|No Intervention|control|in which no mechanical cervical dilatation will be done.
89600714|NCT04879329|Experimental|Cohort E - DV combination therapy (Japan only)|Disitamab vedotin + pembrolizumab
88980192|NCT05997459|Experimental|experimental group|
89600715|NCT04878276||Dimet 5|"Dimet 5 is a certified medical device for the treatment of head lice infestation. It contains only (liquid) dimeticone oil and, when used correctly, enables physical killing of head lice and their eggs."
89600716|NCT04878276||Hedrin Once Liquid Gel|Hedrin Once Liquid Gel is a certified medical product for the removal of head lice and nits. The liquid gel contains 4% dimethicone and nerolidol (Penetrol®).
88980193|NCT05997355|Experimental|Treatment|Patient will be treated with preoperative gabapentin
88980194|NCT05997355|No Intervention|No treatment|Patient will not be treated with preoperative gabapentin
88980195|NCT05997342|Experimental|TQB3912 tablets|TQB3912 tablets, 28 days as a treatment cycle.
88980196|NCT05997303|Other|Continuous norepinephrine administration|continuous norepinephrine infusion via an infusion pump; norepinephrine dose will be at the discretion of the treating anesthesiologists
88980197|NCT05997303|Other|Manual bolus norepinephrine administration|manual bolus norepinephrine administration; norepinephrine dose will be at the discretion of the treating anesthesiologists
88980198|NCT05997251||Patients with spinal cord injury|
88980199|NCT05997251||Healthy group|
89210259|NCT02539524|Experimental|Yoga Group|Yoga Bhastrika Pranayama breathing exercises consisted of: 12-week pulmonary rehabilitation (two 1 hour sessions a week, consisting of: 30 min of aerobic training followed by resistance exercises for upper and lower limbs). After each pulmonary rehabilitation session, participants of this group performed 10 bhastrika pranayama breathing exercises (1 bhastrika is formed by 20 kapalabhati followed by 1 surya bedhana - described earlier).
89210260|NCT00984243|Experimental|Photodynamic Therapy|PHOTODYNAMIC THERAPY (PDT)
89210261|NCT00815750|Other|Phase I - Information Gathering|
89210262|NCT00815750|Other|Phase 2 - Decision Aid|
88980204|NCT05997212|Experimental|Active rTMS frequency at 10 Hz|The intervention will be Repetitive Transcranial Magnetic Stimulation. Each patient will receive treatment stimulation in the left dorsolateral prefrontal cortex (lDLPFC) with a frequency of 10 Hz, that includes 2 sessions per day for 20 consecutive business days for 4 weeks. Each session will consist of the application of rTMS at a frequency of 10 Hz, to 100% of the motor threshold. The lDLPFC target will be determined using their resting state functional connectivity between anterior cingulate cortex and lDLPFC. Our algorithm performs a calculation of the individual localization of the participant's lDLPFC, which will be used for the whole study in that particular participant.
88980205|NCT05997212|Sham Comparator|Sham rTMS frequency at 10 Hz|The intervention will be Repetitive Transcranial Magnetic Stimulation (Sham). For this patients the coil will be located backwards to the skull. Each patient will receive sham stimulation in the left dorsolateral prefrontal cortex (lDLPFC) with a frequency of 10 Hz, that includes 2 sessions per day for 20 consecutive business days for 4 weeks. Each session will consist of the application of rTMS at a frequency of 10 Hz, to 100% of the motor threshold. The lDLPFC target will be determined using their resting state functional connectivity between anterior cingulate cortex and lDLPFC. Our algorithm performs a calculation of the individual localization of the participant's lDLPFC, which will be used for the whole study in that particular participant.
88980206|NCT05997173||Control|Normal control group
88980207|NCT05997173||Non erosive OLP|Non erosive oral lichen planus
88980208|NCT05997173||Erosive OLP|Erosive oral lichen planus
88980209|NCT05997160||hospital name + infection type + number|There is no intervention.
88980210|NCT05997108||cases group|
88980211|NCT05997108||control group|
89600717|NCT04858269|Experimental|Combination of Chemotherapy and Immunotherapy|The intervention will be administered on an outpatient basis. The treatment regimen will consist of combination chemotherapy and immunotherapy administered as: Pembrolizumab PLUS Carboplatin PLUS Paclitaxel.
89600718|NCT04846959||Pregnant Women Exposed to Risankizumab|Pregnant women of any age in the United States (US) who are diagnosed with plaque psoriasis, psoriatic arthritis, Crohn's disease, or other conditions for which risankizumab is an FDA-approved treatment and exposed to risankizumab at any time during pregnancy.
89608569|NCT00533182||Immunocompromised|Immunocompromised individuals
89608570|NCT00533182||Non-Immunocompromised|Non-immunocompromised individuals
89608571|NCT00533182||Pregnant|Pregnant women
89032072|NCT04690647|Experimental|Regional anaesthesia, dexamethasone, opioid and non opioid postoperative analgesia|Group of patients with opioid and non opioid based postoperative analgesia with preoperative regional anaesthesia and dexamethasone.
89032073|NCT00519311|Experimental|School based health intervention|Educational intervention based on health diary + health check
89032074|NCT00519311|No Intervention|Usual care|Normal school curriculum and usual medical care
88980212|NCT05997043|Experimental|Experimental group|Experimental group
88980213|NCT05997043|Placebo Comparator|Control group|Control group
88980214|NCT05996991|Experimental|G1 - Positive Expectation Group + Spinal Manipulative Therapy|The participants of G1 will watch a short video (no more than 3 minutes) delivering a positive message regarding SMT. Secondly, a physiotherapist will administer one session of SMT and participants will be re-assessed to investigate the immediate effect of the videos on the pain intensity, global perceived effect of improvement, and expectations. Ultimately, patients will be submitted to a semi-structured interview in which their perceptions about the videos will be investigated.
88980215|NCT05996991|Active Comparator|G2 - Neutral Expectation Group + Spinal Manipulative Therapy|The participants of G1 will watch a short video (no more than 3 minutes) delivering a neutral message regarding SMT. Secondly, a physiotherapist will administer one session of SMT and participants will be re-assessed to investigate the immediate effect of the videos on the pain intensity, global perceived effect of improvement, and expectations. Ultimately, patients will be submitted to a semi-structured interview in which their perceptions about the videos will be investigated.
89210263|NCT05712681|Experimental|Sequence 1|T → Washout period(7-14days) → R
89210264|NCT05712681|Experimental|Sequence 2|R → Washout period(7-14days) → T
88980216|NCT05996991|Active Comparator|G2 - Negative Expectation Group + Spinal Manipulative Therapy|The participants of G1 will watch a short video (no more than 3 minutes) delivering a negative message regarding SMT. Secondly, a physiotherapist will administer one session of SMT and participants will be re-assessed to investigate the immediate effect of the videos on the pain intensity, global perceived effect of improvement, and expectations. Ultimately, patients will be submitted to a semi-structured interview in which their perceptions about the videos will be investigated.
88980217|NCT05996978||Intensive Drug Therapy|Dual antiplatelet therapy (DAPT) (aspirin 100 mg per day and clopidogrel 75 mg per day were administered for 90 days, followed by aspirin 100 mg per day for long term) and atorvastatin (40 mg per day for 14 days, followed by 20 mg per day long term) after enrollment.
88980218|NCT05996952|Experimental|Adjuvant RC48-ADC|In this arm, RC48-ADC is evaluated in patients with HER2-positive high-risk non-muscle-invasive bladder cancer as an adjuvant treatment.
88980219|NCT05996952|Experimental|Salvage RC48-ADC|In this arm, RC48-ADC is evaluated in patients with HER2-positive non-muscle-invasive bladder cancer who failed BCG treatment as an adjuvant treatment.
88980220|NCT05996939|Experimental|Unstable shoes|Use of unstable shoes for 8 weeks
88980221|NCT05996939|No Intervention|Usual sports footwear|Use of conventional shoes for 8 weeks
88980222|NCT05996926|Experimental|Three-Dimensional Transvaginal Ultrasound (3D TVS)|"In this study, Three-Dimensional Transvaginal Ultrasound will be employed as one of the interventions to evaluate Cesarean Scar Defects (CSD) and associated complications in symptomatic patients with a history of cesarean section.~A specialized ultrasound machine (Samsung WS80A) equipped with a transvaginal 2-11 MHz probe will be used for the Three-Dimensional Transvaginal Ultrasound examination. The examination will be conducted in the 1st half of the menstrual cycle. The ultrasound probe will be introduced into the posterior fornix of the vagina to capture three-dimensional images of the uterus and scar area. The examiner will identify and measure the characteristics of the Cesarean Scar Defects (CSD), including length, depth, width, volume, residual myometrial thickness, adjacent myometrial thickness, and presence of any branches."
88980223|NCT05996926|Experimental|Saline-Infused Sonography (Sonohystrography)|The Sonohystrography will be performed using a Toshiba ECCO CEE SSA-340A ultrasound equipment with a 7.5 MHz transvaginal probe. A sterile vaginal speculum will be inserted, the cervix cleansed with an antiseptic solution, and a thin Foley's catheter inserted into the cervical os. Sterile saline solution will be infused into the uterus through the catheter to distend the uterine cavity. The examiner will use the ultrasound probe to visualize and assess the uterine cavity, focusing on identifying and measuring Cesarean Scar Defects (CSD) characteristics, including depth, width, volume, and myometrial thickness.
88980224|NCT05996887|Placebo Comparator|non- enhanced recovery after surgery|All patients will receive antiemetics as haloperidol 2 mg and dexamethasone 8 mg and ondansetron 8 mg in addition to standard care protocol.
88980225|NCT05996887|Active Comparator|enhanced recovery after surgery|All patients will receive antiemetics as haloperidol 2 mg and dexamethasone 8 mg, and ondansetron 8 mg in addition to following the recommendation of ERAS society guidelines.
88980226|NCT05996861||Pre-sleep protocol group|Patients with inclusion criteria assessed before the implementation of the sleep protocol.
88980227|NCT05996861||Post-sleep protocol group|Patients with inclusion criteria after the implementation of the sleep protocol.
88980228|NCT05996848|Experimental|CagriSema|Participants will receive once-weekly subcutaneous (s.c) injections of 2.4 mg cagrilintide and 2.4 mg semaglutide for 44 weeks.
88980229|NCT05996848|Active Comparator|Semaglutide|Participants will receive once-weekly s.c injection of 2.4 mg semaglutide for 44 weeks.
88980230|NCT05996848|Placebo Comparator|Placebo|Participants will receive placebo matched to cagrilintide and placebo matched to semaglutide once weekly for 44 weeks.
88980231|NCT05996796|Experimental|Opt-out first-void urine|"Women will receive a first-void urine self-sampling study package at home.~The study package will include an invitation letter/informed consent form, information brochure, first-void urine self-sampling device, safety bag with absorbent paper, pre-stamped return envelope, and instructions explaining how to collect the sample and send it to the lab."
88980232|NCT05996796|Experimental|Opt-in first-void urine|"Women will receive a letter at home with instructions how to order (via phone, e-mail, or webform) a first-void urine self-sampling study package.~The study package will include an invitation letter/informed consent form, information brochure, first-void urine self-sampling device, safety bag with absorbent paper, pre-stamped return envelope, and instructions explaining how to collect the sample and send it to the lab."
88980233|NCT05996796|Experimental|Opt-out vaginal self-sample|"Women will receive a vaginal self-sampling study package at home.~The study package will include an invitation letter/informed consent form, information brochure, vaginal self-sampling device, safety bag with absorbent paper, pre-stamped return envelope, and instructions explaining how to collect the sample and send it to the lab."
88980234|NCT05996796|Experimental|Opt-in vaginal self-sample|"Women will receive a letter at home with instructions how to order (via phone, e-mail, or webform) a vaginal self-sampling study package.~The study package will include an invitation letter/informed consent form, information brochure, vaginal self-sampling device, safety bag with absorbent paper, pre-stamped return envelope, and instructions explaining how to collect the sample and send it to the lab."
88980235|NCT05996783|No Intervention|Control - no intervention|"This control group will receive no intervention. Cervical cancer screening (having a Pap smear taken by a clinician for cytology-based screening) is completely opportunistic, i.e. based on the initiative of the participant or their clinician.~No reminder letter will be sent."
88980236|NCT05996783|No Intervention|Control - (recall) invitation letter|"This control group will receive the standard (recall) invitation letter send out by the Centre for Cancer Detection (CvKO). In this invitation letter, participants are encouraged to make an appointment with their clinician to have a Pap smear taken (for cytology-based screening).~A reminder letter will be sent after 5-6 months."
88980237|NCT05996783|Experimental|Opt-out first-void urine|"Women will receive a first-void urine self-sampling study package at home.~The study package will include an invitation letter/informed consent form, information brochure, first-void urine self-sampling device, safety bag with absorbent paper, pre-stamped return envelope, and instructions explaining how to collect the sample and send it to the lab.~A reminder letter will be sent after 5-6 months."
89600719|NCT04846959||Pregnant Women Not Exposed to Risankizumab|Pregnant women of any age in the US who are diagnosed with plaque psoriasis, psoriatic arthritis, Crohn's disease, or other conditions for which risankizumab is an FDA-approved treatment and not exposed to risankizumab, but who are exposed to other medications in the same class or line of therapy as risankizumab at any time during pregnancy.
89600720|NCT04840589|Experimental|Doublet treatment (ZEN003694, nivolumab)|Patients receive nivolumab IV over 30 minutes on day 1 and ZEN003694 PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo MRI, a CT scan, a PET scan, and/or an x-ray as well as blood sample collection throughout the trial. Patients also undergo a biopsy during screening.
89600721|NCT04840589|Experimental|Triplet treatment (nivolumab, ZEN003694, ipilimumab)|Patients receive nivolumab IV over 30 minutes on day 1, ipilimumab IV over 90 minutes on day 1, and ZEN003694 PO QD on days 1-21 of each cycle. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Beginning cycle 5, patients are no longer treated with ipilimumab, but receive nivolumab IV over 30 minutes on day 1 and ZEN003694 PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo MRI, a CT scan, a PET scan, and/or an x-ray as well as blood sample collection throughout the trial. Patients also undergo a biopsy during screening and on study.
89600722|NCT04832841||SARS-CoV-2 naive|Kidney transplant recipients without previous SARS-CoV-2 infection verified by absence of RT-PCR test in national database who receive SARS-CoV-2 mRNA vaccine after transplantation.
89600723|NCT04832841||SARS-Cov-2 exposed|Kidney transplant recipients with previous SARS-CoV-2 exposition verified by positivity of RT-PCR test in national database who receive SARS-CoV-2 mRNA vaccine after transplantation.
89600724|NCT04832841||Waiting list|Kidney transplant recipients who were vaccinated on waiting list (a) SARS-CoV-2 naive (b) SARS-Cov-2 exposed
89600725|NCT04810611|Experimental|Arm 1: MBG453 single agent|Treatment with MBG453 single agent Q4W to confirm safety and tolerability of RD.
89600726|NCT04810611|Experimental|Arm 2: NIS793 single agent|Treatment with NIS793 single agent Q3W to establish RD in this indication and confirm safety and tolerability.
89600727|NCT04810611|Experimental|Arm 3: canakinumab single agent|Treatment with single agent canakinumab Q4W to confirm safety and tolerability of RD.
89600728|NCT04810611|Experimental|Arm 4: MBG453 + NIS793 combination|Treatment with combination of MBG453 and NIS793 Q3W to confirm safety and tolerability of combination RD.
89600729|NCT04810611|Experimental|Arm 5: MBG453 + canakinumab combination|Treatment with MBG453 + canakinumab combination Q4W to confirm safety and tolerability of combination RD.
89600730|NCT04802720|Experimental|ERT-C: Emotion Regulation Therapy for Cancer Caregivers|Emotion Regulation Therapy for Cancer Caregivers (ERT-C) is an 8-session intervention that builds upon the foundations of CBT-C and addresses earlier motivational processing components of the caregivers context while targeting earlier and later components of internal distress and resultant maladaptive behavioral coping.
89600731|NCT04802720|Experimental|CBT-C: Cognitive Behavioral Therapy for Cancer Caregivers|Cognitive Behavioral Therapy (CBT-C) is an evidence-based psychotherapeutic approach that is grounded in the cognitive model that purports that a person's emotional, behavioral, and physiological reactions to a situation is based on their appraisal of that situation. The focus of therapy is on changing cognitions and beliefs about a situation and altering automatic behavioral responses evoked by that perception. CBT-C aims to improve emotion regulation by challenging and changing unhelpful cognitions and behaviors and improving personal coping strategies.
89600732|NCT04802720|Experimental|Training case group|Will be assigned to receive ERT-C only and will not complete questionnaires.
89600733|NCT04801862||Patients diagnosed of C.difficile infection|Open cohort of consecutive patients diagnosed of Clostridioides difficile infection
89600734|NCT04799301|Experimental|Diet with 20% of carb intake from soda|This group will receive a weight-maintaining diet with 20% of carbohydrates provided as soda. The carbohydrates from sources other than corn and sugar cane will be reduced accordingly to meet the total carbohydrate supply.
89600735|NCT04799301|Experimental|Diet with 50% of carb intake from soda|This group will receive a weight-maintaining diet with 50% of carbohydrates provided as soda. The carbohydrates from sources other than corn and sugar cane will be reduced accordingly to meet the total carbohydrate supply.
89600736|NCT04799301|Experimental|Diet with no soda|This group will receive a weight-maintaining diet without soda. All 50% of carbohydrates will originate from sources other than corn and sugar cane.
89600737|NCT04794725|Other|Blood Sampling|blood samples from venepuncture (10mL)
89600738|NCT04794517|Experimental|IMP|Dapagliflozin 10 mg/die will be administered orally for six-weeks.
89600739|NCT04794517|Placebo Comparator|Placebo|Placebo, one tablet/die will be administered orally for six-weeks.
89600740|NCT04784572|Other|First injection delay and second injection delay|"During the first injection, the patient will make 3 scales: END, EVAF and insight and there will be an assessment of induration, redness and swelling done with nurses.~During the second injection, the patient will perform the END and EVAF scale and then follow up with a maintenance"
89600741|NCT04783506||Suicidal Behavior|Adolescents who have suicidal behavior, which for this study, is defined by a recent (within 3 months of enrollment) suicide attempt or suicidal ideation warranting urgent evaluation.
89600742|NCT04783506||At Risk for Mood Disorders|Adolescents at risk for mood disorders, which for this study, is defined by either personal history of anxiety disorder or substance use disorder or a history of trauma, or a first degree relative with a history of a mood disorder or suicidal history.
89600743|NCT04783506||Healthy Control|Healthy adolescents with no lifetime history of any psychiatric or substance use disorders or a history of trauma. Additionally, no first-degree family member with a history of a mood disorder or suicidal history.
89032075|NCT02938845|Experimental|total laparoscopic hysterectomy(TLH)|Each patient's anxiety was measured using Spielberger's State-Trait Anxiety Inventory immediately before, immediately after the operation.
89032076|NCT02938845|Experimental|total abdominal hysterectomy(TAH)|Each patient's anxiety was measured using Spielberger's State-Trait Anxiety Inventory immediately before, immediately after the operation.
89032077|NCT00519350||I|Liver surgery
89032078|NCT00519350||II|Colon surgery
89032079|NCT00519350||III|Femur Fracture
89032080|NCT02940483|Experimental|5-Azacytidine Infusion|12 infusions (once a week) into implanted fourth ventricle catheter/Ommaya reservoir following surgical catheter placement into fourth ventricle.
89032081|NCT04974684|Experimental|Interventional group|
89600744|NCT04766320|Experimental|Tumor Infiltrating Lymphocytes (TIL)|1x10^9-3x10^11 in vitro expanded autologous TILs will be infused i.v. to patients with relapsed/refractory malignant gynecological tumors after NMA lymphodepletion treatment with fludarabine and cyclophosphamide. PD-1 checkpoint inhibitor would be applied as combination treatment to those patients.
89600745|NCT04763772|Experimental|Detailed Report|A detailed body composition profile report that consists of the following elements: basic demographic data, percent body fat, weight to muscle ratio, visceral fat and abdominal subcutaneous fat volume, visceral fat ratio (the fraction of visceral divided by total abdominal fat), muscle fat infiltration and liver fat (%), and thigh muscle volumes (also separated into right and left, anterior and posterior compartments). Each parameter is presented on a visual scale in the context of the individual value, general population defined by reference data (from United Kingdom (UK) Biobank population), a metabolic disease-free population (also from UK Biobank), low/high and very low/very high, corresponding to 15th and 5th percentiles, respectively. There are also descriptions of each biomarker and how they are derived to provide context for the recipient.
89600746|NCT04763772|Placebo Comparator|Basic Weight Information|A simple informational report consisting of weight, BMI, and a visual representation of their BMI. This report also categorizes their BMI into underweight, normal weight, overweight, or obese categories according to the World Health Organization categorization schema.
89600747|NCT04763772|Experimental|Patient Provided|Report provided directly to the patient.
89600748|NCT04763772|Placebo Comparator|Physician Provided|Report provided directly to the provider to translate/counsel the patient.
89600749|NCT04751383|Experimental|Arm A (magrolimab, dinutuximab)|Patients receive magrolimab IV and dinutuximab IV on study. Patients also undergo CT, MRI, and blood sample collection on study, as well as bone marrow aspiration and biopsy throughout the trial.
89600750|NCT04751383|Experimental|Arm B (magrolimab, dinutuximab, surgery)|Patients receive magrolimab IV and dinutuximab IV on study. Patients with pulmonary osteosarcoma may undergo surgical resection of tumor after cycle 1. After surgery, these patients continue receiving magrolimab and dinutuximab on study. Patients also undergo CT, MRI, and collection of blood samples on study, as well as bone marrow aspiration and biopsy throughout the trial.
89600751|NCT04750954|Experimental|Treatment (peposertib, lutetium Lu 177 dotatate)|Patients receive peposertib PO QD or BID on days 1-21 and lutetium Lu 177 dotatate IV over 30 minutes on day 1. Treatment repeats every 56 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT/MRI throughout the trial and undergo collection of blood samples on study.
89600752|NCT04744662|Experimental|Treatment Group A|ONL1204 Ophthalmic solution (dose A) administered by intravitreal injection
89600753|NCT04744662|Experimental|Treatment Group B|ONL1204 Ophthalmic solution (dose B) administered by intravitreal injection
89600754|NCT04744662|Sham Comparator|Treatment Group C|sham injection without penetrating the eye
89600755|NCT04744493|Experimental|treatment arm of Exablate 4000 as a single arm|Only one arm of treatment by Exablate 4000 was established.
89600756|NCT04740112|Placebo Comparator|Control breakfast bar with low dietary fiber without product claims|
89600757|NCT04740112|Experimental|Test breakfast bar with high dietary fiber without product claims|
89600758|NCT04740112|Experimental|Test breakfast bar with high dietary fiber with product claims|
89032082|NCT04974684|No Intervention|Control group|
89032083|NCT00520091|Active Comparator|Cohort 1|Induction chemotherapy and chemoradiation without celecoxib
89032084|NCT00520091|Experimental|Cohort 2|Induction chemotherapy and chemoradiation with celecoxib
89032085|NCT00520169|Active Comparator|A|oral ketamine
89032086|NCT00520169|Experimental|B|intranasal ketamine
89032087|NCT00520169|Active Comparator|C|intravenous ketamine
89032088|NCT02938533|No Intervention|Standard of Care|Standard HIV primary care services available at HIV care and treatment clinics in Tanzania.
89032089|NCT02938533|Experimental|Behavioral Intervention Using Social Norms and Priming|Patients in this arm may have been exposed to the behavioral intervention, which included the following components: 1) visual feedback about clinic-level retention in care through an interactive poster; 2) a self-relevant priming image that appeared on all components; and 3) a take-home item (i.e., pillbox or calendar) with the priming image.
89032090|NCT04932681||Qualitative group|Interview about the use of Complementary and Alternative Medecine
89032091|NCT04932681||Quantitative group|Questionnaire about the use of Complementary and Alternative Medecine
89032092|NCT00519545|Experimental|1|scripted prayer group (intervention group)
89032093|NCT00519545|No Intervention|2|no prayer intervention group (non-intervention group)
89032094|NCT02949050|Experimental|Treatment Group|the treatment -patients underwent SCIT and antihistamine/nasal steroid/use.
89032095|NCT02949050|No Intervention|Control Group|Control patient group only used antihistamines/nasal steroids but no SCIT
89032096|NCT02940132|Experimental|SC10914|SC10914 Dose Escalation： Dose Level 1：30mg(QD) Dose Level 2：60mg(QD) Dose Level 3：120mg(QD) Dose Level 4：200mg(QD) Dose Level 5：100mg(BID) Dose Level 6：300mg(QD) Dose Level 7：150mg(BID) Dose Level 8：400mg(QD) Dose Level 9：200mg(BID) Dose Expansion： Receiving SC10914 in one of three dosage regimens(low, middle or high dose-level and QD or BID) based on the assessment of dose escalation study.
89032097|NCT00519662|Experimental|Dose escalating cohorts of SNS-314|Sequential groups, starting at a dose of 30 mg/m2, will be escalated according to identification of dose limiting toxicities against various criteria. Doses escalated by doubling the dose until the first observation of clinically significant Grade 2 or greater toxicity related to SNS-314 injection. Results in dosing increments of 67%, 50%, 40%, 33%, and subsequently 25% based on modified Fibonacci schema.
89032098|NCT00520325|Other|0.5 mg/kg|
89032099|NCT00520325|Other|1.0 mg/kg|
89032100|NCT04925466|Experimental|Treatment with CPAP at 10cmH2O|Patients with OSA will be treated with CPAP at 10cmH2O during sleep.
89032101|NCT04925466|Experimental|Treatment with CPAP at minimal effective pressure|Patients with OSA will be treated with CPAP at minimal effective pressure derived from manual titration during sleep.
89600759|NCT04724811|Experimental|Weight-bearing as tolerated|Patients are instructed to mobilise the hip and weight-bear as tolerated
89600760|NCT04724811|Active Comparator|Touch-down weight-bearing|Patients are instructed to mobilise the hip. Touch-down weight-bearing for 6-8 weeks
89600761|NCT04715438|Experimental|Cohort A: Individuals without cancer|A cohort of individuals without a cancer diagnosis is included for comparison. Because age is an important predictor of the ability to mount an effective immune response to vaccination, partners of patients in cohort B, C, and D.
89600762|NCT04715438|Experimental|Cohort B: patients receiving immunotherapy|Cancer patients receiving immunotherapy
89600763|NCT04715438|Experimental|Cohort C: patients receiving chemotherapy|Cancer patients receiving chemotherapy
89600764|NCT04715438|Experimental|Cohort D: patients receiving chemo-immunotherapy|Cancer patients receiving chemo-immunotherapy
88980238|NCT05996783|Experimental|Opt-in first-void urine|"Women will receive a letter at home with instructions how to order (via phone, e-mail, or webform) a first-void urine self-sampling study package.~The study package will include an invitation letter/informed consent form, information brochure, first-void urine self-sampling device, safety bag with absorbent paper, pre-stamped return envelope, and instructions explaining how to collect the sample and send it to the lab.~A reminder letter will be sent after 5-6 months."
88980239|NCT05996783|Experimental|Opt-out vaginal self-sample|"Women will receive a vaginal self-sampling study package at home.~The study package will include an invitation letter/informed consent form, information brochure, vaginal self-sampling device, safety bag with absorbent paper, pre-stamped return envelope, and instructions explaining how to collect the sample and send it to the lab.~A reminder letter will be sent after 5-6 months."
88980240|NCT05996783|Experimental|Opt-in vaginal self-sample|"Women will receive a letter at home with instructions how to order (via phone, e-mail, or webform) a vaginal self-sampling study package.~The study package will include an invitation letter/informed consent form, information brochure, vaginal self-sampling device, safety bag with absorbent paper, pre-stamped return envelope, and instructions explaining how to collect the sample and send it to the lab.~A reminder letter will be sent after 5-6 months."
88980241|NCT05996757|Active Comparator|Wet clothing removal|
88980242|NCT05996757|No Intervention|Vapor barrier|
88980243|NCT05996692||Patients who walked regularly for exercise|"Walking for exercise was explored according to a specific criterion (walking at least 30 min, in bouts of 15 min, with a small rest between bouts, twice a week, over a minimum of six consecutive weeks) based on previous recommendations.~According to this criterion, the patients were divided into 2 groups as those who walked regularly for exercise and those who did not walk regularly for exercise."
88980244|NCT05996692||Patients who did not walk regularly for exercise|"Walking for exercise was explored according to a specific criterion (walking at least 30 min, in bouts of 15 min, with a small rest between bouts, twice a week, over a minimum of six consecutive weeks) based on previous recommendations.~According to this criterion, the patients were divided into 2 groups as those who walked regularly for exercise and those who did not walk regularly for exercise."
88980245|NCT05996666||Liver cancer arm|Participants with new diagnosis of liver cancer, from whom blood samples will be collected.
88980246|NCT05996666||Benign diseases arm|Participants with benign diseases of cancer, from whom blood samples will be collected.
88980247|NCT05996666||Healthy arm|Participants without known presence of malignancies or benign diseases of liver, from whom blood samples will be collected.
88980248|NCT05996666||Interfering cancer arm|Participants with new diagnosis of interfering cancer types, from whom blood samples will be collected.
88980249|NCT05996653|Other|ST-MRI scans|All patients will undergo Saturation Transfer (ST)-MRI during their standard of care imaging visits (or within 14 days of their standard MRI).
88980250|NCT05996614|Experimental|group with PRP|Group of patients with post burn raw areas treated with application of platelet rich plasma
88980251|NCT05996614|Experimental|group without PRP|Group of patients with post burn raw areas treated with conventional methods
88980252|NCT05996601|Experimental|Intervention arm|All participants would undergo educational intervention by pharmacist.
88980253|NCT05996588|Active Comparator|Propofol|Propofol at a rate of 50 microgram/kg/min
88980254|NCT05996588|Experimental|Sevoflurane|Sevoflurane inhalation with oxygen via nasal prongs at a concentration 4-5% to achieve a MAC of 0.25
88980255|NCT05996562|Experimental|Pulmonary Artery Denervation (PADN)|
88980256|NCT05996549|Experimental|Influenza vaccination arm|In the Influenza vaccination hospital, the investigators have run an influenza vaccination campaign before the influenza season, where the vaccines are free to high-risk patients. Posters and leaflets containing information on influenza vaccination have been displayed at the vaccination booths and key hospital locations with information on the vaccination. Eligible patients from inpatients and outpatients of all departments have been offered to take the vaccine during the vaccination campaign. Nurses/ Health Assistants (HA) have provided vaccines after receiving written consent. Vaccination cards have been issued to the participants. All enrolled vaccine recipients are informed about notifying of possible adverse events after immunization (AEFI). To report any AEFI, the investigators are following the existing surveillance channel established by the WHO and the Ministry of Health and Family Welfare(MoHFW), the government of Bangladesh.
89032102|NCT00520364||History of chemotherapy|IVF after chemotherapy
89032103|NCT00520364||IVF without history of chemotherapy|IVF without history of prior chemotherapy
89600765|NCT04699773|Experimental|LITT with Hypofractionated RT|Laser interstitial thermal therapy (LITT) followed by hypo-fractionated radiation therapy, 25Gy/10 fractions.
89600766|NCT04698902||Circumferential calcification|Patients with circumferential pattern of coronary artery calcification by OCT (Optical coherence tomography) assessment (arc of calcium >180 degrees)
89600767|NCT04698902||Eccentric calcification|Patients with an eccentric pattern of coronary artery calcification by OCT (Optical coherence tomography) assessment (arc of calcium <180 degrees)
89600768|NCT04698902||Nodular calcification|Patients with calcium nodules identified by OCT (Optical coherence tomography) assessment
89600769|NCT04690946|Active Comparator|Cognitive Behavioral Therapy|14-18 sessions of psychotherapy according to principles of Cognitive Behavioral Therapy
89600770|NCT04690946|Active Comparator|Emotion-Focused Therapy|14-18 sessions of psychotherapy according to principles of Emotion Focused Therapy
89600771|NCT04690140|Active Comparator|modified coronally advanced tunnel technique|Initial sulcular incisions and flap separation were then carried out with tunnel knives. Dissection was extended at least 8 mm apically to the mucogingival junction and the muscle attachments were removed with curettes so that the flap could be moved in a coronal direction without tension. Interdental papillae were undermined to prepare the bed for connective tissue graft placement. Connective tissue graft was then inserted under the tunnel at the sites of recession and retracted laterally by sutures towards each end of the tunnel. After connective tissue graft positioning, the flap was gently stretched coronally to obtain passive flap closure. The exposed connective tissue was covered by connecting the adjacent flap margins with additional sutures.
89600772|NCT04690140|Active Comparator|epithelialized free gingival graft|A partial-thickness flap was elevated (blade #15c) with horizontal incisions at the cemento-enamel junction level of the adjacent teeth. Then, two vertical incisions extending to the apical were made from two ends of the horizontal incision. The epithelium in the framed region was removed with a scalpel and the underlying connective tissue was exposed. To achieve the best vascularization from the recipient site, bed preparation was completed with a split-thickness horizontal incision that joins the vertical incisions in the apical region.
89600773|NCT04676529|Experimental|PXS-5505, Dose Level 1, Escalation Phase (Cohort A)|Patients will receive PXS-5505 dose level 1, twice daily for a period of 4 weeks.
89600774|NCT04676529|Experimental|PXS-5505, Dose Level 2, Escalation Phase (Cohort B)|Patients will receive PXS-5505 dose level 2, twice daily for a period of 4 weeks.
89600775|NCT04676529|Experimental|PXS-5505, Dose Level 3, Escalation Phase (Cohort C)|Patients will receive PXS-5505 dose level 3, twice daily for a period of 4 weeks.
89600776|NCT04676529|Experimental|PXS-5505, Expansion Phase|All patients will receive PXS-5505 at the selected twice daily dose for a period of 24 weeks, or until progressive disease, unacceptable toxicity, dose-limiting toxicity or withdrawal of consent.
89600777|NCT04676529|Experimental|PXS-5505, Add-on Phase|Patients already receiving a stable dose of ruxolitinib for at least 12 weeks, will receive PXS-5505 (the dose used in the cohort expansion phase) on top of their ruxolitinib dose for up to 52 weeks or until progressive disease, unacceptable toxicity, dose-limiting toxicity, or withdrawal of consent.
89600778|NCT04675775|Experimental|Medically-tailored meals|Participants will receive meals that adhere to their specified nutritional targets dependent upon their cirrhosis complication of hepatic encephalopathy (HE) and/or ascites. Participants with HE will receive high-protein (approximately 1 gram of medication per kilogram of the body weight (1g/kg/day) and high-calorie (approximately 30c/kg/day) meals. Participants with HE and ascites will receive high-protein and high-calorie meals that are also low-sodium (less than or equal to 2000 milligrams a day).
89600779|NCT04667715|Active Comparator|Exablate Test Arm|Subjects will undergo ExAblate BBBD prior to their standard of care tumor removal
89600780|NCT04667715|No Intervention|Control Test Arm|Subjects will undergo their standard of care tumor removal
89600781|NCT04667494|Experimental|Sonotherapy|All participants will undergo sonotherapy
89600782|NCT04662931|Experimental|Crizanlizumab|Participants will receive Crizanlizumab at a dose of 5.0 mg/kg.
89600783|NCT04657289|Experimental|Arm A [Q36W] 36-weeks between refill-exchange procedures|Participants randomized to the Q36W arm will receive PDS implant refill-exchange procedures (ranibizumab 100 mg/mL) on a Q36W fixed interval.
89600784|NCT04657289|Active Comparator|Arm B [Q24W] 24-weeks between refill-exchange procedures|Participants randomized to the Q24W arm will receive PDS implant refill-exchange procedures (ranibizumab 100 mg/mL) on a Q24W fixed interval.
89600785|NCT04652960|Experimental|Treatment (duvelisib, nivolumab)|Patients receive duvelisib PO QD or BID on days 1-28 or days 1-14 and nivolumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo PET-CT or CT scan at baseline. Patients also undergo punch biopsy and collection of blood samples throughout the trial.
89600786|NCT04648878|Experimental|Group A - Hybrid combination|Group A (n=12) will receive 18 alternating visits of conventional physical therapy and powered exoskeleton gait training with a wearable robotic powered exoskeleton , three times a week for approximately 6 weeks.
89600787|NCT04648878|Experimental|Group B - Powered Exoskeleton only|Group B (n=12) will receive 18 visits of powered exoskeleton only, three times a week for approximately 6 weeks.
89600788|NCT04648878|Experimental|Group C - Physical Therapy only|Group C (n=12) will receive 18 visits of physical therapy, three times a week for approximately 6 weeks. Upon completion of the data collection portion of the study, group C will receive 9 sessions, three times a week for approximately three weeks of powered exoskeleton therapy. Data will not be collected or reported during this phase, but but may be retained for future approved use.
89600789|NCT04638816|Experimental|Restylane Volyme|Hyaluronic Acid
89600790|NCT04638816|Experimental|Restylane Lyft Lidocaine|Hyaluronic Acid
89600791|NCT04637763|Experimental|Dose Escalation of CB-010|Patients with relapsed or refractory non-Hodgkin lymphoma will receive CB-010 following lymphodepletion.
89600792|NCT04637763|Experimental|Expansion of CB-010|Patients with relapsed or refractory non-Hodgkin lymphoma will receive CB-010 following lymphodepletion.
89600793|NCT04618367|Experimental|HAIC plus Lenvatinib and Sintilimab|Hepatic arterial infusion of oxaliplatin , fluorouracil, and leucovorin every 6 weeks. Lenvatinib 12 mg (or 8 mg) once daily (QD) oral dosing. Toripalimab 200 mg intravenously every 3 weeks.
89032104|NCT02949089|Experimental|ACH04|Dosage: 1 capsule, PO, 24/24h for 10 days.
89600794|NCT04614558|Experimental|Isatuximab for MGRS|Subjects will receive Isatuximab for 6 months and will be followed for an additional one year post therapy for outcome follow-up.
89600795|NCT04612699|Experimental|Jaktinib 50mg Bid|Jaktinib 50mg Bid+ Placebo 50mg Bid+ Placebo 75mg Bid
89600796|NCT04612699|Experimental|Jaktinib 75mg Bid|Jaktinib 75mg Bid+ Placebo 50mg*2 Bid
89600797|NCT04612699|Experimental|Jaktinib 100mg Bid|Jaktinib 50mg*2 Bid+ Placebo 75mg Bid
89600798|NCT04612699|Placebo Comparator|Placebo|Placebo 50mg*2 Bid+ Placebo 75mg Bid
89600799|NCT04612179||All Comer Patients|All-comer patients (≥80 years) affected by acute coronary syn-drome (NSTE-ACS), stabile angina, or silent angina, who qualify for percutaneous coronary intervention (PCI) according to ESC-treatment guidelines and physicians' clinical routine estimation.
89032105|NCT02940210|Experimental|Mediclore®|adhesion barrier Mediclore 5cc, to apply medical device fully around thyroid gland following thyroidectomy
89032106|NCT02940210|No Intervention|No treatment|No treatment, standard treatment for thyroidectomy
89600800|NCT04609046|Experimental|Treatment (rituximab, methotrexate, lenalidomide, nivolumab)|"INDUCTION: Patients receive rituximab IV on day 1, methotrexate IV over 2 hours or PO on day 2, lenalidomide PO daily on days 5-14, and nivolumab IV over 30 minutes on day 14. (In dose level IV that includes nivolumab, the doses of rituximab for cycles 2-6 may be given on the same day as nivolumab for the previous cycle). Treatment repeats every 14 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients who achieve complete response, partial response, or stable disease proceed to maintenance therapy.~MAINTENANCE: Within 6 weeks after the last dose of lenalidomide in induction therapy, patients receive lenalidomide PO daily on days 1-21, and nivolumab IV over 30 minutes on day 1. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.~Patients also undergo MRI, CT, PET/CT, lumbar puncture, bone marrow aspirate and biopsy, testicular ultrasound and ECHO. (See Detailed Description)"
89600801|NCT04608318|Experimental|I (Ibrutinib)|Ibrutinib p.o. will be administered until occurrence of unacceptable toxicity, progression of CLL or end of trial, whichever occurs first.
89600802|NCT04608318|Experimental|VG (Obinutuzumab + Venetoclax)|12 cycles (q 28d): Obinutuzumab i.v. + Venetoclax p.o. will be administered for 6 cycles, followed by 6 additional cycles of Venetoclax alone
89600803|NCT04608318|Experimental|VI (Venetoclax + Ibrutinib)|15 cycles (q 28d): Ibrutinib p.o. + Venetoclax p.o. will be administered for a total of 12 cycles with a prior Ibrutinib monotherapy lead-in of 3 cycles
89600804|NCT04605185|Experimental|Donafenib/JS001/TACE|Donafenib and JS001 Combined With TACE
89600805|NCT04604548|Experimental|Open Label treatment|Oral administration of 100 mg KH176 twice daily
89600806|NCT04601584|Experimental|GNR-084, dose level 1|Anti-CD19/CD3 antibody
89600807|NCT04601584|Experimental|GNR-084, dose level 2|Anti-CD19/CD3 antibody
89600808|NCT04601584|Experimental|GNR-084, dose level 3|Anti-CD19/CD3 antibody
89600809|NCT04601584|Experimental|GNR-084, dose level 4|Anti-CD19/CD3 antibody
89600810|NCT04601584|Experimental|GNR-084, dose level 5|Anti-CD19/CD3 antibody
89600811|NCT04601584|Experimental|GNR-084, dose level 6|Anti-CD19/CD3 antibody
89600812|NCT04597294|Experimental|Perioperative FLOT + prophylactic HIPEC + surgery|After 4 doses of preoperative FLOT chemotherapy diagnostic laparoscopy will be performed - patients without distant metastases will be randomised, in those randomised to experimental arm HIPEC with irinotecan will be performed (a dose of 300 mg/m2 body surface area will be administered over 45 minutes at a temperature of 42 degrees Celsius)
89600813|NCT04597294|Active Comparator|Perioperative FLOT + surgery|Standard treatment regimen for advanced gastric cancer
89600814|NCT04595747|Experimental|Treatment (rogaratinib)|Patients receive rogaratinib PO BID on days 1-28 of each cycle. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo biopsy at baseline and progression and CT, MRI, and PET-CT every 8 weeks. Patients may also undergo blood sample collection on study.
89600815|NCT04593498||ESVEA|ESVEA (Excessive supraventricular ectopic activity): Participants with at least 30 supraventricular extra systole (SVES)/h or a supraventricular run of at least 20 beats.
89600816|NCT04593498||Non-ESVEA|Participants not meeting inclusion criteria
89600817|NCT04587791|Active Comparator|CBD 400mg|CBD 400 mg
89600818|NCT04587791|Active Comparator|CBD 800mg|CBD 800mg
89600819|NCT04587791|Active Comparator|CBD 1200mg|CBD 1200mg
89600820|NCT04587791|Placebo Comparator|Saline|saline
89600821|NCT04586478|Experimental|Single dose of CNCT19|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by investigational treatment, CNCT19.
89600822|NCT04581473|Experimental|CT041 autologous CAR T-cell injection|Two stages: Phase 1b: dose escalation and dose expansion; Phase 2: verify CT041 efficacy and safety
89600823|NCT04581473|Active Comparator|Physician's Choice|Participants will receive physician's choice of treatment in Phase II
89600824|NCT04580121|Experimental|Part A: Single Participant Dose Escalation|Participants from Group I will receive escalating doses of RO7283420, once every 3 weeks (Q3W) starting on Cycle 1, Day 1 (C1D1) for up to 6 cycles with a starting dose of 0.15mg.
88980257|NCT05996549|No Intervention|Control arm ( unvaccination arm)|In the control hospital, the investigators are also enrolling participants meeting the high-risk group individual criteria. However, no vaccination campaigns are conducted.
88980258|NCT05996510|Active Comparator|diseased shoulder|
88980259|NCT05996510|Active Comparator|sturdy shoulder|
88980260|NCT05996484|Experimental|Neoadjuvant Anlotinib Combined With Toripalimab and Chemotherapy|Toripalimab+ Anlotinib+Albumin-bound paclitaxel+Cisplatin
88980261|NCT05996445|Experimental|Dose Escalation and Expansion XmAb662 administered as monotherapy|
88980262|NCT05996445|Experimental|Dose Escalation and Expansion XmAb662 administered in combination with pembrolizumbab|
88980263|NCT05996432|Experimental|Locally Advanced Squamous Cell Carcinoma of the Head and Neck|Participants will undergo magnetic resonance imaging (MRI) scans and positron emission tomography (PET) scans and administered the imaging agent 18F-fluoromisonidazole.
88980264|NCT05996432|Experimental|Brain metastases|Participants will undergo magnetic resonance imaging (MRI) scans and positron emission tomography (PET) scans and administered the imaging agent 18F-fluoromisonidazole.
88980265|NCT05996406|Experimental|Ven-D|Venetoclax combined with dexamethasone
88980266|NCT05996393|Experimental|CsA+ATG+AVA|Ciclosporine: 3-5 mg/kg/d orally, with ciclosporine trough concentrations maintained at 100-200 ng/ml for 3 months to achieve maximum efficacy and then tapered; Anti-human thymocyte: rabbit anti-human thymocyte globulin (r-ATG 3mg/kg/d) was administered intravenously for 5 days; Avatrombopag:60 mg/d orally, for a total of 24 weeks. Adjust the dose according to the platelet counts of patients.
89600825|NCT04580121|Experimental|Part B: Multiple Participant Dose Escalation|Multiple-participant cohorts of >= 3 participants will be enrolled for dose escalation for Group I and Group II independently. Participants will be administered a starting dose of 0.15 mg or highest dose administered in Part A. Each participant will receive up to 6, 9, and 18 cycles of treatment with RO7283420, when treated with Q3W, every-2-weeks (Q2W), or once-a-week (QW) dosing regimens, respectively to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D). Additionally, step-up dosing regimens with more frequent administrations of RO7283420 during cycle 1 will be evaluated.
89600826|NCT04580121|Experimental|Part C: Dose Expansion|Participants will receive the respective RP2D for Group I and Group II.
89600827|NCT04576091|Experimental|Treatment (pembrolizumab, BAY 1895344, SBRT)|Patients receive pembrolizumab IV over 30 minutes on day 1 of each cycle. Starting on day 7, patients also receive BAY 1895344 PO BID on days 7-9 and 14-16 during cycle 1, and before and after each SBRT treatment during cycle 2 for a total of 9 doses. Beginning cycle 2, patients undergo SBRT starting between days 2 and 8 for 3 fractions with 2-3 days between fractions. Treatment repeats every 21 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT scan and/or PET-CT scan and collection of blood samples throughout the trial.
89600828|NCT04572854|Experimental|Group 1|Pegcetacoplan treatment of 1080 mg (sub-cutaneous infusion) twice weekly will be given throughout the entire study.
89600829|NCT04572854|Other|Group 2|No intervention given during the randomized controlled portion of the study (through week 12). After week 12, subjects will receive pegcetacoplan treatment.
89600830|NCT04564703|Experimental|cohort 1|Iberdomide will be given orally at 1.3 mg/day, from day 1 to 21 of a 28-day cycle, continuously, until progressive disease (PD) or unacceptable toxicity.
89600831|NCT04564703|Experimental|cohort 2|Iberdomide will be given orally at 1.0 mg/day, from day 1 to 21 of a 28-day cycle, continuously, until progressive disease (PD) or unacceptable toxicity.
89032107|NCT02948816|Experimental|Facebook|Participants will spend 30 minutes interacting with a Facebook page that is made up of 20% food-related posts, and 80% non food-related posts (news, sports, etc). They will be provided with bowls of snacks, which will be weighed before and after their session.
89600832|NCT04564703|Experimental|cohort 3|Iberdomide will be given orally at 0.75 mg/day, from day 1 to 21 of a 28-day cycle, continuously, until progressive disease (PD) or unacceptable toxicity.
89600833|NCT04550494|Experimental|Treatment (talazoparib)|Patients receive talazoparib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo biopsy and blood sample collection throughout the study. Patients undergo CT scan or MRI throughout the study.
89600834|NCT04544748|Other|Cohort 1|GNR-051 (0.1 mg/kg)
89600835|NCT04544748|Other|Cohort 2|GNR-051 (0.3 mg/kg)
89600836|NCT04544748|Other|Cohort 3|GNR-051 (1 mg/kg)
89600837|NCT04544748|Other|Cohort 4|GNR-051 (3 mg/kg)
89600838|NCT04544748|Other|Cohort 5|GNR-051 (10 mg/kg)
89600839|NCT04543097|No Intervention|Usual care|Participants randomised to the usual care arm will continue to receive care as usual for their health and vocational needs. For most patients, this will comprise usual clinical care, without formal vocational advice.
89600840|NCT04543097|Experimental|Usual care plus vocational support|Vocational support following a stepped care model based on the principles of case management in addition to usual primary care.
89600841|NCT04541017|Experimental|Arm I (magrolimab, mogamulizumab), Phase Ib and Phase II|Patients receive magrolimab IV over 2-3 hours weekly during cycles 1-2, then Q2W during cycles 3-12. Patients also receive mogamulizumab IV over at least 60 minutes weekly during cycle 1, then Q2W during cycles 2-12. Cycles repeat every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo PET/CT or diagnostic CT, blood sample collection, and may undergo a skin punch biopsy during screening and on study.
89600842|NCT04541017|Active Comparator|Arm II (mogamulizumab), Phase II|Patients receive mogamulizumab IV over at least 60 minutes weekly during cycle 1, then Q2W during cycles 2-12. Cycles repeat every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients who have received at least 2 full treatment cycles and have PD or have received at least 6 full treatment cycles and have SD may crossover to Arm I. Patients undergo PET/CT or diagnostic CT, blood sample collection, and may undergo a skin punch biopsy during screening and on study.
89600843|NCT04539938|Experimental|Single Arm|Tucatinib + trastuzumab deruxtecan
89600844|NCT04536298|Active Comparator|Vitamin D|Daily vitamin D3 (9600 IU/day on days 1 and 2; 3200 IU/day on days 3 through 28)
89600845|NCT04536298|Placebo Comparator|Placebo|Placebo
89600846|NCT04530032|Experimental|TBI KD/MAD|TBI subjects on a ketogenic/modified Atkins diet
89600847|NCT04530032|Sham Comparator|TBI SD|TBI subjects on a standard (normal) diet
89600848|NCT04526899|Experimental|BNT111 + cemiplimab|
89032108|NCT02948816|Experimental|Facebook + Food|Participants will spend 30 minutes interacting with a Facebook page that is made up of 70% food-related posts, and 30% non food-related posts (news, sports, etc). They will be provided with bowls of snacks, which will be weighed before and after their session.
89032109|NCT02948816|Active Comparator|Colouring|Participants will spend 30 minutes colouring. They will be provided with bowls of snacks, which will be weighed before and after their session.
89032110|NCT04880694|Experimental|Cohort 1: STC3141 58.3mg/hr|Drug: STC3141 Continuous infusion of STC3141 at rate 58.3mg/hr up to 3 days (72 hours) N=10
89032111|NCT04880694|Experimental|Cohort 2: STC3141 87.5mg/hr|Drug: STC3141 Continuous infusion of STC3141 at rate 87.5mg/hr up to 3 days (72 hours) N=10
89032112|NCT04880694|No Intervention|Cohort 3: Comparator|Only to receive appropriate standard of care N=5
89032113|NCT00520442|Experimental|Ibuprofen|
89032114|NCT00520442|Active Comparator|acetamin w codeine|
89600849|NCT04526899|Experimental|BNT111 monotherapy|
89600850|NCT04526899|Experimental|Cemiplimab monotherapy|
89600851|NCT04525755|Experimental|Varenicline (.5mg BID)|Participants will be randomized in a 2:1:1 ratio to receive a 4-week sample of varenicline (.5 mg, 60 tablets total), NRT, or not, with outcomes assessed through 12 weeks of follow-up. 324 participants will be enrolled in this group. Participants in the varenicline sampling group will be given standard instructions on titration but ultimately will decide on their own as to if and how it is used. Dosing is lower than most industry trials of varenicline (1mg BID) but consistent with two trials of lower dosing that showed efficacy and with fewer side effects. Varenicline participants can choose to titrate 2mg if they wish, with shorter duration of sampling experience.
89600852|NCT04525755|Active Comparator|Nicotine Replacement Therapy (NRT)|Participants will be randomized in a 2:1:1 ratio to receive a 4-week sample of varenicline, NRT, or not, with outcomes assessed through 12 weeks of follow-up. 162 participants will be enrolled in this group. Participants in NRT group will receive 28 day supply of nicotine patch (1patch x 28 days @ 14mg) and lozenge (14 per day x 28 days @4mg) with instructions to use based on number of cigarettes smoked per day. Like varenicline participants, smokers in NRT group can use as much or as little of the NRT as they wish.
89600853|NCT04525755|No Intervention|Control Group|Participants will be randomized in a 2:1:1 ratio to receive a 4-week sample of varenicline, NRT, or not, with outcomes assessed through 12 weeks of follow-up. 162 participants will be enrolled in this group.
88980267|NCT05996393|Experimental|CsA+AVA|Ciclosporine: 3-5 mg/kg/d orally, with ciclosporine trough concentrations maintained at 100-200 ng/ml for 3 months to achieve maximum efficacy and then tapered; Avatrombopag:60 mg/d orally, for a total of 24 weeks. Adjust the dose according to the platelet counts of patients.
88980268|NCT05996367|Experimental|Single Arm|Single-dose radiation to involved-site
88980269|NCT05996328|Active Comparator|Control|Study-defined standard of care
88980270|NCT05996328|Experimental|Home-delivered meals and short-term dietary counseling|Home-delivered, low-sodium, nutritionally robust meals for 6 weeks plus two additional remotely delivered dietary counseling sessions in addition to the study-defined standard of care.
88980271|NCT05996237||Registry participants|Participants in the University of Pittsburgh Claude D. Pepper Center community research registry. Potential participants will have stable regimens of 5+ prescribed medications and recent physician contact but no hospitalization in the prior 6 months.
88980272|NCT05996224|Experimental|Mesenchymal progenitor cells|Mesenchymal progenitor cells group
88980273|NCT05996224|Active Comparator|Sodium hyaluronate|Sodium hyaluronate injection group
88980274|NCT05996146||hoarseness group|"This study recruited all patients admitted at Seoul National University Hospital.~Age range is 20 to 80 years old. Patients who require surgical treatment for degenerative spine conditions. Patients who voluntarily consent to participate in the study."
88980275|NCT05995743||Cases: Children with sickle cell disease|Children aged 6 to 17 years with a confirmed diagnosis of sickle cell disease (i.e., homozygous HbS/S or heterozygous HbS/C mutations)
88980276|NCT05995743||Controls: Healthy children referred for a non-severe functional symptom linked to exercise|Children aged 6 to 17 years with a completely normal check-up, including physical examination, ECG, echocardiography, and spirometry. Children with any chronic disease, medical condition, or medical treatment and those requiring any further specialized medical consultation were not eligible.
88980277|NCT05995587|Experimental|MBCT (mindfulness teacher)|Participants in the MBCT (mindfulness teacher) group will receive mindfulness training from a certified mindfulness teacher.
88980278|NCT05995587|Experimental|MBCT (social workers)|Participants in the MBCT (social workers) group will receive mindfulness training from social workers (supervised by a certified mindfulness teacher).
88980279|NCT05995587|No Intervention|Care as usual group|The care as usual group will receive usual service provided in District Elderly Community Centres (DECC) and Integrated Community Centre for Mental Wellness (ICCMW).
88980280|NCT05995392|Experimental|Treatment|Subjects receive topical spironolactone ophthalmic solution, 0.005 mg/cc four times a day for 4 weeks.
88980281|NCT05995392|Placebo Comparator|Placebo|Subjects receive topical spironolactone vehicle as placebo four times a day for 4 weeks.
88980282|NCT05995314|Placebo Comparator|PLACEBO|placebo (0 mg/kg of body mass of caffeine). The capsule will be filled with 3 mg/kg of body mass of cellulose.
88980283|NCT05995314|Experimental|3mg/kg|3 mg/kg of body mass of caffeine (99% caffeine, Bulkpowders, United Kingdom).
88980284|NCT05995314|Experimental|6mg/kg|6 mg/kg of body mass of caffeine (99% caffeine, Bulkpowders, United Kingdom).
89032115|NCT02948894|Experimental|MAD|Mandibular advancement device. A dentist, who is otherwise not involved in HF care, will open a sealed envelope at the time of randomization and program the MAD device accordingly. Each mode will be maintained for 3 months
88980285|NCT05995288||Children suffering from PFAPA|Children suffering from periodic fever, with at least one of the following symptoms: aphthous stomatitis, pharyngitis, cervical adenitis
88980286|NCT05995119|Other|Comparative Bioavailability of apixaban film (TAH3311) and Eliquis Tablet in fed conditions|
88980287|NCT05995119|Other|Comparative Bioavailability of apixaban film (TAH3311) and Eliquis Tablet in fast conditions|
88980288|NCT05995028|Experimental|Universal 4SCAR7U cells to treat CD7-positive hematological malignancies|
88980289|NCT05994092|Experimental|Experimental|
88980290|NCT05994092|No Intervention|Control|
88980291|NCT05993468||TMC - group 1|TMC - group 1 was a closed group treated at a specialized outpatient facility for adult clients with CPTSD and complex dissociative disorders. Group 1 was led by two clinical psychologists
89600854|NCT04522323|Experimental|Dose Exploration|The Dose exploration Phase is made up of Part A, B and Part C. Part A will evaluate the safety and tolerability of MEDI5752 in combination with Axitinib (2 patients), and Part B and C will evaluate the safety and tolerability of MEDI5752 in combination with Lenvatinib (~72 patients)
89600855|NCT04522323|Experimental|Dose Expansion|Evaluate safety and anti-tumor activity of MEDI5752 in combination with Lenvatinib (~105 patients )
89600856|NCT04514497|Experimental|Cohort I (elimusertib, irinotecan)|Patients receive elimusertib PO BID on days 1 and 2 and irinotecan IV over 90 minutes on day 1 of each cycle. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT and/or MRI throughout the study, tumor biopsy at screening and on study, and collection of blood samples at screening.
89600857|NCT04514497|Experimental|Cohort II (elimusertib, irinotecan)|Patients receive elimusertib PO QD on days 2, 3, 9, 10, 16, and 17 of cycle 1 and 2, and on days 2, 3, 9, and 10 of each cycle thereafter. Patients receive irinotecan IV over 90 minutes on days 1, 8, and 15 of cycle 1 and 2, and on days 1 and 8 of each cycle thereafter. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT and/or MRI throughout the study, tumor biopsy at screening and on study, and collection of blood samples at screening.
89600858|NCT04514497|Experimental|Cohort III (elimusertib, topotecan)|Patients receive elimusertib PO QD on days 2 and 5 and topotecan IV over 30 minutes on days 1-5 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT and/or MRI throughout the study, tumor biopsy at screening and on study, and collection of blood samples at screening.
89600859|NCT04514484|Experimental|Treatment (cabozantinib s-malate, nivolumab)|Patients receive cabozantinib s-malate PO QD on days 1-28 of each cycle and nivolumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 28 days for up to 1 year or 1 year after a partial response is achieved, or 6 months after a complete response is achieved in the absence of disease progression or unacceptable toxicity. Patients also undergo a CT scan and/or MRI as well as blood sample collection throughout the trial.
89600860|NCT04509167|Experimental|Treatment|Patients will receive intradermal injection of individualized neoantigen peptides vaccine at a dose of ~500ug per peptide once a week for 8 weeks.
89600861|NCT04506151|Experimental|Sleep-Opt|12-week intervention that includes self-monitoring, goal setting, motivational enhancement.
89600862|NCT04506151|Active Comparator|Healthy Living|12-week intervention that includes weekly telephone contact, didactic content equal in time and attention to intervention group.
89600863|NCT04505566|Experimental|Adult Type II Diabetics - Moderate NPDR - Ketorolac|59 Adult type II diabetic patients with baseline moderate non-proliferative diabetic retinopathy and HbA1c ≥ 8 randomized to Ketorolac treatment.
89600864|NCT04505566|Placebo Comparator|Adult Type II Diabetics - Moderate NPDR - Placebo|59 Adult type II diabetic patients with baseline moderate non-proliferative diabetic retinopathy randomized to placebo treatment.
89600865|NCT04505566|Other|Adult Type II Diabetics - No Diabetic Retinopathy (DR)|23 Adult type II diabetic patients with no diabetic retinopathy as a control group.
89600866|NCT04505566|Other|Adult Type 2 Diabetics-Proliferative Diabetic Retinopathy(PDR)|23 Adult type II diabetic patients with proliferative diabetic retinopathy as a control group.
89600867|NCT04505566|Other|Age-matched Non-diabetics|We will also enroll 100 age-matched patients without diabetes who are undergoing unilateral vitrectomy surgery for non-inflammatory conditions such as epiretinal membrane or macular hole. Removed aqueous fluid that is typically discarded will instead be collected and stored at -80° C. Aqueous fluid will be tested for inflammatory markers as detailed below to provide a reference level for cross-comparison analysis.
89600868|NCT04495556||Typical|Patients with typical symptom onset including: acute unilateral optic neuritis, double vision due to an internuclear ophthalmoplegia or sixth nerve palsy, facial sensory loss or trigeminal neuralgia in a young adult (<40 years of age), cerebellar ataxia and nystagmus, partial myelopathy, sensory symptoms in a CNS (central nervous system) pattern, Lhermitte's symptom, asymmetric limb weakness, urge incontinence or erectile dysfunction, or other neurological presentation considered to be typical by the site investigator.
88980292|NCT05993468||TMC - group 2|TMC - group 2 was connected to specialized mental health services, but the intervention itself was carried out at a community centre. The community centre has collaborated with the District Psychiatric Centre (DPS) for many years, hosting an TMC group open to anyone attending the community centre in addition to clients connected to the DPS. This open concept was continued through the study intervention, but only clients connected to the DPS were included in the study.
88980293|NCT05993325|Experimental|1 dose of AdCLD-CoV19-1 OMI|Test group will receive 1 dose of AdCLD-CoV19-1 OMI
88980294|NCT05993325|Active Comparator|1 dose of Comirnaty Bivalent|Control group will receive 1 dose of Comirnaty Bivalent
88980295|NCT05992961||Patients not undergoing troponin I surveillance|Patients undergoing acute high-risk abdominal surgery during the period February 1, 2018, to February 28, 2019. No troponin I measurements were made.
88980296|NCT05992961||Patients undergoing troponin I surveillance|Patients undergoing acute high-risk abdominal surgery during the period March 1, 2019, to February 28, 2021 as well as postoperative troponin I surveillance .
88980297|NCT05992558||Very elderly HFpEF|Prospective cohort of very elderly patients (≥80 years old) with heart failure with preserved ejection fraction (HFpEF) consecutively admitted for acute HF
88980298|NCT05992545|Experimental|Mobile application 'DangDang Care' under usual care|The intervention group receives 'DangDang Care' alongside usual diabetes care.
88980299|NCT05992545|No Intervention|Usual care|The control group receives only usual diabetes care.
88980300|NCT05992389||Children with asthma|School aged participants (6-14 yrs) with an established diagnosis of asthma
88980301|NCT05992389||Non-asthmatic subjects (healthy control)|School aged participants (6-14 yrs), non-asthmatic subjects (negative history of allergic diseases)
88980302|NCT05991804|Active Comparator|Inpatient rehabilitation alone|Standard inpatient rehabilitation received at the Royal National Orthopaedic Hospital NHS Trust
88980303|NCT05991804|Experimental|Transcutaneous spinal cord stimulation added to inpatient rehabilitation|Transcutaneous spinal cord stimulation added to standard inpatient rehabilitation, targetting the upper limbs, received at the Royal National Orthopaedic Hospital NHS Trust
88980304|NCT05991492|Active Comparator|Web-based Cognitive Behavioral Therapy for Insomnia (wCBT-I) with general sleep education|
88980305|NCT05991492|No Intervention|General Sleep Education|
89600869|NCT04495556||Atypical|Patients with atypical onset including: bilateral optic neuritis or unilateral optic neuritis with a poor visual recovery, complete gaze palsy or fluctuating ophthalmoparesis, intractable nausea, vomiting, or hiccups, complete transverse myelopathy with bilateral motor and sensory involvement, encephalopathy, subacute cognitive decline, headache or meningismus, isolated fatigue or asthenia, constitutional symptoms, other clinical presentations considered atypical by the site investigator (examples include: vague or patchy sensory symptoms, pain, short lasting bilateral blurred vision, etc.), or absence of clinical symptoms with MRI features suggestive of MS.
89600870|NCT04494282|Active Comparator|Same day|The ERP will be performed the same day of the endoscopic drainage of PP
89600871|NCT04494282|Active Comparator|Other day|The ERP will be performed 6 weeks after the endoscopic drainage of PP.
89600872|NCT04486378|Experimental|RO7198457|Participants will receive a recommended dose of RO7198457.
89600873|NCT04486378|Other|Observational Group|Observational group will undergo watchful waiting, which is the standard of care in this setting.
89600874|NCT04486378|Experimental|Biomarker Cohort|15 patients
89600875|NCT04486378|Experimental|Exploratory Cohort|20 patients
89600876|NCT04483297|Experimental|AK1320 MS|AK1320 MS + Local Autologous Bone + Posterior Fixation
89600877|NCT04483297|Other|Control|Local Autologous Bone + Posterior Fixation
89600878|NCT04463914|Other|Group A- Treatment as Usual|Participants in the treatment as usual group will be provided educational material about mood management available via the EHR with the suggestion to discuss questions with their PCP. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment.
89600879|NCT04463914|Experimental|Group B- Moodivate|Participants randomized to the Moodivate condition will be instructed to utilize Moodivate regularly, at least once per day, for the treatment of depressed mood. Participants in the Moodivate group will receive a download code to download the Moodivate mobile application. Moodivate is a mobile app for individuals with elevated symptoms of depression. Within the app, users identify values, create activities, schedule activities, and rate mood daily. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment.
89600880|NCT04463914|Experimental|Group C- Moodivate + EHR|Participants randomized to the Moodivate + EHR condition will receive similar instructions as those randomized to Moodivate, but will also be instructed that their PCP will have access to metrics related to their app utilization and may choose to follow-up with them regarding treatment utilization and response. The PCP for each participant randomized to this condition will be provided EHR access to Moodivate metrics which will include metrics related to change in mood, frequency of app utilization, and frequency of activity completion. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment.
89600881|NCT04445363|Experimental|Cohort 1,0.5% Bid|Jaktinib hydrochloride cream 0.5% concentration, twice daily
89600882|NCT04445363|Experimental|Cohort 1,1.5% Bid|Jaktinib hydrochloride cream 1.5% concentration, twice daily
89600883|NCT04445363|Experimental|Cohort 1,2.5% Qd|Jaktinib hydrochloride cream 2.5% concentration, once daily
89600884|NCT04445363|Experimental|Cohort 1,2.5% Bid|Jaktinib hydrochloride cream 2.5% concentration, twice daily
89600885|NCT04445363|Placebo Comparator|Dose extension: Placebo|Placebo, twice daily
89600886|NCT04445363|Experimental|Dose extension: 1.5% Bid|Jaktinib hydrochloride cream 1.5% concentration, twice daily
89600887|NCT04445363|Experimental|Dose extension: 2.5% Bid|Jaktinib hydrochloride cream 2.5% concentration, twice daily
89600888|NCT04444622|Experimental|AlloStim|"AlloStim is administered in three cycles:~Cycle 1 Day 0: 0.5ml ID AlloStim® Day 7: 0.5ml ID AlloStim® Day 14: 0.5ml ID AlloStim® Day 21: 0.5ml ID AlloStim® Day 28: 0.5ml ID AlloStim®~Cycle 2 Day 42: 0.5ml ID AlloStim® Day 49: 0.5ml ID AlloStim® Day 56: 0.5ml ID AlloStim® Day 63: 0.5ml ID AlloStim® Day 70: 0.5ml ID AlloStim® + 3ml IV AlloStim®~Cycle 3 Day 84: 0.5ml ID AlloStim® Day 91: 0.5ml ID AlloStim® Day 98: 0.5ml ID AlloStim® Day 105: 0.5ml ID AlloStim® Day 112: 0.5ml ID AlloStim® + 3ml IV AlloStim®"
89600889|NCT04435392|Experimental|Part 1: Cohort 1, 0.5% Jaktinib Bid|Subjects were randomly assigned to receive either Jaktinib cream or a placebo in a ratio of 3 to 1.The Jaktinib hydrochloride 0.5% Cream will be applied topically twice daily.
89032116|NCT02948894|Placebo Comparator|Sham-MAD|Mandibular advancement device (non-advanced device). A dentist, who is otherwise not involved in HF care, will open a sealed envelope at the time of randomization and program the MAD device accordingly. Each mode will be maintained for 3 months
89032117|NCT04870320|Experimental|Arm I (Endeavor)|Patients play Endeavor over 25 minutes daily 5 days a week for 4 weeks.
89032118|NCT04870320|Active Comparator|Arm II (Words!)|Patients play Words! over 25 minutes daily 5 days a week for 4 weeks.
89032119|NCT03458013|Experimental|Mindfulness Meditation plus Hand Therapy|Participants will be recruited from patients suffering from a traumatic injury who are entering hand therapy at a community based clinic in the Los Angeles area.
89032120|NCT03458013|No Intervention|Standard Care in Hand Therapy|Participants will be recruited from patients suffering from a traumatic injury who are entering hand therapy at a community based clinic in the Los Angeles area.
89032121|NCT02948738|Experimental|Interactive Education|Interactive asthma education
89032122|NCT02948738|Active Comparator|Standard Education|Standard asthma education
89032123|NCT02938572|Experimental|NNC0143-0406|
89032124|NCT02938572|Active Comparator|Insulin aspart|
88980306|NCT05991271|Experimental|procedure|implant valve by TAVR
88980307|NCT05991128|Experimental|Ferric derisomaltose|"Iron to be administered as ferric derisomaltose.~The treatment dose (mL) to be administered will be determined by the patient's body weight and haemoglobin (Hb) value.~Where Hb ≥10 g/dL, dosage according to body weight is as follows:~Body weight <50 kg: 20 mg/kg; Body weight 50 to <70 kg: 1000 mg; Body weight ≥70 kg: 20 mg/kg up to a maximum of 1500 mg.~Where Hb <10 g/dL, dosage according to body weight is as follows:~Body weight <50 kg: 20 mg/kg; Body weight 50 to <70 kg: 20 mg/kg; Body weight ≥70 kg: 20 mg/kg up to a maximum of 2000 mg.~Infused over a minimum of 15mins for doses up to and including 1000mg, and a minimum of 30 mins for doses >1000mg"
89600890|NCT04435392|Experimental|Part 1: Cohort 2,1.5% Jaktinib Bid|Subjects were randomly assigned to receive either Jaktinib cream or a placebo in a ratio of 3 to 1.The Jaktinib hydrochloride 1.5% Cream will be applied topically twice daily.
89600891|NCT04435392|Experimental|Part 1: Cohort 3, 2.5% Jaktinib Qd|Subjects were randomly assigned to receive either Jaktinib cream or a placebo in a ratio of 3 to 1.The Jaktinib hydrochloride 2.5% Cream will be applied topically Once daily.
89600892|NCT04435392|Experimental|Part 1: Cohort 4, 2.5% Jaktinib Bid|Subjects were randomly assigned to receive either Jaktinib cream or a placebo in a ratio of 3 to 1.The Jaktinib hydrochloride 2.5% Cream will be applied topically twice daily.
89600893|NCT04435392|Placebo Comparator|Dose extension: Vehicle Control|the Vehicle Control cream will be applied topically twice daily
89600894|NCT04435392|Experimental|Dose extension: low-dose group, X%|X% based on results of part 1. The Jaktinib Hydrochloride X% Cream will be applied topically twice daily
89600895|NCT04435392|Experimental|Dose extension: high-dose group, Y%|Y% based on results of part 1. The Jaktinib Hydrochloride Y% Cream will be applied topically twice daily
89600896|NCT04433520||ASD/PFO cohort|"Subjects indicated for atrial septal defect (ASD) closure with either the ASO or ASD-MF devices as well as subjects indicated for patent foramen ovale (PFO) closure with the Amplatzer PFO Occluder.~The Amplatzer Trevisio Delivery System is to be used for facilitating percutaneous, transcatheter implantation of the occluders."
89600897|NCT04433520||VSD cohort|Subjects indicated for ventricular septal defect (VSD) closure with either the MuscVSD or PIVSD occluders.
89600898|NCT04426786|Active Comparator|Immediate intervention start: active exercise|Immediately starts the six month intervention of active exercise following the baseline scan.
89600899|NCT04426786|Placebo Comparator|Delayed intervention start: passive exercise|Starts the six month intervention of active exercise six months after the baseline scan. During the six month delay, participants in this arm undergo passive exercise.
89600900|NCT04405037|Experimental|Alvimopan Group|"Patients randomized to the study group will be given a maximum of 3 doses of Alvimopan 12mg orally, 12 hours apart. Alvimopan will be given from the time of diagnosis of postoperative ileus to the time of return of bowel function or the maximum 3 doses. Subsequent Alvimopan doses will be given if there is no return of bowel function or if symptoms of distension and/or nausea persist despite some return of bowel function.~All patients will follow a standard ERAS pathway after surgery, with early feeding and ambulation, along with opioid minimizing measures as is our standard postoperative protocol."
89600901|NCT04405037|No Intervention|Control Group|Control patients will follow a standard ERAS pathway after surgery, including NPO status, IV fluid rehydration, and nasogastric decompression, early feeding and ambulation, along with opioid minimizing measures as is our standard postoperative protocol.
89600902|NCT04381689|Experimental|IL-YANG PFS|IL-YANG FLU Vaccine Prefilled Syringe INJ.
89600903|NCT04381689|Active Comparator|GSK PFS|Fluarix Tetra Pre-filled Syringe
89600904|NCT04372459|Experimental|Online integrated and stepped psychosocial care|A group of breast cancer survivors will be randomly allocated (1:1 allocation) to the online integrated and stepped psychosocial care group
89600905|NCT04372459|Experimental|Usual psychosocial care|A group of breast cancer survivors will be randomly allocated (1:1 allocation) to the usual psychosocial care group
89600906|NCT04358705|Experimental|Young Cigarillo User (YCU) Sample|"Aim 1: Online survey. 392 participants from the full YCU sample~Supplemental Aim 1: A sample of 196 heterosexual females from the Aim 1 survey will be compared to the SGM females~Aim 2: 150 participants from Columbus, Ohio, and surrounding areas will be recruited for an Eye Tracking Activity to capture visual attention to cigarillo packaging. Visual attention will be examined in 3 conditions: 1) flavored product images, 2) unflavored product images, and 3) a mixture of flavored and unflavored product images.~Aim 3: (162 participants from Aim 1 survey). Consists of the Online Electronic Tobacco Marketplace (ETM) and the aim 3 survey components:~Demographic screener questions~Tobacco product withdrawal scale~ETM~Quality Assurance Question~Tobacco product withdrawal scale~Survey (nicotine dependence & flavor preferences)~A sample of 88 from the 162 Aim 3 participants will be compared with 88 SGM participants from supplemental Aim 1."
89600907|NCT04358705|Experimental|Sexual and Gender Minority (SGM) Female Cigarillo Users|"Supplemental Aim 1: An online convenience sample of 196 SGM females will complete the Aim 1 online survey and will be compared to sample of 196 heterosexual females from the YCU sample~Supplemental Aim 3: (88 SGM females who participated in the Supplemental Aim 1 survey). Consists of the ETM and the aim 3 survey components in the following order:~Demographic screener questions~Tobacco product withdrawal scale~ETM~Quality Assurance Question~Tobacco product withdrawal scale~Survey (nicotine dependence & flavor preferences)"
89600908|NCT04358705|Other|Cognitive interview|Separate population of participants (n=29) who were a mix of cigarillo users, dual e-cigarette and cigarillo users, e-cigarette users, and non-users. The cognitive interviews informed the Aim 1 survey
89032125|NCT02940054||Patents with suspected Crohn's disease|"Adult patients showing at least one of the following symptoms, from at least 4 weeks:~diarrhea~nocturnal diarrhea~body weight loss (>5%)~abdominal pain~perianal lesions."
89032126|NCT02940093||Stem cell transplant recipient|
89032127|NCT02940093||Stem cell donor|
89032128|NCT02940015||Anonymous Sample Collection - Adults (ASCA)|Healthy Volunteers ages 18 and older
89032129|NCT04691193||study and control group|The study group included patients with low back pain for less than 3 months. The control group consists of healthy volunteers.
89032130|NCT02948699|Experimental|Nutrition support|Nutrison was added to regular diet while the patients can be fed through mouth. Nutrison will replace regular diet by NG or PEG while the patients can not eat for serious oral mucositis.
89032131|NCT02948699|No Intervention|Regular diet|Regular diet without other nutritional intervention.
89032132|NCT00521417|Experimental|short-term dynamic therapy|Group therapy 20 sessions, give insight
89032133|NCT00521417|Active Comparator|long-term dynamic therapy|Group therapy 80 sessions, give insight
89032134|NCT02938728||Melanoma|Advanced melanoma treated by immunotherapies
89032135|NCT02938767||peritoneal dialysis patients|37 peritoneal dialysis patients followed at the Istanbul Medical Faculty from October 1994 to October 2011
89032136|NCT02938767||renal transplant recipients|20 renal transplant recipients followed at the Istanbul Medical Faculty from October 1994 to October 2011 setted as the control group
89032137|NCT02938650|Other|Nitrosomonas eutropha spray|Subjects will receive nitrosmonas eutropha spray that they will apply twice a day.
89032138|NCT04694417|Experimental|Compression stocking|Compression stockings are mainly used for the prevention and reduction of lower limb oedema or venous thrombosis. There are three compression classes used in health care. The compression stocking group of the study will receive CE-marked stockings within the compression class of 1 (25-40 mmHg compression). The correct size for the compression stockings will be defined by the reported circumference of the participant's ankle and calf. The participants will be given instructions to put the stockings on immediately after getting out of bed in the morning and to take them off before going to bed in the evening for the last four weeks of the study. Stockings within the mild compression class have no harmful effects on individuals when the exclusion criteria are considered. The participants will be instructed to communicate with a dedicated research assistant via e-mail or phone in case of any problems or questions.
89032139|NCT04694417|Active Comparator|Magnesium|"Magnesium is a mineral substance which regulates many biochemical reactions in the body, for example protein synthesis and the function of the muscles and nerves. It has a significant role in controlling blood sugar, blood pressure, energy generation and the formation of the bones. The recommended dietary allowance for magnesium is 420 mg for males and 320 mg for females over 50 years old. Dark green vegetables, leguminous plants, nuts, seeds and wholegrains are good sources of magnesium (11,12).~In the average Finnish diet, the recommendation is usually exceeded, and excessive amounts of magnesium in the body are extremely rare. The magnesium arm of the study will take oral tablets containing 620 mg of magnesium hydrochloride daily for the last four weeks of the study, which is equivalent to 250 mg of pure magnesium per day. The magnesium tablets for this study were manufactured and analysed by the Pharmia pharmaceutical company in Finland."
89032140|NCT04694417|Placebo Comparator|Placebo|The placebo tablets will consist of microcrystalline cellulose, magnesium stearate (anti-caking agent) and silicon dioxide. The placebo tablets were manufactured and analysed by the Pharmia pharmaceutical company in Finland. The placebo arm will receive placebo tablets to be taken daily for the last four weeks of the study. The participants will not know whether they are randomised into the magnesium arm or the placebo arm. The packaging and the appearance of the placebo and magnesium tablets are identical.
89032141|NCT00520598|Active Comparator|1|Arm 1: 0.5 ml injection of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine as 3 dose regimen.
89600909|NCT04345913|Active Comparator|Group I (eribulin)|Patients receive eribulin IV over 2 to 5 minutes on days 1 and 8 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo a CT scan and/or MRI at screening, cycle 3 day 1, and every 9 weeks thereafter. Patients also undergo a biopsy at baseline, cycle 2 day 1, and at time of disease progression and blood sample collection at baseline, cycle 2 day 1, every 9 weeks and at time of disease progression.
89600910|NCT04345913|Experimental|Group II (eribulin, copanlisib)|Patients receive copanlisib IV over 1 hour and eribulin IV over 2 to 5 minutes on days 1 and 8 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo a CT scan and/or MRI at screening, cycle 3 day 1, and every 9 weeks thereafter. Patients also undergo a biopsy at baseline, cycle 2 day 1, and at time of disease progression and blood sample collection at baseline, cycle 2 day 1, every 9 weeks and at time of disease progression.
89600911|NCT04340843|Experimental|Treatment (belinostat, guadecitabine, ASTX727)|Patients receive guadecitabine SC or ASTX727 PO on days 1-5. Patients also receive belinostat IV over 30 minutes on days 1-5. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood during screening, tumor biopsy during screening and on study, and MRI or CT throughout the trial.
89600912|NCT04339959||Phase I|First, we will test proof-of-concept that participants will be able to follow the testing protocol and use the tablet computer to communicate with the investigator (10-12 participants). The test protocol will be refined based on what is learned after a minimum of 10 participants. We anticipate no more than 12 participants needed for this phase.
89600913|NCT04339959||Phase II|Next, 10-20 new participants will be enrolled to evaluate the validity of videoconference vs. face-to-face assessment (i.e., direct observation) of physical performance. Communication will occur between the remote assessor and the participant. The direct observer will not communicate directly to the participant, unless there is a safety issue. After completing 10 participants without a major change in the test protocol, we will proceed to the next phase.
89600914|NCT04339959||Phase III|This phase involves participants repeating the test protocol, but without the face-to-face assessment (i.e., direct observation). This will test the ability of the participant to receive the box of test instructions and materials in the mail, unpack the box, communicate with the remote assessor via videoconferencing, pack up the box, and return it (postage paid) to the study team. This step will involve 5-10 participants from Phases 1 and 2, who have provided approval for future contact (see approved Future Contact form). Once 5 participants have successfully and safely completed the test protocol, we will proceed to Phase 4.
89600915|NCT04339959||Phase IV|This phase is the same as Phase 3, except it includes newly enrolled participants, i.e., representing the first-time participants have enrolled/participated in this study. This will eliminate the practice effect that will occur in phase 3. This step will enroll 5-10 participants.
89032142|NCT00520598|Experimental|2|Arm 2: 0.5 ml injection of V505 formulation 1 as 3 dose regimen.
89032143|NCT00520598|Experimental|3|Arm 3: 0.5 ml injection of V505 formulation 2 as 3 dose regimen
89032144|NCT00520598|Experimental|4|Arm 4: 0.5 ml injection of V505 formulation 2 as 2 dose regimen and 1 Pbo injection
89032145|NCT00520598|Experimental|5|Arm 5: 0.5 ml injection of V505 formulation 3 as 2 dose regimen and 1 Pbo injection
89032146|NCT02939898|Placebo Comparator|Lactose Monohydrate|2 tablets of placebo are administered daily from stimulation start to day before hCG as adjunctive therapy to 150 International Units of recFSH
89032147|NCT02939898|Active Comparator|Letrozole|2 tablets of 2,5 mg Letrozole are administered daily from stimulation start to day before hCG as adjunctive therapy to 150 International Units of recFSH
89032148|NCT02938338||Obese patients with BMI above 35|Bariatric surgery
89600916|NCT04339738|Experimental|Arm I (nivolumab, paclitaxel)|Patients receive nivolumab IV over 30 minutes on day 1 and paclitaxel IV over 1 hour on days 1, 8, and 15. Cycles repeat every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood at baseline and on study, CT scan, spiral CT, or MRI, or FDG-PET scan throughout the trial.
89600917|NCT04339738|Experimental|Arm II (paclitaxel)|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15. Cycles repeat every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood at baseline and on study, CT scan, spiral CT, or MRI, or FDG-PET scan throughout the trial.
89600918|NCT04339738|Experimental|Arm III (nivolumab, cabozantinib S-malate)|Patients receive nivolumab IV over 30 minutes on day 1 and cabozantinib S-malate PO daily. Cycles repeat every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood at baseline and on study, CT scan, spiral CT, or MRI, or FDG-PET scan throughout the trial.
89600919|NCT04334941|Active Comparator|Arm I (atezolizumab)|Patients receive atezolizumab IV over 30-60 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients may undergo MRI during screening. Patients undergo tumor biopsy while on study. Patients undergo CT scan and blood sample collection throughout the study.
89600920|NCT04334941|Experimental|Arm II (atezolizumab, talazoparib)|Patients receive atezolizumab IV over 30-60 minutes on day 1 and talazoparib PO QD on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients may undergo MRI during screening. Patients undergo tumor biopsy while on study. Patients undergo CT scan and blood sample collection throughout the study.
89600921|NCT04320888|Experimental|Treatment (selpercatinib)|Patients receive selpercatinib PO BID on days 1-28. Treatment repeats every 28 days for up to 26 cycles (2 years) in the absence of disease progression or unacceptable toxicity. Patients may also undergo PET, CT, MRI, PET/CT, PET/MRI, and/or CT/MRI, scintigraphy, and x-ray imaging throughout the trial.
89600922|NCT04317105|Experimental|Trial I (copanlisib, nivolumab)|Patients receive copanlisib hydrochloride IV over 1 hour on days 1, 8, and 15 of cycle 1. Beginning in cycle 2, patients also receive nivolumab IV over 60 minutes on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo an x-ray and/or CT scan during screening and every 8 weeks, as well as a tumor biopsy at baseline, cycle 1 day 15, cycle 2 day 15, and every 3 weeks thereafter, and at disease progression. Patients also undergo blood sample collection at baseline, cycle 1 days 8 and 15, cycle 2 day 15, cycle 4 day 1 and disease progression. Patients undergo ECHO during screening and as clinically indicated on study.
89600923|NCT04317105|Experimental|Trial II (copanlisib, nivolumab, ipilimumab)|Patients receive copanlisib hydrochloride IV over 1 hour on days 1, 8, and 15 of cycle 1. Beginning in cycle 2, patients also receive nivolumab IV over 60 minutes on day 1 and ipilimumab IV over 90 minutes every 8 weeks for 4 doses. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo an x-ray and/or CT scan during screening and every 8 weeks, as well as a tumor biopsy at baseline, cycle 1 day 15, cycle 2 day 15, and every 3 weeks thereafter, and at disease progression. Patients also undergo blood sample collection at baseline, cycle 1 days 8 and 15, cycle 2 day 15, cycle 4 day 1 and disease progression. Patients undergo ECHO during screening and as clinically indicated on study.
89600924|NCT04314401||Ancillary-correlative (biospecimen collection, chart review)|Patients undergo collection of tissue and blood samples prior to initiation of treatment, during treatment, post treatment and at disease progression. Patients with hematological malignancies also undergo collection of bone marrow and cerebral spinal fluid at the same time points. Archival blood and tissue, as well as bone marrow of patients with hematological malignancies, is also collected, if available. Patient medical records are reviewed, and data is collected for at least 5 years.
88980308|NCT05991128|Placebo Comparator|Placebo|Participants in this arm will receive normal saline 0.9% in analogy to treatment arm.
88980309|NCT05990985|Experimental|RCMOP|RiTUXimab Injection+Cyclophosphamid+Mitoxantrone hydrochloride liposome injection+Vincristine+Prednisolone, 4 cycles of treatment
88980310|NCT05990595|Experimental|Adlay with white rice|Group A eat cooked adlay with white rice to replace their carbohydrates: a box of 200 grams of adlay rice per day
88980311|NCT05990595|Placebo Comparator|White rice|Group B ate a box of 200 grams of cooked white rice per day
88980312|NCT05990283|Experimental|Socket shield technique with immediate implant placement|For the patients in the shield group, shields were prepared with the Root Membrane Kit. After the palatal part was removed, the buccal fragment was prepared at the crest level, and an internal bevel chamfer was formed on the fragment. Implants were placed 3-4 mm apical to the gingival margin of the adjacent teeth.
88980313|NCT05990283|Experimental|Guided bone regeneration with immediate implant placement|For the patients in the regeneration group, teeth were extracted atraumatically, implants were placed 3-4 mm to the gingival margin, and the space between the implant and buccal bone was filled with anorganic bovine bone graft at the time of implant placement. The graft particles were covered by a pericardium membrane. The membrane was fixed to the bone with titanium pins.
88980314|NCT05989542|Experimental|PLB1001|Subjects will receive 200mg of PLB1001 twice daily in cycles of 28-day duration until disease progression, death, adverse event (AE) leading to discontinuation or withdrawal of consent.
88980315|NCT05989399||ASyS patients|Patients with antisynthetase syndrome
88980316|NCT05989269|No Intervention|Control Period|Laboratory reporting of respiratory cultures will continue per regular or routine laboratory protocols (standard reporting).
88980317|NCT05989269|Other|Intervention|The lab will publish a modified report for respiratory cultures which do not meet clinical criteria for pneumonia and have growth of organisms (other than normal respiratory flora). The modified report will include the likelihood of colonization instead of reporting bacterial identification.
88980318|NCT05988905|Experimental|robot assisted gait training|RAGT enables training of automatically programmed normal gait pattern. Patients underwent 30 min of RAGT using SUBAR® and conventional exercise rehabilitation each for 30 min once a day for 5 days a week for 8 weeks.
88980319|NCT05988905|Active Comparator|conventioanl training|The conventional training group focused on gait training such as active range of motion (ROM) exercise, weight bearing training, manual lymphatic drainage, and hypertrophic scar care for 60 min once a day for 5 days a week for 8 weeks.
89032149|NCT00521495|Experimental|A|Surface magnetic field strength at target 450 Gauss permanent magnet
89032150|NCT00521495|Experimental|B|Surface field strength at target 150 Gauss permanent magnet
89600925|NCT04310943|Experimental|Arm 1|Tislelizumab (200mg,Q3W )+Bevacizumab(15 mg/kg,Q3W)+Albumin paclitaxel(100mg/m2,d1,8,15) for 4 cycles, and if there is no disease progression, patients will receive Tislelizumab(200mg,Q3W) until progression or death.
89032151|NCT00521495|Active Comparator|C|
89600926|NCT04310007|Experimental|Step 1, Arm A (cabozantinib S-malate)|Patients in Step 1, Arm A receive cabozantinib S-malate PO QD. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients may continue to receive therapy after investigator-assessed RECIST 1.1 defined progression, including stable clinical and performance status and have potential for continued clinical benefit. Patients also undergo ECHO as clinically indicated, CT throughout the trial, and collection of blood on study.
89600927|NCT04310007|Experimental|Step 1, Arm B (cabozantinib S-malate, nivolumab)|Patients in Step 1, Arm B receive cabozantinib S-malate PO QD and nivolumab IV over 30 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients may continue to receive therapy after investigator-assessed RECIST 1.1 defined progression, including stable clinical and performance status and have potential for continued clinical benefit. Patients also undergo ECHO as clinically indicated, CT throughout the trial, and collection of blood on study.
89600928|NCT04310007|Active Comparator|Step 1, Arm C (standard chemotherapy)|Patients in Step 1, Arm C receive ramucirumab IV over 30-60 minutes and docetaxel IV over 1 hour on day 1, or docetaxel IV over 1 hour on days 1 and 8, or gemcitabine hydrochloride IV on days 1 and 8, or paclitaxel IV over 3 hours on day 1, or nab-paclitaxel IV over 30 minutes on days 1 and 8. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity and at the discretion of the treating physician. Patients also undergo ECHO as clinically indicated, CT throughout the trial, and collection of blood on study.
89600929|NCT04310007|Experimental|Step 2, Arm Z (cabozantinib S-malate, nivolumab)|Patients in Step 2, Arm Z receive cabozantinib S-malate PO QD and nivolumab IV over 30 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients may continue to receive therapy after investigator-assessed RECIST 1.1 defined progression, including stable clinical and performance status and have potential for continued clinical benefit. Patients also undergo ECHO as clinically indicated, CT throughout the trial, and collection of blood on study.
89600930|NCT04302805|Placebo Comparator|PE/rATG|Study participants will undergo therapeutic plasma exchange (PE, 1 plasma volume) before the transplant surgery and receive rATG (Thymoglobuline®) induction (1.5 mg/kg intraoperatively and 1 mg/kg when possible daily within first week up to cumulative dose 5-7 mg/kg).
89600931|NCT04302805|Active Comparator|PE/rATG/IVIG|Study participants will undergo therapeutic plasma exchange (PE, 1 plasma volume) before the transplant surgery and receive rATG (Thymoglobuline®) induction (1.5 mg/kg intraoperatively and 1 mg/kg when possible daily within first week up to cumulative dose 5-7 mg/kg) and IVIG 0.5g/kg intravenous infusions, on 1st, 3rd and 5th postoperative day. This is a center standard of care regimen.
89600932|NCT04301076|Experimental|Treatment (lenalidomide, EPOCH)|"INDUCTION THERAPY: Patients receive lenalidomide PO QD on days 1-14 of 21 day cycles or days 1-21 or 1-28 of 28 day cycles. Patients receive doxorubicin hydrochloride IV continuously on days 1-4, vincristine sulfate IV continuously on days 1-4, etoposide IV continuously on days 1-4, prednisone PO on days 1-5, and cyclophosphamide IV over 1-4 hours on day 5. Treatment repeats every 21 or 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients with CR, PR, or SD may receive up to 2 additional cycles of lenalidomide, doxorubicin hydrochloride, vincristine sulfate, etoposide, prednisone, and cyclophosphamide at the discretion of the investigator and/or up to an additional 2 years of lenalidomide in the absence of disease progression or unacceptable toxicity.~Patients undergo bone marrow biopsy at baseline and as clinically indicated. Patients undergo PET/CT or CT, tissue and blood sample collection throughout."
89600933|NCT04294875|Other|MPT0B640|There is Single Arm in this Clinical Trials.
89032152|NCT02939703|Active Comparator|Control Western diet|Participants will consume a control western diet prepared by our metabolic research kitchen for an outpatient period followed by an inpatient period.
89032153|NCT02939703|Experimental|Microbiome Enhancer diet|Participants will consume an experimental microbiome enhancer diet prepared by our metabolic research kitchen for an outpatient period followed by an inpatient period
89032154|NCT00520715||Patients at hospital admission|Patients at hospital admission in medical wards on our tertiray care hospital (Hôpital Beaujon, Clichy, France).
89032155|NCT02938221|Experimental|Telemedical video-oculography|Execution of three oculomotor tests using a telemedical video-oculography system
89032156|NCT00520832|Experimental|MC-E|20 minutes of sub-threshold microcurrent 2 hours before bedtime per day for 21 days.
89032157|NCT00520832|Placebo Comparator|MC-P|Participants will receive a device identical to the active device used in the experimental condition, but which produces no current.
89032158|NCT02939859|Experimental|Microcannula Harvest Adipose|Acquisition AD-tSVF via closed syringe microcannula
89032159|NCT02939859|Experimental|Centricyte 1000|Autologous Adipose-Derived Tissue Stromal Vascular Fraction (AD-tSVF) via enzymatic isolation/concentration via Centricyte 1000 Closed System to create AD-cSVF
89032160|NCT02939859|Experimental|Sterile Normal Saline|Re-suspension of Autologous AD-cSVF pellet in Normal Saline deployment via IV
89032161|NCT00521534||A|CRT programmed to VDD pacing mode
89032162|NCT00521534||B|CRT programmed to DDD with overdrive pacing based on first night average sinus rate.
89032163|NCT02277132|Active Comparator|Sildenafil|Sildenafil 25 mg tablets three times daily orally from randomization until delivery
89032164|NCT02277132|Placebo Comparator|Placebo|Placebo tablets three times daily orally from randomization until delivery
89032165|NCT00520949|Experimental|Quadruple Therapy|
89032166|NCT02938104|Experimental|Prehabilitation|"Immediately after randomization, until surgery and to be continued for 8 weeks after surgery, patients in this arm will:~Receive a personalized physical exercise program~Receive nutritional counselling with whey protein isolate powder~Receive relaxation techniques"
89032167|NCT02938104|Active Comparator|Rehabilitation|Patients in this arm will receive the same personalized physical exercise program, nutritional intervention and relaxation techniques as patient in the other arm but to be started after surgery.
89032168|NCT02948504||Observation|Aneurysms are left untreated based on patients and family's wishes. These patients will be included in the observation group.
89032169|NCT02948504||Coiling or Clipping|Patients are included in the coiling group if they undergo endovascular coiling, such as single coiling, stent-assisted coiling and balloon-assisted coiling. Or Patients are included in the clipping group if they undergo surgical coiling, such as aneurysm neck clipping, aneurysm isolation or trapping.
89032170|NCT02938260||Diltiazem|
89032171|NCT02938260||Metoprolol|
89032172|NCT00520988|Experimental|1|Usual care plus use of Interactive Voice Recognition system
89032173|NCT00520988|No Intervention|2|Usual care
89032174|NCT00521027|Other|Treatment|Debridement with Versajet Hydrosurgery system
89032175|NCT00521027|Other|Control|Conventional surgical debridement techniques
89032176|NCT02938182|Experimental|clopidogrel|clopidogrel tablet 75mg daily for three months
89032177|NCT00521066||1|Prosima Pelvic Floor Repair System
89032178|NCT02931552|Experimental|Nuevo Amancer-II Stress Management Program|Nuevo Amanecer-II (NA-II) is a 10-week peer-delivered cognitive-behavioral stress management program. Participants receive the stress management program as soon as possible after randomization.
89032179|NCT02931552|No Intervention|Wait-list Control Group|Waits six months and at the end of the six months is offered the option of receiving the NA-II program.
89032180|NCT00521105|No Intervention|1|Participants will be seen every 3-4 months with a physician-only visit alternating with a multidisciplinary visit (MD, RN and RD). This is the current standard of practice.
89032181|NCT00521105|Experimental|2|Participants will be seen every 3-4 months with a phone contact, with the diabetes nurse educator, alternating with a multidisciplinary visit (MD, RN and RD).
89032182|NCT02938065|Other|2% Milk|16 participants will drink 10 ounces of 2% milk Ultrasound scan will be performed at the time of beverage administration and then every 30 minutes thereafter until beverage has been cleared from the stomach
89032183|NCT02938065|Other|Apple Juice|16 participants will drink 10 ounces of apple juice Ultrasound scan will be performed at the time of beverage administration and then every 30 minutes thereafter until beverage has been cleared from the stomach
89032184|NCT02938065|Other|Ensure Clear|16 participants will drink 10 ounces of ensure clear Ultrasound scan will be performed at the time of beverage administration and then every 30 minutes thereafter until beverage has been cleared from the stomach
89032185|NCT00521183|Experimental|CldC + H4U|
89032186|NCT02937987||Group 1|non-obese type 2 DM
89600934|NCT04294628|Experimental|Treatment (trastuzumab deruxtecan)|Patients receive trastuzumab deruxtecan IV over 30-90 minutes on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo ECHO or MUGA, CT or MRI, biopsies, and collection of blood samples throughout the study.
89600935|NCT04286607|Experimental|ARQ-151 Cream 0.3%|
89032187|NCT02937987||Group 2|obese type 2 DM
89032188|NCT02938026|No Intervention|Control|Usual care
89032189|NCT02938026|Experimental|Telephone intensive lifestyle counseling|Telephone intensive lifestyle counseling
89032190|NCT02938026|Experimental|Bariatric surgery|Bariatric surgery
89032191|NCT02937714|Experimental|School mental health training|Teachers Training workshop Workshop based on local adaptation of WHO-EMRO school mental health manual will be conducted in school. The duration of the workshop will be 3 days. Teachers can decline to participate or withdraw at any stage.
89032192|NCT02937714|No Intervention|Wait list control group|Wait list control group of teachers in same schools. Half of teachers in the same school will be the wait list control group.
89032193|NCT00521612|Experimental|A|Sevoflurane group, experimental group
89032194|NCT00521612|Active Comparator|B|Isoflurane group, control group
89032195|NCT02937909|Experimental|Prospective Data|Use of BSN medical UK range of wound dressings and compression products for 12 weeks treatment period Training and testing of woundcare nursing competencies Quality of Life questionnaire for patients
89032196|NCT02937909|No Intervention|Historical data|Historical data from the three months prior to the study on time needed for nurse training, number of referrals to the Tissue Viability Team, costs of dressings used, number of patients with wounds treated, types of wounds, number of wound closures and duration of treatment .
89032197|NCT00521651||Community Cohort|Men and Women from two Shanghai cohort studies.
89032198|NCT02931591|Active Comparator|GH+Metformin|The children will be given both Growth Hormone and Metformin for 6 months
89032199|NCT02931591|Placebo Comparator|GH+Placebo|Children will be given both GH and Placebo for 6 months
89032200|NCT00521300|Experimental|octreotide|6 months preoperative treatment with octreotide before transsphenoidal surgery for acromegaly
89032201|NCT00521300|Active Comparator|standard surgery|Standard transphenoidal surgery soon after the diagnosis of acromegaly
89600936|NCT04284774|Experimental|Treatment (tipifarnib)|Patients receive tipifarnib PO or via nasogastric or gastric tube BID on days 1-7 and 15-21. Treatment repeats every 28 days for up to 26 cycles (2 years) in the absence of disease progression or unacceptable toxicity. Patients undergo tumor disease evaluation with PET scan, CT scan, MRI, or MIBG scintigraphy throughout the trial. Patients may undergo bone marrow aspiration or biopsy at baseline, or if there is suspicion of bone marrow metastasis, or when a complete or partial response is identified, or if there is disease progression in the marrow suspected. Patients may undergo blood specimen collections throughout the trial.
89032202|NCT02931435|Active Comparator|Nerve Block with Radiofrequency Ablation|A 10 cm 18-gauge RF cannula with a 10 mm active tip will be placed at the superior lateral, superior medial, and inferior medial nerve positions under fluoroscopic guidance. Sensory stimulation at 50 Hz will be performed to identify nerve position and to assure no motor nerves will be ablated. Lidocaine (2 ml of 2%) will be administered in each location prior to RF generator activation.
89600937|NCT04266431|Experimental|EMPOWER|EMPOWER is a multichannel, behavioral lifestyle intervention delivered remotely. The goals of EMPOWER are to induce a loss of 5% or more of initial weight within 6 months and to maintain these improvements at 12 and 24 months, by meeting dietary and physical activity goals. Coach-participant contacts will occur by phone and email, without in-person visits. Coaching contacts will be weekly for the first 12 weeks and then monthly thereafter. Men will have access to a web-based system that (1) provides support for behavioral methods of weight management and (2) allows coaches to review participant self-monitoring data and monitor participant progress towards goals. Men will record diet, exercise, and weight on the web or on a smart phone application.
89600938|NCT04266431|No Intervention|Standard of Care|Men randomized to the standard of care group will continue to receive treatment from the mens' medical oncologist. These men will also be provided with a one page informative brochure on lifestyle recommendations adapted from the American Cancer Society Prostate Cancer Survivorship Care Guidelines, at the time of randomization. At the end of the trial, men in this arm will be offered a one-time counseling session with an intervention coach on healthy lifestyle.
89600939|NCT04263467|Experimental|Intervention group|Participants in the intervention group will receive a 6-weeks exercise-based intervention with supervised and group-based exercise training three times a week at the hospital setting. Each training session will consist of intermediate and high intensity interval training. The exercise-based intervention will be combined with standard oncological treatments; checkpoint inhibitors, checkpoint inhibitors combined with chemotherapy or oncological surveillance. Additional monitoring of patient will include physical tests, questionnaires and blood samples.
89600940|NCT04263467|Experimental|Control group|Participants in the control group will receive standard oncological treatments; immune checkpoint inhibitors, checkpoint inhibitors combined with chemotherapy or oncological surveillance. Additional monitoring of patient will include physical tests, questionnaires and blood samples.
89600941|NCT04262843|Experimental|Treatment (fludarabine, TMLI, HCT, cyclophosphamide)|"CONDITIONING: Patients receive fludarabine IV QD on days -7 to -5, and undergo TMLI BID on days -4 to 0 in the absence of disease progression or unacceptable toxicity.~TRANSPLANT: Patients undergo hematopoietic cell transplantation on day 0.~GVHD PROPHYLAXIS: Patients receive cyclophosphamide IV QD on days 3-4 in the absence of disease progression or unacceptable toxicity. Beginning on day 5, patients also receive granulocyte colony stimulating factor and tacrolimus/mycophenolate mofetil per institutional standard."
89600942|NCT04260048||Normal weight|Group defined based on BMI percentile for age and sex.
89600943|NCT04260048||Overweight|Group defined based on BMI percentile for age and sex.
89600944|NCT04260048||With obesity|Group defined based on BMI percentile for age and sex.
89600945|NCT04258605||ASHCOM Shoulder System subjects|Subjects implanted with the ASHCOM Shoulder System
89600946|NCT04250922|Placebo Comparator|Arm A: SoC + placebo for LAM561|"Chemoradiation Phase: all subjects undergo focal RT, with a treatment given 5 days per week over ~6 weeks (no more than 7 weeks). TMZ will be administered at 75 mg/m2 orally, once daily, continuously throughout the RT for a maximum of 49 days. Subjects in Arm A will receive placebo every day from Day 1 of week 3 to the end of this Phase.~The start of the first cycle during the Maintenance (Adjuvant) Phase will be scheduled ~28 days (and never more than 42 days) after the last day of chemoradiation. During the Maintenance Phase, subjects will receive oral TMZ 150-200 mg/m2 once daily on Days 1-5 of each 28-day cycle for 6 cycles.~Subjects in Arm A will receive placebo every day during the first 3 weeks of each 28-day cycle and until progression. Patients will continue with Placebo after cycle 6 of the monotherapy phase until end of study. Adjuvant treatment will be discontinued upon determination of tumour progression, unacceptable toxicity or refusal to continue study treatment."
89600947|NCT04250922|Experimental|Arm B: SoC + 12 g/day of LAM561|"Chemoradiation Phase: all subjects undergo focal RT, with a treatment given 5 days per week over ~6 weeks (no more than 7 weeks). TMZ will be administered at 75 mg/m2 orally, once daily, continuously throughout the RT for a maximum of 49 days. Subjects in Arm B will receive LAM561 every day from Day 1 of week 3 to the end of this Phase.~The start of the first cycle during the Maintenance Phase will be scheduled ~28 days (and never more than 42 days) after the last day of chemoradiation. During the Maintenance Phase, subjects will receive oral TMZ 150-200 mg/m2 once daily on Days 1-5 of each 28-day cycle for 6 cycles.~Subjects in Arm B will receive LAM561 during the Maintenance Phase. Patients will continue to be administered with LAM561 after cycle 6 of the monotherapy phase until end of study. Adjuvant treatment will be discontinued upon determination of tumour progression, unacceptable toxicity or refusal to continue study treatment."
89600948|NCT04248205|Active Comparator|Intraoperative ketamine infusion|Subjects in this group will receive standard anesthesia during surgery and a dose of ketamine at 0.3 mg/kg IV bolus prior to surgical incision. If the procedure lasts more than 1 hour, an additional bolus dose will be given.
89600949|NCT04248205|No Intervention|Control group|This group will only receive the standard anesthesia during surgery with no ketamine.
89600950|NCT04240392|Experimental|Collaborative Care (CC)|The CC team includes an obstetrical provider and a nursing case manager. The obstetrician will see all participants, initially to discuss preferences for addiction treatment, buprenorphine, methadone (MAT) or no MAT. The obstetrician will see participants every 1-2 weeks, as needed and will provide prenatal care. The care team will meet at least monthly and review the participants' status. For research purposes, the CM will obtain informed consent, collect and enter results of the urine drug screen (UDS) into a database. At enrollment and at 26 and 34 weeks' gestation the care manager will ask participants to complete an assessment battery of self-reported measures.
89600951|NCT04240392|Active Comparator|Extension for Community Healthcare Outcomes (ECHO)|ECHO is a remote education model that provides mentorship and guided practice and participation in a learning community, via video conferencing. The practice members who participate in ECHO will include obstetricians and nurses as well as other members of the care team who wish to join. Providers are given access to a password-protected website containing the recorded sessions, a discussion board, and resource library. CME credits are available for each session and can motivate providers to attend.
89600952|NCT04234568|Experimental|Treatment (lutetium Lu 177 dotatate, triapine)|Patients receive lutetium Lu 177 dotatate IV for 30 to 40 minutes on day 1 of each cycle and triapine PO on days 1 throughout 14 of each cycle. Cycles repeat every 56 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan or MRI scan throughout the trial. Patients undergo blood specimen collection on study.
89600953|NCT04231760|Experimental|Chronic Obstructive Pulmonary Disease|Mild & Moderate COPD to receive either placebo or inhaled nitric oxide (40ppm)
89600954|NCT04231760|Active Comparator|Healthy Controls|Control group to receive either placebo or inhaled nitric oxide (40ppm)
89600955|NCT04220814|Experimental|Patients|
89600956|NCT04220814|Other|Healthy Volunteer|
89600957|NCT04216290|Experimental|Step 1, Arm C (durvalumab, radiation therapy, chemotherapy)|Patients undergo radiation therapy for 6.5-8 weeks. Beginning 4 days before or after starting radiation therapy, patients receive durvalumab IV over 60 minutes on day 1 of each cycle. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Beginning 4 days before or after starting radiation therapy, patients also receive gemcitabine hydrochloride IV over 30-60 minutes BIW for 6 weeks; cisplatin IV over 30-60 minutes QW for 6 weeks; or mitomycin IV over 30 minutes on day 1 of radiation and fluorouracil IV continuous infusion on days 1-5 and 16-20 of radiation in the absence of disease progression or unacceptable toxicity.
89600958|NCT04216290|Active Comparator|Step 1, Arm D (radiation therapy, chemotherapy)|Patients undergo radiation therapy for 6.5-8 weeks. Beginning 4 days before or after starting radiation therapy, patients also receive gemcitabine hydrochloride IV over 30-60 minutes BIW for 6 weeks; cisplatin IV over 30-60 minutes QW for 6 weeks; or mitomycin IV over 30 minutes on day 1 of radiation and fluorouracil IV continuous infusion on days 1-5 and 16-20 of radiation in the absence of disease progression or unacceptable toxicity.
89600959|NCT04216290|Experimental|Step 2, Arm E (durvalumab)|Patients previously randomized to Arm C (chemoradiation and durvalumab) who achieve clinical CR or clinical benefit receive durvalumab IV over 60 minutes on day 1 of each cycle. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity.
89600960|NCT04216290|Active Comparator|Step 2, Arm F (observation)|Patients previously randomized to Arm D (chemoradiation) who achieve clinical CR or clinical benefit, or patients previously randomized to Arm C with no clinical CR or clinical benefit undergo observation.
89600961|NCT04214067|Active Comparator|Arm I (EBRT, brachytherapy)|Patients undergo pelvic EBRT daily for 5-6 weeks and vaginal brachytherapy completed within 7 days after completion of EBRT in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood samples and CT scans, MRI scans, or x-ray imaging throughout the trial.
89600962|NCT04214067|Experimental|Arm II (EBRT, brachytherapy, pembrolizumab)|Patients undergo EBRT and brachytherapy as in Arm I. Within 7 days prior to the start of radiation therapy, patients also receive pembrolizumab IV over 30 minutes on day 1. Treatment with pembrolizumab repeats every 6 weeks for up to 1 year (9 cycles) in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood samples and CT scans, MRI scans, or x-ray imaging throughout the trial.
89600963|NCT04208529|Experimental|CTX001|All participants who complete or discontinue one of the multiple parent studies (CTX001-111, CTX001-121, CTX001-141, CTX001-151, CTX001-161 and CTX001-171) after CTX001 infusion will be asked to participate in this long-term follow-up study.
89600964|NCT04200378||Subjects undergoing TMVr|Subjects with severe, symptomatic primary mitral regurgitation (MR) scheduled to undergo a transcatheter mitral valve repair (TMVr) as standard of care will have intra-op baseline and post repair blood draws. Pre-procedure and post-procedure transthoracic echocardiograms (TTE) will assess the hemodynamic implications of the repair.
89600965|NCT04197258|Experimental|intervention group|"For 6 months after discharge, patients in the intervention group will benefit from peer support by a trained patient (number and frequency of contacts defined according to the patient's needs).~The intervention aims to improve the patient's ability to manage his or her situation and meet his or her needs upon discharge at home, including identifying and seeking for the necessary health or social resources"
89600966|NCT04197258|No Intervention|control group|Patients included in the control group before intervention will receive the usual practices. As part of the study, they will be contacted for data collection 6 months after the transition to home by a clinical research associate.
89600967|NCT04195399|Experimental|Treatment (nirogacestat)|Patients receive nirogacestat PO BID on days 1-28. Cycles repeats every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO and CT or MRI on study. Patients may also undergo x-ray imaging and blood sample collection on study.
89600968|NCT04191499|Experimental|Inavolisib + Palbociclib + Fulvestrant|Participants will receive inavolisib, palbociclib, and fulvestrant.
89600969|NCT04191499|Placebo Comparator|Placebo + Palbociclib + Fulvestrant|Participants will receive placebo, palbociclib, and fulvestrant.
89600970|NCT04187391|Experimental|Active tDCS plus individual language training|Active tDCS plus individual language training
89600971|NCT04187391|Active Comparator|placebo tDCS plus individual language training|placebo tDCS plus individual language training
89600972|NCT04187391|Active Comparator|Active tDCS plus unstructured cognitive stimulation|Active tDCS plus unstructured cognitive stimulation
89600973|NCT04137185|Experimental|rhTSH|Phase 1: 0.9mgx1d、0.9mgx2d、1.8mgx1d、1.8mgx2d, intramuscularly (IM) ; Phase 2: patients will be treated at the recommended dose for phase 2(RP2D).The RP2D will be determined by the Phase 1.
89600974|NCT04130516|Other|Active|Phase 1/2 open-label
89600975|NCT04125836|Experimental|CAM2029 (octreotide subcutaneous depot)|CAM2029 (octreotide subcutaneous depot) 20mg/1.0 mL for 20 mg dose, subcutaneous injection once monthly, 12 months treatment with an option of extension. If down-titration is required, 10mg/0.5 mL for 10 mg dose is available.
89600976|NCT04118452|Experimental|Intervention + Usual Care + Developmental Screening Results|Intervention group families will receive usual care and developmental screening results will be shared with each child's primary care provider. In addition, they will be connected via telephone to 2-1-1 prior to their scheduled well-child visit for the telephone-based early childhood development care coordination intervention.
89600977|NCT04118452|No Intervention|Usual Care + Developmental Screening Results|This group will receive usual care. In addition, developmental screening results will be shared with each child's primary care provider.
89600978|NCT04103151||Febrile infants|Febrile Infants less than 3 months presenting to the emergency department with a temperature of ≥ 38oC.
89600979|NCT04103151||Afebrile infants|Afebrile Infants less than 3 months presenting to the emergency department
89600980|NCT04100486||Healthy, Able-Bodied Individuals|This study will only enroll healthy, able-bodied individuals.
89600981|NCT04096638|Experimental|Part 1a: Monotherapy Dose Escalation|SB 11285 weekly on Days 1, 8, 15 and 22 on repeated 28-day cycles in escalating doses
89600982|NCT04096638|Experimental|Part 1b: PD-L1 Combination Dose Escalation|SB 11285 weekly on Days 1, 8, 15 and 22 on repeated 28-day cycles in escalating doses plus 1680mg every 4 weeks (Q4W) atezolizumab
89600983|NCT04096638|Experimental|Part 2: Combination Expansion Cohorts at RP2D (Cohort A)|"Cohort A: Patients with Melanoma~After determination of maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) in SB 11285 plus atezolizumab combination the Part 2 with expansion cohorts will commence to further evaluate the RP2D."
89600984|NCT04096638|Experimental|Part 2: Combination Expansion Cohorts at RP2D (Cohort B)|"Cohort B: Patients with HNSCC~After determination of maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) in SB 11285 plus atezolizumab combination the Part 2 with expansion cohorts will commence to further evaluate the RP2D."
89600985|NCT04096638|Experimental|Part 2: Combination Expansion Cohorts at RP2D (Cohort C)|"Cohort C: Patients with tumor types other then Cohort A and B (Naïve or relapsed refractory to anti PD-1/PD-L1)~After determination of maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) in SB 11285 plus atezolizumab combination the Part 2 with expansion cohorts will commence to further evaluate the RP2D."
89600986|NCT04093869|Experimental|Coping Skills Training combined with Exercise (CSTEX)|The CSTEX intervention will consist of 12, 30 minute weekly sessions conducted by a respiratory therapist knowledgeable about lung transplantation and trained in motivational interviewing, Cognitive Behavioral Therapy (CBT), and exercise therapy.
89600987|NCT04093869|Experimental|Standard of Care plus Education (SOC-ED)|The SOC-ED intervention will consist of 12, 30 minute weekly sessions conducted by a health educator knowledgeable about transplantation and skilled in educational instruction.
89600988|NCT04077099|Experimental|REGN5093|Monotherapy in dose escalation cohorts (phase 1) followed by an expansion phase (phase 2)
89600989|NCT04069026|Experimental|Dose escalation of BAY2416964|Approximately 8 dose levels of BAY2416964 are planned
89600990|NCT04069026|Experimental|Dose expansion of BAY2416964 in tumor type specific|Patients with NSCLC, HNSCC
89600991|NCT04068311|No Intervention|Pre Implementation|Adult patients >65 years of age in the Emergency Department Observation Unit.
89600992|NCT04068311|Active Comparator|Post Implementation|Adult patients >65 years of age in the Emergency Department Observation Unit.
89600993|NCT04062994||Intervention Group|All patients scheduled for surgery at a UCLA site in the one year period after go-live
89600994|NCT04054180|Experimental|CPAP S.Box associated with its 3 connected devices|S.BOXTM CPAP associated with its 3 connected devices Each patient will be monitored by a CPAP S.Box, with a Sefam Access application installed on their Smartphone to collect data from 3 connected measuring devices: PROMs, an activity monitor and a blood pressure monitor.
89600995|NCT04048707|Active Comparator|Midodrine/Octreotide|This arm will receive standard of care treatment of midodrine, octreotide, and albumin.
89600996|NCT04048707|Experimental|Angiotensin 2|This arm will receive the experimental treatment of angiotensin 2 infusion and albumin.
89608572|NCT00735670|Experimental|Venlafaxine|Venlafaxine HCl is classified as a selective serotonin and norepinephrine reuptake inhibitor (SSNRI) and has been approved by the FDA for the treatment of major depressive disorder. The treatment group will receive a sub-therapeutic dose over a two week period, with a two week titration, starting at 37.5 mg up to a maximum dose of 150 mg per day. At the end of the treatment period, dosage was tapered down in a step-wise fashion over a period of three weeks; 75 mg. for two weeks and 37.5 mg. for one week. While this was the standard protocol, study drug tapering was individualized based on side effects and the clinical judgment of the prescriber.
88811353|NCT00494234|Experimental|Olaparib 100 mg|Participants will receive two 50 mg capsules in the morning and two 50 mg capsules in the evening in 28-days cycle until confirmed disease progression, continuous treatment interruption, unacceptable toxicity or any other discontinuation criterion is met.
88811354|NCT00494234|Experimental|Olaparib 400 mg|Participants will receive eight 50 mg capsules in the morning and eight 50 mg capsules in the evening in 28-days cycle until confirmed disease progression, continuous treatment interruption, unacceptable toxicity or any other discontinuation criterion is met.
88811355|NCT01268111|Experimental|Vitamin D|ERgocalcifoerol 50,000 units q weekly for 8 weeks
88811356|NCT01268111|Placebo Comparator|Placebo|
88811357|NCT01349231|Experimental|Ketamine|Ketamine will be given at a dose of 0.5mg/kg over 40 minutes. This dose is identical to that used in previous anti-depressant studies of ketamine.
88811358|NCT01349933|Experimental|Treatment (Akt inhibitor MK2206)|Patients receive 200 mg Akt inhibitor MK2206 PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88811359|NCT01350245|Experimental|TJU 2 Step Regimen|All patients treated on this trial will have hematological malignancies that are in remission at the time of the transplant. Their diseases would be expected to relapse with standard therapy alone.
88811360|NCT01350401|Experimental|NY-ESO-1/LAGE-1 and HLA-A*02 Positive Subjects|
88811361|NCT01350479||MRSA colonized|Residents with history of MRSA in the past year
88811362|NCT01350479||Not MRSA colonized|Residents without history of MRSA in the past year
88811363|NCT01320137|Other|Allergy Group|Subjects with ages ranging from 18-45 years and inclusive, presenting symptomatic allergy to birch pollen.
88811364|NCT01320137|Other|Control Group|Subjects with ages ranging from 18-45 years and inclusive, with no known allergies.
89600997|NCT04034992||Retrospective CKD cohort|Retrospective (secondary) data refers to patient data extracted from existing electronic health records (EHRs)/registries/databases. It represents existing real-world data, regardless of reason for collection or location of storage and is analogous to those represented in the study protocol for which feasibility assessments are conducted. Retrospective data will be collected from registries, databases, and EHRs. The aim is to identify and extract clinical data retrospectively from a minimum of 100000 (no set maximum) CKD patients via existing databases/registries/EHRs across geographies. The retrospective data will be captured beginning 1 January 2008 through the most currently available data.
89600998|NCT04034992||Prospective CKD cohort|Prospective (primary and secondary) data refers to manual collection/extraction of data in a de novo manner for the purpose of addressing study objectives. Collection/extraction of patient data in the prospective cohort will be done via electronic case report form, questionnaires, and mobile phone/tablet application. The initial aim is to identify and collect/extract data from approximately 1000 (no set maximum) enrolled CKD patients until the decision to stop the study is taken, with the possibility of prospective follow-up for a minimum of approximately 1 year up to a maximum of approximately 3 years. The patient specific data in the prospective cohort will be collected by utilizing Rapid Assessment of Physical Activity (RAPA) questionnaire, Work Productivity and Activity Impairment (WPAI) questionnaire, Short Form (SF)-36 questionnaires, simple food diary, and other patient reported outcomes - including a set of questions to collect patient symptoms.
89600999|NCT04032899|Experimental|L. fermentum CECT5716 3x109 ufc|Volunteers will take 1 capsule per day with L. fermentum CECT5716 3x109 cfu mixed with maltodextrin from week 28-32 of gestation up to 16 weeks after delivery.
89601000|NCT04032899|Placebo Comparator|Maltodextrin|Volunteers will take 1 capsule per day with maltodextrin from week 28-32 of gestation up to 16 weeks after delivery.
89601001|NCT04014179|Experimental|Dried Blood Spot (Intervention)|Blood samples will be tested for HCV RNA from dried blood spot cards.
89601002|NCT04014179|Experimental|Point-of-care RNA (Intervention)|Blood samples will be tested for HCV RNA using the Xpert HCV Viral Load Fingerstick point-of-care assay.
89601003|NCT04014179|No Intervention|Standard of Care (Control)|Sites will continue with their standard of care for hepatitis C testing.
89601004|NCT03999996|Experimental|Takeda's Dengue Tetravalent Vaccine (Live, Attenuated) (TDV)|TDV 0.5 mL, injection, subcutaneously, once at Month 15 for participants from parent trials DEN-304 (US) or once at Month 42 for participants from parent trial DEN-315 (Mexico).
89601005|NCT03999996|Placebo Comparator|Placebo|TDV placebo-matching 0.5 mL injection, subcutaneously, once at Month 15 for participants from parent trial DEN-304 (US) or once at Month 42 for participants from parent trial DEN-315 (Mexico).
89601006|NCT03994874|Experimental|PolyCore PUF|PolyCore peritoneal ultrafiltration (PUF) (over the top of patient's prescribed heart failure medications), for 6 months.
89601007|NCT03994874|No Intervention|Control|Patients in the control arm (receiving no PUF therapy) will remain on their prescribed heart failure medications.
89601008|NCT03984968|Experimental|CAR-T cells infusion combined with feeding T cells (FTCs)|
89601009|NCT03984448|Active Comparator|Arm 1 (R-CHOP, DA-EPOCH-R)|"DEL: Patients with DEL receive R-CHOP chemotherapy regimen consisting of rituximab IV on day 1, cyclophosphamide IV on day 1, doxorubicin hydrochloride IV on day 1, vincristine sulfate IV on day 1, and prednisone PO QD on days 1-5. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo PET scan, CT scan and blood sample collection and may undergo bone marrow biopsy and lumbar puncture throughout the study.~DHL: Patients with DHL receive DA-EPOCH-R chemotherapy regimen consisting of rituximab IV on day 1, doxorubicin hydrochloride IV on days 1-4, etoposide IV on days 1-4, vincristine sulfate IV on days 1-4, prednisone PO BID on days 1-5, and cyclophosphamide IV on day 5. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo PET scan, CT scan and blood sample collection and may undergo bone marrow biopsy and lumbar puncture throughout the study"
89608573|NCT00735670|Placebo Comparator|Placebo|Placebo capsules were compounded by filling a matching gelatin capsule with lactose. Titration up and down followed the same schedule as the treatment group.
88980320|NCT05987865|Experimental|People with Parkinson's disease or Healthy Control|The experimental arm involves either patients with PD or healthy control, who will receive both experimental or non-experimental (control) intervention conditions.
88980321|NCT05986617|Experimental|Wearable Device Group|Will be given InBody Band 2 to use while trying to achieve weight loss goal prior to total joint arthroplasty.
88980322|NCT05986617|No Intervention|Control Group|Will not be given InBody Band 2 to use while trying to achieve weight loss goal prior to total joint arthroplasty.
88980323|NCT05986513|Active Comparator|OA-PF|Individuals with knee OA without knee or bodily pain. All participants will complete the same study protocol with pre- post-perturbation MRI scans and pain assessment questionnaires, as well as breath samples collected at multiple time points during the study visit.
88980324|NCT05986513|Experimental|OA-Knee|Individuals with knee OA with localized knee pain. All participants will complete the same study protocol with pre- post-perturbation MRI scans and pain assessment questionnaires, as well as breath samples collected at multiple time points during the study visit.
88980325|NCT05986513|Experimental|OA-Knee+Body|Individuals with knee OA with localized knee pain and widespread bodily pain. All participants will complete the same study protocol with pre- post-perturbation MRI scans and pain assessment questionnaires, as well as breath samples collected at multiple time points during the study visit.
88980326|NCT05985707|Experimental|A|Arm A will include HER2-positive treatment-naive metastatic colorectal cancer patients, and the patients in this cohort will receive XELOX and KN026 treatment.
88980327|NCT05985707|Experimental|B|Arm B will include HER2-positive treatment-naive metastatic colorectal cancer patients, and the patients in this cohort will receive XELOX and KN026 + KN046 treatment.
88980328|NCT05985707|Experimental|C|Arm C will include HER2-positive treatment-naive metastatic biliary tract cancer patients, and the patients in this cohort will receive XELOX and KN026 + KN046 treatment.
88980329|NCT05985499|Experimental|"Dumpling suture for ileostomy"|The stoma is fixed with sutures in a skin fold method, and the incision is progressively reduced in a process similar to the process of folding and pinching the Chinese small dumplings. This procedure may reduce stoma complications by progressively reducing the incision and realizing the effect of hiding the skin incision.
89601010|NCT03984448|Experimental|Arm 2 (R-CHOP, DA-EPOCH-R, venetoclax)|"DEL: Patients with DEL receive R-CHOP chemotherapy regimen as in Arm 1. Patients also receive venetoclax PO QD on days 4-8 of cycle 1 and days 1-5 for cycles 2-6. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo PET scan, CT scan and blood sample collection and may undergo bone marrow biopsy and lumbar puncture throughout the study.~DHL: Patients with DHL receive DA-EPOCH-R chemotherapy regimen as in Arm 1. Patients also receive venetoclax PO QD on days 4-8 of cycle 1 and days 1-5 for cycles 2-6. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo PET scan, CT scan and blood sample collection and may undergo bone marrow biopsy and lumbar puncture throughout the study."
89601011|NCT03981211|Experimental|Cohort A: 8 weeks G/P standard therapy|8 weeks treatment of a three fixed-dose combination of glecaprevir/pibrentasvir 100/40 mg tablets administered once daily with food (standard duration therapy).
89601012|NCT03981211|Experimental|Cohort B: 4 weeks SOF/G/P shortened therapy|4 weeks treatment of 1 tablet sofosbuvir 400 mg and a three fixed-dose combination of glecaprevir/pibrentasvir 100/40 mg tablets administered once daily with food (shortened duration therapy).
89601013|NCT03980132|Experimental|Preoperative Lugol Solution preparation|Patients will receive Lugol Solution preparation for 10 days before thyroidectomy
89601014|NCT03980132|No Intervention|No preparation|Patients will not receive preparation before thyroidectomy
89601015|NCT03973918|Experimental|Treatment Cohort 1 AA & GBM|"Encorafenib 450mg QD Binimetinib 45mg BID 28 day cycle~Research Bloods"
89601016|NCT03973918|Experimental|Treatment Cohort 2 anaplastic PXAs|"Encorafenib 450mg QD Binimetinib 45mg BID 28 day cycle~Research Bloods"
89601017|NCT03973918|Experimental|Surgical Arm|"Pre-op -14 days: Encorafenib 450mg QD and Binimetinib 45mg BID last dose of both drugs 2hrs prior to surgery~Tumor; research blood; CSF samples~post surgery: Encorafenib 450mg QD Binimetinib 45mg BID 28 day cycle"
89601018|NCT03973918|Experimental|Treatment Cohort 3 Other Tumors|"Encorafenib 450mg QD Binimetinib 45mg BID 28 day cycle~Research Bloods"
89601019|NCT03968406|Experimental|Treatment (talazoparib, radiation therapy)|Patients receive talazoparib PO QD beginning on days -10 to -7 and continuing for up to 8 weeks in the absence of disease progression or unacceptable toxicity. Patients also undergo radiation therapy 5 days a week (Monday-Friday) for up to 7 weeks.
89601020|NCT03952585|Active Comparator|Arm I (IMRT, IGRT, cisplatin)|Patients undergo IMRT or IGRT over 6 fractions per week and receive cisplatin IV over 30-60 minutes on days 1 and 22. Treatment continues for 6 weeks in the absence of disease progression or unacceptable toxicity. Patients receive FDG and undergo PET/CT or CT during screening and during follow up, and undergo MRI during follow up. Patients may also undergo tissue biopsy and blood sample collection throughout the study.
89601021|NCT03952585|Experimental|Arm II (IMRT, IGRT, cisplatin)|Patients undergo reduced dose IMRT or IGRT QD over 5 fractions per week and receive cisplatin IV over 30-60 minutes on days 1 and 22. Treatment continues for 6 weeks in the absence of disease progression or unacceptable toxicity. Patients receive FDG and undergo PET/CT or CT during screening and during follow up, and undergo MRI during follow up. Patients may also undergo tissue biopsy and blood sample collection throughout the study.
89601022|NCT03952585|Experimental|Arm III (IMRT, IGRT, nivolumab)|Beginning 1 week prior to radiation, patients receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 2 weeks (14 days) for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo reduced dose IMRT or IGRT over 6 fractions per week for 5 weeks in the absence of disease progression or unacceptable toxicity. Patients receive FDG and undergo PET/CT or CT during screening and during follow up, and undergo MRI during follow up. Patients may also undergo tissue biopsy and blood sample collection throughout the study.
89601023|NCT03948789|Active Comparator|A Myomectomy|Removement of uterine fibroids by myomectomy
89601024|NCT03948789|Experimental|B MRgFUS-TUF|Removement of uterine fibroids by Magnetic Resonance Imaging-controlled high-focussed ultrasound therapy (MRgFUS-TUF)
89601025|NCT03941860|Experimental|Arm A (lenalidomide, ixazomib citrate)|Patients receive lenalidomide PO QD on days 1-28 and ixazomib citrate PO on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspirate and/or biopsy and PET and CT scan at screening and on study as well as undergo collection of blood samples throughout the trial.
89601026|NCT03941860|Placebo Comparator|Arm B (lenalidomide, placebo)|Patients receive lenalidomide PO QD on days 1-28 and a placebo PO on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspirate and/or biopsy and PET and CT scan at screening and on study as well as undergo collection of blood samples throughout the trial.
89601027|NCT03938792|Experimental|PF-06741086|Participants will be assigned to treatment with PF-06741086 after a 6 month Observation Phase on their current hemophilia regimen.
89601028|NCT03934216|Experimental|BMS-986165|
89601029|NCT03934216|Placebo Comparator|Placebo|
89601030|NCT03926338|Experimental|Neoadjuvant treatment with PD-1 blockade plus COX-2 inhibitor|Toripalimab plus celecoxib
89601031|NCT03926338|Experimental|Neoadjuvant treatment with PD-1 blockade|Toripalimab monotherapy
89601032|NCT03919877|Other|Optimizing Diet for Glycemic Control|"Phase 1: Metabolic testing will include 3 metabolic tests:~The Oral Glucose Tolerance Test. The participant will wear the CGM while undergoing the OGTT + will be asked to repeat the test at home twice.~The Insulin Sensitivity Test (Steady State Plasma Glucose). This test is designed to measure how well cells remove glucose from the blood in response to insulin.~The Isoglycemic Intravenous Glucose Infusion (IIGI). This test is designed to measure the incretin hormone effect.~Phase 2: Participants follow their own diet while using the CGM. Participants are provided with 5-10 standardized foods to test during this phase.~Phase 3: Participants are provided with additional standardized foods and counseled to continue their own diet during this phase.~Phase 4: Participants are counseled on reducing or limiting the foods that caused glucose spikes and they are also counseled on macronutrient composition of their diet based on lipid profile."
88811365|NCT01321151|Placebo Comparator|Sugar Pill|Placebo control
88811366|NCT01321151|Experimental|Resveratrol|Intervention
88811367|NCT01350947|Experimental|All patients|All participants enrolled.
89601033|NCT03914300|Experimental|Treatment (cabozantinib S-malate, nivolumab, ipilimumab)|Patients receive cabozantinib S-malate PO QD on days -14 to -1 prior to cycle 1, days 1-42 of cycles 1-4 and days 1-28 of subsequent cycles. Patients also receive nivolumab IV over 30 minutes on days 1, 15, and 29 of cycles 1-4 and day 1 of subsequent cycles and ipilimumab IV over 90 minutes on day 1 of cycles 1-4. Treatment repeats every 42 days for cycles 1-4 and every 28 days for subsequent cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT or MRI during screening, and blood sample collection throughout the study.
89601034|NCT03907852|Experimental|Lymphodepletion followed by gavo-cel|fludarabine 30 mg/m2/d on days -7 through -4 and cyclophosphamide 600 mg/m2/d on days -6 through -4 followed by gavo-cel
89601035|NCT03907852|Experimental|Lymphodepletion followed by gavo-cel plus nivolumab|fludarabine 30 mg/m2/d on days -7 through -4 and cyclophosphamide 600 mg/m2/d on days -6 through -4 followed by gavo-cel with nivolumab 360mg every 3 weeks starting on Day 21 post gavo-cel
89601036|NCT03907852|Experimental|Lymphodepletion followed by gavo-cel plus nivolumab and ipilimumab|fludarabine 30 mg/m2/d on days -7 through -4 and cyclophosphamide 600 mg/m2/d on days -6 through -4 followed by gavo-cel with nivolumab 360mg every 3 weeks starting on Day 21 post gavo-cel and ipilimumab 1mg/kg every 6 weeks starting on Day 42 post gavo-cel
89601037|NCT03907475|Active Comparator|Arm I (durvalumab)|Patients receive durvalumab IV over 60 minutes on days 1 and 15 of cycles 1 and 2 and day 1 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT throughout the trial. Patients also undergo tissue biopsy and blood sample collection during screening and on the trial.
89601038|NCT03907475|Experimental|Arm II (gemcitabine hydrochloride, durvalumab)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15 and durvalumab IV over 60 minutes on days 8 and 22 of cycles 1 and 2 and day 8 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who discontinue gemcitabine hydrochloride continue receiving durvalumab alone as in Arm I. Patients undergo CT throughout the trial. Patients also undergo tissue biopsy and blood sample collection during screening and on the trial.
89601039|NCT03907475|Experimental|Arm III (pegylated liposomal doxorubicin, durvalumab)|Patients receive pegylated liposomal doxorubicin hydrochloride IV over 60 minutes on day 1 and durvalumab IV over 60 minutes on days 8 and 22 of cycles 1 and 2 and day 1 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO during screening. Patients undergo CT throughout the trial. Patients also undergo tissue biopsy and blood sample collection during screening and on the trial.
89601040|NCT03907475|Experimental|Arm IV (capecitabine, durvalumab)|Patients receive capecitabine orally (PO) twice daily (BID) on days 1-14, and durvalumab IV over 60 minutes on days 8 of cycle 1, day 8 and 15 of cycle 2, day 8 of cycles 3, and day 1 of subsequent cycles. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT throughout the trial. Patients also undergo tissue biopsy and blood sample collection during screening and on the trial.
89601041|NCT03907475|Experimental|Arm V (carboplatin, durvalumab)|Patients receive carboplatin IV over 30-60 minutes on day 1 and durvalumab IV over 60 minutes on day 8 of cycle 1, days 8 and 15 of cycle 2, day 8 of cycles 3, and day 1 of subsequent cycles. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT throughout the trial. Patients also undergo tissue biopsy and blood sample collection during screening and on the trial.
89601042|NCT03907475|Experimental|Arm VI (paclitaxel, durvalumab)|Patients receive paclitaxel IV over 60 minutes on day 1 and durvalumab IV over 60 minutes on day 8 of cycle 1, days 8 and 15 of cycle 2, day 8 of cycles 3, and day 1 of subsequent cycles. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT throughout the trial. Patients also undergo tissue biopsy and blood sample collection during screening and on the trial.
89601043|NCT03907475|Experimental|Arm VII (nab-paclitaxel, durvalumab)|Patients receive nab-paclitaxel IV over 30 minutes on day 1 and durvalumab IV over 60 minutes on day 8 of cycle 1, days 8 and 15 of cycle 2, day 8 of cycles 3, and day 1 of subsequent cycles. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT throughout the trial. Patients also undergo tissue biopsy and blood sample collection during screening and on the trial.
89601044|NCT03896269|Experimental|Treatment (liposome-encapsulated daunorubicin-cytarabine)|"INDUCTION THERAPY: Patients receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1, 3, and 5 in the absence of disease progression or unacceptable toxicity. After 2-5 weeks, patients who do not achieve a CR/CRi/CRp, have acceptable or no toxicity, and have stable disease and no disease progression may receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1 and 3 in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION THERAPY: Patients who achieve at least a HI response, receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1 and 3. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. After 5-8 weeks, patients who do not show clinically significant disease progression or unacceptable toxicity may receive liposome-encapsulated daunorubicin-cytarabine for up to 12 additional cycles."
89601045|NCT03878095|Experimental|Treatment (olaparib, ceralasertib)|Patients receive olaparib PO BID on days 1-28 of each cycle and ceralasertib PO QD on days 1-7 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo tumor biopsies during screening and on study, collection of blood samples throughout the trial, and undergo CT and/or MRI scans throughout the trial. Patients may also undergo bone marrow aspiration and biopsy as clinically indicated on study.
89601046|NCT03877653|Experimental|Interventional|Single arm, active stimulation
89601047|NCT03877653|Placebo Comparator|Placebo|"When receiving sham stimulation, devices will be programmed to not actively deliver electrical stimulation but still deplete battery life to maintain blinding. Subjects will have to recharge batteries similar to receiving active stimulation.~Sites will not have access to WaveCrest programmer. Study devices can only be programmed by Stimwave representatives."
89601048|NCT03855917|Experimental|Sof plus G/P|Four weeks of sofosbuvir (400mg) plus glecaprevir-pibrentasvir (300mg/120mg) will be administered, followed by immediate retreatment of virological relapse with glecepravir/pibrentasvir (300mg/120mg) for 12 weeks, in treatment-naïve participants with chronic HCV infection and early liver disease (F0-F2).
89601049|NCT03842228|Experimental|Treatment (copanlisib hydrochloride, olaparib, and durvalumab)|Patients receive copanlisib hydrochloride IV over 1 hour on days 1 and 15 or days 1, 8, and 15 depending on dose level and olaparib PO BID on days 1-28 of each cycle. Beginning cycle 2, patients receive durvalumab IV over 1 hour on day 1 of each cycle. Cycles repeat every 28 days for 24 months in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood samples at baseline within 7 days of C1D1, days 8 and 15 of cycle 1 and day 15 of subsequent cycles, at time of restaging, and end of treatment/progression. Patients undergo x-ray, CT, and MRI at the end of cycle 2 and then every 8 weeks. Patients also undergo an ECHO during pre-study within 28 days of C1D1 and tumor biopsy at baseline within 7 days of C1D1 and day 15 of cycle 1 or 2, and may undergo an optional biopsy at end of treatment/progression.
89601050|NCT03839862||Responder|Patient responding to TNF-inhibition
89601051|NCT03839862||non-Responder|Patient not responding to TNF-inhibition
89601052|NCT03835065|Active Comparator|Long Arm Fiberglass Cast|Conscious sedation will be provided to patient while the reduction is performed by a cast trained orthopedic resident using standard techniques under fluoroscopic guidance. The arm will be held by an assistant or finger traps in the absence thereof. The arm will not be suspended until after the manipulation is performed. A stockingette and webril will first be applied, after which the short arm fiberglass portion of the cast will be applied. After short arm casting has been appropriately placed, randomization group will be revealed. Casting will be extended to the shoulder joint if the patient is assigned to the long arm cast group. The mold will then be applied and cast construct will be bivalved and taped.
89601053|NCT03835065|Experimental|Short Arm Fiberglass Cast|Conscious sedation will be provided to patient while the reduction is performed by a cast trained orthopedic resident using standard techniques under fluoroscopic guidance. The arm will be held by an assistant or finger traps in the absence thereof. The arm will not be suspended until after the manipulation is performed. A stockingette and webril will first be applied, after which the short arm fiberglass portion of the cast will be applied. After short arm casting has been appropriately placed, randomization group will be revealed. Casting will be complete at this point if the patient is assigned to the short arm cast group. The mold will then be applied and cast construct will be bivalved and taped.
89601054|NCT03833700|Experimental|Dose Escalation Part: E7386|Participants will receive E7386 10, 15, 20 mg (milligram) or more, tablets, orally, twice daily, in 28-days treatment cycle until disease progression (PD), development of unacceptable toxicity, participant's request to discontinue, withdrawal of consent, or termination of the study program. Dose escalation of E7386 will be based on the available safety data from the previous cohorts.
89601055|NCT03833700|Experimental|Expansion Part 1|Participants will receive E7386, tablets, orally, twice daily in 28-days treatment cycle until PD, development of unacceptable toxicity, participant's request to discontinue, withdrawal of consent, or termination of the study program. The highest dose of E7386 which is deemed tolerable, or the optimal dose based on PK or PD analysis in dose escalation part will be used for Expansion Part 1.
89601056|NCT03833700|Experimental|Expansion Part 2|Participants will receive E7386, tablets, orally, twice daily in 28-days treatment cycle until PD, development of unacceptable toxicity, participant's request to discontinue, withdrawal of consent, or termination of the study program. The dose of Expansion Part 2 will be based on the available safety data from Dose Escalation and Expansion Part 1 of the study.
89601057|NCT03831932|Experimental|Treatment (telaglenastat HCl, osimertinib)|Patients receive telaglenastat hydrochloride PO BID and osimertinib PO QD (starting cycle 1 day 16 of phase I). Patients undergo blood sample collection and may undergo x-ray imaging, CT scan, MRI, or PET scan throughout the study. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89601058|NCT03827382|Active Comparator|Intervention|Patients with intensive Lifestyle intervention
89601059|NCT03827382|No Intervention|Control|Patients with Standard Diabetes care
89601060|NCT03826030|Sham Comparator|Sham tDCS + mCIMT|Sham tDCS (Transcranial direct current stimulation) administers no dose or zero milliampere stimulation through the tDCS device, during Constraint Induced Movement Therapy (mCIMT)
89601061|NCT03826030|Active Comparator|2 mA tDCS + mCIMT|2 mA tDCS (Transcranial direct current stimulation) administers low dose or 2 milliampere stimulation through the tDCS device, during Constraint Induced Movement Therapy (mCIMT)
89601062|NCT03826030|Active Comparator|4 mA + mCIMT|4 mA tDCS (Transcranial direct current stimulation) administers high dose or 4 milliampere stimulation through the tDCS device, during Constraint Induced Movement Therapy (mCIMT)
89601063|NCT03820830|Experimental|Palbociclib plus standard endocrine therapy|Palbociclib 125 mg/day tablet taken orally for 21 days, followed by 7 days rest for 3 years from randomization, plus standard endocrine therapy for at least 3 years from randomization.
89601064|NCT03820830|Active Comparator|Standard endocrine therapy|Aromatase inhibitor (anastrozole or exemestane or letrozole) oral daily tablet, or Selective Estrogen Receptor Modulator (SERM) such as tamoxifen oral daily tablet or fulvestrant (Faslodex) injection once every 2 weeks for 3 doses then every month. Premenopausal women and men may also receive an LHRH (luteinizing hormone-releasing hormone) agonist by injection. Standard endocrine therapy will be given for at least 3 years from randomization.
89601065|NCT03814187|Experimental|Inclisiran|"Inclisiran sodium 300 milligrams (mg) was administered as a single SC injection on Day 1*, 90, then every 180 days to Day 990.~*Subjects who received blinded placebo in the feeder study received blinded inclisiran and subjects who received blinded inclisiran in the feeder study received blinded placebo on Day 1 in ORION-8. Subjects from the open label ORION-3 study did not receive any injection of study drug on Day 1. Their first dose of study medication was at day 90"
88980330|NCT05985499|Other|Traditional suture for ileostomy|The stoma was fixed at the skin using traditional sutures. The incision is narrowed by 2-3 interrupted sutures at the distal and proximal ends of the skin incision on the abdominal wall. The stoma is then fixed at the right lower abdominal incision with sutures.
88980331|NCT05984550|Experimental|treated group|NMN(Vital NAD) treated group
89032203|NCT02931435|Sham Comparator|Nerve Block with Sham Radiofrequency Ablation|A 10 cm 18-gauge RF cannula with a 10 mm active tip will be placed at the superior lateral, superior medial, and inferior medial nerve positions under fluoroscopic guidance.Control patients will undergo the same procedure without RF generator activation. Sensory stimulation at 50 Hz will be performed to identify nerve position and to assure no motor nerves will be ablated. Lidocaine (2 ml of 2%) will be administered in each location prior to RF generator sham activation.
89601066|NCT03784014|No Intervention|Arm No NGS|"Patients will be treated by standard first-line systemic treatment and tumor assessment will be performed every 2 cycles during treatment. Thereafter, disease will be managed as per standard care depending on tumor response observed at the end of the first-line treatment.~Note that for these participants and under specific conditions, subsequent NGS analyses may be allowed within the scope of the trial"
89601067|NCT03784014|Experimental|Arm NGS|"Patients will be treated by standard first-line systemic treatment and tumor assessment will be performed every 2 cycles during treatment. After tumor assessment at the end of first-line systemic treatment and regardless of tumor response as per RECIST v1.1, participants will be discussed within a multidisciplinary tumor board (molecular tumor board-MTB) which aims at discussing the genomic profiles and at providing a therapeutic decision for each participant.~Patients for whom a targetable genomic alteration has been highlighted will be proposed to enter in a subsequent single-arm phase II sub-trials. Otherwise, thereafter, disease will be managed as per standard care depending on tumor response observed at the end of the first-line treatment"
89601068|NCT03784014|Experimental|Arm NGS - Targeted therapy|Targeted therapy from a list of 10 targeted treatment strategies, guided by the genomic analyses: Nilotinib capsule per os 400 mg bd, continuous dosing ; Ceritinib capsule per os 450 mg od, continuous dosing; Capmatinib tablet per os 400 mg bd, continuous dosing; Lapatinib tablet per os 1500 mg od, continuous dosing; Trametinib tablet per os 2 mg od, continuous dosing; association of Trametinib tablet per os 2 mg od and Dabrafenib capsule per os 150 mg bd, continuous dosing; association of Olaparib tablet per os 300 mg bd, continuous dosing and Durvalumab intra-veinous 1500 mg on day 1, Q4W; Palbociclib capsule 125 mg od, 3 weeks on/1 week off; Glasdegib tablet per os 300 mg od, continuous dosing; TAS-120 tablet per os 20 mg od, continuous dosing.
89601069|NCT03756142||Multiple sclerosis patients|Analysis of orthostatic posture, initiation of walking and walking in MS patients with an EDSS between 0 and 4 (included) by a motion analysis system
89601070|NCT03756142||Healthy volunteers|Analysis of orthostatic posture, initiation of walking and walking in a group of healthy volunteers
89601071|NCT03744793|Experimental|Treatment (pemetrexed, avelumab)|Patients receive pemetrexed IV over 10 minutes on day 1. Starting cycle 2, patients also receive avelumab IV over 60 minutes. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89601072|NCT03723655|Experimental|Group 1|Active Treatment for participants with base target trough concentration
89601073|NCT03723655|Experimental|Group 2|Active Treatment for participants with higher target trough concentration
89601074|NCT03723655|Experimental|Group 3|Active Treatment for participants dose titrated to clinical response
89601075|NCT03722420|Experimental|Radotinib 300mg|Oral adminstration of Radotinib 300mg BID (600mg/day) for 12months
89601076|NCT03722420|Active Comparator|Imatinib 400mg|Oral administration of Imatinib 400mg QD (400mg/day) for 12months
89601077|NCT03707730|Experimental|AGY|capsule containing egg yolk with AGY
89601078|NCT03707730|Placebo Comparator|placebo|capsule containing plain egg yolk
89601079|NCT03706027|Active Comparator|Stereotactic body radiotherapy- 3 fractions|
89601080|NCT03706027|Active Comparator|Stereotactic body radiotherapy- 5 fractions|
89601081|NCT03672539|Experimental|Treatment (CPX-351, gemtuzumab ozogamicin)|"INDUCTION CYCLE: Patients receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1, 3, and 5 of cycle 1 and days 1 and 3 of cycle 2 and gemtuzumab ozogamicin IV over 120 minutes on day 1. Treatment repeats every 28 days for up to 2 cycles in the absence of unacceptable toxicity.~CONSOLIDATION CYCLE: Patients receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1 and 3 and gemtuzumab ozogamicin over 120 minutes on day 1. Treatment repeats every 28 days for up to 2 cycles in the absence of unacceptable toxicity.~MAINTENANCE CYCLE: Patients receive gemtuzumab ozogamicin IV over 120 minutes on day 1. Treatment repeats every 6 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity."
89601082|NCT03666273|Experimental|Dose escalation_Monotherapy|Patients with solid tumor types considered immunosensitive
89601083|NCT03666273|Experimental|Dose escalation_Combination therapy|Patients with solid tumor types considered immunosensitive
89601084|NCT03666273|Experimental|Expansion HNSCC_Combination therapy|Patients with head and neck squamous cell carcinoma (HNSCC)
89601085|NCT03661307|Experimental|Treatment (decitabine, quizartinib, venetoclax)|Patients receive decitabine IV over 1 hour on days 1-10, quizartinib PO every day beginning on day 1 of cycle 1, and venetoclax PO on days 1-14 (days 1-21 if persistent leukemia). Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88980332|NCT05980546|No Intervention|Group 1 Standard TKA|"The standard TKA group will receive the standard of care analgesia. Those in the control group will be given 7 mg of the preservative dexamethasone intravenously.~The standard group will be given 2-5 mg of intravenous midazolam and up to 100 mcg fentanyl for sedation and analgesia while the peripheral nerve blocks and spinal anesthesia are being performed. All patients will receive a spinal anesthetic (1.5% mepivacaine 52.5 - 60mg) as well as the standard adductor canal block and infiltration between the popliteal artery and posterior knee capsule block (20 ml of 0.25% bupivacaine with 2 mg preservative free dexamethasone for each block)."
89032204|NCT02931825|Experimental|Reminder letter|A letter is sent for remind the importance of compliance with colonoscopy AND to encourage people to to consult their general practitioner or gastroenterologist (if they haven't done their follow-up in time).
89032205|NCT02931825|No Intervention|Control|No intervention (what is done currently)
89032206|NCT02937792|No Intervention|CONTROL|one with intrathecal 12.5 mg bupivacaine
89032207|NCT02937792|Experimental|experimental|one group with intrathecal 15 mg bupivacaine
89032208|NCT02931474|Placebo Comparator|Placebo|Salt Water Solution
89032209|NCT02931474|Experimental|Tesamorelin|Growth Hormone-Releasing
89601086|NCT03652428|Other|Pancreatic Proton Therapy With Concurrent Gem + Nab-paclitaxel|"Part I:~Gemcitabine + nab-paclitaxel:~• Administered per institutional standard every 7 days for 3 weeks~Part II:~Hypofractionated ablative pancreatic proton radiation therapy 67.5 Gy fractions once per day Monday - Friday for 3 weeks, for a total of 15 fractions.~Part III:~Surgery, if resectable, then adjuvant chemo per discretion of MD or no further therapy~OR~Chemo per discretion of MD if not resectable"
89601087|NCT03641300|Experimental|Magnetic Seizure Therapy (MST)|MST treatments will be administered using the MagPro MST with Cool TwinCoil.
89601088|NCT03641300|Active Comparator|Electroconvulsive Therapy (ECT)|ECT treatments will be administered using the MECTA spECTrum 5000Q or MECTA Sigma
89601089|NCT03640520|Experimental|Intervention|Family-centered & Trauma-informed Support in Pediatric Resuscitation (FACETS: Pediatric Resuscitation) is an online skills training module for health care professionals involved in pediatric resuscitation in general EDs. The module combines didactic information and scenario-based learning with opportunities for the learner to practice applying their knowledge of Family Centered Care (FCC) practices at key choice points in realistic pediatric resuscitation case scenarios. Training content is guided by evidence regarding FCC practices that are effective in reducing concurrent and ongoing emotional distress in children and family members, and in promoting child and family involvement and satisfaction with care.
89601090|NCT03640520|Active Comparator|Control|An online training module in which participants will receive information and policy education about national pediatric readiness standards for all EDs, including a brief mention of FCC as one of these standards, with no specific skills training in FCC. The module provides practice-relevant knowledge related to pediatric differences and pediatric readiness.
89601091|NCT03629171|Experimental|Treatment (CPX-351, venetoclax)|"INDUCTION: Participants receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1, 3, and 5 of cycle 1 and on days 1 and 3 of cycle 2. Participants also receive venetoclax PO QD on days 2-21. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Participants receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1 and 3 and venetoclax PO QD on days 2-21. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity."
89601092|NCT03620266|Experimental|Bilberry|Dietary supplement with bilberry shakes 2 times daily for 3 months (containing in total 40g of dried bilberry powder equalling 480 g of fresh berries per day). Product development in collaboration with Glucanova AB.
89601093|NCT03620266|Placebo Comparator|Reference/Placebo|Dietary supplement with reference shakes 2 times daily for 3 months (containing no active bilberry or no active oats, but with similar texture and taste as both bilberry and oat). Product development in collaboration with Glucanova AB.
89601094|NCT03620266|Experimental|Bioprocessed oat bran|Dietary supplement with bioprocessed oat bran shakes 2 times daily for 3 months (containing beta glucans from the Glucanova® technology, invented by Glucanova AB).Product development in collaboration with Glucanova AB.
89601095|NCT03620266|Experimental|Combination of oat and bilberry|Dietary supplement with a combination of bioprocessed oat bran and dried bilberry (shakes) 2 times daily for 3 months. Product development in collaboration with Glucanova AB.
89601096|NCT03617770|Experimental|Sleep-Opt-In|Sleep optimization intervention
89601097|NCT03617770|Active Comparator|Healthy Living|Health education
89601098|NCT03607188|Experimental|ZG0418 200mg QD|ZG0418 200mg/day,oral
89601099|NCT03607188|Experimental|ZG0418 300mg QD|ZG0418 300mg/day,oral
89601100|NCT03607188|Experimental|ZG0418 400mg QD|ZG0418 400mg/day,oral
89601101|NCT03607188|Experimental|ZG0418 500mg QD|ZG0418 500mg/day,oral
89601102|NCT03607188|Experimental|ZG0418 600mg QD|ZG0418 600mg/day,oral
89601103|NCT03606980|Experimental|Iontophoresis with Dexamethasone|Iontophoresis is a non-invasive delivery mechanism for transmitting a medication to a local area of the body. The I-Bresis™ System and I-Bresis™ Patch will be the delivery system used for this study. The I-Bresis™ Patch is an adhesive patch. 1.5 ml of the dexamethasone sodium phosphate (4ml/1mL) will be placed on one side and 1.5 ml of 0.9% sodium chloride (saline) solution will be placed on the other. Duration of exposure: 123 minutes. Frequency of exposure: twice per week for a total of 12 sessions over a maximum of 8 weeks or until Return to Sport Criteria are met, whichever is sooner. Participants will also receive the standard PT protocol for apophysitis of the knee. This will involve up to 20 visits.
89601104|NCT03606980|Placebo Comparator|Iontophoresis with Sodium Chloride|Iontophoresis is a non-invasive delivery mechanism for transmitting a medication to a local area of the body. The I-Bresis™ System and I-Bresis™ Patch will be the delivery system used for this study. The I-Bresis™ Patch is an adhesive patch. 1.5 ml of 0.9% sodium chloride (saline) solution will be placed on one side and 1.5 ml of 0.9% saline solution will be placed on the other. Duration of exposure: 123 minutes. Frequency of exposure: twice per week for a total of 12 sessions over a maximum of 8 weeks or until Return to Sport Criteria are met, whichever is sooner. Participants will also receive the standard PT protocol for apophysitis of the knee. This will involve up to 20 visits.
89601105|NCT03606980|Active Comparator|Physical Therapy alone|Participants will only receive the standard PT protocol for apophysitis of the knee. This will involve up to 20 visits.
89601106|NCT03598998|Experimental|Treatment (pralatrexate and pembrolizumab)|Patients receive pralatrexate IV over 3-5 minutes on days 1 and 8 and pembrolizumab IV over 30 minutes on day 1. Courses repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
89601107|NCT03595592|Active Comparator|HPCT|Patients will receive a combination of trastuzumab, pertuzumab, carboplatin and paclitaxel as neoadjuvant therapy for 6 cycles every 3 weeks. Trastuzumab (H) will be delivered on day 1 at the dose of 8 mg/kg loading dose i.v., then 6 mg/kg i.v. Pertuzumab (P) will be delivered on day 1 at the dose of 840 mg loading dose i.v., then 420 mg i.v. Carboplatin (C) will be administered at AUC 2 i.v. on day 1 and day 8. Paclitaxel (T) will be given at 90 mg/m2 i.v. on day 1 and day 8. Definite surgery will be performed not later than 4 weeks after the last dose of neoadjuvant therapy. Trastuzumab and pertuzumab will then be delivered for 12 additional cycles as adjuvant therapy.
89608574|NCT00735826|Experimental|Vorinostat 400 mg|Vorinostat will be administered orally once daily in an open-labeled unblinded manner to all subjects enrolled in the study. Subjects will received 400 mg once daily on a continuous daily basis for 7 to 10 days prior to surgical resection.
89608575|NCT04765995|Experimental|HZBio1 0.96mg/kg|Participants will receive intramuscularly 0.96 milligram per kilogram (mg/kg) of HZBio1.
89601108|NCT03595592|Experimental|ACy followed by HPCT and atezolizumab|Patients will receive a combination of doxorubicin (A, 60 mg/m2 i.v.), cyclophosphamide (C, 600 mg/m2 i.v.) and atezolizumab (1200 mg i.v.) on day 1 every 3 week for 3 cycles. Subsequently they will be given trastuzumab on day 1 (H, at the loading dose of 8 mg/kg i.v. then 6 mg/kg i.v.), pertuzumab on day 1 (P, at the loading dose of 840 mg .v., then 420 mg i.v.), carboplatin (C) at AUC 2 i.v. on day 1 and day 8, paclitaxel (T) at 90 mg/m2 i.v. on day 1 and day 8, and atezolizumab 1200 mg i.v. on day 1 for 3 cycles every 3 weeks. Definite surgery will be performed not later than 4 weeks after the last dose of neoadjuvant therapy. Trastuzumab and pertuzumab will then be delivered for 15 additional cycles and atezolizumab for 12 additional cycles as adjuvant therapy.
89601109|NCT03595592|Experimental|HPCT and atezolizumab|Patients will receive a combination of trastuzumab, pertuzumab, carboplatin, paclitaxel and atezolizumab as neoadjuvant therapy for 6 cycles every 3 weeks. Trastuzumab (H) will be delivered on day 1 at the dose of 8 mg/kg loading dose i.v., then 6 mg/kg i.v. Pertuzumab (P) will be delivered on day 1 at the dose of 840 mg loading dose i.v., then 420 mg i.v. Carboplatin (C) will be administered at AUC 2 i.v. on day 1 and day 8; paclitaxel (T) will be given at 90 mg/m2 i.v. on day 1 and day 8; atezolizumab at the dose of 1200 mg i.v. on day 1. Definite surgery will be performed not later than 4 weeks after the last dose of neoadjuvant therapy. Trastuzumab, pertuzumab and atezolizumab will then be delivered for 12 additional cycles as adjuvant therapy.
89601110|NCT03580109|Active Comparator|Immediate spa treatment|Spa treatment linked with education therapeutic during 18 days just after randomization : common to all of spa resorts
89601111|NCT03580109|Sham Comparator|Late spa treatment|Spa treatment linked with education therapeutic during 18 days 6 months visit after randomization
89601112|NCT03571789|Experimental|Vine™ implantation bilaterally in the common carotid arteries|Vine™ is a permanent carotid filter made from a single nitinol wire. It is configured to capture emboli exceeding 1.2mm in size, which originate in the heart and large arteries below the neck. Vine™ has a helical structure, with leading and supporting coils interposed by a filter section.
89601113|NCT03549715|Experimental|ARM A: durvalumab + ddMVAC|Durvalumab + ddMVAC Durvalumab 1500 mg IV D1 every 28 days Durvalumab will be administered at the hospital every 28 days prior to administration of ddMVAC on D1.
89601114|NCT03549715|Experimental|ARM B: durvalumab + tremelimumab+ ddMVAC|"durvalumab + tremelimumab + ddMVAC Tremelimumab 75 mg IV D1 every 28 days Tremelimumab will be administered first, with durvalumab infusion starting approximately 1 hour (maximum 2 hours) after the end of the tremelimumab infusion.~Infusion of ddMVAC will start approximately 1 hour after completion of durvalumab."
89601115|NCT03525964|Experimental|Individualized treatment|"The ruptured achilles tendon is examined by ultrasonography. If the overlap of the tendon ends is less than 25 % or the tendon is elongated 7 % or more the patient receives conventional open operative treatment. The tendon is sutured with double fiberwire size 2 a.m. Kessler under prophylactic Dicloxacillin 2 g and in local anaesthesia or alternatively popliteal or spinal block. The injured leg is placed in a circulated below-the-knee cast after surgery. The ankle is held at maximal, unforced plantar flexion. Weight bearing is not allowed and the patient should walk with the aid of crutches. After 3 weeks from initiated treatment in the Emergency Department the cast is removed in the Outpatients Department and the injured leg is transferred to a functional brace (Walker boot) with 3 heel wedges promoting 20 degrees plantar flexion over the ankle.~The patient will follow standard functional rehabilitation and the follow-up evaluations."
89601116|NCT03525964|Active Comparator|Control group 1|"For the patients allocated to non-operative treatment the injured leg is placed in a circulated below-the-knee cast from the time of the first appointment in the Outpatients Department. The ankle is held at maximal, unforced plantar flexion. Weight bearing is not allowed and the patient should walk with the aid of crutches. After 3 weeks from initiated treatment in the Emergency Department the cast is removed in the Outpatients Department and the injured leg is transferred to a functional brace (Walker boot) with 3 heel wedges promoting 20 degrees plantar flexion over the ankle.~The patient will follow standard functional rehabilitation and the follow-up evaluations."
89601117|NCT03525964|Active Comparator|Control group 2|"The tendon is sutured with double fiberwire size 2 a.m. Kessler under prophylactic Dicloxacillin 2 g and in local anaesthesia or alternatively popliteal or spinal block. The injured leg is placed in a circulated below-the-knee cast from the time of the first appointment in the Outpatients Department. The ankle is held at maximal, unforced plantar flexion. Weight bearing is not allowed and the patient should walk with the aid of crutches. After 3 weeks from initiated treatment in the Emergency Department the cast is removed in the Outpatients Department and the injured leg is transferred to a functional brace (Walker boot) with 3 heel wedges promoting 20 degrees plantar flexion over the ankle.~The patient will follow standard functional rehabilitation and the follow-up evaluations."
89601118|NCT03502733|Experimental|Cohort I (Doublet) (copanlisib, nivolumab)|Patients receive copanlisib IV over 1 hour on days 1 and 15 or days 1, 8, and 15 of each cycle and nivolumab IV over 30 minutes on day 1 or days 1 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT scan and/or MRI throughout the trial. Patients undergo blood sample collection on study and during follow-up, as well as tumor biopsy on study. Patients also undergo an ECHO during screening and as clinically indicated on study.
89601119|NCT03502733|Experimental|Cohort II (Triplet Safety) (copanlisib, nivolumab, ipilimumab)|Patients receive copanlisib IV over 1 hour on days 1, 8, and 15 of each cycle, nivolumab IV over 30 minutes on day 1 of each cycle, and ipilimumab IV over 90 minutes on day 1 for cycles 1-4. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT scan and/or MRI throughout the trial. Patients undergo an ECHO during screening and as clinically indicated on study.
89601120|NCT03502733|Experimental|Cohort III (Triplet) (copanlisib, nivolumab, ipilmumab)|Patients receive copanlisib IV over 1 hour on days 1, 8, and 15 of each cycle, nivolumab IV over 30 minutes on day 15 of cycle 1 and then day 1 of each subsequent cycles, and ipilimumab IV over 90 minutes on day 1 for cycles 2-5. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT scan and/or MRI throughout the trial. Patients undergo blood sample collection on study and during follow-up, as well as tumor biopsy on study. Patients also undergo an ECHO during screening and as clinically indicated on study.
89601121|NCT03496220|Experimental|Feedback|The ICU with feedback will be equipped with display device corresponding to each Angulus device with an interactive software interface which displays the patient's elevation.
89601122|NCT03496220|Other|No Feedback|The Angulus device will be on the patient but will NOT have the corresponding display data on patient elevation available to nurses.
89601123|NCT03495141|Active Comparator|Supervised|Participants first take part in supervised/coached colonoscopy module session twice (case one and case two) and then transition to performing an unassisted colonoscopy module twice (case three and case four).
89601124|NCT03495141|Active Comparator|Unsupervised|Participants will either first partake in an unsupervised colonoscopy module twice (case one and case two) and then transition to a supervised/coached colonoscopy module session twice (case three and case four).
89601125|NCT03486704|Experimental|Face to Face VRRS and telerehabilitation|Participants will receive 12 sessions of an individualized Face to Face cognitive training using VRRS over 4 weeks followed by 36 sessions of home-based VRRS cognitive training, three sessions for week.
89601126|NCT03486704|Active Comparator|Usual rehabilitation program|The usual rehabilitation group will receive 12 sessions of face-to-face usual cognitive training program.
89601127|NCT03486704|Active Comparator|FTF VRRS plus unstructured CS|Participants will receive 12 sessions of an individualized Face to Face (FTF) cognitive training using VRRS over 4 weeks followed by 36 sessions of home-based unstructured cognitive stimulation (CS), three sessions for week.
89601128|NCT03486704|Experimental|Face to Face VRRS plus active tDCS and telerehabilitation|Participants will receive 12 sessions of an individualized Face to Face cognitive training using VRRS combined with active (anodal) tDCS applied to the left dorsolateral prefrontal cortex over 4 weeks followed by 36 sessions of home-based VRRS cognitive training, three sessions for week.
89601129|NCT03486704|Active Comparator|Face to Face VRRS plus placebo tDCS and telerehabilitation|Participants will receive 12 sessions of an individualized Face to Face cognitive training using VRRS combined with placebo tDCS applied to the dorsolateral prefrontal cortex of the left hemisphere over 4 weeks followed by 36 sessions of home-based VRRS cognitive training, three sessions for week.
89601130|NCT03481387|Other|Aortic Valve Replacement with Perceval S sutureless heart valve|Patient undergoing Aortic Valve Replacement with Perceval S sutureless heart valve
89601131|NCT03467789|Experimental|Group A: D3 prior to first PDT|"In both groups, one PDT session is preceded by neoadjuvant PDT while the other PDT session has no pretreatment.~Group A will take dietary D3 pills prior to the first PDT treatment (day 1), and placebo pills prior to the second PDT treatment (at 2 months). Both Group A and Group B will take continuous serum D3 prior to the third PDT visit (Month 4). A final assessment of lesion clearance will be performed at 6 months"
89601132|NCT03467789|Experimental|Group B: D3 prior to second PDT visit|"In both groups, one PDT session is preceded by neoadjuvant PDT while the other PDT session has no pretreatment.~Group B will receive placebo prior to their first PDT visit (day 1), and Vitamin D3 prior to their second PDT visit (at 2 months). Both Group A and Group B will take continuous D3 prior to the third PDT visit (Month 4). A final assessment of lesion clearance will be performed at 6 months"
89601133|NCT03444337||Catheter Ablation Group|Patients undergoing FIRM guided ablation of paroxysmal or persistent atrial fibrillation with pre-procedure high resolution cardiac MRI
89601134|NCT03421639|Active Comparator|GnRH analog alone|control group treated with GnRH analog alone
89601135|NCT03421639|Experimental|Aromatase inhibitor plus GnRH analog|experimental group treated with aromatase inhibitor plus GnRH analog
88980333|NCT05980546|Experimental|Group 2 Genicular TKA|"The genicular group will receive the study intervention of a genicular nerve block and anterior femoral cutaneous nerve block. The intervention group (genicular nerve block/anterior femoral cutaneous nerve block) will receive additional nerve blocks totaling 30 ml of 0.25% bupivacaine with 4 mg preservative-free dexamethasone (5 ml for each block: SMGN, IMGN, SLGN, NVI; 10ml for AFCN).~The genicular group will be given 2-5 mg of intravenous midazolam and up to 100 mcg fentanyl for sedation and analgesia while the peripheral nerve blocks and spinal anesthesia are being performed. All patients will receive a spinal anesthetic (1.5% mepivacaine 52.5 - 60mg) and the standard adductor canal block and infiltration between the popliteal artery and posterior knee capsule block (20 ml of 0.25% bupivacaine with 2 mg preservative free dexamethasone for each block)."
88980334|NCT05980325|Experimental|Nordic Walking|Patients in this arm will be assigned to a 12-week exercise intervention twice weekly based on Nordic Walking (NW). The intervention will be structured as follows: i) 10 min warm-up, ii) 40 min NW with muscle strengthening exercises interspersed in between and iii) 10 min cool-down. Intensity will be monitored with a heart rate monitor (when available) and/or Borg Scale to reach a moderate intensity for the first 6 weeks (4 - 6 or 55-65% HR reserve) to a moderate-to-high intensity the following weeks (7 - 8 or 65-75% HR reserve).
88980335|NCT05980325|Experimental|Aquatic Exercise|Patients in this group will be assigned to a 12-week, twice weekly water-based exercise programme to be conducted at a chest-high swimming pool kept around 30 to 32 degrees Celsius. Each session will be structured as previous: i) 10 min warm up; ii) 40 min of combined endurance and strength exercise training and iii) 10 min cool down. Intensity will be monitored using the Borg Scale to be moderate during the first 6 weeks (4 - 6) and moderate-to-high the following 6 weeks (7-8).
89032210|NCT02931357|Experimental|Hyaluronic Acid 0.54%|Administration: application of the gel on the gingival tissue, massage it in gently, five to six times a day.
89032211|NCT02931357|Active Comparator|Calgel®|Administration: application of the gel on the gingival tissue, massage it in gently, three/four times a day (away from meals). In any case the interval between gel applications must be at least 3 hours.
89601136|NCT03420833|Experimental|CRT-On first, then CRT-Off|Subjects will be randomized to have the cardiac resynchronization therapy pacemaker (CRT-P) programmed on in the first intervention period, and after six months the CRT function will be turned off in the second intervention period.
89601137|NCT03420833|Experimental|CRT-Off first, then CRT-On|Subjects will be randomized to have the cardiac resynchronization therapy pacemaker (CRT-P) programmed off in the first intervention period, and after six months the CRT function will be turned on in the second intervention period.
89601138|NCT03420664|Experimental|Cast immobilisation|A below knee cast is applied in order to achieve ankle immobilisation for one hour
89032212|NCT02937597|Active Comparator|National e-learning programme only (HSE)|Active Comparator: National e-learning programme only (HSE) National e-learning programme only Recent successful completion of the National e-learning programme by certificate will be displayed. Students then undergo performance assessment via low fidelity simulation and complete a questionnaire.
89601139|NCT03420664|Experimental|Orthosis (VACOped) immobilisation|A below knee orthosis which allows for ankle movement is applied for one hour.
88980336|NCT05980325|Active Comparator|Functional Exercise Training|In this group, patients will participate in a traditional, circuit-based exercise training at a fitness facility twice daily during 12 weeks. Each session will consist of: i) 10 min warm up; ii) 40 min of combined resistance and endurance training using a circuit-based structure and iii) 10 min cool-down. Intensity will be monitored with a HR monitor (when available) and/or Borg Scale to reach a moderate intensity for the first 6 weeks (4 - 6 or 55-65% HR reserve) and will progress to moderate-to-high over the following weeks (7-8 or 65-75% HR reserve).
89601140|NCT03405389||Patients|Patients diagnosis of a mandibular fracture requiring Open Reduction and Internal Fixation (ORIF) and use of Mandibulo-Maxillary fixation (MMF) during or subsequent to surgical intervention for a minimum of two weeks
89601141|NCT03372278||Patients who received the Maxera Cup|Subjects in need of a total hip arthroplasty, who met the inclusion/exclusion criteria and who received the Maxera Cup.
88980337|NCT05980273||school children, their mothers and teachers|educational session program
88980338|NCT05979792|Experimental|CAR-T Therapy|
88980339|NCT05975463|Experimental|HAIC+Adebrelimab+Bevacizumab|hepatic artery infusion of Adebrelimab 1200mg, d1, q3w, combined with hepatic artery infusion of Bevacizumab 5mg/kg, d1, q3w, HAIC treatment for 3-4 times.
88980340|NCT05973981|Active Comparator|Status Quo Packages|Cigarette packages appear as they normally do - no standardization
89601142|NCT03371719|Placebo Comparator|Arm 1 (Radiation Therapy + Placebo)|Patients undergo external beam radiation therapy on Day 1 for 7.5 weeks. Beginning on Day 1 of radiation therapy, patients receive placebo PO QD on Days 1-30. Treatment repeats every 30 days for up to 6 courses (6 months) in the absence of disease progression or unacceptable toxicity.
89601143|NCT03371719|Experimental|Arm 2 (Radiation Therapy + Apalutamide)|Patients undergo external beam radiation therapy on Day 1 for 7.5 weeks. Beginning on Day 1 of radiation therapy, patients receive apalutamide PO QD on Days 1-30. Treatment repeats every 30 days for up to 6 courses (6 months)in the absence of disease progression or unacceptable toxicity.
89601144|NCT03340675|Experimental|Oral Ifetroban - Low Dose|Weight based, once daily oral ifetroban
89601145|NCT03340675|Experimental|Oral Ifetroban - High Dose|Weight based, once daily oral ifetroban
89601146|NCT03340675|Placebo Comparator|Placebos|Matching Placebo
89601147|NCT03337360|Active Comparator|Impryl|One tablet daily for 6 months
89601148|NCT03337360|Placebo Comparator|Placebo|One tablet daily for 6 months
89601149|NCT03321643|Experimental|Treatment (rituximab, gemcitabine, oxaliplatin, atezolizumab)|"INDUCTION PHASE: Patients receive rituximab IV, gemcitabine IV, and oxaliplatin IV every 2 weeks. Starting cycle 2, patients also receive atezolizumab IV over 30-60 minutes every 2 weeks. Treatment repeats every 14 days of cycle 1 and every 28 days for up to 4 cycles in the absence of disease progression or unaccepted toxicity. Patients also undergo CT, PET-CT, MRI, bone marrow biopsy, collection of blood samples, and tumor biopsy throughout induction phase.~MAINTENANCE PHASE: Patients receive rituximab IV and atezolizumab IV over 30-60 minutes on day 1. Cycles repeat every 3 weeks in the absence of disease progression or unaccepted toxicity. Patients also undergo CT, PET-CT, MRI, bone marrow biopsy, and collection of blood samples throughout maintenance phase."
89601150|NCT03317392|Experimental|Arm I (radium Ra 223 dichloride, olaparib)|Patients receive radium Ra 223 dichloride IV over 1 minute on day 1. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive olaparib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI as well as blood sample collection and a tissue biopsy during screening and on study.
89601151|NCT03317392|Experimental|Arm II (radium Ra 223 dichloride)|Patients receive radium Ra 223 dichloride as in Arm I. Patients with radiographic progression may crossover to Arm I. If patients have already completed all 6 infusions of radium, they will receive monotherapy with olaparib. If they have not yet completed all 6 radium-223 infusion, they will continue radium-223 infusion until completion and receive concurrent treatment with olaparib. Patients also undergo CT or MRI as well as blood sample collection and a tissue biopsy during screening and on study.
88980341|NCT05973981|Experimental|Partial standardization|Cigarette packages appear with half of the package using a standardized color
88980342|NCT05973981|Experimental|Full standardization|Cigarette packages appear with all of the packages fully standardized (by color and font)
88980343|NCT05973734|Experimental|Recipient T Regulatory Cell|T regulatory cells prior to islet transplantation, induction therapy with ATG and Belatacept and maintenance immunosuppression with Tacrolimus Extended-release tablets (Envarsus XR) and Mycophenolate Mofetil (MMF).
89601152|NCT03278925|Experimental|Prevention (defined green tea catechin extract)|Participants receive defined green tea catechin extract PO QD or BID for 24 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo ultrasound, CT, or MRI at screening and on study, undergo collection of blood samples on study, and may undergo biopsy at screening and on study.
89601153|NCT03276130||Part A: Retrospective register study|To describe the usage of prescribed pain, anti-depressive and anti-anxiety medication during a 10-year period based on retrospective data from patient and drug registries. Population: All People with Haemophilia A and B identified through national administrative register or from local register at each treatment centre. The People with Haemophilia group will be compared against an age and gender matched control group from the general population.
89601154|NCT03276130||Part B1: Survey to HTC|The survey will be sent out to the relevant physician at each Haemophilia Treatment Centers (HTC) with direct and frequent patient contacts.
88980344|NCT05973734|Experimental|Donor Derived Vertebral Bone Marrow|Deceased donor vertebral bone marrow (VBM) cells, induction therapy with ATG and Belatacept and maintenance immunosuppression with Tacrolimus Extended-release tablets (Envarsus XR) and Mycophenolate Mofetil (MMF).
88980345|NCT05973656|Experimental|Group I (alcohol consumption)|Participants who consume alcohol receive a standard drink or an alcohol dose that will result in a 0.03% BAC PO on study. Participants also undergo collection of saliva and breathalyzer testing throughout the trial.
88980346|NCT05973656|Active Comparator|Group II (biospecimen collection)|Participants who do not drink alcohol undergo collection of saliva, mouthwash, and cheek brush samples throughout the trial.
88980347|NCT05972759|Experimental|Experimental Arm|Two modes of high intensity exercise.
89032213|NCT02937597|Active Comparator|eS: eScenarios|Recent successful completion of the National e-learning e-learning programme by certificate will be displayed. Students will proceed to an online learning course with 4 scenarios to work through but no requirement to meet a proficiency benchmark. Following training students undergo performance assessment via low fidelity simulation and complete a questionnaire.
89517894|NCT03495089|Experimental|control group|Patients without glucose alterations (normal glucose tolerance). Intervention(s) to be administered:After verifying the inclusion criteria and receiving written informed consent to participate, during the first visit to the Primary Care centres the medical history of the patient will be obtained and a physical examination will be performed using the Monofilament testing -MFT and the Neuropathy Disability Score-NDS and Utah Early Neuropathy Scale-UENS questionnaires will be given to screen for polyneuropathy-PN. The patient will also undergo dermal electrochemical conductance-DEC quantification using the Sudoscan® device.
89517895|NCT03493373|Experimental|Exercise and nervous system mobilization|This group will receive neural mobilization and therapeutic exercise: two sessions of 60 minutes during 8 weeks.
89517896|NCT03493373|Experimental|Exercise|This group will receive therapeutic exercise: two sessions of 60 minutes during 8 weeks.
89517897|NCT02324231|Other|39.0°C temperature limit defining fever|Temperature limit defining fever, for definition of fever in neutropenia (FN), is single temperature >=39.0°C measured in the ear by infrared tympanic thermometry. If clinically indicated, the treating physician is allowed to make the diagnosis of FN at lower temperatures.
89517898|NCT02324231|Other|38.5°C temperature limit defining fever|Temperature limit defining fever, for definition of fever in neutropenia (FN), is single temperature >=38.5°C measured in the ear by infrared tympanic thermometry. If clinically indicated, the treating physician is allowed to make the diagnosis of FN at lower temperatures.
89517899|NCT03494855||Neonates|<1 month of age SyMRI software used for brain imaging and radiological interpretation
89517900|NCT03494855||Infants|1mth - 2 years of age SyMRI software used for brain imaging and radiological interpretation
89517901|NCT03494855||Adolescents|2 - 12 years of age SyMRI software used for brain imaging and radiological interpretation
89517902|NCT03494855||Teenagers|13-18 years of age SyMRI software used for brain imaging and radiological interpretation
89517903|NCT03494855||Healthy Adults|Preliminary Evaluation SyMRI software used for brain imaging and radiological interpretation
89517904|NCT03494699|Experimental|Intervention group|
89517905|NCT03494699|No Intervention|Control group|
89517906|NCT05118737|Active Comparator|colchicine|Intervention arm: colchicine to be used among COVID-19 patients admitted to HMGH, CH, and CDC and already received tocilizumab
89517907|NCT05118737|Placebo Comparator|Control|COVID-19 patients admitted to HMGH, CH, and CDC and already received tocilizumab according to local protocol
89517908|NCT05107973|Experimental|intervention|in this arm of participants will be receiving the Baduajin intervention.
89517909|NCT05107973|No Intervention|control|in this arm of participants will not receive any intervention
89517910|NCT05129111|Active Comparator|STIMULATOR OF THE SALIVARY EXCRETION BASED ON PHYSICAL VIBRATION|Measurement of salivary secretion at rest and stimulated conditions.
89517911|NCT05129111|Placebo Comparator|STIMULATOR OF THE SALIVARY EXCRETION PLACEBO|Measurement of salivary secretion at rest and stimulated conditions.
89517912|NCT03493139|Experimental|PAAC-R|Physical Activity Across the Curriculum-Remote (PAAC-R) will include protocol specific activity breaks delivered remotely via a television in the classroom.
89517913|NCT03493139|Experimental|PAAC-T|Physical Activity Across the Curriculum-Teacher (PAAC-T) will include protocol specific activity breaks delivered by the classroom teacher.
89517914|NCT04734275|Experimental|Treatment A (Test Formulation): AZD5718 Dose A, fasted|Subjects will receive single dose of AZD5718 (Dose A), in fasted condition.
89517915|NCT04734275|Experimental|Treatment B (Test Formulation): AZD5718 Dose A, fed|Subjects will receive single dose of AZD5718 (Dose A) in fed condition
89517916|NCT04734275|Active Comparator|Treatment C (Reference Formulation): AZD5718 Dose A, fasted|Subjects will receive single dose of AZD5718 (Dose A) in fasted condition
89517917|NCT04714151|Experimental|Treatment A|K-877 ER 0.2 mg/day (once daily)
89517918|NCT04714151|Experimental|Treatment B|K-877 ER 0.4 mg/day (once daily)
89517919|NCT04714151|Active Comparator|Control A|K-877 IR 0.2 mg/day (twice daily)
89517920|NCT04702217|Experimental|POTS patients|All POTS patients in the study will perform a 16 week-training program. The present study will be using longitudinal comparisons, meaning that the 100 POTS patients are their own controls. The questionnaires and exercise capacity will be compared before and after the 16-weeks training program.
89517921|NCT04894019|Experimental|Continuous monitoring group|In patients randomized to the continuous monitoring group, continuous invasive arterial blood pressure monitoring will be displayed on the patient monitor. The treating anesthesiologist will be blinded to intermittent blood pressure monitoring using upper-arm cuff oscillometry.
89517922|NCT04894019|Active Comparator|Intermittent monitoring group|In patients randomized to the intermittent monitoring group, intermittent blood pressure monitoring will be displayed on the patient monitor. The treating anesthesiologist is blinded to continuous invasive arterial blood pressure monitoring.
89517923|NCT04831307|Experimental|[68Ga]Ga-HTK03149 PET/CT|200 MBq/m2 of body surface area, with a 200 MBq minimum adult administered activity will be injected intravenously prior to perform the PET/CT
89517924|NCT04441931|Experimental|LY3832479|Participants received single Intravenous (IV) doses of 700, 2800 and 7000 milligrams (mg) LY3832479.
89517925|NCT04441931|Placebo Comparator|Placebo|Participants received single IV dose of Placebo.
89517926|NCT03492983|No Intervention|Control group|No intervention
89517927|NCT03492983|Experimental|Intervention group|Addition of 10 g/day of high cocoa content chocolate to the usual diet for six months
89517928|NCT03491735||Group A|Patients referred to glaucoma sub-specialty clinics in Kasr Al-Aini Hospital, Cairo University, Egypt in the year 2018
89517929|NCT03491735||Group B|Patients referred to glaucoma sub-specialty clinics in Sadguru Netra Chikitsalaya Postgraduate Institute of Ophthalmology, Mumbai, India in the year 2018
89517930|NCT03492905|Experimental|Internet-based CBT|Internet-based Cognitive Behaviour Therapy (iCBT)
88980348|NCT05972486|Experimental|Muse-S headband system for management of sleep disturbances|Study participants will receive a new Muse-S headband system at study entry and will be asked to utilize it daily for a minimum of 10 minutes day for a period of 6 months (24 weeks). Three of the seven sessions per week will specifically be asked to be mind meditation.
88980349|NCT05971823|Active Comparator|Own Brand Cigarette|
88980350|NCT05971823|Experimental|NJOY Ace 2.4% nicotine ECIG - Menthol flavor|
88980351|NCT05971823|Experimental|NJOY Ace 2.4% nicotine ECIG - Classic Tobacco flavor|
88980352|NCT05971823|Experimental|NJOY Ace 5.0% nicotine ECIG - Menthol flavor|
88980353|NCT05971823|Experimental|NJOY Ace 5.0% nicotine ECIG - Classic Tobacco flavor|
88980354|NCT05971823|Experimental|NJOY Daily 6.0% nicotine ECIG - Menthol flavor|
88980355|NCT05971823|Experimental|NJOY Daily 6.0% nicotine ECIG - Extra Rich Tobacco flavor|
88980356|NCT05969678|Experimental|Intervention group ( breathing training with incentive spiromete)|The experimental group will receive the breathing training of abdominal diaphragmatic breathing method combined with incentive spiromete.
88980357|NCT05969678|No Intervention|control group|The control group is only taught the breathing training of abdominal diaphragmatic breathing.
88980358|NCT05969470|Experimental|Short intramedullary nails|The patients receives bone fixation with short intramedullary nails for extremity metastases.
88980359|NCT05969470|Active Comparator|Long intramedullary nails|The patients receives bone fixation with long intramedullary nails for extremity metastases.
88980360|NCT05966246|Experimental|Prucalopride succinate group|Taking prucalopride succinate from the first day to the fifth day after surgery.
88980361|NCT05966246|Placebo Comparator|Control (mosapride citrate) group|Taking mosapride citrate from the first day to the fifth day after surgery.
88980362|NCT05959564|Experimental|Personalized Chatbot Condition|After reading a standard CDC HPV vaccine message, participants will interact with a chatbot designed to deliver personalized HPV vaccine messages (i.e., tailored to their personalities).
88980363|NCT05959564|Experimental|Non-Personalized Chatbot Condition|After reading a standard CDC HPV vaccine message, participants will interact with a chatbot designed to deliver HPV vaccine messages, which are not tailored to their personalities.
88980364|NCT05959564|Active Comparator|No Chatbot Control Condition|Participants will read a standard CDC HPV vaccine message without interacting with any chatbot that delivers additional messages.
88980365|NCT05957354|Active Comparator|active cTBS group|active cTBS combined with speech language therapy
88980366|NCT05957354|Sham Comparator|sham cTBS group|sham cTBS combined with speech language therapy
88980367|NCT05955651||Pelvic washings|Three Samples of peritoneal washings will be collected and send to pathology. looking for myometrial cell spillage at three designated points in surgery. 1st before hysterectomy, 2nd after hysterectomy, and 3rd after morcellation and extraction of the uterus out of the abdominal cavity.
89517931|NCT03492827|Experimental|gargle group|drugs，chlorhexidine acetate gargle dosage，15ml，twice daily， duration，3days before ESD
89517932|NCT03492827|No Intervention|Control group|Control group will not be interventioned with gargle
88980370|NCT05954481|Other|HHT patients with hepatic involvement and high cardiac index|HHT patients with a dilated (diameter > 6mm) or tortuous hepatic artery and an elevated cardiac index (> 3.5 l/mn/m²)
88980371|NCT05954481|Other|HHT patients with hepatic involvement and normal cardiac index|HHT patients with a dilated or tortuous hepatic artery and a normal cardiac index
88980372|NCT05952713||SSRI|"Group 1: Selective serotonin reuptake inhibitors (reference: sertraline)~Comparisons of the following with sertraline:~Citalopram, Fluoxetine, Paroxetine, Escitalopram"
88980373|NCT05952713||NARI|Group 2: Noradrenaline reuptake inhibitors (reference: sertraline) Comparisons of the following with sertraline: Reboxetine
88980374|NCT05952713||SNRI|Group 3: Serotonin and noradrenaline reuptake inhibitors (reference: venlafaxine) Comparisons of Duloxetine with venlafaxine
88980375|NCT05952713||ARI|Group 4: Adrenergic receptor inhibitors (reference: Mirtazapine) Comparisons of Mianserin with Mirtazapine
88980376|NCT05952713||Other drugs|Group 5: Other drugs (reference: sertraline) Comparisons of Vortioxetine and Agomelatine with sertraline
88980377|NCT05952713||TCA|"Group 6: Tricyclic antidepressants (reference: amitriptyline)~Comparisons of Nortriptyline, Imipramine, Clomipramine and Dosulepin with amitriptyline"
88980378|NCT05948683|Experimental|Familiar partner with placebo|Participant engages in social interaction with 'familiar' partner under placebo
88980379|NCT05948683|Experimental|Familiar partner with MDMA|Participant engages in social interaction with 'familiar' partner under MDMA
89517933|NCT04461197|Experimental|ESWT + orthotic insole|(shock waves + orthotic insole +Stretches of the posterior muscle chain)
89517934|NCT04461197|Placebo Comparator|ESWT + flat insole|(shock waves + flat insole + Stretches of the posterior muscle chain)
89517935|NCT04254809|Experimental|Re-Evaluating Suicidal Thoughts|Participants in this condition will complete the experimental intervention at the baseline appointment.
89517936|NCT04254809|Sham Comparator|Healthy Social Living|Participants in this condition will complete the sham control intervention at the baseline appointment, and given the option to complete the experimental intervention at the conclusion of the follow-up period.
89517937|NCT04620005||ECMO|The first group will include practitioners who work in intensive care unit with ECMO services
89517938|NCT04620005||Non-ECMO|The second group will include practitioners who work in non-ECMO inventive care unit
89517939|NCT03491657|Experimental|virtual reality distraction (Yes VR)|In addition to their standard pain medications, patients will play a virtual realty game named SnowWorld during some portions of their burn wound cleaning procedure, on each study day.
89517940|NCT03491657|Active Comparator|music distraction (No VR condition)|In addition to their standard pain medications, patients will listen to music during comparable portions of their burn wound cleaning procedure, on each study day.
89517941|NCT03492749||Group Busulfan|Patients submitted a Bone marrow transplantation with the busulfan chemotherapy in the conditioning. Saliva monitoring
88980380|NCT05948683|Experimental|Unfamiliar partner with placebo|Participant engages in social interaction with 'unfamiliar' partner under placebo
88980381|NCT05948683|Experimental|Unfamiliar partner with MDMA|Participant engages in social interaction with 'unfamiliar' partner under MDMA
89601155|NCT03276130||Part B2: Survey to PwH|All People with Haemophilia (PwH) listed at HTCs will be invited to participate in the patient survey.
89601156|NCT03275103|Experimental|Arm A: Single Step Dose Escalation for Cevostamab|Study drug will be administered intravenously on a 21-day cycle. The step-up dose will be given on Cycle 1 Day 1 and the target dose will be given on C1D8. Subsequently the target dose will be administered on Day 1 of each 21-day cycle.
88980382|NCT05942976||group 1: axial spondyloarthritis|SpA patients identified according to the Assessment of Spondyloarthritis classification criteria
88980383|NCT05942976||group 2: Rheumatoid arthritis|RA patients identified according to the 2010 American College of Rheumatology/Europan Leage Against Rheumatism classification criteria
88980384|NCT05942976||group:3 Healthy Control|healthy controls with no history of rheumatic diseases
88980385|NCT05941988|Experimental|pre grafting partial maxillary expansion with post grafting expansion|pregrafting partial maxillary expansion then grafting left bone to consolidate for 2 months followed by post grafting expansion till full arch alignment
88980386|NCT05941988|Active Comparator|pre grafting full maxillary expansion|pre grafting full maxillary expansion till full arch alignment then grafting and let bone to consolidate
89601157|NCT03275103|Experimental|Arm B: Double Step Dose Escalation for Cevostamab|In Cycle 1, participants will receive 2 step-up doses and a target dose. The step-up dose will be given on Cycle 1 Day 1 and C1D8. The target dose will be given on C1D15. Subsequently the target dose will be administered on Day 1 of each 21-day cycle.
89601158|NCT03275103|Experimental|Arm C: Single Step Dose Expansion for Cevostamab|The single step dose expansion stage of the study may use the dosing and assessment schedule from the single dose escalation arm in Cycle 1, based on data from Arm A.
89601159|NCT03275103|Experimental|Arm D: Double Step Dose Expansion for Cevostamab|The double step dose expansion stage of the study may use the dosing and assessment schedule from the double step dose escalation arm in Cycle 1, based on data from Arm B.
89601160|NCT03275103|Experimental|Arm E: Expansion Phase for Tocilizumab Pretreatment|All participants will receive a single dose of tocilizumab intravenously. An additional dose of tocilizumab may be instituted as premedication for subsequent Cycle 1 dose(s) of cevostamab and Cycle 1 cevostamab doses for other treatment arms.
89601161|NCT03275103|Experimental|Arm F: Single Step Dose Expansion for Cevostamab|The single step dose expansion stage of the study may use the dosing and assessment schedule from the single dose escalation arm in Cycle 1, based on data from Arm A.
89601162|NCT03275103|Experimental|Arm G: Double Step Dose Expansion for Cevostamab|The double step dose expansion stage of the study may use the dosing and assessment schedule from the double step dose escalation arm in Cycle 1, based on data from Arm B.
89601163|NCT03275103|Experimental|Arm H: Triple Step Dose Escalation for Cevostamab|In Cycle 1, participants will receive 3 step-up doses and a target dose. The doses will be given on Cycle 1 Days 1, 2-4, 8, and 9-11. Subsequently the target dose will be administered on Day 1 of each 21-day cycle.
89601164|NCT03275103|Experimental|Arm I: Triple Step Dose Expansion for Cevostamab|The triple step dose expansion stage of the study may use the dosing and assessment schedule from the triple step dose escalation arm in Cycle 1, based on data from Arm H.
89608576|NCT04765995|Experimental|HZBio1 3mg/kg|Participants will receive intramuscularly 3 milligram per kilogram (mg/kg) of HZBio1.
88980387|NCT05940623|Active Comparator|Management Paradigm I: Standard care and home IOP telemonitoring with smart phone-based intervention|Eligible patients randomized to Management Paradigm I will be provided with an iCare Home and instructed to measure and upload 6 IOP measurements weekly (2 days a week, 1 measurement in the early morning (5 am to 9 am), 1 during the mid-day (12 pm to 4 pm) and 1 in the evening (7 pm to 11pm)) to a secure server via iCare. Patients will be treated with topical prostaglandin analogue after baseline IOP measurements. A text message will be sent to the patient's smart phone to (1) inform whether the treatment goal is achieved over the past 4 weeks (i.e., ≥75% of the self- measured IOP measurements are below the target IOP) and (2) remind adherence to medications. The patients will need to reply via a text message reporting how many times eyedrops are missed over the past 4 weeks. A nurse will phone the patient if a reply message is not received or the number of home IOP measurements is less than 20 over the past 4 weeks.
88980388|NCT05940623|No Intervention|Management paradigm II: Standard care and smart phone-based intervention|Patients will be treated with a topical prostaglandin analogue after baseline IOP measurements (described below). Additional treatment will be provided in the following order: carbonic anhydrase inhibitor, brimonidine, beta blocker, and selective laser trabeculoplasty (SLT) when the target IOP is not achieved. Fixed combination will be given whenever possible to improve adherence. Similar to Management Paradigm I, smart phone-based intervention includes (1) a text message from the investigators to inform whether the target pressure is attained (with reference to the latest clinic GAT measurement) and remind medication adherence every 4 weeks and (2) a reply message from the patients regarding how many times eyedrops are missed over the past 4 weeks.
88980389|NCT05939505|Experimental|Su Jok Therapy Group|Su jok Therapy According to Sujok therapy, sujok therapy will be applied 14 times with an interval of one day with Mexican bean seeds on the points representing the kidney.
88980390|NCT05939505|Placebo Comparator|placebo group|Instead of the Mexican bean seed used in Sujok therapy, plastic beans will be applied 14 times with an interval of one day.
88980391|NCT05939505|Active Comparator|Control group|Routine applications will be made in the Dialysis Unit.
88980392|NCT05934591|Experimental|Population Type: Under Supervision or Not Under Supervision|1 group of 24 people under supervision (those on parole, drug court, probation, or methadone maintenance) and 1 group of 24 people not under supervision (those on parole, drug court, probation, or methadone maintenance) will attend groups of the Community Wise intervention.
88980393|NCT05934591|Experimental|Participation Incentive: Paid and Not Paid|1 group of 24 people will receive a financial incentive and 1 group of 24 people will not receive a financial incentive for attending the Community Wise intervention.
88980394|NCT05934591|Experimental|Group Type: Open and Closed Group Format|1 group of 24 people will attend a closed group format and 1 group of 24 people will attend an open group format of the Community Wise intervention.
89601165|NCT03275103|Experimental|Arm J: Expansion Phase for Tocilizumab Pretreatment|All participants will receive a single dose of tocilizumab intravenously. An additional dose of tocilizumab may be instituted as premedication for subsequent Cycle 1 dose(s) of cevostamab and Cycle 1 cevostamab doses for other treatment arms.
89601166|NCT03275103|Experimental|Arm K: Compressed Double Step Dose Expansion for Cevostamab|In Cycle 1, participants will receive 2 step-up doses and a target dose. The doses will be given on Cycle 1 Days 1, 4, and 8. Subsequently the target dose will be administered on Day 1 of each 21-day cycle.
89601167|NCT03270982||Comprehensive SRS Replacement|Comprehensive SRS Device
89601168|NCT03260478|Experimental|Liberal Transfusion Strategy|Patients will receive red blood cells transfusion if Hb ≤ 100 g/L.
89601169|NCT03260478|Experimental|Restrictive Transfusion Strategy|Patients will receive red blood cells transfusion if Hb ≤ 70 g/L.
89601170|NCT03252938|Experimental|Solid tumors|Biweekly intra-tumoral injections of escalating doses (6 mg, 12 mg, 24 mg and 30 mg) of IMP321 as a monotherapy (intratumoral injections in parenchymatous organs (e.g. liver, spleen, adrenal gland, pancreas) are not allowed)
89601171|NCT03252938|Experimental|Solid tumors + peritoneal carcinomatosis|Biweekly intra-peritoneal, escalating doses of IMP321 (1 mg, 3 mg, 6 mg, 12 mg and 30 mg)
89601172|NCT03252938|Experimental|Solid tumors + chemotherapy|Subcutaneous (s.c.) injections with the optimal dose of IMP321 defined in the AIPAC trial for a maximum of 24 weeks
89601173|NCT03252938|Experimental|Solid tumors + Avelumab/IMP321 therapy|"Avelumab and IMP321 as follows:~800 mg avelumab every 2 weeks i.v. (for a maximum of 24 cycles [48 weeks])~6 mg (cohort 1) or 30 mg (cohort 2) IMP321 every 2 weeks s.c. (for a maximum of 12 cycles [24 weeks])"
89601174|NCT03252938|Experimental|Solid tumors + Avelumab/IMP321 combination therapy|"Avelumab and IMP321 as follows:~• 800 mg avelumab every 2 weeks i.v. and 30 mg IMP321 every 2 weeks s.c. for a maximum of 24 cycles [12 months]"
89601175|NCT03244384|Experimental|Arm A (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 18 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan, CT urography, and/or MRI throughout the trial. Patients may also undergo a cystoscopy and blood sample collection during screening and on study.
89601176|NCT03244384|Active Comparator|Arm B (observation)|Patients undergo observation. Patients undergo a CT scan, CT urography, and/or MRI throughout the trial. Patients may also undergo a cystoscopy and blood sample collection during screening and on study.
89601177|NCT03231670||lobar pneumonia|Inpatient with lobar pneumonia will undergo a blood sampling during their hospitalization and after resolution of the infection (2 Months)
89601178|NCT03228732|Placebo Comparator|Placebo 1|"Visit 1:~Study Day 1: Hyperinsulinemia/ euglycemia clamp in the AM and PM. Study Day 2: Hyperinsulinemia/ hypoglycemia clamp in the AM only. 8-weeks of treatment with placebo~Visit 2:~same as visit 1"
89601179|NCT03228732|Placebo Comparator|Placebo 2|"Visit 1:~Study Day 1: Hyperinsulinemia/ hypoglycemia clamp in the AM and PM. Study Day 2: Hyperinsulinemia/ hypoglycemia clamp in the AM only. 8-weeks of treatment with placebo~Visit 2:~same as visit 1"
89601180|NCT03228732|Active Comparator|Fluoxetine|"Visit 1:~Study Day 1: Hyperinsulinemia/ hypoglycemia clamp in the AM and PM. Study Day 2: Hyperinsulinemia/ hypoglycemia clamp in the AM only. 8-weeks of treatment with fluoxetine~Visit 2:~same as visit 1"
89601181|NCT03228732|Active Comparator|DHEA|"Visit 1:~Study Day 1: Hyperinsulinemia/ hypoglycemia clamp in the AM and PM. Study Day 2: Hyperinsulinemia/ hypoglycemia clamp in the AM only. 8-weeks of treatment with DHEA~Visit 2:~same as visit 1"
89601182|NCT03228732|Active Comparator|Fluoxetine and DHEA|"Visit 1:~Study Day 1: Hyperinsulinemia/ hypoglycemia clamp in the AM and PM. Study Day 2: Hyperinsulinemia/ hypoglycemia clamp in the AM only. 8-weeks of treatment with fluoxetine and DHEA~Visit 2:~same as visit 1"
89601183|NCT03228459|Experimental|Mobile Unit Follow-up Group|In the Mobile Unit (MU), clinical, sociodemographic and anthropometric data will be recorded. Patients will be evaluated with artery ultrasound (carotid, femoral, transcranial and abdominal aorta), ankle-brachial index, pulse wave velocity, spirometry, determination of advanced glycation-end products, atrial fibrillation screening, dried blood spot test and urine analysis. Moreover, DNA, RNA, Saliva, blood and urine samples will be collected and stored in the biobank to identify new biomarkers using omic studies. Additionally, climate, air pollutant and airborne pollen data form the entire province of Lleida will be registered. Finally, a report with the exploration results and recommendations based on the current guidelines will be uploaded to the e-CAP history for the Primary care evaluation.
89601184|NCT03228459|No Intervention|Electronic Medical History Follow-up Group|Participants will be followed through their electronic medical records. Sociodemographic (age, sex, race, marital status, education and labour status), clinical and anthropometric data and will be electronically collected.
89608577|NCT04765995|Experimental|HZBio1 6mg/kg|Participants will receive intramuscularly 6 milligram per kilogram (mg/kg) of HZBio1.
88980395|NCT05934370|Other|Study Participants|Participants will receive an intervention kit that will include two at-home visits and the following products: child bedroom HEPA-air purifier, HEPA upright vacuum, hypoallergenic dust-mite cover for child's mattress and pillow covers; Non-toxic household cleaning products and non-toxic pest/rodent traps.
88980396|NCT05928598|Other|Standard care arm - patient participants|This group will be enrolled first.
88980397|NCT05928598|Experimental|Intervention arm (Epilepsy Visit Planner) - patient participants|This group will be enrolled after the standard care arm enrollment is completed.
88980398|NCT05928598|Other|Intervention arm (Epilepsy Visit Planner) - provider participants|Epilepsy providers will be recruited from the University of Michigan (approximately 10 providers).
89608578|NCT04765995|Experimental|HZBio1 9mg/kg|Participants will receive intramuscularly 9milligram per kilogram (mg/kg) of HZBio1.
89608579|NCT04765995|Experimental|HZBio1 12mg/kg|Participants will receive intramuscularly 12 milligram per kilogram (mg/kg) of HZBio1.
89608580|NCT01276054|Experimental|SNB plus ARM or ALND (+/- SNB) plus ARM|Patients undergo sentinel lymph node biopsy (SNB) and/or axillary lymph node biopsy (ALND) using technetium Tc 99m sulfur colloid followed by methylene blue or indocyanine green solution tracer for localization of the arm lymph node. Patients then undergo an axillary reverse mapping.
88980399|NCT05928260|Active Comparator|Real time CGMS(rt-CGMS)|Medtronic Guardian Connect sensor 3 will be applied for 2 weeks at the beginning of this study in this arm for blood glucose monitoring and insulin dose adjustments for glycemic control.
88980400|NCT05928260|Active Comparator|Intermittently scanned CGMS(is-CGMS)|Abott Freestyle Libre Sensor will be applied for 2 weeks at the beginning of this study in this arm for blood glucose monitoring and insulin dose adjustments for glycemic control.
88980401|NCT05928260|Placebo Comparator|Self Monitoring of Blood Glucose(SMBG)|This group will monitor blood glucose using glucometer and needle pricks throughout the study duration and insulin doses will be adjusted based on these readings as per the standard management of Type-1 Diabetes Mellitus patients endorsed by American Diabetic Association in 2023.
88980402|NCT05927584||Local excision|"Patients older than 18 years~Diagnosis of rectal cancer~Inferior edge of the tumour not further than 2 cm above the anorectal ring~Clinical TNM staging T1N0M0"
88980403|NCT05927272|Experimental|Patients with active non-segmental vitiligo|
88980404|NCT05926011|Experimental|Active RGn600|RGn600 with a 10 Hz-pulsed wave mode light emission
88980405|NCT05926011|Sham Comparator|Sham|Inactivated RGn600
88980406|NCT05925023|Experimental|Sirolimus on refractory/relapsed wAIHA|A prospective research of the sirolimus efficiency on refractory/relapsed primary wAIHA patients. Sirolimus dosage: 1-3 mg/d with plasma concentration 4-15ng/mL. Medication time should last at least 6 months. After reaching the optimal response, responders continue to use sirolimus for 1 year, and then gradually reduce the dosage.
88980407|NCT05918250|Experimental|mRNA-2736|Participants will receive mRNA-2736.
89517942|NCT03492749||Group no busulfan|Patients submitted a Bone marrow transplantation without busulfan chemotherapy in the conditioning.Saliva monitoring
88980408|NCT05914818|Experimental|EXPLORER V2|1 session with the exoskeleton EXPLORER V2 in healthy subjects 3 sessions with the exoskeleton EXPLORER V2 in subjects with disease
88980409|NCT05905419||Female adults with chronic pain who take prescribed opioid medications|"Opioid taking participants will undergo two study visits, one for each opioid phase (peak or trough)"
88980410|NCT05905419||Female adults with chronic pain who do not take opioid medications|Participants with chronic pain who are not taking opioids will undergo one study visit
88980411|NCT05905419||Healthy controls|Healthy female participants who are not taking opioids will undergo one study visit
89517943|NCT03491579|Experimental|Dosis finding|Epacadostat is given for 2 cycles of 28 days at a dose according to the titration design together with standard chemotherapy (Cladribine and Cytarabine)
89517944|NCT03901391||Retinitis Pigmentosa|
89517945|NCT04600895|Experimental|Favipiravir|Favipiravir 200mg tablet
89517946|NCT04600895|Placebo Comparator|Placebo|Placebo 200mg tablet
89517947|NCT03492593|Experimental|lycopene|A dose of lycopene (20 mg) is provided as part of an emulsified liquid meal (with or without 160 mg powdered ferrous sulfate). Samples from the upper digestive tract (gastric or duodenal) are aspirated over 4 hours, and blood collected over 7 hours. Blood plasma and chylomicron fractions isolated. The subject returns for 3 additional visits with 2 weeks between each visit. The same protocol is followed, with the subject receiving all combinations of meal (w/ and w/o iron) and upper digestive tract sampling (gastric or duodenal)
89517948|NCT03492593|Experimental|13C beta-carotene|A dose of 13C beta-carotene (20 mg) is provided as part of an emulsified liquid meal. Samples from the upper digestive tract (gastric or duodenal) are aspirated over 5 hours, blood collected over 7 hours, and urine collected over 7 hours. Blood plasma and chylomicron fractions isolated. The subject returns for 1 additional visit with a minimum of 4 weeks between each visit. The same protocol is followed, with sampling taken from the remaining upper digestive tract compartment (gastric or duodenal)
89517949|NCT03492593|Placebo Comparator|control|The same procedure is followed (as detailed in the experimental arms) but the subject receives an emulsified liquid meal without carotenoids or vitamin E.
89517950|NCT03492515|Experimental|experimental group|Accepting the treatment of rhTPO according platelet and bleeding condition
89517951|NCT03492515|Active Comparator|non-administered group|No rhTPO will be used. If necessary, the patients will be given transfusion of platelets according to the their conditions.
89517952|NCT03492515|No Intervention|healthy control group|Healthy pregnant women and no use of any medicine。
89517953|NCT03491501||Industrial employees|Ergonomic evaluation using questionnaires in different Industrial settings will be conducted and thus Industrial employees form the included subject group.
89517954|NCT04499729|Active Comparator|Treatment as Usual (TAU)|TAU will be the treatment that is provided through the Rush Collaborative Care program as part of their service
89517955|NCT04499729|Experimental|IntelliCare|Patients will be offered IntelliCare as part of their care in the Rush Collaborative Care service. Patients who agree will download the IntelliCare app, which provides self management and collects symptom self-report data. Symptom severity scores are displayed to the care manager, allowing them to manage the patient's care. The app also provides a secure messaging service for communication between the care manager and the patient.
89517956|NCT03491423|Experimental|Patients|
89517957|NCT03492359|Active Comparator|Normal Control|Participants with no diagnosis of respiratory disease between the ages of 0 and 80 whose breathing will be measured using Thora-3Di structured light plethysmography, body plethysmography and spirometry.
89517958|NCT03492359|Active Comparator|COPD Patients|Participants with chronic obstructive pulmonary disease between the ages of 0 and 80 whose breathing will be measured using Thora-3Di structured light plethysmography, body plethysmography and spirometry.
89517959|NCT03130621||Adenocarcinoma of upper digestive tract|Early-onset carcinomas ; Family History of Malignancy; Special pathological type; MSI or dMMR; Multiple primary malignant tumors;
89517960|NCT03130621||Esophageal squamous cell carcinoma|Family History of Malignancy; Multiple primary malignant tumors; MSI or dMMR;
89517961|NCT03132077||satisfaction post total knee arthroplasty|The focus of this project is exploring outcomes post-primary total knee arthroplasty (TKA) using the available pre/post-operative Oxford Knee Score (OKS), University of California Los Angeles (UCLA) Activity Score, EQ-5D General Health Questionnaire, Visual Analogue (VAS) for pain, age and smoking status data, and correlations between these data and post operation patient satisfaction.
89517962|NCT04384055||Covid-19 Positive Patients|This group includes individuals who were diagnosed with Covid-19 based on reverse transcriptase polymerase chain reaction (RT-PCR) of the nasopharynx
89517963|NCT04384055||Covid-19 Negative Patients|This group includes individuals who did NOT have a positive test for Covid-19 based on reverse transcriptase polymerase chain reaction (RT-PCR) of the nasopharynx.
88980412|NCT05905302|Experimental|Experimental Arm|Two modes of high intensity exercise
88980413|NCT05900713|Experimental|D. N.S|dynamic neuromuscular stabilization training methods demonstrated efficacy in improving global trunk stabilizing patterns with noted gains in extremity movement and strength
88980414|NCT05900713|Experimental|balance exercises plus diaphragmatic breathing|balance exercises plus diaphragmatic breathing The balance exercises is balance training while standing and walking and The patient assume a semi-Fowler's position and perform diaphragmatic breathing.
88980415|NCT05899335|Experimental|SmartCP app|The SmartCP app is provided to patients to assist in the management of chronic pancreatitis for 16 weeks
88980416|NCT05898971|Experimental|Group A|received robotic gloves training
88980417|NCT05898971|Experimental|Group B|received mirror therapy
88980418|NCT05898971|Active Comparator|Group C|received traditional physical therapy
88980419|NCT05896969|Experimental|SAD Cohort|SAD Cohort 1 - 8 : Subjects in each cohort will be randomised will receive a single SC dose of SNK-396 within the dose range of 25 to 800 mg, or matching placebo.
88980420|NCT05896969|Experimental|MAD cohort|MAD Cohort 1 - 8 : Subjects in each cohort will be randomized will receive the active SNK-396 with dose range of SNK-396 anticipated to be from 25 to 800 mg or matching placebo
88980421|NCT05895981|Experimental|Sacral nerve stimulation|
88980422|NCT05894928|Experimental|LOXO-783 alone|Single dose of LOXO-783 administered orally.
88980423|NCT05894928|Experimental|LOXO-783 + Cholestyramine 1 hour post dose|Single dose of LOXO-783 administered orally followed by a single dose of cholestyramine administered orally after 1 hour.
88980424|NCT05894928|Experimental|LOXO-783 + Cholestyramine 4 hours post dose|Single dose of LOXO-783 administered orally followed by a single dose of cholestyramine administered orally after 4 hours.
88980425|NCT05893264||Epidural placement|All patients undergoing epidural placement will be enrolled.
88980426|NCT05885022|Experimental|Investigational Device Arm|Subjects will receive a Calibreye glaucoma device (permanent implant)
88980427|NCT05876780|Experimental|SRP-9003|Participants will receive single IV infusion of SRP-9003 on Day 1.
88980428|NCT05874375|Other|Group A (Urge and Time limited)|The participant self-administer electrical stimulation to the dorsal genital nerve (DGN) using UCon with a stimulation mode that is activated for 60 seconds by the participant when he experience urgency (urge stimulation).The urge stimulation can be activated repeatedly during the day as the participant wears the device from morning to evening at home for 14 days. Following a stimulation wash-out period (14 days), the participants then stimulates with UCon for another 14 days using the time limited stimulation mode.
88980429|NCT05874375|Other|Group B (Time limited and Urge)|The participant self-administer electrical stimulation to the dorsal genital nerve (DGN) using UCon with a stimulation mode that is activated for 30 minutes once a day, at a time that is convenient for the particiant. The participant uses the device at home for 14 days. Following a stimulation wash-out period (14 days), the participant then stimulates with UCon for another 14 days using the urge stimulation mode.
88980430|NCT05866185|Active Comparator|Therapy|Standard regular therapy.
88980431|NCT05866185|Experimental|Therapy + Adhere.ly|Standard regular therapy, enhanced with Adhere.ly
88980432|NCT05865418|Experimental|Loaded high intensity circuit training|These participants will be familiarized to all the exercises. All exercises will have 3 sets, and the participants will be asked to perform as many repetitions as they can in 30s for each set. They will have 30 seconds to rest between sets (if they want more rest, we can let them more time but not exceed 60 seconds to limit the total amount of time for completing the exercise protocol) and 90 seconds to rest between exercises. Training sessions will occur twice per week with at least 24 hours between sessions. From the week 2-5 of the intervention, the participants will perform the exercises with an adjustable weight vest starting with 2.5% to finally reaching 10% of their body weight.
89517964|NCT05396989||First-onset of depressed patients|first attack
89517965|NCT05396989||Patients with recurrent depression|relapse
89608581|NCT01276054|Active Comparator|SNB or ALND (+/- SNB)|Patients undergo SNB and/or ALND using technetium Tc 99m sulfur colloid followed by methylene blue or indocyanine green solution tracer for localization of the arm lymph node.
89601185|NCT03221426|Experimental|Pembrolizumab+Chemotherapy|"Neoadjuvant: Prior to surgery, participants receive 3 cycles of pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle (Q3W) PLUS cisplatin 80 mg/m^2 via IV infusion on Day 1 Q3W and capecitabine 1000 mg/m^2 via oral tablets twice each day (BID) on Days 1 to 14 of each 3-week cycle OR cisplatin 80 mg/m^2 via IV infusion on Day 1 Q3W and 5-fluorouracil (5FU) 800 mg/m^2 via continuous IV infusion on Days 1 to 5 of each 3-week cycle.~Adjuvant: 4 to 10 weeks post-surgery, participants receive 3 cycles of pembrolizumab 200 mg via IV infusion on Day 1 Q3W PLUS cisplatin 80 mg/m^2 via IV infusion on Day 1 Q3W and capecitabine 1000 mg/m^2 via oral tablets BID on Days 1 to 14 of each 3-week cycle OR cisplatin 80 mg/m^2 via IV infusion on Day 1 Q3W and 5FU 800 mg/m^2 via continuous IV infusion on Days 1 to 5 of each 3-week cycle, followed by pembrolizumab monotherapy 200 mg via IV infusion on Day 1 Q3W for up to 11 additional cycles."
89601186|NCT03221426|Placebo Comparator|Placebo+Chemotherapy|"Neoadjuvant: Prior to surgery, participants receive 3 cycles of placebo (normal saline solution) via IV infusion on Day 1 Q3W PLUS cisplatin 80 mg/m^2 via IV infusion on Day 1 Q3W and capecitabine 1000 mg/m^2 via oral tablets BID on Days 1 to 14 of each 3-week cycle OR cisplatin 80 mg/m^2 via IV infusion on Day 1 Q3W and 5FU 800 mg/m^2 via continuous IV infusion on Days 1 to 5 of each 3-week cycle.~Adjuvant: 4 to 10 weeks post-surgery, participants receive 3 cycles of placebo via IV infusion on Day 1 Q3W PLUS cisplatin 80 mg/m^2 via IV infusion on Day 1 Q3W and capecitabine 1000 mg/m^2 via oral tablets BID on Days 1 to 14 of each 3-week cycle OR cisplatin 80 mg/m^2 via IV infusion on Day 1 Q3W and 5FU 800 mg/m^2 via continuous IV infusion on Days 1 to 5 of each 3-week cycle, followed by placebo monotherapy via IV infusion on Day 1 Q3W for up to 11 additional cycles."
89601187|NCT03221426|Experimental|Pembrolizumab+FLOT Cohort|"FLOT=docetaxel+oxaliplatin+5FU+leucovorin (calcium folinate). Neoadjuvant: Prior to surgery, participants receive 3 cycles of pembrolizumab 200 mg via IV infusion on Day 1 Q3W PLUS docetaxel 50 mg/m^2 via IV infusion, oxaliplatin 85 mg/m^2 via IV infusion, 5FU 2600 mg/m^2 via IV infusion, and leucovorin (calcium folinate) 200 mg/m^2 via IV infusion Q2W (on Days 1 and 15 of Cycle 1; Day 8 of Cycle 2, and Day 1 of Cycle 3, for 4 administrations).~Adjuvant: 4 to 10 weeks postsurgery, participants receive 3 cycles of pembrolizumab 200 mg via IV infusion Day 1 Q3W PLUS docetaxel 50 mg/m^2, oxaliplatin 85 mg/m^2, 5FU 2600 mg/m^2, and leucovorin 200 mg/m^2 Q2W (on Days 1 and 15 of Cycle 1; Day 8 of Cycle 2, and Day 1 of Cycle 3, for 4 administrations), followed by pembrolizumab monotherapy 200 mg via IV infusion on Day 1 Q3W for up to 11 additional cycles."
89601188|NCT03221426|Placebo Comparator|Placebo+FLOT Cohort|"Neoadjuvant: Prior to surgery, participants receive 3 cycles of placebo (normal saline solution) via IV infusion on Day 1 Q3W PLUS docetaxel 50 mg/m^2 via IV infusion, oxaliplatin 85 mg/m^2 via IV infusion, 5FU 2600 mg/m^2 via IV infusion, and leucovorin 200 mg/m^2 via IV infusion Q2W (on Days 1 and 15 of Cycle 1; Day 8 of Cycle 2, and Day 1 of Cycle 3, for 4 administrations).~Adjuvant: 4 to 10 weeks postsurgery, participants receive 3 cycles of placebo via IV infusion on Day 1 Q3W PLUS docetaxel 50 mg/m^2 via IV infusion, oxaliplatin 85 mg/m^2 via IV infusion, 5FU 2600 mg/m^2 via IV infusion, and leucovorin 200 mg/m^2 via IV infusion Q2W (on Days 1 and 15 of Cycle 1; Day 8 of Cycle 2, and Day 1 of Cycle 3, for 4 administrations), followed by placebo monotherapy via IV infusion on Day 1 Q3W for up to 11 additional cycles."
89601189|NCT03213704|Experimental|Treatment (larotrectinib sulfate)|Patients receive larotrectinib sulfate PO or via NG- or G-tube BID on days 1-28. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan, MRI, an x-ray, bone scan, and/or MIBG scintigraphy during screening and on study. Patients also undergo bone marrow aspiration and/or biopsy during screening and may undergo blood sample collection on study.
89601190|NCT03213678|Experimental|Treatment (samotolisib)|Patients receive samotolisib PO BID on days 1-28. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unexpected toxicity. Patients undergo an x-ray, CT, MRI, FDG-PET, and blood sample collection on study.
89601191|NCT03212274|Experimental|Treatment (olaparib)|Patients receive olaparib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan and/or MRI, as well as a tumor biopsy and blood sample collection on study.
89601192|NCT03210714|Experimental|Treatment (erdafitinib)|Patients receive erdafitinib PO QD on days 1-28 of each cycle. Treatment repeats every 28 days for up to 26 cycles (2 years) in the absence of disease progression or unacceptable toxicity. Patients undergo an x-ray, CT scan, MRI, PET scan, radionuclide imaging, and/or bone scan, as well as a bone marrow aspiration and/or biopsy during screening and on study. Patients also undergo blood sample collection on study.
89601193|NCT03200574|Other|Aortic Valve|LivaNova bioprosthetic aortic heart valve replacement
89601194|NCT03141684|Experimental|Arm I (atezolizumab)|Patients receive atezolizumab IV over 30-60 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT imaging, and collection of blood and urine at baseline.
89601195|NCT03141684|Experimental|Arm II (atezolizumab, bevacizumab)|Patients receive atezolizumab IV over 30-60 minutes and bevacizumab IV over 30-90 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT imaging, and collection of blood and urine at baseline.
89601196|NCT03123094|Experimental|Spesolimab low dose group (intravenous)|
89601197|NCT03123094|Experimental|Spesolimab medium dose group (intravenous)|
89601198|NCT03123094|Experimental|Spesolimab high dose group (intravenous)|
89601199|NCT03123094|Experimental|Spesolimab low dose group (subcutaneous)|
89601200|NCT03123094|Placebo Comparator|Placebo matching to spesolimab|
89601201|NCT03104543|Experimental|Education|Educational materials
89601202|NCT03104543|Active Comparator|Test results|Test results only; with delayed access to the experimental materials
89601203|NCT03098576||Matched|Matched targeted drug treatment
89601204|NCT03098576||Control|Unmatched standard of care
89601205|NCT03093142|Experimental|tDCS & neurofeedback|30 minutes tDCS & 30 minutes neurofeedback
89601206|NCT03093142|Active Comparator|real neurofeedback|30 minutes real neurofeedback.
89601207|NCT03093142|Sham Comparator|sham neurofeedback|30 minutes sham neurofeedback.
89601208|NCT03051659|Experimental|Eribulin Mesylate|-Eribulin mesylate will be administered on Days 1 and 8 of each 21 day cycle for 1.4mg/m^2 intravenously.
89608582|NCT05580627|Experimental|Livestream Modality|The livestream modality is considered the treatment group for the purpose of this quasi-experimental study.
89032214|NCT02937597|Experimental|ePBP: eProficiency Based Progression|Recent successful completion of the National e-learning programme by certificate will be displayed. Students will proceed to a PBP e-learning course using the same series of cases as S. PBP students will be scored according to predefined metrics and will be required to reach proficiency benchmarks for the cases within the e-learning course to allow progression through the cases. Following training students undergo performance assessment via low fidelity simulation and complete a questionnaire.
89032215|NCT04694027|Active Comparator|group a|will receive omega 3 plus vitamin E
89032216|NCT04694027|Active Comparator|Group b|will receive vitamin E
89032217|NCT04694027|No Intervention|Group c|no intervention just reassurance and analgesics on need
89032218|NCT00521807|No Intervention|A 1|
89032219|NCT00521807|Experimental|A 2|Treatment group
89032220|NCT04577274|Experimental|smoothie with regular formulas (SM)|Participants were given 300 kcal smoothie with regular formulas within 3-5 minutes and blood collection after drinking at 30, 60, 90, 120, 180 and 240 minutes.
89032221|NCT04577274|Experimental|smoothie with low carbohydrate formulas (SMLS)|Participants were given 300 kcal smoothie with low carbohydrate formulas within 3-5 minutes and blood collection after drinking at 30, 60, 90, 120, 180 and 240 minutes.
89032222|NCT04577274|Active Comparator|conventional diabetic enteral drinks (Glucerna)|Participants were given 300 kcal Glucerna within 3-5 minutes and blood collection after drinking at 30, 60, 90, 120, 180 and 240 minutes.
89032223|NCT02937675|Experimental|Tomivosertib (eFT-508) Escalation Cohort|This portion of the study will evaluate the safety and pharmacology of a range of Tomivosertib (eFT-508) doses administered daily in subjects with previously treated lymphomas
89032224|NCT02937675|Experimental|Tomivosertib (eFT-508) Expansion Cohort|This portion of the study provides cohort expansion to further explore the safety, pharmacology, and clinical activity of a single dose level of Tomivosertib (eFT-508) monotherapy in subjects with specific previously treated lymphomas
89032225|NCT00523172|Active Comparator|Group A|"1) Group A will receive 9 manipulative therapy treatments (adjustments) to one area: the hip with pre-manipulative static and post active-assisted stretch of tight hip muscles. After the last (or 9th) treatment these patients will receive general advice and recommendations on managing HOA and how to gently and safely increase general exercise.~• Based on a previous trial, Group A treatment appears superior than placebo. There will be a 3, 6 and 9 month follow up."
89032226|NCT00523172|Active Comparator|Group B|2) Group B will receive 9 treatments with manipulative therapy treatments (adjustments) to the entire kinetic chain (five areas): the lumbosacral, sacroiliac, hip, knee, ankle and foot joints with pre-manipulative static and post active-assisted stretch of tight hip muscles. There will be a 3, 6 and 9 month follow up.
89032227|NCT00523172|Other|Supportive Care|"Supportive Care 3) Groups A and B will receive supportive care after the 9th visit consisting of (up to a maximum of) 6 visits, PRN or as needed, until the 9 month follow up. This is to see if peak gains may be maintained (as noted in the previous trial) throughout the follow up period.~Enrolled subjects will commonly receive 2 treatments per week (occasionally, less or more than 1 to 2 treatments per week due to (College or University) semester breaks, exams, clinic closures and so forth) until 9 treatments are completed."
89032228|NCT02937519|Experimental|Melodie group|Induction chrono-chemotherapy followed by cisplatin chrono-chemotherapy concurrent combined with intensity-modulated radiation therapy
89032229|NCT02937519|Other|Routine-Chemotherapy|Induction routine-chemotherapy followed by cisplatin routine-chemotherapy concurrent combined with intensity-modulated radiation therapy
89032230|NCT03457974|Experimental|congenital heart disease|42 patients
89032231|NCT03457974|Other|helathy children|42 children
89032232|NCT00521963|Experimental|E|
89032233|NCT02937402|Experimental|Bronchoscopy with bronchoalveolar lavage|Patients undergo bronchoscopy with bronchoalveolar lavage over 45 minutes
89032234|NCT02937363|Experimental|Alpha-lipoic acid|Alpha-lipoic acid supplementation (600 mg/day) for 4 weeks in a counterbalanced manner to 12 G6PD deficient individuals.
89032235|NCT02937363|Placebo Comparator|Placebo|Placebo administration for 4 weeks in a counterbalanced manner to 12 G6PD deficient individuals.
89601209|NCT03051659|Experimental|Eribulin Mesylate Combine with Pembrolizumab|"Pembrolizumab will be administered in clinic once per cycle, given 200mg/m^2 intravenously prior to Eribulin Mesylate.~Eribulin mesylate will be administered on Days 1 and 8 of each 21 day cycle for 1.4 mg/m^2 intravenously."
89601210|NCT03050671|Active Comparator|Rapid calf-IPC|Cyclic external compression in both calves through a cuff connected to VenaFlow® Elite System, DJO, CA, USA
89601211|NCT03050671|Active Comparator|subjects under slow calf-IPC|Cyclic external compression in both calves through a cuff connected to Kendall SCD™ 700, Covidien, Medtronic, USA
89032236|NCT04693871||high-flow rate group|
89032237|NCT04693871||low-flow rate group|
89032238|NCT02948348|Experimental|Nivolumab & Ipilimumab(Only Cohort D)|chemoradiotherapy with capecitabine+ Nivolumab + Ipilimumab(Only Cohort D) + surgical therapy
89032239|NCT02937480|Experimental|Experimental group|Task-specific training
89032240|NCT02937480|Sham Comparator|Control group|Global stretching, memory exercises, health care orientation
89032241|NCT04693910|Experimental|Multimedia information group|The experimental group received a weekly multimedia hormone therapy information program for 6 weeks.
89032242|NCT04693910|No Intervention|Routine care group|The control group will receive routine care.
89032243|NCT00523211|Experimental|Test Arm|Vicriviroc 30 mg QD
89032244|NCT00523211|Placebo Comparator|Placebo Control Arm|Placebo
89601212|NCT03033576|Active Comparator|Arm I (ipilimumab)|Patients receive ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
89032245|NCT02931318|Experimental|Nevsehir|People Living in the City Center of Nevşehir
89032246|NCT03458897|Experimental|MRI arm|Subjects with sickle cell disease undergoing bone marrow transplantation will undergo serial functional MRI (up to 4 scans).
89032247|NCT02937246|Experimental|the intervention group|Partial covered double bare metal stent
89032248|NCT02937246|Active Comparator|the control group|Uncovered double bare metal stent
89032249|NCT02937324|Active Comparator|Clinical Assessment|Motor assessment will be performed by a clinician using the Unified Parkinson's Disease Rating Scale.
89601213|NCT03033576|Experimental|Arm II (nivolumab, ipilimumab)|Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive nivolumab IV over 30 minutes on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89601214|NCT03030378|Experimental|Treatment (recombinant interleukin-12, pembrolizumab)|Patients receive recombinant interleukin-12 SC on days 2, 5, 9, and 12 and pembrolizumab IV over 30 minutes on day 8 of cycle 1 and day 1 of subsequent cycles. Treatment continues for 28 days for cycle 1 and repeats every 21 days for subsequent cycles for up to 8 cycles in the absence of disease progression or unacceptable toxicity. Patient then receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 8 additional cycles in the absence of disease progression or unacceptable toxicity. Patients undergo a CT, PET, and MRI, as well as collection of blood during screening, on study, and during follow-up. Patients also undergo a tumor biopsy during screening and on study.
89601215|NCT03018834|Experimental|A: ANAKINRA|ANAKINRA 100 mg/daily subcutaneously once a day until hospital discharge, for a maximum of 14 days, in addition to standard care: ACE and Beta-blocker for 6 months.
89601216|NCT03018834|Placebo Comparator|B: Placebo|PLACEBO 100 mg/daily subcutaneously once a day until hospital discharge, for a maximum of 14 days, in addition to standard care: ACE and Beta-blocker for 6 months.
89601217|NCT02973828||A) Volunteer Imaging Studies|Non-patient Volunteer Imaging Studies of Normal Tissue (n = 18 - 54) per centre In the first stage, participants will be non-patient volunteers who agree to undergo MR imaging on the MR Linac on a single or multiple occasions (up to 12) to examine the anatomic sites listed above for normal tissue visualisation.
89601218|NCT02973828||B) Patient Volunteer Imaging Studies|Patient Volunteer Imaging Studies of Normal Tissue (n = 39 - 72 per centre) In the second stage, participants will be patient volunteers, who agree to undergo MR imaging on the MR Linac on a single or multiple (up to 12) occasions to examine multiple tumour sites (n=11) for tumour/target visualisation.
89601219|NCT02973828||C) Pathway development studies|Pathway development studies (n = 39 - 208 per centre) In the third stage, participants will be patient volunteers, who agree to undergo MR imaging on the MR Linac on a single or multiple (up to 12) occasions to examine intra and inter observer variability on target and organs at risk visualisation using the exam cards from Stage B.
89601220|NCT02973828||D) On going imaging development & quality improvement|This stage of the study will run in parallel or subsequent to stages B and C. The purpose will be to recruit patient or non-patient volunteers to help optimise MR guided radiotherapy delivery e.g. investigate radiotherapy immobilisation and equipment for patient positioning and set up development and/or development of new/novel imaging sequences, optimisation of existing sequences and undertaking continuing image quality improvement.
89601221|NCT02956239|Experimental|Thermocoagulation (device)|VIA Positive women will be treated by the new device for thermocoagulation
89601222|NCT02956239|Active Comparator|Cryotherapy (device)|VIA positive women will be treated by cryotherapy
89601223|NCT02956239|Active Comparator|LEEP (device)|VIA Positive women not suitable for thermo-coagulation or cryotherapy will be treated by LEEP
89601224|NCT02950051|Active Comparator|Standard chemoimmunotherapy (SCIT)|"Patients up to age 65: 6 cycles (q28d) of Fludarabine + Cyclophosphamide + Rituximab (FCR)~Patients older than 65 years: 6 cycles (q28d) of Bendamustine + Rituximab (BR)"
89601225|NCT02950051|Experimental|Rituximab + Venetoclax (RVe)|6 cycles (q28d) of RVe + 6 cycles (q28d) of Venetoclax (alone)
89601226|NCT02950051|Experimental|Obinutuzumab + Venetoclax (GVe)|6 cycles (q28d) of GVe + 6 cycles (q28d) of Venetoclax (alone)
89601227|NCT02950051|Experimental|Obinutuzumab + Ibrutinib + Venetoclax (GIVe)|"6 cycles (q28d) of GIVe + 6 cycles (q28d) of Ibrutinib plus Venetoclax.~Administration of ibrutinib will be continued for a maximum of 36 months or until MRD negativity, start of new anti-CLL therapy or inacceptable toxicity, whatever occurs first."
89601228|NCT02943265|Experimental|Complex Care Survivors|Patients eligible for the study who will receive Care Coordination Strategies.
89032250|NCT02937324|Experimental|Smartphone assessment|CloudUPDRS smartphone software assessment will be performed.
89601229|NCT02941107|Experimental|Rotarix|Rotarix (RV1) vaccine, 1mL liquid suspension administered orally.
89601230|NCT02941107|Placebo Comparator|Placebo|Placebo liquid suspension manufactured to mimic Rotarix (RV1) vaccine, 1ml administered orally
89601231|NCT02926833|Experimental|Phase 1 Cohort 1: KTE-C19 + ATZ (After 21 Days of KTE-C19)|Participants received conditioning chemotherapy consisting of 30 mg/m^2 fludarabine and 500 mg/m^2 cyclophosphamide intravenous (IV) infusion per day for 3 days followed by KTE-C19 IV infusion at a target dose of 2 x 10^6 anti-CD19 chimeric antigen receptor (CAR) T cells/kg followed by 4 doses of atezolizumab (ATZ) (1200 mg/dose) IV infusion every 21 days, beginning 21 days following KTE-C19.
89601232|NCT02926833|Experimental|Phase 1 Cohort 2: KTE-C19 + ATZ (After 14 Days of KTE-C19)|Participants received conditioning chemotherapy consisting of 30 mg/m^2 fludarabine and 500 mg/m^2 cyclophosphamide IV infusion per day for 3 days followed by KTE-C19 IV infusion at a target dose of 2 x 10^6 anti-CD19 CAR T cells/kg followed by 4 doses of ATZ (1200 mg/dose) IV infusion every 21 days, beginning 14 days following KTE-C19.
89601233|NCT02926833|Experimental|Phase 1 Cohort 3: KTE-C19 + ATZ (After 1 Day of KTE-C19)|Participants received conditioning chemotherapy consisting of 30 mg/m^2 fludarabine and 500 mg/m^2 cyclophosphamide IV infusion per day for 3 days followed by KTE-C19 IV infusion at a target dose of 2 x 10^6 anti-CD19 CAR T cells/kg followed by 4 doses of ATZ (1200 mg/dose) IV infusion every 21 days, beginning 1 day following KTE-C19.
89608583|NCT05580627|Experimental|Live Modality|The live modality is considered the control group for the purpose of this quasi-experimental study.
89032251|NCT00522197|Active Comparator|ACAPHA|
89032252|NCT00522197|Placebo Comparator|Sugar Pill|
89032253|NCT00522236|Experimental|Arm 1|
89032254|NCT02931123|No Intervention|standard|
89032255|NCT02931123|Experimental|treatment|rifaximine and lattulose plus low proteine diet
89032256|NCT02948114|Active Comparator|Control: Cow milk-based infant formula|Cow milk-based infant formula
89032257|NCT02948114|Experimental|Experimental 1: Cow milk-based infant formula|Cow milk-based infant formula with prebiotics
89601234|NCT02926833|Experimental|Phase 2: KTE-C19 + ATZ (After 1 Day of KTE-C19)|Participants received conditioning chemotherapy consisting of 30 mg/m^2 fludarabine and 500 mg/m^2 cyclophosphamide IV infusion per day for 3 days followed by KTE-C19 IV infusion at a target dose of 2 x 10^6 anti-CD19 CAR T cells/kg followed by 4 doses of ATZ (1200 mg/dose) IV infusion every 21 days, beginning 1 day following KTE-C19.
89601235|NCT02923778|Experimental|Treatment (talimogene laherparepvec, radiation therapy)|Patients receive talimogene laherparepvec IT or via intralesional injection at weeks 1, 4, 6 and 8. Beginning 1 week after the start of talimogene laherparepvec, patients undergo radiation therapy on Monday-Friday of weeks 2-6. Patients undergo collection of blood and a tumor biopsy on study and undergo MRI throughout the trial.
89601236|NCT02913456||HER2-positive unresectable LA/mBC|Participants with HER2-positive unresectable LA/mBC diagnosed up to 6 months prior to enrollment will be included in the study. Enrolled participants will receive treatment and clinical assessments for their HER2-positive unresectable LA/mBC as determined by their treating physician, according to the standard of care and routine clinical practice at each site.
89601237|NCT02879448|Experimental|Amulet|Amulet left atrial appendage occluder
89601238|NCT02879448|Active Comparator|WATCHMAN (Control)|WATCHMAN left atrial appendage closure device
89601239|NCT02862275|Experimental|Treatment (atezolizumab)|Patients receive atezolizumab IV over 30- 60 minutes on day 1. Cycles repeat every 21 days for a total of 17 doses over up to 12 months in the absence of disease progression or unacceptable toxicity. Patients undergo CT, MRI, and biopsy on study. Patients also undergo blood sample collection on study.
89601240|NCT02862249|Experimental|Faecal microbiota transplantation|Faecal microbiota transplantation.
89601241|NCT02862249|Placebo Comparator|Placebo|Placebo solution.
89601242|NCT02849496|Experimental|Arm I (olaparib)|Patients receive olaparib PO BID on days 1-21 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may cross-over to Arm II. Patients undergo an x-ray, CT scan, MRI, bone scan, and/or PET scan as well as a biopsy and blood sample collection throughout the trial. Patients may also undergo a bone marrow aspiration and biopsy on study.
89601243|NCT02849496|Experimental|Arm II (olaparib, atezolizumab)|Patients receive olaparib as in Arm I and atezolizumab IV over 30-60 minutes on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo an x-ray, CT scan, MRI, bone scan, and/or PET scan as well as a biopsy and blood sample collection throughout the trial. Patients may also undergo a bone marrow aspiration and biopsy on study.
89601244|NCT02834013|Experimental|Arm I (nivolumab, ipilimumab)|Patients receive nivolumab IV over 30 minutes on days 1, 15, and 29 and ipilimumab IV over 60 minutes on day 1. Treatment repeats every 42 days for up to 17 cycles (2 years) in the absence of disease progression or unacceptable toxicity. Patients who complete 17 cycles (2 years) of therapy, may continue receiving the same treatment with nivolumab and ipilimumab, or receive nivolumab once every 14 or 28 days (2 weeks or 4 weeks) per physician discretion in the absence of disease progression or unacceptable toxicity. Patients who stop treatment prior to the completion of 17 cycles of therapy may receive nivolumab once every 14 or 28 days (2 weeks or 4 weeks) in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO during screening and on study. Patients also undergo MRI or CT throughout the trial. Additionally, patients undergo blood sample collection throughout the trial.
89601245|NCT02834013|Experimental|Arm II (nivolumab)|Patients receive nivolumab IV over 30 minutes on days 1, 15 and 29. Treatment repeats every 42 days for up to 17 cycles (2 years) in the absence of disease progression or unacceptable toxicity. After 17 cycles (2 years) of therapy, patients may receive nivolumab once every 14 or 28 days (2 weeks or 4 weeks) in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO during screening and on study. Patients also undergo MRI or CT throughout the trial. Additionally, patients undergo blood sample collection throughout the trial.
89601246|NCT02808897|Active Comparator|Standard drainage|The control arm consist of consecutively enrolled cardiac surgery patients receiving one standard chest tube in the mediastinum and at most three (3) commercially available standard or silastic chest tubes in the mediastinal, right or left pleural space.
89601247|NCT02808897|Experimental|Active Tube Clearance drainage|The test arm consists of consecutively enrolled cardiac surgery patients receiving one (1) chest tube using active tube clearance (PleuraFlow®) in the mediastinum and at most three (3) other commercially available standard or silastic chest tubes in the mediastinal, right or left pleural space.
89601248|NCT02800499||KOCOSS|The KOrea COpd Subgroup Study team (KOCOSS) cohort is an ongoing, longitudinal, prospective, non-interventional observational study within the Korean COPD patients
89601249|NCT02752685|Experimental|HR-Positive Participants|Participants with HR-positive metastatic breast cancer will receive nab-paclitaxel 100 mg/m2 on days 1 and 8 of the first 21-day treatment cycle. On the second 21-day treatment cycle, the participants will receive pembrolizumab 200 mg IV on the first day of the cycle, in addition to nab-paclitaxel 100 mg/m2 on days 1 and 8 of the cycle.
89601250|NCT02752685|Experimental|cTNBC Participants|Participants with TNBC-positive metastatic breast cancer who in the chemotherapy run-in group (cNTBC) will receive nab-paclitaxel 100 mg/m2 on days 1 and 8 of the first 21-day cycle. On the second 21-day treatment cycle, the participants will receive pembrolizumab 200 mg IV on the first day of the cycle, in addition to nab-paclitaxel 100 mg/m2 on days 1 and 8 of the cycle.
89601251|NCT02752685|Experimental|iTNBC Participants|Participants with TNBC-positive metastatic breast cancer in the immunotherapy run-in group (cNTBC) will receive pembrolizumab 200mg IV on day 1 of the first 21-day treatment cycle. nab-paclitaxel 100 mg/m2 on days 1 and 8 of the first 21-day cycle. On the second 21-day cycle, the participants will receive nab-paclitaxel 100 mg/m2 on days 1 and 8 of the cycle, in addition to pembrolizumab 200mg IV on day 1 of the cycle.
89601252|NCT02743910||Stage II-III breast cancer|Up to 229 newly diagnosed stage II-III invasive HER2-positive or triple-negative breast cancer patients planning neoadjuvant therapy (NAT) will be enrolled. ptDNA blood samples as well as a representative tumor tissue sample from both the diagnostic and surgical procedure (if available) will be collected.
89601253|NCT02692313|Placebo Comparator|Saline infusion|Hyperinsulinemic euglycemic glucose clamp with saline infusion
89601254|NCT02692313|Experimental|Epinephrine infusion-0.015ug/kg/min|Hyperinsulinemic euglycemic glucose clamp with epinephrine infusion of 0.015 ug/kg/min
89032258|NCT02948114|Experimental|Experimental 2: Cow milk-based infant formula|Cow milk-based infant formula with probiotics
89601255|NCT02692313|Experimental|Epinephrine infusion-0.03 ug/kg/min|Hyperinsulinemic euglycemic glucose clamp with epinephrine infusion of 0.03 ug/kg/min
89601256|NCT02692313|Experimental|Epinephrine infusion-0.06 ug/kg/min|Hyperinsulinemic euglycemic glucose clamp with epinephrine infusion of 0.06 ug/kg/min
89601257|NCT02684201|Experimental|Boston Scientific cord stimulator lead|A Boston Scientific Stimulator Lead (PMA P030017) will be placed in the cervical epidural space of ten upper-limb amputees and steered laterally towards the dorsal spinal roots under fluoroscopic guidance.
89601258|NCT02649582|Experimental|Single Arm|Dendritic cell vaccine plus temozolomide chemotherapy
89601259|NCT02620280|Active Comparator|Carbo-abrax, surgery, anthra|Patients will receive a combination of carboplatin and abraxane as neoadjuvant treatment. Definite surgery will be performed not later than 6 weeks after the last dose of neoadjuvant therapy. Four cycles of AC or EC or FEC will then be delivered as adjuvant chemotherapy
89601260|NCT02620280|Experimental|Carbo-abrax-MPDL3280A, surgery, anthra|Patients will receive a combination of carboplatin, abraxane and MPDL3280A as neoadjuvant treatment. Definite surgery will be performed not later than 6 weeks after the last dose of neoadjuvant therapy. Four cycles of AC or EC or FEC will then be delivered as adjuvant chemotherapy
89601261|NCT02595931|Experimental|Treatment (irinotecan, M6620)|Patients receive irinotecan hydrochloride IV over 90 minutes and M6620 IV over 60 minutes on days 1 and 15. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo biopsy and collection of blood samples throughout the study and undergo CT at screening, throughout the study, and during follow up.
89601262|NCT02541994|Other|Ultrasound Testing|Single arm with all patients getting measurements of axial length and central corneal thickness.
89601263|NCT02527304|Experimental|Treatment (adaptive staged SBRT)|Patients undergo adaptive staged SBRT. Within 14-21 days, patients may undergo a second treatment of adaptive staged SBRT at the discretion of the treating physician based on clinical parameters, diagnostic interval imaging, and achievement of spinal cord dose constraints.
89601264|NCT02526264|Experimental|Krankenhaus Nordwest Concept|specific preoperative education program realised by a specialized stoma-therapist containing individualized information on material maintenance, hygiene, nutrition, complications, activities of daily life and occupation
89601265|NCT02526264|Experimental|Standard concept|standard preoperative education program administered by a surgeon containing information on surgery, outcome, risks and alternatives
89601266|NCT02506153|Active Comparator|Arm I (high-dose recombinant interferon alfa-2B, ipilimumab)|"INDUCTION THERAPY: Patients receive high-dose recombinant interferon alfa-2B intravenously (IV) over 20 minutes on days 1-5. Treatment repeats weekly for 4 weeks in the absence of disease progression or unacceptable toxicity. Or patients receive ipilimumab IV over 90 minutes on day 1. Treatment repeats every 3 weeks for a total of 4 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive high-dose recombinant interferon alfa-2B subcutaneously (SC) on days 1, 3, and 5. Treatment repeats every 6 weeks for up to 48 weeks in the absence of disease progression or unacceptable toxicity. Or patients receive ipilimumab IV over 90 minutes on day 1. Treatment repeats every 12 weeks for 3 years in the absence of disease progression or unacceptable toxicity.~Patients undergo CT scan, PET scan, MRI and blood sample collection throughout the study."
89601267|NCT02506153|Experimental|Arm II (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for up to 52 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan, PET scan, MRI and blood sample collection throughout the study.
89601268|NCT02503709|Experimental|Treatment (onalespib, CDKI AT7519)|Patients receive onalespib IV over 1 hour on days 1 and 4 (cycle 0 only). Patients then receive onalespib IV over 1 hour and CDKI AT7519 IV over 1 hour on days 1, 4, 8, and 11 (cycle 1 and subsequent cycles thereafter). Cycles repeat every 21 days (7 days for course 0 only) in the absence of disease progression or unacceptable toxicity.
89601269|NCT02496208|Experimental|Part I (cabozantinib s-malate, nivolumab)|Patients receive cabozantinib s-malate PO QD on days 1-28 and nivolumab IV over 30 minutes on days 1 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. After 21 cycles, patients receive nivolumab IV over 30 minutes every 4 weeks in the absence of disease progression or unacceptable toxicity. After progression, patients may receive cabozantinib s-malate PO, nivolumab IV, and ipilimumab IV at the part II RP2D for 4 cycles followed by cabozantinib s-malate PO QD and nivolumab IV every 2 weeks or 4 weeks if post-cycle 21 in the absence of disease progression or unacceptable toxicity. Patients undergo computed tomography or magnetic resonance imaging and collection of blood samples throughout the trial. Patients may also undergo echocardiography at baseline and biopsies throughout the trial.
89601270|NCT02496208|Experimental|Part II (cabozantinib s-malate, nivolumab, ipilimumab)|See detailed description.
89601271|NCT02485418|Experimental|Propofol infusion|"All subjects will be treated with an intravenous propofol infusion at the following escalating rate schedule:~20 mcg/kg/min for 10 minutes, followed by an increase to 30 mcg/kg/min for 10 minutes and then by an increase to 40 mcg/kg/min for 40 minutes"
89601272|NCT02483429|Experimental|VRT Care|Patients randomized to VRT (VOG-guided Rapid Triage) care will have an algorithm-determined patient-specific diagnosis and treatment pathway in the emergency department. Patients will complete a 1 week in-person follow up and a 1 and 6 month phone follow up.
89601273|NCT02483429|No Intervention|Standard of Care (SOC)|Patients randomized to Standard of Care will undergo usual emergency department care without revealing results of VOG testing. Patients will complete a 1 week in-person follow up and a 1 and 6 month phone follow up.
89601274|NCT02483429|No Intervention|Observational|Patients who signed an informed consent but did not meet inclusion/exclusion criteria and don't randomize will enter a parallel track observational sub-study with limited 1 and 6 month phone follow-up.
89601275|NCT02459327|Experimental|VIP/FCU|VIP (Video Interaction Project) will be offered to all families assigned to the treatment group. FCU (Family Check Up) will be offered to families identified as high risk within the treatment group. Both treatments are parenting interventions.
89601276|NCT02459327|No Intervention|Control|
89601277|NCT02399124|Other|single arm, open label, treatment|single arm, open label, treatment; ProSenseTM Cryoablation treatment, post marketing surveillance
89032259|NCT02948114|Experimental|Experimental 3: Cow milk-based infant formula|Cow milk-based infant formula with prebiotics and probiotics
89032260|NCT02948114|No Intervention|Human Milk Reference|Human Milk Reference
89608584|NCT01798849|Experimental|Panel A-Healthy|Within each of the 5 rising dose treatment periods, 6 participants received a single dose of MK-8892 0.5 mg, 2.0 mg, 6.0 mg, 14 mg or 2.0 mg fed, and 2 participants received placebo. Dosing periods will alternate with Panel B.
89032261|NCT02937207|Experimental|Hanxiao treatment group|36 patients of exacerbation group belongs to cold type of asthma will take Ke Chuan Liu Wei Mixture oral therapy twice everyday for 14 days and background therapy of ICS and beta2-agonist.
89032262|NCT02937207|Placebo Comparator|Hanxiao control group|36 patients of exacerbation group belongs to cold type of asthma will take Ke Chuan Liu Wei Mixture placebo oral therapy twice everyday for 14 days and background therapy of ICS and beta2-agonist.
89032263|NCT02937207|Experimental|Fengtanxiao treatment group|36 patients of exacerbation group belongs to wind phlegm type of asthma will take Chuan Xiong Ping Chuan Mixture and Xie Wu Capsule oral therapy twice everyday for 14 days and background therapy of ICS and beta2-agonist.
89032264|NCT02937207|Placebo Comparator|Fengtanxiao control group|36 patients of exacerbation group belongs to wind phlegm type of asthma will take Chuan Xiong Ping Chuan Mixture placebo and Xie Wu Capsule placebo oral therapy twice everyday for 14 days and background therapy of ICS and beta2-agonist.
89032265|NCT02937207|Experimental|Rexiao treatment group|36 patients of exacerbation group belongs to hot type of asthma will take Dan Ma Jia Tablet oral therapy thrice everyday for 14 days and background therapy of ICS and beta2-agonist.
89032266|NCT02937207|Placebo Comparator|Rexiao control group|36 patients of exacerbation group belongs to hot type of asthma will take Dan Ma Jia Tablet placebo oral therapy thrice everyday for 14 days and background therapy of ICS and beta2-agonist.
89032267|NCT02937207|Experimental|Xuxiao treatment group|36 patients of remission phase of Yang deficiency of asthma will take Zhi Chuan Capsule and Bu Shen Na Qi Granule oral therapy thrice everyday for 14 days and background therapy of ICS and beta2-agonist.
89032268|NCT02937207|Placebo Comparator|Xuxiao control group|36 patients of remission phase of Yang deficiency of asthma will take Zhi Chuan Capsule placebo and Bu Shen Na Qi Granule placebo oral therapy thrice everyday for 14 days and background therapy of ICS and beta2-agonist.
89032269|NCT00522314|Active Comparator|1|NIV & ACBT
89032270|NCT00522314|Placebo Comparator|2|Active cycle of breathing techniques
89032271|NCT04690062|Experimental|BEOVU|Intravitreal injection of BEOVU 3 loading injections ( monthly) then every 3 months
89032272|NCT04694495||volunteers from health examination center|volunteers(n = 50/center) doing gynecologial examination recruited from health examination center, who shows no symptoms and signs in reproductive tract and are potentially regarded as the healthy controls
89032273|NCT04694495||volunteers from gynecology outpatient|volunteers(n = 150/center) recruited from gynecology outpatient, who show abnormal symptoms and signs in reproductive tract and are potentially regarded as the cases with conditions in reproductive tract
89032274|NCT02936934|Active Comparator|Morphine|Multimodal analgesia to morphine
89032275|NCT02936934|Experimental|Oxycodone|Multimodal analgesia to oxycodone
89032276|NCT02936973|Experimental|Real catgut implantation|Participants will receive real catgut implantation at acupoints plus lifestyle modification. Participants will receive catgut implantation treatment every two weeks to fulfill a 8-session treatment course.When the acupoints and surrounding skin are disinfected, an absorbable surgical suture of an appropriate length will be embedded into the muscular layer or subcutaneous tissue of the acupoints by the specified disposable embedding needles. The absorbable surgical suture then stimulated those points over a long period.
89032277|NCT02936973|Sham Comparator|sham catgut implantation|Participants will receive sham catgut implantation at acupoints and lifestyle modification every two weeks to fulfill a 8-session treatment course.The operation process will be similar to that applied in the real catgut implantation group. Empty needles without catgut will be pushed into the chosen position, to a depth equivalent to that used for catgut implantation at acupoints. The frequency and duration were the the same as the catgut embedding group.
89032278|NCT00522353|Active Comparator|1|Oligofructose
89032279|NCT00522353|Placebo Comparator|2|Placebo
89032280|NCT04690296|Experimental|US group|a group underwent real time USG-SCV catheterization
89032281|NCT04690296|Experimental|LM group|a group in whom anatomical LM method was used
89032282|NCT04689789||Patients with RAP|Patients with previous diagnosis of retinal angiomatous proliferation
88811368|NCT01268189|Experimental|Burn wound patients with donor sites|Oxygen diffusing dressing applied to wound vs standard of care dressing (Xeroform) applied to wound (patient serves as own control as s/he receives 1 dressing on 1 donor site and the other on a 2nd donor site)
89032283|NCT04689789||Patients with reticular pseudodrusen|Patients with previous diagnosis of reticular pseudodrusen
89032284|NCT04689789||Control group|Healthy eyes without actual and previous ocular diseases
89032285|NCT02937090||Polycystic Ovary Syndrome|"Premenopausal women between 18-40 years of age.~Diagnosed with PCOS using Rotterdam criteria (meet 2 of the 3):~chronic oligo- or amenorrhea (irregular periods during more than a year in combination with a cycle length longer than 35 days);~total or free T levels above the reference interval and/or excessive facial hair, acne;~transvaginal ultrasound with polycystic ovaries.~Exclusion of common medical disorders (normal thyroid function tests and serum prolactin and exclusion of 21-hydroxylase deficiency)."
89032286|NCT02937090||Control|Women matched for age and BMI.
89032287|NCT00522587|Experimental|1|Fixed sevoflurane dose 1
89032288|NCT00522587|Experimental|2|Fixed sevoflurane dose 2
89032289|NCT00522587|Experimental|3|Fixed sevoflurane dose 3
89032290|NCT00522587|Experimental|4|Fixed sevoflurane dose 4
89032291|NCT00522587|Experimental|5|Fixed sevoflurane dose 5
89032292|NCT00522587|Experimental|6|Fixed sevoflurane dose 6
89032293|NCT00522587|Experimental|7|Fixed remifentanil dose 1
89032294|NCT00522587|Experimental|8|Fixed remifentanil dose 2
89032295|NCT00522587|Experimental|9|Fixed remifentanil dose 3
89032296|NCT00522587|Experimental|10|Fixed remifentanil dose 4
89032297|NCT00522587|Experimental|11|Fixed remifentanil dose 5
89032298|NCT00522587|Experimental|12|Fixed remifentanil dose 6
89032299|NCT04689633|Active Comparator|Quadratus lumborum block|received bilateral ultrasound-guided Quadratus lumborum block using 20 ml bupivacaine 0.25% on each side
89601278|NCT02392429|Experimental|Diagnostic (anthracycline, cytarabine, FLT PET/CT)|Patients receive anthracycline IV on days 1-3 and cytarabine IV on days 1-7 for up to 2 courses. Patients then undergo FLT PET/CT within 3 days before or after the nadir bone marrow biopsy (between days 10-17 after initiation of first induction cycle and prior to reinduction). Patients may undergo an optional FLT PET/CT prior to induction chemotherapy if it does not interfere with commencement of treatment. Patients also undergo bone marrow biopsy and aspiration and blood sample collection during screening and on the trial.
89601279|NCT02318472|Experimental|Early mobilization|Functional mobilization initiated directly post-operative with a weight-bearing VACOped orthosis with adjustable range of motion of the ankle
89032300|NCT04689633|Active Comparator|Erector spinae block|received bilateral ultrasound-guided erector spinae block using 20 ml bupivacaine 0.25% on each side
89032301|NCT04689633|No Intervention|Control|didn't received any block
89032302|NCT00522665|Active Comparator|Arm A: Irinotecan + Cetuximab +/- RAD001|
89032303|NCT00522665|Active Comparator|Arm B: Ironotecan + Cetuximab|
89601280|NCT02318472|Active Comparator|Immobilization|Treatment as usual using plaster cast immobilization
89601281|NCT02314169|Experimental|Part A (nivolumab)|Patients receive nivolumab IV over 60 minutes once every two weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan, MRI and blood sample collection throughout the study.
89601282|NCT02314169|Experimental|Part B Arm I (nivolumab)|Patients receive nivolumab IV over 30 minutes once every 4 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan, MRI and blood sample collection throughout the study.
89601283|NCT02314169|Experimental|Part B Arm II (nivolumab, ipilimumab)|Patients receive nivolumab as in Arm I. Patients also receive ipilimumab IV over 30 minutes once every 8 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan, MRI and blood sample collection throughout the study.
89601284|NCT02311933|Experimental|Arm I (z-endoxifen hydrochloride)|Patients receive z-endoxifen hydrochloride PO on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89601285|NCT02311933|Experimental|Arm II (tamoxifen citrate)|Patients receive tamoxifen citrate PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression and bone metastases may cross over to Arm I and receive z-endoxifen hydrochloride starting no later than 28 days after documentation of disease progression.
89601286|NCT02298959|Experimental|Treatment (pembrolizumab and ziv-aflibercept)|Patients receive pembrolizumab intravenously (IV) over approximately 30 minutes and ziv-aflibercept IV over 1-2 hours on day 1. Cycles repeat every 2 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan, MRI, blood sample collection and tumor biopsy throughout the study.
89601287|NCT02286726|Experimental|Arm I (lower-dose (50 units/m^2) CPX-351)|Patients receive lower-dose liposomal cytarabine-daunorubicin CPX-351 IV over 90 minutes on days 1, 3, and 5 of a 28-day course. Patients with persistent disease may receive a second course with treatment on days 1 and 3.
89601288|NCT02286726|Experimental|Arm II (intermediate-dose (75 units/m^2) CPX-351)|Patients receive intermediate-dose liposomal cytarabine-daunorubicin CPX-351 IV over 90 minutes on days 1, 3, and 5. Patients with persistent disease may receive a second course with treatment on days 1 and 3.
89601289|NCT02286726|Experimental|Arm III (standard-dose (100 units/m^2) CPX-351)|Patients receive standard-dose liposomal cytarabine-daunorubicin CPX-351 IV over 90 minutes on days 1, 3, and 5. Patients with persistent disease may receive a second course with treatment on days 1 and 3.
89608585|NCT01798849|Experimental|Panel B-Healthy|Within each of the 4 rising dose treatment periods, 6 participants received a single dose of MK-8892 1.0 mg, 4.0 mg, 9.0 mg or 12 mg, and 2 participants received placebo. Dosing periods will alternate with Panel A.
89032304|NCT00522743|Experimental|1|GH & GNRHa treatment
89032305|NCT00522743|Active Comparator|2|GH treatment
89032306|NCT02937012|Experimental|Bezafibrate & Ursodeoxycholic acid|Bezafibrate 200 mg capsule every 12 hours and ursodeoxycholic acid at a dose of 13 to 15 mg per Kg per day, for 12 months
89032307|NCT02937012|Placebo Comparator|Placebo & Ursodeoxycholic acid|Placebo capsule (for bezafibrate 200 mg capsule) every 12 hours and ursodeoxycholic acid at a dose of 13 to 15 mg per Kg per day, for 12 months
88811369|NCT01269047|Experimental|Pramlintide + Insulin Group|These kids will get Pramlintide (Symlin) along with insulin before breakfast and supper.
88811370|NCT01269047|Experimental|Exenatide + Insulin Group|This group will get Exenatide(Byetta) along with insulin before breakfast and supper.
89032308|NCT00522782|Active Comparator|A|Nebulized budesonide
89032309|NCT00522821|Other|Antibiotics|"A: co-trimoxazole prophylactically for 12 months followed by intravenous immunoglobulin treatment for 12 months.~Treatments will be separated by a washout period of 3 months during which co-trimoxazole will be given."
89032310|NCT00522821|Other|intravenous immunoglobulins|"B: intravenous immunoglobulin treatment for 12 months followed by co-trimoxazole prophylactically for 12 months.~Treatments will be separated by a washout period of 3 months during which co-trimoxazole will be given."
89032311|NCT02937051|Active Comparator|Own Brand Cigarette Condition|
89032312|NCT02937051|Experimental|Original-flavor Black&Mild cigar|
89032313|NCT02937051|Experimental|Apple-flavor Black&Mild cigar|
89032314|NCT02937051|Experimental|Cream-flavor Black&Mild cigar|
88811371|NCT01269047|Active Comparator|Insulin monotherapy|This group will be on their regular insulin therapy.
89032315|NCT02937051|Experimental|Wine-flavor Black&Mild cigar|
89032316|NCT02930928||Accuracy of weight estimation|Computer based comparison of the two algorithms based on collected patient data
89032317|NCT00522860|Experimental|Vicryl Suture|Vicryl sutures, 5/0, 3/8 curved cutting needle
89032318|NCT00522860|Active Comparator|Silk Suture|Silk suture, 4/0, 3/8 curved cutting needle
89032319|NCT02936895|Experimental|Vitamin D3 (Low dose)|vitamin D at a dose of 50,000 IU per day for 2 days
89032320|NCT02936895|Placebo Comparator|Placebo|Placebo (same size and shape) for 2 days
89601290|NCT02278900|Experimental|Communication aids|Patients in the intervention group will receive the QPL at home in advance of the consultation along with information about the clinic.The consultations will be recorded in both the control and intervention group. The recording will be done on the computer, and the patients in the intervention group will be given the recording immediately after the consultation on a memory stick.
89601291|NCT02278900|No Intervention|Control group|No intervention.
89601292|NCT02240498|Experimental|MB-PDT, 5 min illumination|Each subject in this group will receive methylene blue, 20% I.V. fat emulsion, insertion of optical fiber, and laser illumination, 5 minutes.
89601293|NCT02240498|Experimental|MB-PDT, 10 min illumination|Each subject in this group will receive methylene blue, 20% I.V. fat emulsion, insertion of optical fiber, optical spectroscopy measurement, and laser illumination, 10 minutes.
89601294|NCT02240498|Experimental|MB-PDT, 15 min illumination|Each subject in this group will receive methylene blue, 20% I.V. fat emulsion, insertion of optical fiber, optical spectroscopy measurement, and laser illumination, 15 minutes.
89601295|NCT02240498|Experimental|MB-PDT, 20 min illumination|Each subject in this group will receive methylene blue, 20% I.V. fat emulsion, insertion of optical fiber, optical spectroscopy measurement, and laser illumination, 20 minutes.
89601296|NCT02240498|Experimental|MB-PDT, 25 min illumination|Each subject in this group will receive methylene blue, 20% I.V. fat emulsion, insertion of optical fiber, optical spectroscopy measurement, and laser illumination, 25 minutes.
89601297|NCT02240498|Experimental|MB-PDT, 30 min illumination|Each subject in this group will receive methylene blue, 20% I.V. fat emulsion, insertion of optical fiber, optical spectroscopy measurement, and laser illumination, 30 minutes.
89601298|NCT02224781|Experimental|Arm A (immunotherapy)|"IMMUNOTHERAPY INDUCTION (CYCLES 1-2): Patients receive nivolumab IV over 30-60 minutes and ipilimumab IV over 30-90 minutes on days 1 and 22. Treatment repeats every 6 weeks for 2 cycles in the absence of disease progression or unacceptable toxicity.~IMMUNOTHERAPY MAINTENANCE (CYCLES 3-14): Patients receive nivolumab IV over 30-60 minutes on days 1, 15, and 29. Treatment repeats every 6 weeks for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Upon disease progression (or before), patients re-register and cross over to Arm C.~Patients undergo CT at baseline, and day 1 of cycles 3-14. Patients undergo ECHO or MUGA at baseline and end of treatment."
89601299|NCT02224781|Experimental|Arm B (BRAF inhibitor therapy)|"Patients receive dabrafenib mesylate PO BID and trametinib dimethyl sulfoxide PO daily on days 1-42. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. Upon disease progression (or before), patients re-register and cross over to Arm D. Patients undergo CT at baseline, and day 1 of each cycle.~Patients undergo ECHO or MUGA day 1 of each cycle and end of treatment."
89601300|NCT02224781|Experimental|Arm C (BRAF inhibitor therapy)|"Patients receive dabrafenib mesylate PO BID and trametinib dimethyl sulfoxide PO daily on days 1-42. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.~Patients undergo CT at baseline, and day 1 of each cycle. Patients undergo ECHO or MUGA day 1 of each cycle and end of treatment."
89608586|NCT01798849|Experimental|Panel C-Mild/Moderate Hypertension|Within each of the 5 single dose treatment periods, 6 participants with mild to moderate hypertension received a single dose of MK-8892 0.5 mg, 1.0 mg, 2.0 mg or 6.0 mg, and 2 participants received placebo. Dosages will be determined by the results of Panels A and B.
89608587|NCT05580471|Experimental|Use 4DryField|One group use 4DryField before wound closure.
89608588|NCT05580471|No Intervention|Not Use 4DryField|One group do not use 4DryField before wound closure.
88811372|NCT01351337|Other|intraoperative functional monitoring|intraoperative functional monitoring
88811373|NCT02147990|Experimental|Rociletinib Mono-Therapy, T790M +ve (625mg BID)|Starting dose of 625mg rociletinib, taken orally twice daily, with 8 oz (240 mL) of water and with a meal or within 30 minutes after a meal. Tablets should be swallowed whole. Treatment with rociletinib is continuous and each cycle will comprise of 28 days.
88811374|NCT02147990|Experimental|Rociletinib Mono-Therapy, T790M +ve (500mg BID)|Starting dose of 500mg rociletinib, taken orally twice daily, with 8 oz (240 mL) of water and with a meal or within 30 minutes after a meal. Tablets should be swallowed whole. Treatment with rociletinib is continuous and each cycle will comprise of 28 days.
88811375|NCT02147990|Experimental|Rociletinib Mono-Therapy, T790M -ve (500mg BID)|Starting dose of 500mg rociletinib, taken twice daily, with 8 oz (240 mL) of water and with a meal or within 30 minutes after a meal. Tablets should be swallowed whole. Treatment with rociletinib is continuous and each cycle will comprise of 28 days.
88811376|NCT02148302|Experimental|Harvesting Device (CelluTome©)|"open-label trial designed to evaluate the safety and effectiveness of Epidermal grafting plus multi-layer compression therapy versus multi-layer compression alone in the healing of venous leg ulcers.~Epidermal grafting will be applied up to three times in the treatment arm: at day zero, week 4 and week 8.~A run-in period of two weeks followed by twelve weeks of active treatment"
88811377|NCT02148302|No Intervention|Control: SOC alone|The Standard of Care therapy in this study is multi-layer compression therapy. A number of compression bandaging systems are commercially available. The trial will utilize Coban-2 (3M, Minneapolis, MN).
88811378|NCT03800498|Experimental|Intervention|For twelve weeks, only intervention group were given DASH education
88811379|NCT03800498|No Intervention|Controlled|Controlled group not received DASH education
89601301|NCT02224781|Experimental|Arm D (immunotherapy)|"IMMUNOTHERAPY INDUCTION (CYCLES 1-2): Patients receive nivolumab IV over 30-60 minutes and ipilimumab IV over 30-90 minutes on days 1 and 22. Treatment repeats every 6 weeks for 2 cycles in the absence of disease progression or unacceptable toxicity.~IMMUNOTHERAPY MAINTENANCE (CYCLES 3-14): Patients receive nivolumab IV over 30-60 minutes on days 1, 15, and 29. Treatment repeats every 6 weeks for up to 12 cycles in the absence of disease progression or unacceptable toxicity.~Patients undergo CT at baseline, and day 1 of cycles 3-14. Patients undergo ECHO or MUGA at end of treatment."
89601302|NCT02196181|Experimental|Arm I (continuous dosing)|Patients receive dabrafenib PO BID and trametinib PO QD on days 1-56 of each cycle. Cycles repeat every 56 days in the absence of disease progression or unacceptable toxicity. Patients also undergo PET/CT or CT scans in week 1 of cycle 2 and at off treatment follow up prior to progression.
89601303|NCT02196181|Experimental|Arm II (intermittent dosing)|Patients receive dabrafenib PO BID and trametinib PO QD on days 1-7 and 29-56 of each cycle. Cycles repeat every 56 days in the absence of disease progression or unacceptable toxicity. Patients also undergo PET/CT or CT scans in week 1 of cycle 2 and at off treatment follow up prior to progression.
89601304|NCT02168049|Experimental|Heart and Lung Function Monitioring|
89601305|NCT02160015|Experimental|Treatment (lenalidomide, ibrutinib, rituximab)|Patients receive rituximab IV on day 1 (up to 6 cycles), lenalidomide PO QD on days 1-21 (up to 12 cycles), and ibrutinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo ECG on screening and CT scan or MRI, bone marrow biopsy and blood sample collection throughout the study.
89601306|NCT02158858|Experimental|Arm 1: Prior JAKi (JAK inhibitor) Monotherapy Arm (MF patients treated with pelabresib alone)|"Cohort 1A: Open to patients with MF who are Transfusion Dependent (TD) and who have previously been treated with a JAKi and are intolerant, resistant, refractory or lost response to the JAKi, or are ineligible to be treated with a JAKi (pelabresib alone)~Cohort 1B: Open to patients with MF who are not TD and who have previously been treated with a JAKi and are intolerant, resistant, refractory or lost response to the JAKi, or are ineligible to be treated with a JAKi. (CPI-0610 alone)"
89601307|NCT02158858|Experimental|Arm 2: Prior JAKi Combination Arm|"Cohort 2A: Open to patients with MF who are Transfusion Dependent (TD) and are currently taking ruxolitinib but have disease that is not being adequately controlled by ruxolitinib (pelabresib + Ruxolitinib)~Cohort 2B: Open to patients with MF who are not TD and are currently taking ruxolitinib but have disease that is not being adequately controlled by ruxolitinib. (CPI-0610 + Ruxolitinib)"
89601308|NCT02158858|Experimental|Arm 3: JAKi Naïve Combination Arm|Open to patients with MF who have not previously received a JAKi (pelabresib + Ruxolitinib) and have DIPSS risk category Intermediate-2 or higher
89601309|NCT02158858|Experimental|Arm 4: Essential Thrombocythemia (ET) Monotherapy Arm|Open to high-risk patients with ET who are resistant or intolerant to hydroxyurea (HU)
89601310|NCT02094794|Experimental|Treatment (TMLI, chemotherapy)|Patients undergo image guided TMLI on days -9 to -5, receive etoposide IV on day -4 and cyclophosphamide IV on day -2, and undergo allogeneic peripheral blood stem cell or bone marrow transplant on day 0.
89601311|NCT02075736|Experimental|KTP laser|device
89601312|NCT02075736|Active Comparator|TUR-P|device
89601313|NCT02047994|Experimental|Group 1:Triple therapy|Among those assigned to Group 1, participants who are Helicobacter pylori positive will receive Triple therapy and/or upper endoscopy. Participants with serological evidence of atrophic gastritis will undergo upper endoscopy and further endoscopic follow-up. H. pylori positive individuals will be offered Helicobacter pylori eradication as appropriate, independently of the pepsinogen results. From subjects in this group, breath samples will also be collected for volatile markers study. In addition, fecal occult blood test (FOBT) will be offered to this group as a benefit to participate in the study.
89601314|NCT02047994|No Intervention|Group 2:No intervention|Those who assigned to Group 2 will receive no intervention and will be offered FOBT as a benefit of study participation. Any participants who show positive FOBT will be referred to colonoscopy. This will be the benefit to this group together with initial medical evaluation at the time of inclusion. During the follow-up period this group will be offered to consult a specialist when required due to clinical symptoms.
89601315|NCT02045524|Experimental|Injection location1|Single dose IM injection
88980433|NCT05865418|Active Comparator|High Intensity Training|These participants will be familiarized to all the exercises. All exercises will have 3 sets, and the participants will be asked to perform as many repetitions as they can in 30s for each set. They will have 30 seconds to rest between sets (if they want more rest, we can let them more time but not exceed 60 seconds to limit the total amount of time for completing the exercise protocol) and 90 seconds to rest between exercises. Training sessions will occur twice per week with at least 24 hours between sessions.
88980434|NCT05865418|No Intervention|Control|They will continue their standard-of-care plan and will not involve in any new structured exercise program for 6 weeks.
88980435|NCT05858788|Experimental|SAR441566|Participants will receive single ascending doses of SAR441566 on day 1 of each 8-12-day cycle
88980436|NCT05853419||Study population|Adult patients with coronary artery disease and a clinical indication for PCI
88980437|NCT05848115|Experimental|BiPAP|Patients randomized to the study group (BiPAP) will receive continuous nebulized albuterol through the FDA approved Respironics Trilogy BiPAP machine as per routine practice and institutional guidelines for albuterol dosing. Participants will receive BiPAP for four hours or until weaned off continuous beta-agonist therapy by the treating clinician.
89601316|NCT02045524|Experimental|Injection location 2|Single dose IM Injection
88980438|NCT05848115|Sham Comparator|Control|Patients randomized to the control group (sham BiPAP) will receive continuous nebulized albuterol through the same set-up as the study group and institutional guidelines for albuterol dosing. Participants will remain on sham BiPAP for four hours or until weaned off continuous beta-agonist therapy per the treating clinician.
88980439|NCT05847621|Experimental|In-person peer recovery coaching with linkage to recovery resources|"PRCs will meet patients at bedside (in person). They will also schedule and perform follow up calls after the participant is discharged from the ED to provide ongoing support and facilitate re-linkage to recovery resources, if needed.~Follow-up data collection on day 7, 30, 90 post discharge."
89601317|NCT02024152|Experimental|JDP-205 IV high dose|
89601318|NCT02024152|Experimental|JDP-205 IV low dose|
89601319|NCT02024152|Experimental|JDP-205 IM high dose|
89601320|NCT02024152|Active Comparator|Control|
89601321|NCT01989585|Experimental|Arm I (dabrafenib, trametinib)|ARM I: Patients receive dabrafenib PO BID and trametinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo MRI or CT, biopsy, and collection of blood samples throughout the trial.
89601322|NCT01989585|Experimental|Arm II (dabrafenib, trametinib, and navitoclax)|Patients receive navitoclax PO QD days -7 to -1 of cycle 1 only. Patients also receive dabrafenib PO BID, trametinib PO QD, and navitoclax PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo MRI or CT, biopsy, and collection of blood samples throughout the trial.
89601323|NCT01923506|Experimental|Treatment (SBRT)|Patients receive 5 fractions of SBRT over 1.5 weeks.
89601324|NCT01896999|Experimental|Phase I Arm I (brentuximab vedotin, ipilimumab)|Patients receive brentuximab vedotin IV over 30 minutes on day 1 of cycles 1-16 and ipilimumab IV over 90 minutes on day 1 of cycles 1-4, 8, 12, and 16. Treatment repeats every 21 days for up to 16 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or PET scan throughout the trial. Patients undergo blood sample collection and may undergo tumor biopsy on study.
89601325|NCT01896999|Experimental|Phase I Arm II (brentuximab vedotin, nivolumab)|Patients receive brentuximab vedotin IV over 90 minutes on day 1 of cycles 1-16 and nivolumab IV over 30 minutes on day 1 of cycles 1-46. Treatment repeats every 21 days for up to 16 cycles and every 14 days beginning cycle 17 for up to 46 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or PET scan throughout the trial. Patients undergo blood sample collection and may undergo tumor biopsy on study.
89601326|NCT01896999|Experimental|Phase I Arm III (brentuximab vedotin, nivolumab, ipilimumab)|Patients receive brentuximab vedotin IV over 90 minutes on day 1 of cycles 1-16, nivolumab IV over 30 minutes on day 1 of cycles 1-46, and ipilimumab IV over 30 minutes on day 1 every 12 weeks for up to 9 doses. Treatment repeats every 21 days for up to 16 cycles and every 14 days beginning cycle 17 for up to 46 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or PET scan throughout the trial. Patients undergo blood sample collection and may undergo tumor biopsy on study.
89601327|NCT01896999|Experimental|Phase II Arm I (brentuximab vedotin, nivolumab)|Patients receive brentuximab vedotin IV over 90 minutes on day 1 of cycles 1-16 and nivolumab IV over 30 minutes on day 1 of cycles 1-34. Treatment repeats every 21 days for up to 34 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or PET scan throughout the trial. Patients undergo blood sample collection and may undergo tumor biopsy on study.
89601328|NCT01896999|Experimental|Phase II Arm II (brentuximab vedotin, nivolumab, ipilimumab)|Patients receive brentuximab vedotin IV over 90 minutes on day 1 of cycles 1-16, nivolumab IV over 30 minutes on day 1 of cycles 1-34, and ipilimumab IV over 30 minutes on day 1 every 12 weeks for up to 9 doses. Treatment repeats every 21 days for up to 34 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or PET scan throughout the trial. Patients undergo blood sample collection and may undergo tumor biopsy on study.
89601329|NCT01858896|Active Comparator|Glucagon-Like Peptide -1 (GLP-1) infusion|Infusion of GLP-1 during experimental period
89601330|NCT01858896|Placebo Comparator|Saline Infusion|Saline infusion during experimental period
89601331|NCT01849146|Experimental|Arm I (adavosertib, temozolomide, radiation)|"INITIATION CYCLE: Patients receive adavosertib PO on days 1, 3, and 5 or 1-5 weekly and temozolomide PO QD for 6 weeks. Patients also undergo concurrent radiation therapy 5 days per week for 6 weeks.~MAINTENANCE CYCLES: Beginning in week 10, patients receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity."
89601332|NCT01849146|Experimental|Arm II (adavosertib, temozolomide)|Patients receive adavosertib PO QD on days 1, 3, and 5 or 1-5 weekly, and temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
89601333|NCT01812174|Experimental|17mm On-X Aortic Heart Valve|Patients receiving the 17mm On-X aortic heart valve as a replacement for diseased native or prosthetic aortic heart valve.
89601334|NCT01812174|Experimental|23mm On-X Mitral Heart Valve|"Patients receiving the 23mm On-X mitral heart valve as a replacement for diseased native or prosthetic mitral heart valve.~Enrollment into the 23mm On-X mitral arm has been terminated."
89601335|NCT01807728|Experimental|Group 1 Training Program|For Group 1, participants will aim to be recruited within the first week of their inpatient rehabilitation stay (admission time point).
89601336|NCT01807728|Experimental|Group 2 Training Program|For Group 2, individuals may be enrolled in the study at any time over their inpatient rehabilitation stay. Data collection may occur at admission (Group 2 only), just prior to discharge and at 3, 6 and 12 months after discharge.
89601337|NCT01783587|Experimental|High Risk Group|Dose escalation of afatinib + docetaxel + radiation therapy
89601338|NCT01783587|Experimental|Intermediate Risk Group|Dose escalation of afatinib + radiation therapy
89601339|NCT01712763|Experimental|Degarelix|180 women will be treated with degarelix 120mg in one administration
89601340|NCT01712763|Active Comparator|leuprolide acetate 11.25 mg/ml|180 women will be treated with leuprolide acetate 11.25 mg/ml only once covering three months
89608589|NCT04405947|Other|deltopectoral|deltopectoral surgical approach
89608590|NCT04405947|Other|antero-superior|antero-superior approach
89608591|NCT00724594|Experimental|N-acetylcysteine|Mother/infant pairs were stratified by gestational age into premature (P) and term (T) cohorts.
88980440|NCT05847621|Experimental|Telemedicine-based peer recovery coaching with linkage to recovery resources|"PRCs will meet patients via a tablet-based video call (telemedicine). They will also schedule and perform follow up calls after the participant is discharged from the ED to provide ongoing support and facilitate re-linkage to recovery resources, if needed.~Follow-up data collection on day 7, 30, 90 post discharge."
88980441|NCT05847621|Active Comparator|Usual Care|"Participants in the usual care arm will be provided with a list of community recovery resources. No callbacks or re-linkage to recovery resources.~Follow-up data collection on day 7, 30, 90 post discharge."
88980442|NCT05843604||obsessive compulsive disorder patients|
89032321|NCT00522899|Experimental|Aerobic exercise|Study-specific group exercise classes include 10' warm-up, 30' cardio, 5' cool down, 15' stretching/toning. Target heart rate is 60-75% of maximum. Study participants attend classes 60 min/day, 3 days/week for 12 weeks.
89032322|NCT00522899|Active Comparator|Stretching/toning|Study-specific stretching/toning exercise classes include 10' warm-up, 40' stretching/toning, 10' relaxation. Participants attend classes 60 minutes/day, 3 days/week for 12 weeks.
89032323|NCT00522899|Experimental|Computer-based mental activity training|Computer-based visual and auditory stimulation training programs developed by Posit Science corporation. Participants perform assigned mental activity on computers in their homes for 60 minutes/day, 3 days/week for 12 weeks.
89032324|NCT00522899|Active Comparator|Educational DVD training|Watching and listening to in-depth, college-level lectures on art, history and science on the computer. Participants perform assigned mental activities 60 minutes/day, 3 days/week for 12 weeks.
89032325|NCT02931006|Placebo Comparator|control|
89032326|NCT02931006|Active Comparator|experimental|
89032327|NCT02936856|Experimental|After Hepatic Arteriography|
89032328|NCT02936856|Active Comparator|Before Hepatic Arteriography|
89032329|NCT04694105|Active Comparator|dexmedetomidine|Bupivacaine 30 ml 0.25% was combined with 50 microgram (0.5 ml) peri-neural dexmedetomidine plus 1.5 ml normal saline
89032330|NCT04694105|Active Comparator|dexamethasone|Bupivacaine 30 ml 0.25% was combined with 4 mg peri neural dexamethasone (2 ml)
89601341|NCT01585805|Experimental|Arm A (veliparib, gemcitabine hydrochloride, cisplatin)|Patients receive veliparib PO BID on days 1-12 or 1-21 of each cycle. Patients also receive gemcitabine hydrochloride IV over 30 minutes and cisplatin IV over 30 minutes on days 3 and 10 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI throughout study. Patients also undergo tumor tissue and blood sample collection throughout the trial and undergo tumor biopsy during screening and on study.
89601342|NCT01585805|Active Comparator|Arm B (gemcitabine hydrochloride, cisplatin)|Patients receive gemcitabine hydrochloride IV and cisplatin IV as patients in arm A. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI throughout study. Patients also undergo tumor tissue and blood sample collection throughout the trial and undergo tumor biopsy during screening and on study.
89601343|NCT01585805|Experimental|Arm C (veliparib)|Patients receive veliparib PO BID on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI throughout study. Patients also undergo tumor tissue and blood sample collection throughout the trial.
89601344|NCT01561157||Acute Intermittent Porphyria (AIP)|Patients with a documented diagnosis of AIP
89601345|NCT01561157||Hereditary Coproporphyria (HCP)|Patients with a documented diagnosis of HCP
89601346|NCT01561157||Variegate Porphyria (VP)|Patients with a documented diagnosis of VP
89601347|NCT01561157||Congenital Erythropoietic Porphyria (CEP)|Patients with a documented diagnosis of CEP
89601348|NCT01561157||Hepatoerythropoietic Porphyria (HEP)|Patients with a documented diagnosis of HEP
89601349|NCT01561157||Porphyria Cutanea Tarda (PCT)|Patients with a documented diagnosis of PCT
89601350|NCT01561157||Erythropoietic Protoporphyria (EPP)|Patients with a documented diagnosis of EPP
89601351|NCT01561157||X-Linked Protoporphyria (XLP)|Patients with a documented diagnosis of XLP
89601352|NCT01561157||Aminolevulinate-Dehydratase Deficiency Porphyria (ALAD, ADP)|Patients with a documented diagnosis of ALAD, ADP
89601353|NCT01561157||Homozygous Dominant Acute Hepatic Porphyria|Patients with a documented diagnosis of Homozygous Dominant AHP
89601354|NCT01546181||Controls|subjects older than 10 years old, with no know ocular or general disease
89032331|NCT04694105|Placebo Comparator|control group|Bupivacaine 30 ml 0.25% was combined with 2 ml normal saline
89032332|NCT02930694|Experimental|Group 1: Treatment Sequence AB|Participants will receive Treatment A [JNJ-54175446, 50 milligram (mg) capsule] on Day 1 of period 1 followed by Treatment B [JNJ-54175446, 50 mg suspension] on Day 1 of period 2. Both the treatment periods will be separated by washout period of minimum 10 days.
89032333|NCT02930694|Experimental|Group 1: Treatment Sequence BA|Participants will receive Treatment B on Day 1 of period 1 followed by Treatment A on Day 1 of period 2. Both the treatment periods will be separated by washout period of minimum 10 days.
89032334|NCT02930694|Experimental|Group 2: Treatment Sequence CD|Participants will receive Treatment C [JNJ-54175446, 100 mg capsule] on Day 1 of period 1 followed by Treatment D [JNJ-54175446, 100 mg suspension] on Day 1 of period 2. Both the treatment periods will be separated by washout period of minimum 10 days.
89601355|NCT01546181||Age-related macular degeneration|
89601356|NCT01546181||inherited retinal dystrophies|
89032335|NCT02930694|Experimental|Group 2: Treatment Sequence DC|Participants will receive Treatment D on Day 1 of period 1 followed by Treatment C on Day 1 of period 2. Both the treatment periods will be separated by washout period of minimum 10 days.
89601357|NCT01546181||retinal trauma|
89601358|NCT01546181||toxic retinopathies|
89601359|NCT01546181||arterial hypertensive patients|
89601360|NCT01546181||diabetic patients|
89601361|NCT01546181||inflammatory diseases|
89601362|NCT01368666|Experimental|Perceval S Valve Prosthesis|Patients who underwent replacement of diseased or malfunctioning native aortic valve with the Perceval S Valve prosthesis
89601363|NCT01286467|Experimental|1|
89601364|NCT01149083|Experimental|Phase II (veliparib, carboplatin)|Patients receive veliparib PO BID on days 1-21 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Upon progression, patients are taken off treatment for 1 week and may then continue to recieve veliparib along with carboplatin IV over 30 minutes on day 1 of each cycle. Cycles repeats every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI and may optionally undergo biopsies throughout the study. Patients undergo blood sample collection during screening and on study.
89601365|NCT01149083|Experimental|Safety Lead-In Phase (veliparib, carboplatin)|Patients receive veliparib PO BID twice daily on days 1-21 of each cycle and carboplatin IV over 30 minutes on day 1 of each cycle. Cycles repeats every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI and may optionally undergo biopsies throughout the study. Patients undergo blood sample collection during screening and on study.
89601366|NCT01085435||EFFORTLESS Main Study|Patients implanted with a CE marked S-ICD System, not participating in Cameron Health's Investigational Device Exemption (IDE) Clinical Study.
89601367|NCT01085435||Extension Phase Sub Study|The Sub-Study patients were preferably recruited from the active EFFORTLESS S-ICD patient population. Patients, who had already completed the EFFORTLESS S-ICD Registry in the past, were considered secondarily for participation in the Sub-Study.
89601368|NCT00933400|Active Comparator|Traditional Strategy [Group A]|In the traditional-care arm (Group A:Standard of Care (SOC)), all management and disposition decisions will be made by the healthcare providers caring for the participant. Participants will receive disposition (admit to hospital, admit to cardiac diagnostic unit, or discharge to home), diagnostic testing (none, stress testing, or cardiac catheterization), and treatment according to the team caring for the participant.
89601369|NCT00933400|Experimental|CT Coronary Angiography (CTCA)[Group B]|"In the study CT coronary angiography-based rapid rule out arm (Group B), participants will receive initial cardiac troponin and creatinine tests. Upon return of normal laboratory values (including a calculated creatinine clearance), the participants will receive a CT coronary angiography an estimated 90 minutes or as soon as the CT scanner is available following the initial values assessment. Participants with negative test results will be discharged unless other indications for admission per standard of care and follow up will comprise telephone interviews 30 days and 1 year after triage/presentation. Participants with positive test results will be admitted to the hospital for further management as dictated by the admitting team."
89601370|NCT00569127|Experimental|Arm I (octreotide acetate and bevacizumab)|Patients receive depot octreotide acetate IM and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
89601371|NCT00569127|Experimental|Arm II (octreotide acetate and recombinant interferon alfa-2b)|Patients receive octreotide acetate IM as in arm I on day 1 and recombinant interferon alfa-2b SC on days 1, 3, 5, 8, 10, 12, 15, 17, and 19. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
89601372|NCT00330447||Studygroup|Cancer in Pregnancy - all diagnoses and treatments Children born from mothers diagnosed with cancer during pregnancy
89601373|NCT00330447||Control group|Children from the general population
89601374|NCT02481648|Experimental|ARM1: Exercise Intervention|"The exercise program is a 4-12 weeks progressive combined resistance and aerobic exercise for participants from time of diagnosis to RP.~Participants will undergo twice weekly group-training (four-six participants/group) combined aerobic-resistance sessions (1hr per session), supervised by trained exercise therapists. In addition, participants will undergo home-based aerobic exercise independently three times a week with the goal to meet the current physical activity guidelines for cancer survivors (150min/week of moderate intensity aerobic activity and two resistance training sessions per week). Participants will also be supplied with the Canadian Physical Activity and Sedentary Behavior Guidelines Handbook and accompanying Log Sheets."
89601375|NCT02481648|No Intervention|ARM2: Control Group|Participants will be asked to exercise as they normally would and will be asked to record their exercise activity on provided activity logs.
89601376|NCT02444429|Experimental|Sub-study A experimental arm|"This experimental arm corresponds to patients with borderline infiltrates at 3 months, who will be randomized to receive a treatment for rejection (intensification of the corticotherapy with corticosteroid boluses = Corticosteroid boluses Methylprednisolone )"
89601377|NCT02444429|Active Comparator|Sub-study A control arm|"This control arm corresponds to patients with borderline infiltrates at 3 months, who will be randomized to not change their immunosuppressive treatment (No therapeutic modification)"
88980443|NCT05843604||Control Patients|
88980444|NCT05843500||Chronic thromboembolic disease|Patients with chronic thromboembolic disease/pulmonary hypertension
88980445|NCT05840263||Metastatic Colorectal Cancer Patients|We anticipate enrolling up to a total of 18 patients who have been diagnosed with metastatic colorectal cancer; 12 patients will participate in the qualitative interview, and 6 patients will participate in the cognitive interview.
88980446|NCT05840263||Metastatic Colorectal Cancer Patients Partners|We anticipate enrolling up to a total of 18 partners of patients who have been diagnosed with metastatic colorectal cancer; 12 partners will participate in the qualitative interview, and 6 paartners will participate in the cognitive interview.
88980447|NCT05840263||Clinicians|We anticipate enrolling 12 clinicians (including physicians, nurse practitioners, physician assistants, mental health providers, other advanced practice clinicians) who treat patients with colorectal cancer at the University of Colorado to participate in qualitative interviews. We seek to enroll a variety of clinicians from advanced practiced clinical roles (physicians, nurse practitioners, and mental health providers) to capture diverse perspectives.
88980448|NCT05838430|Experimental|Solriamfetol+ CBT-I|
88980449|NCT05838430|Experimental|Solriamfetol Only|
88980450|NCT05838430|Active Comparator|Placebo + CBT-I|
88980451|NCT05838430|Placebo Comparator|Placebo Only|
88980452|NCT05833269|Experimental|Mindfulness and compassion based intercare program|"This 8-week intervention aims to reduce parental burnout by adapting the Mindfulness-based Inter-care Program and incorporating elements from MBSR, MBCT, and CBCT. The program includes 8 modules with practical and theoretical activities, weekly tasks, journaling, and daily meditation practices such as body exploration, seated and moving meditation, walking and eating meditation, acceptance, compassion, and gratitude.~The program also promotes values such as time management, attentive parenting, and emotional management while addressing factors of risk for parental burnout such as perfectionism, low emotional intelligence, lack of parenting practices, excessive responsibilities, and lack of support. Participants will receive two weekly reminders via email to perform the practices and review information. Additionally, they will have the option to participate in a virtual group via the WhatsApp platform with other participants."
89032336|NCT00523016|Experimental|Electroacupuncture|Subjects will receive Lyndhurst Central Neuropathic Pain Acupuncture Protocol (LCCNPAP) electroacupuncture protocol for 20 minutes per treatment session; a total of 13 treatments will be administered over 3-4 weeks.
89032337|NCT00523016|Sham Comparator|Sham acupuncture|Subjects will receive simulated acupuncture that includes insertion of acupuncture needles on the head. During each treatment session, needles will be stimulated with electricity for 20 minutes. A total of 13 treatments will be administered over 3-4 weeks. This group will be offered the LCCNPAP treatment at the completion of study participation.
89032338|NCT02936739|Experimental|Elastic spine pad|Patients, who receive Elastic Spine Pad (TM) as cervical disc prosthesis after ventral discectomy.
89032339|NCT02936739|Active Comparator|Rotaio|Patients, who receive Rotaio (TM) as cervical disc prosthesis after ventral discectomy.
89601378|NCT02444429|Experimental|Sub-study B experimental arm|This experimental arm corresponds to patients without significant infiltrates 3 months, who will be randomized to stop maintenance corticotherapy (Stop maintenance corticotherapy )
89032340|NCT02948153||asthma with bronchial hypersecretion|In a clinical study, participants are often divided into groups. Group one: they were defined as those who expectorated daily for at least three months for a minimum period of two consecutive years, without attribution to any other cause or disease.
89032341|NCT02948153||asthma without hypersecretion|In a clinical study, participants are often divided into groups. Group two: We defined asthma as a history of variable respiratory symptoms and evidence of variable expiratory airflow limitation.
89032342|NCT02930733|Active Comparator|ultrasound guided serratus plane block|Bilateral ultrasound guided serratus plane block with 30 ml %0,25 bupivacaine
89032343|NCT02930733|Placebo Comparator|ultrasound guided sham block|Bilateral ultrasound guided sham block with 2 ml saline subcutaneously
89601379|NCT02444429|Active Comparator|Sub-study B control arm|This control arm corresponds to patients without significant infiltrates 3 months, who will be randomized to not change their immunosuppressive treatment (No therapeutic modification)
89601380|NCT02426073||HE|Healthy elderlies
89601381|NCT02426073||DM|Elderlies with type 2 diabetes
89601382|NCT02426073||SA|Elderlies with sarcopenia
89601383|NCT02426073||DS|Elderlies with both type 2 diabetes and sarcopenia
89601384|NCT02318342|Experimental|Pre-existing bioprosthetic aortic valve|Patients with a history of surgical or transcatheter valve replacement with bioprosthetic valves undergo cardiac contrast CT imaging and transthoracic echocardiography to evaluate structural and functional integrity of the aortic valves. Patients with prosthetic valve abnormalities suggestive of thrombus will be administered anticoagulation therapy with Vitamin K antagonists (Warfarin) for 3 months with goal INR 2-3, followed by repeat contrast CT of the chest and transthoracic imaging. Repeat imaging following 3 months of anticoagulation therapy is performed to evaluate the response to anticoagulation therapy.
89601385|NCT02296216|Active Comparator|Exposed patients|Exposed patients have been treated by Gamma Knife Radiosurgery after unsuccessful surgery 10-20 years before inclusion
89601386|NCT02296216|Placebo Comparator|Unexposed patients|Unexposed patients have not been treated by Gamma Knife Radiosurgery after unsuccessful surgery 10-20 years before inclusion
89601387|NCT02258165||Advanced ovarian cancer|gated PET/CT imaging
89032344|NCT02948270||Adolescents with ADHD|Adolescents who met diagnostic criteria in previous clinical/research assessment are invited to come back to SickKids to participate (ages 13-17)
89032345|NCT02948270||Adolescents without ADHD|Adolescent controls (ages 13-17) are tested through local high schools
89032346|NCT02931162|Experimental|Herb-partitioned moxibustion|Drug: Herbal cake, Device: Moxibustion. Herbal cakes formula: Monkshood 10g, Cinnamon 2g, Salvia miltiorrhiza 3g, Flos Carthami 3g, Radix Aucklandiae 2g. Herbs are smashed into powder. Every 2.5g medicine powder is mixed with 3g millet wine and then pressed into herbal cakes using a specific mold. Each cake should be 23mm in diameter and 5mm in height. Then, ignited moxa cones are placed on top of each herbal cake. Herbal cakes with moxa cones will be positioned at acupuncture points ST25 and ST37. The entire treatment will be done once a day for 1 moxa cone every acupuncture point, 30 minutes at a time, 3 times a week, for a total of 12 weeks.
89032347|NCT02931162|Sham Comparator|Sham herb-partitioned moxibustion|Drug: Herbal cake, Device: Sham moxibustion. Herbal cakes formula: Monkshood 10g, Cinnamon 2g, Salvia miltiorrhiza 3g, Flos Carthami 3g, Radix Aucklandiae 2g. Herbs are smashed into powder. Every 2.5g medicine powder is mixed with 3g millet wine and then pressed into herbal cakes using a specific mold. Each cake should be 23mm in diameter and 5mm in height. Then, ignited moxa cones are placed on top of each herbal cake. Small cardboard sheets with the same size as the herbal cakes will be wrapped with aluminum foil and placed under each herbal cake. These herbal cakes will be positioned at acupuncture points ST25 and ST37. The entire treatment will be done once a day for 1 moxa cone every acupuncture point, 30 minutes at a time, 3 times a week, for a total of 12 weeks.
89601388|NCT02154516|Active Comparator|Control Total Hip Replacement Device|"Total Hip replacement surgery using control device consisting of a hard-on-soft bearing or a ceramic-on-ceramic bearing which includes:~R3 acetabular cup, and an uncemented SYNERGY or ANTHOLOGY femoral stem~OXINIUM heads on polyethylene liners or~Ceramic heads on ceramic liners (all uncemented components)"
89601389|NCT02154516|Experimental|Investigational Hard-on-Hard Total Hip Replacement Device|"Total Hip replacement surgery using an experimental device consisting of a hard-on-hard bearing which includes:~R3 acetabular cup, and an uncemented SYNERGY or ANTHOLOGY femoral stem~R3 ODH acetabular cup liners (sizes 38/50, 40/52, 42/54 and 44/56 mm)~R3 ODH femoral heads (sizes 38, 40, 42 and 44 mm)~Taper sleeves Ti -6AL-4V (sizes -4, +0, +4, and +8)"
89601390|NCT02134184|Experimental|CMV negative group|Participants will receive Fluzone® 2012-2013 Formula NDC No 498281-012-50
89601391|NCT02134184|Experimental|CMV positive group|Participants will receive Fluzone® 2012-2013 Formula NDC No 498281-012-50
89601392|NCT02134184|Experimental|Recent CMV Converters|Participants will receive Fluzone® 2012-2013 Formula NDC No 498281-012-50
89601393|NCT02109367||Pelvic mass|Women who present to the Gynecologic Oncology clinic with a pelvic mass who are scheduled to undergo surgical excision.
89601394|NCT02029846|Active Comparator|Standard Treatment|A regimen with traditional drugs only
89601395|NCT02029846|Experimental|Incretin-based Treatment|A regimen including incretin-based drugs
89601396|NCT06018649|Experimental|Short ambulatory balneotherapy (SAB)|Group I will be given a complex of balneological procedures: swimming pool 20 min, 34-36° mineral/geothermal water procedure 20 min, sapropel wrapping 20 min, salt therapy 25 min. Duration of treatment - 6 days, outpatient.
89032348|NCT02930967|Experimental|CSR T cells|"A dose escalation clinical study aimed to assess the safety and efficacy of CSR T cells in patients with PD-L1 positive tumors.~CSR T dosage ranging from: 5×10^4 /kg to 1×10^7 /kg will be tested."
89032349|NCT02947958|Experimental|Teleconsultation|Tele consultation (experimental) - after the randomization the patient is guided to seek primary care under teleconsultation supervision to keep his treatment. One year later the patient's symptoms are reassessed in a medical consultation.
89032350|NCT02947958|Active Comparator|Hospital|Hospital (control) - after the randomization the patient is guided to keep his treatment in the tertiary care as usual. One year later the patient's symptoms are reassessed in a medical consultation.
89032351|NCT04761081||South Asians who are lean|"The south Asian group who are lean will be of south Asian ethnicity and a waist circumference <90cm.~The group will receive an accelerometer (Actigraph GT3x) to wear for 7 days to measure habitual physical activity. They will then provide a single blood donation in a fasted state which we will use to quantify the migration of pro-inflammatory monocytes towards adipose tissue specific media. This will then be compared to the other 3 groups to investigate the interaction between ethnicity, central obesity, and physical activity with the migration of pro-inflammatory monocytes.~Metabolic markers will be analysed and presented in a participant characteristics table."
89032352|NCT04761081||South Asians with central obesity|"The south Asian group with central obesity will be of south Asian ethnicity and a waist circumference of 90cm or greater.~The group will receive an accelerometer (Actigraph GT3x) to wear for 7 days to measure habitual physical activity. They will then provide a single blood donation in a fasted state which we will use to quantify the migration of pro-inflammatory monocytes towards adipose tissue specific media. This will then be compared to the other 3 groups to investigate the interaction between ethnicity, central obesity, and physical activity with the migration of pro-inflammatory monocytes.~Metabolic markers will be analysed and presented in a participant characteristics table."
89032353|NCT04761081||White Europeans who are lean|"The white European group who are lean will be of white European ethnicity and a waist circumference <94cm.~The group will receive an accelerometer (Actigraph GT3x) to wear for 7 days to measure habitual physical activity. They will then provide a single blood donation in a fasted state which we will use to quantify the migration of pro-inflammatory monocytes towards adipose tissue specific media. This will then be compared to the other 3 groups to investigate the interaction between ethnicity, central obesity, and physical activity with the migration of pro-inflammatory monocytes.~Metabolic markers will be analysed and presented in a participant characteristics table."
89210265|NCT00898404||Arm I|Tumor diagnostic specimens from patients who subsequently failed therapy within 4 years of diagnosis or who did not fail therapy within 4 years of diagnosis (control patients) are obtained from the Children's Oncology Group cellbank. Specimens are studied for molecular determinants of human reduced folate carrier (hRFC) gene expression and gene sequence alterations using reverse transcriptase-polymerase chain reaction (RT-PCR), thymidylate synthase inhibition assay, Rnase protection assay, or 5'RACE. Multidrug resistance proteins are also studied by RT-PCR.
89601397|NCT06018649|Experimental|Long ambulatory balneotherapy (LAB)|"Group II will be given a complex of balneological procedures as group I- swimming pool 20 min, 34-36° mineral/geothermal water procedure 20 min, sapropel wrapping 20 min, salt therapy 25 min.~Duration of treatment - 11 days, outpatient treatment."
89601398|NCT06018649|Experimental|Combined nature resources treatment (CNT)|"Group III will be given a complex of balneological procedures like groups I and II plus natural therapy procedure developed by the researchers: a 45-minute walk in nature (forest, seaside), a complex of simple strength and breathing low-intensity exercises, sensory impulses (landscape , forest smells - aromatherapy, natural sounds of nature, collecting nature's goodies (berries, pine cones, leaves, etc.), awareness therapy, heliotherapy.~Duration - 11 days., outpatient treatment."
89601399|NCT06018649|Experimental|Long inpatient balneotherapy (LIB)|"Group IV will be accommodated in the research/resort center and will receive balneological treatment (as groups I and II).~Duration of treatment 11 days, inpatient treatment."
89601400|NCT06018649|Active Comparator|Nature therapy (NT)|Group V will be given only the natural therapy procedure (as in group III). Duration 11 days, outpatient, self-managed according instructions and training provided.
89601401|NCT06018649|No Intervention|Control|Group VI - the control group, the participants of which will not be given any procedures. Duration 11 days.
89601402|NCT06018636||Group 1|Infants and young children residing in agropastoral communities of District Swat, Pakistan
89601403|NCT06018636||Group 2|Infant and young children residing in urban areas of district Swat, Pakistan
89601404|NCT06018597||percent age difference < -6.6%|"The percentage age difference in the negative direction represents patients whose metabolic age is greater than their chronological age.~When we analyze the ROC analysis in the negative direction,between Percent Age Difference and Sevoflurane Consumption Amount Calculated According to Metabolic Age, the cut-off value of the percentage age difference is -6,6%.~This group refers to those whose percentage age difference is less than -6.6%"
89601405|NCT06018597||percent age difference -6.6% to 11.7% those between|"When we analyze the ROC analysis in the negative direction,between Percent Age Difference and Sevoflurane Consumption Amount Calculated According to Metabolic Age, the cut-off value of the percentage age difference is -6,6%. When we analyze the ROC analysis in the positive direction, the cut-off value of the percent age difference is 11.7%.~This group refers to those whose percentage age difference between -6.6% and 11.7%"
89601406|NCT06018597||percent age difference > 11.7%|"the percent age difference in the positive direction represents patients whose metabolic age is less than their chronological age.~When we analyze the ROC analysis in the positive direction,between Percent Age Difference and Sevoflurane Consumption Amount Calculated According to Metabolic Age, the cut-off value of the percent age difference is 11.7%.~This group refers to those whose percentage age difference is more than 11.7%"
89601407|NCT06018584|Sham Comparator|Control Group|No application was made after the tooth extraction procedure in the control group.
89601408|NCT06018584|Experimental|Low- Level Laser Group (Doctor Smile Wiser)|In the Laser group, the diode laser device Doctor Smile Wiser (Wiser, Doctor Smile, Milan, Italy) (Figue 1) with a wavelength of 980 nm and a power of 0.5 W was used for LLLT. During the procedure, the patient, physician, and assistant staff wore protective glasses (Wiser, Doctor Smile, Milan, Italy). With 300 mW of energy, a 400 m tip held 1 cm away from the extraction socket was applied to the extraction socket for 60 seconds from three points determined from the vestibule, lingual/palatal, and occlusal surfaces.
89601409|NCT06018532|Experimental|Intervention|
89601410|NCT06018519|Other|CTD patients|Case group 24 male CTD patients having a confirmed mutation in the SLC6A8 gene, aged > 5 to < 35 years.
89601411|NCT06018519|Other|Sex and chronological age matched controls|Control group 24 male, sex and chronological age matched controls, aged > 5 to < 35 years
89601412|NCT06018519|Other|Sex and mental age matched controls|Control group 24 male, sex and mental age matched controls, aged > 3 to < 8 years
89601413|NCT06018519|Other|Typically developed children|"Control group 80 typically developed children aged > 3 to < 8 years, which corresponds to the mental age of CTD patients.~40 children aged > 3 to < 5 years, and 40 children aged > 6 to < 8 years will perform the newly developed outcome measures."
89601414|NCT06018506|Experimental|BR108|
89601415|NCT06018454|No Intervention|Provider counseling with pre-test|Counseling regarding PGT-A only with a provider(current standard of care), pre-test provided.
89601416|NCT06018454|Experimental|Handout on PGT-A and provider counseling with pre-test|Counseling regarding PGT-A with a provider and review of a handout(educational intervention), pre-test provided.
89601417|NCT06018454|Experimental|Handout on PGT-A, provider counseling and brief genetic counselor counseling with pre-test|Counseling regarding PGT-A only with a provider, review of a handout(educational intervention) and genetic counseling (counseling intervention), pre-test provided.
89601418|NCT06018363|Experimental|ARM|Patients with refractory or relapsed B7H3 positive GBM
89601419|NCT06018285|No Intervention|Treatment As Usual|Treatment as Usual
89601420|NCT06018285|Experimental|STARRS-PC|Intervention consists of implementation of clinical pathway for youth suicide risk
89601421|NCT06018259|Experimental|healthy volunteers|One blood sample will be taken from healthy volunteers in order to isolate PBMC and to assess the effect of the lipid of interest on them
89601422|NCT06018246|Experimental|Intervention Group|"Before operation：The patients' dietary intake was assessed by a 24-hour dietary review by a professional dietitian.According to the diet of the patients, the intervention was carried out by a professional nutritionist according to the five-step treatment mode of malnutrition.If the food intake cannot meet 60% of the daily requirement, the previous step of treatment is used, and it is adjusted at any time according to the situation of the patient.~After operation:Same as control group.~Out-of-hospital: Same as before operation.~Strengthening Health Education and psychological intervention:Dietitians need to strengthen health education and communicate with patients during the implementation of nutrition intervention.For patients who actively cooperate with treatment, dietitians can give encouragement.~Exercise Instruction:After the operation, according to the tolerance, the dietitian can instruct the patient to take a certain time walking every day."
88980453|NCT05833269|Active Comparator|Audio guide relaxation control group|"The active control group in this study will be provided with a 20-minute relaxation audio containing Jacobson's progressive relaxation instructions. This intervention aims to control for attention and time while allowing for comparison to the experimental group. Also, journaling was included.~Additionally, the program will include information on risk factors for parental burnout, such as parental perfectionism, low emotional intelligence, lack of parenting practices, excessive responsibilities, and lack of support. Two weekly email reminders will be sent to encourage daily practice and review of the information provided. Participants will also have the option to participate in a virtual support group through the WhatsApp platform with other participants. This active control group intervention aims to improve participant well-being by providing relaxation techniques and support for the challenges of parenting."
88980454|NCT05833269|No Intervention|Waiting List Group|The waiting list group will receive the intervention after the primary outcome is measured. No intervention was provided before this point.
88980455|NCT05831358|Experimental|Multiple Myeloma Screening Experience|Participants will partake in a multiple myeloma screening program. The screening involves a blood sample and the completion of a questionnaire to gauge participants' multiple myeloma knowledge.
88980456|NCT05829668|Experimental|ABA-based functional analysis and treatment|Assessment and Treatment for problem behavior exhibited by children with CdLS
88980457|NCT05829668|No Intervention|No Problem behavior Control Group|Quarterly Monitoring of children with CdLS that do not exhibit problem behavior
88980458|NCT05828966|Active Comparator|HUMAN CHORIONIC GONADOTROPIN (HCG) Group|H.C.G. will be given in Group A and in a dose of 5000units intramuscular injection followed by a drip of 10,000 units in 500ml of dextrose 5%, at the rate of 20 drops per minute. Half hourly assessment of uterine contractions, maternal vital signs, fetal heart rate monitoring will be done.
88980459|NCT05828966|Active Comparator|Magnesium Sulphate(MgSO4) Group|4gm of MgSO4 will be given in Group B as intravenously as continuous dose followed by 2gm/hr till uterine quiescence is achieved.
88980460|NCT05827042|Experimental|Endovascular thrombectomy alone|Patients will receive endovascular thrombectomy without intravenous thrombolysis.
88980461|NCT05827042|Active Comparator|Intravenous thrombolysis plus endovascular thrombectomy|Patients will receive intravenous alteplase (0.9mg/kg, maximum 90mg) or tenecteplase (0.25mg/kg, maximum 25mg) before endovascular thrombectomy.
88980462|NCT05826964|Experimental|Step 2 Arm 1: No Modification of Therapy|"Participants in Step 2 Arm 1 will first undergo ctDNA monitoring in Step 1, providing blood samples for ctDNA testing at the following timepoints until a rise in ctDNA leading to a ratio (ctDNA result at time of assessment/ctDNA level at baseline) greater than (>) 1 occurs:~Cycle 1 day 1 (C1D1),~Day 30 (D30) post-treatment initiation (±3 days),~Day 60 (D60) post-treatment initiation (±3 days), and then~every 8-9 weeks (±1 week).~Participants will have no change in standard of care therapy administered in Step 1."
89601423|NCT06018246|Other|Control Group|Routine nutrition support in department.Nutritionists will give patients routine parenteral nutrition support via peripheral or central vein 0-48 hours after surgery and then start enteral nutrition support 48-72 hours after surgery.Patients were initially given half of their enteral nutrition and the rest was supplemented with parenteral nutrition.After adaptation, the patient stopped parenteral nutrition and all nutrition came from enteral nutrition.After the patient's gastrointestinal function gradually recovered, the enteral nutrition could gradually decrease.At this time, nutritionists can let the patient eat some light liquid food, but pay attention to eating a small amount of multiple times.After adaptation, patients can gradually transition from liquid diet to semi-liquid diet.We will educate patients and their families about diet and encourage them to eat more high-quality protein-rich foods.
89601424|NCT06018207|Experimental|An Up-and-Down Sequential Allocation|An Up-and-Down Sequential Allocation is that the dose is varied based on the hypnosis response of the previous patient after taking midazolam oral solution for 1 hour.
89601425|NCT06018181||Exposure group|"The exposure group was defined as patients receiving Shuxuetong injection and guideline-standardized treatment after intravenous alteplase or tenecteplase.~Mainly based on the following guidelines:(1)Guidelines for the diagnosis and treatment of acute ischemic stroke in China 2018; (2)Guidelines for secondary prevention of ischemic stroke and transient ischemic attack in China 2022."
89601426|NCT06018181||Non-exposure group|The non-exposed group was defined as patients receiving guideline-standardized treatment after intravenous alteplase or tenecteplase.
89601427|NCT06018090||Acute Ischemic Stroke Patients with Atrial Fibrillation|
89601428|NCT06018077||Colorectal Cancer Group|Individuals aged 18-65 years, who applied to Ankara City Hospital Oncology Hospital Medical Oncology Outpatient Clinic, newly diagnosed with colorectal cancer as a result of the necessary examinations, at least 3 weeks after the surgical procedure and without metastasis (except for Stage IV)
89601429|NCT06018077||Healthy Group|A healthy adult between the ages of 18-65 who has not been diagnosed with any malignant disease and consented to participate in the study.
89601430|NCT06017986|Experimental|Stimulus: UPF1|In a whole room metabolic chamber participants will consume a ~300 kcal meal consisting of ultra-processed foods as determined by the widely used NOVA scale. The whole room metabolic chamber will allow for collection of simultaneous measurement of multiple metabolic responses (glucose, insulin, and metabolic rate). Measures will be collected for 45 min before consumption of the meal (baseline) and for 3 hours after consumption (post-prandial).
89601431|NCT06017986|Experimental|Stimulus: UPF2|In a whole room metabolic chamber participants will consume a ~300 kcal meal consisting of ultra-processed foods as determined by the widely used NOVA scale. The whole room metabolic chamber will allow for collection of simultaneous measurement of multiple metabolic responses (glucose, insulin, and metabolic rate). Measures will be collected for 45 min before consumption of the meal (baseline) and for 3 hours after consumption (post-prandial).
89601432|NCT06017986|Experimental|Stimulus: UPF3|In a whole room metabolic chamber participants will consume a ~300 kcal meal consisting of ultra-processed foods as determined by the widely used NOVA scale. The whole room metabolic chamber will allow for collection of simultaneous measurement of multiple metabolic responses (glucose, insulin, and metabolic rate). Measures will be collected for 45 min before consumption of the meal (baseline) and for 3 hours after consumption (post-prandial).
89601433|NCT06017986|Active Comparator|Stimulus: MPF1|In a whole room metabolic chamber participants will consume a ~300 kcal meal consisting of minimally processed foods as determined by the widely used NOVA scale. The whole room metabolic chamber will allow for collection of simultaneous measurement of multiple metabolic responses (glucose, insulin, and metabolic rate). Measures will be collected for 45 min before consumption of the meal (baseline) and for 3 hours after consumption (post-prandial).
89601434|NCT06017986|Active Comparator|Stimulus: MPF2|In a whole room metabolic chamber participants will consume a ~300 kcal meal consisting of minimally processed foods as determined by the widely used NOVA scale. The whole room metabolic chamber will allow for collection of simultaneous measurement of multiple metabolic responses (glucose, insulin, and metabolic rate). Measures will be collected for 45 min before consumption of the meal (baseline) and for 3 hours after consumption (post-prandial).
89601435|NCT06017986|Active Comparator|Stimulus: MPF3|In a whole room metabolic chamber participants will consume a ~300 kcal meal consisting of minimally processed foods as determined by the widely used NOVA scale. The whole room metabolic chamber will allow for collection of simultaneous measurement of multiple metabolic responses (glucose, insulin, and metabolic rate). Measures will be collected for 45 min before consumption of the meal (baseline) and for 3 hours after consumption (post-prandial).
89601436|NCT06017830|Experimental|Patients with low back pain|
89601437|NCT06017778|Experimental|whole body viberation group|
89601438|NCT06017778|Active Comparator|control group|
89601439|NCT06017752|Experimental|STAC Teacher Module|
89601440|NCT06017726||Multiple sclerosis patients without insulin resistance|Cognitive status will be evaluated with BICAMS test. Physical disability will be evaluated by the EDSS score, 9-hole pig and 25-foot-walk test. Patients will be assessed for other comorbid conditions like fatigue and depression. Serum light chain neurofilaments as a laboratory marker for axonal degeneration will be used. brain imaging will be done with with Diffusion tensor imaging.
89601441|NCT06017726||Multiple sclerosis patients with treated insulin resistance|before and after treatment of insulin resistance Cognitive status will be evaluated with BICAMS test. Physical disability will be evaluated by the EDSS score, 9-hole pig and 25-foot-walk test. Patients will be assessed for other comorbid conditions like fatigue and depression. Serum light chain neurofilaments as a laboratory marker for axonal degeneration will be used. brain imaging will be done with with Diffusion tensor imaging.
89601442|NCT06017726||Multiple sclerosis patients with untreated insulin resistance|at the end of the 1st and 2nd year of the study, Cognitive status will be evaluated with BICAMS test. Physical disability will be evaluated by the EDSS score, 9-hole pig and 25-foot-walk test. Patients will be assessed for other comorbid conditions like fatigue and depression. Serum light chain neurofilaments as a laboratory marker for axonal degeneration will be used. brain imaging will be done with with Diffusion tensor imaging.
89608592|NCT00724594|Active Comparator|Control|Mother/infant pairs were stratified by gestational age into premature (P) and term (T) cohorts.
89210266|NCT05712603||Prospective care path arm|"Participants who enter the care path will make up the prospective care path arm.~In patients entering the care path three diagnostic tests for liver fibrosis will be performed. FIB4-score, Vibration controlled transient elastography and Enhanced Liver Fibrosis test"
89210267|NCT05712603||Prospective arm of 'regular care'|Patients who are referred to the hepatologist in participating centers during the study period without using the care path (e.g. because of altered liver function tests for instance), will be the prospective 'regular care' arm
89608593|NCT04142931|Active Comparator|filtration of 2X PV|filtration of 2X PV through the ImmunicomAIAC
89601443|NCT06017700|Experimental|IPT-G|Participants in the intervention arm will receive group interpersonal therapy in schools facilitated by trained laypersons. Groups are gender specific and comprise 6-8 adolescents. There are ten group sessions (approximately 90 min each, delivered weekly): in the first session the facilitator will focus on encouraging participants to review and share their interpersonal problems and instilling hope for recovery. In the middle sessions (2-9) participants will learn and practice interpersonal skills and offer and receive support from group members to resolve their problems. In the last session, they will review and celebrate progress and make plans to tackle future problems.
89601444|NCT06017700|Active Comparator|Enhanced Usual Care|Participants in the control arm will receive enhanced usual care. In intervention and control arms we will train health workers in health posts and primary care centres using the WHO mental health GAP Action training package. Participants in the control clusters will receive a handout with information about the location of these trained health workers and how they can access treatment. Participants in the control cluster reporting a current suicide plan or a suicide attempt in the past three months at baseline or in subsequent surveys will be assessed by a psychosocial counsellor employed through the project and offered one to one counselling as needed.
89601445|NCT06017674|Experimental|Group 1|Intra-articular Pulsed Radiofrequency and Steroid Injection
89601446|NCT06017674|Experimental|Group 2|Only Intra-articular Steroid Injection
89601447|NCT06017661|Experimental|Nutridrink Skin Repair with a mixture of plant extracts rich in polyphenolic compounds|Group of 15 patients undergoing surgical resection of tumour
89601448|NCT06017661|Active Comparator|Nutridrink Skin Repair|Group of 15 patients undergoing surgical resection of tumour
89601449|NCT06017648|Experimental|Experimental: Group 1 - Non Invasive Ultrasound (FUBA5200)|Treatment with the Focused Ultrasound Fat Reduction device (FUBA5200) 4 times in total, once every two weeks
89601450|NCT06017648|Active Comparator|Active comparator: Group 2 - Non Invasive Ultrasound (Contour I V3)|Treatment with the focused ultrasound fat reduction device (Contour I V3) 4 times in total, once every two weeks
89601451|NCT06017635||Case|1. Age 1-18 years old, male or female. 2. Diagnosed with cerebral contusion/cerebral hemorrhage/intracranial tumor postoperative / intracranial infection/septic encephalopathy/metabolic encephalopathy. 3. The research purpose, significance, risks, benefits, and informed consent of patients and their families to the study.
89601452|NCT06017635||Contral|1. Age 1-18 years old, male or female. 2. Non-cranial organic injury diseases. 3. Physical condition allows them to participate in the study. 4. The research purpose, significance, risks, benefits, and informed consent of patients and their families to the study.
89601453|NCT06017609|Experimental|JTT-861 Dose 1|JTT-861 Capsules Dose 1 orally once daily for 12 weeks
89601454|NCT06017609|Experimental|JTT-861 Dose 2|JTT-861 Capsules Dose 2 orally once daily for 12 weeks
89601455|NCT06017609|Experimental|Placebo|Placebo Capsules orally once daily for 12 weeks
89601456|NCT06017596|Experimental|PEEK group|Patients received PEEK framework prosthesis
89601457|NCT06017492|No Intervention|Hospital Patient Education Method|"Control Group:~Implementation will be carried out in 2 phases; Phase 1(intervention): participants will receive hospital-based patient education method(printouts, verbal instruction). This intervention will be carried out in a 2 weeks period; starting 2 weeks before day surgery and ending after day surgery has been carried out.~Phase 2 (post test): In this part, participants will be asked to answer questions in the in the descriptive data, the Quality of Discharge Teaching Scale (QDTS) and Patient Satisfaction with Nursing Care Quality Questionnaire (PSNCQQ). The questionnaire will be printed and distributed to participants after Day Surgery. The questionnaire will also be in Google form format and sent to emails of participants who are not physically present at the clinic."
89601458|NCT06017492|Experimental|Audio-Visual Patient Education Method|"Implementation will be carried out in 2 phases; Phase 1(intervention): participants will recieve video assisted teaching as patient education method. Series of short videos will be played for the participants to watch and also sent to their phones through Whatsapp application or email. This intervention will be carried out in a 2 weeks period; starting 2 weeks before day Surgery and ending after day Surgery has been carried out.~Phase 2(post test): In this part, participants will be asked to answer questions in the in the descriptive data, the Quality of Discharge Teaching Scale (QDTS) and Patient Satisfaction with Nursing Care Quality Questionnaire (PSNCQQ). The questionnaire will be printed and distributed to participants after Day Surgery. The questionnaire will also be in Google form format and sent to emails of participants who are not physically present at the clinic."
89601459|NCT06017466|Experimental|Chronic Vertigo|Chronic vertigo patients can be divided into three groups. The first pathway is episodic vertigo (caused by e.g. migraine, Ménière's disease, benign paroxysmal positional vertigo (BPPV)) progressively leading to chronic dizziness. The second pathway is initiated by a single attack of vertigo (e.g. neuritis vestibularis) with some initial recovery but later on residual symptoms. The third pathway is the presence of chronic, slowly progressive, continuous, or unchanging symptoms (e.g. bilateral vestibular failure, CNS disorders). All patient with chronic vertigo (see above) will included.
89601460|NCT06017349|Experimental|Non-invasive glucose meter|The noninvasive glucose meter was entrained on the finger, Glucose concentration levels were measured by measuring physiological parameters related to metabolic heat and local oxygen supply.
89601461|NCT06017349|Active Comparator|Accu-Chek Guide blood glucose meter|Being used for quantitative determination of blood glucose concentration in fresh capillary whole blood taken from fingers.
89601462|NCT06017349|Active Comparator|EKF Biosen C-Line|Using the hexosyl enzymatic method to detect plasma glucose values
89601463|NCT06017310||Replicative viruses|Presence of a replicative virus determined by viral culture
89601464|NCT06017310||Unreplicative viruses|Absence of a replicative virus determined by viral culture
89601465|NCT06017271||PE group|The CTPA diagnosis suggest pulmonary embolism
89601466|NCT06017271||control group|The CTPA diagnosis did not suggest pulmonary embolism
89601467|NCT06017232|Experimental|Intervention group|Group of participants receiving the hybrid telerehabilitation intervention
89601468|NCT06017167|Active Comparator|Dexmedetomidine Group|will receive ondansetron 4mg + dexmedetomidine 0.5 ug/kg + normal saline to complete 10 ml. volume IV infusion over 10 minutes.
89601469|NCT06017167|Active Comparator|Dexamethasone Group|will receive Ondansetron 4mg + dexamethasone 8mg + normal saline to complete 10 ml. volume IV infusion over 10 minutes.
89601470|NCT06017154|Experimental|Physically active females|Healthy active females between 18 and 25
89210268|NCT05712603||Retrospective arm of 'regular care'|The investigators will do an data extraction of the electronic health records of patients referred to the hepatologist in the five years prior to the study. They will make up the retrospective comparative arm of regular care
89210269|NCT00898482||Healthy individuals|
89601471|NCT06017141|Active Comparator|Arm I (sevoflurane, fentanyl citrate, propofol)|Patients receive SOC sedation with sevoflurane via inhalation and fentanyl IV on study during to SOC surgery. All patients also undergo blood sample collection throughout the study and collection of tissue sample during surgery.
89601472|NCT06017141|Experimental|Arm II (fentanyl citrate, propofol)|Patients receive SOC sedation with fentanyl IV and propofol IV on study during to SOC surgery. Patients also undergo blood sample collection throughout the study and collection of tissue sample during surgery.
89601473|NCT06017076|Placebo Comparator|warming matress group|From the end of anesthesia, warming matriss at 40 ℃ was used for insulation until the end of surgery.
89601474|NCT06017076|Experimental|oral functional drinks group|Patients drank energy drinks (Red Bull®) 250ml about 2-2.5 hours before operation.
89601475|NCT06017063|Experimental|Intervention arm|Patients and caregivers will participate in support program encompassing six video interventions with the BPI. Both participate in the intervention at the same time and together. The intervention starts within two weeks after start of the radiochemotherapy phase, see also figure 2. Patients and caregivers will receive an invitation link to the Vidyo sessions and can log in together to participate in the sessions.
89601476|NCT06017063|No Intervention|Control arm|Patients and caregivers randomized to the control group, they will not receive the 6-week intervention by the psycho-oncologist. However, they are still entitled to guideline-based psycho-oncology counseling according to the guideline and local standard if they wish. Subsequently, they will be supported regarding coping with the disease, how to improve their mood, or which strategies are available in dealing with the disease. This conversation will last 30-60 minutes.
89601477|NCT06017037|Experimental|Citalopram|Citalopram 20mg p.o. once daily for 7-9 days
89601478|NCT06017037|Placebo Comparator|Placebo|Lactose p.o. once daily for 7-9 days
89601479|NCT06017024|Experimental|Current microprocessor-controlled knee (MPK) then New MPK|Start using current MPK for 4 weeks before fitting new MPK and use it for 4 weeks
89601480|NCT06017024|Experimental|New MPK then Current MPK|Start using new MPK for 4 weeks before fitting back current MPK and use it for 4 weeks
89601481|NCT06016933|Placebo Comparator|oral hygiene instructions and SRP of all teeth plus placebo gel.|
89601482|NCT06016933|Active Comparator|oral hygiene instructions and SRP of all teeth, followed by insertion of the spirulina gel.|
89601483|NCT06016894|Active Comparator|Nanocrystalline hydroxyapatite|Nanocrystalline hydroxyapatite loaded in PRF+ coronally advanced flap
89601484|NCT06016894|Active Comparator|Nanocrystalline tricalcium phosphate (NcTCP)|Nanocrystalline tricalcium phosphate (NcTCP) loaded in PRF+ coronally advanced flap
89601485|NCT06016868||Interventional|
89601486|NCT06016803|Experimental|Subjects having undergone a Cryotherapy for benign cutaneous lesions, warts, or hyperpigmentation|Group applying the tested medical device
89601487|NCT06016803|Experimental|Subjects having undergone a Laser or IPL procedure for dermatological or aesthetical indications|Group applying the tested medical device
89601488|NCT06016803|Experimental|Subjects having undergone a skin lesion excision for which stitches were removed|Group applying the tested medical device
89601489|NCT06016751||cranial damage|Our study was a prospective observational study which included only a group of patients who were diagnosed with acute craniocerebral injury.
89601490|NCT06016699||Chemoradiation with protons|HNSCC patients treated with standard-of-care chemoradiation with protons.
89601491|NCT06016699||Chemoradiation with photons|HNSCC patients treated with standard-of-care chemoradiation with photons.
89601492|NCT06016699||Radiation with protons|HNSCC patients treated with standard-of-care radiation with protons.
89601493|NCT06016699||Radiation with photons|HNSCC patients treated with standard-of-care radiation with photons.
89601494|NCT06016660|Experimental|Resistance exercise|Resistance exercise
89601495|NCT06016660|Experimental|Neuromuscular electrical stimulation|Neuromuscular electrical stimulation
89601496|NCT06016660|Experimental|Transcutaneous electrical stimulation|Transcutaneous electrical stimulation
89601497|NCT06016660|No Intervention|Control|No intervention
89601498|NCT06015581|Experimental|Implementation Package|Continuous Quality Improvement (CQI)
89601499|NCT06015581|Other|Observation|Usual Care
89601500|NCT06015581|No Intervention|EPIS Qualitative|5 providers of 42 sites will participate in Exploration, Preparation, Implementation, Sustainment (EPIS) qualitative interviews (N=210)
89601501|NCT06014918|Experimental|Patients using a new application|Patients will enter pain intensity and opioid analgesic side effects using a new application named 'Smart APS', developed for acute pain services, and later assess for adherence and satisfaction with the application use.
89601502|NCT06014372|Experimental|Envafolimab Group|Patients diagnosed with colon cancer, with T stage determined as 3-4 based on enhanced MR imaging, or with any T stage accompanied by imaging findings suggestive of lymph node metastasis, and excluding patients with distant metastasis, who are confirmed to have microsatellite instability-high (MSI-H)/deficient mismatch repair (dMMR) colon cancer, will be enrolled in Group A
89601503|NCT06014372|Active Comparator|Envafolimab+CAPEOX Group|Patients diagnosed with colon adenocarcinoma, with T stage determined as 3-4 based on enhanced MR imaging, or with any T stage accompanied by imaging findings suggestive of lymph node metastasis, and excluding patients with distant metastasis, who are confirmed to have microsatellite stable (MSS)/proficient mismatch repair (pMMR) colon cancer, will be enrolled in Group B.
89608594|NCT04142931|Active Comparator|filtration of 2X PV combined with Nivolumab 240mg|filtration of 2X PV through the Immunicom AIAC, and nivolumab 240 mg given every 14 days for 4 times. Nivolumab will be initiated in C2.
89601504|NCT06013254|Experimental|Intervention group|4 ml of freshly squeezed lemon juice with a pH of 2.8 at room temperature was administered under the supervision of the physician before breakfast, lunch, and dinner for patients with ischemic stroke. For patients with severe swallowing disorders according to the GUSS, lemon juice was administered using a syringe, drop by drop, at a volume of 4 ml over approximately 15-20 minutes, as tolerated by the patient, under the supervision of the physician. Patients with severe swallowing disorders were unable to swallow and consequently drooled the lemon juice out of their mouths. This procedure was continued for seven days.
89601505|NCT06013254|No Intervention|Control group|4 ml of room temperature water was administered under the supervision of the physician before breakfast, lunch, and dinner. For patients with severe swallowing disorders according to the GUSS, water was administered using a syringe, drop by drop, at a volume of 4 ml over approximately 15-20 minutes, as tolerated by the patient, under the supervision of the physician. Patients with severe swallowing disorders were unable to swallow and consequently drooled the water out of their mouths. This procedure was continued for seven days.
89601506|NCT06012227|Experimental|"kent'erbas pecorino from extensive farming with crossover Arm 1"|"This study was a 4-week, randomized, controlled, crossover clinical trial. Arm 1: Volunteers will be randomize to be allocated to eat 350g/week of kent'erbas pecorino from extensive farming with a crossover with arm 2 after 6 weeks of washout."
89601507|NCT06012227|Active Comparator|"industrial pecorino from intensive farming with crossover Arm 2"|"This study was a 4-week, randomized, controlled, crossover clinical trial. Arm 2 : Volunteers will be randomize to be allocated to eat 350g/week of industrial pecorino from intensive farming for 4 weeks in total, with a crossover with arm 1 after 6 weeks of washout."
88980463|NCT05826964|Experimental|Step 2 Arm 2: Early Switch in Therapy|"Participants in Step 2 Arm 2 undergo an early switch in standard of care therapy received in Step 1:~From AI+CDK4/6i in Step 1 to one of the following alternate endocrine therapies (ET) or chemotherapy:~SERD+CDK4/6i~mTOR Inhibitor + AI~mTOR Inhibitor+SERD~mTOR inhibitor + Selective estrogen receptor modulator~PI3K inhibitor + SERD~oral SERD~Chemotherapy~From SERD+CDK4/6i in Step 1 to one of the following alternate ET or chemotherapy:~mTOR Inhibitor + AI~mTOR Inhibitor+SERD~mTOR inhibitor + Selective estrogen receptor modulator~PI3K inhibitor + AI~PI3K inhibitor + SERD~oral SERD~Chemotherapy~Participants will receive this therapy for approximately 14 months."
88980464|NCT05826964|Experimental|Step 3: Optional Treatment for Patients in Arm 1|Optional for participants who were randomized to Step 2 Arm 1 and experience clinical progression. Participants may change from their AI+CDK4/6i to SERD+CDK4/6i, or from SERD+CDK4/6i treatment to alternative endocrine therapy or chemotherapy. Therapy options for Step 3 are the same as listed for participants randomized to Step 2 Arm 2 and is administered standard of care. For those patients who decline to crossover into Step 3, further treatment and disease management will occur at their treating physician's discretion.
88980465|NCT05826574|Experimental|Part 1: Period 1: Brensocatib|Period 1: Participants will receive a single oral dose of brensocatib on Day 1 in Part 1 of the study.
88980466|NCT05826574|Experimental|Part 1: Period 2: Brensocatib + Rifampin|Period 2: Participants will receive rifampin 600 mg once daily (QD), orally, on Days 8 to 23 along with a single oral dose of brensocatib prior to the rifampin administration on Day 17 in Part 1 of the study.
88980467|NCT05826574|Experimental|Part 2: Period 1: Brensocatib|Period 1: Participants will receive a single oral dose of brensocatib on Day 1 in Part 2 of the study.
88980468|NCT05826574|Experimental|Part 2: Period 2: Brensocatib + Esomeprazole|Period 2: Participants will receive esomeprazole 40 mg QD, orally, on Days 8 to 12 along with a single oral dose of brensocatib prior to the esomeprazole administration on Day 12 in Part 2 of the study.
89601508|NCT06011330||study group|fruquintinib combined with anti-PD-1 antibodies
89601509|NCT06011213|Experimental|Early-warning interventions|The elderly in the intervention group will receive warning messages through WeChat mini programs and monitor daily exposure temperature, electrocardiogram (ECG), and blood pressure indicators
88980469|NCT05820932||Participants with prostate cancer, ADT (ADT Cohort)|This group is comprised of adult men with hormone-sensitive prostate cancer who are starting androgen deprivation therapy as part of standard of care prostate cancer (not as part of this protocol).
88980470|NCT05820932||Participants in remission, No ADT (Prostate cancer Control (PC) Cohort))|This group is comprised of adult men who are in remission from prostate cancer who have never received ADT.
88980471|NCT05820932||Partners of Participants|Study partner participants will also be recruited
88980472|NCT05818410|Experimental|New prosthesis|20 participants will be fitted with the Lunaris foot and follow the protocol
88980473|NCT05818410|Active Comparator|Standard prosthesis|20 participants will be fitted with the SACH foot and follow the protocol
88980474|NCT05818410|Other|Control group of able-bodied individuals|20 able-bodied individuals will be recruited to enable comparison with both groups of participants with lower limb amputation
88980475|NCT05814887|Experimental|ReLink|Medical device to be tested
88980476|NCT05814887|No Intervention|Control|Control, no medical device
88980477|NCT05757115|Experimental|Intervention Group|It is the group to which individualized training will be applied to develop play skills.
89210270|NCT00898482||At risk individuals|
89210271|NCT00898482||Cancer patients|
89210272|NCT03667443|Active Comparator|Myo-inositol plus folic|
89210273|NCT03667443|Active Comparator|Myo-inositol + folic a. + α-lactalbumin|
89210274|NCT00902694|Experimental|ACHIEVE Intervention|Group and individual weight counseling and group physical activity classes for 18 months.
89210275|NCT00902694|Other|Control|Control arm receives group health classes quarterly with topics not related to weight
89210276|NCT03646071|Experimental|Dose Escalation Phase|The Dose-Escalation Phase will employ a standard 3+3 algorithm to investigate ascending dose cohorts of RX108.
89210277|NCT03646071|Experimental|Dose Expansion Phase|In the Expansion Phase, subjects will receive RX108 at the maximum tolerated dose.
89210278|NCT00902772|Placebo Comparator|A|Placebo
89210279|NCT00902772|Active Comparator|B|Lorazepam
89210280|NCT00902772|Active Comparator|C|Lorazepam
89210281|NCT00902772|Active Comparator|D|Lorazepam
89210282|NCT00902772|Experimental|E|AZD7325
89210283|NCT00902772|Experimental|F|AZD7325
89601510|NCT06011213|Other|Health monitoring|The exposure temperature, electrocardiography (ECG), and blood pressure indicators will be monitored every day during the study period in the monitoring group
89601511|NCT06011213|No Intervention|Blank control|The blank control group will only monitor the exposure temperature every day.
89601512|NCT06011018|Experimental|Mirror therapy|
89601513|NCT06011018|Experimental|Mirror Therapy + Electrical Stimulation|
89601514|NCT06011018|Experimental|Mirror Therapy + Binaural Beat|
89601515|NCT06010589|Experimental|Intervention: DWJ1558|
89601516|NCT06010589|Experimental|Intervention: DWC202310 and DWC202311|
89601517|NCT06007391|Experimental|nicotinamide|
89601518|NCT06006403|Experimental|Acute Myeloid Leukemia|Infusion of CD123-targeted CAR-NK cells by dose of 1-10x10^6 cells/kg
89601519|NCT06006403|Experimental|Blastic Plasmacytoid Dendritic Cell Neoplasm|Infusion of CD123-targeted CAR-NK cells by dose of 1-10x10^6 cells/kg
89601520|NCT06002945||Neurological Outpatients|Participants in this group will be recruited from the outpatient clinical population at MGNet participating sites. Treating physicians will make the initial determination of patients' potential eligibility to participate in the study.
89601521|NCT05997563|Active Comparator|Micronized progesterone|
89601522|NCT05997563|No Intervention|Control|
89601523|NCT05990452|Experimental|9MW2921|
89601524|NCT05980910||Major abdominal surgery|Patients undergoing elective major abdominal surgery. The definition of major surgery is the estimated surgery time >= 2 hours.
89601525|NCT05980572|Experimental|App intervention group|Patients will receive instructions on performing the seven sets of frozen shoulder exercises mentioned earlier. The APP intervention group will be guided through the exercises using the mobile app. Each set of exercises will involve 10 repetitions, and it is recommended to perform four sessions per day.
89601526|NCT05980572|Active Comparator|Conventional group|patients will receive instructions on performing the seven sets of frozen shoulder exercises mentioned earlier. The conventional group will be provided with a printed pamphlet illustrating the exercises. Each set of exercises will involve 10 repetitions, and it is recommended to perform four sessions per day.
89601527|NCT05980182|Experimental|Tailored Screen to Save (S2S) content|Content to be delivered using a combination of short video and text-based information optimized for delivery via Quick Response (QR) codes for smartphones.
89601528|NCT05978570|Experimental|A personally tailored exercise|A personally tailored exercise program will be offered to the participants after the Physical Therapy assessment, before the surgery.
89601529|NCT05975515|Active Comparator|immediate implant placement with bone grafts till crest|Group1 (control group): immediate implant placement with bone grafts till crest and customized healing abutment.
89601530|NCT05975515|Experimental|immediate implant placement with customized healing abutment|Group 2 (intervention 1 group): immediate implant placement with customized healing abutment
89601531|NCT05975515|Experimental|immediate implant placement with CTG and customized healing abutment.|Group 3 (intervention 2 group): immediate implant placement with CTG and customized healing abutment.
89601532|NCT05967585|Experimental|Phase I and Phase II|Phase 2: Implementation processes for assessing vaping behaviors and referring patients to a vaping cessation intervention (This is Quitting-TIQ) developed in Phase 1 will be tested within oncology survivorship clinics. Participants who opt to enroll in TIQ will also be asked to answer acceptability and applicability questions about their experience with the program.
89601533|NCT05964673|No Intervention|education program group|"this group will receive patient education program for four weeks.~limiting screen time~blinking awareness training~keeping the home environment cool and moist~using artificial tears (Hylo®gel) twice daily~contact lens use can preferably be limited,~adding omega-3 poly unsaturated fatty acids in the diet or as dietary supplements."
89601534|NCT05964673|Experimental|bioptron light therapy group|Patients will be sitting in a comfortable chair, with their eyes closed, with cleaned eyelids, and occasionally blinking. Bioptron lamp will be lined at an angle of 90°, at a distance from 5 cm to 10 cm, exposure time will be 5 min. Energy is very low, 1 - 2.4 J/cm without thermal effects, energy density is 40mW. Bioptron light is polychrome, wave frequency is from 400 nm (including blue, visible radiation) up to 2000 nm (representing infrared waves)
89601535|NCT05964153|Experimental|Circulating free DNA analysis|"Correlate the results of the tissue samples with those of the blood samples, the concentration of ctDNA found, and the magnetic resonance images prior to the biopsies.~Compare other variables such as time, money, and the impact on the patient (recovery time after biopsies, pain, sequelae,...) between the liquid biopsy procedure and the conventional tissue biopsy procedure."
89601536|NCT05961046||1|Patients with a history of successful myopic LASIK/PRK and underwent bilateral uncomplicated cataract surgery with non-toric Alcon Vivity IOL
89601537|NCT05954988|Experimental|2.5 mg LTI-03 BID|2.5 mg LTI-03 BID x 14 days
89601538|NCT05954988|Experimental|5 mg LTI-03 BID|5 mg LTI-03 BID x 14 days
89601539|NCT05954988|Placebo Comparator|Placebo|Matching placebo BID x 14 days
89601540|NCT05936645|Experimental|Tourniquet Group|A temporary sub-placental uterine tourniquet will be temporarily applied before fetal extraction.
89601541|NCT05936645|Experimental|Non-Tourniquet Group|No tourniquet will be used in this arm.
89601542|NCT05936606|Active Comparator|Uniform Therapy|Patients will continue clopidogrel monotherapy for 24 months from randomization, irrespective of their PRU measurement.
89601543|NCT05936606|Experimental|Tailored Therapy|Patients in the intervention arm will receive tailored anti-platelet therapy according to PRU and bleeding risk
89601544|NCT05936086|Experimental|CTX(Cytoxan) group|
89210284|NCT00902772|Experimental|G|AZD7325
89601545|NCT05936086|Active Comparator|Normal treatment group|
89601546|NCT05932511|Experimental|30% Ascorbic Acid in DMSO|Topical application twice daily of 300ul 30% (w/v) solution of ascorbic acid in DMSO
89601547|NCT05927792|Experimental|Intervention Group|participants in intervention group will receive accelerated continuous theta-burst stimulation (a-cTBS) on the left primary motor cortex (M1) for 5 consecutive days.
89608595|NCT00724750|Experimental|G-SUC|Gauze suction (G-SUC) Negative Pressure Wound Therapy, continuous wall suction at 75 to 80 mm Hg was applied and dressings were changed daily.
89210285|NCT03637647||Upper gastrointestinal cancer|Upper gastrointestinal cancers including oesophagus and stomach
89601548|NCT05927792|Sham Comparator|Sham Group|The sham group will be stimulated with a pseudo-stimulation coil, which emitted sounds with the same intensity, rhythm and vibratory sensation as the real stimulation, and the intervention target, duration and frequency are the same as the real intervention group.
89601549|NCT05925101|Experimental|Clinical (Human) Study on Effects of Reinforcement-Rate Drop|Based on the TWML, we hypothesize that a large drop in reinforcement rate at the start of treatment with extinction alone or with FCT will increase the probability of an extinction burst. Preventing such drops will lessen the probability of an extinction burst. We will test the effects of eliminating reinforcement in the extinction-only condition and the effects of substantially decreasing the rate of reinforcement in the rate-drop condition. We will compare these two suboptimal treatments with one in which we ensure that the rate of reinforcement remains equal to baseline, called the rate-hold condition, which the TWML predicts will prevent an extinction burst.We will equate reinforcement magnitude (i.e., each reinforcer delivery will be 20 s) and quality (i.e., the functional reinforcer identified during the functional analysis) across the baseline and the rate-drop and rate-hold conditions (no reinforcement will be delivered in the extinction-only condition).
89601550|NCT05925101|Experimental|Clinical (Human) Study on Effects of Reinforcement-Magnitude Drop|Based on the TWML, we hypothesize that a large drop in reinforcement magnitude at the start of treatment will increase the probability of an extinction burst. Preventing drops will lessen the probability of an extinction burst. We will test the effects of eliminating reinforcement in the extinction-only condition and the effects of substantially decreasing the magnitude of reinforcement in the magnitude-drop condition. We will compare these two suboptimal treatments with one in which we ensure that the magnitude of reinforcement remains equal to baseline, called the magnitude-hold condition, which the TWML predicts will prevent an extinction burst. We will equate reinforcement rate (i.e., independent, VI 1.5-s schedules) and quality (i.e., the functional reinforcer identified during the functional analysis) across baseline and both FCT conditions (no reinforcement will be delivered in the extinction-only condition).
89601551|NCT05925101|Experimental|Clinical (Human) Study on Effects of Reinforcement-Quality Drop|Note: We will conduct Ex 3 with participants who display destructive behavior reinforced by access to tangible items so that we can vary reinforcement quality using the results of a paired-stimulus preference assessment. Based on the TWML, we hypothesize that a large drop in reinforcement quality at the start of FCT will increase the probability of an extinction burst. Preventing such drops will lessen the probability of an extinction burst. Therefore, we will program a large drop in the quality of reinforcement in our quality-drop condition and ensure that the quality of reinforcement remains equal to the quality of reinforcement in baseline in the quality-hold condition. In Experiment 3, we will equate reinforcement rate (i.e., independent, VI 1.5-s schedules) and magnitude (i.e., each reinforcer delivery will be 20 s) across baseline and both FCT conditions.
89601552|NCT05925101|Experimental|Clinical (Human) Study on Counteracting Reinforcement-Rate Drop with Quality Increase|Based on the TWML, we hypothesize that a large drop in reinforcement rate at the start of FCT will increase the probability of an extinction burst but that simultaneously increasing reinforcement quality will counteract the negative effects of a drop in reinforcement rate. We will program a large drop in the rate of reinforcement in the rate-drop-only condition, and in the rate-drop/quality-increase condition we will program the same drop in reinforcement rate but also program a large increase in reinforcement quality.
89601553|NCT05924919|Experimental|Experimental Arm: Whole-body Passive Heat Therapy (HT)|Heat therapy will be administered using an infrared sauna. The intervention duration will last 25 minutes at a temperature of 60°C.
89601554|NCT05924919|Active Comparator|Control Arm: Thermoneutral Control (CON)|The control arm will consist of 25 minutes in a thermoneutral environment to serve as a comparator condition. Participants will be exposed to the exact conditions as the intervention arm, however, the temperature of exposure will be 22°C.
89601555|NCT05922514||Group 1 Baseline and 3 month Questionnaires|"170 participants with BERN imaging score with completion of baseline and 3 month questionnaires being : headache impact test (HIT-6), migraine disability assessment test (MIDAS), pain numerical rating scale (NRS), and spontaneous intracranial hypotension symptom severity scale (SIHSS).~Each participant will keep a daily headache diary for 90 days."
89601556|NCT05922514||Group 2 Baseline, 7 days and 3 month Questionnaires|"30 participants with BERN imaging score with completion of baseline and 3 month questionnaires being : headache impact test (HIT-6), migraine disability assessment test (MIDAS), pain numerical rating scale (NRS), and spontaneous intracranial hypotension symptom severity scale (SIHSS).~Each participant will keep a daily headache diary for 90 days."
89601557|NCT05911204||Mothers|One single group of mothers exposed to intense and sustained noises during pregnancy
89601558|NCT05888974||patients with shock (MAP < 65 mmHg) requiring vascular filling|The study population consisted of patients with shock (MAP < 65 mmHg) requiring vascular filling indicated by the referring physician physician, recruited consecutively in the emergency department of the CHU of Nîmes and Montpellier.
89608596|NCT00724750|Active Comparator|Vacuum Assisted Closure|Vacuum Assisted Closure Device (VAC) Negative Pressure Wound Therapy, continuous suction at 75 to 125 mm Hg and the dressing was changed every 48 hours.
88980480|NCT05751109||ipack+adductor canal block|The 40 patients received ACB + IPACK (Group 1, n = 40),. All patients were evaluated with VAS score for pain recorded at 1h, 8 h, postoperative day (POD) 1 and 3. month after the surgery. The secondary outcome measures assessed were movement time and discharge time.
88980481|NCT05751109||epidural analgesia|The 40 patients received combine spinal epidural (Group 2, n = 40),. All patients were evaluated with VAS score for pain recorded at 1h, 8 h, postoperative day (POD) 1 and 3. month after the surgery. The secondary outcome measures assessed were movement time and discharge time.
88980482|NCT05741866|Active Comparator|Control|Bordered Polyurethane Dressing
88980483|NCT05741866|Experimental|Intervention|CHG Bordered Polyurethane Dressing
88980484|NCT05735873|Experimental|Low-energy diet arm|Subjects who receive low-energy premade meals for three meals each day for 12 weeks.
88980485|NCT05734053||Nilotinib|patients prescribed with nilotinib in routine medical practice
89210286|NCT00894660|Experimental|Amodiaquine (Pfizer)|
89210287|NCT00894660|Active Comparator|Amodiaquine tablets (Arsuamoon-Guilin China)|
89210288|NCT02539212|Active Comparator|microwave ablation|microwave ablation
89601559|NCT05882903|Experimental|Betamethasone Dipropionate Nasal Cream 0.0644% Treatment|Betamethasone Dipropionate Nasal Cream 0.0644% is applied topically to the inflamed tissue of the sinus using a pre-filled syringe and applicator under the guidance of an endoscope. Up to 5g on each side of the sinus (10g in total).
89601560|NCT05875116|Experimental|Group I: virtual reality activities|The patient will practice the corresponding activities of the software indicated in the virtual reality equipment.
89601561|NCT05875116|Experimental|Group II: Modified Constraint-Induced Movement Therapy|"Patients will have the healthy upper limb fixed to the thorax with a sling and a horizontal shoulder immobilizer; The participants will practice physical and occupational therapy activities with the paretic upper limb."
89601562|NCT05875116|Active Comparator|Group III: Usual Physical and Occupational Therapy|The participants will practice physical and occupational therapy activities that are usually provided in the Medical Unit, without any restrictions on the upper extremities.
89601563|NCT05872737|Experimental|Facilitator-guided Acceptance and Commitment Bibliotherapy (FAB)|A 12-week facilitator-guided Acceptance and Commitment Bibliotherapy, which includes general parenting advice and is delivered via a website
89601564|NCT05872737|Placebo Comparator|Control Group|Routine family support services and four video-conferencing sessions over the course of 12 weeks
89601565|NCT05872451|Experimental|Current intensity|"An I-gel mask is inserted for the mechanical ventilator of the patient who is sedated with propofol.~For the ultrasound-guided obturator nerve (ON) block, and needle tip gradually advanced to the anterior branch of the ON. The current intensity for the stimulation of ON starts at 1.0 mA (using the sequential electrical nerve stimulation mode), and the needle is advanced gradually to the location where the contraction of the adductor longus muscle (ALM) occurs at 0.3-0.5 mA.~After fixing the needle in that position, measure the current intensity.~Then, rocuronium (0.6 mg/kg) is administered under quantitative neuromuscular-blockade monitoring.~When the train-of-four count becomes 0, the current intensity is increased until the contraction of the ALM occurs.~The current intensity is measured when the contraction of the ALM occurs."
89601566|NCT05868278|No Intervention|Control|It is the group in which the traditional learning method will be used.
89601567|NCT05868278|Experimental|Experimental|It is the group in which the interactive learning method will be used.
89601568|NCT05862987|Experimental|Hydrogen rich water|Hydrogen rich water supplied in 420 ml packages. Two days before testing - 2 packages (morning and evening), one day before testing - 3 packages (morning, afternoon, and evening), testing day - 4 packages (2 h before the run, 1 h before the run, immediately after the run, and 1 h after the run), 9 packages in total.
89601569|NCT05862987|Placebo Comparator|Placebo|Tap water supplied in 420 ml packages. Two days before testing - 2 packages (morning and evening), one day before testing - 3 packages (morning, afternoon, and evening), testing day - 4 packages (2 h before the run, 1 h before the run, immediately after the run, and 1 h after the run), 9 packages in total.
89601570|NCT05862623|Experimental|AER-01|Specified dose on specified days
88980486|NCT05733351|Experimental|Cohort A (Vudalimab, Abiraterone)|Patients receive vudalimab IV on days 1 and 15 plus abiraterone PO QD of 4-week cycles on study. Patients also undergo PSMA PET and FDG PET scans during screening. Patients also undergo CT and/or MRI scans, bone scans, and blood sample collection throughout the study.
88980487|NCT05733351|Experimental|Cohort B (Vudalimab, Enzalutamide)|Patients receive vudalimab IV on days 1 and 15 plus enzalutamide PO QD of 4-week cycles on study. Patients also undergo PSMA PET and FDG PET scans during screening. Patients also undergo CT and/or MRI scans, bone scans, and blood sample collection throughout the study.
88980488|NCT05733351|Experimental|Cohort C (Vudalimab, Docetaxel, Abiraterone)|Patients receive vudalimab IV on days 1 and 15, docetaxel IV on days 1 and 22 plus abiraterone PO QD of 6-week cycles on study. Patients also undergo PSMA PET and FDG PET scans during screening. Patients also undergo CT and/or MRI scans, bone scans, and blood sample collection throughout the study.
88980489|NCT05729425||Observational (microvessel ultrasound imaging)|Patients undergo microvessel ultrasound imaging on study.
88980490|NCT05727306||People with Alopecia Areata|Children and adults aged 12+ with new onset Alopecia Areata registered with a contributing General practitioner (GP) practice during the study period.
88980491|NCT05727306||People without Alopecia Areata|Children and adults aged 12+ without Alopecia Areata registered with a contributing GP practice during the study period.
88980492|NCT05725421|Experimental|cT1a Radical Nephrectomy + Donor Kidney Transplantation|Radical nephrectomy will be used to remove a cT1a renal mass in an altruistic kidney donor. The kidney obtained from the radical nephrectomy participant with the cT1a mass removed will be transplanted to the recipient using an allograft.
88980493|NCT05722340|Experimental|NIVATS|Lung biopsy is performed using non-intubated video-assisted thoracic surgery (NIVATS).
88980494|NCT05722340|Active Comparator|IGAVATS|Lung biopsy is performed using Intubated general anaesthesia video-assisted thoracic surgery (IGAVATS).
88980495|NCT05721027|Experimental|Ibuprofen + dexamethasone + educational intervention|Ibuprofen 400 mg PO every 8 hours as needed for 7 days + dexamethasone 16 mg PO for day 1 and day 2. Research personnel will provide each participant with a 15-minute educational intervention.
88980496|NCT05721027|Placebo Comparator|Ibuprofen + placebo + educational intervention|Ibuprofen 400 mg PO every 8 hours as needed for 7 days + placebo PO for day 1 and day 2. Research personnel will provide each participant with a 15-minute educational intervention.
88980497|NCT05714865|Experimental|LISA Arm|Eligible subjects who have respiratory distress syndrome (Anderson Silverman Score >4) managed on continuous positive airway pressure (CPAP) will receive surfactant via a thin catheter while on CPAP.
88980498|NCT05714449|Experimental|Patching group|part-time patching following PEDIG guidelines.
88980499|NCT05714449|Experimental|foveation therapy|After-image foveation therapy training is 10 mins; MIT training is 5 minutes.
88980500|NCT05713058|Experimental|eTRC diet|
88980501|NCT05713058|Active Comparator|Control diet|
88980502|NCT05706753|Experimental|Milvexian + Midazolam + Ethinylestradiol/Drospirenone|Participants will receive midazolam on Day 1 and Day 19; ethinylestradiol and drospirenone on Day 2 and Day 20; and milvexian from Day 7 to Day 24.
89210289|NCT02539212|Active Comparator|radiofrequency ablation|radiofrequency ablation
89210290|NCT00721409|Experimental|Arm A|letrozole + PD 0332991
89210291|NCT00721409|Active Comparator|Arm B|letrozole
89601571|NCT05862623|Placebo Comparator|Placebo|Specified dose on specified days
89601572|NCT05861921|Experimental|Single-retainer Lithium Di-silicate Resin Bonded Fixed Partial Denture|Intervention will be the delivery of Lithium Di-silicate resin bonded fixed partial denture as final prosthetic restorative material for replacing missing upper anterior tooth.
89601573|NCT05861921|Active Comparator|Single-retainer Zirconia Resin Bonded Fixed Partial Denture|Comparator will be the delivery of Zirconia resin bonded fixed partial denture as final prosthetic restorative material for replacing missing upper anterior tooth.
89601574|NCT05854953|Experimental|Hawley retainers in dry storage condition|Acrylic retainers to be stored in a dry retainer box the entire time when not in use.
89601575|NCT05854953|Experimental|Hawley retainers in wet storage condition|Acrylic retainers to be stored in a glass of clean tap water the entire time when not in use.
89601576|NCT05854953|Experimental|Vacuum-formed retainers in dry storage condition|Thermoplastic retainers to be stored in a dry retainer box the entire time when not in use.
89601577|NCT05854953|Experimental|Vacuum-formed retainers in wet storage condition|Thermoplastic retainers to be stored in a glass of clean tap water the entire time when not in use.
89601578|NCT05854953|Active Comparator|Baseline characteristics|Newly constructed Hawley retainers and VFRs will be labeled as baseline samples.
89601579|NCT05854498|Experimental|Participants with Metastatic or Unresectable Colorectal Cancer|Male and females aged 18 years and older with histologically confirmed metastatic or unresectable (not amenable to curative therapy) colorectal cancer.
89601580|NCT05844852|Other|OCT|Device: P200TE The P200TE provides OCT imaging including retina topography and ONH (optic nerve head) scans.
89601581|NCT05841472|Experimental|Camrelizumab, Pemetrexed and Carboplatin|
89601582|NCT05831449|Experimental|CPL-01|Local infiltration of study drug
89601583|NCT05831449|Active Comparator|Ropivacaine HCl|Local infiltration of study drug
89601584|NCT05831449|Placebo Comparator|Placebo|Local infiltration of study drug
89601585|NCT05824130||B/F/TAF group|B/F/TAF
89601586|NCT05824130||other INSTI-based ART regimen|1-2 NRTI(s) plus an INSTI other than bictegravir
89601587|NCT05824130||non-INSTI-based ART regimen|2 NRTIs plus NNRTI or protease inhibitor
89601588|NCT05822011|Active Comparator|Erector spinae block|Under strict aseptic precautions, we will begin the scout scan with a high-frequency (6-12 MHz) linear US probe placed parasagitally in cephalocaudal orientation adjacent to C7 spinous process and the first rib will be identified with ultrasound. Then, we can directly count the ribs and come down to desired level of ribs or corresponding transverse process (the 8th thoracic spinous process). Once located, erector spinae and trapezius muscles will be identified overlying it. The skin will be infiltrated by 2 ml of lidocaine 1% subcutaneously and a 22- gauge, 80 mm needle (Stimuplex D, B-Braun, Germany) will be advanced in plane in the cranio-caudal direction. When the needle contacted the transverse process, 1 ml normal saline will be injected to confirm correct needle placement by visualizing the linear pattern of hydrodissection. After aspiration, 30 ml bupivacaine 0.25% will be injected.
89601589|NCT05822011|Active Comparator|Rhomboid intercostal block|While the patient in the sitting position, the 5th thoracic spinous process can be identified, a high-frequency (6-12 MHz) linear US probe will be placed in the sagittal plane medial to the medial border of the scapula and then rotated to be 1 to 2 cm medial to the medial scapular border. The plane between the rhomboid major and the intercostal muscles will be identified. 2 ml of lidocaine 1% subcutaneously and a 22- gauge, 80 mm needle (Stimuplex D, B-Braun, Germany) will be advanced in plane from a superomedial to an inferolateral direction then 15 ml of bupivacaine 0.25% will be administered (at the T5 level). Then the probe will be moved caudally and laterally to identify the tissue plane between the serratus anterior and the external intercostal muscle at the T8 level. The needle will be directed caudally and laterally beyond the inferior angle of the scapula. 15 ml of bupivacaine 0.25% will be administered.
89601590|NCT05822011|Active Comparator|Thoracic epidural analgesia|While the patient in the sitting position, the T7-T8 interspace can be identified. Then, skin infiltration with 2 ml of 1% lidocaine will be performed. Then, an 18-G Tuohy needle with a 20-G catheter (Perifix®, B.Braun, Germany) will be inserted through, and the epidural space will be located using the loss of resistance approach, then the patient will be given (5-10 mL) of bupivacaine 0.25% and rested into the supine position.
88980503|NCT05703711|No Intervention|Enhanced Usual Care|In the Enhanced Usual Care arm, all healers are invited to participate in an interactive session reviewing ways to reduce inhumane and potentially harmful treatments in practices at their camps.
88980504|NCT05703711|Experimental|M&M Intervention Package|M&M is a 8-week long combination of mHealth designed to train healers to deliver basic psychosocial interventions while preserving human rights with pharmacotherapy delivered directly to their patients via visiting nurse.
88980505|NCT05701254||Type 1 Diabetics|All participants will complete 4 visits over 6-8 weeks. Visit 1 is a screening visit which includes a physical exam, a bone mineral density scan, a blood draw and an EKG. Visit 2 consists of dispensing the Tetracycline antibiotic required for the bone biopsy. Visit 3 is the bone biopsy and includes a blood draw. Visit 4 is to remove the stitches.
88980506|NCT05701254||Non-Type 1 Diabetics|All participants will complete 4 visits over 6-8 weeks. Visit 1 is a screening visit which includes a physical exam, a bone mineral density scan, a blood draw and an EKG. Visit 2 consists of dispensing the Tetracycline antibiotic required for the bone biopsy. Visit 3 is the bone biopsy and includes a blood draw. Visit 4 is to remove the stitches.
88980507|NCT05698589|Experimental|Compassion Focused Therapy|
89601591|NCT05821725|Experimental|Group I|A gel containing Hyaluronic acid in combination with a hemostatic sponge
89601592|NCT05821725|Active Comparator|Group II|A hemostatic sponge alone
89601593|NCT05819450|Experimental|Sonography-guided hand|One hand of the participant will be treated with sonography-guided filler injection in random
89601594|NCT05819450|No Intervention|Blinded injected hand|One hand of the participant will be treated with filler injection by physician's experience without sonography-guidance in random
89601595|NCT05818046|Experimental|Single Group Assignment|intervention consiste to non-invasive arterial assessment by doppler (arterial waveform) and external oxygen probe (Transcutaneous oxygen pressure) at 3,6 and 9 weeks of supervised exercise therapy
89601596|NCT05813743|Other|Pregnant in 3rd trimester with abnormally invasive placenta|
88980508|NCT05698589|Active Comparator|Ending Self Stigma|
88980509|NCT05698589|No Intervention|Treatment As Usual|
89601597|NCT05810467||Control Arm|"Men diagnosed with low-grade PrCa undergoing Active Surveillance and are not known to have an increased genetic risk for PrCa e.g. Men without high-risk mutations or high polygenic risk score (PRS).~Men diagnosed with PrCa suitable for Active Surveillance who wish to continue follow up at The Royal Marsden Hospital (RMH) will be offered enrolment in collection and monitoring of various biological samples. These men will act as a control group, as they do not have a known higher genetic risk of PrCa. The control group will have genetic analysis carried out on provided saliva samples. Their family history will be captured. They will be genotyped using the latest technology and at a minimum have PRS testing done.~Men may be moved out of the control arm and into the high-risk arm, if identified at a higher genetic risk or as having a strong family history of PrCa for the purposes of the analysis. Any clinically significant genetic results will be discussed with the participants."
89601598|NCT05810467||High-risk Arm|"Men who have been diagnosed with low grade PrCa and are undergoing active surveillance who are at genetically higher risk of PrCa defined as:~Men of European ancestry with a family history defined as at least one first degree (or second degree if through the female line) relative with PrCa diagnosed at <70 years (diagnosis verified).~Men of Black African or Caribbean ancestry irrespective of family history~Men of any ethnicity known to carry a mutation in a high-risk gene (Appendix A).~Men with a high genetic risk (common and/or rare variants) defined as those with a RR of ≥2."
89601599|NCT05810233|Experimental|Vitamin C|Commercially available Tablet Vitamin C 1000mg per day for 7 days
89601600|NCT05810233|Placebo Comparator|Placebo|Glucose chewable table 1x per day for seven days
89601601|NCT05805891|Experimental|bortezomib|bortezomib added on previous treatment
89601602|NCT05805358|No Intervention|Conventional Imaging Group|60 participants who accepted ICI treatment will receive conventional imaging
89601603|NCT05805358|Experimental|Next Generation Imaging Group|30 participants who accepted ICI treatment will receive next generation imaging including MRF and MR Relaxometry and hyperpolarized 13C pyruvate DNP scanning.
89601604|NCT06133764|Experimental|Enucleation + Peripheral ostectomy + Carnoy's solution chemical cauterization (E+ PO+ CS)|The odontogenic keratocysts will be treated using enucleation, followed by peripheral ostectomy and then Carnoy's solution
89601605|NCT06133764|Experimental|Decompression/marsupialization (D/M)|The odontogenic keratocysts will be managed by either Decompression or marsupialization
89601606|NCT06133764|Experimental|Enucleation (E)|The odontogenic keratocysts will only be managed by Enucleation (E)
89601607|NCT06133764|Experimental|Enucleation+Carnoy's solution (E+CS)|odontogenic keratocysts will be managed by Enucleation, followed by Carnoy's solution
89601608|NCT06133764|Experimental|Enucleation+ Peripheral Ostectomy (E+PO)|The odontogenic keratocysts will be treated using Enucleation, followed by peripheral ostectomy (E+PO)
89601609|NCT06133751|Experimental|Supplemented group|"Athletes in the supplemented group (n=7) consumed capsules with highly concentrated 18% chokeberry extract. One capsule contained 200 mg. In addition to chokeberry extract, each capsule also contained chokeberry fiber, E460b magnesium salts of stearic acid (anti-caking agent), E551 silicon dioxide (anti-caking agent), hydroxypropyl methylcellulose (capsule shell) and E171 titanium dioxide (shell color).~The rowers (both supplemented and control group) took 3 capsules a day (at breakfast, lunch and dinner) for 8 weeks. The athletes sipped each capsule with a glass of water."
89601610|NCT06133751|Placebo Comparator|Placebo group|"The control group (n=8) consumed capsules that were made from chokeberry fiber.~The rowers (both supplemented and control group) took 3 capsules a day (at breakfast, lunch and dinner) for 8 weeks. The athletes sipped each capsule with a glass of water."
89601611|NCT06133738|Experimental|Intervention Group|Participants in this group will be given 8 sessions of a standardized exercise program, a link to access online educational sessions, in addition to internet based cognitive behavioural therapy sessions.
89601612|NCT06133738|Active Comparator|Control Group|Participants in this group will be given 8 sessions of a standardized exercise program and a link to access online educational sessions.
89601613|NCT06133725|Experimental|ESPB|erector spinae plane block
89601614|NCT06133725|Active Comparator|TAPB&RSB|transversus abdominis plane block combined with rectus sheath block
88980510|NCT05697497|Experimental|Immediate start group with gait cadence assessment|This group will wear an activPAL device for 10 days prior to their baseline assessment and for 10 days after their week 12 assessment. The exercise intervention consists of a 2.5 to 3.5 minute daily routine that includes 2 upper body and 2 lower body exercises.
88980511|NCT05697497|Experimental|Immediate start group without gait cadence assessment|The exercise intervention consists of a 2.5 to 3.5 minute daily routine that includes 2 upper body and 2 lower body exercises.
89601615|NCT06133686|Other|Group A|Oral Tenofovir disoproxil fumarate/emtricitabine (TDF-FTC) followed by choice of TDF-FTC or CAB-LA
88980512|NCT05697497|No Intervention|Delayed-treatment control group with gait cadence assessment|This group will wear an activPAL device for 10 days prior to their baseline assessment and for 10 days after their week 12 assessment. The exercise intervention consists of a 2.5 to 3.5 minute daily routine that includes 2 upper body and 2 lower body exercises. Participants in the this arm will not start the exercise intervention until the day after the week 12 assessment.
89601616|NCT06133686|Other|Group B|Long-acting injectable cabotegravir (CAB-LA) followed by choice of TDF-FTC or CAB-LA
89601617|NCT06133660||PPV（pars plana vitrectomy） group|
89601618|NCT06133660||Silicone oil removal group|
89601619|NCT06133634|Active Comparator|Fisetin|Fisetin will be administered in an intermittent manner with two, three-day dosing periods at a dose of 2 mg/kg/day separated by two weeks.
89601620|NCT06133634|Placebo Comparator|Placebo|Placebo capsules identical in appearance to fistin capsules will be administered in an intermittent manner with two, three-day dosing periods separated by two weeks.
89601621|NCT06133608|Experimental|Experimental|"Patients in the intervention group will be educated by watching videos on the first day after surgery, in addition to routine clinical education. On the 10th post-operative day, the patients will be called by the researcher and the Tampa Kinesiophobia Scale and Fall Activity Scale will be administered."
89601622|NCT06133608|No Intervention|Control|"The control group will receive routine clinical training. On the 10th post-operative day, the patients will be called by the researcher, and the Tampa Kinesiophobia Scale and Fall Activity Scale will be administered."
89608597|NCT04140825||Group 1|Subjects>=18 years old will measure as a minimum FOT and spirometry.
88980513|NCT05697497|No Intervention|Delayed-treatment control group without gait cadence assessment|The exercise intervention consists of a 2.5 to 3.5 minute daily routine that includes 2 upper body and 2 lower body exercises. Participants in the this arm will not start the exercise intervention until the day after the week 12 assessment.
88980514|NCT05695118|Experimental|non-contrast low-dose abdomen CT|non-contrast low-dose abdomen CT (target effective dose: < 1.5 mSv). CT based body composition analysis is performedd with commercially available automatic segmentation software (DeepCatch, Medical IP, South Korea).
89601623|NCT06133595|Experimental|Experimental: MiBridge|MiBridge: A series of five conversations over three weeks to help participants understand more about themselves and their willingness to change, and to help participants connect with the care they need and want.
89601624|NCT06133595|No Intervention|No Intervention: Waitlist|Participants are on a waitlist which means they have no active intervention, only weekly measurements with the same questionnaires as in the active arm
89601625|NCT06133569|Experimental|ReDirection|ReDirection is a self help program based on cognitive behavioral therapy methodology and consists of five modules. The program aims to help participants reduce their CSAM use by gaining a better understanding of, and skills to manage risky sexual thoughts, feelings, and behaviors.
89601626|NCT06133569|No Intervention|Waitlist|Participants are on a waitlist which means they have no active intervention, only weekly measurements with the same questionnaires as in the active arm.
89601627|NCT06133556|Active Comparator|control arm|"Busulfan/Cyclophosphamide, standard conditioning regimen as a control group. including Bu3.2mg/kg -5~-3d; Cy 80mg/kg，-2~-1d。 or alternative Bu/Cy regimen, Bu3.2mg/kg -9~-7d；Flu 30mg/m2 -6~-4d；Ara-C 2g/m2 -6~-4d；Cy 80mg/kg -3~-2d。"
89601628|NCT06133556|Experimental|MCBC group|using MCBC as conditioning regimen, Mel 60mg/ m2 -9~-8d, Cladribine 5 mg/m2 -9~-5d, Bu3.2mg/kg -5~-3d； Cy 30mg/kg -2~-1 d
89601629|NCT06133543|Experimental|Negative sentinel lymph node|Patients with negative sentinel lymph node biopsy are enrolled to active surveillance after surgery
89601630|NCT06133543|Experimental|Positive sentinel lymph node|Patients with positive lymph node biopsy undergo a template retroperitoneal lymph node dissection in the same procedure
89601631|NCT06133530|Placebo Comparator|Maltose|The placebo contains maltose powder applied orally.
89601632|NCT06133530|Experimental|Human milk oligosaccahride|The experimental group HMO powder applied orally.
89601633|NCT06133387|Experimental|Single-arm, Open-label|Subjects will undergo partial thickness resection of benign lesions in the rectum and sigmoid colon using the EndoQuest ELS System.
89601634|NCT06133361|Experimental|PRP group|PRP will be injected in the palatal mucosa of the upper anterior teeth to accelerate orthodontic tooth movement. Patients in this group will undergo en-masse retraction of their upper front teeth using the same technique as the control group.
89601635|NCT06133361|Active Comparator|Traditional retraction group|In this group, patients will undergo en-masse retraction of their upper front teeth using a frictionless method by using coil springs attached between the anterior portion of the dental arch (which is an anterior segment only) to the miniscrews placed between the upper second premolars and the upper first molars.
89601636|NCT06133335|Other|cystic fibrosis subjects|Adult patients with cystic fibrosis consulting the Resource and Competence Center for Cystic Fibrosis at the C.H.U. from Reims
89601637|NCT06133296|Active Comparator|Group A (Conventional fixed treatment)|Roth brackets (.018; Gemini Roth System, 3M Unitek, USA) were used for the fixed orthodontic attachment. Tooth surfaces were etched with 35% gel phosphoric acid for 30 seconds and then washed with water for 15 seconds. A primer was applied to the etching surface with the manufacturer's applicator. After an adhesive was applied to the bases of the brackets, the brackets were placed in their appropriate positions. Afterward, LED was irradiated for 20 seconds and 5 seconds for each surface. For leveling after bonding, .012 nickel titanium archwires (3M Unitek Monrovia, CA, USA) were tied with an elastic ligature.
89601638|NCT06133296|Active Comparator|Group B (Clear aligner treatment)|Clear aligners were ordered after the recordings were evaluated in the Clincheck program, and the final treatment plan was created. After the clear aligners came from the manufacturer (Align Technology, Santa Clara, CA), the compatibility of the guide aligner with each patient's mouth was checked for attachments. The enamel surfaces on which the attachments will be applied were etching with the same method as in Group A. After an adhesive was condensed into the attachment spaces inside the guide plate, the guide aligner was placed in the correct position in the mouth, and each attachment was applied from the buccal surface with an LED light device for 20 seconds. After the guide plate was removed, the composite residues around the attachments were cleaned, and the first treatment aligner was applied. The individuals were informed that they should use their clear aligner continuously, except during meals, and replace them after 10 days.
89601639|NCT06133270|Experimental|NNC0560-0004|"The study will be conducted in 3 parts.~Participants will be randomized to receive NNC0560-0004 in Part A: Single ascending dose (SAD) Part B: Multiple ascending dose (MAD)~No randomisation - only active treatment in Part C: Single dose"
89601640|NCT06133270|Placebo Comparator|Placebo (NNC0560-0004)|"Participant will be randomized to receive placebo in:~Part A: Single ascending dose (SAD) Part B: Multiple ascending dose (MAD)"
89601641|NCT06133257|Active Comparator|GD Group|Patients will take oral clear fluids with carbohydrates content 2 hours preoperatively and intraoperative fluid intake will be guided by Inferior vena cava(IVC) diameter.
89601642|NCT06133257|Active Comparator|C Group|the standard fluid management group patients will be fasting 6 hours preoperatively and will receive intraoperative fluid in standard manner.
88980515|NCT05693064|Experimental|Wait-list followed by chiropractic|
88980516|NCT05688098|Other|Irbesartan/Amlodipine High Fixed dose combination|participants will receive one tablet of Irbesartan/Amlodipine High FDC in a crossover design
89601643|NCT06133231|Experimental|Micronutrient|All participants will take the active micronutrient treatment; capsules of broad spectrum micronutrients.
89601644|NCT06133218|Active Comparator|Intervention side - Mepitel Film|This was an intra-patient randomized study. The patient was randomized for Mepitel film (barrier film) applied on the medial or lateral side of their breast or chest wall during the entire course of radiotherapy; making the patients their own control.
88980517|NCT05688098|Other|Co-administration of Irbesartan and Amlodipine High|participants will receive one table each of Irbesartan and Amlodipine High in a crossover design
89601645|NCT06133218|No Intervention|Control side - standard care|The other side of the breast or chest wall is the intra-patient control as the skin on this side was treated according to standard guidelines for skin care during radiotherapy when symptoms or skin reactions occured.
89601646|NCT06133205|Experimental|intervention group|"In both groups, catgut embedding using disposable single-strand surgical suture Polydioxanone threads was embedded to the following abdominal acupoints: ST-24 (Huaroumen), ST-25 (Tianshu), ST26 (Wailing), REN-12 (Zhongwan), REN-9 (Shuifen), REN-6 (Qihai), REN-4 (Guanyuan) as baseline treatment.~Patients in this arm also received auricular acupressure using ear seeds (Vaccaria seeds) in the following auricular acupoints: Shen Men, Stomach, Endocrine. Those points were chosen due to function that are related to weight loss."
89601647|NCT06133205|Sham Comparator|sham group|"In both groups, catgut embedding using disposable single-strand surgical suture Polydioxanone threads was embedded to the following abdominal acupoints: ST-24 (Huaroumen), ST-25 (Tianshu), ST26 (Wailing), REN-12 (Zhongwan), REN-9 (Shuifen), REN-6 (Qihai), REN-4 (Guanyuan) as baseline treatment.~Patients in this arm also received auricular acupressure using ear seeds (Vaccaria seeds) in the following auricular acupoints:Lung, Eye, Ear Apex. The points were selected as control points as there is no clear indication on their ability to contribute to weight loss."
89601648|NCT06133192|Active Comparator|Steroids alone|Steroids 2 mg/kg/day
89601649|NCT06133192|Experimental|ECP + steroids|Steroids 2 mg/kg abd ECP x 2 per week for 1 months and once a week for 2 months
89601650|NCT06133153|Experimental|Arm THIODERM ELATE|Subjects randomized to Arm A (approx. 66.7% of subjects) will receive THIODERM ELATE injected into both lips (Experimental Device) at the initial treatment and a potential touchup treatment.
89601651|NCT06133153|Active Comparator|Arm JUVÉDERM ULTRA|Subjects randomized to Arm A (approx. 33.3% of subjects) will receive Juvéderm(R) Ultra injected into both lips (Comparator Device) at the initial treatment and a potential touchup treatment. .
89601652|NCT06133127|Other|single group assignment|Same assessments for all patients.
89601653|NCT06133101|Placebo Comparator|2% Fat Cows Milk|Participants randomized to this arm will consume 2% fat cow's milk twice daily for 12 weeks.
89601654|NCT06133101|Experimental|Standard Soy Milk|Participants randomized to this arm will consume standard soy milk twice daily for 12 weeks.
89601655|NCT06133088|Experimental|single arm|This is a single-arm, Phase II clinical study to explore the efficacy and safety of dalpiciclib combined with fluvestrant and compound gossypol acetate tablets in advanced HR-positive and HER2-negative breast cancer after CDK4/6 treatment failed.
89601656|NCT06133049||Ozanimod exposed|
89601657|NCT06133049||Other DMT exposed|
89601658|NCT06133049||Not DMT exposed|
89601659|NCT06133023|Experimental|Plastic stent group|In the plastic stent group, two (at least one) 7-Fr double pigtail stents will be placed. Following EUS-guided puncture of a pseudocyst, a guidewire will be coiled within the lesion, and another guidewire will be inserted alongside the prepositioned guidewire. The puncture tract will be dilated if needed.
89601660|NCT06133023|Active Comparator|LAMS group|In the LAMS group, a LAMS with electrocautery enhanced delivery will be placed (Hot AXIOS; Boston Scientific Japan, Tokyo, Japan). A guidewire or dilator will be used if needed.
89601661|NCT06132997|Active Comparator|Medical thoracoscopy group|Medical thoracoscopy is a minimally invasive endoscopic procedure utilized by pulmonologists to evaluate, diagnose, and treat pleural pathologies of the lung, mainly pleural effusions.
89601662|NCT06132997|Active Comparator|Intercostal tube group|Intercostal chest tube placed without thoracoscopy for patients with confirmed empyema.
89601663|NCT06132971|Active Comparator|NBP2|Participants were assigned to the 2-session New Beginnings Program intervention
89601664|NCT06132971|Experimental|NBP10|Participants were assigned to the 10-session New Beginnings Program
89601665|NCT06132945|Experimental|Cabozantinib and Nivolumab With Radiation Therapy|"Patients being newly initiated on cabo/nivo will be started on with cabozantinib 40 mg PO daily and nivolumab 240 mg IV Q2 weeks~Dose de-escalation of cabozantinib for toxicity will be allowed per prespecified toxicity dose levels~A switch to nivolumab 480mg IV Q4 weeks will be allowed starting C3 per investigator discretion.~Radiation will be stereotactic radiosurgery, delivered over 1-5 fractions with a total dose of 18-30Gy depending on fractionation schedule per the discretion of the treating radiation oncologist. Standard institutional regimens such as 18-24 Gy in a single fraction, 24-27 Gy in three fractions, and 25-30 Gy in five fractions are permissible."
88980518|NCT05688085|Experimental|Irbesartan High/Amlodipine Fixed dose combination|participants will receive one tablet of Irbesartan High/Amlodipine FDC in a crossover design
88980519|NCT05688085|Experimental|Co-administration of Irbesartan High and Amlodipine|participants will receive one table each of Irbesartan High and Amlodipine in a crossover design
88980520|NCT05686863|Active Comparator|P group|induction: Propofol 3 mg/kg+Esketamine 0.25 mg/kg intravenously, mantainance: propofol 5-10 mg/kg/h+remifentanil 0.5-1 μg/kg/h continuous pumping
88980521|NCT05686863|Experimental|R group|induction: Remimazolam 0.3 mg/kg+Esketamine 0.25 mg/kg intravenously, mantainance: Remimazolam 1-3 mg/kg/h+remifentanil 0.5-1 μg/kg/h continuous pumping
88980522|NCT05686369||Cohort A: Well-controlled Celiac Disease|Cohort A: Well-controlled celiac disease participants who should be asymptomatic or mildly symptomatic
88980523|NCT05686369||Cohort B: Non-Responsive Celiac Disease|Cohort B: Celiac disease participants with persistent symptoms who are known to be symptomatic and show positivity to serum auto-antibodies even though participants have been adhering to gluten-free diet
88980524|NCT05683288|Experimental|IASTM|"EYYDM will be applied to the upper trapezius and sternocleideomastoid muscles of the participants for 90 seconds, with a frequency of 60 beats per minute. The instruments will be applied to the soft tissue at 30º-60º angles with multidirectional strokes (stroking) movements."
89601666|NCT06132932|Experimental|WX390|Participants will receive WX390 continuous oral dosing (1.1 mg once a day).
89601667|NCT06132906|Experimental|(Study group) will be treated with locating guides to reposition the maxilla with pre-bent plates|After le fort 1 osteotomy, locating guides will be used to reposition the maxilla with pre-bent plates.
88980525|NCT05683288|Experimental|Myofascial Release|Basic movements will be used in the rectus capitis, sternocleidomastoideus, hyoid region and upper trapezius regions within the scope of myofascial release application. The application will take 3 minutes for each region.
88980526|NCT05683288|Experimental|Control|It will include 250W infrared application on the cervical region from 50cm away for 15 minutes and TENS application for 20 minutes at 80Hz frequency with 150ms current transit time, home exercise program.
88980527|NCT05677373|Experimental|Treatment (PLX2853, trametinib)|Patients receive PLX2853 PO in combination with trametinib PO throughout the study. Patients also undergo collection of blood at screening and on study. Patients also undergo CT or MRI with contrast and collection of blood at screening and on study.
88980528|NCT05663073|Experimental|Irbesartan/Amlodipine Fixed dose combination|participants will receive one tablet of Irbesartan/Amlodipine FDC in a crossover design
88980529|NCT05663073|Experimental|Co-administration of Irbesartan and Amlodipine|participants will receive one table each of Irbesartan and Amlodipine in a crossover design
88980530|NCT05654506|Experimental|Daratumumab treatment in PGNMID|Subjects with native kidney biopsy consistent with membranoproliferative glomerulonephritis with monoclonal immunoglobulin deposits will receive daratumumab.
88980531|NCT05630547|Experimental|SAR443820|Oral SAR443820
89601668|NCT06132906|Active Comparator|(Control group) will be treated with Intermediate wafer.|After le fort 1 osteotomy, Intermediate wafer will be used with intermaxillary fixation.
89601669|NCT06132815|Experimental|Laser troughing|
89601670|NCT06132815|Experimental|Retraction cord and astringent|
88980532|NCT05630547|Placebo Comparator|Placebo|Oral placebo
88980533|NCT05621083|Experimental|Fish oil (the omega-3 fatty acid supplement)|"Participants will be randomized to either start to receive fish oil (the omega-3 fatty acid supplement) for 6 weeks. Followed by a wash-out period of a minimum of 12 weeks before the treatment is changed.~Once the classical Randomized Controlled Trial (RCT) has finished, all the participants will repeat the fish oil intervention period (adaptive design) to determine if those the investigators defined as responders continue to be defined in the same category."
89210292|NCT05712369|Experimental|Prospective cohort|Patients with INS due to biopsy-proven MCD or FSGS or MesGN candidate to anti-CD20 monoclonal antibodies therapy.
89601671|NCT06132815|Experimental|Cordless retraction paste with astringent|
89601672|NCT06132815|Active Comparator|Cordless retraction paste without astringent|
89601673|NCT06132802|Experimental|Group I: Patients who received treatment involving ARS and arthrocentesis only|
89601674|NCT06132802|Experimental|Group II: Patients who received treatment involving ARS, arthrocentesis, and an I-PRF injection|
89601675|NCT06132776|Experimental|Verum group|
89601676|NCT06132776|Placebo Comparator|Placebo group|
89601677|NCT06132750||SELENON-related myopathy or LAMA2-related muscular dystrophy|"Participants diagnosed with congenital myopathy/muscular dystrophy due to mutations in the SEPN1 (SELENON) or LAMA2 gene~Interventions: No intervention"
89601678|NCT06132711|Experimental|Patients treated with CAR T cells|Peripheral blood mononuclear cells were collected and subjected to CD3+T cells were enriched, transfected with APRIL-BAFF-Bicephali lentiviral vector, expanded by in vitro culture, and pretreated with clear lymphocytes using the FC protocol before infusion of APRIL-BAFF-Bicephali CAR-T cells.
89601679|NCT06132646|No Intervention|Control group|Patients that had suffered a wrist fracture and are going to receive standard rehabilitation for the wrist.
89601680|NCT06132646|Experimental|Experimental group|Patients that had suffered a wrist fracture and are going to receive standard rehabilitation for the wrist.
89601681|NCT06132633|Experimental|Neospot Vitals Measurement|Neospot is a 5-in-1 wearable vitals measurement device designed to measure temperature, blood pressure, pulse rate, respiratory rate and blood oxygen saturation. For the standard of care vitals measurement, conventional vital signs will be measured using mercury blood pressure cuffs and infrared or mercury thermometers for blood pressure and temperature respectively, pulse oximeter for oxygen saturation and a 1-minute count of heart rate and breathing rate.
89601682|NCT06132620|Experimental|the experimental group|
89601683|NCT06132620|Active Comparator|the control group|
89601684|NCT06132607|Experimental|Preoperative 3D lung reconstruction|Patients who were planned for an anatomical lung resection with preoperative 3D lung reconstruction.
89601685|NCT06132594|Experimental|Group I; Conventional arthrocentesis followed by I-PRF injection|Patients received arthrocentesis followed by I-PRF injection, employing the conventional TMJ injection technique aided by facial anatomical landmarks
89601686|NCT06132594|Experimental|Group II; 3d surgical guided Arthrocentesis followed by I-PRF injection|Patients received arthrocentesis followed by I-PRF injection with the assistance of a CT-guided 3D printed surgical guide.
89601687|NCT06132555||Drug abusers|"Drug abusers who registered in any of the 80 streets and 40 towns selected according to the economic level and population distribution of each city and other reference standards have been included in the study. A total of 6906 valid questionnaires have been collected.~The interviewees were selected from 5000 participants in the quantitative questionnaire. Priority is given to drug users who have abstained for more than three years, and all age groups under 30 years old, between 30 and 50 years old and over 50 years old are covered."
89608598|NCT01797835|Placebo Comparator|Usual Care|Youth in usual care will receive screening for alcohol and drug use. Those youth who are at risk will have a chance to talk to their provider about their use. They will also receive an informational brochure.
88980534|NCT05621083|Placebo Comparator|High-oleic sunflower oil (HOSO) containing no omega-3 fatty acids|Participants will be randomized to either start to receive high-oleic sunflower oil (HOSO) for 6 weeks. Followed by a wash-out period of minimum 12 weeks, before the treatment is changed.
88980535|NCT05620862|Experimental|mitoxantrone hydrochloride liposome alone or combined with Irinotecan+Vincristine|In phase Ia, patients with relapsed and refractory lymphoma and solid tumors will receive mitoxantrone hydrochloride liposome alone (at three doses of 16 mg/m2, 20 mg/m2 and 24 mg/m2, ) or combination of Irinotecan 50mg/ m2，d1-5, Vincristine 1.5mg/ m2，d1 for up to 6 cycles (21 days per cycle). In phase Ib, patients will recive mitoxantrone hydrochloride liposome 24 mg/m2, combination of Irinotecan 50mg/ m2，d1-5, Vincristine 1.5mg/ m2
89210293|NCT05712369|Experimental|Retrospective cohort|Patients with INS due to biopsy-proven MCD or FSGS or MesGN, treated with anti-CD20 monoclonal antibodies therapy.
89601688|NCT06132555||Drug rehabilitation institutions|The drug rehabilitation institutions included social work organization, compulsory detoxification center and rehabilitation center, which were selected according to the specific conditions of the selected cities, and the final number of participants was determined according to the personnel Settings of these institutions.
89601689|NCT06132542|Experimental|Experimental|Open label study
89601690|NCT06132529||Post-Traumatic Headache Group|Subjects diagnosed with having post-traumatic headache complete an MRI, speech sample, and electronic daily headache diary.
89601691|NCT06132529||Healthy Control Group|Subjects identified as health and not having any headaches will complete an MRI and speech sample.
89601692|NCT06132516|Experimental|High Intensity Interval Training (HIIT)|HIIT 16 sessions of 12 to 30 minutes, over 6 weeks.
89601693|NCT06132516|Placebo Comparator|Low Intensity Group Training (LIGT)|LIGT 16 sessions of 12 to 30 minutes, over 6 weeks.
89601694|NCT06132464|Experimental|Expanding Communication and Language Generated in Conversation Treatment|Participants will complete 20 one-hour therapy sessions over 10 weeks with an experienced, trained, and licensed speech-language pathologist delivering Expanding Communication and Language Generated in Conversation Therapy, following the therapy protocol. Sessions will take place through casual conversational interactions, with incremental problem-solving and communication support by the speech-language pathologist.
89601695|NCT06132451|No Intervention|Usual practice arm|Patients will be treated according to their treating physicians' decision.
89601696|NCT06132451|Other|Postponement of treatment arm|Antihypertensive treatment adaptions will be postponed until after a 24h ambulatory blood pressure measurement (ABPM) 4 weeks after hospital discharge.
89601697|NCT06132438|Experimental|Glioblastoma|
89601698|NCT06132425|Experimental|Positive Rehearsal|After every two exposure trials, participants will complete a rehearsal exercise prompting reflection of expectancy violation and rehearsal of the inhibitory association between the conditional stimulus (i.e., speech) and the unconditional stimulus (i.e., rejection). During rehearsal, participants are prompted to identify positive emotional experiences associated with exposure trial outcomes.
89601699|NCT06132425|Active Comparator|Neutral Rehearsal|After every two exposure trials, participants will complete a rehearsal exercise prompting reflection of expectancy violation and rehearsal of the inhibitory association between the conditional stimulus (i.e., speech) and the unconditional stimulus (i.e., rejection). During rehearsal, participants are prompted to maintain a neutral, non-emotional stance and focus on overall exposure trial outcomes.
89601700|NCT06132412|Experimental|active tDCS+PT|For those participants assigned to the active or sham tDCS groups, the overall set-up will be identical between groups and will use the Chattanooga Ionto tDCS device. However, the sham tDCS group will have the tDCS device turned off after 30 seconds of stimulation. Saline-soaked sponge electrodes that are 35 cm^2 in size will be used for both the active and sham tDCS groups. For electrode placement, the active electrode (anode) will be placed over M1 contralateral to the side of primary knee pain (over C3/4 using the 10-20 system for electrode placement), while the reference electrode (cathode) will be over the contralateral supraorbital region, which is ipsilateral to the painful knee (Fp2 using the 10-20 system). The intensity will be set at 2mA for the active tDCS group, following a 30 second ramp-up time. The participants in the active tDCS group will undergo 20 minutes of tDCS treatment prior to receiving individualized PT intervention.
89601701|NCT06132412|Sham Comparator|sham tDCS+PT|For those participants assigned to the active or sham tDCS groups, the overall set-up will be identical between groups and will use the Chattanooga Ionto tDCS device. However, the sham tDCS group will have the tDCS device turned off after 30 seconds of stimulation. Saline-soaked sponge electrodes that are 35 cm^2 in size will be used for both the active and sham tDCS groups. For electrode placement, the active electrode (anode) will be placed over M1 contralateral to the side of primary knee pain (over C3/4 using the 10-20 system for electrode placement), while the reference electrode (cathode) will be over the contralateral supraorbital region, which is ipsilateral to the painful knee (Fp2 using the 10-20 system). The participants in the sham tDCS group will undergo 20 minutes of sham tDCS treatment prior to receiving individualized PT intervention.
89601702|NCT06132386||Healthy Volunteers, not taking Tenofovir (TFV) based PrEP|
89601703|NCT06132386||Healthy volunteers, steady state Tenofovir (TFV) based regimen|
89601704|NCT06132386||Persons infected with HIV taking Tenofovir (TFV) and emtricitabine (FTC) based HIV treatment|
89601705|NCT06132373|Experimental|Single arm study|We will apply evidence-based Problem Solving Therapy (PST), a transdiagnostic, low-intensity approach shown to improve mental health problems among adolescents with demonstrated effectiveness in global settings. PST for adolescents is a brief 5 session individual treatment with demonstrated efficacy when delivered by lay providers. PST is theorized to function by increasing adolescent capacity to cope with perceived and experienced stress through the use of problem- and emotion- focused coping skills that then allow engagement in positive, healthy activities.
89601706|NCT06132321||Patients operated for vulvar cancer without reconstruction|
89601707|NCT06132321||Patients operated for vulvar cancer with reconstruction|
89601708|NCT06132308|Active Comparator|PENG Block with 0.25% bupivacaine (20 cc)|For PENG block, patients are in the supine position is deposited. The convex ultrasound probe is initially placed over the anterior superior iliac spine, then the probe moves medially until the femoral artery is visualized. In this view, iliopectineal eminence (IPE), iliopsoas muscle and tendon, femoral artery and iliac muscle are observed. Between the psoas tendon and the IPE 22 gauge 80 mm block needle is guided and 20cc local anesthetic used in % 0.25 bupivacaine is administered by intermittent aspiration.
88980536|NCT05617859|Other|Lenvatinib mesylate capsule|Eligible subjects with bone and soft tissue sarcoma were selected and treated with the following treatment regimens:Subjects will receive Lenvatinib mesylate capsules, 8mg (body weight ≤60kg) or 12mg (body weight >60kg) orally once daily. Take the medicine about half an hour after meals (the time of taking the medicine should be the same as possible every day) and take it with warm water.
88980537|NCT05615688|Experimental|Orthodontic Separators Placed|Elastomeric separators will be placed on the mesial and distal of the lower first permanent molars for a total of four separators per subject.
88980538|NCT05611177||Derivation cohort|It will contain 700 patients (70% of 1000 ARDS patients)
88980539|NCT05611177||Validation cohort|It will contain 300 patients (30% of 1000 ARDS patients)
88980540|NCT05611177||Confirmatory cohort|It will contain 303 patients (for external validation)
89210294|NCT05712369|Active Comparator|Healthy volunteers cohort|Subjects not known to suffer of any significant illness, not assuming any medication or drug on a regular basis.
89601709|NCT06132308|Experimental|PENG Block with 0.25% bupivacaine (30 cc)|For PENG block, patients are in the supine position is deposited. The convex ultrasound probe is initially placed over the anterior superior iliac spine, then the probe moves medially until the femoral artery is visualized. In this view, iliopectineal eminence (IPE), iliopsoas muscle and tendon, femoral artery and iliac muscle are observed. Between the psoas tendon and the IPE 22 gauge 80 mm block needle is guided and 30cc local anesthetic used in % 0.25 bupivacaine is administered by intermittent aspiration.
89601710|NCT06132308|Experimental|PENG Block with 0.25% bupivacaine (40 cc)|For PENG block, patients are in the supine position is deposited. The convex ultrasound probe is initially placed over the anterior superior iliac spine, then the probe moves medially until the femoral artery is visualized. In this view, iliopectineal eminence (IPE), iliopsoas muscle and tendon, femoral artery and iliac muscle are observed. Between the psoas tendon and the IPE 22 gauge 80 mm block needle is guided and 40cc local anesthetic used in % 0.25 bupivacaine is administered by intermittent aspiration.
89601711|NCT06132295|Experimental|Nursing care|Investigators used in-house-designed radiotherapy red and green light markers to distinguish individual measures after the provision of the initial nursing care to participants, added a homemade health education leaflet to collect data via actual observation, and counted the disappearance or fading of participants' body markers
89601712|NCT06132217|Experimental|Dose Escalation Phase Cohort 1|
89601713|NCT06132217|Experimental|Dose Escalation Phase Cohort 2|
89601714|NCT06132217|Experimental|Dose Escalation Phase Cohort 3|
89601715|NCT06132217|Experimental|Dose Expansion Phase Cohort A|
89601716|NCT06132217|Experimental|Dose Expansion Phase Cohort B|
89601717|NCT06132217|Experimental|Dose Expansion Phase Cohort C|
89601718|NCT06132204|Experimental|HRS-7535 Tablets-Moderately renal insufficiency subjects|
89601719|NCT06132204|Experimental|HRS-7535 Tablets-Healthy subjects|
89601720|NCT06132152|Active Comparator|Open hemorrhoidectomy with 'cold' scalpel|Open hemorrhoidectomy will be performed in traditional way, including radial skin-mucosal excision of enlarged hemorrhoids with ligation of the vascular pedicle. 'Cold' scalpel will be used for cutting the perianal skin and anal mucose. To stop and prevent bleeding the monopolar coagulation may be used but on low energy level and with no touching the skin and mucose.
89601721|NCT06132152|Active Comparator|Open hemorrhoidectomy with electrosurgical scalpel|Open hemorrhoidectomy will be performed in traditional way, including radial skin-mucosal excision of enlarged hemorrhoids with ligation of the vascular pedicle. Electrosurgical scalpel will be used during all steps including cutting the perianal skin and anal mucose and to stop and prevent bleeding.
89601722|NCT06132100|Placebo Comparator|traditional incentive spirometry|patients with traditional incentive spirometry
89601723|NCT06132100|Experimental|digitalized incentive spirometry|patients with digitalized incentive spirometry
89601724|NCT06132061|Experimental|Intervention group for universal prevention|Level 1 intervention (universal prevention) group
89601725|NCT06132061|Experimental|Intervention group for selective prevention|Level 2 intervention(selective prevention) group
89601726|NCT06132061|Experimental|Intervention group for targeted prevention|Level 3 intervention(targeted prevention) group
89601727|NCT06132061|Other|Control group|
89601728|NCT06132048|Experimental|MuCopilot - Summative evaluation|Performance of digital tests and questionnaire from MuCopilot, during the visit.
89601729|NCT06132035|Experimental|CG-P5 peptide eye drops|
89601730|NCT06132035|Placebo Comparator|Placebo Eye drops|
89601731|NCT06132035|Active Comparator|Intravitreal injection of Eylea®|
89601732|NCT06132009||Remission group|Group of women who underwent cystectomy or unilateral oophorectomy due to endometriosis but were in remission during follow-up
89601733|NCT06132009||Recurrent group|Group of women who underwent cystectomy or unilateral oophorectomy due to endometriosis but developed an endometrioma of at least 2 cm in size in a single ovary during follow-up.
89601734|NCT06131996|Active Comparator|Volar-assisted splint group|Participants used volar supported splint during sleep for 4 weeks. Exercise was performed at home for a total of 12 sessions, three sessions per week.
88980541|NCT05607030|Experimental|Experimental|Local antibiotic irrigation via the VT-X7 Treatment System adjuvant to two-stage exchange arthroplasty per SOC.
88980542|NCT05607030|Active Comparator|Control|SOC for treatment of chronic PJI - two-stage exchange arthroplasty: surgical removal of the infected implant, aggressive debridement, and exchange arthroplasty with administration of adjuvant systemic antibiotics and temporary antibiotic-impregnated cement spacer.
88980543|NCT05603988|Placebo Comparator|Placebo group|• Mock laser application (Placebo group): The fiber optic tip will be inserted inside the root canal, mimicking the laser irradiation group, but not activated
88980544|NCT05603988|Other|Diode Laser group|Intracanal Diode laser application
89601735|NCT06131996|Active Comparator|Elastic splint group|Participants used velastic splint during sleep for 4 weeks. Exercise was performed at home for a total of 12 sessions, three sessions per week.
89601736|NCT06131931|Experimental|Connecting Latinxs en Pareja (CLP)|CLP is a four-session intervention grounded in social cognitive theory and a relationship oriented ecological framework.
89601737|NCT06131931|Active Comparator|Wellness Promotion (WP)|WP focuses on nutrition, fitness, healthcare, and stress management and emphasizes adherence to medical regimens and medication management.
89601738|NCT06131515|Experimental|Group A (experimental group)|This group includes 34female patients who will receive extra corporeal shock wave therapy one session per week for 4 weeks in addition to physical therapy exercises (including carpal bone mobilization, nerve glide skin care and manual lymph drainage 2 sessions per week for 4 weeks.
89601739|NCT06131515|Experimental|Group B (control group)|This group includes 34female patients who will receive shame extra corporeal shock wave therapy one session per week for 4 weeks in addition to physical therapy exercises (including carpal bone mobilization, nerve glide exercises, skin care and manual lymph drainage 2 sessions per week for 4 weeks.
89601740|NCT06130215|Experimental|Fix meal annoucement with three presets of carbohydrates|simple meal management
89601741|NCT06130215|Active Comparator|Flex meal annoucement with precise carbohydrate counting|precise meal management
89601742|NCT06130020|Experimental|Self|The Self group is instructed to carry out the expressive writing exercise as if they were writing to themselves.
89601743|NCT06130020|Experimental|Other|The Other group is instructed to carry out the expressive writing exercise as if they were writing to someone they feel close to.
89601744|NCT06130020|Placebo Comparator|Control|The Control group is asked to write down a factual description of their routine that day, as if they were writing to themselves.
89601745|NCT06129526|Active Comparator|EPAVasc 2g|
89601746|NCT06129526|Active Comparator|EPAVasc 2g x 2|
89601747|NCT06129526|Placebo Comparator|Corn Oil|
89601748|NCT06129448||Diabetes Mellitus|We will include in this group patients with a diagnosis of T1DM, determined according to the World Health Organization criteria, who need insulin treatment and whose diabetes duration is more than 1 year. Patients will not have additional chronic diseases and will not have any other medical treatments other than insulin.
89601749|NCT06129448||Healthy Children|Patients will not have additional chronic diseases or other medical treatments. They will often be selected on a voluntary basis from patients who apply to pediatric cardiology with symptoms such as murmur or chest pain.
89601750|NCT06129188|Experimental|Remimazolam|2.5-5 mg IV remimazolam will be administered no more frequently than every 2 minutes for the duration of the TEE procedure.
88980545|NCT05600283|Experimental|Self-collected vaginal swab samples|Subjects will self-collect a vaginal swab (Evalyn brush) and complete a scheduled standard of care clinician-collected cervical swab
88980546|NCT05599022|Placebo Comparator|Sham Stimulation|With the coil directed away from the patient, 600 pulses of TcMS will be delivered at minimal energy output.
88980547|NCT05599022|Active Comparator|Low Frequency TcMS|With the coil directed at the stellate ganglion, 60 minutes of 1Hz stimulation will be delivered targeting the stellate ganglion.
88980548|NCT05599022|Active Comparator|Theta Burst Stimulation TcMS|With the coil directed at the stellate ganglion, 600 pulses of continuous theta burst stimulation will be delivered targeting the stellate ganglion.
88980549|NCT05597124|Experimental|Cardio-Dance Fitness|This is the experimental group. Participants will meet three times a week for dance classes for approximately 60 minutes per session, over 24 weeks (approximately 6 months).
88980550|NCT05597124|Active Comparator|Strength, Flexibility & Balance|This is the active control group. Participants will meet three times a week for strength, flexibility, and balance exercises for approximately 60 minutes per session, over 24 weeks (approximately 6 months).
88980551|NCT05593874||Diabetic foot ulcer with osteoarticular infections|Diabetic patients suffering from ulcer that led to an osteoarticular infection (e.g. chronic osteomyelitis, septic arthritis)
88980552|NCT05590039|Experimental|Treatment for MyEllevate Procedure|The subjects were treated with the MyEllevate procedure.
89601751|NCT06129188|Active Comparator|Propofol|Standard-of-care IV propofol administration will be administered at the discretion of the anesthesia team caring for the patient for the duration of the TEE procedure
88980553|NCT05579574|Experimental|BMS-986322 and Loestrin|Loestrin, then progress to combination
88980554|NCT05572034|Sham Comparator|Group A|A diagnostic electrophysiological study will be performed in patients of group A
88980555|NCT05572034|Active Comparator|Group B|A electrophysiological study with cardiac denervation, with right Ganglionated Plexi ablation exclusively will be performed in patients of group B
88980556|NCT05572034|Active Comparator|Group C|A electrophysiological study with cardiac denervation, with right and left Ganglionated Plexi ablation will be performed in patients of group C.
88980557|NCT05569746|Experimental|INM004|2 doses of 4 mg/kg separated by 24 h
89601752|NCT06128447|Active Comparator|Treatment A|ZP5-9676 600 mg dose
89601753|NCT06128447|Placebo Comparator|Treatment B|Placebo
89601754|NCT06127862|Other|Education group|The forms used in the study were collected by the researcher through face-to-face interviews in seminar halls in schools. First of all, students in the experimental group were educated about environmental health and microplastica, and nursing interventions were made. The training was organized for twenty minutes in each session, with a total of four sessions at two-week intervals. Personal Information Form and Microplastica Pollution Awareness Scale (MPAS) were filled out as a pre-test in the seminar halls of the schools under the supervision of the researcher.
88980558|NCT05564767|Experimental|B. adolescentis Bif-038|Probiotic capsule (single strain)
88980559|NCT05564767|Experimental|Lacticaseibacillus rhamnosus, LGG® and Bifidobacterium, BB-12®|Probiotic capsule (combination strain)
89601755|NCT06127862|Other|Control group|"Personal information form and Microplastica Pollution Awareness Scale (MPAS) were applied to the students in the control group as a pre-test. No training was given to the control group. Fifteen days after the end of the fourth training of the intervention group, the MPAS was applied to the control group as a post-test, and data collection was terminated. After the post-test was administered to the groups, training materials were also given to individuals from the control group who requested them."
89601756|NCT06126757|Experimental|PelviSense-assisted pelvic floor muscle training group|Women assigned to the experimental group will perform pelvic floor muscle training exercises with the wearable PelviSense device sensor to the perineal region.
89601757|NCT06126757|Active Comparator|Pelvic floor muscle exercise (training) without the Pelvisense device|Women assigned to the unassisted PFMT group will perform the exercise without the PelviSense device.
89601758|NCT06126549|Active Comparator|Usual Care|Usual Care (UC) consists of nurse instruction in care routines, case management family support for discharge, referral to family counseling and community services as indicated, and general information resources about brain injury. Usual Care participants also have access to peer support services, including peer mentoring, brain injury education classes, and workshops for caregivers.
89601759|NCT06126549|Active Comparator|Building Better Caregivers|Building Better Caregivers (BBC) was developed for caregivers of patients with Alzheimers' Disease and has been adapted for caregivers of patients with ABI. BBC is a peer-led, problem-solving intervention delivered in 6 group workshop sessions. Key components include problem-solving; making an action plan; managing stress and fatigue, difficult care partner behavior, and difficult thoughts/emotions. Each of the workshops last 60 minutes and usually take place once a week over a 6-8 week span of time.
89601760|NCT06126549|Active Comparator|Problem Solving Training|Problem Solving Training (PST) is a clinician-led intervention, administered one-on-one via phone calls, assigned readings, and practice assignments between calls. PST teaches caregivers how to address problems and apply a specific problem-solving technique that calls for brainstorming, consideration, development, and evaluation to address current problems the caregiver may be facing. The training aims to teach the strategy, so caregivers can apply it in the present, as well as the future. Each of the 6 Problem Solving Training Sessions last from 30-60 minutes and usually take place once a week over a 6-week span of time.
89601761|NCT06126393||POLE Mut|The POLE gene mutation detection was performed, and the mutation Changes were classified as POLE mutation.
89601762|NCT06126393||dMMR|The mismatch repair (MMR) proteins were detected by immunohistochemistry, and the deletion of one or more proteins was classified as d-MMR subtype
88980560|NCT05564767|Placebo Comparator|Placebo|Placebo capsule
88980561|NCT05562388|Experimental|MAD therapy|MAD Therapy
88980562|NCT05562258|Experimental|Parent Coaching and Patient Education|This group includes 12 weeks of eating disorder therapy provided to the patient. Outside of therapy, parents will have access to a coach and patients will have access to weekly educational material.
88980563|NCT05562258|Experimental|Parent Education and Patient Coaching|This group includes 12 weeks of eating disorder therapy provided to the patient. Outside of therapy, parents will have access to weekly educational material and patients will have access to a coach.
88980564|NCT05562063|Experimental|Sotagliflozin|Daily administration of sotagliflozin (2x200 mg, orally, once a day) for 6 months.
88980565|NCT05562063|Placebo Comparator|Placebo|Daily administration of placebo (2 tablet identical in appearance and color to sotagliflozin tablets, orally, once a day) for 6 months.
88980566|NCT05561751|Experimental|GPC-100 in combination with propranolol;|"Patients will be randomly assigned to 1 of 2 treatment arms prior to study drug administration.~Approximately 40 patients will be randomized in a 1:1 ratio to the following treatment arm:~• GPC-100 in combination with propranolol; or"
89601763|NCT06126393||P53abn|The expression of p53 was detected by immunohistochemistry. The abnormality of p53 protein expression (completely negative or diffusely strong positive in the nucleus) or expression location (cytoplasmic expression) was judged as p53abn, otherwise it was p53wt.
89601764|NCT06126393||P53wt|The expression of p53 was detected by immunohistochemistry. The abnormality of p53 protein expression (completely negative or diffusely strong positive in the nucleus) or expression location (cytoplasmic expression) was judged as p53abn, otherwise it was p53wt.
89601765|NCT06124287||Crohn's Disease patients stopping biologic therapy|Crohn's Disease patients stopping biologic therapy and undergoing MR Enterography 3 months before or 1 month after this decision as part of standard clinical care.
89601766|NCT06124131|Experimental|Full financial incentives|$50/service patient financial incentive for completion of: COVID-19 shot, flu shot, colorectal cancer screening
89601767|NCT06124131|Active Comparator|Partial financial incentives|$50/service patient financial incentive for completion of: COVID-19 shot, flu shot
89601768|NCT06124001|Experimental|Experimental: Single Arm|"VG161:~1)1.0 × 10 ^ 8 PFU daily for 2 consecutive days on Days 1-2 of each cycle (D1-D2); 2)1.0 × 10 ^ 8PFU daily for 3 consecutive days on Days 1-3 of each cycle (D1-D3); camrelizumab: 3 mg/kg every 3 weeks (D8)~Part2:~Depends on the recommended dose in Part1"
89601769|NCT06115577||endometrial polyp|pathology according to histological examination
89601770|NCT06115577||endometrial hyperplasia without atypia|pathology according to histological examination
89601771|NCT06115577||atypical endometrial hyperplasia|pathology according to histological examination
89601772|NCT06115577||endometrial cancer|pathology according to histological examination
88980567|NCT05561751|Experimental|GPC-100 in combination with propranolol and G-CSF|"Patients will be randomly assigned to 1 of 2 treatment arms prior to study drug administration.~Approximately 40 patients will be randomized in a 1:1 ratio to the following treatment arm:~• GPC-100 in combination with propranolol and G-CSF."
88980568|NCT05558982|Experimental|BXCL701 plus Pembrolizumab|
88980569|NCT05554315||1|Male or female, aged 18 or greater in good general health as evidenced by medical history
88980570|NCT05551793|Experimental|Dupilumab|Dupilumab: weekly 300mg SC injections Manufacturer: Regeneron
88980571|NCT05551793|Placebo Comparator|Placebo|Placebo: weekly SC injections of equivalent volume Manufacturer: Regeneron
88980572|NCT05551728|Experimental|Intervention group|12, 1-hour ESDM-informed caregiver coaching sessions, delivered by non-specialists. Intervention materials and approach have been adapted for the South African context.
88980573|NCT05551728|No Intervention|Delayed intervention control group|Usual care.
89601773|NCT06114147|Experimental|pregnant women|pregnant women with eligibility criteria with gestational age from 12 to 16+6/7 WA and then from 32 to 36+6/7 WA.
89601774|NCT06111898||High-risk infants|
89601775|NCT06111898||Typically developing infants|
88980574|NCT05547854|Active Comparator|In-Person Therapist Training|
88980575|NCT05547854|Experimental|Online Therapist Training|
88980576|NCT05545787|Experimental|Cold snare endoscopic mucosal resection (CS-EMR)|Eligible colorectal polyps sized 10-19mm will be resected by CS-EMR
89601776|NCT06107634|No Intervention|Standard paraesophageal hernia repair|Standard paraesophageal hernia repair(Crura suture with total (Nissen) fundoplication))
89601777|NCT06107634|Active Comparator|Standard paraesophageal hernia repair +gastropexy|Standard paraesophageal hernia repair with the addition of gastropexy(anterior, posterior and left gastropexy)
89601778|NCT06105567|Experimental|Effect of Education on Premenstrual Symptoms, Emotional Eating Behavior and Perceived Stress|Students who score over 110 on the premenstrual syndrome scale and meet the study criteria will be included in the experimental and control groups. Personal Information Form, PMS Scale, Premenstrual Eating Habits Form, Healthy Lifestyle Behaviors Scale, Emotional Eating Scale, Perceived Stress Scale and Visual Visual Pain Scale will be administered to the students in this group before the training. Premenstrual syndrome periods will be determined by creating a menstrual cycle calendar for the participants. Students will be trained with their first powerpoint presentation. Afterwards, brochures will be distributed. It will be applied according to the Philips 66 technique. 4 weeks after the first training, students will be given general reminder training online during pms periods. Survey forms will be filled out by the group 4 weeks after the second training.
89601779|NCT06105567|No Intervention|control group|Students who score over 110 on the premenstrual syndrome scale and meet the study criteria will be included in the experimental and control groups. Students in this group will not receive training and will be administered the Personal Information Form, PMS Scale, Premenstrual Eating Habits Form, Healthy Lifestyle Behaviors Scale, Emotional Eating Scale, Perceived Stress Scale and Visual Vissual Pain Scale. Data will be collected by face-to-face research method. Survey forms will be filled out by the control group.
89601780|NCT06099964|Active Comparator|Pain Coping Information|
89601781|NCT06099964|Experimental|Mindful Pain Management|
89601782|NCT06099509|Experimental|Self-administered diabetes screen|"Self-administered 75-gram oral glucose tolerance test with 4-week virtual follow-up visit.~Drug: GlucoCrush"
89601783|NCT06099509|No Intervention|Routine postpartum care|"Office based oral glucose tolerance test at 6 weeks postpartum, per normal protocol.~Drug: GlucoCrush"
89601784|NCT06096428||Pulsed-field group|Patients will undergo catheter ablation for atrial fibrillation using pulsed-field energy
89601785|NCT06096428||Radiofrequency group|Patients will undergo catheter ablation using radiofrequency energx
89601786|NCT06095349|Experimental|Bone turnover markers|Concentrations of bone turnover markers will be assessed before and after treatment. Correlation will be sought for with H2S levels and clinical features of the patients
89601787|NCT06094855||Persons with Multiple sclerosis|Persons with a diagnosis of Multiple Sclerosis
89601788|NCT06094049||Preference test|A preference test using a 5-unit hedonic scale will be conducted to assess the women liking of the meal prepared with fortified flour only.
89601789|NCT06094049||Triangle test|A triangle tests will be carried out to detect any difference between the food prepared with fortified and unfortified flour.
89601790|NCT06081335|Active Comparator|Continuous Rotation group|EdgeEndo x7 continuous rotation files system (Albuquerque, New Mexico, USA)
89601791|NCT06081335|Active Comparator|Reciprocation group|EdgeOne Fire reciprocating files system (Albuquerque, New Mexico, USA)
89601792|NCT06075615||dacomitnib|
89608599|NCT01797835|Experimental|CHAT brief MI intervention|Youth in CHAT will receive screening for alcohol and drug use. Those youth who are at risk will have a chance to talk to their provider about their use. In addition, these youth will CHAT. CHAT is a brief motivational intervention that takes places in the primary care setting. It is a 15-20 minute intervention for adolescents age 12-18 focused on discussing alcohol and drug use. They will also receive a booster call one month later to check in on how they are doing.
89608600|NCT01275430|Experimental|Sherlock 3CG|Sherlock 3CG is indicated for central venous catheter guidance and positioning during catheter placement. The Sherlock 3CG provides real time catheter tip location information through the use of passive magnet and cardiac electrical signal detection.
88980577|NCT05545787|Experimental|Hot snare endoscopic mucosal resection (HS-EMR)|Eligible colorectal polyps sized 10-19mm will be resected by HS-EMR
88980578|NCT05541926|Experimental|e-Connect|County receives training and materials and subsequently begins the e-Connect intervention
88980579|NCT05541926|No Intervention|Standard of Care|Standard of care practice in counties prior to the implementation of e-Connect
88980580|NCT05534451|Experimental|video rigid laryngoscope group|Similarly during intubation, the patient should be placed in the supine position with the neutral head. The endoscopic body of video rigid laryngoscope covered by a lubricated endotracheal tube enters the airway through the nasal cavity, then proceeds under visual conditions. When the epiglottis is exposed, if necessary, gently lift the patient's lower jaw so that the glottis is fully visible. The tube is pushed to approach and pass the glottis. Withdraw the endoscopic body while adjusting the depth of tube in the trachea. The intubation ends with tube fixation.
88980581|NCT05534451|Experimental|video laryngoscope group|First of all, participants will be asked to take supine position with neutral head. The operator will insert a lubricated endotracheal tube through the nasal cavity into the oropharynx, while he/she holds the handle of video laryngoscope in his/her left hand. Laryngoscope blade can be placed into oral cavity along the right corner of the patient's mouth, and the tongue is pushed to the left by moving the handle. Blade should arrive at a suitable depth to fully expose the epiglottis and glottis. After that, the operator can push the catheter with the right hand to approach and pass the glottis, sometimes Magill forceps are necessary. Finally, the tube is inserted into the trachea to the appropriate depth and fixed firmly.
89210295|NCT02539290|Experimental|Uterine flushing|Detection of ovulation, injection of 20 millilitres of physiological saline by an intra-uterine catheter the day of the luteinizing hormone surge, and sexual intercourse within 12 hours after intervention
89601793|NCT06073626|Experimental|Relational Agent (RA)|Participants in the RA arm will receive a clinical letter from the institution's clinical genetics program with a link to the RA. The fully HIPAA-compliant RA will provide comparable educational information to traditional genetic counseling (GC) but in a streamlined and tailored manner including video, education and decision support, patient testimonial and answers to questions in real-time. Participants will be informed that they may speak to a genetic risk specialist free of charge. For participants who wish to proceed directly to GT, the RA will alert staff to these requests and a GT kit will be mailed to them. Results will be shared with the participant, their oncologist and tailored per the result. Participants who indicate that they are unsure or do not want GT will be encouraged by RA to discuss their risk and GT options with their oncology provider and to schedule a GC appointment with the clinic or via a link to the automated scheduling tool in the RA.
89601794|NCT06073626|Active Comparator|Enhanced Usual Care (EUC)|Participants in the EUC arm will also be mailed a clinical letter signed by the Medical Director of the institution's clinical genetics program. The letter sent to EUC participants will inform them of their own and their family's potential risk for carrying a pathogenic variant (PV) related to hereditary cancer. The letter will emphasize their eligibility for GT, include a recommendation to consider scheduling a GC appointment to obtain more information, and include a link to the CINJ or LCCC high-risk clinic website. The study team will help facilitate GT when requested by the participant. Results will be shared with the participant, their oncologist and tailored per the result.
88980582|NCT05534451|Experimental|video fiberoptic scope group|It is suggested to apply paraffin oil to the surface of the insertion tube of video fiberoptic scope, where the friction with the inner wall of the endotracheal catheter will be reduced. The insertion tube together with a lubricated endotracheal tube will be placed into the nasopharynx through the nasal cavity of patient who takes supine position with neutral head. Push the insertion tube slowly and continuously along the airway until cuff passes through the glottis. Next carefully, the endotracheal tube can be delivered into the trachea, and the insertion tube can be withdrawn from the trachea. At last, the tracheal catheter can be fixed after the depth is adjusted to an appropriate level.
88980583|NCT05533554|Experimental|Experimental group with intervention|The experimental group will receive the intervention. First, the group will undergo a pre-intervention evaluation lasting 120 minutes. The intervention will consist of two synchronized virtual sessions of brief intervention with a cognitive-behavioral approach where various persuasive communication strategies will be implemented, definition of hazardous alcohol consumption, establishment of a consumption goal, social skills to deal with pressure to consume and plan of pleasant activities alternative to consumption, each session will last 120 minutes. Four weeks after the end of the intervention, the experimental group will carry out the post-intervention evaluation session in a virtual synchronized manner with a duration of 120 minutes.
88980584|NCT05533554|No Intervention|Control group|The control group will participate in a pre-intervention evaluation session. Four weeks after the end of the last intra-session evaluation session, the control group will participate in the post-intervention evaluation in a virtual synchronized manner with a duration of 120 minutes.
88980585|NCT05527964||Patients with severe refractory atopic dermatitis|Patients eligible for Dupixent therapy of AD
88980586|NCT05527015|Active Comparator|Single vision spectacles (SVLs)|
88980587|NCT05527015|Experimental|Bifocal spectacles (BFLs)|
88980588|NCT05526404|Experimental|Mobile application-based Bristol stool scale|Subjects with cirrhosis who are taking lactulose for the treatment of hepatic encephalopathy will download the Dieta mobile application on their mobile device and take a photo of each bowel movement using the Dieta application
88980589|NCT05523180|Experimental|Probiotic|1 capsule of 15 Billion CFU proprietary probiotic blend with 120 mg herbal extracts, taken twice daily.
88980590|NCT05523180|Placebo Comparator|Placebo|1 capsule of placebo, taken twice daily.
88980591|NCT05518253|Experimental|Intravenous of CD70-targeted CAR-T|Infusion of CD70-targeted CAR-T cells by dose of 1-10x106 cells/kg
88980592|NCT05518253|Experimental|intraperitoneal injection of CD70-targeted CAR-T|Infusion of CD70-targeted CAR-T cells by dose of 1-10x106 cells/kg
88980593|NCT05515432|Experimental|Mildly impaired renal funtion: eGFR (mL/min/1.73 m^2) ≥60 - <90|Participants with renal impairment
88980594|NCT05515432|Experimental|Moderately impaired renal funtion: eGFR (mL/min/1.73 m^2) ≥30 - <60|Participants with renal impairment
88980595|NCT05515432|Experimental|Severely impaired renal funtion: eGFR (mL/min/1.73 m^2) <30|Participants with renal impairment
89210296|NCT02539290|Sham Comparator|Vaginal flushing|Detection of ovulation, injection of 10 millilitres of physiological saline intravaginally the day of the luteinizing hormone surge, and sexual intercourse within 12 hours after intervention
88980596|NCT05515432|Experimental|ESRD (end stage renal disease) on dialysis|Participants with renal impairment
88980597|NCT05515432|Experimental|Normal renal function (control group): eGFR (mL/min/1.73 m^2) ≥90|Age-, weight-, and gender-matched participants with normal renal function as control group
88980598|NCT05515224|Experimental|5-Cog Paradigm (5-Cog battery coupled with clinical decision tool)|A cognitive concern screening will be conducted with patients aged 65 and older prior to their appointment with their primary care physician. If cognitive concerns are endorsed the 5-Cog battery will be conducted. The simple, <5-minute cognitive assessment will reliably identify older persons with cognitive impairment in primary care settings, and flag them for further evaluation. Depending on whether the 5-Cog results are normal or abnormal on any one of the 3 tests, appropriate clinical decision support tools are provided to the primary care physicians in electronic medical record. The primary care physicians are not instructed to follow 5-Cog suggestions verbatim but use their clinical judgment.
88980599|NCT05515224|Active Comparator|Enhanced usual care|Educational sessions for primary care physicians and clinic staff regarding cognitive detection and medical billing will be conducted. A cognitive concern screening will be conducted with patients aged 65 and older prior to their appointment with their primary care physician. The results will be provided to primary care physicians.
88980600|NCT05513638||The First Affiliated Hospital of Nanjing Medical University|
88980601|NCT05513638||The First Affiliated Hospital of Soochow University|
88980602|NCT05512039|Active Comparator|Botox: Standard dose|The standard dose of 100 units of botox will be injected into the bladder.
88980603|NCT05512039|Experimental|Botox: Low dose|A lower dose of 50 units of botox will be injected into the bladder.
89210297|NCT00898716|Experimental|BMS-754807|
89601795|NCT06072378|Experimental|Value-manipulation|Participants with epilepsy will complete a behavioral task in which they use a laptop computer to do a decision-making and memory task.
89601796|NCT06052592||Group A|Newborns fed with formula milk supplemented with 20 mg/day of fermented FOS from Lactobacillus paracasei strain CNCM I-5220 and Vitamin D (0.5 ml of SMART D3 MATRIX)
89601797|NCT06052592||Group B|Newborns fed with formula milk
88980604|NCT05507125||Control|Participants without inflammatory skin disease
88980605|NCT05507125||Patients with HS|Patients with HS
88980606|NCT05505097|Other|ABCD-sequence|Hydroxymethylquinoxalindioxyde administration in a sequence A-B-C-D during the corresponding study periods 1, 2, 3, and 4
88980607|NCT05505097|Other|BCDA-sequence|Hydroxymethylquinoxalindioxyde administration in a sequence B-C-D-A during the corresponding study periods 1, 2, 3, and 4
88980608|NCT05505097|Other|CDAB-sequence|Hydroxymethylquinoxalindioxyde administration in a sequence C-D-A-B during the corresponding study periods 1, 2, 3, and 4
89601798|NCT06052592||Group C|Newborns fed with exclusive breast milk
89601799|NCT06045611|Experimental|Isolated Pea Protein/Isolated Whey Protein/Isolated Faba Bean Protein/Placebo|"Study day 1: 0.6g isolated pea protein/kg/body weight + 400 ml water~Study day 2: 0.6g isolated whey protein/kg/body weight + 400 ml water~Study day 3: 0.6g isolated faba bean protein/kg/body weight + 400 ml water~Study day 4: 400 ml water~The fat and energy content of the drinks will be adapted using a plant based oil"
89601800|NCT06045611|Experimental|Isolated Whey Protein/Placebo/Isolated Pea Protein/Isolated Faba Bean Protein|"Study day 1: 0.6g isolated whey protein/kg/body weight + 400 ml water~Study day 2: 400 ml water~Study day 3: 0.6g isolated pea protein/kg/body weight + 400 ml water~Study day 4: 0.6g isolated faba bean protein/kg/body weight + 400 ml water~The fat and energy content of the drinks will be adapted using a plant based oil"
89601801|NCT06045611|Experimental|Isolated Faba Bean Protein/Isolated Pea Protein/Placebo/Isolated Whey Protein|"Study day 1: 0.6g isolated faba bean protein/kg/body weight + 400 ml water~Study day 2: 0.6g isolated pea protein/kg/body weight + 400 ml water~Study day 3: 400 ml water~Study day 4: 0.6g isolated whey protein/kg/body weight + 400 ml water~The fat and energy content of the drinks will be adapted using a plant based oil"
89601802|NCT06045611|Experimental|Placebo/Isolated Faba Bean Protein/Isolated Whey Protein/Isolated Pea Protein|"Study day 1: 400 ml water~Study day 2: 0.6g isolated faba bean protein/kg/body weight + 400 ml water~Study day 3: 0.6g isolated whey protein/kg/body weight + 400 ml water~Study day 4: 0.6g isolated pea protein/kg/body weight + 400 ml water~The fat and energy content of the drinks will be adapted using a plant based oil"
89601803|NCT06039774|Experimental|α-Mangostin Hydrogel Film With Chitosan Alginate Base|Subjects will receive α-Mangostin Hydrogel Film With Chitosan Alginate Base in the form of a patch. Subjects will apply the patch once a day after breakfast or at night before sleep, subjects will be told to avoid drinking or eating for 1 hour after using the hydrogel film because these activities can remove the hydrogel film. Ulcer size and VAS score will recorded on the first day (baseline), the 3rd day, the 5th day, and the 7th day
89601804|NCT06039774|Placebo Comparator|Placebo|Subjects will receive Hydrogel Film With Chitosan Alginate Base without an active compound in the form of a patch. Subjects will apply the patch once a day after breakfast or at night before sleep and will be told to avoid drinking or eating for 1 hour after using the hydrogel film because these activities can remove the hydrogel film. Ulcer size and VAS score will recorded on the first day (baseline), the 3rd day, the 5th day, and the 7th day
89601805|NCT06037980|Experimental|Preoperative chemotherapy|Triplet combination of gemcitabine, cisplatin and nabpaclitaxel as neoadjuvant treatment followed by surgery and adjuvant chemotherapy
89601806|NCT06037980|Active Comparator|Upfront surgery|Standard upfront surgery and adjuvant chemotherapy
89601807|NCT06023602|Experimental|Generic cetrorelix acetate|
89601808|NCT06023602|Active Comparator|Reference cetrorelix acetate|
89601809|NCT06014112|Experimental|Freestyle Libre PRO iQ sensor|Eligible patients
89601810|NCT06013813|Experimental|Distal radial approach|"Clean and dry the puncture site.~Simple lidocaine 2% is infiltrated.~The artery is punctured in the radial distal zone, and a 6 Fr hydrophilic radial introducer is placed with the Seldinger technique.~Verapamil 2.5 mg and Heparin 5000 IU are administered.~PCI is performed.~Finally, the introducer is withdrawn with the patent hemostasis technique, and a radial compression device is placed (prelude mostly or terumo)."
89601811|NCT06013813|Active Comparator|Conventional radial approach (proximal radial approach).|"Clean and dry the puncture site.~Simple lidocaine 2% is infiltrated.~The artery is punctured in the radial proximal zone, and a 6 Fr hydrophilic radial introducer is placed with the Seldinger technique.~Verapamil 2.5 mg and Heparin 5000 IU are administered.~PCI is performed.~Finally, the introducer is withdrawn with the patent hemostasis technique, and a radial compression device is placed (terumo)."
89601812|NCT06007781|Placebo Comparator|Placebo|One dose of placebo on Day 1 and one dose of placebo between Day 29 and Day 57
89601813|NCT06007781|Experimental|Experimental|One dose of HIL-214 on Day 1 and one dose of HIL-214 between Day 29 and Day 57
89601814|NCT06007482|Experimental|Dose Escalation Cohort|ES009 monotherapy dose level will be escalated in participants with advanced solid tumors.
89601815|NCT06006286|Experimental|ADI-PEG20/ATEZO/BEV|Participants will first receive the study drug combination for up to 12 weeks. If participants have stable disease or a partial response to the study drug after 12 weeks, participants may continue to receive ADI-PEG 20 for up to 2 years of total dosing, and participants may continue to receive atezolizumab and bevacizumab indefinitely (no limit)
89601816|NCT06004973|Experimental|STAR Particles|Participants will receive the 8 interventions (different application pressures) plus the control (Site and treatment will not be randomly assigned on the arm) by the investigator.
89601817|NCT06004115|Experimental|Lorazepam|Participants will receive a single 1mg dose of Lorazepam, to be taken orally under registered nurse (RN) supervision
88980609|NCT05505097|Other|DABC-sequence|Hydroxymethylquinoxalindioxyde administration in a sequence D-A-B-C during the corresponding study periods 1, 2, 3, and 4
88980610|NCT05503394|Experimental|Peer support WeChat platform intervention group|Peer support WeChat platform intervention for primary caregivers of children with biliary atresia based on routine care during the postoperative period up to one month postoperatively
88980611|NCT05503394|Other|Routine nursing care group|Perform routine nursing care for primary caregivers of children with biliary atresia during the postoperative period up to one month postoperatively
89601818|NCT06004115|Placebo Comparator|Placebo|Participants will receive a single dose of placebo, to be taken orally under RN supervision
89601819|NCT06003751|Experimental|Phase 2 Cohort A|Cohort A - Low Dose or Sham
89601820|NCT06003751|Experimental|Phase 2 Cohort B|Cohort B - High Dose or Sham
89601821|NCT05999695|Experimental|self-management interventions|"self-management interventions: According to the results of literature search and based on the theory of self-efficacy, the intervention measures of the self-management program were designed.~regular care:regular care"
89601822|NCT05999695|Active Comparator|regular care|regular care
89601823|NCT05999032|Active Comparator|Low-Intensity (Virtual) Intervention Implementation|During low intensity implementation, families of children with poorly controlled asthma will be referred to the remote version of HARP (HARP-V) and will receive CASE remotely (CASE-V). Children with not well controlled asthma will receive only CASE-V remotely.
89210298|NCT05277948|Active Comparator|treatment group|Active thumbtack needle will be used for the treatment group
89601824|NCT05999032|Active Comparator|High Intensity (in-Person) Intervention Implementation|"During high intensity implementation, all interventions are administered in person.~Specifically, families of children with poorly controlled asthma will receive in-person versions of HARP and CASE. Children with not well controlled asthma will receive an in-person version of CASE only."
89601825|NCT05992662|Experimental|Intervention Group|"In this research, the training program was designed as an intervention.~Summary of the research's implementation plan:~Preparation of Mindfulness-based training program in bariatric surgery Inviting adult individuals to participate in the research before bariatric surgery and reaching the targeted number of participants Participants who agreed to participate in the study fill out the individual introduction form, complete the short story, and administer the Mindful Eating Questionnaire to the participants Conducting mindfulness-based 4-session training program Focus group discussion after the training Reminder of weekly practices Recording changes in mindful eating in participant experience diaries during the follow-up At the end of the monitoring phase (3rd-6th months), individual in-depth interviews and Mindful Eating Questionnaires are conducted with each participant in the action group"
89601826|NCT05992662|No Intervention|Control Group|Mindful Eating Questionnaire will be applied before the surgery, at the 3rd and 6th months after the surgery. No intervention will be applied to the control group.
89601827|NCT05988138|Experimental|Family Promoting Positive Emotions|
89601828|NCT05988138|Active Comparator|Psychoeducation|
89601829|NCT05984706||Trauma-exposed children and adolescents|Focus group and Delphi survey
89601830|NCT05984706||Caregivers of trauma-exposed children and adolescents|Focus group and Delphi survey
89601831|NCT05984706||Clinical experts|Delphi survey
89601832|NCT05983575|Experimental|LIPUS-Brain|
89601833|NCT05983575|Placebo Comparator|Placebo|
89601834|NCT05978661|Experimental|Treatment arm|
89601835|NCT05976724|Experimental|Mobilization with movement|Mobilization with movement technique and traditional physiotherapy will be applied to the intervention group. Also patients will receive a traditional therapy program consisting of Conventional TENS and stretching and strengthening exercises.
89601836|NCT05976724|Active Comparator|Control group|Patients will receive a traditional therapy program consisting of Conventional TENS and stretching and strengthening exercises.
89601837|NCT05968690|Experimental|Cohort 1 - Propranolol|"Patients will receive intravenous ipilimumab 3 mg/kg + nivolumab 1 mg/kg every 21 days for up to 4 cycles followed by intravenous nivolumab monotherapy 480 mg every 28 days.~Propranolol will be administered as 30 mg orally twice a day, continuously."
89601838|NCT05968690|Experimental|Cohort 2 - Propranolol + Naltrexone 4.5 mg|"Patients will receive intravenous ipilimumab 3 mg/kg + nivolumab 1 mg/kg every 21 days for up to 4 cycles followed by intravenous nivolumab monotherapy 480 mg every 28 days.~Propranolol will be administered as 30 mg orally twice a day, continuously.~Naltrexone will be administered as 4.5 mg orally once a day, continuously."
89601839|NCT05968690|Experimental|Cohort 3 - Propranolol + Naltrexone 9 mg|"Patients will receive intravenous ipilimumab 3 mg/kg + nivolumab 1 mg/kg every 21 days for up to 4 cycles followed by intravenous nivolumab monotherapy 480 mg every 28 days.~Propranolol will be administered as 30 mg orally twice a day, continuously.~Naltrexone will be administered as 9 mg orally once a day, continuously."
89601840|NCT05968690|Experimental|Cohort 4 - Propranolol + Naltrexone 25 mg|"Patients will receive intravenous ipilimumab 3 mg/kg + nivolumab 1 mg/kg every 21 days for up to 4 cycles followed by intravenous nivolumab monotherapy 480 mg every 28 days.~Propranolol will be administered as 30 mg orally twice a day, continuously.~Naltrexone will be administered as 25 mg orally once a day, continuously."
89601841|NCT05966168|Experimental|Micra AV Exercise Testing|All participants will have Micra AV 2.0 implanted then undergo exercise testing while wearing Holter Monitor
89601842|NCT05963048|Experimental|Rituxmab|1000 mg Rituxmab IV infusion at 1st day then after 15 weeks then after 6 months for 1 year
89601843|NCT05963048|Experimental|IL-6 inhibitor|6 mg/kg IV infusion every month not exceed 600 mg for 1 year
89601844|NCT05948059|Experimental|Part 1: SHR-2106 injection or placebo single dose, iv|
89601845|NCT05948059|Experimental|Part 2: SHR-2106 injection or placebo single dose, sc|
89601846|NCT05935579|Experimental|Durvalumab and Lenvatinib|
89601847|NCT05935579|Active Comparator|Durvalumab and Lenvatinib plus chemotherapy|
89608601|NCT01275430|Active Comparator|"Blind Placement"|"PICCs will be placed blindly, without the use of any tip location/positioning device."
89608602|NCT04142775||intracranial hemorrhage (ICH)|ARDS patients treated with ECMO developing ICH
89210299|NCT05277948|Sham Comparator|control group|Sham thumbtack needle will be used for the control group
89608603|NCT04142775||no intracranial hemorrhage|ARDS patients treated with ECMO not developing ICH
89608604|NCT01838551|Experimental|Levoketoconazole DL0|Levoketoconazole Tablets Dose Level 0 Once Daily
89608605|NCT01838551|Experimental|Levoketoconazole DL1|Levoketoconazole Tablets Dose Level 1 Twice Daily
89608606|NCT01838551|Experimental|Levoketoconazole DL2|Levoketoconazole Tablets Dose Level 1 Twice Daily
89210300|NCT00894816|Active Comparator|1|Infant cereals with the addition of Lactobacillus paracasei subsp. paracasei strain F19 (LF19) 10E8 CFU per serving
89210301|NCT00894816|Placebo Comparator|2|Placebo (infant cereals without any additions)
89210302|NCT00542997|Experimental|IgPro20|
89601848|NCT05924334|Experimental|reiki|"Processing steps of Reiki application; During the Reiki process, the practitioner will keep the hands just above the recipient. It will be explained to the individual that he may feel the feeling of temperature, tingling, drowsiness, refreshment or healing during therapy.~During the application, the person does not need to be in a lying position or remove their clothes. It is enough to remove the jewelry on it.~In order to ensure the flow of energy during the application, the arms and legs of the individual should stand open on both sides of the body, and the hands and feet will not be crossed in order not to disrupt the flow of energy.~The practitioner will pass the right side of the individual and correct the energy existing around the body with the right hand to the feet and from top to bottom by correcting the energy field of the individual.~The application time will be between 20 and 30 minutes on average."
89601849|NCT05924334|Experimental|placebo control|The same intervention procedure will be performed with the Reiki Group. Only the placebo group practitioner does not have a Reiki Master certificate. In other words, despite the apparent reiki applied, there will be no energy flow in its real meaning.
89601850|NCT05922085|Experimental|patient under mechanical ventilation for at least 7 days|
89601851|NCT05910697|No Intervention|Control arm - Baseline comparison|The Control group treats their simulated patients using standard practice and has no introduction to the new MyProststate 2.0 test.
89601852|NCT05910697|Experimental|MyProstateScore 2.0|The intervention will receive information regarding the MyProstateScore 2.0 test and will be given the test results in their round of CPV information and for each sample that they submit.
89601853|NCT05906251|Experimental|SRP-6004|Participants will receive single IV infusion of SRP-6004 on Day 1.
89601854|NCT05899868|Other|Time to intubation using FASTER device|Time from fiberoptic placement into airway to documentation of end-tidal carbon dioxide waveform through the endotracheal tube.
89601855|NCT05889039|Sham Comparator|OMT + BEMER PLACEBO|Participants in the CONTROL group received light touch and BEMER sham treatments. Researchers placed their hands lightly on the subject's cervical paraspinal muscles in the supine position and on the upper thoracic paraspinal muscles in the prone position for approximately 5 minutes. This was done to mimic myofascial release techniques; however, no pressure or action was done. In addition, the subject's laid supine on the BEMER mat (as they would do during a BEMER session), but the device was not activated.
89601856|NCT05889039|Active Comparator|Experimental: Bio Electro-Magnetic Regulation (BEMER) Therapy|Participants receiving BEMER therapy laid supine on the BEMER mat (BEMER International AG). The BEMER was set at intensity 3 for week 1, intensity 4 for week 2, and intensity 5 for week 3. The B.Pad (BEMER International AG) was placed under their cervical region. B.Pad® settings were set at Program 1 (8 minutes long) in week 1 through week 3. These settings were selected based on the manufacturer's recommendations.
89601857|NCT05889039|Active Comparator|OMT (Osteopathic Manipulative Treatment)|Participants receiving OMT were treated with a standardized sequence to the areas where somatic dysfunctions were found.
89601858|NCT05889039|Experimental|OMT+BEMER|Participants receiving BEMER therapy laid supine on the BEMER mat (BEMER International AG). The BEMER was set at intensity 3 for week 1, intensity 4 for week 2, and intensity 5 for week 3. The B.Pad (BEMER International AG) was placed under their cervical region. B.Pad® settings were set at Program 1 (8 minutes long) in week 1 through week 3. These settings were selected based on the manufacturer's recommendations. OMT was performed prior to BEMER therapy for those in the combined group. Participants were treated with a standardized sequence to the areas where somatic dysfunctions were found.
89601859|NCT05885113|Experimental|Intervention|NIDCAP developmental care group receiving intervention
89601860|NCT05885113|No Intervention|standard of care|NO intervention, control group, receiving standard of care
89601861|NCT05873374|Experimental|50 μg Baiya SARS-CoV-2 Vax 2|0.5 mL of Baiya SARS-CoV-2 Vax 2 Vaccine as a booster dose via IM injection on Day 1 for adult participants (18 - 64 years old)
89601862|NCT05873374|Placebo Comparator|Placebo|0.5 mL of placebo via IM injection on Day 1 for adult participants (18 - 64 years old)
89601863|NCT05868096|Experimental|Experimental group|During the 12 weeks of the internship, the experimental group took a pre-test after a case report-1 in weeks 4-5, which included completing the holistic thinking case analysis form and the personal learning self-efficacy questionnaire, followed by a 2-hour structured holistic thinking course. At the end of the session, subjects took the first post-test, revised the case analysis form completed in the pre-test based on the case report-1 observed in the pre-test, and completed the personal learning self-efficacy questionnaire and the satisfaction questionnaire again. During weeks 6-11 of the internship, participants continue to receive clinical practice training in assessment, intervention planning, and patient intervention skills. In weeks 11-12 of the internship, subjects took a second post-test after reading case report-2, which included completing the holistic thinking case analysis form and again completing the personal learning self-efficacy questionnaire.
89608607|NCT01838551|Experimental|Levoketoconazole DL3|Levoketoconazole Tablets Dose Level 3 Twice Daily
88980612|NCT05503017|Experimental|Intervention|
88980613|NCT05503017|Active Comparator|Control Condition|
88980614|NCT05496140|Experimental|CLS-R-FUERTE|Active program participation in: a remote school clinician training and comprehensive psychosocial intervention designed to improve attention and behavior in Mexican school-aged youth (grades 1-5). via school clinician training by a clinical research team to lead parent skill groups, child skill groups, and teacher consultation in a behavioral classroom management system.
88980615|NCT05496140|No Intervention|Care-As-Usual|Continued participation in school care-as-usual
88980616|NCT05489991|Experimental|TmPSMA-02|
88980617|NCT05489302|Active Comparator|(MSE) Alt-RAMEC protocol|
88980618|NCT05489302|Active Comparator|(MSE) conventional protocol|
88980619|NCT05488457|Experimental|Oxytocin PK/PD Arm|Eligible subjects will receive a single, 1 IU bolus of deuterated oxytocin (d5OT) intra-operatively, followed by an infusion of standard therapeutic d0 oxytocin immediately after umbilical cord clamping.
88980620|NCT05486403|Experimental|Intervention|Preschool Educators deliver the Appetite Toolbox programme directly to children over a period of six weeks after the pre-test and before the post-test effectiveness measures.
88980621|NCT05486403|Other|Waitlist Control|Preschool Educators continue to deliver their usual preschool curriculum over a period of six weeks after the pre-test and before the post-test effectiveness measures. They will deliver the Appetite Toolbox programme directly to children after the post-test measures.
89601864|NCT05868096|Active Comparator|Control group|During the 12 weeks of the internship, the control group had no structured holistic thinking course. During weeks 4-5 of the internship, after viewing case report-1, a pretest consisting of completing the holistic thinking case analysis form and the personal learning self-efficacy questionnaire was completed and a holistic thinking case analysis form - introductory version was given. Subjects will revise the holistic thinking case analysis form completed in the pretest and complete the personal learning self-efficacy questionnaire again. During weeks 6-11 of the internship, participants continue to receive clinical practice training in assessment, intervention planning, and patient intervention skills. In weeks 11-12 of the internship, subjects received the post-test, viewed the case report-2, and were given the holistic thinking case analysis form - introductory version and completed the holistic thinking case analysis form and the personal learning self-efficacy questionnaire.
89601865|NCT05866406|Experimental|TRE group|Participants assigned to the TRE group will have to consume all their daily meals and snacks during a 9-hour window for 12 weeks.
89601866|NCT05866406|Active Comparator|Control group|Participants assigned to the control group will have to consume all their daily meals and snacks during a 14-hour window for 12 weeks.
89601867|NCT05864859|Experimental|Normal birth group|It consisted of preliminary information (10 minutes), practice (10 minutes) and analysis (20 minutes) sessions with groups of 2 people (1 midwife, 1 pregnant) accompanied by a scenario where there was no complication during labor.
89601868|NCT05864859|Experimental|Breech birth group|It consisted of preliminary information (10 minutes), practice (10 minutes) and analysis (20 minutes) sessions with groups of 2 people (1 midwife, 1 pregnant) accompanied by a scenario that experienced complications during labor.
89601869|NCT05864859|No Intervention|Control group|She continued her education in accordance with the (1+32) hour curriculum within the scope of the midwifery undergraduate program Integrated Practice I and EBE402 Integrated Practice II courses.
89601870|NCT05863130|Experimental|BI 764198 (C-14) (approach 1)|
89601871|NCT05863130|Experimental|BI 764198 (C-14) (approach 2)|
89601872|NCT05861245|Experimental|Skull base chordomas and chondrosarcomas|"Patients > 18 years old.~With a baseline classification on the Karnofsky performance status scale ≥ 70%.~With confirmed histological diagnosis of chordoma or chondrosarcoma of the skull base.~With a maximum tumor size of 50 cc.~Whose relationship to organs at risk (OARs) allows compliance with the necessary dose restrictions to receive hypofractionated proton therapy in 5 fractions.~Patients included in the study must meet dosimetric parameters that include:~Clinical Target Volume (CTV) coverage of at least D95>90%.~Correct compliance with the dose restrictions, at least in the nominal scenario, for critical organs (optic pathway, brain stem and spinal cord) according to the guidelines published and available in the literature."
89601873|NCT05839470|Experimental|Cadonilimab+ FOLFOXIRI+bevacizumab|Cadonilimab (6mg/kg, iv, Q2W, Day1)+irinotecan* 165 mg/m² iv continue for 1.5 hours, D1; oxaliplatin 85 mg/m² iv continue for 2 hours, D1; leucovorin 400 or levoleucovorin 200 mg/m² iv continue for 2 hours, D1; 5-FU 2400 mg/m² cont. inf. 48h; repeat every 2 weeks (Q2W) + bevacizumab （5mg/kg，d 1）
89601874|NCT05836103|Experimental|Micro-randomized trial group|The micro-randomized trial will determine if CBT and Mindfulness/ACT messages are superior to control messages in reducing the primary outcome momentary smoking urges. Based on participants' training data collected in the initial 14 days of EMA monitoring, intervention messages will be delivered during time-periods and at high-risk locations for smoking. In the intervention phase, participants will be prompted to complete 3 geofence-triggered EMAs per day for a total of 30 days. Each EMA will be followed by an intervention message and the type of message (CBT, Mindfulness/ACT, control) will be randomly selected at each time point (within-subject randomization).
89608608|NCT01838551|Experimental|Levoketoconazole DL4|Levoketoconazole Tablets Dose Level 4 Twice Daily
88980622|NCT05485090||Test Phase : Test-Retest Reliability|Caregivers will complete the questionnaire twice with the same investigator. The interval between the two questionnaires is 3 to 10 days.
88980623|NCT05485090||Test Phase : Inter-rater Reliability|Caregivers will complete the questionnaire twice with two different investigators. The interval between the two questionnaires is 3 to 10 days.
88980624|NCT05480865|Experimental|Dose Escalation: BBP-398 Level 1 and sotorasib|BBP-398 dose Level 1 capsules administered once a day (QD) for a 28-day treatment cycle in combination with sotorasib tablets administered once a day (QD) for a 28-day treatment cycle
88980625|NCT05480865|Experimental|Dose Escalation: BBP-398 Level 2 and sotorasib|BBP-398 dose Level 2 capsules administered once a day (QD) for a 28-day treatment cycle in combination with sotorasib tablets administered once a day (QD) for a 28-day treatment cycle
88980626|NCT05480865|Experimental|Dose Escalation: BBP-398 Level 3 and sotorasib|BBP-398 dose Level 3 capsules administered once a day (QD) for a 28-day treatment cycle in combination with sotorasib tablets administered once a day (QD) for a 28-day treatment cycle
88980627|NCT05480865|Experimental|Dose Expansion/Optimization: BBP-398 Dose Regimen 1 and sotorasib|BBP-398 Dose Regimen 1 capsules administered once a day (QD) for a 28-day treatment cycle in combination with sotorasib tablets administered once a day (QD) for a 28-day treatment cycle
88980628|NCT05480865|Experimental|Dose Expansion/Optimization: BBP-398 Dose Regimen 2 and sotorasib|BBP-398 Dose Regimen 2 capsules administered once a day (QD) for a 28-day treatment cycle in combination with sotorasib tablets administered once a day (QD) for a 28-day treatment cycle
88980629|NCT05476900|Experimental|12 mg HR19042 Capsules QD|
88980630|NCT05476900|Experimental|4 mg HR19042 Capsules TID|
88980631|NCT05476900|Experimental|8 mg HR19042 Capsules QD|
88980632|NCT05476354|Experimental|Irbesartan/Amlodipine low|
88980633|NCT05476354|Experimental|Irbesartan/Amlodipine high|
88980634|NCT05476354|Active Comparator|Irbesartan|
88980635|NCT05475665|Experimental|Irbesartan/Amlodipine|
88980636|NCT05475665|Active Comparator|Irbesartan|
88980637|NCT05475015||Training cohort|Training cohort was set to develop the novel non-invasive model for virtual HVPG
88980638|NCT05475015||Validation cohort|Validation cohort was set to validate the novel non-invasive model for virtual HVPG in different people in same environments
88980639|NCT05468190|Experimental|Intravenous of CD70-targeted CAR-T|Infusion of CD70-targeted CAR-T cells by dose of 1-10x10^6 cells/kg
88980640|NCT05468190|Experimental|intraperitoneal injection of CD70-targeted CAR-T|Infusion of CD70-targeted CAR-T cells by dose of 1-10x10^6 cells/kg
89601875|NCT05836103|No Intervention|EMA-only control group|A total of N=80 participants will be randomized into an EMA-only control group, parallel to the micro-randomized trial intervention group. This group will conduct 14-day EMA only training phase just like the micro-randomized trial group, but will not be switched over to the intervention phase after these initial 14 days. Instead, participants will continue the EMA-only data collection procedure for an additional 30-days (analogous to the 30-day intervention phase of the micro-randomized trial). During these 30 days, the EMA-only control group will continue to receive 3 randomly prompted EMA surveys per day and an additional 3 EMA surveys triggered by smoking reports.
89601876|NCT05825729|Active Comparator|ABC|"The arms of the study are just the order of the interventions are performed~º Dry suction technique~º Slow pull technique~º Wet suction technique"
89601877|NCT05825729|Active Comparator|ACB|"The arms of the study are just the order of the interventions are performed~º Dry suction technique~º Wet suction technique~º Slow pull technique"
89601878|NCT05825729|Active Comparator|BAC|"The arms of the study are just the order of the interventions are performed 2º Slow pull technique~1º Dry suction technique 3º Wet suction technique"
89601879|NCT05825729|Active Comparator|BCA|"The arms of the study are just the order of the interventions are performed~º Slow pull technique~º Wet suction technique~º Dry suction technique"
89601880|NCT05825729|Active Comparator|CAB|"The arms of the study are just the order of the interventions are performed~º Wet suction technique~º Dry suction technique~º Slow pull technique"
89601881|NCT05825729|Active Comparator|CBA|"The arms of the study are just the order of the interventions are performed~º Wet suction technique~º Slow pull technique~º Dry suction technique"
89601882|NCT05824741|Experimental|Intervention|All participants will be enrolled into the intervention arm of this pilot study.
89601883|NCT05822531|Experimental|Maternal Cardiovascular health (CVH) Intervention|The pilot maternal CVH intervention will be delivered by NFP partners starting as early as NFP program enrollment in the first trimester after confirmation of a viable pregnancy and no later than the 28th week of pregnancy and will continue up to 6 months postpartum. The visit schedule will be consistent with the NFP visit structure to deliver intervention content at regularly scheduled visits that are typically 60 minutes long (weekly visits for the first month following enrollment followed by twice monthly visits until delivery). The pilot study will include an enhanced behavioral component target decreased sedentary time and increase physical activity and utilizing a technology/monitoring component. All women be monitored using a wrist-worn actigraphy device to record daily activity, intermittent home blood pressure self-monitoring, intermittent home weight self-monitoring, and carbon monoxide monitoring administered by the NFP nurse.
89601884|NCT05814653|Experimental|FBT-PC delivered by a primary care provider|Subjects will receive up to 18 sessions of FBT-PC, delivered by a primary care provider, at their primary care clinic over 6 months.
89601885|NCT05814653|Active Comparator|Standard FBT|Subjects will receive up to 18 session of FBT, delivered by a specialist mental health provider at Mayo Clinic in Rochester, MN over 6 months.
89601886|NCT05810181||Young Adult|15-25 parents/families of children (or young adults aged 18-35 years) with rare genetic diseases, who have recently received gene therapy
89601887|NCT05810181||Parent/caregiver|10-20 patients/families of children with rare genetic diseases who were offered but have decided against receiving gene therapy or who were ultimately not eligible for a clinical trial.
89601888|NCT05810181||Healthcare Worker|10-20 health care workers' who provide care to patients receiving gene therapy.
89601889|NCT05793684|Experimental|Order: Period A, Period B, Period C|The sequence of periods for each participant are assigned in random order. Each of the three crossover periods is 14 days of uninterrupted nightly dosing, with an initial lower-dose week of investigational product (IP) followed by a higher dose week (or placebo each week).
89601890|NCT05793684|Experimental|Order: Period B, Period C, Period A|The sequence of periods for each participant are assigned in random order. Each of the three crossover periods is 14 days of uninterrupted nightly dosing, with an initial lower-dose week of investigational product (IP) followed by a higher dose week (or placebo each week).
89601891|NCT05793684|Experimental|Order: Period C, Period A, Period B|The sequence of periods for each participant are assigned in random order. Each of the three crossover periods is 14 days of uninterrupted nightly dosing, with an initial lower-dose week of investigational product (IP) followed by a higher dose week (or placebo each week).
89601892|NCT05793684|Experimental|Order: Period A, Period C, Period B|The sequence of periods for each participant are assigned in random order. Each of the three crossover periods is 14 days of uninterrupted nightly dosing, with an initial lower-dose week of investigational product (IP) followed by a higher dose week (or placebo each week).
89601893|NCT05793684|Experimental|Order: Period B, Period A, Period C|The sequence of periods for each participant are assigned in random order. Each of the three crossover periods is 14 days of uninterrupted nightly dosing, with an initial lower-dose week of investigational product (IP) followed by a higher dose week (or placebo each week).
89601894|NCT05793684|Experimental|Order: Period C, Period B, Period A|The sequence of periods for each participant are assigned in random order. Each of the three crossover periods is 14 days of uninterrupted nightly dosing, with an initial lower-dose week of investigational product (IP) followed by a higher dose week (or placebo each week).
89601895|NCT05790967|Experimental|Education Group|
89601896|NCT05790967|No Intervention|CONTROL|
89601897|NCT05790408|Other|AS-OCT and iOCT|This prospective study will include approximately 25 patients with open-angle glaucoma who will undergo TCNR of trabeculectomy bleb by a glaucoma specialist at Northwestern Medicine. These patients will have a history of glaucoma and failed trabeculectomy bleb (as evidenced by clinical features and elevated IOP). During routine clinic visit, the patient will undergo lit lamp grading of bleb by Indiana Bleb Appearance Grading Score (IBAGS). Subjects who agree to participate and provide written informed consent will undergo AS-OCT imaging (Spectralis OCT, Heidelberg) of the bleb. During their operation, the Zeiss Artevo digital microscope integrated with iOCT (Zeiss Artevo 800, Carl Zeiss Meditec AG), a commercially available device will be utilized to visualize and evaluate the morphology of the trabeculectomy bleb at the start and conclusion of the case.
89601898|NCT05774301|Experimental|Nurses|A simulation-based training will be done for all nurses
89608609|NCT01838551|Experimental|Levoketoconazole DL5|Levoketoconazole Tablets Dose Level 5 Twice Daily
89601899|NCT05767749|Experimental|Lidocaine + epinephrine vs Ropivacaine|Each site of the nasal ala will be tested for normal sensation using sterile 30-gauge needles. Other eligibility criteria will be confirmed. Participants in this arm will receive an injection of 0.5ml of . Xylocaine + epinephrine 1:100,000 (lidocaine + epinephrine 1:100,000), buffered 1/10 with sodium bicarb into one side of the nose (nasal ala) and 0.5ml of Naropin (ropivacaine) 0.5% into the opposite nasal ala. Laterality of each anesthetic administration will be randomly assigned for each patient. Subjects will be evaluated for duration of effect of anesthesia every 15 minutes on both sides of the face, until the patient reports return of a sharp sensation upon the pinprick test.
89601900|NCT05767749|Experimental|Lidocaine + epinephrine vs Bupivacaine|Each site of the nasal ala will be tested for normal sensation using sterile 30-gauge needles. Other eligibility criteria will be confirmed. Participants in this arm will receive an injection of 0.5ml of lidocaine + epinephrine into one side of the nose (nasal ala) and 0.5ml of Marcaine (bupivacaine) 0.5% into the opposite nasal ala. Laterality of each anesthetic administration will be randomly assigned for each patient. Subjects will be evaluated for duration of effect of anesthesia every 15 minutes on both sides of the face, until the patient reports return of a sharp sensation upon the pinprick test.
89601901|NCT05767749|Experimental|Ropivacaine vs Bupivacaine|Each site of the nasal ala will be tested for normal sensation using sterile 30-gauge needles. Other eligibility criteria will be confirmed. Participants in this arm will receive an injection of 0.5ml of Naropin (ropivacaine) 0.5% into one side of the nose (nasal ala) and 0.5ml of Marcaine (bupivacaine) 0.5% into the opposite nasal ala. Laterality of each anesthetic administration will be randomly assigned for each patient. Subjects will be evaluated for duration of effect of anesthesia every 15 minutes on both sides of the face, until the patient reports return of a sharp sensation upon the pinprick test.
89601902|NCT05754359|Experimental|I'm an Active Hero (IAAH) Intervention program (intervention group)|Preschool where the intervention implement will be run.
89601903|NCT05754359|No Intervention|Usual physical activities (control group)|No intervention will be delivered in the control group, and children were requested to continue their usual physical activities.
89601904|NCT05752500|Experimental|BASM + PA Coaching|Brief Advice and Self-Monitoring Physical Activity Coaching
89601905|NCT05752500|Experimental|BASM + CB-PA|Brief Advice and Self-Monitoring Cognitive-Behavioral Intervention to Increase Physical Activity
89601906|NCT05752500|Experimental|BASM + SS-PA|Brief Advice and Self-Monitoring Social support for Physical Activity
89601907|NCT05752500|Experimental|BASM + PA Coaching + CB-PA|Brief Advice and Self-Monitoring Physical Activity Coaching Cognitive-Behavioral Intervention to Increase Physical Activity
89601908|NCT05752500|Experimental|BASM + PA Coaching + SS-PA|Brief Advice and Self-Monitoring Physical Activity Coaching Social support for Physical Activity
89601909|NCT05752500|Experimental|BASM + CB-PA + SS-PA|Brief Advice and Self-Monitoring Cognitive-Behavioral Intervention to Increase Physical Activity Social support for Physical Activity
89601910|NCT05752500|Experimental|BASM + PA Coaching + CB-PA + SS-PA|Brief Advice and Self-Monitoring Physical Activity Coaching Cognitive-Behavioral Intervention to Increase Physical Activity Social support for Physical Activity
89601911|NCT05752500|Other|BASM|Brief Advice and Self-Monitoring
89601912|NCT05752292|Experimental|Condition 1|Standard health message + VA + TRI + MI+ AP
89601913|NCT05752292|Experimental|Condition 2|Standard health message + VA + TRI + MI
89601914|NCT05752292|Experimental|Condition 3|Standard health message + VA + TRI + AP
89601915|NCT05752292|Experimental|Condition 4|Standard health message + VA + TRI
89601916|NCT05752292|Experimental|Condition 5|Standard health message + VA + MI+ AP
89601917|NCT05752292|Experimental|Condition 6|Standard health message + VA + MI
89601918|NCT05752292|Experimental|Condition 7|Standard health message + VA + AP
89601919|NCT05752292|Experimental|Condition 8|Standard health message + VA
89601920|NCT05752292|Experimental|Condition 9|Standard health message + TRI + MI+ AP
89601921|NCT05752292|Experimental|Condition 10|Standard health message + TRI + MI
89601922|NCT05752292|Experimental|Condition 11|Standard health message + TRI + AP
89601923|NCT05752292|Experimental|Condition 12|Standard health message + TRI
89601924|NCT05752292|Experimental|Condition 13|Standard health message + MI+ AP
89601925|NCT05752292|Experimental|Condition 14|Standard health message + MI
89601926|NCT05752292|Experimental|Condition 15|Standard health message + AP
89601927|NCT05752292|Experimental|Condition 16|Standard health message
89601928|NCT05736016|Active Comparator|Active Therapy|Active comparator will undergo a 6-week in-patient rehabilitation aimed at: pharmacologic and non-pharmacologic pain management, improvement of vascular function, cardiopulmonary function, functions of skeletal muscles, range of motion and stability of peripheral joints, gait function, body position, with treadmill walking training being a mandatory part of the program. The rehabilitation program will also address individual needs with psychotherapy and vocational therapy. Follow-up period will be 6 weeks. For the time of the treatment and follow-up period the treatment arm will be provided with individually made corrective medial wedge insoles to be used during all therapeutic and other everyday activities.
88980641|NCT05467670|Experimental|ALX148 + Doxorubicin (PLD) + Pembrolizumab|"Given on Day 1 of each 21 day cycle, in the following order of administration:~200 mg IV pembrolizumab* (maximum of 2 years (approximately 35 cycles)~45 mg/kg IV ALX148~30 mg/m^2 IV doxorubicin (Pegylated Liposomal Doxorubicin (PLD)*~*standard of care"
88980642|NCT05464563|Experimental|Patient group|"Patients have electroencephalogram records during :~a phase of rest;~a task of self-compassion~a task of empathy."
89601929|NCT05736016|Sham Comparator|Sham Therapy|Sham comparator arm will undergo a 6-week in-patient rehabilitation aimed at: pharmacologic and non-pharmacologic pain management, improvement of vascular function, cardiopulmonary function, functions of skeletal muscles, range of motion and stability of peripheral joints, gait function, body position, with treadmill walking training being a mandatory part of the program . The rehabilitation program will also address individual needs with psychotherapy and vocational therapy. Follow-up period will be 6 weeks. For the treatment and follow-up the control arm will be provided with individually made sham insoles to be used during all therapeutic and other everyday activities.
89601930|NCT05732142|Experimental|PIVoT|Gender-transformative family planning counseling and contraception provision at the time of infant vaccination
89601931|NCT05732142|No Intervention|Standard of care|Standard infant vaccination and family planning referrals
89601932|NCT05725837|Placebo Comparator|Placebo|40mg, single dose a day, by mouth or enteric tube
89601933|NCT05725837|Experimental|Paroxetine|40mg, single dose a day, by mouth or enteric tube
89601934|NCT05719935||KinematX patients|Patients undergoing total wrist replacement with the KinematX implant.
89601935|NCT05716516|Other|Treatment Arm|Treatment Phase: Patients will be treated with 17b-estradiol until disease progression. At this point, the patient will end protocol therapy
89601936|NCT05703061|No Intervention|Normal Sleep Condition Group|This group will not partake in the intervention, they will sleep the normal amount that they do on a regular basis. Participants will wear a hip physical activity monitor and a wrist actigraph to measure sleep.
89601937|NCT05703061|Experimental|10-hour Time in Bed Group|This group will partake in the intervention of increasing time in bed to 10 hours per night. Participants will wear a hip physical activity monitor and a wrist actigraph to measure sleep.
89601938|NCT05702424|Experimental|IGM-7354 Single-Agent Dose Escalation|IGM-7354 will be administered intravenously as a single agent.
89601939|NCT05702424|Experimental|IGM-7354 Single-Agent Dose Expansion Serial Biopsy|IGM-7354 will be administered intravenously as a single agent and patients will undergo pre-treatment and on-treatment biopsies.
89601940|NCT05695885|Experimental|STEPS|14 session counseling targeting adult independence skills
89601941|NCT05695885|Other|Control|Services as usual
89601942|NCT05687292||CDSS Ventilator Weaning Group|This group will be exposed to the CDSS to inform weaning and discontinuation of mechanical ventilation.
89601943|NCT05686499|Active Comparator|High Fidelity (HF) Arm|The HF simulator will be Limbs and Things Colonoscopy Training Model product KKM40.
89601944|NCT05686499|Experimental|Low Fidelity (LF) Arm|The LF simulator will be made in Nigeria, based on low fidelity models that have been published in the literature
89601945|NCT05678439|Experimental|sesame extract|"Dietary supplement: sesame extract (contains sesamin 37-56mg per capsule)~This group will be given supplements for 8 weeks."
89601946|NCT05678439|Placebo Comparator|placebo|Placebo treatment ( identical capsules containing Lactose, Silica, Magnesium Stearate, Gelatin)
89601947|NCT05667207|Experimental|Point-of-care microscopy and dipstick guided management|GPs whose practice is allocated to the intervention will have their management guided by POCTs, namely phase-contrast microscopy and urinary dipsticks for all patients consenting for participation.
89601948|NCT05667207|No Intervention|Usual care|Practices in the control arm will not have their management guided by POCTs. They will perform usual care. The treatment decision is usually based on symptoms and dip-stick test results (i.e., erythrocytes, leukocytes, nitrites).
89601949|NCT05658484|Experimental|Dimethyl fumarate (DMF)|Participants will receive DMF 120 mg capsules, orally, twice daily (BID) for the first 7 days, followed by 240 mg BID (maintenance dose) after 7 days for up to Week 48.
89601950|NCT05658198||Unvaccinated patients|Patients who are unvaccinated against HPV when they arrive at Plan A.
89601951|NCT05653882|Experimental|AB248 Monotherapy Dose-Escalation|AB248 will be administered intravenously as a single agent
89601952|NCT05653882|Experimental|AB248 + Pembrolizumab Combination Dose-Escalation|AB248 and pembrolizumab will be administered intravenously
89601953|NCT05653882|Experimental|AB248 Monotherapy Indication Expansion|AB248 will be administered intravenously as a single agent in disease specific cohorts
89210303|NCT04035720|Experimental|Quantitative risk estimation|Participants will be exposed to case-scenarios. Each case scenario provides a description of the current clinical situation (e.g. patient age, current treatment, number of relapses, current EDSS, MRI findings, etc). In addition, participants will see a squared box indicating the probability of risk progression (20%, 25%, 85%, 90%). This information may or may not be accurate to reflect potential errors of risk prediction tools.
88980643|NCT05464563|Experimental|Control group|"Healthy volunteers have electroencephalogram records during :~a phase of rest;~a task of self-compassion~a task of empathy."
89601954|NCT05653882|Experimental|AB248 + Pembrolizumab Combination Indication Expansion|AB248 and pembrolizumab will be administered intravenously in disease specific cohorts
89601955|NCT05620329||Pleural Fluid Registry|Any subject who has pleural fluid buildup from lung cancer, breast cancer, or lung infection
89601956|NCT05613985|Active Comparator|Arm A: Usual Care alone|
89601957|NCT05613985|Experimental|Arm B: system VULNOFAST® plus / VULNOLIGHT® in addition to Usual Care|
89601958|NCT05609110|Active Comparator|RIC group|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mmHg.
89601959|NCT05609110|Placebo Comparator|Sham RIC group|Sham remote ischemic conditioning (Sham RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mm Hg.
89601960|NCT05598723|Active Comparator|OnabotulinumtoxinA (BOTOX®)|OnabotulinumtoxinA (BOTOX®) Group: Administration consists of 31 injections (5 onabotulinumtoxinA (BOTOX®) units per injection, for a total of 155units) in the head and neck at two time points (12 weeks apart). Injection sites include the forehead, temples, back of the head, upper neck, and the junction of the shoulder and the neck. A very small (e.g., 30-gauge), very sharp needle will be used to perform the injections.
89601961|NCT05598723|Experimental|IncobotulinumtoxinA (XEOMIN®)|IncobotulinumtoxinA (XEOMIN®) Group: Administration consists of 31 injections (5 incobotulinumtoxinA (XEOMIN®) units per injection, for a total of 155 units) in the head and neck at two time points (12 weeks apart). Injection sites include the forehead, temples, back of the head, upper neck, and the junction of the shoulder and the neck. A very small (e.g., 30-gauge), very sharp needle will be used to perform the injections.
89601962|NCT05595382|Experimental|Emotional Group|Participants will be randomly assigned to receive an emotional or rational appeal, stratified by sex.
89601963|NCT05595382|Experimental|Rational Group|Participants will be randomly assigned to receive an emotional or rational appeal, stratified by sex.
89601964|NCT05592158|Experimental|Test|Amnion-chorion membrane with collagen plug
89601965|NCT05592158|Active Comparator|Control|Collagen plug
89608610|NCT01838551|Experimental|Levoketoconazole DL6|Levoketoconazole Tablets Dose Level 6 Twice Daily
89608611|NCT01838551|Experimental|Levoketoconazole DL7|Levoketoconazole Tablets Dose Level 7 Twice Daily
89601966|NCT05589194|Experimental|Intervention Group|After the first interview with the patients in the intervention group, a phone call will be made for regarding the implementation of nursing interventions based on the Comfort Theory, and they will be informed about the planned dates for the implementation. The implementation phase of nursing interventions based on Comfort Theory will be carried out for 6 weeks at the Communication Laboratory of the Faculty of Nursing of Akdeniz University on the planned dates with the patients. In addition, a handbook will be given to the patients at the beginning of the practice, and the Home Yoga Diary in the handbook will be expected to be filled in daily by the patients during the research. Immediately after the implementation of the nursing interventions based on Comfort Theory (week 6), patients will be asked to fill in ISI, IQO-L, and the Urinary Incontinence and Frequency Comfort Scale. During this whole process, patients will continue their planned routine care and treatment.
89601967|NCT05589194|No Intervention|Control Group|After the first interview with the patients in the control group, the routine care and treatment practices planned by the polyclinic physician and nurse will continue. No additional intervention is planned for the patients in this group. A new interview will be planned with the patients in the control group 6 weeks after the first interview, and they will be asked to fill in the ISI, IQO-L, and the Urinary Incontinence and Frequency Comfort Scale.
89601968|NCT05577403|Experimental|Experimental Group|Mulligan's mobilization with movement added isometric strength training will be given 3 days a week for six weeks.
89601969|NCT05577403|Active Comparator|Control Group|Mobilization-added isometric strength training will be given 3 days a week for six weeks.
89601970|NCT05577000|Experimental|Dose Escalation (150 x 10^6 CAR + T cells/ infusion)|Participants will undergo apheresis with collection of autologous peripheral blood mononuclear cells that will be used to generate CAR-T cells. After successful generation of the anti-BCMA CAR-T cells, participants will undergo lymphodepleting chemotherapy with fludarabine and cyclophosphamide followed by 2-5 days of rest. A single infusion of anti-BCMA CAR-T cells at the starting dose of 150 x 10^6 flat dose will then be given on Day 1.
89601971|NCT05577000|Experimental|Dose Escalation (450 x 10^6 CAR + T cells/ infusion)|Participants will undergo apheresis with collection of autologous peripheral blood mononuclear cells that will be used to generate CAR-T cells. After successful generation of the anti-BCMA CAR-T cells, and no dose limiting toxicities were reported for the previous dose level, participants will undergo lymphodepleting chemotherapy with fludarabine and cyclophosphamide followed by 2-5 days of rest. A single infusion of anti-BCMA CAR-T cells at the next highest dose of 450 x 10^6 flat dose will then be given on Day 1.
89601972|NCT05577000|Experimental|Dose Escalation (600 x 10^6 CAR + T cells/ infusion)|Participants will undergo apheresis with collection of autologous peripheral blood mononuclear cells that will be used to generate CAR-T cells. After successful generation of the anti-BCMA CAR-T cells, and no dose limiting toxicities were reported for the previous dose level, participants will undergo lymphodepleting chemotherapy with fludarabine and cyclophosphamide followed by 2-5 days of rest. A single infusion of anti-BCMA CAR-T cells at the next highest dose of 600 x 10^6 flat dose will then be given on Day 1.
89601973|NCT05577000|Experimental|Dose Expansion: Maximum Tolerated Dose (MTD)|Participants will undergo apheresis with collection of autologous peripheral blood mononuclear cells that will be used to generate CAR-T cells. After successful generation of the anti-BCMA CAR-T cells, and no dose limiting toxicities were reported for the previous dose level, participants will undergo lymphodepleting chemotherapy with fludarabine and cyclophosphamide followed by 2-5 days of rest. A single infusion of anti-BCMA CAR-T cells at the MTD will then be given on Day 1.
89608612|NCT03021369|Active Comparator|Pleural drainage system Medela|These patients receive the digital Medela system
89608613|NCT03021369|Active Comparator|Pleural drainage system Ocean|These patients receive the analogue Maquet system
89608614|NCT04142853|Experimental|Persons with MS, dance group|
89608615|NCT04142853|Active Comparator|Persons with MS, art group|
88980644|NCT05461196|Experimental|Mobile App + BP|Patients use a mobile application in addition to electronic monitoring blister packs for pain medications.
88980645|NCT05461196|No Intervention|BP|Patients' pain medication is in electronic monitoring blister packs.
88980646|NCT05461196|Experimental|Mobile App Only|Patients use a mobile application.
88980647|NCT05461196|No Intervention|Control|
88980648|NCT05447533|Other|Geriatric tailored assessment and intervention|"The geriatric tailored intervention consists of the following components:~Comprehensive Geriatric Assessment~Continued geriatric care during 8 weeks follow-up or until cured."
88980649|NCT05447533|Active Comparator|Standard care|Standard care: Patients are not contacted by the geriatric team. They receive usual treatment at the treating physician's discretion. Standard care of Clostridioides difficile infection in Denmark is described in the National clinical guideline.
89608616|NCT05580081|Experimental|i-CAN|18 weeks of access to the online consulting platform
89608617|NCT05580081|No Intervention|waitlist control|No offered support or consultation
89608618|NCT05587413|Experimental|treatment group|
89608619|NCT05587413|No Intervention|control group|
88980650|NCT05447325|Experimental|Message exposure (sequence: regular PSAs then flavor PSAs)|Participants randomly assigned to this arm will receive weekly emails and text messages of regular PSAs (i.e., focused in general on the negative consequences of vaping) for the first 6 months of the study, and will then receive weekly emails and text messages of flavor PSAs (i.e., focused specifically on harms and negative consequences associated with vaping flavored e-cigarette products) for the second 6 months of the study.
88980651|NCT05447325|Experimental|Message exposure (sequence: flavor PSAs then regular PSAs)|Participants randomly assigned to this arm will receive weekly emails and text messages of flavor PSAs (i.e., focused specifically on harms and negative consequences associated with vaping flavored e-cigarette products) for the first 6 months of the study, and will then receive weekly emails and text messages of regular PSAs (i.e., focused in general on the negative consequences of vaping) for the second 6 months of the study.
88980652|NCT05447325|Experimental|No message exposure (control condition)|Participants will not be receiving any PSA exposure over the 12 months.
88980653|NCT05446714|Active Comparator|conventional hyrax|CH 4 BANDS for expansion of maxilla and observation improvement of the air way
88980654|NCT05446714|Active Comparator|Hybrid hyrax|HH 2 BANDS for expansion of maxilla and observation improvement of the air way
88980655|NCT05446714|Active Comparator|Maxillary skeletal expander|MSE 2 BANDS AND 4 for expansion of maxilla and observation improvement of the air way
88980656|NCT05445739|Other|The effect of an online exercise course on the increase of elders' regular exercise intention|The effect of an online exercise course on the increase of elders' regular exercise intention.
88980657|NCT05435066||Arm 1 - cancer group|Arm 1 - newly diagnosed cancer subjects
88980658|NCT05435066||Arm 2 - non cancer group|Arm 2 - non-cancer subjects
88980659|NCT05433701|Active Comparator|RFA group|"RFA are performed under local anesthesia or monitored anesthesia care with either a 15-gause or 17-gause internally cooled electrode, depending on the size of the tumor.~RFA procedures are continued by modifying the output power based on the location and size of the tumor until the entire tumor and border area sizes of greater than 0.5 cm are included in the detected target lesion on ultrasound or CT."
88980660|NCT05433701|Experimental|SBRT group|A total dose of 45 Gy is presecribed using 15 Gy per fraction over 3 consecutive days.
88980661|NCT05433051|Active Comparator|Buccal miniscrews with TPA|active comparator double center
88980662|NCT05433051|Active Comparator|vertical holding appliance|active comparator double center
88980663|NCT05426083||Physiological Assessment|Prospective physiological assessment of LV work and oxygen consumption in patients with SCAI D/E cardiogenic shock due to acute coronary syndrome treated with peripheral VA-ECMO support.
88980664|NCT05425641|Experimental|Goal Setting and Action Planning and Self-Monitoring and Feedback|Participants in this arm will receive daily text messages that include the Goal Setting, Action Planning, Self-Monitoring, and Feedback behavior change techniques (BCTs) with the goal of increasing daily walking by 1,000 more steps than their baseline average step count.
89517966|NCT04461353|Active Comparator|Hydroxychloroquine Sulfate|The study drug AHCQ will be administered by inhalation through the mouth. The starting dose will be 20 mg (Cohort A1) with a proposed subsequent dose of 50 mg (Cohort A2). At each dose level 8 participants (including at least 3 female participants and 3 participants older than 50 years old) will be enrolled. Six participants will receive the active study drug and 2 participants will receive placebo.
89517967|NCT04461353|Placebo Comparator|Placebo|Placebo will be administered by inhalation through the mouth. It will be administered in both Cohort A1 and Cohort A2. Six participants will receive the active study drug and 2 participants will receive placebo.
89517968|NCT05191615|Experimental|Intervention Group|"The proposed study will be implemented as an intervention study at two levels within the organization, managerial and registered nurses. The intervention comprises three major phases: a pre-intervention phase, an implementation-intervention phase, and a post-intervention phase. The interventions will be provided face-to-face by trained interventionists. At baseline, all participants will complete questionnaires and get labs completed, blood pressure checked, and weight/height measured.~Consists of two main parts. In the first part, both managers and employees will be trained in the principles of SDT and JD-R. For managers, particular attention will be paid to the provision of need support and work values. For employees, particular attention will be paid to employees' opportunities for job crafting and promoting their basic psychological need satisfaction at work."
89517969|NCT05191615|No Intervention|Control Group|Participants randomized to the control group will complete the baseline questionnaires and lab tests at baseline and three follow-up times. Lab values will be collected using the current standard of care and American Heart Association (AHA) guidelines (2019).
89517970|NCT03284021|Other|Fraxel laser|
89517971|NCT03491189|Active Comparator|Lag screw fixation|Lag screw fixation
89517972|NCT03491189|Active Comparator|Helical Blade fixation|Helical Blade fixation
89517973|NCT03491111|Experimental|IMT & EMT|Interventions: Respiratory muscle training for EMT+IMT. Respiratory muscle training for IMT (Inspiratory muscle training)+EMT (Expiratory muscle training). Respiratory muscle breathing training for patients with inspiratory muscle weakness and swallowing disturbance (MIP less than 70% of normal range).
89517974|NCT03491111|Active Comparator|Control group|Intervention: Non-training group, receive regular rehabilitation. All participants will receive usual rehabilitation care including body positioning instruction, postural correction, breathing control, cough maneuver, respiratory muscle stretch, chest wall mobility exercise and ventilation, fatigue management.
89517975|NCT03491111|Experimental|EMT group|Intervention: Respiratory muscle training for EMT. Respiratory muscle breathing training for swallowing disturbance. EMT for patients with swallowing disturbance will commence from 15% to 75% of threshold load of an individual's MEP.
89517976|NCT03491033||advanced-stage ovarian cancer group|250 patients with pathologically confirmed epithelial ovarian cancer who received at least 1 cycle of NAC at Yonsei Cancer Hospital from 2006 to 2017.
89517977|NCT03490955|Sham Comparator|Salad|Subjects will consume a vegetable salad without dressing one time in the morning.
89517978|NCT03490955|Active Comparator|Salad dressing (canola oil)|Subjects will consume a vegetable salad with dressing (canola oil) one time in the morning
89517979|NCT03490955|Active Comparator|black pepper|Subjects will consume a vegetable salad without dressing (canola oil) but with black pepper one time in the morning
89517980|NCT03490955|Active Comparator|Salad dressing (canola oil) and black pepper|Subjects will consume a vegetable salad with dressing (canola oil) and with black pepper one time in the morning
89517981|NCT03490955|Active Comparator|Salad dressing (olive oil) and black pepper|Subjects will consume a vegetable salad with dressing (olive oil) and with black pepper one time in the morning
89517982|NCT03490955|Active Comparator|Salad dressing (corn oil) and black pepper|Subjects will consume a vegetable salad with dressing (corn oil) and with black pepper one time in the morning
89517983|NCT03490955|Active Comparator|Salad dressing (sunflower oil) and black pepper|Subjects will consume a vegetable salad with dressing (sunflower oil) and with black pepper one time in the morning
89517984|NCT03490955|Active Comparator|Salad dressing (flaxseed oil) and black pepper|Subjects will consume a vegetable salad with dressing (flaxseed oil) and with black pepper one time in the morning
89517985|NCT03779243|Experimental|5mg Melatonin and Sleep Education|Participants will take 5mg Melatonin nightly, 1 hour before bedtime and be provided educational materials to improve sleep hygiene. They will have study visits in clinic as part of standard-of-care at 6 weeks and 12 weeks. They will complete Pittsburgh Sleep Quality Index and SF-36 Quality of Life questionnaires at enrollment and at their clinic visits.
89601974|NCT05572554|Experimental|Foot Bath Group|"This group of elderly people were taught the foot bath practically by a researcher at the pre-study meeting and were given the Foot Bath Information Brochure and a personalized water thermometer. The other researcher administered the Elderly Information Form and PSQI to all elderly people before the study using individual interviews lasting approximately 15 minutes and pen and paper method. The elderly were asked to soak their feet in the water in a marked plastic container with a depth of 10 centimeters and a temperature of 41-42°C for 20 minutes up to their ankles 50 minutes before normal sleeping hours every night for 8 weeks. In addition, the PSQI, which provides information about sleep quality, type, and severity of sleep disturbance, was applied to the elderly before the study (pretest), 4th week (interim measurement/1st measurement), and at the end of the study (8th week) for a total of 3 times during 8 weeks."
89601975|NCT05572554|No Intervention|Control Group|No application was made to the elderly in this group. Only the PSQI, which gives information about sleep quality, type, and severity of sleep disturbance, was administered to the elderly before the study (pretest), at the 4th week (interim measurement/1st measurement), and at the end of the study (8th week) for a total of 3 times for 8 weeks.
89601976|NCT05571228|Experimental|Internalized stigma group|BOOST is an 8 session group intervention, delivered over 4 weeks. The program uses evidence based therapeutic techniques and integrates cognitive behavioural therapy and peer support to reduce or prevent the internalization of stigma in early psychosis. Sessions 1-4 focus on dispelling stigmatizing myths about psychosis and evaluating the accuracy of group members or societies stigmatizing beliefs in order to normalize experiences associated with and reactions to the symptoms of psychosis. Sessions 5-8 teach behavioural approaches for self-empowerment through social skills training, development of assertiveness skills, and goal setting. Role-plays that are specific to young people with psychosis, which were co-developed with people with lived experience, provide opportunities to practice these skills in session. During role plays, participants monitor stigmatizing beliefs that may interfere with communication or pursuing goals.
89601977|NCT05561595|Experimental|Healing HEARTS Intervention|The Healing Health-Related Stigma (Healing HEARTS) intervention will provide group telehealth sessions adapted from prior disease-specific interventions for internalized stigma and from standard techniques and structures used in evidence-based cognitive-behavioral therapies. Fifty-minute sessions will be delivered weekly for 12 weeks, followed by 2 every-other-week and 2 monthly sessions. Groups will consist of 8-10 participants and will be led by a doctoral- or masters-level clinician in clinical or counseling psychology or social work. Handouts and homework assignments will be used as part of the group meetings. All group sessions will be conducted remotely using telehealth technology.
89601978|NCT05561595|Active Comparator|Peer Support|The peer support condition will provide group telehealth sessions without any tailored stigma content. Group sessions will be 50 minutes and will meet weekly for 12 weeks, followed by 2 every-other-week and 2 monthly sessions. Groups will consist of 8-10 participants and will be led by a doctoral- or masters-level clinician in clinical or counseling psychology or social work. All group sessions will be conducted remotely using telehealth technology.
89601979|NCT05561595|No Intervention|Waitlist Control|The waitlist control group will not receive any active intervention until after completing week 12 and week 26 assessments. Participants will receive periodical updates and reminders from study staff to enhance retention. After assessments are completed, participants will be provided with 12 weeks of the Healing HEARTS intervention.
89601980|NCT05553327|No Intervention|Control|This group of patients will not receive a pre-hab program
89601981|NCT05553327|Experimental|Multimodal prehabilitation|This patients will receive the pre-hab program
89601982|NCT05543629|Experimental|Part A: BMS-986442 + Nivolumab|
89601983|NCT05543629|Experimental|Part B1: BMS-986442 + Nivolumab|Second line (2L) + Post-immuno-oncology (IO)/Platinum-Doublet Non-small cell lung cancer (NSCLC)
89601984|NCT05543629|Experimental|Part B2: BMS-986442 + Nivolumab|Post IO Gastric Cancer/Gastroesophageal Junction and Post-IO squamous cell carcinoma of the head and neck (SCCHN)
89601985|NCT05543629|Experimental|Part C: BMS-986442 + Nivolumab + Docetaxel|
89601986|NCT05543629|Experimental|Part D: BMS-986442 + Nivolumab + Carboplatin + Pemetrexed|
89601987|NCT05543629|Experimental|Part E: BMS-986442 + Nivolumab + Carboplatin + Paclitaxel|
89601988|NCT05517265||first-line therapy|Patients enrolled for first-line acalabrutinib (+/- obinutuzumab).
89601989|NCT05517265||later-line therapy|Pre-treated patients enrolled for later-line acalbrutinib therapy.
89601990|NCT05499520|No Intervention|No Message Condition|Participants will receive no anti-smoking messages. They will receive the threat message during the baseline survey. Outcomes will be measured before and immediately after seeing the threat message, and at 1 month.
89601991|NCT05499520|Experimental|Single Message Immediate|Participants will receive a single anti-smoking message followed by the threat message during the baseline survey. Outcomes will be measured before seeing the anti-smoking message and threat message, immediately after seeing the threat message, and at 1 month.
89601992|NCT05499520|Experimental|Single Message 1 Week Delay|Participants will receive a single anti-smoking message during the baseline survey, followed by the threat message one week later in a separate survey. Outcomes will be measured before seeing the anti-smoking message at baseline, immediately after seeing the threat message at 1 week, and at 1 month.
89601993|NCT05499520|Experimental|Single Message 1 Month Delay|Participants will receive a single anti-smoking message during the baseline survey, followed by the threat message one month later in a separate survey. Outcomes will be measured before seeing the anti-smoking message at baseline, and immediately after seeing the threat message at 1 month.
88980665|NCT05425641|Experimental|Goal Setting and Action Planning and Feedback|Participants in this arm will receive daily text messages that include the Goal Setting, Action Planning, and Feedback behavior change techniques (BCTs) with the goal of increasing daily walking by 1,000 more steps than their baseline average step count.
88980666|NCT05425641|Experimental|Goal Setting and Self-Monitoring and Feedback|Participants in this arm will receive daily text messages that include the Goal Setting, Self-Monitoring, and Feedback behavior change techniques (BCTs) with the goal of increasing daily walking by 1,000 more steps than their baseline average step count.
88980667|NCT05425641|Experimental|Goal Setting and Action Planning, and Self-Monitoring|Participants in this arm will receive daily text messages that include the Goal Setting, Action Planning, and Self-Monitoring behavior change techniques (BCTs) with the goal of increasing daily walking by 1,000 more steps than their baseline average step count.
88980668|NCT05425641|Experimental|Action Planning and Self-Monitoring, and Feedback|Participants in this arm will receive daily text messages that include the Action Planning, Self-Monitoring, and Feedback behavior change techniques (BCTs) with the goal of increasing daily walking by 1,000 more steps than their baseline average step count.
88980669|NCT05425641|Experimental|Goal Setting and Action Planning|Participants in this arm will receive daily text messages that include the Goal Setting and Action Planning behavior change techniques (BCTs) with the goal of increasing daily walking by 1,000 more steps than their baseline average step count.
88980670|NCT05425641|Experimental|Goal Setting and Self-Monitoring|Participants in this arm will receive daily text messages that include the Goal Setting and Self-Monitoring behavior change techniques (BCTs) with the goal of increasing daily walking by 1,000 more steps than their baseline average step count.
88980671|NCT05425641|Experimental|Goal Setting and Feedback|Participants in this arm will receive daily text messages that include the Goal Setting and Feedback behavior change techniques (BCTs) with the goal of increasing daily walking by 1,000 more steps than their baseline average step count.
88980672|NCT05425641|Experimental|Action Planning and Self-Monitoring|Participants in this arm will receive daily text messages that include the Action Planning and Self-Monitoring behavior change techniques (BCTs) with the goal of increasing daily walking by 1,000 more steps than their baseline average step count.
88980673|NCT05425641|Experimental|Action Planning and Feedback|Participants in this arm will receive daily text messages that include the Action Planning and Feedback behavior change techniques (BCTs) with the goal of increasing daily walking by 1,000 more steps than their baseline average step count.
88980674|NCT05425641|Experimental|Self-Monitoring and Feedback|Participants in this arm will receive daily text messages that include the Self-Monitoring and Feedback behavior change techniques (BCTs) with the goal of increasing daily walking by 1,000 more steps than their baseline average step count.
88980675|NCT05425641|Experimental|Goal Setting|Participants in this arm will receive daily text messages with the Goal Setting behavior change technique (BCT) with the goal of increasing daily walking by 1,000 more steps than their baseline average step count.
88980676|NCT05425641|Experimental|Action Planning|Participants in this arm will receive daily text messages with the Action Planning behavior change technique (BCT) with the goal of increasing daily walking by 1,000 more steps than their baseline average step count.
88980677|NCT05425641|Experimental|Self-Monitoring|Participants in this arm will receive daily text messages with the Self-Monitoring behavior change technique (BCT) with the goal of increasing daily walking by 1,000 more steps than their baseline average step count.
88980678|NCT05425641|Experimental|Feedback|Participants in this arm will receive daily text messages with the Feedback behavior change technique (BCT) with the goal of increasing daily walking by 1,000 more steps than their baseline average step count.
88980679|NCT05425641|No Intervention|Control|"Participants in this arm will not receive any daily BCT text messages. Instead, individuals receive daily text messages with the text Please acknowledge that you have received this text message."
88980680|NCT05424471|Experimental|Family Spirit Nurture (FSN)|Intervention group participants receive 1 Family Spirit Nurture lesson taught by Family Health Coaches. Mothers will receive the lesson within 1-2 weeks of completing the 4-year Follow-up Assessment. The lesson focuses on age-appropriate parental feeding practices, including snack routines, avoidance of SSBs and promotion of water consumption. The lesson is highly visual and interactive, and incorporates cultural teachings related to child feeding and nutrition that support aims. The Family Health Coaches also provide social support and will facilitate referrals to community resources.
88980681|NCT05424471|Other|Control Vehicle Safety|Control group participants receive 1 lesson with vehicle safety information, taught by Family Health Coaches. Mothers will receive the lesson within 1-2 weeks of completing the 4-year Follow-up Assessment. The Family Health Coaches also provide social support and will facilitate referrals to community resources.
89601994|NCT05499520|Experimental|Single Message 1 Month Delay, Repeated Exposure|Participants will receive a single anti-smoking message during the baseline survey, followed by the threat message one month later. Participants will also receive repeated exposures of a single anti-smoking message at 1, 2, and 3 weeks in separate surveys. Outcomes will be measured before seeing the anti-smoking message at baseline and immediately after seeing the threat message at 1 month.
89601995|NCT05499520|Experimental|Three Messages Immediate|Participants will receive three anti-smoking messages, followed by the threat message during the baseline survey. Outcomes will be measured before seeing the anti-smoking messages and threat message, immediately after seeing the threat message, and at 1 month.
88980682|NCT05424445|Experimental|Cytotec®|IOL with misoprostol oral solution (Cytotec®) 25 ug every second hour, up to eight doses, or until painful contractions are obtained. Thereafter IOL will proceed according to clinical practice.
88980683|NCT05424445|Active Comparator|Angusta®|IOL with misoprostol oral tablets (Angusta®) 25 ug every second hour, up to eight doses, or until painful contractions are obtained. Thereafter IOL will proceed according to clinical practice.
88980684|NCT05422729|Experimental|Personalised mHeatlh-supported coaching programme|Three monthly individual consultation session, supported with a specific mobile application.
88980685|NCT05422729|Active Comparator|Traditional in-person health coaching programme|Three monthly individual consultation sessions.
88980686|NCT05421325|Experimental|QBKPN SSI|QBKPN SSI (0.1 mL) by subcutaneous injection 3 times per week (Monday, Wednesday & Friday) for 16 weeks
89601996|NCT05499520|Experimental|Three Messages 1 Week Delay|Participants will receive three anti-smoking messages during the baseline survey, followed by the threat message one week later in a separate survey. Outcomes will be measured before seeing the anti-smoking messages at baseline, immediately after seeing the threat message at 1 week, and at 1 month.
89601997|NCT05499520|Experimental|Three Messages 1 Month Delay|Participants will receive three anti-smoking messages during the baseline survey, followed by the threat message one month later in a separate survey. Outcomes will be measured before seeing the anti-smoking messages at baseline, and immediately after seeing the threat message at 1 month.
89601998|NCT05499520|Experimental|Three Messages 1 Month Delay Repeat Exposure|Participants will receive three anti-smoking messages during the baseline survey, followed by the threat message one month later. Participants will also receive repeated exposures of three anti-smoking messages at 1, 2, and 3 weeks in separate surveys. Outcomes will be measured before seeing the anti-smoking messages at baseline and immediately after seeing the threat message at 1 month.
89601999|NCT05499143||Parents of children with DCD or related movement difficulties|
89602000|NCT05487170|Experimental|RNK05047|Dose-escalation of RNK05047 IV infusion
89602001|NCT05480761|Experimental|Single Arm Open Labeled Commercial Sucraid|All subjects will complete a 7-day treatment period of open-labeled FDA approved commercial Sucraid.
89602002|NCT05469165|Experimental|Cyproheptadine 4 Mg Oral Tablet|Participants will receive cyproheptadine 4mg tablet orally three times a day for three months, with a daily increase of 4mg/dose if the previous dose was well tolerated, up to 0.5 mg/kg/day.
89602003|NCT05469165|Placebo Comparator|Placebo|Participants will receive a matched placebo orally three times a day for 3 months. Daily titration similar to the treatment arm.
89602004|NCT05459831|Active Comparator|Pulmonary vein isolation with 50W energy setting|In this group of subjects, the initial pulmonary vein isolation procedure will be performed using 50W radiofrequency energy. This power setting will be used for all the ablation points.
89602005|NCT05459831|Active Comparator|Pulmonary vein isolation with 90W energy setting|In this group of subjects, the initial pulmonary vein isolation procedure will be performed using 90W radiofrequency energy. This power setting will be used for all the ablation points.
89602006|NCT05458102|Experimental|Vesatolimod (VES) + Cobicistat (COBI) + Voriconazole (VOR)|"Participants will receive:~In Period 1 (duration 1 day): a single dose of VES 2 mg on Day 1~In Period 2 (duration 5 days): COBI 150 mg once daily on Days 1 to 5; a single dose of VES 2 mg will be coadministered on Day 2~In Period 3 (duration 6 days): a loading dose of VOR 400 mg twice daily on Day 1, then VOR 200 mg twice daily on Days 2 to 6; a single dose of VES 2 mg will be coadministered in the morning on Day 3~There will be a washout period of 7 to 14 days between treatments in Period 1 Day 1 and Period 2 Day 1 and a washout period of 14 to 21 days between treatments in Period 2 Day 5 and Period 3 Day 1. Participants should inform the site of any adverse event (AE) during the washout period."
89602007|NCT05458102|Experimental|Vesatolimod (VES) + Rifabutin (RFB)|"Participants will receive:~In Period 1 (duration 1 day): participants will receive a single dose of VES 6 mg on Day 1~In Period 2 (duration 9 days): participants will receive RFB 300 mg once daily on Days 1 to 9; a single dose of VES 6 mg will be coadministered on Day 6~There will be a washout period of 7 to 14 days between treatments in Period 1 Day 1 and Period 2 Day 1. Participants should inform the site of any AE during the washout period."
89602008|NCT05449067|Experimental|Automated Peritoneal Dialysis (APD)|In APD, a mechanical device is employed to assist in the delivery and drainage of dialysate. Continuous Cycling Peritoneal Dialysis (CCPD)means patients receive four automated exchanges of 2 liters of dialysate each over 10 hours a night, with 2 liters left in the peritoneal cavity during the daytime. The overall dialysate volume is 10 liters.
89602009|NCT05449067|Active Comparator|Continuous Ambulatory Peritoneal Dialysis (CAPD)|CAPD involves the manual instillation of 2 liters(L) of dialysis fluid into the peritoneal cavity, four times a day. This typically means three short dwells during the daytime and a long dwell overnight. The total volume of dialysate is 8 liters.
89602010|NCT05440643|Experimental|Cohort 1|Adults and adolescents - peanut SLIT-tablet once daily for 2 weeks
89602011|NCT05440643|Experimental|Cohort 2|Adults and adolescents - peanut SLIT-tablet once daily for 2 weeks
89602012|NCT05440643|Experimental|Cohort 3|Adults and adolescents - peanut SLIT-tablet once daily for 2 weeks
89602013|NCT05440643|Experimental|Cohort 4|Adults and adolescents - peanut SLIT-tablet once daily for 2 weeks
89602014|NCT05440643|Experimental|Cohort 5|Adults and adolescents - peanut SLIT-tablet once daily for 2 weeks
88980687|NCT05421325|Placebo Comparator|Placebo|Placebo (Normal Saline) (0.1 mL) by subcutaneous injection 3 times per week (Monday, Wednesday & Friday) for 16 weeks
88980688|NCT05420766|Experimental|Shortened Sleep|In this 4-week sleep protocol, children in this experimental condition follow a Stabilized Sleep schedule (i.e., their usual bed time) during weeks 1, 3 and 4. During week 2, they follow a Shortened Sleep schedule, during which they go to bed 90 later than is typical.
88980689|NCT05420766|Active Comparator|Usual Sleep Schedule|In this control arm of the 4-week sleep protocol, children follow the Stabilized Sleep schedule for all 4 weeks.
88980690|NCT05420545|Experimental|Intravenous of CD70-targeted CAR-T|Infusion of CD70-targeted CAR-T cells by dose of 1-10x106 cells/kg
89602015|NCT05440643|Experimental|Cohort 6|Adults and adolescents - UDR with once daily peanut SLIT-tablet
89602016|NCT05440643|Experimental|Cohort 7|Adolescents - UDR with once daily peanut SLIT-tablet
89602017|NCT05440643|Experimental|Cohort 8|Children - UDR with once daily peanut SLIT-tablet
89602018|NCT05440643|Experimental|Cohort 9|Highly sensitized Adults/Adolescents - UDR with once daily peanut SLIT-tablet
89602019|NCT05440643|Experimental|Cohort 10|Highly sensitized Children - UDR with once daily peanut SLIT-tablet
89602020|NCT05439980||CKD aged 8-<13 years|8-<13 years n = 25
89602021|NCT05439980||CKD aged 13-18 years|13-18 years n = 25
89602022|NCT05439980||Parents/caregivers|Parent/caregivers of children and young people with CKD 4-5D n=50
89602023|NCT05431413|Placebo Comparator|Control group: Fluoxetine and Placebo|Cap Fluoxetin 20mg OD for four weeks and injection 100ml normal saline(NS) BD for two weeks.
89602024|NCT05431413|Experimental|Experimental group: Fluoxetine and ATP|Cap Fluoxetin 20mg OD for four weeks and injection ATP 100mg in NS BD for two weeks.
89602025|NCT05431413|Active Comparator|Control group: Fluoxetine and Phosphocreatine|Cap Fluoxetin 20mg OD for four weeks and injection phosphocreatine(1g) in NS BD for two weeks.
89602026|NCT05417334|Active Comparator|ON Radiofrequency treatment|Application of the technique in the intervention group (activated resistive capacitive monopolar radiofrequency therapy): the intervention group will receive treatment with activated RF, with the electrode at a medium intensity for 20 minutes per session during a total of 5 sessions, the 3 first ones held weekly and the 2 last ones every other week.
89602027|NCT05417334|Sham Comparator|Sham Radiofrequency treatment|Application of the technique in the intervention group (inactive resistive capacitive monopolar radiofrequency therapy): the intervention group will receive treatment with inactive RF, with the electrode at a medium intensity for 20 minutes per session during a total of 5 sessions, the 3 first ones held weekly and the 2 last ones every other week.
89602028|NCT05413590|Active Comparator|Young, Active group|"From 18 to 35 years old.~The subjects will be considered as active if after completion of the Global Physical Activity Questionnaire (GPAQ), the subjects count:~at least 20 minutes of vigorous physical activity per day for 3 or more days per week OR~at least 30 minutes of moderate physical activity or walking per day for 5 or more days per week OR~At least 5 days of walking and moderate or vigorous physical activity, reaching a minimum of 600 Metabolic Equivalent of Task (MET)-minutes per week"
89602029|NCT05413590|Active Comparator|Young, sedentary group|From 18 to 35 years old. Subjects who are below these thresholds will be considered as sedentary. To avoid including a subject who recently changed his lifestyle (sedentary becoming active or vice versa), the investigator will ensure the subject kept this physical activity level (expressed using the GPAQ) constant for the last 5 years.
89602030|NCT05413590|Active Comparator|Old, Active group|"From 65 to 80 years old.~The subjects will be considered as active if after completion of the Global Physical Activity Questionnaire (GPAQ), the subjects count:~at least 20 minutes of vigorous physical activity per day for 3 or more days per week OR~at least 30 minutes of moderate physical activity or walking per day for 5 or more days per week OR~At least 5 days of walking and moderate or vigorous physical activity, reaching a minimum of 600 MET-minutes per week"
88980691|NCT05420545|Experimental|intraperitoneal injection of CD70-targeted CAR-T|Infusion of CD70-targeted CAR-T cells by dose of 1-10x106 cells/kg
88980692|NCT05420519|Experimental|CD70-targeted CAR-T|Infusion of CD70-targeted CAR-T cells by dose of 1-10x106 cells/kg
88980693|NCT05418257||Usual-Outpatients with Epilepsy|Patient who received treatment at Samsung Medical Center more than twice for epilepsy
88980694|NCT05418257||Tele-Outpatients with Epilepsy|Patient who received telemedicine at the time of recruitment and treatment at Samsung Medical Center more than twice for epilepsy
88980695|NCT05412927||Patients who have had prior ACS events.|Patients who have had prior ACS events and who remain at high risk for recurrent ACS events will be implanted with PMA P150009 AngelMed Guardian® System and enrolled in the PAS, for the purpose of accruing 314 adjudicated True Positive (TP) or False Positive (FP) ACS events.
88980696|NCT05412901|Other|Visual spatial discrimination task|exp 1.1
88980697|NCT05412901|Other|Visual spatial discrimination task with temporal manipulation|exp 1.2
88980698|NCT05412901|Other|Crossmodal discrimination task|exp 3.1
88980699|NCT05412901|Other|Visual rule-switching discrimination task [gratings]|exp 3.2
88980700|NCT05412901|Other|Visual rule-switching discrimination task [images]|exp 3.3
88980701|NCT05407792|Experimental|Experimental group|Oral staphylococcus albicans tablet group.
88980702|NCT05407792|Other|Control group|On-demand treatment group
88980703|NCT05407636|Experimental|RGX-314 Dose 1|RGX-314 Dose 1 administered via subretinal delivery one time.
88980704|NCT05407636|Experimental|RGX-314 Dose 2|RGX-314 Dose 2 administered via subretinal delivery one time.
88980705|NCT05407636|Active Comparator|Control Arm|Aflibercept administered via intravitreal injection approximately every 8 weeks
88980706|NCT05407051|Active Comparator|Treatment as Usual|In the Treatment as Usual condition, parents will simply be given a list of mental health referrals and crisis numbers.
88980707|NCT05407051|Experimental|Family Centered Treatment|In the Family-Centered Treatment Arm, parents would be given the same list of mental health referrals and crisis numbers, but in this condition, they would authorize researchers to share their contact information with the partner agency, Catholic Charities, and would then be linked directly to bilingual adult mental health services there with a behavioral health provider who would provide collateral therapy to parents via telehealth. Although parents will be referred to the community partner for therapy as a part of the research intervention, the behavioral health providers at the community partner will be providing therapy as they usually do for these participants in line with their usual job duties.
89602031|NCT05413590|Active Comparator|Old sedentary group|From 65 to 80 years old. Subjects who are below these thresholds will be considered as sedentary. To avoid including a subject who recently changed his lifestyle (sedentary becoming active or vice versa), the investigator will ensure the subject kept this physical activity level (expressed using the GPAQ) constant for the last 5 years.
89602032|NCT05413590|Active Comparator|Very old, Active group|"From 81 years old.~The subjects will be considered as active if after completion of the Global Physical Activity Questionnaire (GPAQ), the subjects count:~at least 20 minutes of vigorous physical activity per day for 3 or more days per week OR~at least 30 minutes of moderate physical activity or walking per day for 5 or more days per week OR~At least 5 days of walking and moderate or vigorous physical activity, reaching a minimum of 600 MET-minutes per week"
89602033|NCT05413590|Active Comparator|Very old sedentary group|From 81 years old. Subjects who are below these thresholds will be considered as sedentary. To avoid including a subject who recently changed his lifestyle (sedentary becoming active or vice versa), the investigator will ensure the subject kept this physical activity level (expressed using the GPAQ) constant for the last 5 years.
89602034|NCT05408884|Active Comparator|Miracle Friends|"Participants selected to receive a social support phone buddy program."
89602035|NCT05408884|No Intervention|waitlist|"Waitlisted for the social support phone buddy program."
89602036|NCT05408884|Experimental|Miracle Money|Participants who receive $750 monthly income for 12 months based on having engaged in the Miracle Friends program
89602037|NCT05400330|Experimental|Previously administered LX1001|"This is a long-term follow-up study to evaluate the safety following LX1001, a gene therapy, for participants who are APOE4 homozygotes with clinical diagnoses varying from MCI or dementia due to AD who have previously received LX1001. Study LX1001-01 was designed to assess the safety of LX1001 at 3 ascending doses (1.4 × 1010, 4.4 × 1010, 1.4 × 1011 gene copy [gc]/mL CSF) as per droplet digital polymerase chain reaction methodology, with each group consisting of approximately n=5 individuals for a total of approximately 15 participants for the entire study.~In this study, participants who have received LX1001 in the parent protocol (LX1001-01) will be followed for up to 260 weeks post gene therapy administration"
89602038|NCT05395507|Active Comparator|Recombinant Interferon Alpha|Recombinant Interferon Alpha, with an initial dose of 300 wu three times a week. Other interferons that have been listed can be used if Recombinant Interferon Alpha (300 wu) is not available.
89602039|NCT05395507|Experimental|Pegylated Interferon Alfa-2b|Pegylated Interferon Alfa-2b, with an initial dose of 135 ug at week 0 , and then 180 ug once a week from week 1 to week 52.
88980710|NCT05405452|No Intervention|No topical anesthesia|No topical anesthesia will be given during the trigger finger injection.
88980711|NCT05405452|Experimental|Topical coolant|The subject will have 5 seconds of sterile ethyl chloride sprayed at the site of the trigger finger injections just prior to the administration of the injection.
88980712|NCT05405452|Experimental|Vibration|The subject will have a vibration device placed just proximal to the site of the trigger finger injection concurrent with the administration of the injection.
88980713|NCT05401929|Experimental|Active|
88980714|NCT05401929|Sham Comparator|Sham|
88980715|NCT05401916|Active Comparator|Intravenous paracetamol|Intravenous paracetamol 1 g paracetamol will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received Tramadol with intravenous patient controlled analgesia (IV PCA) pump during postoperative 24 hours. The PCA solution will be prepared with 500 mg tramadol in 100 mL of saline (5 mg/ml). The PCA device was adjusted as infusion: 2 ml/h, bolus: 2 ml, lockout period: 15 min.
88980716|NCT05401916|Active Comparator|Intravenous ibuprofen|"800 mg ibuprofen (diluted with 250 ml saline) will be administered 30 minutes before the end of surgery.~All administrations will be applied through IV infusion over 30 minutes. Patients will be received Tramadol with intravenous patient controlled analgesia (IV PCA) pump during postoperative 24 hours. The PCA solution will be prepared with 500 mg tramadol in 100 mL of saline (5 mg/ml). The PCA device was adjusted as infusion: 2 ml/h, bolus: 2 ml, lockout period: 15 min."
88980717|NCT05386043||Baseline Imaging and Biopsy|Subjects will receive a PET-CT with the radiopharmaceuticals FET and O-15 Water (under RDRC approval for basic research) prior to their standard of care neurosurgery via stereotactic core biopsy. Research samples will be collected for analysis intraoperatively.
89210304|NCT04035720|Active Comparator|Qualitative risk estimation|Participants will be exposed to the same case-scenarios as the intervention arm. Each case scenario provides a description of the current clinical situation (e.g. patient age, current treatment, number of relapses, current EDSS, MRI findings, etc). In addition, participants will see a squared box indicating a qualitative probability of risk progression (low, high). This information may or may not be accurate to reflect potential errors of risk prediction tools.
89602040|NCT05391711|Experimental|Culturally Smart Relationships|The mentors assigned to this group will receive additional trainings and support related to Justice, Equity, Diversity and Inclusion (JEDI).
89602041|NCT05391711|No Intervention|Control Group|The mentors assigned to this group will NOT receive an intervention. They will receive the regular training activities that the agency provides.
89602042|NCT05388032|Experimental|sodium reduction intervention|The sodium reduction intervention is a dietician-led behavioral intervention consisting of two phases, first a 3-month intensive intervention phase, followed by a 9-month maintenance phase. The overall goal of the intervention is to reduce sodium intake to <2,300 mg per day based on the most recent guideline from the National Academies of Medicine. Both phases will include individual and group behavioral modification counseling designed to facilitate a reduction in dietary sodium intake.
88980718|NCT05382910|Experimental|MG-K10 Q2W|Received MG-K10 300 mg subcutaneous injection every 2 weeks
88980719|NCT05382910|Experimental|MG-K10 Q4W|Received MG-K10 300 mg subcutaneous injection every 4 weeks
88980720|NCT05382910|Placebo Comparator|Placebo|The placebo group will receive 2 ml of placebo subcutaneously administered every 2 weeks.
89602043|NCT05388032|No Intervention|Usual Diet|Participants randomized to the usual diet group will receive standard care from their providers with no study intervention.
89602044|NCT05374785|Experimental|CPL409116 60mg|60 mg BID of CPL409116
89602045|NCT05374785|Experimental|CPL409116 120mg|120 mg BID of CPL409116
89602046|NCT05374785|Experimental|CPL409116 240mg|240 mg BID of CPL409116
89602047|NCT05374785|Placebo Comparator|Placebo|Placebo
89602048|NCT05337566|Experimental|Azithromycin + Cefuroxime|"Changed with renewed study permissions:~These patients will receive Azithromycin 500 mg (2 tablets) per orally on the operation day when they arrive to the hospital and a single dose Cefuroxime 1.5g (when body mass index is under 30) or 3g (for those whose bosy mass index is 30 or more) in the operating theatre before the incision.~The previous description:~These patients will receive Azithromycin 500 mg (2 tablets) per orally in the evening before the operation and single dose Cefuroxime 1.5g (when body mass index is under 30) or 3g (for those whose body mass index is 30 or more) in the operating theatre before the incision."
89602049|NCT05337566|Active Comparator|Placebo + Cefuroxime|"Changed with new study permissions:~These patients will receive placebo (2 tablets) per orally on the operation day when they arrive to the hospital and a single dose Cefuroxime 1.5g (when body mass index is under 30) or 3g (for those whose bosy mass index is 30 or more)in the operating theatre before the incision.~The previous description:~These patients will receive placebo (2 tablets) per orally in the evening before the operation and a single dose Cefuroxime 1.5g (when body mass index is under 30) or 3g (for those whose body mass index is 30 or more) in the operating theatre before the incision."
89602050|NCT05333874|Active Comparator|Neoadjuvant chemotherapy|"If Circulating tumor DNA (ctDNA) blood test is positive, change in treatment can be made. Participants will be monitored with ctDNA at 60days, 3 months, 6 months, 9 months, 12 months, 18months and 24months from surgery.~The participant's core biopsy specimens will be sent to NateraTM to sequence the primary tumor. The baseline blood work for ctDNA will be collected prior to the initiation of systemic therapy. Subsequently, ctDNA will be collected prior to each cycle of neoadjuvant chemotherapy. Participants will undergo surgery and ctDNA needs to be collected fourteen days post-surgery The treating oncologist will complete a questionnaire to determine how ctDNA impacts treatment decisions in the adjuvant setting once the results from the fourteen day ctDNA is available and at the time of ctDNA re-emergence. Participants will complete participant questionnaire at 3 months, 6months, 12months and 24 months post-operatively."
88980721|NCT05382039|No Intervention|Subjects without Pain|This group will include twenty participants with no neck and/or upper quadrant pain that will not receive transcutaneous electrical nerve stimulation treatment.
88980722|NCT05382039|No Intervention|Subjects with Pain and No Intervention|This group will include twenty participants with neck and/or upper quadrant pain that will not receive transcutaneous electrical nerve stimulation treatment.
88980723|NCT05382039|Experimental|Subjects with Pain and Intervention|This group will include twenty participants with neck and/or upper quadrant pain that will receive transcutaneous electrical nerve stimulation treatment.
88980724|NCT05375903|Experimental|UGN-301 monotherapy dose escalation (Arm A)|Dose escalation of UGN-301 monotherapy in patients with recurrent NMIBC with high grade (HG) Ta and/or T1 disease and/or CIS or recurrent intermediate risk (IR) low grade (LG) Ta and/or T1 disease.
88980725|NCT05375903|Experimental|UGN-301 dose escalation + UGN-201 combination (Arm B)|Dose escalation of UGN-301 in combination with a fixed dose of UGN-201 in patients with recurrent NMIBC with HG Ta and/or T1 disease and/or CIS.
88980726|NCT05375903|Experimental|UGN-301 dose escalation + gemcitabine combination (Arm C)|Dose escalation of UGN-301 in combination with a fixed dose of gemcitabine in patients with recurrent NMIBC with HG Ta and/or T1 disease and/or CIS.
88980727|NCT05369156|Experimental|Chiropractic care Group|A registered chiropractor will assess the entire spine, and both sacroiliac joints will be assessed for vertebral subluxation by a registered chiropractor with at least five years of clinical experience.The clinical indicators that will be used to assess the function of the spine before spinal adjustment intervention include assessing for joint tenderness to palpation manually palpating for a restricted intersegmental range of motion, assessing for palpable asymmetric intervertebral muscle tension, and any abnormal or blocked joint play and end-feel of the joints. Chiropractors use these biomechanical characteristics as clinical indicators of spinal dysfunction and vertebral subluxation.
88980728|NCT05369156|Placebo Comparator|Control Group|The participants head and/or spine will be moved in ways that include passive and active movements, similar to what is done when assessing the spine by a chiropractor. The control intervention will also include the participants moving into adjustment setup positions similar to how the chiropractor would typically set up a patient with no joint pre-loading or adjustive thrust. No spinal adjustment will be performed during any control intervention. This control intervention is not intended to act as a sham treatment session
88980729|NCT05369143|Experimental|Chiropractic care Group|A registered chiropractor will assess the entire spine, and both sacroiliac joints will be assessed for vertebral subluxation by a registered chiropractor with at least five years of clinical experience.The clinical indicators that will be used to assess the function of the spine before spinal adjustment intervention include assessing for joint tenderness to palpation manually palpating for a restricted intersegmental range of motion, assessing for palpable asymmetric intervertebral muscle tension, and any abnormal or blocked joint play and end-feel of the joints. Chiropractors use these biomechanical characteristics as clinical indicators of spinal dysfunction and vertebral subluxation.
88980730|NCT05369143|Placebo Comparator|Control Group|The participants head and/or spine will be moved in ways that include passive and active movements, similar to what is done when assessing the spine by a chiropractor. The control intervention will also include the participants moving into adjustment setup positions similar to how the chiropractor would typically set up a patient with no joint pre-loading or adjustive thrust. No spinal adjustment will be performed during any control intervention. This control intervention is not intended to act as a sham treatment session
88980731|NCT05368454|Experimental|Integrated Solution|
89602051|NCT05333874|Other|Observational|Observation for triple negative breast cancer (TNBC): No adjuvant chemotherapy. Patients may complete checkpoint inhibitor from neoadjuvant setting. human epidermal growth factor receptor 2 (HER2) positive breast cancer: complete twelve months of anti-HER2 therapy, which was initiated in neoadjuvant setting), participants in the observation arm, will be monitored for Circulating tumor DNA (ct-DNA) re-emergence and systemic therapy can be added at the time of ctDNA re-emergence.
89602052|NCT05332626|Experimental|Probiotic group|The probiotic group will receive a supplement diet capsule consisting of Lactobacillus acidophilus UALa-01™ with a dose of 1x10^9 CFU for 12 weeks
89602053|NCT05332626|Placebo Comparator|Placebo group|The placebo group will receive a capsule that consists of the excipient (maize starch and maltodextrins) for 12 weeks
89602054|NCT05324293|Experimental|HMI-115 240mg|
89602055|NCT05321862|Experimental|[68Ga]Ga-PentixaFor|
89602056|NCT05320666|Experimental|Yes You Can…Make Smart Choices! (YYC…MSC!) Program|The intervention/treatment participants in the treatment condition will be exposed to NJPAG's YYC…MSC! program. The program is designed to be delivered five days a week for two weeks and contains 11 lessons.
89602057|NCT05320666|No Intervention|Control|"The control schools were randomly selected out of a list of eligible schools in the Newark Public School system. Control schools will receive their health class as business-as-usual with no additional programming. There is no other place that provides the YYC…MSC! program in which participants could receive programming or information. Also, there are no future plans to provide the control group with the intervention. To our knowledge, there is no other similar programming operating in the Newark Public School area."
89602058|NCT05308108||Children with Obstructive Sleepapnea|
89602059|NCT05304195||DLB patients|Dementia with lewy bodies according to the revised criteria of Mc Keith 2017
89602060|NCT05304195||Control|Absence of cognitive impairment and clinical element for a neurodegenerative disease
89602061|NCT05279417|Experimental|ATI-450 20mg BID plus Methotrexate|ATI-450 20mg oral tablet BID with a stable weekly dose of Methotrexate
89602062|NCT05279417|Experimental|ATI-450 50mg BID plus Methotrexate|ATI-450 50mg oral tablet BID with a stable weekly dose of Methotrexate
89602063|NCT05279417|Placebo Comparator|Placebo plus Methotrexate|Placebo oral tablet BID with a stable weekly dose of Methotrexate
88980732|NCT05368454|Active Comparator|Standard of Care|
88980733|NCT05352139||Elbow Tendinosis (Epicondylitis)|Treatment of participants who present with either lateral or medial epicondylitis
88980734|NCT05352139||Hip Tendinosis (Gluteal Tendinopathy)|Treatment of participants diagnosed with Recalcitrant Gluteal Tendinopathy
88980735|NCT05352139||Shoulder Calcific Tendinosis (Calcific Shoulder Tendinopathy)|Treatment of participants diagnosed with Calcific Shoulder Tendinopathy
89210305|NCT00903084|Active Comparator|1|Participants will receive 7 doses per week, then 4 doses per week, then 2 doses per week (each for 6 weeks) of tenofovir, with a break in between dosing periods.
89210306|NCT00903084|Active Comparator|2|Participants will receive 7 doses per week, then 2 doses per week, then 4 doses per week (each for 6 weeks) of tenofovir, with a break in between dosing periods.
89602064|NCT05270694|Experimental|COVID-19 Testing|The cohort participants will attend an in-person training on how to take an at-home COVID-19 test and also be provided with five at-home test kits at the training and every other month for a total of 35 kits over the course of a year.
89602065|NCT05267652|Active Comparator|Preoxygenation with Non-Invasive Positive Pressure Ventilation Group|Patients assigned to preoxygenation with non-invasive positive pressure ventilation will receive non-invasive mechanical ventilation via a tight-fitting mask from the initiation of preoxygenation until the initiation of laryngoscopy. Trial protocol will not dictate the brand or type of mechanical ventilator that will be used to deliver non-invasive ventilation.
89602066|NCT05267652|Active Comparator|Preoxygenation with Facemask Oxygen Group|For patients randomized to preoxygenation with facemask oxygen, supplemental oxygen will be administered via a non-rebreather mask or bag-mask device without manual ventilation from the initiation of preoxygenation until induction. Trial protocol will not dictate the brand or type of facemask. The decision between use of a non-rebreather mask and use of a bag-mask device will be made by treating clinicians. The decision of whether to provide manual ventilation with a bag-mask device between induction and laryngoscopy will be made by treating clinicians.
89602067|NCT05253352||Healthy volunteers|Healthy female volunteers with no history of lymphedema. Physical therapy examination, ICG lymphography, venous ultrasound and lymphoscintigraphy with SPECT/CT imaging
89602068|NCT05253352||Women with breast cancer who did not develop lymphedema|Women who have had an axillary lymph node dissection (ALND) and did not develop lymphedema. Physical therapy examination, ICG lymphography, venous ultrasound and lymphoscintigraphy with SPECT/CT imaging
89602069|NCT05251389|Experimental|A: FMT from an ICI non-responding donor|Patients will receive FMT from an ICI non-responding donor (defined as ≥20% increase according to RECIST 1.1 criteria within the past 3 months). Patients will continue their anti-PD-1 treatment.
88980736|NCT05349513|Experimental|interventionnal arm|Administration of the experimental questionnaire ESSME in patient's environment.
88980737|NCT05347628|Experimental|PLB1004|PLB1004 given alone as monotherapy.
88980738|NCT05346354|Experimental|Ravulizumab|"During the Primary Treatment Period, all participants will receive weight-based dosing of ravulizumab IV for a total of 50 weeks of treatment.~During the Extension Period, participants will continue to receive weight-based dosing of ravulizumab IV for up to 104 weeks."
88980739|NCT05345054||Phase 1|Study Population and Enrollment. To ensure survey feasibility and acceptability for our target population we will purposively recruit older African American patients at each of the three participating sites. Using conservative estimates of clinical volume as well as US county level census data we estimate enrolling 3 elderly (>65 years of age) African American participants per site per week with a target enrollment of 12 patients per site.
89602070|NCT05251389|Experimental|B: FMT from an ICI responding donor|Patients will receive FMT from an ICI responding donor (defined as ≥30% decrease or disappearance of all lesions according to RECIST 1.1 criteria within the past 24 months). Patients will continue their anti-PD-1 treatment.
89602071|NCT05215158|Active Comparator|Peribulbar dexmedetomidine|The peribulbar block will be done using a mixture of 4 ml Lidocaine 2%, 4 ml Bupivacaine 0.5%, and 2 ml normal saline containing 50 μg dexmedetomidine perineurally (30 patients).
89602072|NCT05215158|Active Comparator|Intravenous dexmedetomidine|The peribulbar block will be done using a mixture of 4 ml Lidocaine 2%, 4 ml Bupivacaine 0.5%, and 2 ml normal saline. Patients received 50 μg dexmedetomidine in 50 mL of normal saline administered as an infusion over 10 minutes, and given 10 minutes before the peribulbar block (30 patients).
89602073|NCT05197569|No Intervention|Control group|No intervention will be applied to the control group and the measurements will be recorded simultaneously.
89602074|NCT05197569|Experimental|Thyme oil group|After filling out the forms, thyme oil aromatherapy will be applied to the patients assigned to the experimental group .The oregano oil to be prepared must have a high carvacrol ratio. Thyme oil with a carvacrol ratio of at least 74% will be specific to each patient and will be given to the patient in the form of an inhaler stick. According to expert opinion; The patient's own room should be visited every 8 hours and the patient-specific inhaler stick should be sniffed into 8 breathing lungs. Each patient will use an inhaler stick for 5 days. Hemodynamic parameters (ph, CO 2, O 2 ) and Covid-19 symptoms will be measured before the intervention with the patient (pretest) and at the end of the 5th day (posttest). Vital signs will be measured and recorded three times a day in the patient's room at 08:00, 16:00 and 24:00.
89602075|NCT05196841|Experimental|Experimental group|Anastatica Hierochuntica
89602076|NCT05196841|No Intervention|Control group|routine care
89602077|NCT05195437||Growth hormone treatment|Adolescents and young adults followed or having been followed by the endocrinology, gynecology and pediatric diabetology department of the Necker Enfants Malades hospital, who reached their final height and who have been treated with growth hormone due to short stature.
89602078|NCT05180838||BioSticker|This cohort will place BioStickers at least 3 days prior to completion of standard of care therapy and discharge home post therapy.
89602079|NCT05178927|Sham Comparator|Standard of Care-Group 1|"During treatments 1-5, radiation therapists will position the participant for treatment using the standard of care method.~During treatments 6-10, radiation therapists will use the hologram the investigators created to initially position the participant for treatment. The participant's final position will be obtained using a standard of care method."
88980740|NCT05345054||Phase 2|To gain a broad understanding of barriers to surgical access and care in the Deep South, each study site will conduct key informant interviews. Participants will be recruited from five socioecological levels: patient, caregivers/provider, organizational, community, and policy-levels. At each site, two key informant interviews will be performed at each socioecological level (2 patients, 2 caregivers, 2 providers, 2 organizational leaders, 2 community leaders, and 2 policy leaders = 12 per site). We will purposively sample 100% of the participants at the patient and caregiver level (n=12) to be African American and >65 years old.
88980741|NCT05345054||Phase 3|"Enrollment Process. Eligibility criteria for this phase of study enrollment will be broadened to include all English-speaking patients >18 years of age undergoing or having recently undergone (<7 days) an ACS-NSQIP defined surgical procedure. At each site, eligible participants will be approached by a trained research associate pre-operatively in clinic (for elective cases) or post-operatively in the hospital (for emergency cases <7 days). Because each enrollment site has a unique schedule, site representatives will coordinate the most efficient weekly schedule.~We expect to reach our target enrollment (100 participants total, 33 at each site) in 1 year based on conservative estimates of clinical case volume. We expect to enroll at least 20% elderly participants (>65 years of age) and between 30-50% African American participants based on county level (Greenville - Butler County, Demopolis - Marengo County, Alexander City - Tallapoosa County) census data."
88980742|NCT05342519|Experimental|Topical rapamycin 0.001%|Patients randomized to this arm of the study will apply 2 finger tip units (FTU) or 0.5 cc topical rapamycin 0.001% cream daily for 6 months
88980743|NCT05342519|Active Comparator|Topical rapamycin 0.1%|Patients randomized to this arm of the study will apply 2 FTU (0.5 cc) topical rapamycin 0.1% cream daily for 6 months
88980744|NCT05342519|Placebo Comparator|Placebo|All patients will apply 2 FTU (0.5 cc) topical placebo cream daily for 6 months to the corresponding anatomic location on the opposite side of the body where the experimental drug is not being applied
88980745|NCT05337267|Experimental|sintilimab (after the change)|
88980746|NCT05337267|Active Comparator|sintilimab (before the change)|
89602080|NCT05178927|Experimental|Mixed-reality guided patient setup-Group 2|"During treatments 1-5, radiation therapists will use the hologram the investigators created to initially position the participant for treatment. The participant's final position will be obtained using a standard of care method.~During treatments 6-10, radiation therapists will position the participant for treatment using the standard of care method."
89602081|NCT05168813|Experimental|Group 1|This arm will assess the relative vaccine efficacy (RVE) of a 3- vs. 2-dose COVID-19 mRNA vaccine regimen to prevent virologically confirmed, symptomatic COVID-19 in adult people living with HIV who are SARS-CoV-2 negative at baseline.
89602082|NCT05168813|Experimental|Group 2|This arm will assess the relative vaccine efficacy (RVE) of a 2- vs. 1-dose COVID-19 mRNA vaccine regimen to prevent virologically confirmed symptomatic COVID-19 in adult people living with HIV who are SARS-CoV-2 positive at baseline.
89210307|NCT00903084|Active Comparator|3|Participants will receive 4 doses per week, then 7 doses per week, then 2 doses per week (each for 6 weeks) of tenofovir, with a break in between dosing periods.
89210308|NCT00903084|Active Comparator|4|Participants will receive 4 doses per week, then 2 doses per week, then 7 doses per week (each for 6 weeks) of tenofovir, with a break in between dosing periods.
89602083|NCT05168813|Experimental|Group 3|This arm will assess the relative vaccine efficacy (RVE) of a 3- vs. 2-dose COVID-19 mRNA vaccine regimen to prevent virologically confirmed, symptomatic COVID-19 in HIV negative adults who are SARS-CoV-2 negative at baseline.
89602084|NCT05168813|Experimental|Group 4|This arm will assess the relative vaccine efficacy (RVE) of a 2- vs. 1-dose COVID-19 mRNA vaccine regimen to prevent virologically confirmed symptomatic COVID-19 in HIV negative adults who are SARSCoV-2 positive at baseline.
89602085|NCT05166265|Experimental|Sentio system|Prospective, open label, single-arm multi-centre investigation following clinical practice for bone conduction devices.
89602086|NCT05165225|Experimental|Pyrotinib|Experimental: Patients will receive Pyrotinib combined with Epirubicin and Cyclophosphamide followed by Docetaxel
89602087|NCT05145400|Experimental|Single Arm|All subjects will receive the same treatment on the study, consisting of isatuximab, lenalidomide, and dexamethasone with 28 days cycles.
89602088|NCT05143177|Placebo Comparator|Placebo|
89602089|NCT05143177|Active Comparator|DA-1229 5mg|
89602090|NCT05143177|Active Comparator|DA-1229 10 mg|
89602091|NCT05142709||ESCC patients treated with anti-PD-1 immunotherapy as 1st line treatment.|
89602092|NCT05137665||Amyotrophic Lateral Sclerosis ALS|Amyotrophic Lateral Sclerosis (ALS): Clinical diagnosis of ALS requires the presence of UMN and LMN involvement in different body regions and evidence of progressive spread of symptoms or signs according to EEC. ALS clinic patients with suspected, possible, probable, probable-laboratory supported, or definite ALS will be included. ALS clinic participants with suspected, possible, probable, probable-laboratory supported, and definite Amyotrophic Lateral Sclerosis (ALS) according to revised El Escorial Criteria (EEC) will participate in 5 longitudinal visits; Screening/Baseline Visit 1, and four (4) follow-up visits which will occur at approximate 4-month intervals. Upon IRB approved consent, the study participant will undergo the assessments and bio-fluid collections at each visit as outlined in the Schedule of Events.
89602093|NCT05137665||Healthy|Healthy participants (family or friends) will have a neurologic exam to confirm non-neurologic disease status and will participate in 2 longitudinal visits; Screening/baseline Visit 1, and one (1) follow-up which will occur at approximate 12-month interval. Upon IRB approved consent, the study participant will undergo the assessments and bio-fluid collections at each visit as outlined in the Schedule of Events.
89602094|NCT05124977|Experimental|Experimental group|Antimicrobial stewardship based on daily clinical assessment of clinical cure (experimental group). Discontinuation of antibiotic therapy antibiotics if criterions of clinical cure (regression of tracheal secretions, regression of temperature, improvement of PaO2/FiO2 ratio, absence of hemodynamic failure) of confirmed VAP are met. In the intervention group, intensivists will perform clinical assessment daily in order to decide on the pursuit or discontinuation of antibiotic therapy.
89602095|NCT05124977|Other|Control group|Standard management: duration of appropriate antibiotic therapy for confirmed VAP according to guidelines. In the control group, intensivists will perform clinical assessment daily, but a minimum duration of 7 days, as highly recommended of antibiotic therapy will be mandatory whatever the clinical cure.
89602096|NCT05116566||Patients|Three distinct sub-cohorts will be targeted for recruitment to represent perspectives across the advancing illness course: patients ≤3 months from a poor- prognosis diagnosis (cohort 1), patients ≤ 3 months from disease relapse or progression (cohort 2), and patients actively enrolled on a phase I/II trials (cohort 3).For cohorts 1-3, patient-parent dyads will be enrolled when eligible; however, an independent patient is eligible for enrollment if the parent consents for the patient's enrollment but declines his/her own enrollment.
89602097|NCT05116566||Parents|Four distinct sub-cohorts of parents will be targeted for recruitment, including cohorts 1-3 and a fourth bereavement cohort. For cohorts 1-3, patient-parent dyads will be enrolled when eligible; however, an independent parent is eligible for enrollment if the patient declines enrollment, but the parent wishes to participate.
89602098|NCT05116566||Oncologist|Pediatric oncologists who treat or refer patients for treatment at St. Jude Children's Research Hospital (SJCRH) will be eligible to participate.
89602099|NCT05114941|Experimental|Immunoadsorption group|Protein A immunoadsorption therapy
89602100|NCT05114941|Active Comparator|intravenous immunoglobulin group|Treatment with intravenous immunoglobulin
89602101|NCT05112237||Retrospective|All patients who meet the eligibility criteria will be eligible for retrospective chart review.
89602102|NCT05112237||Prospective|100 patients meeting the eligibility criteria will be followed for 5 years, in addition to a retrospective chart review. Assessments will be completed as part of a participant's regular schedule of physician visits, no additional visits will be required. Aside from a simple annual blood draw, assessments are non-invasive, including a Quality of Life questionnaire.
89602103|NCT05111093|Experimental|all participants|All participants will be provided with the ARC-IM Investigational System (implantable and non-implantable parts)
89602104|NCT05094791||Telescoping Lag Screw|Intertrochanteric fractures treated with Arthrex Hip Nail with Telescoping Screw
89602105|NCT05094791||Standard lag Screw|Intertrochanteric fractures treated with Zimmer Natural Nail Cephalomedullary Nail
89602106|NCT05094791||Standard lag screw with addition of worm screw|Intertrochanteric fractures treated with Smith and Nephew TRIGEN INTERTAN
89602107|NCT05073159|Active Comparator|0 degree Head-of-Bed (HOB) position|Patients would be randomized 1:1 to elevated head of bed (30-degrees or more) or flat (0-degree) position
89602108|NCT05073159|Active Comparator|Elevated (30-degree or more) head-of-bed|Patients would be randomized 1:1 to elevated head of bed (30-degrees or more) or flat (0-degree) position
89602109|NCT05062707||AYA cancer patients|Patients aged 18-39 years, with a first histological and/or cytological diagnosis of a haematological or solid malignancy, scheduled to start systemic therapy with curative intent.
89602110|NCT05061238|Other|Vibrating Device|you will be asked to walk up and down a hallway 5 times with the vibrating device strapped to different parts of your leg.
89602111|NCT05057312|Experimental|Experimental arm 1|Video narrative persuasion
89602112|NCT05057312|Experimental|Experimental arm 2|Written narrative Persuasion
89602113|NCT05057312|Experimental|Experimental arm 3|Enhanced Access to HPV vaccines
89602114|NCT05057312|Experimental|Experimental arm 4|Video narrative persuasion; Enhanced Access to HPV vaccines
89602115|NCT05057312|Experimental|Experimental arm 5|Written narrative Persuasion
89602116|NCT05057312|No Intervention|Control/ active comparator Arm 6|CDC information
89602117|NCT05043207|Experimental|uAud|Patients which hearing aid is fitted based on the audiometry obtained with user-operated automated audiometry.
89602118|NCT05043207|Active Comparator|control|Patients which hearing aid is fitted based on the audiometry obtained with traditional audiometry.
89602119|NCT05025449|Experimental|Non-enhanced FAST exam followed by BEFAST exam|Participants in the emergency department with hemodynamically stable blunt abdominal trauma will receive the standard of care Focused Assessment with Sonography for Trauma (FAST) exam followed by a Bubble-Enhanced FAST exam.
89602120|NCT05012371|Experimental|Arm A (lenvatinib, everolimus)|Patients receive lenvatinib PO QD and everolimus PO QD. Cycles repeat every 30 days in the absence of disease progression or unacceptable toxicity.
89602121|NCT05012371|Active Comparator|Arm B (cabozantinib)|Patients receive cabozantinib PO QD. Cycles repeat every 30 days in the absence of disease progression or unacceptable toxicity.
89602122|NCT05011279|Experimental|Pilot Study|"Participants in the pilot study will participate as members of family-based dyads (n=5 dyads). One member of each dyad will be a breast cancer survivor and one will be a blood relative.~Study involves interviews, questionnaires, Use of Move Together app with Garmin activity tracker watch"
89602123|NCT05004935|Experimental|beetroot juice|single intake of beetroot juice containing 800mg nitrates
89602124|NCT05004935|Active Comparator|nitrates|single intake of 800mg nitrates (NaNO3)
89602125|NCT05002816|Experimental|Belantamab Mafodotin and Elotuzumab Arm|"Elotuzumab will be administered via intravenous infusion at an established dose of 10 mg/kg on days 1, 8, 15, 22 every 28 days for cycles 1 and 2, followed by 20mg/kg on day 1 of each cycle thereafter, cycles repeated every 28 days.~Belantamab mafodotin will be administered via IV infusion. There will be 2 dose levels for belantamab mafodotin, with the starting dose of 1.9 mg/kg IV at every 4 week interval. Up to 12 subjects will be treated at this dose level. If the initial dose is found to be too toxic, dose of belantamab mafodotin 1.9 mg/kg every 8 weeks will be tested. ."
89602126|NCT04999358|Experimental|Protein group|Participants in the protein group will receive their usual education session(s) as part of standard practice cardiac rehabilitation. The session(s) will be the same for both study arms and will align with the dietary education sessions that these patients would usually be given during their normal cardiac rehabilitation programme. Participants in the protein group will be provided with an additional targeted protein education session, which will aim to increase the amount of foods eaten with protein in them (≥1.2 g/kg protein/day) and improve the quality of protein sources that are eaten. The content and materials for these sessions can be provided in-person or are available as pre-recorded videos, accessed by participants via the internet or DVD
89602127|NCT04999358|Placebo Comparator|Control group|Participants in the control group will receive their usual education session(s) as part of standard practice cardiac rehabilitation. The session(s) will be the same for both study arms and will align with the dietary education sessions that these patients would usually be given during their normal cardiac rehabilitation programme. Participants in the control group will receive an additional dietary education session that is similar to the standard practice sessions, containing only information that is usually provided in the cardiac rehabilitation programme.The content and materials for these sessions can be provided in-person or are available as pre-recorded videos, accessed by participants via the internet or DVD.
89602128|NCT04999332|Experimental|Perioperative chemotherapy with LOTS|"LOTS as one cycle:~Leucovorin (30 mg) twice daily per oral, day 1 to 7; Oxaliplatin (85 mg per square meter) intravenously, day 1; Docetaxel (40 mg per square meter) intravenously, day 1; S-1 (35 mg per square meter) twice daily per oral, day 1 to 7~Pre-operative part:~Four cycles of LOTS every two weeks~Operative part:~Curative gastrectomy or gastroesophagectomy plus D2 lymphadenectomy~Post-operative part:~Four cycles of LOTS every two weeks"
89602129|NCT04993885|Experimental|Treatment group|Fifty-two subjects will be enrolled with the indicated treatment dose of avatrombopag
89602130|NCT04988490||Daily cannabis users|Patients undergoing inpatient abdominal surgery for the treatment of cancer who self-report daily cannabis use
89602131|NCT04988490||Cannabis non-users|Patients undergoing inpatient abdominal surgery for the treatment of cancer who self-report no cannabis use
89602132|NCT04987814|Experimental|Elderly patients suspected of sarcopenia|
89602133|NCT04982952|Experimental|Contingency Management (CM)|In addition to receiving usual cessation care at the Tom Waddell Urban Health Center (TWUHC), CM intervention participants with CO-verified abstinence will obtain a CM incentive payment, via gift cards and/or cash redeemable in national retail chains.
89602134|NCT04982952|Other|Control Group|Participants who choose to attend smoking cessation in the usual care setting at TWUHC will receive a basic $5 payment for attending each study visit.
89602135|NCT04964726|Experimental|Real-time fMRI dyadic neurofeedback|
89602136|NCT04948476|Experimental|Standardized Dialysis and Structured Discontinuation (S2D2)|Prescription to minimize dialysis-induced ischemia and standardize dialysis discontinuation
89602137|NCT04948476|Active Comparator|Usual Care|Dialysis prescription ordered by their primary nephrologist/intensivist.
89602138|NCT04944992|Experimental|Efinopegdutide|Efinopegdutide 20 mg/mL administered by injection once weekly for 24 weeks in a dose-escalation regimen: 2.4 mg from day 1 to week 3, 5.0 mg from week 4 to 7, and 10.0 mg from week 8 to 24.
88980750|NCT05331664|Active Comparator|Group 1|"Subconjunctival antibiotic (cefazolin 50 mg/0.5 mL, moxifloxacin 0.5 mg/0.1 mL, or vancomycin 1 mg/0.1 mL) and subconjunctival dexamethasone (4 mg/mL) at the time of surgery~Topical atropine 1% and antibiotic-steroid ointment (neomycin-polymyxin B-dexamethasone) at the time of surgery~Topical moxifloxacin 0.5% or Polymyxin/Trimethoprim if patient is allergic to moxifloxacin; 4 times per day for 1 week after surgery.~Topical prednisolone 1% 1 drop 4 times per day tapered by one drop weekly for 4 weeks (4/3/2/1 taper)~Topical atropine 1% daily for 1 week"
89210309|NCT00903084|Active Comparator|5|Participants will receive 2 doses per week, then 7 doses per week, then 4 doses per week (each for 6 weeks) of tenofovir, with a break in between dosing periods.
89602139|NCT04944992|Active Comparator|Semaglutide|Semaglutide 1.34 mg/mL administered by injection once weekly for 24 weeks in a dose-escalation regimen: 0.25 mg from day 1 to week 3, 0.5 mg from week 4 to 7, and 1.0 mg from week 8 to 24.
89602140|NCT04914507|Other|Anterior Vertebral Body Tethering|The subject is will receive anterior vertebral body tethering surgery, as clinically indicated, after all pre-operative assessments are complete.
89602141|NCT04900506|Active Comparator|cemented hemiarthroplasty , posterior SPAIRE approach|Posterior SPAIRE approach: lateral decubitus position, preservation of the piriformis tendon and obturator internus, detatchment of obturator externus , capsular T-incision, femoral neck resection, femoral canal reaming according to preoperative templating, third generation cementation technique, capsular repair, repair of obturator externus.
89602142|NCT04900506|Active Comparator|cemented hemiarthroplasty, anterior approach|Anterior approach: supine position, both legs washed and draped, intermuscular plane between m. tensor fascia lata and m. sartorius, capsular T-incision, femoral neck resection, femoral canal reaming according to preoperative templating, third generation cementation technique, capsular repair
89602143|NCT04874194|Experimental|Treatment (omacetaxine, venetoclax)|Patients receive omacetaxine SC BID on days 2-3 or 2-4, and venetoclax PO on days 1-7, 1-10 or 1-14. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
89602144|NCT04862455|Experimental|Treatment (NBTXR3, RT, pembrolizumab)|Patients receive hafnium oxide-containing nanoparticles NBTXR3 via injection intratumorally or intranodally on day 1. Beginning as early as day 3 and within 8 days of NBTXR3 injection, patients undergo SBRT QOD or hypofractionated RT QD over 1-2 weeks at the discretion of the treating radiation oncologist. Starting on the same day as radiation therapy, patients also receive pembrolizumab IV over 30 minutes every 3 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity.
89602145|NCT04857788|Experimental|Pandah Application only|Design is a controlled randomized Study with two parallel arms after randomization with a three months follow-up of the two arms that are (Group 1) Care as usual for patients in follow-up list; (Group 2) PANDAH App proposed alone with only 15-20 minutes setup with investigator at start-up (digital accompaniment only); Patients of the 2 groups will have a three months follow-up period before secondary evaluation and entering into the so-called extension period.
89602146|NCT04857788|No Intervention|Care as usual|Design is one period of 3 months with 2 parallel groups (with or without application) following by extension period of 3 months with all subject accessing to the application.
89602147|NCT04851678||Individuals with Tourette syndrome (TS)|Individuals previously diagnosed with Tourette syndrome (TS). Participants must be 18 years of age or older.
89602148|NCT04842773|Experimental|US measurement of sarcopenia|
89032354|NCT04761081||White Europeans with central obesity|"The white European group with central obesity will be of white European ethnicity and a waist circumference of 94cm or greater.~The group will receive an accelerometer (Actigraph GT3x) to wear for 7 days to measure habitual physical activity. They will then provide a single blood donation in a fasted state which we will use to quantify the migration of pro-inflammatory monocytes towards adipose tissue specific media. This will then be compared to the other 3 groups to investigate the interaction between ethnicity, central obesity, and physical activity with the migration of pro-inflammatory monocytes.~Metabolic markers will be analysed and presented in a participant characteristics table."
89032355|NCT00523289|Active Comparator|B|Arm number B corresponds to the Bupivacaine group.
89032356|NCT00523289|Active Comparator|R|Arm number R corresponds to the Ropivacaine group.
89032357|NCT03457857|Other|Group 1 - Cleanser|Regimen with Baby Cleanser Only
89602149|NCT04837209|Experimental|Niraparib + Dostarlimab + Radiation therapy|"Study cycle length is 3 weeks. Participants will receive:~Niraparib 1x daily during each study cycle~Dostarlimab 1x every 3 weeks for 4 study cycles, then 1x every 6 weeks beginning on Cycle 5~Radiation therapy will be given on Days 1, 2, and 3 of Cycle 1."
89602150|NCT04837092|Experimental|FR104 Treatment|
89602151|NCT04836897|Experimental|Treatment|Transcatheter aortic valve replacement
89032358|NCT03457857|Other|Group 2 - Cleanser and Lotion|Regimen containing Baby Cleanser/Shampoo and Baby Lotion
89032359|NCT04506216|Experimental|cohort|adult patients with type 1 diabetes and insulin pump treatment . Duration of participation: 30 minutes
89602152|NCT04820530|Experimental|LNP023|Participants receive LNP023 at a dose of 200 mg orally b.i.d
89032360|NCT03457779|Experimental|Non Glucose Arm|4 patients without glucose infusion
89032361|NCT03457779|Experimental|Glucose Arm|12 Patients with glucose infusion
89602153|NCT04813627||Participants with R0 resected Stage II (high risk) or Stage III CRC|The participants eligible for this epidemiological study are those with completely resected Stage II (high risk)/III CRC (per the American Joint Committee on Cancer (AJCC) 8th revised edition staging system) due to receive standard of care chemotherapy for at least 3 months following surgery.
89602154|NCT04812795|Experimental|Culturally tailored (Non-smokers)|"The anti-smoking and anti-industry messages will be culturally tailored to specifically reach out to young adult SMW. They will receive only messages that are culturally tailored at baseline and weeks 1, 2, and 3.~Culturally tailored anti-smoking messages: Anti-smoking messages that are culturally tailored for sexual minority women."
89602155|NCT04812795|Active Comparator|Non-culturally tailored (Non-smokers)|"The anti-smoking and anti-industry messages will not be culturally tailored. They will receive only messages that are not culturally tailored at baseline and weeks 1, 2 and 3.~Non-culturally tailored interventions: Anti-smoking messages that are not culturally tailored for sexual minority women."
89602156|NCT04812795|Experimental|Culturally Tailored (Smokers)|"The anti-smoking and anti-industry messages will be culturally tailored to specifically reach out to young adult SMW. They will receive only messages that are culturally tailored at baseline and weeks 1, 2, and 3.~Culturally tailored anti-smoking messages: Anti-smoking messages that are culturally tailored for sexual minority women."
89602157|NCT04812795|Active Comparator|Non-culturally Tailored (Smokers)|"The anti-smoking and anti-industry messages will not be culturally tailored. They will receive only messages that are not culturally tailored at baseline and weeks 1, 2 and 3.~Non-culturally tailored interventions: Anti-smoking messages that are not culturally tailored for sexual minority women."
88980751|NCT05331664|Active Comparator|Group 2|"Subtenon triamcinolone acetonide (40 mg/1mLl) at the time of surgery~Subconjunctival antibiotic (cefazolin 50 mg/0.5 mL, moxifloxacin 0.5 mg/0.1 mL, or vancomycin 1 mg/0.1 mL) and subconjunctival dexamethasone (4 mg/mL) at the time of surgery~Topical atropine 1% and antibiotic-steroid ointment (neomycin-polymyxin B-dexamethasone) at the time of surgery~No postoperative eye drops"
88980752|NCT05325567|Active Comparator|1 incision technique|a mini-open incision that allows adequate exposure of the transverse carpal ligament (TCL), while staying distal to the distal wrist crease.
88980753|NCT05325567|Active Comparator|Two incision technique|A two-incision open carpal tunnel release techniques to ensure complete release both proximally and distally
88980754|NCT05324046||Liver metastasis|Patients with suspicion of liver metastasis and scheduled for CT
88980755|NCT05321940|Experimental|Combination STAVs and DC Vaccine Group|Participants will receive STAV-loaded cells for a total of 5 doses on Days 3, 17, 31, 45 and 59. Participants will also receive up to 4 doses of dendritic vaccine on Days 10, 17, 24 and 31.
88980756|NCT05319444|Experimental|Healthy Scalp and one treatment|Participants with healthy scalps who will receive one treatment with the device and complete one in-person follow-up.
88980757|NCT05319444|Experimental|Healthy Scalp and three treatments|Participants with healthy scalps who will receive three treatments with the device and complete one in-person follow-up.
88980758|NCT05319444|Experimental|Dandruff and one treatment|Participants with dandruff who will receive one treatment with the device and complete one in-person follow-up.
88980759|NCT05319444|Experimental|Dandruff and three treatments|Participants with dandruff who will receive three treatments with the device and complete one in-person follow-up.
88980760|NCT05319444|Experimental|Hair loss disease and one treatment|Participants with hair loss disease who will receive one treatment with the device and complete one in-person follow-up.
88980761|NCT05319444|Experimental|Seborrheic Dermatitis with one treatment|Participants with seborrheic dermatitis disease who will receive one treatment with the device and complete one in-person follow-up.
88980762|NCT05319444|Experimental|Seborrheic Dermatitis and three treatments|Participants with seborrheic dermatitis who will receive three treatments with the device and complete one in-person follow-up.
88980763|NCT05319444|Experimental|Hair loss disease and three treatments|Participants with hair loss disease who will receive three treatments with the device and complete one in-person follow-up.
88980764|NCT05315115|Experimental|Experimental group|A registered chiropractor will assess the entire spine, and both sacroiliac joints will be assessed for vertebral subluxation by a registered chiropractor. The clinical indicators that will be used to assess the function of the spine before spinal adjustment intervention include assessing for joint tenderness to palpation manually palpating for a restricted intersegmental range of motion, assessing for palpable asymmetric intervertebral muscle tension, and any abnormal or blocked joint play and end-feel of the joints.
88980765|NCT05315115|Sham Comparator|Control group|The participant's head and/or spine will be moved in ways that include passive and active movements, similar to what is done when assessing the spine by a chiropractor.No spinal adjustment will be performed during any control intervention.
88980766|NCT05314478|Experimental|Participants|Participants will be required to attend a single consultation and screening appointment to discuss the investigation procedure, and this will occur at least a week before the Continuous Laryngoscopy during Exercise (CLE) test. Participants will then attend one appointment for the CLE test. There will be no follow up assessments using the headgear.
88980767|NCT05307874|Experimental|Part 2 ICT01 + Low dose SC IL-2 + Pembrolizumab|The best regimen of ICT01+IL-2 will be combined with pembrolizumab at the approved dose since the combination of ICT01+IL-2 induces upregulation of PD-1 on g9d2 T cells and in the TME.
89602158|NCT04807907|Experimental|Infant Directed Speech (IDS) Video + IDS Calendar|The participant will be shown a 3-minute video describing the value of IDS and how the participant can use IDS with their child. The participant will receive an IDS-themed wall calendar.
88980768|NCT05307874|Experimental|Dose level 2 ICT01 + Low dose SC IL-2|For all arms, ICT01 IV is given on Day 1 of every 21-day cycle. SC IL-2 is administered Days 1-5 of cycles 1/2/3 only.
89602159|NCT04807907|No Intervention|Control|No intervention. The participant will receive a regular wall calendar with an image of Stanford.
89602160|NCT04797767|Experimental|Treatment (CLAG-M, venetoclax)|Patients will receive induction with granulocyte colony-stimulating factor on days 0-5 (if peripheral white blood cell count is less than 20,000/uL), cladribine on days 1-5, cytarabine on 1-5, and mitoxantrone on days 1-3. Patients also receive venetoclax orally (PO) on days 1-14. Treatment repeats every 28-35 days for up to 2 induction cycles including mitoxantrone, and up to 4 consolidation cycles without mitoxantrone in the absence of disease progression or unacceptable toxicity.
89602161|NCT04770207|Experimental|Group 1: DC-Beads loading with Chemodrug/IL2/PD1/CTLA4 antibodies|Intra-tumor injection of above drugs for patients with previous treatment with PDL1 antibody and relapsed.
89602162|NCT04770207|Experimental|Group 2: DC-Beads loading with Chemodrug/IL2/PDL1/CTLA4 antibodies|Intra-tumor injection of above drugs for patients with previous treatment with PD1 antibody and relapsed.
89602163|NCT04770207|Experimental|Group 3: DC-Beads loading with Chemodrug/IL2/PD1/PDL1/CTLA4 antibodies|Intra-tumor injection of above drugs for patients with previous heavily treated with PD1/PDL1/CTLA4 antibodies and relapsed.
89602164|NCT04759105|Experimental|Autologous BM-MSC injection|"Two interventions:~Bone marrow harvesting from the posterior superior iliac crest region~Single injections of a dose of 15 million of autologous BM-MSC each disc affected by IDD (up to 4 discs) via imaging control"
89602165|NCT04759105|Sham Comparator|Sham Procedure|"Two sham procedures:~Simulated bone marrow harvesting without insertion into the posterior iliac crest region~Simulated injection under only local anaesthesia without disc injection, without placebo injection."
89602166|NCT04752163|Experimental|Cohort A and B (DS-1594b)|Patients with MLLr or NPM1m receive DS-1594b PO BID on days 1-28. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
89602167|NCT04752163|Experimental|Cohort C (DS-1594b, venetoclax, azacitidine)|Patients receive DS-1594b PO BID on days 1-28, venetoclax PO QD on days 1-28, and azacitidine IV or SC on days 1-7. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
88980769|NCT05307874|Experimental|Dose Level 1 ICT01 + High dose SC IL-2|For all arms, ICT01 IV is given on Day 1 of every 21-day cycle. SC IL-2 is administered Days 1-5 of cycles 1/2/3 only.
88980770|NCT05307874|Experimental|Dose level 1 ICT01 + Low dose SC IL-2|For all arms, ICT01 IV is given on Day 1 of every 21-day cycle. SC IL-2 is administered Days 1-5 of cycles 1/2/3 only.
89602168|NCT04752163|Experimental|Cohort D (DS-1594b, mini-HCVD)|Patients receive DS-1594b PO BID on days 1-28. For additional information, see trial description.
89602169|NCT04752163|Experimental|Drug-Drug Interaction (DS-1594b, posaconazole, voriconazole)|Patients receive DS-1594b PO BID on days 1-8 and 19-28, and posaconazole PO BID on day 9 and QD on days 10-18 or voriconazole PO BID on days 9-18 in the absence of disease progression or unacceptable toxicity.
89602170|NCT04752163|Experimental|Food-Effect (DS-1594b)|Patients receive DS-1594b PO BID on days 1-8 within 30 minutes after eating a standard meal and PO BID on days 9-15 under fasting conditions in the absence of disease progression or unacceptable toxicity.
89602171|NCT04752163|Experimental|Phase I (DS-1594b)|Patients receive DS-1594b PO BID on days 1-28 in the absence of disease progression or unacceptable toxicity.
89602172|NCT04749030|Other|Faecal microbiota transplantation (FMT)|Donor faeces is obtained from thoroughly screened healthy blood donors and processed in compliance with the European Tissue and Cells Directive.
89602173|NCT04749030|Placebo Comparator|Placebo|Placebo capsules will be identical in terms of visual appearance, weight, and vials and number
89602174|NCT04744428|Experimental|Autism Parent Navigators Intervention|Autism Parent Navigators Intervention is a manualized, in-home, peer support model for parents with a young child recently diagnosed with ASD.
89602175|NCT04744428|Active Comparator|Peer mentoring|Peer mentors will offer an equivalent number of in-home or telephone visits for families, providing non-manualized peer support.
89602176|NCT04732598|Active Comparator|Arm A|
89602177|NCT04732598|Experimental|Arm B|
89602178|NCT04726683|Experimental|Dry needling|Trigger point dry needling on an active myofascial trigger point of the masseter muscle.
89602179|NCT04726683|Experimental|Injection|Trigger point injection of lidocaine on an active myofascial trigger point of the masseter muscle.
89602180|NCT04726683|Placebo Comparator|Placebo|Combines sham dry needling + sham injection.
89602181|NCT04726683|Active Comparator|Dry needling + Injection|Combines experimental dry needling and injection
89602182|NCT04709978||Pneumonia|Participants will be over the age of 60 and diagnosed with pneumonia in the UW Emergency Department or treated for pneumonia in the past 6 months.
89602183|NCT04694456|Experimental|Facioscapulohumeral muscular dystrophy|Adult ambulant patients with facioscapulohumeral muscular dystrophy type 1 (FSHD1)
89602184|NCT04617444|Experimental|Intervention group|
89602185|NCT04617444|Active Comparator|Control group|
89602186|NCT04615988||Participants being treated with immunotherapy|Participants who are to receive standard of care immunotherapy targeting PD-1 or PDL1 as treatment for malignancy
89602187|NCT04603352|Experimental|Intervention group: Hip Helpers home program|Participants in the intervention group will be given a custom pair of Hip Helpers® to use at home. Parents will begin the Hip Helpers® home program upon study entry and stop the program once the child is able to pull to stand independently. The Hip Helpers® home program protocol, which consists of using the orthotic garment twice daily for 30 minutes each time, will be given to the parents and supervised by the physical therapist. The Hip Helpers® should be donned when the child is actively playing, and not used sleep or when child is inactive.
89602188|NCT04603352|No Intervention|Control group: No additional home program|Participants assigned to the control group will continue with their usual care.
89602189|NCT04581629|Experimental|Cohort 1: Ascending + Steady-State Dose|"Period 1: Participants will receive an ascending dose of encaleret once daily for the first 3 days. Participants will then receive an individualized dose of encaleret twice daily for 2 days.~Period 2: Participants will receive encaleret twice daily for 5 days at a single dose level based on responses from Period 1.~Period 3: After completion of Period 2, participants will be eligible to receive encaleret for an additional 24 weeks.~Long-Term Extension (LTE): At the end of the study, participants will also have an option to receive encaleret for up to an additional 2 years."
89602190|NCT04581629|Experimental|Cohort 2: Steady-State Dose|"Participants will directly be enrolled into Period 2, and receive encaleret twice daily at a dose based on data and responses from Cohort 1 Period 1.~Period 2: Participants will receive encaleret twice daily for 5 days.~Period 3: After completion of Period 2, participants will be eligible to receive encaleret for an additional 24 weeks.~LTE: At the end of the study, participants will also have an option to receive encaleret for up to an additional 2 years."
89602191|NCT04568382|Experimental|Intervention|Enhanced PVP
89602192|NCT04568382|Active Comparator|Standard|Standard PVP
89602193|NCT04551391||Case|"(i) Adult aged 16 or over; (ii) Ability to provide informed consent; (iii) Diagnosis of AKI determined as:~Previous (within 3 years) eGFR >45 mL/min/1.73m2 OR no history of kidney disease if no recent (within 3 years) blood results available AND~Elevated creatinine over 1.5 x previous result OR over 150 μmol/L if no previous value AND~Increasing creatinine >= 27μmol/L above index value within 48 hours"
89602194|NCT04551391||Control|"(i) Adult aged 16 or over; (ii) Ability to provide informed consent; (iii) Admitted to hospital without AKI: (eGFR > 60).~This group will be recruited contemporaneously with, and matched to, AKI participants by:~Age (± 5 years)~Sex~AKI aetiology (ischaemic, infected, nephrotoxic) 4 (i) History of diabetes or not AND/OR (ii) History of cardiovascular disease or not"
89602195|NCT04540406|Experimental|NBT-NM108 + Usual Care|
89602196|NCT04540406|Active Comparator|Usual Care Only|
88980771|NCT05307874|Experimental|Dose level 3 ICT01 + Low dose SC IL-2|For all arms, ICT01 IV is given on Day 1 of every 21-day cycle. SC IL-2 is administered Days 1-5 of cycles 1/2/3 only.
88980772|NCT05307874|Experimental|Dose level 4 ICT01 + Low dose SC IL-2|For all arms, ICT01 IV is given on Day 1 of every 21-day cycle. SC IL-2 is administered Days 1-5 of cycles 1/2/3 only.
88980773|NCT05307874|Experimental|Dose level 5 ICT01 + Low dose SC IL-2|For all arms, ICT01 IV is given on Day 1 of every 21-day cycle. SC IL-2 is administered Days 1-5 of cycles 1/2/3 only.
88980774|NCT05301894|Experimental|NBI-827104|NBI-827104 administered orally
88980775|NCT05297786|Experimental|Lanadelumab|Subjects will receive lanadelumab (300 mg) subcutaneously at the beginning of the study and 14 days later
88980776|NCT05297786|Placebo Comparator|Placebo|Subjects will receive placebo subcutaneously at the beginning of the study and 14 days later
88980777|NCT05289830|Experimental|Participants receiving Escitalopram|
88980778|NCT05289830|Placebo Comparator|Participants receiving Placebo|
88980779|NCT05289739|Experimental|Exercise group|Usual medical care + supervised exercise training during intensive medical treatment
89602197|NCT04539808|Experimental|Treatment (mFOLFIRINOX, chemotherapy)|"mFOLFIRINOX REGIMEN: Oxaliplatin intravenously (IV) over 2 hrs, leucovorin calcium IV over 2 hrs, and irinotecan hydrochloride IV over 90 minutes on day 1. Also receive fluorouracil IV over 46 hrs starting on day 1. Repeats every 14 days for up to 4 cycles. Those with response and no disease progression may receive an additional 2 months.~GA REGIMEN: Those with disease progression or toxicity to mFOLFIRINOX switch to GA regimen comprising gemcitabine hydrochloride IV over 30-60 mins and nab-paclitaxel IV over 30-40 mins on days 1, 8, and 15. Repeats every 28 days for 2 cycles.~LOSARTAN: Cycle 1 day 1, start losartan potassium orally once daily until end of RT.~RT/SURGERY: Short-course RT for 10 fractions over 5 days weekly or long-course RT with 15-25 fractions over 5 days weekly along with oral capecitabine twice daily on Monday-Friday or fluorouracil IV over 5-7 days weekly until completion of RT. Patients then undergo surgery 1-4 weeks following RT"
89602198|NCT04538716|Experimental|SVF-gel|Transconjunctival blepharoplasty associated with associated with stromal vascular fraction gel (SVF-gel)
89602199|NCT04538716|Experimental|fat transposition|Transconjunctival blepharoplasty associated with fat transposition
89602200|NCT04535583||EMA plus passive sensing|Participants will be responding to up to 3 ecological momentary assessments per day plus carrying a smartphone and wearing a smartwatch. Both the smartphone and smartwatch will passively collect sensor data continuously.
89602201|NCT04530487|Experimental|Treatment (conditioning regimen, HSCT)|"CONDITIONING REGIMEN: Patients receive thiotepa IV over 2-4 hours, etoposide IV over 60 minutes on days -8 to -6, melphalan IV over 20 minutes on days -5 and -4, and fludarabine phosphate IV over 1 hour on days -5 to -3 in the absence of disease progression or unacceptable toxicity. Patients receiving umbilical cord transplant also receive rabbit anti-thymocyte globulin IV on days -3 and -4.~TRANSPLANT: Patients undergo HSCT on day 0.~GVHD PROPHYLAXIS: Beginning day -2, patients receive tacrolimus or cyclosporine IV continuously until able to receive PO. Patients continue tacrolimus or cyclosporine PO to day 60 and tapered to day 100. Patients also receive mycophenolate mofetil PO or IV every 8 hours until day 40 and tapered to day 90."
89602202|NCT04528680|Experimental|SC9/ABX (phase 1); SC9/ABX/Carboplatin (phase 2)|Infusion of albumin-bound paclitaxel immediately followed by sonication using the SC9 device and microbubbles in order to open the blood-brain barrier in phase 1. In phase 2, patients will receive carboplatin immediately prior to sonication using the SC9 device and microbubbles in order to open the blood-brain barrier, then will receive albumin-bound paclitaxel upon completion of sonication.
89602203|NCT04523324|Active Comparator|RIV4 (Flublok Quadrivalent)|Flublok® Quadrivalent by Sanofi Pasteur, 45µg of HA per strain
89602204|NCT04523324|Active Comparator|IIV4 (Vaxigrip Quadrivalent)|VaxigripTetra™ by Sanofi, Inc., 15µg of HA per strain, egg-based
89602205|NCT04513808|Active Comparator|Propofol-based total intravenous anesthesia|Propofol-based total intravenous anesthesia. A target-controlled infusion will be set to 2-4 µg/ml plasma concentrations, and varied as clinical necessary.
89602206|NCT04513808|Active Comparator|Sevoflurane intravenous anesthesia|Anesthesia will be maintained with sevoflurane, typically at an end-tidal concentration of 0.6-1.0 MAC, but adjusted as clinically necessary
89602207|NCT04494113|Experimental|Treatment (triapine, surgical resection)|Patients receive triapine IV over 2 hours on day 1. Patients then undergo surgical resection and tissue collection 6-8 hours after the initiation of the triapine infusion. Patients also undergo biopsy and collection of blood samples on study.
89602208|NCT04484935|Experimental|Nirsevimab|"1st RSV season: 50mg nirsevimab~st RSV season: 100mg nirsevimab~nd RSV season: 200mg nirsevimab"
89602209|NCT04478734|Experimental|Moderate doses|moderate doses of combination therapy applying the minimum average dosage of thiamine and biotin used in patients with BTBGD
89602210|NCT04478734|Experimental|High doses|high doses of the combination therapy applying the average standard dosage of thiamine and biotin used in patients with BTBGD.
89602211|NCT04478292|Experimental|Group A|"Group A1： tumor is completely resected at diagnosis and receives no adjuvant chemotherapy（well differentiated fetal [WDF] histology HB) ；~Group A2：tumor is completely resected followed by 2 cycles of standard dose cisplatin monotherapy （non-well differentiated fetal histology HB)"
89608620|NCT04143477|Experimental|Peficitinib 50 mg|Participants will receive a single dose of 50 milligrams (mg) under fasted condition Day 1, followed by multiple doses of 50 mg under fed condition once daily in the morning from Day 8 till Day 13.
88980780|NCT05289739|No Intervention|Control group|Usual medical care
88980781|NCT05288023|Active Comparator|Programmatic azithro 1-11|Biannual oral azithromycin administration to children aged 1-11 months distributed by community health workers
88980782|NCT05288023|No Intervention|no intervention|No additional intervention.
88980783|NCT05287711|Experimental|Motivational Enhancement Therapy|Motivational enhancement therapy for alcohol use problems, which includes empathic support, feedback and advice, strategies for enhancing self-efficacy, techniques for eliciting self-motivational statements from the participant, strategies for addressing participant ambivalence about change and participant resistance to change, and methods for eliciting and affirming commitment to a specific change plan (active intervention).
88980784|NCT05287711|Experimental|Alcohol Education Control|Psychoeducational intervention intended to: (1) dispel myths about the effects of alcohol, (2) provide information about the general risks of drinking and process of recovery from alcohol problems, (3) provide information about the specific risks related to family relationships and IPV, (4) offer self-help program information and related strategies to address drinking problems, (5) promote and encourage healthy decision-making, and (6) reinforce the benefits of abstinence or controlled drinking.
88980785|NCT05287711|Other|Telephone Monitoring|Brief supportive telephone monitoring sessions that are commonly delivered while Veterans wait to begin their groups (treatment as usual).
88980786|NCT05280405|Experimental|Early-Proactive Therapeutic Drug Monitoring (E-pTDM)|Infliximab (IFX) at 5mg/kg, IV at week 0, 2 and 6. From week 6, the infusion interval will be adjusted based on pre-infusion IFX concentrations to target a trough level grater or equal to (>=) 5 mcg/ml (> 10 μg/ml in patients with perianal disease). For IFX concentrations below target, the infusion interval will be shortened (minimum interval 2 weeks). IFX dose increase will be performed as a second step.
89602212|NCT04478292|Experimental|Group B|"Patients will be randomized to one of 2 arms: Arm CDDP or Arm CDDP plus STS. In each arm, patients will be stratified by resectablity after completion of 2 cycles of protocol therapy (6 cycles of standard dose cisplatin monotherapy with or without STS). All the patients in 2 arms will receive 6 cycles chemotherapy in total.~Resection of the primary tumor will be performed after completing the 2nd cycle of chemotherapy.~Those patients whose tumors after 2 cycles do not meet criteria for definitive surgical, 2nd resectablity evaluation will be scheduled after 4 cycles of chemotherapy."
89602213|NCT04478292|Experimental|Group C|"Patients in Group C will have locally advanced tumors including PRETEXT I-III tumors with a positive VPEFR annotation factor and all PRETEXT IV tumors.~Patients will be randomized to one of 2 arms: Arm C5VD or Arm C5VD plus STS. In each arm, patients will be stratified by resectablity after completion of 2 cycles of protocol therapy. All the patients in 2 arms will receive 6 cycles chemotherapy in total.~Resection of the primary tumor will be performed after completing the 2nd cycle of chemotherapy.~Those patients whose tumors after 2 cycles do not meet criteria for definitive surgical, 2nd resectablity evaluation will be scheduled after 4 cycles of chemotherapy."
89602214|NCT04478292|Experimental|Group D|"These patients have metastatic disease, suspected HB patients ≥ 8 years of age, or have an AFP ≤ 100 at diagnosis.~Patients will receive initial chemotherapy according to the cisplatin-intensive SIOPEL-4 induction regimen. Resection (including transplant) of the primary tumor should be completed after induction Block 3, but primary tumor resection can be planned any time after completing induction therapy.~Following 3 blocks of induction chemotherapy, patients will be stratified into 2 risk groups: Group D1 includes patients who either have a chemotherapy-induced lung CR or are rendered a lung CR by surgical metastasectomy. These patients will have chemotherapy consolidation with carboplatin/doxorubicin. In Group D2, patients will have not yet achieved a lung CR at the end of induction Block 3. These patients will get intensified consolidation therapy of carboplatin/doxorubicin with vincristine/irinotecan.~Resection of pulmonary nodules should be considered in Group D2."
89602215|NCT04466033|Experimental|Magneto Microcatheter|
89602216|NCT04464174|Experimental|Ipatasertib plus capecitabine|Arm A: Ipatasertib (GDC-0068) 400 milligrams (mg) tablets administered orally once a day (noon) on Days 1-14 of each 21-day cycle plus capecitabine 1000 mg/m2 tablets orally twice a day (morning and evening; equivalent to 2000 mg/m2 total daily dose), for 14 days (followed by a 7-day rest period) every 21-day cycle.
89602217|NCT04464174|Experimental|Ipatasertib plus Eribulin|Arm B: Ipatasertib (GDC-0068) 400 mg tablets administered orally once a day on Days 1-14 of each 21-day cycle plus eribulin 1.23 mg/m2 (equivalent to eribulin mesylate at 1.4 mg/m2) administered intravenously over 2 to 5 minutes on Days 1 and 8 of every 21-day cycle.
89602218|NCT04464174|Experimental|Ipatasertib plus carboplatin plus gemcitabine|Arm C: Ipatasertib (GDC-0068) 400 mg tablets administered orally once a day on Days 1-14 of each 21-day cycle plus carboplatin AUC5 on Day 1 administered intravenously plus gemcitabine 1000 mg/m2 administered intravenously over 30 minutes on Days 1 and 8, every 21-day cycle.
89602219|NCT04459117|Active Comparator|Acetaminophen|The active product is a 10 ml polyethylene ampoule of acetaminophen containing 100 mg of acetaminophen, solution for infusion, B BRAUN.
89602220|NCT04459117|Placebo Comparator|NaCL 0.9%|The placebo product is a polyethylene ampoule of 10ml of NaCL 0.9%, B BRAUN. Polyethylene ampoule of active and placebo products are with the same appearance, in accordance with Good Manufacturing Practices Drugs for Clinical Trials.
89602221|NCT04428112|Experimental|Building Better Caregivers Workshop Group|Building Better Caregivers Workshop is a 6-week online self-management and skills building workshop. Participants receive the online workshop as soon as possible after randomization.
89602222|NCT04428112|Active Comparator|Attention Control Group|Participants will be offered the online workshop after the 12 month trial is completed if they so desire.
89602223|NCT04408690|Experimental|Rehabilitation and optional delayed ACL reconstruction|
89602224|NCT04408690|Active Comparator|Immediate ACL reconstruction + rehabilitation|
89602225|NCT04407754|Placebo Comparator|Control Arm|This group will receive placebo powder twice daily.
89602226|NCT04407754|Active Comparator|Inositol Arm|This group will receive myo-inositol (2,000mg) plus d-chiro-inositol (50mg) supplement powder twice daily.
89602227|NCT04407364||Intervention Cohort|The CoMatryx surgical collagen powder is a soft tissue repair product made of 100% type I bovine collagen
89602228|NCT04407364||Historical Cohort|Primary and Revision total hip arthroplasty patients between 18-85 years of age
89602229|NCT04387305|Experimental|Tranexamic acid 15 mg/kg bolus|Subjects will receive a 15 mg/kg bolus of tranexamic acid over 30 minutes followed by a 2 mg/kg/h infusion over 8 hours. This represents 31 mg/kg total dose of TXA.
89602230|NCT04387305|Experimental|Tranexamic acid 30 mg/kg bolus|Subjects will receive a 30 mg/kg bolus of tranexamic acid over 30 minutes followed by a 4 mg/kg/h infusion over 8 hours. This represents 62 mg/kg total dose of TXA.
89602231|NCT04387305|Experimental|Tranexamic acid 45 mg/kg bolus|Subjects will receive a 45 mg/kg bolus of tranexamic acid over 30 minutes followed by a 6 mg/kg/h infusion over 8 hours. This represents 91 mg/kg total dose of TXA. This dosing arm will only open if a dose-effect is determined based on accumulating data.
89602232|NCT04387305|Placebo Comparator|Placebo|Subjects in the placebo group will receive a bolus dose of normal saline over 10 minutes followed by a normal saline infusion over 8 hours
88980787|NCT05280405|Active Comparator|Standard dosing|Infliximab (IFX) at 5mg/kg, IV at week 0, 2 and 6 followed by 5mg/kg infusions every 8 weeks.
89032362|NCT03458858|Other|Mixed Berry Diet|Participants will receive between 400 to 800 grams of mixed berries daily, as a proportion of their daily caloric intake added to their base diet. The base diet will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet.
89210310|NCT00903084|Active Comparator|6|Participants will receive 2 doses per week, then 4 doses per week, then 7 doses per week (each for 6 weeks) of tenofovir, with a break in between dosing periods.
89602233|NCT04377217|Experimental|Video recording|The experimenter will make a standardized video of the patient during the inclusion process, and a second one after 18 months.
89602234|NCT04351958|Experimental|"Augmented Reality (No Time Wasted)"|
89602235|NCT04317742|Active Comparator|Sleep Healthy Using the Internet (SHUTi) Intervention Group|Participants will receive a direct link to access the SHUTi program (per randomization) from the study team.
89602236|NCT04317742|Active Comparator|Online Patient Education (PE) Control Group|Participants will receive a direct link to access online patient education (per randomization) from the study team.
89602237|NCT04299906|Experimental|Solaris Vascular Stent Graft|Implant of Solaris Vascular Stent Graft in aorto-iliac lesions
89602238|NCT04297254|Experimental|Lenvatinib 12 mg or 8 mg|Participants with body weight (BW) greater than or equal to (>=) 60 kilogram (kg), will receive lenvatinib 12 milligram (mg) (03 capsules), and participants with BW less than (<) 60 kg, will receive lenvatinib 8 mg, (02 capsules), orally, once daily with or without food in 28-day cycles for a maximum 6 cycles of 4 weeks each for a total of 24 weeks or until disease progression, death, intolerable or unacceptable toxicity, or withdrawal of consent, whichever occurs earlier.
89602239|NCT04262882|Experimental|Multilevel Family Planning Intervention|A multi-level, community-based intervention delivered in groups of couples to increase contraceptive uptake, reduce discontinuation, and reduce the incidence of unintended pregnancy, and improve intermediate outcomes (knowledge, attitudes, norms, communication, equity).
89602240|NCT04262882|Active Comparator|Time and attention-matched control|A community sanitation intervention delivered in groups of couples to increase at-home and community hygiene practices.
89602241|NCT04244981|Experimental|PCC group|When APTT is prolonged (> 45 s) measured 20 minutes after CPB or excessive bleeding observed, patients will be given 8～15 IU/kg PCC.
89602242|NCT04244981|Active Comparator|FFP group|When APTT is prolonged (> 45 s) measured 20 minutes after CPB or excessive bleeding observed, patients will be given 6～10 mL/kg FFP.
89602243|NCT04244773|Experimental|Intervention group: ENDS and smoking cessation|
89602244|NCT04244773|Active Comparator|Control group: Smoking cessation counseling|
89602245|NCT04201184|Experimental|Little Holy One intervention|The participants will receive 12 1-hour lessons on parenting, stress, and culture over a period of 16 weeks.
89602246|NCT04201184|Active Comparator|Nutrition control|The active control condition will receive nutrition information, weekly food boxes and recipes based on seasonal foods, as well as a shopping list for making future meals.
89602247|NCT04198922|Experimental|Treatment (acalabrutinib)|Patients receive acalabrutinib 100 mg PO BID on days 1-28. Treatment repeats every 28 days for up to 6 cycles with an option to continue for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
89602248|NCT04189991|Active Comparator|Manual then automated oxygen titration|First will be performed the manual oxygen titration and then the automatic oxygen titration.
89602249|NCT04189991|Active Comparator|Automatic then manual oxygen titration|First will be performed the automatic oxygen titration and then the manual oxygen titration.
89602250|NCT04182373|Experimental|KW-3357|72 IU/kg
89602251|NCT04182373|Placebo Comparator|placebo|
89602252|NCT04180085|Experimental|BELATACEPT|
89602253|NCT04175977|Experimental|Wave 1: Usual Care for Months 1-7, Transition for Months 8-9, Intervention for Months 10-26|PWD at the hospice sites randomized to Wave 1 will receive usual care for 7 months, followed by the 2-month-long transition to the intervention over months 8 and 9, followed by the QAPI intervention for 16 Months from Month 10-26.
89602254|NCT04175977|Experimental|Wave 2: Usual Care for Months 1-8, Transition for Months 9-10, Intervention for Months 11-26|PWD at the hospice sites randomized to Wave 2 will receive usual care for 8 months, followed by the 2-month-long transition to the intervention over months 9 and 10, followed by the QAPI intervention for 15 months from Month 11-26.
89602255|NCT04175977|Experimental|Wave 3: Usual Care for Months 1-9, Transition for Months 10-11, Intervention for Months 12-26|PWD at the hospice sites randomized to Wave 3 will receive usual care for 9 months, followed by the 2-month-long transition to the intervention during months 10 and 11, followed by the QAPI intervention for 14 months from Months 12-26.
89602256|NCT04175977|Experimental|Wave 4: Usual Care for Months 1-10, Transition for Months 11-12, Intervention for Months 13-26|PWD at the hospice sites randomized to Wave 4 will receive usual care for 10 months, followed by the 2-month-long transition to the intervention during months 11 and 12, followed by the QAPI intervention for 13 months from Months 13-26.
89602257|NCT04175977|Experimental|Wave 5: Usual Care for Months 1-11, Transition for Months 12-13, Intervention for Months 14-26|PWD at the hospice sites randomized to Wave 5 will receive usual care for 11 months, followed by the 2-month-long transition to the intervention during months 12 and 13, followed by the QAPI intervention for 12 months from Months 14-26.
89602258|NCT04175977|Experimental|Wave 6: Usual Care for Months 1-12, Transition for Months 13-14, Intervention for Months 15-26|PWD at the hospice sites randomized to Wave 6 will receive usual care for 12 months, followed by the 2-month-long transition to the intervention during months 13 and 14, followed by the QAPI intervention for 11 months from Months 15-26.
89602259|NCT04175977|Experimental|Wave 7: Usual Care for Months 1-13, Transition for Months 14-15, Intervention for Months 16-26|PWD at the hospice sites randomized to Wave 7 will receive usual care for 13 months, followed by the 2-month-long transition to the intervention during months 14 and 15, followed by the QAPI intervention for 10 months from Months 16-26.
89602260|NCT04175977|Experimental|Wave 8: Usual Care for Months 1-14, Transition for Months 15-16, Intervention for Months 17-26|PWD at the hospice sites randomized to Wave 7 will receive usual care for 14 months, followed by the 2-month-long transition to the intervention during months 15 and 16, followed by the QAPI intervention for 9 months from Months 17-26.
89602261|NCT04168060|Experimental|Crura Dissection|Participants with a visually detectable hiatal hernia at the time of sleeve gastrectomy procedure will undergo a crura dissection and hiatal hernia repair.
89602262|NCT04168060|Experimental|National Practice|Participants with no detectable hiatal hernia will be randomized to either Group 2 or 3. Group 2 participants will be treated to the national practice patterns of complete dissection of the curvature of the stomach without dissection of the crura.
89602263|NCT04168060|Experimental|Standard of Care|Participants with no detectable hiatal hernia will be randomized to either Group 2 or 3. Group 3 participants will undergo the institutional standard of care with the dissection of the crura.
89602264|NCT04161235||Treatment|Patients undergoing Zephyr Valve treatment with the use of at least one Zephyr Valve 5.5-LP EBV.
89602265|NCT04140305|Experimental|Administration of RPC-1063|Patients with relapsing MS will receive RPC-1063 orally:
89602266|NCT04135859|Active Comparator|Fitbit Only|In the Fitbit Only arm, participants will receive their exercise prescription, as devised from their baseline exercise stress test results, and a Fitbit. They will undergo a 9 week (interim) and a 22 week assessment (follow-up).
89602267|NCT04135859|Experimental|Fitbit + Coaching Sessions|In the Fitbit + Coaching Sessions arm, participants will receive their exercise prescription, as devised from their baseline exercise stress test results, a Fitbit, and will have 8 sessions with a coach (interventionist) over the course of 20 weeks. They will undergo a 9 week (interim) and a 22 week assessment (follow-up).
89602268|NCT04133948|Experimental|A|For IFN-gamma high patients: patients will receive pre-surgically 2 courses nivolumab 240 mg (q3weeks)
89602269|NCT04133948|Experimental|B|For IFN-gamma high patients: patients will receive pre-surgically 2 courses nivolumab 240 mg (q3weeks) + domatinostat 200 mg BID, on days 1-14 (q3weeks)
89602270|NCT04133948|Experimental|C|For IFN-gamma low patients: patients will receive pre-surgically 2 courses nivolumab 240 mg (q3weeks) + domatinostat 200 mg BID, on days 1-14 (q3weeks)
89602271|NCT04133948|Experimental|D|For IFN-gamma low patients: patients will receive pre-surgically 2 courses nivolumab 240 mg (q3weeks) + ipilimumab 80 mg (q3weeks) + domatinostat. Patients in arm D will start with once daily (OD) dosing scheme of domatinostat 200 mg, on days 1-14 (q3weeks). Based on safety data of the first 5 patients in this arm, the next patients will be treated with either a higher dosing scheme (200 mg BID, days 1-14, q3weeks), a lower dosing scheme (100 mg OD, days 1-14, q3weeks), or the same dosing scheme (200 mg OD, days 1-14, q3weeks).
89602272|NCT04126642|Other|Assessment only group|Standard care + Daily ecological momentary assessments (EMAs)
89602273|NCT04126642|Experimental|Intervention group|"Intervention group will receive same measures and interventions as the assessment only group AND will receive messaging that is tailored to patient responses on EMAs. When participants provide a pattern of responses that are suggestive of heightened emotional distress, they will receive feedback and/or a prompt to complete one of the self-management exercise. The app will prompt participants to complete a brief educational video on relaxation strategies and guided relaxation exercises. Participants will have access to: 1) a Help me Cope button in the app that contains links to evidenced-based self-management techniques, and 2) a Contact Counselor button that will send a secure email to a study psychologist requesting a call. Participants will receive a coping focused message at the completion of the Report Distress EMAs. Participants can access these on demand intervention components and review them at any time in addition to receiving the tailored intervention messages."
89602274|NCT04107948|Experimental|fibromyalgia patients with physical activity program|"Two weekly exercise sessions at the university hospital of St-Etienne for 1 month then relay outside in a sports association or club certified Sports Health in the Loire (42) or Haute-Loire (43) for 2 months."
89602275|NCT04107948|Other|fibromyalgia patients with physical activity at home|Advice and recommendations of physical activity at home (= current clinical practice, from 1 to 3 sessions per week in autonomy).
89602276|NCT04103892|Experimental|Part A - CLE-100 (oral esketamine)|Part A: 1 oral tablet of CLE-100 once daily for 1 week.
89602277|NCT04103892|Placebo Comparator|Part A - Placebo|Part A: 1 oral tablet of Placebo once daily for 1 week.
89602278|NCT04103892|Experimental|Part B - CLE-100 (oral esketamine)|Part B: 1 oral tablet of CLE-100 once daily for 4 weeks.
89602279|NCT04103892|Placebo Comparator|Part B - Placebo|Part B: 1 oral tablet of Placebo once daily for 4 weeks.
89602280|NCT04082936|Experimental|Phase 1a (Dose Escalation)|Subjects will receive imvotamab via intravenous (IV) infusion weekly. No longer enrolling.
89602281|NCT04082936|Experimental|Phase 1a (Q3W)|Subjects will receive imvotamab via intravenous (IV) infusion every 3 weeks. No longer enrolling.
89602282|NCT04082936|Experimental|Phase 1a (Prior bi-specific)|Subjects treated with prior bi-specifics will receive imvotamab via IV infusion weekly. No longer enrolling.
89602283|NCT04082936|Experimental|Phase 2 (DLBCL)|DLBCL subjects will receive imvotamab via IV infusion at a dose and schedule to be determined after reviewing all available response and safety data. No longer enrolling.
89602284|NCT04082936|Experimental|Phase 2 (FL)|FL subjects will receive imvotamab via IV infusion at a dose and schedule to be determined after reviewing all available response and safety data. No longer enrolling.
88811380|NCT03800186||Trauma femoral fracture|Patients to be aged ≥20 years and hospitalized for the treatment of femoral fracture following injury. Patients were grouping into five subgroups as patients with fracture of proximal type A, proximal type B, proximal type C, femoral shaft, and distal femur.
88811381|NCT04383860|Experimental|5-0 suture|5-0 suture administration during surgery
88811382|NCT04383860|Active Comparator|4-0 suture|4-0 suture administration during surgery
88811383|NCT03800264|Active Comparator|BISOPROLOL|BISOPROLOL 5mg per oral (P.O.) in the evening of the operation and then one dose (5 mg) every twenty four hours during the next two days.
88811384|NCT03800264|Active Comparator|hydrocortisone|hydrocortisone 100 mg intravenously is given in the evening of the operation and then 100 mg every eight hours during the next two days.
88811385|NCT03800342|Experimental|Healthy|Healthy individuals will participate in two separate days of cardiopulmonary exercise testing (CPET) (separated by a minimum of two, maximum of 7 days apart) prior to starting the aerobic exercise training program (AET). Individuals will then complete a 4-5 week (4x/week x 17 sessions) continuous, high-intensity AET. Each training session will consist of cycling for 3-5 minutes to warm-up, 45 minutes at 70% of heart rate reserve (HRR-determined from pre-training CPET), and 5-10 minutes to cool down. Following the AET, individuals will repeat the two separate days of CPET performed pre-training.
88811386|NCT01321541|Experimental|Pixantrone + Rituximab|Pixantrone and Rituximab
89602285|NCT04082936|Experimental|Phase 1b (Combination)|Subjects will receive imvotamab via IV infusion weekly and loncastuximab tesirine via IV infusion every 3 weeks.
89602286|NCT04070183|Other|Attention Control (Home Safety Evaluation)|A nurse will complete a home visit with the patient and their surrogate decision maker or other family member (if they've designated one), in which he or she will provide suggestions on how to improve the safety of the patient's home.
89602287|NCT04070183|Experimental|Intervention (POST Facilitation)|A nurse will complete a home visit with the patient and their surrogate decision maker or other family (if they've designated one), in which he or she will provide education about the POST form. The POST facilitators will be nurses trained using the Respecting Choices Advanced Steps model.
89602288|NCT04068610|Experimental|Part 1 (S1): FOLFOX + Bevacizumab + Durvalumab + Oleclumab|Participants in Part 1 safety run-in arm (S1) will receive intravenous (IV) infusions of FOLFOX (5-fluorouracil [5-FU]: 2400 mg/m^2 over 46-48 hours [Day 1 and 2 of every 14-day Cycle], oxaliplatin: 85 mg/m^2, folinic acid: 400 mg/m^2) and bevacizumab 5 mg/kg on Day 1 of every Cycle (14-day cycle) in combination with IV durvalumab 1500 mg every 4 weeks (Q4W) and IV oleclumab 3000 mg every 2 weeks (Q2W) till 4 doses (Cycle 4) then Q4W starting on Cycle 5 Day 1 until disease progression, unacceptable toxicity, withdrawal of participant consent, or another discontinuation criterion will be met.
89602289|NCT04068610|Experimental|Part 2 (C1): FOLFOX + Bevacizumab|Participants in Part 2 control 1 arm (C1) will receive IV infusions of FOLFOX (5-FU: 2400 mg/m^2 over 46-48 hours [Day 1 and 2 of every 14-day Cycle], oxaliplatin: 85 mg/m^2, folinic acid: 400 mg/m^2) in combination with IV bevacizumab 5 mg/kg on Day 1 of every Cycle (14-day cycle) until disease progression, unacceptable toxicity, withdrawal of participant consent, or another discontinuation criterion will be met.
89602290|NCT04068610|Experimental|Part 2 (E1): FOLFOX + Bevacizumab + Durvalumab + Oleclumab|Participants in Part 2 experimental 1 arm (E1) will receive IV infusions of FOLFOX (5-FU: 2400 mg/m^2 over 46-48 hours [Day 1 and 2 of every 14-day Cycle], oxaliplatin: 85 mg/m^2, folinic acid: 400 mg/m^2) and bevacizumab 5 mg/kg on Day 1 of every Cycle (14-day cycle) in combination with IV durvalumab 1500 mg Q4W and IV oleclumab 3000 mg Q2W till 4 doses (Cycle 4) then Q4W starting on Cycle 5 Day 1 until disease progression, unacceptable toxicity, withdrawal of participant consent, or another discontinuation criterion will be met.
89602291|NCT04057833|Experimental|E-CEL UVEC|"Patients will receive an injection of the Cell therapy vehicle into their supraspinatus muscle and tendon at the time of rotator cuff repair.~E-CEL UVEC cells suspended in autologous plasma and combined with thrombin at the implantation site (tendon delivery).~E-CEL UVEC cells suspended in 6.0% Dextran 40 and 10.0% human serum albumin (HSA) (infusion solution) (muscle delivery)."
89210311|NCT00984477|Experimental|1|AZD5122 oral suspension (part A and B)
89210312|NCT00984477|Placebo Comparator|2|Placebo oral suspension (part A)
89602292|NCT04057040|Experimental|Dose finding PTG-300 (Part 1); PTG-300 (Part 2); Open label extension PTG-300 (Part 3)|
89602293|NCT04057040|Experimental|Dose finding PTG-300 (Part 1); Placebo (Part 2); Open label extension PTG-300 (Part 3)|
89602294|NCT04048330||Women of reproductive age|Women 15 to 49 years of age who are not pregnant or lactating
89602295|NCT03997370|Experimental|Treatment (iohexol, standard care carboplatin, blood samples)|Patients receive iohexol IV over 30-60 seconds. Patients then receive standard of care carboplatin IV. Patients also undergo collection of 7-8 blood samples for analysis.
88811387|NCT01321541|Active Comparator|Gemcitabine + Rituximab|Gemcitabine and Rituximab
88811390|NCT01270529|Experimental|CKD Stages 1-4|
88811391|NCT01270529|Experimental|ESRD on Dialysis|
88811392|NCT01270529|Experimental|Kidney Transplant recipients|
88811393|NCT05254262||Elderly patients|Patients age 70 or older, who are admitted in hospital for surgical operation (elective or emergency surgery)
88811394|NCT04351607|Experimental|Verum|oral dose of 2 x 30mg (=60mg) Oleovital® Eisen Forte p.o. per day over a limited intake of 3-6 weeks due to increased physiological iron demand
88811395|NCT04351607|No Intervention|Control group|no intervention
88811396|NCT04351607|Other|Patient with menstral bleeding - subcollective A|verum or control
88811397|NCT04351607|Other|Patient without menstral bleeding - subcollective B|verum or control
88811398|NCT03801434|Experimental|Treatment (ruxolitinib)|Patients receive ruxolitinib PO BID on days 1-28. Treatment repeats for up to 6 cycles (28 days each) in the absence of disease progression or unacceptable toxicity.
88811399|NCT01322633||Pantoprazole|Patients who received treatment with pantoprazole tablets for at least 240 days within a 12-month period from 2000 through 2003.
88811400|NCT01322633||Other proton pump inhibitors|Patients who received treatment with any other proton pump inhibitor for at least 240 days within a 12-month period from 1996 through 2003.
88811401|NCT03804008|Active Comparator|Fundamental advice and a heel cup|
88811402|NCT03804008|Active Comparator|Fundamental advice and a heel cup plus exercise|
88811403|NCT03804008|Active Comparator|Fundamental advice and a heel cup plus exercise and injection|
88811404|NCT01322945||Endonasal surgery|Single cohort of patients undergoing endonasal surgery
88811405|NCT01271543|Active Comparator|MacIntosh group|
88811406|NCT01271543|Experimental|Shikani optical stylet|
88811407|NCT05655572|Experimental|Action Observation therapy|This group will perform exercises in stages. First stage consists of movements to improve balance in sitting position with exercises upright the pelvis, move weight forward, move weight to the left and right and rotate right and left. Second stage consist of sit to stand movements with exercises upright the pelvis in sitting position, move weight forward from a sitting position and stand up from a sitting position. Third stage consist of standing movements to improve balance with exercises move weight right and left, forward weight shift with right foot and left foot (lateral view) and forward weight shift with right foot and left foot (front view). Fourth stage consist of walking side ways to left and then towards right. Therapist will perform these tasks and video will be made which will play in front of patients.
88811408|NCT05655572|Active Comparator|Functional Training Group|participants including in this group will perform the tasks including lying to sitting position, moving in the sitting posture, sitting and standing up, posture training for learning a normal gait pattern, weight bearing and weight movement training in the straight posture, walking training on the flat floor, and stair walking
89602296|NCT03981926|No Intervention|In-Person|In-person care is the control group because it is currently considered the standard of care in delivering dermatologic services. The intervention includes regular visits to a physician, and may include such treatments as ointments, steroids or ultraviolet therapy at the discretion of a physician. In-person care is the major healthcare-delivery model for managing chronic skin diseases and a realistic, primary option that patients face. The patients in the in-person arm can seek atopic dermatitis care from primary care practitioners or dermatologists, just as they would in the real world.
89602297|NCT03981926|Experimental|Team-Based Connected Health (TCH)|The intervention arm is the team-based connected health (TCH) model, which purports to increase access to specialists and improve outcomes. Specifically, TCH offers multiple modalities for patients and primary care providers (PCPs) to access dermatologists online directly and asynchronously. TCH also fosters team care and patient engagement through active sharing of management plans and multidirectional, informed communication among patients, PCPs, and dermatologists.
89602298|NCT03961971|Experimental|Treatment (MBG453, spartalizumab, stereotactic radiosurgery)|Patients receive MBG453 and spartalizumab IV over 30 minutes on Day 1. Patients then undergo stereotactic radiosurgery on Day 8. Courses with MBG453 and spartalizumab repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89602299|NCT03938298|Experimental|Intervention group|
89602300|NCT03938298|Active Comparator|Control group|
89602301|NCT03921827|Experimental|EECP therapy|Half of the study sample will be allocated to EECP therapy (35 sessions) of 1-hour each. Acetazolamide challenged HMPAO-SPECT will be performed before randomization and repeated 2-months after the completion of EECP therapy. MRI of the brain would be performed after completion of EECP therapy to document any silent stroke.
89602302|NCT03921827|No Intervention|Best Medical Therapy|This group will receive the best medical therapy according to our institutional practice and as per the recommendations of American Stroke Association.
89602303|NCT03919968|Experimental|Martial Arts|The training will be performed 3 times a week, for 12 weeks, during 60 minutes, being that will be divided into 20 min of general exercises, 20 min of specific exercises and 20 min of fight simulation and / or play activities. The activities will be carried out in a way adapted for the elderly. Will be used kickers, gauntlets, thorax and head protectors, shin guards, gloves, and other devices.
89602304|NCT03919968|Active Comparator|Functional Training|The training will be performed 3 times a week, for 12 weeks, during 60 minutes, being that will be divided into 20 min of general exercises, 20 min of specific exercises and 20 min of play activities. The activities will be carried out in a way adapted for the elderly. Will be carried out neuromotor control / coordination, balance, flexibility and static and dynamic stabilization. They will also have acceleration and deceleration activities, rotation and counter-rotation, extension and counter-extension, flexion and counter-flexion.
89602305|NCT03882372|Experimental|Nasal high flow|"Following baseline assessment, patients randomized to the nasal high flow arm will be equipped with a nasal high flow device (myAIRVO2) administrated through the Optiflow nasal canula. Flow will be set at the highest flow tolerated (20-30 L/min): initially 30 L/min, progressively decrease if not tolerated. Temperature will be set between 34-37°C according to the tolerance : initially 37°C and decreased if not tolerated. Patients will be asked to use the device 8h per day.~Patients under long-term oxygen will preserve their usual flow. The usual prescribed oxygen flow will then be titrated during nasal high flow to maintain the same baseline transcutaneous oxygen saturation as their conventional oxygen therapy (≥ 90%) to prevent any oxygen dilution effect of nasal high flow."
89602306|NCT03882372|No Intervention|Usual care|"Patient randomized to the control group will have no other specific intervention than their usual care.~Patients under long-term oxygen will preserve their usual flow."
89602307|NCT03879135|Experimental|On-Demand|Participants will receive recombinant von Willebrand factor (rVWF) (with or without ADVATE).
89602308|NCT03879135|Experimental|Prophylaxis|Participants will receive recombinant von Willebrand factor (rVWF).
89602309|NCT03878550||Cases|Male and female adult patients with early-stage hepatocellular carcinoma against a background of liver cirrhosis.
89602310|NCT03878550||Controls|Male and female adult patients with liver cirrhosis at risk for hepatocellular carcinoma.
89602311|NCT03870854|Experimental|PEFA targeted substrate ablation|Use of PEFA strategy to identify and target VT isthmuses.
89602312|NCT03860844|Experimental|Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia|This arm includes participants from 3 cohorts: AML, T-ALL and B-ALL.; AML: Weekly dosing of isatuximab with induction chemotherapy. The therapy may be repeated one more cycle; ALL: (Includes T-ALL and B-ALL) Weekly dosing of isatuximab with induction chemotherapy, then biweekly dosing of isatuximab with consolidation chemotherapy.
89602313|NCT03856814||Patients with varicose veins|Patients with varicose veins, indicative for treatment with EndoVenous Laser Ablation (EVLA) using the ELVeS® Radial® 2ring slim fiber or Surgery (ligation/stripping) according to the standard of care of the participating investigators.
89602314|NCT03853304|Experimental|Quadruple-Fortified Salt (QFS)|Salt fortified with iron, iodine, folic acid, and vitamin B12
89602315|NCT03853304|Experimental|DFS + Folic acid|Salt fortified with iron, iodine, and folic acid
89602316|NCT03853304|Experimental|DFS + Vitamin B12|Salt fortified with iron, iodine, and vitamin B12
89602317|NCT03853304|Active Comparator|Double-fortified salt (DFS)|Salt fortified with iron and iodine
89602318|NCT03845218||Healthy Controls|Participants without RP
89602319|NCT03845218||Participants with RP|Participants must have evidence of RP as defined by characteristic ERG responses, visual fields, clinical exam and/or genetic testing
89602320|NCT03841149||VolUS3D patients|Patients with renal tumour
89602321|NCT03808272|Experimental|HOT AXIOS Stent and Electrocautery- Enhanced Delivery System|HOT AXIOS Stent and Electrocautery- Enhanced Delivery System
89608621|NCT04143477|Experimental|Peficitinib 100 mg|Participants will receive a single dose of 100 mg under fasted condition Day 1, followed by multiple doses of 100 mg under fed condition once daily in the morning from Day 8 till Day 13.
89210313|NCT00984477|Experimental|3|AZD5122 oral and IV infusion (part B)
89210314|NCT02541006|Experimental|Tiotropium 18 mcg dry powder for inhalation|Tiotropium 18 mcg dry powder for inhalation, one inhalation, once daily with the DISCAIR
89602322|NCT03787264|Experimental|BAAG|"Debulking: 2 debulking cycles (q 28d) of bendamustine will be administered unless the patient has a contraindication or a debulking is not clinically indicated~Induction: 6 cycles (q 28d) of Obinutuzumab + Acalabrutinib + Venetoclax~Maintenance: max. 8 cycles (q 84d) of Obinutuzumab + Acalabrutinib + Venetoclax~Maintenance treatment will be continued until (whichever occurs first):~12 weeks (approx. 3 months) after confirmation of achievement of a CR/CRi and MRD negativity~maintenance cycle 8~progression of CLL or start of a subsequent therapy~unacceptable toxicity"
89602323|NCT03786523|Experimental|TRF|Time Restricted Feeding
88980788|NCT05253209|Experimental|Active|"Patients will receive:~an L-citrulline bolus of 150 mg/kg at the initiation of cardiopulmonary bypass~the addition L-citrulline to maintain a steady state target concentration of approximately 100 μmol/L of L-citrulline during cardiopulmonary bypass~an L-citrulline bolus of 10 mg/kg 30 minutes after decannulation from cardiopulmonary bypass, followed immediately by a 9 mg/kg/hour continuous L-citrulline infusion or placebo for up to 48 hours post-first dose. The infusion rate will be adjusted (up or down titration of drug infusion) to achieve a target steady state concentration of 100 μmol/L.~Infusion will be discontinued once invasive arterial blood pressure monitoring is discontinued or at 48 hours, whichever occurs first."
88980789|NCT05253209|Placebo Comparator|Placebo|Plasmalyte A administered to the same schedule as the active treatment arm.
88980790|NCT05240313|Experimental|keepin' it REAL (kiR)|The standard keepin' it REAL intervention, adapted for an online format. This includes 10 one-hour small group sessions focused on helping youth to develop drug refusal skills and improve decision making, risk assessment, and emotion regulation. Additionally, short videos highlight various aspects of the program (refuse, explain, avoid, leave). All materials are available in Spanish and English.
88980791|NCT05240313|Experimental|kiR + aggression|The standard keepin' it REAL intervention, adapted for an online format, plus content on interpersonal aggression
88980792|NCT05240313|Active Comparator|Stress Management|A single session focused on stress management skills.
88980793|NCT05237713|Other|Canakinumab treatment|200 mg canakinumab subcutaneously every three weeks
88980794|NCT05237167|Experimental|Ultrasound|After randomization, these subjects will undergo diagnostic point-of-care ultrasound
88980795|NCT05237167|Active Comparator|Radiograph|After randomization, these subjects will undergo diagnostic plain radiograph
88980796|NCT05233787|Experimental|Arm A: Tailored use of defunctioning stoma after TME|"The tailored use of defunctioning stoma includes two steps:~Firstly, the decision to use or not a defunctioning stoma will be based on the personalized risk of anastomotic leakage (according to AFOR score). This score is ranked from 0 to 6, and includes gender, Body Mass Index, smoking, diabetes, tumor size and preoperative radiotherapy.~Patients with AFORS equal to 0 or 1 (risk of anastomotic leakage less than 10%) will not have defunctioning stoma;~Patients with AFORS equal to or between 2 and 6 (risk of anastomotic leakage more than 20%) will have a defunctioning stoma.~Secondly, in patients with a defunctioning stoma, an early closure will be performed day 8-12 after TME if:~No fever postoperatively (≤ 38°C),~CRP at day 2 lower than 115mg/L (+/- 10 mg/L), decreasing at day 4,~CT-scan with colonic contrast retrograde enema showing no anastomotic leakage."
88980797|NCT05233787|Active Comparator|Arm B: Systematic use of defunctioning stoma|Systematic use of defunctioning stoma for 3 months after TME according to French national guidelines
88980798|NCT05229666|Other|Cognitive Challenge|
88980799|NCT05227742|Placebo Comparator|Placebo (0 mg psilocybin)|Participants in this arm will receive 0 mg of psilocybin once per week for 5 weeks.
88980800|NCT05227742|Experimental|1 mg psilocybin|Participants in this arm will receive 1 mg psilocybin once per week for 5 weeks.
88980801|NCT05227742|Experimental|2.5 mg psilocybin|Participants in this arm will receive 2.5 mg psilocybin once per week for 5 weeks.
88980802|NCT05227742|Experimental|5 mg psilocybin|Participants in this arm will receive 5 mg psilocybin once per week for 5 weeks.
88980803|NCT05226104|Other|Healthy Participants|Subjects who are interested in treatment for facial fine lines and wrinkles will be recruited for the study.
88980804|NCT05221749|Active Comparator|Silver diamine fluoride|These active caries lesions will receive silver diamine fluoride treatment
88980805|NCT05221749|Experimental|Nanosilver fluoride|These active caries lesions will receive nanosilver fluoride treatment
88980806|NCT05219552|Experimental|Intervention group- lactation support and unconditional cash transfers|Women in this arm will receive personal lactation support from a professional lactation specialist at 5 time points: pregnancy and at 2-weeks, 4-weeks, 6-weeks and 3-months postpartum. Women in the intervention group will also receive monthly unconditional cash transfers of 10,000 Kenyan shillings sent directly to a a mobile phone-based money transfer service accounts associated with their personal cell phone.
88980807|NCT05219552|No Intervention|Control group- standard care|The women enrolled in the control arm will receive standard care at a clinic similar to, but distinct from, the intervention site.
88980808|NCT05208359|Experimental|STRONG immediate group|Small mental health support group delivered immediately
88980809|NCT05208359|Other|STRONG delayed group|Small mental health support group delivered after a delay of approximately 3 months
88980810|NCT05197946||Subjects with CP survey|Subjects in this group are age 8 and older with a diagnosis of cerebral palsy. Participants are either able to affirmatively consent or assent with LAR consent. This sample will have a CFCS score ranging between 1 and 3 and should be able to unambiguously respond to a 65 item multiple choice survey.
88980811|NCT05197946||Control Subjects survey|Subjects in this group are age 8 and older with no clinically significant neurologic or developmental diagnosis. Participants are either able to affirmatively consent or assent with LAR consent.
89602324|NCT03786523|Active Comparator|CER|Continuous Energy Restriction
89602325|NCT03777631|No Intervention|Standard medical therapy group|The preferred anticoagulant is edoxaban. Antiarrhythmic drugs are administered as needed for the patient by well-trained cardiologists.
89602326|NCT03777631|Active Comparator|Catheter ablation group|Catheter ablation (CA) should be performed within 1-6 months from the onset of cerebral infarction. CA is based on pulmonary vein isolation, with atrial ablation as required. For conducting CA by a trained and experienced cardiologist, only institutions in which performed >100 CA annually were participated in the present study in principle.
89602327|NCT03745612|Experimental|TRF|Time restricted feeding
89210315|NCT02541006|Active Comparator|SPIRIVA 18 mcg HANDIHALER|Tiotropium 18 mcg dry powder capsul for inhalation one capsule once daily with the HandiHaler
89602328|NCT03745612|Active Comparator|CER|continuous energy restriction
89602329|NCT03739372|Experimental|Newly diagnosed HGG (Stratum A)|Children and young adults with newly diagnosed HGG receive an individualized treatment plan. Each treatment is different and depends on what the Specialized Tumor Board recommends depending on the molecular profile of the patient's tumor.
89602330|NCT03739372|Experimental|Diffuse midline HGG (Stratum B)|Children and young adults with diffuse midline high grade gliomas receive an individualized treatment plan. Each treatment is different and depends on what the Specialized Tumor Board recommends depending on the molecular profile of the patient's tumor.
89602331|NCT03732950|Experimental|Treatment (pembrolizumab)|Participants receive pembrolizumab intravenously IV on day 1. Courses repeat every 3 weeks for up to 35 courses (2 years) in the absence of disease progression or unacceptable toxicity.
89602332|NCT03721068|Experimental|iC9.GD2.CAR.IL-15 T-cells|The continuous reassessment method (CRM) will be used to estimate the maximum-tolerated dose (MTD) of cells that to be given in dose escalation cohorts comprised of 2-6 subjects. The final MTD will be the dose with estimated probability of dose limiting toxicity (DLT) closest to the target toxicity rate of 20%. Three cell doses will be evaluated: 0.5 x 10^6 cells/kg, 1.0 x 10^6 cells/kg, 1.5 x 10^6 cells/kg. Cohort enrollment will be staggered and each subject must complete at least 2 weeks of the cell treatment without incident of DLT before another subject can be enrolled at that dose level. A minimum of two subjects must complete the 4-week post-infusion DLT period before enrollment at the next higher dose level will be considered. If dose level 1 is determined to be above a tolerable dose, de-escalation would occur to dose level -1 where subjects would receive 0.25 x 10^6 cells/kg.
89602333|NCT03710109||Concussion|Individuals who have sustained a recent concussion
89602334|NCT03710109||Control Healthy Volunteers|No Intervention
89602335|NCT03691493|Experimental|Radiation, palbociclib, hormone therapy|Patients undergo radiation therapy over 5-10 days and receive palbociclib PO QD on days 1-21. At the discretion of treating physician, patients also receive letrozole, anastrozole, exemestane, or tamoxifen PO QD on days 1-28, or fulvestrant IM on days 1 and 15 of cycle 1 and on day 1 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89602336|NCT03634007|Experimental|Cohort 1: 1.4 x 10^10 gc/mL CSF|Participants will receive 1.4 x 10^10 gc/mL CSF of LX1001.
89602337|NCT03634007|Experimental|Cohort 2: 4.4 x 10^10 gc/mL CSF|Participants will receive 4.4 x 10^10 gc/mL CSF of LX1001.
89602338|NCT03634007|Experimental|Cohort 3: 1.4 x 10^11 gc/mL CSF|Participants will receive 1.4 x 10^11 gc/mL CSF of LX1001.
89602339|NCT03634007|Experimental|Cohort 4: 1.4 x 10^14 gc (fixed dose)|Participants will receive 1.4 x 10^14 gc (fixed dose; approximately 3.4 × 10^11 gc/mL CSF based on an average CSF volume of 409 mL) of LX1001.
89602340|NCT03632421|Experimental|Intervention group|
89602341|NCT03632421|Active Comparator|Control group|
89602342|NCT03623464|Active Comparator|Mobile app and Fitbit + Standard of care|Mobile health application and Fitbit + standard of care: Participants will utilize mobile app and Fitbit and standard of care. Mobility data will be generated using a mobile health tracker designed for smartphone devices.
89602343|NCT03623464|Other|Standard of care|Participants will receive standard of care
89602344|NCT03621592|Experimental|Cutimed® Sorbact®|Participants in this group will receive the Cutimed Sorbact intervention for 6 weeks.
89602345|NCT03621592|Active Comparator|Acticoat®|Participants in this group will receive the Acticoat intervention for 6 weeks.
89602346|NCT03612544|Experimental|Intervention group|
89602347|NCT03612544|Active Comparator|Control group|
89032363|NCT03458858|Other|Carbohydrate Control Jello|Participants will receive between 400 to 800 grams of strawberry jello daily, as a proportion of their daily caloric intake added to their base diet. The jello will be matched to the mixed berries in both total carbohydrate level and gram quantity. The base diet will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet.
89210316|NCT02591771|Experimental|adrenaline|i.v. adrenaline infusion as an early and fast haemodynamic stabilizer, associated with a tight tissue perfusion monitoring, in the context of a stepwise progression in the treatment of cardiogenic shock, including ventricular mechanical support
89602348|NCT03612453|Experimental|Intervention group|
89602349|NCT03612453|Active Comparator|Control group|
89602350|NCT03612375|Experimental|Intervention group|
89602351|NCT03612375|Active Comparator|Control group|
89602352|NCT03612336|Experimental|Intervention group|
89602353|NCT03612336|Active Comparator|Control group|
89602354|NCT03603353|Experimental|Intervention group|
89602355|NCT03603353|Active Comparator|Control group|
89602356|NCT03603340|Experimental|Intervention group|
89602357|NCT03603340|Active Comparator|Control group|
89602358|NCT03587064|Active Comparator|3-lead CRT implantation (CRT-D)|In the 3-lead CRT implantation (CRT-D) group, conventional 3-lead CRT defibrillator system implantation will be performed. The CRT-D system is composed by three leads, one in atrium and two in both ventricles
89602359|NCT03587064|Experimental|2-lead CRT implantation (CRT-DX)|In the 2-lead CRT implantation (CRT-DX) group, 2-lead CRT defibrillator system implantation will be performed. The CRT-DX system is composed by two ventricular leads, the right one is provided with a dipole for atrial sensing
89602360|NCT03575351|Active Comparator|Arm A - Standard of Care (SOC)|Subjects should receive SOC (R-DHAP, R-ICE or R-GDP) followed by HDCT (BEAM) and HSCT. Standard of care regimen will be administered as per investigator decision.
89602361|NCT03575351|Experimental|Arm B - JCAR017|Lymphodepleting chemotherapy with intravenous (IV) fludarabine (30 mg/m2/day for 3 days) plus cyclophosphamide IV (300 mg/m2/day for 3 days) (flu/cy) concurrently followed by JCAR017 infusion.
89602362|NCT03529422|Other|Open-label, single-arm|Durvalumab in combination with intensity modulated radiotherapy (IMRT) treatments
89602363|NCT03493685|Experimental|sparsentan for double-blind and open-label extension|Sparsentan will be administered as a single oral morning dose; an initial dose of 400 mg daily titrating up to a target dose of 800 mg, daily
89602364|NCT03493685|Active Comparator|Irbesartan|Irbesartan will be administered as a single oral morning dose; an initial dose of 150 mg daily titrating up to a target dose of 300 mg, daily
88980812|NCT05197946||Subjects with CP MRI|Subjects are 8 years or older with a diagnosis of cerebral palsy and clinical imaging demonstrating isolated periventricular white matter injury. Clinical assessment states that neurologic symptoms are attributed to this isolated injury. Subjects in this group must be able to lie still in a scanner for 1.5 hours in at most 2 sessions and be able to have an MRI. Participants must be able to affirmatively consent or assent with LAR consent.
88980813|NCT05197946||Control Subjects MRI|Subjects in this group are age 8 and older with no clinically significant neurologic or developmental diagnosis. Participants are able to affirmatively consent and are able to have an MRI. Subjects also should be able to lie still in a scanner for 1.5 hours.
88980814|NCT05194631|Experimental|Regeneration Capacity of Satellite Cells|In vitro Regeneration Capacity of Satellite Cells from the Quadriceps Compared to That of the Diaphragm isolated From one patient
88980815|NCT05194540|Experimental|Tralokinumab subcutaneous dosing with Device A|An initial SC dose of 600 mg tralokinumab at baseline followed by self-administration of a 300 mg dose of tralokinumab every other week for 14 weeks.
88980816|NCT05191758|No Intervention|control|no supplements will be taken
88980817|NCT05191758|Experimental|3 grams of supplements|subjects will take 3 grams of supplements once per day
88980818|NCT05191758|Experimental|6 grams of supplements|subjects will take 3 grams of supplements twice per day
88980819|NCT05191758|Experimental|9 grams of supplements|subjects will take 3 grams of supplements three times per day
89602365|NCT03486197|Experimental|Treatment (Pembrolizumab, neutron radiation therapy)|Participants receive pembrolizumab IV on days 1 and 22. On day 23, participants may undergo an optional tumor biopsy and receive 3-5 treatments of neutron radiation therapy over 2 weeks on days 23-42. Participants receive pembrolizumab IV on day 43 and continue per standard of care in the absence of disease progression or unacceptable toxicity.
89602366|NCT03439683||Physicians|"Definition: Physicians working in the ICU for at least 50% of their time in the hospital~Intervention: Survey about patient-ventilator asynchrony"
89602367|NCT03439683||Nurses|"Definition: Nurses working in the ICU for at least 20 hours/week~Intervention: Survey about patient-ventilator asynchrony"
89602368|NCT03439683||Respiratory Therapists|"Definition: Respiratory Therapists working in the ICU for at least 20 hours/week~Intervention: Survey about patient-ventilator asynchrony"
89602369|NCT03417583|No Intervention|Clinical Standard Care Group|These patients will continue to be seen by their regular neurology provider for Huntington's disease. They will not be treated explicitly according to the protocol, though they may be prescribed some of the same medications.
88980820|NCT05190471|Experimental|Relapsed/Refractory AML - BP1002 monotherapy|BP1002 monotherapy dose escalation
88980821|NCT05190471|Experimental|Relapsed/Refractory AML - BP1002 in combination with decitabine|BP1002 single dose in combination with decitabine
88980822|NCT05187611|Experimental|Conduction system pacing|"Pacing the His-Purkinje system.~Crossover to biventricular pacing was allowed in case of failed conduction system pacing: failed His bundle pacing and failed Left bundle branch pacing (high thresholds (>3.5V / 1ms); no left bundle branch pacing criteria; no left bundle branch correction).~Electrocardiographic optimization allowed in order to obtain the narrowest QRS."
88980823|NCT05187611|Active Comparator|Biventricular pacing|"Pacing from the right ventricular and coronary sinus leads. Electrocardiographic optimization with fusion-optimized intervals.~Crossover from biventricular pacing to conduction system pacing will be allowed in the following situations: coronary sinus cannot be cannulated; no lateral or posterolateral branches; or phrenic stimulation."
88980824|NCT05180786|Other|Group 1|
88980825|NCT05180786|Other|Group 2|
88980826|NCT05178342|Other|CA-4948 treatment|Single-arm design. all patients are treated with IMP
88980827|NCT05175755|Experimental|Patients|The procedure involves taking a total of 12 ml of blood.
89602370|NCT03417583|Experimental|Protocol Intervention Group|These participants will transfer their clinical care to the study provider for the duration of the study, and their symptom treatment will be guided by the study protocol.
89602371|NCT03370406|No Intervention|Control Group|Control group will receive neither 5-fluorouracil (5FU) injection nor topical Imiquimod 5% cream. This group will receive standard of care only. Lesion will be surgical resected on day 21 of study.
89602372|NCT03370406|Experimental|5FU Group|5-fluorouracil (5FU) Group participants will receive a 1ml intralesional injection of 5FU 50mg/ml aqueous injectable solution. One injection will be administered weekly for 3 weeks. Injections will occur on d0, d7, and d14. Standard of care will be administered on d21 of study and lesion will be surgical resected.
89602373|NCT03370406|Experimental|5FU + Imiquimod 5% Group|5-fluorouracil (5FU) + Imiquimod 5% cream Group participants will receive intralesional 5FU as in the previous group, additionally participants will also receive three-times-weekly topical application of 5% imiquimod to the same lesion. Standard of care will be administered on d21 of study and lesion will be surgical resected.
89602374|NCT03362294|Experimental|GA Depot 40mg once monthly|Monthly IM injection
89602375|NCT03362294|Experimental|GA Depot 25mg once monthly|Monthly IM injection
89602376|NCT03362060|Experimental|PVX-410|"PVX-410 vaccine at W0, 1, 2, 3, 4, and 5 followed by booster PVX-410 vaccine doses at W10 and 28~Pembrolizumab will be administered every 3 weeks intravenously starting with week 1"
88980828|NCT05156021|Experimental|pre-vitrectomy anti-VEGF injection group|Patient in this group receive an intravitreal injection of anti-VEGF drug 3-5 days before surgery, followed by PPV combined with PRP and pressure-reducing valve implantation
88980829|NCT05156021|Experimental|pre and post-vitrectomy anti-VEGF injection group|Patient in this group receive two intravitreal injections of anti-VEGF drugs. One is injected 3-5 days before surgery, the other is at the same time as the PPV combined with PRP and pressure reducing valve implantation is completed.
88980830|NCT05151185|No Intervention|Control group|The dementia case manager in the control group undergo existing training. The family caregiver in the control group receive routine service.
88980831|NCT05151185|Experimental|training program|The dementia case manager in experiment group will undergo training (Competency-based Dementia Case Management Train-the-trainer Program; CDCMTP); The family caregiver in experiment group will receive competency-based Dementia Case Management Service Program.
89210317|NCT00986817|Experimental|Terlipressin|
89210318|NCT00986817|Placebo Comparator|Placebo|
89032364|NCT03458858|Other|Fiber Enriched Jello|Participants will receive between 400 to 800 grams of fiber enriched strawberry jello daily, as a proportion of their daily caloric intake added to their base diet. The jello will be matched to the mixed berries in both total carbohydrate level and fiber content, and in the same gram quantity. The base diet will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet.
89032365|NCT03458858|Other|Low Fiber Mixed Berry Juice|Participants will receive 1 liter per day of low fiber mixed berry juice added to their base diet. The juice will be squeezed from the mixed berries, then filtered. The sugar level of the juice will match that of the mixed berries. The base diet will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet.
89032366|NCT03457740|Experimental|Formula 1|Formula 1 with nutrients and herbs, 4 capsules daily, 6 weeks
89032367|NCT03457740|Experimental|Formula 2|Formula 2 with nutrients and herbs, 4 capsules daily, 6 weeks
89032368|NCT03457740|Placebo Comparator|Placebo|Placebo, 4 capsules daily, 6 weeks
89032369|NCT04502667|Experimental|cholecalciferol (Vitamin D)|Children under 12 months they will be given 1000U and in children over 12 months they will be given 2000U every 24 hours orally during hospitalization
89032370|NCT04502667|No Intervention|Control|No intervention
89032371|NCT00524498|Experimental|A|FAIT
89032372|NCT00524498|Active Comparator|B|BST
89032373|NCT04492917|Experimental|Cranial Technique CV4|"All subjects received a combination of the active technique (CV4) and the corresponding sham technique (shamCV4).~CV4: the lateral angles of the occipital squama are manually approximated slightly exaggerating the posterior convexity of the occiput and taking the cranium into sustained extension. The technique ended when the osteopath perceived the still point, a condition in which the balanced membranous or ligamentous tension is achieved.~ShamCV4: sham intervention was performed by placing the hands in the same position as the corresponding active technique, applying a light touch"
89032374|NCT04492917|Active Comparator|Sacral Technique ST|"All subjects received a combination of the active technique (ST) and the corresponding sham technique (sST).~ST: The subject was lying in the supine position, while the osteopath positioned the index and middle fingers of the caudal hand on either side of the subject's sacrum. Then establishes a point of balance between the coccyx and the vertex facilitating the sacral extension until the achievement of the still point.~ShamST: sham intervention was performed by placing the hands in the same position of the corresponding active technique, applying a light touch"
89032375|NCT00523406|Active Comparator|A|standard fluence photodynamic therapy and intravitreal triamcinolone combination
89032376|NCT00523406|Active Comparator|B|reduced fluence photodynamic therapy and intravitreal triamcinolone combination
89032377|NCT03457662|Active Comparator|OMC and pseudo-SDT|Optimal medical care (OMC) and pseudo-SDT are administrated in this arm. OMC is established according to the standards established by the 2016 ACC-AHA Guidelines for the Management of Patients with Peripheral Artery Disease in order to promote best practices for risk factor management.
89032378|NCT03457662|Experimental|OMC and SDT|OMC and SDT are administrated in this arm.
89032379|NCT00524615|Active Comparator|1|25 mg of Spironolactone oraly once daily
89032380|NCT00524615|Placebo Comparator|2|placebo oraly once daily
89032381|NCT02936778||PICU (= case group)|Children aged 2-18 years admitted to a Paediatric Intensive Care Unit in the Netherlands, with a diagnosis of acute wheeze or SAA.
89032382|NCT02936778||MC (= control group)|Children aged 2-18 years admitted to a Medium Care in the Netherlands, with a diagnosis of acute wheeze or SAA.
89032383|NCT03458819||Control|Patients on neither active Vitamin D or a statin
89602377|NCT03354741|Other|Laser then Sham therapy|2nd cycle of chemotherapy : administration of laser therapy 3th cycle of chemotherapy : administration of a sham laser according to the same modalities
89602378|NCT03354741|Other|Sham therapy then laser|2nd cycle of chemotherapy : administration of a sham laser 3th cycle of chemotherapy : administration of laser therapy according to the same modalities
89602379|NCT03325985|Experimental|Nurse-led telephonic case management|"Telephonic nurses will contact patients within 72 hours of enrollment~Patients will speak with the telephonic nurse over the phone once a week (or as often as needed) for a duration of 6 months."
89602380|NCT03325985|Active Comparator|Facilitated, outpatient specialty palliative care|"Patients will be scheduled for their first in-person palliative care visit within two weeks of enrollment and then once a month for 6 months.~Clinic visits will be scheduled the same day as other specialty appointments if possible"
89032384|NCT03458819||Vit D|Patients on active Vitamin D but not a statin
89032385|NCT03458819||Statin|Patients on a statin but not active Vitamin D
89032386|NCT03458819||D + Statin|Patients on both active Vitamin D and a statin
89032387|NCT04689750||Allogeneic HSCT recipients and donors|
89032388|NCT02948192||Preterm Delivery|African american women who present for prenatal care who experience spontaneous preterm birth
89032389|NCT02948192||Term delivery|African american women who present for prenatal care who experience term birth
89032390|NCT02936817|Other|Aerobika® device|For a period of 15 +/- 3 days all subjects will use the Aerobika® device before administration of their stable standard of care treatment regimen (i.e. study patients should use the device before each inhalation medication administration, with a minimum use of the device of twice daily). HRCT scans wil be taken at visit 1 and visit 3.
89032391|NCT00523445|Experimental|Varenicline|The effect of varenicline on cognitive function of Varenicline(Chantix) is being compared to that of placebo
89032392|NCT00523445|Placebo Comparator|Placebo|The effect of placebo comparator is being compared to that of varenicline
89032393|NCT02936661|Experimental|Tranexamic acid|Tranexamic acid 1 g（10ml） IV in 2 minutes after the baby delivered during ceasarean section
89032394|NCT02936661|Placebo Comparator|placebo|NS 10ml IV in 2 minutes after the baby delivered during ceasarean section
89032395|NCT02948075|Experimental|Quisinostat 12 mg & Paclitaxel & Carboplatin|One 3-weeks course includes 6 doses of Quisinostat 12 mg at Days 1, 3, 5, 7, 9 and 11 and Paclitaxel 175 mg/m2 and Carboplatin (mg/ml x min) x [GFR (ml/min) + 25] on Day 7 up to 6 cycles.
89032396|NCT04690725|Experimental|TQB3525 arm|3+3 design for phase I for RP2D (Recommended Phase 2 Dose) for adolescents (12-17 years old) (15mg QD or 20mg QD); phase II for efficacy exploration for another 17 patients using RP2D QD
89602381|NCT03298984|Experimental|Alvocidib and Cytarabine/Daunorubicin|The starting dose of alvocidib will be 20 mg/m2 as a 30-minute intravenous (IV) bolus followed by 30 mg/m2 over 4 hours as an IV infusion administered daily on Days 1-3 of Induction. Patients will have a one day drug holiday (Day 4) before initiation of the 7+3 regimen. Beginning on Day 5, cytarabine will be administered as a 100 mg/m2/day continuous IV infusion for seven consecutive days (Days 5-11) plus daunorubicin administered at a dosage of 60 mg/m2 IV on Days 5-7.
89602382|NCT03270358|Experimental|patient with stenosis|Patient coming to the vascular surgery unit to receive surgery regarding their fistula stenosis
89602383|NCT03270358|Other|patient without stenosis|Patient coming for their dialysis
89602384|NCT03248492|Experimental|DS-8201a Low Dose|T-DM1 resistant/refractory (R/R) patients in the low dose treatment group
89602385|NCT03248492|Experimental|DS-8201a Medium Dose|T-DM1 resistant/refractory (R/R) patients in the medium dose treatment group
89602386|NCT03248492|Experimental|DS-8201a High Dose|T-DM1 resistant/refractory (R/R) patients in the high dose treatment group
89602387|NCT03248492|Other|Exploratory Arm|In Part 2b- Continuation Stage, about 10 T-DM1 Intolerant patients will receive the DS-8201a recommended dose (RD) as an exploratory arm
89602388|NCT03232164|Experimental|18F-DCFPyL PET|Four separate substudies evaluating 18F-DCFPyL PET imaging of prostate cancer in four prostate cancer clinical scenarios under the following subheadings: (1) primary prostate cancer, (2) biochemical recurrence post-prostatectomy prior to radiation therapy, (3) androgen-resistant metastatic disease and (4) detection of clinically significant prostate cancer in low to intermediate risk primary prostate cancer
89602389|NCT03225560|Experimental|Smart Phone Application|A novel smart phone application available for both Apple iOS and Google Android platforms with capabilities to populate the phone calendar with automated reminders/notifications at the appropriate times prior to the colonoscopy.
89602390|NCT03225560|Active Comparator|Traditional Paper Instructions|Traditional paper instructions for bowel preparation
89602391|NCT03224468|Active Comparator|Medical Marijuana Arm|This group can begin using medical marijuana immediately.
89602392|NCT03224468|No Intervention|Waitlist Control Arm|This group agrees to wait 3 months before using medical marijuana.
89602393|NCT03219528|Active Comparator|Rifaximin|Rifaximin 550 mg three times daily for 14 days
89602394|NCT03219528|Active Comparator|Low FODMAP Group|Low FODMAP diet for 4 weeks
89602395|NCT03216252|Other|biological samples|biological samples on patients with MITOCHONDRIAL DISEASES
89602396|NCT03172195|Experimental|Patients with ulcerative colitis|Patients with ulcerative colitis will have a rectosigmoidoscopy, biopsies and blood sample.
89602397|NCT03163511|Experimental|Cohort 1|VC-02 Combination Product; Up to six (6) VC-02-20 implants and up to two (2) VC-02-300 implants
89602398|NCT03163511|Experimental|Cohort 2|VC-02 Combination Product; Up to twelve units implanted of which up to ten (10) are VC-02-300 implants and the rest are VC-02-20 implants.
88980832|NCT05148780|Other|Participants with Acute Respiratory Infections (ARI) in Outpatient Setting|Participants presenting with ARIs in an outpatient setting who are at high risk of progressing to severe disease will be screened for viral respiratory pathogens (respiratory syncytial virus [RSV], Influenza, severe acute respiratory syndrome coronavirus 2 [SARS-COV-2]) by collecting a nasal swab. If a participant is positive for RSV and/or influenza virus and/or SARS-CoV-2 based on a study test or standard-of-care (SOC) polymerase chain reaction (PCR)-based test, the participant will be eligible for enrollment in the study in the home-based short-term and long-term follow-up phases.
89032397|NCT02930811|Experimental|Sildenafil|Single Sildenafil oral morning intake (100mg/day) per day for a total duration of 6 months (Sildenafil 100 mg oral morning dose)
89032398|NCT02930811|Placebo Comparator|Placebo|Single Placebo oral morning intake per day for a total duration of 6 months (Placebo oral morning dose)
89032399|NCT02947919|Experimental|Intervention|Music in the perioperative period
89602399|NCT03162016|Experimental|Transplants of acellular matrix|
89602400|NCT03162016|Active Comparator|Transplants of connective tissue|
89602401|NCT03160430|Experimental|Part A PK Arm|a single 100 mg dose of RVX000222 (apabetalone) on the day of dialysis, followed by a one (1) week washout period, and a second dose of RVX000222 (apabetalone) administered on a non-dialysis day (total of two (2) 100 mg RVX000222 doses)
89602402|NCT03160430|Placebo Comparator|Part B Sequence A|RVX000222 (apabetalone) 100 mg b.i.d (total 200 mg/day) for 6 weeks; 4 Week Washout (No RVX000222/placebo administration); Placebo b.i.d for 6 weeks
89602403|NCT03160430|Placebo Comparator|Part B Sequence B|Placebo b.i.d for 6 weeks; 4 Week Washout (No RVX000222/placebo administration); RVX000222 (apabetalone) 100 mg b.i.d (total 200 mg/day) for 6 weeks
89602404|NCT03149003|Experimental|Arm 1: DSP-7888 Dosing Emulsion plus Bevacizumab|
89602405|NCT03149003|Active Comparator|Arm 2: Bevacizumab|
89602406|NCT03148275|Experimental|Treatment (trametinib)|Patients receive trametinib PO QD on days 1-28. Treatment repeats every 28 days for up to 52 cycles in the absence of disease progression or unacceptable toxicity.
89602407|NCT03103581|Experimental|BLI4700|BLI4700 Bowel Preparation (Investigational Regimen)
89602408|NCT03093974|Experimental|CMS (Colimesthate sodium)|Inhaled colistimethate sodium twice daily. The active pharmaceutical ingredient consisting of pure CMS one million international units (MIU) / 80 mg of CMS / 33 mg colistin base activity (CBA) was provided as a powder for nebuliser solution in 10R International Organization for Standardization (ISO) glass vials.
89602409|NCT03093974|Placebo Comparator|Placebo|Saline solution inhaled twice daily, provided and administered at the same way of the IMP.
89602410|NCT03089606|Other|Single Arm|This is a single arm study. All participants completed the study interventions which are pembrolizumab treatment, FDG PET, C11-AMT PET and CT scans.
89602411|NCT03084510|Experimental|Lotus Edge™ Valve System|The Lotus Edge™ Valve System is intended to improve the aortic valve function for symptomatic patients with severe calcific aortic stenosis (aortic valve area [AVA] of <1.0 cm2 or index of <0.6 cm2/m2) who are at high risk for standard surgical valve replacement.
89602412|NCT03029949|Experimental|ACT with VR|acceptance and commitment therapy with vestibular rehabilitation in addition to clinical management
89602413|NCT03029949|Active Comparator|Self-treatment VR|self-treatment vestibular rehabilitation in addition to clinical management
89032400|NCT02947919|No Intervention|Control|Usual treatment
89602414|NCT03023332|Experimental|Self-management need|SM-need (i.e. need for bipolar education or resourcefulness training or HRV-focused biofeedback training or no need for any)
89602415|NCT03023332|Experimental|Self-management preference|SM-preference (i.e. preference for bipolar education or resourcefulness training or HRV-focused biofeedback training or no intervention)
89602416|NCT03023332|No Intervention|Control|No intervention or treatment
89602417|NCT03023332|Active Comparator|Usual care|Bipolar education
89602418|NCT03023085|Experimental|BLI4700|BLI4700 Bowel Preparation
89602419|NCT02993731|Experimental|Arm 1: Napabucasin plus Nab-paclitaxel with Gemcitabine|Patients randomized to this arm will receive napabucasin administered orally, twice daily in combination with weekly nab-paclitaxel and gemcitabine administered intravenously, once weekly, on 3 of every 4 weeks.
89602420|NCT02993731|Active Comparator|Arm 2: Nab-paclitaxel with Gemcitabine|Patients randomized to this arm will receive weekly nab-paclitaxel and gemcitabine administered intravenously, once weekly, on 3 of every 4 weeks.
89602421|NCT02991703|Active Comparator|SphygmoCor®|
89602422|NCT02991703|Experimental|pOpmètre®|
89602423|NCT02991573|Active Comparator|existing adhesive (control)|control adhesive
89602424|NCT02991573|Experimental|new adhesive: technique 1|Prime & Bond Universal: technique 1
89602425|NCT02991573|Experimental|new adhesive: technique 2|Prime & Bond Universal: technique 2
89602426|NCT02977052|Experimental|Arm A: 2 courses ipi 3 + nivo 1|Patients receive 2 courses standard combination of ipilimumab 3 mg/kg + nivolumab 1 mg/kg q3wk prior to surgery at week 6. Blood for PBMCs and biopsies will be taken for translation research.
89602427|NCT02977052|Experimental|Arm B: 2 courses ipi 1 + nivo 3|Patients receive 2 courses ipilimumab 1 mg/kg + nivolumab 3 mg/kg q3wk prior to surgery at week 6. Blood for PBMCs and biopsies will be taken for translation research.
89602428|NCT02977052|Experimental|Arm C: 2 courses ipi 3 + 2 courses nivo 3|Patients receive 2 courses of ipilimumab 3 mg/kg q3wks, directly followed (> 2 hours and < 24 hours) by 2 courses nivolumab 3 mg/kg every 2 weeks prior to surgery at week 6. Blood for PBMCs and biopsies will be taken for translation research.
89602429|NCT02977052|Experimental|PRADO extension cohort|"Patients will be treated with 2 courses ipilimumab and nivolumab at the dose level defined as the winner dosing scheme from OpACIN-neo, which is the dosing schedule of arm B.~Surgery and adjuvant therapy~Patients achieving a pCR or pnCR will not undergo CLND and will not receive any adjuvant treatment. Structural follow-up will be perfomed every 12 weeks by CT, ultrasound of regional lymph nodes.~Patients achieving a pPR will undergo CLND and start structural follow-up (including CT and physical examination) every 12 weeks thereafter without any adjuvant treatment.~Patients achieving no response (pNR) will undergo CLND and start at week 12 with adjuvant nivolumab 480mg q4wks for 52 weeks + radiotherapy (according to patient's and physicians' decision). In patients that are BRAF V600E/K mutation positive, adjuvant BRAF+MEK"
89602430|NCT02945722|Active Comparator|Decolonization|persistent carriers will be decolonized. Decolonization schedule associate the use of mupirocin nasal ointment 3 times a day and chlorhexidine bath once a day for 5 days.
88980833|NCT05143385|No Intervention|Control|"The variables to be filled in upon admission are: age, sex, reason for admission and main caregiver. The variables that will be collected on admission and discharge are: Mississippi Aphasia Screening test, Canadian scale, Duke-UNK-11 subjective support scale, UCLA loneliness scale, oropharyngeal dysphagia screening test, Pfreiffer scale, State assessment mood, Hamilton Rating for Depression and Hospital Anxiety Depression Scale and HLS-EU Q16., Will be performed on all patients who are part of the trial.~Those patients where conventional rehabilitative treatment is performed will be:~Physiotherapy sessions~Speech therapy sessions~Neuropsychology sessions~Occupational therapy sessions"
89032401|NCT04690569||Infectious|Eligible pediatric and adult patients from ED\Urgent care and hospital admitted, with symptoms consistent with acute bacterial or viral infection.
89032402|NCT04690569||Healthy|For the purpose of establishing a normal reference range.
89602431|NCT02945722|Placebo Comparator|No decolonization|HD patients in which decolonization is not performed including impersistent carriers.
89602432|NCT02934529|Active Comparator|A1|"FOLFIRI plus cetuximab: one cycle (cycle duration 14 days) consists of Irinotecan, Folinic acid 5-FU, cetuximab~Administration every two weeks until progression in first-line or emergence of unacceptable toxicity.~De-escalation (e.g. to irinotecan plus cetuximab or FUFA plus cetuximab) is allowed, but cetuximab should be administered until progression if safety is adequate."
89602433|NCT02934529|Experimental|B1|"FOLFIRI plus cetuximab: one cycle (cycle duration 14 days) consists of Irinotecan, Folinic acid 5-FU, cetuximab~Administration every 2 weeks for a maximum of 12 cycles~Treatment may be de-escalated to irinotecan plus cetuximab or FUFA plus cetuximab, prior to 12 cycles, for toxicity if necessary, if the best response has been SD,~Treatment may undergo 'switchover' to a fluoropyrimidine and bevacizumab, between 8 and 12 cycles, for toxicity if necessary, if the best response has been CR or PR,"
89602434|NCT02934529|Experimental|B1 Switchover regimens|"Switchover to FUFA plus bevacizumab every three weeks (cycle duration 21 days) until progression in first-line or emergence of unacceptable toxicity.~Folinic acid, 5-FU, Bevacizumab~1st administration 90 min. in case of good safety, the second 60 min. further administration 30 min.~Or alternatively Switchover to capecitabine plus bevacizumab every three weeks (cycle duration 21 days) until progression in the first-line or emergence of unacceptable toxicity."
89602435|NCT02934529|Active Comparator|A2 (third line)|"Treatment at the treating physician's discretion depending on the patient's general condition, with the exclusion of any anti-EGFR treatment whatsoever (such as for example cetuximab, panitumumab). Recommendations include Regorafenib in line with Grothey A et al, Lancet. 2013~or alternatively another anti-EGFR-free treatment according to the investigating physician's choice~Administration until progression occurs in the third line or unacceptable toxicity"
89032403|NCT00523523|Experimental|A|This group will complete a 2 week program of functional task practice with auditory rhythm cuing.
89032404|NCT00523523|Active Comparator|F|This group will complete a 2 week program of functional task practice without auditory rhythm cuing.
89210319|NCT00572832|Active Comparator|6 mon. 3rd dose of quadrivalent human papillomavirus vaccine|Receipt of three doses of quadrivalent human papillomavirus vaccine according to the regular schedule of 0,2, and 6 months.
89602436|NCT02934529|Experimental|B2 (third line)|"one cycle (cycle duration 14 days) consists of Irinotecan 125mg, Folinic acid, 5-FU, cetuximab wkly~Administration every 2 weeks until progression occurs in the third line or unacceptable toxicity~or depending on the patient's general condition and the study physician's decision~Irinotecan plus cetuximab in line with Cunningham D et al, N Engl J Med. 2004"
89602437|NCT02934399||Healthy controls (HC)|Definition of the normal circadian and ultradian profiles of pituitary and adrenal hormones in healthy subjects:Each subject (total number 200, anticipated 50 per study centre) will be sampled by the ULTRADIAN sampling device for 27 hours. Day to day hormonal variability:A subgroup of 20 subjects will be asked to undergo sampling on three occasions to assess reproducibility of hormonal levels over time. Comparison of tissue and blood concentrations of hormones: 20 subjects will be asked to participate in the study comparing hormonal tissue level and blood levels.
89602438|NCT02934399||Cushing syndrome (CS)|"Diagnosis of Cushing's syndrome by ULTRADIAN dynamic cortisol measurements The primary objective is to establish circadian and ultradian hormonal profiles of patients with Cushing's from 24 hour ambulatory sampling of subcutaneous fluid.~A secondary aim is to compare the pre and post-operative hormonal profiles of patients with Cushings and to compare these results to age/sex matched control~Study subjects: Subjects with established clinical and biochemical Cushing's syndrome (ACTH-producing pituitary adenoma or ACTH-independent adrenal source)."
89602439|NCT02934399||Adrenal insufficiency (AI)|"Monitoring of adrenal insufficiency (AI) by ULTRADIAN dynamic cortisol and ACTH measurements Aims and objectives: to compare hormonal profiles of patients with Adrenal insufficiency on conventional replacement regimes to age/sex matched controls.~Study subjects: Subjects with established primary (adrenal) AI"
89602440|NCT02934399||Congenital adrenal hyperplasia (CAH)|"Monitoring of congenital adrenal hyperplasia (CAH) by ULTRADIAN dynamic cortisol, ACTH, and androgen measurements Aims and objectives: to compare hormonal profiles of patients with CAH on conventional replacement regimes to age/sex matched controls.~Study subjects: Individuals with established CAH either salt- wasting or simple virilisation forms on glucocorticoid replacement therapy"
89602441|NCT02934399||Primary hyperaldosteronism (PHA)|"Diagnosis of primary hyperaldosteronism (PHA) by ULTRADIAN dynamic aldosterone and renin measurements Aims and objectives: The primary objective is to establish circadian and ultradian profiling of free aldosterone and renin in subcutaneous tissue.~Secondary objectives are (1) to compare pre and post-operative profiles (2) to identify profiles typical for adenoma as opposed to bilateral hyperplasia and (3) to compare profiles to age/sex matched controls.~Study subjects: Subjects with suspected PHA."
89602442|NCT02934399||Growth hormone insufficiency (GHD)|"Diagnosis of growth hormone deficiency (GHD) by ULTRADIAN dynamic growth hormone measurements Aims and objectives: The primary objective is to establish hormonal circadian and ultradian profiles of adult GHD by analysing the growth hormone profile in the subcutaneous tissue fluid.~Study subjects: Adult subjects with established clinical and biochemical GHD."
89602443|NCT02934399||Acromegaly (A)|"Diagnosis and treatment of acromegaly by ULTRADIAN dynamic growth hormone measurements Aims and objectives: The primary objective is to establish hormonal profiles of patients with Acromegaly A secondary objective is to compare pre and post-operative profiles and to compare these profiles to age/sex matched controls.~Study subjects: Patients with established clinical and biochemical Acromegaly by current diagnostic criteria"
89602444|NCT02932865||MD-TESE (A)|Azoospermic men, MD-TESE operation (standard treatment). Semen sample, serum sample and physical examination with testicular ultrasound.
89602445|NCT02932865||Subfertile men (B)|Subfertile men receiving medication (standard treatment). Semen sample, serum sample and physical examination with testicular ultrasound.
89602446|NCT02932865||Control (C)|Control group, men scheduled for semen analysis. Semen sample, serum sample and physical examination with testicular ultrasound.
89602447|NCT02922816|Placebo Comparator|Control arm|The control arm will participate in the bowel preparation and stool or perirectal swab sampling but will not receive Fecal Microbiota Transplant (FMT) nor will they be fasting during their first study cycle (Cycle 0). Participants testing positive for a multi-drug resistant organism at the of Cycle 0 will be eligible to receive microbiota restoration transplant (MRT) for up to two cycles, as necessary (Cycles 1 and 2).
89602448|NCT02922816|Experimental|Fecal Microbiota Transplant (FMT)|The experimental arm will participate in the bowel preparation, stool or perirectal swab sampling, and will receive Fecal Microbiota Transplant (FMT) using Allogeneic Human Stool in Glycerol 10% (AHSG) on Day 1 of each cycle (Cycles 1 and 2).
89602449|NCT02914951|Experimental|Cognitive-Behavioral Therapy|CBT is a behavioral intervention where children are taught various skills for coping with frustration and parents are taught various strategies for managing situations that can be anger-provoking for their child.
89602450|NCT02903368|Experimental|Arm 1A: AAPL Neoadjuvant Therapy [Part 1]|"Eligible Participants will be randomized to receive:~AAPL: Abiraterone acetate (240 mg/day orally), Apalutamide (1000 mg/day orally), Leuprolide (22.5 mg every 12 weeks intramuscularly), Prednisone (5 mg/twice daily orally) for 6 months~Pts x weeks to RP"
89602451|NCT02903368|Experimental|Arm 1B: APL Neoadjuvant Therapy [Part 1]|"Eligible Participants will be randomized to receive:~APL: Abiraterone acetate (1000 mg/day orally), Leuprolide (22.5 mg every 12 weeks intramuscularly), Prednisone (5 mg/day orally) for 6 months"
89602452|NCT02903368|Experimental|Arm 2A: AAPL Adjuvant Therapy [Part 2]|"Eligible Participants will be randomized to receive:~AAPL: Abiraterone acetate (240 mg/day orally), Apalutamide (1000 mg/day orally), Leuprolide (22.5 mg every 12 weeks intramuscularly), Prednisone (5 mg/twice daily orally) for 12 months"
89602453|NCT02903368|No Intervention|Arm 2B: Observation [Part 2]|
89602454|NCT02855554|Experimental|Additional 5 minute research MR scan of heart.|The purpose of this is to evaluate new, faster MR scans
89602455|NCT02841839|Experimental|2-step system|Subjects are to brush with 2-step system for 4 weeks; stannous fluoride
89602456|NCT02826161|Experimental|Napabucasin plus Weekly Paclitaxel|Patients randomized to this arm will receive napabucasin administered orally, twice daily in combination with paclitaxel administered intravenously, once weekly, on 3 of every 4 weeks.
89210320|NCT00572832|Active Comparator|12 mon. 3rd dose of quadrivalent human papillomavirus vaccine|Receipt of three doses of quadrivalent human papillomavirus vaccine on a delayed schedule of 0,2, and 12 months.
89602457|NCT02826161|Active Comparator|Weekly Paclitaxel|Patients randomized to this arm will receive weekly paclitaxel alone administered intravenously, once weekly, on 3 of every 4 weeks.
89602458|NCT02799901|Experimental|Patient|patient with Advanced melanoma
89602459|NCT02796885||Possible hypophosphatasia|Patients attending metabolic bone services, not previously know to have HPP, with biochemistry suggestive of HPP Will have TNSALP gene test, clinical assessment for possible features of HPP, bone turnover marker profile.
89602460|NCT02796885||Normal|Patients attending metabolic bone services, not previously know to have HPP, with normal HPP biochemistry Will have TNSALP gene test, clinical assessment for possible features of HPP, bone turnover marker profile.
89602461|NCT02796885||Known hypophosphatasia|Patients attending metabolic bone services or registered with RUDY database, known to have HPP Will have TNSALP gene test, clinical assessment for possible features of HPP, bone turnover marker profile.
89602462|NCT02766543|Experimental|MRI-guided Transurethral Ultrasound Ablation Device|Magnetic resonance imaging-guided transurethral ultrasound ablation of whole-gland prostate tissue.
88980834|NCT05143385|Experimental|Intervention Group|The variables are to be filled in upon admission are: age, sex, reason for admission and main caregiver. The variables that will be collected on admission and discharge are: MAST, Canadian scale, Duke-UNK-11 subjective support scale, UCLA loneliness scale, oropharyngeal dysphagia screening test, Pfeiffer scale, State assessment mood, Hamilton Rating for Depression and Hospital Anxiety Depression Scale and HLS-EU Q16.The beginning of the intervention will be once you have completed 15 calendar days from your admission.The intervention will be carried out once a week with a duration of 20 min with one of the games chosen by the patient together with the physiotherapist.The completion of the intervention will be until the patient is discharged from hospital, with a minimum of four sessions carried out in order to participate in the study.A registration table will be executed where the number of sessions of each patient and the type of session are quantified like a control group.
88980835|NCT05137067|Other|Chemotherapeutic agent A (Docetaxel)|The patients with breast cancer will receive chemotherapeutic agent A
88980836|NCT05137067|Placebo Comparator|Chemotherapeutic agent A (Docetaxel) plus placebo|The patients with breast cancer will receive chemotherapeutic agent A plus a placebo.
88980837|NCT05137067|Active Comparator|Chemotherapeutic agent A (Docetaxel) plus RaproCell|The patients with breast cancer will receive chemotherapeutic agent A plus RaproCell.
88980838|NCT05137067|Other|Chemotherapeutic agent B (Cisplatin)|The patients with lung cancer will receive Chemotherapeutic agent B
88980839|NCT05137067|Placebo Comparator|Chemotherapeutic agent B (Cisplatin) plus placebo|The patients with lung cancer will receive Chemotherapeutic agent B plus placebo.
88980840|NCT05137067|Active Comparator|Chemotherapeutic agent B (Cisplatin) plus RaproCell|The patients with lung cancer will receive Chemotherapeutic agent B plus RaproCell.
88980841|NCT05137067|Other|Chemotherapeutic agent C (Docetaxel)|The patients with prostate cancer will receive Chemotherapeutic agent C
88980842|NCT05137067|Placebo Comparator|Chemotherapeutic agent C (Docetaxel) plus placebo|The patients with prostate cancer will receive Chemotherapeutic agent C plus placebo.
88980843|NCT05137067|Active Comparator|Chemotherapeutic agent C plus (Docetaxel) RaproCell|The patients with prostate cancer will receive Chemotherapeutic agent C plus RaproCell.
88980844|NCT05135702|Experimental|Sodium Propionate First|Subjects in this arm will consume 500mg sodium propionate powder twice daily for four weeks, mixed into their food/drink. This is followed by four weeks of placebo twice daily.
88980845|NCT05135702|Placebo Comparator|Placebo First|Subjects in this arm will consume a placebo twice daily for four weeks, mixed into their food/drink. This is followed by four weeks of 500mg sodium propionate powder, twice daily.
89602463|NCT02753127|Experimental|Napabucasin plus FOLFIRI|Addition of bevacizumab to the FOLFIRI regimen will be permissible. FOLFIRI chemotherapy infusion will start at least 2 hours following the first daily dose of napabucasin and will be administered every 2 weeks. Irinotecan/leucovorin infusion will follow bevacizumab infusion in selected patients to receive standard dose of bevacizumab (5 mg/kg). Irinotecan 180 mg/m^2 together with leucovorin 400 mg/m^2 will be administered intravenously, over approximately 90 minutes and 2 hours, respectively, starting on Day 1 of Cycle 1, following bevacizumab infusion or at least 2 hours following the first daily dose of napabucasin if bevacizumab is not administered. 5-FU 400 mg/m^2 bolus will be administered intravenously immediately following irinotecan/leucovorin infusion, followed by 5-FU 1200 mg/m^2/day (total 2400 mg/m^2) continuous infusion. This regimen will be repeated on Day 1 of every 14 day cycle.
89602464|NCT02753127|Active Comparator|FOLFIRI|Addition of bevacizumab to the FOLFIRI regimen will be permissible. FOLFIRI chemotherapy infusion will be administered every 2 weeks. Irinotecan/leucovorin infusion will follow bevacizumab infusion in selected patients to receive standard dose of bevacizumab (5 mg/kg). Irinotecan 180 mg/m^2 together with leucovorin 400 mg/m^2 will be administered intravenously, over approximately 90 minutes and 2 hours, respectively, starting on Day 1 of Cycle 1, following bevacizumab infusion. 5-FU 400 mg/m^2 bolus will be administered intravenously immediately following irinotecan/leucovorin infusion, followed by 5-FU 1200 mg/m^2/day (total 2400 mg/m^2) continuous infusion. This regimen will be repeated on Day 1 of every 14 day cycle.
89602465|NCT02746796|Experimental|ONO-4538 + SOX Therapy Cohort (Part 1)|"ONO-4538 360 mg solution intravenously for 30 min in every 3 weeks. Oxaliplatin 130 mg/m2 (BSA) solution intravenously for 2 hours once-daily, followed by 20 days off.~Tegafur-gimeracil-oteracil potassium combination drug 40 - 60 mg bid orally in 14 days, followed by 7 days off Each drug will be continued until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends."
89602466|NCT02746796|Experimental|ONO-4538 + CapeOX Therapy Cohort (Part 1)|"ONO-4538 360 mg solution intravenously for 30 min in every 3 weeks. Oxaliplatin 130 mg/m2 (body surface area) solution intravenously for 2 hours once-daily, followed by 20 days off.~Capecitabine 1200 - 2100 mg bid orally in 14 days, followed by 7 days off. Each drug will be continued until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends."
89602467|NCT02746796|Experimental|ONO-4538 + chemotherapy group (Part 2)|"With regard to the ONO-4538 + chemotherapy group, either SOX therapy or CapeOX therapy will be selected as the chemotherapy by the investigator or the subinvestigator, taking into account the condition of each subject.~ONO-4538 360 mg solution intravenously for 30 min in every 3 weeks. Oxaliplatin 130 mg/m2 (body surface area) solution intravenously for 2 hours once-daily, followed by 20 days off.~Tegafur-gimeracil-oteracil potassium combination drug 40 - 60 mg bid or Capecitabine 1000 mg/ m2 (body surface area) bid orally in 14 days, followed by 7 days off.~Each drug will be continued until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends."
89602468|NCT02746796|Placebo Comparator|Placebo + Chemotherapy group (Part 2)|"With regard to the placebo + chemotherapy group, either SOX therapy or CapeOX therapy will be selected as the chemotherapy by the investigator or the subinvestigator, taking into account the condition of each subject.~Placebo solution intravenously for 30 min in every 3 weeks. Oxaliplatin 130 mg/m2 (body surface area) solution intravenously for 2 hours once-daily, followed by 20 days off.~Tegafur-gimeracil-oteracil potassium combination drug 40 - 60 mg bid or Capecitabine 1000 mg/ m2 (body surface area) bid orally in 14 days, followed by 7 days off.~Each drug will be continued until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends."
89602469|NCT02735928|Experimental|PIPAC|PIPAC stands for Pressurized IntraPeritoneal Aerosol Chemotherapies. Enrolled patients will undergo to explorative laparoscopy as usual and PC index will be determined according to Fagotti score (PIV). Pathological response will be determined by serial peritoneal biopsies. Then a pressurized aerosol containing cisplatin followed by doxorubicin will be applied via a nebulizer. The PIPAC procedure can be repeated after 4-6 weeks until progression or limiting toxicity
89602470|NCT02692885||Healthy Volunteers|Individuals known to have brown adipose tissue, identified by PET/CT following participation/scanning in other clinical studies
89602471|NCT02692885||Surgical Patients|Individuals undergoing planned, clinically-indicated surgeries
89602472|NCT02657551|Experimental|Regorafenib|Regorafenib tablets 80mg orally, once daily at predetermined dosage for 21 days per cycle
89602473|NCT02624271|Experimental|GastroPanel|GastroPanel test on blood samples
89602474|NCT02580604|Experimental|Calcium Infusion|Continuous calcium infusion during exercise
89602475|NCT02580604|Placebo Comparator|Saline Infusion|Continuous saline infusion during exercise
89602476|NCT02531048|Experimental|healthy volunteers|"Healthy volunteers are able to participate to this study. They must not have neurological troubles. They will have different stimulations :~laser stimulations on lower limbs~laser stimulations cervical~20 laser stimulations for each site on the upper limbs~laser stimulations on face and neck"
89602477|NCT02527434|Experimental|treme mono to be sequenced to MEDI4736 mono or combination|tremelimumab monotherapy, with the option for eligible patients to be sequenced to MEDI4736 monotherapy or MEDI4736 + tremelimumab combination therapy after progressive disease (PD)
89602478|NCT02508038|Experimental|TCRαβ+/CD19+ depleted Haploidentical HSCT+ Zoledronate|Patients with high-risk leukemia (who are at least one year of age and who have not received TBI as conditioning for a previous HSCT) will receive myeloablative conditioning with ATG, Fludarabine, Thiotepa, and TBI. All other subjects will undergo a reduced-intensity conditioning regimen consisting of ATG, Fludarabine, Thiotepa, and Melphalan prior to transplant with a KIR/KIR ligand mismatched haploidentical donor peripheral blood stem cell graft depleted of TCR-αβ+ and CD19+ cells. Patients will receive 5 doses of zoledronate (at 28 day intervals) starting 28 days after stem cell transplant.
89602479|NCT02469844||Patients with epilepsy having seizures in sleep|
89602480|NCT02460835|Experimental|Adaptive Radiation Therapy|
89602481|NCT02432690|Experimental|Arm A|
89602482|NCT02422550||participants undergoing radiation therapy & normal volunteers|
89602483|NCT02320292|Active Comparator|Arm A (rituximab)|Patients receive rituximab IV on days 1, 8, 15, and 22.
89602484|NCT02320292|Experimental|Arm B (rituximab, yttrium Y-90 ibritumomab tiuxetan)|Patients receive rituximab IV on days 1 and 8 and yttrium Y-90 ibritumomab tiuxetan over 10 minutes on day 8.
89602485|NCT02315534|Experimental|Arm A|Patients for whom surgery is recommended as part of treatment for recurrent Glioblastoma.
89602486|NCT02315534|Experimental|Arm B|Patients for whom surgery is not recommended as part of the treatment for recurrent Glioblastoma.
89602487|NCT02278887|Active Comparator|Ipilimumab|4 cycles of ipilimumab treatment, the standard treatment
89602488|NCT02278887|Experimental|TIL treatment|non-myeloablative lymphocyte depleting regimen of chemotherapy followed by infusion of tumor infiltrating lymphocytes and interleukin-2
89602489|NCT02231749|Experimental|Arm A: Nivolumab 3 mg/kg + Ipilimumab 1 mg/kg|Nivolumab 3 mg/kg combined with Ipilimumab 1 mg/kg solutions intravenously every 3 weeks for 4 doses then Nivolumab 3 mg/kg solutions intravenously every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
89602490|NCT02231749|Active Comparator|Arm B: Sunitinib 50 mg|"Sunitinib 50 mg capsules by mouth once daily for 4 weeks then 2 weeks off, continuously until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends~After completion of final analysis eligible participants may switch from receiving Sunitinib to receiving Nivolumab 3 mg/kg IV combined with Ipilimumab 1 mg/kg IV every 3 weeks for 4 doses then Nivolumab 240mg flat dose IV every 2 weeks"
89602491|NCT02212886|Experimental|GA Depot 80mg|Monthly IM injection
89602492|NCT02212886|Experimental|GA Depot 40mg|Monthly IM injection
89602493|NCT02188745|Experimental|Alternating Therapy|"Study will use an 8-week/16-week alternating regimen of 17B-estradiol/AI (aromatase inhibitor) therapy. Use of only one Aromatase inhibitor throughout the study is preferred.~17B-estradiol: One tablet containing 2 mg 17B-estradiol will be taken orally three times daily, for a total dose of 6 mg/day.~Letrozole: One tablet containing 2.5 mg letrozole will be taken orally once per day.~Anastrozole: One tablet containing 1 mg anastrozole will be taken orally once per day.~Exemestane: One tablet containing 25 mg exemestane will be taken orally once per day."
89602494|NCT02024607|Experimental|ARM A- BBI608 in combination with FOLFOX6|BBI608 is administered orally twice daily, continuously. Oxaliplatin 85 mg/m^2 together with leucovorin 400 mg/m^2 will be administered intravenously. 5-FU 400 mg/m^2 bolus will be administered intravenously immediately following oxaliplatin/leucovorin infusion, followed by 5-FU 1200 mg/m^2/day (total 2400 mg/m^2 over 46-48 hours) continuous intravenous infusion. This regimen will be repeated every 14 days thereafter.
88980848|NCT05119998|Experimental|IBI325 and sintilimab combination does-escalation|
88980849|NCT05119998|Experimental|IBI325 monotherapy does-escalation|
88980850|NCT05111912|Experimental|Cohort A|Participants will follow a fixed up-titration scheme. For XW003 groups, the dose will be up-titrated to 1.2, 1.8, or 2.4 mg once weekly starting with 0.2 mg in dose increments of 0.2, 0.4, 0.6, or 0.8 mg. In order to mitigate the dose-related side effects, liraglutide is up-titrated over 4 weeks to the maintenance dose, 3.0 mg once daily.
89602495|NCT02024607|Experimental|ARM B- BBI608 in combination with FOLFOX6 and Bevacizumab|BBI608 is administered orally twice daily, continuously. Oxaliplatin 85 mg/m^2 together with leucovorin 400 mg/m^2 will be administered intravenously. 5-FU 400 mg/m^2 bolus will be administered intravenously immediately following oxaliplatin/leucovorin infusion, followed by 5-FU 1200 mg/m^2/day (total 2400 mg/m^2 over 46-48 hours) continuous intravenous infusion. Bevacizumab 5 mg/kg will be administered intravenously following oxaliplatin/leucovorin infusion. This regimen will be repeated every 14 days thereafter.
89602496|NCT02024607|Experimental|ARM C- BBI608 in combination with CAPOX|BBI608 is administered orally twice daily, continuously. CAPOX regimen will be administered orally (capecitabine) and IV (oxaliplatin). Capecitabine 850 mg/m^2 will be administered orally twice-daily for 14 consecutive days and be repeated every 21 days. Oxaliplatin will be administered IV and be repeated every 21 days thereafter. If capecitabine is tolerated at the 850 mg/m^2 twice daily dose, dosage may be increased to 1000 mg/m^2 twice daily as tolerated after the first cycle.
88980851|NCT05111912|Experimental|Cohort B|Participants will follow a fixed up-titration scheme. For XW003 groups, the dose will be up-titrated to 1.2, 1.8, or 2.4 mg once weekly starting with 0.2 mg in dose increments of 0.2, 0.4, 0.6, or 0.8 mg. In order to mitigate the dose-related side effects, liraglutide is up-titrated over 4 weeks to the maintenance dose, 3.0 mg once daily.
88980852|NCT05111912|Experimental|Cohort C|Participants will follow a fixed up-titration scheme. For XW003 groups, the dose will be up-titrated to 1.2, 1.8, or 2.4 mg once weekly starting with 0.2 mg in dose increments of 0.2, 0.4, 0.6, or 0.8 mg. In order to mitigate the dose-related side effects, liraglutide is up-titrated over 4 weeks to the maintenance dose, 3.0 mg once daily.
88980853|NCT05111912|Active Comparator|Cohort D|Dose titration Saxenda (from 0.6 mg to 3.0 mg liraglutide once daily), should take place during the first 4 weeks after randomisation as described: Dose Escalation Schedule of Reference Product (Saxenda). All participants assigned to the open-labeled control group should aim to reach the final target dose of 3.0 mg liraglutide once daily.
88980854|NCT05103176|Experimental|To PPC, with concurrent task|This arm will receive intermittent theta bust stimulation to the PPC site while subjects perform a grasp task
88980855|NCT05103176|Experimental|To PPC, without a concurrent task|This arm will receive intermittent theta bust stimulation to the PPC site without a concurrent task
88811409|NCT01323959|Experimental|BOOSTRIX POLIO GROUP|Healthy subjects who had received one booster dose Boostrix™ Polio vaccine in the NCT01277705 study received one additional booster dose of Boostrix™ Polio vaccine in this study, administered as an intramuscular injection into the deltoid region of the left arm.
88980856|NCT05103176|Experimental|To vertex, with concurrent task|This arm will receive intermittent theta bust stimulation to the vertex site (control condition) while subjects perform a grasp task
88980857|NCT05102292|Experimental|HLX208|Participants receive HLX208 450mg bid po
88811410|NCT01323959|Experimental|BOOSTRIX+POLIORIX GROUP|Healthy subjects who had received one booster dose of the co-administered Boostrix™ and Poliorix™ vaccines in the NCT01277705 study received one booster dose Boostrix™ Polio vaccine in this study, administered as an intramuscular injection into the deltoid region of the left arm.
88980858|NCT05099328|Experimental|Recast Therapy Provided By Clinician|Children will be exposed to recasts at a rate of 1/minute. Treatment will be provided 2x/week for 8 weeks for a total of 16 visits (960 recasts). 2 additional weeks are allocated for make up visits. Treatment will be provided by a trained, certified, licensed Speech Language Pathologist (SLP).
88980859|NCT05099328|Experimental|Illustrated Syntax Stories Provided by Clinician|Children will be listen to books that are specially scripted to promote the use of a particular syntax target. Treatment will be provided 2x/week for 8 weeks for a total of 16 visits (960 exposures), with 2 books read at each visit. 2 additional weeks are allocated for make up visits. Treatment will be provided by a trained, certified, licensed SLP.
88980860|NCT05099328|Experimental|Recast Therapy Provided by a Caregiver|Caregivers will receive two training sessions on how to provide recast therapy and demonstrate their skill at providing recast therapy with support from the clinician. Caregivers will then provide recast therapy at a rate of 1 recast per minute to their children for a minimum of 16 hrs (960 exposures) scheduled at their own convenience.
88980861|NCT05099328|Experimental|Illustrated Syntax Stories Provided by a Caregiver|Caregivers will receive two training sessions on how to provide read illustrated syntax stories to their children and demonstrate their skill at reading these stories with support from the clinician. Caregivers will then read these stories to their children for a minimum of 32 book readings (960 exposures)
88980862|NCT05098236|Experimental|Cortically Blind Subjects|
88980863|NCT05098236|Placebo Comparator|Control|
88980864|NCT05094102|Experimental|Axillary Surgery|Breast cancer patients undergoing SLN biopsy (n=0-20) or axillary lymph node dissection (n=0-15) will be enrolled to undergo standard of care axillary reverse mapping (ARM) using isosulfan blue dye. Participants will also receive ICG injection with visualization through the OnLume Imaging System to allow comparison of blue dye versus ICG lymphatic identification.
88980865|NCT05093699|Active Comparator|Control Group|Arterial line placement via standard mechanism; utilization of a single-plane ultrasound probe
88980866|NCT05093699|Experimental|Butterfly iQ+ ultrasound probe|Arterial line placement utilizing dual-plane, Butterfly iQ+ ultrasound probe
88980867|NCT05093335|Experimental|[68Ga]-Pentixafor|An intravenous bolus of 4.1 mCi (150 MBq) ± 10% of [68Ga]-Pentixafor will be injected in all participants that will be imaged on a hybrid PET/CT device. Any of the following factors may determine if imaging cannot be performed: tolerance/compliance in the PET/CT scanner; dose availability; dose quality control; availability of the PET/CT scanner or availability of study personnel. [68Ga]-Pentixafor uptake dynamics / pharmacokinetics will be evaluated by PET/CT performed with a low-dose CT component used for PET attenuation correction (1-2 mSv). [68Ga]-Pentixafor-PET/CT scan duration will be approximately 1.5 hours. Some patients will have two scans.
88980868|NCT05085613|Active Comparator|Vaccine Corrective Control|A message that explains why people are hesitant to accept the FDA authorized COVID vaccines are safe and effective and how the vaccines are evaluated as safe and effective by FDA.
88980869|NCT05085613|Experimental|Vaccine corrective with economic recovery framing|"The content of the control message with the addition of the text, If everyone gets vaccinated, we can keep schools, stores, and other businesses open so more Americans can keep working and supporting their families. The message will also include a picture of an open for business sign."
88980870|NCT05085613|Experimental|Vaccine corrective with freedom framing|"The content of the control message with the addition of the text, Everyone getting vaccinated is the key to freedom! A vaccine can give us the freedom to hang out with friends, shop, and worship together again safely. The message will also include a picture of an American flag."
88980871|NCT05085613|Experimental|Vaccine corrective with humor|"The content of the control message with the addition of the text, Unfortunately, everyone getting vaccinated means leaving the house again. The message will include a meme of a cat being pulled/rescued from a window with text boxes labeling the cat as People at home working in sweatpants and the rescuer as COVID Vaccines."
88980872|NCT05083117|Experimental|XW001|Treatment arm patients will receive inhaled XW001 1 mg, once daily, using a commercially available nebulizer (Aerogen Solo, Aerogen Ireland) for up to 14 days. Treatment should be continued until discharge or progression to score 6 or higher but maximum up to 14 days. Dosing must be started within 48 hours of hospitalization.
88980873|NCT05083117|Placebo Comparator|Placebo|Placebo arm patients will receive volume-matching placebo 1 mL, once daily, using a commercially available nebulizer (Aerogen Solo, Aerogen Ireland) for up to 14 days. Treatment should be continued until discharge or progression to score 6 or higher but maximum up to 14 days. Dosing must be started within 48 hours of hospitalization.
88980874|NCT05079282|Experimental|ONO-4685 monotherapy|Patients with relapsed or refractory T cell Lymphoma who meet eligibility criteria will be enrolled to receive ONO-4685 monotherapy
88980875|NCT05076552|Experimental|Phase 1a: Dose Escalation|In Phase 1a, participants will receive TACH101 in a 48 hour single-dose lead-in period followed by repeated dosing on a 3-day on/4-day off schedule in each 28 day cycle.
88980876|NCT05076552|Experimental|Phase 1b: Dose Expansion|"In Phase 1b, participants will receive TACH101 at the RP2D identified in Phase 1 on a 3-day on/4-day off schedule. Two cohorts of participants will be enrolled:~Participants with gastrointestinal cancers.~Participants with high microsatellite instability (MSI-H) metastatic colorectal cancer (CRC)."
89517986|NCT03779243|Placebo Comparator|Placebo Control|"Participants will be given placebo pills to be taken daily 1 hour before bedtime and are a sleep aid. Participants will not receive any sleep education materials. They will have study visits in clinic as part of standard-of-care at 6 weeks and 12 weeks. They will complete Pittsburgh Sleep Quality Index and SF-36 Quality of Life questionnaires at enrollment and at their clinic visits."
89517987|NCT03274271|Experimental|AP+CP+M|"Participants will receive the e- and mHealth intervention 'MyPlan 2.0' with all three behaviour change techniques of interest: action planning (AP), coping planning (CP) and self-monitoring (M).~They will also receive general tips and tricks and other behaviour change techniques included in the intervention: tailored feedback and eliciting social support."
89517988|NCT03274271|Experimental|AP+CP|"Participants will receive the e- and mHealth intervention 'MyPlan 2.0' with two of the behaviour change techniques of interest: action planning (AP) and coping planning (CP).~They will also receive general tips and tricks and other behaviour change techniques included in the intervention: tailored feedback and eliciting social support."
89517989|NCT03274271|Experimental|AP+M|"Participants will receive the e- and mHealth intervention 'MyPlan 2.0' with two of the behaviour change techniques of interest: action planning (AP) and self-monitoring (M).~They will also receive general tips and tricks and other behaviour change techniques included in the intervention: tailored feedback and eliciting social support."
89517990|NCT03274271|Experimental|CP+M|"Participants will receive the e- and mHealth intervention 'MyPlan 2.0' with two of the behaviour change techniques of interest: coping planning (CP) and self-monitoring (M).~They will also receive general tips and tricks and other behaviour change techniques included in the intervention: tailored feedback and eliciting social support."
89517991|NCT03274271|Experimental|M|"Participants will receive the e- and mHealth intervention 'MyPlan 2.0' with only one of the behaviour change techniques of interest: self-monitoring (M).~They will also receive general tips and tricks and other behaviour change techniques included in the intervention: tailored feedback and eliciting social support."
89517992|NCT03274271|Experimental|CP|"Participants will receive the e- and mHealth intervention 'MyPlan 2.0' with only one of the behaviour change techniques of interest: coping planning (CP).~They will also receive general tips and tricks and other behaviour change techniques included in the intervention: tailored feedback and eliciting social support."
89517993|NCT03274271|Experimental|AP|"Participants will receive the e- and mHealth intervention 'MyPlan 2.0' with only one of the behaviour change techniques of interest: action planning (AP).~They will also receive general tips and tricks and other behaviour change techniques included in the intervention: tailored feedback and eliciting social support."
89517994|NCT03274271|Active Comparator|Control|Participants will receive the e- and mHealth intervention 'MyPlan 2.0' without the three behaviour change techniques of interest (action planning, coping planning, self-monitoring). They will receive general tips and tricks and other behaviour change techniques included in the intervention: tailored feedback and eliciting social support.
89517995|NCT03757013||Patients treated with Apremilast|Patients with moderate to severe chronic plaque psoriasis after failure or contra-indication or intolerance to other systemic therapy including ciclosporin, methotrexate, or phototherapy UVA + psoralen (PUVA therapy).
89517996|NCT02736409|Experimental|Arms A OBS Completers/ Responders|Arm A Oral Budesonide Suspension Completers/ Responders
89517997|NCT02736409|Placebo Comparator|Arm B OBS Completers/ Responders|Arm B Oral Budesonide Suspension Completers/ Responders. 1:1 randomization for Arms A and B
89517998|NCT02736409|Experimental|Arm C OBS Completers/ Non-Responders|Arm C Oral Budesonide Suspension Completers/ Non-Responders
89517999|NCT02736409|Experimental|Arm D Placebo Completers|Arm D Placebo Completers
89518000|NCT03490721|Experimental|Intervention|Clustering care for 20 minutes.
89518001|NCT03490721|No Intervention|Control|Standard care non clustered.
89518002|NCT03503357|Experimental|IFT Testing 1|Participants will be fitted with and IFT cuff and randomized to command list A intra-operatively to assess awareness.
89518003|NCT03503357|Experimental|IFT Testing 2|Participants will be fitted with and IFT cuff and randomized to command list B intra-operatively to assess awareness.
89518004|NCT03503357|Experimental|IFT Testing 3|Participants will be fitted with and IFT cuff and randomized to command list C intra-operatively to assess awareness.
89602497|NCT02024607|Experimental|ARM D- BBI608 in combination with FOLFIRI|BBI608 is administered orally twice daily, continuously. Irinotecan 180 mg/m^2 together with leucovorin 400 mg/m^2 will be administered intravenously. 5-FU 400 mg/m^2 bolus will be administered intravenously immediately following irinotecan/leucovorin infusion, followed by 5-FU 1200 mg/m^2/day (total 2400 mg/m^2) continuous infusion. This regimen will be repeated every 14 days thereafter.
88980877|NCT05074173|Other|Patient Group|Participants will be enrolled in a bidirectional text messaging system from Tulane University Medical Group where they will receive and send text from their mobile phones to monitor their anti-hypertension medication regimen. Text messages will be sent: daily for medication and refill reminders; weekly for hypertension education messages and asking if a support person helped them with medication reminders. Study personnel will educate participants on proper blood pressure technique to conduct self-measured blood pressure (SMBP) at home. These blood pressure values will be automatically uploaded twice daily from a Bluetooth device to a phone application to allow the participant and healthcare team track their blood pressure. Participants will receive the Bluetooth blood pressure device to perform SMBP at enrollment.
88980878|NCT05065918|Active Comparator|Control - alcohol use reduction content|Alcohol use reduction content
88980879|NCT05065918|Experimental|Intervention - sexual violence and alcohol use harm reduction content|sexual violence and alcohol use harm reduction content
88980880|NCT05065424|Experimental|IV Atropine and Fentanyl Premedication Arm|Participants will receive premedication regimen of 20 micrograms/kilogram intravenous atropine and 0.5 micrograms/kilogram intravenous fentanyl prior to performance of LISA.
88980881|NCT05065424|Placebo Comparator|IV Normal Saline Placebo Arm|Participants will receive two intravenous Normal Saline infusions in quantities equivalent to the calculated volumes of atropine and fentanyl for participant's weight prior to performance of LISA.
88980882|NCT05064761|Experimental|Treatment group|PLLA new dilution for treatment to improve appearance of cellulite.
88980883|NCT05063734|Experimental|Part A, THR-687 1.2 mg|
88980884|NCT05063734|Experimental|Part A, THR-687 2.0mg|
88980885|NCT05063734|Experimental|Part B, treatment naïve subjects, THR-687 selected dose level|Due to the discontinuation of the study after Part A, the dose level for Part B has not been selected
88980886|NCT05063734|Active Comparator|Part B, treatment naïve subjects, aflibercept 2.0mg|
88980887|NCT05063734|Experimental|Part B, previously treated subjects, THR-687 selected dose level|Due to the discontinuation of the study after Part A, the dose level for Part B has not been selected
88980888|NCT05063734|Active Comparator|Part B, previously treated subjects, aflibercept 2.0mg|
88980889|NCT05060822|Experimental|HEC585 dose A|Drug: HEC585 dose A once daily, up to 24 weeks-120 weeks
88980890|NCT05060822|Experimental|HEC585 dose B|Drug: HEC585 dose B once daily, up to 24 weeks-120 weeks
88980891|NCT05060822|Experimental|HEC585 dose C|Drug: HEC585 dose C once daily, up to 24 weeks-120 weeks
88980892|NCT05060822|Active Comparator|pirfenidone|Drug: pirfenidone three times a day (target dose), up to 24 weeks
88980893|NCT05060822|Placebo Comparator|placebo|Drug: placebo once daily, up to 24 weeks-120 weeks
88980894|NCT05050266|Active Comparator|REP|Replicating Effective Practices (REP) is a lower-intensity implementation strategy with explicit process framework for local tailoring
88980895|NCT05050266|Experimental|EBQI|Evidence-Based Quality Improvement (EBQI) is a higher-intensity implementation strategy that entails external facilitation and formal training in quality improvement.
88980896|NCT05049291|Experimental|Intervention|One time receipt and review of an information sheet
88980897|NCT05049291|No Intervention|Non-Intervention|Usual care will be delivered per standards of care.
88980898|NCT05046795|Experimental|Revefenacin inhalation solution 175 mcg QD.|Revefenacin inhalation solution 175 mcg QD.
88980899|NCT05046795|Placebo Comparator|Placebo inhalation solution QD.|Placebo inhalation solution QD.
88980900|NCT05040295|Experimental|Treatment sequence 1|Treatment sequence 1 will receive a single 30 milligrams (mg) ritlecitinib intact adult capsule during the first period, three 10 mg ritlecitinib pediatric capsules during the second period and 30 mg ritlecitinib spray congealed beads in the third period.
88980901|NCT05040295|Experimental|Treatment Sequence 2|Treatment sequence 2 will receive three 10 mg ritlecitinib pediatric capsules during the first period, a single 30 mg intact adult capsule during the second period and 30 mg ritlecitinib spray congealed beads in the third period.
88980902|NCT05036707|Active Comparator|1|Healthy Volunteer
88980903|NCT05035407|Experimental|Treatment at dose levels 1 through 7|Non-myeloablative, lymphocyte depleting preparative regimen, followed by KK-LC-1 TCR T cells plus aldesleukin at escalating doses
88980904|NCT05030662|Experimental|Experimental:Walking stick exercise|"The experimental:Walking stick exercise~Education of walking stick exercise by research nurses twice before discharge (on the day before surgery and before discharge)~The video clip of walking stick exercise is available to the patients.~The research nurses encourage our patients to keep rehabilitation by phone calls once a week after discharge."
88980905|NCT05030662|No Intervention|Control group: conventional physical therapy.|"Perform bed mobility and transfers with the least amount of assistance while maintaining appropriate weight bearing (WB) precautions.~Ambulate with an assistive device for 25-100 feet and ascend/descend stairs to allow for independence with household activities while maintaining appropriate WB.~Verbalize understanding of post-operative activity recommendations/precautions including use of proper positioning of the lower extremity, range of motion and strengthening exercises."
88980906|NCT05029687|Experimental|Intervention Arm|The intervention is a youth-led HTN education digital intervention, which will be comprised of a 6-week playlist of one module per week comprising the playlist. Youth will learn from the module and will teach the adult in their dyad about hypertension education in each week's themed module.
88980907|NCT05027906|Experimental|AT-1501 Single Arm|AT-1501 monoclonal antibody targeting CD40L given as an IV infusion
88980908|NCT05019664|Experimental|Treatment Group|Subject target population suffers from fractures or osteotomies of the humerus which require temporary fixation and stabilization.
88980909|NCT05011383|Experimental|ATM|Patients with castration resistant prostate cancer which contains ATM alterations are treated with high dose testosterone
89602498|NCT02024607|Experimental|ARM E- BBI608 in combination with FOLFIRI and Bevacizumab|BBI608 is administered orally twice daily, continuously. Irinotecan 180 mg/m^2 together with leucovorin 400 mg/m^2 will be administered intravenously 5-FU 400 mg/m^2 bolus will be administered intravenously immediately following irinotecan/leucovorin infusion, followed by 5-FU 1200 mg/m^2/day (total 2400 mg/m^2) continuous infusion. Bevacizumab 5 mg/kg will be administered intravenously following oxaliplatin/leucovorin infusion. This regimen will be repeated every 14 days thereafter.
89602499|NCT02024607|Experimental|ARM F- BBI608 in combination with Regorafenib|BBI608 is administered orally twice daily, continuously. Regorafenib 120 mg will be administered orally once daily, with a low-fat meal and be continued for 21 consecutive days of every 28 days thereafter. If regorafenib is tolerated in the first cycle, dosage may be increased to 160 mg once daily as tolerated after the first cycle.
89602500|NCT02024607|Experimental|Arm G- BBI608 in combination with Irinotecan|BBI608 is administered orally twice daily, continuously. Irinotecan 180 mg/m^2 will be administered intravenously. This regimen will be repeated every 14 days thereafter.
89602501|NCT01966159|Experimental|SYNERGY Investigational Device|SYNERGY Stent System
89602502|NCT01966159|Active Comparator|PE Plus Investigational Device|PE Plus Stent System
89602503|NCT01938248|Active Comparator|Control|Aspirin 81 mg once daily
89602504|NCT01938248|Experimental|Intervention|Apixaban, 5 mg twice daily (or 2.5 mg twice daily if 2 or more of: age > 80, weight ≤ 60 kg or serum creatinine ≥ 133 mmol/L)
89602505|NCT01776307|Experimental|BBI608 in combination with cetuximab|
89602506|NCT01776307|Experimental|BBI608 in combination with panitumumab|
89602507|NCT01776307|Experimental|BBI608 in combination with capecitabine|
89602508|NCT01622322|Experimental|Nitrous oxide|Subjects will receive General anesthesia with Nitrous Oxide.
89602509|NCT01622322|Placebo Comparator|Oxygen|Subjects will receive General anesthesia with oxygen.
89602510|NCT01531803|Experimental|Kedbumin 25%|"Albumin (Human) 25% solution for intravenous (IV) infusion in the dosage strength of 250g/L human albumin, supplied in 50 mL type II vial (each vial containing 12.5g human albumin).~The dose will be 0.5 to 1g/kg body weight (2 to 4 mL/kg of 25% albumin). The duration of treatment is based on the subject's response to treatment until hemodynamic stability is achieved. If hemodynamic stability is not achieved within 72 hours of starting the study treatment, the subject will be withdrawn from the study and will be treated according to standard practice and data collected during the study period will be used for the safety evaluation."
89602511|NCT01531803|Placebo Comparator|Normal Saline Solution|Normal (0.9%) saline solution administered via IV infusions of 10 to 20 mL/kg as appropriate per standard of care based on the subject's clinical status and response to treatment.
89602512|NCT01325441|Experimental|BBI608 and Paclitaxel 200mg BID|Patients will receive BBI608 orally continuously at 200mg BID. A treatment cycle will be 4 weeks (28 days). BBI608 will be administered twice daily. On days 3, 10, and 17 of each 28 day cycle, patients will receive a 1 hour infusion of paclitaxel. Cycles will be repeated until progression of disease, unacceptable toxicity, or another discontinuation criterion is met. In the case of toxicity, adjustment is permitted.
89602513|NCT01325441|Experimental|BBI608 and Paclitaxel 240mg BID|Patients will receive BBI608 orally continuously at 240mg BID. A treatment cycle will be 4 weeks (28 days). BBI608 will be administered twice daily. On days 3, 10, and 17 of each 28 day cycle, patients will receive a 1 hour infusion of paclitaxel. Cycles will be repeated until progression of disease, unacceptable toxicity, or another discontinuation criterion is met. In the case of toxicity, adjustment is permitted.
89602514|NCT01325441|Experimental|BBI608 and Paclitaxel 400mg BID|Patients will receive BBI608 orally continuously at 400mg BID. A treatment cycle will be 4 weeks (28 days). BBI608 will be administered twice daily. On days 3, 10, and 17 of each 28 day cycle, patients will receive a 1 hour infusion of paclitaxel. Cycles will be repeated until progression of disease, unacceptable toxicity, or another discontinuation criterion is met. In the case of toxicity, adjustment is permitted.
89602515|NCT01325441|Experimental|BBI608 and Paclitaxel 480mg BID|Patients will receive BBI608 orally continuously at 480mg BID. A treatment cycle will be 4 weeks (28 days). BBI608 will be administered twice daily. On days 3, 10, and 17 of each 28 day cycle, patients will receive a 1 hour infusion of paclitaxel. Cycles will be repeated until progression of disease, unacceptable toxicity, or another discontinuation criterion is met. In the case of toxicity, adjustment is permitted.
89602516|NCT01325441|Experimental|BBI608 and Paclitaxel 500mg BID|Patients will receive BBI608 orally continuously at 500mg BID. A treatment cycle will be 4 weeks (28 days). BBI608 will be administered twice daily. On days 3, 10, and 17 of each 28 day cycle, patients will receive a 1 hour infusion of paclitaxel. Cycles will be repeated until progression of disease, unacceptable toxicity, or another discontinuation criterion is met. In the case of toxicity, adjustment is permitted.
89602517|NCT01073475||Pregnant women|Pregnant women in the MNH cluster
89602518|NCT01073475||Male and Female Infants|Male and Female Infants delivered in the clusters
89602519|NCT00815789|Experimental|Intervention|A nurse-administered intervention, which includes a behavioral and a medication management component. The intervention consists of very brief monthly telephone calls and occurs over 12 months. Upon request, participants may also be mailed additional supportive educational material to supplement phone intervention. They will also receive a letter clarifying medications reviewed with them during the nurse-administered intervention.
89602520|NCT00815789|No Intervention|Control|Receive educational material about CVD reduction at baseline
89602521|NCT00742807|Experimental|1|Administration of low dose of alfentanil hydrochloride before paracervical block
89602522|NCT00742807|Active Comparator|2|Administration of alfentanil hydrochloride dose after paracervical block
89602523|NCT00590850|No Intervention|Closed|Closed Treatment
89602524|NCT00590850|Active Comparator|ORIF|Open Reduction and Internal Fixation (ORIF) with Plate and Screws
89602525|NCT00590850|Active Comparator|Pin|Pin Fixation
89602526|NCT00484770|Other|Congestion Score Strategy|
89602527|NCT00484770|Other|BNP Strategy|
89602528|NCT05795296|Experimental|Fruquintinib+Sintilimab|"Fruquintinib: 5mg po, d1-d14, q3w~Sintilimab: 200mg ivgtt, d1, q3w"
88980910|NCT05011383|Experimental|CDK12|Patients with castration resistant prostate cancer which contains CDK12 alterations are treated with high dose testosterone
89602529|NCT05792631|Other|Patients scheduled for radiographic dental caries assessment|"BWR-The most common type of dental x-ray taken during a routine dental checkup is called a bitewing radiograph. This type of X-ray shows the upper and lower back teeth in a single view and is taken to see how the upper and lower teeth line up, to check for decay, and discover bone loss due to infection and serious gum disease."
89602530|NCT05792345|Other|Control|Infiltration will be performed by surgeon at the site of sternotomy
89602531|NCT05792345|Active Comparator|With TTMPB|Regional anesthesia is performed with direct view of the nerves and vascular position
89602532|NCT05783648||Before TXA recommendations|All patients operated between october 1st, 2021 and december 31st 2021, that means before the publication of the POISE-3 trial and the recommendations on the use of tranexamic acid.
89602533|NCT05783648||After TXA recommendations|All patients operated between october 1st, 2022 and december 31st 2022, that means after the publication of the POISE-3 trial and the recommendations on the use of tranexamic acid.
89602534|NCT05783076|Experimental|stereotactic body radiation therapy plus vNKT cells|"Stereotactic body radiatuon therapy is performed by Cyberknife, an image-guided frameless stereotactic robotic radiosurgery system (Accuray Corporation, Sunnyvale CA). Prescription doses ranged from 35-40Gy/5f.~Allogeneic peripherial blood monocytes (PBMC) are collected from healthy individuals. vNKT cells are isolated from PBMC and then expanded. Quality tests shoud be performed before isolated cells become cell therapy products. After quality control, vNKT cells should be transfused into patients within 24 hours. Adoptive cell therapy is initiated 2-3 weeks after SBRT. Cell therapy is performed twice a month with the interval of 24-48 hours within 6 months after SBRT. The number of vNKT cells transfused once is 1.5×10^8/Kg±15%. While cell therapy is performed once a months 6 months after SBRT. Cell therapy will be delivered for one year or until disease progression if it occurs within one year."
89602535|NCT05752786|Experimental|"Eat Less Meat challenge"|"Participants take part in the Eat Less Meat challenge"
89602536|NCT05752786|Other|"Eat Less Meat challenge later"|"Participants take part in the Eat Less Meat challenge 4 months after the participants in the experimental arm, i.e., after all measures completion"
89602537|NCT05746884|Experimental|Experimental Group with PuraStat®|Endoscopic mucosectomy or endoscopic ampullectomy with standard resection technique, per-procedure hemostasis at operator discretion and application of PuraStat®
89602538|NCT05746884|Active Comparator|Control Group|Endoscopic mucosectomy or endoscopic ampullectomy with standard resection technique, per-procedural hemostasis at operator discretion
89602539|NCT05739474|Experimental|Flu-M Tetra vaccine, children aged 10 to 17 years old|Сhildren will be vaccinated a single 0.5 mL dose of the Flu-M Tetra vaccine intramuscularly
89602540|NCT05739474|Active Comparator|VaxigripTetra vaccine, children aged 10 to 17 years old|Сhildren will be vaccinated a single 0.5 mL dose of the VaxigripTetra vaccine intramuscularly
89602541|NCT05739474|Experimental|Flu-M Tetra vaccine, children aged 3 to 9 years old|Сhildren will be vaccinated a single 0.5 mL dose of the Flu-M Tetra vaccine intramuscularly or double dose for volunteers who have not been vaccinated before
89602542|NCT05739474|Active Comparator|VaxigripTetra vaccine, children aged 3 to 9 years old|Сhildren will be vaccinated a single 0.5 mL dose of the VaxigripTetra vaccine intramuscularly or double dose for volunteers who have not been vaccinated before
89602543|NCT05739474|Experimental|Flu-M Tetra vaccine, children aged 6 to 35 months old|Сhildren will be vaccinated twice 0.25 mL dose of the Flu-M Tetra vaccine intramuscularly
89602544|NCT05739474|Active Comparator|VaxigripTetra vaccine, children aged 6 to 35 months old|Сhildren will be vaccinated twice 0.25 mL dose of the VaxigripTetra vaccine intramuscularly
89602545|NCT05733169|Experimental|Hearing impaired group|The hearing impaired group will compare the reference condition with the intervention condition.
89602546|NCT05726669|Experimental|Intervention group|Self-help intervention based on cognitive behavioural therapy for depression in pulmonary hypertension. There will be four booklets which will take four weeks for participants to work through in their own time at home.
89602547|NCT05726669|No Intervention|Wait list control group|The wait list control group will not receive the self-help intervention, and will be compared to the intervention group on the outcome measures. The wait-list control group will receive the intervention after study completion if it is found to be helpful (June 2024).
89602548|NCT05726084|Experimental|Convacell, 1 dose (Stage IIb)|Participants (230) will be vaccinated Convacell Vaccine, recombinant subunit vaccine for prevention of coronavirus infection, once intramuscularly. A cohort of participants will be allocated (115 participants) for evaluating cell-mediated immunity parameters.
89602549|NCT05726084|Experimental|Convacell, 2 doses (Stage IIb)|Participants (230) will be vaccinated Convacell Vaccine, recombinant subunit vaccine for prevention of coronavirus infection, twice intramuscularly. A cohort of participants will be allocated (115 participants) for evaluating cell-mediated immunity parameters.
89602550|NCT05726084|Experimental|Convacell, chosen regimen (Stage III)|Participants (10 562) will be vaccinated Convacell Vaccine, recombinant subunit vaccine for prevention of coronavirus infection, the regimen chosen in Stage IIb intramuscularly.
89602551|NCT05726084|Placebo Comparator|Placebo, chosen regimen (Stage III)|Participants (5 282) will be vaccinated Placebo, the regimen chosen in Stage IIb intramuscularly.
89602552|NCT05721690|Experimental|UED-A|Tracheal Intubation with UED-A videolaryngoscope
89602553|NCT05721690|Active Comparator|GLIDESCOPE|Tracheal Intubation with Glidescope Titanium videolaryngoscope
89602554|NCT05716087|Experimental|LP-168|Subjects who have previously received BTK inhibitors treatment failed or relapsed after remission or intolerated
89602555|NCT05700331|Experimental|Chronic Widespread Pain patients|3 FMT infusions, 2 weeks apart Procedures for Infusion: 100-200 ml of FMT solution or sterile saline will be infused over 2-3 minutes into the distal duodenum or jejunum via oesophago-gastro-duodenoscopy (OGD). After infusion, subjects will be monitored for 1 hour before discharged.
89602556|NCT05690698|Experimental|Quatiapine group (n=50)|Quetiapine (25-50 mg/day) according to their symptoms of agitations.
89602557|NCT05690698|Active Comparator|Haloperidol group (n=50)|Haloperidol (1-2 mg/day) according to their symptoms of agitations.
89602558|NCT05687695|Experimental|backward walking training group|six weeks of backward walking training program 3 times per week
89602559|NCT05687695|Active Comparator|core training group|six weeks of core training 3 times per week
89602560|NCT05687695|No Intervention|control group|patients will not receive any intervention for six weeks
89602561|NCT05686278||Hip hemiarthroplasty with BiPolar i and cemented stems (Meije or Oceane+)|Subjects clinically suitable for a hip hemiarthroplasty surgery with Corin hip devices
89602562|NCT05661123|Experimental|will receive kinesio tape in addition to complete decongestive therapy for 6 successive weeks.|will receive Complete decongestive therapy in combination with kinesio tape
89602563|NCT05661123|Other|will receive complete decongestive therapy for 6 successive weeks.|"Complete Decongestive Therapy(traditional physical therapy) that includes:~Education.~Skin care .~Pneumatic compression device .~Manual lymph draining .~Multilayer short stretch compression bandages.~Exercises."
89602564|NCT05650749|Experimental|Dose Escalation Arm|The dose escalation arm will determine the maximum tolerated dose of GPC2 CAR T cells using a standard 3+3 trial design.
89602565|NCT05650749|Experimental|Dose Expansion Arm|If at least one dose from the dose expansion arm is determined to be safe, additional patients will be enrolled to the dose expansion arm to preliminarily evaluate the rate of response to GPC2 CAR T cells and further characterize the safety profile of GPC2 CAR T cells.
89602566|NCT05644431||Gastric and gastroesophageal junctional adenocarcinomas|Patient under standard chemotherapy in localized and resectable gastric and gastroesophageal junctional adenocarcinomas
89602567|NCT05640843|Experimental|Whole Foods Plant-based Diet|For 12 weeks, on the WFPBD arm, patients will receive two premade meals per day, for lunch and dinner for 6 days weekly, prepared and shipped by U.S.-based WFPBD company Plantable weekly.
89602568|NCT05640843|Experimental|Supplements|For 12 weeks on the supplement arm, patients will be given algae omega 3 supplements (QWell pharmaceuticals) and curcumin supplements (Sabinsa pharmaceuticals) twice daily.
89602569|NCT05640843|Placebo Comparator|Placebo|For 12 weeks on the placebo arm, patients will be given placebo supplements twice daily (QWell and Sabinsa pharmaceuticals).
89602570|NCT05636189|Active Comparator|warming group|warming of the patient with whole body warming blanket in the OR during induction of anesthesia, prewarmed intravenous fluid during the operation.
89602571|NCT05636189|No Intervention|no warming group|There will be no whole body warming during induction.
89602572|NCT05627349|Experimental|wrist splinting group|wrist splinting at night for 2 weeks
89602573|NCT05627349|Experimental|FSN group|The needle inserted at the midpoint of the anterior forearm of the affected side. Swaying movement (SM) frequency is 200 times in 2 minutes. Reperfusion approach (RA) was performed with slow repetitively grasping movement while SM. On the 1st, 2nd, and 4th days, three times of FSN treatment were arranged.
89602574|NCT05626998|No Intervention|Control|The participants will not receive premedication
89602575|NCT05626998|Active Comparator|Dexmedetomidine|The participants will receive intramuscular dexmedetomidine injection (1 µg/kg) diluted in 2ml normal saline thirty minutes before surgery in the ward
88811411|NCT01323959|Experimental|REVAXIS GROUP|Healthy subjects who had received one booster dose of Revaxis® vaccine in the NCT01277705 study received one booster dose of Boostrix™ Polio vaccine in this study, administered as an intramuscular injection into the deltoid region of the left arm.
88811412|NCT05652608||Particpants|participating in Immune Strength, a multi-week wellness program
88811413|NCT00792428|Active Comparator|Real-tDCS + PT-OT|Each subject will receive up to 5 days of traditional physical-occupational therapy for at least 1 hour per day in the stroke recovery laboratory in combination with real transcranial direct current stimulation (tDCS) over the motor region for up to 30 min.
88980911|NCT05011383|Experimental|CHEK2|Patients with castration resistant prostate cancer which contains CHEK2 alterations are treated with high dose testosterone
89602576|NCT05626998|Active Comparator|Gabapentin|The participants will receive 600 mg gabapentin (two capsules each containing 300 mg) thirty minutes before surgery in the ward
89608622|NCT04143477|Experimental|Peficitinib 150 mg|Participants will receive a single dose of 150 mg under fasted condition Day 1, followed by multiple doses of 150 mg under fed condition once daily in the morning from Day 8 till Day 13.
89608623|NCT04142463|No Intervention|Before-group|This arm comprises patients who are recruited in phase 3 of the study, i.e. before the implementation of the care pathway. It is intended that patients included in phase 3 serve as a control-group for patients included in phase 6.
88811414|NCT00792428|Sham Comparator|Sham-tDCS + PT-OT|Each subject will receive up to 5 days of traditional physical-occupational therapy for at least 1 hour per day in the stroke recovery laboratory in combination with sham (pretend) tDCS for up to 30 min. over the motor region.
88811415|NCT05201612|Experimental|Pembrolizumab plus olaparib|"Treatment cycles will be 21 days in length. All participants will receive treatment as follows:~Olaparib 300 mg, orally (po), twice a day (BID) continuously. Pembrolizumab 200 mg, intravenously (IV), every 21 days. Treatment will be continued in the absence of disease progression, unacceptable toxicity, withdrawal of consent or death. Pembrolizumab will be administered up to a maximum of 2 years (35 cycles)."
88811416|NCT01271855|Placebo Comparator|Glycerin suppository|Women assigned to this arm receive a glycerin suppository (placebo) every 8 hours after delivery during the first 24 hours postpartum
88811417|NCT01271855|Experimental|Belladonna and opioid suppository|Women assigned to this arm receive a belladonna and opioid (B&O) suppository every 8 hours after delivery during the first 24 hours postpartum
88811418|NCT00777764|Experimental|Healthy Volunteers|Healthy participants were tested sequentially in a skin prick test procedure with positive control (histamine 6 mg/mL), negative control (saline), and 1:1000, 1:100, 1:10 dilution and full concentrations of both omalizumab and omalizumab excipients.
88811419|NCT00777764|Experimental|Allergic Asthma Participants|Allergic asthma participants were tested sequentially in a skin prick test procedure with positive control (histamine 6 mg/mL), negative control (saline), and a succession of 1:1000, 1:100, 1:10 dilutions and full concentration of both omalizumab and omalizumab excipients.
88811420|NCT00808340|Active Comparator|senofilA test/senofilA prod/balafilconA|Subjects wear 3 multifocal contact lenses: senofilcon A test worn first, senofilcon A production worn second, and balafilcon A worn third.
88811421|NCT00808340|Active Comparator|senofilcon A test/balafilcon A/senofilcon A prod|Subjects wear 3 multifocal contact lenses: senofilcon A test worn first, balafilcon A worn second, and senofilcon A production worn third.
88811422|NCT00808340|Active Comparator|senofilcon A prod/senofilcon A test/balafilcon A|Subjects wear 3 multifocal contact lenses: senofilcon A production worn first, senofilcon A test worn second, and balafilcon A worn third.
89602577|NCT05620225|Experimental|Axon Therapy + CMM|"Subjects will be consented, screened, and then undergo a 7-day baseline assessment period. Subjects will be asked to record pain, numbness, and sleep scores via a twice daily electronic diary. Subjects who meet inclusion criteria, including diary compliance, will undergo an in-clinic baseline evaluation (Day 1), be randomized, and start their treatments.~All subjects will return to the clinic for treatments as follows:~● Day 1 - 30: 6 treatments~Week 1: 3 treatments~Week 2-4: Weekly treatments~All subjects will return to the clinic for follow-up assessment at Day 30 (± 5 days). At the Day 30 visits subjects will be asked if they want to participate in Phase 2 of the study."
89602578|NCT05620225|Sham Comparator|Sham + CMM|"Subjects will be consented, screened, and then undergo a 7-day baseline assessment period. Subjects will be asked to record pain, numbness, and sleep scores via a twice daily electronic diary. Subjects who meet inclusion criteria, including diary compliance, will undergo an in-clinic baseline evaluation (Day 1), be randomized, and start their treatments.~All subjects will return to the clinic for treatments as follows:~● Day 1 - 30: 6 treatments~Week 1: 3 treatments~Week 2-4: Weekly treatments~All subjects will return to the clinic for follow-up assessment at Day 30 (± 5 days). At the Day 30 visits subjects will be asked if they want to participate in Phase 2 of the study."
89602579|NCT05607121|Experimental|iTBS then cTBS|iTBS day 1, cTBS day 2
89602580|NCT05607121|Experimental|cTBS then iTBS|cTBS day 1, iTBS day 2
89602581|NCT05582174|Active Comparator|PPI infusion|esomeprazole 80mg iv bolus followed by 8mg per hour for 72 hours
89602582|NCT05582174|Experimental|Vonoprazan|Vonoprazan 40 mg bid orally for 72 hours, and from day 4-30 VPZ 20 mg daily
89602583|NCT05578664|Experimental|ARM A|Pembrolizumab will be administered at flat dose of 400 mg IV every six weeks for a total of 9 cycles (one year of therapy) and metastasis directed treatment (surgery or RadioTherapy, RT) from day 21 of cycle 1 to day 42 of cycle 1.
89602584|NCT05578664|Active Comparator|ARM B|Local therapy alone (tumor resection or definitive RadioTherapy, RT) within 42 days from randomization.
89602585|NCT05576493|Experimental|A:phaco+MP-TSCPC|22 patients with primary angle closure glaucoma will undergo phacoemulsification and micropulse cyclophotocoagulation
89602586|NCT05576493|Experimental|B:phaco+TSCPC|22 patients with primary angle closure glaucoma will undergo phaco and transscleral cyclophotocoagulation
89602587|NCT05576493|Experimental|C:phaco+endocyclophotocoagulation|22 patients with primary angle closure glaucoma will undergo phaco and endocyclophotocoagulation after cataract removal
89602588|NCT05576493|Experimental|D:phaco GSL|22 patients with primary angle closure glaucoma will undergo phaco and goniosynechiolysis
89602589|NCT05569629|Experimental|Pre & post-EBBx/BB group|BW will be performed once before endobronchial biopsy and bronchial brushing, and once after endobronchial biopsy and bronchial brushing
89602590|NCT05569629|No Intervention|Post-EBBx/BB group|BW will be performed once after endobronchial biopsy and bronchial brushing
89602591|NCT05555901|Experimental|Fruquintinib+ chemotherapy|Patients will receive fruquintinib+ FOLFIRI once every four weeks as the second-line treatment. After receiving 4-6 months of second-line treatment, patients who achieve disease control will receive fruquintinib + capecitabine as maintenance treatment.
89602592|NCT05555901|Active Comparator|Bevacizumab+ chemotherapy|Patients will receive bevacizumab+ FOLFIRI once every two weeks as the second-line treatment. After receiving 4-6 months of second-line treatment, patients who achieve disease control will receive bevacizumab + capecitabine as maintenance treatment.
89602593|NCT05540028|Experimental|Adult Cohort Group 1|Participants will receive a single 0.5mL dose of IVT PCV-25 administered by intramuscular injection on Day 1
88811423|NCT00808340|Active Comparator|senofilcon A prod/ balifilcon A/ senofilcon A test|Subjects wear 3 multifocal contact lenses: senofilcon A production worn first, balafilcon A worn second, and senofilcon A test worn third.
88811424|NCT00808340|Active Comparator|balafilcon A/senofilcon A test/senofilcon A prod|Subjects wear 3 multifocal contact lenses: balafilcon A worn first, senofilcon A test worn second, and senofilcon A production worn third.
88811425|NCT00808340|Active Comparator|balafilcon A/senofilcon A prod/senofilcon A test|Subjects wear 3 multifocal contact lenses: balafilcon A worn first, senofilcon A production worn second, senofilcon A test worn third.
88811426|NCT01354145|Experimental|Chondroitin sulfate (Condrosan)|CHONDROITIN SULPHATE Group: 1200 mg (three capsules of 400 mg each) taken once a day in the morning
88811427|NCT01354145|Active Comparator|Celecoxib|CELECOXIB Group: 200 mg (one capsule of 200 mg CELECOXIB + two placebo capsules) taken in the morning
88811428|NCT05168462|Experimental|Reduced noradrenaline (MAP ≥ 55 mmHg)|
88811429|NCT05168462|No Intervention|Usual care (MAP ≥ 65 mmHg)|
88811430|NCT04383782|Active Comparator|Expectancy Challenge|The expectancy challenge intervention will involve two brief videotaped testimonials in which former smokers discuss their experiences with smoking-related health conditions. Participants will be encouraged to reflect back on the content of each video once per week leading up to the follow-up assessment.
88811431|NCT04383782|Experimental|Expectancy Challenge + Behavioral Activation|In addition to the expectancy challenge intervention (see Expectancy Challenge condition), participants in the Expectancy Challenge + Behavioral Activation group will also receive a novel behavioral activation intervention. Participants will be presented with brief psychoeducation about behavioral activation, several examples of possible functions of cigarette smoking, and several suggestions of behavioral strategies. All participants will receive the same information, but they will be encouraged to apply the information to their personal circumstances and to consider additional examples of rewarding activities they may engage in over the next four weeks. Participants will also be encouraged to engage in at least one behavioral activation activity each week leading up to the follow-up assessment.
88811432|NCT04383782|Placebo Comparator|Neutral Reading|The control group will receive neutral reading materials related to the components and structure of a cigarette. The content will be strictly curated so as to avoid inadvertently encouraging or discouraging smoking among participants.
88811433|NCT02196857|Experimental|Azacytidine + Sorafenib|Azacitidine 75 mg/m2 administered subcutaneously (SQ) or intravenously (IV) daily for 7 days per 28 day cycle. Sorafenib administered orally at a dose of 400 mg twice daily every day continuously.
88811434|NCT01272245|Experimental|Omacetaxine and Cytarabine|Omacetaxine 1.25 mg/m2 SQ every 12 hours x 3 days + Cytarabine 20 mg SQ x 7 days of 4-7 week cycle.
89602594|NCT05540028|Active Comparator|Adult Cohort Group 2|Participants will receive a single 0.5mL dose of PCV 20 administered by intramuscular injection on Day 1
89608624|NCT04142463|Experimental|After-group|This arm comprises patients who are recruited in phase 6 of the study, i.e. after the implementation of the care pathway.
88980912|NCT05009732|Experimental|Proxalutamide (GT0918) plus standard of care|Participants receive 300mg once daily orally plus standard of care for 7 days and can be extended up to 14 days per investigator discretion
88980913|NCT05009732|Placebo Comparator|Placebo plus standard of care|Participants will receive placebo tablets matching Proxalutamide (GT0918) orally plus standard of care for 7 days and can be extended up to 14 days per investigator discretion
88980914|NCT05005780|Experimental|µ-alpha oscillation coupled ipsilesional 100 Hz triplet bursts|µ-rhythm (The µ rhythm frequency band is defined by activity falling between 8 and 13 Hz and recorded by scalp electrodes over the sensorimotor cortex during waking neural activity) negative peak triggered TMS of ipsilesional primary motor cortex, consisting of 400 triple pulses at 100 Hz, delivered at a mean inter-triple pulse interval of 3.0 s. Stimulation intensity: 100% resting motor threshold.
88980915|NCT05005780|Active Comparator|contralesional 1 Hz rTMS|1200 stimuli to the contralesional primary motor cortex at 1 Hz. Stimulation intensity: 115% resting motor threshold.
88980916|NCT05004311|Experimental|Group A (severe renal function impairment)|Eight (8) participants with severe renal impairment.
88980917|NCT05004311|Experimental|Group B (healthy)|Eight (8) control participants, matched to the 8 severe renal impaired participants enrolled in Group A.
88980918|NCT05001789|Experimental|Active|Working memory training with task-difficulty increasing across sessions
88980919|NCT05001789|Active Comparator|Sham|Working memory training with task-difficulty remaining constant across sessions.
88980920|NCT04999085|Experimental|Supportive Care|
88980921|NCT04998331||Participants With CD30-positive Lymphoma|All participants diagnosed with relapsed/refractory (R/R) cHL, CTCL (mycosis fungoides [MF] and cutaneous anaplastic large cell lymphoma [pcALCL]) and sALCL with CD30 positive, and who have previously achieved a CR or PR with BV treatment and subsequently experienced disease progression/relapse and were administered BV retreatment will be observed retrospectively from their initiation of BV treatment until participant's inclusion date in the study or until treatment discontinuation due to toxicities or any cause. All study data will be collected retrospectively from the medical records.
88980922|NCT04997447|Experimental|Intervention group|Two weeks of daily step reduction (limited to 2000 steps per day) followed by four weeks of supervised gym-based exercise rehabilitation (twice per week strength training and twice per week cycle endurance training)
88980923|NCT04997447|No Intervention|Control group|Continued monitoring of habitual daily step count without structured intervention. Classic control.
88980924|NCT04993209|Experimental|NDV-HXP-S 1μg|NDV-HXP-S 1μg with an interval of 28 days apart. A dose escalation will be performed with an interval of two days between each dose in a blinded form. The aim is to verify the product safety and support the decision on the dose selection among three alternatives, 1 μg, 3 μg and 10 μg, based on the immune response evaluation. These results will also explore the response against two variants of concern in SARS-CoV-2: γ and β. The Phase I (former stage A) is designed as a non-inferiority test comparing the three different doses.
88980925|NCT04993209|Experimental|NDV-HXP-S 3μg|NDV-HXP-S 3μg with an interval of 28 days apart. A dose escalation will be performed with an interval of two days between each dose in a blinded form. The aim is to verify the product safety and support the decision on the dose selection among three alternatives, 1 μg, 3 μg and 10 μg, based on the immune response evaluation. These results will also explore the response against two variants of concern in SARS-CoV-2: γ and β. The Phase I (former stage A) is designed as a non-inferiority test comparing the three different doses.
89518005|NCT03503357|Experimental|IFT Testing 4|Participants will be fitted with and IFT cuff and randomized to command list D intra-operatively to assess awareness.
89518006|NCT03099707|No Intervention|Standard of Care|Participants are administered baseline, 3 month, and 6 month questionnaires and provided with study incentive (100 Rand per survey plus an additional 200 Rand to complete all three surveys) only. This group will not receive any additional engagement to care intervention. Investigators intend to follow their clinical outcomes through medical registries, pharmacy data, and the National Health Laboratory Service (a national database for all individuals living with HIV in South Africa regarding engagement in care).
89518007|NCT03099707|Active Comparator|Treatment Ambassador Intervention|Participants are administered baseline, 3 month, and 6 month questionnaires and provided with study incentive (100 Rand per survey plus an additional 200R to complete all three surveys). For participants randomized to the intervention arm, they will immediately meet with a Treatment Ambassador to begin the 8 session intervention, which has components of motivational interviewing, peer-support, and peer navigation. The protocol is detailed in a study manual that has been reviewed and undergone multiple iterative revisions to ensure cultural acceptability.
89518008|NCT03414515||Patients with peripheral artery disease|located in the common and external iliac artery, the common and superficial femoral artery, the popliteal artery and/or the below-the-knee (BTK) arteries (anterior tibial artery, posterior tibial artery or peroneal artery).
89518009|NCT05396677|Experimental|Acetaminophen Condition|1000 mg acetaminophen
89518010|NCT05396677|Placebo Comparator|Placebo Condition|1000 mg microcrystalline cellulose
89518011|NCT03490643|Other|TMD Group|people who has TMD
89518012|NCT03490643|Other|Control Group|individuals who dont have healthy temporomandibular joint
89518013|NCT04461743||Patients with normal lac|
89518014|NCT04461743||Patients with abnormal lac|
89518015|NCT02906033|Experimental|Intervention group|New perioperative practice model.
89518016|NCT02906033|No Intervention|Control group|Traditional practice model.
89518017|NCT05396521|Active Comparator|Standard of Care|
89518018|NCT05396521|Experimental|Blood Flow Restriction Supplemented|
89518019|NCT05131867|Active Comparator|triple H group|The patients will receive nimodipine (60 mg/4 hours) orally or via nasogastric tube from the first day of admission, then after the diagnosis of vasospasm is confirmed, Triple H therapy (hypertension, hypervolemia and hemodilution) will be started. norepnnephrine (0.01-0.2ug/kg/min) to mentain main arterial blood pressure >100mmhg and hypervolemia to maintain the CVP around 12---14 mmHg and hemodilution to maintain the haematocrit between 30% and 33%.
89602595|NCT05531136|Experimental|Foot strengthening training|12-week foot strengthening training in addition to an already joined functional exercise program. The foot strengthening training is supervised and progressing and consists of isolated and functional exercises. Participants keep a training diary.
89602596|NCT05531136|No Intervention|Control|The control group continues the functional exercise program as usual. The subjects in this group are asked to keep a diary in which the subjects weekly report other physical activities, fall incidents and mobility related discomfort. The trainer calls the participants in the control group every week to pay attention to these topics.
89602597|NCT05515445|Experimental|Normal Hepatic Function|Subjects with normal hepatic function will receive a single 48 mg oral dose of Chiglitazar
89602598|NCT05515445|Experimental|Mild Hepatic Impairment|Subjects with mild hepatic impairment will receive a single 48 mg oral dose of Chiglitazar
89602599|NCT05515445|Experimental|Moderate Hepatic Impairment|Subjects with moderate hepatic impairment will receive a single 48 mg oral dose of Chiglitazar
89602600|NCT05515445|Experimental|Severe Hepatic Impairment|Subjects with severe hepatic impairment will receive a single 48 mg oral dose of Chiglitazar
89602601|NCT05494671|Experimental|conjunctival limbal autologous transplant|patients with unilateral stem cell deficiency due to chemical burn
89602602|NCT05490654|Experimental|Abdominal Massage|Study participants who will receive abdominal massage by manual or device delivered for 6 weeks
89602603|NCT05490654|No Intervention|Control|Participants who will have no change to their normal treatment regime
89602604|NCT05489484|Experimental|MD-Shoulder Medical Device|MD-Shoulder Medical Device type I collagen based
89602605|NCT05485181|Experimental|Cohort 1|8 subjects get psychological assessments and fMRI brain scan followed by 9 week psychotherapeutic intervention. With intervention completion, psychological assessments and fMRI scan are repeated.
89602606|NCT05485181|Active Comparator|Cohort 2|"8 subjects get psychological assessments at same time as Cohort 1, but do not receive the intervention at that time - serving as control group.~When Cohort 1 is completed, Cohort 2 will repeat psychological assessments, receive fMRI scan, then receive same 9 week intervention as Cohort 1, followed by repeat psychological assessments and fMRI scan."
89602607|NCT05479006|Active Comparator|Anodal stimulation|Anodal stimulation targets the primary motor cortex (arm area) in the lesioned hemisphere, sham on the contralesional hemisphere.
89602608|NCT05479006|Active Comparator|Cathodal stimulation|Cathodal stimulation targets the dorsal premotor cortex (arm area) in the contralesional hemisphere, sham on the lesioned hemisphere.
89602609|NCT05479006|Active Comparator|Bilateral Stimulation|Anodal stimulation targets the primary motor cortex (arm area) in the lesioned hemisphere and cathodal stimulation targets the dorsal premotor cortex (arm area) in the contralesional hemisphere at the same time.
89602610|NCT05479006|Sham Comparator|Sham stimulation|Sham stimulation to both hemisphere of the brain
89608625|NCT04144803||Cerebral desaturation group|absolute drop of forehead cerebral oxygen saturation ≥ 10% from baseline for ≥ 5 minutes during prehospital anesthesia
89608626|NCT04144803||Control group|no absolute drop of forehead cerebral oxygen saturation ≥ 10% from baseline for ≥ 5 minutes during prehospital anesthesia
88811435|NCT00802100|Experimental|Olanzapine|Participants will receive treatment with olanzapine and metformin, with the possible addition of simvastatin or benztropine, depending on side effects.
88811436|NCT00802100|Experimental|Perphenazine|Participants will receive treatment with perphenazine and benztropine, with the possible addition of simvastatin or metformin, depending on side effects.
88811437|NCT00802100|Experimental|Aripiprazole|Participants will receive treatment with aripiprazole, with the possible addition of simvastatin, metformin, or benztropine, depending on side effects.
88811438|NCT01354691|Experimental|ladostigil hemitartrate|Ladostigil capsules 80 mg
88811439|NCT01354691|Placebo Comparator|Placebo|Placebo capsules
88811440|NCT03009617|Experimental|Intervention Group|The educational program and counseling Pre-test before intervention Monitoring, education, and consultation through the Web At least two reminders via e-mail or phone message a week The last test after three months The website was closed three months later.
88811441|NCT03009617|No Intervention|Control Group|Pre-test No intervention The last test after three months Opening the website to the control group
88811442|NCT01355471|Experimental|CD07805/47 gel|
88811443|NCT01355471|Placebo Comparator|Placebo|
88811444|NCT00802412|Other|Topiramate|The subjects for the proposed study will be 180 currently smoking, treatment-seeking male veterans with alcohol and nicotine dependence. Ninety subjects will be randomized to the topiramate arm and 90 subjects will be randomized to the placebo group.
88811445|NCT00802412|Placebo Comparator|Placebo|90 participants, will receive matching placebo
88811446|NCT01355705|Experimental|Amrubicin + Lenalidomide + Dexamethasone|"Amrubicin will be given intravenously on Day 1 of each 3-week cycle beginning with 40 mg/m2, for a maximum of 4 cycles.~Concurrent therapeutic medications:~Lenalidomide: 10 or 15 mg daily by mouth, Days 1 to 14~Dexamethasone: 40 mg weekly by mouth (Days 1, 8, and 15)~Other drugs:~Aspirin: 81 or 325 mg daily oral~Pegfilgrastim subcutaneous on Day 2"
88811447|NCT03009071|Experimental|Doin with Acupuncture|An acupuncture physician will administer acupuncture at 6-12 acupoints in the upper and middle trapezius area (mandatory points: both SI15, TE15, and LI16; and selective points: GB20, BL10, GV14, SI14, and Hyeopcheok (Huatuo Jiaji, EX B2) points at C3-5 levels). Cervical Doin (conduction exercise) will be performed with the needles in situ by increasing the cervical range of motion (rotation) with physician guidance and isometric resistance exercise (rotation) as needed.
88811448|NCT03009071|Active Comparator|Acupuncture|An acupuncture physician will administer acupuncture at 6-12 acupoints in the upper and middle trapezius area (mandatory points: both SI15, TE15, and LI16; and selective points: GB20, BL10, GV14, SI14, and Hyeopcheok (Huatuo Jiaji, EX B2) points at C3-5 levels).
88811449|NCT01274585|Sham Comparator|No active treatment|
88811450|NCT01274585|Experimental|stimulation/treatment|
88811451|NCT01327157|Placebo Comparator|Visual Analog Scale (VAS)|"Initial consultation, dental cleaning and performing the visual analog scale. Consultation three months after achieving visual analog scale final~VAS and dental cleaning at the first query.~VAS at the last query. In the second period (91-180 days) that participants have been moved from the Placebo group (VAS) to the Experimental group(Occlusal Adjustment)."
89602611|NCT05469828|Experimental|treatment|The effects of Crizanlizumab will be assessed in 20 nontransfused SCD subjects. After comprehensive baseline assessment one month prior the time of study initiation, patients will be started on 5mg/kg of body weight to be initiated at week 1 with follow up dosing at week 3 and week 7 then q4weeks until week 23, which will be the last dose given (7 total doses). Safety laboratories will be drawn at each infusion visit. There will be a follow up phone call the day after receiving the medication. Comprehensive blood and vascular testing will be repeated at Week 11 and Week 23 of treatment.
89602612|NCT05469828|Active Comparator|control|A total of 10 SCD subjects will be recruited from the hematology clinic at CHLA, generating a similar distribution of SS and Sß0 hemoglobin. They will be studied twice, once at the beginning of the study, time 0, and once at the end of study, after 6 months. They will undergo the same cerebral, peripheral and cardiopulmonary testing procedures as the patients undergoing therapy. They will also have monthly phone calls to determine clinical outcomes such as crisis frequency, medication use, hospitalizations and other pertinent clinical findings that may arise.
89602613|NCT05460845|Experimental|Phase 2 Intervention|Low-Carbohydrate Diet
88980926|NCT04993209|Experimental|NDV-HXP-S 10μg|NDV-HXP-S 10μg/0.5mL intramuscularly, with an interval of 28 days apart. A dose escalation will be performed with an interval of two days between each dose in a blinded form. The aim is to verify the product safety and support the decision on the dose selection among three alternatives, 1 μg, 3 μg and 10 μg, based on the immune response evaluation. These results will also explore the response against two variants of concern in SARS-CoV-2: γ and β. The Phase I (former stage A) is designed as a non-inferiority test comparing the three different doses.
89602614|NCT05451524|Experimental|Insomnia prevention program|"The preventive program has been developed and modified as based on the evidence-based CBT-I insomnia treatment.~Active intervention group will be conducted in group size with 6-8 subjects who are from the same education level (i.e. secondary vs university). Youths in the intervention group will receive 4 weekly insomnia prevention program conducted by the sleep therapists who has received training in conducting CBT-I under close supervision of sleep experts. Each session will last for about 60-90 mins."
88980927|NCT04993209|Active Comparator|Adsorbed inactivated COVID-19 vaccine (CoronaVac)|Adsorbed inactivated COVID-19 vaccine 600 SU dose (0.5 mL) with an interval of 28 days apart Intramuscular (deltoid). In the original version of protocol, the control arm consisted in placebo use. There was a changing post hoc to Adsorbed inactivated COVID-19 vaccine (CoronaVac) due to decision of Data and Safety Monitoring Board, when 219 (50% of original sample) subjects have already included in the study. Therefore, those who received a placebo at the first vaccine visit started to receive active control vaccine and those who were included from that moment forward received two doses of active control vaccine. The original study protocol provided for the inclusion of the placebo arm (10% of population of study), in order to serve as a control for safety evaluations and to assess the attack rate of natural infection to which participants will be exposed during the study.
88980928|NCT04989491|Experimental|Experimental group|Prophylactic treatment with Rituximab: one single dose of 375mg/m2 intravenous 7 days before transplantation in case of living donor or at time of transplantation (D0 or D1) in case of transplantation with a deceased donor.
89602615|NCT05451524|Active Comparator|General health education|In order to control for placebo effect and other non-specific factors such as contact time, youths in the control group will be provided with group-based general health education with same dosage (4 weeks) as intervention group. Modules will contain information about general well-being, diet, nutrition, and activity. It is expected that this health education will be an active control group to account for most of the non-specific effects including time, attention, therapist, and peer support.
89602616|NCT05450926|No Intervention|healthy volunteers|Two Algology Specialists will record the localization and number of cervical spinal nerve, transverse process cornes and surrounding vascular structures at cervical C4-5-6-7 levels in healthy volunteers by Doppler USG.
89602617|NCT05450926|Active Comparator|patients with cervical radicular pain|Two Algology Specialists will apply cervical root block to patients with cervical radicular pain guided by Doppler USG, and pain scores of the patients will be evaluated with VAS (visual analog scale) before and after the procedure.
89602618|NCT05450926|Other|human cadavers|Seven formalin-containing human cadavers will be examined by 3 anatomy doctors at Ankara University Faculty of Medicine, Department of Anatomy to determine the morphology of the spinal nerve, vertebral artery, assending and deep arteries in the cervical foraminal region, as well as the radicular arteries.
89602619|NCT05447026|Active Comparator|Control group|Regenerative surgical treatment of periodontal infrabony defects without any adjunctive therapies.
88980929|NCT04989491|Active Comparator|control group|Immunosuppression treatment will be given according to the practice of the centers; use of Thymoglobuline is strongly discouraged because of EBV seronegativity and risk of lymphoma. Basiliximab is recommended for induction therapy. Recommended maintenance immunosuppression consists in a calcineurin inhibitor (tacrolimus or ciclosporine), MMF and Steroids
88980930|NCT04984369|Experimental|Never use other BRAF inhibitor therapy|Never use other BRAF inhibitor therapy
88980931|NCT04984369|Experimental|PD after other BRAF inhibitor therapy N=5~40|PD after other BRAF inhibitor therapy
88980932|NCT04984369|Experimental|SD but intolerant after other BRAF inhibitor therapy|SD but intolerant after other BRAF inhibitor therapy
88980933|NCT04981158|Placebo Comparator|control group, group I|standard general anesthetic (GA) technique
88811965|NCT03439280|Experimental|Phase 1 Dose Escalation Cohort: Mezagitamab 1200 mg|Mezagitamab 1200 mg, SC, once weekly for 8 weeks, then once every 2 weeks for 16 weeks, and then once every 4 weeks thereafter in a 28-day treatment cycle until PD, unacceptable toxicities or withdrawal due to other reasons.
88811966|NCT03439280|Experimental|Phase 1 Combination Cohort: Mezagitamab 300 mg + PomDex|Mezagitamab 300 mg, SC, once weekly for 8 weeks, then once every 2 weeks for 16 weeks, and then once every 4 weeks thereafter along with pomalidomide, at product-labelled dose, orally, once daily on Days 1 to 21 and dexamethasone, at product-labelled dose, orally, once on Days 1, 8, 15, and 22 in a 28-day treatment cycle until PD.
88980934|NCT04981158|Active Comparator|Epidural /GA using TET group, group II|patients will undergo a single shot epidural bupivacaine (15 ml with 0.25% concentration) followed by a standard general anesthetic technique in which the trachea was intubated using tolerable endotracheal tube (TET)
88980935|NCT04980976|Active Comparator|Conventional blind insertion technique.|Transesophageal echocardiography probe will be inserted using a conventional blind insertion technique.
89602620|NCT05447026|Active Comparator|antimicrobial photodynamic therapy (aPDT) group|Regenerative surgical treatment of periodontal infrabony defects in conjunction with irradiation by a diode laser and a photosensitizer
89602621|NCT05447026|Active Comparator|LED photobiomodulation group|Regenerative surgical treatment of periodontal infrabony defects in conjunction with irradiation by a LED device
89602622|NCT05447026|Active Comparator|Topical ozone group|Regenerative surgical treatment of periodontal infrabony defects in conjunction with topical ozone application
89602623|NCT05441306|Experimental|Access to Personal Health Library (PerHL) + MyChart|Participants randomized to the PerHL arm will have access to PerHL and the standard of care patient portal (Epic®MyChart).
89602624|NCT05441306|Active Comparator|Control - MyChart|Participants randomized to the control arm will receive the standard of care patient portal (Epic®MyChart).
89602625|NCT05432011|Experimental|PENG block plus Femoral Cutaneous Nerve Block|Participants receiving PENG block combined to Lateral Femoral Cutaneous Nerve Block
89602626|NCT05432011|Active Comparator|PENG block plus Wound Infiltration|Participants receiving PENG block combined to wound infiltration
89602627|NCT05419908|Experimental|Fezolinetant|Participants received 90 milligrams (mg) fezolinetant capsules orally, twice daily (BID) for a period of 12 weeks
89602628|NCT05419908|Placebo Comparator|Placebo|Participants received fezolinetant matching placebo capsules orally, BID for a period of 12 weeks.
89602629|NCT05418972|Experimental|Neoadjuvant immunotherapy +/- Adjuvant immunotherapy|"NEOADJUVANT: All participants will receive neoadjuvant therapy with the fixed dose combination of intravenous relatlimab 160 mg and nivolumab 480 mg x 2 doses on days 1 and 29.~SURGERY: All participants will have sentinel lymph node mapping and biopsy prior to a wide local excision of the primary melanoma between days 43 and 56.~ADJUVANT: Participants with no pathological response or partial pathological response will receive the fixed dose combination of intravenous relatlimab 160 mg and nivolumab 480 mg for a further 11 doses."
89602630|NCT05403697|Experimental|Individualized MAP group|Individualized MAP strategy aimed at achieving a mean arterial pressure within 10% of the reference value (ie, patient's resting MAP measured during the preoperative anesthesiology consultation) during the operating room period and the 24h following surgery in the ICU.
89602631|NCT05403697|No Intervention|Control group|Standard management strategy of treating MAP ≥ 65 mmHg, during the operating room period and the 24h following surgery in the ICU. No intervention to actively decrease MAP.
89602632|NCT05399173|Experimental|an infrared (gallium aluminum arsenide laser)|Each female in study group will be treated by laser acupuncture for 3 sessions per week, for 6 weeks. An infrared (gallium aluminum arsenide) laser will be used at a wavelength of 808 nm and a power of 200 m W applied for 26 s to produce energy of less than 4 J/cm. participants will receive the same medical treatment (desmopressin acetate) and advice as in control group in addition to low level laser therapy 3 session / week for 6 weeks.
89602633|NCT05399173|Active Comparator|conventional therapy|They will receive medical treatment (desmopressin acetate) per-night dose of 120 g (for 6 weeks) & advice.
89602634|NCT05396534|Experimental|byLAWT arm|Personalized protocol that uses a contact-force catheter, a multichannel radiofrequency generator, and integrated MDCT-derived Left Atrial Wall Thickness (LAWT) information to adapt the ablation index target to the subjacent LAWT.
89602635|NCT05396534|Active Comparator|CLOSE arm|In the CLOSE arm, the use of MDCT-derived LAWT information will not be available for the operator. We uses a contact-force catheter. Ablation will be performed according to the CLOSE study settings: Power-controlled mode (without ramping) with 25 to 35 W (irrigation flow 30 ml/min). RF will be delivered until an AI of 400 at the posterior wall/roof an 550 at the anterior wall are reached.
89602636|NCT05394246|Experimental|FluoAB intraoperative fluorescence imaging|The patients will receive an injection of FluoAB. Surgery will be performed with guidance by FluoAB fluorescence imaging.
89602637|NCT05371899|Other|Chiauranib|Take 50 mg ChiauranibCioroni capsules orally on an empty stomach once a day, every day; except on the eighth day 8, when you start taking Cioroni capsules liquid, take a single oral dose of ~50 mg/about 100 Ci of [14C]Chiauranib suspensionCioroni solution once on an empty stomach.
89602638|NCT05362578|Experimental|Treatment group|Subjects will be trained to use the devices at the treatment points and will undergo the treatment twice per day for 8 weeks. Following the first 8 weeks, at visit two, the devices will be collected by the study team.
88980936|NCT04980976|Experimental|C-MAC videolaryngoscope insertion technique|Transesophageal echocardiography probe will be inserted using a C-MAC videolaryngoscope insertion technique to advance into esophagus under direct vision.
88980937|NCT04975438|Experimental|Group 1: Biologic Naïve participants receiving GSK1070806|
88980938|NCT04975438|Placebo Comparator|Group 1: Biologic Naïve participants receiving Placebo|
88980939|NCT04975438|Experimental|Group 2: Dupilumab inadequate responders receiving GSK1070806|
88980940|NCT04975438|Placebo Comparator|Group 2: Dupilumab inadequate responders receiving Placebo|
88980941|NCT04969367||Observational (activity monitor)|Patients wear an activity monitor (Fitbit) for 90 days. Patients also undergo collection of blood samples and complete questionnaires twice weekly for up to 90 days.
88980942|NCT04965389|Experimental|Treatment Sequence 1|
88980943|NCT04965389|Experimental|Treatment Sequence 2|
88980944|NCT04965389|Experimental|Treatment Sequence 3|
88980945|NCT04965389|Experimental|Treatment Sequence 4|
88980946|NCT04959968|Experimental|Intervention group|An eye patch and earplug will be applied to the intervention group in the intensive care unit on the day of craniotomy and on the post-operative 1st day between 22:00 and 06:00
88980947|NCT04959968|No Intervention|Control group|Standard care procedure will be applied to the control group
88980948|NCT04951076|Experimental|BNC210|
88980949|NCT04951076|Placebo Comparator|Placebo|
88980950|NCT04950725|Experimental|Low respiratory muscle training|Low dose of RMT and fewer repetitions and use of RMT device per week
88980951|NCT04950725|Experimental|Respiratory muscle training for strengthening|Higher number of sets with a slightly lower number of repetitions per set
88980952|NCT04950725|Experimental|Respiratory muscle training for strengthening and nasal breathing|Higher number of sets with a slightly lower number of repetitions per set RMT accompanied with sets of nasal breathing
88980953|NCT04950725|Experimental|Respiratory muscle training for endurance|One set of RMT with a higher number of repetitions
89602639|NCT05362578|Sham Comparator|Sham group|Subjects will be trained to use the devices at sham points and will undergo sham stimulation for the first 8 weeks. At visit two, after unmasking, subjects will optionally be trained on the treatment points and may participate in treatment for 4 weeks.
89602640|NCT05353868||Early PD|"Recruited in the baseline study as a subject of the Early PD group~Completed baseline assessment and stool sample collection~Being capable of giving informed consent for participation of the study"
89602641|NCT05353868||iRBD|"Recruited in the baseline study as a subject of the iRBD group~Completed baseline assessment and stool sample collection~Being capable of giving informed consent for participation of the study"
89602642|NCT05353868||First degree relatives of patient with iRBD|"Recruited in the baseline study as a subject of the 'First degree relatives of patients with iRBD' group~Completed baseline assessment and stool sample collection~Not cohabiting with iRBD proband"
89602643|NCT05353868||Health control|"Recruited in the baseline study as a subject of the 'healthy controls' group~Completed baseline assessment and stool sample collection~Being capable of giving informed consent for participation of the study"
89602644|NCT05353842|Experimental|WOWii Intervention|Workout on Wheels Internet Intervention (WOWii) program which includes: 1) WOWii website to guide participants in an exercise program, 2) home exercise starter program; 3) weekly support from a peer facilitator via online (video) meetings.
89602645|NCT05353322|Experimental|Sedentary Break Condition > Control Condition|Participants will be assigned to the sedentary break or control condition at each lab visit. If assigned to the sedentary break condition at lab visit 1, participants will be assigned to the control condition at visit 2 (and vice versa). During the lab visit, participants will wear a heart rate monitor and ambulatory blood pressure monitor, and eat a controlled diet. Participants will have an IV inserted and blood will be drawn 11 times throughout the visit. Participants will also eat a controlled diet for two days prior to the lab visit.
89602646|NCT05353322|Experimental|Control Condition > Sedentary Break Condition|Participants will be assigned to the sedentary break or control condition at each lab visit. If assigned to the sedentary break condition at lab visit 1, participants will be assigned to the control condition at visit 2 (and vice versa). During the lab visit, participants will wear a heart rate monitor and ambulatory blood pressure monitor, and eat a controlled diet. Participants will have an IV inserted and blood will be drawn 11 times throughout the visit. Participants will also eat a controlled diet for two days prior to the lab visit.
89602647|NCT05341960|Experimental|Food Delivery|Food box delivered to participant home every 2 weeks until 6 weeks post delivery
89602648|NCT05341960|Experimental|Financial Support and Navigation|$30 provide on gift card every two weeks until 6 weeks post delivery + neighborhood food retail navigation support.
89602649|NCT05341960|No Intervention|Control Group|Selected from claims data, matched.
89602650|NCT05322707|Experimental|Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg|Inhalation Aerosol, 2 actuations orally inhaled twice daily
89602651|NCT05322707|Active Comparator|Symbicort®|Inhalation Aerosol, 2 actuations orally inhaled twice daily
89602652|NCT05322707|Placebo Comparator|Placebo for Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg|Inhalation Aerosol, 2 actuations orally inhaled twice daily
89602653|NCT05316233|Experimental|VOLITE XC|Participants will receive VOLITE XC for initial treatment and followed for up to 14 Months. Participants will have the opportunity to receive optional touch-up and optional repeat treatment of VOLITE XC during the follow-up duration period.
89602654|NCT05316233|Other|Control Group|The control group received no treatment and will be followed for up to 6 months after randomization. Participants can then opt to receive VOLITE XC and followed for 6 Months.
89602655|NCT05295160|Other|type 2 diabetes - less than 4 years duration|Patients with a duration of less than 4 years since diagnosis of type 2 diabetes, BMI > 28 kg/m², non-insulin treated who agree to loose 15 kg body weight by eating a very low calorie formula diet of 800 kcal/day for men and 600 kcal/day for women. The duration of the diet is until the weight loss is achieved.
89602656|NCT05295160|Other|type 2 diabetes - more than 8 years|Patients with a duration of more than 8 years since diagnosis of type 2 diabetes, BMI > 28 kg/m², non-insulin treated who agree to loose 15 kg body weight by eating a very low calorie formula diet of 800 kcal/day for men and 600 kcal/day for women. The duration of the diet is until the weight loss is achieved.
89602657|NCT05278598|Active Comparator|ESPB group|Erector Spinae Plane Block
89602658|NCT05278598|Active Comparator|TPVPB group|Thoracic Paravertebral Plane Block
88980954|NCT04950725|Experimental|Respiratory muscle training for endurance and nasal breathing|One set of RMT with a higher number of repetitions accompanied with sets of nasal breathing
88980955|NCT04938765|Experimental|Magnesium sulfate arm|MgSo4 diluted to 20% will be administered at 40 mg/kg dosed to ideal body weight over 10min to the study arm followed by 10mg/kg/hr infusion.
88980956|NCT04938765|Placebo Comparator|Normal Saline|20 ml of normal saline bolus will be administered to the control group over 10 mins.
88980957|NCT04937400||Pediatric Stem Cell Transplant Patients|A consecutive cohort of children admitted to the hospital for stem cell transplantation
88980958|NCT04935931|Experimental|Pilot|Pre/post fMRI
88980959|NCT04935164||Male patients with gender dysphoria|"male patients with gender dysphoria according to DSM-V criteria (axis I), confirmed by MINI evaluation~patients without psychotropic treatments~patients who do not benefit of hormone therapy~patients who have not yet received gender reassignment surgery~patients aged 18 to 60 years~patients with normal or corrected vision~patients without mental defect~patients without neurological impairment"
88980960|NCT04935164||Female patients with gender dysphoria|"female patients with gender dysphoria according to DSM-V criteria (axis I), confirmed by MINI evaluation~patients without psychotropic treatments~patients who do not benefit of hormone therapy~patients who have not yet received gender reassignment surgery~patients aged 18 to 60 years~patients with normal or corrected vision~patients without mental defect~patients without neurological impairment"
89602659|NCT05278598|Active Comparator|QLPB group|Quadratus Lumborum Plane Block
89602660|NCT05278247|Experimental|single arm for all subjects|all subjects receive the same diagnostic measurement
89602661|NCT05273931|Experimental|Lifestyle intervention|Lifestyle intervention among participants of the French colorectal cancer screening program
89602662|NCT05270512|Experimental|Treatment with Dermal Cooling System|Dermal Cooling System will be used in all eligible subjects.
89602663|NCT05259852|Experimental|Food Assistance and Cessation Resources Navigation Plus Economic Assistance|
89602664|NCT05259852|Active Comparator|Food Assistance and Cessation Resources Navigation|
89602665|NCT05254340|Experimental|Healthy volunteers|Adults ages 18-75 years with no prior history of gastrointestinal diseases or symptoms.
89602666|NCT05254054|Experimental|Vibration group|Participants in Vibration group will receive an 8-week whole body vibration training in addition to conventional exercise training.
89602667|NCT05254054|Active Comparator|Control group|Participants in Vibration group will only receive conventional exercise training.
89602668|NCT05251636|Experimental|ESB adjunct to IAI|Single ESB treatment adjunct to intravitreal aflibercept injections (IAI)
89602669|NCT05251636|Active Comparator|IAI monotherapy|Intravitreal aflibercept injections (IAI)
89602670|NCT05221697|Experimental|Intervention|PRESAGE Care ATIH + Nurse or GP consultation
89602671|NCT05221697|No Intervention|Control group|usual care
89602672|NCT05214820|Experimental|Single arm with 68Ga-PSMA|All participants will undergo a PET scan with 68Ga-PSMA
89602673|NCT05212649||More-GDMT|Baseline guideline-directed medications therapy (GDMT), including angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blocker (ARB), beta-blockers, mineralocorticoid receptor antagonist (MRA), and angiotensin receptor neprilysin inhibitor (ARNI) were documented at discharge. More-GDMT group was defined as patient population received GDMT >=2 kinds of above medications.
89602674|NCT05212649||Few-GDMT group|Baseline guideline-directed medications therapy (GDMT), including angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blocker (ARB), beta-blockers, mineralocorticoid receptor antagonist (MRA), and angiotensin receptor neprilysin inhibitor (ARNI) were documented at discharge. Few GDMT-group was defined as patients who received GDMT < 2 kinds of the above medications.
89602675|NCT05211141||Patient with knee arthroplasty|patient with HLS KneeTec Deep Dish prosthesis
89602676|NCT05179889|Experimental|Arm A|mFOLFIRINOX
89602677|NCT05179889|Active Comparator|Arm B|mFOLFOX 6
89602678|NCT05173506||Adolescent Depression Screening|"> 3 visits to clinic~Diagnosis of epilepsy - International Classification of Diseases, Tenth Revision - Epilepsy and recurrent seizures (ICD-10:G40)~Age > 12 years at last visit (before CHICA-CN)~Computer assistant depression screening and management"
89602679|NCT05173506||Genetic Testing|"> 3 visits to clinic~Diagnosis of global developmental delay - International Classification of Diseases, Tenth Revision - autistic disorder (ICD-10: F84)~Age < 6 years at last visit (before CHICA-CN)~Computer reminders to test for genetic disorders"
89602680|NCT05173506||Rescue seizure therapy|"> 3 visits to clinic~Diagnosis of epilepsy - International Classification of Diseases, Tenth Revision - Epilepsy and recurrent seizures (ICD-10: G40)~Age < 18 years at last visit (before CHICA-CN)~Computer reminders to prescribe and adjust rescue anti-seizure medications"
89602681|NCT05173506||Adolescent Transition|"> 3 visits to clinic~Age > 13 years at last visit (before CHICA-CN)~Computer supported screening and counseling regarding transition to adult care"
89602682|NCT05163522|Experimental|Part 1 (SAD): Participants receiving VH4004280|
89602683|NCT05163522|Placebo Comparator|Part 1 (SAD): Participants receiving placebo|
89602684|NCT05163522|Experimental|Part 2 (MAD) Non Drug-Drug Interaction (DDI) cohort: Participants receiving VH4004280|
89602685|NCT05163522|Placebo Comparator|Part 2 (MAD) Non DDI cohort: Participants receiving placebo|
89602686|NCT05163522|Experimental|Part 2 (MAD) DDI cohort: Participants receiving VH4004280 and Midazolam|
89602687|NCT05163522|Placebo Comparator|Part 2 (MAD) DDI cohort: Participants receiving Placebo and Midazolam|
89602688|NCT05163522|Experimental|Part 3 (Single dose): Participants receiving VH4004280 (new formulation)|
89602689|NCT05163158|Experimental|Central BP target|Participants randomized to central BP target will be treated with anti-hypertensive agents to achieve a clinic central SBP < 130 mmHg.
89602690|NCT05163158|Active Comparator|Brachial BP target (standard of care)|Participants randomized to a brachial BP target will be treated with anti-hypertensive drugs to achieve a clinic brachial SBP <130 mmHg.
89602691|NCT05159960|Experimental|180/low|SLT treatment in either half of the trabecular meshwork (180 degrees) consisting of 50+/-5 adjacent laser effects. The energy is adjusted 0,1 mJ below the threshold of formation of micro bubbles.
89602692|NCT05159960|Experimental|180/high|SLT treatment in either half of the trabecular meshwork (180 degrees) consisting of 50+/-5 adjacent laser effects. The energy is adjusted to achieve the formation of micro bubbles at 50-75% of laser effects.
89602693|NCT05159960|Experimental|360/low|SLT treatment in the full circumference of the trabecular meshwork (360 degrees) consisting of 100+/-10 adjacent laser effects. The energy is adjusted 0,1 mJ below the threshold of formation of micro bubbles.
89602694|NCT05159960|Experimental|360/high|SLT treatment in the full circumference of the trabecular meshwork (360 degrees) consisting of 100+/-10 adjacent laser effects. The energy is adjusted to achieve the formation of micro bubbles at 50-75% of laser effects.
89602695|NCT05156723|Experimental|Group 1: Subunit recombinant vaccine for the prevention of coronavirus infection|5 volunteers have been vaccinated with a single dose (Stage I)
89602696|NCT05156723|Experimental|Group 2: Subunit recombinant vaccine for the prevention of coronavirus infection|15 volunteers have been vaccinated with a single dose (Stage I)
89602697|NCT05156723|Experimental|Group 3: Subunit recombinant vaccine for the prevention of coronavirus infection|45 volunteers will be vaccinated with the coronavirus vaccine intramuscularly twice (Stage II)
89602698|NCT05156723|Experimental|Group 4: Subunit recombinant vaccine for the prevention of coronavirus infection|45 volunteers have been vaccinated with a single dose of the coronavirus vaccine intramuscularly and then treated with a single dose of placebo (Stage II)
89602699|NCT05156723|Placebo Comparator|Group 5: Placebo|45 volunteers have been vaccinated with placebo intramuscularly twice (Stage II)
89602700|NCT05140915|Experimental|Intervention|Students in school randomized to the intervention will receive: (1) peer messages, written by current and former adolescent e-cigarette users and tailored by age and readiness-to-quit; (2) peer coaching, facilitated by texting; and (3) gamification, designed to motivate participation.
89608627|NCT05586009|Active Comparator|Group 1|(n=25): receive cisplatin with hydration 1000mg magnesium (8 Meq) intravenous infusion ( IVI ).
89608628|NCT05586009|Active Comparator|Group 2|(n=25): receive cisplatin with hydration 2000mg magnesium (16 Meq) ( IVI ).
89602701|NCT05140915|Active Comparator|Control|Students in schools randomized to the control condition will be provided written e-cigarette cessation materials by the Research Coordinator at the time of study enrollment. The written materials will consist of two pamphlets from Journeyworks, selected based on: (1) their clear and attractive layout designed for a low-literacy audience, and (2) their providing both information re: e-cigarette use with a strong message about nicotine and nicotine addiction, E-Cigarettes: 8 Things Everyone Should Know, and support in quitting, How to Quit Vaping.
89602702|NCT05134363|Active Comparator|Dexmedetomidine 0.5 mic/kg bolus|selective alpha 2 adrenergic receptor agonist
88980961|NCT04935164||Male volunteers without gender dysphoria|"male volunteer without gender dysphoria according to DSM-V criteria (axis I), confirmed by MINI evaluation~volunteer aged 18 to 60 years~volunteer with normal or corrected vision~volunteer without mental defect~volunteer without neurological impairment"
88980962|NCT04935164||Female volunteers without gender dysphoria|"female volunteer without gender dysphoria according to DSM-V criteria (axis I), confirmed by MINI evaluation~volunteer aged 18 to 60 years~volunteer with normal or corrected vision~volunteer without mental defect~volunteer without neurological impairment"
88980963|NCT04933305||RYGB patients|Patients that already received RYGB one year prior commencement of their participation in the study
88980964|NCT04932122|Active Comparator|Dorsal wrist ganglion alone (DWG)|Dorsal wrist ganglion excision alone
88980965|NCT04932122|Active Comparator|DWG with PIN|Dorsal wrist ganglion excision with posterior interosseus neurectomy (PIN)
88980966|NCT04931199|Active Comparator|CBT|
88980967|NCT04931199|Experimental|CBT+App|
88980968|NCT04926181|Experimental|Single Arm: Apalutamide + Cetrelimab|Participants will be given Apalutamide tablets combined with infusions of Cetrelimab in 28-day cycles, for up maximum of two years.
88980969|NCT04921189|Active Comparator|The combined supplement of Ascorbic acid, Thiamine, and Cortisol|The combined administration of 3 drugs will be administered through intravenous infusion over 60 min every 12 h for 3 days for the out-of-hospital cardiac arrest survivors treated with targeted temperature management.
88980970|NCT04921189|Placebo Comparator|Placebo|An identical volume of 0.9% saline (150mL) administered through intravenous infusion over 60 min every 12 h for 3 days.
88980971|NCT04919499|Experimental|Part A: BI 765128 low dose|
88980972|NCT04919499|Experimental|Part A: BI 765128 medium dose|
88980973|NCT04919499|Experimental|Part A: BI 765128 high dose|
88980974|NCT04919499|Experimental|Part B: BI 765128|Highest safe dose from Part A
88980975|NCT04919499|Sham Comparator|Part B: Sham comparator|
88980976|NCT04917874|Experimental|B-VEC|Open label B-VEC topical treatment of DEB wounds.
88980977|NCT04917328|Experimental|Patient with clinical suspicion of deep vein thrombosis|
88980978|NCT04902482|Experimental|iCycle training|Participants will attend 3 training sessions per week at the RNOH. During these sessions, participants will tether their wheelchair (from under the seat) to the front of the iCycle, and their feet will be attached to the iCycle pedals. For training, participants will complete virtual reality cycle races displayed on a large screen in front of the iCycle: the more voluntary effort the participant contributes the greater the speed of the avatar. During cycling, a motor will control cycling speed, and muscle stimulation (FES) will be applied to the leg muscles (right and left gluteus, quadriceps and hamstrings) on alternative revolutions of the pedals. A dashboard screen will display controls for the stimulation, speed, brake, game switch and an emergency stop. Sessions will increase from 20 mins or the maximum achievable at the start (whichever is lower) up to at least 1 hour.
88980979|NCT04899869|Other|Group A (active microbiota first)|Patients will first receive two enemas of active study microbiota mixture (deep-frozen stored stool microbiota mixed from eight donors in order to increase its diversity), then after eight weeks they will receive two enemas with placebo.
88980980|NCT04899869|Other|Group B (inactive microbiota first)|Patients will first receive placebo, then the active study microbiota mixture.
88980981|NCT04899869|Other|Group C (inactive microbiota only)|Patients will receive similarly timed enemas with placebos only.
88980982|NCT04899856|Other|Control / Crossover to TransAeris Therapy|"The Control group will be treated per standard hospital policy following electrode implant. If the participant is not liberated from mechanical ventilation after 120 hours (5 days), the participant will begin using TransAeris therapy. The participant will use the study device in the ICU until liberated from the ventilator but no longer than 30 days after implant surgery."
88980983|NCT04899856|Experimental|Treatment with TransAeris Therapy|"The Treatment group will start TranAeris therapy shortly after arrival in the Intensive Care Unit (ICU). Participants will use the study device in the ICU until liberated from the ventilator but no longer than 30 days after implant surgery."
88980984|NCT04895618|Experimental|Erchonia GVL|520 nanometers (nm) and 405 nm dual-diode laser application
88980985|NCT04889521||HIV and painful neuropathy|Persons living with HIV who also have painful distal sensory polyneuropathy in the feet.
88980986|NCT04889521||HIV without painful neuropathy|Persons living with HIV who do NOT have painful distal sensory polyneuropathy in the feet.
88980987|NCT04886063|Experimental|Treatment|Daily subcutaneous (SC) injection of ATH-1017 - 40mg Dosage
88980988|NCT04885530|Experimental|Arm A - Ivermectin 400|"Ivermectin - 7-mg tablets~Participant will be instructed to take a pre-specified number of tablets for 3 consecutive days based on their weight for a daily dose of approximately 300-400 µg/kg."
88980989|NCT04885530|Placebo Comparator|Arm A - Placebo|"Placebo - appearance and size matched to active study drug.~Participant will be instructed to take a pre-specified number of tablets for 3 consecutive days based on their weight, matched to active study drug dosing."
88980990|NCT04885530|Experimental|Arm B - Fluvoxamine|Fluvoxamine will be self-administered orally by each participant at a dose of 50 mg twice a day for 10 days.
89602703|NCT05134363|Active Comparator|dexmedetomidine 0.75 mic/kg bllus|selective alpha 2 adrenergic receptor agonist
89602704|NCT05134363|Placebo Comparator|Placebo group|receving equal volume of normal saline
89602705|NCT05110976|Experimental|Part A1: SAD (AZD8630)|Healthy participants will receive single inhaled doses 1 to 5 of AZD8630.
89602706|NCT05110976|Experimental|Part A1: IV (AZD8630)|Healthy participants will receive a single IV dose of AZD8630.
89602707|NCT05110976|Placebo Comparator|Part A1: IV (Placebo)|Healthy participants will receive single IV dose of Placebo.
88980991|NCT04885530|Placebo Comparator|Arm B- Placebo|Placebo - appearance and size matched to active study drug. Placebo will be self-administered orally by each participant twice a day for 10 days.
88980992|NCT04885530|Experimental|Arm C - Fluticasone|Fluticasone is a self-administered inhaled drug. Participants will self-administer 200 µg (1 blister) of fluticasone once daily for 14 days. After inhaler activation, the powder within the blister is exposed and the participant inhales the study drug through the mouthpiece.
88980993|NCT04885530|Placebo Comparator|Arm C - Placebo|Placebo is a self-administered by inhalation. Participants will self-administer 1 blister of placebo once daily for 14 days. After inhaler activation, the powder within the blister is exposed and the participant inhales the placebo through the mouthpiece.
88980994|NCT04885530|Experimental|Arm D - Ivermectin 600|"Ivermectin - 7-mg tablets~Participant will be instructed to take a pre-specified number of tablets for 6 consecutive days based on their weight for a daily dose of approximately 400-600 µg/kg."
89602708|NCT05110976|Experimental|Part A2: SAD (AZD8630)|Healthy participants of Chinese and Japanese ethnicity will receive single inhaled dose 5 of AZD8630.
88980995|NCT04885530|Placebo Comparator|Arm D - Placebo|"Placebo - appearance and size matched to active study drug.~Participant will be instructed to take a pre-specified number of tablets for 6 consecutive days based on their weight, matched to active study drug dosing."
88980996|NCT04885530|Experimental|Arm E - Fluvoxamine 100|Fluvoxamine will be self-administered orally by each participant at a dose of 50 mg twice a day for 1 day, followed by a dose of 100 mg twice a day for 12 days.
89602709|NCT05110976|Experimental|Part A3: MAD (AZD8630)|Healthy participants will receive once daily inhaled doses 3, 4, and 5 of AZD8630.
89602710|NCT05110976|Experimental|Part A4: MAD (AZD8630)|Healthy participants of Chinese and Japanese ethnicity will receive once daily inhaled dose 5 of AZD8630.
89602711|NCT05110976|Placebo Comparator|Part A: SAD (Placebo)|Healthy participants and healthy participants of Chinese and Japanese ethnicity will receive single inhaled doses of placebo.
89602712|NCT05110976|Placebo Comparator|Part A: MAD (Placebo)|Healthy participants and healthy participants of Chinese and Japanese ethnicity will receive once daily inhaled dose of placebo.
89602713|NCT05110976|Experimental|Part B (AZD8630)|Participants with asthma will be randomized to one of 3 inhaled dose levels 3, 6, and 7 of AZD8630 once daily.
89602714|NCT05110976|Placebo Comparator|Part B (Placebo)|Participants with asthma will receive once daily inhaled dose of placebo.
89602715|NCT05104658|Experimental|Intervention arm|"Usual rehabilitation: training (1 hour 2 times a week for 6 weeks), dietary training (2x3 hours), cardiac education (2x3 hours), referred to municipal rehabilitation: training (1 hour 2 times a week for 6-12 weeks), patient education (3x2 hours by a cardiac nurse and 1x2 hours by a dietician).~In addition:~Information book on rehabilitation and physical activities in local community~1:1 conversation with patient supporters from the Heart Association~Employer material on post-treatment and potential work adjustments~Support café for relatives~Supported transition to local sports associations~Motivating phone calls from physiotherapists supporting physical activities.~In addition for patients with vulnerabilities:~patient education in small groups~pro-active counselling with a cardiac nurse, a psychologist, or a social worker from the Heart Association~paid transportation to the municipal rehabilitation Center"
89602716|NCT05104658|No Intervention|Control arm|Usual rehabilitation: training (1 hour 2 times a week for 6 weeks), dietary training (2x3 hours), cardiac education (2x3 hours), referred to municipal rehabilitation: training (1 hour 2 times a week for 6-12 weeks), patient education (3x2 hours by a cardiac nurse and 1x2 hours by a dietician).
89602717|NCT05091060|Experimental|Erchonia HLS|635 nanometers (nm) laser application
89602718|NCT05078047|Experimental|Experimental arm|"Reduced dose intensity of IO:~IO will be administered every 3 months (at the same dose levels) until disease progression, unacceptable toxicity, death or patient's choice or investigator's decision"
89602719|NCT05078047|No Intervention|Control arm|"Standard IO:~Continuation of IO at the same dose levels and rhythmicity until disease progression, unacceptable toxicity, death or patient's choice."
89602720|NCT05072743|Experimental|Post-Concussion Patients with Non-Apneic Sleep Disorder|Patients will be treated with PBMT using the BIOFLEX® DUO+ system that utilizes a Light Emitting Diode (LED) array pad followed by laser probes. Both delivery methods will be applied to the cervical spine and will entail the use of red light at 660 nm wavelength and near-infrared light at 830-840 nm wavelength. Treatment is provided twice per week for 6 weeks for a total of 12 treatments utilizing Health Canada approved device specific protocol guidelines for the treatment of the cervical spine soft tissue injuries.
88980997|NCT04885530|Placebo Comparator|Arm E - Placebo|"Placebo - appearance and size matched to active study drug.~Placebo will be self-administered orally by each participant, with number of tablets matched to active study drug dosing."
88980998|NCT04885530|Experimental|Arm F - Montelukast|Montelukast will be self-administered orally by each participant at a dose of 10 mg once a day for 14 days.
88980999|NCT04885530|Placebo Comparator|Arm F - Placebo|"Placebo - appearance and size matched to active study drug.~Placebo will be self-administered orally by each participant, with number of tablets matched to active study drug dosing."
88981000|NCT04885530|Experimental|Arm G - Metformin|"Metformin IR tablets will be self-administered orally according to the following dosing schedule:~500 mg on Day 1;~500 mg in the morning and 500 mg in the evening on Day 2 through Day 5; and~500 mg in the morning and 2 x 500 mg (a total of 1000 mg) in the evening on Day 6 through Day 14."
88981001|NCT04885530|Placebo Comparator|Arm G - Placebo|"Placebo - appearance and size matched to active study drug.~Placebo will be self-administered orally by each participant, with number of tablets matched to active study drug dosing."
89602721|NCT05072340|Experimental|RISE (Blended learning)|"Students will undergo a training that comprises of six sessions: (1) introducing resilience, (2) coping strategies, (3) creating positivity, (4) shifting mindsets, (5) building social competency and (6) preparing for the future.~RISE training will be hosted via the NUS' online learning platform, LumiNUS and virtual face-to-face platform, Zoom. Each session will take approximately one to two hours per week. One session is made available each week to encourage completion before moving onto the next session. Students will be provided with materials in the form of interactive videos. Virtual face-to-face sessions, online forum, quizzes and homework will be additionally available to students."
89608629|NCT05586009|Active Comparator|Group 3|(n=25): receive cisplatin with hydration 3000 mg magnesium (32 Meq) ( IVI ).
89602722|NCT05072340|Active Comparator|RISE (Asynchronous learning)|"Students will also undergo a six-session training comprising of: (1) introducing resilience, (2) coping strategies, (3) creating positivity, (4) shifting mindsets, (5) building social competency and (6) preparing for the future.~RISE training will be hosted via the NUS' online learning platform, LumiNUS. One session is made available each week to encourage completion before moving onto the next session. Participants will be reminded via emails and short message service (SMS) to complete the intervention. Students will be provided with materials in the form of interactive videos in LumiNUS."
89602723|NCT05068648|Active Comparator|MWC Configuration 1|"standard upholstery back that promotes posterior pelvic tilt set at or below cushion level and 1 above inferior angle"
89602724|NCT05068648|Active Comparator|MWC Configuration 2|active contour back positioned with seat gap and with free scapulae
89602725|NCT05068648|Active Comparator|MWC Configuration 3|active contour back positioned with seat gap and with blocked scapulae
89602726|NCT05068648|Active Comparator|MWC Configuration 4|deep contour back positioned with seat gap and with free scapulae
89602727|NCT05068648|Active Comparator|MWC Configuration 5|deep contour back positioned without seat gap and with free scapulae
89602728|NCT05063045|Experimental|smart-cloth|Participants receive smart-cloth assisted home nursing care
89602729|NCT05063045|No Intervention|routine care|This group receive routine care
89602730|NCT05059834|Experimental|online mindfulness resources + usual care|The mindfulness online resources consisted of 4 weekly modules. Mindfulness exercises, including body scan, mindful breathing, mindful eating, mindful walking, 3-min breathing space, and thought distancing exercise, are audio-recorded to facilitate participants to practice mindfulness. Readings and graphics are included to explain the concept of mindfulness and to share with participants the common difficulties that participants may come across during mindfulness practices.
89602731|NCT05059834|Other|usual care|patients will receive usual care from doctors
89602732|NCT05057026||Adult mental health support program|The investigators will evaluate the Impact of an Adult mental health support program on stigmatization and confidence of medical residents working with people with mental health concerns. The intervention will be delivered to approximately 30 residents from the University of Dalhousie family medicine residency program from the 2021-2022 academic year. The training will be delivered by resident groups. The first group will receive the PSP training October - November 2022. The second will receive the training November 2021 to February 2022. The third will take the training March to May 2022. Each group will include approximately 10 residents.
88981002|NCT04880044|Experimental|EC/EG & EGD|"Participants will complete a study questionnaire about reflux symptoms. Performance of an EsoCheck (EC) procedure; the EC sample will subsequently be tested with the EsoGuard (EG) assay~If EG assay results come back positive, participant is requested to complete standard of care (SOC) upper endoscopy (tissue samples collected)~If EG assay results come back negative, selected participants (100 volunteers) will also undergo a research EGD if they consent"
89602733|NCT05056662||Group 1|Patients with negative invasive functional evaluation
89602734|NCT05056662||Group 2|Patients with positive invasive functional evaluation undergoing PCI
89602735|NCT05056662||Group 3|Patients with positive invasive functional evaluation undergoing PCI and subsequent retest of functional indexes
89602736|NCT05056311|Experimental|Parent Utilization of Decision Aid Website|All enrolled parents will view the decision aid website for as long and as frequently as they wish before the initial visit to the urologist.
89602737|NCT05054309|Active Comparator|Probiotic|Bifidobacterium longum [BL NCC3001]
89602738|NCT05054309|Placebo Comparator|Placebo|Maltodextrin
89602739|NCT05047510|Experimental|Anti-GPC3-IRDye800CW Intraoperative Fluorescence|The patients will receive an injection of fluorophore (Anti-GPC3-IRDye800CW) before the surgery. Then intraoperative fluorescence imaging will be performed to guide lesion resection.
89602740|NCT05043961||study group|"Patients who report >50% pain relief after an intra articular sacroiliac joint injection but lasting less than 3 months who are scheduled to receive a SIJ RFA at the Maisonneuve-Rosemont Hospital's Chronic Pain Clinic and who meet inclusion criteria will be offered to participate in this study.~Intervention:~Sacroiliac joint rafiofrequency ablation using the bipolar palissade approach and 3-tined needles"
89602741|NCT05034224|Sham Comparator|Sham|The index of microvascular resistances will be measured while a balloon placed in the coronary sinus is kept deflated.
89602742|NCT05034224|Active Comparator|Coronary sinus occlusion|The index of microvascular resistances will be measured while a balloon placed in the coronary sinus is inflated.
89602743|NCT05033548||Managed with AlloCare Monitoring|
89602744|NCT05033548||Managed with Standard of Care|
89602745|NCT05028881||HIV positive|No interventions
89602746|NCT05028881||HIV uninfected|No interventions
89602747|NCT05020899|Experimental|Quit for Life group|Participants randomized to this arm will receive a 8 week quit smoking program delivered by trained counselors and messages to their cell phones. Participants will also be offered nicotine replacement therapy (gum or patch, depending on which one is available) and a self-help guide with information about quitting smoking.
89602748|NCT05020899|Active Comparator|Control group|Participants randomized to this arm will be offered nicotine replacement therapy (gum or patch, depending on which one is available) and a self-help guide with information about quitting smoking.
89602749|NCT05008120||MDD + RBD|"Clinical diagnosis of lifetime major depressive disorder, based on the M.I.N.I.;~RBD diagnosis according to the International classification of sleep disorder (ICSD) 3rd edition, fulfilling both the clinical and video-polysomnography (vPSG) criteria;~Depressive symptoms onset before RBD onset"
89602750|NCT05008120||MDD|"Age-and sex-matched with MDD+RBD probands;~Lifetime diagnosis of MDD based on M.I.N.I.;~Without a personal history or a family history of RBD or neurodegenerative diseases (i.e. dementia and PD)~Free of RBD symptoms or other hallmark features of RBD (e.g. REM Sleep Without Atonia, RWSA) by vPSG"
89602751|NCT05008120||Health control|"Age-and sex-matched with MDD+RBD subjects;~Free of psychiatric disorders based on M.I.N.I.;~Without a personal history or a family history of RBD or neurodegenerative diseases (i.e. dementia and PD)~Free of RBD symptoms or RWSA by vPSG"
89602752|NCT05000385||Healthy|healthy complete dentition
89602753|NCT05000385||Dental caries|complete dentition with bilateral dental caries (ICDAS 4,5 or 6)
89602754|NCT05000385||Occlusal contacts|occlusal contacts are lost bilaterally due to extraction, changing dentition or orthodontic anomalies; no dental caries
88981003|NCT04872790|Experimental|Treatment (prednisone, dasatinib, venetoclax, rituximab)|See detailed description
88981004|NCT04869228|Experimental|GT0918 in the treatment arm|GT0918 tablets : oral, 1 time / day, 2 tablets / time, after meals
88981005|NCT04869228|Placebo Comparator|Placebo in the placebo arm|placebo : oral, 1 time / day, 2 tablets / time, after meals
88981006|NCT04868123|Experimental|Mindfulness Meditation|6 weeks of daily mindfulness meditation (guided by audio recordings) performed at home
88981007|NCT04868123|Experimental|Transcutaneous nerve stimulation (TENS)|6 weeks of daily TENS treatment performed at home
88981008|NCT04868123|No Intervention|Usual Care|Usual care (no additional treatment)
89602755|NCT05000385||Dentures|patients with dentures, no caries and/or missing occlusal contacts on remaining teeth
89602756|NCT04997109|Experimental|APPLES-tele first, then PCA|Participants receiving the APPLES-tele intervention for 6 weeks followed by the PCA intervention for 6 weeks.
89602757|NCT04997109|Experimental|PCA first, then APPLES-tele|Participants receiving the PCA intervention for 6 weeks followed by the APPLES-tele intervention for 6 weeks.
89602758|NCT04997109|Active Comparator|Standard of Care Control Arm|Participants receiving the standard of care for 6 weeks.
89602759|NCT04982328||NAFLD|patients diagnosed with NAFLD and hospitalized due to the severe COVID-19
89602760|NCT04982328||non-NAFLD|patients hospitalized due to the with severe COVID-19 without NAFLD
89602761|NCT04978610|Experimental|Intervention (Immediate)|Participants in the intervention group will begin their 6-week vACT sessions first and complete baseline, the weekly surveys during intervention, post, one month follow-up, and three month follow-up.
88981009|NCT04865679|Experimental|Axoguard Nerve Cap®|"Active Comparator: Porcine derived extracellular matrix (ECM) based Nerve Termination Device~Implantation of appropriate diameter of Axoguard Nerve Cap® (sizes 5-7 mm) at the time of surgery"
88981010|NCT04860453|Experimental|Affected participants with 5 or more discordant cancers - WES|"Affected individuals with a family history of 5 or more discordant cancers in unilateral descent with a 3-generation pedigree will receive SOC CLIA/CAP multicancer panel (DNA collected via blood draw or punch biopsy) to examine monogenic variant diagnostic yield. Eligible participants (families with no mutations and at least 2 affected and 1 non-affected family members) may move forward with WES.~Any identified monogenic variants of interest will be sent to an industry partner with CLIA/CAP certification for validation. A 6-month follow-up visit will take place during which variants will be discussed and participants who underwent gHFI variant counting (those who were not considered a gene candidate) will have results explained. Appropriate genetic counselling, recurrence risk, and additional clinical referrals will be made as necessary"
88981011|NCT04860453|Active Comparator|SOC genetic counseling (routine clinical care)|"Affected individuals (cancer) with a family history suggestive of a known hereditary syndrome or meeting NCCN criteria for germline testing will receive SOC CLIA/CAP multicancer panel in order to examine monogenic variant diagnostic yield (retrospective data)~This arm would also include prospective participants from the 5 or more discordant cancers group who DID have a variant identified and therefore did not move on to WES."
88981012|NCT04844450|Experimental|Single Ascending Dose (SAD)|Participants in cohorts 1-5 and cohorts 3a-5a will receive subcutaneous (SC) injection of single dose (Part A) of JNJ-75220795 or matching placebo.
88981013|NCT04844450|Experimental|Multiple Ascending Dose (MAD)|Participants in cohorts 6-8 will receive SC injection of 2 doses (Part B) of JNJ-75220795 or matching placebo. Participants in cohorts 9-11 will receive SC injection of 4 doses (Part C) of JNJ-75220795 or matching placebo.
89602762|NCT04978610|Other|Control (Waitlist)|Upon the intervention group's completion of the 6-week long vACT, the control group will then enroll into their own 6-week long ACT intervention. The research protocol for the second 6-week long ACT intervention will mirror the protocol with the original 6-week long ACT intervention, except for one change: participants will NOT complete an additional baseline questionnaire prior to starting the 6-week ACT therapy group. The rest of the protocol remains the same. Namely, before each session, each participant will be required to fill out a short survey on their stress and pain throughout previous week. At the conclusion of the final session, participants will follow the complete post-intervention battery of surveys, which mirrors the baseline measures plus the inclusion of satisfaction surveys assessing the effectiveness of the virtual therapy intervention. Participants will complete the post-intervention follow up battery of questionnaires at 1 and 3 months post-intervention.
89602763|NCT04978129|Experimental|Online and Text Message Intervention|Participants randomized to the intervention will receive a link to the online intervention following baseline completion. The online and Text Message intervention, and its delivery, will be designed and adapted based on the results of the formative focus groups and cognitive interviews and is meant to be non-confrontational in tone, seeks to increase motivation to increase the quality use of PBS and decrease motivations for non-use of PBS. Intervention participants will receive personalized PBS Text Messages 3x per week (based on self-selections from the interactive online intervention) for 8 consecutive weeks timed to occur on a random weekday as well as Friday and Saturday.
89602764|NCT04978129|No Intervention|Wait List Control|The wait-list control condition will not receive any intervention content during the 8-week period of data collection, but will complete baseline, 2-month, and daily surveys according to the same schedule as the intervention group in order to assess event-level PBS use, PBS non-use, alcohol and marijuana use, CAM and SAM use, and related consequences for up to 24 days over an 8-week period. All wait-list control participants will receive the intervention at the end of the 8-week period of data collection for the pilot study.
89602765|NCT04965649||Chronic Myeloid Leukemia|There will be approximately 10 patients with Chronic Myeloid Leukemia in this group
89602766|NCT04965649||Philadelphia+ Acute Lymphoblastic Leukemia|There will be approximately 20 patients with Philadelphia chromosome-positive Acute lymphocytic leukemia in this group
89602767|NCT04953767|Experimental|Blue light therapy|The participants receive blue light therapy for 1 hours, between 8am to 12pm in the morning.
89602768|NCT04953767|Sham Comparator|White light|The participants receive white light for 1 hour, between 8am to 12pm in the morning.
88981014|NCT04843111||Pregnant women and their offspring(s)|Pregnant women and their offspring(s) exposed to MenQuadfi® during their pregnancy or within 30 days prior to their LMP
88981015|NCT04839393|Experimental|Part A - Sequence 1|Treatment A - PF-06882961 single dose followed by Treatment B - PF-06882961 single dose and PF-06865571 single dose
88981016|NCT04839393|Experimental|Part A - Sequence 2|Treatment B - PF-06882961 single dose and PF-06865571 single dose followed by Treatment A - PF-06882961 single dose
89602769|NCT04948671||not bone looser|patients affected by primary hyperparathyroidism not bone looser
89602770|NCT04948671||bone looser|patients affected by primary hyperparathyroidism bone looser
88981017|NCT04839393|Experimental|Part B|Period 1: PF-06865571 single dose, Period 2: PF-06882961 twice daily dose titration, Period 3: PF-06865571 single dose and PF-06882961 twice daily dosing, Period 4: PF-06865571 twice daily dosing and PF-06882961 twice daily dosing
88981018|NCT04838314|No Intervention|Standard of cares|Peri operative analgesia by opioids
88981019|NCT04838314|Experimental|regional analgesia|Peri operative analgesia by continuous bilateral ESP catheters
88981020|NCT04826965|Active Comparator|Wound vac application|Wound vac application for open upper/lower extremity open wound
88981021|NCT04826965|Active Comparator|Wound vac application including irrigation|Wound vac application WITH irrigation for upper/lower extremity open wound
88981022|NCT04802837|Experimental|Ridinilazole|Ridinilazole dosed BID and a comparator placebo dosed QID, to maintain blind, for 40 doses over 10 days.
88981023|NCT04802837|Active Comparator|Vancomycin|Vancomycin dosed QID and a Ridinilazole placebo dosed BID, to maintain blind, for 40 doses over 10 days.
88981024|NCT04798820|Active Comparator|SE-STG|simplified dietary education arm in subtotal gastrectomy group.
88981025|NCT04798820|Active Comparator|IE-STG|intensive dietary education arm in subtotal gastrectomy group
88981026|NCT04798820|Active Comparator|SE-TG|simplified dietary education arm in total gastrectomy group.
88981027|NCT04798820|Active Comparator|IE-TG|intensive dietary education arm in total gastrectomy group
88981028|NCT04798612|Experimental|Intervention arm|Two 45 mikrogram doses of interferon-alfa2a (Pegasys). Both will be applied subcutanously. First dose is at least one week before surgery. Second dose on the day of surgery before the procedure.
88981029|NCT04798612|Placebo Comparator|Placebo|Two 1 ml doses of saline liquid. Both will be applied subcutanously. First dose is at least one week before surgery. Second dose on the day of surgery before the procedure.
88981030|NCT04795713|Experimental|PD-L1 Positive NSCLC|Subjects with PD-L1 Positive Lung Carcinoma (NSCLC) who received prior PD-1/PD-L1 treatment
88981031|NCT04795713|Experimental|PD-L1 Positive SCCHN|Subjects with PD-L1 Positive Squamous Cell Carcinoma of the head and neck (SCCHN), refractory to or ineligible for platinum-based therapy, who received prior PD-1/PD-L1 treatment
88981032|NCT04795713|Experimental|Other relapsed/refractory PD-L1 positive solid tumors|Subjects with any other relapsed or refractory PD-L1 positive solid tumor who received PD-1/PD-L1 treatment.
88981033|NCT04795713|Experimental|PD-L1 positive advanced cancer|Subjects with PD-L1 positive advanced cancer (solid tumors)
88981034|NCT04782713|Other|PCP Evaluation of Smart PSA Screening Guidelines|Completing surveys at baseline, 3, 6, 9 and 12 months
88981035|NCT04771975|Experimental|MatchQEP group|"Phase 1: All participants will receive an 'Exercise Peer Support Guide' that provides suggestions for supporting their exercise partner and a one-page document describing current exercise guidelines for cancer survivors [16-18]. All participants will also be given a Fitbit device, which will be used for device-measured MVPA.~Participants in the MatchQEP group will receive exercise information and program sessions tailored by a qualified exercise professional (QEP) specifically for each BCS in the dyad. Dyads will meet with the QEP via Zoom once per week for 10 weeks for up to 60 minutes. For four weeks following the 10-week intervention period, the QEP will be available for consultation (i.e., a post-intervention tapering period) as needed by the MatchQEP group participants.~Phase 2: Was not an RCT (i.e., all Phase 1 participants were approached to participate in Phase 2). Phase 2 is a pre-post intervention design, with no control group."
88981036|NCT04771975|Active Comparator|Match group|"Phase 1: All participants will receive an 'Exercise Peer Support Guide' that provides suggestions for supporting their exercise partner and a one-page document describing current exercise guidelines for cancer survivors [16-18]. All participants will also be given a Fitbit device, which will be used for device-measured MVPA.~Participants in the Match (control) group will independently communicate and support each other around exercise for 10 weeks. They will not have any contact with a QEP during this time.~Phase 2: Was not an RCT (i.e., all Phase 1 participants were approached to participate in Phase 2). Phase 2 is a pre-post intervention design, with no control group."
88981037|NCT04769895|Experimental|MaaT013|"Route of administration: rectal (enema)~Study drug dose: 4 enemas in total:~Week 1:~D0-D1: vancomycin pre-treatment (250mg per os, 4 times a day for 2 days)~D2: 1 dose~Between D3 to D5: 1 dose Week 2: 1 dose (7 +/- 2 days after the last dose) Week 3: 1 dose (7 +/- 2 days after the last dose) A supplementary dose can be prescribed in case of GvHD relapse or massive antibiotic use during the study."
88981038|NCT04764656||Brolucizumab|Naïve (Patients being the first time treated) and pre-treated patients
88981039|NCT04757220|Experimental|Patients with schizophrenia|"5 subjective questionnaires~4 cognitive tasks with EEG recordings"
88981040|NCT04757220|Experimental|Patients with depression|"5 subjective questionnaires~4 cognitive tasks with EEG recordings"
88981041|NCT04757220|Active Comparator|Healthy controls|"5 subjective questionnaires~4 cognitive tasks with EEG recordings"
89602771|NCT04942665|Experimental|Low Dose|Prior to surgery these patients will be given a ICG dose of 0.05 mg IV.
88981042|NCT04742686|No Intervention|Usual care|
88981043|NCT04742686|Experimental|Intervention|
88981044|NCT04737785||Case group|HSCT recipients who developed a CNS disorder after HSCT
89602772|NCT04942665|Placebo Comparator|Standard Dose|Prior to surgery these patients will be given the ICG standard dose of 2.5 mg IV.
88981045|NCT04737785||Control group|HSCT recipients whom did not develop a CNS disorder
88981046|NCT04737707|Experimental|Dialectical Behavior Therapy (DBT)|Psychotherapy (duration 5 months) will begin within a maximum of 1 month (the time to set up the group) and will be accompanied by individual follow-up. Evaluations will be carried out within 6 months of the end of the psychotherapy in order to measure its effects.
89602773|NCT04934748|Active Comparator|Tight Pressure Management with phenylephrine|Pressure maintenance with phenylephrine infusion at a rate sufficient to maintain the intraoperative MAP designated in the underlying GUARDIAN trial.
89608630|NCT03020979|Experimental|500mg apatinib|Patients will receive 500mg of apatinib tablet orally, once daily.
89602774|NCT04934748|Active Comparator|Tight Pressure Management with norepinephrine|Pressure maintenance with norepinephrine infusion at a rate sufficient to maintain the intraoperative MAP designated in the underlying GUARDIAN trial.
89602775|NCT04934748|Active Comparator|Routine Pressure Management with phenylephrine|Pressure maintenance with phenylephrine infusion at a rate sufficient to maintain the intraoperative MAP designated in the underlying GUARDIAN trial
89602776|NCT04934748|Active Comparator|Routine Pressure Management with norepinephrine|Pressure maintenance with norepinephrine infusion at a rate sufficient to maintain the intraoperative MAP designated in the underlying GUARDIAN trial.
89602777|NCT04895982|Experimental|BNT162b2|Intramuscular Injection
89602778|NCT04895605|Experimental|Erchonia HLS Laser|The Erchonia HLS Laser is administered 8 times across 4 weeks for 5 minutes each time to the skull at the base of the brain and temporal areas.
89602779|NCT04895605|Placebo Comparator|Placebo Laser|The Placebo Laser is administered 8 times across 4 weeks for 5 minutes each time to the skull at the base of the brain and temporal areas.
89602780|NCT04889495||Participants receiving Zirabev|Participants receiving Zirabev
89602781|NCT04868591|Active Comparator|Single session APP arm|Participants in this group will received one session with the advanced practice physiotherapist.
89602782|NCT04868591|Experimental|Multiple sessions APP arm|Participants in this group will received 6 sessions (in 12 weeks) with the advanced practice physiotherapist.
88981047|NCT04737707|Other|Therapy|waiting list for 5 months before starting psychotherapy (duration 5 months). During this time, the patient can continue your usual therapeutic follow-ups. Likewise, assessments will be carried out within 6 months after the end of the psychotherapy in order to measure its effects. the patient will thus benefit from DBT regardless of the group.
88981048|NCT04735536|Experimental|Active Treatment- CT1812|Active Treatment- CT1812 at a dose of 300mg
88981049|NCT04735536|Placebo Comparator|Control - Placebo|Drug: Placebo Non-active study drug
88981050|NCT04722172|Experimental|Acalabrutinib Combined With Obinutuzumab|Patients will receive acalabrutinib for a minimum of 13 cycles and maximum 26 cycles and Obinutuzumab will be administered during Cycles 2-7. This will be followed by treatment-free observation through the 65th cycle. Patients who progress during the observation period, per iwCLL criteria, will receive 13 cycles of acalabrutinib in combination with obinutuzumab in the retreatment phase of this study.
88981051|NCT04716010|Other|Control|Products that contain red meat will not have warning labels or an increase in price.
88981052|NCT04716010|Experimental|Warning Labels|"The warning labels are black octagons with white text that appear next to images of products that contain red meat. One label says WARNING: Eating red meat contributes to colon and rectal cancer and the other label says WARNING: Eating red meat harms the environment."
88981053|NCT04716010|Experimental|Tax|The tax is a 30% increase in the price of products that contain red meat.
88981054|NCT04716010|Experimental|Combined Warning Labels and Tax|"The Combined Warning Labels and Tax arm features both the warning labels and tax. The warning labels are black octagons with white text that appear next to images of products that contain red meat. One label says WARNING: Eating red meat contributes to colon and rectal cancer and the other label says WARNING: Eating red meat harms the environment. The tax is a 30% increase in the price of red meat products."
88981055|NCT04712942|Experimental|pevonedistat + azacitidine|pevonedistat in combination with azacitidine
88981056|NCT04712942|Other|azacitidine monotherapy|administration of azacitidine monotherapy
88981057|NCT04710901|Active Comparator|uTECH + Young Men's Health Project (YMHP)|Approximately 165 participants will be randomly assigned to this arm and will receive the uTECH intervention over the course of 12 months and YMHP intervention over the course of 3 months.
88981058|NCT04710901|Active Comparator|Young Men's Health Project (YMHP)|Approximately 165 participants will be randomly assigned to this arm and will receive the YMHP intervention over the course of the first 3 months. Months 3-12 will be inactive, and they will be followed for a total of 12 months.
88981059|NCT04710901|Active Comparator|uTECH|Approximately 60 participants will be randomly assigned to this arm and will receive the uTECH intervention over the course of 12 months.
88981060|NCT04710576|Experimental|Axatilimab Dose Cohort 1|Participants will be administered axatilimab 0.3 milligrams (mg)/kilogram (kg) intravenously (IV) every 2 weeks for up to 2 years.
88981061|NCT04710576|Experimental|Axatilimab Dose Cohort 2|Participants will be administered axatilimab 1 mg/kg IV every 2 weeks for up to 2 years.
88981062|NCT04710576|Experimental|Axatilimab Dose Cohort 3|Participants will be administered axatilimab 3 mg/kg IV every 4 weeks for up to 2 years.
88981063|NCT04708145|Experimental|Group 1|"Study eyes without PRP from the PANORAMA trial. Subjects will be evaluated every 16 weeks and treated if DRSS level is 47 or worse as determined by the treating investigator.~Subjects may be evaluated every 8 weeks if a 2-step DRSS level worsening compared to the last protocol-scheduled 16-week visit occurs, the DRSS level is 53 or worse, or if a subject has active PDR. Visits can continue every 8 weeks until there is no active PDR, and the DRSS improves to the level observed at the visit before the subject began being seen at 8-week intervals. Thereafter, visits will continue at 16 week intervals."
88981064|NCT04708145|Experimental|Group 2|"Study eyes with PRP from the PANORAMA trial. Subjects will be evaluated every 16 weeks and treated if the neovascular disease process is active and stable (not new or worse) as determined by the treating investigator. If the neovascular disease is inactive, no treatment will be given.~If new or worsening neovascularization develops, subjects may be seen and treated every 8 weeks until the neovascular disease is stable or inactive, at which time the interval between visits will increase to 16 weeks."
88981065|NCT04701411|Experimental|Darvadstrocel|Darvadstrocel (Cx601), 24 mL suspension of 120 million cells as a perilesional injection, once on Day 0.
88981066|NCT04700657||15 patients affected by ocular GVHD|
88981067|NCT04700657||15 age-matched normal volunteers.|
88981068|NCT04699890||preserved ejection fraction|Patients with a preserved ejection fraction (HF / FEp)
88981069|NCT04699890||reduced ejection fraction|Patients with a reduced ejection fraction (HF / FEr)
89602783|NCT04856319|Active Comparator|Prophylaxis|2 g amoxicillin+clavulanic acid 1 hour prior to dental implant surgery
89602784|NCT04856319|Placebo Comparator|Placebo|placebo 1 hour prior to dental implant surgery
89602785|NCT04830813|Experimental|Chiauranib|Patients take Chiauranib capsules 50mg, orally once daily, 21 days as a cycle until objective disease progression.
89602786|NCT04830813|Placebo Comparator|Placebo|Participants received Chiauranib placebo capsule matching Chiauranib orally once daily until objective disease progression.
89602787|NCT04813120|Experimental|Uni-MVF condition and unimanual training mode using the new MT system (UM-UT)|The following common categories of upper-limb movements and actions will be selected and included in this group: (a) active range of motion (AROM) exercises, (b) reaching movements, and (c) object manipulation.
89602788|NCT04813120|Experimental|Uni-MVF condition and bimanual training mode using the new MT system (UM-BT)|The following common categories of upper-limb movements and actions will be selected and included in this group: (a) active range of motion (AROM) exercises, (b) reaching movements, and (c) object manipulation.
89602789|NCT04813120|Experimental|Bi-MVF condition and bimanual training mode using the new MT system (BM-BT)|The following common categories of upper-limb movements and actions will be selected and included in this group: (a) active range of motion (AROM) exercises, (b) reaching movements, and (c) object manipulation.
89602790|NCT04813120|Active Comparator|Traditional MT using a mirror box|The following common categories of upper-limb movements and actions will be selected and included in this group: (a) active range of motion (AROM) exercises, (b) reaching movements, and (c) object manipulation.
89602791|NCT04806503|Experimental|UNR844 5 mg/mL|UNR844 5 mg/mL ophthalmic solution; one drop twice-a-day for three months
89602792|NCT04806503|Experimental|UNR844 13.3 mg/mL|UNR844 13.3 mg/mL 1 ophthalmic solution; one drop twice-a-day for three months
89602793|NCT04806503|Experimental|UNR844 23 mg/mL|UNR844 23 mg/mL ophthalmic solution; one drop twice-a-day for three months
89602794|NCT04806503|Experimental|UNR844 30 mg/mL|UNR844 30 mg/mL ophthalmic solution; one drop twice-a-day for three months
89602795|NCT04806503|Placebo Comparator|Placebo Ophthalmic Solution|placebo ophthalmic solution; one drop twice-a-day for three months
89602796|NCT04788108|Active Comparator|Dydrogesterone|dydrogesterone 10 mg by mouth every 12 hours until 1 week after bleeding stops or until 6 weeks.
89602797|NCT04788108|Placebo Comparator|Placebo|placebo by mouth every 12 hours until 1 week after bleeding stops or until 6 weeks.
89602798|NCT04747405|No Intervention|A standard|standard of care
89602799|NCT04747405|Experimental|B therapy group|standard of care and therapy group
89602800|NCT04741724|Experimental|transcutaneous electrical diaphragmatic stimulation (TEDS)|"Subjects received daily TEDS (30min/day, 5days/week ) until the end of the weaning trial.~During TEDS, rectangular electrodes were placed on the parasternal region beside the xiphoid process; the sixth and seventh intercostal spaces in line with the mid-axillary line. TEDS was performed by applying biphasic waves at a stimulation frequency of 30 Hz, pulse width of 400 μs. TEDS intensity was gradually increased until visible muscle contraction was observed. Each session lasts for 30 min day."
89602801|NCT04741724|No Intervention|Control group|Subjects in the control group did not received TEDS program. Subjects in the control group received the same pre- and post-measurement as those in TEDS group. The control group received medical treatment as those in TEDS group. The pulmonary function was measured at the beginning and end of the intervention.
89602802|NCT04741438|Experimental|Arm A|"Arm A (Experimental arm).~Nivolumab 3 mg/kg~Ipilimumab 1 mg/kg"
89602803|NCT04741438|Active Comparator|Arm B|Arm B (Control arm). Pazopanib 800 mg/day
89602804|NCT04731961|Active Comparator|Controls|Subjects in this arm will be administered the standard injection site protocol (15 sites).
89602805|NCT04731961|Experimental|Experimental|Subjects in this arm will be administered the same amount of Botox in 5 injection sites.
89602806|NCT04692337|Experimental|Ommaya Reservoir placement|Subjects undergoing surgery for a confirmed or suspected brain tumor will have an Ommaya Reservoir placed at the time of surgery.
89602807|NCT04682652|Experimental|GAE Treatment|Subjects will be treated with a genicular artery embolization (GAE) procedure performed with Embozene Microspheres. The microspheres will be delivered in a saline-contrast medium solution and will be delivered to the arteries supplying the areas of the subject's pain.
88981070|NCT04699890||without heart failure|Patient without heart failure
88981071|NCT04697927||MSK Patients|Patients include those undergoing cancer screening and treatment as well as cancer survivors that received COVID-related care. Both adult and pediatric patients will be included.
89602808|NCT04682652|No Intervention|Observational|"Subjects randomized to the observational group will not undergo the experimental GAE Treatment.~PI will offer subjects enrolled into the observational group to crossover to the experimental GAE Treatment group after they have completed their 6-month follow-up assessments."
89602809|NCT04675411|Other|usual care|After a fall leading to hip fracture, patients are cared for by orthopedists and receive internal fixation or arthroplasty. Consultations for internal medicine care are occasionally made depending on the patient's condition. During the first 1 to 2 days after surgery, nurses teach patients how to exercise while still in bed, using caution while changing their position. Pain-relief medications and antibiotics are also administered (for 2-3 days). The first day after surgery, physical therapy usually starts with rehabilitation training only on patients receiving arthroplasty. The average hospital stay is 5 to 7 days. After hospital discharge, very few patients use in-home or community rehabilitation or are admitted to a 2-week subacute rehabilitation unit. Patients usually come back to the clinic around 1, 3, 6, and 12 months after hospital discharge. However, adherence to this follow-up schedule is poor. Telephone follow-ups are seldom used.
89602810|NCT04675411|Experimental|Smart Care Model|"The smart care model (SCM) will contain the components of geriatric assessment, continuous rehabilitation, and discharge planning.~Sensors will be installed in bedrooms and living areas of the patient's home to receive signals from the smart clothing. Instant alerts and feedbacks from research nurses to family caregivers about the patient's condition and activity level will be provided."
89602811|NCT04675073|Experimental|ABLATE arm|Ventricular tachycardia substrate ablation intending to: i) eliminate all the potential arrhythmogenic substrate, aiming for complete electrical isolation/elimination of all the electrograms with delayed components or showing hidden slow conduction properties, and ii) non-inducibility or ventricular tachycardias at the end of the procedure. Standard medical treatment will also be given for these patients.
89602812|NCT04675073|No Intervention|NO-TREAT arm|Only standard medical treatment will be offered for these patients.
88981072|NCT04697927||Household Members (identified by MSK Patient)|Individuals over the age of 18 (i.e., individuals currently living in the same household as the MSK enrollee).
89602813|NCT04672655|Experimental|ONBOARD Intervention Group|Those randomized to the ONBOARD group will receive 12 weeks of CGM supplies and provide hemoglobin A1c values, data downloads, and survey responses during various time points in the study. They will also receive the intervention which consists of four 60-minute sessions with study interventionist, held 2 weeks apart.
88981073|NCT04694846|Experimental|Arm I (ETIP)|Patients receive nicotine replacement therapy via trans-dermal patch, gum, nasal spray, inhaler or lozenges for 12 weeks in the absence of unacceptable toxicity. Patients also receive bupropion PO QD BID or varenicline PO QD and BID for 24 weeks in the absence of unacceptable toxicity. Patients undergo 3 cessation counseling sessions in person, via telehealth or phone within 7 days of enrollment into study, 1 week after established quit date and 3 weeks after establishing quit date.
88981074|NCT04694846|Active Comparator|Arm II SOC|Participants randomly assigned to the standard treatment (ST) group will receive an in-office smoking cessation recommendation by the physician and referral to a quit line.
88981075|NCT04681508|Experimental|All patients|All patients undergo chest CT without contrast enhancement and chest X-ray. Blood and urine sampling from patients subsequently undergoing emergency laparoscopy or laparotomy. Otherwise standard care
88981076|NCT04677712|Active Comparator|Cohort 1: CCH-aaes|CCH-aaes was administered without mitigation treatment (control group).
88981077|NCT04677712|Active Comparator|Cohort 2: CCH-aaes + Compression Garment|CCH-aaes was administered with compression garment.
88981078|NCT04677712|Active Comparator|Cohort 3: CCH-aaes + Instant Cold Packs|CCH-aaes was administered with instant cold packs.
88981079|NCT04677712|Active Comparator|Cohort 4: CCH-aaes + Arnica Gel Patches (OcuMend)|CCH-aaes was administered with arnica gel patches (OcuMend).
88981080|NCT04677712|Active Comparator|Cohort 5:CCH-aaes + INhance Post-Injection Serum with TriHex Technology®|CCH-aaes was administered with INhance Post-Injection Serum with TriHex Technology®
88981081|NCT04677712|Active Comparator|Cohort 6: CCH-aaes + Pulse Dye Laser Treatment (PDL)|CCH-aaes was administered with PDL.
88981082|NCT04670510|Experimental|Aerobic Exercise|The Aerobic Exercise (AE) condition will involve 150-minutes of moderate-intensity AE per week for 6-months and will involve a graded decline in supervision. Supervised AE will occur in groups, though each participant's AE prescription will be personalized based on baseline exercise capacity, as assessed by a maximal cardiopulmonary fitness test. Supervised AE sessions will involve the treadmill, elliptical, and/or bike, and routines will be varied to promote adherence. Supervised AE sessions will gradually increase to 50-minutes per session; however, participants will be encouraged to engage in home-based AE sessions according to their own preference of length and frequency in order to achieve 150 minutes of AE per week.
89602814|NCT04672655|No Intervention|CGM Only Group|Those randomized to the CGM Only group will not receive the ONBOARD intervention during their 12-month participation in the study. There will only receive 12 weeks of CGM supplies and provide hemoglobin A1c values, data downloads, and survey responses during various time points in the study.
89602815|NCT04671693|Experimental|PASCA intervention|
89602816|NCT04660331|Experimental|Aim I (interview)|Participants participate in a semi-structured interview in-person or via phone over 90 minutes about barriers/facilitators of HPV vaccination in pharmacies.
89602817|NCT04660331|Experimental|Aim 2 (survey, training, communication intervention, and environmental scan)|"Participants provide feedback on survey questions via cognitive testing. Pharmacy staff complete an online survey over 10-15 minutes to assess the acceptability, appropriateness, and feasibility of providing HPV vaccination to children aged 9-17 in their pharmacies. Pharmacy staff then attend two, 60- minute vaccine communication training sessions, consisting of identifying vaccine-eligible children and recommending HPV and other vaccines. Pharmacy staff employ the new communication strategy in their pharmacy up to 6 months, and then complete an online survey over 10-15 minutes.~Pharmacies of which the pharmacy staff participants work undergo an environmental scan to characterize the pharmacy's environment, vaccination workflow, and team dynamics."
89602818|NCT04648540|Experimental|Opioid-Free Anesthesia (OFA)|"The following drugs will be administered 10 minutes before induction of anesthesia in group I (OFA):~Pregabalin 150 mg orally with a small sip of water~Acetaminophen 1 gm and Ketorolac 30 mg in 100 mL i.v. over 10 minutes~Dexmedetomidine loading dose of 0.5 mic/kg i.v. over 10 minutes~Lidocaine loading dose of 1.5 mg/kg i.v. over 10 minutes~For simplicity, the weight-based doses of dexmedetomidine and lidocaine will be prepared in a 20 mL syringe~the following drugs will be administered as a continuous infusion:~Dexmedetomidine 0.5 mic/kg/h~Lidocaine 0.5 mg/kg/h~Patients in both groups will be extubated when they meet our institutional criteria for extubation. Postoperative analgesia will be started as follows:~Group I (OFA):~Acetaminophen 1 gm/6h~ketorolac 30 mg/8h~Pregabalin 150 mg once at night~Celecoxib 200 mg/24 hours"
89602819|NCT04648540|Active Comparator|Opioid Anesthesia (OA)|"Before induction In Group II (OA) patients will receive placebo pills and normal saline in equivalent volumes .~Maintenance~In Group II (OA) patients will receive a continuous infusion of Fentanyl (1 mic/kg/h)~Patients in both groups will be extubated when they meet our institutional criteria for extubation. Postoperative analgesia will be started as follows:~• Morphine 0.1 mg /kg PRN every 8 hours"
89602820|NCT04645823|Active Comparator|Spinal fentanyl|Using a combined spinal epidural technique a single dose of 20 µg of fentanyl diluted into 2 ml with NaCl 0.9 % will be injected into the CSF at lower lumbar interspace. An epidural catheter is left in place for subsequent analgesic doses.
89602821|NCT04645823|Experimental|Epidural lidocaine and fentanyl|Using a catheter in the epidural space in the lower lumbar interspace a single dose of lidocaine (80 mg) and fentanyl (100 µg) is given. The epidural catheter is left in place for subsequent analgesic doses.
89602822|NCT04645628|Experimental|All subjects will have an MRI examination|
88981083|NCT04670510|Active Comparator|Social Engagement|The Social Engagement (SE) condition will be designed to control for the social component of the AE intervention (i.e., supervised on-site sessions with professional staff, frequent phone contact from study staff). A variety of enjoyable group-based activities centered around the dimensions of wellness (spiritual wellness, physical wellness, emotional wellness, etc.) will be scheduled throughout the intervention. This condition will involve once weekly meetings (grand total of ~26 sessions). Some participants will meet in-person and others will meet remotely via zoom (this will vary week to week) to increase flexibility to accommodate participant availability to attend as many sessions as possible.
89602823|NCT04629508|Experimental|Part 1 : Dose Escalation of itacitinib|Participants will be dosed at different dose levels with a maximum of up to 9 participants per dose level.
89602824|NCT04629508|Experimental|Part 2 : Dose Expansion of itacitinib|Participants will be dosed at the recommended Phase 2 dose (RP2D) identified in Part 1.
89602825|NCT04607070||Stroke patient|This is a registry-based study that will involve consecutive adult patients with known AF who developed ischaemic stroke or TIA in years 2010, 2012, 2014, 2016 and 2018.
89602826|NCT04602468|Other|Standard group|The standard testing group will be available for both age cohorts with sites having a predefined recruitment cap for each testing group. The standard testing will involve the following assessments; sweat chloride, LCI, height/weight/BMI, FEV1, airway sampling (micro), FeNO, liver function testing, liver ultrasound, liver examination, stool collection, blood collection, abdominal symptom score, CFQ-R, pharmacy records medication pick up rate, adherence questionnaires, MEMs caps and antibiotic use.
89602827|NCT04602468|Other|Advanced group|In addition to all elements of the standard testing group, the advanced testing group will undergo: Ultra-low dose spirometry-controlled CT scanning, sputum collection and nasal lavage collection. This will be available for both age cohorts with sites having a predefined recruitment cap for each testing group.
89602828|NCT04594382|Active Comparator|T30/60|Before extubation, opioid administration will be given by a single dose of opioids in case of measured PDR values of ≥12.
89602829|NCT04594382|Active Comparator|Non-T30/60|A standardized single dose of opioid will be given intravenously before extubation, regardless of the measured pupillometry PDR values.
89602830|NCT04594382|No Intervention|Standard Care group|The amount of administered piritramid in the OR will be left to the discretion of the anesthesiologist attending the participant.
89602831|NCT04579094||1/elderly dependent persons|
89602832|NCT04579094||2/healthcare workers (HCW)|
89602833|NCT04573543||Patients with Non-alcoholic fatty liver disease|120 patients diagnosed with NAFLD
89602834|NCT04573543||Controls|40 healthy controls
89602835|NCT04558112|Experimental|100 mg L-DOPA|Complete a ~40 min fMRI scan with either hearing their trauma or neutral narrative, ingest a pill (placebo or 100mg L-DOPA) upon leaving the scanner and wait in a waiting room for ~45 minutes, then undergo a 7 min resting-state fMRI scan.Participants return ~24 hours later for Day 2 fMRI, in which they will complete a single ~40-minute fMRI scan while listening to either their trauma or neutral narrative.
89602836|NCT04558112|Placebo Comparator|Placebo|Complete a ~40 min fMRI scan with either hearing their trauma or neutral narrative, ingest a pill (placebo or 100mg L-DOPA) upon leaving the scanner and wait in a waiting room for ~45 minutes, then undergo a 7 min resting-state fMRI scan.Participants return ~24 hours later for Day 2 fMRI, in which they will complete a single ~40-minute fMRI scan while listening to either their trauma or neutral narrative.
88981084|NCT04668326|Active Comparator|Manual Standing Wheelchair|Mobile in seated position; Not mobile in standing position
88981085|NCT04668326|Experimental|Mobile Manual Standing Wheelchair|Mobile in BOTH seated and standing positions
88981086|NCT04663152|Experimental|INSTACARE arm|Participants in this arm will receive the INSTACARE intervention for three months.
88981087|NCT04659382|Experimental|Single arm|XELOX + bevacizumab + atezolizumab + SIRT (Therasphere)
88981088|NCT04652700|Experimental|Islatravir (ISL) Once Monthly (QM) Group|Participants receive 60 mg tablet of ISL QM, orally plus Placebo to Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) tablet once daily (QD) or Placebo to Emtricitabine/Tenofovir Alafenamide (FTC/TAF) tablet QD, orally for up to 24 months of treatment duration.
88981089|NCT04652700|Active Comparator|FTC/TDF or FTC/TAF QD Group|Participants receive 200/245 mg or 200/300 mg of FTC/TDF combination tablet, QD, orally or 200/25 mg of FTC/TAF combination tablet, QD, orally at investigator's discretion plus Placebo to ISL tablet QM, orally for up to 24 months of treatment duration.
88981090|NCT04647084|Experimental|Intradermal Lidocaine 2%|
88981091|NCT04647084|Experimental|Buzzy|
88981092|NCT04639531|Experimental|Orientation and Mobility Training with VR-IOMSs|Low vision subjects with Orientation and Mobility (O&M) difficulties learning O&M skills from Virtual Reality-base Intelligent O&M Specialists (VR-IOMSs). VR-IOMSs are intelligent, computer-controlled automatic O&M skill training programs in virtual streets.
88981093|NCT04639531|Active Comparator|Orientation and Mobility Training with COMS|Low vision subjects with Orientation and Mobility (O&M) difficulties learning O&M skills from human Certified O&M Specialists (COMS) in real streets
88981094|NCT04639531|Placebo Comparator|No Orientation and Mobility Training|Low vision subjects with Orientation and Mobility (O&M) difficulties watching low vision education videos and discuss low vision issues not related to O&M with COMSs.
88981095|NCT04634227|Experimental|Gemcitabine + High-Dose Ascorbate|Ascorabte is administered on Days 1, 2, 8, 9, 15 and 16 of a 28-day cycle. Gemcitabine will be administered on Days 1, 8 and 15, after the infusion of ascorbate. Concomitant treatment will continue for 6 cycles. Patients whose disease has not progressed while receiving gemcitabine and ascorbate and who are tolerating therapy may continue either single agent gemcitabine or concomitant treatment beyond 6 cycles at the discretion of the investigator. Treatment will be terminated with progression of disease. Disease will be assessed by CT of the chest, abdomen and pelvis or MRI of the lesion every 2 cycles for progression.
88981096|NCT04633408|Experimental|Intervention|The investigators will recruit 15 Latino caregivers for each study arm (total sample size of 30). The sample size was based on a rule of thumb of 12 to 15 participants per group for pilot studies. This group will have access to the app.
88981097|NCT04633408|No Intervention|Control|12 to 15 participants, will not have access to the app.
88981098|NCT04630002|Experimental|Cohort 1: GSK3640254 then DRV/RTV then GSK3640254 + DRV/RTV|Cohort 1 will include 3 periods. In Period 1 GSK3640254 will be administered (Treatment A). In Period 2 DRV/RTV will be administered (Treatment B). In Period 3 GSK3640254 (Treatment A) and DRV/RTV (Treatment B) will be administered.
88981099|NCT04630002|Experimental|Cohort 2: GSK3640254 then ETR then GSK3640254 + ETR|Cohort 2 will include 3 periods. In Period 1 GSK3640254 will be given (Treatment A). In Period 2 ETR will be given (Treatment C). In Period 3 GSK3640254 (Treatment A) and ETR (Treatment C) will be administered.
88981100|NCT04630002|Experimental|Cohort 3: GSK3640254 then GSK3640254 + DRV/RTV + ETR|Cohort 3 will include 2 periods. In Period 1 GSK3640254 will be administered (Treatment A). In Period 2 GSK3640254 (Treatment A), DRV/RTV (Treatment B), and ETR (Treatment C) will be administered.
89602837|NCT04532866|Experimental|Isolation and Confinement|Six crew members will spend 8 months isolated and confined in the spaceflight analog NEK in Moscow.
89602838|NCT04532866|No Intervention|Control Group|Up to ten participants matched for age, gender, and educational background undergo the same test protocol as the experimental group at identical points in time but without being isolated and confined in the NEK facility.
89602839|NCT04530071|Experimental|CordSTEM-DD(0.7x10^7 cells)|HA+saline+CordSTEM-DD(0.7x10^7 cells)
89602840|NCT04530071|Experimental|CordSTEM-DD(2.1x10^7 cells)|HA+saline+CordSTEM-DD(2.1x10^7 cells)
89602841|NCT04530071|Placebo Comparator|Control group|HA + saline + placebo comparator
89602842|NCT04519775|Experimental|HOBSCOTCH-V (virtual)|"Participants will receive the HOBSCOTCH intervention consisting of 1:1 sessions delivered once per week, including:~1 pre-HOBSCOTCH Session (on webcam)~1 educational session (on webcam)~6 telephone sessions~1 wrap-up session (webcam or telephone)~Participants will also receive 3 booster sessions, via webcam or telephone, once per month."
89602843|NCT04519775|Other|Control|Participants will be wait listed and will receive HOBSCOTCH-V (above) following a 6 month wait period.
89602844|NCT04508751|Other|Healthy Pregnancy|"Patient will have a fetal MRI performed in the third trimester. All MRI scans will be performed on 3 T scanners (e.g., Skyra or Prisma, Siemens). Our newly developed FB-MRI quantification technique leverages a multi-echo 3D stack-of-radial sampling trajectory with golden-angle acquisition ordering to suppress motion artifacts and enable free-breathing imaging of the abdomen in around 5 minutes. In addition, our FB-MRI technique is compatible with data under sampling to accelerate the free-breathing scan to 1-2 min. In this study, we will optimize the parameters of our FB-MRI technique (spatial resolution, spatial coverage, acceleration factor) to balance trade-offs between scan time, image quality, fat quantification accuracy, and patient comfort/compliance. Subjects will be provided ear plugs to limit amount of noise from MRI machines.~Maternal demographics, pregnancy clinical course and infant growth parameters will be recorded."
89602845|NCT04508751|Other|Pregnant Mothers with gestational diabetes|"Patient will have a fetal MRI performed in the third trimester. All MRI scans will be performed on 3 T scanners (e.g., Skyra or Prisma, Siemens). Our newly developed FB-MRI quantification technique leverages a multi-echo 3D stack-of-radial sampling trajectory with golden-angle acquisition ordering to suppress motion artifacts and enable free-breathing imaging of the abdomen in around 5 minutes. In addition, our FB-MRI technique is compatible with data under sampling to accelerate the free-breathing scan to 1-2 min. In this study, we will optimize the parameters of our FB-MRI technique (spatial resolution, spatial coverage, acceleration factor) to balance trade-offs between scan time, image quality, fat quantification accuracy, and patient comfort/compliance. Subjects will be provided ear plugs to limit amount of noise from MRI machines.~Maternal demographics, pregnancy clinical course and infant growth parameters will be recorded."
89602846|NCT04508751|Other|Pregnant Mothers with infants diagnosed with IUGR|"Patient will have a fetal MRI performed in the third trimester. All MRI scans will be performed on 3 T scanners (e.g., Skyra or Prisma, Siemens). Our newly developed FB-MRI quantification technique leverages a multi-echo 3D stack-of-radial sampling trajectory with golden-angle acquisition ordering to suppress motion artifacts and enable free-breathing imaging of the abdomen in around 5 minutes. In addition, our FB-MRI technique is compatible with data under sampling to accelerate the free-breathing scan to 1-2 min. In this study, we will optimize the parameters of our FB-MRI technique (spatial resolution, spatial coverage, acceleration factor) to balance trade-offs between scan time, image quality, fat quantification accuracy, and patient comfort/compliance. Subjects will be provided ear plugs to limit amount of noise from MRI machines.~Maternal demographics, pregnancy clinical course and infant growth parameters will be recorded."
89602847|NCT04506255|Experimental|Silicone tape|Adult subjects will act as their own control and will be randomized to have silicone tape applied to one half of their abdominoplasty incision. Patients will apply silicone tape on a daily basis, with each piece lasting 24 hours. Tape may be removed for showers and replied after drying. Total length of treatment will be two and a half months.
89602848|NCT04506255|No Intervention|No dressing|Control treatment using the current standard of care at our institution to the other half, which is no dressing after the initial two week post-op period, will be used on the other half of the incision for comparison. Each individual patient will act as their own control.
88981101|NCT04629703|Active Comparator|Fostamatinib (150 mg twice daily for 14 days) + Standard of Care|Fostamatinib (150 mg twice daily for 14 days) + Standard of Care
88981102|NCT04629703|Placebo Comparator|Placebo (twice daily for 14 days) + Standard of Care|Placebo (twice daily for 14 days) + Standard of Care
88981103|NCT04627857|Active Comparator|Arm 1: Manual toothbrush|
88981104|NCT04627857|Experimental|Arm 2: Manual toothbrush and water flosser (Philips Sonicare AirFloss Ultra)|
88981105|NCT04627857|Experimental|Arm 3: Manual toothbrush and water flosser (Philips Sonicare AirFloss Ultra)|
88981106|NCT04627857|Experimental|Arm 4: Sonic toothbrush (Philips Sonicare ProtectiveClean) and water flosser|
88981107|NCT04620486|Experimental|Active Best Practice Alert|Care providers taking care of these patients will receive a Best Practice Alert (BPA) in the electronic medical record (EMR) one hour before an antibiotic expires with no subsequent doses ordered. The BPA will prompt the care provider to re-order the antibiotic and give information on recommended dosage and frequency based on indication and patient characteristics.
88981108|NCT04620486|No Intervention|Inactive Best Practice Alert|The Best Practice Alert described in the Experimental Arm will not be active for patients in this arm. Care providers will proceed with usual care.
88981109|NCT04608812|Experimental|Direct Infusion of OS2966|OS2966 will be directly infused into the brain tumor and surrounding tumor infiltrated brain via convection-enhanced delivery
88981110|NCT04605679|Experimental|Recipient of HCV positive kidney graft|A single center, open-label, pilot study examining 20 adult HCV negative kidney transplant patients who receive an HCV infected graft. Target start date for antiviral therapy will be within 3 months after kidney transplantation, unless extenuating clinical circumstances arise (such as the development of fibrosing cholestatic HCV, which would prompt earlier treatment, or clinical events or comorbidities which would prompt delay in treatment).
88981111|NCT04605393|Experimental|Placebo/THC|Oral placebo followed by inhalation of cannabis containing THC.
88981112|NCT04605393|Experimental|CBD/THC|Oral CBD 1000mg followed by inhalation of cannabis containing THC.
88981113|NCT04600596||Roux-en-Y gastric bypass patients|Severely obese non-diabetic adult female patients scheduled for RYGB.
89602849|NCT04489225||Observational|This single arm observational study includes all patients implanted with a Medtronic Cobalt™ XT ICD or CRT-D MRI SureScan™ (with Attain StabilityQuad™ MRI SureScan™ Model 4798 Lead (ASQ)), who are enrolled in the Medtronic CareLink (CL) Network and Product Surveillance Registry (PSR). Patients will be followed per the standard of care practices of their care provider. All patients must provide a signed informed consent.
89602850|NCT04473482|Experimental|MAIN-ART Behavior Tool|The Michigan Alcohol Improvement Network- Alcohol Reduction and Treatment Tool (MAIN-ART) behavioral intervention is an online web application with two modules: misconception correction and tailored, preference-sensitive alcohol use disorder (AUD) treatment matching.
89602851|NCT04473482|No Intervention|Routine care|Patients randomized to usual care will receive a pamphlet for alcohol treatment referral to the University of Michigan Addiction Treatment Services, but will receive no further education from the research team.
89602852|NCT04472936|Active Comparator|Group A|Double venous femoral access will be obtained. A duodecapolar catheter placed around tricuspid annulus will be used to prove isthmus block after CTI ablation.
89602853|NCT04472936|Experimental|Group B|Ablation will be performed similar as described in the Group A. After the ablation line is over, PRI on the surface ECG will be used to prove isthmus block after CTI ablation.
89602854|NCT04467619|Active Comparator|Early Illusory Movements|"Phase 1: A patient enrolled in group A will have standard rehabilitation according to the instructions of the attending surgeon and performed by an independent physiotherapist from the start of the study (Day 1), and also FPS performed by a study nurse will take place for 30 minutes twice a day, 2 hours or more after the end of standard rehabilitation, for 14 days (Day 15).~Phase 2: From Day 16 onwards, the patient will undergo standard rehabilitation only according to the instructions of the attending surgeon and performed by an independent physiotherapist for 14 days (Day 30)."
89602855|NCT04467619|Active Comparator|Deferred Illusory Movements|"Phase 1: A patient enrolled in group B will have standard rehabilitation according to the instructions of the attending surgeon and performed by an independent physiotherapist, from the start of the study (Day 1) for 14 days (Day 15).~Phase 2: Then, from Day 16 onwards, in addition to standard physiotherapy, FPS performed by a study nurse will take place for 30 minutes twice a day, 2 hours or more after the end of standard rehabilitation, for 14 days (Day 30)."
89602856|NCT04440735|Experimental|DSP107 monotherapy in advanced solid tumors|DSP107 will be administered by intravenous infusion over 1 hour on Days 1, 8 and 15 of each 21-day cycle for up to 12 treatment cycles. Starting dose will be 0.01 mg/kg and maximum dose will not exceed 10 mg/kg.
89602857|NCT04440735|Experimental|DSP107 in combination with atezolizumab in advanced solid tumors|DSP107 will be administered by IV infusion over 1 hour on Days 1, 8 and 15 of each 21-day cycle. Subjects will receive atezolizumab 1200 mg by intravenous infusion over 30 mins (first infusion over 1 hour) on Day 1 of every treatment cycle. DSP107 infusion will commence 1 hour following completion of atezolizumab infusion. The study will include up to 12 treatment cycles.
89602858|NCT04440735|Experimental|DSP107 in combination with atezolizumab in non-small cell lung cancer|DSP107 10mg/kg will be administered by IV infusion over 1 hour on Days 1, 8 and 15 of each 21-day cycle. Subjects will receive atezolizumab 1200 mg by intravenous infusion over 30 mins (first infusion over 1 hour) on Day 1 of every treatment cycle. DSP107 infusion will commence 1 hour following completion of atezolizumab infusion. The study will include up to 12 treatment cycles.
89602859|NCT04440735|Experimental|DSP107 monotherapy in colorectal cancer|DSP107 10mg/kg will be administered by intravenous infusion over 1 hour on Days 1, 8 and 15 of each 21-day cycle for up to 12 treatment cycles..
89602860|NCT04440735|Experimental|DSP107 in combination with atezolizumab in colorectal cancer|DSP107 10mg/kg will be administered by IV infusion over 1 hour on Days 1, 8 and 15 of each 21-day cycle. Subjects will receive atezolizumab 1200 mg by intravenous infusion over 30 mins (first infusion over 1 hour) on Day 1 of every treatment cycle. DSP107 infusion will commence 1 hour following completion of atezolizumab infusion. The study will include up to 12 treatment cycles.
89602861|NCT04432311|Experimental|Binge Focused Therapy (BFT)|Guided self-help - Three online group sessions, homework, and self-guided check-ins to monitor continued progress and/or signs of relapse.
89602862|NCT04432311|Active Comparator|CBT Unguided Self Help (CBT USH)|Pure self-help - The use of the book Overcoming Binge Eating and its associated homework.
89602863|NCT04422392|Experimental|Neoadjuvant PD-1 antibody puls chemotherapy|"Neoadjuvant treatment (PD-1 antibody+carboplatin+pemetrexed or nab-paclitaxel ) will start within 1-3 days from enrollment. 3 cycles will be administered at 21-day (+/- 3 days) intervals (QW3) prior to surgery. Before surgery a tumor assessment will be done. Patients with stable disease or partial response may be considered for surgery.~Surgery: Surgery must be done within the 4rd-6th week from day 1 cycle 3 of neoadjuvant treatment (day 29-43 after day 1 of cycle 3) Adjuvant treatment: Patients that are R0 confirmed by surgical pathology evaluation will receive the first adjuvant administration within the 2rd to 8th week from surgery. Three cycles of combinded adjuvant treatment (PD-1 antibody+carboplatin+pemetrexed or nab-paclitaxel ) will be administered. Thirteen cycles of PD-1 antibody will start within day 21-24 days from day 1 of adjuvant cycle 2."
89602864|NCT04422392|Active Comparator|Neoadjuvant chemotherapy|"Neoadjuvant treatment (carboplatin+pemetrexed or nab-paclitaxel ) will start within 1-3 days from enrollment/randomisation. 3 cycles will be administered at 21-day (+/- 3 days) intervals (QW3) prior to surgery. Before surgery a tumor assessment will be done. Patients must leave the study if there is evidence of progression. Patients with stable disease or partial response may be considered for surgery.~Surgery: Surgery must be done within the 4rd-6th week from day 1 cycle 3 of neoadjuvant treatment (day 29-43 after day 1 of cycle 3).~Adjuvant treatment: Patients that are R0 confirmed by surgical pathology evaluation will receive the first adjuvant administration within the 2rd to 8th week from surgery. Three cycles of adjuvant treatment (carboplatin+pemetrexed or nab-paclitaxel ) will be administered."
89602865|NCT04414761|Active Comparator|Antagonist group|Women will receive antagonist (Cetrorelix or Ganirelix 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger.
89032405|NCT02947880|Experimental|Bumetanide group|"During 3 months in the double blind, the patient will receive the experimental treatment. For the patient of 25kg and more the bumetanide is used at the posology of 1mg in the morning and 1mg in the evening, for patient under 25kg the posology is 0.5mg in the morning and 0.5mg in the evening.~After the 3 months in the double blind trial (bumetanide versus placebo), all the patient will receive (in the open phase of the trial) the bumetanide during 3 months with the posology fitting with their weights."
89602866|NCT04414761|Experimental|PPOS group|Women will receive oral medroxyprogesterone 10 mg daily or duphaston 10mg bd daily from Day 3 till the day of ovulation trigger.
89602867|NCT04378062|Active Comparator|Traction Neurectomy|Traction neurectomy - of digital sensory nerves at the time of amputation.
89602868|NCT04378062|Experimental|Targeted Muscle Reinnervation|Targeted Muscle Reinnervation - of digital sensory nerves at the time of amputation
89602869|NCT04378062|Experimental|Regenerative Peripheral Nerve Interface|Regenerative Peripheral Nerve Interface - of digital sensory nerves at the time of amputation
89602870|NCT04372485|Other|mHealth|Adolescents enrolled in this arm will receive treatment-related text messages.
89602871|NCT04372485|No Intervention|Usual care|Adolescents in this arm will receive usual care.
89602872|NCT04354233|Experimental|Physical activity intervention with connected devices|Women randomized to the intervention arm will follow a 6-month physical activity intervention using a connected device that includes an activity tracker, a smartphone and a mobile application. Patients will also receive physical activity international recommendations
89602873|NCT04354233|No Intervention|Standard care|Women will receive stardard care and physical activity international recommendations, without further intervention
89602874|NCT04318678|Other|CD123-CAR T cell therapy|CD123-CAR T-cell dose and infusion Up to 4 Dose levels will be evaluated with a maximum dose of 2.5 x 10^8 CAR+ T cells. If dose limiting toxicities (DLTs) are observed on Dose level 1 then the cell dose is de- escalated.
89602875|NCT04315142|Experimental|Transcutaneous tibial nerve stimulation (TTNS)|
89602876|NCT04315142|Sham Comparator|TTNS sham stimulation|
89602877|NCT04307238|Other|Propofol group|General anesthesia will be maintained by continually intravenous administered propofol.
89602878|NCT04307238|Other|Sevoflurane Group|General anesthesia will be maintained by inhalative administered sevoflurane.
89602879|NCT04289961|Other|Single Arm|Observational study of CTC microemboli in portal vein blood samples.
88981114|NCT04600596||Obese (BMI ≥ 35) controls|Severely obese non-diabetic adult female patients not undergoing surgery.
88981115|NCT04600596||Lean (BMI ≤ 25) controls|Lean healthy non-diabetic adult females.
88981116|NCT04592393|Experimental|Abbreviated PB MRI|Short and Focused non-contrast MRI for surveillance
88981117|NCT04591054|Active Comparator|Extended Vision IOL|Vivity
88981118|NCT04591054|Active Comparator|Neutral Aspheric Monofocal IOL|enVista [MX60E]
88981119|NCT04587908|Experimental|TAS-205|
88981120|NCT04587908|Placebo Comparator|Placebo|
88981121|NCT04587622|Experimental|Group 1 - Healthy subjects with normal hepatic function|Healthy subjects with normal hepatic function - Control
88981122|NCT04587622|Experimental|Group 2 - Mild Hepatic Impairment|Mild hepatic impairment: Child-Pugh A (Score 5-6)
88981123|NCT04587622|Experimental|Group 3 - Moderate Hepatic Impairment|Moderate hepatic impairment: Child-Pugh B (Score 7-9)
88981124|NCT04587622|Experimental|Group 4 - Severe Hepatic Impairment|Severe hepatic impairment: Child-Pugh C (Score 10-15)
88981125|NCT04586959|Experimental|Surgery With UM (Arm MAN UA)|Subjects that undergo a MIS approach with a uterine manipulator (experimental arm)
88981126|NCT04586959|Active Comparator|Surgery Without UM (Arm Control)|Subjects that undergo a MIS approach without a uterine manipulator (control arm)
89602880|NCT04282642|Experimental|Cognitive Training|Computerized Cognitive Training
89602881|NCT04282642|Experimental|WLC|Waitlist Control
89602882|NCT04281940|Experimental|Permanent Implant|Insertion of the Chordal Repair System tethering the mitral leaflets to the left ventricle.
89602883|NCT04278534|Experimental|Arm I (VERT)|Patients complete a radiation therapist-led education module using virtual reality over 30 minutes at the first treatment appointment, prior to radiation therapy treatment.
89602884|NCT04278534|Active Comparator|Arm II Control Group I (usual education materials)|Patients receive the usual verbal and written education materials at the first treatment appointment, prior to radiation therapy treatment.
89602885|NCT04278534|Active Comparator|Arm II Control Group II (face-to-face education module)|Patients complete a radiation therapist-led face-to-face education module at the first treatment appointment, prior to radiation therapy treatment.
89602886|NCT04278534|Active Comparator|Observational Cohort (usual education materials)|Observational patients receive the usual verbal and written education materials at the first treatment appointment, prior to radiation therapy treatment.
89602887|NCT04249557|Experimental|EIM group|This contains: A 12-week Exercise is medicine teaching class containing 6-18 patients per group (class size may be limited by social distancing policy in Hong Kong), homework are prescribed to participants to encourage regular exercise. The exercise level will be recorded by a tracker and provides feedback to the participants and physical trainer. The physical parameters such as fat percentage and blood pressure level will be feedback to the patients to encourage exercise. (If sports center are closed by the Government, the classes will be conducted online)
89602888|NCT04246892||group before alarm withdrawal|
89602889|NCT04246892||groupe after alarm withdrawal|
89602890|NCT04244656|Experimental|CTX120|Administered by IV infusion following lymphodepleting chemotherapy.
89602891|NCT04237857||LSG|Chinese patients who received laparoscopic sleeve gastrectomy at Prince of Wales Hospital, The Chinese University of Hong Kong for more than 36 months
89602892|NCT04224571|Experimental|rituximab and bortezomib|to test whether adding rituximab in CD20 positive patients will have improvement in remission rate. (this arm terminated in October 2020) to add bortezomib in high risk patients at Induction to improve remission rate.
89602893|NCT04222062|No Intervention|Standard of Care Arm|The tumor will be removed surgically. Within 6 weeks after surgery, the resection will be treated with stereotactic radiosurgery (SRS).
89602894|NCT04222062|Experimental|GLIADEL Arm|Once the tumor has been removed, GLIADEL wafers will be applied to the resection cavity. The number of wafers used will be determined by the size of the cavity. Enough wafers should be used so that as much of the cavity is covered as possible.
89602895|NCT04218604|Experimental|Personalized AF ablation using MDCT-derived LAWT|Pre-procedural MDCT images will be analysed in Teknon Medical Center (core-lab), using ADAS-3D™ (Galgo Medical, Barcelona, Spain) to obtain 3D atrial wall thickness maps that will be introduced into CARTO® navigation system (Biosense Webster, Diamond Bar, California, US). PVI will be performed point-by-point, aiming to complete a RF circle around the PV ostia (nephroid shape) on the 3D geometry using a ThermoCool® SmartTouch® 3.5-mm irrigated tip contact force-sensing RF ablation catheter (Biosense Webster, Inc.). AI targets will be defined by LAWT on the thickness color map, as follows: Thickness < 1 mm (red): 300; 1-2 mm (yellow): 350; 2-3 mm (green): 400; 3-4 mm (blue): 450; > 4 mm (purple): 500. The recommended power settings to reach these AI values will be, in general, 35 W for the posterior wall and 40 W for the anterior wall. Wherever local AWT is > 3 mm (green and blue colors), an increased RF power (50 W) will be permitted.
89602896|NCT04215029|Experimental|Group I (exercise plan, coaching calls, nutrition counseling)|Patients and their partners receive an exercise plan and printed materials that includes instructions for walking or other moderate-intensity activities. Patients and their partners also receive coaching calls discussing physical activity and diet related questions, each lasting 45-60 minutes and occurring every 2 weeks for 6 months. In addition, patients and their partners complete 2 nutrition counseling sessions over 1 hour each at baseline and before month 3 with an MD Anderson registered dietitian.
89602897|NCT04215029|Active Comparator|Group II (physical activity/healthy eating information)|Patients and their partners receive information/materials regarding physical activity and healthy eating.
89602898|NCT04215029|Experimental|Provider Interviews (interviews)|Healthcare providers participate in an interview regarding their opinions on family-focused care and its ability to improve health behaviors.
89602899|NCT04212884||PLWH|PLWH followed up at the five participating HIV centers
89602900|NCT04212884||HIV-uninfected individuals|Age and sex-matched HIV-uninfected individuals
89602901|NCT04211506|Experimental|Sleep Arm 1|This will be the first of four arms of controlled sleep manipulation.
89602902|NCT04211506|Experimental|Sleep Arm 2|This will be the second of four arms of controlled sleep manipulation.
89602903|NCT04211506|Experimental|Sleep Arm 3|This will be the third of four arms of controlled sleep manipulation.
89602904|NCT04211506|Experimental|Sleep Arm 4|This will be the fourth of four arms of controlled sleep manipulation.
89602905|NCT04123054|Active Comparator|Sensor-Augmented MDI + Mobile App (control)|Participants will continue their usual multiple daily injections (MDI) therapy along with the use of Freestyle Libre glucose sensors (Abbott Diabetes Care) and a mobile application that facilitates insulin dose calculations while collecting insulin and meal data.
89602906|NCT04123054|Experimental|Sensor-Augmented MDI + Mobile App + Basal-Bolus Optimization Algorithm|Participants will undergo multiple daily injections (MDI) therapy along with the use of Freestyle Libre glucose sensors (Abbott Diabetes Care) and a mobile application that facilitates insulin dose calculations while collecting insulin and meal data. Every week, participants' insulin doses will be updated by the optimization algorithm's recommendations.
89602907|NCT04098354|Active Comparator|home-based BP telemonitoring|Patients will receive a Bluetooth-enabled and validated electronic upper arm oscillometric BP device (A&D Ltd. UA-651BLE; San Jose, CA) that will be paired to their smartphone. Patients will be required to sit with their back rested for at least 5 minutes with the BP cuff around their arm. They will then be required to push the start button on the HBPT device to initiate BP measurement. HBPT values will be based on a series comprised of the mean of duplicate measures, for morning and evening, for a 7-day period and the first day home BP values will not be considered. The BP data will be auto transmitted via Bluetooth to their smartphone and relayed to a secure web portal for review.
89602908|NCT04098354|Placebo Comparator|usual care|Patients in the control arm will also follow the same BP measurement protocol as the 'active comparator (intervention) group, however, there will be no interactions with the case manager; they will share their BP readings with their primary care physicians or nurse practitioners at scheduled visits.
89602909|NCT04064840|Active Comparator|IVF: dual trigger|When at least three follicles reach 18 mm in diameter, recombinant hCG 0.25mg and decapeptyl 0.2mg will be injected subcutaneously.
89602910|NCT04064840|Placebo Comparator|IVF: hCG trigger|When at least three follicles reach 18 mm in diameter, recombinant hCG 0.25mg and normal saline will be injected subcutaneously.
89602911|NCT04064840|Active Comparator|FET: agonist|On the day of FET, decapeptyl 0.1 mg will be injected subcutaneously.
89602912|NCT04064840|Placebo Comparator|FET: control|On the day of FET, normal saline will be injected subcutaneously.
89602913|NCT04052126|Experimental|Individualized physical activity program|
89602914|NCT04050462|Active Comparator|Nivolumab Monotherapy|
89602915|NCT04050462|Experimental|Nivolumab/BMS-986253 combination|
89602916|NCT04050462|Experimental|Nivolumab/Cabiralizumab combination|
89602917|NCT04041102||Infantile (Type 1) or Juvenile (Type 2) GM1 Gangliosidosis|This study observes one cohort: up to 40 Infantile GM1 (Type 1) or Juvenile GM1 (Type 2) subjects.
89602918|NCT03983434|Experimental|Healthy volunteers|Adults ages 18-65 years with no prior history of gastrointestinal diseases or symptoms.
89602919|NCT03983434|Experimental|Irritable Bowel Syndrome Patients with Diarrhea|Patients with irritable bowel syndrome (IBS) with diarrhea, ages 18-65 years fulfilling Rome IV criteria for IBS
88981127|NCT04584151|No Intervention|standard of care|Peri operative analgesia by opioid
88981128|NCT04584151|Experimental|Continuous regiona analgesia|Peri operative algesia by continuous bilateral ESP catheters
89602920|NCT03983434|Experimental|Irritable Bowel Syndrome Patients with Constipation|Patients with irritable bowel syndrome (IBS) with constipation, ages 18-65 years fulfilling Rome IV criteria for IBS
89602921|NCT03970057|Experimental|MoodUP|
89602922|NCT03970057|Placebo Comparator|HealthyMUM|
89602923|NCT03967743||Infants with rare genetic disorders|This is a prospective, registry study of infants with genetic disorders being seen clinically in the NICU GraDS program.
89602924|NCT03955627|No Intervention|Enhanced Standard Care|Participants will receive standard care, plus a brochure about hormonal therapy use.
89602925|NCT03955627|Experimental|Treatment (Education plus Exercise)|Participants will receive the same materials as the standard care group, plus participate in group exercise and group discussion sessions.
89602926|NCT03948724|Experimental|Therapeutic patient education|Patient will receive 5 therapeutic education sessions.
89602927|NCT03948724|Active Comparator|Standard Care|Patient will receive usual informations
89602928|NCT03934814|Experimental|Part 1A - TJ011133 Monotherapy|TJ011133 alone will be administered at up to 7 dose levels (0.3, 1, 3, 10, 20, 30, 45 mg/kg) once weekly (Q1W) (the 0.3 mg/kg dose level cohort will be enrolled if a DLT in 1 out of 3 subjects is observed following the 1 mg/kg dose level).
89602929|NCT03934814|Experimental|Part 1B - Combination therapy of TJ011133 with pembrolizumab|TJ011133 will be administered Q1W, starting at 20 mg/ kg, in combination with pembrolizumab.
89602930|NCT03934814|Experimental|Part 1C - Combination therapy of TJ011133 with rituximab|TJ011133 will be administered Q1W, starting at 20 mg/kg, in combination with rituximab.
89602931|NCT03934814|Experimental|Part 2 - Dose Expansion|30 participants (with DLBCL or indolent lymphoma) in the TJ011133 combination therapy with rituximab expansion and 20 participants with solid tumors in the TJ011133 combination therapy with pembrolizumab expansion.
89602932|NCT03919799|Experimental|Belumosudil QD/Belumosudil QD|Participants received belumosudil 200 mg tablet, QD orally for 28 weeks during the DB period. After completion of DB period, participants entered open-label extension (OLE) period and continued to receive belumosudil 200 mg tablet QD orally for 24 weeks in OLE period (i.e., up to Week 52).
89602933|NCT03919799|Experimental|Belumosudil BID/Belumosudil BID|Participants received belumosudil 200 mg tablet BID orally, for 28 weeks during the DB period. After completion of DB period, participants entered OLE period and continued to receive belumosudil 200 mg tablet BID orally for 24 weeks in OLE period (i.e., up to Week 52).
89602934|NCT03919799|Placebo Comparator|DB Period: Placebo|Participants received placebo (matched to belumosudil) tablet, orally for 28 weeks during the DB period.
89602935|NCT03919799|Experimental|OLE Period: Placebo/Belumosudil QD|Participants who had received placebo in the DB period were entered and re-randomized into OLE period and received belumosudil 200 mg tablet QD orally for 24 weeks (i.e., up to Week 52) in the OLE period.
89602936|NCT03919799|Experimental|OLE Period: Placebo/Belumosudil BID|Participants who had received placebo in the DB period were entered and re-randomized into OLE period and received belumosudil 200 mg tablet BID orally for 24 weeks (i.e., up to Week 52) in the OLE period.
89602937|NCT03913351|Experimental|Lifestyle modification program|The dietary intervention program will be scheduled for 12 months, and conducted by a dietitian.The program aims to increase energy expenditure and reduce caloric intake, with an emphasis on long-term lifestyle and behavioural change. An exercise instructor will provide advice on physical activity. A mobile tracking device to monitor calories expenditure will be provided to each participant during they study period to encourage physical activity.
89602938|NCT03913351|No Intervention|Control|standard care of treatment, as in routine clinical practice
89602939|NCT03885128|Experimental|Vest arm|high frequency chest wall oscillation vest performed 4 times per week for 6 successive weeks for 30 patients
89602940|NCT03885128|Experimental|Quake arm|Vibratory positive expiratory pressure quake performed 4 times per week for 6 successive weeks for 30 patients
89602941|NCT03884010||Participants|Professional male soccer players from the second professional Mexican division
89602942|NCT03867578|Other|Exploratory Phase - Standard CT Imaging and HR-MRI|The goal is to test several different novel Magnetic Resonance sequences to determine which gives the best visualization of peritoneal disease.
89602943|NCT03867578|Other|Testing Phase- Conventional and HR-MRI and Ultrasound|Patients will undergo conventional and HR-MRI imaging as well as abdominal ultrasound to define the performance of these methods.
89602944|NCT03830476|Experimental|Acceptance- and Commitment therapy group|Experiment group that receives the treatment direct after the baseline measurement.
89602945|NCT03830476|Active Comparator|Treatment as usual|Comparison group that receives treatment as usual and the Navigator ACT intervention appr 6 months later.
89602946|NCT03820232||Surgical patients|Patients who were candidates for major or urological surgery under general anaesthesia will be observed. In particular, the core body temperature will be measured with both a single-use oesophageal probe and a SpotOn® heated controlled servo sensor.
89602947|NCT03794479||Travellers|Adults planning for travel
89602948|NCT03794453||Stroke patients|
89602949|NCT03775343||General Anesthesia|"General anesthesia:~25 patients older than 65 years, undergoing elective eye surgery under general anesthesia.~Intervention: neurocognitive testing (Neurocognitive Test Battery) preoperative, 6 and 24 hours postoperative.~Blood sampling before surgery (baseline), immediately postoperative, 6 and 24 hours after surgery."
89602950|NCT03775343||Local anesthesia with sedoanalgesia|"25 patients older than 65 years, undergoing elective eye surgery under local anesthesia in combination with sedoanalgesia.~Intervention: neurocognitive testing (Neurocognitive Test Battery) preoperative, 6 and 24 hours postoperative Blood sampling before surgery (baseline), immediately postoperative, 6 and 24 hours after surgery."
89602951|NCT03775343||Control Group|"25 patients, not undergoing any operative intervention. To determine a normal reference value of cognitive functions, a group of 25 individuals without an operative intervention will be recruited as a control group.~Intervention: neurocognitive testing (Neurocognitive Test Battery) at 3 determined time points (0, 6 and 24 hours)"
88981129|NCT04576923|Experimental|Velacur by Sonic Incytes|Patients with known or suspected Non-Alcoholic Fatty Liver Disease (NAFLD) or Non-Alcoholic Steatohepatitis (NASH) will be scanned with Velacur for assessment of liver fibrosis.
88981130|NCT04566133|Experimental|Cohort 1/Arm 1: Trametinib + Hydroxychloroquine (HCQ)|Trametinib + hydroxychloroquine (HCQ)
88981131|NCT04559984|Experimental|JUVÉDERM VOLUX®|Participants will be treated with VOLUX XC hyaluronic acid (HA) injectable gel on day 1 with an optional touch-up treatment at week 4 if agreed upon by both the participant and Treating Investigator.
88981132|NCT04559984|Other|Control- No treatment|No-treatment during the control period. Optional delayed-treatment with VOLUX XC (initial with optional touch-up) during the Post-Control period.
88981133|NCT04558736|Experimental|Haploidentical HCT|"To assess the safety and efficacy of haploidentical donor transplantation for patients with severe aplastic anemia who lack an available HLA-matched donor. The goal of this study is to develop a novel, reduced-toxicity, post-transplant pharmacologic immunosuppression (GVHD prophylaxis)- free, highly tolerogenic haploidentical transplant regimen that is associated with few post- transplant complications or late toxicities and is available promptly to all patients, irrespective of matched donor availability.~Cells for infusion are prepared using the CliniMACS System."
89602952|NCT03759678|Experimental|Treatment with IB1001|"6-weeks treatment with IB1001 administered orally.~Patients ≥13 years old will receive a total daily dose of 4 g/day (administered as 3 doses per day).~Patients 6-12 years old will receive weight-tiered doses:~Patients aged 6-12 years weighing 15 to <25 kg will take 2 g per day: 1 g in the morning and 1 g in the evening.~Patients aged 6-12 years weighing 25 to <35 kg will take 3 g per day: 1 g in the morning, 1 g in the afternoon, and 1 g in the evening.~Patients aged 6-12 years weighing ≥35 kg will take 4 g per day: 2 g in the morning, 1g in the afternoon and 1 g in the evening (as per adults)~After the 6-week treatment period, patients will enter a 6-week post-treatment washout period."
89602953|NCT03759678|No Intervention|Post-Treatment Washout|After the 6-week treatment period, patients will enter a 6-week post-treatment washout period.
89602954|NCT03733886|Active Comparator|Burst SCS|"In the active comparator the burst SCS system will be turned on according to randomisation.~A treatment period is a 2-week period where the patient receives either active treatment or sham. Each patient will go through 6 treatment periods (in total 12 weeks). A treatment cycle is a 4-week period with two treatment periods, one of active treatment and one of sham. Each patient will go through three treatment cycles."
89602955|NCT03733886|Sham Comparator|Sham|In the sham comparator the burst SCS system will be turned off according to randomisation.
89602956|NCT03703115|Active Comparator|Fasting|"Patients will have periodic fasting for 4 weeks prior to the treatment cycle. The fasting method involves daily fasts of 14-16hours and restrict eating to an 8-10 hour eating window as 2-3 or more meals of balanced diet with 2-3 litres of water and non calorie fluids allover the day."
89602957|NCT03703115|No Intervention|Nonfasting|Patients will have usual balanced diet as 3 meals and 2 snacks all over the day. Both groups should take adequate water and non calorie beverages intake daily ( 2-3 liters daily)
89602958|NCT03702998||HIV-infected individuals +/- HBV/ HCV|"1 All HIV-infected individuals followed up in all public HIV clinics with and without HBV and/or HCV co-infection will be included in the analysis.~1.1 Inclusion criteria for HIV-infected individuals with and without HBV or HCV co-infection: 1.1.1 Positive HIV antibody 1.1.2 At least one visit in one of the HIV clinics 1.1.3 Subjects with positive HBsAg and/or anti-HBc will be regarded as having HBV co-infection 1.1.4 Subjects with positive HCV antibody will be regarded as having HCV co-infection"
89602959|NCT03702998||HBV/HCV mono-infected individuals|"2 All HBV and/or HCV-infected individuals followed up in public hospitals will be identified from the Hospital Authority electronic database.~2.1 Inclusion criteria for HBV/HCV mono-infected individuals 2.1.1 Documented diagnosis of hepatitis B or hepatitis C infection, or 2.1.2 Positive HBsAg and/or anti-HBc, or 2.1.3 Positive HCV antibody, and 2.1.4 Negative HIV antibody result, or no record of HIV diagnosis or anti-retroviral therapy prescription"
89602960|NCT03697811|Experimental|DE-117 Ophthalmic Solution 0.002%|Interventional treatment will be made with DE-117 Ophthalmic Solution 0.002% once daily in the evening for the duration of the 3 month treatment period.
89602961|NCT03691649|Experimental|DE-117 Ophthalmic Solution|Topical DE-117 Ophthalmic Solution once daily and Vehicle once daily for 3 months for all subjects, followed by DE-117 Ophthalmic Solution once daily for additional 9 month for adult subjects only
89602962|NCT03691649|Active Comparator|Timolol Maleate Ophthalmic Solution 0.5%|Topical Timolol Maleate Ophthalmic Solution 0.5% twice daily for 3 months for all subjects, followed by DE-117 Ophthalmic Solution once daily for additional 9 month for adult subjects only
89602963|NCT03687190|Experimental|Tai chi|participants in this group accepted Tai chi exercise and conventional medicine.
89602964|NCT03687190|Active Comparator|controlled group|participants were not received Tai chi exercise, but only routine conventional medicine
89602965|NCT03682523|No Intervention|Control Group|Fitted with an accelerometer to measure time spent out of bed while in hospital. Otherwise, participants in the control group will receive usual care from the hospital medical team during their hospital stay. Daily activities of participants will not be restricted if patients are assigned to the control group.
89602966|NCT03682523|Experimental|Intervention Group|Fitted with accelerometer to measure time spent out of bed while in hospital; daily goals set for time spent out of bed; mobilization feedback real-time feedback on goal attainment; hands on mobilization by physiotherapist for participants in late afternoon for participants who do not meet daily goal.
89602967|NCT03655002|Experimental|Treatment (nivolumab, cyclophosphamide, IRX-2)|Patients receive nivolumab IV over 30 minutes on day 1, cyclophosphamide IV on day 1, and IRX-2 SC for 10 days between days 4 and 15. Cycles repeat every 28 days for up to 18 months in the absence of disease progression or unacceptable toxicity. Patients receive booster IRX-2 SC at 3, 6, 9, 12, and 15 months.
89602968|NCT03645226||Early PD subjects converted from iRBD|"Chinese aged 50 or above~Being capable of giving informed consent for participation of the study~PD diagnosis confirmed by neurologists according to the United Kingdom Parkinson's Disease Survey Brain Bank. Assessment tools including Unified Parkinson's Disease Rating Scale (UPDRS) and Hoehn & Yahr Staging will be used for severity grading.~Onset of PD symptoms of <5 years~In view of the heterogeneity of PD, we will only include those patients with RBD preceding the onset of motor symptom of PD."
89602969|NCT03645226||iRBD subjects|"Age-and sex-matched with PD subjects~Chinese aged 50 or above~Being capable of giving informed consent for participation of the study~RBD diagnosis according to the International classification of sleep disorder 3rd edition (ICSD 3rd), fulfilling both the clinical and video-polysomnography (vPSG) criteria."
89602970|NCT03645226||First degree relatives of patients with iRBD|"First degree relatives of patients with iRBD;~Age-and sex-matched with PD subjects~Chinese aged 40 or above;~Absence of dream enactment behaviors;~Not cohabiting with proband"
89602971|NCT03645226||Healthy Controls|"Age-and sex-matched with PD subjects;~Chinese aged 50 or above;~Being capable of giving informed consent for participation of the study;~Without a personal history or a family history of PD or RBD;~Absence of dream enactment behaviors;~A total score on REM Sleep Behavior Questionnaire (RBDQ-HK) less than 19, which is the suggestive cut-off of a diagnosis of RBD;~Absence of RSWA as measured by v-PSG."
88815030|NCT03021434|Active Comparator|Comparison|Households will participate in community and household water safety education sessions, during which they will be given generalized information on water quality and safe water handling. A water sample from these households will be collected for laboratory analysis. Results from this analysis will be returned to the household at project endline. A study team member will return to the household within 72 hours to review the information on safe water handling, storage, and use behaviours.
89602972|NCT03621735|Other|Sham then Active|"Active: Bimodal auditory-somatosensory stimulation~Sham: Sham Bimodal auditory-somatosensory stimulation~Subjects receive both a sham treatment and an active treatment. The subjects will be blinded to which treatment they are receiving. Both treatments are delivered using a take-home device programmed in the lab.~During active treatment, the device will deliver electric somatosensory and auditory stimulation."
89602973|NCT03621735|Other|Active then Sham|"Active: Bimodal auditory-somatosensory stimulation~Sham: Sham Bimodal auditory-somatosensory stimulation~Subjects receive both an active treatment and a sham treatment. The subjects will be blinded to which treatment they are receiving. Both treatments are delivered using a take-home device programmed in the lab.~During active treatment, the device will deliver electric somatosensory and auditory stimulation."
89602974|NCT03596424|Active Comparator|Ketamine hydrochloride|Intraoperative bolus (0.25 mg/kg) and infusion (0.25mg/kg/h) of ketamine plus an intraoperative bolus (over 20 min) and infusion of normal saline;
89602975|NCT03596424|Active Comparator|dexmedetomidine hydrochloride|Intraoperative bolus (1µg/kg over 20 min) and infusion (0.5µg/kg/h) of dexmedetomidine plus an intraoperative bolus and infusion of normal saline
89602976|NCT03596424|Active Comparator|dexmedetomidine hydrochloride and ketamine hydrochloride|Intraoperative bolus (1µg/kg over 20 min) and infusion (0.5 µg/g/h) of dexmedetomidine plus an intraoperative bolus (0.25mg/kg) and infusion (0.25mg/kg/h) of ketamine
89602977|NCT03592563||Red group|"Those participants who had established diagnosis of one or more neurological and/or psychiatric conditions~Baseline: The participants' medical history, signs, symptoms and diagnoses of neurological and/or psychiatric disorders would be recorded. Neuro-QoL questionnaire plus an additional subset of questions based on their clinical diagnosis should be done."
89602978|NCT03592563||Yellow group|"Those participants who are high-risk to develop one or more neurological and/or psychiatric conditions, for example:~family history (first degree relative) one or more neurological and/or psychiatric conditions;~examination, imaging or laboratory findings consistent with pre-symptomatic stages of one or more neurological and/or psychiatric disorders.~Baseline: The participants' medical history, signs, symptoms and diagnoses of neurological and/or psychiatric disorders would be recorded. Neuro-QoL questionnaire should be done."
89602979|NCT03592563||Green group|"Those participants who are not meeting criteria for Red or Yellow groups, but interested in longitudinal research on maintenance and/or improvement of their brain health.~Baseline: The participants' medical history would be recorded and Neuro-QoL questionnaire should be done."
89602980|NCT03579277|Active Comparator|Radial forearm free flap|Subjects in this arm will receive a radial forearm free flap.
89602981|NCT03579277|Active Comparator|Ulnar forearm free flap|Subjects in this arm will receive an ulnar forearm free flap.
89210321|NCT02591849|Active Comparator|Glucagon-like peptide-1 (GLP-1)|Twelve eligible renal transplant recipients with PTDM and twelve age, gender, BMI and renal function-matched non-diabetic renal transplant recipients will be randomized to continuous unblinded intravenous infusion of GLP-1 with an infusion rate of 0.8 pmol/kg/min or isotonic saline (placebo) on two experimental days performed 2-4 weeks apart. The GLP-1 infusion will consist of 42.5 nmol/mL GLP-1 (7-36) amide, 12.5 mL 5% human albumin and isotonic saline added to a total volume of 50 mL. After 60 min, a 2 hour hyperglycemic clamp will be initiated, where plasma glucose will be elevated by 5 mmol/L from each individual fasting plasma glucose in both groups. This will be done to measure concentrations of glucagon and insulin in hyperglycemic conditions.
89210322|NCT02591849|Placebo Comparator|Isotonic saline|The included patients will receive concomitant intravenous infusion of isotonic saline on one of the two experimental days
89210323|NCT02593877|Experimental|VHA algorithm|Massive transfusion protocol resuscitation aiming at ratio 1:1:1 of blood components (RBC 1: plasma 1: platelets 1) and VHA-guiding further resuscitation with blood products and procoagulant factors
89210324|NCT02593877|No Intervention|Control|Massive transfusion protocol resuscitation aiming at ratio 1:1:1 of blood components (RBC 1: plasma 1: platelets 1) and conventional coagulation tests guiding further resuscitation with blood products and procoagulant factors
89210325|NCT05712135||supine|The patient group whose cuff pressure was measured in the supine position in neurosurgery
89210326|NCT05712135||prone|The patient group whose cuff pressure was measured in the prone position in neurosurgery
89210327|NCT05712135||semi-fowler|The patient group whose cuff pressure was measured in the semi-fowler position in neurosurgery
89602982|NCT03531918|Experimental|Treatment (GO, GCLAM)|"INDUCTION THERAPY: Participants receive gemtuzumab ozogamicin IV either as a single dose on day 1, or as three doses on days 1, 4, and 7. Participants also receive G-CSF SC on days 0-5, cladribine IV over 2 hours on days 1-5, cytarabine IV over 2 hours on days 1-5, and mitoxantrone hydrochloride IV on days 1-3. Patients who do not achieve a CR or CRi following the first cycle of induction are eligible for a second cycle, which is given without gemtuzumab ozogamicin. Participants with a CR or CRi may then proceed to Post-Remission Therapy.~POST-REMISSION THERAPY: Participants receive G-CSF, cladribine, and cytarabine as in Induction Therapy during cycle 1, and cytarabine IV every 12 hours on days 1-6 of cycles 2-3. Treatment repeats every month for up to 3 cycles in the absence of disease progression or unacceptable toxicity."
89602983|NCT03499704|Experimental|Pioglitazone + Alogliptin + Metformin (PAM)|Pioglitazone 15 milligram (mg) and alogliptin 25 mg in fixed dose combination (FDC) tablet (SYR-322-4833), orally once daily and metformin greater than or equal to (>=) 500 mg, tablet, orally, twice a day for up to 26 weeks. At Week 12, if participants has HbA1c >=7.5%, pioglitazone dose will be titrated up to 30 mg based on investigator's opinion and up-titrated dose will be maintained up to Week 26.
88981134|NCT04551313|Experimental|social skill training group|We plan to address basic interactional and conversational skills first, then focus on teaching perspective-taking and theory of mind skills.
88981135|NCT04551313|Active Comparator|control group|Regular therapy
88981136|NCT04548830|Experimental|Transbronchial cryobiopsy|All study participants will undergo transbronchial biopsies via our proposed standardized cryo-biopsy protocol in place of the traditional forceps transbronchial biopsy that is typically used at MSK.
88981137|NCT04526197|Experimental|Treatment Sequence A-B|"Participants received 1 treatment during each study period in the following sequence:~Treatment A: Celecoxib.~Treatment B: Celecoxib plus ALXN1840."
88981138|NCT04526197|Experimental|Treatment Sequence B-A|"Participants received 1 treatment during each study period in the following sequence:~Treatment B: Celecoxib plus ALXN1840.~Treatment A: Celecoxib."
89602984|NCT03499704|Active Comparator|Dapagliflozin + Alogliptin + Metformin (DAM)|Dapagliflozin 10 mg, tablet, orally, once daily with alogliptin 25 mg, tablet, orally, once daily, and metformin >=500 mg, tablet, orally, twice a day, for up to Week 26.
89602985|NCT03362515|Experimental|Furosemide|
89602986|NCT03362515|Placebo Comparator|Placebo|
89602987|NCT03339492|Active Comparator|Active PEMF|Subjects have 2 out of 3 chance to get the active device which emits a pulsed electromagnetic field (PEMF) from the RCStim Model 1114 device (right and left side models available). Double-blind randomization.
89602988|NCT03339492|Sham Comparator|Control/placebo PEMF|Subjects have a 1 out of 3 chance to get the control/placebo device which does not emit a pulsed electromagnetic field (PEMF) from the RCStim Model 1114 device (right and left side models available). Double-blind randomization.
89602989|NCT03328598|Experimental|Positive psychology therapy group|This arm will be given a positive psychological group intervention developed from an foreign psychotherapy.
89602990|NCT03328598|Experimental|Resilience promotion therapy group|This arm will be given a resilience group intervention developed from our pervious research results.
89210328|NCT02540148|Experimental|Active Treatment|Patients will be fully consented before the start of the study. In the treatment group, subjects will undergo a treatment session to the enrolled eyes for three days during Week 1, followed by a single treatment session during Weeks 2, 14 and 26 with the Nova Oculus device. A treatment session is 15 minutes of treatment on each closed eye lid for a total of 30 minutes. ETDRS visual acuity will be performed on all subjects at enrollment (prior to the first treatment), prior to each treatment session, and at four weeks from enrollment. The effect of treatments with the Nova Oculus device compared to sham treatment on the visual acuity of subjects with dry AMD will be determined.e.
89602991|NCT03328598|Active Comparator|Controlled routine activity group|This arm will continue to participate in conventional community activities.
89602992|NCT03324477|Experimental|preload group|Patients will receive 4 ml/kg of hypertonic saline 3% via G14 cannula over 15-20 min before the induction of spinal anaesthesia.
89602993|NCT03324477|Experimental|coload group|Patients will receive 4 ml/kg of hypertonic saline 3% via G14cannula at the maximal possible rate at the time of identification of C.S.F .
89602994|NCT03292926|Active Comparator|Adductor Canal Block (ACB)|The adductor canal block will be ultrasound-guided sonosite. The anesthesiologist will administer 15 cc bupivacaine 0.5% with 2 mg preservative-free dexamethasone with a 22 gauge (G)/4 inch Chiba needle to the mid-thigh of the surgical limb while subject lays in the supine position post IV sedation.
89602995|NCT03292926|Active Comparator|Adductor Canal Block & IPACK (ACB/IPACK)|"The adductor canal block will be ultrasound-guided. The anesthesiologist will administer 15 cc bupivacaine 0.5% with 2 mg preservative-free dexamethasone with a 22G/4 inch Chiba needle to the mid-thigh of the surgical limb while subject lays in the supine position post IV sedation.~The IPACK will be ultrasound-guided with c60 sonosite probe (5-2Hz). While laying in the prone or supine, frog-leg position the IPACK will be administered using a 22G/4inch Chiba needle. The anesthesiologist will identify the popliteal artery at the popliteal crease and move cephalad just beyond the femoral condyles at the confluence with the femur. Then the anesthesiologist will identify the space between the femur and the popliteal artery and moving from medial to lateral place the needle in between the popliteal artery and femur with the tip ending 2-3 cm lateral to the artery and inject 25 cc bupivacaine 0.25% with 2 mg preservative-free dexamethasone."
89602996|NCT03291392||Atherosclerosis|"Patient with intracranial stenosis or extracranial stenosis equal to or more than 70% would be invited to join the study for blood taking.~Biobank: Gene expression or biomarkers exploration for atherosclerotic-related genetic diseases"
89602997|NCT03291392||Family members|"The stroke patient who had family history of stroke, their parents and siblings would also be invited to join the study for blood taking or buccal swab/ saliva collection.~Biobank: Gene expression or biomarkers exploration for atherosclerotic-related genetic diseases"
89602998|NCT03291392||Normal subjects|"Normal subjects without ischemic stroke or intracranial/extracranial stenosis would be invited to join the study for blood taking.~Biobank: Gene expression or biomarkers exploration for atherosclerotic-related genetic diseases"
89602999|NCT03288324|Experimental|Tofacitinib Arm|open-label study
89603000|NCT03282994|Experimental|Treatment with cryotherapy|Dermal Cooling System
89603001|NCT03266016|Experimental|REDvent-acute|Acute Phase: The acute phase is defined as the time from intubation until the patient meets weaning criteria, passes the initial oxygenation test (decrease PEEP to 5 cmH2O and FiO2 to 0.5, maintains SpO2 > 90%), and undergoes a Spontaneous Breathing Trial (SBT). Patients will be managed with pressure control plus pressure support ventilation using a computerized decision support tool that will recommend changes to ventilator settings approximately every 4 hr (with or without a new blood gas). If the patient is spontaneously breathing, it will incorporate real-time measures of effort of breathing (esophageal manometry) to keep it in a target range.
88981139|NCT04522648|Experimental|Intervention (INT)|INT participants will be asked to perform self-measurements of arm circumference at five points along the arm at home every three months. Additional measurements can be performed if the participants experience signs of BCRL. Participants will report the self-measurements in cm and mm in an online questionnaire, or over the phone to a physiotherapist navigator, along with reporting sign and symptoms of BCRL.
88981140|NCT04522648|No Intervention|Control (CON)|The CON group will follow the usual post-operative care. CON participants will be prompted every 6 months by an online questionnaire to report if they have been diagnosed with BCRL and if so, month of initiation of treatment.
88981141|NCT04506762|No Intervention|Control|Standard of care for peri operative analgesia
88981142|NCT04506762|Experimental|Intervention|Bilateral ESP catheters for peri operative regional analgesia
88981143|NCT04500119|Experimental|Behavioral Testing|Behavioral and Neuronal Recordings
88981144|NCT04498806|Experimental|Intervention|Pre-op appointment, patient will receive Fitbit device to track physical activity.
88981145|NCT04490915|Experimental|Crinecerfont|Crinecerfont capsule, administered orally, twice daily for 24 weeks during the placebo-controlled treatment period, followed by active treatment with crinecerfont for at least 1 year.
88981146|NCT04490915|Placebo Comparator|Placebo|Placebo capsule, administered orally, twice daily for 24 weeks, followed by active treatment with crinecerfont for at least 1 year.
88981147|NCT04488497|Experimental|Peer coach guided online learning program|
89603002|NCT03266016|Placebo Comparator|Control-acute|Acute Phase: The acute phase is defined as the time from intubation until the patient meets weaning criteria, passes the initial oxygenation test (decrease PEEP to 5 cmH2O and FiO2 to 0.5, maintains SpO2 > 90%), and undergoes a Spontaneous Breathing Trial (SBT). Ventilator management will be per usual care until the patient meets weaning criteria and passes the oxygenation test.
89603003|NCT03266016|Experimental|REDvent-weaning|Weaning Phase: The weaning phase is defined as the time from the first Spontaneous Breathing Trial (SBT) until the patient successfully passes an SBT or is extubated (whichever comes first). Patients who pass the initial SBT at the end of the acute phase will not undergo weaning phase randomization. Patients will be managed in a pressure support/CPAP mode of ventilation with assessments or changes to the level of pressure support every 4 hours, targeting maintaining effort of breathing (esophageal manometry) in a normal range. An SBT will be conducted daily, and the weaning phase will continue until the patient passes the SBT.
89603004|NCT03266016|Placebo Comparator|Control-weaning|Weaning Phase: The weaning phase is defined as the time from the first Spontaneous Breathing Trial (SBT) until the patient successfully passes an SBT or is extubated (whichever comes first). Patients who pass the initial SBT at the end of the acute phase will not undergo weaning phase randomization. Ventilator management will be per usual care. An SBT will be conducted daily, and the weaning phase will continue until the patient passes the SBT.
89603005|NCT03249220|Experimental|CBMS|
89603006|NCT03245151|Experimental|Phase 1: Phase 1; Recurrent or refractory solid tumors|During Phase 1 (Treatment Phase: 1 cycle; 28 days of treatment), utilizing a rolling 6 design, participants with recurrent or refractory solid tumors will receive escalating doses of lenvatinib in combination with everolimus for determination of the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D). Participants who complete 1 cycle of treatment will transition to the Extension Phase, in which they will continue to receive the same study treatment in 28-day cycles.
89603007|NCT03245151|Experimental|Phase 2: Cohort 1, Ewing sarcoma|During Phase 2 (four 28-day cycles [up to 16 weeks of treatment]), utilizing Simon's optimal 2-stage design, participants with recurrent or refractory Ewing sarcoma (Cohort 1) will receive the RP2D of lenvatinib in combination with everolimus determined in Phase 1. Participants who discontinue study treatment before completing 4 cycles will transition to the Off-treatment Visit. Participants who complete 4 cycles will transition to the Extension Phase, in which they will continue to receive the same study treatment in 28-day cycles.
89603008|NCT03245151|Experimental|Phase 2: Cohort 2, Rhabdomyosarcoma|During Phase 2 (four 28-day cycles [up to 16 weeks of treatment]), utilizing Simon's optimal 2-stage design, participants with recurrent or refractory rhabdomyosarcoma (Cohort 2) will receive the RP2D of lenvatinib in combination with everolimus determined in Phase 1 (1 cycle; 4 weeks of treatment). Participants who discontinue study treatment before completing 4 cycles will transition to the Off-treatment Visit. Participants who complete 4 cycles will transition to the Extension Phase, in which they will continue to receive the same study treatment in 28-day cycles.
88981148|NCT04488497|Placebo Comparator|Self-administered online learning program|
88981149|NCT04487808|Active Comparator|Average American Diet|Diet representative of average American intake in terms of diet quality measured by the Healthy Eating Index-2015.
88981150|NCT04487808|Active Comparator|Average American Diet + Pecans|Diet that approximates average American intake in terms of diet quality measured by the Healthy Eating Index-2015, but includes 2 oz./day of pecans.
88981151|NCT04487808|Active Comparator|Healthy Diet + Pecans|High diet quality, measured by Healthy Index-2015 score >95, and includes 2 oz./day of pecans.
88981152|NCT04486638||Pregnant women and their offspring(s)|Women and their offspring(s) exposed to Dengvaxia during pregnancy
88981153|NCT04458428|No Intervention|Control|No other non-standard of care activities will be performed
88981154|NCT04458428|Experimental|Intervention|Will be signed up for the automated short message service (SMS)
88981155|NCT04438174|Experimental|Amniotic Fluid Injection|Processed Amniotic Fluid. Dose is 1ml/5cm2; Route: injected directly into wound; Limited to two injections. The wound will then be dressed according to standard of care.
88981156|NCT04438174|Active Comparator|Standard of Care Wound Treatment Regimen|Primary dressings are variable and based on the moisture content and microorganism load. In general, wounds respond differently to various topical treatments. Through our clinical practice, we have found that wounds plateau with the same topical for greater than 4 weeks, hence changing antimicrobial topical helps to manage the bacterial overgrowth. We will start with our application of our slurry, a 1:1:1 ratio of Nystatin ointment, Mupirocin Ointment, and Bacitracin Ointment. This slurry will be applied directly to the cleansed wound, followed by silver gauze/foam product to all wounds. Types of silver product- site and comfort predict use of Restore, Mepilex-AG, or Mepitel-AG. If allergies to the above slurry occurs, we will use medical honey with or without bacitracin. If ointment related rash present with transition to silver product only or silver product plus medical honey.
88981157|NCT04434664|Active Comparator|Amlodipine besylate|Initial dose 5mg (1 capsule) daily, titrated up to 10mg (2 capsules) daily for a home systolic BP ≥135 mmHg and heart rate ≥50 bpm after the first week of use
88981158|NCT04434664|Active Comparator|Metoprolol succinate|Initial dose 100mg (1 capsule) daily, titrated up to 200mg (2 capsules) daily for a home systolic BP ≥135 mmHg and heart rate ≥50 bpm after the first week of use
88981159|NCT04430192|Experimental|177Lu-PSMA-617 followed by prostatectomy|177Lu-PSMA-617 followed by prostatectomy
88981160|NCT04419272|Experimental|Methylphenidate|Subjects who will receive methylphenidate in the double-blinded period; when assigned to the active drug, the dosage of MPH will begin at 10mg twice per day, at 8am and 12pm, for one week. The dosage will then increase to 20mg twice daily, at 8am and 12pm, for the next 7 weeks.
88981161|NCT04419272|Placebo Comparator|Placebo|Subjects who will receive placebo in the double-blinded period; when assigned to receive the placebo during the double-blinded period, subjects will be given a sugar pill for 8 weeks. The sugar pill will be taken twice per day, at 8am and 12pm.
89032406|NCT02947880|Placebo Comparator|Placebo group|"During 3 months in the double blind, the patient will receive the placebo. For the patient of 25kg and more the bumetanide is used at the posology of 1mg in the morning and 1mg in the evening, for patient under 25kg the posology is 0.5mg in the morning and 0.5mg in the evening.~After the 3 months in the double blind trial (bumetanide versus placebo), all the patient will receive (in the open phase of the trial) the bumetanide during 3 months with the posology fitting with their weights."
89032407|NCT00523562|Experimental|normal weight male high fructose diet|"Effects of diet intervention  high fructose in normal weight subjects"
89032408|NCT00523562|Experimental|offsprings of T2DM high fructose diet|"Effect of diet intervention high fructose in healthy non-obese offsprings of patients with type 2 diabetes"
89603009|NCT03245151|Experimental|Phase 2: Cohort 3, High Grade Glioma (HGG)|During Phase 2 (four 28-day cycles [up to 16 weeks of treatment]), utilizing Simon's optimal 2-stage design, participants with recurrent or refractory HGG (Cohort 3) will receive the RP2D of lenvatinib in combination with everolimus determined in Phase 1 (1 cycle; 4 weeks). Participants who discontinue study treatment before completing 4 cycles will transition to the Off-treatment Visit. Participants who complete 4 cycles will transition to the Extension Phase, in which they will continue to receive the same study treatment in 28-day cycles.
89603010|NCT03216343|Experimental|Study Arm|Patients take Chiauranib capsules 50mg, orally once daily, 28 days as a cycle until objective disease progression
89603011|NCT03173534|Active Comparator|TAVR + Medical Therapy|n=175 will undergo Transcatheter Aortic Valve Replacement (TAVR) alone with medical management for atrial fibrillation
89603012|NCT03173534|Experimental|TAVR + WATCHMAN|n=175 will undergo simultaneous Transcatheter Aortic Valve Replacement (TAVR) with a WATCHMAN device.
89603013|NCT03127761||Allogeneic HCT|Prospectively enrolled cohort of patients receiving allogeneic hematopoietic cell transplantation for multiple myeloma
89603014|NCT03127761||Historical autoHCT|Historical cohort of patients with autologous hematopoietic cell transplantation between 2010 and 2016
89603015|NCT03108443||Glaucoma|Subjects identified as having glaucoma. No interventions will be performed.
89603016|NCT03108443||Healthy controls|Subjects identified as having healthy eyes with no disease.
89603017|NCT03106376|Experimental|Healthy subjects|16% O2 gas in breathed air for 30 minutes 26% O2 gas in breathed air for 30 minutes
89603018|NCT03096275|Experimental|MMF+MTX+Glucocorticoids|Patients were treated with Glucocorticoids combined with mycphenolate mofetil(MMF) as well as methotrexate(MTX) treatment for 52 weeks and were followed for 52 weeks.
89603019|NCT03096275|Active Comparator|CYC/AZA+Glucocoticoids|Patients were treated with Glucocorticoids combined with cyclophosphamide(CYC)/azathioprine(AZA) for 52 weeks and were followed for 52 weeks
89603020|NCT03070223||Experimental: Pitavastatin|Participants who receive pitavastatin in the main study REPRIEVE (A5332).
89603021|NCT03070223||Placebo Comparator: Placebo|Participants who receive placebo for pitavastatin in the main study REPRIEVE (A5332).
89603022|NCT03012321|Active Comparator|Arm I: Abiraterone + Prednisone|Abiraterone 1000 mg orally once daily and prednisone 5 mg orally twice daily, days 1-28 in 28 day cycles.
89603023|NCT03012321|Active Comparator|Arm II: Olaparib|Olaparib 300 mg orally twice daily for days 1-28 in 28 day cycles.
89603024|NCT03012321|Active Comparator|Arm III: Abiraterone + Prednisone + Olaparib|Abiraterone 1000 mg orally once daily, prednisone 5 mg orally twice daily, olaparib 300 mg orally twice daily for days 1-28 in 28 day cycles.
89603025|NCT03012321|Active Comparator|Olaparib|Olaparib 300 mg orally twice daily for days 1-28 in 28 day cycles.
89603026|NCT03000101|Experimental|Pomegranate juice|The pomegranate juice is 100% pomegranate juice, not from concentrate.
89603027|NCT03000101|Placebo Comparator|Placebo beverage|The placebo beverage consists in water added with sugar and citric acid.
89603028|NCT02988895|Experimental|episcleral brachytherapy|single fraction of 24 Gy Strontium90 episcleral brachytherapy
89603029|NCT02985593|Experimental|KHK4083|IV/SC administration
89603030|NCT02985593|Placebo Comparator|Placebo|IV/SC administration
89603031|NCT02981888||IBS-C|all patients with IBS -C will undergo an abdominal x-ray for assessment of colonic transit
89032409|NCT00523562|Experimental|normal weight subjects high fat diet|"effects of diet intervention high fat in healthy male subjects"
89032410|NCT00523562|Experimental|Normal weight high fat+protein diet|"effect of diet intervention high fat + protein subjects in healthy male subjects"
89032411|NCT02930655|Experimental|Lucerastat group|Ten subjects with Fabry Disease received 1000 mg of oral lucerastat twice daily for 12 weeks in addition to their standard of care treatment (enzyme replace therapy).
89603032|NCT02981888||IBS-D|all patients with IBS-D will undergo an abdominal x-ray for assessment of colonic transit
89603033|NCT02981888||heathy control|all healthy controls will undergo an abdominal x-ray for assessment of colonic transit
89603034|NCT02975895|Other|Hydrophobic IOL: Vivinex (HOYA)|Intraocular lens with hydrophobic properties: Vivinex (HOYA).
89603035|NCT02975895|Other|Hydrophilic IOL: INCISE (Bausch+Lomb)|Intraocular lens with hydrophilic properties: INCISE (Bausch+Lomb).
89603036|NCT02943525|Experimental|packing|Patients after laparoscopic sacrocolpopexy with a vaginal packing at the end of surgery
89603037|NCT02943525|No Intervention|no packing|Patients after laparoscopic sacrocolpopexy without a vaginal packing at the end of surgery
89603038|NCT02934477||Hematopoietic Stem Cell Transplant (HCT)|Patients undergoing alloHCT in a US transplant center and reported to the CIBMTR
89603039|NCT02934477||Non-HCT|Historical non-transplant controls collected from 14 US academic centers. Centers will provide data on all consecutive patients with PMF, post-ET MF, or post-PV MF referred to their institutions between 2000 and 2012.
89603040|NCT02858921|Experimental|Sequential D + T, THEN Pembrolizumab|Dabrafenib 150mg orally twice a day + Trametinib 2mg orally once a day for 1 week, then followed by treatment with Pembrolizumab 2mg/kg delivered intravenously at weeks 1, 3, and 6, then once every 3 weeks from week 6 for 46 weeks.
89603041|NCT02858921|Experimental|Concurrent D + T AND Pembrolizumab|Dabrafenib 150mg orally twice a day + Trametinib 2mg orally once a day + Pembrolizumab 200mg intravenously once every 3 weeks for 6 weeks, the Pembrolizumab alone for 46 weeks
89603042|NCT02858921|Experimental|Pembrolizumab ONLY|Pembrolizumab 200mg intravenously once every 3 weeks alone for 52 weeks.
89032412|NCT02930655|Experimental|Control group|Four subjects with Fabry Disease under enzyme replace therapy (ERT) as standard of care treatment were included as a control group.
89032413|NCT04690803|Active Comparator|treatment with forced-air cooling|comparing treatment with and without forced-air cooling in a comparative lower extremity model
89032414|NCT04690803|No Intervention|treatment without forced-air cooling|comparing treatment without forced-air cooling in a comparative lower extremity model
89603043|NCT02836080|Experimental|Integrated Collaborative Care Team|Integrated Collaborative Care Team (ICCTs) are housed in the local community to improve youth access, in three neighborhoods across Toronto (East Metro Youth Services [EMYS]-Scarborough, EMYS-Southeast Toronto, and Delisle Youth Services-Central Toronto). Each ICCT will include a variety of service providers and coordinated patient care delivering evidence-informed interventions in a stepped-care model.
89603044|NCT02836080|Active Comparator|Treatment as Usual (TAU)|"The comparator arm consists of out-patient TAU in a hospital setting and will occur at one of four outpatient hospital sites across Toronto.~Partners include the following four hospitals: Hospital for Sick Children (SickKids), the Centre for Addiction and Mental Health (CAMH), Michael Garron Hospital (formerly the Toronto East General Hospital), and Sunnybrook Hospital."
89603045|NCT02764476|Experimental|Virtual Reality Therapy|Eight 30 minute sessions of embodied virtual reality therapy with use of a body transfer experience into an egocentric perspective avatar that encourages motor activity and desensitization to emotional cues.
89603046|NCT02764476|Active Comparator|Control|Eight 30 minute sessions of virtual reality therapy.
89603047|NCT02667951|No Intervention|Control group|Caregivers received general information on dementia care and follow-up phone calls simply to maintain contact, but without any training for developing a behavioral problem-management plan and strategies.
89603048|NCT02667951|Experimental|Intervention group|Caregivers received solutions for managing behavioral problems, with referrals to community services and telephone consultation, further assurance and consultation were provided in monthly telephone follow-ups, and progress in behavior management was evaluated.
89603049|NCT02645149|Experimental|A1. Non-V600 BRAF, BRAF wildtype, NRAS wildtype. Actionable gene mutation, matched drug available|Patients will receive targeted drug matched to the actionable gene mutation detected on NGS testing. If a patient cannot receive the matched targeted therapy because of the existence of one or more drug specific exclusion criteria, an alternative matched therapy may be assigned, or trametinib, or clinical trials if available.
89603050|NCT02645149|Experimental|A2. Non-V600 BRAF, BRAF wildtype, NRAS wildtype. Actionable gene mutation, no matched drug available|Patients may have an actionable aberration for which there is no current study-specific drug supply available. In this scenario, access will be sought for compassionate use of the relevant approved targeted therapy.
89603051|NCT02645149|Experimental|A3. Non-V600 BRAF, BRAF wild type and NRAS wild type melanoma - no actionable genetic aberration|Patients for whom there is no actionable genetic aberration will receive trametinib, based upon the known MAPK excess activity in the majority of melanomas that may be inhibited by a MEK inhibitor
89603052|NCT02645149|Experimental|B. Mucosal melanoma|Patients will receive combined trametinib and ribociclib based on evidence to suggest that combined MEK inhibition and CDK4/6 inhibition may be effective. After failure of trametinib and ribociclib, actionable genetic aberrations from the NGS testing will be reviewed for the opportunity to use a further targeted therapy off label.
89603053|NCT02645149|Experimental|C. NRAS mutant melanoma|Patients with an NRAS mutation detected on standard gene testing only will receive combined trametinib and ribociclib based on evidence that combining MEK inhibition and CDK4/6 inhibition is a viable treatment option.
89603054|NCT02645149|Other|D. BRAF V600 mutant melanoma|Patients will receive standard of care treatment only.
89603055|NCT02600429|Experimental|RGN-259|It is a preservative-free, sterile eye drop solution containing Tβ4
89603056|NCT02600429|Placebo Comparator|Placebo|It is composed of the same excipients as RGN-259 but does not contain Tβ4.
89603057|NCT02523859|Active Comparator|Propofol|Propofol for induction will be given as a bolus administered manually at 2.0-2.5 mg/kg slowly over approximately 1 minute. Immediately after the propofol bolus for induction has been given, propofol maintenance will be started at a dose of 3.0-9.0 mg/kg/hr and adjusted as needed.
89603058|NCT02523859|Experimental|Remimazolam|Remimazolam for induction will be given at 6.0 mg/kg/hr, which can be increased to 12.0 mg/kg/hr for one minute if loss of consciousness is not reached after 3 minutes. Immediately after the remimazolam dose for induction has been given, remimazolam maintenance will be given at 1.0 mg/kg/hr and adjusted by down-titration or up-titration to a maximum of 3.0 mg/kg/hr.
89603059|NCT02510625|Active Comparator|Bankart repair|Arthroscopic bankart repair
89603060|NCT02510625|Experimental|Anatomic Glenoid Reconstruction|Arthroscopic distal tibia bone graft
89603061|NCT02370329|Experimental|Treatment (PEG-proline-interferon alpha-2b)|Patients receive PEG-proline-interferon alpha-2b SC on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89603062|NCT02308358||Allograft Transplantation|Subjects with femoral condyle osteochondral defects ≥10mm, as determined by MRI or diagnostic knee arthroscopy, will be recruited for allograft transplantation.
89603063|NCT02308358||Microfracture Treatment|Subjects with femoral condyle osteochondral defects <10mm, as determined by MRI or diagnostic knee arthroscopy, will be recruited for microfracture treatment.
89603064|NCT02229422|Experimental|GA101/HDMP|"All subjects will receive GA101 - Obinutuzumab by IV infusion for up to 6 cycles (28-day cycles) as follow:~On Cycle 1, Day 1, 100 mg GA101-obinutuzumab will be administered.~On Cycle 1, Day 2, 900 mg of GA101-obinutuzumab will be administered.~On Cycle 1, Days 8 and 15, 1,000 mg of GA101-obinutuzumab will be administered.~On Cycles 2-6, Day 1, 1,000 mg of GA101-obinutuzumab will be administered.~All subjects will receive HDMP by IV infusion for up to 4 cycles (28-day cycles) as follow:~•On Cycle 1-4, Days 1 to 3, 1,000 mg/m2 Methylprednisolone will be administered."
89032415|NCT00523757|Experimental|1|Spironolactone
89032416|NCT00523757|Placebo Comparator|2|
89032417|NCT00524693|Active Comparator|1|4mg Singulair© sachets
89032418|NCT00524693|Placebo Comparator|2|
89032419|NCT02931201|Experimental|DLBCL patients with 18F-FDG PET/CT|18F-FDG PET/CT scans is to be evaluated using liver SUVmax-based criteria, Deauville 5-point criteria and reduction of SUVmax criteria
89603065|NCT02158793|Experimental|Face Transplant recipient|Single Arm study, all participants will receive Craniomaxillofacial allotransplantation
89603066|NCT02087865|Active Comparator|Donepezil HCL|Participants will receive 5mg of donepezil HCL for 4 weeks and then 10mg of donepezil HCL for 20 weeks.
89603067|NCT02087865|Placebo Comparator|Placebo|Participants will receive placebo for 24 weeks.
89603068|NCT02087865|No Intervention|Control Group|Participants without a family history of AD will undergo the study evaluations but will not receive any study drug
89603069|NCT01980823|Experimental|Metformin-Atorvastatin combination|Patients will receive metformin and atorvastatin for approximately 2 weeks prior to breast surgery.
89603070|NCT01972347|Experimental|Dabrafenib and Trametinib|Dabrafenib 150mg bid orally and Trametinib 2mg od orally for 52 weeks
89603071|NCT01942616|Experimental|Condition 1|"Each study arm contains different scenarios presented to the participant.~Condition 1 is a Perpetrator Positive scenario.~The content of the Condition 1 group is as follows:~Framing: Episodic Labeling: DV label Extraneous Information: Perpetrator positive non relevant Victim/Perp Characteristic: Negative victim"
89603072|NCT01942616|Experimental|Condition 2|"Each study arm contains different scenarios presented to the participant.~Condition 2 is a Perpetrator Negative scenario.~The content of the Condition 2 group is as follows:~Framing: Thematic Labeling: Assault label Extraneous Information: Perpetrator neutral non relevant Victim/Perp Characteristic: Negative Perpetrator"
89603073|NCT01942616|Placebo Comparator|Condition 3|"Each study arm contains different scenarios presented to the participant.~The content of the Condition 3 group is as follows:~Framing: Neither Labeling: No label Extraneous Information: None Victim/Perp Characteristic: None"
89603074|NCT01889992|Active Comparator|Cardiac biopsy C4D stain|A procedure that removes a very small sample of your heart muscle so that it can be evaluated in the lab. This procedure may be done to determine the cause of cardiac myopathy (a weakened heart muscle) or to check for rejection after a heart transplant.
89603075|NCT01889992|Experimental|Genetic Mechanism of M-TOR|"To identify the molecular and genetic mechanisms associated with development of early post-transplant CAR, and to evaluate the impact of mTOR-inhibitor Sirolimus on this process.~Sirolimus dosage is based on blood levels."
89603076|NCT01889992|Active Comparator|Cardiac MRI|Cardiac Magnetic Resonance Imaging (MRI) produces no side effects from the magnetic fields and radio waves and doesn't carry a risk of cancer or birth defects. Serious reactions to the special contrast dyes used for MRI are very rare. The MRI examination poses almost no risk to the average patient when appropriate safety guidelines are followed, however side effects are possible and include headache, nausea, dizziness, change in taste and allergic reaction. Such reactions usually are mild and easily controlled by medication.
88815031|NCT02246309|Experimental|Embryoscope Time Lapse System|All embryos from patients randomized to this arm will be cultured in the Embryoscope culture system from the time of insemination until the time of transfer on day 3. All staff interaction with the embryos or with maintenance or supervision of the system will be timed.
88815032|NCT02246309|Active Comparator|Standard Embryo Culture|All embryos from patients randomized to this arm will be cultured in the standard embryo culture system from the time of insemination until the time of transfer on day 3. All staff interaction with the embryos or with maintenance or supervision of the system will be timed.
88815033|NCT01680653|Experimental|Mini-Glucagon and Remote Monitoring|"Subjects glucose data are remotely monitored at night using the University of Virginia (UVA) Diabetes Assistant (DiAs) Android Platform. Study staff intervenes with a fingerstick blood glucose measurement when sensor value falls below 70mg/dL. If fingerstick value is less than 70 mg/dL, hypoglycemic treatment is administered as below.~Administer mini-glucagon as treatment for nocturnal hypoglycemia. Administer 0.01 cc per number of years in age via insulin syringe, subcutaneously. This amounts to 1 unit per age, for example: an 8 year old gets 8 units glucagon."
88815034|NCT01680653|Other|Carbohydrates and Remote Monitoring|"Subjects glucose data are remotely monitored at night using the University of Virginia (UVA) Diabetes Assistant (DiAs) Android Platform. Study staff intervenes with a fingerstick blood glucose measurement when sensor value falls below 70mg/dL. If fingerstick value is less than 70 mg/dL, hypoglycemic treatment is administered as below.~Administration of carbohydrate per camp protocol to treat nocturnal hypoglycemia. Expected treatment is 15-45g."
89032420|NCT00524732||1|18 to 30 months since last prior dose of TD/Td vaccine.
89032421|NCT00524732||2|30 to 42 months since last prior dose of TD/Td vaccine.
89032422|NCT00524732||3|42 to 54 months since last prior dose of TD/Td vaccine.
89032423|NCT00524732||4|54 to 66 months since last prior dose of TD/Td vaccine.
89603077|NCT01889992|Active Comparator|Coronary Angiography with IVUS|"Coronary angiography is a test that uses dye and special x rays to show the insides of your coronary arteries. The coronary arteries supply oxygen-rich blood to your heart.~Intravascular ultrasound is a test that uses sound waves to see inside blood vessels. This article discusses intravascular ultrasound to see inside the coronary arteries, the blood vessels that supply the heart."
88815035|NCT01680653|Other|Carbohydrates No Remote Monitoring|"Subjects wear a continuous glucose monitor for their own use, but they are not remotely monitored.~If hypoglycemia occurs and is acknowledged through standard camp protocol it will be treated with standard camp protocol administration of carbohydrates. Expected treatment is 15g-45g."
88815036|NCT01680653|Other|Mini-Glucagon and No Remote Monitoring|"Subjects wear a continuous glucose monitor for their own use, but they are not remotely monitored.~If hypoglycemia occurs and is acknowledged through standard camp protocol it will be treated with mini-glucagon.~Administer mini-glucagon as treatment for nocturnal hypoglycemia. Administer 0.01 cc per number of years in age via insulin syringe, subcutaneously. This amounts to 1 unit per age, for example: an 8 year old gets 8 units glucagon."
88815037|NCT02448810|Experimental|Part 1: Subjects with mutated tumor (mt) (KRAS or NRAS)|Subjects stratified according to their mutation status.
88815038|NCT02448810|Experimental|Part 1: Subjects with wild-type (wt) tumor (KRAS and NRAS wt)|Subjects stratified according to their mutation status.
88815039|NCT02448810|Experimental|Part 2: Subjects with KRAS or NRAS mutated|Subjects stratified according to their mutation status.
88815040|NCT02448810|Experimental|Part 2: Subjects with KRAS and NRAS wt tumor|Subjects stratified according to their mutation status.
88815041|NCT02448810|Active Comparator|Part 2: Standard of Care- Subjects with KRAS or NRAS mutated|Subjects stratified according to their mutation status.
89032424|NCT00524732||5|66 to 78 months since last prior dose of TD/Td vaccine.
89032425|NCT00524732||6|78 to 90 months since last prior dose of TD/Td vaccine.
89032426|NCT00524732||7|90 to 102 months since last prior dose of TD/Td vaccine.
89032427|NCT00524732||8|102 to 114 months since last prior dose of TD/Td vaccine.
89032428|NCT00524732||9|Control - over 114 months since last prior dose of TD/Td vaccine.
89603078|NCT01889992|Active Comparator|Cardiopulmonary Exercise Test (CPET)|Is a highly sensitive, non-invasive stress test. It is considered a stress test because the exercise stresses your body's systems by making them work faster and harder. A disease or condition that affects the heart, lungs or muscles will limit how much faster and harder these systems can work. A CPET assesses how well the heart, lungs, and muscles are working individually, and how these systems are working in unison. Your heart and lungs work together to deliver oxygen to your muscles, where it is used to make energy, and to remove carbon dioxide from your body.
89603079|NCT01889992|Experimental|MTor Immunosuppression|"Sirolimus~Sirolimus dosage is based on blood levels.~To assess the potential of mTOR immunosuppressant Sirolimus in attenuation of CAR in HTx recipients and therefore, improve pre-existing cardiac allograft function, vasculopathy, and exercise capacity."
89603080|NCT01889992|Experimental|Cardiac Allograft Remodeling|A surgical procedure in wich a diseased heart is replaced with a healthy heart from a deceased person.
89603081|NCT01885767||NF1|Patients meeting clinical and/or genetic criteria for Neurofibromatosis 1
89603082|NCT01885767||NF2|Patients meeting clinical and/or genetic criteria for Neurofibromatosis 2
89603083|NCT01885767||SchW|Patients meeting clinical and/or genetic criteria for Schwannomatosis
89603084|NCT01858740|Experimental|Treatment (CD45RA+ T cell depleted PBSCT)|"CONDITIONING REGIMEN: Patients undergo TBI BID on days -10 to -7, receive thiotepa IV over 4 hours on days -6 and -5 and fludarabine phosphate IV over 30 minutes on days -6 to -2.~TRANSPLANT: Patients undergo CD34+ enriched, CD45RA+ T cell-depleted allogeneic PBSCT on day 0.~POST-TRANSPLANT IMMUNOSUPPRESSION: Patients receive tacrolimus IV continuously or PO every 12 hours beginning on day -1 and continuing through day 50 with taper. Patients also receive methotrexate IV on days 1, 3, 6, and 11."
88811452|NCT01327157|Experimental|Occlusal adjustment|In all consultations, was performed VAS and occlusal adjustment. Three sessions of intervention are doing. The Gnathostatic models were performed in the first and last query. To reach a terminal axis of rotation of the jaw the patient to perform the act of swallowing for 3 times, and after palpation of the muscles, masseter and temporal on both sides and compared with the marks of carbon found in the teeth and started the adjustment following the rules of Guichet with a cylindrical drill with a thin cut.. The rules to guide the occlusal adjustment selective grinding were in this sequence: Occlusal adjustment to the centric relation: with sliding towards anterior; with sliding towards the medium line; with sliding opposite to the medium line; No sliding.
89032429|NCT02930772|Experimental|BAY987516|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
89032430|NCT04693481|Experimental|experimental group: 5 seconds for each photo|receive the intervention, which is viewing each nature photo for 5 seconds
89032431|NCT04693481|Experimental|experimental group: 15 seconds for each photo|receive the intervention, which is viewing each nature photo for 15 seconds
89032432|NCT04693481|Experimental|experimental group: 30 seconds for each photo|receive the intervention, which is viewing each nature photo for 30 seconds
89032433|NCT04693481|No Intervention|control group|not receive the intervention, which is viewing each nature photo for 0 seconds.
89032434|NCT02930382|Experimental|BAROREFLEX|
89032435|NCT02947724|No Intervention|drainage only|50 patients underwent laparoscopic fenestration and electrocautery of the endometrioma cyst wall
89032436|NCT02947724|No Intervention|cystectomy only|50 patients underwent laparoscopic excision of the endometrioma cyst wall
89032437|NCT02947724|Active Comparator|drainage & Surgicel|50 patients underwent laparoscopic fenestration of the endometrioma cyst wall. Insertion of 4 pieces of SURGICEL® inside the cyst cavity
89032438|NCT02947724|Active Comparator|cystectomy & Surgicel|50 patients underwent laparoscopic excision of the endometrioma cyst wall. Insertion of 4 pieces of SURGICEL® inside the remaining ovarian tissues.
89032439|NCT00523835||KS|Patients with Klinefelter syndrome verified by chromosome analysis
89032440|NCT00523835||Normal|Normal men Age matched to KS patients
89032441|NCT02936583|Experimental|BAY987521|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
89603085|NCT01839734|Experimental|Lubiprostone|4 weeks of treatment with lubiprostone 24 mcg by mouth (PO) once-daily (Interventional Group)
89603086|NCT01839734|No Intervention|No intervention|No intervention
89603087|NCT01682083|Experimental|Dabrafenib and trametinib|Subjects received dabrafenib (150 mg twice daily) and trametinib (2 mg once daily) orally for 12 months.
89603088|NCT01682083|Placebo Comparator|Dabrafenib and trametinib placebos|Subjects received matching placebos orally for 12 months
89603089|NCT01511068|Experimental|Inhaled Leukine (rhGM-CSF)|Inhaled recombinant human GM-CSF in individuals with hereditary Pulmonary Alveolar Proteinosis (hPAP) due to partial dysfunction of the GM-CSF receptor
89603090|NCT01180790|Experimental|Segment 1: 200 milligrams (mg) ACH-0141625|200 mg ACH-0141625 for 28 days plus pegylated interferon (Peg-IFN) alpha-2a and ribavirin (RBV) for 48 weeks
89603091|NCT01180790|Experimental|Segment 1: 400 mg ACH-0141625|400 mg ACH-0141625 for 28 days plus Peg-IFN alpha-2a plus RBV for 48 weeks
89603092|NCT01180790|Experimental|Segment 1: 800 mg ACH-0141625|800 mg ACH-0141625 for 28 days plus Peg-IFN alpha-2a plus RBV for 48 weeks
89603093|NCT01180790|Placebo Comparator|Segment 1: Placebo|Placebo for 28 days plus Peg-IFN alpha-2a plus RBV for 48 weeks
89603094|NCT01180790|Experimental|Segment 2: 200 mg ACH-0141625|200 mg ACH-0141625 for 12 weeks plus Peg-IFN and RBV for up to a total of 24 or 48 weeks
89603095|NCT01180790|Experimental|Segment 2 : 400 mg ACH-0141625|400 mg ACH-0141625 for 12 weeks plus Peg-IFN and RBV for up to a total of 24 or 48 weeks
89603096|NCT01180790|Experimental|Segment 2 : 800 mg ACH-0141625|800 mg ACH-0141625 for 12 weeks plus Peg-IFN and RBV for up to a total of 24 or 48 weeks
89603097|NCT00798122|Experimental|Women|IVUS and MRI performed in women with no obstructive CAD at angiography
89603098|NCT00792675|Experimental|Exercise|Exercise consists of 30 minutes of treadmill exercise at approximately 85% of heart rate max and 2 sets of 6 resistance weight lifting exercises resulting in volitional fatigue at 12 to 15 repetitions.
89603099|NCT00721526|Experimental|Disulfiram plus lorazepam|Disulfiram plus lorazepam
89603100|NCT00679042|Experimental|Treatment|All subjects will receive up to 3 transplantations of allogeneic human islets of Langerhans.
89603101|NCT00589459||1|non-diabetic women with acute coronary syndrome (ACS)
89603102|NCT00589459||2|non-diabetic men with acute coronary syndrome (ACS)
89603103|NCT00588874||1|men 50 yrs of age or older
89603104|NCT00505063|Other|A|Immunization Schedule patients <7 years.
89603105|NCT00505063|Other|B|Immunization Schedule patients > or = to 7 years and <11 years of age
88811453|NCT00802880|Experimental|Dacarbazine|Dacarbazine 850 mg/m^2 IV Day 1 of each 21 day cycle.
88811454|NCT04814186|Experimental|Chinese participants treated with Tafamidis|treatment group with tafamidis
88811455|NCT04382378|No Intervention|control group|Group that will receive a standard care from physiotherapy staff not involved in delivering the intervention whenever feasible.
88811456|NCT04382378|Experimental|50 electrically evoked contractions|Group that will receive a standard care from physiotherapy staff plus neuromuscular electrical stimulation with the following parameters: pulsed current; freqeuncy 50Hz; pulse witdh 400 us, current intensity that get level 4/5 of evoked contractions proposed by Segers et al; on/off time and duration of therapy that allow 50 ellectrically evoked contractions with surface electrodes positioned on the quadriceps femoris.
88981162|NCT04419272|Other|Open-Label Methylphenidate|All subjects will be offered open-label methylphenidate during Weeks 9-16. the dosage of MPH will begin at 10mg twice per day, at 8am and 12pm, for one week. The dosage will then increase to 20mg twice daily, at 8am and 12pm, for the next 7 weeks.
88981163|NCT04412668|Experimental|Efzofitimod 1 mg/kg|Participants will receive single dose of efzofitimod 1 milligrams/kilograms (mg/kg) IV infusion on Day 1.
88981164|NCT04412668|Experimental|Efzofitimod 3 mg/kg|Participants will receive single dose of efzofitimod 3 mg/kg IV infusion on Day 1.
88981165|NCT04412668|Placebo Comparator|Placebo|Participants will receive placebo matched to efzofitimod IV infusion on Day 1.
88981166|NCT04409314||Diagnostic (18F-FAZA PET scan)|Prior to CAR T-cell therapy, patients receive administration of 18F-FAZA IV. Patients will then undergo a vertex-thigh PET scan approximately 2 hours after injection of 18FFAZA lasting 30-45 minutes.
88981167|NCT04406441|No Intervention|Standard of Care|Participants will attend regularly scheduled well child visits (WCV) that follow standard clinical guidelines. Well child visits will include review of history, age-appropriate measurements (height/length, weight, body mass index (BMI), blood pressure), sensory and developmental screenings, physical exam, immunizations, oral health review, and anticipatory guidance (preventive counseling).
88981168|NCT04406441|Active Comparator|Patient Reported Outcome|Arm 2 builds on the standard of care WCV by adding a patient reported outcome measure, the Family Nutrition and Physical Activity risk assessment, to inform family-centered preventative counseling during clinical care.
89603106|NCT00505063|Other|C|Immunization Schedule patients > or = to 11 years of age
89603107|NCT00350272|Experimental|Elvucitabine, Efavirenz, Tenofovir|"Elvucitabine (blinded) 10 milligrams (mg)/day in combination with open-label efavirenz 600 mg daily and open-label tenofovir 300 mg daily, all administered orally, over 12 weeks. Eligible participants continued with an additional 84 weeks of open-label treatment (through Week 96).~Participants who experienced at least a 2 log10 decrease in HIV-1 RNA from Baseline or who had an HIV-1 RNA level of less than 400 copies/ mL at Week 10 and had not experienced any Grade 3 or 4 hematological toxicity as of the Week 10 measurement were considered eligible for an additional 84 weeks of open-label treatment after Week 12."
89603108|NCT00350272|Active Comparator|Lamivudine, Efavirenz, Tenofovir|"Lamivudine (blinded) 300 mg daily in combination with open-label efavirenz 600 mg daily and open-label tenofovir 300 mg daily, all administered orally, over 12 weeks. Eligible participants continued with an additional 84 weeks of open-label treatment (through Week 96).~Participants who experienced at least a 2 log10 decrease in HIV-1 RNA from Baseline or who had an HIV-1 RNA level of less than 400 copies/mL at Week 10 and had not experienced any Grade 3 or 4 hematological toxicity as of the Week 10 measurement were considered eligible for an additional 84 weeks of open-label treatment after Week 12."
89603109|NCT02028884|Experimental|Satralizumab + Baseline Treatment|Participants randomized to this arm for the double-blind period will receive satralizumab in addition to baseline treatment. The double-blind period ends when either the participant has a treated relapse or the total number of protocol-defined relapses confirmed by the Clinical Endpoint Committee (CEC) reaches 26. In the open-label extension period, the participant will receive (with or without baseline treatment) an SC injection of satralizumab at Weeks 0, 2, and 4, and Q4W thereafter, with the last study drug administration on or before 31 December 2021.
89603110|NCT02028884|Placebo Comparator|Placebo + Baseline Treatment|Participants randomized to this arm for the double-blind period will receive placebo in addition to baseline treatment.The double-blind period ends when either the participant has a treated relapse or the total number of protocol-defined relapses confirmed by the Clinical Endpoint Committee (CEC) reaches 26. In the open-label extension period, the participant will receive (with or without baseline treatment) an SC injection of satralizumab at Weeks 0, 2, and 4, and Q4W thereafter, with the last study drug administration on or before 31 December 2021.
89603111|NCT02020694|Experimental|Vitamin D and Diet|"Cholecalciferol (vitamin D3) 25,000 I.U./2.5 mL oral solution. 25,000 I.U. (one bottle) per week.~Hypocaloric diet"
89603112|NCT02020694|Placebo Comparator|Placebo & Diet|"Oral solution mimicking cholecalciferol (vitamin D3) 25,000 I.U./2.5 mL. One bottle per week.~Hypocaloric diet"
89603113|NCT02019875|Placebo Comparator|Water|200 mL of water once a day for 14 days
89603114|NCT02019875|Active Comparator|Rifampin|Rifampin 600 mg once a day for 14 days
89603115|NCT02019875|Active Comparator|Grapefruit Juice|200 mL of grapefruit juice once a day for 14 days
89603116|NCT02019875|Active Comparator|Grapefruit Juice Plus Rifampin|200 mL of grapefruit juice once a day for 8 days plus rifampin 600 mg once a day for 14 days
88981169|NCT04406441|Active Comparator|Patient Reported Outcome + Food Care|Participants will receive all Arm 2 components, in addition to be referred to both the Geisinger Wellness Program for a Parent Training Program and a grocery store nutritionist for a tour aligned with the Cooking Matters program.
89603117|NCT02019875|Active Comparator|Clarithromycin|Clarithromycin 250 mg twice a day for 14 days
89603118|NCT02019875|Active Comparator|Clarithromycin Plus Rifampin|Clarithromycin 250 mg twice a day for 14 days plus rifampin 600 mg once a day for 14 days
88981170|NCT04400175|Experimental|B-ESP|B-ESP group will be fed with a feeding system with a valved ergonomic teat.
88981171|NCT04400175|Sham Comparator|B-STD|B-STD will be fed with a standard feeding system.
89603119|NCT01907009|Experimental|Registration.|"MELCAP study has only one arm. All suitable patients will receive 3 cycles of melphalan and lenograstim alternately.~Patient will start with a 3 day lenograstim (at 10mcg/kg/day) to boost up the blood cell count.~Upon reaching sufficient blood cell count, patients will undergo a venesection and roughly a pint of blood is taken. After this patients will receive first cycle of Melphalan (60mg/m2). The following day patient will receive back the previously given whole blood. A treament break of 6 days between the cycles is given. After the break the patient will be given Lenograstim (10mcg/kg/day)for 6 days (until sufficient).~The above regimen is repeated for cycle 2 and cycle 3 with only exception of Melphalan is given at 40mg/m2. After the cycle 3, Lenograstrim is given at 263 mcg/day for 10 days.~Upon treatment completion, patients will be followed for 2 years. If the patients show disease progression, they will start hormone therapy."
89603120|NCT01882933|Experimental|Curative Gastrectomy + HIPEC|Curative gastrectomy with D1-D2 lymph node dissection + HIPEC with oxaliplatin
89603121|NCT01882933|Other|Curative Gastrectomy|Curative gastrectomy with D1-D2 lymph node dissection
89603122|NCT01821976|Active Comparator|Ertl Procedure|Patients randomized to the Ertl Procedure Arm will receive an amputation very similar to the Burgess Procedure, except the surgeon will perform an additional step to make the cut end of the tibia bone heal to the cut end of the fibula bone with a bone bridge. This bone bridge connects the two bones together.
89603123|NCT01821976|Active Comparator|Burgess Procedure|Patients randomized to the Burgess Procedure Arm will receive a below the knee amputation where the bone is cut and skin and muscle from the back of the leg are rotated to cover the cut end of your bone. This provides good soft tissue padding to the bone and a good shape to the leg for later fitting of your prosthesis.
88981172|NCT04377009|Experimental|Active CBT-I|Internet-guided cognitive behavioral therapy
88981173|NCT04377009|Other|Control|Education control program
89603124|NCT01787929|Other|Cemented hemiarthroplasty|hemiarthroplasty surgery with cement for displaced femoral neck fractures
89603125|NCT01787929|Other|Uncemented hemiarthroplasty|hemiarthroplasty surgery without cement is a surgery for displaced femoral neck fractures
89603126|NCT01778738|Experimental|Sleeve gastrectomy|Sleeve gastrectomy.
89603127|NCT01778738|Experimental|Gastric bypass|Gastric bypass surgery.
89603128|NCT01778738|No Intervention|Control group|This is an extra control group without diabetes. All subjects are morbidly obese patients recruited from the Morbid Obesity Centre.
89603129|NCT01744145|Active Comparator|Interventional 40-60|Interventional group aged 40-60
88981174|NCT04376255|Experimental|Mixed Reality Simulation|Participants in the experimental arm will be introduced to workplace training modules through an Augmented Reality (AR) headset.
88981175|NCT04362358|Experimental|7 sessions of the online CBT programme|
89603130|NCT01744145|No Intervention|Control 40-60|Control group aged 40-60
89603131|NCT01744145|Active Comparator|Interventional 60 and above|Interventional group aged 60 and above
89603132|NCT01744145|No Intervention|Control 60 and above|Control group aged 60 and above
89603133|NCT01713062||Vitelene|Plasmacup DC® with Vitelene® inlay manufactured by UHMWPE-XE (Ultra High Molecular Weight Polyethylene highly cross-linked with 0.1% Vitamin E) in combination with one of four different Aesculap® stems (Bicontact®, TRJ®, Metha®, Excia®)
89603134|NCT01713062||XLPE|Plasmacup DC® with a standard polyethylene inlay manufactured by UHMWPE-X (Ultra High Molecular Weight Polyethylene highly cross-linked) in combination with one of four different Aesculap® stems (Bicontact®, TRJ®, Metha®, Excia®)
89603135|NCT01686126|Experimental|Mirena + Metformin|Metformin tablets, 500mg twice daily orally, 6 months Levonorgestrel (Mirena®) 52mg Intrauterine drug delivery system, 6 months
89603136|NCT01686126|Experimental|Mirena|Levonorgestrel (Mirena®) 52mg Intrauterine drug delivery system, 6 months
89603137|NCT01686126|Experimental|Mirena + Weight Loss Intervention|Levonorgestrel (Mirena®) 52mg Intrauterine drug delivery system, 6 months Weight Loss Intervention will be delivered via Weight Watchers
88981176|NCT04362358|Active Comparator|Bibliotherapy|
88981177|NCT04360551|Experimental|Telmisartan|Telmisartan 40 mg po daily x 21 days
88981178|NCT04360551|Placebo Comparator|Placebo|Placebo
88981179|NCT04354675|Experimental|Artificial intelligence program|Will complete consult with the use of an artificial intelligence program Chatbot.
88981180|NCT04354675|Active Comparator|in-person genetic counseling|Will complete a traditional in-person genetic counseling. consult by meeting with a Genetics Counselor
88981181|NCT04348123|Experimental|Outreach educational program|"Participants will be given a survey to elucidate beliefs and barriers around breast health and mammography.~A brief, culturally-appropriate educational session about breast health and mammography will follow and will be delivered by a female public health educator.~After education, eligible women will be offered a free on-site mammogram"
88981182|NCT04344769||Patients with a previous diagnosis of ADPKD|Patients that have been diagnosed with ADPKD and meet the study's inclusion criteria
88981183|NCT04344769||Healthy individuals as controls|Age and gender-matched healthy controls
88981184|NCT04334590||Cleft Lip/Nose Repair without PSIO|Participants who will undergo cleft lip/nose repair prior to addition of PSIO as part of standard of care in Hopkins.
89603138|NCT01588041||Vitreoretinal Interface Disease Group|A minimum of 50 subjects with vitreoretinal interface disease will be imaged with MIOCT prior to surgery, during surgical maneuvers, during a normal pause in surgery, and at 2 post-operative follow-up visits.
89603139|NCT01588041||Macular Hole Group|A minimum of 50 subjects with macular hole with be imaged with MIOCT prior to surgery, during surgical maneuvers, during a normal pause in surgery, and at 2 post-operative follow-up visits.
89603140|NCT01588041||Retinal Detachment Group|A minimum of 50 subjects with retinal detachment will be imaged with MIOCT prior to surgery, during surgical maneuvers, during a normal pause in surgery, and at 2 post-operative follow-up visits.
89603141|NCT01588041||Diabetic Retinopathy Group|A minimum of 50 subjects with diabetic retinopathy will be imaged with MIOCT prior to surgery, during surgical maneuvers, during a normal pause in surgery, and at 2 post-operative follow-up visits.
89603142|NCT01588041||Rare Related Macular Disease Group|Up to 70 subjects with rare related macular diseases will be imaged with MIOCT prior to surgery, during surgical maneuvers, during a normal pause in surgery, and at 2 post-operative follow-up visits.
89603143|NCT01588041||Generation 2 MIOCT Transition Group|80 of the subjects recruited in years 1 through 5 (40 normal, 40 diseased) will be imaged with both the generation 1 MIOCT and the generation 2 MIOCT systems prior to surgery, during surgical maneuvers, during a normal pause in surgery, and at 2 post-operative follow-up visits.
89603144|NCT01588041||Endothelial Keratoplasty Group|150 subjects undergoing Descemet Stripping Endothelial Keratoplasty (DSEK) will be imaged with MIOCT at the conclusion of the surgical procedure and may be imaged during follow-up visits.
89603145|NCT01588041||Anterior Lamellar Keratoplasty Group|150 subjects undergoing Deep Anterior Lamellar Keratoplasty (DALK) will be imaged with MIOCT at the conclusion of the surgical procedure and may be imaged during follow-up visits.
89603146|NCT01531582|Experimental|Children with Angelman Syndrome|Children with a molecularly confirmed diagnosis of Angelman Syndrome meeting the protocol requirements will be selected randomly. All participants will receive the study drug, minocycline, over an identical time course. Participants will undergo identical baseline, 8 and 16 week follow up assessments.
89603147|NCT01512888|Experimental|Treatment|Participants will undergo a bone marrow harvest in the operating room to obtain bone marrow cells. Cells will be isolated and purified utilizing the CliniMacs device. These cells will undergo vector transduction with the lentiviral vector that contains a normal copy of the γc gene gene (CL20-i4-EF1α-hγc-OPT) and then the transduced cells will be reinfused back into the patient. Participants will receive a conditioning regimen of busulfan 3 days prior and 2 days prior to infusion of vector-corrected cells.intervention: CL20-i4-EF1α-hγc-OPT
89603148|NCT01500733|Experimental|Elderly greater than 65|
89603149|NCT01500733|Experimental|17p Deletioin|
89603150|NCT01493453|Experimental|Single Arm - aCD19z cells, interleukin 2, Chemotherapy|
89603151|NCT01436864|Experimental|0.5 mg KH902|Patients will receive intravitreal injection of KH902 0.5mg/eye once per month for three times in the study eye, and then patients will receive 2 sham injections monthly, respectively, at the end of month 3 (visit 5), and following these injections you will receive intravitreal injection of KH902 once every three months, till month 12 (respectively at month 5, month 8 and month 11)
89603152|NCT01436864|Sham Comparator|Sham-injection|Patients will receive sham injection once per month for three times, and then you will receive intravitreal injection of KH902 0.5mg/eye once per month for three times in the study eye, after three months' treatment they will receive intravitreal injection of KH902 once every three months, till month 12 (respectively at month 8 and month 11.
89603153|NCT01422187|Experimental|Taliglucerase alfa 30 units/kg|Subjects randomized to receive 30 units/kg
89603154|NCT01422187|Experimental|Taliglucerase alfa 60 units/kg|Subjects randomized to 60 units/kg
89603155|NCT01191775|Experimental|PNT2258|PNT2258 is composed of PNT100, a 24-mer oligonucleotide, the active drug substance encapsulated in a liposome.
89603156|NCT01116765|Experimental|experimental group|Infants in the experimental group receive an oral stimulation program consisting of stimulation of the oral structures during 10 consecutive days
89603157|NCT01116765|Other|control group|Infant in the control group receive no stimulation only non nutritive sucking during feeding
88811457|NCT04382378|Experimental|100 electrically evoked contractions|Group that will receive a standard care from physiotherapy staff plus neuromuscular electrical stimulation with the following parameters: pulsed current; freqeuncy 50Hz; pulse witdh 400 us, current intensity that get level 4/5 of evoked contractions proposed by Segers et al; on/off time and duration of therapy that allow 100 ellectrically evoked contractions with surface electrodes positioned on the quadriceps femoris.
88811458|NCT04932824|No Intervention|Subjects Without Treatment Cross-over|these subjects will not receive any vaccination during this study.
89603158|NCT01041989|No Intervention|Standard health counseling at baseline|
89603159|NCT01041989|Experimental|Lifestyle counseling|Multi-domain lifestyle counseling including nutritional guidance, increased physical activity, cognitive training, increased social activity and intensive monitoring of vascular and metabolic risk factors.
89603160|NCT00843375||Higher risk, no neoplasia|"Negative study colonoscopy and one or more of the following:~Subjects with a personal history of adenomas (confirmed by pathology) with none present on qualifying colonoscopy~Subjects with a personal history of colorectal cancer (CRC) (longer than 3 years ago because of exclusion criteria of cancer within last 3 years) with none present at time of qualifying colonoscopy~Any family history of CRC (1st degree relative)~Current positive screening stool test for blood, for DNA or for both within 12 months with no follow up intervention"
89603161|NCT00843375||Adenoma|"Pathologically confirmed adenomas, both non-advanced adenoma and advanced. Advanced adenoma includes any of the following:~Sessile serrated adenoma~Tubulovillous adenoma~Villous adenoma~Sessile serrated polyp/adenoma~Traditional serrated adenoma~Any adenoma ≥1 cm"
89603162|NCT00843375||Colorectal adenocarcinoma|Pathologically confirmed colorectal cancer either present at time of stool collection or discovered during colonoscopy
89603163|NCT00843375||Average risk, no neoplasia|"No neoplasia found at colonoscopy and:~No prior history of adenomas or sessile serrated adenomas~No prior history of CRC~No first degree family history of CRC~Negative colorectal cancer screening test (if performed) for blood, for DNA or for both within 12 months."
89603164|NCT00734487||1. AREDS2 subjects|Subjects enrolled in the AREDS2 clinical trial with a diagnosis of age-related macular degeneration.
89603165|NCT00734487||2. Controls|Age-matched subjects without retinal pathology
89603166|NCT00667199|Experimental|Radium-223 dichloride (Xofigo, BAY88-8223)-5kBq/kg|"Each patient received a single injection of radium-223 , based on the randomised dose level (5kBq/kg) and individual body weight.~A second injection of radium-223 set to 50 kBq/kg b.w. could be offered to patients in the Follow-up Period at the discretion of the investigator."
89603167|NCT00667199|Experimental|Radium-223 dichloride (Xofigo, BAY88-8223)-25 kBq/kg|"Each patient received a single injection of radium-223 , based on the randomised dose level (25kBq/kg) and individual body weight.~A second injection of radium-223 set to 50 kBq/kg b.w. could be offered to patients in the Follow-up Period at the discretion of the investigator."
89603168|NCT00667199|Experimental|Radium-223 dichloride (Xofigo, BAY88-8223)-50 kBq/kg|"Each patient received a single injection of radium-223 , based on the randomised dose level (50kBq/kg) and individual body weight.~A second injection of radium-223 set to 50 kBq/kg b.w. could be offered to patients in the Follow-up Period at the discretion of the investigator."
89603169|NCT00667199|Experimental|Radium-223 dichloride (Xofigo, BAY88-8223)-100 kBq/kg|"Each patient received a single injection of radium-223 , based on the randomised dose level (100kBq/kg) and individual body weight.~A second injection of radium-223 set to 50 kBq/kg b.w. could be offered to patients in the Follow-up Period at the discretion of the investigator."
89603170|NCT00605982|Experimental|1|Women with core biopsy proven DCIS with or without microinvasion seen for surgical consultation at Memorial Sloan-Kettering Cancer Center and for whom operative intervention is planned.
89603171|NCT00537225|Experimental|A-Exercise group|Home based exercise
89603172|NCT00537225|No Intervention|B- Usual Care|Exercise as usually prescribed by provider
89603173|NCT00472212|Experimental|Spectacles|Spectacles with hyperopic lenses
89603174|NCT00472212|Placebo Comparator|Control|Spectacles with placebo lenses
89603175|NCT00139477|Experimental|Diet/Exercise only, then Diet/Exercise plus Metformin|Diet/Exercise only in first intervention period and Diet/Exercise plus Metformin in second intervention period (no washout period).
89603176|NCT00139477|Active Comparator|Diet/Exercise plus Metformin, then Diet/Exercise only|Diet/Exercise plus Metformin in first intervention period and Diet/Exercise only in second intervention period (no washout period).
89603177|NCT00004935|Active Comparator|Herceptin™ (Her)|Herceptin™ (Her) loading dose 4 mg/kg iv, followed by 2 mg/kg iv weekly or loading dose 8 mg/kg iv, followed by 6 mg/kg iv every 3 weeks; at time of progression add chemotherapy
89603178|NCT00004935|Active Comparator|Herceptin™+Chemo|Herceptin™ (Her) loading dose 4 mg/kg iv, followed by 2 mg/kg iv weekly or loading dose 8 mg/kg iv, followed by 6 mg/kg iv every 3 weeks, and chemotherapy
89603179|NCT00119158|Placebo Comparator|placebo|Placebo cream
89603180|NCT00119158|Active Comparator|pimecrolimus cream|
89603181|NCT00119392|Experimental|Treatment (90Y ibritumomab tiuxetan, hematopoietic transplant)|See Detailed Description
89603182|NCT04410484||1|Admitted patients with IBD (with IBD OR due to COVID) whether tested or not tested for COVID between 1st March and 30th June 2020
89603183|NCT04410484||2|Patients with IBD self-isolating with suggestive COVID19 symptoms (Fever or persistent Cough) or tested positive for COVID19 during same period
89603184|NCT04410484||3|Patients with active IBD identified during the same study period. (definition: increased symptoms suggestive of flare, raised calprotectin, raised CRP, endoscopy or imaging during the previous 6 weeks showing active disease and contacted/reviewed during the study period , admission with IBD ( These will be identified through your helpline/ virtual clinics/Hot clinics/flare lines
89603185|NCT04410484||Control Group|Consecutive patients with active IBD between 1st March 2019-30th June 2019
88981185|NCT04334590||Presurgical Infant Orthopedic Therapy|Participants who will undergo cleft lip/nose repair after addition of PSIO as part of standard of care in Hopkins.
88981186|NCT04314934|Experimental|Active|ANAVEX2-73
88981187|NCT04310826|Experimental|Prevention (dietary intervention)|Patients receive a dietary magnesium intervention consisting of a food reference list and phone calls or video interviews from a registered dietitian, integrative medicine physician, or a mid-level provider over 10-20 minutes once a week for up to the 6th cycle of chemotherapy (average 15 weeks).
89603186|NCT00218062|Experimental|D-Amphetamine 60mg + Therapy|"During the 16 weeks of outpatient treatment, participants took three capsules daily (two in the morning, one in the afternoon). All active and placebo capsules were identical in appearance and each contained 50mg riboflavin for subsequent evaluation of medication compliance. Medication administration was initiated during a 5 day run-up period. d-Amphetamine sustained release (SR) (Dexedrine Spansules) started at 15 mg (day 1-2), increased to 30mg (day3; 15mg, BID), 45mg (day4; 15mg, TID), and 60mg (day5; 15mg bid plus 30mg qd). A 5-day dose reduction schedule occurred at week 17.~Manual-based, cognitive-behavioral therapy was provided for 1 hour each week by master's-level therapists. The cognitive-behavioral therapy emphasized relapse prevention and coping skills."
88981188|NCT04304482|Experimental|ANAVEX2-73 Active|ANAVEX2-73 liquid oral solution
88981189|NCT04304482|Placebo Comparator|ANAVEX2-73 Placebo|Placebo liquid oral solution
88981190|NCT04300946||TMS on the cerebellum followed by placebo TMS|TMS preceding the time prediction and language tests
88981191|NCT04300946||Placebo TMS followed by TMS on the cerebellum|TMS preceding the time prediction and language tests
88981192|NCT04300946||TMS on the cerebellum set in time on waiting periods|
88981193|NCT04300946||TMS on the cerebellum not set in time on waiting periods|
88981194|NCT04299087|Experimental|Dystonia and/or tremor|Adults with a diagnosis of dystonia and/or tremor
88981195|NCT04299087|Experimental|Control|Healthy adults without a history of any neurological disorder, with a similar age distribution and sex ratio as the dystonia and/or tremor group
88981196|NCT04293653|Experimental|Care bundle|Patients above 75 years where emergency surgery is indicated, deemed fit for surgery, will be included in a perioperative care-bundle. While waiting for surgery, patients will be monitored and optimized if their condition deteriorates. Antibiotics will be administered if indicated. Surgery will be delivered within 2h to 72h, depending on the suspected abdominal pathology and the patient's clinical condition.
89603187|NCT00218062|Experimental|Modafinil 400mg + Therapy|"During the 16 weeks of outpatient treatment, participants took three capsules daily (two in the morning, one in the afternoon). All active and placebo capsules were identical in appearance and each contained 50mg riboflavin for subsequent evaluation of medication compliance. Medication administration was initiated during a 5 day run-up period. Modafinil started at 200mg (day1) and increased to 400mg (days2-5). A 5-day dose reduction schedule occurred at week 17.~Manual-based, cognitive-behavioral therapy was provided for 1 hour each week by master's-level therapists. The cognitive-behavioral therapy emphasized relapse prevention and coping skills."
89603188|NCT00218062|Experimental|Modafinil 200mg + D-Amphetamine 30mg + Therapy|"During the 16 weeks of outpatient treatment, participants took three capsules daily (two in the morning, one in the afternoon). All active and placebo capsules were identical in appearance and each contained 50mg riboflavin for subsequent evaluation of medication compliance. Medication administration was initiated during a 5 day run-up period. For the combination condition, dosages of modafinil and d-amphetamine were escalated to one-half of that for the single medication conditions. A 5-day dose reduction schedule occurred at week 17.~Manual-based, cognitive-behavioral therapy was provided for 1 hour each week by master's-level therapists. The cognitive-behavioral therapy emphasized relapse prevention and coping skills."
89603189|NCT00218062|Placebo Comparator|Placebo + Therapy|"During the 16 weeks of outpatient treatment, participants took three capsules daily (two in the morning, one in the afternoon). All active and placebo capsules were identical in appearance and each contained 50mg riboflavin for subsequent evaluation of medication compliance.~Manual-based, cognitive-behavioral therapy was provided for 1 hour each week by master's-level therapists. The cognitive-behavioral therapy emphasized relapse prevention and coping skills."
89603190|NCT00121186|Experimental|Nonmyeloablative allogeneic stem cell transplant|Patients are given fludarabine 30 mg/m^2 on days -6 to -2 and melphalan 70 mg/m^2 on days -3 and -2, then transplanted with donor peripheral blood stem cells or harvested bone marrow stem cells on day 0. Patients are then given post-transplant immunosuppression consisting of tacrolimus 0.06 mg/kg/day on days -3 to 100 and methotrexate 5 mg/m^2 on days 1, 3, and 7.
89603191|NCT00121810|Experimental|1|
89603192|NCT00121810|Active Comparator|2|
89603193|NCT00053014|Experimental|treatment|patient conditioning - fludarabine 30 mg/m2 IV over 1 hour Days -4, -3, -2; TBI 6-7 cGy/min Day 0 post-transplant immunosuppression - cyclosporine 6.25 mg/kg bid PO D -3 to +180 (begin taper on D+35); mycophenolate mofetil 15mg/kg bid PO D0 to +27
89603194|NCT00123604|Experimental|Carvedilol|Carvedilol, orally, 25 mg, twice daily for five months
89603195|NCT00123604|Active Comparator|Metoprolol|Metoprolol, orally, 200 mg, twice daily for five months.
89603196|NCT00123682|Experimental|Arm 1 - proactive, intensive counseling|Proactive outreach to counseling; multi-session counseling from California Smokers' Helpline
89603197|NCT00123682|Experimental|Arm 2 - reactive, intensive counseling|Reactive outreach to counseling; multi-session counseling from California Smokers' Helpline
89603198|NCT00123682|Experimental|Arm 3 - proactive, self-help|Proactive outreach to engage smoker in treatment; mailed self-help materials
89603199|NCT00123682|Experimental|Arm 4 - reactive, self-help|Reactive approach to engaging smoker in treatment; mailed self-help materials
89603200|NCT00125788|Experimental|investigational product|L-glutamine
89603201|NCT00125788|Placebo Comparator|placebo|maltodextrin
89603202|NCT00221338|Experimental|Gabapentin|Double blind, placebo controlled
89603203|NCT00221338|Placebo Comparator|Placebo|Double blind
89603204|NCT00223678|Active Comparator|1|pt will switch from calcineurin inhibitor (CYA, prograf) to Rapamycin
89603205|NCT00223678|No Intervention|2|Patient will remain on calcineruin inhibitor
89603206|NCT04752436|Experimental|Supra high intensity interval training|The experimental group will engage in the high intensity interval training.
89603207|NCT00130780|Active Comparator|A|Pre-surgical Treatment with Bevacizumab plus Chemotherapy
89603208|NCT00130780|Active Comparator|B|Pre-Surgical Docetaxel and Cisplatin and Adjuvant Bevacizumab
89603209|NCT04752748||Woman with Early Rheumatoid Arthritis|
89603210|NCT00041392|Active Comparator|Magnesium|100 mg/kg magnesium
89603211|NCT00041392|Placebo Comparator|0.9 % saline|100 mg/kg 0.9 % saline
89603212|NCT02091778|Experimental|Fast Gelling Dressing|
89603213|NCT04752046|Active Comparator|obturator group|patients with resected maxillary defects were managed with surgical obturator
89603214|NCT04752046|Active Comparator|scapular flap group|
89603215|NCT04752202|Experimental|Test group (group A)|The women were randomly assigned to group A. Test group included 50 women aged 18-65 years with previously diagnosed Hashimoto's disease and obesity. Hashimoto's disease (AITD) was diagnosed by a specialist based on the ultrasound image characteristic of AITD and high levels of anti-thyroid antibodies.
89603216|NCT04752202|Other|Control group (group B)|The women were randomly assigned to group B. Control group included 50 women aged 18-65 years with previously diagnosed Hashimoto's disease and obesity. Hashimoto's disease (AITD) was diagnosed by a specialist based on the ultrasound image characteristic of AITD and high levels of anti-thyroid antibodies.
89603217|NCT02091856|Experimental|Conventional-CBT (C-CBT)|This arm represents the classical Cognitive Behavioral Therapy (CBT) approach for major depression disorder (MDD) plus a set of exercises devised from the mindfulness paradigm.
89603218|NCT02091856|Experimental|Religious CBT (R-CBT)|This arm represents the classical Cognitive Behavioral Therapy (CBT) approach for major depression disorder (MDD) plus a set of exercises devised from the general Christian belief.
89603219|NCT02091856|No Intervention|Wait List Control Group (WLCG)|This arm represents the wait-list comparison group.
89603220|NCT00225784|Experimental|Cetuximab, Gemcitabine, RT|weekly cetuximab, twice-weekly gemcitabine and intensity modulated radiotherapy
89603221|NCT02092168|Experimental|BIA 9-1067 30 mg (once daily) - Elderly Subjects|BIA 9-1067 was administered as oral doses of 30 mg (5 and 25 mg capsules), once-daily in the morning, during 7 days.
89603222|NCT02092168|Experimental|BIA 9-1067 30 mg (once daily) - Young Subjects|BIA 9-1067 was administered as oral doses of 30 mg (5 and 25 mg capsules), once-daily in the morning, during 7 days.
89603223|NCT00132964|Active Comparator|Immobilizaton device|Below Knee walking cast
89603224|NCT00132964|Experimental|Immobilization device|Removable ankle brace
89603225|NCT01897246|Active Comparator|Computer-assisted pre-operative planning|Patients enrolled in this arm will undergo corrective surgery of the distal radius, with pre-operative computer-assisted planning and virtual osteotomy.
89603226|NCT01897246|Active Comparator|Conventional pre-operative planning|Patients in this group will undergo corrective osteotomy of the distal radius wit conventional pre-operative planning.
89603227|NCT00133978|Experimental|Glutamine|Glutamine supplementation
89603228|NCT00133978|Experimental|Antioxidants|Antioxidant supplementation
89603229|NCT00133978|Experimental|Glutamine + Antioxidants|Glutamine and antioxidant supplementation
89603230|NCT00133978|Placebo Comparator|Placebo|Non-isonitrogenic, iso-caloric placebo solution
89603231|NCT01897324|Experimental|The Long protocol|Patients in the group A received a long protocol of pituitary down-regulation with triptorelin (Decapeptyl; Ferring, Switzerland) which started on day 21 of preceding cycle at a dose of 0.1 mg/day. On the second day of menstruation HMG was started and this was associated with reduction of triptorelin to 0.05 mg/day. This reduced daily dose was administered until the day hCG was given. Growth hormone co-treatment was administrated on day 6 of HMG stimulation daily in a dose of 2.5 mg S.C. till the day of hCG administration.
89603232|NCT01897324|Experimental|The Short protocol|The short agonist protocol was started on cycle day 1 with triptorelin (Decapeptyl Ferring Pharmaceuticals, Germany) 0.05 mg/day S.C. Human menopausal gonadotropin IM daily (HMG 75 IU, Merional, IBSA) were also administered starting from days 2 to 3 of cycle. The dose was adjusted for each patient according to the diameter of the follicles detected in their follow up ultrasound. Growth hormone (Norditropin, Novo nordisk) was administrated on day 6 of HMG stimulation daily in a dose of 2.5 mg S.C. till the day of hCG administration.
89603233|NCT01897324|Experimental|The Antagonist protocol|Gonadotrophins IM daily (HMG 75 IU, Merional, IBSA)was administrated from day 2 of the cycle. Growth hormone (Norditropin, Novo nordisk) was administrated on day 6 of HMG stimulation daily in a dose of 2.5 mg S.C. till the day of hCG administration. The GnRH antagonist (Cetrotide) was given when the leading follicle was from 12 to 14 mm, at a daily dose of 0.25 mg SC.
89603234|NCT01897324|Experimental|The Microflare protocol|the patients in this group were given oral contraceptive pills (OCPs) for 28 days, this was followed by 2 days free. Triptorelin (Decapeptyl Ferring Pharmaceuticals, Germany) 0.05 mg/day S.C. was then started daily followed by human menopausal gonadotropin IM daily (HMG 75 IU, Merional, IBSA) 3 days later. Growth hormone (Norditropin, Novo nordisk) was administrated on day 6 of HMG stimulation daily in a dose of 2.5 mg S.C. till the day of hCG administration.
89603235|NCT01897948|Experimental|Milk-based beverage with DHA at mid-level|
89603236|NCT01897948|Experimental|Milk-based beverage with DHA at high level|
89210329|NCT02540148|Sham Comparator|Non-active treatment|A second group of subjects will act as the control group. This group will undergo sham treatment to the enrolled eyes at the same intervals as the treatment group (Weeks 2, 14 and 26), but with a nonfunctional Nova Oculus device. A treatment session is 15 minutes of treatment on each closed eye lid for a total of 30 minutes. ETDRS visual acuity will be performed on all subjects at enrollment (prior to the first treatment), prior to each treatment session, and at four weeks from enrollment. The effect of treatments with the Nova Oculus device compared to sham treatment on the visual acuity of subjects with dry AMD will be determined.
89210330|NCT04086719|Experimental|BMS- 986185 + Pyrimethamine|
89603237|NCT01897948|Active Comparator|Milk-based beverage without DHA|
89603238|NCT00253708|Experimental|massage|"Patients received 3 massage therapy visits from massage therapists in initial week with a duration of 15-45 minutes.NOTE: Intervention 'management of therapy complications' has not been included in any Arm/Group Descriptions.~Patients were intended to receive pain therapy, psychosocial assessment and care, and quality-of-life assessment"
89603239|NCT00253708|Active Comparator|no-touch control|Patients received 3 no-touch therapy visits from massage therapists who provided no-touch without healing intention.Patients were intended to receive pain therapy, psychosocial assessment and care, and quality-of-life assessment
88815042|NCT02448810|Active Comparator|Part 2: Standard of Care- Subjects with KRAS and NRAS wt tumor|Subjects stratified according to their mutation status.Subjects stratified according to their mutation status.
88815043|NCT05709587|Experimental|Virtual Reality training group|Virtual Reality training group: Three virtual environments employed in this study,time constraints,terrain changes, and moving obstacles were set to increase the difficulty of the walking task.The participants had to complete a task three times to proceed to the next level.
88815044|NCT00958334|Experimental|Proellex 25 mg|Two Proellex® 12.5 mg capsules once daily
88815045|NCT00958334|Experimental|Proellex 12.5 mg|One Proellex® 12.5 mg capsules once daily
88815046|NCT00958334|Placebo Comparator|Placebo|Capsule once a day
88815047|NCT01015976|Experimental|Post bariatric surgery|Roux en Y bariatric surgery
88815048|NCT01015976|Other|Control|No surgery
88815049|NCT03021200|Experimental|Indocyanine green in Conventional Oncological Surgery|Use of indocyanine green laser fluorescence angiography (AFLIICG) platforms (SPY-Elite) for conventional oncological surgeries
88815050|NCT03021200|Experimental|Indocyanine green in minimally invasive Oncological Surgery|Use of indocyanine green laser fluorescence angiography (AFLIICG) platforms (Pinpoint) for minimally invasive oncological surgeries
88815051|NCT03021200|Experimental|Indocyanine green in robot-assisted Oncological Surgery|Use of indocyanine green laser fluorescence angiography (AFLIICG) platforms (Firefly) for robot-assisted oncological surgeries
88815052|NCT01680887|Experimental|Varenicline|Oral 1.0 mg BID.
88815053|NCT01680887|Placebo Comparator|Placebo|Oral 1.0 mg BID.
88815054|NCT01016678|Other|Active, Active, Active, Placebo|One fifth of the 105 subjects will be randomized to this arm and treat their four migraines in this order. First three will be treated with Active Treximet and the last or 4th migraine will be treated with Placebo.
88815055|NCT01016678|Other|Active, Active, Placebo, Active|This is another of the five treatment arms. One fifth of the 105 subjects will be randomized to this group and will treat the first two migraines with Active drug, Treximet, and then the third migraine with placebo and the last (4th) migraine with Treximet.
88815056|NCT01016678|Other|Active, Placebo, Active, Active|Approximately one fifth of the 105 subjects will be randomized to this group and treat their first migraine with Active Treximet and the second migraines with Placebo. The final two migraines treated will be with Active study drug.
89210331|NCT04086719|Experimental|BMS-986185|
89210332|NCT00898950|Experimental|Aspirin low dose|Effects of using aspirin 75 mgs/day for 2 weeks.
89603240|NCT00253708|No Intervention|Usual care|Patients did not receive visits from massage therapists. Patients were intended to receive pain therapy, psychosocial assessment and care, and quality-of-life assessment
89603241|NCT00254410|Experimental|FCM-R + Pegylated Filgrastim|Fludarabine 25 mg/m2 on Days 2,3,4 i.v. 5-30 mins for course 1, and on Days 1 - 3 for courses 2 - 6. Cyclophosphamide 250 mg/m2 on Day 2,3,4 i.v. 5-30 mins for course 1, and on Days1 - 3 for courses 2 - 6. Mitoxantrone 6 mg/m2 on Day 2 i.v. 30-60 mins for course 1, and on Day 1 for courses 2 - 6. Rituximab 375 mg/m2 on Day 1 i.v. 2-6 hours for course 1 and 500 mg/m2 on Day 1 for courses 2 - 6. Pegylated Filgrastim - 6 mg on Day 4,s.c. for course 1 and on Day 3 for courses 2 - 6.
89603242|NCT00254488|Experimental|Lithium (LI)|Participants will receive 9 weeks of treatment with lithium
89603243|NCT00254488|Experimental|Divalproex (DV)|Participants will receive 9 weeks of treatment with divalproex
89603244|NCT00255970|Experimental|Regenafil graft|Regenafil
89603245|NCT00255970|Active Comparator|DFDBA|Demineralized Freeze Dried Bone Allograft
89603246|NCT01899118|Experimental|Nimotuzumab plus chemoradiotherapy|
89603247|NCT00231868|Experimental|A|Drug:Carboplatin and Paclitaxel and Radiation: Pelvic Radiation Therapy
89603248|NCT00257686|Experimental|Pitavastatin 1 mg|Pitavastatin 1 mg once daily
89603249|NCT00257686|Active Comparator|Pravastatin 10 mg|Pravastatin 10 mg once daily
89603250|NCT00257686|Experimental|Pitavastatin 2 mg|Pitavastatin 2 mg once daily
89603251|NCT00257686|Active Comparator|Pravastatin 20 mg|Pravastatin 20 mg once daily
89603252|NCT00257686|Experimental|Pitavastatin 4 mg|Pitavastatin 4 mg once daily
89603253|NCT00257686|Active Comparator|Pravastatin 40 mg|Pravastatin 40 mg once daily
89603254|NCT00234286|Experimental|Arm 1|Comfort care education intervention, consisting of intensive, on-site staff training together with an electronic order set for palliative care and educational materials
89603255|NCT01469013|Placebo Comparator|Placebo|"2 placebo capsules administered orally once daily for 12 weeks. Participants who complete this treatment arm will be randomized in a 1:1 ratio to either the 4-mg baricitinib or 8-mg baricitinib arms. Participants rerandomized to 8-mg baricitinib arm at Week12 will switch to 4-mg baricitinib once a day after the approval of protocol amendment (d) and will receive that switched dose until Week 64.~The dosage form changed from capsule in treatment period (up to Week 12) to tablet in extension period (Week 13 to 64) per protocol amendment (b)."
89603256|NCT01469013|Experimental|1-mg Baricitinib (LY3009104)|"1 x 1-mg baricitinib capsule + 1 identical placebo capsule, both administered orally once daily for 12 weeks. Participants who complete this treatment arm will be randomized in a 1:1 ratio to either the 4-mg baricitinib or 8-mg baricitinib arms. Participants rerandomized to 8-mg baricitinib arm at Week 12 will switch to 4-mg baricitinib once a day after the approval of protocol amendment (d) and will receive that switched dose until Week 64.~The dosage form changed from capsule in treatment period (up to Week 12) to tablet in extension period (Week 13 to 64) per protocol amendment (b)."
89603257|NCT01469013|Experimental|2-mg Baricitinib (LY3009104)|"2 x 1-mg baricitinib capsules administered orally once daily for 12 weeks. Participants who complete this treatment arm will be randomized in a 1:1 ratio to either the 4-mg baricitinib or 8-mg baricitinib arms. Participants rerandomized to 8-mg baricitinib arm at Week 12 will switch to 4-mg baricitinib once a day after the approval of protocol amendment (d) and will receive that switched dose until Week 64.~The dosage form changed from capsule in treatment period (up to Week 12) to tablet in extension period (Week 13 to 64) per protocol amendment (b)."
89603258|NCT01469013|Experimental|4-mg Baricitinib (LY3009104)|1 x 4-mg baricitinib capsule + 1 identical placebo capsule, both administered orally once daily for 12 weeks. Participants who complete this 12-week period will remain on this treatment regimen in tablet form.
89603259|NCT01469013|Experimental|8-mg Baricitinib (LY3009104)|2 x 4-mg baricitinib capsules administered orally once daily for 12 weeks. Participants who complete this 12-week period will remain on this treatment regimen in tablet form. Participants taking 8-mg baricitinib tablet form will switch to 4-mg baricitinib once a day after the approval of protocol amendment (d) and will receive that switched dose until Week 64.
89603260|NCT01493427|Experimental|TRAVATAN® BAK-free|Travoprost 0.004%, 1 drop self-administered to the study eye(s) once daily, every evening at around 8:00 pm, for 12 weeks
89603261|NCT01523457|Experimental|MPC modified FOLFIRINOX|Patients with metastatic pancreatic cancer (MPC) were treated with modified FOLFIRINOX every 2 weeks as follows: oxaliplatin 85 mg m 2 infused over 120 min, immediately followed by folinic acid 400 mg m 2 infused over 120 min with the addition, after 30 min, of irinotecan 135 mg m 2 infused over 90 min, followed by 5FU 300 mg m 2 IV bolus, followed by 2400 mg m 2 continuous infusion for 46 h (25% reduction in bolus 5FU and irinotecan doses). All patients received pegylated filgrastim with each cycle on day 3 or 4 in the absence of severe leukocytosis. All patients routinely received palonosetron, aprepitant and dexamethasone for emesis prophylaxis.
89603262|NCT01523457|Experimental|LAPC modified FOLFIRINOX|Patients with locally advanced pancreatic cancer (LAPC) were treated with modified FOLFIRINOX every 2 weeks as follows: oxaliplatin 85 mg m 2 infused over 120 min, immediately followed by folinic acid 400 mg m 2 infused over 120 min with the addition, after 30 min, of irinotecan 135 mg m 2 infused over 90 min, followed by 5FU 300 mg m 2 IV bolus, followed by 2400 mg m 2 continuous infusion for 46 h (25% reduction in bolus 5FU and irinotecan doses). All patients received pegylated filgrastim with each cycle on day 3 or 4 in the absence of severe leukocytosis. All patients routinely received palonosetron, aprepitant and dexamethasone for emesis prophylaxis.
89603263|NCT01523301|Experimental|Rotigotine|Rotigotine, daily doses, treatment group
89603264|NCT01523301|Placebo Comparator|Placebo|Placebo, daily doses, placebo group
89210333|NCT00898950|Experimental|Aspirin medium dose|Effects of using aspirin 300 mgs/day
89210334|NCT00898950|Experimental|aspirin high dose|aspirin 900mgs QID orally for 2 weeks
88811459|NCT04932824|Experimental|Subjects With Treatment Cross-over (From 1st Dose of Active Study Vaccine Onwards)|Once the treatment assignments of study CLO-SCB-2019-001 are unblinded, those subjects who have received placebo and provided there is active study vaccine available, will be given the option to receive 2 doses of active study vaccine 21 days apart (ie, treatment cross-over)
89603265|NCT02985567||Intraocular pressure evaluation|Intraocular pressure evaluation using Icare tonometer 25 minutes after sedation, and then every 10 minutes until sedation is complete
89603266|NCT02985567||Safety of sedation|"Documentation of:~The need for repeat dosing of chloral hydrate.~The level of alertness of the patient at the end of sedation and the total time between induction and readiness for discharge~Interventions required for the patient including administration of oxygen, and need for intubation."
89603267|NCT01806506|Experimental|Laparoscopic sleeve gastrectomy|The group of morbidly obese patients assigned to laparoscopic sleeve gastrectomy.
89603268|NCT01806506|Experimental|Roux-en-Y Gastric Bypass|The group of morbidly obese patients assigned to Roux-en-Y gastric bypass.
89210335|NCT00898950|Placebo Comparator|placebo|
89603269|NCT01766336|Experimental|Group 1 ELND005/ELND005|Patients who received ELND005 during Study AG201 will continue on the same maintenance dose for 36 weeks.
89603270|NCT01766336|Experimental|Group 2 PLACEBO/ELND005|Patients who received placebo during Study AG201 will receive ELND005 at the same dosing regimen as the active group in Study AG201 for 36 weeks.
89603271|NCT01797536|Experimental|Mild Hepatic Insufficiency|Single oral dose of 5 x 10 mg capsules of elbasvir administered to participants with mild hepatic insufficiency, defined as a score of 5 to 6 on the Child-Pugh scale
89603272|NCT01797536|Experimental|Moderate Hepatic Insufficiency|Single oral dose of 5 x 10 mg capsules of elbasvir administered to participants with moderate hepatic insufficiency, defined as a score of 7 to 9 on the Child-Pugh scale
89603273|NCT01797536|Experimental|Severe Hepatic Insufficiency|Single oral dose of 5 x 10 mg capsules of elbasvir administered to participants with severe hepatic insufficiency, defined as a score of 10 to 15 on the Child-Pugh scale
89603274|NCT01797536|Experimental|Healthy Participants|Single oral dose of 5 x 10 mg capsules of elbasvir administered to participants matched to the mean of all hepatic insufficiency participants for age, gender, and weight
89603275|NCT01797302|Active Comparator|Vitamin D3 2000 IU|Vitamin D3 2000 IU tablet once daily by mouth for 6 months
89603276|NCT01797302|Active Comparator|Vitamin D3 1000 IU|Vitamin D3 1000 IU tablet by mouth once daily for 6 months
89603277|NCT01797302|Placebo Comparator|Vitamin D3 600 IU|Vitamin D3 600 IU tablet by mouth once daily for 6 months
89603278|NCT01805180|Other|Arm 1: Spectra Optia followed by COBE Spectra|Controlled evaluation of Granulocyte/Polymorphonuclear Cell Collection on the Spectra Optia device followed by the COBE Spectra device.
89603279|NCT01805180|Other|Arm 2: COBE Spectra followed by Spectra Optia|Controlled evaluation of Granulocyte/Polymorphonuclear Cell Collection on the COBE Spectra device followed by Spectra Optia.
89603280|NCT04413968|Experimental|Interventional|nasopharyngeal and blood sample
89603281|NCT01804946|Experimental|Ergoferon (1 tablet 3 times a day)|1 tablet per 1 intake: on day 1 of the treatment 8 tablets (1 tablet every 30 minutes for the first 2 hours, then 1 tablet 3 times a day with equal intervals starting on the same day. From day 2 to day 5 1 tablet TID.
89603282|NCT01804946|Active Comparator|Oseltamivir(Tamiflu): 75 mg two times a day.|Oseltamivir for 5 days (75 mg b.i.d.).
89603283|NCT01737398|Active Comparator|Inotersen|300 mg inotersen administered subcutaneously (SC) 3 times on alternate days in the first week and then once-weekly for 64 weeks
89603284|NCT01737398|Active Comparator|Placebo|Placebo administered SC 3 times on alternate days in the first week and then once-weekly for 64 weeks
89603285|NCT01795898|Experimental|Fentanyl transdermal patch|Fentanyl transdermal patches releasing 12.5 microgram of fentanyl will be applied for 3 days. The patches will be replaced every 3 days (Day 3, 7 and 10).
89603286|NCT01736696|Experimental|5 mg BID|5 mg BID for 13 days and once on Day 14
89603287|NCT01736696|Experimental|10 mg BID|10 mg BID for13 days and once on Day 14*
89603288|NCT01736696|Experimental|20 mg BID|20 mg BID for 13 days and once on Day 14
89603289|NCT01736696|Experimental|30 mg BID|30 mg BID for 13 days and once on Day 14
89210336|NCT04034784|Experimental|Discrete(TM)|Intraperitoneal injection
89603290|NCT01736696|Experimental|60 mg QD|60 mg QD for 14 days
89603291|NCT01736696|Experimental|50 mg BID|50 mg BID x 13 days and once on day 14
89210337|NCT04034784|Sham Comparator|Control Lactated Ringer's Solution (Control LRS)|Intraperitoneal injection
89603292|NCT01736540|Other|Magnetic Resonance Imaging (MRI)|All participants were subjected to a non-invasive hepatic and cardiac MRI within 60 days of enrollment to measure iron overload.
89603293|NCT01794338|Experimental|Bio-A Arm|"Patients will receive underlay mesh tissue reinforcement followed by standard fascial closure with #1 PDS. As described by Dr. Stoppa10-12, the mesh will be secured via abdominal wall sutures. Additional full thickness sutures will be placed every 8 cm circumferentially. After securing the mesh in place, #1 PDS sutures will be used to close the fascia in a running fashion with 1.5-2 cm bites from the fascial edge and a 1cm walk between stitches. Skin will be closed with staples or monofilament suture according to surgeon preference. Drains will be placed on the mesh in each case, and one or two drains will be placed in the subcutaneous tissues at the discretion of the surgeon depending on the amount of subcutaneous tissue dissected."
89603294|NCT01794338|Active Comparator|Strattice Arm|"Patients will receive underlay mesh tissue reinforcement followed by standard fascial closure with #1 PDS. As described by Dr. Stoppa10-12, the mesh will be secured via abdominal wall sutures. Additional full thickness sutures will be placed every 8 cm circumferentially. After securing the mesh in place, #1 PDS sutures will be used to close the fascia in a running fashion with 1.5-2 cm bites from the fascial edge and a 1cm walk between stitches. Skin will be closed with staples or monofilament suture according to surgeon preference. Drains will be placed on the mesh in each case, and one or two drains will be placed in the subcutaneous tissues at the discretion of the surgeon depending on the amount of subcutaneous tissue dissected.."
89603295|NCT01609478|Experimental|indacaterol acetate 75 µg|"indacaterol acetate 75 µg od delivered via Concept 1 inhaler~Background therapy: mometasone furoate 200 mcg od"
89603296|NCT01609478|Experimental|indacaterol acetate 150 µg|"indacaterol acetate 150 µg od delivered via Concept 1 inhaler~Background therapy: mometasone furoate 200 mcg od"
89603297|NCT01609478|Placebo Comparator|placebo|"placebo delivered via Concept 1 inhaler~Background therapy: mometasone furoate 200 mcg od"
89603298|NCT01764854|Experimental|AZD1722- in patient|Tenapanor administered in a clinical pharmacology unit
89603299|NCT01764854|Placebo Comparator|Placebo- in patient|Placebo (size and color matched to experimental drug) administered in a clinical pharmacology unit
89210338|NCT03622515|Experimental|Group S|Sedline monitoring Adjust the depth of anesthesia by adjusting the amount of anesthesia, and adjust the cerebral perfusion pressure by adjusting blood pressure
89603300|NCT01764854|Experimental|AZD1722 out-patient|Tenapanor
89603301|NCT01764854|Experimental|Placebo out-patient|Placebo
89603302|NCT01764464|Other|Group A|14 day titration (days 1-7 at 600 mg daily Gralise®; days 8-14 at 1200 mg daily Gralise®). 28 day maintenance (1800 mg daily Gralise®). 7 day taper (days 1-4 at 1200 mg daily Gralise®; days 5-7 at 600 mg daily Gralise®). 10 day washout (no intervention). 14 day titration (days 1-7 at 600 mg daily placebo; days 8-14 at 1200 mg daily placebo). 28 day maintenance (1800 mg daily placebo). 7 day taper (days 1-4 at 1200 mg daily placebo; days 5-7 at 600 mg daily placebo).
89603303|NCT01764464|Other|Group B|14 day titration (days 1-7 at 600 mg daily placebo; days 8-14 at 1200 mg daily placebo). 28 day maintenance (1800 mg daily placebo). 7 day taper (days 1-4 at 1200 mg daily placebo; days 5-7 at 600 mg daily placebo). 10 day washout (no intervention). 14 day titration (days 1-7 at 600 mg daily Gralise®; days 8-14 at 1200 mg daily Gralise®). 28 day maintenance (1800 mg daily Gralise®). 7 day taper (days 1-4 at 1200 mg daily Gralise®; days 5-7 at 600 mg daily Gralise®).
89603304|NCT01764386|Experimental|NB + CLI|Naltrexone SR 32 mg/Bupropion SR 360 mg/day (NB) with comprehensive lifestyle intervention (CLI)
89603305|NCT01764386|Other|Usual Care|"Usual Care (self-directed lifestyle intervention)~Usual Care: Usual Care was a self-directed lifestyle intervention in which subjects were given calorie targets, instructions to increase exercise, and a pamphlet about weight loss by study site staff."
89603306|NCT01763918|Placebo Comparator|Placebo Q2W|Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for up to 12 weeks.
89603307|NCT01763918|Placebo Comparator|Placebo QM|Participants received placebo subcutaneous injection once every month (QM) for up to 12 weeks.
89603308|NCT01763918|Experimental|Evolocumab Q2W|Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.
89603309|NCT01763918|Experimental|Evolocumab QM|Participants received 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.
89603310|NCT01763684|Active Comparator|Signature Custom Guides|Oxford Partial Knee implanted using Signature Custom Guides
89603311|NCT01763684|Active Comparator|Conventional Instrumentation|Oxford Partial Knee implanted using Conventional Instrumentation
89603312|NCT01606748|Experimental|Necitumumab, Gemcitabine and Cisplatin|The study will be conducted in two sequential periods: a 3-week PK run-in participants will be treated sequentially with single doses of cisplatin, gemcitabine, and necitumumab. Cycle 1 will begin immediately following the PK run-in period.
89603313|NCT01597622|Experimental|Open-label Belimumab|Belimumab 10 mg/kg administered intravenously every 4 weeks. All study subjects will receive standard SLE therapies during the study. Subjects will continue to receive belimumab treatment until such time belimumab becomes commercially available in a subject's country of participation, or the subject elects to participate in another belimumab continuation study for SLE, or until either the subject's physician withdraws the subject from the study, or upon the decision by the sponsor to discontinue further development of belimumab for SLE.
89603314|NCT01761266|Active Comparator|Lenvatinib|Participants received lenvatinib capsules 12 milligram (mg) based on the participant's body weight greater than or equal to (>=) 60 kilogram (kg) or 8 mg based on the participant's body weight less than (<) 60 kg at baseline, orally, once daily (QD) in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
89603315|NCT01761266|Active Comparator|Sorafenib|Participants received sorafenib 400 mg tablets, orally, twice daily (BID) in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
89603316|NCT01760954|Experimental|Elagolix 150 mg QD|Participants received elagolix 150 mg tablets once a day (QD) for 6 months.
89603317|NCT01760954|Experimental|Elagolix 200 mg BID|Participants received elagolix 200 mg tablets twice a day (BID) for 6 months.
89603318|NCT01760876|Experimental|Biofreedom stent|Coronary intervention
89603319|NCT01759862|Experimental|Aminophylline|"Patients will receive aminophylline loading dose 5mg/kg prior to transplant and will continue to receive aminophylline 1.8mg/kg Q6h for a total of 20 doses.~Theophylline drug levels will be monitored daily for 4 days."
89603320|NCT01759862|Placebo Comparator|Control|"Patients will receive placebo infusion of normal saline, pre-transplant, followed by normal saline infusions matched by volume and frequency to treatment arm for a total of 20 doses.~Drug levels will be monitored daily for 4 days."
89603321|NCT01606670||Neupro® Treatment|Routine treatment with Neupro® (2, 4, 6, 8, 10, 12, 14, 16 mg/24 h) as per approved label in the EU, which is applicable in the EU member state Germany.
89603322|NCT04579874|Experimental|LIVERFASt validation|blood draw for LIVERFASt
89603323|NCT01793792|Other|Device: LVIS|"The LVIS Device is intended for use with embolization coils for the treatment of wide neck, intracranial aneurysms.~Device: LVIS™ and LVIS™ Jr. MicroVention Low-profile Visualized Intraluminal Support Device"
89603324|NCT01790984|Experimental|High sugar low starch diet|A high sugar, low starch diet was provided by the exchange of two thirds of the participants daily intake of carbohydrate. This was achieved by exchanging foods with low sugar to starch content, with foods containing a high sugar to starch content to reach a target ratio of starch to sugar of 1:1.2
89210339|NCT03622515|No Intervention|Group C|Bispectral index (BIS)/Sedline monitoring
88811460|NCT04932824|Experimental|Subjects who will receive Booster Vaccine|For subjects out of those who received SCB-2019 CpG/Alum-adjuvanted vaccine in study CLO-SCB-2019-001: the subjects will receive a booster dose.
88811461|NCT03839888|Experimental|0.125% atropine group|patients used the 0.125 % atropine eyedrop every night before sleep for 7 days
88811462|NCT03839966|Experimental|Active Treatment|Interpretation Bias Modification for Loneliness
88811463|NCT03839966|Active Comparator|Control Treatment|Healthy Habits Psychoeducation and Relaxation.
89603325|NCT01790984|Experimental|Low sugar high starch diet|A high sugar, low starch diet was provided by the exchange of two thirds of the participants daily intake of carbohydrate. This was achieved by exchanging foods with a high sugar to starch content, with foods containing a low sugar to starch content to reach a target ratio of starch to sugar of 5:1
89603326|NCT01735994|Experimental|Healthy Weight Intervention|Eating Disorder Prevention Program
89603327|NCT01735994|Other|Brochure wait list|Brochure wait list control group
89603328|NCT01790828||Xyntha group|Xyntha will be administered according to physician's discretion.
89603329|NCT01790594|Active Comparator|Immunosuppression without Belatacept|"Induction: 5 day course of methylprednisolone or equivalent;~Induction: Anti-thymocyte Globulin (Rabbit);~Maintenance Immunosuppression: Tacrolimus (or generic). The site investigator will identify a starting tacrolimus dose at his or her discretion, in order to achieve the target trough levels, no later than 5 days post-transplantation. Tacrolimus dosing will be initiated on the day of surgery or post-operative day 1 depending upon when during the day the surgery is completed, then adjusted to target trough levels of 8-12 ng/ml during the first 24 weeks post-transplant, then adjusted to target trough levels of 5-8 ng/ml thereafter.~Maintenance Immunosuppression: Mycophenolate mofetil (or Myfortic (mycophenolate sodium), or generic)."
89603330|NCT01790594|Experimental|Immunosuppression Including Belatacept|"Induction: 5 day course of methylprednisolone or equivalent;~Induction: Anti-thymocyte Globulin (Rabbit);~Maintenance Immunosuppression: Belatacept~Maintenance Immunosuppression: Tacrolimus (or generic)- The site investigator will identify a starting tacrolimus dose at his or her discretion, in order to achieve the target trough levels no later than 5 days post-transplantation. Tacrolimus dosing will be initiated on the day of surgery or post-operative day 1 depending upon when during the day the surgery is completed. The dosage will be adjusted to achieve the following therapeutic trough levels: 5-8 ng/ml during the first 24 weeks post-transplant and then 3-5 ng/ml until day 280 (week 40). Subjects may be withdrawn if they meet all the criteria defined below.~Maintenance Immunosuppression: Mycophenolate mofetil (or Myfortic (mycophenolate sodium), or generic)."
89603331|NCT01790516|Experimental|Cisplatin|Cisplatin
89603332|NCT01790516|Experimental|Cetuximab|cetuximab
89603333|NCT01790438|Experimental|LY2605541|Administered by subcutaneous (SC) injection once daily in the morning or at bedtime. Initial dose is 10 units (or less for some of the participants in Korea) and is adjusted weekly based on Fasting Blood Glucose (FBG). LY2605541 will be given alone or in combination with up to 3 pre-study oral antihyperglycemic medications [OAM(s)] whose use is not excluded in combination with insulin. Treatment may last up to 26 weeks.
89603334|NCT01790438|Active Comparator|Human Insulin NPH|Administered by SC injection once daily at bedtime. Initial dose is 10 units (or less for some of the participants in Korea) and is adjusted weekly based on FBG. Human insulin NPH will be used alone or in combination with up to 3 pre-study OAM(s) whose use is not excluded in combination with insulin. Treatment may last up to 26 weeks. Some participants who are unable to achieve glycemic control after at least 12 weeks of treatment with a single injection of NPH may be asked to add a second injection prior to the morning meal.
89603335|NCT01735916|Active Comparator|CRT-P ON|CRT-P Implant CRT-P ON
89603336|NCT01735916|Placebo Comparator|CRT-P OFF|CRT-P Implant CRT-P OFF
89603337|NCT01790126|Active Comparator|ARN-509|ARN-509 Tablets, 240 mg/day administered orally
89603338|NCT01790126|Active Comparator|LHRH agonist + ARN-509|Choice of LHRHa per investigator discretion/site practice guidelines (e.g, Eligard®, Zoladex®, Lupron Depot®, Trelstar®) and ARN-509 Tablets, 240 mg/day administered orally
89603339|NCT01790126|Active Comparator|LHRH agonist|Choice of LHRHa per investigator discretion/site practice guidelines (e.g., Eligard®, Zoladex®, Lupron Depot®, Trelstar®).
89603340|NCT01734902|Experimental|1 Hyoscine butylbromide|drops, oral administration with 240 mL water
89603341|NCT01734902|Experimental|2 Hyoscine butylbromide|sugar coated tablets, oral administration with 240 mL water
89603342|NCT01790048|Experimental|Whey permeate RUSF|75 kcal/kg/day (314 k Joules (kJ)/kg/day) of whey RUSF. Whey RUSF contains whey permeate, Whey Permeate (WPC) 80 (contains at least 80% protein), peanut paste, sugar, soy oil, a customized micronutrient premix to account for the minerals in whey permeate, and an emulsifier. Whey permeate RUSF will be locally produced and will undergo quality assurance and safety testing for aflatoxin and microbial contamination at the Malawi Bureau of Standards and Eurofins Scientific Inc., Des Moines, Iowa, USA.
89603343|NCT01790048|Active Comparator|Soy Protein RUSF|75 kcal/kg/day (314 kJ/kg/day) of whey RUSF. Soy RUSF contains extruded soy flour, peanut paste, sugar, soy oil, palm oil, a premix containing concentrated minerals and vitamins, an emulsifier and dicalcium phosphate or calcium carbonate (Roche, Mumbai, India). Soy RUSF has no protein from animal sources. Soy RUSF will be locally produced and will undergo quality assurance and safety testing for aflatoxin and microbial contamination at the Malawi Bureau of Standards and Eurofins Scientific Inc., Des Moines, Iowa, USA.
89603344|NCT01789970|Placebo Comparator|Placebo|Participants were administered hydrocodone ER tablets orally at dosages of 15, 30, 45, 60, or 90 mg every 12 hours at the dosage deemed successful for managing their pain during the titration period. During the treatment period, participants were administered placebo tablets twice a day that matched the dosage deemed successful for managing their pain during the titration period. A step-wise, double-blind schedule to tamper off active drug was implemented during the first 2 weeks of the 12-week, double-blind, placebo-controlled treatment period to reduce the risk of withdrawal effects in participants randomly assigned to placebo.
89603345|NCT01789970|Experimental|Hydrocodone ER|Participants were administered hydrocodone ER tablets orally at dosages of 15, 30, 45, 60, or 90 mg every 12 hours at the dosage deemed successful for managing their pain during the titration period. During the 12-week, double-blind, placebo-controlled treatment period, participants randomly assigned to hydrocodone ER were administered tablets twice a day at the dosage deemed successful for managing their pain during the titration period.
89603346|NCT01734434||Pregnant women|24 weeks or more of gestation
89603347|NCT01788566|Experimental|Gemcitabine + Cisplatin + Necitumumab|"Necitumumab administered intravenously (IV) 800 milligram (mg) on Days 1 and 8 of each 3-week cycle.~Gemcitabine administered IV at 1250 milligram per square meter (mg/m^2) on Days 1 and 8 of each 3 week cycle for a maximum of 6 cycles.~Cisplatin administered IV at 75 mg/m^2 on Day 1 of each 3 week cycle for a maximum of 6 cycles."
89603348|NCT01733732|Experimental|Systane Balance|SYSTANE® BALANCE Lubricant Eye Drops, 1 drop in each eye 4 times a day for 30 days
89603349|NCT01733732|Active Comparator|Systane Gel|SYSTANE® Gel, 1 drop in each eye 4 times a day for 30 days
89603350|NCT01732874|Other|Expecta 200 mg|Breastfeeding mothers of pre-mature infants randomly assigned to 200 mg Expecta to be taken orally once a day. Expecta to be taken for approximately 8 weeks post-partum or a shorter time if infant is discharged sooner from NICU.
89603351|NCT01732874|Other|Expecta 1 Gram|Breastfeeding mothers of pre-mature infants randomly assigned to one Gram of Expecta to be taken orally once a day. Expecta to be taken for approximately 8 weeks post-partum or a shorter time if infant is discharged sooner from NICU.
89603352|NCT01732796|Experimental|Allocated 24 weeks BI 207127 + BI 201335|24 weeks of BI 207127 and BI 201335 in combination with Ribavirin
89603353|NCT01732796|Experimental|Randomized 16 weeks BI 7127+BI1335 + RBV|16 weeks of BI 207127 and QD BI 201335 RBV, followed by additional 8 weeks of placebo BI 207127+ placebo BI 201335 in combination with placebo RBV
89603354|NCT01732796|Experimental|Randomized 24weeks BI 7127+ BI1335 + RBV|24 weeks of BI 207127and BI 201335 in combination with RBV
89603355|NCT01732640|Experimental|Study Arm|Eligible patients will begin with a 14-day lead-in period with afatinib alone. This will be followed immediately by 2 cycles of induction chemotherapy (IC) with carboplatin AUC 6 IV Day 1, paclitaxel 175mg/m2 IV Day 1, and oral afatinib as a continuous daily dosing. Each cycle is repeated every 21 days. After completion of 2 cycles of IC, patients will be assessed for response by CT/MRI and clinical exam. After the induction, all patients will receive Intensity Modulated Radiation Therapy (IMRT) with weekly cisplatin 40mg/m2 IV. Chemoradiotherapy (CRT) will begin 2-3 weeks after the completion of the second cycle of IC. The patients will be evaluated with a MRI or CT, and FDG PET approximately 12 weeks after completion of CRT.
89603356|NCT01732484|Other|iMics1 NY-60|eyes with implantation of iMics1 NY-60 IOL
89603357|NCT01732484|Other|AcrySof SN60WF|eyes with implantation of AcrySof SN60WF IOL
89603358|NCT01786148|Active Comparator|Educational music mobile app|A prerecorded program of songs on various topics in a mobile phone application (app). It is designed to provide education about non-health related topics and will be equivalent in length to the intervention app.
89603359|NCT01786148|Experimental|Live Network mobile phone App|The LN is a prerecorded mobile phone application (app). It employs a radio talk show format in which a Disc Jockey entertains HIV medication-, adherence-, and self-management-related questions and comments from callers and poses them to expert care providers, whose responses to these questions are augmented by songs that shed additional light on these issues.
89603360|NCT04560686|Experimental|Treatment (bintrafusp alfa, surgical resection)|Patients receive bintrafusp alfa IV on days 1, 15, and 29 in the absence of unacceptable toxicity. Within 4-6 weeks after last dose of bintrafusp alfa, patients undergo surgery at the discretion of the treating surgeon. Within 8 weeks after surgery, patients may receive chemotherapy or undergo radiation therapy at the discretion of the treating physician.
89603361|NCT01785602|Experimental|QAW039|Participants received QAW039 450 mg daily by mouth.
89603362|NCT01785602|Placebo Comparator|Placebo|Participants received matching placebo to QAW039.
89603363|NCT01785524|Experimental|BR Juice (Beet-It Stamina Shot) & Supervised Exercise Training|Subjects consume 70 ml of Beetroot Juice (Beet-It Stamina Shot) to assess acute effects of beverage supplementation at the start (between Testing Visits 1 & 2) and at the end of the trial (between Visits 3 & 4). It also allows for comparisons of the combination of beetroot juice and chronic training effects (between Visits 2 & 3) to when the subject has not consumed the beverage (Visits 1 & 4). All subjects will consume Beet-It Stamina Shot 3 hours prior to all beverage tolerance visits, Testing Visits 2 & 3 and for all supervised exercise training visits during the 12 week intervention.
89603364|NCT01785524|Placebo Comparator|BR Juice Placebo and Exercise Training|Subjects consume 70 ml of Beetroot Juice (Beet-It Stamina Shot; Placebo) to assess acute effects of beverage supplementation at the start (between Testing Visits 1 & 2) and at the end of the trial (between Visits 3 & 4). It also allows for comparisons of the combination of placebo beverage and chronic training effects (between Visits 2 & 3) to when the subject has not consumed the beverage (Visits 1 & 4). All subjects will consume Beet-It Stamina Shot (Placebo) 3 hours prior to all beverage tolerance visits, Testing Visits 2 & 3 and for all supervised exercise training visits during the 12 week intervention.
89603365|NCT01757288|Active Comparator|PACLITAXEL (Phase II, Arm A)|PACLITAXEL PLUS CARBOPLATIN WITH CONCURRENT RADIATION THERAPY
89603366|NCT01757288|Experimental|NAB-PACLITAXEL (Phase II, Arm B)|NAB-PACLITAXEL PLUS CARBOPLATIN WITH CONCURRENT RADIATION THERAPY nab-Paclitaxel 40 mg/m2 IV/30min/wk x6 wks
89603367|NCT01757288|Experimental|NAB-PACLITAXEL (Phase I)|NAB-PACLITAXEL PLUS CARBOPLATIN WITH CONCURRENT RADIATION THERAPY nab-Paclitaxel 50 mg/m2 IV/30min/wk x6 wks
89603368|NCT01756898|Experimental|Low dose ASB17061|Oral administration of low dose ASB17061 taken once daily for 28 consecutive days.
89603369|NCT01756898|Experimental|Middle dose ASB17061|Oral administration of middle dose ASB17061 taken once daily for 28 consecutive days.
89603370|NCT01756898|Experimental|High dose ASB17061|Oral administration of high dose ASB17061 taken once daily for 28 consecutive days.
89603371|NCT01756898|Placebo Comparator|Placebo|Oral administration of placebo taken once daily for 28 consecutive days.
89603372|NCT01731938|Experimental|Fibrin Sealant (FS) Grifols|Fibrin Sealant Grifols consisting of 3 mL fibrinogen and 3 mL thrombin in separate syringes assembled on a syringe holder (6 mL of solution in total).
89603373|NCT01731938|Active Comparator|Surgicel®|Surgicel® is a sterile, absorbable knitted fabric prepared by the controlled oxidation of regenerated cellulose.
89603374|NCT01731470|Experimental|Liposomes|Liposomes
89603375|NCT01756352|Experimental|GBM Avastin receiving 18F-FET|Recurrent GBM patients receiving Avastin, imaged twice with 18F-FET PET before and approximately 8 weeks after receiving Avastin
88981197|NCT04288778|Experimental|Canagliflozin + Metformin Hydrochloride Immediate Release (IR)|Participants will receive canagliflozin + metformin hydrochloride IR fixed-dose combination, 50 milligram (mg) + 500 mg or 50 mg + 1000 mg, will be provided as tablets for oral administration.
89032442|NCT02936544|Experimental|BAY987521|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
89603376|NCT01756274|Experimental|Neonates 'Left-over' Blood Samples|Blood samples used in this study were 'left-over samples'. The blood samples were from heel sticks of neonates, collected (into a tube) and sent to the laboratory. Two left-over samples could be obtained from a single neonate. Laboratory professionals tested the BG concentration using three Bayer Blood Glucose Monitoring Systems (BGMS): Contour® NEXT BGMS, Contour® PLUS BGMS, and Contour® Next EZ BGMS.
89603377|NCT01731002|Experimental|AR-13324 Ophthalmic Solution 0.01%|1 drop to study eye once daily
89603378|NCT01731002|Experimental|AR-13324 Ophthalmic Solution 0.02%|1 drop to study eye once daily
89603379|NCT01731002|Active Comparator|Latanoprost Ophthalmic Solution 0.005%|1 drop to study eye once daily
89603380|NCT01783886|Experimental|Intravitreal Aflibercept Injection 2Q4|Participants received 2 mg Intravitreal aflibercept injection (IAI) (Eylea, VEGF [vascular endothelial growth factor] Trap-Eye, BAY86-5321) every 4 weeks (2Q4) over 48 weeks.
89603381|NCT01783886|Experimental|Intravitreal Aflibercept Injection 2Q8|Participants received 2 mg Intravitreal aflibercept injection (IAI) (Eylea, VEGF Trap-Eye, BAY86-5321) every 4 weeks until Week 16 and every 8 weeks (2Q8) thereafter, over 48 weeks.
89603382|NCT01783886|Active Comparator|Macular Laser Photocoagulation|Participants received laser treatment at baseline and as needed at visits at which laser retreatment criteria were met, but no more frequently than every 12 weeks over 48 weeks.
89603383|NCT01609556|Experimental|Dose Escalation: Schedule A (Mirvetuximab Soravtansine Q3W)|Participants will receive mirvetuximab soravtansine intravenous (IV) infusion on Day 1 of every 21-day (every 3 weeks [Q3W]) cycle. Dose escalation for this group schedule will start at 0.15 milligrams per kilogram (mg/kg) and proceed through 7.0 mg/kg. Doses calculated initially based on participant's total body weight (TBW); then from protocol amendment 5 onwards, calculated based on adjusted ideal body weight (AIBW). Participants will continue to receive mirvetuximab soravtansine (for clinical benefit) until unacceptable toxicity or withdrawal of consent, whichever comes first, or until the sponsor terminate the study.
89603384|NCT01609556|Experimental|Dose Escalation: Schedule B (Mirvetuximab Soravtansine Weekly)|Participants will receive mirvetuximab soravtansine IV infusion on Days 1, 8, and 15 of every 28-day cycle. Dose escalation for this group schedule will start at 1.1 mg/kg (calculated based on AIBW) and proceed through 2.5 mg/kg. Participants will continue to receive mirvetuximab soravtansine (for clinical benefit) until unacceptable toxicity or withdrawal of consent, whichever comes first, or until the sponsor terminate the study.
89603385|NCT01609556|Experimental|Dose Expansion:EOC Participants(Mirvetuximab Soravtansine Q3W)|Participants with epithelial ovarian cancer (EOC) will receive mirvetuximab soravtansine 6.0 mg/kg (maximum tolerated dose [MTD]) IV infusion on Day 1 of every 21-day (Q3W) cycle (calculated based on AIBW). Participants will continue to receive mirvetuximab soravtansine (for clinical benefit) until unacceptable toxicity or withdrawal of consent, whichever comes first, or until the sponsor terminated the study.
89603386|NCT01609556|Experimental|Dose Expansion: EC Participants(Mirvetuximab Soravtansine Q3W)|Participants with endometrial cancer (EC) will receive mirvetuximab soravtansine 6.0 mg/kg (MTD) IV infusion on Day 1 of every 21-day (Q3W) cycle (calculated based on AIBW). Participants will continue to receive mirvetuximab soravtansine (for clinical benefit) until unacceptable toxicity or withdrawal of consent, whichever comes first, or until the sponsor terminate the study.
89603387|NCT00234832|Experimental|Sibutramine|Subjects were randomized to receive sibutramine 10 mg once daily (QD) during the Treatment Period after a 6-week Lead-in Period
89603388|NCT00234832|Placebo Comparator|Placebo|Subjects were randomized to receive placebo QD during the Treatment Period after a 6-week Lead-in Period
89603389|NCT00234832|Experimental|Lead-in sibutramine|All subjects received 10 mg sibutramine QD during a 6-week Lead-in Period
89603390|NCT00259090|Active Comparator|1|Anastrozole Monotherapy
89603391|NCT00259090|Experimental|2|Fulvestrant Monotherapy
89603392|NCT00259090|Experimental|3|Anastrozole + Fulvestrant
89603393|NCT00235456|Active Comparator|80% perioperative oxygen|Perioperative supplemental oxygen: Patients were randomly assigned to 80% fraction of inspired oxygen (FIO2) intraoperatively and for 6 hours after surgery. Anesthetic treatment and antibiotic administration were standardized.
89603394|NCT00235456|Placebo Comparator|30% perioperative oxygen|Standard oxygen: Patients were randomly assigned to 30% fraction of inspired oxygen (FIO2) intraoperatively and for 6 hours after surgery. Anesthetic treatment and antibiotic administration were standardized.
89603395|NCT00236938|Experimental|Group A|Fixed dose of erythropoietin (EPO) and Venofer (300mg) administered intravenous infusion over 1.5 hours on Days 1 and 15, and Venofer (400mg) administered intravenous infusion over 2.5 hours on Day 29.
89603396|NCT00236938|Active Comparator|Group B|Stable erythropoietin (EPO) dose and no supplemental iron.
89603397|NCT01898728|Active Comparator|Liquid preoperative medications|Liquid preoperative medications
89603398|NCT01898728|Active Comparator|Gel preoperative medications|Gel preoperative medications
88981198|NCT04286165|Active Comparator|BPS webSTAIR 6 Levels with Peer Support|Participants in BPS webSTAIR will complete a baseline, posttreatment and 2-month follow-up assessment. In the BPS webSTAIR condition, participants will first complete a welcome module to orient them to the program. After randomization, participants will have 10 weeks to complete the 6 modules. Every time the Veteran logs on they will have the opportunity to engage with a Veteran peer for support through the web program. Contacts can last for up to an hour. Veterans will receive a series of automated reminders and engagement emails that the Vets Prevail program sends at various points in the program.
88981199|NCT04286165|No Intervention|Wait List|In Wait list, participants will be asked to go about their life as usual. They will be asked not to participate in any other programs for PTSD or depression symptoms for 10 weeks. After the 10 weeks, WL participants can begin any other program for PTSD or depression. They will also be given the option of participating in BPS webSTAIR or be provided with information about other web-based programs that might be of interest or relevant to them.
88981200|NCT04278781|Experimental|Chondrosarcoma|Participants will have locally advanced/metastatic or recurrent operable chondrosarcoma
89210340|NCT05279235|Experimental|JT001& Favipiravir Placebo|JT001 (VV116):Day 1: 600mg, Q12H X 1 day; Day 2~5: 300mg, Q12H X 4 days Favipiravir placebo:Day 1: 1600mg, Q12H X 1 day; Day 2~5: 600mg, Q12H X 4 days
88981201|NCT04275154||CAR-T patients|Relapsed or refractory Diffuse large B-cell lymphoma (DLBCL) or acute lymphoblastic leukemia (ALL) with intent to undergo commercially available CAR-T cell therapy
89603399|NCT00260962|Placebo Comparator|Placebo|Placebo and Treatment as usual (Day Hospital Program). After a 2-week baseline period, placebo was administered for 10 weeks (weeks 3-12 of the study). Day hospital program involved attendance 4 days a week from 9:00 am to 6:00 pm for 12 to 14 weeks, and supervised meals and group therapy.
89603400|NCT00260962|Experimental|Olanzapine Plus Day Hospital|After a 2-week baseline period, Olanzapine was administered for 10 weeks (weeks 3-12 of the study). Olanzapine was prescribed according to a flexible dose regimen, starting at the minimum dose of 2.5 mg/day and titrated slowly by increments of 2.5 mg/week to a maximum dose of 10 mg/day. Day hospital program involved attendance 4 days a week from 9:00 am to 6:00 pm for 12 to 14 weeks, and supervised meals and group therapy.
89603401|NCT00261040|Active Comparator|Minimally Invasive Surgery (MIS)|In minimally invasive surgery, the surgeon makes a shorter incision (about 10 cm or less) along the side of the thigh and replaces the hip through this smaller incision. The surgeon is able to do the surgery through a shorter incision by using special instruments which can guide him or her.
89603402|NCT00261040|Sham Comparator|Standard Surgery|The standard way an orthopaedic surgeon performs a hip replacement surgery is that they make a long incision (about 20 cm) down the side of the thigh and then replaces the hip joint through this long incision
89603403|NCT00237718|Active Comparator|ALA and Vitamin E|600 mg (2 pills 300 mg each) of alpha lipoic acid (ALA) and 666 IU (1 pill) of alpha, gamma, beta and delta (mixed) tocopherols (Vitamin E) taken orally on a daily basis for 6 months
89603404|NCT00237718|Placebo Comparator|Placebo|placebo for ALA (2 pills) and for Vitamin E (1 pill) taken orally on a daily basis for 6 months
89603405|NCT00238108|Experimental|1|Melatonin (2,5 mg, by mouth, 1 per day, for 3-4 weeks)
89603406|NCT00238108|Placebo Comparator|2|Placebo
89603407|NCT01899196|Other|no Arm|
89603408|NCT01898962|Experimental|Definitive locoregional treatment|All sites of active disease should be treated definitively (with one of the interventions listed below). Definitive treatment does not have to be the same for all sites of disease.
89603409|NCT04752124|Active Comparator|HIIT+CT|HIIT combined with conventional rehabilitation.
89603410|NCT04752124|Placebo Comparator|Conventional therapy|Conventional rehabilitation will be provided to this group of patients.
89603411|NCT00266110|Experimental|Dendritic Cell Vaccine|Therapeutic autologous dendritic cells (Dendritic Cell Vaccine) i.d. injection, 20 x 106 DCs given per treatment Trastuzumab infusion Vinorelbine ditartrate infusion
89603412|NCT00240526|Experimental|Engerix 4D + HBIg Group|Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, 6 and 60 with hepatitis B immunoglobulins (HBIg) administered concomitantly at birth in the opposite arm.
89603413|NCT00240526|Experimental|Engerix 3D + HBIg Group|Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, and 6 with hepatitis B immunoglobulins (HBIg) administered concomitantly at birth in the opposite arm.
89603414|NCT00240526|Experimental|Engerix 4D|Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, 6 and 60.
89603415|NCT00240526|Experimental|Engerix 3D Group|Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, and 6.
89603416|NCT01899274|Experimental|bant Group|Subjects in the bant Group will receive care as usual, as well as an iPhone loaded with the bant iPhone application and a bluetooth enabled glucometer. Participants will have their A1C levels measured every 3 months (for 1 year), and also complete questionnaires/interviews relating to their diabetes management and lifestyle.
89603417|NCT01899274|No Intervention|Control Group|Subjects in the control group will continue care as usual with their diabetes team, without supplementation of the bant application. Participants will have their A1C levels measured every 3 months (for 1 year), as well as complete questionnaires/interviews relating to their diabetes management and lifestyle.
89603418|NCT00242632|Experimental|ApoE Non-Carriers|Subjects in this group did not carry the apolipoprotein E-epsilon 4 (apoE-e4) allele. During week 1 of the study, subjects were administered 5 mg of namenda once daily. During week 2 of the study, subjects were administered 5 mg of namenda in the morning and 5 mg in the evening (10 mg/day). During week 3 of the study, subjects were administered 10 mg in the morning and 5 mg in the evening (15 mg/day). During week 4 of the study, subjects were administered 10 mg in the morning and 10 mg in the evening (20 mg/day).
89603419|NCT00242632|Experimental|ApoE Carriers|Subjects in this group carried the apolipoprotein E-epsilon 4 (apoE-e4) allele. During week 1 of the study, subjects were administered 5 mg of namenda once daily. During week 2 of the study, subjects were administered 5 mg of namenda in the morning and 5 mg in the evening (10 mg/day). During week 3 of the study, subjects were administered 10 mg in the morning and 5 mg in the evening (15 mg/day). During week 4 of the study, subjects were administered 10 mg in the morning and 10 mg in the evening (20 mg/day).
88811464|NCT03839654|Experimental|continuous positive airway pressure|The CPAP treatment group received both baseline medicine and CPAP treatment for 7 days preoperatively.
88811465|NCT03839654|No Intervention|non-continuous positive airway pressure|The non-CPAP treatment group received baseline medicine treatment without CPAP treatment.
88811466|NCT04768868|Other|IMP7068|"Part 1: Dose Escalation~The study will begin with open-label dose escalation in IMP7068 monotherapy treatment to determine the Maximum tolerated dose (MTD)~Part 2: Dose Expansion The dose-expansion stage will commence after the Recommended Phase 2 Dose (RP2D) is determined during the dose-escalation stage. A total of 100 patients each with advanced solid tumor who has exhausted available treatment options will be evaluated."
88811467|NCT04754048|Experimental|Traumatic wounds|Treatment with negative pressure wound therapy.
89210341|NCT05279235|Active Comparator|Favipiravir & JT001 Placebo|Favipiravir:Day 1: 1600mg, Q12H X 1 day; Day 2~5: 600mg, Q12H X 4 days JT001 (VV116) placebo:Day 1: 600mg, Q12H X 1 day; Day 2~5: 300mg, Q12H X 4 days
89210342|NCT00903318||Mexican American Men and Women|Rural and urban Mexican American men and women , aged 18 to 40, in urban Baytown, TX and rural Rio Grande Valley (Hidalgo County) communities along the Texas-Mexico border
89603420|NCT01899352|Other|Tracheostomy|The investigators will enroll all the critical ill patients undergoing tracheostomy performed in intensive care units
88811468|NCT04754048|Experimental|Subacute wounds (e.g., dehisced wounds)|Treatment with negative pressure wound therapy.
88811469|NCT04754048|Experimental|Flaps and Grafts|Treatment with negative pressure wound therapy.
88811470|NCT05089526|Active Comparator|ketamine-lidocaine-dexmedetomidine (KLD) group|combination of ketamine-lidocaine-dexmedetomidine in one syringe
89210343|NCT04035252||1. Young healthy group|Male or female between the age of 18 and 40 years old. No presence of systolic blood pressure >140 and/or diastolic blood pressure >90, cardiovascular history or antihypertensive medication
89210344|NCT04035252||2. Patients with an AAA|Individuals (>60 years) with a small, stable, abdominal aortic aneurysm (i.e. AAA diameter of 30-50 mm)
89210345|NCT04035252||3. Healthy older group|Healthy age- and sex- matched with group 2 with no presence of systolic blood pressure >140 and/or diastolic blood pressure >90, cardiovascular history or antihypertensive medication
89603421|NCT01899040|Active Comparator|active device|A standardized active neuromodulation waveform will be used for all active Device patients at all Study sites. The Device will be used twice daily.
89603422|NCT01899040|Placebo Comparator|placebo device|A standardized placebo neuromodulation waveform will be used for all placebo Device patients at all Study sites. The Device will be used twice daily.
89603423|NCT01899430|Active Comparator|metformin|In the MET group metformin was initiated at a dose of 500 mg once per day and increased by 500 mg every 3 days up to 1000 mg BID per os.
89603424|NCT01899430|Experimental|liraglutide|In the LIRA group liraglutide was initiated at a dose of 0.6 mg injected sc once per day and increased to 1.2 mg/day after 1 week.
89603425|NCT00245518|Experimental|Isoflavone|Isoflavone
89603426|NCT00245518|Placebo Comparator|Placebo|
89603427|NCT00267670|Experimental|Pentoxifylline|400mg PO TID
89603428|NCT00267670|Placebo Comparator|Placebo|1 pill PO TID
89603429|NCT00247624|Experimental|A|Participants will receive treatment with eszopiclone and fluoxetine
89603430|NCT00247624|Active Comparator|B|Participants will receive treatment with placebo and fluoxetine
89603431|NCT00248560|Experimental|Gemcitabine, docetaxel|Gemcitabine given 3000 mg/m2 IV over 30 minutes and Docetaxel given 60mg/m2 IV over 60 minutes. The Docetaxel should be administered after the Gemcitabine.
89603432|NCT00248638|Active Comparator|Glutamine dipeptide|Glutamine dipeptide supplemented nutrition to be given to participants.
89603433|NCT00248638|Placebo Comparator|standard|Participants given standard nutrition without glutamine dipeptide
89603434|NCT00249496|Active Comparator|Employment Only|Employment Only participants will be offered employment for one year, but these participants will not have to provide drug-free urine samples to work.
89603435|NCT00249496|Experimental|Contingency Management|Participants in the Contingency Management group will be employed for one year in a Therapeutic Workplace business and will have to provide drug-free urine samples to work and earn salary.
89603436|NCT00268762|Experimental|Intervention|Argatroban IV Infusion 1 mcg/kg/min for 48 hours
89603437|NCT00252382|Experimental|Treatment with 48 mg/m2 of SNS-595|Patients are treated with 48 mg/m2 of the drug SNS-595 injection once every 21 days for up to 6 cycles as a second -line therapy to patients with advanced non-small cell lung cancer (NSCLC)
89603438|NCT00270634|Active Comparator|Low Dose Voclosporin|Low dose voclosporin
89603439|NCT00270634|Active Comparator|Mid Dose Voclosporin|Mid Dose Voclosporin
89603440|NCT00270634|Active Comparator|High Dose Voclosporin|High Dose Voclosporin
89603441|NCT00270634|Active Comparator|Tacrolimus|Standard Dose Tacrolimus
89603442|NCT01899586|Experimental|Regional Specific Training (RSTS)|The RSTS protocol was designed to focus on specific peripheral muscle groups without imposing a significant cardiorespiratory strain. Each exercise involved contractions with moderate load but with an extended duration of up to six minutes. Eight specific exercises were performed to target all major muscle groups and enable the routine to be completed within 60 minutes including warm-up, rest periods and stretching between exercises, and cool down exercises.
89603443|NCT01899586|Experimental|Aerobic Exercise (AE)|Whole-body aerobic exercise at >50% of heart rate reserve (HRR) for 45 minutes, three days per week.
89603444|NCT00252538||Group 1|Research participants are: 1) male or female, 2) age 18 or older, 3) chronically infected with the hepatitis C virus, 4) candidates for interferon therapy, 4) not on antidepressant treatment , and 5) not currently abusing any substances such as alcohol or intravenous drugs, or having abused in the past 6 months
89603445|NCT04110340|Active Comparator|Ciprofloxacin Arm|"Adults: Ciprofloxacin 500mg orally twice daily (or 400mg IV twice daily for those who cannot take oral medication) for 10 days;~Children:Ciprofloxacin 15mg/kg twice daily (max 500mg per dose) orally (or 10mg/kg IV twice daily for those who cannot take oral - maximum dose 400mg) for 10 days."
88811471|NCT05089526|Active Comparator|fentanyl (control) group|syringe of fentanyl
88811472|NCT00804596|Other|Subjects with diabetes|Subjects with diabetes use a new blood glucose monitoring system with subject capillary blood.
88811473|NCT01327313|Experimental|EMD525797 250 milligram (mg)|
88811474|NCT01327313|Experimental|EMD525797 500 mg|
88811475|NCT01327313|Experimental|EMD525797 1000 mg|
88811476|NCT01327313|Experimental|EMD525797 1500 mg|
88811477|NCT04382846|Experimental|Nitazoxanide|Nitazoxanide with standard protocol of treatment
88811478|NCT04382846|No Intervention|Control group|Standard protocol alone
88811479|NCT04641260|Experimental|Fezolinetant: Fed State then Fasted State|Participants will receive a single oral dose of fezolinetant in fed state on day 1 of study period 1. After a washout of 5 days the participants will receive a single oral dose of fezolinetant in fasted state on day 1 of study period 2.
88811480|NCT04641260|Experimental|Fezolinetant: Fasted State then Fed State|Participants will receive a single oral dose of fezolinetant in fasted state on day 1 of study period 1. After a washout of 5 days the participants will receive a single oral dose of fezolinetant in fed state on day 1 of study period 2.
88811481|NCT02200055|Experimental|Bioimpedance Assessment|"The only group will be those patients having major intra-abdominal surgical procedures.~Each patient involved in the study will be evaluated with a bioimpedance monitor ('Bodystat Quadscan 4000') to assess total body water, estimated body water, and intravascular body water volume preoperatively, postoperatively, and daily during the postoperative recovery period.~Bioimpedance Assessment"
88811482|NCT05034926||Cohort 1|Participants with locally advanced or metastatic (stage IIIB-IV) non-small cell lung cancer (NSCLC)
88811483|NCT02200523|Experimental|SARA electrode|new electrode
88811484|NCT02200523|Active Comparator|Gold cup|gold standard
88811485|NCT01328405|Experimental|Air-Q LMA|Air-QⓇ intubating laryngeal mask (Mercury Medical, Clearwater, Fl.)
89603446|NCT04110340|Other|Control arm|"Adults: streptomycin 1g twice daily for three days, followed by ciprofloxacin 500mg orally twice daily (or ciprofloxacin 400mg twice daily by IV for those who cannot take it orally) for an additional 7 days.~OR~2.5mg/kg IV gentamicin twice daily for 3 days followed by ciprofloxacin 500 mg orally twice daily (or ciprofloxacin 400 mg twice daily IV for those who cannot take oral) for a further 7 days.~Children: streptomycin 15mg/kg twice daily for three days followed by ciprofloxacin 15mg/kg twice daily (max 500mg per dose) orally (or 10mg/kg IV twice daily for those who cannot take oral - maximum dose 400mg) for 7 additional days.~OR~2.5mg/kg IV gentamicin twice daily for 3 days, followed by ciprofloxacin 15mg/kg (max 500mg per dose) orally (or 10mg/kg IV twice daily for those who cannot take the oral route) for a further 7 days."
89603447|NCT00270790|Experimental|AMIFOSTINE +CARBOPLATIN, TAXOL +RT|EVALUATION OF AMIFOSTINE FOR MUCOSAL AND HEMOPOETIC PROTECTION AND CARBOPLATIN, TAXOL, RADIOTHERAPY IN THE MANAGEMENT OF PATIENTS WITH HEAD AND NECK CANCER.
89603448|NCT00271570|Active Comparator|Second Dose of IVIG (2g/kg)|Subjects who did not respond to the first dose of IVIG received a 2nd dose of IVIG in this arm (2g/kg)
89603449|NCT00271570|Experimental|Infliximab (5mg/kg)|Remicade (5mg/kg) single dose
89603450|NCT00273364|Experimental|Hematopoietic Stem Cell Transplantation|Hematopoietic Stem Cell Therapy will be performed as follows: Autologous stem cells will be infused after conditioning with Cyclophosphamide and rATG
89603451|NCT00273364|Active Comparator|Standard therapy for MS|Standard treatment with a conventional drug is the treatment with one of the following drugs: Avonex (interferon beta 1a), Betaseron (interferon beta 1b), Copaxone (glatiramer acetate), Aubagio (teriflunomide), Tysabri (natalizumab), Gilenya (fingolimod) or Dimethyl fumarate (Tecfidera or BG-12)
89603452|NCT05237596||Prescription-grade Crystalline Glucosamine Sulfate Group (pCGS Group)|pCGS Group includes patients treated with pCGS (Dona®, VIATRIS), in sachets of powder for oral solution, at the dose of 1500 mg glucosamine sulfate once daily, for a total period of 6 consecutive months according to the approved indication for knee OA, in addition to conventional therapy for HOA.
89603453|NCT05237596||Control Group|Control Group includes patients treated with conventional therapy alone for at least 6 consecutive months.
89603454|NCT02102932|Experimental|12.5 mg empagliflozin/850 mg metformin|24 subjects (12 male and 12 female) will be assigned to 2 treatment sequences. cross-over design was adopted to ensure each patient would take fixed dose combination tablets of 12.5 mg empagliflozin/850 mg metformin and single 10 mg empagliflozin, 2.5 mg empagliflozin, 850 mg metformin tablets single dose in randomized order
89603455|NCT02102932|Experimental|5 mg empagliflozin/850 mg metformin|24 subjects (12 male and 12 female) will be assigned to 2 treatment sequences. cross-over design was adopted to ensure each patient would take fixed dose combination tablets of 5 mg empagliflozin/850 mg metformin and single Empagliflozin(5mg) and metformin (850mg) tablets single dose in randomized order
89603456|NCT02102932|Experimental|12.5 mg empagliflozin/500 mg metformin|24 subjects (12 male and 12 female) will be assigned to 2 treatment sequences. cross-over design was adopted to ensure each patient would take fixed dose combination tablets of 12.5 mg empagliflozin/500 mg metformin and single 10 mg empagliflozin, 2.5 mg empagliflozin, 500 mg metformin tablets single dose in randomized order
89603457|NCT02102932|Experimental|5 mg empagliflozin/500 mg metformin|24 subjects (12 male and 12 female) will be assigned to 2 treatment sequences. cross-over design was adopted to ensure each patient would take fixed dose combination tablets of 5 mg empagliflozin/500 mg metformin and single Empagliflozin(5mg) and metformin (500mg) tablets single dose in randomized order
89603458|NCT00273754|Placebo Comparator|Placebo|Saline
89603459|NCT00273754|Active Comparator|Caffeine|Caffeine benzoate
89603460|NCT04751344|Experimental|Liposomal Bupivacaine|The liposomal bupivacaine study arm will receive 8cc (13.3 mg/mL) liposomal bupivacaine via intravenous route at the completion of the procedure.
89603461|NCT04751344|Active Comparator|Bupivacaine HCl|The Bupivacaine HCl study arm will receive 10cc (5mg/mL) of bupivacaine HCl via intravenous route at the completion of the procedure.
89603462|NCT01790386||Surgical Patients Group|Patients undergoing cardiovascular surgery and cardiology procedures
89603463|NCT01790386||Reference Ranges Group|Healthy volunteer subjects for determination of normal hemostasis parameter results
89603464|NCT05211232|Experimental|GP combined with Tislelizumab neoadjuvant therapy+CCRT+Tislelizumab adjuvant therapy|Patients receive neoadjuvant therapy with gemcitabine(1000mg per square meter on day 1,8) , cisplatin (80mg per square meter on day 1) and tislelizumab(200mg) every three weeks for three cycles before radiotherapy, then followed by concurrent IMRT and cisplatin (100mg per square meter) concurrent every three weeks during radiotherapy (D1,D22,D43 of RT) ,then followed by adjuvant therapy with tislelizumab(200mg) every three weeks for eight cycles after radiotherapy
89603465|NCT05211232|Placebo Comparator|GP combine with Placebo neoadjuvant therapy+CCRT+Placebo adjuvant therapy|Patients receive neoadjuvant therapy with gemcitabine(1000mg per square meter on day 1,8) , cisplatin (80mg per square meter on day 1) and Placebo(200mg) every three weeks for three cycles before radiotherapy, then followed by concurrent IMRT and cisplatin (100mg per square meter) concurrent every three weeks during radiotherapy (D1,D22,D43 of RT) ,then followed by adjuvant therapy with Placebo(200mg) every three weeks for eight cycles after radiotherapy
89603466|NCT00273910|Experimental|Adj-3 A2 gp209(2M) in IFA SQ (vortex)|gp100:209-217(210M) peptide emulsified in MONTANIDE ISA-51 or Montanide ISA 51 VG injected subcutaneously on day one every three weeks (1 cycle) for a total of twelve cycles (33 weeks).
88981202|NCT04270695|Experimental|blood flow restriction|An inflatable cuff (14 cm in width * 84 cm in length) is warped around abdominal muscles below ribs which may cause to at least 60% restriction of blood flow detected by Power Doppler ultrasonography. All participants are instructed to perform abdominal draw-in maneuver both condition of BFR and BFR-free twice a week, for six weeks.
89210346|NCT03917823|Experimental|Cryoneurolysis (active)|The cryoneurolysis device will be triggered using 3 cycles of 2-minute gas activation (active or sham) separated by 1-minute defrost periods.
88981203|NCT04270695|Sham Comparator|sham blood flow restriction|an inflatable cuff (14 cm in width * 84 cm in length) is warped around abdominal muscles below ribs without inflation. All participants are instructed to perform abdominal draw-in maneuver.
89603467|NCT00273910|Experimental|Adj-3 A2 gp209(2M) in IFA SQ + Imiquimod (vortex)|gp100:209-217(210M) peptide emulsified in MONTANIDE ISA-51 or Montanide ISA 51 VG injected subcutaneously on day one every three weeks (1 cycle) for a total of twelve cycles (33 weeks); following the injection patients will apply imiquimod to the skin at the site of injection daily for 5 days.
89603468|NCT00273910|Experimental|Adj-3 A2 gp209(2M) in saline ID|gp100:209-217(210M) in 0.9% Sodium Chloride Injection injected intradermally on day one every three weeks (1 cycle) for a total of twelve cycles (33 weeks).
89603469|NCT00273910|Experimental|Adj-3 A2 gp209(2M) in saline ID + Imiquimod|gp100:209-217(210M) peptide in 0.9% Sodium Chloride Injection injected intradermally on day one every three weeks (1 cycle) for a total of twelve cycles (33 weeks); following the injection patients will apply imiquimod to the skin at the site of the injection daily for 5 days.
89603470|NCT00273910|Experimental|Adj-3 A2 gp209(2M) in IFA SQ (2 Syringe)|gp100:209-217(210M) peptide emulsified in Montanide ISA 51 VG injected subcutaneously on day one every three weeks (1 cycle) for a total of twelve cycles (33 weeks).
89603471|NCT00273910|Experimental|Adj-3 A2 gp209(2M) in IFA SQ + Imiquimod (2 Syringe)|gp100:209-217(210M) peptide emulsified in Montanide ISA 51 VG injected subcutaneously on day one every three weeks (1 cycle) for a total of twelve cycles (33 weeks); following the injection patients will apply imiquimod to the skin at the site of injection daily for 5 days.
89603472|NCT04389034||Adults|Patients with IgE-induced Rhinitis, Conjunctivitis and/or asthma due to tree- and/or grass pollen induced allergy
89603473|NCT00274768|Experimental|Capecitabine|26 patients received the pre-defined starting dose of capecitabine of 3,000 mg orally daily given in two divided doses. Two thirds of the patients received either the same dose or a 500 mg lower dose compared to what would have been administered with a commonly used body surface area (BSA)-dosing schedule (2,000 mg/m2 with rounding down to nearest 500 mg multiple).
89603474|NCT00280384|Active Comparator|E2014 (Botulinum toxin type B)|
89603475|NCT00280384|Placebo Comparator|E2014 (Botulinum toxin type B) Placebo|
89603476|NCT01763996|Experimental|Sequence 1: Febuxostat 80 mg + Placebo|Febuxostat 80 mg, capsules, orally, once daily for 6 weeks in Period 1, followed by febuxostat placebo-matching capsules, orally, once daily for up to 6 weeks in Period 2.
89603477|NCT01763996|Experimental|Sequence 2: Placebo + Febuxostat 80 mg|Febuxostat placebo-matching capsules, orally, once daily for 6 weeks in Period 1, followed by febuxostat 80 mg, capsules, orally, once daily for up to 6 weeks in Period 2.
89603478|NCT01790464|Placebo Comparator|NS gauze|Standard airway anesthesia with 20 ml of aerosolized 2% lidocaine and peritonsillar instillation of gauze soaked in normal saline (Control Group)
89603479|NCT01790464|Active Comparator|Lidocaine gauze|20 ml of aerosolized 2% lidocaine and peritonsillar instillation of gauze soaked with 2% lidocaine (Glossopharyngeal Group).
89603480|NCT01790542|Other|A|Iron fortified cereal
89603481|NCT01790542|Other|B|Iron fortified cereal with fruit
89603482|NCT01790542|Other|C|Meat
89603483|NCT01899820|Active Comparator|Artemether lumefantrine|Tablets, 1-4 tablets (weight calculated dose), BD, at hr 0, 8, 24, 36, 48 and 60.
89603484|NCT01899820|Experimental|Dihydroartemisinin piperaquine|Tablets, 2 paediatric tablets/1 adult tablet, OD, every 24 hours for 48 hours
89603485|NCT02099266|Experimental|Hyperbaric Oxygen Treatment|Administration of hyperbaric oxygen the morning of UCB transplant.
89210347|NCT03917823|Sham Comparator|Sham|For the sham probes, the nitrous oxide will be vented prior to reaching the probe shaft, resulting in a lack of perineural temperature change.
89210348|NCT00229723|Placebo Comparator|1|Radiation + cisplatin; followed by placebo as maintenance therapy
89210349|NCT00229723|Experimental|2|250 mg gefitinib + radiation + cisplatin; followed by placebo as maintenance therapy
89210350|NCT00229723|Experimental|3|500 mg gefitinib + radiation + cisplatin; followed by placebo as maintenance therapy
89603486|NCT04511338|Experimental|Sequence AB: circuit A follow by circuit B|Circuit (A) includes the dialyzer with Endexo and the CombiSet bloodline Circuit (B) includes dialyzer with Endexo and the Streamline bloodline
89603487|NCT04511338|Experimental|Sequence BA: circuit B follow by circuit A|Circuit (B) includes dialyzer with Endexo and the Streamline bloodline Circuit (A) includes the dialyzer with Endexo and the CombiSet bloodline
89603488|NCT04480528|Experimental|BFRT Group|This group will receive physical therapy plus active BFRT.
89603489|NCT04480528|Sham Comparator|Standard of Care Group|This group will receive physical therapy plus sham BFRT.
89603490|NCT02100748|Experimental|TRV130 1 mg|TRV130 1 mg IV Q4H x 48 h
89603491|NCT02100748|Experimental|TRV130 2 mg|TRV130 2 mg IV Q4H x 48 h
88811486|NCT01328405|Experimental|Proseal LMA|LMA-Proseal TM (LMA North America, San Diego, Ca.)
88811487|NCT05021510|Experimental|Simultaneous Cervical Traction & Neural Mobilization|Traction is a maneuver of distracting force to the cervical spine to cervical segments/grants decompression of nerve roots. For traction, 10% of the total body weight would be taken. Previous researches that investigated cervical traction found adequate effectiveness on pain reduction in neck and arm as well as improvement in nerve function parameters, and enhancement in neck mobility. The patient would be placed in a supine lying position with the cervical spine placed at 15º of flexion. The head strap will be fitted under the patient's occiput and chin. A safety switch will be given to the patient and ask him to press it if he would feel any kind of discomfort.
88811488|NCT05021510|Active Comparator|consecutive Cervical Traction & Neural Mobilization|the same description is for active comparator except for treatment mode to consecutive.
89603492|NCT02100748|Experimental|TRV130 3 mg|TRV130 3 mg IV Q4H x 48 h
89603493|NCT02100748|Experimental|TRV130 4 mg|TRV130 4 mg IV Q4H x 48 h
89603494|NCT02100748|Active Comparator|Morphine|Morphine 4 mg IV Q4H x 48 h
89603495|NCT02100748|Placebo Comparator|Placebo|Placebo (D5W) IV Q4H x 48 h
89603496|NCT00283504|Experimental|all patients received Xolair/active drug|One arm:active drug
89603497|NCT04407676|Experimental|Experimental|Patients eligible for an investigator initiated trial are given the standard PIS by email, and are also emailed a summary PIS and access to an online set of 10 video educational modules. They are then administered a demographic data collection form, the Quality of Informed Consent Questionnaire Parts A and B, and a user feedback survey form. They then present for their standard of care consent visit.
89603498|NCT04407676|Placebo Comparator|Control|Patients eligible for an investigator initiated trial are given the standard PIS by email and are then administered a demographic data collection form, the Quality of Informed Consent Questionnaire Parts A and B, and a user feedback survey form. They will then be emailed and are also emailed a summary PIS and access to an online set of 10 video educational modules. They will then perform the QuIC-A and QuIC-B again. They will then present for their standard of care consent visit.
88981204|NCT04262687|Experimental|Immunotherapy + chemotherapy|Xelox bevacizumab plus pembrolizumab every 3 weeks up until disease progression, unacceptable toxicity, refusal by the patient, withdrawal of consent, pregnancy or decision by the investigator.
89603499|NCT04370236|Placebo Comparator|Placebo + Standard of Care|Patients will receive placebo + standard medical care
89603500|NCT04370236|Experimental|INB03 + Standard of Care|Patients will receive INB03 + standard medical care
89603501|NCT00283816|Active Comparator|1|metformin
89603502|NCT00283816|Placebo Comparator|0|placebo
89603503|NCT00284518|Experimental|botulinum toxin Type A 300 U|Botulinum toxin Type A 300 U transperineal or transrectal injection on Day 1.
89603504|NCT00284518|Experimental|botulinum toxin Type A 200 U|Botulinum toxin Type A 200 U transperineal or transrectal injection on Day 1.
89603505|NCT00284518|Experimental|botulinum toxin Type A 100 U|Botulinum toxin Type A 100 U transperineal or transrectal injection on Day 1.
89603506|NCT00284518|Placebo Comparator|Placebo (Normal Saline)|Placebo (Normal Saline) transperineal or transrectal injection on Day 1.
89603507|NCT04339426|Experimental|Atovaquone/Azithromycin|Atovaquone 750 mg PO Q12H for up to 10 days Azithromycin 500 mg PO Day 1 followed by 250 mg PO daily for up to 10 days (Days 2-10)
89603508|NCT01899898|Experimental|Simplified Modified Atkins Diet|
89603509|NCT01899898|Active Comparator|Antiepileptic drugs alone|
89603510|NCT00286078|Experimental|Treatment|Active occipital nerve stimulation (stimulation on)
89603511|NCT00286078|Sham Comparator|Control|Sham occipital nerve stimulation from activation to 12 weeks post-activation. Active occipital nerve stimulation from 12 weeks post-activation on.
89603512|NCT04217902||People living with diabetes in Grenoble and Lyon areas|Eligible patients with type 1 or type 2 diabetes 1) during or after hospitalization for decompensation, ketoacidosis, or other emergency or elective interventions such as insulin pump installation, 2) followed in routine care in specialized diabetes services, 3) participating in patient associations.
89603513|NCT04217902||Health care professionals working in diabetes care in Grenoble|Health care professionals working with diabetes care in specialized services or ambulatory care.
89603514|NCT00287716|Active Comparator|2403 mg/day pirfenidone|Active arm 1, 2403 mg/day pirfenidone dose group.
89603515|NCT00287716|Active Comparator|1197 mg/day pirfenidone|Active arm 2, 1197 mg/day pirfenidone.
89603516|NCT00287716|Placebo Comparator|placebo|Placebo equivalent.
88981205|NCT04250311|Experimental|MMH-407|Oral administration. Single dose: 1 tablet. First 24 hours of therapy: 1 tablet every 30 minutes for the first 2 hours, followed by 3 more tablets taken at regular intervals during the rest of the day. Days 2 to 5: 1 tablet 3 times daily.
88981206|NCT04250311|Placebo Comparator|Placebo|Oral administration. Single dose: 1 tablet. First 24 hours of therapy: 1 tablet every 30 minutes for the first 2 hours, followed by 3 more tablets taken at regular intervals during the rest of the day. Days 2 to 5: 1 tablet 3 times daily.
88981207|NCT04246697|Active Comparator|Standard of Care A|"Randomized controlled prospective trial to compare two standards of care for head and neck surgery pain management. Arm A, will include:~Scheduled Tylenol 1000 mg IV one time dose intra-operatively, then 650 mg via PEG tube or PO Q4H to a max dose of 4gm/24 hrs~Opioids prn based on Numeric Pain Scale (0-10, with 0 indicating no pain and 10 indicating worst pain ever):~0-3: no prn meds, reassurance, listen to music, watch TV.~4-7: Oxycodone 5 mg q4h prn via PEG tube or PO with a maximum of 30 mg/24 hours.~8-10 Morphine 2 mg IV q2h prn breakthrough pain."
88981208|NCT04246697|Experimental|Standard of Care B|"Arm B, will include:~Arm A description with addition..~Scheduled Ketorolac starting post-op day #1, 15 mg q6h (max 120 mg/day), for a total of 5 days~Scheduled Gabapentin starting 7 days preoperatively to continue postoperatively~Regional block per anesthesia protocol - Initial block: 0.5% bupivacaine, 20 ml Continuous infusion: 0.125% bupivacaine at 6 ml/hr with a 5 ml bolus available every 30 mins"
88981209|NCT04246112|Experimental|Treatment group|Participants are diagnosed with tic disorder and/or Tourette syndrome. They will undergo treatment to improve overall handwriting skills.
88981210|NCT04237519|Experimental|SFL training|"Practice recommendation 3 times per week:~Physical exercises: between 30 to 45 minutes that can be split during the day (e.g. 2x15 or 20 minutes, or 3x10 or 15 minutes during the same day).~Cognitive exercises: minimum of 15 min."
88981211|NCT04237519|Active Comparator|Active control training|"Practice recommendation 3 times per week:~Physical exercises: between 30 to 45 minutes that can be split during the day (e.g. 2x15 or 20 minutes, or 3x10 or 15 minutes during the same day).~Cognitive exercises: minimum of 15 min."
88981212|NCT04233242|Experimental|Intervention|The viral load ≥400 c/mL before enrolment triggers genotypic resistance testing (GRT), followed by GRT-informed patient management and counselling. Onward treatment is informed by the resistance profile determined through GRT, with a GRT Expert Committee issuing a treatment recommendation.
89603517|NCT00287872|Experimental|Bortezomib and Thalidomide|The patients will receive Bortezomib on days 1, 4, 8 and 11 of each 21 day cycle in combination with daily oral Thalidomide.
88981213|NCT04233242|No Intervention|Control|Standard of care according to national guidelines and recommendations of the World Health Organization: The viral load ≥400 c/mL before enrolment is followed by 3 sessions of enhanced adherence counselling and a follow-up viral load test. Onward treatment is informed by viral load testing.
89210351|NCT00229723|Experimental|4|gefitinib 250 mg + cisplatin + radiotherapy; followed by gefitinib 250 mg as maintenance therapy
89603518|NCT00288574|Experimental|fluoxetine|fluoxetine up to 80 mg per day
89603519|NCT00288574|Placebo Comparator|Placebo|Placebo
89603520|NCT01791010|Experimental|Inspiratory muscle training|Inspiratory muscle training for 8 weeks using a device that provides a linear resistance in the inspiratory phase. 7 days a week. 8 sets of 2 minutes twice a day. Intensity was at 40% of Maximal Inspiratory Pressure.
89603521|NCT01791010|Sham Comparator|Training sham|Training sham for 8 weeks using a device without provides resistance. 7 days a week. 8 sets of 2 minutes twice a day. Intensity was canceled.
89210352|NCT00229723|Experimental|5|gefitinib 500 mg + cisplatin + radiotherapy; followed by gefitinib 500 mg as maintenance therapy
89603522|NCT00288886|Experimental|Contracts, Prompts and Reinforcement arm|Participants were provided with contracting, prompting and reinforcement of continuing care attendance and substance use abstinence.
89603523|NCT00288886|Active Comparator|Control Arm|Participants were provided with routine care- they did not receive contracting, prompting and reinforcement of continuing care attendance and substance use abstinence.
89603524|NCT00289120|Experimental|Cola beverage|Subjects will be given 500cc of Cola twice daily.
89603525|NCT00289120|Placebo Comparator|Deionized water|Subjects will be given 500cc of deionized water.
89603526|NCT04061590|Experimental|Cohort A (pembrolizumab)|Patients receive 200mg pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery within 4 weeks following study treatment.
89603527|NCT04061590|Experimental|Cohort B (pembrolizumab, cisplatin pemetrexed)|Patients receive 200mg pembrolizumab IV over 30 minutes and chemotherapy (cisplatin/pemetrexed) IV on day 1. Treatment repeats every 21 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery within 4 weeks following study treatment.
89603528|NCT01791088|Experimental|Treatment (sirolimus)|Patients receive sirolimus PO on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89603529|NCT00289744|Experimental|Twinrix Group|Subjects who received 2 doses (at Day 0 and Month 6) of Twinrix in the primary study (208127/076)
89603530|NCT00289744|Experimental|Engerix-B Additional Dose (Adult)|Subjects aged 16 years and above who received an additional dose of EngerixTM-B (adult dose).
89603531|NCT00289744|Experimental|Engerix-B Additional Dose (Pediatric)|Subjects under the age of 16 years who received an additional dose of EngerixTM-B (pediatric dose).
89603532|NCT00291226|Experimental|Glycine|Glycine dosing was fixed at an initial dose of 0.2 g/kg q.h.s for 3 days, then 0.2 g/kg b.i.d. for 4 days, then 0.2 g/kg in the a.m. and 0.4 g/kg in the p.m. for 4 days, and finally 0.4 g/kg b.i.d. Subjects weighing > 100 kg were limited to a total daily dose of 80 g daily. Glycine was dispensed under IND 33,515 (DCJ).
89603533|NCT00291226|Placebo Comparator|Placebo Group|Placebo was dispensed as a proprietary formulations developed by Glytech, Inc, consisting of microencapsulated sucrose. Recommended administration of the sprinkles was to spoon them onto pudding or applesauce and swallow them with minimal chewing. Since earlier product testing by Glytech revealed that a few individuals did not like the somewhat granular texture of the sprinkles, subjects could switch to a second Glytech placebo formulation, consisting of proprietary pre-flavored sugar powders to be dissolved in 8 ounces of water.
89603534|NCT01791166|Experimental|Pulmonary transplant|
89603535|NCT00291694|Active Comparator|1|Oral Celecoxib 400 mg twice daily for 12 months
89603536|NCT00291694|Placebo Comparator|2|Matched blinded placebo twice daily for 12 months
89603537|NCT00292162|Active Comparator|medical therapy|Standard therapy for heart failure with angiotensin converting enzyme inhibitors(ACE) - (Ramipril, enalapril, lisinopril, captopril, perindopril), beta-blocker (BB) - (carvedilol, bisoprolol, metoprolol), Aldosterone antagonists (spironolactone) +/- diuretics and digoxin
89603538|NCT00292162|Active Comparator|Radiofrequency ablation (RFA)|Isolation of the pulmonary veins using radiofrequency ablation
89603539|NCT00296296|Active Comparator|Cyclosporin|Patients receive cyclosporin (dose-adjusted to pre-established targets) as immunosuppressive calcineurin inhibitor (CNI) and Diabetes Education / Management (therapeutic adjustment to target American Diabetes Association (ADA) criteria)
89603540|NCT00296296|Active Comparator|Tacrolimus|Patients receive tacrolimus (dose-adjusted to pre-established targets) as CNI and Diabetes Education / Management (therapeutic adjustment to target ADA criteria)
89603541|NCT03880786|Experimental|PNE test lead|
89603542|NCT01791400|Other|sumatriptan|Patients who underwent 6 mg sumatriptan subcutaneous one time
89603543|NCT01791400|Other|Metoclopramide|Patients who underwent 20 mg Metoclopramide intravenous one time
89603544|NCT00298090||StO2 values|StO2 monitoring
89603545|NCT00298558|Active Comparator|Memory Training|Memory training focused on verbal episodic memory. Participants were taught mnemonic strategies for remembering lists and sequences of items, text material, and main ideas and details of stories and other text-based information.
89603546|NCT00298558|Active Comparator|Reasoning Training|Reasoning training focused on the ability to solve problems that follow a serial pattern. Participants were taught strategies to identify the pattern or sequence required to solve a problem.
89603547|NCT00298558|Active Comparator|Speed of Processing Training|Speed of processing training focused on visual search and the ability to identify and locate visual information quickly in a divided attention format. Participants practiced increasingly complex speeded tasks on a computer.
89603548|NCT00298558|Placebo Comparator|Control|This group did not complete any cognitive training interventions
89603549|NCT00300430|Active Comparator|A|20 mg drug and ABT-335
89603550|NCT00300430|Active Comparator|B|40 mg drug and ABT 335
89603551|NCT00300430|Active Comparator|C|40 mg drug and ABT-335
89210353|NCT00229723|Placebo Comparator|6|placebo + cisplatin + radiotherapy; followed by gefitinib 250 mg as maintenance therapy
89603552|NCT02104414|Active Comparator|Exparel|266mg/20mL Exparel (to be diluted with 10 mL sterile saline to make 30 mL)
89603553|NCT02104414|Active Comparator|Bupivacaine HCl with epinephrine|75mg/30mL 0.25% Bupivacaine HCl with epinephrine
89603554|NCT02104414|Placebo Comparator|Normal Saline|30mL Normal Saline
89603555|NCT02100826|Active Comparator|Cephalexin (Test)|Cephalexin manufactured in Italy by Facta administered once orally in one of two study periods.
89603556|NCT02100826|Experimental|Cephalexin (Reference)|Cephalexin manufactured in Mexico by Eli Lilly administered once orally in one of two study periods.
89603557|NCT02101918|Experimental|Treatment (ziv-aflibercept, perfusion CT)|Patients receive ziv-aflibercept IV over 60-120 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo computed tomography perfusion imaging at baseline, day 21 of course 1, and at time of progression.
89603558|NCT04271722|Experimental|Mifepristone|Mifepristone 200mg 24hours before the induction day
89603559|NCT04271722|Active Comparator|Balloon catheter|Balloon catheter with 40ml placed 24hours before the induction day
89603560|NCT02102230|Experimental|CBT-I|Group Cognitive-Behavioral Therapy for Insomnia (CBT-I)
89603561|NCT02102230|Active Comparator|CBT-I-MA|Group Cognitive-Behavioral Therapy for Insomnia Plus Mobile App (CBT-I-MA)
89603562|NCT02102230|Placebo Comparator|PC|Desensitization Treatment for Insomnia (DTI)
89603563|NCT00300742|Experimental|Topiramate|Drug: Topiramate Other Name for Topiramate: Topamax
89603564|NCT00301756|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive belinostat IV over 30 minutes on days 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89603565|NCT00302068|Experimental|1|Supervised aerobic exercise, three times per week for 16 weeks.
89603566|NCT00302068|Active Comparator|2|Sertraline (Zoloft), for 16 weeks.
89603567|NCT00302068|Placebo Comparator|3|Placebo control, for 16 weeks.
89603568|NCT00302848||Users of Drospirenone (DRSP)|
89603569|NCT00302848||Users of Levonorgestrel (LNG)|
89603570|NCT00302848||Users of other oral contraceptives (OCs)|
89603571|NCT00138034|Active Comparator|Percutaneous coronary intervention (PCI)|Stenting of the culprit lesion of the infarct related artery and aspirin and clopidorgel for at least 6 months
89603572|NCT00138034|Other|Dual antiplatelet therapy|Aspirin and clopidogrel for at least 6 months
89603573|NCT00303862|Experimental|Treatment (cediranib maleate)|Patients receive oral AZD2171 once daily for 4 weeks. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.
89603574|NCT00304096|Experimental|Stratum 1: Receiving Hormone Therapy|Patients treated with 9 peptide vaccine who received hormone therapy
89603575|NCT00304096|Experimental|Stratum 2: Not receiving hormone therapy|Patients receiving 9 peptide vaccine who did not receive hormone therapy
89603576|NCT05267392|Experimental|Durvalumab|All subjects enrolled in the study will receive open-label neoadjuvant durvalumab 1500 mg followed by standard of care RT/RCT
89603577|NCT00140842||Obese girls|The inclusion criteria will be girls 12-18 years of age. According to the Centers for Disease Control and Prevention, the definition of obesity is a BMI higher than the 95th percentile for age and sex, and that of overweight is a BMI between the 85th and 95th percentiles. Cases will be defined as having a body mass index (BMI) greater than the 95th percentile for age according to the 2000 Centers for Disease Control and Prevention growth charts.
89603578|NCT00140842||Normal-weight girls|
89603579|NCT00142168|Experimental|CC-5103 (Lenalidomide) and Rituximab|Intended therapy consisted of 48 weeks of CC-5103 (lenalidomide)(25 mg/d for 3 weeks and then 1 week off) along with rituximab (375 mg/m(2)/wk) dosed on weeks 2 to 5 and 13 to 16.
89603580|NCT02501434|No Intervention|Control|Standard of Care
89603581|NCT02501434|Experimental|LDIVH (Unfractionated Heparin)|Continuous Low-Dose IV Unfractionated Heparin Infusion
89603582|NCT02247232|Placebo Comparator|Placebo|
89603583|NCT02247232|Experimental|Z-100|
89603584|NCT01791634|Experimental|proximal open wedge osteotomy with LPS system|Proximal open wedge osteotomy with Low profile plate and screws
89603585|NCT01791634|Active Comparator|proximal wedge osteotomy|Proximal wedge osteotomy procedure
89603586|NCT02159560|Active Comparator|End holed catheter|Single holed, end holed epidural catheter
89603587|NCT02159560|Active Comparator|Three holed catheter|closed ended, three side holed epidural catheter
89603588|NCT05267314|No Intervention|standard therapy|standard therapy
89603589|NCT05267314|Experimental|exerciser and standard therapy|exerciser and standard therapy
89603590|NCT01594372|Active Comparator|Laparoscopic Repair|Laparoscopic supracervical hysterectomy with sacropexy
89603591|NCT01594372|Active Comparator|Vaginal Repair|Vaginal hysterectomy with uterosacral colposuspension
89603592|NCT00147082||COPD|Patients with COPD - no intervention
89603593|NCT00147082||Smokers without COPD|Smokers without COPD - no intervention
88981214|NCT04233164|Experimental|Group A: Glucocorticoids 1 mg/kg dose|Participants with Systemic Lupus Erythematosus (SLE) received a single intravenous dose of methylprednisolone 1 mg/kg and blood was collected two hours and four hours after the start of the infusion.
89603594|NCT00147082||Non-smokers|Non-smokers with no history of respiratory disease - no intervention
89603595|NCT00147316|Experimental|Alteplase|0.6mg/kg intravenous alteplase with 10% being administered as a bolus followed by continuous infusion of the remainder over 1 hour
89603596|NCT00148798|Experimental|Cetuximab plus chemotherapy|cetuximab + cisplatin + vinorelbine
89603597|NCT00148798|Active Comparator|Chemotherapy alone|cisplatin + vinorelbine alone
89603598|NCT00148954|Active Comparator|Implantable Cardioverter Defibrillator - Boston Scientific|VITALITY 2 ICD
89603599|NCT00148954|Active Comparator|Implantable Cardioverter Defibrillator - Medtronic|Selected Medtronic family ICD
89603600|NCT00149734|Experimental|Ondansetron followed by placebo|Participants will take ondansetron then placebo plus an atypical antipsychotic drug
88981215|NCT04233164|Experimental|Group B: Glucocorticoids 250 mg dose|Participants with Systemic Lupus Erythematosus (SLE) received a single intravenous dose of 250 mg of methylprednisolone and blood was collected two hours and four hours after the start of the infusion.
89210354|NCT00229723|Placebo Comparator|7|placebo + cisplatin + radiotherapy; followed by gefitinib 500 mg as maintenance therapy
89210355|NCT04035798|Experimental|memantine (MM)|The participants will receive memantine 5mg (1 capsule) per day for 12 weeks.
89603601|NCT00149734|Experimental|Placebo followed by Ondansetron|Participants will take placebo then ondansetron plus an atypical antipsychotic drug
89603602|NCT00198328|Active Comparator|Surgery Control|Patients receive surgical excision of their tumor.
89603603|NCT00198328|Experimental|MedPulser EPT|Patients receive electroporation with injection of Bleomycin Sulfate.
89603604|NCT00305578|Placebo Comparator|Placebo|Placebo daily
89603605|NCT00305578|Active Comparator|Memantine|Daily dose Memantine
89603606|NCT01790074|Experimental|TrP therapy|TrP manual therapy comprises different manual approaches, e.g., compression, stretching, or transverse friction massage applied over active TrPs in the sternocleidomastoid muscle
89603607|NCT01790074|Placebo Comparator|TrP manual control therapy|The treatment consisted of a simulation of the same TrP therapy treatment applied to the experimental group without the application of any therapeutic pressure.
89603608|NCT01492101|Experimental|NKTR-102|
88981216|NCT04230265|Experimental|UniCAR02-T-CD123|Preconditioning (lymphodepletion) with cyclophosphamide and fludarabine, followed by combination treatment of genetically modified T-cells carrying universal chimeric antigen receptors (UniCAR02-T) with the recombinant antibody derivative TM123.
88981217|NCT04227275|Experimental|Dose Escalation|Dose escalation of intravenous CART-PSMA-TGFβRDN cells for patients with metastatic castration resistant prostate cancer
88981218|NCT04222023|Experimental|IVIG group|Administration of a single dose of IVIG at day 10+/- 4 days, day 41 +/- 7 days and day 62 +/- 7 days. The dose of IVIG is defined according the donor BKV genotype: genotype I: 0.4 g/Kg/day; genotype II and IV: 1g/kg/day.
88981219|NCT04222023|No Intervention|Control group|
88981220|NCT04221061|Other|Non-surgical candidates|In this arm, subjects that do not have a clinical indication for surgical resection of the recurrent tumor will start TTFields therapy 5-7 days prior to starting oral niraparib (a PARP inhibitor).
88981221|NCT04221061|Other|Surgical candidates|In this arm, subjects who have a clinical indication for surgical resection of the recurrent tumor will receive TTFields therapy for 5-7 days prior to planned surgical resection, undergo resection, and then resume TTFields therapy and initiate niraparib post-operatively.
88981222|NCT04215887||Sleep unit|Children admitted to sleep unit for sleep study
88981223|NCT04215887||School|Healthy children in school
88981224|NCT04215887||Emergency department|Children seen in triage in emergency department at SCH
88981225|NCT04215887||General practice|Adults or children attending general practice
88981226|NCT04215887||Ambulance|Adults or children in rapid response vehicle
88981227|NCT04207580||Inclusion and follow up of pediatric patients|"Inclusion and follow up of pediatric patients with an idiopathic nephrotic syndrome, from the beginning of the disease to 18 years old or transfer of the follow-up to a nephrology unit for adults.~130 new patients are expected to be included on an annual basis."
88981228|NCT04204993|Experimental|Experimental: Influenza A|Participants will be inoculated with Influenza A/Belgium/4217/2015 at a dose of 5x105 TCID50 in a volume of 0,5mL via intranasal drops or spray. They will then be monitored as in-patients for 10 days with daily clinical assessment and blood, respiratory tract sampling, and sensor monitoring. Following discharge, they will be followed up for up to 6 months post-inoculation.
88981229|NCT04198649|Experimental|Azithromycin|62 patients Non-surgical periodontal treatment and two 250mg azithromycin tablets one time daily for 3 days
88981230|NCT04198649|Placebo Comparator|Placebo|62 patients Non-surgical periodontal treatment and two 250mg starch tablets one time daily for 3 days
88981231|NCT04197141|Active Comparator|Conventionally-fractionated WPRT|15 Gy HDR brachytherapy boost will be administered followed by 45 Gy WPRT in 25 fractions. Androgen Deprivation Therapy (ADT) may also be prescribed at the discretion of the treating physician.
88981232|NCT04197141|Experimental|Hypofractionated WPRT|15 Gy HDR brachytherapy boost will be administered followed by 25 Gy WPRT in 5 fractions. Androgen Deprivation Therapy (ADT) may also be prescribed at the discretion of the treating physician.
88981233|NCT04188535|Experimental|Esophageal Cohort|"The research study procedures include:~Screening for eligibility~Three MRI scans (prior to start of standard cancer treatment, in the middle, and at the end of radiation treatment). Imaging with MRI will be performed as per disease site standards."
88981234|NCT04188535|Experimental|Glioblastoma Cohort|"The research study procedures include:~Screening for eligibility~Three MRI scans prior to start of standard cancer treatment, in the middle, and at the end of radiation treatment). Imaging with MRI will be performed as per disease site standards."
88981235|NCT04188535|Experimental|Glioblastoma Expansion Cohort Serial MR Imaging Registry|"The research study procedures include:~Screening for eligibility~Three MRI scans prior to start of standard cancer treatment, in the middle, and at the end of radiation treatment). Imaging with MRI will be performed as per disease site standards."
88981236|NCT04188535|Experimental|Prostate Cancer Cohort|"The research study procedures include:~Screening for eligibility~Three MRI scans prior to start of androgen deprivation therapy, prior to the start of radiation treatment, and after radiation treatment). Imaging with MRI will be performed as per disease site standards.~Genomic testing of biopsy sample"
89210356|NCT04035798|Placebo Comparator|Placebo|The participants will receive one capsule of placebo per day for 12 weeks.
89210357|NCT01075477||Cohort|
89603609|NCT01492101|Active Comparator|Physician's Treatment of Choice|
88981237|NCT04188535|Experimental|Prostate Cancer Expansion Cohort Serial MR Imaging Registry|"The research study procedures include:~Screening for eligibility~Three MRI scans prior to start of androgen deprivation therapy, prior to the start of radiation treatment, and after radiation treatment). Imaging with MRI will be performed as per disease site standards.~Genomic testing of biopsy sample"
88981238|NCT04188535|Experimental|Vulvar Cancer Cohort|"The research study procedures include:~Screening for eligibility~Three MRI scans prior to start of standard cancer treatment, in the middle, and at the end of radiation treatment). Imaging with MRI will be performed as per disease site standards."
88981239|NCT04188535|Experimental|Pediatric Glioma Cohort|"The research study procedures include:~Screening for eligibility~Three MRI scans prior to start of standard cancer treatment, in the middle, and at the end of radiation treatment). Imaging with MRI will be performed as per disease site standards."
88981240|NCT04177706|Experimental|Group A (Ketamine)|
88981241|NCT04177706|Placebo Comparator|Group B (Placebo)|
88981242|NCT04166513|Experimental|Targeted tDCS with Phonologic-Focused Speech Therapy|Participants will receive phonologic-focused speech therapy with targeted anodal-tDCS for 10 therapy sessions before.
88981243|NCT04166513|Active Comparator|Active Control tDCS with Phonologic-Focused Speech Therapy|Participants will receive phonologic-focused speech therapy with active control tDCS for 10 therapy sessions.
88981244|NCT04166513|Experimental|Targeted tDCS with Semantic-Focused Speech Therapy|Participants will receive semantic-focused speech therapy with targeted anodal-tDCS for 10 therapy sessions.
88981245|NCT04166513|Active Comparator|Active Control tDCS with Semantic-Focused Speech Therapy|Participants will receive semantic-focused speech therapy with active control tDCS for 10 therapy sessions.
88981246|NCT04163328|Experimental|HydroEye®|Subjects will take a total of four capsules daily, with meals (two capsules taken orally, twice a day).
89603610|NCT01468311|Experimental|Yttrium-90-labeled Daclizumab + Chemotherapy|Yttrium-90-labeled Daclizumab + BCNU, etoposide, cytarabine and melphalan (BEAM) + Auto stem cell transplant (ASCT)
89603611|NCT00306202|Experimental|Stratum 1 (Ph+ CP-CML)|Participants with imatinib-resistant Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in chronic phase (CP)
89603612|NCT00306202|Experimental|Stratum 2/3 (Ph+ ALL or AP/BP-CML)|Participants with imatinib-resistant or imatinib-intolerant Ph+ CML in accelerated phase (AP), or in myeloid blast phase (MBP), or in lymphoid blast phase (LBP); or relapsed or refractory Ph+ acute lymphoblastic leukemia (ALL) after imatinib use; or second or subsequent relapse of Ph+ acute myeloid leukemia (AML)
89603613|NCT00306202|Experimental|Stratum 4 (Ph- ALL/AML)|Participants with second or subsequent relapse of Ph- ALL or Ph- AML
89603614|NCT05267002|Experimental|Suture removal at 1 week|Cutaneous nylon suture removal of half of the split-scar at one week.
89603615|NCT05267002|Experimental|Suture removal at 2 weeks|Cutaneous nylon suture removal of half of the split-scar at two weeks.
89603616|NCT00308230|Placebo Comparator|Normal Heart|Control Group with Normal Heart
89603617|NCT00308230|Active Comparator|Congenital Heart Disease|Tetralogy of Fallot, DTGA, CCTGA
89603618|NCT00308230|Active Comparator|Heart Failure|Left ventricular heart failure, no congestive heart disease
89603619|NCT00325078|Experimental|Treatment|Study drug (TNFa inhibitor-infliximab or adalimumab) treated group.
89603620|NCT00325078|No Intervention|Observation|Subjects with IBD without TNFa inhibitor treatment
89603621|NCT00325780|Experimental|Pitavastatin 4 mg QD|Pitavastatin 4 mg once daily
89603622|NCT00326170|Experimental|VPA + 5-aza + ATRA|Daily for 7 days, Valproic acid (VPA) starting dose 75 mg/m^2 subcutaneously in combination with 5-azacytidine (5-aza) 50 mg/kg orally; and all-trans retinoic acid (ATRA) 45 mg/m^2 orally daily (in two divided doses) for 5 days starting on day 3.
89603623|NCT00326872|Experimental|Treatment (cediranib maleate)|Patients receive oral AZD2171 once daily on days 1-28. Treatment repeats every 28 days for 26 courses in the absence of disease progression or unacceptable toxicity. Patients with responding or stable disease may continue treatment beyond 26 courses in the absence of disease progression or unacceptable toxicity. Quality of life is assessed at baseline, prior to course 2, prior to course 4, and every 6 courses thereafter.
89603624|NCT05266690|Experimental|Sequence 1|Roquette Glucidex 40 - Roquette Glucidex 2 - Pharmacosmos Dextran 10 - Promitor 70
89603625|NCT05266690|Experimental|Sequence 2|Roquette Glucidex 2 - Promitor 70 - Roquette Glucidex 40 - Pharmacosmos Dextran 10
89603626|NCT05266690|Experimental|Sequence 3|Promitor 70 - Pharmacosmos Dextran 10 - Roquette Glucidex 2 - Roquette Glucidex 40
89603627|NCT05266690|Experimental|Sequence 4|Pharmacosmos Dextran 10 - Roquette Glucidex 40 - Promitor 70 - Roquette Glucidex 2
89603628|NCT00328042|Experimental|Self-Management Workshop|
89603629|NCT00328042|Active Comparator|Information Only|
89603630|NCT00329524|Sham Comparator|Active versus Sham Treatment|Subjects randomly assigned to active and sham TMS separated by one week interval.
89603631|NCT01730534|Experimental|Dapagliflozin|Dapagliflozin + standard of care therapy for Type 2 Diabetes and for co-morbidities and cardiovascular risk factors
89603632|NCT01730534|Placebo Comparator|Placebo|Placebo + standard of care therapy for Type 2 Diabetes and for co-morbidities and cardiovascular risk factors
89603633|NCT00329836||Subjects with cluster headache|Subjects with both episodic and chronic cluster (as defined by the International Headache Society-IHS) were enrolled.
89603634|NCT00330382|Experimental|Arm I (Bowman-Birk inhibitor concentrate)|Patients receive oral Bowman-Birk inhibitor concentrate twice daily for 6 months
89603635|NCT00330382|Placebo Comparator|Arm II (placebo)|Patients receive oral placebo twice daily for 6 months
88981247|NCT04163328|Placebo Comparator|Placebo|Subjects will take a total of four capsules daily, with meals (two capsules taken orally, twice a day).
88981248|NCT04161443|Experimental|Experimental|"Following physiotherapy treatment will be given to the participants in this group for 4 weeks and each session last for 30 minutes.~i. MET Quadratus lumborum ii. Ultrasound iii. Gluteus medius exercises iv. Hamstring stretch Posture advice and home exercise program"
88981249|NCT04161443|Active Comparator|Comparator|"Following physiotherapy treatment will be given to the participants in this group for 4 weeks and each session last for 30 minutes.~i. Ultrasound ii.Gluteus medius exercises iii.Hamstring stretch"
88981250|NCT04147195|Experimental|LYS006|LYS006 20 mg was administered orally twice per day (b.i.d) for 12 weeks
88981251|NCT04147195|Experimental|LYS006 + LJN452|LYS006 20 mg was administered orally twice per day (b.i.d) in addition to LJN452 200ug administered orally once daily for 12 weeks
88981252|NCT04140344|Experimental|ARM 1: Text Message Group|The intervention group will receive automated text messages every day for the first week, and every other day for the second week post-operatively. The text messages will follow a series of pre-defined standardized scripts (Appendix 3) with embedded hyperlinks to a video from the providers with further advice. The patient is directed not to respond to the text messages, but to call for any questions or concerns. The text message group will receive a 30-day post-operative phone call to evaluate: number of ED visits, hospital readmissions, and to re-administer the questionnaires completed at baseline visit. Other data to be collected may include the following: number of phone calls to provider, MyChart messages to provider, pain medications, and new problems like pain and infection.
88981253|NCT04140344|No Intervention|ARM 2: Control group|The control group will be given the standard post-op packet that includes detailed instructions on proper wound care and signs and symptoms of infection. They will not receive text messages. The same outcomes will be assessed in both groups through a 30-day post-operative phone call.
89603636|NCT01791712|Experimental|On-line hemodiafiltration|On-line hemodiafiltration is a type of renal replacement therapy that was assigned as the intervention to compare with the control arm
89603637|NCT01791712|Active Comparator|High-flux hemodialysis (control)|The standard high-flux hemodialysis is the routine renal replacement therapy in sepsis-related acute kidney injury patients and is assigned as the intervention for the control group.
89603638|NCT01783730||Participants with high rheumatoid arthritis disease activity|Participants who received adalimumab treatment
89603639|NCT05266534|Active Comparator|intramyometrial Terlipressin injection in women undergoing open myomectomy|intramyometrial Terlipressin injection
89603640|NCT05266534|Active Comparator|intramyometrial Carbetocin injection in women undergoing open myomectomy|intramyometrial Carbetocin injection
89603641|NCT05266534|Placebo Comparator|intramyometrial saline injection in women undergoing open myomectomy procedure|intramyometrial saline injection in women
89603642|NCT01730378|Experimental|Prepandrix Group|Subjects in this group received 2 doses of Prepandrix™ vaccine at Days 0 and 21. The vaccine was administered intramuscularly in the deltoid region of arm (non-dominant arm at Day 0 and dominant arm at Day 21).
89603643|NCT01730378|Active Comparator|Fluarix Group|Subjects in this group received 1 dose of Fluarix™ vaccine at Day 0. The vaccine was administered intramuscularly in the deltoid region of non-dominant arm.
89603644|NCT01783496|Active Comparator|Framed Tip|Treatment with Thermage CPT Framed Tip
89603645|NCT01783496|Experimental|Pattern Tip|Treatment with the Thermage CPT Pattern Tip
88981254|NCT04133883|Other|Haemophilia A patients|Treated on-demand or prophylaxis with any Factor VIII (FVIII) product, plasma derived or recombinant (conventional or extended-half life) FVIII, according to routine clinical practice.
88981255|NCT04126473|Experimental|ELX-02|Eukaryotic ribosomal selective glycoside (ERSG)
88981256|NCT04119336|Experimental|Nivolumab and Ixazomib|"- Participants will receive Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone on a 28-day cycle.~Oral:~Ixazomib given weekly on days 1, 8, 15~Dexamethasone given weekly during cycle~Infused:~Nivolumab given once per cycle~Cyclophosphamide given on days 1, 8, 15 during cycle"
88981257|NCT04118374|Experimental|Standard Carb Diet then Low Carb Diet|
88981258|NCT04118374|Experimental|Low Carb Diet then Standard Carb Diet|
88981259|NCT04115306|Experimental|PMD-026|Oral PMD-026 (dose: 25 - 1000 mg), given daily until disease progression or unacceptable toxicity
88981260|NCT04112316|Active Comparator|Liothyronine (LT3)|Liothyronine (L-triiodothyronine or LT3) in the 5 mcg tablet dose formulation. Minimum LT3 dose will be 2.5 mcg three times daily and the maximum LT3 dose will be 12.5 mcg three times daily.
88981261|NCT04112316|Placebo Comparator|Placebo|A placebo tablet matching in appearance to LT3 tablets dosed equivalently. Minimum placebo tablet dose will be 1/2 tablet (2.5 mcg equivalent) three times daily and the maximum placebo dose will be 2 1/2 tablets (12.5 mcg equivalent) three times daily.
88981262|NCT04111354|Active Comparator|Short-term (4-hours) immobilization.|Short-term (4-hours) immobilization after primary pacemaker implantation.
88981263|NCT04111354|Active Comparator|Long-term (16-24 hours) immobilization.|Long-term (16-24 hours) immobilization after primary pacemaker implantation.
88981264|NCT04107649|Other|Arm1|Participants in this arm receive usual post-operative care and complete all basic study activities, which include: attending 2 in-clinic visits at designated time-points, having regular check-in calls with study staff over the intervention period, wearing and returning waist-worn activity trackers at 5 time points over two years, and completing 6 study surveys.
88981265|NCT04107649|Experimental|Arm2|Participants in this arm receive usual post-operative care, complete all basic study activities (as described in arm 1) and receive the wrist-based activity tracker intervention.
88981266|NCT04107649|Experimental|Arm3|Participants in this arm receive usual post-operative care, complete all basic study activities (as described in arm 1), receive wrist-based activity tracker intervention, and receive the TAC(MI)+FI.
88981267|NCT04100109|Active Comparator|Polylactose|Subjects randomized to this arm of the study will be asked to consume 15 grams/day of foods containing polylactose
88981268|NCT04100109|Active Comparator|Placebo|Subjects randomized to this arm of the study will be asked to consume 15 grams/day of foods containing cellulose, which is an inert dietary fiber, and which will act as our placebo for this project.
88981269|NCT04092816|Experimental|FAMILY|Patient-co-parent dyads will participate in the FAMILY intervention in-person.
88981270|NCT04092101|Experimental|RC 1 only|Research Cigarettes #1
88981271|NCT04092101|Experimental|RC 2 only|Research Cigarettes #2
88981272|NCT04092101|Experimental|RC 2 + EC 1|Research Cigarettes #2 plus E-cigarettes #1
88981273|NCT04092101|Experimental|RC 2 + EC 2|Research Cigarettes #2 plus E-cigarettes #2
88981274|NCT04090879|Experimental|RC 1 only|Research Cigarettes #1
88981275|NCT04090879|Experimental|RC 2 only|Research Cigarettes #2
88981276|NCT04090879|Experimental|RC 2 + EC 1|Research Cigarettes #2 plus E-cigarettes #1 (participants receive tobacco flavor only)
89603646|NCT01783496|Experimental|Pattern Tip Group 2|Treatment with the Thermage CPT Pattern tip
88981277|NCT04090879|Experimental|RC 2 + EC 2|Research Cigarettes #2 plus E-cigarettes #2 (participants can choose among varying flavors)
88981278|NCT04089020|Experimental|Psychosocial intervention|Text messaging and health coaching over the telephone to address goal setting, monitoring, motivation, problem solving, and related skills, delivered over 6 weeks.
88981279|NCT04087291|Active Comparator|Phase 1: Low Dose (1-5 visits)|Veterans with cLBP who will be randomly allocated to undergo a course of a low dose (1-5 visits) of multimodal, evidence-based chiropractic care for 10 weeks (Phase 1).
88981280|NCT04087291|Active Comparator|Phase 1: Higher Dose (8-12 visits)|Veterans with cLBP who will be randomly allocated to undergo a course of a higher dose (8-12 visits) of multimodal, evidence-based chiropractic care for 10 weeks (Phase 1).
88981281|NCT04087291|Active Comparator|Phase 2: CCPM|After Phase 1, Veterans with cLBP who will be randomly allocated again to receive chiropractic chronic pain management (CCPM) consisting of scheduled monthly chiropractic care for 10 months.
88981282|NCT04087291|No Intervention|Phase 2: No CCPM|After Phase 1, Veterans with cLBP who will be randomly allocated again to receive no CCPM in which they will receive no chiropractic care for 10 months.
88981283|NCT04056208|Active Comparator|Evening Pistachio Consumption|Participants will consume two ounces per day (57 g) of pistachios as an evening snack (i.e., after dinner and before sleep).
89603647|NCT01783496|Experimental|Total Tip|Treatment with the Thermage CPT Total tip
89603648|NCT01783496|Experimental|Framed and Patterned Tip|Split face treatment with the Thermage CPT Framed and Patterned tips
89603649|NCT01783496|Experimental|Total and Patterned Tip|Split face treatment with the Thermage CPT Total and Patterned tips
89603650|NCT04559750|Experimental|Internet-delivered behavior therapy (I-BT|10 weeks of (I-BT) delivered via the Internet.
89603651|NCT00314236|Experimental|Microfracture with BST-CarGel|BST-CarGel applied to a Microfractured lesion in repair of focal articular cartilage lesions on the femoral condyle
89603652|NCT00314236|Active Comparator|Microfracture without BST-CarGel|Microfractured lesion in repair of focal articular cartilage lesions on the femoral condyle
89603653|NCT01729208|Experimental|Dual Focus Soft Contact Lens|Dual Focus Soft Contact Lens
89603654|NCT01729208|Placebo Comparator|Single Vision Soft Contact Lens|Single Vision Soft Contact Lens
89603655|NCT00331162|Active Comparator|1|Alemtuzumab
89603656|NCT00331162|Active Comparator|2|Anti-Thymocyte Globulin
89603657|NCT01790230|No Intervention|Standard of Care|Standard of Care Arm - subjects treated by routine manner
89603658|NCT01790230|Experimental|LifeSeal™ Kit|LifeSeal™ Kit Arm - subjects treated with the LifeSeal™ Kit device + Standard of Care treatment
89603659|NCT01790308|Active Comparator|CSII|continuous subcutaneous insulin infusion for 2-4 weeks
89603660|NCT01790308|Active Comparator|Liraglutide|continuous subcutaneous insulin infusion for 2-4 weeks combined with combined with Liraglutide 0.6mg/d for 2-4 weeks and 1.2mg/d for next 9 weeks
89603661|NCT01609010|Active Comparator|Rituximab Monotherapy|Participants received 375 milligrams per square meter (mg/m2) rituximab intravenously (i.v.) weekly for 4 weeks. Participants achieving minor response (MR), partial response (PR), or completer response (CR) received a second cycle of treatment.
89603662|NCT01609010|Experimental|Rituximab, Interferon|Participants received 375 mg/m2 rituximab i.v. weekly for 4 weeks; and 3 million international units per day (MIU/day) interferon-a2a subcutaneously (s.c.) during Week 1, and 4.5 MIU/day s.c. 6 days per week during Weeks 2 through 5. Interferon-a2a was not administered on days of rituximab administration. Participants achieving MR, PR, or CR received a second cycle of treatment.
89603663|NCT01608308|Experimental|IV Acetaminophen|The experimental group will receive a preoperative dose of 1000mg IV acetaminophen over 15 minutes. This will occur at least 15 minutes before the start of surgery. Another 1000mg dose of IV acetaminophen will be administered 4 hours after the first dose. A rescue analgesic containing oxycodone will also be provided (with APAP concentrations of 325 mg per Hospital and FDA recommendations).
89603664|NCT01608308|Placebo Comparator|Control|The control group (Placebo) will receive 100 mL of 0.9% normal saline in place of IV acetaminophen in the same manner as the experimental group; the investigator/physician in question will be blinded to the agent that is being administered. Patients will be discharged with instruction to continue APAP 500 mg PO every 6-8 hours. A rescue analgesic containing oxycodone will also be provided (with APAP concentrations of 325 mg per Hospital and FDA recommendations).
89603665|NCT00332644|Experimental|1|nicotine patch alone treatment
88811489|NCT04639622|Other|asymptomatic at-risk individual|First-degree relative of a family member affected with the frontotemporal dementia.
89603666|NCT00332644|Experimental|2|nicotine lozenge alone treatment
89603667|NCT00332644|Experimental|3|nicotine patch + lozenge combination treatment
89603668|NCT00332644|Experimental|4|bupropion alone treatment
89603669|NCT00332644|Experimental|5|bupropion + nicotine lozenge combination treatment
89603670|NCT00332644|Placebo Comparator|6|placebo control (no active medication) treatment
89603671|NCT01755416|Placebo Comparator|Closed loop with sensor and Insulin|subject will be on the closed loop device with enlite sensors for about 27 hours. They will not be on any study medication and will be on insulin alone.
89603672|NCT01755416|Active Comparator|Closed loop with sensor, Insulin and Liraglutide|Subject will be on the closed loop device with enlite sensors for about 27 hours. In addition to being on insulin, they would take a single injection of 1.2 mg of Liraglutide subcutaneously before dinner, on Day 1.
89603673|NCT01755026|Active Comparator|2 gram dose of cefazolin|2 gram dose of pre-operative cefazolin
88811490|NCT04639622|Other|symptomatic individual|Patient who has been clinically diagnosed by a neurologist as having frontotemporal dementia or a disorder in the FTD spectrum
88811491|NCT01274897|Experimental|MenACWY-CRM|Subjects received one dose of MenACWY-CRM conjugate vaccine.
88811492|NCT01274897|Placebo Comparator|Placebo|Subjects received the saline placebo.
88811493|NCT04693130|Experimental|Mindfulness-based prenatal education|The intervention includes 3-hour classes per week during the duration of eight weeks and a 7- hour silent meditation practice as well.
88811494|NCT04693130|Placebo Comparator|Hospital-based antenatal education|Hospital-based antenatal education program.
89603674|NCT01755026|Experimental|4 gram Dose|4 gram dose of pre-operative prophylaxis
88811495|NCT02323217|Experimental|Healthy Volunteers|
88811496|NCT01275053|Experimental|Leptin|
88811497|NCT02324075|Experimental|Behavior change|Behavior change messaging with facilitating hardware
88811498|NCT02324075|No Intervention|Control Arm|Standard habits and practices
88811499|NCT04979234|Experimental|Interventional|Endoscopic gastric reduction
88811500|NCT04382768|Experimental|Luarprofen|Inhaled Hypertonic ibuprofen 50 mg tid
88811501|NCT04617548|Experimental|tDCS and CO-OP Group|One-hour session three times per week for 4 weeks. Participants will receive anodal tDCS (1.5 mA) to the dorsolateral prefrontal cortex (dlPFC) for 20 minutes at the beginning of each session. Following each tDCS session, the participants will complete a sensations questionnaire.The basis for each session will be task-based practice of client-chosen goals and the use of cognitive strategies using CO-OP.
88811502|NCT00811382|Experimental|1: Access to HMSC (Home Monitoring Service Center)|Full functionality of the Home Monitoring System for an early optimization of CRT and management of AF with a full access for the treating physician to the HMSC
88811503|NCT00811382|Active Comparator|2: No access to HMSC|Limited access of the treating physician to the HMSC where only events regarding implant and lead status will be generated and sent to the physician.
89603675|NCT00332722|Active Comparator|Group 1- without steroid|Cervical Facet Joint Nerve block with Local Anesthetic (0.5 mL of 0.25% Bupivacaine with/without 0.5 mL of Sarapin)
89603676|NCT00332722|Active Comparator|Group 2 - with steroid|Cervical Facet Joint nerve block with Local Anesthetic (0.5 mL of 0.25% Bupivacaine with/without 0.5 mL of Sarapin) and 0.15 mg of non-particulate betamethasone)
89603677|NCT01491945|Experimental|Ventana Fenestrated Stent Graft System|Ventana Fenestrated Stent Graft System
89603678|NCT00333814|Active Comparator|1|Dexamethasone 350 µg
89603679|NCT00333814|Active Comparator|2|Dexamethasone 700 µg
89603680|NCT00333814|Sham Comparator|3|Sham
88811504|NCT04155164|Experimental|Metformin|Participants will receive Metformin for 12 months.
88811505|NCT04155164|Placebo Comparator|Placebo|Participants will receive placebo for 12 months.
89603681|NCT01728584|Experimental|Standard NMB and Standard Insufflation Pressure|Treatment condition for this arm is Standard NMB (depth of blockade at a targeted Train of Four [TOF] ratio of 10%)/Standard insufflation pressure (starting pressure of 12 mmHg).
89603682|NCT01728584|Experimental|Standard NMB and Low Insufflation Pressure|Treatment condition for this arm is Standard NMB (depth of blockade at a targeted TOF ratio of 10%)/Low insufflation pressure (starting pressure of 8 mmHg).
89603683|NCT01728584|Experimental|Deep NMB and Standard Insufflation Pressure|Treatment condition for this arm is Deep NMB (depth of blockade of 1-2 PTCs)/Standard insufflation pressure (starting pressure of 12 mmHg).
89603684|NCT01728584|Experimental|Deep NMB and Low Insufflation Pressure|Treatment condition for this arm is Deep NMB (depth of blockade of 1-2 PTCs)/Low insufflation pressure (starting pressure of 8 mmHg).
89603685|NCT00315328|Active Comparator|Patching|Patching 2 hours per day plus near activities for one hour while patching (with increase to 4 hours per day for moderate amblyopes and >4 hours per day for severe amblyopes at 5 weeks if acuity not improved at least 5 letters)
89603686|NCT00315328|Active Comparator|Atropine|Atropine 1% once each weekend day in the sound eye plus near activities for at least one hour every day (with increase to daily atropine at 5 weeks if acuity not improved by at least 5 letters)
89603687|NCT05265988|Experimental|Meridian|Cabozantinib at initial dosage of 40 mg per day and continuation of androgen deprivation therapy
89603688|NCT04345822||normotension|patients without diagnosis or treatment for hypertension
89603689|NCT04345822||hypertension|patients with diagnosis or treatment for hypertension
89603690|NCT01522443|Experimental|Cabozantinib|"Subjects randomized to the cabozantinib arm will also receive placebo mitoxantrone injections (color-matched with methylene blue) and placebo prednisone capsules.~There will be a maximum of 10 infusions for mitoxantrone placebo."
89603691|NCT01522443|Active Comparator|Mitoxantrone/prednisone|"Subjects randomized to the mitoxantrone + prednisone arm will also receive placebo cabozantinib tablets.~There will be a maximum of 10 infusions for mitoxantrone."
89603692|NCT00334204|Other|Measure Platelet Function Analyser -100 (PFA-100)|measuring Platelet Function Analyser (PFA)-100 test (an in vitro platelet function test, in addition to the rest of the routine/uusal clinical care)
89603693|NCT00336700|Experimental|Gemcitabine and Erlotinib|Erlotinib (oral) 150 mg/day x 12 months Gemcitabine 1500 mg/m2 IV over 150 minutes q 2 weeks x 4 months
89603694|NCT01468233|Placebo Comparator|Placebo|Placebo for 12 weeks.
89603695|NCT01468233|Experimental|Adalimumab Every Week (EW)|Adalimumab ew for 12 weeks (160 mg at Week 0; 80 mg at Week 2; and 40 mg ew from Week 4 to Week 12).
89603696|NCT01468233|Placebo Comparator|Placebo/Placebo|Participants randomized to receive placebo in Period 1 received placebo every week from Week 12 to Week 35 in Period 2 (up to 24 weeks).
89603697|NCT01468233|Experimental|Adalimumab Every Week (EW)/Placebo|Participants randomized to receive adalimumab ew in Period 1 were re-randomized to receive placebo ew from Week 12 to Week 35 in Period 2 (up to 24 weeks).
89603698|NCT01468233|Experimental|Adalimumab Every Week (EW)/ Adalimumab Every Other Week (EOW)|Participants randomized to receive adalimumab ew in Period 1 were re-randomized to receive 40 mg adalimumab eow from Week 12 to Week 35 in Period 2; placebo injections were administered eow from Week 13 to Week 35 (up to 24 weeks).
89603699|NCT01468233|Experimental|Adalimumab Every Week (EW)/Adalimumab Every Week (EW)|Participants randomized to receive adalimumab ew in Period 1 were re-randomized to receive 40 mg adalimumab ew from Week 12 to Week 35 in Period 2 (up to 24 weeks).
89603700|NCT01468077|Experimental|Tocilizumab, Normal Administration|Tocilizumab 8 mg/kg infusion of 60 minutes duration every 4 weeks for 6 infusions (up to 24 weeks)
89603701|NCT01468077|Experimental|Tocilizumab, Fast Administration|Tocilizumab 8 mg/kg infusion of 31 minutes duration every 4 weeks for 6 infusions (up to 24 weeks). The first infusion was 1 hour. If an infusion reaction occurred during any treatment, 1 hour infusions were used for all subsequent infusions
89603702|NCT01522365|Active Comparator|Abutment-supported XiVE CAD/CAM bridge|After randomization one side of the jaw will be provided with a XiVE CAD/CAM bridge placed on an abutment.
89603703|NCT01522365|Active Comparator|Implant-supported XiVE CAD/CAM bridge|After randomization one side of the jaw will be provided with a XiVE CAD/CAM bridge placed directly on an implant.
89603704|NCT03026673||NSAID use|The purpose of this study is to establish that NSAIDS are an appropriate analgesic to be used in the postpartum period, and thus women in the immediate postpartum period are the focus of this study.
89603705|NCT01783418|Experimental|Mindfulness intervention|
89603706|NCT01783418|Active Comparator|Wait-list control|
89603707|NCT01521897||7-valent vaccine injection|Infants starting to receive Prevenar at the age of more than 2 and less than 7 months
89603708|NCT01782872|Active Comparator|Interscalene Block (ISB) - 0.375% Ropivacaine + additives|
89603709|NCT01782872|Active Comparator|Interscalene Block (ISB) - 0.2% Ropivacaine + additives|
89603710|NCT01782872|Active Comparator|Interscalene Block (ISB) - 0.1% Ropivacaine + additives|
89603711|NCT01782872|Active Comparator|Interscalene Block (ISB) - Systemic Control|
89603712|NCT01490697|Experimental|Mifepristone plus d-Cycloserine (DCS)|DCS 100 mg capsule orally followed by mifepristone1800 mg tablet orally 4 hours later and 90 minutes prior to traumatic memory retrieval via the traumatic event script preparation procedure, all on Day 7.
89603713|NCT01490697|Placebo Comparator|Placebo plus Placebo|Placebo-matching DCS 100 mg capsule orally followed by placebo-matching mifepristone1800 mg tablet orally 4 hours later and 90 minutes prior to traumatic memory retrieval via the traumatic event script preparation procedure, all on Day 7.
89603714|NCT01728194|Experimental|Escitalopram|Target dose 20mg for 12 weeks
89603715|NCT01728194|Other|Control|Non-psychiatric comparison participants.
89603716|NCT04408911||Midazolam|Critically ill intensive care unit patients receiving midazolam
89603717|NCT04408911||Lormetazepam|Critically ill intensive care unit patients receiving lormetazepam
89603718|NCT01782482|Experimental|AIR OPTIX® COLORS|Lotrafilcon B contact lens with color worn on a daily wear basis for 7 days. Lenses were worn bilaterally for a minimum of 5 days per week, 8 hours per day.
89603719|NCT01782482|Active Comparator|FRESHLOOK® COLORBLENDS|Phemfilcon A contact lens with color worn on a daily wear basis for 7 days. Lenses were worn bilaterally for a minimum of 5 days per week, 8 hours per day.
89603720|NCT01466673|Experimental|Ethinyl estradiol/Norgestimate (EE/NGM)|
89603721|NCT01466673|Active Comparator|Ethinyl estradiol/Desogestrel (EE/DSG)|
89603722|NCT01753856|Experimental|Teriparatide|"20 micrograms (µg) teriparatide administered subcutaneously (SC) once every day for 6 months.~Demeclocycline (DEM): Beginning 18 days prior to randomization: Days 1, 2, 3 and 16, 17, 18: 150 milligrams (mg) DEM will be taken orally every 6 hours; Days 4 to15: DEM will not be administered.~Tetracycline (TET): Beginning 22 days prior to the biopsy procedure: Days 1, 2, 3 and 16, 17, 18: 250 mg TET will be taken orally every 6 hours; Days 4 through 15: TET will not be administered.~Calcium: Approximately 1000 milligrams per day (mg/day) administered orally.~Vitamin D: Approximately 800 to 1200 International Units per day (IU/day) administered orally."
89603723|NCT01753856|Active Comparator|Denosumab|"60 mg denosumab administered SC once in 6 months.~DEM: Beginning 18 days prior to randomization: Days 1, 2, 3 and 16, 17, 18: 150 mg DEM will be taken orally every 6 hours; Days 4 to 15: DEM will not be administered.~TET: Beginning 22 days prior to the biopsy procedure: Days 1, 2, 3 and 16, 17, 18: 250 mg TET will be taken orally every 6 hours; Days 4 through 15: TET will not be administered.~Calcium: Approximately 1000 mg/day administered orally.~Vitamin D: Approximately 800 to 1200 IU/day administered orally."
89603724|NCT01464333||Humira|Participants who were prescribed Humira per approved prescribing information of Humira in Japan.
89603725|NCT01464255|Experimental|ocufilcon D|Participants wear a first pair of lenses for one week and then crossover and wear an alternate second pair of lenses for one week.
89603726|NCT01464255|Active Comparator|ocufilcon B|Participants wear a first pair of lenses for one week and then crossover and wear an alternate second pair of lenses for one week.
89603727|NCT04559204|Experimental|experimental group|408 subjects from experimental group will be simultaneously administrated with one dose of IIV (0.5 ml) and one dose of PPV23 (0.5 ml). Blood samples are collected before vaccination and one month (30 days) later.
89603728|NCT04559204|Active Comparator|control group A|408 subjects from control group A will be only administrated with one dose of IIV (0.5 ml). Blood samples are collected before vaccination and one month (30 days) later.
89603729|NCT04559204|Active Comparator|control group B|408 subjects from control group B will be only administrated with one dose of PPV23 (0.5 ml). Blood samples are collected before vaccination and one month (30 days) later.
89603730|NCT01464021||Adalimumab|Chinese adult participants with a diagnosis of rheumatoid arthritis (RA) (any disease duration) who meet the requirements per the local label for treatment with adalimumab. Participants must be naïve to adalimumab at the Baseline visit.
89603731|NCT01753310|Active Comparator|Dysport®|Dysport® (intramuscular injection), between 250 and 500 units (U)/vial using 2mL dilution, 1 cycle only
89603732|NCT01753310|Placebo Comparator|Placebo|Placebo, up to 2mL
89603733|NCT01463631|Experimental|LY3007113|Study has a dose escalation phase (Part A) and dose confirmation phase (Part B). Participants in the dose escalation phase will receive 1 of 6 doses of LY3007113 administered orally every 12 hours for at least one cycle. Participants in the dose confirmation phase will receive the maximum tolerated dose from the dose escalation phase administered orally every 12 hours for at least 1 cycle. Three days prior to the start of the first cycle, participants will receive 1 dose at their assigned level to allow for the collection of single dose pharmacokinetics. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met.
89603734|NCT04408365||COVID-19 patients|Adult COVID-19 patients admitted to intensive care units
89603735|NCT04100577|Experimental|TNT PISP intervention|Participants in TNT PISP intervention group will come to once monthly educational support group sessions and will be additionally enrolled in the community based doula program where they will receive 1 on 1 doula and lactation support throughout their pregnancy, delivery, and postpartum period. They will receive prenatal care clinical visits on their own with their prenatal care provider. In phase 2 of the study, participants will be offered on site prenatal care once per month.
89603736|NCT04100577|No Intervention|Control|Participants in control group will have no enhanced prenatal care support. They will attend visits on their own with their prenatal care provider and participation in this research study will not interfere with the prenatal care.
89603737|NCT01521507|Experimental|LipiFlow System|Treatment with LipiFlow System at randomization in Stage 1 of study
89032443|NCT02936427|No Intervention|Control|Control group will receive normal post operative care including intercostal wound catheters however will not receive dexamethasone
89603738|NCT01521507|Active Comparator|Warm Compress and Lid Hygiene|Control group receiving warm compress therapy and lid hygiene at randomization in Stage 1 of study and crossover LipiFlow System treatment in Stage 2 of study
89603739|NCT01521117|Experimental|Donepezil, Then Placebo|Donepezil 5 mg a day for weeks 1 - 3, if tolerated increased to 10 mg a day for weeks 4 - 6. After a washout period of 4 weeks, placebo 5 mg a day for weeks 1 - 3, if tolerated increased to 10 mg a day for weeks 4 - 6.
89603740|NCT01521117|Experimental|Placebo, Then Donepezil|"Placebo 5 mg a day for weeks 1 - 3, if tolerated increased to 10 mg a day for weeks 4 - 6.~After a washout period of 4 weeks, donepezil 5 mg a day for weeks 1 - 3, if tolerated increased to 10 mg a day for weeks 4 - 6."
88811506|NCT00806078|Experimental|1|Single dose intact capsules 2 x 324 mg
88811507|NCT00806078|Experimental|2|Single dose contents of two capsules (2 x 324 mg) opened and mixed in 120 mL of chocolate pudding
88811508|NCT00806234|Active Comparator|1|Participants will continue on current antipsychotic medication.
88811509|NCT00806234|Experimental|2|Participants will undergo a staggered switch from current antipsychotic medication to aripiprazole or perphenazine.
88811510|NCT00806234|Experimental|3|Participants will add metformin to current antipsychotic medication treatment.
88811511|NCT00807560|Experimental|FBT-PO|Family Based Therapy for Pediatric Overweight.
88811512|NCT00807560|Active Comparator|NEC-control|Nutritional Educational Control Condition (NEC).
88811513|NCT01275365|No Intervention|Placebo/Low Protein|Placebo injections weekly; 0.8 g/kg/day protein
88811514|NCT01275365|No Intervention|Placebo/High Protein|Placebo injections weekly; 1.3 g/kg/day protein
88811515|NCT01275365|Other|Testosterone/Low Protein|Testosterone enanthate 100 mg intramuscularly weekly; 0.8 g/kg/day protein
88811516|NCT01275365|Other|Testosterone/High Protein|Testosterone enanthate 100 mg intramuscularly weekly; 1.3 g/kg/day protein
89603741|NCT01466595|Experimental|Arm A: Treatment with rifaximin|Participants were administered one 550 mg tablet of rifaximin to be taken orally two times a day for 4 weeks.
89603742|NCT01466595|No Intervention|Arm B: No study treatment|No study treatment for 4 weeks
89603743|NCT02073747|Placebo Comparator|Normal Saline Control Group|Control group will be administered a one hour normal saline inhaled treatment.
89603744|NCT02073747|Active Comparator|Albuterol Trial Group|Trial group to be administered one hour treatment of ten milligrams of inhaled albuterol
89603745|NCT01728116|Experimental|Device (EndoBarrier)|Device for glycemic control
89603746|NCT01728116|Sham Comparator|Sham Procedure|sham procedure
89603747|NCT01465659|Experimental|Temozolomide 100 mg/m2 and Pazopanib 400 mg|Temozolomide 100 mg/m2 on days 1-7 and 15-21 , Pazopanib 400 mg on days 1-28
89603748|NCT01465659|Experimental|Temozolomide 75 mg/m2 and Pazopanib 400 mg|Temozolomide 75 mg/m2 on days 1-7 and 15-21 , Pazopanib 400 mg on days 1-28
89603749|NCT01465659|Experimental|Temozolomide 150 mg/m2 and Pazopanib 400 mg|Temozolomide 150 mg/m2 on days 1-7 and 15-21 , Pazopanib 400 mg on days 1-28
89603750|NCT03027531|Experimental|Control|Control group entered sexual history via computer assisted self-interview and provided specimens for chlamydia, gonorrhea and pregnancy(females) testing. The do not receive the feedback intervention of eKISS: electronic KIOSK for safer-sex
89603751|NCT03027531|Experimental|Intervention|Intervention group entered sexual history via computer assisted self-interview and received the interactive computer-based intervention with individualized feedback eKISS: electronic KIOSK for safer-sex. They provided specimens for chlamydia, gonorrhea and pregnancy(females) testing.
88811517|NCT00811850|Active Comparator|Combigan®|Combigan® (fixed combination of brimonidine tartrate 0.2%/timolol maleate 0.5% ophthalmic solution). One drop of study medication taken approximately 12 hours apart, dosed 2 times a day for a total of two weeks.
88811518|NCT00811850|Active Comparator|Cosopt®|Cosopt® (fixed combination of dorzolamide hydrochloride - timolol maleate ophthalmic solution). One drop of study medication taken approximately 12 hours apart, dosed 2 times a day for a total of two weeks.
88811519|NCT03678506|Experimental|Positive D-Dimer|At the first positive D-dimer results (during anticoagulation or after its temporary withdrawal) the patients are invited to assume Eliquis (apixaban) 2.5 mg twice daily, and continue this therapy for the following 18 months.
88811520|NCT03678506|No Intervention|Negative D-Dimer|Patients with persistently negative results at the four serial D-dimer measurements, stay definitively without anticoagulation and discouraged to resume any antithrombotic drug for secondary VTE prevention.
88811521|NCT01328873|Experimental|Laboratory testing|All patients will receive the lab testing on bronchoscopy specimens
88811522|NCT00844298|Experimental|Nilotinib+mVPD|Patients who were Philadelphia-positive, newly-diagnosed adult ALL and treated with nilotinib + mVPD treatment plan
88811523|NCT01329185|Placebo Comparator|Placebo|Eligible consenting kidney transplant donors who are randomized to receive placebo will be given 1 placebo in morning and 1 in evening for 14 days prior to transplant date
89210358|NCT04006275|Experimental|Sonovue and Sonazoid Group|"Subjects were randomized to receive SonoVue firstly and Sonazid secondly after wash out period. Between the wash out period(at least 30min) and after whole trial, the patients was carefully observed at observing room for at least 30min.~Contast agent dose: Sonazoid (0.12 μL/kg of perflubutane microbubbles) or SonoVue (2.4 mL) in a 1:1 ratio."
89603752|NCT01753076|Experimental|Ozanezumab IV|Administered by IV route. Treatment period - 48 Weeks
89603753|NCT01753076|Placebo Comparator|Placebo|Normal saline by IV route. Treatment period - 48 weeks
89603754|NCT01463007|Experimental|Radiation|AccuBoost APBI- 34.0 Gy in 10fx
89603755|NCT01463007|Experimental|Extended Follow up|This arm extends follow up at the Rhode Island Hospital location to 5 years. Annual mammograms and additional documentation is required to be submitted only if completed.
89603756|NCT01462929|Experimental|Aclidinium bromide|Aclidinium bromide 400 µg administered twice per day during 6 weeks of treatment
89603757|NCT01462929|Active Comparator|Tiotropium|Tiotropium bromide 18 µg administered once per day during 6 weeks of treatment
89603758|NCT01462929|Placebo Comparator|Placebo|Placebo comparator administered during 6 weeks of treatment
89603759|NCT01462695|Experimental|Treatment (sunitinib)|Patients receive sunitinib malate orally (PO) once daily (QD) on days 1-28. Treatment repeats every 42 days for up to 18 courses in the absence of disease progression or unacceptable toxicity.
89603760|NCT01465347|Experimental|TSC 0.25 mg/kg for 9 or 18 doses|This was an open-label, sequential-cohort, dose-escalation study in two phases. Phase 1 was a safety run-in evaluating Trans Sodium Crocetinate (TSC) in 3 subjects who received 3 doses per week for 3 weeks (9 doses in total). Phase 2 engaged 56 subjects who received 3 doses per week for 6 weeks (18 doses in total). TSC was consistently dosed at 0.25mg/kg in both phases.
89603761|NCT03027687|Experimental|Real transcranial Direct Current Stimulation|This group will receive bilateral tDCS (left cathodal/right anodal) over the DLPFC. The stimulation will take place two times daily for 13 minutes with a rest interval of 20 minutes for three days in one week.
89603762|NCT03027687|Sham Comparator|Sham tDCS|The control group receives sham, for which the stimulator will be gradually turned off after 30 seconds.
89603763|NCT01465191|Experimental|50 micrograms (mcg) spinal morphine|Subjects will receive 50 mcg morphine in their spinal anesthetic for cesarean section
89603764|NCT01465191|Experimental|100 micrograms spinal morphine|Subjects will receive 100 mcg morphine in their spinal anesthetic for cesarean section
89603765|NCT01465191|Experimental|150 micrograms spinal morphine|Subjects will receive 150 mcg morphine in their spinal anesthetic for cesarean section
89603766|NCT01519947|Active Comparator|Pre-dialysis, sea level|Participants received 50-250 mcg SC according to local label.
89603767|NCT01519947|Active Comparator|Dialysis, sea level|Participants received 50-250 mcg SC according to local label.
89603768|NCT01519947|Experimental|Pre-dialysis, >1800 meters|Participants received 50-250 mcg SC according to local label.
89603769|NCT01519947|Experimental|Dialysis, >1800 meters|Participants received 50-250 mcg SC according to local label.
89603770|NCT01462227|Experimental|Naltrexone (higher dose)|Naltrexone 100mg tablets were randomly given on 1 of 2 occassions (the other was placebo). The drug was administered 12 hours and 1 hour orally pre-procedure to participants. Placebo was given to the high dose group on 1 of their 2 visits- the order in which placebo was given was randomized by dosage arm.
89603771|NCT01462227|Experimental|Naltrexone (lower dose)|Naltrexone 50mg tablets were randomly given on 1 of 2 occassions (the other was placebo). The drug was administered 12 hours and 1 hour orally pre-procedure to participants. Placebo was given to the low dose group on 1 of their 2 visits- the order in which placebo was given was randomized by dosage arm.
89603772|NCT01464879|Experimental|Testosterone 2.50 mL (hand)|Subjects in this arm self-applied two strokes (2.50 mL) of testosterone gel by hand, one stroke to the shoulder/upper arm and a second stroke to the contralateral shoulder/upper arm every day for seven days.
89603773|NCT01464879|Experimental|Testosterone 1.25 mL (applicator)|Subjects in this arm self-applied one stroke (1.25 mL) of testosterone gel by applicator to the shoulder/upper arm every day for seven days.
89603774|NCT01464879|Experimental|Testosterone 2.50 mL (applicator)|Subjects in this arm self-applied two strokes (2.50 mL) of testosterone gel by applicator, one stroke to the shoulder/upper arm and a second stroke to the contralateral shoulder/upper arm every day for seven days.
89603775|NCT01464879|Experimental|Testosterone 3.75 mL (applicator)|Subjects in this arm self-applied three strokes (3.75 mL) of testosterone gel by applicator, one stroke to the shoulder/upper arm and a second stroke to the contralateral shoulder/upper arm and a third stroke to the first shoulder/upper arm, every day for seven days.
89603776|NCT01519869|Experimental|neoadjuvant chemotherapy|platinum-based neoadjuvant chemotherapy followed by interval surgical debulking with platinum-based adjuvant chemotherapy
89603777|NCT03026205|Experimental|Single Arm|ARMS-I dosage of 0.75 mg will be sprayed orally in the mouth once as a single dose of four sprays on Day 1, and then three times a day starting on Day 3 for 4 Days.
89603778|NCT01519791|Experimental|Certolizumab Pegol + Methotrexate|
89603779|NCT01519791|Placebo Comparator|Placebo + Methotrexate|
88811524|NCT01329185|Experimental|Valganciclovir|Eligible consenting kidney transplant donors who are randomized to the experimental arm of the study will receive 450mg of Valganciclovir twice a day for 14 days prior to the transplant date
88811525|NCT01276301|Experimental|Reference|single dose BI 10773
88811526|NCT01276301|Active Comparator|Test|single dose BI 10773 + single dose verapamil
88811527|NCT00845000|Experimental|SCH 420814 10 mg→SCH 420814 100 mg→Placebo|Participants were to receive their assigned experimental treatment based on randomly assigned treatment sequence at Hour 0 following an overnight withdrawal of their antiparkinsonian medications of each treatment period. The levodopa infusion was to be started at Hour 1 and was to run for 2 hours. The participants were to also receive 25 mg of carbidopa at the following times: Hours 0, 2, and 4. Treatment periods were to be separated by at least 7 days but not more than 28 days washout between each dose.
88815057|NCT01016678|Other|Placebo, Active, Active, Active|One fifth of the 105 subjects will be randomized to this treatment arm, where they will treat the first headache with placebo and the remaining three migraines will be treated with Active treximet.
88815058|NCT01016678|Other|Active, Active, Active, Active|One fifth of the subject will treat all their migraines with Active Treximet.
89603780|NCT01461993|Active Comparator|Group 1|rLP2086 + Gardasil
89603781|NCT01461993|Placebo Comparator|Group 2|rLP2086 and saline
89603782|NCT01461993|Active Comparator|Group 3|Saline + Gardasil
89603783|NCT01782326|Experimental|QVA149|QVA149 (110/50 μg) once daily
89603784|NCT01782326|Active Comparator|Long acting B2 agonist (LABA) and inhaled corticosteroid (ICS)|Salmeterol/fluticasone (50/500μg) b.i.d
89603785|NCT01439373|Experimental|GSK2336805|Study Part 1
89603786|NCT01439373|Placebo Comparator|Placebo|Study Part 1
89603787|NCT01439373|Experimental|GSK2336805 + pegylated interferon alfa-2a + ribavrin|Study Part 2
89603788|NCT01439373|Active Comparator|Placebo + pegylated interferon alfa-2a + ribavirin|Study Part 2
89603789|NCT04077801||Study group (group A)|"Maximal vertical mouth opening (MIO):~From sitting position, with the use of the calliper, the distance between the incisal edges along the midline of the upper and lower central incisors without pain was measured, by placing one end of the poley gauge against the incisal edge of one of the upper central incisors, and the other end against the incisal edge of the opposing lower incisor.~The distance recorded in millimetres, the subjects was instructed to open your mouth as wide as possible without causing pain or discomfort. The poley gauge was sterilized with antiseptic solution before and after each measure"
89603790|NCT04077801||Control group (group B):|"Maximal vertical mouth opening (MIO):~From sitting position, with the use of the calliper, the distance between the incisal edges along the midline of the upper and lower central incisors without pain was measured, by placing one end of the poley gauge against the incisal edge of one of the upper central incisors, and the other end against the incisal edge of the opposing lower incisor.~The distance recorded in millimetres, the subjects was instructed to open your mouth as wide as possible without causing pain or discomfort. The poley gauge was sterilized with antiseptic solution before and after each measure"
89603791|NCT01461369|Experimental|Diclofenac Capsules 35 mg bid|
89603792|NCT01461369|Experimental|Diclofenac Capsules 35 mg tid|
89603793|NCT01461369|Placebo Comparator|Placebo Capsule|
89603794|NCT04414124|Other|KB109 + Self Supportive Care (SSC)|
89603795|NCT04414124|Other|Self Supportive Care (SSC) Alone|
89603796|NCT04575662|Experimental|STAR Treatment|Patients performing STAR treatment
89603797|NCT01727258|Experimental|Mouth Rinse|Twice daily for 28 days, brush in usual manner for at least one minute using at least a one-inch strip of Fluoride Toothpaste provided. Rinse with water after brushing teeth. Then rinse for 60 seconds with 10 mL of the experimental Mouth Rinse 12027-033 (KOX).
89603798|NCT01727258|Active Comparator|Fluoride Toothpaste|Twice daily for 28 days, brush in usual manner for at least one minute using at least a one-inch strip of the Fluoride Toothpaste (NEG) provided.
89603799|NCT01727258|Active Comparator|Potassium Nitrate Toothpaste|Twice daily for 28 days, brush in usual manner for at least one minute using at least a one-inch strip of the Potassium Nitrate Toothpaste (POS) provided.
89603800|NCT04583306||Healthy Subjects|40 Healthy Subjects in a good state of health comparable by age and sex with the other selected groups and with a negative test for SARS-CoV-2 or collected before the pandemic event
89603801|NCT04583306||COVID-19 Positive|40 subjects affected by COVID-19, determined by positive nasopharyngeal test for SARS-CoV-2 and with comparable age and sex for the other selected groups
89603802|NCT04583306||COVID-19 Negative|40 subjects with a past infection by SARS-CoV-2 confirmed and with at least two consecutive negative tests determined by nasopharyngeal SARS-CoV-2 assay, comparable by age and sex with the other selected groups
89603803|NCT01781390|Placebo Comparator|Placebo|Participants received matching-placebo solution 2 milliliters per minute (mL/min) infused Intracoronary for 60 min including line flush [0 Mesenchymal Precursor Cells (MPCs)/min] on Day 0.
89603804|NCT01781390|Experimental|Mesenchymal Precursor Cells (MPC) 12.5 M|Participants received MPC 12.5 solution 2 mL/min infused Intracoronary for 60 min including line flush (2.5x10^5 MPCs/min) on Day 0.
89603805|NCT01781390|Experimental|Mesenchymal Precursor Cells (MPC) 25 M|Participants received MPC 12.5 solution 2 mL/min infused Intracoronary for 60 min including line flush (5.0x10^5 MPCs/min) on Day 0.
89603806|NCT01781234|Experimental|Intranasal Insulin|Intranasal Insulin
89603807|NCT01781234|Placebo Comparator|Placebo|Placebo
89603808|NCT01752842|Experimental|Fenofibrate|One fenofibrate 160 mg capsule per day for 12 weeks
89603809|NCT01752842|Placebo Comparator|Placebo for fenofibrate|One inert sugar pill per day for 12 weeks
89603810|NCT01461057|Experimental|Pertuzumab 840/420 mg|Participants received pertuzumab as an intravenous (IV) infusion at a loading dose of 840 milligrams (mg) for cycle 1 and a dose of 420 mg every three weeks (Q3W) for cycles 2-6. Participants in both arms received trastuzumab, cisplatin, and capecitabine. Capecitabine 1000 milligram per meter squared (mg/m^2) was administered orally twice daily, from the evening of Day 1 to the morning of Day 15 of each cycle. Cisplatin 80 mg/m^2 was administered as an IV infusion on Day 1 of each cycle. Trastuzumab was administered as an IV infusion at a loading dose of 8 mg/kg for Cycle 1 and a dose of 6 milligram per kilogram (mg/kg) Q3W for subsequent cycles.
89603811|NCT01461057|Experimental|Pertuzumab 840/840 mg|Participants received 840 mg as an IV infusion Q3W for cycles 1-6. Participants in both arms received trastuzumab, cisplatin, and capecitabine. Capecitabine 1000 mg/m^2 was administered orally twice daily, from the evening of Day 1 to the morning of Day 15 of each cycle. Cisplatin 80 mg/m^2 was administered as an IV infusion on Day 1 of each cycle. Trastuzumab was administered as an IV infusion at a loading dose of 8 mg/kg for Cycle 1 and a dose of 6 mg/kg Q3W for subsequent cycles.
89603812|NCT01460901|Experimental|GD2 CAR modified Tri-virus CTL infusion|A single infusion of 2x10e6 cells per meter squared was performed 30 to 120 days following allogeneic stem cell transplant.
89603813|NCT01519635|Active Comparator|Aliskiren|Aliskiren 150 to 300 mg once a Week for 8 weeks
89603814|NCT01519635|Active Comparator|Hydrochlorothiazide|HCTZ 12.5 - 25 mg/d once a day for 8 weeks
89603815|NCT01519323|Experimental|Vemurafenib|Participants received vemurafenib into two separate cohorts with different starting doses based on greater than or equal to (>=)45 kilogram (kg) and other weighing less than (<)45 kg. The starting dose for participants (>=45 kg) was 720 milligram (mg) of vemurafenib by mouth twice daily (BID) and the next dose level for participants in this cohort was 960 mg by mouth BID. The starting dose level for participants weighing <45 kg was to be 480 mg of vemurafenib by mouth BID, but no participants were enrolled into this cohort.
89603816|NCT01519245|Experimental|Trial Drug|Solution containing 2 grams tranexamic acid + normal saline
89603817|NCT01519245|Placebo Comparator|Placebo|Normal saline
89603818|NCT01519167|Experimental|Dexmedetomidine|
89603819|NCT00343564|Experimental|Phase 1 Dose Escalation|Phase 1 dose escalation without and with GCSF support
89603820|NCT00343564|Experimental|Phase 2 Fixed Dose|Phase 2 fixed dose based on Phase I findings stratified by NHL type
89603821|NCT00318136|Experimental|Treated with Bevacizumab|
89603822|NCT00318292|Experimental|PLA|Active preemptive local analgesia.
89603823|NCT00318292|Placebo Comparator|Placebo|Placebo for preemptive local analgesia.
89603824|NCT01791868|Experimental|Intravenous sodium valproate|"Intravenous sodium valproate:~30 mg/kg during 15 min then 1 mg/kg/h during 12 h"
89603825|NCT01791868|Placebo Comparator|Intravenous Placebo|"Intravenous Placebo:~NaCl 0,9 % during 15 min at first then during 12 h."
89603826|NCT01791946|Experimental|Treatment Group A (Post-Surgery)|Subjects enrolled in this arm will first have eye alignment corrective surgery and then complete six weeks of the investigational binocular treatment training.
89603827|NCT01791946|Experimental|Treatment Group B (Pre-Surgery)|Subjects enrolled in this arm will first complete six weeks of the investigational binocular treatment training and then have eye alignment corrective surgery.
89603828|NCT01791946|Sham Comparator|Sham Treatment|Subjects enrolled in this arm will first complete six weeks of the sham binocular treatment and then undergo eye alignment corrective surgery.
89603829|NCT02105740|Experimental|Hypnosis|Use of hypnosis in the reduction of the levels of pain, depression and anxiety.
89210359|NCT04006275|Experimental|Sonazoid and Sonovue Group|"Subjects were randomized to receive Sonazoid firstly and SonoVue secondly after wash out period. Between the wash out period(at least 30min) and after whole trial, the patients was carefully observed at observing room for at least 30min.~contast agent dose: Sonazoid (0.12 μL/kg of perflubutane microbubbles) or SonoVue (2.4 mL) in a 1:1 ratio."
89603830|NCT02105740|Active Comparator|Control|Comparison of the effects of hypnosis between the control group and the experimental group regarding pain, anxiety and depression with the application of the scales.
89603831|NCT01792180|No Intervention|Control group|No intervention besides weekly telephone calls from the computerized falls telephone system
89603832|NCT01792180|Experimental|Intervention group|Weekly use of the mobility feedback device, use of instruction book with every day exercises, use of activity diary in intervention group.
89603833|NCT00320242|Active Comparator|1 mo baseline|1 mo baseline before visual cue: Cane or walker, no laserlight visual cue x 1 mo; + laserlight visual cue for 2nd mo
89603834|NCT00320242|No Intervention|2 month baseline|Cane or walker, no laserlight visual cue x 2 mo, + laserlight visual cue for 3rd mo
89603835|NCT00348946|Active Comparator|Oxandrolone|Androgen oxandrolone: Oxandrolone, 0.6 > mg/kg/day, orally, for 2 years.
89603836|NCT00348946|Placebo Comparator|Placebo|An inactive substance.
89603837|NCT00349336|Experimental|1|
89603838|NCT00349336|Experimental|2|
89603839|NCT04888468|Experimental|pCAR-19B cells|Infusion of pCAR-19B cells by dose-escalating
89603840|NCT04751188|Experimental|Bezafibrate and Ursodeoxycholic acid|Bezafibrate 200 mg every 12 hours and ursodeoxycholic acid at a dose of 13 to 15 mg per Kg per day, for 6 months.
89603841|NCT04751188|Placebo Comparator|Placebo and Ursodeoxycholic acid|Placebo tablet every 12 hours and ursodeoxycholic acid at a dose of 13 to 15 mg per Kg per day, for 6 months.
89603842|NCT00352612|Placebo Comparator|cephalexin|
89603843|NCT00352612|Active Comparator|clindamycin|
88815059|NCT02457546|Experimental|EVICEL Fibrin Sealant|EVICEL is a human plasma-derived fibrin sealant composed of two components - thrombin and fibrinogen
88815060|NCT02457546|Active Comparator|Hydrogel sealant|The sealant is composed of two solutions, a polyethylene glycol (PEG) ester solution and a trilysine amine solution
88815061|NCT01681121|Experimental|ADX-N05|ADX-N05 to be taken once a day for 12 weeks
88815062|NCT01681121|Placebo Comparator|Placebo|Placebo to match ADX-N05 to be taken once a day for 12 weeks
88815063|NCT04930692|Experimental|Preoperative SLNs mapping provided by CT-lymphography method|Sentinel lymph nodes will be mapped by contrast-enhanced CT lymphography in breast cancer patients. A mixture of 4 mL iopamidol and 2 mL of 1% lidocaine hydrochloride will be used as a contrast agent provided by periaoreolar injection. No later than 10 days after the CT lymphography patients will receive surgical treatment with sentinel lymph node biopsy using the ICG-fluorescence method.
88815064|NCT01016834|Other|Sumavel(R) DosePro(R)|Single arm study (Sumavel DosePro)
88815065|NCT05708651|Experimental|Use of investigational device during sedation|Intra-individual randomised paired crossover evaluation of airway patency with investigational device in volunteer study participants [I-II] and study patients [III-IV] at low, moderate and deep levels of steady-state sedation [I-II], and during procedural sedation according to SOC for scheduled colonoscopy [III] or ureteral catheterisation [IV].
88815066|NCT05708651|Active Comparator|Use of comparator during sedation|Intra-individual randomised paired crossover evaluation of airway patency with comparator (biteblock [I-II] or no device [II-IV]) in volunteer study participants [I-II] and study patients [III-IV] at low, moderate and deep levels of steady-state sedation [I-II], and during procedural sedation according to SOC for scheduled colonoscopy [III] or ureteral catheterisation [IV].
88815067|NCT04924283|Experimental|Cognitive Interference Task|Participants in this arm will complete random assessments of alcohol use and cravings on their phone, and be prompted to play Tetris on their phone after reporting cravings for alcohol.
88815068|NCT04924283|Active Comparator|Assessment Only|Participants in this arm will complete random assessments of alcohol use and cravings on their phone.
88815069|NCT02447952|Experimental|Pilot and Core Study Phase|During Pilot phase,subjects will attend clinic at least once to perform a series of set reference tasks while wearing the accelerometer and electrode. Subjects will also continuously wear the accelerometer and electrode in their routine home-life setting for approximately 3 days after the clinic visit (home monitoring). During 48 week Core Study, subjects will attend 5 clinic visits to perform gold standard measures of function (ALS Functional Rating Scale-Revised and Forced Vital Capacity) and perform a series of set reference tasks while wearing the accelerometer and electrode. Subjects will also continuously wear the accelerometer and electrode in their routine home-life setting for approximately 3 days after the clinic visits (home monitoring). In between clinic visits, subjects will attach the accelerometer and electrode and wear it for approximately 3 days in their home. A telephone contact with the subject will be made by the site at the end of each 3-day home monitoring period
88815070|NCT00959660|Active Comparator|Exercise Training|Exercise participants will undergo a 1-hour supervised exercise program 3 times per week for 20 weeks consisting primarily of walking exercise using an individualized exercise prescription based on the initial exercise stress testing results.
88815071|NCT00959660|Active Comparator|Dietary Intervention|A hypocaloric diet will be developed to achieve a 2800 kcal/week deficit, which should produce about 0.4 kg (1 lb) weight loss per week.
88815072|NCT00959660|Active Comparator|Attention control|Attention control participants will be provided a counseling session regarding general health education at baseline and will be contacted by staff via telephone every 2 weeks to discuss general health status.
88815073|NCT00959660|Active Comparator|Diet and Exercise|A hypocaloric diet will be developed to achieve a 2450 kcal/week deficit in addition to undergoing a 1-hour supervised exercise program 3 times per week for 20 weeks consisting primarily of walking exercise using an individualized exercise prescription based on the initial exercise stress testing results.
88815074|NCT03020732|Experimental|test groups|In this split mouth study, bilaterally gingival recession defects were randomly treated in test(CGF+CAF) or control(SCTG+CAF) groups.In test groups, a special centrifuge machine(Medifuge) and subjects venous blood were used to obtain Concentrated growth factor. A special compress was used to transform Concentrated growth factor membrane.
88815075|NCT03020732|Active Comparator|control groups|In this split mouth study, bilaterally gingival recession defects were randomly treated in test(CGF+CAF) or control(SCTG+CAF) groups. In control groups, subepithelial connective tissue graft was taken from the palatal canine teeth-first molar teeth area with a trap door technique according to the width of the exposed root surface and the adjacent bone margins. The graft's thickness was adjusted between 1.5 and 2 mm.
88815076|NCT03020186|Placebo Comparator|Physical activity|Physical activity (PA) group will receive free gym memberships and the instruction necessary to engage in moderate-intensity physical activity, ~80% of which will have an aerobic component. The participants will get basic health promoting guideline for healthy diet .
88815077|NCT03020186|Experimental|Physical activity+ MED diet|On top of the PA intervention described in Arm 1, the participants will be guided for moderate weight loss with a traditional Mediterranean (MED) diet, low in simple carbohydrates. The diet will include 1oz/day of walnuts that will be provided free of charge.
88815078|NCT03020186|Experimental|Physical activity+ green-MED diet|"On top of the PA intervention described in Arm 1, the participants will guided for moderate weight loss with a MED diet, low in simple carbohydrates that will be rich in plants and polyphenols and low in processed meat. The diet will include 1oz/day of walnuts, 3-4 cups/day of green tea and ~500cc green shake/dinner based on specific strain of duckweed [Wolffia globose, Mankai], an aquatic plant, which might serve as a plant protein source. All the above will be provided free of charge."
88815079|NCT04923594|Active Comparator|NLS-2 (mazindol extended release)|2 mg dosed orally, once daily for 1 week; followed by 3 mg dosed orally, once daily for up to 3 weeks (total of 4 weeks)
88815080|NCT04923594|Placebo Comparator|Placebo|Dosed orally, once daily for up to 4 weeks
88815081|NCT00961532|Experimental|DDAVP|DDAVP 0.4 mcg/kg intravenously in 250 mL NS over 30 minutes
89603844|NCT01793584|Active Comparator|Laparoscopic hysterectomy|Total laparoscopic hysterectomy, laparoscopic assisted vaginal hysterectomy
89603845|NCT01793584|Active Comparator|Abdominal hysterectomy|Total Abdominal Hysterectomy
89603846|NCT01793740|Experimental|Cogmed|These children are enrolled in the Cogmed intervention.
89603847|NCT01793740|No Intervention|Waitlist|These children are enrolled in a waitlist condition, after which they will be offered the opportunity to complete the intervention.
88981284|NCT04056208|Active Comparator|Usual care|Advice to consume a snack that contains 1-2 exchanges (15-30 g of carbohydrate) as an evening snack - this is consistent with the current standard of care for people with impaired fasting glucose.
89603848|NCT00323284|Active Comparator|A--iStent plus Cataract Surgery|iStent plus Cataract Surgery
89210360|NCT00987051|Experimental|1|Patients with endometrial cancer
89603849|NCT00323284|Active Comparator|B--Cataract Surgery Only|Cataract Surgery only
89603850|NCT00323362|Experimental|Gemcitabine hydrochloride and imatinib mesylate|
89603851|NCT01793896|Sham Comparator|control period|control period with no intervention. Comparison of parameters at entrance and one month later without any intervention
89603852|NCT01793896|Experimental|Diet group|Mediterranean diet prescription during 3 months
89603853|NCT01793896|Experimental|Exercise group|Subjects will be trained 3 times a week during 3 months
89603854|NCT01793896|Experimental|Diet + Exercise|Both a dietary prescription plus exercise training during 3 months
89603855|NCT00354484|Experimental|Ferric Carboxymaltose (FCM)|Up to a maximum cumulative dose of 2,500 mg administered IV based on iron-deficit calculations; the calculated dose was given in divided doses of up to 1,000 mg weekly.
89603856|NCT00354484|Active Comparator|Ferrous Sulfate tablets|325 mg of ferrous sulfate 3 times daily (TID) x 6 weeks.
89603857|NCT00354640|Experimental|Anastrozole and Simvastatin|This is a pharmacological study for women on anastrozole as adjuvant therapy for breast cancer to receive concurrent simvastatin for up to 14 days.
89603858|NCT02107300|Experimental|NeutraSal|NeutraSal, dosed 2 times per day at waking and bedtime (indications 2-10 times per day or PRN), swish and spit, daily for a term of 12 weeks.
89603859|NCT02107300|Placebo Comparator|Placebo|Placebo dosed 2 times per day at waking and bedtime (indications 2-10 times per day or PRN), swish and spit, daily for a term of 12 weeks.
88815082|NCT00962000|Other|600 mL/min|Dialysis Flow Rate Start 600mL/min Subject starting dialysis flow rate set at 600mL/min. ABAB sequence where A represents three consecutive dialysis treatments with a dialysate flow rate of 600 mL/min and B represents three consecutive treatments with a dialysate flow rate of 800 mL/min.
88815083|NCT00962000|Other|800 mL/min|Dialysis Flow Rate Start 800mL/min Subject starting dialysis flow rate set at 800mL/min. BABA sequence where B represents three consecutive treatments with a dialysate flow rate of 800 mL/min and A represents three consecutive dialysis treatments with a dialysate flow rate of 600 mL/min.
88815084|NCT02447718|Active Comparator|Experimental|Children who were diagnosed with ALL at ≥1 year of age, and are within 6-8 months of completing chemotherapy will receive 1 dose each of: Prevnar®13 and Pediacel® vaccines, followed by 1 dose of Pneumovax® 23 given 2 months after PCV13.
88815085|NCT02447718|No Intervention|Healthy Control|Children 3-18 years of age who are not immunocompromised age-matched to cases from Group 1.
88815086|NCT01017536|Placebo Comparator|Placebo|Thirteen subjects received placebo vaccine that did not contain any AERAS-402.
88815087|NCT01017536|Experimental|Investigational Vaccine|Thirteen subjects received active vaccine 3 x 10^10 vp AERAS-402.
88815088|NCT00962078|Other|interval training|interval training in lung transplant candidates
88815089|NCT00962078|Other|Continuous Training|continuous training in lung transplant candidates
88815090|NCT00963482|Experimental|Intervention group|Cognitive-behavioural smoking cessation program
88815091|NCT00963482|Other|Control group|Autogenic training
88815092|NCT05395988|No Intervention|Control group|The control group receives no screen next to the sink.
88815093|NCT05395988|Experimental|Instruction group|The reward group receives a screen next to each sink in kindergarten. On the screen, hand washing instructions are shown during hand washing. After a defined time period, the screen is removed.
88815094|NCT05395988|Experimental|Reward group|"The reward group receives a screen next to each sink in kindergarten. On the screen, hand washing instructions are shown during hand washing. If hands are washed correctly (time and soap usage), a reward (animal animation) is shown on the screen.~After a defined time period, the screen is removed."
88815095|NCT05395988|Experimental|Reward plus instruction-only group|"The reward plus instruction group receives a screen next to each sink in kindergarten.~On the screen, hand washing instructions are shown during hand washing. If hands are washed correctly (time and soap usage), a reward (animal animation) is shown on the screen.~After a defined time period, the screen only shows instructions, the reward is not shown anymore.~After a defined time period, the screen is removed."
88815096|NCT00963560|Experimental|ReSTOR +3|Bilateral implantation of ReSTOR +3 Intraocular Lens (IOL)
88815097|NCT00963560|Active Comparator|Crystalens HD|Bilateral implantation of Crystalens HD Intraocular Lens (IOL)
88815098|NCT00963560|Active Comparator|Crystalens AO|Bilateral implantation of Crystalens AO Intraocular Lens (IOL)
88815099|NCT03019718|Experimental|GSA-Online plus|Patients receive access to the internet-based aftercare program after inpatient treatment.
88815100|NCT00963638|Experimental|MagTabSR|
88815101|NCT00963638|Placebo Comparator|Sugar Pill|
88815102|NCT02246036|Experimental|APD probe|Placement of a duodenal probe during 24 hours.
88815103|NCT03016442|Experimental|Cook double balloon catheter|A double- balloon catheter (Cook Cervical Ripener Balloon,Cook OB/GYN,Spencer IN) is inserted into cervical canal under direct visualisation during a sterile speculum examination İt is placed for 12 hours
88815104|NCT03016442|Active Comparator|Dinoprostone|10 mg of dinoprostone in a hydrogel insert is placed high in the vaginal fornix. İt is placed for 12 hours.It is a controlled release formulation which has been found to release dinoprostone in vivo at a rate of approximately 0.3 mg/hr.
88815105|NCT01682135|Experimental|Ramucirumab|Ramucirumab administered intravenously (IV) at escalating doses (6 milligrams per kilogram [mg/kg] up to 10 mg/kg) every 2-3 weeks for 6 weeks (1 Cycle). Treatment may continue until discontinuation criterion is met.
89603860|NCT00392236|Experimental|A|Participants will receive treatment as usual and a 2-way pager for 6 months
89603861|NCT00392236|Active Comparator|B|Participants will receive treatment as usual
89603862|NCT00392392|Experimental|Intervention|Patients received treatment with nab-paclitaxel (100 mg/m2 IV days 1, 8, 15) and carboplatin (AUC 6 IV day 1) every 28 days for 6 cycles. Trastuzumab (4 mg/kg loading dose, followed by 2 mg/kg) and bevacizumab (5 mg/kg IV) were administered weekly for 23 weeks, beginning concurrently with chemotherapy. Patients then underwent either mastectomy or breast conserving surgery and pathologic treatment responses were assessed. After surgery, trastuzumab 6 mg/kg and bevacizumab 15 mg/kg were administered at 3 week intervals for a total of 52 weeks.
89603863|NCT01519089|Experimental|CP-690,550 10 mg BID|
89603864|NCT01519089|Experimental|CP690,550 5 mg BID|
89603865|NCT00392704|Experimental|Intervention|"All patients initially received treatment with paclitaxel 200 mg/m2, 3 hour IV infusion days 1 and 22; carboplatin area under the curve (AUC) 6.0 IV, days 1 and 22; 5-fluorouracil (5-FU) 200 mg/m2 daily by 24-hour continuous IV infusion, days 1 to 43; bevacizumab 15 mg/kg IV infusion days 1 and 22.~One to three weeks after completing neoadjuvant therapy, patients began treatment with concurrent chemoradiation, bevacizumab, and erlotinib. Radiation therapy began on day 1, with 1.8-Gy single daily doses, Monday through Friday, to a total dose of 68.4 Gy. Paclitaxel 50 mg/m2 was administered by 1-hour IV infusion on days 1 and 22. Erlotinib 150 mg by mouth daily began concurrently with radiation therapy and continued daily during the 7-week course of radiation."
89603866|NCT00392782|Experimental|Natural Killer Cell Kir Epitope|
89603867|NCT01795300|Experimental|Carbon Ion Radiotherapy|Treatment Schedule Carbon Ion Radiation Total Dose 45 Gy E, 15 fractions, 3 Gy E single dose
88981285|NCT04050449||Group 1: Switch to TLD from NNRTI first-line regimen|Participants switching to TLD from a first-line regimen containing a NNRTI. These participants will be divided into two subgroups based upon their HIV-1 RNA level in a sample obtained at entry, before starting TLD. Group 1a will include participants with viremia (HIV-1 RNA >1000 copies/mL at start of TLD) and Group 1b will include participants with suppressed viral load (HIV-1 RNA ≤1000 copies/mL at start of TLD).
88981286|NCT04050449||Group 2: Switch to TLD from boosted PI second-line regimen|Participants switching to TLD from a second-line regimen containing a boosted PI. These participants will be divided into two subgroups based upon their HIV-1 RNA level in a sample obtained at entry, before starting TLD. Group 2a will include participants with viremia (HIV-1 RNA >1000 copies/mL at start of TLD) and Group 2b will include participants with suppressed viral load (HIV-1 RNA ≤1000 copies/mL at start of TLD).
88981287|NCT04050449||Group 3: Concomitant TLD and RIF-containing TB treatment|Participants initiating concomitant TLD and RIF-containing TB treatment, with an additional daily dose of dolutegravir (DTG) 50mg. For participants already on RIF-containing TB treatment when TLD treatment is started, TLD treatment must be started within 8 weeks (56 days) of the start of RIF-containing TB treatment. Group 1, 2, or 4 participants who start RIF-containing TB treatment after enrollment will have additional evaluations at the start and end of concomitant HIV and TB treatment but will not be co-enrolled in Group 3 (their additional evaluations will, however, be considered when analyzing data from Group 3).
88981288|NCT04050449||Group 4: ART-naive initiating TLD therapy|Antiretroviral therapy (ART)-naïve participants initiating therapy with TLD
88981289|NCT04039867|Experimental|Oxaliplatin with Gemcitabine|Oxaliplatin will be given as an intravenous infusion over 60 minutes on Days 1 and 14 at a dose of 100 mg/m2 for each cycle. Gemcitabine (1000 mg/m2) will be given on days 1 and 14 as an intravenous infusion over 30 minutes immediately prior to Oxaliplatin.
88981290|NCT04032925|Experimental|PICSO therapy Group|"This will be the only treatment of the PICSO VIPER study. Within this group patients will be randomised to have cycles of 2 minutes of balloon-induced myocardial schema with PICSO device in ON vs OFF modality."
88981291|NCT04029038|Experimental|Treatment (CD19-CD22 CAR T cells)|Patients receive standard of care cyclophosphamide IV over 30 minutes and fludarabine IV over 30 minutes on days -5, -4, and -3, and then receive CD19-CD22 CAR T cells IV on day 0. Patients with relapsed or persistent disease after a protocol assessment may receive a second infusion of CD19-CD22 CAR T cells.
88981292|NCT03996772|Experimental|Direct Oral Anticoagulant|"If the patient is randomized in this arm, a direct oral anticoagulant (DOAC) included:~Direct thrombin inhibitor: Dabigatran~Factor Xa inhibitors: Apixaban or Rivaroxaban or Edoxaban will be prescribed to the patient. Choice and dose of DOAC treatment as well as the use of concomitant medication during the study treatment will be at the Principal Investigator´s discretion within the spectrum of licensed doses labelled for stroke prevention in atrial fibrillation patients in Europe following the Summary of Product Characteristics."
88981293|NCT03996772|No Intervention|No Anticoagulant|If the patient is randomized in this arm investigators will use their best judgment to decide upon the prescription of an antiplatelet drug of their choice or no such therapy
88981294|NCT03996044|Experimental|Group 1|Thirteen patients who will receive treatment with teeth brushing, dental floss and tongue scraper.
88981295|NCT03996044|Experimental|Group 2|Thirteen patients who will receive treatment with teeth brushing, dental floss and antimicrobial photodynamic therapy applied to the back and middle third of the tongue.
88981296|NCT03996044|Experimental|Group 3|Thirteen patients who will receive treatment with teeth brushing, dental floss and probiotics.
88981297|NCT03996044|Experimental|Group 4|Thirteen patients who will receive treatment with teeth brushing, dental floss, antimicrobial photodynamic therapy applied to the back and middle third of the tongue and probiotics..
88981298|NCT03995537||Patients with severe liver disease waiting liver transplant|Only patients with the most frequent LT indications will be eligible: complicated cirrhosis of hepatocellular carcinoma (HCC), acute or chronic decompensation of cirrhosis, with or without multi-visceral failure and fulminant hepatitis.
89210361|NCT01075555|Active Comparator|sorafenib|sorafenib
89210362|NCT01075555|Experimental|sorafenib + pravastatine|sorafenib + pravastatine
89210363|NCT03972787|Experimental|Proactive Social Robot (Intervention)|Participants will have the opportunity to use ElliQ for a total of 8 weeks to determine the impacts of the system on participants' loneliness, mood, technology use, and quality of life.
89603868|NCT01795300|Experimental|Proton Therapy|Treatment Schedule Proton Radiation Total Dose 45 Gy E, 15 fractions, 3 Gy E single dose
89603869|NCT01795300|Experimental|Hypofractionated Photon Therapy|Treatment Schedule Photon Radiation 3 Gy E Total Dose 45 Gy E, 15 fractions, 3 Gy E single dose
89603870|NCT01795300|Active Comparator|Conventional Photon Radiotherapy|Treatment Schedule Photon Radiation 1.8 Gy E Total Dose 57.6 Gy Gy E, 32 fractions, 1.8 Gy E single dose
89603871|NCT01518699|Experimental|HA44 Abametapir Lotion|Study drug plus positive-control placebo.
89603872|NCT01518699|Placebo Comparator|Placebo|Placebo plus positive-control placebo.
89603873|NCT01518699|Active Comparator|Moxifloxacin|Placebo plus positive control
89603874|NCT04556266|Experimental|Cohort -1|"Cohorts of 3-6 patients each will be treated with escalating doses of consolidative modified T cells at Day 30 (+/- 5 days) post allo-HSCT~Total T-Cell Dose: 1 x 10^4 cells/kg"
89603875|NCT04556266|Experimental|Cohort 1|"Cohorts of 3-6 patients each will be treated with escalating doses of consolidative modified T cells at Day 30 (+/- 5 days) post allo-HSCT~Total T-Cell Dose: 1 x 10^5 cells/kg"
89603876|NCT04556266|Experimental|Cohort II|"Cohorts of 3-6 patients each will be treated with escalating doses of consolidative modified T cells at Day 30 (+/- 5 days) post allo-HSCT~Total T-Cell Dose: 2 x 10^5 cells/kg"
89603877|NCT04556266|Experimental|Cohort III|"Cohorts of 3-6 patients each will be treated with escalating doses of consolidative modified T cells at Day 30 (+/- 5 days) post allo-HSCT~Total T-Cell Dose: 4 x 10^5 cells/kg"
89603878|NCT01792648|Active Comparator|Standard Reference Diet|
89603879|NCT01792648|Experimental|Almond Supplemented Diet|
89603880|NCT01792648|Active Comparator|Low Carbohydrate Reference Diet|
89603881|NCT01792726|Experimental|TARGIT|The experimental policy is to give targeted intra-operative radiotherapy (TARGIT-Boost) in a single dose to substitute for the usual boost dose, in addition to whole breast external beam radiotherapy delivered according to local treatment guidelines.
89603882|NCT01792726|Active Comparator|External beam radiotherapy boost|The conventional policy is to receive radiation boost to the tumour bed delivered by external beam radiotherapy (EBRT) in addition to whole breast external beam radiotherapy delivered according to local treatment guidelines.
89603883|NCT01518309|Experimental|pimavanserin tartrate (ACP-103)|Tablets taken once daily by mouth at 20, 40, or 60 mg doses
89603884|NCT04067895||human bone graft screw|human bone graft screws will be used during the epiphysiodesis
89603885|NCT01419717|Experimental|Denosumab|Participants received 120 milligrams of denosumab injected subcutaneously every 4 weeks until denosumab was approved and available for sale.
89603886|NCT04748133|Active Comparator|acupuncture|"Patients in the acupuncture group will receive a standardised treatment with 12 needles (sharp tip, stainless steel needles, size 0.3 X 40 mm) at 7 acupuncture points Du 26 and Ren 17 (on the middle body line), and bilateral LI 4, HE 7, LV 3, ST 36 and PC 6). Application of the needles is performed by a licensed medical acupuncturist.~The needles will be inserted after endotracheal intubation and mechanical ventilation and will be removed immediately before patient extubation."
89603887|NCT04748133|Placebo Comparator|placebo|no treatment
89603888|NCT01458951|Experimental|tofacitinib 10 mg BID|
89603889|NCT01458951|Placebo Comparator|Placebo BID|
88981299|NCT03990454|Experimental|Dose escalation|"The starting dose will be 25 mg/day and subsequent doses will be determined after an internal review by Data Review Committee of all available safety, PK and PD data from the minimum required number of subjects who complete cycle 1. All dose-escalation decisions and the rationale for progressing to the next cohort will be documented.~A subject may continue treatment with SLC-391 in 21-day cycles until the treatment discontinuation criteria are met."
88981300|NCT03985878|Experimental|Eteplirsen|Participants will receive eteplirsen via IV infusions, once weekly, for up to 284 weeks.
88981301|NCT03971539|Placebo Comparator|SRD part: Placebo|Single rising dose (SRD) part: Placebo film-coated tablet matching BI 894416 taken once orally with 240 milliliter of water after an overnight fast of at least 10 hours.
88981302|NCT03971539|Experimental|SRD part: 75 mg BI 894416|Single rising dose (SRD) part: 75 milligram (mg) BI 894416 film-coated tablet taken once orally with 240 milliliter of water after an overnight fast of at least 10 hours.
88981303|NCT03971539|Experimental|SRD part: 125 mg BI 894416|Single rising dose (SRD) part: 125 milligram (mg) BI 894416 film-coated tablet taken once orally with 240 milliliter of water after an overnight fast of at least 10 hours.
88981304|NCT03971539|Experimental|SRD part: 170 mg BI 894416|Single rising dose (SRD) part: 170 milligram (mg) BI 894416 film-coated tablet taken once orally with 240 milliliter of water after an overnight fast of at least 10 hours.
88981305|NCT03971539|Placebo Comparator|MRD part: Placebo|Multiple rising dose (MRD) part: Placebo film-coated tablet matching BI 894416 taken for 9 days orally with 240 milliliter of water. Administration of Placebo at Day 1 and Day 9 once daily in the morning (q.d.) and at Day 2 to Day 8 three times daily at an interval of 8 hours (t.i.d.). Morning dose to be taken after an overnight fast of at least 10 hours, afternoon dose to be taken after fasting for 2 hours.
89603890|NCT01458639|Experimental|Technegas|Technegas V SPECT imaging with Technetium-99m (Tc-99m) labeled carbon particles; approximately 1.1 milliCuries of Technegas, compared with the results of Xenon-133 ventilation scan
89603891|NCT01458639|Active Comparator|Xenon-133|Xenon-133 ventilation Planar imaging compared with the results of the Technegas scan.
89603892|NCT01437423|Experimental|TETRAXIM™ vaccine|Participants will receive a primary or booster dose of TETRAXIM™
89603893|NCT00393796|Active Comparator|SUTENT|Study participants randomized to received SUTENT will receive a dose of 50 mg PO (capsules) as a single agent to be taken once daily for four consecutive weeks followed by a two week rest period to form a complete cycle of six weeks.
89603894|NCT00393796|Placebo Comparator|Placebo|Study participants randomized to receive placebo will receive 50 mg/day PO (capsules) of an inactive substance to be taken once daily for four consecutive weeks followed by a two week rest period to form a complete cycle of six weeks.
89603895|NCT00393874|Active Comparator|Medication|Treatment will be conducted under double blind conditions and will last a total of 8 weeks. Participants will also receive printed educational material about sleep hygiene developed by the American Academy of Sleep Medicine. Items include going to bed when drowsy, avoiding clock watching while awake in bed, avoidance of caffeine and alcohol, engaging in moderate exercise, and ensuring comfortable sleep environment. Clinical ratings will be obtained weekly throughout the trial.Medications will be administered in a single dose to be taken 30 minutes prior to bedtime because the onset of action occurs within 30 to 90 minutes after a single dose. The research pharmacy will prepare each dose in identical gelatin capsules to prevent identification.
89603896|NCT00393874|Active Comparator|Behavioral|"Participants randomized to BSI will receive the intervention aimed at reducing nightmares, insomnia, and sleep avoidance behavior. The treatment will be administered over 8 weeks. The intervention sessions will consist of two individual, 45-minute treatment sessions, delivered on Weeks 1 and 3. A 45-minute booster session will be conducted on Week 5. Thirty-minute face-to-face contacts will be scheduled on other weeks (i.e., Weeks 2, 4, 6, 7 and 8) to address any difficulty with the treatment instructions and techniques, to answer questions that may have occurred, and to complete weekly clinical ratings (CGI-I/SR and ASES)."
89603897|NCT00393874|Placebo Comparator|Placebo|Participants randomized to PLA will take 4 capsules each night, and capsule will be identical to prazosin capsules. As for participants randomly assigned to PRZ, they will receive a one-week medication supplies in daily dose dispensers. Similarly, participants will also be instructed to be ready for bed at the time they take the medication, and not to engage in any activities that will prevent them from going to bed. A placebo pill condition is included for several reasons. First, there is no approved treatment approach currently recognized as being effective for sleep disturbances associated with combat-related PTSD, and which is being withheld from subjects assigned to the placebo arm of the study. We will monitor subjects carefully and on a weekly basis.
89603898|NCT01458249|Experimental|eribulin mesylate 1.4 mg/m^2|
89603899|NCT00394888|Other|Facial Hemangioma|Patients with large facial hemangioma.
89603900|NCT00394888|Other|Lumbosacral Hemangioma|Patients with lumbosacral hemangioma.
89603901|NCT00394888|Other|Multiple Hemangiomas|patients with multiple hemangiomas (>5)
89603902|NCT01458171|Experimental|IgPro20|
89603903|NCT00395044|Experimental|Gabapentin|1200 mg/daily of Gabapentin
89603904|NCT00395044|Placebo Comparator|Placebo|1200mg/d of Placebo
89603905|NCT01457703|Active Comparator|BMI ≥30 kg/m2|"Group 2:~BMI ≥30 kg/m2~History of regular menstrual cycles every 25-40 days~Gonadorelin-GnRH (Lutrepulse), GnRH antagonists - Cetrorelix (Cetrotide), Recombinant LH (Luveris) were administered in Aim 1. GnRH or gonadorelin (Lutrepulse) and Letrozole were administered in Aim 2."
89603906|NCT01457703|Experimental|BMI 18-25 kg/m2|"BMI 18-25 kg/m2~History of regular menstrual cycles every 25-35 days~Gonadorelin-GnRH (Lutrepulse), GnRH antagonists - Cetrorelix (Cetrotide), Recombinant LH (Luveris) were administered in Aim 1. GnRH or gonadorelin (Lutrepulse) and Letrozole were administered in Aim 2."
89603907|NCT04445428|Experimental|Intervention|Standard dose bivalent oral polio vaccine, 0.1ml, and information regarding prevention of COVID-19
89603908|NCT04445428|Other|Control|Information regarding prevention of COVID-19
89603909|NCT00356434|Active Comparator|1|Patients will have the Kendall, A-V foot impulse pump, model 6060 applied to their lower extremities to prevent DVT
89603910|NCT00356434|Active Comparator|2|Patients will have the Kendall,sequential compression device, model 9525 applied to the lower extremities to prevent DVT
89603911|NCT01419015|Experimental|TAVI-TF Approach|Transcatheter aortic valve implantation and transfemoral approach. SAPIEN XT NovaFlex delivery system will be used.
89603912|NCT00357214|Active Comparator|potassium bicarbonate|Participants will receive potassium bicarbonate in dosage of 67.5 mmol/d. This compound has no other name.
89603913|NCT00357214|Active Comparator|Sodium bicarbonate|Participants will receive sodium bicarbonate in dosage of 67.5 mmol/d. This compound has no other name.
89603914|NCT00357214|Active Comparator|Potassium chloride|Participants will receive potassium chloride in dosage of 67.5 mmol/d. This compound has no other name.
89603915|NCT00357214|Placebo Comparator|microcrystalline cellulose|Participants will receive placebo is microcrystalline cellulose. This compound has no other name.
89603916|NCT01418937|Experimental|HPV Group|
89603917|NCT02076321|Other|Acetaminophen|control group
89603918|NCT02076321|Other|NSAID (Ibuprofen)|Study group
89603919|NCT01793974||Latent Autoimmune Diabetes in Adult|Individuals who meet criteria for Latent Autoimmune Diabetes in Adult
89603920|NCT01793974||Without Latent Autoimmune Diabetes in Adult|Individuals who do not meet criteria for Latent Autoimmune Diabetes in Adult
89603921|NCT01417377||Cohort|Mircera
88981306|NCT03971539|Experimental|MRD part: 10 mg BI 894416|Multiple rising dose (MRD) part: 10 milligram (mg) BI 894416 film-coated tablet taken for 9 days orally with 240 milliliter of water. Administration of BI 894416 at Day 1 and Day 9 once daily in the morning (q.d.) and at Day 2 to Day 8 three times daily at an interval of 8 hours (t.i.d.). Morning dose to be taken after an overnight fast of at least 10 hours, afternoon dose to be taken after fasting for 2 hours.
89603922|NCT00358462|Active Comparator|Active azithromycin+placebo doxycycline|Active azithromycin (1g) and placebo doxycycline
89603923|NCT00358462|Active Comparator|Active doxycycline+placebo azithromycin|Active doxycycline and placebo azithromycin
89603924|NCT00396292|Experimental|VIT-45|A maximum of 1,000 mg iron as IV VIT-45 given at weekly intervals until the the cumulative dose has been reached or a maximum of 2,500 mg has been administered
89603925|NCT00396292|Active Comparator|Oral iron tablets|325 mg tablets (65 mg elemental iron) with instructions to take 1 tablet by mouth (PO) TID with 8 ounces of tap water, 1 hour before meals from Day 0 until Day 42
89603926|NCT00397150|Experimental|Intervention|Peer-support for exclusive breastfeeding
89603927|NCT00397150|No Intervention|No intervention|No intervention
89603928|NCT01437267|Experimental|Vi-CRM, Older infants|Older Infants (9 to 12 months) receiving 2 doses of NVGH Vi-CRM197 vaccine
89603929|NCT01437267|Active Comparator|PNC13, Older infants|Older infants (9 to 12 months) receiving 2 doses of Pneumococcal conjugate vaccine
89603930|NCT01437267|Experimental|Vi-CRM, Infants|Infants (6 to 8 weeks) receiving 3 doses of NVGH Vi-CRM197 vaccine
89603931|NCT01437267|Active Comparator|PNC13, Infants|Infants (6 to 8 weeks) receiving 3 doses of Pneumococcal conjugate vaccine
89603932|NCT01437267|Experimental|Vi-CRM, Children|Children (24 to 59 months) receiving 2 doses of NVGH Vi-CRM197 vaccine
89603933|NCT01437267|Active Comparator|Vi-PS, Children|Children (24 to 59 months) receiving 1 dose of licensed Vi Polysaccharide vaccine and 1 dose of Pneumococcal conjugate vaccine
89603934|NCT00397462|No Intervention|Control|No change to usual behavior
89603935|NCT00397462|Experimental|Low dose|Request that calf muscle pump stimulation be used less than four hours per day
89603936|NCT00397462|Experimental|High dose|Request that calf muscle pump stimulation be used at least four hours per day
89603937|NCT01794052|Experimental|DSS enabled health care delivery model|Evidence based, DSS enabled, health care delivery model
89603938|NCT01437111|Experimental|Fosamax Plus|Calcium supplement (elemental calcium and/or calcium carbonate) without vitamin D will also be supplied to participants
89603939|NCT04767477|Other|Face-to-face rehabilitation and Telerehabilitation|The Face-to-face rehabilitation and Telerehabilitation protocol will consist of flexibility exercises, aerobic and resistance training, with two sessions per week.
89603940|NCT04065555|Experimental|CIVO Microdose Injection of TAK-981, Cetuximab, and Avelumab|Patients who are scheduled for surgical biopsy or tumor resection surgery will be injected one day (Cohort 1) or three days (Cohort 2) prior to surgery using the CIVO device. Each needle of the CIVO device will deliver up to 8.3 microliters of solution, including a vehicle control (sterile saline) or subtherapeutic microdoses of TAK-981, cetuximab, avelumab, TAK-981 combined with cetuximab, or TAK-981 combined with avelumab. Each microdose is simultaneously injected in a columnar fashion through each of 8, 5, or 3 needles (in a device configuration determined by tumor dimensions) into a single solid tumor or effaced metastatic lymph node. Approximately six patients will be assigned to each time point cohort. Cohort assignment is not sequential and will be selected by the Investigator based on clinic logistics and patient scheduling. Should one cohort fill in advance of the other, sites will be directed by Presage to enroll patients into the second cohort only.
89603941|NCT00359944|Experimental|AC-3933|AC-3933, 5mg twice daily
89603942|NCT00359944|Experimental|AC-3933, 20 mg twice daily|AC-3933, 20 mg twice daily
89603943|NCT00359944|Placebo Comparator|Placebo|Sugar Pill twice daily
89603944|NCT00360724|Experimental|duloxetine (cymbalta)|Duloxetine medication: a medication currently marketed in the USA that is reported to have pharmacological effects including reuptake blockage for serotonin and norepinephrine
89603945|NCT00360724|Placebo Comparator|Placebo treatment|placebo treatment: treatment with placebo capsules that match active medication capsules
89603946|NCT00398398|Experimental|Capecitbine, oxaliplatin, cetuximab|Capecitbine, oxaliplatin and cetuximab every three week; Capecitabine 1,000 mg/m2 was administered twice daily on days 1-14. Oxaliplatin 130 mg/m2 i.v. for 2 h was given on day 1 after cetuximab infusion. Cetuximab at an initial loading dose of 400 mg/m2 i.v. for 2 h and, thereafter, maintenance dose of 250 mg/m2 for 1 h every week.
89603947|NCT00398476|Active Comparator|fluticasone propionate (FP)|200 micrograms (mcg); an aqueous suspension of microfine FP
89603948|NCT00398476|Active Comparator|fluticasone furoate (FF)|110 mcg; an aqueous suspension containing 0.05% w/w of micronized FF
88981307|NCT03971539|Experimental|MRD part: 25 mg BI 894416|Multiple rising dose (MRD) part: 25 milligram (mg) BI 894416 film-coated tablet taken for 9 days orally with 240 milliliter of water. Administration of BI 894416 at Day 1 and Day 9 once daily in the morning (q.d.) and at Day 2 to Day 8 three times daily at an interval of 8 hours (t.i.d.). Morning dose to be taken after an overnight fast of at least 10 hours, afternoon dose to be taken after fasting for 2 hours.
89603949|NCT01436643|Experimental|Fluoxetine and Fingolimod|Fingolimod 0.5 mg per capsule(hard gelatin capsules) was taken p.o. once daily. Fluoxetine, supplied in blistered packs containing 20 tablets; starting dose 20 mg; final dose 40 mg
89603950|NCT01436643|Experimental|Venlafaxine and Fingolimod|Fingolimod 0.5 mg per capsule(hard gelatin capsules) was taken p.o. once daily. Venlafaxine, supplied in blistered packs containing 14 capsules; starting dose 75 mg; final dose 150 mg
89603951|NCT01436643|Experimental|Citalopram and Fingolimod|Fingolimod 0.5 mg per capsule(hard gelatin capsules) was taken p.o. once daily. Citalopram, supplied in blistered packs containing 20 tablets; starting dose 20 mg, final dose 40 mg
89603952|NCT00399880|Experimental|Health literacy intervention|Illustrated medication schedules, pill boxes, pharmacist counseling
89603953|NCT00399880|No Intervention|Usual care|
89603954|NCT04239196|Experimental|tocilizumab and IV steroids combination|Every patient will receive the reference treatment for GCA with ocular complication, i.e. high dose corticosteroid therapy (intravenous pulses of 7,5 to 15 mg/kg/day of methylprednisolone with an upper limit of 1000 mg/day for 3 days followed by oral prednisone at 1 mg/kg/day with progressive decrease as usually done) and aspirin 75 mg/day. The mean duration of this reference treatment is 18 months. Patients will receive in addition to the reference treatment four subcutaneous injections of tocilizumab 162 mg over one month (1 injection per week).
88981308|NCT03971539|Experimental|MRD part: 50 mg BI 894416|Multiple rising dose (MRD) part: 50 milligram (mg) BI 894416 film-coated tablet taken for 9 days orally with 240 milliliter of water. Administration of BI 894416 at Day 1 and Day 9 once daily in the morning (q.d.) and at Day 2 to Day 8 three times daily at an interval of 8 hours (t.i.d.). Morning dose to be taken after an overnight fast of at least 10 hours, afternoon dose to be taken after fasting for 2 hours.
88981309|NCT03971539|Experimental|MRD part: 60 mg BI 894416|Multiple rising dose (MRD) part: 60 milligram (mg) BI 894416 film-coated tablet taken for 9 days orally with 240 milliliter of water. Administration of BI 894416 at Day 1 and Day 9 once daily in the morning (q.d.) and at Day 2 to Day 8 three times daily at an interval of 8 hours (t.i.d.). Morning dose to be taken after an overnight fast of at least 10 hours, afternoon dose to be taken after fasting for 2 hours.
88981310|NCT03968445|Experimental|Recent Myocardial Infarction|
88981311|NCT03968445|Experimental|undergoing elective percutaneous coronary intervention|
88981312|NCT03951103||Hemophili A patients|Patients treated with rFVIIIFc for ITI
88981313|NCT03949491|Experimental|3-D virtual planning and medical modeling of breast|"3-D virtual planning and medical modeling in breast cancer patients undergoing breast reconstruction.~Preoperative CT-Angiogram of the abdominal wall~Volumetric analysis preformed~3D printed models made~Pre operative BREAST-Questionnaires given~Free tissue transfer performed: Operative/Dissection Time Recorded~Flap/Abdominal donor site complications recorded~Standard Digital Photography and Harris Scoring~BREAST-Questionnaires given at 3, 6 months"
88981314|NCT03908593|Active Comparator|One month of therapy|Pantoprazole, 40mg, tablet, oral, once daily for 1 month
88981315|NCT03908593|Experimental|Twelve months of therapy|Pantoprazole, 40mg, tablet, oral, once daily for 12 months
89603955|NCT04239196|Other|IV steroids combination alone|Every patient will receive the reference treatment for GCA with ocular complication, i.e. high dose corticosteroid therapy (intravenous pulses of 7,5 to 15 mg/kg/day of methylprednisolone with an upper limit of 1000 mg/day for 3 days followed by oral prednisone at 1 mg/kg/day with progressive decrease as usually done) and aspirin 75 mg/day. The mean duration of this reference treatment is 18 months.
89603956|NCT00361972|Active Comparator|Lansoprazole therapy|Lansoprazole 30 mg orally twice daily
89603957|NCT00361972|Placebo Comparator|Placebo|placebo orally twice daily
89603958|NCT00362440|Experimental|Leptin|Leptin replacement therapy
89603959|NCT00362440|Placebo Comparator|Pioglitazone or metformin|Diabetes treatment therapy
89603960|NCT01792960||familial hypertrophic cardiomyopathy|familial hypertrophic cardiomyopathy patients and their relatives
89603961|NCT00401518|Experimental|ACADIA®|Investigational surgical treatment using the ACADIA Facet Replacement system
89603962|NCT00401518|Active Comparator|Control Instrumented PLF|Control surgical treatment using an instrumented posterolateral fusion
89603963|NCT02109640|Experimental|Targinact|Oral Targinact 10-20mg bd following laparoscopic segmental colectomy
89603964|NCT02109640|Active Comparator|Oxycodone|Oral oxycodone 10-20mg bd following laparoscopic segmental colectomy
89603965|NCT00401986||Alair Treatment|Alair Treated subjects from PREDECESSOR STUDY (NCT00214539).
89603966|NCT00365872|Experimental|EBRT + DC Injection + Resection|Single Arm: EBRT + DC Injection + Resection. Prior to the fourth DC Injection, participants were assigned to 3 cohorts as outlined in that intervention.
89603967|NCT00366028|Other|Organizational Model|Organizational Model: Participants in this arm of the study will receive information regarding the organizational model and work closely with the research team throughout the project to implement various aspects of the model. Participants in this arm of the study will be interviewed and participate in the data feedback portion of the study as well.
89603968|NCT00366028|Other|Data Feedback|Data Feedback Only: Participants in this arm will be interviewed periodically and participate in the data feedback portion of the study.
89603969|NCT01454739|Experimental|On-Demand|The individual dose of rFVIIIFc to treat bleeding episodes will be based on participant's clinical condition, type and severity of the bleeding event, and if indicated, Factor VIII (FVIII) levels.
89603970|NCT01454739|Experimental|Prophylaxis|Tailored prophylaxis, Weekly prophylaxis or Personalized prophylaxis available.
89603971|NCT01794286|Active Comparator|Control Group|Trigger alerts only
89603972|NCT01794286|Experimental|Intervention Group|Trigger alerts + provider bulletins
89603973|NCT00368290|Experimental|1|modafinil plus CBT
89603974|NCT00368290|Placebo Comparator|2|placebo plus CBT
89603975|NCT00369226|Experimental|Bortezomib/Tacrolimus/Methotrexate post HSCT|
89603976|NCT01416441|Experimental|Aripiprazole|Participants received oral aripiprazole tablets once weekly (QW) with a titrated dose starting from 52.5 milligram (mg), on Day 1 and increasing to 77.5 mg and 110 mg for the remainder of the trial (Up to Week 52), the dose could be adjusted between these 3 dose levels as determined by investigator's discretion based on safety and tolerability.
89603977|NCT01793194|No Intervention|No Stocking Use|For pregnant women randomized to the no stocking use group, no compression stockings will be worn.
89603978|NCT01793194|Experimental|Compression Stocking Use|Patients who are randomized to the stocking use group (Treatment Subgroup A) will be formally measured for their stockings by a certified stocking fitter, given (at no charge) two pair of 20-30mmg Hg maternity pantyhose compression stockings, and will undergo a brief tutorial regarding how to put the stockings on. Each patient will be instructed to wear the stockings on a daily basis, during the day.
89603979|NCT00406276|Experimental|RAD001+Docetaxel|RAD001 in combination with Docetaxel.
89603980|NCT01436253||Croatian participants with hyperlipidemia|Participants being treated in a physician's office for hyperlipidemia who have not achieved target lipid levels on their current hypolipemic therapy.
89603981|NCT03854656|No Intervention|Control|Control group for 13 weeks (n=50). Participants will receive advice about a healthy lifestyle according to the national dietary recommendations from the Danish Health Authority.
89603982|NCT03854656|Experimental|Time-restricted eating|Time-restricted eating for 13 weeks (n=50). In addition to the intervention, participants will receive advice about a healthy lifestyle according to the national dietary recommendations from the Danish Health Authority.
88981316|NCT03901755||Prophylactic patients|Alprolix will be prescribed according to local practice and administered by patients with haemophilia B for prophylactic treatment
88981317|NCT03901755||On demand patients|Alprolix will be prescribed according to local practice and administered by patients with haemophilia B for on-demand treatment
89603983|NCT00408070|Experimental|I|This is a single Arm study. Two of the study drugs used are non-experimental. One of the study drugs is experimental.
89603984|NCT01794442||Controls|Healthy volunteers with no family history of glaucoma, an increased or asymmetrical cup/disc ratio or any other optic disc structural change (notching, disc hemorrhage) or an intraocular pressure (IOP) above 21 mmHg that could suggest possible glaucoma suspects.
89603985|NCT01794442||Primary open-angle glaucoma|Patients with a characteristic optic disc damage (based on cup/disc ratio, thinning of neuroretinal rim, notching, disk hemorrhages, etc.) and visual field defects, with at least one measurement of IOP of >21 mmHg required
89603986|NCT01794442||Normal Tension Glaucoma|Patients with a characteristic optic disc damage (based on cup/disc ratio, thinning of neuroretinal rim, notching, disk hemorrhages, etc.) and visual field defects, with at maximum recorded IOP of < 21 mmHg
89603987|NCT00408460|Experimental|Treatment (enzyme inhibitor, chemotherapy)|Patients receive paclitaxel IV on days 3, 10, and 17 and imatinib mesylate PO QD on days 1-4, 8-11, and 15-18. Treatment repeats every 28 days for 4-6 courses in the absence of disease progression or unacceptable toxicity.
89603988|NCT02111200|Active Comparator|Sodium Benzoate arm|Sodium benzoate 5.5 g/m2/day divided into three equal doses per day (maximum dose 12 g/day) for 3 days
89603989|NCT02111200|Active Comparator|Sodium Phenylbutyrate arm|Sodium phenylbutyrate 7.15 g/m2/day divided into three equal doses per day (maximum dose of 20 g/day) for 3 days
89603990|NCT02111200|Active Comparator|Mix Arm|Sodium Phenylbutyrate 3.575 g/m2/day and Sodium Benzoate 2.75 g/m2/day will be given in three equal doses per day for 3 days
89603991|NCT02111746|Experimental|Exparel®|Patients in this group will receive will receive the study drug [bupivacaine liposomal injectable suspension (Exparel®)] and Patient Controlled Analgesia (PCA). Exparel® is an FDA-approved bupivacaine liposome injectable suspension produced by Pacira Pharmaceuticals.
89603992|NCT02111746|Active Comparator|Regular Bupivacaine|Patients in this group will receive will receive the standard regular bupivacaine hydrochloride (HCl) and PCA. Bupivacaine HCl is an FDA-approved injectable suspension. The standard non-liposomal bupivacaine will be from Hospira pharmaceuticals
89603993|NCT02111980|Experimental|RF Assure Scanning|The patient's CIED will be interrogated prior to the study to obtain a baseline reading. The patient will be asked to lie down on the RF Assure® Detection Mat with a sponge placed underneath his or her shoulder. The RF Assure® mat and wand will be activated to detect the sponge. The sponge will be removed from underneath the patient's shoulder, and the RF system will be re-activated to obtain a clear reading. The patient's CIED will be re-interrogated to determine if the RF Assure system caused any changes to the CIED parameters or function.
89603994|NCT01793272|Other|Pentoxifylline|effect of pentoxifylline on ICSI outcome
89603995|NCT00369928|Placebo Comparator|Placebo|Placebo, oral dose, BID
89603996|NCT00369928|Experimental|25 mg PG-760564|25 mg BID, of oral PG-760564
89603997|NCT00369928|Experimental|100 mg PG-760564|100 mg BID, of oral PG-760564
89603998|NCT03650920|Experimental|Recipient of HCV positive liver graft|A single center, open-label, pilot study examining 10 adult HCV negative liver transplant subjects who receive an HCV infected graft. Target start date for antiviral therapy will be within 3 months after liver transplantation, unless extenuating clinical circumstances arise (such as fibrosing cholestatic HCV, which would prompt earlier treatment, or non-hepatic comorbidities which would prompt delay in treatment).
89603999|NCT00409240|Experimental|MEDIC Intervention|Receives pharmacist-led behavioral and pharmacologic group intervention for cardiac risk reduction
89604000|NCT00409240|No Intervention|Usual Care|Patient continued on usual care
89604001|NCT02110108|Experimental|Revlite Laser System- Single Wavelength|Revlite Laser System- 1064nm wavelength will be used on half of the face.
89604002|NCT02110108|Experimental|Revlite Laser System- Dual Wavelength|Revlite Laser System- treatment will consist of 1064 nm and 532 nm wavelengths on half of the face.
89604003|NCT03387982||Balloon Cryotherapy Treatment Group|Subjects will undergo endoscopic balloon cryotherapy for dysplastic Barrett's Esophagus as per standard of care. The treatment type (balloon cryotherapy vs RFA) is determined by the endoscopy physician at the time of the procedure and is based on several clinical factors including co-existing medical conditions, the anatomy of the esophagus, and the length and amount of tissue affected with Barrett's.
89604004|NCT03387982||RFA Treatment Group|Subjects will undergo radio frequency ablation treatment for dysplastic Barrett's Esophagus as per standard of care. The treatment type (balloon cryotherapy vs RFA) is determined by the endoscopy physician at the time of the procedure and is based on several clinical factors including co-existing medical conditions, the anatomy of the esophagus, and the length and amount of tissue affected with Barrett's.
89604005|NCT05287438|Active Comparator|Group A - Culture|Following local standard of care, treatment will be based on standard culture
89604006|NCT05287438|Experimental|Group B - NGS|Treatment will be based on NGS results reviewed by an infectious disease doctor
89604007|NCT00410488|Active Comparator|Palonosetron - 1 Dose|"Arm 1: Palonosetron 0.25 mg intravenous (IV) for 1 dose (day 0).~Dexamethasone: IV piggyback daily for 5 days (12 mg on day 0, and 8 mg on days 1-4) 30 minutes prior to chemotherapy. Chemotherapy treatment regimen: Zinecard: 750 mg/m2 as an IV bolus; Doxorubicin: 75 mg/m2 as an IV bolus OR 75 mg/m2 as continuous IV infusion over 72 hours (without zinecard) on Day 0. Mesna: 500 mg/m2 given simultaneously with ifosfamide day 0; then 1500 mg/m2 over 24 hours for days 0, 1, 2, and 3 (infusion completing on day 4); Ifosfamide: 2.5 g/m2 IV bolus over 3 hours; days 0, 1, 2, 3 (total dose = 10 g/m2); Vincristine: 2 mg IV by rapid administration on day 0 (for patients with small cell histology)."
88981318|NCT03901612|Placebo Comparator|Saline solution|Post operative analgesia throw the thoracic Erector spinae catheter with saline solution and opioid rescue
88981319|NCT03901612|Experimental|Ropivacaine|Post operative analgesia throw the thoracic Erector spinae catheter with Ropivacaine 0.2% solution and opioid rescue
89604008|NCT00410488|Active Comparator|Palonosetron - 3 Doses|"Arm 2: Palonosetron 0.25 mg IV for 3 doses (days 0, 2, 4).~Dexamethasone: IV piggyback daily for 5 days (12 mg on day 0, and 8 mg on days 1-4) 30 minutes prior to chemotherapy. Chemotherapy treatment regimen: Zinecard: 750 mg/m2 as an IV bolus; Doxorubicin: 75 mg/m2 as an IV bolus OR 75 mg/m2 as continuous IV infusion over 72 hours (without zinecard) on Day 0. Mesna: 500 mg/m2 given simultaneously with ifosfamide day 0; then 1500 mg/m2 over 24 hours for days 0, 1, 2, and 3 (infusion completing on day 4); Ifosfamide: 2.5 g/m2 IV bolus over 3 hours; days 0, 1, 2, 3 (total dose = 10 g/m2); Vincristine: 2 mg IV by rapid administration on day 0 (for patients with small cell histology)."
89604009|NCT01794598|Experimental|Educational materials|Receiving educational materials of depression care
89604010|NCT01794598|Sham Comparator|No educational materials|Receiving an envelope but no inclusion of educational materials of depression care
89604011|NCT00412516|Other|Group 1|JE live attenuated SA 14-14-2 vaccine then measles vaccine after one month
89604012|NCT00412516|Experimental|Group 2|JE live attenuated SA 14-14-2 vaccine and measles vaccine concurrently
89604013|NCT00412516|Other|Group 3|Measles vaccine then JE live attenuated SA 14-14-2 vaccine after one month
89604014|NCT01793350|Active Comparator|BC-DN-01 topically applied cream, DPN|4g topically applied BC-DN-01 cream applied twice daily to each leg and foot, for 12 weeks
88981320|NCT03893487|Experimental|Treatment (fimepinostat, tumor resection)|"Patients receive fimepinostat by mouth once daily, on Days -2 to 0. Within 2 hours of receiving fimepinostat on Day 0, patients undergo tumor resection or biopsy as part of their standard of care.~MAINTENANCE PHASE: Patients receive fimepinostat by mouth, once daily for days 1-5 each week. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity for up to 12 months from the time treatment begins. Should patients continue to derive clinical benefit, and not experience excess toxicity or progression, patients can continue to receive drug for up to 24 months or longer pending discussion with study chairs and study sponsor."
88981321|NCT03887273|Experimental|Q-Cells dose level 1|One time surgical transplantation of Q-Cells dose level 1 unilaterally into spinal cord demyelinated lesion
88981322|NCT03887273|Experimental|Q-Cells dose level 2|One time surgical transplantation of Q-Cells dose level 2 unilaterally into spinal cord demyelinated lesion
88981323|NCT03887273|Experimental|Q-Cells dose level 3|One time surgical transplantation of Q-Cells dose level 3 unilaterally into spinal cord demyelinated lesion
89604015|NCT01793350|Placebo Comparator|Placebo topically applied cream, DPN|4g topically applied cream applied twice daily to each leg and foot, for 12 weeks
89604016|NCT03303898|Other|asymptomatic carriers|
89604017|NCT03303898|Other|uninfected patient|
89604018|NCT01794676||Family 1|Approximately a 10 ml of blood draw will be taken from each participant for genetic testing.
89604019|NCT01794676||Family 2|Approximately a 10 ml of blood draw will be taken from each participant for genetic testing.
89604020|NCT01794676||Family 3|Approximately a 10 ml of blood draw will be taken from each participant for genetic testing.
89604021|NCT05286970|Experimental|0.5mg AK115 SC|
89604022|NCT05286970|Experimental|1mg AK115or placebo SC|
89604023|NCT05286970|Experimental|3mg AK115or placebo SC|
89604024|NCT05286970|Experimental|10mg AK115or placebo SC|
89604025|NCT05286970|Experimental|30mg AK115or placebo SC|
89604026|NCT05286970|Experimental|60mg AK115or placebo SC|
89604027|NCT00414700|Experimental|ChondroCelect|
89604028|NCT00414700|Active Comparator|Microfracture|
89604029|NCT01794832||Elderly with severe aortic stenosis|Patients with severe symptomatic aortic stenosis referred for consideration of surgical aortic valve replacement
89604030|NCT00415870|Experimental|PACE|Received text messages and counseling calls
89604031|NCT00415870|No Intervention|Control|
89604032|NCT01795612|Other|Arm A|6-month ETP, during adjuvant or neoadjuvant therapy
89604033|NCT01795612|Other|Arm B|6-month ETP, after adjuvant or neoadjuvant therapy
89604034|NCT01795612|Other|Arm C|12-monthETP, during and after adjuvant or neoadjuvant treatment
89604035|NCT00416182|Experimental|Pulmozyme|2.5 mg Pulmozyme (dornase alfa) delivered intranasally once daily
89604036|NCT00416182|Placebo Comparator|placebo|2.5 mg/2mL placebo administered intranasally once daily
89604037|NCT00416494|Experimental|Initial Cohort|
89604038|NCT00416494|Experimental|Second cohort|
89604039|NCT02616172|Experimental|Autologous bone marrow infusion|One time administration of autologous bone marrow mononuclear cells intravenously, minimum dose of 6 million cells per kg Total nucleated cells.
89604040|NCT02460484|Experimental|Cord Blood Infusion|Autologous cord blood infusion
89604041|NCT00416572|Experimental|Education Intervention|Participants attended 4 2-hr education sessions. The overall goal of the sessions was to provide information that would reduce participants' uncertainty about their illness and its treatment, to enhance coping in productive ways with the issues and problems confronting them, and to facilitate communication between the participants and their partners.
89604042|NCT00416572|Experimental|Nutrition Education Intervention|Participants attended 4 2-hr nutrition education sessions. Each session provided information and encouragement on setting and attaining measurable goals for healthy eating and on the benefits of thinking positively about dealing adaptively with problems in life and living a healthy lifestyle.
88981324|NCT03885765||Test group|The first 60 patients recruited.
88981325|NCT03885765||Validation group|The last 100 patients recruited.
89604043|NCT00416572|No Intervention|Control Condition|Participants received care as usual.
89604044|NCT00417274|Experimental|Quinacrine|Uncontrolled treatment arm
89604045|NCT01793428||Injured patient admitted in vital emergency unit|
89604046|NCT04749940|Experimental|Hospitalized burn patients|Half of the donor site area will be dressed with PRF dressing, and half with Aquacel®.
89604047|NCT01976962|Experimental|Prostate stereotactic body RT with MR-guided boost|Patients will receive a dose of 36.25 Gy in 5 fractions to the entire prostate and proximal seminal vesicles with an additional boost to the dominant lesion for a total of 40 Gy in 5 fractions.
89604048|NCT04750096||Esophagectomy post enhanced recovery after surgery|Patients undergoing esophagectomy due to oesophageal cancer under Enhanced Recovery After Surgery protocol.
89604049|NCT05286346|Experimental|Experimental group|Tenolid Tab
89604050|NCT05286346|Active Comparator|Control group|Viread Tab
89604051|NCT05286268||Study group|Patients with confirmed COVID-19 disease
89604052|NCT05286268||Control group|Healthy volunteers without any of the exclusion criteria
89604053|NCT00422032|Experimental|15 mg/m^2 Clofarabine|Lower Dose Clofarabine Group A: 15 mg/m^2 intravenous (IV) over 1 hour daily for 5 days
89604054|NCT00422032|Experimental|30 mg/m^2 Clofarabine|Higher Dose Clofarabine Group B: 30 mg/m^2 IV over 1 hour daily for 5 days
89604055|NCT01856140|Experimental|1 million cells/ml of ALLO-ASC|1 million cells/ml of ALLO-ASC(allogeneic adipose derived mesenchymal stem cell) will be injected by ultrasound guided intervention.
89604056|NCT01856140|Active Comparator|10 million cells/ml of ALLO-ASC|10 million cells/ml of ALLO-ASC(allogeneic adipose derived mesenchymal stem cell) will be injected by ultrasound guided intervention.
89604057|NCT01388920|Experimental|Tesamorelin 2 mg|Tesamorelin 2 mg/day
89604058|NCT01388920|Experimental|Tesamorelin 3 mg|Tesamorelin 3 mg/day
89604059|NCT01388920|Placebo Comparator|Placebo|Placebo
89604060|NCT00422656|Experimental|Perifosine|Patients receive oral perifosine (150 mg) daily each cycle. Cycle duration is 28 days. After cycle 2, response is assessed and patients with stable or responding disease can continue for another 4 cycles or until disease progression (PD). Protocol treatment duration is 6 cycles but patients may receive perifosine maintenance per investigator discretion in absence of PD.
89604061|NCT00422812|Placebo Comparator|Inhaled Placebo|Inhaled Staccato Placebo
89604062|NCT00422812|Experimental|Inhaled PCZ 5 mg|Inhaled Staccato Prochlorperazine 5 mg
89604063|NCT00422812|Experimental|Inhaled PCZ 7.5 mg|Inhaled Staccato Prochlorperazine 7.5 mg
89604064|NCT00422812|Experimental|Inhaled PCZ 10 mg|Inhaled Staccato Prochlorperazine 10 mg
89604065|NCT00423358|Active Comparator|vitamin D|ergocalciferol 50,000 IU Twice monthly
89604066|NCT00423358|Placebo Comparator|placebo|matching placebo tablet
89604067|NCT00423436|Experimental|IVR Assessment Plus Triage|Interactive Voice Response Telephone System (IVR) Plus Triage (Participants report symptoms to telephone system and doctor/nurse notified when symptom is severe) + Questionnaire
89604068|NCT00423436|Experimental|IVR Assessment Only|IVR (Phone calls twice weekly) + Questionnaire
89604069|NCT00424840|Experimental|Bortezomib 1.3 mg/m2|Level 1 of Bortezomib Dose Escalation in combination with Carboplatin AUC6, Bevacizumab 15 mg/kg and Taxotere 70 + G-CSF
89604070|NCT00424840|Experimental|Bortezomib 1.6 mg/m2|Level 2 of Bortezomib Dose Escalation in combination with Carboplatin AUC6, Bevacizumab 15 mg/kg and Taxotere 70 + G-CSF
89604071|NCT00424840|Experimental|Bortezomib 1.8 mg/m2|Level 3 of Bortezomib Dose Escalation in combination with Carboplatin AUC6, Bevacizumab 15 mg/kg and Taxotere 70 + G-CSF
89604072|NCT00425386|Experimental|Erlotinib and Sunitinib|"Drug: erlotinib hydrochloride Dose Level 0 = 50 mg/day, continuous daily; 0.5= 75 mg/day, continuous daily;~100 mg/day, continuous daily; 1.5= 125 mg/day, continuous daily;~150 mg/day, continuous daily~Drug: sunitinib malate Will be administered at 50 mg daily, 4 weeks on, 2 weeks off"
89604073|NCT04345978|Placebo Comparator|Normal Fasting|The patient starts fasting 8 hours before the operation,and does not take any solid or liquid foods and nutrients during the fasting process.The fasting period does not strictly limit the consumption of pure water,After surgery 8 hours,the patients was allowed to feeding.
89604074|NCT04345978|Experimental|Prolong Fasting|The patient starts fasting 24 hours before the operation, and does not take any solid or liquid foods and nutrients during the fasting process. The fasting period does not strictly limit the consumption of pure water.After surgery 24 hours,the patients was allowed to feeding.
89604075|NCT01164202|Placebo Comparator|Placebo|placebo 3cps/days 4 weeks over 6 during 1 year
89604076|NCT01164202|Experimental|Sunitinib|sunitinib (SUTENT®) 37,5 mg/d (3 cps of 12,5 mg) orally 4 weeks over 6 (4 weeks of treatment followed by 2 weeks without treatment) during 1 year
89604077|NCT01794910|Experimental|Plevic floor muscle therapy|The pelvic floor muscle therapy to women with vaginal or cesarean deliveries involved perineal contraction exercises in the dorsal decubitus, sitting, and standing positions and was applied twice per week for a total of 15 sessions.
89604078|NCT01794910|No Intervention|Controll group|Women with vaginal or cesarean deliveries did not did not undergo muscle training
89604079|NCT05281588|Experimental|Micro-osteoperforations|Micro-osteoperforations- assisted upper incisors retraction
89604080|NCT05281588|No Intervention|Control|Upper incisors retraction not associated with any clinical intervention to accelerate tooth movement
89604081|NCT01793506||PID|Any subject having testing done to evaluate the immune system is eligible for this study. This will include patients with known PIDs as well as patients evaluated for a suspected immunodeficiency.
89604082|NCT02112370|Placebo Comparator|Placebo|100cc normal saline is injected into the subcutaneous layer for the initial flap dissection.
89604083|NCT02112370|Experimental|Ropivacaine with epinephrine injection|1 mg/mL 1cc epinephrine is diluted in 100cc normal saline and then 7.5 mg/mL 30cc ropivacaine is diluted in the same normal saline. The mixture is injected into the subcutaneous layer for the initial flap dissection.
89604084|NCT02112838|Active Comparator|Fostamatinib 150 mg|Fostamatinib 150 milligram (mg) tablet twice daily by mouth, over the course of 24 weeks
89604085|NCT02112838|Active Comparator|Fostamatinib 100 mg|Fostamatinib 100 mg tablet twice daily by mouth, over the course of 24 weeks
89604086|NCT02112838|Placebo Comparator|Placebo|Placebo tablet twice daily by mouth, over the course of 24 weeks
89604087|NCT00427336|Experimental|Fludarabine + Cyclophosphamide + ATG|Fludarabine 30 mg/m^2/day by vein (IV), Cyclophosphamide IV 300 mg/m^2/day, ATG (Antithymocyte Globulin) IV 3.75 mg/kg/day
89604088|NCT00371176|Experimental|D-Cycloserine|Brief imaginal exposure therapy plus DCS pill
89604089|NCT00371176|Placebo Comparator|Placebo|Brief imaginal exposure therapy plus Placebo pill
89604090|NCT00371644|Experimental|Arm 1|Participants receive 12 biweekly sessions of Cognitive Processing Therapy (CPT).
89604091|NCT00371644|Active Comparator|Arm 2|Participants receive 12 biweekly sessions of Present Centered Therapy (PCT).
88981326|NCT03874884|Experimental|177Lu-PSMA + olaparib|Patients will receive a fixed 7.4 GBq of 177Lu-PSMA every 6 weeks together with olaparib on days 2-15 of each cycle. A cycle is 42 days long. Patients will receive 4 cycles of treatment. An additional 2 cycles of treatment can be given based on clinical benefit achieved and toxicity experienced.
89604092|NCT00428584|Experimental|1|interferon beta-1a
89604093|NCT00428584|Active Comparator|2|interferon beta-1b
88981327|NCT03867162|Experimental|Live Attenuated Tularemia Vaccine|0.06 mL of Tularemia Vaccine, Live, Attenuated, NDBR 101, Lot 4
88981328|NCT03840915|Experimental|Cohort A: Cisplatin or Carboplatin + Pemetrexed + Bintrafusp alfa|Participants received 2400 miligrams (mg) Bintrafusp alfa along with Cisplatin or Carboplatin, and Pemetrexed every 3 weeks until confirmed disease progression, unacceptable toxicity, study withdrawal or death.
88981329|NCT03840915|Experimental|Cohort B: Carboplatin + Paclitaxel or Nab-paclitaxel + Bintrafusp alfa|Participants received 2400 mg Bintrafusp alfa along with Carboplatin, and Paclitaxel or Nab-paclitaxel every 3 weeks until confirmed disease progression, unacceptable toxicity, study withdrawal or death.
88981330|NCT03840915|Experimental|Cohort C: Cisplatin or Carboplatin + Gemcitabine + Bintrafusp alfa|Participants received 2400 mg Bintrafusp alfa along with Cisplatin or Carboplatin, and Gemcitabine every 3 weeks until confirmed disease progression, unacceptable toxicity, study withdrawal or death.
88981331|NCT03840915|Experimental|Cohort D: Docetaxel + Bintrafusp alfa|Participants received 2400 mg Bintrafusp alfa along with Docetaxel every 3 weeks until confirmed disease progression, unacceptable toxicity, study withdrawal or death.
88981332|NCT03840733||Participants from NCT01985568 or NCT03411356|All subjects who previously enrolled in the Parent Study's behavioral weight loss intervention (NCT01985568 or NCT03411356).
88981333|NCT03837327||Adnexal Mass|Women with an adnexal mass (pelvic mass) as confirmed by imaging
89604094|NCT00428974|Experimental|CF101 1 mg|
89604095|NCT00428974|Experimental|CF101 2mg|
89604096|NCT00428974|Experimental|CF101 4mg|
89604097|NCT00428974|Placebo Comparator|Placebo|
89604098|NCT00372970|Active Comparator|Botulinum Toxin A|200 U of Botox injected endoscopically into pylorus
89604099|NCT00372970|Placebo Comparator|Placebo|saline into pylorus.
89604100|NCT00373360|Experimental|1|
89604101|NCT00430768|Experimental|Group 1 Low Dose|"rAAV1-CB-hAAT 6.9 x10e12 vector genomes (vg) administered in a 9.9 ml volume of study agent in nine separate 1.1 mL injections in the deltoid muscle of the non-dominant side under ultrasound guidance"
89604102|NCT00430768|Experimental|Group 2 Middle Dose|"rAAV1-CB-hAAT 2.2 x 10e13 vg administered in a 9.9 ml volume of study agent in nine separate 1.1 mL injections in the deltoid muscle of the non-dominant side under ultrasound guidance"
89604103|NCT00430768|Experimental|Group 3 High Dose|"rAAV1-CB-hAAT 6.0 x10e13 vg administered in a 9.9 ml volume of study agent in nine separate 1.1 mL injections in the deltoid muscle of the non-dominant side under ultrasound guidance"
89604104|NCT00455650|Active Comparator|Schizophrenia, Mecamylamine|
89604105|NCT00455650|Active Comparator|Schizophrenia, Varenicline|
89604106|NCT00455650|Placebo Comparator|Schizophrenia, Placebo|
89604107|NCT00455650|Active Comparator|Control, Mecamylamine|
89604108|NCT00455650|Active Comparator|Control, Varenicline|
89604109|NCT00455650|Placebo Comparator|Control, placebo|
89604110|NCT01794988|Experimental|Group Cognitive Behavioral Therapy|Participants will undergo 11 weeks of group cognitive behavioral therapy (CBT) and a pre- and post-intervention MRI brain scan.
89604111|NCT01794988|Active Comparator|Pain Education|Participants will receive 11 weeks of pain education and a pre- and post-intervention MRI brain scan.
89604112|NCT01794988|Experimental|Therapeutic Interactive Voice Response|Four months of therapeutic interactive voice response (TIVR).
88981334|NCT03821792|Experimental|Treatment (abiraterone acetate, prednisone, apalutamide)|Patient receive abiraterone acetate PO daily, prednisone PO BID, and apalutamide PO daily. Cycles repeat every 28 days for 1 year in the absence of disease progression or unacceptable toxicity.
88981335|NCT03818386|Experimental|AGuIX® + Whole Brain Radiation Therapy|"Intervention: Drug: AGuIX® + WBRT~Other Names:~Gadolinium-chelated polysiloxane based nanoparticles~3 intravenous injections at 100mg/kg~D0: AGuIX® injection followed by MRI (within 7 days before commencement of WBRT)~Fr1: AGuIX® injection before the first radiation session~Fr6: AGuIX® injection before the sixth radiation session~30 Gy in 10 fractions of 3 Gy over 2-3 weeks"
88981336|NCT03818386|Active Comparator|Whole Brain Radiation Therapy|Intervention: Radiation: Whole Brain Radiation Therapy ( WBRT) 30 Gy in 10 fractions of 3 Gy over 2-3 weeks
88981337|NCT03796871|Experimental|Dermapol|Use of the experimental medical device
88981338|NCT03786614|Active Comparator|Discontinuation arm|This group will be discontinued from serotonergic antidepressants and shifting them to other categories of antidepressants, i.e., medications that work through dopamine or nor-epinephrine, or by reducing the serotonin signal rather than increasing synaptic serotonin, as might be accomplished with low dose, sub-anti-psychotic doses of some second-generation anti-psychotics.
88981339|NCT03786614|Active Comparator|Continuation arm|This group will continue taking serotonergic antidepressants which is the standard care of treatment.
88981340|NCT03774394|Experimental|Diabetes Mellitus patients with Chronic Kidney Disease|"Patients with CKD will be administered a 600-mg LD of Clopidogrel followed by a single 75-mg MD administered after 24 hours.~Blood samples collected at baseline will be incubated with clopidogrel active metabolite."
88981341|NCT03774394|Active Comparator|Diabetes Mellitus patients without Chronic Kidney Disease|"Patients without CKD will be administered a 600-mg LD of Clopidogrel followed by a single 75-mg MD administered after 24 hours.~Blood samples collected at baseline will be incubated with clopidogrel active metabolite."
88981342|NCT03774238|Experimental|COPD patients|FMD analysis Endothelial progenitors Exercise test Exercise training
88981343|NCT03774238|Experimental|Healthy subject|FMD analysis Endothelial progenitors Exercise test
88981344|NCT03770481|Experimental|Assess the NLCS' feasibility|"Hypothesis: No significant differences will be observed in recruitment and attrition between NLCS intervention and control groups.~Approach: Determine rates of enrollment and drop-outs between groups."
88981345|NCT03770481|Experimental|Assess the NLCS' acceptability|"Hypothesis: More surrogates agree that the NLCS is suitable, appropriate, effective and willing to adhere versus treatment as usual (TAU) communication.~Approach: Assess outcome using the validated instrument, Client Satisfaction Questionnaire (CSQ-8)."
88981346|NCT03770481|Experimental|Assess the NLCS' preliminary effects|Hypothesis: NLCS improves communication and decreases surrogates' psychological distress (e.g., anxiety and depression) Approach: Compare pre- and post-intervention scores of the Quality of Communication (QOC) questionnaire, Hospital Anxiety and Depression Scale (HADS), and Decisional Conflict Scale (DCS) between intervention and control groups.
89210364|NCT03972787|No Intervention|Waitlist Control|Participants will not receive any intervention for a total of 8 weeks to determine whether any impacts noted for participants' loneliness, mood, technology use, and quality of life are unique to ElliQ or are influenced by other factors.
89210365|NCT00606684|Active Comparator|GW642444|GW642444
89604113|NCT01794988|Active Comparator|No TIVR|Control - no intervention
89604114|NCT02114164|Active Comparator|AirSeal System|This group receives the AirSeal System for intraoperative insufflation.
89604115|NCT02114164|Active Comparator|Standard Endopath|This group receives the Standard Endopath Trocar for intraoperative insufflation.
89604116|NCT00374842|Experimental|GSK1247446A Formulation 1 Group|Subjects aged 18 - 59 years at the time of enrolment received one dose of the GSK1247446A vaccine adjuvanted with a full dose of adjuvant at Day 0. The adjuvanted GSK1247446A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
89604117|NCT00374842|Experimental|GSK1247446A Formulation 2 Group|Subjects aged 18 - 59 years at the time of enrolment received one dose of the GSK1247446A vaccine adjuvanted with a half dose of adjuvant at Day 0. The adjuvanted GSK1247446A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
89604118|NCT00374842|Active Comparator|Fluarix Group|Subjects aged 18 - 59 years at the time of enrolment received one dose of the Fluarix™ vaccine at Day 0. The Fluarix™ vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
89604119|NCT00431626|Experimental|Laser TURP with dutasteride|Prior to and after standard treatment with laser TURP, dutasteride is applied to each patient
89604120|NCT00431626|Placebo Comparator|Laser TURP with placebo|Prior to and after standard treatment with laser TURP, placebo is applied to each patient
89604121|NCT01796626|Experimental|Wrinkle treatment|Wrinkle treatment with ResurFX 1565nm module
89604122|NCT01796626|Experimental|Striae treatment|Striae treatment with the REsurFX 1565nm module
89604123|NCT01796704||healthy and mild heart failure|diversity of patients
89604124|NCT00376558|Active Comparator|Contingency Management w/ CRA|Cocaine users: Contingency management w/ Community Reinforcement Approach
89604125|NCT00376558|No Intervention|Healthy Control|A group of healthy matched comparison subjects with no DSM-IV axis I Disorder was included; they were matched for cigarette smoking, gender, and ethnicity.
89604126|NCT00455962|Active Comparator|African American women 18-35 yo|intervention: estradiol steroid infusion and progesterone steroid infusion
89604127|NCT00455962|Active Comparator|Caucasian women 18-35 yo|intervention: estradiol steroid infusion intervention: progesterone steroid infusion
89604128|NCT00434278|Placebo Comparator|Placebo|
89604129|NCT00434278|Experimental|Dornase alfa|
89604130|NCT00434356|Experimental|1|
89604131|NCT00434356|Placebo Comparator|2|
89604132|NCT00376948|Experimental|Novasoy®, Gemcitabine & Erlotinib|Novasoy® 396 mg (177 mg of Isoflavones) twice-daily starting daay -7 until day 28; Gemcitabine 1000 mg/m2 days 1, 8, & 15; Erlotinib 150 mg day 1 until day 28
89604133|NCT01795768|Experimental|Single Treatment Arm|16-24 patients per tumour group will be treated with AZD4547 administered 80mg twice daily, 2 weeks on, 1 week off in 21 days cycles.
89604134|NCT01795924|Experimental|PD-616 plus low-dose Cytarabine|Patients will receive low-dose cytarabine (20 mg/m2) subcutaneously (SC) once daily (QD), followed by a 1-hour intravenous (IV) infusion of PD-616 for 5 consecutive days during Week 1 (D1 to D5) and Week 2 (D8 to D12) of a 28-day treatment cycle. Cytarabine is to be administered approximately 30 minutes before PD-616. In Phase 1 part, the starting dose of PD-616 is 0.0875 mg/m2, with sequential increments of 0.0375 mg/m2, to 0.125, and 0.1625 mg/m2. The dose of PD-616 to be administered in Phase 2 part will be the maximum tolerated dose (MTD)determined from Phase 1 part of the study.
89604135|NCT01796080|Active Comparator|Mueller manoeuvre|Mueller manoeuvre lasting for 20 seconds
89604136|NCT01796080|Active Comparator|Inspiratory threshold|One continuous inspiration through an inspiratory threshold load for 20 seconds
89604137|NCT01796080|Active Comparator|Expiratory apnoea|Expiratory apnoea (without respiratory effort) lasting for 20 seconds
89604138|NCT01796080|Sham Comparator|Steady state normal breathing|Steady state normal breathing for 20 seconds
89604139|NCT00438100|Active Comparator|Capecitabine arm|Capecitabine (Xeloda): 1600 mg/m2 orally bid daily for day 1 through day 21 followed by 7-day washout; repeat this as a course.
89604140|NCT00438100|Experimental|S-1 arm|S-1: 80 mg/m2 orally bid daily for day 1 through day28 followed by 14-day washout; repeat this as a course.
89604141|NCT00438490|Experimental|recombinant human prolactin|Recombinant Human Prolactin 60 mcg/kg once daily subcutaneous injection
88981347|NCT03766126|Experimental|Treatment Arm|CART123 cells; cyclophosphamide; fludarabine
88981348|NCT03765788|Experimental|Secukinumab|Participants received secukinumab at a dose of 300 milligrams (mg) as subcutaneous (s.c.) injection at Baseline, Week 1,2,3,4 and then every 4 weeks thereafter through to week 48 along with a 26-week prednisolone tapering regimen.
88981349|NCT03765788|Placebo Comparator|Placebo|Participants received placebo as subcutaneous (s.c.) injection at Baseline, Week 1,2,3,4 and then every 4 weeks thereafter through to week 48 along with a 26-week prednisolone tapering regimen.
88981350|NCT03763253|Active Comparator|Control Arm: Standard of Care (SOC)|"Standard of Care (SOC) treatment as determined by treating physician (positive control) (androgen deprivation with or without docetaxel chemotherapy or other systemic standard of care treatment including but not limited to Abiraterone or Enzalutamide).~Radiotherapy to the prostate in this arm is defined as cytoreductive (for symptom control) in high volume (>/=4) metastases or to mirror current accepted local radiotherapy dose regimens for men with low volume metastases (<4 metastases).~Metastases directed therapy will not be permitted in the control arm. Palliative radiotherapy for symptom control or for prevention of fracture will be permitted as standard clinical practice."
88981351|NCT03763253|Active Comparator|Intervention Arm 1: Minimally Invasive Ablative Therapy (MIAT)|"MIAT to prostate in form of cryotherapy or high intensity focused ultrasound (HIFU), in addition to SOC systemic treatment. No local prostate radiotherapy will be given as part of this intervention. Radiotherapy can be given subsequently for palliative reasons.~Metastatic directed therapy will be available for use in this arm (if declared at randomisation)."
88981352|NCT03763253|Active Comparator|Intervention Arm 2: Radical Therapy|"Radical therapy in form of prostatectomy (any approach) or external beam radiotherapy (radical dose) in addition to SOC systemic treatment. Modality based on physician and patient preference and patient co-morbidities.~For patients undergoing radical prostatectomy no local prostate radiotherapy will be given as part of the intervention. Radiotherapy can be given subsequently for palliative reasons.~Radical radiotherapy doses in this arm will be higher than SOC.~Metastatic directed therapy will be available for use in this arm (if declared at randomisation)."
89210366|NCT00606684|Placebo Comparator|placebo|
89604142|NCT00438490|Placebo Comparator|Placebo|Normal saline placebo subcutaneous injection
89604143|NCT00456508|Experimental|DX-88 (ecallantide)|DX-88 (ecallantide) Patients were treated with DX-88 (ecallantide) when they experienced an HAE attack. 30 mg dose of ecallantide given via 3 SC injections; a second 30 mg dose can be administered if needed. Patients were to be assessed until 4 hrs post-dose. Patients were asked to return for 3 follow-up visits: 7 days, 28 days and 90 days post-dose.
89604144|NCT02115646|Experimental|fractionated carbon dioxide laser|fractionated carbon dioxide laser
89604145|NCT00457366|Active Comparator|Quetiapine|Quetiapine is being used in an ER setting on agitated patients, being administered orally.
89604146|NCT00457366|Active Comparator|Haloperidol|"Haloperidol is being used in an ER setting on agitated patients, administered IM. This is being used in combination with lorazepam and cogentin. We are comparing the use of this cocktail to quetiapine alone."
89604147|NCT00457366|Active Comparator|Lorazepam|"Lorazepam is being used in an ER setting on agitated patients, administered IM.This is being used in combination with haloperidol, and cogentin. We are comparing the use of this cocktail to quetiapine alone."
89604148|NCT00457366|Active Comparator|Cogentin|"Cogentin is being used in an ER setting on agitated patients, administered IM.~This is being used in combination with haloperidol, and lorazepam. We are comparing the use of this cocktail to quetiapine alone."
89604149|NCT00459862|Experimental|Arm I|Patients receive 800 mg oral pazopanib hydrochloride once daily on days 1-21. Treatment repeats every 21 days for 2 years in the absence of disease progression or unacceptable toxicity.
89604150|NCT00461734|Active Comparator|RV Apex|
89604151|NCT00461734|Experimental|RV High Septum|
89604152|NCT00438802|Experimental|alefacept|Determine both the maximum tolerated dose level as well as the optimal immunologic dose and toxicity.
89604153|NCT00377572|Experimental|Omalizumab (Xolair) + Conventional Therapy|Omalizumab was administered subcutaneously every 2 or 4 weeks over a period of 60 weeks to participants classified as having moderate to severe asthma. Doses (mg) and dosing frequency were determined by serum total IgE level (IU/mL) and body weight (kg). Also, participants continued with their conventional asthma therapy according to the National Asthma Education and Prevention Program (NAEPP-II, 2002) guidelines, under the management of an asthma specialist health care provider.
89604154|NCT00377572|Placebo Comparator|Placebo + Conventional Therapy|Placebo was administered subcutaneously every 2 or 4 weeks over a period of 60 weeks to participants classified as having moderate to severe asthma. Doses (mg) and dosing frequency were determined by serum total IgE level (IU/mL) and body weight (kg). Also, participants continued with their conventional asthma therapy according to the National Asthma Education and Prevention Program (NAEPP-II, 2002) guidelines, under the management of an asthma specialist health care provider.
89604155|NCT00438880|Experimental|Arm I|See Detailed Description
89604156|NCT00462124|Other|Balloon|Implantation of a biodegradable balloon spacer (absorbable perirectal spacer)
89604157|NCT00378352|Placebo Comparator|Dose Escalation Safety|The objective of the first phase is to evaluate the safety of escalating doses of Epoetin alfa in patients with STEMIs.
89604158|NCT00378352|Placebo Comparator|Single Dose Efficacy|Single parenteral administration of 60000 U of epoetin alfa. The objectives of the second phase are to investigate the effects of the highest safe dose on infarct size, left ventricular remodeling and endothelial progenitor cells.
89604159|NCT00462280|Experimental|Two matched nevi group - Lovastatin|Patients with two matched nevi received lovastatin PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity.
89604160|NCT00462280|Placebo Comparator|Two Matched Nevi Group - Placebo|Patients with two matched nevi received placebo PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity
89604161|NCT00462280|Experimental|One large nevi group - Lovastatin|Patients who have one large nevi received lovastatin PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity
89604162|NCT00462280|Placebo Comparator|One Large Nevi Group - Placebo|Patients who have one large nevi received placebo PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity
89604163|NCT00381004|Experimental|FCR + Sargramostim|Fludarabine + Cyclophosphamide + Rituximab (FCR) = Fludarabine - Course 1: 25 mg/m^2 IV Days 2-4; Course 2-6: 25 mg/m^2 IV Days 1-3. Cyclophosphamide - Course 1: 250 mg/m^2 intravenous (IV) Days 2-4; Course 2-6: 250 mg/m^2 Days 1-3. Rituximab - Course 1: 375 mg/m^2 IV over 2-6 hours Day 1; Course 2-6: 500 mg/m^2 IV Day 1. Sargramostim - Course 1: 250 mcg/m^2 subcutaneous (SQ) Days -1 and 5-11; Course 2-6: 250 mcg/m^2 SQ Days -1 and 4-10.
89604164|NCT00440050|Experimental|1.|DHA
89604165|NCT00440050|Placebo Comparator|2.|Placebo
89604166|NCT00440596|Experimental|Mindfulness based stress reduction|Mindfulness based stress reduction
89604167|NCT00440596|Active Comparator|Progressive Muscle Relaxation|Progressive Muscle Relaxation
89604168|NCT00381550|Experimental|Arm I|Patients receive 3-AP (Triapine®) IV over 4 hours followed by fludarabine phosphate IV over 30 minutes on days 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89604169|NCT00440830|Experimental|Smokers-nicotine|Smokers who were treated with nicotine
89604170|NCT00440830|Experimental|Nonsmokers-nicotine|Nonsmokers who were treated with nicotine
89604171|NCT00440830|Placebo Comparator|Smokers-placebo|Smokers who were treated with placebo
89604172|NCT00440830|Placebo Comparator|Nonsmokers-placebo|Nonsmokers who were treated with placebo
89604173|NCT00464464|Active Comparator|1|cognitive-behavioral therapy
89604174|NCT00464464|No Intervention|2|standard medical care
89604175|NCT00381628||Stable subjects with CF|These subjects will undergo epithelial cells and blood lymphocyte extraction. Nasal curettage will be performed to obtain nasal epithelial cells and blood will be obtained to isolate circulating lymphocytes one time from these subjects (age 15 years and above) when they are in their usual state of well-health. These cells will be studied in vitro.
89604176|NCT00381628||Exacerbating subjects with CF|These subjects will undergo epithelial cells and blood lymphocyte extraction. Nasal curettage will be performed to obtain nasal epithelial cells and blood will be obtained to isolate circulating lymphocytes one time from these subjects (age 15 years and above) at the beginning and end of treatment for a pulmonary exacerbation. These cells will be studied in vitro.
89604177|NCT00381628||Stable subjects with asthma|These subjects will undergo epithelial cells and blood lymphocyte extraction. Nasal curettage will be performed to obtain nasal epithelial cells and blood will be obtained to isolate circulating lymphocytes one time from these subjects (age 15 years and above) when they are in their usual state of well-health. These cells will be studied in vitro. This is the disease control group.
89604178|NCT00381628||Healthy volunteers|These subjects will undergo epithelial cells and blood lymphocyte extraction. Nasal curettage will be performed to obtain nasal epithelial cells and blood will be obtained to isolate circulating lymphocytes one time from these subjects (age 15 years and above) when they are in their usual state of well-health. These cells will be studied in vitro. This is the control group
89604179|NCT00427804|Experimental|Calcitriol|Calcitriol 0.25 mcg orally twice a day for 7 days or calcitriol 0.50 mcg orally twice a day for 7 days.
89604180|NCT00381862|Experimental|Aprepitant and Palonosetron|
89604181|NCT00464698|Experimental|All Study Participants|Duloxetine 30mg: Dose level 1 (Week 1) Duloxetine 60mg: Dose level 2 (Wks 2-4) Duloxetine 120mg: Dose level 3 (Wks 3-7)
88981353|NCT03760822|Experimental|Ramucirumab|IV ramucirumab at 8 mg/kg on D1 and D15
89604182|NCT00383110||Group 1|Adults (age 18 or older) with type 2 diabetes.
89604183|NCT00465088|Experimental|1|
89604184|NCT00465088|Experimental|2|
89604185|NCT01796782|Active Comparator|Xeloda|Subjects will receive Xeloda until progression
89604186|NCT01796782|Experimental|QYHJ Granules|patients will receive QYHJ Granules until progression
89604187|NCT00441766|Experimental|AGN 203818 3 mg|Part A: AGN 203818 3mg capsule every 12 hours for 4 weeks
88981354|NCT03760822|Active Comparator|Ramucirumab + Paclitaxel|IV ramucirumab at 8 mg/kg on D1 and D15 IV paclitaxel at 80 mg/m² on D1, D8 and D15
88981355|NCT03754725|Experimental|Deferiprone|This is the drug arm (deferiprone). Patients will receive oral deferiprone
89604188|NCT00441766|Experimental|AGN 203818 20 mg|Part A: AGN 203818 20mg capsule every 12 hours for 4 weeks
89604189|NCT00441766|Experimental|AGN 203818 60 mg|Part A: AGN 203818 60mg capsule every 12 hours for 4 weeks
89604190|NCT00441766|Placebo Comparator|Placebo|Part A: Placebo capsule every 12 hours for 4 weeks
89604191|NCT00466960|Experimental|Treatment (colony stimulating factor and chemotherapy)|"INDUCTION THERAPY: Patients receive GM-CSF SC once daily on days 16-26. Patients also receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for 4-6 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Beginning 14 days after last GM-CSF injection, patients receive GM-CSF SC once daily on days 1-15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity."
89604192|NCT00383266|Experimental|Pemetrexed + Carboplatin|"Pemetrexed 500 mg/m^2 IV over 10 minutes~Carboplatin AUC 5 IV over 30 minutes on day 1 of each cycle~Each cycle will last 21 days."
89604193|NCT00384670|Experimental|Dengue and Japanese Encephalitis vaccine|1 mL subcutaneous injection Dengue Vaccine Formulation 17 on Day 0 and Day 60. 0.5 mL subcutaneous injection Licensed Japanese Encephalitis (JE) Vaccine on months 7 and 7.5.
89604194|NCT00467038|Other|Dialectical Behavior Therapy|Dialectical Behavior Therapy
89604195|NCT00467038|No Intervention|Healthy Controls|Healthy controls
89604196|NCT00467350|Active Comparator|enema|Rectal enema containing mixture of milk and molasses
89604197|NCT00467350|Active Comparator|PEG 3350|Medication to be taken orally once each day for three consecutive days
89604198|NCT00444028|Experimental|Cohort A: Inhaled Loxapine 0.625 mg or Placebo|Single 0.625 mg dose of inhaled loxapine or Single Placebo dose of inhaled loxapine
89604199|NCT00444028|Experimental|Cohort B: Inhaled Loxapine 1.25 mg or Placebo|Single 1.25 mg dose of inhaled loxapine or Single Placebo dose of inhaled loxapine
89604200|NCT00444028|Experimental|Cohort C: Inhaled Loxapine 2.5 mg or Placebo|Single 2.5 mg dose of inhaled loxapine or Single Placebo dose of inhaled loxapine
89604201|NCT00444028|Experimental|Cohort D: Inhaled Loxapine 5 mg or Placebo|Single 5 mg dose of inhaled loxapine or Single Placebo dose of inhaled loxapine
89604202|NCT00444028|Experimental|Cohort E: Inhaled Loxapine 10 mg or Placebo|Single 10 mg dose of inhaled loxapine or Single Placebo dose of inhaled loxapine
89604203|NCT00444964|Experimental|Primary Cohort|Nutropin AQ
89604204|NCT00445588|Experimental|Treatment|"Patients receive oral erlotinib hydrochloride 150mg once daily and oral sorafenib tosylate 400mg twice daily on days 1-28. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.~Other: pharmacological study"
89604205|NCT00445744|Experimental|Treatment (cyclophosphamide, busulfan, transplant)|"CONDITIONING REGIMEN: Patients receive cyclophosphamide IV on days -7 and -6 and busulfan IV over 3 hours on days -5 to -2.~TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell transplant on day 0.~POST-TRANSPLANT IMMUNOSUPPRESSION: Patients receive tacrolimus IV or PO twice daily on days -1 to 200 with taper on day 56 and methotrexate on days 1, 3, 6, and 11."
89604206|NCT00468208|Experimental|1|Participants will receive abatacept intravenously at study visits on Days 1, 15, and 29, and then once a month thereafter.
89604207|NCT00384748|Experimental|Tele-visit Group|TR intervention targets safe functional mobility within a home environment and consists of: 1) exercise targeting underlying stroke-related impairment and 2) adaptive strategies targeting external factors to help compensate for disability. TR uses a combination of tele-video visits, an in-home messaging device, and telephone contact over a 3-month study period. A video camera is used in the home to provide visual and audio to a therapist located at the base hospital. An interactive, in-home messaging device is used to facilitate adherence with treatment recommendations and to screen for depression, falls, and difficulty with self-care. This allows evaluations of problem areas during tele-visits, rapid response to new functional problems.
89604208|NCT00384748|Active Comparator|Usual Care Group|Patients randomized to the Usual Care group receive routine VA care, as directed by their physicians. Therapy services are tracked via a weekly diary for the entire 6 month study period. In this weekly diary, patients in both the usual care and intervention group will record receipt of therapy. Usual Care group will be asked whether they exercised, and if so how frequently. They will be administered telephone interviews at baseline, 3-and 6-months. The interview outcome measures are FONEFIM, Late-Life Function and Disability Instrument, Falls Self Efficacy Scale and Stroke Specific Patient Satisfaction with Care. In addition, sociodemographics, stroke severity, length of time since stroke onset, and depression at baseline will be measured.
89604209|NCT00385138|Experimental|Cangrelor|cangrelor bolus (30 mcg/kg) & infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion) + placebo capsules (to match) at end of PCI + active clopidogrel (600mg) immediately post infusion
89604210|NCT00385138|Active Comparator|Clopidogrel|placebo bolus & infusion (to match) + clopidogrel capsules (600 mg) at end of PCI + placebo capsules (to match) immediately post infusion
89604211|NCT00446290|Experimental|Docetaxel, Capecitabine and Oxaliplatin|
89604212|NCT00385216|Active Comparator|Nicotine nasal spray|In one sitting the subject will receive a nicotine nasal spray, 3 mg, one application.
89604213|NCT00385216|Placebo Comparator|Placebo spray|In one sitting the subject will receive a placebo nasal spray (0 mg), one application.
89604214|NCT00385996|Experimental|Erlotinib|Erlotinib 150mg/day for 3 weeks followed by surgical resection at week 4 then daily Tarceva® at 150 mg/day for 2 years for those patients who had a response rate of at least 50% tumor volume reduction and/or have EGFR-positive tumor tissue determined by IHC and/or FISH.
89604215|NCT01796158|Experimental|cASBI+cMET|Participants will complete the computerized alcohol screening and brief intervention (cASBI)protocol at the time of an office visit and also complete the 2-session computerized Motivational Enhancement Therapy intervention (cMET).
89604216|NCT01796158|Active Comparator|cASBI|Participants will complete the computerized screening and brief intervention protocol at the time of a primary care office visit.
88981356|NCT03754725|Placebo Comparator|Control|this group will only receive the placebo (sugar pill)
89604217|NCT00470392|Other|Imiquimod|Each study subject served as his/her own control. For this arm of the study, topical vehicle was applied to one plaque for 5 days. Imiquimod (5% topical cream) was applied to two psoriasis plaques for 5 days. Skin biopsies were taken from half of each of the 3 plaques at specific time points after completion of topical pre-treatment. The other half of the plaques were exposed to UVB light (via Excimer laser). Biopsies were subsequently taken at a specified time point.
89604218|NCT00470392|Other|Clobetasol|Each study subject served as his/her own control. For this arm of the study, topical vehicle was applied to one plaque for 5 days. Clobetasol propionate 0.05% was applied to two psoriasis plaques for 5 days. Skin biopsies were taken from half of each of the 3 plaques at specific time points after completion of topical pre-treatment. The other half of the plaques were exposed to UVB light (via Excimer laser). Biopsies were subsequently taken at a specified time point.
89604219|NCT00470548|Experimental|Phase I: Abraxane and Alimta|Three dose levels were tested. Pemetrexed 500mg/m2 day 1 and nab-paclitaxel day 1 at 180, 220, and 260 mg/m2 every 21 days.
89604220|NCT00470548|Experimental|Phase II: Abraxane and Alimta|Pemetrexed 500mg/m2 day 1 and nab-paclitaxel day 1 at 260 mg/m2 every 21 days.
89604221|NCT04388488|Experimental|CONNECT TF|Trans-femoral amputees currently using a conventional handmade socket will be fitted with the CONNECT TF adaptable socket system for 6 weeks and their current existing conventional socket for 6 weeks, data collection on both sockets will be performed and outcomes compared.
89604222|NCT00472576|Experimental|Placebo then MK-0657|Double-blind crossover administration of placebo then MK-0657 (4-8 mg/day)
89604223|NCT00472576|Experimental|MK-0657 then Placebo|Double-blind crossover administration of MK-0657 (4-8 mg/day) then placebo
88981357|NCT03746535|Active Comparator|patients without endometriosis|Control subjects will be healthy women, with regular menses every 26-34 days. Subjects will be excluded if they have any symptoms of endometriosis, including severe dysmenorrhea or progressive cyclic pelvic pain or prior surgery showing evidence of endometriosis
89604224|NCT00388414|Placebo Comparator|Placebo - sugar pill|
89604225|NCT00388414|Experimental|Duloxetine|
89604226|NCT00472732||1|Female carriers of ornithine transcarbamylase deficiency (OTCD) or males with late onset presentation of OTCD
89604227|NCT00472732||2|Healthy males or females without known medical or metabolic disorder (control group)
89604228|NCT00475150|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive oral cediranib maleate QD on days 1-28. Treatment repeats every 28 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.
89604229|NCT04388410|Experimental|convalescent plasma|Convalescent plasma obtained from volunteers who have recovered from COVID 19. Enclosed with a similar material as the control
89604230|NCT04388410|Placebo Comparator|Normal saline|Normal saline solution in 200 ml plasma bags enclosed with with a similar material as the plasma
89604231|NCT00450424|No Intervention|Counseling|Participants will be given one of two counseling interventions regarding MSI testing: standard counseling or a CD-ROM intervention.
89604232|NCT00451048|Experimental|Arm I|Patients will receive sunitinib malate (SU11248) by mouth once a day. Treatment may continue for as long as benefit is shown.
89604233|NCT00388804|Active Comparator|RT Group 1|Radiation Therapy (RT) over 8 1/2 weeks: 42 treatments, 5 days per week with 2 days rest in between.
89604234|NCT00388804|Active Comparator|RT Group 2 + Hormone Therapy|Radiation Therapy over 8 1/2 weeks; + Hormone Therapy (Bicalutamide 50 mg orally/day or Flutamide 250 mg orally 3 times daily on first 21-30 Days) + Leuprolide (22.5 mg Intramuscularly (IM)/every 3 months or 7.5 mg IM monthly) or Goserelin (10.8 mg subcutaneously every 3 months or 3.6 mg subcutaneously monthly)
88981358|NCT03746535|Experimental|patients with endometriosis|Endometriosis will be diagnosed by history of the disease seen at the time of prior surgery or will be diagnosed by classic clinical symptoms of the disease (cyclic progressive pelvic pain) using prior surgical report reviewed by Dr. Taylor.
89604235|NCT01795066|Experimental|EUS-FNB with 25-gauge|
89604236|NCT00389818|Experimental|DR-COP|Single arm interventional study: all subjects receive DR-COP regimen.
89604237|NCT00452374|Experimental|Oxaliplatin, Fludarabine, Cytarabine + Rituximab|Starting dose oxaliplatin 17.5mg/m^2/day intravenous (IV) for 4 days; Fludarabine 30 mg/m^2 IV and Cytarabine 1 g/m^2 IV for two days, + Rituximab 375 mg/m^2 IV on Day 3, Cycle 1 then Day 1 following cycles.
89604238|NCT01454583||Aliskiren|Patients getting Aliskiren at baseline
89604239|NCT01454583||ACE-I/ARB|Patients getting ACE-I (angiotensin-converting enzyme inhibitors) or ARB (angiotensin-receptor blockers) at baseline, but not Aliskiren
89604240|NCT01454583||No RAS-inhibition|Patients getting no drugs at baseline that inhibit the renin-angiotensin-aldosterone-system (RAAS)
89604241|NCT03286114|Experimental|Pembrolizumab|
89604242|NCT00476242|Experimental|Memantine and Vivitrol|intramuscular injection of Vivitrol 380 mg and 20 mg bid Memantine (PO)
89604243|NCT00476242|Placebo Comparator|Placebo and Vivitrol|intramuscular injection of Vivitrol 380 mg and Placebo
89604244|NCT00476788|Experimental|Omnipod Device|Patients will be placed on an Omnipod insulin pump
88981359|NCT03740139|Experimental|Intervention|"The Police-Mental Health Linkage System~In the case of an encounter between law enforcement and subjects randomized to this group, the officer will receive a notice disclosing that the participant receives services in a mental health clinic and that he/she has the opportunity to call to speak with a mental health professional."
89604245|NCT01795144|Active Comparator|Healthy controls|"Healthy controls will be matched (age, gender, BMI) to monogenic diabetes subjects. Healthy controls will participate in the following:~OGTT~IGI~IGI with GLP-1 infusion~OGTT with Exendin 9-39 infusion"
89604246|NCT01795144|Experimental|Monogenic diabetes|"Monogenic diabetes subjects will be matched (age, gender, BMI) to healthy controls. Monogenic diabetes subjects will participate in the following:~OGTT~IGI~IGI with GLP-1 infusion~OGTT with Exendin 9-39 infusion"
89604247|NCT01436175|Experimental|SPD489 + Antidepressant|
89604248|NCT00453388|Experimental|Arm I (2 vs 2.5 vs 3 Gy TBI dose-escalation)|Patients with a history of hematologic malignancy and HLA-haploidentical donor receive fludarabine phosphate (FLU) intravenously (IV) over 1 hour on days -6 to -2, and undergo TBI on day -1 and allogeneic bone marrow transplant on day 0. Patients then receive CY IV over 1 hour on days 3 and 4, MMF orally (PO) thrice daily (TID) on days 5-35, and CSP IV or PO on days 5-84, with taper until day 180, in the absence of GVHD.
89604249|NCT00453388|Experimental|Arm II (2 vs 2.5 vs 3 vs 1 vs 0 Gy TBI de-escalation)|Patients with no history of hematological malignancy and HLA-haploidentical donors receive FLU IV over 1 hour on days -6 to -2, and undergo TBI on day -1 and allogeneic bone marrow transplant on day 0. Patients then receive CY IV over 1 hour on days 3 and 4, MMF PO TID on days 5-35, and CSP IV or PO on days 5-84, with taper until day 180, in the absence of GVHD.
89604250|NCT00453388|Experimental|Arm III (2 vs 2.5 vs 3 Gy TBI dose-escalation)|Patients with history of hematologic malignancy and HLA-matched unrelated donors receive FLU IV over 1 hour on days -6 to -2, and undergo TBI on day -1 and allogeneic bone marrow transplant on day 0. Patients then receive CY IV over 1 hour on days 3 and 4, MMF PO TID on days 5-35, and CSP IV or PO on days 5-84, with taper until day 180, in the absence of GVHD.
89604251|NCT00453388|Experimental|Arm IV (2 vs 2.5 vs 3 vs 1 vs 0 Gy TBI de-escalation)|Patients with no history of hematological malignancy and HLA-matched unrelated donors receive FLU IV over 1 hour on days -6 to -2, and undergo TBI on day -1 and allogeneic bone marrow transplant on day 0. Patients then receive CY IV over 1 hour on days 3 and 4, MMF PO TID on days 5-35, and CSP IV or PO on days 5-84, with taper until day 180, in the absence of GVHD.
89604252|NCT00389974|Experimental|Treatment (sunitinib malate)|Patients receive sunitinib malate PO daily for 4 weeks. Treatment repeats every 6 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients achieving CR or PR may receive 2 courses after CR or PR is reached.
89604253|NCT01453725|Experimental|Golimumab→Golimumab|In Part 1, participants receive golimumab 50 mg, administered subcutaneously (SC) every 4 weeks for up to 12 weeks (16 weeks of treatment). In Part 2, participants receive golimumab 50 mg, administered SC every 4 weeks for up to 28 weeks (32 weeks of treatment). (Combined total of up to 48 weeks treatment with golimumab.)
89604254|NCT01453725|Placebo Comparator|Placebo→Golimumab|In Part 1, participants receive placebo, administered SC every 4 weeks for up to 12 weeks (16 weeks of treatment). In Part 2, participants receive golimumab 50 mg, administered SC every 4 weeks for up to 28 weeks (32 weeks of treatment). (Combined total of up to 32 weeks treatment with golimumab.)
89604255|NCT03026439||Non-dyspneic smokers/ normal spirometry|Male or female current or former smokers. Forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) >0.7. FVC >lower limit of normal (LLN). Modified Medical Research Council (mMRC) dyspnea score = 0.
89604256|NCT03026439||Dyspneic smokers/ normal spirometry|Male or female current or former smokers. FEV1/FVC >0.7. FVC >LLN. mMRC dyspnea score ≥1.
89604257|NCT03026439||Non-dyspneic mild COPD patients|Male or female current or former smokers. FEV1/FVC ≤0.7. FEV1 >80% of predicted value. mMRC dyspnea score =0.
89604258|NCT03026439||Dyspneic mild COPD patients|Male or female current or former smokers. FEV1/FVC ≤0.7. FEV1 >80% of predicted value. mMRC dyspnea score ≥1.
89604259|NCT04076241|Experimental|Combined intervention|Combined intervention group consisted of 16 pulmonary arterial hypertension (PAH) patients. Three different yoga breathing exercises were applied after osteopathic manipulative treatment (OMT). This combined intervention was applied 2 times a week for a period of 8 weeks with a total of 16 training sessions. There remained a 3-workday gap between two sessions. Patients in this group were thought about pathophysiology of PAH, benefits of physical activity, airway clearance, oxygen therapy, and importance of proper nutrition, adequate sleep, effective breathing after baseline assessment.
88981360|NCT03740139|No Intervention|No Intervention|In the case of an encounter between law enforcement and subjects randomized to this arm of the study, the officer will not receive any notice.
88981361|NCT03731923|Experimental|High risk group of HCC|High risk group of HCC with chronic hepatitis or liver cirrhosis. Participants undergo biannual ultrasonography and annual abbreviated liver MRI.
88981362|NCT03721796||Arm 1 Physician/APP|Surgical, medical, and radiation oncologists and/or Advanced Practice Provider (APP)
88981363|NCT03721796||Arm 2 Patients|For each participating oncologist, we will may enroll up to three adult cancer patients presenting for consultation, since certain disease sites have a higher incidence in the HIV population.
88981364|NCT03713801|Experimental|Metformin|Dosage is increased over the first 3 weeks up to three 500 mg tablets a day at 3 weeks, then continued on 3 tablets daily for a further 9 weeks.
88981365|NCT03713801|Placebo Comparator|Placebo|Placebo tablet dosage is increased over the first 3 weeks up to three tablets a day at 3 weeks, then continued on 3 tablets daily for a further 9 weeks.
88981366|NCT03699995|Experimental|Screening (imaging, biopsy)|Participants undergo imaging of suspicious moles via smartphone app MoleMapper/Sklip app/native smartphone camera app, digital dermoscopy, and confocal microscopy. Participants then receive lidocaine SC and undergo shave or punch biopsy of suspected melanomas.
88981367|NCT03692403|Experimental|Quinagolide 360 µg|Vaginal ring containing Quinagolide 360 μg, with daily target release rate of 4.5 μg
88981368|NCT03692403|Experimental|Quinagolide 720 µg|Vaginal ring containing Quinagolide 720 μg, with daily target release rate of 9 μg
88981369|NCT03692403|Experimental|Quinagolide 1080 µg|Vaginal ring containing Quinagolide 1080 μg, with daily target release rate of 13.5 μg
88981370|NCT03692403|Placebo Comparator|Placebo|Vaginal ring containing matching placebo
88981371|NCT03681535|Experimental|Single arm interventional study|RT to 19.5-20Gy is given after 3 cycles of rituximab containing chemotherapy. RT is administered daily, 5 days per week in 1.5-2Gy fractions (treatments).
88981372|NCT03672916||Patients who received the Allofit IT with BIOLOX delta|Subjects in need of a primary total hip arthroplasty, who met the inclusion/exclusion criteria and who received the Allofit IT Shell in combination with the BIOLOX delta Taper Liners
88981373|NCT03655340||Prophylactic patients|Alprolix will be prescribed according to local practice and administered by patients with haemophilia B for prophylactic treatment
88981374|NCT03655340||On demand patients|Alprolix will be prescribed according to local practice and administered by patients with haemophilia B for on-demand treatment
88981375|NCT03654651|Experimental|Evening Peanut Consumption|Participants will consume one ounce per day (28 g) of peanuts as an evening snack (i.e., after dinner and before sleep).
88981376|NCT03654651|Active Comparator|Evening Snack|Participants will consume an isocaloric higher carbohydrate snack as an evening snack (i.e., after dinner and before sleep).
88981377|NCT03652636|Other|One: Patient population with hepatic lesion(s)|Patient scheduled to get MRI will also be asked to receive an ultrasound of the liver
88981378|NCT03649581|Experimental|patient with schizophrenia and periodic catatonia|
88981379|NCT03649581|Experimental|patient with schizophrenia and hebephrenia|
88981380|NCT03649581|Active Comparator|healthy volunteers|
88981381|NCT03626545|Experimental|Safety run-in part: Canakinumab+docetaxel|Participants were treated with full doses of docetaxel 75mg/m^2 intravenous and canakinumab 200 mg subcutaneous on Day 1 of each 21-Day cycle (dose level 1). Subjects were assessed for at least 2 complete cycles of treatment (21 days per cycle; a total of 42 days) for safety evaluation (DLT) to define RP3R. De-escalation to canakinumab 200 mg subcutaneous every 6 weeks + docetaxel 75 mg/m^2, every 3 weeks could also be considered.
88981382|NCT03626545|Experimental|Randomized part: Canakinumab + docetaxel|Participants were treated with canakinumab subcutaneous at RP3R and docetaxel at 75 mg/m^2 every 3 weeks
88981383|NCT03626545|Placebo Comparator|Randomized part: Placebo + docetaxel|Participants were treated with placebo subcutaneous at RP3R and docetaxel at 75 mg/m^2 every 3 weeks
88981384|NCT03620201|Experimental|Treatment (M7824)|Participants receive anti-PD-L1/TGFbetaRII fusion protein M7824 IV over 1 hour on days 1 and 15. During days 28-56 participants receive planned neoadjuvant chemotherapy.
88981385|NCT03591614|Experimental|Dendritic cell DKK1 vaccine|5-10x106 DKK1 loaded dendritic cells. Three doses will be given two weeks apart, followed by 11 months of observations.
88981386|NCT03584711|Experimental|FOLFOX + panitumumab|"1 cylce every 14 days : Panitumumab : 6 mg/kg en IV (J1) during 60 minutes for 1st infusion followed by 30 to 60 minutes Oxaliplatine : 85 mg/m² inG5% orNaCl 0.9% in IV (D1) during 2 hours Acide folinique : 400 mg/m² (or200 mg/m² if Elvorine) in IV (D1) 5Fu bolus : 400 mg/m² in IV 5FU continu : 2400 mg/m² in IV during 46 hours~LV5FU2 : 1 cycle every 14 days Acide folinique : 400 mg/m² (or 200 mg/m² ifElvorine) in IV (D1) during 2 hours 5FU bolus : 400 mg/m² in IV 5FU continu : 2400 mg/m² in IV during 46 hours"
88981387|NCT03575143||PLWH+OSA|Subjects diagnosed with both Human Immunodeficiency Virus and Obstructive Sleep Apnea based on overnight sleep study
88981388|NCT03575143||PLWH-OSA|Subjects diagnosed with both Human Immunodeficiency Virus without Obstructive Sleep Apnea based on overnight sleep study
88981389|NCT03575143||PLWH?OSA|Those who signed consent but did not complete all the baseline assessments and overnight sleep study
88981390|NCT03559569||Patients with circulatory shock|500 patients with circulatory shock hospitalize in ICU will be prospectively included to assess the effect of this pathology on the senescence phenotype
88981391|NCT03559569||Healthy volunteers|20 healthy volunteers will be included to assess the effect of no pathology on the senescence phenotype.
88981392|NCT03557749||Immune and Microbial Reconstitution|
88981393|NCT03557749||Immune Response Triggered by Severe, Systemic Viral Infection|
88981394|NCT03557749||Immune Response Triggered by Acute Graft-versus-Host Disease|
88981395|NCT03557749||Immune Response Triggered by Chronic Graft-versus-Host Disease|
88981396|NCT03557749||Immune Response Triggered by Relapse|
88981397|NCT03557749||Immune Response Triggered by Cytokine Release Syndrome|
88981398|NCT03557749||Allogeneic Related Donor Samples|
88981399|NCT03557749||Cellular Therapy Products|
88981400|NCT03548064|Experimental|Regimen A|5 µg of dmLT oral on days 1, 15, 29, n=12; placebo oral on days 1, 15, 29, n=3
88981401|NCT03548064|Experimental|Regimen B|25 µg of dmLT oral on days 1, 15, 29, n=12; placebo oral on days 1, 15, 29, n=3
88981402|NCT03548064|Experimental|Regimen C|5 µg of dmLT sublingual on days 1, 15, 29, n=12; placebo sublingual on days 1, 15, 29, n=3
88981403|NCT03548064|Experimental|Regimen D|25 µg of dmLT sublingual on days 1, 15, 29, n=12; placebo sublingual on days 1, 15, 29, n=3
88981404|NCT03548064|Experimental|Regimen E|0.3 µg of dmLT intradermal on days 1, 22, 43, n=12; placebo intradermal on days 1, 22, 43, n=3
88981405|NCT03548064|Experimental|Regimen F|1.0 µg of dmLT intradermal on days 1, 22, 43, n=12; placebo intradermal on days 1, 22, 43, n=3
88981406|NCT03548064|Experimental|Regimen G|50 µg of dmLT oral on days 1, 15, 29, n=12; placebo oral on days 1, 15, 29, n=3
88981407|NCT03548064|Experimental|Regimen H|50 µg of dmLT sublingual on days 1, 15, 29, n=12; placebo sublingual on days 1, 15, 29, n=3
88981408|NCT03548064|Experimental|Regimen I|2.0 µg of dmLT intradermal on days 1, 22, 43, n=12; placebo intradermal on days 1, 22, 43, n=3
88981409|NCT03532542|Experimental|Casimersen|Patients amenable to exon 45 skipping who have completed a clinical trial evaluating casimersen will receive open-label casimersen intravenous (IV) infusions, weekly, at 30 mg/kg for up to 144 Weeks.
88981410|NCT03532542|Experimental|Golodirsen|Patients amenable to exon 53 skipping who have completed a clinical trial evaluating golodirsen will receive open-label golodirsen intravenous (IV) infusions, weekly, at 30 mg/kg for up to 144 Weeks.
88981411|NCT03527108|Experimental|Patients with prior IO therapy|
89210367|NCT01075633|Experimental|Fecal occult blood testing|Immunochemical fecal occult blood test Annual (3 rounds), without diet restriction, 1 stool sample. Positive cut-off level: 50 ng/ml.
89210368|NCT01075633|Active Comparator|Colonoscopy|Colonoscopy with sedation.
88981412|NCT03523377|Experimental|prolonged overnight fasting|Participants randomized to the fasting arm will be instructed on how to use the SMS texting app to indicate the beginning and end of the nightly fast. In the first 2-4 weeks following the first overnight fast, intervention participants will complete three phone calls with study staff trained in motivational interviewing. These calls will be used to reinforce the prolonged overnight fasting instructions, identify barriers to prolonged overnight fasting, and support successes where they have occurred.
88981413|NCT03523377|Active Comparator|usual care|Participants randomized to the usual care arm will be instructed to eat a heart-healthy diet and exercise for at least 30 minutes five days a week, which is usual counseling in our clinics.
88981414|NCT03514069|Experimental|ruxolitinib + radiation x 60 Gy for 6 weeks|Unmethylated O6-methylguanine DNA methyltransferase (MGMT) Glioblastoma and grade III glioma Every patient gets ruxolitinib + radiation x 60 Gy for 6 weeks over 6 weeks. The dose of radiation therapy is fixed at 60 Gy over 6 weeks
89604260|NCT04076241|Active Comparator|Osteopathic manipulative treatment|OMT group consisted of 16 PAH patients. Six different OMT techniques were applied 2 times a week for a period of 8 weeks with a total of 16 sessions. The same osteopathic manipulative treatment techniques applied to combined intervention group were used for this study group. There remained a 3-workday gap between two sessions. Patients in this group were thought about pathophysiology of PAH, benefits of physical activity, airway clearance, oxygen therapy, and importance of proper nutrition, adequate sleep, effective breathing after baseline assessment.
89604261|NCT04076241|No Intervention|Control|Control group also consisted of 16 PAH patients and serves as the controls. No interventions were applied for the patients in this group. Similar with the patients in other two groups, pharmacological treatment of the patients in this group continued and they were advised for using their medication properly, Patients in this group were also thought about pathophysiology of PAH, benefits of physical activity, airway clearance, oxygen therapy, and importance of proper nutrition, adequate sleep, effective breathing after baseline assessment.
89604262|NCT00454324|Experimental|Arm A|Carboplatin + Abraxane (240mg/m2) on Day 1 of a 21 Day cycle, up to 6 cycles
89604263|NCT00454324|Experimental|Arm B|Carboplatin + Abraxane (80mg/m2)given on Days 1, 8 and 15 of a 21 Day Cycle, up to 6 cycles
89604264|NCT02076399|Experimental|Fostamatinib Disodium|Subjects begin with Fostamatinib Disodium tablet 100 mg PO bid and increase to 150 mg big after week 4 based on platelet count and tolerability.
89604265|NCT02076399|Other|Placebo|Placebo tablet PO bid (morning and evening) over the course of 24 weeks
89604266|NCT02110264|Experimental|Vivitrol (XR-NTX)|50 participants will be randomized to the long-acting naltrexone condition (XR-NTX) which will include monthly injections of study drug.
89604267|NCT02110264|Experimental|XR-NTX+PN|50 participants will be randomized to receive long-acting naltrexone (XR-NTX) and will be assigned to a patient navigator (PN).
89604268|NCT02110264|Active Comparator|ETAU|50 participants will be randomized to the drug-education/treatment-as-usual group.
89604269|NCT01795222|Active Comparator|Oral Midazolam|Midazolam oral syrup 1mg/Kg twenty minutes before starting the procedure
89604270|NCT01795222|Placebo Comparator|placebo|placebo oral syrup twenty minutes before starting the procedure
89604271|NCT01415349|Experimental|SSP-002358 alone|
89604272|NCT01415349|Experimental|SSP-002358 + omeprazole|SSP-002358 + omeprazole
89604273|NCT00528190|Experimental|Itraconazole|Itraconazole 5mg/kg/day for 24 weeks
89604274|NCT00528190|Placebo Comparator|Placebo|Placebo/day for 24 weeks
89604275|NCT02334813|Active Comparator|Arm A: daily prednisone|During the first week of treatment patients in both arms receive prednisone at 1 mg/kg/d. In arm A prednisone is continued at 1 mg/kg/d for a second week. If platelets increase to ≥50/nl, its dose is reduced to <25 mg/d by week 14 and <7.5 mg/d by week 20 according to a step-wise reduction scheme provided in the protocol. In patients without response after 2 weeks of treatment, the prednisone dose is increased to 2 mg/kg/d for another 2 weeks, then tapered as described above.
89604276|NCT02334813|Active Comparator|Arm B: pulsed dexamethasone|During the first week of treatment patients in both arms receive prednisone at 1 mg/kg/d. In arm B patients subsequently receive six 21-day courses of pulsed dexamethasone (0.6 mg/kg/d, days 1-4).
89604277|NCT00478036|Active Comparator|Acular LS|Acular LS - 1 drop in treated eye, 4 times a day, for 4 days
89604278|NCT00478036|Active Comparator|Pred Forte|Pred Forte - 1 drop in treated eye, 4 times a day, for 4 days
89604279|NCT00478036|Placebo Comparator|Refresh Tears|Refresh Tears - 1 drop in treated eye, 4 times a day, for 4 days
89604280|NCT04048863|Active Comparator|Stage 1 Baseline|Study site to use standard of care PIVC device(s) and procedure(s) on patients.
89604281|NCT04048863|Other|Stage 2 Education|RN education and training in the use of B. Braun PIVC products, devices and procedures.
88981415|NCT03514069|Experimental|ruxolitinib + radiation x 60 Gy + temozolomide 75 mg/m|"Methylated MGMT Glioblastoma and grade III glioma. Arm 2 will start once the safe dose has been established for Arm 1 for every dose level.~Every patient gets ruxolitinib + radiation x 60 Gy + daily temozolomide at 75 mg/m2 for 6 weeks over 6 weeks.~The dose of radiation therapy is fixed at 60 Gy over 6 weeks (2 Gy x 30). The dose of temozolomide is 75 mg/m2 daily for 6 weeks"
88981416|NCT03512197|Experimental|Midostaurin + chemotherapy|Participants received Midostaurin in Induction 50mg twice daily on Day 8 until 48 hrs before start of next cycle. During Induction 2 and consolidation 50mg twice daily on Day 4 until 48 hrs before start of next cycle. During post-consolidation 50mg twice daily for 28 consecutive days of each 28-day treatment cycle up to 12 cycles. For participants who could not tolerate the protocol-specified dosing schedule, dose interruptions and/or reductions were either recommended or mandated allowing participants to continue the study treatment. Chemotherapy consisted of daunorubicin or idarubicin and cytarabine for induction and intermediate dose cytarabine for consolidation.
89604282|NCT04048863|Other|Stage 3 Run-In|Familiarization of study RNs with the B. Braun devices and procedures in a clinical setting.
89604283|NCT04048863|Other|Stage 4 Post-Education|Study site uses B. Braun PIVC device(s) and procedure(s) on patients.
89604284|NCT04522557|Experimental|Experimental: Participants with breast cancer enrolled in grou|
89604285|NCT01453023|Active Comparator|Fluticasone Furoate|One of two study treatments subjects will receive. Given to allow comparison of FF exposure in combination versus as mono therapy.
89604286|NCT01453023|Experimental|Fluticasone Furoate/Vilanterol|One of two study treatments subjects will receive. FF/VI combined is being tested and compared to fluticasone furoate.
89604287|NCT04767321|Experimental|LTX-109 treatment|Nasal application of LTX-109 gel 3% (w/w), 250 mikroliters in each nostril, 4 times in one day, every two hours.
89604288|NCT04767321|Experimental|Placebo|Nasal application of placebo, 250 mikroliters in each nostril, 4 times in one day, every two hours.
89604289|NCT01452789|Experimental|sublingual buprenorphine|This is the group that received active sublingual buprenorphine and placebo for oral morphine
89604290|NCT01452789|Active Comparator|oral morphine|This is the group that received active oral morphine and placebo for sublingual buprenorphine
89604291|NCT01451931|Experimental|Point-of-care Ultrasound|Patient with suspected urolithiasis will receive ultrasonography performed in the emergency department. Perform ultrasonography in the ED (physician).
89032444|NCT02936427|Experimental|Dexamethasone 4mg|Participants will receive 4mg of dexamethasone into the intercostal space surrounding the intercostal nerve prior to the first incision. They will then receive routine post operative care including intercostal wound catheters.
89032445|NCT02936427|Experimental|Dexamethasone 8mg|Participants will receive 8mg of dexamethasone into the intercostal space surrounding the intercostal nerve prior to the first incision. They will then receive routine post operative care including intercostal wound catheters.
89032446|NCT02930499|Experimental|Hyaluronic Acid ECM (Hyalomatrix)|Hyalomatrix ECM will be applied to the target ulcer once weekly
89604292|NCT01451931|Experimental|Radiology Ultrasound|Patient with suspected urolithiasis will receive diagnostic ultrasonography in the radiology department. Diagnostic ultrasound completed in the radiology department at time 0.
89604293|NCT01451931|Experimental|Radiology CT|Patient with suspected urolithiasis will receive computed tomography in the radiology department. Computed tomography of abdomen completed in the radiology department at time 0.
89604294|NCT00478192|Experimental|Regimen 1 Conivaptan QD|20 mg conivaptan once a day
89604295|NCT00478192|Experimental|Regimen 2 Conivaptan BID|20 mg conivaptan two times a day
89604296|NCT00478192|Placebo Comparator|Regimen 3 Placebo|
89604297|NCT04048551|No Intervention|No S&D Reduction Training; PrEP and SRH only|Arm 1 does not receive stigma and discrimination (S&D) reduction training to clinic staff, but provides PrEP (pre-exposure prophylaxis) and SRH (sexual and reproductive health) services to AGYW (adolescent girls and young women).
89604298|NCT04048551|Experimental|No S&D Reduction Training; PrEP and SRH + YWHC|Arm 2 does not receive stigma and discrimination (S&D) reduction training to clinic staff, but provides PrEP (pre-exposure prophylaxis), SRH (sexual and reproductive health) services, and YWHC (Young Women's Health CoOp) to AGYW (adolescent girls and young women).
89604299|NCT04048551|Active Comparator|S&D Reduction Training; PrEP and SRH only|Arm 3 receives stigma and discrimination (S&D) reduction training to clinic staff and provides PrEP (pre-exposure prophylaxis) and SRH (sexual and reproductive health) services to AGYW (adolescent girls and young women).
89604300|NCT04048551|Experimental|S&D Reduction Training; PrEP, SRH + YWHC|Arm 4 receives stigma and discrimination (S&D) reduction training to clinic staff and provides PrEP (pre-exposure prophylaxis), SRH (sexual and reproductive health) services, and YWHC (Young Women's Health CoOp) to AGYW (adolescent girls and young women).
89604301|NCT01414257||Methotrexate (MTX)|Patients who receive the MTX Preparation at the dose higher than 8 mg/week for the treatment of Rheumatoid Arthritis.
89604302|NCT00528268|Experimental|Cohort 1|Family history of SMA type I 0-3 months old Confirmation of no more than 3 SMN2 copies
89604303|NCT00528268|Experimental|Cohort 2|Family history of SMA type II 0-6 months old Confirmation of no more than 4 SMN2 copies
89604304|NCT04490044|Active Comparator|1|Participants in Arm 1 will be posted the Under & Over study pack (1) and asked to complete the Under & Over tool daily for up to 30 minutes per day, 5 days per week for 3 months. They will be instructed to follow the instruction booklet and complete each pattern in the specific order described in the booklet.
89604305|NCT04490044|Active Comparator|2|Participants in Arm 2 will be posted the Under & Over study pack (2) and asked to complete the Under & Over tool daily for as long or short as they choose or are able to. They will be asked to complete 5 days per week for 3 months. They will be instructed to follow the instruction booklet in any order they wish, choosing which pattern they would like to complete. They will also be encouraged to create their own patterns. These participants will have access to a section of the study website where they will be able to upload photographs of their patterns and see other participants' patterns over the 3-month period.
89604306|NCT04490044|Placebo Comparator|3|Participants in Arm 3 will be posted the Under & Over study pack (3). For the first three months of the study they will be asked to complete the c9HPT 5 days a week. After three months, they will be able to complete the Under & Over tool daily for as long or short as they choose. Similar to Arm 2, They will be asked to do this 5 days per week for 3 months. They will be instructed to follow the instruction booklet in any order they wish, choosing which pattern they would like to
89604307|NCT00528580|Experimental|1|Simvastatin 80 mg once daily PO (or via NG or G-tube)
89604308|NCT00528580|Placebo Comparator|2|Identical-appearing placebo PO (or via NG or G-tube)
89604309|NCT00529126|Experimental|SKY0402 high dose|SKY0402, single administration
89604310|NCT00529126|Experimental|SKY0402 middle dose|SKY0402, single administration
89604311|NCT00529126|Experimental|SKY0402 low dose|SKY0402, single administration
89032447|NCT02930499|Active Comparator|Non-Adherent wound dressing (Mepilex)|Mepilex wound dressing will be applied to the target ulcer once weekly
89032448|NCT02947763|Active Comparator|multiple visit|multiple visit root canal treatment with triple antibiotic paste intracanal medication (a mixture of metronidazole, ciprofloxacin, and minocycline)
89032449|NCT02947763|No Intervention|single visit|single visit root canal treatment without any intra-canal medication
89032450|NCT02947841|Placebo Comparator|Placebo|In the placebo cohort, subjects will alternate their DBS parameters between group A and group B every week for 12 weeks, but they will be blinded to the fact that their group A and group B are equivalent.
89032451|NCT02947841|Active Comparator|Treatment|In the treatment cohort, subjects will alternate their DBS parameters between group A and group B every week for 12 weeks.
89032452|NCT02930421|Experimental|Exercise training (ET)|Patients will enter an 8-week ET program of 3 days per week supervised exercise training at the Rehabilitation Physiotherapy Gymnasium. Exercise training will include high-intensity endurance training at 60-80% of baseline peak work rate and strength training of upper and lower limbs with 3 sets of 6 repetitions at 50% of one repetition maximum. Each session will be 60 min duration, 30 min dedicated to cycle exercise.
89032453|NCT02930421|No Intervention|Usual care (UC)|The UC group will receive usual outpatient care and follow-up.
89032454|NCT00523952|Experimental|1|
89032455|NCT02936193|Experimental|Pylorus preservation|Patients undergo Laparoscopic Gastrectomy with Pylorus-preservation
89604312|NCT00529126|Active Comparator|Bupivacaine HCl|Bupivacaine HCl
89604313|NCT01434693|Experimental|TSO 500|
89604314|NCT01434693|Experimental|TSO 2500|
89604315|NCT01434693|Experimental|TSO 7500|
89604316|NCT01434693|Placebo Comparator|Placebo|single dose
89604317|NCT00529204|Experimental|Exenatide|exenatide 5 µg BID s.c. daily for 28 days, followed by 10 µg BID s.c. daily from day 29 to week 24
89604318|NCT01451541|Active Comparator|ciclesonide nasal aerosol 37mcg|ciclesonide nasal aerosol 37mcg - the dose is administered as 1 actuation per nostril to give a total dose of 37mcg once daily
89604319|NCT01451541|Active Comparator|ciclesonide nasal aerosol 74 mcg|ciclesonide nasal aerosol 74 mcg - the dose is administered as 1 actuation per nostril to give a total dose of 74 mcg once daily
89604320|NCT01451541|Placebo Comparator|Placebo|
89604321|NCT00530764|Experimental|Sativex Low Dose|Range of 1 to 4 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 10.8mg THC and 10mg CBD.
89604322|NCT00530764|Experimental|Sativex Medium Dose|Range of 6 to 10 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 27mg THC and 25mg CBD.
89604323|NCT00530764|Experimental|Sativex High Dose|Range of 11 to 16 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 43.2mg THC and 40mg CBD.
89604324|NCT00530764|No Intervention|Placebo|Range of 1-16 sprays per day of placebo spray.
89604325|NCT00532480|Other|Duolxetine|Open-label duloxetine 30 - 60 mg oral administration
89604326|NCT00483262|Experimental|CCI779 and Bortezomib Phase I/II|In Phase I part, 15 or 25 mg temsirolimus (CCI-779)and 1·3 or 1·6 mg/m² bortezomib was given once a week.In Phase II, patients received intravenous temsirolimus once a week on days 1, 8, 15, 22, and 29 for a cycle of 35 days, and intravenous bortezomib once a week on days 1, 8, 15, and 22 for a cycle of 35 days, the MTD ascertained in the Phase I part.
89604327|NCT00483496|Experimental|V0096CR actives and vehicle|"Each patient received each one of the 8 test products on their respective randomly allocated sites on grid (grid to be applied on the back skin; 1 product by grid window).~Single application of the test materials at the dosage of 2mg/cm² (total of 8 treated sites), prior to irradiation using a solar simulator."
89604328|NCT00484354|Active Comparator|1|Bicarbonate administration
89604329|NCT00484354|Placebo Comparator|2|Normal saline administration
89604330|NCT00485836|Sham Comparator|Sham injection|
89604331|NCT00485836|Experimental|Ranibizumab injection 0.3 mg|
89604332|NCT00485836|Experimental|Ranibizumab injection 0.5 mg|
89604333|NCT00534118|Experimental|Infusion|Patients receive up to four donor lymphocyte infusions at least 1 month apart in the absence of disease progression, unacceptable toxicity, or uncontrolled graft-versus-host disease
89604334|NCT04249024|Experimental|Laser treatment|Laser treatment with diode laser 970nm and settings 1.2W in intervals of max 20s, until satisfactory removal of diseased epithelium and granulation tissue.
88981417|NCT03512197|Placebo Comparator|Placebo + chemotherapy|Participants received matching placebo to midostaurin with same dose, plus chemotherapy. Chemotherapy consisted of daunorubicin or idarubicin and cytarabine for induction and intermediate dose cytarabine for consolidation
88981418|NCT03505723|Active Comparator|Tranexamic Acid (TXA)|Patients will receive a 1g loading dose of intravenous TXA before surgery and a 1g loading dose of intravenous TXA at the end of surgery (wound closure).
88981419|NCT03505723|Placebo Comparator|Placebo (0.9% normal saline)|Patients will receive a 1g loading dose of placebo (0.9% normal saline) before surgery and a 1g loading dose of placebo (0.9% normal saline) at the end of surgery (wound closure).
88981420|NCT03505723|Active Comparator|Hypotension-avoidance strategy|Aims to avoid hypotension before surgery (preoperative), during surgery (intraoperative) and for the first 2 days after the day of surgery (postoperative).
88981421|NCT03505723|Placebo Comparator|Perioperative hypertension-avoidance strategy|Aims to avoid hypertension before surgery (preoperative), during surgery (intraoperative) and for the first 2 days after the day of surgery (postoperative).
88981422|NCT03502330|Experimental|Cohort 1 Advanced Solid Tumors|Cabiralizumab 4mg/kg plus APX005M 0.03 mg/kg administered in 14 day cycles.
88981423|NCT03502330|Experimental|Cohort 2 Advanced Solid Tumors|Nivolumab 240 mg plus Cabiralizumab 4mg/kg plus APX005M 0.03 mg/kg administered in 14 day cycles.
88981424|NCT03502330|Experimental|Cohort 3 Advanced Solid Tumors|Cabiralizumab 4mg/kg plus APX005M 0.1 mg/kg administered in 14 day cycles.
88981425|NCT03502330|Experimental|Cohort 4 Advanced Solid Tumors|Nivolumab 240 mg plus Cabiralizumab 4mg/kg plus APX005M 0.1 mg/kg administered in 14 day cycles.
89604335|NCT04249024|Active Comparator|Mucosal flap surgery|Conventional mucosal flap surgery of affected dental implant.
89604336|NCT04200508|Experimental|Intervention|Targeted gown and glove use for high risk care activities in high risk residents
89604337|NCT04200508|No Intervention|Baseline|Standard of Care
89604338|NCT00488488||A|
88981426|NCT03502330|Experimental|Cohort 5 Advanced Solid Tumors|Cabiralizumab 4mg/kg plus APX005M 0.3 mg/kg administered in 14 day cycles.
88981427|NCT03502330|Experimental|Cohort 6 Advanced Solid Tumors|Nivolumab 240 mg plus Cabiralizumab 4mg/kg plus APX005M 0.3 mg/kg administered in 14 day cycles.
88981428|NCT03502330|Experimental|Cohort 7 Advanced Melanoma|Patients will be treated at the estimated APX005M RP2D in combination with nivolumab 240 mg IV and cabiralizumab 4 mg/kg on day 1 of each 14-day cycle.
88981429|NCT03502330|Experimental|Cohort 8 NSCLC|Patients will be treated at the estimated APX005M RP2D in combination with nivolumab 240 mg IV and cabiralizumab 4 mg/kg on day 1 of each 14-day cycle.
89604339|NCT00489268|Active Comparator|Phase I: 6 J/cm2|Subjects randomized to the energy density group of 6 J/cm2 through the HALO Ablation System.
89604340|NCT00489268|Active Comparator|Phase I: 8 J/cm2|Subjects randomized to the energy density group of 8 J/cm2 through the HALO Ablation System.
89604341|NCT00489268|Active Comparator|Phase I: 10 J/cm2|Subjects randomized to the energy density group of 10 J/cm2 through the HALO Ablation System.
89604342|NCT00489268|Active Comparator|Phase I: 12 J/cm2|Subjects randomized to the energy density group of 12 J/cm2 through the HALO Ablation System.
89604343|NCT00489268|Active Comparator|Phase II|All Halo 360 treatments performed at 10 J/cm2 through the HALO Ablation System. All Halo 90 treatments performed at 12 J/cm2 through the HALO Ablation System.
89032456|NCT02936193|Active Comparator|Distal gastrectomy|Patients undergo Laparoscopic Gastrectomy procedure detailing in distal gastrectomy with D2 lymphadenectomy
89032457|NCT00524810|Experimental|Caelyx - Taxotere|
89032458|NCT00524849|Active Comparator|conventional Zometa|Zometa 4mg IV q4w, in combination with other antitumor agents one month after the initial dosing.
89032459|NCT00524849|Experimental|weekly Zometa|Weekly Zometa in combination with other antitumor agents one month after the initial dosing.
89604344|NCT01450761|Experimental|Ipilimumab+Etoposide+Cisplatin/Carboplatin|"Ipilimumab: IV solution, Intravenous (IV), 10 mg/kg, Once every 3 weeks for 4 doses, then every 12 weeks, Until progression of disease or unacceptable toxicity, or until the maximum treatment period of 3 years is reached~Etoposide: IV solution, IV, 100 mg/m2, Days 1-3 every 3 weeks, 4 cycles~Cisplatin: IV solution, IV, 75 mg/m2, Once every 3 weeks, 4 doses~Carboplatin: IV Solution, IV, Area Under the Curve (AUC) 5, Once every 3 weeks, 4 doses"
89604345|NCT01450761|Placebo Comparator|Placebo matching Ipilimumab+Etoposide+Cisplatin/Carboplatin|"Placebo matching Ipilimumab: IV solution, IV, 0 mg/kg, Once every 3 weeks for 4 doses, then every 12 weeks, Until progression of disease or unacceptable toxicity, or until the maximum treatment period of 3 years is reached~Etoposide: IV solution, IV, 100 mg/m2, Days 1-3 every 3 weeks, 4 cycles~Cisplatin: IV solution, IV, 75 mg/m2, Once every 3 weeks, 4 doses~Carboplatin: IV Solution, IV, Area Under the Curve (AUC) 5, Once every 3 weeks, 4 doses"
89604346|NCT04075539|Experimental|Home-based cycling program associated to usual care|
89604347|NCT04075539|Other|Outpatient physiotherapy|
89604348|NCT02120716|Experimental|Health Check-Up of Expectant Moms|Participants receive computer delivered intervention (Health Check-up for Expectant Moms)
89604349|NCT02120716|No Intervention|Time and attention matched control group|Participants will be presented a brief series of videos of television shows, with subsequent ratings of subjective preference
89604350|NCT00491374|Experimental|MFNS|
89604351|NCT00491374|Placebo Comparator|Placebo|
89604352|NCT00538642|No Intervention|Stay on current antipsychotic|Subjects stay on same daily oral antipsychotic treatment as at baseline. Dose adjustments allowable as clinically indicated.
89604353|NCT00538642|Active Comparator|ziprasidone treatment|Subjects switch to daily oral ziprasidone from current antipsychotic(s). Dose titrated to clinically effective level.
89604354|NCT00539110|Experimental|zolpidem|zolpidem or ramelteon dosed at 2200 and 0200 per feeding tube depending on randomization
89604355|NCT00539110|Active Comparator|ramelteon|ramelteon or zolpidem dosed at 2200 and 0200 per the feeding tube depending on randomization
89604356|NCT03846232||Cognitive impairment. Alzheimer's disease|Diagnosed with AD as defined per the International Working Group IWG 2 criteria (fulfilling core clinical criteria plus positive core AD CSF biomarkers)
89604357|NCT03846232||Cognitively unimpaired, preclinical Alzheimer's disease|Normal cognition as defined by the ALFA study cognitive workup Positive amyloid PET in the last 30 months
89604358|NCT03846232||Cognitively unimpaired, control|Normal cognition as defined by the ALFA study cognitive workup Negative amyloid PET in the last 30 months
89032460|NCT02936154|Experimental|300 mg|
89032461|NCT02936154|Placebo Comparator|placebo|
89032462|NCT00524888|Active Comparator|1|suturing lacerations of the hand
89032463|NCT00524888|Active Comparator|2|using bioadhesive on lacerations of hand
89604359|NCT00539656|Experimental|Receive two cord blood units|One cord blood unit will be thawed on day -14 before transplantation and selected using the CliniMACS for primitive cells that express CD133. These cells will be expanded ex vivo for a total of 14 days, using a two-stage procedure. On Day 0 the expanded cells will be harvested, washed three times with CliniMACS buffer (Miltenyi) plus 1% HSA per standard laboratory and clinical practice and the expanded cell product will be infused to a patient who has been prepared with a standard, myeloablative preparative regimen. A second, unexpanded, cord blood product will be infused on Day +1 for safety.
89604360|NCT01433991|Experimental|Phase 1B|Participants with unresectable advanced or metastatic solid tumors will receive E7050 in combination with lenvatinib to identify a Maximum Tolerated Dose. Dose escalation will begin at low doses of both E7050 and lenvatinib, and then gradually increase in future cohorts until a recommended combination dose is identified. A dose of E7050 and lenvatinib to be used in combination in Phase 2 will be recommended (RP2 dose). Participants will continue on treatment until disease progression, development of unacceptable toxicity, or withdrawal of consent.
89604361|NCT01433991|Experimental|Phase 2 Cohort 1 Arm A:|Participants with recurrent glioblastoma (bevacizumab-naïve) will receive E7050 and lenvatinib at the RP2 dose.
88981430|NCT03502330|Experimental|Cohort 9 RCC|Patients will be treated at the estimated APX005M RP2D in combination with nivolumab 240 mg IV and cabiralizumab 4 mg/kg on day 1 of each 14-day cycle.
88981431|NCT03495284|Experimental|Potato treatment|Participants will be provided with one potato-based side dish, equivalent to one medium sized potato, every day for 4 weeks for incorporation into their self-selected diet. The potato-based side dish will be prepared at the Penn State Metabolic Kitchen. The potato side dish will consist of commonly consumed potato-based sides in the U.S. and there will be limited inclusion of ingredients high in saturated fat, refined sugars or sodium. French fries will not be provided. The variety of potatoes will represent consumption patterns in the U.S. including white, russet, yellow and red potatoes.
89032464|NCT02936115|Experimental|TruSkin®|Cryopreserved skin allograft
89032465|NCT02936115|Active Comparator|Wound Cover|Active Comparator for Diabetic Foot Ulcers
89032466|NCT00524927|Active Comparator|A|
89032467|NCT00524927|Placebo Comparator|B|
89032468|NCT02936310|Experimental|mindfulness intervention|"The proposed Mindful Living With Stress Intervention will be conducted weekly, 2 hours per session, 4-6 sessions, group based program in mindfulness.The proposed topics include: 1) mindfulness: dealing with stress in a new way, 2) mindful awareness of stress: listening to our body, 3) mindful working with thoughts, 4) mindful working with emotions, 5) mindful interactions, and 6) dealing with obstacles of mindful practices and wrap-up. Mindfulness practices embedded in the program will include mindfulness breathing meditation, sitting meditation, standing meditation, walking meditation, movement meditation (Taichi or Yoga), body scan meditation and daily life meditation.~Data will be collected at pre-intervention (one week before the first session) and post-intervention (one week after the last session) to assess stress, burnout, mindfulness, anxiety,depression,the feedback on the MLWS intervention and the feedback on the influence of MLWS intervention."
89604362|NCT01433991|Experimental|Phase 2 Cohort 1 Arm B:|Participants with recurrent glioblastoma (bevacizumab-naïve) will receive single agent lenvatinib 24 mg/day (1*4 mg capsule + 2*10 mg capsule) and at time of progression, E7050 add-on therapy at the RP2 dose (in combination with lenvatinib at dose of either the RP2 dose or the most recent dose of single agent lenvatinib, whichever is the lowest).
89604363|NCT01433991|Experimental|Phase 2 Cohort 2 Arm C:|Participants with unresectable Stage III or Stage IV melanoma and disease progression after prior systemic treatment will receive E7050 and lenvatinib at the RP2 dose.
89604364|NCT01433991|Experimental|Phase 2 Cohort 2 Arm D:|Participants with unresectable Stage III or Stage IV melanoma and disease progression after prior systemic treatment will receive single agent E7050 400 mg/day.
89604365|NCT01450683|Experimental|Itraconazole|600 mg/day oral (PO)
89604366|NCT01433055|Active Comparator|Minocycline|
89604367|NCT01433055|Placebo Comparator|Sugar Pill|
89604368|NCT01450137|Experimental|Tocilizumab|Tocilizumab 8mg/kg every 4 weeks until week 52.
89604369|NCT01450137|Placebo Comparator|Placebo|Placebo every 4 weeks until week 52.
89604370|NCT01412229|Experimental|Treatment|"nab-paclitaxel 100mg/m2~Carboplatin area under curve (AUC)2 (IV)~Cetuximab 400mg/m2 week 1 then 250mg/m2 for six weeks"
89604371|NCT01412151|Other|Creatine monohydrate|single arm long-term open label follow-up
89604372|NCT01432275|Experimental|ADC, Then Comparator, Then ADC With Calculator|Subject used the ADC blood glucose meter for 7 days with the insulin calculator not activated, followed by a comparator blood glucose meter for 7 days. For the last 10 days the subject used the ADC blood glucose meter with insulin calculator active.
89604373|NCT01432275|Experimental|Comparator, Then ADC, Then ADC With Calculator|Subject used a comparator blood glucose meter for 7 days, followed by the ADC blood glucose meter for 7 days, with the insulin calculator not activated. For the last 10 days the subject used the ADC blood glucose meter with insulin calculator active.
89604374|NCT03025815|Experimental|Intervention group|Oral stimulation program consists of the a 15 minutes stimulation program, whereby the first 12 minutes involved stroking the cheeks, lips, gums, and tongue, and the final 3 minutes consists of sucking on a pacifier routinely.
89604375|NCT03025815|Sham Comparator|Control group|sham stimulation program consists of the same researcher placing her hands for 15 minutes.
89604376|NCT01411995|Experimental|2% Lidocaine gel|Women randomized to the Lidocaine arm will receive a total of 3-5cc of 2% gel at the tenaculum site and within the endocervical canal
89604377|NCT01411995|Placebo Comparator|Water based lubricant|Women randomized to the placebo arm will receive a total of 3-5cc of water based lubricant at the tenaculum site and within the the endocervical canal
89604378|NCT01411917|Experimental|TAP block group|Patients in this group will have a preoperative, ultrasound guided injection of 30ml of 0.375% bupivacaine into the muscle plane between the transversus abdominis muscle and internal oblique muscles.
89604379|NCT01411917|Placebo Comparator|Placebo|Patients in this group will have an ultrasound guided subcutaneous injection of 30 ml of sterile preservative free saline.
89032469|NCT02935920|Experimental|Individual, tailored follow-up|Patient symptoms are evaluated by the use of PRO-data to uncover the needs of a consultation. The outcome of the questionnaire is used to customize the follow-up program to the individual patient.
89032470|NCT02935920|No Intervention|Standard follow-up|Scheduled clinical examination every six months throughout the course of adjuvant treatment. Performed by a doctor or nurse.
89032471|NCT02935725|Experimental|Low dose AUT00206 800 mg + Ketamine|Low dose AUT00206 (800 mg) + ketamine
89032472|NCT02935725|Experimental|High dose AUT00206 2000 mg + Ketamine|High dose AUT00206 (2000 mg) + ketamine
89604380|NCT01411839|Experimental|Cognitive-Behavioral Therapy (CBT-AD)|This arm type is a cognitive-behavioral therapy program intervention for issues of medication adherence and depression. The intervention is a therapy program intervention involves 10-weekly or biweekly sessions, with 2 booster session, and focused on psychoeducation, behavioral activation, cognitive restructuring, and problem-solving. A letter was sent to their medical provider indicating that mild symptoms of depression were detected and that they were enrolled in this intervention, but no details were provided regarding their assignment to one of two conditions/arms.
89604381|NCT01411839|No Intervention|Control-Standard Care|Those randomized to the control condition are not involved in the CBT-AD therapy intervention. They receive standard care as usual. A letter was sent to their medical provider indicating that mild symptoms of depression were detected and that they were enrolled in this intervention, but no details were provided regarding their assignment to one of two conditions/arms. The participants in the control arm are followed and matched to a participant in the intervention arm.
89604382|NCT01411215||RA, AS|Rheumatoid arthritis patients Ankylosing spondylitis patients
89604383|NCT01449279|Experimental|Ipilimumab Treatment + Radiation Therapy|Ipilimumab (BMS-734016, MDX010, MDX-CTLA4, Yervoy) will be administered as standard of care with base dose of 3 mg/kg iv over approximately 90 minutes every 3 weeks for a total of 4 treatments. Palliative radiation therapy to 1 to 2 sites of disease will start within 5 days of the first ipilimumab dose. Subjects will have follow up visits 2 to 4 weeks after the last ipilimumab dose and then every 3 months (±2 weeks) thereafter until progression of disease.
89604384|NCT04408053|Experimental|Preventive fixation of the contralateral femoral neck|Mini-invasive preventive fixation of the contralateral femoral neck : 6.5mm titanium cannulated self-tapping/self-drilling screws (Stryker Trauma and Depuy Synthes) : 2 screws per patients
89604385|NCT04408053|No Intervention|No fixation|
89604386|NCT01431963|Experimental|Lamotrigine|No comparison.
89604387|NCT01447407|Active Comparator|NDV-3 vaccine with alum IM|300 ug Als3 and 0.5 mg Al as alum in PBS per dose, one dose administered IM
89604388|NCT01447407|Active Comparator|NDV-3 vaccine without alum IM|300 ug Als3 in PBS per dose, one dose administered IM
89604389|NCT01447407|Placebo Comparator|Placebo IM|0.5 mg Al as alum in PBS per dose, one dose administered IM
89604390|NCT01447407|Active Comparator|NDV-3 vaccine without alum ID|30 ug Als3 in PBS per dose, one dose administered ID
89604391|NCT04056819|Experimental|UMSC01|UMSC01 cells mixed with normal saline will be administered to patients after the onset of heart attack.
89032473|NCT02935725|Placebo Comparator|Placebo + Ketamine|Placebo + ketamine
89032474|NCT02935725|Placebo Comparator|Placebo + Saline|Placebo + saline
89604392|NCT01446237|Experimental|Acne system - benzoyl peroxide 2.5%, Salicylic Acid 0.5%|open label - no comparator; only Acne system - benzoyl peroxide 2.5%, Salicylic Acid 0.5%
89604393|NCT00540982|Experimental|Normal Liver Function|
89604394|NCT00540982|Experimental|Mild Liver Dysfunction|
89604395|NCT00540982|Experimental|Moderate Liver Dysfunction|
89604396|NCT00540982|Experimental|Severe Liver Dysfunction|
89604397|NCT00542620|Experimental|Mixed injection|
89604398|NCT00542620|Active Comparator|Separate injection|
89604399|NCT00543400|Active Comparator|70 U/kg of unfractionated heparin given IV|Venous injection (IV) of 70 units per kilogram (U/kg) of unfractionated heparin prior to percutaneous coronary intervention. If procedure lasts longer than 30 minutes a 1/2 rebolus of the original therapy will be given.
89604400|NCT00543400|Experimental|50 IU/KG of M118|Venous injection of 50 international units per kilogram (IU/kg) of M118 prior to percutaneous coronary intervention. If procedure lasts longer than 30 minutes a 1/2 rebolus of the original therapy will be given.
89604401|NCT00543400|Experimental|75 IU/KG of M118|Venous injection of 75 IU/kg of M118 prior to percutaneous coronary intervention. If procedure lasts longer than 30 minutes a 1/2 rebolus of the original therapy will be given.
89604402|NCT00543400|Experimental|100 IU/KG of M118|Venous injection of 100 IU/kg of M118 prior to percutaneous coronary intervention. If procedure lasts longer than 30 minutes a 1/2 rebolus of the original therapy will be given.
89604403|NCT01796938|Experimental|Group 1: Healthy subjects|Single dose of 100 mg Lacosamide
89604404|NCT01796938|Experimental|Group 2: Subjects with mild renal insufficiency|Single dose of 100 mg Lacosamide
89604405|NCT01796938|Experimental|Group 3: Subjects with moderate renal insufficiency|Single dose of 100 mg Lacosamide
89604406|NCT01796938|Experimental|Group 4: Subjects with severe renal insufficiency|Single dose of 100 mg Lacosamide
89604407|NCT01796938|Experimental|Group 5: Subjects with end stage renal insufficiency|Single dose of 100 mg Lacosamide
89604408|NCT00492544|Experimental|Cervarix|Subjects received 3 doses of Cervarix™ (HPV-16/18 L1 VLP AS04) according to a 0, 1, 6-month schedule.
89604409|NCT00492622|Experimental|Immediate-release omeprazole release first|subjects receive immediate release omeprazole for 7 days then delayed release for 7 days
89604410|NCT00492622|Experimental|Delayed-release omeprazole first|subjects receive delayed release omeprazole for 7 days then immediate release for 7 days
89604411|NCT00494494|Active Comparator|Standard Treatment|topical antibiotic for 10 days and a topical corticosteroid for 1 month
89604412|NCT00494494|Experimental|Nepafenac|1 drop per study eye three times per day for 30 days in addition to standard care
89604413|NCT00494806|Experimental|Rocking Group|Patients rocked in a rocking chair in 10-20 minute increments for at least one hour per day beginning on the first day after surgery. Activity was increased each day and continued until passage of first postoperative flatus.
89604414|NCT00494806|No Intervention|Standard Care|Standard care group got out of bed and sat in a non-rocking chair and ambulated beginning the first day after surgery. Activity was increased each day and continued until passage of first postoperative flatus.
89604415|NCT03145558|Experimental|Trans-Arterial Tirapazamine Embolization (TATE)|Patients will receive a fixed dose of Tirapazamine combined with embolization using Lipiodol and Gelfoam.
89604416|NCT03145558|Active Comparator|Trans-Arterial ChemoEmbolization (TACE)|Patients will receive a mixture of doxorubicin and Lipiodol into the tumor feeding artery followed by injection of Gelfoam to induce embolization per standard procedure.
89604417|NCT03837496|Experimental|STRIDE Run-In|"Stride is delivered as a Five weekly one-hour virtual (videophone) or in-person sessions in small groups with a trained clinician~Two 15-minute check-in phone calls later in the study~Participants will store hormonal therapy medication in a bottle provided by the study team.~Participants will complete questionnaires at enrollment and 3-months post- enrollment"
89604418|NCT03837496|Experimental|STRIDE|"Stride is delivered as six weekly one-hour virtual (videophone) sessions in small groups with a trained clinician (or individually, in the rare instance in which scheduling doesn't allow for groups and the participant is approaching the 12-week assessment window)~Two 15-minute check-in phone calls later in the study~Participants will store hormonal therapy medication in a bottle provided by the study team.~Participants will complete questionnaires at enrollment, 12-weeks, and 24-weeks post-enrollment"
89604419|NCT03837496|Active Comparator|Medication Monitoring Control|"Medication monitoring plus standard care~Participants will store hormonal therapy medication in a bottle provided by the study team.~Participants will complete questionnaires at enrollment, 12-weeks and 24-weeks post-enrollment"
89604420|NCT04750018||COVID-19 2019|Patients receiving biopsies with a BI-RADS assessment of 4 or 5 from mammographic or ultrasonographic exams or combinations of tests were analyzed [4]. We further categorized the biopsy data as ultrasound-guided or mammograph-guided biopsy based on procedure coding. Ultrasound-guided core needle biopsy (CNB) was performed for breast lesions visible on ultrasound.
89604421|NCT04750018||COVID-19 2020|Patients receiving biopsies with a BI-RADS assessment of 4 or 5 from mammographic or ultrasonographic exams or combinations of tests were analyzed [4]. We further categorized the biopsy data as ultrasound-guided or mammograph-guided biopsy based on procedure coding. Ultrasound-guided core needle biopsy (CNB) was performed for breast lesions visible on ultrasound.
89604422|NCT01797874|Experimental|Pazopanib|pazopanib maintenance after 4 cycles of etoposide/platinum in SCLC
89604423|NCT01797874|Placebo Comparator|placebo|placebo after 4 cycles of etoposide/platinum chemotherapy in SCLC
89604424|NCT04750174|Active Comparator|Kinesiotape Group|In active group, KT was applied with stretching to the suprahyoid muscles with right method.
89604425|NCT04750174|Sham Comparator|Sham Kinesiotape Group|In sham group, KT was applied without stretching to the suprahyoid region and not including the origins of mylohyoid and digastric muscles
89604426|NCT00497770||Caucasian|Caucasian patients receiving Alimta for 2nd line NSCLC
89604427|NCT00497770||African American|African American patients receiving Alimta for 2nd line NSCLC
89604428|NCT00497770||Asian American|Asian American patients receiving Alimta for 2nd line NSCLC
89604429|NCT00497770||Hispanic|Hispanic patients receiving Alimta for 2nd line NSCLC
89604430|NCT00498550|Experimental|Clozapine|Clozapine, Clozaril
89604431|NCT00498550|Active Comparator|Treatment as usual|Treatment as usual with any antipsychotic other than Clozapine.
89604432|NCT00498628|Experimental|1|Quetiapine fumarate plus medical management
89604433|NCT00498628|Placebo Comparator|2|Medical management plus placebo comparator
89604434|NCT04749706|Active Comparator|Normal weight|the normal weight women will receive the 12-week physical activity intervention and serve as a control group.
89604435|NCT04749706|Experimental|constitutionally lean women - Physical training only|women will receive the 12-week physical activity intervention
89604436|NCT04749706|Experimental|constitutionally lean women - Physical training + proteins|women will receive the 12-week physical activity intervention in addition to a protein supplementation
89604437|NCT04749472|Experimental|Study Group|Participants received intervention.
89604438|NCT00498706|Experimental|Telephone-administered CBT|Participants will receive telephone-administered cognitive behavioral therapy.
89604439|NCT00498706|Active Comparator|Face-to-face CBT|Participants will receive face-to-face cognitive behavioral therapy.
88981432|NCT03495284|Active Comparator|Refined grain treatment|Participants will be provided with a calorie-matched refined grain-based side dish every day for 4 weeks for incorporation into their self-selected diet. The refined grain-based side dishes will be prepared at the Penn State Metabolic Kitchen and ingredients high in saturated fat, refined sugar or sodium will not be used. These will be sides commonly eaten in the U.S. (e.g. pasta made with white flour and white rice, white bread rolls). During this treatment, participants will be told not to consume potatoes.
88981433|NCT03463057|Other|Atezolizumab|18 cycles atezolizumab followed by 12 months of observation
88981434|NCT03460756|Experimental|Ganaxolone|Oral
88981435|NCT03460756|Placebo Comparator|Placebo|Oral
88981436|NCT03459443|Experimental|Danicopan|Danicopan was to be administered to participants with C3G or IC-MPGN at a starting dose of 100 milligrams (mg) 3 times daily (TID) for the first 2 weeks, then the dosage was to be increased to 200 mg TID for the remainder of the study.
88981437|NCT03455569|Experimental|Behavioral sleep education|manual-based sleep hygiene recommendations and a behavioral sleep intervention including sleep compression therapy
88981438|NCT03455569|Experimental|Education only|education on sleep, aging, and dementia but without specific or individualized recommendations
88981439|NCT03430427||Community-Dwelling Older Adults|The group will consist of 240 community-dwelling older adults with a range of mobility function based on the short physical performance battery (SPPB).
88981440|NCT03430297|Experimental|JS001 240mg Q2W|
88981441|NCT03430297|Active Comparator|Dacarbazine 1000mg/m2 Q3W|
88981442|NCT03425838|Active Comparator|Strategy A CDK4/6 inhibitor in 1st line|Non-steroidal aromatase inhibitor (letrozole or anastrozole, at the discretion of the treating physician) plus CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib, depending on availability and physician's preference) in first line followed by fulvestrant in second line.
88981443|NCT03425838|Active Comparator|Strategy B CDK4/6 inhibitor in 2nd line|Non-steroidal aromatase inhibitor (letrozole or anastrozole, at the discretion of the treating physician) in first line followed by fulvestrant plus CDK4/6 inhibitor in second line (palbociclib, ribociclib or abemaciclib, depending on availability and physician's preference).
88981444|NCT03424915||Regular exercisers and non-exercising groups who have been diagnosed with breast cancer|There is no treatment on this study, it is a onetime assessment. exercisers: ≥120 minutes of vigorous-intensity aerobic exercise;There is no treatment on this study, it is a onetime assessment. non-exercisers: ≤ 30 minutes of moderate-intensity exercise per week.
88981445|NCT03424915||Regular exercisers who are at high risk of developing breast cancer|≥120 minutes of vigorous-intensity aerobic exercise;
88981446|NCT03423940|Experimental|Evaluation of Treatment Dosage|The goal of intervention for arm 1 is to examine the optimal duration of treatment with functional communication training (FCT). Investigators will treat each subject's behavior using FCT in three distinct contexts which will be associated with either short, moderate, or extended treatment durations. The investigators will counterbalance the order of treatment durations (short, moderate, and extended) across subjects, but each subject will receive treatment at each duration. Resurgence will be tested following each treatment duration.
89032475|NCT04693442||Burn patients|with the condition
89032476|NCT04693442||Control group|without the condition (blood sampling only for adults) and children undergoing general anaesthetic procedures that involve skin resections (blood sampling and excised skin)
89032477|NCT02935764|Experimental|FOLFIRI|5-fluorouracil,folinate combined with irinotecan
89032478|NCT02935764|Active Comparator|IRINOTECAN|irinotecan
89604440|NCT01446159|Experimental|MEDI-573 10 mg/kg + AI|Participants who will be enrolled in Phase 1b Cohort A of the study will receive intravenous infusion of MEDI-573 10 mg/kg on Day 1 of each 21-day cycle and AI of the investigator's choice (letrozole, anastrozole, or exemestane) orally once daily until unacceptable toxicity, documentation of disease progression, or withdrawal for other reasons.
89604441|NCT01446159|Experimental|MEDI-573 30 mg/kg + AI|Participants who will be enrolled in Phase 1b Cohort B of the study will receive intravenous infusion of MEDI-573 30 mg/kg on Day 1 of each 21-day cycle and AI of the investigator's choice (letrozole, anastrozole, or exemestane) orally once daily until unacceptable toxicity, documentation of disease progression, or withdrawal for other reasons.
89604442|NCT01446159|Experimental|MEDI-573 45 mg/kg + AI|Participants who will be enrolled in Phase 1b Cohort C and Phase 2 Arm 1 of the study will receive intravenous infusion of MEDI-573 45 mg/kg on Day 1 of each 21-day cycle and AI of the investigator's choice (letrozole, anastrozole, or exemestane) orally once daily until unacceptable toxicity, documentation of disease progression, or withdrawal for other reasons.
89604443|NCT01446159|Experimental|Aromatase Inhibitor|Participants who will be enrolled in Phase 2 Arm 2 of the study will receive oral AI of the investigator's choice (letrozole, anastrozole, or exemestane) orally once daily until unacceptable toxicity, documentation of disease progression, or withdrawal for other reasons.
89604444|NCT00498940|Active Comparator|Biventricular Pacing|After weaning from bypass, patients received temporary biventricular pacing for 24 hours. Values obtained from optimization testing determined pacemaker settings (AVD, VVD, heart rate).
89604445|NCT00498940|Active Comparator|Standard of Care|No continuous pacing occurred about surgery. Patients underwent optimization testing.
89604446|NCT00499096|Experimental|Chronic Care Model for Bipolar Disorder|An intervention group of patients with bipolar disorder and 1 or more risk factor for cardiovascular disease; group will receive self-management group sessions, followed by phone contacts by the Care Manager. This is the chronic care model for bipolar disorder
89604447|NCT00499096|No Intervention|Enhanced Usual Care|A group of patients with bipolar disorder and one or more risk factors for cardiovascular disease will be randomized to receive enhanced usual care. This group will receive usual care, plus mailings on wellness topics (attention control), and their providers will receive information on guideline concordant care.
89604448|NCT03025737||athletes|Healthy highly trained elite athletes, recreational athletes, young and master athletes free of known structural myocardial disease
89604449|NCT03025737||controls|Healthy volunteers without a history of competitive physical exercise
89604450|NCT00499408|Experimental|Soy and Vitamin D|Patients will receive oral supplementation with both 2,000 IU per day of vitamin D (cholecalciferol) and soy (160 mg per day soy isoflavones). Serum PSA and plasma levels of vitamin D will be assessed monthly. Soy isoflavones levels will be assessed every three months.
89604451|NCT01446003|Experimental|MK-8457-Placebo Sequence|Participants received MK-8457 100 mg twice daily (BID) for 10 days followed by Placebo for 10 days. Each treatment was separated by a 10-day washout.
89604452|NCT01446003|Experimental|Placebo-MK-8457 Sequence|Participants received Placebo for 10 days followed by MK-8457 100 mg BID for 10 days. Each treatment was separated by a 10-day washout.
89604453|NCT03025659||Pediatric post-cardiac surgery|All immediately post-operative pediatric cardiac patients will be enrolled. Standard of care laboratory analysis will be performed based on current clinical protocols. Results for lactate, blood gases, liver enzymes, creatinine, glucose, hemoglobin, hematocrit and other direct and indirect measure of cardiac output will be collected. Investigators will also measure pyruvate levels at specific time points, which is not part of standard of care. To measure pyruvate, an additional 1 ml of arterial blood will be drawn at each routine postoperative blood draw. The lactate/pyruvate ratio will be calculated and compared to direct and indirect measure of cardiac output described above.
89604454|NCT03019666|Experimental|Multiple Myeloma|After a lymphodepleting preparative regimen of cyclophosphamide and fludarabine, patients receive expanded NAM-NK cells followed by a short course of interleukin-2 (IL-2) to facilitate natural killer cell survival and expansion in vivo. Monoclonal antibodies and elotuzumab for Multiple Myeloma patients, will be administered prior to and after the natural killer cell infusion(s) to facilitate tumor targeting and antibody dependent cellular cytotoxicity (ADCC).
89604455|NCT03019666|Experimental|Non-Hodgkin Lymphoma|After a lymphodepleting preparative regimen of cyclophosphamide and fludarabine, patients receive expanded NAM-NK cells followed by a short course of interleukin-2 (IL-2) to facilitate natural killer cell survival and expansion in vivo. Monoclonal antibodies and rituximab for Non-Hodgkin Lymphoma patients, will be administered prior to and after the natural killer cell infusion(s) to facilitate tumor targeting and antibody dependent cellular cytotoxicity (ADCC).
89604456|NCT02888860||Group 1|Patients with candidemia
89604457|NCT02888860||Group 2|Patients without colonization during follow up
89604458|NCT02888860||Group 3|Patients without colonization at admission, with subsequent colonization during hospitalization
89604459|NCT02888860||Group|Patients colonized at admission, and during the whole hospitalization
89604460|NCT02888860||Group 5|Patients who develop colonization during hospitalization and become negative at discharge
89604461|NCT00500578|Experimental|1: Standard Schedule - Ribavirin|Aerosolized Ribavirin 6 grams over 18 hours every 24 hours
89604462|NCT00500578|Experimental|2: Modified Schedule - Ribavirin|Aerosolized Ribavirin 2 grams over 3 hours every 8 hours
89604463|NCT01430559|Other|Meloxicam|
89604464|NCT01430559|Placebo Comparator|Placebo|2 Placebo capsules once a day for 12 weeks
89604465|NCT01410357|Experimental|Targeted Training in Illness Management (TTIM)|Participants in this arm will receive the TTIM intervention as well as receiving regular treatment for their DM and SMI from their normal medical and mental health care providers.
89604466|NCT01410357|No Intervention|Treatment As Usual (TAU)|Participants in this arm will continue to receive Treatment as Usual from their usual medical and mental health care providers. They will not receive any intervention.
88981447|NCT03423940|Active Comparator|Empirically Derived Schedule Thinning|The goal of the intervention for arm 2 is to develop the optimal progression for reinforcement schedule thinning during functional communication training. The investigators will use measurements of destructive behavior, appropriate behavior, and reinforcer deliveries during each treatment session to inform the frequency of reinforcers that will be available during upcoming treatment sessions. The investigators will develop the schedule thinning progression by plugging these measurements into the quantitative model to describe the proper steps to schedule thinning to decrease the probability of a relapse of destructive behavior. The investigators will compare these results to those in the extant literature.
88981448|NCT03413449||Resections|Frailty model for patients undergoing esophagectomy and pneumonectomy/lobectomy for cancer
88981449|NCT03411044||Subjects with a Fitmore Hip Stem|Subjects in need of a total hip arthroplasty who met the inclusion/exclusion criteria and who received the Fitmore Hip Stem
88981450|NCT03410667|Other|Standard Care|Standard of care arm
88981451|NCT03410667|Experimental|Intervention Arm|Intervention arm
88981452|NCT03372460|Active Comparator|Active Stimulation|Active stimulation (tDCS) will be used in the dose of 2mA /25 min per day, for 6 sessions over the course of 2 weeks (3 sessions per week).
88981453|NCT03372460|Sham Comparator|Sham Stimulation|Sham tDCS uses the device study mode (10 µA over 15 ms current pulse applied every 550 ms, 3ms peak current). This process will be used for each of the 6 sessions during a 2 week period.
88981454|NCT03367013|Experimental|Intervention Group|The intervention group will receive a daily dose of 200 mg/kg of bovine lactoferrin in breast/donor human milk or formula milk until 34 weeks corrected gestation or for a minimum of 2 weeks, whichever is longer, or until discharge home or transfer, if earlier.
88981455|NCT03367013|Sham Comparator|Control Group|The control group will receive daily study feed with no bovine lactoferrin added in breast/donor human milk or formula milk until 34 weeks corrected gestation or for a minimum of 2 weeks, whichever is longer, or until discharge home or transfer, if earlier.
89604467|NCT00500656|Experimental|Randomized controlled -Icatibant|"Subjects received S.C icatibant+ oral placebo~Icatibant Form: solution for injection, 3 mL, 10 mg/mL Single dose: 30 mg (3 mL)~Placebo Form: hard capsule Single dose: 2 capsules Frequency: 3 x 2 capsules for 2 days, taken orally, 6 to 8 hours apart"
89604468|NCT00500656|Active Comparator|Randomized controlled-Tranexamic acid|"Subjects received oral Tranexamic acid+ S.C. placebo~Tranexamic acid Form: over encapsulated film tablet Single dose: 1000 mg (2 capsules) Frequency: 3 x 2 capsules for 2 days, taken orally, 6 to 8 hours apart~Placebo Form: solution for injection, matched to icatibant for injection Single dose: 3 mL Frequency: one subcutaneous injection in the abdominal region"
89604469|NCT00500656|Experimental|Controlled Open-label / laryngeal attack|Patients with laryngeal symptoms at the baseline were not randomised but treated with icatibant open label during the controlled phase.
89604470|NCT00500656|Experimental|Untreated patients at the baseline|Patients who were screened and found eligible but did not experience an angioedema attack, or had an attack that was not severe enough to merit treatment while the controlled phase was ongoing were treated in the open label phase with icatibant
89604471|NCT01409811|Experimental|Treatment (zoledronic acid)|"Patients receive a single dose of zoledronic acid 4 mg IV over 15 minutes on day 1. Patients then undergo planned definitive surgery (lumpectomy or mastectomy) on day 10-23. Tissue and blood samples from the initial biopsy and definitive surgery are collected to measure changes in biomarkers of tumor growth and metastasis, immunologic function, and the expression of genes important to breast cancer progression and metastasis.~zoledronic acid: Given IV~laboratory biomarker analysis: Correlative studies~therapeutic conventional surgery: Undergo definitive lumpectomy or mastectomy"
89604472|NCT01445847|Active Comparator|Lidocaine|Lidocaine 1% was prepared in 10 mL syringe= 10 mg/mL, dosage was 1mg/kg, one bolus or 10 mL/kg, with range of 2mg could be added or missed. The maximum dose is 100 mg for patients with weight of more than 100
89604473|NCT01445847|Placebo Comparator|Placebo|Normal saline was prepared in 10 mL syringe, dosage was 1 mL/10 kg.
89604474|NCT00501592|Active Comparator|25 mg INT-747|
89604475|NCT00501592|Active Comparator|50 mg INT-747|
89604476|NCT00501592|Placebo Comparator|Placebo|
89604477|NCT01445769|Experimental|Ruxolitinib|Participants initially received ruxolitinib 10 mg twice a day (bid) for 24 weeks. Dose increases of 5 mg bid were possible at Weeks 12 and 18 up to a maximum dose of 20 mg bid.
89604478|NCT00502216|Experimental|1|Arm 1 (Experimental) = Varenicline (Chantix) 1 mg oral tablet twice per day + naltrexone 25 mg oral capsule once per day
89604479|NCT00502216|Placebo Comparator|2|Arm 2 (Placebo Comparator) = Varenicline (Chantix) 1 mg oral tablet twice per day + placebo naltrexone 25 mg oral capsule once per day
89604480|NCT00545662|Experimental|Placebo|Placebo tablets formulated to resemble the citicoline treatment.
89604481|NCT00545662|Experimental|Citicoline|Experimental treatment administered orally or enterally depending upon whether the participant can swallow at 1,000 mg twice a day for 90 days or until the 90-day outcome assessment.
89604482|NCT00545974|Experimental|1|Memantine 10mg BID
89604483|NCT00545974|Placebo Comparator|2|Placebo condition
88981456|NCT03354143|Active Comparator|Standard Care|Subjects in the standard care arm will receive calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs to reduce 24-hour SBP ≤ 130 mmHg. Drug doses will be titrated to reach the BP target.
88981457|NCT03354143|Experimental|Intensive Treatment|Subjects in the intensive treatment arm will receive calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs to reduce 24-hour SBP ≤ 120 mmHg.
88981458|NCT03348995|Experimental|Bridge-Enhanced ACL Restoration (BEAR)|The BEAR technique involves surgically placing an absorbable implant (the BEAR Implant) between the torn ends of the ACL, providing a scaffold for the ligament ends to grow into
88981459|NCT03344757|Experimental|Cultural-Cognitive Behavioral Stress Management (CCBSM)|Participants randomized to this arm will receive 10 weekly group-based C-CBSM intervention.
88981460|NCT03344757|Active Comparator|Cognitive Behavioral Stress Management (CBSM)|Participants randomized to this arm will receive 10 weekly group-based standard CBSM intervention.
88981461|NCT03339271|Active Comparator|Technology-Enhanced Group|Family caregivers will have daily visits from the study nurse while the patient is in the hospital and will receive weekly technology-enhanced support (video chats) from the study nurse for 8 weeks after the patient is discharged from the hospital.
88981462|NCT03339271|Active Comparator|Usual Care Group|Family caregivers will have usual care support from the doctors and nurses to plan for taking care of the patient upon return home and will receive a weekly telephone call for 8 weeks after the patient is discharged from the hospital.
88981463|NCT03336398|Experimental|Tinnitus Distressed Patients|Tinnitus distressed patients are patients who experience symptoms of anxiety or depression with tinnitus. This group will receive both 0.5 mg/kg ketamine hydrochloride in saline and placebo, saline, with Magnetic Resonance Spectroscopy scans and audiometry testing and scales.
88981464|NCT03336398|Experimental|Tinnitus Patients|Tinnitus patients are patients who do not experience symptoms of anxiety or depression with tinnitus. This group will receive both 0.5 mg/kg ketamine hydrochloride in saline and placebo, saline, with Magnetic Resonance Spectroscopy scans and audiometry testing and scales.
88981465|NCT03331731|Experimental|Single arm|Single Arm
88981466|NCT03322995|Experimental|Restaging: Response to Treatment|After the first restaging evaluation, further treatment will be based on treatment response. Patients who demonstrate a response [decline in carbohydrate antigen 19-9 (CA19-9) values] and radiographic response, along with preserved performance status) will be maintained on the first line chemotherapy for an additional two months.
88981467|NCT03322995|Experimental|Restaging: Patients with Stable Disease|Patients who do not have a significant decline in CA19-9 values will be changed to a second-line therapy for an additional two months.
89604484|NCT02928718||High risk patients|Patients who are at high risk of post-ERCP pancreatitis, who have at least one of the following factors: clinically suspected sphincter of Oddi dysfunction, history of post-ERCP pancreatitis, pancreatic sphincterotomy, precut sphincterotomy, difficult cannulation, balloon dilatation of intact sphincter, endoscopic ampullectomy, and 2≥minor criteria(an age of less than 50 years and female sex, a history of recurrent pancreatitis (≥2 episodes), three or more injections of contrast agent into the pancreatic duct with at least one injection to the tail of the pancreas, excessive injection of contrast agent into the pancreatic duct resulting in opacification of pancreatic acini,the acquisition of a cytologic specimen from the pancreatic duct with the use of a brush).
88981468|NCT03322995|Experimental|Restaging: Local Disease Progression|After the first restaging evaluation, further treatment will be based on treatment response. If, at the initial restaging, the patient has local disease progression amenable to surgical resection, he or she will receive chemoradiation, rather than continued chemotherapy, so the window of opportunity for surgical resection is not lost.
88981469|NCT03319498|Active Comparator|Peppermint Oil Vapor|Exposure of the perineum to the vapor of the active comparator, 2 ml peppermint oil. The perineum will NOT come into contact with the oil directly.
88981470|NCT03319498|Placebo Comparator|Mineral Oil Vapor|Exposure of the perineum to the vapor of the placebo comparator, 2 ml mineral oil. The perineum will NOT come into contact with the oil directly.
88981471|NCT03316885|Experimental|Clareon IOL|Clareon® aspheric hydrophobic acrylic intraocular lens implanted with the Alcon Monarch III-D delivery system as a replacement of the human crystalline lens during cataract surgery
89604485|NCT00507208|Experimental|Dynasplint|Participants randomized to this arm will be treated with the Dynasplint Trismus System
89604486|NCT00507208|Active Comparator|Control|Participants randomized to this arm will use tongue depressors for 3 months and if there is no improvement in their mouth opening at this timepoint, they will crossover to the Dynasplint Trismus System
89604487|NCT00548470|Experimental|varenicline|open label varenicline 2mg/day
89604488|NCT02732704|Experimental|Transcatheter Aortic Valve Replacement (TAVR)|TAVR with JenaValve Pericardial Valve and Delivery System
89604489|NCT00548860|Experimental|Ferric Carboxymaltose (FCM)|Undiluted dose of iron as FCM IV (15 mg/kg up to a maximum of 1000 mg)
89604490|NCT00548860|Active Comparator|Standard Medical Care (SMC)|Varied as determined by the Investigator
89604491|NCT00508300|Other|A|Epidural Analgesia (EDA) An epidural catheter was inserted at thoracic level (Th8-Th10) before induction of anesthesia. A bolus of 5 mL of bupivacaine 0.5% was started as soon as the epidural catheter was in place, and a continuous perfusion of bupivacaine 0.5% at 5 mL/hr was initiated until the end of surgical procedure.
89604492|NCT00508300|Other|B|Patient controlled analgesia (PCA) was assured by fentanyl (morphine-based) as needed.
89604493|NCT00509002|Experimental|Adenoid Cystic Salivary Gland Carcinoma Group|Participants receive Gefitinib daily by mouth until progressive disease, unacceptable toxicity or patient withdrawal.
89604494|NCT00509002|Experimental|Other Carcinoma of Salivary Gland Group|Participants receive Gefitinib daily by mouth until progressive disease, unacceptable toxicity or patient withdrawal.
89604495|NCT02231008|Experimental|Tasimelteon|Single dose oral capsule or equivalent age-appropriate oral formulation, daily dosage
89604496|NCT02231008|Placebo Comparator|Placebo|Placebo comparator
89604497|NCT00509392|Active Comparator|Seg. RF Ablation & ClosureFAST catheter|Seg. RF Ablation & ClosureFAST catheter
89604498|NCT00509392|Active Comparator|Endovenous Laser|Treatment invention of venous disease with an Endovenous Laser.
89604499|NCT01797172|Experimental|Percutaneous Cervical Nucleoplasty|Percutaneous Cervical Nucleoplasty
89604500|NCT01797172|Active Comparator|Pulsed Radio Frequency|Pulsed Radio Frequency treatment
89604501|NCT00550654|Experimental|Radiation Therapy in Metastatic Cancer|Patients undergo hypofractionated highly conformal radiotherapy with helical tomotherapy once every other day over 5 days for a total of 3 fractions.
89604502|NCT00887380|Active Comparator|Arm A: Concurrent|Investigational treatment: Anastrozole commenced before (Pre-radiotherapy commencement of anastrozole) and continued during radiotherapy.
89604503|NCT00887380|Active Comparator|Arm B: Sequential|Standard Treatment: Anastrozole and subsequent anti-oestrogen therapy delayed until after radiotherapy (Post radiotherapy commencement of anastrozole)
88981472|NCT03310983||ADORE Participants|Participants enrolled in the ADORE study are invited to participate in this study.
88981473|NCT03293615|Experimental|Dermatomyositis (DM)|Patients with dermatomyositis according to ENMC criteria
88981474|NCT03293615|Active Comparator|Non-dermatomyositis inflammatory myopathies|Patients with other inflammatory myopathy than dermatomyositis according to ENMC criteria
88981475|NCT03293615|No Intervention|No myopathy|Patients without myopathy on muscle biopsy
89604504|NCT01445613|Other|RX Acculink Carotid Stent System (RX Acculink)|Those patients receiving the RX Acculink used with an Embolic Protection System (EPS) approved for use with RX Acculink.
89604505|NCT00551200|Active Comparator|BUPHENYL® to HPN-100 vs. HPN-100|Buphenyl treatment for one week was followed by dose escalation to HPN-100. Dose of Buphenyl was gradually decreased while HPN-100 dose was gradually increased until subject reached dosing of 100% HPN-100. HPN-100 at 100% of the dose was given for 1 week before subject was switched back to original Buphenyl treatment.
89604506|NCT00557284|Experimental|1|Montelukast
89604507|NCT00557284|Placebo Comparator|2|
89604508|NCT00551746|Active Comparator|1|Grape Juice
89604509|NCT00551746|Placebo Comparator|2|Grape Juice Placebo
89604510|NCT00552448|Experimental|1|Use of the HFCC device in addition to standard therapy for status asthmaticus. The use of HFCC will not affect the therapy received
89604511|NCT00552448|No Intervention|2|This group will not use the VEST or HFCC. They will just have standard therapy for status asthmaticus. The standard therapy will not be affected if they are in this group.
89604512|NCT00557362|Active Comparator|1|Topical voriconazole with corneal de-epithelialization
89604513|NCT00557362|Active Comparator|2|Topical voriconazole without corneal de-epithelialization
89604514|NCT00557362|Active Comparator|3|Topical natamycin with corneal de-epithelialization
89604515|NCT00557362|Active Comparator|4|Topical natamycin without corneal de-epithelialization
89604516|NCT00558844|Active Comparator|A|Arikayce™ at 560 mg Subjects randomized 2:1 to receive Arikayce 560 mg or Placebo.
89210369|NCT00627926|Placebo Comparator|PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week|Placebo (PBO) matched to telaprevir 750 mg tablet thrice daily for 12 weeks in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (<) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (>=) 75 kg, for 48 weeks.
89604517|NCT00558844|Placebo Comparator|B|Matching placebo for 560 mg Subjects randomized 2:1 to receive Arikayce 560 mg or Placebo.
89604518|NCT00558844|Active Comparator|C|Arikayce™ at 70 mg Subjects randomized 1:1:1 to receive Arikayce 70 mg, Arikayce 140 mg or Placebo.
89604519|NCT00558844|Active Comparator|D|Arikayce™ at 140 mg Subjects randomized 1:1:1 to receive Arikayce 70 mg, Arikayce 140 mg or Placebo.
89604520|NCT00558844|Placebo Comparator|E|Matching placebo for 70 mg/140 mg Subjects randomized 1:1:1 to receive Arikayce 70 mg, Arikayce 140 mg or Placebo.
89604521|NCT00512278|Experimental|Infliximab|Infliximab: 48 weeks of therapy with the combination of PEG INF-2b/RBV plus adjuvant infliximab
89604522|NCT00512278|Placebo Comparator|Placebo|Placebo: 48 weeks of therapy with Placebo and PEG INF-2b/RBV
89604523|NCT01445535|Experimental|siplizumab + EPOCH (combo chemo) + rituximab|siplizumab will be given with EPOCH (combo chemo) and rituximab every 21 days
89604524|NCT01445301|Experimental|GSK2585823(CLDM 1%-BPO 3% gel) once daily|Subjects will apply in a quantity sufficient to cover the entire face (including the forehead, nose, cheeks, and chin). Also, the dose regimen will be once daily in the evening/bedtime.
89604525|NCT01445301|Experimental|GSK2585823(CLDM 1%-BPO 3% gel) twice daily|Subjects will apply in a quantity sufficient to cover the entire face (including the forehead, nose, cheeks, and chin). Also, the dose regimen will be twice daily in the morning and evening/bedtime.
89604526|NCT01445301|Active Comparator|CLDM 1% gel twice daily|Subjects will apply in a quantity sufficient to cover the entire face (including the forehead, nose, cheeks, and chin). Also, the dose regimen will be twice daily in the morning and evening/bedtime.
89604527|NCT01409031|Experimental|Intravenous Sildenafil|
89604528|NCT01409031|Placebo Comparator|Placebo|0.4 mg/kg bolus, followed by a continuous infusion of 1.6 mg/kg/day or an equivalent volume of placebo (D5W); infusion will be initiated as a bolus over 3 hours, followed by a controlled continuous infusion for up to 7 days.
89604529|NCT01430403|Experimental|Omalizumab|Participants receive active omalizumab (Xolair®) injections and a placebo Flovent® Diskus® (fluticasone) inhaler. Each participant will receive omalizumab (Xolair®) subcutaneous injections at minimum dose of 0.016 mg/kg/IgE (immunoglobulin E) [IU/mL] every 2 or 4 weeks during the 4-5 months treatment period. In addition, all participants receive standardized specialist asthma care.
89604530|NCT01430403|Experimental|Inhaled Corticosteroid Boost Therapy (ICS)|Participants in this group, the Inhaled Corticosteroid (ICS) boost arm, receive active ICS and placebo omalizumab (Xolair®) injections. Self-administered fluticasone (Flovent ® Diskus®) inhalers sufficient to deliver the required 200 mcg or 500 mcg daily boost of fluticasone will be used. In addition, all participants receive standardized specialist asthma care.
89604531|NCT01430403|Placebo Comparator|Placebo|The placebo group receive placebo omalizumab (Xolair®) injections and placebo Flovent® Diskus® (fluticasone) inhaler. In addition, all participants receive standardized specialist asthma care.
89604532|NCT01429623|Experimental|ladostigil hemitartrate|10mg ladostigil base
89604533|NCT01429623|Placebo Comparator|Placebo Control|drug product excipients
89604534|NCT01408641|Experimental|Topiramate|Topiramate arm will be titrated (dose will increase slowly) over 6 weeks to 400mg or highest tolerated dose.
89604535|NCT01408641|Placebo Comparator|Placebo (Sugar Pill)|Placebo arm will receive matching capsules without topiramate.
89604536|NCT01429077|Active Comparator|Levodopa/carbidopa|The study drug (100 mg levodopa / 25 mg carbidopa), is received orally 30-45 minutes before 1 hour of speech-language treatment, five days a week, for six weeks.
89604537|NCT01429077|Placebo Comparator|Inactive pill|The placebo comparator (inactive pill) is received orally 30-45 minutes before 1 hour of speech-language treatment, five days a week, for six weeks.
89604538|NCT01428453|Experimental|250mg rilapladib|Experimental drug
89604539|NCT01428453|Placebo Comparator|placebo|Placebo comparator
89604540|NCT01408563|Experimental|Fludarabine/Melphalan/TBI|All patients receive same therapy
89604541|NCT01442493|Experimental|Patient-Centered Methadone Treatment|Patient-Centered Methadone Treatment alters the rules and staff roles in methadone treatment as usual in an attempt to increase treatment retention and improve patient outcomes.
89604542|NCT01442493|Active Comparator|Methadone Treatment as Usual|Methadone treatment provided as usual in the U.S.
89604543|NCT04069923|Experimental|Treatment (OsteoCrete)|Participants receive OsteoCrete intraoperatively to fill voids that occur in bones during surgery or to augment screw fixation.
89604544|NCT01442181|Active Comparator|Minimally Invasive Surgery|Thumb sized incisions are made on each sides of the chest wall where instruments are placed in the chest to perform the surgery.
89604545|NCT01442181|Active Comparator|Medical Therapy|Patients are treated with rhythm and rate control medications.
89604546|NCT04407975|Experimental|Betamethasone|Patients will receive 14 mg (2 ml) intramuscular betamethasone
89604547|NCT04407975|Placebo Comparator|Placebo|Patients will receive an equivalent volume of normal saline
89604548|NCT01442103|Experimental|Device, dressing|Normlgel Ag is an opaque, amorphous hydrogel containing a high water content, water soluble polymer chains and an antimicrobial silver compound.
89604549|NCT04069767|Experimental|ICoreDIST|The intervention starts with an assessment by the physiotherapist to identify the patient's movement problems in order to choose among the 48 exercises in the intervention. Each session lasts for 60 minutes + exercises 5-10 minutes outside of therapy and is performed 5-6 days/per week in the rehabilitation units, and 3 sessions/week + home exercises 30 minutes 3 days per week in home based or outpatient treatment during the 12 weeks period.To allow for individualisation, each exercise contains five levels of difficulty. All exercises demand enhancement of dynamic trunk stability and functional movements.
89604550|NCT04069767|Active Comparator|Standard Care|Consists of standard inpatient rehabilitation, home-based and outpatient-based physiotherapy with the same dose as the intervention group.
89604551|NCT01428219|Experimental|Cabozantinib (XL184)|Cabozantinib is available in capsule form. The dose is 60 mg daily by mouth. Subjects with disease progression at 6 weeks who do not have significant toxicities may remain on therapy for an additional six weeks until a progression is confirmed. Further study drug administration beyond 12 weeks will be at the discretion of the investigator provided that the subject does not have disease progression, does not have unacceptable side effects, does not withdraw from study, or does not have a medical condition or illness that renders the subject unacceptable to receive further study drug.
88981476|NCT03283384|Other|Advise letrozole, treatment choice free.|All patients initially start with two weeks of letrozole treatment. Patients with a Ki67 of <1% in the biopsy taken after those two weeks of treatment are advised to stay on letrozole treatment until surgery. However, treatment choice is free.
88981477|NCT03283384|Active Comparator|Chemotherapy|All patients initially start with two weeks of letrozole treatment. Patients with a Ki67 of ≥1% in the biopsy taken after those two weeks of treatment are randomized between chemotherapy (standard AC-T chemotherapy) or ribociclib plus letrozole (ribociclib 600 mg/day (days 1-21, q4 weeks) plus letrozole 2.5 mg daily (days 1-28, q4 weeks)).
89604552|NCT01428063|Experimental|Daclatasvir + Asunaprevir + PegIFNα-2a + Ribavirin|Patients received daclatasvir, 60-mg tablet, by mouth once daily + asunaprevir, 100-mg capsule or 200-mg tablet, by mouth twice daily + pegIFNα-2a, 180-μg solution, subcutaneously weekly + ribavirin, weight-based dosing (<75 kg=1000 mg once daily; >=75 kg=1200 mg once daily) for 24 weeks
89604553|NCT01428063|Experimental|Daclatasvir + PegIFNα-2a + Ribavirin|Patients received daclatasvir, (two 30-mg tablets or one 60-mg tablet, by mouth once daily) + pegIFNα-2a, 180-μg solution, subcutaneously weekly + ribavirin, weight-based dosing (<75 kg=1000 mg once daily; >=75 kg=1200 mg once daily) for 24 weeks
89604554|NCT01428063|Experimental|Daclatasvir + Asunaprevir|Patients received daclatasvir, 60-mg tablet, by mouth once daily + asunaprevir, 100-mg capsule, by mouth twice daily for 24 weeks
89604555|NCT00513292|Active Comparator|FEC-75 then Paclitaxel/trastuzumab|Patients receive FEC comprising fluoroucacil IV, epirubicin hydrochloride IV, and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses. Beginning 21 days after completion of FEC, patients receive paclitaxel IV once weekly and trastuzumab (Herceptin) IV once weekly for 12 weeks. Within 6 weeks after completion of paclitaxel and trastuzumab, patients undergo surgery. Beginning 3-4 weeks after surgery, patients receive trastuzumab IV once every 3 weeks for up to 52 weeks.
89604556|NCT00513292|Experimental|Paclitaxel/trastuzumab then trastuzumab/FEC-75|Patients receive paclitaxel IV once weekly and trastuzumab IV once weekly for 12 weeks. Beginning 7 days after the completion of paclitaxel and trastuzumab, patients receive FEC comprising fluoroucacil IV, epirubicin IV, and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses. Patients also receive trastuzumab IV once weekly for an additional 12 weeks. Within 6 weeks after completion of FEC and trastuzumab, patients undergo surgery. Beginning 3-4 weeks after surgery, patients receive trastuzumab as in arm I.
89604557|NCT00513370|Experimental|1|
89604558|NCT00559468|Experimental|Sugammadex + Sevoflurane|After receiving sevoflurane and the last dose of rocuronium, at the reappearance of first twitch (T1; 3-10% starting amplitude), a dose of 4.0 mg/kg sugammadex was administered.
89604559|NCT00559468|Experimental|Sugammadex + Propofol|After receiving propofol and the last dose of rocuronium, at the reappearance of first twitch (T1; 3-10% starting amplitude), a dose of 4.0 mg/kg sugammadex was administered.
89604560|NCT00560560|Experimental|1|Single arm study
89604561|NCT00561418|Experimental|Vorinostat (SAHA)|Vorinostat (SAHA) will be administered orally starting approximately day +60 post HSCT for 21 consecutive days of a 28-day cycle for up to a maximum of 11 cycles with the dose escalations.
88981478|NCT03283384|Experimental|Ribociclib plus letrozole|All patients initially start with two weeks of letrozole treatment. Patients with a Ki67 of ≥1% in the biopsy taken after those two weeks of treatment are randomized between chemotherapy (standard AC-T chemotherapy) or ribociclib plus letrozole (ribociclib 600 mg/day (days 1-21, q4 weeks) plus letrozole 2.5 mg daily (days 1-28, q4 weeks)).
88981479|NCT03283072|Experimental|Sequence 1|Intervention 1: 15 bouts of 2mins:1min hypoxia:hyperoxia Intervention 2: 15 bouts of 1mins:1min hypoxia:hyperoxia Intervention 3: 8 bouts of 2mins:1min hypoxia:hyperoxia 15 bouts of 1min:1min normoxia (sham)
88981480|NCT03283072|Experimental|Sequence 2|Intervention 2: 15 bouts of 1mins:1min hypoxia:hyperoxia Intervention 3: 8 bouts of 2mins:1min hypoxia:hyperoxia 15 bouts of 1min:1min normoxia (sham) Intervention 1: 15 bouts of 2mins:1min hypoxia:hyperoxia
88981481|NCT03283072|Experimental|Sequence 3|Intervention 3: 8 bouts of 2mins:1min hypoxia:hyperoxia 15 bouts of 1min:1min normoxia (sham) Intervention 1: 15 bouts of 2mins:1min hypoxia:hyperoxia Intervention 2: 15 bouts of 1mins:1min hypoxia:hyperoxia
88981482|NCT03283072|Experimental|Sequence 4|15 bouts of 1min:1min normoxia (sham) Intervention 1: 15 bouts of 2mins:1min hypoxia:hyperoxia Intervention 2: 15 bouts of 1mins:1min hypoxia:hyperoxia Intervention 3: 8 bouts of 2mins:1min hypoxia:hyperoxia
89604562|NCT00514852|Experimental|1|Carboxymethylcellulose and Glycerin based artificial tear
89604563|NCT00514852|Active Comparator|2|Carboxymethylcellulose
89604564|NCT00555880|Experimental|1|
89604565|NCT00555880|Placebo Comparator|2|
89604566|NCT00563290|Experimental|Arm I (dasatinib 100 mg PO BID)|Patients receive 100 mg dasatinib PO BID on days 1-28
89604567|NCT00563290|Experimental|Arm II (dasatinib 70 mg PO BID)|Patients receive 70 mg dasatinib PO BID on days 1-28
89604568|NCT00556504|Experimental|TCM-700C|an add-on drug (2 tablets/t.i.d) to conventional treatment(Peginterferon alfa-2a + ribavirin) of Hepatitis C
88981483|NCT03260504|Experimental|Treatment (pembrolizumab, aldesleukin)|Patients receive pembrolizumab intravenously (IV) over 30 minutes on day 1. Patients also receive aldesleukin subcutaneously (SC) 5 days per week for 6 weeks; or aldesleukin IV on days 2-6 of pembrolizumab cycles 1 and 2. Pembrolizumab treatment repeats every 3 weeks for 4 cycles per treatment course in the absence of clinical disease progression or unacceptable toxicity.
89604569|NCT00556504|Placebo Comparator|Placebo|placebo add on(2 tablets/t.i.d) to conventional treatment(Peginterferon alfa-2a + ribavirin) of Hepatitis C
89604570|NCT05560828||Zio Cohort|Patients who have been prescribed Zio
89604571|NCT05560828||Holter Cohort|Patients who have been prescribed Holter
89604572|NCT02127892|Other|unrelated BM with T cell depletion|Acceptable matching for matched unrelated donor (MUD) bone marrow will be genotypic matches at 10 of 10 HLA alleles (HLA-A, B, C, DR and DQ) or 9 of 10 HLA alleles.
89604573|NCT02127892|Other|unrelated cord blood|Acceptable matching for unrelated cord blood will be a genotypic match at 6 of 6 alleles (HLA A, B and DR) or 5 of 6 alleles, but not with mismatches at both alleles of a single locus (e.g. not mismatched for both HLA A alleles).
89604574|NCT02127892|Other|haplo BM with T cell depletion|If there is no unrelated donor available meeting the matching criteria for unrelated bone marrow or unrelated cord blood donors.
89604575|NCT02127892|Other|unrelated PBSC with T cell depletion|The preferred source will be bone marrow, however, if a donor is unable or unwilling to donate bone marrow, peripheral blood stem cells (PBSC) will be allowed.
89604576|NCT02128828|Experimental|cenicriviroc|cenicriviroc 50 mg tablets, number of tablets adjusted for other antiretroviral medications or other drugs, given once daily
89604577|NCT00520234|Active Comparator|1 prophylaxis|Caspofungin 50 mg Intravenous (IV) daily up to 28 days of therapy
89604578|NCT00520234|Placebo Comparator|2 placebo|Normal Saline 100 cc IV daily
89604579|NCT05560672|Experimental|Experimental group|Cord blood mononuclear cell transplantation is performed at the same time as medical treatments such as fasting, rehydration, hemostasis, anti-infection, vasodilation, repair of intestinal mucosa, regulation of intestinal flora, etc.
89604580|NCT05560672|No Intervention|Control group|Medical treatments such as fasting, rehydration, hemostasis, anti-infection, vasodilation, repair of intestinal mucosa, and regulation of intestinal flora are given.
89604581|NCT00520468|Experimental|Cytokine-Immunotherapy|Erythropoietin 40,000 units subcutaneously (SQ) weekly; G-CSF 300 mcg SQ twice a week; Prednisone 60 mg/Day for 7 days, taper over 1 month; Cyclosporin A 300 mg orally daily
88981484|NCT03259074|Experimental|AIN457 150 mg/placebo|AIN457 150 mg and a matching placebo was administered subcutaneously via pre-filled syringes at Baseline, Weeks 1, 2, 3 and 4, followed by dosing every 4 weeks until Week 100
88981485|NCT03259074|Experimental|AIN457 300 mg|AIN457 300 mg (2 x 150 mg) was administered subcutaneously via pre-filled syringes at Baseline, Weeks 1, 2, 3 and 4, followed by dosing every 4 weeks until Week 100
89604582|NCT01908712|Experimental|Lamazym|1 mg Lamazym/kg body weight
89604583|NCT05622526|Experimental|Group 1 or Experimental group|treatment with an initial dose of 24 oral capsules of MBK-01 and a maintenance dose of 12 oral capsules of MBK-01 every 3 months (4 maintenance doses).
88981486|NCT03259074|Active Comparator|GP2017 40mg|GP2017 (adalimumab biosimilar) 40 mg was administered subcutaneously via pre-filled syringes at Baseline followed by dosing every 2 weeks until Week 102
88981487|NCT03246074|Experimental|Fostamatinib and Paclitaxel|Participants will receive paclitaxel on Days 1, 8 and 15 of each cycle and fostamatinib at a fixed oral dose twice daily throughout each 28-day cycle. The dose of fostamatinib will be determined by the enrollment dose level. Given the mTPI design, dose-escalation decisions will be made based on the three dosing intervals, where the underdosing interval corresponds to dose escalation (E), overdosing interval corresponds to dose de-escalation (D), and proper dosing corresponds to staying at the current dose (S). The initial dose level will be Level 1 of Table 1. Participants will be individually continually assessed for DLT. The associated dose-escalation decisions are presented in Table 2. For illustration, suppose a cohort of 3 patients is at the current dose.
88981488|NCT03216967|Active Comparator|IS lowering alone|50% decrease of the dose of mycophenolic acid at M1 (target AUC 20 mg.h/L)
88981489|NCT03216967|Experimental|Everolimus + IS lowering|Stop mycophenolate acid (Cellcept or myfortic) Introduction of everolimus : 2 x 0.75 mg/d per os in patiens treated by ciclosporine
88981490|NCT03210662|Experimental|Treatment (EBRT, pembrolizumab)|Beginning on day 1, patients undergo fractionated EBRT daily for 5 consecutive days a week for up to 12 or 22 treatments. Patients also receive pembrolizumab IV over 1 hour on day 2. Treatment with pembrolizumab repeats every 21 days for up to 35 cycles in the absence of disease progression or unacceptable toxicity.
88981491|NCT03208374||MSK-IMPACT genetic panel testing|Participants have completed MSK-IMPACT genetic panel testing on Memorial Sloan Kettering Cancer Center protocol IRB #12-245 and/or IRB #06-107 and/or IRB # 09-141 in the last 3 years.
88981492|NCT03190330|Experimental|Ibrutinib|Participants will receive ibrutinib 420 milligram (mg) (three 140 mg capsules) as a single daily dose for chronic lymphocytic leukemia (CLL) and 560 mg (four 140 mg capsules) as a single daily dose for mantle cell lymphoma (MCL) for up to 12 months or till disease progression, whichever is earlier.
88981493|NCT03159104|Experimental|Tenoten for children|Dose per administration: 1 tablet. 1 tablet three times daily (3 tablets per day). The tablets should be held in the mouth until complete dissolution, without meal.
88981494|NCT03159104|Placebo Comparator|Placebo|Dose per administration: 1 tablet. 1 tablet three times daily (3 tablets per day). The tablets should be held in the mouth until complete dissolution, without meal.
89210370|NCT00627926|Experimental|Telaprevir 8 Week, PBO 4 Week+Peg-IFN-alfa-2a, RBV 24/48 Week|Telaprevir 750 mg tablet thrice daily for 8 weeks, then PBO matched to Telaprevir 750 mg tablet thrice daily for 4 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 24 to 48 weeks depending on individual response to telaprevir treatment.
89604584|NCT05622526|Placebo Comparator|Group 2 or Control group|treatment with an initial dose of 24 oral capsules of MBK-01 and a maintenance dose of 12 oral capsules of MBK-01 every 3 months for 12 months (4 maintenance doses)
89604585|NCT05560438|Experimental|Technorehab|Rehabilitation using Tyromotion Amadeo and Armeo Senso
89604586|NCT05622448|Active Comparator|RPD with metallic framework|removable partial denture with cobalt chromium framework
89604587|NCT05622448|Experimental|RPD with PEEK framework|removable partial denture with poly ether ether ketone framework
89604588|NCT05559268|Experimental|Denosumab|
89604589|NCT05559268|Placebo Comparator|Placebo|
89604590|NCT02338960|Experimental|Bremelanotide (BMT/BMT)|"(Main Study) Subjects will self-administer a fixed dose (1.75 mg) of bremelanotide (BMT) subcutaneously (SC) via auto-injector on an as needed basis with no more than 1 dose taken every 24 hours for 24 weeks~(OLE Study) Subjects will self-administer a fixed dose (1.75 mg) of bremelanotide (BMT) subcutaneously (SC) via auto-injector on an as needed basis with no more than 1 dose taken every 24 hours for 52 weeks"
89604591|NCT02338960|Placebo Comparator|Placebo (PBO/BMT)|"(Main Study) PBO administered SC on an as-desired basis for 24 weeks~(OLE Study) subjects will self-administer a fixed dose (1.75 mg) of bremelanotide (BMT) subcutaneously (SC) via auto-injector on an as needed basis with no more than 1 dose taken every 24 hours for 52 weeks"
89604592|NCT05622214|Experimental|Plant based nutrition|Plant based nutritional formula based on almond and buckwheat
89604593|NCT05621902|Experimental|Weekly symptom monitoring|Web-based weekly symptom monitoring in addition to standard follow-up
89604594|NCT05621902|No Intervention|Standard care|Standard follow-up according to guidelines
89604595|NCT02121418|Experimental|Treatment (decitabine, cytarabine)|Patients receive decitabine IV daily on days 1-10 and cytarabine IV QD on days 1-7. Treatment repeats every 28-35 days for 2 courses in the absence of disease progression or unacceptable toxicity. After course 3, patients achieving remission will receive 1-2 more courses of therapy at the same dose. Patients in remission with significant side effects will receive decitabine and cytarabine at decreased doses. Patients not achieving remission will not receive any more treatment.
89604596|NCT01441635|Experimental|Cohort 4 Elagolix 400 mg QD|Participants received elagolix 400 mg once a day (QD) for 3 months.
89604597|NCT01441635|Experimental|Cohort 4 Elagolix 100 mg BID|Participants received elagolix 100 mg twice a day (BID) for 3 months.
89604598|NCT01441635|Placebo Comparator|Cohort 4 Placebo|Participants received placebo to elagolix BID for 3 months.
89604599|NCT01441635|Experimental|Cohort 1 Elagolix 200 mg BID|Participants received elagolix 200 mg twice a day for 3 months.
89604600|NCT01441635|Placebo Comparator|Cohort 1 Placebo|Participants received placebo to elagolix twice a day for 3 months.
89604601|NCT01441635|Placebo Comparator|Cohort 3 Elagolix 200 mg BID + LD E2/NETA|Participants received elagolix 200 mg twice a day plus continuous low-dose (LD) estradiol (E2) 0.5 mg/norethindrone acetate 0.1 mg (NETA) once a day for 3 months.
89604602|NCT01441635|Experimental|Cohort 5 Elagolix 600 mg QD|Participants received elagolix 600 mg once a day for 3 months.
89604603|NCT01441635|Experimental|Cohort 2 Elagolix 300 mg BID|Participants received elagolix 300 mg twice a day for 3 months.
89604604|NCT01441635|Experimental|Cohort 2 Placebo|Participants received placebo to elagolix BID for 3 months.
89604605|NCT01441635|Experimental|Cohort 6 Elagolix 300 mg BID + CEP|Participants received elagolix 300 mg twice a day plus cyclical estrogen/progesterone (CEP, consisting of estradiol 1 mg a day and progesterone 200 mg on days 17 to 28 of each 30-day treatment cycle) for 3 months.
89604606|NCT01408485|Experimental|Treatment Arm|Radio-frequency cardiac ablation for treatment of isthmus-dependant atrial flutter using the Therapy™ Cool Flex™ Irrigated Ablation System
89604607|NCT01427907|Experimental|Phoslyra - Calcium Acetate Oral Solution|The investigational compound is calcium acetate oral solution (COS) or Phoslyra. It is a pale, light greenish-yellow clear liquid with a characteristic black cherry odor and flavor for oral ingestion. Each 5 mL of COS contains 667 mg calcium acetate equal to 169 mg of elemental calcium. Each subject will follow their usual prescription.COS will be taken either prior to or during meals and snacks.
89604608|NCT01427907|Active Comparator|Sevelamer Carbonate|Sevelamer carbonate is an anion exchange resin that binds phosphate in the gastrointestinal tract and is a buffered form of sevelamer hydrochloride developed for the treatment of hyperphosphatemia in End-Stage Renal Disease (ESRD) patients. Each film-coated tablet of sevelamer carbonate (trade name Renvela™) contains 800 mg of sevelamer carbonate on an anhydrous basis. Subjects will receive sevelamer tablets according to their prescription.
89604609|NCT02985333|Experimental|Intervention|paclitaxel 175 mg/m(2) IV over 3 h d1,cyclophosphamide 200 mg/m(2) IV d1,3,5 and dexamethasone 20mg IV d1-4 in patients with relapsed or refractory MM.
89604610|NCT01427751|Active Comparator|Ozurdex®|Injection of Ozurdex® (dexamethasone intravitreal implant) into the study eye on Day 1 and Month 5. Patients may receive up to one additional treatment, thereafter.
88981495|NCT03149237|No Intervention|Standard of Care|The 12 clinics randomized to the control arm will continue to provide standard of care (SOC) EMTCT services that include: standard HoPS male engagement (male invitation to ANC services and couples HIV testing), opt-out rapid HIV testing of all pregnant women attending ANC, HIV-specific counseling and support for all women who test positive, provision of cotrimoxazole prophylaxis, and universal ART, as per option B+ guidelines.
88981496|NCT03149237|Experimental|Couples-based Services|The 12 clinics randomly assigned to the intervention arm will receive a combination of community and clinical EMTCT services, including: (1) ANC-based couples HIV testing, couples-based treatment enrollment, and clinical care for sero-concordant HIV+ expectant couples; (2) couple-centered treatment in the post-partum period at the EID clinic; (3) couples-based education and skills building during the ANC and post-partum period; and (4) treatment continuity support by expert-patient (peer) navigators selected among couples who have successfully navigated EMTCT.
88981497|NCT03138070|Experimental|Arm 1|14 days of BYL719 treatment, open label
88981498|NCT03132467|Experimental|Treatment (tremelimumab, durvalumab)|Patients receive tremelimumab IV over 1 hour and durvalumab IV over 1 hour on day 1. Treatment repeats every 4 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo a biopsy and receive standard of care neoadjuvant chemotherapy before undergoing surgery.
88981499|NCT03127852|Experimental|Telemonitoring (Medly)|The telemonitoring technology will enable patients with complex chronic illnesses, to take clinically relevant physiological measurements with wireless home medical devices and to answer symptom questions on the mobile phone. The measurements will be automatically and wirelessly transmitted to the mobile phone and then to a data server. Automated self-care instructions/messages will be sent to the patient based on the readings and reported symptoms. If there are signs of their status deteriorating, an alert will be sent to a clinician that is responsible for the particular chronic condition of concern. The clinicians will have all the relevant patient data sent to them and will be able to access (through a secure web portal) to view historical and trending data for their patients.
89604611|NCT01427751|Active Comparator|Lucentis®|Injection of Lucentis® (ranibizumab) into the study eye on Day 1 and monthly for five months. Patients will receive additional treatment thereafter based on re-treatment criteria.
88981500|NCT03127852|No Intervention|Control|Standard of care: Patients are followed in a specialty care clinic treating their primary conditions. Patients typically have scheduled appointments every six months.
88981501|NCT03121586|Experimental|Drug - Pimavanserin|Pimavanserin 34 mg, 20 mg, or 10 mg, + background antipsychotic, taken once daily by mouth
89604612|NCT01920061|Experimental|Arm A|
89604613|NCT01920061|Experimental|Arm B|
89604614|NCT01920061|Experimental|Arm C|
89604615|NCT01920061|Experimental|Expansion Arm 1|
89604616|NCT01920061|Experimental|Expansion Arm 2|
89604617|NCT01426425|Experimental|Cryoablation|Subjects diagnosed with atrioventricular nodal reentrant tachycardia and treated by cryoablation with Freezor Xtra.
89604618|NCT02074995|Experimental|BVS857 Grp 1A open label|0.03 mg/kg of BVS857intravenously in open label manner
89604619|NCT02074995|Experimental|BVS857 Group 1B/1C, 2, 3, 4 Double Blind|
89604620|NCT02074995|Placebo Comparator|Placebo Group 1B/1C, 2, 3, 4|
89604621|NCT01426347|Placebo Comparator|placebo group|"RA Patients with vitamin D deficiency will be randomized to placebo and active intervention arms.~Patients in the placebo arm will receive I placebo pill per week for 16 weeks. After completing this arm, they will cross-over to the active treatment arm."
89604622|NCT01426347|Active Comparator|Ergocalciferol|Patients with vitamin D deficiency will be randomized to either active or placebo group. In the active group, patients will receive ergocalciferol 50,000 IU per week for 16 weeks.
89604623|NCT01882465|Other|etafilcon A/2-HEMA, EGDMA/hefilcon A|Subjects were randomized to one of six unique sequences. Subjects randomized to this sequence will wear the etafilcon A lens first, the 2-HEMA, EGDMA Non-ionic material lens second and the hefilcon A lens third. The lenses are to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
89604624|NCT01882465|Other|etafilcon A/hefilcon A/2-HEMA, EGDMA Non-ionic|Subjects were randomized to one of six unique sequences. Subjects randomized to this sequence will wear the etafilcon A lens first, the hefilcon A lens second and the 2-HEMA, EGDMA Non-ionic material lens third. The lenses are to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
89604625|NCT01882465|Other|2-HEMA, EGDMA Non-ionic/etafilcon A/hefilcon A|Subjects were randomized to one of six unique sequences. Subjects randomized to this sequence will wear the 2-HEMA, EGDMA Non-ionic material lens first, the etafilcon A lens second and the hefilcon A lens third. The lenses are to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
89604626|NCT01882465|Other|2-HEMA, EGDMA Non-ionic/hefilcon A/etafilcon A|Subjects were randomized to one of six unique sequences. Subjects randomized to this sequence will wear the 2-HEMA, EGDMA Non-ionic material lens first, the hefilcon A lens second and the etafilcon A lens third. The lenses are to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
89604627|NCT01882465|Other|hefilcon A/2-HEMA, EGDMA Non-ionic/etafilcon A|Subjects were randomized to one of six unique sequences. Subjects randomized to this sequence will wear the hefilcon A lens first, the 2-HEMA, EGDMA Non-ionic material lens second and the etafilcon A lens third. The lenses are to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
89604628|NCT01882465|Other|hefilcon A/etafilcon A /2-HEMA, EGDMA Non-ionic|Subjects were randomized to one of six unique sequences. Subjects randomized to this sequence will wear the hefilcon A lens first, the etafilcon A lens second and the 2-HEMA, EGDMA Non-ionic material lens third. The lenses are to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
89604629|NCT04612309||Treated|Patient with colorectal cancer already treated with immunotherapy
89604630|NCT04415983|Experimental|Nitazoxanide group|Clarithromycin, Nitazoxanide and Proton pump inhibitor
89604631|NCT04415983|Active Comparator|Traditional group|Clarithromycin, Metronidazole and Proton pump inhibitor
89604632|NCT01426269|Placebo Comparator|Placebo|Subjects will receive placebo during phase 2 (week 12 - week 52)
89604633|NCT01426269|Other|Doxycycline and Metronidazole|Subjects will receive Oracea® (oral doxycycline 40 mg USP (30 mg immediate release and 10 mg delayed release beads)) and MetroGel® 1% (topical metronidazole) during phase 1 (baseline to week 12)
89604634|NCT01426269|Active Comparator|Doxycycline|Subjects will receive Oracea® (oral doxycycline 40 mg USP (30 mg immediate release and 10 mg delayed release beads)) during phase 2 (week 12 - week 52)
88981502|NCT03107793|Experimental|All Participants|At Week (Wk) 0, all eligible participants will initiate intravenous (IV) induction treatment with ustekinumab (UST) on a weight-tiered basis at a dose of approximately 6 milligram per kilogram (mg/kg). At Week 8, all participants will receive a 90 milligram (mg) subcutaneous (SC) injection of ustekinumab. At Week 16, participants who do not achieve a Crohn's Disease Activity Index (CDAI) improvement of greater than or equal to (>=) 70 points versus Week 0 (CDAI 70) will leave the study. Remaining participants will be randomized in a 1:1 ratio to either one of two arms for open label maintenance treatment up to Week 48: the treat to target arm or the routine care arm. From Week 48, participants will continue ustekinumab treatment in the study extension period, up to Week 104. Dosing frequency will be adjusted in the extension period for the participants failing to meet the treatment target.
88981503|NCT03107793|Experimental|Routine Care Arm|In the routine care arm, assessment visits will be scheduled according to the timing of maintenance treatment injections up to Week 48, which will be in compliance with the EU SmPC for ustekinumab for the treatment of Crohn's disease, in which dosing every 12 weeks is recommended. At Week 16, (that is, 8 weeks after the first SC dose) participants continuing in the study will have demonstrated a CDAI-70 response. Nonetheless, participants who have not shown adequate response based on the investigator's judgment may receive a second SC dose at Week 16. During the routine care maintenance treatment period, in case of clinical worsening reported by the participant, consistent with disease flare in the investigator's judgment, clinical assessments of disease flare will be performed at the investigator's discretion.
89032479|NCT02935998|Experimental|ziprasidone|The injection mesylate ziprasidone used in this study have been marketed, manufactured by Pfizer and provided study drug for research purposes.Strength:Each vial contains Ziprasidone 30 mg, Sulfobutyl betadex sodium 441 mg. When reconstituted as directed the solution for injection contains the equivalent of 20 mg per mL of Ziprasidone.The initial dosage of ziprasidone injection：Most patients are suggested with 20mg i.m. Those with first-episode, lower age, emaciated body, or BARS score at 5 are suggest with 10mg i.m. Doses of 10 mg may be administered every two hours; doses of 20 mg may be administered every four hours up to a maximum of 40 mg/day.
89032480|NCT02930616|Experimental|group 1|Patients in Group 1 will receive probe-based confocal endomicroscopy (pCLE) at first and Wight light endoscopy (WLE) 2 months later
89604635|NCT01426113|Experimental|bimatoprost ophthalmic solution formulation A and vehicle|1 drop bimatoprost vehicle in the affected eye(s) in the morning and 1 drop of bimatoprost ophthalmic solution formulation A in the affected eye(s) in the evening for 6 weeks, followed by 1 drop bimatoprost ophthalmic solution formulation A in the affected eye(s) in the morning and 1 drop bimatoprost vehicle in the affected eye(s) in the evening for 6 additional weeks.
89604636|NCT01426113|Active Comparator|timolol ophthalmic solution|1 drop timolol ophthalmic solution in the affected eye(s) in the morning and evening for 12 weeks.
89604637|NCT01864603|Experimental|1st: universal test and treat; 2nd: targeted PrEP and cascade|"Intervention arm first phase: annual universal community-based HIV and multi-disease testing; ART for all HIV+ using streamlined care delivery~Intervention arm second phase: baseline universal community-based HIV and multi-disease testing; ART for all HIV+ using streamlined care delivery + targeted PrEP, and targeted HIV testing interventions"
88981504|NCT03107793|Experimental|Treat to Target (T2T) Arm|UST maintenance treatment assignment will be based on centrally-read colonoscopy (at Wk16). Participants with <25% improvement in SES-CD score at Wk16 will be assigned to Q8 (8-weekly) treatment and will receive UST 90mg SC at Wk16. In contrast, participants with >=25% improvement in SES-CD score at Wk16 will be assigned to Q12 treatment and will receive next UST dose (90 mg SC) at Wk20. At assessment visits (from Wk24 for participants assigned to the Q8 regimen or from Wk20 for the Q12 group) UST maintenance treatment (up to Wk 48) will be directed by T2T assessments. Participants meeting target will continue with same UST dosing frequency. The dosing frequency will be optimized for all participants failing to meet the target at assessment visit. Those previously on Q12 regimens will be adjusted to Q8 dosing; those previously on Q8 regimens will be adjusted to Q4 dosing. Participants subsequently failing to meet the target will not be able to adjust further and will leave the study.
88981505|NCT03107793|Experimental|Exploratory Extension period: From Week 48 to Week 104|At Week 48, dose de-escalation will be implemented for participants with both endoscopic remission (SES-CD score <=2) and corticosteroid-free clinical remission of at least 16 weeks duration. Participants receiving 12 weekly dosing frequency (Q12) ustekinumab will maintain this dosing frequency. Participants with either clinical remission or endoscopic remission, but not both, at Week 48 will continue with same dosing frequency or de-escalate provided maintenance of corticosteroid-free clinical remission and biomarker remission at 2 consecutive visits. Participants with neither corticosteroid-free clinical remission nor endoscopic remission will escalate dose or leave study if already on 4 weekly dosing frequency (Q4) dose. If neither clinical remission nor biomarker remission is evident at the next visit, participant will leave study. Later in the extension period, only those who achieve corticosteroid-free clinical remission and biomarker remission will undergo dose de-escalation.
88981506|NCT03097536|Experimental|Luna Bar Intervention|Participants will be asked to monitor their blood sugar during migraine. Study data will also include blood glucose levels, pain severity, 24-hour food diary, 24-hour exercise diary, duration of sleep, perception of quality of sleep, and last menstrual period. This information will be recorded at times when a Luna bar is not consumed, and at times when a Luna Bar is consumed. Participants will serve as their own controls.
88981507|NCT03097536|No Intervention|Morning Migraine|Participants will be asked to monitor their blood sugar on headache free days as well as during migraine. This arm is only for participants who identify as having morning migraine. Study data will also include blood glucose levels, pain severity, 24-hour food diary, 24-hour exercise diary, duration of sleep, perception of quality of sleep, and last menstrual period. Participants will serve as their own controls.
88981508|NCT03076697||Diabetic Eye Disease|Photographs will be taken with our smartphone-based camera along with the standard of care, including traditional desktop fundus photography. We will test the feasibility and accuracy of a smartphone-based camera for diagnosing diabetic retinopathy along with the stage of diabetic retinopathy. Several ophthalmology specialists will grade the smartphone fundus photographs, the traditional retinal photographs, and the documented eye examination. We will assess the agreement between the graders for the diagnosis of eye disease. We will also assess the sensitivity and specificity of diabetic retinopathy diagnoses with the smartphone, using traditional retinal imaging as the reference standard and in a separate analysis using the ophthalmologist's examination as the reference standard.
89032481|NCT02930616|Active Comparator|goup 2|patients in Group 2 will receive WLE at first and pCLE 2 months later.
89032482|NCT02930304|Experimental|first physiotherapy|cold pack, TENS, exercise
89032483|NCT02930304|Experimental|second physiotherapy|cold pack, TENS, exercise, kinesiotaping
89032484|NCT02930304|Experimental|third physiotherapy|cold pack, TENS, ESWT, exercise
89604638|NCT01864603|Active Comparator|1st: baseline community testing; 2nd: None|Comparator arm first phase: baseline community-based HIV and multi-disease testing; ART by country standard of care
89604639|NCT01892293|Experimental|Autologous genetically modified T cells|Patients with a confirmed diagnosis of myeloma, with measurable disease, and who have received prior therapy for their myeloma that includes an IMiDs and a proteasome inhibitor and who have relapsed or progressive disease, will receive treatment with NY-ESO-1c259-modified T cells. An intended total dose of ≥0.1-1e10 total cells will be administered as a single infusion. A low dose infusion of 1e8 to < 1e9 will be allowed for patients if cells do not expand sufficiently to reach the target dose range.
89604640|NCT01393899|Placebo Comparator|Placebo BID|
89604641|NCT01393899|Experimental|5mg BID|
89604642|NCT01393899|Experimental|10mg BID|
89604643|NCT01393743|Experimental|Perampanel|Participants received 6 tablets (initially 1 tablet of 2-mg perampanel plus 5 tablets of perampanel matched placebo) and up-titrated weekly in 2-mg increments to a target dose range of 8 mg per day maintaining the blind with administration of 6 tablets per day of either perampanel/placebo.
89604644|NCT01393743|Placebo Comparator|Placebo|Participants received 6 tablets of perampanel matched placebo, once a day.
89604645|NCT02078193|Experimental|Belatacept|Participants will be converted from their current MMF to once a month infusions of Belatacept
89604646|NCT01405911|Placebo Comparator|Placebo|Participants will take one tablet of placebo for sitagliptin 25 mg and one tablet of placebo for sitagliptin 50 mg orally once daily for 8 weeks.
89604647|NCT01405911|Experimental|Sitagliptin 25 mg|Participants will take one tablet of sitagliptin 25 mg and one tablet of placebo for sitagliptin 50 mg orally once daily for 8 weeks.
89604648|NCT01405911|Experimental|Sitagliptin 50 mg|Participants will take one tablet of sitagliptin 50 mg and one tablet of placebo for sitagliptin 25 mg orally once daily for 8 weeks.
89604649|NCT01425801|Experimental|LAS100977 0.625 μg|Single-dose LAS100977 0.625 μg, during double-blind treatment period
89604650|NCT01425801|Experimental|LAS100977 1.25 μg|Single-dose LAS100977 1.25 μg, during double-blind treatment period
89604651|NCT01425801|Experimental|LAS100977 2.5 μg|Single-dose LAS100977 2.5 μg, during double-blind treatment period
89604652|NCT01425801|Active Comparator|Salbutamol|Single-dose salbutamol 400 μg, during double-blind treatment period
88981509|NCT03076697||Glaucoma|Photographs will be taken with our smartphone-based camera along with the standard of care, including traditional desktop fundus photography. We will test the feasibility and accuracy of a smartphone-based camera for diagnosing glaucoma. Several ophthalmology specialists will grade the smartphone fundus photographs, the traditional optic disc photographs, and the documented eye examination. We will assess the agreement between the graders for the diagnosis of glaucoma. We will also assess the sensitivity and specificity of glaucoma diagnoses with the smartphone, using traditional retinal imaging as the reference standard and in a separate analysis using the ophthalmologist's examination as the reference standard.
88981510|NCT03076697||Age related macular degeneration (AMD)|Photographs will be taken with our smartphone-based camera along with the standard of care, including traditional desktop fundus photography. We will test the feasibility and accuracy of a smartphone-based camera for diagnosing age-related macular degeneration along with the stage. Several ophthalmology specialists will grade the smartphone fundus photographs, the traditional retinal photographs, and the documented eye examination. We will assess the agreement between the graders for the diagnosis of eye disease. We will also assess the sensitivity and specificity of age-related macular degeneration diagnoses with the smartphone, using traditional retinal imaging as the reference standard and in a separate analysis using the ophthalmologist's examination as the reference standard.
88981511|NCT03076697||Retinopathy of Prematurity (ROP)|Photographs will be taken with our smartphone-based camera along with the standard of care, including Retcam photography or traditional desktop fundus photography. We will test the feasibility and accuracy of a smartphone-based camera for diagnosing ROP. Several ophthalmology specialists will grade the smartphone fundus photographs, the traditional retinal photographs, and the documented eye examination. We will assess the agreement between the graders for the diagnosis of eye disease. We will also assess the sensitivity and specificity of ROP diagnosis with the smartphone, using traditional retinal imaging as the reference standard and in a separate analysis using the ophthalmologist's examination as the reference standard.
88981512|NCT03066336|Experimental|Erchonia LunulaLaser|The Erchonia LunulaLaser emits both red light (635 nm) and blue light (405 nm) to the affected toenail for 12 minutes per treatment for 4 treatments, each treatment one week apart.
88981513|NCT03064958|Active Comparator|Control|Consumption of a high fat meal (1000kcal, 45g fat)
88981514|NCT03064958|Experimental|Spice 2g|Consumption of a high fat meal (1000kcal, 45g fat) with 2g of spice (mix of black pepper, basil, bay leaf, cinnamon, coriander, cumin, ginger, oregano, parsley, rosemary, red pepper, turmeric and thyme) incorporated into the meal.
88981515|NCT03064958|Experimental|Spice 6g|Consumption of a high fat meal (1000kcal, 45g fat) with 6g of spice (mix of black pepper, basil, bay leaf, cinnamon, coriander, cumin, ginger, oregano, parsley, rosemary, red pepper, turmeric and thyme) incorporated into the meal.
88981516|NCT03064932|Active Comparator|SD-Low|"Average American Diet (32% of calories from fat, 11% of calories from saturated fat and 3400mg sodium/day) with a minimal amount of spices (<1g/day for all diets).~Post prandial test meal will be contain minimal amounts of spice."
88981517|NCT03064932|Experimental|SD-Mod|"Average American Diet (32% of calories from fat, 11% of calories from saturated fat and 3400mg sodium/day) with a moderate amount of spices (~3g/day in the 2100kcal diet).~Post prandial test meal will be contain a moderate amount of spice."
88981518|NCT03064932|Experimental|SD-Culinary|"Average American Diet (32% of calories from fat, 11% of calories from saturated fat and 3400mg sodium/day) with a culinary dose of spices (6g/day in the 2100kcal diet).~Post prandial test meal will be contain a culinary amount of spice."
88981519|NCT03056638|Experimental|Degarelix in conjunction with stereotactic body radiosurgery|Degarelix monthly for 6 months SBRT 8 Gy x 5
89604653|NCT01425801|Placebo Comparator|Placebo|Placebo to LAS100977, and placebo to salbutamol
89604654|NCT01425801|Experimental|LAS100977 0.313 μg|Single-dose LAS100977 0.313 μg, during double-blind treatment period
89604655|NCT03025503|Experimental|nipple stimulation|
89604656|NCT03025503|No Intervention|no intervention|
89604657|NCT02335125|Experimental|Intervention|The intervention aims to prevent the development of chronic PTSD and depressive symptoms, alcohol use problems, and enduring physical disability in survivors of both TBI and non-TBI injuries. The intervention utilizes a computerized decision support tool to flexibly target these multiple conditions including and includes care management, medication, and psychotherapy elements.
89604658|NCT02335125|No Intervention|Usual Care|Only standard care practices will be administered to this arm.
89604659|NCT01425723|Experimental|On-Demand|The individual dose of rFIXFc to treat bleeding episodes will be based on participant's clinical condition, type and severity of the bleeding event, and if indicated, Factor IX peak (recovery) levels.
89604660|NCT01425723|Experimental|Prophylaxis|Weekly prophylaxis, individualized prophylaxis or personalized prophylaxis available.
89604661|NCT02076243|Experimental|nab-paclitaxel|weekly dosed nab-paclitaxel chemotherapy (days 1, 8 , 15 of a 28 day cycle) administered as an I.V. infusion over approximately 30 minutes. Dosage is determined by weight and height of participant.
89604662|NCT01424397|Experimental|SB-705498|Experimental
89604663|NCT01424397|Active Comparator|Fluticasone Propionate|Active Comparator
89604664|NCT01424397|Placebo Comparator|Placebo|Placebo Comparator
89604665|NCT01424397|Experimental|SB-705498+FP|Experimental
89604666|NCT01392963|Experimental|Botox, Then Placebo|At baseline visit (week 0) participants received an injection of clostridium botulinum toxin type A neurotoxin complex (Allergan; total injection of 29-40 U) in the glabella region according to standard protocols of cosmetic botulinum toxin applications. After a 3 month evaluation period, participants received a placebo injection (matching botulinum toxin) to glabella region at study visit 4 (week 12).
89604667|NCT01392963|Experimental|Placebo, Then Botox|At baseline visit (week 0) participants received a placebo injection (matching botulinum toxin) to glabella region. After a 3 month evaluation period, participants received an injection of clostridium botulinum toxin type A neurotoxin complex (Allergan; total injection of 29-40 U) in the glabella region according to standard protocols of cosmetic botulinum toxin applications at study visit 4 (week 12).
88981520|NCT03056638|Experimental|stereotactic body radiosurgery (SBRT)|SBRT 8 Gy x 5
89604668|NCT01392573|Experimental|IDegLira + metformin|IDegLira was injected subcutaneously once daily for 26 weeks.
89604669|NCT01392573|Experimental|IDeg + metformin|IDeg was injected subcutaneously once daily for 26 weeks.
89604670|NCT01392495|Experimental|QTI571|Participants received 200 mg or 400 mg every day (qd) based on their highest tolerated dose in CQTI571A2102 (NCT01392469).
89604671|NCT01405053|Active Comparator|Rufinamide|
89604672|NCT01405053|Active Comparator|Any other approved AED|
89604673|NCT01403805|Experimental|Oral care and vaccines|Oral care and pneumococcal plus influenza vaccines
89604674|NCT01403805|Active Comparator|Vaccine|Influenza vaccine only
89604675|NCT01423617|Active Comparator|Zenoctil|
89604676|NCT01423617|Placebo Comparator|Placebo|
89604677|NCT01392183|Experimental|Pazopanib|Pazopanib 800 mg by mouth daily. Quality of Life Assessment - Completion of full assessment battery at baseline, prior to treatment then every 8 weeks at clinical evaluation.
89604678|NCT01392183|Experimental|Temsirolimus|Temsirolimus 25 mg by vein infused over 30-60 minutes weekly. Benadryl 25 to 50 mg by vein approximately 30 minutes before the start of each dose of temsirolimus. Quality of Life Assessment - Completion of full assessment battery at baseline, prior to treatment then every 8 weeks at clinical evaluation.
89604679|NCT02985489|Experimental|Experimental Group|Participants assigned to the experimental group will commence Olimel Parenteral Nutrition therapy delivered through central venous catheter (CVC) access within 24-48 hours of admission.
89604680|NCT02985489|No Intervention|Control Group|Participants assigned to the control group will receive standard of care (SOC) nutritional therapy. Control group patients will be assessed by the RD assigned to the medical unit to which the patient has been admitted (independent RD assessment). The unit RD will follow standard nutrition screening processes to determine nutrition risk, followed by a complete nutrition assessment in the presence of nutrition risk.
89604681|NCT01402947|Experimental|Ciprofloxacin + MMX placebo|
89604682|NCT01402947|Experimental|MMX Mesalazine/mesalamine + Ciprofloxacin|
89604683|NCT03025893|Experimental|Sunitinib|Patients in this experimental arm will receive sunitinib in a high-dose, intermittent schedule.
88981521|NCT03054779|Experimental|Canola oil|regular canola oil
88981522|NCT03054779|Experimental|High oleic acid canola oil|high stability/high oleic canola oil
88981523|NCT03054779|Active Comparator|Western diet oil combination|"a typical Western diet fat intake comprised of 11% MUFA, 11% PUFA (9% omega-6 fatty acids and 2% omega-3 fatty acids), and 13% SFA"
88981524|NCT03044210|Other|Cockayne patients|"Interventions performed:~blood sample~urinary collection~metabolic evaluation~clinical evaluation"
88981525|NCT03044210|Other|Control subjects|"Interventions performed:~urinary collection~metabolic evaluation~clinical evaluation"
88981526|NCT03033043|Experimental|Experimental: Relay Pro|The Relay Pro arm includes subjects who receive the device. The Relay Pro Stent Graft System is administered to treat complicated Type B aortic dissections.
88981527|NCT03032744|Experimental|Intervention|All participants will undergo an initial asthma assessment per the NAEPP-EPR3 (National Asthma Education and Prevention Program - Expert Panel Report 3) guidelines, as well as asthma education. Participants randomized to the intervention group will be prescribed the appropriate asthma therapy based on their assessment (i.e. providing 'asthma assessment & management'), and receive the morning dose of their daily asthma controller medication at school on school days.
89032485|NCT02930109|Experimental|PTX-200 and cytarabine|"PTX-200 administered intravenously over 1 hour~Phase I: 4 dose levels: 25 to 55 mg/m2 (with reduction to 15 mg/m2 if needed.~Phase II: maximum tolerated dose. given as a 1 hour infusion~Cytarabine administered by continuous infusion at a dose of 400 mg/m2/day for 4 days."
89604684|NCT03025893|Active Comparator|Lomustine|Patients in this control arm will receive lomustine, currently used as second-line treatment in the case of recurrence.
89604685|NCT01402869|Experimental|Prilocaine|30 subjects will receive 5mg/kg of 4% prilocaine plain local anesthetic for restorative dental treatment under general anesthesia
89604686|NCT01402869|Experimental|Lidocaine|30 subjects will receive 2.5mg/kg of 2% lidocaine with 1:100,000 epinephrine local anesthetic for restorative dental treatment under general anesthesia
89604687|NCT01402869|No Intervention|No local anesthetic|30 subjects will not receive local anesthetic for dental treatment under general anesthesia-Negative control
89604688|NCT01391793|Active Comparator|Adjuvant dexamethasone|
89604689|NCT01391793|Placebo Comparator|Placebo|
89604690|NCT01422915|Experimental|colestipol treatment|2 grams morning and bedtime for 180 days
89604691|NCT04037943|Experimental|Low-dose group|Low-dose group will received 30 grams of walnuts everyday during the study period of 6 months.
89604692|NCT04037943|Experimental|High-dose group|High-dose group will received 60 grams of walnuts everyday during the study period of 6 months.
89604693|NCT04037943|No Intervention|Control group|Control group will received non-edible gifts during the study period of 6 months.
89604694|NCT01727024|Experimental|Indacaterol (QAB149) Breezhaler®|In period 1, participants received Indacaterol 150 mcg once daily via Breezhaler® device for 7 days, followed by a 7-day washout. In period 2, participants received Tiotropium 2.5 mcg, in 2 consecutive puffs, once daily via Respimat® device for 7 days.
89604695|NCT01727024|Active Comparator|Tiotropium Respimat®|In period 1, participants received Tiotropium 2.5 mcg, in 2 consecutive puffs, once daily via Respimat® device for 7 days, followed by a 7-day washout. In period 2, participants received Indacaterol 150 mcg once daily via Breezhaler® device for 7 days.
89604696|NCT01422213|Placebo Comparator|Placebo|
89604697|NCT01422213|Experimental|Vortioxetine 10 mg|
89604698|NCT01422213|Experimental|Vortioxetine 20 mg|
89604699|NCT01390857||Pediatric patients prescribed valaciclovir|Pediatric patients with chickenpox prescribed valaciclovir during study period.
89210371|NCT00627926|Experimental|Telaprevir 12 Week+Peg-IFN-alfa-2a, RBV 24/48 Week|Telaprevir 750 mg tablet thrice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 24 to 48 weeks depending on individual response to telaprevir treatment.
89210372|NCT03973021|Experimental|VSEL Max|Each treatment: 120,000 VSELs each time, suspending with 20 mL platelet-rich plasma(PRP), transfusion for 3 times with a interval of 1 month, intracavernous injection
89210373|NCT03973021|Experimental|VSEL Medium|Each treatment: 90,000 VSELs each time, suspending with 20 mL platelet-rich plasma(PRP), transfusion for 3 times with a interval of 1 month, intracavernous injection
89604700|NCT01725386||Monotherapy|Capecitabine as monotherapy according to prescribing information and normal clinical practice.
89604701|NCT01725386||Combination Therapy|Capecitabine as part of combination therapy according to prescribing information and normal clinical practice.
89604702|NCT01402011|Experimental|25% dextrose in shoulder entheses|25% dextrose and .1% lidocaine injected in the shoulder entheses (ligament and tendon insertions on the periosteum).
89604703|NCT01402011|Active Comparator|.1% lidocaine in shoulder entheses|.1% lidocaine injected in the shoulder entheses (ligament and tendon insertions on the periosteum).
89604704|NCT01402011|Placebo Comparator|.1% lidocaine subcu. above shouldr enth.|.1% lidocaine injected subcutaneously above the shoulder entheses (ligament and tendon insertions on the periosteum).
89604705|NCT01421667|Experimental|Brentuximab vedotin+rituximab|
88981528|NCT03032744|Active Comparator|Usual Care|All participants will undergo an initial asthma assessment per the NAEPP-EPR3 (National Asthma Education and Prevention Program - Expert Panel Report 3) guidelines, as well as asthma education. Participants randomized to the usual care group will be provided with the results of their asthma assessment and be instructed to follow up with their primary care provider. They will continue to receive all of their daily asthma controller medication at home.
88981529|NCT03020758|Experimental|Dried Fruit|Daily consumption of ¾ cup blend of dried plums, figs, dates and raisins (DPFDR) for 4 weeks
88981530|NCT03020758|Experimental|Control|Daily consumption of isocaloric and macronutrient matched snack food for 4 weeks
89604706|NCT01421667|Experimental|Brentuximab vedotin|
89604707|NCT01390779|Experimental|SENSIMED Triggerfish|All subjects enrolled in the trial were housed in a sleep laboratory for 24 hours, during which they underwent SENSIMED Triggerfish recording on one randomly selected eye.
89604708|NCT01891669|Experimental|Part 1|
89604709|NCT01421511|Experimental|TR-701 FA|• TR-701 FA IV followed by TR-701 FA tablets
89604710|NCT01421511|Active Comparator|Linezolid|• Linezolid IV followed by Linezolid Tablets
89604711|NCT01864525|Placebo Comparator|Inactive capsule|Participants will receive a pill/capsule with an inactive ingredient during the placebo arm of this study.
89604712|NCT01864525|Experimental|Octanoic acid|Participants will receive a pill/capsule with octanoic acid (amount determined by the participant's weight) during the experimental arm of this study.
89604713|NCT01421277||Participants Enrolled in Protocol Version (V)1.1|Participants with physician-diagnosed migraine with or without aura who are treatment-naive to triptans, who received their first prescription for a triptan and took at least one dose within 6 months prior to being included in Protocol V1.1 of this study.
89604714|NCT01421277||Participants Enrolled in Protocol V2|Participants with physician-diagnosed migraine with or without aura who are treatment-naive to triptans, who received their first prescription for a triptan and took at least one dose within 6 months prior to being included in Protocol V2 of this study.
89604715|NCT01891357|Experimental|Paclitaxel + Lapatinib + Trastuzumab|Paclitaxel 80 mg/m2 weekly for 12 weeks with lapatinib 750 mg P.O. daily and trastuzumab 2 mg/kg IV (loading dose 4 mg/kg) weekly for 12 weeks, biopsy before and after three weeks of study treatment
88981531|NCT03013543|Experimental|16p11.2 Cohort|Participants with chromosomal rearrangement of the p11.2 region of chromosome 16 (16p11.2) locus causing obesity received setmelanotide once daily (QD) via subcutaneous (SC) injection for 16 weeks. All participants initiated treatment with setmelanotide (starting dose being age dependent) and the dose was escalated up to a maximum dose of 3.0 mg QD. Participants either continued setmelanotide treatment by enrolling in an extension study (RM-493-022; NCT03651765) immediately following the last dose in this study or if the extension study was not open at the current clinic site, participants continued treatment in the current study for up to 1 year, resulting in treatment duration of up to 16 months.
89032486|NCT00524186|Experimental|Oral Sunitinib|Patients receive oral sunitinib malate on day -7 and then once daily on days 2-28 in course 1 and on days 1-28 in all subsequent courses
89032487|NCT04442178|Experimental|CYT107 Treatment|Intramuscular (IM) administration of CYT107 twice a week for 3 weeks
89032488|NCT04442178|Placebo Comparator|Placebo|Intramuscular (IM) administration of Saline twice a week for 3 weeks
89210374|NCT03973021|Experimental|VSEL Mini|Each treatment: 60,000 VSELs each time, suspending with 20 mL platelet-rich plasma(PRP), transfusion for 3 times with a interval of 1 month, intracavernous injection
89210375|NCT03973021|No Intervention|Control|In this group, the patients will receive 20 mL platelet-rich plasma(PRP) treatment and as a control group.
89210376|NCT05711589|Placebo Comparator|conventional group|cryoablation (CBA) was performed under fluoroscopic guidance
89210377|NCT05711589|Experimental|Zero-X group|CBA was performed under intracardiac echocardiography guidance without fluoroscopy
88981532|NCT03013543|Experimental|AS Cohort|Participants with Alström syndrome (AS) received setmelanotide QD via SC injection for 16 weeks. All participants initiated treatment with setmelanotide (starting dose being age dependent) and the dose was escalated up to a maximum dose of 3.0 mg QD. Participants either continued setmelanotide treatment by enrolling in an extension study (RM-493-022; NCT03651765) immediately following the last dose in this study or if the extension study was not open at the current clinic site, participants continued treatment in the current study for up to 1 year, resulting in treatment duration of up to 16 months.
88981533|NCT03013543|Experimental|BBS Cohort|Participants with Bardet-Biedl syndrome (BBS) received setmelanotide QD via SC injection for 16 weeks. All participants initiated treatment with setmelanotide (starting dose being age dependent) and the dose was escalated up to a maximum dose of 3.0 mg QD. Participants either continued setmelanotide treatment by enrolling in an extension study (RM-493-022; NCT03651765) immediately following the last dose in this study or if the extension study was not open at the current clinic site, participants continued treatment in the current study for up to 1 year, resulting in treatment duration of up to 16 months.
89604716|NCT01420965|Active Comparator|Arm A|Sipuleucel-T autologous active cellular immunotherapy only for 3 cycles (cycle = 14 days)
88981534|NCT03013543|Experimental|MC4R Cohort|Participants with melanocortin-4 receptor (MC4R) deficiency obesity received setmelanotide QD via SC injection for 16 weeks. All participants initiated treatment with setmelanotide (starting dose being age dependent) and the dose was escalated up to a maximum dose of 3.0 mg QD. Participants either continued setmelanotide treatment by enrolling in an extension study (RM-493-022; NCT03651765) immediately following the last dose in this study or if the extension study was not open at the current clinic site, participants continued treatment in the current study for up to 1 year, resulting in treatment duration of up to 16 months.
88981535|NCT03013543|Experimental|POMC/PCSK1/LEPR Heterozygous Cohort|Participants with pro-opiomelanocortin (POMC)/proprotein convertase subtilisin/kexin type 1 (PCSK1)/leptin receptor (LEPR) heterozygous mutations received setmelanotide QD via SC injection for 16 weeks. All participants initiated treatment with setmelanotide (starting dose being age dependent) and the dose was escalated up to a maximum dose of 3.0 mg QD. Participants either continued setmelanotide treatment by enrolling in an extension study (RM-493-022; NCT03651765) immediately following the last dose in this study or if the extension study was not open at the current clinic site, participants continued treatment in the current study for up to 1 year, resulting in treatment duration of up to 16 months.
89604717|NCT01420965|Experimental|Arm B|Sipuleucel-T for 3 cycles (cycle = 14 days) + CT-011 (3mg/kg) IV infusion delivered over approximately 2 hours, 2 days after each Sipuleucel-T infusion
89604718|NCT01420965|Experimental|Arm C|Sipuleucel-T for 3 cycles (cycle = 14 days)+ cyclophosphamide (125 or 250mg/m2) IV [first cycle only] + CT-011 (3mg/kg) IV infusion delivered over approximately 2 hours, 2 days after each Sipuleucel-T infusion
89604719|NCT04033575|Sham Comparator|Fluoride Control|Colgate Cavity Protection 0.76% as Na MFP Toothpaste
89604720|NCT04033575|Active Comparator|Colgate Total SF|Colgate Total Clean Mint White Paste 1100 ppm F Toothpaste
89604721|NCT04767087|Active Comparator|Honey and Nigella sativa Arm|0.5 g/kg/day honey 40 mg/Kg/day Nigella sativa seeds
89604722|NCT04767087|Placebo Comparator|Placebo Arm|empty capsule with sugar water
89604723|NCT01390389|Experimental|CoQ10|"Subjects who meet DSM-IV diagnostic criteria for Bipolar Disorder, Current Episode Depressed are assigned to this arm and administered the Coenzyme Q10 intervention. CoQ10 dosing guidelines:~Visit 1 (Baseline) start at 400mg once a day for two weeks~Visit 2 (within 7 days of Baseline visit) increase to 800 mg once a day for two weeks~The dosage of CoQ10 can be titrated in a more gradual manner depending on clinical response and tolerability of the medication, but cannot be titrated any more rapidly than the schedule above."
89604724|NCT01390389|No Intervention|Control|Subjects without a known psychiatric disorder and/or unstable medical illness are assigned to the control group. The control subjects are not given CoQ10.
89604725|NCT03835533|Experimental|Cohort A: NKTR-214 + Nivolumab|
89604726|NCT03835533|Experimental|Cohort B: SBRT + CDX-301 + Poly-ICLC + Nivolumab|
89604727|NCT03835533|Experimental|Cohort C: CDX-301 + INO-5151 + Nivolumab|
89604728|NCT03025347|Experimental|Control|Experimental day where participants rest.
88981536|NCT03013543|Experimental|POMC/PCSK1/LEPR Composite Heterozygous Cohort|Participants with POMC/PCSK1/LEPR composite heterozygous mutations received setmelanotide QD via SC injection for 16 weeks. All participants initiated treatment with setmelanotide (starting dose being age dependent) and the dose was escalated up to a maximum dose of 3.0 mg QD. Participants either continued setmelanotide treatment by enrolling in an extension study (RM-493-022; NCT03651765) immediately following the last dose in this study or if the extension study was not open at the current clinic site, participants continued treatment in the current study for up to 1 year, resulting in treatment duration of up to 16 months.
89604729|NCT03025347|Experimental|Exercise|Experimental day where participants complete a run.
89604730|NCT01401465|Experimental|Ciclesonide Nasal Aerosol|74 mcg ciclesonide nasal aerosol once daily
89604731|NCT01401465|Active Comparator|Mometasone Nasal Spray|200 mcg mometasone aqueous nasal spray once daily
89604732|NCT01401153|Experimental|Having lunch/skipping lunch|Lunch ad libitum on test day 1 and no lunch on test day 2. Water available on both days.
89604733|NCT01401153|Experimental|Skipping lunch/having lunch|No lunch on test day 1 and lunch ad libitum on test day 2. Water available on both days.
89604734|NCT01890967|Experimental|20 mg LY3015014 Q4W|"20 milligrams (mg) LY3015014 given subcutaneously (SC) once every 4 weeks (Q4W) for 16 weeks.~Participants will remain on stable diet and physician-prescribed statin therapy, if tolerated, with or without ezetimibe."
89604735|NCT01890967|Experimental|120 mg LY3015014 Q4W|"120 mg LY3015014 given SC Q4W for 16 weeks.~Participants will remain on stable diet and physician-prescribed statin therapy, if tolerated, with or without ezetimibe."
89604736|NCT01890967|Experimental|300 mg LY3015014 Q4W|"300 mg LY3015014 given SC Q4W for 16 weeks.~Participants will remain on stable diet and physician-prescribed statin therapy, if tolerated, with or without ezetimibe."
89604737|NCT01890967|Experimental|100 mg LY3015014 Q8W|"100 mg LY3015014 given SC once every 8 weeks (Q8W) for 16 weeks.~Participants will remain on stable diet and physician-prescribed statin therapy, if tolerated, with or without ezetimibe."
89604738|NCT01890967|Experimental|300 mg LY3015014 Q8W|"300 mg LY3015014 given SC Q8W for 16 weeks.~Participants will remain on stable diet and physician-prescribed statin therapy, if tolerated, with or without ezetimibe."
88981537|NCT03013543|Experimental|POMC/PCSK1/LEPR Compound Heterozygous Cohort|Participants with POMC/PCSK1/LEPR compound heterozygous mutations received setmelanotide QD via SC injection for 16 weeks. All participants initiated treatment with setmelanotide (starting dose being age dependent) and the dose was escalated up to a maximum dose of 3.0 mg QD. Participants either continued setmelanotide treatment by enrolling in an extension study (RM-493-022; NCT03651765) immediately following the last dose in this study or if the extension study was not open at the current clinic site, participants continued treatment in the current study for up to 1 year, resulting in treatment duration of up to 16 months.
88981538|NCT03013543|Experimental|SH2B1 Cohort|Participants with steroid receptor coactivator (SRC) homology 2B adapter protein 1 (SH2B1) haploinsufficiency received setmelanotide QD via SC injection for 16 weeks. All participants initiated treatment with setmelanotide (starting dose being age dependent) and the dose was escalated up to a maximum dose of 3.0 mg QD. Participants either continued setmelanotide treatment by enrolling in an extension study (RM-493-022; NCT03651765) immediately following the last dose in this study or if the extension study was not open at the current clinic site, participants continued treatment in the current study for up to 1 year, resulting in treatment duration of up to 16 months.
88981539|NCT03013543|Experimental|SMS Cohort|Participants with Smith-Magenis Syndrome (SMS) received setmelanotide QD via SC injection for 16 weeks. All participants initiated treatment with setmelanotide (starting dose being age dependent) and the dose was escalated up to a maximum dose of 3.0 mg QD. Participants either continued setmelanotide treatment by enrolling in an extension study (RM-493-022; NCT03651765) immediately following the last dose in this study or if the extension study was not open at the current clinic site, participants continued treatment in the current study for up to 1 year, resulting in treatment duration of up to 16 months.
88981540|NCT03013543|Experimental|SRC1 Cohort|Participants with steroid receptor coactivator 1 (SRC1) mutations received setmelanotide QD via SC injection for 16 weeks. All participants initiated treatment with setmelanotide (starting dose being age dependent) and the dose was escalated up to a maximum dose of 3.0 mg QD. Participants either continued setmelanotide treatment by enrolling in an extension study (RM-493-022; NCT03651765) immediately following the last dose in this study or if the extension study was not open at the current clinic site, participants continued treatment in the current study for up to 1 year, resulting in treatment duration of up to 16 months.
88981541|NCT02978690|Experimental|Spesolimab|
89604739|NCT01890967|Placebo Comparator|Placebo Q4W|"Placebo given SC Q4W for 16 weeks.~Participants will remain on stable diet and physician-prescribed statin therapy, if tolerated, with or without ezetimibe."
89604740|NCT01400919|Experimental|Protégé™ EverFlex™ and GPS™ Self-Expanding Stent Systems|The objective of the study is to confirm the safety and effectiveness of the Protégé EverFlex and Protégé GPS Self-Expanding Stent Systems in the treatment of stenotic, restenotic or occluded lesions in the common and external iliac artery.
89604741|NCT01864291|Experimental|Non-NF2 ABI surgery|All subjects will be part of a single arm involving placement of the ABI541 Auditory Brainstem Implant (ABI) device. The Nucleus 24 was discontinued and is no longer available.
89604742|NCT01400841|Experimental|HAART 300 Annuloplasty Device|Implantation of HAART 300 Annuloplasty Device for aortic valve repair
89604743|NCT01863667|Experimental|Omarigliptin|Participants receive an omarigliptin (MK-3102) 25 mg capsule once weekly and glimepiride placebo tablet(s) once daily, for 54 weeks.
89604744|NCT01863667|Active Comparator|Glimepiride|Participants receive glimepiride 1 mg and/or 2 mg tablet(s) (maximum dose 6 mg/day) once daily and an omarigliptin placebo capsule once weekly, for 54 weeks.
89604745|NCT01614769|Experimental|Placebo → Glimepiride 2 mg → Glimepiride 4 mg|Participants received placebo in the first period, 2 mg glimepiride in the second period and 4 mg glimepiride in the third period, with a 7-day washout between each period.
89604746|NCT01614769|Experimental|Glimepiride 2 mg → Glimepiride 4 mg → Placebo|Participants received 2 mg glimepiride in the first period, 4 mg glimepiride in the second period and placebo in the third period, with a 7-day washout between each period.
89604747|NCT01614769|Experimental|Glimepiride 4 mg → Placebo → Glimepiride 2 mg|Participants received 4 mg glimepiride in the first period, placebo in the second period and 2 mg glimepiride in the third period, with a 7-day washout between each period.
89604748|NCT01614769|Experimental|Placebo → Glimepiride 4 mg → Glimepiride 2 mg|Participants received placebo in the first period, 4 mg glimepiride in the second period and 2 mg glimepiride in the third period, with a 7-day washout between each period.
89604749|NCT01614769|Experimental|Glimepiride 2 mg → Placebo → Glimepiride 4 mg|Participants received 2 mg glimepiride in the first period, placebo in the second period and 4 mg glimepiride in the third period, with a 7-day washout between each period.
89604750|NCT01614769|Experimental|Glimepiride 4 mg → Glimepiride 2 mg → Placebo|Participants received 4 mg glimepiride in the first period, 2 mg glimepiride in the second period and placebo in the third period, with a 7-day washout between each period.
89604751|NCT01614457|Experimental|Ivacaftor|Ivacaftor 150 milligram (mg) tablet orally twice daily for 24 weeks.
89604752|NCT01614457|Placebo Comparator|Placebo|Placebo matched to Ivacaftor tablet orally twice daily for 24 weeks.
89604753|NCT01863433|Experimental|Trivalent Influenza Vaccine|The study vaccine is a sterile, thiomersal-free suspension containing 45 mcg total haemagglutinin antigen per 0.5 mL dose (15 mcg each of the three recommended influenza strains for the Northern Hemisphere 2013/2014 influenza season). The vaccine will be administered by intramuscular or deep subcutaneous injection.
89604754|NCT01862029|Experimental|Roflumilast|
88981542|NCT02977793||Non-pathologic young adults|18-28 years old
88981543|NCT02977793||Non-pathologic adults|29-80 years old
88981544|NCT02977793||Pathologic adults|29-80 years old
89604755|NCT01835431|Experimental|Insulin degludec/insulin aspart|
89604756|NCT01835431|Active Comparator|Insulin detemir|
89604757|NCT01880593|Experimental|Ketamine and Lithium|Subjects in this arm take 600-1200mg of Lithium pills at night for duration of the study
89604758|NCT01880593|Placebo Comparator|Ketamine and Placebo|Subjects in this arm take placebo pills at night for duration of the study.
89604759|NCT01400451|Experimental|Ipilimumab + Vemurafenib|
88981545|NCT02959619|Experimental|Ensartinib|Escalating dose of ensartinib was orally given once er day
88981546|NCT02933554|Experimental|NASH- Left gastric artery embolization|Embospheres Microspheres as artificial embolic agent for left gastric artery embolization
89604760|NCT01400139|Experimental|Hydrocodone bitartrate|Hydrocodone bitartrate (HYD) once daily (q24h) tablets
89604761|NCT01399905|Experimental|High carbidopa followed by low carbidopa|450 mg of carbidopa per day for four weeks followed by 75 mg of carbidopa per day for four weeks
89604762|NCT01399905|Experimental|Low carbidopa followed by high carbidopa|75 mg of carbidopa per day for four weeks followed by 450 mg of carbidopa per day
89604763|NCT01725308|Placebo Comparator|Placebo|Participants who received placebo once daily at bedtime for 8 weeks in Treatment Period I and were evaluated against the transition criteria to transfer to Treatment Period II. If transition criteria were not met, participants underwent to a dose-tapering period (1 week) and a follow-up period (1 week) thereafter. If transition criteria were met, participants went into Treatment Period II.
89604764|NCT01725308|Experimental|FK949E 150 mg|After 2 days of up-titration, participants who received FK949E 150 mg once daily at bedtime for 8 weeks in Treatment Period I and were evaluated against the transition criteria to transfer to Treatment Period II. If transition criteria were not met, participants underwent to a dose-tapering period (1 week) and a follow-up period (1 week) thereafter. If transition criteria were met, participants went into Treatment Period II.
89604765|NCT01725308|Experimental|FK949E 300 mg|After 4 days of up-titration, participants who received FK949E 300 mg once daily at bedtime for 8 weeks in Treatment Period I and were evaluated against the transition criteria to transfer to Treatment Period II. If transition criteria were not met, participants underwent to a dose-tapering period (1 week) and a follow-up period (1 week) thereafter. If transition criteria were met, participants went into Treatment Period II.
89604766|NCT01725308|Experimental|Placebo / FK949E|Participants received placebo administered orally once daily at bedtime for 8 weeks in Treatment Period I. Participants who met the transition criteria continued to Treatment Period II which consisted of a transition period in which participants continued to receive placebo for 4 weeks, followed by a 1-week dose adjustment period, and a treatment period in which participants received either open-label FK949E 150 mg or 300 mg (depending on dose increase or reduction guidelines) administered orally for 39 weeks. Participants underwent a dose-tapering period (1 week) and a follow-up period (1 week) thereafter.
89604767|NCT01725308|Experimental|FK949E 150 mg / FK949E|After 2 days of up-titration, participants received FK949E 150 mg administered orally once daily at bedtime for 8 weeks in Treatment Period I. Participants who met the transition criteria continued to Treatment Period II which consisted of a transition period in which participants continued to receive FK949E 150 mg for 4 weeks followed by a 1-week dose-adjustment period and a treatment period in which participants received either open-label FK949E 150 mg or 300 mg (depending on dose increase or reduction guidelines) administered orally for 39 weeks. Participants underwent a dose-tapering period (1 week) and a follow-up period (1 week) thereafter.
89604768|NCT01725308|Experimental|FK949E 300 mg / FK949E|After 4 days of up-titration, participants received FK949E 300 mg administered orally once daily at bedtime for 8 weeks in Treatment Period I. Participants who met the transition criteria continued to Treatment Period II which consisted of a transition period in which participants continued to receive FK949E 300 mg for 4 weeks followed by a 1-week dose-adjustment period and a treatment period in which participants received either open-label FK949E 150 mg or 300 mg (depending on dose increase or reduction guidelines) administered orally for 39 weeks. Participants underwent a dose-tapering period (1 week) and a follow-up period (1 week) thereafter.
89604769|NCT04573634||Health Care Workers|Health-care workers undergoing standard of care assessment of SARS-CoV-2 serology testing at UKHC.
89604770|NCT04573634||Eligible Patients|Patients undergoing standard of care assessment of SARS-CoV-2 serology testing at UKHC.
89604771|NCT04573634||Quarantining Individuals|Individuals with a COVID-19 exposure requiring quarantine who are asymptomatic and who will receive standard of care SARS-CoV-2 PCR testing.
89604772|NCT01724528|Experimental|Febuxostat|Febuxostat for 7-9 days
89604773|NCT01724528|Active Comparator|Allopurinol|Allopurinol for 7-9 days
88981547|NCT02912715|Experimental|Paclitaxel releasing angioplasty balloon|Intervention treatment of balloon angioplasty with Paclitaxel releasing angioplasty balloon(Passeo-18 Lux) in new and non-stented re-stenotic lesions in the superficial femoral artery (SFA) and proximal popliteal artery (PPA)
88981548|NCT02896777|Experimental|Transfer embryos from 7.20±0.02 pH|In this arm, the intervention is to culture the inseminated oocytes in vitro in a pH of 7.2±0.02 from day 0 to 5/6 post IVF/ICSI. Then according to the result of the randomization, women will receive their embryos that will be cultured in this pH on either Day 3 or Day 5/6 post IVF/ICSI.
88981549|NCT02896777|Experimental|Transfer embryos from 7.3±0.02 pH|In this arm, the intervention is to culture the inseminated oocytes in vitro in a pH of 7.3±0.02 from day 0 to 5/6 post IVF/ICSI. Then according to the result of the randomization, women will receive their embryos that will be cultured in this pH on either Day 3 or Day 5/6 post IVF/ICSI.
88981550|NCT02896777|Experimental|Transfer embryo from 7.4±0.02|In this arm, the intervention is to culture the inseminated oocytes in vitro in a pH of 7.4±0.02 from day 0 to 5/6 post IVF/ICSI. Then according to the result of the randomization, women will receive their embryos that will be cultured in this pH on either Day 3 or Day 5/6 post IVF/ICSI.
88981551|NCT02886962|Experimental|No anticoagulation|No oral anticoagulation, and no monitoring of the INR.
88981552|NCT02886962|Active Comparator|Oral anticoagulation with vitamin K antagonists|"VKA use as recommended in the guidelines with INR target range between 2 and 3. Daily administration or thrice weekly at the end of dialysis sessions upon Nephrologist's choice.~Antiplatelet therapy will be provided only if recent acute coronary syndrome (< 6 months) or active coronary stent. Aspirin should be preferred in dialysis patients as clopidogrel has an unpredictable reduced activity and there is no safety data on combination of VKA with prasugrel or ticagrelor in this population."
88981553|NCT02885753|Experimental|Experimental arm FOLFOX with oxaliplatin intraarterial + targeted therapy to RAS status|Panitumumab (6 mg/kg if RAS wild) or Bevacizumab (5 mg/Kg if RAS mutated) Oxaliplatin (85 mg/m²) intraarterially Folinic Acid (400 mg/m²) intravenously 5Fu: 400 mg/m² in bolus of 10 minutes 5Fu: 2400 mg/m² intravenously over 46 hours
88981554|NCT02885753|Active Comparator|Reference arm FOLFOX with oxaliplatin intravenous + targeted therapy to RAS status|Panitumumab (6 mg/kg if RAS wild) or Bevacizumab (5 mg/Kg if RAS mutated) Oxaliplatin (85 mg/m²) intravenously Folinic Acid (400 mg/m²) intravenously 5Fu: 400 mg/m² in bolus of 10 minutes 5Fu: 2400 mg/m² intravenously over 46 hours
89604774|NCT01779440|Other|Electronic Decision Support System|The Electronic Decision Support System is a web-based computer program designed to motivate, educate, and engage people with severe mental illness into evidence-based smoking cessation treatment.
89604775|NCT01779440|Placebo Comparator|Control Computer Program|A computer program aimed to educate people about smoking cessation treatment.
88981555|NCT02885753|Experimental|Experimental arm mFOLFIRINOX with oxaliplatin intraarterial + Bevacizumab|Bevacizumab (5 mg/Kg) Oxaliplatin (85 mg/m²) intraarterially Irinotecan (150 mg/m²) intravenously Folinic Acid (400 mg/m²) intravenously 5Fu: 2400 mg/m² intravenously over 46 hours
88981556|NCT02885753|Active Comparator|Reference arm mFOLFIRINOX with oxaliplatin intravenous + Bevacizumab|Bevacizumab (5 mg/Kg) Oxaliplatin (85 mg/m²) intravenously Irinotecan (150 mg/m²) intravenously Folinic Acid (400 mg/m²) intravenously 5Fu: 2400 mg/m² intravenously over 46 hours
88981557|NCT02853019|Sham Comparator|Healthy volunteers|Healthy volunteers
88981558|NCT02853019|Experimental|Patients with schizophrenia|Patients with schizophrenia
88981559|NCT02849158|Experimental|Biopsy|Patients will have new biopsy before starting RT-CT and samples will be taken on rectum surgery at the level of the tumor and away from the rectum.
88981560|NCT02835950|Experimental|Pulmonary Denervation|Pulmonary Denervation (PDN) using the TIVUS™ System will be performed in patient suffering from pulmonary arterial hypertension after completion of screening and eligibility phase, The procedure will be performed during right heart catheterisation. Safety and effectiveness of the PDN treatment will be assessed during one year follow up.
89604776|NCT01750346|Active Comparator|0.05% AH-8|Participants in the 0.05% AH-8 arm received the higher dose of the study drug, Acetyl Hexapeptide 8 (AH-8), which is sold under the brand name, Argireline.
89604777|NCT01750346|Active Comparator|0.025% AH-8|Participants in the 0.025% AH-8 arm received the lower dose of the study drug, Acetyl Hexapeptide 8 (AH-8), which is sold under the brand name, Argireline.
89604778|NCT01750346|Placebo Comparator|Placebo|Participants in the Placebo arm received the placebo.
89604779|NCT01750268|Experimental|Topiramate|Topiramate capsules daily - up to 300 mg
89604780|NCT01750268|Placebo Comparator|Placebo|Placebo capsules daily - up 300 mg
89604781|NCT01880437|Experimental|Vismodegib|
89604782|NCT01861717|Experimental|Somatuline Depot Subcutaneous (SC)|Somatuline Depot SC 90mg deep subcutaneous injection every 4 weeks for 3 doses before surgery. The dose will be 60 mg for patients with mild liver or kidney dysfunction.
89604783|NCT01834729|Experimental|Alfuzosin|"In Part A, subjects randomized to this arm will receive a single dose of oral alfuzosin immediate release (IR) 2.5 mg.~In Part B, only constipated patients will receive oral alfuzosin (10 mg extended release (ER)) capsules."
89604784|NCT01834729|Placebo Comparator|Placebo|Subjects randomized to this arm will receive a single placebo capsule identical to the study drug.
89604785|NCT01860703|Experimental|Arm A - Maximum Therapeutic Dose|Single dose of 33 mg/kg rounded to the nearest 250 mg of deferiprone tablets
89604786|NCT01860703|Experimental|Treatment Arm B - Supratherapeutic Dose|Single dose of 50 mg/kg rounded to the nearest 250 mg of deferiprone tablets
89604787|NCT01860703|Experimental|Arm C - Placebo Control|Single dose of matching deferiprone and moxifloxacin placebo tablets.
89604788|NCT01860703|Experimental|Arm D - Positive Control|Single dose of one 400 mg moxifloxacin tablet.
88981561|NCT02811549|Experimental|HiResolution Bionic Cochlear Implant|HiRes 90K™ Advantage implant with HiFocus™ 1J electrode, HiRes 90K™ Advantage implant with the HiFocus Helix™ electrode, HiRes 90K™ Advantage implant with the HiFocus™ Mid-Scala electrode or the HiRes™ Ultra Implant with the HiFocus™ Mid-Scala electrode will be implanted in adults who have severe to profound sensorineural hearing loss in one ear, and up to moderate sensorineural hearing loss in the other ear (asymmetric hearing loss).
88981562|NCT02765880|Experimental|Healthy volunteer|
88981563|NCT02765880|Experimental|Patients with schizophrenia|
88981564|NCT02765880|Experimental|Patient with bipolar disorder|
89604789|NCT01399593|Experimental|Eculizumab|Patients were to receive eculizumab 1200 mg prior to allograft transplantation (Day 0, starting approximately one hour prior to kidney allograft reperfusion), eculizumab 900 mg (Days 1, 7, 14, 21, and 28), and eculizumab 1200 mg (Weeks 5, 7 and 9). All doses of eculizumab were administered intravenously: the median infusion time was 39 minutes.
89604790|NCT01399593|No Intervention|Standard of Care|Patients received standard of care (SOC) prophylactic therapy for acute AMR according to the SOC choice at each participating investigative site, which could have included any combination of plasmapheresis (PP) and intravenous immunoglobulin (IVIg). Patients randomized to SOC who were diagnosed with AMR could have received eculizumab for the treatment of AMR after initially receiving PP and/or IVIg.
89604791|NCT01833169|Experimental|BKM120|BKM120 100 mg (oral gelatine capsules) was administered orally once daily starting from cycle 1 day 1 and will be dosed continuously every day for each 28- day cycle
89604792|NCT03814083|Experimental|Active-tDCS and Sham-tDCS|For active-tDCS condition, participants will receive stimulation on the dorsolateral prefrontal cortex with ramp up and ramp down mode for 10 seconds, eliciting a tingling sensation on the scalp that fades over seconds. Following that, a twenty-minute executive functional training task will be initiated five minutes subsequent to the stimulation mode, and the stimulation will be terminated when the training task ends. On the other hand, for sham-tDCS condition, participants will receive initial stimulation with ramp up and ramp down mode for 30 seconds, eliciting a tingling sensation on the scalp then it will be discontinued. Participant will also receive the twenty-minute executive functional training task five minutes subsequent to the stimulation mode.
89604793|NCT03814083|Active Comparator|Active-tDCS and wait-list|For active-tDCS condition, participants will receive stimulation on the dorsolateral prefrontal cortex with ramp up and ramp down mode for 10 seconds, eliciting a tingling sensation on the scalp that fades over seconds. Following that, a twenty-minute executive functional training task will be initiated five minutes subsequent to the stimulation mode, and the stimulation will be terminated when the training task ends. On the other hand, participants in the wait-list control group will not receive any intervention.
89032489|NCT00525005|Experimental|DOS (Docetaxel, Oxaliplatin and S-1)|Docetaxel 52.5mg/m2 IV on D1 (diluted in 250 ml of normal saline over a 1 hour of each cycle before oxaliplatin) Oxaliplatin 105mg/m2 IV on D1 (diluted in 250 ml of 5% DW for 2 hours) S-1 80mg/m2/day on D1-14 (2 weeks of treatment followed by a 1-week rest period)
89604794|NCT03814083|Sham Comparator|Sham-tDCS and wait-list|For sham-tDCS condition, participants will receive initial stimulation with ramp up and ramp down mode for 30 seconds, eliciting a tingling sensation on the scalp then it will be discontinued. Participant will also receive the twenty-minute executive functional training task five minutes subsequent to the stimulation mode. On the other hand, participants in the wait-list control group will not receive any intervention.
89604795|NCT01860079|Active Comparator|Early discharge group|In the early discharge group, patients are actively targeted for hospital discharge within 48-56 hours.
89604796|NCT01860079|No Intervention|Standard discharge group|Patients who stay longer (96-120 hours) as of a standard procedure
89604797|NCT04032639||Prader-Willi Syndrome|24 children and adolescents (7-16 years) with diagnosed Prader-Willi Syndrome will be recruited
89604798|NCT04032639||Controls|24 children and adolescents (7-16 years) without diagnosed Prader-Willi Syndrome will be matched for age, sex, and BMI-percentile to the Prader-Willi group
89604799|NCT04407819||diabetes mellitus type 2|36 patients with diabetes mellitus type 2, aged 20-80 years, attending endocrinology outpatient clinics were studied for the assessment of muscle mass and function compared to controls.
89604800|NCT04407819||CONTROLS|14 community people who visited the endocrinology outpatient hospital clinic for a routine checkup, or with a non-related to diabetes disease.
89604801|NCT01388985|Active Comparator|Standard vaccination schedule|One injection will be given on three different days (day 0, day 7 and day 21 or 28)
89604802|NCT01388985|Experimental|Accelerated vaccination schedule|Two injections will be given on the same day (day 0 and day 7): one on each forearm.
89604803|NCT01388907|Experimental|Prevadh film|Patient randomized in this arm have been treated with Prevadh film applied on the uterine surgical sites, at the end of the myomectomy surgery to prevent post-surgey adhesion formation.
89604804|NCT01388907|Active Comparator|Ringer solution|Patients randomized in the Ringer solution group have been treated with Ringer lactate solution directly applied to the uterine surgical sites at the end of the myomectomy surgery.
89604805|NCT01388361|Experimental|IDeg (non-randomised)|
89604806|NCT01388361|Experimental|IDeg + IAsp|
89604807|NCT01388361|Experimental|IDeg + liraglutide|
89604808|NCT04028895|Other|Experimental|
89604809|NCT05368935|Experimental|Healthy Control Match (RF ≥ 90 mL/min)|500 mg Twice Daily for 7 days
89604810|NCT05368935|Experimental|Mild Renal Impairment (RF ≥ 60 to < 90 mL/min)|500 mg Twice Daily for 7 days
89604811|NCT05368935|Experimental|Moderate Renal Impairment (RF ≥ 30 to < 60 mL/min)|500 mg Twice Daily for 7 days
89604812|NCT05368935|Experimental|Severe Renal Impairment (RF < 30 mL/min and not on dialysis)|500 mg Twice Daily for 7 days
89604813|NCT01399125|Experimental|Rivastigmine patch|Once-daily target patch size 10 cm²
89604814|NCT01399125|Active Comparator|Rivastigmine capsules|Twice-daily target dose of 6 mg oral capsule
89604815|NCT04015791||Match Group|Surgery conducted at the disc level corresponding with the highest level of NOCISCORE value in the subject and that is classified as either NOCI + or NOCI mild
89604816|NCT04015791||Miss Group|Surgery conducted at a disc that: (a) corresponds with a low relative NOCISCORE value in the subject and that is classifies as NOCI - or (b) excludes the disc level with the highest NOCISCORE value in the subject and that is classifies as NOCI+ or NOCI mild
89604817|NCT04026633|Experimental|Experimental: Enhanced Intervention|Participants assigned to this arm will complete a personal writing task about alcohol use.
89604818|NCT04026633|Placebo Comparator|Placebo Comparator|Participants assigned to this arm will complete a personal writing task about eating behaviors.
89604819|NCT01399047|Active Comparator|Mycophenolate Mofetil|
89604820|NCT01399047|Placebo Comparator|Placebo liquid|
89604821|NCT05369169|Experimental|Resonance paced breathing|Active resonance breathing task consisting of synchronizing breathing with a visual pacer (E-Z Air, Thought Technology, Ltd., Plattsburgh, NY) that moves up (inhale) and down (exhale) at the rate of 0.1 Hz (6 breaths per min)
89604822|NCT05369169|Active Comparator|Low demand vanilla control|"A low-demand cognitive vanilla task wherein different colored rectangles are presented for 10 sec each, and participants are instructed to silently count the number of blue rectangles"
89604823|NCT01387737|Experimental|TA-7284-Low|
89604824|NCT01387737|Experimental|TA-7284-High|
89604825|NCT01387347|Active Comparator|Thymosin Beta 4|RGN-259 is a preservative-free, sterile eye drop solution containing 0.1% (w/w) Tβ4
89032490|NCT02946749||Shanghai First Maternity and Infant Hospital|
89032491|NCT02946749||the Putuo District Maternity and Child Health Care Hospital|
89032492|NCT02946749||the Xinhua hospital affiliated to Shanghai jiaotong University|
89604826|NCT01387347|Placebo Comparator|Placebo|The placebo solution is composed of the same excipients as RGN-259 but does not contain Tβ4. The Placebo is identical to the RGN-259 eye drops in color, consistency, and odor.
89604827|NCT04012827|Experimental|Apatinib Mesylate Combined With Doxorubicin and Ifosfamide|A course of treatment every 21 days. For patients with disease control (CR+ PR+SD) and tolerable adverse reactions after 6 courses of treatment, continuous drug use was considered by the researchers as inappropriate for patients to continue drug use or when the efficacy was assessed as disease progression (PD).No other antitumor treatment can be given during the treatment.
89604828|NCT01859923|Experimental|Group 1: 12 to 17 Years of Age|Participants 12 to 17 years old (inclusive) received adult formulation of delamanid 100 milligrams (mg) (2x50 mg tablets), orally, twice daily (BID) plus optimized background regimen (OBR) up to Day 182. Participants continued to receive OBR up to Day 365.
89032493|NCT02946749||The Sixth people's hospital of Shanghai|
89032494|NCT00525122||1|Patients with hyperthyroidism who are will be treated with radioactive iodine.
89032495|NCT00525200|Active Comparator|A|
89032496|NCT00525200|Experimental|B|
89032497|NCT02929992|Experimental|Home ART initiation|Participants who are eligible to initiate ART will start in the home and will pick up their medication refills from a mobile van.
89604829|NCT01859923|Experimental|Group 2: 6 to 11 Years of Age|Participants 6 to 11 years old (inclusive) received adult formulation delamanid 50 mg (1x50 mg tablet), orally, BID plus OBR up to Day 182. Participants continued to receive OBR up to Day 365.
89604830|NCT01859923|Experimental|Group 3: 3 to 5 Years of Age|Participants 3 to 5 years old (inclusive) received 25 mg pediatric formulation of delamanid (DPF - suspension prepared using dispersible tablet), orally, BID plus OBR up to Day 182. Participants continued to receive OBR up to Day 365.
89604831|NCT01859923|Experimental|Group 4: Birth to 2 Years of Age|"Participants from birth to 2 years old (inclusive) received DPF (suspension prepared using dispersible tablet) for 182 days plus OBR. Participants continued to receive OBR up to Day 365. The DPF dose was based on the participant's body weight during the baseline visit:~Participants >10 kilograms (kg) received DPF 10 mg BID plus OBR~Participants >8 kg and ≤10 kg received DPF 5 mg BID plus OBR~Participants ≥5.5 kg and ≤8 kg received DPF 5 mg once per day (QD) plus OBR~Delamanid dose was adjusted as needed for Group 4 participants based on the weight measurement at specified study visits [Visits 5 (Day 28), 7 (Day 56), 9 (Day 84), 11 (Day 126) and 12 (Day 154)]."
89604832|NCT01832155|Experimental|yoga intervention|The yoga intervention received eight 60 minute weekly Hatha yoga intervention classes and asked to practice additional 30 minute yoga per day at home.
89604833|NCT01832155|Other|wait list control|The wait list control group received the same 8-week Hatha yoga intervention involving group and home-based exercise sessions after the yoga intervention group completed the intervention at the end of 8 weeks.
89604834|NCT04766619||Staff and stakeholders|For the longitudinal process evaluation - staff and stakeholders who have had direct contact or involvement with and have an understanding of OptmiseRx and/or PINCER will be invited to take part in an interview or focus group, an observation and/or complete a questionnaire. For the consolidated learning exercise - those who are in a position to influence the wider adoption of these interventions will be invited to take part in an interview or development workshop.
89604835|NCT04766619||Patients|Patients registered with a practice who have attended a consultation (or other related activity) for the PINCER intervention OR selected by their clinical care team OR attached to a patient group within a Clinical Commissioning Group (CCG) or practice OR patients identified through social media who have a long-term health condition and/or are taking any medication that requires them to have regular blood tests and have had a medication review in the past six month will be invited to take part in an interview or focus group.
89032498|NCT02929992|Experimental|Hybrid model|Participants will be referred to the clinic to initiate ART, once started they will pick up their medication refills from a mobile van.
89032499|NCT02929992|Active Comparator|Clinic ART initiation, monitoring and resupply|This is the standard of care arm. Participants will be given a referral to the clinic to initiate ART and will pick up their medication refills from the clinic.
89604836|NCT04766619||Public and patient representatives|For the consolidated learning exercise - patient and public representatives who have an understanding of the related medicines management issues in primary care will be invited to take part in an interview or workshop.
89604837|NCT05364333|Sham Comparator|Sham RIPC|Control patients will be submitted to 3 cycles of sham RIPC. Each cycle of Sham RIPC consists of a pseudo ischemia of the left upper limb caused by inflating a blood pressure cuff to 20mmHg for 5 minutes followed by 5 minutes of reperfusion time.
89604838|NCT05364333|Experimental|RIPC|Patients in the intervention group will be submitted to 3 cycles of RIPC. For each cycle of RIPC, a blood pressure cuff will be inflated at 200mmHg for 5 minutes (or at least 50mmHg above the systolic arterial blood pressure) followed by 5 minutes of reperfusion time.
89604839|NCT01879579|Experimental|Mobile Insulin Titration Intervention|Mobile Insulin Titration Intervention (MITI) arm patients will relay their fasting blood glucose levels to the study staff via text message. The patient will receive insulin titration instructions through a weekly phone call with a diabetes nurse.
89604840|NCT01879579|No Intervention|Current Best Practice|Current Best Practice (CBP) arm patients will be treated according to the current best practice of insulin titration. They will attend scheduled clinic visits during which the provider will review their blood glucose logs and provide insulin titration instructions.
89604841|NCT01386645|Active Comparator|Low GI diet|low glycemic index diet
89604842|NCT01386645|Placebo Comparator|High GI diet placebo|high glycemic index diet plus placebo
89604843|NCT01386645|Active Comparator|High GI diet NAC|high glycemic index diet plus N-acetylcysteine
89604844|NCT01387269|Experimental|100 mg QD|Anamorelin HCL 100 mg will be administered daily
89604845|NCT01387269|Placebo Comparator|Placebo|Placebo tablets identical in appearance to active tablets; oral administration once daily
89032500|NCT03458780||Yellow Fever Vaccine Participant|Healthy participants who receive the Yellow fever vaccine for travel and/or occupational risk will have peripheral blood samples collected longitudinally at time points selected for different immune events post-vaccination according to published studies (Day 0 baseline; Days: 3, 7, 14, and 42).
89032501|NCT02930148|Experimental|Intervention|Participants will be provided with a smart phone (android, version 5.0), two smart garments, a smart garment sensor and an activity bracelet will be provided at month 2 (to minimise the burden on the schools and participants allocating time and resources). The smart phones will have all apps of the PEGASO ecosystem installed.
89032502|NCT02930148|No Intervention|Comparative|Participants will be asked to continue their routine daily physical and educational activities related to leading a healthy lifestyle.
89604846|NCT01859143|Experimental|Trivalent Influenza Vaccine|A single dose of 10^(7.0 +/- 0.5) fluorescent focus units (FFU) of trivalent influenza vaccine will be administered as intranasal spray on Day 1.
89604847|NCT01859143|Placebo Comparator|Placebo|A single dose of placebo matched to trivalent influenza vaccine will be administered as intranasal spray on Day 1.
89604848|NCT01878253|Experimental|Investigational|This arm will include all subjects who are implanted with the investigational Sidus Stem-Free Total Shoulder Arthroplasty System.
89032503|NCT02930070||qSOFA(+)SOFA(+)|Infection patients who has a qSOFA>=2 and SOFA>=2 in a same day within 28 day of hospital stay.This group has the greatest priority in the competition of inclusion of groups.
89604849|NCT01878175|Experimental|Functional Movement Retraining|15-week rehabilitation / exercise intervention, including visits at the Durham VA medical center, in-home with clinical personnel, and via telephone. The intervention is tailored to participants' post-operative functional status, particularly unilateral balance asymmetries. The exercise program will focus on three areas: lower extremity mobility (ankle, knee and hip), muscle stability (quadriceps and gluteal muscle strength) and functional movement patterns (lower extremity focus). Participants will be instructed to perform their prescribed stretching exercises daily and strengthening exercises three times per week (on non-consecutive days).
89604850|NCT01878097|Experimental|Green Dot Bystander Training|Green Dot intervention
89604851|NCT01878097|Active Comparator|Control|Awareness Eduation
89604852|NCT01750190|Experimental|Roxadustat|Participants will receive roxadustat tablets orally 3 times a week (TIW). The initial dose will be according to the tiered weight-based approach, with starting roxadustat doses of 70 milligrams (mg) TIW to participants weighing <70 kilograms (kg) and roxadustat doses of 100 mg TIW to participants weighing ≥70 kg. Dose-titration (up to a maximum dose of 300 mg) will be performed based upon regular measurement of Hb levels until the participant achieves central Hb value of ≥11.0 grams/deciliter (g/dL) and Hb increase from baseline (BL) of ≥1.0 g/dL at 2 consecutive study visits, separated by at least 5 days. Once target Hb level is reached, the participant will enter the maintenance period during which roxadustat dosage will be adjusted every 4 weeks to maintain participant's Hb level within the target range of 10.0 g/dL and 12.0 g/dL. The maximum treatment duration will be up to 234.9 weeks.
89604853|NCT01750190|Placebo Comparator|Placebo|Participants will receive roxadustat-matching placebo tablets orally TIW. The initial dose will be according to the tiered weight-based approach, with starting roxadustat-matching placebo doses of 70 mg TIW to participants weighing <70 kg and roxadustat-matching placebo doses of 100 mg TIW to participants weighing ≥70 kg. Dose-titration (up to a maximum dose of 300 mg) will be performed based upon regular measurement of Hb levels until the participant achieves central Hb value of ≥11.0 g/dL and Hb increase from BL of ≥1.0 g/dL at 2 consecutive study visits, separated by at least 5 days. Once target Hb level is reached, the participant will enter the maintenance period during which roxadustat dosage will be adjusted every 4 weeks to maintain participant's Hb level within the target range of 10.0 g/dL and 12.0 g/dL. The maximum treatment duration will be up to 208.1 weeks.
89604854|NCT01831765|Experimental|Meal time FIAsp and insulin detemir|
89604855|NCT01831765|Active Comparator|Meal time insulin aspart and insulin detemir|
89604856|NCT01831765|Experimental|Post meal FIAsp and insulin detemir|
89604857|NCT01749800|Experimental|Cognitive test with/without GVS|Subjects with attention span deficits and no significant motor impairments undergo solely a cognitive test. The test is carried out in multiple trials. For some of the trials (randomly selected), subjects receive galvanic vestibular stimulation (GVS). For other trials, subjects received sham GVS. GVS is delivered using a device by A-M Systems.
88815132|NCT05395208|Experimental|Therapeutic touch group accompanied by white noise|"Camera recording was started 5 minutes before intravenous catheter intervention, vital signs and pain were evaluated.~Therapeutic touch application with white noise was started.~Vital signs and pain were evaluated during intravenous catheterization.~Vital signs and pain were evaluated when the intravenous catheter intervention was terminated and 5 minutes later, and the camera recording was stopped."
89032504|NCT02930070||qSOFA(-)SOFA(+)|Infection patients who has a qSOFA<2 and SOFA>=2 in a same day within 28 day of hospital stay.This group has the secondary priority in the competition of inclusion of groups.
89032505|NCT02930070||qSOFA(+)SOFA(-)|Infection patients who has a qSOFA>=2 and SOFA<2 in a same day within 28 day of hospital stay.This group has the third priority in the competition of inclusion of groups.
89032506|NCT02930070||qSOFA(-)SOFA(-)|Infection patients who has a qSOFA<2 and SOFA<2 in a same day within 28 day of hospital stay.This group has the least priority in the competition of inclusion of groups.
89032507|NCT02947568||CKD|chronic kidney disease
89604858|NCT01749800|Active Comparator|Armeo Spring +GVS|Subjects with both attention span deficits and significant motor impairments undergo robot-assisted upper-limb rehabilitation in combination with galvanic vestibular stimulation (GVS). Robot-assisted training is carried out using the Armeo Spring system by Hocoma AG. GVS is delivered using a device by A-M Systems.
89604859|NCT01749800|Sham Comparator|Armeo Spring + sham GVS|Subjects with both attention span deficits and significant motor impairments undergo robot-assisted upper-limb rehabilitation in combination with sham GVS. Robot-assisted training is carried out using the Armeo Spring system by Hocoma AG. Sham stimulation is delivered by connecting the subject to a device by A-M Systems, but the device is not active.
89604860|NCT04556396|Experimental|Intervention arm|This arm will receive cone beam CT to perform an abdomen-pelvis CT scan immediately following initial percutaneous nephrolithotomy, before the patient emerges from general anesthesia, to allow the surgeon to determine whether additional work is needed or whether the procedure can be concluded without requiring further imaging or future interventions.
89604861|NCT04556396|No Intervention|Retrospective arm|This arm will contain a retrospective cohort of patients who underwent surgery prior to the enrollment of the intervention arm. These patients received the standard of care, namely helical CT postoperative day one.
89604862|NCT04414891|Experimental|NAVA arm|"Delivery of NIV-NAVA NIV NAVA will be administered using Servo-i ventilator (Maquet, Getinge Group, Sweden) with software to compensate for air leaks.~Subjects randomised to this arm will undergo placement of Edi catheter and will be initiated on NIV. Appropriate NAVA level will be selected based on the scalars corresponding to stable ventilation in pressure support mode. During NAVA, the NAVA level would be increased in multiples of 0.2 cm H2O/µV to attain favourable response (tidal volume 6-8mL/kg RR ≤25). Once the patient's clinical condition stabilises, and the Edi maximum starts declining or remains unchanged with stable tidal volumes, NAVA level will be decreased in steps of 0.2 cm H2O/μV every 2 hours. If response to new settings is not favourable earlier settings will be restored. If favourable response is attained the weaning is continued until peak pressure is <12cm H20 and PEEP requirement is <5cm H2O. NIV will be replaced by a venture mask to titrate SpO2 between 88-92%"
88981565|NCT02754583|Experimental|WASH arm (WUHA)|"WUHA I, Behavioral: Water, sanitation, and hygiene (WASH) intervention: Communities will receive the water, sanitation, and hygiene (WASH) intervention including community water point construction, hygiene and sanitation education and promotion, community-based hygiene promotion workers, household wash stations, household WASH education books, household soap distribution, and a hygiene curriculum for primary schools.~WUHA II, Behavioral and Treatment: WASH intervention communities will continue to receive the water, sanitation, and hygiene (WASH) intervention.~A single mass azithromycin distribution will be given in all 40 WUHA I communities (both intervention and control) after the final study visit (i.e., month 36). Children 6 months and up will be offered azithromycin 20mg/kg; those under 6 months will be offered tetracycline."
88981566|NCT02754583|Other|Standard of care WASH arm (WUHA)|"WUHA I: Standard of care WASH intervention: Communities will continue to receive the standard of care WASH programming offered by the Ethiopian government.~WUHA II: Standard of care WASH intervention and treatment: Communities will continue to receive the standard of care WASH programming offered by the Ethiopian government.~A single mass azithromycin distribution will be given in all 40 WUHA I communities (both intervention and control) after the final study visit (i.e., month 36). Children 6 months and up will be offered azithromycin 20mg/kg; those under 6 months will be offered tetracycline.~These communities will receive a WASH package at the conclusion of the SWIFT II study, including water point construction, hygiene and sanitation promotion, and educational materials."
88981567|NCT02754583|Experimental|Targeted antibiotics arm (TAITU)|Targeted antibiotic treatment: Communities will receive targeted antibiotic treatments for children testing positive for ocular chlamydia at 3, 6, 9, and 12 months after baseline testing. After testing for ocular chlamydia at 12 months, any children testing positive at this time point will receive antibiotic treatments at 15, 18, 21, and 24 months. Children 6 months and up will be offered azithromycin 20mg/kg; those under 6 months will be offered tetracycline.
88981568|NCT02754583|Other|Delayed mass antibiotics arm (TAITU)|Delayed mass antibiotic treatment: Communities will receive no mass azithromycin treatment during the study period. Communities in this treatment group have previously received at least 8 rounds of mass azithromycin treatment. These clusters will be enrolled in an antibiotics treatment program (azithromycin or tetracycline) after the completion of the study.
88981569|NCT02754583|Active Comparator|Mass antibiotics arm (TAITU)|Mass antibiotic treatment: Communities will receive mass azithromycin treatment of all individuals aged 6 months and up (20mg/kg for children; 1 g for adults); those younger than 6 months, pregnant, or allergic to macrolide antibiotics will be offered a 2-week course of tetracycline.
88981570|NCT02741323|Experimental|Arm 1: Maraviroc (MVC)|Participants will receive MVC at the time of admission for transplantation and prior to transplant. Participants will receive MVC throughout their participation in the study, which will be 1 to 3 years depending on when they enroll.
88981571|NCT02741323|Placebo Comparator|Arm 2: Placebo|Participants will receive placebo at the time of admission for transplantation and prior to transplant. Participants will receive placebo throughout their participation in the study, which will be 1 to 3 years depending on when they enroll.
88981572|NCT02741037|Experimental|Dyadic lifestyle intervention|Mothers and daughters participate in the Unidas partner intervention together.
88981573|NCT02741037|Experimental|Individual lifestyle intervention|Mothers participate in the Unidas intervention alone, without their related daughters. Unrelated daughters participate in the Unidas intervention alone without their related mothers.
88981574|NCT02741037|Other|Usual Care|Mothers and daughters receive usual care.
88981575|NCT02725840||Proton beam radiation therapy|The participants in this group will be receiving proton therapy of the affected breast and chest wall as part of their standard of care. In addition, a Computed Tomography (CT) Scan of the chest wall will be performed, and pulmonary function test (PFT).
88981576|NCT02725840||X-ray based radiation therapy|The participants in this group will be receiving X-ray radiation therapy of the affected breast and chest wall as part of their standard of care. In addition, a Computed Tomography (CT) Scan of the chest wall will be performed, and pulmonary function test (PFT).
88981577|NCT02703220|Experimental|Hyperoxia|Determine the effect of sustained hyperoxia overnight vs room air overnight on ventilatory control during sleep, including the apneic threshold, carbon-dioxide reserve and chemosensitivity measured via pressure support ventilation (PSV) during (non-rapid eye movement sleep) NREM sleep.
88981578|NCT02703220|Experimental|Acetazolamide (ACZ)|Determine the effect of acetazolamide on cerebrovascular responsiveness to CO2 during wake and sleep. Participants will receive oral ACZ therapy for 7 days prior to the experimental night, on the night of the study and the subsequent night when polysomnography (PSG) will be performed.
89032508|NCT02947568||DM|diabetes mellitus
89032509|NCT02947568||CKD+DM|chronic kidney disease + diabetes mellitus
89604863|NCT04414891|Active Comparator|ASV arm|Patients randomised to the ASV arm will receive NIV using a Galileo GOLD ventilator (Hamilton Medical, AG, Switzerland). The patients will be ventilated with an initial setting of 100%-minute volume (MV%). Increments of 10% will be made every 15 minutes to achieve clinical response (relief of dyspnea, RR<30, and tidal volume 6-8mL/kg). The expiratory trigger sensitivity will be set at 35% and adjusted accordingly. PEEP will be commenced at 3-4 cm H2O and increased by 1 cm of H2O to achieve SpO2 between 89-92% and maximum PEEP of 10 cm of H2O. Weaning would be performed by reducing the MV% gradually in decrements of 10%/hour to a MV% of 60% after the peak inspiratory pressure decreases to <8 cm of H2O, and the respiratory rate is < 28 breaths per minute and patient is able to maintain SpO2 > 90% at FiO2< 30%. Once the patient is comfortable on these settings, NIV will be replaced with oxygen supplementation using a venturi mask to maintain SpO2 between 89 and 92%.
89604864|NCT01830595|Active Comparator|Recombinant Lactoferrin|Recombinant lactoferrin will be administered by mouth twice daily
89604865|NCT01830595|Placebo Comparator|Placebo|Matched placebo will be administered by mouth twice daily
89604866|NCT01748552|Placebo Comparator|Placebo (Part A)|Single oral dose of placebo administered to healthy participants in up to 1 of 3 study periods in Part A
89604867|NCT01748552|Experimental|LY2922083 (Part A)|Single ascending dose of LY2922083 (starting at 0.5 milligrams [mg]) administered orally to healthy participants in up to 2 of 3 study periods in Part A
88811528|NCT00845000|Experimental|SCH 420814 100 mg→Placebo→ SCH 420814 10 mg|Participants were to receive their assigned experimental treatment based on randomly assigned treatment sequence at Hour 0 following an overnight withdrawal of their antiparkinsonian medications of each treatment period. The levodopa infusion was to be started at Hour 1 and was to run for 2 hours. The participants were to also receive 25 mg of carbidopa at the following times: Hours 0, 2, and 4. Treatment periods were to be separated by at least 7 days but not more than 28 days washout between each dose.
88981579|NCT02703220|Experimental|Finasteride|Determine the effect of oral finasteride therapy vs placebo for 1 month on SDB and the AT and chemosensitivity during NREM sleep.
88981580|NCT02677051|Placebo Comparator|Placebo|About 15 subjects will be randomized into this arm, receiving pills with an inactive placebo.
88981581|NCT02677051|Experimental|Sulforaphane|"About 30 subjects will be randomized into this arm, receiving pills with glucoraphanin rich broccoli seed powder containing active myrosinase resulting in sulforaphane once ingested Doses will be weight dependent with each pill resulting in ~ 50 µmol sulforaphane.~Body weight Dose of sulforaphane 34 kg ~ 50 µmol 68 kg ~ 100 µmol 102 kg ~ 150 µmol"
88981582|NCT02638701|Experimental|Infliximab treatment|Administer infliximab intravenously to patients with DVB aneurysms (3 mg/kg at 0, 3 and 7 weeks, then at 8-week intervals x 7) for a total of 12-months. Patients will undergo MR imaging at 0, 12, and 24-month time points.
88981583|NCT02615184|Experimental|Healing Period: Dexlansoprazole 60 mg|Dexlansoprazole 60 mg, capsules, orally, once, daily, for 8 weeks.
88981584|NCT02615184|Experimental|Healing Period: Dexlansoprazole 30 mg|Dexlansoprazole 30 mg, capsules, orally, once, daily, for 8 weeks.
88981585|NCT02615184|Experimental|Maintenance of Healed EE: Dexlansoprazole 30 mg|Participants on Dexlansoprazole 60 mg treatment arm in Healing Period will receive half dose, dexlansoprazole 30 mg, capsules, orally, once, daily, for 16 weeks in the Maintenance Period.
88981586|NCT02615184|Experimental|Maintenance of Healed EE: Dexlansoprazole 15 mg|Participants on Dexlansoprazole 30 mg treatment arm in Healing Period will receive half dose, dexlansoprazole 15 mg, capsules, orally, once, daily, for 16 weeks in the Maintenance Period.
88981587|NCT02597738|Experimental|Lung/ Head and Neck Cancer Group|Blood/Urine Sample Collection Fresh tissue biopsy A one time fresh tissue biopsy of the patient's lung cancer (outside of their normal standard of care biopsy) will be collected for the research. Patients will also complete research blood and urine sample collections every two to four weeks for one year, then up to 120 days for years two through five.
89604868|NCT01748552|Placebo Comparator|Placebo (Part B)|Single oral dose of placebo administered to participants with type 2 diabetes mellitus (T2DM) in up to 1 of 3 study periods in Part B
89604869|NCT01748552|Experimental|LY2922083 (Part B)|Single ascending dose of LY2922083 administered orally to participants with T2DM in up to 2 of 3 study periods in Part B. Dose determined by Part A
89604870|NCT01748162|Experimental|Inhaled steroids|Daily inhaled steroids. Fluticasone 2 puffs inhaled orally twice daily for six months.
88981588|NCT02597738|Experimental|Chronic inflammatory disease|Blood/Urine Sample Collection A one time blood and urine sample collection will be completed.
88981589|NCT02597738|Experimental|At risk for lung cancer|Blood/Urine Sample Collection A one time blood and urine sample collection will be completed.
89032510|NCT02930265|Active Comparator|Liraglutide intervention group|Liraglutide intervention group will accept ischemic cardiomyopathy conventional drugs and Liraglutide (Novo Nordisk, specifications: 18mg / 3ml; 1.8mg subcutaneous injection of 1 / day)
89032511|NCT02930265|No Intervention|Control group|Control group will accept ischemic cardiomyopathy conventional drugs and a placebo
89032512|NCT02947490|Sham Comparator|Standard BP management|Participants will continue to receive routine measurement of BP and management of treatment from their General Practitioner (GP).
89032513|NCT02947490|Placebo Comparator|Self BP measurement and standard care|Participants in this group (Se-Mo) will be taught to use a validated British Hypertension Society (BHS) approved home BP monitor (with built in memory/printer) by the study nurse along with written information on the procedure and a copy of the BHS Home BP Monitoring DVD. Participants will be contacted before each recording week & arrangements will be made to deliver and demonstrate the use of self BP monitor by the study nurse. Home BP monitoring will be performed over a 7 day period 3 times during the 6 month follow-up and on each occasion the patient will be given a copy of the BP results and asked to inform the GP of the results and the GP will decide if any alteration in therapy is needed.
89604871|NCT01748162|Active Comparator|Oral control|Patient and clinician observation with short term oral prednisolone as needed. Offered at 1mg/kg (body weight) daily dosing for symptomatic treatment on as needed basis for three days, but may be modified per managing physician's discretion.
89604872|NCT01724216|Experimental|pulse sequence software|The central aim of this study is to acquire a set of images and associated technical and clinical information to facilitate regulatory submission of the pulse sequences being studied by GEHC. Segment 1 allows to collect a minimum of 10 subjects then evaluate if additional scans/enrollment needed Segment 2 will allow an additional 90 subjects if data needed
89604873|NCT01723904|Experimental|Rotigotine|"- Titration Period: Weekly titration to the subject's optimal dose of Rotigotine between 2 mg/24 h and 8 mg/24 h. In case of intolerable Adverse Events (AEs) one back-titration is allowed during the Titration Period.~Duration of the Titration Period: Between 1 week and 5 weeks.~- Maintenance Period: Starts once subject reached either optimal or maximal dose of Rotigotine. Subjects receive stable dose of Rotigotine throughout the Maintenance Period. No back-titration is allowed during the Maintenance Period.~Duration of the Maintenance Period: Between 3 weeks and 7 weeks."
89604874|NCT01747772|Experimental|Shear Wave Sonoelastography for Fibrosis Assessment|Shear Wave sonoelastography (SWE) was performed in patients who were scheduled for a non-focal liver biopsy.
89604875|NCT01830127|Experimental|cohort A CPA|Cohort A CPA BI 207127/QD Faldaprevir Ribavirin
89604876|NCT01830127|Experimental|cohort A CPB|Cohort B CPB BI 207127/QD Faldaprevir Ribavirin
89604877|NCT04611295|Experimental|Teleneurological evaluation and support|teleneurological evaluation using a medical device certified as telemedicine system
89604878|NCT01614067|Experimental|Delayed Start|Study subjects will receive 7 days of pre-treatment with a GnRH antagonist (Delayed Start) before standard ovarian stimulation with FSH/LH.
89604879|NCT01614067|Active Comparator|Conventional Start|Ovarian stimulation with standard antagonist protocols (no delay).
89604880|NCT01777490|Active Comparator|Arm 1: Control - Caregiver|Caregivers in the control arm will be referred to the VA Caregiver Support Program (usual care), as a resource for them as they care for the patient in the home.
89604881|NCT01777490|Experimental|Arm 2: HI FIVES - Caregiver|Caregivers will take part in three phone training sessions and will attend four group training sessions at the VA. They will also be given the option of participating in 2 booster phone training sessions post-group sessions. Caregivers will be asked to provide one in-person (baseline) and three phone assessments (3, 9, and 15 months). Patients will also be enrolled and contact will be limited to assessments
89604882|NCT01777490|Active Comparator|Arm 1: Control - Patient|The patient of each caregiver will also be enrolled and contact will be limited to assessments.
89604883|NCT01777490|Experimental|Arm 2: HI-FIVES - Patient|The patient of each caregiver will also be enrolled and contact will be limited to assessments.
89604884|NCT01397409|Experimental|Stage 1: AGN-150998 4.2 mg|Stage 1: AGN-150998 4.2.mg given as a single intravitreal injection.
89604885|NCT01397409|Experimental|Stage 1: AGN-150998 3.0 mg|Stage 1: AGN-150998 3.0 mg given as a single intravitreal injection.
89604886|NCT01397409|Experimental|Stage 1: AGN-150998 2.0 mg|Stage 1: AGN-150998 2.0 mg given as a single intravitreal injection.
89604887|NCT01397409|Experimental|Stage 1: AGN-150998 1.0 mg|Stage 1: AGN-150998 1.0 mg given as a single intravitreal injection.
89604888|NCT01397409|Experimental|Stage 2: AGN-150998 4.2 mg|Stage 2: AGN-150998 4,2 mg (highest tolerated dose from Stage 1) given as a single intravitreal injection at baseline. A second intravitreal injection will be given by week 16.
89604889|NCT01397409|Experimental|Stage 2: AGN-150998 3.0 mg|Stage 2: AGN-150998 3.0 mg (one dose below highest tolerated dose) from Stage 1 given as a single intravitreal injection at baseline. A second intravitreal injection will be given by week 16.
88981590|NCT02597738|Experimental|Healthy people who exercise|Blood/Urine Sample Collection Blood and urine collection one time prior to exercise and one time after exercise.
89604890|NCT01397409|Active Comparator|Stage 2: ranibizumab 0.5 mg|Stage 2: ranibizumab 0.5 mg given as a single intravitreal injection at baseline. A second intravitreal injection will be given by week 16.
89604891|NCT01397409|Experimental|Stage 3: AGN-150998 2.0 mg|Stage 3: AGN-150998 2.0 mg given as intravitreal injections at Baseline, Weeks 4 and 8, followed by sham injections at Weeks 12 and 16.
89604892|NCT01397409|Experimental|Stage 3: AGN-150998 1.0 mg|Stage 3: AGN-150998 1.0 mg given as intravitreal injections at Baseline, Weeks 4 and 8, followed by sham injections at Weeks 12 and 16.
89604893|NCT01397409|Active Comparator|Stage 3: ranibizumab 0.5 mg|Stage 3: ranibizumab 0.5 mg given as intravitreal injections every 4 weeks for 16 weeks.
89604894|NCT04407429||Health care workers|Physicians, Nursing staff, Midwives, Medical-technical assistants (including medical, therapeutic and diagnostic healthcare staff, and medical and nursing assistants), administrative personnel with patient contact
89604895|NCT04407429||Patients|Patients admitted for non-COVID related symptoms to the Vienna General Hospital with available residual serum samples.
89604896|NCT01397253|No Intervention|(Usual) MedTrak system of PCP notification|MedTrak, the information system used by the University of Pittsburgh Medical Center (UPMC), currently notifies PCPs when patients are admitted and discharged from the hospital.
89604897|NCT01397253|Experimental|Automated communication tools|An enhanced version of MedTrak (the present system of PCP notification). Electronic medical record links will be developed and used to allow automated communication with the PCP.
88981591|NCT02597738|Experimental|Lung cancer with planned resection|"Blood/Urine Sample Collection Blood and/or urine sample collection one time before surgery and one time after surgery. Blood and/or urine sample collection at subsequent visits.~Fresh tissue biopsy Tissue sample collection from surgery is there is any tissue considered to be pathological waste that would normally be discarded."
88981592|NCT02597738|Experimental|Solid tumor cancer w/ radiation therapy|Blood/Urine Sample Collection Blood and/or urine sample collection prior to radiation treatment. Blood and/or urine collection after completion of radiation therapy. Blood and/or urine collection at subsequent visits for next 5 years.
88981593|NCT02566122||muscle strength ,muscle mass|
88981594|NCT02557334|Experimental|Low Dose Strawberry Powder|40 g composed of 13 g freeze dried strawberry powder + 27 g placebo powder
88981595|NCT02557334|Experimental|High Dose Strawberry Powder|40 g freeze dried strawberry powder
88981596|NCT02557334|Placebo Comparator|Placebo Powder|40 g color and taste matched placebo powder
88981597|NCT02556749|Experimental|Cranberry Juice Beverage|16 ounces of 54% cranberry juice cocktail
88981598|NCT02556749|Placebo Comparator|Placebo Beverage|Color, calorie, and taste matched beverage without cranberry bioactives
89604898|NCT04766775|Other|Application of Silver Diamine Fluoride onto the carious teeth surfaces|The patients will receive Silver Diamine Fluoride (SDF) treatment to the carious primary teeth. These are teeth with no sign or symptom, radiographically the deepest layer of the caries lesion does not involve the pulp, the inter-radicular area appears normal). Procedure: apply vaseline, isolate the tooth with a cotton roll, remove the food debris, and gross plaque on the tooth cavity with a spoon excavator, dry the tooth, apply the SDF (a clear, colorless solution) onto the tooth cavity. This application lasts for one minute. Take the urine and hair sample to assess the silver and fluoride levels. Take the urine sample before the SDF treatment, in the first and second 24 hours after the SDF treatment. Take the hair samples before the SDF treatment, followed by days 7,14,30,60,75, and 90 after the SDF treatment. Send the hair and urine samples to the laboratory to assess the silver and fluoride levels. If caries remains active, restore the SDF treated after the day 90 review.
89604899|NCT01777334|Experimental|Umeclidinium/Vilanterol|Long-acting muscarinic antagonist (LAMA)/Long-acting Beta agonist (LABA)
89604900|NCT01777334|Active Comparator|Tiotropium|Long-acting muscarinic antagonist (LAMA)
89604901|NCT03024879|Active Comparator|Erythromycin|40 mg of erythromycin will be administered intravenously over a period of 20 min in a saline solution of 100 ml
89604902|NCT03024879|Placebo Comparator|Placebo|a saline solution of 100 ml will be administered intravenously over a period of 20 min
89604903|NCT05369013||A|Biosimilar Teriparatide
89604904|NCT05369013||B|Original Teriparatide
89604905|NCT01383993|Experimental|1.0|Immunocompromised children aged 2 to <15 and 12 to <15 years weighing <50 kg who are at high risk for systemic fungal infection.
89604906|NCT01383993|Experimental|2.0|Immunocompromised children aged 12 to <15 years weighing more than 50 kg who are at high risk for systemic fungal infection.
89604907|NCT05369637|Experimental|Non-pharmacological Intervention|Participants in the intervention group will receive a multidomain non-pharmacological program, including cognitive training, physical exercise, nutrition education, psychoeducation, and diagnosis and correction of hearing impairment.
89604908|NCT05369637|No Intervention|Control group|Control group will receive the usual standard of care provided to these clinical diseases.
89604909|NCT05368545|Active Comparator|usual care lipid lowering|Usual care: atorvastatin 40 mg
89604910|NCT05368545|Experimental|Intensive lipid lowering|Intensive: rosuvastatin 40 mg + ezetimibe 10 mg
89604911|NCT01396395|Experimental|Standard treatment plus nicorandil|The subjects will receive nicorandil 5 milligram (mg ) tablet orally three times daily for a period of 12 weeks along with one of the standard antianginal therapies (such as aspirin, beta-blockers, lipid lowering statins and angiotensin-converting enzyme inhibitors [(ACEIs] as permitted by disease condition /as per standard local practices/prescribed per discretion of investigators).
89604912|NCT01396395|Other|Standard treatment|
89604913|NCT01396317|Experimental|Tocilizumab|This is a single-arm study. All subjects will receive the active study treatment for 12 months, and will then be evaluated for 3 months of long-term follow-up.
89604914|NCT01396161|Experimental|30 mg PF-05175157 or Placebo QD|
88981599|NCT02531217|Experimental|ATYR1940|Participants will receive ATYR1940 3.0 milligrams per kilograms (mg/kg) intravenous (IV) infusion once weekly for 24 weeks.
88981600|NCT02522182|Experimental|Intensive Secondary Prevention Programme|The Nurse-led Intensive Secondary Prevention Programme consists of programmed 9 sessions involving the trained nurses and the patients randomised to the experimental programme: before discharge, and one, three, six, 12, 18, 24, 36 and 48 months follow up. During the sessions the nurse will record the main clinical parameters (risk factors, lifestyle habits, adherence to therapy, psychological characteristics), any discrepancies between patient reports and the recommended goals and then activate the interventions in order to correct the discrepancies. The activation of the pre-established multidisciplinary network (anti-smoking, anti-diabetes and anti-hypertension centres, and psychological support) is completely under the nurses' control.
89604915|NCT01396161|Experimental|100 mg PF-05175157 or Placebo QD|Planned dose might be modified based on emerging safety and PK data.
89604916|NCT01396161|Experimental|200 mg PF-05175157 or Placebo QD|Planned dose might be modified based on emerging safety and PK data.
89604917|NCT01396161|Experimental|100 mg PF-05175157 or Placebo BID|Planned dose might be modified based on emerging safety and PK data.
89604918|NCT01396161|Experimental|xxx mg PF-05175157|Dose will be determined based on results obtained from Arms 1 to 4.
89604919|NCT01396083|Experimental|Ranibizumab|
89604920|NCT01396083|Active Comparator|Standard of Care|
89604921|NCT04345263|Active Comparator|MTA pulpotomy|Tooth will receive MTA & resin composite restoration
89604922|NCT04345263|Active Comparator|Biodentine pulpotomy|Tooth will receive Biodentine & resin composite restoration
89604923|NCT04345263|Active Comparator|Bioceramic pulpotomy|Tooth will receive Bioceramic & resin composite restoration
89604924|NCT01723826|Experimental|Crenezumab|Participants will receive intravenous infusion of crenezumab every 4 weeks for 144 weeks.
89604925|NCT01721954|Active Comparator|Control Arm|Systemic chemotherapy with FOLFOX6m plus or minus bevacizumab repeated every two weeks until evidence of treatment failure.
89604926|NCT01721954|Experimental|Experimental Arm|Systemic chemotherapy with FOLFOX6m plus or minus bevacizumab plus SIR-Spheres microspheres.
89604927|NCT01776554|Experimental|aH5N1c-High dose|
89604928|NCT01776554|Experimental|aH5N1c-Low dose|
89604929|NCT01776008|Experimental|Treatment (MK2206, anastrozole, goserelin acetate)|Patients receive Akt inhibitor MK-2206 PO on days 2, 9, 16, and 23; anastrozole PO daily on days 1-28; and goserelin acetate SC on day 1 (premenopausal patients only). Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.
89604930|NCT01746368|Experimental|Nurse-Supported Advance Care Planning Intervention|The Nurse-Supported Advance Care Planning Intervention was a manualized education, support, and guidance session provided by a Registered Nurse that included information about risks, benefits, and alternatives of specific choices.
89032514|NCT02947490|Active Comparator|Self BP measurement and treatment|Participants in this group will undergo exactly the same self BP monitoring training process as the Se-MO group and will undertake monitoring at the same time intervals. However they will be equipped with a validated BP monitor with a Bluetooth interface phone, BP values recorded by the patient will be transmitted automatically via mobile telephone to the trial coordinating centre. The data will be password protected and saved on a secure server and be available only to the trial team (study nurse & supervising physicians). The patient would then be contacted by the study nurse and depending on BP levels recorded the patient will alter their medication to achieve target BP levels. This will be recorded on the CRF and the GP notified of any treatment changes.
89032515|NCT02929953||Diabetes mellitus type 1|"all T1DM patients in Israel, born during 2000-2013 and diagnosed prior to January 2015.~chart review"
89604931|NCT01746368|Active Comparator|Care-as-Usual|The Care-as-Usual was a session with the social worker who explained what the Advance Directive is, and guided the Veteran regarding the process of completing the Advance Directive document, without providing information about risks, benefits, and alternatives of specific choices. Subjects in this arm who desired information about risks, benefits, and alternatives of specific choices before randomization were scheduled for the Care-as-Usual session after they received that information from the Primary Care Provider.
89032516|NCT02929953||Non-diabetic|non-diabetic general population born in Israel during 2000-2013, according to the Israeli Health Ministry's Birth Registry (IHMBR) chart review
89032517|NCT02947178|Active Comparator|Bupivicaine|Bupivicaine fascial iliaca regional soft tissue infiltration blockade
89604932|NCT01381575|Experimental|Cervarix 1 Group|Female subjects aged 9 to 14 years at the time of the first vaccination, who received 2 doses of the Cervarix vaccine at Day 0 and at Month 6, respectively. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.
89604933|NCT01381575|Active Comparator|Cervarix 2 Group|Female subjects aged 15 to 25 years at the time of the first vaccination, who received 3 doses of the Cervarix vaccine at Day 0, at Month 1 and at Month 6, respectively. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.
89604934|NCT01381575|Experimental|Cervarix 3 Group|Female subjects aged 9 to 14 years at the time of the first vaccination, who received 2 doses of the Cervarix vaccine at Day 0 and at Month 12, respectively. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.
89604935|NCT01858363|Experimental|Paclitaxel-coated balloon|Subjects with de novo occluded/stenotic or re-occluded/restenotic lesions will be randomly assigned to treatment with a Paclitaxel-coated balloon or bare balloon.
89604936|NCT01858363|Placebo Comparator|Bare balloon|Subjects with de novo occluded/stenotic or re-occluded/restenotic lesions will be randomly assigned to treatment with a Paclitaxel-coated balloon or bare balloon.
89604937|NCT01877551|Active Comparator|tauroursodeoxycholic acid|This group will receive 1.75 grams per day of tauroursodeoxycholic acid given once daily for 30 days.
89604938|NCT01877551|Placebo Comparator|placebo|This group will receive a placebo tablet that is identical to the treatment group except that it does not contain tauroursodeoxycholic acid. The pills will be taken once daily for 30 days.
89604939|NCT01396005|Experimental|Methadone + boceprevir|Participants receive standard methadone maintenance therapy (20-150 mg tablets, liquid, or disket, orally, once per day) on Days 1 through 8 + boceprevir (800 mg [4 x 200 mg capsules], orally, every 8 hours) on Days 2 through 7)
89604940|NCT01396005|Experimental|Buprenorphine/naloxone + boceprevir|Participants receive standard buprenorphine/naloxone maintenance therapy (8/2-24/6 mg, tablets, sublingual, once per day) on Days 1 through 8 + boceprevir (800 mg [4 x 200 mg capsules], orally, every 8 hours) on Days 2 through 7
89604941|NCT01877239||Full Analysis Set|Full Analysis Set (FAS): The FAS contains any patient that has given written informed consent.
89604942|NCT03024957|Active Comparator|Dexmedetomidine group|patients received 10 mg of hyperbaric bupivacaine 0.5% in 2 mL volume and 5 μg of dexmedetomidine in 1 mL volume intrathecally.
89604943|NCT03024957|Active Comparator|Morphine group|patients received 10 mg of hyperbaric bupivacaine 0.5% in 2 mL volume and 0.5 mg morphine sulphate in 1 mL volume intrathecally.
89604944|NCT03024957|Active Comparator|Dexmedetomidine + morphine group|patients received 10 mg of hyperbaric bupivacaine 0.5% in 2 mL volume and 5 μg of dexmedetomidine plus 0.5 mg of morphine sulphate in 1 mL volume intrathecally.
89032518|NCT02947178|Active Comparator|Bupivacaine plus liposomal bupivacaine|Bupivacaine plus liposomal bupivacaine fascial iliaca regional soft tissue infiltration blockade
89032519|NCT02929797|Experimental|AKT + gemcitabine|gemcitabine dose 1000mg/M^2, d1,8,15，q4w ×6 AKT 5*10^8/M^2, d16,q4w ×6 Drug: gemcitabine Biological: AKT, CD8+NKG2D+ AKT Cell
89604945|NCT03025113|Experimental|EMS association|The patient will take 2 tablets (Combination of ketoprofen and cyclobenzaprine), oral, per day, each 12h.
89604946|NCT03025113|Active Comparator|Miosan®|The patient will take 2 tablets (cyclobenzaprine isolated), oral, per day, each 12h.
89604947|NCT01877083|Experimental|Lenvatinib|
89604948|NCT01380327|Experimental|Cockroach Sublingual Immunotherapy (SLIT) - Low Dose|Glycerinated German cockroach (Blatella germanica) allergen extract administered sublingually with a maximally tolerated dose of 420 microliters daily
89604949|NCT01380327|Placebo Comparator|Placebo|Placebo administered sublingually not to exceed the maximally tolerated dose of either 1.) 420 microliters daily (placebo - low dose randomization) or 2.) 840 microliters twice daily (placebo - high dose randomization)
89604950|NCT01380327|Experimental|Cockroach Sublingual Immunotherapy (SLIT) - High Dose|Glycerinated German cockroach (Blatella germanica) allergen extract administered sublingually with a maximally tolerated dose of 840 microliters taken twice daily
89604951|NCT01829425|Active Comparator|Anticholinergic medications|Either of two standard, long acting anti-cholinergic medications (Long acting Tolterodine or Extended Release Oxybutynin)will be given. Subjects receive 8 weeks of medication counseling in conjunction with the medications. Medications will be continued for 1 year.
89032520|NCT02929797|Active Comparator|gemcitabine|gemcitabine hydrochloride dose 1000mg/M2 d1,8,15，q4w ×6 Drug: gemcitabine
89032521|NCT00525239|Experimental|1: Ritonaivr|Pre and post ritonavir, lopinavir/ritonavir or atazanavir/ritonavir
89032522|NCT02929758|Active Comparator|Control Initial Training Group|Healthy Controls will receive initial SOPT training and will be compared against controls in the delayed training group and the PD subjects in the initial training group
89604952|NCT01829425|Active Comparator|Hypnotherapy|Subjects will receive approximately weekly hypnotherapy sessions over 8 weeks and will receive/download digital recordings for home practice. Subjects will be encouraged to practice self-hypnosis +/or listen to their recordings for 1 year.
89604953|NCT03796689|Experimental|Smartphone-linked|
89604954|NCT03796689|Active Comparator|Standard|
89604955|NCT05630079||Metaneb®|"Patients admitted for severe acquired brain injury (sABI) in Neurological Rehabilitation Unit of IRCCS Santa Maria Nascente - Fondazione Don Gnocchi received the MetaNeb® system treatment. It consist of simultaneous combination of positive pressure, continuous high frequency oscillations and aerosol delivery"
89604956|NCT05630079||IPV®|Patients with severe acquired brain injury from Neurological Rehabilitation Unit of IRCCS Fondazione Don Gnocchi, S.M. Nascente received the IPV® treatment. The principle of IPV® is to open collapsed airways and mobilize intrabronchial secretions through the delivery of small tidal volume at high frequency. IPV® adjusts the percussions to the changes in the mechanical properties of the patient's respiratory system: in case of high resistance, it produces small tidal volume at high pressure and low frequency; vice versa in case of low resistance, it produces large tidal volume at low pressure and high frequency
89604957|NCT01394991|Experimental|001|Epoetin alfa 450 IU/kg once a week (QW) 450 IU/kg once a week (QW) by subcutaneous injection preferably in the abdomen for up to 4 weeks after the last dose of chemotherapy for a maximum of 26 weeks
89604958|NCT01394991|Experimental|002|Epoetin alfa 150 IU/kg 3 times a week (TIW) 150 IU/kg 3 times a week (TIW) by subcutaneous injection preferably in the abdomen for up to 4 weeks after the last dose of chemotherapy for a maximum of 26 weeks.
89604959|NCT04407663||Bariatric Patient|Inclusion criteria were as follows: obese adults (> 18 years of age, BMI> 40 or > 35 with comorbidities) older than 18 years; patients undergoing bariatric surgery within 6 months; patients who required clinical and instrumental control; presence of a caregiver in case of subject with cognitive impairment; patients with a history of bariatric surgery who requested a first outpatients access or established patients who requested an outpatients' visit for an emerging problem.
89604960|NCT05632653|Experimental|CTO-PCI|
89604961|NCT05632653|No Intervention|non-CTO-PCI|
89604962|NCT01829347|Experimental|ELAD (plus Standard of Care)|ELAD is a human cell-based bio-artificial liver support system developed to improve survival of patients with acute liver failure and to provide liver support continuously to a subject with compromised liver function. Standard of care is predefined treatment for sAAH complications (ascites, hepatic encephalopathy, varices, etc.) per AASLD/EASL Guidelines.
89604963|NCT01829347|Other|Standard of Care (Control)|Standard of care is predefined treatment for sAAH complications (ascites, hepatic encephalopathy, varices, etc.) per AASLD/EASL Guidelines.
89604964|NCT01394523|Active Comparator|Caudal epidural|The caudal epidural block will be delivered with 1.5ml/kg of 0.25% Bupivacaine up to a maximum of 30 mL.
89604965|NCT01394523|Active Comparator|Rectus sheath|The rectus sheath block will be performed with 0.1ml/kg of 0.25% Bupivacaine on each side at the T9-T10 distribution under ultrasound guidance.
89604966|NCT01394523|Active Comparator|Local|The surgeon will inject either 0.5% Bupivicaine 0.5ml/kg or 0.25% Bupivicaine 1ml/kg at the surgeon's discretion.
89604967|NCT01857973|Experimental|Hybrid Closed Loop|In-clinic evaluation of the HCL System under various conditions.
89604968|NCT04304469||women|women consulting for domestic violence
89604969|NCT04407273||with statins|Covid-19 infected patients with statins
89604970|NCT04407273||without statins|Covid-19 infected patients without statins
89604971|NCT01857583|Experimental|SRI 15mg (15 mL/min ≤ CLCR < 20mL/min)|Severe Renal Impairment group orally administered 15mg DU-176b once daily for 14 days.
89604972|NCT01857583|Experimental|MiRI 30mg (50 mL/min ≤ CLCR ≤ 80mL/min)|Mild Renal Impairment group orally administered 30mg DU-176b once daily for 14 days.
89604973|NCT01857583|Active Comparator|Fondaparinux (20 mL/min ≤ CLCR < 30mL/min)|Fondaparinux subcutaneously administered at a dose of 1.5mg once daily for 14 days.
89032523|NCT02929758|Active Comparator|Control Delayed Training Group|Healthy Controls will receive delayed SOPT training and will be compared against controls in the initial training group and the PD subjects in the delayed training group
89604974|NCT01857583|Experimental|SRI 15mg (20 mL/min ≤ CLCR < 30mL/min)|Severe Renal Impairment group orally administered 15mg DU-176b once daily for 14 days.
89604975|NCT04000347|Active Comparator|2.5% benzoyl peroxide|43 patients with 2.5% benzoyl peroxide gel
89604976|NCT04000347|Active Comparator|5% benzoyl peroxide|43 patients with 5% benzoyl peroxide gel
89604977|NCT01829191|Experimental|Test Lens A|Test lenses will be worn in a daily wear modality
89604978|NCT01829191|Experimental|Test Lens C|Test lenses will be worn in a daily wear modality
89604979|NCT05360745|Experimental|Experimental arm|ARACOMPLEX® (food supplement). 2 tablets per day, during 6 months.
89604980|NCT05360745|Placebo Comparator|Control arm|Placebo. 2 tablets per day, during 6 months.
89604981|NCT00211185|Experimental|Denileukin diftitox in combination with CHOP|Unblinded denileukin diftitox at 18 micrograms/kilogram/day (ug/kg/d) was administered intravenously (IV) on Days 1 and 2 of each 21-day cycle. Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) was administered on Day 3 of each 21-day cycle. On Day 4 of each 21-day cycle, pegfilgrastim (a granulocyte colony-stimulating factor (G-CSF)) was started as a prophylaxis to prevent neutropenia. After completion of two 21-day cycles, participants were evaluated for clinical response. Two 21-day cycles with denileukin and CHOP were repeated followed by response evaluations after each set of two 21-day cycles with intent to treat for 6 cycles, with a maximum of 8 cycles.
89604982|NCT00210639||Levofloxacin-treated cohort|Participants receiveing levofloxacin in previous levofloxacin studies will be observed.
89604983|NCT00210639||Comparator-treated cohort|Participants receiveing comparator in previous levofloxacin studies will be observed.
89604984|NCT05632029|Active Comparator|laser (active laser)|32 lupus prediabetic women will receive laser acupuncture (active laser) for one month (3 days week) on acupoint number 14 of GV meridian, acupoint number 4 and 11 of large intestine, acupoint number 34 of gall bladder meridian, acupoint number 3 of liver meridian, acupoint number 4, 12, and 9 of conception vessel meridian, acupoint number 40, 36, and 25 of stomach meridian, acupoint number 6 of spleen meridian, and acupoint number 5 of triple energizer meridian, laser will be applied for 1 min on every acupiont)
89604985|NCT05632029|Sham Comparator|laser (sham laser)|32 lupus prediabetic women will receive laser acupuncture (sham . i.e power of the device will be zero) for one month (3 days week) on acupoint number 14 of GV meridian, acupoint number 4 and 11 of large intestine, acupoint number 34 of gall bladder meridian, acupoint number 3 of liver meridian, acupoint number 4, 12, and 9 of conception vessel meridian, acupoint number 40, 36, and 25 of stomach meridian, acupoint number 6 of spleen meridian, and acupoint number 5 of triple energizer meridian, laser will be applied for 1 min on every acupiont)
88981601|NCT02522182|Active Comparator|Usual Treatment|The patients randomised to the control group will follow the Usual Treatment for secondary prevention of the hospital to which they were admitted
88981602|NCT02478450|Experimental|Cohort 1|Unilateral lumbar surgical transplantation of Q-Cells dose level 1
88981603|NCT02478450|Experimental|Cohort 2|Unilateral cervical surgical transplantation of Q-Cells dose level 1
88981604|NCT02478450|Experimental|Cohort 3|Unilateral cervical surgical transplantation of Q-Cells dose level 2
88981605|NCT02478450|Experimental|Cohort 4|Unilateral cervical surgical transplantation of Q-Cells dose level 3
88981606|NCT02478450|Experimental|Cohort 5|Unilateral cervical surgical transplantation of Q-Cells dose level 4
88981607|NCT02478450|Experimental|Cohort 6|Unilateral cervical surgical transplantation of Q-Cells dose level 5
88981608|NCT02473926|Experimental|Physical Activity Program Intervention|"The intervention seeks to increase physical activity and improve strength by addressing individual , behavioral, and social/environmental factors. Health promotion clinic staff will deliver counseling by phone on a bi-weekly basis - a clinic physician assistant will coordinate with the counselor during in-person clinic visits, teach participants to perform strengthening exercise, and assess for safety concerns associated with type 2 diabetes.~In addition to behavioral counseling targeting social cognitive theory constructs, counselors will assist participants in the intervention group to set specific goals for physical activity in a paper log and on an electronic FitBit activity tracking device.Health promotion clinic staff will encourage participants to advance goals towards meeting U.S. physical activity guidelines of 150 minutes/week of moderate intensity activity and 2-3 days/week of strength activities."
88981609|NCT02473926|Other|Usual Care Group|Participants in the usual care arm will receive three mailings (Intervention Questionnaires) during the intervention phase. Health promotion clinic staff will mail materials from the Center for Disease Control and Prevention website that address general health aging topics.
88981610|NCT02471391|Experimental|Ibrutinib + ABT-199|
88981611|NCT02446249|Experimental|single arm dose escalation|single arm dose escalation
88981612|NCT02426125|Experimental|Ramucirumab + Docetaxel|Ramucirumab (10 milligram/kilogram [mg/kg]) intravenously (IV) plus docetaxel (75 milligram/square meter [mg/m²]) IV on day 1 of each 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
88981613|NCT02426125|Placebo Comparator|Placebo + Docetaxel|Placebo IV plus docetaxel (75 mg/m²) IV on day 1 of each 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
88981614|NCT02395497|Experimental|Treatment: Transplantation|Penile transplantation with an immunomodulatory protocol consisting of monoclonal antibody induction therapy of humanized anti CD52 followed by donor bone marrow infusion and tacrolimus monotherapy.
88981615|NCT02394860||blood and cardiological examination|
88981616|NCT02379338|Experimental|Dynamic Brain Cohort|The Dynamic Brain cohort will include up to 10 patients who will undergo a dynamic brain [18F]Fluortriopride PET/CT scan over a period of approximately 2 hours. Subjects in this cohort will also undergo a research brain MRI, generally on a separate day from the PET/CT.
88981617|NCT02379338|Experimental|Biodistribution Cohort|The Biodistribution cohort will include up to10 patients who will undergo a series of whole body biodistribution [18F]Fluortriopride PET/CT scans over a period of approximately 4 hours.
89604986|NCT05631873|Experimental|Intervention|
89604987|NCT05631873|No Intervention|Control|
88981618|NCT02362594|Experimental|Pembrolizumab|In Part 1, participants receive pembrolizumab 200 mg intravenously (IV) as post-surgery therapy every 3 weeks (Q3W) for up to 1 year. During Part 2, participants with documented recurrence may receive optional re-treatment with pembrolizumab Q3W for up to 2 years or disease progression.
88981619|NCT02362594|Placebo Comparator|Placebo|In Part 1, participants receive placebo IV as post-surgery therapy Q3W. During Part 2, participants with documented recurrence who received placebo in Part 1 may receive optional treatment with pembrolizumab Q3W for up to 2 years or disease progression.
88981620|NCT02355379|Experimental|GROUP1 -ARM A|LV5FU2 or capecitabine
88981621|NCT02355379|Experimental|GROUP1-ARMB|FOLFOX4 or XELOX
88981622|NCT02355379|Experimental|GROUP2- ARM C|Observation
88981623|NCT02355379|Experimental|GROUP2-ARM D|LV5FU2 or capecitabine
88981624|NCT02331277|Experimental|BI 655064|Subjects received BI 655064 240 milligram (mg) via subcutaneous injection every week, until 4 weeks.
89604988|NCT01829113|Experimental|OGX-427|Three loading doses of OGX-427 at 600mg intravenously (IV) will be administered over 9 days. Following the loading dose period, OGX-427 will be administered at 600mg IV weekly Days 1, 8 and 15 of each 21 day cycle during the Treatment Phase. The Treatment Phase will be followed by a Maintenance Phase of OGX-427 administered at 600mg IV weekly Days 1, 8 and 15 of each 21 day cycle.
89604989|NCT01829113|Placebo Comparator|Placebo|Three loading doses of placebo will be administered intravenously (IV) over 9 days. Following the loading dose period, placebo will be administered IV weekly Days 1, 8 and 15 of each 21 day cycle during the Treatment Phase. The Treatment Phase will be followed by a Maintenance Phase of placebo administered IV weekly Days 1, 8 and 15 of each 21 day cycle.
89604990|NCT00219297|Experimental|Single Arm|
88981625|NCT02331277|Placebo Comparator|Placebo|Subjects received placebo matching to BI 655064 via subcutaneous injection every week, until 4 weeks.
89032524|NCT02929758|Other|PD Initial Training Group|PD subjects will received initial SOPT training and will be compared against PD subjects in the delayed training group and the control subjects in the initial training group
89604991|NCT01857271|Experimental|Treatment (erlotinib hydrochloride and thoracotomy)|Patients receive erlotinib hydrochloride PO QD for 2 months and then undergo thoracotomy.
89604992|NCT00216255|Experimental|Pagoclone|.15mg, .30mg, .60mg
89604993|NCT00216255|Placebo Comparator|Placebo|Placebo
89604994|NCT01745120|Experimental|LentiGlobin BB305 Drug Product|
89604995|NCT03024723||FmCPAP|CPAP ventilation administered via face mask
89604996|NCT01828567|Experimental|Intervention|Primary care phone-based prevention coaching using shared decision making following a Healthy Living Assessment
89604997|NCT01828567|No Intervention|Control|Usual care
89604998|NCT01721486|Experimental|Study Group|IV acetaminophen 15 mg/kg (up to 1000 mg) administered intraoperatively over a 15 minute infusion.
89604999|NCT01721486|Active Comparator|Control Group|PO acetaminophen elixir 15 mg/kg (up to 1000 mg) administered approximately 90 minutes (+/- 30 minutes) prior to induction of anesthesia in the pre-operative area.
89605000|NCT04610905|No Intervention|Control group|This group will be asked to maintain their daily routine.
89605001|NCT04610905|Experimental|Reducing sedentary behavior|This group needs to download an app on their computer and their smartphone. This app will give a notification every 30 minutes to walk during 2 minutes during working hours.
88981626|NCT02218151|Experimental|Patient-Centered Medical Home (PCMH)|"Day-to-Day Care:~Advanced Practice Providers (APP) will travel to subjects' homes in the morning, where they will perform the same daily assessment as standard care. They will draw labs and bring them back to the hospital for processing. When results are available, a second home visit is made to deliver necessary interventions. Subjects will have internet access through cellular-networked iPads and have daily videoconferences with their physicians. Daily follow up at home will continue until discharge as per above criteria.~Caregivers: identified by the subject as the person taking primary care of them will answer surveys and also collect stool samples to analyze in conjunction with those from subjects."
89605002|NCT04610905|Experimental|Increase physical activity|This group will be asked to be more physically active. They need to be active during 150min/week. Additionnaly they need to be active in periods of at least 10 minutes.
89605003|NCT05631639|Experimental|PillSense System|The device is composed of an orally ingested sensor capsule and a wireless handheld receiver for real-time display of sensor data. The capsule contains a measuring slot for blood entry. The sensor capsule is used for diagnosis in patients with suspected acute bleeding in the upper gastrointestinal tract.
88981627|NCT02218151|Active Comparator|Standard Care|"These subjects will begin as inpatients or outpatients, where advanced practice providers (APPs) (nurse practitioners and physician assistants) will perform histories and physical exams. Nurses will collect labs and providers will enter orders in our electronic health record (EHR). All steps will be repeated daily until discharge to home. Suitability for discharge is determined by standard clinical criteria including stable blood counts, freedom from active or severe complications (e.g. active infection, severe GVHD), and ability to care for self.~Caregivers: identified by the subject as the person taking primary care of them will answer surveys and also collect stool samples to analyze in conjunction with those from subjects."
89605004|NCT05366517|Other|Group|LiST active treatment group
89605005|NCT01775930|Experimental|Carfilzomib|Patients receive Carfilzomib at dose of 20 mg/m2 over 30 minutes by vein infusion on Days 1 and 2 and a dose of 56 mg/m2 over 30 minutes by vein infusion on Days 8, 9, 15, and 16 of each 4 week cycle.
89605006|NCT01856569||observational|
89605007|NCT04273425||Study cohort (Confirmed myeloma patients)|"Patients with suspected multiple myeloma will be recruited. They will be asked to fill in questionnaires (regarding pain, quality of life, catastrophizing), donate serum samples and allow the research team to access their clinical data and their diagnostic bone biopsy.~Those who receive a positive diagnosis will be followed up upon completion of first-line treatment, and questionnaire data and blood samples collected again."
89605008|NCT04273425||Control cohort (non-confirmed myeloma patients)|"Patients with suspected multiple myeloma will be recruited. They will be asked to fill in questionnaires (regarding pain, quality of life, catastrophizing), donate serum samples and allow the research team to access their clinical data and their diagnostic bone biopsy.~Samples from patients who receive a negative myeloma diagnosis will be used as negative controls."
89605009|NCT03024645|Experimental|BeAMom|High-risk (HR) women will receive a web-based preventive intervention for PPD (the Be a Mom program). In addition, women will receive postpartum and and pediatric treatment as usually performed in primary care settings (TAU).
89605010|NCT03024645|Active Comparator|Control|High-risk (HR) women will receive postpartum and pediatric treatment as usually performed in primary care settings (TAU). During medical appointments, health professionals may ask women and provide information about psychological problems during the postpartum period.
89605011|NCT01721408|Experimental|Group A|
88981628|NCT02210767|Experimental|Walnut Diet|Provides ~2 oz. walnuts/day (2-3% of total calories from alpha-linolenic acid [ALA])
88981629|NCT02210767|Active Comparator|Walnut Control Diet|Provides same fatty acid profile (<7% SFA, 9% MUFA, 14-15% PUFA, 2-3% ALA) as Walnut Diet, but is devoid of walnuts and their bioactives
88981630|NCT02210767|Placebo Comparator|Low ALA Diet|Provides similar macronutrient and linoleic acid profile but replaces ALA with oleic acid (<7% SFA, 12% MUFA, 12% PUFA, 0.5% ALA)
88981631|NCT02180841|Experimental|Soy 25g|Soy protein powder (25g/day)
88981632|NCT02180841|Experimental|Soy 50g|Soy protein powder 50 g/day
88981633|NCT02180841|Placebo Comparator|Control|Control powder
89605012|NCT01721408|Active Comparator|Group B|
89605013|NCT03998709|Other|Elevation of fasting FFA and Glucose|People with normal fasting glucose and normal fasting FFA (normal fasting glucose / normal glucose tolerance - NFG / NGT) will be studied on 2 occasions. On one occasion they will receive saline overnight and on the other they will receive intralipid and dextrose to raise fasting glucose and fasting FFA. Subsequently (on either study day) they will undergo a hyperglycemic clamp for 2 hours. After this somatostatin will be infused acutely to inhibit endogenous insulin secretion and observe clearance of beta-cell polypeptides.
89605014|NCT03998709|Other|Lowering of fasting FFA and glucose|People with elevated fasting glucose and elevated fasting FFA (Impaired fasting glucose / impaired glucose tolerance - IFG / IGT) will be studied on 2 occasions. On one occasion they will receive saline overnight and on the other they will receive insulin to lower fasting glucose and fasting FFA. Subsequently (on either study day) they will undergo a hyperglycemic clamp for 2 hours. After this somatostatin will be infused acutely to inhibit endogenous insulin secretion and observe clearance of beta-cell polypeptides.
89605015|NCT03025191|Experimental|Prison Connect|
89605016|NCT01744496|Experimental|Rotigotine|Rotigotine Transdermal Patches
89605017|NCT01744496|Placebo Comparator|Placebo|Placebo Transdermal Patches
89032525|NCT02929758|Other|PD Delayed Training Group|PD subjects will receive delayed SOPT training and will be compared against PD subjects in the initial training group and the control subjects in the delayed training group
89605018|NCT05366205|Experimental|Oral nutritional supplements|Patients in this arm will receive oral nutritional supplements 24-48 hours after admission，which is enteral nutrition emulsion(TPF-T).
89605019|NCT05366205|Sham Comparator|nutrition consultation|Patients in this arm will receive nutrition consultation was given in addition to basic treatment.
89605020|NCT01721330|Active Comparator|Naltrexone|Active Naltrexone administered twice daily up to a maximum total dose of 100mg/day.
89605021|NCT01721330|Placebo Comparator|Placebo|Naltrexone-masked placebo administered twice daily up to a maximum total dose of 100mg/day.
89605022|NCT05366127||Patient with bullous pemphigoid|IGA score and BPDAI score will be assessed to patient with bullous pemphigoid
89605023|NCT05631015||Artificial Intelligence support decision group|According the endoscopic reports and pathological reports, the decision support system recognise patients' disease types and grades, and generate guidelines based survilliance or treatment recommendations.
89605024|NCT03595605|Experimental|FitBit Group|Will receive a wearable device (FitBit) designed to track number of steps for the duration of their hospital stay. They will receive nudges twice/day to ambulate
88981634|NCT02173509|Experimental|Educational multifaceted intervention|Multidisciplinary and multifaceted educational intervention about antibiotic prescription and dispense, in physicians and pharmacists.
88981635|NCT02173509|No Intervention|Control|Physicians and pharmacists that not received the multidisciplinary and multifaceted educational intervention about antibiotic prescription and dispense.
88981636|NCT02157974|Experimental|PCOS, medication naive + Byetta|PCOS, medication naive; 10 girls with PCOS will receive 2 doses of Byetta.
88981637|NCT02157974|No Intervention|Control|Up to 25 girls without PCOS
88981638|NCT02157974|No Intervention|PCOS medication naive|Up to 45 girls with PCOS with no exposure to hormone therapy or metformin in the preceding 6 months.
88981639|NCT02157974|No Intervention|PCOS on COCPs|Up to 10 girls with PCOS and 6 months of therapy with combined oral contraceptives (COCPs) prior to study procedures.
88981640|NCT02157974|No Intervention|PCOS on metformin|Up to 10 girls with PCOS and 6 months of therapy with metformin prior to study procedures
88981641|NCT02140255|Experimental|Cohort 1, Regimen 1L: 2 NRTIs + NVP + LPV/r|Participants will receive 2 NRTIs + NVP + LPV/r.
88981642|NCT02140255|Experimental|Cohort 2, Regimen 1L: 2 NRTIs + NVP + LPV/r|Participants will receive 2 NRTIs + NVP + LPV/r.
88981643|NCT02140255|Experimental|Cohort 1, Regimen 2R: 2 NRTIs + NVP + RAL|Participants will receive 2 NRTIs + NVP + RAL.
88981644|NCT02140255|Experimental|Cohort 2, Regimen 2R: 2 NRTIs + NVP + RAL|Participants will receive 2 NRTIs + NVP + RAL.
88981645|NCT02140255|Experimental|Cohort 1, Regimen 2RV: 2 NRTIs + NVP + RAL + VRC01|Participants will receive 2 NRTIs + NVP + RAL + VRC01.
88981646|NCT02120365|Experimental|Perampanel 6mg|Participants will have 3 test days each, 2 weeks apart, in a randomized order, following either pretreatment with daily perampanel 2mg days prior to each test day, and then observed dosing moderate 6mg dose perampanel in the lab 1 hour before a one-time alcohol infusion . Each lab session occurs exactly a week after starting the medication for that round. The wash out period between lab test session phases will be 7-10 days. Subjects will receive 2 days of 2mg perampanel after each lab to taper down (included in the washout period). The next appointment will be brief at the start of the next phase, at which point the next week of low dose perampanel or placebo will be started. With the washout period and the 7 day taper of the next phase, the actual lab sessions will occur 14-17 days apart. All test days will involve administration of alcohol with the same 3 target doses [target Breath Alcohol Concentration (BrAc) =20mg%, 60mg%, and 100mg%] in a step-wise fashion.
88981647|NCT02120365|Placebo Comparator|Placebo|Participants will have 3 test days each, 2 weeks apart, in a randomized order, following either pretreatment with placebo 7 days prior to each test day, and then observed dosing of placebo in the lab 1 hour before a one-time alcohol infusion . Each lab session occurs exactly a week after starting the medication for that round. The wash out period between lab test session phases will be 7-10 days. Subjects will receive 2 days of 2mg perampanel after each lab to taper down (included in the washout period). The next appointment will be brief at the start of the next phase, at which point the next week of low dose perampanel or placebo will be started. With the washout period and the 7 day taper of the next phase, the actual lab sessions will occur 14-17 days apart. All test days will involve administration of alcohol with the same 3 target doses [target Breath Alcohol Concentration (BrAc) =20mg%, 60mg%, and 100mg%] in a step-wise fashion.
89032526|NCT02947139|Experimental|Study effect of DWC20161 on DWC20155/DWC20156 PK|To study effect of DWC20161 on DWC20155/DWC20156 PK
89032527|NCT02947139|Experimental|Study effect of DWC20155/DWC20156 on DWC20161 PK|To study effect of DWC20155/DWC20156 on DWC20161 PK
89032528|NCT02929836|Active Comparator|PVI+LA linear ablation +CFAE ablation|The ablation procedure for atrial fibrillation guided by CARTO system, including PVI, LA linear ablation (roof line and mitral isthmus)and CFAE ablation.
89032529|NCT02929836|Active Comparator|PVI+linear ablation +CFAE ablation|The ablation procedure for atrial fibrillation guided by CARTO system, including PVI,roof line and mitral isthmus,cavotricuspid isthmus abaltion and CFAE ablation.
89032530|NCT02929836|Active Comparator|PVI+CFAE ablation|The ablation procedure for atrial fibrillation guided by CARTO system, including PVI and CFAE ablation.
89032531|NCT04693052||Patients receiving mental health care prior to and during the COVID-19 pandemic|
89605025|NCT03595605|Active Comparator|Control Group-Standard of Care|300 subjects who will receive usual standard of care on a general inpatient medicine unit with the addition of a wearable device (FitBit) to track usual mobility in this setting. will complete their admission without push for increased activity (although having the device may influence their steps taken).
89605026|NCT04407195||Healthcare Providers|Healthcare workers (physicians and nurses) who have interacted with patients with known or suspected COVID-19.
89605027|NCT03592407|Experimental|Treatment (epacadostat, pembrolizumab)|Starting 14 days after completion of standard of care chemoradiotherapy, participants receive epacadostat PO BID during weeks 3-8 and pembrolizumab IV over 30 minutes on day 1 of weeks 3 and 6 in the absence of disease progression or unacceptable toxicity.
89605028|NCT03593187|Experimental|Cal-1( LVsh5/C46) drug product|
89032532|NCT02929914|Experimental|Control|Local anesthesia, rubber dam isolation, remove caries incompletely, microbiological sample with otoscope curette, dentin washed with sodium 0.9% saline, sampling again. Indirect pulp treatment with calcium hydroxide(CH). Restoration with resin(Z350,3M). Follow up at 6, 12 and 24 months.
89032533|NCT02929914|Experimental|PDT+CH|Local anesthesia, rubber dam isolation, remove caries incompletely, microbiological sample with otoscope curette, disinfect the remaining dentin with antimicrobial photodynamic therapy (DENFOTEX PADplus), sampling again. Indirect pulp treatment with calcium hydroxide(CH). Restoration with resin(Z350,3M). Follow up at 6, 12 and 24 months.
89032534|NCT02947334|Experimental|Bococizumab|Bococizumab Q2wks
89032535|NCT02947334|Placebo Comparator|Placebo|Bococizumab placebo Q2wks
89032536|NCT02929641||HDWL and OE with magnification|The polyps found will be observed by HDWL and OE with magnicication model and recorded.
89605029|NCT04254159|Experimental|Neuromuscular Electrical Stimulation Group|Asthma Education Aerobic Exercise Quadriceps Strengthening by superimposed NMES
89605030|NCT04254159|Active Comparator|Control Group|Asthma Education Aerobic Exercise Quadriceps Strengthening
89605031|NCT03978585|Experimental|HTEMS Arm|High tone therapy (home based) daily for 30 minutes on at least 5 of 7 days per week
89605032|NCT03978585|Active Comparator|TENS Arm|TENS therapy (home based) daily for 30 minutes on at least 5 of 7 days per week
89605033|NCT02079987|Experimental|ED-to-home care transition intervention|The ED-to-home care transition intervention is a coaching intervention. It is a 4-week program that uses an Area Agency on Aging healthcare coach to conduct a home visit and at least 3 follow-up phone calls to help patients develop the skills needed for self-management and to communicate with healthcare providers.
89605034|NCT02079987|Experimental|Usual Care|Patients randomized to usual care will receive verbal and written discharge instructions from the treating ED physician and nurse as is the standard of care.
89605035|NCT03996135|Experimental|Experimental : Cannulation with AccuVein AV400|Cirrhotic patients benefit from the support of a venous illumination device for each peripheral venous cannulation
89605036|NCT03996135|No Intervention|Control|Cirrhotic patients benefit from the standard technique of peripheral veinous catheter placement.
89605037|NCT03995511|Experimental|Bilateral sagittal split|
89605038|NCT03595137|Experimental|sono with simple needle guide device group (Group D)|sono with simple needle guide device Simple needle guide device was attached to the sono probe. Device was designed to assist the detection of the puncture site. After induction of anesthesia, sono-guided internal jugular vein cannulation was performed.
89605039|NCT03595137|Placebo Comparator|sono only group (Group S)|sono only group After induction of anesthesia, sono-guided internal jugular vein cannulation was performed.
89605040|NCT03594903|Experimental|Expectation violation (positive outcome of therapy)|Experimental: patients' report about therapy outcome Video with patients giving information about (mostly) positive therapy outcome
89605041|NCT03594903|Other|Control group (symptoms + expectation)|"Control group: patient´s report about symptoms and therapy expectations~Participants in the control group are watching a video with the same patients (actors) as in the experimental video. In this video patients are shown before or after the first therapy session. They are giving information about symptoms and their expectation on therapy but NOT about therapy outcome."
89605042|NCT05633589|Experimental|Experimental: Sc610 cell injection|This trial is designed single arm. All the subjects enrolled will receive the experimental intervention: Sc610 cell injection.
89605043|NCT01828021|Experimental|margetuximab|Monotherapy of Anti-HER2 monoclonal antibody
89605044|NCT03594669|Experimental|Intervention|"When enrolled into the study, the participants will be asked to join a group in WhatsApp for purposes of the research study. The application will be used to: deliver reminders for each treatment session; deliver daily prompts for the home exercise program; and present a web-link to the home exercise program (HEP).~Participants will receive physical therapist delivered multi-modal sensorimotor training interventions. The exercises delivered at each intervention will be delivered in a group format, using a circuit of exercises that each athlete will complete in a session. Subsequent sessions will build upon previous sessions to work the sensorimotor control system in progressively more challenging and sport-specific scenarios. This present study will complete 8 sessions over 4 weeks."
89605045|NCT03994653||Cases|Participants diagnosed with ovarian cancer
89605046|NCT03994653||Controls|Participants without ovarian cancer
89605047|NCT05633199|Experimental|cytoreduction surgery followed by chemotherapy|
89605048|NCT05633199|No Intervention|chemotherapy alone|
89605049|NCT03594279|Experimental|Community Mobilization|This arm will receive specific messages regarding the prevention and management of childhood diarrhea and pneumonia. The investigators will form village committees (VC) consisting of prominent members of the community (6-8 in a group) to carry out awareness and motivational activities for the uptake of the identified interventions.
89032537|NCT00525317|Active Comparator|Magnesium tablet suplementation (1)|"Nycoplus Magnesium (120 mg x 3 daily for 2 weeks)"
89032538|NCT00525317|Placebo Comparator|Placebo tablet suplementation (2)|Placebo (3 times daily for 2 weeks)
89605050|NCT03594279|Experimental|Community Mobilization and Community Incentive|In this arm, along with the interventions in the community mobilization arm, community based incentives will also be provided. The clusters which improve the practices for preventive and curative strategies for diarrhea and pneumonia will receive community-based incentive including structural benefits linked to health including tube wells, water supply, toilets in community/schools, water storage facility or any other incentive as decided with the respective village committees.
89605051|NCT03594279|No Intervention|Control|This arm will receive the routine standard of care.
89605052|NCT03784599|Experimental|Trastuzumab-emtansine and osimertinib|"Trastuzumab-emtansine 3.6 mg/kg, intravenously, every 3 weeks~Osimertinib 80 mg once daily, orally, continuous~Treatment will be continued until tumor progression (according to RECIST v1.1) confirmed by tumor imaging, unacceptable toxicity, or death occurs."
89605053|NCT01827943|Experimental|Temsirolimus|Temsirolimus was administered intravenously at a dose of 25 mg in a weekly 30 min infusion and was associated to anti-H1 treatment. One cycle corresponded to 4 weeks of treatment.
89605054|NCT03594201||group1|A+B grade sperm count after treatment=0
89605055|NCT03594201||group2|0<A+B grade sperm count after treatment≤10^6
89605056|NCT03594201||group3|10^6<A+B grade sperm count after treatment<2*10^6
89605057|NCT03594201||group4|A+B grade sperm count after treatment≥2*10^6
89605058|NCT02985255|Experimental|Neoadjuvant Arm|Study Subjects, eligible for NACT would undergo a pretreatment workup with Evaluation Under Anesthesia for tumor Mapping and tissue biopsy along with a PET-CT scan. They would undergo 3 cycles of NACT (weekly thrice) with injection Docetaxel, Cisplatin and 5-FU after which reassessment with PET-CT and EUA +/- biopsy would be done. Those achieving CR would undergo adjuvant CTRT while subjects with PR in PET-CT scan will be reclassified based on the biopsy report. If biopsy is negative for malignancy, they will undergo adjuvant CTRT but would undergo surgery if in the PR group. Subjects with SD or PD would undergo surgery. PET-CT and EUA +/- HPE analyses would be repeated on follow-up after 3 months of treatment completion.
89605059|NCT04609813||Screening population|Participants underwent opportunistic endoscopic screening for esophageal cancer in high-risk regions in China will be enrolled in this study. Esophageal cell specimen will be collected by esophageal sponge cell collection device (Esoheal 1.0) prior to endoscopic examinations.
89605060|NCT05633043||16-18 year, CAST binary version|"Enrollment estimates are based on COSMIN recommendations (https://www.cosmin.nl/) (3). To achieve psychometric validity of the CAST, 110 patients should be included, 50 of whom would be retested. It is proposed to include 110 patients for each of the 3 age categories under study (16-18 years, 18-25 years and 25-45 years) and for each of the 2 scales tested, i.e. a total of 110*3 (age classes)*2 versions of the CAST = 660 patients. In each age category and for each scale: 50 patients (among the 110) will have to complete the Retest phase, i.e. 50*3*2=300 patients (among the 660).~Five inclusion centers (DMG) will participate in the study, which makes 132 patients per investigating center (66 patients for each scale, i.e. 22 patients for each scale and each age category in each DMG). The GPs will have to include 13.2 patients, during the 12 months of the study."
89605061|NCT05633043||16-18 year, CAST Likert version|"Enrollment estimates are based on COSMIN recommendations (https://www.cosmin.nl/) (3). To achieve psychometric validity of the CAST, 110 patients should be included, 50 of whom would be retested. It is proposed to include 110 patients for each of the 3 age categories under study (16-18 years, 18-25 years and 25-45 years) and for each of the 2 scales tested, i.e. a total of 110*3 (age classes)*2 versions of the CAST = 660 patients. In each age category and for each scale: 50 patients (among the 110) will have to complete the Retest phase, i.e. 50*3*2=300 patients (among the 660).~Five inclusion centers (DMG) will participate in the study, which makes 132 patients per investigating center (66 patients for each scale, i.e. 22 patients for each scale and each age category in each DMG). The GPs will have to include 13.2 patients, during the 12 months of the study."
89605062|NCT05633043||18-25 year, CAST binary version|"Enrollment estimates are based on COSMIN recommendations (https://www.cosmin.nl/) (3). To achieve psychometric validity of the CAST, 110 patients should be included, 50 of whom would be retested. It is proposed to include 110 patients for each of the 3 age categories under study (16-18 years, 18-25 years and 25-45 years) and for each of the 2 scales tested, i.e. a total of 110*3 (age classes)*2 versions of the CAST = 660 patients. In each age category and for each scale: 50 patients (among the 110) will have to complete the Retest phase, i.e. 50*3*2=300 patients (among the 660).~Five inclusion centers (DMG) will participate in the study, which makes 132 patients per investigating center (66 patients for each scale, i.e. 22 patients for each scale and each age category in each DMG). The GPs will have to include 13.2 patients, during the 12 months of the study."
89605063|NCT05633043||18-25 year, CAST Likert version|"Enrollment estimates are based on COSMIN recommendations (https://www.cosmin.nl/) (3). To achieve psychometric validity of the CAST, 110 patients should be included, 50 of whom would be retested. It is proposed to include 110 patients for each of the 3 age categories under study (16-18 years, 18-25 years and 25-45 years) and for each of the 2 scales tested, i.e. a total of 110*3 (age classes)*2 versions of the CAST = 660 patients. In each age category and for each scale: 50 patients (among the 110) will have to complete the Retest phase, i.e. 50*3*2=300 patients (among the 660).~Five inclusion centers (DMG) will participate in the study, which makes 132 patients per investigating center (66 patients for each scale, i.e. 22 patients for each scale and each age category in each DMG). The GPs will have to include 13.2 patients, during the 12 months of the study."
89605064|NCT05633043||25-45 year, CAST binary version|"Enrollment estimates are based on COSMIN recommendations (https://www.cosmin.nl/) (3). To achieve psychometric validity of the CAST, 110 patients should be included, 50 of whom would be retested. It is proposed to include 110 patients for each of the 3 age categories under study (16-18 years, 18-25 years and 25-45 years) and for each of the 2 scales tested, i.e. a total of 110*3 (age classes)*2 versions of the CAST = 660 patients. In each age category and for each scale: 50 patients (among the 110) will have to complete the Retest phase, i.e. 50*3*2=300 patients (among the 660).~Five inclusion centers (DMG) will participate in the study, which makes 132 patients per investigating center (66 patients for each scale, i.e. 22 patients for each scale and each age category in each DMG). The GPs will have to include 13.2 patients, during the 12 months of the study."
89605065|NCT05633043||25-45 year, CAST Likert version|"Enrollment estimates are based on COSMIN recommendations (https://www.cosmin.nl/) (3). To achieve psychometric validity of the CAST, 110 patients should be included, 50 of whom would be retested. It is proposed to include 110 patients for each of the 3 age categories under study (16-18 years, 18-25 years and 25-45 years) and for each of the 2 scales tested, i.e. a total of 110*3 (age classes)*2 versions of the CAST = 660 patients. In each age category and for each scale: 50 patients (among the 110) will have to complete the Retest phase, i.e. 50*3*2=300 patients (among the 660).~Five inclusion centers (DMG) will participate in the study, which makes 132 patients per investigating center (66 patients for each scale, i.e. 22 patients for each scale and each age category in each DMG). The GPs will have to include 13.2 patients, during the 12 months of the study."
89605066|NCT03593967|Experimental|Intervention Group|Youths and seniors in the intervention group will be paired to receive a novel five-week (3 hours/ week) bilingual (English/ Mandarin), intergenerational arts programme which includes guided museum tours, collaborative art-making and story telling as well as reflective writing. These sessions will be held at the National Museum, and facilitated by experienced artists and trained art therapists.
89605067|NCT03593967|Experimental|Waitlist Control Group|Participants will serve as a waitlist control group before receiving the intervention that the intervention group receives at the end of 5 weeks.
89605068|NCT05632887||Control|The population who do not use eyeliner.
89605069|NCT05632887||Eyeliner|The population who using eyeliner and the duration and frequency are appropriate。
89605070|NCT05632731|Other|Double Cleavage-stage Embryos transfer|In group A, two embryos at cleavage stage were transplanted on the third day after oocyte retrieval.
89605071|NCT05632731|Other|Single Blastocyst Stage Embryos transfer|Group B was graded by Gardner blastocyst grading method, and one blastocyst was transplanted on the 5th or 6th day after oocyte retrieval.
89605072|NCT03596541|Experimental|An open real-time tele-stethoscopy system|EHAS-Fundatel digital stethoscope is an open real-time tele-stethoscopy system. The interventions in this arm will be to make a respiratory and heart auscultation with this tele-stethoscope. After that, we will do the comparison or agreetment between the auscultation of two protocols: tele-stethoscopy system and conventional stethoscope.
89605073|NCT03596541|Active Comparator|Conventional stethoscope|Conventional stethoscope used is the 3M Littmann Classic II S.E. stethoscope. The interventions in this arm will be to make a respiratory and heart auscultation with this conventional stethoscope. After that we will do the comparison or agreetment between the ascultation of two protocols: conventional stethoscope and tele-stethoscopy system.
89605074|NCT00212121|Active Comparator|1|low dose boost (16 Gy)
89605075|NCT00212121|Experimental|2|high boost (26 Gy)
89605076|NCT00217971|Active Comparator|Dronabinol|Dronabinol: 20mg bid for a daily maximum dose of 40mg.
89605077|NCT00217971|Placebo Comparator|Placebo|placebo
89605078|NCT03593421|Experimental|synthetic preImplantation factor 1 mg/kg|Patients will be dosed SQ with 14 doses of sPIF
89605079|NCT03593421|Experimental|synthetic preImplantation factor 2 mg/kg|Patients will be dosed SQ with 14 doses of sPIF
89605080|NCT03593421|Experimental|synthetic preImplantation factor 3 mg/kg|Patients will be dosed SQ 14 doses
89605081|NCT03593421|Experimental|synthetic preImplantation factor 4 mg/kg|Patients will be dosed SQ with 14 doses of sPIF
89605082|NCT03593421|Experimental|synthetic preImplantation factor 5 mg/kg|Patients will be dosed SQ with 14 doses of sPIF
89605083|NCT00217581|Experimental|Docetaxel, Oxaliplatin & Bevacizumab|Must be administered 1st before Docetaxel & Oxaliplatin.7.5 mg/kg, IV, day 1 of each cycle; During the first cycle, bevacizumab will be delivered over 90 + or - 15 minutes. If the 1st IV infusion is tolerated w/o infusion-associated adverse events, the 2nd infusion may be delivered over 60 + or - 10 minutes. If the 60 min infusion is well tolerated, all subsequent infusions may be delivered over 30 min + or - 10 mins.
89605084|NCT03991455|Other|Apyx device treatment|The Apyx device enables approximation and fixation of the vaginal apex to the SSL using a deployable anchoring system. Using the device, SSLF can be performed transvaginally without the need for any incisions or blind dissections and without the requirement of heavy anesthesia.
89605085|NCT03593343|Experimental|Short overnight fast|Overnight fasting duration intervention: Participants will receive their last evening meal at 11 pm and stay overnight fasted afterwards for (9.5h).
89605086|NCT03593343|Experimental|Long overnight fast|Overnight fasting duration intervention: Participants will receive their last evening meal at 4.30 pm and stay overnight fasted afterwards for (16h).
88981648|NCT02120365|Experimental|Perampanel 10 mg|Participants will have 3 test days each, 2 weeks apart, in a randomized order, following either pretreatment with daily perampanel 2mg 7 days prior to each test day, and then observed dosing of high dose perampanel (10mg) in the lab 1 hour before a one-time alcohol infusion . Each lab session occurs exactly a week after starting the medication for that round. The wash out period between lab test session phases will be 7-10 days. Subjects will receive 2 days of 2mg perampanel after each lab to taper down (included in the washout period). The next appointment will be brief at the start of the next phase, at which point the next week of low dose perampanel or placebo will be started. With the washout period and the 7 day taper of the next phase, the actual lab sessions will occur 14-17 days apart. All test days will involve administration of alcohol with the same 3 target doses [target Breath Alcohol Concentration (BrAc) =20mg%, 60mg%, and 100mg%] in a step-wise fashion.
88981649|NCT02046395|Other|Washout Period for 30 days|In the washout period, the Ace Inh or ARB classes of medicine(s) that are part of the patient's antihypertensive regimen will be discontinued. The patient will be started on alternative therapy with medications that are approved by the Food and Drug Administration for treatment of high blood pressure (such as amlodipine, hydralazine, terazosin or Hydrochlorothiazide) for control of their blood pressure. The goal for their blood pressure will be set at < 140/90 mm/Hg. The washout period will last for four weeks at the end of which the patient will enter the test period.
88981650|NCT02037126|Experimental|Psilocybin administration|Psilocybin will be administered in pill form at a dose of .36 mg/kg. Psilocybin will be administered in one session over the course of 8 hours.
88981651|NCT02037126|Active Comparator|Diphenhydramine administration|Diphenhydramine will be administered in pill form at a dose of 100 mg. Diphenhydramine will be administered in one session over the course of 8 hours.
89605087|NCT03593265|Experimental|Healthy group|healthy subjects MUNIX will be performed
89605088|NCT01856257|Active Comparator|Thymoglobulin®+tacrolimus+MMF|Induction with Thymoglobulin®, methylprednisolone, and maintenance immunosuppression with tacrolimus and mycophenolate mofetil (MMF)
89605089|NCT01856257|Experimental|Thymoglobulin®+belatacept+MMF|Induction with Thymoglobulin®, methylprednisolone, and maintenance with belatacept and mycophenolate mofetil (MMF)
89605090|NCT01856257|Experimental|Basiliximab+20 weeks of tacrolimus+MMF + belatacept|"Induction basiliximab and methylprednisolone, administration of NULOJIX® (belatacept) 24 hours post reperfusion (+/-12 hrs); maintenance immunosuppression with 1. )20 week course of Prograf® (tacrolimus) or equivalent 2.) CellCept® (mycophenolate mofetil- MMF), or Myfortic® (mycophenolate sodium), or equivalent.~Subjects participating in this arm may have tacrolimus reinstated, at a dose to be determined by the site investigator, if any of the following events occur: 1 - An acute rejection episode 2- Request of the subject or site Investigator."
89605091|NCT00215943|Active Comparator|VAD Treatment|"VAD (vincristine, adriamycin, dexamethasone). Vincristine and adriamycin was administered by continuous infusion via a venous catheter for 96 hours every 28 days. Each 28 days is considered one cycle of therapy. Patients were to receive 4 to 6 cycles of therapy. Dexamethasone was taken in pill form. During the first 2 cycles it was taken on days 1-4, 9-12, 17-20. For all other cycles dexamethasone was taken only on days 1-4. Patients were randomized to receive zoledronic acid IV on either Day 1 or 15 of each cycle."
88981652|NCT01982786|Active Comparator|Arm 1|IGRT* 60 Gy in 20 fractions OR IGRT 78 Gy in 39 fractions
88981653|NCT01982786|Active Comparator|Arm 2|"IGRT 37.5 Gy in 15 fractions~+ HDR brachytherapy boost 15 Gy"
89032539|NCT02929719|Experimental|Test Gel 5%|Topical, twice daily on the face for 84 days.
89605092|NCT00215943|Active Comparator|Thalidomide and Dexamethasone Treatment|Thalidomide was taken orally once every day in the evening for four to six months. The dexamethasone was taken in a pill form. During the first 2 cycles it was taken on days 1-4, 9-12, 17-20. For all other cycles dexamethasone was taken only on days 1-4.
89605093|NCT03593031|Active Comparator|CI OBVAT|Patients with Convergence Insufficiency in Active Vision Therapy
89605094|NCT03593031|Sham Comparator|CI Sham therapy|CI Sham therapy
89605095|NCT03593031|Active Comparator|Controls OBVAT|Control receive active therapy
89605096|NCT03593031|Sham Comparator|Controls Sham|Subjects with Normal Binocular Vision will receive a therapy that appears to be therapeutic but does not have any binocular coordination benefits.
89605097|NCT03990207|Experimental|PowerSpiral Enteroscopy System|Subjects who have a medical indication for antegrade enteroscopy
89605098|NCT01827163|Experimental|Paclitaxel With Trastuzumab and Lapatinib|Paclitaxel (T) at 175 mg/m2 q 2 weeks x 4 with filgrastim/pegfilgrastim + trastuzumab (H) + daily oral lapatinib (L), followed by trastuzumab q 3 weeks x 15 doses + daily oral lapatinib (HL). Pegfilgrastim 6mg will be given subcutaneously (SQ) on day # 2 of each paclitaxel administration. Filgrastim may be used in lieu of pegfilgrastim at physician's discretion. Trastuzumab will be administered weekly (4 mg/kg bolus followed by 2 mg/kg weekly) starting with paclitaxel treatment cycle # 1. After 4 cycles of paclitaxel, pts will receive trastuzumab on a q 3 weeks x 15 doses (to complete about one year). The q 3 week trastuzumab may be started from 1-3 weeks after the last dose of paclitaxel. A total of 15 infusions of trastuzumab will be given q 3 weeks after the completion of paclitaxel during the HL phase. Lapatinib will be given orally at 1000 mg daily, starting with paclitaxel during the THL phase & continued for the remaining year during the HL phase for about a year.
89605099|NCT00215553|Experimental|A.1 Lucinactant|3 30-mL aliquots per bronchopulmonary segment using concentrations of 5, 5, and 10 mg/mL total phopholipids. One re-treatment at 48 hours.
89605100|NCT00215553|Experimental|A.2 Lucinactant|3 30-mL aliquots per bronchopulmonary segment using concentrations of 10, 10, and 10 mg/mL total phospholipids. One lavage re-treatment at 48 hours.
89605101|NCT00215553|Experimental|A.3 Lucinactant|2 50-mL aliquots per bronchopulmonary segment using concentrations of 10 and 20 mg/mL total phospholipids. One lavage re-treatment at 48 hours.
88981654|NCT01851642||AAT Deficiency|Those diagnosed with Alpha-1 Antitrypsin (AAT) Deficiency. At every study visit, a history and physical exam (H&P), blood draw, and pulmonary function testing (PFTs) with the use of an albuterol inhaler will be done.
88981655|NCT01851642||Cystic Fibrosis|Those diagnosed with Cystic Fibrosis (CF) with mutation Delta F508. At every study visit, a history and physical exam (H&P), blood draw, and pulmonary function testing (PFTs) with the use of an albuterol inhaler will be done.
88981656|NCT01851642||Without Lung Disease Diagnosis|Those without the diagnosis of AAT Deficiency or CF. At every study visit, a history and physical exam (H&P), blood draw, and pulmonary function testing (PFTs) with the use of an albuterol inhaler will be done.
88981657|NCT01580657|Experimental|Detailed baseline interview, enhanced HIV intervention|Participants in this group will receive a detailed sexual behavior interview, similar to measures used in major intervention trials. This measure will identify the instances in which participants engaged in sexual behaviors with specific partners during a 90 day retrospective reporting period. Participants will then complete an empirically validated 60-minute session HIV-risk reduction intervention (Simbayi, Kalichman, Skinner et al., 2004) consisting of exercises to increase HIV/AIDS knowledge, motivation to reduce risk, behavior self-management skills, and sexual communication skills and reduce HIV-related stigma.
88981658|NCT01580657|Experimental|General baseline interview, enhanced HIV intervention|Participants in this group will receive the same procedures as in (A) except that the behavioral measure will consist of single-item frequency questions regarding sexual behaviors during the prior 90 days, questions that do not lead the participant to focus on specific instances of behavior.
88981659|NCT01580657|Experimental|No baseline interview, enhanced HIV intervention|This group will receive the same enhanced intervention procedures as in (A) and (B), but they will not be interviewed at baseline.
89605102|NCT00215553|Experimental|A.4 Lucinactant|2 50-mL aliquots per bronchopulmonary segment using concentrations of 10 and 20 mg/mL total phospholipids (TPL). One re-treatment at 48 hours. One bolus re-treatment (20 mg/mL TPL) in another 48 hours. A second bolus re-treatment (20 mg/mL TPL) administered 48 hours later.
89605103|NCT00215553|Experimental|B.1 Lucinactant|2 50-mL aliquots per bronchopulmonary segment using concentrations of 10 and 20 mg/mL total phospholipids. One lavage re-treatment at 48 hours.
89605104|NCT00215553|Experimental|B.2 Lucinactant|2 50-mL aliquots per bronchopulmonary segment using concentrations of 10 and 20 mg/mL total phospholipids (TPL). One re-treatment at 48 hours. One bolus re-treatment (20 mg/mL TPL) in another 48 hours. A second bolus re-treatment (20 mg/mL TPL) administered 48 hours later.
89605105|NCT00215553|Other|B.3 SoC|Received standard ARDS management and ICU care (Standard of Care [SOC]). Included, but was not limited to, support with oxygen, conventional mechanical ventilation, sedations, and paralysis.
89605106|NCT03592953|Experimental|Serious game Control group|The participants spend on three different scenarios from the game PerinatSims; basic scenarios designed to train Technical Skills (management of post partum hemorrhage according to the algorithm).
89605107|NCT03592953|Experimental|Serious game Experimental group|"The participants spend on three PerinatSims scenarios in which critical situations have been implemented, aiming to mobilize some of the non-technical skills of the learners: situation awareness, decision making, communication..."
89605108|NCT03592953|No Intervention|Classical teaching group|the students received the classical teaching of postpartum hemorrhage management and a reminder of the algorithm before the high fidelity simulation session.
89605109|NCT00214461|Placebo Comparator|Placebo Vaccine Group|Participants will receive a dose of vaccine diluent (placebo) on Days 0, 28 and 56, respectively.
89605110|NCT00214461|Experimental|Low Dose Vaccine Group|Participants will receive a dose of vaccine containing of 2 µg Clostridium Difficile toxoid on Days 0, 28 and 56, respectively.
89605111|NCT00214461|Experimental|Medium dose vaccine group|Participants will receive a dose of vaccine containing of 10 µg Clostridium Difficile toxoid on Days 0, 28 and 56, respectively.
89605112|NCT00214461|Experimental|High dose vaccine group|Participants will receive a dose of vaccine containing of 50 µg Clostridium Difficile toxoid on Days 0, 28 and 56, respectively.
89605113|NCT03592875||Professional nurses|A semi-structured interview will be used for data collection with 16 guiding questions addressing aspects related to Nursing Care Systematization knowledge and practices.
89605114|NCT03599583|Experimental|Intervention|Arm 1 will receive the STOP-HPV prompts intervention
89605115|NCT03599583|No Intervention|Control|Arm 2 will receive standard of care
89605116|NCT04407351|Other|Arm Green LED light - Red LED light|Every morning between 7-8 o'clock, participants will receive 7,500 Lux at home at 470 nm as a full-band (bright light) light-emitting diode (Green LED light) luminaire with a distance of 80-100 cm at a 45-degree angle Light exposure for 30-60 minutes for 12 weeks, the rest of the time indoors is not limited by light. Then crossover to red light after 2 weeks for wash out. Every morning between 7-8 o'clock, participants receive 50 Lux of Red LED light (dim light) at their own homes and illuminate at a distance of 80-100 cm at a 45-degree angle for 30-60 minutes for 12 weeks.
89605117|NCT04407351|Other|Arm Red LED light - Green LED light|Every morning between 7-8 o'clock, participants receive 50 Lux of Red LED light (dim light) at their own homes and illuminate at a distance of 80-100 cm at a 45-degree angle for 30-60 minutes for 12 weeks, and the rest of the time indoors is not restricted by light. Then crossover to green light after 2 weeks for wash out. Every morning between 7-8 o'clock, participants will receive 7,500 Lux at home at 470 nm as a full-band (bright light) light-emitting diode (Green LED light) luminaire with a distance of 80-100 cm at a 45-degree angle Light exposure for 30-60 minutes for 12 weeks.
89605118|NCT00214383|Experimental|CHESS + Case Mgt|Case Management (with monthly support calls) and CHESS services were available for a 12 month intervention period. Support calls refer to check in calls by a nurse to the parents to see how the child is doing. CHESS services include access to a website with information on asthma management, discussion groups and a case manager. The website also include a management tool for asthma symptoms check in, and the case manager used the information entered to tailor the homepage to individual clients.
89605119|NCT00214383|No Intervention|Control|Control-usual care. Usual care refers to the manner in which clients generally manage their asthma.
89605120|NCT03599973|Other|Patient|One-arm study, where all patients are given the same standard fluidotherapy and anesthetic conditions to compare measures of Aortic VTI before and after the IV fluid.
89605121|NCT00212355|Experimental|NPC-02|zinc acetate
88981660|NCT01580657|Active Comparator|D. Detailed baseline interview, standard of care intervention|Participants in this group will receive the same interview procedure as in (A) but instead of the enhanced intervention, They will undergo the standard clinical exam and health education that at the Spencer Rd. Clinic.
88981661|NCT01580657|Active Comparator|E. General baseline interview, standard of care intervention|Participants in this group will complete the general baseline interview described in (B) and then receive the standard care at the clinic.
89605122|NCT03599895|Experimental|3D printing group|the radical gastrectomy for gastric cancer of Davinci robotic surgery with the assistance of 3D printing model
89605123|NCT03599895|Experimental|non 3D printing group|the radical gastrectomy for gastric cancer of Davinci robotic surgery without the assistance of 3D printing model
88981662|NCT01580657|Active Comparator|F. No baseline interview, standard of care intervention|Participants assigned to this group will be consented on the day they are recruited, but will not receive further study contact on that day other than being scheduled to return for follow up assessments.
88981663|NCT01488539|Experimental|STAIR/NT|Patients will receive STAIR/NT treatment
88981664|NCT01488539|Other|Treatment as Usual (TAU)|Patients will receive Treatment as Usual (TAU)
88981665|NCT01454154|Experimental|Glyburide|Glyburide delivered by injection as an approximately 2 minute loading dose followed by 72 hours of continuous infusion.
89605124|NCT03592797|Experimental|Laser acupuncture therapy group|Each subject in the experimental group will receive laser acupuncture therapy using Handylaser Trion device (RJ Laser, Germany) to stimulate acupuncture points with laser beam irradiation.
89605125|NCT03592797|Sham Comparator|Sham laser acupuncture therapy group|Each subject in the sham control group will receive laser acupuncture therapy using Handylaser Trion device (RJ Laser, Germany). The laser device in the sham group will be deactivated and won't produce any laser beam irradiation on acupuncture points
89605126|NCT03592719|Experimental|MI-PrEP|"Participants in this arm will receive the manualized two-session intervention entitled Motivational Interviewing to Increase PrEP Uptake"
88981666|NCT01454154|Placebo Comparator|Placebo|Matching placebo delivered by injection as an approximately 2 minute loading dose followed by 72 hours of continuous infusion.
88981667|NCT01367301|Experimental|Treatment (paclitaxel, carboplatin, radiotherapy)|"CHEMOTHERAPY (weeks 1-9, 14-22): Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 3 courses during weeks 1-9 and 14-22.~RADIATION THERAPY (weeks 8-16): Patients undergo external beam pelvic radiation therapy once a day, 5 days a week for 5 weeks during weeks 8-13. Patients then undergo HDR brachytherapy or IMRT once weekly during weeks 14-16."
88981668|NCT01329965|Experimental|LPS|LPS will be injected at a dose of 0.6 ng/kg body weight through a catheter by a trained GCRC staff member involved with this study.
88981669|NCT01329965|Placebo Comparator|Saline|A saline solution will be injected through a catheter by a trained GCRC staff member involved with this study.
89032540|NCT02929719|Active Comparator|ACZONE Gel 5%|Topical, twice daily on the face for 84 days
89032541|NCT02929719|Placebo Comparator|Placebo Gel|Topical, twice daily on the face for 84 days
88981670|NCT01235832|Active Comparator|Lower-Fat Diet|The Lower-Fat diet will provide ~24% of calories from fat and meet the SFA and cholesterol recommendations of a Step-II diet recommended by the National Heart, Lung, and Blood Association's National Cholesterol Education Program. SFA will provide 7% of calories, and cholesterol will be less than 200mg/day. Vegetables and fruits in the Lower-Fat diet will be selected from foods that are low in antioxidants.
89605127|NCT03592719|Active Comparator|Enhanced Treatment as Usual (E-TAU)|Participants in this arm will receive two sessions which entail psychoeducation on PrEP.
89605128|NCT00211887|Active Comparator|Interferon beta 1-a|"Active Interferon B1a Weekly vs. Placebo Glatiramer Acetate~Interferon b-1a (IFN) intramuscularly weekly"
89605129|NCT00211887|Active Comparator|glatiramer acetate|"Placebo Interferon B1a Weekly vs. Active Glatiramer Acetate~Glatiramer acetate 20mg daily"
89605130|NCT00211887|Active Comparator|IFN and GA|Active Interferon B1a Weekly and Active Glatiramer Acetate
89605131|NCT04002453||Outpatient parenteral antimicrobial therapy|Patients with an infectious disease that receive an outpatient parenteral antimicrobial therapy
89605132|NCT03599817|Experimental|Healthy lifestyle promotion program|All the participants of the intervention program will be offered group sessions focused on healthy eating, promotion of physical activity and behavioral changes. In this way, the loss of body weight and the increase of physical activity will be promoted. Translating into an improvement in obesity parameters and cardiovascular and metabolic risk factors, to reduce the risk of developing type 2 diabetes.
89605133|NCT03592485|Experimental|ESP|Before the induction of general anesthesia, Erector Spinae Plane (ESP) blockade will be done. Postoperative analgesia is provided with intravenous oxycodone. Patient-controlled analgesia pump (PCA) will be used for this purpose.
89605134|NCT03592485|Experimental|PECS|Before the induction of general anesthesia, Erector Spinae Plane (ESP) block and Pectoral fascia type I and II will be done. Postoperative analgesia is provided with intravenous oxycodone. Patient-controlled analgesia pump (PCA) will be used for this purpose.
89605135|NCT04199013|Active Comparator|Ropivacaine With Fentanyl|2.5ml of 0.75% Isobaric ropivacaine with 0.5ml (25mcg) Fentanyl
89605136|NCT04199013|Active Comparator|Ropivacaine Without Fentanyl|2.5ml of 0.75% Isobaric Ropivacaine with 0.5ml of Normal Saline
89605137|NCT03592251|Placebo Comparator|Olive oil Placebo|3 x 1 g capsules daily Placebo: olive oil
89605138|NCT03592251|Active Comparator|EPA-rich|3 x 1 g capsules daily containing a SMEDDS formulation of an EPA-enriched oil totalling 900 mg EPA and 360 mg of DHA
89605139|NCT03592251|Active Comparator|DHA-Rich|3 x 1 g capsules daily containing a SMEDDS formulation of an DHA-enriched oil totalling 900 mg DHA and 270 mg of EPA
89605140|NCT04747665||Patients|Patients who have undergone or refused to undergo colonoscopy
89605141|NCT04747665||Endoscopists|Endoscopists who perform or are training to perform colonoscopy
89605142|NCT03592095|Experimental|DN group|The intervention group will receive real dry needling (DN) (fast in and fast out needling technique) in an active MTrP within upper trapezius muscle.
89605143|NCT03592095|Placebo Comparator|Placebo needle|The placebo group will receive sham needling in an active MTrP within the upper trapezius muscle. A sham needle will be used as placebo. This needle has a blunt tip and retractable handle that created the illusion of a needle penetrating the skin.
89605144|NCT04198935|Experimental|Intervention|Participants will be enrolled on to a 12 week structured diabetes education program for type 2 diabetes delivered through a mobile application. The application also allows for interaction with a registered nutritionist via text messaging.
89605145|NCT01855945|Experimental|Group A|3.75 µg H3N2c HA + 0.125 mL MF59
88981671|NCT01235832|Active Comparator|Moderate Fat Diet|This diet is designed to be the control diet for the avocado diet and will have an identical fatty acid profile. MUFA-enriched food (fats) will be substituted for avocado. The substitution foods will not contain antioxidant or cholesterol-lowering components similar to those in avocado.
89032542|NCT00525980|Experimental|Group 1: Written Materials|One group asked to read educational materials.
89032543|NCT00525980|Experimental|Group 2: Computer Program Only|Group 2 use an educational computer program to learn about breast cancer risk and genetic testing without guidance.
89605146|NCT01855945|Experimental|Group B|7.5 µg H3N2c HÁ + 0.250 mL MF59
89605147|NCT01855945|Experimental|Group C|15 µg H3N2c unadjuvanted
89605148|NCT03592017|Experimental|Patients with various retinal diseases|Patients with various retinal diseases will be examined using long-wavelength autofluorescence imaging to assess the performance compared to conventional imaging methods and to quantify the signal compared to a normative database
89605149|NCT03592017|Experimental|Healthy participants|Healthy participants will be examined using long-wavelength autofluorescence imaging to optimize the signal with additional laser sources and device settings and to compile a normative database for the quantification of the signal.
89605150|NCT04198389|Experimental|partial knee replacement|medial UNI, lateral UNI, patellofemoral replacement, combined UNI+ patellofemoral replacement, combined medial and lateral UNI
89605151|NCT04198467|Experimental|PRP (100billion platelets)|platelet rich plasma having 100 billion platelets in 10 ml plasma prepared from 60 ml blood
89605152|NCT04198467|Placebo Comparator|hyaluronic acid|Four ml of high-molecular-weight hyaluronic acid (HMWHA) with a concentration of 22mg/ml
89605153|NCT03591783||study group|All patients will be subjected to: Baseline investigations, end of treatment investigations and 3 months after treatment investigations.
89605154|NCT04198155|Experimental|stereotactic body radiotherapy (SBRT)|Noninvasive SBRT will be delivered in a single fraction to bilateral renal arteries determined by CT-guidance.
89605155|NCT03591705|Experimental|TACE-HAIC|hepatic artery chemo-lipiodolization with EADM, followed by FOLFOX-based chemotherapy artery infusion
89605156|NCT03591705|Active Comparator|HAIC|FOLFOX-based chemotherapy hepatic artery infusion
89605157|NCT03599427|Active Comparator|systemic lidocaine|Lidocaine 2% IV bolus: 1.5 mg/kg at induction of anesthesia and at the end of surgery.
89605158|NCT03599427|Placebo Comparator|Placebo|Saline 0.9% IV bolus: 0.075 ml/kg at induction of anesthesia and at the end of surgery.
89605159|NCT01855789|Experimental|Non-Randomized Participants (TCZ + MTX)|All participants will receive initial treatment with open-label TCZ + MTX. Participants who complete 24-week treatment with open-label TCZ + MTX and did not achieve a DAS28 score </=3.2 at Week 24, will continue receiving TCZ + MTX in open label manner up to Week 52.
89605160|NCT01855789|Experimental|Randomized Participants (TCZ + MTX)|Participants who complete the initial 24-week treatment with open-label TCZ + MTX and achieve a DAS28 score </=3.2 at Week 24, will be randomized to receive TCZ along with MTX up to Week 52.
89605161|NCT01855789|Active Comparator|Randomized Participants (TCZ + PBO)|Participants who complete the initial 24-week treatment with open-label TCZ + MTX and achieve a DAS28 score </=3.2 at Week 24, will be randomized to receive TCZ along with MTX matched placebo (PBO) up to Week 52.
89605162|NCT03591627||AF or AFl patients|Patients with AF or AFl in whom TEE will be performed (to assess their eligibility for cardioversion or ablation), hospitalized in a participating center during study period.
89605163|NCT04198233|Experimental|Diazepam group|Rectal Diazepam suppository
89605164|NCT04198233|Placebo Comparator|Placebo group|Placebo suppository
89605165|NCT04197375|Experimental|Pre-cooling scenario|One hour before a tennis match, the pre-cooling group was wearing a Cooling Cap (WElkins Sideline Cooling System, SCS) for 45 minutes.
89605166|NCT04197375|Sham Comparator|Sham evaluation|Participants were monitored during a usual game without any kind of pre-cooling strategy
89605167|NCT03986853|Experimental|Blood sample|Blood sampling Under general anesthesia
89605168|NCT03591471|Experimental|TCM multistep therapy|"Light HSPN:1.Glycosides Of Tripterygium Wilfordii Hook(GTW): initial dosage is 1.5mg/kg/d(4 weeks),continued with 1mg/kg/d(8 weeks),12weeks in total. Severe HSPN:1.GTW:the initial dosage is 2mg/kg/d(2 weeks), continued with 1.5mg/kg/d(2 weeks) and 1mg/kg/d(8 weeks); 12weeks in total.~On the above base,Sulfotanshinone Sodium Injection(1mg/kg/d,2weeks) and Qingrezhixue granules(a nosocomial preparation) combined with Chinese herbs(12weeks) based on TCM syndrome differentiation are taken at the same time."
89605169|NCT03591471|Active Comparator|Routine medicine|"Light HSPN:1.Lotensin: 5-10mg/d,12weeks; 2.Low Molecular Weight Heparin(LMWH):100u/kg,2weeks;3.Dipyridamole:3mg/kg/d,Tid,12weeks.4.Chinese medicine placebo,12weeks.~Severe HSPN:Add pednisone on the treatment of Light HSPN,and gradually reduce the dosage in 12 weeks,the initial dosage is 2mg/kg/d(maximum to 30mg,4 weeks),continue to reduce the dosage until discontinued（Reduce the dosage at the rate of 5mg every other day in 4-8 weeks，then reduce the dosage at the rate of 5-10mg per week in 8-12weeks）"
89605170|NCT04407039||Glioma molecular subtype: G-CIMP-low|one of molecular subtypes according to gene expression, DNA copy number, DNA methylation, exome sequencing and protein expression of glioma
89605171|NCT04407039||Glioma molecular subtype: G-CIMP-high|one of molecular subtypes according to gene expression, DNA copy number, DNA methylation, exome sequencing and protein expression of glioma
89605172|NCT04407039||Glioma molecular subtype: codel|one of molecular subtypes according to gene expression, DNA copy number, DNA methylation, exome sequencing and protein expression of glioma
89605173|NCT04407039||Glioma molecular subtype: classic-like|one of molecular subtypes according to gene expression, DNA copy number, DNA methylation, exome sequencing and protein expression of glioma
89605174|NCT04407039||Glioma molecular subtype: mesenchymal-like|one of molecular subtypes according to gene expression, DNA copy number, DNA methylation, exome sequencing and protein expression of glioma
89605175|NCT04407039||Glioma molecular subtype: LGM6-GBM|one of molecular subtypes according to gene expression, DNA copy number, DNA methylation, exome sequencing and protein expression of glioma
89605176|NCT04407039||Glioma molecular subtype: PA-like|one of molecular subtypes according to gene expression, DNA copy number, DNA methylation, exome sequencing and protein expression of glioma
89605177|NCT04406805||Severe aortic stenosis|Patients will be enrolled among those who will be (i) aged from 18 to 99 years, (ii) admitted to the hospital due to severe aortic stenosis, and (iii) qualified for treatment with either surgical aortic valve replacement or transcatheter aortic valve implantation
89605178|NCT01610791|Experimental|Single Arm|
89605179|NCT03832491|Other|Control Group|"Home Based Therapy: 16 patients with PCD~Airway clearence techniques, everday of the week, during eight weeks"
88981672|NCT01235832|Experimental|Avocado Diet|The avocado diet will be designed to ensure that all subjects incorporate 1 avocado (~136g) per day into a moderate fat diet. Both the Lower-Fat diet and avocado diet will be matched for SFA and dietary cholesterol, but will differ in total fat, primarily MUFA as provided by the avocado. The moderate fat plus avocado diet will provide 34% of calories from total fat, 18% calories from MUFA, and 9% calories from PUFA.
89605180|NCT03832491|Experimental|Game and home based therapy group|"Game based approach programme: 16 patients with PCD~Game based approach programme will be done using the exergame with the game console, fourty minutes three times per week for eight weeks.~Exergame includes five games selected from two kinects games CD. Each game will be played for five games set.~Airway clearence techniques, everday of the week, during eight weeks"
89605181|NCT03591315||TG group|Patients with visual impairment caused by chiasma compression from sellar area tumors will undergo the following examinations: resting state fMRI, visual tasking state fMRI, diffusion tensor imaging (DTI), visual acuity and automated visual field test.
89605182|NCT03591315||HC group|Volunteers with no visual impairment(visual acuity of both eyes >1.0) or Nervous System disease will undergo the following examinations: resting state fMRI, visual tasking state fMRI, diffusion tensor imaging (DTI), visual acuity and automated visual field test.
88981673|NCT01233778|Experimental|Canola Oil|
88981674|NCT01233778|Experimental|High Oleic Acid Canola + DHA|
88981675|NCT01233778|Experimental|High Oleic Canola Oil|
88981676|NCT01233778|Experimental|Flax & Safflower Oil (60:40)|
88981677|NCT01233778|Experimental|Safflower & Corn Oil (75:25)|
89605183|NCT03591081|Other|Intellin smart phone application|Participants will download a smart phone app, the platform will give the patients daily hints and tips on how to look after their feet.
89605184|NCT01876381|Experimental|OPC-41061|
89605185|NCT03591003||HIV-infected patients|HIV-infected patients vaccinated at least once in their life against yellow fever
88981678|NCT01220583|Experimental|Arm I|Patients undergo 3-dimensional conformal radiotherapy (3D-CRT) or intensity-modulated radiotherapy (IMRT) 5 days a week for 6-6.5 weeks. Patients also receive cisplatin IV over 60 minutes on days 1, 8, 15, 22, 29, 36, and 43 during radiotherapy.
88981679|NCT01220583|Experimental|Arm II|Patients undergo 3D-CRT or IMRT as in arm I.
88981680|NCT01173042|Placebo Comparator|Control|Shake containing heavy whipping cream, glucose and chocolate syrup
89605186|NCT03984513|Experimental|STRW|Participants will receive the daily living skills intervention, Surviving and Thriving in the Real World (STRW).
89605187|NCT03984513|Active Comparator|PEERS|Participants will receive a social skills intervention, Program for the Education and Enrichment of Relational Skills (PEERS).
88981681|NCT01173042|Experimental|Peanut|Shake containing control (whipping cream, glucose and chocolate syrup) + 3oz of peanuts
89605188|NCT01855399|Experimental|Peer Coaching + Decision Aid|All participants will be assigned to one of up to 87 peer coaches, who also are Detroit VA diabetes patients who previously had poor glycemic control but are currently in good control. After their baseline assessment, participants in both arms will receive information on their lab and blood pressure values and will be randomized to one of the two study arms. Participants in the TEC arm will be scheduled for an initial visit with their coach to review the decision aid, which has incorporated their personal baseline data.
89605189|NCT01855399|Active Comparator|Peer Coaching Alone|Participants randomized to the 'print materials' group will be scheduled for an initial visit with their coach. The coach will then help them list questions and concerns they wish to discuss with their health care provider, practice raising their questions and concerns and develop an action plan to address barriers to self-management they have identified. During the next six months coaches in both arms will call their assigned peers once a week to provide support for their action steps.
89605190|NCT03590925||new screening and referring system of ICD|Non-randomized, non-blinded, multi-center study receiving new screening and referring system of ICD
89605191|NCT01875991|Experimental|Autoinjector A|Participants self-injected 50 mg etanercept once a week (RA) or twice a week (PsO) using Autoinjector A for 4 weeks.
89605192|NCT01875991|Experimental|Autoinjector B|Participants self-injected 50 mg etanercept once a week (RA) or twice a week (PsO) using Autoinjector B for 4 weeks.
89605193|NCT04203927|Active Comparator|Empagliflozin + insulin infusion|vascular measurements in overnight fasted state and during insulin infusion
89605194|NCT04203927|Active Comparator|Empagliflozin + mixed meal|vascular measurements in overnight fasted state and 2 hours after mixed meal 10kcal/kg body weight ( 55% Cho, 30%Fat, 20% Pro)
89605195|NCT04196985|Experimental|Patients with HNSCC|Patients who have histologically confirmed HNSCC and have received CRT for it
89605196|NCT04201431|Experimental|Group 1|Up to 12 volunteers in Group 1 will receive three doses of the PvDBPII 50ug/Matrix M1 50ug candidate vaccine at 1, 2 and 12-18 months prior to blood-stage CHMI 2-4 weeks after the third vaccination.
89605197|NCT04201431|Experimental|Group 2|If fewer than 8 volunteers complete the study in Group 1, then new volunteers will be recruited into Group 2, to make up a total of 10 to 12 volunteers who complete 3 vaccinations and CHMI between Groups 1 and 2. Group 2 volunteers will receive three doses of the PvDBPII 50ug/Matrix M1 50ug candidate vaccine at monthly intervals, prior to blood-stage CHMI 2-4 weeks after the third vaccination.
89605198|NCT04201431|Experimental|Group 3|Up to 6 volunteers from Group 1 will receive a fourth dose of PvDBPII 50ug/Matrix M1 50ug, at 5 months post the third dose, prior to a second CHMI 2-4 weeks later.
88981682|NCT01173042|Experimental|Oil blend|Shake containing control (heavy whipping cream, glucose and chocolate syrup) + oil blend (equivalent to fatty acids provided in 3oz peanuts)
88981683|NCT01166594|Experimental|Bevacizumab|Tested Drug
88981684|NCT01166594|Placebo Comparator|Control|Control - BSS
88981685|NCT01101230|Experimental|Almond|
88981686|NCT01101230|Placebo Comparator|Muffin|
88981687|NCT01078909|Experimental|300mg Fish Oil (EPA + DHA) Supplement|
88981688|NCT01078909|Experimental|600mg Fish Oil (EPA+DHA) Supplement|
88981689|NCT01078909|Experimental|900mg Fish Oil (EPA + DHA) Supplement|
88981690|NCT01078909|Experimental|1800mg Fish Oil (EPA + DHA) Supplement|
88981691|NCT01078909|Placebo Comparator|Placebo|
88981692|NCT00938340|Experimental|Whole walnut|85g whole walnuts, ground, incorporated into inert food carrier
88981693|NCT00938340|Experimental|"Walnut meat"|Separated, ground walnut de-fatted nut meat incorporated into inert food carrier
88981694|NCT00938340|Experimental|Walnut oil|Walnut oil extracted from nut meat and incorporated into inert food carrier
88981695|NCT00938340|Experimental|Walnut skins|Separated, ground walnut skins incorporated into inert food carrier
88981696|NCT00937963|Experimental|Palm Oil|Traditional palm oil normally used in foods
88981697|NCT00937898|Experimental|DASH Diet|High fruit and vegetable, low sodium diet
88981698|NCT00937898|Active Comparator|Average American Diet|Typical American diet (16% protein, ~50% carbohydrate, 33% fat)
88981699|NCT00937742|Experimental|Non-tomato products|Non-tomato products (i.e. teriyaki marinade, sprite, applesauce) to be consumed daily in replace of tomato products
88981700|NCT00937638|Experimental|Modified-DASH Diet|
88981701|NCT00937638|Experimental|BOLD diet|
88981702|NCT00937638|Experimental|BOLD-X|
88981703|NCT00924521|Active Comparator|Refined grain|Participants in this group will receive only refined grains as typically consumed in the average American diet.
89605199|NCT01855243|Active Comparator|glargine plus supplemental glulisine|Patients who will be recruited to be treated with glargine/glulisine, will received 50% of TDD as detailed demonstrated in Umpierrez et al., studies . as This includes administration of glargine (Lantus®) once every night plus glulisine (Apidra®) before each meal for BG ≥ 150 mg/dL. Glargine dose will be calculated as 0.2 U/kg/day for admission BG less than 200 mg/dL or 0.3 U/kg/day for BG exceeding 200 mg/dL. Glargine was given using Solostar Flex-Pen® once daily in the evening around 8:00 pm. Glulisine was given using the Solostar Flex-Pen® three times just before the meals for BG > 150 mg/dL according to hospital sliding scale. To avoid hypoglycemia, if for any reason, a subject missed a meal, the dose of glulisine will be held.
89605200|NCT01855243|Active Comparator|70/30 insulin plus supplemental lunch insulin|Modified split-mixed insulin protocol adopted by Umpierrez et al., will be applied to patients treated with 70/30 insulin. Insulin dose will be started at 0.4 U/kg/day for admission BG less than 200 mg/dL or 0.5 U/kg/day for BG above 200 mg/dL. Two thirds of total daily dose (TDD)will be given before breakfast and 1/3 of TDD before dinner. Supplemental lunchtime regular insulin dose will given for BG > 150 mg/dL . Patients previously treated with 70/30 insulin before admission initially will receivethe same regimen as at in home.
89605201|NCT01855243|Active Comparator|Sliding Scale insulin (SSI)|For SSI group, regular insulin will be administered three times daily subcutaneously approximately 30 min before meal for BG > 150 mg/dL (or every 8 hours if a patient was not eating) according to hospital sliding scale table
89605202|NCT03590847|Experimental|Intermittent fasting|Study participants will be asked to fast for a target of 16 hours per day for a period of 4 weeks.
89605203|NCT04196829|Experimental|silver diamine fluoride ⁄ potassium Iodide|38% silver diamine fluoride and a saturated solution of potassium iodide
89605204|NCT04196829|Active Comparator|silver diamine fluoride|38% silver diamine fluoride
89605205|NCT03023787|Experimental|Hepalatide|Hepalatide 4.2mg, 6.3mg and 8.4mg
89605206|NCT03023787|Placebo Comparator|Placebo|Placebo 4.2mg, 6.3mg and 8.4mg
89605207|NCT03832725|Active Comparator|High protein (HP) weight loss diet|A weight loss high protein (HP) (30% Kcal protein, 40% Kcal carbohydrate (CHO) and 30% Kcal fat) diet will be given to the subjects on that arm of study to pick up weekly for 6 months.
89605208|NCT03832725|Active Comparator|High carbohydrate (HC) weight loss diet|"A weight loss high carbohydrate (HC) (15% Kcal protein, 55% Kcal CHO and 30% Kcal fat) diet will be given to the subjects on that arm of study to pick up weekly for 6 months.~Intervention with the HC diet will be 6 months. If subjects have not had remission of Type 2 Diabetes by the end of the 6 months, they will be referred to an endocrinologist for pharmaceutical treatment"
89605209|NCT01825837|Experimental|BIA 2-093 1800 mg (Group 1)|BIA 2-093 1800 mg once daily (Part II followed a double-blind, parallel-group design in which participants were randomly assigned to treatment with BIA 2-093 300 mg, 900 mg, or 1800 mg once daily). Study medication was administered orally, once daily in the evening.
89605210|NCT01825837|Experimental|BIA 2-093 900 mg (Group 2)|BIA 2-093 900 mg once daily (Part II followed a double-blind, parallel-group design in which participants were randomly assigned to treatment with BIA 2-093 300 mg, 900 mg, or 1800 mg once daily). Study medication was administered orally, once daily in the evening.
89605211|NCT01825837|Experimental|BIA 2-093 300 mg (Group 3)|BIA 2-093 300 mg once daily (Part II followed a double-blind, parallel-group design in which participants were randomly assigned to treatment with BIA 2-093 300 mg, 900 mg, or 1800 mg once daily). Study medication was administered orally, once daily in the evening.
89605212|NCT01825837|Experimental|ESL (Part I)|In Part I, all participants received open-label treatment with BIA 2-093 900 mg once daily for 2 weeks.
89605213|NCT03599115|Experimental|Inhibitory Control Training to Food Items|Participants complete a 10 minute training task once a day, 4 days a week, for 4 weeks. Task is administered using a mobile app (Paradigm mobile) that is installed on an iPhone or iPad. Participants receive an instruction text/email at 9am on their chosen weekdays with instructions on what task to complete and a reminder text/email at 5pm if the task has not yet been completed. Research team receives an email when the task has been completed. When the task is administered, participants see a picture for 1250ms with an inter-stimulus interval of 1250ms and have to indicate which side of the screen the picture appears (go trials). Participants are instructed to not make a response when the picture is surrounded by a black box (no-go trials). There are 6 blocks with 36 trials each, half being go and half being no-go trials. High-calorie foods are always no-go trials and low-calorie foods are always go trials.
89605214|NCT03599115|Active Comparator|Inhibitory Control Training to Neutral Items|Participants complete a 10 minute training task once a day, 4 days a week, for 4 weeks. Task is administered using a mobile app (Paradigm mobile) that is installed on an iPhone or iPad. Participants receive an instruction text/email at 9am on their chosen weekdays with instructions on what task to complete and a reminder text/email at 5pm if the task has not yet been completed. Research team receives an email when the task has been completed. When the task is administered, participants see a picture for 1250ms with an inter-stimulus interval of 1250ms and have to indicate which side of the screen the picture appears (go trials). Participants are instructed to not make a response when the picture is surrounded by a black box (no-go trials). There are 6 blocks with 36 trials each, half being go and half being no-go trials. All pictures are of household items.
89605215|NCT04196673|Experimental|Alcon SN60WF|Implantation of an intraocular lens Alcon SN60WF
89605216|NCT04196673|Experimental|Hoya Vivinex|Implantation of an intraocular lens Hoya Vivinex
89605217|NCT03590379|Experimental|CHF 5993 DPI|BDP/FF/GB DPI 100/6/12,5 mcg
89605218|NCT03590379|Active Comparator|CHF 5993 pMDI|BDP/FF/GB pMDI 100/6/12,5 mcg
89605219|NCT03590379|Active Comparator|CHF 1535 pMDI|BDP/FF pMDI 100/6 mcg
89605220|NCT03590301|Experimental|FUNPALs Playgroup|Based on Self-Determination Theory, the FUNPALs Playgroup will enable and inspire parents to encourage their children to improve their diet and activity behaviors through general authoritative parenting, structured feeding practices, and a healthy home environment. Parents and toddlers will participate in the FUNPALs Playgroup together where they will be led through a series of open but structured activities including free play, exercise, snack preparation, discussion, singing, and yoga stretches.
89605221|NCT03590301|Active Comparator|Healthy Toddlers Parent Group|The goal of the Healthy Toddlers Parent Group is to deliver the same nutrition and activity messages to parents as those delivered in the FUNPALs Playgroup. In the Healthy Toddlers Parent Group, parents (without children) will meet in groups to receive information on nutrition and activity as it relates to their toddlers and they will engage in a discussion around how they do or can implement these behaviors. No experiential learning, children, play, or parenting instruction will be included in this control condition.
88981704|NCT00924521|Experimental|Whole grain diet|Participants in this group will receive 6-9 servings of whole grain daily to replace the refined grains typically included in the average American diet. Number of servings will depend upon calorie assignment.
88981705|NCT00921986||Arrhythmias|Patients with arrhythmias
88981706|NCT00921986||Control Subjects|Subjects that do not have a history of cardiac arrhythmias.
88981707|NCT00898456||Group 1|Leukemia blast cells obtained from bone marrow aspirate or peripheral blood at diagnosis are used to study polymorphisms and haplotypes of ATP-binding cassette (ABC) B1, ABCC1, ABCG2, and other candidate genes. Multidrug resistance (MDR) protein expression and function are also analyzed using leukemia blast cells from patients enrolled on CALGB-9760.
89605222|NCT03599037|Experimental|ICOUGH Recovery App|The ICOUGH Recovery app v2.0 will be downloaded to participants who have a smartphone and want to use the app after their surgery. These participants will be instructed to use the app daily after their surgery until discharge and to select a care coach. Prior to discharge subjects will complete a questionnaire to assess usability and will participate in a brief recorded interview of their experience using the app. Inpatient post operative complications will be abstracted from medical records.
89605223|NCT03599037|No Intervention|Standard of care|Participants who either do not have a smartphone or have a smartphone but don't want to use the app will receive the standard of care after surgery which includes an ICOUGH protocol checklist. Inpatient post operative complications will be abstracted from medical records.
89605224|NCT03598881|Experimental|Treatment|Toothpaste containing 0.32%NaF and no sodium lauryl sulphate (SLS)
89605225|NCT03598881|Active Comparator|Comparator|Toothpaste containing 0.8% sodium monofluorophosphate (SMFP) and sodium lauryl sulphate (SLS)
89605226|NCT04196517|Experimental|Arm 1 - PALS|The Patient Activated Learning System (Palsforhealth.com)
89605227|NCT04196517|Experimental|Arm 2 - WebMD|WebMD.com
89605228|NCT04196361||Ventilated72h|Patient that were ventilated for at least 72 hours
89605229|NCT03590067||Heamodialysis group|
89605230|NCT03590067||Kidney transplantation group|
89605231|NCT01854697|Experimental|Arm A: 3-DAA + RBV in GT1a|ABT-450/r/ABT-267 150 mg/100 mg/25 mg once daily (QD) and ABT-333 250 mg twice daily (BID) and weight-based RBV for 12 weeks (3 direct-acting antivirals [DAAs] with RBV in GT1a)
89605232|NCT01854697|Active Comparator|Arm B: TPV/PR in GT1a|Telaprevir (TPV) 750 mg every 8 hours (q8h) and pegIFN 180 µg/week and weight-based RBV (PR) for 12 weeks followed by an additional 12 or 36 weeks of pegIFN and weight-based RBV according to response guided therapy per the prescribing information for telaprevir (telaprevir with pegIFN/RBV in GT1a)
89605233|NCT01854697|Experimental|Arm C: 3-DAA + RBV in GT1b|ABT-450/r/ABT-267 150 mg/100 mg/25 mg QD and ABT-333 250 mg BID and weight-based RBV for 12 weeks (3 DAAs with RBV in GT1b)
89605234|NCT01854697|Experimental|Arm D: 3-DAA in GT1b|ABT-450/r/ABT-267 150 mg/100 mg/25 mg QD and ABT-333 250 mg BID for 12 weeks (3 DAAs without RBV in GT1b)
89605235|NCT01854697|Active Comparator|Arm E: TPV/PR in GT1b|Telaprevir 750 mg q8h and pegIFN 180 µg/week and weight-based RBV for 12 weeks followed by an additional 12 or 36 weeks of pegIFN and weight-based RBV according to response guided therapy per the prescribing information for telaprevir (telaprevir with pegIFN/RBV in GT1b)
89032544|NCT00525980|Experimental|Group 3: Computer Program + Promotora|Group 3 use the computer program with the guidance of a promotora.
88981708|NCT00871013|Experimental|MEL-VTD-PACE|Melphalan, Velcade, Thalidomide, Dexamethasone, CisPlatin, Adriamycin, Cyclophosphamide, Etoposide
88981709|NCT00847574|Experimental|Moderate-fat|35% of calories from fat
88981710|NCT00847574|Experimental|Lower-fat|20% of calories from fat
88981711|NCT00599118||atrial fibrillation|Atrial fibrillation
88981712|NCT00599118||Control|Control subjects with no atrial fibrillation
88981713|NCT00585650|Experimental|Treatment Group|Etanercept (Enbrel) 50mg twice weekly injections for 12 weeks
88981714|NCT00585650|Placebo Comparator|Placebo Group|Placebo Injections twice weekly for 12 weeks
89605236|NCT03591159|Active Comparator|Membrane Sweeping Group|
88981715|NCT00539643|Active Comparator|Bead Arm|Hepatic arterial embolization with Bead Block microspheres, beginning with 100 - 300 micron beads, and using larger particles if necessary until stasis is evident.
88981716|NCT00539643|Active Comparator|Bead + Dox Arm|Hepatic arterial embolization with 100-300 micron drug eluting microspheres (LC Bead) loaded with 150 mg Doxorubicin, followed by embolization with Bead Block microspheres (100-300 micron and larger size beads as necessary) until stasis is evident.
88981717|NCT00195052||Epilepsy Patients|
88981718|NCT00172029|Experimental|ZOL446 Standard radiotherapy dosage|
88981719|NCT00172029|Experimental|ZOL446 Low radiotherapy dosage|
88981720|NCT00080912|Experimental|Arm I|Patients receive single-fraction radiotherapy (8 Gy) on day 1.
88981721|NCT00080912|Active Comparator|Arm II|Patients receive multiple-fraction radiotherapy (to a total of 20 Gy) over 5 days or over 8 days if re-irradiation of the spine and/or whole pelvis is involved AND prior initial radiotherapy was given in multiple fractions.
89032545|NCT02929875|Experimental|Case (Educational based on TPB)|"Educational intervention delivered to subjects. The content of education includes:~Three training sessions were given to the case group; each lasted for one hour, during a period of twenty days. During each one-hour training session a period of 45 minutes was dedicated to listening to lectures, having discussions, and discussing methods of using teaching aids such as pamphlets and manuals. The last 15 minutes was used to summarize issues and answer questions."
89032546|NCT02929875|No Intervention|Control (No intervention)|No educational intervention provided to subjects in control group
89032547|NCT00525356|Active Comparator|1|Anti-hypertensive medical treatment
89032548|NCT00525395|Experimental|A|Group A: 2 months treatment-1 month no treatment-2 months treatment-1 month no treatment
89605237|NCT03591159|No Intervention|Control Group|
89605238|NCT03590535||Patients with Possible ACS|Adult patients presenting to the Emergency Department with symptoms that maybe be caused by acute coronary syndrome, who are clinically considered to be at enough risk for ACS to send a cardiac enzyme as part of the diagnostic evaluation.
89605239|NCT01824979|Experimental|Pilairo mask|Pilairo nasal pillows mask during CPAP titration
89605240|NCT01824979|Active Comparator|Other CPAP mask|Other CPAP mask during CPAP titration
89605241|NCT04195971|Experimental|Liver CT with dual arterial phase|
89605242|NCT01824823|Experimental|Arm A (afatinib)|Patients receive afatinib PO QD on days 1-28.
89605243|NCT01824823|Placebo Comparator|Arm B (placebo)|Patients receive placebo PO QD on days 1-28.
89605244|NCT04196205|Experimental|Anti-CD19 CAR-T|Anti-CD19 CAR-T
89605245|NCT03598725|Experimental|ITI strategy|The low-dose ITI was Coagulation Factor VIII (50IU/kg, every other day) alone or combined with prednisone (2mg Kg-1/day, one month, then taper in three months) depending on the tendency of inhibitor, and Rituximab (375mg/square meter every week for 4 weeks) when the inhibitor titer ≥40BU/ml before or during ITI.Inhibitor and hemorrhage should be retested and recorded periodically.
89605246|NCT04196127||TTH|Patients with tension-type headache. They may not experience migraine, but can experience neck pain and/or temporomandibular dysfunction.
89605247|NCT04196127||Healthy controls|Participants without frequent headaches. They may experience neck pain and/or temporomandibular dysfunction.
88981722|NCT00039130|Experimental|Rituximab with High Intensity Chemotherapy|Cycle1: Cyclophosphamide 100 mg/m^2/day (d) IV (d 1-5), Prednisone 60 mg/m^2/d oral (d 1-7), Allopurinal 300 mg/d oral (d 1-14) Cycle 2, 4 & 6 (21 day): Ifosfamide 800 mg/m^2/d (d 1-5), Dexamethasone 10 mg/m^2/d (d1-5), Methotrexate 150 mg/m^2 load, then 1.35 g/m^2 over 23.5 h (d 1), Leucovorin 25 mg/m^2 36 h after methotrexate (d 2) then 10 mg/m^2 every 6 h, Vincristine 2 mg push (d 1), Cytarabine 1000 mg/m^2/d over 2 h (d 4-5), Etoposide 80 mg/m^2.d over 1 h (d 4-5), Filgrastim 5 mg/kg/d (d 7-21 as needed), Rituximab 50 mg/m^2 d 8 cycle 2 only, 375 mg/m^2/d (d 10, 12 cycle 2, d 8 cycle 4 & 6) Cycle 3, 5 & 7 (21 day): Cyclophosphamide 200 mg/m^2/day (d) IV (d 1-5), Dexamethasone 10 mg/m^2/d (d1-5), Methotrexate 150 mg/m^2 load, then 1.35 g/m^2 over 23.5 h (d 1), Leucovorin 50 mg/m^2 36 h after methotrexate (d 2) then 10 mg/m^2 every 6 h, Vincristine 2 mg push (d 1), Doxorubicin 25 mg/m^2/d (d 4-5), Filgrastim 5 mg/kg/d (d 7-21 as needed), Rituximab 375 mg/m^2/d (d 8)
88981723|NCT00005957|Active Comparator|Standard Breast Irradiation|
88981724|NCT00005957|Experimental|Breast Radiation plus regional radiation|regional radiation therapy (to the ipsilateral supraclavicular, axillary and internal mammary nodes)
88981725|NCT00003692|Experimental|video-assisted surgery|Patients undergo video-assisted thoracic surgery (VATS) lobectomy, which requires 3 small incisions on the side of the chest. The entire anatomic pulmonary lobe is removed, as well as all peribronchial lymph nodes and anterior hilar lymph nodes. If it is not possible to remove the lobe using the VATS approach, then 1 of the incisions is converted to a standard thoracotomy. Patients are followed every 4 months for the first 2 years, and then every 6 months for the next 3 years.
88981726|NCT00419029|Active Comparator|control|brief telephone check-in (no motivational interviewing)
88981727|NCT00419029|Experimental|telephone-administered motivational interviewing|motivational interviewing sessions
88981728|NCT00425074|Experimental|SR-ASA|slow release acetylsalicylic acid 150 mg
88981729|NCT00425074|Active Comparator|ASA|normal release acetylsalicylic acid
88981730|NCT00314314|Experimental|1|
88981731|NCT00314314|Placebo Comparator|2|
88981732|NCT00122616|Active Comparator|Peginterféron alpha-2a + Ribavirin+ HIV antiretroviral therapy|Day0 to week 96:Peginterféron alpha-2a + Ribavirin+ HIV antiretroviral therapy
88981733|NCT00122616|Placebo Comparator|HIV antiretroviral therapy|Day0 to week 96: HIV antiretroviral therapy
88981734|NCT04984070|Experimental|PCOS treatment|Lifestyle intervention, oral contraceptive pills and metformin will be given to improve the symptoms of PCOS patients, such as obesity, hyperandrogegism, and insulin resistance, and to compare the different psychological status in PCOS.
88981735|NCT00314548|Experimental|Cases|PGE1 drug
88981736|NCT00314548|Placebo Comparator|Placebo|normal saline via same nebulizer
88981737|NCT00314626|Experimental|A|abacavir 600 mg + lamivudine (3TC) 300 mg in 1 tablet + efavirenz 600 mg 1/24h
88981738|NCT00314626|No Intervention|B|efavirenz + 2 NUCS
88981739|NCT02960074|Experimental|Non-antibiotics Arm|The first 10 patients will not receive antibiotics prior to receiving the investigational agent, which consists of screened-donor inoculum of a biologically active human substance (FMT). We will give oral frozen FMT over 2 days.
88981740|NCT02960074|Experimental|Antibiotics Arm|An additional 5 patients will receive antibiotics prior to receiving the investigational agent, which consists of screened-donor inoculum of a biologically active human substance (FMT). We will give oral frozen FMT over 2 days.
88981741|NCT04943627|Experimental|Monotherapy with Balstilimab (BAL)|300 mg IV once every 3 weeks for up to 24 months
89605248|NCT03598569||lung cancer|
89605249|NCT03598569||other lung diseases|
88981742|NCT04943627|Active Comparator|Monotherapy with Investigator Choice (IC) Chemotherapy per Institutional guidelines|Topotecan: 1 or 1.25 mg/m^2 IV on Days 1 to 5, every 21 days or Vinorelbine: 30 mg/m^2 IV on Days 1 and 8, every 21 days or Gemcitabine: 1000 mg/m^2 IV on Days 1 and 8, every 21 days or Irinotecan: 100 or 125 mg/m^2 IV weekly for 28 days, every 42 days or Pemetrexed: 500 mg/m^2 IV on Day 1, every 21 days
88981743|NCT00314743|Active Comparator|Control (No aprepitant)|"Regimen #1 (BEAM; NHL and HL)~Carmustine 300 mg/m2 IV on day -7 (premedicate with ondansetron 32 mg IV and dexamethasone 20 mg IV)~Etoposide 100 mg/m2 IV Q 12 hours x 8 doses on days -6 to -3 (premedicate first daily dose ondansetron 32 mg IV and dexamethasone 20 mg IV)~Cytarabine 100 mg/m2 IV Q 12 hours x 8 doses on days -6 and -3 (no additional premedication)~Melphalan 140 mg/m2 IV on day -2 (premedicate with ondansetron 32 mg IV and dexamethasone 20 mg IV)~Regimen #2 (MM and Amyloidosis)~Melphalan 100 mg/m2 IV on days -3 and -2 (premedicate each dose with ondansetron 32 mg IV and dexamethasone 20 mg IV)"
88981744|NCT00314743|Experimental|Experimental (with aprepitant)|"Aprepitant 125 mg PO will be given 30 minutes prior to the first dose of chemotherapy followed by Aprepitant 80 mg PO QD for the remainder of chemotherapy and continuing for a total of 2 days after completing the regimen.~Regimen #1 (BEAM; NHL and HL)~Carmustine 300 mg/m2 IV on day -7 (premedicate with ondansetron 32 mg IV and dexamethasone 10 mg IV)~Etoposide 100 mg/m2 IV Q 12 hours x 8 doses on days -6 to -3 (premedicate first daily dose ondansetron 32 mg IV and dexamethasone 10 mg IV)~Cytarabine 100 mg/m2 IV Q 12 hours x 8 doses on days -6 and -3 (no additional premedication)~Melphalan 140 mg/m2 IV on day -2 (premedicate with ondansetron 32 mg IV and dexamethasone 10 mg IV)~Regimen #2 (MM and Amyloidosis)~Melphalan 100 mg/m2 IV on days -3 and -2 (premedicate each dose with ondansetron 32 mg IV and dexamethasone 10 mg IV)"
88981745|NCT00314782|Experimental|Part A|Part A (dose-finding): ZD4054 (Zibotentan) 10 mg oral tablet once daily, with docetaxel 75mg/m^2 intravenous infusion once per cycle
89605250|NCT04766307|Experimental|experimental group|"Experimental group regimen:2H(Isoniazid)R(Rifampicin)Z(Pyrazinamide)E(Ethambutol)/4HR+Interleukin-2 （500000 units daily, subcutaneous injection in the first month）~Dosage: isoniazid 300mg(given once daily),rifampin 450mg(less than 50kg,given once daily) or 600mg(more than 50kg,given once daily),pyrazinamide 1500mg(less than 50kg,given once daily) or 30mg/kg(more than 50kg,given once daily),ethambutol 750mg(less than 50kg,given once daily) or 1000mg(more than 50kg,given once daily)."
89605251|NCT04766307|Active Comparator|Control regimen group|"The control group regimen: 2H(Isoniazid)R(Rifampicin)Z(Pyrazinamide)E(Ethambutol)/4HR~Dosage: isoniazid 300mg(given once daily),rifampin 450mg(less than 50kg,given once daily) or 600mg(more than 50kg,given once daily),pyrazinamide 1500mg(less than 50kg,given once daily) or 30mg/kg(more than 50kg,given once daily),ethambutol 750mg(less than 50kg,given once daily) or 1000mg(more than 50kg,given once daily)."
89605252|NCT03024801|Experimental|autologous platelet-rich plasma group|The patients with knee cartilage injury were randomized to the intra-articular injection of autologous platelet-rich plasma group.
89605253|NCT03024801|Experimental|normal saline group|The patients with knee cartilage injury were randomized to the normal saline group.
88981746|NCT00314782|Experimental|Part A (ZD4054 (Zibotentan) 15 mg + docetaxel)|Part A (dose-finding): ZD4054 (Zibotentan) 15 mg oral tablet once daily, with docetaxel 75mg/m^2 intravenous infusion once per cycle
88981747|NCT00314782|Experimental|Part B|Part B (randomised, placebo-controlled): ZD4054 (Zibotentan) Maximum Tolerated Dose (MTD), 15mg, oral tablet once daily, with docetaxel 75mg/m^2 intravenous infusion once per cycle
88981748|NCT00314782|Experimental|Part B (placebo)|Part B (randomised, placebo-controlled): Matching placebo oral tablet once daily, with docetaxel 75mg/m^2 intravenous infusion once per cycle
88981749|NCT00313339|No Intervention|Control Group|A concurrent group meeting eligibility criteria but not receiving CD34+cells will be evaluated similar to the study group to assess the extent, if any, of significant improvement in cardiac perfusion/function without the CD34+cell product infusion.
88981750|NCT00313339|Experimental|Treatment Group|Intra-coronary infusion of an autologous bone marrow derived CD34+ stem cell product.
88981751|NCT00313378|Experimental|ketamine|This study compares two groups of patients undergoing thoracotomy for partial pneumonectomy, one receiving intravenous ketamine since the beginning of procedure and then during 48 hours, the other receiving inactive normal saline (placebo).
88981752|NCT00313378|Other|placebo|This study compares two groups of patients undergoing thoracotomy for partial pneumonectomy, one receiving intravenous ketamine since the beginning of procedure and then during 48 hours, the other receiving inactive normal saline (placebo).
88981753|NCT00313417|Active Comparator|1|
88981754|NCT00313417|Placebo Comparator|2|
89605254|NCT03591237|Experimental|MBCT|As patients with significant pain are identified and accept the offer of receiving 'Mindfulness-Based Cognitive Therapy' (MBCT) for pain, they will be consecutively included in groups of 12-20 participants. The patients will participate in eight weekly two hour group sessions and will be asked to do an additional 45 minutes of daily training at home.
89605255|NCT04195191|Placebo Comparator|Placebo|The usual practice by community pharmacies
89605256|NCT04195191|Experimental|ANM|This is an intervention based on pharmaceutical-patient communication through an open and fluid conversation, aimed at evaluating the patient's relationship with their new prescription, detecting possible problems, concerns and false beliefs or visual expectations.
89605257|NCT01875367|Experimental|Arm A: T-IV + T-SC vial + T-SC device|Trastuzumab intravenous (T-IV) x 1 cycle (usual dose of Trastuzumab), followed by 600mg of Trastuzumab Subcutaneous (T-SC) with vial (Injectable Solution) x 2 cycles, followed by 600mg of T-SC with single injection device (SID) x 2 cycles.
89605258|NCT01875367|Experimental|Arm B: T-IV + T-SC device + T-SC vial|Trastuzumab intravenous (T-IV) x 1 cycle (usual dose of Trastuzumab), followed by 600mg of Trastuzumab Subcutaneous (T-SC) with single injection device (SID) x 2 cycles, followed by 600mg of T-SC with vial (Injectable Solution) x 2 cycles.
89605259|NCT04194879||Cancer|Case subjects (at least 50) will be men and women age 40-74 who are recently diagnosed, through colonoscopy, with different stages of colorectal cancer and have not yet had surgical intervention.
89605260|NCT04194879||Negative|Approximately 250 prospectively enrolled subjects will be men and women age 40-74 who are at average risk of developing colorectal cancer and eligible for colonoscopy. About 150 Control subjects will be enrolled prospectively, who have no colorectal neoplasia detected on colonoscopy, including cancer, advanced adenoma, sessile serrated lesions and small, non-advanced adenoma.
88981755|NCT04861727|No Intervention|Group control|will be attended by Pharmacists and will have the data collected according to the standard collection instrument, will make MRPA and will receive the report and general guidance on blood pressure control and pharmacotherapy assessment
88981756|NCT04861727|Active Comparator|Intervention group|will be attended by Pharmacists and will have the data collected according to the standard collection instrument, will receive general guidance on blood pressure control and pharmacotherapy assessment, will also do MRPA whose result will guide pharmaceutical suggestions, when necessary, they will also receive a Referral Letter to the Prescriber containing pharmaceutical suggestions for optimization of pharmacotherapy, considering the current clinical protocols.
88981757|NCT00313807|Active Comparator|1|Intravenous saline infusion plus amino acid infusion
88981758|NCT00313807|Placebo Comparator|2|Intravenous saline infusion plus placebo infusion
88981759|NCT00313885|Experimental|1|1 mg daily
88981760|NCT00313885|Experimental|2|5 mg daily
88981761|NCT00313885|Placebo Comparator|3|
88981762|NCT04898452||Patients needing antibiotics infusion|Patients needing antibiotics infusion A new model of interaction across health services with use of welfare technology and telemedicine Instead of admitted to the hospital, patients are followed up at home by the municipal regional response center and nurses in the response team according to the individual treatment plan. Hospital physicians are medically responsible throughout the course.
89032549|NCT00525395|Active Comparator|B|Group B: 6 months non-stop treatment.
89032550|NCT04693559|Other|autogenous iliac bone graft (group A)|autogenous iliac bone graft will be used to fill the alveolar defect
89032551|NCT04693559|Other|Nano crystalline Hydroxyapatite (group B)|Nano crystalline Hydroxyapatite will be used to fill the alveolar defect
89032552|NCT04323150|Experimental|Closed suction systems|
89032553|NCT04323150|Other|Open (conventional) suction|control group
89032554|NCT00526019||Complete remission of their asthma|Subjects in complete remission of their asthma Subjects in complete remission of their asthma: absence of respiratory symptoms, no rescue asthma medication need and an optimal pulmonary function and normal PC20 methacholine (>16 mg/ml) for more than two years (with no current treatment).
89605261|NCT04197999|Experimental|Single Ascending Dose followed by Multiple Doses|Up to 3 single ascending doses of GMI-1359 followed by the highest tolerated dose given for 3 consecutive days.
89605262|NCT04195659||Top Surgery|Individuals assigned the female sex at birth, who identify as a gender other than female, are between the ages of 13 and 25 years, and who are undergoing mastectomy and chest masculinization in one of three plastic surgery practices in Chicago.
89605263|NCT04195659||Control|Individuals assigned the female sex at birth, who identify as a gender other than female, are between the ages of 13 and 25 years, were seen in a gender development clinic in Chicago, and who are not planning to undergo top surgery. Controls will be matched with top surgery patients on age and number of months of testosterone.
89605264|NCT03598491||Iohexol|Iohexol was applied in video-fluoroscopic-swallowing study
89605265|NCT03598491||Barium|Barium was applied in video-fluoroscopic-swallowing study
89605266|NCT03598335||Women with malignant tumor|Women with malignant tumor in reproductive system
89605267|NCT03598335||Women with benign tumor|Women with benign tumor in reproductive system
89605268|NCT03598335||Women with no observed tumor|Women with no observed tumor in reproductive system
89605269|NCT04194957|Experimental|Wild type for DPYD|Patients screened for four single nucleotide polymorphisms (SNPs) in DPYD (DPYD*2A, c.2846A>T, c.1236G>A/HapB3 and DPYD*13) that are found to be wild type for these SNPs
89605270|NCT04194957|Experimental|heterozygous carrier of c.1236G>A or c.2846A>T DPYD variant|Patients screened for four single nucleotide polymorphisms (SNPs) in DPYD (DPYD*2A, c.2846A>T, c.1236G>A/HapB3 and DPYD*13) that are found to be heterozygous for c.1236G>A or c.2846A>T of these SNPs
89605271|NCT04194957|Experimental|Homozygous or compound heterozygous carrier of DPYD variants|Patients screened for four single nucleotide polymorphisms (SNPs) in DPYD (DPYD*2A, c.2846A>T, c.1236G>A/HapB3 and DPYD*13) that are found to be homozygous or compound heterozygous for these SNPs
89605272|NCT03023943|Experimental|IASTM group|Intervention will be 10 minutes of GT1 instrument application at anterior thigh using sweep technique.
89605273|NCT03598101|Experimental|Test group|
89605274|NCT04194567|Experimental|Black Ragi|During one week of the study, participants are to consume pancakes made from the dark variety of ragi.
89605275|NCT04194567|Experimental|White Ragi|During the second week of the study, participants are to consume pancakes made from the white variety of ragi
89605276|NCT04177797|Experimental|Toripalimb|Single arm, non randomized, open label study.The patients will receive Toripalimb concurrently caboplatin and paclitaxel treatment.
89605277|NCT04194255|Experimental|ferrous fumarate|labelled iron as ferrous fumarate
88981763|NCT04898452||Next of kin|Next of kin A new model of interaction across health services with use of welfare technology and telemedicine Instead of admitted to the hospital, patients are followed up at home by the municipal regional response center and nurses in the response team according to the individual treatment plan. Hospital physicians are medically responsible throughout the course.
88981764|NCT04898452||Health professionals|A new model of interaction across health services with use of welfare technology and telemedicine Instead of admitted to the hospital, patients are followed up at home by the municipal regional response center and nurses in the response team according to the individual treatment plan. Hospital physicians are medically responsible throughout the course.
88981765|NCT04767919|Active Comparator|Standard Percutaneous Nephrolithotomy (sPCNL)|The first arm will consist of a Standard of Care standard percutaneous nephrolithotomy (sPCNL)- performed using a 30 Fr access sheath following balloon dilation.
88981766|NCT04767919|Active Comparator|Minimally Invasive Percutaneous Nephrolithotomy (MIP)|The second arm will consist of a Standard of Care mini percutaneous nephrolithotomy (mPCNL)- performed using an 18 Fr access sheath following either balloon dilation or dilation using a single step metal dilator.
88981767|NCT00091182|Experimental|Arm I|Patients receive oxaliplatin IV over 2 hours on day 1. Treatment repeats every 21 days for up to 17 courses in the absence of disease progression or unacceptable toxicity.
89605278|NCT04194255|Experimental|ferrous fumarate + 15 g GOS|labelled iron as ferrous fumarate + prebiotics in the form of 15 g GOS
89605279|NCT04194255|Experimental|ferrous fumarate + 15 g FOS|labelled iron as ferrous fumarate + prebiotics in the form of 15 g FOS
89605280|NCT04194255|Experimental|ferrous fumarate + 15 g acacia gum|labelled iron as ferrous fumarate + prebiotics in the form of 15 g acacia gum
89605281|NCT03598023|Active Comparator|Group 1|Cytal® Burn Matrix
89605282|NCT03598023|Active Comparator|Group 2|EZ-Derm® Porcine Xenograft
89605283|NCT04406883|Active Comparator|A (Simavastatin 10 mg with gelatin sponge graft)|A group: After atraumatic extraction, filled the tooth socket with Simvastatin10 mg solution impregnated gelatin sponge.
89605284|NCT04406883|Active Comparator|B(Gelatin sponge graft )|B group: Following atraumatic extraction, put in the tooth socket with gelatin sponge.
88981768|NCT04635280|Experimental|Closed-loop automatic insulin delivery system|Adults type 1 diabetic patients equiped with a closed-loop automatic insulin delivery system (or artificial pancreas)
89032555|NCT00526019||Symptomatic remission ofasthma|Subjects in symptomatic remission of their asthma (No asthma symptoms in the last 2 years, no asthma medication, PC20 methacholine <16 mg/ml)
89605285|NCT04199949|No Intervention|Control|5 consecutive days of normal daily levels of physical activity and matched food intake
89605286|NCT04199949|Experimental|Inactivity|5 consecutive days of reduced step count by 80% compared to the Control trial, whilst placing the non-dominant arm in a sling, and reduced food intake (~ 20%) to match the reduction in energy expenditure induced by inactivity
89605287|NCT04194177|Experimental|protective|
89605288|NCT04194177|Active Comparator|conventional|
89605289|NCT04199559|Experimental|Autologous dendritic cells pulsed with antigen|peptide(WT1-H/K-HELP, Survivin-H/K-HELP,MAGE-A4-H ⁄ K-HELP and MUC1-22) . Each dose contains of 10 million activated autologous DCs. Route of Administration: Intradermal.
89605290|NCT03597867|Placebo Comparator|Placebo|Placebo using single-use vials of hyaluronic acid 0.2% preservative-free lubricating tear drops three days before surgery.
89605291|NCT03597867|Experimental|Dicloftil|"Diclofenac Na 0.1% Oph Soln, Dicloftil®, NSAID eyedrops administered three days before surgery"
89605292|NCT03597867|Experimental|Nevanac|"Nepafenac 0.3% Ophthalmic Suspension, Nevanac 3mg/ml®, NSAID eyedrops administered three days before surgery"
89605293|NCT03597867|Experimental|Indom|"Indomethacin 5 MG/ML Ophthalmic Suspension, Indom ®, NSAID eyedrops administered three days before surgery"
89605294|NCT03597867|Experimental|Yellox|"Bromfenac 0.09 % Ophthalmic Solution, Yellox®, NSAID eyedrops administered three days before surgery"
89605295|NCT03597477||Autism Spectrum Disorder|Patients with a diagnosis of autism spectrum disorder
89605296|NCT03597477||Control|Patients with no developmental diagnoses
89605297|NCT04199715|Experimental|Heplisav-B Vaccine Recipient|There will be a single group of 18 immune compromised patients who will receive the Heplisav-B vaccine.
89605298|NCT04193319|Other|Single arm|
89605299|NCT04192851|Experimental|Tent Pole Grafting Technique|"Bone graft [NanoBone® granulate 0,6 mm (24% Silica / 76% Hydroxylapatite)] is mixed with the patient blood and placed to cover the screws completely, the defect is overcorrected with particulate material in anticipation of future graft resorption.~PRF membrane is prepared by:~Ten milliliters of whole venous blood will be collected in sterile glass test tubes without anticoagulant. Then the test tubes will be placed in a table centrifuge machine at 3000 revolutions per minute (rpm) for 10 minutes.After separation of PRF, the membrane is prepared compression device."
89605300|NCT03957135|Experimental|Laparoscopic distal pancreatectomy|Patients receiving laparoscopic distal pancreatectomy for pancreatic tail and body cancer
89605301|NCT03957135|Active Comparator|open distal pancreatectomy|Patients receiving open distal pancreatectomy for pancreatic tail and body cancer
89605302|NCT04190901|Experimental|Simulated Black Male Physician|Participants are randomized to view the clinical vignette with a simulated Black Male physician.
89605303|NCT04190901|Experimental|Simulated Black Female Physician|Participants are randomized to view the clinical vignette with a simulated Black Female physician.
89605304|NCT04190901|Experimental|Simulated White Male Physician|Participants are randomized to view the clinical vignette with a simulated White Male physician.
89605305|NCT04190901|Experimental|Simulated White Female Physician|Participants are randomized to view the clinical vignette with a simulated White Female physician.
89605306|NCT03597321|Experimental|Arm A-DLI|Patients will be planned to receive prophylactic Donor Lymphocyte Injection
89605307|NCT03597321|No Intervention|Arm B- No intervention|
89605308|NCT03597243|Experimental|Intervention|AGYW in the standard Sauti cash transfer (Arm I) will receive unconditional cash transfer (UCT) in the presence of behavioral and biomedical interventions in quarterly installments of 70,000 TSH. The first installment will take place after completion of 10 hours of BCC sessions and the AGYW has registered into CTP.
89605309|NCT03597243|No Intervention|Control|AGYW in the control group (Arm II) will not receive cash payment but will receive behavioral and biomedical interventions. The behavioral and biomedical interventions are provided by Sauti program to all project beneficiaries.
89605310|NCT04193007|Experimental|molecular targeted therapy group|Molecular targeted therapy(according to the results of gene detection, targeted drugs were selected, such as EGFR mutation using the first generation of EGFR-TKI,ALK or ROS1 mutation using the first generation of ALK inhibitors)
89605311|NCT04193007|Experimental|Brain Radiotherapy and molecular targeted therapy group|Brain Radiotherapy (stereotactic radiotherapy was used for 1-3 intracranial lesions, and simultaneous modulated accelerated radiation therapy for Brain(SMART-Brain )was used for more than 3 intracranial lesions);Molecular targeted therapy(according to the results of gene detection, targeted drugs were selected, such as EGFR mutation using the first generation of EGFR-TKI,ALK or ROS1 mutation using the first generation of ALK inhibitors)
89605312|NCT04190355|Active Comparator|5.25% NaOCl solution|5.25% NaOCl solution will be used as irrigation solution at every file change during root canal preperation
89605313|NCT04190355|Active Comparator|5.25% Cloraxid gel/ distilled water|5.25% Cloraxid gel/ distilled water will be used as irrigation solution at every file change during root canal preperation
88981769|NCT04729790|Active Comparator|Patients with RCDI will receive FMT capsules from single donor|"Capsules made with intestinal bacteria from single healthy donor~st treatment day, lyophilized product generated from single donor (90g of stool)~nd treatment day, lyophilized product generated from single donor (90g of stool)"
89605314|NCT04193163||Patients receiving ESOP 2 stem|
89605315|NCT03023475|Active Comparator|LigaSure endoscopic radial harvesting|The endoscopic vessel harvesting will be performed using the LigaSure device.
89605316|NCT03023475|Active Comparator|TLS2 endoscopic radial harvesting|The endoscopic vessel harvesting will be performed using the TLS2 device.
89605317|NCT03596931||Statin|History of statin use prior to Acute Coronary Syndrome
89605318|NCT03596931||Non-Statin|No documented history of statin use prior to Acute Coronary Syndrome
88981770|NCT04729790|Experimental|Patient will receive FMT capsules from three donors|"Capsules made of intestinal bacteria from three healthy donors~st treatment day, lyophilized product generated from three donors (90g of stool)~nd treatment day, lyophilized product generated from three donors (90g of stool)"
88981771|NCT04593901|Other|Video and App Review|Single arm study in which home healthcare workers review and provide feedback on scripts and/or videos and on the usefulness, usability, and desirability of an interactive app in an iterative, participatory manner.
88981772|NCT04563208|Placebo Comparator|Arm A: Placebo|Placebo administered
89605319|NCT03596853|Experimental|Experimental: Mobilization|These patients will receive standard rehabilitation delivered by non-study physiotherapist. In addition, the patients will undergo a protocol of progressive mobilization with individualized dose control and training load stratified according to functional levels and performance.
89605320|NCT03596853|Sham Comparator|Control: Usual care|These patients will receive standard rehabilitation delivered by non-study physiotherapist.
89605321|NCT04192617|Experimental|SM03 600 mg*2|SM03: 600 mg intravenous (IV) on week 0,2, and week 12,14; placebo: 600 mg intravenous (IV) on week 4 and16; Methotrexate: 7.5-20 mg/wk oral.
89605322|NCT04192617|Experimental|SM03 600 mg*3|SM03: 600 mg intravenous (IV) on week 0,2, 4, and week 12,14,16; Methotrexate: 7.5-20 mg/wk oral.
89605323|NCT04192617|Placebo Comparator|placebo*3|placebo: 600 mg intravenous (IV) on week 0,2, 4, and week 12,14,16; Methotrexate: 7.5-20 mg/wk oral.
89605324|NCT04192539|Active Comparator|Control|
89605325|NCT04192539|Active Comparator|Inflammation|
89605326|NCT04192539|Active Comparator|Benign group|
89605327|NCT04192539|Active Comparator|Malignant group|
89605328|NCT04192383||Cyberknife|
89605329|NCT01874665|Experimental|Cohort A|Participants with KIT exon 11-mutant GIST.
89605330|NCT01874665|Experimental|Cohort B|Participants with GIST that lack KIT exon 11 mutations (Cohort B).
89605331|NCT04192305||lung protective ventilation (LPV)|lung protective ventilation low tidal volume, minimum PEEP and higher PEEP and lung recruitment based on total lung compliance, low inspiratory oxygen concentration and CPAP during extubation without prior suctioning inside the endotracheal tube.
89605332|NCT04192305||routine lung ventilation (LV)|ventilation and adapting PEEP, LRM and oxygen only when saturation drops.
89605333|NCT04192149|Experimental|Patients receiving Craniotomy|Patients receiving an awake or asleep craniotomy for brain tumors and/or epilepsy will undergo a brain mapping procedure using electrical stimulation as a part of their normal care. The research procedures will duplicate this mapping with an invasive Focused Ultrasound mapping.
89605334|NCT04192149|Experimental|Epilepsy Patients|Patients undergoing long term monitoring for epilepsy will receive a non-invasive form of Focused Ultrasound stimulation which will be measured by their EEG cap and intracranial electrodes which are a part of their normal care.
89605335|NCT04192149|Experimental|Tremor Patients receiving FUS|Patients undergoing high intensity FUS treatment for tremor will be asked to wear a research provided EEG cap while undergoing a non-invasive low intensity Focused Ultrasound research procedure and changes in their tremor will be monitored.
89605336|NCT04192149|Experimental|Tremor Patients receiving DBS|Patients undergoing Deep Brain Stimulation (DBS) treatment for tremor will receive a non-invasive Focused Ultrasound stimulation observed through their newly implanted electrode.
89605337|NCT04192149|Experimental|Patients receiving Spinal Surgery|Patients receiving a spinal surgery will undergo a spinal stimulation using electrical stimulation as a part of their normal care. The research procedures will duplicate this with an invasive Focused Ultrasound stimulation.
89605338|NCT03596619|Experimental|PBN-ALA-PDT Group|The PBN-ALA-PDT group underwent vertical skin tapping with PBN before applying 10% ALA cream and narrow-band light-emitting diode (LED) irradiation (mean 633 nm, with a standard deviation [SD] of 10 nm; 100-200 J/cm2).
89605339|NCT03596619|No Intervention|ALA-PDT Group|The ALA-PDT group received ALA cream and irradiation only.
89605340|NCT04191525|Experimental|BPL-1 Probiotic capsules|BPL-1 Probiotic 1 capsule/day
89605341|NCT04191525|Placebo Comparator|Placebo|1 capsule/day
88981773|NCT04563208|Active Comparator|Arm B: Ribavirin/Nitazoxanide (RBV/NTZ)|Ribavirin/Nitazoxanide (RBV/NTZ) administered
88981774|NCT02965131|No Intervention|Non-temporary portocaval shunt|No temporary portacaval shunt is created. Full mobilization of the liver was followed by dissection of the hilar structure.
88981775|NCT02965131|Experimental|Temporary portocaval shunt|Temporary portocaval shunt is created when inadvertent massive perihepatic bleeding or technical difficulties due to untypical patients' perihepatic anatomy are encountered during total hepatectomy. Hilar dissection preceded the dissection of the retrohepatic vena cava from the native liver. Its creating prolongs the duration of the anhepatic phase.
88981776|NCT04383496|Experimental|Physical Activity|In-person, virtual conferencing, and telephone sessions, wearable device for daily feedback and motivation
88981777|NCT04613141|Sham Comparator|Mobility-plus|"Mobility-plus is a pseudo placebo comparator program using non-slip socks, a low intensity paper-based exercise program and health information specific to Parkinson's Disease."
88981778|NCT04613141|Experimental|WalkingTall-PD|WalkingTall-PD is a novel neuro-rehabilitation program delivered through a tablet/smart phone and smart garments (socks, insoles or ankle bands) for people with Parkinson's disease that aims to improve mobility and reduce falls. WalkingTall-PD combines a variety of PD-specific rhythmic stimuli (auditory, visual and haptic cues) which are synchronised with high intensity stepping, walking and balance training.
88981779|NCT00091299|Experimental|warfarin|
88981780|NCT04363957|Other|Standard Consent|Patients only receive the standard brachytherapy consent process
88981781|NCT04363957|Experimental|Standard Consent and Video Intervention|Patients receive the standard brachytherapy consent process and the addition of an informational video about brachytherapy
88981782|NCT04607603|Experimental|Cannabidiol|In the Cannabidiol (CBD) arm CBD will be titrated up to 600 mg per die (titration 1 week) in capsules (3 daily doses) and maintained at 600mg per die (3 daily doses) for 7 weeks
88981783|NCT04607603|Placebo Comparator|Placebo|In the placebo arm the placebo comparator will be administered in capsules in 3 daily doses
88981784|NCT00122772|Experimental|EBR plus 2 HDBT fractions|External Beam Radiotherapy High Dose Brachytherapy (2 fractions of 9Gy)
88981785|NCT00122772|Active Comparator|EBR plus 4 fractions HDBT|External Beam Radiotherapy High Dose Brachytherapy (4 fractions of 7Gy)
88981786|NCT00122772|Experimental|EBR/2 HDBT fractions/Chemotherapy|"External Beam Radiation~High Dose Brachytherapy (2 fractions of 9Gy)~Cisplatin"
89605342|NCT04029987|Active Comparator|Trans Muscular Quadratus Lumborum fascial plane Block|"In group (Trans Muscular Quadratus Lumborum Block),will undergo ultrasound guided trans-muscular quadratus lamborum block as follows:~A 22 G echogenic needle will be inserted in plane from the posterior (medial) end of the probe and directed for the fascial plane between the Quadratus Lumborum and the Psoas Major muscles through the Quadratus Lumborum muscle. Once the needle is confirmed in correct location, 1 mL of saline will be injected after negative aspiration. Then 0.5 mL/Kg per side of bupivacaine 0.25% will be injected. The spread of the injectate should be observed to distribute within this plane. This technique will be repeated to the other side."
89605343|NCT04029987|Active Comparator|Intra Muscular Quadratus Lumborum fascial plane Block|"In group Intra Muscular Quadratus Lumborum Block ,will undergo ultrasound guided intra-muscular quadratus lamborum (QL) block as follows:~A 22 G echogenic needle will be inserted in plane from ventral (lateral) edge of the probe and advanced until penetration of QL muscle fascia is observed. Once the needle is confirmed in correct location, 1 mL of saline will be injected after negative aspiration. Then 0.5 mL/Kg per side of bupivacaine 0.25% will be injected. The spread of the injectate should be observed to distribute within this plane. This technique will be repeated to the other side."
89605344|NCT04029987|Placebo Comparator|group c → control|group c → control ,will receive conventional analgesia in the form of paracetamol with 15 mg\ k.g every 6 hours, and naluphin 0.1 mg \kg on demands
89605345|NCT04191837|Experimental|Self-administered acupressure|A training course will be offered to subjects in this group to train them to perform self-acupressure.
89032556|NCT00526019||Current asthma (mild asthma)|Subjects with current asthma (Mild asthma)
89032557|NCT00526019||Healthy controls|Healthy controls
89605346|NCT04191837|Active Comparator|Knee health education|A course regarding knee health will be offered to the subjects in this group.
89605347|NCT04191759|Experimental|Test-Retest reproducibility group|Protocol is the same for extended or flexed knee. The testing apparatus was set up as described in the constructor owner's manual and subjects were positioned in the supine lying position. The After a 5 min rest period, the participant's ankle is passively stretched through slow loading cycles from 15° of ankle flexion to 35° of ankle extension. Oral instruction is given to the participants to stay relaxed and avoid any muscle contraction and movement of the leg throughout the passive stretching. To familiarize, participant have 3 repetitions of passive ankle flexion-extension at 5°.s-1, and after 2min rest, data are collected from one repetitions at 5°.s-1 in passive mode. The measurements are also performed at an angular rate of 90°.s-1, according to the same protocol. Data for maximal voluntary isokinetic contraction are collected from 3 maximal repetitions at 60°.s-1 in concentric mode and participant are encouraged by constant verbal stimulation.
89605348|NCT03596463||Group A|Patients treated according to suggestions of tumor board
89605349|NCT03596463||Group B|Patients not treated according to suggestions of tumor board
89605350|NCT04191603|Active Comparator|MONOPOLAR HOOC|COLPOTOMY WITH USAGE MONOPOLAR HOOC
89605351|NCT04191603|Active Comparator|PLASMAKINETIK BIPOLAR SPATULA|COLPOTOMY WITH USAGE MONOPOLAR HOOC
89605352|NCT04029909|Experimental|Gimatecan 0.6mg/m2/d|Three or six patients will be treated with the dose of 0.6mg/m2/d for once a day for 5 consecutive days of Gimatecan. DLT will be observed within 28 days after administration.
89605353|NCT04029909|Experimental|Gimatecan 0.8mg/m2/d|Three or six patients will be treated with the dose of 0.8mg/m2/d for once a day for 5 consecutive days of Gimatecan. DLT will be observed within 28 days after administration.
89605354|NCT04029909|Experimental|Gimatecan 0.4mg/m2/d|Three or six patients will be treated with the dose of 0.4mg/m2/d for once a day for 5 consecutive days of Gimatecan. DLT will be observed within 28 days after administration.
89605355|NCT04190979|Experimental|Single arm|TrackCath
89605356|NCT03596307|Experimental|Ashwagandha extract|180 mg Shoden once daily before breakfast for 2 days in Acute Phase and 16 days in Short Term Phase.
89605357|NCT03596307|Placebo Comparator|Placebo|180 mg identical placebo once daily before breakfast for 2 days in Acute Phase and 16 days in Short Term Phase.
89605358|NCT04406337|Experimental|Low intensity pulsed ultrasound|Participants in this arm will receive low intensity pulsed ultrasound therapy on the affected knees for 20 minutes per day, 5 days a week for 4 weeks. Conventional physiotherapy of quadriceps muscle exercise and health education about life style will also be given.
89605359|NCT04406337|Active Comparator|High intensity continuous ultrasound|Participants in this arm will receive high intensity continuous ultrasound therapy on the affected knees for 10 minutes per day, 5 days a week for 4 weeks. Conventional physiotherapy of quadriceps muscle exercise and health education about life style will also be given.
89605360|NCT04029441||the successful eradication cohort|the subjects who eradicate the Hp successfully after recieving the therapy or rescue therapy based on antimicrobial susceptibility test
89605361|NCT04029441||the failure eradication cohort|the subjects who fail to eradicate the Hp after recieving the therapy or rescue therapy based on antimicrobial susceptibility test
89605362|NCT04766151|Experimental|Transdermal glyceryl trinitrate patches|
89605363|NCT04766151|Placebo Comparator|Transdermal placebo patches|
89605364|NCT04029207||African Surgical OutcomeS-2 Trial|The ASOS-2 Trial is a cluster randomised trial purposively recruiting hospitals across Africa. To be eligible for inclusion a hospital must perform at least 20 cases of adult in-patient surgery with anaesthesia per week, have local ethics approval for the trial, have local hospital management approval and have established a local hospital study team. The trial excludes hospitals with lower surgical volume. The trial aims to include all consecutive adult in-patient surgical cases at participating hospitals (both elective and emergency surgery). Patients under the age of 18 and patients who have already been recruited into the trial are excluded from recruitment. Follow-up is in-hospital, censored at 30 days.
89605365|NCT04191213|Experimental|Intervention Group|This arm will receive 100% natural Gum Arabic provided in a powder form in 30-grams-dose for participants above 5 years of age and 15-grams-dose for participants below 5 years of age for 12 weeks
89605366|NCT04191213|Placebo Comparator|Control group|This group will be provided with pectin powder provided as one-gram-dose for children below 5 years of age & two-gram-dose for children above 5 years of age
89605367|NCT03024177|Experimental|Vapendavir 528 mg|
89605368|NCT03024177|Placebo Comparator|Placebo|
89605369|NCT01874431|Experimental|Finerenone (BAY94-8862) (1.25 mg)|1.25 mg dose oral once daily for 90 days
89032558|NCT00525434|Experimental|A|
89032559|NCT02929524|Experimental|Ketamine group|This group was used intranasal ketamine, syringes were made with 4 ml of the drug (50mg/ml), 1 randomized per patient. The validity stability and were 7 days after drawing the solution. The drug began to take effect in 10 minutes and lasted about 40 minutes.
89032560|NCT02929524|Placebo Comparator|Placebo Group|This group was used intranasal saline, syringes were made with 4 ml of liquid 1 per patient randomized. The validity stability and were 7 days after drawing the solution.
89032561|NCT04310475|Experimental|Active Treatment|This is a case series
89032562|NCT00526136|Placebo Comparator|1|Placebo (b.i.d.)
89032563|NCT00526136|Experimental|2|Vernakalant (oral), 150 mg (b.i.d.)
89032564|NCT00526136|Experimental|3|Vernakalant (oral), 300 mg (b.i.d.)
89032565|NCT00526136|Experimental|4|Vernakalant (oral), 500 mg (b.i.d.)
89032566|NCT02929446|Experimental|Mobilisation|Mobilisation out of bed to sit in an armchair or on the bedside, instructed to sit as long as possible
89605370|NCT01874431|Experimental|Finerenone (BAY94-8862)(2.5 mg)|2.5 mg dose oral once daily for 90 days
89605371|NCT01874431|Experimental|Finerenone (BAY94-8862)(5 mg)|5 mg dose oral once daily for 90 days
89605372|NCT01874431|Experimental|Finerenone (BAY94-8862)(7.5 mg)|7.5 mg dose oral once daily for 90 days
89605373|NCT01874431|Experimental|Finerenone (BAY94-8862) (10 mg)|10 mg dose oral once daily for 90 days
89605374|NCT01874431|Experimental|Finerenone (BAY94-8862) (15 mg)|15 mg dose oral once daily for 90 days
89605375|NCT01874431|Experimental|Finerenone (BAY94-8862)(20 mg)|20 mg dose oral once daily for 90 days
89605376|NCT01874431|Placebo Comparator|Placebo|Placebo oral dose once daily for 90 days
89605377|NCT04028817|Experimental|group treatment|This group will receive laser treatment combined with low intensity exercises
89605378|NCT04028817|Placebo Comparator|group control|This group will receive placebo laser treatment combined with low intensity exercises
89605379|NCT04190511|Experimental|Prebiotic-containing dairy intervention group|
89605380|NCT04190511|Active Comparator|Dietary intervention group|
89605381|NCT04190511|No Intervention|Conventional care group|
89605382|NCT04028739|Experimental|Theracurmin CR-033P|1 Capsule with 150mL water, Single, curcumin 90mg/day
89605383|NCT04028739|Experimental|Theracurmin CR-031P|3 Capsule with 150mL water, Single, curcumin 90mg/day
89605384|NCT04028739|Experimental|Curcumin|1 Capsule with 150mL water, Single, curcumin 90mg/day
89605385|NCT04028661|Experimental|Intervention group|use of 3D printed Modified Twin Block Appliance.
89605386|NCT04028661|No Intervention|Untreated control group|No treatment phase of 8 months.
89605387|NCT04028583|Experimental|PIM-Check group|
89605388|NCT04028583|Active Comparator|STOPP/START group|
89605389|NCT04028505|Experimental|Terlipressin Continuous Infusion|Standard of care being given at AKUH + Continuous infusion of Terlipressin (Terlipressin Injectable Product) at a rate of 0.5mg/hour for the first 24 hours
89605390|NCT04028505|Active Comparator|Terlipressin Bolus Infusion|Standard of care being given at AKUH + Bolus infusion of Terlipressin (Terlipressin Injectable Product) at a frequency of 2mg every six hourly for first 24 hours
89605391|NCT01824355|Experimental|Intended Users of the Monitoring System|"Untrained subjects with diabetes used the Ninja 3 PLUS Investigational BG Monitoring System. General enrollment criteria for the 'Intended Users' population:~At least 60% of subjects were younger than 65 years of age.~At least 20% had type 1 diabetes.~At least 50% with type 2 diabetes were insulin users."
89605392|NCT04042623|Experimental|Treatment with AVB-S6-500|Patients will receive AVB-S6-500 by intravenous infusion every 2 weeks for total of 6 doses.
89605393|NCT04190745|Experimental|The control group|
89605394|NCT04190745|Experimental|The experimental group|
89605395|NCT01823341|Active Comparator|Pump suspension algorithm|The pump suspension algorithm will be running actively on the study laptop during the night and suspend the pump if the algorithm predicts hypoglycemia.
89605396|NCT01823341|No Intervention|Standard of Care|The control algorithm will run passively and not suspend the patient's pump.
89605397|NCT04028427|Experimental|Participants randomly assigned to VGI|
89605398|NCT04028427|Experimental|Participants randomly assigned to MBI|
89605399|NCT04190121|Experimental|GROUP A|
89605400|NCT04190121|No Intervention|GROUP B|
89605401|NCT04028349|Experimental|Single Arm|Ad26.ZEBOV/ MVA-BN-Filo Vaccines
89605402|NCT01853137|Experimental|FLMGM Treatment Group|
89605403|NCT01853137|No Intervention|Untreated Class II Control Group|
89605404|NCT04028271|Experimental|experimental|local anesthesia applyed with Comfort in system
89605405|NCT04028271|Active Comparator|conventional injection|local anesthesia applyed with conventional syringe
88981787|NCT00122772|Experimental|EBR/4 fractions HDBT/chemotherapy|"External Beam Radiation~High Dose Brachytherapy (4 fractions of 7Gy)~Cisplatin"
89032567|NCT02929446|No Intervention|Control|No mobilisation or breathing exercises until discharge or maximum 6 hours
89605406|NCT03595839|Active Comparator|Fistulotomy with Marsupialization|Lay open and Marsupialization of the fistula track
89605407|NCT03595839|Active Comparator|Fistulotomy without Marsupialization|lay open of the fistula track
89605408|NCT01823107|Experimental|Meso BioMatrix Device|All subjects will have the Meso BioMatrix device implanted along with a tissue expander during the first stage of breast reconstruction. During the second stage of breast reconstruction, the tissue expander is replaced with a breast implant.
89605409|NCT04190277|Experimental|36-week Closed-Loop|2-week baseline period in open-loop condition, then 12-week period in closed-loop condition followed by a 24-week extension period in closed-loop condition
89605410|NCT04190277|Active Comparator|12-week open-loop and 24-week closed-loop|2-week baseline period in open-loop condition, then 12-week period in open-loop condition followed by a 24-week extension period in closed-loop condition
89605411|NCT01874275|Experimental|VECTTOR|nerve stimulator treatment twice daily for duration of study - 365 days
89605412|NCT01874275|Placebo Comparator|Device - sham|placebo treatment - no electrical stimulation treatment twice daily for duration of study, 180 days - if VECTTOR arm experiencing improvement, subjects in Device-Sham arm will be crossed over into the VECTTOR group and followed for an additional 180 days, for a total study involvement (duration) of 365 days>
89605413|NCT01873729|Experimental|Naltrexone|Naltrexone
89605414|NCT01873495|Experimental|Omacetaxine: Consolidation/Maintenance|
89605415|NCT04194411||Valve surgery|Patients older than 65 years and undergoing elective valvular heart surgery
89605416|NCT04027959|Experimental|Epilation|Hair epilated prior to application of Vitamin B12 solution to skin
89605417|NCT04027959|Experimental|Oleic Acid|Oil is allowed to soak the skin prior to application of Vitamin B12 solution to skin
89605418|NCT04027959|Experimental|No Prep|Skin is cleansed with an alcohol wipe prior to application of Vitamin B12 solution to skin
89605419|NCT04027569|Active Comparator|PSFS group|Patients in this arm will complete the patient specific functional scale (PSFS) during their visits
89605420|NCT04027569|Experimental|PROMIS PF group|Patients in this arm will complete the PROMIS Physical Function during their visits
89605421|NCT01852825|Experimental|NAC + MK-8237 (Part 2)|Nasal Allergen Challenge (NAC) treatment consisting of 1800 Biological Units (BU) of HDM extract on Days -14, 56 and 84; starting on Day 1 a single tablet of MK-8237 with 12 Development Units (DUs), administered sublingually, at approximately the same time each day for 84 days (+/- 5 days)
89605422|NCT01852825|Placebo Comparator|NAC + Placebo (Part 2)|NAC treatment consisting of 1800 BU of HDM extract on Days -14, 56 and 84; starting on Day 1 a single placebo tablet administered sublingually, at approximately the same time each day for 84 days (+/- 5 days)
89032568|NCT02929446|Experimental|Mobilisation and breathing exercises (PEP)|Mobilisation out of bed to sit in an armchair or on the bedside, instructed to sit as long as possible and breathing exercises with PEP
89032569|NCT02930031|Experimental|n-acetylcysteine|orally in three daily dosages, at 20 mg/kg/day, daily for eight days after exercise
89032570|NCT02930031|Active Comparator|Placebo|orally in three daily dosages, content: 500 mL drink that contained water (375 mL), sugar-free cordial (125 ml), and 2 g of low-calorie glucose/dextrose powder
89032571|NCT02929563|Experimental|pantoprazole|pantoprazole 1 mg/kg (maximum 40 mg) IV once daily until the participants no longer need mechanical ventilation - to a maximum of 30 days or until Pediatric Intensive Care Unit (PICU) discharge.
89032572|NCT02929563|Placebo Comparator|placebo (for pantoprazole)|an equivalent volume of normal saline IV once daily until the participants no longer need mechanical ventilation - to a maximum of 30 days or until PICU discharge.
89032573|NCT00525551|Active Comparator|1|
89605423|NCT01852825|Experimental|NAC (Part 1)|Nasal Allergen Challenge (NAC) consisting of 100 µl fixed volume of 10,000 biological units (BU) of HDM extract delivered with a Pfeiffer Bidose Nasal Delivery System (or equivalent) to each nostril for a total dose of 1800 BU at the start of Part 1
89605424|NCT04027413|Placebo Comparator|Placebo/ Control|participants in this group will receive carbohydrate product which does not include protein at all
89605425|NCT04027413|Experimental|Intervention group|Participants in this group will receive high protein product
89605426|NCT04344951|Experimental|UNIKINON (Chloroquine phosphate)|Once a patient is considered eligible for the study, they will receive oral chloroquine phosphate. The total duration of treatment will be 7 days. The dosage will be 500mg every 12 hours. It is clarified that any other treatment at the discretion of the therapist is permitted except for the administration of hydroxychloroquine.
89605427|NCT01822561|Experimental|Eplerenone|All patients in this study will receive Eplerenone 50mg once daily for 4 weeks.
89605428|NCT02080455|Experimental|Lomitapide & Atorvastatin - Taken Together|"2 single oral doses of lomitapide (20 mg) with a 14-day washout between (Day 1 & Day 15)~11 single oral doses of atorvastatin (80 mg) (Day 11 through day 21)"
89605429|NCT02080455|Experimental|Lomitapide & Atorvastatin - Approx. 12 hours between|"2 single oral doses of lomitapide (20 mg) with a 14-day washout between (Day 1 & Day 15)~11 single oral doses of atorvastatin (80 mg) (Day 12 through day 22)"
89605430|NCT01852591|Experimental|PCV 13|Pneumococcal conjugate vaccine (PCV 13), 0.5ml, 3 to 30 days prior to transplant and then again at 7-10 and 21-24 days after transplant
89605431|NCT04027491|Experimental|Virtual reality intervention|"Participant undergo 12 treatment sessions, during a 4-week period (3 sessions per week).~Each intervention session lasts 45 minutes."
89605432|NCT04027491|No Intervention|Observational|Participant undergo a 4 weeks observational period. No intervention are performed.
89605433|NCT04596241|Experimental|Experimental|Subjects will be required to complete four (4) treatment visits and two follow-up visits. All of the study subjects will receive the treatment with the subject device.
89605434|NCT04406493|Experimental|COVID 19 patients|"COVID 19 patients are admitted to the Infectious Diseases Unit, will undergo examination using a lung impedance device. The first value that has been measured will be set as BASAL.~During the hospitalization each patient will undergo this examination twice a day until discharged.~Changes in impedance values during admission will be evaluated as POSITIVE AND NEGATIVE PREDICTIVE values for clinical deterioration and improvement of COVID 19 patients and as a factor which predicts mechanical ventilation The time between lung impedance started to decrease (expression of the lung fluids accumulation) and the need for mechanical ventilation will be measured."
89605435|NCT04021251|Experimental|Short term collection of IMD data|Subjects will collect spectral raman data on P0.2 for minimum 10 hours per day with a maximum of 15 minutes between each measurement for 5 days distributed over a time period of 10 days. Spectral data will be compared to standard BG and/or FGM measurements.
89605436|NCT04021251|Experimental|Medium term collection of IMD data|Subjects will collect spectral raman data on P0.2 for four times a day for 30 days distributed over a time period of 40 days. Spectral data will be compared to standard BG measurements.
89032574|NCT00525551|Placebo Comparator|2|
89032575|NCT04288323|Experimental|Single arm|This is a single arm study in which all participants have one ultrasound and one abbreviated MR exam
89032576|NCT02946359|Experimental|Patients with ALK translocation|Treatment-naive lung adenocarcinoma cancer patients with ALK translocation with locally advanced or metastatic lung adenocarcinoma cancer and with at least one measurable tumor lesion will be considered eligible for the trial and they will receive crizotinib 250 mg BID p.o combined with bevacizomab 7.5mg/kg every three weeks until disease progression, unacceptable toxicity or patient refusal
89032577|NCT02946359|Experimental|Patients with ROS1 translocation|Treatment-naive lung adenocarcinoma cancer patients with ROS1 translocation with locally advanced or metastatic lung adenocarcinoma cancer and with at least one measurable tumor lesion will be considered eligible for the trial and they will receive crizotinib 250 mg BID p.o combined with bevacizomab 7.5mg/kg every three weeks until disease progression, unacceptable toxicity or patient refusal
89605437|NCT04021251|Experimental|Long term collection of IMD data|Subjects will collect spectral raman data on P0.2 for four times a day for 90 days distributed over a time period of 6 months. Spectral data will be compared to standard BG measurements.
89032578|NCT02946359|Experimental|Patients with MET amplification|Treatment-naive lung adenocarcinoma cancer patients with MET amplication with locally advanced or metastatic lung adenocarcinoma cancer and with at least one measurable tumor lesion will be considered eligible for the trial and they will receive crizotinib 250 mg BID p.o combined with bevacizomab 7.5mg/kg every three weeks until disease progression, unacceptable toxicity or patient refusal
89032579|NCT02929173|Active Comparator|Group 2|E-max is un allceram crown
89032580|NCT02929173|Experimental|Group 1|Bio HPP crown is a hybrid crown
89032581|NCT02946437|Experimental|Sevoflurane|"Sevoflurane postconditioning will start after the bleeding source is excluded by coiling or clipping as soon as the patient returns to the ICU and will be continued for 4 hours. 0.5-1.5vol% sevoflurane will be administrated into the ventilation circuit by a MIRUS™System.~The used dose (0.5-1.5vol%) is a lower dose as used for anaesthesia for a surgical intervention (0.5-3vol%), but high enough to provide sufficient sedation."
89605438|NCT04021251|Experimental|Medium term collection of IMD data, increased # of sessions|Subjects will collect spectral raman data on P0.2 four times a day for 30 days distributed over a time period of 40 days. Spectral data will be compared to standard BG measurements. The number of optical sessions performed each time measurements are done are increased compared to the investigation's second arm.
89605439|NCT03961581|Experimental|car|Children who will use cars to go from the double-door entrance of the block to the operative room.
89605440|NCT03961581|No Intervention|bed|Children who will use bed to go from the double-door entrance of the block to the operative room.
89605441|NCT04021407|Active Comparator|LMA|36 patients were ventilated with LMA during dacryocystorhinostomy surgery
89605442|NCT04021407|Active Comparator|AirQ|36 patients each were ventilated with air Q airway during dacryocystorhinostomy surgery
89605443|NCT04021173|Experimental|Anfibatide|
89605444|NCT04021173|Placebo Comparator|Placebo|
89605445|NCT04027881|Experimental|STAR - immediate|Receive 15-week STAR intervention immediately after pretest.
89605446|NCT04027881|No Intervention|STAR - waitlist control|No intervention for the 15 weeks after pretest.
89605447|NCT04027335|Experimental|Leva Arm|Subjects will undergo training in the use of a vaginal device and its associated app, to be used twice daily to perform pelvic floor muscle exercises guided by the device/app for 10 weeks.
89605448|NCT04027725|Experimental|Sensorimotor neurofeedback training group|"Three interventions will be administered :~An electroencephalography recording (EEG) for 30 minutes with an electrocap of 19 scalp locations according to the international 10-20 EEG placement system.~The second intervention is the neuropsychological assessments and questionnaires. They will be done in one session for approximately 2hours.~The third intervention is the neurofeedback training sensorimotor that will be recorded at channel Cz according to the international 10-20 system."
89605449|NCT04027725|No Intervention|Control Group|"Three interventions will be administered :~An electroencephalography recording (EEG) for 30 minutes with an electrocap of 19 scalp locations according to the international 10-20 EEG placement system.~The second intervention is the neuropsychological assessments and questionnaires. They will be done in one session for approximately 2hours~The psychopedagogical care: each session will be organized using the same video material"
89605450|NCT01852045|Experimental|OnabotulinumtoxinA 50 U|OnabotulinumtoxinA (botulinum toxin Type A) 50 U (not to exceed 6 U/kg) injected into the detrusor wall on Day 1. Participants were eligible for retreatment in study 191622-121 (NCT01852058) if qualified.
89605451|NCT01852045|Experimental|OnabotulinumtoxinA 100 U|OnabotulinumtoxinA (botulinum toxin Type A) 100 U (not to exceed 6 U/kg) injected into the detrusor wall on Day 1. Participants were eligible for retreatment in study 191622-121 if qualified.
89605452|NCT01852045|Experimental|OnabotulinumtoxinA 200 U|OnabotulinumtoxinA (botulinum toxin Type A) 200 U (not to exceed 6 U/kg) injected into the detrusor wall on Day 1. Participants were eligible for retreatment in study 191622-121 if qualified.
89605453|NCT04027257|Experimental|STAR|Receive 15-week STAR intervention immediately after pretest.
89605454|NCT04027257|No Intervention|Waitlist Control|No intervention for the 15 weeks after pretest.
89605455|NCT03960957|Experimental|Experimental|AbobotulinumtoxinA
89605456|NCT03960957|Placebo Comparator|Placebo|
89605457|NCT03960645|Experimental|B/F/TAF|B/F/TAF for up to approximately 38 weeks
89605458|NCT04020939|Experimental|Patients undergoing intestinal resections|"Interventions to be administered: indocyanine green intravenous injection and subsequent visualisation of intestinal viability under fluorescence~Drug:~Indocyanine green dye (ICG) Dosage: 0.5 mg/kg (diluted with aqueous solution) Maximum: 2 mg/kg Frequency: maximum of 3 boluses Duration: intraoperative use only"
89605459|NCT04027179|Experimental|FMS chlorhexidine mouthwash|Full-mouth scaling and root planning with manual curettes, 20 ml of 0.12% chlorhexidine gluconate mouthwash irrigation of each periodontal pocket of 5mm of more. Patients will rinse with 0.12% chlorhexidine gluconate mouthwash (20mL/60 seconds/ 2 times a day/ 3 weeks).
89605460|NCT04027179|Placebo Comparator|FMS placebo mouthwash|Full-mouth scaling and root planning with manual curettes, 20 ml of placebo mouthwash irrigation of each periodontal pocket of 5mm of more. Patients will rinse with placebo mouthwash (20mL/60 seconds/ 2 times a day/ 3 weeks).
89605461|NCT04027179|Active Comparator|FMS no mouthwash|Full-mouth scaling and root planning with manual curettes.
88981788|NCT04346212||Patients infected by SARS-CoV-2|Patients infected by SARS-CoV-2 at the Hospital de Mataró, Hospital de St. Jaume i Sta. Magdalena and other medicalized facilities in Mataró.
88981789|NCT04298671|Experimental|Yoga-Pilates Group|The 30-minute web-based video exercise program will combine the best yoga-Pilates exercises focused on the pelvic floor, based on prior research and expert opinion, in collaboration with yoga-Pilates instructors that participants will complete 4 times per week for 8 weeks.
88981790|NCT04224025|Experimental|exercise and respiratory therapy|Rehabilitation program for three weeks in-Hospital and continuation at home
88981791|NCT04188262|Experimental|NVS Therapy|NVS Therapy will be delivered to de novo lesions in Superficial Femoral Artery (SFA) and/or Proximal Popliteal Artery (PPA) during PTA in patients with symptomatic peripheral artery disease.
88981792|NCT04132414|Experimental|NIRS open|Cerebral NIRS monitoring applied and visible to caregiver. Interventions according to protocol in phases of cerebral hypoxia
89605462|NCT04199169|Experimental|Cohort 1, Group 1|"Ten subjects in the first cohort will receive a 10 mcg dose of HeV-sG-V on Visits 1 and 6.5 (Days 1 and 169*).~*Second dose was administered at 6 months due to study pause from local COVID-19 shutdown."
89605463|NCT04199169|Placebo Comparator|Cohort 1, Group 2|"Two subjects in the first cohort will receive a dose of the placebo on Visits 1 and 6.5 (Days 1 and 169*).~*Second dose was administered at 6 months due to study pause from local COVID-19 shutdown."
89605464|NCT04199169|Experimental|Cohort 2, Group 3|Thirty subjects in the second cohort will receive a 30 mcg dosage of HeV-sG-V on Visits 1 and 2 (Days 1 and 8) with placebo on Visit 3 (Day 29).
89605465|NCT04199169|Experimental|Cohort 2, Group 4|Thirty subjects in the second cohort will receive a 30 mcg dosage of HeV-sG-V on Visits 1 and 3 (Days 1 and 29) with placebo on Visit 2 (Day 8)
89605466|NCT04199169|Placebo Comparator|Cohort 2, Group 5|Twelve subjects in the second cohort will receive a dose of the placebo on Visits 1, 2, and 3 (Days 1, 8 and 29).
89605467|NCT04199169|Experimental|Cohort 3, Group 6|Thirty subjects in the third cohort will receive a 100 mcg dosage of HeV-sG-V on Visit 1 (Day 1) and placebo on Visits 2 and 3 (Days 8 and 29).
89032582|NCT02946437|Active Comparator|Propofol or Midazolam|Propofol or midazolam will be administrated intravenously before and after the postconditioning with sevoflurane as in the standard sedation regimen of the Neurointensive Care Unit, University Hospital Zurich (propofol 0.3-4.0mg/kg/h cont. i.v.; midazolam 0.03-0.2mg/kg/h cont. i.v.)
89032583|NCT02946437|Other|MIRUS™System|MIRUS™ is a newly developed device, considered as vaporizer system, which can be used in the setting of operating rooms or in intensive care units. The MIRUS™System is successfully in use in daily clinical practice. This type of device is similar to the well-known AnaConDa® system (AnaConDa®, Sedana Medical, Uppsala, S) with several advantages. Since 2005 the anaesthetic-conserving device AnaConDa® facilitates, from a technical viewpoint, the routine use of volatile anaesthetics in intensive care patients as part of prolonged sedation, using ICU ventilators (Soukup J et al., 2009). The MIRUS™System forms a closed loop. It measures the end-tidal concentration of the anaesthetic gas and governs the application of the anaesthetic gas according to these values and the ventilation parameters.
89032584|NCT02946632|Experimental|Triple combination therapy group|Xigduo (metformin 1000mg + dapagliflozin 10mg), saxagliptin 5mg once daily for 104 weeks
89605468|NCT04199169|Experimental|Cohort 3, Group 7|Thirty subjects in the third cohort will receive a 100 mcg dosage of HeV-sG-V on Visits 1 and 2 (Days 1 and 8) and placebo on Visit 3 (Day 29).
89605469|NCT04199169|Experimental|Cohort 3, Group 8|Thirty subjects in the third cohort will receive a 100 mcg dosage of HeV-sG-V on Visits 1 and 3 (Days 1 and 29) and placebo on Visit 2 (Day 8).
89605470|NCT04199169|Placebo Comparator|Cohort 3, Group 9|Eighteen subjects in the third cohort will receive a dose of the placebo on Visits 1, 2, and 3 (Days 1, 8 and 29).
89605471|NCT04021095|Experimental|Decompressive craniectomy|3D printed skull replacement piece will be fitted to subject.
89605472|NCT04026789|Active Comparator|Same-day-start|Patients seeking medication abortion who are shown to have an asymptomatic, low-risk pregnancy of unknown location who are randomized to same-day start will have their medication abortion initiated on the day that they present for services while simultaneously ruling out ectopic pregnancy with serial hcg testing
89605473|NCT04026789|Active Comparator|Delay-for-diagnosis|Patients seeking medication abortion who are shown to have an asymptomatic, low-risk pregnancy of unknown location who are randomized to delay-for-diagnosis will first have ectopic pregnancy ruled out with serial hcg and ultrasounds prior to initiating medication abortion
89605474|NCT04191291|Experimental|Shortened lunch period|The amount of seated lunch time will be 10 minutes.
89605475|NCT04191291|Experimental|Longer lunch period|The amount of seated lunch time will be 20 minutes.
89605476|NCT04026555|Active Comparator|MEWS++ Monitoring|This consists of all the patients that will be receiving MEWS++ escalation monitoring and provider alerting.
89605477|NCT04026555|Placebo Comparator|Standard of Care Monitoring|Patients in the control arm will have a score calculated but no alert will be sent.
89605478|NCT04026321|Experimental|SQ-001 125mL/day|
89605479|NCT04026321|Experimental|SQ-001 250mL/day|
89605480|NCT04026321|Experimental|SQ-001 500mL/day|
89605481|NCT04026321|Experimental|SQ-001 625mL/day|
89605482|NCT04026321|Placebo Comparator|saline(0.9% NaCl injection)|
89605483|NCT04026243|Active Comparator|QL group (n = 25)|After general anesthesia (GA), patient will be placed in lateral position with side to be anesthetised upwards. U/S probe will be placed in the transverse plane at the abdominal flank immediately cranial to the iliac crest. Then moved dorsally until the QL muscle is identified with its attachment to lateral edge of the transverse process of the L4 vertebral body with identification of shamrock sign. The needle is inserted in-plane to transducer (lateral edge) and tip of needle is advanced through the QL muscle. Once the tip of the needle correctly placed and confirmed by negative aspiration, 2 ml of normal saline will be instilled to confirm correct separation of the plane. Following this, 30 ml of 0.25% bupivacaine will be injected between the QL and psoas major.
89605484|NCT04026243|Active Comparator|TF group (n = 25)|After GA, patient will be placed in lateral position with side to be anesthetised upwards. U/S probe will be placed in midaxillary line just cephalad to the iliac crest. Scanning anteriorly will identify the three muscles of the anterior abdominal wall. The transversus abdominis typically tapers to form a hyper echoic aponeurosis that passes posterior to quadratus lumborum. Scan will be continued posteriorly to visualize solid organs or viscera deep to the transversus abdominis. The needle will be positioned such that it enters the skin anterior to the ultrasound probe and passes in-plane posterolateral through the three lateral abdominal muscles. Once the tip of the needle correctly placed and confirmed by negative aspiration, 2 ml of normal saline will be instilled to confirm correct separation of the plane. Following this, 30 ml of 0.25% bupivacaine will be injected between the transversus abdominis muscle and the transversalis fascia anterolateral to quadratus lumborum.
89605485|NCT01821937|Experimental|faldaprevir(high dose)|10 subjects (approximate sex ration: 1:1) will be assigned to trial by single and multiple dose.
89605486|NCT01821937|Experimental|Faldaprevir(low dose)|10 subjects (approximate sex ration: 1:1) will be assigned to trial by single and multiple dose.
89605487|NCT03832335||Phakic group|21 eyehealthy individuals examined for baseline stereopsis and impact of aniseikonia on stereopsis. An non-invasive measurement.
89605488|NCT03832335||Cataract group|11 patients awaiting cataract surgery on both eyes. Measurement of baseline stereopsis and impact of artificial induced aniseikonia on stereopsis. A non invasive measurement that are repeated after dilatation of the eyes and again six weeks after surgery.
89605489|NCT01821625|Experimental|Thrombocytopenic (Low Platelet) Patients|"All study patients will undergo intervention in this study.~The intervention will be a lead-in with eltrombopag and antiviral triple therapy (interferon, ribavirin and boceprevir)."
89605490|NCT03022929|No Intervention|Adapted Intervention|The investigators will use GetSmart materials published by the CDC appropriate to the emergency department and urgent care settings and select and adapt brochures and other campaign messages for acute care providers.
89518020|NCT05131867|Active Comparator|Milrinone group|"The patients will receive oral Nimodipine (60 mg/4) will be given orally or in the gastric tube also from the first day of admission, then after the diagnosis of vasospasm is confirmed, start milrinone bolus of 0.1-0.2 mg/kg followed by 0.75mcg/k/min, if no response after 30min increase the infusion to 1-25mcg/kg/min with maintaining CVP 5:8.~Norepinephrine (0.01-0.2ug/kg/min) is used only to restore the mean arterial pressure (MAP) to its previous values If there was no recurrence of symptoms after 72 h, we decreased the milrinone infusion by 0.25 mcg/kg/min every 24 or 48 h until discontinuation. If there are any recurrent of symptoms of vasospasm, the patients are placed back on the dose they were previously receiving. If required, another Milrinone bolus is administered if the patient's deficits do not revert12."
89518021|NCT02221882|Experimental|LY3164530|LY3164530 in escalating dose cohorts given intravenously (IV) once on Days 1 and 15 or on Days 1, 8, 15, and 22 of a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met.
89518022|NCT05213689|Experimental|HIV self-testing + educational comic book|At the first visit participants will receive a HIVST kit and a detailed description of how to use the HIVST kits, pictorial and written guide for HIVST kits, in addition to contact information for confirmatory testing and linkage to care at local clinics. Participants will also receive an educational comic book focused on HIV testing information and decision making that was developed with qualitative data collected from an earlier study phase. PNs will meet with small groups of participants to read through and discuss the comic book together.
88981793|NCT04132414|No Intervention|NIRS blinded|NIRS monitoring applied and masked for caregiver.
88981794|NCT00091377|Experimental|Arm A|Phenoxodiol IV 3 mg/kg combined with cisplatin 40 mg/m2 on Day 2 6 week cycles
88981795|NCT00091377|Experimental|Arm B|Phenoxodiol IV 3 mg/kg combined with paclitaxel 80 mg/m2 on Day 2 6 week cycles
89518023|NCT05213689|Active Comparator|HIV self-testing|At the first visit participants will receive a HIVST kit and a detailed description of how to use the HIVST kits, pictorial and written guide for HIVST kits, in addition to contact information for confirmatory testing and linkage to care at local clinics.
89518024|NCT05213689|Active Comparator|Educational comic book|Participants will receive an educational comic book focused on HIV testing information and decision making that was developed with qualitative data collected from an earlier study phase. PNs will meet with small groups of participants to read through and discuss the comic book together.
89518025|NCT05213689|No Intervention|Standard of Care|PNs will provide information about HIV testing, care and support services at local clinics.
89518026|NCT02837783|Experimental|290 μg linaclotide|Linaclotide Oral, once daily
89518027|NCT02837783|Placebo Comparator|Matching Placebo|Matching Placebo Oral, once daily
89518028|NCT02221648|Placebo Comparator|Placebo|Subjects will be randomization to receive injections with either the study drug (abobotulinumtoxinA) or the placebo group. The subjects will be blinded to which intervention they will receive.
89518029|NCT02221648|Active Comparator|AbobotulinumtoxinA Treatment|Subjects will be randomized to receive intervention injections with the study drug arbobotulinumtoxinA.
89518030|NCT05007145|Experimental|PD-1 Inhibitor+albumin-bound paclitaxel+cisplatin|Participants receive PD-1 Inhibitor 200mg on Day 1 every 3 weeks (Q3W), albumin-bound paclitaxel 125 mg/m^2 on Day 1, 8 Q3W, and cisplatin 75 mg/m^2 on Day 1 Q3W, a total of 2-4 cycles，followed by surgery.
89518031|NCT05007145|Active Comparator|Albumin-bound paclitaxel+cisplatin+radiotherapy|Participants receive albumin-bound paclitaxel 125 mg/m^2 on Day 1, 8 Q3W, and cisplatin 75 mg/m^2 on Day 1 Q3W, a total of 2 cycles combined with radiotherapy(40Gy/2Gy),followed by surgery.
89518032|NCT04952857|Experimental|Intervention|Vitamn D 6 lakh IU oral stat
89518033|NCT04952857|Placebo Comparator|Placebo|Placebo equal volume/ weight
89518034|NCT05440279|No Intervention|Standard Care (SC)|Treatment in the control group takes place as standard care that includes an education session with a respiratory therapist about OSA and its consequences, proper use and maintenance of the CPAP device and mask, and therapy and study expectations, provision with a fixed or auto CPAP device (prismaSMART/ prismaSOFT, Löwenstein Medical Technology GmbH & Co. KG), a heated humidifier (prismaAQUA, Löwenstein Medical Technology GmbH & Co. KG) if needed, and a fitting interface, the initiation of therapy with anamnesis, diagnosis night, titration night, education, etc., as well as standardized therapy control after 12 weeks.
89518035|NCT05440279|Active Comparator|Standard Care (SC) + digital patient support (DPS) tool|"Treatment in the intervention group takes place as standard care (please see description of arm 1 - control group) and electronic therapy support in addition. The electronic therapy support consists of:~Emails to patients with personalized, automated feedback on their therapy (derived from device data received via modem or data entered by the patient via electronic questionnaire),~electronic questionnaires (web-based) on possible problems during therapy, personal adherence goals and subjective therapy success,~possibility to set personal adherence goals every week,~links to explanations and videos on therapy and the handling of therapy equipment and accessories,~provision of data for the trial center in the event of contact by the patient, as well as for routine therapy monitoring."
89518036|NCT02220712|Experimental|Drug: OPC-14597 IMD|
89518037|NCT04923295|Experimental|Pre Treatment and post treatment|Patients on Peritoneal Dialysis will be evaluated by PET and transport status Patients on Peritoneal Dialysis will be evaluated by PET after treatment with Dapagliflozin
89518038|NCT05396209|Active Comparator|Hydrated Amniotic Membrane Plug|Patients suffering from refractory macular holes as documented by spectral-domain OCT will undergo pars plan vitrectomy with Hydrated Amniotic Membrane insertion into the macular hole.
89518039|NCT05396209|Active Comparator|ILM filling|The ILM filling technique, in which free ILM is plug into the macular hole area
89518040|NCT05396209|Active Comparator|Conventional ILM peeling|Peeling with complete removal of the internal limiting membrane within the vascular arch
89518041|NCT05396131|Active Comparator|Collateral Ventilation Negative|Collateral Ventilation Negative participants will have endobronchial valve implant
89518042|NCT05396131|Experimental|Collateral Ventilation Positive|Collateral Ventilation Positive participants will have the lung sealant applied and the endobronchial valve implant
89518043|NCT02219932|Experimental|Fampridine 10 mg BID|Prolonged-release fampridine 10 mg twice daily (BID) for up to 24 weeks
89518044|NCT02219932|Placebo Comparator|Placebo|Matched placebo 10 mg BID for up to 24 weeks
89032585|NCT02946632|Active Comparator|Stepwise add-on therapy group|"Participants were started on metformin 1000mg once daily after screening & assignment~At each visits, FPG and HbA1c are measured. Sequential add-on therapy regimen is described"
89032586|NCT02929134|Active Comparator|Doxycycline|The Doxycycline treated group will enroll 125 participants. 100 patients with Grades 1-3 lymphedema per study site (based on end point and duration) and up to 25 patients with grade 4-6 lymphedema/per study site. Each patient will receive Doxycycline hyclate 200 mg per day x 6 weeks for patients >50 kg or 100 mg per day for patients <50 kg).
89518045|NCT04453813|Experimental|Toripalimab plus concurrent chemo-radiotherapy arm|Concurrent chemo-radiotherapy plus concurrent and adjuvant toripalimab.
89518046|NCT04453813|Active Comparator|Concurrent chemo-radiotherapy arm|Concurrent chemo-radiotherapy alone.
89518047|NCT01138696||Stryker Dacron synthetic graft|
89518048|NCT01138696||Trevira synthetic graft|
89518049|NCT04642690||Group 1-NSE|Patients found to have grossly normal squamous epithelium during endoscopy
89518050|NCT04642690||Group 2-EEG|Patients found to have grossly apparent erosive esophagitis >1cm with Los Angeles Classification A-D
89518051|NCT04642690||Group 3-NDBE Short|Patients with non-dysplastic Barrett's Esophagus (NDBE) > 1cm (Short Segment)
89518052|NCT04642690||Group 4-NDBE Long|Patients with non-dysplastic Barrett's Esophagus (NDBE) > 1cm (Long Segment)
89518053|NCT04642690||Group 5|Barrett's Esophagus (BE) with high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC)
89518054|NCT04642690||Group 6-Esophagectomy|Patients undergoing resection of esophageal cancer
89518055|NCT04642690||Group -7 Pilot and Feasibility|Patients undergoing EGD with NSE, NDBE, BE-HGD, or EAC for feasibility of analytical techniques
89518056|NCT04631965||Cohort in Finland|253 young patients who attend clinics in Finland with no hospital-wide transition support service available
89518057|NCT04631965||Cohort in Australia|250 young patients who attend clinics in Victoria, Australia and who have received support from a hospital-wide transition support service
89518058|NCT00846430|Experimental|Open-Label Intervention|This is a phase II single arm study with sequential treatments available by response where all participants begin therapy with a combination of celecoxib and interferon alpha-2b (CI, treatment-1). Response to CI therapy will be assessed at six months by clinical and radiographic evaluations. Those patients who have achieved a partial response (improvement in pain, improvement in functioning, or ≥50% reduction in tumor size) or complete response (resolution of pain, and normalization of functioning with a ≥ 90% reduction in tumor size) will continue with the same CI therapy for up-to two years on study.
89518059|NCT02219464|Active Comparator|Nasopharyngeal catheter|Patients in this arm will receive oxygen supplementation through the use of a Nasopharyngeal catheter. Sedation will be standardized to ensure consistency between groups.
89518060|NCT02219464|Other|Nasal Cannula|Patients will receive oxygen supplementation through the use of a traditional nasal cannula. Sedation will be standardized to ensure consistency between groups.
89518061|NCT04454047||Extracapsular method group|50 patients with refractory tennis elbow who received extracapsular arthroscopic surgery.
89518062|NCT04418284||Veterinary Medical students|Veterinary Medical students who are studying anatomy during COVID-19 pandemic lockdown
89518063|NCT04592575||TBI that are positive on screening tool|Patients that are identified on the AbilityLab Vestibular screening tool as possibly having vestibular dysfunction
89518064|NCT04592575||TBI patients not positive on screening tool|Patients that are not identified on the Ability Lab Vestibular screening tool as possibly having vestibular dysfunction
89518065|NCT02219308|Experimental|Paracervical Block (PCB)|"Subject receives 2 mL 1% buffered Lidocaine anesthetic at anterior lip of cervix, where tenaculum will be placed.~Subject then receives paracervical block of 18 mL 1% buffered Lidocaine. Provider then places IUD."
89518066|NCT02219308|Sham Comparator|No Paracervical Block (Sham PCB)|"Subject receives 2 mL 1% buffered Lidocaine anesthetic at anterior lip of cervix, where tenaculum will be placed.~Subject then receives Sham paracervical block with capped needle. Provider then places IUD."
89518067|NCT05439577||Mucopolysaccharide Polysulfate Cream|Prescribed only for patients with Mucopolysaccharide Polysulfate Cream.
89518068|NCT05439577||Mucopolysaccharide Polysulfate Cream and glucocorticoids|Patients whose prescriptions contain Mucopolysaccharide Polysulfate Cream and glucocorticoids (Combination therapy, but not always).
89518069|NCT05387005|Experimental|UBT|
89518070|NCT05387005|Experimental|HpSA|
89518071|NCT05387005|Experimental|Both|
89518072|NCT05387005|Experimental|Two-stage screening method|
89518073|NCT03087175|Experimental|MGuard stent|MGuard stent is a novel thin-strut metal stent with a polyethylene terephthalate micronet covering designed to trap and exclude thrombus and friable atheromatous debris to prevent distal embolization
89518074|NCT03087175|Active Comparator|Drug eluting stent and bare metal stent|Drug eluting stent and bare metal stent
89518075|NCT05385523|Experimental|dexamedatomidine|Patients will receive general anaesthesia and RISS block with 20 ml of 0.25% bupivacaine + 1 Mcg/kg dexamedatomidine in 2 mL.
89518076|NCT05385523|Experimental|dexamethasone|Patients will receive general anaesthesia and RISS block with 20 ml of 0.25% bupivacaine + 8mg dexamethasone in 2 mL.
89518077|NCT05385523|Experimental|saline|Patients will receive general anaesthesia and RISS block with 20 ml of 0.25% bupivacaine+ 2 mL normal saline.
89518078|NCT04318561|Experimental|Gallium-68 NODAGA-LM3 group|Patients will undergo a Gallium-68 NODAGA-LM3 PET/CT as well as a Gallium-68 DOTATATE PET/CT.
89518079|NCT04318561|Experimental|Gallium-68 DOTA-LM3 group|Patients will undergo a Gallium-68 DOTA-LM3 PET/CT as well as a Gallium-68 DOTATATE PET/CT.
89518080|NCT05439265||Prior to 11/01/2014|Group prior to the implementation of an electronic medical record order panel and pharmacy resident involvement
89518081|NCT05439265||After 11/30/2014|Group after implementation of an electronic medical record order panel and pharmacy resident involvement
89518082|NCT04655053|Active Comparator|Goal intention condition|"Participants in this condition are asked to form the goal condition: I will walk as fast as I can for as long as I can"
89605491|NCT03022929|Experimental|Enhanced Intervention|"The investigators will use all of the methods of the Adapted Intervention. In addition to these methods, the investigators will add posters within exam rooms which will include modified GetSmart content and other nudges such as physician pictures with their signed public commitment to antibiotic stewardship or flair denoting commitment to stewardship. The investigators will also provide physicians with personalized monthly performance ranking with each physician receiving the designation of top performer or not a top performer based on their appropriate antibiotic prescribing practices for acute respiratory infections. This will be the Enhanced Antimicrobial Stewardship Commitment and Feedback intervention."
89605492|NCT03022695|Experimental|Treatment with high-intensity focused ultrasound|
89605493|NCT04406571||"pancreatic adenocarcinoma before COVID-19 containment  group"|patients with pancreatic adenocarcinoma assessed during multidisciplinary meeting in one participating center between 01/09/2019 and 16/03/2020.
89605494|NCT04406571||"pancreatic adenocarcinoma after COVID-19 containment  group"|patients with pancreatic adenocarcinoma assessed during multidisciplinary meeting in one participating center between 17/03/2020 and 31/10/2020.
89605495|NCT04020783||Observation group|sequential
89605496|NCT01821391|Experimental|NDL-PDT/c-PDT|Metvix natural daylight photodynamic therapy and Metvix conventional photodynamic therapy
89605497|NCT01821391|Experimental|NDL-PDT/placebo c-PDT|Metvix natural daylight photodynamic therapy and Metvix-placebo conventional photodynamic therapy
89605498|NCT04020393||Block group|The patients that had received Sphenopalatine ganglion block(SPGB) before the surgery
89605499|NCT04020393||Control Group|The patients that had not received SPBG before the surgery
89605500|NCT04020705|Experimental|Citicoline eye drops (OMK1)|45 patients will be treated with active treatment (OMK1)
89605501|NCT04020705|Placebo Comparator|hypromellose based ocular lubricant|45 patients will be treated with placebo (lubricant eye drops)
89605502|NCT04020627|Experimental|BiPAP Group|Bilevel Positive Airway Pressure
89605503|NCT04020627|Experimental|CPAP Group|Continuous Positive Airway Pressure
89605504|NCT01873417|Experimental|Dimethyl Fumarate|120 mg DMF twice daily (BID) for the first 7 days and 240 mg DMF BID thereafter for 12 weeks of treatment. Participants will be instructed to take the DMF dose with food (with a meal or within 1 hour after a meal).
89605505|NCT04025697|Placebo Comparator|Conventional CD|A conventional Complete denture will be constructed and the amount of denture tooth movement will be measured
89605506|NCT04025697|Active Comparator|Rapid Prototyped Denture|A digital light processed denture will be constructed and the amount of tooth movement will be measured
89605507|NCT03934827|Experimental|Part A|"Open label, preliminary phase~20 participants"
89605508|NCT03934827|Experimental|Part B|"Randomised, double blinded phase~100 participants"
89605509|NCT01872715|Experimental|Oracea|"Oracea (doxycycline USP, 40mg[30mg immediate release/ 10mg delayed release beads] taken once daily in the morning on an empty stomach, one hour before meals or two hours after.~Oral dose for 12 weeks"
89605510|NCT04025385|No Intervention|Control Group|Patients will participate in regular training units
89605511|NCT04025385|Active Comparator|HIIT Group|Patients will participate in high intensity interval training
89605512|NCT03947931||General group|Patient with extremely severe ulcerative colitis
89605513|NCT01871545|Experimental|Magnetic Resonance Imaging|dynamic contrast-enhanced MRI measuring arterial and portal flow
88981796|NCT03968731|Experimental|ZEST treatment|The study subjects will receive the ZEST treatment protocol (Zocular Eyelid System treatment) to treat Meibomian Gland Dysfunction causing Contact Lens discomfort symptoms.
88981797|NCT04716556|Experimental|Standard Therapy+Convalescent Plasma|Patients will receive standard therapy + 200-300 ml of convalescent plasma for a maximum of 3 times in 5 days, according to clinical conditions.
88981798|NCT04716556|No Intervention|Standard Therapy|Patients will receive standard therapy for the treatment of SARS-CoV2 infection, according to AIFA indications
88981799|NCT03897868|Experimental|Experimental 1|HCP1803 High
89605514|NCT01871545|No Intervention|Healthy Controls|
89605515|NCT04020315|Experimental|Generalized aggressive periodontitis|Non-surgically performed scaling and root planing.
88981800|NCT03897868|Experimental|Experimental 2|HCP1803 Middle
88981801|NCT03897868|Experimental|Experimental 3|HCP1803 Low
88981802|NCT03897868|Active Comparator|Active Comparator 1|HGP0904 High
88981803|NCT03897868|Active Comparator|Active Comparator 2|HGP0904 Low
88981804|NCT03897868|Active Comparator|Active Comparator 3|HGP0608
89605516|NCT04020549|Experimental|Intervention|
88981805|NCT03897868|Placebo Comparator|Placebo Comparator|Placebo
88981806|NCT04453787|Experimental|Arch support orthoses with forefoot medial wedge|The intervention of this group include orthoses with arch support and added forefoot medial wedge.
88981807|NCT04453787|Experimental|Arch support orthoses|The intervention of this group include orthoses with arch support.
88981808|NCT04453787|Sham Comparator|Flat insole|This group will wear a flat insole. It is made from ethylene-vinyl acetate copolymer with 4mm thickness. It only provide shock absorbtion.
89605517|NCT04020549|Sham Comparator|Study Skills Control|
89605518|NCT03933657|Experimental|SoundBite™ Crossing System - Peripheral|SoundBite™ Crossing System-Peripheral is indicated to facilitate the intraluminal placement of conventional guidewires or treatment devices beyond peripheral artery chronic total occlusions via atherectomy.
89605519|NCT04020237|No Intervention|Observational arm|General counselling to particulate matter practice score.
89605520|NCT04020237|Other|Interventional arm|Active education and feedback on the particulate matter practice score that affects real life.
89605521|NCT04025307|Experimental|bacTRL-IL-12|single-dose, 1 mL IV infusion of bacTRL-IL-12
89605522|NCT01613599||Rituximab|Participants with granulomatosis with polyangiitis (GPA) (Wegener's granulomatosis) or microscopic polyangiitis (MPA) who received rituximab as per investigator's discretion were followed for a maximum of 4 years.
89605523|NCT04025619|Experimental|treatment group|the data is collected from the same participant after the intervention.
89605524|NCT04025619|No Intervention|Control group|The Collect the data from the same participant before the intervention as control
89605525|NCT01850641|Experimental|PA21|
89032587|NCT02929134|Placebo Comparator|Placebo|The Placebo treated group will enroll 125 participants. 100 patients with Grades 1-3 lymphedema per study site (based on end point and duration) and up to 25 patients with grade 4-6 lymphedema/per study site. Each patient will receive matching tablets containing no active ingredients.
89032588|NCT04693091|Experimental|Senti Arm|"In stage 1 of this study (6 patients), the patient will apply the device and complete the initial patient survey; questions are around usability, comfort (including feelings of pressure), and acceptability. The Investigator will record the time taken to apply the device. A brief 30 seconds of chest sounds will be recorded from each of the nine sensors on the device in three different settings: standing up, lying down, walking around.~In stage 2 of this study (10 patients; 6 of whom would be re-recruited from the first stage), the participant will use the device at home over five days. The Investigator will assess the participant daily for any signs of pressure sores or complications from using the device (including topical allergic reactions). The participant will complete a daily survey. The participant is encouraged to remove the device and apply it at their discretion. The participant can opt-out of wearing the device at any stage."
89032589|NCT02929212|Other|Solid Meal Study Group A|Patients Pre and Post-GBP who are randomly assigned to receive solid meals on study days given as one, 600 kcal, meal.
89518083|NCT04655053|Experimental|Implementation intention (behavior initiation) condition|"Participants in this condition are asked to form the same goal intention ( I will walk as fast as I can for as long as I can) and add the if-then plan (and if I do the task, then I will walk as much as I can!)"
89518084|NCT04655053|Experimental|Implementation intention (goal preference management) condition|"Participants in this condition are asked to form the same goal intention ( I will walk as fast as I can for as long as I can) and add the if-then plan (and if at this moment I prefer not to walk because of my pain (or fatigue; depending on person), then I will accept that I have this difficulty and I will walk as much as I can!)"
89518085|NCT03910621|Experimental|Miglustat|Miglustat is administered three times a day as an oral capsule
89518086|NCT03950401|Active Comparator|Monocryl|Closure of the skin at the completion of surgery by interrupted subcuticular technique with absorbable Monocryl suture.
89518087|NCT03950401|Active Comparator|Nylon|Closure of the skin at the completion of surgery by interrupted technique on top of the skin with non-absorbable Nylon suture. These will be removed at the first postoperative visit.
89518088|NCT02218372|Experimental|Fidaxomicin|Participants from birth to < 6 years of age received weight based doses of fidaxomicin oral suspension (32 mg/kg/day with a maximum dose of 400 mg/day divided in 2 doses) 2 times daily for 10 days. Participants aged ≥ 6 years to < 18 years of age received a 200 mg fidaxomicin tablet 2 times daily for 10 days.
89518089|NCT02218372|Active Comparator|Vancomycin|Participants from birth to < 6 years of age received weight based doses of vancomycin oral liquid (40 mg/kg/day with a maximum dose of 500 mg/day divided in 4 doses) 4 times daily for 10 days. Participants aged ≥ 6 years to < 18 years of age received a 125 mg vancomycin capsule 4 times daily for 10 days.
89518090|NCT05439109|Experimental|Topographical landmark technique|Surface anatomic landmarks of an individual's trachea will be measured from the mid-thyroid level (corresponds to vocal cords) to manubriosternal joint (corresponds to carina) in the sagittal plane to estimate tracheal length. Three centimeters will be deducted from the estimated tracheal length to provide the length of the endotracheal tube from the tube tip to be inserted inside the trachea.
89518091|NCT05439109|Active Comparator|Intubation guide mark technique|Already established and commonly practiced technique, in this technique, the guide mark present above the proximal end of the endotracheal tube cuff will be placed just beyond the vocal cords.
89518092|NCT02218216|Experimental|Experimental: Diagnostic mTBI|MRI Diagnostic of subjects with mild Tramatic Brain Injury (mTBI)
89518093|NCT02218216|Placebo Comparator|Experimental: Diagnostic Non mTBI|MRI Diagnostic of Non injured subjects that are closely matched to mTBI
89518094|NCT02217982|No Intervention|Control Group|Patients randomized to the standard therapy arm will be instructed to follow the normal dosing regimen for DMF with a food bolus of their choice prior to dosing. If severe symptoms (MAGIS >6.5) are noted at any time post randomization in any MAGIS category, crossover to the treatment arm will be allowed. Both groups will be asked to rate their GI symptoms over the past 24 hours using the MAGIS scale once daily.
89518095|NCT02217982|Active Comparator|Treatment Arm|Patients who are randomized to the treatment arm will be instructed to take 125 mg simethicone and one tablespoon of a high fat food (peanut butter)10 minutes prior to each DMF dose. If the average MAGIS score is greater than 3.5 in the diarrhea category they will also be instructed to take 2 mg loperamide three times daily.
89518096|NCT00587314||1|Patients with Barrett's Esophagus or early esophageal adenocarcinoma who will or have had ablation therapy will be enrolled in this long term follow up study
89518097|NCT02254408|Experimental|Presatovir|Participants will receive presatovir on Days 1, 5, 9, 13, and 17, with follow-up visits through Day 28, and may continue in an optional extended monitoring phase with visits through Day 56.
89518098|NCT02254408|Placebo Comparator|Placebo|Participants will receive placebo on Days 1, 5, 9, 13, and 17, with follow-up visits through Day 28, and may continue in an optional extended monitoring phase with visits through Day 56.
89518099|NCT02207608|Active Comparator|BCG alone (Immucist®)|Group A receive BCG (Immucist® 81 mg, Sanofi-Aventis Group) alone
89518100|NCT02207608|Experimental|Hyaluronic acid|Group B receive BCG and HA 40 mg (Cystistat, Mylan, Pittsburgh, PA, U.S.A.).
89518101|NCT03530995|Experimental|Part 1, Period 1|Drug: Belumosudil. Subjects will receive belumosudil 200 mg single dose on Day 1
89518102|NCT03530995|Experimental|Part 1, Period 2|"Drug: Itraconazole. Subjects will receive itraconazole 200 mg QD on Day 1 through Day 7.~Drug: Belumosudil. Subjects will receive belumosudil 200 mg + itraconazole 200 mg QD on Day 8 Subjects will receive itraconazole 200 mg QD on Day 9"
89518103|NCT03530995|Experimental|Part 1, Period 3|"Drug: Rabeprazole. Subjects will receive rabeprazole 20 mg BID on Day 1 through Day 3.~Drug: Belumosudil. Subjects will receive belumosudil 200 mg + rabeprazole 20 mg QD on Day 4."
89518104|NCT03530995|Experimental|Part 1, Period 4|"Drug: Rifampicin. Subjects will receive rifampicin 600 mg QD on Day 1 through Day 9.~Drug: Belumosudil. Subjects will receive belumosudil 200 mg on Day 10."
89518105|NCT03530995|Experimental|Part 2, Period 1|Drug: Belumosudil. Subjects will receive belumosudil 200 mg BID on Day 1.
89605526|NCT04020081|Experimental|Effect of yoga exercises in COPD patients after 12 weeks.|Yoga group
89605527|NCT04020081|No Intervention|COPD patients lung functions without yoga excercises.|Control group
89605528|NCT01850563|Other|HBO feasibility|
89605529|NCT03931473|Experimental|Interceptor G2|Chlorfenapyr/alpha-cypermethrin
89605530|NCT03931473|Experimental|Royal Guard|Pyriproxyfen/alpha-cypermethrin
89605531|NCT03931473|Active Comparator|Interceptor|Alpha-cypermethrin
88981809|NCT04729868|Other|group Levo-bupivacaine|Group A (20 patients): Anesthesia will be performed with 35 ml of 0.5% levo-bupivacaine plus 1ml normal saline under the guidance of ultrasound for infraclavicular brachial plexus block.
88981810|NCT04729868|Other|group levo-bupivacaine plus 50µg dexmedetomidine|Group B (20 patients): Anesthesia will be performed with 35 ml of 0.5% levo-bupivacaine plus 50µg dexmedetomidine under the guidance of ultrasound for infraclavicular brachial plexus block.
88981811|NCT04729868|Other|group levo-bupivacaine plus 100µg dexmedetomidine|Group C (20 patients): Anesthesia will be performed with 35 ml of 0.5% levo-bupivacaine plus 100µg dexmedetomidine under the guidance of ultrasound for infraclavicular brachial plexus block.
88981812|NCT00122928|Experimental|High intensity environmental intervention|Intense intervention
88981813|NCT00122928|Experimental|Moderate intensity environmental intervention|Moderate intervention
88981814|NCT00122928|No Intervention|Individual intervention only|Control
88981815|NCT04409990|Other|Shear Wave Elastography|SWE value measurement will be added during the ERUS examination.
88981816|NCT04371614|Active Comparator|Prime Time Sister Circle Intervention|The women in this arm participate in a Prime Time Sister Circle (PTSC). The PTSC is a multi-faceted, facilitated, curriculum- and community-based, intensive, support group intervention with 25-30 mid-life African American women per group. PTSC addresses three key modifiable health risk factors for chronic disease: unmanaged stress, physical inactivity, and unhealthy nutritional choices. It also addresses additional risk factors that contribute to unhealthy lifestyles: lack of knowledge or misinformation about major illnesses-cardiovascular disease (CVD), hypertension, diabetes, cancer, stress and depression-and the failure of African American women to prioritize their health and take proactive steps to manage their health and health outcomes. PTSC gives African American women the information, motivation, tools, skills, and consultative support they need to improve and maintain their health.
88981817|NCT04371614|No Intervention|Usual Care|The women in the arm do not receive the intervention but provide data at baseline, 3 months, 9 months and 15 months.
88981818|NCT00400257||1|People at high risk of heart failure.
88981819|NCT03690544|Experimental|Single Arm|Apremilast 30mg orally twice daily for 16 weeks, sixteen weeks on active study. Post treatment follow-up period of 8 weeks, in the Treatment of Subjects with Severe Recurrent Aphthous Stomatitis (RAS)
88981820|NCT03685591|Experimental|Dose Level 1 (Part 1A)|PF-06952229 at 20mg twice daily (BID)
88981821|NCT03685591|Experimental|Dose Level 2 (Part 1A)|PF-06952229 at 40 mg BID
88981822|NCT03685591|Experimental|Dose Level 3 (Part 1A)|PF-06952229 at 80 mg BID
88981823|NCT03685591|Experimental|Dose Level 4 (Part 1A)|PF-06952229 at 150 mg BID
88981824|NCT03685591|Experimental|Dose Level 5 (Part 1A)|PF-06952229 at 250 mg BID
88981825|NCT03685591|Experimental|Dose Level 6 (Part 1A)|PF-06952229 at 375 mg BID
88981826|NCT03685591|Experimental|Dose Level 7 (Part 1A)|PF-06952229 at 500 mg BID
88981827|NCT03685591|Experimental|Dose Level 8 (Part 1A)|PF-06952229 at 625 mg BID
88981828|NCT03685591|Experimental|Dose Level 9 (Part 1A)|PF-06952229 at 750 mg BID
88981829|NCT03685591|Experimental|Prostate Cancer Dose Level 1 (Part 1B)|PF-06952229 at 375 mg BID in combination with enzalutamide
88981830|NCT03685591|Experimental|Prostate Cancer Dose Level 2 (Part 1B)|PF-06952229 at 500 mg BID in combination with enzalutamide
88981831|NCT03685591|Experimental|Prostate Cancer Dose Level 3 (Part 1B)|PF-06952229 at 625 mg BID in combination with enzalutamide
88981832|NCT03685591|Experimental|Prostate Cancer Dose Level 4 (Part 1B)|PF-06952229 at 750 mg BID in combination with enzalutamide
88981833|NCT03685591|Experimental|Prostate Cancer (Part 2A)|PF-06952229 at recommended Phase 2 Dose BID
88981834|NCT03685591|Experimental|Prostate Cancer (Part 2B)|PF-06952229 at recommended phase 2 dose BID in combination with enzalutamide
88981835|NCT00123006|Active Comparator|1|Dietary Approaches to Stop Hypertension (DASH)
88981836|NCT00123006|Placebo Comparator|2|Control diet
88981837|NCT00314977|Experimental|A|Cycles 1-4 q 3 weeks: doxorubicin plus cyclophosphamide Cycles 5-8 q 3 weeks: docetaxel
88981838|NCT00314977|Experimental|B|Cycles 1-6 q 3 weeks: doxorubicin, cyclophosphamide and docetaxel
88981839|NCT00400296|Experimental|1|
88981840|NCT00315016|Placebo Comparator|1|placebo (double dummy)
88981841|NCT00315016|Active Comparator|2|eplerenone
88981842|NCT00315016|Active Comparator|3|doubling of fosinopril dose
88981843|NCT00419146|Experimental|Ethyl EPA (active) and Vitamins E + C (active)|
88981844|NCT00419146|Experimental|Ethyl EPA (active) and Vitamins E+C (placebo)|
88981845|NCT00419146|Experimental|Ethyl EPA (placebo) and Vitamins E+C (active)|
88981846|NCT00419146|Placebo Comparator|Ethyl EPA (placebo) and Vitamins E+C (placebo)|
88981847|NCT04239365|Experimental|Group A: WLE followed by NBI|EMR scar is interrogated using WLE followed by NBI
88981848|NCT04239365|Active Comparator|Group B: NBI followed by WLE|EMR scar is interrogated using NBI followed by WLE
88981849|NCT00315094|Experimental|1|
88981850|NCT00315094|No Intervention|2|After a control period, this group crosses over to experimental interventions (Arm 1)
88981851|NCT03426475|No Intervention|Control Group|Care of nursing home residents as usual.
88981852|NCT03426475|Experimental|Interventional Group|Implementation of interprof ACT measures to improve collaboration and communication between general practitioners and nursing staff. Measures are selected and adapted by nursing home management / nurses, GPs and residents' relatives or representatives.
88981853|NCT00123084|Experimental|Voice/Respiratory Treatment|4 Days a week for 4 weeks with focus on high intensity voice exercises
89032590|NCT02929212|Other|Liquid Meal Study Group A|Patients Pre and Post-GBP who are randomly assigned to receive liquid meals on meal study days, given as one, 600 kcal, meal
89032591|NCT02929212|Other|Solid Meal Study Group B|Patients Pre and Post-GBP who are randomly assigned to receive solid meals on study days given as three, 200 kcal, meals.
89032592|NCT02929212|Other|Liquid Meal Study Group B|Patients Pre and Post-GBP who are randomly assigned to receive liquid meals on meal study days, given as three, 200 kcal, meals.
89032593|NCT02947373|Other|Imaging Arm|Patients will receive a one-time injection of Hyperpolarized Pyruvate prior to a single MR imaging examination that includes the acquisition of HP carbon-13 metabolic data.
89032594|NCT02929251|Active Comparator|Adalimumab|Adalimumab (40mg/14 days subcutaneously) (n=40) for 16 weeks
89032595|NCT02929251|Experimental|Anakinra|Anakinra (100 mg/day subcutaneously) (n=40) for 16 weeks
89032596|NCT02929251|Experimental|Tocilizumab|Tocilizumab (162 mg/7 days subcutaneously) (n=40) for 16 weeks.
89032597|NCT02929368|Active Comparator|Fluoroscopy|PICC Implantation under x-ray
89032598|NCT02929368|Active Comparator|Sherlock System (BARD)|PICC Implantation with Integrated Magnetic Tracking and ECG-guided Tip Location System
89605532|NCT03930771|Experimental|All Patients|"All subjects will receive:~Capecitabine (oral 5-Fluorouracil) 1500mg/m2 orally per day (divided into two doses with maximum daily dose of 2500mg) on days 1 through 14.~Temozolomide (second generation alkylating agent) 150 to 200 mg/m2 orally on days 10 through 14.~After completion of 6 cycles, patients achieving a complete or partial tumor response may continue to receive capecitabine temozolomide at the investigator's discretion in the absence of disease progression or unacceptable toxicity. Patients will be monitored for six months after they come off the study (either after completing 6 cycles or in setting of disease progression or unacceptable toxicity)."
89605533|NCT04024683||Serratus block group|Realization of a serratus block and para-vertebral catheter
89605534|NCT04024683||Control group|Realization of a para-vertebral catheter
89605535|NCT04024527|Active Comparator|Dual therapy|Esomeprazole 40mg bid and Amoxicillin 1.0g tid for 14 days
89605536|NCT04024527|Experimental|Metronidazole plus dual therapy|Esomeprazole 40mg bid, Amoxicillin 1.0g tid and Metronidazole 0.4g tid for 14 days
89605537|NCT06061965|Experimental|Web-based resilience-building|The web-based resilience-building intervention will be implemented on a website and consist of (1) assessments to help participants (a) understand their coping strategies and (b) appraise their beliefs, values, and goals about advance care planning and (2) 6 weekly modules.
89605538|NCT06061874|Experimental|FAPI PET/CT|"Patients with known or suspected peritoneal metastases from colorectal and ovarian cancers scheduled for complete cytoreductive surgery undergo FAPI PET/CT before the planned surgery.~In the target population, patients receiving neoadjuvant chemotherapy undergo FAPI PET/CT both before and after chemotherapy."
89605539|NCT06061835|Experimental|"Non-contrast MRA (MRA -)"|Participants in this group underwent preoperative planning with a contrast-free magnetic resonance angiography (MRA) using an enhanced protocol that eliminates the use of potentially hazardous contrast agent and radiation exposure while providing high accuracy of visualization.
89605540|NCT06061835|Other|"CTA with contrast (CTA +)"|Control group. Participants in this group underwent preoperative planning using the standard commonly used method - computed tomography angiography (CTA) with IV (intravenous) iodine-containing contrast injection.
89605541|NCT06061783|Active Comparator|Intravenous hypotonic solution|"In this group, the administration will be according to the presence of basal hyperglycemia on the day before the assignment (>180mg/dL).~If hyperglycemia is present, it will be glucose solution 5% 500ml + injectable water 500ml intravenous every 8 hours for a total of 3,600ml daily.~If there is no hyperglycemia, it will be 5% glucose solution 1,200ml every 8 hours for a total of 3,600ml per day."
89605542|NCT06061783|Placebo Comparator|Enteral water|This group will receive bottled water through the nasogastric or orogastric tube at a dose of 150 ml/hour for a total of 3,600 ml per day.
89605543|NCT06061770|Experimental|First APA program|"The evaluation of the primary endpoint to meet our main objective will be done at W13 for both groups. The addition of an APA program in autonomy following the structured program for group 1 will make it possible to answer a secondary question focusing on the comparison of the effectiveness of the self-directed program carried out alone or following a structured program.~1st group: D0: Include S1-S12: APA program at IUR Valmante S13: Break S14-S25: APA Autoprogram~In addition, the patients in group 1 are maintained in the follow-up to study the maintenance of any observed effect."
89605544|NCT06061770|Active Comparator|Second APA program|"Our study design provides for compensatory participation in the structured program for patients in group 2, following the self-program. From an ethical point of view, this scheme allows all patients included in the structured APA program to benefit.~2nd group: D0: Include S1-S12: APA Autoprogram S13: End of study S14-S25: APA program at IUR Valmante compensatory"
89605545|NCT06061757|Experimental|Arm 1 - TEE Primary imaging guidance|TEE is the primary imaging guidance with 4D ICE is the secondary
89605546|NCT06061757|Experimental|Arm 2 - ICE Primary Imaging Guidance|4D ICE is the primary imaging guidance and TEE is the secondary
89605547|NCT06061744||Open approach|Gallbladder cancer with hepatectomy and lymphadenectomy which underwent surgery by classical open approach
89605548|NCT06061744||Robotic approach|Gallbladder cancer with hepatectomy and lymphadenectomy which underwent surgery by any type of robotic surgical device approach
89605549|NCT06061744||Laparoscopic approach|Gallbladder cancer with hepatectomy and lymphadenectomy which underwent surgery by laparoscopic approach
89032599|NCT02946281|Experimental|Intervention|
89032600|NCT02946281|No Intervention|Care as usual|
89032601|NCT02929290|Experimental|BPI-9016M|"Part I：Four dose cohorts will be evaluated, including 300mg, 450mg, 600mg, 800mg. BPI-9016M Tablet will be administered orally to patients once daily for each dose cohort.~Part II：400mg BPI-9016M Tablet will be administered orally to patients twice a day."
89032602|NCT02947451|Experimental|Manual therapy|In manual therapy group will be assigned a protocol with manual passive stretching for the quadriceps muscles, hamstrings, triceps surae, adductors and abductors of the hip; myofascial release peripatellar; joint mobilization grades 1 and 2 for tibiofemoral joint and femoro - patellar in the affected knee, in a single application.
89032603|NCT02947451|Experimental|TENS|In TENS group will be applied to continuous current mode, frequency 100Hz and pulse width of 50μs for 40 minutes in a single application.
89605550|NCT06061731|Active Comparator|Low frequency group treatment|Low frequency group treatment: The treatment frequency is selected as 50Hz, pulse width 0.3ms, waveform is intermittent waveform, stimulation intensity is tolerated by the patient, the instrument program is set to stimulate the first group of acupoints → second group → first group → third group, forming a set of programmed movements, cyclic operation, appearing alternate movements of flexor and extensor muscles, namely: wrist dorsal extension, five-finger extension → five-finger flexion → wrist dorsal extension, five-finger extension → thumb-index finger pair pinching, simulating fine movements Grasp of the hand, thumb-index finger pair pinch. The treatment course was the same as that of the electroacupuncture group.
89605551|NCT06061731|No Intervention|Electroacupuncture group treatment|Electroacupuncture group treatment: After the above acupuncture to deqi, choose KWD-808 Ⅰ type Indy brand pulse acupuncture treatment instrument, the waveform is continuous wave, the stimulation frequency is 2Hz, the intensity to be tolerated by the patient. There should be muscle contraction at the acupuncture site during electroacupuncture treatment. The treatment time should be 30 minutes each time, once a day, 6 days a week with 1 day off, for a total of 3 weeks.
89605552|NCT06061718|Experimental|iDose TR|Travoprost Intraocular Implant administered intracamerally in the study eye at the Day 1 Visit following successful cataract surgery
89605553|NCT06061692|Experimental|Test group|Tongxinluo Capsule, 4 capsules/time, tid, p.o
89605554|NCT06061692|Placebo Comparator|Control group|Tongxinluo Capsule placebo, 4 capsules/time, tid, p.o
89605555|NCT06061679|Experimental|Omron C28P cohort|Patients diagnosed with COPD using the study device (OMRONC28P) for 24 weeks.
89605556|NCT06061666|Experimental|Treated group|Group treated with MG-C of Tilia tomentosa
89605557|NCT06061666|Placebo Comparator|Placebo Group|Group treated with placebo
89605558|NCT06061640||case group|MAFLD patients
89605559|NCT06061640||control group|health people
89605560|NCT06061601|Experimental|Exoskeleton Stroke group|This group will receive gait rehabilitation with the exoskeleton for 20 sessions in clinic.
89605561|NCT06061601|No Intervention|Healthy control group|The quantitative data, including EMG and 3D kinematics, from 10 healthy controls walking with the exoskeleton will serve as comparative data for the experimental group.
89605562|NCT06061549|Experimental|SRD-001 Gene Therapy|AAV1/SERCA2a 3E13 vg
88981854|NCT00123084|Experimental|Articulation Treatment|4 days a week for 4 weeks with focus on high intensity articulation tasks
88981855|NCT00123084|No Intervention|Subjects with PD in a no treatment group|Subjects do not receive therapy during experimental phases, and will be offered therapy at the end of the study enrollment period.
88981856|NCT00123084|No Intervention|Healthy Control Subjects|Subjects are without Parkinson disease and will not receive therapy.
88981857|NCT02965196|Active Comparator|Dexamethasone Therapy|Three consecutive doses of IV Dexamethasone with be administered over three days. The doses will be tapered according to the following: 1st dose, 26mg., 2nd dose, 20mg., and the third dose will be 10 mg. Each dose will be administered over 24 hours in a slow drip, in a 100cc. normal saline bag (0.9%).
88981858|NCT02965196|Placebo Comparator|Placebo Therapy|Three consecutive doses of 100cc IV normal saline (0.9%), will be administered over three days. Each dose will be administered over 24 hours in a slow drip.
88981859|NCT03325426|No Intervention|Usual care|No physical activity tracker or feedback x 6 months, then crossover to physical activity tracker x 6 months
88981860|NCT03325426|Experimental|Physical activity tracker|Physical activity tracker x 12 months (6 months with study feedback and 6 months without)
88981861|NCT00315133|Experimental|Transplant arm|This is a single arm study. The intervention is immunosuppression and autologous stem cell transplantation.
88981862|NCT04729478|Other|Natural sleep|"Natural sleep endoscopy (NSE)~OSA patients will be endoscopically evaluated during natural sleep.~During NSE additional physiological measurements (flow shape analysis, acoustic analysis of snoring sounds and esophageal pressure measurements) will be carried out."
88981863|NCT04729478|Other|Drug-induced sleep|"Drug-induced sleep endoscopy (DISE)~OSA patients will be endoscopically evaluated during drug-induced sleep.~During DISE additional physiological measurements (flow shape analysis, acoustic analysis of snoring sounds and esophageal pressure measurements) will be carried out."
88981864|NCT03195088|Placebo Comparator|Placebo|Healthy participants were administered a single dose of placebo matching BI 473494 solution via subcutaneous injection.
88981865|NCT03195088|Experimental|BI 473494 35 μg|Healthy participants were administered a single dose of 35 micrograms (μg) BI 473494 solution via subcutaneous injection.
88981866|NCT03195088|Experimental|BI 473494 75 μg|Healthy participants were administered a single dose of 75 micrograms (μg) BI 473494 solution via subcutaneous injection.
88981867|NCT03031483|Experimental|Experimental: clarithromycin and lenalidomide|CLARITHROMYCIN: daily orally administration in cycles of 28 days; 500mg film-coated tablets LENALIDOMIDE: every cycle of treatment lasts 28 days; daily orally administration is of 21 consecutive days with a week of rest. 20mg capsule hard. The maximum treatment duration is 12 months.
88981868|NCT02838979|Experimental|Oral L-Glutamine first, then Maltodextrin|"Subjects will receive 0.4 g/kg/day of L-glutamine (Nutrestore, EMMAUS Life Sciences, Inc Torrance, CA) in three divided daily doses OR identical appearing maltodextrin powder.~Duration 2 weeks"
88981869|NCT02838979|Experimental|Maltodextrin first, then L-glutamine|"Subjects will crossover to receiving the study product which they did not receive in the first period.~Either 0.4 g/kg/day of L-glutamine in three divided daily doses OR identical appearing maltodextrin powder.~Duration 2 weeks"
88981870|NCT02728726|Experimental|Sugammadex|Subjects will have Sugammadex administered after routine reversal of anesthesia is performed and patient is extubated.
88981871|NCT02728726|Placebo Comparator|Placebo|Subjects will have Placebo administered after routine reversal of anesthesia is performed and patient is extubated.
88981872|NCT04716517|Experimental|Cention N|Intervention Alkasite Restoration will be used to restore cervical carious in adult patients.
89032604|NCT02929095|Experimental|Patients in the dexmedetomidine group|Patients in the dexmedetomidine group are given 1 μg/kg/h of dexmedetomidine for 10 minutes on initiation of the procedure and then 0.2-0.7 μg/kg/h until end of the procedure and are given 1.2-7.2 μg/kg/h of remifentanil until end of the procedure
89032605|NCT02929095|Active Comparator|Patients in the midazolam group|Patients in the midazolam group are given midazolam 0.02-0.05mg/kg bolus on initiation of the procedure and are given 1.2-7.2 μg/kg/h of remifentanil until end of the procedure
89518106|NCT03530995|Experimental|Part 2, Period 2|"Drug: Omeprazole. Subjects will receive omeprazole 20 mg QD on Day 1 through Day 3.~Drug: Belumosudil. Subjects will receive belumosudil 200 mg BID + omeprazole 20 mg QD on Day 4."
89518107|NCT02217436|Experimental|iPad|iPad with age-appropriate applications, videos, and music
89518108|NCT02217436|Active Comparator|Standard Care|All study participants will receive standard care, which consists of procedural explanation and preparation by providers, verbal encouragement and comforting by providers and parents, and topical anesthetic (LET) followed by injectable lidocaine administration (whether one or both of these anesthetics will be used will be determined by the provider prior to randomization).
89518109|NCT03467503|No Intervention|Prenatal Care/Nutrition Education|Participants were given nutrition educational counseling on healthy dietary habits and gestational weight gain as part of standard prenatal care.
89518110|NCT03467503|Experimental|Dietary Intervention|Participants were given dietary blueberries (2 cups) and soluble fiber (12g). They also received nutrition educational counseling on healthy dietary habits and gestational weight gain as part of standard prenatal care.
89518111|NCT05373979||Narcolepsy|Narcolepsy type 1 (NT1 or narcolepsy with cataplexy) and Narcolepsy type 2 (NT2 or narcolepsy without cataplexy)
89518112|NCT05373979||Obstructive Sleep Apnea|mild to moderate obstructive sleep apnea (OSA; obstructive AHI of 1-15/hour)
89032606|NCT02946554|Other|Low dose cohort|"Two dose regimens of HepaStem will be given, which differ in the amount of cells per infusion.~The low dose regimen will be given to the first cohort (first 6 patients included in the study)."
89032607|NCT02946554|Other|High dose cohort|The high dose regimen will be given to the second cohort after evaluation of the safety of the 1st cohort (stepwise approach)
89032608|NCT02928861|Experimental|18F-FDG PET/CT-based prognostic model|The new prognostic model is based on 18F-FDG PET/CT scans, and combined with clinical and pathological prognostic factors.
89032609|NCT02946476||HFrEF|patients with heart failure and reduced ejection fraction
89032610|NCT02946476||HFpEF|patients with heart failure and preserved ejection fraction
89032611|NCT02928900|Experimental|Intervention period|In this stepped-wedge trial design, the experimental arm refers to the time period when the study sites receive the clinician training intervention. The intervention is a clinician training using standardized patient actors to improve communication and empathy skills of health care providers who serve HIV-positive adolescents and youth.
89518113|NCT05371483||Narcolepsy Type 1|Study participant will complete test(s) before and after taking a stable dose of a new/different hypersomnia medication. All hypersomnia medications will be prescribed and titrated by a clinical sleep specialist outside of this protocol.
89032612|NCT02928900|No Intervention|Control period|In this stepped-wedge trial design, the no intervention arm refers to the time period before the study sites receive the clinician training intervention, during which standard of care is provided.
89518114|NCT05371483||Narcolepsy Type 2|Study participant will complete test(s) before and after taking a stable dose of a new/different hypersomnia medication. All hypersomnia medications will be prescribed and titrated by a clinical sleep specialist outside of this protocol.
89518115|NCT05371483||Idiopathic Hypersomnia|Study participant will complete test(s) before and after taking a stable dose of a new/different hypersomnia medication. All hypersomnia medications will be prescribed and titrated by a clinical sleep specialist outside of this protocol.
89518116|NCT02207530|Experimental|MEDI4736|MEDI4736 monotherapy
89518117|NCT05438797|Experimental|adoptive TIL-TCM transfer|TIL-TCM cells are isolated from the patients' Tumor tissue (or ascites) and peripheral blood obtained before standard chemotherapy and then cultured ex-vivo. The first infusion will be conducted in 7-10 days after chemotherapy and is assessed by the investigators.TIL-TCM cells are transfused to patients in a dosage escalated manner.The total dose was 1× 109-1 ×1010 cells.After cell infusion, IL-2 was administered at 720000 IU/kg (based on whole body weight) by intravenous (I.V.),every 8 hours for up to 4 days.
89518118|NCT03467347|Experimental|VR used continuously for approximately 90 days|One silicone elastomer vaginal ring (VR) containing the active 200 mg dapivirine (DPV) and 320 mg levonorgestrel (LNG), used continuously for approximately 90 days.
89518119|NCT03467347|Experimental|VR used cyclically for approximately 90 days|One silicone elastomer vaginal ring (VR) containing the active 200 mg dapivirine (DPV) and 320 mg levonorgestrel (LNG), used cyclically for approximately 90 days. Use the VR for 28 days, remove for 2 days.
89518120|NCT05438641||Conventional Benzodiazepine-based treatment group|Conventional Benzodiazepine-based group includes any subject primarily treated with BZDP agents (e.g., diazepam, lorazepam, chlordiazepoxide).
89518121|NCT05438641||Benzodiazepine-Sparing|BZDP-Sparing group includes subjects primarily treated with a non-BZDP agent (e.g., Alpha-2 agonists and/or anticonvulsants).
89518122|NCT05359315||Experimental|Ingaron + basic TB therapy 500,000 IU once daily for 3 months followed by 3 months follow-up
89518123|NCT05359315||No Intervention|only basic anti-tuberculosis therapy
89518124|NCT02616055|Experimental|50mg Daily|One 50mg tesevatinib tablet per day
89518125|NCT02616055|Experimental|100mg Daily|Two 50mg tesevatinib tablets per day
89518126|NCT02616055|Experimental|150mg M/Th|Three 50mg tesevatinib tablets every Monday and Thursday.
89518127|NCT02616055|Experimental|150mg MWF|Three 50mg tesevatinib tablets every Monday, Wednesday and Friday.
89518128|NCT05331391|Experimental|Brief mobile SMART Exercise Support Program|Patients will receive a brief SMART Exercise individual session with instant messages and telephone coaching for exercise habit formation and maintenance.
89518129|NCT05331391|Placebo Comparator|General Hygiene Information (GHI)|Patients will receive an individual session, instant messages and telephone coaching regarding general hygiene information.
89605563|NCT06061497|Experimental|Abdomino-diaphragmatic breathing|"There are four consultations with autonomous rehabilitation nursing intervention: abdomino-diaphragmatic breathing.~In addition to adding the health care that is recommended in the Integrated Care Process for Asthma in Children and Adults, of the Portuguese Directorate-General for Health, namely:~Health education:~Inhalation technique Adherence to treatment; Presence of comorbidities; Smoking; Other environmental factors; Promotion of physical activity."
89605564|NCT06061497|Placebo Comparator|Usual care|"They will have the care recommended in the Integrated Care Process for Asthma in Children and Adults, of the Portuguese Directorate-General for Health, namely:~Health education:~Inhalation technique Adherence to treatment; Presence of comorbidities; Smoking; Other environmental factors; Promotion of physical activity."
89605565|NCT06061484|Active Comparator|Control Group|Standard weight-based dosing of Ready-to-Use Therapeutic Food (RUTF) at a dose of 150-200 kcal/kg/day
89605566|NCT06061484|Experimental|SAM Experimental A|2 sachets (1000 kcal) of RUTF per day
89605567|NCT06061484|Experimental|SAM Experimental B|2 sachets (1000 kcal) per day while MUAC < 115mm and/or edema and/or WHZ < -3; then decreasing to 1 sachet (500 kcal) per day while MUAC 115-124 and WHZ -2 to -3 and no edema
89605568|NCT06061445|Experimental|treatment group|Radiotherapy Combined with TKI and Anti-PD-1 Antibody
89605569|NCT06061432|Experimental|Endoscopic Ultrasound- Guided Hartmann Reversal Procedure|Participants after Hartmann procedure, who were qualified and underwent Endoscopic Ultrasound- Guided Hartmann Reversal Procedure.
89605570|NCT06061419|Active Comparator|Huel Powder|This arm of the study will receive Huel as their first study meal with cornflakes and milk as their second
89605571|NCT06061419|Active Comparator|Cornflakes and Milk|This arm of the study will receive cornflakes and milk as their first study meal with Huel as their second
89605572|NCT06061406|Experimental|group1|Bariatric-metabolic surgery (Gastric sleeve, Roux-Y gastric bypass, omega-loop bypass) at least 24 months ago, 25-45 patients in this group (total sum of patients in all three groups: 100).
89605573|NCT06061406|Experimental|group 2|Patients participating in a full or partial (if primary indication) multimodal approach prior to bariatric surgery, 25-45 patients in this group (total sum of patients in all three groups: 100).
89605574|NCT06061406|Experimental|group 3|Conservative therapy: patients with overweight/obesity grade 1 (BMI 28-34.9 kg/m2), 25-45 patients in this group (total sum of patients in all three groups: 100).
89605575|NCT06061315|Experimental|Collagen peptide group|This group will consume 1 serving of Collagen peptides, which is produced and marketed ® by GELITA AG, Germany under the brand name BODYBALANC each day.
89605576|NCT06061315|Placebo Comparator|Placebo group|This group will consume 1 serving of silicon dioxide (Sipernat 350, Evonik, Germany) each day. The product is absorbed in negligible amounts by the intestine and does therefore induce minor metabolic effects.
89605577|NCT06061289|No Intervention|Education and healthy diet|The healthy diet education session included a PowerPoint presentation on healthy dietary guidelines and sample recipes of healthy meals.
89605578|NCT06061289|Experimental|Detox|The guided component of the detoxification program included an additional PowerPoint presentation with the information about the investigational product, directions, and dosing information for its consumption.
89605579|NCT06061276|Experimental|bTAE-HAIC combined with Lenvatinib and Camrelizumab|bTAE procedure was a 2.8-F microcatheter was super-selectively inserted into the tumor feeding artery using the coaxial technique. Then blank microspheres were used according to the tumor blood supply vessels (40-120um, 100-300um, 300-500um, 500-700um). Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin every 4 weeks.
88981873|NCT04716517|Active Comparator|Resin Modified Glass Ionomer|Comparator Resin-modified glass ionomer material will be used to restore cervical carious in adult patients.
88981874|NCT02662153||Long-term opioid-use cohort|Persons who have received 70 or more days of Schedule II opioid dispensed in a 90-day period, after at least 183 days with no opioid dispensing.
88981875|NCT02662153||IR/SA to ER/LA Switchers|Persons who have switched to or added on an ER/LA product after stable use of an IR/SA opioid regimen.
88981876|NCT02662153||IR/SA to IR/SA Switchers|Persons who have switched to or added on a new IR/SA opioid after stable use of a different IR/SA opioid regimen.
88981877|NCT02357719|Experimental|VistaO2 FLUX device|This device combines the transcutaneous oxyhemoglobin saturation (allowing to compute the oxyhemoglobin desaturation index), the slow variations in heart rate, the nasal flow and an index of nocturnal respiratory events calculated by analyzing the movements of the chest performed by chest impedance variations.
88981878|NCT02958306|Experimental|platelet rich plasma|autologous blood product
88981879|NCT02958306|No Intervention|no platelet rich plasma|control
88981880|NCT04004273|Experimental|Exercise|Participants randomised to the exercise training intervention will complete 24 moderate-intensity exercise training sessions over the subsequent six weeks (four times per week; ~50 min per session). Each week, one exercise training session will be supervised by the research team, whilst three sessions will be unsupervised but monitored objectively using a heart rate monitor.
88981881|NCT04004273|No Intervention|Control|Participants randomised to control will receive no interventions and will be requested to maintain their habitual lifestyle during the six week intervention phase
88981882|NCT01691833|Experimental|Vitamin D|Patients that are deficient in Vitamin D will be assigned to the randomized arm of the study. They will be randomly chosen to receive either the Vitamin D supplement or the placebo.
88981883|NCT01691833|Placebo Comparator|Placebo|Patients that are deficient in Vitamin D will be assigned to the randomized arm of the study. They will be randomly chosen to receive either the Vitamin D supplement or the placebo.
88981884|NCT01691833|No Intervention|Normovitaminosis|Patients with normovitaminosis( levels greater than or equal to 30ng/ml) will receive no intervention.
88981885|NCT00123240|Active Comparator|High Fat/Protein Diet|
88981886|NCT00123240|Active Comparator|High Carbohydrate Diet|
88981887|NCT04729166|Experimental|Study group|The study group were provided with education with structured educational material and followed in this study, in addition to the usual care provided by healthcare professionals.
88981888|NCT04729166|No Intervention|Control group|Control group was int the usual care.
88981889|NCT00123279|Experimental|1|
88981890|NCT00123279|Experimental|2|
89605580|NCT06061263||PCR patients with eaophageal squamous cell carcinomas|patients with esophageal squamous cell carcinoma (ESCC) patients who achieved pathologic complete response after neoadjuvant chemoradiotherapy (nCRT).
89605581|NCT06061224|No Intervention|non-PT group|with no physical treatment intervention (group 1)
89605582|NCT06061224|Experimental|Early-PT group|with physical treatment intervention started in ICU admission day 3 (group 2)
89605583|NCT06061224|Experimental|Delayed-PT|with physical treatment intervention started after ICU admission day 3 (group 3)
89605584|NCT06061198|Active Comparator|group of patients who underwent surgery with the virtual reality experience|patients underwent surgery wearing a virtual reality mask
89605585|NCT06061198|No Intervention|patients who underwent surgery in standard conditions without the virtual reality experience|patients underwent surgery without a virtual reality mask
89605586|NCT06061120||Questionnaire - Supraventricular arrhythmia|Questionnaire about triggers and stops of supra ventricular arrhythmia
89605587|NCT06061120||Extended ECG - Effect of electrophysiological ablation|Extended signal-averaged ECGs in patients with ablation of supra ventricular ablation
89605588|NCT06061120||Extended ECG - Virtual atrial Electrocardiogram|Improve visualisation of atrial arrhythmia by means of extended signal-averaged ECGs
89605589|NCT06061094|Active Comparator|A: Imatinib + low dose chemotherapy|Imatinib 600mg QD + low dose chemotherapy induction and consolidation I (Standard Arm of Randomization I)
89605590|NCT06061094|Experimental|B: Ponatinib + low dose chemotherapy|Ponatinib 45mg QD (reduction to 30mg QD after Induction) + low dose chemotherapy induction and consolidation I (Experimental Arm of Randomization I)
89605591|NCT06061094|Active Comparator|C: Molecular CR: End of therapy with indication for SCT|Molecular CR: End of therapy with indication for SCT (Standard Arm of Randomization II)
89605592|NCT06061094|Experimental|D: Molecular CR: continuation with Imatinib/Ponatinib (per Rando I), chemotherapy and Blinatumomab|Molecular CR: No end of therapy with indication for SCT but and continuation with Imatinib/Ponatinib (per Randomization I), chemotherapy and Blinatumomab (Experimental Arm of Randomization II)
89605593|NCT06061094|Experimental|E: Mol Fail / Mol NE: Continuation with Imatinib/Ponatinib (per Rando I) and addition of Blina|Molecular Failure / Molecular Not Evaluable: Continuation with Imatinib/Ponatinib (per Randomization I) and addition of Blinatumomab (Experimental Arm)
89605594|NCT06061081|Experimental|Participants receiving VH3739937|
89605595|NCT06061081|Placebo Comparator|Participants receiving Placebo|
89605596|NCT06061055|Experimental|Anchor|Patient group who are intubated with triple-cuffed double-lumen endobronchial tube (VentiBronc Anchor)
89605597|NCT06061055|Active Comparator|Shiley|Patient group who are intubated with conventional double-lumen endobronchial tube (Shiley)
88981891|NCT00123279|Experimental|3|
88981892|NCT00123279|Experimental|4|
88981893|NCT00123279|Experimental|5|
88981894|NCT00123279|Experimental|6|
88981895|NCT00091806|Experimental|Cohort 1|6mg/kg of panitumumab administered once every 2 weeks until subjects develop disease progression or are unable to tolerate the study drug
88981896|NCT00091806|Experimental|Cohort 2|Panitumumab 9 mg/kg administered once every 3 weeks until subjects develop disease progression or are unable to tolerate the study drug.
89605598|NCT06061042|Experimental|Early time-restricted eating|"50% of daily calories at breakfast, 35% at lunch and 15% at dinner. 85% of calories consumed in 6h, i.e., between 7AM and 1PM.~Eating period, 10h (7AM-5PM); fasting period, 14h; Breakfast between 7 and 8 AM; lunch between 12 AM and 1 PM; dinner between 4 and 5 PM."
89605599|NCT06061042|Experimental|Late time-restricted eating|"15% of daily calories at breakfast, 35% at lunch and 50% at dinner. 85% of calories consumed in 6h, i.e., between 2PM and 8PM.~Eating period, 10h (10AM-8PM), fasting period, 14h; Breakfast between 10 and 11 AM; lunch between 2 and 3 PM; dinner between 7 and 8 PM."
89605600|NCT06061029|Experimental|Yoga- and Mindfulness-Based Psychoeducation Program Group|
89605601|NCT06061029|No Intervention|Waitlist Control Group|
89605602|NCT06060990|Other|Open-label single arm of patients with metastatic BTCs|"Systemic therapy:~Identification of trace elements as novel predictive and prognostic biomarkers for response to systemic therapy in metastatic BTCs"
89605603|NCT06060964|Experimental|Intervention Group|Participants in this group will use the Breathe Easier progressive web application each day for a period of 8-weeks.
89605604|NCT06060964|No Intervention|Non-intervention Group (Control Group)|Participants in this group will receive no intervention.
89605605|NCT06060951||Incident cohort|Including all patients from the time of PD catheter insertion until 8 weeks after starting PD
89605606|NCT06060951||Prevalent cohort|Including all patients treated with PD who are greater than 8 weeks from the start of dialysis.
89605607|NCT06060925||Active myofascial pain syndrome|Subjects that experience spontaneous pain
89605608|NCT06060925||Latent myofascial pain syndrome|Subjects that elicit pain only when palpated and disturbed.
89605609|NCT06060925||Subjects without pain|No symptoms of chronic pain.
89605610|NCT06060886|Experimental|First episode of psychosis patients|"Operational definition for a first episode of psychosis included individuals with a non-affective psychosis who have not received previous antipsychotic treatment regardless of the duration of psychosis."
89605611|NCT06060834|Experimental|Application of product|Apply intervention to wet hair on scalp and massage in for 30 seconds after shampooing (if applicable), daily.
89605612|NCT06060795||Experimental Group|Patient infected by COVID19
89605613|NCT06060795||Control group|Patient non infected by COVID19
89605614|NCT06060782|Experimental|subject group|
89605615|NCT06060769||HCC group|Patients who develop HCC during follow-up
89605616|NCT06060769||non-HCC group|Patients who did not develop HCC during follow-up
89605617|NCT06060743|No Intervention|control group|Data collection tools were applied to individuals in the control group on day 0 (Z0), day 14 (Z1) and day 28 (Z2) of follow-up. Data collection tools applied to the control group are as follows: Patient Introduction Form, Insulin Treatment Appraisal Scale,, Insulin Therapy Self-Management Scale, Insulin Information Form, Insulin Injection Skill Observation Form and Metabolic Control Variables Form.
89605618|NCT06060743|Experimental|application group|Individuals in the application group will be given individual training on how to use the application through the application demo. Data collection forms will be applied to individuals in the application group on day 0 (Z0), day 14 (Z1) and day 28 (Z2). The forms to be used are: Patient Introduction Form, Insulin Treatment Appraisal Scale, Insulin Therapy Self-Management Scale, Insulin Information Form, Metabolic Control Variables Form, Insulin Injection Skill Observation Form and Digital Literacy Scale.
89605619|NCT06060652||Retrospective cohort|34 OMPC patients enrolled in the ADAPT-CTC trial
89605620|NCT06060652||Prospective cohort|A minimum sample size of 70 OMPC patients undergoing SBRT must be enrolled in this study to satisfy the study endpoints
89605621|NCT06060600||Natural History Cohort:|"Treatment records from a cohort of approximately 200 patients who were hospitalized between 1901 and 1910 during the 1900-1920 HAT epidemic~Treatment records must have sufficient information for analysis including:~Demographic data: age or sex must be included~Diagnosis: HAT diagnosis is confirmed by blood or lymph gland fluid analysis and parasites observed or HAT symptoms during the epidemic. For example, if the records state that a lymph node biopsy was performed, any result of the biopsy (e.g., documentation that trypanosomes were observed), a documentation of the HAT diagnosis, or mention of HAT symptoms such as sleepiness or excess sleeping are all acceptable. Symptoms alone are not sufficient, but a notation of biopsy and mention of HAT symptoms is acceptable.~Outcome: An outcome is required; any mention of a clinical outcome is acceptable."
89605622|NCT06060600||Retrospective cohort|The hospital records of TBR HAT patients will be examined for date of symptom onset (if available) and hospital admission, race, sex, age, geographic area of origin, parasites, concomitant medications and illnesses, co-infections, and disease stage. Patients are normally screened for HAT and other tropical diseases using standard parasitological World Health Organization (WHO) criteria. Briefly, blood is obtained from the patients and checked for the presence of trypanosomes using direct wet smear and capillary centrifugation technique methods. Disease stage determination is by examination of CSF using the WHO criteria which classify patients with the presence of trypanosomes in the CSF and/or a WBC count >5 cells/mm3 as Stage 2 TBR HAT. Stage 2 patients would be disqualified from inclusion in the study.
89605623|NCT06060574||Menstrual Cycle 1-2nd days|The Blood samples will be drawn from the participants on 1st-2nd day of the menstrual cycle of each of these 36 participants. PRF will be obtained from the blood taken these days.
89605624|NCT06060574||Menstrual Cycle 8-10. days : proliferative phase (PP)|The Blood samples will be drawn from the participants on 8-10. days of the menstrual cycle of each of these 36 participants. PRF will be obtained from the blood taken these days.
89605625|NCT06060574||Menstrual Cycle 12-14. days: ovulation phase (OP)|The Blood samples will be drawn from the participants on 12-14. days of the menstrual cycle of each of these 36 participants. PRF will be obtained from the blood taken these days.
89605626|NCT06060574||premenstrual (PmD) 22-24. days|The Blood samples will be drawn from the participants on 22-24. days of the menstrual cycle of each of these 36 participants. PRF will be obtained from the blood taken these days.
89605627|NCT06060561||Observational|Patients undergo saliva sample collection and complete questionnaires on study. Patients' medical records are reviewed.
89605628|NCT06060535|Active Comparator|Usual Care|Usual care suicide prevention pathway
89605629|NCT06060535|Experimental|Intervention|Implementation of the suicide risk model
89605630|NCT06060483|Experimental|CGM group|Wear CGM continuously and manage patients based on CGM. The treatment goals are TIR>70%, TBR<4%, TAR<25%, and HbA1c<7.0%. After the treatment reaches the standard, CGM is worn every six months.
89605631|NCT06060483|No Intervention|HbA1c group|HbA1c testing is performed every three months, patient management is based on HbA1c, and the treatment target is HbA1c <7.0%.
89605632|NCT06060444|Other|In-Person|Control group
89605633|NCT06060444|Experimental|Telemedicine|
89032613|NCT00525668|Active Comparator|verum|Sunphenon plus glatiramer acetate
89605634|NCT06060431|Experimental|Experimental group|The experimental group will carry out the sessions of the specific Pain Sciences program. This intervention is based on two educational sessions of 90 and 60 minutes each, separated by one week.
89605635|NCT06060431|No Intervention|Control Group|The control group will not perform any specific intervention and will follow their usual academic curriculum.
89605636|NCT06060327|Active Comparator|Oxytocin Group|o In Oxytocin group (n=111), patients will receive 10 IU oxytocin (Syntocinon, Novartis, Basel, Switzerland) given as infusion in 500 ml lactated ringer/s solution at a rate of 125ml/hour after delivery of the placenta.
89605637|NCT06060327|Active Comparator|Tranexamic acid|"o In Tranexamic group (n=111), patients will be given 1 gm (10 ml) TXA (Kapron, Amoun, Egypt) diluted in 20 ml of Glucose 5% (administered as intravenous infusion over 5 minutes, at least 15 minutes prior to skin incision).~Oxytocin 5 IU will be given slowly intravenous following delivery of the baby."
89605638|NCT06060327|Active Comparator|Misoprostol|o In Misoprostol group (n=111), 400 microgram misoprostol (2 tablets - Cytotec, Pfizer, G.D. Searle LLC) will be inserted intraoperative inside the uterus after delivery of the placenta Oxytocin 5 IU will be given slowly intravenous following delivery of the baby.
89605639|NCT06060327|Active Comparator|Carbetocin|"o In carbetocin group (n=111) 100 microgram carbetocin (Pabal, Ferring, Kiel, Germany) will be given as an intravenous bolus dose following the delivery of the placenta.~Oxytocin 5 IU will be given slowly intravenous following delivery of the baby."
89605640|NCT06060314|Other|Patients|Patients presented with symptoms of numbness at night, pain, or tingling sensation in the fingers particularly at night diagnosed by a consultant orthopedic surgeon on physical examination.
88981897|NCT01397110|Active Comparator|Respiratory and exercise therapy|Randomized, prospective, controlled, blinded study of three-week inpatient rehabilitation and subsequent continuing of the training at home for 12 weeks. The control group received conventional rehabilitation without a specific training program. After 15 weeks training is also offered to patients in the control group.
88981898|NCT01397110|No Intervention|Control group without exercise training|"patients of the control group continue their sedentary lifestyle without given advice for exercise training.~The time before start of rehabilitation (three months) serves as control group. Afterwards patients take part in the training program as well."
88981899|NCT00123318|Experimental|1|Single-arm, non-randomised feasibility study to evaluate new regimen of adjuvant chemoradiotherapy (Epirubicin, Cisplatin, 5-Fluorouracil + radiotherapy)
89605641|NCT06060314|Other|Principle Investigator|The principal investigator will carry out the whole study.
89605642|NCT06060314|Other|Consultant Orthopedic Surgeon|Consultant Orthopedic Surgeon will be outcome assessor.
89605643|NCT06060301|Experimental|study group (S group)|The patients will use topical sulfasalazine prepared by dissolving one tablet of commercially available in 100 ml of distilled water 4 times per day as a mouth wash combined with topical corticosteroids 4 times per day as a topical gel in an alternate sequence.
89605644|NCT06060301|Active Comparator|Control group (C group)|The 23 patients categorized as control group (C group) will receive topical corticosteroids gel only 4 times per day. The treatment regimen will be continued for 4 weeks.
88981900|NCT01005277||Ancillary-Correlative (genetic polymorphisms)|Previously collected DNA samples are analyzed for polymorphisms at a variety of loci. Gene expression and expression profiles are correlated with genotype and therapy outcomes.
88981901|NCT00327535|Experimental|Mircera 6.3 micrograms/kg|
88981902|NCT00327535|Experimental|Mircera 9 micrograms/kg|
88981903|NCT00327535|Experimental|Mircera 12 micrograms/kg|
88981904|NCT00327535|Active Comparator|Darbepoetin alfa|
88981905|NCT03913832|Experimental|sirolimus drug coated balloon (SCB)|Magic TouchTM (Concept Medical) is a sirolimus drug coated balloon (SCB)
88981906|NCT03913832|Active Comparator|paclitaxel releasing coronary balloon catheter.|SeQuent PleaseTM (B. Braun Melsungen AG, Vascular Systems,Berlin, Germany) is a paclitaxel releasing coronary balloon catheter
88981907|NCT00123357||Group 1|
88981908|NCT00123396|Experimental|Arm 1|Test the effectiveness of the BioCASES teaching modules by way of a randomized controlled trial of VAMCs using the BioTESTS to evaluate their effectiveness for increasing and sustaining VA clinician knowledge, skills, and ability to respond to bioterrorism events.
88981909|NCT04716868|Experimental|Agave Fructans 5 g|Agave tequilana Weber blue variety 5 g once a day for 8 week.
88981910|NCT04716868|Experimental|Agave Fructans 10 g|Agave tequilana Weber blue variety 10 gf once a day for 8 week.
88981911|NCT04716868|Experimental|Maltodextrin 10 g + Agave Fructans 5 g|Maltodextrin 10 g + Agave tequilana Weber blue variety 5 g once a day for 8 week.
88981912|NCT04716868|Active Comparator|Psyllium plantago 15 g|Psyllium plantago 15 g once a day for 8 week.
88981913|NCT00327769|Active Comparator|1|Anastrozole
88981914|NCT00327769|Experimental|2|Anastrozole + Fulvestrant
88981915|NCT00092001|Experimental|1|
88981916|NCT03883919|Experimental|Group 1: Paricalcitol 75 mcg Days 1 and 8|"5-FU, LV, and nal-IRI will be administered at standard fixed doses. Briefly, 5-FU will be given at a dose of 2400 mg/m^2 continuous IV infusion over 46 hours, LV will be given at 400 mg/m^2 IV over 30 minutes, and liposomal irinotecan will be given at a dose of 70 mg/m^2 IV over 90 minutes (unless homozygous for the UGT1A1*28 7/7 allele, in which case the dose will start at 50 mg/m^2 and escalate to 70 mg/m^2 in subsequent cycles if no excessive toxicity is experienced) on Day 1 of each 14-day cycle.~Paricalcitol 75 mcg on Days 1 and 8~Treatment with liposomal irinotecan plus 5FU/ LV may continue indefinitely, and treatment with paricalcitol may continue for up to 10 cycles (20 weeks)"
88981917|NCT03883919|Experimental|Group 2: Paricalcitol 7 mcg/kg Days 1 and 8|"5-FU, LV, and nal-IRI will be administered at standard fixed doses. Briefly, 5-FU will be given at a dose of 2400 mg/m^2 continuous IV infusion over 46 hours, LV will be given at 400 mg/m^2 IV over 30 minutes, and liposomal irinotecan will be given at a dose of 70 mg/m^2 IV over 90 minutes (unless homozygous for the UGT1A1*28 7/7 allele, in which case the dose will start at 50 mg/m^2 and escalate to 70 mg/m^2 in subsequent cycles if no excessive toxicity is experienced) on Day 1 of each 14-day cycle.~Paricalcitol 7 mcg/kg on Days 1 and 8~Treatment with liposomal irinotecan plus 5FU/ LV may continue indefinitely, and treatment with paricalcitol may continue for up to 10 cycles (20 weeks)"
88981918|NCT04708366|Experimental|1L PEG|Patients will be prepared with 1L-PEG-based bowel preparation.
88981919|NCT04708366|Active Comparator|2L PEG|Patients will be prepared with 2L-PEG-based bowel preparation.
88981920|NCT04708366|Active Comparator|4L PEG|Patients will be prepared with 4L-PEG-based bowel preparation.
88981921|NCT00327808|Experimental|Inhaler|TPI 1020
88981922|NCT00327808|Active Comparator|Inhaler cortico.|Budesonide inhaler
88981923|NCT03719066|Active Comparator|DIG 1 (dose interval group)|This group will receive two doses of killed whole cell oral cholera vaccine. The second dose being administered two weeks after the first dose.
88981924|NCT03719066|Experimental|DIG 2 (dose interval group)|This group will receive two doses of killed whole cell oral cholera vaccine. The second dose being administered 6 months after the first dose.
88981925|NCT03719066|Experimental|DIG 3 (dose interval group)|This group will receive two doses of killed whole cell oral cholera vaccine. The second dose being administered 11 months after the first dose.
88981926|NCT00327964||study population|601 children enrolled in an on-going longitudinal antimalarial treatment efficacy trial in Kampala, Uganda.
88981927|NCT00123435|Active Comparator|Arm 1|5-session nutritional counseling program
88981928|NCT00123435|Experimental|Arm 2|5-session nutritional counseling program + simple pedometer feedback
88981929|NCT00123435|Experimental|Arm 3|5-session nutritional counseling program + simple pedometer feedback + enhanced pedometer feedback web-based feedback
88981930|NCT03709550|Experimental|Treatment (decitabine, enzalutamide)|Participants receive decitabine IV over 1 hour on days 1-5 and enzalutamide PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88981931|NCT00315211|Other|Arm A|Weekly intravenous topotecan with intravenous docetaxel
88981932|NCT02960191|Other|healthy volunteers|subject with no current or past personal history of psychiatric disorders and about never having carried out suicide attempt
88981933|NCT02960191|Other|emotional witness|subject having had a personal history of unipolar or bipolar depressive disorder and who have never done in his life attempted suicide
88981934|NCT02960191|Other|patient suicide|subject having had a personal history of unipolar or bipolar depressive disorder and having realized in his life at least one suicide attempt
88981935|NCT00123513|Experimental|1|Worksite intervention for obesity prevention
88981936|NCT00123513|No Intervention|2|Control group
88981937|NCT00315562|Experimental|Early|Early
88981938|NCT00315562|Active Comparator|Delayed|Delayed
89518130|NCT04697173|No Intervention|Standard consent|This group will be consented for invasive procedures using standard Hospital policy. Informed consent will be obtained either in person or via telephone with a witness from the patient or his/her legal guardian for any/all procedures medically indicated at that time, at the discretion of the Attending Physician.
89518131|NCT04697173|Experimental|Bundled consent|"Upon admission, this group will received the document titled Common PICU Procedures Explained and encourage to read the document. They will then, within 24 hours of admission be consented using the Bundle Consent Document for the group of invasive procedures listed and explained in that document."
89518132|NCT03467035||desaturation|"ΔSpO2 >10% or lowest SpO2<90 during baseline six minute walk test~Check serum level of inflammasone, such as IL-1beta, TGF-beta TRT-PCR for PBMC"
89518133|NCT03467035||non-desaturation|"ΔSpO2 <10% and lowest SpO2>90 during baseline six minute walk test~Check serum level of inflammasone, such as IL-1beta, TGF-beta TRT-PCR for PBMC"
89518134|NCT02207374|Experimental|Semaglutide 0.5 mg|
89518135|NCT02207374|Experimental|Semaglutide 1.0 mg|
89518136|NCT02207374|Active Comparator|One additional OAD + pre-trial treatment|The type and dosage of the additional OAD will be selected by the investigators according to the approved Japanese labelling including drug combinations and contraindications. One of DPP-4 inhibitor (dipeptidyl peptidase-4), SU (sulfonylurea), glinide, biguanide, α-GI (α-glucosidase inhibitor)or TZD (thiazolidinediones) will be selected as the additional OAD. For the subjects treated with OAD monotherapy as pre-trial treatment, the type and dosage of the additional OAD with a different mechanism of action from the pre-trial OAD should be chosen.
89518137|NCT03466957|Experimental|3D printed applicator|individually designed applicator for BT
88981939|NCT03468686|Active Comparator|bilateral rTMS|sequential bilateral repetitive Transcranial Magnetic Stimulation (rTMS)
88981940|NCT03468686|Sham Comparator|Sham rTMS|Sham Transcranial Magnetic Stimulation (rTMS)
88981941|NCT03468686|Active Comparator|Unilateral rTMS|Unilateral (High frequency) repetitive Transcranial Magnetic Stimulation (rTMS)
88981942|NCT00315913|Experimental|IV Propranolol|IV dose propranolol
88981943|NCT00315913|Placebo Comparator|IV Placebo|IV Placebo of saline solution equal to propranolol in volume
88981944|NCT00477724|Placebo Comparator|sedentary control group|patients are treated by conventional rehabilitation
88981945|NCT00477724|Active Comparator|exercise and respiratory therapy|rehabilitation with exercise and respiratory therapy
88981946|NCT00315991|Experimental|BGAT Intervention|Blood Glucose Awareness Training for Parents
88981947|NCT00315991|No Intervention|Control|Enter PDA data and complete questionnaires only. No intervention received.
88981948|NCT00399971|Experimental|Hemathera|Patients will receive cell-based immunotherapy.
88981949|NCT04728867|Active Comparator|Surgical textbook|Volunteers in four groups were given 4 weeks to review their educational material at least two times. For this group, this will be a textbook chapter explaining the details for laparoscopic rectal surgery.
88981950|NCT04728867|Active Comparator|3D animation|Volunteers in four groups were given 4 weeks to review their educational material at least two times. For this group, this will be an educational animation video showing laparoscopic rectal surgery.
88981951|NCT04728867|Active Comparator|Cadaveric video|Volunteers in four groups were given 4 weeks to review their educational material at least two times. For this group, this will be an educational cadaveric dissection video showing laparoscopic rectal surgery.
88981952|NCT04728867|Active Comparator|Both 3D animation + cadaveric video|Volunteers in four groups were given 4 weeks to review their educational material at least two times. For this group, this will be both animation and educational cadaveric dissection video showing laparoscopic rectal surgery.
88981953|NCT00316108|Experimental|Arm 1|
89518138|NCT03466879||Active device users|Users will use an active SYNUS Pain Relief device
89518139|NCT03466879||Sham device users|Users will use a sham SYNUS Pain Relief device that is not providing treatment
89518140|NCT02217280|Experimental|Injection with Gadolinium|This group of patients identified by the PI as having cervical radiculopathy will receive gadolinium (the intervention) in their epidural cervical injection along with steroid (DepoMedrol). There is no control group in this study.
89518141|NCT02786537|Active Comparator|EBR/GZR (elbasvir/grazoprevir) with RBV|Patients received 1 EBR/GZR (elbasvir/grazoprevir) (Zepatier) tablet (50/100mg) once daily for 12 to 16 weeks (provider discretion) with Ribavirin (RBV) 200 mg/tablet, 1-3/day, taken 1-2 times per day (dosage at discretion of provider).
89518142|NCT02786537|Active Comparator|EBR/GZR (elbasvir/grazoprevir)|Patients received 1 EBR/GZR (elbasvir/grazoprevir) tablet (50/100 mg) once daily for 12 to 16 weeks (provider discretion) (without Ribavirin)
89518143|NCT02786537|Active Comparator|SOF/LDV (sofosbuvir/ledipasvir) with RBV|Patients received 1 SOF/LDV (sofosbuvir/ledipasvir) (Harvoni) tablet (400/90 mg) orally once daily with or without food 12 to 24 weeks with ribavirin (RBV) (at discretion of provider). RBV taken as 200 mg/tablet(capsule), 1-3 pills/day, 1-2 times/day.
89518144|NCT02786537|Active Comparator|SOF/LDV (sofosbuvir/ledipasvir)|Patients received 1 SOF/LDV (sofosbuvir/ledipasvir) tablet (400/90 mg) orally once daily with or without food 12 to 24 weeks without ribavirin (RBV) (per discretion of provider)
89518145|NCT02786537|Active Comparator|PrOD (Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir) with RBV (Phase 1 only)|"Patients received Pr0D (Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir) orally daily with food for 12 to 24 weeks with RBV (Ribavirin). Ombitasvir/Paritaprevir/Ritonavir (12.5/75/50 mg/tablet) -2 tablets once daily with food for 12 to 24 weeks and 1 dasabuvir tablet (250 mg) twice daily with food for 12 to 24 weeks.~RBV (200 mg/pill) 1-3 pills/day, 1-2 times/day (use and dosage at provider discretion). Total daily RBV dosage ranged from 200 to 1200 mg."
89518146|NCT02786537|Active Comparator|PrOD (ombitasvir/paritaprevir/ritonavir and dasabuvir)|Patients received 2 ombitasvir/paritaprevir/ritonavir tablets (12.5/75/50 mg) once daily and 1 dasabuvir (250 mg) tablet twice daily with food for 12 to 24 weeks without Ribavirin (as per provider instructions)
89518147|NCT03307759|Active Comparator|SABR plus pembrolizumab|SABR followed by pembrolizumab
89518148|NCT03307759|Active Comparator|Pembrolizumab plus SABR|Pembrolizumab followed by SABR after cycle 1
89605645|NCT06060184|Experimental|Retrospective cohort|Subjects with unclear molecular cause of the disease. The subjects are clinically characterized in the context of outpatient/ inpatient standard care at the University Hospital Tübingen (UKT) or cooperating locations.
89605646|NCT06060184|Experimental|Prospective cohort|Subjects with indication for genome diagnostics (e.g. within the initiative for genomic medicine (genomDE) based on §64e German Social Code (SGB) Fifth Book (V) (SGB V).
89605647|NCT06060158|Experimental|CBT-I online group|Twelve eligible participants will meet weekly for 6 weeks while undergoing the CBT-I program. At the end of each weekly session, participants will complete a survey reviewing the acceptability of undergoing insomnia treatment in an internet-based small-group setting.
89605648|NCT06060145|Experimental|Plants placed in an office environment|Participants in this group will receive an intervention of plants placed in an office environment.
89605649|NCT06060145|Active Comparator|Devoid of any plant presence in an office environment|Participants in this group will be exposed to an office environment devoid of any plant presence.
89605650|NCT06060119|Experimental|Comparison of Microneedling for Gingival Augmentation- A Randomized Case Control Trial|1. TEST GROUP (n = 12) - Microneedling on the selected a non-steroidal anti-inflammatory drug (Tab Ibuprofen 400mg) and antibiotic Amoxicillin 500mg thrice daily for three days after meals will be prescribed. In patients allergic to Amoxicillin, Clindamycin 300mg thrice daily is prescribed13
89605651|NCT06060119|Experimental|Comparison of Microneedling with for Gingival Augmentation- A Randomized Case Control Trial|2.CONTROL GROUP (n = 12) - Subepithelial connective tissue grafting at the contralateral site non-steroidal anti-inflammatory drug (Tab Ibuprofen 400mg) and antibiotic Amoxicillin 500mg thrice daily for three days after meals will be prescribed. In patients allergic to Amoxicillin, Clindamycin 300mg thrice daily is prescribed13
89605652|NCT06060106||Endoscopic submucosal dissection|Early esophageal cancer patients treated with ESD
89605653|NCT06060106||Esophagectomy|Early esophageal cancer patients treated with esophagectomy
89605654|NCT06060093|Placebo Comparator|Normoxia - placebo|Both training and sleep in normoxia, supplemented with placebo
89605655|NCT06060093|Experimental|Hypoxia - placebo|Training in normoxia and sleep in hypoxia, supplemented with placebo
89605656|NCT06060093|Experimental|Hypoxia - ketones|Training in normoxia and sleep in hypoxia, supplemented with ketones
89605657|NCT06060080|Experimental|Clinical Study on PEG-rhG-CSF in the Treatment of Lymphoma/Multiple Myeloma|In this study, lymphoma/multiple myeloma patients who meet the inclusion criteria will be administered PEG-rhG-CSF injection at a fixed dose of 6 mg on the second day after hematopoietic stem cell infusion, and the effectiveness and safety of the treatment will be observed.
89605658|NCT06060015|Experimental|5mg bupivacaine|Anesthetic technique, the patient receives subarachnoid hyperbaric bupivacaine at a dose of 5mg
89605659|NCT06060015|Experimental|10mg bupivacaine|Anesthetic technique, the patient receives subarachnoid hyperbaric bupivacaine at a dose of 10mg
89605660|NCT06060002|Active Comparator|Group A - Patients will undergo stent removal and cholangiogram at 3 months of follow up|In group A, patients will undergo stent removal and cholangiogram at 3 months of follow up. If we detect recurrent stone/s on cholangiogram, clearance will be done accordingly. If the patient is dated for cholecystectomy beyond 3 months then stent exchange will be done and patient will be followed up till they undergo cholecystectomy. During this waiting period in the later group, patients will undergo monthly follow up for development of any new onset symptoms that are suggestive of biliary pain, pancreatitis, cholangitis and cholecystitis.
89605661|NCT06060002|Sham Comparator|Group B - Patients will undergo endoscopic ultrasound (EUS) at 3 months of follow up.|"In group B, patients will undergo endoscopic ultrasound (EUS) at 3 months of follow up. If we detect recurrent stone/s in EUS then ERC and clearance will be done accordingly. Those who are dated for cholecystectomy beyond 3 months will undergo monthly follow up clinically (biliary pain, pancreatitis, cholangitis and cholecystitis) till they undergo cholecystectomy.~Those patient in group B who are unwilling for EUS will be requested to get an magnetic resonance cholangiopancreatography (MRCP) while those unwilling for both EUS/MRCP will be followed up with ultrasound abdomen and liver function test (LFT)."
89605662|NCT06059989|Experimental|Monotherapy|"Group 1: Monotherapy group~Patients randomized to IFX monotherapy start with subcutaneous IFX 240mg at week 0 and 2 and then from week 4, 120mg s.c.EOW."
89605663|NCT06059989|Experimental|Combination therapy|"Group 2: Combination therapy group~Patients randomized to IFX combination therapy start with subcutaneous IFX 240mg at week 0 and 2 and then from week 4, 120mg s.c. EOW.~Patients randomized to IFX combination therapy also receive Immunosuppressives EOW."
89605664|NCT06059976||Hypnosis|"Inclusion of patients undergoing major cardiac surgery who have received perioperative hypnosis sessions from January 2023.~After obtaining their consent to participate in this study"
89605665|NCT06059950|Experimental|Mindfulness Flow Program|Mindfulness flow program, with 11 sessions conducted via Zoom video meeting and one in-person session of sport-specific session.
89605666|NCT06059924||leak|Patients with diagnosed anastomotic leakage after low rectal resection for rectal cancer UICC stage I to III
89605667|NCT06059924||noleak|Patients without anastomotic leakage after low rectal resection for rectal cancer UICC stage I to III
89605668|NCT06059898|Experimental|NOVAMag membrane|GBR procedure / membrane placement
89605669|NCT06059898|Active Comparator|Jason membrane|GBR procedure / membrane placement
89605670|NCT06059885|Experimental|Tislelizumab combined with tyrosine kinase inhibitor (TKI) treatment group|
89605671|NCT06059885|No Intervention|No-intervention group|
89605672|NCT06059859|Experimental|Augmented reality robot-assited radical prostatectomy|Robot-assisted radical prostatectomy using the Da Vinci surgical robot system (XI model; Intuitive Surgical, Sunnyvale, Calif) and a port device (Alexis; Applied Medical, Rancho Santa Margarita, Calif) system for prostate extraction. Virtual image of the prostate will be overlapped onto the endoscopic view of the Da Vinci surgical robot system using the TilePro system.
89605673|NCT06059859|Active Comparator|Robot-assited radical prostatectomy|Robot-assisted radical prostatectomy using the Da Vinci surgical robot system (XI model; Intuitive Surgical, Sunnyvale, Calif) and a port device (Alexis; Applied Medical, Rancho Santa Margarita, Calif) system for prostate extraction
89605674|NCT06059833||cases group|
89605675|NCT06059833||control group|
89605676|NCT06059807|Experimental|hyrax group|
89605677|NCT06059807|Experimental|hybrid hyrax group|
89032614|NCT00525668|Active Comparator|placebo|placebo plus glatiramer acetate
89032615|NCT02928783|Experimental|Intervention|In interventional group, we arranged individualized rehabilitation programs including home-based cardiac rehabilitation, diet education and management of daily activity for 3 months.
89518149|NCT02216812|Experimental|500 mg vitamin C|Arm will take 1 pill of 500 mg vitamin C per day for 6 weeks
89518150|NCT02216812|Placebo Comparator|Placebo|Arm will take 1 placebo pill per day for 6 weeks
88981954|NCT00400010|Experimental|Expert System Intervention|Computerized Expert System Intervention based on the Transtheoretical Model of Change: 1. Normative feedback and feedback on motivational variables during the first week of hospital stay 2. Ipsative feedback on drinking behavior and motivation to change after three months
89032616|NCT02928783|No Intervention|Control|We didn't arrange individualized rehabilitation programs including home-based cardiac rehabilitation, diet education and management of daily activity for 3 months.
88981955|NCT00400010|No Intervention|Control group|Controls received a brochure on health behavior
88981956|NCT00123552|Experimental|1|
88981957|NCT00123552|Experimental|2|
88981958|NCT00123552|Experimental|3|
88981959|NCT03352427|Experimental|Dasatinib+Everolimus|"Dasatinib = 60 mg/m2 orally twice daily~Everolimus = starting dose of 3.0 mg/m2, with titration of dosing after first cycle to keep everolimus trough level of 5-15 ug/ml~Both agents will be taken daily for 28 day cycles. Cycles will be repeated every 28 days and patients may receive up to 24 cycles."
88981960|NCT00316810|Experimental|Campath|"Day 0: Before revascularisation patients are given 500 mg of Methylprednisolone i.v. followed by Campath 30 mg i.v. infusion over 3-6 hours.~Day 1: No treatment~Day 2: Initial dose of Tacrolimus 0.05 - 0.1 mg/kg/d orally.~till Month 6: Aim at blood level of 12-15 ng/ml (try to prevent the Tacrolimus trough level falling below 12 ng/ml in the first 6 months).~Month 7-12: Maintain the Tacrolimus blood level at 6-12 ng/ml after 6 months."
89518151|NCT05433727||Mycosis fungoides group|Patients who routinely have punch skin biopsy for diagnostic purposes and who were both clinically and histopathologically diagnosed with mycosis fungoides will be included. Patients who only have mycosis fungoides patch lesion on their body, over the age of 18, and who have not received topical treatment for the last 2 weeks or systemic therapy for 4 weeks will be included. Demographic, clinical, videodermoscopy, capillaroscopy (lesional) and histopathological data will be recorded.
89518152|NCT05433727||Parapsoriasis group|Patients who routinely have punch skin biopsy for diagnostic purposes and who were both clinically and histopathologically diagnosed with parapsoriasis will be included. Patients who only have parapsoriasis patch lesion on their body, over the age of 18, and who have not received topical treatment for the last 2 weeks or systemic therapy for 4 weeks will be included. Demographic, clinical, videodermoscopy,capillaroscopy (lesional) and histopathological data will be recorded.
89518153|NCT05433259|Experimental|CRT type lens|Subjects fitted with CRT type lenses
89518154|NCT05433259|Experimental|VST type lens|Subjects fitted with VST type lenses
89518155|NCT04762186|Experimental|Dose escalation|SARS CoV-2 infected participants will receive a single infusion over 15 to 30 minutes
89518156|NCT03466645|Active Comparator|1st group, receiving vancomycin|The 1st group receives vancomycin an hour before craniotomy
89518157|NCT03466645|Active Comparator|2nd group, receiving cefazolin|The 2nd group receives cefazolin an hour before craniotomy
89518158|NCT05432557|Experimental|Group E|patients will receive ultrasound guided external oblique intercostal plain block.
89518159|NCT05432557|Experimental|Group T|patients will receive ultrasound guided subcostal transversus abdominis plane block.
89518160|NCT05432557|Placebo Comparator|Group C|patients won't receive LA injection
89518161|NCT05432479|Experimental|Active|Arm receiving investigation product (probiotic)
89518162|NCT05432479|Placebo Comparator|Placebo|Arm receiving placebo
89518163|NCT02695277|Experimental|Hybrid Procedure|Endoscopic epicardial surgical ablation (first stage) combined with endocardial catheter ablation (second stage) performed between 91 and 180 days post index procedure.
89518164|NCT02695277|Active Comparator|Catheter Procedure|Standard catheter ablation with pulmonary vein (PV) isolation (minimum lesion set) and optional additional lesions (index procedure). When required due to AF recurrence, ablation may be repeated within 6 months after the index-procedure according to clinical indications and consistent with the Heart Rhythm Society (HRS)/European Heart Rhythm Association (EHRA)/European Cardiac Arrhythmia Society (ECAS) Consensus Statement
89518165|NCT04461665|No Intervention|Control|Enroll 6 months old breast feeding infant, who have not supplement vitamin D at pediatric clinic.
89518166|NCT04461665|Experimental|VitD supplement|Enroll 4 months old breast feeding infant, and provide 10 μg vitamin D daily for 2 months.
89518167|NCT02252536|Placebo Comparator|Sugar Pill|Matching placebo, sugar pill
89518168|NCT02252536|Active Comparator|Gabapentin Enacarbil|600 mg Gabapentin Enacarbil (Horizant)
89518169|NCT05277259|Active Comparator|Extracorporeal Shock Wave Therapy|Extracorporeal shock wave therapy (ESWT) is a noninvasive treatment that involves delivery of shock waves to injured soft tissue to reduce pain and promote healing.
89518170|NCT05277259|Active Comparator|Kinesiotaping|The Kinesiotaping method is a therapeutic taping technique which alleviates pain.
89518171|NCT05277259|Active Comparator|Conventional Physical Therapy|Hotpack, therapeutic ultrasound and tens applications.
89518172|NCT03490487|Active Comparator|A antiepileptic|will receive conventional antiepileptic drugs only
89518173|NCT03490487|Experimental|B steroid|will receive oral steroid for 3 months beside conventional antiepileptic drugs
89518174|NCT05277103|Experimental|Stay-Play-Talk with iPad Intervention|Peers without disabilities will be taught to be active communication partners using an iPad with voice output app as a speech-generating device, then paired up to play with one child with ASD for 16 sessions over 8 weeks. Focal child behaviors are assessed in different pre-treatment contexts (i.e., eye tracking, structured play, and naturalistic classroom settings), and rate of communication will be collected to predict gains children make in social communication with peers after treatment.
89518175|NCT03492203|Experimental|Active Cognitive Remediation -Long-term|Participants in the long-term treatment will receive 24 weeks of active cognitive remediation. Participants will complete 24 weeks of on-line computer exercises and participate in an on-line forum to facilitate strategy monitoring and bridging strategies.
89518176|NCT03492203|Active Comparator|Active Cognitive Remediation -Short-term|Participants in the short-term treatment will receive 12 weeks of active cognitive remediation (the standard length of time in the literature). Participants will complete 12 weeks of on-line computer exercises and participate in an on-line forum to facilitate strategy monitoring and bridging strategies.
89518177|NCT03492203|Placebo Comparator|Cognitive Remediation Control|Participants in the comparison training group will login to the same training environment but the cognitive load will not adjust as it does in the experimental conditions. Participants in this group will complete 12 weeks of on-line computer exercises.
89518178|NCT05271331|Experimental|ESP block|Patient will receive ESP block one level above surgery with ropivacaine 0.35% 20 ml per side Patient will receive preoperative wound infiltration with Saline 40 ml
89518179|NCT05271331|Active Comparator|Wound infiltration|Patient will receive ESP block one level above surgery with Saline 20 ml per side Patient will receive preoperative wound infiltration with ropivacaine 0.35% 40 ml
89032617|NCT02946593|Experimental|Treatment|Participants in the treatment group will attend a once a week 7-week outdoor fall prevention program that includes didactic presentations, group discussions/problem solving, practice in strategy use, and action planning for safe community mobility.
89032618|NCT02946593|Active Comparator|Control|Participants in the control group will receive written information about preventing outdoor falls.
89518180|NCT02206828||1 GROUP|Only 1 group not predetermined
89518181|NCT03490409|Experimental|compression stocking|The intervention group will receive a thigh compression stocking, which is to be used for 24 hours a day for 14 days after surgery.
89518182|NCT03490409|No Intervention|Conventional treatment|The control group will receive conventional treatment, a compression bandage placed at the end of surgery and removed on the night of the surgery.
89518183|NCT05267197||3D Telemedicine|Clinical consultation conducted with 3D Telemedicine
89518184|NCT05267197||2D Telemedicine|Clinical consultation conducted with 2D Telemedicine
89518185|NCT03466567|Experimental|Oral semaglutide, ciclosporin, probenecid|Participants will receive oral semaglutide in treatment period 1, ciclosporin in treatment period 2, and probenecid in treatment period 3.
89518186|NCT03466567|Experimental|Probenecid, oral semaglutide, ciclosporin|Participants will receive probenecid in treatment period 1, oral semaglutide in treatment period 2, and ciclosporin in treatment period 3.
89518187|NCT03466567|Experimental|Ciclosporin, probenecid, oral semaglutide|Participants will receive ciclosporin in treatment period 1, probenecid in treatment period 2, and oral semaglutide in treatment period 3.
89518188|NCT01209767|Experimental|cryolipolysis|
89518189|NCT01209767|Active Comparator|subcision|
89518190|NCT01209767|Active Comparator|Control|Areas with cellulite that had no treatment performed were considered the control arm.
89518191|NCT03466489|Experimental|Floraseal|The surgical site will first be cleaned with isopropyl alcohol. Once the site is dry, alcohol based chlorhexidine gluconate preparatory solution will be applied to the surgical site. Once dry, the FloraSeal surgical preparatory solution will be applied per the manufacturers recommendations. The extremity will be draped in sterile fashion however adhesive drapes over the surgical site itself will not be applied.
89518192|NCT03466489|No Intervention|Control|The operative site is first cleaned with isopropyl alcohol. Once the site is dry, alcohol based chlorhexidine gluconate preparatory solution will be applied to the surgical site. The operative site will then be draped in sterile fashion. An iodine impregnated adhesive drape will then be applied to the surgical site.
89518193|NCT03490175||All patients|Patients undergoing general anesthesia for elective surgery
89518194|NCT02252146|Experimental|IMO-8400|IMO-8400 0.3 mg/kg twice weekly, 0.6 mg/kg twice weekly, or 1.2 mg/kg twice weekly
89518195|NCT03130153|Experimental|hypertensives on Aspirin mouthwash|
89518196|NCT03130153|Active Comparator|non-hypertensives on Aspirin mouthwash|
89518197|NCT03130153|Active Comparator|hypertensives on Saline mouthwash|
89518198|NCT05391373|Experimental|Laughter Therapy Group|The women with breast cancer in the intervention group received two sessions of laughter therapy per week for eight weeks.Each laughter therapy session lasted 40 minutes.
89518199|NCT05391373|No Intervention|Control group|The control group did not receive any intervention during the study period.
89518200|NCT03466333|Experimental|Investigational medicinal product|Oral enalapril maleate once daily: 5mg for 1 week, then 10mg for 2 weeks, then 20mg maintenance (for total of 6 months postpartum)
89518201|NCT03466333|Placebo Comparator|Placebo|Oral placebo once daily for 6 months postpartum
89518202|NCT03466333|No Intervention|Observational arm|For participants who decline to be take part in the interventional part of the study (decline randomisation to IMP/placebo) however they consent to the observational components of the study (serial echocardiography and biomarkers postpartum).
89518203|NCT05382715||Cohort 1|
89518204|NCT03492047|Active Comparator|control|they will receive paclitaxel 80 mg/m2 once per week for 12 weeks only
89518205|NCT03492047|Experimental|high dose N-acetyl cysteine|they will receive paclitaxel 80 mg/m2 once per week for 12 weeks and high dose N-acetylcysteine (1200 mg twice daily) for the paclitaxel treatment period
89518206|NCT03492047|Experimental|low dose N-acetyl cysteine|they will receive paclitaxel 80 mg/m2 once per week for 12 weeks and low dose N-acetylcysteine (600mg twice daily) for the paclitaxel treatment period.
89518207|NCT02251990|Experimental|Immediate Treatment Group (ITG): Grazoprevir/Elbasvir|Participants receive a grazoprevir/elbasvir FDC tablet once daily (q.d.) by mouth during a 12-week Active Treatment period (Week 1 to Week 12) and are followed-up for 24 weeks to Week 36.
89518208|NCT02251990|Placebo Comparator|Deferred Treatment Group (DTG): Placebo > Grazoprevir/Elbasvir|Participants receive a placebo tablet q.d. by mouth for 12 weeks (placebo treatment period). After a 4-week Follow-Up period, participants receive open-label grazoprevir/elbasvir FDC during a 12-week Active Treatment period (Week 16 to Week 28). Participants are then followed-up for 24 weeks to Week 52.
89518209|NCT03490097|Experimental|Group I|low dose of simvastatin10 mg plus sofosbuvir 400mg / daclatasvir 60 mg daily for 12 weeks.
89518210|NCT03490097|Active Comparator|Group II|sofosbuvir plus daclatasvir
89518211|NCT04453735|Active Comparator|Intervention|Atorvastatin mylan 40 mg once daily
89518212|NCT04453735|No Intervention|Control|No statin therapy
89518213|NCT03490019|Experimental|Metformin Therapy|Metformin therapy once daily for 24 weeks with a dose of 500, 850 or 1000 mg depending on body weight
89518214|NCT03491969|Experimental|Alpha-Lipoic Acid(α-LA)|Double blind treatment period consisted of treatment with CHF standard treatments, followed by α-LA 200 mg tid over a total duration of 24 months.
89032619|NCT02928822|Experimental|Experimental Group|Virtual reality based sensorimotor aphasia therapy.
89032620|NCT02928822|Active Comparator|Control Group|Conventional aphasia therapy.
89032621|NCT00525707|Experimental|1|tezosentan delivered i.v. at 20 mL/h (5 mg/h) for 30 min followed by 4ML/h (1 mg/h) for 23.5 to 71.5 h (24 to 72 h in total)
89032622|NCT00525707|Placebo Comparator|2|
89032623|NCT02929017|Other|Intervention|Group will receive SUPPORT, an intervention that provides information about the disease, self-management strategies, and introduction to advanced care planning in a format with enhanced content available across multiple domains (face-to-face, printed material, and digitally (via use of a tablet) delivered by an interventionist.
89032624|NCT02929017|Other|Usual Care|Group will receive usual standard-of-care, and be provided with currently available printed material for information about their illness.
89032625|NCT00526214|No Intervention|1|In the control group, patients will not take the drug. We do not use placebo drugs.
89518215|NCT03491969|Placebo Comparator|Placebo|Double blind treatment period consisted of treatment with CHF standard treatments, followed by Placebo 200 mg tid over a total duration of 24 months.
89518216|NCT05349409|Experimental|Treatment group|SHR-A1811, Fluzoparib
89032626|NCT00526214|Experimental|2|In the intervention group, patients will take celecoxib.
89032627|NCT02928744|Experimental|COPD|
89032628|NCT02928705||telemedicine group|physician operated telemedical prehospital analgesia
89032629|NCT02928705||historical control group|prehospital analgesia by on-scene EMS physicians
89032630|NCT00526253|Active Comparator|Low Dose|Patient will undergo biopsy. Skeletal myoblasts will be cultured in growth media.
89032631|NCT00526253|Active Comparator|High Dose|Patient will undergo biopsy. Skeletal myoblasts will be cultured in growth media.
89518217|NCT02251912|Experimental|Active|Intranasal oxytocin doses 2-3 times/day for 12 weeks
89518218|NCT02251912|Placebo Comparator|Control|Intranasal placebo doses 2-3 times/day for 12 weeks
89518219|NCT04453579||116 patients completed a survey|116 patients were assessed during the Italian lockdown by means of a telephone interview performed by a trained researcher. The interview was composed of socio-demographic items (e.g. employed before and during the lockdown, own accommodation during lockdown etc.) and questions about physical and mental health in relation to the COVID-19 emergency
89518220|NCT01976273|Active Comparator|1064nm Q-switch Laser|The 1064 Q-Switch Laser is a medical device that uses a focused laser to remove dark pigment (color) from the skin.
89518221|NCT01976273|Active Comparator|Glycolic Acid Peels|A Glycolic Acid Chemical Peel is a mild skin treatment used to correct uneven texture and color by removing dead cells from the skin's outermost layer.
89518222|NCT02206048|Experimental|High-Resolution Microendoscopy (HRME)|Before participant's cold knife cone biopsy (CKC), topical application of 0.01% proflavine solution applied to cervix. HRME probe applied to cervix and high-resolution images obtained. Participant undergoes cervical biopsies of any abnormal areas noted with colposcopy and/or HRME. Immediately following the CKC, the removed surgical specimen evaluated. Proflavine reapplied to surgical specimen and repeat evaluation with HRME performed and high-resolution images obtained.
89518223|NCT01704209|Experimental|Fibroblast Treatment|The fibroblast treatment will be randomly injected into one side of the face.
89518224|NCT01704209|Placebo Comparator|Vehicle|The vehicle will be injected randomly to the other side of the face.
89518225|NCT03489785||Movement|If there is unexpected movement
89518226|NCT03489785||No movement|If there is no unexpected movement
89518227|NCT03466021|Active Comparator|Liraglutide|Liraglutide injection 3.0 mg daily
89518228|NCT03466021|Placebo Comparator|Placebo|Placebo, matching injection pen
89518229|NCT03489083|Experimental|Trained Group|Subjects performing strength training three times per week for twelve weeks.
89518230|NCT03489083|Placebo Comparator|No Training Group|"Subjects performing placebo stretching/relaxing session once a week (for adherence purposes) for twelve weeks."
89518231|NCT03465943|Active Comparator|Ringer|This group will receive 1 L of Ringer's solution as a preload
89518232|NCT03465943|Active Comparator|Voluven|This group will receive 500 ml of 6% hydroxyethyl starch ( Voluven ) and 500 ml Ringer's solution as a preload
89518233|NCT00793169||lidocane|Patients undergoing Mohs micrographic surgery of the face or neck will have their blood drawn before, during, and after the procedure.
89518234|NCT05335447|Experimental|Period 1 - Absolute Bioavailability|
89518235|NCT05335447|Experimental|Period 2 - Mass Balance|
89518236|NCT03465865||ILM-flap|Patients after surgical repair of macular holes with ILM-flap transposition are invitied to a follow-up for optical coherence tomography and visual acuity testing one year after surgery
89518237|NCT04112407|Experimental|Control|Standard preparation of the surgical site without P. acnes pretreatment
89518238|NCT04112407|Experimental|BPO Group|Pretreatment with 10% Benzoyl peroxide body wash for two consecutive days of washes prior to surgery at home. The anterior shoulder area is wet before treatment; the wash is massaged in for 20 seconds producing a lather and washed off, patting dry.
89518239|NCT04112407|Experimental|BPO and Phototherapy|2 days of benzoyl peroxide washes and 3 treatments of blue light phototherapy. Pretreatment with 10% Benzoyl peroxide body wash for two consecutive days of washes prior to surgery at home. The anterior shoulder area is wet before treatment; the wash is massaged in for 20 seconds producing a lather and washed off, patting dry. The blue light phototherapy is administered to the shoulder for 3 minutes on three occasions; 2 days before, the day before surgery and in the preoperative area by the patient.
89518240|NCT03462277||Control group|Control group was defined as people with negative findings in coronary angiograms.
89518241|NCT03462277||Coronary Heart Disease group|CHD patients was defined as at least one lesion in a coronary artery or branches in coronary angiograms.
89518242|NCT02205814|Experimental|Fasitibant low dose|Drug: solution for intra-articular injection
89518243|NCT02205814|Experimental|Fasitibant intermediate dose|Drug: solution for intra-articular injection
89518244|NCT02205814|Experimental|Fasitibant high dose|Drug: solution for intra-articular injection
89518245|NCT02205814|Placebo Comparator|PLACEBO|Drug: solution for intra-articular injection
89518246|NCT02662985|Active Comparator|Group 1|"In Treatment Period-1:~Patients in this group were administered secukinumab with 12 weeks of treatment from baseline.~In Treatment Period-2:~Patients continued to receive the same active dose of secukinumab every 4 weeks until Week 24~In Treatment Period 3 (extension period):~the extension period allowed responder patients the possibility to continue open-label secukinumab treatment up to Week 52"
89518247|NCT02662985|Placebo Comparator|Group 2|"In Treatment Period-1:~Patients received placebo at baseline and same time points as secukinumab until Week 8.~In Treatment Period-2:~Patients commenced open-label secukinumab every 4 weeks from Week 12, as follows, based on their clinical characteristics at Week 12~In Treatment Period-3:~Open-label secukinumab continued to be assigned to patients"
89518248|NCT03462199|Placebo Comparator|Placebo|
89518249|NCT03462199|Experimental|Actazin High Dose|
89518250|NCT03462199|Experimental|Actazin Low Dose|
89518251|NCT03462199|Active Comparator|Control Formula|
89032632|NCT00526253|Placebo Comparator|Control|Patient will undergo biopsy of muscle tissue and biopsy tissue will be sent to lab.
89032633|NCT02928939||Multimorbid patients|
89032634|NCT04692935||Asian lung adenocarcinoma|Asian LUADs patients who had broad-panel next-generation sequencing (NGS) performed on their primary tumor between January 2018 and December 2019 at the department of thoracic surgery of Peking University People's Hospital
89518252|NCT03462199|Experimental|Livaux High Dose|
89518253|NCT03462199|Experimental|Livaux Low Dose|
89518254|NCT03489005|Other|Treatment Period 1|"Interventions to be administered:~Schema 1:~400 mg BIA 5-1058~1200 mg BIA 5-1058~Placebo~Moxifloxacin~Schema 2:~1200 mg BIA 5-1058~Placebo~400 mg BIA 5-1058~Moxifloxacin"
89518255|NCT03489005|Other|Treatment Period 2|"Interventions to be administered:~Schema 1~1200 mg BIA 5-1058~Moxifloxacin~400 mg BIA 5-1058~Placebo~Schema 2:~Placebo~Moxifloxacin~1200 mg BIA 5-1058~400 mg BIA 5-1058"
89518256|NCT03489005|Other|Treatment Period 3|"Interventions to be administered:~Schema 1~Placebo~400 mg BIA 5-1058~Moxifloxacin~1200 mg BIA 5-1058~Schema 2~400 mg BIA 5-1058~1200 mg BIA 5-1058~Moxifloxacin~Placebo"
89518257|NCT03489005|Other|Treatment Period 4|"Interventions to be administered:~Schema 1~Moxifloxacin~Placebo~1200 mg BIA 5-1058~400 mg BIA 5-1058 Schema 2~1. Moxifloxacin 2. 400 mg BIA 5-1058 3. Placebo 4. 1200 mg BIA 5-1058"
89518258|NCT03462121|Experimental|RPh201|A 26-week schedule consisting of twice-weekly subcutaneous administration of 400 μL of the IMP (20 mg RPh201).
89518259|NCT03462121|Placebo Comparator|Placebo|A 26-week schedule consisting of twice-weekly subcutaneous administration of 400 μL of the vehicle control.
89518260|NCT03462043|Active Comparator|Sequence A|
89518261|NCT03462043|Active Comparator|Sequence B|
89518262|NCT03462043|Active Comparator|Sequence C|
89518263|NCT03462043|Active Comparator|Sequence D|
89518264|NCT01631812|Experimental|SPM 962|
89518265|NCT02323295|Experimental|Non Surgical-Radiation Only|Non-surgical candidates receive 72 up to 77.l4 Gy of radiation depending on the histology (72 Gy for osteosarcoma and chondrosarcoma and 77.4 Gy for chordoma
89518266|NCT02323295|Experimental|Malignant Tumor Surgery And Radiation|The standard treatment includes pre-operative radiation of 50.4 Gy, followed by a recovery period of approximately 4 to 5 weeks. Surgery involves removing the malignant tumor in the sacrum in one piece, preferably with a cuff of normal tissue around the tumor. After approximately 6 weeks of recovery, the patient is treated with another 19.8 Gy up to 27 Gy of radiation postoperatively depending on the final margin status (higher for gross residual disease). If the wound is not healed or there is another medical reason to delay adjuvant radiation, then radiation may begin later.
89518267|NCT03461809||Ocular motor nerve palsy treated by ocular acupuncture|Ocular motor nerve palsy patients who received ocular acupuncture treatment
89518268|NCT02215954|Experimental|Treatment arm [1]: FE 999169|One sachet on the day before colonoscopy, and another sachet on the day of colonoscopy
89518269|NCT02215954|Experimental|Treatment arm [2]: FE 999169|Two sachets on the day before colonoscopy
89518270|NCT02215954|Active Comparator|Treatment arm [3]: Niflec|One to two pack(s) on the day of colonoscopy
89518271|NCT04641949|Active Comparator|Methoxyflurane|Inhalation methoxyflurane 99,9%, 3 ml, single dose. Intravenous NaCl 9 mg/ml, XX ml, single dose.
89518272|NCT04641949|Active Comparator|Fentanyl|Intravenous fentanyl 50 microgr/ml, XX ml, single dose Inhalation NaCl 9 mg/ml, 3 ml, single dose.
89518273|NCT04641949|Placebo Comparator|Placebo|Intravenous NaCl 9 mg/ml, XX ml, single dose. Inhalation NaCl 9 mg/ml, 3 ml, single dose.
89518274|NCT01941719|Experimental|enhanced foot care education|In addition to the standard diabetic foot self-care instruction, the importance of daily foot self-care was reinforced at baseline by viewing personal barefoot plantar pressure in gait
89518275|NCT01941719|Active Comparator|Standard Foot Care Education|Reviewed the standard diabetic foot self-care instructions, including daily foot inspection and proper footwear at all times.
89518276|NCT02215252|Experimental|PF-05089771|
89518277|NCT02215252|Experimental|Placebo|
89518278|NCT02215252|Experimental|Pregabalin|
89518279|NCT02215252|Experimental|PF-05089771 + Pregabalin|
89518280|NCT04630093|Experimental|Panel-based pharmacogenetic genotyping|All patients will receive clinical preemptive pharmacogenetic testing. Genotype results and consult notes will returned in the EHR pre-emptively. Data on implementation success metrics and PROs via patient report and TSQM measures will be collected. In addition, data on effectiveness outcomes and socioeconomic measures will be collected via the EHR and patient report, respectively.
89518281|NCT03488771||Control|Kidney transplant recipients without clinical/laboratory/biopsy signs of infection or graft rejection
89518282|NCT03488771||Infection|Kidney transplant recipients presenting with clinical or laboratory signs of infection (bacterial or viral)
89518283|NCT03488771||Rejection|Kidney transplant recipients presenting with clinical, laboratory or biopsy signs of graft rejection.
89518284|NCT03461731|Sham Comparator|Control|Participant will receive a sham treatment that consists of just the 660-nm aiming beam
89518285|NCT03461731|Experimental|800 nm laser|800 nm laser will be applied at 4.4 Joules per square cm on the forearm during 40 repetitive hand grips
89032635|NCT04692935||Caucasian lung adenocarcinoma|Caucasian LUADs patients who had targeted NGS (Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets [MSK-IMPACT]) will be identified in the AACR GENIE database, which consists of 6673 primary lung adenocarcinoma samples with clinical annotations
89032636|NCT03457584|Active Comparator|BSS arm|BSS is given at the end of surgery
89032637|NCT03457584|Experimental|air arm|air-tamponade is given at the end of surgery
89518286|NCT03461731|Experimental|combination laser|905 nm and 800 nm will be applied at 4.4 joules per square cm with a total of 8.8 Joules per square cm during 40 repetitive handgrips.
89518287|NCT03461731|Experimental|905 nm laser|905 nm laser will be applied at 4.4 Joules per square cm on the forearm during 40 repetitive hand grips
89518288|NCT04894721|Experimental|Experimental Group|The EG receives ivermectin 0,6mg/kg of weight orally on days 1 (one) and 7 (seven) plus standard biosecurity care
89518289|NCT04894721|Placebo Comparator|Control Group|The CG receives a placebo on days 1 (one) and 7 (seven) plus standard biosecurity care
89518290|NCT03129607||POPF group|Patients who had POPF will be included into POPF group.
89518291|NCT03129607||Observation group|Patients without POPF will be included into observation group.
89518292|NCT02204410|Experimental|Omega-3 Fatty Acids and Stimulant Treatment|Participants will receive open-label treatment with Omega-3 Fatty Acids. All participants must also be treated with a stable dose of a traditional ADHD medication at the time of enrollment.
89518293|NCT05149079|Placebo Comparator|Placebo (whey protein supplement)|Participants will consume 18 g of the placebo whey protein supplement each day for 12 weeks.
89518294|NCT05149079|Active Comparator|Cod protein hydrolysate supplement|Participants will consume 18 g of the cod protein supplement each day for 12 weeks.
89518295|NCT02522143|Sham Comparator|Informational Sessions|Control intervention consists of informational sessions describing BPD characteristics/ treatment and time- / stress-management skills
89518296|NCT02522143|Experimental|Condensed-DBT treatment intervention|Condensed-DBT treatment intervention includes all DBT components, tailored to students.
89518297|NCT04043377|Experimental|All patients|
89518298|NCT03488537|Other|patients referred for colonoscopy|All patients referred for colonoscopy where invited to participate in our study.
89518299|NCT03488459|Other|Routine preoperative information from a nurse|
89518300|NCT03488459|Experimental|Additional information support from a psychologist|
89518301|NCT02250274|Other|LAIV 2014-15|Will receive LAIV this year. Includes 5-8 year olds and approximately half of the 9-17 year olds. Prior history includes vaccine failures, vaccinated/uninfected and unvaccinated/uninfected last year. PBMC available for those who were infected last year, all ages.
89518302|NCT02250274|Other|IIV 2014-15|Will receive IIV this year. Includes only 9-17 year olds (unless shortages of LAIV encountered). Prior history includes vaccine failures, vaccinated/uninfected and unvaccinated/uninfected last year. PBMC available for those who were infected last year, only 9-17 year olds.
89518303|NCT03129997|Active Comparator|Gluten test food|volunteers will receive 2 corn based muffins containing 7,5g of gluten/muffin to be consumed daily for 3 weeks
89518304|NCT03129997|Placebo Comparator|Placebo test food|volunteers will receive 2 corn based muffins to be consumed daily in any meal for 3 weeks
89518305|NCT03465631|Experimental|SMART Glove system with dual-tDCS|VR-based SMART Glove system with dual-tDCS
89518306|NCT03465631|Sham Comparator|SMART Glove system with sham-tDCS|VR-based SMART Glove system with sham-tDCS
89518307|NCT04772092||Seniors|70 years of age and over, inpatients or outpatients
89518308|NCT04255511|Experimental|Twin block|Removable Functional appliance
89518309|NCT04255511|Active Comparator|Fixed appliance|Preadjusted fixed appliance
89518310|NCT03465553|Experimental|Short course radiotherapy|The radiotherapy is delivered over 2 days with accelerated hypo-fractionation.
89518311|NCT03488381|Experimental|Soccer Heading|
89518312|NCT03488381|Sham Comparator|Kicking-Control|
89518313|NCT05230849|Active Comparator|control group|conventional physiotherapy treatment
89518314|NCT05230849|Experimental|dry needling treatment|group that includes a dry needling treatment on the tibialis anterior and posterior muscles.
89518315|NCT04461431|Experimental|Knee joint lateral reconstruction group|
89518316|NCT03465475||Group 1|The patient who receive 300 mL fresh gas flow with AGC mode during the general anesthesia
89518317|NCT03465475||Group 2|The patient who receive 600 mL fresh gas flow with AGC mode during the general anesthesia
89518318|NCT03465475||Group 3|The patient who receive 600 mL fresh gas flow with manuelly during the general anesthesia
89518319|NCT04461119|Experimental|Evenamide 7.5 mg bid|Evenamide capsules 7.5 mg BID for a total of 28 dosing days
89518320|NCT04461119|Experimental|Evenamide 15 mg bid|Evenamide capsules 15.0 mg BID for a total of 28 dosing days
89518321|NCT04461119|Placebo Comparator|Placebo|Matching placebo capsules BID for a total of 28 dosing days
89518322|NCT03465397|Experimental|experimental|Biomarkers driven immunosuppressive therapy: the immunosuppressive treatment of the patients is determined according to the result of 2 biomarkers of immunological risk
89518323|NCT03465397|No Intervention|control|All patients receive the usual triple immunosuppressive treatment, without depending on the results of any biomarker.
89518324|NCT03488303||Main group|Study has only one group
89518325|NCT03461575|Experimental|HU007|"Cyclosporine 0.02%, trehalose 3%~1 drop b.i.d at 12hr interval for 12 weeks"
89518326|NCT03461575|Active Comparator|Restasis|"Cyclosporine 0.05%~1 drop b.i.d at 12hr interval for 12 weeks"
89518327|NCT03461575|Active Comparator|Moisview|"trehalose 3%~1 drop b.i.d at 12hr interval for 12 weeks"
89518328|NCT03131843|Experimental|Alcohol|Alcohol will be wiped on the vaccine injection site immediately before vaccine injection.
89518329|NCT03131843|Placebo Comparator|No alcohol|Alcohol will be wiped adjacent to the vaccine injection site immediately before vaccine injection.
89518330|NCT03461341||Patients post curative intent surgery for esophageal cancer|Patients post potentially curative surgery for cTxNxM0 esophageal or esophagogastric junction (Siewert type I, II and III) cancer.
89518331|NCT04125173|Active Comparator|1. Pneumoperitoneum pressure = 15mmHg|1. Pneumoperitoneum will be set at 15mmHg
89518332|NCT04125173|Active Comparator|2. Pneumoperitoneum pressure = 12mmHg|2.Pneumoperitoneum will be set at 12mmHg
88981961|NCT00316810|Active Comparator|ATG|"Day 0: Prior to revascularisation patients are given 500 mg of Methylprednisolone i.v. followed by a single shot of a polyclonal antilymphocyte preparation. Tacrolimus will be given immediately after transplantation(0.05-0.1 mg/kg/d) orally. Preoperative loading dose MMF: 2 g orally.~From Day 1: Total initial daily dose of 0.05-0.1 mg/kg administered orally in 2 doses. Blood trough levels 12-15 ng/ml during the first 6 months and maintain blood levels 6-12 ng/ml after 6 months. Total daily dose of MMF is 2 g administered orally in 2 doses. Patients will receive Methylprednisolone 250 mg IV 12h post surgery and 125 mg of Methylprednisolone 24 h post transplantation.~Steroid taper (orally):~Day 2: 100 mg of Prednisolon Day 3: 80 mg of Prednisolon Day 4: 60 mg of Prednisolon Day 5: 40 mg of Prednisolon Day 6: 25 mg of Prednisolon Day 21: 20 mg of Prednisolon~Reduction by 5 mg in two week intervals/complete withdrawal by 3 months post-tx."
88981962|NCT00092391|Active Comparator|Control Group|M-M-R(TM) II at current release potency
88981963|NCT00092391|Experimental|Mumps Expiry Group 1|M-M-R(TM) II at intermediate expiry potency
88981964|NCT00092391|Experimental|Mumps Expiry Group 2|M-M-R(TM) II at expiry potency
89518333|NCT04125173|Active Comparator|3. Pneumoperitoneum set at 10mmHg|3. Pneumoperitoneum will be set at 10mmHg
89518334|NCT05072561|Experimental|Experimental|
89518335|NCT02213380|Other|group GA|General anesthesia
89518336|NCT02213380|Other|group RA|Regional anesthesia
89518337|NCT03488147|Experimental|Esomeprazole Only|Subjects assigned to the treatment group 'A' will receive one 20 mg esomeprazole tablet daily starting 1 week prior to the cervical operation and will continue to receive the esomeprazole until the end of the study
89518338|NCT03488147|Active Comparator|Esomeprazole and Placebo Oral Tablet|Subjects belonging to the treatment group 'B' will receive one placebo tablet (physically resembling an esomeprazole tablet 20 mg ) daily starting one week prior to the cervical operation. Subjects will then receive one 20 mg esomeprazole daily starting immediately after the operation and will continue to receive the esomeprazole until the end of the study.
89518339|NCT03488147|Placebo Comparator|Placebo Oral Tablet Only|Subjects belonging to the treatment group 'C' will receive one placebo tablet (physically resembling a 20 mg esomeprazole tablet) daily starting one week prior to the cervical operation and will continue to receive the placebo tablet until the end of the study
89518340|NCT05234801||DARCO™ Headed Cannulated Screw|Patients who received a device from the DARCO™ Headed Cannulated Screw family of devices during routine lower limb surgery.
89518341|NCT05234801||ORTHOLOC™ 3Di Recon-Midfoot/Flatfoot System|Patients who received a device from the ORTHOLOC™ 3Di Recon-Midfoot/Flatfoot System family of devices during routine lower limb surgery.
89518342|NCT05234801||ORTHOLOCTM 3Di 2 Foot Reconstruction System: CROSSCHECK™ Module|Patients who received a device from the ORTHOLOCTM 3Di 2 Foot Reconstruction System: CROSSCHECK™ Module family of devices during routine lower limb surgery.
89518343|NCT03797261|Experimental|Venetoclax + AMG 176|Venetoclax and AMG 176 will be administered in combination. Different combinations of dose levels for venetoclax and AMG 176 will be explored.
89518344|NCT03487991|Experimental|personalized behavioral recommendations|Will receive recommendations for altering sleep related behavior based on data from in-home monitoring.
89518345|NCT03487991|No Intervention|educational control|Will receive the data without recommendations. Will receive personalized recommendations after the follow up assessment.
89518346|NCT03487835|Experimental|Kinesiotape group|
89518347|NCT03487835|Experimental|Control group|
89518348|NCT03447041||the keratoplasty group|Patients with limbal dermoid who accepted cornea transplantation surgery after 1 year were performed quick CSF from Adaptive Sensory Technology company
89518349|NCT03447041||the normal group|normal children without ocular disease
89518350|NCT03413735|Placebo Comparator|Placebo Confection|Confection without green tea extract consumed daily for 4 weeks
89518351|NCT03413735|Experimental|Green Tea Extract-Confection|Confection with green tea extract consumed daily for 4 weeks
89518352|NCT02202850||Etanercept First|Adults patients with AS receiving Etanercept as first biologic, according to prevailing reimbursement criteria in Belgium
89518353|NCT02202850||Etanercept second|Adults patients with AS receiving Etanercept as second biologic, according to prevailing reimbursement criteria in Belgium
89518354|NCT03489395|Experimental|Edoxaban|Used for Treatment. All patients will receive edoxaban 60 mg once a day, with open-label design, for 4 weeks. Edoxaban daily dose will be reduced to 30 mg/day in case of: body weight ≤60 kg, or concomitant therapy with verapamil/quinidine/dronedarone.
89518355|NCT03489317||No metabolic syndrome|Participants who do not fulfill any of the five criteria for metabolic syndrome defined by the International Diabetes Federation.
89518356|NCT03489317||Metabolic syndrome- partial|Participants who fulfill one or two of the five criteria for metabolic syndrome defined by the International Diabetes Federation.
89518357|NCT03489317||Metabolic syndrome- full|Participants who fulfill three or more of the five criteria for metabolic syndrome defined by the International Diabetes Federation.
89518358|NCT02212678|Experimental|N-acetylcysteine|Subjects will be provided 6000 mg/day of N-acetylcysteine (capsule) to be divided into 2 equal daily doses and taken orally for approximately 28 days
89518359|NCT03489239|Experimental|Single Arm|SingleArm: TAF 25 mg
89518360|NCT04870775|Experimental|Experimental group|The intervention administered to the experimental group will be a mindfulness training program
89518361|NCT04870775|No Intervention|Control group|The control group will not receive any intervention
89518362|NCT04761250|Experimental|Intervention|Lifestyle intervention i.e. diet, exercise, smoking cessation, alcohol limitations, dietary supplementation
89518363|NCT03489161|Experimental|Buprenorphine|Buprenorphine administered in the emergency room after patients presenting to the emergency department (ED) due to opioid OD who have been treated with opioid antagonist (naloxone) and are stable and alert.
89518364|NCT04804709|Experimental|FUS using Oral Panobinostat|All patients enrolled in the study will be treated with oral Panobinostat after receiving Focused Ultrasound treatment (FUS) with microbubbles and neuro-navigator-controlled sonication.
89032638|NCT02928666|Experimental|DSS for recommendation interactions|participants may use the DSS for mitigating interactions between recommendations to detect interactions between guideline recommendations and find sets of non-conflicting recommendations. In addition, they may look at the relevant clinical guidelines and additional medical knowledge sources regarding drug-drug relationships, indications and contraindications.
89518365|NCT04690673|Experimental|Study group|All healthy volunteers are in this group. They receive 1g paracetamol orally. Saline-, urine-, venous blood and fingerprick samples will be collected at timely intervals.
89518366|NCT03104075|Active Comparator|Prevnar 13|Prevnar 13 (Pneumococcal 13valent Conj Vaccine Diphtheria CRM197 Protein) will be administered at the single 0.5 ml dose, by intramuscular injection with routine clinical care.
89518367|NCT03104075|Active Comparator|Pneumovax 23|Pneumovax 23 (Pneumococcal Vaccine Polyvalent) will be administered at the single 0.5ml dose, by intramuscular injection with routine clinical care.
89032639|NCT02928666|No Intervention|No DSS|participants use only the relevant clinical guidelines and additional medical knowledge sources regarding drug-drug relationships, indications and contraindications to detect interactions between guideline recommendations and find sets of non-conflicting recommendations
89032640|NCT02947256|Active Comparator|standard laparoscopic cholecystectomy|This included the classic dissection of Calot's triangle to achieve the CVS, with separate clipping and division of cystic duct and artery.
89032641|NCT02947256|Experimental|RI approach|"Retroinfundibular laparoscopic cholecystectomy: This included separation of the lower third of GB from its bed down to its pedicle (artery and duct) with mass ligation of both.~Operative procedure of by RI approach:"
89518368|NCT03038087|Experimental|SENSE Device Monitoring in ICH Patients|"The SENSE device transmits a low power tailored electro-magnetic (EM) pulse in the radio-frequency range across the patient's brain and detects changes in the signal that may indicate intracranial hemorrhage. The device consists of two parts:~A molded plastic headpiece containing the antenna array, and~A processing control unit that contains:~The driving electronics for the array;~A spectrum analyzer coupled with a computer; and,~The operating software that controls the device function and data acquisition, processing and archiving.~For this study, the research personnel will place the headset over the subject's head. The headset will be sized to fit snuggly. Each headset is marked with a unique headset identification number. The patient-contacting components of the molded plastic form are made from a medical grade (USP Class VI), biocompatible plastic and foam."
89518369|NCT03487679|Experimental|Fasting|Participants will undergo one day of habitual eating followed by 36 hours of water only fasting and final day of habitual eating of the exact same diet consumed on the first eating day. Blood draws will be performed on Day 1 in a 10-12 hr fasted state and 2 hour postprandial state and again on Day 3 in a 36hr fasted state and a 2 hour post prandial state. Microbiome samples and blood glucose data will be collected throughout the course of the study.
89518370|NCT03487601|Active Comparator|Active tDCS|Active transcranial direct current stimulation: Participants will undergo five consecutive days (Monday-Friday) of active stimulation beginning the Monday after their on-study chemotherapy administration. Questionnaires and cognitive assessment will be completed on the first and last days of stimulation (i.e., Monday and Friday). On all 5 days, participants will engage in cognitive tasks while receiving stimulation (either active or sham) in order to maximize stimulation effects 43. In order to assess for duration of subjective effects, participants will complete self-report measures of subjective fatigue, cognitive function and QOL immediately prior to their next chemotherapy (approximately 10-14 days after completion of stimulation).
89518371|NCT03487601|Sham Comparator|Sham tDCS|Sham transcranial direct current stimulation: Participants will undergo five consecutive days (Monday-Friday) of sham stimulation beginning the Monday after their on-study chemotherapy administration. Questionnaires and cognitive assessment will be completed on the first and last days of stimulation (i.e., Monday and Friday). On all 5 days, participants will engage in cognitive tasks while receiving stimulation (either active or sham) in order to maximize stimulation effects 43. In order to assess for duration of subjective effects, participants will complete self-report measures of subjective fatigue, cognitive function and QOL immediately prior to their next chemotherapy (approximately 10-14 days after completion of stimulation).
89518372|NCT03487523|Active Comparator|Intervention 1|Text message (SMS Message)
89518373|NCT03487523|Active Comparator|Intervention 2|Text message (SMS Message)
89518374|NCT03487523|No Intervention|Intervention 3|no intervention
89518375|NCT03486041|Experimental|immediate ComB|12 weekly sessions of ComB treatment in individual therapy, following a detailed manual.
89518376|NCT03486041|Placebo Comparator|Minimal Attention Control|Weekly brief phone call from therapist to check on participant safety, medication changes if any, and recent stressors. After week 12, participants in this arm received delayed ComB [as in the Experimental condition -- 12 weekly sessions of individual therapy for TTM based on ComB model].
89518377|NCT03485885||Maqui Berry Extract (MBE)|To be tested for the extracts bioavailability
89518378|NCT04388501|Experimental|Treatment Sequence ABC|Participants will receive milvexian capsule once daily (qd) for 5 days (Treatment A) in Period 1 followed by Atorvastatin tablets qd for 5 days (Treatment B) in Period 2 followed by milvexian capsules qd and atorvastatin tablets qd for 5 days (Treatment C) in Period 3. Each period is separated by a washout period of 7 days.
89518379|NCT04388501|Experimental|Treatment Sequence BCA|Participants will receive Treatment B in Period 1 followed by Treatment C in Period 2 and Treatment A in Period 3. Each Period is separated by a washout period of 7 days.
89518380|NCT04388501|Experimental|Treatment Sequence CAB|Participants will receive Treatment C in Period 1 followed by Treatment A in Period 2 and Treatment B in Period 3. Each Period is separated by a washout period of 7 days.
89518381|NCT04388501|Experimental|Treatment Sequence CBA|Participants will receive Treatment C in Period 1 followed by Treatment B in Period 2 and Treatment A in Period 3. Each Period is separated by a washout period of 7 days.
89518382|NCT04388501|Experimental|Treatment Sequence ACB|Participants will receive Treatment A in Period 1 followed by Treatment C in Period 2 and Treatment B in Period 3. Each Period is separated by a washout period of 7 days.
89518383|NCT04388501|Experimental|Treatment Sequence BAC|Participants will receive Treatment B in Period 1 followed by Treatment A in Period 2 and Treatment C in Period 3. Each Period is separated by a washout period of 7 days.
89518384|NCT03485807|Experimental|Mindfulness Training (MT)|
89605678|NCT06059781|Experimental|Rhtyhmical auditory stimulation and Visual cues (Experimental group)|"For auditory stimulation, walking exercises are performed on a flat floor walking path without rhythmic or musical influence. Rhythmical auditory stimulation (RAS) is produced by using Metronome App on a mobile phone.~For visual stimulation, white chalk will use to draw visual signals on the ground. For gait recovery, a 10-meter walkway will draw on the floor with parallel lines 2.5cm broad and 90cm long. Interline distance will maintain at 110% of the length of the initial step.~Routine rehablitation treatment includes a range of motion exercises for the lower extremity, passive stretching of tight muscles and conventional march exercises including marching, forward, backward and sideways walking.~Experimental group will be treated for 45 minutes per session, 3 days per week for 6 weeks."
89605679|NCT06059781|Other|Rhtyhmical auditory stimulation (control group)|"For auditory stimulation, walking exercises are performed on a flat floor walking path without rhythmic or musical influence. Rhythmical auditory stimulation (RAS) is produced by using Metronome App on a mobile phone.~Routine rehablitation treatment includes a range of motion exercises for the lower extremity, passive stretching of tight muscles and conventional march exercises including marching, forward, backward and sideways walking.~Control group will be treated for 45 minutes per session, 3 days per week for 6 weeks."
89605680|NCT06059755|Experimental|Group A: Cross education|For strength training resistance exercises with a load of 60% of one repetition maximum will be performed targeting the muscles involved in upper limb function. It includes exercises like shoulder presses, wrist curls, elbow flexion, and triceps extensions. Among the functional movements that are the focus of motor skill training activities for non-paretic limbs are reaching, gripping, and object manipulation. Patient will be encouraged to mentally visualize themselves performing movements and tasks with the affected limb, while actively engaging the non-paretic limb. Strength will be measured using the grip strength test/ hand held dynamometer. Patients will undergo 45-minute session per day, 3 days per week for 6 weeks.
89605681|NCT06059755|Experimental|Group B: Mirror Therapy|Participants will be asked to sit in front of a table of appropriate height with their arms resting on the table and a mirror (35 cm × 35 cm) placed between the patient's arms. The non-affected arm will be placed in front of the mirror and the affected arm will be placed and obscured. Patient will engage in specific exercises or movements using the affected limb while observing the mirror reflection. The movements will consist of forearm rotation, elbow, wrist, and finger flexion and extension movements, and hand grasping. Appropriate movement tasks will be selected according to the function of the affected upper limb. This exercise will be performed 45 minutes per day, 3 times per week for 6 weeks.
89605682|NCT06059742|Experimental|Action Observation Therapy with Acoustic Stimulation|The patients in the action observation therapy with acoustic stimulation group will be required to observe the lower limb movements or functional actions with sound of beats in video clips. (i.e., the observation phase) and to execute what they had observed to the best of their ability with sound of beats given through headphones (i.e., the execution phase). Three common categories of movements will be elected in the protocol for each week based on the related literature
89518385|NCT03485807|Experimental|Active Coping Training (CT)|
89518386|NCT04339595|Experimental|Tildrakizumab|
89518387|NCT03487289|Experimental|natural orifice|Patients who underwent laparoscopic surgery and removed the specimen from the natural orifice will be gathered. demographic data and perioperative results will be compiled
89518388|NCT03487289|No Intervention|conventional|patients who underwent laparoscopic surgery and removed specimen with conventional will be gathered. demographic data and perioperative results will be compiled. (conventional extraction is suprapubic or median incision)
89518389|NCT02249182|Experimental|12 to < 18 Years Old|"Participants between 12 to < 18 years of age weighing ≥ 45 kg will receive LDV/SOF FDC (90/400 mg tablet or 4 x 22.5 mg/100 mg tablets or 8 x 11.25/50 mg granules based on swallowability assessment during screening).~Treatment duration will be dependent on HCV genotype, prior treatment experience, cirrhosis status, and country of enrollment.~United Kingdom:~HCV genotypes (GT) 1, 4, 5, or 6 treatment-naive (TN) with or without cirrhosis = LDV/SOF 12 weeks~HCV GT 1, 4, 5, or 6 treatment-experienced (TE) without cirrhosis = LDV/SOF 12 weeks~HCV GT 1, 4, 5, or 6 TE with cirrhosis = LDV/SOF 24 weeks~HCV GT 3 TE with or without cirrhosis = LDV/SOF+RBV 24 weeks~United States/Australia/New Zealand:~HCV GT 1, 4, 5, or 6 TN with or without cirrhosis = LDV/SOF 12 weeks~HCV GT 1, 4, 5, or 6 TE without cirrhosis = LDV/SOF 12 weeks~HCV GT 1 TE with cirrhosis = LDV/SOF 24 weeks~HCV GT 4, 5, or 6 TE with cirrhosis = LDV/SOF 12 weeks"
89518390|NCT02249182|Experimental|6 to < 12 Years Old|"Participants between 6 to < 12 years of age weighing ≥ 17 kg and < 45 kg will receive LDV/SOF FDC (45/200 mg as 2 x 22.5/100 mg tablets or 4 x 11.25/50 mg granules based on swallowability assessment during screening).~Treatment duration will be dependent on HCV genotype, prior treatment experience, cirrhosis status, and country of enrollment.~United Kingdom:~HCV GT 1, 4, 5, or 6 TN with or without cirrhosis = LDV/SOF 12 weeks~HCV GT 1, 4, 5, or 6 TE without cirrhosis = LDV/SOF 12 weeks~HCV GT 1, 4, 5, or 6 TE with cirrhosis = LDV/SOF 24 weeks~HCV GT 3 TE with or without cirrhosis = LDV/SOF+RBV 24 weeks~United States/Australia/New Zealand:~HCV GT 1, 4, 5, or 6 TN with or without cirrhosis = LDV/SOF 12 weeks~HCV GT 1, 4, 5, or 6 TE without cirrhosis = LDV/SOF 12 weeks~HCV GT 1 TE with cirrhosis = LDV/SOF 24 weeks~HCV GT 4, 5, or 6 TE with cirrhosis = LDV/SOF 12 weeks"
88811529|NCT00845000|Experimental|Placebo→SCH 420814 10 mg→SCH 420814 100 mg|Participants were to receive their assigned experimental treatment based on randomly assigned treatment sequence at Hour 0 following an overnight withdrawal of their antiparkinsonian medications of each treatment period. The levodopa infusion was to be started at Hour 1 and was to run for 2 hours. The participants were to also receive 25 mg of carbidopa at the following times: Hours 0, 2, and 4. Treatment periods were to be separated by at least 7 days but not more than 28 days washout between each dose.
89605683|NCT06059742|Active Comparator|Action Observation Therapy Without Acoustic Stimulation|The patients in the action observation therapy without acoustic stimulation group will be required to observe the lower limb movements or functional actions without sound of beats in video clips. (i.e., the observation phase) and to execute what they had observed to the best of their ability without sound of beats (i.e., the execution phase). Three common categories of movements will be elected in the protocol for each week based on the related literature
88981965|NCT00316849|Experimental|Treatment (temsirolimus, temozolomide, radiation therapy)|GROUP 1: (temsirolimus with radiation and temozolomide) Patients receive temsirolimus IV over 30 minutes once weekly. Beginning 7-10 days later, patients also receive oral temozolomide daily and undergo concurrent 3-D conformal radiotherapy or intensity-modulated radiotherapy once daily, 5 days a week, for 6 weeks. Patients with stable or responding disease proceed to adjuvant therapy. GROUP 2: (radiation and temozolomide) Patients receive oral temozolomide daily and undergo concurrent 3-D conformal radiotherapy or intensity-modulated radiotherapy once daily, 5 days a week, for 6 weeks. Patients with stable or responding disease proceed to adjuvant therapy. ADJUVANT THERAPY: Beginning 4-6 weeks after the completion of chemoradiotherapy patients receive oral temozolomide on days 1-5. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
88981966|NCT02959957|Experimental|Temocillin|Temocillin powder for solution för injection/infusion, per day 6 g (2 g three times per day). Treatment length 7-10 days of which at least 3 days administration with the study drug.
89605684|NCT06059716|Active Comparator|Standard of Care|Participants will be provided with continuous Telehealth dietitian follow-up
89605685|NCT06059716|Experimental|Standard of Care Plus Technology|In addition to standard of care, participants will be provided with gluten detection technologies so as to assist in navigating the gluten-free diet.
89605686|NCT06059703|Experimental|Idiopathic intracranial hypertension (IHH) patient|IHH patient with bilateral stenosis of the transversal sinus
89605687|NCT06059690|Other|Arm I en vivo Glycolic Index measurement|All biopsies are acquired for standard of care and according to standard of care procedures. A 13-gauge biopsy needle and plastic cannula will be inserted into the region of interest identified on MRI and PET. The biopsy needle will be removed, and the Softcell® pH probe, consisting of a 1.8mm diameter high quality glass tip and 1.6m long wire, will be guided down the cannula and inserted at least 15mm into the tissue. Recordings will be made for 1 minute to stabilize the reading, then the pH probe will be removed from the region of interest and placed into a saline vial for the next biopsy target.
89605688|NCT06059677|Experimental|Active Smoked Cannabis|"Participants in this arm will smoke an active cannabis cigarette containing 18.16% Δ9-tetrahydrocannabinol (THC). The smoking will occur at each participant's preferred pace, but will be limited to a maximum ten-minute period. While individual doses vary in this type of paradigm (ad libitum dosing), the anticipated dose of THC within the cannabis condition can be approximated by the following formula: (700 mg of cannabis) x [% of cigarette smoked; maximum of 70% (allowing room to hold the cigarette)] x (% THC). Therefore, the maximum dose in this arm is 700 mg x 70% x 18.2% = 89.18 mg of THC. Individual participants will only take part in the study under a single condition and receive the active cannabis once.~Bulk cannabis for this arm will be provided by the National Institute on Drug Abuse Drug Supply Program; cannabis cigarettes will be prepared and prescribed by the Research Pharmacy of the University of California, San Diego."
89605689|NCT06059677|Placebo Comparator|Placebo Smoked Cannabis|"Participants in this arm will smoke a placebo cannabis cigarette containing <.01 THC. The smoking will occur at each participant's preferred pace, but will be limited to a maximum ten-minute period. Individual participants will only take part in the study under a single condition and receive the placebo cannabis once.~Bulk placebo for this arm will be provided by the National Institute on Drug Abuse Drug Supply Program; placebo cannabis cigarettes will be prepared and prescribed by the Research Pharmacy of the University of California, San Diego."
89605690|NCT06059677|No Intervention|Control|Participants in this arm receive no cannabis. Individual participants will only take part in the study under a single condition.
89605691|NCT06058546|Placebo Comparator|Placebo group|Jiuweihuaban Pill placebo, 1 bag each time, p.o. , tid
89605692|NCT06058546|Experimental|Low dose group|Jiuweihuaban Pill , 1 bag each time, p.o. , tid
89605693|NCT06058546|Experimental|High dose group|Jiuweihuaban Pill , 1 bag each time, p.o. , tid
89605694|NCT06058468|Experimental|Cardioneuroablation of right anterior ganglionated plexus|
89605695|NCT06058468|Active Comparator|Pulmonary vein isolation|
89605696|NCT06057896||inositol, phytoestrogens, cocoa polyphenols|
89605697|NCT06057714||All Participants|All subjects to receive inhaled perfluoropropane via standard Douglas bag at every visit (3-5 visits). They will breathe the gas for 5 breath hold cycles (variable volumes as lung capacity/size varies per participant). Not to exceed 30 liters inhaled at each visit as this is the max capacity of our Douglas bag.
89605698|NCT06057662|Active Comparator|Intervention|personalized comprehensive diabetes support for 6 months following type 1 diabetes diagnosis
89605699|NCT06057662|No Intervention|Control|
89605700|NCT06057636|Experimental|Self-Administered Hypnosis|Self-administered hypnosis will be practiced daily, at home for 6 weeks. Hypnosis sessions are expected to last ~20 minutes. Practices using the recordings will be documented on the Hypnosis Practice Log.
88981967|NCT02959957|Active Comparator|Cefotaxime|Cefotaxime powder for solution för injection/infusion, per day 3-6 g (1-2 g three times per day). Treatment length 7-10 days of which at least 3 days administration with the study drug.
88981968|NCT02958033|Experimental|HF WBI-SIB breast radiation|WBI-SIB breast radiation(WBI 2.5Gy x18 and SIB 2.88Gy x18)
88981969|NCT02958033|Placebo Comparator|CF WBI-SIB breast radiation|WBI-SIB breast radiation(WBI 1.8Gy x28 and SIB 2.15Gy x28)
88981970|NCT00123669|No Intervention|Control|Patient will not receive Inj Progesterone 500 mg
88981971|NCT00123669|Experimental|Treatment|An intramuscular injection of 500mg depot hydroxy-progesterone 5-14 days prior to surgery.
88981972|NCT00317200|Active Comparator|1|Paclitaxel + Devacizumab in patients with chemosensitive relapsed small cell lung cancer.
88981973|NCT00317278|Experimental|A,1|Massage therapy
88981974|NCT00317278|Sham Comparator|A,2|
89605701|NCT06057636|Active Comparator|Self Administered White Noise Hypnosis|Self-administered white noise hypnosis will be practiced daily using a white noise recording. Participants will practice hypnosis at home after completing the virtual consent/baseline visit and the virtual education visit.
89605702|NCT06057623||Group 1|- Group 1: HFpEF patients with diabetes mellitus (HF-T2DM): patients with a diagnosis of diabetes mellitus in optimized drug therapy, documented by values of glycated hemoglobin (HbA1c) between 6% and 9%
89605703|NCT06057623||Group 2|- Group 2: HFpEF without diabetes mellitus (HF-NotT2DM): patients with HF in absence of diabetes evidenced by values of glycated hemoglobin (HbA1c) < 6.0%
89605704|NCT06057610|Experimental|Treatment group A: SHR-A1811 Injection|
89605705|NCT06057610|Experimental|Treatment group B: SHR-A1811 Injection and Pertuzumab Injection|
89605706|NCT06057610|Active Comparator|Treatment group C: Trastuzumab Injection, Pertuzumab Injection and Docetaxel Injection|
89605707|NCT06057584|Experimental|somatosensory-motor integration training|
89605708|NCT06057584|Active Comparator|pure somatosensory training|
89605709|NCT06057584|Active Comparator|pure motor training|
89605710|NCT06057558|No Intervention|Observational part of the study|During this part, we will collect saliva, throat and sputum samples from cystic fibrosis patients during their routine consultations in the hospital for one year.
89605711|NCT06057558|Experimental|Probiotic group|Daily use of a probiotic throat spray for 4 weeks
89605712|NCT06057545|Experimental|Group A - Envarsus followed by Prograf|4 weeks treatment sequence 1 (Envarsus) followed by 4 weeks treatment sequence 2 (Prograf)
89605713|NCT06057545|Experimental|Group B - Prograf followed by Envarsus|4 weeks treatment sequence 2 (Prograf) followed by 4 weeks treatment sequence 1 (Envarsus)
89605714|NCT06057532|Experimental|UCAN SuperStarch study drinks|Intervention group will receive UCAN SuperStarch study drinks. 100g carbohydrate will be consumed the night before surgery and 50g carbohydrate will be consumed 2 - 3 hours before surgery.
89605715|NCT06057532|Active Comparator|Gatorade study drinks|Active Control group will receive Gatorade study drinks. 100g carbohydrate will be consumed the night before surgery and 50g carbohydrate will be consumed 2 - 3 hours before surgery.
89605716|NCT06057506|Experimental|Investigational Device|"Medical device for the treatment of head lice infestation: Paranix® Shampoo, already in the market in Europe~Single topical application administered to hair and scalp for 10 minutes. Applied by principal investigator on site."
89605717|NCT06057506|Active Comparator|Comparator Device|"Medical device for the treatment of head lice infestation: Paranix® Lotion, already in the market in Europe~Single topical application administered to hair and scalp for 10 minutes. Applied by principal investigator on site."
89605718|NCT06057415|No Intervention|Standard care|Will receive standard of care according to the institutional protocol and principles of developmental care which currently belongs to (inter-) national guidelines and is regarded as safe.
89605719|NCT06057415|Experimental|Standard care supplemented with HAPTOS intervention|Will receive standard of care according to the principles of developmental care which currently belongs to (inter-) national guidelines plus HAPTOS intervention which includes: tactile/ kinaesthetic massage of the trunk and extremities twice daily and stimulation of oral function by providing perioral stimulation up to 4 times a day. Interventions will be continued until clinical improvement.
89605720|NCT06057389|Experimental|Intervention group|Intervention group: an energy-restricted diet + aronia melanocarpa extract
89605721|NCT06057389|Placebo Comparator|Control group|control group: an energy-restricted diet + maltodextrin
89605722|NCT06057376|Other|Low FODMAP group|Participants randomized to this group will be instructed based on published low-FODMAP diet guidelines and provided with sample meal plans to aid in compliance. Each participant will be randomized to low-FODMAP diet group (LFD) for 3 weeks.
89605723|NCT06057376|Other|Low Added Sugar group|Each participant will be randomized to either the low-FODMAP diet group (LFD) or the low added sugar diet group (LAS) for 3 weeks. Each participant will be randomized to the low added sugar diet group (LAS) for 3 weeks.
89605724|NCT06057363||patients requiring vestibular soft tissue augmentation at implant sites|The present study was planned as prospective analysis with 12-month follow-up. It enrolled 12 partially edentulous patients (mean age 62; range 42-86) requiring vestibular soft tissue augmentation at implant sites in second-stage surgery because of mild horizontal ridge deficiency. As a whole, 16 implants were placed (8 single, 4 dual).
88815133|NCT05395208|No Intervention|Control group|"Camera recording was started 5 minutes before the intravenous catheter intervention, vital signs and pain were evaluated.~No application was made other than intravascular catheter intervention.~Vital signs and pain were evaluated during intravenous catheterization.~Vital signs and pain were evaluated when the intravenous catheter intervention was terminated and 5 minutes later, and the camera recording was stopped."
88815134|NCT02243813|Experimental|Delayed Participation|Participants will begin the psilocybin intervention 6 months after study enrollment.
89605725|NCT06057285|No Intervention|AR technologies to develop a first aid cart learning system|The control group received traditional teaching.
89605726|NCT06057285|Experimental|An ACLs cart training course was developed using augmented reality (AR) technologies|The developed first aid cart learning system was applied to ACLs drills in a regular ACLs training program, and an AR group used this learning system to assist in their learning. The AR group scanned the dedicated AR marker using a mobile device
89605727|NCT06057259||Inclinometer|Measuring Wrist Joint Position Sense with a Inclinometer
89605728|NCT06057259||Goniometer|Measuring Wrist Joint Position Sense with a Goniometer
89605729|NCT06057259||Joint position sense goniometer|Measuring Wrist Joint Position Sense with a joint position sense goniometer
89605730|NCT06057220||Group 1|Adult patients referred for oesophago-gastro-duodenoscopy (OGD) to investigate any of the following symptoms: difficulty swallowing, vomiting, reflux, anaemia, gastrointestinal (GI) bleeding, upper abdominal pain and weight loss.
89605731|NCT06057220||Group 2|Adult patients with known BO who are undergoing OGD for surveillance
89605732|NCT06057220||Group 3|Adult patients who have been diagnosed with OGc (Ac or SCc) and are having further investigations as part of the disease staging process such as a staging laparoscopy or further OGD
89605733|NCT06057220||Group 4|Adult patients with OGc (Ac or SCc) who are having surgical resection of the cancer
89605734|NCT06057207||obese|This group will include patients with BMI > 25 kg/m2
89605735|NCT06057207||non obese|This group will include patients with BMI < 25 kg/m2
89605736|NCT06057194|Experimental|Letermovir (prospective cohort)|2 tablets of 240 milligrams (mg) Letermovir orally once daily. during 12 months
89605737|NCT06057194|No Intervention|Valganciclovir (retrospective cohort)|Retrospective cohort, of patients treated with Valganciclovir during 12 months
89605738|NCT06057168|Experimental|Elucirem®|Patient will undergo a DSC-MRI perfusion using Elucirem®
89605739|NCT06057168|Active Comparator|Dotarem®|Patient will undergo a DSC-MRI perfusion using Dotarem®
89605740|NCT06057116|Experimental|massage|Massage was applied to people who were hospitalized in the obstetrics ward of the pregnant woman, had a single fetus, awaiting spontaneous delivery, had no pregnancy complications, had no systemic disease, and agreed to voluntarily participate in the study.
89605741|NCT06057116|Experimental|acupressure|Acupressure for pregnant women who are hospitalized in the obstetrics service, have a single fetus, expect spontaneous delivery, do not have pregnancy complications, do not have any systemic disease, and agree to voluntarily participate in the study.
89605742|NCT06057116|No Intervention|control group|No intervention was performed on the patients who were hospitalized in the obstetrics service of the pregnant woman, had a single fetus, awaiting spontaneous delivery, had no pregnancy complications, had no systemic disease, and agreed to voluntarily participate in the study.
89605743|NCT06057103|Other|ZX-7101A-1|
89605744|NCT06057103|Other|ZX-7101A-2|
89605745|NCT06057103|Other|Oseltamivir-1|
89605746|NCT06057103|Other|Oseltamivir-2|
89605747|NCT06057103|Other|Combined-1|
89605748|NCT06057103|Other|Combined-2|
89605749|NCT06057090|Experimental|Therapy Dog|This group will have a certified therapy dog present in the treatment room throughout the procedure. Prior to the procedure, the participant will be briefly introduced to the therapy dog and handler, who will remain in the room until the end of the procedure.
89605750|NCT06057090|No Intervention|Control|The control group receives standard of care and does not have a therapy dog present in the room during their treatment.
89605751|NCT06057077|Active Comparator|60 early type 1 diabetes with semaglutide and degludec basal bolus insulin|degludec administered once daily bolus insulin three times daily and time in range and Semaglutide once weekly
89605752|NCT06057077|No Intervention|60 early type 1 diabetes with degludec basal bolus insulin with regular standard of care|60 patients' Basal insulin degludec administered once daily according to the SMBG and continuous plan at the clinic bolus insulin three times daily according to the meals and time in range and carbohydrate index Dosing adjusted based on SMBG results
89605753|NCT06057025|Experimental|Healthy patients|Drug: Sputnik Light vector vaccine for the prevention of coronavirus infection caused by the SARS CoV-2 virus (with altered antigenic composition); A total of 50 people will be randomized and receive the study drug. A single intramuscular injection of the investigational medicinal product (IMP) will be performed.
88981975|NCT02960035|Experimental|etanercept 50mg/week|Patients who entered the study continued on the same NSAIDs medications. The NSAIDs dose was kept unchanged throughout the study. All patients were provided with the once-weekly 50 mg dose in the form of etanercept for 24 weeks. After 24 weeks, those patients who had maintained a ASDAS-CRP ≤2.1 during period 1 will be randomised to one of three arms (period 2): this arms will receive ETN 50 mg weekly (unchanged). In all three arms, the patients continued NSAIDs, and other medications, at the same dose.
89605754|NCT06056986|Experimental|Patients|Chron's disease patients scheduled for ileo-colonic resection
89605755|NCT06056973|Experimental|Trials group|PPI treatment for 8 weeks, ( d1-d56 ), Jinghua weikang capsules 2 tid, 28 days of treatment.
89605756|NCT06056973|Active Comparator|Control group|Control group ( 130 cases ) : PPI treatment for 8 weeks, ( d1-d56 ), PPI treatment for 28 days.
89605757|NCT06056960|Experimental|Physical Activity|The experimental group will perform a combination of endurance and balance training tailored to the subject.
89605758|NCT06056960|No Intervention|Usual Activity|The control group will perform their usual daily activities.
89605759|NCT06056947|Experimental|fenticonazole + tinidazole + lidocaine vaginal ovule (EVEGYN A)|EVEGYN A is a fixed-dose combination of 600 mg fenticonazole nitrate + 1000 mg tinidazole + 100 mg lidocaine vaginal ovule.
89605760|NCT06056947|Experimental|fenticonazole + tinidazole + lidocaine vaginal ovule (EVEGYN B)|EVEGYN B is a fixed-dose combination of 600 mg fenticonazole nitrate + 2000 mg tinidazole + 100 mg lidocaine vaginal ovule.
89605761|NCT06056947|Active Comparator|Gynomax® XL Vaginal Ovule|Gynomax® XL is a fixed-dose combination of 300 mg tinidazole + 200 mg tioconazole nitrate + 100 mg lidocaine
89605762|NCT06056921|Experimental|CD19-targeted CAR-T|CD19 targeted CAR-T cells treat
89605763|NCT06056908||Patients with SDS/SDS-Like conditions and their families|
89605764|NCT06056882||Study group|
89605765|NCT06056856|Active Comparator|PSG group|The group of patients who will undergo penile skin graft substitituion of long anterior urethral stricture
89605766|NCT06056856|Active Comparator|BMG group|The group of patients who will undergo buccal mucosal graft substitituion of long anterior urethral stricture
89605767|NCT06056817|Experimental|Treatment|Chronic implantation of the Calyan pacemaker device
89605768|NCT06056726||Obese Patients|Patients candidates for resective surgery for rectal cancer and also elegible for bariatric surgery
89605769|NCT06056713|Experimental|Experimental Interventions|Hand massage should be done for 10 minutes, 5 minutes for each hand, before each brachytherapy (3 times in total in the 1st, 2nd and 3rd sessions).
89605770|NCT06056713|No Intervention|Control Group|The control group did not receive any intervention during the study period.
89605771|NCT06056700|Experimental|Intervention Group|Women were informed of the study, and their participation was requested. Those who offered their willingness to participate signed the informed consent and were randomly assigned to the intervention group (IG) or the control group (CG). Randomization was performed using Microsoft Excel spreadsheet software. All study follow-up information was collected through this app. The information offered to all the mothers through the mobile application contained a welcome message, contact data, sociodemographic and clinical variables, and access to the TMM-24 questionnaire. However, the GI through the app had access to complementary information content regarding the CG. The mothers of the IG had additional training material related to the first two prenatal face-to-face training sessions and new information during the postnatal period throughout consecutive weeks 1 to 8.
89605772|NCT06056700|No Intervention|Control Group|Women were informed of the study, and their participation was requested. Those who offered their willingness to participate signed the informed consent and were randomly assigned to the intervention group (IG) or the control group (CG). Randomization was performed using Microsoft Excel spreadsheet software. All study follow-up information was collected through this app. The information offered to all the mothers through the mobile application contained a welcome message, contact data, sociodemographic and clinical variables, and access to the TMM-24 questionnaire. However, the GI through the app had access to complementary information content regarding the CG. The mothers of the IG had additional training material related to the first two prenatal face-to-face training sessions and new information during the postnatal period throughout consecutive weeks 1 to 8.
89605773|NCT06056622|Other|Combined Exercise Group|Multisensory stimulation with active range of motion movement, progressive Cawthorne-Cooksey exercises, and balance exercises with external perturbation on soft and hard surfaces while eyes are open or closed.
89605774|NCT06056622|Other|Control Group|A placebo exercise program consist of 10 minute reaction time game which requires mouse clicking on screen color changes will be used in control group.
89605775|NCT06056609|Active Comparator|Yoga - Intervention Group|"The participants in the intervention group (n.20) will obtain access to an eight-week online mother and baby programme. They will be given access to one video per week and asked to complete the session at least once within the week. The participants are also free to repeat the session as many times as they wish.~The researchers will record the participants access to the online videos. All participants will be asked to complete a daily activity diary.~The participants will be asked to complete pre, intermediate, and post intervention questionnaires relating to maternal mental health, body satisfaction, and their feelings about the mother and infant bond.~A subset of participants will also undergo a telephone interview upon completion of the study, which will be subject to qualitative analysis. A short two weekly questionnaire will be sent to all participants for the duration of the study to monitor participant mood and allow for follow up should it be deemed necessary."
89605776|NCT06056609|No Intervention|Control Group|The participants in the control group (n. 20) will follow the usual standard care pathway and will be offered access to the programme at the end of the study.
89605777|NCT06056570|Experimental|dotinurad 2mg|dotinurad 2mg q.d.
89605778|NCT06056570|Experimental|dotinurad 4mg|dotinurad 4mg q.d.
89605779|NCT06056531|Experimental|NIR light visualization|The participant performing PVC carried out the procedure on the arm vein of another volunteer classmate with the help of vein imaging by NIR. All interventions were conducted under the observation of the researchers. The researchers used a chronometer to measure and record how long the PVC took. Participants were asked about the degree of vein prominence under NIR light after the tourniquet was applied, using inspection and palpation. The chronometer was started after the tourniquet was applied and stopped when the catheter plaster was applied. The time that it took to choose the materials needed for the PVC was not added to this time. The researchers recorded whether the PVC procedure was successful or unsuccessful. The cannula's placement during PVC was evaluated by drawing blood and returning it to the vein with a syringe. The PVC procedure was considered a failure if the vein was not opened or no blood reached the syringe.
88815135|NCT02243813|Experimental|Immediate Participation|Participants will begin psilocybin intervention immediately after study enrollment.
88815136|NCT02991209|Experimental|Tostran 2%|1 years treatment with transdermal Tostran 2%
88815137|NCT02991209|Placebo Comparator|Placebo|1 years treatment with placebo gel
88815138|NCT00954356|Experimental|XPF-001|
88815139|NCT00954356|Placebo Comparator|Placebo|
88815140|NCT00954824|Experimental|Endotoxin (LPS)|Single administration low-dose (3 ng/kg) endotoxin (LPS).
88815141|NCT03019562|Experimental|Oxycodone|4mg of oxycodone iv bolus
88815142|NCT03019562|Active Comparator|Fentanyl|50ug of fentanyl iv bolus
88815143|NCT01685567|Experimental|MICHI NPS+f|The MICHI™ NPS+f is a flow reversal circuit consisting of two proprietary sheaths connected by standard surgical tubing. The sheaths each have a standard hemostasis valve and sidearm. An in-line flow regulator allows the clinician to modify to the flow through the circuit (either high flow or low flow) in addition to permitting temporary cessation of flow.
88815144|NCT05394584|Experimental|CST group|A total of 64 people with mild-to-moderate cognitive impairment will receive group cognitive stimulation therapy (CST), which consists of 14 sessions of mentally stimulating activities delivered two times a week for 7 weeks by supportive staff and volunteers trained in CST, on top of their usual care in community centres or residential care homes.
88815145|NCT05394584|No Intervention|Usual care group|A total of 64 people with mild-to-moderate cognitive impairment will receive the usual care in community centres or residential care homes.
88981976|NCT02960035|Experimental|etanercept 25mg/week|Patients who entered the study continued on the same NSAIDs medications. The NSAIDs dose was kept unchanged throughout the study. All patients were provided with the once-weekly 50 mg dose in the form of etanercept for 24 weeks. After 24 weeks, those patients who had maintained a ASDAS-CRP ≤2.1 during period 1 were randomised to one of three arms (period 2): this arms will receive ETN 25 mg weekly (half dose). In all three arms, the patients continued NSAIDs, and other medications, at the same dose.
88981977|NCT02960035|Placebo Comparator|PLACEBO|Patients who entered the study continued on the same NSAIDs medications. The NSAIDs dose was kept unchanged throughout the study. All patients were provided with the once-weekly 50 mg dose in the form of etanercept for 24 weeks. After 24 weeks, those patients who had maintained a ASDAS-CRP ≤2.1 during period 1 were randomised to one of three arms (period 2): this arms will receive placebo weekly. In all three arms, the patients continued NSAIDs, and other medications, at the same dose.
88981978|NCT03034226|Active Comparator|Single episode of hypoglycemia|Day 1: Hyperinsulinemic hypoglycemic clamp 30 min Day 2: Hyperinsulinemic euglycemic clamp and hyperinsulinemic hypoglycemic clamp 7 hours
88981979|NCT03034226|Active Comparator|Two episodes of hypoglycemia|Day 3: No intervention (normal blood glucose) Day 4: Hyperinsulinemic euglycemic clamp and hyperinsulinemic hypoglycemic clamp 7 hours
88981980|NCT04716790|Experimental|Ultrasounds once a week|Patients will undergo the application of ultrasound therapy with a frequency of once a week.
88981981|NCT04716790|Experimental|Ultrasounds once every two weeks|Patients will undergo the application of ultrasound therapy with a frequency of once every two weeks.
88981982|NCT04716790|Active Comparator|Standard of care|Patients will be treated using the conventional treatment established by the protocol of the Diabetic Foot Unit of the University Podiatry Clinic of Complutense University of Madrid.
88981983|NCT04729283||Sigmoidectomy for sigmoid cancer|Sigmoid resection surgery for patients who suffer from sigmoid cancer
88981984|NCT04729283||Sigmoidectomy for diverticulitis|Sigmoid resection surgery for patients who suffer from symptomatic diverticulitis
88981985|NCT00328393|Active Comparator|Pioglitazone|Pioglitazone 45 mg, 8 weeks
88981986|NCT00328393|Placebo Comparator|Placebo|Placebo
88981987|NCT00328588|Experimental|1|7 days continuous infusion
88981988|NCT00328744|Experimental|1|Behavioral: Behavioral weight loss (Standard)
88981989|NCT00328744|Experimental|2|Behavioral: Behavioral weight loss (Limited Variety)
88981990|NCT00328822|Experimental|A|Quetiapine
88981991|NCT00328822|Placebo Comparator|B|Placebo
88981992|NCT00420043|Experimental|imatinib 800mg|
88981993|NCT00420043|Active Comparator|imatinib 400mg|
88981994|NCT00420082|Experimental|1|Bilastine 20 mg
88981995|NCT00420082|Active Comparator|2|Fexofenadine 120 mg
88981996|NCT00420082|Active Comparator|3|Cetirizine 10 mg
88981997|NCT00420082|Placebo Comparator|4|Placebo
88981998|NCT00420160|Experimental|Exercise|3x/wk 50 minutes of moderate intensity walking on treadmills + health education videos
88981999|NCT00420160|Other|Health Education|Contact control group attending 3x/wk 50 minutes of health education videos
88982000|NCT01821833|Experimental|Arm I (Omega-3 fatty acid)|"Four Omega-3 fatty acid capsules (at 1 gram/capsule) are administered orally daily.~The capsules may be administered either once daily or as 2 capsules two times daily."
88982001|NCT01821833|Placebo Comparator|Arm II (placebo)|"Four placebo capsules (at 1 gram microcrystalline cellulose/capsule) are administered orally daily.~The capsules may be administered either once daily or as 2 capsules two times daily."
88982002|NCT02965014|Experimental|Face-to-Face Young Women's CoOp (YWC)|Participants in this arm will be offered a two-session face-to-face Young Women's CoOp (YWC) intervention.
88982003|NCT02965014|Experimental|mHealth Young Women's CoOp (YWC)|Participants in this arm will be offered training on the mobile health application mHealth Young Women's CoOp (YWC) and offered tablets with the mHealth application to complete the two-session intervention.
88982004|NCT02965014|Active Comparator|HIV Counseling and Testing|Participants will be offered standard HIV counseling and testing services.
88982005|NCT01479608|Experimental|A: Transplantation or resection (randomized)|Liver transplantation or liver resection by 1:1 randomization (open label)
88982006|NCT01479608|Experimental|B: Liver transplantation|For non-resectable patients metachronous disease.
88982007|NCT01479608|Experimental|C:Liver transplantation|For non-resectable patients synchronous disease.
88982008|NCT01479608|Experimental|D:Liver transplantation|For non-resectable patients synchronous disease.
88982009|NCT00329017||1|Post-menopausal women who are at increased risk for development of breast cancer on the basis of family or personal history.
88982010|NCT00329056|Experimental|1|40 mg MitoQ OD
88982011|NCT00329056|Experimental|2|80 mg MitoQ OD
88982012|NCT00329056|Placebo Comparator|3|Placebo
88982013|NCT00434408|Experimental|1|4.0% chlorhexidine cleansing of the cord during home visits by project workers for the first 7 days after birth
88982014|NCT00434408|Experimental|2|4.0% chlorhexidine cleansing of the cord applied once by a project worker visiting the newborn in the home as soon as possible after birth
88982015|NCT00434408|Active Comparator|3|dry cord care
88982016|NCT00329563|Experimental|Cold fluid|
88982017|NCT00329563|No Intervention|control, standard of care|
88982018|NCT00420277|Experimental|Hemospan (MP4OX)|4.3 g/dL MalPEG-Hb solution
88982019|NCT00420277|Active Comparator|Control|Voluven (HES 130/0.4)
88982020|NCT04716751|Experimental|Toripalimab|
88982021|NCT04716673|Experimental|Children (4-11y) with epilepsy|Down-phase-targeted closed-loop auditory stimulation is administered in each arm.
88982022|NCT04716673|Experimental|Teenagers (12-17y) with epilepsy|
88982023|NCT04716673|Experimental|Young adults (18-30y) with epilepsy|
89605780|NCT06056531|Experimental|isometric hand exercise|In this group, the participants performing PVC carried out the procedure by observing vein dilation after isometric exercise. Before the procedure, the students on whom PVC was to be performed were given two stress balls, and they were told how to use them for 15 minutes. The stress balls used in the study were 6 cm in diameter and yellow in color. They were of medium hardness and made of high-quality silicone. The participants were told to squeeze and relax the stress ball in the palm of their hands after counting from one to three, to continue doing this until the procedure began, and to concentrate on squeezing the ball. Participants were asked about the degree of vein prominence after the isometric exercise and tourniquet was applied, using inspection and palpation. The remaining stages were carried out in the same way as with all of the groups.
89605781|NCT06056531|No Intervention|Control group: no intervention|The students in this group performed the PVC procedure directly on each other's arm veins without NIR or isometric exercise. Participants were asked about the degree of vein prominence after the tourniquet was applied, using inspection and palpation. The remaining stages were carried out in the same way as with all of the groups.
88982024|NCT04716673|Experimental|Healthy children (4-11y)|
88982025|NCT04716673|Experimental|Healthy teenagers (12-17y)|
88982026|NCT04716673|Experimental|Healthy young adults (18-30y)|
88982027|NCT00329680|Experimental|1|Experimental arm will receive an enteral diet enriched with EPA, GLA and Antioxidant vitamins
88982028|NCT00329680|Placebo Comparator|2|"This arm will receive an enteral diet considered as a standard ICU diet, isocaloric to the control diet but not enhanced with EPA, GLA and antioxidant vitamins"
88982029|NCT00329758|Active Comparator|1|
88982030|NCT00329758|Placebo Comparator|2|
88982031|NCT00329914|Placebo Comparator|Placebo|
88982032|NCT00329914|Active Comparator|Progesterone|
88982033|NCT04716478||Patient in need of endodontic care|
88982034|NCT00329992|Experimental|Treatment group|16 sessions Brief Eclectic Psychotherapy
88982035|NCT00329992|Placebo Comparator|Control group|Minimal attention waitlist group
88982036|NCT00330226||Psychopharmacotherapy|patients under antipsychotic or mood stabilizer treatment
88982037|NCT00330265|Experimental|1|KC-002
88982038|NCT00330265|Other|2|Conventional Wound Therapy
88982039|NCT04729244|Active Comparator|CBD(hemp oil) cream|cream 2000mg/1oz (50mg/dose) once daily dosing for a total of 4 weeks to area of most pain.Patients will record outcome in pain, anxiety, sleep, and report any adverse effects.
88982040|NCT04729244|Active Comparator|CBD (Hemp oil) Tincture|1500mg CBD/30ml (50mg/dose) once daily dosing for total of 4 weeks. Patients will record outcome in pain, anxiety, sleep, and report any adverse effects.
88982041|NCT00330304|Experimental|Isoniazid preventive therapy|HIV infected children living in a high TB prevalence area receive isonaizid prophylaxis daily, together with cotrimoxazole prohpylaxis either 3 times a week or daily.
88982042|NCT00330304|Placebo Comparator|Placebo|HIV infected children living in a high TB prevalence area receive placebo once daily
88982043|NCT00330499|Experimental|A|Synchronous chemo / radiation therapy
88982044|NCT00330499|Active Comparator|B|Radiation Alone
88982045|NCT00123981|Active Comparator|CCABG|Coronary artery bypass surgery using cardiopulmonary bypass
88982046|NCT00123981|Experimental|OPCAB|Coronary artery bypass surgery NOT using cardiopulmonary bypass
88982047|NCT00323713|Experimental|VLPD diet|Adavnced CKD patients (stage 4-5) on a very low protein diet
88982048|NCT00323713|Active Comparator|LPD diet|Adavnced CKD patients (stage 4-5) on a low protein diet
88982049|NCT00323830|Experimental|capecitabine/cisplatin/radiotherapy|postoperative XP/RT
88982050|NCT00323830|Active Comparator|capecitabine/cisplatin|postoperative XP
88982051|NCT00317512|Active Comparator|1|Voluven will be administered at 7.7 ml/min over 15 minutes,followed by Voluven at 7.7 ml/min over 15 minutes
88982052|NCT00317512|Active Comparator|2|HBOC-201 will be administered at 7.7 ml/min over 15 minutes,followed by Voluven at 7.7 ml/min over 15 minutes
88982053|NCT00317512|Experimental|3|HBOC-201 will be administered at 7.7 ml/min over 15 minutes,followed by HBOC-201 at 7.7 ml/min over 15 minutes
88982054|NCT00124059|Experimental|Type A SERO|
88982055|NCT00124059|Experimental|Type B SERO|
88982056|NCT00124059|Placebo Comparator|Type A PLA|
88982057|NCT00124059|Placebo Comparator|Type B PLA|
88982058|NCT00084032|Experimental|1|In Step 1, participants will receive ARV therapy for 24 weeks. Upon entering Step 2, participants will continue taking ARV therapy for 16 weeks and then stop ARVs for 64 weeks.
88982059|NCT00084032|Experimental|2|In Step 1, participants will receive ARV therapy for 24 weeks. Upon entering Step 2, participants will stop ARVs for 4 weeks, take ARVs for 8 weeks, stop ARVs for 4 weeks, take ARVs for 8 weeks, and then stop ARVs for 56 weeks.
88982060|NCT00323947|Active Comparator|1|Participants will take OROS-MPH then switch to placebo
88982061|NCT00323947|Placebo Comparator|2|Participants will take placebo then switch to OROS-MPH
88982062|NCT00324025|Experimental|1|Mycograb
88982063|NCT00324025|Active Comparator|2|biological
88982064|NCT00317629|Active Comparator|1|
88982065|NCT00317629|Experimental|2|
88982066|NCT00093249|Experimental|clevidipine|Clevidipine was administered in a blinded fashion by intravenous (IV) infusion, starting at a rate of 0.4 μg/kg/min (non weight-based equivalent is 2 mg/hr) and titrating upward, as tolerated, in doubling increments approximately every 90 seconds to achieve the desired blood pressure-lowering effect. Up-titration to 3.2 μg/kg/min (16 mg/hr) was allowed. Infusion rates above 3.2 μg/kg/min could be used, guided by the patient's response, by increasing in serial increments of 1.5 μg/kg/min up to the maximum recommended clevidipine infusion rate of 8.0 μg/kg/min. Clevidipine was to be administered for a minimum of 30 minutes, unless bailout occurred, and up to a maximum of one hour.
88982067|NCT00093249|Placebo Comparator|placebo|Placebo consisted of 20% lipid emulsion (the same lipid vehicle used for clevidipine) administered in a blinded fashion intravenously following the same study drug administration guidelines as with clevidipine study drug administration guidelines. As with clevidipine, placebo was to be administered for a minimum of 30 minutes, unless bailout occurred, and up to a maximum of one hour.
88982068|NCT00317707|Experimental|N-3 PUFA|
89605782|NCT06056492|Active Comparator|Control Group|Participants assigned to the control group received assessment without experience N2O/O2 sedation and they tried the mask with O2 only.
89605783|NCT06056492|Experimental|Study Group|Participants assigned to the study group received assessment with experience of N2O/O2 sedation
89605784|NCT06056453|Experimental|IPT|Participate in IPT 6-week intervention group.
89605785|NCT06056453|No Intervention|UC|Continue with usual care.
89605786|NCT06056440|Experimental|VR group|The VR intervention program for the experimental group will be carried through the Oculus Quest 2 device (which consists of VR glasses and different accessories) will be used, in conjunction with software specifically designed for physical rehabilitation of upper and lower limbs: Dynamics VR. This VR intervention will be performed in addition to the patient's usual treatment program.
89605787|NCT06056440|Other|Control group|
89605788|NCT06056414|Experimental|Energy Resonance by Cutaneous Stimulation|one Energy Resonance by Cutaneous Stimulation session performed before macrobiopsy
89605789|NCT06056401|Experimental|VCV group|For patients assigned in this group, after standard anesthesia, in which the following drugs were used (midazolam 0.05 mg / kg;propofol 1.5-2.5 mg / kg; sufentanil 0.3-0.5 μg / kg; and cisatracurium0.2-0.3 mg / kg), their mechanical ventilation mode was adjusted to the VCV mode.
89605790|NCT06056401|Experimental|PCV group|For patients assigned in this group, after standard anesthesia, in which the following drugs were used (midazolam 0.05 mg / kg;propofol 1.5-2.5 mg / kg; sufentanil 0.3-0.5 μg / kg; and cisatracurium0.2-0.3 mg / kg), their mechanical ventilation mode was adjusted to the PCV mode.
89605791|NCT06056388|Active Comparator|Deep-threaded implants|Straumann BLX implants
89605792|NCT06056388|Placebo Comparator|Regular-threaded implants|Straumann BLT implants
89605793|NCT06056375|Other|Waitlist Control|Waitlist control; all participants receive the treatment but are in a control condition prior to the treatment
89605794|NCT06056362|Experimental|Arm A: Al18F-NOTA-LM3 and 68Ga-DOTATATE group|Patients will perform an Al18F-NOTA-LM3 PET/CT as well as a 68Ga-DOTATATE PET/CT.
89605795|NCT06056362|Experimental|Arm B: Al18F-NOTA-LM3 and 68Ga-NODAGA-LM3 group|Patients will perform an Al18F-NOTA-LM3 PET/CT as well as a 68Ga-NODAGA-LM3 PET/CT.
89605796|NCT06056336|Experimental|Adjuvant tislelizumab plus chemothearpy|Tislelizumab：200mg d1, q3w × 2 cycles，up yo 1 year; Nad-paclitaxel 260 mg/m2 d1 q3w 2 cycles;carboplatin AUC = 5 d1, q3w × 2 cycles.
89605797|NCT06056284|Experimental|Progressive relaxation exercise and sleep hygiene training|It is planned to include 26 patients in the experimental group. Voluntary Consent Form, Personal Information Form, Pittsburgh Sleep Quality Index (PSQI), Sleep Hygiene Index (SHI) and Beck Anxiety Scale (BAS) will be applied to the patients in the experimental group in the first week of the 7-week study. Data will be collected by face-to-face interviews with the patients and an appointment will be made for the post-test after seven weeks. In the second week, the individuals in the experimental group will be taught progressive relaxation exercise in the hospital environment by the researcher using the compact disc (CD) prepared by the Turkish Psychological Association and after the sleep hygiene training, the progressive relaxation exercise brochure and sleep hygiene training brochure created by the researcher will be distributed. As of the second week, the individuals in the experimental group will be expected to apply the trainings given twice in the hospital environment.
89605798|NCT06056284|No Intervention|Control group|It is planned to include 26 patients in the control group. Voluntary Consent Form, Personal Information Form, Pittsburgh Sleep Quality Index (PSQI), Sleep Hygiene Index (SHI) and Beck Anxiety Scale (BAS) will be applied to the individuals in the control group in the first week of the 7-week research programme. Data will be collected by face-to-face interview with the patients. Individuals in the control group will not be given any training by the researcher. Individuals in the control group will be given an appointment for the post-test after seven weeks. At the end of seven weeks, individuals in the control group will be asked to fill in the Pittsburgh Sleep Quality Index (PSQI), Sleep Hygiene Index (SHI) and Beck Anxiety Scale (BAS) again.
89605799|NCT06056206|Active Comparator|Plain Balloon Angioplasty|Plain Balloon Angioplasty will be used to treat lesions.
89605800|NCT06056206|Active Comparator|Sirolimus-coated Balloon Angioplasty|Sirolimus-coated Balloon Angioplasty will be used to treat lesions after preparing vessel with plain balloon angioplasty.
89605801|NCT06056193|Active Comparator|Plain Balloon Angioplasty|Plain Balloon Angioplasty will be used to treat lesions
89605802|NCT06056193|Active Comparator|Sirolimus-coated Balloon Angioplasty|Sirolimus-coated Balloon Angioplasty will be used to treat lesions after preparing vessel with plain balloon angioplasty
89605803|NCT06056167|Experimental|Degludec|
89605804|NCT06056115|Experimental|Tislelizumab Combined With Platinum-containing Drug Chemotherapy|"Tislelizumab PD-1 inhibitor~Platinum-containing drug chemotherapy"
88982069|NCT00317707|Placebo Comparator|Olive oil|
88982070|NCT00317746|Placebo Comparator|Placebo|Placebo + PEG-interferon-alfa2b + ribavirin
89605805|NCT06056089|Active Comparator|Control Group|1 sachet (535 kcal) of RUSF per day
89210378|NCT05711511|Experimental|coventional obturation technique|In conventional method, paper point will be used to coat the walls of the canal with sealer, Standardized Protaper F-3 master gutta-percha cone will slid to the working length and ISO No.25 finger spreader was applied under vertical loading.The first accessory cone will slid promptly to proper length with a light coating of sealer. Compaction and accessory cone insertion will be continued;each spreader insertion will be seen to be slightly less deep than former, as mirrored by shorter and shorter accessory cone insertion. Condensation continued until the spreader reached 2-3 mm into the canal. Heat will be applied with to the root filling at or below canal orifice level, and the filling will then compacted apically with the help of a cold plugger.
89605806|NCT06056089|Experimental|MAM Experimental A|1 sachet (500 kcal) of RUTF per day
89605807|NCT06056089|Experimental|MAM Experimental B|2 sachets (1000 kcal) of RUTF per day
88982071|NCT00317746|Experimental|Citalopram|Citalopram + PEG-interferon-alpha2b + ribavirin
88982072|NCT00317980|Experimental|Low dose|Meglumine antimoniate 5 mg/kg/d for 20 days
88982073|NCT00317980|Active Comparator|Standard dose|Meglumine antimoniate 15 mg/kg/d for 20 days
88982074|NCT00419497|Active Comparator|Paleolithic diet vs Mediterranean diet|Prudent diets with or without grains and dairy
88982075|NCT00318019|Experimental|OPC Factor(TM)|
88982076|NCT00318019|Placebo Comparator|Placebo|
89605808|NCT06056076|Experimental|Group A|Mini Squats at a rate of ten squats at minimum range around 10-15 degrees at start along with Interferential Therapy for 10 minutes.
89605809|NCT06056076|Active Comparator|Group B|Endurance training by the use of medium resistance therapeutic band at start along with Interferential Therapy for 10 minutes.
89605810|NCT06056037|Experimental|Making ART Work|A culturally tailored, theoretically grounded social support intervention that includes receipt of daily text messages and provider-facilitated group adherence counseling (4 sessions)
89605811|NCT06056037|Active Comparator|Standard of Care|Standard clinical care referrals and basic medication adherence education
89605812|NCT06055907||NOR+ARG|Critically ill patients receiving norepinephrine and argipressin, with antithrombotic prophylaxis with 5000 IU of dalteparin.
89605813|NCT06055907||NOR|Critically ill patients receiving norepinephrine alone, with antithrombotic prophylaxis with 5000 IU of dalteparin.
89605814|NCT06055868||Qualitative Focus Group|Participants will be asked to a series of questions to help place them in a focus group with other individuals of shared identity and will also complete a short quantitative survey either emailed to the participant or the outreach worker/study coordinator will administer the survey by phone. Participants will then participate in one 1.5-2 hour, facilitated, focus group discussions (FGD).
89605815|NCT06055816|Experimental|Gemcitabine Combined With Endostar and Envafolimab|Neoadjuvant therapy consisting of gemcitabine (1000mg/m2 d1,8) , endostar (150mg 3-day continuous infusion) and envafolimab (240mg d1) was given every 3 weeks for 3 cycles. Endostar, administered every 3 weeks (150mg 3-day continuous infusion), was given concurrently with intensity-modulated radiotherapy.
89605816|NCT06055777|Active Comparator|Single intravenous doses of SZEY-2108|Single escalating doses of SZEY-2108
89605817|NCT06055777|Placebo Comparator|Single intravenous doses of placebo|Single intravenous doses of placebo to match SZEY-2108
89605818|NCT06055777|Active Comparator|Multiple intravenous doses of SZEY-2108|Multiple intravenous doses of SZEY-2108 at Q8h or Q6h on D1~D7 and on the morning of D8.
89605819|NCT06055777|Placebo Comparator|Multiple intravenous doses of placebo|Multiple intravenous doses of placebo at Q8h or Q6h on D1~D7 and on the morning of D8.
89605820|NCT06055738|Experimental|Zimberelimab combined with albumin-bound paclitaxel and cisplatin|Zimberelimab combined with albumin-bound paclitaxel and cisplatin in neoadjuvant treatment of locally advanced cervical cancer
89605821|NCT06055699||Patients with psoriasis in remission|Patients with psoriasis in remission after IL23i or IL17inhibitor treatments and who have stopped their medication for 2 to 4 weeks.
89605822|NCT06055673||cases group|patients with ISR confirmed by coronary angiography
89605823|NCT06055673||patients without restenosis non ISR group|
89605824|NCT06055634||patients more than 40 years|
89605825|NCT06055634||patients less than 40 years|
89605826|NCT06055634||controls|
88815146|NCT01686503|Experimental|2/5 dose intradermal IPV|Participants in this arm will receive 2/5 dose (0.2 mL) of inactivated polio vaccine (IPOL, Sanofi Pasteur) as a one-time dose intradermally using the NanoPass MicronJet 600 microneedle device
88815147|NCT01686503|Experimental|1/5 dose intradermal IPV|Participants in this study arm will receive 1/5 dose (0.1 mL) of inactivated polio vaccine (IPOL, Sanofi Pasteur) as a one time dose intradermally using the NanoPass MicronJet 600 microneedle device.
88815148|NCT01686503|Active Comparator|full dose intramuscular IPV|Participants in this study arm will receive the standard full dose (0.5 mL) of inactivated polio vaccine (IPOL, Sanofi Pasteur) as a one time dose intramuscularly.
88815149|NCT01686503|Active Comparator|2/5 dose intramuscular IPV|Participants in this study arm will receive 2/5 dose (0.2 mL) inactivated polio vaccine (IPOL, Sanofi Pasteur) as a one time dose intramuscularly.
88815150|NCT00969878|Placebo Comparator|Placebo injection|TA-CD placebo will be administered intra muscular. A total of 5 injections will be given over 12 weeks (i.e., at Day 1 and at the beginning of Weeks 3, 5, 9 and 13).
88815151|NCT00969878|Experimental|TA-CD Vaccination|TA-CD 400 μg will be administered intramuscular. A total of 5 injections will be given over 12 weeks (i.e., at Day 1 and at the beginning of Weeks 3, 5, 9 and 13).
89605827|NCT06055296|Experimental|COMPRENDO Intervention|"Parent participants randomized to the intervention group will receive the COMPRENDO intervention that includes 2-4 visits led by a peer navigator across a 4-week period. Navigator visits will last about 16 - 60 minutes depending upon the needs and desires of the parent. Navigator sessions will be conducted in the parents' preferred language (either English or Spanish). Peer navigators will:~Discuss general concepts related to informed consent and treatment options, including standard of care and clinical trials. The navigator will not discuss specific medications with parents.~Attend the informed consent discussion parents have with their child's oncologist.~Help parents come up with questions when the oncologist talks about cancer treatment options.~Go over the consent forms. Answer questions parents may have to the best of their ability.~Meet with parents over 4 weeks. During these meetings, the navigator will facilitate decision-making."
89605828|NCT06055296|No Intervention|Usual Care|Parents will participate in an informed consent conference with the oncologist to discuss treatment options for the child as per each institution's procedure.
89605829|NCT06054945||SIFIB|Patients who underwent SIFIB in knee arthroplasty patients under spinal anesthesia will be evaluated retrospectively in terms of opioid consumption and NRS scores.
89605830|NCT06054945||SIFIB+IPACK|Patients who underwent SIFIB+IPACK blocks in knee arthroplasty patients under spinal anesthesia will be evaluated retrospectively in terms of opioid consumption and NRS scores.
89605831|NCT06054724|Experimental|Yoga-based Respiration Group|This group will be given yoga-based breathing exercises
89605832|NCT06054724|Experimental|Pilates-based Respiration Group|This group will be given pilates-based breathing exercises
89605833|NCT06054399|Experimental|Audiovisual educational intervention|Audiovisual educational intervention will be apply within 3 moments of the pregnancy pf patients.
89605834|NCT06054165|No Intervention|Standard-of-care|
89605835|NCT06054165|Active Comparator|Best-practice|
89605836|NCT06053502||Masked condition|Participants who underwent the graded exercise test with the respirator.
89605837|NCT06053502||Unmasked condition|Participants who underwent the graded exercise test without the respirator.
89605838|NCT06053385|Experimental|Melatonin sleep lotion Night 1; Placebo control lotion Night 2|"Participants in this arm received melatonin-containing sleep lotion to apply on the first night of saliva sampling. On the second night of saliva sampling, they received placebo control lotion."
89605839|NCT06053385|Experimental|Placebo control lotion Night 1; Melatonin sleep lotion Night 2|"Participants in this arm received placebo control lotion to apply on the first night of saliva sampling. On the second night of saliva sampling, they received melatonin-containing sleep lotion."
88982077|NCT00084461|Experimental|Treatment (romidepsin)|Patients receive romidepsin IV over 4 hours on days 1, 8, and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients achieving CR receive 2 additional courses beyond CR.
88982078|NCT00318097||MAS patients|patient with clinical diagnosis of MAS
88982079|NCT00318097||controls|age matched, tanner stage matched controls
89605840|NCT06053294|Experimental|CS- First|Participants who receive the conditional stimulus (CS) - first.
89605841|NCT06053294|Experimental|CS+Fast First|Participants who receive the CS+Fast First
89605842|NCT06053294|Experimental|CS+Slow First|Participants who receive the CS+Slow First
89605843|NCT06052956|Experimental|MB-PDT at pre-defined dose plus standard of care abscess drainage|Each subject in this arm will receive standard of care abscess drainage, methylene blue, lipid emulsion, and laser illumination at an optical power defined by their abscess size.
89605844|NCT06052956|Experimental|MB-PDT at patient-specific dose plus standard of care abscess drainage|Each subject in this arm will receive standard of care abscess drainage, methylene blue, lipid emulsion, optical spectroscopy, and laser illumination. The optical power for laser illumination will be determined by their abscess morphology and the results of optical spectroscopy.
89605845|NCT06052956|Other|Standard of care abscess drainage|Each subject in this arm will receive standard of care abscess drainage
89605846|NCT06052943|Experimental|Health without Barriers/ Salud Sin Barreras|Health Without Barriers/Salud Sin Barreras is 12-session community-delivered, family-based lifestyle intervention to reduction the risk of for chronic diseases (i.e., T2D) in adolescence and to improve whole family health and wellness. The program is based upon a lifestyle intervention called the Healthy Living Program (HeLP), which includes 6 weekly 2 hour nutrition/cooking sessions through Cooking Matters and 6 weekly 2 hour Multidisciplinary Sessions that include parent education, a teen and sibling (ages 6-10 years) group physical fitness class, preschool curriculum for children 2-5 years of age, and a teen mindfulness curriculum called Learning 2 BREATHE. Health Without Barriers/Salud Sin Barreras has been tailored for adolescents at risk for depression and chronic diseases (i.e., T2D) in Southwest Colorado based on community input.
89605847|NCT06052787|No Intervention|standard of care|"patients receiving the standard protocol of management of head injury in the ICU including~Ventilatory support, sedation and analgesia.~Hemodynamic support.~Hyperosmolar therapy.~Early post traumatic seizure prophylaxis.~Nutritional support: will try to start enteral feeds as soon as possible or total parenteral~nutrition will be used in the case of enteral feeding intolerance.~Temperature management: to maintain normothermia~Glycemic control: to maintain a glucose level of [140 -180 mg/dl]~Peptic ulcer prophylaxis:~Deep venous thrombosis (DVT) prophylaxis"
89605848|NCT06052787|Experimental|standard of care + Cerebrolysin|patients receiving the standard protocol of management of head injury in the ICU plus 2 cycles of Cerebrolysin , each cycle 10 days, for total 20 days. From day 1 to day 10: cerebrolysin 50 ml once daily diluted in 250 ml normal saline intravenous infusion over 15 minutes. From day 21-30 : cerebrolysin 20 ml once daily diluted in 250 ml normal saline intravenous infusion over 15 minutes.
89605849|NCT06052787|Experimental|standard of care + Cerebrolysin + Amantadine sulfate|patients receiving the standard protocol of management of head injury in the ICU plus amantadine sulfate at a dose of 100 mg twice daily on the day after randomization, with this dose will be continued for 14 days. The dose will be increased to 150 mg twice daily at week 3 and to 200 mg twice daily at week 4 (total 4 weeks), combined with 2 cycles of Cerebrolysin , each cycle 10 days, for total 20 days. From day 1 to day 10: cerebrolysin 50 ml once daily diluted in 250 ml normal saline intravenous infusion over 15 minutes. From day 21-30 : cerebrolysin 20 ml once daily diluted in 250 ml normal saline intravenous infusion over 15 minutes.
89605850|NCT06052774|Active Comparator|Stage I grade B periodontitis patients|Nonsurgical periodontal debridement was performed on patients using an ultrasonic scaler and universal curettes (2R - 2L and 4R- 4L). Oral Hygiene measures were instructed following treatment and maintenance visits were given to them.
89605851|NCT06052774|Active Comparator|Stage II grade B periodontitis patients|Nonsurgical periodontal debridement was performed on patients using an ultrasonic scaler and universal curettes (2R - 2L and 4R- 4L). Oral Hygiene measures were instructed following treatment and maintenance visits were given to them.
89605852|NCT06052774|No Intervention|Periodontally healthy individuals|No intervention
89605853|NCT06052579|Experimental|study group|the patients included in the study group underwent Wiltse TLIF
89605854|NCT06052579|Active Comparator|control group|the patients included in the control group underwent traditional posterior -TLIF
89605855|NCT06052540|Active Comparator|Probiotics|Probiotic supplement: Mix of probiotic strails. Administration: 1 stick per day or 5 drops per day. Study duration for each patient: 14 days.
89605856|NCT06052540|Placebo Comparator|Placebo|Placebo: Medium Chain Triglycerides. Administration: 1 stick per day or 5 drops per day. Study duration for each patient: 14 days.
88982080|NCT00084539|Experimental|Radiation therapy|"Radiation Therapy~Daily 5 days per week for 4 weeks~45 Gy in 20 fractions whole breast~56 Gy in 20 fractions to boost volume"
88982081|NCT00324727|Experimental|Arm I|"Patients undergo an isolated hepatic arterial infusion of melphalan over 30 minutes on day 1. Treatment repeats every 4 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Patients with complete or partial response undergo 2 additional courses~in the absence of ongoing or increasing toxicity."
88982082|NCT00324727|Active Comparator|Arm II|"Patients receive the best alternative therapy comprising supportive care, systemic or regional chemotherapy, hepatic artery (chemo)-embolization, or any other appropriate therapy at the National Cancer Institute or therapy at the discretion of their physician.~Patients may cross over to arm I if they have evidence of disease progression."
88982083|NCT00324766|Active Comparator|1|levosimendan
88982084|NCT00324766|Placebo Comparator|2|Placebo, 1 h infusion, 0.2 microgs/kg/min, 24 h infusion,0.1 microgs/kg/min
89605857|NCT06052020||Alirocumab added to statin therapy|Alirocumab (75 mg every 2 weeks for 6 months) added to statin (Atorvastatin 20-40mg). Anti-platelet aggregation and risk factor management.
89605858|NCT06051565|Experimental|Polysaccharide superparamagnetic iron oxide injection|Intravenous injected polysaccharide superparamagnetic iron oxide injection at 3 mg/kg dose
89605859|NCT06051487|Other|Titanium dioxide nanoparticles containing group|participants using twin block appliance in which titanium dioxide nanoparticles added to acrylic baseplates to evaluate its antibacterial effect
89605860|NCT06051487|Other|control|participants use twin block appliance without any addition to acrylic base plates
89605861|NCT06051253|Experimental|TDM-based group|At week 0,2, and 6, infliximab (CT-P13, RemsimaTM) is intravenously administered at a dose of 5 mg/kg. From week 14 to 46 (at week 14, 22, 30, 38, and 46), infliximab dose can be increased to 10 mg/kg, targeting trough level (TL) of infliximab 10 mcg/mL or over (If TL is 10 mcg/mL or over under treatment with 5 mg/kg infliximab, 5 mg/kg of infliximab is continued. If TL is lower than 10 mcg/mL, infliximab dose is increased to 10 mg/kg). Once infliximab dose was increased to 10 mg/kg, the next doses are fixed to 10 mg/kg.
89605862|NCT06051253|Active Comparator|Standard group|Infliximab (CT-P13, RemsimaTM) is intravenously administered at a dose of 5 mg/kg at week 0, 2, 6, 14, 22, 30, 38, and 46. Therapeutic dose monitoring (TDM, checking trough levels of infliximab) is performed at week 14, 22, 30, 38, and 46, but TDM results are not reflected in determining doses of infliximab.
89605863|NCT06051058|Experimental|Experimental: Care Transitions App|Use of the Care Transitions App to support the care transition for patients hospitalized and discharged with multiple chronic conditions will be compared to usual care.
89605864|NCT06051058|No Intervention|No Intervention: Usual Care|Usual care transition care for patients hospitalized and discharged with multiple chronic conditions.
89605865|NCT06048991|Experimental|Knees termographic evaluation|All 30 patients will undergo thermographic evaluation of the operated knee of ACL reconstruction and of the controlateral knee.
89605866|NCT06048497||Preload|Patients with baseline FTc < 327 ms were assigned to the preload group, and Ringer Lactate (RL) preload fluid administration to these patients was continued until FTc > 327 ms.
89605867|NCT06048497||Non-preload|Patients with baseline FTc > 327 ms were assigned to the non-preload group, and preload fluid was not administered to these patients
88982085|NCT02965118|Experimental|PAC-14028 cream 1.0%|PAC-14028 cream 1.0% will be applied to treatment area twice daily for 8 weeks.
88982086|NCT02965118|Placebo Comparator|PAC-14028 cream Vehicle|PAC-14028 cream Vehicle will be applied to treatment area twice daily for 8 weeks.
88982087|NCT00318331|Active Comparator|A|Will receive enteral glutamine
88982088|NCT00318331|No Intervention|B|No enteral glutamine given
88982089|NCT00124254|Experimental|1|Surgical group undergoing SMPA
88982090|NCT00124254|Active Comparator|2|Nosurgical group
88982091|NCT00084695|Experimental|Regimen A|Patients undergo total body irradiation (TBI) two times daily on days -7 to -4. Patients receive cyclophosphamide IV over 30-60 minutes on days -3 and -2 and anti-thymocyte globulin (ATG) IV over at least 6 hours on days -3 to -1.
88982092|NCT00084695|Experimental|Regimen B (patients who do not receive TBI)|Patients receive oral busulfan 4 times daily on days -8 to -5, and ATG IV over at least 6 hours and melphalan IV over 15-20 minutes on days -4 to -2.
88982093|NCT00084695|Experimental|Regimen C (patients with Fanconi's anemia/related disorders)|Patients undergo TBI on day -6. Patients receive ATG IV over at least 6 hours and methylprednisolone IV on days -5 to -1 and fludarabine IV over 30 minutes and cyclophosphamide IV over 30-60 minutes on days -5 to -2.
88982094|NCT00084695|Experimental|Regimen D|Patients receive oral or IV busulfan 4 times daily on days -9 to -5, ATG IV over at least 6 hours on days -5 to -3, and cyclophosphamide IV over 30-60 minutes on days -5 to -2.
88982095|NCT00325273|Experimental|probiotics & allergy|"To understand the preventive effect of probiotics in neonatal peroid~To investate the possible mechanism"
88982096|NCT00325351|Experimental|Arm 1|
88982097|NCT00084773|Experimental|Cetuximab, Fluorouracil, and Pelvic Irradiation|"Patients receive cetuximab IV over 1-2 hours on days 1, 8, 15, 22, 29, 36, 43, 50, 57, and 64 and fluorouracil IV continuously on days 1-42. Patients undergo whole-pelvic radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36-40. Treatment continues in the absence of disease progression or unacceptable toxicity.~Approximately 1-3 weeks after completion of study treatment, patients undergo surgical resection followed by adjuvant chemotherapy off-study.~Patients are followed for up to 5 years."
88982098|NCT04727580|Experimental|HSK7653 10 mg|
88982099|NCT04727580|Experimental|HSK7653 25 mg|
88982100|NCT04727580|Placebo Comparator|Placebo|
89605868|NCT06048276||Drug exposure|Herbal medicines
89605869|NCT06046456|Experimental|PACT|Receive the intervention
89605870|NCT06046456|No Intervention|CAU|Receive care as usual, i.e., the standard care provided to pregnant women without any additional experimental interventions. It typically involves routine prenatal care, which may include regular check-ups, medical assessments, and general support from healthcare professionals
89605871|NCT06045676||Drug Resistant Epilepsy|Seizures Not Respond to two lines of Anti epileptic Medications
89605872|NCT06045676||Drug Responsive Epilepsy|Seizures Respond to one or two lines of Anti epileptic Medications
89605873|NCT06045676||Febrile Seizures|type of seizure occurring due to fever over 38 °C without a history of convulsion
89605874|NCT06045676||Breath Holding Spells|children's behaviors look like epileptic seizures due to crying up to a minute followed by losing consciousness
89605875|NCT06045676||Control|Healthy Children free from any convulsion
89605876|NCT06045468|Experimental|Study group|Patients in inpatient rehabilitation in study center.
89605877|NCT06045468|Experimental|Control group|Patients in inpatient rehabilitation facility of collaborating clinics.
89605878|NCT06045351|Experimental|VD supplementation|"Experimental Group (Group A; n=71):~The intervention (experimental) group will receive VD injections 600,000 I.U I/M once with 1 gram calcium supplemental daily in the initial 12 weeks. After that standard PCOS care; i) Glucophage XR 750 mg (once for 15 days then twice daily) ii) progesterone supplementation (1 capsule Progeffik 100 mg every 3 weeks, then 1 week off) and iii) calcium supplements will be given for next 12 weeks."
89605879|NCT06045351|Active Comparator|Control|"Control Group (Group B; n=71):~Participants will receive standard PCOS treatment; Glucophage XR 750 mg once at dinner for 15 days then twice daily and Capsule Progeffik 100 mg once at night every 3 weeks, then 1 week off for initial-- 12 weeks.~Then VD supplementation (600,000 IUI/M) will be given once during the study period with Calcium 1000 mg/day and continued Standard PCOS treatment from 12- 24 weeks"
89605880|NCT06044558||Combined with voriconazole group|Methylprednisolone sodium succinate was administered intravenously the day after transplantation at an initial dose of 500 mg/day, with the dose being tapered evenly to 40 mg/day during the first week. During the second week, methylprednisolone tablets were administered continuously at a dose of 40 mg/day, after which the dose was tapered to 16 mg/day as a maintenance dose. Immunosuppression was maintained with oral mycophenolate sodium 720 mg twice daily. For renal transplant patients, the initial oral tacrolimus dose should be 0.15 - 0.30 mg/kg per day divided into morning and evening doses. The starting dose of voriconazole should be 400 mg twice a day, which should be changed to 200 mg twice a day from the next day as a maintenance dose.
89605881|NCT06044558||Combined with caspofungin group|Methylprednisolone sodium succinate was administered intravenously the day after transplantation at an initial dose of 500 mg/day, with the dose being tapered evenly to 40 mg/day during the first week. During the second week, methylprednisolone tablets were administered continuously at a dose of 40 mg/day, after which the dose was tapered to 16 mg/day as a maintenance dose. Immunosuppression was maintained with oral mycophenolate sodium 720 mg twice daily. For renal transplant patients, the initial oral tacrolimus dose should be 0.15 - 0.30 mg/kg per day divided into morning and evening doses. The dosage of caspofungin was 70 mg intravenous injection once on the first day after surgery and 50 mg intravenous injection once a day starting from the second day.
89605882|NCT06044558||Tacrolimus-alone treatment group|Methylprednisolone sodium succinate was administered intravenously the day after transplantation at an initial dose of 500 mg/day, with the dose being tapered evenly to 40 mg/day during the first week. During the second week, methylprednisolone tablets were administered continuously at a dose of 40 mg/day, after which the dose was tapered to 16 mg/day as a maintenance dose. Immunosuppression was maintained with oral mycophenolate sodium 720 mg twice daily. For renal transplant patients, the initial oral tacrolimus dose should be 0.15 - 0.30 mg/kg per day divided into morning and evening doses.
89605883|NCT06043063|Experimental|Topical anesthesia alone|2.5% EMLA cream + intraurethral 2% lidocaine gel for 15 min
89605884|NCT06043063|Active Comparator|Topical anesthesia with periurethral block|"2.5% EMLA cream + intraurethral 2% lidocaine gel for 15 min~+ periurethral block (5 cc 1% lidocaine or 0.25% bupivacaine at 3 and 9 o'clock to depth of 1.5 cm using 25G needle)~Block sits for 5 min if lidocaine, 10 min if bupivacaine"
89605885|NCT06041308||Bioprothetic valve|Groups undergoing cardiac valve surgery with bioprothetic valve.
89605886|NCT06041308||Mechanical valve|Groups undergoing cardiac valve surgery with mechanical valves.
89605887|NCT06037681||Black cannabis users|African Americans that use cannabis at least once a week
89605888|NCT06037681||Black non-cannabis users|African Americans that do not use cannabis for at least 3 months prior to enrollment
89605889|NCT06037681||White cannabis users|Caucasians that use cannabis at least once a week
89605890|NCT06037681||White non-cannabis users|Caucasians that do not use cannabis for at least 3 month prior to enrollment
88815152|NCT00970814|Active Comparator|Levetiracetam XR|Group received Levetiracetam
88815153|NCT00970814|Placebo Comparator|Sugar Pill|Placebo
88815154|NCT02486406|Experimental|Adult tablet, 12-17 yr, Part 1|Participants with HCV GT1b without cirrhosis received the adult 3-DAA (OBV/PTV/RTV and DSV) regimen: two 12.5 mg ombitasvir /75 mg paritaprevir /50 mg ritonavir tablets taken orally every morning (QD) and one dasabuvir 250 mg tablet taken orally twice a day (BID) for 12 weeks. Participants with HCV GT1a without cirrhosis received 12-week treatment with the adult 3-DAA regimen and ribavirin 200 mg tablets were administered orally per local label.
88815155|NCT02486406|Experimental|Adult tablet, 12-17 yr, Part 2|Participants with HCV GT1b received the adult 3-DAA (OBV/PTV/RTV and DSV) regimen: two 12.5 mg ombitasvir /75mg paritaprevir /50 mg ritonavir tablets taken orally every morning (QD) and one dasabuvir 250 mg tablet taken orally twice a day (BID) for 12 weeks. Participants with HCV GT1a without cirrhosis received 12-week treatment with the adult 3-DAA regimen and ribavirin 200 mg tablets were administered orally per local label. Participants with HCV GT1a with compensated cirrhosis received 24-week treatment with the adult 3-DAA regimen and ribavirin 200 mg tablets were administered orally per local label. Participants with HCV GT4 received 12-week treatment with the OBV/PTV/RTV formulation and ribavirin 200 mg tablets were administered orally per local label.
88815156|NCT02486406|Experimental|Mini tablet, 9-11 yr, Part 1|Participants with HCV GT1b without cirrhosis were to receive the mini-tablet 3-DAA (OBV, PTV, RTV, and DSV) regimen for 12 weeks: ombitasvir 0.3 mg, paritaprevir 1.0 mg, and ritonavir 1.0 mg mini-tablets administered orally QD based on body weight and dasabuvir taken orally BID as 3.08 mg mini-tablets based on body weight. Participants with HCV GT1a without cirrhosis received 12-week treatment with the mini-tablet 3-DAA regimen and ribavirin was provided as a 40 mg/mL oral solution and administered per local label.
88815157|NCT02486406|Experimental|Mini tablet, 3-8 yr, Part 1|Participants with HCV GT1b without cirrhosis were to receive the mini-tablet 3-DAA (OBV, PTV, RTV, and DSV) regimen for 12 weeks: ombitasvir 0.3 mg, paritaprevir 1.0 mg, and ritonavir 1.0 mg mini-tablets administered orally QD based on body weight and dasabuvir taken orally BID as 3.08 mg mini-tablets based on body weight. Participants with HCV GT1a without cirrhosis received 12-week treatment with the mini-tablet 3-DAA regimen and ribavirin was provided as a 40 mg/mL oral solution and administered per local label.
88815158|NCT00971282|Experimental|intra-individual comparison|
88815159|NCT01688141|No Intervention|Control|Usual care
89605891|NCT06036810|Experimental|Study Phase 1|Pre-testing and cognitive interviews for the Decision Support Tool
89605892|NCT06036810|Experimental|Study Phase 2|Usual Care (Control Group) or Participants utilize the Decision Support Tool with Provider guidance (Intervention Group).
89605893|NCT06036238|Active Comparator|Standard of Care (Control)|Standard of care; alcohol counseling per Ministry of Health (MoH) guidelines
88982101|NCT00084812|Experimental|Safingol and Cisplatin|"Patients receive safingol IV over 1 hour and cisplatin IV over 1 hour on day 1. Courses repeat every 21 days* in the absence of disease progression or unacceptable toxicity.~NOTE: *Patients receive safingol on days 1 and 8 and cisplatin on day 8 for course 1 only; course 1 is 28 days in duration.~Cohorts of 3-6 patients receive escalating doses of safingol until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, 10 additional patients are treated at that dose level."
88982102|NCT00318721|Experimental|Intervention|
88982103|NCT00318721|No Intervention|control|
89605894|NCT06036238|Experimental|Healthy Living Intervention|Healthy Living Intervention in-person alcohol counseling with booster phone calls
89605895|NCT06035250||Gastric Cancer Patients Undergoing Neoadjuvant Chemotherapy|This group comprises participants diagnosed with advanced gastric cancer. The participants will be treated with standard neoadjuvant chemotherapy regimens recommended by clinical guidelines. Treatment details, including the generic name of the drugs, dosage form, dosage, frequency, and duration, will be recorded according to the specific regimen.
89605896|NCT06035003|Experimental|iMIED+TAU group|Internet-based Mindfulness Intervention for Emotional Distress (iMIED) program provide standard audio instructions for mindfulness exercises, introduce the nature and law of anxiety, depression and other emotions, the source of anxiety, depression and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems.
89605897|NCT06035003|No Intervention|the TAU-only group|treatment as usual (TAU) group consisted of all medicinal and psychological treatments received between baseline and follow-up (about five months). Medicinal treatments included receiving Lorazepam, Olanzapine, Paroxetine Hydrochloride, Sertraline, etc. Psychological treatments included receiving cognitive behavior therapy or psychodynamic therapy.
89605898|NCT06034821|Active Comparator|Subanesthetic dose intravenous ketamine (KET)|This trial will use standard dose of ketamine (0.5mg/kg infusion over 40 min period) in accordance with research studies that have used ketamine as an antidepressant.
89605899|NCT06034821|Active Comparator|Electroconvulsive therapy (ECT)|ECT will be given in a standard manner 3 times a week for 4 weeks.
88982104|NCT02959879|Experimental|FOLFOX neoadjuvant chemotherapy|4 cycles of FOLFOX neoadjuvant chemotherapy are administrated to patient. Curative surgery for resectable pancreatic duct adenocarcinoma will be done after neoadjuvant chemotherapy. 8 cycles of adjuvant chemotherapy are administrated following the surgery
88982105|NCT02959879|Experimental|FOLFIRINOX neoadjuvant chemotherapy|4 cycles of FOLFIRINOX neoadjuvant chemotherapy are administrated to patient. Curative surgery for resectable pancreatic duct adenocarcinoma will be done after neoadjuvant chemotherapy. 8 cycles of adjuvant chemotherapy are administrated following the surgery
88982106|NCT02959879|Active Comparator|standard adjuvant chemotherapy|"Curative surgery for resectable pancreatic duct adenocarcinoma will be done after randomization.~12 cycles of standard adjuvant chemotherapy are administrated following the surgery"
88982107|NCT04717609|Active Comparator|Partial Meniscectomy without Saphenous Nerve Block|Participants scheduled for partial meniscectomy will preoperatively receive 0.5% ropivacaine with epinephrine
88982108|NCT04717609|Experimental|Partial Meniscectomy with Saphenous Nerve Block|Participants scheduled for a partial meniscectomy will preoperatively receive a saphenous nerve block at the medial femoral condyle in addition to an injection of 0.5% ropivacaine with epinephrine
88982109|NCT00318760|Experimental|ARM 1|
89605900|NCT06032533|Experimental|Remote Ischemic Conditioning|After randomization a large thigh blood pressure cuff will be placed on the lower limb. The cuff will be inflated to a pressure 30 mm Hg greater than the systolic arterial blood pressure measured by the patient's arterial line or upper limb blood pressure cuff. The adequate level of inflation will be confirmed by the absence of pulse in the ipsilateral pedal artery detected by palpation. If the pulse signal is still present, the cuff will be inflated further until it disappears. The cuff will remain inflated for 5 minutes. Then the cuff will be deflated and the limb allowed to re-perfuse for 5 minutes. The procedure will be repeated five times followed by reperfusion. The first session will be performed 24-72 hours after the initial hemorrhage, within the first 24 hours after treatment of aneurysm, and repeated every 24 hours, between 8-10 am, until post hemorrhagic day 14.
89605901|NCT06032533|Sham Comparator|Sham-RIC|After randomization a large leg blood pressure cuff will be placed on the lower limb. This cuff is not attached to the device, but appears to be. The device will the be operated by trained staff. A hidden cuff is attached to the device to ensure that the device produces regular operation noises. The hidden cuff (not attached to patient) is inflated. The cuff will remain inflated for 5 minutes, then the cuff will be deflated for 5 minutes. The procedure will be repeated for five cycles. The first session will be performed 48-72 hours after the initial hemorrhage, at least 24 hours after treatment of aneurysm and repeated every 24 hours, between 8-10 am, until post hemorrhagic day 14.
88982110|NCT00318760|Placebo Comparator|ARM 2|
88982111|NCT00318799|Experimental|Arm 1|
88982112|NCT00318799|Active Comparator|Arm 2|
88982113|NCT02959801|Experimental|Percutaneous Mechanical Thrombectomy|Percutaneous mechanical thrombectomy（PMT）uses a number of catheter-based mechanical devices to deliver the thrombolytic agent as well as to produce some combination of thrombus fragmentation, distribution of thrombolytic drugs throughout the thrombus, and/or thrombus aspiration.
88982114|NCT04728945|Experimental|lung recruitment|Standard ventilatory management with lung recruitment every 30 minutes
88982115|NCT04728945|Active Comparator|control|Standard ventilatory management
88982116|NCT00318838|Placebo Comparator|1|Placebo tablet every 12 hours for 3 days followed by placebo tablet every 24 hours for three days
89605902|NCT06029413|Experimental|Research arm|After the myofascial trigger points are determined by ultrasonography (HI VISION Preirus; Hitachi Aloka Medical, Ltd., Tokyo, Japan), injections will be given to the myofascial layers from the deep to the superficial. First, the local anesthetic solution will be injected to create a separation in the intermuscle (epimysial) fascia. The injectable will then be infiltrated into the intermuscular hypoechoic nodule. Then, the deep fascia will be infiltrated layer by layer. Finally, the procedure will be completed by infiltrating the superficial fascia.
89605903|NCT06029413|Active Comparator|Control arm|Patients in the control group will be injected with the same amount of local anesthetic solution under ultrasound guidance to intramuscular hypoechoic nodules detected by ultrasonography (HI VISION Preirus; Hitachi Aloka Medical, Ltd., Tokyo, Japan).
89605904|NCT06028360|Active Comparator|Progressive Muscle Relaxation|Progressive muscle relaxation will be applied for 15-20 minutes for 3 consecutive days for 1 week.
89605905|NCT06028360|Experimental|Virtual Reality|Virtual reality session will be given for 8 mins for 3 consecutive days for 1 week.
89605906|NCT06028048|Experimental|PLACES intervention|Participants in the intervention group will receive the PLACES intervention during 12-months after randomization.
89605907|NCT06028048|No Intervention|Care as usual|Participants in the control group will receive usual care from the SSA.
89605908|NCT06017687|Other|Principal Arm|Each participant will use the OptiBP Study app on their smartphone
89605909|NCT06016673|Experimental|Intermittent theta burst stimulation to right dorsolateral prefrontal cortex|Participants will receive intermittent theta burst stimulation (iTBS) to the experimental target area, the right dorsolateral prefrontal cortex (rDLPFC)
89605910|NCT06016673|Active Comparator|Intermittent theta burst stimulation to vertex of the skull|Participants will receive intermittent theta burst stimulation (iTBS) to the active comparator area, the vertex of the skull
89605911|NCT06016465|Experimental|Dexamethasone|single oral dose of dexamethasone (8mg)
89605912|NCT06016465|Placebo Comparator|Placebo|Single oral dose of placebo pill
89532745|NCT05989815|Experimental|PBMT post muscle damage protocol (PBMT-post)|"Group submitted to pre-exercise Sham (placebo) photobiomodulation therapy (PBMT), and post-exercise active PBMT.~PBMT will be administered using the Joovv Elite System, which has 6 panels of red Light-Emiting Diodes (LEDs) (660±10nm) and 74 panels of infrared LEDs (850±10nm), totaling 900 LEDs covering an area of 12,193 cm². Athletes will stand 20 cm in front of the device, wearing only swim shorts to expose their thigh muscles and other body areas to the light. The total irradiation time will be 20 minutes, with 10 minutes (600 seconds) of irradiation for the anterior region and another 10 minutes (600 seconds) for the posterior region. The active PBMT dose applied in each region (anterior or posterior) will be 48.97 J/cm², with an irradiance of 81.62 mW/cm²."
89605913|NCT06008314|Experimental|Implementation at Vanderbilt University Medical Center (VUMC) & Vanderbilt Wilson County Hospital|ePNa (the decision support tool) will be implemented at 2 EDs that are part of the Vanderbilt Health system.
89605914|NCT06006117|Experimental|Arm 1: Mosunetuzumab and Lenalidomide|"- Mosunetuzumab and Lenalidomide~Mosunetuzumab will be administered SC (21 days first cycle, then 28 days next cycles)~C1 (21-days cycle): step-up dosing schedule 5 mg Day 1, 45 mg on Day 8 and 45 mg Day 15~C2 to C12: 45 mg D1 28-days cycles~Lenalidomide PO 20 mg/day from Day 1 to Day 21 from cycles C2 to C6 (cycles of 28 days)"
89605915|NCT06006117|Active Comparator|Arm 2: Rituximab-Lenalidomide (28-days cycles)|"Lenalidomide PO 20 mg/day, D1-21 from cycle 1 to cycle 6~Rituximab* 375 mg/m2 intravenously at Day 1 cycle 1, and then subcutaneous (1400 mg, flat dose) at D1 of cycles 2-12"
89605916|NCT06006117|Active Comparator|Arm 3: Rituximab-Bendamustine (28-days cycles)|"Bendamustine IV 70 or 90 mg/m² (according to the investigator's judgment) D1 and D2/28 days x 6 cycles 28 days cycles). For patients in complete response (CR) at 3 cycles, Bendamustine and Rituximab could be stopped after 4 cycles at investigator discretion~Rituximab* 375 mg/m2 intravenously at cycle 1 Day 1, and then subcutaneous (1400 mg, flat dose) at D1 of cycles 2 to 6** (28-days cycles) and then at D1 of three additional 56-days cycles (C7 to C9). **For patients in complete response (CR) at 3 cycles, if Bendamustine is stopped, then Rituximab should also be omitted for C5 and C6."
89605917|NCT06006117|Active Comparator|Arm 4: Rituximab-CHOP (21-days cycles|"CHOP, IV standard dose from cycle 1 to 6~Rituximab* 375 mg/m2 intravenously at Day 1 cycle 1, and then subcutaneous (1400 mg, flat dose) at D1 of cycles 2 to 6 (21-days cycles), and then at D1 of three additional 56-days cycles (C7 to C9)"
89605918|NCT06001099||Cancer arm|Participants with new diagnosis of gynecologic cancers, from whom blood samples will be collected
89605919|NCT06001099||Healthy arm|Participants without a known cancer or certain benign disease, from whom blood samples will be collected
89605920|NCT05988892|Experimental|Community Oncology patients entering cancer survivorship|Patients participate in a virtual cancer rehabilitation program with weekly virtual visits by a cancer exercise specialist who provides a personalized synchronous exercise plan and receive weekly phone calls over 12 weeks. Patents also wear a Fitbit on study.
89605921|NCT05985590|Experimental|Treatment A: DRSP/EE|
89605922|NCT05985590|Experimental|Treatment B: BMS-986278/DRSP/EE|
89032642|NCT02928510||Basic Science (biospecimen collection, idelalisib)|Patients receive a physical examination during visit 1. A stool sample, blood sample, and 6 biopsies are collected at visit 2, and patients undergo a flexible fiberoptic sigmoidoscopy. Patients receive idelalisib PO twice daily BID after visit 2. Treatment continues in the absence of disease progression or unacceptable toxicity. A third research visit occurs upon development of idelalisib-associated diarrhea/colitis symptoms. Patients with diarrhea/colitis symptoms undergo a full colonoscopy and collection of stool and blood samples. Control patients with no diarrhea/colitis symptoms undergo all needed tests and assessments including a flexible fiberoptic sigmoidoscopy and collection of stool and blood samples. All patients undergo optional biospecimen collection at the time of disease progression.
89605923|NCT05979493|Experimental|QL Block with Bupivacaine|Participants will get a QL block using 30cc Bupivacaine bilaterally in quadratus lumborum muscle (60cc total).
89605924|NCT05979493|Sham Comparator|Control|Participants will get a sham injection of 30cc saline bilaterally in quadratus lumborum muscle (60cc total).
89605925|NCT05971147|Experimental|Fish Oil Group|All participants will be placed in this group
89605926|NCT05967247|Experimental|MBSR|"The experimental group used App for MBSR intervention The main app of this experiment is Mindfulness in life (Taiwan) (this system is only applicable to Android devices). The content is divided into two parts. The course is compressed and simplified, mainly focusing on mindfulness learning and practising audio-visuals. There are eight-week themed audio-visuals and mindful caring words guided by mindfulness-based stress reduction, mindfulness-stretching guidance, and the function of recording the reading time of the research subjects. App platform for researchers to communicate."
89605927|NCT05967247|Placebo Comparator|waiting list|"The waiting list used only the Heart Care Life app for the first eight weeks, as self-management is an essential element of heart failure treatment (Tsami et al., 2023), following the situation-specific theory of heart failure self-management (the situation- specific theory of heart failure self-care:) (Riegel et al., 2022) and American heart failure guidelines (Heidenreich et al., 2022) design (Tsami et al., 2023; Vellone et al., 2020), mainly for Disease-related knowledge and self-management tools, built-in disease health education electronic audiobooks, diet sodium content calculator, diet water content calculator, activity step calculation, etc., to help research subjects self-manage the disease.~Measure T2 at week 8. From the ninth to the sixteenth week, use the Mindful Live app."
89605928|NCT05966961||Novosyn®|Sutures will be used to close the laparotomy or trocar incision in emergency or elective surgery. The suture material will be applied for fascia closure (and subcutaneous closure if applicable) in the context of daily clinical routine
89605929|NCT05966961||Polyglactin 910|Sutures will be used to close the laparotomy or trocar incision in emergency or elective surgery. The suture material will be applied for fascia closure (and subcutaneous closure if applicable) in the context of daily clinical routine
89605930|NCT05965427||PLHIV and Mpox coinfection|
89605931|NCT05965427||HIV negative PrEP users with Mpox infection|
89605932|NCT05965089|Experimental|AX-202|Single and multiple ascending doses of AX-202
89605933|NCT05965089|Placebo Comparator|Placebo|Single and multiple doses of placebo
89605934|NCT05953337|Experimental|EYE90 Microspheres Treatment|Radioembolization with Eye90 Microspheres
89605935|NCT05952726|Experimental|Prolonged expiratory cycling|15% expiratory cycling during pressure support ventilation
89605936|NCT05952726|Experimental|Late expiratory cycling|30% expiratory cycling during pressure support ventilation
89605937|NCT05952726|Experimental|Medium expiratory cycling|45% expiratory cycling during pressure support ventilation
89605938|NCT05952726|Experimental|Early expiratory cycling|60% expiratory cycling during pressure support ventilation
89605939|NCT05937971|Experimental|plantar sensitivity training group|Conventional exercises (with the addition of warm-up and cool-down periods) will be applied to all multiple sclerosis patients participating in the study; In addition, aerobic exercise training will be given. In addition to these exercises, plantar sensory training will be given to the sensory training group. Exercises and plantar sensory training will be given to the participants at intervals of three weeks, with progressively progressive sessions, 2 days a week for 12 weeks. Patients will be evaluated twice, before treatment and at the end of treatment 12 weeks later. Within the scope of the evaluation, balance, functional capacity, gait, proprioception and plantar sensory parameters will be measured in patients.
89605940|NCT05937971|Active Comparator|aerobic exercise training group|Conventional exercises (with the addition of warm-up and cool-down periods) will be applied to all multiple sclerosis patients participating in the study; In addition, aerobic exercise training will be given. In addition to these exercises, plantar sensory training will be given to the sensory training group. Exercises and plantar sensory training will be given to the participants at intervals of three weeks, with progressively progressive sessions, 2 days a week for 12 weeks. Patients will be evaluated twice, before treatment and at the end of treatment 12 weeks later. Within the scope of the evaluation, balance, functional capacity, gait, proprioception and plantar sensory parameters will be measured in patients.
89605941|NCT05937295|Experimental|FusionVAC-XS15 and Atecolizumab treatment|
89605942|NCT05936346|Experimental|Lower dose (175mg)|The study intervention consists of a single daily oral intake 175 mg of Salvia haenkei as soft capsule over a period of 3 months.
89605943|NCT05936346|Experimental|Higher dose (350mg)|The study intervention consists of a single daily oral intake 350 mg of Salvia haenkei as soft capsule over a period of 3 months.
89605944|NCT05931770||Group Child Preference|The children will prefer parents (mother or father) who will accompany them in the preoperative holding area and at induction
89605945|NCT05931770||Group Parent's Preference|Parents will decide among themselves and prefer the parents (mother or father) who will accompany them from the side of the parent, in the pre-operative waiting area and during induction.
89605946|NCT05928585|Experimental|MAD HIB210|Increasing doses of HIB210 will be administered for cohorts 1-4 in a multiple ascending dose format
89605947|NCT05928585|Placebo Comparator|MAD Placebo|Placebo will be administered for cohorts 1-4 in a multiple ascending dose format
89605948|NCT05926479||physiotherapy patient|
89605949|NCT05926336|Experimental|Sevoflurane|The sevoflurane group was maintained via sevoflurane vaporizer between 1% and 3% (target minimum alveolar concentration of 0.7-1.3).
89605950|NCT05926336|Experimental|Propofol|The propofol group was both induced and maintained at an effect-site concentration (Ce) of 2.0-4.0 mcg/mL by a target-controlled infusion (TCI) system.
89605951|NCT05925621||Lecanemab|Patients with Alzheimer Disease receiving anti-amyloid mAb therapy at the BIDMC
89605952|NCT05921591|Experimental|Dose A IRL201104|IRL201104 or placebo IV on days 1 and 7
89605953|NCT05921591|Experimental|Dose B IRL201104|IRL201104 or placebo IV on days 1 and 7
89605954|NCT05921591|Experimental|Dose C IRL201104|IRL201104 or placebo IV on days 1 and 7
89605955|NCT05920577|Experimental|Exergames and resistance training group|Participants will receive exergaming and resistance training programme over a period of 12 weeks
89605956|NCT05920577|Active Comparator|Resistance training group|Participants will receive resistance training programme over a period of 12 weeks
89605957|NCT05916677|Experimental|Patient remediate using the virtual training method|
89605958|NCT05916677|Active Comparator|Patient remediate using the traditional training method|
88982117|NCT00318838|Experimental|2|125 mg azimilide tablet every 12 hours for 3 days followed by 125 mg azimilide tablet every 24 hours for three days
89605959|NCT05916625|Experimental|Pet scan with the specific radioligand [11C]SB207145|"The following examen are added by the study :~neuropsychologic consultation PET scan MRI biological sample Questionnaires"
89605960|NCT05915390|Active Comparator|walnut group|walnut group will receive 15% of their total energy as walnuts
89605961|NCT05915390|Active Comparator|control group|continue with habitual diet and abstain from eating walnuts
89605962|NCT05914688|Experimental|LY3209590 (Formulation 1)|Single dose of LY3209590 as formulation 1 administered subcutaneously (SC).
89605963|NCT05914688|Experimental|LY3209590 (Formulation 2)|Single dose of LY3209590 as formulation 2 administered SC.
89605964|NCT05912062||early-stage HER2-positive breast cancer neoadjuvant treatment|"For a total of 16 weeks, patients will be given dual antiHER2 blockade consisting of Cycle 1 Day 1 Pertuzumab 840mg + Trastuzumab 8mg/kg loading dose, followed by Paclitaxel starting at Cycle 1 day 8 and 15 at 80mg/m2. Followed by Pertuzumab 420mg + Trastuzumab 6mg/kg every three weeks and Paclitaxel days 1, 8, and 15 of a 21-day cycle for up to fifteen weeks.~Adjuvant treatment (including the need of Anthracyclines) will be administered according clinical practice."
89605965|NCT05904236|Experimental|ICVB-1042|Part A: Dose escalation Part B: Dose expansion
89605966|NCT05900453||Usual Care TKA rehabilitation|This cohort of patients received Usual Care TKA rehabilitation at two outpatient physical therapy clinics in the Greenville, South Carolina, USA area. These patients received treatment guided by their clinician's professional judgment and the clinic's best practice guidelines for TKA.
89605967|NCT05900453||CDS tool TKA rehabilitation|This cohort of patients received TKA rehabilitation at the same two outpatient physical therapy clinics in the Greenville, South Carolina, USA area. These patients also received treatment guided by their clinician's professional judgement and the clinic's best practice guidelines. Additionally, this cohort of patients was exposed to the CDS tool (i.e., clinicians used the tool to view personalized information about the patient at least once during the patient's episode of care).
89605968|NCT05897905|No Intervention|Standard care|All participants will receive a brief routine stroke medical follow-up appointment.
89605969|NCT05897905|Experimental|Personalised, holistic based follow-up appointments underpinned by self determination theory.|Participants will receive two follow-up appointments at two and six weeks after discharge.
89605970|NCT05891821|Experimental|Balstilimab|300 mg IV every 3 weeks for a maximum of 24 months
89605971|NCT05891353|Active Comparator|Cold Water Immersion|Participants will complete a cold water immersion task to the hand for one minute, four times. Change in Pressure Pain Threshold will be measured between each one-minute interval on the web space of the foot between the first and second toes.
89605972|NCT05891353|Experimental|Pain Inducing Stretch|Participants will be seated in a chair and asked to complete an upper trapezius stretch. They will feel a gentle stretch in the area between the top of their shoulder and the base of their neck. Participants will be asked to stretch until the point of pain. They will hold this stretch for 1 minute, 4 times. Change in Pressure Pain Threshold will be examined on the web space of their foot between each one minute interval of the stretch. Participants will be notified that they may stop the stretch at any point if needed.
89605973|NCT05891353|Active Comparator|Pain Free Stretch|Participants will be seated in a chair and asked to complete an upper trapezius stretch. They will feel a gentle stretch in the area between the top of their shoulder and the base of their neck. Participants will be asked to stretch in a pain free range. They will hold this stretch for 1 minute, 4 times. Change in Pressure Pain Threshold will be examined on the web space of their foot between each one minute interval of the stretch. Participants will be notified that they may stop the stretch at any point if needed.
89605974|NCT05889104|Experimental|The Progressive Loading Group (PLG)|using Progressive Loading protocol.
89605975|NCT05889104|Other|TheControl Group (CG)|using a randomization program
89605976|NCT05886335||Cystitis hemorrhagic|Cystitis hemorrhagic grade II-III
89605977|NCT05886335||Non Cystitis hemorrhagic|Non cystitis hemorrhagic or grade I
89605978|NCT05883488|Experimental|Robotic rehabilitation group|The robotic rehabilitation group will receive a robot-assisted upper extremity rehabilitation program in addition to the conventional rehabilitation program.The robotic rehabilitation program (with the Armeo Spring Pediatric Robotic Rehabilitation system) will be implemented 3 days a week for 30 minutes.
89605979|NCT05883488|Active Comparator|Conventional rehabilitation group|Conventional rehabilitation program will be applied 5 days a week, lasting 60 minutes.
89605980|NCT05883137||Tight facemask or NIV|Preoxygenation with tight fitting facemask or NIV (non-invasive ventilation) according to the paitents need before anaesthesia induction.
89605981|NCT05883137||High Flow Nasal Oxygen and Tight facemask/ NIV|Pre and peri-oxygenation with HFNO using Optiflow Switch in addition to tight fitting facemask or NIV (non-invasive ventilation).
89605982|NCT05880095|Experimental|Unrestricted Mediterranean diet (MedD)|The aim of this group is to serve as control group. Participants will be advised to adhere to a traditional Mediterranean diet
89518391|NCT02249182|Experimental|3 to < 6 Years Old|"Participants between 3 to < 6 years of age weighing ≥ 17 kg will receive LDV/SOF FDC (45/200 mg granules as 4 x 11.25/50 mg packets) and participants weighing < 17 kg will receive LDV/SOF FDC (33.75/150 mg oral granules as 3 x 11.25/50 mg packets).~Treatment duration will be dependent on HCV genotype, prior treatment experience, cirrhosis status, and country of enrollment.~United Kingdom:~HCV GT 1, 4, 5, or 6 TN with or without cirrhosis = LDV/SOF 12 weeks~HCV GT 1, 4, 5, or 6 TE without cirrhosis = LDV/SOF 12 weeks~HCV GT 1, 4, 5, or 6 TE with cirrhosis = LDV/SOF 24 weeks~HCV GT 3 TE with or without cirrhosis = LDV/SOF+RBV 24 weeks~United States/Australia/New Zealand:~HCV GT 1, 4, 5, or 6 TN with or without cirrhosis = LDV/SOF 12 weeks~HCV GT 1, 4, 5, or 6 TE without cirrhosis = LDV/SOF 12 weeks~HCV GT 1 TE with cirrhosis = LDV/SOF 24 weeks~HCV GT 4, 5, or 6 TE with cirrhosis = LDV/SOF 12 weeks"
89518392|NCT05150561||Cohort I - Patients newly diagnosed with malignant lymphoma (n=72)|These patients will undergo two assessments: A baseline-assessment prior to treatment for the hematologic cancer disease and a follow-up assessment at 6 months after treatment start
89518393|NCT05150561||Cohort II - Patients newly diagnosed with acute leukaemia (n=72)|These patients will undergo two assessments: A baseline-assessment prior to treatment for the hematologic cancer disease and a follow-up assessment at 6 months after treatment start
89518394|NCT05150561||Cohort III - Patients newly diagnosed with multiple myeloma (n=72)|These patients will undergo two assessments: A baseline-assessment prior to treatment for the hematologic cancer disease and a follow-up assessment at 6 months after treatment start
89518395|NCT03487211|Active Comparator|Duloxetine Group|Duloxetine 30mg once daily to be started for 1 week. Dose will then be titrated to 60mg once daily and the patients followed for a total of 12 weeks.
89518396|NCT03487211|Experimental|Escitalopram Group|Escitalopram 10mg once daily to be started for 1 week. Dose will then be titrated to 20mg once daily and the patients followed for a total of 12 weeks.
88982118|NCT00318877|Experimental|After school sports|After school team sports
88982119|NCT00318877|Active Comparator|Health and Nutrition Education|Health and Nutrition Education Active Placebo Control
88982120|NCT00085124|Experimental|Arm I|"Remission induction therapy: Patients receive oblimersen IV continuously on days 1-10, cytarabine IV continuously on days 4-10, and daunorubicin IV on days 4-6.~Patients who achieve CR proceed to consolidation therapy. Patients who do not achieve CR receive a second course of induction therapy.~Second remission induction therapy: Patients receive oblimersen IV continuously on days 1-8, cytarabine IV continuously on days 4-8, and daunorubicin IV on days 4-5.~Patients who achieve CR proceed to consolidation therapy.~Consolidation therapy: Patients receive oblimersen IV continuously on days 1-8 and high-dose cytarabine IV over 3 hours on days 4-8. Patients with a continuing CR receive a second course of consolidation therapy."
89518397|NCT03485339||Case|Ketamine user with psychotic disorders
89518398|NCT03485339||Control Group 1|Ketamine user without psychotic disorders
89518399|NCT03485339||Control Group 2|Non-ketamine-using drug user with psychotic disorders
89518400|NCT03485339||Control Group 3|Non-ketamine-using drug user without psychotic disorders ( identified from register-based medical record system)
89518401|NCT03485261||Group A|patient group include 50 female patients with chronic renal failure (eGFR <15ml/min/1.7m2 )
89518402|NCT03485261||Group B|the control group including 50 healthy females age matched with the patient group
89518403|NCT03487133|Experimental|bortezomib/dexamethasone|Subjects who have been diagnosed with stable lesions more than 4 cycles of induction therapy (Induction Therapy Part I) will receive additional induction therapy 4 cycles (Induction Therapy Part II) Patients who have been diagnosed with a stable disease response after a total of eight cycles of induction therapy receive up to one year of maintenance therapy.
89518404|NCT03641339|Experimental|Cohort A: One vector feeding and three biopsies|Undergo one vector feeding and three biopsies on Day 0
89518405|NCT03641339|Experimental|Cohort B: Four vector feedings and three biopsies|Undergo 4 vector feedings over 8 weeks and 3 biopsy procedures after the 4th and final feeding
89518406|NCT02248480|Experimental|Duloxetine|Duloxetine 20 milligram (mg) for first week, 40 mg for second week and 60 mg for next 12 weeks administered orally once daily. Tapering week doses of 40 mg for three days and 20 mg for four days.
89518407|NCT02248480|Placebo Comparator|Placebo|Placebo administered orally once a day for 15 weeks.
89518408|NCT03564587|Experimental|AWAKE|The AWAKE intervention is an 8 week program including a mobile app and phone-based coaching, focused on improving hope in order to increase quality of life and health-promoting behaviors in young adult cancer survivors.
89518409|NCT03564587|No Intervention|No treatment|Control participants will receive the surveys to complete only; however, they may opt to receive the intervention after the 4-month assessment.
89518410|NCT01653158|Experimental|CP-751,871 combined with docetaxel|
89518411|NCT00701207|No Intervention|2.|control group-no intervention
89518412|NCT00701207|No Intervention|3|Healthy control group-blood and sputum samples
89518413|NCT00701207|Experimental|1.|nicotine patch; transdermal patch 7mg, 14 mg., 21 mg. 3 months
89518414|NCT02247466|Active Comparator|Group A - Saline, assesment, rocuronium and assesment|Intervention after intubation and placement of trocars without NMB. Bolus of saline (placebo) 6mL (TOF 100%) the surgeon assesses the surgical workspace with pneumoperitoneum 12 mmHg. After administration of rocuronium 0.6 mg/kg when TOF=0 the surgical workspace is assessed again
89518415|NCT02247466|Active Comparator|Group B - Rocuronium, assesment, sugammadex and assesment|Intervention after intubation and placement of trocars without NMB. Bolus of rocuronium 0.6 mg/kg when TOF=0 the surgeon assesses the surgical workspace with pneumoperitoneum 12 mmHg. Three minutes after administration of sugammadex (TOF 100%) the surgical workspace is assessed again
89518416|NCT03417479||1:1 Randomization|Patients will be randomized to either a single dose of 15mg/kg up to 600 mg of gabapentin or a placebo equivalent at a 1:1 ratio. The subjects will be enrolled in the study at the orthopedic surgeon's office with randomization occurring on the day of surgery by the hospital pharmacist. The method for the randomization will be the creation of a sequence of sealed envelopes containing assignment information for a dose of 600 mg of gabapentin or placebo.
89605983|NCT05880095|Experimental|Energy-reduced Mediterranean diet (MedD_RC)|The aim of this group is to allow the comparison between a traditional caloric restriction approach and a time-restricted eating program without caloric restriction.
89518417|NCT03317795|Active Comparator|Levonorgestrel IUS|Levonorgestrel-releasing intrauterine system (Mirena) contains 52 mg of levonorgestrel, a progestin, and is intended to provide an initial release of approximately 20 mcg/day. Levonorgestrel intrauterine system is effective immediately upon placement in the uterus and can be kept in place for up to 5 years.
89518418|NCT03317795|Active Comparator|Tranexamic Acid|Tranexamic Acid (Lysteda) is an antifibrinolytic drug. Tranexamic Acid will be dosed at 1300mg by mouth three times a day at the start of menses and used during the days that bleeding is heaviest (not to exceed 5 days per menstrual cycle).
89518419|NCT02202616|Other|ULTIBRO BREEZHALER|Patients diagnosed with chronic obstructive pulmonary disorder (COPD) who are symptomatic (CAT score over 10) and who are treated with Tiotropium (SPIRIVA HANDALER) or Fluticasone propionate/Salmeterol- ADVAIR DISKUS (FDC).
89518420|NCT04863677|Experimental|High Intensity Interval Training(HIIT)|The HIIT sessions include brief, intermittent bouts of high-intensity exercise interspersed with periods of low-intensity exercise (active recovery).HIIT include 20 intervals of high-intensity (30-60s at rating of perceived exertion (RPE; Borg scale of 6-20) of 15 to 17) and low-intensity (1min at RPE <10 or totally rest). The whole exercise cycle takes around 40-50 minutes.
89518421|NCT04863677|Experimental|Moderate Intensity Continuous Training(MICT)|Patients perform 40-50 minutes at a RPE of 12 to 14(a total of 4 groups, each group 5-8 min, interspersed with 2-minute rest)
89518422|NCT04863677|No Intervention|Control Group|No additional rehabilitation treatment or physical exercise was added in Control Group.
89518423|NCT03315221|Experimental|Test product|Human Milk Fortifier (HMF) with added lipids.
89518424|NCT03315221|Active Comparator|Control product|Commercially available HMF (without lipids).
89518425|NCT02455388|Experimental|Low, then high added sugar diet|Participants will consume a low added sugar (5% total energy) diet for 7 consecutive days. After a 4-week washout period, participants will then consume a high added sugar (25% total energy) diet for 7 consecutive days.
89518426|NCT02455388|Experimental|High, then low added sugar diet|Participants will consume a high added sugar (25% total energy) diet for 7 consecutive days. After a 4-week washout period, participants will then consume a low added sugar (5% total energy) diet for 7 consecutive days
89518427|NCT02455388|No Intervention|Dietary recall and fingerstick|Participants will complete 4 in-person 24-hr dietary recalls and 2 fingerstick blood samples at Visit 1 and 3 within 3 weeks.
89518428|NCT03245411|No Intervention|Standard of Care (Control Group)|All participants in this group will receive the standard of care intervention provided by the RN.
89518429|NCT03245411|Experimental|Intervention Group|"In addition to the standard of care, the participants randomized to Intervention Group will be invited to a separate room. The following activities will be undertaken, in order to address patients' questions and concerns, and discuss potential solutions to their barriers to care~The patient will be asked to watch brief educational videos on Life with oral cancer treatment. The information contained in the videos will be reinforced with materials written at a 4th grade level, that correspond to each of the brief videos.The patient will receive a brief phone call (from the study coordinator) on the first business day following the baseline interview, and thereafter, two weeks following each visit to the oncology clinic."
89518430|NCT03876119|Experimental|Intraarterial alteplase|"All the patients will be given a 15 minutes IA infusion of alteplase (Actylise®) at a drug concentration of 1.0 mg/ml. At 15 minutes of IA treatment onset, the infusion will be stopped and the angiographic score assessed. If the angiographic score is improved compared with the baseline score the procedure is terminated, otherwise a new angiographic series will be repeated in 10 minutes before the end of the procedure in front and profile projections.~Study drug will be prepared according to the following steps:~Dilute 3 vials of 10 mgs (alteplase) in 30 cc of sterile water for injection (SWI), to attain a 30 cc solution at a concentration of 1mg/ml~Calculate the volume of cc of infusion and therefore the total dose as per the formula: (Patient's weight in Kgs multiplied by 0.225)"
89518431|NCT03876119|Placebo Comparator|Placebo|"The placebo will consist of a lyophilized white powder containing 0.2 mol/L arginine phosphate, 0.01% polysorbate 80, and pH 7.4 after reconstitution.~Study drug will be prepared according to the following steps:~Dilute 3 vials of 10 mgs (placebo) in 30 cc of sterile water for injection (SWI), to attain a 30 cc solution at a concentration of 1mg/ml~Calculate the volume of cc of infusion and therefore the total dose as per the formula: (Patient's weight in Kgs multiplied by 0.225)"
89518432|NCT03487055|Experimental|treatment group|The subjects would receive 120 mg TK006 every 4-week over a period of 84 days.
89518433|NCT04751045|Active Comparator|Percutaneous Liver biopsy|"Technique: The preprocedure time out protocol will be completed prior to initiation of the procedure. The patient will be positioned supine and right hepatic lobe was localized with ultrasound. Conscious sedation with Versed and fentanyl will be initiated and the patient's vital signs were monitored by an independent trained observer during the procedure.~After placing a mark on the skin overlying the right upper quadrant, the skin was then prepped and draped in the usual sterile fashion. Maximum sterile barrier technique used at the procedure. Under direct sonographic guidance, a 15 gauge percutaneous liver biopsy needle will be used with a 2 cm throw was advanced into the right hepatic lobe. The biopsy samples will be obtained and submitted to pathology."
89518434|NCT04751045|Active Comparator|Endoscopic ultrasound guided liver biopsy|Procedure details: patients will be screened preoperatively to assess cardiovascular health prior to undergoing procedure as this is standard of care. Patients will follow all standard preoperative instructions prior to anesthesia. Upon undergoing general anesthesia, a videoendoscope will be introduced into the esophagus under direct vision. Once endoscope is in position near the liver, a 19-gauge sharkcore needle will be used to puncture the left lobe with a 3 accentuation and another pass from right lobe with 4 accentuation. Doppler study will be used to interrogate for any significant doppler signals in needle path. Post procedure, patients will be provided instructions to avoid NSAIDs for 4 days and perform lightweight activity for 4 days. Patients will be observed for bleeding and significant abdominal pain postoperatively
89518435|NCT03486977||Establishments with telemedicine system|Establishments equipped for telemedicine (teleconsultation, casualty) as part of the regional project of the Aquitaine regional program telemedicine device deployment.
89605984|NCT05880095|Experimental|Mediterranean diet with time-restricted eating (MedD_TRE)|This is the intervention group designed to asses the main hypothesis.
89605985|NCT05875259|Experimental|Sequence 1|"The Investigational products will be administered according to the treatment groups(A,B,C) assigned to each sequence group in Period 1, Period 2, and Period 3.~*sequence 1: A-B-C"
89605986|NCT05875259|Experimental|Sequence 2|"The Investigational products will be administered according to the treatment groups(A,B,C) assigned to each sequence group in Period 1, Period 2, and Period 3.~*sequence 2: A-C-B"
89605987|NCT05875259|Experimental|Sequence 3|"The Investigational products will be administered according to the treatment groups(A,B,C) assigned to each sequence group in Period 1, Period 2, and Period 3.~*sequence 3: B-A-C"
89605988|NCT05875259|Experimental|Sequence 4|"The Investigational products will be administered according to the treatment groups(A,B,C) assigned to each sequence group in Period 1, Period 2, and Period 3.~*sequence 4: B-C-A"
89605989|NCT05875259|Experimental|Sequence 5|"The Investigational products will be administered according to the treatment groups(A,B,C) assigned to each sequence group in Period 1, Period 2, and Period 3.~*sequence 5: C-A-B"
89605990|NCT05875259|Experimental|Sequence 6|"The Investigational products will be administered according to the treatment groups(A,B,C) assigned to each sequence group in Period 1, Period 2, and Period 3.~*sequence 6: C-B-A"
89605991|NCT05874791|Experimental|Goal management training|Cognitive rehabilitation:14 hours of GMT in groups of 4-6 participants, administered following a script with accompanying PowerPoint slides and participant workbooks, over the course of 7 weeks (one 2-hour session per week). In addition, the participants receive Treatment as Usual
89605992|NCT05874791|No Intervention|Treatment as Usual|Norway has established clinical guidelines for ADHD assessment and treatment in public health, emphasizing psychoeducation, parent management training, school counseling, and pharmacological treatment adapted to the needs of each patient
89605993|NCT05871437|Experimental|Huaier Granule|Huaier Granules: oral administration, 10g once, 3 times a day, used for 1 year, or intolerable toxicity, withdrawal from the study for any reason, or death, whichever occurs first; Or the researcher determines that they no longer benefit. If the patient experiences grade 3-5 (NCI CTC AE V5.0) adverse reactions related to Huai'er granules, and the adverse reactions do not recover after 2 weeks (returning to grade 1 or 2), it can be considered to reduce dosage or stop Huai'er granules treatment. If the medication is suspended for more than 2 weeks, the medication can be interrupted according to the judgment of the researcher. If the same adverse reaction occurs again, the Huaier granules will be permanently discontinued.
89605994|NCT05871320|Experimental|[99mTc]Tc-TECANT1|The injection volume will be up to 5 mL over 20 seconds with an activity of 10 MBq/kg body weight (range between min. 500 and max. 800 MBq). To ensure application of the complete activity additionally 10 mL of 0.9% saline will be infused via the same system.
89605995|NCT05860673|Experimental|mini invasive scoliosis surgery (MIS)|This technique involves making small, noncontiguous, midline skin incisions at the levels to be instrumented, usually proximal and distal to the area of arthrodesis. A median fascial incision is then made to expose the vertebral segments on which to thread the screws while the bar is inserted submuscularly in a cranio-caudal direction, after appropriate maneuvers to correct the deformity.
89605996|NCT05860673|Active Comparator|posterior spinal fusion technique (PSF)|This technique is the surgical gold standard. It consists of an instrumented arthrodesis with posterior access and requires a wide median incision with extensive muscle dissection.
89605997|NCT05857150||Lean Group|Participants with body mass index 20-25 kg/m^2 will complete an outpatient study visit (body composition, blood draw, treadmill test, strength test) and an inpatient visit (muscle biopsies, fat biopsies, indirect calorimetry, exercise test).
89605998|NCT05857150||Obese Group|Participants with body mass index 30-45 kg/m^2 will complete an outpatient study visit (body composition, blood draw, treadmill test, strength test) and an inpatient visit (muscle biopsies, fat biopsies, indirect calorimetry, exercise test).
89605999|NCT05857007||Libre 2.0 CGM in patients taking EndoTool IV insulin|Ten patients with Hyperglycemia or/and Diabetes in the neuro ICU requires IV insulin through EndoTool algorithm will wear Libre 2.0 CGM for either 14 days or their stay in the neuro ICU
89606000|NCT05852145|Placebo Comparator|Tea lemon flavor|"355 ml of tea lemon flavor should be drunk~Salivary pH will be collected at 0,5,10,15,30,45 and 60 minutes later~Dental biofilm pH will be collected at 0,5,10,15,30,45 and 60 minutes later~Streptococcus mutans dental biofilm formation ( Colony Forming Units) will be collected at 0 and 120 minutes later~Operative Taxonomic Units of dental biofilm will be analyzed at 0 minutes and 120 minutes later"
89606001|NCT05852145|Experimental|Stevioside|"355 ml of tea lemon flavor added with 2.2 grams of stevioside should be drunk~Salivary pH will be collected at 0,5,10,15,30,45 and 60 minutes later~Dental biofilm pH will be collected at 0,5,10,15,30,45 and 60 minutes later~Streptococcus mutans dental biofilm formation ( Colony Forming Units) will be collected at 0 and 120 minutes later~Operative Taxonomic Units of dental biofilm will be analyzed at 0 minutes and 120 minutes later"
89606002|NCT05852145|Active Comparator|Sucrose|"355 ml de tea lemon flavor added 7.5 grams with should be drunk.~Salivary pH will be collected at 0,5,10,15,30,45 and 60 minutes later~Dental biofilm pH will be collected at 0,5,10,15,30,45 and 60 minutes later~Streptococcus mutans dental biofilm formation ( Colony Forming Units) will be collected at 0 and 120 minutes later~Operative Taxonomic Units of dental biofilm will be analyzed at 0 minutes and 120 minutes later"
89606003|NCT05850494|Experimental|Treatment A: HFO propellant only MDI|Test arm, 4 inhalations per dose
89606004|NCT05850494|Active Comparator|Treatment B: HFA propellant only MDI|Reference arm, 4 inhalations per dose
89606005|NCT05850351|Experimental|Virtual reality|Children with cystic fibrosis will be given exercise in the form of a game in a virtual environment in groups of 4-6 children, accompanied by a physiotherapist, for 12 weeks, 3 days a week, between 30-45 minutes.
89518436|NCT03486977||Establishments without telemedicine system|"Defined and equipped for telemedicine EHPAD after mating on the number of residents, the GMP (average weighted GIR), the PMP (weighted average PATHOS), the distance to a hospital with an emergency shelter service.~The rate of unscheduled hospitalizations will be collected during follow-up visits in clinical departments of the healthcare of the Gironde by a research staff"
89518437|NCT02455076|Active Comparator|Exenatide inpatient|Patients with Type 2 Diabetes treated with diet, oral antidiabetic drugs, or with low-dose insulin will receive exenatide (Byetta®) twice daily. Supplemental (correction) doses of rapid-acting insulin analogs will be given for blood glucose levels > 140 mg/dL per the sliding scale.
89518438|NCT02455076|Active Comparator|Exenatide plus glargine insulin inpatient|Patients with Type 2 Diabetes treated with diet, oral antidiabetic drugs, or with low-dose insulin will receive exenatide twice daily and glargine once daily. Glargine insulin will be given once daily at the same time. Supplemental (correction) doses of rapid-acting insulin analogs will be given for blood glucose levels > 140 mg/dL per the sliding scale.
89518439|NCT02455076|Active Comparator|Basal bolus regimen inpatient|Patients with Type 2 Diabetes treated with diet, oral antidiabetic drugs, or with low-dose insulin will receive the Basal Bolus Regimen with Glargine and Rapid-Acting Insulin Analogs. Patients treated with insulin previously will receive 80% of total home daily insulin dose as the basal bolus. Half of the total daily dose will be given as glargine and half as rapid-acting insulin analogs. Supplemental (correction) doses of rapid-acting insulin analogs will be given for blood glucose levels > 140 mg/dL per the sliding scale.
89606006|NCT05850351|Experimental|Online|Children with cystic fibrosis will be given online aerobic exercise for 12 weeks, 3 days a week, 30-45 minutes, in groups of 4-6 children, accompanied by a physiotherapist.
89606007|NCT05846113|Experimental|Renacare patients|"Male or female patients, age 18 years or older at the time of signing the informed consent form (ICF). If over the age of 65, patient must have a family history of CKD or clinical suspicion of genetic disorder.~Diagnosis of kidney disease"
89606008|NCT05844904||General|This research is an observational study. There's no control and experimental group.
89606009|NCT05842512|Experimental|Drug: ADI-PEG 20|Dose: 36 mg/m2 given weekly Route of Administration: Intramuscular (IM)
89606010|NCT05842512|Placebo Comparator|Drug: Placebo|Dose: 36 mg/m2 given weekly Route of Administration: Intramuscular (IM)
89606011|NCT05839743|Experimental|Aerobic Exercise Group|
89606012|NCT05839743|Experimental|Balance Exercise Group|
89606013|NCT05839743|Experimental|Combined Exercise Group|
89606014|NCT05839639|Active Comparator|NrtIs|
89606015|NCT05839639|Experimental|HH-003|
89606016|NCT05839639|Experimental|HH-003+NrtIs|
88982121|NCT00085124|Experimental|Arm II|"Remission induction therapy: Patients receive cytarabine IV continuously on days 1-7 and daunorubicin IV on days 1-3.~Patients who achieve CR proceed to consolidation therapy. Patients who do not achieve CR receive a second course of induction therapy.~Second remission induction therapy: Patients receive cytarabine IV continuously on days 1-5 and daunorubicin IV on days 1 and 2.~Patients who achieve CR proceed to consolidation therapy.~Consolidation therapy: Patients receive high-dose cytarabine IV over 3 hours on days 1-5. Patients with a continuing CR receive a second course of consolidation therapy."
88982122|NCT00318955|Experimental|Dexmedetomidine group|
88982123|NCT00318955|Active Comparator|Propofol group|
88982124|NCT00325936|Active Comparator|Nifedipine|parrallel design
89606017|NCT05839145|Other|Home to onsite monitoring|Patients will be monitored and evaluate in a first time at home then onsite.
89606018|NCT05839145|Other|Onsite to Home monitoring|Patients will be monitored and evaluate in a first time onsite then at home .
89606019|NCT05837897|Experimental|Induction Period: Vedolizumab 300 mg|Participants will receive vedolizumab 300 mg IV infusion on Days 1,15, and 43 (Weeks 0, 2, and 6) in the 14-week Induction Period.
89606020|NCT05837897|Placebo Comparator|Induction Period: Placebo|Participants will receive vedolizumab placebo-matching IV, infusion on Days 1,15, and 43 (Weeks 0, 2, and 6) in the 14-week Induction Period.
89606021|NCT05837897|Experimental|Open-label Extension (OLE) Period: Vedolizumab 300 mg|All participants completing the Week 14 visit, irrespective of their response status, will continue in the OLE without unblinding of their baseline treatment group and will receive vedolizumab 300 mg, IV infusion, Q8W, on Days 99, 155, 211, 267, 323, and 379 (Weeks 14, 22, 30, 38, 46 and 54). Starting from Day 127 (Week 18) until the end of OLE Period up to approximately 58 weeks, participants who are nonresponders or who have disease worsening are eligible to receive 300 mg vedolizumab Q4W.
89606022|NCT05821868|Active Comparator|Aerochamber Plus® Flow-Vu®|1. Inhaled space chamber commonly use in our lung function lab for Bronchodilator Testing
89606023|NCT05821868|Experimental|Dosivent|2. Newer and different inhaled space chamber for Bronchodilator Testing
89606024|NCT05813132|Active Comparator|BeEAM Regimen|BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan)
89606025|NCT05813132|Active Comparator|CEM Regimen|CEM (Carboplatin, Etoposide, Melphalan)
89606026|NCT05811442|Experimental|50561 256mg|50561 at a dose of 256mg n=20 group
89606027|NCT05811442|Experimental|50561 128mg|50561 at a dose of 128mg n=20 group
89606028|NCT05811442|Placebo Comparator|placebo|Placebo n=20 group
89606029|NCT05803486||experimental group|examined by ultrasound image to measure quadratus lumborum thickness, pelvic floor muscles force and diaphragm excursion in patients with urinary incontinence
89606030|NCT05803486||control group|examined by ultrasound image to measure quadratus lumborum thickness, pelvic floor muscles force and diaphragm excursion in patients with urinary incontinence
89518440|NCT02455076|Active Comparator|Exenatide outpatient|Patients with Type 2 Diabetes treated with diet, oral antidiabetic drugs, or with low-dose insulin will receive exenatide (Byetta®) twice daily. Supplemental (correction) doses of rapid-acting insulin analogs will be given for blood glucose levels > 140 mg/dL per the sliding scale.
89518441|NCT02455076|Active Comparator|Insulin Only|Patients with Type 2 Diabetes will be treated with Insulin only
89518442|NCT03485183|Experimental|Intervention Group|The PI will set up the PicTek white/pink noise machine on the bedside table, and it will automatically turn on at 2200 and off at 0700 to the patient's preferred sound. The staff nurses will chart Nu-DESC scores every shift and as needed for change in mental status as is the current policy. The PI will collect Nu-DESC scores for the duration of the participants' hospital stays, age, race, gender, presence of a dementia diagnosis, and use of a pharmacological sleep aid.
89606031|NCT05800834|Experimental|Morphine sulfate|Topical morphine with hydrogel base.
89606032|NCT05800834|Active Comparator|Lidocaine Hcl 2% jelly|2% lidocaine jelly
89518443|NCT03485183|Other|Control Group|The PI will perform a chart review of patients who were admitted the month prior to the intervention being implemented. The PI will collect Nu-DESC scores for the duration of the participants' hospital stays, age, race, gender, presence of a dementia diagnosis, and use of a pharmacological sleep aid. These patients will receive the standard of care for delirium prevention.
89518444|NCT02433080|Active Comparator|Shape-Up following cancer treatment|"In addition to usual care, cancer survivors in the intervention group will participate in a behaviour change programme, called Shape-Up following cancer treatment: a self-help programme on eating well and being active. Participants will be allocated to groups of eight to ten. These groups will meet every week for eight weeks and each session will last approximately 90 minutes. The programme focuses on strategies for improving diet and physical activity in a self-help and peer education format. Each week, one participant will volunteer to present a new concept (e.g. regular eating, being active, eating a balanced diet, keep an eye on portion sizes, and manage internal and external triggers, and understanding food labeling) to the rest of the group."
89606033|NCT05798325|Other|Principal|
89606034|NCT05797766|Experimental|Treatment|The fluid distribution timetable as defined by Mina et al. (2019) is a scheduled distribution of predetermined amounts of fluid intake daily depicted in a 5x6 table. The timetable has three major columns. The first column has six-time points of a day with a four-hour interval. The second column, which was divided into four sub-columns, reflects the percentage of fluid allotment for food, activities, medication, and thirst encounters. The percentage of fluid allocation was computed based on the patient's prescribed fluid restriction, usual time of food intake per day, usual level of activity, time of medication intake, and common time they encounter thirst for a day. The third column indicates the converted percentage of fluid allotment into milliliters.
89606035|NCT05797766|No Intervention|Control|Standard care that consists of 10 to 15 minutes of face-to-face health teaching of their treatment regimen including management of medication, vascular access, dietary and fluid, and hemodialysis schedule.
89606036|NCT05793905|Experimental|Buffered lidocaine|Inferior alveolar nerve block with buffered anesthetic solution (2% lidocaine with 1/80000 adrenaline mixed with sodium bicarbonate 8.4%)
89606037|NCT05793905|Other|Lidocaine 2%|"Control group:~Inferior alveolar nerve block with anesthetic solution (Lidocaine 2% with adrenaline 1.80000)."
89606038|NCT05793099|Experimental|Aqueous propolis 5% gum|The children will be given aqueous propolis gums to chew for 15 minutes.
89606039|NCT05793099|Placebo Comparator|Placebo gum|The children will be given placebo gums gums to chew for 15 minutes.
89606040|NCT05792046||Normal|Subjects with normal visual function
89606041|NCT05786534|Experimental|Metabolic Syndrome patients|Green seaweed Ulva Lactuca is used for preventing symptoms in Metabolic Syndrome patients
89606042|NCT05785819|Experimental|VLX-1005|VLX-1005 200 mg given every 12 hours by intravenous infusion over 1 hour.
89606043|NCT05785819|Placebo Comparator|Placebo|Placebo given every 12 hours by intravenous infusion over 1 hour.
89606044|NCT05781711|Experimental|Control Group|Control group ( Levo-dopa group, n =30 ) who will receive levodopa/carbidopa (50/250 mg) three times daily for 3 months
89606045|NCT05781711|Active Comparator|Metformin group|Patients will receive levodopa/carbidopa (50/250 mg) three times daily plus metformin 500 mg two times daily for 3 months
89606046|NCT05778591|Experimental|Placebo, buprenorphine|One group will receive placebo first, then buprenorphine (0.15mg).
89606047|NCT05778591|Experimental|Buprenorphine, placebo|One group will receive buprenorphine (0.15mg) first, then placebo.
89606048|NCT05774353|Other|Patient questionnaire|Patients included in the study will complete an online questionnaire (LimeSurvey).
89606049|NCT05767762|Experimental|Idiopathic Clubfoot|
89606050|NCT05766488|Experimental|Continuous Glucose Monitoring Arm|Participants in this arm will use a Freestyle Libre 2 monitoring device for 6 months to track their blood glucose levels while receiving usual patient care within an interprofessional primary care team.
89606051|NCT05766488|Active Comparator|Traditional Glucometer Arm|Participants in this arm will use a traditional glucose monitoring device (glucometer) to self-monitor their blood glucose for 6 months while receiving usual patient care within an interprofessional primary care team.
89606052|NCT05766215|Experimental|Therapeutic patients education|3 sessions of structured therapeutic patient education (TPE) in which diet, exercise, alcohol abuse and insulin or pharmacological treatment management advise is given.
88982125|NCT00325936|Experimental|Cilnidipine|
88982126|NCT00093600|Experimental|PKC412 administered sequentially|twice daily oral dosing of PKC412 administered sequentially
89606053|NCT05761795|Experimental|IVMED-85 Low Dose and placebo|Total subjects n=6 n=4 IVMED 85 Low Dose n=2 placebo BID for 1 month
89606054|NCT05761795|Experimental|IVMED-85 Mid Dose and placebo|Total subjects n=6 n=4 IVMED 85 Mid Dose n=2 placebo BID for 1 month
89606055|NCT05761795|Experimental|IVMED-85 High Dose and placebo|Total subjects n=6 n=4 IVMED 85 High Dose n=2 placebo BID for 1 month
89606056|NCT05761795|Experimental|IVMED-85 Low Dose|Total subjects n=48 IVMED 85 Low Dose BID for 12 month
89606057|NCT05761795|Experimental|IVMED-85 Mid Dose|Total subjects n=48 IVMED 85 Mid Dose BID for 12 month
89606058|NCT05761795|Experimental|IVMED-85 High Dose|Total subjects n=48 IVMED 85 High Dose BID for 12 month
89606059|NCT05761795|Placebo Comparator|Placebo|Total subjects n=54 Placebo BID for 12 month
89606060|NCT05759260||Cases|Athletes with QT interval prolongation
89606061|NCT05759260||Controls|Athletes without QT interval prolongation
89518445|NCT02433080|No Intervention|Control intervention|"Participants in the control group will be offered usual care until the 24-week follow-up. Quantifying usual care is challenging, but preliminary qualitative work suggested that most survivors do not received any unsolicited advice about healthy eating and physical activity from their health care professionals after treatment.~During the course of their participation in the trial, participants will be contacted only for the assessments. After the completion of the 24-week follow-up, participants will receive the booklet Healthy living after cancer; a brief self-help manual produced by the World Cancer Research Fund. Providing only this information aims to match the currently offered usual care as accurately as possible but also meet ethical standards."
89518446|NCT03092219|Experimental|TEOSYAL RHA Redensity|Injection of TEOSYAL RHA Redensity into the perioral lines (n=150). Up to 6.0 mL (max 3 mL for upper and max 3 mL for lower) injected into the dermis, including the superficial dermis. Touch-up treatment provided at 2 weeks.
89518447|NCT03092219|No Intervention|No Treatment|No treatment control group (n=52).
89518448|NCT04634123|Experimental|Primary anterior teeth pulpotomy by White Portland Cement|
89518449|NCT04634123|Other|Primary anterior teeth pulpotomy by White MTA|
89518450|NCT04460261|Experimental|COPD Group|Patients with COPD
89518451|NCT04460261|Experimental|Non-COPD Group|Non-COPD
88982127|NCT00093600|Experimental|PKC412 administered concomitantly|PKC412 administered concomitantly with standard induction daunorubicin and cytarabine therapy followed by high-dose consolidation therapy with cytarabine
88982128|NCT00326014|Experimental|A|
89518452|NCT04460105|Experimental|Lanadelumab|Participants receive 300 milligram (mg) of lanadelumab intravenous (IV) infusion on Day 1 during Cohort 1 (single dose cohort) and on Day 1 and Day 4 during Cohort 2 (repeat-dose cohort).
89518453|NCT04460105|Placebo Comparator|Placebo|Participants will receive placebo matching IV infusion on Day 1 during Cohort 1 (single dose cohort) and on Day 1 and Day 4 during Cohort 2 (repeat-dose cohort).
89518454|NCT03486743|Experimental|Intervention arm|Participants in the intervention arm will be asked to watch a short educational video on LARC (Long acting reversible contraceptive) and to complete a survey before and after watching the video.
89518455|NCT03486743|No Intervention|Control arm|Participants in the intervention arm will only be asked to complete a survey.
89518456|NCT03485105||CTX-benefit group|CTX-benefit group: based on the result of nProfiler Stomach cancer assay kit which was decided by expression level of mRNA, this group will be beneficial from adjuvant chemotherapy
89518457|NCT03485105||no-benefit group|no-benefit group: based on the result of nProfiler Stomach cancer assay kit which was decided by expression level of mRNA, this group will not be beneficial from adjuvant chemotherapy
89518458|NCT03485105||high-risk group|high-risk group: based on the result of nProfiler Stomach cancer assay kit which was decided by expression level of mRNA, the prognosis of this group will be worse compared to others regardless of the response to adjuvant chemotherapy
89518459|NCT03485027|Experimental|The rechallenge regimens|"XELOX ± BEV, repeating every 3 weeks.~FOLFOX ± BEV, repeating every 2 week~FOLFOX ± Cetuximab, repeating every 2 week~FOLFIRI ± BEV, repeating every 2 weeks.~FOLFIRI ± Cetuximab, repeating every 2 weeks.~IRI ± BEV, repeating every 2 weeks.~IRI ± Cetuximab, repeating every 2 weeks.~Raltitrexed ± BEV, repeating every 3 weeks.~Raltitrexed ± Cetuximab, repeating every 2 weeks."
89518460|NCT03486665||Diagnosed with Multiple Sclerosis|Patients previously diagnosed with Multiple Sclerosis
89518461|NCT03486665||Newly Diagnosed with Multiple Sclerosis|Patients diagnosed for the first time with Multiple Sclerosis and hospitalized
89518462|NCT03486665||Healthy Volunteers|Health volunteers who do not have an autoimmune diseases, including Multiple Sclerosis
89518463|NCT03486587|Experimental|Changfukang® group|Patients in Changfukang group will receive Changfukang® (Bacillus Cereus tablets).
89518464|NCT03484949|Experimental|pre-endoscopic screening risk assessment|
89518465|NCT03484949|No Intervention|routine screening|
89518466|NCT02432846|Experimental|Intuvax (INN: ilixadencel)+ Nephrectomy+Sunitinib|Two Intuvax (INN: ilixadencel) doses (10 million cells/dose) 14 days apart before nephrectomy, followed by Sunitinib treatment post-nephrectomy according to clinical practice until RECIST verified progressive disease or End-of-Study (78 weeks after screening).
89518467|NCT02432846|Active Comparator|Nephrectomy+Sunitinib|Sunitinib treatment post-nephrectomy according to clinical practice until RECIST verified progressive disease or End-of-Study (78 weeks after screening).
89518468|NCT03484793|Experimental|AESOP integrated to CPOE for reducing medication errors|18 were assigned to the experimental group
89518469|NCT03484793|No Intervention|Non AESOP|19 were assigned to the traditional CPOE system
89518470|NCT03486509|Experimental|afatinib 40mg bid plus chemotherapy|afatinib 40mg bid po plus chemotherapy
89518471|NCT03484715|Experimental|Physical Activity Intervention|Each participant in this arm will outline a small number of activity-related goals and will receive a 4 month personalised physical programme where additional physical activity will be incorporated into their daily routines. Nursing home staff will receive two educational sessions, which will provide them with the necessary skills to monitor participants physical activity programmes within the nursing home.
89518472|NCT03484715|No Intervention|Usual Care Control|The participants in the control arm will receive usual care, which will be guided by current nursing and medical care plans.
89518473|NCT01546571|Placebo Comparator|POL-103A without API|
89518474|NCT01546571|Experimental|POL-103A|
89518475|NCT03484637||Lifestyle-medicine intervention|Photographic follow-up every 4 weeks
89518476|NCT02432144|Experimental|UX003|4 mg/kg UX003 every other week (QOW)
89518477|NCT03484559||1|
89518478|NCT05388383||free-hand|spine surgery without robot
89518479|NCT05388383||robot-assisted|Robot-assisted open surgery
89518480|NCT05388383||mi|Robot-assisted minimally invasive surgery
89518481|NCT02246998|Experimental|STB+iohexol|Participants will receive STB+iohexol for 24 weeks.
89518482|NCT02246998|Experimental|RTV+ATV+TVD+iohexol|Participants will receive RTV+ATV+TVD+iohexol for 24 weeks.
89518483|NCT02246998|Experimental|ATR+iohexol|Participants will receive ATR+iohexol for 24 weeks.
89518484|NCT02246998|Experimental|RTV+ATV+ABC/3TC+iohexol|Participants will receive RTV+ATV+ABC/3TC+iohexol for 24 weeks.
89518485|NCT04928222|Active Comparator|Doxorubicin-containing MNA - 100 µg|A doxorubicin-containing array of 100 µg will be applied to subjects.
89518486|NCT04928222|Experimental|Placebo MNA for Training|Training phase for application of arrays
89518487|NCT02486588|No Intervention|Control--no weekly message|10% cash back level, no weekly message, and the standard monthly message
88982129|NCT00319150|No Intervention|Standard of Care|Epo dose to remain constant throughout study
88982130|NCT00319150|Active Comparator|Dosage Decrease Arm|Arm 2 is to have an decrease of erythropoietin at regular intervals.
88982131|NCT00400088|Experimental|lithium group|Start at 600 mg po hs. Dose titrated up to a serum level of between 0.6 and 1.1 mmol/l.
88982132|NCT00400088|Active Comparator|paroxetine group|Start dose at 20 mg po od. If no clinical improvement(<20% reduction in MADRS score) by week 4 dose to be increased to 40 mg po od.
88982133|NCT04727385|Experimental|single-arm of 3 cohorts|"These patients will be sequentially recruited in 3 cohorts :~One disc level cohort: 5 patients with only one disc to be treated; First enrolled cohort with 48 weeks of follow-up (9 visits V1-V9)~Two disc level cohort: 5 patients with 2 discs to be treated; Second enrolled cohort with 36 weeks of follow-up (8 visits, same visits except for V9)~One or two disc level cohort: 10 patients with 1 or 2 discs to be treated; Third enrolled cohort with 24 weeks of follow-up (6 visits, V1 to 7 except for V4)"
88982134|NCT00319267|Experimental|Bosentan|The initial dose of bosentan was 2 mg/kg b.i.d. for 4 weeks. After 4 weeks, the initial dose was up-titrated to the maintenance dose of 4 mg/kg b.i.d. up to the end of the study treatment at Week 12. If the maintenance dose was not well tolerated, the dose could be down-titrated to the initial dose.
88982135|NCT00085280|Experimental|Treatment (erlotinib hydrochloride)|"Patients receive oral erlotinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Patients complete the Smoking Status Survey, a questionnaire regarding smoking habits, at baseline, and then every 3 months during study treatment."
88982136|NCT00326248|Experimental|Arm 1|
88982137|NCT04727112||asthma and rhinitis|Screening of patients with upper and lower airway symptoms
88982138|NCT04727112||asthma and rhintis follow-up|same Group as screened in 2000, was followed up three years later
88982139|NCT00085358|Experimental|Treatment (carboplatin, paclitaxel, docetaxel, bevacizumab)|"Patients receive IP carboplatin on day 1, and paclitaxel IV over 3 hour (part A) or docetaxel IV over 1 hour (Part B) on day 1, and IP paclitaxel on day 8. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.~Patients receive IP carboplatin on day 1, paclitaxel IV on day 1, and IP paclitaxel on day 8 in course 1 as in part A dose-escalation phase. Beginning in course 2 and all subsequent courses, patients receive IP carboplatin on day 1, IV paclitaxel on day 1, and IP paclitaxel on day 8 as in the dose-escalation phase, and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity."
88982140|NCT00319423|Active Comparator|Patient education|Patient education according to Klassbo et al 2003
88982141|NCT00319423|Experimental|Patient education and supervised exercise|Patient education according to Klassbo et al 2003. Supervised exercise containing strengthening, functional and flexibility exercises.
88982142|NCT00124293||Factor VII|
89518488|NCT02486588|Experimental|General Weekly Message|10% cash back, general weekly message, standard monthly message
89518489|NCT02486588|Experimental|Personalized Weekly Message|10 % cash back, personalized weekly message, standard monthly message
89518490|NCT02486588|Experimental|25 percent cash back|25% cash back, personal weekly message, standard monthly message
89518491|NCT02486588|Experimental|Standard monthly message|10%+15% cash back, personal weekly message, standard monthly message
89518492|NCT02486588|Experimental|Unbundled monthly message|10%+15% cash back, personal weekly message, unbundled monthly message
89518493|NCT00805961|Experimental|Intervention|"Combined Modality Treatment and Systemic Therapy~Combined Modality Therapy - Radiation Therapy: 2 Gy/fraction, single daily fractions Monday-Friday, to total of 60 Gy Temozolomide: 75 mg/m2 by mouth daily Bevacizumab: 10 mg/kg IV every 2 weeks (Weeks 1, 3, 5, and 7)~After the last dose of radiation, patients exhibiting an objective response, stable disease on MRI scan, or have stable/improved tumor-related symptoms will begin systemic therapy~Systemic Therapy - Bevacizumab: 10 mg/kg IV every 2 weeks Everolimus: 10 mg by mouth daily"
89518494|NCT02202538|Experimental|Indego|Indego
89518495|NCT03484481||1;Oral nutritional support (ONS)|patients ongoing hemodialysis who received only oral nutritional support (Nutrena) and refused intradialytic parenteral nutrition; n: 14
89518496|NCT03484481||2; Intradialytic Parenteral Nutrition|patients ongoing hemodialysis who received only Intradialytic Parenteral Nutrition (Kabiven central) and refused parenteral nutrition; n: 14
89518497|NCT03484481||group 3; combination group|patients ongoing hemodialysis received both ONS and Intradialytic Parenteral Nutrition NS; n: 10
89518498|NCT03484481||group 4; dietetic support group;|patients ongoing hemodialysis who refused all types of nutritional support and only followed by counselling, n: 18
89518499|NCT02454608|Experimental|Treatment|Verapamil HCl, capsules for oral administration, 80mg, TID, for 8 weeks
89518500|NCT02454608|Placebo Comparator|Control|Placebo, capsules for oral administration, TID, for 8 weeks
89518501|NCT02454608|Experimental|Open Label|Verapamil HCl, capsules for oral administration, 80mg, TID, for 1 year
89518502|NCT05152433|Active Comparator|Conventional therapy|Length of period: 2 weeks
89518503|NCT05152433|Experimental|Therapy assisted by a humanoid robot (E-BRAiN)|Length of period: 2 weeks Fixed dose: 10 therapy sessions with E-BRAiN
89518504|NCT05152355|Experimental|Budesonide HFA MDI (Treatment A)|Participants assigned to Experimental arm will inhaled 2 puffs of budesonide 200 mcg HFA MDI bid (am 08:00 and pm 16:00) for 4 weeks
89518505|NCT05152355|Active Comparator|Budesonide DPI (Turbuhaler) (Treatment B)|Participants assigned to Active Comparator arm will inhaled 4 puffs of budesonide 100 mcg powder for inhalation bid (am 08:00 and pm 16:00) for 4 weeks
89518506|NCT03484247|Active Comparator|Group Infraclavicular|Infraclavicular Brachial Plexus Block: The inferolateral of the subclavian artery will be targeted with a 85 mm peripheral nerve stimulator needle with ultrasound guidance. When the needle tip was seen near the posterior cord of brachial plexus local anesthetic will be administered with single injection after aspiration.
89606062|NCT05754697|Experimental|instrument assisted soft tissue mobilization in addition to traditional treatment|study group
89606063|NCT05754697|Experimental|positional release technique in addition to traditional treatment|study group
89606064|NCT05754697|Active Comparator|traditional treatment|control group
89518507|NCT03484247|Active Comparator|Group Axillary|Axillary Brachial Plexus Block: The procedure will be performed with a 50 mm peripheral nerve stimulator needle with ultrasound guidance. Local anesthetic will be administered with multiple injection (radial, ulnar, median and musculocutaneous nerves) after aspiration.
89518508|NCT02246764|Experimental|AR-13324 Ophthalmic Solution 0.02% & placebo|1 drop AR-13324 in the evening (PM) and 1 drop placebo in the morning (AM) in both eyes (OU)
89518509|NCT02246764|Experimental|AR-13324 Ophthalmic Solution 0.02% BID|1 drop AR-13324 twice daily (BID) in the morning (AM) and evening (PM) in both eyes (OU)
89518510|NCT02246764|Active Comparator|Timolol maleate Ophthalmic Solution 0.5% BID|1 drop Timolol maleate twice daily (BID) in the morning (AM) and evening (PM) in both eyes (OU)
89518511|NCT03484169|No Intervention|Control group|No intervention
88982143|NCT00085397|Experimental|Arm I|Patients undergo surgical harvesting of tumor cells for subsequent fusion. Patients receive vaccination comprising dendritic cells (DC) fused with autologous tumor cells subcutaneously on day 1. Treatment repeats every 21 days for 3 courses. Patients who achieve a partial (PR) or complete response (CR) may receive an additional 3 courses.
88982144|NCT00085397|Experimental|Arm II|Patients receive vaccination comprising DC pulsed with gp100 antigen IV on day 1. Treatment repeats every 21 days for 6 courses. Patients who achieve a PR or CR may receive an additional 6 courses.
88982145|NCT00326404|Experimental|1|
88982146|NCT00326404|Active Comparator|2|
88982147|NCT00326443|Experimental|1|14 subjects Oral CVD 909 with buffer on Day 0. Parental Vi polysaccharide vaccine on Day 21.
88982148|NCT00326443|Placebo Comparator|2|14 subjects oral buffer placebo. Parental Vi polysaccharide vaccine on Day 21.
89518512|NCT03484169|Experimental|intervention group|"The training of PNF pelvic patterns for motor learning in GI will be performed twice a week by a trained and experienced researcher for six weeks (CHRISTIANSEN et al., 2017). At each training session, there will be three repeated movements in each pelvic pattern:~Combination of isotonic (concentric, stabilizing and eccentric) of the anterior elevation pattern; Combination of isotonic (concentric, stabilizing and eccentric) of the posterior depression pattern; Combination of isotonic (concentric, stabilizing and eccentric) of the previous depression pattern; Combination of isotonic (concentric, stabilizing and eccentric) of the posterior elevation pattern;"
89518513|NCT04508153|Other|Leva PDHS arm|"Upon randomization, subjects randomized to the leva® arm will receive the leva® PDHS, and instructions for how to download the smartphone app to facilitate use of the device. They will be instructed to use leva® based on the in-app training provided.~Within the app, subjects will be instructed to use the leva® device to perform PFMT according to the training program provided through the smartphone app associated with the device. This entails 2 ½ minute training sessions, three times daily, 7 days per week for a total of 8 weeks."
89518514|NCT04508153|Other|Kegel arm|Subjects randomized to the Kegel arm will be provided links to view instructions on how to perform PFMT (written instructions per the handout adapted from Voices for PFD, the patient advocacy arm of the American Urogynecologic Society), as well as an audio/visual didactic instructing them to perform Pelvic Floor Muscle Exercises (PFME) three times daily, seven days per week throughout the 8-week study period.
89518515|NCT03487757|Active Comparator|Control Group|After recording the demographic and clinical information at the beginning of the study and after 8 weeks, respiratory muscle strength, respiratory functions and postural control evaluations will be performed to the children. They won't receive any intervention by this time. At the end of 8 weeks, they may be included in the 8-week physiotherapy program, which will be once a week and 45-60 minutes by supervision of physiotherapist and 4 days a week home exercise program. The program will include core stabilization exercise training.
89518516|NCT03487757|Experimental|Training Group|After recording the demographic and clinical information at the beginning of the study, respiratory muscle strength, respiratory functions and postural control evaluations will be performed to the children. They will be included in the 8-week physiotherapy program, which will be once a week and 45-60 minutes by supervision of physiotherapist and 4 days a week home exercise program. The program will include core stabilization exercise training. After the eight week training program the evaluations will be repeated.
89518517|NCT03484091|Experimental|H group|Single dose of Hyruan-One 3 mL intra-articular knee injection.
89518518|NCT03484091|Active Comparator|S group|Single dose of Hylan G-F 20 (Synvisc) 6 mL intra-articular knee injection.
89518519|NCT03484091|Placebo Comparator|N group|Single dose of normal saline 6 mL intra-articular knee injection.
89518520|NCT03486353|Experimental|Run-In Phase, Regimen 1|Patients will be treated with FF-10501-01 at a dose of 400 mg/m2 twice daily (BID) for 14 days plus azacitidine at a dose of 75 mg/m2 either subcutaneously (SC) or intravenously (IV) x 7 days every 28 days. One treatment cycle will be 28 days in duration.
89518521|NCT03486353|Experimental|Run-In Phase, Regimen 2|Patients will be treated with FF-10501-01 at a dose of 400 mg/m2 BID for 21 days plus azacitidine at a dose of 75 mg/m2 either SC or IV x 7 days every 28 days.
89518522|NCT02454530||Cancer patients treated with Nivestim®|
89518523|NCT04460651|Active Comparator|Active treatment|Participants in this arm will receive study medication icosapent ethyl (IPE) with a specific dose scheme.
89518524|NCT04460651|Placebo Comparator|Placebo|Participants in this arm will receive Placebo with the same dose scheme as the active comparator:
89518525|NCT03483857|Experimental|Peer Navigation|Individuals assigned to the PN condition will be assigned to one of 10 PN case managers who will follow an SOP described for initial intake and follow up visits with each participant. Participants will be asked to provide contact information for themselves and up to 3 individuals whom study staff can contact in case they cannot make direct contact with the study participant assigned to PN. PN will meet with their clients at least once monthly to discuss treatment related issues including medication access, side effects, adherence, stigma or discrimination related to HIV or their taking ART medication, etc. Participants will have contact information for their assigned PN and may contact them for reasons related to their treatment between scheduled monthly visits if they choose. All visits with PN will be recorded by the PN. and participants who fail to attend up to 3 scheduled PN appointments will be considered LTFU for the intervention.
89518526|NCT03483857|No Intervention|Standard of Care|Individuals assigned to SOC will be referred directly to the NCHC/RLS staff for treatment initiation or continuation. At intake they will receive standard treatment information per MPDOH guidelines, as well as information about Anova's RLS and Health4Men clinical and psychosocial services available at the NCHC. They will receive monthly text message reminders from study staff to refill ART prescriptions, and a separate reminder in month 6 to schedule complete their 6-month clinical visit. Study staff will verify that participants have picked up medications and attended all scheduled clinical visits by means of chart review and data extraction. Per MPDOH guidelines, individuals who fail to collect medications 3 months in a row, or who fail to attend their 6-month HIV clinical follow-up appointment, will be considered non-engaged and lost to follow up (LTFU).
89518527|NCT04460729|Experimental|Cohort 1|Participants who are asymptomatic and without prior brain therapy
89518528|NCT04460729|Experimental|Cohort 2|Participants who are symptomatic with or without prior brain therapy or asymptomatic with prior brain therapy or with leptomeningeal disease
89518529|NCT04927832|Experimental|Patient with chronic autoimmune pathology|
89518530|NCT04927832|Experimental|Patients with unexplained pain syndrome|
89518531|NCT03483779|Experimental|Experimental group:Ginkgo biloba pills|Five Ginkgo biloba pills a time and three times a day. One treatment period including 8 weeks.
89606065|NCT05753878|Experimental|HH-120 nasal spray, Part A cohort 1|Nasal endoscopic examination is performed at 3min (±2 min), 30min (±5 min), 1h (±10 min), and 2h (±10 min) after dosing.
89606066|NCT05753878|Experimental|HH-120 nasal spray, Part A cohort 2-7|Nasal/nasopharyngeal samples are collected at 3min (±2 min) , 1h (±10 min) ,2h (±10 min),4h (±30 min),8h (±30 min),24h (±30 min).
89606067|NCT05753878|Experimental|HH-120 nasal spray, Part A cohort 8-9|Nasal/nasopharyngeal samples are collected at 4h (±30 min) , 8h (±30 min).
89606068|NCT05753878|Experimental|HH-120 nasal spray, Part B|
89606069|NCT05753878|Placebo Comparator|Placebo nasal spray, Part B|
89518532|NCT03483779|Placebo Comparator|Control group:placebo pills|Five placebo pills a time and three times a day. One treatment period including 8 weeks.
89606070|NCT05753787|Active Comparator|preservatives-free dexamethasone 0.1% eye drops|
89606071|NCT05753787|Placebo Comparator|preserved dexamethasone 0.1% eye drops|
89606072|NCT05752045|Other|Diabetic patient group assessed for multiple eye diseases|Each patient eye disease status will be assessed by expert readers so to provide ground truth against which algorithms performances will be assessed
88982149|NCT00319657|Experimental|Immune tolerance, kidney transplantation|Intervention: Participants will receive hematopoietic cell transplantation and Total lymphoid irradiation. The intervention is intended to induce immune tolerance in HLA-matched living donor kidney transplantation, to allow withdrawal of the immunosuppressive drugs. Immune tolerance is achieved through the development of donor/recipient mixed chimerism following combined kidney and hematopoietic stem cell transplantation from the living donor.
88982150|NCT00085553|Experimental|Treatment (erlotinib hydrochloride, tipifarnib)|Patients receive erlotinib hydrochloride PO QD on days 1-28 (days 8-28 of course 1 as of 11/4/2013) and tipifarnib PO BID on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. (Closed to accrual as of 2/2/06)
89518533|NCT04492241|Experimental|Study Arm|Ginkgo Leaf Extract and Armillariella Mellea Powder Oral Solution, TID
89518534|NCT04492241|Placebo Comparator|Control Arm|Simulation of Ginkgo Leaf Extract and Armillariella Mellea Powder Oral Solution, TID
89518535|NCT04927286|Experimental|Mentoring+Mindfulness|
89518536|NCT04927286|Active Comparator|Mentoring as usual|
89518537|NCT05151575|Experimental|group-based walking intervention with professional trainer's supervision|Participants will conduct the intervention in groups under the supervision of a professional fitness trainer.
89518538|NCT05151575|Active Comparator|individual-based walking intervention without professional trainer supervision|Participants will conduct the intervention individually, without the supervision of a professional fitness trainer
89518539|NCT05151575|No Intervention|control group|No intervention will be given to the control group.
89518540|NCT03483701|Experimental|Cognitive Remediation Therapy|Participants in the experimental group will continue to receive IPS services, which is part of their standard care. In addition, they will be required to complete up to 5 hours per week of computerized cognitive exercises. Cognitive training can be done at home on a computer, on their own schedule. Participants will also receive 1 hour/week of individual coaching to discuss cognitive remediation progress, learn about different cognitive domains and develop ways to generalize their cognitive remediation gains.
89518541|NCT03483701|No Intervention|Treatment as Usual|Participants in the control condition will continue to receive IPS services as usual.
89518542|NCT02431676|Active Comparator|Self-Directed|In this group, the study staff will meet with you once at the beginning of the study to give you written information about weight management.
89518543|NCT02431676|Experimental|Coach Directed Behavioral Weight Loss|The Remote Lifestyle Coaching intervention is based on the Call Center Directed intervention to help you loss weight
89518544|NCT02431676|Experimental|Metformin|This group will be given the study drug called Metformin. Metformin comes in tablet form that you take with meals
89518545|NCT04460417|Experimental|Enhanced care|Participants will take part in an approximate one-hour health and smoking feedback session at the University of Chicago in Dr. King's Clinical Addictions Research Laboratory (CARL). The session will follow the Courage to Quit™ (CTQ) Roadmap program (developed by Dr. King with the Respiratory Health Association). This roadmap shorter version of the larger CTQ program has been specifically designed as an inpatient bedside or outpatient brief intervention guide to assess smoking cessation motivation, consequences of smoking, facts and myths about smoking, barriers to making a change, approved medications, de-bunking myths about medications or treatments without scientific evidence (e-cigarette, laser treatments, herbals, etc.), and gaining social support.
89606073|NCT05750121|Experimental|Treatment group|The intervention group will receive home-based motor-cognitive training and usual emergency care.
89606074|NCT05750121|No Intervention|Usual care group|Usual care includes wound care, community nurse service, medications and on-site physiotherapy, occupational therapy, community nurse service, medical social work service, and geriatric nurse follow-up service will be referred when necessary.
89606075|NCT05748288||Personal Equipment|Participants assigned to use technology they currently own
89606076|NCT05748288||HSG Equipment|Participants provided technology by the sponsor
89606077|NCT05746871|Experimental|GroupA_Agilik first|This arm will be assessed at T0, then it will receive the intervention with Agilik (10 training sessions in 5 weeks) and will perform T1 evaluations, and then it will repeat the evaluations after other 5 weeks (T2) during which they performed they standard care
89606078|NCT05746871|Experimental|GroupB_standard care first|This arm will be assessed at T0, then it will continue with their standard care and will perform T1 evaluation after 5 weeks, and then it will receive the intervention with Agilik (10 training sessions in 5 weeks) and the final evaluation (T2)
89606079|NCT05745961||PAH|
89606080|NCT05745961||Healthy volunteer|
89606081|NCT05743400|Experimental|Experimental treatment arm|Children over two years and adults undergoing a first hematopoietic stem cell transplantation will receiveThymoglobulin® as part of the conditioning.
89606082|NCT05739422|Experimental|Intervention|Participants in the intervention group will participate in a once weekly, 6 week online, remotely supervised neuropilates programme. Exercises will be taught by a chartered Physiotherapist who is also a pilates instructor with experience with stroke rehabilitation. Exercises will be aligned to the Australian Physiotherapy and Pilates Institute's (r) core teaching with modifications based on participant need and aligned to neurorehabilitation principles
89606083|NCT05739422|Active Comparator|Control Group A|Participants in control group A will participate in a once weekly, 6 week, online, remotely supervised generalised exercise class. This class will be instructed by a chartered Physiotherapist and will consist of general strengthening and flexibility exercises for upper and lower limbs.
89606084|NCT05739422|Active Comparator|Control Group B|Participants in control group B will be given a tailored, individualised home exercise programme to practice unsupervised at home over a 6 week period. They will receive a follow up phone call to discuss any issues they might be having and a training diary to log their exercise.
89606085|NCT05734820|Experimental|HD-colonoscopy + AI-HD colonoscopy|This group is comprised by patients >45 years of age submitted for diagnostic colonoscopy. In the same session a HD-colonoscopy will be performed followed by an HD-colonoscopy with artificial intelligence assistance. The second procedure will be performed by an operator with the same-level-of -expertise in comparison to the initial procedure (expert or non-expert) and blinded to the results of the previous intervention.
89606086|NCT05734820|Experimental|AI-HD colonoscopy + HD-colonoscopy|This group is comprised by patients >45 years of age submitted for diagnostic colonoscopy. In the same session a HD-colonoscopy assisted by artificial intelligence will be performed followed by an HD-colonoscopy alone.The second procedure will be performed by an operator with the same-level-of -expertise in comparison to the initial procedure (expert or non-expert) and blinded to the results of the previous intervention.
89606087|NCT05734807|Active Comparator|NrtIs|
89606088|NCT05734807|Experimental|HH-003+NrtIs|
89606089|NCT05734807|Experimental|HH-003+NrtIs+PEG-IFN-α|
88982151|NCT00326638|Other|Arm A: 3D-Conformal Radiation|"Intervention: Standard radiation treatment for high risk prostate cancer. Once daily Monday to Friday for 8 weeks.~3DCRT 7800 cGY/39 Fractions/ STD Technique*~Initial 4F 3DCRT to Nodes/ Prostate + Seminal Vesicles 4,600 cGy/23~Boost 6 F 3DCRT to Prostate 3,200 cGy/16"
88982152|NCT00326638|Experimental|Arm B: Helical Tomotherapy Intensity Modulated Radiotherapy|"Intervention: Helical Tomotherapy Intensity Modulated Radiotherapy (IMRT) once daily Monday to Friday for 8 weeks.~IMRT using Helical Tomotherapy* 7800 cGY/39 Fractions Boost IMRT to Prostate 3,200 cGy/16"
88982153|NCT00085670||Group 1|Bone marrow failure subjects
88982154|NCT00319852|Experimental|1|
88982155|NCT00319852|Active Comparator|2|
88982156|NCT04728828||In-center adult haemodialysis patients eligible and voluntary for COVID19 vaccination|
88982157|NCT00326989|Active Comparator|Low-dose shock wave treatment & Placebo|
88982158|NCT00326989|Active Comparator|low-dose shock-wave treatment & Cell therapy|
88982159|NCT00326989|Active Comparator|High-dose shock-wave treatment & Placebo|
88982160|NCT00326989|Active Comparator|High-dose shock-wave treatment & cell therapy|
88982161|NCT00326989|Active Comparator|Placebo shock-wave treatment & cell therapy|
88982162|NCT00320008|Active Comparator|Standard Treatment Arm|This arm will at any time during the active intervention period follow treatment guidelines by the Danish Medical Association for the treatment of type 2 diabetes.
88982163|NCT00320008|Experimental|Intensive Treatment Arm|This arm will during the active intervention period be treated according to intensified multiple risk factor intervention following strict guidelines set out by the study protocol.
88982164|NCT04728984|Experimental|Nalfurafine Hydrochloride 5μg|Oral administration after dinner, once daily for 14 consecutive days
88982165|NCT04728984|Experimental|Nalfurafine Hydrochloride 2.5μg|Oral administration after dinner, once daily for 14 consecutive days
88982166|NCT04728984|Placebo Comparator|Placebo|Oral administration after dinner, once daily for 14 consecutive days
88982167|NCT00085787|Experimental|ARRY-142886|
88982168|NCT04717102|Experimental|0.75 MAC desflurane|The effects of 0.75 MAC desflurane on the amplitude and latency of evoked potentials in spinal surgeries will be examined.
88982169|NCT04717102|Active Comparator|0.5 MAC desflurane|The effects of 0.5 MAC desflurane on the amplitude and latency of evoked potentials in spinal surgeries will be examined.
88982170|NCT00320047|Experimental|1|Participants will take baclofen for 10 weeks.
88982171|NCT04708405||Inflammatory bowel disease patients|Inflammatory bowel disease patients screened for Helicobacter Pylori Infection
88982172|NCT04708483|Experimental|Malignant thoracic tumoral pathology.|Patients suffering from primary malignant thoracic tumoral pathology or second line patients having had a therapy pause of at least 6 weeks.
88982173|NCT00320125|No Intervention|1|Usual diet
88982174|NCT00320125|Active Comparator|2|Orange juice fortified with calcium
88982175|NCT00320125|Active Comparator|3|Dairy products
88982176|NCT00320164||Group A: Leukapheresis|Subject's peripheral blood mononuclear cells are collected via leukapheresis.
88982177|NCT00320164||Group B: Buffy Coats Collection|Subject's peripheral blood mononuclear cells are collected via the buffy coats from blood.
88982178|NCT00093873|Experimental|AMG 706|AMG 706 QD
88982179|NCT00327106|Active Comparator|1|Exacyl
89606090|NCT05732077|Other|Not stenting|Hyperemic FFR induced by 50μg/kg of dopamine via renal artery will be measured. If FFR is ≥0.80, randomization will be applied, and no stenting will be implanted. If FFR is <0.80, randomization will be ignored, and stenting will be performed.
89606091|NCT05732077|Other|Stenting|Hyperemic FFR induced by 50μg/kg of dopamine via renal artery will be measured. No matter FFR is, stenting will be performed as planned.
89606092|NCT05731271|Experimental|Phase 1a Part - TST003 Dose Escalation|"TST003 administered every 3 weeks at increasing doses~1 mg/kg, 3 mg/kg, 10 mg/kg, 20 mg/kg, 30 mg/kg"
89606093|NCT05731271|Experimental|Phase 1b Part - Dose Expansion at Recommended Phase 2 dose|Administer TST003 every 3 weeks to patients with positive GREM1 tumor expression at the recommended Phase 2 Dose,
89606094|NCT05730192|Experimental|CADDIE colonoscopy (CADDIE Arm)|CADDIE is a computer-assisted detection (CADe) device used in conjunction with endoscopy for the detection of abnormal lesions in the gastrointestinal tract.
89606095|NCT05730192|Active Comparator|Standard high-definition white light colonoscopy (Control Arm)|Patients will receive a standard colonoscopy
89606096|NCT05725460|Experimental|dextrose 5%|10 mls of dextrose under ultrasound to separate the median nerve from adjacent structures
89606097|NCT05725460|Active Comparator|steroid|10 mls of steroid used to separate the median nerve from adjacent structures
89606098|NCT05722184||CNHU-HKM|BactInsight system compared to BacT/ALERT® 3D
89606099|NCT05722184||Hôpital Saint Jean de Dieu, Boko|BactInsight system compared to manual blood culture system (visual inspection)
89606100|NCT05722184||Centre Hospitalier Universitaire Yalgado Ouédraogo|BactInsight system compared to BacTec FX40
89606101|NCT05717062|Experimental|Varespladib Intravenous Form (IV) + Varespladib Oral tablet (LY315920) + SOC|Participants will receive intravenous (IV) infusion of varespladib at dose of 0.45 milligrams per kilogram per hour (mg/kg/hr) for six hours. This infusion will continue until when the participant meets clinical criteria for transition to oral drug, -If criteria are met, they will be transitioned to varespladib-methyl (initial dose of 500 mg) then continued oral dosing q12 (once every 12 hours) of 250 mg for the remainder of the study period. Participants that do not meet the criteria for transitioning to the oral drug will remain on the IV infusion at 0.45 mg/kg/hr (along with SOC) and assessed twice a day until they meet criteria for transition to oral drug.
89606102|NCT05717062|Active Comparator|Placebo Intravenous (IV) + Placebo Oral + SOC|Participants will receive intravenous (IV) infusion of placebo matched to varespladib for six hours. This infusion will continue until the participant meets clinical criteria for transition to oral drug. If criteria are met, they will be transitioned to the oral placebo then continued oral dosing for the remainder of the study period. Participants that do not meet the criteria for transitioning to the oral drug will remain on the IV infusion (along with SOC) and assessed twice a day until they meet criteria for transition to oral drug.
89606103|NCT05714943|Experimental|Educational website intervention|Participants will have access to an intervention between pre-test and post-test assessments. The intervention, DigiKnowIt News: Teen, is an educational website designed to teach youth (12-17 years) about pediatric clinical trials and give parents and youth resources for communication and shared decision-making about research.
89606104|NCT05714943|No Intervention|Wait-List Control|Participants will not have access to the educational website between the pre-test and post-test assessments. After completing the post-test questionnaires, participants in the wait-list control group will receive access to the intervention (DigiKnowIt News: Teen).
89606105|NCT05713890|Experimental|VR-AOT|Home-based Action Observation Treatment with virtual-reality for upper limb rehabilitation
88982180|NCT00327106|Placebo Comparator|2|Physiologic serum
88982181|NCT00320359|Active Comparator|Arm A|Cisplatin 75 mg/m2 i.v., day 1, Etoposide 100 mg/m2 i.v., days 1-3
88982182|NCT00320359|Experimental|Arm B|Topotecan 1 mg/ m2, i.v., days 1-5 Cisplatin 75 mg/m2 i.v., days 5
88982183|NCT00093912|Experimental|clevidipine|Clevidipine (0.5 mg/mL in 20% lipid emulsion) was initiated after insertion of an arterial line upon the occurrence of perioperative hypertension, as determined by the investigator, and was administered intravenously (IV) at an initial infusion rate of 0.4 μg/kg/min (non weight-based equivalent is 2 mg/h). Clevidipine was titrated to blood pressure lowering effect by doubling increments approximately every 90 seconds up to a maximum infusion rate of 3.2 μg/kg/min (16 mg/h). Infusion rates above 3.2 μg/kg/min were permitted up to the maximum infusion rate of 8.0 μg/kg/min. Treatment was maintained as long as was deemed clinically necessary or until discharge from the ICU. Infusion rates between 4.4 and 8.0 μg/kg/min were to be administered for no more than 2 hours.
88982184|NCT00093912|Active Comparator|sodium nitroprusside|Sodium nitroprusside (SNP) was initiated after insertion of an arterial line upon the occurrence of perioperative hypertension, as determined by the investigator, and was administered intravenously as per institutional practice. Treatment was maintained as long as was deemed clinically necessary or until discharge from the ICU.
88982185|NCT00327184|Experimental|Group Hib-MenC|Subjects receive 2 primary vaccination doses at 3 and 5 months of age and a booster dose at 11 months of age of Hib-MenC + Infanrix™ penta vaccines.
89606106|NCT05713890|Active Comparator|VR-LO|Home-based landscape observation with virtual-reality for upper limb rehabilitation
89606107|NCT05711251|Experimental|Physical Activity in Health Promotion Group|"Students who chose the Physical Activity in Health Promotion course were included in the experimental group. The participants in this group took the courses shown in the weekly schedule below during the semester.~Historical Development of Physical Activity~Physical Activity Definition and Types~Physical Activity Measurement~Physical Fitness and Inactivity~Physical Activity in Healthy Adults~Physical Activity in Children~Physical Activity in the Elderly~Physical Activity for the Disabled~Physical Activity at Work-I~Physical Activity at Work-II"
88982186|NCT00327184|Active Comparator|Group NeisVac-C|Subjects receive 2 primary vaccination doses at 3 and 5 months of age and a booster dose at 11 months of age of NeisVac-C™ + Infanrix™ hexa vaccines.
88982187|NCT00327223|Experimental|imexon|Dose escalation of imexon
88982188|NCT00327379|Experimental|Arm 1|
88982189|NCT00327379|Placebo Comparator|Arm 2|
88982190|NCT00086060|Experimental|1 - Relaxation Training|Participants will receive relaxation training and standard care for FM
88982191|NCT00086060|Experimental|2 Exercise Regimen|Participants will receive an exercise regimen and standard care for FM
89606108|NCT05711251|No Intervention|Control Group|"Students who chose the Posture Disorders and Waist and Neck Health courses given by different instructors at the same time and day were included in the control group. the participants in this group took 2 different courses, shown in the weekly schedule below, at the same time, from different physiotherapists during the semester.~Waist and Neck Health~Functional anatomy, biomechanics and pathomechanics of the spine~Risk factors for low back and neck pain~Back and neck pain related disorders~Outcome measures in low back and neck pain~Treatment approaches~Cervical and Lumbar disc lesions and physiotherapy~Exercise principles for low back and neck pain~Core stabilization, strengthening and stretching exercises~Neck school: Organization, methods and principles~Ergonomics"
89606109|NCT05709548|No Intervention|control group|patients who undergo urgent laparoscopic cholecystectomy according to the usual technique without the administration of indocyanine green
89606110|NCT05709548|Active Comparator|intervention group|Patients who undergo urgent laparoscopic cholecystectomy for acute cholecystitis with the administration of indocyanine green preoperatively.
88982192|NCT00086060|Active Comparator|3 Standard Care|Participants will receive standard of care for FM
88982193|NCT00086060|No Intervention|4 Health Controls|Health participants will act as a control
88982194|NCT00086099|Experimental|1|Idarubicin plus amifostine
88982195|NCT00086099|Experimental|2|Idarubincin
88982196|NCT00086177|Active Comparator|1|Progesterone 8% vaginal gel
88982197|NCT00086177|Placebo Comparator|2|Placebo Vaginal Gel
88982198|NCT05459038|Experimental|Interventional group|Patients assigned to the interventional group will undergo an identical surgical procedure as patients assigned to the control group. The only difference with the control group is that tibial alignment will be obtained according to the standardized CARV-protocol.
88982199|NCT05459038|No Intervention|Control group|Patients assigned to the control group will undergo an identical surgical procedure as patients assigned to the interventional group. The only difference with the intervention group is that tibial alignment will be obtained according to present unstandardized clinical standards
88982200|NCT05458999|Experimental|Virtual reality headset|Virtual reality headset during percutaneous coronary intervention
88982201|NCT05458999|No Intervention|Control|Routine clinical practice
88982202|NCT05458687|Experimental|intervention group|"Chinese herbal medicine decoction.~Acupuncture or Laser acupuncture pen treatment.~Acupoint Tuina massage.~Acupoint application of traditional Chinese herbal medicinal cake.~Nursing and health education and guidance.~Diet and health education."
88982203|NCT05458687|No Intervention|control group|"Nursing and health education and guidance~Diet and health education"
88982204|NCT05458570||Breast cancer|Breast cancer patients presenting to single center in Karachi over the period of 10 years. The aim was to look for ethnic predisposition of population, age of breast cancer, stage at arrival and menopausal status specific to our population. No intervention done.
88982205|NCT00321178|Experimental|SR4/CR4|after 4 weeks of standard treatment with streptomycin and rifampicin, patients in the experimental arm switch to oral treatment consisting of rifampicin and clarithromycin
88982206|NCT00321178|Active Comparator|SR8|standard treatment consisting of 8 weeks of streptomycin and rifampicin
89606111|NCT05709301|Experimental|Donepezil|
89606112|NCT05709301|Placebo Comparator|Placebo|
89606113|NCT05706714||Patients with urea cycle disorder|Patients with inborn errors of metabolism resulting from defects in one of the enzymes or transporter molecules involved in the hepatic removal of ammonia from the bloodstream
88982207|NCT05458492|Experimental|Sirolimus Arm|"Sirolimus, tablets 2 mg/day with dose adjustment of 1 to 3 mg/day for residual concentrations between 4 and 10 ng/mL~1 dose daily for 16 weeks"
88982208|NCT04717648||Patients with anastomotic leakage|Post operative anastomotic leakage
88982209|NCT04717648||Patients without anastomotic leakage|Post operative without anastomotic leakage
88982210|NCT00094185||General|No intervention
88982211|NCT05458414|Experimental|Endoscopic Breast Conserving Surgery With Intra-operative Navigation System|Surgerons will use Intra-operative navigation system during the surgery to delineate the margins of tumor.
88982212|NCT05458336|Experimental|Cases|Subjects who have been given nasal lavages
88982213|NCT05458336|No Intervention|Controls|Subjects who haven't been given nasal lavages
88982214|NCT05458180|Experimental|CMOEP|dose-escalation： Untreated Peripheral T-cell Lymphoma Patients will receive sequentially higher doses of liposomal mitoxantrone hydrochloride in combination with Cyclophosphamide, Vincristine, Etoposide and Prednisone for 6 cycles (planned) (21 days per cycle). The initial dose of liposomal mitoxantrone hydrochloride is 15 mg/m2.
88982215|NCT00419653|Experimental|1|
88982216|NCT00419653|Active Comparator|2|
88982217|NCT00419653|Active Comparator|3|Haloperidol
88982218|NCT00321334|Active Comparator|Docetexel|Chemotherapy+Surgery
88982219|NCT00086489|Experimental|10 mg/kg|pts treated at 10 mg/kg dose level on a monthly regimen
88982220|NCT00086489|Experimental|15 mg/kg|pts treated at 15 mg/kg dose level on a quarterly regimen
88982221|NCT00321451|Experimental|1|
88982222|NCT00321451|Sham Comparator|2|
88982223|NCT00321451|Active Comparator|3|
89032643|NCT04692974|Experimental|Intervention Group|Participants in the intervention group will be given the wearables which they will use together with the accompanying mobile application for the period of the study (6 months). During the period of intervention, the wearable will track the physical activity of the older adults via the number of steps taken and number of hours of moderate physical work (based on heart rate). Heart rate and steps will be tracked whenever participants are wearing the watch, which is when they are awake. The watch is to be charged every night when they are sleeping. Participants will have to log down their physical activity by activating the physical activity tracker either on the watch or on the mobile application. If they did not hit the required level of physical activity, they will be sent a notification prompt through the mobile application with details of nearby workout locations as recommendation.
89606114|NCT05706714||Patients with lysinuric protein intolerance|Patients with disorder caused by the body's inability to digest and use certain protein building blocks (amino acids), namely lysine, arginine, and ornithine
89606115|NCT05706714||Healthy control|Children without any comorbidity and chronic diseases.
89518546|NCT04460417|Active Comparator|Treatment as Usual|"Participants will receive the National Cancer Institute (NCI) pamphlet Clearing the Air and access to related online resources, which includes brief advice to quit smoking and medication information."
89518547|NCT05151419|Other|bronchoscope ,forceps,cryo-biopsy|biopies were taken from the lung mass using forceps and cryo-biopsy to evalute diagnostic yield of cryo-biosy versus forceps in the diagnosis of lung cancer
89032644|NCT04692974|No Intervention|Control Group|For the control group, they will wear the wearables as a tracking device for the period of the study (6 months). No prompts will be given and the mobile application will only be installed but not used for this group.
89032645|NCT02928393|Experimental|Basmisanil|Basmisanil at a dose of 240 milligrams (mg) orally twice daily for 90 days.
89032646|NCT02928393|Placebo Comparator|Placebo|Placebo matched to basmisanil orally twice daily for 90 days.
89032647|NCT02947412||sleeve gastrectomy|laparoscopic sleeve gastrectomy
89518548|NCT03483545|Experimental|Follitropin delta and HP-hMG|Follitropin delta combined with highly purified human menopausal gonadotrophin
89518549|NCT03483467|Experimental|1|Application of Omnigen
89518550|NCT03483467|Placebo Comparator|2|Dummy Omnigen Packaging
89518551|NCT03483389|Experimental|Alcohol, placebo|Alcohol, ethyl - Placebo
89518552|NCT03483389|Experimental|Alcohol, low dose|Alcohol, ethyl - Low dose
89518553|NCT03483389|Experimental|Alcohol, moderate dose|Alcohol, ethyl - Moderate dose
89518554|NCT03486275|Active Comparator|Hygie game|Prototype video game called Hygie on the 5 most common reasons of consultation in general practice using 9 articles from independent journals based on evidence (reviews by Prescrire and Minerva).
89518555|NCT03486275|Active Comparator|Source articles|9 articles from independent journals based on evidence (reviews by Prescrire and Minerva)
89518556|NCT03483311|Experimental|psoriasis patients|Tissue levels of resolvin D1 in psoriatic patients before and after NB-UVB.
89518557|NCT03483311|Experimental|controls|Tissue levels of resolvin D1 in controls
89032648|NCT02928354|Experimental|Treatment A - AZD7594|Treatment A - AZD7594 inhalation powder Particle size Large
89032649|NCT02928354|Experimental|Treatment B - AZD7594|Treatment B - AZD7594 inhalation powder Particle size Medium
89032650|NCT02928354|Experimental|Treatment C - AZD7594|Treatment C - AZD7594 inhalation powder Particle size Small
89032651|NCT02946944|Experimental|double drug therapy|
89518558|NCT03482999||Control|Standard Wound Closure with drains
89032652|NCT02946944|Active Comparator|mono drug therapy|
89032653|NCT02928471||Intensive dietary intervention|Supervised dietary weight loss program lasting 8 weeks.
89032654|NCT02946983|Active Comparator|Fructose - Neutral emotion condition|Intragastric infusion of fructose with neutral emotion induction
89032655|NCT02946983|Active Comparator|Fructose - Sad emotion condition|Intragastric infusion of fructose with sad emotion induction
89032656|NCT02946983|Placebo Comparator|Placebo - Neutral emotion condition|Intragastric infusion of distilled water with neutral emotion induction
89032657|NCT02946983|Placebo Comparator|Placebo - Sad emotion condition|Intragastric infusion of distilled water with sad emotion induction
89032658|NCT02928432|Experimental|Steroids switch|CRPC patients with biochemical and/or limited radiological progression after at least 12 weeks of AA + prednisone.
89032659|NCT02946398||elderly patients who visit the ED|elderly patients (65 years and older) who present to the emergency department for internal medicine or gastroenterology
89032660|NCT02928549||Black Women with Cancer|In this formative qualitative research study we aim to use one-on-one semi-structured interviews with Black women diagnosed with ovarian cancer to learn about their experiences and their journey to accessing care at a high-volume ovarian cancer care center (HVC).
89032661|NCT02947061|Experimental|test group|S1 plus Docetaxel ：S-1 80mg to 120 mg per day on Days 1-14, every 21 days; Docetaxel 75mg/m2 on Day 1
89032662|NCT02947061|Active Comparator|control group|Capecitabine plus Docetaxel ：Capecitabine 1,000 mg/m2 per day on Days 1-14, every 21 days; Docetaxel 75mg/m2 on Day 1
89518559|NCT03482999||TissuGlu Surgical Adhesive|TissuGlu was used for approximation and adhesion of the flaps in conjunction with drains
89518560|NCT03482843||Vitamin D Deficiency|25-Vitamin D level <25 ng/ml
89518561|NCT03482843||Sufficient Vitamin D Level|25-Vitamin D Level >=25-70 ng/ml
89518562|NCT03482765|Experimental|Probiotic 1|Probiotic 1: A dietary probiotic supplement which contains Bifidobacterium lactis. Dose: > 10 billion CFU, Frequency: 1 capsule/day, duration: 6 weeks.
89518563|NCT03482765|Experimental|Probiotic 2|Probiotic 2: A dietary probiotic supplement which contains Lactobacillus acidophilus. Dose: > 10 billion CFU, Frequency: 1 capsule/day, duration: 6 weeks.
89518564|NCT03482765|Placebo Comparator|Placebo|The Placebo contains MCC.
89518565|NCT03482687|Experimental|Me & You: Building Healthy Relationships|Me & You: Building Healthy Relationships is a classroom- and computer-based healthy relationships curriculum for middle school students. It consists of thirteen 25-minute lessons: 5 classroom, 5 computer-only, and 3 classroom-computer hybrid.
89518566|NCT03482687|No Intervention|Comparison Group|No intervention was provided, only usual care.
89518567|NCT03131609||A: Container + Castile-soap wipe|Sterile urine collection container and Castile-soap wipe given to patient to self-obtain a clean catch mid-stream urine specimen - Control group represents usual care in the Emergency Department.
89518568|NCT03131609||B: Container + Silver impregnated wipe|Sterile urine collection container and silver-impregnated cloth-wipe given to patient to self-obtain a clean catch mid-stream urine specimen
89518569|NCT03131609||C: Funnel + Castile-soap wipe|Sterile urine collection funnel and Castile-soap wipe given to patient to self-obtain a clean catch mid-stream urine specimen
89518570|NCT03131609||D: Funnel + Silver-impregnated wipe|Urine collection funnel and sliver impregnated cloth-wipe given to patient to self-obtain a clean catch mid-stream urine specimen
89518571|NCT01654250|Experimental|Active|NWP09
89518572|NCT01654250|Placebo Comparator|Placebo|Placebo
89518573|NCT02523833|Other|Chronic HP patients|Chronic hypersensitivity pneumonitis patients - use of salbutamol
89518574|NCT03482531||before group|"In the before group, the investigators retrospectively included 405 patients who had a dinoprostone vaginal insert for cervical ripening before induction of labor, between January 2015 and September 2016.~Multivariate and regression analysis showed that the factors significantly increasing the time to delivery were: Nulliparity, obesity, a closed cervix on initial examination, and intact membranes at the time of insertion. The investigators also described a regression equation that allows to calculate the mean time from insert placement to delivery for each patient."
89518575|NCT03482531||after group|"The investigators will prospectively include all eligible patients with a vaginal dinoprostone insert for cervical ripening during the next two years, starting on April 1st, 2018. At Angers hospital, there are around 600 cases of dinoprostone vaginal inserts per year, so the investigators will be able to include 400 to 500 patients during the study's duration.~The equation will be incorporated when scheduling patients for cervical ripening with vaginal dinoprostone insert. The main objective of this study is to analyze to evaluate our mathematical model. One of the secondary objectives is to analyze whether the use of the personalized scheduling based on the mathematical model would decrease the rate of nocturnal deliveries (between midnight and 6 a.m.)."
89518576|NCT03482375||No Stones on POC after ERCP|This is a cohort in which there are no stones seen on Cholangioscopy after ERCP and cholangiogram to treat gall stones.
89518577|NCT03482375||Stones seen on POC after ERCP|This is a cohort in which there are no stones seen on Cholangioscopy after ERCP and cholangiogram to treat gall stones.
89518578|NCT04234529|Active Comparator|AMATEA|3x 450mg capsules of AMATEA which contains 270mg of caffeine total
89518579|NCT04234529|Active Comparator|Caffeine|3x 450mg capsules each containing 360mg of microcellulose and 90mg of caffeine (270mg caffeine total)
89518580|NCT04234529|Placebo Comparator|Placebo|3x 450mg capsules of microcellulose
89518581|NCT01652690||Denosumab|Patients with postmenopausal osteoporosis (PMO) who received at least 1 injection of denosumab 60 mg subcutaneously in the Czech Republic and Slovakia.
89032663|NCT02928276|Experimental|All patients|All eligible patients
89032664|NCT02946320|Active Comparator|Non-compliant balloon|15 patients, before BVS implantation is coronary artery stenosis dilated with this type of balloon
89032665|NCT02946320|Experimental|Scoring balloon|15 patients, before BVS implantation is coronary artery stenosis dilated with this type of balloon
89032666|NCT02946320|Experimental|Cutting balloon|15 patients, before BVS implantation is coronary artery stenosis dilated with this type of balloon
89032667|NCT00526370||A|Women with at least moderate dysplasia in biopsies from cervix uteri
89032668|NCT00526370||B|Women with only normal PAP-smears
89032669|NCT02928627||HCC Group|samples obtained from patients with HCC (hepatic tissue and blood)
89518582|NCT05154071||ECMO VV dedicated unit|Patient having benefited from an ECMO within the structured care unit
89518583|NCT05154071||ECMO VV without dedicated unit|Patient having benefited from an ECMO without the structured care unit
89518584|NCT03482219|Experimental|Intensive treatment|"Participants will undergo 8 sessions with an occupational therapist. Participants will meet with the occupational therapist to establish the home exercise program and set up the home exercise app. The app has videos depicting each exercise and ability to track adherence to exercises. The occupational therapy consists of the following which will be provided as appropriate:~Thermal Modalities Hot packs, focused on areas with limitations Paraffin, focused on digital limitations~Application of the Physiotouch (a low-intensity negative pressure device)~Passive Range of Motion~Active Range of Motion~Functional Activities"
89518585|NCT03482219|Active Comparator|Home app intervention|Participants will meet with the occupational therapist to establish the home exercise program and set up the home exercise app. The app has videos depicting each exercise and ability to track adherence to exercises.
89518586|NCT03481517|Experimental|Wound with local anesthesia|5 mL Bupivacaine is injected into subcutaneous area near surgical wound
89518587|NCT03481517|No Intervention|Wound without local anesthesia|Nothing is injected into subcutaneous area near surgical wound
89518588|NCT03482063|Experimental|Swisse Ultiboost Memory + Focus|two tablets daily, one tablet during or immediately after breakfast, and one tablet during or immediately after lunch, for the duration of the trial period
89518589|NCT03482063|Placebo Comparator|Placebo|two tablets daily, one tablet during or immediately after breakfast, and one tablet during or immediately after lunch, for the duration of the trial period
89518590|NCT03481439||Primary cohort|Primary cohort : Cohort of patient between January and February 2017
89518591|NCT03481439||Secondary cohort|Secondary cohort : Cohort of patient between February and March 2018
89518592|NCT02429258|Experimental|Farxiga with metformin or insulin|Farxiga with metformin (>/=1500mg/day) or insulin (>/=30 units/day) and up to 2 OAD medications
89518593|NCT02429258|Placebo Comparator|Placebo with metformin or insulin|Placebo with metformin (>/=1500mg/day) or insulin (>/=30 units/day) and up to 2 OAD medications
89518594|NCT05153993|Experimental|Stretch fascia plantaris|
89518595|NCT05153993|No Intervention|Control group|
89518596|NCT03481127|Active Comparator|Arm 1: Usual Care|-No psychosocial care in clinic
89518597|NCT03481127|Experimental|Arm 2: Integrated Care|-Those who receive integrated care will receive a one-page care plan completed by Dr. Vanderlan including their scores from screening questionnaires , recommendations for coping strategies and available supportive resources.
89518598|NCT02201524|Experimental|Cohort 1|200mg of PF-04965842 twice daily
89518599|NCT02201524|Experimental|Cohort 2|400mg of PF-04965842 once daily
89518600|NCT02201524|Experimental|Cohort 3|200mg of PF-04965842 once daily
89518601|NCT02201524|Placebo Comparator|Cohort 4|Placebo comparator daily
89518602|NCT03982901|Experimental|women with chest pain|women with chest pain and coronary artery stenosis less than 50%
89518603|NCT03982901|Sham Comparator|healthy women|women without chest pain and coronary artery stenosis less than 50%
89518604|NCT03937583|No Intervention|Limited screening|Complete clinical history, along with routine physical, analytical examination (creatinine, sodium, potassium, red series, white series, liver and calcium profile) and chest x-ray.
89518605|NCT03937583|Experimental|Extended screening|Limited screening plus positron emission tomography / computed tomography with 18 FDG (18FDG PET-CT).
89518606|NCT02453048|Experimental|BPZE1 - 10,000,000 cfu|Individuals will be vaccinated once intranasally with the designated dose of BPZE1 or Placebo at a Dose 2 x 0.4 mL (0.4 mL per nostril).
89518607|NCT02453048|Experimental|BPZE1 - 100,000,000 cfu|Individuals will be vaccinated once intranasally with the designated dose of BPZE1 or Placebo at a Dose 2 x 0.4 mL (0.4 mL per nostril).
89518608|NCT02453048|Experimental|BPZE1 - 1,000,000,000 cfu|Individuals will be vaccinated once intranasally with the designated dose of BPZE1 or Placebo at a Dose 2 x 0.4 mL (0.4 mL per nostril).
89518609|NCT02453048|Experimental|BPZE1 - High Antibody 1,000,000,000 cfu|Individuals will be vaccinated once intranasally with the designated dose of BPZE1 at a Dose 2 x 0.4 mL (0.4 mL per nostril).
89518610|NCT05153681||Peloid Therapy|Peloidotherapy is a special balneotherapy method made with natural mud. In both domestic and international scientific studies on peloid treatment, it has been shown that pain in patients decreases, physical functions improve, quality of life increases, and the amount of painkillers use decreases.
89518611|NCT05153681||Kinesio Tape|Kinesio tapes, which have been used in the conservative treatment of plantar fasciitis in recent years, are elastic tapes similar to the structural properties and flexibility of human skin, without limiting joint movements.
89518612|NCT05153681||Home exercise|In addition to the cold application, gastrocnemius and plantar fascia stretching and strengthening exercises were applied to patients with plantar fasciitis.
89518613|NCT02523989||study group|children confirmed to have developmental delays
89518614|NCT02523989||control group|children with typical development
89518615|NCT03798041|Experimental|Debridement group|The subjects in this group will be debrided within 24 hours after surgery.
89518616|NCT03798041|No Intervention|Control group|The subjects in this group will experience wound dressing change regularly 24 hours after surgery.
89032670|NCT02928627||Plasma control Group (PCG)|blood samples obtained from healthy controls
89032671|NCT02928315|Active Comparator|magnesium|Five ampules of 500 mg of magnesium sulfate will be dissolved in 100 ml of normal saline solution infused intravenously over 4 hours, once daily for 3 days starting when the patient is shifted to ICU.
89032672|NCT02928315|Placebo Comparator|control|100 ml of normal saline solution infused intravenously over 4 hours once daily , for 3 days
89032673|NCT00525746||Cases|Patients with a confirmed diagnosis of AML or MDS (cases).
89032674|NCT00525746||Controls|Patients treated for a primary malignancy (controls).
89032675|NCT04692090|Experimental|Yoga Group|Hatha yoga will be practiced twice a week for 10 weeks
89032676|NCT04692090|No Intervention|Control group|This group will not have any intervention.
89032677|NCT02928237|Active Comparator|Real tDCS|In the active stimulation condition a constant current of active transcranial direct current stimulation (tDCS) of 2mA intensity was applied for 30 minutes,over primary motor cortex M1. The treatment was repeated every day for 10 consecutive days.
89032678|NCT02928237|Placebo Comparator|Sham tDCS|Sham tDCS was applied using the same parameters but only for 30 seconds then the machine is deactivated.
89032679|NCT00526448|Experimental|1|Peginterferon alfa-2a 180 mcg/week + ribavirin 2000 mg/day + epoetin beta 450 UI/week
89032680|NCT00526448|Active Comparator|2|Peginterferon alfa-2a 180 mcg/week + ribavirin 1000-1200 mg/day
89032681|NCT02928159|Experimental|Low Pulse Amplitude Seizure Therapy|Course of Right Unilateral Ultrabrief LAP-ST using Mecta spectrum 5000Q Device.
89518617|NCT05153603||Olaparib mono-maintenance therapy group|Olaparib monotherapy in clinical practice and will be conducted in patients with tBRCAwt newly diagnosed high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete response or partial response) to platinum-based chemotherapy following the standard of care from Aug 2018 up to Dec 2020 (the time range could be extended in order to recruit enough eligible subjects as required) at tertiary-referral university hospitals and main cancer centers in China.
89518618|NCT04459325|Experimental|Study drug and best available care|Best available care and Tigerase®/nebulised dornase alfa [2.5 mg BID] for 7 days
89518619|NCT04459325|Other|Control group (best available care)|Patients will receive the usual care in accordance with good practice.
89518620|NCT03697421||Local Evaluation|The SHR program intends to serves couples who are over 18 years of age, are in a romantic relationship, and have at least one child (biological or adopted) under the age of 18 residing in the home or are expecting.
89518621|NCT04459949|Active Comparator|Sharkskin Arm|
89518622|NCT04459949|Placebo Comparator|Grieshaber Arm|
89518623|NCT05153213|Experimental|Finger Lengths|Vernier caliper was used to determine the length of Index Finger to record Vertical Dimensions of Occlusion
89518624|NCT05153213|Active Comparator|Conventional method|Willis gauge was used to determine the Length from Base of the nose to Base of the chin to record Vertical Dimensions of Occlusion
89518625|NCT02137252|Experimental|Naltrexone|The treatment schedule includes a daily dose of naltrexone for 5 weeks. Treatment will be initiated at 25 mg/day during the first week to improve tolerability. The dose will be escalated to 50 mg/day after one week barring significant early improvement in fatigue or adverse events precluding dose escalation, and participants will continue to take 50 mg/day (or 25 mg/day if dose is not escalated) for 4 weeks to complete a 5-week treatment period.
89518626|NCT02137252|Placebo Comparator|Sugar Pill|The treatment schedule includes a daily dose of equivalent placebo for 5 weeks. Treatment will be initiated at 25 mg/day during the first week to improve tolerability. The dose will be escalated to 50 mg/day after one week barring significant early improvement in fatigue or adverse events precluding dose escalation, and participants will continue to take 50 mg/day (or 25 mg/day if dose is not escalated) for 4 weeks to complete a 5-week treatment period.
89518627|NCT02201290|Experimental|Eltrombopag|Eligible subject will be allocated to 1 of 3 age-defined cohorts. Cohort 1: between 12 and 17 years old, Cohort 2: between 6 and 11 years old, and Cohort 3: between 1 and 5 years old. For Cohorts 1 and 2, eltrombopag tablets will be administered, however, subjects in Cohort 2 may use eltrombopag powder for oral suspension (Eltrombopag PfOS) if they have difficulty swallowing tablets and are receiving a dose of eltrombopag of < 40 mg. For Cohort 3, either eltrombopag tablets or PfOS will be administered.
89518628|NCT03481673|Experimental|Intervention|This pre-experimental pilot project is a single group, pretest-posttest design with a 6-week post-intervention follow-up. A single group design was chosen for this feasibility pilot study because the COPE for Asthma intervention is newly adapted for 8 to 12-year-old children with asthma in an urban setting. The intervention will consist of 7 weekly sessions (30 minutes each). COPE for Asthma is a manualized, cognitive behavior skills-building intervention to improve the physical and mental health outcomes of children with asthma and elevated symptoms of anxiety or depression. Surveys with children and their parents/caregivers (CGs) will occur at baseline, immediately post-intervention and 6 weeks' post-intervention.
89518629|NCT02200510|Other|Self-Management Group|Self-management intervention for Adolescents with SCD - 6 week self-management group
89518630|NCT02200510|Other|Patient Portal|Patient Portal Intervention for Adolescents with SCD - 6 week individual patient portal intervention
89518631|NCT05152745|Placebo Comparator|Placebo (OGTT)|The control group participants ingested glucose solution alone (OGTT) prepared with 75 g of anhydrous oral glucose as prescribed by the ADA, dissolved in 200 ml of water.
89518632|NCT05152745|Experimental|Intervention (OGTT plus Ginger extract)|The intervention group ingested glucose solution followed by 100 ml of ginger aqueous extract (0.2g ginger, each dose).
89518633|NCT05152667||Arm 1|Women with adenomyosis pretreated with levonorgestrel-releasing intrauterine device (LNG-IUS) and proceeding with the ICSI
89518634|NCT05152667||Arm 2|"Women with adenomyosis pretreated with oral progestin Dienogest and proceeding with the ICSI"
89518635|NCT02452892|Sham Comparator|LFMS Sham|For sham therapy, the device will be on; however, no magnetic field stimulation will be delivered. Low field magnetic stimulation (no magnetic field for sham) will be administered using a portable tabletop device capable of generating time-varying electromagnetic fields of LFMS.
89518636|NCT02452892|Active Comparator|LFMS 20 minutes|LFMS 20 minutes + Sham 40 min.Low field magnetic stimulation (1 kilohertz oscillating magnetic field) will be administered using a portable tabletop device capable of generating time-varying electromagnetic fields of LFMS.
89518637|NCT02452892|Active Comparator|LFMS 60 minutes|LFMS 60 minutes.Low field magnetic stimulation (1 kilohertz oscillating magnetic field) will be administered using a portable tabletop device capable of generating time-varying electromagnetic fields of LFMS.
89518638|NCT02452892|Other|LFMS 120 min|Week 2 subjects may be re-randomized to receive LFMS 120 minutes. Low field magnetic stimulation (1 kilohertz oscillating magnetic field) will be administered using a portable tabletop device capable of generating time-varying electromagnetic fields of LFMS.
89518639|NCT03185663|Placebo Comparator|a pillow between the legs|
89518640|NCT03185663|Experimental|traction-stuck|
89518641|NCT03048227|Experimental|Continuous Glucose Measurement (CGM)|Patients will manage their diabetes with the help of Continuous Glucose Measurements (Abbott Freestyle Navigator II).
89518642|NCT03048227|No Intervention|Control|Patients will manage their diabetes as usual as recommended by their care team.
89518643|NCT05152589||gestational diabetic mother|Hearing tests of the babies of pregnant women who are being followed up with the diagnosis of gestational diabetes in the peritanotogy clinic
89518644|NCT05152589||pregestational diabetic mother|Hearing tests of the babies of pregnant women who are being followed up with the diagnosis of pregestational diabetes in the peritanotogy clinic
89518645|NCT05152589||non diabetic mother|Hearing tests of babies whose mothers do not have gestational or pregestational diabetes
89518646|NCT05152511||All male children who had penile ischaemia after circumcision were included in the study|It is a cohort prospective study. All male children who had penile ischaemia after circumcision were included in the study between April 2017 and October 2020.
89518647|NCT04459481|Experimental|70-degree bending angle group|intubation with a 70-degree bending angle
89518648|NCT04459481|Experimental|90-degree bending angle group|intubation with a 90-degree bending angle
89518649|NCT02135848|Experimental|GSK1278863|Study Drug
89518650|NCT02135848|Placebo Comparator|Placebo|Placebo
89518651|NCT02568449|Experimental|Treatment (nintedanib)|Patients receive nintedanib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89518652|NCT03477227|Experimental|Short stocking|After radiofrequency ablation of the GSF and phlebectomy varicose tributaries, patients will wear compression socks without foot for four weeks
89518653|NCT03477227|Active Comparator|Usual stocking|After radiofrequency ablation of the GSF and phlebectomy varicose tributaries, patients will wear usual compression socks for four weeks (usual care)
89518654|NCT03480815|Active Comparator|TLA device|These patients will be withdrawal of omalizumab treatment and receive nocturnal temperature controlled laminar flow device at nighttime for 12 months.
89518655|NCT03480815|Placebo Comparator|None device|These patients will be withdrawal of omalizumab treatment and do not receive TLA device for 12 months.
89518656|NCT03477149|Experimental|Embolization with Easyx|Patients requiring embolization of varicocele, portal vein before ablation, type 2 endoleak, angiomyolipoma or active bleeding will be treated with the liquid embolic agent Easyx during index procedure.
89518657|NCT03480737|Experimental|10 Hz rTMS|
89518658|NCT03480737|Sham Comparator|Sham rTMS|
89518659|NCT03480737|Experimental|iTBS rTMS|
89518660|NCT03480503||study group|Patients with acne vulgaris , measurement of serum apelin12 by using ELISA technique ,complete lipid profile and fasting blood glucose.
89518661|NCT03480503||Control group|Healthy control volunteers, measurement of serum apelin12 by using ELISA technique ,complete lipid profile and fasting blood glucose.
89518662|NCT03476993|Experimental|BCD-085|All patients will receive BCD-085 (subcutaneous injection) in combination with ursodeoxycholic acid (UDCA) in standard dose 13-15 mg/kg/day
89518663|NCT03476915||screened infants|Asymptomatic infants under age of 6 months, presenting to the pediatric orthopaedic outpatient clinic at Assiut university hospital for other problems will be subjected to ultrasound examination of the hip joint.
89518664|NCT02738333|Experimental|LDV/SOF (Cohort 1)|LDV/SOF FDC for 12 weeks
89518665|NCT02738333|Experimental|SOF+RBV (Cohort 1)|SOF+RBV for 12 weeks
89518666|NCT02738333|Experimental|LDV/SOF (Cohort 2)|Participants who are ineligible for or intolerant to RBV therapy will receive LDV/SOF FDC for 12 weeks.
89518667|NCT04900103|Experimental|Tech-volunteer|"A complex intervention with two phases is proposed.~First phase: volunteers new technologies training (tech-volunteering). Volunteers will be trained in the use of NT and their interconnectivity as tools to support their volunteer work. This training will be integrated into the PC volunteer training programme.~Second phase: using the NT with patients and relatives."
89518668|NCT04900103|No Intervention|Usual volunteer|the control group will receive standard volunteer service.
89518669|NCT04884893|Experimental|Intermittent nitrous oxide|10 minutes of 50% nitrous oxide + 10 min 100% oxygen + 10 min 50% nitrous oxide + 10 min 100% oxygen
89518670|NCT04884893|Experimental|Continuous nitrous oxide|20 min 50% nitrous oxide + 20 min 100% oxygen
89518671|NCT02135692|Experimental|Mepolizumab 100 mg|All subjects will receive mepolizumab 100mg administered SC into the upper arm or thigh approximately every 4 weeks.
89518672|NCT04839809|Experimental|CC-92480-02 (Formulation A) with Placebo|CC-92480-02 (Formulation A) or matching placebo to be administered orally under fasted conditions.
89518673|NCT04839809|Experimental|CC-92480 (Formulation B)- fasted condition|A single oral dose of CC-92480 (Formulation B) administered under fasted conditions.
89518674|NCT04839809|Experimental|CC-92480-02 (Formulation A) - fasted condition|A single oral dose of CC-92480-02 (Formulation A) administered under fasted conditions.
89518675|NCT04839809|Experimental|CC-92480 (Formulation B) - Low-fat meal|A single oral dose of CC-92480 (Formulation B) administered under fed conditions (low-fat meal).
89032682|NCT02928198|Active Comparator|Fenestration|Fenestration of the Absorb Biovascular Scaffold towards the side-branch
89032683|NCT02928198|Active Comparator|No Fenestration|No fenestration of the Absorb Biovascular Scaffold towards the side-branch
89032684|NCT04692545||A|patients receiving immunonutrition supply
89032685|NCT04692545||B|patients receiving standard dietary advice
89518676|NCT04839809|Experimental|CC-92480-02 (Formulation A) - high-fat meal|A single oral dose of CC-92480-02 (Formulation A) administered under fed conditions (high-fat meal).
89518677|NCT04830839|Experimental|Recovery after Stress Toolkit (ReSeT)|"ReSeT is comprised of interactive web-based psychoeducational modules that are developmentally tailored for school age children (8-17 years) for use with synchronous e-health therapy sessions with a trained therapist.~Participants in the ReSeT treatment will complete 8 modules and therapy sessions. Parents will also have access to 4 modules During the study, children/youth will be asked to complete all eight sessions of the online treatment together with the therapist over an 8 -12 week time period (to allow for scheduling/cancellations). For younger children, parents will participate in the beginning and end of each session. Sessions will last approximately 30-60 minutes and will occur approximately every week for an anticipated 4-8 hour time commitment. Parents of older children will be permitted to review the content independently and participate in feedback sessions."
89518678|NCT04664309||Participants|Adults who are receiving a COVID-19 vaccine
89518679|NCT02429414|Experimental|Non-Video Double Lumen Tube (DLT) Group|Participants receive a non-video DLT for lung isolation before surgery. Once non-video DLT is in correct place, its final position before surgery checked with a fiberoptic bronchoscopy (FOB).
89518680|NCT02429414|Experimental|Video Double Lumen Tube (VDLT) Group|Participants receive a VDLT for lung isolation before surgery. Once VDLT is in correct place, its final position before surgery checked with the camera inside the tube.
89518681|NCT02135614|Experimental|Presatovir|Participants will receive a single dose of presatovir.
89518682|NCT02135614|Placebo Comparator|Presatovir placebo|Participants will receive a single dose of presatovir placebo.
89518683|NCT04331483|Experimental|Physical activity intervention|"The intervention consists of an adapted physical activity (APA) program defined at baseline, incorporating supervised sessions with an APA teacher, as well as autonomous sessions. The program is individualized according to age, aerobic capacity, and PA preferences.~The total duration of the intervention is a maximum of 3 months (during the period of hospitalization in a sterile room)."
89518684|NCT03480113|Experimental|Mindfulness-based Intervention|1 session of health education regrading the harms from smoking and 6 sessions of Mindfulness-based intervention, 1 hour each session.
89518685|NCT03480113|Active Comparator|Physical Fitness intervention|1 session of health education regrading the harms from smoking and 6 sessions of physical fitness and stretch exercise, 1 hour each session.
89518686|NCT03479879|Experimental|Estradiol + Misoprostol|
89518687|NCT03479879|Placebo Comparator|Placebo + Misoprostol|
89518688|NCT03476447|Active Comparator|High dose B. infantis EVC001|10 participants will receive powdered B. infantis EVC001 at a high dose per daily oral feeding
89518689|NCT03476447|Active Comparator|Medium dose B. infantis EVC001|10 participants will receive powdered B. infantis EVC001 at a medium dose per daily oral feeding
89518690|NCT03476447|Active Comparator|Low dose B. infantis EVC001|10 participants will receive powdered B. infantis EVC001 at a low dose per daily oral feeding
89518691|NCT03476447|Placebo Comparator|Lactose Placebo|10 participants will receive powdered lactose per daily oral feeding
89518692|NCT03479801||Conventional Open|Conventional open thyroidectomy group (thyroid neoplasms patients who underwent conventional thyroidectomy procedure with or without postoperative central node dissection)
89518693|NCT03479801||Transoral Endoscopic Surgery|Transoral endoscopic thyroidectomy via vestibular approach group (thyroid neoplasms patients who underwent conventional thyroidectomy procedure with or without postoperative central node dissection)
89518694|NCT03479801||Endoscopic Thyroidectomy via Breast|Endoscopic thyroidectomy via breast approach or bilateral areola approach group (thyroid neoplasms patients who underwent conventional thyroidectomy procedure with or without postoperative central node dissection)
89518695|NCT03476291||Normal|normal macular structure of horizontal OCT B-scans
89518696|NCT03476291||Abnormal|abnormal macular structure of horizontal OCT B-scans, including many sub-categories of pathological features, like epiretinal membrane, pigment epithelium detachment, ect.
89518697|NCT03479645|No Intervention|Control|Control arm - usual practice. Simple SMS reminder that informs patients they are overdue for CRC screening and requests they contact the clinic.
89518698|NCT03479645|Experimental|Intervention|Serial text messages and mailed FIT kit
89518699|NCT03479489|Experimental|Human dehydrated amnion/chorion allofraft|Closed hemorrhoidectomy patched with human dehydrated amnion chorion allograft
89518700|NCT03479411|Experimental|Part 1 single ascending dose|Intervention: drug Itraconzaole powder: single dose of 5mg, 10mg or 25 mg Other name: PUR1900
89518701|NCT03479411|Experimental|Part 2 multiple ascending dose|Intervention: drug Itraconzaole powder: 10 mg or 20 mg daily for 14 days Other name: PUR1900
89518702|NCT03479411|Active Comparator|Part 3 2-period crossover single dose|Intervention: drug Itraconzaole powder: 20 mg single dose and Itraconzaole oral solution 200 mg single dose Other names: PUR1900, Sporanox
89518703|NCT03476057||Advanced gastrointestinal tumor|200 patients with pathologically confirmed Advanced gastrointestinal tumor who never treated with chemotherapy at Fujian Cancer Hospital
89518704|NCT03131297|Experimental|Anal fistula treated by radiofrequency|treatment by radiofrequency: patient with anal fistula treated by radiofrequency
89518705|NCT04134455|Active Comparator|Onlay Mesh Reinforcement group|The midline fascia was closed with running, slowly absorbable sutures (PDS 1-0) with a recommended suture length to wound length ratio of 4:1. An anterior plane with a width of about 8 cm was created between the anterior fascia and the subcutis. A Lightweight polypropylene mesh was used and placed on the anterior rectus fascia with an overlap of 3 cm. The mesh was fitted in the dissected space and it was fixed with PDS 2-0 suture. Fixing points are placed taking the mesh and the anterior fascia of the rectus muscle, at a distance of 3 cm between each point until completing its circunference.
89518706|NCT04134455|Experimental|RTL reinforcement group|The RTL suture is placed parallel at a distance of 0.5 cm from the fascial margin. Ideally the thread should lie between the anterior and the posterior rectus muscle sheath; there should be no contact with the rectus muscle. A nonabsorbable monofilamental polypropylene thread and a 65-mm ½ needle are used. Around this longitudinal thread, the continuous suture for fascial closure is introduced immediately lateral to the thread; with running, slowly absorbable sutures (PDS 1-0) with a recommended suture length to wound length ratio of 4:1. An anterior plane with a width of about 8 cm was created between the anterior fascia and the subcutis
89518707|NCT03131375|Active Comparator|Group A|In Group A: Anesthesia induction drugs: propofol , fentanyl , rocuronium iv. After induction, Group A receives a 50 ml NS infusion containing the drug Dexmedetomidine 1 mcg kg-1 slowly. Anesthesia maintainance drugs: propofol and remifentanil. Reversal of neuromuscular block drugs: Sugammadex according to TOF measurements. Postoperative analgesia drugs: nalbuphine 0.16 mg kg-1 . Monitoring devices: ECG, NIBP , ETCO2, SpO2, Bispectral index, Train of four ratio.
89518708|NCT03131375|Placebo Comparator|Group B|In Group B: Anesthesia induction drugs: propofol , fentanyl , rocuronium iv. After induction, Group B receives a volume matched normal saline infusion slowly. Anesthesia maintainance drugs: propofol and remifentanil. Reversal of neuromuscular block drugs: Sugammadex according to TOF measurements. Postoperative analgesia drugs: nalbuphine 0.2 mg kg-1 . Monitoring devices: ECG, NIBP , ETCO2, SpO2, Bispectral index, Train of four ratio.
89518709|NCT03475901|Experimental|Virtualy Reality App|Virtual reality app produced by KindVR played via a stereoscopic head mounted display (Samsung GearVR) and headphones that the patient will wear over their eyes and ears.
88982224|NCT00094380|Experimental|Dose-escalation portion: Low dose CTLA4-IgG4m (RG2077)|Three patients will receive a single intravenous infusion of 0.2 mg/kg CTLA4-IgG4m following the scheduled cyclophosphamide infusion on the same day. If one or more dose-limiting toxicities (CTC grade 3 or higher adverse event in the first 28 days after CTLA4-IgG4m administration that is possibly, probably, or definitely related to CTLA4-IgG4m (RG2077)). are observed, enrollment in the trial will be suspended pending DSMB review. If no dose-limiting toxicity is observed in the 0.2mg/kg dose, three patients will receive a single intravenous infusion of 2 mg/kg of CTLA4-IgG4m following the scheduled cyclophosphamide infusion on the same day. If one or more dose-limiting toxicities are observed, enrollment will be suspended pending review by the Data Safety and Monitoring Board (DSMB).If no dose-limiting toxicity is observed in the 2 mg/kg dose, treatment of patients with 10 mg/kg of CTLA4-IgG4m in combination with cyclophosphamide will proceed.
88982225|NCT00094380|Experimental|Part IIA: CTLA4-IgG4m|Participants randomized to the CTLA4-IgG4m Arm will receive a single intravenous infusion of 10 mg/kg CTLA4-IgG4m (RG2077) following the scheduled cyclophosphamide infusion on the same day
88982226|NCT00094380|Experimental|Part IIA: Control Group|Participants randomized to the control group will not receive treatment with CTLA4-IgG4m (RG2077); these participants will undergo all study evaluations with the exception of the CTLA4-IgG4m (RG2077) pharmacokinetic evaluations and immunogenicity evaluations.
88982227|NCT05457829|Experimental|AI Regimen|Doxorubicin hydrochloride liposome injection combined with Irinotecan
88982228|NCT05457829|Active Comparator|VIT Regimen|Temozolomide combined with Irinotecan and Vincristine
88982229|NCT05457751||M|Group M: patients currently using metoprolol and who did not receive lidocaine before the application of rocuronium.
88982230|NCT05457751||ML|Group ML: patients currently using metoprolol and who received lidocaine before rocuronium application.
88982231|NCT05457751||L|Group L: patients currently not using metoprolol and received lidocaine before rocuronium application.
89518710|NCT03479333|Experimental|Short implant|
89518711|NCT03479333|Active Comparator|standard implant with sinus lift|
89518712|NCT03475823|Placebo Comparator|Placebo control|Inert comparator indistinguishable from active interventions
89518713|NCT03475823|Active Comparator|Active control|240 mg ginkgo biloba
89518714|NCT03475823|Experimental|Low dose sideritis scardica|475 mg sideritis scardica
89518715|NCT03475823|Experimental|High dose sideritis scardica|950 mg sideritis scardica
89518716|NCT03479177|Experimental|High Intensity Interval Training|The exercise group will participate in a home and telephone-based program consisting of a 12-week high intensity interval training workout (HIIT). The home-based exercise sessions will be prescribed by the program exercise counselor, with a goal to exercise three times per week. The program will be tailored to meet specific fitness and strength needs of the participant. The participant will receive weekly telephone calls during the first month and bi-weekly calls during months 2 and 3. At 12 weeks, participants in both the exercise and wait-list control group will complete online questionnaires. The ActiGraph will be returned to the University of Minnesota research staff via a pre-paid postage envelope.
89518717|NCT03479177|No Intervention|Wait-List Control Group|Participants in the wait-list control condition will have the option of receiving the exercise intervention program after completion of the final assessment.
89518718|NCT03475745||Aphasia|Post stroke aphasia patients without any additional interventions for research purposes.
89518719|NCT03475745||Control|Healthy controls
89518720|NCT03946553||Allergic Rhinitis Group|Individuals with allergic rhinitis
89518721|NCT03946553||Control Group|Individuals without allergic rhinitis
89518722|NCT05259215||non-walking group|
89518723|NCT05259215||independently walking group|
89518724|NCT03475589|Other|single group|
89518725|NCT03929471|Experimental|Intervention group|Patients to be subjected to a fluid overload correction protocol.
89518726|NCT03929471|No Intervention|Control group|Patient will be followed but no fluid overload correction protocol will be applied.
89518727|NCT03478709||Volume expansion|
89518728|NCT03478709||norepinephrine|
89606116|NCT05704803|Experimental|Study Groups|"Positives: Symptomatic vs. Asymptomatic Negatives: Symptomatic vs. Asymptomatic~Each broken down by age groups:~2-14 years old 15-24 years old 25-64 years old 65+ years old"
89606117|NCT05683600|Experimental|LYB001 Booster Group|Subjects 18 years of age or older who has completed two or three-dose inactivated COVID-19 will receive 30μg LYB001 at day 0 as a booster vaccination.
89606118|NCT05683600|Active Comparator|Placebo Booster Group|Subjects 18 years of age or older who has completed two or three-dose inactivated COVID-19 will receive placebo at day 0 as a booster vaccination
89606119|NCT05674448|Experimental|HH-003 20mg/kg|HH-003 20mg/kg, intravenously, Q2W
89606120|NCT05674448|Experimental|HH-003 3mg/kg|HH-003 3mg/kg, intravenously, Q2W
89606121|NCT05665309|Experimental|With 3D anatomical model|Surgery prepared using 3D anatomical model of the aneurysm
89606122|NCT05665309|No Intervention|Without 3D anatomical model|Surgery prepared without 3D anatomical model of the aneurysm (routine care)
89606123|NCT05659602|Experimental|HH-120 group|HH-120 Nasal Spray
89606124|NCT05656898|Experimental|Piezosurgery pulse Low-level laser therapy|Piezocision will be applied in this group of patients using a piezosurgery knife and after 6 weeks of initial retraction, low-level laser therapy will be applied in this group of patients using a diode laser device.
89606125|NCT05656898|Experimental|Piezosurgery|Piezocision will be applied in this group of patients using a piezosurgery knife.
89518729|NCT03478631|Experimental|High Nitrate Dehydrated Vegetables|Participants are given high-nitrate dehydrated vegetable powders contained in opaque sachets. Participants are advised to consume three sachets per day, over the course of three meals, for 16 weeks.
89518730|NCT03478631|Active Comparator|Low-Nitrate Dehydrated Vegetables|Participants are given low-nitrate dehydrated vegetable powders contained in three opaque sachets. Participants are advised to consume three sachets per day, over the course of three meals, for 16 weeks.
89518731|NCT03478475|Experimental|Vitamin D group|The vitamin D group received three times per week a supplement of 10,000 IU cholecalciferol (Euro-Pharm International, Canada)
89518732|NCT03478475|Placebo Comparator|Placebo group|The placebo group received three times per week a tablet containing microcrystalline cellulose (66.3%), starch (33.2%), and magnesium stearate (0.5%), per serving.
89606126|NCT05656898|Active Comparator|Traditional treatment|En masse retraction in this group will be performed in a conventional method.
89606127|NCT05655195|Active Comparator|Alzheimer's Active Arm|Exposure to active sensory stimulation (40Hz) for 60 minutes daily for the length of the trial (6 months).
89606128|NCT05655195|Sham Comparator|Alzheimer's Control Arm|Exposure to control stimulation (sham) for 60 minutes daily for the length of the trial (6 months).
89606129|NCT05650320|Experimental|0.3% OPA-15406 Ointment|The 0.3% formulation of OPA-15406 ointment will be administered twice-daily (approximately 12 hours apart between morning and night administration) for 4 weeks. The amount of IMP (g) per dose is 10 g/m2 BSA and calculated.
89606130|NCT05650320|Experimental|1% OPA-15406 Ointment|The 1% formulation of OPA-15406 ointment will be administered twice-daily (approximately 12 hours apart between morning and night administration) for 4 weeks. The amount of IMP (g) per dose is 10 g/m2 BSA and calculated.
89606131|NCT05650320|Placebo Comparator|0% OPA-15406 Vehicle|The 0% formulation of OPA-15406 venicle will be administered twice-daily (approximately 12 hours apart between morning and night administration) for 4 weeks. The amount of IMP (g) per dose is 10 g/m2 BSA and calculated.
89606132|NCT05649059|Active Comparator|Cannabidiol|300mg Cannabidiol (3mL Epidiolex), oral, single-dose
89606133|NCT05649059|Placebo Comparator|Placebo|Placebo (3mL sesame seed oil), oral, single-dose
89606134|NCT05638620|Experimental|Active|This is a non-randomized, non-blinded study. Participants eligible for this study will receive active treatment. Dual Sympathetic Blocks of the stellate ganglion are minimally- invasive outpatient procedures performed under monitored care anesthesia (light sedation). Under ultrasound visualization, a small needle is guided into the neck region that contains the stellate ganglion nerve cluster at C6-C7. Once the needle position is confirmed, a local anesthetic (7 cc of 0.5% bupivacaine/Marcaine) is injected around the stellate ganglion by the Principal Investigator. This procedure is repeated at the C3-C4 level to block the superior cervical ganglion nerve cluster (3 cc of 0.5% bupivacaine/Marcaine).
89606135|NCT05637606|Experimental|MAP 80|Intervention group: intraoperative mean blood pressure target > 80 mmHg. Treatment of hypotension (defined as a mean blood pressure of below 80 mmHg) using intravenous bolus or continuous infusion of vasopressors, or fluids using a dedicated algorithm considering the pulse pressure or stroke volume variation and the mini fluid challenge to optimize mean blood pressure values.
88982232|NCT05457751||C|Group C: patients currently not using metoprolol and who did not receive lidocaine before rocuronium application.
88982233|NCT05457712|Experimental|Intervention group|In the first evaluation and after the patient's consent, a standardized complementary questionnaire will be applied, with demographic and clinical information. The nutritionist will carry out the anthropometric assessment, questionnaires and application of the protocol for this group. The energy and protein value of the prescribed diet will be followed according to the original protocol considering plans A, B or C, via a hypercaloric formula with a caloric density of 1kcal/ ml for infants starting 60 days preoperatively. The return for nutritional monitoring will take place after evaluation: weekly, biweekly or monthly.
89518733|NCT03475433||Beast cancer patients|All participants that suffer from breast cancer.
89518734|NCT03475433||Prostate cancer patients|All participants that suffer from prostate cancer.
89518735|NCT03475355|Experimental|EG1|Each patient will be instructed to carefully observe the finalized movement of the upper limb of an experimenter seated in front (the experimenter's left hand is right in front of the patient's right hand), without moving or imagining the movement.
89518736|NCT03475355|Experimental|EG2|Each patient will be instructed to look at a computer screen that is in front of him that will show a daily routine task (actions).
89518737|NCT03475355|Experimental|EG3|Each patient will be instructed to carefully observe the finalized movement performed by an experimenter standing in front of him (the examiner's left leg will be in front of the patient's right leg).
89518738|NCT03475355|Experimental|EG4|Each patient will be instructed to look at a computer screen that is in front of him that will show a daily routine task (actions).
89606136|NCT05637606|Other|MAP 65|Control group: intraoperative mean blood pressure target > 65 mmHg. Treatment of hypotension (defined as a mean blood pressure of below 65 mmHg) using intravenous bolus or continuous infusion of vasopressors, or fluids using a dedicated algorithm considering the pulse pressure or stroke volume variation and the mini fluid challenge to optimize mean blood pressure values.
88982234|NCT05457712|Other|Control group|In the first evaluation and after the patient's consent, a standardized complementary questionnaire will be applied, with demographic and clinical information. The nutritionist will carry out the anthropometric assessment and questionnaires. Afterwards, they will be evaluated through the standard nutritional protocol of the nutrition clinic of the Institute of Cardiology and Children's Hospital Santo Antonio of Porto Alegre, whose standard nutritional prescription is a polymeric formula with a caloric density of 0.67 kcal/ml. Nutritional monitoring will take place through telephone contact for information on the baby's clinical data and in person before the surgery is performed.
88982235|NCT00124566|Experimental|1|Irofulven + prednisone
88982236|NCT00124566|Experimental|2|Irofulven + capecitabine + prednisone
88982237|NCT00124566|Active Comparator|3|Mitoxantrone + prednisone
88982238|NCT00321724|Experimental|Treatment (cediranib maleate)|Patients receive oral AZD2171 once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88982239|NCT00086645|Experimental|citalopram hydrobromide|citalopram hydrobromide, up to 20 mg daily
88982240|NCT00086645|Placebo Comparator|placebo|placebo, up to equivalent of 20 mg of active comparator daily
88982241|NCT00321802|Experimental|1|Patients randomized to active drug, then AF burden and CRP values will be compared to those in placebo arm.
88982242|NCT00321802|Placebo Comparator|2|Patients take placebo once daily for 6 Months, then AF burden and CRP values will be compared to those in experimental arm.
88982243|NCT00124605|Experimental|Treatment (pamidronate disodium and arsenic trioxide)|Patients receive pamidronate IV and over 2 hours on days 1 and 15 and arsenic trioxide IV over 2 hours on days 1-5 and 15-19. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88982244|NCT02959528|Active Comparator|Control|ADHD group treated with visual-perceptual training
88982245|NCT02959528|Experimental|Experiment|ADHD group treated with working memory training
88982246|NCT00400127|Experimental|amputee|
88982247|NCT05457361|Experimental|VAH regimen|VEN begins at 100 mg on day 1 and increases stepwise over 3 days to reach the target dose of 400 mg (100 mg, 200 mg, 400 mg); dosing is continued at 400 mg per day from day 4 through day 14; azacitidine (75 mg/m²) is administered subcutaneously on days 1-7, and HHT (1 mg/m²) on days 1-7.
88982248|NCT05457361|Active Comparator|VA regimen|The use of VEN is just the same as it dose in VAH regimen except lasting for 28 days. The use of azacitidine is exactly the same as VAH group does.
88982249|NCT05456854|Experimental|Kisspeptin|Intravenous administration of kisspeptin 112-121 x 16 hours
88982250|NCT05456854|Placebo Comparator|Placebo|Intravenous administration of placebo x 16 hours
88982251|NCT05456386|Experimental|The Circadian Rhythm Approach to Weight Loss (CRAWL) Intervention Arm|The Circadian Rhythm Approach to Weight Loss (CRAWL) intervention subjects will continuously wear their Fitbit Versa 2 (aside from periodic charging periods) and participate in the pre-scheduled CRAWL sessions. Every week, subjects will complete a sleep diary, which assesses subject's time in bed, sleep latency, awakenings, wake after sleep onset, awakening time, overall sleep quality, overall refreshed rating, naps, exercise, energy level and mood. Subjects are to ensure their Fitbit is sufficiently charged every night before bed and they are to wear their Fitbit continuously throughout the night. Subjects will weigh themselves using their home scale each week prior to exercise, taking a shower or eating breakfast. They will record their weight in their provided weight tracking sheet
88982252|NCT05456386|No Intervention|Waitlist Control Arm|Waitlist control subjects will follow the same protocol outlined above for 16 weeks minus the scheduled CRAWL sessions. When the initial treatment arm has completed their 16 weeks of group sessions, the waitlist control group will begin their CRAWL sessions.
88982253|NCT00086801|Experimental|doxorubicin + vinblastine + gemcitabine|"Patients receive doxorubicin IV over 3-5 minutes, vinblastine IV over 3-5 minutes, and gemcitabine IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.~Patients undergo fludeoxyglucose F 18 positron-emission tomography (PET) scanning and CT scan before treatment and after courses 2 and 6 of therapy to assess response. Patients with a positive PET scan after completion of study therapy may undergo biopsy. A PET scan is performed 3 months later if biopsy is negative or biopsy is unable to be performed.~Patients are followed every 3 months for 1 year, every 4 months for 2 years, every 6 months for 2 years, and then annually for 5 years."
88982254|NCT05452837|Active Comparator|Free Dermal Fat Graft|Free Dermal Fat Graft (FDFG) is applied to the superficial parotidectomy defect site
88982255|NCT05452837|Active Comparator|Superficial musculoaponeurotic system flap|Superficial musculoaponeurotic system (SMAS) Flap is dissected and tailored to fill the defect after superficial parotidectomy
88982256|NCT05425771|Experimental|Mucosa Ablation Arm|Treatment group
88982257|NCT00086840|Experimental|Treatment (temsirolimus)|Patients receive CCI-779 IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients achieving an objective response may receive 3 consolidation courses of therapy.
88982258|NCT00124683|Experimental|1|Nicotine Patch + Bupropion
88982259|NCT00124683|Placebo Comparator|2|Nicotine patch + placebo
88982260|NCT04717063|Active Comparator|Peroxyl|"Drug: Peroxyl Mouthwash Mouthwash~Other Names:~• 1.5% HP"
88982261|NCT04717063|Placebo Comparator|placebo mouthwash|"Drug: Placebo Mouthwash Mouthwash~Other Names:~• 0.0% HP Mouthwash"
88982262|NCT04717180|Active Comparator|group I|patients who received rehabilitation using the software program for aphasia rehabilitation
88982263|NCT04717180|Active Comparator|group II|patients who received rehabilitation using the conventional therapy
89606137|NCT05632640|Active Comparator|Standard of Care|
88982264|NCT00124722|Experimental|0.45 mg/kg Zemuron|0.45 mg/kg Zemuron
88982265|NCT00124722|Active Comparator|0.6 mg/kg Zemuron|0.6 mg/kg Zemuron
88982266|NCT00124722|Experimental|1.0 mg/kg Zemuron|1.0 mg/kg Zemuron
88982267|NCT00322036|Experimental|1|Oral 800 mg BID dosing
89606138|NCT05632640|Experimental|Weighted blanket|
89606139|NCT05626985||Hepatocellular Carcinoma patients|Blood samples are collected before liver resection.
89606140|NCT05626985||Liver cirrhosis|The diagnosis of liver cirrhosis are based on triple-phase contrast enhanced computed tomography, magnetic resonance imaging.
89606141|NCT05626985||Hepatitis|Patients with various hapatitis.
89606142|NCT05626985||Benign tumor-like lesions|Benign hepatic tumors were diagnosed based on imaging findings and histological examinations after hepatic resection.
89606143|NCT05626985||Healthy control|The healthy control group consist of people undergoing routine medical examination. Blood samples are collected.
89606144|NCT05623774|Active Comparator|Dose Calibration|In Part A, cohorts will consist of 8 subjects who will receive a single dose of Ikt-001Pro and then cross over to a single does of imatinib following a 7 day washout.
89606145|NCT05623774|Active Comparator|Dose Equivalance|In Part B, up to 16 subjects will receive IkT001-Pro and up to 16 subjects will receive 400mg of imatinib mesylate. After a 7 day washout period the subjects will switch to receive the drug they did not previously receive.
89606146|NCT05622045||Story-LCSS|
89606147|NCT05611775|Other|Activity Monitor Assessment|Subjects will be assessed in the Motion Analysis Laboratory at Mayo Clinic Rochester and have activity monitored in the free-living environment.
89606148|NCT05608707|Experimental|Personalised diet plus physical activity intervention|"A personalised diet intervention involving the incorporation of the developed plant-based protein and fibre product.~Participants will also undertake 2 weekly group exercise sessions incorporating strength and balance exercises, along with home-based exercise"
89606149|NCT05608707|Experimental|Usual diet plus physical activity|Participants will consume their usual diet and undertake 2 weekly group exercise sessions incorporating strength and balance exercises, along with home-based exercise
89606150|NCT05608707|Experimental|Personalised diet plus usual physical activity|A personalised diet intervention involving the incorporation of the developed plant-based protein and fibre product.
89606151|NCT05608707|No Intervention|Control (usual diet and physical activity)|This arm will not be given any nutritional or physical activity support. They will be instructed to carry on with their usual activities.
89606152|NCT05598138|Experimental|Intervention|A blood sample (10 ml) will be taken for each patient included in the study
89606153|NCT05591404|Experimental|Film + TSST|Nature Film + Trier Social Stress Test (TSST)
89518739|NCT03475355|Active Comparator|CG1|"Participants will be shown for 3 minutes 5 static images that expose objects, none will represent animals or people.~The participant's attention will be kept high through a cognitive task. For each CGail patient condition a sequence of images will be presented for 3 minutes, the images will be displayed separately, each for 30 seconds, and then during the last 30 seconds, will be displayed together with an intrusive image (intruder) that the patient will be asked to identify so that his attention span can be controlled in real time. Participants will then be invited to perform movements of the limbs as far as possible for 2 minutes according to a standard sequence that involves articular mobilizations of upper limbs and simulates that performed by the experimental groups."
89606154|NCT05591404|No Intervention|Film Only (No-TSST)|Nature Film Only
89606155|NCT05589675|Experimental|Intervention arm|Invitation letter to the screening program with the FIT test
89606156|NCT05589675|Experimental|Intervention arm - sub study|Prior notification to the new entrants, followed by an invitation letter to the screening program with the FIT test
89606157|NCT05589675|No Intervention|Control arm|Invitation letter to visit its own GP who will deliver the FIT test
89606158|NCT05585450|Experimental|Electroacupuncture (EA) group|"Participants in the EA group will receive treatment at bilateral Bladder Meridian (BL) 32 [Ciliao], BL33 [Zhongliao], BL35 [Huiyang], and Spleen Meridian (SP) 6 [Sanyinjiao].~BL32, in the second posterior sacral foramen; BL33, in the third posterior sacral foramen; BL35, 0.5 cun (≈10mm) lateral to the extremity of the coccyx; SP6, posterior to the medial border of the tibia, 3 cun (≈60mm) superior to the prominence of the medial malleolus.~The treatment will last 30 minutes for each session, 3 sessions per week (ideally every other day) for a succession of 8 weeks."
88982268|NCT00322036|Placebo Comparator|2|Oral BID dosing
89606159|NCT05585450|Sham Comparator|Sham Electroacupuncture (SA) group|"Participants in the SA group will receive treatment at bilateral sham BL32, BL33, BL35, and SP6.~Sham BL32, in the area of 1 cun (≈20mm) horizontally outside BL32; Sham BL33, in the area of 1 cun (≈20mm) horizontally outside BL33; Sham BL35, 1 cun (≈20mm) horizontally outside BL35; Sham SP6, in the middle of SP6 and tendons.~The treatment will last 30 minutes for each session, 3 sessions per week (ideally every other day) for a succession of 8 weeks."
89606160|NCT05582538|Experimental|TNBC patients treated with ceralasertib, durvalumab e nab-paclitaxel|"Patients will be assessed for eligibility during the 28-day screening period prior to enrollment. Enrolled patients will be treated with:~Ceralasertib at 240 mg administered orally, twice daily on Days -6 to 0 prior to Day 1 Cycle 1 and thereafter on Days 22 to 28 (priming period) of Cycle 1 and every subsequent cycle;~Durvalumab at 1500 mg administered via IV infusion on Day 1 of every 28-day cycle; Nab-paclitaxel at 100 mg/m2 administered via IV infusion on Days 1,8 and 15 of every 28- day cycle.~A safety run-in phase will be carried out at the start of the present study using a 3+3 de-escalating schema down to -2 ceralasertib dose level. Nab- paclitaxel or durvalumab doses will not be de-escalated. Once the definitive dose for ceralasertib is established, treatment will be continued until progression or unacceptable toxicity, which ever come first."
89606161|NCT05578547|Experimental|combined Kndell and McKenzie group|patients receivee combined Kndell and McKenzie cervical posture correction exercises, ultrasound, hot packs, cervical extensors stretching and strengthening exercise.
89606162|NCT05578547|Active Comparator|Conventional therapy group|patients receive ultrasound, hot packs, cervical extensors stretching and strengthening exercise.
89606163|NCT05576610|Experimental|Enzyme containing mouth spray + Standard Preventive Advice|Usage of Oral7 mouth spray along side with the Standard Preventive Advice
89606164|NCT05576610|Placebo Comparator|Normal Saline mouth spray +Standard Preventive Advice|Usage of normal saline containing mouth spray along side with the Standard Preventive Advice
89606165|NCT05575947||robotic-assisted|"Robotic-assisted cases converted to open will be part of the robotic cohort.~Comparison of the following safety and effectiveness related surgical outcomes across robotic-assisted and laparoscopic cohorts:~Safety Related Outcomes~Intraoperative Complication Rates~Transfusion Rates~30-Day Post-Operative Complication Rates~30-Day Readmission Rates~30-Day Reoperation Rates~30-Day Mortality~Effectiveness Related Outcomes~Conversion Rate to Open Surgery~Operative Time~Length of Hospital Stay"
89606166|NCT05575947||laparoscopic|"Laparoscopic cases converted to open will be part of the laparoscopic cohort.~Comparison of the following safety and effectiveness related surgical outcomes across robotic-assisted and laparoscopic cohorts:~Safety Related Outcomes~Intraoperative Complication Rates~Transfusion Rates~30-Day Post-Operative Complication Rates~30-Day Readmission Rates~30-Day Reoperation Rates~30-Day Mortality~Effectiveness Related Outcomes~Conversion Rate to Open Surgery~Operative Time~Length of Hospital Stay"
89606167|NCT05570305|Experimental|Treatment order 1|Subjects will start with 4 weeks of placebo in treatment period one, then 4 weeks of zibotentan during treatment period two. The order of the first two treatment periods is random which means that patients can start with either placebo or zibotentan. Then in treatment period three, patients are randomized to either either placebo or dapagliflozin for 2 weeks followed immediately by 4 weeks of both zibotentan and dapagliflozin. Between treatment periods there is a 4-week wash-out.
89606168|NCT05570305|Experimental|Treatment order 2|Subjects will start with 4 weeks of dapagliflozine in treatment period one, then 4 weeks of zibotentan during treatment period two. The order of the first two treatment periods is random which means that patients can start with either dapagliflozine or zibotentan. Then in treatment period three, patients are randomized to either either placebo or dapagliflozin for 2 weeks followed immediately by 4 weeks of both zibotentan and dapagliflozin. Between treatment periods there is a 4-week wash-out.
89606169|NCT05565716|Experimental|Support Person|A support person not in the study will receive the participant's weekly blood pressure performance details and will contact them at least on a weekly basis to encourage continued blood pressure monitoring. Prior to randomization, the participant will select a preference between a support person that is close to them (e.g., friend or family member) or a support person who is provided by the study, a Peer Mentor.
89606170|NCT05565716|Experimental|Social Norms|In this arm, participants will be texted reports of blood pressure performance statistics of the other participants in the study and also receive weekly feedback about how their blood pressure information compares to others in the study. Participants in this arm will have access to a leaderboard that displays this information.
89606171|NCT05562518|Active Comparator|Estrogen|locally administered estrogen (oestriol)
89606172|NCT05562518|Active Comparator|Dehydroepiandrosterone|locally administered dehydroepiandrosterone (DHEA)
89606173|NCT05562518|Active Comparator|Estrogen + probiotics|locally administered estrogen (oestriol) + probiotics
89606174|NCT05562518|Active Comparator|Moisturizer|locally administered hyaluronic acid
89606175|NCT05556356|Placebo Comparator|Control Group|Preoperative multivitamin and postoperative standardized pain management regimen
89606176|NCT05556356|Experimental|Test Group|: Preoperative acetaminophen and postoperative standardized pain management regimen
89032686|NCT02928120||CRC group (exploratory)|"Blood samples from approximately 210 patients diagnosed with colorectal carcinoma collected prospectively and consecutively at the Department of Surgical Gastroenterology, Aalborg University Hospital during the time period 2003-2006 will be used. The blood samples were collected at the time of diagnosis, before and after treatment (surgery and radio-chemo-therapy) and at regular intervals for a time period of two years after treatment. These blood samples were collected during a previous PhD-study: Pre- and postoperative Venous Thromboembolism in Patients with Colorectal Cancer - implications of Radiotherapy (ID-number VN 2003/102)."
89606177|NCT05553522|Experimental|Investigational Treatment|
89606178|NCT05553132|Experimental|CartiLage Auto/Allo IMplantation for Focal Hip Cartilage Defects|Subject will receive the combined product of autologous cartilage cells and allogeneic AMSCs in a fibrin glue carrier.
89606179|NCT05550753|Experimental|Intervention|Will be offered the BT coaching intervention during of 4-months (February 1st 2023- May 31st 2023).
89606180|NCT05550753|Placebo Comparator|Control|Will NOT be offered the BT coaching intervention during of 4-months (February 1st 2023- May 31st 2023). Will be offered the coaching intervention after the study completion (from September 1st 2023 - December 31st 2023).
89606181|NCT05544734|Active Comparator|Hydrocodone 5mg/acetaminophen 325mg|Participants receive oral hydrocodone 5 mg/acetaminophen 325 mg every 4 hours for 2 days, followed by oral acetaminophen 1000 mg and oral ibuprofen 400 mg every 6 hours for 4 days
89606182|NCT05544734|Active Comparator|Acetaminophen 1000mg + Ibuprofen 400mg|Participants receive oral acetaminophen 1000 mg and oral ibuprofen 400 mg every 6 hours for 6 days
89606183|NCT05542030|Experimental|Endoscopic mucosal resection + CAD-Eye™|"This group constitutes patients with lesions suggestive of high-grade dysplasia or early invasive cancer approached with endoscopic mucosal resection, subjected to colonoscopy + CAD-Eye™ system evaluation for the detection of remaining malignant tissue.~For this group, the investigators used as a complement tool an AI system (CAD-Eye™) for the detection of remaining lesions immediately after EMR and in a three-month follow-up."
89606184|NCT05542030|Active Comparator|Endoscopic mucosal resection without CAD Eye|"This group constitutes patients with lesions suggestive of high-grade dysplasia or early invasive cancer approached with endoscopic mucosal resection and subjected to colonoscopy. The detection of remaining lesions immediately after EMR is based on the visual impression of the expert.~For this group, the investigators used as a complement tool an AI system (CAD-Eye™) only for the evaluation of the post-procedure scar to detect remaining lesions in the three-month follow-up."
89606185|NCT05539040|Experimental|Intervention|Right atrial GP ablation in addition to pulmonary vein isolation
89606186|NCT05539040|Active Comparator|Control|PVI alone with no GP mapping or ablation
89606187|NCT05537714||Vaccine hesitant|We will conduct quantitative (survey) and qualitative assessments (interviews/focus groups) with 40 vaccine hesitant, Black, Hispanic, and medical underserved individuals living in rural eastern North Carolina (ENC)
89518740|NCT03475355|Active Comparator|CG2|"Participants will be shown for 3 minutes 5 static images that expose objects, none will represent animals or people.~The participant's attention will be kept high through a cognitive task. For each CGail patient condition a sequence of images will be presented for 3 minutes, the images will be displayed separately, each for 30 seconds, and then during the last 30 seconds, will be displayed together with an intrusive image (intruder) that the patient will be asked to identify so that his attention span can be controlled in real time. Participants will then be invited to perform movements of the limbs as far as possible for 2 minutes according to a standard sequence that involves articular mobilizations of lower limbs and simulates that performed by the experimental groups."
89518741|NCT03475199|Experimental|FabLife group|Fablife personnalised support and telephone follow-up with a dietician.
89518742|NCT03475199|No Intervention|Control group|General dietary recommendations.
89518743|NCT03645707|Experimental|CAR Training and Psychoeducational Sessions|"This is a secondary study to the primary study titled A Randomized Controlled Trial of a Resilience Intervention for Critical Care Nurses (IRBNet #1234568). In the primary study, participants will be randomized into the intervention group or wait-list control group.~In this secondary study, all participants will attend the 1-day CAR Training Program and the follow-up psychoeducational group sessions."
89518744|NCT03478319|Experimental|Cohort 1|ACE-2494 or placebo 0.06 mg/kg SC Day 1
89518745|NCT03478319|Experimental|Cohort 2|ACE-2494 or placebo 0.2 mg/kg SC Day 1
89518746|NCT03478319|Experimental|Cohort 3|ACE-2494 or placebo 0.6 mg/kg SC Day 1
89518747|NCT03478319|Experimental|Cohort 4|ACE-2494 or placebo 1.0 mg/kg SC Day 1
89518748|NCT03478319|Experimental|Cohort 5|ACE-2494 or placebo 2.0 mg/kg SC Day 1
89032687|NCT02928120||Control group (exploratory)|"Blood samples (8ml) from patients (n=142) who underwent work-up for lower gastrointestinal malignancy during the time period 2003-2006. Colonoscopy was performed, and no malignancy or premalignant lesions found. Blood samples were collected before/after colonoscopy. These blood samples were collected during a previous PhD-study: Pre- and postoperative Venous Thromboembolism in Patients with Colorectal Cancer - implications of Radiotherapy (ID-number VN 2003/102)."
89032688|NCT02928120||CRC group (validation)|Blood samples from 143 patients were collected prospectively and consecutively for a previous study on the effect of omega 3 fatty acids an postoperative complications after colorectal surgery. All study participants have provided written informed consent (N-VN-20050035).
89032689|NCT02928120||Control group (validation)|There will be recruited approximately 100 control subjects with a positive occult faecal blood but with a normal colonoscopy for blood sampling (28 ml).
89518749|NCT03478319|Experimental|Cohort 6|ACE-2494 or placebo TBD (not to exceed 3.0 mg/kg SC) Day 1
89518750|NCT03131063||Septic patient under ECMO treatment|Every adult patient admitted to ICU, under ECMO treatment, with known or suspected sepsis and receiving antibiotic therapy, was eligible for inclusion. The concentration of the studied antibiotics was determined by a combination of liquid chromatography and mass spectrometry from blood samples. For intermittent administration of antibiotic, two successive samples were performed both at 50% (Cmax) and 100% (Cmin) of the dosing interval.
89518751|NCT03478241|Active Comparator|Group 1: single file rotary motion|after the previous root canal filling was removed, the shaping procedure of the root canal system was carried out using OneShape Ni-Ti system.
89518752|NCT03478241|Active Comparator|Group 2: multiple file rotary motion|after the previous root canal filling was removed, the shaping procedure of the root canal system was carried out using Revo S Ni-Ti system.
89518753|NCT03478241|Active Comparator|Group 3: single file reciprocal motion|after the previous root canal filling was removed, the shaping procedure of the root canal system was carried out using WaveOne Ni-Ti system.
89518754|NCT02523755|Active Comparator|Epidural analgesia Ropivacaine|Placement of an epidural catheter to achieve pain relief
89518755|NCT02523755|Sham Comparator|Absence of epidural analgesia|No placement of an epidural catheter either because of patient refusal or contraindication
89518756|NCT05258123|Active Comparator|active drug|A fixed titration to 360mg （or nine tables） daily of Ginkgo biloba extract was administered with three times daily dosage throughout the study
89518757|NCT05258123|Placebo Comparator|placebo|A nine tables of placebo were administered with three times daily dosage throughout the study
89518758|NCT03478085|Active Comparator|Traditional exercise therapy|Training will be performed three times a week for 12 weeks. Each session will take place on a GaitKeeper treadmill (Sammons Preston, IL) treadmill and will last 45 minutes with a 5 minute warm up and cool down of either cycling or walking.
89518759|NCT03478085|Experimental|Oxygen guided exercise therapy|Training will be performed three times a week for 12 weeks. Each session will take place on a GaitKeeper treadmill (Sammons Preston, IL) treadmill and will last 45 minutes with a 5 minute warm up and cool down of either cycling or walking. All patients will be outfitted during exercise with the PortaMon NIRS device on the most affected calf (including subjects in the symptom-driven exercise cohort). The intensity of training will be adjusted to either pain (claudication) rating or oxygen tension. In preliminary studies, a 50% reduction in the tissue saturation index is typically not associated with severe claudication and will be used as the lower level threshold to gauge physical effort (i.e., if subjects do not desaturate by >50% then the intensity of training - the walking pace - will be increased). The training duration, intensity, pain rating, and oxygen tension will be recorded.
89518760|NCT03478085|Placebo Comparator|Control|Patients will be advised to walk independently.
89518761|NCT02168842|Active Comparator|Isradipine|Oral capsule of up to 5 mg of isradipine taken twice daily for 36 months.
89518762|NCT02168842|Placebo Comparator|Placebo (for Isradipine)|Oral capsule taken twice daily for 36 months.
89518763|NCT02200042|Experimental|Radiation therapy|Liver-directed radiation therapy
89518764|NCT02200042|No Intervention|Observation|No radiation therapy
89606188|NCT05537714||Trusted community leaders|We will conduct quantitative (survey) and qualitative assessments (interviews/focus groups) with 40 trusted individuals such as clergy/church leaders, community health workers, and community leaders who serve medical underserved individuals living in rural eastern North Carolina (ENC) .
89606189|NCT05530694|No Intervention|Control|Usual care
89606190|NCT05530694|Experimental|Intervention|Intervention phase
89606191|NCT05528900|Experimental|FPEIS children|
89606192|NCT05521737|Sham Comparator|Sham group|Sham acupuncture will be administered in a total of 32 sessions within five months.
89606193|NCT05521737|Experimental|Interventional group|Electroacupuncture will be administered in a total of 32 sessions within five months.
89606194|NCT05517200||Normal Control|These participants are normal control in good mental and psychiatric health.
89606195|NCT05517200||Migraine|These participants have migraines according to ICHD-3 criteria.
89606196|NCT05515939||InPen|Patients who will begin using the InPen device as per standard of care
89606197|NCT05515029|Experimental|GVHD prevention: post-transplantation cyclophosphamide, abatacept, vedolizumab,calcineurin inhibitor|
89606198|NCT05514483|Placebo Comparator|Placebo|All participants will receive a single injection of placebo, followed, three hours later, by a single injection of ondansetron.
89032690|NCT02928120||IBD group (validation)|In collaboration with The Department of Medical Gastroenterology, Aalborg University Hospital, there will be recruited approximately 120 patients with ulcerous colitis for blood sampling (28 ml).
89606199|NCT05514483|Active Comparator|Ondansetron|All participants will receive a single injection of placebo, followed, three hours later, by a single injection of ondansetron.
89518765|NCT02199028|Experimental|Hyaluronidase, Then Control|"Participants assigned to active treatment arm (Hylenex) for weeks 1 and 3.~On weeks 1 and 3 (Hyaluronidase weeks) subjects injected 1 milliliter (ml) Hyaluronidase (150 units/ml) into the catheter hub prior to connecting the insulin infusion set on Day 1 and 3 of infusion set wear.~On weeks 2 and 4 (control weeks) no Hyaluronidase was administered."
89518766|NCT02199028|Experimental|Control, Then Hyaluronidase|"Participants were first assigned to the control arm. They received active treatment (Hyaluronidase) on weeks 2 and 4.~On weeks 1 and 3 (control weeks) no Hyaluronidase was administered.~On weeks 2 and 4 (Hyaluronidase weeks) subjects injected 1 milliliter (ml) Hyluronidase (150 units/ml) into the catheter hub prior to connecting the insulin infusion set on Day 1 and 3 of infusion set wear."
89518767|NCT03347123|Experimental|Phase 1: Dose Escalation: Treatment Group A: Cohort 1 Epacadostat 50 mg BID|Participants with advanced or metastatic solid tumor who have received no more than 2 prior treatment regimens received epacadostat 50 mg BID orally in combination with nivolumab 240 mg on day 1 of each 14 day cycle and ipilimumab 1 mg/kg intravenous (IV) every 6 weeks thereafter on Day 1 of every third treatment cycle until disease progression or occurrence of unacceptable drug-related toxicities or discontinuation or up to 24 months.
89606200|NCT05500235|Experimental|Smart phone based training|Smartphone-based training for Headmasters to implement the Tobacco Free Teachers-Tobacco Free Society program in their schools in Madhya Pradesh, India
89032691|NCT04692506|Active Comparator|Low dose: Sachet with B. longum|"The IP will be self-administered by the subject. Subjects will be asked to consume the IP (1 sachet) once per day, at approximately the same time every day, for 28 days.~The sachet should be emptied in, and mixed with, a bottle of milk."
89032692|NCT04692506|Active Comparator|High dose: Sachet with B. longum|"The IP will be self-administered by the subject. Subjects will be asked to consume the IP (1 sachet) once per day, at approximately the same time every day, for 28 days.~The sachet should be emptied in, and mixed with, a bottle of milk."
89518768|NCT03347123|Experimental|Phase 1: Dose Escalation: Treatment Group A: Cohort 2 Epacadostat 100 mg BID|Participants with advanced or metastatic solid tumor who have received no more than 2 prior treatment regimens received epacadostat 100 mg BID orally in combination with nivolumab 240 mg on day 1 of each 14 day cycle and ipilimumab 1 mg/kg intravenous (IV) every 6 weeks thereafter on Day 1 of every third treatment cycle until disease progression or occurrence of unacceptable drug-related toxicities or discontinuation or up to 24 months.
89606201|NCT05500235|Experimental|In person training|In person training for Headmasters to implement the Tobacco Free Teachers-Tobacco Free Society program in their schools in Madhya Pradesh, India
89606202|NCT05499052||REKOVELLE®|
89606203|NCT05497973|Experimental|eHealth ecosystem of stepped psychosocial care|"Patients will be monitored allowing the delivery of timely and personalized care via a 4-level program:~Screening and psychosocial monitoring through a mobile application where patients have a messaging system to contact their psychologist and reference nurse.~Psychoeducation and health education campus, where patients can consult videos and online resources developed by health professionals, containing scientifically validated information.~Psychosocial support community where patients can share doubts, fears, and experiences with other patients with advanced lung cancer. This private social network is monitored by team specialists when necessary.~Online group psychotherapy of 8 weekly sessions of 90 minutes based on Meaning-Centered Group Psychotherapy (MCGP; Breitbart et al., 2010). Patients at this level will be on a waiting list, so the pool starts when there are 4-8 users available."
89606204|NCT05497973|Active Comparator|Usual psychosocial care|This group will receive standard psychosocial care for cancer survivors at ICO Hospitalet center led by a clinical psychologist. It consists of 7 individual sessions of 45-60 minutes, scheduled every 2-3 weeks during 9 months and focused on emotional support and psychoeducation. Moreover, they will be offered the education materials from the 2nd step of the platform, as they are compiled in a website open to all patients and relatives.
89606205|NCT05492695|Active Comparator|Galcanezumab + BMPT|"240 mg of galcanezumab will be administered once as a loading dose at Visit 2, followed by monthly doses of 120 mg at Visits 3 and 4.~All participants will be required to continue BMPT. For consistency purposes visit 2/ randomization should be scheduled within +/- 3 days of subjects next Botox administration as part of BMPT."
89606206|NCT05492695|Placebo Comparator|Placebo + BMPT|• Galcanezumab matching placebo will be administered at Visits 2, 3 and 4.
89606207|NCT05484557|Experimental|study|treatment with Apixaban
89606208|NCT05484557|Active Comparator|Control|treatment with Enoxaparin
89606209|NCT05482854|Experimental|Patients treated early and carrying the MHC B35/53Bw4TTC2 Genotype|Patients included in the ANRS CO6 PRIMO cohort, treated early and carrying the MHC B35/53Bw4TTC2 Genotype
89606210|NCT05482347|Active Comparator|Control (knowledge assessment before video)|The patient will complete the knowledge assessment, then they will be presented with the educational video. After watching the video, they will complete the acceptability scale questionnaire and will be asked to select a gift card preference at the end of the survey.
89606211|NCT05482347|Experimental|Video (video before knowledge assessment)|The patient will be presented with the educational video, then they will complete the knowledge assessment and the acceptability scale questionnaire. They will be asked to select a gift card preference at the end of the survey.
89606212|NCT05474794|Experimental|Subepithelial lesions|"Patients with subepithelial lesions of the gastrointestinal (GI) tract (GISTs or leiomyomas) at EUS evaluation.~Two interventions: EUS-DFI examination for the detection of slow flow vascularization in SELS. Then, CE-EUS for diagnosis confirmation."
89606213|NCT05473962||exposed to Alex storm|"Child and/or young adult aged under 18 at the time of exposure having been assessed by the CUMPS teams during the ALEX Storm interventions of October 2020"
89606214|NCT05467358||Patients with preendoscopic ppi order|Patients receiving 80 mg esomeprazole loading and 8 mg esomeprazole infusion per hour before endoscopic treatment
89518769|NCT03347123|Experimental|Phase 1: Dose Escalation: Treatment Group B: Cohort 1 Epacadostat 50 mg BID|Participants with advanced or metastatic solid tumor who have received no more than 2 prior treatment regimens received epacadostat 50 mg BID orally in combination with nivolumab 240 mg on day 1 of every 14 day cycle and lirilumab 240 mg IV every 4 weeks until disease progression or occurrence of unacceptable drug-related toxicities or discontinuation or up to 24 months.
89518770|NCT03347123|Experimental|Phase 1: Dose Escalation: Treatment Group B: Cohort 2 Epacadostat 100 mg BID|Participants with advanced or metastatic solid tumor who have received no more than 2 prior treatment regimens received epacadostat 100 mg BID orally in combination with nivolumab 240 mg on day 1 of every 14 day cycle and lirilumab 240 mg IV every 4 weeks until disease progression or occurrence of unacceptable drug-related toxicities or discontinuation or up to 24 months.
89518771|NCT03347123|Experimental|Phase 2: Dose Expansion: Treatment Group A: Cohort A1|Participants with unresectable or metastatic melanoma (MEL) were planned to be included in this cohort, who did not receive prior systemic therapy for advanced or metastatic disease to receive epacadostat in combination with nivolumab and ipilimumab at the MTD/PAD determined from dose escalation phase.
88982269|NCT00087035|Experimental|Taxotere plus Tarceva|"Patients receive Tarceva 150 mg daily for 21 consecutive days (one treatment cycle). In addition, all patients will receive single agent Taxotere 60 mg/m2 IV over 1 hour infusion every 21 ± 2 days and have it administered on day 1.~Taxotere + Tarceva to be taken for three cycles past maximal response or until one of the following occurs: 1) a drug-related toxicity requiring discontinuation, 2) disease progression, or 3) for a maximum of 9 cycles.~Upon completion of 9 cycles of Taxotere plus Tarceva, patients showing evidence of objective response (CR, PR or stable disease) may continue in the extension phase of the study and receive treatment with Tarceva alone. Treatment response evaluated after four cycles of Tarceva treatment(immediately prior to cycle 14). Patients with progression of disease will be taken off study. Responding and stable disease patients will remain on study for up to 8 extension-phase cycles for a total of 17 cycles."
88982270|NCT00322114|Experimental|Arm I|Participants receive an oral tomato dietary supplement containing lycopene twice daily for 3 weeks.
88982271|NCT00322114|Experimental|Arm II|Participants receive an oral tomato dietary supplement containing lycopene at a higher dose twice daily for 3 weeks.
88982272|NCT00322114|Placebo Comparator|Arm III|Participants receive oral placebo twice daily for 3 weeks.
88982273|NCT00124761|Other|Surgery + Whole Brain Radiotherapy|
88982274|NCT00124761|Experimental|RadioSurgery + Whole Brain Radiotherapy|
88982275|NCT00087074|Experimental|Treatment (temsirolimus)|Patients receive CCI-779 IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 2 additional courses beyond CR.
88982276|NCT00332176|Experimental|1|
88982277|NCT00332176|Experimental|2|
88982278|NCT00332176|Active Comparator|3|
88982279|NCT05317702|Experimental|Moderately Painful Massage|Participants will be seated in a chair with his or her shirt on. Participants will receive 60 seconds of manual pressure applied to the myofascial trigger point identified in the participant's upper back. The researcher's thumb or index finger will apply a deep manual pressure such that the participant rates the pain = 50/100 on a 101-point numeric pain rating scale with 0 indicating no pain and 100 indicating the most severe pain imaginable. The participant will be asked to rate his or her pain during the massage so the pressure may be adjusted to maintain the 50/100 related pain. Massage will be applied for 60 seconds, 4 times for a total contact time of 240 seconds. During each 30 second break in which manual pressure is released, Pressure Pain Threshold (PPT) to the foot will be examined. PPT will be assessed 2 times immediately after each of the 4 massage applications.
88982280|NCT05315167|Experimental|Monotherapy Escalation|3+3 Dose escalation arm with PRJ1-3024 which will begin with 2 subjects treated at the lowest planned dose level. PRJ1-3024 is administered orally once daily. The starting dose is 80mg/day.
88982281|NCT05315167|Experimental|Monotherapy Exploration of the recommended dose|Upon completing Phase 1 and depending on data obtained, dose expansion may proceed in Phase 2 with several cohorts enrolled to confirm the tolerability of the RP2D of PRJ1-3024 (determined in Phase 1). PRJ1-3024 is administered orally once daily. The starting dose is determined by clinical effecacy data from Phase 1, and treatment may continue for up to 2 years as long as the subject experiences clinical benefit in the opinion of the Investigator and shows no signs or symptoms of unequivocal progression of disease.
89518772|NCT03347123|Experimental|Phase 2: Dose Expansion: Treatment Group A: Cohort A2|Participants with advanced or metastatic non-small cell lung cancer (NSCLC) were planned to be included in this cohort, who have received no more than 1 prior line of platinum-based chemotherapy for advanced or metastatic disease to receive epacadostat in combination with nivolumab and ipilimumab at the MTD/PAD determined from dose escalation phase.
89518773|NCT03347123|Experimental|Phase 2: Dose Expansion: Treatment Group B: Cohort B1|Participants with recurrent or metastatic serotonin norepinephrine reuptake inhibitor (SCCHN) were planned to be included in this cohort, who received no more than 1 prior line of platinum-based chemotherapy for recurrent or metastatic disease to receive epacadostat in combination with nivolumab and lirilumab at the MTD/PAD determined from dose escalation phase.
89518774|NCT03131141|Experimental|Cohort A|Cohort A will receive a single IV administration of 14C-BC-3781 containing 150 mg BC-3781 and NMT 4.3 MBq (117 µCi) 14C, administered as an infusion over 60 min after a light breakfast
89518775|NCT03131141|Experimental|Cohort B|Cohort B will receive a single oral administration of 14C-BC-3781 containing 600 mg BC-3781 and NMT 4.1 MBq (112 µCi) 14C, in the fasted state
89518776|NCT05258045||SUV ratio of mediastinal blood pool to the lesion and SUV ratio of liver to lesion|Avidity of SUV of blood pool
89518777|NCT03477929|Experimental|ganirelix|multiple dose of Ganirelix acetate (0.25mg) are administered when the lead follicle is ≥ 14 mm until hCG criteria are met
89518778|NCT03477929|Experimental|cetrorelix|multiple dose of Cetrorelix acetate (0.25mg) are administered when the lead follicle is ≥ 14 mm until hCG criteria are met
89518779|NCT03474341||Resectable esophageal squamous cell- or adenocarcinoma|"Patients (>18 years) with potentially resectable locally advanced squamous cell- or adenocarcinoma of the esophagus or gastroesophageal junction, receiving nCRT according to the CROSS regimen prior to surgery.~CROSS regimen: weekly carboplatin (doses titrated to achieve an area under the curve of 2 mg per milliliter per minute) and paclitaxel (50 mg per square meter of body-surface area) for 5 weeks and concurrent radiotherapy (41.4 Gy in 23 fractions, delivered 5 days per week on workdays with intensity modulated radiotherapy, including photon and proton therapy)"
88982282|NCT00332254|Experimental|1|Intra-articular IL-1Ra
88982283|NCT00332254|Placebo Comparator|2|Intra-articular saline
88982284|NCT00332293|Experimental|Moxifloxacin|
88982285|NCT00332293|Active Comparator|VIGAMOX|
88982286|NCT02964975|Active Comparator|Optimal medical therapy|conservative treatment
88982287|NCT02964975|Active Comparator|Percutaneous coronary intervention|Percutaneous coronary intervention of chronic total occlusion
89518780|NCT03477773|Experimental|Intervention|Perform three session of high-intensity, interval training sessions per week over the 6-week intervention
89518781|NCT03477773|No Intervention|Control|Continue with their normal habitual lifestyle over the 6-week intervention
89518782|NCT03477695|Experimental|Upright device|Ambulatory use of the Upright device
89518783|NCT03474263|Experimental|IC14 (monoclonal anti-CD14 antibody)|Biologic: IC14 (monoclonal anti-CD14 antibody) 4 mg/kg intravenously followed by IC14 2 mg/kg intravenously on Days 2-4. This four-day cycle will be repeated on Days 8-11.
89518784|NCT02817815|Active Comparator|Group 1|Volunteers
89518785|NCT02817815|Experimental|Group 2|Paroxysmal AF patients in sinus rhythm the day of inclusion
89518786|NCT02817815|Experimental|Group 3|Paroxysmal AF patients in atrial fibrillation the day of inclusion
89518787|NCT02817815|Experimental|Group 4|Persistent AF patients in sinus rhythm the day of inclusion
89518788|NCT02817815|Experimental|Group 5|Persistent AF patients in atrial fibrillation the day of inclusion
89518789|NCT03477617|Experimental|Intraoperative Hemodynamic Algorithm|In the experimental group, the anesthesiologist will have complete access to data from the minimal invasive cardiac output monitor. During the intraoperative period, the anesthesiologist will be instructed to use a hemodynamic management algorithm to manage episodes of significant hypotension
89518790|NCT03477617|Active Comparator|Usual Hemodynamic Management|In the control arm, the participant will be monitored by the cardiac output monitor, but the anesthesiologists in the operating room will be blinded to hemodynamic data from the monitor. Data from the monitor will be stored electronically and used to compare hemodynamic parameters between study arms.
89518791|NCT03473951||Hyperuricemia|Hyperuricemia is defined as a serum uric acid level of 7 mg/dl or more in men or 6 mg/dl or more in women
89518792|NCT03477461||terlipressin group|patients presented with oliguria or high levels creatinine
89518793|NCT03473717|Active Comparator|classic method group|IUD/IUS insertion will be done using the conventional method
89518794|NCT03473717|Active Comparator|direct method group|IUD/IUS insertion will be done using the direct method
89606215|NCT05467358||Patients with preendoscopic cannot be ppi order|patients who could not get ppi before endoscopy
89518795|NCT04987697|Other|Counseling and Surveys|nine 90-minute weekly psychoeducational group sessions facilitated by a licensed mental health counselor (LMHC).
89606216|NCT05467072||Discectomy + annular closure|All patients treated with lumbar discectomy and implantation of an annular closure device
89606217|NCT05465213||Retrospective cohort|Patients who have initiated treatment with dapagliflozin for HFrEF between 1st of March 2021 and 31st of October 2021 (prior to study initiation date).
89606218|NCT05465213||Prospective Cohort|Patients who have started treatment with dapagliflozin for HFrEF from 1st April 2022 onwards. At least 30 days must have elapsed (but no more than 60 days) from first prescription of dapagliflozin before a patient can be enrolled.
89606219|NCT05464784|Experimental|MN-001|
89606220|NCT05464784|Placebo Comparator|MN-001 Placebo|The placebo comparator is a tablet identical in appearance to MN-001.
89606221|NCT05459389|No Intervention|Group A|antibiotic regimen guided by conventional culture technique (n=24)
89606222|NCT05459389|Experimental|Group B|targeted antibiotics therapy guided by resistance genotyping (n=24)
89606223|NCT05458843|Experimental|Fluid replacement|
89606224|NCT05458843|Sham Comparator|No fluid replacement|
89606225|NCT05453292|Experimental|EUS guided RFA|This group is comprised by patients with diagnosis of resectable GISTs with/without liver metastasis. The patients included are naïve (without previous treatment) or patients with stable/progressive disease following systemic therapy with tyrosine kinase inhibitors.
89606226|NCT05453097||Perioperative Myocardial Injury Occured|Patients with troponin elevation from the preoperative basal level do not meet the criteria for myocardial infarction according to the fourth universal myocardial infarction guideline, do not describe active anginal complaints, and underwent surgery in the operating room.
89606227|NCT05453097||Perioperative Myocardial Injury Not Occured|Patients without troponin elevation from the preoperative basal level, do not describe active anginal complaints, and underwent surgery in the operating room.
89606228|NCT05452850||Light Chain Cardiac Amyloidosis|Participants with light chain cardiac amyloidosis actively receiving chemotherapy or undergoing autologous bone marrow transplant
89606229|NCT05452200|Experimental|Lyon hospital employees with high risk of lung cancer.|Lyon Hospital employees meeting criteria for high risk of lung cancer according French recommendation criteria.
89606230|NCT05448716||Light Chain Cardiac Amyloidosis|Participants with light chain cardiac amyloidosis actively receiving chemotherapy or undergoing autologous bone marrow transplant
89606231|NCT05445375|No Intervention|Current education regimen|Participants will be given a PAD pamphlet and ad hoc verbal teaching by vascular providers.
89518796|NCT04961723|Experimental|MSM Postal delivery|Participants who identify primarily as MSM will receive a home delivered HCV self-test kit in non-identifiable packaging. The kit will include the test, instructions for use (IFU), and information about additional supporting materials, such as access to live chat and a call center for questions about testing
88982288|NCT00087191|Experimental|Diagnostic (EF5, motexafin lutetium)|Patients receive EF5 IV over 1-2.5 hours on day 1 and motexafin lutetium IV over 10-15 minutes on day 2. Patients undergo definitive surgical resection approximately 3 hours after motexafin lutetium administration. Hypoxia and motexafin lutetium levels in the resected tumors are evaluated. Tumor to normal tissue ratios are also determined.
88982289|NCT00400166|Experimental|1|Recovery Mentor: peer-based supportive care
88982290|NCT00400166|No Intervention|0|No Recovery Mentor, services as usual
89518797|NCT04961723|Experimental|MSM Peer delivery|Participants who identify primarily as MSM will schedule a peer delivery of the HCV self-test kit and IFU. The peer will provide basic information about the test, what to do if the test is reactive, and how to access to live chat and a call center for questions about testing
89606232|NCT05445375|Active Comparator|Intervention|Participants will be given the current education regimen and watch a 20 minute online PAD education video.
89518798|NCT04961723|No Intervention|MSM control|Participants who identify primarily as MSM will receive information about standard of care HCV antibody testing available at local testing sites in their community. Participants will also have access to live chat and a call center for questions about HCV testing
89518799|NCT04961723|Experimental|PWID peer delivery|Participants who identify primarily as PWID will schedule a peer delivery of the HCV self-test kit and IFU. The peer will provide basic information about the test, what to do if the test is reactive, and how to access to live chat and a call center for questions about testing
88982291|NCT05181007|Active Comparator|MFA|mefanamic acid
88982292|NCT05181007|Active Comparator|VPA|valproate
88982293|NCT00332371|Experimental|1|
88982294|NCT00332371|No Intervention|2|
88982295|NCT00124839|Other|1|Blinded sequential administration: naltrexon 50 mg (3 weeks)- placebo (3 weeks)- placebo (1 week)
88982296|NCT00124839|Other|2|Blinded sequential administration: 200mg naltrexone (3 weeks) - placebo (3 weeks)- placebo (1 week)
88982297|NCT00124839|Other|3|Blinded sequential administration: placebo (3 weeks) - 200mg naltrexone (3 weeks) - placebo (1 week)
88982298|NCT00124839|Other|4|Blinded sequential administration: placebo (3 weeks) - 50mg naltrexone (3 weeks) - placebo (1 week)
89518800|NCT04961723|No Intervention|PWID control|Participants who identify primarily as PWID will receive information about standard of care HCV antibody testing available at local testing sites in their community. Participants will also have access to live chat and a call center for questions about HCV testing
89518801|NCT02523521|No Intervention|Bronchopylmonary Dysplasia Control|Nothing
89518802|NCT02523521|Experimental|Bronchopylmonary Dysplasia Intervention|physical activity program.
89518803|NCT02523521|No Intervention|Healthy children|Nothing.
89518804|NCT04458779|Experimental|CPAP group|Subjects will receive CPAP treatment in addition to optimal standard therapy for acute stroke.
89518805|NCT04458779|No Intervention|Usual-care group|Subjects will receive optimal standard therapy for acute stroke.
89518806|NCT01296581|Experimental|X-82|
89518807|NCT03223805|Other|Control Arm|Usual Care
89518808|NCT03223805|Experimental|Intervention Arm|Respiratory Distress Symptom Intervention plus Usual Care
89518809|NCT03067961|Experimental|Wild type S. Typhi Quailes strain|Administered by the oral route with sodium bicarbonate at a dose of 1-5x10 4 CFU.
89518810|NCT03067961|Experimental|Quailes typhoid toxin knock-out|Administered by the oral route with sodium bicarbonate at a dose of 1-5x10 4 CFU.
89518811|NCT02962817|Experimental|Educational intervention through a web platform|"This group will have access to our web platform where they will find information related to nonspecific chronic low back pain. This information will be presented through dynamic explanatory 3D videos made by the author.~The aim of this intervention is to change and modify wrong beliefs and attitudes about chronic low back pain of physicians and nurses working in primary care settings, using a web-based educational tool with the additional result of increasing knowledge on pain neurophysiology and reducing fear-avoidance beliefs."
89518812|NCT02962817|Active Comparator|Clinical practice guidelines on low back pain|Control group: They will have access to a video where medical staff and primary care nurses explain the content of the clinical practice guideline for addressing back pain.
89518813|NCT03473093|Active Comparator|morphine|This group will receive only morphine infusion (20microgram/kg/h)
89518814|NCT03473093|Active Comparator|pregabalin|This group will receive only morphine infusion (20microgram/kg/h) and oral pregabalin (150 mg)
89518815|NCT02523131|Experimental|24/7 closed loop insulin delivery|Unsupervised home use of day and night automated closed loop insulin delivery system (FlorenceM) combined with pump suspend feature over a 12-week period using 24/7 Medtronic insulin pump 640G and Android smartphone.
89518816|NCT02523131|Active Comparator|Sensor augmented pump therapy|Insulin pump therapy combined with unmasked real-time continuous glucose monitoring system for 12 weeks using Medtronic insulin pump 640G. Pump suspend features will be turned off.
89518817|NCT04339049|Experimental|lidocaine spray|four puffs (10 mg/puff) of lidocaine spray before tenaculum placement plus vaginal placebo 3 hours before IUD insertion
89518818|NCT04339049|Active Comparator|vaginal misoprostol|vaginal misoprostol 200 mcg given 3 hours before IUD insertion plus four puffs of saline spray before tenaculum placement
89518819|NCT04339049|Placebo Comparator|placebo|vaginal placebo given 3 hours before IUD insertion plus four puffs of saline spray before tenaculum placement
89518820|NCT02198794|Experimental|Part A: SD-809|Participants will receive SD-809 orally twice daily (BID) starting at 12 mg/day, which will be titrated based on dyskinesia control and tolerability up to a maximum total dose of 48 mg/day. Participants who decline to participate in Part B, will continue at their stable dose of SD-809 BID up to Week 158.
89606233|NCT05444712|Active Comparator|Chemotherapy|"The chemotherapy is one of the following regimen administrated every 3 weeks for 6 cycles according to local investigator's choice based on usual practices and European Medical Agency (EMA) approval :~Cyclophosphamide, doxorubicin, Vincristine and prednisone: (CHOP)~Cyclophosphamide, doxorubicin, vincristine, etoposide and prednisone: (CHOEP)~Brentuximab vedotin, cyclophosphamide, doxorubicin, prednisone: (BV-CHP) for ALCL lymphoma only (based on EMA approval)"
89606234|NCT05444712|Active Comparator|Chemotherapy + ASCT|"Chemotherapy administrated every 3 weeks for 6 cycles according to local investigator's choice based on usual practices:~Patients with ASCT strategy in Complete Response after 6 cycles will receive a High Dose Therapy (HDT) composed of BCNU, etoposide, cytarabine and melphalan (BEAM) as conditioning regimen before transplantation. That consolidation phase will lasts between 2 to 3 months"
89606235|NCT05443867||MPX-Assess|Contacts of MPX index cases
89606236|NCT05431439||Cohort 1|Participants with cancer or cancer predisposition
89606237|NCT05430828||Group 1|Subjects with hyperlipidaemia under PCSK9 inhibitors treatment (Repatha/Praulent).
89606238|NCT05430191||Qualitative Interviews|Conduct 15 interviews with patients diagnosed with FH. Interviews will be 30-60 minutes in length and will focus on how individuals understand cascade screening, barriers to engagement including reasons why individuals do and do not share health information with family members, and preferred approaches to engaging family members, with a focus on acceptability, appropriateness, and feasibility of the planned implementation strategies. Interviewers will also attend to structural factors such as medical mistrust and experiences of racism in health care, and ask about preferences and logistics to incorporate preference into the future clinical trial design.
89606239|NCT05430191||Penn-mediated implementation strategy|The Penn-mediated implementation strategy will be designed and then iterated upon during mini-pilots. As part of this strategy, the patients would receive text messages and/or emails containing information about FH and cascade screening from Penn Medicine. This would include a request for the patient to identify first-degree biological relatives. They would be given a choice of either contacting their family members directly or sharing their contact information so someone from Penn Medicine can contact them. If the proband chooses to contact their family members, they receive educational information to share with them. Family members would be offered FH screening at no cost by blood lipid panel.
89606240|NCT05430191||Family Heart Foundation-mediated implementation strategy|The Family Heart Foundation (FHF)-mediated implementation strategy will be designed and then iterated upon during mini-pilots. As part of this strategy, the patient would be contacted by a FHF patient navigator. The patient navigator would ask to set up a time to talk to the patient to talk about options for contacting family members, introduce them to the services they can provide to the patient and/or family members and obtain some details about the patient's family. The patient would come up with a plan to either contact their family members directly or have the patient navigator contact them. Family members will be offered FH screening at no cost by blood lipid panel. The patient and/or family members will be able to contact the patient navigator at any time with questions.
89606241|NCT05428631|Experimental|CARDIOMEMS(TM) HF device|Renal failure patients testing the CARDIOMEMS(TM) HF device
89606242|NCT05428488|Experimental|Experimental|"All included patients will receive TNF inhibitors subcutaneous for 12 weeks. In the experimental arm, a therapeutic sequential strategy will be proposed from W12 visit.~At 12 weeks (W12), patients who have at least a moderate EULAR response (delta DAS28-CRP between W0 and W12>0.6 and DAS28-CRP≤5.1 at W12) will be randomized with a 1:1 ratio in the sequential strategy arm or the control arm.~In the sequential strategy (experimental) arm, the 88 randomized RA patients will be switched to abatacept subcutaneous for 36 weeks."
89606243|NCT05428488|Active Comparator|Control|"All included patients will receive TNF inhibitors subcutaneous for 12 weeks. In the control group, the 88 randomized RA patients will be treated with TNF inhibitor subcutaneous for another 36 weeks (from W12 visit).~In case of insufficient response to a first TNF inhibitor at 24 or 36 weeks, a second TNF inhibitor will be proposed."
89606244|NCT05428007|Experimental|Study Group|Participants receive sarilumab at 150 mg flat dose is administered subcutaneously every 2 weeks for 12 doses from day 1, cycle 1 in combination with a regimen of ipilimumab at 1 mg/kg every 8 weeks and fixed dose nivolumab at 480 mg and relatlimab at 160 mg flat dose every 4 weeks two times during the 8-week induction period, then the same regimen again up to week 16, and up to week 24 in maintenance. After week 24 the regimen will be ipilimumab at 1 mg/kg every 8 weeks and fixed dose nivolumab at 480 mg with relatlimab at 160 mg flat dose every 4 weeks for 8 week cycles for up to a total of 2 years in patients with unresectable Stage III/Stage IV melanoma.
89606245|NCT05419934|Experimental|EMDR|"Patient receiving  EMDR therapy  over 6 to 10 sessions."
89606246|NCT05419934|Sham Comparator|Routine Care|"Patient receiving the  routine care  over 6 to 10 sessions"
89606247|NCT05415722|Experimental|Arm 1: TERN-501 1 mg|Orally administered.
89606248|NCT05415722|Experimental|Arm 2: TERN-501 3 mg|Orally administered.
89606249|NCT05415722|Experimental|Arm 3: TERN-501 6 mg|Orally administered.
89606250|NCT05415722|Experimental|Arm 4: TERN-501 3 mg + TERN-101 10 mg|Orally administered.
89032693|NCT04692506|Placebo Comparator|Placebo Sachet|"The IP will be self-administered by the subject. Subjects will be asked to consume the IP (1 sachet) once per day, at approximately the same time every day, for 28 days.~The sachet should be emptied in, and mixed with, a bottle of milk."
89606251|NCT05415722|Experimental|Arm 5: TERN-501 6 mg + TERN-101 10 mg|Orally administered.
89606252|NCT05415722|Experimental|Arm 6:TERN-101 10 mg|Orally administered.
89606253|NCT05415722|Placebo Comparator|Arm 7: Matching placebo|Orally administered.
89606254|NCT05412407|Other|Questionnaire : Taken analgesics|the patient will complete a questionnaire
89606255|NCT05406453|No Intervention|Madagascar standard of care|"Description :~Passive case finding,~Smear microscopy testing, and~household contact tracing"
89606256|NCT05406453|No Intervention|Best practices|"Description :~Active case finding,~Smear microscopy~Xpert MTB/RIF Ultra testing (= rapid test by Genexpert for tuberculosis (TB) and rifampin resistance (RIF-R)) and~household contact tracing"
89518821|NCT02198794|Placebo Comparator|Part B: Placebo|Participants will receive placebo matched to SD-809 for 1 week in randomized withdrawal period and thereafter will receive SD-809 (stable dose) for 12 weeks.
89518822|NCT02198794|Active Comparator|Part B: SD-809|Participants will receive SD-809 (stable dose) for 1 week in randomized withdrawal period and will continue to receive the same dose of SD-809 for an additional 12 weeks.
89518823|NCT02198794|Experimental|Part C: SD-809|EU participants who complete Part B and willing to continue in the study will continue treatment with SD-809 for 52 weeks at the dose administered during the 12-week open-label period of Part B.
89518824|NCT02133664|Experimental|lipoic acid and omega-3 fatty acids|lipoic acid and omega-3 fatty acids
89518825|NCT02133664|Placebo Comparator|placebo|placebo oil and placebo lipoic acid
88982299|NCT05160181||Yogatherapy|Retrospective study on medical file of patients seen in consultation for chronic pain with prescription of Yogatherapy
88982300|NCT00087269|Experimental|Treatment (erlotinib)|Patients receive oral erlotinib once daily on days 1-14 or days 1-21 in the absence of unacceptable toxicity. Patients then undergo surgical resection on the last day of study drug administration (day 14 or day 21). Patients may receive chemotherapy and/or radiotherapy after surgical resection at the discretion of the primary physician.
88982301|NCT05137873||Surgery before 6 months of age|Babies with heart disease surgery, great vessels transposition surgery type before 6 months of age
88982302|NCT00124878|Active Comparator|Arm 1 Male circumcision|Men receive circumcision after randomization; procedure is generally provided within two weeks. A man randomized to the intervention arm who then declines circumcision for 6 or more months is considered a cross over.
88982303|NCT00124878|No Intervention|Arm 2|Men wait for two years of follow up before being offered male circumcision
88982304|NCT05020171|Experimental|intervention group|group focus on lower limb strength training with a seated robotic device
89518826|NCT02133508||NSCLC Participants|Participants with advanced non-small cell lung cancer (NSCLC), treated in second-line with erlotinib, presenting wild-type, not tested or unknown Epidermal Growth Factor Receptor (EGFR) status, and with stable disease at the first revaluation after start of erlotinib therapy.
89518827|NCT02133352|Experimental|Ranolazine|Ranolazine- initiated at 500mg twice daily and increased to 1000mg twice daily as tolerated after 2wks; the tolerated dose will be used for the remainder of the Treatment Period.
89518828|NCT04750252|Experimental|Subjects with moderate to severe OA of the Knee|
89518829|NCT02167594|Experimental|PSP Subjects|Amyloid negative subjects with PSP receiving a flortaucipir PET scan at baseline and at 9 months.
89518830|NCT02167594|Experimental|CBD subjects|Amyloid negative subjects with CBD receiving a flortaucipir PET scan at baseline and at 9 months.
89518831|NCT02167594|Experimental|Healthy volunteers|Healthy volunteers receiving a flortaucipir PET scan at baseline.
89518832|NCT04418128|No Intervention|Conventional therapy|The conventional therapy comprised, as necessary, Lopinavir/ritonavir, Hydroxychlorquine, supplemental oxygen, Non-invasive and invasive ventilation, antibiotic agents, renal-replacement therapy (e.g.: CRRT, HD), extracorporeal membrane oxygenation (ECMO).
89518833|NCT04418128|Experimental|Conventional therapy + Nafamostat mesylate|"The conventional therapy comprised, as necessary, Lopinavir/ritonavir, Hydroxychlorquine, supplemental oxygen, Non-invasive and invasive ventilation, antibiotic agents, renal-replacement therapy (e.g.: CRRT, HD), extracorporeal membrane oxygenation (ECMO).~Nafamostat mesylate injection day), taking into account the severity and underlying disease of the clinical trial patient.~Method of administration: Nafamostat injection is mixed with 1,000 ml of 5% DW infusion, followed by continuous infusion over 24 hours.~Duration of administration: The researcher administers for 10-14 days considering the severity and underlying disease of the clinical trial patient."
89518834|NCT02555657|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg intravenously (IV) every 3 weeks (Q3W) for up to 35 administrations (up to ~2 years). Qualified participants who receive first course of pembrolizumab but continue to experience disease progression may, at investigator's discretion, initiate a second course of pembrolizumab at 200 mg IV Q3W for up to 17 administrations (up to ~1 year).
89518835|NCT02555657|Active Comparator|Chemotherapy|Participants receive capecitabine, eribulin, gemcitabine, or vinorelbine as TPC in accordance with local regulations and guidelines.
89518836|NCT01998815||Obese patients|Laparoscopic Roux-en-Y gastric bypass
89518837|NCT00908687|Experimental|Group 1: 30 µg HA, no LT patch|A/H5N1 Vaccine 30 µg HA i.m. on Day 0
89518838|NCT00908687|Experimental|Group 2: 30 µg HA + 50 µg LT patch|A/H5N1 Vaccine 30 µg HA i.m. + LT adjuvant patch containing 50 µg of LT on Day 0
89518839|NCT00908687|Experimental|Group 3: 30 µg HA + 100 µg LT patch|A/H5N1 Vaccine 30 µg HA i.m. + LT adjuvant patch containing 100 µg of LT on Day 0
89518840|NCT00908687|Experimental|Group 4: 45 µg HA, no LT patch|A/H5N1 Vaccine 45 µg HA i.m. on Day 0
89518841|NCT00908687|Experimental|Group 5: 45 µg HA + 50 µg LT patch|A/H5N1 Vaccine 45 µg HA i.m. + LT adjuvant patch containing 50 µg of LT on Day 0
89518842|NCT00908687|Experimental|Group 6: 45 µg HA + 100 µg LT patch|A/H5N1 Vaccine 45 µg HA i.m. + LT adjuvant patch containing 100 µg of LT on Day 0
89518843|NCT05155475||Patient with jaundice|
89518844|NCT02523365|Experimental|HepaSphere|cervical carcinoma patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
89518845|NCT02523365|Placebo Comparator|control|cervical carcinoma patients received traditional therapy
89518846|NCT03473405|Sham Comparator|Control|In the control arm, the ABS device will be placed as usual on the patient, but the airflow will NOT be activated. Only the technician in the room will be aware whether the device is turned on or not.
89518847|NCT03473405|Experimental|Air Barrier System|In the experimental (intervention) arm, the ABS device will be placed as usual on the patient, and the airflow will be activated. Only the technician in the room will be aware whether the device is turned on or not.
89518848|NCT02195518|Experimental|Tenofovir Disoproxil Fumarate|All enrolled subjects will receive open label TDF at a dose of 300 milligram (mg) orally once daily during the study period.
89518849|NCT05154617|Other|Standard surgical monitoring, along with the Flo Trac® system monitoring.|
89606257|NCT05406453|Experimental|Novel intervention|"Description :~Active case finding,~Smear microscopy~Xpert MTB/RIF Ultra testing and~household contact tracing"
89606258|NCT05405738||normal group|
89606259|NCT05405738||2flap palatoplasty group|
89606260|NCT05405738||Furlow with buccinator group|
89606261|NCT05400031|No Intervention|Control|In this group, the researcher will provide the participants with routine care.
89606262|NCT05400031|Placebo Comparator|placebo group|In this group, the researcher will provide the participants with a propolis vehicle
89606263|NCT05400031|Active Comparator|propolis group|In this group, the researcher will provide the participants with a propolis solution.
89606264|NCT05398380|Experimental|Transplantation|Liver transplantation for the treatment of unresectable colorectal cancer liver metastases
89606265|NCT05392803|Experimental|Active then Sham Treatment|"Application of 30 days of nonthermal, pulsed shortwave (radiofrequency) therapy, 7 day washout, 30 days of sham."
89606266|NCT05392803|Experimental|Sham then Active Treatment|"Application of 30 days of a nonfunctional sham device, 7 day washout, then 30 days of nonthermal, pulsed shortwave (radiofrequency) therapy"
89606267|NCT05381961||Stable hemodialysis regimen|Up to 50 patients on hemodialysis >6 months, with stable target/dry weight, and have not been hospitalized recently
89606268|NCT05381961||Unstable hemodialysis regimen|Up to 20 patients who have been on hemodialysis <6 months, or have unintended weight loss/gain, or have recently been hospitalized
89606269|NCT05380427|Experimental|Single Dose 1|0.0025%(0.025 mg/mL)
89606270|NCT05380427|Experimental|Single Dose 2|0.005%（于0.05 mg/mL）
89606271|NCT05380427|Experimental|Single Dose 3|0.01%（0.1 mg/mL）
89606272|NCT05380427|Experimental|Single Dose 4|0.02%（0.2 mg/mL）
89606273|NCT05380427|Experimental|Multiple Dose 1|0.05%（0.05 mg/mL）
89606274|NCT05380427|Experimental|Multiple Dose 2|0.01%（0.01 mg/mL）
89606275|NCT05380427|Experimental|Multiple Dose 3|0.02%（0.02 mg/mL）
89606276|NCT05380427|Placebo Comparator|Placebo|Liniment containing anhydrous ethanol, propylene glycol and polyethylene glycol 400
89606277|NCT05379790|Experimental|Intraperitoneal irinotecan 50 mg + CAPOX|Intraperitoneal irinotecan, dose level 1 50 mg flat dose + oral capecitabine and systemic oxaliplatin (CAPOX) (dose via standard of care)
89606278|NCT05379790|Experimental|Intraperitoneal irinotecan 75 mg + CAPOX|Intraperitoneal irinotecan, dose level 2 75 mg flat dose + oral capecitabine and systemic oxaliplatin (CAPOX) (dose via standard of care)
89606279|NCT05379790|Experimental|Intraperitoneal irinotecan 100 mg + CAPOX|Intraperitoneal irinotecan, dose level 3 100 mg flat dose + oral capecitabine and systemic oxaliplatin (CAPOX) (dose via standard of care)
89606280|NCT05379790|Experimental|Intraperitoneal irinotecan 150 mg + CAPOX|Intraperitoneal irinotecan, dose level 4 150 mg flat dose + oral capecitabine and systemic oxaliplatin (CAPOX) (dose via standard of care)
89606281|NCT05379790|Experimental|Intraperitoneal irinotecan 200 mg + CAPOX|Intraperitoneal irinotecan, dose level 5 200 mg flat dose + oral capecitabine and systemic oxaliplatin (CAPOX) (dose via standard of care)
89606282|NCT05379790|Experimental|Intraperitoneal irinotecan 250 mg + CAPOX|Intraperitoneal irinotecan, dose level 6 250 mg flat dose + oral capecitabine and systemic oxaliplatin (CAPOX) (dose via standard of care)
89606283|NCT05374538|Experimental|Dose Escalation Phase, Cohort 1a: VIC-1911 monotherapy|Subjects with locally advanced or metastatic KRAS G12C-mutated NSCLC refractory to or relapsed on prior KRASG12C inhibitor therapy will receive VIC-1911 monotherapy.
89606284|NCT05374538|Experimental|Dose Escalation Phase, Cohort 1b: VIC-1911 plus sotorasib combination therapy|Subjects with locally advanced or metastatic KRAS G12C-mutated NSCLC refractory to or relapsed on prior KRASG12C inhibitor therapy or are naive to KRAS G12C inhibitor therapy will receive VIC-1911 plus sotorasib combination therapy.
89606285|NCT05374538|Experimental|Expansion Phase, Cohort 2a: VIC-1911 monotherapy|Subjects with locally advanced or metastatic KRAS G12C-mutated NSCLC refractory to or relapsed on prior KRASG12C inhibitor therapy will receive VIC-1911 monotherapy.
89606286|NCT05374538|Experimental|Expansion Phase, Cohort 2b: VIC-1911 plus sotorasib combination therapy|Subjects with locally advanced or metastatic KRAS G12C-mutated NSCLC refractory to or relapsed on prior KRASG12C inhibitor therapy will receive VIC-1911 plus sotorasib combination therapy.
88982305|NCT05020171|Active Comparator|control group|physiotherapy group as usual, not focused on strength training
89032694|NCT00527865|Experimental|1|6 subjects DAS181 dosage 0.5 mg; 3 subjects placebo
89606287|NCT05374538|Experimental|Expansion Phase, Cohort 2c: VIC-1911 plus sotorasib combination therapy|Subjects with locally advanced or metastatic KRAS G12C-mutated NSCLC naive to KRAS G12C inhibitor therapy will receive VIC-1911 plus sotorasib combination therapy.
89606288|NCT05373264|Active Comparator|Hydrochlorothiazide|Oral hydrochlorothiazide 25mg, once daily, for a total of 156 weeks
89606289|NCT05373264|Placebo Comparator|Placebo|Matching oral placebo, once daily, for a total of 156 weeks. The placebo is inert.
89606290|NCT05370521|Experimental|Treatment with Tildacerfont|Subjects randomized in this arm will receive 4 weeks of 50mg of oral tildacerfont tablet, followed by 4 weeks of 100 mg oral tildacerfont tablet, and then 4 weeks of 200 mg oral tildacerfont tablet for a total of 12 weeks of treatment.
89606291|NCT05370521|Placebo Comparator|Placebo Control Arm|Subjects randomized in this arm will receive 12 weeks of oral matched-placebo tablet
89606292|NCT05370040|Experimental|Phase 1 Cohort 1A|AAHI-SC2 on Day 1 at dosage 25 μg IM
89606293|NCT05370040|Experimental|Phase 1 Cohort 1B|AAHI-SC2 on Day 1 at dosage 50 μg IM
89606294|NCT05370040|Experimental|Phase 1 Cohort 1C|AAHI-SC2 on Day 1 at dosage 70 μg IM
89606295|NCT05370040|Experimental|Phase 1 Cohort 2A|AAHI-SC3 on Day 1 at dosage 25 μg IM
89606296|NCT05370040|Experimental|Phase 1 Cohort 2B|AAHI-SC3 on Day 1 at dosage 50 μg IM
89606297|NCT05370040|Experimental|Phase 1 Cohort 2C|AAHI-SC3 on Day 1 at dosage 85 μg IM
89606298|NCT05370040|Placebo Comparator|Phase 2 Control arm|EUA or approved vaccine on Day 1
89606299|NCT05370040|Experimental|Phase 2 Experimental arm 1|AAHI-SC2 on Day 1 Dose TBD as determined in phase 1 study
89606300|NCT05370040|Experimental|Phase 2 Experimental arm 2|AAHI-SC3 on Day 1 Dose TBD as determined in phase 1 study
89606301|NCT05370040|Experimental|Phase 2 Experimental arm 3|AAHI-SC3 on Day 1 and 29 Dose TBD as determined in phase 1 study
89606302|NCT05368649|Experimental|Healthy Volunteers|Short-wave diathermy
89518850|NCT03990077|Experimental|dose escalation of HL-085 plus Docetaxel|"HL-085 will be administered as BID with specified dose. And Docetaxel will be taken as the instruction in the label ( 75mg/m2，IV).~f no Dose-limiting toxicity (DLT) occurs in the first three subjects in Cycle 1, the dose will be escalated to the next dose level; If a DLT occurs in one of the first three subjects, three additional subjects will be enrolled for the same dose cohort, and undergo the same procedures. Dose -escalation is performed based on the scheduled dose groups until DLT occurs in two or more subjects in a dose group which consists of 3 or 6 subjects."
89518851|NCT05134415|Experimental|Product Use Sequence 1|Period 1 - RELX ENDS tobacco flavor 1 Period 2 - RELX ENDS tobacco flavor 2
89518852|NCT05134415|Experimental|Product Use Sequence 2|Period 1 - RELX ENDS tobacco flavor 2 Period 2 - RELX ENDS tobacco flavor 1
89518853|NCT05134415|Experimental|Product Use Sequence 3|Period 1 - RELX ENDS menthol flavor 1 Period 2 - RELX ENDS menthol flavor 2
89518854|NCT05134415|Experimental|Product Use Sequence 4|Period 1 - RELX ENDS menthol flavor 2 Period 2 - RELX ENDS menthol flavor 1
89518855|NCT03461861|Experimental|AGB101 220 mg, then Placebo|AGB101 220 mg/day capsule, once daily dosing for 2 weeks. After a 4 week washout, to be followed by Placebo, given as a capsule, once daily dosing for 2 weeks.
88982306|NCT00087386|Experimental|Treatment (tanespimycin)|Patients receive tanespimycin IV over 1-6 hours once weekly for 6 weeks. Courses repeat every 56 days in the absence of disease progression or unacceptable toxicity.
89518856|NCT03461861|Experimental|Placebo, then AGB101 220 mg|Placebo, given as a capsule, once daily for 2 weeks. After a 4 week washout, to be followed by AGB101 220 mg/day capsule, once daily dosing for 2 weeks.
89518857|NCT04458389|Experimental|TY101|"Dose escalation：Humanized anti-PD-1 monoclonal antibody is to be injected intravenously 0.3mg/kg or 1mg/kg or 3mg/kg or 10mg/kg 200mg (fix dose) until disease progresses or unacceptable tolerability occurs.~Dose expansion：After completion of the DLT observation, the sponsor and principal investigator will select a possible dose（RP2D）for dose expansion to further confirm the efficacy and safety of RP2D."
89518858|NCT03380507|Experimental|Triple therapy group|"Experimental group will receive usual care according to Hamad Medical Corporation Adult Sepsis Care Pathway (CPW 10311, May 2017) PLUS triple therapy.~Triple therapy regimen:~Intravenous vitamin C (1.5 gm q 6 hourly for 4 days or until ICU discharge, whichever is earlier), hydrocortisone (50 mg q 6 hourly for 7 days or until ICU discharge, whichever is earlier, followed by a taper over 3 days) as well as intravenous thiamine (200 mg q 12 hourly for 4 days or until ICU discharge, whichever is earlier)."
89518859|NCT03380507|No Intervention|Control group|Control group will receive usual care only according to Hamad Medical Corporation Adult Sepsis Care Pathway (CPW 10311, May 2017).
89518860|NCT03390335|Experimental|Altitude Dive Altitude profile|Subjects are exposed to Pressure profiles (Altitude followed by a Dive with a return to Altitude) and Breathing Gases during dive exposures.
89518861|NCT03471533|Experimental|Ëxperimental|"Consumption during 84 days of Lippia citriodora 325 mg + Hibiscus sabdariffa 175 mg.~Two capsules a day will be consumed thirty minutes before breakfast for 84 days."
89518862|NCT03471533|Placebo Comparator|Placebo|Consumption during 84 days of saccharose. Two capsules a day will be consumed thirty minutes before breakfast for 84 days.
89518863|NCT03471455|Active Comparator|Terbinafine alone|Patients of recurrent dermatophytosis (recurrent episodes for more than 6 months) will receive oral terbinafine 250 mg once a day for 4 weeks.
89518864|NCT03471455|Active Comparator|Terbinafine plus isotretinoin|Patients of recurrent dermatophytosis (recurrent episodes for more than 6 months) will receive oral terbinafine 250 mg once a day for 4 weeks and oral isotretinoin 20 mg/ day for 6 months.
89518865|NCT03471455|Active Comparator|Itraconazole only|Patients of recurrent dermatophytosis (recurrent episodes for more than 6 months) will receive oral itraconazole 200 mg twice a day for 4 weeks.
89518866|NCT03471455|Active Comparator|Itraconazole plus isotretinoin|Patients of recurrent dermatophytosis (recurrent episodes for more than 6 months) will receive oral itraconazole 200 mg twice a day for 4 weeks and oral isotretinoin 20 mg/ day for 6 months.
89518867|NCT04902677||School|
89518868|NCT04749173|Experimental|Cohort 1 (96 mg)|- Ventrogluteal area: 48 mg/0.2 mL x 2 sites
89518869|NCT04749173|Experimental|Cohort 2 (432 mg)|"Deltoid area: 72 mg/0.3 mL x 2 sites~Ventrogluteal area: 144 mg/0.6 mL x 2 sites"
89518870|NCT04749173|Experimental|Cohort A (144 mg)|- Deltoid area: 72 mg/0.3 mL x 2 sites
89518871|NCT04749173|Experimental|Cohort B (144 mg)|- Ventrogluteal area: 72 mg/0.3 mL x 2 sites
89518872|NCT03258905|Experimental|Grounding enhanced app|A mobile app that uses the Seeking Safety grounding chapter content, enhanced with features designed to create strong engagement and interactivity
89518873|NCT03258905|Active Comparator|Grounding text-only app|A mobile app that uses the Seeking Safety grounding chapter content in text format only
89518874|NCT04745897|Experimental|eTB Catalogue of Recommendation (eTB)|New eTB catalogue of recommendations website (eTB).
89518875|NCT04745897|Active Comparator|World Health Organization Tuberculosis Website (WHO TB)|Current method of accessing tuberculosis (TB) recommendations using World Health Organization (WHO) website (WHO TB).
89518876|NCT04670159|Experimental|Online Education Group|
89518877|NCT04670159|Experimental|Brochure Group|
89518878|NCT02952365|Other|Eyes undergoing LASIK enhancement|Eyes undergoing LASIK enhancement will have tissue sealant applied to the eye to prevent epithelial ingrowth
89518879|NCT02824679|Active Comparator|20mg hyoscine butylbromide|They received (20mg) hyoscine butylbromide (one ml HBB+ one ml saline) intravenously
89518880|NCT02824679|Active Comparator|40 mg hyoscine butylbromide|They received (40mg) hyoscine butylbromide (one ml HBB+ one ml saline) intravenously
89518881|NCT02824679|Placebo Comparator|Saline|They received two ml of normal saline intravenously as a placebo
89518882|NCT03472937|Active Comparator|Inpatient cervical ripening group|Subjects in this arm will be seen in the outpatient setting, and if they qualify and are randomized to the inpatient (control) group, they will be admitted to labor and delivery the next day for cervical ripening with a transcervical Foley catheter.
89606303|NCT05368649|No Intervention|Shoulder Pain|Volunteers with unilateral shoulder pain
89518883|NCT03472937|Active Comparator|Outpatient cervical ripening group|Subjects in this arm will undergo cervical ripening with a transcervical Foley catheter in the outpatient setting (intervention arm). The transcervical catheter will be placed in the office after confirmation of fetal well-being. They will then return the next day to be admitted to labor and delivery for induction of labor with oxytocin.
89518884|NCT02287493||Meropenem|Adult ICU patients receiving meropenem during SLED will be analyzed for meropenem pharmacokinetics.
89518885|NCT02287493||Ceftazidim|Adult ICU patients receiving ceftazidim during SLED will be analyzed for ceftazidim pharmacokinetics.
89518886|NCT03665363|Experimental|SCOPE|Participants allocated to SCOPE, will receive an internet-based psychoeducation intervention, eight weeks of ASD-theme modules with coaching.
89518887|NCT03665363|Active Comparator|Self-study|Participants allocated to self-study will receive eight weekly emails containing informative and relevant websites about ASD. The emails are accessed on the same platform as the experimental condition (SCOPE), no active contact with the coaches is available.
89518888|NCT03665363|No Intervention|Wait-list controls/Treatment as usual|Participants allocated to wait-list will receive prompts to answer outcome measures but otherwise no other contact with the study coordinators or coaches. Participants may receive treatment as usual.
89518889|NCT05159141|No Intervention|control|Infant sleep monitoring (Actigraphy and sleep dairy) and parental surveys
88982307|NCT00419692|Experimental|Sequence WAXBYZCDE|Subjects will receive ropinirole as follows W: 1 x 0.5 mg CR-RLS (normal fed), A: 1 x 1 mg CR-RLS (fasted), X: 1 x 2 mg CR-RLS (normal fed), B: 1 x 3 mg CR-RLS (fasted), Y: 2 x 2 mg CR-RLS (normal fed), Z: (2 x 2 mg) + (1 x 1 mg) CR-RLS (normal fed), C: 1 x 6 mg CR-RLS (fasted), D: 1 x 6 mg CR-RLS (high fat fed) and E: 2 x 3 mg CR-RLS (fasted).
89518890|NCT05159141|Experimental|Infant behavioral sleep intervention|Interventionists collaborate with the family to design a tailored sleep intervention strategy, which involves appropriate sleep schedule and bedtime routine, putting the child to bed while still sleepy rather than when already asleep, and waiting 1 to 2 minutes before attending to the child during nocturnal awakenings. Parents are educated to implement the behavioral protocol at bedtime and subsequent night wakings.
89518891|NCT05158985|Experimental|group A|diclofenac sodium phonophoresis using continuous ultrasound with a frequency of 1MHz, an intensity of 1.5W/Cm2 for 4 minutes
89518892|NCT05158985|Experimental|group B|diclofenac sodium phonophoresis using pulsed US with 1:1 duty cycle with a frequency of 1MHz, an intensity of 1.5W/Cm2 for 4 minutes
89518893|NCT05158985|Experimental|group C|diclofenac sodium phonophoresis using pulsed US with 1:4 duty cycle with a frequency of 1MHz, an intensity of 1.5W/Cm2 for 10 minutes
89518894|NCT05158985|Experimental|group D|exercises only in form of (strengthening, stretching and occupational exercises).
89518895|NCT03602495|Experimental|Donafenib|Participants randomly assigned in a 2:1 ratio to receive blinded study drug (Donafenib or matching placebo) until documentation of disease progression (confirmed by IRC), development of unacceptable toxicity, or withdrawal of consent.
89518896|NCT03602495|Placebo Comparator|Placebo|Participants randomly assigned in a 2:1 ratio to receive blinded study drug (Donafenib or matching placebo) until documentation of disease progression (confirmed by IRC), development of unacceptable toxicity, or withdrawal of consent.
89518897|NCT03259373|Experimental|Intervention|Educational mailing to (1) AF patients with guideline-based indications for oral anticoagulation (CHA₂DS₂-VASc score of 2 or greater) who appear to not have received OAC treatment at time of randomization and (2) their providers, where an individual provider may be identified
89518898|NCT03259373|Experimental|Control|Educational mailing to providers of AF patients with guideline-based indications for oral anticoagulation (CHA₂DS₂-VASc score of 2 or greater) who appear to not have received OAC treatment in the time following randomization. These patients will have received 'usual care' for the time between randomization and delayed educational mailing.
89518899|NCT03226847|Experimental|Pulmonary Vein Isolation|ablation
89518900|NCT05158673|Placebo Comparator|Group A (Placebo)|The administration of two capsules of 500 mg orally of placebo (excipient q.s. starch capsule) 1 every 12 hours, for 12 weeks.
89518901|NCT05158673|Active Comparator|Group B (Flavonoid)|Two capsules of 500 mg of the flavonoid supplement (whose total flavonoid content is 15 mg/capsule) orally every 12 hours for 12 weeks.
89518902|NCT03202667|Active Comparator|Empagliflozin|Treatment with empagliflozin 25mg tablets once daily for 28 days
89518903|NCT03202667|Placebo Comparator|Placebo|Treatment with Placebo tablets once daily for 28 days
89518904|NCT02133742|Experimental|Dose finding phase and dose expansion phase|To test the maximum tolerated dose of MK-3475 at 2 mg/kg every three weeks intravenous infusion in combination with approved axitinib dose
89518905|NCT03472859|Experimental|Split-face group 1|In group 1 the left side of the face will be treated with KTP and right side with PHOTOLASE.
89518906|NCT03472859|Experimental|Split-face group 2|In group 2 the right side of the face will be treated with KTP and left side with PHOTOLASE.
89518907|NCT03472781||Children with intraocular inflammation|All children diagnosed with intraocular inflammation at Singapore National Eye center from from January 1989 to January 2017.
89518908|NCT03472703|Other|Hungry|Her subjects will first have a break, then undergo all measurement and at the end of the study-day they will receive their lunch
89518909|NCT03472703|Other|Satiated|Her subjects will first receive their lunch, then perform all the tasks and last will have a break
89518910|NCT05157893|Experimental|VR analgesic therapy|Patients receive a single VR therapy lasting 15 min.
89518911|NCT03032705|Experimental|SonicFill™ 2|Composite: SonicFill™ 2; Bonding Agent: Optibond XRT
89518912|NCT03032705|Active Comparator|Filtek™ Supreme|Composite: Filtek™ Supreme Ultra Universal Restorative; Bonding Agent: Scotchbond™ Universal Adhesive
89518913|NCT05157815|Experimental|Soluble Corn Fibre|12g compound per Sachet (providing 10g fibre) consumed twice per day
89518914|NCT05157815|Placebo Comparator|Maltodextrin|Calorie matched control of 2 g compound per sachet (0 g fibre), composed of: Maltodextrin, consumed twice per day
89518915|NCT02523053|Active Comparator|Hepatectomy|Surgical removal of all lesions
89518916|NCT02523053|Experimental|Hepatectomy plus 5-Fluorouracil|Surgical removal of all lesions and intraoperative controlled release 5-Fluorouracil therapy
89032695|NCT00527865|Experimental|2|6 subjects DAS181 dosage 1.0 mg; 3 subjects placebo
89032696|NCT00527865|Experimental|3|6 subjects DAS181 dosage 2.25 mg; 3 subjects placebo
89032697|NCT00527865|Experimental|4|6 subjects DAS181 dosage 4.5 mg; 3 subjects placebo
89032698|NCT00526487|Other|1|Endovascular Repair
89032699|NCT02928081|Experimental|Extended lymphadenectomy|In addition to the standard lymphadenectomy, the nerve tissues around CHA and the SMA and nodes around the celiac trunk and SMA (No.16a2, 16b1) must be dissected. Retroperitoneal lymphatic tissue, nerves and connective tissue range from the hepatic portal down to the beginning part of the inferior mesenteric artery, the right to the right renal hilus, left to the left edge of the abdominal aorta is included.
89032700|NCT02928081|Other|Standard lymphadenectomy|Lymph node dissection includes the superior and inferior pyloric nodes (LN5, LN6), anterior and posterior nodes along the common hepatic artery (CHA) (LN8a, 8b), nodes along the common hepatic duct, common bile duct and cystic duct (LN12b1, 12b2, 12c), posterior pancreatoduodenal nodes (LN13a, 13b), nodes along the superior mesenteric artery (SMA) (LN14a, 14b), anterior pancreatoduodenal nodes (LN17a, 17b), but excluding the nerve tissues around common hepatic artery and the superior mesenteric artery.
89518917|NCT05157737||BFNS group|(1) Epileptic seizure in neonatal period; (2) Epileptic seizure duration is short, which under spontaneous control in 4~6 months; (3) The patient was in normal state of feeding, physical examination and psychomotor development; (4) There were no signs of hypsarrhythmia or burst suppression in EEG.
89518918|NCT05157737||DEE group|(1) Epileptic seizures occur within a week after birth and recur frequently; (2) Epilepsy is refractory; (3) Feeding difficulties, accompanied by moderate to severe mental retardation and psychomotor retardation; (4) The EEG showed hypsarrhythmia or burst suppression.
89518919|NCT05157347|Experimental|Robot-assisted Training Group|- After the baseline test, the training is performed with 20 sessions in total (60 min / session); five sessions a week for four weeks. The robot-assisted training group is given 30 min conventional gait training and another 30 min (excluding robot attachment and detachment time) gait training using an exoskeletal wearable robot, while the control group is given 1 hr conventional gait training for the same time as the robot-assisted training group. In all participants in each group, no other robot-assisted rehabilitation such as Lokomat, Erigo, or Morning Walk could be performed.
89518920|NCT05157347|Other|Control Group|- After the baseline test, the training is performed with 20 sessions in total (60 min / session); five sessions a week for four weeks.
89518921|NCT03472625||Acute stroke patients|All acute stroke patients will be screened for aphasia, dysarthria or dysphagia. When one of the symptoms is present, standardized assessments will follow to evaluate the severity. Recovery in time will be measured +/- 1 week following stroke.
89518922|NCT05138315|Experimental|Study Group|Alleye App and M-chart examinations will be performed pre- and postsurgically.
89518923|NCT03472391|Active Comparator|Intervention|Supervised exercise therapy by physical therapist: patients allocated to physical therapy will participate in a 4-week (2 sessions a week of 40 minutes) supervised and tailored exercise program mainly consisting of light strength training. The exercise program is an add-on treatment to the primary treatment of re-nutrition and somatic stabilization.
89518924|NCT03472391|No Intervention|Control|The control group follows ordinary treatment in consisting of re-nutrition and somatic stabilization
89518925|NCT05121857||ACLR group|Individuals who are 7 months post primary ACLR
89518926|NCT05121857||healthy control group|Healthy uninjured individuals who are actively playing sport and have not sustained any knee injuries, ankle injuries or concussions.
89518927|NCT05115071|Experimental|Experimental|
89518928|NCT05115071|No Intervention|No intervention|
89518929|NCT04457609|Placebo Comparator|Control Group|Patients receive standardized treatment, consisting of Oseltamivir and Azithromycin
89518930|NCT04457609|Experimental|Experiment Group|Patients receive intravenous infusion of 1x10^6 unit of umbilical-cord derived mesenchymal stem cells (UC-MSCs)/kgBW in 100 cc of 0.9% NaCl for 1 hour, in addition to standardized treatment
89518931|NCT05157269|Active Comparator|Nitazoxanide|Nitazoxanide 300 mg extended release tablets
89518932|NCT05157269|Placebo Comparator|Placebo|Placebo tablets
89518933|NCT04457765|Experimental|group 1|All participants will have PVP-I at 1.25% administered as an intranasal topical preparation prior undergoing rhinoplasty
89518934|NCT04457375||Healthy Adults|Healthy
89518935|NCT03472313|Experimental|Experimental: [18F]MNI-958|To assess the safety and tolerability and to determine the radiation dosimetry of [18F]MNI-958.
89518936|NCT03130907|Active Comparator|Stent|
89518937|NCT03130907|Experimental|No stent|
89518938|NCT03130985||Cardiac surgery patients|The study cohort will comprise of patients without a history of AF that undergo cardiac surgery (CABG or mitral valve surgery) with increased CHADSVASC scores of ≥2.
89518939|NCT03130751|Experimental|Mobile application|
89518940|NCT05156801|Experimental|ArchSinus stent|Post-FESS implantation of the study device (ArchSinus) into ethmoid sinus cavity
89518941|NCT05156801|Active Comparator|Propel stent|Post-FESS implantation of the comparator device (Propel) into ethmoid sinus cavity.
89518942|NCT05156801|Active Comparator|NasoPore packing|Post-FESS implantation of the comparator device (NasoPore) into ethmoid sinus cavity.
89518943|NCT04865393|Experimental|SPR206|SPR206 100mg single-dose IV infused over 1 hour
89518944|NCT04806971||Periodontitis|Patients with grade B / C, stage III periodontitis were classified based on the new classification criteria.Clinical attachment loss ≥5 mm, probing depth (PD) ≥6 mm, ≥20 teeth and radiographic bone loss extending to the root middle third. Grade was assessed considering the radiographic bone loss in the most affected tooth in the dentition as a function of age (Grade B=0.25-1.0, Grade C= >1.0).
89518945|NCT04806971||Healthy|The periodontally healthy subjects without any clinical sign of inflammation,not showing a history of periodontitis; PD ≤3 mm; <10% of sites with BOP; an absence of detectable bone loss and/or attachment ; without extensive caries or restorations and presence of at least 28 permanent teeth. In addition, all the control subjects showed the absence of any local or systemic pathology.
89518946|NCT04457999|Experimental|Lipiflow treatment|Lipiflow thermal pulsation prior to cataract surgery
89606304|NCT05368376|Active Comparator|Group L (n=30)|Labetalol group
89606305|NCT05368376|Active Comparator|Group M (n=30)|Metoprolol group
89606306|NCT05366751|Experimental|SAGE-324 60 mg|Participants will receive SAGE-324 oral tablets from Day 1 to the End of Treatment (EOT) Period at a starting dose of 15 milligrams (mg). The dose will be up titrated in 15 mg increments to 60 mg. In case of intolerable adverse events, the dose will be down titrated in 15 mg decrements.
89606307|NCT05364463|Experimental|Ultrasound and hyperemia|Use of ultrasound and hyperemia to puncture radial artery.
89606308|NCT05364463|Experimental|Ultrasound only|Use of ultrasound only to puncture radial artery.
89606309|NCT05364463|Experimental|Hyperemia only|Use of hyperemia and palpation to puncture radial artery.
89606310|NCT05364463|No Intervention|Palpation|Use of palpation to puncture radial artery (control group).
89606311|NCT05360680|Experimental|CUE-102 (1mg/kg) Dose Escalation|CUE-102 (1 mg/kg) Monotherapy IV infusion every 3 weeks for up to 2 years
89606312|NCT05360680|Experimental|CUE-102 (2 mg/kg) Dose Escalation|CUE-102 (2 mg/kg) Monotherapy IV infusion every 3 weeks for up to 2 years
89606313|NCT05360680|Experimental|CUE-102 (4 mg/kg) Dose Escalation|CUE-102 (4 mg/kg) Monotherapy IV infusion every 3 weeks for up to 2 years
89606314|NCT05360680|Experimental|CUE-102 (8 mg/kg) Dose Escalation|CUE-102 (8 mg/kg) Monotherapy IV infusion every 3 weeks for up to 2 years
89606315|NCT05360680|Experimental|CUE-102 Dose Expansion at Determined RP2D|Dose expansion of CUE-102 at determined RP2D Monotherapy IV infusion every 3 weeks for up to 2 years
89606316|NCT05357144|Experimental|Drug shops, also known as Accredited Drug Dispensing Outlets (ADDOs), owners or staff|All drug shopkeepers in intervention areas (within Shinyanga or Mwanza) will be invited to participate in Malkia Klabu, a loyalty card program. Consenting drug shops in intervention areas should be willing and able to keep records of referrals and sexual and reproductive health (SRH) product distribution given to AGYW through the use of Maisha Meds during the one month run-in period.
89606317|NCT05357144|Placebo Comparator|Shopkeepers in control arm for comparison area|Drug shopkeepers, staff and/or owners as part of the control arm will receive standard HIV training, guidance on referring AGYW to proximal HIV care, and HIVST for free distribution to AGYW.
89606318|NCT05356962|Experimental|Interventional group|The surgeons will undergo a multi-module training on how to use the StOP?-protocol and perform the StOP?-protocol during all their operations during a 4-month period.
89606319|NCT05356962|No Intervention|Control group|Surgeons in the control group will not be trained to the StOP?-protocol and will communicate as usual during their operations.
89606320|NCT05348317|Experimental|MI-CBT Teletx|The intervention consists of an initial 30-60 min phone-delivered Engagement session that focuses on MI to help participants build self-efficacy and motivation to engage and to empower them to plan change and use Elicit-Provide-Elicit (EPE) to address treatment barriers (e.g., stigma, appeal, accessibility). Participants will then complete up to 8 ~50 minute Teletx weekly sessions via videoconference (or phone if needed). The intervention is highly patient-centered, by meeting and assessing patients where they are including in their unique context (i.e. rural community), helping them identify reasons and motivations for change, and centered around their goals (e.g. substance use reduction or abstinence).
89606321|NCT05343130|Experimental|Brain-Computer Interface controlled functional electrical stimulation feedback|
89606322|NCT05343130|Sham Comparator|Sham Brain-Computer Interface controlled functional electrical stimulation feedback|
89606323|NCT05342402|Experimental|Somatosensory Rehabilitation Program|Includes minimizing contact with the painful zone of the vulva and uses tactile stimulation at a tolerated distance from the vulva. Each participant will also receive advice on resuming sexual activities with vaginal penetration.
89606324|NCT05342402|Active Comparator|Educational Pain Management Program (PMP)|Includes education on decreasing irritative contacts with the vulva and relaxation techniques. Each participant will also receive advice on resuming sexual activities with vaginal penetration.
88982308|NCT00419692|Experimental|Sequence WAXBYZCED|Subjects will receive ropinirole as follows W: 1 x 0.5 mg CR-RLS (normal fed), A: 1 x 1 mg CR-RLS (fasted), X: 1 x 2 mg CR-RLS (normal fed), B: 1 x 3 mg CR-RLS (fasted), Y: 2 x 2 mg CR-RLS (normal fed), Z: (2 x 2 mg) + (1 x 1 mg) CR-RLS (normal fed), C: 1 x 6 mg CR-RLS (fasted), E: 2 x 3 mg CR-RLS (fasted) and D: 1 x 6 mg CR-RLS (high fat fed).
89032701|NCT00526565|Experimental|1|TAT (Tapas Acupressure Technique)
89606325|NCT05337228|Experimental|IN-C006 Peri inj.|IN-C006 Peri inj. 1904 mL
89606326|NCT05337228|Active Comparator|RPN301|RPN301 2020 mL
89606327|NCT05329506||Supportive care patient population|Attitudes and Believes About Vaccinations, questionnaires
89606328|NCT05328076||Surgical group|Patients who undergo thyroid surgery and receive indocyanine green angiography
89606329|NCT05317806|Experimental|Metformin Treatment Group|Subjects with PAI-1 deficiency with or without cardiac fibrosis, receiving daily treatment with metformin for a daily range of 500-2000mg
89606330|NCT05317806|No Intervention|Observation Group|"Subjects with PAI-1 deficiency with or without cardiac fibrosis, not receiving treatment with metformin~Subjects are allowed to switch between the two groups"
89606331|NCT05317299|Active Comparator|Resistance Exercise Group|During 8 week progressive resistance exercises (three times a week)
89606332|NCT05317299|Active Comparator|Plyometric Exercise Group|During 8 week progressive plyometric exercises (three times a week)
89606333|NCT05317299|Active Comparator|High Intensity Interval Training Group|During 8 week progressive Hight Intensity Interval Training (three times a week)
89606334|NCT05309928|Experimental|Amox 500 mg|Amoxicillin 500 mg PO
89606335|NCT05309421|Experimental|EVX-01 in combination with pembrolizumab|EVX-01 is administered im. Pembrolizumab is administered according to label
89606336|NCT05306925|No Intervention|Standard parenteral nutrition|These infants will form the control group and will receive standard parenteral nutrition. They will be sub-stratified into gestational brackets - preterm (born <30 weeks) and term/near term.
89032702|NCT00526565|Active Comparator|2|SS (Professionally facilitated social support groups)
89032703|NCT02928003|Experimental|Lung Surgery|
89518947|NCT03472235|Active Comparator|A|include 20 patients will be treated with TCA25% +microneedle 8 sessions for TCA 25 peel and 4 sessions for microneedle (derma pen).
89518948|NCT03472235|Active Comparator|B|include 20 patient will be treated with TCA 25% only ( 8 sessions)
88982309|NCT00419692|Experimental|Sequence WAXBYZDCE|Subjects will receive ropinirole as follows W: 1 x 0.5 mg CR-RLS (normal fed), A: 1 x 1 mg CR-RLS (fasted), X: 1 x 2 mg CR-RLS (normal fed), B: 1 x 3 mg CR-RLS (fasted), Y: 2 x 2 mg CR-RLS (normal fed), Z: (2 x 2 mg) + (1 x 1 mg) CR-RLS (normal fed), D: 1 x 6 mg CR-RLS (high fat fed), C: 1 x 6 mg CR-RLS (fasted) and E: 2 x 3 mg CR-RLS (fasted).
88982310|NCT00419692|Experimental|Sequence WAXBYZDEC|Subjects will receive ropinirole as follows W: 1 x 0.5 mg CR-RLS (normal fed), A: 1 x 1 mg CR-RLS (fasted), X: 1 x 2 mg CR-RLS (normal fed), B: 1 x 3 mg CR-RLS (fasted), Y: 2 x 2 mg CR-RLS (normal fed), Z: (2 x 2 mg) + (1 x 1 mg) CR-RLS (normal fed), D: 1 x 6 mg CR-RLS (high fat fed), E: 2 x 3 mg CR-RLS (fasted) and C: 1 x 6 mg CR-RLS (fasted).
89518949|NCT05156489|Experimental|Fractionated Laser|
89518950|NCT03470987||Group 1:nO-Ctrl|Non-obese patients without generalized chronic periodontitis who were undergone Phase I periodontal therapy
89518951|NCT03470987||Group 2:nO-CP|Non-obese patients with generalized chronic periodontitis who were undergone Phase I periodontal therapy
89518952|NCT03470987||Group 3: O-Ctrl|Obese patients without generalized chronic periodontitis who were undergone metabolic control and Phase I periodontal therapy
89518953|NCT03470987||Group 4: O-CP|Obese patients with generalized chronic periodontitis who were undergone metbolic control and Phase I periodontal therapy
89518954|NCT03470909|Other|Skin-Sparing Mastectomy (SSM)|
89518955|NCT03470909|Other|Nipple-Sparing Mastectomy (NSM)|
89518956|NCT05151497|Experimental|Experimental group: Halliwick + Método Watsu|"The experimental group is made up of 7 subjects, the duration of the session being 75 minutes, divided into 45 minutes of Halliwick, 15 minutes of Watsu and finally 15 minutes of immersion in hot water. .~In the application of the Halliwick Concept, it will be carried out in a pool at a temperature of 30ºC, and through the Ten Points Program.~To carry out Watsu, the pool water must be at a temperature of 35ºC. The Watsu Basic Maneuver will be performed, consisting of a sequence of various positions where the subject must be as relaxed as possible, placed in a supine position, floating with eyes closed, and supported by the physiotherapist who is standing, with a wide base of support."
89518957|NCT05151497|Active Comparator|Control group:Halliwick|The control group is made up of 7 subjects, the duration of the session being 75 minutes, divided into 60 minutes of Halliwick and 15 minutes of immersion in hot water. Treatment using the Halliwick Concept is carried out in a pool where the water temperature is 30ºC, following the Ten Points Program.
89518958|NCT04476251|Experimental|Arm 1/E7 T-Cell Receptor (TCR) T Cell Therapy|E7 TCR T Cell Therapy
89518959|NCT05075681|Experimental|Ruxolitinib combined with Chidamide|All recipients in this arm received the modified Bu/Cy conditioning regimen intensified by Ruxolitinib and Chidamide. The conditioning regimen for allogeneic hematopoietic stem cell transplantation consist of ruxolitinib (35 mg bid [p.o.], days -15 to -10, diminishing to day -1), chidamide (30 mg/day, twice per week from days -15 to -2), cytarabine (4g/m2/day, days -10 to -9), busulfan (0.8mg/kg, Q6h, days -8 to -6), cyclophosphamide (1.8 g/m2/day, days -5 to -4), carmustine(BCNU) (250mg/m2/day, day -3)
89518960|NCT03472001|Experimental|Training group|2-hour training based on reflection and feedback
89518961|NCT03472001|Active Comparator|Lecture group|1-hour lecture
89518962|NCT03472001|No Intervention|Control group|The remaining students only attending dermatology electives
89518963|NCT03470753|Active Comparator|Exercise Amount|Phase 1: 2 or 4 exercises.
89518964|NCT03470753|Active Comparator|Type of instruction|Phase 1: Handout on paper versus handout and visual demonstration/performance.
89518965|NCT03470753|Active Comparator|Delivery Type|Phase 2: Handout vs electronic delivery
89518966|NCT03470753|Experimental|Reminder Type|Phase 2: Mobile reminders vs no mobile reminders
89518967|NCT04939181|Experimental|Non-invasive Neuromodulation|Intervention with microcurrents: application of 6 electrodes per extremity and an adhesive electrode at C7 level.
89518968|NCT04939181|Placebo Comparator|Placebo Non-invasive Neuromodulation|Placebo microcurrents Intervention with microcurrents: application of 6 electrodes per extremity and an adhesive electrode at C7 level.
89518969|NCT03902093|Experimental|Hearing Aid|Actual Patients in the clinic will be evaluated by their Audiologist, if they are candidates to use the Lyric Hearing aid they will be asked if they want to participate in the study which will include imaging of the ear canal with a device similar to the regular ear device used in the clinic to check if there are any changes to the morphology of the ear canal.
89518970|NCT03795233|Experimental|Fecal microbiota transplantation|Fecal microbiota transplant G3 capsules will be administered after standard of care with oral vancomycin therapy in participants with primary Clostridium difficile infection.
89518971|NCT03795233|Active Comparator|Oral vancomycin alone (Control)|Oral vancomycin therapy will be administered as per standard of care in participants with primary clostridium difficile infection.
89518972|NCT03564119|Experimental|S5G4T-1|Participants will topically apply S5G4T-1 cream, once daily to face for 12 weeks.
89518973|NCT03564119|Placebo Comparator|S5G4T-2 Vehicle Cream|Participants will topically apply S5G4T-2 vehicle cream, once daily to face for 12 weeks.
89518974|NCT04457063|Experimental|penetrating keratoplasty|A prospective non-comparative non-randomized clinical study which was conducted on 12 eyes of 8 patients 4 males and 4 females who underwent PKP for keratoconus, and then toric ICL was implanted after minimum of one year with stable refraction
89518975|NCT04531241|Experimental|Test/Control|Eligible subjects that are habitual wearers of daily disposable contact lenses in both eyes will be randomly assigned to sequence, Test/Control.
89518976|NCT04531241|Experimental|Control/Test|Eligible subjects that are habitual wearers of daily disposable contact lenses in both eyes will be randomly assigned to sequence, Control/Test.
89518977|NCT04503707||Follitropin Delta|Treatment according to routine clinical practice.
89518978|NCT03471923||CD Patients|Subjects must have a prior diagnosis of cervical dystonia and be capable of participating in all study procedures. Subjects will undergo assessment of non-motor features.
89518979|NCT03471923||Family Members|Subjects must be a first order relation of a Vanderbilt patient diagnosed with cervical dystonia. The subject must pass a short neurological examination to ensure the subject does not have cervical dystonia or any sensory deficits. Subjects will undergo assessment of non-motor features.
89518980|NCT03471923||Healthy volunteers|Subjects must be healthy volunteers who are neurologically normal. The subject must pass a short neurological examination to ensure the subject does not have cervical dystonia or any sensory deficits. Subjects will undergo assessment of non-motor features.
89518981|NCT03470597||Pregnant women with pre-gestational HSG history|All enrolled pregnant women with pre-gestational ethiodized-oil HSG will be followed up without grouping and be kept track for maternal and offspring's health outcomes in this case registry study.
89518982|NCT02522897|Active Comparator|Ranibizumab|"Patients receive intravitreal injections of 0,5 mg Ranibizumab (Lucentis®) / injection following the treat-and-extend scheme for 12 months."
89518983|NCT02522897|Experimental|Ranibizumab + Laser|"Apart from receiving intravitreal injections of 0,5 mg Ranibizumab (Lucentis®) / injection following the treat-and-extend scheme for 12 months, patients receive a panretinal photocoagulation on visit 3 and / or 4."
89518984|NCT04406987||decompression|patients treated with decompression for lumbar spinal stenosis
88982311|NCT00419692|Experimental|Sequence WAXBYZECD|Subjects will receive ropinirole as follows W: 1 x 0.5 mg CR-RLS (normal fed), A: 1 x 1 mg CR-RLS (fasted), X: 1 x 2 mg CR-RLS (normal fed), B: 1 x 3 mg CR-RLS (fasted), Y: 2 x 2 mg CR-RLS (normal fed), Z: (2 x 2 mg) + (1 x 1 mg) CR-RLS (normal fed), E: 2 x 3 mg CR-RLS (fasted),C: 1 x 6 mg CR-RLS (fasted) and D: 1 x 6 mg CR-RLS (high fat fed).
89518985|NCT04406987||fusion|patients treated with decompression with fusion for lumbar spinal stenosis
89518986|NCT04351061|Experimental|Acetazolamide Arm|Participants in this arm will receive the Acetazolamide intervention for 7 consecutive days post standard of care endoscopic skull base surgery.
89518987|NCT03130829|Experimental|Oligo Fucoidan|Oligo Fucoidan 4.4 g, sachet, oral, twice a day from Study Day -2 to End of Treatment.
89518988|NCT03130829|Placebo Comparator|Placebo|Placebo 4.4 g, sachet, oral, twice a day from Study Day -2 to End of Treatment.
89518989|NCT04318145|Experimental|Part A: PL-3994 Dose Ascension|Dose ascension: up to 15 subjects with HFpEF. N = 3 per dose level, up to 5 dose levels.
89518990|NCT04318145|Experimental|Part B: PL-3994 Single Dose|Up to 40 subjects with HFpEF (20 Females, 20 Males) will receive a single dose of PL-3994.
89518991|NCT04206761|Experimental|Treatment - QVM149|Participants will complete a two week treatment with QVM149 (indacaterol acetate/glycopyrronium bromide/mometasone furoate) 150/50/160 μg delivered as powder in hard capsules via Breezhaler, a breath-activated device which will deliver a specific dose of medication via inhalation.
89518992|NCT04206761|Active Comparator|Control|Participants will continue their clinically prescribed treatment with a high dose dual therapy of Inhaled Corticosteroid (ICS)/Long-Acting Beta2-Agonist (LABA) in any approved drug formulation and delivery device for the treatment period of two weeks. (Participants will continue receiving high dose ICS/LABA therapy at the same dose and in the same formulation as at baseline).
89518993|NCT03931187|Experimental|Women intervention arm|Intervention will be applied to the women within the couple.
89518994|NCT03931187|Experimental|Couple intervention arm|Intervention will be applied to the couple, both men and women.
89518995|NCT03931187|No Intervention|Control arm|The couple will receive the normal nursing care.
89518996|NCT03181529|Experimental|Immediate Treatment|Participants will begin psilocybin intervention immediately after study enrollment.
89518997|NCT03181529|Experimental|Delayed Treatment|Participants will begin the psilocybin intervention 8 weeks after study enrollment.
89518998|NCT02726009|Experimental|Degarelix|
89518999|NCT03914105|Active Comparator|Without music|Test without music
89519000|NCT03914105|Experimental|With music|
89519001|NCT02259725|Experimental|Treatment (regorafenib)|Patients receive regorafenib PO QD on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89519002|NCT03668639|Other|Akynzeo plus dexamethasone|Akynzeo (capsule 300mg/0.5mg) Day 1 plus dexamethasone 12 mg Day 1, 8 mg Day 2-3, and 4 mg Day 4 to be administered weekly for five weeks.
89519003|NCT03556319|Placebo Comparator|Placebo|Placebo
89519004|NCT03556319|Experimental|2-HOBA Low Dose|2-Hydroxybenzylamine acetate: 500mg dose
89519005|NCT03556319|Experimental|2-HOBA High Dose|2-Hydroxybenzylamine acetate: 750mg dose
89519006|NCT03470441|Experimental|FDY-5301 Low Dose|Anticipated n=20
89519007|NCT03470441|Experimental|FDY-5301 Intermediate Dose|Anticipated n=20
89519008|NCT03470441|Experimental|FDY-5301 High Dose|Anticipated n=20
89519009|NCT03470441|Placebo Comparator|Placebo|Anticipated n=20
89519010|NCT03470363|Active Comparator|Group Spinal anesthesia|"Knee surgery under spinal anesthesia~Intervention involves spinal administration of 12,5 mg bupivacaine and 2,5 microgram sufentanil."
89519011|NCT03470363|Active Comparator|Group Sevoflurane anesthesia|"Knee surgery under sevoflurane anesthesia~Intervention involves administration of inhaled sevoflurane for maintenance of general anesthesia"
89519012|NCT03471689|Experimental|Mindfulness|
89519013|NCT03471689|Active Comparator|Positive reappraisal|
89519014|NCT03469895||active CLL treated with ibrutinib or idelalisib for CAI|"Patient with CLL Active autoimmune cytopenia Initiation of a treatment with ibrutinib or idelalisib for autoimmune cytopenia.~The progressive nature of contemporary CAI LLC is not a criterion of exclusion."
89519015|NCT05160857|Experimental|test group|
89519016|NCT03469817|No Intervention|Patients who have undergone THR with Trident Cup|Patients who have had THR with Trident Cups and have previously had an MRI taken at the Hospital for Special Surgery at 1 year post-op.
89606337|NCT05306925|Experimental|Arginine supplementation (combined)|These infants will form an intervention group and will receive parenteral nutrition with additional arginine (up to 18% of amino acid make-up) for up to 14 days post-op and oral arginine supplementation up to 30 days post-op. They will be sub-stratified into gestational brackets - preterm (born <30 weeks) and term/near term.
89606338|NCT05306925|Experimental|Arginine supplementation (oral only)|These infants will form an intervention group and will receive standard parenteral nutrition and oral arginine supplementation up to 30 days post-op. They will be sub-stratified into gestational brackets - preterm (born <30 weeks) and term/near term.
89606339|NCT05301036|Experimental|Active stimulation|Personalized low-intensity transcranial focused ultrasound stimulation of deep brain target (subgenual cingulate or alternative targets)
89606340|NCT05301036|Sham Comparator|Sham stimulation|Personalized low-intensity transcranial focused ultrasound stimulation of lateral ventricle
89606341|NCT05300568||post-menopausal women|post-menopausal women with moderate to severe VMS associated with menopause
89606342|NCT05299099|Experimental|IN-C006 inj.|IN-C006 inj. 1970 mL
89606343|NCT05299099|Active Comparator|RCN301|RCN301 1820 mL
89606344|NCT05295056||Permanent atrial fibrillation|Known to have permanent atrial fibrillation
89606345|NCT05295056||Healthy control|Healthy controls
89606346|NCT05293392|Experimental|Culturally-Tailored COVID-19 Vaccine Uptake Intervention|
89606347|NCT05293392|Active Comparator|Standard Care|
89606348|NCT05291611|Experimental|Treatment with cbt|Treatment for 26 patients with obsessive-compulsive disorder, 14 sessions, each about 90 minutes.
89606349|NCT05290727|Other|0.15% Aquoral Lipo (Esteve) and 0.15% Hyabak (Thea)|Dosage form: topical administration multidose ophthalmic eye drops Product usage order will be determined through randomization Duration: 15 days + 15 days Frequency: dosage between 3 and 6 drops per day
89606350|NCT05290727|Other|0.15% Hyabak (Thea) and 0.15% Aquoral Lipo (Esteve)|Dosage form: topical administration multidose ophthalmic eye drops Product usage order will be determined through randomization Duration: 15 days + 15 days Frequency: dosage between 3 and 6 drops per day
89606351|NCT05290402||an application-based digital navigator|"JEEVA is a new digital health navigator app. This app can be used on a mobile phone or tablet. JEEVA has all of the surgical teaching information from the traditional paper packet and also has additional resources like brief videos, checklists, and reference photos."
89606352|NCT05285202|Experimental|Hotspot-focused ACF/TPT|ACF/TPT intervention will be delivered in a community setting, in geographic areas judged likely to have a high burden of undiagnosed TB
89606353|NCT05285202|Experimental|Facility-based ACF/TPT|ACF/TPT intervention will be delivered on the grounds of a health facility (hospital or large public health center)
89606354|NCT05285202|No Intervention|No intervention|
89606355|NCT05283252|Experimental|Guided Endodontic Micro-Surgery|Use of the 3-D printed guide in endodontic micro-surgery
89606356|NCT05283252|Placebo Comparator|Conventional Endodontic Micro-Surgery|Free-hand endodontic micro-surgery
89606357|NCT05278663|Experimental|Cohort 1: E6742 100 mg or Placebo|Participants will receive E6742 100 milligram (mg) tablet or E6742-matched placebo tablet, orally, twice daily for up to 85 days.
89606358|NCT05278663|Experimental|Cohort 2: E6742 200 mg or Placebo|Participants will receive E6742 200 mg tablets (two tablets of each 100 mg) or E6742-matched placebo tablets, orally, twice daily for up to 85 days.
89606359|NCT05274646||E1784K (glu1784lys) in SCN5A expressing either Long QT syndrome type 3 or Brugada syndrome|
89606360|NCT05274646||E1784K (glu1784lys) in SCN5A expressing both syndromes (Long QT syndrome and Brugada syndrome)|
89606361|NCT05271604|Experimental|BA3021 Q2W dosing|BA3021 Q2W dosing regimen
89606362|NCT05271604|Experimental|BA3021 2Q3W dosing|BA3021 2Q3W dosing regimen
89606363|NCT05270408|Experimental|Active stimulation at 1mA|Participants will receive 1 mA active HD-tDCS for 20 minutes.
89606364|NCT05270408|Experimental|Active stimulation at 2mA|Participants will receive 2 mA active HD-tDCS for 20 minutes.
89606365|NCT05270408|Sham Comparator|Sham group|Participants will receive sham HD-tDCS for 20 minutes, meaning no stimulation.
88982312|NCT00419692|Experimental|Sequence WAXBYZEDC|Subjects will receive ropinirole as follows W: 1 x 0.5 mg CR-RLS (normal fed), A: 1 x 1 mg CR-RLS (fasted), X: 1 x 2 mg CR-RLS (normal fed), B: 1 x 3 mg CR-RLS (fasted), Y: 2 x 2 mg CR-RLS (normal fed), Z: (2 x 2 mg) + (1 x 1 mg) CR-RLS (normal fed), E: 2 x 3 mg CR-RLS (fasted), D: 1 x 6 mg CR-RLS (high fat fed) and C: 1 x 6 mg CR-RLS (fasted).
88982313|NCT00419731|Active Comparator|1|Bupropion+Placebo
88982314|NCT00419731|Experimental|2|Bupropion+Naltrexone
88982315|NCT00419848|Experimental|1|
88982316|NCT00419848|Active Comparator|2|
88982317|NCT00330694|Experimental|I|Implementation of ParkNet within 8 regions
88982318|NCT00330694|Other|II|Usual Care in 8 regions
88982319|NCT00094926|Experimental|001|
88982320|NCT00094926|Placebo Comparator|002|
88982321|NCT02964702|Experimental|Thrombectomy Device(T-01)|Mechanical Thrombectomy with T-01
88982322|NCT00331045|Placebo Comparator|Placebo|
89519017|NCT03469817|Other|Patients who have undergone THR with Trident II Cup|Patients who have had THR with Trident II Cups and will have an MRI taken at their one year post-operative visit.
88982323|NCT00331045|Experimental|Alvimopan 0.25 mg/yday|
88982324|NCT00331045|Experimental|Alviompan 0.5 mg/day|
88982325|NCT00331045|Experimental|Alvimopan 1 mg/day|
88982326|NCT00331084|Experimental|antibiotic steroid drops/single vial|efficacy of antibiotic steroid combination compared with individual administration in prevention of postoperative inflammation in patients having cataract surgery
88982327|NCT00331084|Active Comparator|antibiotic steroids drops|efficacy of antibiotic steroid combination compared with individual administration in prevention of postoperative inflammation in patients having cataract surgery
88982328|NCT00420355|Experimental|Arm A|Subjects on atazanavir/ritonavir will add lopinavir/ritonavir.
88982329|NCT00420355|Experimental|Arm B|Subjects on lopinavir/ritonavir will add atazanavir.
88982330|NCT00331123|Placebo Comparator|Placebo|Placebo patch
88982331|NCT00331123|Experimental|Testosterone Patch|
89519018|NCT05160779|Active Comparator|Mild/asymptomatic cases|For the collection of cells from the oral cavity, a sterile swab will be used for the procedure, and will be opened by the collector in the presence of the participant. The biological material will be collected from the participant's cheek mucosa (rotating the swab 360º using light pressure (approximately 75N) on the mucosa tissue and then packed in a tube containing 3ml of sterile 0.9% saline solution) of the participant. confirmation of identification data in order to analyze and relate polymorphisms found in components of vasoactive peptide systems in DNA samples collected from patients diagnosed with SARS-CoV-2 (COVID-19) who developed mild or asymptomatic conditions.
89519019|NCT05160779|Active Comparator|Serious cases|For the collection of cells from the oral cavity, a sterile swab will be used for the procedure, and will be opened by the collector in the presence of the participant. The biological material will be collected from the participant's cheek mucosa (rotating the swab 360º using light pressure (approximately 75N) on the mucosa tissue and then packed in a tube containing 3ml of sterile 0.9% saline solution) of the participant. confirmation of identification data in order to analyze and relate polymorphisms found in components of vasoactive peptide systems in DNA samples collected from patients diagnosed with SARS-CoV-2 (COVID-19) who developed severe pathology.
89519020|NCT05160623|Experimental|Study eyes|Once-daily eyelid hygiene with povidone-iodine 1%
89519021|NCT05160623|Active Comparator|Control eyes|Once-daily eyelid hygiene with available lid wipes
89519022|NCT03469661||Immune Thrombocytopenia Diagnosis|
89519023|NCT03469661||Myelodysplastic Syndrome Diagnosis|
89519024|NCT04713137|Active Comparator|Erythritol|20 volunteers receive 50g erythritol dissolved in 300mL tap water as an oral pre-load.
89519025|NCT04713137|Active Comparator|Sucrose|20 volunteers receive 33.5g sucrose dissolved in 300mL tap water as an oral pre-load.
89519026|NCT04713137|Active Comparator|Sucralose|20 volunteers receive 0.0558g sucralose dissolved in 300mL tap water as an oral pre-load.
89519027|NCT04713137|Placebo Comparator|Water|20 volunteers receive 300mL tap water as an oral pre-load.
89519028|NCT03470207|No Intervention|Post-Intervention Cohort (Aim 1)|This arm will not have the intervention of the implementation of the structured post-pulmonary embolism follow up protocol that is outlined in Aim 1.
89519029|NCT03470207|Experimental|Pre-Intervention Cohort (Aim 3)|This arm will have the intervention of the implementation of the structured post-pulmonary embolism follow up protocol that is outlined in Aim 1.
89519030|NCT05159921|No Intervention|Standard Consent|Standard consent procedure: The rationale, risks, benefits, and alternatives for the intended procedure (diagnostic or screening OGD or colonoscopy) will be discussed in the outpatient clinic by a consultant general surgeon (DOK) or members of the surgical team. Patients will be given the opportunity to ask questions. All patients will receive a written information leaflet, which includes contact details for the endoscopy department should patients wish to ask further questions (supplemental data). Those undergoing colonoscopy will receive further instructions along with prescribed colonoscopy 'prep' medication by post. On the day of the procedure, patients are required to sign a standardised consent form.
89519031|NCT05159921|Experimental|Standard consent + access to an automated conversational agent (SurgInfoBot)|Patients in the SurgInfoBot arm will be consented as above, but will also be granted access to the SurgInfoBot, which they will be invited to use between their outpatient appointment and their endoscopy procedure date. Participants will be provided with an access link and Unique Study Identifier in order to pseudonymise participant data. Participants will be able to access the SurgInfoBot as many times as they wish, and can ask any questions they see fit.
89519032|NCT05159843|Experimental|Diabetes Self-Management education|"Participants randomized to this arm receive therapeutic education during four sessions of four consecutive days. An advanced practice nurse who specializes in diabetes will teach these sessions. The sessions will have small groups of five patients and it will last of one hour each day. The outline of the session is as follow (Figure 1):~First session: Insulin administration and blood glucose self-analysis Second session: Management of hypoglycemia and hyperglycemia Third session: Healthy diet adapted to the diabetic patient Four session: Physical exercise"
88982332|NCT00331279|Active Comparator|Cinnamon Extract|A purified aqueous abstract of cinnamon in a 500mg tablet will be taken by each patient before lunch and dinner, making a total of one gram per day for eight weeks.
88982333|NCT00331279|Placebo Comparator|Placebo|
88982334|NCT00087581|Experimental|Group A: Monitored MMF + Reduced CNI|Group A will receive concentration-controlled/monitored MMF with an oral CNI, either cyclosporine or tacrolimus. Depending on body surface area and age, MMF may be given in capsule, tablet, oral suspension, or intravenous (IV) form. The initial dose will be at least 1 gram twice a day (BID) in adults and 600 milligrams per meter-squared (mg/m^2) in pediatrics. Subsequent doses will be adjusted to maintain blood mycophenolic acid (MPA) levels greater than or equal to (≥) 1.3 micrograms per milliliter (μg/mL) with cyclosporine or ≥1.9 μg/mL with tacrolimus. The selected CNI will be dosed to maintain reduced blood concentrations. Cyclosporine target concentrations are as follows: Days 1-30, 250-325 nanograms per milliliter (ng/mL); Days 30-90, 125-165 ng/mL; Days 90 through end of study, 95-145 ng/mL. Tacrolimus target concentrations areas follows: Days 1-30, 8-12 ng/mL; Days 30-90, 4-6 ng/mL; Days 90 through end of study, 3-5 ng/mL.
89032704|NCT02946827|Experimental|Low FODMAPs /balanced gluten free diet|An expert in nutrition will give a balanced gluten free diet to patients, low in FODMAPs foods.
89032705|NCT02946827|Active Comparator|Balanced gluten free diet|An expert in nutrition will give a balanced gluten free diet to patients.
89519033|NCT05159843|Experimental|Usual care|Participants in control group receive usual services offered in University Hospital and other local health systems for patients with diabetes, which include regular visits with a diabetes provider (primary care or endocrine) and standard Spanish Diabetes Society information pamphlets. Consultation care is centralized in the pharmacological treatment regimen, dosage and guidelines.
89519034|NCT04456985|Active Comparator|Intervention group|Before the operation, the patient took 20ml of brown sugar aqueous solution containing folic acid and VitB12 for 3 days (folic acid concentration is 0.4mg / d for 2 year old children + 1.2μg / d of VitB12, dissolved in 20ml brown sugar water once a day). Postoperatively, PAED scores were performed at the time of awakening, extubation and every 10min within 30min after extubation. 10 points is defined as delirium during the recovery period). Long-term neurobehavioral changes were evaluated using the Gesell scale, followed up every six months until the age of three
89519035|NCT04456985|Placebo Comparator|Placebo group|The patients in the placebo group took 20 ml of brown sugar aqueous solution with the same concentration as the intervention group 3 days before the operation. Postoperatively, PAED scores were performed at the time of recovery, extubation, and every 10 minutes within 30 minutes after extubation. The PAED scores of all children were measured by the same person. (The total score is 0-20, and the score ≥10 is defined as delirium during the recovery period). Long-term neurobehavioral changes were evaluated using the Gesell scale, followed up every six months until the age of three
89519036|NCT05159609|Active Comparator|Stim First|Participants slept for one night while auditory sounds were played at specific points during slow wave sleep. At least one week later, an identical procedure occured with no acoustic sounds.
89519037|NCT05159609|Sham Comparator|Sham First|Participants slept for one night while no acoustic sounds were played. At least one week later, an identical procedure occured while acoustic sounds were played at specific points during slow wave sleep.
89519038|NCT04456907|Experimental|PPR group|Receive PRP injection
89519039|NCT04456907|Sham Comparator|Saline group|Receive saline injection
89519040|NCT03470129|Active Comparator|Helioseal F|fissure sealing with the conventional product
89519041|NCT03470129|Experimental|Helioseal F Plus|fissure sealing with the new product
89519042|NCT04456751||No redo op|Patients with a single cardiac operation under extracorporeal bypass
89519043|NCT04456751||Redo op|Patients with a redo cardiac operation under extracorporeal bypass
89519044|NCT03469583|Experimental|EYP001 dose1|EYP001 capsules by mouth
89519045|NCT03469583|Active Comparator|Entecavir 1mg|2 tablets of 0.5mg, by mouth
89519046|NCT03469583|Experimental|EYP001 dose 1 + Entecavir 1mg|EYP001 capsules and 2 tablets of Entecavir 0.5mg by mouth
89519047|NCT04442477||Experimental: Enriched Protein Fractions|This group was given Infant formula with enriched protein fractions
89519048|NCT04442477||Active Comparator: Protein Fractions|This group was given Infant formula with protein fractions
89519049|NCT03470051||(2) QT Ultrasound scans prior to breast biopsy|Subjects will undergo a baseline QT scan, and a follow-up QT scan performed between 90 days and 180 days from their baseline QT Scan accompanied by a HHUS and ultrasound-guided breast biopsy following the first follow-up QT scan. BI-RADS will be confirmed by the radiologist at the time of the first HHUS. Subjects will receive a telephone follow-up contact approximately 2-3 business days after their ultrasound-guided breast biopsy to assess if any adverse events have occurred. Subjects will be asked to come back for an additional follow-up QT Scan 12 months from the time of their baseline QT Scan.
89519050|NCT03470051||(0-1) QT Ultrasound scans prior to breast biopsy|"Subjects that have not had (2) two QT Scans before their breast biopsy and who haven't yet had a breast biopsy will undergo an optional baseline QT scan accompanied by a HHUS and ultrasound-guided breast biopsy. BI-RADS will be confirmed by the radiologist. Subjects will receive a telephone follow-up contact approximately 2-3 business days after their ultrasound-guided breast biopsy to assess if any adverse events have occurred. Subjects will be asked to come back for a follow-up QT Scan between 90 and 180 days from the time of their study biopsy.~Subjects that have had a breast biopsy on their identified breast mass(es) prior to study enrollment and have not already had two (2) QT Scans will undergo an optional baseline QT scan if between 0 and 30 days from their breast biopsy.~Subjects will be asked to come back for a follow-up QT Scan 12 months from the time of their study biopsy."
89519051|NCT05096039||Treatment Group 1 (use of sacubitril/valsartan)|Beneficiaries with one or more prescription claim with an NDC for sacubitril/valsartan during the 90-day episode window (for BPCA) and CY2018 (for MSSP). Patients who met these criteria were assigned a value of '1'; patients that did not meet these criteria were assigned a value of '0'
89519052|NCT05096039||Treatment Group 2 (use of ACEI or ARB and no use of sacubitril/valsartan)|Beneficiaries with one or more prescription claim with an NDC for any ACEI/ARB and no prescription claims for sacubitril/valsartan during the 90-day episode window (for BPCA) and CY2018 (for MSSP). Patients who met these criteria were assigned a value of '1'; patients that did not meet these criteria were assigned a value of '0'
89032706|NCT02928042||Lactobacillus bacteria|Pseudomonas aeruginosa, Acinetobacter baumanii, Staph aureus and Klebsiella pneumoniae will be isolated from tracheal aspiration cultures. 80 isolates associated with pneumonia will be identified and made antibiogram with VITEK. Then antimicrobial effects of Lactobacillus bacteria (LAB) (Lc. lactis subsp. lactis (IL 1403), Lc. lactis subsp. lactis (ATCC 11454), Lactobacillus plantarum (FI8595), Leuconostoc mesenterodies subsp. cremoris (DSMZ 20346), Streptococcus thermophilus (NCFB2392), Pediococcus acidophilus (ATCC 25741)) and nisin bacteriocin will be investigated on the bacteria's growth rate in the laboratory.
89032707|NCT02946671|Experimental|Cohort 1|KW-0761 (Mogamulizumab): 0.1 mg/kg, every week, 4 times ONO-4538 (Nivolumab): 3.0 mg/kg, every two weeks, 3 times
89032708|NCT02946671|Experimental|Cohort 2|KW-0761 (Mogamulizumab): 0.3 mg/kg, every week, 4 times ONO-4538 (Nivolumab): 3.0 mg/kg, every two weeks, 3 times
89032709|NCT02946671|Experimental|Cohort 3|KW-0761 (Mogamulizumab): 1.0 mg/kg, every week, 4 times ONO-4538 (Nivolumab): 3.0 mg/kg, every two weeks, 3 times
89032710|NCT02927886|Experimental|Per-oral Endoscopy Pyloromyotomy (G-POEM)|
89032711|NCT02927886|Placebo Comparator|Intrapyloric injection of botulinum toxin|
89032712|NCT00526604|Active Comparator|2|The control group will have an clinical examination and exercise and then return to general practitioner, which will take decision about sick leave or return to work.
89606366|NCT05266079|Experimental|Syndrome differentiation treatment(GMBHDHT, TWBXD,SG,LWDHP and EZP, YGP and LZP)|"Syndrome differentiation treatment group of participants will be given medication by syndrome differentiating from qualified TCM Practitioners. TCM Practitioners will base on the syndrome of the participants to evaluate and modify the prescription after each assessment.~Liver and Kidney Yin Deficiency syndrome use Gan Mai Bai He Di Hung Tang(GMBHDHT);~Non Interaction Between Heart and Kidney syndrome use Tian Wang Bu Xin Dan(TWBXD);~Liver Stagnation and Qi Stagnation syndrome use Shugan Granules(SG);~Kidney Yin Deficiency syndrome use Liu Wei Di Huang Pill and Er Zhi Pill(LWDHP and EZP) ;~Spleen and Kidney Yang Deficiency syndrome use You Gui pill and Li Zhong pill addition and subtraction(YGP and LZP).~Each dose will be prepackaged in two identical foil sachets. Participants will be instructed to drink one sachet of granules dissolved in 200 mL of warm water twice daily."
89606367|NCT05266079|Experimental|Fixed formula treatment|Fixed formula treatment Group will be given the standard formula Er-Xian decoction consisting of six herbs. The dosages of each herb were standardized according to the latest Chinese Medicine Recipe Dictionary (1997). The standard formula Er-Xian decoction are in the form of water-soluble granules. Each dose contains 11.8g and prepackaged in two identical foil sachets. Participants were instructed to drink one sachet of granules dissolved in 200 mL of warm water twice daily.
89606368|NCT05265351|Experimental|Patients with confirmed or suspected diaphragm dysfunction|"Diaphragm function will be assess. Surface electromyography of the diaphragm will be performed in parallel. The abdominals displacement will be recorded using strain gauge. The intra-thoracic and intra-abdominal pressure will be measured using esophageal and gastric catheter-balloon.~Ultrafast ultrasound imaging will be performed during Cervical and bi-lateral anterior magnetic stimulation, and during phrenic electrical stimulation."
89606369|NCT05261646|Experimental|Hetrombopag|
89606370|NCT05261646|Placebo Comparator|Matching placebo|
89606371|NCT05257278||MonoPlus®|Patients undergoing orthopedic surgery with soft tissue approximation
89606372|NCT05255302|Active Comparator|Arm A : control Arm|6 months treatment by chemotherapy + pembrolizumab followed by pembrolizumab ± pemetrexed for patients with non-squamous cell carcinoma (SCC) until 2 years max
89606373|NCT05255302|Experimental|Arm B : experimental arm|6 months treatment by chemotherapy + pembrolizumab followed by pemetrexed for patients with non-SCC or observation for patients with SCC
89606374|NCT05249387|Experimental|A-967079 Injections + BAM8-22|
89606375|NCT05249387|Experimental|A-967079 Injections and vehicle|
89606376|NCT05249322|Experimental|Follow-up alternating between face-to-face consultation and teleconsultation every three months|Patients of this arm will be followed alternating between face-to-face consultation and teleconsultation respecting the recommended frequency (every three months) during 12 months (M+3:teleconsultation - M+6:in-hospital consultation - M+9:teleconsultation - M+12 : in-hospital consultation)
89606377|NCT05248269|Experimental|Thermocoagulation of epileptogenic zone|
89606378|NCT05243550|Experimental|UGN-102|Patients will receive 6 once-weekly intravesical instillations of UGN-102.
89606379|NCT05243290|Active Comparator|Study Supplement: NR|26 subjects will take the supplement (nicotinamide riboside) during the first phase of the study. 300mg will be taken once a day for the 10-week period in phase one.
89606380|NCT05243290|Placebo Comparator|Control|26 subjects will take the placebo during the first phase of the study (10 weeks).
89032713|NCT02946164|No Intervention|Comparison: Standard of Care|Standard services available to all men at AHF Wellness Centers.
89032714|NCT02946164|Active Comparator|Intervention: 'Stick To It' Intervention|Behavioral intervention.
89032715|NCT02927730||positive retainted placenta histology|base on chorionic villi in the pathalogic sample
89032716|NCT02927730||negative retainted placenta histology|
89032717|NCT04692402|Other|open label|open label prospective feasibility trial.
89519053|NCT05096039||Treatment Group 3 (no use of ACEI, ARB, or sacubitril/valsartan)|Beneficiaries who did not qualify for Group 1 or Group 2 were assigned a value of '1'; patients that did not meet this criteria were assigned a value of '0'
89519054|NCT05096039||Cohort Group 1 (Overall cohort)|"The beneficiaries who met the inclusion criteria and were divided into the three treatment groups were considered Cohort Group 1 or the overall cohort."
89519055|NCT05096039||Cohort Group 2 (subgroup 1)|Patients with evidence of systolic HF defined as: having at least 2 medical claims (on different dates) with an ICD-9/-10 diagnosis code for systolic HF in any position during the lookback period and/or during the entire 90-day episode window (for BPCA) and CY2017 and/or CY2018 (for MSSP). Patients who met these criteria were assigned a value of '1'; patients that did not meet these criteria were assigned a value of '0'
89606381|NCT05240599|Experimental|Shaker|"Shaker exercises consist of isotonic and isometric contractions of the neck flexor muscles. Participants will be asked to lie on their back with their knees straight. Participants will first wait for 60 seconds by lifting their head and looking at their feet. He will repeat the movement three times in total, resting for 60 seconds in between. Then, the participants will raise their heads again, look at the toes, and put their head back on the bed without waiting. By repeating this movement 30 times in total, the exercise program will be completed.~Individuals will perform this exercise, which consists of isometric components to be repeated 3 times and isotonic components to be performed once, in 3 sets of 10 repetitions per day."
89606382|NCT05240599|Experimental|Chin Tuck Against Resistance|"In this exercise, participants have to place an inflatable ball with a diameter of 12 cm between their chin and sternum. This exercise has two subcomponents, isotonic and isometric. In the isometric component, individuals must compress the ball with maximum force between their chin and sternum, hold for 60 seconds, and rest for 60 seconds. One should repeat this isometric component 3 times. In the isotonic parameter, on the other hand, the participants must slowly squeeze the ball between their chin and sternum 30 times with the maximum force they can do. Participants will perform the exercise in an upright sitting position on a back-supported chair.~Individuals will perform this exercise, which consists of isometric components to be repeated 3 times and isotonic components to be performed once, in 3 sets of 10 repetitions per day."
89606383|NCT05240599|Experimental|Chin Closure Against Resistance|This exercise will be performed in the form of closing the chin against the manual resistance to be given from the tip of the mandible, starting from the maximum voluntary mouth opening. In this way, eccentric contact will be created as the suprahyoid muscles will move from the shortest position to the longest position with resistance. Participants will perform the exercise by maintaining the upright posture in the upright sitting position on the back-supported chair.
89606384|NCT05239546|Experimental|Neoadjuvant Dostarlimab|Participants will receive Dostarlimab 500 mg IV every 3 weeks for 9 cycles followed by 1000 mg every 6 weeks for 12 cycles until 2 years
89606385|NCT05236751||Elective intracranial intervention patients|Adult patients (18-89 years at the time of surgery) scheduled for elective intracranial (open surgical or endoscopic) intervention and require general anesthesia and a hospital stay of at least one day post-procedure.
89606386|NCT05236517|Experimental|Semaglutide|
89606387|NCT05236517|Placebo Comparator|Placebo|
89606388|NCT05236127|Experimental|Fasted|Fasted Group: Individuals randomly assigned to undergo a 20 hour fast with a four hour eating window for the entire 8-day period of the study.
89606389|NCT05236127|Experimental|Pre-heading fasted|Pre-Heading Fasted Group: Individuals randomly assigned to undergo a 20 hour fast with a 4 hour eating window for a 5-day period prior to the soccer heading.
89606390|NCT05236127|Experimental|Post-heading fasted|Post-Heading Fasted Group: Individuals randomly assigned to undergo a 20 hour fast with a four hour eating window for a 3-day period following the soccer heading.
89606391|NCT05236127|Experimental|Control|Control Group: Individuals randomly assigned to eat per usual over the course of the entire 8-day study period.
89606392|NCT05236127|Active Comparator|Subconcussive Head Impact|"All four groups undergo the same soccer heading model as described below.~Device: Soccer Heading Soccer Heading: Subjects stood approximately 40 feet away from a JUGS soccer ball launcher and participated in 20 consecutive soccer headings, separated by 30 second intervals."
89606393|NCT05230251|Active Comparator|High Dose Radiation (HDR) arm|Patients in the HDR arm will receive two fractions of HDR brachytherapy. HDR brachytherapy will be administered as per local practice and as previously described. All procedures will be conducted under general anesthesia in a dedicated brachytherapy suite using transrectal three dimensional ultrasound for image guidance. For all HDR fractions at least 10Gy will be delivered to the entire prostate with a boost to 13.5Gy to the involved prostate as determined by biopsy and PSMA PET/MRI results. In instances of multi-focal/diffuse involvement of the prostate, the entire prostate will receive 13.5Gy/fraction (respecting OAR constraints).
89606394|NCT05230251|Experimental|Lutetium Arm|Patients in Lutetium Arm will receive 1 cycle of 177Lu-PSMA radioligand therapy plus 1 fraction of HDR brachytherapy.
89606395|NCT05222685|Experimental|Intervention Group|Will receive the 6 month online group coaching program from 9/1/2022-3/1/23
89606396|NCT05222685|No Intervention|Control Group|"Control group - no coaching intervention from 9/1/2022-3/1/23.~(They will receive the coaching intervention after study completion from 3/1/23-9/1/23)"
89606397|NCT05213806|Active Comparator|Withholding feeds around transfusion|All enteral feeds will be discontinued (the infant will be placed nil by mouth) for 4 hours prior to packed red cell transfusion, during the transfusion and until 4 hours post transfusion. During this period, hydration and blood glucose will be maintained according to local practice, commonly by providing parenteral nutrition or intravenous dextrose. Four hours after the red cell transfusion has finished, feeds will be recommenced to how they were being received prior to the decision to transfuse. This duration of withholding feeds will follow the approach used in other trials and observational studies, and identified as the most acceptable in a survey of UK neonatal units. It gives time for milk in the small bowel to transit into the large bowel before the transfusion and for the circulation to stabilize after the transfusion before milk feeds given into the stomach pass through into the small intestine.
89606398|NCT05213806|Active Comparator|Continuing feeds around transfusion|Enteral feeds will continue to be given prior, during and after the packed red cell transfusion, in the manner in which they were being given prior to the decision to transfuse. Infants will remain allocated to the same care pathway until 34(+6) weeks(+days) gestational age.
89606399|NCT05213559|Experimental|wheat-based biscuit enriched with plant proteins|Subjects follow a hypocaloric dietary intervention supplemented with certain amount of wheat-based biscuits enriched with plant proteins daily.
89606400|NCT05213559|Active Comparator|wheat biscuit|Subjects follow a hypocaloric dietary intervention supplemented with certain isocaloric amount of common wheat biscuits daily.
89606401|NCT05210751||Women patients with fibromyalgia|women with fibromyalgia beween age 30-75
89606402|NCT05210751||Control group|Healthy female volunteers aged 30-75 years
89606403|NCT05200702|Experimental|Knee-hip Powered Soft Exoskeleton|Patients and healthy subjects will use a Knee-hip Powered Soft Exoskeleton to perform different standardised tasks
89606404|NCT05200702|No Intervention|No assistance device|Patients and healthy subjects will perform different standardised tasks without Knee-hip Powered Soft Exoskeleton
89606405|NCT05199246|Experimental|Lower-limb powered dermoskeleton|Patients and healthy subjects will use a lower-limb powered dermoskeleton to perform different standardised tasks
89606406|NCT05199246|No Intervention|No assistance device|Patients and healthy subjects will perform different standardised tasks without lower-limb powered dermoskeleton
89606407|NCT05190081|Experimental|single-task training group|Tasks were completed separately in the single-task training group
89606408|NCT05190081|Experimental|dual-task training group|Tasks were completed at the same time in the dual-task training group
89606409|NCT05190081|No Intervention|control group|No intervention was performed in the control group
89606410|NCT05188703|Experimental|Intervention arm|Intervention consists of standard of care eye exam and enrollment in a patient navigation program.
89606411|NCT05187819|Experimental|Patients with positive blood test for biomarkers for Alzheimer's disease|"The positive blood tests results for this group will be compared with the results from the investigation at the at the memory outpatient clinic to calculate the number of false positive blood tests (using the results from the outpatient clinic as a gold standard for the diagnosis)"
89606412|NCT05187819|Active Comparator|Patients with negative blood test for biomarkers for Alzheimer's disease|"The negative blood tests results for this group will be compared with the results from the investigation at the at the memory outpatient clinic to calculate the number of false negative blood tests (using the results from the outpatient clinic as a gold standard for the diagnosis)"
89606413|NCT05187585|Sham Comparator|radiograph interpretation without the support of the RAYVOLVE app|
89606414|NCT05187585|Experimental|radiograph interpretation with the support of the RAYVOLVE app|
89606415|NCT05183113|Experimental|Acute Intermittent Hypoxia|Both healthy participants and those with spinal cord injury will receive the acute intermittent hypoxia (AIH) intervention. All participants are imaged pre- and post-AIH intervention, and thus serve as a self-comparison to observe the hypothesized improvement in bilateral hand strength.
89606416|NCT05177289|Experimental|Treatment group|Patients allocated to the treatment group will receive scalp cooling combined with thrice weekly PBM sessions during the CTx course and until one month after the end of CTx.
89606417|NCT05177289|Active Comparator|Control group|Patients allocated to the control group will receive scalp cooling during their CTx course.
89606418|NCT05177263|Placebo Comparator|Supportive Positions + Oral Sterile Water|The enrolled premature infants will be administered 1ml of the sterile water a first time 2 minutes before the procedure. After 2 minutes, heel-stick sampling (with an auto lancet for premature infants) will be performed immediately after administering 1 ml of sterile water a second time.
89606419|NCT05177263|Active Comparator|Supportive Positions + 10% Oral Dextrose|"The enrolled premature infants will be administered 1ml of the 10% oral dextrose solution a first time 2 minutes before the procedure. After 2 minutes, heel-stick sampling (with an auto lancet for premature infants) will be performed immediately after administering 1 ml of 10% oral dextrose solution a second time.~(%10 oral dextrose solution: osmolarity= 550 mOsm/L, pH= 3.5-6.5, calorie=400 kcal/L)"
89606420|NCT05177263|Active Comparator|Supportive Positions + 20% Oral Dextrose|"The enrolled premature infants will be administered 1ml of the 20% oral dextrose solution a first time 2 minutes before the procedure. After 2 minutes, heel-stick sampling (with an auto lancet for premature infants) will be performed immediately after administering 1 ml of 20% oral dextrose solution a second time.~(%20 oral dextrose solution: osmolarity= 1010 mOsm/L, pH= 3.2-6.5, calorie= 680 kcal/L)"
89606421|NCT05177263|Active Comparator|Supportive Positions + 30% Oral Dextrose|"The enrolled premature infants will be administered 1ml of the 30% oral dextrose solution a first time 2 minutes before the procedure. After 2 minutes, heel-stick sampling (with an auto lancet for premature infants) will be performed immediately after administering 1 ml of 30% oral dextrose solution a second time.~(%30 oral dextrose solution: osmolarity= 1515 mOsm/L, pH= 3.2-6.5, calorie= 1020 kcal/L)"
89606422|NCT05176665|Experimental|Phase Ib and Phase II|The study will consist of Phase Ib and Phase II. The study is planning to recruit approximately 152 patients in total for advanced/metastatic GI cancers, which include 24 patients in Phase Ib and up to approximately 128 patients in Phase II. For GC, HCC, and BTC groups, up to approximately 24 patients may be enrolled in Phase Ib and Phase II. For CRC group, up to approximately 80 patients may be enrolled in Phase Ib and Phase II with up to 40 patients in each subgroup.
89606423|NCT05174832|Active Comparator|Cisplatin+ Nab-paclitaxel + Pembrolizumab followed by Pembrolizumab monotherapy|4~6 cycles combination therapy of Cisplatin, Nab-paclitaxel and Pembrolizumab as induction therapy; Pembrolizumab monotherapy as maintenance therapy
89606424|NCT05174832|Experimental|Cisplatin+Nab-paclitaxel+Pembrolizumab followed by Pembrolizumab+Olaparib|4~6 cycles combination therapy of Cisplatin, Nab-paclitaxel and Pembrolizumab as induction therapy; Pembrolizumab plus Olaparib as maintenance therapy
89606425|NCT05173922|Experimental|Safety in Dementia|Safety in Dementia is an online tool that, in a stepwise fashion, guides a caregiver individual through decisions related to firearm access for a person with dementia. It includes information and a comparison of the options and their risks and benefits. It guides the caregiver through clarification of personal feelings and values and identifying their decision/plan.
89606426|NCT05173922|Active Comparator|Web control|The control group will view National Institute on Aging Home Safety Checklist.
89519056|NCT05096039||Cohort Group 3 (subgroup 2)|Patients with evidence of Heart Failure Reduced Ejection Fraction (HFrEF) identified based on a published algorithm
89519057|NCT05391035||Symptomatic patients attending a sexual health clinic.|A cohort of 160 symptomatic people attending a sexual health clinic in the UK will be recruited to this observational study.
89519058|NCT05162963|Active Comparator|Patients treated with fixed implant denture|Patients quality of life will be compared when using a removable implant denture and a fixed implant denture, in a cross-over design. Fixed denture is considered the standard protocol.
89519059|NCT05162963|Experimental|Patients treated with removable implant denture|Patients quality of life will be compared when using a removable implant denture and a fixed implant denture, in a cross-over design. Removable denture is considered the experimental protocol.
89519060|NCT03500237|Experimental|Team-Guided ICBT|An 8-week transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) for persons with chronic conditions course will be delivered to participants. In addition to the online program, a guide from the Online Therapy Unit team will provide support within one business day of the client's email. The team of guides consist of registered social workers, psychologists or supervised graduate students, with experience delivering ICBT. Amount of contact will be personalized to participants' needs.
89519061|NCT03500237|Active Comparator|Self-Guided ICBT|An 8-week transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) for persons with chronic conditions course will be delivered to participants. Participants are able to contact the Online Therapy Unit regarding any technical issues with logging onto the site. However, no psychological intervention will be provided. A team member from the Unit will contact the participant only if there is a significant clinical issue requiring attention (e.g., sudden increase in symptoms).
89519062|NCT03361865|Experimental|Pembrolizumab 200 mg + epacadostat 100 mg BID|Pembrolizumab + epacadostat
89519063|NCT03361865|Active Comparator|Pembrolizumab 200 mg + placebo BID|Pembrolizumab + placebo
89519064|NCT05053763|Other|Experimental: age<65 group|The 90% effective dose of remimazolam for duodenoscopy insertion with alfentanil 10µg/kg
89519065|NCT05053763|Other|Active Comparator:age ≥65 group|The 90% effective dose of remimazolam for duodenoscopy insertion with alfentanil 10µg/kg
89519066|NCT02982083|Active Comparator|Evista|20 postmenopausal women suffering from rheumatoid arthritis that take raloxifene hydrochloride 60 mg oral tablets every day for one year.
89519067|NCT02982083|Placebo Comparator|Placebo|20 postmenopausal women suffering from rheumatoid arthritis that take placebo pills every day for one year.
89519068|NCT04996901||derivation cohort|Data from Renmin Hospital of Wuhan University, The First College of Clinical Medical Science, China Three Gorges University, The Central Hospital of Enshi Tujia And Miao Autonomous Prefecture, Xiangyang No.1 People's Hospital，and Wuhan Third Hospital will be used as a derivation cohort.
89519069|NCT04996901||validation cohort|Data from The First Affiliated Hospital of Dalian Medical University and Jiangxi Provincial People's Hopital will be used as a derivation cohort.
89519070|NCT02421341|Experimental|Drug - Fentanyl|Study visit 1 you will be asked to get a blood draw, DEXA bone scan, perform pulmonary function tests, and exercise on a stationary bike at maximal exertion while breathing into a mouth piece. Study visits 2 and 3 you will be asked to again exercise at maximal exertion while breathing into a mouth piece. During these two visits you will be receiving an intrathecal injection of either fentanyl or placebo, randomly selected and you will be blinded as to which you are receiving. Catheters will also be placed in an artery in your arm and a vein in your leg, helping us to measure blood flow, blood pressure and draw blood. You will also perform a chemosensitivity test, breathing in and out your own air, after you are done exercising.
89519071|NCT02421341|Placebo Comparator|Placebo|Study visit 1 you will be asked to get a blood draw, DEXA bone scan, perform pulmonary function tests, and exercise on a stationary bike at maximal exertion while breathing into a mouth piece. Study visits 2 and 3 you will be asked to again exercise at maximal exertion while breathing into a mouth piece. During these two visits you will be receiving an intrathecal injection of either fentanyl or placebo, randomly selected and you will be blinded as to which you are receiving. Catheters will also be placed in an artery in your arm and a vein in your leg, helping us to measure blood flow, blood pressure and draw blood. You will also perform a chemosensitivity test, breathing in and out your own air, after you are done exercising.
89519072|NCT02149121|Experimental|CT-P10|rituximab, CT-P10(experimental drug), 1000mg by intravenous infusion. 2 infusions with a 2-week interval between the first and second infusion
89519073|NCT02149121|Active Comparator|Rituxan|US-licensed referece product, 1000mg by intravenous infusion. 2 infusions with a 2-week interval between the first and second infusions
89519074|NCT02149121|Active Comparator|MabThera|EU-approved reference product, 1000mg by intravenous infusion. 2 infusions with a 2-week interval between the first and second infusions
89519075|NCT04456205||Dual Therapy|Dual Therapy (long-acting muscarinic antagonist [LAMA] + long-acting beta-agonist [LABA])
89519076|NCT04456205||Triple Therapy|Triple Therapy (inhaled corticosteroid [ICS]/ long-acting beta-agonist [LABA] + long-acting muscarinic antagonist [LAMA])
89519077|NCT01353521|Experimental|Contrast-enhanced ultrasound|
89519078|NCT04456283||Incomplete pathological response with less than 12 LN.|Patients with incomplete pathological response after Chemoradiation theraphy for Rectal Cancer and less than 12 lymph nodes
89519079|NCT04456283||Incomplete pathological response with 12 or more LN.|Patients with incomplete pathological response after Chemoradiation theraphy for Rectal Cancer and 12 lymph or more nodes
89519080|NCT04456283||Complete pathological response with less than 12 LN.|Patients with complete pathological response after Chemoradiation theraphy for Rectal Cancer and less than 12 lymph nodes
89519081|NCT04456283||Complete pathological response with 12 or more LN.|Patients with complete pathological response after Chemoradiation theraphy for Rectal Cancer and 12 lymph or more nodes
89606427|NCT05166369|Experimental|Intervention targeted to healthcare providers (paediatricians, nurses and pharmacists) (ITHP)|"Professionals in the PC centres allocated to this group will receive a complex intervention, delivered remotely, which will include the following components:~i) Web based training that will include: communication skills training and optimal management of acute non-complicated RTI, including a specific training on delayed antibiotic prescription.~ii) By-monthly feedback about the rate of antibiotic prescription and consumption for RTI, center level and individual pediatrician level (information automatically gathered from electronic health records)."
89606428|NCT05166369|Experimental|Intervention targeted to parents (ITP)|PC centres allocated to this group will display posters and flyers to inform parents and/or caregivers about a mobile app. It will provide detailed information about respiratory tract infections and optimal use of antibiotics. The app will include information that will be of use before the consultation, but it will also allow the patient to interact with the physician during the consultation, potentially improving share decision-making. Importantly, the app will allow tailoring the guidance provided according to the type of infection or number of days with symptoms. The app will be accessible through an app store or directly using a QR (quick response) code to facilitate uptake. Professionals in the primary care centres allocated to this group will also receive a by-monthly feedback about the rate of antibiotic prescription and consumption for RTI, at center level and individual pediatrician level (information automatically gathered from electronic health records).
89606429|NCT05166369|Experimental|Intervention targeted to patients and/or patient´s parents and to the healthcare providers (ITHP*P)|Centres allocated to this group will receive the two interventions described above (intervention targeted to parents plus intervention targeted to providers).
89606430|NCT05166369|No Intervention|Control group|The centers allocated to this arm of the study will continue with their usual care. To avoid a potential Hawthorne effect (observer effect) these centers will not be informed about their participation as controls.
89606431|NCT05165056|Experimental|Treatment group|Patients allocated to the treatment group will receive institutional standard vaginal care in combined with twice weekly PBMT sessions during the radiotherapy course and until two weeks after the end of radiotherapy.
89606432|NCT05165056|No Intervention|Control group|Patients allocated to the control group will receive institutional standard vaginal care.
89606433|NCT05163717|Experimental|INP105|POD-olanzapine (INP105), 5 mg, single dose, to be delivered to each participant
89606434|NCT05163717|Placebo Comparator|Placebo|POD-placebo, single dose, to be delivered to each participant
89606435|NCT05157243|Experimental|Nitazoxanide|Nitazoxanide 300 mg extended release tablets
89606436|NCT05157243|Placebo Comparator|Placebo|Placebo tablets
89606437|NCT05156125|Experimental|VTX002 Dose A|VTX002 Dose A tablet administered orally once daily
89606438|NCT05156125|Experimental|VTX002 Dose B|VTX002 Dose B tablet administered orally once daily
89606439|NCT05156125|Placebo Comparator|Placebo|Placebo tablet administered orally once daily
89606440|NCT05153941||Main Study (tier 1)|Observational Study -The main study (tier 1) comprises 3,510 subjects matched by age and gender at a group level and aged over 50 years with a study partner available to actively contribute to the study will be recruited from memory clinics and/or ongoing observational studies in 3 sites across Greece
89606441|NCT05153941||Tier 2|Observational Study- Sub-study at the baseline visit (Tier 2) Amyloid Positron Emission Tomography (PET): groups (1), (2), (3), (4) as described below fluorodeoxyglucose (FDG) PET : groups (1), (2), (3), (4) as described below More than 400 subjects comprised of (1) >100 of cognitively unimpaired with (A-, T-, (N)-) group, (2) >100 of cognitively unimpaired with (A+, T+, (N)- or A+, T+, (N)+) groups, (3) >100 of mild cognitive impairment with (A+, T+, (N)- or A+, T+, (N)+) groups and (4) >100 of mild cognitive impairment with (A-, T-, (N)-) group will take Amyloid PET and FDG PET as sub-study.
89606442|NCT05153434|Experimental|ARD-101|First week 400 mg of ARD-101 twice daily, second week 600 mg of ARD-101 twice daily, third week 800 mg of ARD-101 twice daily, fourth week 800 mg of ARD-101 twice daily.
89606443|NCT05137132|Active Comparator|Best Standard of Care + CARDIO®|6 gram/day ( 1000 mg per capsule) of unrefined salmon oil, duration of 20 weeks. CARDIO® capsule contains 1000 mg of full spectrum of omega fatty acids, including 21 different fatty acids, with a minimum of 270 mg polyunsaturated fatty acids (PUFA) and10 mg lipopeptides
89606444|NCT05137132|Placebo Comparator|Best Standard of Care + Placebo|6 gram/day (1000 mg per capsule) of natural oil, duration of 20 weeks. The placebo is a medium-chain triglyceride (MCT), with triglyceride from natural fatty acid, mainly caprylic- and capric acid.
89032718|NCT02927808|Experimental|Intervention group - Motivational Interview|"Patients assigned to the intervention group will be given a leaflet entitled Information leaflet about LDL Cholesterol that will educate them about the risks of high LDL-C and the importance of adherence to lipid-lowering medication. Patients assigned to the intervention group will be contacted via telephone for a pre-specified interview (motivational interview again stressing the importance of adherence to lipid-lowering medication) at 1 month and 6 months after discharge, and for an in-person interview plus lipid profiling at 1 year after discharge."
89606445|NCT05136820|Active Comparator|Randomization to 6mm AFR device|AFR Device 6mm vs Sham procedure
89606446|NCT05136820|Active Comparator|Randomization to 8mm AFR device|AFR device 8mm vs Sham procedure
89606447|NCT05136820|Sham Comparator|Randomization to sham procedure|Sham procedure to AFR device (6mm or 8mm)
89606448|NCT05136820|Other|Roll-in Arm|Patients in the Roll-in Arm will receive the AFR device
89606449|NCT05128630|Experimental|Single-arm|Chemotherapy plus durvalumab, hypofractionated RT plus durvalumab, durvalumab maintenance
89606450|NCT05123612|Experimental|Fiber|Participants will be asked to increase their usual dietary fiber intake by 20 grams/day.
89032719|NCT02927808|No Intervention|Control group|Patients assigned to the control group will be contacted for a pre-specified in-person interview plus lipid profiling at 1 year after discharge.
89606451|NCT05123612|Experimental|Fermented Foods|Participants will be asked to consume 6 servings of fermented foods per day.
89606452|NCT05123612|Experimental|Fiber + Fermented Foods|Participants will be asked to increase their usual dietary fiber intake by 20 grams/day and to consume 6 servings of fermented foods per day.
89606453|NCT05123612|No Intervention|Comparator|Participants will receive usual care for pregnancy and postpartum.
89606454|NCT05122663||ED Physical Therapy|Patients in the ED physical therapy group will have been evaluated by an emergency department physical therapist for dizziness/vertigo during their index ED visit.
89606455|NCT05122663||Usual Care|Patients in the usual care group will NOT have received an evaluation by an ED physical therapist for dizziness/vertigo symptoms during their index ED visit.
89606456|NCT05119660|Experimental|Patient Arm|"In a 2x2 factorial double-blind design, we will randomize a sample of adolescents (13-18 years) with WM deficits to intermittent theta burst stimulation (iTBS) at the left dorsolateral prefrontal cortex (DLPFC) or inferior parietal lobule (IPL), based on each participant's structural brain MRI.~Participants in both arms will complete an active iTBS session and a sham iTBS session. The primary outcome will be theta-gamma coupling during WM demands, as measured via electroencephalography (EEG) during a Sternberg spatial WM task (SWMT) immediately before and after iTBS."
89606457|NCT05119660|Experimental|Healthy Control Arm|"Control Arm: A sample of healthy young adults (18-25 years) will receive an individualized theta-gamma parameters protocol of iTBS to the left DLPFC.~Participants in both arms will complete an active iTBS session and a sham iTBS session. The primary outcome will be theta-gamma coupling during WM demands, as measured via electroencephalography (EEG) during a Sternberg spatial WM task (SWMT) immediately before and after iTBS."
89606458|NCT05109429|Experimental|No Craving|Each participant will attend three sessions where the participant will experience three distinct cue-induced craving tasks in a randomized fashion.
89606459|NCT05094401|Experimental|Intervention BT-001 + Standard of Care|BT-001 is a software program used with physician guidance, being investigated to improve glycemic control. Patients randomized to this arm of the study will interact with the BT-001 software program in addition to receiving Standard of Care for type 2 diabetes
89606460|NCT05094115|No Intervention|Training as usual|Training as Usual for the 3rd SFAB is the U.S. Army Master Resilience Trainer (MRT). It focuses on teaching resilience skills and is one of the foundational pillars of the Comprehensive Soldier Fitness program. MRT course is intended to impart training resilience skills, designed to introduce other resilience concepts that soldiers will likely encounter through their careers. Key focus of course are (1) resilience, (2) building mental toughness, (3) identifying character strengths, and (5) strengthening relationships. The 3rd SFAB uses a a team training grounded in strengths-based leadership. The Small Team Development Consultant and Brigade Behavioral Health Provider serves as a consultant to units conducting their own resiliency training as usual. No booster sessions will be offered to Training as Usual.
89606461|NCT05094115|Active Comparator|Training as usual with psychological flexibility training|"Training as usual, with psychological flexibility training delivered during a 2-day workshop.~Day 1 provides an overview of the training and describes the posture or stance to prepare for response to challenging situations in a psychologically flexible manner.~Day 2 provides common coping strategies."
89606462|NCT05092750|Experimental|FerroTraceTM (magnetic tracer)|a special type of fluorescent dye called indocyanine green (ICG) during surgery can help surgeons find the lymph nodes that the cancer is most likely to have spread to in colorectal cancer patients.
89606463|NCT05091489||Men who have sex with men (MSM) non-using PrEP|Focus group (10 persons)
89606464|NCT05091489||Male entertainment workers|Focus group (10 persons)
89606465|NCT05091489||Free-lance based entertainment female workers non-using PrEP|Focus group (10 persons)
89606466|NCT05091489||Venue-based entertainment female workers non-using PrEP|Focus group (10 persons)
89606467|NCT05091489||Transgender women (TGW) non-using PrEP|Focus group (10 persons)
89606468|NCT05091489||Healthcare workers in charge of key-populations|Focus group (10 persons)
89606469|NCT05091489||Community workers in charge of key-populations|Focus group (10 persons)
89606470|NCT05091489||PrEP users|Focus group (10 persons)
89606471|NCT05091489||NCHADS|Individual semi-directive interview (1 person) (NCHADS: operational unit of the Ministry of Health in charge of health sector policy development for HIV/AIDS)
89606472|NCT05091489||National Aids Authority|Individual semi-directive interview (1 person) (National Aids Authority: in charge to lead, manage, coordinate and facilitate the comprehensive and multi-sectoral response to HIV and AIDS in Cambodia)
89606473|NCT05091489||Ministry of Health|Individual semi-directive interview (1 person)
89606474|NCT05091489||Key influencer in the MSM and/or TGW community|Individual semi-directive interview (1 person)
89606475|NCT05091489||Key influencer in the EW community|Individual semi-directive interview (1 person)
88982335|NCT00087581|Experimental|Group B: Monitored MMF + Full CNI|Group B will receive concentration-controlled/monitored MMF with an oral CNI, either cyclosporine or tacrolimus. Depending on body surface area and age, MMF may be given in capsule, tablet, oral suspension, or IV form. The initial dose will be at least 1 gram BID in adults and 600 mg/m^2 in pediatrics. Subsequent doses will be adjusted to maintain blood MPA levels ≥1.3 μg/mL with cyclosporine or ≥1.9 μg/mL with tacrolimus. The selected CNI will be dosed to maintain standard/full blood concentrations. Cyclosporine target concentrations are as follows: Days 1-30, 250-325 ng/mL; Days 30-90, 250-270 ng/mL; Days 90 through end of study, 190-220 ng/mL. Tacrolimus target concentrations are as follows: Days 1-30, 8-12 ng/mL; Days 30-90, 8-10 ng/mL; Days 90 through end of study, 6-8 ng/mL.
89032720|NCT02927652||Questionnaires for new patients|New patients seen at Duke Clinic for Head and Neck Surgery & Communication Sciences or Duke Raleigh Otolaryngology will be administered questionnaires (BSI-18, CG-CAHPS, and patient control scale).
89032721|NCT02946086|Experimental|prismatic adaptation|Including 8 hours of therapy with prismatic adaptation wearing prismatic goggles during bimanual intensive and locomotor intensive intervention (HABIT-ILE).
89032722|NCT02946086|Active Comparator|sham goggles|"Including 8 hours of therapy wearing sham goggles during bimanual intensive and locomotor intensive intervention (HABIT-ILE)."
89032723|NCT00526643|Experimental|Arm B|combination chemotherapy
89032724|NCT00526643|Active Comparator|Arm A|monochemotherapy
89032725|NCT02945163|Experimental|Arm 1|Tenofovir 200mg + Lamivudine 300mg +Efavirenz 400mg PO Quaque die
89032726|NCT02945163|Active Comparator|Arm 2|Tenofovir 300mg + Lamivudine 300mg +Efavirenz 600mg PO Quaque die
89032727|NCT00526682|Active Comparator|1|Comparison of actives for synergy
89032728|NCT02927574||DCB|Treatment with Paclitaxel drug-coated balloon angioplasty (DCB)
89032729|NCT02927574||POBA|Treatment with plain old balloon angioplasty (POBA)
89032730|NCT02927418|Experimental|Strength & Conditioning|Supervised S & C program based on the Long Term Athlete Development Model. Participants will attend 2-3 sessions per week for about one hour each session for 4 months. The comprehensive program will include strength and power training as well as plyometrics, agility and flexibility exercises.
89032731|NCT02927418|Active Comparator|Control|Athletes in the control group will continue with their usual sports and activities but will not receive any type of training.
89032732|NCT00526760|Experimental|Dexmedetomidine|
89032733|NCT00526838|Experimental|1|once-weekly dosing
89032734|NCT00526838|Experimental|2|twice-weekly dosing
89606476|NCT05091489||Khana|"Individual semi-directive interview (1 person)~Khana : an umbrella organization belonging to the HIV/AIDS international Alliance"
89606477|NCT05091489||High class and hidden MSM|Individual semi-directive interview (1 person)
89606478|NCT05091489||Discontinued PrEP user|Individual semi-directive interview (1 person)
89606479|NCT05087082|Other|App and Case Management system with algorithms|Feasibility study of hospital at home model including telemedicine and specifically developed app and case management system
89606480|NCT05080803||Early DME|Functional results after the loading therapeutic phase. The efficacy of different drugs (bevacizumab, ranibizumab, aflibercept, desamethazone) will be analyzed separately
89606481|NCT05080803||Advanced DME|Functional results after the loading therapeutic phase. The efficacy of different drugs (bevacizumab, ranibizumab, aflibercept, desamethazone) will be analyzed separately
89606482|NCT05080803||Severe DME|Functional results after the loading therapeutic phase. The efficacy of different drugs (bevacizumab, ranibizumab, aflibercept, desamethazone) will be analyzed separately
89606483|NCT05080803||Atrophic diabetic maculopathy|Functional results after the loading therapeutic phase. The efficacy of different drugs (bevacizumab, ranibizumab, aflibercept, desamethazone) will be analyzed separately
89606484|NCT05072665|Experimental|PATIENT WITH Irritable Bowel Syndrome|"2.5 ml of 10% fluorescein (SERB) will be administered to the patient intravenously. after the fluorescein injection.~A first food allergen will be applied to the duodenal mucosa starting with the most distal part of the duodenum. After 2 minutes following the application of the allergen, observation using the endomicroscopy system can begin by applying the GastroFlex ™ UHD probe to the duodenal mucosa where the allergen has been projected. . Observation will last up to 3 minutes per site observed. If no reaction is observed, the same manipulation will be carried out using a new allergen. If the observed reaction is positive, the test will be stopped"
89606485|NCT05072067|Experimental|OBESE PATIENT|OverStitch™ Sx with a Single channel endoscop CO2 Insufflation, patient on decubitus dorsal, with intubate 3 to 7 sutures, from the antral ogiv to the cardia are done
89606486|NCT05064943||Total Knee Replacement|Patients who have undergone total knee replacement
89606487|NCT05057754|Experimental|Experimental Group|A total of 50 participants are estimated to be recruited, each completing six conditions in the following order: 1) wrist cooling, 2) wrist heating, 3) exercising, 4) typing, 5) using a mouse, 6) cooking, with an observation of intraneural blood flow assessed with Doppler sonography before and after each condition.
89606488|NCT05055830||Children (<21 years of age) who are prescribed drugs of interest|Children and young adults who are prescribed drugs of interest as part of their routine medical care and are admitted to the pediatric cardiac intensive care unit
89606489|NCT05053412||HCC diagnosed Stage 1 (both A and B)|200 stage 1 (A and B) HCC diagnosed patients
89606490|NCT05053412||HCC diagnosed Stage 2|150 stage 2 HCC diagnosed patients
89606491|NCT05053412||HCC diagnosed Stage 3|100 stage 3 HCC diagnosed patients
89606492|NCT05053412||HCC diagnosed Stage 4|50 stage 4 HCC diagnosed patients
89032735|NCT02927379|Active Comparator|ketamine group|intervention: local wound infiltration 30 patients receive local anesthetic wound infiltration with with 20 ml of bupivacaine 0.5 % diluted in 20 ml saline +1 mg /kg ketamine (total volume 40 ml) in two divided doses i.e. 20 ml is administered on each side of incision.
89606493|NCT05053412||Control liver cancer surveillance subjects|500 patients total: 250 Subjects with liver cirrhosis, 250 subjects without liver cirrhosis
89606494|NCT05046496|No Intervention|Observational arm|Patients recruited to this arm will undergo no intervention.
89606495|NCT05046496|Active Comparator|Interventional arm|Patients recruited to this arm will undergo intra-arterial digital subtraction angiography, with or without intra-arterial stent placement
89606496|NCT05044195|Experimental|aQIV|Adjuvanted QIV containing 2 influenza type A strains and 2 influenza type B strains
89606497|NCT05044195|Active Comparator|Comparator QIV|Non-adjuvanted comparator QIV containing 2 influenza type A strains and 2 influenza type B strains
89606498|NCT05041166|Experimental|Protocol optimization cohort|Following the [13C]pyruvate injection, dynamic imaging and 3D volumetric imaging of volunteers in the first cohort (HP MRI protocol optimization, Aim 1) will be performed on the 3-T MRI scanner, using different [13C] RF excitation/detection coils.
89032736|NCT02927379|Active Comparator|dexmedetomidine group|intervention: local wound infiltration 30 patients receive local anesthetic wound infiltration with with 20 ml of bupivacaine 0.5 % diluted in 20 ml saline + 1µg/kg dexmedetomidine (total volume 40 ml) in two divided doses i.e. 20 ml is administered on each side of incision.
89032737|NCT02927379|Placebo Comparator|bupivacaine group|intervention: local wound infiltration 30 patients receive local anesthetic wound infiltration with with 20 ml of bupivacaine 0.5 % diluted in 20 ml saline (total volume 40 ml) in two divided doses i.e. 20 ml is administered on each side of incision( control group).
89032738|NCT00526877|Experimental|Risperidone|Risperidone long-acting injectable 25 milligram (mg) or 37.5 mg or 50 mg will be administered intramuscularly (into a muscle) depending on Investigator's discretion every 2 weeks for 24 weeks.
89606499|NCT05041166|Experimental|Tissue reference cohort|The optimal setup will then be used for HP MRI of the second cohort.
89606500|NCT05029063|Experimental|Experimental|Rivaroxaban 10mg OD
89606501|NCT05029063|Placebo Comparator|Control|Identical Placebo 10mg OD
89606502|NCT05024591||same as study population|Use of AI-based CADe/x by breast radiologists
89606503|NCT05018611|Experimental|LifeSkills Mobile|Access to LifeSkills Mobile app. Participants will complete 4 modules with 20 activities across 6 months. Participants can log in at their convenience but will not be able to access the next module until the previous module is completed.
89032739|NCT02927496|Active Comparator|Doxycycline|The Doxycycline treated group will enroll 125 participants. 100 patients with Grades 1-3 lymphedema per study site (based on end point and duration) and up to 25 patients with grade 4-6 lymphedema/per study site. Each patient will receive Doxycycline hyclate 200 mg per day x 6 weeks for patients >50 kg or 100 mg per day for patients <50 kg).
89032740|NCT02927496|Placebo Comparator|Placebo|The Placebo treated group will enroll 125 participants. 100 patients with Grades 1-3 lymphedema per study site (based on end point and duration) and up to 25 patients with grade 4-6 lymphedema/per study site. Each patient will receive matching tablets containing no active ingredients.
89032741|NCT00527033|Experimental|1|Oral
89032742|NCT00527033|Experimental|2|Oral
89032743|NCT00527033|Experimental|3|Oral
89032744|NCT00527033|Placebo Comparator|4|Oral
89032745|NCT02945891|Experimental|Study group|Each women recruited for the study belong to the study group. Intervention is performance of HPV testing on Evalyn®Brush and FloqSwab specimens compared to clinician-sampled specimen. Providing an urinary sample (Colli-PeeTM), blood, and a questionnaire data is optional.
89032746|NCT02945072|Active Comparator|Sevoflurane group|general anesthesia will be maintained with sevoflurane
89032747|NCT02945072|Experimental|TIVA group|general anesthesia will be maintained with total intravenous anesthesia (propofol and remifentanyl)
89606504|NCT05018611|No Intervention|Standard of Care|HIV home testing every 6 months, information regarding sexual and other behaviors that potentiate one's risk for HIV infection, receipt of a fact sheet about PrEP and PEP and referrals to the local PrEP clinics, and sexually transmitted infection testing via an on-line location findings app.
89606505|NCT05009394|Active Comparator|Targeted Muscle Reinnervation (TMR)|The surgical procedure comprises three steps: preparation of the donor nerve, identification of a motor branch to the targeted muscle, and nerve coaptation. To prepare the donor nerve, the surgeon will identify the nerve with a painful neuroma and resect the neuroma up to healthy fascicles. Next, the surgeon will identify a motor branch to a nearby target muscle and will confirm muscle contraction using a hand-held nerve stimulator. The motor branch to the target muscle will be transected as close as possible to its entry point without tension. In the final step, the previous nerve stump from which the neuroma was resected will be transferred and coapted to the newly severed motor branch that innervates the target muscle and secured by 2-3 non-resorbable monofilament sutures. The surgery time is approximately 2-3 hours and it takes place in the hospital.
89606506|NCT05009394|Active Comparator|Regenerative Peripheral Nerve Interface (RPNI)|The RPNI procedure involves construction of a residual peripheral nerve split into several nerve fascicles and implanted into free skeletal muscle grafts. First, the surgeon identifies the nerve with a painful neuroma and resect the neuroma up to healthy fascicles. Then, a longitudinal intraneural dissection will be performed exposing its fascicles. Next, autologous muscle grafts will be harvested from a healthy donor site, and the dissected nerve stumps will be placed parallel to the muscle fibers. The nerve stump will be secured to the muscle graft, thereafter the graft will be wrapped around the nerve stump and anchored in the folded graft, thus creating an RPNI. This will be repeated for each fascicle obtained from splitting the transected nerve. Lastly, the RPNIs will be placed in a protected area. The surgery time is approximately 2-3 hours and it takes place in the hospital.
89606507|NCT05009394|Active Comparator|Standard neuroma treatment, neuroma excision, and muscle burying|The standard neuroma treatment, also called neuroma transposition, includes excision of the terminal neuroma and burying the nerve into an adjacent deep muscle.The standard neuroma treatment entails the excision of the terminal neuroma and then implanting the nerve into an adjacent muscle. Firstly, the surgeon will identify the nerve with a painful neuroma and thereafter resect the neuroma up to healthy fascicles. Next, the surgeon will identify a nearby muscle which is not involved in joint motion and has limited output opportunities for the nerve. The nerve will then be channeled at least 1 cm inside the muscle without applying any tension to it and secured by 1-2 non-resorbable monofilament sutures. The identified nerve with the painful neuroma will not be treated with any additional therapy than the resection (e.g., diathermy, pharmacotherapy, crushing, etc.). The surgery time is approximately 1-2 hours and it takes place in the hospital.
89606508|NCT04999839|Placebo Comparator|Placebo|Participants received placebo matched to NDI-034858 oral capsules, once daily (QD) for up to 12 weeks.
89606509|NCT04999839|Experimental|NDI-034858 2 milligrams (mg)|Participants received 2 mg of NDI-034858 oral capsules, QD for up to 12 weeks.
89606510|NCT04999839|Experimental|NDI-034858 5 mg|Participants received 5 mg of NDI-034858 oral capsules, QD for up to 12 weeks.
89606511|NCT04999839|Experimental|NDI-034858 15 mg|Participants received 15 mg of NDI-034858 oral capsules, QD for up to 12 weeks.
89032748|NCT02924922|Active Comparator|Laparoscopic partial nephrectomy|"Inclusion criteria fulfilled:~Baseline Abdomen CT/MRI~Patient Age, Weight, Height, Co-Medication~Informed Consent~Baseline renal function (eGFR, renal scintigraphy, sCreatinine, creatinine clearance)~During hospitalization, one day before laparoscopic partial nephrectomy:~eGFR~sCreatinine~Hemoglobin~After surgery:~Assessment of eGFR 4 days after operation~Hb assessment every 6 H in the first 48 H~Assessment of adverse events~Histological Results~6, 12, 24 months after intervention:~Creatinine Clearance (only performed at 6 months follow-up)~Tc-99m MAG3Dynamic Scintigraphy (only performed at 6 months follow-up)~eGFR~Assessment of adverse events~Assessment of possible recurrence~Assesment of kidney volume variation"
89032749|NCT02924922|Active Comparator|Robot assisted partial nephrectomy|"Inclusion criteria fulfilled:~Baseline Abdomen CT/MRI~Patient Age, Weight, Height, Co-Medication~Informed Consent~Baseline renal function (eGFR, renal scintigraphy, sCreatinine, creatinine clearance)~During hospitalization, one day before robot assisted partial nephrectomy:~eGFR~sCreatinine~Hemoglobin~After surgery:~Assessment of eGFR 4 days after operation~Hb assessment every 6 H in the first 48 H~Assessment of adverse events~Histological Results~6, 12, 24 months after intervention:~Creatinine Clearance (only performed at 6 months follow-up)~Tc-99m MAG3Dynamic Scintigraphy (only performed at 6 months follow-up)~eGFR~Assessment of adverse events~Assessment of possible recurrence~Assesment of kidney volume variation"
89032750|NCT04692896|Experimental|0.1% lidocaine|
89032751|NCT04692896|Experimental|0.2% lidocaine|
89032752|NCT04692896|Experimental|0.3% lidocaine|
89032753|NCT02927340|Experimental|Lorlatinib|Lorlatinib will be administered orally once daily on a 21 day cycle Blood will be collected for biomarker studies
89032754|NCT00528008|Active Comparator|A|povidone-iodine
89032755|NCT00528008|Active Comparator|B|chlorhexidine gluconate
89606512|NCT04999839|Experimental|NDI-034858 30 mg|Participants received 30 mg (2*15 mg) of NDI-034858 oral capsules, QD for up to 12 weeks.
89606513|NCT04994808|Experimental|Arm A (treosulfan, fludarabine, TBI, HCT)|Patients receive treosulfan IV over 2 hours on days -6 to -4 and fludarabine IV over 30 minutes on days -6 to -2. Patients also undergo TBI followed by HCT on day 0.
89606514|NCT04994808|Experimental|Arm B (clofarabine, TBI, HCT)|Patients receive clofarabine IV over 2 hours on days -6 to -2. Patients also undergo TBI followed by HCT on day 0.
89606515|NCT04992598|Experimental|Hypnosis group|
89606516|NCT04992598|Placebo Comparator|Control group|
89606517|NCT04991311|Experimental|once-weekly glepaglutide|All participants will receive 10 mg of glepaglutide as once-weekly injections under the skin (subcutaneous, s.c.)
89606518|NCT04990401|Experimental|Behavioral Activation Teletherapy|All eligible participants will be assigned to receive the behavioral activation teletherapy intervention.
89032756|NCT02925039|Experimental|Experimental|Sit to stand training augmented with technology delivered movement feedback
89032757|NCT02925039|Active Comparator|Control|Sit to stand training as per normal practice
89032758|NCT02946203|Active Comparator|Flavored Beverage Oral Contrast-Breeza|Pediatric patients that are undergoing awake CT and MR enterography at the Cincinnati Children's Hospital Medical Center (CCHMC) base (Burnett) campus will be randomized to either VoLumen (current standard of care oral contrast) or Breeza.
89606519|NCT04986865|Experimental|Single experimental arm for ATG-101|Subjects with advanced or metastatic solid tumors and mature B-NHLs will be enrolled.
89606520|NCT04974008|Experimental|OST31-164|Patients who will receive OST31-164 as a single agent every 3 weeks for 48 weeks with 4 doses constituting 1 treatment cycle (12 weeks per cycle). Each patient will receive treatment at a dose of 1x109 CFU until week 48 or until disease progression, unacceptable toxicity, or the patient meets any other treatment discontinuation criteria.
89606521|NCT04956744|Experimental|Low Dose|Low dose of cells/kg of intravenous (IV) IMS001 as a single dose infusion on Day 1.
89606522|NCT04956744|Experimental|High Dose|High dose of cells/kg of intravenous (IV) IMS001 as a single dose infusion on Day 1.
89606523|NCT04956744|Experimental|Optional Dose|High dose of cells/kg of intravenous (IV) IMS001 as a single dose infusion on Day 1 and at Month 6.
89606524|NCT04954781|Experimental|TACE in combination with Tislelizumab|
89606525|NCT04948502|Experimental|SaExten vena cava filter|Manufacturer: ShenZhen KYD BioTech Co., Ltd., China. SaExten vena cava filter system is a retrievable filter system consisting of two parts: the vena cava filter and the delivering system. The vena cava filter is a mesh filtering device that prevents the formation of pulmonary embolism by filtering the thrombus. The SaExten vena cava filter can be inserted through jugular or femoral veins, and can be retrieved through jugular vein within 90 days or indwelled in vena cava permanently.
89606526|NCT04948502|Active Comparator|Denali inferior vena cava filter|Manufacturer: C. R. BARD, Inc., USA
89606527|NCT04940598|Experimental|High intensity interval exercise|High intensity interval arm crank exercise
89606528|NCT04940598|Other|No-Exercise Control|No-exercise control group
89606529|NCT04938258|Experimental|Intensive Case Management Intervention|"Participants will receive an intensive Case Management (CM) intervention conducted by a multidisciplinary team during 2 months. They will attend weekly or biweekly appointments with the CM team, the interviews will last approximately 30 minutes and will be conducted based on Motivational Interviewing techniques in order to explore values and needs and to enhance motivation to reduce alcohol use and self-efficacy.~Receiving the CM intervention doesn't exclude treatment as usual."
89606530|NCT04936685|Experimental|Group 1|Participants will receive a first booster dose of MenACYW conjugate vaccine at Day 1 and a second booster dose at year 5 of study MEQ00073
89032759|NCT02946203|Active Comparator|Barium Sulfate Oral Contrast-VoLumen|Pediatric patients that are undergoing awake CT and MR enterography at the CCHMC base (Burnett) campus will be randomized to either VoLumen (current standard of care oral contrast) or Breeza.
89032760|NCT02924961|Experimental|Triathlon Mobile-bearing|Primary total knee replacement with cemented Triathlon posterior stabilized mobile-bearing
89032761|NCT02924961|Active Comparator|Triathlon Fixed-bearing|Primary total knee replacement with cemented Triathlon posterior stabilized fixed-bearing
89032762|NCT04692740|Experimental|Chlorambucil|
89606531|NCT04936685|Experimental|Group 2|Participants will receive a single booster dose of MenACYW conjugate vaccine at year 5 of study MEQ00073
89606532|NCT04936061|Experimental|High flow treatment|15 minute transnasal air flow therapy with the CoolStat active device as an abortive treatment for migraine attack.
89606533|NCT04936061|Experimental|Low flow treatment|15 minute transnasal air flow therapy with the CoolStat active device as an abortive treatment for migraine attack.
89606534|NCT04936061|Sham Comparator|Sham flow ambient air|15 minute transnasal air flow therapy with the CoolStat sham device as an abortive treatment for migraine attack.
89606535|NCT04934098|Experimental|Adjustable compression wrap|Daily use of the Adjustable Compression Wrap on the upper limb with breast cancer-related lymphedema during phase 1 compression therapy.
89606536|NCT04934098|Active Comparator|Compression Bandage|Daily use of compression bandage on the upper limb with breast cancer-related lymphedema during phase 1 compression therapy.
89606537|NCT04930367|Active Comparator|Enhanced Standard of Care|To be implemented at all 12 clinic sites, includes a set of interventions aimed at optimizing the national standard of care (billboards/posters and radio shows, healthcare worker training, one-stop adolescent and youth friendly services, information/motivation walls, pill containers and tools to be used by clinic staff during clinical visits)
89606538|NCT04930367|Experimental|CombinADO Strategy|"To be implemented at 6 randomly selected clinic sites, includes all interventions in the Enhanced Standard of Care arm plus five additional intervention components, including 1) Mental health screening and linkage to adolescent-focused mental health support, 2) peer navigation support, 3) an informational video, 4) peer support groups for AYAHIV and 5) support groups for caregivers of AYAHIV"
89606539|NCT04923568|Experimental|EaseVRx sessions|This is a study of patients with chronic pain to identify interest in participating in a large VR trial and, for those willing to join us to test the device in person, to pilot 2 sessions of VR to assess usability and collect preliminary data on pain and mood and to obtain data on patient satisfaction with device use. The entire session will last 45 minutes to 1 hour. All patients recruited will be in the active arm; this is not a randomized pilot study.
89606540|NCT04921371|Other|Healthy Reference Group|Participants who are identified as healthy will be a comparison group. This group will participate in the examinations and plaque sampling only and will not receive a prophylaxis or product.
89606541|NCT04921371|Experimental|5% Hydroalcohol Mouthrinse (Negative control)|Participants after brushing with Colgate® Cavity protection toothpaste and Concept Curve winter series toothbrush will rinse mouth for 30 seconds with 20 milliliter (mL) of 5 percent (%) Hydroalcohol Mouthrinse twice daily (morning and evening) up to 6 weeks.
89606542|NCT04921371|Experimental|Listerine® Cool Mint® (Positive control)|Participants after brushing with Colgate® Cavity protection toothpaste and Concept curve winter series Toothbrush will rinse mouth for 30 seconds with 20 mL of Listerine® Cool Mint® twice daily (morning and evening) up to 6 weeks.
89606543|NCT04921371|Experimental|Mouthrinse Prototype 1|Participants after brushing with Colgate® Cavity protection toothpaste and Concept Curve winter series toothbrush will rinse mouth for 30 seconds with 20 mL of Mouthrinse Prototype 1 twice daily (morning and evening) up to 6 weeks.
89606544|NCT04921371|Experimental|Mouthrinse Prototype 2|Participants after brushing with Colgate® Cavity protection toothpaste and Concept Curve winter series toothbrush will rinse mouth for 30 seconds with 20 mL of Mouthrinse Prototype 2 twice daily (morning and evening) up to 6 weeks.
89606545|NCT04920123|Experimental|Game Intervention|Study participants play Neuro-World 30 minutes per day, twice a week for 12 weeks in your home settings (24 times).
89606546|NCT04920123|No Intervention|No Intervention|Study participants do not engage in any cognitive training.
89606547|NCT04911491|Experimental|IMST|This group will perform high-resistance (75% of maximal inspiratory pressure) inspiratory muscle strength training (IMST), 30 inhalations/session, 6 days/week.
89606548|NCT04911491|Sham Comparator|Control|This group will perform low-resistance (15% of maximal inspiratory pressure) inspiratory muscle strength training, 30 inhalations/session, 6 days/week.
89606549|NCT04911465||Pediatric Trauma Patients|All pediatric patients >31 days who meet criteria for highest level trauma activation (Level Red or Level 1) at the Children's Hospital Colorado.
89606550|NCT04899245|Experimental|School Staff|"50 school staff from Waisman Early Childhood Program (WECP) will be recruited to participate in this study. School staff will send a letter to all WECP staff inviting them to participate. Staff new to the school or who initially decline participation and then reconsider may join at any time.~Additionally, staff who are vaccinated will be asked to participate in testing."
89606551|NCT04899245|Experimental|Parent/Child with Children with medical complexity (CMC)|"65 children and their parents will be recruited to participate. School staff will send a letter to all parents with children enrolled in the Waisman Early Childhood Program (WECP) inviting them to participate. Families new to the school or who initially decline participation and then reconsider may join at any time. Participants will also be offered the option of as needed symptomatic home testing.~Additionally, parents who are vaccinated will be asked to participate in testing. Siblings may be enrolled in the study."
89606552|NCT04895215|Experimental|AB-2004|
89606553|NCT04895215|Placebo Comparator|Placebo|
89606554|NCT04893096|Experimental|MOR202 (felzartamab) infusion|Participants will receive active treatment for a total of nine doses during 24 weeks.
89606555|NCT04889183|Experimental|Semaglutide|Patients will be treated with semaglutide 3 mg/ml s.c. once weekly for 24 weeks. The starting dose of semaglutide will be 0.24 mg subcutaneous injection with increasing doses at 4, 8, 12, and 16 weeks to 0.5, 1,0, 1.7 and 2.4 mg once weekly.
89606556|NCT04889183|Placebo Comparator|Placebo|Patients will receive a matching placebo s.c. once weekly.
89606557|NCT04888741|Active Comparator|Control Arm Thymoglobulin + Cyclosporine + MMF|"Thymoglobulin is given as an intravenous infusion of 2.5 mg/kg/day over 2 days (days -2 and -1; total dose 5 mg/kg) via a central line through a 0.2 micron inline filter. Each dose will be infused over 6-8 hours. No test dose will be given. 30 minutes before Thymoglobulin, the patient should receive methylprednisolone 1mg/kg intravenously, 1g paracetamol PO and 10mg chlorphenamine IV. Patients should be monitored carefully and receive appropriate therapy for any infusion-related or anaphylactic reactions as per local policy.~Patients will receive IV/PO cyclosporine according to local policy to begin on day -1 maintaining a trough level of 100-200 µg/L until day 90 before a subsequent taper in the absence of any active GvHD.~MMF will be given IV/PO according to local policy at a dose of 1g TDS to begin on day -1 and discontinued on day 35 without taper if there is no evidence of active GvHD. In adults weighing <55kg, MMF should be given at a lower dose of 0.75g IV/PO TDS."
88982336|NCT00087581|Experimental|Group C: Fixed MMF + Full CNI|Group C will receive fixed-dose MMF with an oral CNI, either cyclosporine or tacrolimus. Depending on body surface area and age, MMF may be given in capsule, tablet, oral suspension, or IV form. The dose will be at least 1 gram BID in adults and 600 mg/m^2 in pediatrics. Subsequent doses are not to be adjusted, except in the case of unacceptable toxicity. The selected CNI will be dosed to maintain standard/full blood concentrations. Cyclosporine target concentrations are as follows: Days 1-30, 250-325 ng/mL; Days 30-90, 250-270 ng/mL; Days 90 through end of study, 190-220 ng/mL. Tacrolimus target concentrations are as follows: Days 1-30, 8-12 ng/mL; Days 30-90, 8-10 ng/mL; Days 90 through end of study, 6-8 ng/mL.
88982337|NCT00094965|Experimental|1|
88982338|NCT00331435|Active Comparator|1|FA-guided PDT
88982339|NCT00331435|Experimental|2|ICG-guided PDT
88982340|NCT00331513|Active Comparator|Arm I (vorinostat, idarubicin)|Patients receive oral SAHA three times daily on days 1-14 and idarubicin IV over 15 minutes once daily on days 1-3. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients completing 6 courses of therapy or who reach the maximum cumulative dose of idarubicin or an equivalent anthracycline and achieve clinical benefit may continue treatment with SAHA alone 3 times daily on days 1-14 of each course, in the absence of disease progression or unacceptable toxicity.
89032763|NCT02925000|Experimental|TLC178|Liposomal Vinorelbine
89032764|NCT04692857|Experimental|group 30|participants received a supra inguinal fascia iliaca compartment block with 30 ml of 0.2% ropivacaine
89606558|NCT04888741|Experimental|Experimental arm (PTCy + Cyclosporine + MMF)|"Cyclophosphamide is given as an IV infusion of 50 mg/kg/day over 2 days (days 3 and 4; total dose 100 mg/kg) together with IV hydration and Mesna, as per local policy.~Patients will receive IV/PO cyclosporine according to local policy to begin on day 5 maintaining a trough level of 100-200 µg/L until day 90 before a subsequent taper in the absence of active GvHD.~MMF will be given IV/PO according to local policy at a dose of 1g TDS to begin on day 5 and discontinued on day 35 without taper if there is no evidence of active GvHD. In adults weighing <55kg, MMF should be given at a lower dose of 0.75g IV/PO TDS."
89606559|NCT04888741|Experimental|Experimental arm (PTCy + Sirolimus + MMF)|"Cyclophosphamide is given as an IV infusion of 50 mg/kg/day over 2 days (days 3 and 4; total dose 100 mg/kg) together with IV hydration and Mesna, as per local policy.~Sirolimus will be initially given PO as a loading dose of 6 mg on day 5 followed by 2 mg daily; doses will be adjusted to maintain a trough level (in whole blood) of 8 to 14 ng/mL until day 60, thereafter 5-8 ng/mL until day 90. In the absence of active GvHD, the dose of sirolimus will be tapered from day 90. We recommend that the daily maintenance dose of sirolimus is reduced empirically to 0.5-1mg daily with concomitant treatment with a triazole anti-fungal agent.~MMF will be given IV/O according to local policy at a dose of 1g TDS to begin on day 5 and discontinued on day 35 without taper if there is no evidence of active GvHD. In adults weighing <55kg, MMF should be given at a lower dose of 0.75g IV/PO TDS."
89606560|NCT04886388|Experimental|BT-001 + Standard of Care|BT-001 is a software program used with physician guidance, being investigated to improve glycemic control. Patients randomized to this arm of the study will interact with the BT-001 software program in addition to receiving Standard of Care for type 2 diabetes
89606561|NCT04886388|Active Comparator|Standard of Care|Patients randomized to the Standard of Care arm will receive Standard of Care treatment for type 2 diabetes under the guidance of a physician
89606562|NCT04883814|Experimental|Initial Staging|FES PET/CT will be compared to CT/bone scan for detection of unsuspected distant metastases in patients with ER-positive locally advanced breast cancer
89606563|NCT04883814|Experimental|Suspected disease recurrence|FES PET/CT will be compared to CT/bone scan for detection of unsuspected distant metastases in patients with ER-positive breast cancer and suspected disease recurrence
89606564|NCT04883554|Experimental|Olfactory therapy group|"The therapeutic group takes place in specific stages on a weekly basis and lasts approximately 45 minutes. The group consists of a maximum of 6 patients of approximately the same age. The therapists leading the therapeutic group choose in advance the smells that will be offered to patients, based on one odor for each of the following categories: food and woody / flowery. The odors circulate between the participants of the group (patients and therapists), on wipes of blotting paper soaked in the bottles and soaked in the odors. The first step of the therapeutic group is olfactory perception: this is the moment when the odors selected for the session are presented to the patients. Each scent goes around the patients and therapists, three times and without verbalization. Therefore, patients can express their feelings through drawing or writing on distributed sheets. .~In a second step, called rendering, patients are asked to express what they think of the smell presented."
89606565|NCT04883554|Active Comparator|Body therapy group|"The therapeutic group takes place according to very specific stages at a weekly frequency and lasts 1 hour. The group is made up of a maximum of 6 patients.~This workshop includes three times divided equally over a period of 1 hour:~Kinesic time or time to set the body in motion (20 min):~These techniques involve lying on the floor on a mat and approaching the movement slowly. The movements are suggested by the patients and then imitated by the rest of the group.~Kinesthetic time: time of slow movements (20 min):~During this time, the patient is asked to find a period of calm close to immobility without imposing the instruction. They are asked to touch the different parts of the body as slowly as possible in isolation, starting and ending in the center of the body.~Talk time (20 min):~Patients are invited to verbalize what they felt bodily"
89606566|NCT04881604|Experimental|Adjustable Compression Wrap|Daily use of the adjustable compression wrap on the upper limb with breast cancer-related lymphedema during phase 2 of compressive therapy.
89606567|NCT04881604|Active Comparator|Compression Sleeve|Daily use of the compressive sleeve on the upper limb with breast cancer-related lymphedema during phase 2 of compressive therapy
89606568|NCT04869358|Experimental|Vaccination before treatment initiation|Patients will receive SARS-CoV-2 mRNA vaccines before starting ofatumumab treatment (approx. 1 month later)
89606569|NCT04869358|Experimental|Vaccination during treatment|Patients will receive SARS-CoV-2 mRNA vaccines while already stable on ofatumumab treatment (at least 4 weeks since first dose)
89606570|NCT04866576|Experimental|Q CAN PLUS POWDER|QCAN PLUS POWDER: 2 pouches per day, each pouch contains (12-15 gms of fermented soy powder)
89606571|NCT04866576|Placebo Comparator|Placebo|Sprouted brown rice protein with flavor (provided by BESO Biological Research Inc.)
89606572|NCT04840797||Suspected Sudden Cardiac Arrest|All subjects with suspected of a circulatory arrest of any cause.
89606573|NCT04825223|Experimental|Stage 1: MenB vaccine formulation(s)|Assigned MenB vaccine formulation or Placebo single injection in the respective dosing schedule at Day 01, Day 31 and Day 181
89606574|NCT04825223|Active Comparator|Stage 1: vaccine comparator(s)|Bexsero vaccine or Trumenba vaccine or Placebo single injection in the respective dosing schedule at Day 01, Day 31 and Day 181
88982341|NCT00331513|Active Comparator|Arm II (vorinostat, idarubicin)|Patients receive oral SAHA three times daily and idarubicin IV over 15 minutes once daily on days 1-3. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients completing 6 courses of therapy or who reach the maximum cumulative dose of idarubicin or an equivalent anthracycline and achieve clinical benefit may continue treatment with SAHA alone 3 times daily on days 1-14 of each course, in the absence of disease progression or unacceptable toxicity.
88982342|NCT00331669|Placebo Comparator|1|device
88982343|NCT00331708|Experimental|Artesunate plus sulphadoxine-pyrimethamine|
88982344|NCT00420433||1|Patients with breast cancer that has spread to the bones.
88982345|NCT00332020|Experimental|Arm 1|
88982346|NCT00332020|Active Comparator|Arm 2|
88982347|NCT02965274|Experimental|Test|Torrent's Fluoxetine Tablets 20 mg
88982348|NCT02965274|Active Comparator|Reference|Warner Chilcott LLC, USA
88982349|NCT00332098|Experimental|1|Family-Focused Treatment Plus Pharmacotherapy
88982350|NCT00332098|Active Comparator|2|Enhanced Care Plus Pharmacotherapy
89606575|NCT04825223|Experimental|Stage 2: MenB vaccine formulation(s)|Assigned MenB vaccine formulation, MenQuadfi vaccine and Placebo single injection in the respective dosing schedule at Day 01, Day 31, Day 61 and Day 181 + booster dose of leading MenB vaccine formulation single injection at Day 366
89606576|NCT04825223|Active Comparator|Stage 2: vaccine comparator(s)|Bexsero vaccine or Trumenba vaccine and Placebo single injection in the respective dosing schedule at Day 01, Day 31, Day 61 and Day 181 + booster dose of Bexsero vaccine single injection at Day 366
89606577|NCT04825223|Experimental|Stage 3: Men B vaccine formulation(s)|Assigned MenB vaccine formulation and/or MenQuadfi vaccine single injection in the respective dosing schedule at Day 01 and Day 61
89606578|NCT04825223|Active Comparator|Stage 3: MenQuadfi vaccine and vaccine comparator|MenQuadfi vaccine single injection at Day 01 or Bexsero vaccine single injection at Day 01 and Day 61
89606579|NCT04825223|Experimental|Stage 4: MenB vaccine formulation(s)|Assigned MenB vaccine formulation, Routine Vaccines (RV)s and MenQuadfi vaccine single injection in the respective dosing at 2 months of ages [moa] (Day 01), 4moa (Day 61) and 12 moa
89606580|NCT04825223|Active Comparator|Stage 4: MenQuadfi vaccine and vaccine comparator|MenQuadfi vaccine or Bexsero vaccine and RVs in the respective dosing schedule at 2 months of ages [moa] (Day 01), 4moa (Day 61) and 12 moa
89606581|NCT04822649|Other|Heart failure with preserved ejection fraction|Adenosine stress echocardiography, body composition, and cardiopulmonary exercise test will be done in all of the enrolled patients. Left ventricular end-diastolic pressure will be assessed during coronary angiography.
89606582|NCT04819386|Experimental|Active group|18 half-hour in-office active vision therapy sessions with the NEIVATECH Virtual Reality-based system
89606583|NCT04816227||Amyotrophic Lateral Sclerosis (ALS)|Blood draw
89606584|NCT04816227||asymptomatic carriers of ALS mutations|Blood draw
89606585|NCT04816227||patients with motor impairment other than ALS|Blood draw
89606586|NCT04816227||healthy controls|Blood draw
89606587|NCT04815096|Experimental|[18F]F-AraG|"Radiofluorinated imaging agent, [18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine)~Trade name: VisAcT"
89606588|NCT04812678|Active Comparator|Physiotherapy|"Conventional physiotherapy, in line with french Haute Autorité de Santé guidelines"
89606589|NCT04812678|Experimental|Physiotherapy and Fasciatherapy|"Conventional physiotherapy, in line with french Haute Autorité de Santé guidelines, associated with Fasciatherapy Danis Bois Method"
89606590|NCT04812678|Experimental|Fasciatherapy|Fasciatherapy Danis Bois Method
89606591|NCT04810052|Experimental|Condition I (contribution)|Patients do 1 nice thing (can be as large or as small as they wish) BIW for 4 weeks for their caregivers while at home.
89606592|NCT04810052|Experimental|Condition II (gratitude)|Patients write a letter or note of gratitude BIW for 4 weeks to their caregivers who have helped with their treatment or recovery.
88982351|NCT00126789|Experimental|ZR-02-01|ZR-02-01 matrix transdermal fentanyl patch
88982352|NCT02965352|Experimental|Hand strength|Volunteers without motor abnormalities. The tests were performed in a single session lasting 30 minutes, when volunteers used the door handle device, the linear switch device, and the door key device, in order to quantify the hand strength.
88982353|NCT05831969|Experimental|Lenalidomide|lenalidomide be used after Lenvatinib combined with PD-1 inhibitors in the first-line treatment
88982354|NCT05831956||Collagen group /Control group|"Patients who received collagen patches on the anastomotic site during colectomy were allocated to the collagen group.~Patients without collagen patches on the anastomotic site during colectomy were allocated to the control group."
88982355|NCT05831943||Renal CT evaluation|Patients who are planned kidney contrast enhanced CT scan
88982356|NCT05831930|Experimental|Treatment Group|
89606593|NCT04810052|Active Comparator|Condition III (daily activities tracking)|Participants keep track of their daily activities.
89606594|NCT04795167||FlowTriever Arm|FlowTriever Arm subjects are defined as those subjects where FlowTriever is used as the Primary Treatment for pulmonary embolism.
89606595|NCT04795167||Context Arm|Subjects with high-risk pulmonary embolism who are treated with non-FlowTriever therapies.
89606596|NCT04795167||Prior Therapy Arm|Subjects presenting with low/intermediate-risk PE who received advanced therapy but subsequently progressed to high-risk PE in the same hospital setting/admission.
89606597|NCT04792970|Active Comparator|Talc instilled via tunneled pleural catheter combined with standard daily drainage|This arm consists of eligible participants who are randomized to the Talc arm and would receive Talc therapy instilled into the pleural catheter.
89606598|NCT04792970|No Intervention|Standard daily drainage|This arm consists of eligible participants who are randomized to control group and would not receive any intervention.
89606599|NCT04778501|Experimental|PODEYE TORIC IOL Implantation experimental|Mono- or bilateral implantation of toric intraocular lenses PODEYE TORIC
88982357|NCT05831917|Experimental|Treatment Group|
88982358|NCT05831891|Experimental|Fruquintinib combine with Serplulimab|Patients will receive Fruquintinib 5mg, qd, 2w on/1w off, combined with Serplulimab 4.5mg/kg, IV drip, d1, q3w.
89606600|NCT04755309|Experimental|Typical development infants - experimental|Children without familial risk for language disorders, who participate to the rhythmic intervention.
89606601|NCT04755309|No Intervention|Typical development infants - spontaneous development|No intervention is provided and typical development in children without familial risk for language disorders is evaluated.
89606602|NCT04755309|Active Comparator|Typical development infants - control|Children without familial risk for language disorders, who are exposed to passive auditory stimulation.
89606603|NCT04755309|Experimental|Infants at familial risk - experimental|Children with familial risk for language disorders, who participate to the rhythmic intervention.
89606604|NCT04755309|No Intervention|Infants at familial risk - spontaneous development|No intervention is provided and typical development in children without familial risk for language disorders is evaluated.
89606605|NCT04748042|Experimental|Abiraterone, ADT, Radiation and Olaparib|Abiraterone, ADT, radiation to all metastases and Olaparib.
89606606|NCT04743492|Experimental|CBT group|cognitive behavioral therapy (CBT)+routine medical care
89606607|NCT04743492|Experimental|exercise therapy group|physiotherapy-exercise therapy+routine medical care
89606608|NCT04743492|Experimental|breathe training group|using biofeedback devices to train breathing speed+routine medical care
89606609|NCT04743492|No Intervention|usual care|accepting only routine medical care
89606610|NCT04742374|Experimental|Group A|Patients alternating single plasma exchange followed by double filtration plasmapheresis etc.
89606611|NCT04742374|Experimental|Group B|Patients alternating double filtration plasmapheresis followed by single plasma exchange etc.
89606612|NCT04741516|Experimental|Medication arm|
89606613|NCT04741282|Experimental|pulmonary telerehabilitation plus progressive muscle relaxation training|This group will perform six week pulmonary rehabilitation program and progressive muscle relaxation exercise at theirs home, with two supervised sessions by physiotherapist per week via videoconferencing.
89606614|NCT04741282|Active Comparator|pulmonary telerehabilitation|This group will perform six week pulmonary rehabilitation program at theirs home, with two supervised sessions by physiotherapist per week via videoconferencing.
89606615|NCT04730609|Experimental|Dexmedetomidine|IV administration of Dexmedetomidine, using an Up-Down method utilizing a biased coin design to determine that next patient's dose. Initial dose will be 10mcg.
89606616|NCT04721808||Patients with Rheumatoid Arthritis (RA)|Patients receiving tofacitinib from the Corrona RA Registry from November 2012 onward
89606617|NCT04717869||ICU Patients|Adult Surgical, Cardiothoracic, and Neuro- ICU patients will be enrolled within 48 hrs of admission
89606618|NCT04713176|Experimental|DWJ1248 with Remdesivir|Camostat mesylate 200 mg, Remdesivir
89606619|NCT04713176|Placebo Comparator|Placebo with Remdesivir|Placebo, Remdesivir
89606620|NCT04710303|Experimental|Cohort 1 (n = 10): hAd5-S-Fusion+N-ETSD at 5 × 10e10 Viral Particles (VP) per dose|hAd5-S-Fusion+N-ETSD at 5 × 10e10 Viral Particles (VP) per dose on Days 1 and 22
89606621|NCT04710303|Experimental|Cohort 2 (n = 10): hAd5-S-Fusion+N-ETSD at 1 × 10e11 VP per dose|hAd5-S-Fusion+N-ETSD at 1 × 10e11 VP per dose on Days 1 and 22
89606622|NCT04710303|Experimental|Cohort 3 (n = 15): hAd5-S-Fusion+N-ETSD at 1 × 10e11 VP per dose|hAd5-S-Fusion+N-ETSD at 1 × 10e11 VP per dose (or 5 × 10e10 VP per dose if safety concerns identified at higher dose) on Days 1 and 22
89606623|NCT04706845||1|No evident disease
89606624|NCT04706845||2|Metastatic Disease; Watchful Waiting: Tumors bearing NOTCH Mutation
89606625|NCT04706845||3|Metastatic Disease; Watchful Waiting: Tumors bearing Notch Wild Type
89606626|NCT04706845||4|Progressive Disease: Tumors bearing NOTCH Mutation
89606627|NCT04706845||5|Progressive Disease: Tumors bearing Notch Wild Type
89606628|NCT04703621|Experimental|Intervention ( safety run-in, cohort 1, cohort 2)|"Safety run-in( 3 patients): daratumumab once a week x 4 doses. If no worsening of thrombocytopenia can be attributed to study treatment or any other life-threatening events, the study will proceed to the main part.~Cohort 1 ( 9 patients): daratumumab once a week x 8 doses~If response is <100%:~Cohort 2 ( 9 patients): daratumumab once a week x 8 doses followed by daratumumab every 2 weeks x 2 doses"
89606629|NCT04703569|Experimental|Monolayer high compression elastic bandage|An elastic bandage of cotton, viscose, nylon and elastane
89606630|NCT04703569|Active Comparator|Unna boot|A wet bandage with zinc oxide
89606631|NCT04702113|No Intervention|Conventional Therapy (Controls)|Treatment with clopidogrel and no pre-emptive genotyping
89606632|NCT04702113|Experimental|Genotype-guided therapy (experimental)|"Treatment with clopidogrel 75 mg daily for non-carriers~Treatment with ticagrelor 90 mg twice daily for carriers"
89606633|NCT04701723|Experimental|Cardiac Coherence Training|"The cardiac coherence training will consist in the realization during 3 months by the patient, at home :~of 6 respiratory cycles by minute (inspiration : 4,5 seconds/expiration : 5,5 seconds),~during 5 minutes,~3 times a day (morning, late morning and late afternoon)"
89606634|NCT04697784|Experimental|Subjects who receive the TREO Abdominal Stent-Graft System|Eligible subjects will be implanted with the TREO Abdominal Stent-Graft System.
89606635|NCT04696146|Experimental|Berinert|Berinert 500 units
89606636|NCT04696146|Placebo Comparator|Placebo|Normal Saline in identical volume to Berinert
89606637|NCT04693676|Experimental|Prizloncabtagene autoleucel|Prizlon-cel will be intravenously administered as a single infusion after lymphodepletion
89606638|NCT04685486|Experimental|Virtual Reality|Virtual reality-enhanced distraction using a portable head mounted display during panful events (such as wound dressing changes or physical therapy sessions) in addition to standard of care.
89606639|NCT04685486|No Intervention|Treatment as Usual|Standard of care during painful event (such as wound dressing changes or physical therapy sessions).
89606640|NCT04680897|Other|Standard Group|Participants may resume vaginal penetration at 6 weeks.
89606641|NCT04680897|Other|Early Group|Participants may resume intercourse at 2 weeks
89606642|NCT04669665|Experimental|SLS-002 + Standard of care|Participants will receive SLS-002 (intranasal racemic ketamine) 90 milligram (mg) two times per week for 2 weeks with standard of care treatment
89606643|NCT04669665|Placebo Comparator|Placebo + Standard of care|Participants will receive intranasal placebo two times per week for 2 weeks with standard of care treatment
89606644|NCT04660396||Outpatients following discharge for treatment of heart failure|Daxor Corporation's commercially available Blood Volume Analyzer, BVA-100, will be performed at 5 timepoints for each patient.
89606645|NCT04658940|Experimental|Non-randomized|All subjects with typical atrial flutter will undergo percutaneous catheter ablation of the cavotricuspid isthmus using the AcQBlate Force Sensing System.
89606646|NCT04650256|Experimental|CAM arm|Participants will be given the CAM intervention during scheduled, standard of care radiotherapy (up to 6 weeks) and 8-12 weeks (weeks 14-18) after radiotherapy.
89606647|NCT04644055||Chronic liver disease with liver cirrhosis|Evaluation of the right and left hepatic lobe with EUS-guided share wave evaluation. All patients with chronic liver disease will have a transient elastography evaluation, EUS- elastography of the liver and an EUS-guided liver biopsy.
89606648|NCT04644055||Control patients|Patients without history of chronic liver disease after clinical and transient elastography evaluation will be submitted for EUS-guided share wave evaluation of the liver. Patients were originally undergoing EUS evaluation for evaluation of suspected subepithelial lesions.
89032765|NCT04692857|Experimental|group 40|participants received a supra inguinal fascia iliaca compartment block with 40 ml of 0.2% ropivacaine
89032766|NCT04692857|Experimental|group 50|participants received a supra inguinal fascia iliaca compartment block with 50 ml of 0.2% ropivacaine
89032767|NCT00528047|Experimental|PRLX 93936|
89032768|NCT02927106||Acute Myeloid Leukemia (AML)|AML samples will be collected from individuals with newly diagnosed or relapsed/refractory Acute Myeloid Leukemia (AML) as defined by World Health Organization 2016.
89032769|NCT01580462||Children and Adolescent with type 1 diabetes on CSII|
89032770|NCT02945228||Chronic infection of hepatitis C virus (HCV) genotype 2|Participants with confirmed chronic HCV genotype 2, receiving paritaprevir/ritonavir/ombitasvir and ribavirin according to standard of care and in line with the current local label
89032771|NCT02926989|Experimental|Isotonic solution|Plasmalyte Glucos 50 mg/mL; total daily fluid requirements are estimated using the Holiday-Segar method plus possible dehydration (according to child's weight loss during acute illness); intravenous fluids are administered using delivery pumps programmed for an hourly infusion rate (mL/hour); intravenous fluids are administered as long as needed during hospitalization, but no longer than seven days after admission.
89032772|NCT02926989|Active Comparator|Hypotonic solution|0.45% saline in 5% dextrose; total daily fluid requirements are estimated using the Holiday-Segar method plus possible dehydration (according to child's weight loss during acute illness); intravenous fluids are administered using delivery pumps programmed for an hourly infusion rate (mL/hour); intravenous fluids are administered as long as needed during hospitalization, but no longer than seven days after admission.
89032773|NCT02924844||Observation period before presence of clinical pharmacist|The group of patients was observed between Janary 2013 and December 2013
89032774|NCT02924844||Period with presence of clinical pharmacist|The group of patients was observed between January 2014 and June 2015.
89032775|NCT04692272|No Intervention|CONTROL group|The CONTROL group did not exercise.
89032776|NCT04692272|Experimental|XBOX group|"The XBOX group performed exercise for 60 min, three times/week, for 6 weeks, using the Xbox Kinect game Your Shape Fitness evolved. This game was chosen because it simulates an environment with a variety of physical activities, in which the majority can be practiced by older adults. The activities were carried out individually. The game activities selected for the physical activity sessions were: 1) Zen-Develop it (stretching, balance and flexibility activities, similar to Yoga); 2) Pump it (to fill balls until they burst); 3) Wall Breaker (to break blocks, similar to boxing); 4) Kick it (soccer activity); 5) Hurricane (to lift the balls off the floor and not let them fall); 6) Stack in Up (balance activity)."
89032777|NCT02924805||Telemedicine group|Cases of hypertensive emergencies and urgencies in which the prehospital emergency care was performed by on-scene paramedics, guided by a qualified physician in a teleconsultation center.
89032778|NCT02924805||Control group|Historical cases of of hypertensive emergencies and urgencies in which the prehospital emergency care was carried out by on-scene emergency medical service physicians (conventional care).
89032779|NCT00528086||1|Parkinson disease patients and their family members or caregivers randomly assigned to receive their PD care in group visit format.
89606649|NCT04642443|Active Comparator|Intracranial Hemorrhage|"The SENSE device transmits a low power tailored electro-magnetic (EM) pulse in the radio-frequency range across the patient's brain and detects changes in the signal that may indicate intracranial hemorrhage. The device consists of three parts:~A molded plastic headpiece containing the antenna array~An intermediate control unit that contains:~a. The driving electronics for the array of antennae~A processing control unit that contains:~A spectrum analyzer~The operating software that controls the device function and data acquisition, processing and archiving.~The user interface for inputting patient information and displaying the output of the data"
89606650|NCT04642443|Active Comparator|Traumatic Brain Injury|"The SENSE device transmits a low power tailored electro-magnetic (EM) pulse in the radio-frequency range across the patient's brain and detects changes in the signal that may indicate intracranial hemorrhage. The device consists of three parts:~A molded plastic headpiece containing the antenna array~An intermediate control unit that contains:~a. The driving electronics for the array of antennae~A processing control unit that contains:~A spectrum analyzer~The operating software that controls the device function and data acquisition, processing and archiving.~The user interface for inputting patient information and displaying the output of the data"
89606651|NCT04640441|No Intervention|Control group|Participants in the control group received usual care.
89606652|NCT04640441|Experimental|Sit-to-stand care group|Intervention was provided once daily by trained nurses for a maximum of 14 days or until hospital discharge or death.
89032780|NCT00528086||2|Parkinson disease patients and their family members or caregivers randomly assigned to receive their PD care in standard of care format (one-on-one physician-patient visits).
89032781|NCT02924649|Experimental|Early Intensive mobilisation|As early as possible the experimental group will receive mobilisation on a tilt table for up to 20 minutes 5 days a week for four weeks using an ERIGO tilt table. If orthostatic hypotension occur the patient is moved to supine until parameters are stable again. Hereafter the mobilisation will continue until the patient has completed 20 minutes of standing exercise.
89032782|NCT02924649|No Intervention|Standard care group|The standard care group will receive daily mobilisation to the seated position.
89606653|NCT04631770|Experimental|Mediastinal lymph node dissection group|A
89032783|NCT00528125|Active Comparator|A|Active laser acupuncture
89606654|NCT04631770|Active Comparator|Spared mediastinal lymph node dissection group|B
89606655|NCT04629066|No Intervention|Usual care|Usual care will include regularly scheduled visits with the clinical heart failure care team and medical therapy as prescribed by that team.
89032784|NCT00528125|Placebo Comparator|B|placebo laser acupuncture
89032785|NCT02945696|No Intervention|Local port site injection|
89032786|NCT02945696|No Intervention|Ultrasound-guided nerve blocks|
89032787|NCT02945696|Experimental|Laparoscopic guided nerve blocks|These patients will receive the same volume of local anesthetic as those in the ultrasound-guided arm, but the delivery of the local anesthetic will be guided by laparoscopy.
89606656|NCT04629066|Experimental|Remote prescription for aerobic exercise|The exercise prescription will be created by an exercise physiologist after incorporating remotely collected data from a patient directed smartphone app assessing HF symptom severity, vital signs, weight, and blood sugar, and cardiac implant measures of physical activity, heart rate, heart failure volume status and heart rhythm, and Fitbit measures of physical activity.
89606657|NCT04626050|Experimental|Medical Music (Phase I)|Participants will complete four medical music sessions that are 20 minutes in length each.
89532746|NCT05989815|Experimental|PBMT pre (PBMT-pre)|"Group submitted to pre-exercise active photobiomodulation therapy (PBMT), and post-exercise Sham (placebo) PBMT.~PBMT will be administered using the Joovv Elite System, which has 6 panels of red Light-Emiting Diodes (LEDs) (660±10nm) and 74 panels of infrared LEDs (850±10nm), totaling 900 LEDs covering an area of 12,193 cm². Athletes will stand 20 cm in front of the device, wearing only swim shorts to expose their thigh muscles and other body areas to the light. The total irradiation time will be 20 minutes, with 10 minutes (600 seconds) of irradiation for the anterior region and another 10 minutes (600 seconds) for the posterior region. The active PBMT dose applied in each region (anterior or posterior) will be 48.97 J/cm², with an irradiance of 81.62 mW/cm²."
89606658|NCT04626050|Experimental|Narrative Writing (Phase I)|Participants will complete four narrative writing sessions that are 20 minutes in length each.
89606659|NCT04626050|Active Comparator|Interpersonal Psychotherapy (Phase II)|IPT is comprised of ten 75-minute sessions scheduled twice weekly.
89606660|NCT04626050|Active Comparator|Prolonged Exposure Therapy (Phase II)|ET is comprised of ten 75-minute sessions scheduled twice weekly.
89606661|NCT04625023||Cohort of BC patients|Stage-mixed cohort of at least 500 breast cancer patients through their course of treatment, until death or a minimum of 5 years.
89606662|NCT04624074|Experimental|Teen Marijuana Checkup - adapted|Teen Marijuana Checkup will be adapted for youth and young adults with first episode psychosis. The Teen Marijuana Checkup includes two intervention sessions. In Session 1, the interventionist uses motivational interviewing skills to hear the adolescent's history and current concerns with marijuana. The personalized feedback report generated from the baseline assessment is reviewed. In Session 2, the interventionist elicits change talk and guides discussion on making changes to reduce or stop marijuana use.
89606663|NCT04623710|Experimental|Cohort 1: Severe Impaired Renal Function|Participants will receive ALXN2050.
89606664|NCT04623710|Experimental|Cohort 2: Moderate Impaired Renal Function|Participants will receive ALXN2050.
89606665|NCT04623710|Experimental|Cohort 3: Mild Impaired Renal Function|Participants will receive ALXN2050.
89606666|NCT04623710|Experimental|Cohort 4: Healthy Control|Participants will receive ALXN2050.
89606667|NCT04618757|Experimental|Hedonic Reward|Participants' reward for meeting monthly step targets is in the form of reimbursements of up to $50 for expenses on hedonic activities of their choice
89606668|NCT04618757|Experimental|Cash Reward|Participants' reward for meeting monthly step targets is in the form of $50 cash disbursements
89606669|NCT04606459|Active Comparator|Optimal medical therapy|"Optimal medical therapy consisting of acetyl salicylic acid, statins, beta-blockers, calcium channel-antagonists, ranolazine will be administered at the discretion of the physician as recommended by the most recent European Society of Cardiology (ESC) guidelines.~Long-acting nitrates will not be administered unless for patients with fractional flow reserve (FFR)<0.8 or with previously reported good response. Short-acting nitrates may be administered in patients in whom concomitant epicardial spasm is suspected, but they have no documented effect on microvascular angina."
89606670|NCT04606459|Experimental|Coronary sinus reducer|The device being studied is the Neovasc Reducer™ System. Each patient in the Reducer group will be implanted with a single Reducer according to the instructions for use.
89606671|NCT04601363||Patients with Personalized SpineRods|The patient is being treated with the patient-specific rod with a surgery date planned
89606672|NCT04601363||Patient with other hardware|Patients with other hardware not patient-specific
89606673|NCT04598269|Experimental|ATI-1777|ATI-1777 topical solution 2.0% w/w, twice daily
89606674|NCT04598269|Placebo Comparator|Vehicle|Vehicle topical solution, twice daily
89606675|NCT04593407|Active Comparator|Endoscopic Mucosal Resection (EMR):|Piecemeal EMR is a conventional endoscopic resection technique. A submucosal injection of a large volume of a solution (normal saline or other) with or without dilute epinephrine (1/10,000) with or without indigo carmine is performed. Then, sequential piecemeal resection is performed with use of a combination of stiff-type snares. At the end of the procedure when macroscopically visible adenoma has been totally resected, a snare tip soft coagulation (STSC) of the margin of the scar is performed to eliminate non visible residual neoplastic tissue. This procedure is quicker and safer than ESD but led to more recurrent disease (around 20% with the standard technique but recently reduced to 5% after the introduction of STSC)
89606676|NCT04593407|Experimental|: Endoscopic Submucosal Dissection (ESD):|ESD is a newer resection technique that allows en bloc resection for large LSLs. A submucosal injection is also needed but, in this case, different endo-knives are used to achieve the resection instead of diathermic snares. The en bloc resection allows a more precise pathological analysis and the risk of recurrence is lower (<2%) when margins are tumor-free.
89606677|NCT04593212||Septic Shock Survivors|
89606678|NCT04593212||Septic Shock Non-Survivors|
89606679|NCT04591015|Experimental|DD-CA|In the DD-CA arm, participants will be offered a proven digital texting platform in their language of preference (Spanish/English) as part of the diabetes transitions discharge program with added COVID support messages.
89606680|NCT04591015|Active Comparator|Usual Care (UC)|UC participants will not receive the added COVID support messages, both arms will have a referral placed to the Diabetes Transitions Service (DTS) as part of usual care at the time of discharge.
89606681|NCT04588233|Experimental|Administration of Melatonin|
89606682|NCT04588233|Placebo Comparator|Administration of Placebo|
89606683|NCT04583891|Experimental|IntelliCare|IntelliCare is a self-guided, fully automated suite of apps designed for brief, frequent check-ins to promote skill acquisition. IntelliCare has been shown in both general deployment and human-supported trials to be efficacious in reducing symptoms of depression and anxiety.
89606684|NCT04583891|Active Comparator|Patient Education|The patient education app will contain psychoeducational information about distress prevalence and distress management. It will serve as an active control condition to compare with the IntelliCare apps.
89606685|NCT04582994||Young participants|"30 young participants will perform the Mental Time Travel task while tACS stimulation is delivered at three different frequencies on the posterior parietal cortex. Interventions are administered in three different sessions in a pseudo-randomized order as described below:~Day 1. Beta tACS (22Hz)~Day 2. Alpha tACS (10 Hz)~Day 3. Sham tACS"
89606686|NCT04582994||Old participants|"30 old participants will perform the Mental Time Travel task while tACS stimulation is delivered at three different frequencies on the posterior parietal cortex. Interventions are administered in three different sessions in a pseudo-randomized order as described below:~Day 1. Beta tACS (22Hz)~Day 2. Alpha tACS (10 Hz)~Day 3. Sham tACS"
89606687|NCT04570943|Experimental|Gabrinox followed by stereotactic radiotherapy|"Gembrax:~Albumin-bound paclitaxel followed by Gemcitabine Day 1,8,15 followed by 2 weeks of rest~Folfirinox:~Oxaliplatin, irinotecan, leucovorin, 5FU bolus and continuous"
89606688|NCT04566692|Experimental|IGSC 20%: Treatment-experienced Cohort|Participants first received 16 weekly doses of IGSC 20% using a subcutaneous (SC) infusion pump from Week 0 to Week 15. Participants entering study on intravenous immune globulin (IVIG), IGSC 20% was dosed at 1.37 times the equivalent weekly dose and participants entering on subcutaneous immunoglobulin (SCIG) received the same milligram/kilogram (mg/kg) equivalent weekly dose as given prior to study entry, without using a dose adjustment factor (DAF). Participants then received 9 biweekly doses of IGSC 20 % (i.e, IGSC 20% every 2 weeks) using an SC infusion pump, with the first IGSC 20% dose administered at Week 16 and the final dose given at Week 32.
89606689|NCT04566692|Experimental|IGSC 20%: Treatment-naïve Cohort|Treatment-naïve participants received a loading dose of 150 mg/kg/day of IGSC 20% for 5 consecutive days (Week 0, Days 1 to 5) followed by weekly maintenance infusions of 150 mg/kg IGSC 20% starting Week 1 (Day 8) through Week 32. IGSC 20% infusion was administered using an SC infusion pump.
89606690|NCT04564183||Full Cohort|Entire study population
89606691|NCT04564183||Sub-Cohort|Randomly selected sub-cohort from the larger group of all participants
89606692|NCT04548063|Experimental|6,000 word consent form|Subjects who are receiving cancer therapy or have been treated for cancer in the past will be asked to review a mock consent form of approximately 6,000 words.
89606693|NCT04548063|Experimental|4,000 word consent form|Subjects who are receiving cancer therapy or have been treated for cancer in the past will be asked to review a mock consent form of approximately 4,000 words.
89606694|NCT04548063|Experimental|2,000 word consent form|Subjects who are receiving cancer therapy or have been treated for cancer in the past will be asked to review a mock consent form of approximately 2,000 words.
89606695|NCT04548050||mothers informed by untrained nurse|
89606696|NCT04548050||mothers informed by trained nurse|
89606697|NCT04548050||mothers informed by nurses trained 6 months ago|
89606698|NCT04547010|Experimental|Intervention group|In four weeks of intervention study the participants instructed to receive (60 mg) of soy-isoflavone supplement per day, after this period the Bone Mineral Density was assessed by Dual X-ray Absorptiometry scan to evaluate the effect of soy-isoflavone supplement on Bone mineral density.
89606699|NCT04536857||Parkinson's Disease|Subjects who have a PD diagnosis
89606700|NCT04536857||Multiple System Atrophy|Subjects who have an MSA diagnosis
89606701|NCT04536857||Progressive Superanuclear Palsy|Subjects who have a PSP diagnosis
89606702|NCT04536857||Age-matched controls|Subjects who do not have a diagnosed neurological disorder
89606703|NCT04536142||Brain tumors|Subjects with operable supratentorial brain tumors
89606704|NCT04536142||Healthy subjects|Healthy subjects
89606705|NCT04534153|Experimental|Fexofenadine without SLS|Participants will be administered by mouth with a capsule containing 120 mg fexofenadine hydrochloride and 101 mg microcrystalline cellulose
89606706|NCT04534153|Experimental|Fexofenadine and 3 mg SLS|Participants will be administered by mouth with a capsule containing 120 mg fexofenadine hydrochloride, 3 mg SLS and 101 mg microcrystalline cellulose
89606707|NCT04534153|Experimental|Fexofenadine and 30 mg SLS|Participants will be administered by mouth with a capsule containing 120 mg fexofenadine hydrochloride, 30 mg SLS and 101 mg microcrystalline cellulose
89606708|NCT04533412|Experimental|Targeted self-management barrier support|Intervention group - Targeted self-management barrier support, home-based pulmonary rehabilitation, and emergency medication with community health workers
89606709|NCT04533412|Active Comparator|Guided COPD education|Control group - Guided COPD education with a COPD educator
89606710|NCT04524611|Experimental|Risankizumab Dose A Followed by Dose B|Participants will receive intravenous risankizumab dose A at Week 0, 4 ,8 followed by subcutaneous (SC) risankizumab dose B every 8 weeks through Week 48. Participants who complete the Week 48 visit will continue SC risankizumab for up to an additional 220 weeks.
89606711|NCT04524611|Active Comparator|Ustekinumab|Participants will receive weight-based intravenous ustekinumab at Week 0 followed by subcutaneous ustekinumab every 8 weeks through Week 48.
89606712|NCT04519580||Patients with suspected polymyalgia rheumatica|The study investigates patients with suspected polymyalgia rheumatica (PMR). For Patients where the PMR diagnosis is dismissed, the study terminates after the first visit. Patients diagnosed with PMR will be treated with prednisolone with taper corresponding to usual care. At baseline all patients will have medical history taken, physical examination, blood drawn, Synacthen® test, PET/CT, and ultrasound performed. Physical examination, PET/CT, and ultrasound are repeated after 8 weeks of prednisolone treatment while the patients iare on 10 mg prednisolone as well as after prednisolone taper two weeks later, where Synachten® test is also performed. After 10 weeks prednisolone is restarted at 10 mg and the patient is followed by their general practitioner or at the department of rheumatology, where prednisolone is tapered according to usual care. Patients are invited to a follow up visit after one year.
89606713|NCT04515147|Experimental|Part 1, Group 1: CVnCoV 6 μg|Participants will be vaccinated with CVnCoV on Day 1 and Day 29. Participants in this group will be aged between 18 and 60 years old.
89606714|NCT04515147|Experimental|Part 1, Group 2: CVnCoV 6 μg|Participants will be vaccinated with CVnCoV on Day 1 and Day 29. Participants in this group will be aged over 60 years old.
89606715|NCT04515147|Experimental|Part 1, Group 3: CVnCoV 12 μg|"Participants will be vaccinated with CVnCoV on Day 1 and Day 29. Participants in this group will be between the ages of 18 to 60 years old.~CVnCoV will be administered again as a booster vaccination on Day 180 in a sub-group of participants."
89606716|NCT04515147|Experimental|Part 1, Group 4: CVnCoV 12 μg|"Participants will be vaccinated with CVnCoV on Day 1 and Day 29. Participants in this group will be aged over 60 years old.~CVnCoV will be administered again as a booster vaccination on Day 57 or Day 180 in a sub-group of participants."
89606717|NCT04515147|Active Comparator|Part 1, Group 5: Hepatitis A vaccine|Participants will be vaccinated with a hepatitis A vaccine on Day 1 and Day 29. Participants in this group will be aged between 18 and 60 years old.
89606718|NCT04515147|Active Comparator|Part 1, Group 6: Pneumococcal vaccine|Participants will be vaccinated with a pneumococcal vaccine on Day 1 and Day 29. Participants in this group will be aged over 60 years old.
89606719|NCT04515147|Experimental|Part 2, Group 1: CVnCoV 12 µg|Participants will be vaccinated with CVnCoV 12 µg on Day 1 and Day 29. Participants in this group will be aged between 18 and 60 years old.
89606720|NCT04515147|Active Comparator|Part 2, Group 2: Hepatitis A vaccine|Participants will be vaccinated with a hepatitis A vaccine on Day 1 and Day 29. Participants in this group will be aged between 18 and 60 years old.
89606721|NCT04515147|Experimental|Part 2, Group 3: CVnCoV 12 µg|Participants will be vaccinated with CVnCoV 12 µg on Day 1 and Day 29. Participants in this group will be aged over 60 years old.
89606722|NCT04515147|Active Comparator|Part 2, Group 4: Pneumococcal vaccine|Participants will be vaccinated with a pneumococcal vaccine on Day 1 and Day 29. Participants in this group will be aged over 60 years old.
89606723|NCT04511494|Active Comparator|OIT peanut|"Children with peanut allergy receiving peanut OIT. Peanut challenge are done before randomization and one and three years after inclusion.~n=50 patients"
89606724|NCT04511494|No Intervention|Peanut avoidance|"Children with peanut allergy not undergoing OIT peanut. Peanut challenge are done Before randomization and one and three years after inclusion.~n=25 patients"
89606725|NCT04511494|No Intervention|Healthy controls|"Control Group with non-allergic, age-matched children. No challenges are performed in this group.~n=30 patients"
89606726|NCT04511494|No Intervention|Children not reacting at the baseline peanut challenge|"Peanut-allergic children not reacting at the baseline peanut challenge, will not be eligible for randomisation. They will have a clinical visit after 1+3 years. No more challenges in this group.~n=X patients"
89606727|NCT04493411|Experimental|Multiple Myeloma Patients|Patients with pathologically confirmed myeloma for cross-sectional study (detection) or scheduled to undergo induction therapy (or have gone 1-2 cycles of induction therapy), followed by either bone marrow transplantation or consolidation therapy for longitudinal study (therapy response assessment).
89606728|NCT04493177|Experimental|Gestational diabetes intervention|All mothers with gestational diabetes will receive 18 months of educational intervention post-partum. They and their offspring will be evaluated at months 1,2,3,6,9,12,15,and 18.
89606729|NCT04493177|Experimental|No diabetes intervention|Mothers without gestational diabetes will receive 18 months of educational intervention post-partum. They and their offspring will be evaluated at months 1,2,3,6,9,12,15,and 18.
89606730|NCT04493177|Active Comparator|No diabetes no intervention|Mothers without gestational diabetes will receive the conventional care for 18 months post-partum. They and their offspring will be evaluated at months 1,2,3,6,9,12,15,and 18.
89606731|NCT04491877|Experimental|Cohort 1 (RSV vaccine formulation 1)|1 administration of RSV vaccine formulation 1 on Day 0
89606732|NCT04491877|Placebo Comparator|Cohort 1 (Placebo)|1 administration of placebo on Day 0
89606733|NCT04491877|Experimental|Cohort 2 (RSV vaccine formulation 1)|2 administrations of RSV vaccine formulation 1 on Day 0 and Day 56
88982359|NCT05831787||Diagnosis of multiple myeloma and currently receiving active treatment for any phase of the disease|Diagnosis of multiple myeloma must meet the International Myeloma Working Group criteria.
88982360|NCT05831761|Experimental|PCA|Postoperative intravenous infusion of piritramid patient controlled analgesia (PCA) (piritramide 0.5 mg/ml; infusion 1,5 mg/h, bolus 1,5 mg, lock out 30 minutes)
88982361|NCT05831761|Experimental|PCEA|Postoperative patient controlled epidural analgesia (epidural cathterer inserted into Th7-8 intervertebral space, 200 ml of 0.125% levobupivacaine, 4 mg of morphine, 0.075 mg of clonidine; infusion 5 ml/h, bolus 5 ml, lock out 30 minutes).
88982362|NCT05831761|Experimental|tramadol|Continous postoperative infusion of tramadol 300 mg and metamizole 2,5 g (in 500 ml 0.9% NaCl, rate of infusion 40 ml/h)
88982363|NCT05831761|Experimental|lidocaine|Postoperative topical lidocaine and PCA (piritramide 0.5 mg/ml; infusion 0.5 mg/h, bolus 1.5 mg, lock out 20 minutes)
89606734|NCT04491877|Placebo Comparator|Cohort 2 (Placebo)|2 administrations of placebo on Day 0 and Day 56
89606735|NCT04491877|Experimental|Cohort 3 (RSV vaccine formulation 2)|1 administration of RSV vaccine formulation 2 on Day 0
89606736|NCT04491877|Placebo Comparator|Cohort 3 (Placebo)|1 administration of placebo on Day 0
89606737|NCT04491877|Experimental|Cohort 4 (RSV vaccine formulation 1)|2 administrations of RSV vaccine formulation 1 on Day 0 and Day 56
89606738|NCT04491877|Experimental|Cohort 4 (RSV vaccine formulation 2)|2 administrations of RSV vaccine formulation 2 on Day 0 and Day 56
89606739|NCT04491877|Placebo Comparator|Cohort 4 (Placebo)|2 administrations of placebo on Day 0 and Day 56
88982364|NCT05831696|Experimental|Powered Microprocessor-controlled Knee (PMPK)|"the Power Knee is a commercially available PMPK."
88982365|NCT05831657|Experimental|Prevent It 2.0 Swedish|A free, anonymous, internet-delivered, clinician-guided, cognitive behavioral therapy (CBT) intervention delivered in Swedish.
88982366|NCT05831657|Active Comparator|Waitlist Swedish|Waitlist Swedish Participants in the waitlist control will wait thirteen weeks before starting active treatment. While on the waitlist, participants will respond to questions about ongoing problematic sexual behavior in Swedish.
88982367|NCT05831657|Experimental|Prevent It 2.0 German|A free, anonymous, internet-delivered, clinician-guided, cognitive behavioral therapy (CBT) intervention delivered in German
88982368|NCT05831657|Active Comparator|Waitlist German|Participants in the waitlist control will wait thirteen weeks before starting active treatment. While on the waitlist, participants will respond to questions about ongoing problematic sexual behavior in German
88982369|NCT05831657|Experimental|Prevent It 2.0 Portuguese|A free, anonymous, internet-delivered, clinician-guided, cognitive behavioral therapy (CBT) intervention delivered in Portuguese
89606740|NCT04479618|Active Comparator|Usual practice (negative control)|After a member of the UHWI surgical team performs the initial cleansing/debriding, the control group (1) will have their ulcer dressed as usually done at UHWI. Wounds are dressed with saline-soaked gauze, covered with dry gauze. One wrap of stretch gauze will hold the dressing in place. Patients will clean the wound by vigorously wiping with gauze soaked in homemade normal saline (1 tsp salt/500ml water bottle), center to edges, at each dressing change, unless already very clean. Clean wounds will simply be irrigated with normal saline at each dressing change. Patients experienced with using papaya for debridement of their ulcers may apply it only to the open wound, avoiding contact with the periwound, to remove slough or eschar. If patients observe green exudate, they are permitted to add one teaspoon of vinegar to their bottle of saline. Dressings in group (1) will be changed daily. The dressings will be soaked off if they become adherent.
89606741|NCT04479618|Experimental|improvised dressings (experimental)|After initial cleansing/debriding, patients in the improvised dressing group (2) will then have a thin layer zinc oxide paste applied to the dried periwound, carefully avoiding the open wound. A piece of a clean new plastic bag (food-grade World Star 1 mil LD bags, or the equivalent, purchased from the Papine Market across John Golding Road from the University of the West Indies), cut slightly larger than the ulcer will be gently conformed to the moist wound contours and sealed onto the zinc oxide paste. The bag will be fenestrated with a small slit using a number 11 scalpel or clean scissors prior to placing it on the ulcer in order to allow excess fluid to escape. The edges of the slit will be approximated. Clean gauze will be placed lightly over the slit to capture escaping fluid. One wrap of stretch gauze will hold the dressing in place. Patients will be instructed to change the dressings daily, irrigating with normal saline at each dressing change.
89606742|NCT04479618|Active Comparator|advanced dressings (positive control)|"After initial cleansing/debriding, the advanced dressing group (3) will have a cut piece of a 4x24 standard (pink) polymeric membrane dressing roll large enough to extend at least 0.5 cm beyond all open and closed (inflamed or damaged) wound edges applied as per the Instructions for Use (the periwound is blotted dry, but the wound bed remains moist from the final saline rinse). One wrap of stretch gauze will hold the polymeric membrane dressing in place. The approximate open wound edges will be marked on the dressing backing. As per the manufacturer's instructions for use, patients will change the dressings when saturation reaches any of the wound edges, as indicated by a change in color on the backing of the dressing, visible through the stretch gauze. Routine rinsing will not be performed; the wounds will be rinsed at dressing changes only if visible loose debris is present."
88982370|NCT05831657|Active Comparator|Waitlist Portuguese|Participants in the waitlist control will wait thirteen weeks before starting active treatment. While on the waitlist, participants will respond to questions about ongoing problematic sexual behavior in Portuguese
88982371|NCT05831631||Included patients|The study population will comprise 200 (two hundred) adult patients candidate to neurosurgical treatment for newly diagnosed malignant brain tumors, able to express an informed consent.
89606743|NCT04476238|Experimental|Inosine|2 grams of inosine dissolved in 250 ml of tap water
89606744|NCT04476238|Placebo Comparator|Water|250 ml of tap water only
89606745|NCT04476043|Experimental|INCB054707 15 mg|Participants will receive INCB054707 15 milligrams (mg) for 16 weeks in the Placebo-controlled Treatment Period, followed by INCB054707 75 mg for 36 weeks in the Open-label Extension Period. Participants will have the option to continue open-label treatment for an additional 48 weeks.
88982372|NCT05831566|Experimental|Intervention arm (EXACT@home)|"These patients will first undergo the systematic assessment (=EXACT@home) of +/- 6 weeks including a systematic anamnesis, questionnaires and home monitoring with multiple digital devices (digital inhaler, activity tracker, hand-held spirometer and FeNO measuring device) and a Personal Digital Health Environment (PDHE). Based on this evaluation and the degree of asthma control a treatment will be chosen: optimization of treatable traits if present and/or biologics.~The personal digital healthcare environment and digital inhaler will be used for 12 months and the activity tracker, hand-held spirometer and FeNO measuring device will be used for 12 weeks."
88982373|NCT05831566|Active Comparator|Control arm (biologics)|"These patients will immediately receive a biologic after the indication is determined at the regional asthma Multi-Disciplinary Team Meeting (MDTM). These patients also have access to the Personal Digital Health Environment (PDHE) and they will also use the digital inhaler but without being able to see their own results or receiving feedback/reminders (silent).~The personal digital healthcare environment and digital inhaler will be used for 12 months."
88982374|NCT05831527|Experimental|Gut Health Group|Subjects with self-reported digestive issues (abdominal pain, gas production, bloating after meals, or heartburn after meals) Dose: two sachets daily (1g each) mixed with a cold drink, for 12 weeks.
88982375|NCT05831527|Experimental|Exercise Performance Group|Subjects that are physically active three or more days a week. Dose: two sachets daily (1g each) mixed with a cold drink, for 12 weeks.
88982376|NCT05831514|Experimental|Intervention Group|Parents who meet the inclusion criteria will be informed about the study and invited to participate in the study. Verbal and written consent will be obtained from parents who meet the inclusion criteria and agree to participate in the study. In the pretest, the Complications Checklist, Zarit Caregiver Burden Scale, General Self-Efficacy Scale, State/Trait Anxiety Scale are completed by the parents. The mobile application will be introduced to the parents and they will be allowed to download it to their phones. Parents will be ensured to actively use the mobile application for three months. At the first month follow-up, the Complications Checklist, Zarit Caregiver Burden Scale, General Self-Efficacy Scale, State/Trait Anxiety Scale are completed by the parents. In the post-test, the Complications Checklist, Zarit Caregiver Burden Scale, General Self-Efficacy Scale, State/Trait Anxiety Scale are completed by the parents.
89032788|NCT02926872||Entire Study Population|Male or female patients who are between 2 and 16 years of age (inclusive) will be eligible for the study if they meet all components of Criterion A and/or Criterion B below, provided that these abnormalities are of unknown or unconfirmed etiology and the patient has not previously had a normal LAL enzyme activity result, has not received treatment with sebelipase alfa (Kanuma), and has no evidence of neurological dysfunction within the past year. (Note: Female patients who are of childbearing potential or are pregnant may participate in this study.)
89032789|NCT02926794|Experimental|SA and II|Combined self-affirmation and implementations intention arm
89606746|NCT04476043|Experimental|INCB054707 45 mg|Participants will receive INCB054707 45 mg for 16 weeks in the Placebo-controlled Treatment Period, followed by INCB054707 75 mg for 36 weeks in the Open-label Extension Period. Participants will have the option to continue open-label treatment for an additional 48 weeks.
89606747|NCT04476043|Experimental|INCB054707 75 mg|Participants will receive INCB054707 75 mg for 52 weeks in the Placebo-controlled Treatment Period (16 weeks) plus the Open-label Extension Period (36 weeks). Participants will have the option to continue open-label treatment for an additional 48 weeks.
89606748|NCT04476043|Placebo Comparator|Placebo followed by INCB054707 75 mg|Participants will receive placebo for 16 weeks in the Placebo-controlled Treatment Period, followed by INCB054707 75 mg for 36 weeks in the Open-label Extension Period. Participants will have the option to continue open-label treatment for an additional 48 weeks.
89606749|NCT04473534|Experimental|Arm of CBT-I treatment|Web cognitive behavioral therapy was administered before starting CPAP use by a psychologist expert in behavioral sleep medicine and expert in CBT-I. CBT-I was administered according to the same model and standard visual approach in patients with insomnia. Five sessions are scheduled: sleep psycho-education, sleep restriction, stimulus control, sleep hygiene and challenging beliefs and perception of sleep.
89606750|NCT04473534|Experimental|Arm of psycho-education session|Single session of psycho-education about sleep, OSA, insomnia and interaction among them will be administered by web before beginning CPAP use
89032790|NCT02926794|Experimental|SA and No II|Self-affirmation and control intentions condition
89032791|NCT02926794|Experimental|No SA and II|Implementation intentions intervention and control writing task
89606751|NCT04473534|No Intervention|Arm of control TAU (Treatment As Usual)|The control group will receive TAU. Each patient will start to use CPAP after the diagnosis according to AASM (American Academy of Sleep Medicine) guideline.
89606752|NCT04471818|Experimental|Ketamine|Patients allocated to the ketamine arm will receive 0.5 mg/kg of ketamine every week administered intravenously for 4 weeks.
89606753|NCT04471818|Placebo Comparator|Placebo|Patients allocated to the ketamine arm will receive 0.5 mg/kg of ketamine every week administered intravenously for 4 weeks.
89606754|NCT04464434|Experimental|Upfront autologous HSCT|
89606755|NCT04464434|Active Comparator|Immunosuppressive therapy|"12 monthly i.v. pulses CYC 750 mg/m2 (= 9 g/m2 cumulative) followed by at least 12 months of oral MMF daily (3 grams as maximum daily dosage) or mycophenolic acid (up to 2.160 grams daily).~Hyperhydration, alkalinisation of the urine and mesna is recommended, and will be given according to local protocols in order to prevent haemorrhagic cystitis."
89606756|NCT04454658|Experimental|Segment A: ABBV-744 Dose Identification and Optimization|Participants who have been previously treated with Janus Kinase inhibitor(s) (JAKi) and stopped such therapy, will receive different dosing regimens and schedules of ABBV-744 to identify the safe dosing regimen and schedule.
89606757|NCT04454658|Experimental|Segment A: ABBV-744 Monotherapy|Participants will receive the identified safe dosing regimen of ABBV-744 as monotherapy.
89606758|NCT04454658|Experimental|"Segment B: Ruxolitinib + ABBV-744 Add on Therapy"|"Participants whose disease (myelofibrosis) is inadequately controlled by ongoing ruxolitinib therapy will receive ruxolitinib and ABBV-744 as add-on therapy."
89606759|NCT04454658|Experimental|Segment C: ABBV-744 + Navitoclax|Participants who have previously been exposed to JAKi, and stopped such therapy, will receive ABBV-744 and navitoclax.
89606760|NCT04454658|Experimental|Segment D: ABBV-744 + Ruxolitinib|Participants who have never received JAKi will receive ABBV-744 and ruxolitinib.
89606761|NCT04452526|Experimental|ARM I (EARLY INTERVENTION) (educational material, reminders)|Health systems receive educational materials consisting of posters, brochures and handouts. Providers complete survey about HPV knowledge, participate in educational session over 1 hour and receive educational handouts on the HPV vaccine. Patients receive educational materials about HPV vaccine and reminder letters for HPV vaccination
89606762|NCT04452526|Experimental|ARM II (DELAYED INTERVENTION)(education, reminder, usual care)|Health systems, providers, and patients receive usual care for 12 months, then receive multi-level intervention as in Arm I.
89606763|NCT04434482|Experimental|IMP4297(senaparib) and temozolomide|IMP4297 and temozolomide
89606764|NCT04431518|Experimental|Hemodialysis Group|Receipt of JULUCA one pill per day up to 14 days
89606765|NCT04431518|Active Comparator|Normal Renal Function Group|Receipt of JULUCA one pill per day up to 14 days
89606766|NCT04419909|Experimental|Retreatment with CTL019/CTL119|All subjects will receive retreatment with CTL019/CTL119 and be followed per the schedule of procedures.
89032792|NCT02926794|Experimental|No SA and No II|Control writing task and control intentions condition
89032793|NCT00528164|Experimental|Team PLAY Group|6-month family-centered intervention to increase physical activity and healthy eating patterns, primarily directed at parents. Parents will receive intense counseling regarding developmentally appropriate physical activity, strategies for reducing sedentary behaviors, nutritional counseling, and behavioral counseling, including a self-management program to use with their children at home. The group will meet once a week for the initial 8 weeks, bi-weekly for 8 weeks, and monthly for 2 months.
89032794|NCT00528164|No Intervention|Standard Care Group|Participants receive standard care by primary care physician.
89606767|NCT04419870||Group 1a|Patients with mitochondrial disease who are ill with suspected or confirmed COVID19
89606768|NCT04419870||Group 1b|Patients with mitochondrial disease who are NOT ill with acute infection
89606769|NCT04419870||Group 2|Family members of patients with mitochondrial disease in Group 1
89606770|NCT04418843|Experimental|Standard Endoscopic Mucosal Resection|Standard Endoscopic Mucosal Resection, if necessary, multi-piece to resect large nonpedunculated homogeneous colorectal lesions (>20 mm)
89606771|NCT04418843|Experimental|Cold Snare Endoscopic Mucosal Resection|Cold Snare Endoscopic Mucosal Resection, if necessary, multi-piece to resect large nonpedunculated homogeneous colorectal lesions (>20 mm)
89606772|NCT04418765|Placebo Comparator|Placebo|Participants will receive placebo matching to eptinezumab by IV infusion, every 12 weeks starting from Baseline (Day 0) through Week 24.
89606773|NCT04418765|Experimental|Eptinezumab 100 mg|Participants will receive eptinezumab 100 mg by IV infusion, every 12 weeks starting from Baseline (Day 0) through Week 24.
89606774|NCT04418765|Experimental|Eptinezumab 300 mg|Participants will receive eptinezumab 300 mg by IV infusion, every 12 weeks starting from Baseline (Day 0) through Week 24.
89606775|NCT04417634|Experimental|RFR: resting full-cycle ratio|RFR will be used to drive PCI
89606776|NCT04417634|Active Comparator|FFR: fractional flow reserve|FFR will be used to drive PCI
89606777|NCT04416321|Other|Device|All subjects who are entered into this trial will receive the Keos Lumbar Interbody Fusion Device.
89606778|NCT04413461|Experimental|TENS|
89606779|NCT04413461|Placebo Comparator|TENS Sham|
89606780|NCT04399252|Experimental|LGG Arm|Participants in this arm will be given LGG for 28 days.
89606781|NCT04399252|Placebo Comparator|Placebo|Participants in this arm will be given a placebo for 28 days.
89606782|NCT04379687|Experimental|Virtual reality|"st part: Conventional physiotherapy treatment program aimed at achieving functional improvement and increased postural control. 15 minutes~nd part: Experimental training program for static and dynamic balance in sitting and standing by immersive Virtual Reality. 15 minutes"
89606783|NCT04379687|Active Comparator|Control group|"st part: Conventional physiotherapy treatment program aimed at achieving functional improvement and increased postural control.15 minutes~nd part: Training program for static and dynamic balance in sitting and standing, according to Bayouk. 15 minutes"
89606784|NCT04378699|Experimental|SMR Sensory Motor Rhythm (12-15 Hz)|3 X 10 SMR workout sessions (12-15 Hz) C4 unipolar placement, central region
89606785|NCT04378699|Experimental|the alpha band (8 -12Hz)|3 x 10 training sessions of the higher frequencies of the alpha band (8 -12Hz), unipolar placement Fz, fronto-central region
89606786|NCT04378023||Study group|Patients with unresectable hilar cholangiocarcinoma (hCCA) ≤3cm in radial diameter, without evidence of lymph node or distant metastases
89606787|NCT04373837|Experimental|Group 1: Without pre - With post|"Patients will perform two weeks treatment (10 sessions in total). First week: 5 days/week for 1 week, a daily session of pointing with neutral goggles inducing no-adaptation (NA) + Virtual Reality (VR) task (5 sessions).~Second week: 5 days/week for 1 week, a daily session of pointing with prismatic goggles inducing prismatic adaptation (PA) + VR task (5 sessions)."
89606788|NCT04373837|Experimental|Group 2: With pre - Without post|"Patients will perform two weeks treatment (10 sessions in total). First week: 5 days/week for 1 week, a daily session of pointing with prismatic goggles inducing prismatic (PA) + Virtual Reality (VR) task (5 sessions).~Second week: 5 days/week for 1 week, a daily session of pointing with neutral goggles inducing no-adaptation (NA) + VR task (5 sessions)."
89606789|NCT04371666|Experimental|Pamrevlumab|Pamrevlumab 35 milligrams (mg)/kilogram (kg) intravenously (IV) every 2 weeks + systemic deflazacort or equivalent potency of corticosteroids administered orally for up to 52 weeks
89606790|NCT04371666|Placebo Comparator|Placebo|Matching placebo IV every 2 weeks + systemic deflazacort or equivalent potency of corticosteroids administered orally for up to 52 weeks
89606791|NCT04367506|Experimental|BecomeAnEX|Participants will have three individual meetings with a research staff person while they are in the hospital. At these meetings participants will answer questions about their smoking and interest in quitting, learn about BecomeAnEx, and register with the BecomeAnEx program so that they can use it when you leave the hospital. Participants will be given two weeks of nicotine replacement therapy when they leave the hospital. Participants will be asked to use BecomeAnEx as much as they want when they leave the hospital.
89606792|NCT04367506|Active Comparator|Usual Care|Brief individual counseling, NRT during the hospital stay and a prescription for NRT at discharge (consistent with standard hospital procedures), and referral to the MD quitline.
88982377|NCT05831514|No Intervention|Control Group|Parents who meet the inclusion criteria will be informed about the study and invited to participate in the study. Verbal and written consent will be obtained from parents who meet the inclusion criteria and agree to participate in the study. In the pretest, the Complications Checklist, Zarit Caregiver Burden Scale, General Self-Efficacy Scale, State/Trait Anxiety Scale are completed by the parents. At the first month follow-up, the Complications Checklist, Zarit Caregiver Burden Scale, General Self-Efficacy Scale, State/Trait Anxiety Scale are completed by the parents. In the post-test, the Complications Checklist, Zarit Caregiver Burden Scale, General Self-Efficacy Scale, State/Trait Anxiety Scale are completed by the parents.
88982378|NCT05831501|Experimental|TAP block group|At the end of the cesarean section, a TAP block will be given by Injecting of 20ml 0.25% Bupivacaine on both sides of the midline using ultrasound-guided subcostal approach
89606793|NCT04362059|Experimental|Treatment Arm|Patients will be administered surfactant via COVSurf Drug Delivery System
89606794|NCT04362059|Active Comparator|Control Arm|Patients shall receive regular Standard of Care treatment
89606795|NCT04357288|Experimental|Patient Decision Aid|Participants in this arm will use the Patient Decision Aid (PDA), an online education tool about atrial fibrillation designed for patient use, prior to the encounter with their provider.
89606796|NCT04357288|Experimental|Encounter Decision Aid|Participants in this arm will use the Encounter Decision Aid (EDA), an online educational tool about atrial fibrillation designed for patient-provider use, during the encounter with their provider.
88982379|NCT05831501|No Intervention|Placebo group|At the end of the cesarean section, 20 ml of saline will be injected on both sides of the midline
89606797|NCT04357288|Experimental|Patient & Encounter Decision Aids|Participants in this arm will use both the PDA & EDA as described above.
89606798|NCT04357288|No Intervention|Standard Care|Participants in this arm will receive standard care, that is they will not use either the PDA or EDA.
89606799|NCT04338529||Group Alendronate 6m|Postmenopausal Caucasian women who were treated with denosumab and became osteopenic (BMD T-score of > -2.5 at the LS and the non-dominant FN) and were assigned from their treating physician to receive treatment with alendronate in an effervescent tablet formulation for 6 months and then followed for another 6 months without medication. In case serum P1NP levels are > 35μg/L and/or serum CTX levels are > 280 ng/L at 9 months (3 months following alendronate discontinuation) the patients would be strongly advised to restart alendronate treatment.
89606800|NCT04338529||Group Alendronate 12m|Postmenopausal Caucasian women who were treated with denosumab and became osteopenic (BMD T-score of > -2.5 at the LS and the non-dominant FN) and were assigned from their treating physician to receive treatment with alendronate in an effervescent tablet formulation for 12 months.
89606801|NCT04337684||Historical Control|
89606802|NCT04337684||Treated with Copper Histidinate|
89606803|NCT04329767||IRIS Arm|Utilize the CT scan along with the IRIS 3D model preoperatively and intraoperatively
89606804|NCT04329767||CT Arm|Utilize only the standard 2D CT scan preoperatively and intraoperatively
89606805|NCT04310098||CADASIL patients|
89606806|NCT04310098||Asymptomatic carriers of CADASIL|
89606807|NCT04310098||Relatives of CADASIL patients and carriers|
89606808|NCT04310098||Unrelated healthy controls|
89606809|NCT04307212|Active Comparator|Trained|Participants who have been CrossFit training at least 3 times per week for the previous 3 months. These individuals will be invited in person to participate in the study.
89606810|NCT04307212|Active Comparator|Untrained|Nonactive/non--exercise trained participants who have participated in any type of exercise no more than 2 times per week for the past 3 months. These individuals will be recruited from the general public.
89606811|NCT04300205|Experimental|High intensity LED light treatment|Participants treated with high intensity LED phototherapy
89606812|NCT04300205|Experimental|Sham high intensity LED light treatment|Participants set up to be treated with light device but after being masked, the device is moved off the wound
89606813|NCT04283942|Experimental|Intermittent Calorie Restriction (ICR)|Participants in ICR group were instructed to ensure 2 successive days of fasting-mimicking and 5 days of recovery per week. On fasting-mimicking days, the participants were instructed to consume approximately 500 kcal/day and they were provided with plant-based meal replacement (ZhenBaiNian nutrition bar, Beijing Wanlaikang Nutrition and Health Food Science and Technology Research Institute Co., Ltd, China) to improve adherence and ensured adequate intake of micronutrients. In the rest 5 days of recovery per week, participants were allowed to consume their usual diet.
89606814|NCT04283942|Other|Control (Continuous calorie restriction, CCR)|Participants in control group were instructed to consume the prescribed calories (25 kcal / kg × [height (cm) - 100] kg) every day by eating conventional food without time restriction.
89606815|NCT04281992|Experimental|AUP1602-C|AUP1602-C will be administered topically once or repeatedly three times per week during the treatment period.
89606816|NCT04273672||Parkinson's Disease|Subjects with Parkinson's Disease
89606817|NCT04273672||Control|Subjects without Parkinson's Disease
89606818|NCT04262466|Experimental|IMC-F106C - Arm A - Phase 1 and Phase 2|Phase 1 dose escalation and Phase 2 monotherapy dose expansion
89606819|NCT04262466|Experimental|IMC-F106C and an anti-PD(L)1 agent - Arm B - Phase 1|Dose Escalation
88982380|NCT05831462|Active Comparator|Standard dose ticagrelor with aspirin in patients post PPCI for 1 year.|Drug: Ticagrelor 90 mg until 1 year after PPCI (other name: Brillique). Drug: Aspirin 75 mg until 1 year after PPCI.
89606820|NCT04262466|Experimental|IMC-F106C and chemotherapy - Arm C - Phase 1|Dose Escalation
89606821|NCT04262466|Experimental|IMC-F106C and another ImmTAC - Arm D - Phase 1|Dose Escalation
89606822|NCT04259944|Experimental|Liquid Biopsy-Guided Adjuvant Treatment|"A post-surgical LB executed 2-4 weeks after surgery will guide a Molecular Adjuvant treatment:~ctDNA+ patients: CAPOX for 3 months~ctDNA- patients: capecitabine (CAPE) for 6 months. LB after 1 cycle and if found ctDNA+ will be switched to CAPOX.~A post-Molecular Adjuvant treatment LB will be performed and instruct subsequent treatment:~ctDNA+/+ patients: up-scale to a Molecular Metastatic treatment with FOLFIRI for 6 months or until radiological progression or toxicity;~ctDNA-/+ patients: up-scale to a Molecular Metastatic treatment with CAPOX for 6 months or until radiological progression or toxicity. LB after 3 months at the end of treatment and in case of positivity switch to FOLFIRI.~ctDNA+/- patients: de-escalate treatment to CAPE for 3 months. 3 LB performed within 3 months and in case of positivity switch to FOLFIRI.~ctDNA-/- patients: interventional follow-up comprising 2 further LB and in case of positivity switch to CAPOX treatment."
89606823|NCT04256941|Experimental|Arm I (ribociclib, palbociclib, abemaciclib, fulvestrant)|Patients receive ribociclib PO QD, palbociclib PO QD on days 1-21, and/or abemaciclib PO BID on days 1-28. Patients also receive fulvestrant IM for 2 injections over 1-2 minutes each on days 1 and 15 of cycle 1 and day 2 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89606824|NCT04256941|Active Comparator|Arm II (ribociclib, palbociclib, abemaciclib, letrozole)|Patients receive ribociclib orally PO QD, palbociclib PO QD on days 1-21, and/or abemaciclib PO BID on days 1-28. Patients also receive letrozole PO QD or anastrozole PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89606825|NCT04254692|Active Comparator|Liposomal Bupivacaine|Participants in this study arm will receive intraoperative injection of Liposomal Bupivacaine mixed with Bupivacaine to the abdominal wall.
88982381|NCT05831462|Experimental|Low-dose Ticagrelor with aspirin in patients post PPCI|"Patients will recieve the following antiplatlet therapy:~Ticagrelor 2x90 mg + aspirin 1x 75 during the first three months post PPCI.~Ticagrelor 2x60 mg + aspirin 1x 75 after the first three months post PPCI until one year post PPCI."
88982382|NCT05831397||Breast cancer patients candidate for neoadjuvant chemotherapy|Female patients diagnosed with breast cancer, at any TNM stage, who are candidate to neoadjuvant treatment.
88982383|NCT05831397||Healty control|Control group (sex and age matched): healthy volunteers, not affected by breast cancer (with negative mammography, breast ultrasound or breast examination within 12 months of the study enrolment).
88982384|NCT05831345|Active Comparator|S Group|Patients receiving sufentanil during induction of general anesthesia
88982385|NCT05831345|Experimental|M Group|Patients receiving methadone during induction of general anesthesia
88982386|NCT05831267|Experimental|Study group 1|
88982387|NCT05831267|Experimental|Study group 2|
88982388|NCT05831267|Other|Control group|
88982389|NCT05831254|Experimental|HEalth Literacy, e-Pulse (HELP)|
88982390|NCT05831254|Active Comparator|e-Pulse|
88982391|NCT05831137|Experimental|intervention side|duration of intercostal nerves cryolesia: 1 minute per left nerve
88982392|NCT05831137|No Intervention|control side|duration of intercostal nerves cryolesia: 2 minute per right nerve
89606826|NCT04254692|Other|Bupivacaine|Participants in this study arm will receive intraoperative injection of bupivacaine without Liposomal bupivacaine to the abdominal wall.
89606827|NCT04250857||Suspected Sudden Cardiac Arrest|All subject with suspected of a circulatory arrest for any cause.
89606828|NCT04240808|Experimental|UCD19 CAR T Cells|Participants will receive lymphodepleting chemotherapy followed by infusion of UCD19 CAR T Cells (Lentiviral Vector [LV] Transduced Autologous Peripheral Blood Lymphocytes
89606829|NCT04238676|Experimental|PP353|
89606830|NCT04238676|Placebo Comparator|Sham injection|
89606831|NCT04230590||Participants with schizophrenia spectrum disorders|Within 8 weeks post discharge from hospitalization at the Institute of Mental Health
89606832|NCT04225585|Experimental|Coping Skills Training for Persistent Post-Surgical Pain|novel pain coping skills training intervention designed specifically for people with persistent pain (PP) following breast cancer surgery
89606833|NCT04225585|Active Comparator|General health education with a coach|general health education intervention
89606834|NCT04225585|Active Comparator|Self-guided health education|general health education intervention
89606835|NCT04222257|Experimental|Short course|Patients allocated to this group will receive a short course of antibiotic therapy for 2 weeks.
89606836|NCT04222257|Active Comparator|Standard course|Those patients allocated to continue with standard parenteral treatment will maintain the same antibiotic treatment for 4 to 6 weeks.
89606837|NCT04216472|Experimental|Treatment (alpelisib, nab-paclitaxel)|Patients receive alpelisib PO QD on days 1-21, and nab-paclitaxel IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients may then undergo surgery to remove the tumor.
89606838|NCT04212364|Experimental|Peer Education|"During Session 1, participants will be trained in Peer Education and how to use Nasal Narcan. They will be given two Nasal Narcan kit that includes 2 doses. One kit if for their use and one kit is to give someone in their social network after they have trained them in how to use it.~A week after Session 1, participants will be scheduled for Session 2.~During session 1 and 2 participants, Index participants will be taught information and skills pertaining to overdose prevention and response and how to train network members in overdose prevention and response.~At the 2nd session, index participants will be given 1 coupon to give to 1 member from their social network to attend Session 3.~Session 3 will be a dyad session where Index participants will use their peer mentors' skills to train their network member in overdose prevention and response.~Index participants will also be invited to up to 3 Booster Session (monthly) after they complete Sessions 1-3."
89606839|NCT04212364|Active Comparator|Standard of care|"Participants randomized to this condition will participate in one 1-hour session. This session will be an individual session where the participant will meet with a trained staff member in a private room at the Lighthouse.~This session will be standard overdose prevention and response information. Participants will also be trained in Narcan administration. Participants will be given 1 nasal Narcan kit.~At the end of this session, participants will be asked to refer a network member to the study for survey visits"
89606840|NCT04212169|Experimental|MEDI3506 at dose level 1|Participant will receive multiple doses of MEDI3506 at dose level 1.
89606841|NCT04212169|Experimental|MEDI3506 at dose level 2|Participant will receive multiple doses of MEDI3506 at dose level 2.
89606842|NCT04212169|Experimental|MEDI3506 at dose level 3|Participant will receive multiple doses of MEDI3506 at dose level 3.
89606843|NCT04212169|Placebo Comparator|Placebo|Participant will receive multiple doses of Placebo
89606844|NCT04205643|Experimental|CT-P13 SC|
89606845|NCT04205643|Placebo Comparator|Placebo SC|
89606846|NCT04193072||Obstetric brachial plexus palsy|
89606847|NCT04193072||Healthy|
89606848|NCT04184050|Experimental|HPN217 monotherapy dose escalation|HPN217 is IV administered once weekly for about 1 hour. Doses will vary between cohorts as MTD and/or RP2D[s] is being determined.
89606849|NCT04184050|Experimental|HPN217 dose escalation with extended dosing intervals|HPN217 is IV administered either once bi-weekly or weekly for the first cycle followed by a bi-weekly schedule for about 1 hour. Doses will vary between cohorts as MTD and/or RP2D[s] is being determined.
89606850|NCT04176120|Experimental|TTAX01|TTAX01 plus standard care
89606851|NCT04176120|Other|Control|Standard Care alone
88982393|NCT05831072|Experimental|Mindfulness-cognitive oriented group|Participants will receive a 4-week intervention of mindfulness-cognitive oriented group program.
88982394|NCT05831059|Experimental|A group|First receive pulse radio frequency treatment and then receive sham operation treatment
88982395|NCT05831059|Active Comparator|B group|First receive sham operation treatment and then receive pulse radio frequency treatment
88982396|NCT05831033|Experimental|BEN101|BEN101 infusion single dose level between 1x10^9 to 1x 10^11，not lower than 1×10^9 cells, final dose is affected by the starting amount of TILs cells isolated from the tumor tissue sample.
88982397|NCT05831020|Active Comparator|Group A (VAC group)|For Group A, VAC dressing was placed to secure split thickness skin graft. Two sheets of sterilized VAC sponge that was cut to fit the wound contour were placed with a fenestrated tube between the two layers that was secured to the surrounding skin using tincture of benzoin spray and an adhesive dressing (OPSITE). The VAC was placed to intermittent -125 mmHg suction for 2 hours and then decompressed for next 2 hours.
88982398|NCT05831020|Active Comparator|Group B (Bolster dressing group)|For Group B, Bolster dressing was done to secure split thickness skin graft. The recipient site was bolstered with wet bulky cotton gauze dressing and wrapped with cotton bandage. 0.9% normal saline was used for moisture.
88982399|NCT05831007|Experimental|LX102-C01 Injection|"Potential doses:~3E10 vg, 0.06 mL/eye/dose~1E11 vg, 0.06 mL/eye/dose"
88982400|NCT05830994|Active Comparator|G-POEM procedure|Gastric peroral endoscopic myotomy
89606852|NCT04169282|Experimental|nPEP Recipients|Single-patient, adjustable expiratory resistance device that provides positive pressure (5 to 20 cm H2O) during expiration
89606853|NCT04166097|Experimental|Heart Smart Interventional Program|"Subjects participate in this 6-week intervention which include a weekly didactic session, with each week devoted to a different theme (food, exercise, etc). The intervention will follow the program outlined in the book Heart Smart for Women: Six S. T. E. P. S. in Six Weeks to Heart-Healthy Living."
89606854|NCT04157361||Asthma|Children/adults with moderate or IgE mediated asthma with inhaled and/or food allergies before and during inhaled corticosteroid, leukotriene modifiers or long-acting beta agonists treatment.
89606855|NCT04157361||Cystic fibrosis|Children/adults with cystic fibrosis before and after antibiotics treatment and during clinical deterioration.
89606856|NCT04157361||Healthy control|Healthy control children/adults without chronic or autoimmune disease
89606857|NCT04145440|Experimental|Cohort 1|Patients with newly diagnosed or relapsed membranous nephropathy
89606858|NCT04145440|Experimental|Cohort 2|Patients with membranous nephropathy refractory to immunosuppressive treatment
89606859|NCT04144751||Subjects Enrolled in 2019-01 BLUE-C|Subjects will be men and women, 40 years of age or older, who enroll in Exact Sciences Protocol 2019-01 BLUE-C. Subjects will provide a blood sample at time of enrollment.
89606860|NCT04144179|Experimental|Quadrivalent RIV with H3 strain 1|1 injection of Quadrivalent RIV containing H3 strain 1
89606861|NCT04144179|Experimental|Quadrivalent RIV with H3 strain 2|1 injection of Quadrivalent RIV containing H3 strain 2
89606862|NCT04144179|Experimental|Quadrivalent RIV with H3 strain 3|1 injection of Quadrivalent RIV containing H3 strain 3
89606863|NCT04144179|Experimental|Quadrivalent RIV with H3 strain 4|1 injection of Quadrivalent RIV containing H3 strain 4
89606864|NCT04144179|Active Comparator|Quadrivalent RIV Control|1 injection of Quadrivalent RIV containing 2018-19 NH recommended H3 strain
89606865|NCT04127227|Experimental|Sintilimab With P-GemOx|Sintilimab, 200mg, d1, intravenous drip; pegaspargase, 2000U/m2, d1, intravenous drip; gemcitabine, 1000mg/m2, d1,d8, intravenous drip; oxaliplatin, 130mg/m2, d1, intravenous drip; All patients received up to 6 treatment cycles of 21 days. Patients with CR or PR will receive Sintilimab maintenance therapy.
89606866|NCT04120935||Cohort of CRC patients|Stage-mixed cohort of at least 500 patients through their course of treatments, until death or a minimum of 5 years.
89606867|NCT04110353|Active Comparator|Conservative dressings|Use of simple dressings on wound post operatively - to be placed at end of operation
89606868|NCT04110353|Active Comparator|Prevena dressing|Use of Prevena(KCI) dressing on wound post operatively - to be placed at end of operation
89606869|NCT04110353|Active Comparator|ciVAC dressing|Use of closed incision VAC (vacuum assisted closure) dressing on wound post operatively - to be placed at end of operation
89606870|NCT04109313|Experimental|All participants|"Participants with UAS7<16 at Week 16 of CLOU064A2201 were followed up to 12 weeks without receiving treatment (observational period). If participants relapsed (UAS7≥16 at least once), they were transitioned to the treatment period. Otherwise, they were discontinued from the study.~Participants with a UAS7≥16 at Week 12 or Week 16 in the CLOU064A2201, as well as participants who experienced a relapse during the 12-week observational period, were administered 100 mg of LOU064 b.i.d. open-label for up to 52 weeks."
89606871|NCT04103580|No Intervention|Control|Will receive usual hospice care plus measures
89606872|NCT04103580|Experimental|Intervention|Will receive photo elicitation intervention and will join a secret Facebook group to share photos with other caregivers
89606873|NCT04099940|Experimental|Virtual Reality Avatar Therapy (VRAT)|In the VRAT, patients with schizophrenia and acoustic hallucinations design a visual and auditory recreation (avatar) of the entity to which they attribute their hallucinations. Working with a therapist over the course of several sessions, participants change the avatar from controlling to benevolent.
89606874|NCT04099940|Active Comparator|Assertiveness Training Program (ATP)|The ATP is a transdiagnostic cognitive behavioural treatment programme, which aims to increase self-confidence and social competence in patients with a psychiatric disorder.
89606875|NCT04097418|Experimental|Aerobic training in healthy subjects|"For each healthy subject, the treatment will lasts 8 weeks. Each treatment will consists of 35 minutes of training, administered 3 times per week.~Subjects of the experimental groups (both patients and healthy controls) will carry out an aerobic training of moderate intensity (fixed time and variable intensity) on a treadmill. The training will be set individually via direct method: during the first session, the subject will be trained at an intensity that gets the heart rate (HR) corresponding to 46-63% of VO2 peak measured during the exercise test; in subsequent sessions the intensity will increase to maintain the same HR, which will be always monitored. The intensity workout identified will be maintained for 30 minutes each session, preceded and followed by a few minutes of warm-up and cool-down."
89606876|NCT04097418|Active Comparator|Conventional motor training of healthy subjects|"For each healthy subject, the treatment will lasts 8 weeks. Each treatment will consists of 35 minutes of training, administered 3 times per week.~Control groups of both patients and healthy subjects will follow a conventional non-aerobic physiotherapy training, structured in: 15 minutes of passive mobilization of upper and lower limbs and spine, 5 minutes of stretching of the upper and the lower limbs and 10 minutes of balance training."
89606877|NCT04097418|Experimental|Aerobic training in MS patients|"For each MS patient, the treatment will lasts 8 weeks. Each treatment will consists of 35 minutes of training, administered 3 times per week.~Subjects of the experimental groups (both patients and healthy controls) will carry out an aerobic training of moderate intensity (fixed time and variable intensity) on a treadmill. The training will be set individually via direct method: during the first session, the subject will be trained at an intensity that gets the heart rate (HR) corresponding to 46-63% of VO2 peak measured during the exercise test; in subsequent sessions the intensity will increase to maintain the same HR, which will be always monitored. The intensity workout identified will be maintained for 30 minutes each session, preceded and followed by a few minutes of warm-up and cool-down."
89606878|NCT04097418|Active Comparator|Conventional motor training of MS patients|"For each MS patient, the treatment will lasts 8 weeks. Each treatment will consists of 35 minutes of training, administered 3 times per week.~Control groups of both patients and healthy subjects will follow a conventional non-aerobic physiotherapy training, structured in: 15 minutes of passive mobilization of upper and lower limbs and spine, 5 minutes of stretching of the upper and the lower limbs and 10 minutes of balance training."
89606879|NCT04096625|Experimental|Active tDCS|Active tDCS will be delivered at 2mA for 20 minutes.
89606880|NCT04096625|Sham Comparator|Sham tDCS|Sham tDCS: after 40 seconds of stimulation (2mA), a small current pulse was delivered every 550 msec (110 muA over 15 msec).
89606881|NCT04089865|Experimental|Oral Tranexamic Acid (TXA)|100 Total Hip Arthroplasty (THA) and 100 Total Knee Arthroplasty (TKA) patients will be randomized to receive 1950 mg of oral TXA in the pre-operative area.
89606882|NCT04089865|Active Comparator|Intravenous (IV) Tranexamic Acid (TXA)|100 Total Hip Arthroplasty (THA) and 100 Total Knee Arthroplasty (TKA) patients will be randomized to receive 1 g of intravenous (IV) TXA upon transfer to the operating room.
89606883|NCT04088773||Aim 1 Crohn Disease participants (B2 phenotype)|Crohn's Disease participants scheduled for ileal small bowel resection; No intervention; observational only; collection of blood, stool, and perform MRI; completion of Crohn's Activity Questionnaire
89606884|NCT04088773||Aim 2 Crohn Disease participants (B1 phenotype)|Crohn's Disease participants with uncomplicated small bowel disease; No intervention; observational only; collection of blood, stool, and perform MRI; completion of Crohn's Activity Questionnaire
89606885|NCT04088773||Aim 2 Healthy Controls|No intervention; observational only; collection of blood, stool, and completion of Gastrointestinal Symptoms Rating Scale
89606886|NCT04075305||Brain cancer|
89606887|NCT04075305||Lung cancer|
89532747|NCT05989815|Sham Comparator|PBMT placebo (PBMT-sham)|"Group submitted to pre-exercise and post-exercise photobiomodulation therapy (PBMT) Sham (placebo).~PBMT will be administered using the Joovv Elite System, which has 6 panels of red Light-Emiting Diodes(LEDs) (660±10nm) and 74 panels of infrared LEDs (850±10nm), totaling 900 LEDs covering an area of 12,193 cm². Athletes will stand 20 cm in front of the device, wearing only swim shorts to expose their thigh muscles and other body areas to the light. The total irradiation time will be 20 minutes, with 10 minutes (600 seconds) of irradiation for the anterior region and another 10 minutes (600 seconds) for the posterior region. The Sham PBMT dose applied in each region (anterior or posterior) will be 0 J/cm², with an irradiance of 0 mW/cm²."
89532748|NCT05987241|Active Comparator|Cohort A, Arm I (nivolumab)|Patients in Cohort A, Arm I receive nivolumab IV over 30 minutes on day 1 of each cycle. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of tissue during screening and collection of blood throughout the trial. Patients also undergo CT or MRI scans throughout the trial.
89532749|NCT05987241|Experimental|Cohort A, Arm II (nivolumab, relatlimab)|Patients in Cohort A, Arm II receive nivolumab IV over 30 minutes and relatlimab IV over 30 minutes on day 1 of each cycle. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of tissue during screening and collection of blood throughout the trial. Patients also undergo CT or MRI scans throughout the trial.
89532750|NCT05987241|Active Comparator|Cohort B, Arm III (nivolumab)|Patients in Cohort B, Arm III receive nivolumab IV over 30 minutes on day 1 of each cycle. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of tissue during screening and collection of blood throughout the trial. Patients also undergo CT or MRI scans throughout the trial.
89532751|NCT05987241|Experimental|Cohort B, Arm IV (ctDNA surveillance, nivolumab)|Patients in Cohort B, Arm IV undergo ctDNA surveillance consisting of collection of tissue and blood during screening and collection of blood only on study and during follow up. Patients who convert to ctDNA(+) during surveillance then receive nivolumab IV over 30 minutes and relatlimab IV over 30 minutes on day 1 of each cycle. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI scans throughout the trial.
89532752|NCT05986071|Experimental|study arm|administration of M1774 in combination with fulvestrant
89532753|NCT05983250|Placebo Comparator|Placebo|Placebo
89532754|NCT05983250|Active Comparator|TNX-103|levosimendan
89532755|NCT05982678|Experimental|Trastuzumab-deruxtecan|5.4mg/kg on a three weekly (21 day) basis, with the goal of 16 cycles leading to a treatment period of year, including local treatment. The first 8 cycles of T-DXd are administered neo-adjuvant, and 8 cycles adjuvant, after completion of local treatment.
89532756|NCT05980195|Experimental|Hyperbaric oxygen therapy plus standard medical treatment|Patients will receive hyperbaric oxygen therapy plus standard medical treatment after stenting
89532757|NCT05980195|Active Comparator|Standard medical treatment|Patients will receive standard medical treatment after stenting
89532758|NCT05979129|Active Comparator|ZEEP group|
89532759|NCT05979129|Active Comparator|Low PEEP|
89532760|NCT05979129|Active Comparator|High PEEP|
89532761|NCT05972993|Experimental|Part A, Group 1: mRNA CR-04 10 µg +Placebo|mRNA 10 micrograms (µg) or placebo administered on day 1.
89532762|NCT05972993|Experimental|Part A, Group 2: mRNA CR-04 30 µg +Placebo|mRNA 30µg or placebo administered on day 1.
89532763|NCT05972993|Experimental|Part A, Group 3: mRNA CR-04 100 µg +Placebo|mRNA 100µg or placebo administered on day 1.
89532764|NCT05972993|Experimental|Part B: mRNA CR-04 3 µg|mRNA 3 µg administered on day 1.
89532765|NCT05972993|Experimental|Part B: mRNA CR-04 10 µg|mRNA 10µg administered on day 1.
89532766|NCT05972993|Placebo Comparator|Part B: Placebo|Placebo administered on day 1.
89532767|NCT05972083|Active Comparator|Group S = SPSIPB group|A high-frequency linear US probe (11-12 MHz, Vivid Q) will be covered with a sterile sheath, and an 80 mm block needle (Braun 360°) will be used. The procedure will be performed with the patient in the lateral decubitus position. After the scapula is shifted slightly laterally, the US probe is placed sagittal at the upper corner of the spina scapula, and the serratus posterior superior muscle is visualized with the third rib. The in-plane technique will be used. The block needle will be advanced in the craniocaudal direction to enter between the serratus posterior superior and the third rib. The block location will be confirmed by injecting 5 ml of saline between the rib and the muscle. After the block location is confirmed, 30 ml of 0.25% concentration bupivacaine will be used.
89532768|NCT05972083|Other|Group C = Control group|The wound infiltration with 30 ml of 0.25% concentration of bupivacaine will be performed by the surgical team.
89532769|NCT05971160|Active Comparator|Usual Care|Monthly financial education videos and one-time microgrant
89532770|NCT05971160|Active Comparator|Monthly microgrants|Monthly financial education videos and monthly microgrants
89532771|NCT05971160|Active Comparator|Monthly microgrants plus peer mentoring|Monthly financial education videos, monthly microgrants, and peer mentoring support
89532772|NCT05968430|Experimental|Open-Label Arm|lorundrostat once daily for 48 weeks
89532773|NCT05968430|Experimental|Maintenance Arm|lorundrostat once daily for 4 weeks in the double-blind randomized treatment withdrawal sub-study
89532774|NCT05968430|Experimental|Taper Arm|lorundrostat and/or placebo once daily for 4 weeks in the double-blind randomized treatment withdrawal sub-study
89532775|NCT05968430|Placebo Comparator|Placebo|Placebo once daily for 4 weeks in the double-blind randomized treatment withdrawal sub-study
89532776|NCT05966311|Experimental|Percutaneous Ultrasound Gastrostomy (PUG)|Enrolled subjects will receive the PUG procedure using the PUMA-G Pediatric System performed by an Interventional Radiologist
89532777|NCT05966311|No Intervention|Percutaneous Radiologic Gastrostomy|A matched, retrospective control cohort of patients previously admitted to hospital for the placement of gastrostomy tubes by Interventional Radiology will be used to compare performance of the PUMA-G Pediatric System to standard of care.
89606888|NCT04075305||Esophageal cancer|
89606889|NCT04075305||Breast Cancer|
89606890|NCT04075305||Head and Neck Cancer|
89606891|NCT04075305||Pancreatic cancer|
89606892|NCT04075305||Gynecological cancer|
89606893|NCT04075305||Rectal cancer|
89606894|NCT04075305||Prostate cancer|
89606895|NCT04075305||Bladder cancer|
89606896|NCT04075305||Oligometastases|
89606897|NCT04075305||Liver cancer|
89606898|NCT04075305||Other types of cancer|
89606899|NCT04074993|Experimental|Brigatinib|Subject will be treated with Brigatinib 90mg/day for 1 week and then 180mg/day PO daily. A Cycle will be defined as 28-days. Treatment will be continued until disease progression or unacceptable toxicity.
89606900|NCT04062708|Experimental|Treatment|Combined neoadjuvant platinum doublet chemotherapy plus durvalumab followed by surgery, postoperative radiation and adjuvant durvalumab for 13 cycles.
89606901|NCT04059185|Experimental|Program 1|Triple P-Level 2 (TPL2), parenting education and consultation
89606902|NCT04059185|Experimental|Program 2|Play Nicely (PN), multimedia, computer-based parenting education
89606903|NCT04059185|Placebo Comparator|Control|"Our usual care control group participants receive a resource and referral list for local social services"
89606904|NCT04047992|Experimental|Exoskeleton Users|All participants will receive 36 sessions of supervised EAW training using Indego™ for 12 weeks (3 to 4 sessions per week, 4-6 hours per week). The goal is to complete all 36 sessions in 12 weeks, but allowing for a two-week carryover to accommodate schedule conflicts or missed sessions.
89606905|NCT04046445|Experimental|Cohort 1a|6 patients with stage IV CRC who failed SoC therapies
89606906|NCT04046445|Experimental|Cohort 1b|6 patients with stage IV MSS/MMRp CRC in SD or PR after first line of SoC
89606907|NCT04046445|Experimental|Cohort 2a|5 patients with stage IV MSS/MMRp CRC in SD or PR after first line of SoC
89606908|NCT04046445|Experimental|Cohort 2b|15 patients with stage IV MSS/MMRp CRC with liver-limited disease
89606909|NCT04046445|Experimental|Cohort 2c|19 patients with stage IV MSS/MMRp CRC in SD or PR after first line of SoC
89606910|NCT04046445|Experimental|Cohort 3|6 patients with stage IV MSS/MMRp CRC in SD or PR after first line of SoC
89606911|NCT04046445|Experimental|Cohort 4a|24 patients with stage IV MSS/MMRp CRC in SD or PR after first line of SoC
89606912|NCT04046445|Experimental|Cohort 4b|15 patients with stage IV MSS/MMRp CRC with liver-limited disease
89606913|NCT04036435|Experimental|BMS-986165|
89606914|NCT04035447|Experimental|Behavioral Symptom Management for Young Adult Cancer Survivors|The intervention provides systematic training in cognitive and behavioral coping skills (e.g., activity-rest cycling, cognitive defusion, relaxation training) delivered over the course of 8 sessions (12 therapy hours). By employing these strategies, participants learn to adjust their behaviors and emotions as well as interact differently with their thoughts in the service of better managing symptoms.
89606915|NCT04035447|Active Comparator|Waitlist Control|Waitlist control participants will receive the intervention and receive systematic training in cognitive and behavioral coping skills approximately 6 months into their participation in the study.
89606916|NCT04033211||Novosyn® CHD|A population undergoing a primary emergency or early elective (24h - 7 days) laparoscopic appendectomy or a primary emergency or early elective laparoscopic cholecystectomy using Novosyn® CHD suture for fascia and skin closure of trocar wounds.
89606917|NCT04033211||Novosyn®|A population undergoing a primary emergency or early elective (24h - 7 days) laparoscopic appendectomy or a primary emergency or early elective laparoscopic cholecystectomy using either Novosyn® suture for fascia and skin closure of trocar wounds.
89606918|NCT04033107|Experimental|Treatment arm|Vitamin C combined with metformin
89606919|NCT04030312|Active Comparator|Standard Infant Formula|Infants in this randomized treatment arm will receive bottle supplementation of up to 15 milliliters of standard 20 calorie-per-ounce infant formula up to two times during the duration of the study to treat hypoglycemia.
89606920|NCT04030312|Experimental|Commercially-Sterilized Donor Human Milk|Infants in this randomized treatment arm will receive bottle supplementation of up to 15 milliliters of 20 calorie-per-ounce commercially-sterilized donor human milk up to two times during the duration of the study to treat hypoglycemia.
89606921|NCT04029129|Experimental|High exposure|Ambient air was allowed freely into the room.
89606922|NCT04029129|Experimental|Medium exposure|Limited air filtration was used to partially reduce levels of pollution in the room relative to outside.
89606923|NCT04029129|Experimental|Low exposure|Doors and windows were closed and sealed and full filtration was used to maximally reduce pollution in the room.
89606924|NCT04028310|Experimental|Phonological group|
89606925|NCT04028310|Experimental|visual-attention group|
89606926|NCT04025957|Experimental|SHR-1501 dose escalation|SHR-1501 given subcutaneously
89606927|NCT04025957|Experimental|SHR-1501 dose expansion|SHR-1501 given subcutaneously
89606928|NCT04021316|Active Comparator|Standard care arm|Compression bandaging therapy as per standard care
89606929|NCT04021316|Experimental|DCD Arm|DCD graft plus compression bandaging therapy as per standard care
89606930|NCT04017832|Experimental|Oral semaglutide 3 mg and placebo (sitagliptin)|Oral semaglutide tablets 3 mg and sitagliptin placebo tablets for 26 weeks
89606931|NCT04017832|Experimental|Oral semaglutide 7 mg and placebo (sitagliptin)|Oral semaglutide tablets and sitagliptin placebo tablets. The dose of oral semaglutide will be escalated over 4 weeks, after which the target dose of 7 mg is taken for 22 weeks
89606932|NCT04017832|Experimental|Oral semaglutide 14 mg and placebo (sitagliptin)|Oral semaglutide tablets and sitagliptin placebo tablets. The dose of oral semaglutide will be escalated over 8 weeks, after which the target dose of 14 mg is taken for 18 weeks
89606933|NCT04017832|Experimental|Sitagliptin 100 mg and placebo (oral semaglutide)|Sitagliptin tablets and oral semaglutide placebo tablets for 26 weeks
89606934|NCT04006262|Experimental|Experimental arm|"Neo-adjuvant treatment (6 cycles - 12 weeks)~Surgery~Adjuvant treatment (9 cycles - 9 months)"
89606935|NCT04005378|Other|CSC Step-down intervention|Web-based telemedicine and a smartphone app, to decrease disengagement likelihood
89606936|NCT04005378|Other|Usual Care|Usual care provided by CSC center
89606937|NCT03999515|Experimental|Treatment (abiraterone acetate, enzalutamide, erdafitinib)|Patients receive abiraterone acetate orally PO QD or enzalutamide PO QD on days 1-21. Patients also receive erdafitinib PO QD on days 1-21. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity.
89606938|NCT03995472|Experimental|SHR-1501 and SHR-1316 dose escalation|SHR-1501 given subcutaneously with different doses. SHR-1316 given intravenously.
89606939|NCT03995472|Experimental|SHR-1501 and SHR-1316 dose expansion|SHR-1501 given subcutaneously with different doses. SHR-1316 given intravenously.
89606940|NCT03995472|Experimental|SHR-1501 and SHR-1316 Indication expansion|SHR-1501 given subcutaneously with a recommended dose. SHR-1316 given intravenously.
89606941|NCT03994952||Uninjured Physically Active Young Adults|"This is a group of physically active, and currently uninjured young adults. They will complete a single balance assessment, the modified balance error scoring system protocol, as outlined by the Sway Balance application.~There is no comparison group for this investigation."
89606942|NCT03980626|Experimental|Walking Intervention|Walking participants will engage in the 3-times weekly walking program for 12 weeks.
89606943|NCT03980626|No Intervention|Usual Care|Usual care participants will be offered two personalized exercise sessions with a trained exercise specialist after all post-intervention data have been collected.
89606944|NCT03980262|Experimental|Healthy Children, Healthy Families+ (HCHF+)|HCHF+ integrates healthful eating and physical activity with parenting education (parent role modeling and child feeding practices) and was recently shown to improve parent and child nutrition behaviors for participants in the Expanded Food and Nutrition Education (EFNEP) program. OrganWise Guys (OWG) will be used for children in first and second grades (ages 6-8). Choose Health: Food, Fun and Fitness (CHFF), developed by Cornell University, will be used for children in grades three through five (ages 8-10). HCHF+ includes 9 sessions to be delivered weekly.
89606945|NCT03980262|Active Comparator|MoneySmart|A financial education program available through the Federal Deposit Insurance Corporation. Money Smart includes programs for adults and school-aged children, a parent/caregiver guide and a train-the-trainer program. MoneySmart is an Extension-approved program designed to improve money-management practices and financial confidence for parents MoneySmart involves eight weekly sessions that includes one-to-two hour modules with take-home guides for adults. For children, there are eight sessions that include take-home worksheets and a parent/caregiver guide.
89606946|NCT03978611|Experimental|Part 1: Dose Escalation Phase|
88982401|NCT05830994|Placebo Comparator|Sham procedure|sham endsocopy with biopsy
88982402|NCT05830916||ITP with thrombosis|"History taking including any medical history, family history, drug intake, arterial or venous thrombotic events.~Venous blood samples will be collected by vein puncture under aseptic precautions for:~Routine laboratory investigations:~Complete blood picture with assessment of platelet count. Coagulation tests including prothrombin time (PT), activated partial thromboplastin time (APTT), fibrinogen and D-dimer.~Liver and Kidney functions test.~Specific laboratory investigations:~Antiphospholipid antibodies assay which includes:~Lupus anticoagulant (LA) by diluted Russel viper venom method. Anti β2glycoprotien І (β2GPІ), by enzyme-linked immunosorbent assay (ELISA). Anticardiolipin by (ELISA).~Detection of Microparticles and their subtypes by flow cytometry:~Annexin-v for all microparticles. CD 41 for platelet microparticles. CD 146 for endothelial microparticles."
88982403|NCT05830916||ITP without thrombosis|"History taking including any medical history, family history, drug intake, arterial or venous thrombotic events.~Venous blood samples will be collected by vein puncture under aseptic precautions for:~Routine laboratory investigations:~Complete blood picture with assessment of platelet count. Coagulation tests including prothrombin time (PT), activated partial thromboplastin time (APTT), fibrinogen and D-dimer.~Liver and Kidney functions test.~B- Specific laboratory investigations:~Antiphospholipid antibodies assay which includes:~Lupus anticoagulant (LA) by diluted Russel viper venom method. Anti β2glycoprotien І (β2GPІ), by enzyme-linked immunosorbent assay (ELISA). Anticardiolipin by (ELISA).~Detection of Microparticles and their subtypes by flow cytometry:~Annexin-v for all microparticles. CD 41 for platelet microparticles. CD 146 for endothelial microparticles."
88982404|NCT05830812||adenocarcinoma in situ|Adenocarcinoma in situ is defined as a small (≤3 cm) localized nodule with lepidic growth, mostly non-mucinous.
88982405|NCT05830812||minimally invasive adenocarcinoma|Minimally invasive adenocarcinoma defined as a small (≤3 cm) solitary adenocarcinoma with a predominantly lepidic pattern and ≤5 mm invasion in greatest dimension.
88982406|NCT05830812||invasive adenocarcinoma|Invasive adenocarcinoma is a malignant epithelial tumor with glandular differentiation, mucin production, or pneumocyte marker expression. The tumors show an acinar, papillary, micropapillary, lepidic, or solid growth pattern, with either mucin or pneumocyte marker expression. The invasive ademocarcinoma component should be present in at least one focus measuring >5mm in greatest dimension.
88982407|NCT05830786|Experimental|Immersive virtual reality (IVR) group|The experimental group will experience various surgical training modules using immersive virtual reality.
88982408|NCT05830786|Active Comparator|Traditional hands on orthopaedic workshop group|Hands-on orthopaedic workshop sessions (including arthroscopy simulators, cadaveric models, and Sawbones®) in differing orthopaedic subspecialties (including sports, arthroplasty, and spine surgery).
88982409|NCT05830760|Experimental|patients with aortic valve stenosis with heart failure|
88982410|NCT05830760|Experimental|patients with aortic valve stenosis without heart failure|
88982411|NCT05830747|Experimental|Prednisone group (PG)|Patients receiving a preoperative administration of prednisone 25 mg/os.
88982412|NCT05830747|Placebo Comparator|Control group (CG)|Patients receiving a preoperative administration of Placebo.
89606947|NCT03969654|Active Comparator|Robotic Assisted TKA|Robotic Assisted TKA
89606948|NCT03969654|Active Comparator|Conventional TKA|Conventional TKA
89606949|NCT03966781|Active Comparator|ESWL followed by ERCP|Patients enrolled in the active treatment group will be subjected to ESWL followed by ERCP and pancreatic duct stenting.
89606950|NCT03966781|Sham Comparator|Sham ESWL followed by sham ERCP|Patients enrolled in the sham treatment group will be subjected to sham ESWL followed by sham ERCP with no pancreatic duct intervention.
89606951|NCT03952806|Experimental|Verdiperstat|"Participants received verdiperstat 300 mg tablet orally once daily for 1 week, followed by 300 mg twice daily for 1 week, and then 600 mg twice daily for the remaining 46 weeks of the double-blind phase.~Participants who completed the double-blind phase were offered the opportunity to enroll in an open-label extension (OLE) phase to continue verdiperstat 600 mg twice daily for 48 weeks."
89606952|NCT03952806|Placebo Comparator|Placebo|Participants received placebo matching with verdiperstat for 48 weeks. Participants who completed the double-blind phase were offered the opportunity to enroll in an OLE phase to receive verdiperstat 600 mg tablet orally twice daily for 48 weeks.
89606953|NCT03944876|Experimental|Botox injections towards SPG|Botulinum Toxin type A injections
89606954|NCT03944876|Placebo Comparator|Controls|placebo injections
89606955|NCT03944577|Experimental|Treatment Arm|Patients who will receive the study drug.
89606956|NCT03941236|Experimental|Dasiglucagon open-label|Dasiglucagon treatment as sc infusion starting at 10 µg/hr on top of standard of care
89606957|NCT03935724|Experimental|1A Intervention group 8 patients|Neuro-Cells treatment at day 1-2 (= 6-10 weeks after TSCI incident). N=8
89606958|NCT03935724|Placebo Comparator|1B Placebo group 8 patients|Placebo treatment at day 1-2 (= 6-10 weeks after TSCI incident) Neuro-Cells treatment at day 181-182 (= 32-34 weeks after TSCI incident) N=8
89606959|NCT03935724|Experimental|2A Intervention group 27 patients|Neuro-Cells treatment at day 1-2 (= 6-10 weeks after TSCI incident) N=27
89606960|NCT03935724|Placebo Comparator|2B Placebo group 27 patients|Placebo treatment at day 1-2 (= 6-10 weeks after TSCI incident) Neuro-Cells treatment at day 181-182 (= 32-34 weeks after TSCI incident) N=27
89606961|NCT03932799||Washington|Workers in the Washington Department of Labor and Industries state fund insurance system.
89606962|NCT03932799||Ohio|Workers in the Ohio Bureau of Workers' Compensation state fund insurance system.
89606963|NCT03930576||Early Legal Terminations|Participants who receive a legal termination at <10 weeks gestation at a recruiting facility.
88982413|NCT05830734|Experimental|BCL surgery with fatty cell injection arm|Patients will undergo BCL surgery and additionally have to small incisions made in the lumbar region from which 80 ml of fatty cells are harvested. After harvest local anesthetics are injected bilaterally and a compression bandage applied. The fatty cells are injected into the surgical wound before closure. All wounds are lateralized and close with a suction drain removed after 3 days
88982414|NCT05830734|Sham Comparator|BCL surgery alone arm|Patients will undergo BCL surgery. Additionally two small incisions are made in the lumbar region, local anesthetics are injected bilaterally and a compression bandage applied. All wounds are lateralized and close with a suction drain removed after 3 days
88982415|NCT05830708|Experimental|Probiotic group|"Probiotics + conventional drug therapy: treatment includes conventional drug therapy* (initial 2 weeks), then probiotics powder 2g, mixed into water or milk, dissolved and oral; 1 sachet per day for 12 weeks~*Conventional drug treatment: alcohol detoxification treatment was carried out at the early stage of admission, mainly with benzodiazepine replacement therapy, while adequate supplementation of B vitamins, strengthening symptomatic supportive treatment, and corresponding antipsychotic drugs, antidepressants or emotional stabilizers were given according to the condition. Benzodiazepines are gradually discontinued after withdrawal symptoms disappear (2 weeks)."
88982416|NCT05830708|Active Comparator|Acceptance and commitment therapy (ACT) group|"ACT + conventional drug therapy: treatment includes conventional drug therapy* (initial 2 weeks), then 50 minutes, once a week ACT session for 8 weeks (8 sessions).~*Conventional drug treatment: alcohol detoxification treatment was carried out at the early stage of admission, mainly with benzodiazepine replacement therapy, while adequate supplementation of B vitamins, strengthening symptomatic supportive treatment, and corresponding antipsychotic drugs, antidepressants or emotional stabilizers were given according to the condition. Benzodiazepines are gradually discontinued after withdrawal symptoms disappear (2 weeks)."
88982417|NCT05830708|Placebo Comparator|Placebo group|"Placebo + conventional drug therapy: treatment includes conventional drug therapy* (initial 2 weeks), then maltodextrin of the same weight as the test drug treatment group was mixed into water or milk and orally dissolved; 1 sachet per day for 12 weeks.~*Conventional drug treatment: alcohol detoxification treatment was carried out at the early stage of admission, mainly with benzodiazepine replacement therapy, while adequate supplementation of B vitamins, strengthening symptomatic supportive treatment, and corresponding antipsychotic drugs, antidepressants or emotional stabilizers were given according to the condition. Benzodiazepines are gradually discontinued after withdrawal symptoms disappear (2 weeks)."
88982418|NCT05830695|Experimental|human treated dentin matrix|study group
89606964|NCT03930576||Late Legal Terminations|Participants who receive a legal termination at 10+ weeks gestation at a recruiting facility.
89606965|NCT03930576||Turn-aways: Termination outside Legal Setting|Participants who receive a termination at another facility or outside the formal healthcare sector.
89606966|NCT03930576||Turn-aways: Birth|Participants who ultimately carry the pregnancy to term
89606967|NCT03930459|Experimental|Static cold storage (SCS)|Traditional method of organ preservation which involves flushing of cold preservation solution following complete dissection and interruption of blood supply to the donor organ. Although cold preservation slows metabolism by 10- to 12-fold, substantial anaerobic activity continues even at ice temperature. This lead to the generation of reactive oxygen species that are the basis of ischaemia-reperfusion injury, when the organ is re-exposed to oxygenated blood at the time of transplantation. This damage, exacerbated by any prior injury, limits the maximum safe preservation time of the donor organ.
89606968|NCT03930459|Experimental|Normothermic machine perfusion (NMP)|The main goal of NMP is to optimize graft preservation by mimicking physiological conditions. The perfused organ is supplied with nutrients and oxygen to maintain metabolic hemostasis. Under these conditions, ATP and glycogen reserves can be maintained or actively restored. At the same time, toxic products from the cellular milieu are continuously eliminated, so the cell-mediated injury phase of reperfusion injury can be minimized. Thus, ischemic injury is avoided and the activation of cell death cascades is prevented. This allows both hepatocellular and biliary protection.
89606969|NCT03928041|Other|single prospective study|All subjects who are entered into this trial will receive the EVOS Lumbar Interbody System (EVOS- HA).
89606970|NCT03925025|No Intervention|Control|Standard therapy
89606971|NCT03925025|Active Comparator|Magnesium sulfate|Standard therapy plus magnesium sulfate
89606972|NCT03925025|Active Comparator|Nimodipine|Standard therapy plus nimodipine
89606973|NCT03924947|Experimental|Part 1 Double-Blind Creon MP / Creon|After receiving open-label currently marketed Creon delayed release (Creon DR) capsules during a pre-randomization period, participants receive double-blind Creon DR capsules manufactured by modernized process pellets (Creon MP) in treatment period 1, followed by double-blind Creon DR capsules in treatment period 2. Participants also receive open-label currently marketed Creon DR for an interval of up to 28 days between periods 1 and 2, and during a 30-day follow-up period after period 2.
89606974|NCT03924947|Experimental|Part 1 Double-Blind Creon / Creon MP|After receiving open-label currently marketed Creon DR capsules during a pre-randomization period, participants receive double-blind Creon DR capsules in treatment period 1, followed by double-blind Creon MP in treatment period 2. Participants also receive open-label currently marketed Creon DR for an interval of up to 28 days between periods 1 and 2, and during a 30-day follow-up period after period 2.
89606975|NCT03924947|Experimental|Part 2 Double-Blind Creon AAPIS / Creon|After receiving open-label currently marketed Creon DR capsules during a pre-randomization period, participants receive double-blind Creon DR capsules manufactured at an alternate active pharmaceutical ingredient site (Creon AAPIS) in treatment period 1, followed by double-blind Creon DR capsules in treatment period 2. Participants also receive open-label currently marketed Creon DR for an interval of up to 28 days between periods 1 and 2, and during a 30-day follow-up period after period 2.
88982419|NCT05830695|Experimental|mineral tri oxide aggregate|control group
88982420|NCT05830617|Experimental|real tACS|Real tACS will be delivered by applying two conductive electrodes over the left and right central areas, for 30 minutes/day (Monday-to-Friday), for two weeks, with the following parameters: sinewaves at 40Hz, peak-to-peak amplitude=1mA, 3s ramping-up and ramping-down. Intensity will be lowered if perceived as uncomfortable.
88982421|NCT05830617|Sham Comparator|sham tACS|Sham tACS will consist of only 30s of stimulation.
88982422|NCT05830604|Active Comparator|TMD Wilkes Stage I-II and Subjective Tinnitus|Patients with subjective tinnitus and temporomandibular disorder. It was treated with an occlusal splint.
88982423|NCT05830604|Active Comparator|TMD Wilkes Stage I-II, Subjective Tinnitus and Bruxism|Patients with subjective tinnitus and temporomandibular disorder and bruxism. It was treated with an occlusal splint.
88982424|NCT05830591||Children with autism disorders 1-5 years|Children coming to the Division of Child Neurology and Psychiatry for the first clinical evaluation (1 year to 5 years old)
88982425|NCT05830591||Children with autism disorders 6-17 years|Children with confirmed ASD diagnosis (6 years to 17 years old) coming to the Odonto-Stomatology Department for the periodical dental hygiene session
88982426|NCT05830591||Children control group|Children with matched demographic characteristics accessing our Institute for different purposes
88982427|NCT05830552|Experimental|Intervention Group|In the intervention group, the researcher gave feedback on the subjects' exercise amount through telephone contact every 2 weeks during the 12-week study period. Through phone consultations, they answered questions about exercise or discussed problems, encouraged to continue exercising, answered questions or discussed problems related to wearable devices and encouraged continuous data transmission.
88982428|NCT05830552|Placebo Comparator|Control Group|In the case of the control group, physical activity is monitored by itself through wearable devices and smartphone apps without phone counseling.
88982429|NCT05830513|Active Comparator|Group A|Women will be randomly allocated to undergo OPU either with the use of Virtual reality(group A)
88982430|NCT05830513|No Intervention|Group B|Women will be randomly assigned to an OPU in the control group with standard treatment, withouth analgesia (Group B).
88982431|NCT05830487|Experimental|Low AGE diet with reduced energy and fat|Low advanced glycation end products diet with reduced energy and fat
88982432|NCT05830487|Experimental|Energy and fat-reduced normal diet|only energy and fat-reduced diet, advanced glycation end products intake will not be interfered with.
88982433|NCT05830474|Experimental|Test group (group T)|lung isolation was performed with visual double-lumen bronchial catheter, andcontinuous airway monitoring and intervention were performed
88982434|NCT05830474|No Intervention|Control group (group C)|lung isolation was performed with visual double-lumen bronchial catheter, and only intra-airway video was performed without monitoring
88982435|NCT05830435|Active Comparator|TSST VR Friendly|
88982436|NCT05830435|Experimental|TSST VR Neutral|
88982437|NCT05830435|Experimental|TSST VR Unfriendly|
88982438|NCT05830383|Experimental|PDCA circular management|The countermeasure 1-ABC rescue training:Clarify the positions and perform their duties; Countermeasure 2-Advanced Life Support (ACLS) training: Clear division of labor and strengthen the cooperation Tune; Countermeasure 3-Objective Structural Clinical Test (OSCE Exam): Objective, orderly, and organized assessment
88982439|NCT05830370||case|patients complaining of symptoms of IBS fulfilling the Rome criteria , such as abdominal discomfort, diarrhea, and constipation, bloating with any age & sex groups from different locations.
88982440|NCT05830370||control|healthy individuals not suffering from IBS symptoms such as abdominal discomfort, diarrhea, and constipation, bloating.
88982441|NCT05830331|No Intervention|Control|
88982442|NCT05830331|Experimental|Treatment|
88982443|NCT05830266|Experimental|"Mindful with your Baby group-based therapist-guided intervention (Intervention group)"|"Group-based Mindful with your Baby therapist-guided intervention via a video-conferencing tool (e.g., Zoom)."
88982444|NCT05830266|Other|"Mindful with your baby self-guided online intervention (Waitlist control group)"|"The waitlist control group receives an individual self-guided online Mindful with your baby intervention after a 10-week waiting period."
88982445|NCT05830240|Experimental|R130 Treatment Group|Every 7-14 days,1-2 ml R130 （concentration of 1x10^8 plaque-forming Units/mL,PFU/mL）will be injected intratumoral in patients with relapsed/refractory head and neck cancer
88982446|NCT05830227||Primary snoring group|Primary snoring group
88982447|NCT05830227||Critical OSAHS group|Critical OSAHS group
88982448|NCT05830227||Mild OSAHS group|Mild OSAHS group
88982449|NCT05830227||Moderate to severe OSAHS group|Moderate to severe OSAHS group
89606976|NCT03924947|Experimental|Part 2 Double-Blind Creon / Creon AAPIS|After receiving open-label currently marketed Creon DR capsules during a pre-randomization period, participants receive double-blind Creon DR capsules in treatment period 1, followed by double-blind Creon AAPIS in treatment period 2. Participants also receive open-label currently marketed Creon DR for an interval of up to 28 days between periods 1 and 2, and during a 30-day follow-up period after period 2.
89606977|NCT03918577|Experimental|right cold caloric vestibular stimulation|OCRD participants in this arm will receive an approx 60 second infusion of distilled cold(4)c water in their right external ear canal, with before and after measures of OCRD symptom severity and insight.
89606978|NCT03918577|Experimental|left cold caloric vestibular stimulation|OCRD participants in this arm will receive an approx 60 second infusion of distilled cold(4)c water in their left external ear canal, with before and after measures of OCRD symptom severity and insight.
89606979|NCT03914118|Active Comparator|Preoperative modafinil + postoperative placebo|
89606980|NCT03914118|Active Comparator|Preoperative modafinil + postoperative modafinil|
89606981|NCT03914118|Placebo Comparator|Preoperative placebo + postoperative placebo|
89606982|NCT03914118|No Intervention|Control group|
89606983|NCT03903653|Active Comparator|Chemodenervation + Serial Casting|in this group a total of 10 patients will undergo Botulinum Toxin A injection and weekly serial casting Intervention = Weekly Serial Casting AND Botulinum Toxin A injection (350-400 units per treated limb)
89606984|NCT03903653|Active Comparator|Chemodenervation without serial casting|in this group a total of 10 patients will undergo Botulinum Toxin A injection. Intervention = Botulinum Toxin A injection (350-400 units per treated limb) alone.
89606985|NCT03898388|Experimental|Knee Synovial Fluid collection before Regenexx-SD|Measure components of knee synovial fluid 2-4 days before the Regenexx-SD treatment.
89606986|NCT03892928|Experimental|Dexmedetomidine group|Dexmedetomidine was infusion intravenously with a loading dose of 0.5 μg kg-1 for 10 min, then infusion at 0.3 μg kg-1 h-1 according to the ideal body weight of the patient until the end of colonoscopy. If Ramsay sedation scale score reached 3, colonoscope was inserted. During the whole process, maintenance Ramsay score of 3 to 4. Propofol 10 mg was administrated as the rescue dose if body movement occurred during colonoscopy.
89606987|NCT03892928|Other|Propofol group|Propofol was administrated 1 mg kg-1 intravenously, then titrated given by 0.5 mg kg-1 until Ramsay score reached 3. During the whole process, propofol was given intermittently to maintain Ramsay score 3 to 4. If body movement happened, propofol 10mg was administrated every time.
89606988|NCT03889197|No Intervention|Control|Standard of care sodium supplementation as directed by the medical care team
89606989|NCT03889197|Active Comparator|Sodium supplementation algorithm|Beginning on the 14th -16th postnatal day and continuing until 36 weeks postmenstrual age, infants randomized to the algorithm will have a spot urine sodium concentration determined every two weeks and sodium supplementation provided according to the algorithm.
89606990|NCT03888651||Observational (questionnaires, quality of life assessment)|Patients complete questionnaires and quality of life assessments over 10-15 minutes at pre-surgery, after-surgery, at discharge, within 2-3 weeks after surgery, and within 90 days after surgery.
89606991|NCT03886818|Experimental|PICO strategy|"Use of PICO™ device from the ankle surgery to the post-surgery day 7.~Use of usual care by simple dressings after post-surgery day 7 up to wound healing"
89606992|NCT03886818|Active Comparator|Standard of care|-Usual care by simple dressings after the ankle surgery until the wound healing.
89606993|NCT03885232|Experimental|PIVOT with MI|Clinics with providers trained in the Presumptively Initiating Vaccines and Optimizing Talk with Motivational Interviewing intervention (PIVOT with MI)
89606994|NCT03885232|Active Comparator|Control|Control-Care as usual
89606995|NCT03871556|Experimental|Experimental Group|
88815160|NCT01688141|Active Comparator|Enhanced Management|Practices randomised to the intervention group will be offered an enhanced level of CKD disease management led by clinical nurse specialists based on an intervention previously piloted in high risk patients. Here, high risk patients identified will be invited to a CKD clinic for tailored management of bp and proteinuria and referral as needed.
88815161|NCT03019250|Experimental|Colostrum|Intervention patients will be received enteral formula and colostrum powder 20 g/kg/day given via nasogastric tube as boluses q 4hrs.
88815162|NCT03019250|Placebo Comparator|Maltodextrin|Control patients will be received enteral formula and maltodextrin mixed in with water and given via nasogastric tube as boluses q 4hrs.
88815163|NCT03019172|Experimental|Lactobacillus reuteri|Women in experimental branch will receive two sachets. Sachet one contains a total of 5*10^8 CFU of Lactobacillus reuteri DSM 16666 & Lactobacillus reuteri DSM 17938, mixed with maltodextrin for flowability during production. Sachet two contains instant cranberry drink composed of Cranberry extract, xylitol, cranberry aroma, monosodium citrate, zink gluconate, silica.
88815164|NCT03019172|Placebo Comparator|Sachet with cranberry + placebo|Women in control branch will receive two sachets. Sachet one contains only Maltodextrin and sachet two contains instant cranberry drinkcomposed of Cranberry extract, xylitol, cranberry aroma, monosodium citrate, zink gluconate, silica Both sachets should be emptied in a glass and mixed with 200 ml of cold water
88815165|NCT02247245|Placebo Comparator|Placebo|Subjects are given a placebo capsule (double-blinded) to take 90 minutes prior to the cardiopulmonary exercise test.
88815166|NCT02247245|Active Comparator|Ivabradine|Subjects are given an ivabradine capsule (double-blinded) to take 90 minutes prior to the cardiopulmonary exercise test.
88815167|NCT02247245|Experimental|Atrial fibrillation|Subjects are (double blind) randomised to either a low base pacing rate (30) or a standard base rate (60), with rate adaptive algortithms switched on.
88815168|NCT00971750||Ultrasound Study Group|Patients with no history of gallbladder surgery who are undergoing elective laparoscopic roux-en-Y gastric bypass that have consented to undergo a preoperative transabdominal ultrasound in addition to routine preoperative assessment for surgery.
88815169|NCT02485704|Experimental|Natroba (spinosad)|spinosad topical suspension, 0.9% up to 120 mL (enough product is used to cover the body from the neck down to the soles of the feet), one treatment left on for 6 hours
88815170|NCT02485704|Placebo Comparator|Placebo|placebo is a topical suspension that is the same formulation as Natroba without the active ingredient spinosad (vehicle). Up to 120 mL (enough product is used to cover the body from the neck down to the soles of the feet), one treatment left on for 6 hours.
89606996|NCT03864094|Active Comparator|Ephedrine Propofol Remifentanil|Prophylactic Ephedrine
89606997|NCT03864094|Active Comparator|Phenylephrine Propofol Remifentanil|Prophylactic Phenylephrine
89606998|NCT03864094|Active Comparator|Norepinephrine Propofol Remifentanil|Prophylactic Norepinephrine
89606999|NCT03864094|Sham Comparator|Sodium chloride Propofol Remifentanil|NaCl Placebo
89607000|NCT03860792|Experimental|Ketogenic Diet|Study partners will be instructed to assist participants in adherence to a 1:1 ketogenic diet (approximately 70% fat, <10% carbohydrate, and 20% protein as energy). The diet will encourage ≥4 servings of non-starchy vegetables and 1/2 cup of berries daily. Participants will be provided an emulsified medium chain triglyceride supplement with a target intake of 1-2 tablespoons per day and micronutrient supplements consisting of multivitamin, vitamin D, calcium, and phosphorus. After the 3-month ketogenic diet, participants will complete a 1-month washout period in which they halt adherence to the ketogenic diet and resume their normal diet.
89607001|NCT03860792|Active Comparator|Therapeutic Lifestyles Changes Diet|Study partners will be instructed to assist participants in adherence to the Therapeutic Lifestyles Changes diet. The diet consists of 20-35% fat, 50-60% carbohydrate, and ~15% protein as energy. Fat intake will comprise <7% saturated fat, ≤20% monounsaturated fat, and ≤10% polyunsaturated fat as total energy. Cholesterol consumption will be ≤200mg per day. Participants are encouraged to eat ≥2 servings of fruit and ≥5 servings of vegetables per day.
89607002|NCT03855813|Other|Test-retest reliability|Patients with knee osteoarthritis will perform the 30 seconds chair stand test as a self test twice at home to evaluate intra rater reliability. Same patients will be tested with the same performance test by a physical therapist to evaluate the inter rater reliability.
89607003|NCT03851640|Experimental|HC-1119|80mg;
89607004|NCT03851640|Placebo Comparator|placebo|80mg;
89607005|NCT03845985|Experimental|Seeking Safety + Signs of Safety toolkit|Participants randomized to receive the intervention will be provided 12 one-hour weekly individual treatment sessions with one of four ASL-fluent study clinicians in Massachusetts. Assessments will occur at baseline, week 4, week 8, immediate post-treatment/week 12, and one-month follow-up/week 16.
89607006|NCT03845985|No Intervention|Assessment-only Waitlist Control|Participants randomized to the waitlist control condition will be offered the opportunity to receive the 12-session Seeking Safety + Signs of Safety toolkit intervention after an approximate 16 week waiting period. This 16 week waiting period is equivalent to the current waitlist to receive psychotherapy services through the PI's outpatient clinic. Assessments will occur at baseline, week 4, week 8, immediate post-treatment/week 12, and one-month follow-up/week 16.
89607007|NCT03842007|Active Comparator|Healthy Individuals|Sixty healthy individuals (20 men and 40 women) will undergo an anorectal study which comprises of a rectal barostat study followed by fecoflowmetry
89607008|NCT03842007|Active Comparator|Constipated Individuals|60 constipated individuals (20 men and 40 women) will undergo an anorectal study which comprises of a rectal barostat study followed by fecoflowmetry
89607009|NCT03832790||adolescents with type 1 diabetes|Adolescents ages 14-19 with type 1 diabetes
89607010|NCT03827174|Active Comparator|Comparison intervention|Return To Work Coordination: external and internal coordination regarding sick leave. Establishment of a common return to work plan between employer and employee.
89607011|NCT03827174|Experimental|Experimental intervention|"Return To Work Coordination + Behaviour Change Ability Programme~Behaviour Change Ability Programme:~Return to work coordination~Education for employers and employees in pain neuroscience, validation, and problem-solving~Patient specific goal setting for return to work~Exercise and behavioural skills training related to return to work"
89607012|NCT03826693|Experimental|Experimental: Nitrous Oxide|OCD participants in this arm will receive 50%oxygen/50% nitrous oxide admixture for 60 minutes.
89607013|NCT03826693|Placebo Comparator|Control: Nitrogen|OCD participants in this arm will receive 50%oxygen/50% nitrogen admixture for 60 minutes.
88982450|NCT05830175|Experimental|Craniovertebral angle assesment|Craniovertebral angle is the most widely used measurement to assess Forward head posture. Craniovertebral angle is described as the acute angle formed between a horizontal line passing through the spinous process of the seventh cervical vertebra (C7) and the line connecting the midpoint of the tragus to the spinous process of C7.
88982451|NCT05830175|Experimental|Spatio-temporal gait analyz (LEGSystm)|The gait performance of the cases was evaluated with a spatio-temporal gait analysis device named LEGSystm developed by BioSensicstm The device is controlled from the computer with its own software and instantly sends the raw data it collects to the computer via Bluetooth.The Modified Get Up and Go Test (MKYT), which is also supported by the legsyst, was used for assesment. The test was repeated 2 times and the average time was recorded. Legsystm provides information on double stride length, duration and speed of walking, as well as standing, turning, sitting times and total time.
88982452|NCT05830175|Experimental|Portable computerized kinesthetic balance device (SportKAT 550)|The gait performance of the cases was evaluated with a spatio-temporal gait analysis device named LEGSystm developed by BioSensicstm The device is controlled from the computer with its own software and instantly sends the raw data it collects to the computer via Bluetooth.The Modified Get Up and Go Test (MKYT), which is also supported by the legsyst, was used for assesment. The test was repeated 2 times and the average time was recorded. Legsystm provides information on double stride length, duration and speed of walking, as well as standing, turning, sitting times and total time.
88982453|NCT05830045|Experimental|Ia： QLP2117 Dose escalation and PK expansion|
88982454|NCT05830045|Experimental|Ib：QLP2117 Dose expansion|
88982455|NCT05830032|Experimental|Soluble Corn fibre|Soluble corn fibre (SCF) (15g fibre/day)
88982456|NCT05830032|Experimental|Inulin|Inulin (In) (15g fibre/day)
88982457|NCT05830032|Experimental|Soluble corn fibre and inulin|SCF + In (15g/day fibre)
88982458|NCT05830032|Placebo Comparator|Control (Maltodextrin)|Control (Maltodextrin) (0g fibre)
89607014|NCT03809598|Experimental|Mindfulness Based Cognitive Therapy|MBCT adapted for pregnancy includes 8 sequential, weekly 2-hour group sessions co-led by two master's level therapists. Sessions include: 1) introducing new mindfulness skills through in-session practice, 2) reviewing mindfulness practices and troubleshooting barriers to practice, 3) reinforcing mindfulness skills through in-session practice and debriefing, 4) learning about how thoughts influence feelings and behaviors (not all sessions), 5) providing psychoeducational information to support skills, and 6) encouraging the establishment of social support. The intervention is focused on skill development through active engagement in mindfulness practices and exercises to increase awareness of thoughts, feelings and behavior in session, and assignment and review of daily home practices.
89607015|NCT03809598|No Intervention|Treatment as Usual|All participants will receive routine prenatal care from an identified medical provider, which they have initiated on their own. They will be able to engage in any services recommended by their primary medical provider or that they voluntarily initiate. For ethical reasons, they are not prohibited from engaging in any type of therapeutic, complementary, or medication treatment (after enrollment). The TAU group will be offered a delayed treatment option, after the 6 month follow-up. This will be a 2 hour mindfulness psychoeducation session, offered between 6 and 9 months postpartum. Several core mindfulness concepts included in the full MBCT curriculum will be taught and participants will complete several brief mindfulness activities.
89607016|NCT03806842|Other|Easytech group|patients who require a reverse total shoulder, meet the eligibility criteria and receive the Easytech Reversed Shoulder System
89607017|NCT03769415|Experimental|Intrinsic subtyping of Primary Breast Cancer|Intrinsic subtype of primary breast tissue from metastatic breast cancer subject will be determined
88982459|NCT05830019|Experimental|carbon ion radiotherapy|carbon ion radiotherapy
88982460|NCT05830006|Experimental|main group|
88982461|NCT05829980||Group A|Contoura topography-guided LASIK
89532778|NCT05963763|Other|Career Navigator Coaching|"Participants randomized into this group will be invited to participate in the quantitative and qualitative surveys. At baseline, participants in Group1 will receive the intervention- tailored coaching sessions with the Career Navigator which will continue until the end of the 6th month.~The intervention will be tailored for each participant according to their need. The Career Navigator will be in charge to plan and develop tools to help the participant achieve their own goals."
89532779|NCT05963763|Other|Delayed Career Navigator Coaching|"Participants randomized into this group will be invited to participate in the quantitative and qualitative surveys For the first six months, participants in Groups 2 will not receive the intervention and will function as a control group. When the study reaches the sixth-month Group 2 participants will receive the intervention - tailored coaching sessions with the Career Navigator.~The intervention will be tailored for each participant according to their need. The Career Navigator will be in charge to plan and develop tools to help the participant achieve their own goals."
88982462|NCT05829980||Group B|Contoura topography-guided PRK
88982463|NCT05829980||Group C|Wavefront-optimized LASIK
88982464|NCT05829980||Group D|Wavefront-optimized PRK
88982465|NCT05829954||1st dentistry students|1st dentistry students
88982466|NCT05829954||Intern dentistry students|5th dentistry students
88982467|NCT05829954||working dentists|dentists who have worked for at least two years
88982468|NCT05829915|Experimental|Intervention Group|Subjects in the intervention group will perform 24 sessions of multisensory training using ROXPro© system (A-Champs)
88982469|NCT05829915|Active Comparator|Control Group|Subjects in the Control Group will not perform 24 sessions of multisensory training and they will keep doing the current therapy
88982470|NCT05829902|Experimental|Active product|The active product is a drink consisting of 600 mg of lemon balm extract, tea leaves, brown sugar and powdered flavoring agent that is mixed with lukewarm water. The volume per serving is 30 ml. The drink will be taken every night before sleep for a period of two weeks.
88982471|NCT05829902|Placebo Comparator|Placebo|The placebo drink is maltodextrin mixed with water, and the same tea leaves, brown sugar and powdered flavoring agent as the test drink. The volume per serving is 30 ml. The drink will be taken every night before sleep for a period of two weeks.
88982472|NCT05829876|Experimental|HF-ECG guided LV pacing site optimisation|Participants will have the left ventricular pacing site programmed based on the results of HF-ECG mapping to locate the area of latest activation and best pattern of paced resynchronisation.
88982473|NCT05829876|Active Comparator|Q-LV guided LV pacing site optimisation|Participants will have the left ventricular pacing site programmed based on the results of Q-LV measurement to locate the area of latest activation. This is the standard of care method for pacing site optimisation.
88982474|NCT05829863|Experimental|Message exposure|Participants will all be exposed to anti-vaping PSAs utilizing cognitive, emotional, and social appeals, aiming to persuade them to reduce or quit using e-cigarettes.
88982475|NCT05829850|Experimental|SYNOLIS VA 40/80|SYNOLIS VA 40/80 (hyaluronic acid 40 mg, sorbitol 80 mg), intra-articular injection
89532780|NCT05955898|Experimental|Parents THRIVE Group|Participants in this group will receive the Parents THRIVE intervention. Participants will be in this group for up to two hours.
89532781|NCT05955898|Active Comparator|Sharing Feelings Project Group|Participants in this group will receive the Sharing Feelings Group intervention. Participants will be in this group for up to two hours.
89532782|NCT05953545|Experimental|Peginterferon Lambda|A weekly subcutaneous injection of peginterferon lambda at a dose of 180 mcg and an oral twice daily dosing of Lonafarnib at 50mg boosted with twice daily Ritonavir at 100mg for 48 weeks. Following 48 weeks of treatment the subjects will be monitored for outcomes during an additional 6-month time period.
89532783|NCT05949658|Experimental|Sirolimus|1mg tablets of sirolimus that total the assigned dose
89532784|NCT05949658|Experimental|Everolimus|1mg tablets of everolimus that total the assigned dose
89532785|NCT05948475|Experimental|Tinengotinib 8 mg QD|Tinengotinib will be administered in 28-day cycles.
89532786|NCT05948475|Experimental|Tinengotinib 10 mg QD|Tinengotinib will be administered in 28-day cycles.
89532787|NCT05948475|Active Comparator|Physician's Choice|Physician's Choice treatments include FOLFOX or FOLFIRI
89532788|NCT05936437|Experimental|Study arm|Eligible subjects aged 20 to 60 years and in good general health, with grade 3 to 4 moderate-to-severe atrophic post-acne scars according to the Goodman Baron classification
89532789|NCT05932914||Participants|Those who meet the Eligibility Criteria
89532790|NCT05928793|Experimental|Mindfulness|
89532791|NCT05928793|No Intervention|Control|
89532792|NCT05924503||Transcranial Doppler|Serial daily TCD during the ICU stay involving bilateral Middle cerebral artery (MCA) insonation
89532793|NCT05917717|No Intervention|Control (usual care)|Usual care for a cardiac arrest patient with no deviation.
89532794|NCT05917717|Experimental|Intervention 'bundle of care'|The clinical team will follow a specific sequence of actions using three devices (Elegard, Lucas-3, and ITD-16), in addition to standard CPR. Firstly, they will place the ITD onto the i-gel) or ETT, followed by the Elegard device and the LUCAS-3. The team will also place a cerebral saturation monitor on (Near-Infrared Spectroscopy (NIRS)) (if they have access to one). After 2 minutes of CPR via the LUCAS-3 with the ResQPOD-16 (ITD), the Elegard device will be turned on and activated to gradually elevate the head approximately 22cm from the ground to the back of the occiput. If necessary, the clinical team may choose to intubate the trachea at this point. Resuscitation will continue for at least 30 minutes or until ROSC is achieved. If ROSC is achieved, standard post ROSC guidelines will be followed.
89532795|NCT05914324|No Intervention|Controls|Controls will be managed routinely by the clinic staff, including the triage and clinical examination pathway through the facility, treatment and referral decisions, all of which can include the standard care device. After the child has been given a primary diagnosis and decision on onward care (i.e. referral or home-based management), the study data collector will conduct an exit interview. This interview will include the following topics: the clinical examination conducted by the healthcare worker; current intentions for onward care (e.g. are planning to go to hospital, how are the healthcare worker is travelling); extracting clinical information from the patient medical record - including oxygen saturation measurement. Finally, the study data collector will conduct oxygen saturation measurements using the control device and a reference device.
89607018|NCT03765983|Experimental|Cohort A: single-arm, two stage, phase II cohort|GDC-0084 45 mg administered orally once daily Trastuzumab administered at a dose of 8 mg/kg intravenously (IV) loading dose; followed by 6 mg/kg IV every 3 weeks thereafter
89607019|NCT03765983|Experimental|Cohort B: a pre-surgical window cohort|GDC-0084 45 mg administered orally once daily Trastuzumab administered at a dose of 8 mg/kg intravenously (IV) loading dose; followed by 6 mg/kg IV every 3 weeks thereafter Surgical brain metastasis resection
89607020|NCT03761225|Experimental|Masitinib & docetaxel|Participants receive masitinib (6 mg/kg/day), given orally twice daily, plus docetaxel 75 mg/m2 by intravenous infusion during 1 hour, once every 3 weeks (1 cycle = 21 days) for 6 cycles (8 to 10 cycles can be performed according to patient's tolerance) plus prednisone according to usual practice.
89607021|NCT03761225|Placebo Comparator|Placebo & docetaxel|Participants receive placebo (6 mg/kg/day), given orally twice daily, plus docetaxel 75 mg/m2 by intravenous infusion during 1 hour, once every 3 weeks (1 cycle = 21 days) for 6 cycles (8 to 10 cycles can be performed according to patient's tolerance) plus prednisone according to usual practice.
89607022|NCT03755804|Experimental|Low-Risk|Participants receive 2 cycles of BEABOVP: bendamustine, etoposide, Adriamycin® (doxorubicin), bleomycin, Oncovin® (vincristine), vinblastine and prednisone. Filgrastim may be given as clinically indicated. Dexrazoxane may be given at the discretion of the treating investigator. Residual node radiotherapy will be given at the end of all chemotherapy only to involved nodes that do not have an AR after 2 cycles of therapy. Quality of Life measurements may be done.
89607023|NCT03755804|Experimental|Intermediate-Risk|Participants receive 3 cycles of BEABOVP: bendamustine, etoposide, Adriamycin® (doxorubicin), bleomycin, Oncovin® (vincristine), vinblastine and prednisone. For patients with an AR after 2 cycles of therapy, steroids will be omitted from their subsequent cycles of therapy. Filgrastim may be given as clinically indicated. Dexrazoxane may be given at the discretion of the treating investigator. Residual node radiotherapy will be given at the end of all chemotherapy only to involved nodes that do not have an AR after 2 cycles of therapy. Quality of Life measurements may be done.
89607024|NCT03755804|Experimental|High-Risk|Participants receive 2 cycles of AEPA: Adcedris® (brentuximab vedotin), etoposide, prednisone and Adriamycin® (doxorubicin) and 4 cycles of CAPDac: cyclophosphamide, Adcetris® (brentuximab vedotin), prednisone and Dacarbazine® (DTIC). For patients with an AR after 2 cycles of therapy, steroids will be omitted from their subsequent cycles of therapy. Filgrastim may be given as clinically indicated. Dexrazoxane may be given at the discretion of the treating investigator. Residual node radiotherapy will be given at the end of all chemotherapy only to involved nodes that do not have an AR after 2 cycles of therapy. Quality of Life measurements may be done.
89607025|NCT03754660|Experimental|Untreated patients (Part A and Part B)|"Part A: Untreated PAH and CTEPH patients will be enrolled to test 5 ascending doses of BAY1237592 with 4 patients per dose group up to a maximum dose of 4000 µg.~Part B: The highest safe, well tolerated and effective dose of Part A will be tested in further untreated patients."
89607026|NCT03754660|Experimental|Monotherapy (Part B)|The highest safe, well tolerated and effective dose chosen from Part A will be tested in pre-treated patients with any kind of monotherapy for PAH/CTEPH.
89607027|NCT03754660|Experimental|Combined therapy (Part B)|The highest safe, well tolerated and effective dose from Part A will be tested in pre-treated patients with any kind of double combination treatment for PAH/CTEPH.
89607028|NCT03745651|Placebo Comparator|Vehicle Control (VC) Period: Vehicle Cream BID|Participants received ruxolitinib matching vehicle cream, applied topically to the affected areas as a thin film twice daily (BID) 8 hours apart from Day 1 up to Week 8. Participants applied cream BID to areas identified at Baseline even if the areas improved.
89607029|NCT03745651|Experimental|VC Period: Ruxolitinib 0.75% Cream BID|Participants received ruxolitinib 0.75% cream, applied topically to the affected areas as a thin film BID 8 hours apart from Day 1 up to Week 8. Participants applied cream BID to areas identified at Baseline even if the areas improved.
89607030|NCT03745651|Experimental|VC Period: Ruxolitinib 1.5% Cream BID|Participants received ruxolitinib 1.5% cream, applied topically to the affected areas as a thin film BID 8 hours apart from Day 1 up to Week 8. Participants applied cream BID to areas identified at Baseline even if the areas improved.
89607031|NCT03745651|Experimental|Long-Term Safety (LTS) Period: Vehicle Cream to Ruxolitinib 0.75% Cream BID|Participants who applied vehicle cream during the VC Period were randomized at Week 8 to apply ruxolitinib 0.75% cream, topically to the affected areas as a thin film BID as needed from Week 8 up to Week 52. Participants stopped treatment 3 days after lesions disappeared and restarted at the first sign of recurrence.
89607032|NCT03745651|Experimental|LTS Period: Vehicle Cream to Ruxolitinib 1.5% Cream BID|Participants who applied vehicle cream during the VC Period were randomized at Week 8 to apply ruxolitinib 1.5% cream, topically to the affected areas as a thin film BID as needed from Week 8 up to Week 52. Participants stopped treatment 3 days after lesions disappeared and restarted at the first sign of recurrence.
89607033|NCT03745651|Experimental|LTS Period: Ruxolitinib 0.75% Cream BID|Participants who applied ruxolitinib 0.75% cream during the VC Period, continued applying ruxolitinib 0.75% cream, topically to the affected areas as a thin film BID as needed from Week 8 up to Week 52. Participants stopped treatment 3 days after lesions disappeared and restarted at the first sign of recurrence.
88982476|NCT05829837||Motor incomplete paraplegia patients|Participants with the age of 18 - 65, were selected for the study based on the following inclusion criteria: diagnosis of motor incomplete paraplegia at C or D level according to the spinal cord injury classification of the American Spinal Injury Association (ASIA) Impairment Scale with a neurological injury level between T2-S1.
88982477|NCT05829837||Non-ambulatory patients with complete spinal cord injury|Participants with the age of 18 - 65, were selected for the study based on the following inclusion criteria: non-ambulatory patients with diagnosis of motor complete paraplegia at A level according to the spinal cord injury classification of the American Spinal Injury Association (ASIA) Impairment Scale with a neurological injury level between T2-S1.
88982478|NCT05829798|Experimental|SYNOLIS VA 80/160|SYNOLIS VA 80/160 (hyaluronic acid 80 mg, sorbitol 160 mg) Intra-articular injection
88982479|NCT05829798|Experimental|SYNOLIS VA 40/80|SYNOLIS VA 40/80 (hyaluronic acid 40 mg, sorbitol 80 mg) Intra-articular injection
89607034|NCT03745651|Experimental|LTS Period: Ruxolitinib 1.5% Cream BID|Participants who applied ruxolitinib 1.5% cream during the VC Period, continued applying ruxolitinib 1.5% cream, topically to the affected areas as a thin film BID as needed from Week 8 up to Week 52. Participants stopped treatment 3 days after lesions disappeared and restarted at the first sign of recurrence.
89607035|NCT03745638|Placebo Comparator|VC Period: Vehicle Cream BID|Participants received vehicle cream, applied topically to the affected areas as a thin film twice daily (BID) from Day 1 to Week 8 during the Vehicle Control (VC) Period. Participants applied cream BID to areas identified at Baseline even if the areas improved.
89607036|NCT03745638|Experimental|VC Period: Ruxolitinib 0.75% Cream BID|Participants received ruxolitinib 0.75% cream, applied topically to the affected areas as a thin film BID from Day 1 to Week 8 during the VC Period. Participants applied cream BID to areas identified at Baseline even if the areas improved.
89607037|NCT03745638|Experimental|VC Period: Ruxolitinib 1.5% Cream BID|Participants received ruxolitinib 1.5% cream, applied topically to the affected areas as a thin film BID from Day 1 to Week 8 during the VC Period. Participants applied cream BID to areas identified at Baseline even if the areas improved.
89607038|NCT03745638|Experimental|LTS Period: Vehicle Cream to Ruxolitinib 0.75% Cream BID|Participants who applied vehicle cream BID during the VC Period, were randomized to apply ruxolitinib 0.75% cream, topically to the affected areas as a thin film BID from Week 8 to 52 during the Long-term Safety (LTS) Period. Participants stopped treatment 3 days after lesions disappeared and restarted at the first sign of recurrence.
89607039|NCT03745638|Experimental|LTS Period: Vehicle Cream to Ruxolitinib 1.5% Cream BID|Participants who applied vehicle cream BID during the VC Period, were randomized to apply ruxolitinib 1.5% cream, topically to the affected areas as a thin film BID from Week 8 to 52 during the LTS Period. Participants stopped treatment 3 days after lesions disappeared and restarted at the first sign of recurrence.
89607040|NCT03745638|Experimental|LTS Period: Ruxolitinib 0.75% Cream|Arm description: Participants who applied ruxolitinib 0.75% cream during VC Period, continued applying ruxolitinib 0.75% cream topically to the affected areas as a thin film BID from Week 8 to 52 during the LTS Period. Participants stopped treatment 3 days after lesions disappeared and restarted at the first sign of recurrence.
89607041|NCT03745638|Experimental|LTS Period: Ruxolitinib 1.5% Cream|Arm description: Participants who applied ruxolitinib 1.5% cream during VC Period, continued applying ruxolitinib 1.5% cream topically to the affected areas as a thin film BID from Week 8 to 52 during the LTS Period. Participants stopped treatment 3 days after lesions disappeared and restarted at the first sign of recurrence.
89607042|NCT03742050|Active Comparator|Percutaneous coronary intervention|Percutaneous coronary intervention with drug-eluting stents and modern techniques
89607043|NCT03742050|Placebo Comparator|Placebo percutaneous coronary intervention|Placebo percutaneous coronary intervention
89607044|NCT03713515|Experimental|Practice Faciliation|Will be supported by a practice facilitator
89607045|NCT03713515|No Intervention|Usual Care|Using a stepped wedge design, all practice sites begin as part of the Usual Care (UC) control condition and will receive standard hypertension management that is part of the current clinic procedure. No practice facilitation will occur at this time.
89607046|NCT03704948|Experimental|Trial #1: (RCT) Treatment Group: Listening Visits delivered by NICU nurse in person|Listening Visits delivered by a NICU nurse in person in the RCT
89607047|NCT03704948|Active Comparator|Trial #1: (RCT): Control Group -Mental health care delivered by NICU social work|Mental health care provided by NICU social workers.
89607048|NCT03704948|Experimental|Trial #2Open Trial: Listening Visits delivered by NICU nurse over zoom|Open Trial: Listening Visits delivered by NICU nurse over zoom
89607049|NCT03699475|Experimental|single-arm Phase II: 3 x 10E6 BPX-501 cell/kg|"Determining the safety of maximum allowable Dose for BPX-501 starting at 3 x 10E6 cells/kg~Rimiducid will be administered to inactivate rivogenlecleucel in the event of GVHD not responsive to standard of care treatment"
89607050|NCT03699475|Experimental|phase 3 Arm A: Dose Determined in phase 2 group (never completed)|αβ T cell and CD19+ B cell-depleted, related haploidentical hematopoietic stem cell transplantation (haplo-HSCT) plus rivogenlecleucel
88815171|NCT03019016||Robotic RC (IA)|Benign or malignant disease under going a right colectomy.
88815172|NCT03019016||Robotic RC (EA)|Patients with benign or malignant disease under going a right colectomy.
88815173|NCT03019016||Laparoscopic RC (IA)|Patients with benign or malignant disease under going a right colectomy.
88815174|NCT03019016||Laparoscopic RC (EA)|Patients with benign or malignant disease under going a right colectomy.
88815175|NCT01688609|Experimental|Treatment (lapatinib, trastuzumab, paclitaxel, surgery)|"Drug exposure: Patients receive lapatinib ditosylate PO QD and trastuzumab IV over 30-90 minutes once weekly for 6 weeks in the absence of disease progression or unacceptable toxicity.~Preoperative therapy: Patients receive lapatinib ditosylate PO QD, trastuzumab IV over 30 minutes once weekly, and paclitaxel IV over 90 minutes once weekly for 12 weeks in the absence of disease progression or unacceptable toxicity. Patients then undergo lumpectomy or mastectomy."
88815176|NCT02485158|Experimental|AMP, ALC, THC or Placebo 1|All healthy adult volunteers attended 6 sessions in which they received 20mg AMP, 0.8g/kg ALC, and 7.5mg THC, alternating with three placebo sessions.
88815177|NCT02485158|Experimental|AMP, ALC, THC or Placebo 2|All healthy adult volunteers attended 6 sessions in which they received 20mg AMP, 0.8g/kg ALC, and 7.5mg THC, alternating with three placebo sessions.
88815178|NCT01688843|Experimental|INGEVITY lead|INGEVITY lead implant
88815179|NCT02455518|Active Comparator|Oxycodone/acetaminophen|Oxycodone/acetaminophen (5 mg/325 mg)
88815180|NCT02455518|Active Comparator|Hydrocodone/acetaminophen|Hydrocodone/acetaminophen (5 mg/300 mg)
88815181|NCT02455518|Active Comparator|Codeine/acetaminophen|Codeine/acetaminophen (30 mg/300 mg)
88815182|NCT02455518|Active Comparator|Ibuprofen/acetaminophen|Ibuprofen/acetaminophen (400 mg/1000 mg)
88815183|NCT05643911|Experimental|HFNC (Hight-flow oxygen therapy)|In the HFNC group, patients will receive HFNC oxygen therapy for 20 minutes. Oxygen will be passed through a heated humidifier and continuously delivered through medium or large nasal cannulas (OptiflowTM, Fisher and Paykel Healthcare) depending on patient anatomy, with a gas flow of 50 litres per minute and the FiO2 will be adjusted to maintain a SpO2 between 95% and 98%.
89607051|NCT03699475|Active Comparator|phase 3 Arm B: dose determined in the phase 2 group (never completed)|haplo-HSCT followed by post-transplant cyclophosphamide (PTCy) in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)
89607052|NCT03696160|Experimental|Biktarvy|"Bictegravir is an inhibitor of HIV-1 integrase that is being evaluated for the treatment of HIV-1 infection.~Biktarvy® received marketing authorisation valid throughout the European Union (EU) in June 2018.~Biktarvy is a combination of bictegravir, emtricitabine, and tenofovir (B/F/TAF).~Method of administration: One combined B 50mg/F 200mg/TAF 25mg tablet taken orally once daily for up to 48 weeks without regard to food."
89607053|NCT03696160|Experimental|Symtuza|"Symtuza® is a boosted PI indicated for the treatment of HIV-1 infection.~Symtuza® received marketing authorisation valid throughout the EU in September 2017.~Symtuza is a combination of darunavir, cobicistat, emtricitabine and tenofovir alafenamide (D/C/F/TAF)~Method of administration: One combined D 800mg/C 150mg/F 200mg/TAF 10mg tablet taken orally once daily for up to 48 weeks with the addition of food."
89607054|NCT03683004||CRC patients (Ctx+ group)|Postoperative CRC patients scheduled to begin CTX
89607055|NCT03683004||CRC patients (CT- group)|Postoperative CRC patients who do not receive CTX
89607056|NCT03683004||Healthy control group|Study participants that are demographically matched to CRC study patients and meet all inclusion criteria
89607057|NCT03680586|Experimental|Treatment (low-dose radiation therapy)|Patients undergo low-dose radiation therapy over 2 fractions for 2 consecutive days in the absence of disease progression or unacceptable toxicity. Patients with stable or progressive disease at 12-16 weeks post-treatment, or persistent disease at 1 year may undergo higher-dose radiation therapy at the discretion of treating physician.
89607058|NCT03678376|Other|complaint, cognitive and functional assessments|All patients will be included in a single arm. They will complete an evaluation with their General Practitioner, followed by an evaluation at the Memory Clinic with a specialist (neurologist, geriatrician or psychiatrist).
89607059|NCT03675126|Experimental|SRP-5051|Participants will receive SRP-5051 via intravenous (IV) infusion. Dosage and frequency will be determined from the safety profile of other ongoing SRP-5051 studies.
89607060|NCT03674424|Experimental|DD-MVAC + avelumab|"Methotrexate, vinblastine, doxorubicin and cisplatin (DD-MVAC) given in combination with Avelumab.~DD-MVAC consists of Methotrexate 30 mg/m2 iv day 1, Vinblastine 3 mg/m2 iv day 2, Cisplatin 70 mg/m2 iv day 2 and Doxorubicin 30 mg/m2 iv day 2. Each cycle is given every 2 weeks for a maximum of 4 administrations Chemotherapy is associated with Avelumab 10 mg/kg, 1-hour intravenous (iv) infusion, given on day 2 every 2 weeks.~Cystectomy will be performed 3 to 6 weeks after last administration of chemotherapy"
89607061|NCT03674424|Experimental|CG+ avelumab|"Cisplatin, gemcitabine (CG) consists of Gemcitabine 1000 mg/m2 iv in day 1 and day 8 and Cisplatin 70 mg/m2 iv in day 1. Each cycle is given every 3 weeks for a maximum of 4 administrations.~Chemotherapy is associated with Avelumab 10 mg/kg, 1-hour intravenous (iv) infusion, given on day 1 every 2 weeks Cystectomy will be performed 3 to 6 weeks after last administration of chemotherapy"
89607062|NCT03674424|Experimental|PG+ avelumab|"Paclitaxel, gemcitabine (PG) consists of Paclitaxel 80 mg/m2 iv in day 1 and day 15 and Gemcitabine 1000 mg/m2 iv in day 1 and day 15. Each cycle is repeated every 3 weeks for a maximum of 4 administrations.~Chemotherapy is associated with Avelumab 10 mg/kg, 1-hour intravenous (iv) infusion, given on day 1 every 2 weeks Cystectomy will be performed 3 to 6 weeks after last administration of chemotherapy"
89607063|NCT03674424|Experimental|Avelumab|"Avelumab will be administered at a dose of 10 milligram per kilogram (mg/kg) 1-hour intravenous (iv) infusion once every 2 weeks. Dose reductions are not allowed.~Avelumab will be given alone for 4 administrations. Cystectomy will be performed 2 weeks after the last administration of avelumab"
89607064|NCT03672747|Active Comparator|Occipital Anodal Stimulation|Participants will receive occipital anodal stimulation using high-definition tDCS
89607065|NCT03672747|Active Comparator|Occipital Cathodal Stimulation|Participants will receive occipital cathodal stimulation using high-definition tDCS
88982480|NCT05829746|Experimental|Intervention group|Microport NeuroTech Tubridge flow-diverter Stent
88982481|NCT05829720|Active Comparator|a2 Full Cream Milk|a2 Full Cream Milk, 200ml/bag, per 100ml serving Nutrient Composition Energy: 250 kcal Protein:3.2g Fat:3.3g Carbohydrate:4.3g Sodium:40mg Calcium:104mg
88982482|NCT05829720|Active Comparator|Conventional Milk (Weidendorf)|Conventional Milk (Weidendorf), 200ml/bag,per 100ml serving Nutrient Composition Energy: 267 kcal Protein:3.3g Fat:3.5g Carbohydrate:4.8g Sodium:50mg Calcium:120mg
88982483|NCT05829512||Patients group|Individuals with dysmenorrhea
88982484|NCT05828758|Experimental|Study group|Children receiving amoxicillin
88982485|NCT05828758|Placebo Comparator|Comparison group|Children receiving placebo
89607066|NCT03672747|Placebo Comparator|Occipital Sham Stimulation (Placebo)|Participants will receive occipital sham stimulation (placebo) using high-definition tDCS
89607067|NCT03650413|Experimental|UTTR1147A|All participants will have the opportunity to receive treatment with UTTR1147A until clinical remission is achieved. Participants will either receive treatment with UTTR1147A or undergo observation depending on disease status, as described in the protocol.
89607068|NCT03637205|Experimental|ECLS|PCI (or CABG) plus medical treatment + ECLS
88982486|NCT05828030|Experimental|high flow nasal cannula group|All patients will have FiO2 started at 0.4 and titrated to maintain oxygen saturation (SpO2) ≥ 95%. The flow rate will be set at titrated from 60 L/min.
89607069|NCT03637205|Active Comparator|No ECLS|PCI (or CABG) plus medical treatment
88982487|NCT05828030|Active Comparator|Oxygen Mask group|All patients will have FiO2 started at 0.4 and titrated to maintain oxygen saturation (SpO2) ≥ 95%.
88982488|NCT05826665||STAR Apollo Mapping System Group|Patients who have been referred for persistent AF catheter ablation, who have already had AF recurrence post Pulmonary Vein Isolation (PVI), will be considered for this study.
88982489|NCT05826067||patients with UTI or catheter (suprapubic, nephrostomy)|Patients with urinary tract infection caused by E. coli, with or without neurological disorders or patients that are planned to undergo the insertion of a suprapubic or nephrostomy catheter.
88982490|NCT05823805|Experimental|Community Health Worker + Quality Improvement reports|Family physicians with ten or more patients living with schizophrenia and/or bipolar disorder will work with a community health worker who will assist them in reviewing their individualized reports, which presents data on patient's preventive health care status and engagement in care.
89607070|NCT03628989|Experimental|Cardiac Cathertization Patients|Participants will use technology based distraction during procedure.
89607071|NCT03628989|Experimental|Allergy Patients|Participants will use technology based distraction during procedure
89607072|NCT03628989|No Intervention|Procedure-Only Patients|
89607073|NCT03613909|Experimental|All participants|At least 6 months experience with a Nucleus 24 series or later implant in at least one implanted ear and at least 3 months experience with the CP810,CP920 or CP910 sound processor.
89607074|NCT03611374|Experimental|Erector Spinae Plane Block|All participants will get the Erector Spinae Plane block (ESPB) as a prospective cohort study. After anesthesia induction all enrolled patients will have bilateral ESPB catheters placed at the T7 spine level prior to surgery. The surgery is a sternotomy for congenital heart repair in high risk children and adults.
89607075|NCT03608631|Experimental|Treatment (iExosomes)|Participants receive mesenchymal stromal cells-derived exosomes with KrasG12D siRNA IV over 15-20 minutes on days 1, 4, and 10. Treatment repeats every 14 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Participants who respond may continue 3 additional courses.
89607076|NCT03597555|Experimental|Xyrem|"Xyrem (Sodium Oxybate), oral solution 500mg/mL First night after V1: Dose prescribed at 4.5 g per night (2.25 g x 2) for 2 weeks First night after V2: Dose increased to 6 g per night (3 g x 2) for 2 weeks, according to investigator's opinion, tolerance of drug and CGI-S First night after V3: Dose either maintained stable at 6 g or increased to 9 g per night (4.5 g x 2) with dose increments of 1.5 g per night (0.75 g x 2) every week, based on benefit-risk ratio, for 2 weeks.~First night after V4: Dose maintained at 9 g or reduced at 6 g per night according to benefit-risk ratio for 2 weeks. No dose adjustment during the Maintenance period.~First night after V5: Taper period. Dose decrease by 2.25 g x 2 every two days until complete withdrawal"
89607077|NCT03597555|Placebo Comparator|Placebos|Xyrem Placebo: sodium citrate solution in equimolar concentration of sodium in the 500 mg/mL Xyrem oral solution, PH adjusted with malic acid
89607078|NCT03596242|Experimental|High Blood Pressure Monitoring by Short Message Service (SMS)|Will receive the text message intervention and will be provided with a blood pressure cuff in addition to standard blood pressure control education received at clinic visits
89607079|NCT03596242|Active Comparator|Usual Care Plus Standard Blood Pressure Monitoring|Will receive standard blood pressure care and education, as well as a blood pressure cuff at their clinic visits
89607080|NCT03580759|Experimental|Exergaming|Subjects in the exergaming group will participate in three exergaming training sessions with the Wii Fit U exergaming system. The Wii Fit U will then be left in the subjects' homes for a minimum of four weeks prior to left ventricular assist device implantation or heart transplant.
89607081|NCT03580759|No Intervention|Usual Care|Subjects in the usual care group will be encouraged to partake in physical activity as recommended in the 2017 AHA/ACC/HFSA guidelines for heart failure.
89607082|NCT03575026|Experimental|Intervention|Subjects will receive 12-week music-with-movement intervention at home by their trained caregivers for 12 weeks, at least 3 sessions per week and 30 minutes for each session.
89607083|NCT03575026|Placebo Comparator|Wait-list control|Subjects will receive 12-week usual care (social activity) at home. Dose is similar to intervention arm. After the completion of 12-week usual care, subjects will receive the same music intervention as intervention arm.
89607084|NCT03571308|Experimental|R-CHOP + Acalabrutinib|"Open-label non-randomised phase Ib/II study conducted in two stages. Phase I will see two doses of acalabrutinib tested. R-CHOP + acalabrutinib will be given for 6 cycles on a 21 day cycle and then two cycles of acalabrutinib only for a total of 56 days. Acalabrutinib will be introduced at Cycle 2.~Phase II will see the recommended phase 2 dose used on the same treatment regimen."
89607085|NCT03565575|Experimental|Interactive tablet-based quiz|Individuals participate in an interactive tablet-based risk perception and PrEP counselling information session.
89607086|NCT03565575|No Intervention|Control arm|No intervention will be administered to the control arm
89607087|NCT03555708|Experimental|High-Velocity Power Training|Training will consist of unilateral and bilateral leg presses (Total Gym GTS, San Diego CA), which will primarily target the quadriceps followed by the hip extensors and plantarflexors. Target load will be 40% to 80% of 1-repetition maximum (1RM) with progression toward 80%. Each participant will perform 3 to 5 sub-maximal efforts followed by 6 sets of 5 maximum-effort repetitions at the predetermined percentage of 1RM for each leg separately. Following the unilateral leg presses, 6 sets of 5 repetitions of bilateral leg presses will be performed at the predetermined percentage of 1RM. To minimize fatigue, 1-2 minutes of rest will be given between sets.
89607088|NCT03555708|Experimental|Perception-Action Physical Therapy|The therapy includes: activities of adequate intensity that promote gait adaptation and gait speed sustainment, exploratory activities that enhance the somatosensory experience through rich/novel movement, and optimally challenging activities that emphasize planning and problem solving that requires altering the leg kinematics to meet the environmental and task constraints. This includes a 15-minutes of sustaining and adapting gait speed while walking along a 40-meter hallway. Participants will alter their gait through exploratory movements. During the following 20 minutes participants will perform discrete problem solving activities including: waling backward sand stair negotiation.
89607089|NCT03555708|Experimental|Body Weight Supported Treadmill Training|The child will walk on the treadmill for 35-minutes, while the body weight is supported with an overhead system at 30 percent of the child's body weight, reducing every other week by 10 percent until no support is provided during the final 2 weeks. Treadmill speed will be set at 90% of the child's over ground walking speed, gradually increasing each session. Speed adjustments depend on the child's ability to control their steps and achieve: activities that promote symmetry of the leg kinematics, activities that promote maintaining an upright lower limb posture and clearing the tow during the swing, and activities that promote pushing off with ankle at terminal stance.
89607090|NCT03552783|Active Comparator|Fathers for a Lifetime (FFL) only|The participants in the comparison arm will receive the standard, 12-week program curriculum of Father For a Lifetime.
89607091|NCT03552783|Experimental|FFL + Cognitive Behavioral Therapy|The participants in the intervention will receive will the standard, 12-week program curriculum of Father For a Lifetime and the Cognitive Behavioral Therapy. The intervention will be delivered by a gender and culturally-matched Licensed Mental Health Professional (LIMHP). In addition, the men will receive three one-on-one therapy sessions with a Charles Drew LIMHP that will be completed by the end of the FFL program.
89607092|NCT03548792|Other|RSA radiostereometric analysis|30 patients in each Group Persona or Nexgen will receive tantalus beads to achieve RSA analysis comparing micromevements in radiographs.
89607093|NCT03548792|Other|Clinical comparison|Clinical comarison using different patient reported outcome measures and objective measures (ActivePAL, walking speed)
89607094|NCT03529695|Active Comparator|Standard HVP Curriculum|"Participants will receive the standard Healthy Families America (HFA) home visitation curriculum delivered by trained home visitors. The HFA model meets the Department of Health and Human Services criteria for an evidence-based early childhood home visiting service delivery model. HFA services begin prenatally and continue until children are 2-5yo. The curriculum focuses on strengthening parent-child relationships and family functioning, promoting positive child development, and linkage to community resources. Accredited home visitors are matched to families on cultural background and language, to provide culturally sensitive services. Home visitors receive weekly supervision, ongoing developmental training, and have limited caseloads (10-15 families) to meet their families' needs."
89607095|NCT03529695|Experimental|Obesity Prevention|Participants will receive the standard Healthy Families America home visitation curriculum with the obesity prevention enhancement module, delivered by trained home visitors. Families are matched to home visitors based on their ethnicity/race and language preferences. The obesity prevention program targets 4 key behaviors (physical activity, fruit and vegetable consumption, sugary beverages, fried foods) aimed at reducing obesity risks in mothers and their children. Participants will also be provided opportunities to meet in groups with other participating mothers/infants to enhance social networks that support healthy eating and physical activity.
89607096|NCT03529448|Experimental|TN-TC11G, radiotherapy and Temozolomide Oral Product|"During Phase Ib, Four to seven weeks after surgical diagnosis, concurrent with radiotherapy (STUPP)~+ temozolomide (75mg/m2/day for 42 days) +TN-TC11G will be evaluated. During radiation therapy, temozolomide and TN-TC11G will be administered. This last, as the dose that have been selected previously, based on dose-titration period. Patient specific dose will remain until progresion of disease, unacceptable toxicity, non-compliance, consent withdrawal up to 2 years."
89607097|NCT03526250|Experimental|Treatment (palbociclib)|Patients receive palbociclib PO QD on days 1-21. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
89607098|NCT03519412|Experimental|MMR-proficient (MMRp)|MGMT-IHC-negative, MGMT promoter methylation-positive patient population is selected for treatment with temozolomide (induction) orally until disease progression or unacceptable toxicity whichever comes first, followed by pembrolizumab IV if Tumor Mutational Burden post Temozolomide is > 20 Muts/Mb
89607099|NCT03519412|Other|MMR-deficient (MMRd)|Patients receive Pembrolizumab (treatment) IV until disease progression or unacceptable toxicity or 35 cycles, whichever comes first
89607100|NCT03517761|Experimental|Bone Marrow Concentrate treatment|Bone marrow concentrate subjects will undergo a bone marrow aspiration of approximately 30-60 cc. Platelet rich plasma (PRP) and platelet lysate (PL) will be derived from the bone marrow aspirate and later mixed with the bone marrow nucleated cell layer. Injectate will then be used to treat the ligaments in the CCJ and upper cervical injections to C0-C3 ligaments and facets.
89607101|NCT03517761|Sham Comparator|Sham Control|Control subjects will also undergo a bone marrow aspiration of 30-60 cc to maintain blinding. Control subjects will receive a sham procedure of a small skin puncture to the posterior oropharynx guided under fluoroscopy while under anesthesia as well as receive sham upper cervical injections to C0-C3 ligaments and facets.
89032795|NCT02924766|Experimental|Niraparib + Apalutamide/[Abiraterone Acetate + Prednisone]|Participants will receive initial starting dose of Niraparib 200 milligram (mg) once daily in combination either with Apalutamide 240 mg (4*60 mg) once daily or Abiraterone Acetate 1000 mg (4*250 mg) plus 10 mg Prednisone (5 mg twice daily) for 28 days of cycle 1. Once a safe dose of niraparib is selected with each Andrgen Receptor (AR)-targeted therapy [Apalutamide or Abiraterone Acetate plus Prednisone], then an expansion phase (Part 2) will open to further explore safety and assess antitumor activity.
89607102|NCT03514433|No Intervention|Historical Control|This study will be utilizing electronic health record data to identify patients that match the TRIP eligibility criteria and received patient navigation prior to study rollout in June 2018. These patients will receive standard patient navigation at their care site and will act as historical controls in comparison to the TRIP experimental group.
89607103|NCT03514433|Experimental|TRIP Patient Navigation Intervention|This study will be enhancing current patient navigation at the participating 6 hospitals with the 3 components of the TRIP intervention (a shared patient registry, a social determinants of health platform, and additional training and support for Patient Navigators). All patients that are identified as TRIP eligible will receive these intervention benefits and will be categorized into the experimental arm of the study.
89607104|NCT03513406|Active Comparator|Sugammadex|Muscle relaxant reversal will be attained with sugammadex 2 mg/kgm IV.
89607105|NCT03513406|Active Comparator|Neostigmine|Muscle relaxant reversal will be attained with neostigmine 50 mcg/kgm plus glycopyrrolate10 mcg/kgm IV.
89607106|NCT03504163|Experimental|High Risk T1 Bladder Cancer Cohort|Pts will receive pembrolizumab/MK-3475 after transurethral resection of bladder tumor/TURBT in comb w/BCG as initial therapy. Pembrolizumab (MK-3475) will be administered as a 400 mg IV infusion at 6-wk intervals for 9 doses over a 48-wk period, unless there is unacceptable toxicity or other reasons to discontinue treatment occur. Intravesical BCG therapy (TICE strain, 50 mg) will be given 1x-weekly for 6 consecutive wks as a standard induction course, followed by maintenance BCG consistent w/standard clinical practice. BCG will start on wk 3 after the first infusion of pembrolizumab (400 mg) to allow for initial priming of T cells to further enhance the effects of BCG treatment.
89607107|NCT03504163|Experimental|Exploratory cohort for high-grade non-muscle-invasive upper tract urothelial carcinoma|Pts will receive pembrolizumab (MK-3475) administered after ureteroscopy/laser ablation in comb w/BCG as initial therapy. Pembrolizumab (MK-3475) will be administered as 400 mg IV infusion at 6-week intervals for 9 doses over a 48-week period, unless there is unacceptable toxicity or other reasons that would warrant the discontinuation of treatment. Pts will receive once-weekly BCG therapy (TICE strain, 50 mg) for 6 consecutive wks as a standard induction course administered through a percutaneous nephrostomy tube in antegrade fashion for patients with high-grade NMI-UTUC, consistent with standard clinical practice. BCG will start on wk 3 after the first infusion of pembrolizumab (400 mg) to allow for initial priming of T cells to further enhance the effects of BCG treatment.
89607108|NCT03500458|No Intervention|Typical Sleep|All participants will sleep for 6 nights (Sunday - Thursday) in the home environment per their usual school schedule.
89607109|NCT03500458|Experimental|Sleep Extension|Participants will be prescribed a sleep schedule that allows them to obtain 1 hour more time in bed compared to Typical Sleep. For participants completing the study September 2021 and later, they will also be instructed to take exogenous melatonin (500mcg) and maintain dim light conditions 2 hours before bedtime, and use light glasses for 30 minutes in an upright position after waking in the morning (Sleep Extension + Circadian Manipulation).
89607110|NCT03492944||Ultrasound Microbubble Contrast Agent|All subjects will receive intravenous Lumason microbubble contrast agent; there is no comparative ultrasound contrast agent. Contrast Enhanced Ultrasound findings/results will be correlated with comparable, clinically performed, CTE/MRE findings/results
88982491|NCT05823805|No Intervention|Quality Improvement dashboard|Family physicians with ten or more patients living with schizophrenia and/or bipolar disorder will have access to an individualized reports, which presents data on patient's preventive health care status and engagement in care.
88982492|NCT05823025||Hypertension|Hypertensive patient
89607111|NCT03471078|Experimental|Avatrombopag|Study is 2:1 randomization ratio (avatrombopag to placebo). Investigational product administered orally once daily for 5 days prior to chemotherapy and 5 days following chemotherapy treatment.
89607112|NCT03471078|Placebo Comparator|Placebo|Study is 2:1 randomization ratio (avatrombopag to placebo). Investigational product administered orally once daily for 5 days prior to chemotherapy and 5 days following chemotherapy treatment.
89607113|NCT03465748|Experimental|Experimental-OrthoK|The study will be a randomized control study using a single-masked design to investigate axial elongation and myopic progression in children wearing ortho-k lenses (study group) versus single-vision spectacles or soft contact lenses (control group) for a period of 24 months. A minimum of 40 and a maximum of 60 subjects will be recruited from patients at Illinois Eye Institute. Once eligibility has been determined by an unmasked observer, patients will be randomly assigned to either the orthokeratology group or the single-vision contact lens /spectacle group
89607114|NCT03465748|No Intervention|Control|The study will be a randomized control study using a single-masked design to investigate axial elongation and myopic progression in children wearing ortho-k lenses (study group) versus single-vision spectacles (control group) for a period of 24 months. A minimum of 40 and a maximum of 60 subjects will be recruited from patients at Illinois Eye Institute. Once eligibility has been determined by an unmasked observer, patients will be randomly assigned to either the orthokeratology group or the single-vision contact lens /spectacle group
89607115|NCT03464955|No Intervention|Control|The control group will be provided standard of care, which is no use of technologies.
89607116|NCT03464955|Experimental|Intervention Group with Passive Content|Interventional arm will use technology based distractions (VR headsets, AR headset, tablets, or BERT projector) to prevent high anxiety before non-invasive surgical subspecialty procedures.
89607117|NCT03464955|Experimental|Intervention Group with Active Content|Interventional arm will use technology based distractions (VR headsets, AR headset, tablets, or BERT projector) to prevent high anxiety before non-invasive surgical subspecialty procedures.
89607118|NCT03451916|Experimental|PLX-PAD|• Arm 1 - PLX-PAD (120 subjects): 150×10^6 PLX-PAD cells (10×10^6 cells/mL) in a mixture containing 10% DMSO (v/v), 5% HSA (w/v) and PlasmaLyte.
89607119|NCT03451916|Placebo Comparator|Placebo|Arm 2 Placebo (120 subjects): Placebo (solution comprised of 10% DMSO [v/v], 5% HSA [w/v], and PlasmaLyte, without cells).
89607120|NCT03435952|Experimental|Pembrolizumab + Clostridium novyi-NT|"Participants receive Pembrolizumab by vein over about 30 minutes on Day 0 and then every 3 weeks for up to 12 months.~Clostridium novyi-NT injected into the tumor on Day 8.~Starting on Day 15, participant takes Doxycycline by mouth 2 times a day for the rest of participant's life to lower the risk of further growth of Clostridium novyi-NT"
89607121|NCT03421145|Experimental|3M™ Oral Rinse|Subjects assigned to the Experimental Oral Rinse ('Plaque control device) will swish a volume of 15 mL of the Experimental Rinse for 30 seconds followed by expectoration, twice a day (morning and evening), after brushing teeth, for the 6-month duration of the study. They will use the dosing cup provided by the study team to ensure that the proper dose of rinse is used. Subjects will be instructed not to eat or drink for 30 minutes after using the rinse and to complete the subject daily diary.
89607122|NCT03421145|Placebo Comparator|Vehicle Control Oral Rinse|Vehicle control oral rinse (no active ingredient). Subjects assigned to the Placebo Comparator will swish a volume of 15 mL of the Placebo Comparator rinse for 30 seconds followed by expectoration, twice a day (morning and evening), after brushing teeth, for the 6-month duration of the study. They will use the dosing cup provided by the study team to ensure that the proper dose of rinse is used. Subjects will be instructed not to eat or drink for 30 minutes after using the rinse and to complete the subject daily diary.
89607123|NCT03421145|Active Comparator|PerioShield™ Oral Health Rinse|Active control predicate device oral rinse ('Plaque control agent') Subjects assigned to the Active Comparator will swish a volume of 10 mL of the Active Comparator rinse for 30 seconds followed by expectoration, twice a day (morning and evening), after brushing teeth, for the 6-month duration of the study. They will use the dosing cup provided by the study team to ensure that the proper dose of rinse is used. Subjects will be instructed not to eat or drink for 30 minutes after using the rinse and to complete the subject daily diary.
89607124|NCT03421145|Sham Comparator|Water|Water sham control oral rinse (not a Plaque control agent) Subjects assigned to the Sham Comparator will swish a volume of 15 mL of the Sham Comparator rinse for 30 seconds followed by expectoration, twice a day (morning and evening), after brushing teeth, for the 6-month duration of the study. They will use the dosing cup provided by the study team to ensure that the proper dose of rinse is used. Subjects will be instructed not to eat or drink for 30 minutes after using the rinse and to complete the subject daily diary.
89607125|NCT03418779|Experimental|Control Group|Optimized supportive care, YQF placebo (oral granule), immunosuppression therapy comprises oral prednisolone plus intravenous cyclophosphamide.
88982493|NCT05823025||Sleep apnea or COPD|Patient having sleep apnea or COPD (Chronic obstructive pulmonary disease)
88982494|NCT05820997|Active Comparator|Paravertebral Block Pre Procedure|Subject will receive a preoperative paravertebral block only
88982495|NCT05820997|No Intervention|No Paravertebral Block|Subject will receive no paravertebral block.
88982496|NCT05820581|Experimental|Mentalisation|4 mentalisation groups will be defined: hypomentalisation, hypermentalisation, mentalisation correct and lack of mentalisation
88982497|NCT05820178|Experimental|tDCS treatment group|On the basis of conventional treatment, tDCS was given on day 2 after enrollment for a total of 14 days, once a day.
88982498|NCT05820178|Experimental|rTMS treatment group|On the basis of conventional treatment, rTMS was given on day 2 after enrollment for a total of 14 days, once a day.
88982499|NCT05820178|No Intervention|conventional treatment group|Not receiving any neuromodulation treatment.
88982500|NCT05818631||MRI +|PI-RADS 3-5
88982501|NCT05818631||MRI -|PI-RADS 1-2
88982502|NCT05817188||Dementia patients|This register-based project will include all patients diagnosed with dementia and registered in the Swedish Registry for Cognitive/Dementia Diseases. Identification of cases and control and data collation are carried out by Swedish authorities.
89607126|NCT03418779|Experimental|YQF Group|Optimized supportive care, YQF (oral granule), immunosuppression therapy comprises oral prednisolone plus intravenous cyclophosphamide.
89607127|NCT03409588|Experimental|Study Drug|Riociguat (Adempas) 0.5mg to 2.5 mg three time daily - oral medication
89607128|NCT03404297|Experimental|Immediate Compression Therapy Arm|Patients in this arm will receive a locally sourced version of compression therapy while concurrently receiving chemotherapy
89607129|NCT03404297|Placebo Comparator|Delayed Compression Therapy Arm|Patients in this arm will receive a locally sourced version of compression therapy after completing ~ 14 weeks of chemotherapy.
89607130|NCT03387085|Experimental|NANT triple negative breast cancer (TNBC) Vaccine|A combination of agents will be administered to subjects in this study: Aldoxorubicin HCl, N-803, ETBX-011, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK, avelumab, bevacizumab, capecitabine, cisplatin, cyclophosphamide, 5-fluorouracil, leucovorin, nab-paclitaxel, SBRT.
89607131|NCT03385928|Active Comparator|Tranexamic acid|Intravenous tranexamic acid 1000 mg in 100 mL 0.9% NaCl (or in 50ml syringe with 0.9% NaCl) over 10 minutes followed by 1000 mg in 500 mL 0.9% NaCl infusion over 8 hours.
89607132|NCT03385928|Placebo Comparator|Normal Saline (0.9% NaCl)|100 mls (or in 50ml syringe) intravenous 0.9%NaCl over 10 minutes followed by 500 ml intravenous 0.9% NaCl infusion over 8 hours.
89607133|NCT03382340|Experimental|Imx-110|
89607134|NCT03374254|Experimental|Pembrolizumab + Binimetinib (Cohort A)|During Part 1, participants in Cohort A will receive a standard dose (DL1) of pembrolizumab (200 mg) intravenous (IV) every 3 weeks (Q3W) plus binimetinib orally at a starting dose of 30 mg twice a day (BID). Based on dose-limiting toxicities (DLT) assessed during the initial 21 days of Cycle 1, the dose of binimetinib may be escalated to 45 mg orally BID (Dose Level 2 [DL2]). Once a preliminary RP2D for binimetinib is identified in Part 1 for Cohort A, participants will receive pembrolizumab 200 mg IV Q3W plus binimetinib orally at the preliminary RP2D during Part 2.
89607135|NCT03374254|Experimental|Pembrolizumab + mFOLFOX7 (Cohort B)|During Part 1, participants in Cohort B will receive a standard dose (DL1) of pembrolizumab 200 mg IV Q3W plus mFOLFOX7 (oxaliplatin 85 mg/m^2; leucovorin [calcium folinate] 400 mg/m^2; fluorouracil [5-FU] 2400 mg/m^2 over 46-48 hours) IV every 2 weeks (Q2W). Based on DLTs assessed during the initial 28 days of Cycle 1, the dose of mFOLFOX7 may be de-escalated to oxaliplatin 70 mg/m^2; leucovorin (calcium folinate) 400 mg/m^2; 5-FU 2000 mg/m^2 over 46-48 hours] IV Q2W. Once a preliminary RP2D for mFOLFOX7 is identified in Part 1 for Cohort B, participants will receive pembrolizumab 200 mg IV Q3W plus mFOLFOX7 at the preliminary RP2D during Part 2.
89607136|NCT03374254|Experimental|Pembrolizumab + mFOLFOX7 + Binimetinib (Cohort C)|After an RP2D for mFOLFOX7 is identified in Part 1 for Cohort B, participants may enroll in Cohort C and receive pembrolizumab 200 mg IV Q3W plus mFOLFOX7 at the preliminary RP2D Q2W in combination with binimetinib orally at a starting dose of 30 mg BID during Part 1. Based on DLTs assessed during the initial 28 days of Cycle 1, the dose of binimetinib may be escalated to 45 mg orally BID (DL2). Once a preliminary RP2D for binimetinib is identified in Part 1 for this cohort, participants in Part 2 will receive pembrolizumab 200 mg IV Q3W plus mFOLFOX7 at the RP2D determined for Cohort B Q2W plus binimetinib orally at the RP2D determined for Cohort C in Part 1.
89607137|NCT03374254|Experimental|Pembrolizumab + FOLFIRI (Cohort D)|During Part 1, participants in Cohort D will receive a standard dose (DL1) of pembrolizumab 200 mg IV Q3W plus FOLFIRI (irinotecan 180 mg/m^2; leucovorin [calcium folinate] 400 mg/m^2; 5-FU 2400 mg/m^2 over 46-48 hours) IV Q2W. Based on DLTs assessed during the initial 28 days of Cycle 1, the dose of FOLFIRI may be de-escalated to irinotecan 150 mg/m^2; leucovorin (calcium folinate) 400 mg/m^2; 5-FU 2000 mg/m^2 over 46-48 hours) IV Q2W. Once a preliminary RP2D for FOLFIRI is identified in Part 1 for Cohort D, participants will receive pembrolizumab 200 mg IV Q3W plus FOLFIRI at the preliminary RP2D during Part 2.
89607138|NCT03374254|Experimental|Pembrolizumab + FOLFIRI + Binimetinib (Cohort E)|After an RP2D for FOLFIRI is identified in Part 1 for Cohort D, participants may enroll in Cohort E and receive pembrolizumab 200 mg IV Q3W plus FOLFIRI at the preliminary RP2D Q2W in combination with binimetinib orally at a starting dose of 30 mg BID during Part 1. Based on DLTs assessed during the initial 28 days of Cycle 1, the dose of binimetinib may be escalated to 45 mg orally BID (DL2). Once a preliminary RP2D for binimetinib is identified in Part 1 for this cohort, participants in Part 2 will receive pembrolizumab 200 mg IV Q3W plus FOLFIRI at the RP2D determined for Cohort D Q2W plus binimetinib orally at the RP2D determined for Cohort E in Part 1.
89607139|NCT03356028|Other|impacted by the attack of 14 July 2016|characterize the psycho-social factors of risk and / or protection interfering in the children's future with questionnaire following the mass trauma of 14 July 2016 in Nice on a sample of exposed pediatric population
89607140|NCT03356028|Other|control group|characterize the psycho-social factors of risk and / or protection interfering in the children's future with questionnaire of children controls
89607141|NCT03354728|Experimental|Supportive Care (multi-antigen CMV-modified vaccinia ankara)|Patients receive multi-antigen CMV-modified vaccinia ankara vaccine IM on days 28 and 56 post-HCT.
89607142|NCT03350126|Experimental|Experimental arm|Therapy induction (12 weeks) Nivolumab (IV) and Ipilimumab (IV) - every 21 days - 4 cycles Then Nivolumab (IV) alone every 15 days - 20 cycles - until 12 months
89607143|NCT03347929|Experimental|Naproxen|Naproxen 500 mg twice daily
88982503|NCT05807477||Adult healthy subjects|Adult healthy subjects capable of undergoing controlled hypoxemia to the levels outlined in the desaturation profile in an at rest state
89607144|NCT03347929|Placebo Comparator|Placebo|Placebo 1 tablet twice daily
89607145|NCT03341130|Experimental|Treatment Group|The treatment group will will be treated a mandibular advancement oral appliance following standard practices. The treatment group will also receive a mandibular repositioning splint to wear in the mornings for a minimum of 1 hour following removal of their mandibular advancement oral appliance, in an effort to reduce the side effects resulting from use of the mandibular advancement oral appliance.
89607146|NCT03341130|Experimental|Positive Control Group|The positive control group will will be treated a mandibular advancement oral appliance following standard practices. The positive control group will not receive any additional oral appliances. Side effects resulting from use of the mandibular advancement oral appliance will be managed using standard practices, including jaw stretching exercises as needed for comfort.
88982504|NCT05807464||Adult healthy subjects|Adult healthy subjects capable of undergoing controlled hypoxemia to the levels outlined in the desaturation profile in an at rest state
89607147|NCT03341130|No Intervention|Negative Control Group|The negative control group is comprised of 15 healthy individuals recruited specifically from faculty members at the UBC Faculty of Dentistry. This group will undergo the same clinical data collection as the treatment group and the negative control group but will not receive any treatment.
89607148|NCT03335917|Placebo Comparator|Normobaric Normoxia|This will serve as the exercise only control trial
89607149|NCT03335917|Experimental|Normobaric Hypoxia|This arm will provide hypoxia by reducing the amount of oxygen concentration without changing the barometric pressure
89607150|NCT03335917|Experimental|Hypobaric Hypoxia|This arm will provide hypoxia by reducing the barometric pressure without changing the oxygen concentration (terrestrial altitude exposure)
89607151|NCT03326726|Experimental|Chlorhexidine Gluconate|2% CHG
89607152|NCT03308188|No Intervention|Treatment As Usual|Participants randomized to Treatment As Usual will receive treatment for chronic pain as typically provided by their clinician -- they will receive no extra treatment from the study.
89607153|NCT03308188|Experimental|E-Health+|Participants randomized to the E-health+ arm will receive treatment as typically provided by their clinician plus a 4-month subscription to the E-health program, which is an internet based chronic pain program.
89607154|NCT03300336|Experimental|Intervention|Implementation of STRIDE program
88982505|NCT05805722|Experimental|Behavioral Counseling for Tobacco Cessation|Behavioral counseling for tobacco cessation consists of psychoeducation in combination with evidence-based behavior change techniques including stimulus control, self-monitoring, goal-setting, implementation planning, and problem-solving. Specific content topics include the harms of smoking/benefits of quitting, coping with cravings and withdrawal, setting a quit date, managing social influences, and relapse prevention.
88982506|NCT05793242|Active Comparator|Static stretching|The static stretch group participants will perform a self-facilitated stretch by looping a strap around the heel of their foot and grasping it with both hands followed by pulling the strap to raise the fully extended leg into hip flexion. The participant will then lift the leg until they reach their maximal tolerable point and then alternate between periods of resting and stretching for a total of 5 minutes.
88982507|NCT05793242|Experimental|Hypervolt|The HyperVolt percussive massage group participants will receive a therapist-performed HyperVolt technique to the hamstrings for a period of 5 minutes.
88982508|NCT05793242|Experimental|Body tempering|The body tempering group participants will receive a therapist-performed body tempering technique to the hamstrings for a period of 5 minutes.
88982509|NCT05793242|Experimental|Dry cupping|The dry cupping group participants will receive a therapist-performed dry cupping technique to the hamstrings for a period of 5 minutes.
88982510|NCT05780957||Firefighters who receive multi-cancer early detection (MCED) test|
88982511|NCT05776017|Experimental|Test Vaccine|MSP3-CRM-Vac4All/ Alhydrogel®
88982512|NCT05776017|Active Comparator|Control Vaccine|Anti-rabies vaccine
88982513|NCT05754008|Experimental|AURORA Care Strategy|Participants will receive the AURORA Care Strategy in addition to their usual diabetes care.
88982514|NCT05754008|No Intervention|Usual Care|No intervention will be employed. This arm will continue to receive their usual diabetes care.
88982515|NCT05750004|Experimental|Computer guided immediate implant placement|Atraumatic extraction followed by immediate implant placement using safe angle position computer guided surgical stents.
88982516|NCT05749081|Experimental|Lacidophilin tablets group|2400mg lacidophilin tablets three times daily,1000mg amoxicillin capsules three times daily and 20mg vonoprazan Fumarate Tablets twice daily for 10 days
88982517|NCT05749081|Placebo Comparator|Placebo group|2400mg placebo three times daily,1000mg amoxicillin capsules three times daily and 20mg vonoprazan Fumarate Tablets twice daily for 10 days
88982518|NCT05730517|Active Comparator|Test group 1 (CP5HA Group)|Participants will receive investigational product 1 containing collagen (5 g/ 15 mL), hyaluronic acid (30 mg/ 15 mL) and vitamin C (80 mg/ 15 mL).
88982519|NCT05730517|Placebo Comparator|Placebo group|Placebo group participants will receive placebo syrup without active ingredients. (daily dose 15 mL: collagen: 0 mg, HA: 0 mg, vitamin C: 0 mg); continous administration of placebo product for 12 weeks.
89607155|NCT03300336|No Intervention|Usual Care|Pre-implementation before STRIDE program
89607156|NCT03297307|Experimental|Mother-Child with Intervention|Children will attend presurgical visits with their mother
89607157|NCT03297307|No Intervention|Mother-Child Non-Intervention|Children will not attend presurgical visits with their mother
89607158|NCT03294278|Active Comparator|Ablation plus ICD|Epicardial ablation by radio-frequency
89607159|NCT03294278|Active Comparator|ICD alone|Implantation of ICD
89607160|NCT03248570|Experimental|DNA damage repair proficient group|Twenty-five subjects with mismatch repair (MMR) intact
89607161|NCT03248570|Experimental|DNA damage repair defective group|Twenty-five subjects with defective DNA repair
89607162|NCT03244189|Experimental|Intervention|"Participants in the intervention arm will receive an individualized fluid prescription, which will be the additional volume of fluid intake needed to maintain a study-specified urine output. This fluid will be consumed from and measured by a smart water bottle. The intervention arm also includes a behavioral program that consists of financial incentives and structured problem solving (SPS) to maintain the recommended fluid intake."
89607163|NCT03244189|No Intervention|Control|"Participants in the control arm will receive standard care instructions according to American Urological Association (AUA) guidelines to increase overall fluid consumption to achieve study-specified urine output. They will also receive a smart water bottle with capability to self-monitor their fluid intake."
89607164|NCT03237689|Experimental|Hydrocortisone|Low dose hydrocortisone (10mg orally)
89607165|NCT03237689|Placebo Comparator|Placebo|Placebo tablets, made of starch 1500 powder
89607166|NCT03233204|Experimental|Treatment (olaparib)|Patients receive olaparib PO BID on days 1-28. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.
89607167|NCT03216525|Active Comparator|Oral Alvimopan|Oral Alvimopan (Entereg, Merck) 12 mg between 30 minutes and 3 hours before surgery start and twice-daily oral doses postoperatively beginning on day one (AM and PM dosing) until hospital discharge or a maximum of 7 days (15 in-hospital doses).
89607168|NCT03216525|Placebo Comparator|Matching Placebo|Matching placebo between 30 minutes and 3 hours before surgery start and twice-daily oral doses postoperatively beginning on day one (AM and PM dosing) until hospital discharge or a maximum of 7 days (15 in-hospital doses).
89607169|NCT03206060|Experimental|1/Lu-177-DOTATATE|Lu-177-DOTATATE is administered IV every 8 (+/- 2) weeks, for a total of 4 administrations. A Ga-68-DOTATATE PET and F-18-FDG-PET, as well as CT/ MRI for RECIST monitoring, will be obtained post 2 administrations and post 4 administrations. Concomitant administration of an IV infusion of an amino acid (AA) solution will also be done for renal protection. Concomitant administration of an IV infusion of an amino acid (AA) solution will also be done for renal protection.
89607170|NCT03198494|Experimental|Acoustic 1Hz Stimulation|1 Hz acoustic stimulation applied via headphones and downloadable phone application during sleep every night.
89607171|NCT03198494|Sham Comparator|Sham Background Noise|Background noise applied via headphones and downloadable phone application during sleep every night.
89607172|NCT03198494|No Intervention|Baseline Seizure Monitoring|No use of sound system; Patients record seizures in a diary.
89607173|NCT03190915|Experimental|Treatment (trametinib)|Patients receive trametinib PO QD on days 1-28 of each cycle. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo a bone marrow aspiration or biopsy at baseline, on day 28 of cycles 1 and 2, at all subsequent odd numbered cycles, and at end of treatment.
89607174|NCT03190863|Experimental|Motor imagery combined with neurofeedback (MINF)|
89607175|NCT03190863|Active Comparator|Motor imagery (MI)|
89607176|NCT03190863|Sham Comparator|Control (C)|
89607177|NCT03189420||Glioblastoma|Samples of brain tumor diagnosed as glioblastoma
89607178|NCT03189420||Low grade glioma|Samples of brain tumor diagnosed as low grade glioma
89607179|NCT03175159|Active Comparator|Standard of Care (SOC)|Sexual risk-reduction counseling sessions.
89607180|NCT03175159|Experimental|Behavioral Activation & Risk Reduction Counseling|Behavioral activation with risk reduction counseling.
89607181|NCT03143270|Experimental|Cohort 1, deb-TACE + Nivolumab|3 eligible participants will undergo deb-TACE on Day 0 (+/- 5 days). Two weeks after deb-TACE, participants will begin nivolumab every two weeks for up to one year. If no participants experience a dose limiting toxicity (DLT), or 1 of 6 participants experiences a DLT, a new group of participants will be enrolled into Cohort 2.
89607182|NCT03143270|Experimental|Cohort 2, deb-TACE + Nivolumab|3 eligible participants will undergo deb-TACE on Day 0 (+/- 5 days). Participants will receive nivolumab every two weeks for up to one year, starting 4 weeks prior to deb-TACE (week -4). Participants in this cohort will not receive nivolumab on the day of deb-TACE. If no participants experience a DLT in the initial group of 3 participants or if 1 of 6 participants experiences a DLT, a new group of participants will be enrolled into Cohort 3.
89607183|NCT03143270|Experimental|Cohort 3, deb-TACE + Nivolumab|3 eligible participants will undergo deb-TACE on Day 0 (+/- 5 days). Nivolumab will be dosed every two weeks starting 4 weeks prior to deb-TACE (Week 4) and continue every 2 weeks for up to one year. If no participants experience a DLT in the initial group of 3 participants, an additional 3 participants will be added to confirm safety. If less than or equal to 1 of 6 participants experiences a DLT, this will be considered the optimal schedule.
89607184|NCT03130439|Experimental|Abemaciclib|-Abemaciclib will be administered orally, twice daily on days 1 to 28
89607185|NCT03123731|Active Comparator|Control Arm|Participants will wear a Fitbit but will not receive any additional elements of the iSTEP intervention.
89607186|NCT03123731|Experimental|iSTEP PA intervention|Participants will wear a Fitbit and receive interactive daily text messages that are designed to motivate moderate physical activity (PA) and reduce sedentary behavior, including setting weekly goals to increase average daily step counts.
88982520|NCT05730517|Active Comparator|Test group 2 (CP5 Group)|Participants will receive investigational product 2 containing collagen (5 g/ 15 mL) and vitamin C (80 mg/ 15 mL).
88982521|NCT05717543|Experimental|Patient with corneal pathology, crystalline pathology, or pigmentary glaucoma|"Patient with corneal pathology, crystalline pathology, or pigmentary glaucoma will be included.~Imaging by retroillumination will be realized. In case of bilateral disease, both eyes will be photographed"
88982522|NCT05707793||women suffering from vaginal laxity|self-reported perception of vaginal laxity on the Vaginal Laxity Questionnaire
88982523|NCT05707793||normal subjects without vaginal laxity|No self-reported perception of vaginal laxity on the Vaginal Laxity Questionnaire
88982524|NCT05679167|Active Comparator|Supervised digital training: core stability|The patients will be identified at the primary health center and after fulfilling the inclusion criteria and all baseline examination are completed the patients will be randomized. In group 1 the patients will attend supervised digital training with focus on core stability
88982525|NCT05679167|Active Comparator|Supervised digital training: aerobic exercise|The patients will be identified at the primary health center and after fulfilling the inclusion criteria and all baseline examination are completed the patients will be randomized. In group 2 the patients will attend supervised digital training with focus on aerobic exercise
88982526|NCT05679167|Active Comparator|Non-supervised daily physical activity|The patients will be identified at the primary health center and after fulfilling the inclusion criteria and all baseline examination are completed the patients will be randomized. In group 3 will start a daily physical activity program, with regular support from a physiotherapist.
88982527|NCT05665270|Experimental|Dextenza|Group 1 (20 eyes) will receive treatment with topical 1% Prednisolone Acetate drops QID x 1 week, then Dextenza will be inserted at the one-week postoperative evaluation (Day 8).
88982528|NCT05665270|Active Comparator|Prednisolone Acetate|Group 2 (20 eyes) will receive treatment with topical 1% Prednisolone Acetate for five weeks with dosing schedule: QID x 2 weeks, TID x 1 week, BID x 1 week, QD x 1 week.
89607187|NCT03123731|Experimental|iSTEP PA and diet intervention|Participants will wear a Fitbit and receive interactive daily text messages that are designed to motivate moderate physical activity (PA), reduce sedentary behavior, and promote adherence to a Mediterranean-style diet. Participants will also be administered diet counseling from a registered dietitian and receive weekly feedback on both physical activity and diet behaviors.
89607188|NCT03113968|Active Comparator|electroconvulsive therapy (ECT)|Treatments will be given 3 times a week up to a total of 9 treatments over 3 - 5 weeks. Initial ECT treatment is Right Unilateral (RUL) ultra-brief pulse at 6X seizure threshold. Seizure threshold and dose can be increased per investigator and patient discretion.
89607189|NCT03113968|Active Comparator|ketamine infusion|Treatments will be given 2 times a week up to a total of 6 treatment over 3 - 5 weeks. Initial standard dose will be 0.5 mg/kg infusion over 40 min. The dose can be modified if clinically warranted per investigator and patient discretion.
89607190|NCT03112174|Experimental|Safety Run-in Period|"Subjects are enrolled into the open-label Safety Run-in Period to evaluate the occurrence of tumor lysis syndrome (TLS) and DLTs with the concurrent administration of ibrutinib and venetoclax.~Safety run-in phase for the study is closed to further enrollment as of 07-Nov-2018."
89607191|NCT03112174|Experimental|Phase 3: Ibrutinb + Venetoclax|Subjects will be randomized to receive ibrutinib and venetoclax/placebo until clinical disease progression or unacceptable toxicity
89607192|NCT03112174|Placebo Comparator|Phase 3: Ibrutinib + Placebo|Subjects will be randomized to receive ibrutinib and venetoclax/placebo until clinical disease progression or unacceptable toxicity
89607193|NCT03112174|Experimental|Treatment-naive|"This open-label arm is designed to explore the efficacy and safety of the combination of ibrutinib and venetoclax in subjects with treatment-naive MCL.~Approximately 75 subjects (of which ~25 subjects with TP53 mutation) will be enrolled and treated with ibrutinib and venetoclax."
89607194|NCT03095066|Placebo Comparator|Stage 1: Placebo|Participants will receive AVP-786 matching placebo capsules, orally, twice daily (BID) during Weeks 1 to 6 of the Stage 1 treatment period.
89607195|NCT03095066|Experimental|AVP-786|Participants will receive AVP-786-28/4.9 (deudextromethorpan hydrobromide [d6-DM] 28 milligrams (mg)/quinidine sulfate [Q] 4.9 mg) capsule, along with AVP-786 matching placebo capsule, orally, once daily (QD) during Week 1 followed by AVP-786-28/4.9 capsule, orally, BID during Week 2, and AVP-786-42.63/4.9 (d6-DM 42.63 mg/Q 4.9 mg) capsules (target dose), orally, BID during Weeks 3 to 12 of the treatment period.
89607196|NCT03095066|Placebo Comparator|Stage 1: Placebo Non-responders to Stage 2: Placebo|"Participants who will be randomized to receive placebo in Stage 1 and will be classified as non-responders (responders if modified Clinical Global Impression of Severity [mCGI-S] score is ≤ 3 at Day 43 and Neuropsychiatric Inventory Clinician (NPI-C)-3 score has decreased by ≥ 25% from baseline. Participants who will not meet these criteria will be considered non-responders) after Week 6 will be re-randomized to continue receiving AVP-786 matching placebo capsules, orally, BID during Weeks 7 to 12 of the Stage 2 treatment period."
89607197|NCT03095066|Experimental|Stage 1: Placebo Non-responders to Stage 2: AVP-786|"Participants who will be randomized randomized to receive placebo in Stage 1 and will be classified as non-responders (responders if mCGI-S score is ≤ 3 at Day 43 and NPI-C-3 score has decreased by ≥ 25% from baseline. Participants who will not meet these criteria will be considered non-responders) after Week 6 will be re-randomized to receive AVP-786 in Stage 2 using the same dose escalation schedule used in Stage 1 i.e., AVP-786-28/4.9 capsule, along with AVP-786 matching placebo capsule, orally, QD during Week 7 followed by AVP-786-28/4.9 capsule, orally, BID during Week 8, and AVP-786-42.63/4.9 capsules, orally, BID, during Weeks 9 to 12 of the Stage 2 treatment period."
89607198|NCT03095066|Placebo Comparator|Stage 1: Placebo Responders to Stage 2: Placebo|"Participants who will be randomized to receive placebo in Stage 1 and will be classified as responders (responders if mCGI-S score is ≤ 3 at Day 43 and NPI-C-3 score has decreased by ≥ 25% from baseline) after Week 6 will be re-randomized to continue receiving AVP-786 matching placebo capsules, orally, BID during Weeks 7 to 12 of the Stage 2 treatment period."
89607199|NCT03095066|Experimental|Stage 1: Placebo Responders to Stage 2: AVP-786|"Participants who will be randomized to receive placebo in Stage 1 and will be classified as responders (responders if mCGI-S score is ≤ 3 at Day 43 and NPI-C-3 score has decreased by ≥ 25% from baseline) after Week 6 will be re-randomized to receive AVP-786 in Stage 2 using the same dose escalation schedule used in Stage 1 i.e., AVP-786-28/4.9 capsule, along with AVP-786 matching placebo capsule, orally, QD during Week 7 followed by AVP-786-28/4.9 capsule, orally, BID during Week 8, and AVP-786-42.63/4.9 capsules, orally, BID, during Weeks 9 to 12 of the Stage 2 treatment period."
89607200|NCT03085173|Experimental|EGFRt/19-28z/4-1BBL CAR T cells|Following enrollment, patients will undergo leukapheresis of peripheral blood for further T cell enrichment, activation and genetic modification using a retroviral vector encoding a CD19targeted CAR, the co-stimulatory ligand 4-1BBL and the EGFRt safety system (EGFRt/19-28z/4-1BBL). These T cells will be expanded and after the appropriate number of cells is generated, the modified T cells may be infused fresh or frozen for later use according to standard operation procedures. Modified T cell infusions will be administered 2-7 days following completion of the treating investigator's choice of conditioning chemotherapy. Serial sampling of blood and bone marrow will be performed following treatment to assess toxicity, therapeutic effects, and survival of the genetically modified T cells.
89607201|NCT03081390|Experimental|No migraine, normal weight|"Mixed meal tolerance testing~Skin conductance & cold pressor test~Flow-mediated dilation testing"
89607202|NCT03081390|Experimental|No migraine, obese|"Mixed meal tolerance testing~Skin conductance & cold pressor test~Flow-mediated dilation testing"
89607203|NCT03081390|Experimental|Migraine, normal weight|"Mixed meal tolerance testing~Skin conductance & cold pressor test~Flow-mediated dilation testing"
89607204|NCT03081390|Experimental|Migraine, obese|"Mixed meal tolerance testing~Skin conductance & cold pressor test~Flow-mediated dilation testing"
89607205|NCT03076658|Other|asymptomatic EOS Imaging|patients that qualify for study and EOS imaging to analyze spino-pelvic parameters
89607206|NCT03055533|Experimental|Immediate intervention with Headsprout reading program|Participants randomized to this study arm will begin treatment with the Headsprout program right away. Reading assessments will occur at the beginning and end of 12 weeks of treatment. Participation may be in clinic or via telehealth.
89607207|NCT03055533|No Intervention|Delayed intervention|Participants randomized to this study arm will have reading assessments at the beginning and end of the study, but they will not begin treatment with the Headsprout program until after their participation in the study ends (12 weeks). Participation may be in clinic or via telehealth.
89607208|NCT03047135|Experimental|Olaparib 300 mg BID|Patients will be administered olaparib orally twice daily at 300mg bid continually. Two 150mg of olaparib tablets should be taken twice daily, approximately 12 hours apart with one glass of water.
89607209|NCT03042650|Experimental|Intensive Referral Intervention Group|Intensive Referral Intervention will by done by trained probation officers
89607210|NCT03042650|Active Comparator|Standard Practice Facilitated Group|Standard Current Practice will be provided by untrained probation officers
89607211|NCT03028857|Placebo Comparator|Participants will take placebo|Participants will take placebo. Corn oil every day in place of choline
89607212|NCT03028857|Active Comparator|Drug: Choline|Participants will take 4500 mg of phosphatidylcholine twice per day, the equivalent of approximately 1250 mg of choline per day until delivery
89607213|NCT02994576|Experimental|Stage IB(≥ 2 cm)-IIIA non N2, resectable and untreated NSCLC|
89607214|NCT02994576|No Intervention|Comparative cohort (patients receiving standard treatment)|
89607215|NCT02983357||Case Series Study|Subjects who received a total shoulder replacement with an anchor peg glenoid and autologous bone grafting at the department of Orthopaedic Surgery at University of Nebraska Medical Center / Nebraska Medicine and are now at least 9 years out from surgery.
89607216|NCT02973789|Experimental|NovoTTF-200T|Patients receive TTFields using the NovoTTF-200T device together with immune checkpoint inhibitors or docetaxel
89607217|NCT02973789|Active Comparator|Best Standard of Care|Patients receive best standard of care with immune checkpoint inhibitors or docetaxel
89607218|NCT02903667|Experimental|bone grafting|The possibility of counteracting unfavourable ridge modelling after multiple tooth extractions by placing bone grafting material in the fresh extraction sites.
89607219|NCT02903667|Sham Comparator|natural healing|ridge modelling after multiple tooth extractions.
89607220|NCT02901821||Control|No intervention. Collection of medical/demographic info and salivary RNA in children 5-21 years without history of mild traumatic brain injury (mTBI).
89607221|NCT02901821||Concussion|Collection of medical/demographic info and salivary RNA in children 5-21 years with history of mild traumatic brain injury (mTBI). Collection of PCSI concussion assessment interview tool and balance/cognition testing at time of injury, 1-2wks post injury, and 4wks post injury.
89607222|NCT02897973||Transtibial lower limb amputation|unilateral amputation below knee resulting from traumatic injuries (with no upper-extremity amputations), evaluation took place at least 6 months post-injury, no assistive device use (e.g., canes, walkers, crutches), no other documented injuries, such as musculoskeletal impairments in the contralateral limb, neurologic disorder or traumatic brain injury that would affect gait and movement.
89607223|NCT02897973||Transfemoral lower limb amputation|unilateral amputation above knee resulting from traumatic injuries (with no upper-extremity amputations), evaluation took place at least 6 months post-injury, no assistive device use (e.g., canes, walkers, crutches), no other documented injuries, such as musculoskeletal impairments in the contralateral limb, neurologic disorder or traumatic brain injury that would affect gait and movement.
89607224|NCT02897973||Controls|Able-bodied individuals without amputation
89607225|NCT02890940|Experimental|Pet Therapy|
89607226|NCT02883049|Experimental|DS HR B-ALL (RER)|"Patients receive induction, consolidation, interim maintenance, delayed intensification, interim maintenance and maintenance therapies.~See outline for details."
89607227|NCT02883049|Experimental|DS HR B-ALL (SER)|"Patients receive induction, consolidation, interim maintenance, delayed intensification, interim maintenance and maintenance therapies.~See outline for details."
89607228|NCT02883049|Experimental|Group I Arm A (HR B-ALL)|"Patients receive induction, consolidation, interim maintenance, delayed intensification and maintenance therapies.~See outline for details."
89607229|NCT02883049|Experimental|Group I Arm B (HR B-ALL) (CLOSED 03/19/2018)|"Patients receive induction, consolidation, interim maintenance, delayed intensification and maintenance therapies.~See outline for details."
88811530|NCT00845000|Experimental|SCH 420814 10 mg→ Placebo→ SCH 420814 100 mg|Participants were to receive their assigned experimental treatment based on randomly assigned treatment sequence at Hour 0 following an overnight withdrawal of their antiparkinsonian medications of each treatment period. The levodopa infusion was to be started at Hour 1 and was to run for 2 hours. The participants were to also receive 25 mg of carbidopa at the following times: Hours 0, 2, and 4. Treatment periods were to be separated by at least 7 days but not more than 28 days washout between each dose.
89607230|NCT02883049|Active Comparator|Group II Arm A (VHR B-ALL - Control Arm)|"Patients receive induction, consolidation, interim maintenance, delayed intensification and maintenance therapies.~See outline for details."
89607231|NCT02883049|Experimental|Group II Arm B (VHR B-ALL - Exp Arm1) (CLOSED 02/15/2017)|"Patients receive consolidation, interim maintenance, delayed intensification and maintenance therapies.~See outline for details."
89607232|NCT02883049|Experimental|Group II Arm C (VHR B-ALL - Exp Arm 2) (CLOSED 09/12/2014)|"Patients receive induction, consolidation, interim maintenance, delayed intensification and maintenance therapies.~See outline for details."
89607233|NCT02883049|Experimental|Group III PH-like predicted TKI-sensitive kinase mutation|"Patients receive induction, consolidation, interim maintenance, delayed intensification, interim maintenance and maintenance therapies.~See outline for details."
89607234|NCT02870699|Experimental|ARM A|"Evonail film forming solution : 1 daily application on the left hand~Placebo excipient : 1 daily application on the right hand"
89607235|NCT02870699|Active Comparator|ARM B|"Evonail film forming solution : 1 daily application on the right hand~Placebo excipient : 1 daily application on the left hand"
89607236|NCT02864251|Experimental|Nivolumab+Platinum doublet chemotherapy|
89607237|NCT02864251|Experimental|Nivolumab + Ipilimumab|Enrollment is closed for this arm
89607238|NCT02864251|Active Comparator|Platinum doublet chemotherapy|
89607239|NCT02838836||Study sample collection|Blood draws, urine and tissue asservation, and bone marrow aspiration will be done during surgery
89607240|NCT02789956|Experimental|Test: internal connection|Evaluate marginal bone level (MBL) changes at implants that are placed semi-edentulous patient when they are treated with implant level Co/cr Cad/Cam framework.
89607241|NCT02789956|Active Comparator|Test: external connection|Evaluate marginal bone level (MBL) changes at implants that are placed semi-edentulous patient when they are treated with abutment level Co/cr Cad/Cam framework.
89607242|NCT02774148|Active Comparator|PO Acetaminophen|1,000mg Acetaminophen po every 8 hours until discharge.
89607243|NCT02774148|Experimental|IV Acetaminophen|1,000mg Acetaminophen IV every 8 hours until the patient has received 3 doses post-operatively. Then 1,000mg Acetaminophen po every 8 hours until discharge.
89519082|NCT05162885|Active Comparator|implant placement in defective Sockets preserved with alendronic acid sponge|"anesthesia according the site of implant placement were administered using mepivacaine HCl (2%) with levonordefrin 1:20 000 (Scandonest 2%; Septodont, Saint- Maur-des-Fossés, France). Injection to control pain and bleeding for hemostasis. Crestal incision with a full thickness mucoperiosteal flap was reflected .A pilot drill will be used to start the osteotomy preparation, then different drilling sizes will be used to attain the final drill size and the planed implant height and width according to Cone Beam CT. Implants were screwed directly into the osteotomy site, primarily the screwing was done mechanically by Fixture Mount Connection attached to the implant carrier.~The created gap sutured passively to allow tension-free interrupted closure using 3-0 coated undyed braided polyglactin 910 suture material."
89607244|NCT02771197|Experimental|Lymphodepletion plus Pembrolizumab|Fludarabine & Melphalan followed by autologous stem cell transplantation. Pembrolizumab will begin on Day +1.
89607245|NCT02767388||HM - Chemotherapy|Study patients diagnosed with HM that are scheduled to receive chemotherapy treatment.
89607246|NCT02767388||HM - No Chemotherapy|Study patients diagnosed with HM that are scheduled to receive non-chemotherapy treatment options.
89607247|NCT02767388||Healthy Controls|Study participants that are demographically matched to HM study patients and meet all inclusion criteria
89607248|NCT02743468||Healthy Volunteers|Healthy Volunteers
89607249|NCT02722421|Experimental|Efavirenz group|HIV-infected women receiving efavirenz-based antiretroviral therapy plus increased dose levonorgestrel subdermal implants.
89607250|NCT02693184||Fragility Fracture Case|Men and women, age >65 years with a fragility fracture (defined as a fracture sustained after a fall from a standing height or less).
89607251|NCT02676349|Experimental|Arm B|Neoadjuvant chemotherapy with mFolfirinox regimen + concomitant chemoradiotherapy + surgery + adjuvant chemotherapy
89607252|NCT02676349|Active Comparator|Arm A|Neoadjuvant chemotherapy with mFolfirinox regimen + surgery + adjuvant chemotherapy
89607253|NCT02669810|Experimental|PROTHERACYTES|"The interventional investigators will perform the ProtheraCytes® cardiac injections using a catheter introduced via the femoral route up to the left ventricle cavity for intraventricular injections (Helix/Biocardia).~Intracoronary injection will be possible with OTW catheter or microcatheter (UK only) if patient presents a contraindication to intramyocardial injection"
89607254|NCT02669810|Active Comparator|Standard of Care|Patients will be treated as standard treatment for CHF post - AMI.
89607255|NCT02659241|Experimental|Treatment (adavosertib)|Patients receive adavosertib PO QD on days 1-5. Patients then undergo standard of care laparoscopy. Patients may also receive adavosertib PO QD on days 8-12, 15-19, and 22-26 for up to 28 days based on surgery schedule.
89607256|NCT02647385|Experimental|General Anesthesia|Interventions: include pain assessment, inflammatory response and opioid consumption.
89607257|NCT02647385|Experimental|General Anesthesia SAM and PEC I block|Interventions: include pain assessment, inflammatory response and opioid consumption.
89607258|NCT02643043|Other|UC Subjects|Subjects with confirmed metastatic urothelial cancer willing to participate in biospecimen collection (tissue and blood) for genetic studies.
89607259|NCT02597504|Active Comparator|Standardization|individuals assigned to this group will be healthy volunteers and will take the Quick Test.
89607260|NCT02597504|Experimental|Validity and Reliability|"Reliability:~Test-Retest~Validity:~Concurrent:Quick Test administered with ImPACT online Discriminant: Concussed patient administered Quick Test Construct: Determine agreement between Quick Test and and paper and pencil test."
89607261|NCT02588677|Experimental|Masitinib (3.0) & Riluzole|masitinib 3 mg/kg/day + riluzole
89607262|NCT02588677|Experimental|Masitinib (4.5) & Riluzole|masitinib 4.5 mg/kg/day (2) + riluzole
89607263|NCT02588677|Placebo Comparator|Placebo & Riluzole|Matched placebo
89607264|NCT02587897||Dental Hygiene Students|Students enrolled in the 2-year dental hygiene academic coursework programs at the University of Southern California and Loma Linda University who are exposed to high-intensity work-related hand activities as part of their training program.
89607265|NCT02587897||Occupational Therapy Students|Students enrolled in the 2-year occupational therapy academic coursework program at the University of Southern California.
89519083|NCT05162885|Active Comparator|Implant placement in Defective sockets preserved with sticky bone|"anesthesia according the site of implant placement were administered using mepivacaine HCl (2%) with levonordefrin 1:20 000 (Scandonest 2%; Septodont, Saint- Maur-des-Fossés, France). Injection to control pain and bleeding for hemostasis. Crestal incision with a full thickness mucoperiosteal flap was reflected .A pilot drill will be used to start the osteotomy preparation, then different drilling sizes will be used to attain the final drill size and the planed implant height and width according to Cone Beam CT. Implants were screwed directly into the osteotomy site, primarily the screwing was done mechanically by Fixture Mount Connection attached to the implant carrier.~The created gap sutured passively to allow tension-free interrupted closure using 3-0 coated undyed braided polyglactin 910 suture material."
89519084|NCT05390957|Experimental|Single Arm|All participants in this pilot study will complete the active treatment
89519085|NCT04101617|Experimental|Experimental group|Participants will receive previously designed educational material with recommendations for healthy habits and oral health recommendations. Also, pediatricians will give the parents oral health education. Parents and their children will receive toothbrushes as well as toothpaste.
89519086|NCT04101617|No Intervention|Control Group|Parents and their children will receive toothbrushes as well as toothpaste.
89519087|NCT03966989|Experimental|Performance Feedback|Feedback offline either via email or text
89519088|NCT03966989|No Intervention|Control|Standard practice control
89519089|NCT05162339||IBD patients|
89519090|NCT05161949||group 1|200 patients with suspected ovarian cancer
89519091|NCT05161949||group 2|40 non oncological patients of witch 20 with endometriosis
89519092|NCT05390489|Experimental|Cascara pulp arabica gayo coffee cream|The installation of a patch test for the cascara pulp cream of Gayo Arabica coffee with a concentration of 10% was carried out on the upper arm and waited for 30 minutes to see if there were any side effects. If no side effects occur, the patch test is left for 48 hours. After 48 hours, patch test was opened and the skin condition was assessed for irritation/redness and skin moisture. This condition was also re-evaluated at 72 and 96 hours later.
89519093|NCT03770741|Experimental|Monitoring of cerebral oxygenation|Modify cardio-respiratory support to avoid cerebral hypoxia
89519094|NCT03770741|Other|Treatment as usual|Treatment according local guidelines and practices.
89519095|NCT03469115|Active Comparator|BMI above 95%|Serum blood will be taken from obese youths with suspected metabolic syndrome
89519096|NCT03469115|Active Comparator|BMI below 3%|Serum blood will be taken from slim youths
89519097|NCT03755687|Experimental|Art Therapy Intervention|Standardized mixed media art therapy directives (e.g. drawing/painting/collaging within a circle)
89519098|NCT05161559|Experimental|Fuji Bond LC (Glass ionomer based adhesive)|Patients received in Class V cavity preparation Fuji Bond LC (Glass ionomer based adhesive) on one tooth of the mouth
89519099|NCT05161559|Experimental|Riva Bond LC (Glass ionomer based adhesive)|Patients received in Class V cavity preparation Riva Bond LC (Glass ionomer based adhesive) on one tooth of the mouth
89519100|NCT05161559|Experimental|Single Bond Universal (self-etch adhesive)|Patients received in Class V cavity preparation Single Bond Universal (self-etch adhesive) on one tooth of the mouth
89519101|NCT05161559|Experimental|Clearfill S3 Bond (self-etch adhesive)|Patients received in Class V cavity preparation Clearfill S3 Bond (self-etch adhesive) on one tooth of the mouth
89519102|NCT05161559|Experimental|OptiBond FL (three step etch & rinse adhesive)|Patients received in Class V cavity preparation OptiBond FL (three step etch & rinse adhesive) on one tooth of the mouth
89519103|NCT03736655|Experimental|Interposition supraciliary implant|Any patients corresponding to inclusion / exclusion criteria
89519104|NCT05161403|Active Comparator|Hyaluronic acid.|1mm layer of hyaluronic acid on a piece of gauze will be applied directly to the sockets wound for 45 minutes at baseline and on the third & seventh day after extraction of teeth.
89519105|NCT05161403|Active Comparator|Honey|1mm layer of Honey on a piece of gauze will be applied directly to the sockets wound for 45 minutes at baseline and on the third & seventh day after extraction of teeth.
89519106|NCT05161403|Placebo Comparator|Saline|a piece of gauze moistened with normal saline will be applied directly to the sockets wound for 45 minutes at baseline and on the third & seventh day after extraction of teeth.
89519107|NCT05077397|Active Comparator|Group 1|"After the approval of the local ethics committee and written informed consent, 60 ASA I-III patients aged 18-75 years who will undergo liver resection will be included in the study.~Patients of Group 1 will be monitored by the InSpectra Tissue Spectrometer, StO2, added to standard ASA monitorisation."
89519108|NCT05077397|Active Comparator|Group 2|"After the approval of the local ethics committee and written informed consent, 60 ASA I-III patients aged 18-75 years who will undergo liver resection will be included in the study.~Patients of Group 2 will be monitored by O3TM Regional Oximeter System, added to standard ASA monitorisation."
89519109|NCT05077397|No Intervention|Group 3|"After the approval of the local ethics committee and written informed consent, 60 ASA I-III patients aged 18-75 years who will undergo liver resection will be included in the study.~Patients of Group 2 will be monitored by standard ASA monitorisation."
89519110|NCT02523209||Bone quality and quantity|measure of bone quality and quantity parameters by HRpQCT and by DEXA
89519111|NCT03561701|Experimental|Oteseconazole (VT-1161) 150mg capsule|Once daily for 7 days starting at Day 1, followed by once weekly for 11 weeks
89519112|NCT03561701|Placebo Comparator|Placebo capsule|Once daily for 7 days starting at Day 1, followed by once weekly for 11 weeks
89519113|NCT04455893|No Intervention|Condition 1: Combined only|Participants randomized to baseline (control) arm Condition 1 will view only combined transplant survival outcome information (e.g. transplant survival rate not stratified by number and quality of donor hearts accepted at each center) when making a choice between the two hospitals.
89519114|NCT04455893|Experimental|Combined 2: Stratified only|Participants randomized to Condition 2 will view only stratified transplant survival outcome information when making a choice between the two hospitals.
89519115|NCT03426605|Experimental|LAM-003|Open label LAM-003 at three increasing dose levels of 200, 300 and 450 mg.
89519116|NCT04923269|Experimental|LY3532226|Single ascending doses of LY3532226 administered subcutaneously (SC).
89519117|NCT04923269|Placebo Comparator|Placebo|Placebo administered SC.
89607266|NCT02570113|Experimental|Renal Denervation by Neurolysis|Infusion of 0.6 ml of dehydrated alcohol (not less than 95% by volume) into the peri-adventitial space of the renal artery, to achieve renal denervation by neurolysis, via three simultaneous deployed needles, situated at the distal end of the Peregrine System Infusion Catheter.
89607267|NCT02565914|Experimental|TEZ/IVA|"Part A: Participants who received either TEZ/IVA, IVA monotherapy or Placebo in parent studies 103,106,107,108,109 and 111 were administered TEZ 100 milligram (mg)/IVA 150 mg fixed-dose tablet in the morning and IVA 150 mg mono tablet in the evening for 96 weeks.~Part B: Participants who received either TEZ/IVA, IVA monotherapy or Placebo in parent studies 106,108,109,112 and 114 were administered TEZ 100 mg/IVA 150 mg fixed-dose tablet in the morning and IVA 150 mg mono tablet in the evening for 96 weeks.~Part C: Participants who received TEZ/IVA, IVA monotherapy or Placebo in parent studies 106,108, and 114 were administered TEZ 100 mg/IVA 150 mg fixed dose tablet in the morning and IVA 150 mg mono tablet in the evening for 192 weeks."
89607268|NCT02565524|Experimental|genetic and phenotypic profile|blood sample, clinical and neurocognitive assessment
89607269|NCT02543320|Experimental|Supportive care (neurofeedback)|Beginning at weeks 4 and 5 or 5 and 6 of radiotherapy, patients undergo neurofeedback training QID TIW for up to 6 treatments. Patients also complete questionnaires over 10 minutes at baseline and after neurofeedback training.
89607270|NCT02535078|Experimental|Arm 1|IV Tebentafusp (IMCgp100) with durvalumab (MEDI4736)
89607271|NCT02535078|Experimental|Arm 2|IV Tebentafusp (IMCgp100) with tremelimumab
89607272|NCT02535078|Experimental|Arm 3|IV Tebentafusp (IMCgp100) with durvalumab (MEDI4736) and tremelimumab
89607273|NCT02535078|Experimental|Arm 4|Tebentafusp (IMCgp100) (single agent)
89607274|NCT02535078|Experimental|Arm 5|Tebentafusp (IMCgp100) (single agent) subcutaneous injection
89607275|NCT02464644|Experimental|People with HHT|"People with HHT will identify themselves within the questionnaire, first by statement of what they think is their diagnosis, and second by provision of the HHT diagnostic criteria within specific questions.~They will be directed to appropriate questions, according to answers to the previous questions."
89607276|NCT02464644|Other|Controls without HHT|"People without HHT will identify themselves within the questionnaire, first by statement of what they think is their diagnosis, and second by provision of the HHT diagnostic criteria within specific questions.~They will be directed to appropriate questions, according to answers to the previous questions."
89607277|NCT02440295||Lower Extremity Amputations|"All patients >= 18 years of age requiring Below Knee Amputation (BKA) or Above Knee Amputation (AKA) cared for by the Spectrum Health vascular surgery service will be assessed for eligibility.~Subjects with a history of allergies to iodides or iodinated contrast agents, pregnant or nursing women, subjects who are unable to provide consent, and prisoners will be excluded. Eighteen subjects will be enrolled in the pilot study. No special population subjects will be enrolled."
89607278|NCT02436213|Experimental|Healthy control|A group of up to 30 healthy controls will be recruited to have a cardiopulmonary exercise test and a blood test.
89607279|NCT02436213|Experimental|Pulmonary AVM|A group of up to 30 pulmonary AVM patients will be recruited to have a cardiopulmonary exercise test, and a blood test.
89607280|NCT02436213|Experimental|HHT but no pulmonary AVM|Most patients with pulmonary AVMs have underlying hereditary hemorrhagic telangiectasia (HHT). If there is a difference between pulmonary AVM and control groups that does not correct following embolization of pulmonary AVMs, a group of up to 30 people with HHT but no evidence of pulmonary AVMs will be selected to have a cardiopulmonary exercise test and a blood test.
89607281|NCT02408588||Childbirth and epidural|Pregnant women giving childbirth who receive an epidural.
89607282|NCT02408588||Childbirth and general anesthesia|Pregnant women giving childbirth who receive general anesthesia
89607283|NCT02408588||Fetal Intervention and epidural|Pregnant women receiving fetal intervention and an epidural
89607284|NCT02408588||Fetal Intervention and general anesthesia|Pregnant women receiving fetal intervention and general anesthesia
89607285|NCT02405169|Experimental|Test -4 implants-|Evaluate marginal bone level (MBL) changes at implants that are placed in total edentulous patient when they are treated with four with titanium Cad/Cam framework.
89607286|NCT02405169|Active Comparator|Control -6 implants-|Evaluate marginal bone level (MBL) changes at implants that are placed in total edentulous patient when they are treated with six with titanium Cad/Cam framework
89607287|NCT02338518|Experimental|SEEOX group|A three-cycle neo-adjuvant chemotherapy was performed in all cases. In every cycle, oxaliplatin 100 mg/m2, etoposide 80 mg/m2, and pharmorubicin 30 mg/m2 were administered from the celiac artery on day 1. 80～120 mg of oral S-1 per square meter of body-surface area per day was given for 2 weeks. The second cycle was scheduled following a 1-week rest after the first cycle.
89607288|NCT02338518|Active Comparator|SOX group|A three-cycle neo-adjuvant chemotherapy was performed in all cases. In every cycle, patients received intravenous oxaliplatin 130 mg/m2 on day 1, and 80~120 mg of oral S-1 per square meter of body-surface area per day was given for 2 weeks. The second cycle was scheduled following a 1-week rest after the first cycle.
89607289|NCT02336672|No Intervention|Group A Chemotherapy|Patients receiving chemotherapy alone. These patients start standard chemotherapy right after the oncologist's evaluation according to accepted Guidelines of the Italian Association of Medical Oncologists (AIOM). Restaging is performed 2, 4 and 6 months after chemotherapy onset, with MDCT scan and DW-MRI.
89607290|NCT02336672|Experimental|Group B Chemotherapy + HybridTherm|Patients receiving chemotherapy plus EUS-guided Cryothermal Ablation with HybridTherm probe. These patients are first treated by cryothermal ablation and one week after they start with chemotherapy. Cryothermal ablation can be performed up to three times, with interval of 4 +/- 1 weeks. Restaging is performed 2, 4 and 6 months after chemotherapy onset, with MDCT scan and DW-MRI.
89607291|NCT02286687|Experimental|Treatment (talazoparib)|Patients receive talazoparib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89607292|NCT02270658|Experimental|Continuous positive airway pressure|Continuous positive airway pressure therapy (CPAP)
89032796|NCT02926755|Experimental|Angiography to Assess Vulnerable Plaque|In order to characterize plaque a repeat Coronary Angiography within 2 to 40 days will be done to assess vulnerable plaque features such as plaque tears, plaque thickness, plaque volume, and lipid content in plaque) in heart arteries in patients who have suffered a recent acute heart attack, and who have blockages >50% in one or more of the other arteries in the heart.
89607293|NCT02270658|Placebo Comparator|Nasal strips|Nasal strips applied to the outside surface of the nose with adhesive.
89607294|NCT02248701|Experimental|testosterone enanthate, finasteride|Testosterone enanthate via i.m. injection (125 mg/week) and finasteride orally (5 mg/day)
89607295|NCT02248701|Placebo Comparator|placebo treatment|Placebo via i.m. injection (once weekly) and placebo pill orally (daily)
89607296|NCT02224261|Experimental|Physical Therapy|"Physical therapy protocol includes manual lymph-drainage technique in axilla, and proximal ipsilateral arm, specific thumb manual lymph-drainage on the taut cords to make them gradually more flexible, in conjunction with progressive active and action-assisted arm exercises stretching cords and patient education."
89607297|NCT02224261|Active Comparator|Control|Control protocol includes standard progressive active and action-assisted arm exercises & patient education.
89607298|NCT02204982|Experimental|Duvelisib + Rituximab|"Duvelisib is administered orally and supplied as 5 mg and 25 mg formulated capsules.~Rituximab is administered as an intravenous (IV) infusion and is supplied in single-use vials at two strengths, 100 mg and 500 mg."
89607299|NCT02204982|Placebo Comparator|Placebo + Rituximab|"Placebo is administered orally and supplied as formulated capsules to match the active 5 mg and 25 mg capsules.~Rituximab is administered as an intravenous (IV) infusion and is supplied in single-use vials at two strengths, 100 mg and 500 mg."
89607300|NCT02184663|Active Comparator|Standard care without APA program|"The control arm corresponds to usual care (without APA), including :~Weekday hospital chemotherapy (every 7 or 14 days, depending on chemotherapy protocol)~Evaluation by the oncologist at the usual rate~Assessment every 8 weeks (TAP scan + CA-19.9)~Nutritional, psychological and pain management as recommended, according to the usual schedule."
89607301|NCT02184663|Experimental|Standard care with APA program|"The experimental arm corresponds to usual care, combined with a 16-week APA program.~The APA program consisted of personalized aerobic and resistance exercises, with a weekly remote supervision by an APA professional trainer, and unsupervised sessions with a family member or friend (APA partner)."
89607302|NCT02138734|Experimental|N-803+BCG|(Phase Ib and IIb) for BCG-naive patients
89607303|NCT02138734|Active Comparator|BCG alone|(Phase IIb) for BCG-naive patients
89607304|NCT02134392|Experimental|Fecal Microbiota Transplantation|250 ml of a fecal suspension diluted in saline given by colonoscopy or enema.
89607305|NCT02101385|Experimental|Arm A (Genomically Directed Monotherapy)|Participants randomized to Experimental Arm A will receive an FDA approved drug at standard dose for four cycles (12-16 weeks total duration, depending on cycle length). Clinical and laboratory monitoring and dose-reductions will follow the FDA package insert guidelines.
88982529|NCT05662579|Experimental|hip exercises|"PHASE I: (sessions 1 to 4)~Active exercise without weight support (standing) for abductors, adductors, hip flexors and extensors~Hip extension exercise in 4 supports~Hip abduction exercise in 4 supports (hydrant)~Oyster Exercise~Hip abduction exercise in lateral decubitus~Hip extension exercise in ventral decubitus~PHASE II: (sessions 5 to 8)~Hip abduction exercise in lateral decubitus~Progressive resistance exercise for abductors, adductors, flexors and hip extensors with standing theraband~Side walk with theraband positioned at the ankle joint~Squat exercise~Advance exercise~Step down exercise"
89032797|NCT00528281|Experimental|Lapatinib + pemetrexed|This is a single-arm, two-stage, multicenter Phase II study to determine the clinical activity of pemetrexed with lapatinib.
89607306|NCT02101385|Other|Control Arm B (Observation/Standard Therapy)|Currently no standard therapy has proven efficacy in this patient population and thus observation alone would be considered standard of care. Additional therapy is permitted, however, if deemed appropriate by the treating physician.
89607307|NCT02086175|Experimental|Imprime PGG and Rituximab|The study drug, Imprime PGG, will be administered intravenously at a dose of 4mg/kg weekly for 4 weeks. Rituximab will be administered intravenously by institutional standards concurrently at a dose of 375mg/m2 weekly for 4 weeks. Response will be assessed with CT scans 10 weeks +/- 3 days following the completion of treatment
89607308|NCT02073838|Experimental|Ribavirin, vismodegib, decitabine|Decitabine 20mg/m2 IV QD days -7 to -3 for cycle 1. Ribavirin 1400mg BID and vismodegib 150mg QD starting on day 1. On subsequent cycles, decitabine will be administered on days 1 to 5.
89607309|NCT02073838|Experimental|Ribavirin, vismodegib|Ribavirin 1400mg BID, vismodegib 150mg QD
89607310|NCT02068443|Active Comparator|Alogliptin Alone|Alogliptin 25 mg, tablets, orally, once, daily, after breakfast and metformin hydrochloride placebo-matching, tablets, orally, 2 tablets after breakfast and 1 tablet after dinner for 24 weeks.
89607311|NCT02068443|Experimental|Alogliptin + Metformin Hydrochloride QD|Alogliptin 25 mg, tablets, orally, once, daily, after breakfast and metformin hydrochloride 500 mg QD (250 mg x 2 tablets, once daily), tablets, orally, once, daily, after breakfast and 1 metformin hydrochloride placebo-matching, tablet, orally, once, daily, after dinner for 24 weeks.
89607312|NCT02068443|Active Comparator|Alogliptin + Metformin Hydrochloride BID|Alogliptin 25 mg, tablets, orally, once, daily, after breakfast and metformin hydrochloride 250 mg BID (twice daily), tablets, orally, 1 tablet after breakfast and 1 tablet after dinner and 1 metformin hydrochloride placebo-matching, tablet, orally, once, daily, after breakfast for 24 weeks.
89607313|NCT02065869|Experimental|BPX-501 T cells and rimiducid|"TCR alpha beta depleted graft infusion with addback of BPX-501 T cells (rivogenlecleucel).~Rimiducid/AP1903: Dimerizer drug administered to subjects who develop Grade III-IV acute GVHD, Grade II gut/liver acute GVDH or Grade I/II skin-only acute GvHD which is non-responsive after 7 days of standard of care treatment"
89607314|NCT02021006|Active Comparator|ANTIBIOTIC PROPHYLAXIS|"Children in this arm will take antibiotic prophylaxis for 2 years. Patients in this arm will do clinical/instrumental follow-up for 5 years.~The antibiotic for prophylaxis will be chosen by Physicians according to the local resistance spectrum of bacteria responsible of UTIs~Physicians can chose one the following schedules:~nitrofurantoin 1.5-2 mg/kg per day~Amoxicillin-Potassium Clavulanate Combination 15 mg/kg per day (dose expressed in units equivalent to amoxicilline)~cefixime 2 mg/kg per day~trimethoprim/sulfamethoxazole 2.5 mg/kg per day (dose expressed in units equivalent to trimethoprim)"
89607315|NCT02021006|Experimental|NO PROPHYLAXIS|Children in this arm will not take antibiotic prophylaxis. Patients in this arm will do clinical/instrumental follow-up for 5 years
89607316|NCT02018861|Experimental|Parsaclisib 5 mg QD|Parsaclisib 5 milligrams (mg) as an oral tablet once a day (QD) in 21-day treatment cycles
89607317|NCT02018861|Experimental|Parsaclisib 10 mg QD|Parsaclisib 10 mg as oral tablets QD in 21-day treatment cycles
89607318|NCT02018861|Experimental|Parsaclisib 15 mg QD|Parsaclisib 15 mg as oral tablets QD in 21-day treatment cycles
89607319|NCT02018861|Experimental|Parsaclisib 20 mg QD|Parsaclisib 15 mg as oral tablets QD in 21-day treatment cycles
89607320|NCT02018861|Experimental|Parsaclisib 30 mg QD|Parsaclisib 30 mg as oral tablets QD in 21-day treatment cycles
89607321|NCT02018861|Experimental|Parsaclisib 45 mg QD|Parsaclisib 45 mg as oral tablets QD in 21-day treatment cycles
89607322|NCT02018861|Experimental|Parsaclisib 20 mg + itacitinib (INCB039110) 300 mg|Parsaclisib 20 mg as oral tablets QD and itacitinib (INCB039110) 300 mg as oral tablets QD in 21-day treatment cycles
89607323|NCT02018861|Experimental|Parsaclisib 30 mg + itacitinib (INCB039110) 300 mg|Parsaclisib 30 mg as oral tablets QD and itacitinib (INCB039110) 300 mg as oral tablets QD in 21-day treatment cycles
89607324|NCT02018861|Placebo Comparator|Parsaclisib 15 mg QD + R-ICE|Parsaclisib 15 mg as oral tablets QD in 21-day treatment cycles. R-ICE was a standard-of-care chemotherapy combination administered at the following doses: rituximab 375 milligrams per meters squared (mg/m^2) intravenously (IV) on Day 1 and Day 2 of Cycle 1 and on Day 1 of Cycles 2 and 3, ifosfamide 5000 mg/m^2 IV on Day 3 of each cycle, carboplatin area under the curve (AUC) = 5 (maximum dose 800 mg) IV on Day 3 of each cycle, and etoposide 100 mg/m^2 or at doses consistent with institutional practice with approval from the medical monitor on Days 3 and 5 of each cycle. Each cycle was 21 days in duration
89607325|NCT02018861|Placebo Comparator|Parsaclisib 20 mg QD + R-ICE|20 mg as oral tablets QD in 21-day treatment cycles. R-ICE was a standard-of-care chemotherapy combination administered at the following doses: rituximab 375 mg/m^2 IV on Day 1 and Day 2 of Cycle 1 and on Day 1 of Cycles 2 and 3, ifosfamide 5000 mg/m^2 IV on Day 3 of each cycle, carboplatin AUC = 5 (maximum dose 800 mg) IV on Day 3 of each cycle, and etoposide 100 mg/m^2 or at doses consistent with institutional practice with approval from the medical monitor on Days 3 and 5 of each cycle. Each cycle was 21 days in duration.
89607326|NCT01995578|Experimental|low dose 5'-azacitidine|This is a single arm phase II trial to assess the efficacy and confirm the safety of maintenance therapy with 5'-azacitadine compared to historical control after TCD allogeneic hematopoietic stem cell transplant for patients with MDS and AML who are at high risk of relapse.
89607327|NCT01967511||FMD subjects|patients who fulfill standard diagnostic criteria for FMD
89607328|NCT01967511||SCAD subjects|patients who fulfill standard diagnostic criteria for SCAD
89607329|NCT01967511||CvAD subjects|patients who fulfill standard diagnostic criteria for CvAD
89607330|NCT01967511||Healthy control subjects|
89607331|NCT01949337|Experimental|Arm A: (enzalutamide)|Patients receive enzalutamide 160 mg PO QD. Treatment will continue until confirmed disease progression or unacceptable toxicity.
89607332|NCT01949337|Experimental|Arm B: (enzalutamide, abiraterone, prednisone)|Patients receive enzalutamide 160 mg PO QD, abiraterone 1000 mg PO QD, and prednisone 5 mg PO BID. Treatment will continue until confirmed disease progression or unacceptable toxicity.
88982530|NCT05662579|Experimental|hip + core exercises|"In addition to all the exercises in the hip exercise group, this group will do:~PHASE I: (sessions 1 to 4)~Exercise for contraction of the transversus abdominais in the supine position~Bridge exercise~Plank exercise PHASE II: (sessions 5 to 8)~1. Unilateral bridge exercise 2. Plank exercise with hip extension 3. Lateral plank exercise"
88982531|NCT05660447|Experimental|Netarsudil 0.02%|For the study arm: one drop of rho-kinase (ROCK) inhibitor in the vitrectomized eye, once daily in the evening starting on postoperative day 1 after RRD repair surgery, till post-operative day 56
88982532|NCT05660447|Placebo Comparator|Artificial tears|Patients enrolled in the control group will receive a placebo (one drop of artificial tears) once daily in the evening starting on postoperative day 1 after RRD repair surgery, till post-operative day 56
88982533|NCT05658289|Active Comparator|Latarjet|The Latarjet involves the use of a auto-graft to be fixated to the anterior portion of the glenoid to recreate the size of the glenoid.
88982534|NCT05658289|Experimental|Anatomic Glenoid Reconstruction|An allograft will be used for the patients in this group, inserted through a new portal and fixed to the anterior rim of the glenoid to recreate the size of the glenoid.
88982535|NCT05653973|Experimental|assessment of microvascular function|The investigators use intradermal microdialysis to deliver acetylcholine, acetylcholine + L-NAME, endothelin-1, endothelin-1 + BQ-788, and endothelin-1 + BQ-123 to the cutaneous microvasculature.
89607333|NCT01934881||group I|Voltage adjustment only
89607334|NCT01934881||group II|Multiple parameters adjustment
89607335|NCT01872598|Experimental|Masitinib escalating dose|Participants receive masitinib at 4.5 mg/kg/day, given orally twice daily, with a dose escalation to 6 mg/kg/day after 3 months of treatment
89607336|NCT01872598|Experimental|Masitinib fixed dose (4.5 mg/kg/day)|Participants receive masitinib at 4.5 mg/kg/day, given orally twice daily.
89607337|NCT01872598|Experimental|Masitinib fixed dose (3.0 mg/kg/day)|Participants receive masitinib at 3.0 mg/kg/day, given orally twice daily.
89607338|NCT01872598|Placebo Comparator|Placebo (escalating dose)|Participants receive placebo, given orally twice daily, with a matched dose escalation after 3 months of treatment
89607339|NCT01872598|Placebo Comparator|Placebo (fixed dose)|Participants receive fixed dose placebo, given orally twice daily
89607340|NCT01827384|Experimental|Regimen I (veliparib, temozolomide)|Patients receive veliparib by mouth (PO) twice a day (BID) on days 1-7 and temozolomide PO every day (QD) on days 1-5. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89607341|NCT01827384|Experimental|Regimen II (adavosertib, carboplatin)|Patients receive adavosertib by mouth (PO) twice a day (BID) for 5 doses starting on day 1 and carboplatin intravenous (IV) over 30-60 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89607342|NCT01827384|Experimental|Regimen III (everolimus)|Patients receive everolimus by mouth (PO) every day (QD) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89607343|NCT01827384|Experimental|Regimen IV (trametinib)|Patients receive trametinib by mouth (PO) every day (QD) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89607344|NCT01825694|No Intervention|Standard of Care|The Standard of Care condition includes: 1) an individual session with the counselor, once per week; 2) a treatment group with the counselor, twice per week; and 3) parents of youth are invited to attend parent-only educational sessions weekly.
89519118|NCT03205553|Active Comparator|Standard of Care (SoC) Treatment Group|The SoC group will be placed in silo shortly after birth within 2 hours of admission to the NICU per standard practice and subsequently serially reduced in silo (staged silo reduction) until the bowel contents are at the level of fascia and deemed suitable for closure. These subjects will have no change in current clinical management by the neonatologists or pediatric surgeons.
89519119|NCT03205553|Experimental|Direct Peritoneal Resuscitation (DPR) Treatment Group|The DPR group will be placed in silo shortly after birth within 2 hours of admission to the NICU per standard practice. At the time of silo placement for staged procedure, the JP drain will be sterilely placed intra-abdominally through the top of the silo. Subjects will be treated with adjuvant direct peritoneal resuscitation (DPR) and subsequently serially reduced in silo until the abdomen is closed (during the entirety of silo placement), which is usually four to five days.
89519120|NCT03166085|Experimental|PU-H71 With Nab-paclitaxel (Abraxane)|PU-H71 will be given as an intravenous infusion on Day 1 of a 21 day cycle and nab-paclitaxel will be administered at a dose of 260mg/m2 intravenously on Day 1. Both drugs will be administered on the same day, in sequence, with nab-paclitaxel being administered first followed by administration of PU-H71 as close as possible to 6 hours later (+/-1 hour). PU-H71 will be administered intravenously over a 1 hour period; nab-paclitaxel will be administered per standard guidelines as a 30-minute intravenous infusion.
89519121|NCT05390255|Experimental|Nasal spray hormone therapy|This group of patients received nasal steroid therapy throughout the study. The clinical data of patients at baseline and each visit period were collected, the incidence of adverse events was recorded, and the short-term efficacy and safety of different drug treatment regimens were evaluated.
89519122|NCT05390255|Experimental|Nasal spray hormone therapy + oral hormone therapy|The patients in this group were given oral hormone therapy for 14 days in the first month and the fourth month under the background of nasal spray hormone treatment throughout the course. The clinical data of patients at baseline and each visit period were collected, the incidence of adverse events was recorded, and the short-term efficacy and safety of different drug treatment regimens were evaluated.
89519123|NCT05390255|Experimental|Nasal spray hormone therapy + omalizumab therapy|The patients in this group were injected with omalizumab once a month under the background of nasal spray hormone therapy, for a total of 6 times. The clinical data of patients at baseline and each visit period were collected, the incidence of adverse events was recorded, and the short-term efficacy and safety of different drug treatment regimens were evaluated.
89519124|NCT04456829|Experimental|Resveratrol drink|
89519125|NCT04456829|Placebo Comparator|Placebo drink|
89519126|NCT02810171|Active Comparator|Cognitive Behavioral Therapy|
89519127|NCT02810171|Other|Relaxation Therapy|
89519128|NCT02810171|No Intervention|No Intervention: Healthy youth only|Healthy control participants, matched to gender and age with anxiety patients, will be enrolled. These healthy participants will be scanned with fMRI before and after ~16 weeks, but without any intervention (i.e., no therapy).
89519129|NCT01865617|Experimental|ALL (high tumor burden) dose level 1|"Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.~Disease subgroup: ALL Tumor Burden: high Dose level: 1 up to 2x105 EGFR+ cells/kg"
89519130|NCT01865617|Experimental|ALL (high tumor burden) dose level 2|"Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.~Disease subgroup: ALL Tumor Burden: high Dose level: 2 up to 2x106 EGFR+ cells/kg"
89519131|NCT01865617|Experimental|ALL (high tumor burden) dose level 3|"Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.~Disease subgroup: ALL Tumor Burden: high Dose level: 3 up to 2x107 EGFR+ cells/kg"
89519132|NCT01865617|Experimental|ALL (low tumor burden) dose level 1|"Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.~Disease subgroup: ALL Tumor Burden: low Dose level: 1 up to 2x105 EGFR+ cells/kg"
89519133|NCT01865617|Experimental|ALL (low tumor burden) dose level 2|"Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.~Disease subgroup: ALL Tumor Burden: high Dose level: 2 up to 2x106 EGFR+ cells/kg"
89519134|NCT01865617|Experimental|CLL dose level 1|"Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.~Disease subgroup: CLL Dose level: 1 up to 2x105 EGFR+ cells/kg"
89519135|NCT01865617|Experimental|CLL dose level 2|"Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.~Disease subgroup: CLL Dose level: 2 up to 2x106 EGFR+ cells/kg"
89519136|NCT01865617|Experimental|CLL dose level 3|"Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.~Disease subgroup: CLL Dose level: 3 up to 2x107 EGFR+ cells/kg"
89519137|NCT01865617|Experimental|CLL (ibrutinib) dose level 2|"Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.~Disease subgroup: CLL (ibrutinib) Dose level: 2 up to 2x106 EGFR+ cells/kg"
89032798|NCT02926599|Experimental|Personal Optimization Training|"Personal Optimization Training such as positive reinforcement, personalized psycho-physiological relaxation and mental rehearsal (total 5 hours a few weeks before the simulation).~Having 2 min to focus on techniques they were trained, after briefing of the scenario and before the start of the scenario."
89032799|NCT02926599|No Intervention|Control|"No particular training.~Screening of normal labs results during 2 min, after briefing of the scenario and before the start of the scenario."
89607345|NCT01825694|Experimental|Trauma-focused Substance Abuse Intervention|See Intervention Arm description.
89607346|NCT01758653||Biorepository|Patients with acute CO poisoning. Blood collection for biorepository only, no study intervention.
89032800|NCT02924532||Patients with total thiroidectomy|
89032801|NCT00528359||A|36 lean schizophrenic subjects free of metabolic syndrome(M:F 24:12; Caucasian n=23; North-African n=12; South-Asian n=1)aged 35±9 years
89032802|NCT02946008|Experimental|SBRT|Stereotactic Body Radiation Therapy (SBRT) will be delivered over 5 treatment sessions for approximately 1.5 weeks total.
89032803|NCT02944721|Other|Transversal study|Patients who had surgery for breast cancer for 2 years or less
89032804|NCT02944721|Other|Longitudinal study|Patients that must be operated for a breast cancer
89607347|NCT01704157|Other|Open Treatment|Treatment with Cryo-Touch III Device
89607348|NCT01699243||Epidural|subjects under epidural anesthesia
89607349|NCT01633866||Advances in Radio Frequency for MRI|advances in radio frequency (RF) coil magnetic resonance imaging (MRI)
89607350|NCT01569373||Post allogeneic SCT patients|Patients who have undergone an allogeneic stem cell transplant.
89607351|NCT01560663||Docetaxel Carboplatino|Doses of AUC 5-6 of carboplatin in combination with 75 mg/m2 of docetaxel are easily combined, being myelosuppression the most important toxicity. This combination has been studied in metastatic breast cancer as well as in the neoadjuvant setting. The combination of taxanes and platinum salts is increasingly used as neoadjuvant chemotherapy for TNBC. The docetaxel-carboplatin (TCb) regimen is an active and tolerable regimen in metastatic and locally advanced breast cancer, and the efficacy and toxicity characterization in the clinical setting are regaining interest in the era where the role of anthracyclines is controversial in the adjuvant setting. The avoidance of potentially serious long-term toxicities in specific breast cancer subtypes is a real challenge in an attempt to individualize therapies.
89607352|NCT01463371|No Intervention|Control|without azithromycin
89607353|NCT01463371|Active Comparator|azithromycin|treatment with azithromycin during three months
89607354|NCT01448161||Pediatric and Adult ICU patients|Pediatric and Adult ICU patients
89607355|NCT01419067|Other|Craniopharyngioma Patients|"Craniopharyngioma patients will have limited surgery and a 5mm clinical target volume margin in combination with proton therapy. Proton therapy will be indicated for patients with diagnosed craniopharyngioma who are not treated with radical surgery (gross-total resection). Patients who have had radical surgery or limited surgery prior to enrollment on this study and have no evidence of tumor will be observed for 5 years.~Participants receive ^1^8F-fluorodeoxyglucose and ^1^1C-methionine will be given to aid in tumor visualization."
89607356|NCT01377389|Experimental|Ipilimumab + ADT|Ipilimumab 10 mg/kg intravenous (IV) Weeks 5, 9, 13, and 17 plus Androgen Depravation Therapy (ADT) of either Leuprolide 7.5 mg intramuscular (IM) , Goserelin 3.6 mg subcutaneous (SQ) or Degarelix 80 mg SQ once a month for 8 months beginning Week 1.
89607357|NCT01326676|Experimental|polypill|Red Heart Pill Version 1 and Red Heart Pill Version 2.
89607358|NCT01326676|Active Comparator|usual medication|participants continuing to receive cardiovascular disease medications as separate tablets prescribed by their usual physician
89607359|NCT01290588||Children of Caucasian descent|Healthy children of Caucasian descent.
89032805|NCT02924493|Experimental|Low FODMAP diet|This group will follow a exclusion diet called low FODMAP diet, which is a diet with restriction of fermentable carbohydrates. The patients will be guided on how to avoid some foods and how to include others. The patients will follow the diet for four weeks.
89032806|NCT02924493|Placebo Comparator|Control diet|This group will follow a placebo diet, which is designed to imitate the low FODMAP diet by restricting specific foods. However, it is randomly selected foods that will be excluded in this diet, so that it works only as a control diet. The patients in this group will also be guided how to follow the diet for four weeks.
89032807|NCT00527150|Other|Cohort 1|Subjects will be randomized to receive either experimental drug (N=9) or matching placebo (N=3).
89032808|NCT00527150|Other|Cohort 2|Subjects will be randomized to receive either experimental drug (N=9) or matching placebo (N=3).
89032809|NCT00527150|Other|Cohort 3|Subjects will be randomized to receive either experimental drug (N=9) or matching placebo (N=3).
89032810|NCT00527150|Other|Optional Cohort 4|Subjects will be randomized to receive either experimental drug (N=9) or matching placebo (N=3).
89032811|NCT00527150|Other|Optional Cohort 5|Subjects will be randomized to receive either experimental drug (N=9) or matching placebo (N=3).
89032812|NCT00527228|Active Comparator|A|After 6 months of treatment, and a 3-months wash-out, there is cross-over to Arm B
89032813|NCT00527228|Placebo Comparator|B|After 6 months of treatment, and a 3-months wash-out, there is cross-over to Arm A
89607360|NCT01290588||Adults of Caucasian descent|Healthy adult eyes of Caucasian descent.
89607361|NCT01290588||Children of African-American descent|Healthy children of African-American descent.
89607362|NCT01290588||Adults of African-American descent|Healthy adults of African-American descent.
89032814|NCT02926482|No Intervention|Control|This arm will include 35 organizations who receive access to the Prescriber Recruitment Bundle (PRB) materials online via a secure website.
89032815|NCT02926482|Experimental|PRB: organizations implementing the PRB|This arm will include 35 organizations that will implement the intervention, the Prescriber Recruitment Bundle (PRB) using the NIATx Organizational Change Model (a model developed by our center research team).
89032816|NCT00527267|Experimental|AMG 073|AMG 073
89032817|NCT00527267|Placebo Comparator|Placebo|Placebo
89032818|NCT02924298|Experimental|Stage 1-2 Chronic Kidney Disease|Individuals with estimated glomerular filtration rate > 60 mL/min/1.73m^2, to undergo SLIMM intervention
89607363|NCT01287611|Active Comparator|Purse string closure technique|Eighty four patients were allocated to the study group. Due to expanded Kerr incisions 4 patients in study group did not receive their allocated intervention. In addition, 29 patients in the study group were lost to follow up and did not come to the sixth week check up. Statistical analysis is based on data from the remaining 51 study group.
89607364|NCT01287611|Active Comparator|Continuously locked closure technique|Eighty four patients were allocated to the control group. Due to expanded Kerr incisions 3 patients in control group did not receive their allocated intervention. In addition, 16 patients in the control group were lost to follow up and did not come to the sixth week check up. Statistical analysis is based on data from the remaining 65 study group.
88982536|NCT05652790|Experimental|Enhanced Rehabilitation Programme (ERP)|"60-120 MINUTES OF ENHANCED REHABILITATION~Manual Therapy Hydrotherapy Exercise Strength and Conditioning Programmes Gait re-education Pilates/ Yoga Cognitive and Vocational Rehabilitation Occupation Therapy Interventions eg. Anxiety Management, Pacing, Cognitive Behavioural Therapy"
88982537|NCT05652790|Other|Standard Care|Standard care received at usual NHS facility
88982538|NCT05647200|Active Comparator|T (Treatment)|The most optimal prime fluid from part I (based on the effect on perfused vessel density) + additional albumin during cardiopulmonary bypass.
88982539|NCT05647200|Sham Comparator|C (control)|The most optimal prime fluid from part I (based on the effect on perfused vessel density) + additional ringers during cardiopulmonary bypass.
88982540|NCT05644990||T2Bacteria Panel positive|Patients with spondylodiscitis and endocarditis who had positive T2Bacteria Panel test.
89607365|NCT01194271|Experimental|Neoadjuvant Ipilimumab|Leuprolide Acetate 22.5 mg administered as a single intramuscular 3 month depot + Ipilimumab 10 mg/kg by vein administered as 2 single doses, 3 weeks apart after hormone therapy + Radical Prostatectomy Surgery to remove prostate gland approximately 4 weeks after the second dose of Ipilimumab.
89607366|NCT01192048||Study Subjects|Individuals with Congenital Heart Disease and family members with or without Congenital Heart Disease. A blood sample collection will be required for all study participants.
89607367|NCT01172418|Active Comparator|Thymoglobulin and Daclizumab|Group I: Our standard steroid avoidance protocol, i.e., 3 daily doses of 1 mg/kg of Thymoglobulin®, the first to be infused at surgery, accompanied by 2 doses of anti-CD25 humanized monoclonal antibody, the first also to be given at surgery, and the second 2 weeks later. (controls)
89607368|NCT01172418|Experimental|Thymoglobulin and Alemtuzumab|Group II: A new steroid avoidance protocol in which 1 dose of 1 mg/kg of Thymoglobulin® is to be infused at surgery followed by 1 dose of alemtuzumab (Campath-1H) at 0.3 mg/kg within 24 hours. No further antibody therapy will be used.
89607369|NCT01163968|Experimental|Weight reduction program|MOMENTUM intervention
89607370|NCT01132924||EPS Study Participants|Women who participated in the 1982-1986 North Carolina Early Pregnancy Study (EPS)
89607371|NCT01119508|Experimental|Ipilimumab + Temozolomide|Induction: Ipilimumab 10 mg/kg IV over 90 minutes Day 1 + Temozolomide 200 mg/m2 PO on Days 1 - 4, every 3 weeks for 4 courses over 3 months.
89607372|NCT01092156|Active Comparator|Education on Infant-led latching|
89607373|NCT01092156|No Intervention|Standard education|
89607374|NCT01074814|Other|Metastatic Breast Cancer Patients|Blood drawn for molecular profiling
89607375|NCT00958737|Experimental|Arm I|"Patients receive modified FOLFOX 6 comprising oxaliplatin IV 85 mg/m² over 2 hours, leucovorin calcium IV over 2 hours, and fluorouracil IV over 46 hours on day 1. Treatment repeats every 14 days for 6 courses (3 months).~Patients receive CAPOX comprising oxaliplatin IV 130 mg/m² over 2 hours (day 1 every 3 weeks) in combination with capecitabine, which will be administered orally at a dose of 1000 mg/m2 twice-daily (equivalent to a total daily dose of 2000 mg/m2), with first dose the evening of day 1 and last dose the morning of day 15, given as intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment)"
89607376|NCT00958737|Experimental|Arm II|Patients receive modified FOLFOX 6 or CAPOX as in arm I. Treatment repeats every 14 days for 12 courses (6 months)or regarding CAPOX every 21 days for 8 courses (6 month).
89607377|NCT00917592|Experimental|Short intravenous amoxicillin plus clavulanic acid|Intravenous antibiotic 48 hours followed by oral antibiotic for 10 days
89607378|NCT00917592|Active Comparator|Long intravenous amoxicillin plus clavulanic acid|Intravenous antibiotic for 7 days followed by oral antibiotic for 5 days
89607379|NCT00907868|Active Comparator|Arm I|Patients undergo whole breast irradiation (WBI) once daily for 5 weeks (weekdays only).
89607380|NCT00907868|Experimental|Arm II|Patients undergo WBI as in arm I and a radiation tumor bed boost once daily for 8 days (weekdays only).
89607381|NCT00882037||Meth Dependence|Methamphetamine Dependence in residential Substance Abuse Treatment Program
89519138|NCT01865617|Experimental|NHL dose level 1|"Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.~Disease subgroup: NHL Dose level: 1 up to 2x105 EGFR+ cells/kg"
89519139|NCT01865617|Experimental|NHL dose level 2|"Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.~Disease subgroup: NHL Dose level: 2 up to 2x106 EGFR+ cells/kg"
88982541|NCT05644912|Experimental|All subjects|Transanal irrigation (TAI) with new catheter
88982542|NCT05611424|Experimental|FT003 Dose 1|Low dose of FT-003
88982543|NCT05611424|Experimental|FT003 Dose 2|Mid dose of FT-003
88982544|NCT05611424|Experimental|FT003 Dose 3|High dose of FT-003
88982545|NCT05591794|Experimental|Study group|The women in the study group will be asked to walk for 30 minutes/5 days or 50 minutes/3 days a week while performing a diet program for eight weeks and aerobic and resistance exercise program 3 days a week.
88982546|NCT05591794|Active Comparator|Control group|The women in the control group will be asked to walk for 30 minutes/5 days or 50 minutes/3 days a week while performing a diet program.
88982547|NCT05579483|Experimental|Predicted responders with prebiotics|Predicted responders, which are defined as UC patients having a relative abundance of Bacteroidetes <=10% in their feces, will receive 6 grams of prebiotics per day.
89607382|NCT00842010||Hyperglycemic without previous DM diagnosis|Patients with hyperglycemia, without previous diagnosis of diabetes
89607383|NCT00842010||Previous diagnosis of DM|Patients that have previous diagnosis of Diabetes Mellitus
89607384|NCT00842010||No previous DM diagnosis and no hyperglycemia|Patient with NO previous diagnosis of diabetes, and no hyperglycemia
89607385|NCT00754338|Active Comparator|Phase1 - Arm 1|
89607386|NCT00754338|Active Comparator|Phase1 - Arm 2|
89607387|NCT00754338|Active Comparator|Phase 2 - Arm 1|
89607388|NCT00754338|Active Comparator|Phase 2 - Arm 2|
89607389|NCT00745134|Experimental|Arm I (curcumin)|Patients undergo radiation therapy 5 days a week for a total of 28 fractions. Patients also receive capecitabine PO BID on the days of radiation therapy and curcumin PO BID in weeks 1-11.5.
89607390|NCT00745134|Active Comparator|Arm II (placebo)|Patients undergo radiation therapy and receive capecitabine as in Arm I. Patients also receive placebo PO BID in weeks 1-11.5.
89607391|NCT00673010|Experimental|1|131 I-iodine (131-I), 124 I-iodine (124-I)
89607392|NCT00610883|Experimental|1 - LSA4|
89607393|NCT00588198||1|Melanoma patients
89607394|NCT00574496|Experimental|High-Risk or Relapsed Hodgkin Lymphoma|This is a phase 2 intention-to-treat study of salvage chemotherapy followed by allogeneic HSC transplant for the treatment of primary refractory or relapsed HL. Patients who 1) do not progress on salvage chemotherapy, and 2) have both suitable HSC donors and 3) a satisfactory pre-allograft work-up will proceed to allograft. Patients who fail any of these 3 criteria will be off-study and considered treatment failures for the purposes of the intention-to-treat study.
89607395|NCT00533624|Active Comparator|1: Myfortic|Myfortic Group: Myfortic® 1,440 mg/day in two divided doses (induced with either the IL-2 receptor inhibitors or thymoglobulin). Tacrolimus will be dosed to 12-hour trough levels of 8-10 ng/ml. Methylprednisolone is to be given as per our center protocols, weaning to dose levels of <0.1 mg/kg by 3-6 months post-operatively.
88982548|NCT05579483|Placebo Comparator|Predicted responders with placebo|Predicted responders, which are defined as UC patients having a relative abundance of Bacteroidetes <=10% in their feces, will receive 6 grams of placebo per day.
88982549|NCT05579483|Experimental|Predicted non-responders with prebiotics|Predicted non-responders, which are defined as UC patients having a relative abundance of Bacteroidetes >=15% in their feces, will receive 6 grams of prebiotics per day.
88982550|NCT05579483|Placebo Comparator|Predicted non-responders with placebo|Predicted non-responders, which are defined as UC patients having a relative abundance of Bacteroidetes >=15% in their feces, will receive 6 grams of placebo per day.
88982551|NCT05574608|Experimental|Experimental: Experimental: CD123-CAR-NK.|The relapsed/refractory AML patients will receive allogenic CD123-Targeted CAR-NK cells infusion (1x10^9, 1-2x10^7/kg) after precondition chemotherapy.
88982552|NCT05573685|Active Comparator|DiNaMo Study App|Randomization ratio as 3 DiNaMo Study Apps: 1 Digital Control App
88982553|NCT05573685|Placebo Comparator|Digital Control App|Randomization ratio as 3 DiNaMo Study Apps: 1 Digital Control App
89607396|NCT00533624|Active Comparator|2. Cellcept|Cellcept® 2,000 mg/day, in divided doses (induced with either the IL-2 receptor inhibitors or thymoglobulin). Tacrolimus will be dosed to 12-hour trough levels of 8-10 ng/ml. Methylprednisolone is to be given as per our center protocols, weaning to dose levels of <0.1 mg/kg by 3-6 months post-operatively.
89607397|NCT00515060||Cancer Therapy-Induced Pain|Patients with advanced cancer entering chemotherapy or have reported pain as a result of cancer treatment.
89607398|NCT00499083|Experimental|Vaccine|Patients with HER-2/neu negative tumors will receive IT DCs one week after the first three of four cycles of dose dense T therapy and then four cycles of dose dense AC therapy will be given (i.e. T-AC).
89607399|NCT00418886|Placebo Comparator|1|Placebo Vandetanib + Pemetrexed
89607400|NCT00418886|Experimental|2|Vandetanib + Pemetrexed
89607401|NCT00230659||HHT patients|Patients with hereditary haemorrhagic telangiectasia. Blood sample to be taken.
89607402|NCT00230659||Controls|People without hereditary haemorrhagic telangiectasia. Blood sample to be taken.
89607403|NCT00230633||Patients with HHT|People with molecularly confirmed HHT. No intervention, blood sample only
89607404|NCT00230633||Controls|People without HHT No intervention, blood sample only
89607405|NCT00230620||Individuals with HHT and their families|No intervention - blood or saliva sample only
89607406|NCT00089024|Experimental|treatment|see interventions
89607407|NCT01819129|Experimental|Faster-acting insulin aspart (FIAsp)|Meal time faster-acting insulin aspart is given in combination with once daily insulin glargine and metformin in a basal-bolus regimen. Insulin glargine and metformin treatment are open labelled background medication.
89607408|NCT01819129|Active Comparator|Insulin aspart|Meal time insulin aspart is given in combination with once daily insulin glargine and metformin in a basal-bolus regimen. Insulin glargine and metformin treatment are open labelled background medication.
89607409|NCT04147065|Experimental|7-day triple therapy and 7-day bismuth quadruple therapy|7-day triple therapy is consisted of proton pump inhibitor (PPI), amoxicillin and clarithromycin for seven days 7-day bismuth quadruple therapy is consisted of PPI, bismuth, tetracycline, metronidazole for seven days
89607410|NCT04147065|Active Comparator|14-day triple therapy and 14-day bismuth quadruple therapy|14-day triple therapy is consisted of PPI, amoxicillin and clarithromycin for fourteen days 14-day bismuth quadruple therapy is consisted of PPI, bismuth, tetracycline, metronidazole for fourteen days
89607411|NCT04024137|Experimental|ZSP1273-200 mg BID|Subjects will receive 10 doses of ZSP1273 200mg along with placebo twice daily (BID) with approximately 12 hour (+/- 2) intervals, over 5 days.
89607412|NCT04024137|Experimental|ZSP1273-400 mg BID|Subjects will receive 10 doses of ZSP1273 400mg（200mg*2) along with placebo twice daily (BID) with approximately 12 hour (+/- 2) intervals, over 5 days.
89607413|NCT04024137|Experimental|ZSP1273-600 mg QD|Subjects will receive 5 doses of ZSP1273 600mg （200mg *3) and 5 doses of placebo respectively for 5 days.The interval between ZSP1273 and placebo is approximately 12 hour (+/- 2) .
89607414|NCT04024137|Placebo Comparator|Placebo|Subjects will receive 10 doses of matching placebo of ZSP1273 twice daily (BID) with approximately 12 hour (+/- 2) intervals, over 5 days.
89607415|NCT04146831|Experimental|Sintilimab|Sintilimab is administered in this arm.
89607416|NCT04025775|Experimental|Closed loop insulin delivery|"Unsupervised home use of day and night fully automated closed loop insulin delivery system (CamAPS HX) for 20 days~The CamAPS HX closed-loop system comprises~Dana insulin pump (Diabecare, Sooil, Seoul, South Korea)~Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA)~An Android smartphone hosting CamAPS HX Application with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump~Glooko/Diasend cloud upload system to monitor CGM/insulin data."
89607417|NCT04025775|Active Comparator|Standard therapy|Participants in the control arm will continue to follow their current diabetes management plan for the 20 day study period.Participants will be wear a masked continuous glucose monitoring (CGM) system during the 20 day study period.
89607418|NCT03926481|Experimental|Obesity Only|Assess the effect of an intensive lifestyle intervention on cognitive function in adults with obesity who are 65 years and older.
89607419|NCT03926481|Experimental|Sarcopenia and Obesity|Assess the effect of an intensive lifestyle intervention on cognitive function in adults with obesity and sarcopenia who are 65 years and older.
89607420|NCT04028193|Other|Diagnose Dumping after supplement consumption|Carbohydrate ingestion to provoke dumping syndrome related symptoms
89607421|NCT04028193|Other|Fat supplementation|A high fat supplement was added to the carbohydrate liquid meal that was previously used for diagnosis.
89607422|NCT04406181|Other|operation deferred|Adult patients whose operation date has been deferred due to the pandemic
89607423|NCT04406181|Other|no operation date|Patients who did not have had an operation date and who were told to need cardiac surgery before the pandemic started
89607424|NCT04406181|Other|postoperative consultation deferred|Patients who have been operating on during the month before the pandemic
89607425|NCT04765917|Active Comparator|Selected Physical Therapy group|The Control group will receive a selected physical therapy program for 60 minutes, 3 times/week for 3 successive months including the following exercises
89607426|NCT04765917|Experimental|Motor imagery training|Children allocated to the study group will receive the same selected physical therapy program given to the control group for 30 min in addition to 30 minutes motor imagery training program
88982554|NCT05564494|Active Comparator|Bankart Repair|Arthroscopic Bankart repair procedures will be performed according to each individual surgeon's usual technique. Procedures will be performed with the patient in the lateral or beach-chair position. Repairs for associated or conjoined superior labral anterior-to-posterior (SLAP) tears will be documented and performed at the surgeon's discretion. Labral detachments will be repaired with the use of suture-anchor fixation and arthroscopic tying techniques. Either two or three suture anchors will be used. Capsular redundancy will be addressed with arthroscopic suture plication at the surgeon's discretion. Surgeons will mobilize the capsulolabral tissue as deemed necessary. Surgical time and video of the operation will be recorded, and photographs will be taken documenting any bone loss.
88982555|NCT05564494|Experimental|Anatomic Glenoid Reconstruction|The surgical technique was the lateral decubitus all-arthroscopic anatomic glenoid reconstruction procedure for treatment of anterior shoulder instability as described by Wong et al. (2015). The procedure is done in a semi-lateral decubitus position that assists with optimal graft placement on the native glenoid. The investigators utilize the cannulated Bristow-Latarjet Instability Shoulder System (Depuy-Mitek, MA, USA). The surgical technique is identical to that of arthroscopic Bankart repair with one additional step. Prior to insertion of anchors, one additional medal portal is created for insertion of the bone graft. The distal tibia allograft is prepared; the cannulated guide is attached and advanced through the rotator interval and secured with two cannulated screws. Finally, the Bankart repair is performed above the graft. Surgical time and video of the operation will be recorded, and photographs will be taken documenting any bone loss.
88982556|NCT05562167|Experimental|Potassium Nitrate (KNO3) treatment arm|10 mmol of KNO3 via a single gel capsule to be consumed orally once per day for 6 weeks.
88982557|NCT05562167|Placebo Comparator|Placebo-controlled arm|10 mmol of placebo via a single gel capsule to be consumed orally once per day for 6 weeks.
89607427|NCT04023903|Experimental|RTA 402 5mg 3cap at fasting|
89607428|NCT04023903|Experimental|RTA 402 5mg 3cap after meal|
89607429|NCT04023981|No Intervention|Standard care alone|Patients randomly allocated to standard care will be cared for on the appropriate mattress indicated for use in that participating centre according to local policy e.g. foam mattress or dynamic air mattress. Standard care may also include a mattress overlay or the use of a wedge or pillows to maintain the position of the participant, or pressure offloading boots on the foot if the need arises during the study period.
89607430|NCT04023981|Experimental|Parafricta bootees plus standard care|Patients randomly allocated to Parafricta plus standard care will be cared for on the appropriate mattress as above and care may possibly include a mattress overlay or the use of a wedge or pillows. Participants will in addition be issued with Parafricta bootees (one pair and up to two spare pairs). The patient and clinical staff and the patient's carers will be instructed in the use of Parafricta bootees, which are intended to be worn throughout the day and night and removed only for normal daily washing or examination of the patient's feet. Either the slip-on bootees or the Velco-closure bootees will be selected for the participant at the judgment of the clinical ward nurses.
89607431|NCT04146675|Experimental|TRICOT JERSEY VANISE DOUBLE FACE|
89607432|NCT04146675|Placebo Comparator|TRICOT JERSEY SIMPLE|
89607433|NCT03022149|Experimental|Doctormate® (200mmHg)|Patients will be treated with Renqiao Remote Ischemic Conditioning Device (Doctormate®) (200mmHg) once daily for 6 months
89607434|NCT03022149|Sham Comparator|Doctormate® (60mmHg)|Patients will be treated with Renqiao Remote Ischemic Conditioning Device (Doctormate®) (60mmHg) once daily for 6 months
89607435|NCT04194333||Standard Fluoroscopy Guided EMN|Patient is undergoing electromagnetic navigation bronchoscopy using Medtronic super D version 7 EMN system, peripheral endobronchial ultrasound and standard fluoroscopy using the C-arm under general anesthesia.
89607436|NCT04194333||Cone Beam CT Guided EMN|Patient is undergoing electromagnetic navigation bronchoscopy using Medtronic super D version 7 EMN system, peripheral endobronchial ultrasound and Cone Beam CT Guidance using the Philips Azurion 7 C20 FlexMove with Embo Guide and Overlay software to create CT Augmented Fluoroscopy under general anesthesia.
89607437|NCT04023279|Experimental|TENS|Conventional TENS of 100 Hz and 100 usec for 20 minutes
89607438|NCT04023279|Experimental|Myofascial Therapy|Conventional TENS of 100 Hz and 100 usec for 20 minutes plus myofascial release therapy in the brachial biceps; Seven to fifteen transverse sliding repetitions and three repetitions of longitudinal sliding
89607439|NCT04023123||Anterior Cornea Striae|Eyes with anterior cornea striae present
89607440|NCT04023123||Hypotony Maculopathy|Eyes with hypotony maculopathy present
89607441|NCT04023123||Hypotony only|Eyes with intraocular pressure less than 10 without cornea striae and/or maculopathy
89607442|NCT03021915|Other|OvaPrime Treatment|The treatment is based on identified EggPC cells in the outer-most layer of the ovary. During OvaPrime, the EggPC cells are isolated from biopsy tissue obtained from the outer layer of the ovary. OvaScience separates the EggPC cells and these isolated cells are then returned to the IVF clinic - there is no culture or expansion of the EggPC cells during this process. Upon receipt of the autologous EggPC cells, the clinic initiates the process of reintroducing the cells into the follicular development zone of the woman's own ovary using a laparoscopic procedure. Once in the ovary, the EggPC cells have the opportunity to develop and mature into fertilizable eggs naturally or with controlled ovarian hyperstimulation (when stimulated by exogenous gonadotropins) using standard IVF protocols.
89607443|NCT04146519|Experimental|Study group|Autologous MMSC
89607444|NCT04146519|Placebo Comparator|control group|
89607445|NCT04022811|Experimental|Artificial tears|0.1% bromfenac VS Artificial tears
89607446|NCT04022889|Experimental|Stage 1|The study will be performed in two stages. Stage 1 is a randomized, 2-period crossover design. Test platelets stored for 7 days will be radiolabeled based on either the BEST or Variant 1 methods (depending on the period and randomization scheme for the Test platelets) for 12 healthy subjects. The recovery and survival for Test platelets prepared with the BEST and Variant 1 methods will be compared with each other and against the fresh platelet Control. With agreement from the FDA (BQ200481, July 8, 2020), completion of Stage 1 is not required.
89607447|NCT04022889|Experimental|Stage 2|Stage 2 is a single arm design. Test platelets from 24 healthy subjects, stored for 7 days, will be prepared for radiolabeling following the Variant 1 methodology. The recovery and survival for Test platelets will be compared against the fresh platelet Control. Stage 1 subjects with evaluable Variant 1 method data will contribute to the requirement of the 24 subjects for Stage 2.
88982558|NCT05556239|No Intervention|The usual care group|The usual care group receives standard care in accordance to current clinical practice at Rigshospitalet
88982559|NCT05556239|Experimental|Resistance Exercise Training|Patients included in the intervention group will receive usual care plus the exercise training intervention.
88982560|NCT05546359|Experimental|Stage 1 - Group 1: IV amisulpride 0.035 mg/kg + IV dexamethasone|Stage 1 - Group 1: IV amisulpride 0.035 mg/kg + IV dexamethasone
88982561|NCT05546359|Experimental|Stage 1 - Group 2: IV amisulpride 0.07 mg/kg + IV dexamethasone|Stage 1 - Group 2: IV amisulpride 0.07 mg/kg + IV dexamethasone
88982562|NCT05522153|Experimental|Arista group|this group of randomized patients will receive 5 grams of arista hemostatic powder intra-operatively in their wound in addition to 1 gram of IV transexemic acid prior to incision
88982563|NCT05522153|No Intervention|control group|this group of randomized patients will receive just the 1 gram of IV transexemic acid prior to incision
88982564|NCT05518175|Active Comparator|Route A: Traditional laparoscopy|
88982565|NCT05518175|Experimental|Route B: Single site laparoscopy|
89607448|NCT04145973||recurrence and metastasis|breast cancer patients with recurrence and metastasis after surgery
89607449|NCT04146129|Experimental|CDX-0159|Eligible subjects will receive a single dose of CDX-0159
89607450|NCT04146129|Placebo Comparator|Normal saline|Subjects assigned to receive placebo will receive a single dose of normal saline
89607451|NCT04022655||ANCA-associated Vasculitis|Patients with ANCA-associated vasculitis admitted to the ICU
89607452|NCT04145583|Experimental|HSK3486|0.4 mg/kg
88982566|NCT05518175|Experimental|"Route C:V-Notes surgery"|
88982567|NCT05498987|Experimental|448 kilohertz Capacitive Resistive Monopolar Radiofrequency stimulus on the dominant Achilles Tendon|448 kilohertz Capacitive Resistive Monopolar Radiofrequency stimulus on the dominant Achilles Tendon
88982568|NCT05496452|Experimental|Beta-lactoglobulin|Daily supplementation over 12 day period. A nutritional supplement.
89607453|NCT04145583|Experimental|voriconazole , HSK3486|400 or 200 mg; 0.4 mg/kg
89607454|NCT04022421|Experimental|hydroxychloroquine arm|
88982569|NCT05496452|Placebo Comparator|Carbohydrate|Daily supplementation over 12 day period. Energy matched control.
88982570|NCT05488145|Experimental|Single Arm (internet intervention, best practice)|Patients receive access to the app in addition to standard of care for 3 months. Through the app, patients receive weekly reminders about hormone therapy, report any side effects, access educational videos that provide tips to help mitigate some of these side effects, and allow patients to send messages to members of our breast cancer team about any questions patients may have about the side effects they may be experiencing.
88982571|NCT05486546|Experimental|Study: Phorcides|Contoura with Phorcides used for surgical planning of LASIK procedure
88982572|NCT05486546|Active Comparator|Control: Wavefront Optimized|WaveLight Wavefront Optimized used for surgical planning of LASIK procedure
88982573|NCT05466370||AKI|Acute Kidney Injury
88982574|NCT05466370||ARF|Acute Respiratory Failure
88982575|NCT05466370||AKI and ARF|Acute Kidney Injury and Acute Respiratory Failure
88982576|NCT05466370||no complication|no complication
88982577|NCT05438147|Active Comparator|CT-100 DiNaMo (Study App) in Patients with Multiple Sclerosis|Randomized Controlled Study to Evaluate CT-100 DiNaMo (Study App) in Patients with Multiple Sclerosis
88982578|NCT05438147|Sham Comparator|Care-as-Usual control in Patients with Multiple Sclerosis|Randomized controlled Study to Evaluate Care-as-Usual control in Patients with Multiple Sclerosis
88982579|NCT05438147|Active Comparator|CT-100 DiNaMo (Study App) in Patients with Breast or Lung Cancer|Randomized Controlled Study to Evaluate CT-100 DiNaMo (Study App) in Patients with with Breast or Lung Cancer
89607455|NCT04022031||Exposed group|Chinese patent medicine combined with western medicine routine
89607456|NCT04022031||Non-exposed group|Western medicine routine treatment
89607457|NCT03947151|Other|one arm|one arm
89607458|NCT04022109||Gastric cancer patients undergoing surgery|Patients with histologically confirmed gastric cancer (adenocarcinoma) planned for surgical management
89607459|NCT04022109||Gastric cancer patients|Patients with histologically confirmed gastric cancer (adenocarcinoma)
89607460|NCT04022109||Control group patients without gastric cancer|Patients without gastric malignant disease according to data obtained in upper endoscopy
89607461|NCT04022109||Average risk population|Average risk population of both genders aged 40-64 at the time of inclusion lacking alarm symptoms for gastrointestinal cancer
89607462|NCT04022109||Patients with dyspeptic symptoms|Patients with dyspeptic symptoms or other complains being referred for upper endoscopy (Chile)
89607463|NCT04145739|Experimental|Mastectomy group|Patients undergoing mastectomy
89607464|NCT04145739|Experimental|Quadrantectomy group|Patients undergoing quadrantectomy
89607465|NCT04145661|Experimental|DR group|Participants who have cochlear dead regions, identified by the thresholds equalising noise test will be placed in this group.
89607466|NCT04145661|Experimental|No DR group|Participants who have no cochlear dead regions, identified by the thresholds equalising noise test will be placed in this group.
89607467|NCT03923673|Experimental|Subjects with Heart Failure with Preserved Ejection Fraction|Subjects with Heart Failure with Preserved Ejection Fraction (HFpEF) will receive a minimally invasive treatment called a pericardiotomy.
89607468|NCT04021953|Experimental|Intervention Group|"The online intervention comprises a series of six videos, each about 10-minutes in length, entitled the People Like Us series. The intervention was developed by gayhealth.sg and Action for AIDS Singapore in 2018. The series follow the love and sex lives of four ethnically-diverse GBQ men of varying socioeconomic backgrounds, as they negotiate issues of sexual health, mental health, and relationships throughout the six-part miniseries.~The intervention group will also be provided with an e-pamphlet on sexual wellness catered to GBMSM. This e-pamphlet has been developed by the National Skin Centre and Department of Sexually Transmitted Infections Clinic specifically for information on sexual wellness among GBMSM. It comprises segments on HIV/STI symptoms, etiology, information on how to seek help for HIV/STI, behavioral and biomedical methods of HIV prevention."
89607469|NCT04021953|Active Comparator|Control Group|The control group will be provided with an e-pamphlet on sexual wellness catered to GBMSM. This e-pamphlet has been developed by the National Skin Centre and Department of Sexually Transmitted Infections Clinic specifically for information on sexual wellness among GBMSM. It comprises segments on HIV/STI symptoms, etiology, information on how to seek help for HIV/STI, behavioral and biomedical methods of HIV prevention.
89607470|NCT02979717|Experimental|high protein, high fiber|Participants receive a high protein, high fiber dietary supplement pre-load
89607471|NCT02979717|Placebo Comparator|Low protein, low fiber|Participants receive a low protein, low fiber isocaloric pre-load
89607472|NCT04145193|Active Comparator|Control Arm (mFOLFOX6)|Parts of mFOLFOX6 are: Oxaliplatin 85 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Folinic acid (leucovorin) 400 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Fluorouracil (5-FU) 400 mg/m2 IV bolus on Day 1 then 2,400 mg/m2 over 46 to 48 hours IV infusion Q2W (Day 1-2 of every 14-day cycle).
89607473|NCT04145193|Experimental|Durvalumab|Durvalumab 1500 mg IV, Q4W (Day 1 of every other 14-day cycle)
89607474|NCT04145193|Experimental|Oleclumab|Oleclumab 3,000 mg IV Q2W x5 then Q4W (Day 1 of every 14-day cycle through cycle 4 then Day 1 of every other 14-day cycle)
88982580|NCT05438147|Sham Comparator|Care-as-Usual control in Patients with Breast or Lung Cancer|Randomized Controlled Study to Evaluate Care-as-Usual control in Patients with with Breast or Lung Cancer
88982581|NCT05438147|Active Comparator|CT-100 DiNaMo (Study App) in Patients with Mild Cognitive Impairment|Randomized Controlled Study to Evaluate CT-100 DiNaMo (Study App) in Patients with Mild Cognitive Impairment
88982582|NCT05438147|Sham Comparator|Care-as-Usual in Patients with Mild Cognitive Impairment|Randomized Controlled Study to Evaluate Care-as-Usual in Patients with Mild Cognitive Impairment
89607475|NCT04145193|Experimental|Monalizumab|Monalizumab 750 mg IV, Q2W (Day 1 of every 14-day cycle)
89607476|NCT04021563|Experimental|SR419|Ascending single and multiple doses of SR419 orally
88982585|NCT05435040|Experimental|self-comparison|"The patient will be fitted with proprioceptive knee brace and with no knee brace.~the patient will perform tests (Y Balance Test, test with Weinstein monofilaments, and Joint Position Sense test) and complete visual analog scales with and without the proprioceptive knee brace in a randomized order.~There is also a satisfaction questionnaire regarding the proprioceptive knee brace to be completed at the end of the study."
88982586|NCT05426382|Experimental|Digital solution group|"Participants will be instructed to download a lifestyle-changing mobile application to which they will have access for 9 months. The program aims to provide remote symptom monitoring by a health coach and by having participants enter data (on diet, exercise, weight, stress and energy levels, etc) and patient reported outcomes (PROs) via the SidekickHealth platform to empower positive lifestyle changes.~The intervention consists of a 12-week digital behavioral change program with an additional 6-month maintenance program, during which time the patient still has access to the application but with limited features compared to the first 12 weeks. During the total 9-month study period all participants will also receive standard of care."
89607477|NCT04021563|Placebo Comparator|Placebo|Ascending single and multiple doses of placebo orally
89607478|NCT03021837||all patients|Patient receiving antenatal corticosteroid course for fetal lung maturity consisting of betamethasone or dexamethasone Women without known gestational diabetes and women with non-insulin requiring gestational diabetes (A1GDM)
89607479|NCT04765839|Experimental|Intervention Arm - Receives COVID-19 Vaccine messages|Group to receive COVID-19 Vaccine messages during the first two weeks of the study.
89607480|NCT04765839|Experimental|Delayed Intervention Arm|Group to receive COVID-19 Vaccine messages during the last two weeks of the study.
89607481|NCT04141215|Experimental|BIOBank bone paste (PPT322)|Allogeneic bone paste derived from human living donor femoral heads
89607482|NCT04141215|Active Comparator|BIOBank cortico-cancellous bone powder (PPT6)|Allogeneic bone powder derived from human living donor femoral heads (used in current practice)
89607483|NCT04141059|Experimental|Oligopin|Intervention group that will intake 100 mg of Oligopin® for 6 weeks
89607484|NCT04141059|Placebo Comparator|Placebo|Placebo group that will intake 250 mg of Maltodextrin
89607485|NCT03022227|Experimental|group A start with the remote session followed by on site|
89607486|NCT03022227|Active Comparator|group B start with on site followed by telemedecine|
89607487|NCT04747743||Egyptian dental practitioners|170 dental practitioners in Egypt (professionals both academic and nonacademic).
89607488|NCT04144335|Active Comparator|Group 1: N-803 and bNAbs Only|Group 1 will receive only N-803 and the bNAbs; they will not receive the haNK™ cells
89607489|NCT04144335|Experimental|Group 2: N-803 and bNAbs with haNK™ Cells|The protocol for Group 2 will be identical to the one followed by Group 1, except that they will receive haNK™ cells on the same day as each dose of N-803.
89607490|NCT02707497|Experimental|rhTPO|Recombinant Human Thrombopoietin，TPIAO®, Shenyang Sunshine Pharmaceutical Company Limited [SUNSHINE], Shenyang, China）， 15000u/d, qd, subcutaneous injection, daily for no more than 7 consecutive days
89607491|NCT02707497|Placebo Comparator|placebo|The control group will not use any platelet-increased drugs.
89607492|NCT02702895||Phase 1|Former ASPIRE participants
89607493|NCT02702895||Phase 2 HOPE participants|Former HOPE participants
89607494|NCT02702895||Phase 2 Male Partners|Male partners of HOPE participants
89607495|NCT04144257|Experimental|Subjects diagnosed with Multiple Sclerosis (MS)|We plan to enroll 12 subjects with multiple sclerosis (6 with relapsing multiple sclerosis and 6 with secondary progressive multiple sclerosis).
89607496|NCT04147845|Experimental|Fractional Carbon dioxide laser and triamcinolone acetonide|"Group I:Fractional Carbon dioxide laser (CO2 Laser) and triamcinolone acetonide (TrA; 10 mg/ ml) (14, 15) The ablative fractional CO2 laser is delivered to the patients' scalp. The fractional ablative method is applied immediately before the topcial medication.~Laser treatment will be given to the affected area, and immediately after the treatment, triamcinolone solution (10 mg/ml) will be dropped on the treated area and spread evenly.~Each patient will receive four treatments, with an interval of three weeks between the treatment sessions, for a total of 12 weeks.This will be followed by a follow up period of another 4 weeks. The patients will be given no topical treatments for the alopecia areata in between the sessions. Topical post-procedure care in the form of topical antibiotics, emollient or sunscreen may be used. Each patch will be digitally macrophotographed, and evaluated clinically and by dermoscopy at baseline and at the end of the study, for signs of hair regrowth"
89607497|NCT04147845|Experimental|Microneedling with Dermapen and triamcinolone acetonide|"Microneedling is performed using Dermapen. This creates pin point bleeding or mild erythema which will be considered as the end point.~Triamcinolone acetonide in concentration of 10 mg/ml (0.1 ml containing 1 mg of triamcinolone) will be applied on each lesion twice, before and after performing microneedling.~Each patient will receive four treatments, with an interval of three weeks between the treatment sessions, for a total of 12 weeks.This will be followed by a follow up period of another 4 weeks. The patients will be given no topical treatments for the alopecia areata in between the sessions. Topical post-procedure care in the form of topical antibiotics, emollient or sunscreen may be used. Each patch will be digitally macrophotographed, and evaluated clinically and by dermoscopy at baseline and at the end of the study, for signs of hair regrowth"
89607498|NCT04147845|Experimental|Fractional Carbon dioxide laser and Platelet-rich plasma|"The same laser parameters as group I will be used, followed by application of freshly prepared PRP. The applied PRP will be spread over the whole affected area.~Each patient will receive four treatments, with an interval of three weeks between the treatment sessions, for a total of 12 weeks.This will be followed by a follow up period of another 4 weeks. The patients will be given no topical treatments for the alopecia areata in between the sessions. Topical post-procedure care in the form of topical antibiotics, emollient or sunscreen may be used. Each patch will be digitally macrophotographed, and evaluated clinically and by dermoscopy at baseline and at the end of the study, for signs of hair regrowth"
89607499|NCT04147845|Experimental|Microneedling with Dermapen and Platelet-rich plasma|"Microneedling using dermapen is performed as Group II. Microneedling is preceeded and followed by intermittent application of freshly prepared PRP. The applied PRP will be spread over the whole affected area and again rolled till pinpoint bleeding points are noticed.~Each patient will receive four treatments, with an interval of three weeks between the treatment sessions, for a total of 12 weeks.This will be followed by a follow up period of another 4 weeks. The patients will be given no topical treatments for the alopecia areata in between the sessions. Topical post-procedure care in the form of topical antibiotics, emollient or sunscreen may be used. Each patch will be digitally macrophotographed, and evaluated clinically and by dermoscopy at baseline and at the end of the study, for signs of hair regrowth"
89607500|NCT03920709||Chronic HIV-1 infected subjects : 50 Viremic subjects|plasma HIV RNA > 500 copies/mL, treatment-naive or treated (failing) regardless of the cause of persistent viremia
89607501|NCT03920709||Chronic HIV-1 infected subjects : 50 Treated Aviremic subjects|< 50 copies/mL under treatment for at least 12 months
89607502|NCT03920709||Chronic HIV-1 infected subjects :10 Spontaneous Controllers|from the ANRS CO21 CODEX Cohort or not (5 last viral loads < 400 copies /ml)
89607503|NCT01849783|Experimental|autologous stem cell transplant|"Induction : DPACE(dexamethasone,cisplatin,doxorubicin,cyclophosphamide,etoposide) chemotherapy plus stem cell collection. Additional stem cell collection and/or chemotherapy may be required.~After collection, participants will receive dexamethasone x 4 days every 14 days.~Transplant: The transplant preparative regimen will be bortezomib/thalidomide/dexamethasone/melphalan.~Once recovered, participants start thalidomide daily and dexamethasone x 4 days every 21 days.~Consolidation (if administered): VDT-PACE(bortezomib,dexamethasone,thalidomide,cisplatin,doxorubicin,cyclophosphamide, etoposide)~Maintenance: Year 1 - VTD (bortezomib, thalidomide, dexamethasone) cycles. Year 2 - VCD (bortezomib, cyclophosphamide, dexamethasone)cycles."
89607504|NCT01611883|Experimental|Ezetimibe|10 mg oral dose once daily for 24 weeks
89210379|NCT05711511|Active Comparator|Obtura II|The Obtura II system will be prepared ,sealer will be applied to canal wall . A 23G needle is selected and a stopper will place at 4-6 mm of the WL. The control unit of Obtura II will be on, and the display showed the required temperature of 185°C. The gun will be loaded with a fresh pellet of gutta- percha and plunger will be pushed forward.The needle will be then positioned in the canal so that it reached 3 to 5 mm of the apical preparation. 3-4 mm of the gutta-percha was passively injected without any apical pressure and will be compacted gently with a #11 endodontic plugger. Thus, the apical plug will be created in this manner. A segmental technique will be used in which 3 to 4 mm of gutta-percha will be sequentially injected and compacted. Increments will be added until gutta-percha reached top orifice level, and then compaction will be done with a cold plugger. Excess gutta-percha was severed at or below the orifice level.
89210380|NCT02539056|Experimental|Chondron Implantation|Chondron Implantation for the suject with cartilage defect
89210381|NCT05278182|Experimental|Naoxintong Capsule|Naoxintong Capsule
89210382|NCT05278182|Placebo Comparator|Placebo|Placebo
89607505|NCT01611883|Placebo Comparator|Placebo|Placebo to match ezetimibe orally once daily for 24 weeks
89607506|NCT01848457|Experimental|Cycles 1 & 2: HDMTX 4 h, PTZ+C; Cycles 3 & 4: HDMTX 12 h, C|Cycles 1 and 2: HDMTX administered as a 4-hour infusion and pantoprazole is administered with cisplatin Cycles 3 and 4: HDMTX administered as a 12-hour infusion and cisplatin is administered alone
89607507|NCT01848457|Experimental|Cycles 1 & 2: HDMTX 4 h, C; Cycles 3 & 4: HDMTX 12 h, PTZ + C|Cycles 1 and 2: HDMTX administered as a 4-hour infusion and cisplatin is administered alone Cycles 3 and 4: HDMTX administered as a 12-hour infusion and pantoprazole is administered with cisplatin
89210383|NCT00228553|Experimental|1|Armodafinil 100 to 250 mg/day
89210384|NCT00922506|Experimental|doxazosin plus tolterodine SR 2 mg|doxazosin plus tolterodine SR(2 mg, qd) for 12 weeks
89210385|NCT00922506|Experimental|doxazosin plus tolterodine SR 4 mg|doxazosin plus tolterodine SR(4 mg,qd) for 12 weeks
89607508|NCT01848457|Experimental|Cycles 1 & 2: HDMTX 12 h, PTZ+C; Cycles 3 & 4: HDMTX 4 h, C|Cycles 1 and 2: HDMTX administered as a 12-hour infusion and pantoprazole is administered with cisplatin Cycles 3 and 4: HDMTX administered as a 4-hour infusion and cisplatin is administered alone
89607509|NCT01848457|Experimental|Cycles 1 & 2: HDMTX 12 h, C; Cycles 3 & 4: HDMTX 4 h, C + PTZ|Cycles 1 and 2: HDMTX administered as a 12-hour infusion and cisplatin is administered alone Cycles 3 and 4: HDMTX administered as a 4-hour infusion and pantoprazole is administered with cisplatin
89607510|NCT01817725|Experimental|Engerix-B|Engerix-B (20 μg/ml, GlaxoSmithKline) was administered at 0-2-4-6-8-10-12 months in dosage of 40μg for >20 years old and 20μg for < or =20 years old
89607511|NCT01870999|Experimental|400 mg Aripiprazole IM Depot|400 mg aripiprazole IM (intramuscular) depot intramuscular injection once every 4 weeks for 5 months. All participants were on a stable dose of 10 mg aripiprazole tablets once daily in the morning for at least 14 days prior to randomization and continued 10 mg aripiprazole tablets once daily on days 1 to 14.
89607512|NCT01870999|Experimental|300 mg Aripiprazole IM Depot|300 mg aripiprazole IM depot intramuscular injection once every 4 weeks for 5 months. All participants were on a stable dose of 10 mg aripiprazole tablets once daily in the morning for at least 14 days prior to randomization and continued 10 mg aripiprazole tablets once daily on days 1 to 14.
89607513|NCT01870999|Experimental|200 mg Aripiprazole IM depot|200 mg aripiprazole IM depot intramuscular injection once every 4 weeks for 5 months. All participants were on a stable dose of 10 mg aripiprazole tablets once daily in the morning for at least 14 days prior to randomization and continued 10 mg aripiprazole tablets once daily on days 1 to 14.
89607514|NCT01870921|Experimental|Ticargrelor|90 mg/tablet, 1 tablet bid
89607515|NCT00526474|Placebo Comparator|Placebo|1 placebo tablet, orally, daily for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.
88982587|NCT05413330|Experimental|IVTA group|Patients will receive an intravitreal injection of 4 mg/0.1 mL preservative-free triamcinolone acetonide at the end of surgery.
88982588|NCT05413330|No Intervention|No injection group|Patients will receive no additional treatment to the standard phacoemulsification surgery.
88982589|NCT05396430|Experimental|Urinary catheter 8 hours|The urinary cathter is to be removed at 8 hours after the end of surgery
88982590|NCT05396430|Experimental|Urinary catheter 10 hours|The urinary cathter is to be removed at 10 hours after the end of surgery
88982591|NCT05396430|Active Comparator|Urinary catheter 12 hours|The urinary cathter is to be removed at 12 hours after the end of surgery
88982592|NCT05396417||Cesarean delivery|Any urgency any reason
88982593|NCT05395715|Active Comparator|Control|Control patients will receive cubital tunnel surgery and sham stimulation.
88982594|NCT05395715|Experimental|Conditioning electrical stimulation|Patients in the stimulation group will receive surgery as well as 1 hour of 20 Hz electrical stimulation 7 days prior to surgery
88982595|NCT05359965|Experimental|CPAP|Subjects randomized to the treatment arm, will receive continuous positive airway pressure (CPAP) while sleeping via an autoPAP device for 4-8 weeks.
88982596|NCT05359965|No Intervention|No CPAP|Subjects assigned to the no CPAP group will not have any intervention for a 4-8 week period.
88982597|NCT05331989||patient group,healthy group|Cranio- Cervical Flexion Test, cervical mobility, Pressure Pain Threshold,Functional evaluation of the temporomandibular joint,Pittsburg Sleep Quality Index
88982598|NCT05303857|Active Comparator|Treatment|Baseline vascular function parameters will be obtained and the patient will be given semaglutide 1.34 mg/ml (SC, administered by personal injector, once weekly)
88982599|NCT05303857|Placebo Comparator|Placebo|Baseline vascular function parameters will be obtained and the patient will be given placebo (SC, administered by personal injector, once weekly)
88982600|NCT05284006||Mucopolysaccharidosis IVA|Patients affected by MPS IVA. The diagnosis of MPS will be confirmed by deficient enzyme activity of < 5% of normal activity level as measured in plasma, leukocytes, or fibroblasts.
88982601|NCT05264675||Primary suture|primary suture of EPL
88982602|NCT05264675||EIP- transfer|transfer of the EIP to EPL
88982603|NCT05254639|Experimental|Donepezil|5 mg/day for 4 weeks then 10 mg/day for 12 weeks
89210386|NCT00816140|Active Comparator|Klaricid, triple therapy|Klaricid based triple therapy
89210387|NCT00816140|Experimental|Cravit, triple therapy|Cravit based triple therapy
89607516|NCT00526474|Experimental|Vorapaxar|one 2.5 mg tablet daily, orally, for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.
89607517|NCT01848145|Experimental|Ofatumumab|Rapid Infusion of Ofatumumab
89607518|NCT01847755|Experimental|120 Hyperbaric treatments at 1.5 ATA|Patient receives 120 treatments of Hyperbaric at 1.5 ATA. Non randomized trial. Pt will have cognitive assessments and Spect scans at various treatment points. Oxygen is at 1.5 atmospheric pressure.
89607519|NCT00527566|Experimental|Mepolizumab|Subjects will receive open-label mepolizumab
89607520|NCT00527644|Other|Spring Clips|Subjects will undergo laparoscopic cholecystectomy with commercially available 5 mm spring clips utilized for the ligation of the cystic duct and artery.
89607521|NCT00527722|Experimental|Pleural Plug|Experimental lung plug after the lung biopsy.
89607522|NCT00527722|Active Comparator|No Pleural Plug|The standard lung biopsy without placement of the plug.
89607523|NCT01847443|Experimental|Test nicotine gum (2 mg)|A single dose of Nicotine Mint Gum (2 mg) to be chewed.
89607524|NCT01847443|Experimental|Test nicotine gum (4 mg)|A single dose of Nicotine Mint Gum (4 mg) to be chewed.
89607525|NCT01847443|Active Comparator|Reference nicotine gum (2 mg)|A single dose of reference nicotine gum (2 mg) to be chewed.
89607526|NCT01847443|Active Comparator|Reference nicotine gum (4 mg)|A single dose of reference nicotine gum (4 mg) to be chewed.
89607527|NCT00527878|Experimental|Placebo/Ranitidine crossover|Patients took placebo for 12 months and then ranitidine for 12 months
89607528|NCT00527878|Experimental|Ranitidine/placebo crossover|Ranitidine for one year followed by placebo for one year
89607529|NCT01847209|Experimental|CT Marking and VATS lung wedge resection|Each patient with a lung nodule meeting criteria will undergo marking with fiducials followed at the same time by Video-Assisted Thoracic Surgery (VATS) lung wedge resection under CT fluoroscopy.
89607530|NCT05558878|Experimental|Ambroxol (intervention arm)|40 patients will receive conventional therapy for diabetic neuropathy in addition to ambroxol 450 mg/day divided into 3 doses (each dose consists of 2 75mg capsules) daily for 3 months.
89607531|NCT05558878|No Intervention|Control arm|40 patients will receive conventional therapy for diabetic neuropathy for 3 months.
89607532|NCT01846741|Other|Model 106 VNS Therapy System|
89607533|NCT05621590|Experimental|mlc-901 group|
89607534|NCT05621590|Placebo Comparator|placebo group|
89607535|NCT05554042||Instruments Followed By SCID|Participants will complete the Patient Health Questionnaire-9 and Generalized Anxiety Disorder-7 instruments virtually. Participants will then complete a video recorded virtual Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders-5.
89607536|NCT05554042||SCID Followed By Instruments|Participants will complete a video recorded virtual Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders-5. Participants will then complete the Patient Health Questionnaire-9 and Generalized Anxiety Disorder-7 instruments virtually.
89607537|NCT05621434|Experimental|Inetetamab, pyrotinib, chemotherapy|"Inetetamab: was administered as an intravenous (IV) loading dose of 8mg/kg q3w on Day 1 of Cycle 1 (1 Cycle length = 21 days), and 6mg/kg q3w on Day 1 of subsequent cycles, until investigator-assessed radiographic or clinical progressive disease, unmanageable toxicity, or study termination.~pyrotinib: 400 mg once daily orally within 30 minutes after a meal at the same time each day.~chemotherapy:Taxanes (paclitaxel, docetaxel, liposomal paclitaxel, nabpaclitaxel), vinorelbine, capecitabine, eribulin, and other chemotherapeutic agents indicated in advanced breast cancer are permitted. Refer to the appropriate package insert for dosage and administration recommendations."
89607538|NCT05621356||allergen-specific immunotherapy (AIT)|Adults with birch pollen allergy, who are treated with allergen-specific immunotherapy (AIT)
89607539|NCT05621356||control|Adults with birch pollen allergy, who are treated with immunosuppressive medication
89607540|NCT05621278||Children|Grade 5 and grade 6 students (aged 9-12) in primary school.
89607541|NCT05621278||Adolescent|Grade 7 to grade 12 students (aged 12-18) in middle school and high school.
89607542|NCT05621278||Students' teachers|School Teachers
89607543|NCT05621278||Students' parent|Parents of students mentioned above.
89607544|NCT01870843|Experimental|Escitalopram|Participants will receive escitalopram 10 mg per day for 1 week and then the dose of escitalopram will be flexibly adjusted up to maximum of 20 mg per day for the next 7 weeks, based on the investigator's clinical judgment.
89607545|NCT01797952|Active Comparator|Lactobacillus CD 2 lozenges|2x109 (2 billion) viable cells of Lactobacillus CD2 as active ingredient
89607546|NCT01797952|Placebo Comparator|Placebo lozenges|The placebo is a mix of sugars and salts used as excipients in the active formulation
89607547|NCT01816477|Active Comparator|Thoracic epidural|Thoracic epidural with Ropivicaine 0.25% placed pre-operatively by the anesthesiologist. Epidurals will remain in place for 72 hours and discontinued by the anesthesia pain management team.
89607548|NCT01816477|Experimental|ON-Q soaker catheter system|"ON-Q soaker catheter system with Ropivicaine at 7 cc per hour placed by a single surgeon in the operating room. 7.5 catheters will be tunneled subcutaneously in the anterior axilla bilateral and secured with steri-strips and dressing. ON-Q systems will be primed with 750 cc and refilled accordingly to provide for 6 days of analgesia. Catheters will be removed by the surgeon in the hospital or clinic on the 6th post operative day. Patients may request removal of the catheter prior to the 6th day and this will not be considered a withdrawal from the study or complication and will be included in overall analysis, but noted accordingly."
89607549|NCT01846507|Experimental|Tranexamic acid|Subjects will complete a baseline menses (no treatment) followed by 3 menses using tranexamic acid.
89607550|NCT05615038|Experimental|Contact aspiration first line thrombectomy|Patients will have the mechanical thrombectomy by first-line contact aspiration
89607551|NCT05615038|Active Comparator|Stent retriever first line thrombectomy|Patients will have the mechanical thrombectomy by first-line stent retriever
89607552|NCT05613790|Experimental|Active HD-tDCS|Participants in the active arm will receive 20 min of real High-Definition transcranial direct current stimulation. Additional ramp-up and ramp-down phases at the beginning and the end of stimulation will last for 30 s.
89607553|NCT05613790|Experimental|Sham HD-tDCS|During the sham session, the montage will be identical, however, the current amplitude will ramp up for 30 seconds, and for the remaining stimulation time, the current flow will terminate and will be kept to zero. Ramp-down phase at the end of stimulation will last for 30 s.
89607554|NCT01846039|Experimental|JUVÉDERM VOLUMA®|Participants treated with JUVÉDERM VOLUMA® up to 3 mLs administered by intradermal injection.
89607555|NCT01610167|Active Comparator|NUPRO(r) Classic Prophy Paste|
89607556|NCT01610167|Experimental|NUPRO Sensodyne Prophy Paste w/ Novamin(r) w/ fluoride.|
89607557|NCT01610167|Experimental|NUPRO Sensodyne Prophy Paste w/ Novamin|
89607558|NCT04478500|Active Comparator|Minocycline Group|Subjects will be randomized to receive Minocycline 100mg twice daily
89607559|NCT04478500|Placebo Comparator|Placebo Group|Subjects will be randomized to receive placebo.
89607560|NCT01816243|Experimental|Transdermal Therapeutic System (TTS)-fentanyl|Transdermal Therapeutic System (TTS)-fentanyl patches releasing fentanyl in the range of 12.5 to 100 microgram per hour (mcg/hr) rate. The initial dose of fentanyl TTS will be calculated based on each participant's opioid requirement. Patches will be usually replaced every 72 hours. Doses will be escalated in steps of 25 mcg/hr, if pain cannot be controlled. Oral morphine syrup is allowed to titrate the dose of TTS-fentanyl. The study duration will be 30 days after first patch application.
89607561|NCT05484778|Other|Case Group|This group consists of athletes whose are between the ages of 14-30 and are still active at high school or university level in sports involving sudden changes of direction and jump physically and who have a history of injury to only one lower extremity before.
89607562|NCT05484778|Other|Control Group|This group consists of athletes whose age range is 14-30, and who are still active at high school or university level in sports involving sudden changes of direction and jump physically and who do not have a history of lower extremity injuries.
89607563|NCT05576896|Experimental|Treatment (Hydroxychloroquine)|
89607564|NCT01845805|Experimental|Arm A: CC-486|CC-486 (oral azacitidine), 300 mg total, taken daily on days 1-21 (of a 28 day cycle) for up to 12 cycles. Upon disease recurrence, subjects will start on a first-line chemotherapy.
89607565|NCT01845805|Active Comparator|Arm B: observation|Observation until disease recurrence. Upon disease recurrence, subjects will start on a first-line chemotherapy.
89607566|NCT04415125|Experimental|elite male ice hockey players|The subjects were 50 elite men's ice hockey players playing in the super league from Turkish clubs subject to Turkey Ice Hockey Federation. All ice hockey players had practicing training programs after warming up for 10 minutes for at least 3 days a week and 1 hour in a day during the season. They also played a match at least 1 day a week. The inclusion criteria were; being a member of Turkish Ice Hockey Federation and to be subject to any of the licensed athletes who played in the super league team, to be over 18, to be male. Exclusion criteria were; being under the age of 18, being a woman, having not suffered a musculoskeletal injury that would prevent him from going to training in the last 1 year or affect the outcome of the measurements.
89607567|NCT04371094|Active Comparator|stylet|The stylet is a device that is put inside the endotracheal tube to facilitate its insertion into the trachea
88982604|NCT05254639|Placebo Comparator|Placebo|5 mg/day for 4 weeks then 10 mg/day for 12 weeks
89210388|NCT00903708|Experimental|LY2275796|
89607568|NCT04371094|Active Comparator|bougie|The bougie is a device that is inserted into the trachea and an endotracheal tube is loaded over it and is slide into the trachea
89607569|NCT01845025|Experimental|FOM 12 mcg + FP|Formoterol 12 mcg + fluticasone propionate 100 mcg, 250 mcg or 500 mcg for inhalation
89607570|NCT01845025|Active Comparator|fluticasone propionate (FP)|fluticasone propionate 100 mcg, 250 mcg or 500 mcg + Placebo to Match Formoterol 12 mcg for inhalation
88982605|NCT05248815||Study group|Patients scheduled for total knee replacement.
88982606|NCT05248815||Control|Healthy age-matched controls.
88982607|NCT05243940|Active Comparator|dexmedetomidine-ketamine-lidocaine (DKL) group|combination of dexmedetomidine-ketamine-lidocaine in one syringe
88982608|NCT05243940|Active Comparator|remifentanil (control) group|remifentanil infusion (TCI Minto protocol)
88982609|NCT05237206|Experimental|SUPLEXA|autologous cellular therapy comprised predominantly of NK, NK-T, and T cells stored in cryogenic media
88982610|NCT05227846|Experimental|Human Umbilical Cord-derived Mesenchymal Stem Cells|Standard of care (SOC) plus a dose-escalation with 4 cohorts with 3-6 subjects/cohort who receive doses of 5, 10，15 and 20 ×10E7 cells. Proceed from lower dose to next higher dose if no safety concerns for each cohort.
88982611|NCT05225376|Experimental|Establishment of physical activity sessions for pregnant women|All the women will receive the studied intervention
89607571|NCT03830632|Experimental|Plyometric Training Program|The plyometric training group participated in a 6-week training program performing a variety of plyometric exercises designed for the lower extremity , while the control group did not participate in any plyometric exercises. All subjects were instructed not to start any lower extremity strengthening programs during the 6-week period and to only perform activities of normal daily living.
89607572|NCT03830632|Active Comparator|Traditional Training|"AEROBIC TRAINING - A minimum of two low-intensity sessions a week consisting of 1 hour running. .~SHUTTLE SPRINTS - Placed two cones roughly 25 yards apart. Ask cricketer to sprint as fast as back and forth between the cones 12 times, for a total of six round-trips. ask them to finish in one minute. give rest for up to five minutes, then repeat once or twice."
89607573|NCT04257760|No Intervention|Standard care|These ALS patients and their caregivers will receive standard care.
89607574|NCT04257760|Experimental|Early palliative care|These patients will receive a palliative care consultation that would not be requested by their care team as standard of care.
89607575|NCT04242940|Experimental|Ponto 4 sound processor|All patients will be fitted with a bone-anchored sound processor (Ponto 4), unilaterally or bilaterally.
89607576|NCT04233424|Experimental|D-PLEX+SoC|D-PLEX is provided to suitable and willing study subjects as an adjunct to the SoC treatment
89607577|NCT04233424|Other|Standard of care|The SoC for prophylactic antibiotic treatment is based on international guidelines
89607578|NCT04185610|Experimental|Qi Gong|Weekly QiGong for Chemotherapy-Induced Neuropathy classes for 10 weeks
89607579|NCT05534932|Active Comparator|Treatment Arm|35 Subjects will be placed in the sub-study treatment arm. These subjects will receive the remote patient monitoring program therapy offered by the University of Chicago heart failure program.
89607580|NCT05534932|No Intervention|Observational Arm|35 Subjects will be placed in the sub-study Obervational arm. These subjects will not reveive the remote patient monitoring program and will continue with thier standard of care treatment for the duration of the study.
89210389|NCT00894972|Active Comparator|1|General exercise. Participants in this group will perform aerobic exercise, range of motion exercise and general strengthening exercise.
89519140|NCT01865617|Experimental|NHL dose level 3|"Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.~Disease subgroup: NHL Dose level: 3 up to 2x107 EGFR+ cells/kg"
88982612|NCT05198544|Experimental|Hēlaquis Matrix is a hyaluronic acid matrix (HaM)|Subjects will receive weekly application of Ham along with standard of care therapy for eight (8) weeks unless healing occurs prior to 8 weeks.
88982613|NCT05186272|Experimental|Intervention|Use of mHealth stress reduction program 'A' app 5-20 min daily for 6 weeks
88982614|NCT05186272|Active Comparator|Active control|Use of mHealth stress reduction program 'B' app 5-20 min daily for 6 weeks
88982615|NCT05182866|Experimental|Single Arm|ASP-1929 640 mg/m^2 treatment by intravenous (IV) infusion followed approximately 24 hours later by illumination (also termed as photoimmunotherapy [PIT]) of tumor(s) using the PIT690 Laser System with a 690 nm light dose of 50 J/cm^2 for superficial illumination and 100 J/cm of diffuser length for interstitial illumination. During the illumination procedure, fluorescence of the IR700 portion of ASP-1929 will be imaged with a Shimadzu Fluorescence Imaging System camera. Patients will undergo standard of care surgery with or without chemotherapy or radiation approximately 21 days after ASP-1929 PIT treatment.
89519141|NCT01865617|Experimental|NHL (dose dense) dose level 2|"Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.~Disease subgroup: NHL Dose level: 2 up to 2x106 EGFR+ cells/kg"
89519142|NCT04619693||The study population|The study population corresponds to patients hospitalized for proven SARS-COV-2 pneumonia with an indication (hypoxemia) for dexamethasone (see eligibility criteria)
89519143|NCT03469037|Experimental|Oxygen first|Optiflow with an inspired fraction of oxygen of 100% in the first seance Optiflow with an inspired fraction of oxygen of 21 % in the second seance
89519144|NCT03469037|Experimental|Air first|Optiflow with an inspired fraction of oxygen of 21 % in the first seance Optiflow with an inspired fraction of oxygen of 100 % in the second seance
89519145|NCT03465319||Sevoflurane|10 patients receiving an anesthesia with sevoflurane
89519146|NCT03465319||Desflurane|10 patients receiving an anesthesia with desflurane
89519147|NCT02458313|Experimental|DMXB-A|150 mg DMXB-A (3-(2,4-dimethoxybenzylidene anabaseine) b.i.d. for 12 weeks.
89519148|NCT02458313|Placebo Comparator|Placebo|Placebo capsules b.i.d. for 12 weeks.
89519149|NCT05200195||International Cohort Training Set|The Training Set of the International Cohort (N=3,670) was composed of the 80% (n=2936) HCC patients transplanted from 2000 to 2018 across 17 centers in Europe and Asia.
89519150|NCT05200195||International Cohort Test Set|The Test Set of the International Cohort (N=3,670) was composed of the 20% (n=734) HCC patients transplanted from 2000 to 2018 across 17 centers in Europe and Asia.
89519151|NCT05200195||Validation Cohort|The external Validation Cohort was composed of 356 HCC patients transplanted at the Columbia University, New York, during the period 2000-2018.
89519152|NCT02522221|Experimental|Tecarfarin|Tecarfarin will be administered and dose adjusted by the investigator. Dose adjustments will be made in accordance with a target INR range pre-specified by the investigator.
89519153|NCT02522221|Active Comparator|Warfarin|Warfarin will be administered and dose adjusted by the investigator. Dose adjustments will be made in accordance with a target INR range pre-specified by the investigator.
89519154|NCT05389943|Experimental|Postmenopausal women with low BMD|patient with serum 25-hydroxy vitamin D [25(OH)D] less than 32 ng/ml. Vitamin D3 5000 IU/d per oral for the period of 3 months will be administered
89519155|NCT05389943|Active Comparator|Postmenopausal women|Postmenopausal women having serum 25-hydroxy vitamin D [25(OH)D] greater than 32 ng/ml will provided with milk and dietary modifications.
89519156|NCT04413851||Dementia|Subjects with a diagnosis of dementia who are experiencing agitation severe enough that it interferes with activities of daily living or social interaction.
89519157|NCT04542109|Experimental|READyR A|Group A will start the READyR intervention immediately after the baseline Session 1. The READyR program consists of a 3-session, values-based needs assessment intervention designed to match objectively-assessed in-home activity patterns with subjective reports of participants' care values. The goal of the intervention is to address unmet dementia-related care needs and help couples prepare for the future, and reduce strain on their relationship, and help maintain their health and well-being. Session 2 will occur approximately 3 weeks after Session 1, and Session 3 will occur approximately 3 weeks after Session 2. Session 3 also includes follow-up assessments.
89519158|NCT04542109|Active Comparator|READyR B (wait list comparison)|Group B - the wait list comparison group - will have a 60-minute support session (comparator intervention) about 3 weeks after the baseline Session 1. The support session will include general information about dementia-related care needs that does not take into account the individual participant's care values or objective in-home activity patterns. They will also receive a check-in call approximately 3 weeks later, with follow-up assessments. Group B will begin the READyR intervention sessions following completion of follow-up assessments.
89519159|NCT03461263|Active Comparator|Group A|phonophoresis treatment using pumpkin seeds oil
89519160|NCT03461263|No Intervention|Group B|Low intensity Ultrasound
89519161|NCT03461263|No Intervention|Group C|Placebo Low intensity Ultrasound
89519162|NCT02522975|Active Comparator|Reference group|"Generic name: recombinant human erythropoetin injection which is indicated for the treatment of anaemia caused by chronic renal disease.~Dosage form:Injection Strength:2000IU,3000IU,4000IU Frequency and Dosage:subcutaneously injection once a week for a period of 52 weeks. The initial dose of EPREX® will be 60 IU/kg body weight."
89607581|NCT05367856|Experimental|Chi-BEAM|Patients in this arm will receive Chidamide Combined With BEAM(Carmustine, Etoposide Cytarabine and Melphalan) as Pretreatment Regimen of ASCT.
89607582|NCT02124304|Experimental|Cervical Pain|Thera-Band elastic and manual resistance neck exercises for neck strengthening
89210390|NCT00894972|Experimental|2|Specific exercise. Participants in this group will perform aerobic exercise, range of motion exercise, and specific motor control exercises.
89607583|NCT02124304|Experimental|Healthy|Thera-Band elastic and manual resistance neck exercises for neck strengthening
89607584|NCT02124460|No Intervention|Enhanced Primary Care|"We will provide current best practice to the control arm. Patients with a BMI greater than or equal to the 85th percentile will be flagged in the electronic health record. Clinicians are also provided with clinical decision support tools for pediatric weight management. We will encourage providers to schedule a follow up visit for weight management or make a referral to Harvard Vanguard Medical Associates nutritionists for children in this arm. We will also provide this group with a community resource guide and educational text messages."
89607585|NCT02124460|Experimental|Health Coaching|The intervention for this study will consist of the same best practices received by the enhanced primary care group well as the following three elements: visits with a health coach, connection to community resources and an interactive text messaging program.
89607586|NCT04148872|Active Comparator|Neuromuscular Retraining Therapy|Neuromuscular retraining therapy alone for four months, with botulinum toxin injection added during an additional four month period.
89607587|NCT04148872|Active Comparator|Chemodenervation|Ipsilateral chemodenervation with botulinum toxin injections alone for four months (onabotulinumtoxinA/Botox, Allergan or incobotulinumtoxinA/Xeomin, Merz), with neuromuscular retraining therapy added for an additional four months.
89607588|NCT04129294|Experimental|NS-089/NCNP-02|NS-089/NCNP-02
89607589|NCT05310994|Placebo Comparator|Placebo drink|
89607590|NCT05310994|Experimental|Wasabi Leaf Extract Drink|
89607591|NCT05272306|Active Comparator|Sedation and Analgesia|A standardized sedation and analgesia will be administered by an experienced anesthesiologist. After administration of lidocaine and atropine sulfate, and also preoxygenation (100% 4 L/min oxygen for 3 minutes), patients will be induced with propofol and fentanyl via intravenous route at doses calculated according to ideal body weight. Anesthesia was maintained with propofol infusion. Repetitive intravenous boluses of propofol will be administered, if required. Patients will be received oxygen (100%, 3 L/min) through a nasal cannula during sedation and analgesia.
89607592|NCT05272306|Active Comparator|Gastro-laryngeal Tube|After administration of lidocaine and atropine sulfate, and also preoxygenation (100% 4 L/min oxygen for 3 min), patients will be induced with propofol and fentanyl. After induction of anesthesia, supraglottic airway device named Gastro-laryngeal Tube (GLT) will be inserted. Patients will be ventilated mechanically with a tidal volume of 6-8 mL/kg based on ideal body weight and a frequency of 12-14 breaths/min after inserting the GLT. Repetitive intravenous boluses of propofol will be administered, if required.
89607593|NCT04997668|Active Comparator|SOLTIVE Thulium Fiber Laser|SOLTIVE Thulium Fiber Laser group (laser A)
89607594|NCT04997668|Active Comparator|Ho:YAG Laser|Ho:YAG Laser group (laser B)
89607595|NCT04847440|Experimental|ATI-2173 and Viread|ATI-2173 + Tenofovir disoproxil fumarate (Viread)
89607596|NCT04847440|Active Comparator|Placebo and Viread|ATI-2173 Placebo + Tenofovir disoproxil fumarate
89607597|NCT04847440|Experimental|ATI-2173, Viread and AB-729|ATI-2173 + Tenofovir disoproxil fumarate (Viread) + AB-729
88982620|NCT05163639|Experimental|1. Uninjured participants - Immediate and lasting effects of non-invasive paired stimulation|Participants will take part in the following to examine the immediate effects of combining cortical and spinal stimulation: A) Non-invasive pairing of cortical and spinal stimulation; B) Non-invasive repeated pairing of cortical and spinal stimulation (SCAP).
88982621|NCT05163639|Experimental|2. Intraoperative participants - Immediate effects of paired stimulation|Participants will take part in the following if they have been scheduled for a clinically indicated cervical surgery to examine the immediate effects of combining cortical and spinal stimulation: A) Non-invasive pairing of cortical and spinal stimulation; B) Intraoperative pairing of cortical and spinal stimulation.
88982622|NCT05163639|Experimental|3. Intraoperative participants - Lasting effects of SCAP|Participants will take part in the following if they have been scheduled for a clinically indicated cervical surgery, to examine the lasting effects of repeated cortical and spinal stimulation: A) Non-invasive repeated pairing of cortical and spinal stimulation (SCAP); B) Intraoperative repeated pairing of cortical and spinal stimulation (SCAP).
88982623|NCT05163639|Experimental|4. Chronic cervical SCI participants - Lasting effects of non-invasive SCAP|Participants with chronic cervical SCI will take part in the following, to examine the lasting effects of repeated cortical and spinal stimulation: A) Non-invasive repeated pairing of cortical and spinal stimulation (SCAP).
88982624|NCT05163639|Experimental|5. Intraoperative participants - Lasting effects of SCAP at or below myelopathic region|Participants will take part in the following if they have been scheduled for a clinically indicated cervical surgery, to examine the lasting effects of repeated cortical and spinal stimulation: A) Non-invasive repeated pairing of cortical and spinal stimulation (SCAP); B) Intraoperative repeated pairing of cortical and spinal stimulation (SCAP) at or below myelopathic region.
89607598|NCT04847440|Active Comparator|Placebo, Viread and AB-729 Placebo|ATI-2173 Placebo + Tenofovir disoproxil fumarate (Viread) + AB-729 Placebo
89607599|NCT04812106||Participants with LC-FAOD|
89607600|NCT03692572|Active Comparator|Nitrate supplementation|Nitrate rich (6.8 mmol) beet root juice (70ml) twice a day
89607601|NCT03692572|Placebo Comparator|Placebo|Nitrate depleted (0.04 mmol) placebo juice (70ml) twice a day
89607602|NCT03516760|Experimental|GEM333|application of GEM333, a CD33 targeted bispecific antibody engaging T-cells
89607603|NCT01870297|Experimental|LY3025876|Part A: 0.5 milligram (mg), 1.5 mg, 5 mg, and 15 mg of LY3025876 administered as once daily (QD) subcutaneous (SQ) injections for up to 28 days.
89607604|NCT01870297|Placebo Comparator|Placebo|Part B: Placebo matching LY3025876 administered as QD SQ injections for up to 28 days
89607605|NCT01870297|Experimental|LY3025876 + Liraglutide|Part B: 5.0 mg of LY3025876 and 1.8 mg liraglutide administered as separate QD SQ injections for up to 28 days, after titration of liraglutide over 2 weeks.
89607606|NCT01870297|Placebo Comparator|Placebo + Liraglutide|Part B: Placebo doses matching LY3025876 and 1.8 mg liraglutide administered as separate QD SQ injections for up to 28 days, after titration of liraglutide over 2 weeks.
89210391|NCT04035642|Experimental|IGRT 24 Gy Single dose|Patients will be treated using image-guided, volumetric intensity-modulated arc radiotherapy (IGRT-VMAT) with emphasis on normal tissue sparing and delivery accuracy via the use of devices that ensure stability and beam location reproducibility. Patients will be treated with a single fraction at a prescription dose of 24 Gy.
89607607|NCT03275155||AFDAS|patients without history of atrial fibrillation before the qualifying stroke or transient ischemic attack who are diagnosed with atrial fibrillation during the 14 days of monitoring
89607608|NCT03275155||KAF|atrial fibrillation known before the stroke or transient ischemic attack
89607609|NCT03275155||NSR|patients without a history of atrial fibrillation who do not develop atrial fibrillation during the 14 days of cardiac monitoring
89607610|NCT01814761||Pts with POAG or OH (Previously Treatment Naive)|Previously treatment naïve patients with Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH) who require treatment with bimatoprost 0.01% (Lumigan® 0.01%).
89607611|NCT01814761||Pts with POAG or OH (Switched Monotherapy)|Patients previously on another monotherapy treatment with Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH) who require treatment with bimatoprost 0.01% (Lumigan® 0.01%).
89607612|NCT05141110|Experimental|NVP-1705|Tablet formulation for oral administration, single dose of NVP-1705 at Day 1
89607613|NCT05141110|Active Comparator|NVP-1705-R|Tablet formulation for oral administration, single dose of NVP-1705-R at Day 1
89607614|NCT01843933|No Intervention|Standard monitoring and blinded to capnography|Capnostream 20 Portable Capnography Monitor with Internal Printer by Oridion will be used to collect and record data but staff will be blinded to the monitor output.
89607615|NCT01843933|Active Comparator|Capnography|Capnography will be added to standard monitoring practices. A portable capnography monitor (Capnostream 20 Portable Capnography Monitor with Internal Printer by Oridion) will be used to collect and record data.
89607616|NCT01798030||Vitamin D|Specimen analysis
89607617|NCT01814371|Active Comparator|Individualized Approach|The decolonization regimen will be performed only by those household members who experienced SSTI in the prior year.
89607618|NCT01814371|Active Comparator|Household Approach|All members of the household will perform the decolonization regimen.
89607619|NCT05124652|No Intervention|Focus Group Testing|Focus group testing of key-fob device to control adjusting socket system
89607620|NCT05124652|Experimental|In-Lab, Crossover Study|Testing of auto-adjusting algorithm in-lab. Participants will carry out a structured protocol wearing the socket in all modes. Order will be randomly assigned.
89607621|NCT05124652|Experimental|Out-of-Lab Crossover Study|Evaluate socket performance in user free-living environments. Participants will use the prosthesis in all modes by end of study, order will be randomly assigned.
89607622|NCT03232138|Experimental|Sulforaphane (Study Drug)|Sulforaphane four tablets 2 times per day with breakfast and dinner each dose contains approximately 120 micromole of Sulforaphane
89607623|NCT03232138|Placebo Comparator|Placebo|Placebo (containing no active drug) four tablets 2 times per day with breakfast and dinner
89607624|NCT02131402|Experimental|enfilcon A / omafilcon A|Participants wear a pair of lenses, with a test lens in one eye and a control lens in the contra lateral eye. After approximately 1 hour of lens wear, the lenses will be removed and the next pair will be inserted. This will be repeated for a total of three pairs of lenses.
89607625|NCT02131402|Active Comparator|enfilcon A / ocufilcon D|Participants wear a pair of lenses, with a test lens in one eye and a control lens in the contra lateral eye. After approximately 1 hour of lens wear, the lenses will be removed and the next pair will be inserted. This will be repeated for a total of three pairs of lenses.
89607626|NCT02131402|Active Comparator|enfilcon A / methafilcon A|Participants wear a pair of lenses, with a test lens in one eye and a control lens in the contra lateral eye. After approximately 1 hour of lens wear, the lenses will be removed and the next pair will be inserted. This will be repeated for a total of three pairs of lenses.
89607627|NCT01814137|Experimental|IDegAsp BID + IAsp OD|
89607628|NCT01814137|Experimental|IDeg OD + IAsp TID|
89607629|NCT04084288|Experimental|Postoperative Acupuncture|"Neuraxial anesthesia (spinal or combined spinal epidural (CSE) with up to 4cc mepivacaine 1.5%) and 2 blocks for postoperative pain (IPACK and adductor canal peripheral nerve blocks). Sedation will be provided. Tranexemic acid (TXA) will be dosed per surgeon request.~A certified medical acupuncturist will perform ipsilateral Auricular Trauma Protocol (ATP) acupuncture at eight ear points (Hypothalamus, Amygdala, Hippocampus, Prefrontal Cortex, Point Zero, Shen Men, Insula, Vagus) with 30Hz electrostimulation at two of those points (Shen Men and Hypothalamus). Acupuncture needles will be left in place and stimulated for 60 min and then removed. If an epidural is placed, it may be redosed with lidocaine as needed (up to 100mg total) and will be removed prior to transfer to the recovery room.~A periarticular injection (PAI) will be placed by the surgeon during the surgery (timing at the discretion of the surgeon)"
89607630|NCT01813435|Experimental|Experimental treatment strategy|"All patients in the treatment group will receive acetylsalicylic acid (ASA) and ticagrelor for 1 month followed by 23 months of ticagrelor monotherapy.~Dosage and frequency:~Ticagrelor: 90 mg b.i.d. ASA: of 75mg qd (- ≤ 100 mg qd)"
89210392|NCT00895050||1|Patients diagnosed with RA
89210393|NCT00903864||stethoscopy|
89210394|NCT00903864||BPM|blood pressure monitor
89607631|NCT01813435|Active Comparator|Reference treatment strategy|"Acute Coronary Syndrome (ACS) patients incl. unstable angina (UA) patients: ASA and Brilique(ticagrelor) for 12 months followed by 12 months of ASA monotherapy.~Stable Coronary Artery Disease (CAD) patients: ASA and clopidogrel for 12 months followed by 12 months of ASA monotherapy.~Dosage and frequency:~Brilique(Ticagrelor): 90 mg b.i.d. ASA: of 75mg qd (- ≤ 100 mg qd) Clopidogrel: 75 mg qd"
89607632|NCT05037526|Active Comparator|Dexcom G System|The Dexcom G6 or current version intended use is for the management of diabetes. It is a small flexible device that records interstitial glucose levels every 5 min and is intended to replace fingerstick blood glucose testing for diabetes treatment decisions. Interpretation of the Dexcom G6 or current version System results should be based on the glucose trends and several sequential readings over time. The system consists of a sensor, transmitter, receiver and mobile app.
89607633|NCT05037526|Active Comparator|Standard care of gestational diabetes with self monitoring blood glucose (SMBG)|SMBG (self-monitoring of blood glucose) is recommended for women with gestational diabetes that involves finger pricking up to six times daily.
89607634|NCT04008160||healthy persons|
89607635|NCT04008160||individuals with paraplegia|
89607636|NCT01798498|Experimental|Princess® VOLUME|"Injection of Princess® VOLUME into the deep dermis or subcutis of both nasolabial folds.~A touch-up treatment may be performed at Day 14 if correction is not complete after the first injection.~The injected volumes will be estimated by the investigator and depend on the depth of the nasolabial folds"
89607637|NCT01813357|Placebo Comparator|Placebo|sugar pill that is encapsulated so as to appear identical to the active agent
89607638|NCT01813357|Experimental|Rosuvastatin|Rosuvastatin 20mg daily
89607639|NCT01812655|Experimental|Virtual Reality|Virtual reality using a software program designed for burn patients during burn wound care
89607640|NCT01812655|Active Comparator|Passive distraction|watching a movie
89607641|NCT01812655|No Intervention|UC provided by the nurses|
89607642|NCT02346526|Experimental|Radium-223 dichloride|"After the screening procedures confirm that a patient is eligible to participate in the research study.~Ra-223- Each treatment cycle lasts 4 weeks during which the patient receives Ra-223 by intravenous infusion on day 1 only. Treatments are given every 4 weeks for a total of 6 treatments. These treatments are designed to be entirely standard. Extra testing during and after that six month period will be added to standard testing and monitoring.~Blood Tests~CT scan~Bone scan~FACBC PET/MRI in a subset of participants"
89607643|NCT01812109|Experimental|Hutchison Technologies Inspectra StO2 NIRS|Hutchison Technologies Inspectra StO2 SpotCheck Near-Infrared Spectroscopy (NIRS) evaluation of acute scrotum per protocol
89607644|NCT01811953|Experimental|1 Empagliflozin/Metformin (T)|fixed-dose-combination tablet, oral with 240 ml water under fasted conditions
89607645|NCT01811953|Experimental|2 Empagliflozin/Metformin (T)|fixed-dose-combination tablet, oral with 240 ml water under fed conditions
89607646|NCT01811953|Experimental|3 Empagliflozin + Metformin (R)|tablets, oral with 240 ml water under fasted conditions
89607647|NCT01811953|Experimental|4 Empagliflozin + Metformin (R)|tablets, oral with 240 ml water under fed conditions
89607648|NCT01811953|Experimental|5 Empagliflozin/Metformin (T)|fixed-dose-combination tablet, oral with 240 ml water under fed conditions
89607649|NCT01811953|Experimental|6 Empagliflozin + Metformin (R)|tablets, oral with 240 ml water under fed conditions
88982625|NCT05163548|Experimental|Subjects that receive PerQseal Plus Device|Subjects undergoing large hole endovascular percutaneous procedures with a femoral arteriotomy created with 14 to 22 F sheaths (arteriotomy up to 26 F)
88982626|NCT05157659|Experimental|[18F]F-AraG PET procedures|Within one week prior to resection two [18F]F-AraG PET-scans will be performed.
88982627|NCT05157009|Other|Immediate implant placement without reconstruction|Immediate implant placement after tooth extraction
88982628|NCT05157009|Other|Immediate implant placement with reconstruction|Immediate implant placement and simultaneous bone reconstruction after tooth extraction
89607650|NCT03926728|Experimental|Cohort A - 85µg CTH522-CAF01|Cohorts A will receive three IM vaccination of 85µg CTH522-CAF01. This cohort is divided into two groups: A1 will receive placebo at DAY 28 + Day 112 + Day 140, while A2 will receives placebo at Day 28 + Day 112, but non-adjuvanted TO CTH522 boost at Day 140.
89607651|NCT03926728|Experimental|Cohort B - 85µg CTH522-CAF01+ TO CTH522|Cohort B will receive three IM vaccination of 85 µg CTH522-CAF01. This cohort is divided into two groups: B1 will receive TO vaccination of the non-adjuvanted CTH522 at Day 28 + Day 112 and TO placebo at Day 140, while B2 will receive the same for Day 28 + Day 112, but non-adjuvanted TO CTH522 boost at Day 140. The two additional doses TO CTH522 (12µg) is administered in each eye. The rationale for this cohort is to investigate the impact of simultaneous TO administration of the antigen on the immunogenicity results obtained.
88982631|NCT05141474|Experimental|NEXTGEN-TIL|Subjects will receive a therapy based on Tumor-infiltrating Lymphocyte (NEXTGEN-TIL product) preceded by a preparative non-myeloablative lymphodepleting (NMA-DL) regimen and followed by IL-2 infusion. Patients will be followed-up for 2 years, assessed at weeks 2, 3, 4, 6, 9, 12, 18, 24, 30, 36 (9 months), and then at 1 year, 1,5 and 2 years.
88982632|NCT05136963|Experimental|volunteers|"48 volunteers will be included according to the following demographic characteristics (corresponding to the demographic profile of kidney donors according to the national data of the Biomedicine Agency):~aged between 20 and 35 years old: 4 women, 3 men~aged between 35 and 50 years old: 7 women, 5 men~aged between 50 and 65: 11 women, 8 men~> 65 years old: 6 women, 4 men"
88982633|NCT05134727|Experimental|Part 1 (single ascending doses [SAD])|Healthy participants will be randomized to a single dose of AZD5055 or placebo.
88982634|NCT05134727|Experimental|Part 2 (multiple ascending doses [MAD])|Healthy participants will be randomized to repeated dosing with AZD5055 or placebo
89607652|NCT03926728|Experimental|Cohort C - 85µg CTH522-CAF01+ID CTH522|Cohort C will receive three IM vaccination of 85 µg CTH522-CAF01. This cohort is divided into two groups: C1 will receive ID vaccination of the non-adjuvanted CTH522 at Day 28 + Day 12 and TO placebo at Day 140, while C2 will receive the same for Day 28 + Day 112, but TO CTH522 boost at Day 140. The two additional doses of non-adjuvanted CTH522 (24µg) is administered ID. The rationale for this cohort is to investigate the impact of simultaneous ID administration of the antigen on the immunogenicity results obtained.
89607653|NCT03926728|Experimental|Cohort D - 15µg CTH522-CAF01|Cohort D is the same as cohort A except that the dose for CTH522-CAF01 is 15µg.
89607654|NCT03926728|Experimental|Cohort E - 85µg CTH522-CAF09b|Cohort E is the same as cohort A except that the adjuvant is CAF09b and not CAF01. The rationale for the A, D and E cohorts is to investigate the impact of the CTH522 dose and adjuvant on the immunogenicity results.
89607655|NCT03926728|Placebo Comparator|Cohort F - Placebo|Cohort F will receive only placebo in form of 0.9% NaCl saline.
89607656|NCT03895762||Abstral Oral Disintegrating Tablet (ODT)|Abstral Oral Disintegrating Tablet (ODT)
89607657|NCT01811563|Active Comparator|Stryker|Subjects will be receiving the Stryker Triathlon total knee replacement
89607658|NCT01811563|Active Comparator|Zimmer|Subjects will be receiving a Zimmer NexGen total knee replacement
89607659|NCT01033552|Experimental|Transplant in Epidermolysis Bullosa|
89607660|NCT04907890||Cases|All survivor patients hospitalised for COVID-19 and previously recruited in the CORIST study
89607661|NCT04907890||Controls 1|Individuals who had a positive diagnosis for SARS-Cov-2 infection in the past (at least 6 months) and that was never hospitalised for COVID-19 as he/she had not severe symptoms.
89607662|NCT04907890||Controls 2|Individuals who was never diagnosed for SARS-Cov-2 infection
89607663|NCT00997906|Experimental|Arm I|Patients receive cisplatin IV over 2 hours once weekly on weeks 1-8 and undergo intensity-modulated radiotherapy once daily, 5 days a week, on weeks 1-7 (6½ weeks for a total of 33 fractions).
89607664|NCT00997906|Experimental|Arm II|Patients receive induction chemotherapy comprising gemcitabine hydrochloride IV over 30 minutes, carboplatin IV over 1 hour, and paclitaxel IV over 1 hour on days 1 and 8. Treatment repeats every 21 days for 3 courses. Beginning at least 3 weeks after the last dose of induction chemotherapy, patients receive cisplatin and undergo radiotherapy as in arm I.
89607665|NCT01811485|Experimental|LMF237 50/250 mg|Patients took LMF237 50/250 mg twice daily for 14 weeks
89607666|NCT01811485|Experimental|LMF237 50/500 mg|Patients took LMF237 50/500 mg (with a starting dose of LMF 237 50/250 mg for 2 weeks) twice daily for 14 weeks
89607667|NCT01811485|Placebo Comparator|Placebo|Patients took matching placebo of LMF237 (vildagliptin 50 mg) twice daily for 14 weeks
89607668|NCT00001876||Combo|Patients with rheumatoid arthritis and biopsy-proven pulmonary fibrosis.
89607669|NCT00001876||pulmonary fibrosis|Patients with biobsy-proven idiopathic pulmonary fibrosis only.
89607670|NCT00001876||rheumatoid arthritis|Patients with rheumatoid arthritis only.
89607671|NCT03832036|Experimental|Patients with lumbar disc herniation|
89607672|NCT01810939|Active Comparator|Patiromer|Patiromer was administered twice a day as a powder mixed with water.
89607673|NCT01810939|Placebo Comparator|Placebo|Placebo was administered twice a day as a powder mixed with water.
89607674|NCT01798576||Pegylated interferon alfa-2a|Participants with chronic hepatitis C with previous treatment failure received combination therapy with pegylated interferon alfa-2a plus ribavirin or treatment regimens containing direct-acting anti-viral (DAAs)
89607675|NCT00565084|Active Comparator|1|Ibuprofen
88982635|NCT05134532|Experimental|intervention|"Potential subjects will be screened to determine if they meet the eligibility criteria. The screening period is 21 days.~Subjects who meet all the eligibility criteria will be commenced regorafenib 160mg once daily for the first 3 weeks of each 4-week cycle."
88982636|NCT05131139|Experimental|Continuous Glucose Monitoring Device|Eversense 524 CGM System and ROME CGM System.
88982637|NCT05127018|Active Comparator|the average-dose method|With the average-dose method, the dose was individualized according to the severity of anterior gingival exposure pretreatment. For mild gingival smile (3-5 mm), a single-site injection of 2 U botulinum toxin type A [total, 4 U] at both the right and left levator labii superioris alaeque nasi muscles) was administered. For moderate (5-7 mm) and severe (≥7 mm) gingival smile, 3 U and 5 U of botulinum toxin type A, respectively, were injected per side (total, 6 U and 10U, respectively). The injection points were located at bilateral levator labii superioris alaeque nasi muscles and at the Yonsei point26, with half doses administered at each point.
88982638|NCT05127018|Experimental|the higher-dose method|With this method, patients were administered botulinum toxin type A after 8 months when the effect of the previous injection had vanished. The injection dose (U) per side was set as the absolute value of the preoperative anterior gingival exposure (mm). For example, if the preoperative anterior gingival exposure was 5mm, then the patient would be injected with 5 U of botulinum toxin per side (total, 10U). The injection points were located at bilateral levator labii superioris alaeque nasi muscles and at the Yonsei point26, with half doses administered at each point.
88982639|NCT05126719|Experimental|MRG003|"Part A: On the first day of every 3 weeks, MRG003 will be administered via intravenous infusion at 2.0 mg/kg or 2.3 mg/kg calculated based on the actual body weight.~Part B: On the first day of every 3 weeks, MRG003 will be administered via intravenous infusion at 2.3 mg/kg calculated based on the actual body weight."
89210395|NCT00895128|Experimental|Erlotinib + Dasatinib|Erlotinib starting dose of 100 mg taken by mouth 1 time a day every day for 28 day cycle or 50 mg for pediatric patients. Dasatinib starting dose of 50 mg by mouth 1 or 2 times a day every day for 28 day cycle.
89210396|NCT00895206|Experimental|1|individual adapted immunosuppression
89210397|NCT00895206|Active Comparator|2|golden standard therapy
89607676|NCT00565084|Placebo Comparator|2|Placebo 1
89607677|NCT00565084|Placebo Comparator|3|Placebo 2
89607678|NCT01810783|Experimental|Brexpiprazole|
89607679|NCT00565864|Experimental|1 (Low-normal TSH target)|Treatment arm 1 targets a thyroid stimulating hormone (TSH) of 0.28 -2.49 milliunits/liter (mU/L) (the theoretical optimal range). The intervention is as follows: Levothyroxine (L-T4) doses will be adjusted in this arm to achieve this target TSH range. L-T4 is the intervention. L-T4 is given once per day, in the morning, while fasted. Dose ranges for the study are calculated based on each subject's TSH levels monitored during the study. Duration of the intervention is the duration of the study, after which subjects return to taking their usual L-T4 doses.
89607680|NCT00565864|Experimental|2 (High-normal TSH target)|"Treatment arm 2 targeting a TSH of 2.5 - 5.0 mU/L. The intervention is as follows:~Levothyroxine (L-T4) doses will be adjusted in this arm to achieve this target TSH range. L-T4 is the intervention. L-T4 is given once per day, in the morning, while fasted. Dose ranges for the study are calculated based on each subject's TSH levels monitored during the study. Duration of the intervention is the duration of the study, after which subjects return to taking their usual L-T4 doses."
89607681|NCT00565864|Experimental|3 (Mildly elevated TSH target)|"Treatment arm 3 is targeting a TSH level o f 5.1-12.0 mU/L. The intervention is as follows:~Levothyroxine (L-T4) doses will be adjusted in this arm to achieve this target TSH range. L-T4 is the intervention. L-T4 is given once per day, in the morning, while fasted. Dose ranges for the study are calculated based on each subject's TSH levels monitored during the study. Duration of the intervention is the duration of the study, after which subjects return to taking their usual L-T4 doses."
89607682|NCT01808209|Experimental|stenfilcon A|Participants wear a first pair of lenses for one week and then crossover and wear an alternate second pair of lenses for one week.
89607683|NCT01808209|Active Comparator|filcon II 3|Participants wear a first pair of lenses for one week and then crossover and wear an alternate second pair of lenses for one week.
89607684|NCT05246332|Experimental|Patient receive grounding|The investigators use the grounding mat (EARTHING Conductive Earthing Uni-versal Mat with Earthing Cord) as the grounding method. The grounding group use a grounding wire to sit on a chair barefoot in contact with the grounding mat for 30 minutes.
89607685|NCT05246332|Sham Comparator|Patient receive sham-grounding|The investigators use the grounding mat (EARTHING Conductive Earthing Uni-versal Mat with Earthing Cord) as the grounding method. The sham-grounding group use a sham grounding wire to sit on a chair barefoot in contact with the grounding mat for 30 minutes.
89607686|NCT05246176|Experimental|Cases|group of patient with inoperable malignant obstructive jaundice with failed internal drainage.
89607687|NCT03698032|Active Comparator|Water Arm|Participants will consume water only as the intervention
89607688|NCT03698032|Active Comparator|1.5 oz Pistachios|Participants will consume water plus 1.5 oz of pistachios as the intervention
89607689|NCT03698032|Active Comparator|3.0 oz Pistachios|Participants will consume water plus 3.0 oz of pistachios as the intervention
89607690|NCT05246020|Experimental|NHIPEC|Treatment: Four tubes will be placed via the laparoscopic ports and HIPEC will be given within 24 hours after laparoscopic evaluation.
89607691|NCT05246020|Active Comparator|Intravenous NACT|Drug:Three cycles of intravenous NACT will be given in this group. The regimen of intravenous NACT is docetaxel 60-75mg/m2 followed by carboplatin area under curve(AUC) 5 for a 21-day cycle.
89607692|NCT01807117|Experimental|Diagnostic (PET-CT and PET-MRI)|Patients undergo fludeoxyglucose F 18 PET-CT and PET-MRI.
89607693|NCT02804854|Experimental|Patients in ICU|Delivery of Neutrophil Activation Probe (NAP) (80mcgs) to ventilated patients up to three times.
89607694|NCT05245630||Robotic arm assisted PET/CT guided biopsy|"In this group, participants were recruited for robotic-assisted PET/CT guided biopsy from the FDG avid lung lesions.~biopsies were done using an automated robotic arm (MAXIO-EX, Perfint healthcare Pvt Ltd, Chennai, India) to guide the needle for biopsy. It is a robotic arm with a four-ax guide arm and a planning console. Pre-interventional fused PET/CT images from Biograph mCT 16 scanner were sent via LAN cable to the device (MAXIO-EX) console."
89607695|NCT05245630||PET fused CT-Fluoroscopy guided biopsy|"In this group, participants were recruited for PET fused CT-Fluoroscopy guided biopsy from the FDG avid lung lesions.~A biopsy needle was placed to the target lesion on PET/CT under CT fluoroscopy"
89607696|NCT01806961||clearance at end of trial SP848-AK-1101|no trial medication during this follow-up trial
88982640|NCT05126719|Active Comparator|Capecitabine tablets/Docetaxel injection|Part B: Capecitabine tablets: 1000 mg/m2, bid, d1-14, po, Q3W, or Docetaxel injection: 75 mg/m2, d1, IV, Q3W
89607697|NCT05363410|Experimental|MagnéVie B6®|Each film coated tablet contains 100mg magnesium citrate and 10mg pyridoxine hydrochloride.
89607698|NCT05363410|Placebo Comparator|Placebo|Each identical film coated tablet contains inert materials.
88982641|NCT05116020||Chiropractic patient participants|Usual chiropractic care
88982642|NCT05112926|Experimental|Embosphere Microspheres group|Participants in this group who are receiving standard of care (SOC) embolization surgery for the treatment of moderate to severe knee osteoarthritis will receive the Embospheres Microspheres during scheduled SOC surgery.
88982643|NCT05107050|Active Comparator|Normal saline wash and an amorphous gel (NSS-HG)|Normal Saline Wash and Amorphous Gel
88982644|NCT05107050|Experimental|synergistic antimicrobial cleanser (AMC) and antimicrobial gel (AMG)|"Antimicrobial Skin & Wound Cleanser helps in the mechanical removal of debris and foreign material from the skin, wound, or application site. BIAKOS™~BIAKŌS Antimicrobial Wound Gel provides a moist environment to wound surfaces. BIAKŌS Antimicrobial Wound Gel is a safe and gentle colorless gel."
88982645|NCT05097586|Experimental|active tDCS|2mA of direct current delivered to the dorsolateral prefrontal cortex for 30 minutes each, 5 times per week for 3 weeks, for a total of 15 sessions using the Soterix Medical tDCS mini-CT model 1601-LTE.
88982646|NCT05097586|Sham Comparator|control|Sham stimulation where the current is turned off after 30 seconds in a slow ramp down, delivered to the dorsolateral prefrontal cortex for 30 minutes each, 5 times per week for 3 weeks, for a total of 15 sessions using the Soterix Medical tDCS mini-CT model 1601-LTE.
88982647|NCT05097261|Experimental|Ketamine|"Racemic ketamine® will be administered by continuous infusion in a prefilled 50 ml syringe at a concentration of 50 mg/ml, undiluted. The ketamine dose is 1 mg/kg/h, to a maximum dose of 120 mg/hour, which corresponds to an infusion rate of 0.02 ml/kg/h to a maximum rate of 2.4 ml/h. Study patients weighing over 120 kg will not exceed the maximum dose of 120mg/kg of ketamine.~The study medication will be started within 6 hours after randomization. The IMP, ketamine, will be provided directly to each Participating Site by the official supplier of ketamine for Belgium (Pfizer)."
88982648|NCT05097261|Active Comparator|Placebo|The placebo (NaCl 0.9%) will be provided in the same type syringes and administered at the same infusion rate as the IMP (0.02 ml/kg/h to a maximum rate of 2.4 ml/h).
88982649|NCT05095454|Experimental|Percutaneous Epidural Stimulation|Epidural spinal stimulation will be delivered via percutaneously implanted electrodes during rehabilitation. All implanted electrodes will be removed at the end of trial participation. The effects of epidural stimulation will be recorded via electrophysiological and biomechanical metrics described within the outcomes measures.
89032819|NCT02924298|Experimental|Stage 3-4 Chronic Kidney Disease|Individuals with estimated glomerular filtration rate 15 to < 60 mL/min/1.73m^2, to undergo SLIMM intervention
89210398|NCT00899652||All Patients|Completion of Telephone Study Entry Form, Additional On Study Form, and Specimen Transmittal Form.
89607699|NCT05363332||COVID-19 Cohort|Patients with a diagnosis of moderate or severe pneumonia or ARDS secondary to COVID-19.
89607700|NCT05363332||Non COVID-19 Cohort|Patients with a diagnosis of moderate or severe pneumonia or ARDS not secondary to COVID-19.
88982650|NCT05095454|Experimental|Transcutaneous Epidural Stimulation|Transcutaneous spinal stimulation will be delivered via skin surface-level electrodes during rehabilitation. The effects of transcutaneous stimulation will be recorded via electrophysiological and biomechanical metrics described within the outcomes measures.
89607701|NCT01613131|Active Comparator|Mirena + Estradiol Gel|Subjects will be assigned to use of Estradiol gel for use with Mirena.
89607702|NCT01613131|Placebo Comparator|Mirena + Placebo Gel|Subjects will be assigned to use of placebo gel for use with Mirena.
89032820|NCT00528476||1|Patients, who were treated because of recurrent (2 or more urinary tract infections per year) pyelonephritis or cystitis.
89032821|NCT00528476||2|Patients with nonrecurrent urinary tract infections (patients who had no history of more than one urinary tract infections in last year).
89607703|NCT01798342|Active Comparator|Maltodextrin|The volunteers ingested 400ml (4 hours before the exam was carried out) at 8:00AM and 200ml (2 hours before the exam was carried out) at 10:00AM of a beverage containing water plus 12.5% maltodextrin
89607704|NCT01798342|Experimental|Glutamine|The same volunteers ingested 400ml (4 hours before the exam was carried out) at 8:00AM and 200ml (2 hours before the exam was carried out) at 10:00AM of a beverage containing water plus 12.5% maltodextrin plus 15g of glutamine
89607705|NCT04410835||Psychiatric patients|Psychiatric patients with ICD-10 (International Statistical Classification of Diseases and Related Health Problems) F2/F3/F4 diagnosis
89607706|NCT04410835||Healthy Controls|Participants who do not have a psychiatric disorder or a first degree relative with psychiatric disorder.
89607707|NCT05363098||Mechanically ventilated neurosurgical patients|Observational study in mechanically ventilated neurosurgical patients
89607708|NCT05362942|Experimental|venetoclax + Hypomethylation agent + low-dose cytarabine treatment group|patients treated with venetoclax combined with decitabine/azacytidine and low-dose cytarabine
89607709|NCT01798654||Antithrombotic agents|
89607710|NCT01868893|Experimental|Obinutuzumab + Chlorambucil|Obinutuzumab was administered intravenously for 6 cycles (28-day cycles) as: 100 mg on Day 1, 900 mg on Day 2, and 1000 mg on Days 8 and 15 for Cycle 1; and 1000 mg on Day 1 of Cycles 2 to 6. Chlorambucil was administered orally at a dose of 0.5 mg/kg body weight on Days 1 and 15 for Cycles 1 through 6 (28-day cycles).
89607711|NCT03459898|Other|Active Breathing Control|To review our institutional clinical experience of applying the AlignRT system to monitor patient setup and reproducibility when using ABC and DIBH techniques in the treatment of left-sided breast cancer patients.
89607712|NCT03459898|Other|Deep Inspiration Breath Hold|To review our institutional clinical experience of applying the AlignRT system to monitor patient setup and reproducibility when using ABC and DIBH techniques in the treatment of left-sided breast cancer patients.
89607713|NCT01868503|Experimental|Lapatinib Plus Radiation Therapy|Patients receive lapatinib ditosylate PO QD on day 1 until completion of radiation therapy. Beginning on day 7, patients undergo radiation therapy for 5-7 weeks and will have their blood banked for laboratory biomarker analysis.
89607714|NCT05362708|Experimental|Experimental group - VRH|Patients will receive VRH during port-a-cath (Port) placement
89607715|NCT05362708|No Intervention|Control Group|Patients who do not want to receive the VRH but who accept to answer the questionnaires will be considered as a control group.
89607716|NCT04602169|Active Comparator|PVI only group|Patients allocated to this group will receive PV re-isolation alone
89607717|NCT04602169|Active Comparator|PVI + SVC group|Patients allocated to this group will receive PV re-isolation with SVC isolation.
89607718|NCT05204368|Experimental|Imipenem/Cilastatin/XNW4107|Imipenem/Cilastatin 500mg/500mg in combination with XNW4107 250mg ,q6h(0.5h infusion)
89607719|NCT05204368|Active Comparator|Meropenem|Meropenem 1g ,q8h (0.5h infusion)
89607720|NCT03394846|Experimental|Test of Existing MI Products|We will test the impact of three widely available MI products (GoNoodle, Take10, ABC for Fitness) on students' physical activity with 60 elementary classroom teachers.
89607721|NCT03330574||Variability of the device|We will study the repeatability and reliability of the Diopsys® ERG Vision Testing Systems in normal non-glaucomatous people and in those with suspicion of glaucoma or confirmed glaucoma.
89032822|NCT02924415|Experimental|Tele-care support|Online psychoeducation treatment using new technologies
89032823|NCT02924415|Active Comparator|Control group|Standard care
89032824|NCT02944994|Experimental|Unified Protocol|Unified Protocol-psychotherapy
89032825|NCT02944994|Experimental|Routine Care|Routine Care psychotherapy comparison
89032826|NCT02924181|Active Comparator|Lt PV CF guided/rt PV CF blinded|Fifteen patients will be allocated to this group. Left side pulmonary veins isolation will be performed with contact force information guidance. Then, right side pulmonary veins isolation will be performed without contact force information (using same catheter named SmartTouch Catheter).
89032827|NCT02924181|Active Comparator|Lt PV CF blinded/rt PV CF guided|Fifteen patients will be allocated to this group. Left side pulmonary veins isolation will be performed without contact force information (using same catheter named SmartTouch Catheter).Then, right side pulmonary veins isolation will be performed with contact force information guidance.
89210399|NCT05278026||HFrEF|heart failure with reduced ejection fraction
89607722|NCT03330574||Diagnosis and progression of glaucoma|Patients who have a suspicion of glaucoma and patients with confirmed glaucoma will be included. PERG data obtained by the Diopsys® ERG Vision Testing Systems will be analyzed to study the PERG changes in different clinical situations, such as early glaucoma and progression of glaucoma.
89607723|NCT03330574||Effect of medical/surgical intervention|Patients will undergo standard treatment based on their medical history and we will observe the PERG changes induced by these treatments (eye drops, laser or surgery) with the Diopsys® ERG Vision Testing Systems.
89607724|NCT05362240|Experimental|Four corner fusion|Scaphoid excision and fusion between lunate , capitate , hamate and triquetrum using k.wires
89607725|NCT05362240|Experimental|Three corner fusion without triquetrum excision|Scaphoid excision with fusion between lunate , capitate and hamate with preservation of triquetrum
89607726|NCT02132572||Natrelle BIOCELL™ Textured 410 Implant|Previously received a Natrelle BIOCELL™ textured 410 implant for primary breast augmentation.
89607727|NCT01868035|Experimental|Single Arm|tositumomab and iodine I-131 tositumomab
89607728|NCT05162482|Active Comparator|Heterologous 1|"BIBP (CNBG, Sinopharm) WIV (0.5ml) at baseline CanSinoBIO (0.5ml) after 70±7 days (10 wks±2)~(160 participants)"
89607729|NCT05162482|Active Comparator|Heterologous 2|"BIBP (CNBG, Sinopharm) WIV (0.5ml) at baseline AstraZeneca ChAdOx (0.5ml) after 70±7 days (10 wks±2)~(160 participants)"
89607730|NCT05162482|Active Comparator|Heterologous 3|"CanSinoBIO (0.5ml) at baseline BIBP (CNBG, Sinopharm) WIV (0.5ml) after 70±7 days (10 wks±2)~(160 participants)"
89607731|NCT05162482|Active Comparator|Heterologous 4|"CanSinoBIO (0.5ml) at baseline AstraZeneca ChAdOx (0.5ml) after 70±7 days (10 wks±2)~(160 participants)"
89607732|NCT05162482|Active Comparator|Heterologous 5|"AstraZeneca ChAdOx (0.5ml) at baseline BIBP (CNBG, Sinopharm) WIV(0.5ml) after 70±7 days (10 wks±2)~(160 participants)"
89607733|NCT05162482|Active Comparator|Heterologous 6|"AstraZeneca ChAdOx (0.5ml) at baseline CanSinoBIO (0.5ml) after 70±7 days (10 wks±2)~(160 participants)"
89607734|NCT05162482|Active Comparator|Homologous 7|"BIBP (CNBG, Sinopharm) WIV (0.5ml) at baseline BIBP (CNBG, Sinopharm) WIV (0.5ml) after 70±7 days (10 wks±2) Full dose booster: 80 participants (0.5ml) 6 months after second dose Fractional dose booster: 80 participants (dose to be decided) 6 months after second dose No booster: 80 participants~(240 participants)"
89607735|NCT05162482|Active Comparator|Homologous 8|"CanSinoBIO (0.5ml) at baseline CanSinoBIO (0.5ml) after 70±7 days (10 wks±2) Full dose booster: 80 participants (0.5ml) 6 months after second dose Fractional dose booster: 80 participants (dose to be decided) 6 months after second dose No booster: 80 participants~(240 participants)"
89607736|NCT05162482|Active Comparator|Homologous 9|"AstraZeneca ChAdOx (0.5ml) at baseline AstraZeneca ChAdOx (0.5ml) after 70±7 days (10 wks±2) Full dose booster: 80 participants (0.5ml) 6 months after second dose Fractional dose booster: 80 participants (dose to be decided) 6 months after second dose No booster: 80 participants~(240 participants)"
89607737|NCT04414969|Experimental|Anti-PD-1 antibody+Peg-Asparaginase+Chidamide|Anti-PD-1 antibody 200mg ivdrip d1; PEG-ASP 2500U/m2 im d1; Chidamide, 30mg, PO, on d1，d5，d8，d12，d15，d19; repeat every 3 weeks.
89607738|NCT04817098|Experimental|Journey of Life Intervention Group|Community members (caregivers, teachers, and community leaders) will participate in group workshops for a period of 6 weeks.
89607739|NCT04817098|Other|Waitlist Control Group|The waitlist control group will not receive the intervention during the first 6 months of implementation in order to assess the effects of the intervention compared to the control group. However, following intervention completion in the experimental group, the control group will receive 6 months of the intervention.
89607740|NCT01609933|Experimental|2-DAA + PegIFN/RBV|2-direct-acting antiviral (2-DAA: ABT-450 [paritaprevir] 200 mg once daily [QD], ritonavir 100 mg QD, ABT-267 [ombitasvir] 25 mg QD) plus pegylated interferon alpha-2a (pegIFN) 180 mcg once weekly and Ribavirin (RBV) weight-based dosing, 1000 to 1200 mg divided twice daily (BID) for 24 weeks (Substudy 1) and followed by pegIFN and RBV alone for an additional 24 weeks (Substudy 2).
89607741|NCT03255928||VAD-implanted patients|All patients receiving a VAD implant
89607742|NCT03255928||VAD-patients suffering adverse events (AE)|VAD-patients sustaining a thromboembolic/bleeding complication over the course of support
89607743|NCT03241420||Chronic Lung conditions|Study participation will consist of one visit: Informed consent, complete both Lung Clearance Index (LCI) testing and spirometry.
89607744|NCT03241420||Healthy control group|Study participation will consist of one visit: Informed consent, brief questionnaire, LCI testing and spirometry.
89607745|NCT01843777|Active Comparator|Standard-of-Care|"The standard-of-care control group will review and practice with the audiologist content such as: 1) information on hearing-aid batteries and how to change them, 2) cleaning/daily care of the hearing aids, and 3) inserting and removing the hearing aids."
89607746|NCT01843777|Experimental|Treatment|The treatment group, on the other hand, will use a motivational tool (exploring importance) in a manner that is consistent with the spirit of motivational interviewing.
89607747|NCT05361772|Experimental|low-dose colchicine group|colchicine 0.5mg per day for 24 months
89607748|NCT05361772|Placebo Comparator|placebo group|placebo 0.5mg per day for 24 months
89607749|NCT05360368|Experimental|HLX07|"This study uses the 3+3 design to investigate the safety and determine the MTD of HLX07. Four dose levels of 800 mg, 1200 mg, 1500 mg and 1800 mg are planned for dose finding. Enrollment will continue until a maximum of 24 patients are enrolled."
89607750|NCT01842607|Experimental|Mepolizumab Arm|Subjects will receive 100 mg of Mepolizumab (in polypropylene syringe) injected subcutaneously (SC) once every 4 weeks for 12 months
89607751|NCT04794478|Active Comparator|CGM Users|Glucose challenge during clinic sessions to assess performance of CGM compared to comparator measurement.
89607752|NCT04760938|Experimental|Outdoor Behavioral Healthcare (OBH)|Adolescent participants will be asked to complete an intervention in either an OBH program (90 days) or a CBT (12 weeks) program. Parent/guardians and adolescent participants will be asked to complete several surveys before and during the program, and up to one year after.
89032828|NCT02924181|Active Comparator|Rt PV CF guided/lt PV CF blinded|Fifteen patients will be allocated to this group. Right side pulmonary veins isolation will be performed with contact force information guidance. Then, left side pulmonary veins isolation will be performed without contact force information (using same catheter named SmartTouch Catheter).
89032829|NCT02924181|Active Comparator|Rt PV CF blinded/lt PV CF guided|Fifteen patients will be allocated to this group. Right side pulmonary veins isolation will be performed without contact force information (using same catheter named SmartTouch Catheter). Then, left side pulmonary veins isolation will be performed with contact force information guidance.
89032830|NCT00527306|Experimental|I - Multivitamin|The multivitamin will contain 100% of the US reference daily intakes (recommended daily amounts) of vitamins A, B1, B2, B3, B5, B6, B9, B12, C, D, and E. It also contains several inactive ingredients including sodium bisulfite and gelatin.
89032831|NCT00527306|Placebo Comparator|II - Inactive Medication|The placebo will be a gelatin capsule filled with lactose.
89032832|NCT00527345||1|children riding retrofitted school buses or private cars
89032833|NCT00527345||2|children riding old buses who will change to retrofitted buses during the first or second year of the study
89032834|NCT00527345||3|children who ride old diesel buses through the study
89607753|NCT04760938|Experimental|Cognitive Behavioral Therapy (CBT)|Adolescent participants will be asked to complete an intervention in either an OBH program (90 days) or a CBT (12 weeks) program. Parent/guardians and adolescent participants will be asked to complete several surveys before and during the program, and up to one year after.
89607754|NCT01803607|Experimental|Odanacatib 50 mg|Participants will receive odanacatib 50 mg once weekly for 24 months. Additionally, all participants will receive weekly supplementation with 5600 international units (IU) of Vitamin D3 and, if required, will be provided with an open-label daily calcium supplement of 500 mg (sourced locally as calcium carbonate or calcium citrate) to ensure a total daily intake (from both dietary and supplemental sources) of approximately 1200 mg of elemental calcium.
89607755|NCT01803607|Placebo Comparator|Placebo|Participants will receive dose-matched placebo to odanacatib once weekly for 24 months. Additionally, all participants will receive weekly supplementation with 5600 IU Vitamin D3 and, if required, will be provided with an open-label daily calcium supplement of 500 mg (sourced locally as calcium carbonate or calcium citrate) to ensure a total daily intake (from both dietary and supplemental sources) of approximately 1200 mg of elemental calcium.
89607756|NCT02958514|Other|traditional treatment group|Subjects in this group are treated by tobramycin and dexamethasone ophthalmic ointment qn and artificial tears qid.
89607757|NCT02958514|Experimental|IPL treatment group|Subjects in this group are treated with 3 cycles of intense pulsed light of 4 weeks interval and artificial tears qid.
89607758|NCT04388722|No Intervention|Control Arm|
89607759|NCT04388722|Experimental|Investigational Arm|
89607760|NCT04667260|Placebo Comparator|Bone substitue|Bone augmentation with bone substitute
89607761|NCT04667260|Experimental|Coagulum|Bone augmentation with coagulum
89607762|NCT05290168|Experimental|Normal children|normal children undergoing simple surgery
89607763|NCT01867021|Experimental|Agriflu|A single 0.5 mL dose of Investigational vaccine TIV (Agriflu) at visit 1, administered intramuscularly
89607764|NCT01867021|Active Comparator|Fluvirin|A single 0.5 mL dose of control vaccine TIVf (Fluvirin) at visit 1, administered intramuscularly
89607765|NCT01866709|Active Comparator|Sodium Polystyrene Sulfonate|Oral suspension in water of 15g sodium polystyrene sulfonate administered three times (tid) daily for 48 hours without co-administration of Sorbitol.
89607766|NCT01866709|Placebo Comparator|Silicified microcrystalline cellulose|Oral suspension of placebo blended with pigment to have the same appearance, taste, odor and mode of administration as SPS.
89607767|NCT04621630|Experimental|Single Dose|Single dose administration
89607768|NCT04621630|Experimental|Multiple Dose|Multiple dose administration
89607769|NCT04621630|Experimental|Solid Dose Comparison|Solid dose administartion
89607770|NCT01841593|Experimental|Group A|DAYS 1 to 7: raltegravir 400 mg BID DAYS 8 to 14: raltegravir 400 mg BID PLUS amlodipine 5 mg OD DAYS 15 to 21: amlodipine 5 mg OD
89607771|NCT01841593|Experimental|Group B|DAYS 1 to 7: amlodipine 5 mg OD DAYS 8 to 14: raltegravir 400 mg BID PLUS amlodipine 5 mg OD DAYS 15 to 21: raltegravir 400 mg BID
89607772|NCT05238298|Experimental|rTMS Group|Participants will receive continuous theta burst stimulation (cTBS) for a 10-day period (10 sessions). If feasible for the participant, all stimulation sessions will be held at the same time of the day.
88982651|NCT05082051|Active Comparator|CDX-7108|CDX-7108, an oral recombinant lipase. It is a modified version of a triacylglycerol lipase enzyme derived from the bacteria Bacillus thermoamylovans (btLIP) and produced by fermentation of recombinant Escherichia coli.7
88982652|NCT05082051|Placebo Comparator|Placebo|Excipients only
88982653|NCT05060705|Experimental|Efesovir|The patients of experimental arm take study drug Efesovir twice a day as an antiviral therapy in dose 0.125 ml / kg. Daily dose of Efesovir: 0.250 ml / kg. Duration of treatment is 5 - 10 days, depending on the severity of the disease.
88982654|NCT05060705|Active Comparator|Remdesivir|"The patients are treated with the antiviral drug Remdesivir in dose 200 mg intravenously on the 1st day, then by 100 mg intravenously daily for 5 - 10 days, depending on the severity of the disease."
88982655|NCT05046249||Chiropractic clinicians|Swiss chiropractic clinicians
88982656|NCT05037032|Active Comparator|Study drug naltrexone hydrochloride|50 mg Naltrexone PO
88982657|NCT05037032|Placebo Comparator|Matching placebo for naltrexone hydrochloride|Matching placebo for Study Drug Naltrexone
89210400|NCT05278026||HFpEF|heart failure with preserved ejection fraction
89607773|NCT02454322||Magnesium|Hypertensive Disorder of Pregnancy (gestational hypertension or preeclampsia) Treated with Magnesium Sulfate
89607774|NCT02454322||No Magnesium|Hypertensive Disorder of Pregnancy (gestational hypertension or preeclampsia) Not Treated with Magnesium Sulfate
89607775|NCT04387864|Experimental|Whole-body Vibration Exercise Group|"The patients in the WBV exercise group underwent WBV exercise sessions 2 days a week (72 hours in between) for a total of 6 weeks. Each exercise session was performed under the supervision of a physician.~The patients received support from both hands on the WBV platform and both knees were positioned statically at 40-60 degree flexion (high squat position). All patients stood on the platform with sports socks (without shoes) to avoid the shoes absorbing vibration. Vibration was given by a Power Plate® device where a three-plane oscillation occurs (most vertical, Z axis). In all vibrations, 30 Hz frequency and 2 mm amplitude (low amplitude) were used. The vibration time was set to be 30 seconds in the first two weeks, 45 seconds in the next two weeks and 60 seconds in the last two weeks. The repetition of vibration was increased by 1 repetition every week, starting with 5, and 10 repetitions were given in the last week. A 1-minute rest period was given between each repetition."
89607776|NCT04387864|No Intervention|Home Exercise Group|The home program, which included isometric and isotonic exercises, was followed at home for 6 weeks. Three sets of quadriceps setting as 5 repetitions, 5-second contractions, and three sets of isotonic quadriceps exercise in seating position with weights as 12 repetitions were administered to be performed two days a week. While the patients included in the study group came for TVT exercise two days a week, the patients in the control group performed quadriceps setting exercises also on those days. The patients were invited to the physician follow-up on Wednesday every week for motivation and follow-up. The patients were asked to write their complaints during and after the exercise, if any. In addition, they were asked to note the number of repetitions and sets of their exercises on exercise booklets prepared for the patient.
89607777|NCT02132650|Experimental|ACC|Rehabilitation of walking using accurate (ACC) walking tasks
89607778|NCT02132650|Active Comparator|SS|Rehabilitation of walking using typical steady state (SS) walking
89607779|NCT01798420||Corticosteroid|
89607780|NCT01798420||non-corticosteroid group|
89607781|NCT04815070||Diabetic|A group of diabetic patients who have fasted for at least 8 hours undergoing staged bilateral total knee arthroplasty.
89607782|NCT04815070||Non-Diabetic|A group of non-diabetic patients who have fasted for at least 8 hours undergoing staged bilateral total knee arthroplasty.
89607783|NCT04789330|Active Comparator|Norepinephrine|Norepinephrine continuous infusion as the first line vasopressor
89607784|NCT04789330|Active Comparator|Phenylephrine|Phenylephrine continuous infusion as the first line vasopressor
89607785|NCT02339038|Other|Standard of Care|Standard of care treatment using Ledipasvir 90 mg and Sofosbuvir 400 mg fixed dose combination by mouth daily for 2, 3, or 6 months
89607786|NCT04497298|Experimental|COVID-19 vaccine candidate (TMV-083/V-591) - Low dose|Volunteers will receive two administrations of the low dose COVID-19 vaccine candidate by intramuscular (i.m.) injection on day 0 and 28
89607787|NCT04497298|Experimental|COVID-19 vaccine candidate (TMV-083/V-591) - High dose|Volunteers will receive two administrations of the high dose COVID-19 vaccine candidate by intramuscular (i.m.) injection on day 0 and 28.
89607788|NCT04497298|Experimental|One COVID-19 vaccine candidate (TMV-083/V-591) - High and placebo|Volunteers will receive one administration of the high dose COVID-19 vaccine candidate on day 0 by intramuscular (i.m.) injection and one administration of the placebo on day 28 by intramuscular (i.m.) injection.
89607789|NCT04497298|Placebo Comparator|Placebo|Volunteers will receive physiological saline solution (0.9% NaCl), administered by intra muscular (i.m.) injection
89607790|NCT02136004|Experimental|Closer VSS|Rex Medical Closer Vascular Sealing System to close femoral arteriotomy
89607791|NCT00569530|Active Comparator|Treatment Surfactant (Infasurf) ONY, NY|Patients receive inhaled nitric oxide and scheduled doses of Infasurf on study days 0, 3, 7, 10, and 14, if infant remains ventilated.
89607792|NCT00569530|Placebo Comparator|Sham (no treatment)|Infants receiving inhaled nitric oxide will receive Sham (no treatment) on study days 0, 3, 7, 10, and 14, if infant remains ventilated.
88982658|NCT05020418|Experimental|Cardiac Device Cohort|This study is open to any adult VA patient with data about a cardiac device procedure performed in the electrophysiology laboratory entered into the national VA EHR. During FY 20-FY 24, we anticipate that this will include approximately 9,000 patients per year, or a total of 50,000 patients. In addition, cases that were previously accessed and used to develop the infection monitoring system, and the quality metric monitoring system, may also be included. This includes all patients entered in the VA Clinical Assessment Reporting and Tracking - Electrophysiology Cohort (CART-EP) database during the period from 2006-2016, and all VA patients who received a cardiac device procedure during the period from 2010-2019. This includes another approximately 50,000 patients, for a total of 100,000 patients.
88982659|NCT05013593|Experimental|Symptomatic RCE|Bladder symptomatic group receiving red clover extract containing the two isoflavones formononetin and biochanin A. Isoflavone amount is 57.45 mg isoflavones daily (55.84 mg aglycones daily), in 70 ml red clover extract (35 ml twice daily, morning and evening with a meal)
88982660|NCT05013593|Experimental|Healthy RCE|Healthy group without bladder symptoms receiving red clover extract containing the two isoflavones formononetin and biochanin A. Isoflavone amount is 57.45 mg isoflavones daily (55.84 mg aglycones daily), in 70 ml red clover extract (35 ml twice daily, morning and evening with a meal)
88982661|NCT05013593|Placebo Comparator|Symptomatic PL|Bladder symptomatic group receiving placebo
88982662|NCT05013593|Placebo Comparator|Healthy PL|Healthy group without bladder symptoms receiving placebo
89607793|NCT04509622|Experimental|Venetoclax + Low-Dose Cytarabine (LDAC)|Participants will receive venetoclax once daily (QD) on days 1 through 28 plus LDAC QD on days 1 through 10 during the 28-day treatment cycles.
89607794|NCT02137486||sequential ballooning|include BMS or DES
89607795|NCT02137486||final kissing ballooning|include BMS or DES
89607796|NCT04388098||Asthmatic children|Asthmatic children were clinically examined to assess their dental caries experience and periodontal health condition. Stimulated salivary samples were collected and assessed for salivary flow rate, salivary pH and buffering capacity.
89607797|NCT04388098||Non-asthmatic children|Non-asthmatic children were clinically examined to assess their dental caries experience and periodontal health condition. Stimulated salivary samples were collected and assessed for salivary flow rate, salivary pH and buffering capacity.
89607798|NCT00570700|Experimental|Dasatinib|Patients receive oral dasatinib once daily in the absence of disease progression or unacceptable toxicity.
88982663|NCT05012358||Observational Cohort|no intervention
88982664|NCT05001126|Experimental|HIFT 1x/week|HIFT exercise performed one time per week.
88982665|NCT05001126|Experimental|HIFT 2x/week|HIFT exercise performed two times per week.
88982666|NCT05001126|Experimental|HIFT 3x/week|HIFT exercise performed three times per week.
88982667|NCT04920916|Experimental|Dupilimab|Dupilimab: 600 mg, given as two 300 mg subcutaneous injections on day 0/1. If participants are still hospitalized a second and third dose (300 mg) will be given on days 14 and 28.
88982668|NCT04920916|Placebo Comparator|Placebo|Normal saline will be given as two one mL subcutaneous injections on day 0/1. If participants are still hospitalized a second and third dose (1 mL) will be given on days 14 and 28.
88982669|NCT04918225||Progressive Multiple Sclerosis patients|Progressive Multiple Sclerosis patients
88982670|NCT04918225||Healthy Volunteers|Healthy Volunteers
88982671|NCT04884113||Experimental: Motorized Spiral Enteroscopy|"Procedure: Motorized Spiral Enteroscopy:~PowerSpiral enteroscope will be inserted and advanced with the assistance of motorized spiral rotation, After reaching the point of maximum insertion, cecum or if no further advancement of the enteroscope can be achieved, the enteroscope will be withdrawn using motorized counter-clockwise spiral rotation. When no total enteroscopy is reached, submucosal ink dye injection is performed as an endoscopically visible marker of the maximum insertion depth. A retrograde enteroscopy is then performed in the same session or at second session"
88982672|NCT04883333|Experimental|Cohort A1 LEO 153339|Single ascending dose (Part 1)
89607799|NCT00571324|Experimental|Exendin-(9-39) first, the Vehicle|Exendin-(9-39) will be administered intravenously (IV) after an overnight fast. Exendin-(9-39) will be infused over 6 hours with the dose slowly escalating from 100pmol/kg/min for 2 hours, then 300pmol/kg/min for another 2 hours followed by 500pmol/kg/min for the last 2 hours of the infusion. The following day, after another overnight fast, normal saline (control) vehicle infusion will be administered intravenously (IV) over 6 hours. During both infusions, blood glucose levels will be measured every 20 minutes.
89607800|NCT00571324|Placebo Comparator|Vehicle first, then Exendin-(9-39)|Normal saline vehicle infusion will be administered intravenously (IV) after an overnight fast. The infusion will be given over 6 hours. The following day, after another overnight fast, Exendin-(9-39) will be infused over 6 hours with the dose slowly escalating from 100pmol/kg/min for 2 hours, then 300pmol/kg/min for another 2 hours followed by 500pmol/kg/min for the last 2 hours of the infusion. During both infusions, blood glucose levels will be measured every 20 minutes.
88982673|NCT04883333|Experimental|Cohort A2 LEO 153339|Single ascending dose (Part 1)
88982674|NCT04883333|Experimental|Cohort A3 LEO 153339|Single ascending dose (Part 1)
88982675|NCT04883333|Experimental|Cohort A4 LEO 153339|Single ascending dose (Part 1)
89519163|NCT02522975|Experimental|Experimental group|"Generic name: recombinant human erythropoetin injection which is indicated for the treatment of anaemia caused by chronic renal disease.~Dosage form:Injection Strength:2000IU,3000IU,4000IU Frequency and Dosage:subcutaneously injection once a week for a period of 52 weeks. The initial dose of EPIAO® will be 60 IU/kg body weight."
89519164|NCT04508803|Experimental|The main research|Patients diagnosed with HER2 negative metastatic breast cancer with BRCA1/2, PALB2, CHEK2 pathogenic/suspected pathogenic germline mutation are recruited.
88982676|NCT04883333|Experimental|Cohort A5 LEO 153339|Single ascending dose (Part 1)
88982677|NCT04883333|Experimental|Cohort A6 LEO 153339|Single ascending dose (Part 1)
88982678|NCT04883333|Experimental|Cohort A7 LEO 153339|Single ascending dose (Part 1)
88982679|NCT04883333|Experimental|Cohort B1 LEO 153339|Single ascending dose (Part 1)
88982680|NCT04883333|Placebo Comparator|All SAD cohorts placebo|Single ascending dose (Part 1), all participants receiving placebo in Cohorts A1-A7 and B1
88982681|NCT04883333|Experimental|Cohort C1 LEO 153339|Multiple ascending doses (Part 2)
88982682|NCT04883333|Experimental|Cohort C2 LEO 153339|Multiple ascending doses (Part 2)
88982683|NCT04883333|Experimental|Cohort C3 LEO 153339|Multiple ascending doses (Part 2)
88982684|NCT04883333|Experimental|Cohort C4 LEO 153339|Multiple ascending doses (Part 2)
88982685|NCT04883333|Experimental|Cohort C5 LEO 153339|Multiple ascending doses (Part 2)
88982686|NCT04883333|Experimental|Cohort C6 LEO 153339|Multiple ascending doses (Part 2)
89519165|NCT04508803|Experimental|Ancillary Exploration research 1|Patients diagnosed with HER2 negative metastatic breast cancer with DDR gene (include ATM、ATR、BAP1、BARD1、BLM、BRIP1、CHEK1、CDK12、FANCA、FANCC、FANCD2、FANCE、FANCF、FANCM、MRE11A、NBN、PTEN、RAD50、RAD51C、RAD51D、WRN)pathogenic/suspected pathogenic germline mutation except BRCA1/2, PALB2 and CHEK2 are recruited.
89519166|NCT04508803|Experimental|Ancillary Exploration research 2|Patients diagnosed with HER2 positive metastatic breast cancer with DDR gene pathogenic/suspected pathogenic germline mutation are recruited.
89519167|NCT04508803|Experimental|Ancillary Exploration research 3|Patients diagnosed with brain metastases breast cancer with DDR gene pathogenic/suspected pathogenic germline mutation who has not undergone or progressed after brain radiotherapyare recruited.
89519168|NCT04249895||Main Cohort|All patients are undergoing radiotherapy in Tata Medical Center
89519169|NCT04453501||Azithromycin or non-azithromycin group|Patient who received during admission for a severe COVID-19 pneumonia, azithromycin +/-hydroxychloroquine or no azithromycin.
89519170|NCT04106063||deaf children|All Children between 7 and 17 years old attending medical appointment for temporary or persistent deafness in our Ear, Nose and Throat (ENT) department
89519171|NCT04458233|Active Comparator|long axis|
89519172|NCT04458233|Active Comparator|short axis|
89519173|NCT03461185|Experimental|EGFR-TKI plus anti-angiogenesis|EGFR-TKI(erlotinib or gefitinib) plus anti-angiogenesis(endostatin or apatinib or anlotinib)
89519174|NCT03461185|Active Comparator|EGFR-TKI|EGFR-TKI(erlotinib or gefitinib)
89519175|NCT04453423|Other|First-line Treatment|
89519176|NCT04453423|Experimental|Maintenance Treatment A|
89519177|NCT04453423|Experimental|Maintenance Treatment B|
89519178|NCT04453423|Experimental|Maintenance Treatment C|
89519179|NCT04453189|Experimental|Treatment Sequence: AB(Part 1) followed by C(Part 2-Optional)|Participants will received Treatment A (single dose of JNJ-64417184 in fed condition on Day 1) in period 1 followed by Treatment B (lansoprazole on Day 1 to 4 under fasted condition and 2 hours before single dose of JNJ-64417184 in fed condition on Day 5) in period 2 of part 1. There will be a washout period of 7 days between each treatment. Participants will receive Treatment C: optional (famotidine under fasted conditions administered 12 hours before and 12 hours after a single dose of JNJ-64417184 under fed conditions on Day 1) in Part 2, Period 3.
89519180|NCT04453189|Experimental|Treatment Sequence: BA(Part 1) followed by C(Part 2-Optional)|Participants will receive Treatment B in period 1 followed by Treatment A in period 2, Part 1. There will be a washout period of 7 days between each treatment. Participants will receive Treatment C: optional (famotidine under fasted conditions administered 12 hours before and 12 hours after a single dose of JNJ-64417184 under fed conditions on Day 1) in Part 2, Period 3.
89519181|NCT05158855|Experimental|neutralizing antibody booster for vaccinated participants|participants after 6-month vaccinated with COVID-19 vaccine received 1 capsule of B. subtilis spore extract
89519182|NCT03465241||Monitoring by NGS group|This group will accept the ctDNA dynamic monitoring on the following phase:the day before surgery,the 3rd to 7th day after surgery,3 to 4 weeks after adjuvant chemotherapy finished, then every 6 months in the following 2 years.
89519183|NCT02522065||Healthy controls|A sample of 30 healthy volunteers will be recruited to compare the typing signal with that of the cases.
89519184|NCT02522065||Early Parkinson's disease cases|A sample of 30 early PD cases (i.e. less than five years of disease and no axial signs or fluctuations) that are going to be prescribed de novo dopaminergic therapy will be recruited.
89519185|NCT05103085||Experimental|Patient undergoing digestive endoscopy and aged 50 years and over
89519186|NCT03461107||patients with heart failure|
89519187|NCT02521987|Active Comparator|8mm Port|Participates will be randomized to have an 8 mm assistant port used during their surgery. The participate will be asked to specify the point that represents their level of perceived pain intensity and mark it on the scale at four time points: baseline pain prior to the procedure in the pre-operatively holding area, 4 to 6 hours post operatively, on Post Operative Day 1 (POD1). The final pain assessment will be at the two weeks postoperative clinic visit.
89519188|NCT02521987|Experimental|12mm Port|Participates will be randomized to have an 12mm assistant port used during their surgery. The participate will be asked to specify the point that represents their level of perceived pain intensity and mark it on the scale at four time points: baseline pain prior to the procedure in the pre-operatively holding area, 4 to 6 hours post operatively, on Post Operative Day 1 (POD1). The final pain assessment will be at the two weeks postoperative clinic visit.
89607801|NCT04338646||Patients enrolled|Patient with multiple sclerosis and lower urinary tract symptoms, age >18 Expanded Disability Status Scale score between 1 and 6.5
89607802|NCT00573508|Active Comparator|Placebo|Matching placebo tablet taken once daily
89607803|NCT00573508|Experimental|Solifenacin Succinate|5mg or 10mg tablet taken once daily
89607804|NCT00574834|Active Comparator|Ramipril|Patients randomized to 6 months treatment of Ramipril.
89607805|NCT00574834|Active Comparator|HCTZ|PAtients randomized to 6 months treatment of HCTZ.
89607806|NCT00574834|Active Comparator|Ramipril+HCTZ|Patients randomized to 6 months treatment of Ramipril+HCTZ.
89607807|NCT00574990||VA Physicians|VA providers who had worked at least one year in the VA and were familiar with the VA's electronic health record, CPRS.
89607808|NCT00574990||VA Nurses|VA nurses who had worked at least one year in the VA and were familiar with the VA's electronic health record, CPRS.
89607809|NCT00574990||VA Pharmacists|VA pharmacists who had worked at least one year in the VA and were familiar with the VA's electronic health record, CPRS.
89607810|NCT00575146|Experimental|1|ketogenic diet
89607811|NCT04095520|Active Comparator|Paste Type Traditional Composite-GC G Aenial Anterior|Non-carious cervical lesions with shallow depth of less than 3 mm will be restored with microhybrid composite
89607812|NCT04095520|Experimental|Injectable Composite- GC G Aenial Universal Injectable|Non-carious cervical lesions with shallow depth of less than 3 mm will be restored with injectable form composite
89607813|NCT04251520|No Intervention|Control Group|Standard care by Palliative Medicine physician
89210401|NCT05278026||nonfailing control|patients without heart failure
89607814|NCT04251520|Experimental|Intervention Group A|Standard care by Palliative medicine physician plus pharmacist review of medications
89607815|NCT04251520|Experimental|Intervention Group B|Standard care by Palliative medicine plus pharmacogenomics testing and pharmacist review
89210402|NCT00899964|Active Comparator|1|automated tailored feedback per E-mail
89210403|NCT00899964|Active Comparator|2|1 + active contact per E-mail possible
89607816|NCT01592110|Experimental|Cohort 1|25 mg of risperidone-SABER administered as a SC injection of 0.25 mL (100 mg/mL concentration) in the abdominal region
89607817|NCT01592110|Experimental|Cohort 2|50 mg of ZX003 (risperidone-SABER-DosePro) administered as 0.5 mL (100 mg/mL concentration) via the DosePro Needle-free Delivery System in the abdominal region
89607818|NCT01592110|Experimental|Cohort 3|50 mg of risperidone-SABER administered as a SC injection of 0.5 mL (100 mg/mL concentration) in the abdominal region
89607819|NCT01592110|Experimental|Cohort 4|100 mg of risperidone-SABER administered as a SC injection of 1.0 mL (100 mg/mL concentration) in the abdominal region
88982687|NCT04883333|Placebo Comparator|All MAD cohorts placebo|Multiple ascending doses (Part 2, all participants receiving placebo in Cohorts C1-C6)
88982688|NCT04879342|Experimental|VIP Program Group|Participants in this group will receive a 26 week course on risk reduction strategies.
88982689|NCT04871568|Active Comparator|Right subclavian vein catheterization|The temporary central dialysis catheter is placed in the right subclavian vein.
88982690|NCT04871568|Active Comparator|Right internal jugular vein catheterization|The temporary central dialysis catheter is placed in the right internal jugular vein.
88982691|NCT04857931|Active Comparator|Colchicine 0.5 mg die|Colchicine 0.5 mg die
88982692|NCT04857931|Active Comparator|Colchicine 0.5 mg bid|Colchicine 0.5 mg bid
89210404|NCT00899964|Active Comparator|3|2 + active contact by trainer in case of exercise-related problems
88982693|NCT04857931|Placebo Comparator|Placebo|Placebo
88982694|NCT04851756|Experimental|CRet Group|30 min CRet with F.M on the rectus femoris and gastrocnemius medialis and lateralis
88982695|NCT04851756|Sham Comparator|CRet Sham Group|30 min CRet with F.M on the rectus femoris and gastrocnemius medialis and lateralis with turned on CRet device at power 0
89607820|NCT03843580|No Intervention|Standard Allocation|apnea without oxygenation like usual traitement
89607821|NCT03843580|Experimental|oxygenation optiflow|optiflow oxygenation during apnea
89607822|NCT00604552|Other|Lifeline Registry|All comers registry for the on-label treatment of AAA with the AneuRx Stent Graft sponsored by the Foundation of Society for the Vascular Surgery (SVS)
89607823|NCT00604552|Other|PS Registry|All comers registry for the on-label treatment of AAA with the AneuRx Stent Graft sponsored by Medtronic
89607824|NCT03646708||SBCD patients starting a new biologic therapy|As part of your standard clinical care (soc), patient will be started on a biologic (anti-tumor necrosis factor (TNF)s, vedolizumab and ustekinumab) based on your interactions with your treating gastroenterologist after standard of care clinical assessment.
89607825|NCT00605644|Placebo Comparator|Placebo|Placebo
89607826|NCT00605644|Experimental|150 mg|MOA-728
89607827|NCT00605644|Experimental|300 mg|MOA-728
89607828|NCT00605644|Experimental|450 mg|MOA-728
89607829|NCT00605644|Experimental|600 mg|MOA-728
89607830|NCT00578734|Experimental|Lucinactant|SURFAXIN® (lucinactant) for intratracheal instillation
89607831|NCT00578734|Sham Comparator|Sham Air|Sham air (placebo) instillation
89607832|NCT00578968|Experimental|Tiotropium|Participants with chronic obstructive pulmonary disease randomized to this arm received a once daily oral inhalation of 18 mcg tiotropium powder.
89607833|NCT00578968|Placebo Comparator|Placebo|Participants with chronic obstructive pulmonary disease randomized to this arm received a once daily oral inhalation of placebo powder to match the standard active comparator dose.
89607834|NCT00578968|No Intervention|Healthy Controls|Healthy age and gender matched controls were recruited for comparing cardiovascular responses to participants with chronic obstructive pulmonary disease prior to the intervention.
89607835|NCT00579280|Active Comparator|Quetiapine SR|Quetiapine SR (Quetiapine Sustained Release)
89607836|NCT00579280|Active Comparator|Divalproex Sodium ER|Divalproex Sodium ER (Divalproex Sodium Extended Release)
89607837|NCT00579280|Placebo Comparator|Placebo|placebo
89607838|NCT00579436|Active Comparator|Fish oil group|4g Lovaza (omega-3 fatty acid) daily.
89607839|NCT00579436|Placebo Comparator|Control group|placebo (4 non-active capsules daily)
89607840|NCT00580138||Stroke or Head & Neck Cancer|Any subject who has suffered a stroke or has some form of head & neck cancer (non-laryngectomee) may be enrolled.
89607841|NCT03573466|Experimental|Amyotrophic Lateral Sclerosis|
89607842|NCT00580294|Experimental|oxymorphone|participants switched to oxymorphone extended release (ER) via both oral and intravenous patient-controlled analgesia (IV-PCA) oxymorphone. After 24 hours, participants were discharged with oral oxymorphone ER and oxymorphone immediate release (IR) as needed
89607843|NCT00580372|Experimental|Study Treatment|Protocol therapy consists of a remission induction phase with mutually non-cross resistant combinations of vincristine, adriamycin, dexamethasone (VAD), high-dose cyclophosphamide with stem cell procurement and etoposide, dexamethasone, cytarabine, cisplatin (EDAP) followed by two courses of melphalan-based high-dose therapy supported by autologous stem cell transplants 4-6 months apart. Maintenance with interferon alpha will be administered until disease progression.
89607844|NCT00581230|Experimental|Laryngoscopy without RAMP|First, laryngoscopy will be preformed utilizing a traditional Macintosh size 4 blade laryngoscope. The view of the laryngeal aperture will be recorded, and a photo will be taken by the Airway Cam™.
89607845|NCT00581230|Experimental|Laryngoscopy with RAMP|Next, the Rapid Airway Management Positioner (RAMP) will be positioned and inflated underneath the patient so that the patient is placed in the optimal sniffing position. The investigator will again perform laryngoscopy utilizing the same technique and the laryngeal view will be recorded.
89607846|NCT00581386|Experimental|LTS-D|All the cases were divided into one of the group LTS-D, PLMA, and ETC
89607847|NCT00581386|Experimental|ProSeal Laryngeal Mask Airway|All patients were divided into either LTS-D, PLMA, or the ETC group.
89607848|NCT00581386|Experimental|Esophageal Tracheal Combitube (ETC)|All patients are divided into one of the group, LTS-D, PLMA, or the ETC.
89607849|NCT02134210|Active Comparator|Enbrel (etanercept)|Enbrel 50mg twice weekly times 12 weeks
89607850|NCT02134210|Experimental|CHS-0214|CHS-0214 50mg twice weekly times 12 weeks
89607851|NCT02134522|Experimental|C-PAP intervention|Continuous positive airway pressure is a commonly prescribed therapy for obstructive sleep apnea which is recommended for the treatment of obstructive sleep apnea in children and adults.
89607852|NCT02134756|Experimental|NutraStem Active|Daily supplementation with NutraStem Active; 2 capsules per day for 28 days
89607853|NCT02134756|Placebo Comparator|Placebo|Daily supplementation with placebo; 2 capsules per day for 28 days
89607854|NCT01798732|Experimental|Selective laser trabeculoplasty (Tango Laser, Ellex)|Patients treated with selective laser trabeculoplasty (Tango Laser, Ellex, Minneapolis, USA)
89607855|NCT00607126|Experimental|1|locomotor training using body weight support on a treadmill, using robotic device to provide locomotor training. Locomotor training will be done using the Lokomat device. the patient is suspended over a treadmill while their legs are in the Lokomat, which moves the legs on the treadmill.
89607856|NCT00607126|Active Comparator|2|resistive training using weights and therabands
88982696|NCT04824248|Experimental|Experimental intervention|10 weeks online therapy delivered using a blended approach. The online therapy consists of instructive video's, challenges to complete, 1-on-1 video calls with the therapist, online quizzes, online booklets, and online diaries/workbooks. . The experimental group will receive a behavioral weight reduction program combined with pain neuroscience education plus cognition-targeted exercise therapy. The combined therapy will adhere to guidelines for patient-centered care
88982697|NCT04824248|Active Comparator|Control intervention|Identically to the experimental intervention, the therapy is provided online within 10 weeks. Also identical to the experimental intervention, the control intervention will adhere to guidelines for patient-centered care. The control group will receive pain neuroscience education in combination with cognition-targeted exercise therapy alone.
88982698|NCT04818541|Experimental|Protected Percutaneous Coronary Intervention|Subjects with a femoral arteriotomy created with 13 to 14 F sheaths (arteriotomy up to approximately 18 F) and in whom an Impella device was used for PPCI. Duration of Impella use ≤ 6 hours if used for PPCI.
88982699|NCT04818541|Experimental|Cardiogenic shock|Subjects with a femoral arteriotomy created with 13 to 14 F sheaths (arteriotomy up to approximately 18 F) and in whom an Impella device was used for cardiogenic shock. Duration of Impella use > 8 hours and ≤ 4 days.
88982700|NCT04818138|Active Comparator|Narrowband UVB|Narrowband UVB phototherapy (full body) administered three times weekly according to individual clinical protocols.
88982701|NCT04818138|Active Comparator|Broadband UVB|Broadband UVB phototherapy (full body) administered three times weekly according to individual clinical protocols.
88982702|NCT04815954|Experimental|Early group|Early urinary catheter removal: 24±6 hours after completion of surgery.
88982703|NCT04815954|Active Comparator|Delayed group|Delayed urinary catheter removal: 72±6 hours after completion of surgery.
89607857|NCT00607594|Experimental|Treatment (kinase inhibitor therapy)|Patients receive saracatinib PO, at a dose of 175 mg QD in the absence of disease progression or unacceptable toxicity.
89607858|NCT01866319|Experimental|Ipilimumab|Participants receive ipilimumab, 3 mg/kg intravenously (IV), once every 3 weeks (Q3W) for a total of 4 doses (up to approximately 3 months).
88982704|NCT04815733|Active Comparator|Mandatory ventilation|deep neuromuscular block and mandatory ventilation (PCV-VG);
88982705|NCT04815733|Experimental|Pressure support ventilation|partial neuromuscular block and pressure support ventilation (PSVpro).
88982706|NCT04808947|Experimental|Local infiltration analgesia|Patients in this group will receive LIA intraoperatively, as per institutional standard. The injected solution will be comprised of 100cc Ropiv 2%, + Ketorolac 30 mg + Epinephrine 25 ug.
88982707|NCT04808947|Active Comparator|Local infiltration analgesia + ACB-iPACK block|"Patients in this group will receive LIA intraoperatively, as per institutional standard. The injected solution will be comprised of 100cc Ropiv 2%, + Ketorolac 30 mg + Epinephrine 25 ug.~Patients in this group will also receive preoperative nerve blocks under ultrasound guidance. These will include:~Adductor canal block with 0.5% Ropivacaine w/epi 20 mL~iPack block with 0.25% Ropivacaine w/epi 10 mL"
88982708|NCT04800393|Experimental|Inhalation anesthesia|
88982709|NCT04800393|Active Comparator|Total intravenous anesthesia|
88982710|NCT04771442|Experimental|Stromal vascular fraction injection|"Intervention:~Single injection with autologous adipose tissue-derived stromal vascular fraction cells in and around the plaque."
88982711|NCT04735458|Experimental|Treatment|Parkinson's Disease Patients receiving DBS electrodes
88982712|NCT04735458|No Intervention|Control|Control subjects will be non-Parkinson's Disease patients with essential tremor
89210405|NCT00899964|Active Comparator|4|3 + regular active contact by trainer
89607859|NCT01866319|Experimental|Pembrolizumab Q2W|Participants receive pembrolizumab, 10 mg/kg IV, once every 2 weeks (Q2W) for up to approximately 24 months.
89607860|NCT01866319|Active Comparator|Pembrolizumab Q3W|Participants receive pembrolizumab, 10 mg/kg IV, Q3W for up to approximately 24 months.
89607861|NCT00607672|Placebo Comparator|1|Patients are randomized to placebo prior to surgery
89607862|NCT00607672|Active Comparator|2|Patients are randomized to Ramipril prior to surgery
89607863|NCT00607672|Active Comparator|3|Patients are randomized to Candesartan (ARB) prior to surgery
89607864|NCT01802515|Active Comparator|Atomoxetine, low dose|1 capsule containing 40mg of atomoxetine by mouth everyday for 8 weeks followed by 1 week of daily placebo capsules.
89607865|NCT01802515|Active Comparator|Atomoxetine, high dose|One capsule containing 80mg of atomoxetine by mouth everyday for 8 weeks, followed by 1 week of daily 40mg atomoxetine capsules
89607866|NCT01802515|Placebo Comparator|Placebo (sugar pill)|1 placebo capsule by mouth everyday for 8 weeks of treatment invention followed by one week of placebo capsule during study medication taper.
89607867|NCT01802437|Experimental|Talk Therapy 4-Week Decision Point|Interpersonal psychotherapy that focuses on an adolescents relationship and communication skills in the context of of their depression. After 4 weeks of therapy, participants with at less than a 20% reduction in Hamilton Rating Scale for Depression (HRSD) score will be further randomized into 2 groups, increased dose of interpersonal psychotherapy frequency or introduction of fluoxetine therapy starting with 10 mg per day for the first week and 20 mg per day in the following 5 weeks. If HRSD scores meet target, patients continue to receive initial dose of interpersonal psychotherapy
89607868|NCT01802437|Experimental|Talk Therapy 8-Week Decision Point|Interpersonal psychotherapy that focuses on an adolescents relationship and communication skills in the context of of their depression. After 8 weeks of therapy, participants with at less than a 40% reduction in Hamilton Rating Scale for Depression (HRSD) score will be further randomized into 2 groups, increased dose of interpersonal psychotherapy or introduction of fluoxetine therapy starting with 10 mg per day for the first week and 20 mg per day in the following 5 weeks. If HRSD scores meet target, patients continue to receive initial dose of interpersonal psychotherapy.
89607869|NCT00608062|Experimental|Pre1|Premenopausal - GnRHant plus estradiol
89607870|NCT00608062|Placebo Comparator|Pre2|Premenopausal - GnRHant plus placebo
89607871|NCT00608062|Experimental|Peri1|Perimenopausal (early) - GnRHant plus estradiol
89607872|NCT00608062|Placebo Comparator|Peri2|Perimenopausal (early) - GnRHant plus placebo
89607873|NCT00608062|Experimental|Peri3|Perimenopausal (late) - GnRHant plus estradiol
89607874|NCT00608062|Placebo Comparator|Peri4|Perimenopausal (late) - GnRHant plus placebo
89607875|NCT00608062|Experimental|Post1|Postmenopausal - GnRHant plus estradiol
89607876|NCT00608062|Placebo Comparator|Post2|Postmenopausal - GnRHant plus placebo
89607877|NCT02138578|Experimental|Randomized SBRT|Patients who meet eligibility criteria (unilateral primary renal cell carcinoma less than 4 cm in greatest diameter) and are randomized to Stereotactic Body Radiation Therapy (SBRT) will receive SBRT delivered in fractions of 20 Gy, approximately every other day, for a total of three treatments. If the target is deemed too close to organs at risk, 5 fractions of up to 10 Gy per fraction will be prescribed.
89607878|NCT02138578|Active Comparator|Randomized RFA|Patients who meet eligibility criteria (unilateral primary renal cell carcinoma less than 4 cm in greatest diameter) and are randomized to Radiofrequency Ablation (RFA) will receive RFA.
88982713|NCT04729270|Experimental|EXPERIMENTAL GROUP|The intervention for this group consisted of 10 sessions with Transcranial Direct Current Stimulation for a month.
88982714|NCT04729270|Experimental|CONTROL GROUP|The intervention for this group consisted of 10 sessions with Transcutaneous Electrical Nerve Stimulation (TENS) for a month.
88982715|NCT04712461|Experimental|SUPPORTS Implementation Model|The SUPPORTS implementation model will consist of a package of implementation strategies aimed at improving EBP sustainment through reducing provider burnout and turnover and improving organizational climate. The content and structure of SUPPORTS will be informed by the occupational health literature (e.g., psychoeducation about burnout, mindfulness training, or changes involvement of providers in organizational decision-making) and from a needs and context assessment.
88982716|NCT04712461|No Intervention|Implementation as Usual|Agencies in the Implementation as Usual condition will have implementation strategies tied to the implementation of EBPs that these agencies in the community are already using (i.e., the study will measure the implementation strategies being used by the agency but will not provide any additional strategies). There will be no strategies related to reducing provider burnout and turnover and improving organizational climate.
89032835|NCT02926287|Experimental|Ambulatory surgery|All the patients operated for pelvic organ prolapse during the study time will be recruited. All the patient eligible for an Ambulatory surgery will be discharged earlier.
89032836|NCT02924259|Experimental|Foam Roll Group|Subjects will undergo a 2-minute video-guided foam roll intervention on the left quadriceps muscle using the GRID foam roll.
89032837|NCT02944916|Experimental|IryPump R Set|A new set for transanal irrigation composed by 2 parts : 1 pump and 1 rectal catheter . 1 rectal catheter used per irrigation respecting the patient usual frequency of transanal irrigation
89032838|NCT02924454|Experimental|Metoprolol-Lipid emulsion|intervention 1: metoprolol Intervention 2: intravenous lipid emulsion
89607879|NCT02138578|Active Comparator|Non-Randomized SBRT|Patients with renal cell carcinoma's greater than or equal to 4 cm in diameter, and up to 8 cm in diameter, may be placed in the non-randomized stereotactic body radiation therapy arm. Patients with tumors not amenable to RFA, those with metastatic disease, and those who elect a noninvasive means of treatment will also be eligible to receive treatment in the non-randomized SBRT cohort.
89607880|NCT00608140|Experimental|1|Participants will receive optimal medical therapy plus surgical mitral valve repair with complete annular ring placement
89607881|NCT00608140|Active Comparator|2|Participants will receive optimal medical therapy alone
89607882|NCT00608140|Experimental|3|Participants will receive optimal medical therapy plus 18-month delayed surgical mitral valve repair with complete annular ring placement
89607883|NCT02135146|Active Comparator|Plasmalyte 3ml/kg/hr group|
89607884|NCT02135146|Active Comparator|Plasmalyte 6ml/kg/hr group|
89607885|NCT03064204||OSA+CPAP+HIV+|Individuals (40 years or older) diagnosed with OSA and using CPAP, also with HIV treated to viral suppression.
89607886|NCT03064204||OSA+CPAP+HIV-|Individuals (40 years or older) diagnosed with OSA and using CPAP.
89607887|NCT00610480|Active Comparator|Optive, then Systane Artificial Tears|Artificial Tears (Optive, 40 microliters) will be administered at the first study visit, after baseline evaporation rate measurements have been taken. Evaporation rate measurements will be repeated 30 minutes later. At the next study visit, 2-14 days later, artificial tears (Systane, 40 microliters) will be administered using the same procedure protocol.
89607888|NCT00610480|Active Comparator|Systane, then Optive Artificial Tears|Artificial Tears (Systane, 40 microliters) will be administered at the first study visit, after baseline evaporation rate measurements have been taken. Evaporation rate measurements will be repeated 30 minutes later. At the next study visit, 2-14 days later, artificial tears (Optive, 40 microliters) will be administered using the same procedure protocol.
89607889|NCT00582400|Experimental|I|
89607890|NCT00582946|Experimental|Magnetic Contact Hearing Aid|Subjects were treated with a hearing aid which provided amplification intended to treat mild to moderate sensorineural hearing loss. Acute performance and safety assessed at 4 months compared to unaided baseline pre-treatment, followed by longer-term assessment of safety up to 10 months.
89607891|NCT00583414|Experimental|Endovascular Aneurysm Repair|Investigational stent-graft implant to exclude aneurysm
89607892|NCT00583492|Experimental|Ad5-yCD/mutTKSR39rep-ADP + IMRT|Gene Therapy + IMRT
89607893|NCT00583492|Active Comparator|IMRT Alone|IMRT: 40 x 2 Gy for a total dose of 80 Gy or 44 x 1.8 Gy for a total dose of 79.2 Gy
89607894|NCT01801735|Experimental|Meloxicam Test Capsules|One Capsule QD
89607895|NCT00612430|Experimental|Bevacizumab + Etoposide|Grade III and IV patients will receive: Bevacizumab administered intravenously at dose 10 mg/kg every two weeks. If patient tolerates 1st bevacizumab dose, subsequent doses may be given by local oncologists under direct supervision of Duke investigators. Etoposide administered orally, once daily for 1st 21 days of each 28-day treatment cycle. Dose of Etoposide will be 50 mg/m2/day.
89607896|NCT01639924||Study Cohort|Patients with known or suspected gastrointestinal disease
89607897|NCT01571128|Experimental|Male-Specific Intervention Package|Gender-specific interventions targeted specifically for boys offered in an integrated services delivery modality. Cross-Sectional Arm.
89607898|NCT01571128|Experimental|Female-Specific Intervention Package|Gender-specific interventions targeted specifically for girls offered in an integrated services delivery modality. Cross-Sectional Arm.
89607899|NCT01571128|No Intervention|HIV Positive Cohort (Males and Females)|Behavioral data on HIV positive youth. Longitudinal Arm.
89607900|NCT01571128|Experimental|Pre-Exposure Prophylaxis (Females)|PrEP adherence and feasibility. Longitudinal Arm.
89607901|NCT01571128|Experimental|Cash Transfer Cohort (Females)|School attendance, behavioral data, and feasibility. Longitudinal Arm
89607902|NCT00614458|Experimental|Raltegravir and VPA to ART|raltegravir 400mg po BID; valproic acid 1000mg - 2000mg daily
88982717|NCT04680585|Other|Enhanced Usual Care|Access to online resources and educational materials about general mental health, maternal mental health, depression and anxiety in the pregnancy and postpartum period, and an up-to-date listing of treatment services available in Ontario. These resources are maintained by the MOVIN study team.
88982718|NCT04680585|Experimental|MOVIN|Enhanced Usual Care plus MOVIN Care Platform. The MOVIN Care Platform is virtual collaborative care intervention with a stepped care approach in which a care coordinator directs participants to one or more evidence-based virtual interventions as appropriate.
88982719|NCT04647097|Active Comparator|Standard intervention plus repeated intervention|Patients randomized to the standard intervention plus repeated intervention arm
88982720|NCT04647097|Active Comparator|Standard intervention only|Patients randomized to the standard intervention only arm
88982721|NCT04638491|Experimental|single-arm|PM01183-Dose Escalation
88982722|NCT04629300|Experimental|Supportive Care Mobile Application|"Complete study questionnaires at two time points:~upon enrollment at baseline prior to randomization~approximately 12 weeks after the baseline assessment time point.~Participants will be provided with a study-issued tablet computer to access mobile app and receive a comprehensive tutorial and detailed instructions on how to use the app.~Participants will have approximately 10 weeks to complete the intervention modules at self initiated pace. The app will provide prompts as reminders to complete the modules.~Participants will receive standard oncology care. Study staff will monitor participant use of supportive care services, such as social work, psychology, psychiatry, and palliative care."
88982723|NCT04629300|Active Comparator|Usual Care|"Complete study questionnaires at two time points:~upon enrollment at baseline prior to randomization~approximately 12 weeks after the baseline assessment time point.~Participants will receive standard oncology care. Study staff will monitor participant use of supportive care services, such as social work, psychology, psychiatry, and palliative care."
88982724|NCT04616898|Active Comparator|Diode Laser Treatment Only|Group 1: Patient 1- Laser Only This patient will present 20+, 14, 7, and 1 days prior to his/her scheduled abdominoplasty. Between 20 and 30 days prior, the patient will receive the first laser treatment on the 20+ day site 1. 14 days prior, the patient will receive laser treatment on the 14 day site 2. 7 days prior, the patient will receive laser treatment on the 7 day site 3. 1 day prior to the scheduled abdominoplasty, the patient will receive laser treatment on the 24 hour site 4.
88982725|NCT04616898|Active Comparator|Diode Laser and RadioFrequency Treatment|This patient will present 14 days and 7 days prior to his/her scheduled abdominoplasty. 14 days prior, the patient will be treated at site 1 with the laser and radiofrequency and site 3 with the laser only. 7 days prior, the patient will be treated at site 2 with the laser and radiofrequency and site 4 with the laser only.
88982726|NCT04616898|Active Comparator|Multiple Diode Treatments|These patients will present for three treatments, each four weeks apart, with the abdominoplasty scheduled four weeks following the last laser treatment. These patients will receive laser treatment every four weeks for twelve weeks on the sites labelled Multiple Tx below (sites 1 and 2) on Days -90, -60, and -30 prior to abdominoplasty. At the final treatment (Day -30), two additional diodes will be placed on the sites labelled Single Tx below (sites 3 and 4). 4 diodes total will be used at this visit. Four weeks following this last treatment, the scheduled abdominoplasty will be performed and the pannus containing the treated tissue will be excised.
89607903|NCT01429168|Experimental|Part 1: All Enrolled Participants|All participants will receive open-label etoricoxib 60 mg orally daily during Part 1.
89607904|NCT01429168|Experimental|Part 2: Etoricoxib|
89607905|NCT01429168|Placebo Comparator|Part 2: Placebo|
89607906|NCT00771160|Experimental|1|MK0476 5mg
89607907|NCT00771160|Experimental|2|MK0476 10mg
89607908|NCT00756418|Experimental|1|
89607909|NCT00756418|Active Comparator|2|
89607910|NCT00615472|Experimental|Group 1|Inhaled Anesthesia - isoflurane
89607911|NCT00615472|Experimental|Group 2|Intravenous Anesthesia - propofol, remifentanil
89607912|NCT00615784|Experimental|A|
89607913|NCT00755794|Experimental|1|Montelukast
89607914|NCT00652444|Experimental|1|Coadministration arm: simvastatin 20mg and ezetimibe 10mg
89607915|NCT00652444|Experimental|2|Monotherapy arm: simvastatin 20mg and ezetimibe placebo
89607916|NCT00585910|Experimental|1|Total treatment period is 7 weeks. Atomoxetine treatment will be initiated and maintained for 4 weeks. If the subject is a partial responder to atomoxetine treatment, OROS methylphenidate will then be added to his or her treatment regimen for the final 3 weeks of the study.
89607917|NCT00617188|Experimental|Fulvestrant|Fulvestrant 500 milligrams (mg) Day 1; 250 mg Day 1, 29 and every 28 days thereafter.
89607918|NCT00618436|Active Comparator|Levetiracetam|Group 1 - The levetiracetam (Keppra®) group will receive a loading dose of 20 mg/kg IV over 15 minutes (rounded to the nearest 250mg) up to a maximum of 2000 mg, then started on maintenance dose (1000 mg, IV BID)as prophylaxis for 7 days.
89607919|NCT00618436|Active Comparator|Phenytoin|Group 2-The phenytoin group will receive a loading dose of 20 mg/kg IV to a maximum of 2000mg, then started on maintenance dose at 5 mg/kg/day (rounded to nearest 100mg dose, IV, divided into three doses a day) as prophylaxis for 7 days. Phenytoin levels are to be checked daily and dose adjusted as needed to maintain therapeutic levels of 10-20 µg/dL.
89607920|NCT04345900|Experimental|20 mg/m^2 Plinabulin|Docetaxel + 20 mg/m^2 Plinabulin
89607921|NCT04345900|Experimental|10 mg/m^2 Plinabulin|Docetaxel + 10 mg/m^2 Plinabulin
89607922|NCT04345900|Experimental|5 mg/m^2 Plinabulin|Docetaxel + 5 mg/m^2 Plinabulin
89607923|NCT04345900|Active Comparator|6 mg Pegfilgrastim|Docetaxel + 6 mg Pegfilgrastim
89607924|NCT00619060|Experimental|Myristyl (right), Placebo (Left)|Participants apply topical myristyl nicotinate to the right forearm and topical placebo to the left forearm once daily for 4 weeks; Myristyl (Right), Placebo (Left) Topical Myristyl Nicotinate Cream and Placebo
89607925|NCT00619060|Experimental|Myristyl (Left), Placebo (Right)|Participants apply topical myristyl nicotinate to the left forearm and topical placebo to the right forearm once daily for 4 weeks; Myristyl (Left), Placebo (Right)Topical Myristyl Nicotinate Cream and Placebo
89032839|NCT02924454|Experimental|Metoprolol - normal saline|intervention 1: metoprolol intervention 2: Sodium chloride 0.9% solution - lipid emulsion dummy
89210406|NCT00643916|Experimental|Vaccinated at Age 9 and 12 Months|Participants received Menactra® vaccine at 9 and 12 Months of age
89607926|NCT00619684|Experimental|Treatment (lenalidomide)|Patients receive lenalidomide PO on days 1-21. Courses repeat every 28 days for 2 years or longer in the absence of disease progression or unacceptable toxicity.
89607927|NCT01799122|Active Comparator|Precise sling vs TVT-O sling|
89607928|NCT00620698||ALS patients|Patients with clinically established amyotrophic lateral sclerosis
89607929|NCT05246956|Experimental|Intradialytic exercise in hemodialysis patients ( Experimental Group)|Intradialytic exercise group
89607930|NCT05246956|No Intervention|Control Group|No intervention
89607931|NCT05246800|Experimental|Experimental group|a structured 8-week mHealth mindfulness program.
89607932|NCT05246800|No Intervention|Control group|The control group was suggested to read the information about stress and burnout on the website of the TV-programme.
89607933|NCT00588406|Experimental|B|Budesonide, 2mg, 4 doses, plus standard care
89607934|NCT00588406|Placebo Comparator|P|Placebo plus standard care
89607935|NCT00668434|Experimental|Prednisone|Participants will receive a 15-day tapering course of prednisone capsules.
89607936|NCT00668434|Placebo Comparator|Placebo|Participants will receive a 15-day course of placebo capsules.
89607937|NCT00668902|Experimental|EM of CYP2C19|CYP2C19 enzyme activity in extensive metabolizers of CYP2C19 (CYP2C19*1/*1 genotype, or wild type) was measured by 13C)Pantoprazole breath test.
89607938|NCT00668902|Experimental|IM of CYP2C19|CYP2C19 activity in heterozygous for deficient CYP2C19 alleles (*2 and *3, IM of CYP2C19) was measured by (13C)Pantoprazole breath test.
89607939|NCT00668902|Experimental|PM of CYP2C19|Homozygous for CYP2C19 null alleles (*2/*2, *2/*3 or *3/*3, Poor metabolizers) was measured by (13C)Pantoprazole breath test.
89607940|NCT00669214|Experimental|Efalizumab|
89607941|NCT00669214|Placebo Comparator|Placebo|
89607942|NCT00589888|Active Comparator|Intralipid 20%@ 20cc/hour|Intralipid 20% IV infusion at 20cc/hour
89607943|NCT00589888|Active Comparator|Intralipid 20% @ 40cc/hour|Intralipid 20% IV infusion at 40cc/hour
89607944|NCT00589888|Placebo Comparator|Normal Saline infusion @ 40cc/hour|Normal Saline continuous IV infusion at 40cc/hour for 8 hours
89607945|NCT00589888|Active Comparator|32-gram oral fat load|32-gram oral fat load once
89607946|NCT00589888|Active Comparator|64-gram oral fat load|64-gram oral fat load once
89607947|NCT00669682||Group A|The study group will include Class III to IV heart failure patients followed in the device clinic that have a chronically implanted (more than 90 days) Medtronic biventricular defibrillator with the ability to monitor intrathoracic impedance.
89607948|NCT00669916|Experimental|AIN457|AIN457A 3mg/kg was administered intravenously as a single dose.
89607949|NCT00669916|Placebo Comparator|Placebo|Placebo was administered intravenously as a single dose.
89607950|NCT00621946|Placebo Comparator|Placebo|Placebo Matching Escitalopram given orally daily (for a 12-week duration).
89607951|NCT00621946|Active Comparator|Escitalopram|Once daily oral administration (for a 12-week duration) of 10 mg escitalopram tablets with an increase to 20 mg in those with a less than 30% decrease in HAM-D scores at week 4.
89607952|NCT00591760|Experimental|GH|Patients will receive 6 months of substitutive somatotropin (growth hormone) therapy at a dose of 0.012 mg/kg every second day, added to their background optimized CHF therapy
89607953|NCT00591760|No Intervention|Placebo|PLacebo will be admistred with the same devices of GH, also on top of Optimal CHF treatment
89607954|NCT00623506|Active Comparator|1|Pregnenolone
89607955|NCT00623506|Placebo Comparator|2|Placebo
89607956|NCT02139358|Experimental|Dose Escalation / Phase II Treatment|Single arm, non-randomized, open label phase I/II multisite Simon two stage minimax trial. Gemcitabine plus trastuzumab and pertuzumab.
89607957|NCT02140372|Experimental|Volunteer group|Baseline blood draw followed by colchicine followed by blood draw 2 hours and 24 hours later
89607958|NCT00624442|Experimental|Cohort 1|4 treatment periods with a 2 hour infusion. The 4 treatment periods consist of 3 escalating dose levels of CK-1827452 and 1 placebo treatment randomized into the dose escalation sequence. Treatment periods occur at least 7 days apart.
89607959|NCT00624442|Experimental|Cohort 2|4 treatment periods with a 2 hour infusion. The 4 treatment periods consist of 3 escalating dose levels of CK-1827452 and 1 placebo treatment randomized into the dose escalation sequence. Treatment periods occur at least 7 days apart.
89607960|NCT00624442|Experimental|Cohort 3|4 treatment periods with a 24 hour infusion. The 4 treatment periods consist of 3 escalating dose levels of CK-1827452 and 1 placebo treatment randomized into the dose escalation sequence. Treatment periods occur at least 7 days apart.
89607961|NCT00624442|Experimental|Cohort 4|4 treatment periods with a 24 hour infusion. The 4 treatment periods consist of 3 escalating dose levels of CK-1827452 and 1 placebo treatment randomized into the dose escalation sequence. Treatment periods occur at least 7 days apart.
89607962|NCT00624442|Experimental|Cohort 5|2 treatment periods with a 72 hour infusion. The 2 treatment periods are randomly assigned and consist of 1 dose level of CK-1827452 (with dose de-escalation possible depending on tolerability) and 1 placebo treatment. Treatment period 2 occurs at least 7 days after the conclusion of period 1.
89607963|NCT00670462|Active Comparator|Standard Behavioral Treatment (SBT)|"Standard Behavioral Treatment (SBT) for weight loss intervention introduces a core set of instructions on diet and exercise at the beginning of the intervention and then embellishes these instructions with suggested refinements of behavioral choices over time (e.g., different menus and amounts or types of physical activity)."
89607964|NCT00670462|Experimental|Maintenance-Tailored Treatment (MTT)|"Maintenance-Tailored Treatment (MTT) for weight loss intervention treats diet and exercise strategy embellishments as separate interventions with discrete and independent status. MTT differs from SBT in its emphasis on skills for long-term weight control, namely, the strategy of initiating varied weight-control strategies as a response to the demands of changing environmental challenges and to sustain effective cues and reinforcements needed to motivate weight-loss behaviors."
89607965|NCT00670774|Experimental|Eculizumab|Patients received eculizumab intravenously according to details provided in the intervention description.
89607966|NCT00672100|Active Comparator|A|Initial Bolus 5 ml Ropivacaine
89607967|NCT00672100|Active Comparator|B|Initial Bolus 10 ml Ropivacaine
89607968|NCT00672100|Active Comparator|C|Initial Bolus 20 ml Ropivacaine
89607969|NCT00593866|Experimental|Radiation Dose Escalation with Gemcitabine|"INTENSITY MODULATED RADIOTHERAPY~Radiation dose escalation:~Total dose Dose per fraction BED* Dose equivalent (1.8 Gy/fraction) Level 1 45.0 1.8 53.1 45.0 Level 2 50.0 2.0 60.0 50.4 Level 3 52.5 2.1 63.5 54.0 Level 4 55.0 2.2 67.1 57.0 Level 5 57.5 2.3 70.7 60.0 Level 6 60.0 2.4 74.4 63.0 Level 7 62.5 2.5 78.1 66.2 Level 8 65.0 2.6 81.9 69.4~BED=Biological Effective Dose; =10 Five fractions weekly, fraction size determined by dose level~Gemcitabine:~1000mg/m2 will be infused over 100 minutes on days 1, 8, 22 and 29 of the radiation treatment"
89607970|NCT00624910|Experimental|1|A total of three 5 × 5-cm bupivacaine sponges implanted at specified layers in the wound prior to wound closure
89607971|NCT00624910|Placebo Comparator|2|A total of three 5 × 5-cm collagen sponges implanted at specified layers in the wound prior to wound closure
89607972|NCT00624910|No Intervention|3|The patient will recieve the standard of care, but no implant during surgery
89607973|NCT00594022|Active Comparator|"Group 1- VirtuSom - Stim"|Normal sleepers (7.5 - 9.0 hours), MSLT (multiple sleep latency test) >=14 min; phase-advance 5-hours studied under full polysomnogram (PSG) with active device (electric stimulation of the Vestibular nerve).
89607974|NCT00594022|Placebo Comparator|"Group 2- VirtuSom- Sham"|Normal sleepers (7.5 - 9.0 hours), MSLT >=14 min; phase-advance 5-hours studied under full polysomnogram (PSG) with placebo / sham device (NO electric stimulation of the Vestibular nerve).
89607975|NCT00626626|Experimental|"Clofar, Cyclophos, Alemtuzumab"|"Phase 1: 1-3 patients will be treated in order to establish Cyclophosphamide and Clofarabine dose and to confirm reasonable safety and engraftment efficacy.~Drug - Clofarabine,Cyclophosphamide & Alemtuzumab - Clofar (30mg/m2) D -8 to -4; Cyclo (500mg/m2) D -8 & -7 & Alem (20mg over 2hrs)"
89607976|NCT00626626|Experimental|"Clofar, Cyclophos,Alemtuzumab(Ph II)"|"Phase II patients 4-9 will treat at the selected dose level of Clofarabine and Cyclophosphamide.~Drug - Clofarabine, Cyclophosphamide & Alemtuzumab Clofar (30mg/m2) D -8 to -4; Cyclo (1000mg/m2) D -8 & -7 & Alem (20mg)-pts."
89607977|NCT00673114|Other|Transplant Recipients|
89607978|NCT00626782|Experimental|A: Ranibizumab 0.5mg (0.05mL) injection|Ranibizumab 0.5mg (0.05mL) injection at end of trabeculectomy surgery. This intra-operative adjunct therapy was administered sub-conjunctivally 8-10mm posteriorly to the limbus as an antifibrotic agent.
89607979|NCT00626782|Active Comparator|B: Mitomycin C 0.4 mg/ml sponge|Mitomycin C 0.4 mg/ml soaked sponge applied to sclera (for up to 2 min) after flap is made during trabeculectomy surgery. This is the typical method used as an antifibrotic agent.
89607980|NCT00594256|Experimental|Sodium oxybate|Active treatment
89607981|NCT00595114||MIA 1|Participants from the MIA trial who are polymerase chain reaction (PCR) negative and have received treatment with placebo
89607982|NCT00595114||MIA 2|Participants from the MIA trial who are PCR negative and have received treatment with the antibiotic clarithromycin
89607983|NCT00595114||MIA 3|Participants from the MIA trial who are PCR positive and have received treatment with placebo
89607984|NCT00595114||MIA 4|Participants from the MIA trial who are PCR positive and have received treatment with the antibiotic clarithromycin
89607985|NCT00595114||LEUKO 1|Participants from the LEUKO trial who have received treatment with placebo
89607986|NCT00595114||LEUKO 2|Participants from the LEUKO trial who have received treatment with zileuton
89607987|NCT00627406|Experimental|A|More than 14 follicles with a diameter of > 11mm: triggering of ovulation with 0.5 mg GnRHa (Buserelin) (s.c.) + 1500 IU hCG (Pregnyl)
89032840|NCT02924454|Experimental|Normal saline-Lipid emulsion|intervention 1: Sodium chloride 0.9% solution - metoprolol dummy intervention 2: intravenous lipid emulsion
89032841|NCT02924454|Experimental|Normal saline-normal saline|intervention 1: Sodium chloride 0.9% solution - metoprolol dummy intervention 2: Sodium chloride 0.9% solution - lipid emulsion dummy
89607988|NCT00627406|Active Comparator|B|More than 14 follicles with a diameter of > 11mm: triggering of ovulation with hCG (Pregnyl) 5.000 IU (s.c.)
89607989|NCT00627406|Experimental|C|14 or less follicles with a diameter of > 11mm: triggering of ovulation with 0.5 mg GnRHa (Buserelin) (s.c.) + 1500 IU hCG (Pregnyl) (s.c.) at 35 hours and 1500 IU hCG (Pregnyl) (s.c.) 7 days after triggering of ovulation (OPU + 5)
89607990|NCT00627406|Active Comparator|D|14 or less follicles with a diameter of > 11mm: triggering of ovulation with 5000 IU hCG (Pregnyl) (s.c.)
89607991|NCT00673738|Experimental|Cetuximab Plus Radiotherapy|Concurrent Cetuximab plus Conformal Thoracic Radiotherapy (CTRT). Patients were treated with definitive radiotherapy (70 Gy in 35 fractions, per our currently-existing institutional standard) with concurrent cetuximab followed by 3 cycles of consolidation docetaxel plus cetuximab.
89607992|NCT00674206|Experimental|Gemcitabine and Oxaliplatin|All patients enrolled on clinical trial will receive Gemcitabine 1000mg/m^2 on Day 1 and Oxaliplatin 100 mg/m^2 intravenously over 2 hours on Day 2.
89607993|NCT00595270|Other|IC51|In study IC51-305, subjects who had received IC51 in study IC51-304 were tested for seroconversion 6 months after the first vaccination. Subjects who had protective titers were again tested for persistence of immunity at 12 months after the first immunization,whereas subjects who had titers below the seroconversion threshold by Month 6 received a booster dose of 1x6 mcg IC51 at Month 11. Their immune response was also assessed at Month 12. Thereafter, subjects who had no protective titer by Month 12 received a booster dose of 1x6 mcg IC51 at Month 23, regardless of prior treatment; and neutralizing antibody titers were reassessed at Month 24. Subjects who had protective titers at month 12 did not receive a booster at Month 23, and their neutralizing antibody titer was also assessed at Month 24.
89607994|NCT00628498|Experimental|Defibrotide|Defibrotide 25 mg/kg day given in 4 divided doses approximately every 6 hours
89607995|NCT00629122|Experimental|A: Tacrolimus and Nystatin Suspension|"Administer sublingual tacrolimus 2 mg every 12 hours (subject weight < 90 kg) or 3 mg every 12 hours (subject weight > 90kg) (study day 1 - 3). Tacrolimus capsules will be opened and the contents placed under the participants tongue. Oral tacrolimus at same dose every 12 hours (study day 6 - 8). Tacrolimus capsules will be administered by mouth.~Nystatin suspension 5 mL every 12 hours (study days 1 - 3 and 6 - 8)."
89607996|NCT00629122|Experimental|B: Tacrolimus and Clotrimazole Troche|"Administer sublingual tacrolimus 1 mg every 12 hours (subject weight < 90 kg) or 2 mg every 12 hours (subject weight > 90 kg) (study day 1 - 3). Tacrolimus capsules will be opened and the contents placed under the participants tongue. Oral tacrolimus at same dose every 12 hours (study day 6 - 8). Tacrolimus capsules will be administered by mouth.~Clotrimazole troche 10 mg every 12 hours (study day 1 - 3 and 6 - 8)."
89607997|NCT00596440||1|Relatives of Cancer Patients
89607998|NCT00596440||2|Relatives of Orthopedic Patients
89032842|NCT04692038||Treatment Group|The subjects would receive forceps biopsy combined with puncture biopsy under the guidance of Augmented Reality Navigation and Radial EBUS
89032843|NCT02924337|Experimental|Imeglimin therapeutic dose|Tablet, oral, single dose
89032844|NCT02924337|Experimental|Imeglimin supratherapeutic dose|Tablet, oral, single dose
89032845|NCT02924337|Placebo Comparator|Placebo|Tablet, oral, single dose
89032846|NCT02924337|Active Comparator|Moxifloxacin|Tablet, oral, single dose (400 mg)
89032847|NCT00528515|Active Comparator|1|propofol
89032848|NCT00528515|Experimental|2|desflurane
89032849|NCT02923986|Experimental|BP1001 (varying dose) + Dasatinib|Phase 1b: BP1001 (varying dose levels) in combination with Das
89032850|NCT02923986|Experimental|BP1001 (fixed dose) + Dasatinib|Phase IIa: BP1001 (fixed dose based on Phase 1b) in combination with Das
89032851|NCT00528554|Active Comparator|A|Active laser acupuncture
89032852|NCT00528554|Placebo Comparator|B|Placebo laser acupuncture
89032853|NCT02926248|Experimental|Colchicine|Manipulation under Anesthesia (MUA) will be performed prior to 12 weeks after the index TKA. Patients will be randomized to oral colchicine 0.6 mg twice daily for 6 weeks. All patients will follow a standardized post-MUA physical therapy protocol.
89032854|NCT02926248|Placebo Comparator|Placebo|Manipulation under Anesthesia (MUA) will be performed prior to 12 weeks after the index TKA. Patients will be randomized to oral placebo twice daily for 6 weeks. All patients will follow a standardized post-MUA physical therapy protocol.
89607999|NCT00631852|Experimental|American Ginseng root|four, 250mg tablets daily 5-14 days prior to surgery
89032855|NCT02945735|Experimental|gaze-contingent|Attention modification: participants will receive gaze-contingent feedback according to their viewing patterns
89032856|NCT02945735|Placebo Comparator|non-gaze contingent|Participants will receive non-gaze-continent feedback unrelated to their viewing patterns
89032857|NCT02924025|Experimental|Case|The women in this group will receive motivational interviews approximately once every 2 weeks for half a year.
89032858|NCT02924025|No Intervention|Control|The women in this group will have the usual guidance in weightloss with a booklet on the seven health tips from the danish government. They will not be contacted ind the half year between study onset and finish.
89032859|NCT00528593|Active Comparator|1|
89032860|NCT00528632||Cholesterolosis|I. Patients with gallbladder cholesterolosis and symptomatic cholelithiasis
89608000|NCT00632632|Experimental|D-Cycloserine (DCS)|
89608001|NCT00632632|Placebo Comparator|Placebo|
89608002|NCT00633256|Experimental|Cycloserine|50 mg cycloserine
89608003|NCT00633256|Sham Comparator|Placebo|Matched placebo
89210407|NCT00643916|Experimental|Vaccinated at Age 9 and 15 Months|Participants received Menactra® vaccine at 9 and 15 Months of age
89608004|NCT00634270|Experimental|Sirolimus|"Design~Sirolimus oral solution will be administered orally BID on a continuous dosing schedule (28 days = 1 treatment course) with pharmacokinetically-guided dosing.~Disease status will be evaluated using volumetric MRI analysis at regular intervals.~The plasma pharmacokinetics and pharmacodynamics of sirolimus will be evaluated, as will pharmacogenetic polymorphisms and their influence on the metabolism of sirolimus in this patient population.~Pain reduction and quality of life outcomes will also be assessed.~Toxicity of chronic sirolimus administered will be evaluated using physical and laboratory evaluations."
89608005|NCT00635128|Experimental|BOOSTRIX-POLIO GROUP|Healthy male or female subjects aged 9 to 13 years, who were given a single booster dose of Boostrix™-Polio vaccine in the dTpa-IPV-001 (711866/001) study, additionally received a single booster dose of the Boostrix™-Polio vaccine, administered intramuscularly in the deltoid region of the non-dominant arm.
89608006|NCT00635128|Experimental|BOOSTRIX + IPV MÉRIEUX GROUP|Healthy male or female subjects aged 9 to 13 years, who were given a single booster dose of Boostrix™ and IPV Mérieux® vaccines in the dTpa-IPV-001 (711866/001) study, additionally received a single booster dose of the Boostrix™-Polio vaccine, administered intramuscularly in the deltoid region of the non-dominant arm.
89608007|NCT00676780|Experimental|ECGC Extract|Single arm for a phase II study
89210408|NCT00643916|Experimental|Vaccinated at Age 12 and 15 Months|Participants received Menactra® vaccine at Age 12 and 12 Months of age
89608008|NCT00678418|Experimental|VIVITROL® 380 mg|
89608009|NCT00678418|Placebo Comparator|Placebo|
89608010|NCT00678496|Experimental|1|CBT software delivered at home or in a primary care facility (n=12)
89608011|NCT00678496|Other|2|Treatment as usual (n=12)
89608012|NCT00599248|Experimental|1|TissueGene-C single intraarticular injection of 3x10e6 cells/joint
89608013|NCT00599248|Experimental|2|TissueGene-C single intraarticular injection of 1x10e7 cells/joint
89608014|NCT00599248|Experimental|3|TissueGene-C single intraarticular injection of 3x10e7 cells/joint
89608015|NCT00599248|Placebo Comparator|4|Placebo control single intraarticular injection
88982727|NCT04613505||Phase 1: Instrument Development|Parents will be asked to participate in a semi-structured interview with one of the researchers that will explore their attitudes toward day of surgery consent. Particular attention will be given to a) study designs, b) previous research experience, and c) previous medical experiences.
88982728|NCT04613505||Phase 2: Questionnaire Adaptation|Parents will be given approximately 5 minutes to review a questionnaire we developed using participant responses in Phase 1. After reviewing the questionnaire, participants will be asked to participate in a semi-structured interview with one of the investigators.
88982729|NCT04613505||Phase 3: Questionnaire Application & Development of Day of surgery consent Table of Guidelines|Participants will be asked to complete the questionnaire developed in Phase 2.
88982730|NCT04613505||Phase 4: Table of Guidelines Refinement|Participants will be given approximately 5 minutes to review the table of guidelines developed in Phase 3. After reviewing the guidelines, participants will be asked to participate in a semi-structured interview with one of the investigators.
88982731|NCT04583423|Experimental|MK-3655 Low Dose|MK-3655 low dose by subcutaneous (sc) injection once every 4 weeks (Q4W).
88982732|NCT04583423|Experimental|MK-3655 Middle Dose|MK-3655 middle dose by sc injection Q4W.
88982733|NCT04583423|Experimental|MK-3655 High Dose|MK-3655 high dose by sc injection Q4W.
88982734|NCT04583423|Placebo Comparator|Placebo|Matching placebo to MK-3655 by sc injection Q4W.
88982735|NCT04571385|Experimental|Part 1: AP30663|Participants will receive single dose of AP30663.
88982736|NCT04571385|Placebo Comparator|Part 1: Placebo|Participants will receive placebo matched to AP30663.
88982737|NCT04571385|Experimental|Part 2: AP30663|Participants will receive a single dose of one of the multiple dose levels of AP30663.
88982738|NCT04571385|Placebo Comparator|Part 2: Placebo|Participants will receive placebo matched to AP30663.
88982739|NCT04553146|Experimental|Interventional arm|immediate implant placement in posterior sites using a custom-made sealing socket abutment combined to alveolar ridge preservation
88982740|NCT04541446|Experimental|Residents to receive Dynamic Haptic Robotic Training|
88982741|NCT04541446|Experimental|Residents to receive Advanced Dynamic Haptic Robotic Training|
88982742|NCT04521868|Experimental|sulforaphane|The goal of the study is to investigate whether adding sulforaphane will benefit the negative symptoms and cognitive function in individuals who have schizophrenia.
88982743|NCT04521868|Placebo Comparator|placebo|The purpose of including placebo is to judge if the outcome is related to the study medication rather than other reasons.
88982744|NCT04501848||Study|parents of obstructive sleep disordered breathing (OSDB) children before and after surgical treatment
89608016|NCT00599872|Active Comparator|Ragweed Allergenic Extract|Standardized Ragweed Allergenic Extract administered via the sublingual oral route (27.6 to 77.3 Amb a 1 Units)
89608017|NCT00599872|Placebo Comparator|Placebo|Standardized Ragweed Allergenic Extract Placebo via the sublingual oral route
89608018|NCT00600340|Active Comparator|A Bev+Pac|Bevacizumab plus Paclitaxel
89608019|NCT00600340|Active Comparator|B Bev+Cap|Bevacizumab plus Capecitabine
89608020|NCT01799356|Active Comparator|moxifloxacin Group|Treatment at uPID with moxifloxacin
89608021|NCT01799356|Placebo Comparator|Ofloxacin Group|Treatment at uPID with Ofloxacin plus metronidazole
89608022|NCT00602290|Active Comparator|1 - Citalopram and placebo|Participants will take a combination of citalopram and placebo for 16 weeks
89608023|NCT00602290|Active Comparator|2 - Methylphenidate and placebo|Participants will take a combination of methylphenidate and placebo for 16 weeks
89608024|NCT00602290|Active Comparator|3 - Methylphenidate and Citalopram|Participants will take a combination of methylphenidate and citalopram for 16 weeks
89608025|NCT00636220||A, Observational|
89608026|NCT00637780|Experimental|1|Sulfasalazine delayed release tablets 30-60 mg/kg/day (divided into BID doses) for 6 days
89608027|NCT00638014|Active Comparator|1|Conventional wires only
89608028|NCT00638014|Experimental|2|Rapid Sternal Closure System supplemented with wires
89608029|NCT00680524|Experimental|Phone Based Outreach Intervention Group|Open pilot trial
89608030|NCT01799902||Male subjects with LUT predominant storage symptoms (OAB)|male subjects with Overactive Bladder Syndrome (OAB) being treated with solifenacin in monotherapy or combination
89608031|NCT01799980||Cervical mediastinoscopy|This group will undergo cervical mediastinoscopy before surgery to stage their lung cancer (procedure decided by the surgeon).
89608032|NCT01799980||Endo-bronchial ultrasound|This group will undergo endobronchial ultrasound before surgery to stage their lung cancer (procedure decided by the surgeon).
89608033|NCT00602446|Experimental|Deferasirox Treated|Includes patients that were treated with deferasirox for 6 months.
89608034|NCT00635830|Experimental|1|Open Label
89608035|NCT00638716|Experimental|1|12 weekly doses of 1.5 mg CJC-1134-PC
89608036|NCT00638716|Experimental|2|4 weekly doses of 1.5 mg CJC-1134-PC followed by 8 weekly doses of 2.0 mg CJC-1134-PC
89608037|NCT00638716|Placebo Comparator|3|12 weekly doses of placebo
89608038|NCT00602836|Experimental|PCR-Lenalidomide|Pentostatin, Cyclophosphamide, Rituximab + Lenalidomide
89608039|NCT00683020|Active Comparator|ATSM Intervention|ATSM Intervention: Automated Telephone Self-Management Support.
89608040|NCT00683020|No Intervention|WAIT LIST Control|WAIT LIST Control: six month Wait List.
89608041|NCT00683332||A|
89608042|NCT00683410||1|
89608043|NCT00639418||Participants 6 to 23 months|Pediatric influenza vaccine coverage within practicing pediatricians' offices for participants 6 to 23 months of age
89608044|NCT00639418||Participants 24 to 59 months|Pediatric influenza vaccine coverage within practicing pediatricians' offices for participants 24 to 59 months of age
89608045|NCT00639418||Participants 5 to 8 years|Pediatric influenza vaccine coverage within practicing pediatricians' offices for participants 5 to 8 years of age
89608046|NCT00639418||Participants 9 to 17 years|Pediatric influenza vaccine coverage within practicing pediatricians' offices for participants 9 to 17 years of age
89608047|NCT00640822|Experimental|Calcipotriol plus Hydrocortisone ointment|Calcipotriol plus Hydrocortisone ointment once daily for up to 8 weeks
89608048|NCT00640822|Active Comparator|Tacalcitol|Tacalcitol once daily for up to 8 weeks
89608049|NCT00640822|Placebo Comparator|Calcipotriol plus Hydrocortisone ointment vehicle|Calcipotriol plus Hydrocortisone ointment vehicle once daily for up to 8 weeks
89608050|NCT01799434|Experimental|Exercise|All participants had to run 20min on their individual anaerobic threshold
89608051|NCT00642694|Experimental|1|Escitalopram tablets (starting dose of 10 mg with a maximum dose of 20 mg daily) + Ramelteon (One 8 mg capsule at night)
89608052|NCT00642694|Placebo Comparator|2|Escitalopram tablets (starting dose of 10 mg with a maximum dose of 20 mg daily) + Matching Placebo (One capsule at night)
89608053|NCT02998294|Experimental|Respiratory monitoring group|
89608054|NCT00705874|Experimental|1|CGC-11047 in combination with Gemcitabine
89608055|NCT00705874|Experimental|2|CGC-11047 in combination with Docetaxel
89608056|NCT00705874|Experimental|3|CGC-11047 in combination with Bevacizumab
89608057|NCT00705874|Experimental|4|CGC-11047 in combination with Erlotinib
88982745|NCT04501848||Control|A group of parents to healthy children comprised the control group.
88982746|NCT04495127|Experimental|Selumetinib|
89608058|NCT00705874|Experimental|5|Cisplatin: 80 mg/m2 administered IV over 1 hour once every 28 days. CGC-11047 will be administered on Days 1, 8 and 15 of a 28 day cycle.
89608059|NCT00705874|Experimental|6|CGC-11047 in combination with 5-Flurouracil / Leucovorin
89608060|NCT00705874|Experimental|7|CGC-11047 in combination with Sunitinib
89608061|NCT00645970||Group 1|
89608062|NCT00646048|Experimental|Arm 1|This arm is for patient that receive the TriVascular Stent-Graft System.
89608063|NCT00647998|Experimental|Darbepoetin|Patients received 1mg/kg IV Darbepoetin immediately prior to surgery
89608064|NCT00647998|Placebo Comparator|Standard care|No Darbepoetin
89608065|NCT00685516|Active Comparator|Arm I - Green Tea|Patients receive 6 cups of green tea daily for 2-8 weeks in the absence of unacceptable toxicity.
89608066|NCT00685516|Placebo Comparator|Arm II - Water|Patients receive 6 cups of water daily for 2-8 weeks in the absence of unacceptable toxicity.
89608067|NCT00685516|Active Comparator|Arm III - Decaffeinated black tea|Patients receive 6 cups of decaffeinated black tea daily for 2-8 weeks in the absence of unacceptable toxicity.
89608068|NCT00686842|Experimental|VEGF Inhibitor PTC299|Single arm study - all subjects received PTC299
89608069|NCT00687076|Experimental|1|Participants will receive standard of medical care and treatment with intensive lipid modification using a statin plus Ezetimibe and Niaspan.
89608070|NCT00687076|Active Comparator|2|Participants will receive standard of medical care and treatment with standard lipid modifying medications plus placebo Ezetimibe and placebo Niaspan.
89608071|NCT00687544|Experimental|PEG-IFN + RBV|PEG-IFN + RBV therapy in previously untreated chronic HCV subjects coinfected with HIV
89608072|NCT02998060|Active Comparator|Robot-guided|Robotic guidance (SpineAssist®or Renaissance® (Mazor Robotics Ltd. Caesarea, Israel) will be used for navigation and insertion of pedicle screws.
89608073|NCT02998060|Active Comparator|Navigated|A computer-assisted method of navigation (CT- or 3D-Fluoroscopy-based) will be used for navigation and insertion of pedicle screws.
89608074|NCT02998060|Active Comparator|Freehand|Pedicle screws will be inserted using the freehand technique under fluoroscopic control.
89608075|NCT02143648|Experimental|nalbuphine HCl ER 60mg|nalbuphine HCl ER tablets 60 mg BID
89608076|NCT02143648|Experimental|nalbuphine HCl ER 120mg|nalbuphine HCl ER tablets 120 mg BID
89608077|NCT02143648|Placebo Comparator|Sugar pill|Placebo tablets BID
89608078|NCT02997982|Experimental|Valaciclovir treatment|Valaciclovir 500Mg Tablet
89608079|NCT00689260|Active Comparator|1 - Log Aware|Dose Log Aware (patient is aware that the device records their injection information) Half the subjects in the log aware arm will complete a diary. The other half in the log aware arm will not complete the diary.
89608080|NCT00689260|Active Comparator|2 - Log Unaware|Dose Log Unaware (patient is not aware that the device records their injection information) Half the subjects in the log unaware arm will complete a diary. The other half in the log unaware arm will not complete the diary.
89608081|NCT00689572|Experimental|Ondansetron|Ondansetron + Cognitive Behavioral Therapy + Brief Behavioral Enhancement Therapy
89608082|NCT00689572|Placebo Comparator|Placebo|Placebo + Cognitive Behavioral Therapy + Brief Behavioral Enhancement Therapy
89608083|NCT01840579|Experimental|Pembrolizumab 2 mg/kg|In Part A, participants receive intravenous (IV) Pembrolizumab 2 mg/kg on Day 1 of Cycle 1 (28 days), Cycle 2 and any additional cycles (14 days).
89608084|NCT01840579|Experimental|Pembrolizumab 10 mg/kg|In Part A, participants receive IV Pembrolizumab 10 mg/kg on Day 1 of Cycle 1 (28 days), Cycle 2 and any additional cycles (14 days).
89608085|NCT01840579|Experimental|Pembrolizumab+Cisplatin/Pemetrexed|In Part B, participants receive IV Pembrolizumab 200 mg + IV Cisplatin 75 mg/m^2 + IV Pemetrexed 500 mg/m^2 on Day 1 of each 21-day cycle for a maximum of 4 cycles. After completion of the initial therapy, maintenance therapy with IV pemetrexed in combination with IV pembrolizumab is permitted per standard of care, followed by IV pembrolizumab 200 mg every 3 weeks.
89608086|NCT01840579|Experimental|Pembrolizumab+Carboplatin/Pemetrexed|In Part B, participants receive IV Pembrolizumab 200 mg + IV Carboplatin Area Under The Curve (AUC) 5 mg/mL/minute + IV Pemetrexed 500 mg/m^2 on Day 1 of each 21-day cycle for a maximum of 4 cycles. After completion of the initial therapy, maintenance therapy with IV pemetrexed in combination with IV pembrolizumab is permitted per standard of care, followed by IV pembrolizumab 200 mg every 3 weeks.
89608087|NCT01840579|Experimental|Pembrolizumab+Carboplatin/Paclitaxel|In Part C, participants receive IV Pembrolizumab 200 mg + IV Carboplatin AUC 6 mg/mL/minute + IV Paclitaxel 200 mg/m^2 on Day 1 of each 21-day cycle for a maximum of 4 cycles. After completion of the initial therapy, maintenance therapy with IV pembrolizumab 200 mg every 3 weeks.
89608088|NCT01840579|Experimental|Pembrolizumab+Carboplatin/Nab-paclitaxel|In Part C, participants receive IV Pembrolizumab 200 mg + IV Carboplatin AUC 6 mg/mL/minute on Day 1 of each 21-day cycle + IV Nab-paclitaxel 100 mg/m^2 on Days 1, 8, and 15 of each 21-day cycle for a maximum of 4 cycles. After completion of the initial therapy, maintenance therapy with IV pembrolizumab 200 mg every 3 weeks.
89608089|NCT01840579|Experimental|Pembrolizumab+Ipilimumab|In Part D, participants receive IV Pembrolizumab 200 mg on Day 1 of each 21-day cycle + IV Ipilimumab 1 mg/kg on Day 1 of every other 21-day cycle (every 42 days) for a maximum of 18 cycles of Ipilimumab (35 doses of Pembrolizumab).
89608090|NCT01840579|Experimental|Pembrolizumab+Cisplatin/Etoposide|In Part E, participants receive IV Pembrolizumab 200 mg + IV Cisplatin 75 mg/m^2 on Day 1 of each 21-day cycle + IV Etoposide 100 mg/m^2 on Days 1, 2, and 3 of each 21-day cycle for a maximum of 4 cycles. After completion of the initial therapy, maintenance therapy with IV pembrolizumab 200 mg every 3 weeks.
89608091|NCT01840579|Experimental|Pembrolizumab+Carboplatin/Etoposide|In Part E, participants receive IV Pembrolizumab 200 mg + IV Carboplatin AUC 5 mg/mL/minute on Day 1 of each 21-day cycle + IV Etoposide 100 mg/m^2 on Days 1, 2, and 3 of each 21-day cycle for a maximum of 4 cycles. After completion of the initial therapy, maintenance therapy with IV pembrolizumab 200 mg every 3 weeks.
89608092|NCT01840579|Experimental|Pembrolizumab+Cisplatin/Etoposide+G-CSF|In Part E, participants receive IV Pembrolizumab 200 mg + IV Cisplatin 75 mg/m^2 on Day 1 of each 21-day cycle + IV Etoposide 100 mg/m^2 on Days 1, 2, and 3 of each 21-day cycle for a maximum of 4 cycles + lasting granulocyte colony-stimulating factor (G-CSF) (pegfilgrastim) 3.6 mg on Day 4 of Cycle 1. After completion of the initial therapy, maintenance therapy with IV pembrolizumab 200 mg every 3 weeks.
89608093|NCT00690040|Active Comparator|1|Ripening of the unfavorable cervix is done with Single balloon catheter (Foley catheter)
89608094|NCT00690040|Active Comparator|2|Ripening of the unfavorable cervix is done with double balloon catheter (Atad catheter)
89608095|NCT00690274|Placebo Comparator|Placebo|Volunteers are given Placebo, up to 20mg per day
89608096|NCT00690274|Active Comparator|BF2.649|Volunteers are given BF2.649, up to 20mg per day
89608097|NCT00650260|Experimental|vH2 System Group|The vital heat vH2 system consists of a Control Unit containing the heating system and the vacuum generation pump which connects via an umbilical containing the fluid and vacuum tubing to the Warming Sleeve. The Control Unit also contains the user interface and alarm management systems. The disposable Warming Sleeve consists of a manifold attached to the warming pads and a polyurethane pouch (Vacuum Sleeve) that are placed over the patient's hand and forearm and secured with tape. The Warming Sleeve manifold contains connectors for the fluid and vacuum tubing contained in the umbilical. The vital heat vH2 System will be used for patient warming during these surgical procedures. Monitoring of core temperature via esophageal probe will be done for the purpose of data collection.
89608098|NCT00650260|Active Comparator|Control Group|The Bair Hugger system is the current standard of care at Tampa General Hospital. It consists of a Temperature Management Unit that contains the heating element, the air circulating motor and the temperature control mechanisms. This unit connects via a hose to the operating room blankets. The Bair Hugger technology relies on heated air convection. Warm air is circulated evenly through the air space in the specially designed blanket, warming the skin surface as well as any insulating blankets placed over the Bair Hugger blanket. The Bair Hugger System is the site's current approach to patient warming during these surgical procedures. Monitoring of core temperature via esophageal probe will be done for the purpose of data collection.
89608099|NCT00651040|Active Comparator|Prednison|"Prednisone will be administered orally, initially at 1.0 mg/kg/day dosage and then tapered gradually equally in the two arms.~ARM 1 has only Prednisone"
88982747|NCT04475536||Coronary Artery Disease (CAD)|
89210409|NCT00643916|Experimental|Vaccinated at Age 15 Months|Participants received Menactra® vaccine at 15 Months of age
89210410|NCT00643916|Experimental|Vaccinated at Age 18 Months|Participants received Menactra® vaccine at 18 Months of age
89210411|NCT00643916|Active Comparator|Vaccinated at Age 3 Years to <6 Years|Participants received Menomune® vaccine at Age 3 years to <6 years of age
89210412|NCT00895362|Experimental|Erlotinib + Cetuximab|Erlotinib in Combination with Cetuximab
89210413|NCT02538978|Experimental|Device Arm|Device arm subjects will receive an intra-operative point of care aspiration, preparation and intramuscular injection of autologous bone marrow concentrate (aBMC) into the afflicted lower index limb.
89210414|NCT02538978|Placebo Comparator|Placebo Arm|Placebo arm subjects will undergo an intra-operative point of care aspiration and preparation of bone marrow via the investigational device exactly as the Treatment Arm. However, instead of receiving the dosing with the aBMC device output, they will receive an intramuscular injection of diluted autologous peripheral blood into the afflicted lower index limb.
89608100|NCT00651040|Active Comparator|Prednison + methotrexate|MTX will be administered orally (in case of oral intolerance intramusculary (i.m.)), once weekly for 48 weeks. There will be a clinically oriented dose escalation starting from 10 up to 20-25 mg of MTX. Five to ten mg of folic acid will be given 24 hours after each methotrexate dose.
89608101|NCT01184950|Experimental|Trainer Curriculum|
89608102|NCT01184950|No Intervention|No Curriculum|
89608103|NCT02997748|No Intervention|Observational group|No intervention, standard care
89608104|NCT02997748|Sham Comparator|Sham RIPC|Three cycles of 5- min upper limb sham ischemia
89608105|NCT02997748|Experimental|RIPC-Group 1|Three cycles of 5- min upper limb ischemia
89608106|NCT02997748|Experimental|RIPC-Group 2|Three cycles of 7-min upper limb ischemia
89608107|NCT02997748|Experimental|RIPC-Group 3|Three cycles of 10-min upper limb ischemia
89608108|NCT02997748|Experimental|RIPC-Group 4|Three Cycles of 5-min upper limb ischemia. If there is no response this will be followed by 2 cycles of 10-min upper-limb ischemia
89608109|NCT00654784|Experimental|1|
89608110|NCT00654784|Placebo Comparator|2|
89608111|NCT02997514|Active Comparator|Intensive Solution Focused Coaching|Participants will engage in 5 solution focused coaching sessions, each up to 60 minutes in duration
89608112|NCT02997514|Active Comparator|Solution Focused Coaching|Participants will engage in 1 solution focused coaching session up to 60 minutes in duration
89608113|NCT01799824|Experimental|Active|ANT-1403
89608114|NCT01799824|Placebo Comparator|Vehicle|Vehicle
89608115|NCT04387396|Experimental|Physiotherapy|Exercise intervention will be applied to this arm.
89608116|NCT04387396|No Intervention|Control|No intervention will be made to this arm, only evaluations will be made.
89608117|NCT01801111|Experimental|Alectinib|Participants will receive alectinib treatment continuously starting from Day 1 Cycle 1 (in 28-day cycles) until disease progression, death, or withdrawal for any other reasons, whichever occurs first. After PD, participants without EGFR mutation will continue treatment with alectinib alone and participants with EGFR mutation will receive alectinib in combination with erlotinib as per discretion of the treating physician.
89608118|NCT00691600|Active Comparator|oral trimethoprim/sulfamethoxazole|subjects with abscesses less than 5cm will be randomized to either study med or placebo
89608119|NCT00691600|Placebo Comparator|placebo|Placebo after incision and drainage of abscess less than 5 cm.
89608120|NCT00655642|Active Comparator|Ondansetron|Ondansetron 4 mg intravenous administration
89608121|NCT00655642|Active Comparator|Metoclopramide|Metoclopramide 10 mg intravenous administration
89608122|NCT00655642|Active Comparator|Promethazine|Promethazine 10 mg intravenous administration
89608123|NCT00655642|Placebo Comparator|Saline Placebo|Volume-matched saline placebo
89608124|NCT02997436|Experimental|PAD patients|"Patients referred for vascular ultrasound investigation for suspicion of peripheral artery disease (PAD).~Intervention is measurement of microvascular response to current application on the skin by Laser speckle flowmetry"
88982752|NCT04419857|Experimental|High-calorie formula|Infant randomly assigned to high-calorie formula for 14 days
88982753|NCT04419857|No Intervention|Standard calorie formula|Infant randomly assigned to standard-calorie formula for 14 days
88982754|NCT04419493|Experimental|Part B: Alteplase, TPA-02 then Alteplase, TPA-05|
88982755|NCT04419493|Active Comparator|Part B: Alteplase, TPA-05 then Alteplase, TPA-02|
88982756|NCT04419493|Experimental|Part A: Alteplase, TPA-05 then Alteplase, TPA-02|Open-label
88982757|NCT04419493|Active Comparator|Part A: Alteplase, TPA-02 then Alteplase, TPA-05|
88982758|NCT04399408|Experimental|Study group|Device users
88982759|NCT04395183|Active Comparator|5-HTP + Placebo|5-hydroxytryptophan 100mg PO BID plus placebo matched to creatine monohydrate
89608125|NCT02997280|Experimental|Ruxolitinib treatment|Ruxolitinib 10 mg bid for adults and children with body weight > 40 kg, 0.15 mg/kg bid for children with body weight < 40 kg.
89608126|NCT01773967|Experimental|LGG|LGG 10^10 cfu PO bid x 5 days
89608127|NCT01773967|Placebo Comparator|Placebo|micro-crystalline cellulose PO bid x 5 days
89608128|NCT00656656|Other|Immunoadsorption/Dexamethasone/Rituximab|
89608129|NCT01773889|Experimental|Denileukin Diftitox/SC Pegylated IFNα-2A|Administration of Denileukin Diftitox Plus Subcutaneous Pegylated IFNα-2A
89608130|NCT00656968|Active Comparator|10-day concomitant therapy|esomeprazole and amoxicillin and clarithromycin and metronidazole for 10 days
89608131|NCT00656968|Experimental|10-day sequential therapy|esomeprazole and amoxicillin for 5 days, followed by esoprazole and clarithromycin and metronidazole for 5 more days
89608132|NCT00657280|Experimental|All subjects recieve Sitagliptin|All subjects are aware of what they are taking. Nobody is blinded in this study. study
89608133|NCT00692692|Experimental|DermaMatrix|experimental group with DermaMatrix acellular dermis over tissue expanders in addition to skin/soft tissue and muscle to allow for more natural appearing breast and prevention of complications
89608134|NCT00692692|Active Comparator|Standard of care|standard of care using skin/soft tissue and muscle coverage of tissue expander for breast reconstruction after mastectomy without acellular dermal matrix
89608135|NCT00693160|Experimental|Intrathecal Ketorolac|In the presence of a remifentanil infusion subject will receive a single intrathecal injection of ketorolac 2 mg Each subject will receive the topical capsaicin model for hyperalgesia and allodynia assessment.
89608136|NCT00693160|Placebo Comparator|Placebo intrathecal injection|In the presence of remifentanil the subject will receive a single intrathecal injection of placebo (preservative-free normal saline) Each subject will receive the topical capsaicin model for hyperalgesia and allodynia assessment.
89608137|NCT02997046||Pre-transplant assessment|"CTA abdominal and aortoiliac vasculature before transplantation~FeMRA abdominal and aortoiliac vasculature & CMR before transplantation"
89608138|NCT02997046||Mapping & surveillance (for fistula)|"US vascular mapping before fistula creation~6 week US fistula arm~FeMRA fistula arm/central veins & CMR before fistula creation and at 6 weeks"
89608139|NCT02997046||Mapping & surveillance (for graft)|"US vascular mapping before graft creation~6 week US graft arm~FeMRA fistula arm/central veins & CMR before graft creation and at 6 weeks"
89210415|NCT00904098|Experimental|Frovatriptan|Frovatriptan 2.5 mg oral tablet
89608140|NCT00694018|Active Comparator|Education and Standard Care|Received standard care and participated in an educational program for individuals with chronic back pain. Also received an uploading pedometer but no feedback or goals about their walking activity.
89608141|NCT00694018|Experimental|Internet Mediated Enhanced Pedometer|In addition to standard care and participating in an educational program, participants received an enhanced pedometer for uploading step information, e-mail messages with weekly step goals and access to a website that provided step goals and feedback, tailored motivational messages and on on-line community for communication asynchronously with staff and other participants.
89608142|NCT00694564|Experimental|Treatment|This an open-labeled study. All participants will be part of the treatment group and receive SAM-e. S-adenosyl methionine will be dosed as 200 mg tablets with doses ranging from 200 to 1400 mg daily.
89608143|NCT00695188|Other|Standard dose|Escalating dose
89608144|NCT00695188|Active Comparator|High dose|25 mg
89608145|NCT00658138|Experimental|Adhesive A|
89608146|NCT00658138|Active Comparator|Adhesive B|
89608147|NCT00706264|No Intervention|1|Expectant management
89608148|NCT00706264|Experimental|2|Placement of arabin pessary since 23 weeks until 37 weeks
89608149|NCT04344964||Phone consult group|Information collected prospectively on FTA patients and questionnaire (satisfaction)
89608150|NCT04344964||Face-to-face consult group|Information collected retrospectively on FTA patients
89608151|NCT00695500|Experimental|Varenicline|Varenicline tablets, 2 mg per day for 3 weeks
89608152|NCT00695500|Placebo Comparator|Placebo|Placebo tablets, 0 mg per day for 3 weeks
89608153|NCT00695578|Experimental|Biafin on left arm|Subjects were randomized to apply Biafine® to wounds on the left forearm and polysporin (standard of care) to wounds on the right forearm. Medications were applied three times a day for 4 weeks to the areas that have been treated with liquid nitrogen at the baseline visit.
89608154|NCT00695578|Experimental|Biafin on right arm|Subjects were randomized to apply Biafine to wounds on the right forearm and Polysporin to wounds on the left forearm. Medications were applied three times a day for 4 weeks to the areas that have been treated with liquid nitrogen at the baseline visit.
88982760|NCT04395183|Active Comparator|Creatine + Placebo|Creatine 5g PO qday plus placebo matched to 5-HTP
88982761|NCT04395183|Active Comparator|Creatine + 5-HTP|Creatine 5g PO qday plus 5-hydroxytryptophan 100mg PO BID
88982762|NCT04395183|Placebo Comparator|Double Placebo|Creatine-matched placebo and 5-HTP-matched placebo
88982763|NCT04394975|Experimental|Test group|Toripalimab+axitinib combination therapy. Participants receive Toripalimab 240mg intravenously every 3 weeks plus axitinib 5mg orraly twice daily.
89210416|NCT00904098|Active Comparator|Usual Care|Usual care includes the current treatment used to treat all episodes of migraine headache
89210417|NCT00904176|Active Comparator|Dapagliflozin + Warfarin|
89210418|NCT00904176|Active Comparator|Warfarin|
89210419|NCT00904176|Active Comparator|Dapagliflozin + Digoxin|
89210420|NCT00904176|Active Comparator|Digoxin|
89210421|NCT02540070|Active Comparator|Periarticular|Patients in group 1 will receive periarticular infiltration of LA mixture (100 ml) consisting of 0.3% ropivacaine, 2.5 µg/mL of epinephrine, 10 mg of morphine and 30 mg of ketorolac at the end of surgery and sham injections of saline into the motor sparing knee blocks preoperatively.
89210422|NCT02540070|Experimental|Motor free|Patients in group 2 will receive motor sparing knee blocks with 0.5% ropivacaine with 2.5 µg/mL of epinephrine, 30 mg of ketorolac and 10 mg of morphine with a total local anesthetic volume of 60 ml (300 mg). Sham injections of saline (100 ml) will be injected periarticularly at the end of surgery.
89608155|NCT01792102|Experimental|Carfilzomib and Dexamethasone|"Phase 1: Carfilzomib will be administered at an escalating dose with dexamethasone administered at 8mg.~Phase 2: Carfilzomib will be administered at the MTD determined in phase 1. Maintenance: Carfilzomib and dexamethasone will be administered in the same fashion as the previous treatment cycles, but only on days 1, 2, 15, and 16."
89608156|NCT00699010|Active Comparator|Acurox 5/30mg taken first|oxycodone HCl/Niacin 5/30mg tablets; 8 tablets per dose
89608157|NCT00699010|Active Comparator|Oxycodone 5mg taken first|oxycodone HCl 5mg tablets; 8 tablets per dose
89608158|NCT02996812|Active Comparator|Dose A|Subcutaneous injection of Dose A of Exendin (9-39)
89608159|NCT02996812|Active Comparator|Dose B|Subcutaneous injection of Dose B of Exendin (9-39)
89608160|NCT02996812|Active Comparator|Dose C|Subcutaneous injection of Dose C of Exendin (9-39)
89608161|NCT02996812|Active Comparator|Dose D|Subcutaneous injection of Dose D of Exendin (9-39)
89608162|NCT00661570|Experimental|Early feasability arm|
89608163|NCT00706810|Experimental|All participants|
89608164|NCT00661960|No Intervention|1|HIV Negative volunteers
89608165|NCT00661960|Active Comparator|2|HIV-Positive volunteers taking raltegravir in combination with two other nucleoside reverse transcriptase inhibitors (NRTI) medications
89608166|NCT00661960|Active Comparator|3|HIV-Positive volunteers taking efavirenz or any other non-nucleoside reverse transcriptase inhibitors (NNRTI) in combination with two other nucleoside reverse transcriptase inhibitor (NRTI) medications
89608167|NCT00662818|Experimental|Telcagepant 300 mg→Acetaminophen/Paracetamol 1000 mg|Participants receive up to 12 doses of telcagepant (280 mg tablet/capsule 300 mg), orally, and placebo to acetaminophen/paracetamol (APAP) (2- 500 mg dry filled capsules), orally, for up to 12 migraine attacks in Period 1 (6 weeks). Participants receive APAP and placebo to telcagepant for up to 12 doses, for up to 12 migraine attacks in Period 2 (6 weeks). The participant may take a blinded optional second dose of study medication or their own rescue medication if 2 hours after initial treatment, the participant still has a moderate or severe migraine headache or if the headache has returned.
89608168|NCT00662818|Experimental|Placebo and APAP 1000 mg→Telcagepant 300 mg|Participants receive 1 dose of placebo to APAP and placebo to telcagepant for the first migraine attack and then up to 11 doses of APAP and placebo to telcagepant for up to 11 migraine attacks in Period 1 (6 weeks). Participants receive up to 12 doses of telcagepant and placebo to APAP for up to 12 migraine attacks in Period 2 (6 weeks). The participant may take a blinded optional second dose of study medication or their own rescue medication if 2 hours after initial treatment, the participant still has a moderate or severe migraine headache or if the headache has returned.
89608169|NCT00699556|Experimental|patch+spray|Within subject design. All volunteers complete two laboratory sessions. In one session they receive nicotine patch + nicotine nasal spray.
89608170|NCT00699556|Placebo Comparator|patch+placebo spray|Within subject design. All volunteers complete two laboratory sessions. In one session they receive nicotine patch + placebo nicotine nasal spray.
89608171|NCT00700336|Experimental|Pemetrexed, Cisplatin, and CBP501: Phase 2|pemetrexed, cisplatin and CBP501
89608172|NCT00700336|Active Comparator|Pemetrexed and Cisplatin: Phase 2|pemetrexed and cisplatin
89608173|NCT00700336|Experimental|Pemetrexed, Cisplatin, and CBP501:Phase 1|MTD, which was equal to recommended dose for the Phase II part, was determined by 6 patients (3+3)
89608174|NCT02996422|Experimental|School-based water campaign|Students who attend middle and high schools in the intervention counties will receive a school-based water campaign. A sample of students from each school will complete surveys before and after the installation of the water refilling stations to measure beverage consumption, knowledge, attitudes, and self-efficacy.
88982764|NCT04394975|Active Comparator|Control group|Sunitinib monotherapy. Participants receive sunitinib 50mg orally once daily for 4 weeks and then are off treatent for 2 weeks, or once daily for 2weeks and then are off treatent for 1 week.
88982765|NCT04381910|Experimental|LY01610|LY01610(Irinotecan Hydrochloride Liposome Injection),Patients were enrolled in one to three cohorts to receive LY01610 every 2 weeks, initial 30 subjects will be included in each cohort and the number of the cases could be adjusted. Subjects will receive LY01610 start with 60 mg/m2 every 2 weeks，when the sixth subjects of the current cohort completed 14 days safety observation of the first LY01610 administration, the investigators will evaluate the ongoing dose tolerance. If the investigator and the sponsor jointly believe that other doses can provide greater potential benefits for patients while ensuring safety and benefit, other appropriate cohorts could be explored (such as 80, 90 and 100 mg/m2, etc.) Subjects will receive the LY01610 monotherapy until occurrence of progressive disease (PD), death, intolerable toxicity reaction, withdrawal of informed consent, conduct of other antitumor therapy or completion of the whole study.
88982766|NCT04380610||Pediatric SCA|We will develop a novel eGFR equation in 200 pediatric participants
88982767|NCT04380610||Adult SCA|We will develop a novel eGFR equation in 200 adult participants
89608175|NCT02996422|No Intervention|Comparison schools|A sample of students who attend middle and high schools in the comparison county, which does not receive any intervention components, will complete surveys to measure beverage consumption, knowledge, attitudes, and self-efficacy.
89608176|NCT02996422|Experimental|Community cooking classes|Adults in the same intervention counties as the school-based water campaign will enroll in group cooking classes. They will complete a baseline and two follow-up surveys to measure changes in fruit and vegetable consumption, attitudes, and self-efficacy.
88982770|NCT04350957|Experimental|Low-dose Imaging|Enrolled patients will undergo two separate dynamic contrast-enhanced MRI's, one with 25% of the contrast dose and one with 100% of the contrast dose recommended by weight. During the first visit, the subject will receive 25% of the standard dose of contrast media 0.1 mM/kg will be administered at 2 mls/second followed by the acquisition of a series of DCE images. On the second visit, the subject will receive 100% of the contrast media followed by the same imaging protocol as the one subsequent to the first contrast administration.
88982771|NCT04337723|Experimental|Intervention|Clinic participants will be taught how to do ABI testing and WIfI scoring to identify patients with PAD/DM disease for early vascular referral.
88982772|NCT04334876|Other|High Risk Healthcare Workers|At home, finger prick, antibody test.
88982773|NCT04315389||EXPERIMENTAL|OPEN LABEL USING HEALTHCARE ROBOTS IN PARALLEL (non comparison) EXPOSURE: 90 MINUTES 3 TIMES PER DAY FOR 3 DAYS, NON CONSECUTIVE
88982774|NCT04301687|Experimental|Femoral Articular Branch Block|Patients will receive an ultrasound-guided femoral articular branch block with an injection of 20ml of ropivicaine 0.5%
88982775|NCT04301687|Placebo Comparator|Placebo Block|Patients will receive an ultrasound simulation of the location of a femoral articular branch block , this is to maintain blinding. A subcutaneous injection of 1ml of normal sterile saline will be administered
88982776|NCT04267731|Placebo Comparator|Placebo|Cellulose 0.75g per day
88982777|NCT04267731|Experimental|Low dose|0.25g VMK223 per day
88982778|NCT04267731|Experimental|Middle dose|0.5g VMK223 per day
89608177|NCT01795846||monosensitized allergic rhinitis, asthma|adult patients with moderate/severe perennial allergic rhinitis and mild/moderate asthma who were monosensitized to house dust mites
89608178|NCT01795846||polysensitized allergic rhinitis, asthma|adult patients with moderate/severe perennial allergic rhinitis and mild/moderate asthma who were monosensitized to house dust mites or sensitized to at least 2 different allergens including house dust mites.
89608179|NCT00701896|Other|Healthy Control - Non-smoking|Healthy Control arm with 51 subjects who are HIV negative and do not smoke
89608180|NCT00701896|Other|Healthy Control - Smoker|Healthy Control arm, includes 50 subjects who are HIV negative and are smokers.
89608181|NCT00701896|Active Comparator|HIV Smoking Cessation Arm|Includes up to 365 subjects who are HIV positive and initiate smoking cessation
89608182|NCT00701896|Experimental|Motivational Intervention|Includes up to 100 subjects who are HIV positive, do not wish to quit smoking but are willing to undergo one-on-one Motivational Intervention
89608183|NCT01797406|Active Comparator|Air insufflation colonoscopy|Air insufflation colonoscopy is the conventional colonoscopy,which is inflating air to help searching the bowel cavity while advancing the colonoscope until reaching the cecum.All the patients were examined without sedation during the whole procedure.
89608184|NCT01797406|Experimental|Water injection colonoscopy|Water injection colonoscopy : Cut off air inflating before examination. Water was injected through the working channel to follow the intestinal cavity until reaching the caecum .All the patients were examined without sedation during the whole procedure.
89608185|NCT01839487|Experimental|Run-in Phase - PAG: PEGPH20 + Nab-paclitaxel + Gemcitabine|Participants will receive 3.0 micrograms/kilogram (mcg/kg) PEGPH20 with 125 milligrams/square meter (mg/m^2) NAB and 1000 mg/m^2 GEM as intravenous (IV) infusion. In Cycle 1 Week 1, PEGPH20 will be administered alone on Days 1 and 4 and NAB+GEM will be given on Day 2 at approximately 24 hours after first dose of PEGPH20. In Cycle 1 Weeks 2 and 3, PEGPH20 will be given twice/week on Days 8, 11, 15 and 18 and NAB+GEM will be given once/week at 2 to 4 hours after PEGPH20 administration on Days 8 and15. In Cycle 2 onwards, PEGPH20, NAB, and GEM will be given once/week on Days 1 8 and 15. NAB+GEM will be given 2 to 4 hours after PEGPH20 dose. Each cycle will be of 4-weeks with Week 4 of every cycle as a rest week (no treatment will be given). Treatment will continue until documented disease progression or unacceptable toxicity. Dexamethasone 8 mg will be given in each cycle within 2 hours prior and 8 to 12 hours after completion of each PEGPH20 infusion.
89608186|NCT01839487|Active Comparator|Run-in Phase - AG: Nab-paclitaxel + Gemcitabine|Participants will receive 125 mg/m^2 NAB and 1000 mg/m^2 GEM, as an IV infusion once weekly on Days 1, 8, and 15 of each cycle. Each cycle will be of 4-weeks (28 days) with Week 4 of every cycle as a rest week (that is; no treatment will be given). Treatment will continue until documented disease progression or unacceptable toxicity. Dexamethasone 8 mg will be given in each cycle within 2 hours prior to the beginning of each NAB infusion and 8 to 12 hours after the completion of GEM infusion.
89608187|NCT01839487|Experimental|Phase 2: Stage 1 - PAG: PEGPH20 + Nab-paclitaxel + Gemcitabine|Participants will receive 3.0 mcg/kg PEGPH20 with 125 mg/m^2 NAB and 1000 mg/m^2 GEM as an IV infusion. In Cycle 1 Week 1, PEGPH20 will be given alone on Days 1 and Day 4 and NAB+GEM will be given on Day 2 at approximately 24 hours after first dose of PEGPH20. In Cycle 1 Weeks 2 and 3, PEGPH20 will be given twice/week on Days 8, 11, 15, and 18 and NAB+GEM will be given once/week at 2 to 4 hours after PEGPH20 administration on Days 8 and 15. In Cycle 2 onwards, PEGPH20, NAB, and GEM will be given once/week on Days 1, 8, and 15. NAB+GEM will be given 2 to 4 hours after dose of PEGPH20. Each cycle will be of 4-weeks with Week 4 of every cycle as a rest week (no treatment will be given). Treatment will continue until documented disease progression or unacceptable toxicity. Dexamethasone 8 mg will be given in each cycle within 2 hours prior to the beginning and 8 to 12 hours after the completion of each PEGPH20 infusion.
89608188|NCT01839487|Active Comparator|Phase 2: Stage 1 - AG: Nab-paclitaxel + Gemcitabine|Participants will receive 125 mg/m^2 NAB and 1000 mg/m^2 GEM as an IV infusion once weekly on Days 1, 8, and 15 of each cycle. Each cycle will be of 4-weeks (28 days) with Week 4 of every cycle as a rest week (that is; no treatment will be given). Treatment will continue until documented disease progression or unacceptable toxicity. Dexamethasone 8 mg will be given in each cycle within 2 hours prior to the beginning of each NAB infusion and 8 to 12 hours after the completion of GEM infusion.
89608189|NCT01839487|Experimental|Phase 2: Stage 2 - PAG: PEGPH20 + Nab-paclitaxel + Gemcitabine|Participants will receive 3.0 mcg/kg PEGPH20 with 125 mg/m^2 NAB and 1000 mg/m^2 GEM as an IV infusion. In Cycle 1 Week 1, PEGPH20 will be given alone on Days 1 and 4 and NAB+GEM will be given on Day 2 at approximately 24 hours after first dose of PEGPH20. In Cycle 1 Weeks 2 and 3, PEGPH20 will be given twice/week on Days 8, 11, 15, and 18 and NAB+GEM will be given once/week at 2 to 4 hours after PEGPH20 administration on Days 8 and 15. In Cycle 2 onwards, PEGPH20, NAB, and GEM will be given once/week on Days 1, 8, and 15. NAB+GEM will be given 2 to 4 hours after dose of PEGPH20. Each cycle will be of 4-weeks with Week 4 of every cycle as a rest week (no treatment will be given). Treatment will continue until documented disease progression or unacceptable toxicity. Dexamethasone 8 mg will be given in each cycle within 2 hours prior to beginning and 8 to 12 hours after completion of each PEGPH20 infusion. Enoxaparin 40 mg/day or 1 mg/kg/day will be given subcutaneously (SC).
89608190|NCT01839487|Active Comparator|Phase 2: Stage 2 - AG: Nab-paclitaxel + Gemcitabine|Participants will receive 125 mg/m^2 NAB and 1000 mg/m^2 GEM as an IV infusion once weekly on Days 1, 8, and 15 of each cycle. Each cycle will be of 4-weeks (28 days) with Week 4 of every cycle as a rest week (that is; no treatment will be given). Treatment will continue until documented disease progression or unacceptable toxicity. Dexamethasone 8 mg will be given in each cycle within 2 hours prior to the beginning of each NAB infusion and 8 to 12 hours after the completion of GEM infusion. Enoxaparin 40 mg/day or 1 mg/kg/day will be given SC.
89608191|NCT00665470|Experimental|Cohort I - high dose Aldesleukin|Patients receive high-dose aldesleukin intravenous (IV) over 15 minutes every 8 hours beginning within 24 hours after peripheral blood lymphocyte (PBL) infusion and continuing for up to 5 days (maximum of 15 doses).
89608192|NCT00665470|Experimental|Cohort II - low dose Aldesleukin|Beginning within 24 hours after peripheral blood lymphocyte (PBL) infusion, patients receive low-dose aldesleukin subcutaneous (SC) once daily 5 days a week for up to 6 weeks.
89608193|NCT00665704|Experimental|Tobacco Tactics Website|Nine veteran smokers who will pilot test the Tobacco Tactics website
89608194|NCT00666406|Experimental|1|Advate rAHF-PFM
89608195|NCT00666406|Active Comparator|2|Recombinate rAHF
89608196|NCT02996344|Active Comparator|Didactic training|Behavioral; participants will view the approximately one hour Commitment to Living: Primary Care (CTL:PC) didactic training videos.
89608197|NCT02996344|Experimental|Didactics and standardized patients|Behavioral; participants will view the approximately one hour Commitment to Living: Primary Care (CTL:PC) didactic training videos plus two practice standardized patient interactions.
89608198|NCT02999152|Experimental|Total Body Irradiation|Patient suffering from a malignant blood disease that requires a total body radiation, without (or prior to) a concomitant chemotherapy, according to the following protocol: 2x2 Gray per day, for 3 days. Blood and urines samples will be performed at days 0, 1, 2 and 3 of the treatment plan.
88815184|NCT05643911|Active Comparator|Non-invasive ventilation (NIV)|In the NIV Group, patients will receive NIV for 20 minutes delivered with a naso-buccal or face mask according to the patient's tolerance. The pressure-support level will be adjusted with the aim of an expired tidal volume of 6 to 8 ml per kilogram of predicted body weight, with a positive end-expiratory pressure (PEEP) of 5 cmH2O. The FiO2 will be adjusted to maintain a SpO2 between 95% and 98%.
89608199|NCT02999152|Experimental|Partial Body Irradiation|Patient with at least one bone metastasis localized at the pelvis and requiring partial body radiation therapy without associated chemotherapy, according to the following protocol: 4 Gray per day for 5 days will perform blood and urines samples at days 0, 1, 2 and 3 after the beginning of the radiation treatment.
89608200|NCT02996188||Patients with refractory tense ascites|
89608201|NCT02996032||Heart Failure|Patients admitted to the hospital with acute decompensated heart failure expected to be hospitalized for at least 72 hours
89608202|NCT02995954|Active Comparator|Fixed|The Fixed group received one single tablet containing Perindopril/Amlodipine (Reaptan) at the appropriate dose
89608203|NCT02995954|Active Comparator|Free|The Free group, received Perindopril and Amlodipine in separate tablets at the appropriate dose
89608204|NCT01799941|Other|Nuedexta (DM 20 mg/Q 10 mg)|Single Arm, Open Label Dosing with Nuedexta (DM 20 mg/Q 10 mg)
89608205|NCT00702364|Experimental|Atomoxetine|40mg atomoxetine twice a day for 2 weeks
88815185|NCT00972374|Experimental|400 ug Brimonidine Implant|400 ug Brimonidine Tartrate Posterior Segment Drug Delivery system on Day 1 in the study eye.
88815186|NCT00972374|Experimental|200 ug Brimonidine Implant|200 ug Brimonidine Tartrate Posterior Segment Drug Delivery system on Day 1 in the study eye.
88815187|NCT00972374|Sham Comparator|Sham (no implant)|Sham Posterior Segment Drug Delivery system on Day 1 in the study eye.
89608206|NCT00702364|Placebo Comparator|placebo|Placebo twice a day for two weeks
89608207|NCT00667186|Active Comparator|Targeted Screening|"Targeted Screening~Participants approached at ED for voluntary HIV counseling and testing based on risk for HIV"
89608208|NCT00667186|Active Comparator|Routine Screening|"Routine Screening~Participants approached at ED for voluntary HIV counseling and testing regardless of established risk according to age criteria"
89608209|NCT01799239|Experimental|First Test product; then SenSura|"The subject in this arm first test the Test product The test product is a newly developed ostomy appliance with a new top film. Due to company confidentiality the product is not described in further details.~After cross-over the subject test SenSura which is CE-marked and commerical available."
88815188|NCT01689155||Study Group|Participants must have received Menactra Vaccine according to routine clinical practice.
88815189|NCT00972530|No Intervention|Activity|Normal activity without restrictions
88815190|NCT00972530|Active Comparator|immobilisation|48 hours postinjection rest
88815191|NCT01689701|Experimental|Hizikia Fusiformis extract|
88815192|NCT01689701|Placebo Comparator|Placebo|
88815193|NCT05394194||3DCRT group|In this plan, we will create plans using three dimensional conformal radiotherapy, evaluate organs at risk doses, dose homogeneity and planned target volume coverage. Then compare these parameters with the two other plans.
88815194|NCT05394194||IMRT group|In this plan, we will create plans using intensity modulated radiotherapy (IMRT), evaluate organs at risk doses, dose homogeneity and planned target volume coverage. Then compare these parameters with the two other plans.
88815195|NCT05394194||VMAT plan|In this plan, we will create plans using volumetric modulated radiotherapy (VMAT), evaluate organs at risk doses, dose homogeneity and planned target volume coverage. Then compare these parameters with the two other plans.
88815196|NCT03019094|Experimental|Treatment|Implantation of the RENOVA tibial nerve stimulation system
88815197|NCT03018626|Active Comparator|DA-EPOCH-R|DA-EPOCH-R regimen: rituximab (375 mg/m2) given intravenously (IV) on day 0, etoposide(50 mg/m2), doxorubicin(10 mg/m2) and vincristine(0.4 mg/m2) given continuous intravenously (CIV) from day 1-4(96 hours), cyclophosphamide(750 mg/m2)/dayg IV on days 5, prednisone (60 mg/m2) given orally bid on days 1 through to 5.All patients received granulocyte colony-stimulating factor (G-CSF) beginning on day 6 and continued until the ANC was more than 5 × 109/L above the nadir level. The adjustment paradigm was based on the ANC nadir in the previous cycle as previously described(Wilson, Grossbard et al. 2002)
88815198|NCT03018626|Experimental|Modified R-ACVBP|R-ACVBP regimen: rituximab (375 mg/m2) given intravenously (IV) on day 0, doxorubicin (75 mg/m2) and cyclophosphamide (1,200 mg/m2) given intravenously (IV) on day 1, vindesine (2 mg/m2) given on days 1 and 5, bleomycin (10 mg) given IV on days 1 and 5, prednisone (60 mg/m2) given orally on days 1 through to 5.
88815199|NCT05394038||CPC Cohort|A patient with chest tightness and pain during the Covid-19 outbreak.
88815200|NCT01689779|Active Comparator|Cholecalciferol|A maximum of 40 patients will receive a one-time oral dose of 100,000 IU cholecalciferol 3-7 days before their scheduled elective surgery.
88815201|NCT01689779|Placebo Comparator|Placebo|A maximum of 40 patients will receive a one-time oral sugar pill 3-7 days before their scheduled elective surgery.
88815202|NCT05388500|Active Comparator|Group A (Paclitaxel + Trastuzumab)|
88815203|NCT05388500|Experimental|Group B (Trastuzumab)|
88815204|NCT05387174|Experimental|Experimental group nursing intervention with technological support|Experimental group composed of 40 with the same characteristics as above and attending the San Antonio de Pichincha Health Center, this group will additionally receive a nursing intervention of 3 months, to reduce the risk factors of MS and improve the quality of life related to health. The nursing intervention with web application support will consist of three elements: Individual face-to-face individual Nursing Counseling, Group Education and Physical Activity sessions through virtual platform.
88815205|NCT05387174|No Intervention|Group compared regular care at the MSP Health Center|Comparison group composed of 40 women in the climacteric stage between 40 and 59 years old who have two risk factors of MS (abdominal obesity and arterial hypertension), who go to the Health Center of the People's Committee, to the group of the Hypertensive Program that receive the usual attention of the Institution on group talks, health fairs based on general topics of the disease.
88815206|NCT01691027|Experimental|Visuo-motor training for low vision|All participants undergo training on scotoma awareness, Line and Circle Tracing and Video games
88815207|NCT02159768|Experimental|Airtraq visualization|Larynx visualization with Airtraq and attached handphone
88815208|NCT03212885|Experimental|1|STN Monopolar Stimulation
88815209|NCT03212885|Experimental|2|rZI + STN stimulation
88815210|NCT00974246|Experimental|COPD, ECF residents, Advair diskus|open label treatment with Advair diskus in COPD patients
89032861|NCT00528632||Cholelithiasis|II. Patients without gallbladder cholesterolosis and with symptomatic cholelithiasis
89032862|NCT02926326|Other|Period 1 and Period 2|"Period 1 - BCT197 14mg on Day 1~Period 2 - BCT 197 14mg on Day 1 and Azithromycin 500mg on Day 1,2 and 3"
89608210|NCT01799239|Active Comparator|First SenSura, Then Test product|"The subject in this arm first test SenSura which is CE-marked and commerical available.~After cross-over the subject test the Test product The test product is a newly developed ostomy appliance with a new top film. Due to company confidentiality the product is not described in further details."
89608211|NCT02995798||Group A|T-score ≥-1
89608212|NCT02995798||Group B|-2.5<T-score<-1.0
89608213|NCT02995798||Group C|T-score≤-2.5
89608214|NCT00713284|Other|Study|All subjects who enroll in this study will be converted from their calcineurin inhibitor to sirolimus. There is no comparotor arm
89608215|NCT02995720|Experimental|1|A fixed dose combination of Fimasartan/Amlodipine/Rosuvastatin
89608216|NCT02995720|Active Comparator|2|Co-administration of Fimasartan/Amlodipine combination drug and Rosuvastatin
89608217|NCT02990728|Experimental|Mirena® + metformin|The enrolled patient is allocated to either LNG-IUS only or LNG-IUS + metformin by central randomization with study site allocation. A 90-100 days of continuous treatment before first histologic assessment of treatment response is required. The patient will receive endometrial curettage or hysteroscopic evaluation and resection of suspected lesion after 90-100 days of treatment. Patients with good response to assigned treatment will continue the treatment for another 90-100 days and second histologic assessment will be performed. Patients with poor response to assigned treatment at first assessment will receive additive oral progestin therapy, along with the assigned regimen(s) as, Oral progestin, either medroxyprogesterone acetate 500 mg daily or oral megestrol acetate 160 mg daily After a total of at least 6 months treatment period, the patient with good response at first assessment is suggested to keep the Mirena for maintenance until plan to get pregnant
89608218|NCT02990728|Active Comparator|Mirena®|The enrolled patient is allocated to either LNG-IUS only or LNG-IUS + metformin by central randomization with study site allocation. A 90-100 days of continuous treatment before first histologic assessment of treatment response is required. The patient will receive endometrial curettage or hysteroscopic evaluation and resection of suspected lesion after 90-100 days of treatment. Patients with good response to assigned treatment will continue the treatment for another 90-100 days and second histologic assessment will be performed. Patients with poor response to assigned treatment at first assessment will receive additive oral progestin therapy, along with the assigned regimen(s) as, Oral progestin, either medroxyprogesterone acetate 500 mg daily or oral megestrol acetate 160 mg daily After a total of at least 6 months treatment period, the patient with good response at first assessment is suggested to keep the Mirena for maintenance until plan to get pregnant
89608219|NCT02995486|No Intervention|Control|Standard care with only an educational pamphlet.
89608220|NCT02995486|Experimental|Intervention|Post-discharge exercise group
89608221|NCT02995564|Experimental|Social Skills Intervention|The intervention is a 16-week social skills therapy program that will consist of a 90 minute group therapy session followed by a 90 minute peer generalization session meeting once per week. Each cohort will consist of 6 adolescents with Aspergers or high-functioning autism, who will be joined by 6 typically-developing peers for the peer generalization portion. During the group therapy session young adults will discuss and watch video clips addressing social skills topics relevant to their age group. They will have a chance to practice these skills when paired with typically developing peer volunteers.
89608222|NCT04387006|Experimental|Osteopatic Manipulative Treatment (OMT)|
89608223|NCT04387006|Placebo Comparator|Manual Placebo (MP)|
89032863|NCT00528671|Active Comparator|A|Low dose oral anticoagulation, INR self-management once a week
89032864|NCT00528671|Active Comparator|B|very low dose oral anticoagulation, INR self-management once a week
89032865|NCT00528671|Experimental|C|very low dose oral anticoagulation, INR self-management twice a week
89032866|NCT02924103|Active Comparator|Right side|"All included participants serve as their own control. A bacterial swab (Eswab 481CE, Copan Diagnostics, Italy), will be introduced to both sides of the nose (to the middle meatus); on the RIGHT side by using the Contamination free bacterial swab introduction device.~The Contamination free bacterial swab introduction device is a prototype developed for clinical testing."
89032867|NCT02924103|Active Comparator|Left side|All included participants serve as their own control. A bacterial swab (Eswab 481CE, Copan Diagnostics, Italy) will be introduced to both sides of the nose (to the middle meatus); on the LEFT side using the present day clinical procedure (visually guided introduction).
89608224|NCT04386772|Experimental|PVE with coils plus TAGM|PVE with coils proximally plus TAGM distally and subsequent major hepatectomy
89608225|NCT04386772|Active Comparator|PVE with multiple coils|PVE with multiple coils and subsequent major hepatectomy
89608226|NCT02990884|Active Comparator|block and ketamine|Ilioinguinal / iliohypogastric block after ketamine atropine induction and continued with ketamine only in anesthesia
89608227|NCT02990884|Active Comparator|ketamine atropine; laryngeal mask|After ketamine atropine induction, a laryngeal mask was inserted and anesthesia administration was continued with 2 sevoflurane MAC and oxygen / air mixture and applied Ilioinguinal / iliohypogastric block.
89032868|NCT00528710|Placebo Comparator|P|Placebo Control Group
89032869|NCT02926443|Active Comparator|One-on-one Usual Physiotherapy Care (Control)|The Ctl group (n =16) will receive physiotherapy usual care treatments during a 6-week period. The Ctl group will receive 2 physiotherapy treatments (30 minutes) in the clinic per week (total of 12 treatments) as well as an individualized home exercise program (HEP). Treatments will include range of motion exercises, manual therapy treatments, modalities, and strengthening exercises, as determined by the treating physiotherapist. Specific muscle group exercises and parameters will be documented by the treating physiotherapist on a provided summary sheet.
89210423|NCT02540070|Experimental|Motor free with Dex|Patients in group 3 will receive motor sparing knee blocks with 0.5% ropivacaine with 1 µg/Kg of dexmedetomidine, 30 mg of ketorolac and 10 mg of morphine with a total local anesthetic volume of 60 ml (300 mg). Patients in group 3 will receive sham injections of saline (100 ml) periarticularly at the end of surgery.
89210424|NCT00895440||1|Diabetic patients without neuropathy
89608228|NCT02990884|Active Comparator|control group|After ketamine atropine induction, a laryngeal mask was inserted and anesthesia administration was continued with 2 sevoflurane MAC and oxygen / air mixture and Non-block, postoperative analgesia with paracetamol IV
89608229|NCT02990650|Active Comparator|Standard physical therapist|A combination of nine balance training tasks where the physical therapist provides guarding against loss of balance
89608230|NCT02990650|Experimental|standard robotic guarding|A combination of nine balance training tasks where the robotic system provides guarding against loss of balance
89608231|NCT02990650|Experimental|challenge based robotic guarding|A combination of nine balance training tasks where the robotic system provides guarding against loss of balance while the participant works at a level greater than their current balance capability
89608232|NCT02995018|Experimental|SPF evaluation|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
89608233|NCT02992990|Other|Bladder tumor biopsy|All subjects will undergo a bladder tumor biopsy followed by transurethral resection.
89608234|NCT02997592|Experimental|SpinCare|Patients with partial thickness burns treated with the SpinCare System
89608235|NCT02990494|Active Comparator|STANDARD|12-week Internet-delivered behavioral weight loss program
89608236|NCT02990494|Experimental|PREVENT|an enhanced 12-week Internet-delivered behavioral weight loss program focused on preventing future negative consequences
89608237|NCT02990494|Experimental|PROMOTE|an enhanced 12-week Internet-delivered behavioral weight loss program focused on promoting future benefits
89608238|NCT02990416|Experimental|A-dmDT390-bisFv(UCHT1)/Radiation/Pembrolizumab|A-dmDT390-bisFv(UCHT1): 2.5 µg/kg 2x x 4 days, Ionizing Radiation: single treatment on day five of 14-24 Gy to a tumor, Pembrolizumab: 2 mg/kg IV every 3 weeks
89608239|NCT02994862|Experimental|Galla Chinnesis|new Remineralizing Agent before Bonding to teeth with amelogenesis imperfecta
89608240|NCT02994862|Active Comparator|Conventional Bonding|Normal Bonding Method
88815211|NCT00974480|Experimental|Redermic|Cream was applied twice a day every day, morning and evening for 24 weeks.
88815212|NCT00974480|Active Comparator|Rejuva-A|Week 1, Rejuva-A cream was applied to face in the evening twice a week. Weeks 2 & 3, Rejuva-A cream was applied to the face in the evening three times a week. Weeks 4-24, Rejuva-A cream was applied to the face in the evening every other day. In cases of intolerance, returned to the previous dosage and remained there until the end of study. Hydrating cream was applied to the face in the morning every day for 24 weeks.
88982779|NCT04267731|Experimental|High dose|0.75g VMK223 per day
88982780|NCT04267692|Experimental|Harm Reduction Treatment Circles (HaRTC)|Participants will attend 8, weekly Harm Reduction Treatment Circles. We will not limit participants' access to other treatment or services.
88982781|NCT04252690|Experimental|Mobiderm|MOBIDERM® autofit : auto-adjustable compression stocking
88982782|NCT04242823|Other|Baseline screening cohort|This group undergoes HPV testing using self-collected swabs. Triage evaluation occurs in all women who test HPV positive which includes visual inspection with acetic acid, colposcopy and image capture for automated visual evaluation. The WLHIV in the cohort who test HPV positive at baseline but who have concurrent benign histopathology results will be invited back for re-screening at a 2-year interval, and undergo similar HPV testing and triage procedures. The WLHIV in the cohort who test HPV negative at baseline will be invited back for re-screening at a 3-year interval and undergo similar HPV testing and triage procedures.
88982783|NCT04241822|Experimental|Vestibular exercises combined with cognitive therapy|The intervention is in groups of 8-10 patients. The interventions consists of cognitive therapy, vestibular exercises and body awareness therapy, 8 group sessions
88982784|NCT04241822|Experimental|Exergaming|The intervention is individual and consist of non-immersive virtual reality exercises to improve balance
88982785|NCT04238910|Experimental|Maximizing Energy|"The Maximizing Energy (MAX) intervention consists of two weekly 30-minute sessions delivered live via the Internet using web-camera technology for 8 weeks. The interventions are delivered by occupational therapists.~The MAX intervention was developed by combining two active ingredients - Problem Solving Therapy and energy conservation strategy education. Participants engage in two introductory sessions during the first week of the intervention. During the first session in a week, participants practice the steps of MAX Intervention with a fatigue-related problem. At the end of the session, the participants identify a clearly defined action plan for solution implementation. Participants are asked to implement the solution over the next few days. The second session takes place later in the week. The interventionist reviews the problem, the identified solution, and its implementation. Participants use a workbook to support their application of the MAX Intervention."
88982786|NCT04238910|Active Comparator|Health Education|consists of two weekly 30-minute sessions delivered live via the Internet using web-camera technology for 8 weeks. The interventionist delivered health education using a variety of health related topics relevant to individuals with TBI (e.g., characteristics and prevalence of fatigue after TBI, diet and nutrition, importance of exercise, energy conservation strategies).Participants use a workbook to follow along with the interventionist during the weekly sessions.
88982787|NCT04231214|Experimental|Treatment sequence 1|Spiolto® Respimat® on Day 1 0.9% nebulized saline on Day 9 Spiolto® Respimat® from Day 10 to Day 24
88982788|NCT04231214|Experimental|Treatment sequence 2|0.9% nebulized saline on Day 1 Spiolto® Respimat® on Day 9 Spiolto® Respimat® from Day 10 to Day 24
88982789|NCT04229095|Active Comparator|Belsomra,(suvorexant)|20 mg single-dose administration given on an inpatient clinical research unit
88982790|NCT04229095|Placebo Comparator|Placebo|Placebo single-dose administration given on an inpatient clinical research unit
88982791|NCT04223141|Experimental|Study group|Robot-assisted laparoscopic resection of sigmoid colon with colorectal anastomosis constructed by the double purse-string technique
88982792|NCT04182451|Experimental|Meso Wound Matrix and Standard of Care|This is a single arm study
88982793|NCT04179149|Experimental|Environmental enrichment|Subjects randomized to the intervention condition will receive the EE intervention (social support, open spaces, novel stress relief activities) as an adjuvant to standard gynecological care consisting of hormonal, analgesic or surgical treatment as necessary according to their symptoms during the study period.
89210425|NCT00895440||2|Diabetic patients with painless neuropathy
89519189|NCT03465163|No Intervention|Recovery|Two months recovery (no stimulation) following bilateral implantation of Medtronic PC+S devices into the anterior nucleus of the thalamus and the hippocampus. Thirty second EEG snapshots will be recorded every 15 minutes
89519190|NCT03465163|No Intervention|Baseline|No stimulation, 30 second EEG snapshots recorded every 15 minutes We require a minimum of 5 seizures to occur during this phase.
89519191|NCT03465163|Experimental|Probing|"Deep Brain Stimulation Electrically stimulate the thalamus continuously at a low frequency (2Hz). Thirty second EEG snapshots recorded every 15 minutes.~We require a minimum of 5 seizures to occur during this phase."
89519192|NCT03465163|Experimental|Probe Calibrated Deep Brain Stimulation|Deep Brain Stimulation In this phase we explore 18 deep brain stimulation parameter configurations (three stimulus intensities; 3,4,5 Volts, six different frequencies; 125 130, 135, 140,145, 150 Hz) during two of the clinic visits. Each deep brain stimulation parameter configuration will be tested for 1 minute with 4 minutes between each configuration test. The probing responses will be used to optimise the deep brain stimulation parameters for each participant. This phase of the study continues for 2 months.
89519193|NCT03465163|Experimental|Open Deep Brain Stimulation|Deep Brain Stimulation During this phase the deep brain stimulation parameters may be altered from the probing optimised parameters according to patient needs.
89519194|NCT03465085|Experimental|Group I: Heparin nebulized group|Group (I): 20 patients received inhaled Unfractionated Heparin at a dose of 10000 IU/4h by nebulizer, with the total daily dose of nebulized Unfractionated Heparin 60,000 IU
89519195|NCT03465085|Experimental|Group II: Streptokinase group|Group (II): 20 patients received inhaled Streptokinase at a dose of 250,000 IU/4h by nebulizer, with the total daily dose of nebulized Streptokinase 1,500,000 IU.
88982794|NCT04179149|No Intervention|Controls|Participants randomized to the control condition will receive only standard care as necessary according to their symptoms during the study period PLUS an online patient training module.
88982795|NCT04166227|Active Comparator|Hip Arthroscopy|Patients in the Hip Arthroscopy group will undergo arthroscopy in the supine position under general anesthesia, with all procedures performed by two subspecialty-trained hip arthroscopists. An algorithmic surgical approach will be utilized to sequentially address pathology in the central and peripheral compartments of the hip based on both preoperative imaging findings and intraoperative findings. Emphasis will be placed on labral preservation and refixation, with osseous decompression under fluoroscopic guidance.
88982796|NCT04166227|Active Comparator|Total Hip Arthroplasty|Patients randomized to the Total Hip Replacement (THR) group will undergo THR via a direct anterior approach. A slightly oblique skin incision measuring approximately 8 cm will be used, starting 3 cm distally and laterally to the anterosuperior iliac spine. The intervals between tensor fascia lata (TFL) and sartorius will be developed superficially, and between rectus femoris and gluteus minimus deeper. Capsulotomy will be performed. A double osteotomy of the femoral neck will be performed to facilitate removal of the head followed by traditional preparation of the acetabulum using an offset reamer and the acetabular component will be inserted. Next, the superior capsule will be released to elevate the femur to allow access to the femoral canal, followed by standard preparation by use of an offset broach and the stem will be implanted
88982797|NCT04147611|Experimental|Remote Microphone (RM) Technology Group|"The RM technology group will limited to the pediatrics participants.~Participants will be tested separately on the three following conditions:~Bone Conduction Device (BAHA) only~BAHA + Wireless Audio-Streaming Accessory~BAHA + Digital Adaptive RM System"
88982798|NCT04147611|Active Comparator|Normal Hearing Controls|"The normal hearing controls will be limited to 15 adults.~Participants will be tested separately on the six following conditions:~Unaided~Unilateral hearing aid with contralateral plug.~Unilateral hearing aid + Digital Adaptive RM System (using Roger™, Sonova)~Bone Conduction Device (BAHA) only~BAHA + Wireless Audio-Streaming Accessory~BAHA + Digital Adaptive RM System"
88982799|NCT04128644|Other|Standard of care+Thoughts & health|12 sessions of Thoughts & Health. Baseline questionnaires and follow up assessments
88982800|NCT04128644|Other|Standard of care|Baseline questionnaires and follow up assessments, intervention as usual Student Health
88982801|NCT04126837|Other|Patient admitted for Ankle and foot injuries|Diagnosis and treatment of Ankle and foot injuries by an accelerated nursing branch in emergency department
88982802|NCT04088604|Experimental|LY01610-Dose Escalation|The starting dose was 30 mg/m2 IV and the subsequent dose was increased according to the protocol of 60 mg/m2, 90 mg/m2, 120 mg/m2, 150 mg/m2, 180mg/m2. The interval between the first dose and the second dose was 3 weeks, followed by 2 weeks.
88982803|NCT04088604|Experimental|LY01610-Dose Extension|According to the subjects' tolerance, appropriate dose will be selected and the safety, PK characteristics and initial efficacy of LY01610 were further evaluated in 6 - 8 patients. The interval between the first dose and the second dose was 3 weeks, followed by 2 weeks.
88982804|NCT04088604|Experimental|LY01610 with 5-Fu -Dose Escalation|"Dose Escalation:~Based on the results of the first stage, three doses of low, medium and high doses were selected in combination with a fixed dose of 5-Fu to determine the DLT, MTD, PK characteristics and the preliminary efficacy. 5-Fu, 400mg/m2 will be administered intravenously on days 1, followed by 600 mg/m2 given as a 22-hour continuous infusion on day 1 and 2, every 2 weeks."
88982805|NCT04088604|Experimental|LY01610 with 5-Fu -Dose Extension|"Similarly, according to the subjects' tolerance, appropriate dose will be selected and the safety, PK characteristics and initial efficacy of LY01610 combined with a fixed dose of 5-Fu were further evaluated in additional 6 - 8 patients.~In dose escalation and dose extension stages, both LY01610 and fixed dose 5-Fu will be given once every 2 weeks."
89210426|NCT00895440||3|Diabetic patients with painful neuropathy
89210427|NCT00895440||4|Diabetic patients with Charcot neuroarthropathy
89210428|NCT00895440||5|Control non-diabetic subjects
89519196|NCT03465085|No Intervention|Group III: Control group|Twenty patients whom guardian declined to participate actively in the study but accepted to participate passively by consenting for using their data were assigned as Group III or the control group and received conservative management
89519197|NCT03465007|Active Comparator|Hydrocortisone|100mg Hydrocortisone will be administered prior to hemodialysis
89519198|NCT03465007|Placebo Comparator|Placebo|100mg normal saline will be administered prior to hemodialysis
89519199|NCT03464929||Airtraq indirect laryngoscopy|Intubation attempts using Airtraq device.
89519200|NCT03464929||King Vision indirect laryngoscopy|Intubation attempts using King Vision device
89519201|NCT03461029||BIS|Group of 196 patients in whom sedation monitoring is performed using the Bispectral Index Monitoring (BIS) system.
89608241|NCT02990260|Active Comparator|Live Saccharomyces cerevisiae|Live Saccharomyces cerevisiae. 2 capsules per day (1 g).
88982806|NCT04088604|Active Comparator|Hydrochloride Injection- pharmacokinetics comparative study|After receiving the MTD of LY01610, another 8 subjects were enrolled and given Irinotecan Hydrochloride Injection（captol ®） (180mg/m2) once every 2 weeks. Upon completion of the pharmacokinetics study, the sponsor will continue to provide the study drug treatment free of charge, and the researcher will conduct treatment and examination according to the subject's situation, without collecting any safety and efficacy data of the subject.
88982807|NCT04078191|Experimental|RA Subjects on Stable Therapy|RA subjects who are on stable treatment will receive a single dose of 150 mcg tilmanocept radiolabeled with 10 mCi Tc 99m.
88982808|NCT04075253|Experimental|VO2 peak test|All participants enrolled in the planned study on physical activity and ventricular arrhythmias and on baseline will complete an exercise treadmill test to determine VO2 peak
88982809|NCT04075123||CPAP GROUP|Suggested PEEP range 5-10 cmH2O; Minimum required PEEP WILL BE 8 cm water (7 cm water if using bubble CPAP); Maximum allowable† PEEP: 12 cmH2O
88982810|NCT04075123||NIPPV GROUP|Suggested Ranges: PIP 12 to 24 cm water; PEEP 5 to 10 cm water; Rates 20-40 bpm; iTime 0.4-1.0 seconds; Minimum required settings on NIPPV: PEEP 8 cm water; Difference of pressure 6 cm water; Rate 20 bpm; Maximum allowable settings: PEEP 10 cm water; PIP 24 cm water; Rate 60 bpm
88982811|NCT04070300|Experimental|Interval training group|Aerobic interval training during 12 weeks 3 times a week.
88982812|NCT04070300|No Intervention|Control group|No lifestyle recommendations. Usual daily life.
88982813|NCT04021719||OnTrackNY LHS Participants and Stakeholders|OnTrackNY participants and stakeholders, including past participants, family members, clinicians, administrators, payors, and state leadership
88982814|NCT04013321|Experimental|Test intervention group|Chronic insomniacs will track their sleep with the SleepScore Max device and will receive feedback and coaching from the Smartphone app associated with the device.
88982815|NCT04013321|Active Comparator|Active control|Chronic insomniacs in the active control group will be tracking their sleep with the device, without feedback or coaching. But they will also undergo online cognitive behavioral therapy for insomnia (CBTi).
89210429|NCT00904254|Experimental|1, diagnostic comparison|EP 1645/Solution For Injection
89519202|NCT03460951||CIDP patients|15 patients with CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy ) who satisfy the definite CIDP criteria of the Joint Task Force of the EFNS and PNS 1 (situations A and B according to the French CIDP work group2), and who agree to undergo cervical MRI.
89519203|NCT03460951||Normal volunteers|15 healthy subjects matched for age and gender to CIDP patients
89519204|NCT03460951||Charcot-Marie-Tooth disease type 1A patients (CMT-1A)|15 CMT-1A patients (proven by genetic testing), will be included as Charcot-Marie-Tooth disease type 1A patients (CMT-1A) is one of the main differential diagnoses of CIDP characterized by the diffuse demyelination of peripheral nerves.
89519205|NCT04965337|Experimental|ASC42 Dose A|ASC42 tablet Dose A, once daily
89519206|NCT04965337|Placebo Comparator|Placebo Dose A|Placebo Comparator: Single dose of matched placebo to ASC42 tablet Dose A, once daily
89519207|NCT04965337|Experimental|ASC42 Dose B|ASC42 tablet Dose B, once daily
89519208|NCT04965337|Placebo Comparator|Placebo Dose B|Placebo Comparator: Single dose of matched placebo to ASC42 tablet Dose A, once daily
89519209|NCT03460795|Experimental|Conventional plus MSC and Tregs treatment|
89519210|NCT04452799|Experimental|expermintal|1000mg of (Hesperidin and Diosmin mixture) three times daily for 7 days 1000mg of (Hesperidin and Diosmin mixture) two times daily for 3 days
89519211|NCT04452799|Active Comparator|standard|standard care therapy in quarantine hospitals
89519212|NCT04453111|Experimental|Hyaluronic Acid (HA) + P-MMSCs|Experimental Group 1: Three intra-articular injection of allogeneic P-MMSCs up to 2•107cells (target dose up to 6•107 cells) with 20 mg Hyaluronic Acid at 4-weeks intervals - 15 patients
89519213|NCT04453111|Experimental|Hyaluronic Acid (HA) + BM-MMSCs|Experimental Group 2: Three intra-articular injection of autologous BM-MMSCs up to 2•107cells (target dose up to 6•107 cells) with 20 mg Hyaluronic Acid at 4-weeks intervals - 15 patients
89519214|NCT04453111|Active Comparator|Hyaluronic Acid (HA)|Three intra-articular injection of 20 mg Hyaluronic Acid - 15 patients
89519215|NCT03464851||Unknown/Normal/Mild Disease|No prior carotid duplex study or known normal or mild disease in the ICAs (PSV <= 125 cm/sec)
89519216|NCT03464851||Known moderate or severe ICA Stenosis (PSV>125 cm/sec)|
89519217|NCT03464851||Known ICA Fibromuscular Dysplasia|
89519218|NCT03460717|Experimental|Intervention group: PNFS-TMC|Procedure- The patients in the intervention group were examined and the most painful points over the knee with the avoidance of the proposed site for skin incision for a future knee replacement operation were marked. The marked points received an intervention in the form of application of Peripheral Nerve Field Stimulation by Thermal Micro-Cautery (PNFS-TMC), an intense heat by metal rod was applied to the painful points for 0.3 to 0.5 seconds. The patients to receive 4 sessions over a period of 8 weeks with 2 weeks rest after every session.
89519219|NCT03460717|No Intervention|Control group: Stepladder analgesics|Patients with painful knee osteoarthritis and on the waiting list for a total knee replacement surgery and declined to have PNFS-TMC were included in the control group. The control group received the stepladder analgesic protocol for pain management. The analgesic protocol was managed by the orthopaedic team without any interference by the investigators.
89519220|NCT03460639|Active Comparator|Active laser|Three points on the masseter muscle (upper, middle and lower portions) and one point on the anterior temporal on each side of the face will be irradiated with a wavelength of 780 nm, radiant exposure of 134 J/cm2, power of 50 mW and irradiance of 1.675 W/cm2 for 80 seconds per point, resulting in an energy of 4 J per point and total energy of 32 J per volunteer.20,21 Point application will be performed with a conventional tip in contact with the skin (beam spot: 0.04 cm2).
89519221|NCT03460639|Sham Comparator|Sham laser|The same procedures will be performed in the sham group, but the device will be switched off and a recording of the emission sounds will be used to give the volunteer the auditory sensation of laser therapy.
89519222|NCT03460639|Other|Control group|In this group, no treatment will be done, we will only induce fatigue, for evaluation.
89519223|NCT03464773|Other|Pathway|The PIUO Pathway is implemented by clinicians (MD and RN) with expertise in treating pain in children. Each participant proceeds through the PIUO Pathway as long as their pain persists, but will exit the PIUO Pathway at any stage in case their pain is resolved. The Pathway has two steps: Step 1 is a thorough history and patient evaluation, including directed testing. Step 2 is a series of screening tests to further explore any potential underlying disease or injury not apparent based on history and physical examination.
89519224|NCT03464773|No Intervention|Waitlist|Participants randomized to the Waitlist will cross over to the Pathway after 8 weeks.
89519225|NCT03468595|Experimental|test 1|The treatment of periodontitis was performed with ultrasonic instrumentation (Piezonmaster 700; Electro Medical Systems, Nyon, Switzerland) with CHX (Drogsan, Istanbul, Turkey, 0.2%) was performed at one session for once.
89519226|NCT03468595|Experimental|test 2|The treatment of periodontitis was performed with ultrasonic instrumentation (Piezonmaster 700; Electro Medical Systems, Nyon, Switzerland) with Listerine (Johnson & Johnson, Istanbul, Turkey, containing, 21.6% ethanol, 0.092% eucalyptol, 0.064% thymol, 0.042% menthol and 0.06% methyl salicylate) was performed at one session for once.
89519227|NCT03468595|Active Comparator|control|The treatment of periodontitis was performed with ultrasonic instrumentation (Piezonmaster 700; Electro Medical Systems, Nyon, Switzerland) with distilled water was performed at one session for once.
89519228|NCT03464695|Active Comparator|O2matic|Oxygen administered by O2matic. Automatic adjustment based on continuous measurement of SpO2.
88982816|NCT04013321|No Intervention|Passive control|Chronic insomniacs in the passive control group will track their sleep using the SleepScore Max device, but without the feedback or coaching feature.
88982817|NCT04013321|No Intervention|Healthy control|Healthy sleepers will track their sleep using the SleepScore Max device, but without the feedback or coaching feature.
88982818|NCT04006288|Active Comparator|Aspirin and clopidogrel|aspirin 81 mg/qd plus clopidogrel 75mg/qd for 30 days
89210430|NCT00905814|Other|Sequence 1 (BABA)|Treatment A: One 5-mg FCIR tablet Treatment B: Five 1-mg FCIR tablets Subjects in this sequence will participate in 4 periods in the following order: B -> A -> B -> A
89210431|NCT00905814|Other|Sequence 2 (ABAB)|Treatment A: One 5-mg FCIR tablet Treatment B: Five 1-mg FCIR tablets Subjects in this sequence will participate in 4 periods in the following order: A -> B -> A -> B
88982819|NCT04006288|Experimental|Aspirin and rivaroxaban from aspirin and clopidogrel|aspirin 81mg/qd plus rivaroxaban 2.5mg/bid for 30 days
89210432|NCT00905970||1|Patients with LTBI recently diagnosed under prophylactic chemotherapy treatment.
89210433|NCT00905970||2|Patients with LTBI recently diagnosed not following any prophylactic chemotherapy treatment.
89519229|NCT03464695|No Intervention|Manual|Oxygen administered by manual control based on nurse's intermittent measurement of SpO2.
89519230|NCT03468517|No Intervention|Control group|Standard preoperative evaluation process will continue without any intervention.
89519231|NCT03468517|Active Comparator|Bathe Group|In the comparator group of patients, Bathe method will be applied at preoperative evaluation process.
89519232|NCT04453345|Experimental|TPM regimen|thalidomide 50-100mg daily at bedtime + prednisone 0.5mg/kg qod to 1mg/kg qd + methotrexate 10mg/m2 per week. 4 months one cycle, up to 3 cycles. After get partial remission, thalidomide maintenance will continue up to 2 years.
89519233|NCT02322593|Experimental|TAS-118/Oxaliplatin|TAS-118 plus Oxaliplatin
89519234|NCT02322593|Active Comparator|S-1/Cisplatin|S-1 plus Cisplatin
89519235|NCT03464539|Other|CD patients|PG low molecular weight chitosan 3 times per day
89519236|NCT03460561|Active Comparator|TEA group|peri operative thoracic epidural block (TEA) via fentanyl-levo bupivacaine infusion.
89519237|NCT03460561|Active Comparator|RSB group|peri operative rectus sheath block (RSB) via fentanyl-levo bupivacaine infusion.
89519238|NCT03460405|Experimental|VI-DT vaccine (adults,adolescent)|1 dose of 0.5 ml Vi-DT vaccine
89519239|NCT03460405|Active Comparator|Vi polysaccharide (adults,adolescent)|1 dose of 0.5 ml Vi polysaccharide vaccine
89519240|NCT03460405|Experimental|VI-DT vaccine (children)|1 dose of 0.5 ml Vi-DT vaccine
89519241|NCT03460405|Active Comparator|Vi polysaccharide vaccine (children)|1 dose of 0.5 ml Vi polysaccharide vaccine
89519242|NCT03460405|Experimental|VI-DT vaccine (infants)|1 dose of 0.5 ml Vi-DT vaccine
89519243|NCT03460405|Active Comparator|IPV Vaccine (infants)|1 dose of 0.5 ml IPV vaccine
89519244|NCT05166005|Active Comparator|High dose|High dose Vitamin D therapy will initiate at a dosage of 50,000 IU on the first and second week of hospitalization
89519245|NCT05166005|Placebo Comparator|Low dose|Vitamin D therapy will prescribe at a dosage of 2,000 IU/day
89519246|NCT05389397|Placebo Comparator|Mailed Letter|
89519247|NCT05389397|Active Comparator|Secure Message|
89519248|NCT05389397|Active Comparator|Telephone Outreach|
89519249|NCT02522741|Experimental|Parenting STAIR|
89519250|NCT05383781|Active Comparator|Hip and Knee exercise group|Individuals in this group will perform exercises for the Hip and knee only.
89519251|NCT05383781|Experimental|Hip , Knee exercise and SFE group|Individuals in this group will perform exercises for Hip , knee and also short foot exercise
89519252|NCT03464227|Experimental|UCB0107|Subjects randomized to this arm will receive UCB0107. This arm will consist of a maximum of 7 cohorts. The dose for cohort 1 will be fixed, proposed doses for cohorts 2,3,4,5,6 and 7 may be adapted based upon recommendation by the Safety Review Group.
89519253|NCT03464227|Placebo Comparator|Placebo|Subjects randomized to this arm will receive matching Placebo to UCB0107. This arm will consist of a maximum of 7 cohorts.
89519254|NCT04877743||Prospective Cohort|This prospective cohort study will include participants who receive the AZD1222 vaccine. Enrolment is permitted within 28 days of the first dose of AZD1222 and can be completed at the vaccination site or remotely.
89519255|NCT03464149||Study Arm|"One armed study, blood from each patient is analysed by the following assays:~Intact PTH Assay (Siemens Healthcare Diagnostics Inc); LIAISON 1-84 PTH Assay (Diasorin); PTH (1-84), biointact (Roche Diagnostics); PTH, intact (Roche Diagnostics)"
89519256|NCT03936413|Experimental|Bay Labs EchoGPS group|In this arm, medical residents will use the Bay Labs EchoGPS system to perform an echocardiogram.
89519257|NCT03936413|Active Comparator|Native Terason group|In this arm, medical residents will use the native Terason machine to perform an echocardiogram.
89210434|NCT00905970||3|Patients with LTBI diagnosed time ago.
89608242|NCT02990260|Active Comparator|Yeast cell wall|Yeast cell wall. 2 capsules a day (700 mg).
89608243|NCT02990260|Placebo Comparator|Placebo|Maize starch and magnesium stearate. 2 capsules a day.
89608244|NCT02994706|Experimental|Home monitoring|Home monitoring will involve participants recording their symptoms twice weekly on a modified mobile phone and recording their lung function twice weekly using a digital spirometer. This data will be automatically transmitted to the CF team and we will contact patients on the mobile phone if symptoms and/or lung function decline below a set threshold, suggesting the onset of a pulmonary exacerbation. We will contact patients within 24 hours of symptoms and/or lung function falling below this set threshold.
89608245|NCT02994706|Active Comparator|Clinical Care|Throughout the study period, participants will attend outpatient clinic visits as usual and treatment with antibiotics as clinically indicated.
89608246|NCT02999776|Active Comparator|Standard of care|Daily self-administration of 1 to 5g Daivobet (Calcipotriol 50ug/g +Betamethasone, 0,5mg/g Gel) ointment, which is applied topically once per day for 8 weeks on one pre-selected randomized plaque.
89608247|NCT02999776|Experimental|Laser plus etanercept|Immediately following microporation of a 5 cm² area of the designated plaque with the P.L.E.A.S.E.® Professional laser, 0.0625 ml of Etanercept (50 mg/ml) solution for injection in pre-filled syringes will be applied to the microporated surface of the lesion. The treated area will then be covered with OpSiteTM Flexigrid Transparent Dressing for 4 hours. This treatment procedure will be repeated twice weekly for 8 weeks.
89608248|NCT02999776|Active Comparator|Laser alone|The Er:YAG laser induced microporation of 5 cm2 of a plaque surface, followed by application of an OpSiteTM Flexigrid Transparent Dressing for 4 hours. This treatment will also be repeated twice weekly for 8 weeks.
89608249|NCT02999698||Psoriasis Group|Patients with psoriasis complete the questionnaires for psychological impact.
89608250|NCT02999698||Hidradenitis Suppurativa Group|Patients with hidradenitis suppurativa complete the questionnaires for psychological impact.
89608251|NCT02990026|Experimental|Treatment|Specialty mental health probation - delivered by probation officers who receive specialized training and ongoing clinical consultation with a licensed mental health professional and who have reduced caseloads of exclusively mentally ill offenders.
89608252|NCT02990026|Active Comparator|Control|Standard probation - delivered by a standard probation officer - care as usual
89210435|NCT00905970||4|Positive control for the Exhaled Breath condensate assay only. Patients with active TB will conform this group. The n of this group is determined, as it will only be used as a positive control to prove the bacilli's DNA can be detected in the exhaled breath condensate.
89608253|NCT02996656|Active Comparator|Cefazolin|During an open shoulder surgery, the Cefazolin will be administered to some patient. The Cefazolin is a first generation cephalosporin. It is a beta lactam which targets gram positive cocci and some gram negative bacilli. The INESS Antibiotic Prophylaxis in Orthopedic Guide recommends the use of Cefazolin at induction for all orthopaedic procedure with implantation of internal fixation device. The dosage is 2g intravenous if the patient weights less than 120kg or 3g if the patient weights more than 120kg. The dose should be repeated if the procedure lasts for more than three hours or if the blood loss is greater than 1500mL.
89608254|NCT02996656|Experimental|Ceftriaxone|During an open shoulder surgery, the Ceftriaxone will be administered to some patient. The Ceftriaxone is a third generation cephalosporin. It targets gram positive cocci such as staphylococcus and streptococcus, gram negative bacilli and some anaerobes, including P. acnes. The prophylactic dose is of 2g IV given a minimum of 30 minutes prior to skin incision. It is effective 12h so no other dose is needed during surgery.
89608255|NCT04270162|Experimental|New intervention protocol with inspirometer|Respiratory exercises without use of inspirometerwill be taken out 50% and 80% to have it as muscle strength training values for the respiratory muscles based on the contra-relax technique)
89608256|NCT04270162|Active Comparator|Protocol of use of inspirometer in a conventional way|This gonna be a experimental group 2 with conventional use of the conventional way.
89608257|NCT04270162|Active Comparator|Respiratory exercises without use of inspirometer|This group gonna be a control group with breathing exercises without the use of inspirometer.
89608258|NCT04387630|Experimental|metformin group|"metformin 850 mg once daily increased within 3 weeks to a maximum dose of 2550 mg on three divided daily doses.~Neoadjuvant cytotoxic chemotherapy as per MDT (multi-disciplinary team) decision. Patients scheduled for AC-T (adriamycin, Cyclophosphamide, paclitaxel) or AC (adriamycin, cyclophosphamide) will be eligible to randomization."
88982820|NCT04006288|Active Comparator|Aspirin and prasugrel|aspirin 81 mg/qd plus prasugrel 10mg/qd for 30 days
88982821|NCT04006288|Experimental|Aspirin and rivaroxaban from aspirin and prasugrel|aspirin 81mg/qd plus rivaroxaban 2.5mg/bid for 30 days
88982822|NCT04006288|Active Comparator|Aspirin and ticagrelor|aspirin 81 mg/qd plus ticagrelor 60mg/bid for 30 days
88982823|NCT04006288|Experimental|Aspirin and rivaroxaban from aspirin and ticagrelor|aspirin 81mg/qd plus rivaroxaban 2.5mg/bid for 30 days
88982824|NCT04003480|Experimental|FRAME|Vein graft to be treated with FRAME
88982825|NCT03979131|Experimental|Resectable GC and GEJC+avelumab+FLOT preoperative treatment|Peri-operatory treatment consisting of four cycles (each cycle is 14 days) of neoadjuvant chemotherapy (docetaxel, oxaliplatin and fluorouracil/leucovorin) plus avelumab previous to surgery. Surgery is recommended to be scheduled 4 to 6 weeks after the last dose. Afterwards (4 to 10 weeks after surgery), four cycles of adjuvant therapy with the same schema, followed by avelumab up to one year.
88982826|NCT03978663|Experimental|Neoadjuvant radiotherapy|3 doses of stereotactic radiotherapy administered prior to neoadjuvant chemotherapy in high-risk breast cancers.
89210436|NCT00900510|Experimental|Drainage and placebo|Incision and drainage with placebo.
89210437|NCT00900510|Active Comparator|Drainage with TMP/SX|Drainage with Bactrim
89210438|NCT00904410|Experimental|1|
89210439|NCT00160693|Experimental|Certolizumab Pegol|
89210440|NCT00900588|Experimental|10 ug|10 microgram split-virion vaccine per dose
89210441|NCT00900588|Experimental|15 ug|15 microgram split-virion vaccine per dose
89210442|NCT00900588|Experimental|30 ug|30 microgram split-virion vaccine per dose
89210443|NCT00900588|Active Comparator|5 ug|5 microgram whole-virion vaccine per dose
89608259|NCT04387630|Placebo Comparator|Placebo group|placebo. Neoadjuvant cytotoxic chemotherapy as per MDT(multi-disciplinary team) decision. Patients scheduled for AC-T (adriamycin, Cyclophosphamide, paclitaxel) or AC (adriamycin, cyclophosphamide) will be eligible to randomization.
89608260|NCT04270318|Active Comparator|CH pulpotomy-control|After hemorrhage control, pulp chamber was cleansed with physiologic saline prior the CH pulpotomy.Then, canal orifices were sealed with CH (Kalsin, Aktu, Izmir, Turkey) paste (CH powder mixed with physiologic saline). After the canal orifice dressing, the chamber was based with reinforced ZOE (IRM; Dentsply Caulk, Milford, DE) and the tooth immediately restored with a stainless steel crown (SSC; 3M ESPE, Seefeld, Germany).
89608261|NCT04270318|Experimental|CH pulpotomy-NaOCl|After hemorrhage control,pulp chamber was cleansed with 5% NaOCl for 30 s prior the CH pulpotomy. Then, canal orifices were sealed with CH (Kalsin, Aktu, Izmir, Turkey) paste (CH powder mixed with physiologic saline). After the canal orifice dressing, the chamber was based with reinforced ZOE (IRM; Dentsply Caulk, Milford, DE) and the tooth immediately restored with a stainless steel crown (SSC; 3M ESPE, Seefeld, Germany).
89608262|NCT04270318|Active Comparator|MTA pulpotomy-control|After hemorrhage control, pulp chamber was cleansed with physiologic saline prior the MTA pulpotomy. Then, canal orifices were sealed with MTA (ProRoot MTA; Dentsply, Tulsa, OK, USA) and a moistened cotton pellet was placed over the MTA paste to allow setting of the material. Reinforced ZOE was placed as a temporary restoration; the ZOE and the cotton pellets were removed after 24 h, and the teeth finally restored with SSCs.
89608263|NCT04270318|Experimental|MTA pulpotomy-NaOCl|"After hemorrhage control, pulp chamber was cleansed with physiologic saline prior the MTA pulpotomy. MTA NaOCl (n = 31 teeth): Pulp chamber was cleansed with 5% NaOCl for 30 s prior the MTA pulpotomy.~Then, canal orifices were sealed with MTA (ProRoot MTA; Dentsply, Tulsa, OK, USA) and a moistened cotton pellet was placed over the MTA paste to allow setting of the material. Reinforced ZOE was placed as a temporary restoration; the ZOE and the cotton pellets were removed after 24 h, and the teeth finally restored with SSCs."
89608264|NCT02994472|Experimental|Healthy volunteers|"Each participant will have to eat scrambled egg on day 1 and porridge on day 2; both meals will contain the radioactive tracer 99mTc-DTPA.~Participants will be scanned by a trained technologist. The scans will be carried out using a General Electric, Discovery 360 Gamma Camera.The scanning process will take approximately three hours in total, however the imaging will be carried out in stages."
89608265|NCT02993692|Other|fiberoptic bronchoscopy|I want to see the difference between the two group about hemodynamic and intraoculer pressure responses about fiberoptic bronchoscopy.
89608266|NCT02993692|Other|direct laryngoscopy|I want to see the difference between the two group about hemodynamic and intraoculer pressure responses about direct laryngoscopy.
89608267|NCT04386382|Experimental|ridge splitting flapless technique using interchangeable guide|"Fabrication of interchangeable surgical guide stent:~Optical scanning of the dental casts was done using Ceramill map 400~The treatment plan and the surgical stent were designed using Mimics Innovation Suite 19 ™ software~Series of creating and designing special 3D virtual guide slits and boxes that can accommodate and precisely fit the tools used for the ridge splitting technique."
89608268|NCT02999854|Experimental|ATIR101|T-cell depleted HSCT from a related, haploidentical donor, followed by IV infusion with ATIR101 at a single dose of 2×10E6 viable T-cells/kg body weight between 28 and 32 days after the HSCT
89608269|NCT02999854|Active Comparator|PTCy|T-cell replete HSCT from a related, haploidentical donor, followed by IV infusion of post-transplant cyclophosphamide (PTCy) 50 mg/kg/day at 3 and 4/5 days after the HSCT
88982827|NCT03975075|Experimental|Biofeedback|Participants (n=15) will undergo 30 minutes of self-administered 1-channel (ECG) physiological monitoring at home using the Mindfield eSense Pulse twice a week for four weeks (eight sessions in total). The biofeedback training session will be conducted using the eSense Pulse smartphone application. Participants will receive further instruction explaining how physiological information will be displayed and used as a means of training to induce a relaxed state while receiving real time feedback. Participants will be instructed on using controlled breathing to assist with reaching this relaxed state. Prior to each training session, the Study Coordinator will meet with the participant via Zoom to virtually assist with setup. Following each training session, participants will respond to questionnaires over the phone.
88982828|NCT03975075|Active Comparator|Control Group|"Participants (n=15) will undergo 30 minutes of self-administered 1-channel (ECG) physiological monitoring at home using the Mindfield eSense Pulse twice a week for four weeks (eight sessions in total). Participants will be provided with the following instructions: You will be monitored with this equipment for 30 minutes. During this time frame, please try to limit movement and conversation as much as possible. Prior to each training session, the Study Coordinator will meet with the participant via Zoom to virtually assist with setup. Following each training session, participants will respond to questionnaires over the phone."
88982829|NCT03952273|Active Comparator|Combo|PCI with COMBO stent
88982830|NCT03952273|Active Comparator|BioMatrix Alpha|PCI with BioMatrix Alpha stent
88982831|NCT03880422|Experimental|Supportive care (diet, exercise, education)|Patients receive an individualized diet plan for 6 months. Patients complete an individualized home-based exercise program aerobic and resistance exercise over 10-30 minutes per day, at minimum 3 days per week for 6 months, and a progressive resistance exercise program including an individually tailored prescription targeting the chest, shoulders, arms, and leg musculature for 1-4 sets of 10-15 repetitions, 5 days per week over 6 months. Patients also attend monthly educational meetings for 6 months.
88982832|NCT03849326|Experimental|"Non-fatigued patients"|
88982833|NCT03849326|Experimental|"Fatigued patients"|
88982834|NCT03843645|Active Comparator|general anesthesia group|patients allocated to the general anesthesia group will be subjected to general anesthesia with sevoflurane (inhalational agent) used for maintenance
88982835|NCT03843645|Active Comparator|regional anesthesia group|patients allocated to the regional anesthesia group will be subjected to combined spinal-epidural anesthesia with ropivacaine and fentanyl
89210444|NCT00906048|Experimental|1|Levofloxacin and Rifampicin
89608270|NCT02999542|Experimental|Music|Children will receive music via headphones
89608271|NCT02999542|Experimental|No music|Children will listen to silence via headphones
89519258|NCT03464071|Experimental|Group HVM|When randomized to the Hyperinflation with mechanical ventilator (HVM) group, there will be an increase in initial positive inspiratory pressure until reaching a peak pressure of 40 cmH2O and PEEP equal to 7 cmH2O
89519259|NCT03464071|Experimental|Group HM|When randomized to the Manual hyperinflation (HM) group, the manual resuscitation bag will be connected to the oxygen system at five liters per minute. The participant will be disconnected from the ventilator and then initiate a slow inspiration with inspiratory pause followed by abrupt expiration, totaling twelve (12) cycles / minute.
89519260|NCT05165615|Experimental|AndroidAPS versus Control-IQ|Patients with use of the Control-IQ system (closed-loop hybrid system) and previous users of AndroidAPS (closed-loop hybrid system)
89519261|NCT03463837|Experimental|Treatment with JUUL 5%, Virginia Tobacco|JUUL 5%,Virginia Tobacco [5 days] in confinement.
89519262|NCT03463837|Experimental|Treatment with JUUL 5%, Cool Mint, ENDS|JUUL 5%, Cool Mint [5 days] in confinement.
88982836|NCT03826277|Experimental|Melanostop peel treatment group|"Adult women aged between 20-50 years old.~Melasma on the face~Fitzpatrick phototypes I-IV~Presenting facial melasma~In good health condition"
88982837|NCT03796702|Experimental|Early closure of preventive ileostomy|A preventive ileostomy is closed 30 days after the primary surgery
88982838|NCT03796702|Experimental|Late closure of preventive ileostomy|A preventive ileostomy is closed 90 days after the primary surgery
89210445|NCT00906126|Experimental|Oral Misoprostol 1|Oral misoprostol 25 micrograms every 4 hours for up to two doses.
89519263|NCT03463837|Experimental|Treatment with JUUL 5%, Mango, ENDS|JUUL 5%, Mango [5 days] in confinement.
89519264|NCT03463837|Experimental|JUUL 5%, Creme Bruele, ENDS|JUUL 5%, Creme Bruele [5 days] in confinement.
89519265|NCT03463837|Active Comparator|Combustible cigarette|Exclusive use of combustible cigarette [5 days] in confinement.
89519266|NCT03463837|Sham Comparator|Smoking cessation (no smoking)|Smoking cessation (no smoking).
89519267|NCT03460249|Active Comparator|BP table or chair, systolic or diastolic|record the BP obtained in each patient position
89519268|NCT03460249|Active Comparator|as above|as above
89519269|NCT04455737||Patients with indigo carmine stained specimen|Specimen which underwent pathologic work-up after ex vivo indigo carmine injection into the inferior mesenteric artery after transanal total mesorectal excision.
89519270|NCT04455737||Patients with unstained specimen|Specimen which underwent pathologic work-up after transanal total mesorectal excision without indigo carmine dyeing.
89519271|NCT04870801|No Intervention|Low Oxygen Visits without Respirogen Micro-Oxygen|During each visit, study participants will undergo physiological monitoring prior to and during inhalation of hypoxic (FiO2=0.15) gas mixtures.
89519272|NCT04870801|Experimental|Low Oxygen Visits with Respirogen Micro-Oxygen|During each visit, study participants will undergo physiological monitoring prior to and during inhalation of hypoxic (FiO2=0.15) gas mixtures.
89519273|NCT03468439|Other|femoral nerve block|
89519274|NCT05165303|Experimental|lidocaine with propofol|
89519275|NCT03460093||case (SHPB+)|Superior hypogastric plexus block present
89519276|NCT03460093||control (SHPB-)|Superior hypogastric plexus block not present
89519277|NCT03129919|Experimental|Orthodontic patients treated with brackets Carriere SLX®|Subjects requiring orthodontic treatment and will be treated with passive self-ligating braces Carriere SLX®
89519278|NCT03129919|Active Comparator|Orthodontic patients treated with brackets Empower®|Subjects requiring orthodontic treatment and will be treated with interactive self-ligating braces Empower®
89519279|NCT03129841|Experimental|early dinner+Diet|
89519280|NCT03129841|Experimental|late dinner+Diet|
89519281|NCT05165147||physical examination population|From January 2019 to December 2019, who underwent physical examination in Peking University Third Hospital were included in the study.
89519282|NCT03468361|Placebo Comparator|Control Group|Patients in control group will be allowed to continue their conventional medications and with a placebo.
89519283|NCT03468361|Experimental|Intervention Group|Patients in intervention group who would be taking their usual medications along with parsley in a convenient dosage form.
89519284|NCT03511781|Experimental|Single Arm study|Hypofractionated Radiotherapy Schedule of 35 GY in 10 fractions is being administered in advanced Incurable Breast Cancer for female patients
89519285|NCT03468283|Experimental|Intervention|"Intervention was the addition of mobile healthcare-based diabetes self-management education, which consisted of mobile application for diabetes and individualized regular message feedback sent by healthcare professionals, to current diabetes management."
89519286|NCT03468283|No Intervention|control|Participants of control group maintained previous diabetes management in Kangbuk Samsung Hospital throughout this study. Providers were not involved with patient prescriptions.
89519287|NCT03463759||Recurrent Low Back Pain Patients|Participants experiencing a current episode of their recurrent non-specific low back pain at the time of recruitment.
89519288|NCT03463759||Healthy Volunteers|Participants matched in age and gender to one of the recurrent low back pain patients, with no significant past low back pain, chronic pain or other relevant medical disorders.
89519289|NCT03376763|Experimental|Group 1|Schizophrenia patients who are taking oral aripiprazole will be switched to Abilify maintena
89519290|NCT03376763|Experimental|Group 2|Schizophrenia patients who are taking other oral atypical antipsychotics will be switched to Abilify maintena
89519291|NCT03463681|Experimental|Cabozantinib|all subjects will recieve open label Cabozantinib 60 mg orally once daily
89519292|NCT03459703|Experimental|Early Time-Restricted Feeding|
89519293|NCT03459703|Active Comparator|Control Schedule|
89519294|NCT03468881||Breast cancer radiation therapy|Observation over a period of all treatment sessions for radiotherapy.
89519295|NCT03459547|Experimental|dental implant + PEEK (test)|Dental implant insertion, material polyetheretherketone
89519296|NCT03459547|Active Comparator|dental implant + Ti-5 (control)|Dental implant insertion, material titanium group 5
89519297|NCT03459547|Active Comparator|dental implant + zirconia (control)|dental implant insertion, material zirconia
89519298|NCT03459547|Active Comparator|dental implant + Ti-4 (control)|dental implant insertion, material titanium group 4
89519299|NCT03468803|Experimental|Beta D Glucan (BDG) in surgery|Serial Beta D Glucan measurements in each patients before, during, and after surgery
89608272|NCT02999620|Active Comparator|Alpha-cycoldextrin|All subjects randomized to receive Alpha-cycoldextrin will orally ingest two tablets containing Alpha-cyclodextrin, with their standardized liquid breakfast (100 micro Ci of [3H]triolein and 20 micro Ci of [14C]tripalmitin). The tablets will be consumed with 150 ml of still water immediately prior to consuming each meal. Subjects will be observed for a period of 48 hours as an in-patient, and then an additional 24 hours as an out-patient. During this time they will undergo a meal fatty acid metabolism study, through blood and fecal sampling, to assess meal fatty acid oxidation and storage.
89608273|NCT02999620|Placebo Comparator|Placebo|All subjects randomized to receive placebo will orally ingest two placebo tablets with their standardized liquid breakfast (100 micro Ci of [3H]triolein and 20 micro Ci of [14C]tripalmitin). The tablets will be consumed with 150 ml of still water immediately prior to consuming each meal. Subjects will be observed for a period of 48 hours as an in-patient, and then an additional 24 hours as an out-patient. During this time they will undergo a meal fatty acid metabolism study, through blood and fecal sampling, to assess meal fatty acid oxidation and storage.
89608274|NCT04270708|Experimental|Dexmedetomidine|Intranasal Dexmedetomidine 3mcg/kg
89608275|NCT04270708|Active Comparator|Triclofos|Oral Triclofos Sodium 50mg/kg
89608276|NCT02999464|Experimental|Qigong|Experimental group will receive a total of 50 minutes of qigong training 3 times per week and for 16 weeks.
88982839|NCT03776162|Active Comparator|ACL Reconstruction(BPTB Graft)|Procedure/Surgery ACL Reconstruction (Bone Patellar Tendon Bone Graft): Standard of care surgical procedure Patellar Tendon Autograft ACL reconstruction, in which a bone-patellar tendon-bone graft from the front of the knee is taken to replace the torn ACL.
88982840|NCT03776162|Experimental|Bridge Enhanced ACL Restoration|Procedure/Surgery Bridge Enhanced ACL Restoration (BEAR): The surgical repair of the ACL using the BEAR technique involves surgically placing a sponge (the BEAR implant) between the torn ends of the ACL, providing a sponge for the ligament ends to group into.
88982841|NCT03765710|Experimental|Recommended protein intake|Subjects consumed a mixed meal with a macronutrient distribution of 13% protein, 54% carbohydrate, and 33% fat.
88982842|NCT03765710|Experimental|Elevated protein intake|Subjects consumed a mixed meal with a macronutrient distribution of 26% protein, 44% carbohydrate, and 30% fat.
88982843|NCT03760211|Experimental|Multilevel Gaming Adherence|Participants in the intervention arm will receive Multilevel Gaming Adherence Intervention. Participants receive Battle Viro on their mobile phones, an electronic pill monitoring device, and, for 24 weeks, game-related text messages guided by medication adherence data (collected from an electronic pill monitoring device).
88982844|NCT03760211|Active Comparator|Treatment as Usual +|TAU+ participants will receive the Treatment As Usual + intervention, which includes receiving a non-HIV related mobile game and an electronic pill monitoring device.
88982845|NCT03728881|Experimental|Group I (Cervarix)|Participants 9-14 years old receive Cervarix IM at baseline.
88982846|NCT03728881|Active Comparator|Group II (Gardasil)|Participants 18-25 years old receive Gardasil IM at baseline and at 2 and 6 months in the absence of unacceptable toxicity.
88982847|NCT03718858|Experimental|Interscalene block|Under sterile precautions, a high frequency linear array transducer [6-13 Megahertz (MHz), Sonosite M-Turbo] probe will be placed in the transverse plane over the interscalene groove to visualize the carotid artery and the C5 and C6 nerve roots of the brachial plexus between the anterior and middle scalene muscles. A 5 cm 22 G insulated needle will then be inserted in line with the US probe in a lateral-to-medial approach until the needle tip is adjacent to the C5 and C6 roots. After negative aspiration for blood, 15 mL ropivacaine 0.5% will be injected in 5 mL aliquots in order to achieve spread adjacent to C5 and C6 nerve roots.
88982848|NCT03718858|Active Comparator|Superior Trunk Nerve block|Under sterile precautions, a high frequency linear array transducer [6-13 Megahertz (MHz), Sonosite M-Turbo] probe will be placed in the transverse plane over the interscalene groove to visualize the carotid artery and the C5 and C6 nerve roots of the brachial plexus between the anterior and middle scalene muscles. The superior trunk will be identified by tracing the C5 and C6 nerve roots caudally towards the supraclavicular fossa on the anterior lateral portion of the neck. A 5 cm 22 G insulated needle will then be inserted in line with the US probe in a lateral-to-medial approach until the needle tip is properly positioned. After negative aspiration for blood, 15 mL ropivacaine 0.5% will be injected in 5 mL aliquots.
88982849|NCT03711253|Other|Biktarvy|All participants get Biktarvy Bictegravir 50mg+Tenofovir AF 25 mg+emtricitabine 200 mg in this single arm study
88982850|NCT03643822|Active Comparator|Dexamethasone vs. Control comparison|Freezing + dexamethasone(4mg)+1 ml of saline
88982851|NCT03643822|Active Comparator|Dexmedetomidine vs. Control comparison|Freezing + dexmedetomidine(50ug) + 1.5 ml of saline
88982852|NCT03643822|Active Comparator|Dexamethasone and Dexmedetomidine|Freezing+dexamethasone(4mg)+dexmedetomidine(50ug) + 0.5 ml of saline
88982853|NCT03643822|Sham Comparator|Control Group-Placebo|Freezing + 2ml saline
89210446|NCT00906126|Experimental|Oral Misoprostol 2|Oral misoprostol 50 micrograms every 4 hours for up to two doses.
89210447|NCT00906126|Experimental|Oral Misoprostol 3|Oral misoprostol 100 micrograms every 4 hours for up to two doses.
89210448|NCT00906126|Experimental|Oral Misoprostol 4|Oral Misoprostol 50 micrograms every 2 hours for up to two doses.
89608277|NCT02999464|Active Comparator|Fitness Exercise|Fitness exercise group will receive home fitness exercise 3 times per week and for 16 weeks.
89608278|NCT02999308|Experimental|single arm|
89608279|NCT00704938|Experimental|anti-p53 TCR PBL + DC + IL-2: Melanoma/RCC|Patients with melanoma and renal cell cancer will receive anti-p53 T cell receptor (TCR) peripheral blood lymphocytes (PBL) + dendritic cells (DC) + interleukin-2 (IL-2)
89608280|NCT00704938|Experimental|anti-p53 TCR PBL + DC + IL-2: Other histology|Patients with other histologies, such as breast cancer, will receive anti-p53 T cell receptor (TCR) peripheral blood lymphocytes (PBL) + dendritic cells (DC) + interleukin-2 (IL-2)
89608281|NCT02994316|Experimental|children under the age of 16 diabete with ketoacidosis|"At diagnosis mellitus type 1 (measure of blood glucose level) bicarbonate levels will be measured and children will included in the arm with ketoacidosis (bicarbonate < 15mmol/L)"
89608282|NCT02994316|Sham Comparator|children under the age of 16 diabete without ketoacidosis|"At diagnosis mellitus type 1 (measure of blood glucose level) bicarbonate levels will be measured and children will included in the arm without ketoacodosis (bicarbonate> 15 mmol/L)"
89519300|NCT05164913||Control group|No general anesthesia between 0-3 years old or 0-5 years old
89519301|NCT05164913||Single anesthesia group|Only once general anesthesia between 0-3 years old or 0-5 years old
89519302|NCT05164913||Multiple anesthesia group|More than once general anesthesia between 0-3 years old or 0-5 years old
89519303|NCT03459313|Experimental|Active group|The active group will be provided the intervention program, i.e. access to a website.
89519304|NCT03459313|No Intervention|Control group|The control group will continue to train according to their routines and will get access to the website after 4 months.
89519305|NCT03468725|Experimental|XPF-008|Single oral dose
88982854|NCT03603964|Experimental|Guadecitabine|Participants received guadecitabine, subcutaneous (SC) injection on Days 1-5 of each 28-day cycle at the same dose that they were receiving in the last cycle of their prior study or at a different dose as guided by the dose adjustment guidelines in the prior study protocol.
88982855|NCT03588702|Experimental|Venus Legacy LB2 Body applicator group|Liposuction area is divided into 2 equal sections. One section receives RF and PEMF treatment.
88982856|NCT03575000|Experimental|Bromocriptine|This is an open-label study, so there is no comparator group. As such there is only one arm. Subjects will receive bromocriptine at a starting dose of 2.5mg daily which will be increased, if tolerated, to 5mg daily after one week. Bromocriptine will be continued for a total of 6 weeks. Laboratory investigations, telephonic interviews, and face to face visits with subjects will be conducted before, during, and after the time period that bromocriptine will be used as detailed in the study design section.
88982857|NCT03498261|Active Comparator|Gabapentin|The primary outcome of interest will be used to evaluate the efficacy of a single preoperative dose of gabapentin when compared to placebo on opioid consumption in patients undergoing rhinoplasty.
88982858|NCT03498261|Placebo Comparator|Placebo|The primary outcome of interest will be used to evaluate the efficacy of a single preoperative dose of gabapentin when compared to placebo on opioid consumption in patients undergoing rhinoplasty.
88982859|NCT03495921|Experimental|Group A: Vigil + Irinotecan and Temozolomide|"Participants randomized to Group A received oral temozolomide 100 mg/m2 daily (Days 1-5), total dose 500 mg/m2/cycle) and oral irinotecan 50 mg/m2 daily (Days 1-5, total dose 250 mg/m2/cycle). Vigil immunotherapy was administered at a concentration of 1 X 10e6 cells/dose given via intradermal injection on Day 15 of each cycle. 1 cycle = 21 days~Participants continued treatment for a maximum of 12 cycles, or until disease progression, unacceptable toxicity, withdrawal of consent or other criterion is met for discontinuation from study."
88982860|NCT03495921|Active Comparator|Group B: Irinotecan and Temozolomide|"Participants randomized to Group B received oral temozolomide 100 mg/m2 daily (Days 1-5), total dose 500 mg/m2/cycle) and oral irinotecan 50 mg/m2 daily (Days 1-5, total dose 250 mg/m2/cycle).~1 cycle = 21 days~Participants continued treatment for a maximum of 12 cycles, or until disease progression, unacceptable toxicity, withdrawal of consent or other criterion is met for discontinuation from study."
89210449|NCT00906126|Experimental|Oral Misoprostol 5|Oral Misoprostol 75 micrograms every 4 hours for up to two doses.
89519306|NCT03468725|Active Comparator|Placebo|Single oral dose
89519307|NCT03459235|Experimental|population from registry data|the intervention involves completing several quality of life questionnaires validated in the medical literature (LARS score, FSFI, USP, IIEF, IPPS, QLQ C-30, QLQ-CR29)
89519308|NCT05164679|Experimental|MMT|Intervention group performing multimodal training (MMT) 1-2 hours weekly
89519309|NCT05164679|No Intervention|CON|Sedentary control group
89519310|NCT05153135||Ribociclib|Participants who initiated CDK4/6i therapy
89519311|NCT05153135||Palbociclib|Participants who initiated CDK4/6i therapy
89519312|NCT05153135||Abemaciclib|Participants who initiated CDK4/6i therapy
89519313|NCT02950415|Other|virtual + coaching|Parent is present virtually via an internet pad (iPad) and has received coaching about how best to verbally soothe child
89519314|NCT02950415|Other|virtual + no coaching|Parent is present virtually via an internet pad (iPad) and has not received coaching about how best to verbally soothe child
89519315|NCT02950415|Other|physical + coaching|Parent is physically present and has received coaching about how best to verbally soothe child
89519316|NCT02950415|Other|physical + no coaching|Parent is physically present and has not received coaching about how best to verbally soothe child
89519317|NCT03463603||Asian racial identity|"Those who self-report Asian or related terms as their racial identity."
89519318|NCT03463603||South Asian racial identity|"Those who self-report South Asian or related terms as their racial identity."
89519319|NCT03463603||Other racial identity|"All others, who self-report neither Asian, South Asian or their related terms as their racial identity."
89519320|NCT05091749|Experimental|chronic coronary syndromes|
89519321|NCT03463447|Experimental|Hand strength|We selected volunteers without motor abnormalities with aged 6 to 17 years divided in groups (n = 30) according to an age group. The tests were performed in a single session lasting 20 minutes, when volunteers used a hydraulic dynamometer and an electronic dynamometer, in order to quantify the hand strength.
89519322|NCT03463369|Experimental|Placebo + Nucleos(t)ide Analogs (NA)|Participants will receive placebo intramuscular (IM) injection on Day 1, Week 4, and Week 12, along with standard of care NA treatment.
89519323|NCT03463369|Experimental|JNJ-64300535 + NA|Participants will receive JNJ-64300535 IM injection on Day 1, Week 4, and Week 12, along with standard of care NA treatment.
89519324|NCT05697419|Other|DPT students at YSU|
89519325|NCT03468049|Experimental|Topical App. of Allium Cepa Extract|Intervention: 5mg of Allium Cepa Extract (Allium Cepa oil) will be applied on the shoulder joint of the participant, followed by kneading massage until the Allium Cepa oil deeply penetrate into the shoulder joint in addition to standard physiotherapy management of shoulder pain post stroke. Three times in a week for four weeks
89519326|NCT03468049|Experimental|Phonophoresis of Allium Cepa extract|Intervention: 5mg of Allium Cepa extract (Allium Cepa oil) would be applied on the shoulder joint of the participant, followed by phonophoresis using ultrasound set at at treatment parameter of pulse mode (50%), 1mHz transducer frequency and stroking technique of 1.5w/cm square for 5mins to allow deeper penetration of the Allium Cepa oilinto the joint in addition to standard physiotherapy management of shoulder pain post stroke.Three times in a week for four weeks
89608283|NCT02994628|Active Comparator|Water|Intervention, water and no banana carbohydrate: consume 3 ml/kg water every 15 min during 75 km cycling
89608284|NCT02994628|Experimental|Mini banana|Intervention, banana carbohydrate: ingest 0.2 g carbohydrate/kg body weight from Mini banana with 3 ml/kg water every 15 minutes during 75 km cycling
89608285|NCT02994628|Experimental|Cavendish banana|Intervention, banana carbohydrate: ingest 0.2 g carbohydrate/kg body weight from Cavendish banana with 3 ml/kg water every 15 minutes during 75 km cycling
89608286|NCT02994628|Experimental|6% sugar beverage|Intervention: pure banana carbohydrate in sugar beverage; ingest 0.2 g carbohydrate/kg body weight from a 6% sugar beverage every 15 minutes during 75 km cycling (contains 60 grams sugar per liter using the same sugar profile found in Cavendish bananas)
89608287|NCT02995408|Experimental|Experimental: 3RP treatment|"An adapted version of the Relaxation Response Resiliency Program (3RP) for parents of children with ASD. The adapted program incorporates the three prongs of the 3RP: RR elicitation, stress awareness, and adaptive strategies.~Experimental arm participated in the 8-week 3RP program starting immediately after enrollment."
89608288|NCT02995408|Active Comparator|Waitlist control|"An adapted version of the Relaxation Response Resiliency Program (3RP) for parents of children with ASD. The adapted program incorporates the three prongs of the 3RP: RR elicitation, stress awareness, and adaptive strategies.~The waitlist arm participated in the 8-week 3RP program starting 3 months after enrollment."
89608289|NCT02994082|Experimental|Tailored Intervention|The tailored behavioral intervention includes both behavioral and pharmacological components. The behavioral component will consist of six sessions of cognitive behavioral therapy and coping skills training delivered over the telephone. In addition, participants will be screened for conditions commonly associated with tobacco use (depressive symptoms, risky alcohol use, weight concerns) and offered supplementary behavioral treatment modules to address these issues. Participants will also be offered pharmacotherapy for tobacco cessation, with decisions regarding specific medication(s) based on patients' medical history, contraindications, prior experiences, and preferences.
89608290|NCT02994082|Active Comparator|Facilitated tobacco quit line referral|Participants assigned to this condition will receive information about the VA telephone tobacco quit line and educational materials and encouraged to enroll in treatment. In addition, they will be given information regarding available medications for smoking cessation and encouraged to contact their primary care provider to discuss their options.
89608291|NCT01270048|Experimental|Bunsimgieum extract|"name of product: 'mild-x-gwarip'~standard code for item: 200005689~shape, type: extract(brown)~usage, content: adults;three times a day, each taken before or between meals~dose, standard: 2.5g for each sack, capsulated~storage : airtight container, stored in room temperature~expiration date : 36months after manufacture~macufacturing company: KyungBangnShinYak inc."
88982861|NCT03495921|Other|Cross-Over: Vigil monotherapy|Participants randomized to Group B were able to receive Vigil immunotherapy at a concentration of 1 X 10e6 cells/dose given via intradermal injection on Day 15 of each cycle. Confirmation of progression by central radiologist and pre-approval from sponsor was required. 1 cycle = 21 days
88982862|NCT03467724|Active Comparator|Fractional radiofrequency|Each surgical scar will be divided equally into two sections. One section of the scar will receive the study treatment while the other section will receive no study treatment for the duration of the study.
88982863|NCT03467724|No Intervention|No fractional radiofrequency|Each surgical scar will be divided equally into two sections. One section of the scar will receive the study treatment while the other section will receive no study treatment for the duration of the study.
88982864|NCT03453710|Active Comparator|Bankart Repair and Remplissage|Patients randomized to the all-arthroscopic group (Bankart repair and remplissage) will undergo a standard arthroscopic anterior labral repair with a minimum of 3 suture anchors, followed by remplissage with 1 or 2 anchors, at the discretion of the treating surgeon.
88982865|NCT03453710|Active Comparator|Latarjet Coracoid Transfer|Patients randomized to the open Latarjet coracoid transfer will undergo a Latarjet coracoid transfer through a deltopectoral approach and horizontal split in the subscapularis at the superior 2/3, inferior 1/3 junction. The coracoid process will be oriented in the conventional manner, with the inferior surface against the glenoid vault, secured with two cannulated screws
89608292|NCT01270048|Placebo Comparator|Placebo; corn flour,|"raw material: total contents(500㎎); cornstarch 50.0%(250.0㎎), 당수화물 49.45%(247.25㎎), caramel pigment 0.5%(2.5㎎), SsangHwa fragrance 0.05%(0.25㎎)~shape, type: extract(brown)~usage, dose: adults: three times a day, 1 sack before or between meals~dose, standard: 2.5g for each sack, capsulated~storage : airtight container, stored in room temperature~expiration date : 36 months after manufacture~manufacturing company: KyungBangnShinYak inc."
89608293|NCT02993848||Operative Scapula Fracture|No intervention. Inclusion criteria and data collection is the same for both cohort.
89608294|NCT02993848||Non-Operative Scapula Fracture|No intervention. Inclusion criteria and data collection is the same for both cohort.
89608295|NCT00715390||1-Children receiving anesthesia|The sample of patients screened will be the entire electronic anesthesia record database from 1998 until 2004 looking for subjects that have dysrhythmias.
89608296|NCT01275820||Nutralin|All 10 subjects in the study will consume the investigational food product.
89608297|NCT02993770|Experimental|Endoscopic DCR|Endoscopic DCR will be performed by a single ophthalmic plastic surgeon expert in endoscopic surgery (F.P.) with a modified powered endonasal endoscopic technique described by Wormold.
89608298|NCT02993770|Active Comparator|External DCR|External DCR will be performed in a conventional mannervia a nasal side straight skin incision 1 cm medial to medial canthal area, 1 cm long, then orbicularis oculi muscle will be separated using blunt dissection to expose the periosteum overlying and medial to the anterior lacrimal crest
89608299|NCT01275898||Beach chair|Patients scheduled for surgical procedure in beach chair position (Shoulder surgery)
89608300|NCT01275898||Sitting position|Patients scheduled for surgical procedure in sitting position (Neurosurgery)
89608301|NCT01275898||Head down position|Patients scheduled for surgical procedure in head down position (daVinci robotic surgery)
89608302|NCT01275898||Prone position|Patients scheduled for surgical procedure in prone position
89608303|NCT00709306|Placebo Comparator|Education|Participants were given a packet of standard skin cancer prevention educational brochures and handouts from major professional organizations to review independently for 10-15 minutes.
89608304|NCT00709306|Active Comparator|Motivational Interviewing|Participants met with a trained counselor who reviewed any personalized feedback of risk derived from the baseline assessments (e.g., history of sunburns, self-reported UV exposure, protective behaviors). Counselors utilized the basic motivational interviewing skills of open-ended questions, reflection of participant statements, affirmations/positive feedback, and summation of major points throughout the discussion. These sessions took about 22 minutes.
89608305|NCT00709306|Active Comparator|UV-detect photos|"Participants were shown a regular black and white photo and a black and white UV-filtered photo of their face. Participants were told that Any dark, spotted, freckled, wrinkled, uneven, or pitted areas indicate existing underlying skin damage that is difficult to reverse. However, protecting the skin from UV radiation can prevent future damage. Participants were asked what they noticed about the photos, what their reactions were, and how this might affect their behavior. These sessions took 12 minutes on average."
89608306|NCT00709306|Experimental|UV-detect photos & MI|Participants met with a trained counselor who reviewed any personalized feedback of risk derived from the baseline assessments (e.g., history of sunburns, self-reported UV exposure, protective behaviors). Counselors utilized the basic motivational interviewing skills of open-ended questions, reflection of participant statements, affirmations/positive feedback, and summation of major points throughout the discussion. In addition to baseline feedback, participants were also interviewed about the black & white and UV-filtered photos of their faces. These sessions took about 25 minutes.
89608307|NCT01275976|Active Comparator|C1-esterase inhibitor|C1-esterase inhibitor, 100 U/kg bodyweight
89608308|NCT01275976|Placebo Comparator|Saline 0.9%|Saline 0.9%
89608309|NCT00725530|Active Comparator|balafilcon A / etafilcon A|Balafilcon A worn first, with etafilcon A worn second. Each product worn bilaterally in an extended wear (overnight) basis for 7 days.
89608310|NCT00725530|Active Comparator|etafilcon A / balafilcon A|Etafilcon A worn first, with balafilcon A worn second. Each product worn bilaterally in an extended wear (overnight) basis for 7 days.
89608311|NCT01270204||Normal Volunteers|Patients older than 55 years of age with no history of voice, swallowing, reflux, or progressive neurologic disease affecting the swallowing mechanism.
89608312|NCT01270204||Patients with Dysphagia|Patients older than 55 years of age with the following condition: Dysphagia (the sensation of swallowing difficulty), globus, gastroesophageal reflux, or any other condition requiring referral for a dynamic swallowing study.
89608313|NCT01270360||asymptomatic subjects with positive FOBT|individuals having undergone a positive faecal occult blood test (FOBT) and a reference colonoscopy
89608314|NCT01270438|Experimental|Arm I (RO4929097, combination chemotherapy, bevacizumab)|Patients receive FOLFOX6 regimen comprising oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, fluorouracil IV continuously over 46 hours, and bevacizumab IV over 30-90 minutes on days 1-2. Patients also receive oral gamma-secretase inhibitor RO4929097 on days 1-3 and 8-10. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
88982866|NCT03449680|Experimental|Femoral Articular Branch Block|Patients will receive an ultrasound-guided femoral articular branch block with an injection of 20ml of ropivicaine 0.5%
88982867|NCT03449680|Placebo Comparator|Placebo Block|Patients will receive an ultrasound simulation of the location of a femoral articular branch block , this is to maintain blinding. A subcutaneous injection of 1ml of normal sterile saline will be administered
88982868|NCT03400618|Experimental|Moderate carbohydrate diet|A healthy diet containing 30 E % carbohydrates
88982869|NCT03400618|Experimental|Higher carbohydrate diet|A healthy diet containing 50 E % carbohydrates
88982870|NCT03380819|Experimental|Genome sequencing|Patients undergo exome or whole-genome sequencing, and their patients receive an interpreted clinical report.
88982871|NCT03372148|Experimental|pHRMi in evaluation of swallowing function|Pharyngeal High Resolution Manometry and Impedance (pHRMi) evaluation of swallowing function at baseline, 3 months post radiation, then at 9 months
88982872|NCT03363919|Active Comparator|1 Hz left prefrontal rTMS|36 sessions of 1 Hz rTMS at 120% motor threshold applied to the left prefrontal cortex. Each session is 2400 continuous pulses.
88982873|NCT03363919|Active Comparator|10 Hz left prefrontal rTMS|36 sessions of 10 Hz rTMS at 120% motor threshold applied to the left prefrontal cortex. Each session is 2400 pulses with 4 seconds on and 36 seconds off.
88982874|NCT03363165|Active Comparator|VM202|Participants will receive injections of VM202 (4 mgs) in calf skeletal muscle every 14 days for a total of four treatment days.
88982875|NCT03363165|Placebo Comparator|Placebo|Participants will receive injections of placebo in calf skeletal muscle every 14 days for a total of four treatment days.
88982876|NCT03327129||Healthy Controls|Subjects will have no personal or family psychiatric history and no suicide attempts.
88982877|NCT03327129||Patients with SI|Subjects will have suicidal ideation (Hamilton Depression Rating Scale suicide item >=2).
88982878|NCT03317977|Experimental|Reach for Control|Reach For Control is a multi-component, home-based family therapy that targets the multiple causes of poor adolescent asthma management across individual, family and community systems.
88982879|NCT03317977|Active Comparator|Michigan MATCH|Program endorsed by the State of Michigan for treatment of poorly controlled asthma.
88982880|NCT03296592||Investigational subjects|"Patients who have been diagnosed with cervical spondylotic myelopathy and who will be undergoing surgical correction for this diagnosis.~Visit 1 Investigational subjects will undergo a clinical assessment. Patients will undergo a DBSI MRI~Visit 2. 6 months after surgery, investigational subjects will undergo a clinical assessment.~Visit 3 12 months after surgery, investigational subjects will undergo a clinical assessment~Visit 4 18 months after surgery, investigational subjects will undergo a clinical assessment.~Visit 5 24 months after surgery, investigational subjects will undergo a clinical assessment and a DBSI MRI."
88982881|NCT03296592||Control group|Healthy volunteers aged 45-65 Visit 1: DBSI MRI Visit 2: 24 months after first MRI, patient will undergo the second MRI
88982882|NCT03191864|Experimental|APT-1011 1.5 mg HS|Placebo after breakfast, APT-1011 1.5 mg HS
88982883|NCT03191864|Experimental|APT-1011 1.5 mg BID|APT-1011 1.5 mg after breakfast, APT-1011 1.5 mg HS
88982884|NCT03191864|Experimental|APT-1011 3 mg HS|Placebo after breakfast, APT-1011 3 mg HS
88982885|NCT03191864|Experimental|APT-1011 3 mg BID|APT-1011 3 mg after breakfast, APT-1011 3 mg HS
88982886|NCT03191864|Placebo Comparator|Placebo BID|Placebo 30 minutes after breakfast and HS
89210450|NCT04034472|Other|Cardiometabolic risk in women with obesity|The use of interactive digital technology as adjuvant tool to the clinical practices in weight loss therapy emerges as an innovative strategy. However. it was note fully investigated if this can contribute to decrease inflammatory markers in obese women. In the present investigate it was amied to evaluate the effects of clinical approach associated to use of electronic means on inflammatory markers in women with obesity.
89608315|NCT01270438|Experimental|Arm II (combination chemotherapy, bevacizumab)|Patients receive FOLFOX6 regimen and bevacizumab as in arm I. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
89608316|NCT01270594|Experimental|COPD Counseling Intervention|Pharmacist counseling intervention delivered via telephone.
89608317|NCT01270594|Other|Usual Care|
89608318|NCT01270672|Experimental|carvedilol, MDMA, placebo|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but two (actually 4) treatment conditions in the same subject.
89519327|NCT03468049|Experimental|Raw mashed Allium Cepa Application|Intervention: 5g or a small size Raw Allium Cepa (onion)bulb will be cut into pieces and then mashed inside pestle and mortar, thereafter the Raw mashed Allium Cepa will then be applied on the surface of the shoulder joint of the participant and then secured with a gauze bandage for 2 hours to allow deeper penetrationin addition to standard physiotherapy management of shoulder pain post stroke. Three times in a week for four weeks
89519328|NCT03468049|Active Comparator|Standard physiotherapy group (SPG)|Participant in this group will be receiving standard physiotherapy management of shoulder pain post stroke. The standard physiotherapy management will divided into two forms of activities, the first approach is soft tissue manipulation using common massage medium in particular powder would be used in this study. The second approach is the use of therapeutic exercises and this therapeutic exercises will be categorized into three (basic level, intermediate level and advance level of shoulder joint exercises) depending on the stage of recovery of the participants. Three times in a week for four weeks
89608319|NCT02992834|Active Comparator|IL-2 pre-treated CD19 cells|Initial therapy: IL-2 (interleukin,IL)stimulated, CD28-ζ-vector (cluster of differentiation 28,CD28)transfected T cells(TCRζ chimeric antigen receptor-T cell)， were administered at 1×106/kg by single infusion
89608320|NCT02992834|Active Comparator|IL-7/IL-15 pre-treated CD19 cells|Initial therapy: IL-7/IL-15 stimulated, CD28-ζ-vector transfected T cells(TCRζ chimeric antigen receptor-T cell)， were administered at 1×106/kg by single infusion
89519329|NCT05697341|Active Comparator|Ultra-Mini-PCNL Group (A)|In The Ultra-Mini-percutaneous nephrolithotomy group, a 5 Fr open-ended ureteral catheter was introduced and a retrograde pyelogram was performed in the Lithotomy position after the induction of general anesthesia. Patients were then repositioned to the prone position. Ultra-mini-PCNLs were done in a prone position by a single consultant. The desired calyx was punctured with a Cook diamond tip 18G puncture needle under fluoroscopy guidance using standard bull's eye technique. Single tract dilatation with One Step Dilator (11Fr), with central channel for guide wires with its Operating Sheath (Storzz Dilator and Operating Sheaths for MIP XS) under fluoroscopy guidance. Storzz Nephroscope for MIP XS / S along with Swiss Lithoclast master pneumatic lithotripter with 1/0.8 mm probe was used for stone fragmentation. Stone fragments are flushed out on rapid removal of the endoscope, due to a 'vortex' effect and with wash through the operating sheath using a 6 Fr. nelaton catheter.
89608321|NCT01276210|Experimental|Treatment|See Detailed Description
89608322|NCT00727636|Experimental|Gardasil vaccine - Prospective Study|Prospective study participants received the Gardasil vaccine during the study
89608323|NCT00727636|No Intervention|Retrospective Study|Retrospective study participants had blood drawn in the study after they had received the Gardasil vaccine from their primary medical provider
89608324|NCT00709696|Placebo Comparator|1|Placebo Varenicline
89608325|NCT00709696|Active Comparator|2|Varenicline
89608326|NCT01270906|Experimental|CHIR-258 (TKI258)|
89608327|NCT01270984|Experimental|Luckyvec 400mg film coated tablet|400mg/tablet, PO, 1 tablet once daily for Period I & II D1(crossover)
89608328|NCT01270984|Active Comparator|Glivec 100mg film coated tablet|100mg/tablet, PO, 4 tablets once daily for Period I & II D1(crossover)
89608329|NCT01276366|Active Comparator|sucrose|In the third group, newborns receive sucrose 1ml 24% two minutes before procedure, followed by non-nutritive sucking. During the procedure the newborn lies in his cot.
89608330|NCT01276366|Active Comparator|supplemental breast milk|In group two, the newborns receive supplemental breast milk, lying in the arms of a nurse during the heel lance.
89608331|NCT01276366|Active Comparator|Breast feeding|Newborns who are assigned to group one, receive breastfeeding during the blood sample and thereby have skin-skin contact between mother and child.
89210451|NCT05277870|Active Comparator|control|Standard eyedrops of IOP-lowering medications
89608332|NCT02992678|Experimental|Pentoxifylline|Pentoxifylline, 400 mg, 3 times daily by mouth the day before ERCP procedure. Subjects received up to a maximum of 3 doses.
89608333|NCT02992678|Placebo Comparator|Placebo|Placebo, 400 mg, 3 times daily by mouth by mouth the day before ERCP procedure. . Subjects received up to a maximum of 3 doses.
89608334|NCT01276444|Active Comparator|Pulmonary artery catheter (PAC)|PAC was used to guide hemodynamic therapy after combined valve repair
89608335|NCT01276444|Active Comparator|COMPLEX|An combination of transpulmonary thermodilution and continuous monitoring of central venous saturation was used to guide hemodynamic therapy after combined valve repair surgery.
89608336|NCT01271062|Active Comparator|T2DM patients before gastric bypass surgery|oral glucose tolerance test , botnia clamp, preoperative as well as 10 days postoperative and 1 year postoperative, gastric bypass surgery.
88982932|NCT02573493|Experimental|Arm 1: nab-Paclitaxel and cisplatin (AP) + CRT|"Six weeks of nab-paclitaxel (100 mg/m2/week) and cisplatin (75 mg/m2 days 1 and 22) followed by primary tumor site (PTS) assessment~If complete response (CR)/partial response (PR), three more weeks of nab-paclitaxel and cisplatin followed by concurrent chemoradiation therapy (CRT)~If <PR, move directly to CRT if not surgical candidates.~CRT includes cisplatin which will begin 1 to 35 days after the completion of cycle 3. The first dose of cisplatin will be given during the initial 5 days of definitive radiation therapy, the second on approximately Day 22 of radiation, and the third on approximately Day 43 of radiation.~It is strongly recommended that intensity-modulated radiation therapy (IMRT) begin within 21 to 42 days (no later than 56 days) after the start of cycle 3. The total dose will be 7000 cGy in 35 fractions of 200 cGy each over 7 weeks. A dose of 6300 cGy in 35 fractions is optional and may be delivered to areas considered to be an intermediate risk."
88982933|NCT02573493|Experimental|Arm 2: nab-Paclitaxel (A) + CRT|"Six weeks of nab-paclitaxel (100 mg/m2/week) followed by primary tumor site (PTS) assessment~If CR/PR, three more weeks of nab-paclitaxel followed by CRT~If <PR, move directly to CRT if not surgical candidates.~CRT includes cetuximab and will begin 1 to 35 days after completion of cycle -Cetuximab will be started 7 days before starting definitive radiation therapy. The initial loading dose of cetuximab will be 400 mg/m^2. Subsequently, cetuximab will be given weekly at a dose of 250 mg/m^2 for seven additional doses concurrently with radiation therapy.~It is strongly recommended that IMRT begin within 21 to 42 days (no later than 56 days) after the start of cycle 3. The total dose will be 7000 cGy in 35 fractions of 200 cGy each over 7 weeks. A dose of 6300 cGy in 35 fractions is optional and may be delivered to areas considered to be an intermediate risk."
89519635|NCT03916783|Experimental|Combination intervention|"Selected families will be assigned to the treatment condition (delivered over 9 months) to receive BSC plus a family EE intervention comprising of a matched family development account (FDA) for health-related expenses, including transport to UCI, food/nutrition, and health insurance. Combined with the Family EE will be four sessions of Financial Literacy and Management (FL&M) and two sessions of cancer education. The sessions will be conducted over a 4-week period. The two cancer-specific education sessions will use UCI materials to address: 1) definitions of cancer, potential causes, signs and symptoms, and importance of cancer testing; 2) debunking cultural explanations for the causes of cancer and misconceptions (beliefs, values, norms and prevailing attitudes)regarding cancer that largely impede service use.~*Due to insufficient sample size, the open clinical trial is not being conducted."
89519636|NCT03129451||Tremor-dominant|Tremor-dominant Parkinson's disease
89519637|NCT03129451||Akinetic-Rigid|Akinetic-Rigid type Parkinson's disease
88982934|NCT02573493|Experimental|Arm 3: nab-Paclitaxel and cisplatin (AP) + modified CRT|"6 weeks of nab-paclitaxel and cisplatin (days 1 & 22) followed by primary tumor site assessment~If CR/PR, cycle 3 of induction then 42Gy radiation, 1 dose of cisplatin or 6 doses cetuximab~If SD/PD: undergo surgery if candidate followed by CRT with 42 Gy RT and abbreviated cisplatin or cetuximab or 70Gy RT and 3 cycles of cisplatin or 8 doses of cetuximab~CRT includes Cisplatin and will begin 1-35 days after the completion of Cycle 3 of induction. Cisplatin will be given as 1 dose during the initial 5 days of definitive radiation therapy~Strongly recommended that radiation therapy begin within 28-49 days (and no later than 56 days) after the start of Cycle 3. Intensity modulated radiation therapy is to be used exclusively for this study."
89519638|NCT03129451||Multiple systems atrophy|Multiple systems atrophy PD
88982935|NCT02559752||Arm 1: NIH Toolbox Cognitive Battery testing|"This study will use the NIH Toolbox Cognitive Battery computer testing software to investigate the cognitive outcomes in children with CNS tumors receiving PBRT.~Participants recruited for the study will complete one 45-minute testing session prior to the completion of the first week of radiation therapy.~They will then complete serial tests 6-12 months after the completion of PBRT and then yearly thereafter."
88982936|NCT02542917||All patients|IBDoc home test for faecal calprotectin
88982937|NCT02522533|Experimental|Physical Therapy|Patients will be receiving 6 weeks of an exercise program.
89519639|NCT03129451||Levodopa-naïve|Levodopa-naïve Parkinson's disease
89519640|NCT03129451||Tremor-dominant / app|Tremor-dominant Parkinson's disease with an appendectomy
89519641|NCT03129451||Akinetic-Rigid / app|Akinetic-Rigid Parkinson's disease with an appendectomy
89519642|NCT03129451||Levodopa-naïve w/app|Levodopa-naïve Parkinson's disease with an appendectomy
89519643|NCT03446443|Experimental|Honghe Fujie lotion group|
89519644|NCT03446443|Active Comparator|Metronidazole Suppositories group|
89519645|NCT03446365|Experimental|ASMAS|ASMAS is an asthma self-management program based on NHLBI clinical guidelines for optimal school-based asthma management. It involves 4, 1½ hour sessions delivered in group format in the urban, middle school setting by a Latino High School Peer who has asthma. ASMAS focuses on asthma pathophysiology, symptom management, asthma medications, and trigger control.
89519646|NCT03446365|Active Comparator|Asthma education plus child health|"Asthma Education plus Child Health control condition will be delivered by an adult Health Educator , and includes 4 sessions (1 1/2 hrs long) of our existing asthma education (Asthma's Magic Number) with added general health topics (nutrition, physical activity, safety)."
89519647|NCT03446365|No Intervention|No Treatment Control|Students randomly assigned to this arm , will receive standard of care, which is no treatment, and will not participate in any group intervention sessions.
89519648|NCT03443557||oral nutrition supplement group|hospitalized malnourished patients who were received oral nutrition supplement during hospital course
89519649|NCT03443557||control group|hospitalized malnourished patients who were received only hospital food during hospital course
89519650|NCT03443479||Patients with type II ARF|All patients with type II respiratory failure that were deemed by the treating physician to require ventilatory support either with non-invasive ventilation (NIV) or High-Flow Nasal Cannula (HFNC).
89519651|NCT03443401||patient participants|patients with chronic low back pain receiving standard physical therapy care
89519652|NCT03443401||Physical Therapy clinician participants|Licensed physical therapist that is providing standard physical therapy care for a patient participant
89519653|NCT04452487||Patient 2019|Patients hospitalized in selected centers during march and june 2019
89519654|NCT04452487||Patient 2020|Patients hospitalized in selected centers during march and june 2020 (during COVID-19 pandemia)
88982938|NCT02347709||Group 1/Diabetic Foot Ulcer|Group 1 will be recruited from the Wound Center, and will include patients with a diagnosis of Type 2 Diabetes (defined as HgA1c ≥5.9%), and a diabetic foot ulcer (defined as a break in the skin on the foot). Subjects in this group will complete a survey, undergo a Comprehensive Neuropathy Evaluation, and have a photograph and biopsy of their Diabetic Foot Ulcer in addition to the standard of care.
88982939|NCT02347709||Group 2/Diabetic Neuropathy|Group 2 will be recruited from the Neurology clinic and will include patients with a diagnosis of Type 2 Diabetes (defined as HgA1c ≥ 5.9%) and neuropathy. Subjects in this group will complete a survey and undergo a Comprehensive Neuropathy Evaluation in addition to the standard of care.
88982940|NCT02347709||Group 3/Type 2 Diabetes|Group 3 will be recruited from the Endocrinology clinic and will include patients with a diagnosis of Type 2 Diabetes (defined as HgA1c ≥ 5.9%) who currently do not have a diagnosis of neuropathy or a diabetic foot ulcer. Subjects in this group will complete a survey and undergo a Comprehensive Neuropathy Evaluation in addition to the standard of care.
88982941|NCT02329366||Diabetic Foot Ulcer Group|Subjects in this group will have tissue specimens collected from their Diabetic Foot Ulcer during Standard of Care debridement.
88982942|NCT02329366||Control Group|Skin tissue samples will be collected from subjects undergoing routine surgical procedures during which normal skin is removed
88982943|NCT02327078|Experimental|Phase 1 Part 1 Epacadostat 25mg BID +Nivolumab|Epacadostat 25mg oral twice daily (BID) continuous daily dosing in combination with Nivolumab administered intravenously (IV) at 3mg/kg Q2W
88982944|NCT02327078|Experimental|Phase 1 Part 1 Epacadostat 50mg BID +Nivolumab|Epacadostat 50mg oral twice daily (BID) continuous daily dosing in combination with Nivolumab administered intravenously (IV) at 3mg/kg Q2W
88982945|NCT02327078|Experimental|Phase 1 Part 1 Epacadostat 100mg BID +Nivolumab|Epacadostat 100mg oral twice daily (BID) continuous daily dosing in combination with Nivolumab administered intravenously (IV) at 3mg/kg Q2W.
88982946|NCT02327078|Experimental|Phase 1 Part 1 Epacadostat 300mg BID +Nivolumab|Epacadostat 300mg oral twice daily (BID) continuous daily dosing in combination with Nivolumab administered intravenously (IV) at 3mg/kg Q2W.
88982947|NCT02327078|Experimental|Phase 1 Part 2 Epacadostat 100mg BID +Nivolumab +5-FU/Platinum|Epacadostat 100mg oral twice daily (BID) continuous daily dosing in combination with Nivolumab 360mg Q3W and 5-FU/Platinum( Carboplatin or Cisplatin+5-Fluorouracil) administered intravenously (IV).
88982948|NCT02327078|Experimental|Phase 1 Part 2 Epacadostat 100mg BID +Pemetrexed/Platinum|Epacadostat 100mg oral twice daily (BID) continuous daily dosing in combination with Nivolumab 360 mg Q3W and Pemetrexed/Platinum (Carboplatin orCisplatin+Pemetrexed) administered intravenously (IV).
88982949|NCT02327078|Experimental|Phase 1 Part 2 Epacadostat 100mg BID +Paclitaxel/Platinum|Epacadostat 100mg oral twice daily (BID) continuous daily dosing in combination with Nivolumab 360 mg Q3W and Paclitaxel/Platinum(Carboplatin+Cisplatin+Paclitaxel)administered intravenously (IV).
88982950|NCT02327078|Experimental|Phase 2 Epacadostat 100mg BID + Nivolumab|Epacadostat 100mg oral twice daily (BID) continuous daily dosing in combination with Nivolumab 240mg Q2W or 480 mg Q4W based on tumor type administered intravenously (IV).
88982951|NCT02327078|Experimental|Phase 2 Epacadostat 300mg BID + Nivolumab|Epacadostat 300mg oral twice daily (BID) continuous daily dosing in combination with Nivolumab 240mg Q2W administered intravenously (IV).
88982952|NCT02304458|Experimental|Treatment (nivolumab, ipilimumab)|See Detailed Description
88982953|NCT02219373|Experimental|Gabapentin|
88982954|NCT02219373|Experimental|Oxcarbazepine|
88982955|NCT02219373|Placebo Comparator|Placebo|Patients taking placebo will have placebo dose escalated using similar frequency, periods of time, and volumes as those for the active drugs.
88982956|NCT02199769|Experimental|Clinical Decision Support|Visit-based, EMR-enabled case identification and real-time decision support to identify patients without diabetes who have a RBG>= 125mg/dL and no resulted diabetes screening.
88982957|NCT02199769|No Intervention|Usual care|Diabetes screening/testing and diagnosis per usual care at the discretion of the treating physician.
88982958|NCT02198131|Experimental|Supportive Care (pulsed dye laser)|Patients undergo pulsed dye laser monthly for three months.
89057260|NCT04528095|Experimental|DBS|Two electrode emplacement groups (target nucleus accumbens and hippocampus respectively)
89057261|NCT04541264||Model reconstruction cohort|160 patients were recruited retrospectively from May 2015 to April 2020 as discovering group.
89033281|NCT02916849|Experimental|Safe Step - Health Care Centre|Participants will be recruited informed and asked for participation in the study by health care professionals. If included in the study, and choosing the Safe Step exercise program as intervention, participants will be given a green prescription for exercise using the application Safe Step. After an introduction meeting in small groups and pre-assessments the participants will create an individual exercise programme containing ten balance and leg strengthening exercises in the application. During the four month intervention the participants will create weekly exercise plan, keep a digital exercise diary, and receive motivational feed-back within the system. The participants will be recommended to exercise at least three times per week and for at least 30 minutes at a time.
89033282|NCT02916849|Active Comparator|OEP - Health Care Centre|Participants will be recruited informed and asked for participation in the study by health care professionals. If included in the study, and choosing the Otago Exercise Program as intervention in the study participants will be given a green prescription for exercise with the Otago Home Exercise Programme-booklet. After an introduction meeting in small groups and pre-assessments the participants will create an individual exercise programme containing ten balance and leg strengthening exercises using the booklet for guidance. During the four month intervention the participants will keep a paper-based exercise diary that will be sent to the researchers on a monthly basis. The participants will be recommended to exercise at least three times per week and for at least 30 minutes at a time.
89033283|NCT02916849|Experimental|Safe Step - Advertising|Participants are recruited through meetings at senior citizens organisations and interviewed by telephone for background data and choice of intervention before inclusion. After an introduction meeting in small groups and pre-assessments the participants will create an individual exercise programme containing ten balance and leg strengthening exercises in the Safe Step application. During the four month intervention the participants will create weekly exercise plan, keep a digital exercise diary, and receive motivational feed-back within the system. The participants will be recommended to exercise at least three times per week and for at least 30 minutes at a time
89033284|NCT02916849|Experimental|Safe Step mentors- Advertising|This arm is exactly the same as the Safe Step Advertising group except the participants will be invited to attend group meetings with peer mentors, once a month during the intervention. The peer mentors are older adults earlier involved in the research project . They will act as role models and encourage the participants throughout the four months of exercise.
89033285|NCT02916849|Active Comparator|OEP - Advertising|Participants are recruited through meetings at senior citizens organisations and interviewed by telephone for background data and choice of intervention before inclusion. After an introduction meeting in small groups and pre-assessments the participants will create an individual exercise programme containing ten balance and leg strengthening exercises using the Otago booklet for guidance. During the four month intervention the participants will keep a paper-based exercise diary that will be sent to the researchers on a monthly basis. The participants will be recommended to exercise at least three times per week and for at least 30 minutes at a time.
89033286|NCT02941796|Experimental|Sequence 1|"T → R~T : HCP1105 4cap R : HGP0918 4cap + HGP0816 4tab"
89033287|NCT02941796|Experimental|Sequence 2|"R → T~T : HCP1105 4cap R : HGP0918 4cap + HGP0816 4tab"
89519655|NCT04452487||Patient 2021|Patients hospitalized in selected centers during march and june 2021
89519656|NCT03446209|Experimental|Tocilizumab|Tocilizumab Infusion RoAcemtra (EU) or Actemra (Rest of the world)
89519657|NCT03446209|Placebo Comparator|Placebo|0,9% physiological Saline
89519658|NCT03688555|Experimental|ACT-774312|Participants will receive ACT-774312 (400 mg twice daily) in the morning and evening with or without food for 12 weeks together with mometasone furoate nasal spray.
89519659|NCT03688555|Placebo Comparator|Placebo|Participants will receive placebo twice daily in the morning and evening with or without food for 12 weeks together with mometasone furoate nasal spray.
89519660|NCT05102071||Treatment with empagliflozin|as add-on therapy with metformin
89519661|NCT05102071||Treatment with a sulfonylurea|as add-on therapy with metformin
89519662|NCT05386199||Healthy controls|Healthy volunteers without conditions altering serotonin content in blood.
89519663|NCT05386199||Sepsis group|Patients with sepsis or septic shock admitted to ICU and receiving mechanical ventilation.
89519664|NCT05386199||Cardiac arrest group|Patients with cardiac arrest and ROSC admitted to ICU and receiving mechanical ventilation.
89519665|NCT05386199||Multiple trauma group|Patients with severe multiple trauma admitted to ICU and receiving mechanical ventilation.
89519666|NCT05386199||ICU control group|Patients with isolated neurological disease admitted to ICU and receiving mechanical ventilation.
89519667|NCT05383937|Experimental|intensive arm|The children included in this arm will receive two weeks of daily care during which two daily speech therapy sessions of one hour each will be performed. This will be done between M2 and M4 of inclusion in order to avoid potential measurement bias. These sessions will be carried out by a state-qualified speech therapist employed at the CRRF of Bregille. They will guide the intensive rehabilitation of dyslexic children by focusing the exercises on their main difficulties.
89519668|NCT05383937|Active Comparator|classic arm or gold standard|"The speech therapy session will be provided only by private practitioners, with a weekly consultation of 30 minutes. The private speech therapist who initially referred the patient for inclusion in the research protocol will be responsible for his or her classic rehabilitation. The therapy will continue during the 6 months of research."
89519669|NCT04454099||Fecal Occult Blood Test|People in this group will use four kind of fecal occult blood test, including quantitative and qualitative method, to detect Hb in stool before colonoscopy.
89519670|NCT03349723|Experimental|BI 1265162|BI 1265162
89519671|NCT03349723|Placebo Comparator|Placebo|Placebo
89519672|NCT03130361|Experimental|Noninvasive ventilation|Participants will use the device at home by intermittence during or after physical activities for reducing dyspnea or for shortening dyspnea-recovery time over a 4-week period.
89519673|NCT03130673||hip fracture|fracture of proximal femur
89519674|NCT03445975|Experimental|Experimental|The 3-in-1 perineal care washcloth procedure has been adopted to deliver hygiene care (total or perineal) or baths
89519675|NCT03445975|No Intervention|standard|The deliver of hygiene care (total or perineal) or baths has been performed using water and pH neutral soap
89033288|NCT02916654|Active Comparator|sulphate iron|patients administered with sulphate iron
89033289|NCT02916654|Experimental|sucrosomial iron|patients administered with sucrosomial iron
89033290|NCT02916576|Experimental|Blood glucose measurement|
89033291|NCT02941562|Experimental|Preoperative chemotherapy with short-course radiotherapy|Preoperative treatment:4 course of FOLFOX4 therapy combined with short-course radiotherapy
89033292|NCT02941562|Active Comparator|Preoperative neo-adjuvant therapy|Preoperative treatment:neo-adjuvant therapy
89033293|NCT02942888|Active Comparator|Healthy control|Oral administration of NAD precursor, nicotinamide riboside (Niagen; Chromadex Inc.) Dosing will consist of 250mg (week 1), 500mg (week 2), 750mg (week 3), 1g (weeks 4-10). Controls will receive sugar pills.
89033294|NCT02942888|Experimental|MCI|Oral administration of NAD precursor, nicotinamide riboside (Niagen; Chromadex Inc.) Dosing will consist of 250mg (week 1), 500mg (week 2), 750mg (week 3), 1g (weeks 4-10).Controls will receive sugar pills.
89033295|NCT02916420|Experimental|Treatment|Pomalidomide plus low-dose Dexamethasone
89033296|NCT05318924|Experimental|Ghrelin infusion|To achieve approximately stable elevated ghrelin levels during the infusion procedure, the investigators will use a loading dose of 1 mcg/kg as well as an infusion rate of 0.051 mcg/kg/min in line with recent studies (Farokhnia, Grodin, Lee et al., 2017) and general recommendations (Garin, Burns, Kaul et al., 2013).
89033297|NCT05318924|Placebo Comparator|Placebo infusion|Saline
89033298|NCT05318924|No Intervention|Patients with MDD|Patients with major depressive disorder will be enrolled for comparison to healthy participants on the reward task battery, but not randomized to the ghrelin vs. saline infusion.
89033299|NCT02920398|Experimental|N8-GP pivotal|
89033300|NCT02920398|Active Comparator|N8-GP commercial|
89033301|NCT05318885|Experimental|Forward leaning position|The children in asthma attacks were administered nebulization three times, during which the study group children were placed in the forward-leaning position.
89033302|NCT05318885|No Intervention|Fowler position|The children in asthma attacks were administered nebulization three times, during which the control group children in the routine Fowler's position.
89033303|NCT02916342|Active Comparator|Interscalene brachial plexus block|An ultrasound-guided interscalene brachial plexus block will be performed prior to surgery.
89033304|NCT02916342|Experimental|Supraclavicular-axillary nerve blocks|A dual supraclavicular-axillary nerve blocks will be performed prior to surgery.
89033305|NCT05318846|Experimental|Treatment group A|
89033306|NCT05318846|Placebo Comparator|Treatment group B|
89519676|NCT04452409|Active Comparator|study (low level laser plus Mediterranean diet)|Active infra -red laser in addition to diet
89519677|NCT04452409|Other|control (Mediterranean diet only)|diet
89519678|NCT03130517|Other|Intervention group|Use of single dose of intravenous immunoglobulin in a dose 0.5_1gm /kg to intervention group
89033307|NCT02920203||index cases group|unexpected sudden death cases recruited by forensic institutes or pathology departements
89033308|NCT02920203||first degree relatives group|Relatives enrolled of unexpected sudden death index cases
89033309|NCT02942381|Active Comparator|Hydroxychloroquine Sulfate|200mg Bid (eGFR>60 ml/min/1.73m2), 100mg Tid (eGFR45-59 ml/min/1.73m2), 100mg Bid (eGFR 30-44 ml/min/1.73m2) and supportive treatment
89033310|NCT02942381|Placebo Comparator|Placebo|Placebo and supportive treatment
89033311|NCT02941718|Experimental|Sleep Advancement Counseling|"Participants will receive a 15-week intervention targeting smoking cessation and sleep counseling intervention.~Smoking Cessation intervention components include:~6 individual smoking cessation sessions over 15 weeks (week 1, 3, 4, 7, 11, 15)~12 weeks of the quit-smoking drug chantix. The standard dosing will be used - 0.5 mg once per day for days 1-3, 0.5my twice per day for days 4-7; and 1mg twice per day from week 3 until the end of treatment.~Sleep counseling components in the form of CBT for insomnia will be given as part of the smoking cessation counseling."
89033312|NCT02941718|Active Comparator|General Health Intervention|"Participants will receive a 15-week intervention targeting smoking cessation and general health information.~Smoking Cessation intervention components include:~6 individual smoking cessation sessions over 15 weeks (week 1, 3, 4, 7, 11, 15)~12 weeks of the quit-smoking drug chantix. The standard dosing will be used - 0.5 mg once per day for days 1-3, 0.5my twice per day for days 4-7; and 1mg twice per day from week 3 until the end of treatment.~The general health information counseling will be given as part of the smoking cessation counseling and topics include diet, physical activity, oral health, cancer screening and skin protection."
89033313|NCT02920320|Experimental|Internet-based self-help|"Internet-based self-help on the basis of the program Mindfulness-Based Compassionate Living (van den Brink & Koster, 2015). The self-help program consists of seven text-based sessions, various exercises (z.B. breathing meditations, diaries,) and tasks. Participants have the possibility for guidance to the program on request."
89033314|NCT02920320|No Intervention|Waiting control group|
89519679|NCT03130517|Other|Control group|Control group will recieve phototherapy only
89519680|NCT03445897|Experimental|Intervention|miltefosine (150 mg/day for 28 days) plus intralesional pentamidine (120 ug/mm2 lesion area on days 1, 3, and 5).
89519681|NCT03445819|Other|Group A: Surgical Treatment|Open reduction and internal fixation (ORIF) of the patellar fracture will be performed using screws, wires, pins, or plate fixation at the discretion of the treating surgeon. The trial is designed in a pragmatic fashion to allow participating surgeons from the multiple participating sites to perform fixation as per the standard of care at their institution. Post-operative care will include standard-of-care antibiotics and deep vein thrombosis (DVT) prophylaxis, both prescribed at the discretion of the attending surgeon.
89519682|NCT03445819|Other|Group B: Conservative Treatment|Patients randomized to non-operative treatment will receive identical treatment to the operative group, minus the surgery. Patients will be weight bearing as tolerated immediately in a removable knee immobilizer, with progressive range-of-motion exercises begun at two weeks following randomization
89519683|NCT04548791|Experimental|Cohort 1|For Phase 1, a Coagulation Factor VIIa variant by intravenous route, 18 μg/kg, followed by ascending doses by subcutaneous route, 10 μg/kg, 20 μg/kg, 30 μg/kg, 40 μg/kg, and 60 μg/kg, for PK and PD assessment. For Phase 2, Coagulation Factor VIIa, 20 μg/kg by subcutaneous route, administered on demand during bleeding episodes for a maximum of 3 doses as needed for hemostasis.
89033315|NCT03458468|Experimental|Group A|Tranexamic Acid 1g IV
89033316|NCT03458468|Placebo Comparator|Group B|Saline injection
89033317|NCT02919891||Participants with Chronic Pain|Questionnaire results will allow the diagnosis of chronic pain. No intervention will be administered. The results of the IENFD will be compared to the group without chronic pain.
89033318|NCT02919891||Participants without Chronic Pain|Questionnaire results will reveal the absence of chronic pain. No intervention will be administered. The results of the IENFD will be compared to the group with chronic pain.
89033319|NCT02941679|Experimental|HCP1202|Test
89033320|NCT02941679|Active Comparator|HGP1011|Control
89033321|NCT02941679|Active Comparator|HCP0910|Control
89033322|NCT02919930|Other|Oronasal - Nasal|Patients undergo polysomnography with oronasal mask during the first night and nasal mask during the second night.
89033323|NCT02919930|Other|Nasal - Oronasal|Patients undergo polysomnography with nasal mask during the first night and oronasal mask during the second night.
89033324|NCT02942537|Experimental|Intervention|Microwave treatment
89033325|NCT02942537|Active Comparator|Control|Uterine artery embolization
89033326|NCT02916303||Patients|Patients followed up at least during 3 years at PAFIP clinic
89033327|NCT02916537|Experimental|Cohort A: Pre-prostatectomy patients|Patients with prostate cancer prior to radical prostatectomy (N = 5). Single IV dose (370 MBq, or 10 mCi). Combined PET/MR imaging (prostate + whole body) will be performed following tracer injection. Patients in cohort A will undergo radical prostatectomy (plus lymph node dissection) within 12 weeks following CTT1057 PET/MR.
89033328|NCT02916537|Experimental|Cohort B: Metastatic prostate cancer|"Patients with evidence of metastatic castration-resistant prostate cancer (N = 15).~Single IV dose (370 MBq, or 10 mCi). Combined PET/MR imaging (prostate + whole body) will be performed following tracer injection. Patients in cohort B (metastatic prostate cancer) will have the option for metastatic tumor biopsy following CTT1057 PET imaging."
89033329|NCT02916615|Active Comparator|High nitrate vegetables|During 5 weeks subjects receive 100-150 g of a leafy green vegetable (High nitrate vegetables) per day and placebo pills containing 300 mg KCl (2 x 150 mg).
89033330|NCT02916615|Placebo Comparator|Low nitrate vegetables|During 5 weeks subjects receive 100-150 g of tomatoes/sweet pepper (Low nitrate vegetables) per day and placebo pills containing 300 mg KCl (2 x 150 mg).
89533008|NCT05675410|Experimental|Arm F (ABVD, brentuximab vedotin, nivolumab)|Patients receive treatment as in arm B. Patients also undergo FDG-PET, PET, PET-CT, PET-MRI, CT, and/or MRI throughout the trial. Patients may also undergo blood sample collection on trial.
89533009|NCT05675410|Experimental|Arm G (ABVD, eBEACOPP, ISRT)|Patients receive treatment and imaging, and may undergo blood sample collection as in arm C.
89033331|NCT02916615|Active Comparator|Low nitrate vegetables + nitrate|During 5 weeks subjects receive 100-150 g of tomatoes/sweet pepper (Low nitrate vegetables) per day and nitrate pills containing 300 mg KNO3 (2 x 150 mg).
89033332|NCT02916459|Active Comparator|EBUS-TBNA|Mediastinal and hilar lymph node sampling using a standard 21G EBUS-TBNA needle
89033333|NCT02916459|Experimental|Flex 19G EBUS-TBNA|Mediastinal and hilar lymph node sampling using the flexible 19G EBUS-TBNA needle
89033334|NCT02942303|Active Comparator|Technique 1: Lateral orbicularis injections|5 equally spaced injections will be placed intramuscularly into the orbicularis under the lateral eyebrow starting lateral to the level of the lateral limbus and extending to the level of the inferior orbital rim.
89533010|NCT05675410|Experimental|Arm H (ABVD, brentuximab vedotin, nivolumab, ISRT)|Patients receive treatment and imaging, and may undergo blood sample collection as in arm D.
89533011|NCT05669755|Experimental|CagriSema 2.4 mg/2.4 mg|Participants will receive 2.4 milligrams (mg) cagrilintide and 2.4 mg semaglutide subcutaneously (s.c.) once-weekly after a dose escalation period of 16 weeks during the maintenance period of 219 weeks.
89533012|NCT05669755|Placebo Comparator|Placebo|Participants will receive placebo matched to cagrilintide and placebo matched to semaglutide s.c. once weekly for 235 weeks.
89533013|NCT05669664|Experimental|Treatment (darolutamide, leuprolide acetate)|Patients receive darolutamide PO BID on days 1-28 of each cycle and leuprolide acetate IM every 4 or 12 weeks. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo biopsy, collection of blood samples, and CT/MRI throughout the trial.
89533014|NCT05666739||healthy controls|General public population, including females and males, who are over the age of 18, with a mixture of races and ethnicities representative of North Carolina
89533015|NCT05666713|Experimental|Treatment|Patients undergoing TAVR with BASILICA using the Transmural TELLTALE guidewire system for bioprosthetic aortic valve failure or native aortic stenosis ( on label TAVR)
89533016|NCT05665530|Experimental|PRT2527 Monotherapy|PRT2527 will be administered by intravenous infusion once weekly on a 21-day treatment cycle at the dose level assigned during the dose escalation phase and at the defined RP2D dose for indication-specific cohorts during the dose confirmation phase.
89533017|NCT05665530|Experimental|PRT2527/Zanubrutinib Combination|"PRT2527 will be administered by intravenous infusion once weekly on a 35-day treatment cycle for Cycle 1 followed by 21-day treatment for subsequent treatment cycles at the dose level assigned during the dose escalation phase and at the defined RP2D dose for indication specific cohort during the dose confirmation phase.~Zanubrutinib will be administered orally as combination therapy once daily."
89533018|NCT05665361|Experimental|1/ Phase I|Sasanlimab and deescalating doses of palbociclib
89533019|NCT05665361|Experimental|2/Phase II|Sasanlimab and palbociclib at the dose determined in Phase I (RP2D)
89533020|NCT05664178|Experimental|Tele-Resistance Training (RT)|Participants will be encouraged to perform approximately 30 minutes of resistance training exercises approximately twice per week for 12 weeks. Participants will also be encouraged to perform moderate aerobic exercise at least 3 times per week. Participants will wear a FitBit fitness watch to monitor aerobic exercise.
89533021|NCT05664178|No Intervention|Usual Care (UC)|Participants randomized to the Usual Care (UC) arm will be provided with information materials outlining resistance training using body weight or basic equipment. Participants will wear a FitBit fitness watch to monitor aerobic exercise.
89033335|NCT02942303|Active Comparator|2. Technique 2: Lateral orbicularis and Corrugator injections|5 equally spaced injections will be placed intramuscularly into the orbicularis under the lateral eyebrow starting lateral to the level of the lateral limbus and extending to the level of the inferior orbital rim. In addition, 2 injections will be placed into the corrugator at the medial brow
89033336|NCT02920086|Experimental|Nutrition Education Program|Nutrition education for family members of an elderly critically ill patient
89033337|NCT02920086|Experimental|Decision Support Program|Decision support education for family members of an elderly critically ill patient
89033338|NCT02920086|No Intervention|Usual Care|No intervention
89033339|NCT02942147|Active Comparator|conventional radiofrequency therapy|In the conventional radiofrequency method applied to Group 1 patients, the targeted facet joints were marked while the fluoroscope was in antero-posterior position.
89033340|NCT02942147|Active Comparator|conventional TENS|Group 2 patients were administered TENS therapy 30 minutes a day for 15 days at the outpatient physiotherapy unit of the Physiotherapy and Rehabilitation Department. The TENS therapy was applied in the form of conventional TENS subtype with 80-100 Hz frequency by placing four electrodes on the region where the pain was most intense.
89033341|NCT02942147|Active Comparator|pulse radiofrequency therapy|In the pulse radiofrequency method applied to Group 3 patients, the targeted facet joints were marked while the fluoroscope was in antero-posterior position.
89033342|NCT02916381|Experimental|PEC block|Ultrasound-guided PEC block after induction of general anaesthesia.
89033343|NCT02916381|Sham Comparator|Control|No ultrasound-guided PEC block; only general anaesthesia will be provided.
89033344|NCT02920047|Experimental|Sequence A|"Period 1(Treatment A) - Period 2(Treatment A) - Period 3(Treatment B)~There will be a washout of 14 days between the each period."
89033345|NCT02920047|Experimental|Sequence B|"Period 1(Treatment A) - Period 2(Treatment B) - Period 3(Treatment A)~There will be a washout of 14 days between the each period."
89033346|NCT02920047|Experimental|Sequency C|"Period 1(Treatment B) - Period 2(Treatment A) - Period 3(Treatment A)~There will be a washout of 14 days between the each period."
89033347|NCT02942225||ADHD group|Subjects with clinical diagnosis of ADHD according to the DSM-V criteria
89033348|NCT02942225||TD group|Typically development controls without lifetime diagnosis with ADHD
89033349|NCT02920125|Active Comparator|Trial: Ayurvedic SUVED, REIMMUGEN|"Ayurvedic SUVED formulation comprises of 'Ghana' extract form; Dosage :3 months, 1 BD. Content: (500mg per capsule)Terminalia Arjuna: Withania somnifera; Terminalia chebula; Cyperus rotundus; Apium graveolens; Vitis vinifera; Piper longum; Fagonia Arabica; Emblica officinalis; Terminalia belerica; Nymphaea stellata; Punica granatum; Bacopa Monnieri; and stabilizing herbs.~Reimmugen Cow-colostrum is a total natural product, used as nutritional supplement Dosage: 3months, 1 TDS Contents: IgA, IgE, IgM, IgG, IgD, PRPs, Lactoferrin, Transferrin, Interferons, Cytokines, Growth Factors (bFGF, vFGF, IGF I & II & Angiogenesis growth Factor, Endothelial growth Factor, Nerve growth factor, PDGF), natural Vitamins and Minerals."
89033350|NCT02920125|Placebo Comparator|Control: grain flour|Dummy medication in same packing to mask content given in same dose as active medication. Jowari and ragi flour used in capsules
89033351|NCT02942030||ADHD|Children diagnosed with ADHD after a complete psychiatric evaluation.
89033352|NCT02942030||Non-ADHD|Children diagnosed with other mental conditions after a complete psychiatric evaluation.
89033353|NCT02916264|Active Comparator|a scalp block|A standard scalp block ,with 0.5% bupivacaine total dose < 3 mg/kg, is performed by an anesthesiologist.
89033354|NCT02916264|No Intervention|no scalp block|An anesthesiology will pretend to perform the scalp block,
89033355|NCT02941991||uniocular subretinal injection of hESC-RPE cells|Cohort 1. 50,000 cells transplanted; Cohort 2. 100,000 cells transplanted; Cohort 3. 150,000 cells transplanted; Cohort 4. 200,000 cells transplanted
89033356|NCT02915952|Active Comparator|Zip Closure Device|The Zip device is a non-invasive, single use, sterile medical device for closure of the skin layer for surgical incisions or laceration repair.
89033357|NCT02915952|Active Comparator|Conventional Sutures|Conventional subdermal (subcuticular) absorbable sutures
89033358|NCT05318495|Experimental|Standard Colonoscopy+CAD-EYE followed by Standard Colonoscopy|"CAD-EYE is an artificial intelligence software, used in real-time during the colonoscopy procedure for aiding the identification and characterization of polyps and adenomas.~The Standard Colonoscope is a high-definition colonoscope employing advanced optical filtering and enhancement techniques - blue light imaging (BLI) and linked color imaging (LCI)."
89033359|NCT05318495|Active Comparator|Standard Colonoscopy followed by Standard Colonoscopy+CAD-EYE|"CAD-EYE is an artificial intelligence software, used in real-time during the colonoscopy procedure for aiding the identification and characterization of polyps and adenomas.~The Standard Colonoscope is a high-definition colonoscope employing advanced optical filtering and enhancement techniques - blue light imaging (BLI) and linked color imaging (LCI)."
89033360|NCT05318495|Experimental|Standard Colonoscopy+CAD-EYE+G-EYE followed by Standard Colonoscopy|"CAD-EYE is an artificial intelligence software, used in real-time during the colonoscopy procedure for aiding the identification and characterization of polyps and adenomas.~The Standard Colonoscope is a high-definition colonoscope employing advanced optical filtering and enhancement techniques - blue light imaging (BLI) and linked color imaging (LCI).~The G-EYE® balloon is a reusable (reprocessable) balloon permanently installed on the distal tip of a standard colonoscope, and is also intended to assist in flattening colonic folds and control the colonoscope's field of view and tip positioning."
89033361|NCT05318495|Active Comparator|Standard Colonoscopy followed by Standard Colonoscopy+CAD-EYE+G-EYE|"CAD-EYE is an artificial intelligence software, used in real-time during the colonoscopy procedure for aiding the identification and characterization of polyps and adenomas.~The Standard Colonoscope is a high-definition colonoscope employing advanced optical filtering and enhancement techniques - blue light imaging (BLI) and linked color imaging (LCI).~The G-EYE® balloon is a reusable (reprocessable) balloon permanently installed on the distal tip of a standard colonoscope, and is also intended to assist in flattening colonic folds and control the colonoscope's field of view and tip positioning."
89033362|NCT02920164|Active Comparator|Auricular acupuncture|Auricular acupuncture with indwelling fixed auricular acupuncture needles
89033363|NCT02920164|Placebo Comparator|Placebo acupuncture|"Placebo acupuncture with placebo fixed needles"
89033364|NCT02920164|No Intervention|Standard therapy|No intervention, just observation
89033365|NCT02940938|Experimental|Children under general anesthesia|During general anesthesia without surgical stimuli, pulse oximeter sensor is applied with gradually increased contact force, from 0 to maximal 1.5N (increase by about 0.2N), at an index finger and POP waveform is obtained for 60 seconds at each contact force. Delta POP will be calculated and compared.
89033366|NCT02915991||All patients|This is a single-arm study, so all patients enrolled will be in this arm and will undergo diagnostic catheterization procedure as per standard hospital care.
89033367|NCT02941055|Experimental|Fiber diet|50% of daily intake, 5 days a week, a diet rich in fiber, fish and probiotics will be provided to study subjects
89033368|NCT02941055|Active Comparator|Protein diet|50% of daily intake, 5 days a week, a diet rich in protein, red meat and saturated fat will be provided to study subjects
89033369|NCT02919852|Other|laparoscopic retrovesical colpopectinopexia|new operative technic
89519684|NCT04548791|Experimental|Cohort 2|For Phase 1, a Coagulation Factor VIIa variant by intravenous route, 18 μg/kg, followed by ascending doses by subcutaneous route, 30 μg/kg, 45 μg/kg, 60 μg/kg, 120 μg/kg, and 180 μg/kg, for PK and PD assessment. For Phase 2, Coagulation Factor VIIa, 60 μg/kg by subcutaneous route, administered on demand during bleeding episodes for a maximum of 3 doses as needed for hemostasis.
89033370|NCT02941094|Active Comparator|angle 30 group|During central line insertion, After choosing the proper position, the skin was infiltrated with %1 lidocaine. The vein will be localized using linear ultrasound probe (PLT-805AT, 8 MHz, Toshiba Tokyo, Japan) attached to ultrasound machine (Xario, Toshiba Tokyo Japan). The needle will be advanced guided by the ultrasound probe with needle skin angle 30-40 degree.
89033371|NCT02941094|Active Comparator|angle 50 group|During central line insertion,After choosing the proper position, the skin was infiltrated with %1 lidocaine. The vein will be localized using linear ultrasound probe (PLT-805AT, 8 MHz, Toshiba Tokyo, Japan) attached to ultrasound machine (Xario, Toshiba Tokyo Japan). The needle will be advanced guided by the ultrasound probe with needle skin angle 50-60 degree
89033372|NCT02941094|Active Comparator|angle 70 group|During central line insertion,After choosing the proper position, the skin was infiltrated with %1 lidocaine. The vein will be localized using linear ultrasound probe (PLT-805AT, 8 MHz, Toshiba Tokyo, Japan) attached to ultrasound machine (Xario, Toshiba Tokyo Japan). The needle will be advanced guided by the ultrasound probe with needle skin angle 60-80 degree
89033373|NCT02941133|Experimental|Neural Mobilization Group|Patients in this group will be treated with neural mobilization techniques.
89033374|NCT02941133|Experimental|Standard Care Group|Patients in this group will be treated with standard care (ultrasound, exercise, TENS, massage)
89033375|NCT02916069|Active Comparator|Group 1 (Multimodal brain monitoring)|Patients will be monitored with combination of brain monitoring; Nearinfrared Spectroscopy (NIRS), Transcranial Doppler (TCD), and Bispectral index (BIS). Interference will be done to optimize the medical condition based on such monitors.
89033376|NCT02916069|No Intervention|Group 2|Patients will be monitored without any interference based on such monitors
89033377|NCT02941016|Experimental|Lipid lowering|
89519685|NCT04548791|Experimental|Cohort 3|For Phase 1, a Coagulation Factor VIIa variant by intravenous route, 18 μg/kg, followed by ascending doses by subcutaneous route, 30 μg/kg, 45 μg/kg, 60 μg/kg, 120 μg/kg, and 180 μg/kg, for PK and PD assessment. For Phase 2, Coagulation Factor VIIa, 60 μg/kg by subcutaneous route, administered on demand during bleeding episodes for a maximum of 3 doses as needed for hemostasis.
89519686|NCT04938115|Experimental|CD7 CAR-T|
89519687|NCT04676243|Experimental|Quizartinib plus standard of care (SOC)|Daunorubicin/ Cytarabine or Idarubicin/Cytarabine and Quizartinib
89519688|NCT04676243|Active Comparator|Physician's choice|Physician's choice (usually Daunorubicin/ Cytarabine or Idarubicin/Cytarabine and Midostaurin)
89519689|NCT03445741|Active Comparator|Supervised treadmill group (%70 VO2 max)|Supervised treadmill group (%70 VO2 max) (group 1): The participants were instructed walking exercise at their target heart rate, (% 70 of maximum oxygen consumption) on a treadmill in Sports Rehabilitation Unit of Pamukkale University.
89519690|NCT03445741|Experimental|Supervised treadmill group (%50 VO2 max)|Supervised treadmill group (%50 VO2 max) (group 2): The participants were instructed walking exercise at their target heart rate, (% 50 of maximum oxygen consumption) on a treadmill in Sports Rehabilitation Unit of Pamukkale University.
89519691|NCT03445741|Experimental|ECE PEDO pedometer group (%50 VO2 max)|ECE PEDO pedometer group (%50 VO2 max) (group 3): The participants were instructed walking with ECE PEDO which the number of steps taken in a minute corresponding to target HR at % 50 of maximum oxygen consumption were provided.
89519692|NCT03234491|Active Comparator|A-HCL low|Trial arms will entail (a) HCL with RAI analog (insulin lispro or aspart) pre-meal bolus (R-HCL visit), (b) ACL with pre-meal dose titrated down to the lower dose inhaled insulin (AHCL low visit), and (c) ACL with pre-meal dose titrated up to higher dose inhaled insulin (A-HCL high visit).
89519693|NCT03234491|Active Comparator|A-HCL high|Trial arms will entail (a) HCL with RAI analog (insulin lispro or aspart) pre-meal bolus (R-HCL visit), (b) ACL with pre-meal dose titrated down to the lower dose inhaled insulin (AHCL low visit), and (c) ACL with pre-meal dose titrated up to higher dose inhaled insulin (A-HCL high visit).
89519694|NCT03234491|Active Comparator|R-HCL|Trial arms will entail (a) HCL with RAI analog (insulin lispro or aspart) pre-meal bolus (R-HCL visit), (b) ACL with pre-meal dose titrated down to the lower dose inhaled insulin (AHCL low visit), and (c) ACL with pre-meal dose titrated up to higher dose inhaled insulin (A-HCL high visit).
89519695|NCT04285307|Experimental|Study group|Study group
89519696|NCT03445507|Experimental|Intervention|Use of an evidence-based chat bot for smoking cessation
89519697|NCT03445507|Active Comparator|Control|Usual care (Madrid Health System Portfolio).
89519698|NCT04451629|Experimental|Exercises group|intervention group çalışma grubundaki kadın öğrencilere 8 hafta süresince haftada 4 kez 40 dakika boyunca pelvik taban ve core egzersizleri uygulatılacak
89519699|NCT04451629|No Intervention|control group|students will be watched without any intervention
89519700|NCT02951377|No Intervention|Control|Wait list control - usual care - free to pursue other treatments prescribed by the patients family physician
89533022|NCT05663320|Other|1|Intervention Study Arm 1 participants will receive an approximately 11minute educational video on CAH that focuses on transitional goals (at baseline, 3 months, and 6 months. This will be done via a NIH approved webbased REDCap. Completion will be recorded.
89033378|NCT02941172|Other|[18F]FMPEP-d2 in warm conditions|PET scan is performed using PET radiotracer [18F]FMPEP-d2 in standard room temperature conditions.
89033379|NCT02941172|Other|[18F]FMPEP-d2 in cold conditions|PET scan is performed using PET radiotracer [18F]FMPEP-d2 during controlled cold exposure.
89033380|NCT02941172|Other|[18F]FDG in cold conditions|PET scan is performed using PET radiotracer [18F]FDG during controlled cold exposure.
89033381|NCT02916225|Active Comparator|High intensity interval training|exercise protocol for high intensity/aerobic interval training as described by ESC statement (Mezzani et al.)
89033382|NCT02916225|Placebo Comparator|Moderate Continuous Training|exercise protocol for continuous aerobic training as described by ESC statement (Mezzani et al.)
89033383|NCT02916186|Experimental|Tunnel technique with acellular dermal matrix|the tunnel technique involves separation of the gingiva, then acellular dermal matrix interposed between the flap and the root surface.
89608885|NCT04764981|Experimental|Experimental Group 1: Essences Oils|The individuals of this group are 150 individuals with olfactory disorder related to COVID-19 that will be submitted to clinical exams, olfactory test and MRI imaging, after that, participants will undergo an olfactory training with essences oils. Each participant in this group will receive a kit with four 30 ml bottles, each containing a circular piece of watercolor paper soaked in one of the four essences oils (rose, eucalyptus, lemon and cloves) used in olfactory training, a manual to make the olfactory training at home and a self-assessment diary which should be filled weekly. Each participant of this group will use the training kit for three months, the olfactory training consists of inhaling each of the substances for 30 seconds, with an interval of 30 seconds between them, twice a day, upon waking up and before bed, the participants will be reassessed with CCCRT after each month of training. The results of this group will be compared with the other groups.
89608886|NCT04764981|No Intervention|Experimental Group 2: Clinical follow-up|The individuals of this group are 150 individuals with olfactory disorder related to COVID-19. that will be submitted to clinical exams, olfactory test and MRI imaging, after three months they will be reassessed.
89608887|NCT04764981|No Intervention|Control Group|The individuals of this group are 50 healthy individuals, without previous COVID-19 infection, that will be submitted to clinical exams, olfactory test, MRI imaging and the participants will be tested for the ability to identification of the essence oils utilized by Experimental group 1.
89608888|NCT03584607||Idiopathic Pulmonary Arterial Hypertension patients|Blood sampling Insulin resistance-measurement
89608889|NCT03584607||Healthy controls|Blood sampling Insulin resistance-measurement
89608890|NCT03584451|Active Comparator|with rehabilitation sport|rehabilitation sport over 52 weeks after THA, start 6 weeks postoperatively
89608891|NCT03584451|No Intervention|without rehabilitation sport|no further rehabilitation program after THA
89608892|NCT03584529|Experimental|vitamin D deficiency treatment group|patients with vitamin D deficiency (12 ng/ml ≤ serum 25-hydroxyvitamin D3 < 20 ng/ml)and uterine fibroids receive 1600 IU/day of vitamin D3 oral capsule for two years
89608893|NCT03584529|No Intervention|vitamin D deficiency control group|patients with vitamin D deficiency (12 ng/ml ≤ serum 25-hydroxyvitamin D3 < 20 ng/ml)and uterine fibroids receive regular follow-up.
89608894|NCT03584529|Experimental|vitamin D insufficiency treatment group|patients with vitamin D insufficiency (20 ng/ml ≤ serum 25-hydroxyvitamin D3 < 30 ng/ml) and uterine fibroids receive 800 IU/d of vitamin D3
89608895|NCT03584529|No Intervention|vitamin D insufficiency control group|patients with vitamin D insufficiency (20 ng/ml ≤ serum 25-hydroxyvitamin D3 < 30 ng/ml)and uterine fibroids receive regular follow-up.
89608896|NCT00724984|Experimental|1|
89608897|NCT03583983|Other|Personalized Health Recommendations|
89608898|NCT03583983|Other|No Health Recommendations|
89033384|NCT02916186|Active Comparator|subepithelial connective tissue graft|Tunnel is prepared and sub-epithelial connective tissue graft is harvested from the palate and placed under the flap.
89033385|NCT02941484|Experimental|1 early oral intake|early oral intake since postoperative day 1.
89033386|NCT02941484|Experimental|2 jejunostomy tube feeding (JTF)|jejunostomy tube feeding (JTF) was carried out after PD
89033387|NCT02915913|Experimental|High Intensity Interval|One session for 30-60 minutes of high intensity aerobic exercise
89033388|NCT02915913|Experimental|Resistance training|One session for 30-60 minutes of resistance exercise
89033389|NCT02915913|Experimental|Plus: High Intensity Interval + Resistance Training|One session for 30-60 minutes of high intensity aerobic exercise and resistance exercise
89033390|NCT02915913|Placebo Comparator|Non-exercise|Non-exercise
89033391|NCT02277002|Placebo Comparator|Placebo|Participants are exposed to unfiltered cabin air
89033392|NCT02277002|Active Comparator|Cabin Air Filter|Participants are exposed to filtered cabin air
89033393|NCT04688619|Experimental|"Prevention Program young In Favor of Myself, active parents"|"The program young In Favor of Myself will be delivered to adolescence aged 10-12, over 3 months. The program contains nine weekly, 90-min sessions that focus on Media literacy, self-esteem, self-image and body image. The parents will also participate by receiving activities to do with their children, given to the adolescents during the scool program. All participants will complete a self-report questionnaire at baseline, after the program ends, and three months after the completion of the program."
89057262|NCT04541264||Internal validation cohort|40 patients were recruited retrospectively from May 2015 to April 2020 as internal validation group.
89608899|NCT05703165|Experimental|subjects with stress burden and animal-assisted intervention|The 20-minute horse-assisted intervention takes place in compliance with basic safety precautions (safety bar between horse and participant) and after safety instruction in handling the therapy horse. The horse can be touched or stroked more or less intensively, depending on the needs and current state of mind of the study participant.
89057263|NCT04541264||External validation cohort|100 patients will be recruited prospectively during the period from May 2020 to April 2021 as external validation group.
89057264|NCT01647360||Women with Heavy Menstrual Bleeding (HMB)|
89608900|NCT05703165|Active Comparator|subjects with stress burden and without animal-assisted intervention|Study participants only observe the natural environment.
89033394|NCT04688619|Active Comparator|"Prevention Program young In Favor of Myself, passive parents"|"The program young In Favor of Myself will be delivered to adolescence aged 10-12, over 3 months. The program contains nine weekly, 90-min sessions that focus on Media literacy, self-esteem, self-image and body image. The parents won't participate in the program, they will get only a brochure about Media literacy, self-esteem, self-image and body image. All participants will complete a self-report questionnaire at baseline, after the program ends, and three months after the completion of the program."
89033395|NCT02919735|Experimental|CG 428 cutaneous solution|Herbal Medicinal Product, topical use by spray on the scalp
89033396|NCT02919735|Placebo Comparator|Placebo cutaneous solution|Placebo, topical use by spray on the scalp
89033397|NCT02941250|Experimental|treatment|patients receiving ISSD emulator
89033398|NCT02919774|Experimental|POMA 40 mg BID|40 mg BID for 10 days
89033399|NCT02919774|Experimental|POMA 160 mg BID|160 mg BID for 10 days
89033400|NCT02919774|Placebo Comparator|Placebo|Placebo BID for 10 days
89033401|NCT02941445|Experimental|COMBO (sitagliptin and metformin)|metformin 1000 mg BID and sitagliptin 50mg BID for 12 weeks
89533023|NCT05663320|No Intervention|2|Usual care Study Arm 2 participants will have their usual six-month CAH follow up to coincide with study visits at 0, 6 and 12 months. During their visit, study participants will receive standard care that includes self-injection teaching and sick day rules
89533024|NCT05657405||Affected|Individuals with known or suspect genetic conditions
89033402|NCT02941445|Experimental|MET (metformin)|metformin 1000 mg BID
89033403|NCT02941757|Experimental|Mediterranean Diet Intervention group|"In phase I, Group 1 will receive the MDNI for 12-months. Phase II: Group 1 fire houses will cross-over to self-sustained continuation, a less intense, self-directed, maintenance phase for 12 months to examine longer-term persistence of behavior change after the active 12-month MDNI. During self-sustained continuation access to some environmental changes: such as discounted food access, peer education/support, and online learning will remain; however, the stations will not receive investigator-led educational sessions"
89033404|NCT02941757|No Intervention|Control group|"2) In phase I, Group 2 will receive usual care, consisting of existing IFD health and wellness activities, with no investigator-provided interventions. In Phase II, Group 2 fire houses will cross-over to receive the full active MDNI for 6 months. The Group 2 MDNI will test the efficacy of a shorter, but otherwise identical MDNI. It will be followed by a final 6 months of self-sustained continuation (as described above) to examine the shorter MDNI's effect on persistence of adherence."
89033405|NCT02919501|Experimental|IV vortioxetine|
89033406|NCT02919501|Placebo Comparator|IV placebo|
89033407|NCT02940782|Experimental|Reciproc single file system|It is a reciprocating NiTi file used for instrumentation of root canals in endodontic treatment
89033408|NCT02940782|Active Comparator|One Shape single file system|It is a rotary NiTi file used for instrumentation of root canals in endodontic treatment
89033409|NCT02919579|Experimental|Part A: Sequence ABC (Placebo+Alcohol+Esketamine)|Participants will receive intranasal placebo on Day 1 and oral placebo on Day 2 [Treatment A] in Period 1, then intranasal placebo on Day 1 and Oral alcohol on Day 2 [Treatment B] in Period 2, followed by intranasal esketamine on Day 1 and oral placebo on Day 2 [Treatment C] in Period 3.
89033410|NCT02919579|Experimental|Part A: Sequence BCA (Placebo+Alcohol+Esketamine)|Participants will receive Treatment B in Period 1, then Treatment C in Period 2, followed by Treatment A in Period 3.
89033411|NCT02919579|Experimental|Part A: Sequence CAB (Placebo+Alcohol+Esketamine)|Participants will receive Treatment C in Period 1, then Treatment A in Period 2, followed by Treatment B in Period 3.
89033412|NCT02919579|Experimental|Part A: Sequence CBA (Placebo+Alcohol+Esketamine)|Participants will receive Treatment C in Period 1, then Treatment B in Period 2, followed by Treatment A in Period 3.
89533025|NCT05657405||Family member|Family members of individuals with known or suspected genetic conditions
89533026|NCT05652504|Experimental|Arm 1|(n = 30) pregnant women will receive three doses of PfSPZ Vaccine (9x10^5 PfSPZ) via direct venous inoculation (DVI) at 1, 8, 29 days
89533027|NCT05652504|Placebo Comparator|Arm 2|(n = 30) pregnant women will receive normal saline via DVI at 1, 8, 29 days
89533028|NCT05652478|Active Comparator|Dolutegravir|50mg one tablet orally once daily for 8 days.
89533029|NCT05652478|Active Comparator|Tenofovir alafenamide|25mg one tablet orally once a day for 8 days.
89533030|NCT05652465|Experimental|Active|TMS
89533031|NCT05647122|Experimental|Module 1 AZD9592 Monotherapy|"Module 1 has two parts:~Part A aims to determine the safety, tolerability, maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of AZD9592.~Part B aims to determine the safety, tolerability and evaluate anti-tumor activity of AZD9592 as monotherapy in select solid tumors"
89533032|NCT05647122|Experimental|Module 2 AZD9592 Combination with Osimertinib|"Module 2 has two parts:~Part A aims to determine the safety, tolerability, maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of AZD9592 in combination with Osimertinib.~Part B aims to determine the safety, tolerability and evaluate anti-tumor activity of AZD9592 in combination with Osimertinib in NSCLC EGFRm"
89533033|NCT05647122|Experimental|Module 3 AZD9592 Combination 5-FU, Bevacizumab, Leucovorin|"Module 3 has two parts:~Part A aims to determine the safety, tolerability and/or recommended phase 2 dose (RP2D) of AZD9592 in combination with 5-FU, Bevacizumab, Leucovorin in Colorectal Cancer (CRC) Part B aims to determine the safety, tolerability and evaluate anti-tumor activity of AZD9592 in combination with 5-FU, Bevacizumab, Leucovorin in Colorectal Cancer (CRC)"
89533034|NCT05645406|Active Comparator|EstroGel® 0.06%|EstroGel® 0.06% (1.25 g of gel/dose)
89533035|NCT05645406|Active Comparator|Compounded estradiol product|Compounded estradiol product (equivalent to EstroGel®/dose)
89533036|NCT05645393|Active Comparator|EstroGel® 0.06%|EstroGel® 0.06% (1.25 g of gel)
89533037|NCT05645393|Active Comparator|Biest cream|Biest cream (equivalent dose to EstroGel®)
89533038|NCT05645172||Cohort 1|adult CLL patients (≥ 18 years of age) newly prescribed with acalabrutinib according to clinical routine will be included independent of the patient age, disease stage, existence of genetic risk factors, comorbidities, therapy line, and of the application as combination therapy with obinutuzumab or as monotherapy.
89533039|NCT05645146|Active Comparator|Group 1: Standard Treatment|Participants will receive a connection to the Tobacco Free Florida Quitline and a 12 week supply of nicotine replacement therapy (the patch and lozenges)
89522727|NCT03398993|Active Comparator|Scratch group|"Induction of ovulation will be done by clomophine citrate from 3rd day of cycle till 7th day of cycle and HMG 75IU (MerionaL) given from 6th day of cycle till 8th of cycle once daily. folliculometry done regularly during induction of ovulation till dominant follicle reached 18_20mm in size.~Then endometrial injury performed in pre ovulatory day by a thin pipelle (a fine, flexible, sterile, plastic tube) The procedure was carried out in preovulatory day (known when dominant follicle reached 18_20 mm in diameter), usually, done around day 14-day of the cycle"
89522728|NCT03398993|Active Comparator|Non scratch group|They will receive the same induction of ovulation as first group but without performing endometrial injury in preovulatory day
88982959|NCT02187224|Experimental|Progesterone|For the three days prior to each test day every participant in this arm will receive one progesterone capsule (200 mg. bid) on the first day and 2 progesterone capsules per day for days 2 and 3. On the test day the participant will receive the last progesterone capsule (200 mg.bid). On the test day two scripts will be read one trauma related script (most traumatic experience) and one neutral script (relaxed scene given by participant)
88982960|NCT02187224|Placebo Comparator|Placebo|For the three days prior to each test day every participant in this arm will receive one placebo capsule on the first day and 2 placebo capsules per day for days 2 and 3. On the test day the participant will receive the last placebo capsule. On the test day two scripts will be read one trauma related script (most traumatic experience) and one neutral script (relaxed scene given by participant)
88982961|NCT02176226|Experimental|8-Week Single Arm Field Trial|Use of IntelliCare program for 8 weeks.
88982962|NCT02107586|Active Comparator|Biceps tenodesis|32 subjects in the study will receive biceps tenodesis as a surgical intervention
88982963|NCT02107586|Active Comparator|Biceps tenotomy|32 subjects in the study will receive biceps tenotomy as a surgical intervention
88982964|NCT02107547|Active Comparator|Biceps tenodesis|32 subjects in the study will receive biceps tenodesis as a surgical intervention
88982965|NCT02107547|Active Comparator|Labral repair|32 subjects in the study will receive labral repair as a surgical intervention
88982966|NCT02099825|Experimental|Anxious Adult Males|One time dosage of d-cycloserine and mifepristone at Session 2 prior to public speaking exposure sessions.
88982967|NCT02099825|Active Comparator|Non-Anxious Adult Males|One time dosage of d-cycloserine and mifepristone at Session 2 prior to public speaking exposure sessions.
88982968|NCT02057978||EXCEL DES|Use EXCEL DES implatationas as control group,Implant DES for CAD cases
88982969|NCT02057978||EXCEL-II DES|EXCEL-II DES implantation as control group,Implant DES for CAD cases
88982970|NCT01958021|Experimental|LEE011 + letrozole|LEE011 (Ribociclib) oral (3 weeks on/ 1 week off) in combination with oral once daily letrozole. 600mg LEE011 QD + 2.5 mg letrozole QD
88982971|NCT01958021|Placebo Comparator|Placebo + letrozole|Matching ribociclib placebo was the control drug and was administered orally once daily.
88982972|NCT01946477|Experimental|Pomalidomide + dexamethasone|Each subject enrolled in the study will take oral pomalidomide (4 mg) once daily on Days 1-21 and dexamethasone 40 mg/day (< 75 years old) or 20 mg/day (>75 years old) on Days 1, 8, 15 and 22 of a 28-day cycle.
88982973|NCT01946477|Experimental|Pomalidomide + Dexamethasone + Daratumumab|"Each subject enrolled in the study will take oral pomalidomide (4 mg) once daily on Days 1-21 and dexamethasone 40 mg/day (< 75 years old) or 20 mg/ day (>75 years old) on Days 1, 8, 15 and 22 of a 28-day cycle and daratumumab administered intravenously (IV) at a starting dose of 16 mg/kg at following schedule:~Days 1, 8, 15, and 22 of a 28-day cycle for Cycle 1 and Cycle 2~Days 1 and 15 for Cycle 3 through Cycle 6~Day 1 for Cycle 7 and each cycle thereafter until disease progression"
88982974|NCT01853631|Experimental|Dose Escalation: CD19 CAR T Cells for B-cell ALL|Each patient will receive a dose of CD19 CAR T Cells administered as an infusion. Each infusion will consist of CD19.CAR/28 T cells and CD19.CAR/28137 T cells.
88982975|NCT01853631|Experimental|Dose Expansion: CD19 CAR T Cells for B-cell ALL|Each patient will receive the maximum tolerated dose (MTD) of CD19 CAR T Cells administered as an infusion. Each infusion will consist of CD19.CAR/28 T cells and CD19.CAR/28137 T cells.
88982976|NCT01853631|Experimental|Dose Escalation: CD19 CAR T Cells for B-cell NHL/CLL|Each patient will receive a dose of CD19 CAR T Cells administered as an infusion. Each infusion will consist of CD19.CAR/28 T cells and CD19.CAR/28137 T cells.
88982977|NCT01853631|Experimental|Dose Expansion: CD19 CAR T Cells for B-cell NHL/CLL|Each patient will receive the maximum tolerated dose (MTD) of CD19 CAR T Cells administered as an infusion. Each infusion will consist of CD19.CAR/28 T cells and CD19.CAR/28137 T cells.
88982978|NCT01621711|No Intervention|Usual Care|Usual CD treatment, including therapy groups and individual counseling sessions, and six 45-min medical education groups. Physician appointments, pharmacotherapy, and SUD medications were be available as needed.
89522729|NCT03395015||Full-face 3-D images|3-D images acquisition of CLP patients' faces at rest is set at different timepoints: 1 week preoperative, 1- and 6-months postoperative. Therefore, laypeople's assessment of the facial appearance of CLP patients is based on full facial views.
89522730|NCT03395015||Nasolabial 3-D images|The control group is composed of cropped 3-D images of CLP patients' faces at rest, which show isolated nasolabial regions of CLP patients. The judgement of these pictures warrants an assessment based solely on the nasolabial appearance.
89522731|NCT04249297||IVF/Dydrogesteron|Females aged ≥ 18 years, underwent In-Vitro Fertilization with Elective single embryo transfer in fresh cycle, for whom were prescribed treatment with Duphaston® for luteal phase support as part of an Assisted Reproductive Technology
89522732|NCT05063825|Experimental|Simple cognitive task intervention|"A memory cue followed by playing the computer game Tetris (on own smartphone) with mental rotation instructions for ca. 12 minutes."
89522733|NCT05063825|Placebo Comparator|Attention placebo|A memory cue followed by listening to a podcast (on own smartphone) for ca. 12 minutes.
89533040|NCT05645146|Experimental|Group 2: Motivation and Problem Solving (MAPS) counseling|Participants will receive a 12 week supply of nicotine replacement therapy (the patch and lozenges) along with the MAPS intervention, which consists of 6 MAPS counseling calls over 12 months, and individually tailored SMS text content driven by monthly smartphone delivered check-ins for 24 months
89533041|NCT05642273|Experimental|Intervention|Oxiris for 24 h
89533042|NCT05642273|Active Comparator|Control|Usual care
89533043|NCT05642221||1|individuals without known health or medical issues (i.e. healthy volunteers)
89033413|NCT02919579|Experimental|Part A: Sequence ACB (Placebo+Alcohol+Esketamine)|Participants will receive Treatment A in Period 1, then Treatment C in Period 2, followed by Treatment B in Period 3.
89033414|NCT02919579|Experimental|Part A: Sequence BAC (Placebo+Alcohol+Esketamine)|Participants will receive Treatment B in Period 1, then Treatment A in Period 2, followed by Treatment C in Period 3.
89033415|NCT02919579|Experimental|Part B: Placebo+Esketamine|Participants will receive intranasal placebo on Day 1, followed by intranasal esketamine on Days 4, 8, 11, 15, 18, 22 and 25.
89033416|NCT04688697|Experimental|Prepectoral Group|Prepectoral implant-based reconstruction applied for patients in this group
89033417|NCT04688697|Active Comparator|Subpectoral Group|Subpectoral implant-based reconstruction applied for patients in this group
89608901|NCT05703165|Active Comparator|subjects without stress burden and with animal-assisted intervention|The 20-minute horse-assisted intervention takes place in compliance with basic safety precautions (safety bar between horse and participant) and after safety instruction in handling the therapy horse. The horse can be touched or stroked more or less intensively, depending on the needs and current state of mind of the study participant.
89033418|NCT02940821|Active Comparator|Whitening and Dentifrice|
89033419|NCT02940821|Active Comparator|Whitening Dentifrice|
89608902|NCT03589287|Experimental|Chondrochymal® 1 x 10^7 cells|At this stage, 3 patients with knee OA will be treated by the cell products of this dose.
89608903|NCT03589287|Experimental|Chondrochymal® 5 x 10^7 cells|At this stage, 3 patients with knee OA will be treated by the cell products of this dose.
89608904|NCT03589287|Experimental|Chondrochymal® 10 x 10^7 cells|At this stage, 3 patients with knee OA will be treated by the cell products of this dose.
89608905|NCT03113253|Experimental|Tranexamic Acid|"Patient will receive:~1g of tranexamic acid by slow intravenous injection~1g of tranexamic acid by syringe pump during 8 hours"
89608906|NCT03113253|Placebo Comparator|Placebo|"Patient will receive:~10 mL of 0.9% sodium chloride by slow intravenous injection~48 mL of 0.9% sodium chloride by syringe pump during 8 hours"
89608907|NCT02800317|Experimental|RISAS|All patients will undergo RISAS procedure, followed by axillary lymph node dissection in a one-step surgical procedure.
89608908|NCT02753751|No Intervention|Usual Care|No alert will be fired.
89608909|NCT02753751|Experimental|Electronic AKI Alert|A pop-up alert will fire when a provider opens the electronic health record of a patient with AKI until such time as AKI is documented in the problem list, or AKI resolves.
89608910|NCT01836523|Experimental|Liraglutide 0.6 mg + insulin|
89608911|NCT01836523|Experimental|Liraglutide 1.2 mg + insulin|
89608912|NCT01836523|Experimental|Liraglutide 1.8 mg + insulin|
89608913|NCT01836523|Placebo Comparator|Liraglutide placebo 0.6 mg + insulin|
89033420|NCT02940821|Active Comparator|Dentifrice|
89033421|NCT02941601|Experimental|Cohort 1: Necitumumab + Gemcitabine and Carboplatin|Predominately European sites. Gemcitabine administered intravenously (IV) and carboplatin IV plus necitumumab IV.
89033422|NCT02941601|Experimental|Cohort 2: Necitumumab + Gemcitabine and Carboplatin|Predominately United States sites. Gemcitabine administered IV and carboplatin IV plus necitumumab IV.
89033423|NCT02940899|Active Comparator|Intervention: Syracuse University Fir Families Program (SUFFP)|SUFFP is a randomized control trial comparing two groups of families of children with autism spectrum disorders. 20 families participated in the intervention program
89033424|NCT02940899|Active Comparator|Control: Syracuse University Fir Families Program (SUFFP)|20 families served as a wait-list control group. The control group will fill out the same pre and post measures as the intervention families (membership in the control vs. intervention group will be selected semi-randomly such that the average age of each of the two groups is equal), which will allow us to tease apart the effects of development vs. those related to the intervention.
89033425|NCT03631719||Early-release|Resident in areas that receive early Wolbachia deployments.
89033426|NCT03631719||Late-release|Resident in areas that receive late Wolbachia deployments.
89033427|NCT04691453|Active Comparator|QM-C Hysterectomy|QM-C Hysterectomy
89608914|NCT01836523|Placebo Comparator|Liraglutide placebo 1.2 mg + insulin|
89608915|NCT01836523|Placebo Comparator|Liraglutide placebo 1.8 mg + insulin|
89033428|NCT04691453|Experimental|QM-B Hysterectomy|QM-B Hysterectomy
89033429|NCT02940743|Active Comparator|Education (Edu)|
89033430|NCT02940743|Active Comparator|Edu + Self-Monitoring (SM)|
89033431|NCT02940743|Active Comparator|Edu + SM + Social Cognitive Theory (SCT)|
89033432|NCT03458390|Experimental|HyGIeaCare and PillCam COLON|Patient will receive the HyGIeaCare colon irrigation prior to their PillCam COLON procedure
89533044|NCT05642221||2|individuals with known neurocognitive disorders (i.e. affected)
89608916|NCT03020121|Experimental|BD HPV assay on Viper LT|"The BD HPV specimen will be tested with the BD HPV assay on the Viper LT instrument. The results will be compared to adjudicated histology. A portion of the specimens will be compared to a composite comparator generated by results of both Digene HPV and a polymerase chain reaction (PCR) sequencing test.~Device: BD HPV assay on Viper LT The BD HPV specimen will be tested with the BD HPV assay on the Viper LT instrument. The results will be compared to adjudicated histology. A portion of the specimens will be compared to a composite comparator generated by results of both Digene HPV and a polymerase chain reaction (PCR) sequencing test. Colposcopy/biopsy will be performed on all subjects."
89608917|NCT01275196|Experimental|Nilotinib|
89608918|NCT01275196|Active Comparator|Imatinib|
89608919|NCT03584139|Experimental|IRIS HOOK|iris hook assisted maneuver in phacoemulsification
89608920|NCT03584139|Active Comparator|TRADITION|traditional phacoemulsification or phacoemulsification with 25-gauge vitreous irrigation
89608921|NCT03152643|Experimental|blastocyst-stage embryo transfer group|For subjects assigned to blastocyst-stage (D5/D6) embryo transfer group, all embryos will be cultured to D5 or D6. 1 blastocysts of the best quality will be transferred in fresh cycle on D5 or D6 after oocyte retrieval (D5 embryo will be the prior choice). The surplus embryos, if any, will be vitrified for future FET in case the fresh cycle does not result in a live birth. If a patient is at a high risk of OHSS, all embryos on D5 or D6 can be cryopreserved with vitrification for patient's safety. The FET cycle will be initiated on the second menstrual cycle after oocyte retrieval.
89608922|NCT03152643|Experimental|cleavage-stage embryo transfer group|For subjects assigned to the cleavage-stage (D2/3) embryo transfer group, 1 cleavage embryos of the best quality will be transferred in fresh cycle on Day 2/3 after oocyte retrieval. The surplus embryos, if any, will be vitrified for future FET if the fresh cycle does not result in a live birth. If a patient is at a high risk of OHSS, all embryos on Day 2/3 are allowed to be cryopreserved with vitrification for patient's safety. The FET cycle will be initiated on the second menstrual cycle after oocyte retrieval.
89608923|NCT03153579|Other|Placebo, LSD|Cross-over within-subjects design with all treatment conditions, arms starting with either Placebo or lysergic acid diethylamide (LSD)
89608924|NCT03153579|Other|LSD, Placebo|Cross-over within-subjects design with all treatment conditions, arms starting with either Placebo or lysergic acid diethylamide (LSD)
88982979|NCT01621711|Experimental|Linkage patient activation intervention|Usual Care with the exception that the six 45-min Linkage patient activation education groups replaced the six 45-min Usual Care medical education groups, plus a linkage phone call (and/or a facilitated email) with the patient, clinician, and Primary Care physician.
88982980|NCT05953168|Experimental|Trastuzumab Deruxtecan (T-DXd)|
88982981|NCT05953103|Experimental|Part A 1 - Subjects with cerebral hemorrhage (Synbixin 37.5 mg; placebo group )|
88982982|NCT05953103|Experimental|Part A 2 - Subjects with cerebral hemorrhage ( Synbixin 62.5 mg; placebo group )|
88982983|NCT05953103|Experimental|Part B - Subjects with cerebral hemorrhage ( Synbixin TBD mg; placebo group )|
88982984|NCT05952986|Experimental|cohort 1|FB825 300 mg or placebo with single SC administration in 3:1 ratio
88982985|NCT05952986|Experimental|cohort 2|FB825 450 mg or placebo with single SC administration in 3:1 ratio
88982986|NCT05952986|Experimental|cohort 3|300 mg single IV administration
88982987|NCT05952973|Experimental|SkillTalk|"Educators in the treatment group will receive access to an online educator microskill training platform. Parents/caregivers of students in the educators' classes will be assigned to treatment and receive access to a parent-specific online educator microskill training platform. Students in this group will receive business as usual."
88982988|NCT05952973|No Intervention|Business as usual|Business as usual.
88982989|NCT05952960|Other|TAU Rationale|Rationale based on prior OLP studies (e.g. Kaptchuk et al., 2010)
88982990|NCT05952960|Other|Mindfulness Rationale|Rationale based on mindfulness meditation
88982991|NCT05952960|Other|Suspension of Disbelief Rationale|Rationale based on suspending disbelief about the placebo
88982992|NCT05952921|Experimental|Hypochlorous acid|Thirty-two voluntary participants were randomly assigned to receive one of two post-surgical protocols after periodontal surgery: a high concentration rinse with 0.05% HOCl (7 days), followed by 0.025% HOCl /(14 days)
88982993|NCT05952921|Active Comparator|Chlorhexidine|Thirty-two voluntary participants were randomly assigned to receive one of two post-surgical protocols after periodontal surgery: a high concentration of 0.2% CHX (7 days), followed by 0.012% CHX (14 days).
88982994|NCT05952908|Experimental|Proficiency-Based Progression training group|Trainees in this group will follow the simulation-based implant training curriculum (same content/tools in both study arms) and they will be required to demonstrate a quantitatively defined proficiency benchmark at each training stage to be able to advance to the next stage (proficiency-based progression [PBP] approach).
88982995|NCT05952908|Active Comparator|Traditional training group|Trainees in this group will follow the simulation-based implant training curriculum (same content/tools in both study arms) but they will not be required to demonstrate a quantitatively defined proficiency benchmark at each training stage to be able to advance to the next stage.
88982996|NCT05952895||Stage III, Grade C Periodontitis|Conventional quadrant-wise scaling and root planing (SRP)
88982997|NCT05952830|Active Comparator|ESWT Group|ESWT Group: external corporeal shockwave therapy subjects in ESWT-group receiving one session shock wave therapy given 6,000 impulses at 0.06-0.07 mJ/mm2 (1.2-1.4 bar) at 18 Hz on biceps brachii
88982998|NCT05952830|Experimental|DN Group|DN Group: dry needling Subjects in DN-group receiving dry needling using disposable stain less steel sterilized needles, 0.25×0.30. DN perform with patients in supine position, arm away from the trunk, and forearm in supination. The fast-in and fast-out cone shape technique adopt and each muscle needled for one minute
88982999|NCT05952817|Experimental|virtual reality treatment|Virtual reality treatment
88983000|NCT05952817|Other|Exercise programs|Congenital physical therapy exercise
88983001|NCT05952765|Experimental|Partially demineralized dentin matrix graft|"A high-speed fine finishing stone and saline irrigation will be used to clean extracted teeth from periodontal ligaments, soft tissue attachments, caries, and restorations if present.~Teeth particles will be partially demineralized using nitric acid 2% for fifteen minutes.~Finally, the prepared partially demineralized dentin matrix graft granules will be washed twice with distilled water and phosphate buffered saline~Immediate implant of appropriate dimensions will be placed and the previously prepared partially demineralized dentin matrix graft will be used to graft the jumping gap.~Customized healing abutment will be used.~In Osseo integrated implants temporary abutment will be removed and impressions for final restoration will be performed after 3 months."
88983002|NCT05952765|Active Comparator|xenograft|"After tooth extraction, thorough curettage will be performed.~Immediate implant of appropriate dimensions will be placed, and the jumping gap will be grafted with xenograft Cerabone .~Customized healing abutment will be used.~In Osseo integrated implants temporary abutment will be removed and impressions for final restoration will be performed after 3 months."
88983003|NCT05952674|Experimental|Vagus Nerve Stimulation (VNS) + Best Medical Treatment (BMT)|Along with the Optimal Medical Treatment for resistant depression, the VNS + BMT arm will be implanted a medical device of VNS.
88983004|NCT05952674|Active Comparator|Best Medical Treatment|The BMT arm will only receive the Optimal Medical Treatment for resistant depression.
89033433|NCT03160638|Experimental|Azithromycin arm|Patients in this arm will be treated with azithromycin 250 mg once daily on top of standard HRZE treatment.
89033434|NCT03160638|No Intervention|Standard of care arm|Patients in this arm will receive no additional treatment on top of standard HRZE treatment
89033435|NCT02940704|Experimental|Reciproc|"Reciproc (VDW, Munich, Germany) is a single file reciprocating system for mechanical instrumentation of root canals.~Size: R40 (40/0.06)"
89033436|NCT02940704|Active Comparator|One Shape|"One Shape (MicroMega, Besançon Cedex, France) is a single file system that works by continuous rotation for mechanical instrumentation of root canals.~Size: 25/0.06"
89033437|NCT02940587|Experimental|Aurix + UCC|Subjects will be treated on average twice a week for the first 2 weeks, and then, once a week thereafter while under active treatment, but actual frequency of treatment will be determined by the treating physician. All subjects will receive Aurix treatment and usual and customary care, which can include advanced therapeutics.
89033438|NCT02940587|No Intervention|Usual and Customary Care|Subjects will be treated on average twice a week for the first 2 weeks, and then, once a week thereafter while under active treatment, but actual frequency of treatment will be determined by the treating physician. All subjects will receive usual and customary care, which can include advanced therapeutics.
89033439|NCT02919540|Experimental|kangaroo care approach|the kangaroo care approach will be implemented for dyads who agree to participate
89033440|NCT02919540|No Intervention|control group|routine care will be implemented
89033441|NCT02919462|Experimental|Treatment Arm A|"Oral vinorelbine 60-80 mg/m2 on days 1 and 8 (first cycle 60 mg/m2) + Cisplatin 80 mg/m2 on day 1 every 3 weeks, for 4 cycles.~Maintenance with Metronomic Oral Vinorelbine 50 mg three times a week on Monday, Wednesday and Friday continuously until disease progression, patient refusal or excessive toxicity (1 cycle: 3 weeks)."
89033442|NCT02919462|Active Comparator|Treatment Arm B|"Pemetrexed, 500 mg/m2, day 1 + Cisplatin, 75 mg/m2, day 1 every 3 weeks, for 4 cycles.~Maintenance with Pemetrexed 500 mg/m2 day1 q 21 until disease progression (1 cycle: 3 weeks).~7-10 days before treatment administration, premedication with vitamin B12 1000µg intramuscular injection (every 9 weeks) and folate 1mg every day should be commenced."
89033443|NCT02941367|Experimental|Lyxumia|Patients will receive Lyxumia once daily as investigational medicinal product (IMP) on top of patient's previous basal insulin with/without metformin. Non-IMPs will be administrated as per Investigator's indications according to local labeling, guidelines, and clinical judgment.
89608925|NCT03583905|Experimental|Experimental Group 1|Patients assigned to this group are treated with CKD-330, D086
89033444|NCT02941367|Active Comparator|Sulfonylurea|Patients will continue the treatment with previous Sulfonylurea as IMP on top of patient's previous basal insulin with/without metformin. The IMP and non-IMPs will be administrated as per Investigator's indications according to local labeling, guidelines, and clinical judgment.
89033445|NCT03153150|Experimental|Start oral anticoagulant (OAC)|"If the patient is randomized in this arm, an oral anticoagulant:~Factor Xa inhibitors: Apixaban or Rivaroxaban or Edoxaban or~Direct thrombin inhibitor: Dabigatran or~Vitamin K antagonists: Acenocoumarol or Phenindione or Warfarin chosen by the patient's physician before the randomisation, will be prescribed long-term (≥1 year) to the patient."
89608926|NCT03583905|Placebo Comparator|Placebo Group 1|Patients assigned to this group are treated with 1 Placebo Tab.(Placebo of the D086)
89608927|NCT03583905|Placebo Comparator|Placebo Group 2|Patients assigned to this group are treated with 1 Placebo Tab.(Placebo of the CKD-330)
89033446|NCT03153150|No Intervention|Do not start oral anticoagulant (OAC)|"If the patient is randomized in this arm, anticoagulant drugs will not be prescribed to the patient during the entire study period. The standard clinical practice without OAC may include:~antiplatelet drug(s) or~no antithrombotic drugs."
89608928|NCT01984697|Experimental|Girls 9 to 14 Years V503 at Months 0 and 6|Girls aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL intramuscular (IM) injection at Months 0 and 6. An additional dose of V503 0.5 mL IM was administered at Month 36.
89033447|NCT02940431|Experimental|High Autonomy|Children will choose active video games for use during the study.
89033448|NCT02940431|Experimental|Low Autonomy|Children will be assigned active video games for use during the study.
89608929|NCT01984697|Experimental|Boys 9 to 14 Years V503 at Months 0 and 6|Boys aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL IM injection at Months 0 and 6. An additional dose of V503 0.5 mL IM was administered at Month 36.
89608930|NCT01984697|Experimental|Girls and Boys 9 to 14 Years V503 at Months 0 and 12|Girls and boys aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL IM injection at Months 0 and 12. An additional dose of V503 0.5 mL IM was administered at Month 36.
89608931|NCT01984697|Experimental|Girls 9 to 14 Years V503 at Months 0, 2, and 6|Girls aged 9 to 14 years received a 3-dose regimen of V503 0.5 mL IM injection at Months 0, 2, and 6. An additional dose of V503 0.5 mL IM was administered at Month 36 for a subset of participants.
89608932|NCT01984697|Active Comparator|Young Women 16 to 26 Years V503 at Months 0, 2, and 6|Young Women aged 16 to 26 years received a 3-dose regimen of V503 0.5 mL IM injection at Months 0, 2, and 6. An additional dose of V503 0.5 mL IM was administered at Month 36 for a subset of participants.
89608933|NCT03583827|Experimental|Experimental Group|Experimental group patients will be submitted to conventional therapy for 30 minutes and training of the affected upper limb using virtual reality, which will last 20 minutes over twelve sessions (4 weeks).
89033449|NCT05317598|Experimental|Intervention group|Students in the intervention group will be given a 5-week positive psychotherapy-based kindness and honesty psychoeducation.
89033450|NCT05317598|No Intervention|control group|Students in the control group will not receive any intervention during the 5-week period.
89608934|NCT03583827|Active Comparator|Control Group|The control group will undergo 30 minutes of Conventional physical therapy in twelve sessions (4 weeks).
89608935|NCT03155607|No Intervention|Standard Care|
89608936|NCT03155607|Experimental|Virtual Reality Distraction|
89608937|NCT03583749||amoxicillin-clavulanate|followed of SC and IV cohort without any randomization because the route will be chosen before inclusion by the physician in charge.
89608938|NCT03583749||ceftriaxone|followed of SC and IV cohort without any randomization because the route will be chosen before inclusion by the physician in charge.
89608939|NCT03583749||piperacillin-tazobactam|followed of SC and IV cohort without any randomization because the route will be chosen before inclusion by the physician in charge.
89608940|NCT02000531|Experimental|Erlotinib-Chemotherapy|Erlotinib in first-line treatment, followed by chemotherapy in the second-line treatment
89033451|NCT02916147|Experimental|volatile anesthesia|Use 2-3% sevoflurane to maintain the anesthesia during OLV surgery with bispectral index (BIS) 40-60.
89033452|NCT02916147|Active Comparator|intravenous anesthesia|Anesthesia was maintained by a continuous infusion of propofol （4-6mg/kg/h）with BIS 40-60.
89033453|NCT04688970||Acute stroke with affection of the upper extremity|"Subject is 18 years or above.~Subject has an acute stroke affecting one UE (FMA less than 50).~Subject or caregiver understands the study and its procedures and gives informed consent.~If the subject is not able to give informed consent:~The assumed will of the patient is to be determined by the patient's provision (if existing), the health care proxy (if existing) and/or the moral concepts expressed by the patient to close relatives.~The legal representative gives informed consent because participation is the assumed will of the patient as assessed by the aforementioned points."
89608941|NCT02000531|Active Comparator|Chemotherapy-Erlotinib|Chemotherapy in first-line treatment, followed by erlotinib in the second-line treatment
89608942|NCT05647161|Experimental|Treatment Group|"Participants undergo 1st open heart surgery (first operation), and before closing the chest BAX602 will be sprayed on the surface of the heart and large vessels. Efficacy will be evaluated via adhesiolysis after re-do (2nd) open heart surgery.~Re-do open (2nd) heart surgery will be performed ≥3 month (90 days) to ≤12 months (360 days) after 1st open heart surgery. If the re-do open heart surgery is performed later than 12 months (360 days) after the 1st open heart surgery, serious adverse events should be collected until the end of the clinical trial (at the time of discharge after re-do surgery), all observations and endpoints will be collected, including primary endpoints, items related to secondary endpoints, safety endpoints, and other observational items whenever possible. The participants will be observed for safety up to discharge after re-do open heart surgery (up to 30 days)."
89608943|NCT05647161|Active Comparator|Non-Treatment Group|"Participants undergo 1st open heart surgery (first operation) and the chest will be closed without spraying BAX602. Efficacy will be evaluated via adhesiolysis after re-do (2nd) open heart surgery.~Re-do open (2nd) heart surgery will be performed ≥3 month (90 days) to ≤12 months (360 days) after 1st open heart surgery. If the re-do open heart surgery is performed later than 12 months (360 days) after the 1st open heart surgery, serious adverse events should be collected until the end of the clinical trial (at the time of discharge after re-do surgery), all observations and endpoints will be collected, including primary endpoints, items related to secondary endpoints, safety endpoints, and other observational items whenever possible. The participants will be observed for safety up to discharge after re-do open heart surgery (up to 30 days)."
89608944|NCT01609231|Experimental|Arm A: Dalotuzumab + Irinotecan|Participants receive irinotecan intravenously (IV), 180 mg/m^2 once every two weeks + dalotuzumab IV, 10 mg/kg once weekly, during ≥1 42-day treatment cycle(s).
89608945|NCT01609231|Active Comparator|Arm B: Cetuximab + Irinotecan|Participants receive cetuximab IV, initial dose of 400 mg/m^2 and then 250 mg/m^2 IV weekly + irinotecan IV, 180 mg/m^2 once every two weeks, during ≥1 42-day treatment cycle(s).
89608946|NCT04416425||Enrolled Cohort|200 selected patients will be recruited, who have diagnosed with coronary atherosclerosis disease(stenotic extent from 50% to 69% on major epicardial arteries) by coronary computed tomography angiography(CCTA). Every two weeks, these patients will be treated with Elococumab Injection (1ml:140mg),ih.This therapy will last for one year.
89608947|NCT03583593|Experimental|DIAMEL|Study group that receives the active product.
89608948|NCT03583593|Placebo Comparator|Placebo|Control group receiving double-blind placebo.
89608949|NCT03583515|Experimental|Alcohol-Specific Personalized Normative Feedback|Participants will receive feedback about their average number of days on which alcohol was consumed, average drinks per occasion, and average number of drinks per week. This feedback will include the participant's averages reported at baseline, the participant's descriptive norm of others' averages (what they think others drank), and actual others' drinking. Feedback will be about other students at their university of the same sex.
89033454|NCT05317559|Experimental|room light|The room light condition (n=10) included one night of sleep in dim light (< 3 lux) followed by one night of sleep with overhead room lighting (100 lux).
89033455|NCT05317559|No Intervention|dim light|The dim light condition (n=10) included two consecutive nights of sleep in dim light.
89608950|NCT03583515|Placebo Comparator|Social Media Personalized Normative Feedback|Participants will receive feedback about their number of hours texting, on social media websites, and playing video games. This feedback will include the participant's averages reported at baseline, the participant's descriptive norm of others' averages (what they think others did), and actual others' behavior. Feedback will be about other students at their university of the same sex.
89608951|NCT04438187|Other|Aggressive Arm|If an intubated patient is suspected of having an ICU-acquired HAP/VAP during the aggressive period, antimicrobials should be initiated immediately after quantitative or semi-quantitative endobronchial cultures are sent regardless of clinical status. This will include patients who, as determined by the attending intensivist, are in sepsis or septic shock. If, after 72 hours, cultures and other clinical data do not point to a pneumonia, the antimicrobials should be stopped in the absence of another source of infection.
89033456|NCT02915562|Active Comparator|Depressive Group|GDS 15 (Geriatric Depression Score) ≥5 at baseline
89033457|NCT02915562|Active Comparator|Non-depressive Group|GDS 15 (Geriatric Depression Score) <5 Points at baseline
89033458|NCT02915718|Experimental|experimental group|protein A immunoadsorption for 5 days
89033459|NCT02915718|No Intervention|control group|non intervention
89033460|NCT03458351|Active Comparator|Remote ischemic preconditioning|"Remote ischemic conditioning after anesthesia induction~- four cycles of 5 min of ischemia followed by 5 min of reperfusion by inflation to 200 mm Hg and deflation of a blood pressure cuff on the upper arm"
89033461|NCT03458351|Sham Comparator|Sham control|The same blood pressure cuff is placed around the upper arm, but the cuff is inflated to 10mm Hg.
89033462|NCT02915757|Experimental|Depressive patients|EDOR test on depressed patients with or without personal history of suicidal behavior
89217994|NCT03995602|Experimental|Dragon fruit first then placebo|2 weeks of dragon fruit juice intake or placebo with crossover to the other
89217995|NCT03995602|Experimental|Placebo first then dragon fruit|2 weeks of dragon fruit juice intake or placebo with crossover to the other
89033463|NCT02919384|Experimental|2% oxygen concentration in the incubator|"At the time that embryos are changed from cleavage stage media to blastocyst stage media on day 3 of development, half of a given patient's embryos will randomly be placed in an incubator set at 2% oxygen concentration. The splitting of the embryos will be done under low magnification such that the embryologist will have no ability to bias allocation of embryos to 2% or 5% oxygen based on embryo morphology on day 3. The embryos will remain in this incubator until their developmental assessments on day 5 and 6."
89033464|NCT02919384|No Intervention|Control|Embryos in this arm will be cultured at 5% oxygen (current standard of care) from day 3 until blastocyst developmental assessment.
89519701|NCT02951377|Experimental|MDT +/- TESI|Exercise (MDT approach) and/or Transforaminal epidural steroid injection (20mg dexamethasone 0.5cc lidocaine 2%). Patients will further classified into centraliser (group 2a) and non-centralising pain responses (group 2b). Group 2a: will continue with exercise (MDT approach). Group 2b: Patients with a non-centralising pain response will be offered Transforaminal epidural steroid injection (20mg dexamethasone 0.5cc lidocaine 2%), under fluoroscopic guidance with contrast medium (Omni Pac 240). Two weeks after completion of the MDT or TESI intervention, patients will be reassessed and treated consistent with their response: 1) resolved: advice on remaining active; 2) centralising: daily exercises based on MDT principles; 3) non-centralising but significant less pain: advice to remain active, with respect for worsening leg pain; and 4) persisting high levels of pain and/or disability: advise to remain active as tolerated and consult family physician.
89519702|NCT03443089|Experimental|Test formulation|Single intramuscular dose administration (1 ampoule) of medroxyprogesterone acetate 25 mg/mL+ estradiol cypionate 5 mg/mL (Depomês®, Biolab Sanus Farmacêutica Ltda.)
89688339|NCT03405701|Active Comparator|IVF (in vitro fertilization)|Undergoing controlled ovarian hyperstimulation for in vitro Fertilization (IVF) with recombinant FSH (Menopur, Ferring) in GnRH antagonist protocol, treatment monitoring using ultrasound scans and blood tests. GnRH agonist triggering will be used for final oocytes maturation. ICSI will be used for insemination. Freeze-only on day 3 and frozen embryo transfer will be performed on the subsequent cycle using HRT protocol with a maximum of 2 embryos transferred.
89688340|NCT04364971|Experimental|singleradius|Single Radius(SR) femoral design will be perfomed to patients who is going to total knee arthroplasty. Single Radius femoral design is one of knee prosthesis' pattern which shows variation in knee kinematics
89688341|NCT04364971|Experimental|Multiradius|Multi Radius(MR) femoral design will be perfomed to patients who is going to total knee arthroplasty. Multi Radius femoral design is one of knee prosthesis' pattern which shows variation in knee kinematics
89688342|NCT01728935|Other|Tenofovir disoproxil|Tenofovir disoproxil 300mg daily
89688343|NCT03834311|Experimental|isokinetic|
89688344|NCT03834311|Active Comparator|exercise band|
89033465|NCT05296616|Experimental|MSQSLHRV|The group in which the mindfulness-based stress reduction intervention will be implemented.
89033466|NCT05296616|No Intervention|Control|The group to which mindfulness-based stress reduction intervention will not be applied
89033467|NCT02915640|Experimental|Remote technology|Remote technology will be used for an initial patient assessment after being contacted by phone from the peripheral center to transfer an acutely ill pediatric patient as assessed by the referral centre care provider.
89519703|NCT03443089|Active Comparator|Reference formulation|Single intramuscular dose administration (1 ampoule) of medroxyprogesterone acetate 25 mg/ampole + estradiol cypionate 5 mg/ampole (Cyclofemina®, Millet Roux Ltda.)
89519704|NCT05241197|Experimental|Low load training with blood flow restriction (LL-BFR) group.|All participants in this arm will use a BFR tourniquet system during the execution of two exercises, unilateral dynamic standing and sitting calf-raises, with a training load of 20% 1 repetition maximum (RM), being progressively increased by 5% every four weeks. Dynamic strength testing will be implemented to re-evaluate the current strength level and adequately adjust the load, using the PowerLift app, which was validated by Balsalobre-Fernandez in 2017. For each exercise, each participant will perform four sets with 30 repetitions the first set and 15 repetitions in the subsequent three sets, counting a total of 75 repetitions. All exercises will be performed in full range of motion (full plantar flexion to full dorsal flexion), with an interset rest period of 1 minute. Three minutes rest was provided between exercises.
89519705|NCT05241197|Active Comparator|High load training (HLT) group.|The HLT group will performed the same exercises than the BFR group, however with a training load of 70% 1RM, being progressively increased by 5% every four weeks from 70% to 80%. This protocol will consist of three sets of 6-12 repetitions. Dynamic strength testing will be implemented to re-evaluate the current strength level and adequately adjust the load, using the PowerLift app, which was validated by Balsalobre-Fernandez in 2017. All exercises will be performed in full range of motion, with an interset rest period of 1 minute and a rest period between exercises of 3 minutes.
89519706|NCT03445429|Experimental|3D-display system|Subjects in this arm will perform the tasks on the minimal-invasive training set-up first with the 3D-display system. Then they will do the NASA task load index questionnaire. After that they will perform the tasks with the 4 K-display system. After that again a NASA Task load index questionnaire is performed.
89519707|NCT03445429|Experimental|4K-display system|Subjects in this arm will perform the tasks on the minimal-invasive training set-up first with the 4K-display system. Then they will do the NASA task load index questionnaire. After that they will perform the tasks with the 3D-display system. After that again a NASA Task load index questionnaire is performed.
89519708|NCT05239949|Experimental|Hypopressive exercises and electrical muscle stimulation (EMS)|"Women included in this group underwent 24 sessions during 8 weeks (3 days/ week). Treatment will be given for 50 minutes in each session. Electrical muscle stimulation (EMS) will be applied in prone lying before every session of hypopressive exercises (HE). A device will use for muscle stimulation at 7Hz for 15 minutes. The intensity of current will gradually increase from zero to a minimum that can be tolerated by the patient. Two electrodes will place medially to the ischial tuberosity and the remaining two will place on the sacral area.~After a 2-minute interval, the patient will be asked to perform HE in an upright position. For this maneuver, the patient will be instructed to inhale, then breathe to expand the ribcage, and then exhale completely. Hold the breath out before relaxing core and ribcage. Four sets of 10 repetitions with a 3-minute interval between each set will be performed."
89033468|NCT02915640|No Intervention|Control|A Nurse Practitioner or General Practitioner from a remote site has a pediatric acute care referral and arranges a transportation. There is an initial call to obtain a patient history, to provide advice to the remote caregiver to initiate specific therapies and to mobilize the specialized team to the patient.
89033469|NCT06026189|No Intervention|Care-as-usual|In the ''care-as-usual'' arm, all patients undergo 'care-as-usual', i.e. a cystoscopy and upper tract imaging (ultrasound or CT-scan)
89033470|NCT06026189|Experimental|'Urine-first' strategy|In the intervention arm, the urine test is used to triage patients for a diagnostic workup ('urine-first' strategy). Only patients with an abnormal test result undergo cystoscopy and upper tract imaging.
89033471|NCT06026163|Experimental|Caffeine citrate group|Infants receive either caffeine citrate in loading dose 20 mg/kg (equivalent for 10 mg/kg caffeine base) and maintenance dose 10 mg/kg/day (equivalent for 5 mg/kg caffeine base).
89033472|NCT06026163|Placebo Comparator|Control group|Infants received equivalent volume of saline.
89033473|NCT06026137|Experimental|eFisioTrack Group|"Use of the eFisioTrack platform in the experimental group to perform active exercises as part of their shoulder rehabilitation. These will. bee performed independently by each patient in a hospital room, using the efisioTrack system without supervision by the physiotherapist.~The subjects will be previously instructed in the use of the system in two 20-minute sessions. The type of exercise and its parameters will be chosen and progressed considering the functional status of the patient and being similar to those executed under the physiotherapist's supervision."
89033474|NCT06026137|Active Comparator|Excercises Group|Patients who performed the exercise program supervised by the physical physiotherapist in a hospital room.
89033475|NCT06026124|Experimental|Spaced retrieval practice during word learning|"Each child will learn 8 novel nouns referring to unfamiliar plants and animals (nepp) and a related meaning (a nepp likes rain). Four nouns will be learned in a spaced retrieval practice condition; four will be learned in a study only practice condition. In the spaced retrieval condition, children will hear the information (word form and meaning) and be asked to immediately retrieve it. Thereafter, they will be asked to retrieve it after hearing 3 intervening word form/meanings. Each retrieval bid will be followed by feedback in the form of hearing the information again. In the study only practice condition, children will simply hear the information (word form and meaning)."
89033476|NCT06026085|Experimental|CE FERULIC|fraxel laser therapy combined with Skinceuticals skin care product(CE FERULIC) and routine sun protection
89608952|NCT04438187|Other|Conservative Arm|If a patient is suspected of having an ICU-acquired HAP/VAP during the conservative period, quantitative or semi-quantitative endobronchial cultures should be sent. If the patient is in septic shock persistent hypotension requiring vasoactive medications to maintain mean arterial pressure (MAP) ≥65 mm HG or persistent lactic acidosis (>2 mmol/L) despite adequate resuscitation) antimicrobials will be initiated immediately. If the patient has new onset organ dysfunction that is presumed to be due to infection (sepsis) then antimicrobials will be initiated at the discretion of the attending intensivist. In the absence of septic shock or sepsis (intensivist discretion), antimicrobials will not be initiated unless objective evidence of pneumonia is present or another documented source of infection is identified mandating treatment with antimicrobials.
89608953|NCT03583125|Experimental|EOC 317|"Dose-escalation: 20 subjects will be given EOC 317 PO in increasing doses from 5 mg up to 60 mg or higher doses. One dose on Day 1, paused for 2 days, and then daily from Day 4 to Day 24.~Dose-expansion: 120 subjects will be given EOC 317 PO QD from Day 1 to Day 21."
89608954|NCT03155217||patients over 75 years|Patients with MM treated with single or combination therapy over 75 years of age.
89608955|NCT03155217||patients between 65 and 75 years|Patients aged 65-75 years with MM treated with single or dual therapy
89608956|NCT03155217||patients less than 65 years|patients less than 65 years with MM treated with single or dual therapy
89608957|NCT01793935|Experimental|Sensoril®|Sensoril® is a proprietary extract of Withania Somnifera
89608958|NCT01793935|Placebo Comparator|Placebo|Placebo
89608959|NCT03292029|Other|T50 Calcification Inhibition Test (CIT)|Measurement of T50 CIT and fetuin-A serum values
89608960|NCT02092025||Azilsartan|Azilsartan 20 mg - 40 mg, tablet, orally, once daily for up to 12 months in participants based upon the disease severity. Participants will receive interventions as part of routine medical care.
89608961|NCT04405011|Experimental|Entecavir 0.5mg daily for 24 weeks|Entecavir will be delivered for 24-week and will be the experimental arm
89608962|NCT04405011|Active Comparator|Entecavir 0.5mg daily for 12 weeks|12-week entecavir will be served as active comparator
89608963|NCT04405011|No Intervention|Control|Control group does not receive prophylactic ETV
89608964|NCT01769443|No Intervention|No Desensitization Therapy|Subject(s) randomized to no desensitization therapy pre-transplant.
89608965|NCT01769443|Experimental|Desensitization Therapy|"Subject(s) randomized to desensitization therapy pre-transplant.~Desensitization therapy regimen pre-transplant: Plasmapheresis for 3 consecutive days (treatment days 0, 1 and 2) followed by concomitant bortezomib dosed at 1.3 mg/m^2 as a 3 to 5 second bolus intravenous injection on treatment days 0, 3, 7 and 10. The first dose of bortezomib is administered between 4-8 hours after the first plasmapheresis session is completed and there must be at least 96 hours between the second and third dose of bortezomib."
89608966|NCT03154827|Experimental|Combination Treatment Single Arm|Combination Treatment of BL-8040 with Atezolizumab
89608967|NCT03159507|Experimental|MAG-EPA|MAG-EPA softgel (500mg), daily dose between 1g and 3.5g
89608968|NCT01768117|Experimental|rLP2086|
89608969|NCT03582969|Experimental|Fecal transplantation|Fecal transplantation of feces from healthy donor via capsules. Oral application.
89608970|NCT03582969|Placebo Comparator|Placebo|Placebo capsules
89608971|NCT01767493|Experimental|[18F]Florbetapir PET imaging|[18F]Florbetapir and PET imaging
89608972|NCT03159429|Experimental|Experimental arm|"Patients randomized to this arm will participate in the new rehabilitation programme.~Intervention: Nasal breathing rehabilitation"
89608973|NCT03159429|Active Comparator|Comparator arm|"Patients randomized to this arm will participate in the usual rehabilitation programme.~Intervention: Standard rehabilitation"
89608974|NCT03159819|Experimental|CAR-CLD18 T cells|"Autologous T Cells with a Claudin18.2-redirected Chimeric Antigen Receptor. Route of administration: Intravenous injection.~Lymphodepletion conditioning regimen will be applied prior to CAR-CLD18 T cell infusion."
89608975|NCT01274182|Experimental|GP2013|
89033477|NCT06026085|Placebo Comparator|0.9% normal saline|fraxel laser therapy combined with 0.9% normal saline and routine sun protection
89033478|NCT06026072|Other|CLAD-V|All patient with renal colic will be eligible. The CLAD-V score will fills by the doctor and seven days after the patient will call back to know if he had a surgical intervention or no.
89033479|NCT06026059||interview with the dietician|"Initially, parent(s) and child will be interviewed together, details of the dietary record, as well as the data needed to calculate the nutritional risk score will be obtained.~The interview will then be only with the child, he will be asked to determine, on his/her own, the portion of food he/she thinks he/she ate the previous evening, using the SEFI score.~Finally, one of the two parents will determine, on their own, the portion of food they think their child ate the previous evening, using the SEFI score."
89033480|NCT06026020||Behcet's syndrome patients with intestinal involvement|
89033481|NCT06026020||Behcet's syndrome patients without intestinal involvement|
89033482|NCT06026020||Inflammatory bowel disease patients|
89033483|NCT06026020||Health control|
89033484|NCT06026007|Experimental|Control group|patient in this group received advice only for edema relief
89033485|NCT06026007|Experimental|Circulatory exercise group|patient in this group received advice in addition to circulatory exercise for edema relief
89608976|NCT01274182|Active Comparator|MabThera|
89608977|NCT01274182|Active Comparator|Rituxan|
89608978|NCT01984229|Experimental|Cohort A|There will be 3 dosing periods in the study: Period 1 (Days 1 to 7), Period 2 (Days 8 to 14), and Period 3 (Days 15 to 18). Alectinib will be administered as a 40 milligrams (mg) single oral dose on Day 1 (Period 1) and Day 15 (Period 3) with an identical standardized meal (identical meal on Day 1 and Day 15 across all participants). On Days 8 to 14 (Period 2) and Days 15 to 18 (Period 3) posaconazole will be administered as a 400-mg twice daily (BID) oral dose after a high-fat meal. The follow-up assessments will occur within 10 to 14 days after the last dose of posaconazole.
89608979|NCT01984229|Experimental|Cohort B|There will be 3 dosing periods in the study: Period 1 (Days 1 to 7), Period 2 (Days 8 to 14), and Period 3 (Days 15 to 21). Alectinib will be administered as a single oral dose at the dose selected based on Cohort A data on Day 1 (Period 1) and Day 15 (Period 3) with an identical standardized meal (identical meal on Day 1 and Day 15 across all participants). On Days 8 to 14 (Period 2) and Days 15 to 21 (Period 3) posaconazole will be administered as a 400-mg BID oral dose after a high-fat meal. The follow-up assessments will occur within 10 to 14 days after the last dose of posaconazole.
89608980|NCT03582735|Experimental|Nerve gliding exercise|Three series of 15 daily repetition of the rehabilitation exercise targetting nerve excursion
89608981|NCT03582735|No Intervention|Control|No intervention according to current practice.
89608982|NCT03582501|Experimental|Healthy volunteers|All volunteers will be studied at rest and during experimental condition (lower body negative pressure)
89608983|NCT01835899|Experimental|Placebo to BI 1015550|placebo
89608984|NCT01835899|Experimental|BI 1015550 low dose 1|powder for oral solution
89608985|NCT01835899|Experimental|BI 1015550 low dose 2|powder for oral solution
89608986|NCT01835899|Experimental|BI 1015550 medium dose 1|powder for oral solution
89033486|NCT06026007|Experimental|Acupressure group|patient in this group received advice in addition to acupressure for edema relief
89033487|NCT06025981|Other|Preliminary Phase|20 healthy subjects will perform an experimental session for characterization of functional status with clinical scales; characterization of gait with SWalker using ROM and EMG at different speeds and weight bearing; and assessment of system usability with VR using standardized questionnaires.
89608987|NCT01835899|Experimental|BI 1015550 medium dose 2|powder for oral solution
89608988|NCT05701449||Patients applying a prediction model for postoperative pulmonary complications|
89033488|NCT06025981|Other|Phase I and II|In both phases 100 subjects will perform a gait rehabilitation intervention program (phase 1) and maintenance (phase 2), in which they will employ the use of the robotic walker and virtual reality depending on the group and phase. The evolution of functional clinical parameters will be studied for both groups and phases.
89033489|NCT06025968|Experimental|i-CBT|Cognitive behavioral therapy for insomnia with adjustment for MS.
89033490|NCT06025968|Active Comparator|Applied relaxation|Applied relaxation with adjustments for MS.
89033491|NCT06025955|Experimental|minimally invasive non surgical therapy|Experimental sites designated to receive non-surgical treatment will be submitted to careful subgingival debridement using curettes and ultrasonic device using 3.5 x magnification.
89033492|NCT06025955|Active Comparator|open flap debridement|Surgical technique will be used and the full-thickness flap will be minimally elevated. The granulation soft tissue will be dissected with a blade and carefully removed with curettes.
89033493|NCT02916030||Group 1 (hemorrhagic stroke)|All participants will be subjected to thorough history taking, full clinical and neurological examination. Stroke subtype will be classified according to the criteria of Trial of Org 10172 in acute Stroke Treatment (TOAST) classification.
89033494|NCT02916030||Group 2 (Ischemic stroke)|All participants will be subjected to thorough history taking, full clinical and neurological examination. Stroke subtype will be classified according to the criteria of Trial of Org 10172 in acute Stroke Treatment (TOAST) classification.
89608989|NCT05701449||Patients non-applying a prediction model for postoperative pulmonary complications|
89608990|NCT03582423|Experimental|electro-acupuncture group|Eight acupoints are chosen: he gu (LI4), nei guan(PC6), qu chi (LI12), ba xie (EX-UE9), zu san li (ST36), san yin jiao (SP6), tai chung (LV3) and ba feng (EX-LE10). The use of ba xie (EX-UE9) and ba feng (EX-LE10) will be optional if skin lesions of hands and feet occurs due to Capecitabine (Xeloda).Disposable acupuncture needles will be inserted at a depth of 10-25mm into the points. We will deliver electrical stimulation with continuous waves at 2 Hz, at an intensity of each patient's minimum sensation of stimulation through the electrical acupuncture stimulation instrument to the points. The needles will be retained in position for 25 minutes.
89033495|NCT06025916|Active Comparator|Tranexamic acid|Will receive 20ml of tranexamic acid 100mg/ml at a timepoint when the cervix is dilated 6 cn (for multipara) and 8 cm for primipara
89033496|NCT06025916|Placebo Comparator|Placebo|Will receive 20ml of placebo solution, equivalent in appearance and taste to tranexamic acid solution but with no active ingredient, at a timepoint when the cervix is dilated 6 cn (for multipara) and 8 cm for primipara
89519709|NCT05239949|Experimental|Pelvic floor muscle exercises and electrical muscle stimulation (EMS)|"Women included in this group underwent 24 sessions during 8 weeks (3 days/ week). Treatment will be given for 50 minutes in each session. Electrical muscle stimulation (EMS) will be applied in prone lying before every session of pelvic floor muscle exercises. A device will use for muscle stimulation at 7Hz for 15 minutes. The intensity of current will gradually increase from zero to a minimum that can be tolerated by the patient. Two electrodes will place medially to the ischial tuberosity and the remaining two will place on the sacral area.~After a 2-minute interval, the patient will be asked to perform pelvic floor muscle exercises in a sitting position. The patient is instructed to hold each contraction for 6 seconds, with three to four contractions added on the top. Four sets of 10 repetitions with a 2-minute interval between each set will be performed."
89519710|NCT03445351|Experimental|Aerobic, resistance and concorrent|The group underwent exercise program with protocols of resistance training, aerobic training and concurrent training, with frequency of three times per week.
89519711|NCT03879551|Active Comparator|Real rTMS|Real rTMS high frequency stimulation (25 HZ), with intensity of 80% of resting motor threshold detected from the hand motor area, with total 2000 pulses for each hemisphere on the hand motor area for 10 consecutive sessions totally over period of 10 days.
89519712|NCT03879551|Sham Comparator|Sham rTMS|Sham rTMS high frequency stimulation (25 HZ), with intensity of 80% of resting motor threshold detected from the hand motor area, with total 2000 pulses for each hemisphere with coil perpendicular on scalp for 10 consecutive sessions totally over period of 10 days.
89519713|NCT03445117|Experimental|Intervention|Clinics assigned to the intervention arm will receive an educational intervention. This comprises posters on vaccination to be put up in the clinic, as well as a flyer which will be handed out by the clinic assistants to all patients 65 years and above, at the point of registration. The poster and flyer content will provide simple messaging to encourage patients to receive influenza and pneumococcal vaccinations and inform them of available healthcare subsidies.
89519714|NCT03445117|No Intervention|Control|Clinics assigned to control arm will run as per their normal operations and not have the interventions implemented.
89519715|NCT03445039|Experimental|TSFE using osteotomes with bone grafting|The patients in this group will receive transalveolar sinus floor elevation with osteotomes and mallet. The bone substitute is placed in this group.The interventions in the arm are bone grafting and the TSFE will be performed by osteotomes.
89519716|NCT03445039|Experimental|TSFE using osteotomes without bone grafting|The patients in this group will receive transalveolar sinus floor elevation with osteotomes and mallet. The bone substitute will not be placed in this group.The intervention in the arm is the TSFE will be performed by osteotomes.
89033497|NCT06025890|Experimental|Language Disorder|The language disorder group had to complete a two-year follow-up and intervention. Collect blood samples from 600 cases of language disorder.
89033498|NCT06025890|Experimental|Attention Deficit Hyperactivity Disorder|The ADHD group had to complete a two-year follow-up and intervention.Collect blood samples 800 cases of ADHD, and complete a fNIRS task test from 800 ADHD patients.
89519717|NCT03445039|Experimental|modified TSFE with bone grafting|The patients in this group will receive modified transalveolar sinus floor elevation with the Dask drills. The cortical plate of the sinus floor is grinded or removed by the dome like drills. And the membrane is elevated by the surgical instruments. The bone substitute is placed before the implant placement.Interventions in the arm are bone grafting and the TSFE will be performed by dask drills.
89519718|NCT03445039|Experimental|modified TSFE without bone grafting|The patients in this group will receive modified transalveolar sinus floor elevation with the Dask drills. The cortical plate of the sinus floor is grinded or removed by the dome like drills. And the membrane is elevated by the surgical instruments. The bone substitute will not be placed in this group.The intervention in the arm is the TSFE will be performed by dask drills.
89033499|NCT06025890|No Intervention|Normal children|For children aged 1-4, 2 developmental behavioral specialists with associate professor titles or above exclude language barriers.
89033500|NCT06025890|No Intervention|Healthy children|Children aged 3-6, except ADHD with 2 developmental behavioral and/or psychiatrists with associate professor titles or above.
89033501|NCT06025864|Experimental|Intervention Group|Support for breastfeeding and depletion of breast milk throughout the 6 months. Free and professional support through monthly consultations and videos on the subject.
89519719|NCT03444883|Active Comparator|Treatment Group|10mg Ilaprazole x 2 tablets
89519720|NCT03444883|Placebo Comparator|Control Group|10mg placebo of Ilaprazole x 2 tablets
89519721|NCT05206097|Experimental|Physical Activity Program|
89519722|NCT03443011|Experimental|participants|All participants will be examined with both CT techniques. First a low dose CT without intravenous contrast followed by the standard method, a full dose CT with intravenous contrast
89519723|NCT03467399|Experimental|Cochlear implant users|This is a within-subject, repeated measures study. There was one arm in this study, each subject served as their own control. All subjects received all interventions.
89519724|NCT03109717||Treatment Resistant Depression|Screened for eligibility using several psychiatric assessments. If qualifies to participate in the study, will have to stop any antidepressants that they are taking to prepare for the use of Monoamine Oxidase Inhibitor(MAOI). After a two week washout period, subjects will have an fMRI and will be started on a MAOI. Then be followed for 8 weeks, part of routine care.
89519725|NCT03109717||Healthy Control|Screen for eligibility, then MRI.
89519726|NCT03467321||Pregnant group|Balance with the one leg balance test with the eyes open and closed, pulmonary functions with a spirometer, and LBP with the Visual Analogue Scale (VAS) were assessed.
89057265|NCT04543604|Experimental|Test group1 - Leaflet with visual aid|Information concerning etiology, prevalence, risk indicators and preventive measures of peri-implantitis were included. Relevant scientific bibliography supported the statements. Along, pictograms were supplemented to display the prevalence of disease with and without the known indicator.
89519727|NCT03467321||Non-pregnant group|Balance with the one leg balance test with the eyes open and closed, pulmonary functions with a spirometer, and LBP with the Visual Analogue Scale (VAS) were assessed.
89519728|NCT05676229|Placebo Comparator|Placebo|Volunteers supplemented with maltodextrin
89519729|NCT05676229|Active Comparator|Probiotic Blend|Lactobacillus gasseri CCT 7850 and Bifidobacterium lactis CCT 7858 - Final concentration: 1 x 10e10 UFC/ day
89519730|NCT05439785|Experimental|Group 1|Dental floss
89519731|NCT05439785|Experimental|Group 2|Interdental brush
89519732|NCT03442621|Experimental|Relacorilant Fasted|Relacorilant Fasted
89519733|NCT03442621|Experimental|Relacorilant with a high fat breakfast|Relacorilant with a high fat breakfast
89519734|NCT03442621|Experimental|Relacorilant with a moderate breakfast|Relacorilant with a moderate breakfast
89519735|NCT03442543|Experimental|charcoal|
89519736|NCT03442543|Experimental|silver wire|
89519737|NCT03444805||NISSC-2|SSC patients treated with AHSCT
89057266|NCT04543604|Experimental|Test group2 - Leaflet with visual aid (L-NVA)|Information concerning etiology, prevalence, risk indicators and preventive measures of peri-implantitis were included. Relevant scientific bibliography supported the statements. No pictograms were supplemented.
89519738|NCT03467087|Experimental|Electrical muscle stimulation|Electrical muscle stimulation is administered on both thighs and upper arms using a Myopuls 2000D device. Pre-set training time is 30 minutes per day (15 minutes for thighs and 15 minutes for upper arms) for at least 5 days a week.
89519739|NCT03444649|Experimental|Dosis finding|Epacadostat is given for 2 cycles of 28 days at a dose according to the titration design together with Standard chemotherapy (Idarubicin and Cytarabine)
89519740|NCT05439473|Placebo Comparator|Placebo|
89519741|NCT05439473|Active Comparator|Treatment|
89519742|NCT04453241|Experimental|NBP615|Adult : 3 doses of vaccination Adolescent :2 doses of vaccination
89519743|NCT04453241|Active Comparator|GARDASIL|Adult : 3 doses of vaccination Adolescent :2 doses of vaccination
89519744|NCT05439239|Placebo Comparator|Normoxic group females|The participants in this group (12 females) will perform a repeated sprint training in normoxia.
89519745|NCT05439239|Experimental|Hypoxic group females|The participants in this group (12 females) will perform a repeated sprint training in hypoxia.
89519746|NCT05439239|Placebo Comparator|Normoxic group males|The participants in this group (12 males) will perform a repeated sprint training in normoxia.
89519747|NCT05439239|Placebo Comparator|Hypoxic group males|The participants in this group (12 males) will perform a repeated sprint training in hypoxia.
89519748|NCT03444571|No Intervention|Control|
89519749|NCT03444571|Experimental|DNA based diagnosis|
89519750|NCT03442387|Experimental|Positive frame|The numerical expressions were presented in a positive way: e.g. treatment was successful for 4 out of 10 persons.
89519751|NCT03442387|Experimental|Negative frame|The numerical expressions were presented in a negative way: e.g. treatment was unsuccessful for 6 out of 10 persons.
89519752|NCT02572765||Normotensive|Normotensive subjects
89519753|NCT02572765||Hypertensive|Hypertensive subjects
89519754|NCT04898803||conventional gastroscopy training course|physicians receive the DGVS-recommended training, consisting of a 2-day course with 1 hour of simulator training
89519755|NCT04898803||extended simulator course|physicians receive a two-day simulator course with a minimum of 6 hours of simulator training per trainee, structured in stages in the sense of progressive or mastery learning. The initial part of the training will be part-task training.
89519756|NCT03444493|Experimental|Exercise|The exercise group performed specific localized exercises aimed at restoring the stabilizing protective function of the transversus abdominis (TrA). The exercises were designed specifically to activate and train the isometric holding function of the TrA muscle at the affected vertebral segment. Additionally, the exercise group was informed about protecting for biomechanics of lumbar spine.
89519757|NCT03444493|No Intervention|Control|Control group was informed about protecting for biomechanics of lumbar spine.
89519758|NCT01328951|Experimental|Early Erlotinib|Participants will receive blinded erlotinib as 150 mg PO once daily in the maintenance setting until disease progression, death, or unacceptable toxicity. Those who demonstrate disease progression may be unblinded to receive an approved second-line therapy (but not EGFR targeted therapies) until disease progression, death, or unacceptable toxicity. Participants may be observed during a final SFU period after discontinuation from study treatment.
89519759|NCT01328951|Placebo Comparator|Late Erlotinib|Participants will receive blinded placebo tablets PO once daily in the maintenance setting until disease progression, death, or unacceptable toxicity. Those who demonstrate disease progression may be unblinded to receive second-line erlotinib as 150 mg PO once daily until disease progression, death, or unacceptable toxicity. Participants may be observed during a final SFU period after discontinuation from study treatment.
89519760|NCT03467009|Experimental|iPACT Intervention|"In-clinic brief session, introducing basic principles of cognitive behavioral theory and the structure of the text-message portion of the intervention.~Eight-week longitudinal tailored CBT-based text-message program."
89519761|NCT03467009|Active Comparator|Control: Enhanced Usual Care (EUC)|The investigators will provide participants with a standard resource sheet with information on bullying and mental health resources.
89519762|NCT03467009|Experimental|iPACT Intervention- App|"In-clinic brief session, introducing basic principles of cognitive behavioral theory and the structure of the message portion of the intervention delivered via app.~Eight-week longitudinal tailored CBT-based message program delivered via app."
89519763|NCT03466931|Experimental|Dietary intervention|Meals containing Milk and Milk
89519764|NCT03466931|No Intervention|Historical cohort|Standard care
89519765|NCT03466619|Experimental|inflatable penile prosthesis (IPP)|inflatable penile prosthesis (IPP)
89519766|NCT05438459|Experimental|GAIA-102 as a single agent|GAIA-102: 1 vial (2 x 10^8 cells) as dose at a fixed dose, on 1 to 3 times by weekly for 3 consecutive weeks.
89033502|NCT06025864|No Intervention|Control Group|"All mothers were followed up for 6 months and received a breastfeeding support booklet virtually, through a cell phone application. The booklet provides basic information about breastfeeding and possible complications. The recruited mothers also received a notebook to record the date, duration, volume and frequency of breastfeeding and/or milk collections, and the use of alternative routes such as a bottle, cup or enteral nutrition. At the initial visit, all mothers were given a standard measuring cup to measure the volume of milk used up in the household each day.~In addition, all mothers received a call 7 days after delivery to apply the Portuguese version of the Breastfeeding Self-Efficacy Survey - Short Form: BSES-SF. This questionnaire was reapplied after 90 days."
89033503|NCT06025851|Experimental|Anti-human CCL24 monoclonal antibody (CM-101)|Anti-human CCL24 monoclonal antibody (CM-101) Four (4) treatment groups (0.75 mg/kg, 2.5 mg/kg, 5.0 mg/kg, 10 mg/kg)
89033504|NCT06025851|Placebo Comparator|Placebo|Placebo - intravenous infusion
89033505|NCT06025825||Buccal infiltration anesthesia + palatal infiltration anesthesia (with articaine HCl)|Before extraction, buccal and palatal infiltration anesthesia with articaine will perform. Following anesthesia, extraction will carry out.
89033506|NCT06025825||Buccal infiltration anesthesia + palatal infiltration anesthesia (with lidocaine HCl)|Before extraction, buccal and palatal infiltration anesthesia with lidocaine will perform. Following anesthesia, extraction will carry out.
89519767|NCT05438459|Experimental|GAIA-102 and pembrolizumab in combination|"GAIA-102: 1 vial (2 x 10^8 cells) as dose at a fixed dose, on 1 to 3 times by weekly for 3 consecutive weeks.~Pembrolizumab：200 mg on Day 1."
89210697|NCT04085783|Experimental|endometrial PRP|In study group (75 patients), intrauterine infusion of PRP was done 48 hrs. before ET. PRP was prepared from autologous blood and it was made by using two steps centrifuge process. All Blastocyst transfers were performed under ultrasound guidance by one expert gynecologist with infertility fellowship. ET was performed according to American Society for Reproductive Medicine (ASRM) guidelines 2013 (Two or three embryos for each participant). On PRP infusion day, 17.5 ml of peripheral venous blood was drawn into a syringe that contains 2.5 ml of Acid Citrate and centrifuged immediately at 1200 rpm for 12 min to separate red blood cells, then plasma was centrifuged again at 3300 rpm for 7 min to obtain PRP that contained platelet 4-5 times more than peripheral blood. 0.5- 1 ml of PRP was infused into the uterine cavity with embryo transfer catheter (Wallace - Smiths, UK). On the other side, No PRP was done in control group. Pregnancy tests were done 12 days after ET.
89210698|NCT00987363|Experimental|Low dose (1x10 E8)|Dose of 1x10 E8 autologous bone marrow-derived mononuclear cells
89210699|NCT00987363|Experimental|Intermediate dose (5x10 E8)|Dose of 5x10 E8 autologous bone marrow-derived mononuclear cells
89210700|NCT00987363|Experimental|High dose (1x10 E9)|Dose of 1x10 E9 autologous bone marrow-derived mononuclear cells
89210701|NCT00987363|No Intervention|Control|Conventional treatment established by the good clinical practice
89033507|NCT06025825||Buccal infiltration anesthesia (5 minutes waiting time with articaine HCl)|Before extraction, buccal infiltration anesthesia with articaine will perform. After 5 minutes, extraction will carry out.
89033508|NCT06025825||Buccal infiltration anesthesia (5 minutes waiting time with lidocaine HCl)|Before extraction, buccal infiltration anesthesia with lidocaine will perform. After 5 minutes, extraction will carry out.
89033509|NCT06025825||Buccal infiltration anesthesia (8 minutes waiting time with articaine HCl)|Before extraction, buccal infiltration anesthesia with articaine will perform. After 8 minutes, extraction will carry out.
89210702|NCT04086563|Experimental|Action observation|The patients will observe a 25 minutes clip of neurodynamic exercises of the hand.
89519768|NCT05438381|Active Comparator|ART group|Atraumatic restorative technique: excavation of caries then application of Glass ionomer capsule (GC, USA)
89519769|NCT05438381|Experimental|SMART group|SMART technique: excavation of caries and application of silver diamine fluoride (SDF 38%) then glass ionomer cement
89519770|NCT03466385|Experimental|Nasal High Flow|Patients randomized to NHF device with initial settings of flow=50-60 L·min-1, temperature=37ο Celsius and FiO2 adjusted to maintain SpO2 between 88%-92%.
89519771|NCT03466385|Active Comparator|Non-Invasive Ventilation|Patients randomized to NIV with initial settings EPAP=3cmH2O, IPAP=15cmH2O, I:E=1:2 to 1:3, inspiratory time=0.8-1.2sec and FiO2 adjusted to maintain SpO2 between 88%-92%.
89519772|NCT03466307||Group A|Thirty patients with nocturnal shoulder pain
89519773|NCT03466307||Group B|Thirty patients without nocturnal shoulder pain
89519774|NCT03466307||Group C|Healthy controls
89519775|NCT03466229|Active Comparator|Antioxidant|Androferti - 1 twice per day
89519776|NCT03466229|Placebo Comparator|Placebo|Placebo - 1 twice per day
89519777|NCT02611817|Experimental|Vedolizumab SC 108 mg Maintenance Arm|"Open-label Induction: vedolizumab IV 300 milligram (mg), infusion at Week 0 (Day 1) and Week 2 (Day 15)~Double-blind Maintenance: vedolizumab SC 108 mg injection once every 2 weeks (Q2W) starting at Week 6 up to Week 50"
89519778|NCT02611817|Placebo Comparator|Placebo SC Maintenance Arm|"Open-label Induction: vedolizumab IV 300 mg, infusion at Week 0 (Day 1) and Week 2 (Day 15)~Double-blind Maintenance: matching placebo to vedolizumab SC injection Q2W starting at Week 6 up to Week 50"
89519779|NCT03465995||NKI iPAS Diagnostic Protocol|Research participants who qualify for this study will put on EKG leads, and then a non-invasive device called iPAS, which will record heart rate and eye tracking data while participants perform a task on the screen of the device. The testing session will not exceed 30 minutes. Participants will take a total of 3 recordings over a period of roughly 5 weeks.
89519780|NCT05433233|Experimental|HAPA|Participants assigned additional 3,000 steps/day on 5 days/week. Participants also received an additional 15 minutes of structured conversation with research personnel following the Health Action Process Approach Theory for behavior change.
89519781|NCT05433233|Experimental|No HAPA|Participants assigned additional 3,000 steps/day on 5 days/week and general conversation with researchers in regard to behavior change, not following a structured dialogue.
89519782|NCT03465917|Experimental|Renal Denervation|Renal denervation using the Peregrine Catheter for extravascular administration of ethanol
89519783|NCT05430893||Athletic pubalgia|Patients with chronic athletic pubalgia for whom medical and/or surgical treatments have failed and who were treated with an intra-muscular injection of botulinum toxin A injection under ultrasound guidance
89033510|NCT06025825||Buccal infiltration anesthesia (8 minutes waiting time with lidocaine HCl)|Before extraction, buccal infiltration anesthesia with lidocaine will perform. After 8 minutes, extraction will carry out.
89033511|NCT06025812|Experimental|0-1-month immune program study group|According to the 0-1-month immunization schedule, two doses of 25 μg/0.5 ml Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells) were injected into the deltoid muscle of the upper arm.
89033512|NCT06025812|Active Comparator|0-1-month immune program control group|According to the 0-1-month immunization schedule, two doses of 25 μg/0.5 ml recombinant novel coronavirus protein vaccine (CHO cells) were injected into the deltoid muscle of the upper arm.
89033513|NCT06025812|Experimental|0-6-month immune program study group|"The subjects were from the LKM-2023-NCV-02 project and were vaccinated on a voluntary basis with 25 μg/0.5 ml Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells) at the visit 6 months after the exemption."
89033514|NCT06025812|Active Comparator|0-6-month immune program control group|"The subjects were from the LKM-2023-NCV-02 project and were vaccinated on a voluntary basis with 25 μg/0.5 ml recombinant novel coronavirus protein vaccine (CHO cells) at the visit 6 months after the exemption."
89210703|NCT04086563|Experimental|Mirror Therapy|With a mirror glasses, the patients will execute neurodynamic movements of their non-dominant hand during 25 minutes.
89210704|NCT04086563|Active Comparator|Strength Training|Strength protocol for the dominant hand.
89210705|NCT04086563|Experimental|Neurodynamic exercise|Active neurodynamic exercises for the dominant hand.
89519784|NCT02735915|Experimental|GSK1437173A vaccine Group|Subjects who completed vaccination course of 2 doses of HZ/su vaccine (group 50 μg gE/AS01B) in the study Zoster-003 (NCT00434577) were included in this study. 62 of these subjects further received 1 or 2 additional doses of HZ/su vaccine in the revaccination phase of this study
89519785|NCT03465839|Experimental|Bedside handover|Education for improving handovers quality + Education for improving bedside handovers
89519786|NCT03465839|Active Comparator|Control|Education for improving handovers quality
89519787|NCT03130283|Active Comparator|Home Hospitalization|Visit every day at home
89519788|NCT03130283|Placebo Comparator|Conventional Hospitalization|Review Clinical History
89519789|NCT03130049|Experimental|Patients with postoperative pain, NRS >3|Patients reporting postoperative pain (NRS >3) localized to the center of the knee (10 patients) will receive a popliteal plexus block
89519790|NCT03130049|No Intervention|Patients with postoperative pain, NRS ≤ 3|(approx. 90 patients)
89033515|NCT06025786|Experimental|Districts with established and operational BNP implementation|The intervention arm consists of nine districts from four provinces and two regions of Pakistan where the Benazir Nashonuma Program (BNP) is operational, providing reproductive and healthcare services to pregnant women and their children under the age of two.
89033516|NCT06025786|No Intervention|Districts without BNP implementation and functionality|The control arm comprises of nine districts where Benazir Nashonuma Program (BNP) has not been implemented. These districts are comparable to their respective intervention districts in terms of average maternal BMI and prevalence of stunting.
89033517|NCT06025773|Experimental|Arm-A|Period 1 : Reference Drug (AD-2121), Period 2 : Test Drug (AD-212-A)
89033518|NCT06025773|Experimental|Arm-B|Period 1 : Test Drug (AD-212-A), Period 2 : Reference Drug (AD-2121)
89033519|NCT06025630|Experimental|Endoplasmic Reticulum Stress Inhibition|
89033520|NCT06025630|Placebo Comparator|Placebo|
89033521|NCT06025617|Experimental|Intervention arm|Patients referred by their GP under suspicion of suffering from FSD are randomized to the intervention arm.
89210706|NCT00820820|Active Comparator|Rouvax|
89210707|NCT00820820|Placebo Comparator|Placebo|Sub cutaneous injection of vehicle
89210708|NCT00987441|Active Comparator|Local anesthetic plus opioid 1|Local anesthetic (ropivacaine 0.125%) plus first opioid dose (sufentanil 0.3 microgram/ml) delivered peridural space
89519791|NCT05419973||Pregnant Women|Women in third semester of pregnancy who are willing to include their babies as samples for the next study, no history of abortion, and not suffering from hypertension and preeclampsia.
89519792|NCT05419973||Infants|Babies born from mothers who are willing to be included in the study, aterm, with birth weight more than 2500 grams. No congenital abnormalities at birth and no acute infection at birth.
89519793|NCT02522351|Active Comparator|Thicken Up Clear concentration 1|Thicken Up Clear at concentration 1
89519794|NCT02522351|Active Comparator|Thicken Up Clear concentration 2|Thicken Up Clear at concentration 2
89519795|NCT02522351|Active Comparator|Thicken Up Clear concentration 3|Thicken Up Clear at concentration 3
89519796|NCT02522351|Experimental|Cereal extract concentration 1|Cereal extract at concentration 1
89519797|NCT02522351|Experimental|Cereal extract concentration 2|Cereal extract at concentration 2
89519798|NCT02522351|Experimental|Cereal extract concentration 3|Cereal extract at concentration 3
89519799|NCT02557139|Experimental|Regimen A|Single-dose belumosudil 200 mg tablet in the fasted state
89519800|NCT02557139|Experimental|Regimen B|Single-dose belumosudil 200 mg tablet in the fed state
89519801|NCT02557139|Experimental|Regimen C|Single-dose belumosudil capsules (administered as two 100-mg capsules) in the fed state
89519802|NCT04637399||Ulcerative Colitis|Participants diagnoses with Ulcerative Colitis.
89519803|NCT04637399||Crohn's Disease|Participants diagnosed with Crohn's Disease.
89519804|NCT01328717|Experimental|Intended Users of the System|Subjects with diabetes used Contour Link Investigational Blood Glucose Monitoring System
89533100|NCT05538039|Experimental|Distract with play dough|The intervention will begin approximately 30 minutes before premedication. The initiative will be applied to both the child and the parent participating in the research. Attempts to distract with play dough will be conducted under investigative coaching for at least 10 minutes. If after 10 minutes the child or parent wants to continue playing, they will be told that they can play as long as they want. Each family will be given 4 boxes of play dough. After the play is played, the play dough will not be put back in the package, and the child and parents will be told that they can keep the shapes they have made if they wish. The play dough used will be provided by the researchers and will be given to the participants after the intervention.
89519805|NCT01677741|Experimental|Part 1: Dabrafenib treatment|Three subjects will receive a single dose of 3 mg/kg dabrafenib on Day 1 and repeat dose will begin from Day 2, evenly divided in two daily doses. Once all 3 subjects have been fully evaluated for the first 28 days (including Day 15 PK) and no DLTs are observed, a next subject will be enrolled at the next higher dose levels (i.e., dose escalation to 3.75 mg/kg [+1] and may be further to 4.5 mg/kg [+2] and so on). If all 3 subjects have not been fully evaluated for the first 28 days or 1 DLT occurred, the fourth subject will be enrolled at the same dose level. If 2 or more DLTs are observed, the next subject will be enrolled at the next lower dose level (i.e., de-escalated to 2.25 mg/kg [-1] and may be further to 1.5 mg/kg [-2]). Similarly, the process is repeated for the fifth and sixth subjects in a cohort. All subjects will receive treatment till end of study.
89519806|NCT01677741|Experimental|Part 2: Cohort 1 Low-Grade Gliomas with BRAF V600 mutations|Subjects with low-grade gliomas with BRAF V600 mutations will receive the single selected final dose (based on MTD and the age of the subjects) from Part 1 on Day 1. Repeat dosing will begin from Day 2, twice daily till end of study.
89688345|NCT04356547|Active Comparator|Fiberoptic intubation using laryngeal mask AuraGain|Participants should perform an fiberoptic tracheal intubation through the AuraGain laryngeal mask, in a pediatric simulator. Will be evaluated the success rate at the first attempt and other secondary outcomes
89519807|NCT01677741|Experimental|Part 2: Cohort 2 High-Grade Gliomas with BRAF V600 mutations|Subjects with high-grade gliomas with BRAF V600 mutations will receive the single selected final dose (based on MTD and the age of the subjects) from Part 1 on Day 1. Repeat dosing will begin from Day 2, twice daily till end of study.
89519808|NCT01677741|Experimental|Part 2: Cohort 3 LCH with BRAF V600 mutations|Subjects with LCH with BRAF V600 mutations will receive the single selected final dose (based on MTD and the age of the subjects) from Part 1 on Day 1. Repeat dosing will begin from Day 2, twice daily till end of study.
89210709|NCT00987441|Active Comparator|Local anesthetic plus opioid 2|Local anesthetic (ropivacaine 0.125%) plus second opioid dose (sufentanil 0.4 microgram/ml) delivered peridural space
89210710|NCT00987441|Active Comparator|Local anesthetic plus opioid 3|Local anesthetic (ropivacaine 0.125%) plus third opioid dose (sufentanil 0.5 microgram/ml) delivered peridural space
89519809|NCT01677741|Experimental|Part 2: Cohort 4 Melanoma and PTC with BRAF V600 mutations|Subjects with other tumors with BRAF V600 mutations will receive the single selected final dose (based on MTD and the age of the subjects) from Part 1 on Day 1. Repeat dosing will begin from Day 2, twice daily till end of study.
89519810|NCT02457221|Experimental|Tacrolimus group|Tacrolimus capsules + steroid
89519811|NCT02457221|Active Comparator|Cyclophosphamide group|Cyclophosphamide injections + steroid
89519812|NCT03465293||SUDD post-menopausal female|Post-menopausal women with non-specific left side pain and altered bowel habit who are having mechanical bowel preparation for a colonoscopy
89519813|NCT05302427|Experimental|Massage group|The massage group will be shown live one-to-one baby massage training via Microsoft Teams by the researcher, and the mother will be asked to apply it to her baby at the same time. Baby massage training; It consists of leg massage, face-abdominal massage, arm-chest massage and back massage and will be completed in four weeks.
89519814|NCT05302427|No Intervention|Control group|Infant massage training will not be given to the mothers of the babies in the control group until the 20th week.
89519815|NCT04660227|Experimental|Exercise Group|Participants in the online exercise program group will be given a treatment protocol consisting of aerobic exercise and strengthening exercises in the presence of a physiotherapist for a total of 8 weeks, 2 days a week for 1 hour.
89519816|NCT04660227|Other|Control Group|Participants in the control group will be put on the waiting list after all assessment methods have been applied and will be re-evaluated at the end of 8 weeks.
89519817|NCT05263895|Active Comparator|Treatment A: PF-0732133/ritonavir|PF-07321332 ritonavir
89519818|NCT05263895|Experimental|Treatment B: PF-07321332/ritonavir|PF-07321332 ritonavir
89519819|NCT05263895|Experimental|Treatment C: PF-07321332/ritonavir|PF-07321332 ritonavir
89519820|NCT05263895|Experimental|Treatment D: PF-07321332/ritonavir|PF-07321332 ritonavir
89519821|NCT05263895|Experimental|Treatment E: PF-07321332|PF-07321332
89519822|NCT03134781|Experimental|Control|Participated only in measurements at baseline, at 20 weeks and at 40 weeks.
89519823|NCT03134781|Experimental|Training|Participated in a supervised 40-week DoIT workout exercise training program and in measurements at baseline, at 20 weeks and at 40 weeks.
89519824|NCT03134781|Experimental|Training-Detraining|Participated in a supervised 20-week DoIT workout exercise training program and then entered a 20-week detraining period. They also participated in measurements at baseline, at 20 weeks and at 40 weeks.
89519825|NCT05233241|Experimental|Patients with acute drug-induced interstitial nephritis|Patients with acute drug-induced interstitial nephritis
89519826|NCT03465215|Experimental|Assessment of inflammation grade|Tissue obtained by CD patients will be analyzed using digital holographic microscopy and comparing histological analysis.
89519827|NCT03344991|Active Comparator|Cardboard Cot Care|Stable infant will be transferred to cardboard cot, lined with reflective film for duration of hospital stay following weaning from radiant warmer. Infant's axillary temperature will be taken at 1 hour, 6 hours, 24 hours after being placed in the cot or crib, and then once every 24 hours until discharge.
89519828|NCT03344991|Placebo Comparator|Open Crib|Stable infant will be transferred to standard of care open crib for duration of hospital stay following weaning from radiant warmer. Infant's axillary temperature will be taken at 1 hour, 6 hours, 24 hours after being placed in the cot or crib, and then once every 24 hours until discharge.
89519829|NCT01709981|Experimental|Colchicine|1.2mg colchicine 1 to 2 hours prior PCI, followed by 0.6mg one hour later
89519830|NCT01709981|Placebo Comparator|Placebo|Placebo 1-2 hours prior PCI, followed by placebo 1 hour later
89519831|NCT03465137|Experimental|Immediate therapy|Participants randomized to the immediate therapy arm will receive a weekly individual psychotherapy intervention called Coordinated Anxiety Learning and Management (CALM). The CALM program is an evidence based, exposure-focused therapy (http://calmtoolsforliving.org). Its computer-assisted format guides the therapist through psychoeducation, an introduction to cognitive restructuring, in-session and at-home exposures, and relapse prevention. Therapy will be delivered in 10 weekly 50-minute sessions within a 12 week period.
89608991|NCT03582423|Placebo Comparator|sham-acupuncture group|"Streitberger's non-invasive acupuncture needles (Gauge 8 × 1.2/ 0.30 × 30mm) will be applied to serve as a sham control at the same acupoints with the same stimulation modality, except that the needles are only adhered to the skin by a small plastic ring instead of being inserted and the stimulation will be a pseudo-stimulation"
89608992|NCT01274104|Active Comparator|Vitamin D|Subjects will take 5,000 IU-capsules of vitamin D3 three times a day (for a total of 15,000 IU) for 14 days
89608993|NCT01274104|Placebo Comparator|Control|Subjects will take 3 capsules of placebo every day for 14 days
89608994|NCT03582345|Experimental|EEG/fMRI|The presented project will include only one arm constituted by patients affected by pharmacoresistant epilepsies elegible for respective surgery. Patients will be identified by RU1 and RU2. The definition of drug-resistant epilepsy requires: (a) the failure of at least two first-line AEDs; (b) the occurrence of an average of one seizure per month for > 18 months; (c) no more than 3-month seizure free hiatus during those 18 months (Berg et al., 2006).
89608995|NCT01279018||Patients treated with docetaxel|Patients treated according to the DBCG 07 protocol, that have received docetaxel as part of the adjuvant treatment.
89608996|NCT01766401|Placebo Comparator|Placebo|Matching placebo tablets, oral administration
89608997|NCT01766401|Experimental|Vilazadone|Vilazadone tablets, oral administration
89608998|NCT03159273|Experimental|Beetroot Juice Group|Subjects in this group are given 7 daily doses of a dietary nitrate supplement (Beet-it Sport beetroot juice shots) and asked to drink one dose daily during the week of their final academic examinations of that term in college.
89608999|NCT03159273|No Intervention|Control|Subjects in this group are not given a dietary nitrate supplement but are assessed at the same time points as those in the experimental group.
89609000|NCT03582267|Experimental|Dietary Supplement|Docosahexaenoic Acid (DHA)
89609001|NCT03582267|No Intervention|No Intervention|No Docosahexaenoic Acid supplementation
89609002|NCT01279174|Other|Conventional physiotherapy|Patients in this study group will attend physiotherapeutic exercise sessions of one hour three times a week for six weeks. The sessions consist of aerobic and muscle strengthening as well as coordination exercises. Patients will practice activities of daily living. The goals of these exercises are to improve joint stability, optimize knee and ankle proprioception, and advance neuromuscular innervation of the lower extremity and thereby suppress pathologic motion patterns. This should lead to optimized mobility, increased stability, and thus more endogenous analgesia of the affected joint
89609003|NCT01279174|Experimental|Whole-body-vibration exercises|Patients in this study group will attend whole body vibration exercise sessions of one hour three times a week for six weeks, using the Galileo® Fitness device. Initial training sessions will focus on patient acclimatization, and afterwards improved on muscular capacity and body coordination. During exercise sessions, patients will do 6 training cycles of 3 minutes each. The goals of this treatment are improved proprioception of the ankle and knee joints, as well as optimization of neuronal reactivation of the muscles and thereby improved joint stability. This should also increase endogenous analgesia
89609004|NCT03582111||Pregnant women who have a foetus with a cleft lip/palate|Pregnant women who have a foetus with a cleft lip/palate
89609005|NCT01272934|Placebo Comparator|Placebo|
89609006|NCT01272934|Experimental|Diclofenac sodium topical gel 1%|Diclofenac sodium topical gel 1%
89609007|NCT03159117|Experimental|PF 06688992|This clinical study will be a dose-finding phase I study in which patients will be treated with various doses of Pfizer PF-06688992 using a Bayesian dose escalation scheme.
89609008|NCT01279252|Experimental|Antibiotic regimen|
88983005|NCT05952622|No Intervention|Standard rehabilitation protocol|Standard rehabilitation after surgical treatment consisting of initial immobilization followed by physiotherapy.
89609009|NCT03159351|Experimental|active rTMS treatment|received active rTMS treatment 20 times for 20 days
89609010|NCT03159351|Sham Comparator|sham rTMS treatment|received sham rTMS treatment 20 times for 20 days
89609011|NCT01279330|No Intervention|Control|Patients receive by mail the materials needed for stool samples.
88983006|NCT05952622|Active Comparator|Rehabilitation protocol with CPM|Additional treatment of patients with continuous passive motion after initial immobilization for 6 weeks.
88983007|NCT05952609|Experimental|Group 1|Patients receiving Surefil One
88983008|NCT05952609|Experimental|Group 2|Patients receiving Cention N
88983009|NCT05952609|Active Comparator|Group 3|Patients receiving bulkfil resin composite
88983010|NCT05952596|Experimental|Test group|DTaP-HepB-IPV-Hib vaccine
88983011|NCT05952596|Active Comparator|Control group|DTaP-HepB-IPV-Hib vaccine
88983012|NCT05952531|Experimental|68Ga-FAPI|Inject 68Ga-FAPI and then perform PET/CT scan
89609012|NCT01279330|Experimental|Co-signed Letter|
89609013|NCT00739336|Experimental|A, 1|Intervention: Immediate 3 month program
89609014|NCT00739336|No Intervention|A, 2|Wait-List Control
89609015|NCT03158415|Experimental|Parents of Young Adults with T1D|Parents of young adults ages 18 to 25 years with type 1 diabetes who are transitioning to independence. During six weeks, participants will receive a reminder via text and/or email twice per week to invite them to view diabetes education materials on the study's mobile website, T1DToolkit.org. Topics on this website include, among others, Caregiver Burnout; Your Child is Now an Adult; Sharing Responsibility; Sources of Support; Common Fears for Parents of Young Adults; and Your Child, Your Child's Doctor, and You.
89609016|NCT04385836|Active Comparator|alpha one antitrypsin group|- we will give 8 ml of intravenous alpha one antitrypsin (alpha1-proteinase inhibitor (AATD)Glassia 50 ml) add to 2cm of normal saline solution as nebulizer every 12 hours for 5 days
89609017|NCT04385836|Placebo Comparator|placebo group|we will give 8 ml of normal saline as nebulizer every 12 hours for 5 days
89688346|NCT04356547|Active Comparator|Fiberoptic intubation without laryngeal mask|Participants should perform an fiberoptic tracheal intubation without laryngeal mask, in a pediatric simulator. Will be evaluated the success rate at the first attempt and other secondary outcomes
89688347|NCT03833999|Experimental|Ondansetron and lactulose|Ondansetron 8mg three times daily for 48 hours lactulose 20ml twice daily for 48 hours Serial abdominal MRI imaging
89688348|NCT03833999|Placebo Comparator|Placebo and lactulose|placebo oral capsule, one three times daily for 48 hours lactulose 20ml twice daily for 48 hours Serial abdominal MRI imaging
89033522|NCT06025617|Active Comparator|Control arm|"Patients referred by their GP under suspicion of suffering from FSD are randomized to Diagnostic as usual in the control arm."
89033523|NCT06025552|Experimental|TU7710|TU7710 of escalating 5 doses
89033524|NCT06025552|Placebo Comparator|Normal Saline (placebo of TU7710)|Placebo of TU7710 at corresponding TU7710 dose level
89609018|NCT04385524|Other|Vaccination|"Heplisav B vaccine will be administered to subjects demonstrating completion of two prior series of standard 3-dose Hepatitis B vaccine but still without evidence of seroconversion.~One dose (20 mcg) of vaccine will be administered intramuscularly followed by Hepatitis B quantitative antibody titer 30-60 days later.~If still Hepatitis B antibody negative, a second dose (20 mcg) of vaccine will be administered intramuscularly followed by a Hepatitis B quantitative titer 30-60 days later.~If still no evidence of Hepatitis B immunity (10iU antibody or greater), will be deemed a non-responder to this vaccine"
89609019|NCT03154905||Control|Healthy controls
89609020|NCT03154905||Study group|Patient diagnosed with any disorder of the digestive system (including the alimentary tract, hepatobiliary tree, pancreas, insulin resistance or diabetes, obesity or malnutrition)
89609021|NCT01274260|Active Comparator|Experimental Group|Intervention: Subjects in this study group will receive a loading dose of methylprednisolone 2mg/kg followed by 1mg/kg/day of methylprednisolone infusion from day 1 to day 7; 0.5mg/kg/d from days 8 to 10, 0.25mg/kg/d on days 11 and 12, 0.125mg/kg/d on days 13 and 14. The study drug infusion will be discontinued after 14 days.
89609022|NCT01274260|Placebo Comparator|Placebo Group|Intervention: The placebo will be 0.9% (normal) saline and the active medication will be diluted in 0.9% (normal) saline. The placebo group with receive the masked study drug in infusion rates that mimic the infusions received by the experimental group.
89609023|NCT03154983|Experimental|First-line treatment|First-line treatment：treatment including Mesylate Apatinib Combined With Docetaxel and S-1(DS).DS Docetaxel 75mg/m2 d1 iv.drop 1h（one hour）， S-1(BSA<1.25 40mg Po bid(twice a day), BSA >=1.25-<1.5 50mg Po bid, BSA >=1.5 60mg Po bid), Q21d(21 days a cycle); Mesylate Apatinib 500mg Po QD(once a day) continuous use; until disease deterioration.
89609024|NCT03154593||Stage 1|Stage 1 will determine the prevalence of chronic oedema among patients attending weight management services at the Royal Derby Hospital and how it impacts on every day life.
89609025|NCT03154593||Stage 2|Stage 2 will determine whether bariatric surgery improves the oedema.
89609026|NCT01983683|Experimental|Cadazolid|Subjects receive oral cadazolid 250 mg twice daily (bid) and oral vancomycin-matching placebo 4 times per day (qid) for 10 days
89609027|NCT01983683|Active Comparator|Vancomycin|Subjects receive oral vancomycin 125 mg qid and oral cadazolid-matching placebo bid for 10 days
89609028|NCT04405713|Active Comparator|from the onset of symptoms within the first 3 days (group 1)|ELC for ACC from the onset of symptoms within the first 3 days (group 1)
89609029|NCT04405713|Active Comparator|from the onset of symptoms within the 4-7 days|ELC for ACC from the onset of symptoms within the4-7 days (group II)
89609030|NCT04405713|Active Comparator|from the onset of symptoms beyond 7 days|ELC for ACC from the onset of symptoms beyond 7 days (group III)
89609031|NCT03154515|Experimental|Ingavirin|Imidazolyl ethanamide pentandioic acid 90 mg once daily for 5 days
89609032|NCT03154515|Placebo Comparator|Placebo|Placebo capsule identical in appearance to Ingavirin capsule
89609033|NCT03158103|Experimental|MEK162 in combination with Pexidartinib|Pexidartinib will be administered orally by the patients on a twice daily basis throughout the treatment cycle. Pexidartinib is available in 200mg tablets. MEK162 wiIl be administered orally on a twice daily basis throughout the treatment cycle. MEK162 is available in 15mg tablets. In this phase I study all patients will have a 2-week lead in of pexidartinib therapy alone. Thereafter, pexidartinib will be administered in combination with MEK162 on a consecutive daily basis. A treatment cycle consists of 28 days. In the dose escalation portion the dose of pexidartinib and MEK 162 will depend on the dose level cohort onto which the patient is enrolled.
89033525|NCT06025487|Active Comparator|Patients|Asplenic patients receiving two doses of Bexsero (meningococcal B vaccine) with one-month interval between doses
89033526|NCT06025487|Active Comparator|Healthy controls|Healthy controls receiving two doses of Bexsero (meningococcal B vaccine) with one-month interval between doses
89609034|NCT03581799|Other|Oral dispersible tablet|5 mm calcium carbonate based ODT will be administered by placing it in the buccal pouch (children aged 2-5 years) or on the tongue (children aged 6-10 years).
89609035|NCT03158025|Experimental|Placebo, LEM 10 mg, SUV 40 mg, LEM 20 mg, ZOL 30 mg, LEM 30 mg|Participants will receive the following treatments (orally) in Treatments Periods 1 through 6, respectively: Placebo (3 × placebo lemborexant [LEM] tablets; 3 × placebo zolpidem [ZOL] tablets; 2 × placebo suvorexant [SUV], over-encapsulated); LEM 10 milligrams (mg) (1 × 10 mg LEM tablet; 2 × placebo LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); SUV 40 mg (2 × 20 mg SUV tablets, over-encapsulated; 3 × placebo ZOL tablets; 3 × placebo LEM tablets); LEM 20 mg (2 × 10 mg LEM tablets; 1 × placebo LEM tablet; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); ZOL 30 mg (3 × 10 mg ZOL tablets; 3 × placebo LEM tablets; 2 × placebo SUV, over-encapsulated); LEM 30 mg (3 × 10 mg LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated). Each treatment period will be separated by a washout interval of at least 14 days.
89688349|NCT04356313||GORE® EXCLUDER® Iliac Branch Endoprosthesis & HGB|Patients with Aorto-Iliac Aneurysm with implantation of a Iliac Branch device (IBE) and the Hipogastric component (HGB)
89688350|NCT04356313||GORE® EXCLUDER® Iliac Branch Endoprosthesis & VBx|Patients with Aorto-Iliac Aneurysm with implantation of a Iliac Branch device (IBE) and Viabahn Balloon Expandable ( VBx)
89688351|NCT04379219|Active Comparator|surgery|"Valid consent~Anathesia , (regional may br converted into general ). IV antibiotic ( cefotaxime 1 gm I.V )~Laparotomy transverse incision (pfannenstiel incision)~Exploration of the abdominal cavity~Identification of the uterus, dissection of the bladder, incision of the uterus and excision of the CSP mass.~Surgical repair of the uterine incision, and the abdomen"
89033527|NCT06025474|Experimental|Vortioxetine+Pregabalin|VO group(20mg)+ PGB (75mg) N= 136 Vortioxetine 20 mg, encapsulated tablets, orally, once daily, then pregabalin 75 mg, encapsulated tablets, orally, once daily. Pregabalin (75mg/day) was added, with a potential dosage increase to 150mg/day for inadequate responders after 12 weeks
89057267|NCT04543604|No Intervention|• Control group - No leaflet (NL)|Only verbal information was provided to the patient during initial interview.
89057268|NCT04528056|Experimental|Ambrisentan+Sulfasalazine|
89033528|NCT06025474|Active Comparator|Paroxetine+Pregabalin|P group (20mg) + PGB (75mg); N= 10 Paroxetine 20 mg, encapsulated tablets, orally, once daily, then pregabalin 75 mg, encapsulated tablets, orally, once daily. Pregabalin (75mg/day) was added, with a potential dosage increase to 150mg/day for inadequate responders after 12 weeks
89609036|NCT03158025|Experimental|LEM 10 mg, LEM 20 mg, Placebo, LEM 30 mg, SUV 40 mg, ZOL 30 mg|Participants will receive the following treatments (orally) in Treatments Periods 1 through 6, respectively: LEM 10 mg (1 × 10 mg LEM tablet; 2 × placebo LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); LEM 20 mg (2 × 10 mg LEM tablets; 1 × placebo LEM tablet; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); placebo (3 × placebo LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); LEM 30 mg (3 × 10 mg LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); SUV 40 mg (2 × 20 mg SUV tablets, over-encapsulated; 3 × placebo ZOL tablets; 3 × placebo LEM tablets); ZOL 30 mg (3 × 10 mg ZOL tablets; 3 × placebo LEM tablets; 2 × placebo SUV, over-encapsulated). Each treatment period will be separated by a washout interval of at least 14 days.
89609037|NCT03158025|Experimental|LEM 20 mg, LEM 30 mg, LEM 10 mg, ZOL 30 mg, Placebo, SUV 40 mg|Participants will receive the following treatments (orally) in Treatments Periods 1 through 6, respectively: LEM 20 mg (2 × 10 mg LEM tablets; 1 × placebo LEM tablet; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); LEM 30 mg (3 × 10 mg LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); LEM 10 mg (1 × 10 mg LEM tablet; 2 × placebo LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); ZOL 30 mg (3 × 10 mg ZOL tablets; 3 × placebo LEM tablets; 2 × placebo SUV, over-encapsulated); placebo (3 × placebo LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); SUV 40 mg (2 × 20 mg SUV tablets, over-encapsulated; 3 × placebo ZOL tablets; 3 × placebo LEM tablets). Each treatment period will be separated by a washout interval of at least 14 days.
89609038|NCT03158025|Experimental|LEM 30 mg, ZOL 30 mg, LEM 20 mg, SUV 40 mg, LEM 10 mg, Placebo|Participants will receive the following treatments (orally) in Treatments Periods 1 through 6, respectively: LEM 30 mg (3 × 10 mg LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); ZOL 30 mg (3 × 10 mg ZOL tablets; 3 × placebo LEM tablets; 2 × placebo SUV, over-encapsulated); LEM 20 mg (2 × 10 mg LEM tablets; 1 × placebo LEM tablet; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); SUV 40 mg (2 × 20 mg SUV tablets, over-encapsulated; 3 × placebo ZOL tablets; 3 × placebo LEM tablets); LEM 10 mg (1 × 10 mg LEM tablet; 2 × placebo LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); placebo (3 × placebo LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated). Each treatment period will be separated by a washout interval of at least 14 days.
89609039|NCT03158025|Experimental|ZOL 30 mg, SUV 40 mg, LEM 30 mg, Placebo, LEM 20 mg, LEM 10 mg|Participants will receive the following treatments (orally) in Treatments Periods 1 through 6, respectively: ZOL 30 mg (3 × 10 mg ZOL tablets; 3 × placebo LEM tablets; 2 × placebo SUV, over-encapsulated); SUV 40 mg (2 × 20 mg SUV tablets, over-encapsulated; 3 × placebo ZOL tablets; 3 × placebo LEM tablets); LEM 30 mg (3 × 10 mg LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); placebo (3 × placebo LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); LEM 20 mg (2 × 10 mg LEM tablets; 1 × placebo LEM tablet; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); LEM 10 mg (1 × 10 mg LEM tablet; 2 × placebo LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated). Each treatment period will be separated by a washout interval of at least 14 days.
89609040|NCT03158025|Experimental|SUV 40 mg, Placebo, ZOL 30 mg, LEM 10 mg, LEM 30 mg, LEM 20 mg|Participants will receive the following treatments (orally) in Treatments Periods 1 through 6, respectively: SUV 40 mg (2 × 20 mg SUV tablets, over-encapsulated; 3 × placebo ZOL tablets; 3 × placebo LEM tablets); placebo (3 × placebo LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); ZOL 30 mg (3 × 10 mg ZOL tablets; 3 × placebo LEM tablets; 2 × placebo SUV, over-encapsulated); LEM 10 mg (1 × 10 mg LEM tablet; 2 × placebo LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); LEM 30 mg (3 × 10 mg LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); LEM 20 mg (2 × 10 mg LEM tablets; 1 × placebo LEM tablet; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated). Each treatment period will be separated by a washout interval of at least 14 days.
89609041|NCT01998893|Experimental|MabThera/Rituxan|
89609042|NCT01791985|Experimental|Single arm study|"NSAI (anastrozole (1mg) or letrozole (2.5mg)), orally, once daily but together with twice daily AZD4547 (80mg).~AZD4547 will be given on an intermittent schedule of one week on / one week off."
89609043|NCT03157869|Experimental|Transcranial Direct Current Stimulation|"Intervention: anodic tDCS (20 minutes ON, intensity 2milliamps) on the primary motor cortex contralateral of the trained hand (right) simultaneously to the motor training and supraorbital cathode ipsilateral~Motor training will consist of 8 blocks with 300 repetitions of sequential finger movements performed with the right hand."
89609044|NCT03157869|Sham Comparator|Control|"Intervention: simulated anodic tDCS (30 seconds ON, intensity 2milliamps) on the primary motor cortex contralateral of the trained hand (right) simultaneously to the motor training and supraorbital cathode ipsilateral~Motor training will consist of 8 blocks with 300 repetitions of sequential finger movements performed with the right hand."
89609045|NCT04664621|Experimental|HepQuant Testing|
89609046|NCT03157947|Experimental|Decision Aid|Subjects will be asked to complete baseline surveys. Once the surveys are completed, subjects will review the Decision Aid tool with a study team member. Once the subjects have gone through the tool, study team members will answer any additional questions he may have regarding the tool. The subjects will then discuss with the investigator various cancer management options, quality of life implications, and any questions the subjects may have regarding cancer management options. Subjects that are ready may make a cancer management decision at this time, or choose to wait until their next scheduled visit. Subjects will be followed at subsequent urology clinic visits for up to 6 months. Subjects will complete follow-up surveys at the 3, 6, 9 and 12 month visits.
89033529|NCT06025474|Active Comparator|Sertraline+Pregabalin|S group (50mg) + PGB (75mg); N= 8 Sertraline 50 mg, encapsulated tablets, orally, once daily, then pregabalin 75 mg, encapsulated tablets, orally, once daily. Pregabalin (75mg/day) was added, with a potential dosage increase to 150mg/day for inadequate responders after 12 weeks
89609047|NCT01998737||Women under osteoporosis suspicion|
89609048|NCT01998737||Healthy women|
89057269|NCT04528056|Active Comparator|Ambrisentan+Sulfasalazine's placebo|
89057270|NCT04528056|Experimental|Ambrisentan's placebo+Sulfasalazine|
89519832|NCT03465137|No Intervention|Waitlist|Participants randomized to the waitlist arm will receive no intervention for 12 weeks. After this 12 week period they will receive a the same weekly individual psychotherapy intervention as the immediate therapy group: Coordinated Anxiety Learning and Management (CALM). The CALM program is an evidence based, exposure-focused therapy (http://calmtoolsforliving.org). Its computer-assisted format guides the therapist through psychoeducation, an introduction to cognitive restructuring, in-session and at-home exposures, and relapse prevention. Therapy will be delivered in 10 weekly 50-minute sessions within a 12 week period.
89519833|NCT03268083|Experimental|Group A1|3 to 6 years
89519834|NCT03268083|Experimental|Group A2|3 to 6 years
89519835|NCT03268083|Experimental|Group A3|3 to 6 years
89519836|NCT03268083|Experimental|Group B1|2 to 35 months
89519837|NCT03268083|Experimental|Group B2|2 to 35 months
89519838|NCT03268083|Experimental|Group B3|2 to 35 months
89519839|NCT04458467|Active Comparator|Continuous Infusion|Patients will receive a continuous infusion of Ropivacaine 0.2% (6 mL/hr, 4 mL patient controlled bolus with 30-minute lockout).
89519840|NCT04458467|Experimental|Automated Boluses|Patients will receive intermittent boluses of Ropivacaine 0.2% (8 mL automated bolus every 120 minutes, 4 mL patient controlled bolus with 30-minute lockout).
89519841|NCT04438239||Covid-19 discharged|Patients affected by COVID-19 and discharged from hospital wards of the Azienda USL- IRCCS Of Reggio Emilia (Italy).
89519842|NCT04560543|Experimental|McCall suture|Uterus removal by laparoscopy with usual vaginal closure and additional (McCall) suture, which is intended to prevent descent.
89519843|NCT04560543|Sham Comparator|standard cuff closure|Uterus removal by laparoscopy with usual vaginal closure without additional (McCall) suture. (as performed so far)
89519844|NCT03465059|Experimental|Normal Hepatic Function|Participants with normal hepatic function will be administered a single oral dose of Zanubrutinib (80 mg).
89519845|NCT03465059|Experimental|Mild Hepatic Impairment|Participants with mild hepatic impairment (Child-Pugh Class A, score of 5 to 6, inclusive) will be administered a single dose of Zanubrutinib (80 mg).
89519846|NCT03465059|Experimental|Moderate Hepatic Impairment|Participants with moderate hepatic impairment (Child-Pugh Class B, score of 7 to 9, inclusive) will be administered a single dose of Zanubrutinib (80 mg).
89519847|NCT03465059|Experimental|Severe Hepatic Impairment|Participants with severe hepatic impairment (Child-Pugh Class C, score of 10 to 15, inclusive) will be administered a single dose of Zanubrutinib (80 mg).
89519848|NCT04280991|Experimental|Moderate intensity exercise under mild normobaric hypoxia|The participants will perform moderate intensity exercise at heart rate corresponding with 50%WMAX (determined during maximal workload test) under mild normobaric hypoxia (FiO2: 15%), two times 30 minutes per day for 4 consecutive days on a cycle ergometer. 24h glucose concentration will be monitored continuously. Afterwards, a meal test challenge will be performed at day 5 to determine fasting/postprandial substrate oxidation.
89519849|NCT04280991|Placebo Comparator|Moderate intensity exercise under normoxia|The participants will perform moderate intensity exercise at 50% WMAX (determined during maximal workload test) under normoxia (FiO2: 21%) two times 30 minutes per day for 4 consecutive days on a cycle ergometer. 24h glucose concentration will be monitored continuously. Afterwards, a meal test challenge test will be performed at day 5 to determine fasting/postprandial substrate oxidation.
89519850|NCT03170817||N13-ammonia Cardiac Rest/Stress PET/CT|Patients with coronary artery disease (CAD) undergo a Cardiac Perfusion Rest/Stress Digital PET/CT scan using the radiopharmaceutical N13-ammonia and Regadenoson (Lexiscan) to induce pharmacologic stress.
89519851|NCT03464981||Advanced HF patients scheduled to undergo LVAD implantation|
89519852|NCT04453319|Experimental|Application of the device (PICO)|PICO® is a disposable, single-use pump without a canister that generates an effective, non-adjustable, negative pressure of -80 mmHg and that can be used for up to 7 days.(-1113) It incorporates leak detection and low battery indicators and is connected to a 4-layer absorbent dressing that primarily removes wound exudates through evaporative loss. The mechanism of action has been postulated to occur because of the combined effects of a reduction in the frequency of dressing changes, a reduction in stress concentration in the tissue surrounding the incision, and an enhancement in the appositional strength of the incision line, thus reducing dead space and minimizing the risk of wound contamination.(14) PICO® has also been demonstrated to enhance lymphatic clearance and decrease the risk of hematomas or seromas
89519853|NCT04453319|No Intervention|Conventional Dressing of the femoral wound|Conventional Dressing of the femoral wound
89519854|NCT03025425|Experimental|MPV-arm|Subjects use mouth piece ventilation (MPV) according to their will for 24 hours to alleviate dyspnea.
89519855|NCT05101005|Experimental|Drug-coated balloon|Drug-coated balloon is used to treat coronary artery stenosis lesions and improve myocardial blood flow.
89519856|NCT05101005|Active Comparator|Sirolimus-Eluting Stent|Sirolimus-Eluting Stent is treated for coronary artery stenosis lesions.
89519857|NCT05100693|Experimental|Procedure FETO with the Smart-TO balloon|Fetal endoscopic tracheal occlusion using the Smart-TO balloon. Balloon removal procedure by peripheral course around the MR scanner
89519858|NCT04437719|Experimental|Obvio-19 App|"If the patient is willing to participate to the trial, his given oral, free, informed and express consent will be collected and traced in his medical file. After enrollment, patients will be sent an invitation via email to download the Obvio-19 mobile app. After downloading the Obvio-19 app, patients will receive instructions as to how they may communicate with the study investigator. Communication may occur through the chat function of the app or live telephone conversations.~Patients must log into the Obvio-19 app daily to complete the questionnaires. The Obvio-19 system is designed to identify responses that indicate the participant is at an increased risk for serious illness or exhibiting serious symptoms, such as coughing up blood. Such patients will be notified by the app of this status and prompted to seek medical attention."
89519859|NCT05100615|Other|hydroxyappatite|hydroxyapatite powder used for enhancement of bone regeneration
89519860|NCT05100615|Other|nanohydroxyapatite|nanohydroxyapatite powder used for enhancement of bone regeneration
89519861|NCT05100615|Other|PRF with nanohydroxyapatite|platelet rich fibrin mixed with nanohydroxyapatite used for enhancement of bone regeneration
89609049|NCT02665377|Active Comparator|ANP|Infusion of h-ANP at dose of 50ng/kg/min fore 5 days, starting at the induction of anesthesia.
89609050|NCT02665377|Placebo Comparator|Placebo|Infusion of NaCl at the same volyme as for ANP for 5 days.
89609051|NCT05703087|No Intervention|Standard information video before primary total knee arthroplasty|Information video (about procedure, complications, rehabilitation) shown to the participants before TKA in the OLVG.
89609052|NCT05703087|Experimental|Positive cueing in the information video before a primary total knee arthroplasty|"The information video was adapted from the existing standard information video used in OLVG. The concept of positive cueing was applied to the standard video by an expert team including a psychiatrist and clinical psychologist. Illustrations which were incomprehensible or with negative associations were removed.~Four rules were followed to use positive cueing:~make patients aware that they are able to influence their own recovery process,~be descriptive in explanations; objectively describe the performed procedure, name equivalent, not negatively charged feelings,~explain why specific steps and actions during the procedure are performed, so the patients understand what is going to happen,~do not use medical langue, but use accessible, understandable language instead."
89609053|NCT01791517|Other|Lens A (senofilcon A)|Subjects randomized to Lens A will be further randomized to 1 of 12 unique solution sequences; each subject will receive all four study solutions in a random order (Solution 1(Test), Solution 2(Test), Solution 3(Test), Solution 4(Control)).
89609054|NCT01791517|Other|Lens B (galyfilcon A)|Subjects randomized to Lens B will be further randomized to 1 of 12 unique solution sequences; each subject will receive all four study solutions in a random order (Solution 1(Test), Solution 2(Test), Solution 3(Test), Solution 4(Control)).
89609055|NCT01791517|Other|Lens C (etafilcon A)|Subjects randomized to Lens C will be further randomized to 1 of 12 unique solution sequences; each subject will l receive all four study solutions in a random order (Solution 1(Test), Solution 2(Test), Solution 3(Test), Solution 4(Control)).
89609056|NCT01998581|Experimental|JUVEDERM VOLBELLA® XC|Lips injected with JUVEDERM VOLBELLA® XC
89609057|NCT01998581|Active Comparator|Restylane-L®|Lips injected with Restylane-L®
89609058|NCT03581565|Active Comparator|Technique I|"Loading of a zinc polycarboxylate (with the requirements of ISO 9917) cement to fulfill the crown~Cement: Poly-F, DentsplySirona, York, Pennsylvania, United States Mixing Ratio: 1 scoop powder: 2 drops liquid Mixing Time (extraoral): 30 seconds Working Time (extraoral): 45 seconds Application (extraoral): placement of mixture into crown using a heidemann Spatula Setting Time (intraoral): 2-8 minutes"
89609059|NCT03581565|Active Comparator|Technique II|"Loading of a zinc polycarboxylate (with the requirements of ISO 9917) to fill the coronal half of the crown~Cement: Poly-F, DentsplySirona, York, Pennsylvania, United States Mixing Ratio: 1 scoop powder: 2 drops liquid Mixing Time (extraoral): 30 seconds Working Time (extraoral): 45 seconds Application (extraoral): placement of mixture into crown using a heidemann Spatula Setting Time (intraoral): 2-8 minutes"
89609060|NCT03581565|Active Comparator|Technique III|"Application of a zinc polycarboxylate (with the requirements of ISO 9917) to the axial walls of internal surface of crown~Cement: Poly-F, DentsplySirona, York, Pennsylvania, United States Mixing Ratio: 1 scoop powder: 2 drops liquid Mixing Time (extraoral): 30 seconds Working Time (extraoral): 45 seconds Application (extraoral): application of mixture into crown using a bonding applicator tip Setting Time (intraoral): 2-8 minutes"
89609061|NCT03154281|Experimental|Cohort 1|(each cycle is 28 days long) Everolimus 5mg daily on Mondays, Wednesdays, and Fridays Niraparib 100mg daily
89609062|NCT03154281|Experimental|Cohort 2|(each cycle is 28 days long) Everolimus 5 mg daily on Mondays, Wednesdays, and Fridays Niraparib 200 mg daily
89609063|NCT03154281|Experimental|Cohort 3|(each cycle is 28 days long) Everolimus 5 mg daily Niraparib 200 mg daily
89609064|NCT03154281|Experimental|Cohort 4|(each cycle is 28 days long) Everolimus 5 mg daily Niraparib 300 mg daily
89609065|NCT03157791|Experimental|Simethicone with Bowel Prep|Group A will receive 2 simethicone tablets (180mg each) so that one tablet is taken at the same time as each bowel preparation dose.
89609066|NCT03157791|No Intervention|Control|Group B will receive no simethicone tablets.
89609067|NCT01983293|Experimental|QLV based implant strategy|QLV represents the pacing site with the largest amount of dyssynchrony as measured by the left ventricular electrical delay. The QLV based implant strategy finds the left ventricle vein branch and left ventricular lead cathode with the longest QLV measurement and places the lead at this location and programs the device using this lead cathode.
89609068|NCT01983293|Placebo Comparator|Standard of care implant strategy|The placement of LV lead will be carried out according to the physician's standard of care implant approach.
89609069|NCT04765293|Experimental|Gravity group|"GRAVITY® system exercise is conducted on a machine. The tasks were non-weight bearing, and the only external load was the body mass of the trainee. The degree of unloading (the level of exercise) was chosen depending on the patient's body mass, their current health and the difficulty of the exercise. The machine allowed for exercising any chosen muscle group at chosen setting of the bench, platform and ropes. GRAVITY® system exercise aimed at general posture improvement and at strengthening the desired movement path, along with strengthening the deep spinal and abdominal muscles.~GRAVITY therapy group had therapy twice a week for 4 weeks for 40 minutes that made 2x40 minx 4 weeks=320 minutes."
89609070|NCT04765293|Active Comparator|Control group|Control group had standard, two weeks ambulant every day physical therapy sessions ( laser therapy, cryotherapy, magnetotherpy, TENS and interference currents), 5 times a week 30 min, that is 10 sessions 30 min x10=300 min.
89609071|NCT03157479|Experimental|Protective ventilation|Volume controlled ventilation with tidal volume 6-7 ml/kg of predicted body weight (45.5 + 0.91 (height [cm] -152.4)), FiO2 0.4 and PEEP 10 cmH2O during the whole study period. Respiratory rate will be titrated to keep end-tidal CO2 values between 30 and 40 mmHg. I:E ratio will be set in order to obtain an inspiratory time of 0.8 seconds and an inspiratory pause of 0.3 seconds and FiO2 will be kept unchanged during the whole study period. In patients in this group, recruiting maneuvers will be performed throughout a stepwise 5 cmH2O PEEP increase every 30 seconds to achieve a PEEP of 35 cmH2O during Pressure Controlled Ventilation (10 cmH2O of inspiratory pressure while keeping respiratory rate unmodified), followed by a stepwise 5 cmH2O PEEP reduction every 30 seconds until the baseline set peep is reached.
89609072|NCT03157479|Active Comparator|Standard Ventilation|Volume controlled ventilation with tidal volume 10 ml/kg of PBW (45.5 + 0.91 (height [cm] -152.4)), FiO2 0.4 and PEEP 5 cmH2O during the whole study period. Respiratory rate will be titrated to keep end-tidal CO2 values between 30 mmHg and 40 mmHg. I:E ratio will be set in order to obtain an inspiratory time of 0.8-1 seconds and an inspiratory pause of 0.3 second
89609073|NCT03031587|Experimental|MRI examination|Each patient coming to the hospital for cardiac MRI examination can participate to the study if he/she meets the eligibility criteria
89609074|NCT01791205||Monotherapy|Eligible participants who received any biologic drug as a monotherapy in the 12 months prior to the study entry will be observed for Phase I. Participants who were enrolled in Phase I and received tocilizumab (TCZ) as a monotherapy will be observed for 18 months from the first infusion of TCZ in Phase II, where TCZ was prescribed according to the approved product information, local treatment guidelines and/or routine clinical practice.
89210711|NCT00987441|Active Comparator|Local anesthetic 1 plus opioid|First local anesthetic dose (ropivacaine 0.0625%) plus opioid (sufentanil 0.4 microgram/ml) delivered peridural space
89210712|NCT00987441|Active Comparator|Local anesthetic 2 plus opioid|Second local anesthetic dose (ropivacaine 0.1875%) plus opioid (sufentanil 0.4 microgram/ml) delivered peridural space
89609075|NCT01791205||Combination Therapy|Eligible participants who received any biologic drug in combination with disease-modifying anti-rheumatic drugs (DMARDs) in the 12 months prior to study entry will be observed for Phase I.
89609076|NCT01670331|Active Comparator|Psychological preparation|Patients undergo 3 seminar sessions with the bariatric psychologist prior to their surgery. These will aim to prepare them for the lifestyle changes that will occur / they will have to make after surgery
89609077|NCT01670331|No Intervention|Surgery as usual|Patients will proceed to surgery as usual. They will complete psychological assessment forms at their follow up clinic sessions.
89609078|NCT03013491|Experimental|CX-072|Monotherapy CX-072
89609079|NCT03013491|Experimental|CX-072 with Ipilimumab #1|Combination CX-072 + ipilimumab (Schedule 1)
89609080|NCT03013491|Experimental|CX-072 with Ipilimumab #2|Combination CX-072 + ipilimumab (Schedule 2)
89609081|NCT03013491|Experimental|CX-072 with Vemurafenib|Combination CX-072 + vemurafenib
89609082|NCT03013491|Experimental|CX-072 expansion|Monotherapy CX-072
89609083|NCT01272232|Experimental|Lira 3.0 mg|
89609084|NCT01272232|Experimental|Lira 1.8 mg|
89033530|NCT06025474|Active Comparator|Citalopram+Pregabalin|C group (20mg)+ PGB (75mg) N= 8 Citalopram 20 mg, encapsulated tablets, orally, once daily, then pregabalin 75 mg, encapsulated tablets, orally, once daily. Pregabalin (75mg/day) was added, with a potential dosage increase to 150mg/day for inadequate responders after 12 weeks
89033531|NCT06025474|Active Comparator|Escitalopram+Pregabalin|E group (10mg) + PGB (75mg); N= 8 Escitalopram 10 mg, encapsulated tablets, orally, once daily, then pregabalin 75 mg, encapsulated tablets, orally, once daily. Pregabalin (75mg/day) was added, with a potential dosage increase to 150mg/day for inadequate responders after 12 weeks
89609085|NCT01272232|Experimental|Placebo|
89609086|NCT03157401||intravenous infusion group|In the tranexamic acid intravenous infusion group (n = 30), 15 mg/kg tranexamic acid diluted in 100 mL physiological saline was intravenously infused at the beginning of the surgery. After suturing deep fascia, 20 mL of physiological saline was intra-articularly injected.
89609087|NCT03157401||intra-articular injection group|In the tranexamic acid intra-articular injection group (n = 30), 100 mL of physiological saline was intravenously infused at the beginning of the surgery. After suturing deep fascia, the mixture of 1.5 g tranexamic acid and 20 mL physiological saline was intra-articularly injected.
89609088|NCT03157401||control group|In the control group (n = 30), 100 mL of physiological saline was intravenously infused at the beginning of the surgery. After suturing deep fascia, 20 mL of physiological saline was intra-articularly injected.
89609089|NCT03153735|Experimental|CMDHA0101|Maximum injection dose : 22 ml It is a product containing 0.3% lidocaine hydrochloride, a topical anesthetic ingredient, in a crosslinked hyaluronic acid gel
89609090|NCT03153735|Active Comparator|PowerFill®|Maximum injection dose : 22 ml A white solid that was lyophilized with mixed spherical PLA (Poly-D, L-lactide) microparticles and CMC (sodium carboxymethylcellulose)
89609091|NCT03153891|Experimental|Natural Environment|Participants experience a virtual reality natural environment intervention (using VR goggles with Smartphone) for 10 minutes on two occasions, 1 week apart.
89609092|NCT03153891|Experimental|Built Environment|Participants experience a virtual reality built environment intervention (using VR goggles with Smartphone) for 10 minutes on two occasions, 1 week apart.
89609093|NCT03153891|No Intervention|Control|Participants do not experience a VR intervention. Instead they visit with research assistants for 10 minutes on two occasions, 1 week apart.
89609094|NCT01670643||Video camera magnifier|
89609095|NCT03153813|Experimental|Drug|Up to 4 patches to cover a surface of 1200 cm2 will be applied to the painful area depending on the surface of pain during 60 minutes : capsaicin 8% patches (Qutenza)
89609096|NCT03153813|Placebo Comparator|Placebo|Up to 4 patches will be applied to the painful area depending on the surface of pain during 60 minutes : placebo
89210713|NCT00987441|Active Comparator|Local anesthetic 3 plus opioid|Third local anesthetic dose (ropivacaine 0.25%) plus opioid (sufentanil 0.4 microgram/ml) delivered peridural space
89210714|NCT00816686|Experimental|1. AGS-16M18 Dose 1|
89210715|NCT00816686|Experimental|2. AGS-16M18 Dose 2|
89210716|NCT00816686|Experimental|3. AGS-16M18 Dose 3|
89210717|NCT00816686|Experimental|4. AGS-16M18 Dose 4|
89210718|NCT00816686|Experimental|5. AGS-16M18 Dose 5|
89210719|NCT00924768|Experimental|Endotoxin|Inhalation of 20K EU CCRE
89609097|NCT03157167|Experimental|100 mcg/5 mCi Tc99m-Tilmanocept|Four subjects will receive a single IV injection of 100 micrograms of Tc99m tilmanocept radiolabeled with 5 mCi.
89609098|NCT03157167|Experimental|100 mcg/10 mCi Tc99m-Tilmanocept|Four subjects will receive a single IV injection of 100 micrograms of Tc99m tilmanocept radiolabeled with 10 mCi.
89033532|NCT06025474|Active Comparator|Duloxetine+Pregabalin|D group (60mg)+ PGB (75mg) N= 33 Duloxetine 60 mg, encapsulated tablets, orally, once daily, then pregabalin 75 mg, encapsulated tablets, orally, once daily. Pregabalin (75mg/day) was added, with a potential dosage increase to 150mg/day for inadequate responders after 12 weeks
89519862|NCT04387877|Experimental|Graston Group|Graston technique will be applied on the lateral and posterior myofascial chain area tensor fascia lata, gluteus medius, gluteus minimus, gluteus maximus, hamstring, gastrocnemius and soleus muscles) in 15 minutes.
89519863|NCT04387877|Sham Comparator|Sham Group|"Sham graston technique will be applied on lateral and posterior myofascial chain area (tensor fascia lata, gluteus medius, gluteus minimus, gluteus maximus, hamstring, gastrocnemius and soleus muscles) in 15 minutes.~(Sham graston technique will be applied to the patient by partially touching the muscle or fascia region via ultrasound gel with the flat part of the Graston tool so as not to provide the activity of the fascia)"
89033533|NCT06025461||fibroadenoma group|
89033534|NCT06025461||breast hyperplasia group|
89033535|NCT06025461||other types of benign nodules group|
89033536|NCT06025461||non-specific invasive carcinoma group|
89033537|NCT06025461||other types of breast cancer group|
89057271|NCT04528056|Placebo Comparator|Ambrisentan's placebo+Sulfasalazine's placebo|
89519864|NCT04366817|Experimental|women in postpartum period|
89519865|NCT05091983||Restrictive eating disorder group|Adolescents between 12 and 18 y.o. Restrictive eating disorders diagnosis (Anorexia Nervosa or ARFID) answering DSM-5 criteria
89519866|NCT05091983||Control group|Adolescents between 12 and 18 y.o. No eating disorders
89519867|NCT04452773|Experimental|Manremyc|Participants will receive daily oral administration of a capsule of Manremyc for 14 days in the morning with breakfast
89519868|NCT04452773|Placebo Comparator|Placebo|Participants will receive daily oral administration of a capsule of Placebo for 14 days in the morning with breakfast
89519869|NCT04452851|Experimental|Treadmill test with BREATHE|Subjects will perform exercise tests identical to the treadmill tests from the baseline test. However, in this test, after they reach a Borg score of 7, they will be allowed to recover with the prototype BREATHE system until they are fully recovered (Borg: 0).
89519870|NCT04452851|Active Comparator|Treadmill test with BiPAP|Subjects will perform exercise tests identical to the treadmill tests from the baseline test. However, in this test, after they reach a Borg score of 7, they will be allowed to recover with a standard BiPAP machine until they are fully recovered (Borg: 0).
89519871|NCT04452851|Placebo Comparator|Treadmill test with placebo inhaler|Subjects will perform exercise tests identical to the treadmill tests from the baseline test. However, in this test, after they reach a Borg score of 7, they will be allowed to recover with a placebo inhaler until they are fully recovered (Borg: 0).
89519872|NCT04452851|Experimental|Activity of Daily Living with BREATHE|Subjects will be asked to complete Glittre-ADL tests with the BREATHE system being available for use throughout the test and recovery period. Borg scores will be measured after each minute of exercise and every 30 seconds during seated recovery until the subject is fully recovered (Borg: 0).
89519873|NCT04452851|Experimental|Activity of Daily Living with BREATHE during recovery|Subjects will be asked to complete Glittre-ADL tests with the BREATHE system being available for use throughout the test and recovery period. Borg scores will be measured after each minute of exercise and every 30 seconds during seated recovery until the subject is fully recovered (Borg: 0).
89519874|NCT04452851|No Intervention|Activity of Daily Living|Subjects will be asked to complete Glittre-ADL tests with the BREATHE system will NOT be available for use throughout the test and recovery period. Borg scores will be measured after each minute of exercise and every 30 seconds during seated recovery until the subject is fully recovered (Borg: 0).
89519875|NCT05069363|Experimental|Intervention Group|All participants in this feasibility trial will receive a course of whole-body photobiomodulation therapy (18 sessions over 6 weeks)
89519876|NCT05015387|Active Comparator|MINST group|Patients with periodontitis received minimally invasive non-surgical therapy .
89519877|NCT05015387|Experimental|MINST+PACNs group|Patients with periodontitis received minimally invasive non-surgical therapy and subgingival application of collagen hydrogels with proanthocyanidins.
89519878|NCT03464825|Other|Intervention|Participants in the intervention group receive balance training during 3 months 3 times per week
89519879|NCT03464825|No Intervention|Control|Care as usual
89519880|NCT03464513|Other|Patients with GIT bleeding|Patients with active lower Gastrointestinal bleeding
89519881|NCT00003857|Active Comparator|Observation +/- tamoxifen for 5 years|Observation +/- tamoxifen 20 mg per day for 5 years
89519882|NCT00003857|Experimental|Radiation therapy +/- tamoxifen for 5 years|Radiation therapy to the whole breast +/- tamoxifen 20 mg per day for 5 years
89519883|NCT03464435|Experimental|tacrolimus and loteprednol etabonate/tobramycin|topical eye drops
89519884|NCT03464357|Active Comparator|Symptomatic patients with dry eye|8 symptomatic patients with dry eye (mild to severe) assessed using a validated questionnaire (OSDI score, Appendix 1) associated with a disabling photophobia (need to wear sunglasses permanently outside, restriction of the outputs in case of significant brightness, restriction of the use of the screens because of the visual embarrassment ...). The fMRI will be carried out following the inclusion visit after all the necessary checks
89519885|NCT03464357|Active Comparator|Asymptomatic patient|"8 asymptomatic patients presenting neither photophobia (even minimal) or dry eye.~The fMRI will be carried out following the inclusion visit after all the necessary checks"
89519886|NCT03464279|Experimental|Intervention Site|"The intervention Site (Urgent Care Center at LAC+USC Medical Center) will receive a three part intervention consisting of (1) Email Choosing Wisely® guidelines and presented journal club to all 16 urgent care clinicians, (2) leveraging EHR performance data to provide individual clinicians with case-specific audit-feedback (both via emails and in-person while precepting nurse practitioners) on low-value antibiotic prescribing, and (3) using a behavioral nudge, urgent care clinicians will sign a large poster committing to avoid prescribing low-value antibiotics for uncomplicated URIs displayed in the clinic."
89609099|NCT03157167|Experimental|200 mcg/5 mCi Tc99m-Tilmanocept|Up to six subjects will receive a single subcutaneous injection and a single IV injection of 200 micrograms of Tc99m tilmanocept radiolabeled with 5 mCi.
89609100|NCT03157245||participant|
89609101|NCT03156855|Experimental|sequential therapy for 14 days (S14)|14 day sequential therapy
89609102|NCT03156855|Active Comparator|bismuth quadruple therapy (Q10)|Bismuth quadruple therapy
89609103|NCT01791127||Pacemaker Therapy|Patients with a market-released BIOTRONIK pacemaker system including one or two Siello S leads.
89609104|NCT03157011|Experimental|Global symptom score (GSS) questionary|systematic research of digestive symptoms in patients with SGSp with Global symptom score (GSS) questionary.
89609105|NCT01274650|Other|Decubitis Ulcer|Patients admitted to the hospital with decubitus ulcers in the ischial, sacral, or coccyx area.
89609106|NCT00739960|Other|Abatacept|
89609107|NCT05537181|Experimental|BTL-899; HPM-6000UF Treatments|The two devices will be used separately in two different treatments. However one treatment visit can comprise both treatments. The BTL-899 will be applied over the abdomen, and the device will induce visible muscle contractions along with mild heating of the muscles. Four (4) treatments once a week will be delivered. The HPM-6000UF device will induce pelvic floor muscle contractions. Six (6) treatments 2-4 days apart will be delivered.
89609108|NCT00751972|Experimental|HeartWare® VAS|Ventricular Assist Device (HeartWare® VAS)
89609109|NCT03153657|Experimental|Piroxicam-beta-Cyclodextrin|Intervention: Drug Piroxicam-beta-Cyclodextrin
89609110|NCT03153657|Placebo Comparator|Placebo|Intervention: Drug Placebo
89609111|NCT01670955|Active Comparator|Jobelyn + Ferrous Sulphate + Folic Acid|Caps Jobelyn 250mg, 12 hourly + Ferrous Sulphate 600mg thrice daily + Folic Acid 5mg daily
89609112|NCT01670955|Active Comparator|Ferrous Sulphate + Folic Acid|Ferrous Sulphate 600mg, thrice daily + Folic Acid, 5mg daily
89609113|NCT01274806|No Intervention|Usual care|
89609114|NCT01274806|Experimental|Physical therapy|
89609115|NCT01274884|Active Comparator|Acromioclavicular joint dislocation|Surgery: Arthroscopic repair using the Tightrope fixation device
89609116|NCT03156933||Splicing variants|Sample of acute myeloid leukaemia primary cells
89609117|NCT01275040|Experimental|Mobile screening team|The Primary Health Care clinics where the mobile screening team will visit and active screening for DM complications will take place.
89609118|NCT01275040|Active Comparator|No mobile screening team|No mobile team will visit clinics and active screening for DM complications will not be done. Patients and Health Workers will receive Education, same as intervention arm but no enhanced care.
89609119|NCT01275274|Active Comparator|Standard of care|maintenance therapy with azathioprine or mycophenolate mofetil with or without small dose prednisone.
89609120|NCT01275274|Experimental|Retinoic acid|Tretinoin in addition to standard of care
89609121|NCT01671033|Experimental|Muscle Relaxation|The patients of this arm practice on-line muscle relaxation every day.They complete the Brief Symptom Rating Scale(BSRS), Family APGAR(APGAR), the Chinese-version of the Medical Outcomes Study 36-Item Short Form Health Survey(SF-36), and the panic diary via internet browser. The Panic Disorder Severity Scale(PDSS)and Clinical Global Impression (CGI) were performed by well-trained clinicians.
89609122|NCT01671033|Experimental|Muscle Relaxation with Biofeedback|The patients of this arm practice on-line muscle relaxation with finger temperature biofeedback every day. They complete the Brief Symptom Rating Scale(BSRS), Family APGAR(APGAR), the Chinese-version of the Medical Outcomes Study 36-Item Short Form Health Survey(SF-36), and the panic diary via internet browser. The Panic Disorder Severity Scale(PDSS)and Clinical Global Impression (CGI) were performed by well-trained clinicians.
89609123|NCT01671033|No Intervention|Waiting-List|The patients of this arm waited for four weeks. They complete the Brief Symptom Rating Scale(BSRS), Family APGAR (APGAR), the Chinese-version of the Medical Outcomes Study 36-Item Short Form Health Survey(SF-36), and the panic diary via internet browser. The Panic Disorder Severity Scale(PDSS)and Impressions-Improvement(CGI) were performed by well-trained clinicians.
89609124|NCT01997333|Active Comparator|Capecitabine|Capecitabine will be administered on Days 1 through 14 of each 21 day cycle.
89609125|NCT01997333|Experimental|Drug: CDX-011|CDX-011 administered as an intravenous infusion on Day 1 of each 21 day cycle.
89609126|NCT01271920|Experimental|AUY922 + Trastuzumab|
89609127|NCT05479149|Experimental|Experimental: Training protocol with the cervical device for treatment (CDAT).|Endurance training program of deep cervical flexors and deep cervical extensors with the cervical device for treatment.
89609128|NCT05479149|Active Comparator|Conventional training protocol|Endurance training program of deep cervical flexors and deep cervical extensors with the conventional protocol.
89609129|NCT01275352|Active Comparator|Arm 1|Caucasian hypertensive patients who are homozygous for the ClC-Ka Gly/Gly83 allele
89609130|NCT01275352|Active Comparator|Arm 2|Caucasian hypertensive patients who are homozygous for ClC-Ka Arg/Arg 83 allele
89609131|NCT01275352|Placebo Comparator|Arm 3|Caucasian hypertensive patients who are homozygous for ClC-Ka Arg/Arg 83 allele
89609132|NCT01275352|Placebo Comparator|Arm 4|Caucasian hypertensive patients who are homozygous for the ClC-Ka Gly/Gly83 allele
89609133|NCT01279720|Experimental|Intravenous infusion of transduced cells|Intravenous infusion of transduced cells
89609134|NCT01676259|Experimental|siG12D-LODER + chemotherapy|Eight siG12D-LODER+Gemcitabine+nab-Paclitaxel or Eight siG12D-LODER+Folfirinox or Eight siG12D-LODER+modifide Folfirinox
89609135|NCT01270282|Experimental|AM-101 0.81 mg/mL|Gel for injection; single or triple injection
89609136|NCT01270282|Placebo Comparator|Placebo|Gel for injection; single or triple injection
89609137|NCT01671189|Experimental|SMS Appointment Reminders|150 patients will be randomly assigned to the intervention arm of the study and receive text reminders about their upcoming appointments.
89609138|NCT01671189|No Intervention|Existing Reminder Protocol|150 patients will be randomly assigned to the control arm of the study and will not receive SMS reminders about their upcoming appointments. They will, however, be subject to the clinics' existing reminder protocol (phone call reminders by either clinic personnel or computer machine).
89609139|NCT01273012|Placebo Comparator|Placebo|The group of patients treated with placebo.
89609140|NCT01273012|Experimental|Infloran|The group of patients treated with Infloran.
89033538|NCT06025409|Experimental|Experimental: Leuprorelin|Participants with body weight greater than or equal to (≥) 20 kilogram (kg) will receive the recommended dose of leuprorelin 11.25 milligram (mg), injection, subcutaneously, once every 3 months for 6 months. Participants with body weight less than (<) 20 kg will receive leuprorelin 5.625 mg, injection, subcutaneously, once every 3 months for 6 months.
89033539|NCT06025383|Experimental|L-Citrulline|L-Citrulline: 6 grams/day divided in 2 equal doses
89033540|NCT06025383|Placebo Comparator|Placebo|Microcrystalline cellulose: 8 capsules/day divided into 2 equal doses
89033541|NCT06025357|Experimental|L-citrulline|L-citrulline: 10 grams/day
89033542|NCT06025357|Experimental|Placebo|Microcrystalline Cellulose
89033543|NCT06025266|Experimental|Unilateral Heel Raise|Muscle fatigue was created by exercise consisting of a combination of repetitive plantar flexion and dorsiflexion movements performed during the entire range of motion of the ankle at the frequency of movement determined by the metronome on one step.
89033544|NCT06025266|Experimental|Closed Chain Resisted Foot Adduction|The exercise was performed on the designed wooden assembly. The device was used to maintain the neutral position of the subtalar joint, stabilize the lateral and medial malleoli, and prevent compensation with the knee and hip joints. Individuals were seated with the knee flexed approximately 80 degrees and separated from the other extremity by the length of the forearm, and the contralateral knee was stabilized with the ipsilateral hand. The foot was brought from the abduction position to the adduction position and the heel was not lifted from the ground throughout the movement. The exercise was performed using a green elastic band.The movement was performed in sets of 50 concentric/eccentric contractions. A rest period of 10 seconds was added between each set.
89033545|NCT06025266|Experimental|Combined Exercise|Unilateral Heel Raise and Closed Chain Resisted Foot Adduction exercises were performed sequentially.
89033546|NCT06025240||cf-DNA arm|Participants will be recruited on the basis of having received a renal transplant within the last 6-12 months which has been deemed high risk. They will be identified from a database currently held within the renal transplant unit by members of the direct care team. They will be approached at a routine outpatient appointment for inclusion into the study and testing can be performed at their time of routine post-transplant testing where they will undergo blood (dd-cf DNA NGS assay), standard of care tests: blood count, renal profile, donor specific antibodies (DSA) sample, BK virus PCR, CMV PCR, urine testing and an ultrasound of the graft.
89057272|NCT04541342|Experimental|osteoarthritic with genu varus|initial arthroscopy and high tibial osteotomy to be followed later by a second look arthroscopy with plate removal
89609141|NCT01676337|No Intervention|Control|Patients randomized to the control arm will not receive text message reminder regarding their upcoming appointment.
89609142|NCT01676337|Experimental|Text message appointment reminder|Patients randomized to the intervention arm will receive text message appointment reminders including date, time, and location seven, three and one day prior to their scheduled clinic appointments. All appointment reminders will then be delivered automatically.
89609143|NCT00746122|Other|Open repair|Immediate Open Surgery
89609144|NCT00746122|Experimental|Endovascular strategy|Endovascular strategy involves immediate computed tomography (CT) and emergency Endovascular aneurysm repair (EVAR), with open repair for patients anatomically unsuitable for EVAR
89609145|NCT04538079||Feasibility/Accuracy/Reproducibility|The first 20 participants will be analysed for feasibility and the first 40 ECHOs for accuracy/reproducibility of non-invasive Cardiac Output Monitoring with ECHO as reference Method.
89609146|NCT04538079||Prediction of Circulatory Failure|Together with the Feasibility/Accuracy/Reproducibility Cohort this group's results will be analysed for prediction of circulatory failure defined as an ultrasound abnormality (IVH grade 3 - 4) or death within the first two weeks of life.
89609147|NCT02662257|Active Comparator|Sevoflurane group|"Sevoflurane will be administered by inhalation for anesthesia maintenance. The concentration of inhaled sevoflurane will be adjusted to maintain the bispectral index (BIS) value between 40 and 60. Analgesia will be supplemented with remifentanil (administered by continuous infusion), sufentanil (administered by intermittent injection/continuous infusion), or fentanyl (administered by intermittent injection).~Towards the end of surgery, sevoflurane inhalational concentration will be decreased and fentanyl/sufentanil will be administered when necessary. Sevoflurane inhalation will be stopped at the end of surgery."
89609148|NCT02662257|Experimental|Propofol group|"Propofol will be administered by intravenous infusion for anesthesia maintenance. The infusion rate of propofol will be adjusted to maintain the BIS value between 40 and 60. Analgesia will be supplemented with remifentanil (administered by continuous infusion), sufentanil (administered by intermittent injection/continuous infusion), or fentanyl (administered by intermittent injection).~Towards the end of surgery, propofol infusion rate will be decreased and fentanyl/sufentanil will be administered when necessary. Propofol infusion will be stopped at the end of surgery."
89609149|NCT03153267|Active Comparator|EM-7 days doxycycline|
89609150|NCT03153267|Active Comparator|EM-14 days doxycycline|
89609151|NCT03153267|Placebo Comparator|Controls|
89609152|NCT03153501|Other|Diagnostic arm|Patients with pleural diseases; malignant pleural diseases, tuberculous pleurisy, and other exudate required CT-guided Abrams needle biopsy, US-guided cutting needle biopsy, and medical thoracoscopy.
89609153|NCT01671579|Other|Pediatric small bowel Crohn disease|Subjects with previously diagnosed PSBCD (pediatric small bowel Crohn disease)who are scheduled for a clinically MRE (magnetic resonance enterography)imaging exam.
89609154|NCT00746512|Experimental|Prednisone 15 mg|Prednisone 15 mg tablets once daily for 15 days
89609155|NCT00746512|Placebo Comparator|Placebo 15 mg|Prednisone 15 mg placebo tablets once daily for 15 days
89609156|NCT00746512|Experimental|Prednisone 7.5 mg|"Prednisone 7.5 mg over-encapsulated tablets once daily for 15 days~As per adaptive dose-ranging design, this arm was added to the study because a difference between prednisone 15 mg and placebo was demonstrated during interim analysis."
89609157|NCT00746512|Placebo Comparator|Placebo 7.5 mg|"Prednisone 7.5 mg placebo over-encapsulated tablets once daily for 15 days~As per adaptive dose-ranging design, this arm was added to the study because a difference between prednisone 15 mg and placebo was demonstrated during interim analysis."
89033547|NCT06025240||Immunological Events following renal transplant in older age|The renal transplant population will be divided on the basis of age into two cohort: ≥60 and <60. All renal transplant patients are regularly followed up in the outpatient clinic where blood and urine tests are collected, and clinical evaluations are performed. It is not foreseen that this study will necessitate any additional hospital visits or testing above and beyond the usual standard of care. Serum samples are taken at the time intervals indicated for routine storage and we will simply use those samples for HLA testing (either screening alone or screening and single antigen bead testing if screening yields a positive result).
89519887|NCT03464279|Active Comparator|Control Site|The control site (Urgent Care Center at Olive View-Medical Center) will receive broader health system efforts to reduce antibiotic prescribing consisting of Center for Disease Control prescription pads for non-antibiotic treatments (e.g., decongestants) that offer patients alternatives to antibiotics.
89519888|NCT03468647|Experimental|FRAGIL-IT testing group|FRAGIL-IT tools : connected soles, connected weighting machine and measure of gripping force
89033548|NCT06025240||Determining Predictive Models for Post-transplant HLA-specific Antibody Formation|A subset of the cohort of recruits to the immunological factors in older age study will be used to determine machine learning algorithms of predictive factors for the development of de novo donor specific antibody. Only patients who were unsensitised prior to the kidney transplant will be included into the study because prior sensitisation makes determining de novo specificities much harder. The follow up period will be set at 1 year to synchronise with the older age study.
89033549|NCT06025214|Experimental|Test|Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals
89519889|NCT03468569|Experimental|Functional Movement Screen|Movement Analysis for injury risk
89519890|NCT03468569|Experimental|Vertical Jump Test|Jump test Height Measurement, Functional Movement Screen
89519891|NCT03468569|Experimental|Y Balance Test|Functional lower extremity reach with balance, Functional Movement Screen
89519892|NCT03468569|Experimental|Illinois Agility Test|Agility measurement, Functional Movement Screen
89519893|NCT03468569|No Intervention|Injury History|Athletes injury history for last year was recorded as injury count.
89519894|NCT03468491|Experimental|Combined training group|Biomechanical taping will first being applied to the participants of the combined training group. They will be asked to perform following exercises in this session afterwards. As the treatment session goes on, a set of foot intrinsic muscle strengthening exercise and lower extremity neuromuscular exercise will be provided.
89519895|NCT03468491|Active Comparator|Proximal training group|For participants of the proximal training group, only a set of lower extremity neuromuscular exercise will be provided. This set of exercises is designed to be the same as for participants of combined training group.
89519896|NCT03463967|Active Comparator|Lycopene supplemented|Energy-restricted diet supplemented with lycopene-enriched tomato juice
89519897|NCT03463967|Sham Comparator|Calories Restricted|Energy-restricted diet
89519898|NCT03129971|Experimental|control group|Patients with atrophic nonunion of femoral shaft fractures are equally and randomly assigned to control group, which received conventional surgery.
89519899|NCT03129971|Experimental|experimental group|Patients with atrophic nonunion of femoral shaft fractures are equally and randomly assigned to experimental group, which are injected with autologous platelet-rich plasma on the basis of conventional surgery.
89519900|NCT03468413|Experimental|Single ascending dose, CP1050 or Placebo|
89519901|NCT03468413|Experimental|Multiple ascending dose, CP1050 or Placebo|
89519902|NCT03463733|Experimental|Daily hydroxyurea and temozolomide|"Hydroxyurea and temozolomide will be administered every 4 weeks, with 28 consecutive days defined as a treatment cycle. Treatment will be administered on an outpatient basis. Oral hydroxyurea (dose specified by the Dose Cohort below) and oral temozolomide (50 mg/m2/day) will be administered daily in 28-day cycles for 12 cycles or until unacceptable toxicity, intolerance, progressive disease, or withdrawal of consent. Patients will be treated in dose cohorts of 3 with each cohort receiving a specific daily dose assignment of hydroxyurea.~All patients in the study will receive temozolomide at 50 mg/m2/day (dose-intense schedule). The starting dose level for hydroxyurea will be 200 mg daily (QD) up to a maximum of 2000mg hydroxyurea a day."
89519903|NCT03463655||solid cancer in a palliative situation with ascites|Patient over the age of 18, followed for a solid cancer in a palliative metastatic situation, having had a puncture of ascites.
89519904|NCT03463343|Experimental|Manual manipulation|In the Manual manipulation group, the thrust was applied in the right side of C3/C4 with neutral flexion/extension, ipsilateral side bending and contralateral rotation. Then, a low amplitude, high velocity thrust in rotation was delivered.
89519905|NCT03463343|Active Comparator|Mechanical manipulation|In the Mechanical manipulation group, the Activator instrument was applied on the right transverse apophyses of C3.
89519906|NCT03463343|Placebo Comparator|Placebo|The subjects were positioned in the same pre-manipulative position as the manual manipulation group, but the thrust didn't occur. Instead, the position was hold for 3 seconds and then the subject's head returned passively to neutral position.
89519907|NCT03463343|No Intervention|Control|The subjects stayed in supine position and no intervention occurred.
89519908|NCT03468101||Dairy farmers COPD|
89519909|NCT03468101||Non farmers COPD|
89519910|NCT04222595|No Intervention|1- naive|Group 1: up to 10 children aged 4-6 years that never received LAIV before.
89519911|NCT04222595|Active Comparator|2- Fluenz Tetra nasal spray suspension|Group 2: up to 10 children aged 4-6 years that received LAIV once before. Single dose vaccine, administered as a nasal spray (0.2 ml administered as 0.1 ml per nostril).
89519912|NCT04222595|Active Comparator|3- Fluenz Tetra nasal spray suspension|Group 3: up to 10 children aged 4-6 years that were vaccinated twice before.Single dose vaccine, administered as a nasal spray (0.2 ml administered as 0.1 ml per nostril).
89519913|NCT04222595|Active Comparator|4- Fluenz Tetra nasal spray suspension|Group 4: up to 10 children aged 4-6 years that were vaccinated 3 or 4 times before.Single dose vaccine, administered as a nasal spray (0.2 ml administered as 0.1 ml per nostril).
89519914|NCT03468023|Experimental|Short arm cast|Patient treated with below-elbow cast
89519915|NCT03468023|Active Comparator|Long arm cast|Patients treated with above-elbow cast
89519916|NCT04176185|Experimental|Active|HDM SLIT-tablet once daily for approximately 24 weeks
89033550|NCT06025214|Active Comparator|Reference|ADVAIR DISKUS® 500/50
89033551|NCT06025201|Experimental|Single Arm|All participants will complete all interventions
89519917|NCT04176185|Placebo Comparator|Placebo|Placebo tablet once daily for approximately 24 weeks
89609158|NCT05409027|Experimental|Single Arm|"Each subject will receive between 1 to 15 mg SPI-62 QD PO for up to 14 days.~Each subject will receive up to 12 mcg cortisone-d8 SC during each of one or more study visits."
89609159|NCT01275742|No Intervention|Usual Care|
89609160|NCT01671657||Eeva Test Group|Day 3 embryo transfers that used Eeva with morphology grading (Test Group).
89609161|NCT01671657||Matched case control group|Day 3 embryo transfers using morphology grading only (from concurrent Control Group).
89609162|NCT04385134||General parturient|Observe the enterovirus infection in general parturients and their neonates.
89609163|NCT04385134||Puerpera with fever|Observe the enterovirus infection in puerpera with fever and their neonates.
89609164|NCT04385134||Febrile newborns|Observe the enterovirus infection in neonates
89609165|NCT03153423|Other|Basic intermittent exotropia patients|
89519918|NCT03463109|Other|Healthy Volunteers|Electrocutaneous stimulation. A standardized grid will be drawn over the participants' lumbar region. Circular electrodes, connected to a constant current stimulator, will be applied at points on the grid selected at random. Participants will be blinded to the electrode locations. Sets of painful electrocutaneous stimuli will be randomly delivered for each electrode. Participants will be instructed to draw with a stylus pen on a digital body chart displayed on a tablet the location on which they will perceive each painful stimulation.
89609166|NCT00746668|Experimental|Control Group|Subjects randomly assigned to this group had their training delayed for 18 weeks. These subjects underwent four assessments: baseline and at three 6-week intervals' but, they were not given any training during this time. After this data collection period, these control subjects were given training on the three modules. However, their performance after each period of training was not assessed.
89609167|NCT00746668|Experimental|Group 1|"The subjects were trained in 6 weekly sessions of approximately 2 hours each, plus time for rest. This was followed by second assessments. The subjects were then trained on a second module for another 6 weeks, followed by third assessments. Finally, the subjects were trained on a third module for 6 weeks, followed by final assessments.~Subjects in this group were trained according to the following counterbalanced module order:~Training Session 1: Module 1 (Visual Awareness and Eccentric Viewing) Training Session 2: Module 2 (Control of Reading Eye Movements) Training Session 3: Module 3 (Reading Practice with RSVP)"
89609168|NCT00746668|Experimental|Group 2|"The subjects were trained in 6 weekly sessions of approximately 2 hours each, plus time for rest. This was followed by second assessments. The subjects were then trained on a second module for another 6 weeks, followed by third assessments. Finally, the subjects were trained on a third module for 6 weeks, followed by final assessments.~Subjects in this group were trained according to the following counterbalanced module order:~Training Session 1: Module 2 (Control of Reading Eye Movements) Training Session 2: Module 3 (Reading Practice with RSVP) Training Session 3: Module 1 (Visual Awareness and Eccentric Viewing)"
89609169|NCT00746668|Experimental|Group 3|"The subjects were trained in 6 weekly sessions of approximately 2 hours each, plus time for rest. This was followed by second assessments. The subjects were then trained on a second module for another 6 weeks, followed by third assessments. Finally, the subjects were trained on a third module for 6 weeks, followed by final assessments.~Subjects in this group were trained according to the following counterbalanced module order:~Training Session 1: Module 3 (Reading Practice with RSVP) Training Session 2: Module 1 (Visual Awareness and Eccentric Viewing) Training Session 3: Module 2 (Control of Reading Eye Movements)"
89609170|NCT00746668|Experimental|Group 4|"The subjects were trained in 6 weekly sessions of approximately 2 hours each, plus time for rest. This was followed by second assessments. The subjects were then trained on a second module for another 6 weeks, followed by third assessments. Finally, the subjects were trained on a third module for 6 weeks, followed by final assessments.~Subjects in this group were trained according to the following counterbalanced module order:~Training Session 1: Module 1 (Visual Awareness and Eccentric Viewing) Training Session 2: Module 3 (Reading Practice with RSVP) Training Session 3: Module 2 (Control of Reading Eye Movements)"
89609171|NCT00746668|Experimental|Group 5|"The subjects were trained in 6 weekly sessions of approximately 2 hours each, plus time for rest. This was followed by second assessments. The subjects were then trained on a second module for another 6 weeks, followed by third assessments. Finally, the subjects were trained on a third module for 6 weeks, followed by final assessments.~Subjects in this group were trained according to the following counterbalanced module order:~Training Session 1: Module 2 (Control of Reading Eye Movements) Training Session 2: Module 1 (Visual Awareness and Eccentric Viewing) Training Session 3: Module 3 (Reading Practice with RSVP)"
89609172|NCT00746668|Experimental|Group 6|"The subjects were trained in 6 weekly sessions of approximately 2 hours each, plus time for rest. This was followed by second assessments. The subjects were then trained on a second module for another 6 weeks, followed by third assessments. Finally, the subjects were trained on a third module for 6 weeks, followed by final assessments.~Subjects in this group were trained according to the following counterbalanced module order:~Training Session 1: Module 3 (Reading Practice with RSVP) Training Session 2: Module 2 (Control of Reading Eye Movements) Training Session 3: Module 1 (Visual Awareness and Eccentric Viewing)"
89609173|NCT00752908||Obese patients|Obese patients
89609174|NCT00752908||Normal weight patients and volunteers|Normal weight patients and volunteers
89033552|NCT06025188||training set|To determine potential predictive factors, the training set was subjected to LASSO regression analysis, which effectively eliminated several irrelevant or multicollinearity independent variables to reduce high-dimensional data
89033553|NCT06025188||validation set|The multivariable logistic regression analysis was applied to determine the variables of soiling in patients with HSCR following surgery over one year of age. Finally, a nomogram was created based on the training set and validated in the validation set.
89033554|NCT06025175|Experimental|Lazer group|30 patients will receive low level lazer therapy 3 times per week for 12 weeks.
89033555|NCT06025175|Other|Control group|30 patients will receive only exercises.
89033556|NCT06025162||LMWH dosing strategies|"MDMC's trauma VTE prophylaxis guideline will be used to classify patients into two treatment arms (weight-based or standard dose) based on their dose of enoxaparin at 48 hours post-VTE prophylaxis initiation"
89519919|NCT03463109|Other|Chronic Low Back Pain|"Assessment + Electrocutaneous stimulation. Patients with chronic low back pain will be asked to provide information about their lifestyle, level of disability, current pain, general pain and to undergo an assessment of kinesiophobia and health status.~After the assessment, a standardized grid will be drawn over the patients' lumbar region. Circular electrodes, connected to a constant current stimulator, will be applied at points on the grid. Patients will be blinded to the electrode locations. Sets of painful electrocutaneous stimuli will be randomly delivered for each electrode. Patients will be instructed to draw with a stylus pen on a digital body chart displayed on a tablet where they will perceive each painful stimulation."
89033557|NCT06025084|Active Comparator|first group (A1)|About 24 patients hypersensitive teeth. So the hypersensitive teeth will be treated with egg shell nanoparticles
89519920|NCT04803149|Experimental|Cooled Radiofrequency|Cooled radiofrequency energy will be delivered to target medial branch nerves in the lower back to reduce pain
89519921|NCT04803149|Active Comparator|Conventional Radiofrequency|Conventional radiofrequency energy will be delivered to target medial branch nerves in the lower back to reduce pain
89519922|NCT03462953|Placebo Comparator|individuals with healthy gingiva|Gingival tissue samples will be harvested during the premolar extraction (Orthodontic ttt) or third molar extraction for the healthy controls.
89519923|NCT03462953|Placebo Comparator|periodontally diseased individuals|Gingival tissue samples will be harvested during periodontal surgery and extraction of the periodontally hopeless tooth for the periodontitis patients.
89519924|NCT04259151|Experimental|Electric wheelchair with activated assistance module|This condition will be achieved in 3 standardized test circuits of increasing difficulty, one week apart. At each session, the patient will perform the circuit 6 times, including 3 with activated assistance, in a random order established upstream.
89519925|NCT04259151|Other|Electric wheelchair with assistance module not activated|This condition will be achieved in 3 standardized test circuits of increasing difficulty, one week apart. At each session, the patient will perform the circuit 6 times, including 3 without activated assistance, in a random order established upstream.
89519926|NCT03467633|Experimental|High-intensity interval training (HIIT)|Participants in the HIIT group will receive 3-weeks of tri-weekly supervised exercise sessions at the University of Ottawa Heart Institute prior to their scheduled electro-cardioversion. The session will last 23 minutes in duration and consist of a 2-minute warm-up at 50% of peak power output (PPO), 2 x 8-minute interval training blocks of 30 seconds at 80-100% of PPO interspersed with 30-seconds of active recovery and a 1-minute cool down at 25 % of PPO. The sessions will be lead by a Registered Kinesiologist.
89519927|NCT03467633|No Intervention|Usual Care Control|Participants assigned to the control group will have usual care, which involves no behavioural interventions leading up to their electro-cardioversion.
89519928|NCT05100303|Experimental|Mitoxantrone Hydrochloride liposome and cytarabine|"Chemotherapy will be given in 28-day cycles, and total treatment period is 2 cycles.~Dose escalation phase:~Patients will receive 24 mg/m^2, 30 mg/m^2 or 36mg/m^2 of mitoxantrone hydrochloride liposome daily by intravenous (IV) injections on the first day and 1.5 g/m^2 of cytarabine twice daily by IV for 3 days (day 1, day3 and day5).~Dose expansion phase:~Patients with newly diagnosed AML will receive mitoxantrone hydrochloride liposome daily by IV on the first day, 100~200 mg/m^2 of cytarabine by IV for 7 days (day 1~7). Patients with R/R AML will receive mitoxantrone hydrochloride liposome daily by IV on the first day, 1.5 g/m^2 of cytarabine twice daily by IV for 3 days (day 1, day3 and day5). The dose size of mitoxantrone hydrochloride liposome will be determined by the investigator and the sponsor based on the results of the previous study."
89519929|NCT02522585||Conservative management|Patients diagnosed of CIN-II by directed biopsy
89519930|NCT05097105||urilogic patients|
89519931|NCT03467555|Experimental|distalization group|Class II correction using zygomatic miniplates
89519932|NCT04035759|Experimental|APPEAL Program|Participants receive the APPEAL program, consisting of three one-on-one sessions, each lasting approximately one hour, and spaced one month apart. Sessions are designed to promote positive affect. Participants receive optional weekly check-ins to support behavior change efforts. All participants continue to receive standard of care.
89519933|NCT04035759|No Intervention|Standard of care|Participants receive standard of care.
89519934|NCT05096871||Group I|patients with epilepsy
89519935|NCT05096871||Group II|apparently healthy controls with no chronic illness of matched age and sex
89519936|NCT03462173|Experimental|30 mg single dose|Healthy subjects, receiving a single dose of 30 mg yimitasvir(N=6) or placebo(N=2)
89519937|NCT03462173|Experimental|100 mg single dose|Healthy subjects, receiving a single dose of 100 mg yimitasvir (N=6) or placebo(N=2)
89519938|NCT03462173|Experimental|200 mg single dose|Healthy subjects, receiving a single dose of 200 mg yimitasvir (N=6) or placebo(N=2)
89519939|NCT03462173|Experimental|400 mg single dose|Healthy subjects, receiving a single dose of 400 mg yimitasvir (N=6) or placebo(N=2)
89519940|NCT03462173|Experimental|600 mg single dose|Healthy subjects, receiving a single dose of 600 mg yimitasvir (N=6) or placebo(N=2)
89519941|NCT03462173|Experimental|800 mg single dose|Healthy subjects, receiving a single dose of 800 mg yimitasvir (N=6) or placebo(N=2)
89519942|NCT03462173|Experimental|1000 mg single dose|Healthy subjects, receiving a single dose of 1000 mg yimitasvir (N=6) or placebo(N=2)
89519943|NCT05096715|Experimental|Stereotactic beam radiation therapy (SBRT) +Atezolizumab + Bevacizumab|"Study will begin with a safety lead of 6 participants to determine the maximum tolerated dose (MTD) of Stereotactic beam radiation therapy (SBRT) with atezolizumab and bevacizumab followed by study expansion to 14 more participants after maximum tolerated dose (MTD) is established.~Safety Lead-In: 6 cycles/18 weeks (study cycle is 3 weeks/21 days)~Cycle 1: Atezolizumab + Bevacizumab (1x) with Stereotactic beam radiation therapy (SBRT) every 1-3 days~Cycles 2-6: Atezolizumab + Bevacizumab (1x) every 3 weeks~Expanded Study:~Cycle 1: Atezolizumab + Bevacizumab (1x) with Stereotactic beam radiation therapy (SBRT) every 1-3 days~Cycles 2-End:Atezolizumab + Bevacizumab (1x) every cycle"
89519944|NCT03462485|Experimental|Golf intervention|The golf intervention will be an eight-week golf programme in which participants will be taught to play golf in two 150-min sessions each week. Each session will begin with 30 minutes of socialising, then 90 minutes playing golf, followed by another 30 minutes socialising. The golf sessions will progress from putting, to chipping, and then a full swing, with sessions taking place on a nine-hole golf course.
89033558|NCT06025084|Active Comparator|second group (A2)|About 24 patients hypersensitive teeth. treated with the combination therapy of eggshell and TiO2.
89033559|NCT06025071|Experimental|Colchicine group|Drug: Colchicine; Dosage form: Tablets; Dosage: 0.5mg; Frequency: Once daily; Duration: From randomization to one-year follow-up is completed.
89033560|NCT06025071|No Intervention|Control group|No intervention
89033561|NCT06025058|Experimental|Easy Dew MD Regen Cream|In the case of the study group among the subjects of the clinical study, The experimental group apply an appropriate amount of EasyDew MD Regen Cream twice a day (morning and evening) and can be absorbed well.
89033562|NCT06025058|Active Comparator|Physiogel Stability Intensive Cream MD|The subject applies the provided medical device twice a day (morning and evening) to areas with symptoms of dry skin so that it can be absorbed well.
89033563|NCT06025019|Experimental|Electronic Health (eHealth)|Participants allocated to the eHealth intervention group will be delivered the evidence-based information and interactive components via social media (i.e., WeChat, similar to WhatsApp; and TikTok/Douyin, similar to YouTube). The interactive components include game, push notification, social rapport, influence agent, goal setting and personalized feedback.
89033564|NCT06025019|No Intervention|Control group|Participants allocated to the control group will be delivered printed evidence-based educational materials on standard recommendations for PA, diet, and sleep, without interactive components.
89033565|NCT06025006|Experimental|AILSI|
89519945|NCT03462485|No Intervention|Control|Control participants will continue their normal activities.
89519946|NCT05096637|No Intervention|control group|Patients receive the best medical care according to current guideline recommendations without access to the app
89519947|NCT05096637|Experimental|intervention group|Patients receive the best medical care according to current guideline recommendations with full access to the app. This includes access to relevant findings including ultrasound images of the carotid artery, lipid profile, blood pressure values, and weight.
89519948|NCT05099601|Experimental|Silymarin alone versus silymarin and microneedling|There will be one group of patients. Each side of the patients' face will be randomly allocated to either topical silymarin 0.7% and microneedling or topical silymarin 0.7% alone.
89519949|NCT03462095|No Intervention|no Auto-HSCT|After completing prolonged consolidation T-cell ALL patients will continue with 2 years maintenance
89519950|NCT03462095|Experimental|Auto-HSCT|After completing prolonged consolidation T-cell ALL patients will get autologous HSCT followed by 2 years maintenance
88815319|NCT02484690|Experimental|Arm C: Faricimab, 6 mg Q4W|Participants will receive faricimab 6 mg IVT Q4W up to Week 32 (9 injections). The final study visit will take place at Week 36.
89033566|NCT06025006|No Intervention|the standard of care|
89033567|NCT06024967|Experimental|GenSci004|
89057273|NCT04543565|Experimental|Trial group|subject in this group will receive Pradefovir mesylate tablet and the placebo of tenofovir disoproxil fumarate tablet, once daily for 96 weeks
89519951|NCT05099523|Placebo Comparator|group I|50%Fio2
89519952|NCT05099523|Active Comparator|group II|30%Fio2
89519953|NCT05104203|Active Comparator|Thoracolumbar Interfascial Plane block|Patient will receive Thoracolumbar Interfascial Plane block
89519954|NCT05104203|Experimental|Modified Thoracolumbar Interfascial Plane block|Patient will receive modified Thoracolumbar Interfascial Plane Block
89519955|NCT04437147|Placebo Comparator|Placebo|a) Control placebo (P1) Component Vitamin C (Ascorbic acid) 45 mg,Vitamin B1 (Thiamine) 1.1 mg, Vitamin B2 (Riboflavin) 1.1 mg,Vitamin D-3 40,000,000 IU / GR (Cholecalciferol) 34 mcg, Magnesium hydroxide 0.3 g, Calcium Carbonate 0.5 g, Natural Vanilla Flavor Powder 0.03 g,Fos (Fructooligosaccharides) qsp 3 g, for 30 days, once a day by sachet
89519956|NCT04437147|Active Comparator|3 Billion CFU strains of probiotics|b) 3 Billion CFU (P2) Component Lactobacillus acidophilus LA 02 ID 1688 1 billion CFU,Bifidobacterium bifidum BB 01 ID 1722 1 billion CFU, Lactobacillus rhamnosus LR 04 ID 1132 1 billion CFU,Vitamin C (Ascorbic acid) 45 mg,Vitamin B1 (Thiamine) 1.1 mg, Vitamin B2 (Riboflavin) 1.1 mg,Vitamin D-3 40,000,000 IU / GR (Cholecalciferol) 34 mcg, Magnesium hydroxide 0.3 g, Calcium Carbonate 0.5 g, Natural Vanilla Flavor Powder 0.03 g,Fos (Fructooligosaccharides) qsp 3 g, for 30 days, once a day by sachet
89519957|NCT04437147|Active Comparator|8 Billion CFU strains of probiotics|c) 8 Billion UFC (P3) Component Lactobacillus paracasei LPC 00 ID 1076 1 billion CFU;Bifidobacterium longum BL 03 ID 1152 1 billion CFU; Bifidobacterium lactis BS 01 ID 1195 1 billion CFU;Lactobacillus casei LC 03 ID 1872 1 billion CFU; Bifidobacterium animalis LMG 10508 1 billion CFU; Lactobacillus acidophilus LA 02 ID 1688 1 billion CFU,Bifidobacterium bifidum BB 01 ID 1722 1 billion CFU, Lactobacillus rhamnosus LR 04 ID 1132 1 billion CFU,Vitamin C (Ascorbic acid) 45 mg,Vitamin B1 (Thiamine) 1.1 mg, Vitamin B2 (Riboflavin) 1.1 mg,Vitamin D-3 40,000,000 IU / GR (Cholecalciferol) 34 mcg, Magnesium hydroxide 0.3 g, Calcium Carbonate 0.5 g, Natural Vanilla Flavor Powder 0.03 g,Fos (Fructooligosaccharides) qsp 3 g, for 30 days, once a day by sachet
89519958|NCT03461939||ePRIME|"Participants in the study will receive training in using the ePRIME system to report their symptoms and side effects on a weekly basis from home via the internet for 12 weeks while receiving early phase trial treatment. Patients will be sent email/text reminders to enter their symptoms on the system once a week. Patients will be reminded that the data they enter via the online system will not be reviewed promptly by their hospital team and therefore they should continue to contact their treatment team via the contact numbers they have been given.~As part of the research project, we will monitor the number of notifications for severe AE generated by the system to address concerns from the interviews conducted in the first phase of this research project that ePROs will lead to increased workload for clinicians."
89519959|NCT03461783|Experimental|Zorflex Activated Carbon Dressing|Patients randomized into the experimental group will only be treated using an activated carbon dressing (Zorflex® Activated Carbon Cloth Dressing; Chemviron Carbon Cloth Carbon, West Midlands, United Kingdom; a division of Calgon Carbon Corporation, Pittsburgh, PA) for wet wounds or with saline and Zorflex® Activated Carbon Cloth Dressing for dry wounds.
89519960|NCT03461783|Active Comparator|Standard of Care for Wound Care|Patients with wet wounds randomized into the control group will be treated using foam, calcium alginate or compressive dressings, whereas those with dry wounds will be treated with hydrogel and compressive dressings.
89519961|NCT01677507|Experimental|timolol|To compare the variation in response to timolol between individuals
89519962|NCT01677507|Active Comparator|latanoprost|To compare the variation in response to latanoprost between individuals
89033568|NCT06024954|Experimental|music group|"The research is planned as a randomized controlled trial. The individuals in the research group are divided into four groups as music group, aromatherapy group, music and aromatherapy and control group. The relaxing music group will listen to specially composed MusiCure® compositions in soft rhythm, including melodies with harp, cello, strings and natural sound elements (eg rain, bird, forest sound). The patients in the experimental group will listen to the music with headphones for 20 minutes for three consecutive days.~Before and at the end of the intervention, data collection tools [Patient Description Form, Vısual analog scale, facial anxiety scale , Distress Thermometer, Edmonton Symptom Scale] will record the characteristics of pain, anxiety and vital parameters."
89519963|NCT04853693|Experimental|Mom´s Supporting Mom (MSM)|A preventive intervention that involves psychoeducation and peer techniques described in study detailed description.
89519964|NCT04853693|Active Comparator|Enhanced Treatment as Usual|Referral to treatment in the community and monitoring
89033569|NCT06024954|Experimental|aromatherapy group|"Patients in the aromatherapy group use 5% lavender oil with a diffuser for 15-20 minutes in accordance with the Aromatherapy-Clinical Guideline For Midwives. NHS.~Trust 1-15) has been applied. The diffuser was placed 30 cm from the participants and five (5) drops of essential lavender oil were placed on the filter paper. Within 10-15 minutes after the completion of the inhalation, data collection forms were applied again, and pain, anxiety, blood pressure, pulse and respiratory rate were evaluated."
89033570|NCT06024954|Experimental|aromatherapy and music group|Inpatients in the palliative care service will be given music with headphones for three consecutive days with the effect of aromatherapy inhaler. Within 10-15 minutes after the completion of the inhalation, data collection forms will be applied again and pain, anxiety, blood pressure, pulse and respiratory rate will be evaluated.
89210720|NCT00584987|Placebo Comparator|Placebo FF + Placebo OXY|Placebo Fluticasone furoate + Placebo Oxymetazoline, 2 puffs of each nasal spray in each nostril in the pm
89519965|NCT03656367|Experimental|All subjects|"Cross-over study (all subjects receive all interventions)~Cheddar cheese~Blended and homogenized cheddar cheese~An analog milk~An analog cheese"
89519966|NCT03656367|Other|Healthy subjects only (subgroup)|"If any subjects (against our hypothesis) have indices of metabolic syndrome i.e. raised fasting glucose or TG concentration, secondary analyses will be conducted to assess results without these subjects.~All subjects receive all interventions)~Cheddar cheese~Blended and homogenized cheddar cheese~An analog milk~An analog cheese"
89519967|NCT04796363|Experimental|ESPB Bubivacaine 0.25%|20 patients will receive US-guided deep ESPB block before induction of general anaesthesia using 20 ml bupivacaine 0.25 % and 5 ml of radiocontrast dye (Omnipaque) at the level of T4.
89033571|NCT06024954|No Intervention|control group|Participants were not interfered with.
89519968|NCT04796363|Active Comparator|ESPB Bubivacaine 0.125%|20 patients will receive US-guided deep ESPB block before induction of general anaesthesia using 40 ml bupivacaine 0.125 % and 5 ml of radiocontrast dye (Omnipaque) at the level of T4.
89519969|NCT04796363|Placebo Comparator|No ESPB|20 patients will undergo standard general anaesthesia as a control group and postoperative analgesia with intravenous morphine patient controlled analgesia (PCA) and rescue analgesia if required.
89519970|NCT03593109|Experimental|LCAR-L10D treatment group|In LCAR-L10D treatment group, patients will be treated with dual specificity CD19 and CD22 CAR-T cells with a escalation approach, 3 CAR-T dosage will be tested in this study: 0.5×10^6, 1.5×10^6, 5.0×10^6 CAR-T cells/kg.
89519971|NCT03566433|Active Comparator|Endoscopic TEP surgery|Routine total extraperitoneal technique surgery for inguinal hernia
89519972|NCT03566433|Active Comparator|Open Lichtenstein hernioplasty|Routine lichtenstein surgery for inguinal hernia
89519973|NCT05103813|Experimental|Beraprost Sodium Tablets|
89519974|NCT03461627|Experimental|Salmeterol Xinafoate and Fluticasone Propinate Powder|Salmeterol Xinafoate and Fluticasone Propinate Powder for inhalation (50ug/250ug) 50ug/250ug 1 puff twice a day for 4 weeks
89519975|NCT03461627|Active Comparator|Seretide|50ug/250ug 1 puff twice a day for 4 weeks
89519976|NCT04452929|Active Comparator|Randomized treatment phase: Erenumab|Erenumab 140 mg single subcutaneous injection at baseline
89519977|NCT04452929|Placebo Comparator|Randomized treatment phase: Placebo|Saline placebo single subcutaneous injection at baseline
89519978|NCT04452929|Other|Open-label extension treatment phase: Erenumab|Erenumab 140 mg monthly subcutaneous injection for six months after completion of the randomized, double-blinded, placebo-controlled study phase during the open-label extension
89519979|NCT03461471|Experimental|Intervention Group|Exercise intervention
89519980|NCT04452539||Paediatric cardiac surgery patients|All patients undergoing paediatric cardiac surgery
89519981|NCT04708223|Experimental|Fast-curing composites|
89519982|NCT04708223|Other|Conventionally applied composites|
89519983|NCT05103579||Patients with AFib|Patients with AFib
89519984|NCT05103579||Normal patients|Normal patients without AFib
89519985|NCT02521727||exposed siblings/children|"Consecutive subjects with non-advanced adenomas will be identified from the colonoscopy database at Prince of Wales Hospital, Alice Ho Miu Ling Nethersole Hospital, Queen Elizabeth Hospital and the bowel cancer screening center at Siu Lek Yuen. Figure 1 illustrates subject recruitment flow chart. They will be consented to provide details on their number of FDR, their FDR contact details, and cause of death in FDR who are deceased. FDR aged 40 to 70 years of consecutive patients with newly diagnosed non-advanced adenomas confirmed from endoscopy and pathology reports will be contacted via phone and invited for an interview and a colonoscopy.~COLONOSCOPY With informed consents, experienced colonoscopists (GI physicians, colorectal surgeons) will perform colonoscopy under intravenous sedation, midazolam and pethidine after adequate bowel preparation."
89519986|NCT02521727||unexposed siblings/children|"Subjects (Control) FDR aged 40 to 70 years of asymptomatic average risk subjects who had undergone a colonoscopy in our bowel cancer screening programme between 2010 and 2014 and found to have a normal colonoscopy will be invited to participate by phone and invitation letters, to attend a health talk and to undergo a colonoscopy.~Confounding factors including use of drugs (aspirin and non-steroidal anti-inflammatory drugs), lifestyle factors (smoking, and diet questionnaire) and history of medical conditions (obesity with calculation of body mass index, diabetes, history of cardiovascular disease) between cases and controls will be recorded.~COLONOSCOPY With informed consents, experienced colonoscopists (GI physicians, colorectal surgeons) will perform colonoscopy under intravenous sedation, midazolam and pethidine after adequate bowel preparation."
89033572|NCT06024915|Experimental|Itraconazole drug-durg interaction (DDI)|Itraconazole capsule: 0.2g once daily on Days 2 to Day 5; TQ05105 tablets: single oral dose on Days 1 and Day 5.
89033573|NCT06024915|Experimental|Rifampicin DDI|Rifampicin Capsule: 0.6g once daily on Days 2 to Day 9; TQ05105 tablets: single oral dose on Days 1 and Day 9.
89033574|NCT06024850||multiligamentar knee reconstruction|"Any patient who benefits of a multiligamentar knee reconstruction at hospital of Saint-Etienne will be included.~Datas collected by medical record."
89033575|NCT06024837||Patients with Colo-rectal Cancer|Patients with Colo-rectal Cancer will be included.
89033576|NCT06024811||intervention|"Pregnant women over 18 years of age, with cervical dilatation 3 cm or more, planned for spontaneous vaginal delivery, term and singleton pregnancy, who speak Turkish, who did not have language communication problems, and who voluntarily agreed to participate in the study were included.~Pregnant women in the intervention and control groups were randomized using the www.random.org website on the computer (intervention=56 control= 56).Intervention and control groups were randomized according to some basic variables (age group, education level, body mass index, number of births and pregnancies, participation in prenatal preparation classes) considering the literature ."
89057274|NCT04543565|Active Comparator|Control group|subject in this group will receive tenofovir disoproxil fumarate tablet and the placebo of Pradefovir mesylate tablet, once daily for 96 weeks.
89519987|NCT05103501|Experimental|experimental arm|PF regimen (cis-platinum of 75mg/m2/d, d1; 5-fluorouracil of 600mg/m2d1-4) combined with PD-1 inhibitors（pembrolizumab，200mg d1） every 3 weeks for 4 cycles followed by PD-1 inhibitors（pembrolizumab，200mg d1）every 3 weeks up to 2 years in a standard manner.
89519988|NCT03461393||Intervention Group|Repetitive Training with Medical-Eye-Trainer (MET)
89057275|NCT01681329|Experimental|Cognitive-behavioral therapy with interpretation training|14 sessions of cognitive-behavioral therapy combined with computerized interpretation modification training
89057276|NCT01681329|Active Comparator|Cognitive-behavioral therapy with non-active training|14 sessions of cognitive-behavioral therapy combined with computerized non-active training
89519989|NCT02763111|Experimental|BCD-085, 40 mg|Patient will receive 40 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10, 12.
89519990|NCT02763111|Experimental|BCD-085, 80 mg|Patient will receive 80 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10, 12.
89519991|NCT02763111|Experimental|BCD-085, 120 mg|Patient will receive 120 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10, 12.
89519992|NCT02763111|Placebo Comparator|Placebo|Patient will receive placebo subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10, 12.
89519993|NCT02522117|Active Comparator|Atorvastatin|24 patients received oral atorvastatin 40 mg once a day, for 4 weeks.
89519994|NCT02522117|Placebo Comparator|Placebo|24 patients received oral placebo 40 mg once a day, for 4 weeks.
89519995|NCT05103111||FHP group (study group)|it will be consisted of 50 women, suffering from FHP (CVA is less than 48°)
89519996|NCT05103111||control group (without FHP)|it will be consisted of 50 women, not having FHP (CVA is more than 48°).
89519997|NCT03461315|No Intervention|Traditional Mode|Traditional Model: Team That Cares for the Rest of the Community
89519998|NCT03461315|Experimental|Study Model|Study Model:Team Dedicated Exclusively to the Home Patient
89519999|NCT02480595||EVAR|Patients undergoing endovascular repair with the latest generation Aorfix™ AAA Flexible Stent Graft System for treatment of abdominal aortic and aorto-iliac aneurysms where the aorta in the aneurysm neck is bent through an angle between 0° and 90°
89520000|NCT04657211||Group A|Participants will receive treatment from settled general practitioners (GPs) (GPs, primary care, practitioner/registered doctor).
89520001|NCT04657211||Group B|Participants will receive treatment from settled pulmonologists (specialists, primary or secondary care).
89520002|NCT04657211||Group C|Participants will receive treatment at outpatient lung centers (clinics, ambulances, acute care centers).
89520003|NCT03947177|Placebo Comparator|Control|GMIT
89520004|NCT03947177|Experimental|Intervention|Modified GMIT + Parenting support groups
89520005|NCT05204589|Experimental|Group A|Subjects in safety cohort will receive one heterologous booster dose of aerosolized Ad5-nCoV
89520006|NCT05204589|Experimental|Group B|Subjects in immunogenicity cohort will receive one heterologous booster dose of aerosolized Ad5-nCoV
89520007|NCT05204589|Experimental|Group C|Subjects in immunogenicity cohort will receive one homologous booster dose of ICV.
89520008|NCT05020509|Active Comparator|Touhy needle group|medial branch block with touhy needle
89520009|NCT05020509|Placebo Comparator|Quincke needle group|medial branch block with Quincke needle
89520010|NCT03461081|Experimental|Group I|Period I: administration of telmisartan/Amlodipine for 10 days then administration of telmisartan/amlodipine and atorvastatin for 4 days Period II: atorvastatin for 4 days
89520011|NCT03461081|Experimental|Group II|Period I: administration of atorvastatin for 4 days Period II: administration of telmisartan/amlodipine for 10 days then administration of telmisartan/amlodipine and atorvastatin for 4 days
89520012|NCT04526301||Tablo Hemodialysis System|Home dialysis treatment with the Tablo Hemodialysis System
89520013|NCT04571567|Experimental|Secukinumab|300mg subcutaneously
89520014|NCT04670757|Experimental|CPL409116|"PART A. IMP is to be administered orally in single ascending dose in the groups consisting of 3 volunteers according to '3+3' design'. Dose escalation scheme is to be determined based on preclinical results and due to dose limiting observation (DLT).~PART A additional. Assessing the effect of food on bioavailability of CPL409116. IMP is to be administered orally in single dose in fasted and fed state in the group of 12 volunteers.There is to be one week wash-out between two treatment periods for this cohort."
89520015|NCT04670757|Experimental|PLACEBO|PART B. Two participants from each of 4 cohorts (total of 8 participants) are to receive masking placebo tablet once daily for 14 days. There is to be dose escalation between cohorts. Participants are to be randomized within cohorts.
89520016|NCT02522039|Experimental|Latanoprost|solution, 1 drop of 50ug/ml latanoprost, was given to study eye after washout period of 1 week between drugs
89520017|NCT02522039|Experimental|Timolol|solution, 1 drop of 5mg/ml timolol , was given to study eye after washout period of 1 week between drugs
89520018|NCT02522039|Experimental|dorzolamide|solution, 1 drop of 20 mg/ml dorzolamide, was given to study eye after washout period of 1 week between drugs
89520019|NCT02522039|No Intervention|Other|no drug given and pupil measurements were performed before and at 30 and 180 min at equivalent hours as drugs measurements
89520020|NCT04950855||Pregnant Women|Healty pregnant women between 18-45 years,with no history of eye surgery and systemical disease.In 1st , 2nd and 3rd trimesters the measurements will be repeated
89520021|NCT04950855||Control Group|Healty non-pregnant women between 18-45 years with no history of eye surgery and systemical disease.
89520022|NCT04505111|Experimental|Prehabilitation + Enhanced Recovery After Surgery|Patients allocated to the intervention group will undergo prehabilitation protocol (nutrition + exercise + psychological counselling), with individualized monitoring by the multidisciplinary team.
89520023|NCT04505111|Active Comparator|Enhanced Recovery After Surgery|Patients allocated to the control group will not undergo any pre-surgical intervention, except for preoperative counselling, already implicated in ERAS®.
89057277|NCT01681407||Depressed Patients|Patients: Group of patients that are diagnosed for having depression, and are suitable for SSRI treatment.
89520024|NCT04707495|Experimental|Smartphone Application (SPSRS)|"The experimental group receives video-viewing intervention using the SPSRS application, which is a smartphone application. SPSRS is programmed to present 150 ms of positive words after presenting 17 ms of self-confidence-boosting words in videos.~These words are repeated every 5 s. The words to increase self-confidence are can, let us try, good luck, able, and do not worry. These self-confidence-boosting words randomly appear in the four corners of the screen. The positive words are nice, great, fantastic, satisfactory, and enjoyable. These words are displayed at the center of the screen. Interveners use the SPSRS application according to the operating manual. The participants will use an iPhone managed by interveners to watch a pre-determined 10-minute video."
89520025|NCT04707495|Active Comparator|Smartphone Application (YouTube)|The control group uses the same iPhone as the experimental group. The control group uses the YouTube application to receive video-viewing intervention. The control group videos do not show confidence-boosting and positive words. The control group watches the same video as the experimental group for 10 min.
89520026|NCT03460925|Experimental|SBRT plus chemotherapy|"Patients with unresectable or borderline resectable locally advanced pancreatic carcinoma at time of diagnosis"
89520027|NCT05107791|Experimental|Stulln Eyedrops|Augentropfen Stulln Mono Eye Drops (Stulln eyedrops) will be provided to participants in individual single-use vials. Participants will apply the drops to the two eyes 3 times a day, six days a week before sustained eye use (except Sunday).
89520028|NCT05107791|Sham Comparator|Theta Tears|Thera Tears (Sodium Carboxymethylcellulose 0.25%) will be provided to participants in individual single-use vials. Participants will apply the drops to the two eyes 3 times a day, six days a week before sustained eye use (except Sunday).
89520029|NCT05107323|Experimental|CMT-T|The CMT-T is a Compassionate Mind Training program tailored for teachers, delivered in a group format across eight sessions of approximately 2.5 hours each. In each session, besides presenting relevant theoretical constructs addressed in that session, participants are invited to complete experiential exercises, compassion and mindfulness meditation practices, and work in small groups to share their experiences, followed by a plenary session. There are six different modules addressed during the 8-sessions CMT-T
89520030|NCT05107323|No Intervention|Waiting list|Participants in the waiting list control group were not offered an intervention.
89520031|NCT05111769|Experimental|rhBNP in the treatment of sepsis complicated with heart failure|Recombinant human brain natriuretic peptide (rhBNP) on sepsis complicated with heart failure
89520032|NCT05111769|No Intervention|Conventional treatment group|Do not use recombinant human brain natriuretic peptide (rhBNP) to treat sepsis with heart failure
89520033|NCT03460691||Group 1|Group 1:patients who will undergo the bariatric surgery
89520034|NCT04358003|Experimental|Plasma Adsorption Cartridge|Subjects will receive one treatment per day with the D2000 Cartridge for use with the Spectra Optia® Apheresis System (Optia SPD Protocol) for up to 4 hours (treatment cycle) for up to seven (7) days.
89520035|NCT03460613|Other|FGID Patients|
89520036|NCT03460613|No Intervention|Hepatology Control Group|
89520037|NCT03460613|No Intervention|Healthy Volunteers|
89520038|NCT03568409|Experimental|Group A: ABO-GLYC|Libramed
89520039|NCT03568409|Placebo Comparator|Group B: Placebo|
89520040|NCT04642677|Experimental|Group A|"Patients and caregivers were received palliative sedation with healthcare provider's recommended communication with sympathy and printed paper, Regardless of the patient's outward consciousness, talk with the patient and express empathy. Hearing will be maintained until the end. three times a day (8, 14 and 20 o'clock)."
89520041|NCT04642677|No Intervention|Group B|Patients and caregivers were received palliative sedation without intervention.
89520042|NCT05111067||Nova scotia TNBC cohort|DNA and whole transcriptome mRNA sequencing, including total mutational burden and microsatellite instability, will be performed using the TruSight Oncology 500 (TSO500) platform (Illumina Canada, Ulc). Transcriptome data will be used to categorize specimens into one of four distinct mRNA subgroups and will be compared between cohorts.
89520043|NCT05111067||Nigerian TNBC cohort|DNA and whole transcriptome mRNA sequencing, including total mutational burden and microsatellite instability, will be performed using the TruSight Oncology 500 (TSO500) platform (Illumina Canada, Ulc). Transcriptome data will be used to categorize specimens into one of four distinct mRNA subgroups and will be compared between cohorts.
89520044|NCT04519905|Experimental|chemoradiotherapy|50.4Gy/28Fx; Paclitaxel plus carboplatin
89520045|NCT04519905|Active Comparator|radiotherapy|61.2Gy/34Fx
89520046|NCT04289285|Experimental|IBI306 450mg SC Q4W|
89520047|NCT04289285|Placebo Comparator|Placebo SC Q4W|
89520048|NCT04289285|Experimental|IBI306 600mg SC Q6W|
89520049|NCT04289285|Placebo Comparator|Placebo SC Q6W|
89520050|NCT04477473||Vulnerable subjects|Patients under long-term non-invasive ventilation (respiratory support) at home for chronic respiratory failure
89520051|NCT03460457|Experimental|TQB2450|
89520052|NCT04474743||Liver Cirrhosis|Patients diagnosed with liver cirrhosis.
89520053|NCT04474743||Chronic Pancreatitis|Patients diagnosed with chronic pancreatitis.
89520054|NCT04474743||Short Bowel Syndrome|Patients diagnosed with short bowel Syndrome.
89520055|NCT04474743||Control Patients|Otherwise healthy patients visiting hospital with other non-severe diseases.
89033577|NCT06024811||control|"Pregnant women over 18 years of age, with cervical dilatation 3 cm or more, planned for spontaneous vaginal delivery, term and singleton pregnancy, who speak Turkish, who did not have language communication problems, and who voluntarily agreed to participate in the study were included.~During the data collection period of the study, 313 women were evaluated according to the inclusion and exclusion criteria. Women who did not meet the inclusion criteria (n=198) and refused to participate in the study (n=3) were not included in the study sample. Pregnant women in the intervention and control groups were randomized using the www.random.org website on the computer (intervention=56 control= 56).Intervention and control groups were randomized according to some basic variables (age group, education level, body mass index, number of births and pregnancies, participation in prenatal preparation classes) considering the literature (Taghenijad et al. 2010; Erdogan et al. 2017)."
89520056|NCT04474743||Healthy Controls|Healthy subjects recruited from the general population.
89033578|NCT06024746|Experimental|Finerenone plus empagliflozin|
89520057|NCT03129659|Experimental|CT-group|Coronary CT angiography
89520058|NCT04423341|Active Comparator|Group A - active medication followed by placebo|
89520059|NCT04423341|Active Comparator|Group B - placebo followed by active medication|
89520060|NCT05106699|Experimental|Carbon ion followed by Proton radiotherapy|All patients received whole pelvis and prostate region radiotherapy. The dose to metastatic LN was escalated using simultaneous integrated boost (SIB) technique.
89033579|NCT06024746|No Intervention|Usual care|Usual care management
89033580|NCT06024694||patients diagnosed with PMLBL|Patients whose diagnosis met the histological criteria of PMLBL according WHO classification with a diagnosis of CNS involvement at relapse/progression
89520061|NCT03378479|Other|SOC + 'Posaconazole 18 MG/ML'|standard of care (SOC) treatment for influenza pneumonia +posaconazole 2*300mg/d IV on day 1, followed by 1*300mg/d IV from day 2 for 7 days; vials containing 18mg posaconazole /mL, 300mg posaconazole/vial in total)
89520062|NCT03378479|Other|Standard of Care|standard of care treatment for influenza pneumonia (at the investigators discretion)
89520063|NCT04187183|Experimental|Fresh PRP with concentrate Leukocyte|"Three infiltrations of fresh Platelet Rich Plasma with concentrated Leukocytes~1 infiltration weekly, for 3 weeks."
89520064|NCT04187183|Active Comparator|Fresh PRP without concentrated Leukocyte|"Three infiltrations of fresh Platelet Rich Plasma without concentrated Leukocyte.~1 infiltration weekly, for 3 weeks."
89520065|NCT05101395||Patients with Gastritis|Patients who underwent sleeve gastrectomy and the histopathology result of resected gastric specimen showed the presence of gastritis in it.
89520066|NCT03460223|Experimental|Conventional plus MSC treatment|
89520067|NCT04963959|Other|Healthy donor|
89520068|NCT03460145|Experimental|Strip with Lavender Oil (Lx)|"Application of Nasal Strip with essential oil (Lavender), 20minutes before induction.~VAS- Anxiety scores pre and post inhalation."
89520069|NCT03460145|Placebo Comparator|Strip without Lavender Oil (Px)|Application of Nasal strip without essential oil, acting as placebo. VAS- Anxiety scores pre and post placebo.
89520070|NCT04125771|Other|Diclofenac + HBB|Women who will receive Diclofenac + HBB
89520071|NCT04125771|Other|Diclofenav + placebo|Women who will receive Diclofenav + placebo
89520072|NCT05027997|Experimental|Dipraglurant 50 mg|
89520073|NCT05027997|Experimental|Dipraglurant 100 mg|
89520074|NCT05027997|Placebo Comparator|Placebo|
89520075|NCT03129737|Experimental|Tricuspid valve annuloplasty|Concomitant tricuspid valve annuloplasty in patients with tricuspid annulus dilatation (>21mm /m2) with or without TR≤ moderate in pts undergoing mitral valve surgery
89520076|NCT03129737|Active Comparator|Mitral valve repair|No concomitant tricuspid valve annuloplasty in patients with tricuspid annulus dilatation (>21mm/m2) with or without TR ≤ moderate in pts undergoing mitral valve surgery
89520077|NCT03249077||Digital DPP enrolled|The DPP online program is a CDC-certified translation of the DPP lifestyle intervention delivered in an online small group format of 10-15 participants.
89520078|NCT03249077||In-person DPP enrolled|In-person DPP participants will attend group sessions of ~20 participants in size at KPNW clinics. The group facilitator will use the CDC National DPP curriculum,
89520079|NCT03249077||DPP not enrolled (usual care)|Access to usual care services without restrictions.
89520080|NCT04529655||Sepsis|Patients admitted to the ICU with sepsis will be enrolled and monitored at time sequential time points during their treatment
89520081|NCT05115123|Active Comparator|Intervention|patients scheduled for elective LC will receive 60 mg duloxetine before surgery
89520082|NCT05115123|Placebo Comparator|Control|patients scheduled for elective LC will receive placebo before surgery
89520083|NCT04821999|Experimental|group I|a 940-nm diode laser (EPIC™, BIOLASE, www.biolase.com) with an adjustable pain therapy handpiece capable of creating diffuse laser energy patterns ranging from 15 mm to 30 mm in size.
89520084|NCT04821999|No Intervention|group II|No treatment
89520085|NCT03209063||Group I|195 Patients having history of two or more miscarriages.
89520086|NCT03209063||Group II|90 healthy controls less than 35 years with no history of miscarriage and at least one uncomplicated full-term pregnancy
89520087|NCT04636671|Experimental|Methylprednisolone|"A. On day 1, loading dose of methylprednisolone (MP) 80 mg IV in 30 minutes, promptly followed by continuous infusion of MP 80 mg/day in 240 mL of normal saline at 10 mL/h.~B. From day 2 to day 8: infusion of MP 80 mg/day in 240 mL of normal saline at 10 mL/h.~C. From day 9 and beyond:~If not intubated patient and PaO2/FiO2 > 200, taper to MP 20 mg IV in 30 minutes three times a day for 3 days, then MP 20 mg IV twice daily for 3 days, then MP 20 mg IV once daily for 2 days, then switch to MP 16 mg/day PO for 2 days, then MP 8mg/day PO for 2 days, then MP 4mg/day PO for 2 days;~If intubated patient or PaO2/FiO2 <= 200 with at least 5 cmH2O CPAP, continue infusion of MP 80 mg/day in 240 mL of normal saline at 10 mL/h until PaO2/FiO2 > 200 then taper as in a)"
89033583|NCT06024577|Active Comparator|Walking|Participants prescribed 150 minutes/week of moderate to vigorous walking.
89520088|NCT04636671|Active Comparator|Dexamethasone|"A. Dexamethasone (DM) 6 mg IV in 30 minutes or PO from day 1 to day 10 or until hospital discharge (if sooner).~B. After day 10 study treatment is interrupted."
89033584|NCT06024577|Experimental|Variety|Participants prescribed 150 minutes/week of moderate to vigorous variety of exercise. Each week participants will be prescribed a single different exercise (variety) which will include cycling, walking/jogging, yoga/Pilates, and cross-training.
89057278|NCT01681407||Non-Depressed Controls|Controls: Volunteers that had clinical screening with no depression diagnosis.
89520089|NCT03459599|Active Comparator|Prophylaxis|Current protocol of administering antibiotics maintained
89520090|NCT03459599|Active Comparator|No prophylaxis|Antibiotics withheld, with appropriate observation and follow up
89520091|NCT04613583||SAFeR Fetuses|Different maternal lifestyle factors: smoking, BMI, social deprivation, alcohol use, medicines. Depends on specific subproject analyses.
89520092|NCT05106621||Surgical Patients|
89520093|NCT03458507|Active Comparator|Usual interface|"Patients which begin with their usual interface for one week, home polygraphy and side effect assessment at the end of the first week.~Switch for alternative interface, seven days familiarisation, second polygraphy and side effect assessment at the end of the second week."
89520094|NCT03458507|Active Comparator|Alternative interface|"Patients which begin with the alternative interface for one week, home polygraphy and side effect assessment at the end of the first week.~Switch for usual interface, seven days with usual device, second polygraphy and side effect assessment at the end of the second week."
89520095|NCT04867083|Experimental|Arm 1: 4 days/7|4 days/7 Patients included in this arm will take their ARV treatment 4 consecutive days per week during 48 weeks.
89520096|NCT04867083|Active Comparator|Arm 2: 7 days/7|Patients included in this arm will take their ARV treatment 7 days per week during 48 weeks
89520097|NCT03049787|Experimental|home exercise|For the home exercise protocol alone arm, subjects will be given an experimental home exercise program and study team will demonstrate the exercises in the clinic and will direct the subjects to perform the exercises 1-2 times daily until symptom resolution.
89520098|NCT03049787|Active Comparator|physical therapy|Patients will be prescribed routine physical therapy protocol where they will see a physical therapist twice a week and will be instructed by the physical therapist to perform physical therapy exercises at home daily until symptom resolution, as is the routine practice.
89520099|NCT03645603|Experimental|Dexmedetomidine|Dexmedetomidine 100 mcg/ml concentrate solution. Continuous iv infusion. Start dose 0.4 mcg/kg/h, increases by 0.2 mcg/kg/h until 0.8 mcg/kg/h (half dose for neonates). If withdrawal symptoms appear the dose can be increased to a maximum of 1.4 mcg/Kg/h.
89520100|NCT03645603|Placebo Comparator|Placebo|saline solution for IV infusion. The administration of infusion will follow the experimental drug.
89520101|NCT02878499|Other|ASD|
89520102|NCT05059041|Experimental|Dilated first, non-dilated second|Each participant will perform vision testing first through a prescription determined from wavefront measurements obtained after dilation. Second, each participation will perform vision testing through a prescription determined from wavefront measurements obtained before dilation.
89520103|NCT05059041|Experimental|Non-dilated first, dilated second|Each participant will perform vision testing first through a prescription determined from wavefront measurements obtained before dilation. Second, each participation will perform vision testing through a prescription determined from wavefront measurements obtained after dilation.
89520104|NCT04033757||Sub-cohort 1|1,469 participants were enrolled in 2015. Three follow-ups have been completed in 2016, 2017, and 2020. They will be asked to participate in follow-up in 2023 and 2026.
89520105|NCT04033757||Sub-cohort 2|1,267 participants were enrolled in 2018. They will be asked to participate in follow-up in 2021, 2024, 2027, and 2030.
89520106|NCT04033757||Sub-cohort 3|1,340 participants were enrolled in 2019. They will be asked to participate in follow-up in 2022, 2025, 2028, and 2031.
89520107|NCT04890639|Experimental|AIH group|Hypoxia will be administered via a specialized face mask attached to a gas mixing device (HYP123, Hypoxico Inc.), which controls oxygen content in inhaled air. The hypoxia administering unit will be manually adjusted to supply O2 at the target level for a given session (approximately 21%-normal room air, 17%, 13%, and 9% respectively). Each session will include 15 cycles of hypoxia, each lasting up to 60 seconds, interspersed with up to 90-second normoxic episodes. An oxygen monitor will continuously measure and record the fraction of inspired oxygen delivered (MAX-250E, Maxtec Inc.).
89520108|NCT04771689|Active Comparator|Buprenorphine/Naloxone|Subjects will take a maximum dose of 4 mg buprenorphine and 1 mg naloxone with concurrent administration of other intravenous or oral opioids needed.
89520109|NCT04771689|No Intervention|Standard Medication Regiment|Subjects will take conventional intravenous or oral opioid management.
89520110|NCT04452227||eumenorrheic healthy women|women with a regular menstrual cycle for three months, predictable, and a period between 24-38 days that lasts less than 8 days.
89520111|NCT04674345|Experimental|Sorafenib group|Sorafenib will be administered at 45-60 days post-transplantation and taken for one year.
89520112|NCT04674345|No Intervention|Non-maintenance group|Neither sorafenib nor other FLT3 inhibitors will be used, unless the patient experiences relapse.
89520113|NCT03853811|Experimental|Mitchell Shoe + AFO|Group will receive standard Mitchell shoes along with the custom orthotic insert.
89520114|NCT03853811|No Intervention|Standard Mitchell Shoe (Control - Standard Treatment)|Group will receive standard treatment which includes bracing with standard Mitchell shoes (no custom orthotic). Patients would receive this treatment regardless of study participation.
89520115|NCT04165239|Experimental|Treatment A|Oral administration of 50 mg KH176 twice daily
89520116|NCT04165239|Experimental|Treatment B|Oral administration of 100 mg KH176 twice daily
89520117|NCT04165239|Placebo Comparator|Treatment C|Oral administration of matching placebo twice daily
89520118|NCT03329079|Experimental|Mobile Technology Plus (MT+)|Experimental arm will receive a 3-month MT+ intervention using the premium mobile phone app version with social comparison group, behavior change text messaging, and daily self-weighing via Wi-Fi scale.
89520119|NCT03329079|Active Comparator|Mobile Technology (MT)|Comparison group will receive the basic version of the mobile phone app only.
89033585|NCT06024577|Experimental|Progressive|Participants prescribed 150 minutes/week of moderate to vigorous exercise. The exercises include cycling, walking/jogging, yoga/Pilates, and cross-training, and each week another exercise will be added to the list of options for participants. Participants may choose from the list of exercise. They do not have to do them all, and they can do as much or little (none) of whatever they choose.
89609175|NCT01982435|Other|Group I - Monthly|Enrolled subjects will receive multiple open-label intravitreal injections of 0.3 mg ranibizumab administered every 28 days (+/- 7 days from the last treatment) for 12 months in the monthly group.
89033586|NCT06024564|Experimental|Interventional|Participants will receive Acoustic Resonance Therapy using the Sonu headband and App, twice a day, for 90 days
89033587|NCT06024525|Experimental|Paclitaxel-Coated Coronary Balloon Catheters|receiving the treatment with Swide®DCB in small vessel cohort
89609176|NCT01982435|Other|Group II - Treat-and-Extend|Enrolled subjects will initially receive 3 loading doses of open-label Ranibizumab 0.3 mg given via intravitreal injection every 28 days (+/- 7 days from the last treatment). After the third loading dose, the follow-up interval is determined by the Principal Investigator based on OCT results as stated in the protocol. The follow-up interval is increased by 2 weeks (+/- 7 days) at each visit up to a maximum interval of 12 weeks (+/- 7 days). There is criteria built into the protocol in case a reduction in the follow-up intervals becomes necessary based upon worsening OCT results.
89609177|NCT00747214|Experimental|CRx-102 plus DMARD therapy|
89609178|NCT00747214|Placebo Comparator|Placebo plus DMARD therapy|
89609179|NCT03808012|Experimental|Braking after inguinal hernia surgery|Cohort testing of driving performance in a brake simulator in patients before and after scheduled inguinal hernia surgery
89609180|NCT00753142|Active Comparator|Participants with ketosis-prone diabetes|Obese African Americans with type 2 diabetes with history of diabetic ketoacidosis (DKA) receiving Intralipid 20% and a glucose infusion.
89520120|NCT02732951|Experimental|BI 1026706|
89520121|NCT02732951|Active Comparator|Placebo|
89520122|NCT02999373|Experimental|Autologous cord blood mononuclear cells|Autologous Umbilical Cord Blood Mononuclear Cells Therapy 24 hours after birth ,dose is 50 million cells/kg
89520123|NCT02999373|No Intervention|control|
89520124|NCT04474587||OHS-NIV|Patients with obesity-hypoventilation syndrome (OHS) treated with non-invasive ventilation (NIV).
89520125|NCT03129503||Acute coronary syndrome (ACS)|Patients with STE- or NSTE-ACS (acute coronary syndrome)
89033588|NCT06024525|Active Comparator|Paclitaxel-Releasing Coronary Balloon Catheter|receiving the treatment with SeQuent® please Neo in small vessel cohort
89033589|NCT06024499|Active Comparator|PART 2 High-Dose|Active group selected for PART1 as a high-dose
89609181|NCT00753142|Active Comparator|Participants with ketosis-resistant diabetes|Obese African American with type 2 diabetes with hyperglycemia without ketosis receiving Intralipid 20% and a glucose infusion.
89609182|NCT00753142|Active Comparator|Non-diabetic control group|Obese African Americans without diabetes receiving a glucose infusion.
89609183|NCT00762424|Active Comparator|Tamsulosin|
89033590|NCT06024499|Active Comparator|PART 2 Low-Dose|Active group selected for PART1 as a Low-dose
89033591|NCT06024499|Placebo Comparator|PART 2 Placebo|Placebo group
89033592|NCT06024473|No Intervention|Standard Treatment|This arm will be followed without intervention
89609184|NCT00762424|Placebo Comparator|Placebo|
89609185|NCT01620983|Experimental|Pain Coping Skills Training|The pain coping skills training will be delivered by physical therapists in eight one-hour sessions by telephone over a 2-month perioperative period. Patients will be taught a variety of skills designed to improve maladaptive pain related thoughts and actions to enhance recovery following arthroplasty.
89033593|NCT06024473|Active Comparator|rTMS|This group will be randomized to receive rTMS treatment
89033594|NCT06024473|Experimental|rTMS+iVCT|This group will be randomized to receive rTMS and iVCT treatment
89033595|NCT06024447|Other|Stage III and Stage IV Periodontitis|Subgingival Instrumentation will be performed in patients with Stage III and Stage IV periodontitis.
89033596|NCT06024395|Experimental|Dental FearLess App|Dental FearLess app is an e-health intervention that includes psychoeducation about anxiety; affective, cognitive, and behavioral strategies for coping at the dentist.
89033597|NCT06024395|No Intervention|Treatment as Usual|
89057279|NCT01681407||Patients Relatives|Patient Relatives (Optional group for later stage): First degree relatives with no depression diagnosis.
89057280|NCT04541420||Eribulin|Eribulin 1.4mg/m2 d1,8 iv q3w
89057281|NCT01647399||Phenotypic Clusters|500 urban youth
89057282|NCT02215343|Experimental|High fibre diet (wheat bran extract)|
89520126|NCT05106543|Experimental|kinesiologic tape|"first group of 20 people (experimental group) T max branded kinesiology tape was applied to both M. Quadriceps Femoris and M. Gastrocnemius muscles of the experimental group.~Timed get up and go test was applied to evaluate functionality. All evaluations were applied before taping, immediately after taping and 45 minutes after taping. Patients in both groups were asked not to have their tapes removed until the 4th day. Apart from routine physical therapy methods and taping, no other treatment was applied to the patients."
89609186|NCT01620983|Active Comparator|Arthritis Education|The eight one-hour perioperative arthritis education sessions will be delivered by nurse educators via telephone and will use a presentation and discussion format. Figures and discussion sessions will present information on the nature of arthritis, what to expect following knee arthroplasty, treatment of osteoarthritis, the role of exercise, joint protection and making future treatment decisions.
89609187|NCT01620983|Other|Usual Care|Patients randomly assigned to this arm will undergo usual care following knee arthroplasty.
89609188|NCT01279876|Active Comparator|Melatonin|
89609189|NCT01279876|Placebo Comparator|Placebo|
89609190|NCT01996709|Experimental|Clear Care|Hydrogen peroxide-based contact lens solution used with habitual contact lenses for 90 days
89609191|NCT01996709|Active Comparator|Habitual MPS|Habitual contact lens solution used with habitual contact lenses for 90 days
89033598|NCT06024356||Experimental|long course radiotherapy (50 Gy/25f, 2 Gy/f, 5 days/week) for the first 5 weeks and three 21-day cycles capecitabine (1000 mg/m2, bid, po, day1-14) plus three 21-day cycles tislelizumab (200 mg, iv.gtt, day 8) for the first 9 weeks. After that, patients rested for two weeks (week 10-11)。6-8 weeks after the end of radiotherapy, patients underwent TME surgery (12-14 weeks). Thymalfasin was started on the first day of neoadjuvant chemoradiotherapy, 1.6 mg subcutaneously twice a week until the end of the last neoadjuvant treatment.
89033599|NCT06024356||Control|long course radiotherapy (50 Gy/25f, 2 Gy/f, 5 days/week) for the first 5 weeks and three 21-day cycles capecitabine (1000 mg/m2, bid, po, day1-14) plus three 21-day cycles tislelizumab (200 mg, iv.gtt, day 8) for the first 9 weeks. After that, patients rested for two weeks (week 10-11)。6-8 weeks after the end of radiotherapy, patients underwent TME surgery (12-14 weeks).
89057283|NCT02215343|Experimental|High PUFA diet (fish oil supplement)|
89520127|NCT05106543|Placebo Comparator|patch tape|"second group of 20 people (control group) Roll branded patch tape was applied to both M. Quadriceps Femoris and M. Gastrocnemius muscles of the control group.~Timed get up and go test was applied to evaluate functionality. All evaluations were applied to both groups before taping, immediately after taping and 45 minutes after taping. Patients in both groups were asked not to have their tapes removed until the 4th day. Apart from routine physical therapy methods and taping, no other treatment was applied to the patients."
89520128|NCT04576767||Experimental group|interventions:general anesthesia drugs:propofol、muscle relaxant、pain relievers(fentanbyl、sufentanil)
89520129|NCT04576767||control group|interventions:intraspinal anesthesia drugs:ropivacaine、pain relievers(fentanbyl、sufentanil)
89057284|NCT01647477|Active Comparator|questionnaires|4 questionnaires to answer at baseline 45 minutes approx.
89057285|NCT01647477|Experimental|interview|semi directive interview 105 patients
89210721|NCT00584987|Active Comparator|FF + Placebo OXY|Fluticasone furoate + Placebo Oxymetazoline, 2 puffs of each nasal spray in each nostril in the pm
89520130|NCT04454931||Intensive care patients who underwent neurosurgery|Cerebral oxygenation status will be monitored during and after endotracheal suctioning in each patient included in the study. Non-invasive regional oximetry probes are placed in the frontal region of the patient and the patient will be positioned at the head height of 15 degrees with a 3-motor angle determining bearing system. Then, when the patient's need for endotracheal suctioning arises, endotracheal suctioning will be performed and the cerebral oxygenation status before the procedure, 1 minute, 5 minutes and 30 minutes after the procedure will be recorded on the monitor of the non-invasive regional oximeter device operating with NIRS technology. The same procedure will be applied to the patient at head heights of 30 and 45 degrees. Cerebral oxygenation status measured at each head height will be compared with appropriate statistical methods and the most appropriate head height will be determined.
89520131|NCT01377233|Experimental|Zicronapine open-label lead-in 10 mg daily|
89520132|NCT01377233|Experimental|Zicronapine 10 mg daily|
89520133|NCT01377233|Experimental|Zicronapine 20 mg once weekly|
89520134|NCT01377233|Experimental|Zicronapine 30 mg once weekly|
89520135|NCT01377233|Experimental|Zicronapine 45 mg once weekly|
89520136|NCT03458273||Zero fluoro|Patients in whom Zero fluoroscopy ablation was performed under the guidance of Ensite for mapping and ablation and fluoroscopy will not be used during the procedure.
89520137|NCT03458273||Conventional ablation without 3D|"Patients in whom Conventional fluoroscopy ablation was performed under fluoroscopic guidance only.~Additional use of Ensite/Carto/Localisa for mapping was not allowed."
89520138|NCT03458273||Conventional ablation with 3D|"Patients in whom Conventional fluoroscopy ablation was performed under fluoroscopic and Ensite/Carto guidance and ablation during the procedure.~Use of fluoroscopy and additional Ensite/Carto for mapping and ablation was mandatory."
89520139|NCT02521961|Experimental|Arm I (support group sessions)|Participants attend support group sessions over 1-1.5 hours once weekly for 10 weeks. The sessions include facilitated discussions among participants about the following topics: stress management and emotional coping strategies, nutrition and physical activity, sexuality and body image, medical advocacy, self-care and social support. Participants receive a binder in which the rationale for each topic, techniques learned, and activities completed during each session will be summarized and are shown a Chair-robics DVD.
89520140|NCT02521961|Active Comparator|Arm II (control)|Participants receive one phone call to arrange a follow-up with the promotora, a note acknowledging their participation in the study, and a community resource booklet. Participants are then yoked into one of the 3 intervention groups and asked to attend a 30 minute session similar to Arm I.
89520141|NCT03248531|Experimental|Bimekizumab|Subjects will receive one Bimekizumab loading dose 1 and several Bimekizumab dose 2 applications.
89520142|NCT03248531|Active Comparator|Adalimumab|Subjects will receive one Adalimumab loading (dose 1) and several Adalimumab dose 2 and dose 3 applications.
89520143|NCT03248531|Placebo Comparator|Placebo|Subjects will receive several placebo applications to keep the blinding.
89520144|NCT03456167|Experimental|Mobile app for follow-up care|Participants will use an app to submit photos of their surgical site, QoR15 scores, and EORTC selected adverse events scores daily for 2 weeks post-op & weekly for another 4 weeks. Surgeons will use a wireless interface to access that data and monitor the patient's condition. Participants will complete questionnaires and keep diaries related to satisfaction, medical system encounters, surgical complications, followup-related financial costs, and telemedicine satisfaction at 2 & 6 weeks post-op. They will attend prescribed follow-up appointments with their surgeon with the option to skip 1 or more follow-up appointments dependent on their recovery trajectory & surgeon.
89520145|NCT03456167|No Intervention|Conventional inperson followup care|The conventional follow-up care group will keep to conventional follow-up schedules of all surgeons involved. They will complete questionnaires and keep diaries related to satisfaction, medical system encounters, surgical complications, and followup-related financial costs at 2 & 6 weeks post-op and attend all scheduled follow up appointments.
89520146|NCT03129347|Experimental|Nalmefene (high dose)|Nalmefene (high dose) intranasal one time during the 17 day inpatient treatment period
89520147|NCT03129347|Experimental|Nalmefene and Intravail|Nalmefene (high dose) with Intravail intranasal one time during the 17 day inpatient treatment period
89520148|NCT03129347|Experimental|Nalmefene (low dose)|Nalmefene (low dose) intranasal one time during the 17 day inpatient treatment period
89033600|NCT06024343|Experimental|MPD Repair or Reconstruction|In laparoscopic or robotic pancreatic tumor enucleation, it is inevitable that the main pancreatic duct (MPD) may be damaged due to its proximity or encasement by the tumor. After tumor resection, MPD repair or reconstruction can be performed. If there is no associated MPD dilation, a MPD stent can be inserted and secured with interrupted sutures. When placing the stent, it is important to ensure that the distal end of the stent passes through the duodenal papilla to sufficiently reduce the pressure inside the MPD. Vascular remnants or branch pancreatic duct remnants on the pancreatic resection surface should be sutured. After hemostasis, efforts should be made to restore the serosalization of the pancreatic resection surface. The surface can also be left exposed or covered with ligamentum teres hepatis. Fish-mouth-shaped incisions can be closed, but care should be taken to avoid creating dead spaces that may lead to fluid accumulation and hinder drainage.
89033601|NCT06024317|Experimental|Early onset|"20 clusters will be assigned to the early onset arm. A cross-sectional cohort and two longitudinal cohorts will be enrolled from each cluster.~Both longitudinal cohorts will receive all components of the Chanjo Kwa Wakati intervention."
89033602|NCT06024317|Experimental|Delayed onset|"20 clusters will be assigned to the delayed onset arm. A cross-sectional cohort and two longitudinal cohorts will be enrolled from each cluster.~The second longitudinal cohort will receive all components of the Chanjo Kwa Wakati intervention."
89033603|NCT06024278|Experimental|Hospice Caregivers|Culturally tailored educations videos will be administered to participants.
89520149|NCT03129347|Experimental|Nalmefene Intramuscular|Nalmefene intramuscular one time during the 17 day inpatient treatment period
89520150|NCT02980679|Experimental|CTC and G-PERT Imaging|One experimental (CTC) and one standard (G-PERT) scan, at least 48 hours apart, before thyroid surgery. The order of the scans will be randomized.
89520151|NCT03453437|No Intervention|Control group|Receiving no intervention (control groups will be offered the intervention after the experimental group has completed the course)
89520152|NCT03453437|Experimental|Active group|Receiving Mindful Self-Compassion intervention
89520153|NCT02933411||Group A|Adolescent women with heavy menstrual bleeding and low von willebrand factor activity.
89033604|NCT06024265|Experimental|ER2001 Injection|The minimum initial dose is 0.04mg/kg, then escalate to 0.08mg/kg, 0.16mg/kg and 0.32mg/kg. The planned duration of the treatment is 14 weeks, and ER2001 will be administrated intravenously at the first day of weeks 1, 3, 4, 5, 6, 7, 8, and 14.
89033605|NCT06024200|Experimental|whole-process transcutaneous electrical acupoint stimulation|Electrical stimulation is performed within 24h before surgery, 30min before anesthesia induction and 3 days after surgery, each stimulation was 30min. Patients are treated bilaterally at two groups of distal acupoints: one group consisted of Hegu (LI4) and Neiguan (PC6), the other contained Zusanli (ST36) and Shanyinjiao (SP6). Stimulation is delivered with adisperse-dense wave, 2Hz in frequency. The stimulation intensity is adjusted in accordance with the maximal level tolerated by each patient.
89520154|NCT02902445||Case group|250 children from Nantes University Hospital and 150 children from Guyana Hospital admitted in paediatric emergency unit for diagnosed rotavirus acute gastroenteritis: rotavirus rapid screen test and oral swab for polymorphism exploration
89520155|NCT02902445||Control group|"250 children from Nantes University Hospital and 150 children from Guyana Hospital admitted in paediatric emergency unit without signs of infection and / or digestive clinical picture evocative of gastroenteritis.~Paired with a case upon ethnicity or origin if impossible to match the ethnicity of the case.~oral swab for polymorphism exploration"
89520156|NCT02792855|Experimental|snifﬁng Position|Awake fiberoptic bronchoscope(FOB) orotracheal under snifﬁng position.The snifﬁng position was obtained by placement of a 7-cm cushion under the head of the patient. When the FOB was inserted into oral cavity, and the epiglottis and glottis were identified by the FOB. The anterior of FOB was inserted deep into tracheal after the glottis was exposed sufficiently then the tracheal tube was pushed into the trachea via the FOB
89520157|NCT02792855|Experimental|Simple Head Extension|Awake fiberoptic bronchoscope(FOB) orotracheal under Head Extension position.The Head Extension position was obtained by simple head extension.When the FOB was inserted into oral cavity, and the epiglottis and glottis were identified by the FOB. The anterior of FOB was inserted deep into tracheal after the glottis was exposed sufficiently then the tracheal tube was pushed into the trachea via the FOB
89520158|NCT02262923|No Intervention|Control|"Poor responders will be defined as women who have undergone a previous IVF cycle with fewer than 4 oocytes retrieved and at least one of the following two criteria: (1) advanced age (≥40 years) or any other risk factor for poor ovarian response and (2) abnormal ovarian reserve testing (antral follicle count (AFC) < 5-7 or anti-mullerian hormone (AMH) level < 3.6-7.9 pmol/L). Poor responders who will be undergoing a repeat IVF cycle will be recruited for the study with informed consent.~In the control arm, patients will undergo the same ovarian stimulation protocol as the previous IVF cycle in which they experienced a poor response. Starting 3 weeks prior to the first day of stimulation until the time of ovulation trigger (approximately 5 weeks overall), these patients will receive an oral placebo three times daily."
89520159|NCT02262923|Experimental|Experimental|"Poor responders will be defined as women who have undergone a previous IVF cycle with fewer than 4 oocytes retrieved and at least one of the following two criteria: (1) advanced age (≥40 years) or any other risk factor for poor ovarian response and (2) abnormal ovarian reserve testing (antral follicle count (AFC) < 5-7 or anti-mullerian hormone (AMH) level < 3.6-7.9 pmol/L). Poor responders who will be undergoing a repeat IVF cycle will be recruited for the study with informed consent.~In the experimental arm, patients will undergo the same ovarian stimulation protocol as the previous IVF cycle in which they experienced a poor response. Starting 3 weeks prior to the first day of stimulation until the time of ovulation trigger (approximately 5 weeks in total), these patients will receive oral metoclopramide 5mg three times daily.."
89520160|NCT03129425|Experimental|Intervention group|Sessions in groups
89520161|NCT03129425|Sham Comparator|Control group|Sessions in groups
89520162|NCT02194595|Experimental|Basal insulin and exenatide|Participants in this arm will undergo an 8-week course of treatment with exenatide and insulin glargine. Exenatide will be initiated at 5ug subcutaneous (sc) bid (before breakfast and before dinner) for the first 4 weeks, followed by 10ug bid for the next 4 weeks. Glargine sc injection at bedtime will be titrated to fasting glucose.
89520163|NCT02194595|Active Comparator|Basal insulin only|Participants in this arm will undergo an 8-week course of treatment with glargine sc injection at bedtime, titrated to target fasting glucose.
89033606|NCT06024200|Sham Comparator|whole-process transcutaneous electrical acupoint stimulation(sham stimulation)|Patients are treated bilaterally at four sham acupoints of LI4, PC6, ST36 and SP6. These four pseudo-acupoints were located 1 cun ulnarlateral, and 7 cun and 9 cun proximal to Shenmen (HT7) ;and 9 cun and 12 cun proximal of Kunlun (BL60). These sham points are picked because there are no meridians or channels through these four sites. The stimulation intensity is adjusted in the lowest level felt by each patient. Other intervention details are similar to those of the experimental group.
89033607|NCT06024187|Experimental|Cold Dissection|In this group, the septa between the skin flap and parenchyma was dissected using with scissors or scalpel
89033608|NCT06024187|Active Comparator|Electrocautery Dissection|In this group, the septa between the skin flap and parenchyma was dissected using with electrocautery
89033609|NCT06024161||Weight gainers|Weight gain 11-15 months after arthroplasty
89033610|NCT06024161||Weight losers|Weight loss11-15 months after arthroplasty
89033611|NCT06024161||Weight unchanged|Weight unchanged 11-15 months after arthroplasty
89033612|NCT06024148||patients hospitalized in the Geriatric Rehabilitation Department|patients aged 75 and over, admitted with a severe osteoporotic post-fracture, having received a first dose of antiosteoporotic treatment between the day of fracture and discharge from Geriatric Rehabilitation Department
89033613|NCT06024122||Patients with a mTBI|Children with a mTBI aged 3 to 5 years (i.e., up to 71 months and 31 days, i.e., before the 6th birthday) recruited from the paediatric emergency department of Rennes University Hospital.
89609192|NCT00753220|Experimental|VDC2008|Cryoablation of prostate followed by dendritic cell injection (dose of 2.5 x 10^7, 7.5 x 10^7, or 1.0 x 10^8 cells depending on assigned cohort) into prostate and low dose cyclophosphamide therapy (dose: 25 mg, p.o., b.i.d. for 7 days on and 7 days off; a total of 6 cycles [1 cycle = 4 weeks] starting Week 2 after cryoablation and going to Week 26)
89609193|NCT01279642|Experimental|ultrasound|Use of ultrasound to PICC placement
89609194|NCT01279642|Active Comparator|Control group|PICC placement by inspection and visualization of site
89609195|NCT00753298|Experimental|LoFric Primo (POBE) single-use urinary catheter|
89609196|NCT00753298|Active Comparator|LoFric Primo (PVC) single-use urinary catheter|
89609197|NCT01996319|Active Comparator|Treatment sequence I|QVA149 once a day during 21 days cross-over to placebo once a day for up to 21 days
89609198|NCT01996319|Active Comparator|Treatment sequence II|Placebo once a day during 21 days cross-over to QVA149 once a day for 21 days
89609199|NCT04276948|Experimental|Active1|312 mg dose of active
89609200|NCT04276948|Experimental|Active2|812 mg dose of active
89609201|NCT04276948|Placebo Comparator|Placebo|placebo
89609202|NCT01279954|Experimental|open-label abatacept first, then 5 mg/kg abatacept|10 mg/kg abatacept (6 months). Then 5 mg/kg abatacept (18 months)
89609203|NCT01279954|Experimental|open-label abatacept first, then 10 mg/kg abatacept|10 mg/kg abatacept (6 months). Then 10 mg/kg abatacept (18 months)
89609204|NCT01278862|Experimental|DVS veneer|veneer made by CAD/CAM method
89609205|NCT01278862|Active Comparator|Conventional veneer|Veneer made by laboratory technician
89609206|NCT03807388|Experimental|ReMindCare Intervention Group|"Patients from First Episode of Psychosis Unit who will use ReMindCare app.~ReMindCare is an user-friendly app which conducts daily evaluations of the health status of patients with psychosis by some quick questions that patients will have to answer."
89609207|NCT03807388|Other|Treatment as Usual|Patients from First Episode of Psychosis Unit who will follow psychiatric usual care.
89609208|NCT00763048|Placebo Comparator|A -Control|Fluoride toothpaste (Colgate Great Regular Flavor) is the control for this study. All study toothpastes contain fluoride. The study is evaluating the additional ingredients in the other toothpastes.
89609209|NCT00763048|Active Comparator|B|fluoride/triclosan/copolymer toothpaste (Colgate Total Toothpaste)
89609210|NCT03807466|Active Comparator|Dynamic/Interactive Report|LTC physician receives dynamic/interactive report only
89609211|NCT03807466|No Intervention|Static/Paginated Report|LTC physician receives static/paginated report only
89609212|NCT03807466|Active Comparator|LTC Physicians Enrolled in Reports|"All LTC physicians who receive a dynamic or paginated report~[note: this is not part of randomization assignment, but a quasi-experimental study]"
89609213|NCT03807466|No Intervention|LTC Physicians Not Enrolled in Reports|"All LTC physicians who do not receive a dynamic or paginated report~[note: this is not part of randomization assignment, but a quasi-experimental study]"
89609214|NCT01278394|Experimental|Group 1|AN2690 Solution, 5.0%
89609215|NCT01981187|Experimental|LGX818|LGX818 will be dosed on a flat scale of 300 mg (e.g., 3 x 100 mg capsules) once daily on a continuous dosing cycle. A complete treatment cycle is defined as 28 days. There will be no breaks between dosing cycles.
89609216|NCT01278160|Experimental|BIAsp 30 (2:1)|After discontinuation of previous treatment of once daily biphasic insulin aspart 30 (BIAsp 30) or insulin glargine combined with metformin and glimepiride in trial BIAsp-3756, subjects were adminstered BIAsp 30 twice daily with initial dosage split regimen of 2/3 and 1/3 total daily dose before breakfast and before dinner, respectively combined with metformin administered orally with meals
89609217|NCT01278160|Experimental|BIAsp 30 (1:1)|After discontinuation of previous treatment of once daily biphasic insulin aspart 30 (BIAsp 30) or insulin glargine combined with metformin and glimepiride in trial BIAsp-3756, subjects were adminstered BIAsp 30 twice daily with initial dosage split regimen of 1/2 and 1/2 total daily dose before breakfast and before dinner, respectively combined with metformin administered orally with meals
89609218|NCT01996241|Experimental|Intervention Village Clusters|Receive multi-level, structural and norms-based intervention
89609219|NCT01996241|No Intervention|Control Village Clusters|No multi-level, structural and norms-based intervention
89609220|NCT02091869|Experimental|Paper Asthma Action Plan|Participants will utilize a paper-based asthma action plan to record asthma symptoms, peak flows, and medication usage.
89609221|NCT02091869|Experimental|Mobile Phone|Participants will record asthma symptoms, medication usage, and peak flow data on their phones.
89609222|NCT00748072|Placebo Comparator|Saline solution|patients treated with 1 ml of s.c. saline solution
89609223|NCT00748072|Experimental|DDAVP|treated with DDAVP (0.3 mcg/Kg s.c.) 1 hour before renal biopsy
89609224|NCT03806920|Active Comparator|Intervention A|"Nutritional intervention in healthy subjects and T2DM subjects:~Accompanying a carbohydrate based breakfast, participants ingest either 50 g sucrose followed by a standardized lunch on 1 single day. In addition, blood samples are taken over 8 hours."
89609225|NCT03806920|Active Comparator|Intervention B|"Nutritional intervention in healthy subjects and T2DM subjects:~Accompanying a carbohydrate based breakfast, participants ingest either 50 g palatinose followed by a standardized lunch on 1 single day. In addition, blood samples are taken over 8 hours."
89609226|NCT03806920|Active Comparator|Intervention C|"Nutritional intervention in healthy subjects:~Accompanying a protein-based breakfast, participants ingest either 50 g sucrose followed by a standardized lunch on 1 single day. In addition, blood samples are taken over 8 hours."
89609227|NCT03806920|Active Comparator|Intervention D|"Nutritional intervention in healthy subjects:~Accompanying a protein-based breakfast, participants ingest either 50 g isomaltulose followed by a standardized lunch on 1 single day. In addition, blood samples are taken over 8 hours."
89609228|NCT00248794|Experimental|CRT + Skills Training|"The intervention is call Cognitive Remediation Therapy (CRT) with a skill development group. Participants receive 15 weeks of cognitive training (with intake, 15 and 30 week assessment). This intervention is reliant upon didactic exchanges between trainer and participant, minimizing error, and behavioral modeling with the goal of developing better meta-cognitive skills. Procedures include paper and pencil activities (memory, planning and cognitive flexibility training) which are organized by difficulty. Sessions are organized to have a discussion between the trainer and the participant about the task and strategies, trainer modeling with articulation of strategy a participant attempts the task, talking aloud the steps, and finally the participant practices the task covertly. The trainer has the role of error catcher and model. All subjects randomized to this condition also are receiving the weekly skills group (SDG)offered to participants in all experimental conditions."
89609229|NCT00248794|Experimental|ICBCR and Skills Training|This intervention is Individualized Computer Based Cognitive Remediation (ICBCR) and skills development group (SDG). Participants receive 15 weeks of computerized training (with intake, 15 and 30 week assessments). This intervention relies upon intense, frequent, repetition of tasks being made incrementally more challenging. Computer tasks are organized so that the initial trials are easily completed and more challenging levels are then attempted. Parameters such as duration of task, task speed, and intra-task variables all be are manipulated. A trainer will be present at each session to help set up the computer tasks and answer questions. Besides the first two sessions that will be orientation sessions, the trainer has little involvement during the training sessions. The role of the trainer is to help organize, support, and provide feedback to each participant. All subjects randomized to this condition also are receiving the weekly skills group (SDG).
89609230|NCT00248794|Experimental|Skills Group Control|The control intervention is call the skills development group (SDG) and is augmented with up to five individual contacts with research staff. The Skills Group (SDG) control is standard care group which will receive 15 weeks of the skills development group (SDG) similar to that offered as a clinical service at the VA Medical Center. During the 15 weeks participants will attend 1.5 hours of skills group per week. The 15 sessions will include skills training related to: a) cooking and food preparation, b) negotiating the local transportation system, c) shopping, and d) planning leisure activities. The training activities are a blend of didactic learning, modeling and finally in vivo practice. Participants in this group will also be offered up to five weekly contacts with staff to balance out factors related to meeting with staff in the other conditions.
89609231|NCT03806686|Experimental|Low dose ID93+GLA-SE|Participants will receive 0.5 mL (2 μg ID93 + 5 μg GLA-SE) intramuscular injection (IM) into deltoid area, three times in 4-week intervals on Days 0, 28, and 56.
89609232|NCT03806686|Experimental|High dose ID93+GLA-SE|Participants will receive 0.5 mL (10 μg ID93 + 5 μg GLA-SE) IM injection into deltoid area, three times in 4-week intervals on Days 0, 28, and 56.
89609233|NCT03806686|Placebo Comparator|Control group|Participants will receive 0.5 mL Placebo (physiological saline) IM injection into deltoid area, three times on 4-week intervals on Days 0, 28, and 56.
89609234|NCT01995539|Experimental|iPro2 Use|All subjects wearing iPro2, having therapy regimens, and having baseline and EOS A1C tests
89609235|NCT01835587|Experimental|CC-486|Dose of 150 mg, 200 mg, or 300 mg once daily (QD) for the first 7, 10, or 14 days of each 28-day cycle, starting 42-84 days after transplantation.
89609236|NCT01736917|Experimental|Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone|"Patients must have no nausea and/or vomiting for 24 hours and must not have used other anti-emetics for 72 hours prior to starting protocol treatment. Treatment must not start until this criteria is satisfied.~Any germ cell chemotherapy regimen utilizing Cisplatin (20mg/m2 x 5 days).~Acute emesis prophylaxis:~Any 5HT3 receptor antagonist may be used D1 - 5 or D1, 3 and 5 if palonosetron is used per institutional standards.~Dexamethasone 20mg PO (orally) daily, D1 and 2~Fosaprepitant 150mg IV on day 3~Delayed emesis prophylaxis:~Fosaprepitant 150mg IV on D5~Dexamethasone 4mg PO BID (twice a day) on D6, 7 and 8~PRN antiemetics allowed at the discretion of the treating investigator~No additional doses of 5HT3 receptor antagonist, dexamethasone, or fosaprepitant will be given during the acute or delayed treatment periods"
89609237|NCT01277302|Experimental|Ranibizumab 0.5 mg monthly - randomized subjects|Subjects received at least 7 monthly intravitreal ranibizumab 0.5 mg injections until the first month where the study-specific visual acuity and spectral-domain optical coherence tomography (VA-OCT) stability criteria were met and randomization occurred to the monthly arm. At subsequent monthly visits after randomization, injections were given whether the VA-OCT stability criteria were met or not met. Subjects were to receive 15 ranibizumab 0.5 mg injections.
89688352|NCT04379219|Active Comparator|methotrexate before surgery|"Valid consent~patient will receive 50 mgm /m2 of methtrexate after full investigation ( CBC, serum creatinie, AlT, AST), 1 week before surgery.~Anathesia , (regional may br converted into general ). IV antibiotic ( cefotaxime 1 gm I.V )~Laparotomy transverse incision (pfannenstiel incision)~Exploration of the abdominal cavity~Identification of the uterus, dissection of the bladder, incision of the uterus and excision of the CSP mass.~Surgical repair of the uterine incision, and the abdomen"
89033614|NCT06024122||Control with an orthopaedic injury|Children with an orthopaedic injury aged 3 to 5 years (i.e., up to 71 months and 31 days, i.e., before the 6th birthday) recruited from the paediatric emergency department of Rennes University Hospital.
89033615|NCT06023511|Experimental|Intervention group|Volunteers will receive electrical muscle stimulation.
89033616|NCT06023459|Experimental|Injectable extended-release buprenorphine (XR-BUP)|Participants will be randomly assigned to XR-BUP, with approximately 96 in the XR-BUP condition. The XR-BUP condition will use Brixadi/CAM2038 injectable, extended-release buprenorphine (Braeburn Pharmaceuticals, Inc.). After titrating to a stable dosage in approximately two weeks using weekly injection dosages as clinically indicated to relieve cravings and withdrawal symptoms, the target monthly dosage (128mg) of XR-BUP will be administered by injection at approximately Day 14 and approximately four weeks later in Week 6, with a third injection in Week 10. Dosage adjustments will be made as indicated for tolerability.
89033617|NCT06023459|Active Comparator|Sublingual buprenorphine-naloxone (SL-BUP)|Participants will be randomly assigned to SL-BUP with approximately 48 in the SL-BUP condition. The SL-BUP condition will use sublingual buprenorphine-naloxone, with a target maintenance daily dose range of 16-24mg as recommended for clinical practice. Titration to maintenance dosage will be attempted within the first two weeks of the SL-BUP condition. During the initial stabilization weeks, SL-BUP will be flexibly dosed as clinically indicated to relieve cravings and withdrawal symptoms, after which dosage adjustments will be based on clinical decisions by the site clinicians. The maintenance dosage of SL-BUP will be dispensed on a schedule similar to the XR-BUP injections (i.e., at approximately Day 14, Week 6, and Week 10).
89033618|NCT06023394|Other|Cohort A: Receives Laryngeal Mask Airway Device|In this study arm, after induction of general anesthesia, the patients will receive a laryngeal mask airway device.
89609238|NCT01277302|Experimental|Ranibizumab 0.5 mg PRN - randomized subjects|Subjects received at least 7 monthly intravitreal ranibizumab 0.5 mg injections until the first month where the study-specific VA-OCT stability criteria were met and randomization occurred to the PRN arm. No injection was given at the randomization visit. At subsequent monthly visits after randomization, injections were given if the VA-OCT stability criteria were not met and no injections were given if the VA-OCT stability criteria were met. Subjects could receive between 7 and a maximum of 14 ranibizumab 0.5 mg injections.
89609239|NCT01277302|Experimental|Ranibizumab 0.5 mg monthly - non-randomized subjects|Subjects received at least 7 monthly intravitreal ranibizumab 0.5 mg injections and then never met the study-specific VA-OCT stability criteria from month 7 to month 14. Subjects were to receive 15 ranibizumab 0.5 mg injections.
89609240|NCT04414579|No Intervention|No Intervention: Conventional Insulin Aspart (NovoLog®)|In the aspart group, the subject will only take aspart through the their pump. This study population will have an established expertise in diabetes self-management with previous knowledge of insulin pump therapy and Dexcom Continuous Glucose Monitoring (CGM). Allowing the subjects to use their insulin pumps for bolus insulin delivery, as they are accustomed, will minimize the chances of skipping meal boluses and correction doses. Aspart is put into their pump and delivered to their body through a small tube placed under your skin. In this NovoLog®-only treatment group, the subject will take aspart with each meal while your pump also gives you a slow, continuous dose of aspart for basal insulin. This treatment group is very similar (or even identical) to the treatment the subject was receiving prior to starting the study.
89609241|NCT04414579|Active Comparator|Faster Insulin Aspart (Fiasp®)|In the Fiasp group, the subject will only take aspart through the their pump. This study population will have an established expertise in diabetes self-management with previous knowledge of insulin pump therapy and Dexcom Continuous Glucose Monitoring (CGM). Allowing the subjects to use their insulin pumps for bolus insulin delivery, as they are accustomed, will minimize the chances of skipping meal boluses and correction doses. Fiasp is put into their pump and delivered to their body through a small tube placed under their skin. In this Fiasp treatment group, the subject will take fiasp with each meal while their pump also gives them a slow, continuous dose of aspart for basal insulin. This treatment group is very similar (or even identical) to the treatment the subject was receiving prior to starting the study.
89609242|NCT01980875|Experimental|Safety Run-In: Idelalisib+obinutuzumab|Participants will receive idelalisib for 96 weeks and obinutuzumab over 21 weeks. Following 4 weeks of treatment, safety data will be reviewed by an independent data monitoring committee (DMC). If acceptable tolerability is observed, the randomized portion of the study will begin.
89609243|NCT01980875|Experimental|Randomized: Idelalisib+obinutuzumab|Participants will receive idelalisib for 96 weeks and obinutuzumab over 21 weeks.
89609244|NCT01980875|Active Comparator|Randomized: Obinutuzumab+chlorambucil|Participants will receive obinutuzumab over 21 weeks and chlorambucil over 23 weeks.
89609245|NCT01995461|Experimental|BTESI|a prospective, non-randomized, case series investigating bilateral transforaminal epidural steroid injections (BTESI)
89609246|NCT04731623|Experimental|ION904|Single ascending dose of ION904 will be administered by SC injection on Day 1.
89609247|NCT04731623|Placebo Comparator|Placebo|Placebo (0.9% sterile saline) will be administered by SC injection on Day 1.
89609248|NCT01980095|Experimental|RHB-105|RHB-105 is an 'all-in-one' combination oral capsule consisting of 2 different antibiotics and a proton pump inhibitor combined in a single capsule.
89609249|NCT01980095|Placebo Comparator|Placebo|Capsules that look like the RHB-105 product but contain no active ingredient.
89609250|NCT01980017|No Intervention|Wait-Listed Control Group|Usual care for smoking cessation
89033619|NCT06023394|Other|Cohort B: Receives Endotracheal Tube Device|In this arm, after induction of general anesthesia, the patients will receive an endotracheal tube airway device.
89057286|NCT04540991|Active Comparator|Ankylos dental implant group|Patients are divided into two groups depending on the dental implant system used in the therapy. Ankylos dental implants (Dentsplay Sirona, Charlotte, USA) areused in the first group of patients.
89057287|NCT04540991|Active Comparator|Dentium SuperLine implant group|Patients are divided into two groups depending on the dental implant system used in the therapy. Dentium SuperLine implants (Dentium Co., Seoul, Korea) is used in the second group of patients-.
89609251|NCT01980017|Experimental|Ottawa Model for Smoking Cessation|Ottawa Model for Smoking Cessation
89609252|NCT04416347||Workstream 1|Adult patients admitted to SGHFT (St. Georges Hospital Foundation Trust) with or without laboratory confirmed SARS- CoV-2.
89033620|NCT06023342||New users|"Approximately 400 adults (≥18 years old), new to WayBetter app, who have entered into a 7-day free trial, will be studied. Each new user receives a free 1-week trial (that they need to opt into) and $10 USD deposit from WayBetter Inc. They can use the deposit for any game during trial, regardless of continuing membership. To continue to use the app, users pay $69 USD for 6 months. Each game lasts between 1-4 weeks and requires players to achieve a specific behavioural goal. Games require $10-30 deposit, chosen at signup. Validation methods vary; some sync with wearables, others submit activity photos (steps, meals). A user can join up to 10 games simultaneously. Winners of each game share deposits, gaining original deposit plus profit, based on 'losses'."
89033621|NCT06023277|Experimental|ConvitVax|"ConvitVax is a vaccine made of three components: autologous tumor cells homogenate obtained from 0.3 g of tumor tissue, 0.0625 mg of BCG D1331, and 0.02% of formalin.~There is no dose escalation in this study. Four doses of 0.5 mL of ConvitVax will be applied via id injection with a 2-week interval between each dose."
89033622|NCT06023251|Other|Cohort|oral food, enteral nutrition, parenteral nutrition
89033623|NCT06023238||Chronic TKA PJI Group|Patients presenting for surgical management of a chronic total knee arthroplasty (TKA) prosthetic joint infection (PJI). Patients will be excluded if they are less than 18 years of age, have a prior history of ipsilateral or contralateral PJI warranting operative management, or are unable to provide informed consent.
89033624|NCT06023225||Postoperative patients|Pediatric female patients undergoing a surgical procedure
89609253|NCT04416347||Workstream 2|Adult patients admitted to to SGHFT (St. Georges Hospital Foundation Trust) ITU with respiratory failure.
89609254|NCT04659707|Experimental|COVID-19 Survivors|Subjects recovering from COVID-19 disease will be imaged using hyperpolarized 129Xe MRI.
89033625|NCT06023186||Cohort 1|Clinically stable, adult patients with obstructive hypertrophic cardiomyopathy, who meet mavacamten prescribing guidelines will be prescribed mavacamten by their treating physician.
89033626|NCT06023134||Control group|Participants met the indication for right heart catheterization but did not meet the diagnostic criteria for pulmonary hypertension and right heart failure.
89033627|NCT06023134||Pulmonary Hypertension group|Participants were classified according to the 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension, meaning that a mean pulmonary artery pressure (mPAP) ≥20 mmHg was defined as PH.
89609255|NCT01978145|Experimental|Regimen A|Placebo administered BID by multi-dose inhaler followed by FSC (250/50 mcg) administered BID by capsule-based inhaler.
89609256|NCT01978145|Experimental|Regimen B|FSC (250/50 mcg) administered BID by multi-dose inhaler followed by placebo administered BID by capsule-based inhaler.
89609257|NCT01967537|Experimental|68Gallium DOTATATE imaging|68Gallium DOTATATE imaging
89609258|NCT01967225|Experimental|Tedizolid Phosphate (Sivextro, BAY1192631)|Participants received 200 mg BAY1192631 solution or tablet once daily (intravenous (I.V.) or oral (PO))
89609259|NCT01967225|Active Comparator|Linezolid|Participants received 600 mg Linezolid solution or tablet twice daily, every 12 ± 3 hours (intravenous (I.V.) or oral (PO))
89609260|NCT01967147|Experimental|Systane Balance|Propylene Glycol, 0.6% eye drops, 1 drop in each eye, 4 times per day, during Phase I (Day 0-35), followed by 1 drop in each eye as needed during Phase II (Day 35-90).
89609261|NCT01967147|Active Comparator|Saline|Preservative-Free 0.9% Saline solution, 1 drop in each eye, 4 times per day, during Phase I (Day 0-35), followed by 1 drop in each eye as needed during Phase II (Day 35-90).
89033628|NCT06023134||Right heart failure group|Right heart failure was considered present when RV fractional area change (FAC) was <35% or tricuspid annular systolic velocity (RV S') was <9.5 cm/s or tricuspid annular plane systolic excursion (TAPSE) <17mm.
89609262|NCT01790503|Experimental|Phase 1b dose escalation - 600mg/day PLX3397 cohort|600mg/day PLX3397, Radiation Therapy, and Temozolomide
89609263|NCT01790503|Experimental|Phase 1b dose escalation - 800mg/day PLX3397|800mg/day PLX3397, Radiation Therapy, and Temozolomide
89609264|NCT01790503|Experimental|Phase 1b dose escalation - 1000 mg/day PLX3397 cohort|1000 mg/day PLX3397, Radiation Therapy, and Temozolomide
89609265|NCT01790503|Experimental|Phase 2 - Recommended phase 2 dose of PLX3397|Recommended phase 2 dose of PLX3397 (800mg/day), Radiation therapy, and Temozolomide
89609266|NCT01790113|Active Comparator|Univer™ II|Univers™ II Total Shoulder Replacement
89609267|NCT01790113|Experimental|Eclipse™|Eclipse™ Total Shoulder Replacement
89609268|NCT01789567|Other|Engager™ aortic valve|Implantation of the Medtronic Engager™ bioprosthesis via direct aortic approach
89609269|NCT01765543|Experimental|Vemurafenib + Rifampin|There will be 3 intervention periods in the study: Period A (Days 1 to 7), Period B (Days 8 to 16), and Period C (Days 17 to 24). Participants, after an overnight fast of at least 10 hours, will receive vemurafenib at a dose of 960 milligrams (mg) as film-coated tablets orally alone on Day 1 (Period A); with rifampin (at a dose of 600 mg as capsules orally) on Day 17 (Period C); and rifampin alone at a dose of 600 mg as capsules orally once daily will be administered from Days 8 through 16 (Period B) and from Days 18 through 23 (Period C).
89609270|NCT01765153|Experimental|Endurance first|Participants to start with Endurance Training. Participants are trained daily to walk on a treadmill for as fast and as long as possible. A harness supporting part of their body weight can be used if needed. Assistance from a trainer is used if needed. A physical therapist supervises the training. Training was 5x/wk for 2 months, followed by a 2-month rest period. Participants then returned for training in the Precision Training 5x/wk for 2 months.Participants train to walk over ground on 15 m straight hallway with obstacles they must step over, and targets they must step onto. This is followed by another 2-month rest. Measures of walking speed, distance, skill, confidence, as well as mood were obtained at least 3 times before any training, then monthly thereafter.
89033629|NCT06023121||Cases|Gastric cancer cases from two medical centers in China
89033630|NCT06023121||Controls|Controls from two medical centers in China
89057288|NCT01647555||patient with epidermoid cancer|receiving Cetuximab and radiotherapy
89210722|NCT00584987|Active Comparator|Placebo FF + OXY|Placebo Fluticasone furoate + Oxymetazoline, 2 puffs of each nasal spray in each nostril in the pm
89033631|NCT06023082|Experimental|Colon Broom Premium supplement|"Participants will add 1 scoop (0.23 oz/ 6.47 g) to 12-14 fl oz of water, mix well and drink immediately. Participants will take the supplement 30 -60 minutes before their meal and will then drink an additional glass of water. Participants will be instructed not to take the supplement less than 2 hours before bedtime. The test product may be consumed before breakfast, lunch, or dinner.~First week: Start with 1 serving per day Rest of the study period: Increase to 2 servings per day at 2 different times during the day."
89033632|NCT06023056||Delayed vaccination group after gastrointestinal surgery|Newborns undergoing gastrointestinal surgery are delayed from receiving hepatitis B vaccination in the vaccination institutions due to the impact of surgery.
89033633|NCT06023056||The group of vaccination on time after gastrointestinal surgery|Newborns undergoing gastrointestinal surgery shall be vaccinated with hepatitis B vaccine on time by vaccination institutions.
89520164|NCT02194595|Active Comparator|Basal Insulin and bolus insulin|Participants in this arm will undergo an 8-week course of multiple daily insulin injection therapy, consisting of titrated basal insulin glargine at bedtime and insulin lispro before each meal.
89520165|NCT05322083||HIV patients|All patients will be prescribed treatment drugs in accordance with the national protocol by the doctors of the AIDS centers. The decision to prescribe Doravirine will also be made by doctors.
89520166|NCT02656329|Experimental|AdreView™|Participants received 1 intravenous injection of 10 mCi (370 MBq) of AdreView™ (Iobenguane I-123 Injection). Participants with AdreView™ Heart-to-Mediastinal ratio (H/M) <1.6 underwent Implantable Cardioverter Defibrillator (ICD) device implantation and H/M >= 1.6 continued to receive Guideline-Directed Optimal Medical Therapy (GDMT) according to clinical standard practice.
89520167|NCT02656329|Experimental|Standard of Care|Participants received 1 intravenous injection of 10 mCi (370 MBq) of AdreView™ (Iobenguane I-123 Injection) and underwent ICD implantation and were followed up in accordance with internationally accepted Heart Failure (HF) guidelines.
89520168|NCT01454843|Active Comparator|Wavefront-guided LASIK - Allegretto|Wavefront-guided LASIK using the Allegretto excimer laser.
89520169|NCT01454843|Active Comparator|Wavefront-guided LASIK - AMO|Wavefront-guided LASIK using AMO CustomVue excimer laser.
89520170|NCT02712905|Experimental|INCB059872|
89520171|NCT02712905|Experimental|INCB059872 in combination with other therapies|"Initial cohort dose of INCB059872 to evaluate different doses of INCB0599872 in combination with other therapies in the following treatment groups:~Combination with all-trans retinoic acid (ATRA) in subjects with relapsed/refractory AML.~Combination with azacitidine in subjects with newly diagnosed, treatment-naive AML~Combination with nivolumab in subjects with advanced SCLC previously progressed on platinum-based treatment.~Upon identification of the recommended dose(s) for each treatment combination, expansion cohorts of approximately 30 subjects in each treatment group may begin enrollment to further determine safety, tolerability, efficacy, PK, and PD of the selected dose(s)."
89520172|NCT04339803|Experimental|mirror therapy|lower limb mirror therapy using ankle exercise
89520173|NCT01166633|Experimental|Pitavastatin 2 mg|
89520174|NCT01166633|Active Comparator|Atorvastatin 10mg|
89520175|NCT04025541|Other|COHORT 1 BREAST TUMOR/PALBOCICLIB|"Patient with a locally Advanced tumor or metastatic tumor RH+/HER 2 - , treated by palbociclib~BLOOD SAMPLING"
89520176|NCT04025541|Other|COHORT 2 BREAST TUMOR / RIBOCICLIB|"Patient with a locally Advanced tumor or metastatic tumor RH+/HER 2 - , treated by ribociclib~BLOOD SAMPLING"
89520177|NCT05321849||Use Fluoroscopy (Control)|PDA closure in 30 patients with fluoroscopy guide
89520178|NCT05321849||No fluoroscopy (test)|PDA closure in 30 patients with echocardiography guide, without fluoroscopy
89520179|NCT05106075|Experimental|biologic sample collection|Blood samples or gingival exsudat collection
89520180|NCT04315311|Experimental|CREON|Participants will receive daily dose of CREON.
89520181|NCT05321693|Active Comparator|Active tPCS|
89520182|NCT05321693|Sham Comparator|Sham tPCS|The currentwill only be applied forthe first 30 seconds. Patients may notice the same sensation of initial stimulation butwill not receive the current for the remaining time.
89520183|NCT04245657||Breast Cancer Survivors|Female breast cancer survivors who underwent unilateral breast cancer surgery ( total or conservative) and completed their adjuvant therapies such as chemotherapy and radiotherapy prior to participation in this study.
89520184|NCT03776357|Experimental|Experimental|The application used is build upon the company's category-defining, FDA- cleared Virtual Exercise Rehabilitation Assistant (VERA™) and create a platform that streamlines the performance and management of post-acute care physical therapy. The rehab tool will provide us with functional outcome score.
89520185|NCT03875001|Experimental|BI 1358894|
89520186|NCT03875001|Placebo Comparator|Placebo|
89520187|NCT05105295|Experimental|Experimental Group|Subjects receive a third dose of inactivated COVID-19 vaccine
89520188|NCT03449927|Active Comparator|Control Arm: Regular menu|"Calorie count initiated on day +1 of transplant and ending upon count recovery~Symptom worksheet initiated on day +1 of transplant and ending upon count recovery (absolute neutrophil count of 1000)~Goals to monitor: calorie and protein intake, self-reported diarrhea and nausea~Interventions provided for control group: standard of care, verbal or printed handouts, standard educations created by Barnes Jewish Hospital (BJH) oncology dietitians"
89520189|NCT03449927|Experimental|Intervention Arm: Specialized Menu|"Calorie count and tool provided on day +1 and ending upon count recovery~Symptom worksheet initiated on day +1 of transplant and ending upon count recovery (absolute neutrophil count of 1000)~Goals to monitor: calorie and protein intake, self-reported diarrhea and nausea~Interventions provided for intervention group: standard of care provided by BJH oncology dietitians, tools including nausea and diarrhea menus and follow up by registered dietitian (RD) to provide additional counseling on menus as symptoms arise"
89520190|NCT03867435||Individuals with DM1|Individuals with myotonic dystrophy type 1 (DM1)
89520191|NCT03867435||Individuals with DM2|Individuals with myotonic dystrophy type 2 (DM2)
89520192|NCT03449849|Other|Base diet|Subjects will consume a base diet prepared using traditional American foods with a macronutrient composition representative of a typical American diet.
89520193|NCT03449849|Other|Kale Treatment|Subjects will consume 500 g of kale per 2000 kcal of food, split between breakfast and dinner, as a supplement to the base diet.
89520194|NCT03449693|Experimental|Magnesium Oxide Supplement|Magnesium Oxide 250 mg tablet, daily for 30 days.
89210723|NCT00584987|Active Comparator|FF + OXY|Fluticasone furoate + Oxymetazoline, 2 puffs of each nasal spray in each nostril in the pm
89210724|NCT00924846|Active Comparator|HFOV plus iNO|HFOV plus iNO: high frequency oscillatory ventilation plus inhaled nitric oxide
89210725|NCT00924846|Active Comparator|CMV plus iNO|CMV (conventional mechanical ventilation) iNO (inhaled nitric oxide)
89210726|NCT00924924|Experimental|Act Healthy!|Immediate treatment group of six-weeks of classes in self-management training for healthy behaviors
89210727|NCT00924924|Active Comparator|Delayed treatment control|Delayed self-management training group - begins following completion of the experimental group training
89210728|NCT00727961|Experimental|Arm 1|Caelyx Intravenous, 50 mg/m^2, given for 6 cycles
89210729|NCT00568958|Experimental|Naltrexone|Active naltrexone (25 mg daily +25 targeted)+ BASICS counseling
89210730|NCT00568958|Placebo Comparator|Placebo Naltrexone|Placebo Naltrexone (targeted + daily) + BASICS Counseling
89210731|NCT03540771|Active Comparator|Model 1: Consultative Palliative Care|Direct access to Palliative Care provider, who will offer palliative care to patients and caregivers, as guided by a standard PC (palliative care) checklist.
89210732|NCT03540771|Active Comparator|Model 2: Trained Hepatologist- led PC|A hepatologist will receive formal training to deliver Palliative Care (PC) services, and will offer palliative care to patients and caregivers following the same PC checklist as in Model 1
89210733|NCT02590835|Active Comparator|Control group|Treated with conventional orthodontics
89210734|NCT02590835|Experimental|Test group|subjected to piezo-assisted orthodontics
89210735|NCT00821912|Experimental|Taxotere Xeloda|"Taxotere i.v. infusion on cycle day 1, 8 and 15 or cycle day 1 and 8 in an alternating 3 weekly schedule.~Xeloda orally day 1-14 every 3 weeks."
89210736|NCT05690997|Other|Intensive Treatment Group|SBP target 120-129 mmHg
89210737|NCT05690997|Other|Standard Treatment Group|SBP target 130-140 mmHg
89210738|NCT02593253|Experimental|Intervention Audit and Feedback Bundle|Access to the electronic dashboard and weekly feedback rounds
89520195|NCT03449693|No Intervention|No Supplement|No Intervention
89520196|NCT04525911||Symptomatic COVID-19 infection confirmed or probable|Patients and medical staff having symptomatic COVID-19 infection confirmed (by RT-PCR or ELISA serology) or probable (CT criteria)
89520197|NCT03651063|Experimental|social robot group|
89520198|NCT03651063|Active Comparator|computer group|
89520199|NCT03651063|No Intervention|contro: no intervention|This group will only be a follow up: clinical examination at the entrance and follow 5 weeks with clinical examination 5 weeks post, with no intervention.
89520200|NCT05320523|Active Comparator|GPi stimulation + NBM stimulation|effective neurostimulation of the Nucleus basalis Meynert combined with globus pallidus internus (GPi) stimulation using Vercise deep brain stimulation
89520201|NCT05320523|Sham Comparator|GPi stimulation + sham stimulation|ineffective neurostimulation of the Nucleus basalis Meynert combined with subthalamic nucleus (STN) stimulation using Vercise deep brain stimulation
89520202|NCT03514563||Group A|MRI imaging, Optical scan and 3D photography for patients with Class I (non-skeletal) malocclusion with no facial asymmetry or other pathology.
89520203|NCT03514563||Group B|MRI imaging, Optical scan and 3D photography for patients with Class III (skeletal-based) malocclusion with maxillary deficiency and normal vertical facial relationships, with no facial asymmetry or other pathology
89520204|NCT03514563||Group C|MRI imaging, Optical scan and 3D photography for patients with Cleft lip and/or palate and a Class III malocclusion and no other pathology
89520205|NCT03449303|Active Comparator|EOI|10% dilution of Curcuma longa, Piper nigrum, Pelargonium asperum, Zingiber officinale, Mentha x piperita, and Rosmarinus officinalis ct. cineole in Simmondsia chinensis
89520206|NCT03449303|Placebo Comparator|Placebo|Simmondsia chinensis
89520207|NCT05005065|Experimental|Treatment AB|Participants will be randomized to receive IN-C005 Y mg (Treatment A) and IN-A001 Y mg (Treatment B) sequentially in a two-period sequence. There will be a washout period of at least 14 days between Period 1 and Period 2.
89520208|NCT05005065|Experimental|Treatment BA|Participants will be randomized to receive IN-A001 Y mg and IN-C005 Y mg sequentially in a two-period sequence. There will be a washout period of at least 14 days between Period 1 and Period 2.
89520209|NCT05005065|Experimental|Treatment CD|Participants will be randomized to receive IN-C005 Z mg (Treatment C) and IN-C005 X mg (Treatment D) sequentially in a two-period sequence. There will be a washout period of at least 14 days between Period 1 and Period 2.
89520210|NCT05005065|Experimental|Treatment DC|Participants will be randomized to receive IN-C005 X mg and IN-C005 Z mg sequentially in a two-period sequence. There will be a washout period of at least 14 days between Period 1 and Period 2.
89520211|NCT03449225|No Intervention|Control Arm|The participant will be given a digital device (IPad or Kindle Fire) to complete a pre-education survey (web-based pre-intervention survey housed on the Qualtrics platform). Once the survey is complete, the participant will proceed with standard education, provided by a resident/physician in the clinic, about prenatal screening and testing for chromosome conditions and for carrier status. Once the standard education has been completed, the participant will be approached to complete a post-education survey which includes questions about knowledge, intent to have or decline screening or testing, and demographic variables.
89520212|NCT03449225|Experimental|Test Arm|• The participant she will be given a digital device on which to access the computer aided genetics educational module. Prior to accessing the module, the patient will be asked to complete a pre-education survey (web-based pre-intervention survey housed on the Qualtrics platform). Once she has completed the survey, she will interact with the Computer-Aided Genetic Education Module which is tailored for her clinical situation. Once the participant has completed reviewing the module, she will be asked to complete the web-based post-module survey which includes questions about knowledge, intent to have or decline screening or testing, acceptability of the module, and demographic variables.
89033634|NCT06023056||Control group|Children who are free of disease and have vaccination and physical examination on time.
89033635|NCT06023043|No Intervention|No Steroid (NS)|No Dexamethasone (NS)
89033636|NCT06023043|Experimental|With Steroid (WS)|With Dexamethasone (WS)
89609271|NCT01765153|Experimental|Precision first|Participants to start with Precision Training. Participants train to walk over ground on 15 m straight hallway with obstacles they must step over, and targets they must step onto. Training was 5x/wk for 2 months, followed by a 2-month rest period. Participants then returned for Endurance Training 5x/wk for 2 months. Participants are trained to walk on a treadmill for as fast and as long as possible. A harness supporting part of their body weight can be used if needed. Assistance from a trainer is used if needed. A physical therapist supervises the training. followed by another 2-month rest. Measures of walking speed, distance, skill, confidence, as well as mood were obtained at least 3 times before any training, then monthly thereafter.
89609272|NCT00248170|Experimental|Letrozole|2.5 mg by mouth (p.o.) once daily
89609273|NCT00248170|Active Comparator|Anastrozole|1 mg p.o. once daily
89609274|NCT01764997|Experimental|Adalimumab Open Label run-in|Adalimumab 40 mg every 2 weeks (Q2W) for 16 weeks added to stable dose of MTX.
89609275|NCT01764997|Active Comparator|Etanercept + MTX (Randomized)|Etanercept 50 mg in combination with Placebo for sarilumab Q2W and etanercept 50 mg on alternating weeks for 24 weeks added to stable dose of MTX.
89609276|NCT01764997|Experimental|Sarilumab 150 mg + MTX (Randomized)|Sarilumab 150 mg in combination with placebo for etanercept Q2W and placebo for etanercept on alternating weeks for 24 weeks added to stable dose of MTX.
89609277|NCT01764997|Experimental|Sarilumab 200 mg + MTX (Randomized)|Sarilumab 200 mg in combination with placebo for etanercept Q2W and placebo for etanercept on alternating weeks for 24 weeks added to stable dose of MTX.
89609278|NCT01764997|Experimental|Sarilumab 150 mg + MTX Open Label Sub-study|Sarilumab 150 mg Q2W for 52 weeks added to stable dose of MTX.
89609279|NCT01276756|Active Comparator|Standard of care|Group A: comprises 50 treatment-naive chronic hepatitis c patients who will receive the standard of care treatment: peginterferon Alfa 2a 160 ug once weekly and weight-based ribavirin 1000 or 1200 mg/day (based on body weight < 75 kg or ≥ 75 kg, respectively) in divided doses for 48 weeks.
89609280|NCT01276756|Experimental|Triple therapy|Group B: comprises 50 treatment-naive chronic HCV patients who will receive oral Nitazoxanide 500 mg twice daily for 4 weeks (lead-in phase) followed by triple therapy, nitazoxanide 500 mg twice daily plus peginterferon alfa-2a (160ug once weekly) and weight-based ribavirin 1000-1200 mg daily (based on body weight < 75 kg or ≥ 75 kg, respectively) in divided doses for 48 weeks.
89609281|NCT00246376|Placebo Comparator|1|Subjects receive lifestyle advice and placebos for Niaspan and Tricor
89609282|NCT00246376|Experimental|2|Diet, exercise, and two placebos
89609283|NCT00246376|Experimental|3|Diet, exercise, Niaspan, and placebo
89609284|NCT00246376|Experimental|4|Diet, exercise, placebo, and Tricor
89609285|NCT00246376|Experimental|5|Diet, exercise, Niaspan, and Tricor
89609286|NCT03806218|Active Comparator|TICW-RFA|Bipolar RFA using twin internally cooled-wet electrodes
89609287|NCT03806218|Active Comparator|SC-RFA|Switching monopolar RFA using separable clustered electrodes
89609288|NCT03806062|Active Comparator|control group|10 mg domperidone 3 times a day after meals) and advice about lactation, nutrition and fluid intake all through the treatment period (4 weeks)
89609289|NCT03806062|Active Comparator|Laser group|"The laser scan beam was adjusted to the size of the treated breast for 10 minutes with wave length 632.8 nm and power output 25 mw after the end of treatment session on both breasts.~The mother had one session every other day, three sessions weekly for four weeks. (Total 12 sessions)"
89609290|NCT03806062|Active Comparator|Electro acupuncture group|faradic stimulation (Body shaping System, model B-333, made in China) , at the following acupuncture points on both sides: Spleen 6 (Sanyinjiao), Liver 3 (Taichong) and Small Intestine 1 (Shaoze) using surface electrodes
89609291|NCT04385914||COVID positive patients|
89609292|NCT04385914||COVID negative patients|
89033637|NCT06023017|Experimental|Prone Position Training group (PPT group)|All patients were admitted to our hospital at least 3 days before surgery. Patients in the intervention group (PPT group) received the prone position training daily in the hospital, three times a day, and about 1 hours every times, for at least 3 days before surgery. On the day of admission to the hospital, the patients in the PPT group were instructed to perform prone position training by nurses who were previously trained by prone position training.
89033638|NCT06023017|Placebo Comparator|Control group (C group)|Patients in the control group (C group) received standard perioperative care without any prone position training.
89033639|NCT06023004||Controls|Patients diagnosed with diverticulitis through CT scan and scheduled for a colonoscopy. The colonoscopy must result in no detection of colorectal cancer.
89033640|NCT06023004||Cases|Patients diagnosed with CRC immediately after an episode of diverticulitis.
89033641|NCT06022978|No Intervention|EUS only|The enrolled patients will accept ordinary EUS only.
89033642|NCT06022978|Experimental|EUS+SSI|The enrolled patients will be accepted submucosal injection of saline（SSI）,then EUS will be performed.
89609293|NCT00754156|Active Comparator|1 ABRA plus KCI ABThera or KCI VAC|ABRA Abdominal Wound Closure System in combination with KCI ABThera or KCI VAC
89609294|NCT00754156|Active Comparator|KCI V.A.C. Therapy or ABThera Alone|KCI V.A.C. Therapy ABThera Alone
89609295|NCT03805984|Experimental|INO-4500 Group A|Participants will receive 1 ID injection of 1 mg/dose INO-4500 followed by EP using the CELLECTRA® 2000 device
89609296|NCT03805984|Placebo Comparator|Placebo Comparator Group A|Participants will receive 1 ID injection of 1 mg/dose placebo followed by EP using the CELLECTRA® 2000 device
89609297|NCT03805984|Experimental|INO-4500 Group B|Participants will receive 2 ID injections of 1 mg/dose INO-4500 followed by EP using the CELLECTRA® 2000 device
89609298|NCT03805984|Placebo Comparator|Placebo Comparator Group B|Participants will receive 2 ID injections of 1 mg/dose placebo followed by EP using the CELLECTRA® 2000 device
89609299|NCT03805906||Primary group|Ultrasound-Guided L5 Dorsal ramus block
89033643|NCT06022978|Experimental|BLI+ME/EUS+SSI|The enrolled patients will be accepted ordinary endoscope using blue laser Imaging and magnified ensocope system(BLI+ME), firstly. If B3 type intra pillary capillary loops (IPCL) was observed, then the procedure would be finished (no EUS or EUS+SSI) . If B1 or B2 type IPCL was observed, then EUS+SSI would be performed.
89033644|NCT06022965|Experimental|ARM I (GAIN-S)|Patients complete the CARG-GA at baseline and 3 months and receive GA-based interventions using telemedicine over 6 months.
89033645|NCT06022965|Active Comparator|ARM II (SOC)|"Receive SOC over the first 3 months, then switch to receive GA-based interventions using telemedicine for the following 3 months.~Patients complete the CARG-GA at baseline and 3 months and receive SOC over 6 months."
89033646|NCT06022952|Active Comparator|Group A|Patients who have used the Stone MD mobile app
89033647|NCT06022952|Active Comparator|Group B|Patients who have not used the Stone MD mobile app
89033648|NCT06022939|Active Comparator|Consolidation Arm I (Chemotherapy)|Patients receive daratumumab and hyaluronidase-fihj SC over 3-5 minutes on days 1 and 15 as well as bortezomib SC over 3-5 minutes, cyclophosphamide PO or IV, and dexamethasone PO or IV on days 1, 8, 15 and 22 of each cycle. Cycles repeat every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo echocardiography at screening and at progression. Patients undergo bone marrow aspiration and biopsy within14-28 days post consolidation treatment and at progression. Patients undergo blood and urine sample collection at screening, at the start of each cycle, and the end of treatment and during follow up or at progression.
89033649|NCT06022939|Experimental|Consolidation Arm II (Chemotherapy, ASCT)|Patients undergo collection of peripheral blood stem cells. Patients receive melphalan IV for 1 cycle and then 2 days later receive the stem cell transplant IV in the absence of disease progression or unacceptable toxicity. Patients undergo echocardiography at screening and at progression. Patients undergo bone marrow aspiration and biopsy within 60-90 days post initiation of stem cell transplant. Patients undergo blood and urine sample collection at screening, during treatment, and the end of treatment and during follow up or at progression.
89033650|NCT06022939|Experimental|Induction (Chemotherapy)|Patients receive daratumumab and hyaluronidase-fihj SC over 3-5 minutes on days 1, 8, 15 and 22 for 2 cycles and then days 1 and 15 for cycle 3. Patients receive bortezomib SC over 3-5 minutes, cyclophosphamide PO or IV, and dexamethasone PO or IV on days 1, 8, 15 and 22 of each cycle. Cycles repeat every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT, MRI or PET-CT and fat pad aspiration at screening. Patients undergo echocardiography at screening, the completion of induction, and at progression. Patients undergo bone marrow aspiration and biopsy at screening, post induction treatment and at progression. Patients undergo blood and urine sample collection at screening, at the start of each cycle, and the end of treatment and during follow up or at progression.
89210739|NCT02593253|Active Comparator|Bi-weekly audit and feedback emails|Access to biweekly feedback emails with performance on selected quality measures (current practice).
89210740|NCT00816764|Experimental|1. AGS-8M4 Dose 1|
89520213|NCT05001633|Experimental|Intervention|modified media content experience
89520214|NCT05001633|Active Comparator|Control|media content experience
89520215|NCT03479931|Experimental|Without placement of a catheter|Without preoperatively placement of an indwelling catheter during Caesarean section
89520216|NCT03479931|Active Comparator|With placement of a catheter|Normal pre-operative routines with placement of an indwelling catheter during Caesarean section
89520217|NCT05306795||Observational cohort|Observational prospective cohort of kidney transplant allograft biopsies
89520218|NCT03444909|Experimental|cardiotocograph and Toconaute|monitoring with cardiotocograph and next with the Toconaute of Bioserenity
89520219|NCT03444909|Experimental|Cardiotocograph and Toconaute and Electrophysiological device|monitoring withardiotocograph and next with Toconaute and next with the electrophysiological device
89520220|NCT03444909|Experimental|Cardiotocograph and electrophysiological device|monitoring with the cardiotocograph and next with the electrophysiological device (Micromed)
89520221|NCT03374943|Experimental|KB004 dose escalation|Patients will be entered at each KB004 dose level sequentially until 3-6 patients are evaluable for safety. Three sequential cohorts are planned in this study (3.5mg/kg, 5.25 mg/kg, 7.9 mg/kg) Additional dose levels may be explored based on the emerging data in the study.
89520222|NCT03448913||PECS block+ General anesthesia|Patients undergoing mastectomy, partial mastectomy and/or axillary clearance who received PECS block AND general anesthesia for the surgery.
89520223|NCT03448913||General anesthesia|Patients undergoing mastectomy, partial mastectomy and/or axillary clearance who received general anesthesia only for the surgery.
89520224|NCT03371979|Experimental|Pegzilarginase plus Pembrolizumab|Phase 1 & 2
89520225|NCT04958577||Wing A (Ada WRA)|Patients in this group will be filling out the Ada assessment themselves and then heading to a normal consultation by first the usual care doctor and then the study-provided physician.
89520226|NCT04958577||Wing B (Ada HDA)|Patients in this group will be asked questions from the Ada assessment by a health care practitioner and then heading to a normal consultation by first the usual care doctor and then the study-provided physician.
89520227|NCT05104593|Experimental|Intervention tested (CAREPATH)|The intervention tested will be the CAREPATH system.
89520228|NCT05104593|No Intervention|Control group|Control group, no intervention
89520229|NCT05104437|Experimental|0-1-4 schedule group|Subjects receive the booster vaccine 3 months after the second dose.
89520230|NCT05104437|Experimental|0-1-6 schedule group|Subjects receive the booster vaccine 5 months after the second dose.
89520231|NCT05096793|Experimental|Control|the distance in the 6-MRT compared to baseline
89520232|NCT05096793|Experimental|Low doses|the distance in the 6-MRT compared to baseline
89520233|NCT05096793|Experimental|High doses|the distance in the 6-MRT compared to baseline
89520234|NCT03338829|No Intervention|Control|The control arm will received compensation at time of enrollment for agreeing to participate.
89520235|NCT03338829|Experimental|Positive Incentive|The positive incentive arm will receive compensation per prescribed test, payable every month based on testing adherence.
89520236|NCT03338829|Experimental|Loss Aversion|"The loss aversion arm will have compensation deposited into a University of Iowa Women's Health account. The participant will then lose compensation depending on actual adherence to recommended testing"
89520237|NCT05116215|Experimental|Hydrogen inhalation|Participants in the gas group will then undergo exposure to 2% H2 in medical air via a high flow nasal cannula for either 1 (n=3), 2 (n=3) or 4 (n=3) hours every day for one month.
89520238|NCT05116215|Experimental|Hydrogen capsules|Participants in capsule group will receive either 1 (n=3), 3 (n=3) or 6 (n=3) capsules every day for one month.
89520239|NCT05116215|Experimental|Hydrogen water|Participants in the water group will be suggested to drink 1 L hydrogen-rich water every day for one month.
89520240|NCT05090319||Viral Group|known viral infection
89520241|NCT05090319||Bacterial group|known bacterial infection
89520242|NCT03179943|Experimental|Atezolizumab + Guadecitabine|
89057759|NCT01685892|Experimental|Safety Expansion: Previously Untreated CLL|In participants with previously untreated CLL a recommended dose of venetoclax will be administered in combination with obinutuzumab in the safety expansion stage. Schedule A or B will be used for the expansion cohort after a review of available safety data from the dose finding stage.
89057760|NCT02887534|Experimental|Arm 1|three times medication; SPARC1401-low dose
89520243|NCT05115435|No Intervention|control group|No intervention was applied on the control group patients
89520244|NCT05115435|Experimental|experimental group|Sub modality Technique: People experience the world with their five senses, and the thoughts that an individual creates in his brain about a situation are coded with these five senses. When these encodings change, the individual's perception of the situation will also change
89520245|NCT02895087||Cohort 1: Diurnal Variation Group|Cohort recruitment - open to recruitment
89520246|NCT02895087||Cohort 2: External Stress Group|Cohort recruitment - closed to recruitment
89520247|NCT05115279|Other|Breast conservative Surgury after neuadjvant chemotherapy|Breast conservative Surgury
89520248|NCT02789553|Experimental|Meal with glucose syrup|Meal with glucose syrup : 30g of glucose mixed with 150 mL of water and dived into three 50 mL portions. It will be consumed in 15 minutes
89520249|NCT02789553|Experimental|Starch meal|Starch meal with 30g mixed in 120 mL of water. It will be consumed in 15 minutes and it represents 30g of glucose
89520250|NCT02468739|Experimental|Ganglioside-monosialic acid arm|"Patients will receive treatment of adjuvant chemotherapy. Ganglioside-monosialic acid(GM1, 80mg per day) will be given at 1 day before the start of chemotherapy for three days (Day -1, 1 and 2).~Chemotherapy regimens:~Epirubicin (90 mg/m2) combined with cyclophosphamide (600 mg/m2) followed by paclitaxel (175 mg/m2 *4 cycles) after four courses of chemotherapy; Epirubicin (90 mg/m2) combined with cyclophosphamide (600 mg/m2) followed by docetaxel (75 mg/m2 *4 cycles) after four course of chemotherapy; Docetaxel (75 mg/m2 q21d) combined with cyclophosphamide (600 mg/m2) for four courses.~The first day (D1) of each cycle is treated with taxane-based chemotherapy. 14-21 days are usually as one cycle. The methods of pretreatment and hydration shall be decided by the physicians."
89520251|NCT02468739|Placebo Comparator|placebo arm|"Patients will receive treatment of adjuvant chemotherapy. Placebo will be given at 1 day before the start of chemotherapy for three days (Day -1, 1 and 2).~Chemotherapy regimens:~Epirubicin (90 mg/m2) combined with cyclophosphamide (600 mg/m2) followed by paclitaxel (175 mg/m2 *4 cycles) after four courses of chemotherapy; Epirubicin (90 mg/m2) combined with cyclophosphamide (600 mg/m2) followed by docetaxel (75 mg/m2 *4 cycles) after four course of chemotherapy; Docetaxel (75 mg/m2 q21d) combined with cyclophosphamide (600 mg/m2) for four courses.~The first day (D1) of each cycle is treated with taxane-based chemotherapy. 14-21 days are usually as one cycle. The methods of pretreatment and hydration shall be decided by the physicians."
89520252|NCT05114499||Donepezil monotherapy group|Donepezil 5mg qd
89520253|NCT05114499||GV-971 monotherapy group|GV-971 450mg bid
89520254|NCT05114499||Donepezil combined with GV-971 group|Donepezil 5mg qd+GV-971 450mg bid
89520255|NCT04520997|Experimental|Down-up|Participants in this group received up to 2 mL Restylane Defyne on chin at baseline and up to 2 mL of Restylane Defyne per NLF at baseline and up to 2 mL per ML of Restylane Defyne at Week 3. An optional touch-up was administered to participants who had not achieved the optimal aesthetic improvement as agreed between participant and investigator.
89520256|NCT04520997|Experimental|Top-down|Participants in this group received up to 2 mL Restylane Defyne per NLF and up to 2 mL per ML of Restylane Defyne at baseline and up to 2mL on chin Week 3. An optional touch-up was administered to participants who had not achieved the optimal aesthetic improvement as agreed between participant and investigator.
89520257|NCT05114343|Experimental|Exercise group|Participants will be instructed to perform 3 sessions of weight-bearing exercise per week, for 12 weeks. Exercise intensity and duration will be low-to-moderate in the first 4 weeks, and will progressively increase during the program. Participants will be supported by educational materials, a heart rate monitor, and by means of periodic contact with an exercise specialist via video and phone calls, and text messages.
89520258|NCT05114343|No Intervention|Usual care (control group)|Participants in the control group will receive usual care and general instructions about physical activity.
89520259|NCT04568499||Suspected and Confirmed COVID-19 cases|Suspected and confirmed COVID-19 cases (age 5 years and above) identified at health facilities or via mobile teams in Juba, South Sudan and in Eastern Democratic Republic of the Congo.
89520260|NCT04958499|Experimental|Bio-Healthy Park|This group is the experimental group. The intervention program consisted in the realization of the program on bio-healthy machinery.
89520261|NCT04958499|No Intervention|Control|Adults and older assigned to the control group will not received any structured exercise programme. They will maintain their usual physical activities.
89520262|NCT05114109|Experimental|Isatuximab|Isatuximab will be given intravenously.
89520263|NCT05113875||COVID-19 Patients|Completed Sample of all patients admitted to the Mitchells Plain Hospital of Hope COVID-19 Field Hospital between January 1st and February 29th 2021. All patients were diagnosed with COVID-19 prior to admission to the hospital and were transferred directly from a referring hospital.
89520264|NCT05109585||participants willing to receive a 3-dose vaccination schedule|participants who received a 2-dose vaccination schedule, willing to receive a 3rd dose
89520265|NCT05109585||participants unwilling to receive a 3rd dose of vaccination|participants who received a 2-dose vaccination schedule, unwilling to receive a 3rd dose
89210741|NCT00816764|Experimental|2. AGS-8M4 Dose 2|
89520266|NCT03949959|Experimental|Physiotherapy (PRPt)|The 6-week exercise program (2 sessions in each of weeks 1-4 and 1 session in each of weeks 5 and 6) will comprise specific individually-tailored exercises to improve the movement and control of the neck and shoulder girdle. The exercises will be of a low load nature and designed to be pain free. At the same time, the physiotherapist will provide pragmatic multimodal physiotherapy to facilitate ability to pursue exercises and guide the participant's return to normal activities. This specific treatment program has been described in detail (Jull et al., 2008; Ritchie et al., 2015b) and focuses on activating and improving the coordination and endurance capacity of the neck flexor, extensor and scapular muscles in specific exercises and functional tasks. Participants will also perform the exercises at home, once per day. Written and illustrated exercise instructions will be provided. The exercise program follows Australian guidelines for the management of chronic whiplash (TRACsa, 2008).
89533101|NCT05538039|Experimental|Distract with play kaleidoscope|The intervention will begin approximately 30 minutes before premedication. The initiative will be applied to both the child and the parent participating in the research. Attempts to distract with the kaleidoscope will be conducted under investigative coaching for at least 10 minutes. It is a game tool that reproduces the outside image when viewed from inside the kaleidoscope. This image is obtained thanks to the glasses placed inside the kaleidoscope at different angles, and the images change as the kaleidoscope is rotated. If after 10 minutes the child or parent wants to continue playing, they will be told that they can play as long as they want. Each child and parent will be given a separate kaleidoscope.
89609300|NCT03805828|Experimental|Expermental|In the intervention group, the educational program will deliver as a one-day event in four sessions: (1)background of autism spectrum disorder(ASD) and coping mechanism,(2) targeting communication and social difficulties among ASD children using coping mechanism,(3) targeting behavior problems among ASD children using coping mechanism, and (4) stress management as coping mechanism.
89609301|NCT03805828|Active Comparator|Control|In the control group, the educational about communicable disease among childhood deliver as a one-day event in four sessions: (1) introduction and background communicable disease of childhood,(2) communicable diseases of childhood (Chicken Pox, Diphtheria,and pertussis[a whooping cough]),(3) communicable diseases of childhood (Measles,Mumps,rubella[German Measles]and Poliomyelitis(,and (4) infection control.
89609302|NCT00754468|Experimental|Group 1: Cryo Spray Ablation|cryo spray ablation applied to healthy tissue 4 cycles x 10 seconds
89609303|NCT00754468|Experimental|Group 2: Cryo Spray Ablation|cryo spray ablation applied to healthy tissue 2 cycles x20 seconds
89609304|NCT00754546|Active Comparator|Arformoterol tartrate|Bronchodilator therapy with arformoterol solution 15 mcg
89609305|NCT00754546|Placebo Comparator|Normal saline|Placebo using normal saline
89609306|NCT03806140|Active Comparator|Intervention group|Receive daily text messages
89609307|NCT03806140|No Intervention|Control group|No text messages, only written educational materials
89609308|NCT01764841|Experimental|Ciprofloxacin DPI 28 Days on/off (Cipro 28)|Participants received ciprofloxacin (BAYQ3939) 32.5 milligram (mg) corresponding to 50 mg dry powder for inhalation (DPI) administered twice daily (BID) (every 12 hours); a treatment cycle consisted of a 28-day on-treatment phase followed by a 28-day off-treatment phase (48 weeks treatment phase = 6 active cycles).
89609309|NCT01764841|Experimental|Ciprofloxacin DPI 14 Days on/off (Cipro 14)|Participants received ciprofloxacin 32.5 mg corresponding to 50 mg DPI administered BID (every 12 hours); a treatment cycle consisted of a 14-day on-treatment phase followed by a 14-day off-treatment phase (48 weeks treatment phase = 12 active cycles).
89609310|NCT01764841|Placebo Comparator|Placebo 28 Days on/off (Placebo 28)|Participants received placebo matched to ciprofloxacin 32.5 mg powder (containing 40 mg dry powder) administered BID (every 12 hours); a treatment cycle consisted of a 28-day on-treatment phase followed by a 28-day off-treatment phase (48 weeks treatment phase = 6 cycles).
89609311|NCT01764841|Placebo Comparator|Placebo 14 Days on/off (Placebo 14)|Participants received placebo matched to ciprofloxacin 32.5 mg powder (containing 40 mg dry powder) administered BID (every 12 hours); a treatment cycle consisted of a 14-day on-treatment phase followed by a 14-day off-treatment phase (48 weeks treatment phase = 12 cycles).
89609312|NCT00245050|Experimental|Pyridoxine|Arm I: Patients receive doxorubicin HCl liposome IV 40 mg/m2 over 1 hour on day 1 and oral pyridoxine 100 mg twice daily on days 1-28.
89609313|NCT00245050|Placebo Comparator|Placebo|Arm II: Patients receive doxorubicin HCl liposome IV 40 mg/m2 over 1 hour on day 1 and oral placebo twice 100 mg daily on days 1-28.
89609314|NCT04345588|Active Comparator|group received dexamethasone perineural|injection dexamethasone 0.05 mg/kg perineural.
89609315|NCT04345588|Active Comparator|group received dexamethasone intravenous|injection dexamethasone 0.05 mg/kg intravenously.
89609316|NCT00778648|Experimental|Juice Plus|
89609317|NCT00778648|Placebo Comparator|Placebo|
89609318|NCT03806374|Active Comparator|Fentanyl|Administered propofol and fentanyl for induction.
89210742|NCT00816764|Experimental|3. AGS-8M4 Dose 3|
89210743|NCT00816764|Experimental|4. AGS-8M4 Dose 4|
89210744|NCT05325905||Healthy|bleeding on probing (BoP) ≤ 10% of the sites, probing depth (PD) ≤ 3 mm and no indication of clinical attachment level (CAL) or radiographic bone loss
89210745|NCT05325905||Gingivitis|gingival inflammation (BoP ≥ 10% of the sites, red-blue discoloration of the gingiva and edema) PD ≤ 4 mm and no clinical attachment or radiographic bone loss
89210746|NCT05325905||Periodontitis|PD ≤ 5 mm, radiographic bone loss, and 3-4 mm CAL in at least 30% of the sites
89609319|NCT03806374|Active Comparator|Ketamine and lidocaine|Administered propofol, ketamine and lidocaine for induction.
89609320|NCT00763360|Experimental|DisCoVisc®|DisCoVisc® Ophthalmic Viscosurgical Device
89609321|NCT00763360|Active Comparator|Healon|Healon
89609322|NCT00763360|Active Comparator|Amvisc Plus|Amvisc Plus
89609323|NCT00763750|Experimental|PPX +TMZ+XRT|XRT 60Gy at 2 GY/fractions x 30 fractions TMZ 75mg/m2/day PPX 40mg/m2/week x 6 weeks Days 1,8,15,22,22,29,36
89609324|NCT00756106|Experimental|Temozolomide and Radiation Therapy|
89688353|NCT04364659|Experimental|Food-specific ICT + TAU|Participants in the Food-specific ICT + TAU group will be encouraged to complete the FoodT phone app (a food-specific go/no-go task) and a food diary daily for four weeks. After four weeks, they will be asked to complete a post-intervention questionnaire. After eight weeks, they will be asked to complete a follow-up questionnaire.
89609325|NCT00243412|Experimental|Arm A: 500 mg Rituximab|"Rituximab: 1000 mg intravenous (IV) on Days 1 and 15 of the first cycle; 500 mg IV on Days 1 and 15 of each subsequent 6-month cycle (Months 6, 12, and 18).~Corticosteroids: 100 mg IV methylprednisolone prior to each rituximab infusion.~Methotrexate: 15-25 mg/wk oral or parenteral (10-14 mg/wk if intolerant).~Folate: Minimum of 1 mg/day (or folinic acid 5 mg/wk)."
89609326|NCT00243412|Experimental|Arm B: 1000 mg Rituximab|"Rituximab: 1000 mg IV on Days 1 and 15 of each 12-month cycle (Rituximab cycles were administered at baseline and Month 12.) For the Month 6 and 18 cycles, rituximab or placebo was administered.~Corticosteroids: 100 mg IV methylprednisolone prior to each rituximab infusion For the Months 6 and 18 cycles, IV saline was administered prior to each rituximab or placebo infusion.~Methotrexate: 15-25 mg/wk oral or parenteral (10-14 mg/wk if intolerant).~Folate: Minimum of 1 mg/day (or folinic acid 5 mg/wk)."
89609327|NCT00765232|Experimental|Ketorolac|90 mg ketorolac in 1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.
89609328|NCT00765232|Placebo Comparator|Placebo|1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.
89609329|NCT03805282|Experimental|Female 18 to 60 years old|This adaptive dose-finding group will receive continuous infusion lidocaine using the biased coin method for finding the 95% effective dose (ED95%) for cough suppression. All patients will also receive remifentanil 0.025mcg/kg.h during emergence.
89609330|NCT03805282|Active Comparator|Male 18 to 60 years old|This adaptive dose-finding group will receive continuous infusion lidocaine using the biased coin method for finding the 95% effective dose (ED95%) for cough suppression. All patients will also receive remifentanil 0.025mcg/kg.h during emergence.
89609331|NCT03805282|Active Comparator|Male > 60 years old|This adaptive dose-finding group will receive continuous infusion lidocaine using the biased coin method for finding the 95% effective dose (ED95%) for cough suppression. All patients will also receive remifentanil 0.025mcg/kg.h during emergence.
89609332|NCT03805282|Active Comparator|Female > 60 years old|This adaptive dose-finding group will receive continuous infusion lidocaine using the biased coin method for finding the 95% effective dose (ED95%) for cough suppression. All patients will also receive remifentanil 0.025mcg/kg.h during emergence.
89609333|NCT03805750|Experimental|CBD/THC|Treatment arm consisting of Tetrahydrocannabinol (5mg/capsule) and Cannabidiol (100mg/capsule).
89609334|NCT03805750|Placebo Comparator|Placebo|Matched placebo capsule with no active ingredients.
89609335|NCT04385446|Active Comparator|Amniotic membrane transplantation|Amniotic membrane transplantation was used as covering material in the area where the pterygium tissue was removed during the surgery.
89609336|NCT04385446|No Intervention|conjnctival autograft.|Conjunctival autograft was used as a covering material in the area where the pterygium tissue was removed during the surgery.
89609337|NCT03804268|Placebo Comparator|Vehicle|Participants received one drop of vehicle in each eye, once daily, for up to 30 days.
89609338|NCT03804268|Experimental|Pilocarpine HCl Ophthalmic Solution|Participants received one drop of pilocarpine HCl ophthalmic solution 1.25% in each eye, once daily, for up to 30 days.
89609339|NCT00765856|Experimental|Oxymorphone ER|
89609340|NCT03805126|Experimental|Medical Legal Partnership|With the medical legal partnership, lawyers are embedded in clinics, and lawyers consult with patients who are identified as having health-harming legal needs (HHLNs). This arm will also receive usual care, which includes consultation with a social worker and a community health worker.
89609341|NCT03805126|Active Comparator|Usual Care|Usual care includes consultation with a social worker and a community health worker.
89609342|NCT00756496|Experimental|1|
89609343|NCT00780208|Other|Daytrana (methylphenidate patch)|Methylphenidate patch
89609344|NCT00243022|Experimental|Arm I (intervention)|Patients receive oral Boswellia serrata extract 4 times a day and oral cyanocobalamin (vitamin B 12) once a day for 6 months in the absence of unacceptable toxicity.
89609345|NCT00243022|Active Comparator|Arm II (control)|Patients in the control arm receive oral cyanocobalamin (vitamin B 12) once a day for 6 months.
89609346|NCT03805360|Sham Comparator|ESP block with normal saline|An erector spinae plane block will be performed and a single dose of Normal Saline Flush, 0.9% Injectable Solution will be administered into the target muscle plane.
89609347|NCT03805360|Experimental|ESP block with local anesthetic|An erector spinae plane block will be performed and a single dose of 0.5% ropivacaine will be injected into the target muscle plane.
89609348|NCT03805048|Other|Native Vessel PCI|All patients with a significant stenosis (>50% on coronary angiography) in a venous bypass graft discussed in the local heart team for revascularization will be screened for potential inclusion in the study. Percutaneous coronary intervention of the native vessel will be performed according to current standard. In case of a CTO lesion, the aforementioned hybrid approach will be applied.This approach uses several angiographic characteristics to guide strategical planning of the procedure, using four complementary techniques to cross a CTO: antegrade wire escalation, antegrade dissection reentry, retrograde wire escalation and retrograde dissection reentry.
88983013|NCT05952518|Experimental|Peripheral Nerve Stimulation|Peripheral nerve stimulation (PNS) is a procedure used to relieve chronic back pain by targeting the nerves responsible for transmitting pain signals from the back to the brain. It is a minimally invasive approach that aims to disrupt the pain signals and provide pain relief.
88983014|NCT05952518|Active Comparator|Radiofrequency Ablation|Radiofrequency ablation (RFA) is the current standard of care for facet joint pain. It is a minimally invasive procedure used to relieve chronic back or neck pain caused by issues with the small joints in the spine called facet joints.
88983015|NCT05952505|Experimental|Group 1|immunized inactivated SARS-CoV-2 vaccine and varicella vaccine in day 0 followed by measles-mumps-rubella vaccine(MMR) in day 28.
88983016|NCT05952505|Experimental|Group 2|immunized varicella vaccine in day 0 followed by SARS-CoV-2 vaccine and MMR in day 28.
88983017|NCT05952505|Active Comparator|Group 3|immunized inactivated SARS-CoV-2 vaccine in day 0 followed by MMR and varicella vaccine in day 28.
88983018|NCT05952466||COVID-19 infection group|School-age children infected recently with COVID-19
89057761|NCT02887534|Experimental|Arm 2|three times medication; SPARC1401-mid dose
88983019|NCT05952466||control group|School-age children without COVID-19
88983020|NCT05952427||Infertile women|Any patient consulting for the first time at the Grenoble University Hospital in a context of infertility, between 18 and 43 years old
89533102|NCT05538039|Other|Control Group|The participants in the control group will be given routine nursing care.
89533103|NCT05533294|Experimental|ARO-RAGE|single or multiple doses of ARO-RAGE by subcutaneous (sc) injection
89533104|NCT05533294|Placebo Comparator|Placebo|placebo calculated volume to match active treatment by sc injection
88983021|NCT05952427||Non-infertile women|Any patient consulting her gynecologist in town for a reason other than infertility, and having no known infertility, between 18 and 43 years old
88983022|NCT05952414|Experimental|Intervention group|Experimental: Intervention group Group one (study group, 40 nurses): received self-efficacy-based interventions.
88983023|NCT05952414|No Intervention|Control group|Group two(the control group, 40 nurses):act as a control group/ waiting list
88983024|NCT05952375|Experimental|XKDCT086 treatment for patients with Claudin18.2 target positivity|"Drug: XKDCT086 (chimeric antigen receptor T cell preparation targeting Claudin18.2)~Dosage form: Cell suspension~Dose: 30-50mL/bag~Medication method: intravenous drip~Frequency: Once"
88983025|NCT05952245|Experimental|Intervention Group|Receiving CBT-I based EMI messages.
88983026|NCT05952245|No Intervention|Control Group|Receiving stroke education messages.
88983027|NCT05952219|Experimental|Sequence 1|Period 1: Reference drug(D759+D745+D029+D150) Period 2: Test drug(CKD-379)
88983028|NCT05952219|Experimental|Sequence 2|Period 1: Test drug(CKD-379) Period 2: Reference drug(D759+D745+D029+D150)
89057762|NCT02887534|Experimental|Arm 3|three times medication; SPARC1401-high dose
89057763|NCT02887534|Active Comparator|Active comparator|Reference1401; To be administered 3 times a day
89057764|NCT02887534|Placebo Comparator|Arm 5|Placebo1401 - 3 three times a day
89533105|NCT05526560||Patients requiring replacement of their native or prosthetic mitral valve|Patients requiring replacement of their native or prosthetic mitral valve
89533106|NCT05516498|Experimental|Part A: Treatment Group 1|Participants will receive once daily dose of placebo matching zibotentan capsule + placebo matching dapagliflozin tablet for 6 weeks.
89533107|NCT05516498|Experimental|Part A: Treatment Group 2|Participants will receive once daily dose of zibotentan capsule + dapagliflozin tablet for 6 weeks.
89533108|NCT05516498|Experimental|Part B: Treatment Group 1|Participants will receive once daily dose of placebo matching zibotentan capsule + placebo matching dapagliflozin tablet for 16 weeks.
89533109|NCT05516498|Experimental|Part B: Treatment Group 2|Participants will receive once daily dose of placebo matching zibotentan capsule + dapagliflozin tablet for 16 weeks.
89533110|NCT05516498|Experimental|Part B: Treatment Group 3|Participants will receive once daily dose of zibotentan capsule + dapagliflozin tablet for 16 weeks.
89533111|NCT05516498|Experimental|Part B: Treatment Group 4|Participants will receive once daily dose of zibotentan capsule + dapagliflozin tablet for 16 weeks.
89533112|NCT05516498|Experimental|Part B: Treatment Group 5|Participants will receive once daily dose of zibotentan capsule + dapagliflozin tablet for 16 weeks.
89533113|NCT05509582|Experimental|Fostamatinib Arm|The subjects will receive oral fostamatinib daily for up to 2 years.
89533114|NCT05507333|Other|Gedea pessary|Gedea pessary administration
89533115|NCT05495581|Experimental|Mild renal impairment|Participants will receive a single intravenous dose of ASP5354 under fasting conditions on Day 1.
89533116|NCT05495581|Experimental|Moderate renal impairment|Participants will receive a single intravenous dose of ASP5354 under fasting conditions on Day 1.
89533117|NCT05495581|Experimental|Severe renal impairment|Participants will receive a single intravenous dose of ASP5354 under fasting conditions on Day 1.
89533118|NCT05495581|Experimental|Normal renal function|Participants will receive a single intravenous dose of ASP5354 under fasting conditions on Day 1.
89533119|NCT05473429|Experimental|1/ID patients|ID Patients
89533120|NCT05473429|Active Comparator|2/Healthy controls|Healthy controls
89533121|NCT05471414|Experimental|Whole-food, Plant-based Diet (WFPBD)|Home-delivered WFPBD meals will be provided to participants, along with nutritional coaching and education. 12 meals a week will be delivered for the first 4 weeks, followed by 6 meals a week for the next 4 weeks. Finally, for the last 18 weeks they will not receive pre-packed meals, but will continue to receive WFPBD coaching. 30 participants are anticipated to be accrued in this arm.
89533122|NCT05471414|Active Comparator|General Nutrition Counseling|Participants will receive general nutritional counseling weekly for the first 4 weeks, followed by monthly nutritional counseling for the following 18 weeks. 30 participants are anticipated to be accrued in this arm.
89533123|NCT05465174|Experimental|Group 1, Arm A: Neoadjuvant nivolumab|Participants with newly diagnosed craniopharyngioma will receive one (1) dose of nivolumab within 14 days - 5 days prior to planned biopsy or resection. At completion of biopsy or resection, participants having undergone biopsy only or sub-total (STR) or near-total resection (NTR) will continue on combination maintenance therapy of nivolumab given every 2 weeks and Tovorafenib once weekly at the respected recommended phase 2 dose (RP2D) for each agent. Participants having undergone a gross total resection (GTR) will enter into follow-up only and will be part of the exploratory cohort.
89533124|NCT05465174|Experimental|Group 1, Arm B: Neoadjuvant Tovorafenib|Participants with newly diagnosed craniopharyngioma will receive one (1) dose of Tovorafenib within 7 days +/- 2 days prior to planned biopsy or resection. At completion of biopsy or resection, participants having undergone biopsy only or sub-total (STR) or near-total resection (NTR) will continue on combination maintenance therapy of nivolumab given every 2 weeks and Tovorafenib once weekly at the respected RP2D for each agent . Participants having undergone a gross total resection (GTR) will enter into follow-up only and will be part of the exploratory cohort.
89533125|NCT05465174|Experimental|Group 1, Arm C: Neoadjuvant combination nivolumab and Tovorafenib|Participants with newly diagnosed craniopharyngioma will receive one (1) dose of nivolumab (14 days -5 days prior) and one dose of Tovorafenib (7days +/- 2 days prior) to planned biopsy or resection. At completion of biopsy or resection, participants having undergone biopsy only or sub-total (STR) or near-total resection (NTR) will continue on combination maintenance therapy of nivolumab given every 2 weeks and Tovorafenib once weekly at the respected RP2D for each agent. Participants having undergone a gross total resection (GTR) will enter into follow-up only and will be part of the exploratory cohort.
89609349|NCT03805048|Other|Graft PCI|All patients with a significant stenosis (>50% on coronary angiography) in a venous bypass graft discussed in the local heart team for revascularization will be screened for potential inclusion in the study. Percutaneous coronary intervention of the bypass graft will be performed following current standards and at the discretion of the operating interventional cardiologist. Only commercially available second generation DES will be used in the treatment of bypass grafts. The second generation DES used in this study will be the XIENCE Sierra stent. The use of a filter-wire during the procedure will be left at the discretion of the operator.
89609350|NCT03801772|Active Comparator|Metronome|This arm will be using the metronome as a pacing device during aquatic exercises.
89609351|NCT03801772|No Intervention|Control|The patients will be educated on proper performance of aquatic exercises following normal physical therapy procedures. Patients will start with 10-20 repetitions of the exercises depending on their physical ability and progressed as the patient's strength and endurance improve. Each session will last approximately 30 to 45 minutes. The BORG scale (a valid, subjective measure of perceived exertion) will be used as a monitoring device to ensure that a desired level of exercise intensity is reached. The desired level is a score between 12 and 16. The patients will be asked to rate their level of exertion at the end of each session. Intensity of the exercises will be adjusted the next session if the patient's reported level of exertion does not fall within the desired range. The pain rating and the BORG number will be recorded for both groups in the chart and flow
89520267|NCT03949959|No Intervention|Wait and See (PRPu)|"Individuals randomized to usual care will be provided with an advice booklet Whiplash Injury Recovery: A Self Help Guide (MAIC, Qld, 2nd edition). It provides information about whiplash; assurance about prognosis; advice to stay active and resume working as well as information on correct posture; pictorial descriptions of specific exercises for the neck and upper limbs and information on resuming functional daily activities. The booklet is based on the recommendations of the current Australian Guidelines for Whiplash Management (SIRA, 2014).~Usual care involves a 'wait and see' approach (in combination with provision of home exercises) and will include weekly review appointments with a medical doctor, primarily to review the information in the booklet and progress the 'general' exercises and activity recommendations within the booklet. No hands-on physiotherapy will be provided. Education regarding PRP and associated healing cycles will also be provided during this time period."
89520268|NCT04436445|Active Comparator|dry cupping|Dry cupping is considered to be a noninvasive and inexpensive technique, used worldwide to treating patients with pain syndromes It is in fact a type of physical therapy which is applied by the specialists of acupuncture or other individuals. It improves the subcutaneous blood flow and, as a result, stimulates the autonomic nervous system and reduces the pai
89609352|NCT00756964|Active Comparator|Rasburicase|patients receiving rasburicase to lower serum uric acid
89609353|NCT00756964|Placebo Comparator|Placebo|patients will receive a placebo
89609354|NCT00780442|Experimental|DCS|D-Cycloserine 50 mg is a partial glutamate agonist. Participants received DCS prior to cocaine cue exposure sessions.
89609355|NCT00780442|Placebo Comparator|Placebo|Saline comparator. Participants received placebo prior to cocaine cue exposure sessions.
89609356|NCT00767338|Active Comparator|No surgery + IUI|No microsurgical varicocelectomy plus up to four cycles each of alternating intrauterine insemination and timed intercourse starting with intrauterine insemination.
89609357|NCT00767338|Active Comparator|No Surgery + TI|No microsurgical varicocelectomy plus up to four cycles each of alternating intrauterine insemination and timed intercourse starting with timed intercourse.
89609358|NCT00767338|Active Comparator|Surgery + IUI|Microsurgical varicocelectomy plus up to four cycles each of alternating intrauterine insemination and timed intercourse starting with intrauterine insemination.
89609359|NCT00767338|Active Comparator|Surgery + TI|Microsurgical varicocelectomy plus up to four cycles each of alternating intrauterine insemination and timed intercourse starting with timed intercourse.
89609360|NCT04384666|Experimental|LY03003|LY03003 28 mg
89609361|NCT04384666|Active Comparator|Neupro 4Mg/24Hr Transdermal Patch|Neupro 4 mg / 24 Hr. Transdermal Patch
89609362|NCT00767572|Experimental|atorvastatin|Patients are randomized to either atorvastatin or placebo once daily for 12 weeks. There is a 4 week washout, and then the groups are switched for 12 weeks. Brachial artery assessment will be performed before and after each 12 week period on therapy.
89609363|NCT00767572|Placebo Comparator|sugar pill|See above. Patients will be randomized to atorvastatin vs. placebo for 12 weeks and after a 4 week washout period the groups will be switched.
89609364|NCT03804736|Active Comparator|FMT-c|Patients in this arm received FMT-c (15 capsules every 12 h for 2 days)
89609365|NCT03804736|Experimental|FMT-c lactobacillus|Patients in this arm received FMT-c Lactobacillus (15 capsules every 12 h for 2 days)
89609366|NCT04384588|Experimental|Cancer patients with COVID 19 infection and severity criteria|All patients will be treated with 1 or more convalescent plasma units
89609367|NCT04384588|Experimental|Cancer patients with COVID 19 infection and risk factors|All patients will be treated with 1 or more convalescent plasma units
89609368|NCT04384588|Experimental|Non-Cancer patients COVID 19 infection and severity criteria|All patients will be treated with 1 or more convalescent plasma units
89609369|NCT04384588|Experimental|Non-cancer patients COVID 19 (+) and risk factors|All patients will be treated with 1 or more convalescent plasma units
89609370|NCT00780676|Experimental|Dasatinib sensitivity signature|Participants predicted to respond to Dasatinib (Sprycel) by predictive gene signature receive dasatinib 100 mg by mouth daily.
89609371|NCT00780676|Experimental|SRC pathway activity signature|Participants predicted to respond to Dasatinib (Sprycel) by predictive gene signature receive dasatinib 100 mg by mouth daily.
89609372|NCT00780676|Experimental|Dasatinib target index|Participants predicted to respond to Dasatinib (Sprycel) by predictive gene signature receive dasatinib 100 mg by mouth daily.
89609373|NCT00780676|Experimental|Selumetinib pathway predictor|Participants predicted to respond to selumetinib/AZD6244 by predictive gene signature (either MEK pathway activity predictor positive or MEK pathway predictor negative) receive selumetinib 75 mg by mouth twice daily (BID).
89609374|NCT03806998|Experimental|Ketoacid supplementation|Will receive a ketoacid supplement containing 630 mg of ketoacids in a dose of 1 tablet every 5 kg of body weight
89609375|NCT03806998|Placebo Comparator|Placebo|Will receive placebo tablets in a dose of 1 tablet every 5 kg of body weight
89609376|NCT03804502|Experimental|TearCare|Subjects will receive one TearCare treatment at the baseline visit
89609377|NCT00768118|Experimental|Curcumin, Green Tea extract, Polygonum Cuspidatum & Soybean|Total number of visits: 2, pre-intervention blood draw and urine sample collection, post-intervention blood draw and urine sample collection and interview Length of each visit: 15-30 minutes Total expected duration of participants' involvement: 15 days During the two-week intervention, volunteers will take two 1/2g capsules of the combination capsule, twice daily immediately after morning and evening meals.
89609378|NCT04278586|Experimental|Live-Online Mindful Recovery OUD Care Continuum|Live-Online Mindful Recovery OUD Care Continuum (M-ROCC) builds on other mindfulness interventions for addictive disorders, but is specifically designed for patients with OUD prescribed buprenorphine to be delivered in a live-online environment. It focuses on integration of mindfulness practice for living well through stress, anxiety, depression, pain and addiction recovery. The live-online M-ROCC curriculum has three primary components, including a low-dose mindfulness phase, an intensive mindfulness training phase and then a mindfulness maintenance check-in support group.
89609379|NCT04278586|Active Comparator|Live-Online Control|A time- and attention-matched live online control group. The manualized control intervention developed for the basic group-based opioid treatment group in primary care uses 16 core modules and 8 elective modules that are common to eclectic approach in treatment as usual addiction recovery groups (including engagement and group development activities with a mix of basic CBT skills, twelve-step facilitation, community reinforcement, and motivational interviewing). As an active group control, this method will help to isolate mindfulness as the putative mechanism of action by controlling for the therapeutic aspects of group without any reference to mindfulness.
89609380|NCT04275076|Experimental|Holmium laser enucleation of the prostate|Holmium laser enucleation of the prostate
89609381|NCT04275076|Experimental|bipolar transurethral enucleation of the prostate|bipolar transurethral enucleation of the prostate
89609382|NCT03809572|Experimental|Mindfulness Based Cognitive Therapy|Mindfulness Based Cognitive Therapy (MBCT) adapted for pregnancy includes 8 sequential, weekly 2-hour group sessions co-led by two master's level therapists. Sessions include: 1) introducing new mindfulness skills through in-session practice, 2) reviewing mindfulness practices and troubleshooting barriers to practice, 3) reinforcing mindfulness skills through in-session practice and debriefing, 4) learning about how thoughts influence feelings and behaviors (not all sessions), 5) providing psychoeducational information to support skills, and 6) encouraging the establishment of social support.
89609383|NCT03809572|No Intervention|Treatment as usual (TAU)|All participants will receive routine prenatal care from an identified medical provider, which they have initiated on their own. They will be able to engage in any services recommended by their primary medical provider or that they voluntarily initiate. For ethical reasons, they are not prohibited from engaging in any type of therapeutic, complementary, or medication treatment (after enrollment). The TAU group will be offered a delayed treatment option, after the 6 month follow-up. This will be a 2 hour mindfulness psychoeducation session, offered between 6 and 9 months postpartum. Several core mindfulness concepts included in the full MBCT curriculum will be taught and participants will complete several brief mindfulness activities.
89609384|NCT04274218|Experimental|Walking perturbation - Free|Healthy controls without limb loss and individuals with upper limb loss between the wrist and elbow will receive a treadmill belt disturbance while walking. Able-bodied individuals will walk with both arms free and individuals with amputation will walk with their prosthesis.
89609385|NCT04274218|Experimental|Walking perturbation - Limited|Healthy controls without limb loss and individuals with upper limb loss between the wrist and elbow will receive a treadmill belt disturbance while walking. Able-bodied individuals will walk with one arm bound to their side with straps and individuals with amputation will walk without their prosthesis.
89609386|NCT05744284||Sex, age, kind of disease in relation to the organ affected|Sex, age, kind of disease in relation to the organ affected and type of surgical procedure and related incision have been investigated. Patients with diabetes mellitus, coagulation disorders and those submitted to a treatment of steroids and anticoagulant; patients previously operated with scar in the site of the second operations, or with anemia or with active source of infection in any part of the body where excluded from the study.
89609387|NCT05744206|Experimental|Electrocardiogram measurements by holter device and patch-type electrocardiographic at the same time|The patient is measured electrocardiogram simultaneously through a holter device and patch-type electrocardiograph
89609388|NCT04345432|Experimental|Gabapentin|"The experiment will be divided into the following phases:~Baseline phase - Demographic and test data will be collected prior to dispensing trial medication using all measures listed above~7 day trial phase with gradual increase of dose from 100 mg/day to 600 mg/day (300 b.i.d) on day 6 of gabapentin or placebo. A single morning dose (300 mg) will be given at the lab on day 7 followed by post-trial testing (using above measures) 1 hour after drug administration.~7 day drug washout phase - no medication will be taken~7 day crossover trial phase - baseline measurements will be repeated and groups will switch to gabapentin or placebo. Post-trial measurements will be taken 1 hour after a single morning dose (300 mg) on day 7.~Follow-up phone call - Patients will be called 8-10 days after completion of study to ensure that there have been no unexpected events."
89688354|NCT04364659|No Intervention|TAU|Participants in the TAU group will not receive the Food-specific ICT. After four weeks, they will be asked to complete a 'post-intervention' questionnaire. After eight weeks, they will be asked to complete a follow-up questionnaire.
89688355|NCT04356079||Migraine patients|
89688356|NCT04356079||Control|
89688357|NCT03658096|Active Comparator|Healthy volunteer|
89688358|NCT03658096|Active Comparator|DRUJ instability patients|
88983029|NCT05952206|Experimental|Angiolite and abbreviated DAPT|"Acute coronary syndrome patients:~Need for OAC: TAT + OAC for one week. Double therapy composed of clopidogrel + OAC up to 6 months.~No need for OAC: DAPT with acetylsalicylic acid + prasugrel or ticagrelor for 1M. Only the same P2Y12 inhibitor up to 12M.~Chronic coronary syndrome patients:~Need for OAC: TAT + clopidogrel + OAC for one week. Double therapy composed of clopidogrel + OAC up to 6M.~No need for OAC: DAPT with acetylsalicylic acid + clopidogrel for one month. Only clopidogrel up to 12M."
89057765|NCT01685931|Experimental|Paliperidone Palmitate|
89057766|NCT01685970|Placebo Comparator|High volume Split-dose PEG|Patients who are scheduled afternoon colonoscopy ingest high volume split-dose PEG for bowel preparation
89609389|NCT04345432|Placebo Comparator|Placebo|"The experiment will be divided into the following phases:~Baseline phase - Demographic and test data will be collected prior to dispensing trial medication using all measures listed above~7 day trial phase with gradual increase of dose from 100 mg/day to 600 mg/day (300 b.i.d) on day 6 of gabapentin or placebo. A single morning dose (300 mg) will be given at the lab on day 7 followed by post-trial testing (using above measures) 1 hour after drug administration.~7 day drug washout phase - no medication will be taken~7 day crossover trial phase - baseline measurements will be repeated and groups will switch to gabapentin or placebo. Post-trial measurements will be taken 1 hour after a single morning dose (300 mg) on day 7.~Follow-up phone call - Patients will be called 8-10 days after completion of study to ensure that there have been no unexpected events."
89609390|NCT05744050|Experimental|Low energy density|The meal served at lunch time to participants will have a low energy density of ~1.1kcal/g. All other foods are identical across conditions (e.g. snacks, dinner, dessert)
89609391|NCT05744050|Experimental|Medium energy density|The meal served at lunch time to participants will have a low energy density of ~1.7kcal/g. All other foods are identical across conditions (e.g. snacks, dinner, dessert)
89609392|NCT05744050|Experimental|High energy density|The meal served at lunch time to participants will have a low energy density of ~3kcal/g. All other foods are identical across conditions (e.g. snacks, dinner, dessert)
89609393|NCT03804190||1-5years experience|1-5years of experience working as otorhinolaryngologist
89609394|NCT03804190||5-10 years experience|5-10years of experience working as otorhinolaryngologist
89609395|NCT03804190||10-15years experince|10-15years of experience working as otorhinolaryngologist
89609396|NCT03804190||15_20years experience|15-20years of experience working as otorhinolaryngologist
89609397|NCT00757666|Active Comparator|Accelerometer|Patients implanted with a Boston Scientific ALTRUA 60 pacemaker with accelerometer (motion-based) sensor.
89609398|NCT00757666|Active Comparator|Minute Ventilation|Patients implanted with a Boston Scientific ALTRUA 60 pacemaker with minute ventilation sensor.
89609399|NCT03803956|Active Comparator|Active PBMT|Application of PBMT (Photobiomodulation Therapy) with a total dose of 850 Joules.
89609400|NCT03803956|Placebo Comparator|Placebo PBMT|Application of placebo PBMT (Photobiomodulation Therapy) without any dose (0 Joule).
89609401|NCT01736683|Experimental|Sotatercept 0.1 mg/kg|Sotatercept 0.1 mg/kg
89609402|NCT01736683|Experimental|Sotatercept 0.3 mg/kg|Sotatercept 0.3 mg/kg
89609403|NCT01736683|Experimental|Sotatercept 0.5 mg/kg|Sotatercept 0.5 mg/kg
89609404|NCT01736683|Experimental|Sotatercept 1.0 mg/kg|Sotatercept 1.0 mg/kg
89609405|NCT01736683|Experimental|Sotatercept 1.5 mg/kg|Sotatercept 1.5 mg/kg
89609406|NCT01736683|Experimental|Sotatercept 2.0 mg/kg|Sotatercept 2.0 mg/kg
89609407|NCT05743972|Experimental|CEUS-guided core biopsy group|
89609408|NCT05743972|Active Comparator|US-guided core biopsy group|
89609409|NCT01788943||Slow metabolizers|Individuals with an NMR <0.26 will be classified as slow metabolizers.
89609410|NCT01788943||Normal metabolizers|Participants with an NMR >= 0.26 will be classified as normal metabolizers.
89210747|NCT00820976|No Intervention|control|remission induction with cytosine arabinoside amd idarubicine
89210748|NCT00820976|Experimental|G-CSF|G-CSF was administered starting on Day 8 until neutrophil recovery
89210749|NCT00987519||Acute bronchiolitis|Patients with acute bronchiolitis - the presence of nasal discharge, cough, wheezing and/or crackles on lung auscultation.
89210750|NCT00987519||Acute gastroenteritis|Patients with 3 or more loose or liquid stools in 24 hours prior to entering the study.
89210751|NCT00987519||Febrile convulsion|Patients with a cerebral paroxysm accompanied by fever without signs of central nervous system infection.
89609411|NCT00757822|Experimental|Arm 1|dronabinol
89609412|NCT00757822|Active Comparator|Arm 2|ondansetron
89609413|NCT04561765|Experimental|iCanCope|In this group, individuals will receive the iCanCope-NF program. The intervention will be delivered on a restricted password-protected mobile application. Participants will be encouraged to log onto the pain diary app (via automated alerts) once per day over the 8-week period to complete pain diary entries and develop and track their goals related to their pain, physical, social activities, sleep, as well as work through content based on their goals.
89609414|NCT04561765|Experimental|iCanCop+Contingency Management|In addition to the iCanCope-NF activities outlined above, individuals will be rewarded with incentives (contingency management) such as points that are redeemable for prize-based gift card vouchers. Points will be accrued through access to new sections, daily check-ins, and engagement of the mobile application. Based on research, the total amount of money that can be earned by the patient over the course of the two months is 50 dollars USD.
89609415|NCT04561765|No Intervention|Control Group|The control group is designed to assess for potential effects on outcomes of time, attention, during the study. In addition to usual care, participants will be required to complete baseline and follow-up assessments similar to that of the intervention groups. They will be given that patient education, through preapproved flyers and information found from national websites regarding pain management, but no self-management strategies or opportunities for social support. They will not have access to the mobile application during the course of experiment; however, the control group will be offered the full iCanCope-NF program following the trial (T2) for a period of 2 months after the study is over.
89609416|NCT01788163|Other|Locally advanced/metastatic NSCLC pats.|Patients with locally advanced (stage IIIA/B) or metastatic NSCLC who have not received any local or systemic chemotherapy, and are not eligible for curative treatment (including surgery and chemoradiotherapy)
89609417|NCT00758758|Experimental|Experimental Arm 1|Hedrocel 1 level - No plate
89609418|NCT00758758|Experimental|Experimental Arm 2|Hedrocel 1 level with plate
89609419|NCT00758758|Experimental|Experimental Arm 3|Hedrocel 2 levels with plate
89609420|NCT00758758|Active Comparator|Control Arm 1|Autograft alone - Illiac crest
89609421|NCT00758758|Active Comparator|Control Arm 2|Autograft 1 level with plate
89609422|NCT00758758|Active Comparator|Control Arm 3|Allograft 1 level with plate
89609423|NCT00758758|Active Comparator|Control Arm 4|Autograft 2 levels with plate
89609424|NCT00758758|Active Comparator|Control Arm 5|Allograft 2 levels with plate
89609425|NCT00783952|Other|1|Mixed venous oxygen saturation measurement obtained from blood drawn from a pulmonary artery catheter.Calculation of mixed venous oxygen saturation from the measurement of peripheral oxygen saturations using multiple Cerebral/Somatic Tissue Oximeter device probes
89609426|NCT00784030|Other|Polycystic Kidney Disease Patients|Patients who present with polycystic kidney disease (PKD)
89609427|NCT00784030|Other|Healthy Patients|
89609428|NCT03803878||Group 1|Group 1 is anticipated to consist of 300 women with MUI, and the categorization function of MESA questionnaire will be validated among those patients.
89609429|NCT03803878||Group 2|Group 2 is anticipated to consist of 282 women with urgency-predominant MUI.
89609430|NCT03803878||Group 3|Group 3 is anticipated to consist of 94 women with urgency-predominant MUI.
89609431|NCT03803644|Experimental|Administration of CC-92480 - Part 1|dose escalation
89033651|NCT06022939|Experimental|Maintenance (daratumumab and hyaluronidase-fihj)|Patients receive maintenance daratumumab and hyaluronidase-fihj SC over 3-5 minutes on day 1 of each cycle. Cycles repeat every 28 days for up 18 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo echocardiography at screening, 12 months post consolidation treatment and at progression. Patients undergo bone marrow aspiration and biopsy 12 months post consolidation treatment and at progression. Patients undergo blood and urine sample collection at screening, during treatment, 12 months post consolidation treatment and during follow up or at progression.
89033652|NCT06022900|No Intervention|control group|This group was receiving standard breast cancer screening program service during the study period. standard care; It is this standard health service applied to the whole country.
89609432|NCT03803644|Experimental|Administration of CC-92480 under fasted conditions - Part 2|Food effect
89609433|NCT03803644|Experimental|Administration of CC-92480 under fed conditions - Part 2|food effect
89609434|NCT01787461|Experimental|Imedeen|Imedeen is the study product
89609435|NCT01787461|Placebo Comparator|Placebo|
89609436|NCT03803488|Experimental|simulation of injection|The evaluator simulated the injection with the DropSafe safety pen needle and a pen injector with a sterile, water-filled cartridge using an orange.
89609437|NCT03803722|Experimental|Arm A Eyestil Protection®|"No inferiority of Eyestil Protection® unidose versus Vismed® unidose The intervention consists of Eyestil Protection® : sterile preservative free, medical device, class IIa and CE marked. It contains 0.2% xanthan gum, presented in 0.3 ml unidose containers. It is not available yet on the French Market.~dosage: 6 drops a day for three months period."
89609438|NCT03803722|No Intervention|Arm B Vismed®|"Vismed®: sterile preservative free, medical device class IIb and CE marked. It contains 0.18% sodium hyaluronate, presented in 0.3 ml unidose containers. It is already on the French market.~dosage: 6 drops a day for three months period."
89609439|NCT00758836|Placebo Comparator|Placebo|Participants take two placebo tablets and two placebo capsules, orally, at onset of migraine
89609440|NCT00758836|Experimental|Telcagepant 280 mg +Ibuprofen 400 mg|Participants take one telcagepant 280 mg tablet, one ibuprofen 400 mg tablet, and two placebo capsules, orally, at onset of migraine
89609441|NCT00758836|Experimental|Telcagepant 280 mg +APAP 1000 mg|Participants take one telcagepant 280 mg tablet, one placebo tablet, and two 500-mg APAP capsules, orally, at onset of migraine
89609442|NCT00758836|Placebo Comparator|Telcagepant 280 mg|Participants take one telcagepant 280 mg tablet, one placebo tablet, and two placebo capsules, orally, at onset of migraine
89609443|NCT03809806|Other|patients after hysterectomy|modified anterior transvaginal mesh surgery
89609444|NCT03803800|Experimental|Classic training & beta-alanine|Subjects following 12 weeks of classic, progressive endurance training, with the addition of ergogenic supplements (beta-alanine supplementation).
89033653|NCT06022900|Experimental|Online training group|In addition to the standard breast cancer screening program service, the participants in this group were provided with online health education about breast cancer and prevention from breast cancer, and a digital education brochure was given At the end of the fourth week from the day they were assigned to the study, they were called by phone and the participants were reminded in line with the summary information about the importance of screening.
89609445|NCT03803800|Placebo Comparator|Classic training & placebo|Subjects following 12 weeks of classic, progressive endurance training, without the addition of ergogenic supplements (placebo supplements).
89609446|NCT03803800|Experimental|Periodized training & beta-alanine|Subjects following 12 weeks of periodized exercise training, with the addition of ergogenic supplements (beta-alanine supplementation).
89609447|NCT03803800|Placebo Comparator|Periodized training & placebo|Subjects following 12 weeks of periodized exercise training, without the addition of ergogenic supplements (placebo supplements).
89609448|NCT04384432|Experimental|Routine Physical Therapy with Thoracic mobility exercise|Combination of Routine Physical Therapy with Thoracic mobility exercise.
89609449|NCT04384432|Active Comparator|Routine Physical Therapy|Routine Physical Therapy exercise
89609450|NCT01786993|Experimental|Multi-point pacing arm|MultiPoint Pacing
89609451|NCT01786993|Active Comparator|Biventricular arm|Traditional Biventricular Pacing
89609452|NCT00769600|Active Comparator|Itraconazole with Pemetrexed|Pemetrexed IV every 21 days with oral Itraconazole 200mg daily.
89609453|NCT00769600|Active Comparator|Single agent pemetrexed|Pemetrexed IV on day 1 of 21-day cycle.
89609454|NCT03809650|Experimental|Open-label treatment period|oral administration of macitentan 10 mg once daily
89609455|NCT01966445|Experimental|GSK2849330 Part 1|1 hour infusion administered intravenously at intervals of one week or more (escalating doses).
89609456|NCT01966445|Experimental|GSK2849330 Part 2|Intravenous infusion administered at the dose and schedule established in Part 1
89609457|NCT03809494|Experimental|Treatment Arm|Patients assigned to the treatment arm will be injected with autologous concentrated total nucleated cells (TNCs) three times at six week intervals.
89609458|NCT03809494|Placebo Comparator|Saline (Control Arm)|Patients assigned to the control arm will be injected with saline three times at six week intervals.
89609459|NCT04384042||Malaysian COVID-19 Cohort (Cases)|A cohort of COVID-19 positive patients will be recruited from participating Malaysian Ministry of Health-designated COVID-19 treating hospitals across the country.
89609460|NCT04384042||Healthy Volunteers (Controls)|A cohort of age and sex-matched healthy volunteers will be recruited from participating Malaysian Ministry of Health-designated COVID-19 treating hospitals across the country.
89210752|NCT00987519||Control group|Patients referred to pediatric surgery for elective surgical procedure - judged to be free of clinical signs and symptoms of infection.
89210753|NCT00727649|Active Comparator|Arm 1|Fiber (psyllium) powder
88983030|NCT05952206|Experimental|Xience stent family and abbreviated DAPT|"Acute coronary syndrome patients:~Need for OAC: TAT + OAC for one week. Double therapy composed of clopidogrel + OAC up to 6M.~No need for OAC: DAPT with acetylsalicylic acid + prasugrel or ticagrelor for 1 month. Only the same P2Y12 inhibitor up to 12M.~Chronic coronary syndrome patients:~Need for OAC: TAT + clopidogrel + OAC for one week. Double therapy composed of clopidogrel + OAC up to 6M.~No need for OAC: DAPT with acetylsalicylic acid + clopidogrel for one month. Only clopidogrel up to 12M."
88983031|NCT05952206|Active Comparator|Angiolite and standard of care DAPT|"Acute coronary syndrome patients:~Need for OAC: Recommendations of the current ESC guideline: 1M of TAT (acetylsalicylic acid + clopidogrel + OAC). Dual therapy (acetylsalicylic acid or clopidogrel + OAC) up to 12M. If ischemic concerns prevail, TAT can be extended up to 6M and dual therapy up to 12M.~No need for OAC: Recommendations of the current ESC guideline: DAPT with acetylsalicylic acid and prasugrel or ticagrelor is recommended up to 12M.~Chronic coronary syndrome:~Need for OAC: Recommendations of the current ESC guidelines: 1M of TAT (acetylsalicylic acid + clopidogrel + OAC). Dual therapy (acetylsalicylic acid or clopidogrel + OAC) up to 12M. If ischemic concerns prevail, TAT can be extended up to 6M and dual therapy up to 12M.~No need for OAC: Recommendations of the current ESC guidelines: DAPT composed of acetylsalicylic acid + clopidogrel up to 6M. Then, continue with acetylsalicylic acid."
89210754|NCT00727649|Active Comparator|Arm 2|Loperamide
89609461|NCT03809260|Experimental|Part 1|Metformin/Vancomycin
89609462|NCT03809260|Experimental|Part 2|Metformin
88983032|NCT05952206|Active Comparator|Xience stent family and standard of care DAPT|"Acute coronary syndrome patients:~Need for OAC: Recommendations of the current ESC guideline: 1M of TAT (acetylsalicylic acid + clopidogrel + OAC). Dual therapy (acetylsalicylic acid or clopidogrel + OAC) up to 12M. If ischemic concerns prevail, TAT can be extended up to 6M and dual therapy up to 12M.~No need for OAC: Recommendations of the current ESC guideline: DAPT with acetylsalicylic acid and prasugrel or ticagrelor is recommended up to 12M.~Chronic coronary syndrome:~Need for OAC: Recommendations of the current ESC guidelines: 1M of TAT (acetylsalicylic acid + clopidogrel + OAC). Dual therapy (acetylsalicylic acid or clopidogrel + OAC) up to 12M. If ischemic concerns prevail, TAT can be extended up to 6M and dual therapy up to 12M.~No need for OAC: Recommendations of the current ESC guidelines: DAPT composed of acetylsalicylic acid + clopidogrel up to 6M. Then, continue with acetylsalicylic acid."
89210755|NCT00987597|Experimental|cognitive behavioural approach|specific technique of cigarette exposure and nicotinic treatment adjustment
89210756|NCT00987597|Active Comparator|usual approach|recommendations and nicotinic substitutes
89210757|NCT00568334|Experimental|VARILRIX HSA-FREE GROUP|Healthy male or female children between, and including, 11 and 21 months of age, who received 2 doses of Varilrix™ vaccine produced without human serum albumin (HSA-Free), administered subcutaneously into the deltoid region of the left upper arm, at Day 0 and Day 43-57 (Week 6).
89609463|NCT01763905|Active Comparator|Ezetimibe (Q2W)|Participants received placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for up to 12 weeks.
89609464|NCT01763905|Active Comparator|Ezetimibe (QM)|Participants received placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.
89609465|NCT01763905|Experimental|Evolocumab Q2W|Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.
89609466|NCT01763905|Experimental|Evolocumab QM|Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks.
89609467|NCT02091167|Experimental|real tDCS|Ten sessions (every other day) of bilateral transcranial Direct Current Stimulation (tDCS: 2 milliamperes, 3 x 7 cm2, during 20 minutes) over dorsolateral Prefrontal Cortex (cathodal left / anodal right).
89609468|NCT02091167|Sham Comparator|sham-tDCS|Ten sessions (every other day) of placebo control (sham procedure) of transcranial Direct Current Stimulation (sham-tDCS) during 20 minutes with electrodes placed over the dorsolateral Prefrontal Cortex (cathodal left / anodal right). Current was delivered for 30 seconds and was turned off for the rest of the stimulation period. In this way, subjects experienced the initial itching sensation at the beginning of stimulation, but received no current for the rest of the session.
89609469|NCT03803254|Experimental|HAIC plus lenvatinib and PD-1 antibody|Hepatic arterial infusion chemotherapy plus lenvatinib and programmed cell death protein-1 antibody
89609470|NCT03803254|Active Comparator|HAIC plus lenvatinib|Hepatic arterial infusion chemotherapy plus lenvatinib
89609471|NCT02091089|Experimental|755nm Alexandrite laser|755nm Alexandrite laser for the treatment of wrinkles
89210758|NCT00568334|Experimental|VARILRIX GROUP|Healthy male or female children between, and including, 11 and 21 months of age, who received 2 doses of Varilrix™ vaccine, administered subcutaneously into the deltoid region of the left upper arm, at Day 0 and Day 43-57 (Week 6).
89217996|NCT05277506|Experimental|smile arc protection bonding strategy group|female patients with mild crowding will recieve orthodontic brackets bonding using smile arc protection bonding strategy
89609472|NCT03803176||Periodontally healthy subjects|Healthy subjects who attended the restorative dental clinic and have clinically healthy gingiva with zero plaque index (PI), gingival index (GI), and CAL (≤3 mm PD). Oral hygeine instructions will be given to these patients.
89609473|NCT03803176||Chronic Periodontitis|Patients with severe Chronic Periodontitis having a pocket depth (PD) of ≥5 mm and a clinical attachment level (CAL) ≥5 mm. Open flap debridement (surgical periodontal therapy) will be carried out for these patients after scaling & root planing.
89609474|NCT04730999|Experimental|Single Arm|"Induction phase (6 cycles, 21 days duration): carboplatin, etoposide, bevacizumab and atezolizumab.~Maintenance phase (12 cycles, 21 days duration): bevacizumab and atezolizumab"
89609475|NCT00759772|Active Comparator|Teriparatide|
89609476|NCT00759772|Placebo Comparator|Placebo|
89609477|NCT01763203|Experimental|Care Management+Community Health Worker|Care management
89609478|NCT01763203|Active Comparator|Usual Care|Written materials
88983033|NCT05952193||seniority ≥3 years + POSOS|
89609479|NCT00771238|Experimental|P500 Mattress|The new P500 Low Air Loss mattress will be used to replace the standard mattress for this study arm.
89609480|NCT00771238|No Intervention|Standard of Care Mattress|Cardiovascular ICU patients that receive standard of care mattress (Total Care Treatment Mattress) and standard pressure ulcer prevention care. All patients had daily skin assessments, as per normal care.
89609481|NCT03809416|No Intervention|Control|32 biopsy specimens from acne scars will be excised without any treatment.
89609482|NCT03809416|Sham Comparator|Lasers plus Normal Saline Solution|32 biopsy specimens will be excised immediately after being treated with lasers and subsequent injection of normal saline solution.
89609483|NCT03809416|Active Comparator|Lasers plus Platelets Rich Plasma (PRP)|32 biopsy specimens will be excised immediately after being treated with lasers and subsequent injection of platelets Rich Plasma (PRP).
89609484|NCT03802942|Experimental|Glucerna|2 bottles of Glucerna per day (237 ml per bottle for a total of 474 ml/d) on top of the meal plan supplied by the hospital.
89609485|NCT03802942|No Intervention|Control|Regular meal plan supplied by the hospital
89609486|NCT01763047|Active Comparator|etafilcon A/lotrafilcon B|Subjects were randomized to one of two lens wear sequences. Subject randomized to this sequence first wore the etafilcon A lens and then wore the lotrafilcon B lens.
89609487|NCT01763047|Active Comparator|lotrafilcon B/etafilcon A|Subjects were randomized to one of two lens wear sequences. Subject randomized to this sequence first wore the lotrafilcon B lens and then wore the etafilcon A lens.
89609488|NCT04384120|Experimental|Rotator Cuff Rehabilitation Using BFR|"Patients with rotator cuff tears who plan for either nonoperative treatment with physical therapy or operative treatment with arthroscopic rotator cuff repair (RCR) surgery will be randomized to undergo rehabilitation using blood flow restriction cuffs.~Patients who elect for nonoperative treatment of their rotator cuff tear will undergo traditional therapy using blood flow restriction cuffs.~Patients who elect for RCR will undergo preoperative and postoperative traditional therapy using blood flow restriction cuffs."
89609489|NCT04384120|Active Comparator|Rotator Cuff Rehabilitation Without BFR|"Patients with rotator cuff tears who plan for either nonoperative treatment with physical therapy or operative treatment with arthroscopic rotator cuff repair (RCR) surgery will be randomized to undergo rehabilitation without using blood flow restriction cuffs.~Patients who elect for nonoperative treatment of their rotator cuff tear will undergo traditional therapy without using blood flow restriction cuffs.~Patients who elect for RCR will undergo preoperative and postoperative traditional therapy without using blood flow restriction cuffs."
88983034|NCT05952193||seniority ≥3 years without POSOS|
88983035|NCT05952193||seniority <3 years with POSOS|
88983036|NCT05952193||seniority <3 years without POSOS|
89609490|NCT03809338||flight attendant women|Assesment antral follicle count on day 3 5ml blood sample to be taken
89609491|NCT03809338||day working women|Assesment antral follicle count on day 3 5ml blood sample to be taken
89609492|NCT01977677|Experimental|Treatment (radiation therapy, temozolomide, plerixafor)|Within 4 weeks of surgery, patients undergo radiation therapy and receive temozolomide PO over 42 days. Beginning 8 days prior to completion of chemoradiotherapy, patients receive plerixafor IV continuously for 2-4 weeks. Patients also receive temozolomide PO 5 days a month beginning 35 days after completion of radiation therapy.
89609493|NCT01762345|Experimental|pessary device|pessary (disposable intra-vaginal device)
89609494|NCT04384744||GH-POR|Participants diagnosed POR according to POSEIDON criteria with low ovarian reserve undergo IVF in our center with long protocol or antagonist protocol and is adjuvant with GH 2IU/d from previous menstrual period for about six weeks.
89609495|NCT04384744||NGH-POR|Participants diagnosed POR according to POSEIDON criteria with low reserve undergo IVF in our center with long protocol or antagonist protocol without GH adjuvant.
89609496|NCT04384744||NGH-NOR|Participants with normal ovarian reserve undergo IVF in our center with long protocol or antagonist protocol without GH adjuvant.
89609497|NCT02090855||Flutemetamol (18F)|There are no interventions in this study. This study is to assess the images taken previously from another study, GE-067-007.
89609498|NCT03803020||single coronary chronic total occlusion|"symptomatic stable angina of single coronary chronic total occlusion without other coronary artery stenosis scheduled for elective PCI.~fractional flow reserve and SPECT detection before and after intervention."
89609499|NCT01761565|Experimental|Single dose of SUF NT 15 mcg then 40 doses of SUF NT 15 mcg|"Period 1: Single dose of SUF NT 15 mcg~Period 2: 40 consecutive doses of SUF NT 15 mcg taken every 20 minutes"
89609500|NCT04385056|Experimental|Low Dose MSCTC-0010|Participants will receive low-dose cell administration
89609501|NCT04385056|Experimental|Medium Dose MSCTC-0010|Participants will receive medium-dose cell administration
88983037|NCT05952154|Experimental|Nonbstructive Hypertrophic Cardiomyopathy|Transapical beating-heart septal myectomy for the patient with nonobstructive hypertrophic cardiomyopathy and Heart Failure.
89057767|NCT01685970|Active Comparator|2 sachets of picosulfate|Patients who are scheduled afternoon colonoscopy ingest 2 sachets of picosulfate at the day of colonoscopy.
88983038|NCT05952128|Experimental|Fluzoparib+ Dalpiciclib|Fluzoparib in combination with Dalpiciclib
88983039|NCT05952115|Experimental|lumbar motor control exercises|patients will receive lumbar motor control and cervical stabilization exercises three times a week for four weeks
88983040|NCT05952115|Active Comparator|cervical stabilization exercises|the patients will receive cervical stabilization exercises three times a week for four weeks
88983041|NCT05952102|Experimental|52 children with community acquired pneumonia will receive Nigella sativa oil capsules|52 children with community-acquired pneumonia will receive Nigella sativa oil in capsules at a dose of 40 mg/kg/day (8), as an adjunct therapy to the usual pneumonia treatment till the recovery of the disease.
88983042|NCT05952102|No Intervention|52 children|52 children with community-acquired pneumonia with the usual pneumonia treatment as a control group
88983043|NCT05952050|Experimental|Intranasal dexmedetomidine|
88983044|NCT05952050|Active Comparator|Intravenous dexmedetomidine|
88983045|NCT05951933|Experimental|Strenghtening + a-TES real|Protocol of therapeutic exercises + real transcranial electrical stimulation of 8 weeks duration (24 supervised sessions). The program will consist of exercises to strengthen the RM and the scapulothoracic muscles, but the EG will perform the RM strengthening exercises while receiving real a-tDCS.
89609502|NCT04385056|Experimental|High Dose MSCTC-0010|Participants will receive high-dose cell administration
89609503|NCT04576741|Experimental|bMBI standard practice|This is a 12-week online mindfulness-based course blended with therapist support via video link using standard practices for Mindfulness-Based Cognitive Therapy (30-minutes/day).
89609504|NCT04576741|Experimental|bMBI shorter more frequent practice|This is a 12-week online mindfulness-based course blended with therapist support via video link using shorter, more frequent practice than standard Mindfulness-Based Cognitive Therapy (2x15-minutes/day).
89609505|NCT01619579|Experimental|Treatment|Subjects with Fibromyalgia undergo twice daily use of the non-invasive device for 4 weeks.
89609506|NCT01736215||Participants with cancer related anemia|Participants with cancer related anemia receiving chemotherapy will be observed for response to erythropoietin treatment.
89609507|NCT04384900|Experimental|Accelerated prone position|Prone position ventilation initiated as soon as possible following intubation. The patients are maintained in a prone position for 12-16 hrs daily for 5 days, unless one of the following criteria are met: Substantial improvement and/or imminent extubation, Worsening oxygenation with prone position, Serious Adverse Reactions (SARs) occurring during a prone session and leading to its immediate interruption. Following the five day intervention period, prone position ventilation will be continued according to the intervention in the control group
89609508|NCT04384900|Active Comparator|Standard prone position|Standard of care: Prone position applied according to standard indications (severe ARDS not improving with 12-24 hours of mechanical ventilation with PaO2-to-FiO2 ratio (PAF) < 150 mmHg with FiO2 of ≥0.6, a positive end-expiratory pressure (PEEP) of ≥5 cm of water, and a tidal volume of about 6 ml per kilogram of predicted body weight). Until one of the following are met: Substantial improvement and/or imminent extubation, Worsening oxygenation with prone position, Serious Adverse Reactions (SARs) occurring during a prone session and leading to its immediate interruption.
89609509|NCT03808714|Active Comparator|Intervention|We expect the intervention to consist of 3 to 4 group sessions and at least one individual session (delivered by a trained Community Health Worker) plus pharmacological consultation(s) via telemedicine, but this will be determined during pretesting.
89609510|NCT03808714|Active Comparator|Control|"Alabama Tobacco Quitline, which is considered the standard-of-care for smoking cessation in Alabama."
89609511|NCT01786603|Experimental|Rasagiline|Rasagiline 1mg administered orally as a 2mg single dose once daily for 12 months.
89609512|NCT01786603|Placebo Comparator|Placebo|Inactive ingredient equal to 1mg rasagiline 2mg administered as a single dose once daily for 12 months.
89609513|NCT00786916|Placebo Comparator|Group A|Saline
89609514|NCT00786916|Active Comparator|Group B|Lidocaine 0.25 mg/kg
89609515|NCT00786916|Active Comparator|Group C|Lidocaine 0.5 mg/kg
89609516|NCT03802708|Other|control|control
89609517|NCT04414267|Experimental|BCG vaccine|One intradermal injection of 0.1ml of BCG (BCG vaccine Moscow strain 361-1; Serum Institute of India Pvt. Ltd)
89609518|NCT04414267|Placebo Comparator|Placebo|One intradermal injection of 0.1ml of sodium chloride 0.9%
89609519|NCT01619423|Active Comparator|FOLFOX6 + PledOx 2 µmol/kg|PledOx active ingredient= Calmangafodipir; FOLFOX6=Combination of FOLinic Acid, 5-Fluorouracil (5-FU), and Oxaliplatin.
89609520|NCT01619423|Active Comparator|FOLFOX6 + PledOx 5 µmol/kg|PledOx active ingredient= Calmangafodipir; FOLFOX6=Combination of FOLinic Acid, 5-Fluorouracil (5-FU), and Oxaliplatin.
89609521|NCT01619423|Active Comparator|FOLFOX6 + PledOx 10 µmol/kg|PledOx active ingredient= Calmangafodipir; FOLFOX6=Combination of FOLinic Acid, 5-Fluorouracil (5-FU), and Oxaliplatin.
89609522|NCT01619423|Placebo Comparator|FOLFOX6 + 0,9% NaCl|Placebo= 0.9% NaCl; FOLFOX6=Combination of FOLinic Acid, 5-Fluorouracil (5-FU), and Oxaliplatin.
89609523|NCT03802552|Experimental|Cefadroxil then Cephalexin|Receive cefadroxil first, then receive cephalexin after washout.
89609524|NCT03802552|Experimental|Cephalexin then Cefadroxil|Receive cephalexin first, then receive cefadroxil after washout.
89609525|NCT01735279|Placebo Comparator|Placebo|The placebo group will receive 3g per day of mineral oil during 90 days treatment
89609526|NCT01735279|Experimental|Omega3|The omega 3 group will receive 3g per day of fish oil during 90 days treatment
89609527|NCT03802786|Experimental|Moderate hepatic impairment|Single dose of Imeglimin
89609528|NCT03802786|Experimental|Normal hepatic function|Single dose of Imeglimin
89609529|NCT03808792||Ovarian cancer patients|Patients with abdominal or pelvic mass suspicious of primary ovarian, tubal or peritoneal cancer submitted to the index test (Ultrasound, CT and WB/DWI-MRI) with perspective of primary surgery
89609530|NCT01759381|No Intervention|No Negative Pressure Wound Therapy Device|This control group will not receive the negative pressure wound therapy device. Post operative dressings will be per the surgeon's standard routine.
89609531|NCT01759381|Experimental|NPWT Arm Therapy|This group will receive NPWT as opposed to the standard incisional dressing following complex spinal surgery.
89609532|NCT03802318|Experimental|HDDT group|high dose PPI induction (oral rabeprazole 20mg qid) for 3 days, then 14 days combined with amoxicillin (regular dose, daily 2 g, 500mg qid) for high frequency dual therapy.
89609533|NCT03802318|Placebo Comparator|CATT group|conventional triple therapy 14 days (rabeprazole 20 mg bid, amoxicillin 1 g bid, clarithromycin 500 mg bid)
89609534|NCT03802318|Experimental|LHDT group|high dose PPI (oral rabeprazole 20mg qid) induction for 3 days, then Rabeprazole 20 mg qid, amoxicillin 500 mg qid, levofloxacin 500 mg qd for 14 days.
89609535|NCT03802318|Placebo Comparator|LATT group|levofloxacin base rescue therapy 14 days (rabeprazole 20 mg bid, amoxicillin 1 g bid, levofloxacin 500 mg qd)
89609536|NCT04662671|Experimental|RD-X19 Device|Experimental device that uses safe electromagnetic energy to stimulate the proximal repository of respiratory tract infectious disease pathogens.
89609537|NCT04662671|Sham Comparator|Sham Device|Investigational device that uses safe electromagnetic energy to target the oropharynx but at energy levels with a lower inactivation potential against SARS-CoV-2 in vitro.
89609538|NCT01758523|Experimental|dutasteride|4 mg oral loading dose of dutasteride followed by 1 mg/day dutasteride for 12 weeks.
89609539|NCT01758523|Placebo Comparator|Sugar Pill|Placebo pills prepared to appear the same as active medication and taken in the same number as active medication for 12 weeks.
89609540|NCT00773422|Experimental|naltrexone + varenicline|naltrexone (25mg) + varenicline (2mg)
89033654|NCT06022900|Experimental|Face-to-face training group|In addition to the standard breast cancer screening program service, the participants in this group were given face-to-face health education about breast cancer and prevention of breast cancer through home visits, and a training brochure was given. At the end of the fourth week from the day they were assigned to the study, they were called by phone and the participants were reminded in line with the summary information about the importance of screening.
89609541|NCT00773422|Experimental|varenicline|varenicline 2mg
89609542|NCT00773422|Placebo Comparator|placebo|placebo control
89609543|NCT01758289||Paricalcitol IV|Eligible participants with diagnosis of chronic kidney disease stage V undergoing hemodialysis, treated with paricalcitol IV per routine clinical practice according to prescribing information approved in Venezuela and clinical criteria.
89609544|NCT00786994|Experimental|1|Oleogel-S10 100 mg/g ointment for three months once a day (54 patients)
89609545|NCT00786994|Experimental|2|Oleogel-S10 100 mg/g ointment for three months twice a day (54 patients)
89609546|NCT00786994|Placebo Comparator|3|Placebo (petroleum jelly) for three months once a day (27 patients)
89609547|NCT00786994|Placebo Comparator|4|Placebo (petroleum jelly) for three months twice a day (27 patients)
89609548|NCT01757821|Experimental|6-Hz Priming|real 6-Hz primed low-frequency rTMS
89609549|NCT01757821|Sham Comparator|Sham 6-Hz Priming|Sham 6-Hz Primed low-frequency rTMS
89609550|NCT01757821|Active Comparator|Real 1-Hz rTMS only|real 1-Hz rTMS only
89609551|NCT03808636||TB patients|Any patient with possible or diagnosed tuberculosis who is capable to give informed consent will be offered to be included in the trial
89609552|NCT00774202|Active Comparator|Rituximab, Cyclophosphamide, Vincristine, Prednisone|"'Standard Dose of Rituximab administered with C, V, P (CVP)'~Interventions: Rituximab will be administered as an IV infusion at the standard dose of 375 mg/m2 for 4 doses at standard rates and use of premedication. The schedule will be to give the first rituximab infusion 5 days (± 3 days) prior to first administration of CVP, and the following 3 infusions will be given on the same day as the 3 cycles of C, V, P. On those days, the IV Cyclophosphamide and Vincristine will be given first so that the administration of fluids with the rituximab can be used as post-cyclophosphamide hydration, Cyclophosphamide dosing will be 750mg/m2 (maximum 2000mg), vincristine 1.4 mg/m2 (up to 1.6 mg), prednisone 100mg po daily for 5 days."
89609553|NCT00774202|Active Comparator|Higher Dose of Rituximab|In this arm, Rituximab will be administered at a dose of 750 mg/m2 once a week x 4 consecutive weeks (4 infusions in total). We will perform EKG monitor tracings before, during and after Rituxan infusions. This will be a single-lead tracing that will allow us to look at the Q-T interval.
89609554|NCT01735201|Experimental|AGN-199201 Dose A Once Daily|AGN-199201 Dose A applied once daily to the face for 28 days.
89609555|NCT01735201|Experimental|AGN-199201 Dose B Once Daily|AGN-199201 Dose B applied once daily to the face for 28 days.
89609556|NCT01735201|Experimental|AGN-199201 Dose C Once Daily|AGN-199201 Dose C applied once daily to the face for 28 days.
89033655|NCT06022874||Patient's Diagnosed with Atopic Dermatitis|Patient's Diagnosed with Atopic Dermatitis
89033656|NCT06022848|Experimental|Quantitative sensory testing|
89033657|NCT06022835|Experimental|Chlorhexidine Gluconate-gel (CHG) Dressing group|Participants used Tegaderm™ CHG dressing for 4 months. The dressing was changed every seven days or soiled.
89033658|NCT06022796|Experimental|Healthy Ketogenic Ready-To-Eat (HK-RTE) Meals|"Participants in the HK-RTE group (n=25) will be provided with the Healthfull meals for lunch and dinner in the first month. They will be advised to take these meals as part of a healthy ketogenic diet, with a maximum of 50g total net carbohydrates daily.~Participants will receive nutrition education conducted by dietitians over the course of 6 months (total of 5 dietary workshops covering topics such as ketogenic dietary advice and self-monitoring habits). Participants will also receive health coaching via the Nutritionist Buddy (nBuddy) mobile application to facilitate monitoring of diet intake, physical activity and weight throughout the 6 months study period."
89033659|NCT06022796|Active Comparator|Healthy Ketogenic Diet (HKD)|"Participants in the reference group will be instructed to follow a Healthy Ketogenic Diet (n = 25), with a maximum of 50g total net carbohydrates daily.~Similar to the experimental group, participants will receive nutrition education conducted by dietitians over the course of 6 months (total of 5 dietary workshops such as ketogenic dietary advice and self-monitoring habit). Participants will also receive health coaching via the Nutritionist Buddy (nBuddy) mobile application to facilitate monitoring of diet intake, physical activity and weight throughout the 6 months study period."
89033660|NCT06022783|Experimental|with VR-G|The nurses in this procedure were asked to watch a relaxing video with using VR-G for 20 minutes at their break time.
89609557|NCT01735201|Placebo Comparator|AGN-199201 Vehicle Once Daily|AGN-199201 Vehicle applied once daily to the face for 28 days.
89609558|NCT01735201|Experimental|AGN-199201 Dose A Twice Daily|AGN-199201 Dose A applied twice daily to the face for 28 days.
89609559|NCT01735201|Experimental|AGN-199201 Dose B Twice Daily|AGN-199201 Dose B applied twice daily to the face for 28 days.
89609560|NCT01735201|Experimental|AGN-199201 Dose C Twice Daily|AGN-199201 Dose C applied twice daily to the face for 28 days.
89609561|NCT01735201|Placebo Comparator|AGN-199201 Vehicle Twice Daily|AGN-199201 Vehicle applied twice daily to the face for 28 days.
89609562|NCT03808324|Experimental|Heart transplant recipients|
89609563|NCT01734811|Placebo Comparator|Placebo|The subjects will receive daily placebo spray (2 puff of 100 µL) for 6 months, followed by other 6 months of observation
89609564|NCT01734811|Experimental|Biological vaccine|The subjects will receive daily biological vaccines pray (2 puff of 100 µL) of for 6 months, followed by other 6 months of observation
89609565|NCT03802006||fasted patient with previous gastrectomy|The fasted patient with previous subtotal gastrectomy except exclusion criteria are included
89609566|NCT03808168|Active Comparator|Arm 1|Nivolumab, 3 mg/kg Iv, day 1
89609567|NCT03808168|Active Comparator|Arm 2|Nivolumab, 3 mg/kg IV, days 1, 15, 29
89609568|NCT03802162|Experimental|CKD-355A|
89609569|NCT03802162|Experimental|CKD-355B|
89609570|NCT03802162|Active Comparator|D797, D324|
89609571|NCT01757275|Experimental|Esomeprazole|
89609572|NCT01757275|Active Comparator|Cimetidine|
89609573|NCT00787852|Experimental|Group 1: Radiation, Paclitaxel, Carbo, Dasatinib days 1-47|"Locally Advanced Stage III NSCLC DAY Radiation 1-5 8-12 15-19 22-26 29-33 36-40 43-47 Paclitaxel 1 8 15 22 29 36 43 Carboplatin 1 8 15 22 29 36 43 Dasatinib & Maintenance Dasatinib RT: External radiotherapy, 64.8 Gy, for 35 fx Paclitaxel: 50 mg/m2/week over 1 hour IV infusion days 1, 8, 15, 22, 29, 36, 43 Carboplatin: AUC = 2 IV infusion days 1, 8, 15, 22, 29, 36, 43~Dasatinib is to be taken 1x daily~50 mg daily 100 mg daily~70 mg daily 100 mg daily~100 mg daily 100 mg daily~Maintenance x 2 years*"
89609574|NCT00787852|Experimental|Group 2: Radiation, Paclitaxel, carbo, Dasatinib days 1-38|"Group 2: Neoadjuvant Therapy for Potentially Resectable Stage III NSCLC SCHEMA DAY Radiation 1-5 8-12 15-19 22-26 29-33 36-38 Paclitaxel 1 8 15 22 29 36 Surgery Carboplatin 1 8 15 22 29 36 Dasatinib & Maintenance Dasatinib RT: External radiotherapy 50.4 Gy, 1.8 Gy/fx for 28 fx Paclitaxel: 50 mg/m2/week over 1 hour IV infusion days 1, 8, 15, 22, 29, 36 Carboplatin: AUC = 2 IV infusion days 1, 8, 15, 22, 29, 36~Dasatinib is to be taken 1x daily~50 mg daily 100 mg daily~70 mg daily 100 mg daily~100 mg daily 100 mg daily Maintenance x 2 years*"
89609575|NCT01757197|Experimental|All Patients|Toclizumab will be administered on Day 0. The administration of tocilizumab will be every 2 weeks for a total of 8 doses.
89609576|NCT00788008|Active Comparator|1|Inhalational anesthesia with isoflurane
89609577|NCT00788008|Active Comparator|2|total intravenous anesthesia with propofol
89609578|NCT00760006|Active Comparator|Unasyn Antibiotic Arm|Unasyn® is a parenteral antibiotic that combines ampicillin with sulbactam, a beta-lactamase inhibitor. All subjects enrolled in the study will receive a single dose of antibiotic or saline solution (placebo control) intravenously, as the IV will already be in place as standard of care for surgery. The study aims to assess the efficacy of the prophylactic antibiotic in cleft surgery to: decrease the incidence of surgical site infections, speed the progression of postoperative healing, improve the final quality of wound healing achieved, and decrease the rate of palatal fistula formation.
88983046|NCT05951933|Sham Comparator|Strenghtening + a-TES placebo|Protocol of therapeutic exercises + placebo transcranial electrical stimulation of 8 weeks duration (24 supervised sessions). The program will consist of exercises to strengthen the RM and the scapulothoracic muscles, but the CG will perform the RM strengthening exercises while receiving placebo a-tDCS.
88983047|NCT05951907|Active Comparator|control group|A control group in which the extraction of the maxillary premolar's teeth was carried out under buccal and palatal infiltration anesthesia with 1.8 mL 2% lidocaine hydrochloride with 1:80,000 epinephrine.
88983048|NCT05951907|Experimental|study group|A study group in which the extraction of the maxillary premolar's teeth proceeded under buccal without palatal infiltration anesthesia with 1.8 mL, 4% articaine hydrochloride with 1:100,000 epinephrine.
88983049|NCT05951868|Experimental|Continuum of support on breastfeeding|"Content of counselling intervention will be on ideal breast feeding practices,benefits of breastfeeding, weaning, myths & common problems faced during breastfeeding with their solutions,Latching techniques,feeding positions, ways to express milk & storage techniques. Discussion and Q&A session~Women with her female family member of support invited for antenatal visit will be counselled by a trained doctor on breastfeeding in 2 -sessions between 32 & 40 weeks of gestation.~Readable booklet & whats app videos having same content in local Urdu language will be shared with the women during antenatal visit and at discharge from hospital.~At time of delivery skin to skin contact, early initiation, proper latching ,positioning and reemphasising on exclusive breastfeeding done by a trained nurse.~Follow up by trained community lady health workers to visit mothers home to reinforce learned information and support mothers at 0,1,2 weeks & 1,3,4,6 months"
88983050|NCT05951868|No Intervention|Control group/Routine care|The control group will receive routine care in terms of routine counselling done on breastfeeding in the hospital & when mothers at home by lady health workers.
88983051|NCT05951855|Experimental|Selinexor combined with chidamide|R/R AML who are ineligible for intensive chemotherapy will receive selinexor in combination with chidamide, 28 days per cycle, Selinexor will be used as 40 or 60mg BIW for two weeks, and chidamide will be used as 10mg/d from day 1 to 28. Depending on the level of recovery, patients will either be forced to come off study or have the option to continue the medication, receive maintenance therapy, or pursue an allogeneic stem cell transplant.
88983052|NCT05951842|Active Comparator|TIVA group|"In TIVA group, anesthesia will be maintained by propofol and remifentanil infusion under target controlled infusion.~Other names: fresofol MCT 1% inj®; Fresenius kabi, Seoul, Korea, Ultian inj®; Hanlim, Seoul, Korea"
88983053|NCT05951842|Experimental|Balanced anesthesia group.|"Anesthesia will be maintained by sevoflurane and remifentanil infusion in the balanced anesthesia group.~Other names: Sojourn®, Kyongbo, Seoul, Korea, Ultian inj®; Hanlim, Seoul, Korea,"
89609579|NCT00760006|Placebo Comparator|Saline Placebo Arm|Saline Placebo. All subjects enrolled in the study will receive a single dose of antibiotic or saline solution (placebo control) intravenously, as the IV will already be in place as standard of care for surgery. This will act as the placebo control.
88983054|NCT05951829|Other|Cerebral Palsy|
89609580|NCT01784965|Placebo Comparator|placebo|Both groups receive dietary weight loss intervention In addition one group received liraglutide and one group received placebo
89033661|NCT06022783|No Intervention|no VR-G|The nurses in this procedure did not watch any video and completed their routine working shift and break times.
89609581|NCT01784965|Active Comparator|liraglutide|Both groups receive dietary weight loss intervention In addition one group received liraglutide and one group received placebo
89609582|NCT05742724|Experimental|THC/CBD|Oral THC 0.1mg/kg and CBD 2.5mg/kg
89609583|NCT01784419|Experimental|ivacaftor-placebo|The ivacaftor-placebo arm receives a 2 week course of ivacaftor 150 mg twice daily followed by a 2 week washout period followed by a 2 week placebo course.
89609584|NCT01784419|Experimental|placebo-ivacaftor|The placebo-ivacaftor arm receives a 2 week placebo course followed by a 2 week washout period followed by a 2 week course of ivacaftor 150 mg twice daily.
89609585|NCT03801850|Experimental|observational cohort|
89609586|NCT03808246|Experimental|naive/realistic environment|"This arm includes included participants who are naive in terms of self-injector pens and who have been randomly attributed to the realistic environment condition of simulation.~The intervention is using the demo version of a self-injector pen."
88983055|NCT05951816|Experimental|Estimation of dosimetry for 99mTc-p5+14 and Biodistribution Of 99mtc-p5+14 In Healthy Subjects|"For dosimetry, patients with a confirmed diagnosis of systemic AL amyloidosis, patients will be administered a single IV dose of up to 1 mg of 99mTc-p5+14 (~20 mCi) by slow push (~1 mL/5 sec.). Patients will then undergo serial planar scintigraphic imaging at ~30 minutes, ~1 hour, ~2 hours, ~4 hours, ~6 hours, and ~24 hours post-injection. At the 4-hour time point, the patient will also undergo a single SPECT/CT scan to provide additional data for estimating dosimetry. Before injection of the radiotracer and at each imaging session, ~2 -3 mL of blood will be acquired to determine the whole blood radioactivity.~Healthy volunteers will undergo an echo examination, thereafter, they will be administered a single IV dose of 99mTc-p5+14 (20 mCi) and will undergo a single planar image acquisition followed by SPECT/CT imaging at ~1 hour and ~3 hours post-injection."
89033662|NCT06022770|No Intervention|Nutritional Counseling|
89033663|NCT06022770|Experimental|Nutrition Support Therapy|
89033664|NCT06022744|Experimental|LX109|
89033665|NCT06022731||Filling|
89609587|NCT03808246|Experimental|informed/realistic environment|"This arm includes included participants who are informed in terms of self-injector pens and who have been randomly attributed to the realistic environment condition of simulation.~The intervention is using the demo version of a self-injector pen."
89609588|NCT03808246|Experimental|informed/laboratory-like environment|"This arm includes included participants who are informed in terms of self-injector pens and who have been randomly attributed to the laboratory-like environment condition of simulation.~The intervention is using the demo version of a self-injector pen."
89609589|NCT03808246|Experimental|naive/laboratory-like environment|"This arm includes included participants who are naive in terms of self-injector pens and who have been randomly attributed to the laboratory-like environment condition of simulation.~The intervention is using the demo version of a self-injector pen."
89609590|NCT01784029|Experimental|Low Dose|"VItamin D3 1,000 IU~1 x day, 8 weeks"
89609591|NCT01784029|Experimental|Weekly High Dose|"Vitamin D3 50,000 IU~1x week, 8 weeks"
89609592|NCT01784029|Experimental|Daily High Dose|"Vitamin D3 5,000 IU~1x day, 8 weeks"
89609593|NCT00789256|Experimental|Study treatment|All patients will receive the following regimen: 1) Melphalan 2 mg orally, once daily. 2) Bortezomib 1.0 mg/M2 IV on days 1, 4, 8, 11.
89609594|NCT01733329|Experimental|Misoprostol|women with risk factors for uterine atony who underwent cesarean delivery were assigned randomly to 400 mcg misoprostol (2 tablets) (n=60) placed in buccal space after umbilical cord clamping by anesthesiologist. The primary outcome variables were the need for additional uterotonic agents, estimated blood loss and uterine atony.
89609595|NCT01733329|Placebo Comparator|Folic Acid|women with risk factors for uterine atony who underwent cesarean delivery were assigned randomly to 10 mg Folic acid (2 tablets) (n=60) placed in buccal space after umbilical cord clamping by anesthesiologist. The primary outcome variables were the need for additional uterotonic agents, estimated blood loss and uterine atony.
89609596|NCT01783483|Active Comparator|Suture Wire|The closure technique should be per surgeon and institutional preference, with documentation of the wiring technique including the wiring configuration and number of wires used. A minimum of 6 wires that cross the midline sternotomy should be used (e.g. 6 simple wires, 3 double wires, 3 figure of 8 wires, etc.).
89609597|NCT01783483|Experimental|SternaLock Blu closure system|"Patients will receive treatment option for sternal closure with the SternaLock Blue closure system at a minimum of 2 X plates on the sternal body and 1 L plate (or equivalent) on the manubrium. This technique is the standard configuration for this study, and is intended to ensure that at least 3 plates are used to achieve adequate fixation and stability, while allowing for variations in the plating configuration as a result of patient anatomy and surgeon preference. Various Sternal Blu plates may be used on the manubrium as described below, as can an additional plate on the sternal body."
89609598|NCT02145676|Experimental|onabotulinumtoxinA 500U|OnabotulinumtoxinA 500U injected into predefined muscles of the study limb on Day 1.
89609599|NCT02145676|Experimental|onabotulinumtoxinA 300U|OnabotulinumtoxinA 300U injected into predefined muscles of the study limb on Day 1.
89609600|NCT02145676|Placebo Comparator|placebo (normal saline)|Placebo (normal saline) injected into predefined muscles of the study limb on Day 1.
89609601|NCT01607593||sertraline (Zoloft)|
89609602|NCT00789724|Experimental|Anakinra|Anakinra 100 mg given daily by subcutaneous injection for 14 days
89609603|NCT00789724|Placebo Comparator|Placebo|0.67 ml of NaCl 0.9% solution
89609604|NCT01755637|Experimental|Albendazole tablet (Aqua Based)|Albendazole tablets 400 milligram (mg) manufactured under aqua based solvent condition taken orally with 200 millilitre (mL) of water as single dose treatment.
89609605|NCT01755637|Active Comparator|Albendazole tablet (Alcohol Based)|Albendazole tablets 400 mg manufactured under ethanol based solvent condition taken orally with 200 mL of water as single dose treatment.
89609606|NCT03801538|Experimental|PEG-IFN group|"patients were treated with NAs once a day and PEG-IFN once a week for 12 weeks. At week 12, the decrease of HBsAg was evaluated.~①If the decrease of HBsAg is more than 50%. NAs was stopped. PEG-IFN Treatment was continued for a prolonged period (no more than 96 weeks) until the endpoint was achieved, or terminated in week 96.~②If the decrease of HBsAg is less than 50%.NAs and PEG-IFN was extended to week 24. Then, If the decrease of HBsAg is more than 50%. NAs was stopped, PEG-IFN Treatment was continued for a prolonged period (no more than 96 weeks) until the endpoint was achieved, or terminated in week 96. If the decrease of HBsAg is less than 50%. PEG-IFN was stopped, patients were treated with NAs once a day and then followed up for 48 weeks."
89609607|NCT03801538|Other|NAs group|CHB patients do not need to change their NAs treatment.
89609608|NCT03801226|Experimental|10% dextrose in sterile water|Patients randomized to this arm will undergo a two-hour dwell with 10% dextrose in sterile water at their first visit and Dianeal Low-Calcium with 4.25% Dextrose at their second visit.
89609609|NCT03801226|Active Comparator|Dianeal Low-Calcium with 4.25% Dextrose|Patients randomized to this arm will undergo a two-hour dwell with Dianeal Low-Calcium with 4.25% Dextrose at their first visit and 10% dextrose in sterile water at their second visit.
89033666|NCT06022731||Overhanging Filling|
89057768|NCT04530617|Active Comparator|Camostat mesilate|100 mg tablet, 600 mg/day. Oral, 2 tablets three times a day, after a meal (600 mg total daily dose) Days 1-14.
89057769|NCT04530617|Placebo Comparator|Camostat Placebo|Matched placebo
89057289|NCT04541615|Active Comparator|Group 1: Online didactic to proficiency PBP+|Group 1 Pre-trained group will receive information on how to optimally perform the ORSI chicken anastomosis task and the material will be delivered online via the ORSI e-learning platform. They will be given access to the material two weeks before their training. Unlike the other groups, Group 1 will be required to study the material to a pre-defined performance benchmark or proficiency level. Once the online course is completed, participants have to perform the orsi chicken anastomosis task.
89609610|NCT02145754|Active Comparator|MKP media versus BSK-H media|one half of skin specimen obtained from erythema migrans patients was cultivated for Borrelia burgdorferi sensu lato in MKP media and the other half in BSK-H media
89609611|NCT03837808|Experimental|Nimotuzumab|nimotuzumab 200mg/week in concurrent with IMRT
89609612|NCT03837808|Active Comparator|Cisplatin|cisplatin 40mg/m2/week in concurrent with IMRT
89609613|NCT05741398|Experimental|Demaod VR system tratment|Non-invasive light pulse generated by a non-contacting device for treating the symptoms of dry eyes and MDG.
89609614|NCT05739838|Experimental|Periodontally compromised patients subjected to low level laser therapy|periodontally compromised patients with pocket depth of more than 5 mm before receiving nonsurgical periodontal treatment treatment or/and pocket depth of less than 4 mm with periodontal status identified as stable for at least 3 month after nonsurgical periodontal treatment subjected to low-level laser of 940 nm will be applied at day one after start of treatment , weekly during the first month, then monthly.
89609615|NCT05739838|No Intervention|Periodontally compromised patients|periodontally compromised patients with pocket depth of more than 5 mm before receiving nonsurgical periodontal treatment treatment or/and pocket depth of less than 4 mm with periodontal status identified as stable for at least 3 month after nonsurgical periodontal treatment.
89609616|NCT03801070||Less than median number necrosectomies|Group one includes patients who underwent less than median number necrosectomies
89609617|NCT03801070||At least the median number of necrosectomies|Group two includes patients who underwent at least the median number of necrosectomies
89609618|NCT05596708|Experimental|Telitacicept treated group|
89609619|NCT01732549|Experimental|Tasquinimod|1 capsule daily, taken orally with water and food (0.25 mg initially then dose escalated to 0.5 mg or 1 mg per day) until disease progression or toxicity or patient's willingness to stop.
89609620|NCT01732549|Placebo Comparator|Placebo|1 capsule daily, taken orally with water and food until disease progression or toxicity or patient's willingness to stop.
89609621|NCT04383964|Experimental|Transport distraction osteogenesis|"Locally made and designed submerged monodirectional in the vertical (Y) axis distractor was used.~A transport disc is created at the remaining stump of the RCU with an L shaped osteotomy.~The prepared disc is to be wide enough to fit the upper portion of the distrcator.~The submerged distractor will be placed in a position to guide the transport disc moving up and backwards toward the glenoid fossa.~The length of the distractor is determined according to the amount of distraction planned to reach the glenoid fossa."
89609622|NCT02148874||Flu Shot|pregnant women receive a seasonal influenza virus vaccination
89609623|NCT01755091|Placebo Comparator|Sugar Pill|Placebo, once per day (QD) by mouth, 60 minutes before bedtime for 6 weeks after 1-week run-in
89609624|NCT01755091|Experimental|2.5 mg/day|Dronabinol, 2.5 mg QD by mouth, 60 minutes before bedtime for 6 weeks after 1-week placebo run-in
89609625|NCT01755091|Experimental|10 mg/day|Dronabinol, 10 mg QD by mouth, 60 minutes before bedtime for 4 weeks after 1-week placebo run-in and 2-week dose escalation
89609626|NCT00789802|Experimental|transdermal estradiol|participants will be randomized to transdermal estradiol
89609627|NCT00789802|Experimental|oral naproxen|participants will be randomized to oral naproxen
89609628|NCT00789802|Placebo Comparator|oral placebo|participants will be randomized to oral placebo
89609629|NCT04567225|Experimental|Early Glargine|All consecutive adult patients getting admitted to Medical ICU and meet the inclusion criteria and accepted to receive insulin glargine early as per the protocol. They will receive insulin glargine 0.4 unit/kg within 4 hours from initiating the IV Insulin Infusion, as per the Cleveland Clinic DKA protocol.
89609630|NCT04567225|Active Comparator|Standard practice (Late Glargine)|Retrospective, prespecified and matched sample of consecutive adults who admitted to the same Medical ICU with a diagnosis of DKA in the period between January 1st 2019 till the Institutional Review Board (IRB) approval date and didn't receive basal insulin before Anion Gap closure.
89609631|NCT04384510||Patients with placenta accreta spectrum (PAS)|This cohort presents patients who were suspected or diagnosed either antenatal or intrapartum with placenta accreta spectrum
89609632|NCT01754467|Experimental|NEAT!|Participants will use the NEAT! smartphone application and accelerometer over a 1 month period.
89609633|NCT01753999|Active Comparator|Standard CPAP|Use of a standard CPAP (continuous positive airway pressure) device with constant pressure for 4 weeks to improve breathing during sleep
89609634|NCT01753999|Active Comparator|CPAP - Flex|Use of CPAP-Flex (continuous positive airway pressure) device with decreased pressure during expiration for 4 weeks to improve breathing during sleep
89609635|NCT02149342|Experimental|HAL cream and MAL cream|0.2% HAL (Hexvix, Photocure) mixed with Unguentum M (Allmiral) and MAL (Metvix, Galderma) used in a randomized split-face design
89057770|NCT04530617|Active Comparator|Artemisia annua|Tea 225mg per bag,1350 mg/day. Oral, one 8 oz brewed tea (two bags) three times a day, Days 1-14.
89609636|NCT03800446|Other|Intervention|All patients will undergo testing with the study intervention (point of care) and routine testing with serum ferritin (venous blood sample).
89609637|NCT03800368|Experimental|High-endurance group|This group of subjects will receive 2-3 sessions of high-intensity cycling exercise training per week, for a total of 12 weeks. The exercise the subjects received will interchange between the aerobic and anaerobic state.
89609638|NCT03800368|Experimental|Low-endurance group|This group of subjects will receive 2-3 sessions of low-intensity cycling exercise training per week, for a total of 12 weeks. The exercise the subjects received will maintain at an aerobic level.
89609639|NCT03800368|Active Comparator|Psycho-education|This group of subjects will receive 2-3 sessions of psycho-education class per week, for a total of 12 weeks. The content of the class includes non-exercise related psycho-education content to participants (e.g., food hygiene, psychological well being, food nutrition, etc).
89609640|NCT01783015|Experimental|Group A|Subjects who are mAb ADA positive
89033667|NCT06022718|Experimental|Kinesio-taping Group|Kinesio® Tex GoldFP (USA) was applied on both feet in the prone position with the knee extended, and the feet in a slightly plantar flexed position and hanging off the bed. The first Kinesio-taping was cut as an I shape and prepared for the transverse arch ligament correction technique. The non-stretched starting anchor was attached to the dorsum of the 5th metatars on the lateral side of the foot, passed from the plantar surface to the medial side with 75-100% tension. The non-stretched end was attached to the medial side of the ankle over the navicular region. The non-stretched initial anchor of the second Kinesio-taping strip starting from the proximal dorsal of the 5th. metatarsal on the lateral side of the foot.
89033668|NCT06022718|Experimental|Rigid-taping Group|Low dye bandage technique was used with a 3.8 cm wide rigid band (Leuko® Sportstape Premium, Germany) for rigid taping. Rigid taping was performed on both feet in the subtalar neutral position while participants in the prone position with their heels and feet out of the bed. The taping protocol described elsewhere was followed. 21 To optimise rigid tape adhesion, feet were washed and dried before taping. To increase consistency, the same researcher (MU) applied all taping.
89609641|NCT01783015|Experimental|Group B|Subjects who are mAb ADA negative
89609642|NCT01783015|Placebo Comparator|Group C|Subjects who are mAb ADA positive
89609643|NCT01783015|Placebo Comparator|Group D|Subjects who are mAb ADA negative
89609644|NCT01782859|Placebo Comparator|Placebo|Control group
89609645|NCT01782859|Active Comparator|Prednisone/hydrocortisone|"Steroid group will receive the following:~20 mg prednisone pill to be taken in the morning of surgery prior to arrival to the hospital~100 mg hydrocortisone IV 8 hours after first dose of prednisone followed by 3. Second and last dose of 100 mg hydrocortisone IV"
89609646|NCT05723536|Experimental|PLAI (Partial Left Atrial Isolation)|Partial electrical isolation of the left atrium endo-epicardially (pulmonary veins, posterior wall and left atrial appendage) and left atrial appendage isolation using Atriclip (Atricure, Mason OH, USA) in a single procedure in patients with persistent atrial fibrillation.
89609647|NCT05723536|Active Comparator|CA (Catheter Ablation)|Conventional catheter ablation of persistent atrial fibrillation.
89609648|NCT01782469||Rheumatoid Arthritis (RA) participants|Male or female participants at least 18 years of age with diagnosis of RA
89609649|NCT05718622|Experimental|real EECP|
89609650|NCT05718622|Sham Comparator|sham EECP|
89609651|NCT05718622|No Intervention|Health Control|
89609652|NCT01782313|Experimental|Treatment (tivozanib)|Patients receive tivozanib PO daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89609653|NCT04575259|Experimental|ANAVEX2-73 Active|Oral capsules
89609654|NCT00790192|Experimental|Lurasidone 80mg|
89609655|NCT00790192|Experimental|Lurasidone 160mg|
89609656|NCT00790192|Active Comparator|Quetiapine XR|
89609657|NCT00790192|Placebo Comparator|Placebo|
89609658|NCT01781611|Experimental|extended release dipyridamole/aspirin|extended release dipyridamole 200mg/aspirin 25mg twice daily for 24 weeks
89609659|NCT01781611|Active Comparator|aspirin|half a tablet of a 81mg aspirin twice daily for 24 weeks
89609660|NCT00777634||Binge eating disorder (BED)|Individuals who meet criteria for binge eating disorder.
89609661|NCT00777634||Without BED|Individuals who do not meet criteria for binge eating disorder.
89609662|NCT01781299|Active Comparator|AlloDerm RTU|Participants within this arm will have the acellular dermal matrix AlloDerm RTU implanted at the time of tissue expander placement.
89609663|NCT01781299|Active Comparator|SurgiMend PRS|Participants within this arm will have the acellular dermal matrix SurgiMend PRS implanted at the time of tissue expander placement.
89609664|NCT01732471|Experimental|Kuvan®|
89609665|NCT00790270|Active Comparator|Cyclobenzaprine|
89609666|NCT00790270|Active Comparator|Ibuprofen|
89609667|NCT00790270|Experimental|Ibuprophen plus Cyclobenzaprine|
89609668|NCT01780987|Experimental|Apixaban|
89609669|NCT01780987|Active Comparator|UFH/Warfarin|
89609670|NCT00790738|Experimental|1|liothyronine (T3)
89609671|NCT00790738|Placebo Comparator|2|placebo
89609672|NCT03800290|Experimental|Clenbuterol hydrochloride|"Subjects will ingest clenbuterol hydrochloride capsules (20 microgram/each) twice daily (40 microgram/day) for a maximum of 14 days.~Subjects that received the clenbuterol hydrochloride capsules (at random) in the first study period will receive the placebo capsules during the second study period."
89609673|NCT03800290|Placebo Comparator|Placebos|"Subjects will ingest placebo capsules matching the clenbuterol hydrochloride capsules one time per day for a maximum of 14 days.~Subjects that received the placebo capsules (at random) in the first study period will receive the clenbuterol hydrochloride capsules during the second study period."
89609674|NCT00777790|Experimental|Menactra® Group|Received Menactra® vaccine in Study MTA02
89609675|NCT00777790|Experimental|Menomune® Group|Received Menomune® vaccine in Study MTA02
89609676|NCT00777790|Experimental|Control Group|Meningococcal vaccine-naïve Control Group.
89609677|NCT00808834|Other|Senofilcon A / Lotrafilcon A|Senofilcon A, followed by Lotrafilcon A
89609678|NCT00808834|Other|Lotrafilcon A / Senofilcon A|Lotrafilcon A, followed by Senofilcon A
89609679|NCT00809146|Active Comparator|Intramuscular (IM) anticonvulsant|This group gets active treatment with an anticonvulsant by the intramuscular route of administration.
89609680|NCT00809146|Active Comparator|Intravenous (IV) anticonvulsant|This group gets active treatment with an anticonvulsant by the intravenous route of administration.
89609681|NCT00791908|Experimental|electrodessication (ED)|Treatment over 6 weeks using electrodessication (ED) to remove cherry angiomas. Each participant received treatment with PDL, KTP laser, and electrodesiccation to separate randomly selected areas on the torso, with each area bearing 4 cherry angiomata.
89609682|NCT00791908|Experimental|pulsed dye laser (PDL)|Treatment over 6 weeks using pulsed dye laser (PDL) to remove cherry angiomas. Each participant received treatment with PDL, KTP laser, and electrodesiccation to separate randomly selected areas on the torso, with each area bearing 4 cherry angiomata.
89609683|NCT00791908|Experimental|potassium titanyl phosphate (KTP) laser|Treatment over 6 weeks using potassium titanyl phosphate (KTP) laser to remove cherry angiomas. Each participant received treatment with PDL, KTP laser, and electrodesiccation to separate randomly selected areas on the torso, with each area bearing 4 cherry angiomata.
89033669|NCT06022692|Experimental|hyperthermia combined with immune checkpoint inhibitor group|The patients were treated with whole-body hyperthermia on days 1 and 8 of each HIT cycle along with administration of tislelizumab 200 mg on day 2 (24 h after the hyperthermia at day 1).
89033670|NCT06022679||Test group SAHOS|The test group consisted of 23 patients ( 9 girls and 14 boys) recruited on the basis of polysomnography at sleep center of CHU Liege for suspected sleep disorders between 1 january 2022 and 1 april 2023, with IAH >15
89033671|NCT06022679||Control group no SAHOS|Concerning the control group, the participants, adults volunteers are recruited among friends and families of students who collaborate with sleep center for scientific projects. These subjects have no complaints related to OSA and will have to undergo a sleep examination (ventilatory polygraphy) to certify the absence of OSA. This group consisted of 23 patients (14 girls and 9 boys).
89609684|NCT05709184|Experimental|Lyophilized fecal microbiome transfer (Lyo-FMT)|Vancomycin will be given orally in 125 mg capsules/solution 4 times daily for a total of 5 days (day 1 - initiation of therapy by the clinical team), followed by a loading dose of oral Lyo-FMT capsules on day 6 (15 capsules). On days 7-10, patients will receive 10 Lyo-FMT capsules per day. A total of 55 capsules, derived from ~30-40g of the original material, will be administered throughout 5 days. Prior to each Lyo-FMT administration, patients will be asked to fast for 8 hours. Bowel preparation or proton pump inhibitor use will not be required per protocol. The loading dose will be administered under medical supervision, while further dosing can be administered at the patient's home/institute, after training and guidance
89609685|NCT05709184|Active Comparator|Vancomycin monotherapy|Vancomycin will be given orally in 125 mg capsules/solution 4 times daily for a total of 10 days (day 1 - initiation of therapy by the clinical team, not from randomization).
89609686|NCT00794170|Experimental|Telephone and print based intervention|The I-SIGHT intervention consists of twelve interactive voice recognition (IVR) phone calls over a nine-month period and accompanying printed materials that are mailed to participants following each call. The phone call messages and print materials are tailored to individuals' circumstances using data from the screening and baseline interviews. The intervention is based on theoretical constructs from Social Cognitive Theory and the Health Belief Model, and emphasizes self-efficacy, medication taking skills, outcome expectancies, facilitators and barriers to compliance, and social support. The treatment group receives the tailored telephone intervention and mailed, printed materials.
89609687|NCT00794170|No Intervention|Usual care|The control group received usual care at each clinical site and interacted with study personnel only for data collection.
89609688|NCT04843774||COVID-negative Multiple Sclerosis patients treated with ocrelizumab|
89609689|NCT05680948||Enrolled patients exiting the ISS T-003 EF-UP study|No intervention - No intervention is foreseen in this Observational Study
89609690|NCT04383652||Adult cohort|"Diagnosed with SARS-CoV-2 infection (COVID-19; by a registered diagnostic facility)~Age 16 years or older~Have provided informed consent~Blood samples and clinical data related to COVID19 diagnosis, symptoms, and outcomes will be collected."
89609691|NCT04383652||Paediatric cohort|"Diagnosed with SARS-CoV-2 infection (COVID-19; by a registered diagnostic facility)~Age less than 16 years~Parent or caregiver has provided informed consent Blood samples and clinical data related to COVID19 diagnosis, symptoms, and outcomes will be collected."
89609692|NCT00809848|Experimental|AGN-210669 ophthalmic solution, 0.075%|AGN-210669 non-preserved ophthalmic solution, 0.075%. One drop in both eyes each morning once-daily for 2 weeks.
89609693|NCT00809848|Experimental|AGN-210669 ophthalmic solution, 0.05%|AGN-210669 non-preserved ophthalmic solution, 0.05%. One drop in both eyes each morning once-daily for 2 weeks.
89609694|NCT00809848|Experimental|AGN-210669 ophthalmic solution, 0.025%|AGN-210669 non-preserved ophthalmic solution, 0.025%. One drop in both eyes each morning once-daily for 2 weeks.
89609695|NCT00809848|Active Comparator|bimatoprost ophthalmic solution 0.03%|Bimatoprost ophthalmic solution 0.03%. One drop in both eyes each morning once-daily for 2 weeks.
89609696|NCT00809848|Placebo Comparator|AGN-210669 vehicle ophthalmic solution|AGN-210669 vehicle non-preserved ophthalmic solution. One drop in both eyes each morning once-daily for 2 weeks.
89609697|NCT03839836|No Intervention|Baseline|Children between six and 12 years, no pain in the lower limb and back at the time of examination using a backpack without the child's body weight, the spatio-temporal parameters are measured with the OptoGait® system
89609698|NCT03839836|Experimental|5% child's body weight|Children between six and 12 years, no pain in the lower limb and back at the time of examination using a backpack load was added to the BPs 5%, of the child's body weight, the spatio-temporal parameters are measured with the OptoGait® system
89033672|NCT06022666|No Intervention|Standard of care|Patients will undergo the usual preoperative assessment from preoperative clinic which includes standard general internal medicine and anesthesia assessment.
89033673|NCT06022666|Experimental|PATH geriatric care|Pre-operative assessment through the PATH clinic
89609699|NCT03839836|Experimental|10% child's body weight|Children between six and 12 years, no pain in the lower limb and back at the time of examination using a backpack load was added to the BPs 10%, of the child's body weight, the spatio-temporal parameters are measured with the OptoGait® system
89609700|NCT03839836|Experimental|15% child's body weight|Children between six and 12 years, no pain in the lower limb and back at the time of examination using a backpack load was added to the BPs 15%, of the child's body weight, the spatio-temporal parameters are measured with the OptoGait® system
89033674|NCT06022640|Experimental|Group 1|The study included 75 patients in the intervention group who received an educational and supportive program designed by a clinical pharmacist. The intervention group received support through five visits: at admission, monitoring medication, monitoring ovulation, monitoring harmful effects, providing emotional support, and following up after egg retrieval during embryo transfer.
89057771|NCT04530617|Placebo Comparator|Artemisia annua Placebo|Matched placebo
89057772|NCT01686009|Experimental|Intra-nasal ketamine|0.5 mg/kg ketamine intra-nasally; then 0.25 mg/kg repeat dose after 10 minutes if necessary
89609701|NCT03839836|Experimental|20% child's body weight|Children between six and 12 years, no pain in the lower limb and back at the time of examination using a backpack load was added to the BPs 20%, of the child's body weight, the spatio-temporal parameters are measured with the OptoGait® system
89609702|NCT04382716||PANS participants|
89609703|NCT01730053|Active Comparator|Rosuvastatin 20 mg|Participants, who were receiving rosuvastatin 10 mg over-encapsulated tablet orally at baseline, received rosuvastatin 20 mg over-encapsulated tablet orally once daily (QD), placebo for alirocumab SC injection every two weeks (Q2W), and placebo for ezetimibe over-encapsulated tablet orally QD added to stable Lipid-Modifying Therapy (LMT) for 24 weeks.
89609704|NCT01730053|Active Comparator|Ezetimibe 10 mg + Rosuvastatin 10 mg|Participants, who were receiving rosuvastatin 10 mg over-encapsulated tablet orally at baseline, received ezetimibe 10 mg over-encapsulated tablet orally QD, rosuvastatin 10 mg over-encapsulated tablet orally QD, and placebo for alirocumab SC injection Q2W added to stable LMT for 24 weeks.
89609705|NCT01730053|Experimental|Alirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mg|Participants, who were receiving rosuvastatin 10 mg over-encapsulated tablet orally at baseline, received alirocumab 75 mg SC injection Q2W, rosuvastatin 10 mg over-encapsulated tablet orally QD, and placebo for ezetimibe over-encapsulated tablet orally QD added to stable LMT for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when LDL-C levels ≥70 mg/dL (1.81 mmol/L) or ≥100 mg/dL (2.59 mmol/L) at Week 8, based on baseline disease characteristic and medical history.
89609706|NCT01730053|Active Comparator|Rosuvastatin 40 mg|Participants, who were receiving rosuvastatin 20 mg over-encapsulated tablet orally at baseline, received rosuvastatin 40 mg over-encapsulated tablet orally QD, placebo for alirocumab Q2W SC injection, and placebo for ezetimibe QD over-encapsulated tablet orally added to stable LMT for 24 weeks.
89609707|NCT01730053|Active Comparator|Ezetimibe 10 mg + Rosuvastatin 20 mg|Participants, who were receiving rosuvastatin 20 mg over-encapsulated tablet orally at baseline, received ezetimibe 10 mg over-encapsulated tablet orally QD, rosuvastatin 20 mg over-encapsulated tablet orally QD, and placebo for alirocumab Q2W SC injection added to stable LMT for 24 weeks.
89609708|NCT01730053|Experimental|Alirocumab 75 mg/ up to 150 mg + Rosuvastatin 20 mg|Participants, who were receiving rosuvastatin 20 mg over-encapsulated tablet orally at baseline, received alirocumab 75 mg Q2W SC injection, rosuvastatin 20 mg over-encapsulated tablet orally QD, and placebo for ezetimibe over-encapsulated tablet orally QD added to stable LMT for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when LDL-C levels ≥70 mg/dL (1.81 mmol/L) or ≥100 mg/dL (2.59 mmol/L) at Week 8, based on baseline disease characteristic and medical history.
89609709|NCT00794560|Experimental|clinical setting: intervention|"Recruitment of patients in the hospital into the randomized intervention group. Intervention is done by a trained pharmacist/Doctor of Philosophy-student in the study center (a pharmacy) or at patient's bedside in the hospital.~Intervention: patient education"
89609710|NCT00794560|No Intervention|clinical setting: standard care|Recruitment of patients in the hospital into the randomized control group (standard care in community pharmacy)
89609711|NCT00794560|Experimental|daily life setting: intervention|"Recruitment of patients in trained community pharmacies into the intervention group. Intervention is done by trained pharmacists.~Intervention: patient education"
89609712|NCT00794560|No Intervention|daily life setting: standard care|Recruitment of patients in community pharmacies into control group (standard care in community pharmacy)
89609713|NCT01752985|Experimental|Arm A: BMS-813160 150 mg & Placebo matching with BMS-813160|BMS-813160 150 mg capsules by mouth in AM and Placebo matching with BMS-813160 in PM for 12 weeks
89609714|NCT01752985|Experimental|Arm B: BMS-813160 300 mg|BMS-813160 300 mg capsules by mouth twice daily for 12 weeks
89609715|NCT01752985|Placebo Comparator|Arm C: Placebo matching with BMS-813160|Placebo matching with BMS-813160 0 mg capsules by mouth twice daily for 12 weeks
89609716|NCT01751113|Active Comparator|fluticasone propionate/salmeterol|250mcg fluticasone + 50 mcg salmeterol, twice daily 4 week treatment in each treatment sequence (crossover design)
89609717|NCT01751113|Active Comparator|tiotropium bromide|18 mcg tiotropium bromide, once daily 4 week treatment in each treatment sequence (crossover design)
89609718|NCT01751113|Active Comparator|fluticasone propionate/salmeterol plus tiotropium bromide|250mcg fluticasone + 50 mcg salmeterol, twice daily plus 18 mcg tiotropium bromide, once daily 4 week treatment in each treatment sequence (crossover design)
89609719|NCT04761406|Experimental|Phaeosol group|Daily supplementation of Phaeosol softgel capsule (218mg/d), active ingredients of Microphyt. Each randomized subject will consume 1 softgel capsule (before breakfast) per day during 12 weeks
89609720|NCT04761406|Placebo Comparator|Placebo group|Daily supplementation of placebo softgel capsule (218mg/d of 100% sunflower oil) with the same appearance and packaging than experimental product. Each randomized subject will consume 1 softgel capsule (before breakfast) per day during 12 weeks
89609721|NCT01750879|Active Comparator|Peanut Flour|Oral Immunotherapy with peanut flour.
89609722|NCT01750879|Placebo Comparator|Oat Flour|Oral Immunotherapy with oat flour.
89609723|NCT01719380|Experimental|LGX818 + cetuximab|
89609724|NCT01719380|Experimental|LGX818 + BYL719 + cetuximab|
88815320|NCT02484690|Experimental|Arm D: Faricimab, 6 mg Every 4-8 weeks|Participants will receive faricimab, 6 mg IVT Q4W up to Week 12 (4 injections), followed by 6 mg IVT every 8 weeks up to Week 28 (2 injections). On Weeks 16, 24, and 32, participants received the sham procedure in order to maintain masking. The final study visit will take place at Week 36.
89609725|NCT00792142|Experimental|Treatment (stem cell transplant, maintenance treatment)|Patients receive high-dose melphalan IV over 30 minutes on days -2 and -1 and undergo autologous peripheral blood stem cell transplantation on day 0. Patients receive filgrastim IV or SC beginning on day 5 and continuing until blood counts recover. Beginning 4 to 8 weeks after transplantation, patients receive maintenance therapy comprising bortezomib IV on days 1, 8, and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients also receive oral dexamethasone on days 1 to 4. Treatment with dexamethasone repeats every month for 12 months in the absence of disease progression or unacceptable toxicity. Beginning 2 weeks after completion of bortezomib, patients receive oral thalidomide once daily until disease progression.
89609726|NCT00792610|Experimental|Hepatitis B booster|They receive 3 doses of hepatitis B vaccine (Engerix-B Injection, recombinant HBsAg, 20mcg/ml/vial, GSK) at 0, 1st, 6th month during follow-up. Their anti-HBs status were checked at baseline, one week, one month, sixth month, and seven months later after the first dose of hepatitis B vaccine.
89609727|NCT00792688|Experimental|1|GLYC-101 Gel, 0.1% on one eyelid and Placebo Gel on the other eyelid
89609728|NCT00792688|Experimental|2|GLYC-101 Gel, 1.0% on one eyelid and Placebo Gel on the other eyelid
89609729|NCT00792688|Experimental|3|GLYC-101 Gel, 0.1% on one eyelid and GLYC-101 Gel, 1.0% on the other eyelid
89609730|NCT01743560|Experimental|Everolimus and Exemestane|Postmenopausal women diagnosed with oestrogen receptor positive locally advanced or metastatic breast cancer will receive RAD001 at a dose of 10mg daily p.o. and exemestane 25mg daily p.o. for 48 weeks.
89609731|NCT00796744|Placebo Comparator|Placebo Vehicle Control|control placebo vehicle gel
89609732|NCT00796744|Active Comparator|0.03% DSC127|0.03 % DSC127 in Vehicle Control
89609733|NCT00796744|Active Comparator|0.01% DSC127|0.01% DSC127 in Vehicle Control
89609734|NCT01743092|Other|Tutorial Workbook|Tutorial Workbook Group only receives a Tutorial Workbook Group
89609735|NCT01743092|Experimental|Tutorial Workbook Group plus webinar|Tutorial Workbook Group plus webinar will receive in addition, a webinar as an additional resource.
89609736|NCT00797212|Other|Subjects with diabetes|Subjects with diabetes use a new Apollo Blood Glucose Monitoring System with blood obtained from the palm and forearm
89609737|NCT00792922|Active Comparator|≥90% coverage with azithromycin target|Selected communities will receive mass treatment annually for three years.
89609738|NCT00792922|Active Comparator|80%-89% coverage with azithromycin target|Selected communities will receive mass treatment annually for three years.
89609739|NCT00792922|Active Comparator|≥90% coverage with azithromycin , treatment based|"Treatment to be administered at baseline then continued yearly if trachoma prevalence is greater than 5%~In Niger, treatment will be every 6-months for children ages twelve and under."
89609740|NCT00792922|Active Comparator|80%-89% coverage with azithromycin : treatment based|"Treatment to be administered at baseline then continued yearly if trachoma prevalence is greater than 5%~In Niger, treatment will be every 6-months for children ages twelve and under."
89609741|NCT01780831|Experimental|Cohort 1|"HIV-1-exposed full-term infants. Infants received two single doses of RAL: first dose within 48 hours of birth and second dose at 7-10 days of life:~RAL-naive: 3 or 2 mg/kg within 48 hours of birth and 3 mg/kg at 7-10 days of life.~RAL-exposed: 1.5 mg/kg within 48 hours of birth and 3 mg/kg at 7-10 days of life."
89609742|NCT01780831|Experimental|Cohort 2|"HIV-1-exposed full-term infants. Daily RAL through 6 weeks of life with first dosing within 48 hours of birth and between 12-60 hours of birth for in utero RAL-naive and RAL-exposed infants, respectively.~Daily RAL through 6 weeks of life: 1.5 mg/kg once daily during Days 1-7 of life, 3.0 mg/kg twice daily during Days 8-28 of life, and 6.0 mg/kg twice daily during Days 29-42 of life."
89609743|NCT04383730||Usual practice of intravenous sedation|The choice of the intravenous sedative agent, including the type of and dosing of the agent, will be as per the treating clinicians at each center
89609744|NCT04383730||Usual practice of inhaled sedation|The choice of the inhaled sedative agent, including the type of and dosing of the agent, will be as per the treating clinicians at each center.
89609745|NCT04382170|Active Comparator|20 mcg|Participants randomized to the 20mcg group will receive 20mcg of dexmedetomidine sublingual film every 30 minutes, if they continue to have agitation and do not meet any cardiovascular stopping criteria. The maximum dosing for this arm is 80mcg.
89609746|NCT04382170|Experimental|60 mcg|Participants randomized to the 60mcg group will receive 60mcg of dexmedetomidine sublingual film every 30 minutes, if they continue to have agitation and do not meet any cardiovascular stopping criteria. The maximum dosing for this arm is 240mcg.
89609747|NCT01778023|Experimental|hGH:12months treatment|
89609748|NCT01778023|Active Comparator|hGH: 6 month un-treatment + 6 month treatment|
89609749|NCT01753297|Active Comparator|Triptorelin, 11.25 mg|Triptorelin, powder and solvent for suspension (prolonged released form)
89609750|NCT01753297|No Intervention|Active surveillance|Active surveillance after radical prostatectomy (RP)
89057773|NCT01686243|Experimental|"echogenic 17G tuohy needles  Pajunk TuohySono"|Epidural will be placed with the aid of ultrasound and echogenic 17G Tuohy needles (Pajunk TuohySono).
89057774|NCT01686243|Placebo Comparator|standard epidural needles|Epidural will be placed in standard practice with standard needles.
89609751|NCT04382794||DMT2 COVID19 positive patients treated with Sitagliptin|The anonymous data relating to the clinical, laboratory and instrumental parameters of patients hospitalized for COVID-19 and suffering from type 2 diabetes treated with Sitagliptin will be extracted from the medical records currently in use in the centers participating in the study. The data will be anonymous and not attributable to individual subjects
89609752|NCT04382794||DMT2 COVID19 positive patients not treated with Sitagliptin|The anonymous data relating to the clinical, laboratory and instrumental parameters of patients hospitalized for COVID-19 and suffering from type 2 diabetes not treated with Sitagliptin will be extracted from the medical records currently in use in the centers participating in the study. The data will be anonymous and not attributable to individual subjects
89609753|NCT04929496|No Intervention|Angiographical guidance only|Standard of care
89609754|NCT04929496|Experimental|Post-PCI FFR guidance|Post-PCI Fractional Flow Reserve and non-hyperemic pressure ratios measurement
89609755|NCT04920370|Experimental|ALXN1720 Single Dose SC|Participants will receive a single dose of ALXN1720 SC.
89609756|NCT04920370|Experimental|ALXN1720 Multiple Dose SC|Participants will receive multiple doses of ALXN1720 SC.
89609757|NCT04920370|Experimental|ALXN1720 Single Dose SC + rHuPH20|Participants will receive a single dose of ALXN1720 SC in combination with rHuPH20.
89609758|NCT04920370|Experimental|ALXN1720 Single Dose IV|Participants will receive a single dose of ALXN1720 IV.
89609759|NCT04920370|Placebo Comparator|Placebo|Participants will receive Placebo SC or Placebo IV according to their assigned cohort.
89609760|NCT01777321|Experimental|SC HZ/su Group|Subjects will receive HZ/su vaccine administered SC on a 0,2-month schedule.
89609761|NCT01777321|Active Comparator|IM HZ/su Group|Subjects will receive HZ/su vaccine administered IM on a 0,2-month schedule.
89033675|NCT06022640|No Intervention|Group 2|The control group included 75 infertile married ladies attending the hospital for the same purpose and managed in the traditional protocol followed by the hospital system. The study assessed the fertility quality of life and depression status of the patients at the beginning and end of the IVF cycle. All patients received frozen embryo transfers (fertilized eggs), not fresh embryos.
89033676|NCT06022627|Experimental|Pranayam Yoga Group|It was planned to use a simple random sampling method among individuals who met the research inclusion criteria and agreed to participate voluntarily in the study. During randomization; Patients in the study and control groups will be determined using the random.org site. While the routine treatment of the patients in the study group continues, 20 minutes of pranayama yoga training will be given by the yoga instructor to the patient and his relatives, and it is planned that the patient will practice pranayama yoga, which is taught for 20 minutes every day for 21 days. Patients or their relatives will be called every morning by phone or video communication will be made online and pranayama yoga will be provided. In addition, a training booklet describing pranayama yoga exercises in detail, a training video and a 21-day checklist of doing yoga will be given to the patients. function test will be done and checklists will be taken back from patients.
89033677|NCT06022627|No Intervention|Non-Pranayama Yoga Group|The routine treatment of the control group will continue and any intervention will not be applied. After the data collection process of the study is completed, paranayama yoga training will be given to the patients in the control group and they will be advised to do it regularly for at least 21 days.
89033678|NCT06022601|Experimental|DNA Nudge|DNA Nudge wearable and app, DNA-based dietary advice
89033679|NCT06022601|No Intervention|Control|Fitbit, standard dietary advice
89033680|NCT06022588|Placebo Comparator|13C -butyrate control group|5 healthy volunteers performed the breath test without any psychical exercise
89033681|NCT06022588|Experimental|13C -butyrate intervention group|5 healthy volunteers performed the breath test with psychical exercise - bicycle test
89033682|NCT06022588|Placebo Comparator|13C -glucose control group|5 healthy volunteers performed the breath test without any psychical exercise
89609762|NCT04718350|Active Comparator|Intravenous administration of Levosimendan at a dosage of 6 mcg/kg after induction of anesthesia|in this group, 6 mcg/kg of levosimendan will be administered intravenously after anesthesia induction, aiming at prevention of pulmonary hypertension post bypass
89609763|NCT04718350|Active Comparator|Inhalational administration of Milrinone at a dosage of 50 mcg/kg after induction of anesthesia|in this group, 50 mcg/kg of milrinone will be administered via inhalation after anesthesia induction, aiming at prevention of pulmonary hypertension post bypass
89609764|NCT01729819|Experimental|Combination|Tolterodine tartrate extended release capsules + Desmopressin orally disintegrating tablets
89609765|NCT01729819|Active Comparator|Tolterodine|Tolterodine tartrate extended release capsules + Placebo orally disintegrating tablets
89609766|NCT01776541|Experimental|aH5N1c-High Dose|Subjects received 2 injections of a high dose of cell culture-derived adjuvanted monovalent inactivated subunit H5N1 vaccine three weeks apart.
89609767|NCT01776541|Experimental|aH5N1c-Low dose|Subjects received 2 injections of a low dose of cell culture-derived adjuvanted monovalent inactivated subunit H5N1 vaccine three weeks apart.
89609768|NCT00811564|Active Comparator|1|Fixed combination of brimonidine tartrate 0.2%/timolol maleate 0.5% ophthalmic solution
89609769|NCT00811564|Active Comparator|2|Latanoprost 0.005% ophthalmic solution
89210759|NCT04006041|Experimental|Toripalimab group|All patients will receive standard fractionation radiation therapy (RT) scheme: 44Gy in 20 fractions over 4 weeks, concurrently with 4 cycles of paclitaxel/cisplatin (paclitaxel 50mg/m2 and cisplatin 25 mg/m2) on days 1, 8, 15, 22 and 2 cycles of toripalimab 240 mg on days 1, 22. Esophagectomy is performed 6-8 weeks after CRT completion.
88815321|NCT02484690|Experimental|Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W|Participants will receive ranibizumab, 0.5 mg IVT Q4W up to Week 8 (3 injections), followed by faricimab, 6 mg IVT Q4W up to Week 32 (6 injections). The final study visit will take place at Week 36.
89033683|NCT06022588|Experimental|13C -glucose intervention group|5 healthy volunteers performed the breath test with psychical exercise - bicycle test
89033684|NCT06022575||Telehealth Integrated Care Group|Followed up in online Internet hospital, estimated and adjusted treatment accroding to clinical efficacy, and send individualized health education messages regularly.
89033685|NCT06022575||Conventional Group|Followed up face-to-face in cardiacmetabolic clinics, estimated and adjusted treatment accroding to clinical efficacy, and conducted health education.
89033686|NCT06022536|Experimental|1mg dose group|The 1mg dose group is a low dose group and only safety and tolerability will be evaluated, pharmacokinetics and immunogenicity will not be evaluated, therefore one subject is planned to be enrolled.1mg SSS40 was injected subcutaneously on day1.
89033687|NCT06022536|Experimental|3mg dose group|Four subjects were included in the 3mg dose group (trial group: 3:1 placebo group).3mg SSS40/Placebo was injected subcutaneously on day1.
89033688|NCT06022536|Experimental|10mg、20mg、30mg、 45mg、60mg or 80mg dose group|Sentinel dosing was used starting with the 10 mg group, with two subjects first enrolled and randomized 1:1 (test drug:placebo) for sentinel dosing, with sentinels participating in blinding, and then after the sentinel group had completed the 72-h safety assessment, the rest of the subjects in the group were randomized to receive dosing according to the test drug group versus the placebo group.10mg、20mg、30mg、 45mg、60mg or 80mg SSS40/Placebo was injected subcutaneously on day1.
89609770|NCT00811798|Experimental|Cervarix Group|
89609771|NCT01742078|Experimental|7.5 mg LY2541546 - IV|Single dose of 7.5 mg LY2541546 administered intravenously (IV)
89609772|NCT01742078|Experimental|25 mg LY2541546 - IV|Single dose of 25 mg LY2541546 administered IV
89609773|NCT01742078|Experimental|75 mg LY2541546 - IV|Single dose of 75 mg LY2541546 administered IV
89609774|NCT01742078|Experimental|225 mg LY2541546 - IV|Single dose of 225 mg LY2541546 administered IV
89609775|NCT01742078|Experimental|750 mg LY2541546 - IV|Single dose of 750 mg LY2541546 administered IV
89609776|NCT01742078|Experimental|150 mg LY2541546 - SC|Single dose of 150 mg LY2541546 administered subcutaneous (SC)
89609777|NCT01742078|Placebo Comparator|Placebo|Single dose of placebo administered IV or SC
89609778|NCT01742078|Experimental|225 mg LY2541546 - IV, OL|Single dose of 225 mg LY2541546 administered IV, open label (OL)
89033689|NCT06022523|Experimental|Acquisition|Subjects will undergo profound hypoxia with stable plateaus.
89033690|NCT06022471||Stapes surgery|
89033691|NCT06022224|Experimental|hAd5-S-Fusion+N-ETSD|Prime (SC, Day 1) + Boost (SC, Day 22) @ 1x10^11 VP/dose
89033692|NCT06022224|Placebo Comparator|Placebo|Prime (SC, Day 1) + Boost (SC, Day 22)
89033693|NCT06021561||Multiple sclerosis group|Multiple sclerosis patients registered in Varazdin General Hospital from 1 January 2017 - 31 December 2022
89609779|NCT01742078|Experimental|750 mg LY2541546 - IV, OL|Single dose of 750 mg LY2541546 administered IV, OL
89609780|NCT01741688||Tocilizumab|Participants with moderate to severe rheumatoid arthritis (RA), according to the American College of Rheumatology (ACR) criteria and the Disease Activity Score Based on 28 Joints (DAS28), in whom the attending physician has decided to start treatment with tocilizumab (according to the local label).
89609781|NCT01709084|Experimental|Group 1|Patients will receive fixed dose combination (FDC) tablet of tenofovir disoproxil fumarate/emtricitabine/rilpivirine with a meal, until Week 48.
89609782|NCT01709084|Active Comparator|Group 2|Patients will receive FDC tablet of tenofovir disoproxil fumarate/emtricitabine /efavirenz on an empty stomach at bedtime, until Week 48.
89609783|NCT01729039|Experimental|gaze stability|standard balance rehabilitation plus vestibular-specific exercises
89609784|NCT01729039|Placebo Comparator|control|standard balance rehabilitation plus placebo eye exercises
89609785|NCT01775995|Experimental|Meditation-CBT|Participants receiving the meditation-CBT intervention, in addition to usual care for CLBP and opioid therapy management.
89609786|NCT01775995|Other|Wait-list Control|Participants receiving usual care for CLBP and opioid therapy management.
89609787|NCT01741532|Experimental|Deferiprone|Deferiprone 80 mg/mL oral solution
89609788|NCT01741532|Placebo Comparator|Placebo|Matching placebo solution
89609789|NCT01719224|Active Comparator|Elevated body position|We collect data about the apnea- hypopnea index, obstructive and central apneas, as well as oxygen, by comparing supine to 45 degrees elevated body position.
89609790|NCT01719224|Active Comparator|supine body position|We collect data about the apnea- hypopnea index, obstructive and central apneas, as well as oxygen, by comparing supine to 45 degrees elevated body position.
89609791|NCT01717976|Experimental|Intervention|primary care based nurse telephone support
89609792|NCT01717976|No Intervention|Control|usual care
88815322|NCT01027598|Experimental|Erlotinib + Pazopanib|"Erlotinib: 150 mg orally daily~Pazopanib: 600 mg orally daily"
89033694|NCT06020755|Experimental|Toripalimab Plus Actinomycin-D|Toripalimab 200mg intravenously(IV) every 2 weeks (Q2W) Actinomycin-D 1.25mg/m2，2mg max dos, intravenously(IV) every 2 weeks (Q2W)
89033695|NCT06020521|Other|Group of healthy volunteers|This research will take place at the hospital and at the UFR Simone Veil-Santé with single sessions on the same day of approximately 10 minutes and 1 hour respectively. A list of healthy volunteers has already been established at the faculty. A provisional schedule for passing the various examinations provided for in the protocol is also scheduled. The experiments conducted at the UFR Simone Veil - Santé will take place within the Department of Health Biotechnology. This Department already has all the resources necessary for the successful completion of the study, in particular within the mass spectrometry platform which has the instruments (high resolution mass spectrometer Q-Exactive) and human resources (2 analytical science engineers, 1 data science engineer + technical staff and interns) required.
89033696|NCT06020248|Experimental|Low melanin|Individuals with skin reflectance scores below 150 using the Mexameter 18 instrument.
89033697|NCT06020248|Experimental|High melanin|Individuals with skin reflectance scores above 249 using the Mexameter 18 instrument
89033698|NCT06020027|Experimental|Intervention Arm|Water is K'é is a family-based intervention aimed at improving health and wellness of family members and of the family as a whole. The multi-level intervention targets change at environmental, community and family levels through three core activities: a lesson plan, social media campaign and water access plan. ECE staff will receive a brief training on the curriculum and its relation to the Navajo Wellness Model before delivering the lessons and posting messages. Four interactive lesson plans will be delivered by ECE staff. Caregiver and family sessions will be delivered at the Head Start / FACE facility or in the home, depending on staff preference.
89033699|NCT06020027|No Intervention|Control Arm|"Participants attending an ECE site randomly assigned to waitlist will receive usual programs and services at the site."
89033700|NCT06019962||Group A|20 postpartum women who delivered by cesarean section
89033701|NCT06019962||Group B|20 females who did not experience pregnancy
89033702|NCT06019754|Placebo Comparator|Control group|patients who will be recruited in the control group will receive general anesthesia only
89033703|NCT06019754|Active Comparator|Interventional group|Patients who will be recruited in the Interventional will receive combined lumbar and sacral plexus block
89033704|NCT06019741|Experimental|aspirin and rivaroxaban|post coronary bypass patients, received aspirin 80 mg and rivaroxaban 2.5 mg PO twice daily
89033705|NCT06019741|Active Comparator|aspirin|post coronary bypass patients, received aspirin 80 mg
89033706|NCT06019468|Experimental|Neoadjuvant immunotherapy combined with radiotherapy|Treatment arms comprise 10-20 cycles of radiotherapy and 2-4 cycles of maintenance therapy with Envolizumab
89033707|NCT06018701|Experimental|Maxillary Anterior|Dental device will be cemented with PMMA bone cement on group that have missing tooth on maxillary anterior region.
89609793|NCT01740440|Other|BMR Face treatment|BMR Face treatment used once a day for 12 weeks
89609794|NCT01740128|Experimental|Multimodal then Treadmill training|Participants will undergo harness-supported multimodal balance training exercises while simultaneously performing skilled hand exercises. Following a washout period of at least 6 weeks, Participants will undergo body weight supported treadmill training using the Lokomat apparatus.
89609795|NCT01740128|Active Comparator|Treadmill then Multimodal training|Robotic body weight supported treadmill training will be applied using the Lokomat apparatus. Following a washout period of at least 6 weeks, Participants will undergo harness-supported balance training exercises while simultaneously performing skilled hand exercises.
89609796|NCT01976741|Experimental|Rogaratinib total dose escalation|Participants with any type of solid tumor received escalating doses of Rogaratinib oral solution or tablet. The actual dose-escalation cohorts were 100 mg (50 mg BID), 200 mg (100 mg BID), 400 mg (200 mg BID), 800 mg (400 mg BID), 1200 mg (600 mg BID), and 1600 mg (800 mg BID). The participants in the 100 mg and 200 mg dose-escalation cohorts received oral solution and the participants in all the subsequent dose-escalation cohorts received tablet. And as an exception, on C1D-3 in the 200 mg dose-escalation cohort, the participants received tablet instead of oral solution.
89033708|NCT06018701|Experimental|Maxillary Posterior|Dental device will be cemented with PMMA bone cement on group that have missing tooth on maxillary posterior region.
89033709|NCT06018701|Experimental|Mandibular Anterior|Dental device will be cemented with PMMA bone cement on group that have missing tooth on mandibular anterior region.
89609797|NCT01976741|Experimental|Rogaratinib dose expansion (All Comers)|"Participants with cancer types other than bladder cancer (BC), squamous cell carcinoma of the head and neck (SCCHN), and squamous non-small cell lung cancer (sqNSCLC) received 800 mg Rogaratinib oral tablet b.i.d.~(1600 mg/day) in 21-days cycles."
89609798|NCT01976741|Experimental|Rogaratinib dose expansion (BC)|Participants with bladder cancer (BC) received 800 mg Rogaratinib oral tablet b.i.d. (1600 mg/day) in 21-days cycles.
89609799|NCT01976741|Experimental|Rogaratinib dose expansion (SCCHN)|Participants with squamous cell carcinoma of the head and neck (SCCHN) received 800 mg Rogaratinib oral tablet b.i.d. (1600 mg/day) in 21-days cycles.
89609800|NCT01976741|Experimental|Rogaratinib dose expansion (sqNSCLC)|Participants with squamous non-small cell lung cancer (sqNSCLC) received 800 mg Rogaratinib oral tablet b.i.d. (1600 mg/day) in 21-days cycles.
89609801|NCT01727713|Experimental|Aripiprazole|Aripiprazole Immediate Release Once-Daily
89609802|NCT04658927|Experimental|Dexamethosone intracanalicular insert|All 30 eyes will undergo iLUX MGD Treatment System for the treatment of evaporative DED secondary to MGD. Patients will have their most symptomatic eye selected to receive the dexamethasone intracanalicular insert at the day of the iLUX MGD Treatment System (study eye).
89609803|NCT04658927|Active Comparator|Group 1: Prednisolone actetate 1%|15 fellow eye will undergo iLux and receive topical prednisolone acetate 1% on a 4,3,2,1 taper for 30 days.
89609804|NCT04658927|Sham Comparator|Group 2: Sham dilation|"15 fellow eye will undergo ILux and receive punctal sham dilation (control eye)."
89609805|NCT01965431|Experimental|BI 207127 + Faldaprevir|Tablets/capsules
89609806|NCT01965431|Active Comparator|Moxifloxacin (Avalox®)|Tablets
89609807|NCT01965431|Experimental|BI 207127 placebo + Faldaprevir placebo|Tablets/capsules
89609808|NCT01976663|Experimental|VOLIFT® XC NLFs|Nasolabial folds treated with JUVEDERM VOLIFT® XC.
89609809|NCT01976663|Active Comparator|Control NLFs|Nasolabial folds treated with Control.
89609810|NCT01775137|Experimental|TBM100|TIP 112 mg/b.i.d
89609811|NCT01976507|Experimental|dabigatran etexilate mesylate|Immediately following the ablation procedure (4-6 hours after sheath pull and vascular hemostasis), dabigatran etexilate 150mg bid, or 75mg twice daily based on creatinine clearance in the Use in Specified Populations (USPI), will be administered for a minimum of 3 months post RF ablation.
89033710|NCT06018701|Experimental|Mandibular Posterior|Dental device will be cemented with PMMA bone cement on group that have missing tooth on mandibular posterior region.
89033711|NCT06018389|Experimental|Structural Only|The Structural Only condition consists of (1) school policies for school-based social events; and (2) an information-based interactive parent meeting. Interventions in this arm are targeting the school and parent level.
89033712|NCT06018389|Experimental|Structural+Group MI|"The Structural+Group MI condition consists of the elements described in Structural Only and group MI. Interventions in this arm are targeting all three levels: school, parent and student level."
89609812|NCT04661579|Experimental|Group 1: Positive baseline parasitemia, antimalarial treatment, RTS,S/AS01E vaccine|Group 1 subjects have detectable P. falciparum parasitemia at baseline measured by PCR. Anti-malarial treatment with Dihydroartemisinin-piperaquine (DHA/Pip) to clear asexual stage and young gametocyte parasites plus low dose primaquine (LD PQ) to clear mature gametocytes will be given 4 weeks prior to immunization with RTS,S/AS01E. A 2nd course of DHA/Pip plus Primaquine will be given 2 weeks before second RTS,S/AS01E immunization. One week before 3rd RTS,S/AS01E immunization, a three-day course of Artemether/lumefantrine (A/L) plus Primaquine will be administered to clear infection. Rationale for administration of A/L is its preferred shortened half-life allowing for evaluation of vaccine efficacy thereby excluding any confounder effect due to prolonged anti-malarial effect of drug.
89609813|NCT04661579|Experimental|Group 2: Negative baseline parasitemia, antimalarial prophylaxis, RTS,S/AS01E vaccine|Group 2 subjects have no detectable P. falciparum parasitemia as measured by PCR at enrolment. It is proposed to initiate anti-malarial chemoprevention to subjects (prophylaxis effect) with DHA/Pip plus LD PQ 4 weeks prior to immunization with RTS,S/AS01E. A 2nd course of DHA/Pip plus Primaquine will be given 2 weeks before second RTS,S/AS01E immunization. One week before 3rd RTS,S/AS01E immunization, a three-day course of A/L plus Primaquine will be administered to clear infection.
89609814|NCT04661579|Experimental|Group 3: Positive baseline parasitemia, RTS,S/AS01E vaccine|Group 3 subjects have detectable P. falciparum parasitemia at baseline measured by PCR but will not receive any anti-malarial medications to clear PCR-positive parasites. This group includes 35 subjects and is included only for immunological assessment and not for vaccine efficacy. Subjects in Group 3 will be administered RTS,S/AS01E three times on a 0, 1, 7 month schedule.
89688359|NCT04347031|Experimental|group 1 cohort 1|"80 patients who receive Mefloquine prescribed according to the following scheme:~1st day: 750 mg of mefloquine per day, inside, in tablets of 250 mg 3 times a day - 1 tablet every 8 hours.~Day 2: 500 mg of mefloquine, inside, in tablets of 250 mg 2 times a day - 1 tablet every 12 hours.~3rd - 7th day: 250 mg of mefloquine, inside, in tablets of 250 mg 1 time a day at the same time."
89033713|NCT06018389|No Intervention|Control|The Control condition is an assessment-only condition. During the period under study, it includes the same assessments (surveys) as the other two conditions. After the last follow-up (August 2024), control schools can opt-in to receive any of the intervention programs.
89033714|NCT06018298||Therapeutic security|assessment of residents in REMS for need for therapeutic security, treatment response relevant to forensic need and forensic recovery.
89033715|NCT06018298||Risk Measures of Need (RISKMON)|assessed symptom severity, risk and protective factors for violence, global function, personality factors.
89033716|NCT06017843|Experimental|Intervention|Camps site selection for active case finding for TB using MATCH-AI
89609815|NCT04661579|Placebo Comparator|Group 4: Positive baseline parasitemia, antimalarial treatment, rabies vaccine|Group 4 subjects have detectable P. falciparum parasitemia at baseline measured by PCR (note any positive result from PCR will be considered positive for purposes of group selection and study endpoints as with Group 1) and will receive DHA/Pip , Primaquine, and A/L on the same schedule as subjects in group 1. Subjects in Group 4 will be administered Abhayrab rabies vaccine on a 0, 1, 7 month schedule.
89609816|NCT04661579|Placebo Comparator|Group 5: Negative baseline parasitemia, antimalarial prophylaxis, rabies vaccine|Group 5 subjects have no detectable P. falciparum parasitemia as measured by PCR at enrolment and will receive DHA/Pip, Primaquine, and A/L on the same schedule as subjects in group 2. Subjects in Group 5 will be administered Abhayrab rabies vaccine on a 0, 1, 7 month schedule.
89609817|NCT01964963||Alogliptin|Alogliptin 25 mg, tablets, orally, once daily for up to 12 months. Participants will receive interventions as part of routine medical care.
89609818|NCT04739657||Participants|Subjects whose clinical conditions require stent implantation, and the interventional procedure of which needs the guidance of IVUS imaging.
89609819|NCT01964105|Experimental|3D Imaging Simulation|Intervention Group: 3D Image Simulation + Standard Preoperative Evaluation Goal: 50 patients
89609820|NCT01964105|No Intervention|Standard Preoperative Evaluation|"Control Group: Patients will receive standard preoperative evaluation (2D imaging).~Goal: 50 patients"
89609821|NCT01964105|Other|Non-Randomized Cohort: 3D Imaging|"Patients who refuse the option of randomization but otherwise meet the inclusion and exclusion criteria will be offered participation in this study as part of a non-randomized cohort.~Goal: 50 Patients"
89609822|NCT01974323|Experimental|Dapsone Gel|Dapsone gel applied topically to the face and to affected areas of the trunk once daily for 12 weeks.
89609823|NCT01974323|Placebo Comparator|Dapsone Gel Vehicle|Dapsone gel vehicle applied topically to the face and to affected areas of the trunk once daily for 12 weeks.
89609824|NCT01963403|Active Comparator|EE 30mcg/LNG 150mcg|combined oral contraceptive pill: ethinyl estradiol (EE) 30mcg/levonorgestrel 150mcg); 1 pill per day; daily during study participation (up to 84 days)
89033717|NCT06017843|No Intervention|Control|Camps site selection for active case finding for TB using existing approaches.
89033718|NCT06017804|Experimental|MET Group|Received a muscle energy technique
89033719|NCT06017804|Active Comparator|SMFR Group|Received a self-myofascial release technique using a foam roller
89033720|NCT06017544||T2DM patients with GLP-1 RA|T2DM patients hospitalized due to AMI as a primary diagnosis, both STEMI and NSTEMI, referred for PCI, and under GLP-1 RA.
89033721|NCT06017544||T2DM patients with SGLT2-is|T2DM patients hospitalized due to AMI as a primary diagnosis, both STEMI and NSTEMI, referred for PCI, and under SGLT2-is.
89033722|NCT06017544||T2DM patients with GLP-1 RA plus SGLT2-is|T2DM patients hospitalized due to AMI as a primary diagnosis, both STEMI and NSTEMI, referred for PCI, and under GLP-1 RA plus SGLT2-is.
89609825|NCT01963403|Placebo Comparator|Placebo|Placebo
89609826|NCT04416503|Experimental|Intervention group|Foot reflexology was performed for 12 week in the intervention group, whereas the control group continued their routine treatment and follow-up.
89609827|NCT04416503|No Intervention|Control group|Usual follow-up was done to the control group.
89609828|NCT01973387|Experimental|Treatment Arm A|
89033723|NCT06017362|Experimental|Insulin|Topical insulin 1UI/ml 4 times a day
89033724|NCT06017362|Placebo Comparator|Placebo (artificial tears)|Artificial tears 4 times a day
89033725|NCT06016218|Placebo Comparator|PRF|PRF alone was added to extraction site prior to implant insertion
89609829|NCT01973387|Experimental|Treatment Arm B|
89609830|NCT04657445||home-quarantined patients|home-quarantined patients
89609831|NCT04657445||inhospitalized patients|inhospitalized patients
89609832|NCT01973231|Experimental|Metformin + liraglutide 1.8 mg|
89033726|NCT06016218|Active Comparator|SIM+ PRF|PRF + 1.2mg Statin powder are inserted into the extraction site before implant insertion
89033727|NCT06016218|Active Comparator|BO+ PRF|PRF + Bone powder are inserted into the extraction site before implant insertion.
89033728|NCT06013618|Other|naxitamab and GM-CSF only|Suitable for patients with high risk neuroblastoma who obtain CR after chemotherapy combined with surgery, radiotherapy and/or hematopoietic stem cell transplantation. The treatment cycle is repeated every 4 weeks for a total of 5 courses, and discontinuation of nasetuzumab and GM-CSF should be considered if disease progression or unacceptable toxicity occurs.
89609833|NCT01973231|Active Comparator|Metformin + lixisenatide 20 microg|
89609834|NCT01961687|Other|Resorbable Mesh|Phasix Mesh
89609835|NCT04656275|Experimental|BI 1323495 treatment group (part 1)|Part 1
89609836|NCT04656275|Experimental|BI 1323495 treatment group (part 2)|Part 2
89033729|NCT06013618|Other|naxitamab and GM-CSF in combination with irinotecan and temozolomide|Suitable for high-risk group neuroblastoma treated by chemotherapy combined with surgery, radiotherapy and or hematopoietic stem cell transplantation patients with tumor residual or progression during treatment (refractory); Patients who relapse after initial treatment. Repeat every 3 weeks until tumor progression, patient withdrawal, or toxicity becomes intolerable, up to 8 procedures.
89033730|NCT06013618|Other|naxitamab and GM-CSF in combination with irinotecan and temozolomide and PD-1 antibody|Suitable for high-risk group neuroblastoma treated by chemotherapy combined with surgery, radiotherapy and or hematopoietic stem cell transplantation patients with tumor residual or progression during treatment (refractory); Patients who relapse after initial treatment. Repeat every 3 weeks until tumor progression, patient withdrawal, or toxicity becomes intolerable, up to 8 procedures.
89609837|NCT04656275|Placebo Comparator|Placebo group|Placebo
89609838|NCT04174391|Experimental|Mediterranean diet supplemented with extra-virgin olive oil|
89609839|NCT04174391|Active Comparator|Low-fat diet|
89609840|NCT02151994|Experimental|BIA 5-1058|BIA 5-1058 (5, 25 and 100 mg) tablets
89609841|NCT02151994|Placebo Comparator|Placebo|tablets, visually matching active medication
89609842|NCT05356468|Experimental|Structured pain neuroscience education|Pain neuroscience education will be given to both groups. Group A will receive Structured Pain Neuroscience Education along with therapeutic , balance exercises and Postural training.
89609843|NCT05356468|Active Comparator|Conventional treatment|"Group B will receive Pain Neuroscience Education along with therapeutic, balance exercises. The treatment will continue for 6 weeks. Three sessions will be given in a week. Assessment would be done on baseline and at the end of every third week.~Each session will be of 45 minutes. 15min electrotherapy, 15 min conventional treatment, 15 min PNE education."
89609844|NCT04382950|Experimental|Experimental: rbACE2 group plus Aerosolized Isotretinoin|rbACE2 0.4 mg/kg IV BID for 7 days (unblinded) plus Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days
89609845|NCT04382950|No Intervention|No Intervention: Control group|Standard of care; no placebo
89609846|NCT04382560|Experimental|Intervention group|The intervention group will receive a Deep Breathing Training and a Compassion Intervention. Deep Breathing Training and Compassion Intervention will be administered once, on two consecutive days, and will last for 30 minutes.
89609847|NCT04382560|No Intervention|Wait-list control group|The waiting list group will receive the intervention at the end of the study.
89609848|NCT01961609|Experimental|Secukinumab (AIN457) 300 mg|Participants self-administered 300 mg secukinumab loading dose subcutaneously at Day 0 (initiation of study drug) and at weeks 1, 2, 3 & 4, and then every 4 weeks. Following the Primary Endpoint at 16 weeks, participants meeting the NICE criteria of adequate response were eligible to continue on study treatment for a further 32 weeks. Participants not meeting this NICE criterion returned to routine treatment under the care of their usual Clinical Team. Following assessment at week 48, participants meeting the NICE criteria of adequate response were eligible to continue on study treatment for a further 24 weeks. Participants not meeting this NICE criterion returned to routine treatment under the care of their usual Clinical Team.
89033731|NCT06012734|Experimental|LB-100 plus atezolizumab|LB-100 IV over 15 minutes on day 1 and day 3 Atezolizumab IV over 30-60 minutes on day 1 Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity
89609849|NCT01961609|Experimental|Secukinumab (AIN457) 150 mg|Participants self-administered secukinumab 150 mg loading dose subcutaneously at Day 0 (initiation of study drug), weeks 1, 2, 3 & 4 and then every 4 weeks. Following the Primary Endpoint at 16 weeks, participants meeting the NICE criteria of adequate response were eligible to continue on study treatment for a further 32 weeks at the 150mg dose. Participants not achieving the NICE criteria at the Primary Endpoint were up titrated to 300mg. Following assessment at week 48, participants meeting the NICE criteria of adequate response were eligible to continue on study treatment for a further 24 weeks at the 150mg dose. Participants not achieving the NICE criteria at 48 weeks on the 150mg dose were up titrated to 300mg.
89609850|NCT00800254|Experimental|Neuromuscular Electrical Stimulation (NMES)|
89609851|NCT00800254|Active Comparator|Standard Rehabilitation Protocol|
89609852|NCT03753646|Experimental|Lactating allowance and psycho social stimulation|Mothers will receive lactating allowance and psycho social stimulation
89609853|NCT03753646|No Intervention|Only lactating allowance|Mothers will receive only lactating allowance
89609854|NCT04383418|Experimental|High dose group|In the low dose group, 36 subjects will receive a low dose of dexmedetomidine nasal spray.
89609855|NCT04383418|Experimental|Low dose group|In the high dose group, 36 subjects will receive a high dose of dexmedetomidine nasal spray.
89033732|NCT06012461|Experimental|Bilateral STN DBS Modulation|Participants will be implanted with bilateral STN DBS using PINS 106RS system. DBS stimulation will be initiated one month post surgery. Follow-up visits will be conducted 1/3/6/9/12/15 months post surgery with clinical evaluation, STN LFP recording and resting state functional MRI testing. During the 6-15 month's visit, short-term closed-loop DBS modulation (from 24hours to 72hours ) will be conducted to test the safety and efficacy of closed-loop DBS therapy.
89033733|NCT06011551|Experimental|Treatment Arm|"Group A: continued non-surgical conservative medical management plus a percutaneous hydrogel spinal implant delivered via the HYDRAFIL System (the HYDRAFIL implant) (the Treatment Arm)"
89033734|NCT06011551|Sham Comparator|Control Arm|"Group B: continued non-surgical conservative medical management plus advancement of the HYDRAFIL System delivery needle to the outside of the target disc(s) without contacting the outer edge of the annular fibers (the Control Arm)"
89033735|NCT06011369|Experimental|Fluorescence in thyroid surgery|Patients undergoing thyroid surgery with cervical fluorescence.
89033736|NCT06011369|No Intervention|No Fluorescence in thyroid surgery|patients undergoing thyroid surgery without cervical fluorescence.
89609856|NCT04383418|Placebo Comparator|Placebo group|In the placebo group，36 subjects will receive dexmedetomidine hydrochloride nasal spray blank preparation.
89609857|NCT03414112|Placebo Comparator|Intranasal Oxytocin Placebo|Intranasal placebo
89609858|NCT03414112|Experimental|Intranasal Oxytocin|Intranasal oxytocin
89609859|NCT02152540|Experimental|ACTIVE rTMS|Those receiving experimental treatment will receive 20 sessions of rTMS. The treatment will be delivered by trained medical personnel.
89033737|NCT06011278|Experimental|Community-supported videos|"Community-supported videos will be sent to the children in the experimental group once a week for a month. At the end of four weeks, the Chıld Attıtude Toward Illness Scale and the Memorial Symptom Assessment Scale will be administered to the children again."
89033738|NCT06011278|No Intervention|Standard care|"Children in the control group will receive the standard care of the pediatric oncology clinic.At the end of four weeks, the Chıld Attıtude Toward Illness Scale and the Memorial Symptom Assessment Scale will be administered to the children again."
89033739|NCT06010797|Experimental|Orthodontic patients who are shown pre-treatment photographs|Group A included 30 patients who were shown their pre-treatment extra-oral and intra-oral photographs.
89033740|NCT06010797|No Intervention|Orthodontic patients who were not shown pre-treatment photographs|Group B included 30 patients who were not shown their pre-treatment extra-oral and intra-oral photographs.
89057775|NCT04530695|Experimental|Arm A: Deep Cleaning|participants with periodontitis will undergo treatment by scaling and root planing (SRP)
89609860|NCT02152540|Placebo Comparator|Sham rTMS|Those receiving the sham rTMS will receive 20 sessions of sham rTMS. The treatment will be delivered by trained medical personnel.
89609861|NCT04383184||TRACHEAL FORMING GROUP|Left pulmonary artery transplantation and slide tracheoplasty
89609862|NCT04383184||NON-TRACHEAL FORMING GROUP|only Left pulmonary artery transplantation
89033741|NCT06010576|Active Comparator|EUS-guided rendezvous group (EUS RV group)|In the EUS RV group, a linear array echoendoscope would be used to evaluate the common bile duct and left intrahepatic duct in order to identify the optimal route for biliary access by fine needle. Using a 19 gauge EUS needle, the dilated biliary tree will be accessed by either a transduodenal puncture to the common bile duct or a transgastric puncture to the left intrahepatic duct under direct EUS guidance. The optimal access route will be based on patient's anatomy after EUS assessment and left to the discretion of the investigator. Next, a guidewire would be advanced through the needle into the bile duct and out of the papillary orifice. The echoendoscope would then be exchanged to a duodenoscope for ERCP. The EUS rendezvous ERCP procedure will be completed by retrieving the rendezvous guidewire into the duodenoscope or by cannulation alongside the rendezvous guidewire to obtain biliary access.
89033742|NCT06010576|Active Comparator|Early precut papillotomy group (EPP group)|In the EPP group, the precut papillotomy would be performed with 1 of the following acceptable techniques per the usual practice of the study investigator and institution: 1) conventional precut papillotomy by needle knife, 2) precut fistulotomy by needle knife, or 3) transpancreatic precut papillotomy by papillotome
89609863|NCT03839134|Experimental|Pain of buccal injection with DentalVibe®|DentalVibe® Comfort Injection System will be used prior and during the local anesthesia (LA) buccal injection. The LA to be used is Lidocaine 2% with Epinephrine dental injection.
89033743|NCT06009991|Experimental|Age 45-64|Patients aged 45 to 64 years
89033744|NCT06009991|Experimental|Age 65-74|Patients aged 65 to 74 years
89033745|NCT06009991|Experimental|Age 75-84|Patients aged 75 to 84 years
89609864|NCT03839134|Active Comparator|Pain of buccal injection without DentalVibe®|Local anesthesia (LA) for buccal infiltration using Lidocaine Epinephrine dental injection. No tissue vibrations will be performed before or during the injection.
89609865|NCT03839134|Experimental|Pain of palatal injection with DentalVibe®|DentalVibe® Comfort Injection System will be used prior and during the local anesthesia (LA) palatal injection. The LA to be used is Lidocaine 2% with Epinephrine dental injection.
89033746|NCT06009991|Experimental|Age over 75|Patients aged over 85 years
89033747|NCT06009120|Experimental|Intervention|"Intervention (education) group:~In addition to the standard discharge education, mothers in this group received breastfeeding education."
89033748|NCT06009120|No Intervention|Control|"Control group: In this group, first of all, mothers were informed about the study within the first day after birth, and informed consent forms were signed by those who voluntarily agreed to participate. In addition, Personal Information Form, IOWA Infant Feeding Attitude Scale and Psychosexual Theory and Breastfeeding Information Scale were applied to these mothers on the first day. Then, as the routine care of the institution, the standard discharge education program on the third day was applied by the institution nurse. After this education, IOWA Infant Feeding Attitude Scale and Psychosexual Theory and Breastfeeding Knowledge Form were re-administered to mothers as a post-test. No additional intervention was applied other than standard care education. During the 5 days following discharge, mothers were interviewed by phone and Breastfeeding Form'' applied."
89609866|NCT03839134|Active Comparator|Pain of palatal injection without DentalVibe®|Local anesthesia (LA) for palatal infiltration using Lidocaine Epinephrine dental injection. No tissue vibrations will be performed before or during the injection.
89609867|NCT03839134|Experimental|Pain of block injection with DentalVibe®|DentalVibe® Comfort Injection System will be used prior and during the local anesthesia (LA) injection for inferior alveolar nerve (IAN) block. The LA to be used is Lidocaine 2% with Epinephrine dental injection.
89609868|NCT03839134|Active Comparator|Pain of block injection without DentalVibe®|Local anesthesia (LA) injection for inferior alveolar nerve (IAN) block using Lidocaine Epinephrine dental injection. No tissue vibrations will be performed before or during the injection.
89609869|NCT03180580|Experimental|HEAL guideline+ Healthy Tiffin box|"HEAL guideline+ Healthy Tiffin box intervention arm will receive a culturally appropriate healthy eating and active living messages including a specially designed healthy tiffin box to practice healthy eating. HEAL guideline+ Healthy Tiffin box is a combination of intervention to promote healthy eating and physical activity behavior as well as improve the practice.~HEAL guideline-Healthy Eating and Active Living (HEAL) Guideline. A complete intervention guideline for promoting healthy dietary pattern and physical activity.~Healthy Tiffin box- A five chamber snack box that will help to contain food stuffs from all 5 major food groups eg; grain, meat/fish foods, vegetables, fruits and milk or milk products. This box will help to practice healthy eating behaviors."
89609870|NCT03906526|Experimental|Monotherapy Arm 1: Nivolumab|Nivolumab IV every 2 weeks
89609871|NCT03906526|Experimental|Monotherapy Arm 2: Motolimod|Motolimod IT injection weekly
89609872|NCT03906526|Experimental|Combination Arm 3: Nivolumab and Motolimod|Nivolumab IV every 2 weeks and Motolimod IT injection weekly
89609873|NCT03906526|Experimental|Combination Arm 4: Nivolumab and Motolimod|Nivolumab IV every 2 weeks and Motolimod SC injection weekly
89609874|NCT03088930|Experimental|Neoadjuvant treatment with Crizotinib|Patients enrolled in this study will be treated with 6 weeks of induction therapy with crizotinib. On the last day of dosing, patients will then undergo surgical resection. 5 years of follow-up will be done via chart review.
89609875|NCT03035188|Experimental|Vismodegib|Continuous once-daily oral dosing of vismodegib at a dosage of 150 mg per administration
89609876|NCT05265754|Experimental|Experimental group|In the hand area, firstly, the points will be determined by means of the diagnostic stick and massage will be applied with buckwheat seeds. This massage will be 3 sessions a week, and a total of 6 sessions in 2 weeks.
89609877|NCT05265754|No Intervention|control group|A questionnaire will be applied to the patients by the researcher. Questionnaires will be made as pre-test and post-test.
89609878|NCT02923882|Experimental|Intervention group|In the intervention group, the pregnant women at 8-12 weeks of gestational age used biomass fuels for cooking in the '$100Kitchen and improved cookstove'.
89609879|NCT02923882|No Intervention|Control group|In the control group, the pregnant women at 8-12 weeks of gestational age used biomass fuels for cooking in the traditional cookstove.
89609880|NCT02152696|Active Comparator|Expectant Management|Subjects will have their PPUL expectantly managed using serum hCG monitoring.
89609881|NCT02152696|Active Comparator|Uterine evacuation with MTX for some|Subjects will undergo a uterine evacuation. If hCG levels do not sufficiently decrease after the uterine evacuation, the subject will be treated with methotrexate. If hCG levels do sufficiently decrease after the uterine evacuation, no further treatment is required.
89609882|NCT02152696|Active Comparator|Empiric treatment with MTX for all|Subjects will be treated with methotrexate, receiving one dose on day 0 and a subsequent dose on day 4. Additional doses will be administered as needed based on hCG levels.
89609883|NCT02153476|Experimental|2.0mg of ALG-1001|2.0mg of ALG-1001
89609884|NCT02153476|Placebo Comparator|Intravitreal injection in 0.05cc balanced salt solution.|Balanced Salt Solution
89609885|NCT03839290||Bilateral cleft lip and palate patients|Newborns with complete bilateral cleft lip and palate (cBCLP) and bilateral cleft lip and palate with tissue bridges (BCLP + B) analyzed one year after neonatal cheiloplasty
89609886|NCT03839290||Unilateral cleft lip and palate patients|Newborns with complete unilateral cleft lip and palate (cUCLP) and unilateral cleft lip and palate with tissue bridges (UCLP + B) analyzed one year after neonatal cheiloplasty
89609887|NCT02659618||Severe Persistent Asthma|All subjects will have severe persistent asthma diagnosed by a doctor.
89609888|NCT03834922||Total knee arthroplasty|Patients undergoing total knee arthroplasty
89609889|NCT03834922||Sternotomy|Patients undergoing sternotomy
89609890|NCT03834922||Breast|Patients undergoing breast surgery
89609891|NCT03834922||Endometriosis|Patients undergoing endometriosis-related surgery
89609892|NCT05172232||Primary care patients with melanoma suspicious skin lesion(s)|Patients seeking primary care, having one or more skin lesion that the primary care physician cannot by certainty can rule out as being a possible melanoma.
88983056|NCT05951816|Experimental|Biodistribution in patients with systemic AL or ATTR amlyoidosis|"Patients with a confirmed diagnosis of systemic AL or ATTR (with or without a positive PyP scan) will be administered a single IV dose of up to 1 mg of 99mTc-p5+14 (~20 mCi) by slow push (~1 mL/5 sec.). At ~1 hour and ~3 hours post-injection, patients will undergo abdominothoracic planar imaging followed by SPECT/CT imaging covering the same area. Vital signs (blood pressure, respiration rate, temperature, and pulse) will be acquired before injection of the 99mTc-p5+14, and at ~3 hours post injection.~On Day 3, patient will undergo a trans thoracic echo examination. On Day 4, patients will undergo Technescan™ 99mTc-PYP (20 mCi) planar and SPECT/CT imaging at ~1 hour and ~3 hours post-injection. Vital signs (blood pressure, respiration rate, temperature, and pulse) will be acquired before injection of the 99mPYP, and at ~3 hours post injection."
88983057|NCT05951803|Other|Brief Behavioral Intervention in Insomnia through Tele-Consultation (BBII-TC)|Brief therapy organized into four sessions, lasting 60 minutes each, where behavioral therapy techniques are taught (stimulus control, sleep restriction, progressive muscle relaxation, sleep hygiene). The teleconsultation modality is given through the ZOOM platform synchronously.
88983058|NCT05951790|Active Comparator|Inspiratory Muscle Training (IMT)|Use of Powerbreathe Device associated with aerobic excercise tailored for walking and non-walking subjects
89609893|NCT02009176|Experimental|Laparoscop Anatomical Hepatectomy|Total laparoscopic anatomical hepatectomy were performed, combined with cholecystectomy when necessary. The intraoperative ultrasound, hepatic segmental staining were used selectively.
89609894|NCT02009176|Active Comparator|Laparoscope Aon-anatomical Hepatectomy|Total laparoscopic aon-anatomical hepatectomy were performed, combined with cholecystectomy when necessary. The intraoperative ultrasound or hepatic segmental staining will be used to ensure the tumour was completely resected.
89609895|NCT01905436||Annual Mass Drug Administration|This group will receive annual mass drug administration (Albendazole 400 mg plus Ivermectin) provided by the Liberian Ministry of Health.
89609896|NCT01905436||Semiannual Mass Drug Administration|This group will receive semi-annual mass drug administration (Albendazole 400 mg plus Ivermectin) provided by the Liberian Ministry of Health.
89609897|NCT00802204|Active Comparator|Lean controls|Lean complete baseline outcome measures only
89609898|NCT00802204|Experimental|Obese|Obese completing baseline and post-VLCD outcome measures
89609899|NCT01853020|Active Comparator|THC|"Very low dose (0.0015 mg/kg = 0.21 mg in a 70 kg individual) THC, dissolved in alcohol. Administered intravenously over 10 minutes.~Low dose (0.015 mg/kg = 1.05 mg in a 70 kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately ¼ of a marijuana cigarette, or joint. Administered intravenously over 10 minutes.~Medium dose (0.03 mg/kg = 2.1 mg in a 70 kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately ½ of a marijuana cigarette, or joint. Administered intravenously over 10 minutes."
89609900|NCT01853020|Placebo Comparator|Placebo|Control: small amount of alcohol intravenous (quarter teaspoon), with no THC over 10 minutes
89609901|NCT01256086|Experimental|24 µg Formoterol Novolizer|12µg Formoterol Novolizer#1 + 12µg Formoterol Novolizer#2 + Placebo Aerolizer#1 + Placebo Aerolizer #2
89609902|NCT01256086|Experimental|12µg Formoterol Novolizer|12µg Formoterol Novolizer#1 + Placebo Novolizer#2 + Placebo Aerolizer#1 + Placebo Aerolizer #2
88983059|NCT05951790|Experimental|Inspiratory Muscle Training (IMT) + Air Stacking|Use of Powerbreathe Device and application of Air-Stacking maneuvres associated with aerobic excercise tailored for walking and non-walking subjects
88983060|NCT05951751|Experimental|TRI-MOM|Women attending their first postnatal visit in one of the selected maternities (no maternal age limit) will be eligible to participate in the study
88983061|NCT05951738|Other|Depressed|
88983062|NCT05951738|Other|At high risk|
89609903|NCT01256086|Active Comparator|24 µg Formoterol Aerolizer|Placebo Novolizer#1 + Placebo Novolizer#2 + 12µg Formoterol Aerolizer#1 + 12µg Formoterol Aerolizer #2
89609904|NCT01256086|Active Comparator|12µg Formoterol Aerolizer|Placebo Novolizer#1 + Placebo Novolizer#2 + 12µg Formoterol Aerolizer#1 + Placebo Aerolizer #2
89609905|NCT01774981|Placebo Comparator|Placebo (Part A)|Part A: Placebo administered by 60 minute Intravenous (IV) infusion at Week 1 and Week 4.
89609906|NCT01774981|Experimental|10 mg LY3016859 (Part A)|Part A: 10 milligram (mg) LY3016859 administered by 60 minute IV infusion at Week 1 and Week 4.
89609907|NCT01774981|Experimental|100 mg LY3016859 (Part A)|Part A: 100 mg LY3016859 administered by 60 minute IV infusion at Week 1 and Week 4.
89609908|NCT01774981|Experimental|750 mg LY3016859 (Part A)|Part A: 750 mg LY3016859 administered by 60 minute IV infusion at Week 1 and Week 4.
89609909|NCT01774981|Placebo Comparator|Placebo (Part B)|Part B: Placebo administered by 60 minute IV infusion at Weeks 1, 4, 7, 10 and 13.
89609910|NCT01774981|Experimental|50 mg LY3016859 (Part B)|Part B: 50 mg LY3016859 administered by 60 minute IV infusion at Weeks 1, 4, 7, 10 and 13.
89609911|NCT01774981|Experimental|250 mg LY3016859 (Part B)|Part B: 250 mg LY3016859 administered by 60 minute IV infusion at Weeks 1, 4, 7, 10 and 13.
89609912|NCT01774981|Experimental|750 mg LY3016859 (Part B)|Part B: 750 mg LY3016859 administered by 60 minute IV infusion at Weeks 1, 4, 7, 10 and 13.
89609913|NCT01972841|Experimental|1: Solifenacin 5 mg + Mirabegron 25 mg|Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks.
89609914|NCT01972841|Experimental|2: Solifenacin 5 mg + Mirabegron 50 mg|Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks.
89609915|NCT01972841|Placebo Comparator|3: Placebo|Participants who received matching placebo once a day for 12 weeks.
89609916|NCT01972841|Active Comparator|4: Solifenacin 5 mg|Participants who received solifenacin 5 mg once a day for 12 weeks.
89609917|NCT01972841|Active Comparator|5:Mirabegron 25 mg|Participants who received mirabegron 25 mg once a day for 12 weeks.
89609918|NCT01972841|Active Comparator|6: Mirabegron 50 mg|Participants who received mirabegron 50 mg once a day for 12 weeks.
89609919|NCT01774903|Experimental|TTS-fentanyl|
89609920|NCT01774591|Active Comparator|azilsartan medoximil.|Subjects randomized to azilsartan medoximil arm will take 80 mg of azilsartan medoximil tablets by mouth each day.
89609921|NCT01774591|Placebo Comparator|Placebo|Subjects randomized to the placebo arm will take 80 mg of placebo tablets by mouth each day
88983063|NCT05951738|Other|Control|
89210760|NCT00727571||No CKD or Anemia|Chronic kidney disease (CKD) is based on estimated Glomerular Filtration Rate (GFR), calculated by the Modification of Diet in Renal Disease (MDRD) method, of < 60 mL/min/1.73m^2. Anemia is defined as Hemogloblin <12 g/dL in women, < 13 g/dL in men per World Health Organization (WHO) criteria. Participants completed the study after Week 1; data contributed to prevalence estimates.
89210761|NCT00727571||No CKD, but Anemia|CKD is based on estimated GFR calculated by the MDRD method of < 60 mL/min/1.73m^2. Anemia is defined as Hemogloblin <12 g/dL in women, < 13 g/dL in men per WHO criteria. Participants completed the study at Week 2 and completed an anemia work-up; data contributed to prevalence estimates.
89609922|NCT01708915|Active Comparator|nonivamide + nicoboxil (Finalgon)|2cm ointment line for a skin area of approximately 20 cm x 20 cm up to 3 times in a 24h period
89609923|NCT01708915|Active Comparator|nonivamide|2cm ointment line for a skin area of approximately 20 cm x 20 cm up to 3 times in a 24h period
89609924|NCT01708915|Active Comparator|nicoboxil|2cm ointment line for a skin area of approximately 20 cm x 20 cm up to 3 times in a 24h period
89609925|NCT01708915|Placebo Comparator|placebo|2cm ointment line for a skin area of approximately 20 cm x 20 cm up to 3 times in a 24h period
88983070|NCT05951699||minimally invasive preoperative image-guided vacuum-assisted biopsy|"cT1-cT2-cT3 cN0-cN1 breast cancer patients, either with clinical/radiological complete response, or with <1 cm residual breast disease after systemic primary treatment, undergo preoperative image-guided breast VAB with 9-gauge needle.~Patients who are cN1 before systemic primary treatment undergo removal of the tagged axillary nodes.~In both cases the aim is to identify any residual disease. Conservative breast surgery or mastectomy will be performed in all patients after multidisciplinary clinical evaluation.~Surgically confirmed residual tumor will be compared to VAB result."
88983071|NCT05951686|Active Comparator|Group inhalation|Patients will receive desflurane as an inhalation anesthetic and remifentanil infusion for general anesthesia maintenance during the surgery. The doses of desflurane and remifentanil will be adjusted according to the Patient State Index (PSI) where the goal score is 25-50.
88983072|NCT05951686|Active Comparator|Group tiva|Patients will receive total intravenous anesthesia with an infusion of propofol and remifentanil for general anesthesia maintenance during the surgery. The infusion doses will be changed according to the Patient State Index (PSI) where the goal score is 25-50.
88983073|NCT05951673|Experimental|Treatment 1 - Receives Safe Space based life skills training program|Adolescent girls in this group receive a safe space-based life skills training program within their school.
88983074|NCT05951673|Experimental|Treatment 2 - Recieves Safe Space based life skills training program + digital literacy training|Adolescent girls in this group receive a safe space-based life skills training program and a digital literacy training program within their school.
88983075|NCT05951673|No Intervention|Control - No intervention|Adolescent girls in this group receive neither the safe space-based life skills training program nor the digital literacy training program.
88983076|NCT05951647|Placebo Comparator|Scaling|12 patients will be managed by scaling only
89609926|NCT01708291|Active Comparator|Mindfulness Based Stress reduction|attending 10 weekly sessions and comprised of an eight week mindfulness intervention program, and completing pre- and postevaluation measures on the first and last sessions
89609927|NCT01708291|Placebo Comparator|No Mindfulness based intervention|completing only re- and post-evaluation measures on the first and last sessions
89609928|NCT01708057|Experimental|1|Single dose of AZD8683 50 µg
89609929|NCT01708057|Experimental|2|Single dose of AZD8683 150 µg
89609930|NCT01708057|Experimental|3|Single dose of AZD8683 300 µg
89609931|NCT01708057|Experimental|4|Single dose of AZD8683 900 µg
89609932|NCT01708057|Placebo Comparator|5|Single dose of placebo
89609933|NCT01708057|Active Comparator|6|Single dose of tiotropium 18 µg
89609934|NCT01748071||Sufentanil group|Grouped by intravenous injection of sufentanil at the time of anesthesia induction
89609935|NCT01748071||Fentanyl group|Grouped by intravenous injection of fentanyl at the time of anesthesia induction
89609936|NCT01748071||Saline group|Grouped by intravenous injection of saline before the time of anesthesia induction
89609937|NCT01972529|Experimental|Group A (avatrombopag, lower baseline platelet count)|60 mg avatrombopag (3 x 20 mg tablets) once daily on Days 1 through 5
89609938|NCT01972529|Placebo Comparator|Group B (placebo, lower baseline platelet count)|placebo (3 x 20 mg matching placebo tablets) once daily on Days 1 through 5
89609939|NCT01972529|Experimental|Group C (avatrombopag, higher baseline platelet count)|40 mg avatrombopag (2 x 20 mg tablets) once daily on Days 1 through 5
89609940|NCT01972529|Placebo Comparator|Group D (placebo, higher baseline platelet count)|placebo (2 x 20 mg matching placebo tablets) once daily on Days 1 through 5
89609941|NCT01747915|Experimental|Study Drug Level 1|
89609942|NCT01747915|Experimental|Study Drug Level 2|
89609943|NCT01747915|Placebo Comparator|Placebo|
89609944|NCT03189004|Active Comparator|Identification and registration of pregnant women and servic|Pregnant women will receive auto reminder through their mobile for ANC visit prior to their scheduled date for each visit via voice message followed by text message. The schedule visit date will be calculated by the system automatically from the LMP. The reminder will include the date, time, available facilities and services for ANC, and will be sent to the women several times to ensure their ANC visits. The system will also send auto reminder through text message to the concerned service provider to check whether the pregnant woman has received ANC or not. The service provider will provide and update the ANC services and status of the particular pregnant woman. Apart from ANC reminders, the pregnant women will also receive voice message on healthcare during pregnancy, danger signs and birth preparedness.From the LMP, the expected date of delivery (EDD) will be calculated by the system and reminder will be sent to the pregnant women automatically.
89609945|NCT03189004|Active Comparator|Birth notification|The pregnant women will be encouraged and trained to notify immediately after the delivery through SMS by themselves or by anyone on behalf of the delivered women. After receiving birth notification, system will automatically update the particulars of newborns including date of birth, PNC schedule, EPI vaccination due dates for the newborn and location of service centre. The system will also send auto reminder to the mothers with a specific time schedule for PNC visit, newborn care visit and schedule of receiving vaccines for the newborn.
89609946|NCT03189004|Active Comparator|Childhood vaccination services under EPI|After the outcome of the delivery of the registered pregnant women, the system will receive the birth notification as mentioned in the birth notification process. Mothers/caregivers of the newborn will receive auto voice/text messages one day prior to their visit to the vaccination centres. A second reminder will be sent to the parents of all the targeted children through their own phones or their family's numbers collected earlier on the vaccination day at the beginning of the vaccination session for bringing their children for vaccination. A third reminder will be sent to the mothers/caregivers of the children who were not vaccinated after receiving the second reminder as scheduled on that day. The system will also provide auto reminder to the concerned service provider including EPI session wise list of targeted children. The service providers will update the status of vaccination of session using their Smartphone
89609947|NCT03189004|Active Comparator|Newly married couple identification|The Smartphones will contain specific software for newly married couple registration where some necessary information (names of newly married couple, age, address, LMP, current contraceptive use, future fertility plan and mobile phone number) can be updated and sent to the server. A unique ID number will be automatically created. This unique ID will ensure her to get necessary family planning services within the study area. Based on the information gathered through couple registration process, the system will automatically generate the most suitable family planning options for a couple and send the information to the concerned service providers. The service provider will motivate the client for the most suitable FP method option generated by the system and after taking the consent they provide the method accordingly.
89609948|NCT03189004|Active Comparator|e-Referral|There will be online referral system for the registered women and their children for ANC, PNC, delivery care, neonatal management, IMCI and other complication management in which healthcare providers from lower facilities can refer a patient to the higher facilities. The women will be identified in the higher facilities by their unique ID. The service providers will enter referral data to the system during the referral process and the patients and providers from higher facilities will get system generated reminders about the referral. The service providers in higher facilities will be able to check the health status and cause of referral using patient's unique ID number from the system and will manage accordingly as well as update the given management to the system. If the referred woman does not visit the referral facility, she will receive repeated reminders auto-generated by the system to comply the referral
89609949|NCT03189004|Active Comparator|e-monitoring|There will be web based monitoring system to oversee the progress and status of all the activities under this study for policy makers, programme peoples and other supervisors from national to the union levels. All these data will be available in the central database which will be visualized and accessible at all concerned levels through internet in particular website. They can constantly follow up the progression and healthcare delivery system of the respective area and provide regular feedback, when necessary. There will be provision of auto-generation of reports for each and every activity through the system by area and service provider specific.
89609950|NCT01961297|Experimental|Sodium oxybate|Oral administration of a single dose of sodium oxybate (0.75-2.0 gm)
88815323|NCT01027598|Placebo Comparator|Erlotinib + Placebo|"Erlotinib: 150 mg orally daily~Placebo: orally daily"
88815324|NCT01654224|Active Comparator|High Dose Inactivated Influenza Vaccine|For HDIV,0.5 ml of high dose inactivated influenza vaccine consisting of a total of 180mcg (60 mcg each strain) of influenza virus hemagglutinin
88815325|NCT01654224|Active Comparator|Standard Dose Inactivated Influenza Vaccine|For SDIV, 0.5 ml of standard dose inactivated influenza vaccine consisting of a total of 45 mcg (15 mcg of each strain) of influenza virus hemagglutinin
88815326|NCT02447328|Experimental|Single Arm|Faslodex treated in the study
88815327|NCT02447250|Experimental|Single Arm: varied albuterol dose response|Subjects will be evaluated in 3 sessions. The sessions will occur within a 7 day time span, beginning after 14 days of age and at 28w0d to 33w6d corrected gestational age. In each session, pulmonary function tests (PFTs) will be performed prior to and 15 minutes after a dose of albuterol. The dose will be different in each session. In the first session, a single dose of 180 micrograms (2 puffs) of albuterol sulfate via metered dose inhaler. The dose will be 270 micrograms in the second session and 360 micrograms in the third session. PFTs will be performed during quiet sleep while the baby is spontaneously breathing or while the baby is intubated and receiving mechanical ventilation. Resistance and compliance will be measured using the single breath occlusion technique.
88815328|NCT00990938|Placebo Comparator|Saline|If randomized to placebo the patient will receive a subcutaneous injection once per week for 4 weeks
89609951|NCT04656041|Experimental|FOLFOX/ nal-IRI|"Treatment will be administered on an outpatient basis.~FOLFOX with nal-IRI for eight two-week cycles (16 weeks total)~Chemoradiation with proton or photon radiation therapy concurrent with weekly Paclitaxel and Carboplatin for 5 weeks~Surgery"
89609952|NCT01960907|No Intervention|Observational|"Subjects in the observational arm will receive monthly interviews for collecting informations about their status and level of utilization of healthcare resources.~They will follow their usual care path as provided by their local NHS"
89609953|NCT01960907|Experimental|Interventional|"Patients will receive a system form monitoring their health status.~The system is composed by:~a touch-screen pc for the administration of daily questionnaires~RESMONPRO DIARY for the measurement of lung mechanical impedance and breathing pattern~a Medic4all Wrist Clinic for the assessment of heart rate, blood pressure, saturation, 1 lead ECG, body temperature.~Subjects will receive medical treatment following the activation of alarms by the monitoring devices.~Monthly phone interviews will be performed to collect data about their level of utilization of the health care system."
89609954|NCT01747837|No Intervention|standard ICD implantation alone|These subjects will undergo standard ICD implantation alone (if not already present)
89609955|NCT01747837|Experimental|Boston Scientific Vessix Renal Denervation System|"These subjects will undergo standard ICD implantation (if not already present) plus renal sympathetic denervation.~Ablation arm"
89609956|NCT01971203|Experimental|seroquel xr|quetiapine target dosage will be 150 mg/day, beginning at 50 mg/day 16 weeks of treatment including CBT
89609957|NCT01971203|Placebo Comparator|placebo plus CBT|treatment group receiving placebo pill plus CBT
89609958|NCT04654325|Other|Patients attending to the COVID19 screening facility|Patients will have both nasopharyngeal and conjunctival swab for SARS-CV-2 genome detection using PCR. Study will evaluate the prevalence of positive conjunctival swabs in patients with positive nasopharyngeal swab. These results will be corelated to symptoms of disease assessed with a stan
89609959|NCT01605877|Experimental|SN6AD2|AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL Model SN6AD2 [SV25T0], bilateral implantation
89609960|NCT01970501|Experimental|bucindolol hydrochloride|"bucindolol hydrochloride (bucindolol)~Participants were randomized (1:1) to blinded treatment with bucindolol or metoprolol and titrated weekly to target doses of 50 mg twice daily (BID; < 75 kg) or 100 mg BID (≥ 75 kg) for bucindolol or 200 mg once daily (QD) for metoprolol. 84% of bucindolol participants attained target dose and 72% of metoprolol participants attained target dose.~The lowest starting dose of bucindolol was 6.25 mg BID with weekly dose titrations to the weight-based target dose or to the maximum tolerated dose. The starting dose assigned was based on the patient's beta-blocker treatment prior to randomization. Capsules for titration were available in the following dosage strengths to be taken twice daily (with or without food): 6.25mg, 12.5mg, 25mg, 50mg, and 100mg."
89609961|NCT01970501|Active Comparator|metoprolol succinate|"metoprolol succinate (Toprol-XL)~Participants were randomized (1:1) to blinded treatment with bucindolol or metoprolol and titrated weekly to target doses of 50 mg twice daily (BID; < 75 kg) or 100 mg BID (≥ 75 kg) for bucindolol or 200 mg once daily (QD) for metoprolol. 84% of bucindolol participants attained target dose and 72% of metoprolol participants attained target dose.~The lowest starting dose of metoprolol was 25 mg QD with weekly dose titrations to the target dose or to the maximum tolerated dose. The starting dose assigned was based upon the patient's beta-blocker treatment prior to randomization. Capsules for titration were available in the following dosage strengths to be taken twice daily (with or without food): 25mg, 50mg, 100mg, 200mg and/or matching placebo oral capsule to maintain blinded dosing."
89609962|NCT01969799|Experimental|Amikacin fosfomycin inhalation solution|300 mg of amikacin and 120 mg of fosfomycin twice daily for 10 days to be administered by aerosol via the eFlow Inline System.
89609963|NCT01969799|Placebo Comparator|Aerosolized placebo|Aerosolized placebo twice daily for 10 days administered using the eFlow Inline System
89609964|NCT01969721|Experimental|T+O FDC dosage 1|Low dose
89609965|NCT01969721|Experimental|T+O FDC dosage 2|High dose
89609966|NCT01969721|Active Comparator|ICS/LABA FDC Dosage 1|Low dose
89609967|NCT01969721|Active Comparator|ICS/LABA FDC Dosage 2|High dose
89609968|NCT01969565|Experimental|Carfilzomib in combination with dexamethasone|Carfilzomib will be administered at a dose of 20 mg/m², with a dose escalation to 36 mg/m² after Days 1 and 2 of Cycle 1 in level 1; and at a dose of 20 mg/m², with a dose escalation to 45 mg/m² after Days 1 and 2 of Cycle 1 in level 2 in subjects with multiple myeloma who are newly diagnosed and treatment naïve. Dexamethasone will be given as a fixed dose of 20 mg PO/IV (1, 2, 8, 9, 15, 16, 22, and 23) for cycles 1 to 4 and for subsequent cycles.
89609969|NCT01968707|Active Comparator|ChloraPrep Hi-Lite Orange|Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
89609970|NCT01968707|Placebo Comparator|Normal Saline|Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
88983077|NCT05951647|Active Comparator|Scaling and Chlorohexidine mouthwash|Patients will be managed by scaling and will use 0.12%% chlorohexidine mouthwash in a dose of 15 ml twice daily.
88983078|NCT05951647|Experimental|Scaling and Chamomile extract mouthwash|Patients will be managed by scaling and will use 5% chamomile extract mouthwash in a dose of 15 ml twice daily.
88983079|NCT05951647|Experimental|Scaling and Pomegranate peel extract mouthwash|Patients will be managed by scaling and will use 5% pomegranate peel extract mouth wash in a dose of 15 ml twice daily.
88983080|NCT05951647|Experimental|Scaling and Chamomile extract mixed with Pomegranate peel extract mouthwash|Patients will be managed by scaling and will use a combination of 5% chamomile extract and pomegranate peel extract mouthwash in a dose of 15 ml twice daily.
88983081|NCT05951634|Experimental|Investigational Device Arm (PerQseal Elite)|Large hole percutaneous arterial closure device - PerQseal Elite
88983082|NCT05951621|Experimental|Qigong group|On the basis of nutrition and exercise management and guidance, Qigong is exercised. Offline intensive learning once a week, 45-60 minutes each time, study for 12 weeks, and arrange online theory lecture once a week. In addition to concentrated learning, subjects in this group were required to practice themselves at home, at least once a day, each time for 30 minutes.
88983083|NCT05951621|Experimental|Control group|guidance of nutrition and exercise
89033749|NCT06008639|Active Comparator|treatment group|active setting
89609971|NCT01968707|Experimental|3M CHG/IPA Prep Tint 10.5 mL|Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
89609972|NCT01968707|Experimental|3M CHG/IPA Prep Tint 26-mL|Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
89609973|NCT04650191||Mild COVID-19 infection|Patients with confirmed COVID-19 infection who remained asymptomatic and/or never hospitalized.
89609974|NCT04650191||Moderate COVID-19 infection|Patients with confirmed COVID-19 infection who got admitted in general ward in the hospital.
89609975|NCT04650191||Severe COVID-19 infection|Patients with confirmed COVID-19 infection who got admitted in intensive care unit and/or did not survive.
89609976|NCT01959581|Other|Movement enhancing device|Guided play while wearing a movement assisting device
89609977|NCT01746901|Placebo Comparator|Treatment A|
89609978|NCT01746901|Experimental|Treatment B|
89609979|NCT01746901|Experimental|Treatment C|
89609980|NCT01746901|Active Comparator|Treatment D|
89609981|NCT01746901|Experimental|Treatment E|
89609982|NCT01746901|Active Comparator|Treatment F|
89609983|NCT01968551|Experimental|Cohort 1|"Participants will receive E/C/F/TAF FDC + DRV once daily with food for 48 weeks.~Based on safety and efficacy data from Cohort 1 at Week 4, the participants will be randomized into Cohort 2. The participants in Cohort 1 will continue receiving E/C/F/TAF FDC + DRV through 48 weeks."
89609984|NCT01968551|Experimental|Cohort 2, Treatment Group 1|Participants will be randomized to receive E/C/F/TAF FDC+DRV once daily with food for 48 weeks.
89609985|NCT01968551|Active Comparator|Cohort 2, Treatment Group 2|Participants will be randomized to continue on their baseline DRV-containing ARV regimen for 48 weeks.
89609986|NCT01707992|Placebo Comparator|Placebo-Controlled Phase: Placebo|Participants will receive 2 capsules of placebo (matching to laquinimod 0.6 milligrams [mg]) once daily orally for up to 24 months.
89609987|NCT01707992|Experimental|Placebo-Controlled Phase: Laquinimod 0.6 mg|Participants will receive 1 capsule of laquinimod 0.6 mg and 1 capsule of matching placebo once daily orally for up to 24 months.
89609988|NCT01707992|Experimental|Placebo-Controlled Phase: Laquinimod 1.2 mg|Participants will receive laquinimod 1.2 mg (2 capsules of laquinimod 0.6 mg each) once daily orally for up to 24 months.
89033750|NCT06008639|Placebo Comparator|Control group|sham setting
89609989|NCT01707992|Experimental|Active Treatment Phase: Laquinimod 0.6 mg|Participants who completed the placebo-controlled phase on placebo and on laquinimod 0.6 mg treatment group after 01 January 2016, will receive 1 capsule of laquinimod 0.6 mg and 1 capsule of matching placebo once daily orally for 24 months.
89609990|NCT01707992|Experimental|Active Treatment Phase: Laquinimod 1.2 mg|Participants who completed the placebo-controlled phase on placebo and on laquinimod 1.2 mg treatment group prior to 01 January 2016, will receive laquinimod 1.2 mg (2 capsules of laquinimod 0.6 mg each) once daily orally for 24 months.
89609991|NCT01707992|No Intervention|Active Treatment Phase: Off Drug|Participants who were discontinued from treatment with laquinimod 1.2 mg during the placebo-controlled phase due to sponsor decision after 01 January 2016 will continue the active-treatment phase off drug for 24 months.
89609992|NCT01946165|Experimental|Abiraterone Acetate + Prednisone + Enzalutamide + LHRHa|Patients receive abiraterone acetate (1,000 mg daily) plus prednisone (5mg once daily) in combination with enzalutamide (160 mg daily) and LHRHa. Patients receive a LHRHa (monthly injection or three-month injection) for a maximum of 7 months before a prostatectomy is performed. Study doctor will decide what hormone therapy patient receives.
89609993|NCT01946165|Experimental|Abiraterone Acetate + Prednisone + LHRHa|Patients receive abiraterone acetate (1,000 mg daily) plus prednisone (5mg once daily) and LHRHa. Patients receive a LHRHa (monthly injection or three-month injection) for a maximum of 7 months before a prostatectomy is performed. Study doctor will decide what hormone therapy patient receives.
89609994|NCT01707667|Experimental|Prucalopride|
89609995|NCT01707667|Active Comparator|PEG 3350|
89609996|NCT01959503|Experimental|Progel Vascular Sealant|Progel Vascular Sealant after confirmation of anastomotic leakage during intra-procedure leak test.
89609997|NCT01959503|Active Comparator|Gelfoam Plus|Gelfoam Plus Sealant after confirmation of anastomotic leakage during intra-procedure leak test.
89609998|NCT01605799|Active Comparator|IOK Treatment|Six to eight week treatment lasting one to 1.5 hours addressing maladaptive cognitions related to killing in war.
89609999|NCT01605799|Placebo Comparator|Wait list control group|Participants in this group will not receive treatment; however, at the end of 6 weeks, they will be offered the option of receiving treatment.
89610000|NCT01706575|Experimental|Pegylated Interferon (Peginterferon) Alfa-2a|Participants receiving nucleos(t)ide analogues (NA) therapy with Hepatitis B surface Antigen (HBsAg) decline less than <0.5 log 10 international unit/milliliter (IU/ml) at baseline received peginterferon alfa-2a 180 microgram (mcg), subcutaneously (SC) once weekly for 48 weeks along with their NA therapy.
89610001|NCT01959425|Experimental|Off OAT Group (Test)|Discontinuation of OAT Therapy
89610002|NCT01959425|Other|On OAT Group (Control)|Continuation of OAT Therapy
89610003|NCT01725529|Experimental|TMC435 150 mg|Patients will receive 12 weeks TMC435 150 mg once daily (q.d.) plus peginterferon-alpha (PegIFNα-2a) and ribavirin (RBV), followed by PegIFNα-2a and RBV alone. Response-guided treatment criteria will be used to determine total treatment duration of 24 or 48 weeks for patients in the TMC435 treatment groups. Patients in the control group will continue to receive treatment with PegIFNα-2a and RBV until Week 48.
89610004|NCT01725529|Experimental|TMC435 100 mg|Patients will receive 12 weeks TMC435 100 mg once daily (q.d.) plus peginterferon-alpha (PegIFNα-2a) and ribavirin (RBV), followed by PegIFNα-2a and RBV alone. Response-guided treatment criteria will be used to determine total treatment duration of 24 or 48 weeks for patients in the TMC435 treatment groups. Patients in the control group will continue PegIFNα-2a and RBV until Week 48.
89610005|NCT01725529|Placebo Comparator|Control|Patients will receive placebo once daily (q.d.) plus peginterferon-alpha (PegIFNα-2a) and ribavirin (RBV) for 48 weeks.
89057776|NCT04530695|No Intervention|Arm B: No cleaning|participants with periodontitis will undergo no periodontal treatment
89057777|NCT01686282|Placebo Comparator|Placebo|8 weeks of freeze-dried blueberry powder taken in two doses of 22g each per day.
89057778|NCT01686282|Experimental|Blueberry|8 weeks of freeze-dried blueberry powder taken in two doses of 22g each per day.
89210762|NCT00727571||CKD with Anemia|CKD is based on estimated GFR calculated by the MDRD method of < 60 mL/min/1.73m^2. Anemia is defined as Hemogloblin <12 g/dL in women, < 13 g/dL in men per WHO criteria. Participants were observed for 26 weeks and completed an anemia work-up, and mobility and physical performance assessments.
89610006|NCT01605097|Experimental|HDR interstitial brachytherapy|HDR prostate brachytherapy with dose escalation to 1250 cGy to the MRI-defined dominant intraprostatic lesion
89610007|NCT01605019|Experimental|CoSeal Arm|patient randomized to received Coseal during LVAD implantation
89610008|NCT01605019|Placebo Comparator|BioGlue® Surgical Adhesive|BioGlue® Surgical Adhesive or use of no sealant application
89610009|NCT04413721|Experimental|Short-term storage RBCs (stored for ≤ 14 days)|patients in this group were transfused with short-term storage RBCs (stored for ≤ 14 days).
89610010|NCT04413721|Active Comparator|Longer-term storage RBCs (stored for ≥21 days)|patients in this group were transfused with longer-term storage RBCs (stored for ≥21 days).
89610011|NCT04413565|Experimental|Two surgeon bilateral TKA group|2 surgeons will perform simultaneous total knee arthroplasty in this group.
89610012|NCT04413565|Active Comparator|Single surgeon bilateral TKA group|One surgeon will perform sequentially tptal knee arthroplasty in this group
89610013|NCT01705717||cohort|
89610014|NCT01744483|Active Comparator|PVC ETT|Polyvinylchloride cuff endotracheal tube
89610015|NCT01744483|Experimental|PUC ETT|Polyurethane cuff endotracheal tube
89610016|NCT01744483|Experimental|PUC-CASS ETT|Polyurethane cuff with continuous aspiration of subglottic secretions endotracheal tube
89610017|NCT01744093|Active Comparator|Doxycycline|100 mg twice daily (BID orally) x 24 weeks
89610018|NCT01744093|Placebo Comparator|Placebo (sugar pill)|100 mg twice daily (BID orally) x 24 weeks
89610019|NCT01725451|Experimental|Testosterone Unshaved|No deodorant or antiperspirant: Single 30 mg dose of testosterone applied topically to each unshaved axilla in 1 of 6 treatment periods.
89610020|NCT01725451|Experimental|Testosterone Unshaved + Deodorant Spray|Deodorant spray applied to unshaved axillae. At least 2 minutes wait time. Then, single 30 mg dose of testosterone applied topically to each axilla in 1 of 6 treatment periods.
89610021|NCT01725451|Experimental|Testosterone Unshaved + Deodorant Antiperspirant Spray|Deodorant antiperspirant combination spray applied to unshaved axillae. At least 2 minutes wait time. Then, single 30 mg dose of testosterone applied topically to each axilla in 1 of 6 treatment periods.
89610022|NCT01725451|Experimental|Testosterone Unshaved + Deodorant Antiperspirant Stick|Deodorant antiperspirant combination stick applied to unshaved axillae. At least 2 minutes wait time. Then, single 30 mg dose of testosterone applied topically to each axilla in 1 of 6 treatment periods.
89610023|NCT01725451|Experimental|Testosterone Shaved|No deodorant or antiperspirant: Single 30 mg dose of testosterone applied topically to each shaved axilla in 1 of 6 treatment periods.
89610024|NCT01725451|Experimental|Testosterone Shaved + Deodorant Antiperspirant Spray|Deodorant antiperspirant combination spray applied to shaved axillae. At least 2 minutes wait time. Then, single 30 mg dose of testosterone applied topically to each axilla in 1 of 6 treatment periods.
89610025|NCT01707290|Experimental|Ivacaftor|Participants who received Ivacaftor 150 milligram (mg) tablet and/or Placebo matched to Ivacaftor tablet orally, every 12 hours (q12h) in the previous study VX11-770-110 (Study 110; NCT01614457), VX12-770-111 (Study 111; NCT01614470) or VX12-770-113 (Study 113; NCT01685801); received Ivacaftor 150 mg tablet q12h in this VX12-770-112 (Study 112; NCT01707290) up to 104 weeks.
89610026|NCT01707290|No Intervention|Observational|Participants who received Ivacaftor 150 mg tablet and/or Placebo matched to Ivacaftor tablet, orally, q12h in the previous Study 110 (NCT01614457) or Study 111 (NCT01614470), were observed (did not receive study drug) in this Study 112 (NCT01707290) for up to 2 years.
89610027|NCT01717040|Experimental|Pioglitazone|
89610028|NCT01717040|Placebo Comparator|Placebo|
89610029|NCT04552262|Experimental|BAY2327949 / Placebo|Each participant will receive two treatments: a single dose of 90 mg BAY 2327949 (Treatment A) and a single dose of placebo to BAY 2327949 (Treatment B), with a washout period of at least 7 days before the second treatment.
89610030|NCT04552262|Experimental|Placebo / BAY2327949|Each participant will receive two treatments: a single dose of 90 mg BAY 2327949 (Treatment A) and a single dose of placebo to BAY 2327949 (Treatment B), with a washout period of at least 7 days before the second treatment.
89610031|NCT00803062|Active Comparator|Arm I (paclitaxel and cisplatin)|Patients receive paclitaxel IV over 3 hours or 24 hours on day 1 and cisplatin IV on day 1 or 2.
89610032|NCT00803062|Experimental|Arm II (paclitaxel, cisplatin, bevacizumab)|Patients receive paclitaxel IV over 3 hours or 24 hours on day 1 and cisplatin IV and bevacizumab IV over 30-90 minutes on day 1 or 2.
89610033|NCT00803062|Experimental|Arm III (topotecan hydrochloride and paclitaxel)|Patients receive paclitaxel IV over 3 hours on day 1 and topotecan hydrochloride IV over 30 minutes on days 1-3.
89610034|NCT00803062|Experimental|Arm IV (topotecan hydrochloride, paclitaxel, bevacizumab)|Patients receive paclitaxel IV over 3 hours and bevacizumab IV over 30-90 minutes on day 1 and topotecan hydrochloride IV over 30 minutes on days 1-3.
89610035|NCT01743469|Experimental|Hepatocellular Carcinoma Cohort|1 capsule of tasquinimod (0.25 mg or 0.5 mg or 1 mg) taken orally each day until disease progression, lost to follow-up, withdrawal or death.
89610036|NCT01743469|Experimental|Ovarian Carcinoma Cohort|1 capsule of tasquinimod (0.25 mg or 0.5 mg or 1 mg) taken orally each day until disease progression, lost to follow-up, withdrawal or death.
89610037|NCT01743469|Experimental|Renal Cell Carcinoma Cohort|1 capsule of tasquinimod (0.25 mg or 0.5 mg or 1 mg) taken orally each day until disease progression, lost to follow-up, withdrawal or death.
89610038|NCT01743469|Experimental|Gastric Carcinoma Cohort|1 capsule of tasquinimod (0.25 mg or 0.5 mg or 1 mg) taken orally each day until disease progression, lost to follow-up, withdrawal or death.
89610039|NCT01743001|Experimental|Macitentan|Subjects receive macitentan 10 mg oral tablet once daily
89610040|NCT01743001|Placebo Comparator|Placebo|Subjects receive macitentan-matching placebo oral tablet once daily
89217997|NCT05277506|Active Comparator|MBT placement guide group|female patients with mild crowding will recieve orthodontic brackets bonding using MBT placement guide
89610041|NCT00362284|Experimental|NYUCI-AC group|Adult children in this arm received the NYUCI-AC intervention, which consisted of 6 individual and family counseling sessions, the offering of an adult child specific support group, and the provision of ad hoc, or ongoing, consultation throughout the duration of participation.
89610042|NCT00362284|No Intervention|Usual care control|Adult children randomly assigned to the usual care control did not receive the NYUCI-AC intervention. If they were in crisis or required support, the NYUCI-AC counselors provided information and referral on an as-needed basis.
89610043|NCT03839368|Experimental|K plate|fixation of angle fracture using K plate versus two miniplates
89610044|NCT03839368|Active Comparator|Conventional two miniplates|fixation of angle fracture using K plate versus two miniplates
89610045|NCT00821626|Active Comparator|Rapid test|Returning travelers with fever will have a rapid flu test
89610046|NCT00821626|Sham Comparator|Comparator|Returning travelers with fever will benefit of the usual medical care, without rapid flu test
89610047|NCT01704079|Active Comparator|CTAP101 30 μg capsules|1 CTAP101 30 μg capsule daily at bedtime for 12 weeks, with a possible increase to 2 CTAP101 30 μg capsules daily at bedtime for study duration, if needed (26 weeks total). Subjects not requiring a dose increase after 12 weeks would receive 1 CTAP101 30 μg capsule and one sugar pill (to CTAP101 30 μg capsule) for weeks 13-26.
89610048|NCT01704079|Placebo Comparator|Sugar pill to CTAP101 30 μg|1 sugar pill to CTAP101 30 μg capsule daily at bedtime for 12 weeks, with an increase to 2 sugar pills to CTAP101 30 μg capsules daily at bedtime for weeks 13-26.
89610049|NCT04556695||Questionnaire survey|An initial online questionnaire, based on the International Sedentary Assessment Tool (ISAT), will be distributed to General Practice Specialty Trainees (GPSTs) and General Practitioners (GPs) throughout Northern Ireland.
89610050|NCT04556695||Accelerometer study|A purposive sample of questionnaire respondents will be asked to participate in the accelerometer study. This purposive sample will be based on responses to the online questionnaire. The aim will be to obtain a varied sample, based on questionnaire responses, by selecting individuals with a range of demographic characteristics and self-reported levels of sedentary behaviour. Some participants will also be asked to complete a further online survey, while wearing the accelerometer, regarding their health, wellbeing, burnout and fatigue.
89610051|NCT04556695||Semi-structured interview study|A purposive sample comprising participants of the accelerometer study will be asked to participate in semi-structured interviews. This purposive sample will be based on the accelerometer data. The aim will be to obtain a varied sample, based on accelerometer data, by selecting individuals with a range of different levels of sedentary behaviour, demographic and workplace characteristics. The final number of participants will depend on the saturation of information.
89610052|NCT01703845|Experimental|Tiotropium + Olodaterol (high dose)|Tiotropium and Olodaterol fixed dose combination (FDC) solution for inhalation - RESPIMAT
89610053|NCT01703845|Experimental|Tiotropium + Olodaterol (low dose)|Tiotropium and Olodaterol fixed dose combination (FDC) solution for inhalation - RESPIMAT
89610054|NCT01724359|Experimental|Paliperidone ER|
89610055|NCT01703221|Experimental|Omarigliptin 25 mg (Phase A+B)|Omarigliptin 25 mg once weekly for 52 weeks (Phase A + B)
89610056|NCT01703221|Active Comparator|Sitagliptin (Phase A) switching to Omarigliptin (Phase B)|Sitagliptin 50 mg once daily for 24 weeks (Phase A) switching to omarigliptin 25 mg once weekly for 28 weeks (Phase B)
89610057|NCT01703221|Placebo Comparator|Placebo (Phase A) switching to Omarigliptin (Phase B)|Placebo for 24 weeks (Phase A) switching to omarigliptin 25 mg once weekly for 28 weeks (Phase B)
89610058|NCT01722877|Experimental|JetStream Atherectomy|Jetstream NAVITUS System is a rotating, aspirating, expandable catheter for active removal of atherosclerotic disease and thrombus in peripheral vasculature.
89610059|NCT00822094|Experimental|CPX-351 (Arm A)|First induction: 100 units/m2 on Days 1, 3, and 5 by 90-minute IV infusion Second induction: 100 units/m2 on Days 1 and 3 by 90-minute IV infusion Consolidation(s): 100 units/m2 on Days 1 and 3 by 90-minute IV infusion
89610060|NCT00822094|Active Comparator|Salvage Therapy (Arm B)|First induction: Investigator's choice salvage therapy administered according to local practice Second induction: Investigator's choice salvage therapy administered according to local practice Consolidation(s): Investigator's choice consolidation therapy administered according to local practice
89610061|NCT00822328|Experimental|1|Fermented milk with Lactobacillus casei strain Shirota 100ml per day
89610062|NCT00822328|Placebo Comparator|2|Unfermented milk without Lactobacillus casei strain Shirota 100ml per day
89610063|NCT05098600||Cases|Patients with a confirmed histologic/dermatoscopic diagnosis of Alopecia areata within the study period will be included for analysis.
89610064|NCT00803686|Experimental|Part 1 Double Blind Oral rsCT Tablet|Intervention: Oral rsCT tablet given once 4 hours after evening meal.
89610065|NCT00803686|Placebo Comparator|Part 1, Double-blind Oral Placebo Tablet|Intervention: Oral placebo tablet matching the oral rsCT tablet, given once 4 hours after evening meal
89610066|NCT00803686|Experimental|Part 2 Open label, Oral rsCT tablet|Intervention: Oral rsCT tablet given once 2 hours after evening meal.
89610067|NCT00803686|Active Comparator|Part 2, Open Label Fortical Nasal Spray|Intervention: Part 2 Open label. Fortical (rsCT) nasal spray given once 2 hours after evening meal
89057779|NCT04536389||group A|women with normal uterine cavity and normal cervix by office hysteroscopy.
89057780|NCT04536389||group B|women with normal uterine cavity with hysteroscopically detected cervical abnormality.
89610068|NCT01703065|Experimental|Cabozantinib in metastatic CRPC|Metastatic CRPC patients to receive cabozantinib PO QD in the absence of disease progression or unacceptable toxicity.
89610069|NCT01703065|Experimental|Cabozantinib in non-metastatic CRPC|Non-Metastatic CRPC patients to receive cabozantinib PO QD in the absence of disease progression or unacceptable toxicity.
89610070|NCT00823966||Delavirdine Mesilate|Patients administered.
89610071|NCT01702987|Placebo Comparator|Statin + placebo|9 patients taking statin medications and placebo.
89610072|NCT01702987|Active Comparator|Statin + ubiquinol|12 patients on statins and ubiquinol
89610073|NCT00824044|Active Comparator|Cognitive Behavioral Therapy (CBT)|CBT is a manualized therapeutic treatment for depression based on principles of cognitive restructuring and behavioral changes.
89610074|NCT00824044|Active Comparator|Escitalopram|Escitalopram or Lexapro is a Selective Serotonin Reuptake Inhibitor (SSRI) used to treat depression
89610075|NCT01702519|Active Comparator|Reference|nicotine transdermal patch with the existing polyisobutylene adhesive
89610076|NCT01702519|Active Comparator|Treatement|nicotine transdermal patch with the alternate polyisobutylene adhesive
89610077|NCT01739803|Experimental|Intervention Group|Behavioral contract intervention
89610078|NCT01739803|No Intervention|Control Group|No intervention
89610079|NCT00824434|Experimental|Experimental Stent|
89610080|NCT01739335|Experimental|Mifepristone|'Mifepristone Oral Tablet [Korlym] (2 x 300mg =600 mg total, once daily, at bedtime) for 7 days
89610081|NCT01739335|Placebo Comparator|Placebo|Placebo Oral tablet (2 sugar pills, once daily, at bedtime) for 7 days
89610082|NCT00824512|Experimental|EGb 761® 120 mg|
89610083|NCT00824512|Placebo Comparator|Placebo|
89610084|NCT00824746|Experimental|Gefitinib retreatment group|Gefitinib retreatment
89610085|NCT01702363|Experimental|GSK573719|125mcg
89610086|NCT05049928|Experimental|Experimental arm|Patients in the experimental group will be treated with CPAP (PRISMA, LOWENSTEIN®) and will have access to the m-Rehab® telerehabilitation program.
89610087|NCT05049928|No Intervention|Control arm|Patients in the experimental group will be treated with CPAP (PRISMA, LOWENSTEIN) and will receive the usual advice on adapted physical activity and nutrition during the initial consultation.
89610088|NCT01722097|Active Comparator|Deep neuromuscular blockade|Drug: Rocuronium Intravenous use: 0.3 mg/kg before intubation and 0,7 mg after intubation followed by infusion with 0,3-0,4 mg/kg/h Other Name: Esmeron
89610089|NCT01722097|Placebo Comparator|Moderate neuromuscular blockade|Drug: Rocuronium Intravenous use: 0,3 mg/kg followed by NaCl-infusion Other Name: Esmeron
89610090|NCT00824824|Experimental|Brimonidine 0.2%-timolol 0.5% arm|Patients using timolol were switched to brimonidine tartrate / timolol maleate 0.2%/05% 1 get BID OU for six weeks.
89610091|NCT00824824|Active Comparator|Dorzolamide 2%-timolol 0.5% arm|Patients using timolol were switched ti dorzolamide hydrochloride / timolol 0.5% 2%/0.5% bid OU for six weeks
89610092|NCT01701973|Other|Group A (14 healthy subjects)|"In Aim 1: Healthy Lean adults are randomized in a double-blinded cross over fashion to sitagliptin versus placebo.~In Aim 2: Healthy Lean adults receive sitagliptin and are randomized in a double-blinded cross over fashion to pre-treatment with either LNMMA (L-N-Monomethyl-arginine) versus placebo."
89610093|NCT01701973|Other|Group B (14 healthy subjects)|"In Aim 1: Healthy Lean adults are randomized in a double-blinded cross over fashion to sitagliptin versus placebo.~In Aim 2: Healthy Lean adults receive sitagliptin and are randomized in a double-blinded cross over fashion to pre-treatment with either pegvisomant versus placebo."
89610094|NCT01701973|Other|Group C (14 healthy subjects)|"In Aim 1: Healthy Lean adults are randomized in a double-blinded cross over fashion to sitagliptin versus placebo.~In Aim 2: Healthy Lean adults receive sitagliptin and are randomized in a double-blinded cross over fashion to pre-treatment with either Exendin 9-39 versus placebo."
89610095|NCT00825370|Experimental|Protocolized|"1 mg IV hydromorphone followed by an optional 1 mg IV hydromorphone 15 minutes later if the patient answers yes to the question, Do you want more pain medication?"
89610096|NCT00825370|Active Comparator|Discretionary Care|Patients receive an IV opioid the type and dose of which is determined by the treating physician
89610097|NCT01721317|Experimental|Titration Phase: Ezogabine/Retigabine 300 mg|Subjects receive Ezogabine/Retigabine 300 mg equally divided TID over Wk 1
89610098|NCT01721317|Placebo Comparator|Titration Phase: Placebo 300 mg|Subjects receive matching Placebo
89610099|NCT01721317|Experimental|Titration Phase: Ezogabine/Retigabine 450 mg|Subjects receive Ezogabine/Retigabine 450 mg equally divided TID over Wk 2
89610100|NCT01721317|Placebo Comparator|Titration Phase: Placebo 450 mg|Subjects receive matching Placebo
89610101|NCT01721317|Experimental|Dose-Optimization Phase: Ezogabine/Retigabine 600 mg|Subjects receive Ezogabine/Retigabine 600 mg equally divided (200 mg TID) over Wk 3 or until they achieve their optimal tolerated dose as assessed by the Investigator
89057781|NCT04536662|Experimental|Group hydrocortisone|
89057782|NCT04536662|Experimental|Group Prednisone|
89610102|NCT01721317|Placebo Comparator|Dose-Optimization Phase: Placebo 600 mg|Subjects receive matching Placebo
89610103|NCT01721317|Experimental|Dose-Optimization Phase: Ezogabine/Retigabine 750 mg|Subjects receive Ezogabine/Retigabine 750 mg equally or unequally divided TID over Wk 4 or until they achieve their optimal tolerated dose as assessed by the Investigator
89610104|NCT01721317|Placebo Comparator|Dose-Optimization Phase: Placebo 750 mg|Subjects receive matching Placebo
89610105|NCT01721317|Experimental|Dose-Optimization Phase: Ezogabine/Retigabine 900 mg|Subjects receive Ezogabine/Retigabine 900 mg equally or unequally divided TID over Wk 5 or until they achieve their optimal tolerated dose as assessed by the Investigator
89610106|NCT01721317|Placebo Comparator|Dose-Optimization Phase: Placebo 900 mg|Subjects receive matching Placebo
89610107|NCT01721317|Experimental|Dose-Optimization Phase: Ezogabine/Retigabine 1050 mg|Subjects receive Ezogabine/Retigabine 1050 mg equally or unequally divided TID over Wk 6 or until they achieve their optimal tolerated dose as assessed by the Investigator
89610108|NCT01721317|Placebo Comparator|Dose-Optimization Phase: Placebo 1050 mg|Subjects receive matching Placebo
89610109|NCT01721317|Experimental|Dose-Optimization Phase: Ezogabine/Retigabine 1200 mg|Subjects receive Ezogabine/Retigabine 1200 mg equally divided (400 mg TID) over Wk 7 or until they achieve their optimal tolerated dose as assessed by the Investigator
89610110|NCT01721317|Placebo Comparator|Dose-Optimization Phase: Placebo 1200 mg|Subjects receive matching Placebo
89610111|NCT01721317|Experimental|Maintenance Phase:Ezogabine/Retigabine|Subjects receive Ezogabine/Retigabine at the daily dose achieved (equally or unequally divided TID) at the end of the Dose-Optimization Phase for 8 Weeks (600 mg, 750 mg, 900 mg, 1050 mg, or 1200 mg)
89610112|NCT01721317|Placebo Comparator|Maintenance Phase: Placebo|Subjects receive matching Placebo
89610113|NCT01701193|Placebo Comparator|Physiological saline- Laparoscopic|Participants receiving intraperitoneal administration of physiological saline at the time of laparoscopic myomectomy.
89610114|NCT01701193|Experimental|L-Alanyl/L-Glutamine- Laparoscopic|Participants receiving intraperitoneal administration of L-Alanyl-L-Glutamine at the time of laparoscopic myomectomy.
89610115|NCT01701193|Placebo Comparator|Physiological saline- Laparotomy|Participants receiving intraperitoneal administration of physiological saline at the time of myomectomy (laparotomy).
89033751|NCT06008405|Experimental|TQB2928 Injection + Azacitidine for injection|"Dose escalation:~Intravenous infusion of TQB2928 Injection once a week, combined with azacitidine for injection (75 mg/m2, d1-7/q4w), 4 weeks (28 days) as a treatment cycle.~Dose expansion:~The maximum tolerated dose (MTD) or optimal biological dose (OBD) or recommended phase II dose (RP2D) determined in the dose-escalation phase is combined with azacitidine for injection for extended studies to further observe the safety and efficacy."
89033752|NCT06008184||Healthy controls|
89033753|NCT06006975||Subarachnoid hemorrhage (SAH) patients|Patients after aneurysmal subarachnoid hemorrhage who received routine treatment (aneurysm clipping surgery, post operative care and multimodal monitoring in ICU).
89033754|NCT05998382|Experimental|intervention group|There is only one group in the study. This group will participate in a 6-week online group-based parent-mediated intervention program.
89033755|NCT05993390|Experimental|Sugammadex group|Patient is intubated with etomidate 0.1~0.2mg/kg and rocuronium 1mg/kg. 30 minutes after rocuronium administration, patient is administered sugammadex 1mg/kg. Glasgow coma scale as neurologic assessment is assessed at 10-minute intervals before intubation, and at 5-minute intervals up to 30 minutes after administration of sugammadex. After 30 minutes, the assessments are conducted at 10-minute intervals. Additionally, if the patient spontaneously opens their eyes, the GCS is assessed at that specific moment. The GCS evaluation continues until the patient reaches a point of responsiveness, indicated by a Motor score of 6 on the GCS.
89610116|NCT01701193|Experimental|L-Alanyl/L-Glutamine- Laparotomy|Participants receiving intraperitoneal administration of L-Alanyl-L-Glutamine at the time of myomectomy (laparotomy).
89610117|NCT00826150|Experimental|BC-819|BC-819 60, 120 and 240 mg IP administration
89610118|NCT04382092|Experimental|Intervention COVID-19|Respiratory samples are treated according to routine laboratory testing : culture, immuno assays AND molecular testing (FilmArray PNEU) of the endotracheal aspirate sample 24 hours a day.
89610119|NCT00827944|Active Comparator|1|Parietex ProGrip
89610120|NCT00827944|Active Comparator|2|Low weight polypropylene mesh
89610121|NCT02153710|Experimental|Phonomotor therapy|Experimental group
89610122|NCT02153710|Active Comparator|Semantic Feature Analysis therapy|Current standard of care therapy
89610123|NCT01959347|Sham Comparator|Miduretheral Sling (Control)|Miduretheral Sling (Control)
89610124|NCT01959347|Experimental|MUS+BPTx|Miduretheral Sling with behavioral/pelvic floor therapy
89610125|NCT00828178|Active Comparator|Omega-3|3 g of Omega-3 (1.8 g eicosapentaenoic acid, 1.2 g docosahexaenoic acid ethyl esters); flow-mediated dilation of the brachial artery
89610126|NCT00828178|Placebo Comparator|corn starch|corn starch; flow-mediated dilation of the brachial artery
89610127|NCT00828412|Active Comparator|1|EpiCeram Skin Barrier Emulsion
89610128|NCT00828412|Active Comparator|2|Desonide Cream 0.05%
89610129|NCT04638335||travelers over the age of 60|blood sample taken to test the presence of Anti-HAV antibodies
89610130|NCT04638335||travelers having lived in a tropical country for more than 5 years|blood sample taken to test the presence of Anti-HAV antibodies
89610131|NCT01959035|Experimental|Aripiprazole once-monthly|
89610132|NCT01700959|Active Comparator|Melatonin|Participants receive 3 mgs of time-release melatonin 1-2 hours prior to bedtime.
89610133|NCT01700959|Placebo Comparator|Placebo|Participants receive a placebo identical to the time-release melatonin and are instructed to take it 1-2 hours prior to bedtime.
89610134|NCT00829036|Experimental|Wayfinding Prototype|A Wayfinding Prototype is evaluated in terms of the time it takes subjects to use this device to walk to specific indoor locations versus baseline walking time.
89610135|NCT01738477|Experimental|Boostrix Group 2|Healthy male of female subjects, aged 19 to 30 years of age at the time of booster vaccination, who were randomized to the Lot A, Lot B or Lot C groups in study NCT00109330, received a second dose of Boostrix in this study.
89610136|NCT01738477|Active Comparator|Boostrix Group 1|Healthy male of female subjects, aged 19 to 30 years of age at the time of booster vaccination, who received Massachusetts Public Health Biologic Laboratories combined tetanus and diphtheria vaccine in study NCT00109330, received the first dose of Boostrix in this study.
89610137|NCT00829738||Group 1|All patients enrolled
89610138|NCT01737931|Experimental|Topical Steroid|Topical medication of steroid (Dexamethasone) to the application sites after the patch removal
89610139|NCT01737931|Experimental|Topical antihistamine|Topical medication of antihistamine(Diphenhydramine) to the application sites after the patch removal
89610140|NCT01737931|No Intervention|No-treatment|No treatment to the application sites after the patch removal
89610141|NCT04564261|Experimental|myPlan Teen Group|Personalized Healthy Relationship and Safety Planning Tool.
89610142|NCT04564261|Active Comparator|Usual Care Teen Control Group|Usual Care Teen Relationships and Health Resource.
89610143|NCT01958489|Experimental|Pravastatin|Single 40 milligram (mg) oral dose of pravastatin administered on Day 1.
89610144|NCT01958489|Experimental|Evacetrapib + Pravastatin|Oral doses of 130 mg evacetrapib administered once daily on Days 2 through 11, with a single oral dose of 40 mg pravastatin coadministered on Day 11.
89610145|NCT01721161|Experimental|BIIB033|Participants will receive BIIB033 once every 4 weeks for 20 weeks (a total of 6 doses).
89610146|NCT01721161|Placebo Comparator|Placebo|Participants will receive Placebo via IV infusion once every 4 weeks for 20 weeks (a total of 6 doses).
89610147|NCT00830284|Experimental|Recruitment|Patients with hypoxic respiratory failure
89610148|NCT00830362|Active Comparator|Propranolol 40mg|
89610149|NCT00830362|Placebo Comparator|Placebo|
89610150|NCT01699789|Active Comparator|Resources for Services|The Resources for Services condition offers time-limited technical assistance to individual agencies, coupled with outreach from a community engagement specialty, to participate in structured reviews of components of the Quality Improvement Program Intervention as implemented by the Resources for Services Expert Team.
89688360|NCT04347031|Experimental|group 1 cohort 2|"80 patients who receive Hydroxychloroquine prescribed according to the following scheme:~• 1st day: 800 mg of hydroxychloroquine per day, inside, in 200 mg tablets, 2 tablets 2 times a day; 2nd - 7th day: 400 mg of hydroxychloroquine per day, inside, in tablets of 200 mg, 1 tablet 2 times a day."
89610151|NCT01699789|Experimental|Community Engagement and Planning|The Community Engagement and Planning arm supported 4 months of planning for the Community Engagement and Planning Council consisting representatives of all assigned programs in biweekly 2 hour meetings to fit trainings in the Quality Improvement Program to the community and develop strategies across programs to collaborate as a network. The CEP Council developed a written plan for training and monitoring and supported implementation of the training plan. CEP sites were provided with enrolled client lists.
89610152|NCT00830596|Active Comparator|HVLA-SM|High velocity, low amplitude lumbo-pelvic manipulation
89610153|NCT00830596|Active Comparator|LVVA-SM|Low velocity, variable amplitude lumbo-pelvic manipulation
89610154|NCT00830596|Placebo Comparator|Sham Intervention|Light effleurage and a sham mechanically-assisted chiropractic treatment for 2 weeks followed by full spine manipulation for 4 weeks
89610155|NCT00805870|Experimental|Fish Oil|Lovaza, 3 grams/day for 65 days
89610156|NCT00805870|Placebo Comparator|Control|Wheat Germ Oil, 3 grams/day for 65 days
89610157|NCT01944059|Active Comparator|Theramine|"2 capsules before breakfast and dinner (BID) for 16 weeks.~Migraine preventative medications will be permitted, but no changes in dosage will be allowed during the four month study. Migraine abortive meds will be permitted and will be administered per their standard routine."
89610158|NCT01944059|Placebo Comparator|placebo (l-alanine)|"2 capsules before breakfast and dinner (BID) for 16 weeks.~Migraine preventative medications will be permitted, but no changes in dosage will be allowed during the four month study. Migraine abortive meds will be permitted and will be administered per their standard routine."
89610159|NCT04646057|Experimental|Treatment Arm|
89610160|NCT04646057|No Intervention|Historical Control Arm|
89610161|NCT01720225|Experimental|Decitabine|Patients randomized to receive Decitabine 20 mg/m2 by vein daily for 3 days (days 1-3) every 28 days.
89610162|NCT01720225|Experimental|Azacitidine|Patients randomized to receive Azacitidine 75 mg/m2 subcutaneously or by vein daily for 3 days (days 1-3) every 28 days.
89610163|NCT01943591|Experimental|15-caliber platinum coils|Endovascular embolization coiling using 15-caliber platinum coils
89610164|NCT01943591|Active Comparator|10-caliber coils|Endovascular embolization coiling using standard 10-caliber platinum coils
89610165|NCT01699087|Experimental|PRK ALLEGRETTO|Photorefractive keratectomy (PRK) surgery using the ALLEGRETTO WAVE EYE-Q excimer laser system for myopic wavefront-optimized ablation
89610166|NCT01943435|Active Comparator|Medical Care|"Non-steroidal anti-inflammatory drugs (NSAIDs); adjunctive analgesics; adjunctive anti-depressants. Participants assigned to this group will see a board certified physical medicine and rehabilitation physician for a history and examination, after which a determination will be made about a course of treatment that involve medications that are individualized to the needs of each patient.~NSAIDs: ibuprofen, celecoxib, or diclofenac/misoprostol~Adjunctive analgesics: acetaminophen, tramadol, or gabapentin~Adjunctive antidepressant agents: nortriptyline, duloxetine, sertraline, trazodone, or mirtazapine~Lumbar epidural injection: these will be prescribed by the physician if warranted due to severity of symptoms or lack of adequate response to oral medications."
89610167|NCT01943435|Active Comparator|Group Exercise|Group Exercise: community setting. This arm will involve attendance at community based group exercise classes that are taught by senior physical fitness instructors. These classes are designed specifically for older adults. Exercise frequency will be 2 times per week, for a total of 12 visits over the 6-week research period. These exercise classes will be attended at local community senior centers which cater to the needs of older adults. The subjects can self-select which particular exercise class they prefer to attend, based upon their level of fitness and physical function.
89610168|NCT01943435|Active Comparator|Manual therapy and exercise|"This group of subjects will be treated with a combination of manual therapy and rehabilitative exercise procedures that are commonly used in the physical therapy and chiropractic professions. Subjects will be treated at a frequency of 2 times per week, for a total of 12 visits over the 6-week research period. Treatments will be provided by licensed physical therapists and chiropractors using a combination of Joint Mobilizations (spine, sacroiliac, hip), muscle stretching and strengthening exercises.~Individualized exercises: clinical setting. These exercises will be tailored to the individual needs of each research participant by the treating physical therapist or chiropractor."
89610169|NCT04644809|Experimental|LY3561774 (Part A)|Single ascending doses of LY3561774 administered subcutaneously (SC).
89610170|NCT04644809|Experimental|LY3561774 (Part B)|Repeat doses of LY3561774 administered SC.
89610171|NCT04644809|Experimental|LY3561774 (Part C)|Single doses of LY3561774 administered SC in Japanese Participants.
89610172|NCT04644809|Placebo Comparator|Placebo (Part A, B & C)|Placebo administered SC.
89610173|NCT00805948|Experimental|DeNovo|Prospectively enrolled subjects treated with the Talent Thoracic Stent Graft System following U.S. market approval of the device.
89610174|NCT00805948|No Intervention|Valor|Historical control arm, consisting of 195 subjects from the VALOR Test Group (PMA P070007) that were followed for 5 years per the VALOR protocol. The data from these subjects will be combined with the data from the subjects implanted after commercial release (DeNovo) to comprise the final analysis cohort for the THRIVE Study
89610175|NCT01942733|Experimental|Brexpiprazole|Brexpiprazole adjunct to open-label treatment with a commercially available antidepressant treatment (ADT)
89610176|NCT00807586|Experimental|Steroid|
89610177|NCT00807586|Placebo Comparator|Placebo|
88815329|NCT00990938|Experimental|IMO-2125|If randomized to receive the experimental treatment, IMO-2125, the patient will receive a subcutaneous injection once per week for 4 weeks
89610178|NCT01957865|Experimental|Fixed SMS, real-time monitoring|SMS will be sent daily for one month, then weekly for two months. Participants will have real-time adherence monitoring and social supporters will be notified of gaps in adherence of 48+ hours in the last six months of the study.
89610179|NCT01957865|Experimental|Triggered SMS, real-time monitoring|Participants will have real-time adherence monitoring and social supporters will be notified of gaps in adherence of 48+ hours in the last six months of the study.
89610180|NCT01957865|No Intervention|control|Real-time adherence monitoring only (no SMS)
89688361|NCT04347031|Experimental|group 2 cohort 1|A concomitant therapy consisting of Mefloquine in conjunction with azithromycin and tocilizumab will be given for 80 patients. Dosage of Mefloquine is same as for group 1 cohort 1.
89033756|NCT05993390|Experimental|Neostigmine group|Patient is intubated with etomidate 0.1~0.2mg/kg and rocuronium 1mg/kg. 30 minutes after rocuronium administration, patient is administered neostigmine 0.05mg/kg + glycopyrrolate 0.01mg/kg. Glasgow coma scale as neurologic assessment is assessed at 10-minute intervals before intubation, and at 5-minute intervals up to 30 minutes after administration of neostigmine. After 30 minutes, the assessments are conducted at 10-minute intervals. Additionally, if the patient spontaneously opens their eyes, the GCS is assessed at that specific moment. The GCS evaluation continues until the patient reaches a point of responsiveness, indicated by a Motor score of 6 on the GCS.
89610181|NCT01957787|Experimental|Cryoablation|Participants will undergo a cryoablation procedure with the Galil Medical Cryoablation System according to the manufacturer's guidelines. Participant preparation, anesthesia, intra-operative monitoring, and postoperative management for the study cryoablation procedure will be identical to those for standard cryoablation treatment routinely performed at the clinical centers that participated in this study and will be at the discretion of the Investigators. Tumors in both lungs are to be treated at an appropriate interval, determined on an individual basis. Treatment of bilateral index tumors in a single treatment session will not be performed. All participants will receive cryoablation of up to 6 metastatic lung tumors. Treatment of all study index tumors are to be completed within an 8-week window.
89610182|NCT01698775|Experimental|Omarigliptin (Phase A) → Omarigliptin (Phase B)|Phase A: omarigliptin 12.5 mg or 25 mg capsule orally once a week for 24 weeks. Phase B: omarigliptin 12.5 mg or 25 mg capsule orally once a week for 30 weeks. Participants who are not on background insulin therapy or who did not receive open-label glipizide or insulin as rescue therapy during Phase A of the study (Week 1 through Week 24) will receive matching placebo to glipizide daily in a blinded manner during Phase B of the study (Week 24 through Week 54).
89610183|NCT01698775|Active Comparator|Placebo to omarigliptin (Phase A) → Glipizide (Phase B)|Phase A: matching placebo to omarigliptin orally once a week for 24 weeks. Phase B: matching placebo to omarigliptin orally once a week for 30 weeks. Participants who are not on background insulin therapy or who did not receive open-label glipizide or insulin as rescue therapy during Phase A of the study (Week 1 through Week 24) will receive glipizide 2.5 daily up to a maximum of 20 mg daily (based on glycemic control) in a blinded manner during Phase B of the study (Week 24 through Week 54).
89610184|NCT01941095|Experimental|Tocilizumab|Participants will receive tocilizumab 162 milligrams (mg) SC injection once a week (QW) either as monotherapy or in combination with methotrexate or other non-biologic DMARDs during the treatment period of 52 weeks. The choice of monotherapy or combination treatment is according to the physician's judgment up to Week 24. Depending upon the participant's response to study regimen at Week 24, participant may either continue/discontinue/switch to tocilizumab monotherapy or may lead to intensification of methotrexate/non-biologic DMARDs with tocilizumab at a fixed dose of 162 mg SC QW till Week 52. After Week 52, participants who remain in study will enter a 8 week wash-out period and then (from Week 60) will proceed to the extension phase until tocilizumab is commercially available in Greece. Permitted DMARDs include methotrexate, azathioprine, chloroquine, hydroxychloroquine, leflunomide, and sulfasalazine.
89610185|NCT00831766|Experimental|Phase I: Dose Escalation|"Induction: A dose escalation plan for induction therapy using a standard 3x3 design with dose escalation of Lenalidomide only, to determine maximum tolerated dose (MTD). Idarubicin and cytarabine doses will be fixed.~Idarubicin: 12 mg/m^2.~Cytarabine: 200 mg/m^2.~Lenalidomide: According to dose escalation levels. Level 1: 5 mg/d; Level 2: 10 mg/d; Level 3: 15 mg/d; Level 4: 20 mg/d; Level 5: 25 mg/d."
89610186|NCT00831766|Experimental|Phase II: Treatment at MTD|"Idarubicin: 12 mg/m^2.~Cytarabine: 200 mg/m^2.~Lenalidomide: Maximum Tolerated Dose (MTD)."
89610187|NCT01957709|Experimental|Basic science (interferon gamma and MHC expression)|Patients receive recombinant interferon gamma subcutaneously weekly for 4 weeks before surgery.
89610188|NCT00832390|Experimental|1|sitagliptin
89610189|NCT01957553|Experimental|Treatment sequence 1, First Coloplast Test product|Subjects first allocated to Coloplast Test product will after cross-over test SenSura
89610190|NCT01957553|Experimental|Treatment seqence 2; First SenSura|Subjects first allocated to SenSura will after cross-over test Coloplast Test product
89610191|NCT00807664|Experimental|1|Biatain Ag dressing
89610192|NCT00807664|Active Comparator|2|Biatain dressing
89610193|NCT00843622|Experimental|1|Tobacco-based, smokefree product in pouch format for oral use, pouch size 1.0 or 0.5 g to be used ad libitum by participants
89610194|NCT00843622|Placebo Comparator|2|Non-tobacco, non-nicotine placebo product in pouch format for oral use, pouch size 1.0 g or 0.5 g, to be used ad libitum by the participants
89610195|NCT01957475|Experimental|First Coloplast Test product Z; then Coloplast Test product Y|The subjects first test Coloplast Test product Z and after cross-over Coloplast Test product Y
88815330|NCT00992264|Experimental|Message Tone|"Prescriptive or Motivational~Persons are randomized to receive intervention content written in either a prescriptive or motivational tone."
89033757|NCT05993390|No Intervention|Control group|Patient is intubated with etomidate 0.1~0.2mg/kg and rocuronium 1mg/kg. Glasgow coma scale as neurologic assessment is assessed at 10-minute intervals before intubation, and at 5-minute intervals up to 60 minutes after intubation. After 60 minutes, the assessments are conducted at 10-minute intervals. Additionally, if the patient spontaneously opens their eyes, the GCS is assessed at that specific moment. The GCS evaluation continues until the patient reaches a point of responsiveness, indicated by a Motor score of 6 on the GCS.
89057783|NCT04536662|Experimental|Group Dexamethasone|
89610196|NCT01957475|Experimental|First Coloplast Test product Y, Then Coloplast Test product Z|The subjects first test test product Y and after cross-over test product Z
89610197|NCT01940939|Active Comparator|Active rTMS|Active treatment will be delivered at an intensity that is 90% of the resting motor threshold (RMT). Stimulation will be delivered at 20 Hz with 100 stimulation trains of 20 stimuli each (i.e., 2000 stimuli) and an inter-train interval of 9 sec. Treatment will be applied in sequential order to the left dorsolateral prefrontal cortex (DLPFC). Intervention: Device: Repetitive Transcranial Magnetic Stimulation
89610198|NCT01940939|Sham Comparator|Sham rTMS|Sham rTMS stimulation will be delivered using the same stimulation parameters and at the site of active treatment, but the coil will be reversed. This method produces sound and some somatic sensation (e.g., contraction of scalp muscles) similar to those of active stimulation, but with minimal direct brain effects.Intervention: Device: Repetitive Transcranial Magnetic Stimulation
89610199|NCT01957397|Experimental|Coloplast Test 1|"The subjects are randomised to two arms~In both arms the subjects start measuring the performance of own product to collect baseline data.~In this arm the subjects are randomised to test Coloplast Test1 first and thereafter Coloplast Test 2~Finally the all subject test Coloplast Test 3"
89610200|NCT01957397|Experimental|Coloplast Test 2|"The subjects are randomised to two arms~In both arms the subjects start measuring the performance of own product to collect baseline data.~In this arm the subjects are randomised to test Coloplast Test 2 first and thereafter Coloplast Test 1~Finally the all subject test Coloplast Test 3"
89610201|NCT01940705|Active Comparator|Standard of care (SoC)|standard of care hearing-aid orientation as provided by clinical audiologist
89610202|NCT01940705|Experimental|SoC plus hearing-aid informational guide|standard of care hearing-aid orientation as provided by clinical audiologist plus a take-home informational guide regarding their hearing aids
89057784|NCT01686321|Experimental|Bendamustine and subcutaneous Rituximab|single-arm non randomized
89610203|NCT01940705|Experimental|SoC plus hearing aid DVD|SoC hearing-aid orientation as provided by clinical audiologist plus a take-home hearing aid digital video disc
89610204|NCT01940705|Experimental|Soc plus teach-back technique|standard of care hearing-aid orientation as provided by clinical audiologist plus a teach-back technique session reviewing information on the hearing aids
89610205|NCT00834106|Experimental|qHPV|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine administered by intramuscular injection on Day 1, Month 2, and Month 6
89610206|NCT00834106|Placebo Comparator|Placebo|Placebo administered by intramuscular injection on Day 1, Month 2, and Month 6
89610207|NCT01957163|Experimental|FF/VI 100/25 mcg + UMEC (62.5mcg)|Subjects received one inhalation of FF/VI 100/25 mcg via a DPI followed by one inhalation UMEC (62.5mcg) via DPI once-daily in the morning for 12 weeks.
89610208|NCT01957163|Experimental|FF/VI 100/25 mcg + UMEC (125mcg)|Subjects received one inhalation of FF/VI 100/25 mcg via DPI followed by one inhalation of UMEC (125mcg) via a DPI once-daily in the morning for 12 weeks.
89610209|NCT01957163|Experimental|FF/VI 100/25 mcg + Placebo|Subjects received one inhalation of FF/VI 100/25 mcg via DPI followed by one inhalation of matching placebo via a DPI once-daily in the morning for 12 weeks.
89610210|NCT00844090|Placebo Comparator|Arm 1|placebo tablets
89610211|NCT00844090|Experimental|Arm 2|methylphenidate tablets
89610212|NCT00844714|Experimental|Rituxan|
89610213|NCT00834652|Experimental|1|Participants will receive sertraline and metformin.
89610214|NCT00834652|Placebo Comparator|2|Participants will receive sertraline and placebo.
89610215|NCT00834808|Experimental|1: Tramadol HCl 100mg|
89610216|NCT00834808|Experimental|2: Tramadol HCl 200mg|
89610217|NCT00834808|Experimental|3: Tramadol HCl 300mg|
89610218|NCT00850096|Placebo Comparator|Placebo for Nasulin|Placebo for Nasulin Spray
89610219|NCT00850096|Active Comparator|Nasulin|Nasulin (intranasal insulin spray 1%)
89610220|NCT01939223|Experimental|Regorafenib|4 regorafenib tablets taken orally in the morning daily, followed by a low fat meal for 3 weeks on off treatment followed by 1 week off without treatment,Treatment 21 days.
89610221|NCT01939223|Placebo Comparator|Placebo|4 placebo tablets taken orally in the morning daily,followed by a low fat meal for 3 weeks on off treatment followed by 1 week off without treatment,Treatment 21 days.
89610222|NCT00834886|Active Comparator|Combination|Bright light 10.000 lux + melatonin 3 mg
88815331|NCT00992264|Experimental|Testimonials|Persons are randomized to receive a personally tailored testimonial or not.
89057785|NCT01199731|Experimental|GSK2248761 100mg OAD|In combination with darunavir/ritonavir BID and raltegravir BID
89057786|NCT01199731|Experimental|GSK2248761 200mg OAD|In combination with darunavir/ritonavir BID and raltegravir BID
89057787|NCT01199731|Active Comparator|Etravirine|In combination with darunavir/ritonavir BID and raltegravir BID
89610223|NCT00834886|Active Comparator|Melatonin|Melatonin 3 mg + placebo red light 400 lux
89610224|NCT00834886|Active Comparator|Bright light|Bright light 10.000 lux + placebo capsule 3 mg rice flour
89610225|NCT00834886|Placebo Comparator|Placebo|Placebo Red light 400 lux + placebo capsule 3 mg rice flour
89610226|NCT05125289|Experimental|experimental intervention group 1|Graston technique group
89610227|NCT05125289|Experimental|Experimental :interventional group II|Active release technique group
89610228|NCT05125289|Experimental|experimental group III|Proprioceptive Neuromuscular Facilitation stretching group
89610229|NCT00835198|Active Comparator|1|Dapsone gel 5% and Tretinoin gel 0.025%
89610230|NCT00835198|Active Comparator|2|Tretinoin gel 0.025%
89610231|NCT04636073|Experimental|Leaflex™ Performer|
89610232|NCT00835510|Experimental|Butenafine cream 1% (Taro)|Butenafine cream manufactured by Taro applied for 7 days
89610233|NCT00835510|Active Comparator|Lotrimin Ultra (butenafine) 1%|Lotrimin Ultra (butenafine) applied for 7 days
89610234|NCT00835510|Placebo Comparator|Vehicle|Butenafine vehicle applied for 7 days
89610235|NCT01954745|Experimental|Cabozantinib|Patients will be treated with cabozantinib 60 mg daily administered orally continuously for 28-day cycles. Tumor assessments will be performed every 8 weeks until documented disease progression by RECIST criteria or drug intolerance.
89610236|NCT00835900|Experimental|varenicline|drug plus counseling.
89610237|NCT00835900|Active Comparator|placebo|placebo plus counseling
89610238|NCT03838900||Cohort A|Individuals who have not started Loop or who have been on Loop fewer than 7 days at the time of enrollment.
89610239|NCT03838900||Cohort B|Participants who have been using Loop 7 or more days at the time of enrollment.
89610240|NCT01954121|Experimental|Levetiracetam|Levetiracetam 1000 mg/day
89610241|NCT01954121|Active Comparator|Carbamazepine|Carbamazepine 400 mg/day
89610242|NCT04635761|Experimental|Prevention (AIR Program)|Participants complete the Roswell Awareness, Information and Resources for Lung Cancer Screening (AIR) Program over 45 minutes and then receive the High-Risk Lung Cancer Tip Sheet..
89610243|NCT04634045|Experimental|Web-Based Treatment|A web-based treatment for pediatric overweight or obesity will be piloted with 10 caregiver and child pairs. Assessments will take place pre (0 months), post intervention (3.5 months) and at six months post-intervention (9.5 months) to evaluate patient outcomes, acceptability and feasibility.
89610244|NCT00850642|Placebo Comparator|Placebo|12 day repeat dosing with placebo
89033758|NCT05990790|Experimental|Desflurane Group|After induction of anesthesia, maintenance of anesthesia will be performed using goal-directed administration of desflurane with an intraoperative goal of bispectral index (BIS) 50±10.
89033759|NCT05990790|Active Comparator|Sevoflurane Group|After induction of anesthesia, maintenance of anesthesia will be performed using goal-directed administration of sevoflurane with an intraoperative goal of bispectral index (BIS) 50±10.
89033760|NCT05990790|Active Comparator|Propofol Group|After induction of anesthesia, maintenance of anesthesia will be performed using goal-directed administration of propofol with an intraoperative goal of bispectral index (BIS) 50±10.
89033761|NCT05990504|Experimental|Dural Puncture Epidural Group|Dural Puncture Epidural is a new type of labor analgesia technology.
89610245|NCT00850642|Experimental|GSK2190915 100mg|12 day repeat dosing treatment phase with 100mg GSK2190915.
89610246|NCT00836758|Experimental|CPAP Device|Breathing event detection (AED) by the CPAP device will be compared to breathing event detection by a simultaneous PSG (manual PSG scoring).
89610247|NCT00852592|Active Comparator|Active Comparator|7000lux broad-spectrum light
89610248|NCT00852592|Placebo Comparator|Inactive Comparator|50lux dim red light
89610249|NCT01952015|Experimental|AIN457|"All subjects were assigned to receive 150 mg secukinumab (AIN457) by subcutaneous injections. AIN457 was administered at baseline, weeks 1, 2, 3, 4. Prior to receiving the week 8 dose, all subjects were assigned to the following treatment group based on clinical components of their Clinical Global Impression (CGI) evaluation at week 8.~No up-titration group received 1 injection of 150 mg AIN457 at weeks 8, 12, and each visit from week 16 until week 48.~Up-titration group received 2 injections of 150 mg AIN457 at weeks 8, 9, 12 and each visit from week 16 until week 48.~Subjects who received 150 mg AIN457 can be up-titrated to 300 mg AIN 457 at any visit starting at week 16 based on clinical components of their CGI evaluation and investigator's discretion."
89610250|NCT00838006|Experimental|Biofeedback training|Heart rate variability biofeedback training and iPod with Breath Pacer app
89610251|NCT00838006|Experimental|Cognitive bias modification training|Cognitive bias modification training and iPod with cognitive bias training app
89610252|NCT00838006|Sham Comparator|Control Group|No additional resilience training and iPod with no resilience training apps
89610253|NCT01951703|Active Comparator|Control, senofilcon A|Subjects received Control lens, senofilcon A during the first two weeks of the study then Test lens, senofilcon A in the last two weeks of the study.
89610254|NCT01951703|Experimental|Test, senofilcon A|Subjects received Test lens, senofilcon A during the first two weeks of the study then Control lens, senofilcon A in the last two weeks of the study.
89610255|NCT00838162|Experimental|TMC310911/rtv 75/100 mg twice daily|TMC310911 75 mg + ritonavir 100 mg twice daily on Days 1 to 14
89610256|NCT00838162|Experimental|TMC310911/rtv 150/100 mg twice daily|TMC310911 150 mg + ritonavir 100 mg twice daily on Days 1 to 14
89610257|NCT00838162|Experimental|TMC310911/rtv 300/100 mg twice daily|TMC310911 300 mg + ritonavir 100 mg twice daily on Days 1 to 14
89610258|NCT00838162|Experimental|TMC310911/rtv 300/100 mg once daily|TMC310911 300 mg + ritonavir 100 mg once daily on Days 1 to 14
89610259|NCT01937351|Experimental|Pantheris Treatment Arm|Intervention: Atherectomy using the Pantheris system.
89610260|NCT00853606|Experimental|avanafil|
89610261|NCT00841204|Experimental|Arm I|Participants receive oral sulindac twice daily for 8 weeks
89610262|NCT00841204|Placebo Comparator|Arm II|Participants receive oral placebo twice daily for 8 weeks
89610263|NCT00853840|Experimental|1.|Maraviroc + Vardenafil
89610264|NCT00853840|Placebo Comparator|2.|Maraviroc + Placebo
89610265|NCT01737697|Experimental|Zirconium silicate (acute phase)|Randomized oral doses (1.25g, 2.5g, 5g, and 10g) of microporous, fractionated, protonated zirconium silicate administered 3 times (tid) daily with meals for 48 hours.
89033762|NCT05990504|Active Comparator|Epidural Group|Epidural is a traditional labor analgesia technique.
89033763|NCT05990244|Experimental|Diagnostic (MRE, tumor grade, tumor stiffness and adhesion)|"Patients undergo a preoperative routine MRI scan and MRE the day before their scheduled surgery to assess tumor stiffness and adhesion. Additionally, molecular pathological analysis will be performed to identify genetic alterations in gliomas. During surgery, the tumor stiffness and adhesion will be assessed and recorded by the surgeon according to established evaluation criteria.~It is important to note that the surgeon does not have prior knowledge of the tumor's specific stiffness before the surgery. This information is typically obtained through intraoperative assessment and observation."
89033764|NCT05986136|Active Comparator|control group|Control group ( Mesalamine group, n =30 ) who will receive 1 g mesalamine three times daily for 6 months
89033765|NCT05986136|Active Comparator|Dapagliflozin group|Patients will receive 1 g mesalamine three times daily plus dapagliflozin 10 mg once daily for 6 months
89033766|NCT05983016||Patients|All ten patients had their abdominal aortic aneurysm measured by experts and novices using both two-dimensional and three-dimensional ultrasound
89033767|NCT05982392|Active Comparator|Tramadol|Group A will receive premedication of Oral tramadol 100mg,
89033768|NCT05982392|Active Comparator|Naproxen Sodium|Group B will receive premedication of oral naproxen sodium 550mg.
88815332|NCT00992264|Experimental|Navigation|"Dictated or Non-Dictated~Persons are randomly assigned to be able to freely navigate the website or to have their navigation of the website pre-determined based on their baseline readiness to quit smoking."
89033769|NCT05982392|Placebo Comparator|Placebo|Group C, will be the control group and no active preoperative medication will be given to these patients.
89033770|NCT05975619|Experimental|HyperSight Imaging arm|Subjects are imaged with the new HyperSight CBCT imaging system.
89033771|NCT05973162|Active Comparator|Virtual Reality training|Virtual Reality + Conventional PT
89610266|NCT01737697|Placebo Comparator|Placebo (acute phase)|Placebo ( silicified microcrystalline cellulose) randomized to mimic doses of experimental drug administered 3 times (tid) daily with meals.
89610267|NCT01737697|Experimental|Zirconium silicate (subacute phase)|Randomized oral doses (1.25g, 2.5g, 5g, and 10g) of microporous, fractionated, protonated zirconium silicate administered once a day prior to the morning meal for 12 days.
89610268|NCT01737697|Placebo Comparator|Placebo (subacute phase)|Placebo (silicified microcrystalline cellulose) randomized to mimic doses of experimental drug administered once a day (qd) prior to the morning meal for 12 days.
89610269|NCT00853996|Experimental|Prevention (acolbifene hydrochloride)|Patients receive oral acolbifene hydrochloride once daily for 6 months in the absence of unacceptable toxicity.
89610270|NCT00841828|Experimental|Experimental|Epirubicin + Cyclophosphamide -> Docetaxel + Lapatinib
89610271|NCT00841828|Active Comparator|Control|Epirubicin + Cyclophosphamide -> Docetaxel + Trastuzumab
89610272|NCT00855010|Experimental|pioglitazone|pioglitazone tablet 45 mg once daily
89610273|NCT00855010|Placebo Comparator|placebo pill|placebo pill once daily (look-alike pill which contains no active ingredients)
89610274|NCT00842296|Experimental|Seg. RF Ablation with CLF catheter|Single Arm with CLF Catheter
89610275|NCT00842608|Experimental|Haloperidol Eligible Intervention|0.5-1mg Haloperidol Q8h for 7 days, reduced exposure to anticholinergics, reduced exposure to benzodiazepines
89610276|NCT00842608|Active Comparator|Haloperidol Eligible Usual Care|Usual care
89610277|NCT00842608|Experimental|Haldol-Ineligible Arm|"Haldol-Ineligible arm for patients with contraindications for Haldol, unresolvable prolonged QTc, history of torsades de pointes, or history of seizures.~Patients are randomized and will still receive:~reduced exposure to anticholinergics, reduced exposure to benzodiazepines"
89610278|NCT00842608|Active Comparator|Haldol Ineligible Usual Care|Usual Care
89610279|NCT00856024||Group 1: Naïve patients|Patients, from Brazil, with confirmed chronic hepatitis C and who completed 12 weeks of treatment with peginterferon alfa-2b and ribavirin and who previous to this treatment had not been treated with peginterferon alfa-2b.
89610280|NCT00856024||Group 2: Re-treatment|Patients, from Brazil, with confirmed chronic hepatitis C and who completed 12 weeks of treatment with peginterferon alfa-2b and ribavirin and who previous to this treatment had been considered nonresponders or relapsing to prior treatment for chronic hepatitis C.
89610281|NCT00856024||Group 3: HIV/HCV co-infected patients|Patients, from Brazil, with confirmed chronic hepatitis C and infected with Humman Immunodeficiency Virus (HIV) who completed 12 weeks of treatment with peginterferon alfa-2b and ribavirin.
89610282|NCT00856414|Experimental|1|botulinum toxin Type A 20U
89610283|NCT00843466|Active Comparator|Mild moisturizing Hand Cleanser|The test group will be provided with a mild moisturizing hand cleanser for all hand cleansing needs during the duration of the study.
89610284|NCT00843466|No Intervention|Current Hand Cleanser|The control group will continue to use their current cleanser for all hand washing.
89610285|NCT00856726|Experimental|PTH infusion|(1-34) PTH infusion at a rate of 0.055 ug/kg/hour for six hours
89610286|NCT00857272|Active Comparator|HalfLytely with 10mg bisacodyl|Active control
89610287|NCT00857272|Experimental|HalfLytely with 5mg bisacodyl|Investigational dose
89610288|NCT03696784|Experimental|Single Arm iC9.CAR19 T cells|"The safety of iC9-CAR19 cells will be investigated using the 3+3 design. Dose level (DL) Dose (#transduced cells/kg)~-1 1 x 10^5~1 x 10^6~2 x 10^6 DL1 will enroll 3 subjects. If no toxicity within 4 weeks, then DL 2 will enroll 3 subjects. If toxicity in 1/3 subjects in DL 1, 3 more subjects will be enrolled. If DL 1 is not tolerable, a de-escalation to DL -1 will enroll 3 subjects. If 3 subjects at the higher dose do not have DLTs more will be enrolled at that dose to get more information about toxicity.~Lymphodepleting chemotherapy of IV bendamustine 70 mg/m2 and IV fludarabine 30 mg/m2/day for 3 consecutive days will be given within 2-14 days prior to cell infusion.~AP1903 (0.4 mg/kg), a dimerizing agent to engage and activate the caspase 9 safety switch to trigger iC9-CAR19 T cell death by apoptosis will be given to subjects who develop severe cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS)."
89610289|NCT03696784|Experimental|Expansion Cohort iC9-CAR19 cells|After the tolerable cell dose (TCD) has been determined in adults, up to 18 additional subjects may be enrolled in an expansion cohort at the TCD. A TCD is defined as the dose at which approximately 0.20 of subjects experience dose limiting toxicity (0 - 1 out of 6 subjects).
89610290|NCT00858130|Experimental|Veinoplus|Every subject enrolled in study will be in this experimental arm. VeinoPlus device will be used by all enrolled subjects.
89610291|NCT01682863|Experimental|QVA149 dose 1|QVA149 27.5/12.5 μg capsules
89610292|NCT01682863|Experimental|QVA149 dose 2|QVA149 27.5/25 μg capsules
88815333|NCT00992264|Experimental|Proactive Outreach|"Email or No-Email communication~Persons are randomized to receive periodic email reminders to return to the intervention website or not."
89610293|NCT01682863|Active Comparator|QAB149|QAB149 75 μg capsules
89610294|NCT02457832|Experimental|Internal guidance training (IG)|Adapted tango dancing is a sophisticated, yet accessible system of tactile communication that conveys motor intentions and goals between a leader and follower. Those in IG training will choose direction, timing and amplitude of each successive step, and will communicate this information to their partner through moving their frame and center of mass.
89610295|NCT02457832|Experimental|Externally guided training (EG)|Those in EG will learn to attend to sensory cues for movement direction, timing and amplitude of steps, communicated from their partner to them via the frame and center of mass. The 'follower' will wait to receive the movement cue before moving.
89610296|NCT02457832|Active Comparator|Behavioral Control (BC)|BC participants will attend group health education sessions adapted to the needs of individuals with PD, about pharmacological management, nutrition, sleep disorders, cognitive deficits, bereavement coping, mobility, balance and home safety. Participants in this training will be instructed not to change their habitual exercise routines. After completing health education, participants will be assigned to an IG or EG training class but will not undergo evaluations.
89610297|NCT02457832|No Intervention|Normal Control (NC)|Age-matched controls without Parkinson's disease will come in for a single assessment including MRI.
89610298|NCT02417818|Experimental|Second-Degree Burn|"Group A (n=20): Consent-capable male and female patients ≥18 years of age who have sustained a second-degree burn on ≥1% and ≤30% of the surface of the body.~Intervention: Plasma Therapy (PlasmaDerm)"
89610299|NCT02417818|Experimental|Skin Excision (for Skin Graft)|"Group B (n=20): Consent-capable male and female patients ≥18 years of age who require a skin excision for the purpose of a skin graft. The minimal size of the skin-graft donor site must not be less than 1% of TBSA.~Intervention: Plasma Therapy (PlasmaDerm)"
89033772|NCT05973162|Experimental|Transverse friction massage (TFM)|Transverse friction massage (TFM)+ Conventional PT
89610300|NCT02417818|Experimental|Chronic Wound|"Group C (n=20): Consent-capable male and female patients ≥18 years of age suffering from a wound that has not yet healed ≥3 weeks. The minimal size of the wound site must not be less than 1% of TBSA.~Intervention: Plasma Therapy (PlasmaDerm)"
89610301|NCT02417818|Active Comparator|Intact Skin|"Group D (n=20): Consent-capable healthy male and female probands ≥18 years of age serving as sham group. None of the the criteria of groups A-C must be evident.~Intervention: Plasma Therapy (PlasmaDerm)"
89610302|NCT02417818|Experimental|Second-Degree Burn (repetitive)|"Group E (n=20): Consent-capable male and female patients ≥18 years of age who have sustained a second-degree burn on ≥1% and ≤30% of the surface of the body.~Intervention: Repetitive Plasma Therapy (repetitive PlasmaDerm)"
89610303|NCT02417818|Experimental|Skin Excision (for Skin Graft) (repetitive)|"Group F (n=20): Consent-capable male and female patients ≥18 years of age who require a skin excision for the purpose of a skin graft. The minimal size of the skin-graft donor site must not be less than 1% of TBSA.~Intervention: Repetitive Plasma Therapy (repetitive PlasmaDerm)"
89610304|NCT02417818|Experimental|Chronic Wound (repetitive)|"Group G (n=20): Consent-capable male and female patients ≥18 years of age suffering from a wound that has not yet healed ≥3 weeks. The minimal size of the wound site must not be less than 1% of TBSA.~Intervention: Repetitive Plasma Therapy (repetitive PlasmaDerm)"
89610305|NCT02417818|Active Comparator|Intact Skin (repetitive)|"Group H (n=20): Consent-capable healthy male and female probands ≥18 years of age serving as sham group. None of the the criteria of groups A-C must be evident.~Intervention: Repetitive Plasma Therapy (repetitive PlasmaDerm)"
89610306|NCT02417818|Experimental|Hypertrophic burn scar|"Group F (n=20): Consent-capable male and female patients ≥18 years of age who suffer from a hypertrophic burn scar.~Intervention: Repetitive Plasma Therapy (repetitive PlasmaDerm)"
89610307|NCT02417818|Experimental|Hypertrophic burn scar (repetitive)|"Group F (n=20): Consent-capable male and female patients ≥18 years of age who suffer from a hypertrophic burn scar.~Intervention: Repetitive Plasma Therapy (repetitive PlasmaDerm)"
89610308|NCT02417818|Experimental|Flap|"Group F (n=20): Consent-capable male and female patients ≥18 years of age who received a flap.~Intervention: Repetitive Plasma Therapy (repetitive PlasmaDerm)"
89610309|NCT02417818|Experimental|Flap (repetitive)|"Group F (n=20): Consent-capable male and female patients ≥18 years of age who received a flap.~Intervention: Repetitive Plasma Therapy (repetitive PlasmaDerm)"
89610310|NCT01951625|Experimental|Vericiguat (BAY1021189) (10 mg)|2.5 mg orally once daily for 2 weeks, up-titration to 5 mg orally once daily for 2 weeks, up-titration to 10 mg orally once daily for 8 weeks
89610311|NCT01951625|Experimental|Vericiguat (BAY1021189) (5 mg)|2.5 mg orally once daily for 2 weeks, then 5 mg orally once daily for 10 weeks (with sham titration)
89610312|NCT01951625|Experimental|Vericiguat (BAY1021189) (2.5 mg)|2.5 mg orally once daily for 12 weeks (with sham titrations)
89610313|NCT01951625|Experimental|Vericiguat (BAY1021189) (1.25 mg)|1.25 mg orally once daily for 12 weeks (with sham titrations)
89610314|NCT01951625|Placebo Comparator|Placebo|Orally once daily for 12 weeks (with sham titrations)
89610315|NCT04400890|Active Comparator|Resveratrol with Vitamin D3|Resveratrol 1000mg four times per day for 15 days. Vitamin D3 100,000 IU on day 1
89610316|NCT04400890|Placebo Comparator|Placebo with Vitamin D3|Placebo capsules 4 times per day for 15 days. Vitamin D3 100,000 IU on day 1
89057290|NCT04541615|Active Comparator|Group 2: Online didactic PBP+|The Pre-trained group (Group 2) will receive the exact same information as Group 1 on how to optimally perform the ORSI chicken anastomosis task but they are not required to study the material to a pre-defined proficiency benchmark. The time they spend on the task and effort expended will be logged. Once the online course is completed, participants have to perform the orsi chicken anastomosis task.
89057788|NCT01686360|No Intervention|Control group 1: pre/post-test|Group receives pre and post test questions only.
89610317|NCT01936649|Experimental|AdreView (Iobenguane I 123 Injection)|Two administrations of single intravenous (i.v) injection of Iobenguane I 123 10 millicuries (mCi) (370 MBq) over 1 to 2 minutes within an interval of 5 to 14 days.
89610318|NCT04330846|Experimental|EBD group|"Post-procedural admission in the Short Stay Unit (SSU).~Superficial sedation by endoscopist or anesthesiologist depending on the center.~Pneumatic balloon type CRE Boston scientific®; diameter of the balloon at the endoscopist's discretion.~A maximum of 2 dilations will be performed with a minimum interval of 15-30 days between each dilation.~Dilation failure will be considered if > 2 dilations are required."
89610319|NCT04330846|Experimental|SEMS group|"Post-procedural admission in the Short Stay Unit (SSU).~Superficial sedation by endoscopist or anesthesiologist depending on the center.~Fully coated, self-expanding Tae Woong medical®-type metal prostheses; size of the prostheses at the discretion of the endoscopist~Clips can be placed at the distal end of the prosthesis at the endoscopist's discretion.~Removal time of the prosthesis 4 weeks."
89610320|NCT01720069|Active Comparator|Dose 1 VR506|VR506 inhalation powder delivered via a new dry powder inhaler device
89610321|NCT01720069|Active Comparator|Dose 2 VR506|VR506 inhalation powder delivered via a new dry powder inhaler device
89610322|NCT01720069|Active Comparator|Dose 3 VR506|VR506 inhalation powder delivered via a new dry powder inhaler device
89610323|NCT00860314|Active Comparator|AP Position|Cardioversion with antero-posterior electrode position
89610324|NCT00860314|Active Comparator|AL Position|Cardioversion with antero-lateral electrode position
89610325|NCT04135027||CD group|no interventions
89610326|NCT00890656|Experimental|Augmented Hyper-CVAD|Hyper-CVAD (courses 1, 3, 5, and 7) alternated with high-dose methotrexate/ara-C (courses 2, 4, 6, and 8) administered on day 21; Hyper-CVAD = Cyclophosphamide, Vincristine, Doxorubicin, Decadron + Pegaspargase.
89610327|NCT04311112|Placebo Comparator|ZA placebo|
89610328|NCT04311112|Active Comparator|ZA low dose|
89610329|NCT04311112|Active Comparator|ZA high dose|
89610330|NCT00814138|Active Comparator|1|Methotrexate
89610331|NCT00814138|Placebo Comparator|2|Placebo
89610332|NCT00860938|Active Comparator|Budesonide|
89610333|NCT00860938|Placebo Comparator|Placebo|
89610334|NCT00862186|Other|Self-Management Arm|Behavioral: 'Fatigue Facts & Fixes'
89033773|NCT05972031|Experimental|Person-centred integrated care intervention|The core of the person-centered approach is a cyclical process and for EMBOSS developed for patients with low SES. The practice nurse in the GP will act as case manager and can consult other health providers. The first step in the intervention is assessing the integral health status of the patient (health across multiple domains), using a visual conversation tool. The second step is discussing the results with the patient. Personal goals are formulated in the third step. In the fourth step, the healthcare professional and patient will choose through shared-decision making the most appropriate interventions and support to achieve these goals, which are documented in a personal plan. Next, referrals are made if necessary and the treatment is started. An evaluation is planned and carried out. All practices in the EMBOSS intervention group will be trained by Pharos on how to recognize and provide GDM to low SES patients using appropriate communication skills and the specific tools.
89033774|NCT05972031|No Intervention|Usual care|"Practices in the control group provide care as usual, which consists of the SDM programmes according to the national care standards and General Practice guidelines (NHG) for DM2, COPD and CVD. According to these protocolised programmes, patients with COPD, CVD or DM2 visit their general practice at a standard frequency per year (1 - 4 times) and standard monitoring measurements and topics are discussed.~The practices that are randomised to the control group will not receive any additional training related to this study."
89033775|NCT05971966|Active Comparator|Virtual Reality technique|Virtual reality technique+ Conventional PT
89033776|NCT05971966|Experimental|Muscle energy technique|Muscle energy technique + Conventional PT
89033777|NCT05971953|Active Comparator|Muscle Energy Technique|Muscle Energy Technique
89033778|NCT05971953|Other|Conventional PT|Hot pack Ischemic compression
89610335|NCT01719757|Experimental|Oxycodone/naloxone|Trade name is Targin. Oxycodone (10mg)/naloxone (5mg) or Oxycodone (20mg)/naloxone (10mg) tablets. Twice daily per oral. Dose adjustment and asymmetric dose are allowed up to 80/40mg per day
89610336|NCT01718509|Experimental|SPD489 (Lisdexamfetamine dimesylate)|
89033779|NCT05971810|Experimental|Group A (immunonutrition and oral chlorhexidine decontamination, IN&CD)|Patients in this group will receive immunonutrition supplementation from the day of allocation at the preoperative anesthesia clinic until the day before surgery (usually 1-3 weeks), which is oral intake of ORAL IMPACT™ 2 servings per day. Patients will also receive oral chlorhexidine decontamination using 0.12% chlorhexidine oral rinse twice daily from the day before surgery until postoperative day 3.
89033780|NCT05971810|Experimental|Group B (immunonutrition and routine oral care, IN&RC)|Patients in this group will receive immunonutrition supplementation from the day of allocation at the preoperative anesthesia clinic until the day before surgery (usually 1-3 weeks), which is oral intake of ORAL IMPACT™ 2 servings per day. For oral health care, they will receive routine oral care which is routine toothbrushing twice daily.
89033781|NCT05971810|Experimental|Group C (routine nutrition advice and oral chlorhexidine decontamination, RN&CD)|Patients in this group will be advised to follow a standard nutrition advice with a total intake of 30kcal/kg/d and protein intake of 1.2g/kg/d. They will also receive oral chlorhexidine decontamination using 0.12% chlorhexidine oral rinse twice daily from the day before surgery until postoperative day 3.
89033782|NCT05971810|No Intervention|Group D (routine nutrition advice and routine oral care, RN&RC)|Patients in this group will be advised to follow a standard nutrition advice with a total intake of 30kcal/kg/d and protein intake of 1.2g/kg/d. They will also receive routine oral care which is routine toothbrushing twice daily.
89610337|NCT01718509|Placebo Comparator|Placebo|
89610338|NCT01812226||experimental group|This group will consist of men and women who received a liver transplant for alcohol-related liver disease.
89610339|NCT01812226||control group|This group will consist of men and women who had a liver transplant for reasons that are not alcohol-related.
89610340|NCT00862810|Other|Received HPV vaccine first|
89610341|NCT00862810|Other|Received concomitant vaccines first|
89610342|NCT01143532||Kidney transplant donor of black African descent.|Kidney transplant donor of black African descent.
89610343|NCT01143532||Kidney transplant recipient of black African descent|Kidney transplant recipient of black African descent.
89610344|NCT00815698|Active Comparator|no suture|self-adhesive mesh, i.e. no suture for mesh fixation
89610345|NCT00815698|Experimental|Suture|Suture for mesh fixation
89610346|NCT00863122|Experimental|lapatinib|Subjects will receive lapatinib for 10 days prior to surgery for vestibular schwannoma resection.
89610347|NCT00863122|No Intervention|control|Control subjects will not receive any intervention prior to surgery for vestibular schwannoma resection.
89610348|NCT01604941|Experimental|SPD602|50 mg/kg/day orally twice daily for 24 weeks
89610349|NCT01604785|Experimental|Experimental Treatment Group|Propofol at subanesthetic dose via IV push
89610350|NCT01604785|Active Comparator|Standard Treatment Group|Metaclopramide in combination with ketorolac and diphenhydramine via IV infusion
89610351|NCT01681849|Experimental|Paroxetine Group|Women who have experienced early childhood abuse and have PTSD will be randomized in a double blind fashion to receive paroxetine for a three month period followed by an open label phase of three months.
89610352|NCT01681849|Placebo Comparator|Placebo Group|Women who have experienced early childhood abuse and have PTSD will be randomized in a double blind fashion to receive placebo for a three month period followed by an open label phase of paroxetine for three months.
89610353|NCT01681849|Other|PTSD Negative|Women who have experienced early childhood abuse and do not have PTSD will serve as a control group and complete baseline assessments. They do not undergo intervention therefore they are assessed at baseline only.
89610354|NCT01681771|Experimental|Cogntive behaviour therapy|Internet based Cognitive behaviour therapy during 9 weeks
89610355|NCT01681771|Active Comparator|Discussion group|Internet moderated discussion group during 9 weeks
89610356|NCT04250350|Experimental|Lebrikizumab 250 mg|Participants received two subcutaneous (SC) injections of 250 milligram(mg) Lebrikizumab at Baseline and Week 2 followed by a single injection every 2 weeks (Q2W) from Week 4 up to (but not including) Week 52.
89610357|NCT00342550||Pregnant Women|Pregnant women aged 15 and older between 20 and 35 weeks with singleton gestation
89688362|NCT04347031|Experimental|group 2 cohort 2|A concomitant therapy consisting of Hydroxychloroquine in conjunction with azithromycin and tocilizumab will be given for 80 patients. Dosage of Hydroxychloroquine is same as for group 1 cohort 2.
89033783|NCT05970146|Experimental|Ultrasound guided Stellate ganglion block|The procedure is going to be the anterior paratracheal approach on the cervical sympathetic chain
89033784|NCT05970146|Experimental|unilateral cervical epidural|The patient is placed in prone position, with stabilization of the forehead on a padded support
89033785|NCT05969912|Active Comparator|Graston Technique (Instrumented assisted soft tissue mobilization)|Graston technique + Conventional PT
89033786|NCT05969912|Active Comparator|Bowen's Technique (Soft tissue technique)|Bowen's technique + Conventional PT
89033787|NCT05964881|Active Comparator|PDS - resorbable suture|Operation through vaginal route, high posterior colpotomy is made towards the posterior cervix. Blunt preparation towards the right Spina ischiadica to visualise right sacrospinous ligament. PDS (0) sutures will be placed through the ligament (ca. 2 cm medial of the spina). This suture will then be placed through the posterior cervical wall, but not yet knotted. First, colpotomy will be closed via 2/0 vicryl, then pre-laid fixation sutures will be tied, whereby the portio will come to lie about 4-6 cm cranial of the level off the vulva towards the sacrospinous ligament.
89610358|NCT03839602|Experimental|reducing CTV|The gross tumor volume of the nasopharynx and neck nodes (GTVnx and GTVnd) were delineated according to the tumor extension. The CTV was divided into CTV1 (high risk) and CTV2 (low risk) according to the biological behavior and characteristics of early-stage NPC. The prescribe doses of GTVnx, GTVnd, CTV1 and CTV2 were 68Gy, 60-66Gy, 60Gy and 50-54Gy in 30 fractions, respectively.
89610359|NCT00863356|Experimental|Epistaxis Group|"Subjects presenting with epistaxis that have not been controlled by traditional nasal packing, or that recurred immediately upon removal of the nasal packing will be included in this study. Subject will be evaluated during the packing period to determine the effect of hemostasis. Chitosan coated packing will be removed after 48 hours. Subjects' nasal cavities will be examined endoscopically to evaluate bleeding control, morphological changes induced by the chitosan coated packing.~One week after the removal of the packing, the patients will be endoscopically examined to assess the healing of the packed area, to monitor control of bleeding, and observe any potential delayed reaction to the packing material."
89610360|NCT00863434|Experimental|Treatment (colony stimulating factor and chemotherapy)|Patients receive G-CSF SC QD on days 1-5 and clofarabine IV over 1 hour and cytarabine IV on days 2-5. Beginning approximately 1 month later, patients may receive one additional course of treatment in the absence of disease progression or unacceptable toxicity.
89610361|NCT00815776|Experimental|1|Treatment group receiving the CID
89610362|NCT00815776|Active Comparator|2|Group assigned a mouth splint
89610363|NCT00815776|Active Comparator|Exercise Control Group|Group who received no device but were instead assigned a study-specified jaw exercise program
89610364|NCT03535636||Refugees with PTSD|"Adults over the age of 18. Refugees or family members of refugees that has been reunited. PTSD (ICD-10 criteria) and written consent.~No drug or alcohol abuse and no medication that can affect sleep rhythms, such as antipsychotic drugs, benzodiazepine, opioids, antihistamine or CNS stimulating drugs.~A BMI under 35 and no pregnancy."
89610365|NCT03535636||Healthy controls|Matched on age, sex and BMI and signed written consent. No mental illness, drug or alcohol abuse and medication. No pregnancy.
89610366|NCT04209790|Other|Neoadjuvant chemoradiation and surgical resection|The experimental part of the study would be this selection of resectable patients and sequencing neoadjuvant chemoradiation prior to surgery.
89610367|NCT03838822|Experimental|Intervention|Oral administration of cofactors, 1g nicotinamide riboside, 3g L-carnitine, 20g serine and 5g N-acetylcystein, first as single compounds, then combined, on 5 days
89610368|NCT01718353|Experimental|Docetaxel + Prednisone (Treatment A)|Docetaxel 75 mg/m^2 intravenous (IV) infusion on Day 1 of Cycle 1 and every 3 weeks (q3w) thereafter, in combination with Prednisone (or Prednisolone) 10 mg orally daily. Participants with <30% PSA reduction from baseline at the end of Cycle 4 switched to Cabazitaxel 25mg/m^2 IV infusion on Day 1 of Cycle 5 and q3w thereafter, in combination with Prednisone (or Prednisolone) 10 mg orally daily until disease progression (DP), death, unacceptable toxicity or participant's refusal of further study treatment. Participants with ≥30% PSA reduction from baseline at the end of Cycle 4, continued on the same treatment which they received before switching until DP, death, unacceptable toxicity or participant's refusal of further study treatment.
89610369|NCT01718353|Experimental|Cabazitaxel + Prednisone (Treatment B)|Cabazitaxel 25 mg/m^2 IV infusion on Day 1 of Cycle 1 and q3w thereafter, in combination with Prednisone (or Prednisolone) 10 mg orally daily. Participants with <30% PSA reduction from baseline at the end of Cycle 4 switched to Docetaxel 75mg/m^2 IV infusion on Day 1 of Cycle 5 and q3w thereafter, in combination with Prednisone (or Prednisolone) 10 mg orally daily until DP, death, unacceptable toxicity or participant's refusal of further study treatment. Participants with ≥30% PSA reduction from baseline at the end of Cycle 4, continued on the same treatment which they received before switching until DP, death, unacceptable toxicity or participant's refusal of further study treatment.
89610370|NCT01716715|Experimental|Arm I (cabozantinib-s-malate)|Patients receive cabozantinib-s-malate PO QD on days 1-28.
89610371|NCT01716715|Experimental|Arm II (paclitaxel)|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15.
89610372|NCT01697449||Cohort|
89610373|NCT01696279|Experimental|Lanthanum Carbonate|Participants will receive lanthanum carbonate orally at a total daily dose of 1500 mg to 3000 mg divided and mixed equally between in three meals.
89610374|NCT01696279|Active Comparator|Calcium Carbonate|Participants will receive calcium carbonate orally at a total daily dose adjusted as appropriate, until the target serum phosphorus level is achieved or until a maximum daily dose of 6500 mg is reached.
89610375|NCT01681069|Active Comparator|IQP-VV-102|2 tablets twice a day
89610376|NCT01681069|Placebo Comparator|Placebo|2 tablets twice a day
89610377|NCT01716559||Cohort|
89610378|NCT04555759|Experimental|Patient with spinal cord injuries|
89610379|NCT01936181|Experimental|SB2 (proposed biosimilar to inflixmab)|SB2 3 mg/kg at week 0, 2, 6 then every 8 weeks thereafter via intravenous infusion up to Week 70
89610380|NCT01936181|Active Comparator|Remicade (infliximab)|Remicade 3 mg/kg at week 0, 2, 6 then every 8 weeks thereafter via intravenous infusion up to Week 46
89057789|NCT01686360|Experimental|Control group 2: tool and pre/post-test|Group receives decision tool without personalized information. (Behavioral: Decision Aid)
89057790|NCT01686360|Experimental|Gail score in a percentage format|Group receives Gail score in a percentage format. (Behavioral: Decision Aid)
89610381|NCT01936181|Experimental|Remicade (infliximab), switch to SB2|SB2 3mg/kg at week 54, 62, 70
89610382|NCT01936181|Active Comparator|Remicade (infliximab), continue as Remicade|Remicade 3mg/kg at week 54, 62, 70
89610383|NCT04642235|Experimental|Nature Nook|Nature Nook builds on our prior work with a standard vacant lot greening intervention involving: removing trash, grading the land, planting new grass and trees, installing a low wooden perimeter fence, and regular maintenance. This greening intervention was designed as a blight removal strategy. People in this arm receive no intervention.
89610384|NCT04642235|Experimental|Nature Coach|The Nature Coach intervention, developed in a prior study (NCT04146025), will be delivered to people in their homes. Participants will live in the blocks immediately surrounding the study vacant lots randomized to this arm. The lots in this arm receive no intervention.
89610385|NCT04642235|Experimental|Nature Nook + Nature Coach|This is a combined arm: a place-based intervention (Nature Nook) and a person-based intervention (Nature Coach).
89610386|NCT04642235|No Intervention|Control|The study lots randomly selected for this arm, as well as the participants living near them, receive no intervention.
89610387|NCT04641611|Active Comparator|Cavoatrial cannulation|Cannulation of the atrium with 2-stage venous cannula.
89610388|NCT04641611|Experimental|Bicaval cannulation|"Cannulating the superior and inferior vena cavae with separate cannulas, inserted through 2 separate incisions in the right artium going into the superior and inferior vena cavae. No slush added. This technique is used in Right heart procedure (Pulmonic and tricuspid valve) and mitral valve procedures.~This technique is not routinely used in CABG operations."
89610389|NCT01696045|Experimental|Ipilimumab 3 mg/kg|Ipilimumab (3 mg/kg) was administered intravenously (IV) over 90 minutes on Day 1 of each 21-day cycle for 4 cycles.
89610390|NCT01696045|Experimental|Ipilimumab 10 mg/kg|Ipilimumab (10 mg/kg) was administered intravenously (IV) over 90 minutes on Day 1 of each 21-day cycle for 4 cycles.
89610391|NCT01716169|Experimental|Helicoll|"Helicoll will be applied to one chronic wound (approximately 6 months or more duration).~Wound designations of control or Helicoll were placed in a sealed envelope prior to study start. When a subject was enrolled, wounds were identified as A or B. Then the envelope was opened which designated whether A or B would receive control or Helicoll."
89610392|NCT01935947|Experimental|Arm I (azacitidine, entinostat, chemotherapy)|Patients receive azacitidine SC on days 1-6 and 8-10 and entinostat PO on days 3 and 10. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients with stable or progressive disease receive chemotherapy of the treating oncologist's choice comprising irinotecan hydrochloride IV on day 1, docetaxel IV on day 1, pemetrexed disodium IV on day 1, or gemcitabine hydrochloride IV on days 1 and 8. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
89610393|NCT01935947|Experimental|Arm II (azacitidine, entinostat, chemotherapy)|Patients receive azacitidine PO on days 1-21 and entinostat PO on days 3 and 10. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients with stable or progressive disease receive chemotherapy of the treating oncologist's choice as in Arm A.
89610394|NCT01935947|Active Comparator|Arm III (chemotherapy)|Patients receive chemotherapy of the treating oncologist's choice as in Arm A.
89610395|NCT04547803|Experimental|Video Visit and Standard of Care|Participants will participate in a video visit and standard of care
89610396|NCT04547803|Active Comparator|Standard of Care|Participants will participate in standard of care for discharged patients.
89610397|NCT02986321|Experimental|CHF6001 DOSE1|DOSE1
89610398|NCT02986321|Experimental|CHF6001 DOSE2|DOSE2
89610399|NCT02986321|Experimental|CHF6001 DOSE3|DOSE3
89610400|NCT02986321|Experimental|CHF6001 DOSE4|DOSE4
89610401|NCT02986321|Placebo Comparator|Matched placebo|placebo control
89610402|NCT02986321|Active Comparator|Budesonide|Budesonide DPI 800µg
89610403|NCT04554667|Experimental|Exercise Intervention|Single exercise arm
89610404|NCT01618019|Experimental|N-3 PUFA|5 capsules/day of n-3 PUFA, containing 2.09 g eicosapentaenoic acid and 1.165 g docosahexaenoic acid
89610405|NCT01618019|Placebo Comparator|Placebo|5 capsules/day of placebo containing sunflower with oleic acid (DSM Nutritional products, Switzerland)
89610406|NCT01593787|Experimental|LCZ696 100 mg|All participants were started on LCZ696 100 mg once daily on day 1.
89610407|NCT01593787|Experimental|LCZ696 200 mg|All participants were started on LCZ696 100 mg once daily on day 1. For participants who did not achieve msDBP <80 mmHg and msSBP <130 mmHg at or after week 2 and had no signs of safety concerns at specified visits during the treatment epoch, the LCZ696 dose was increased to LCZ696 200 mg.
89057791|NCT01686360|Experimental|Gail score in a frequency format|Group receives Gail score in a frequency format. (Behavioral: Decision Aid)
89217998|NCT00727493|Active Comparator|1|alendronate once weekly 70mg, calcium 1000mg and Vitamin D 800 IU daily, dental implant
89610408|NCT01593787|Experimental|LCZ696 400 mg|All participants were started on LCZ696 100 mg once daily on day 1. For participants who received LCZ696 200 mg and did not achieve msDBP <80 mmHg and msSBP <130 mmHg at or after week 4 and had no signs of safety concerns at specified visits during the treatment epoch, the LCZ696 dose was increased to LCZ696 400 mg.
89610409|NCT04410601|Active Comparator|No dysphagia (after total thyroidectomy-TT)|"Patients s/p post-thyroidectomy without complication~*will NOT be enrolled to standard dysphagia-rehabilitation treatment"
89610410|NCT04410601|Experimental|Dysphagia (with at least one more complication of TT)|"Patients s/p post-thyroidectomy with both dysphagia and other documented TT complication such as vocal cord paralysis/hypocalcemia/surgical site infection etc.~*will be enrolled to standard dysphagia-rehabilitation treatment for 6-week."
89610411|NCT04410601|Experimental|Dysphagia (the only complication after TT)|"Patients s/p post-thyroidectomy dysphagia only.~*will be enrolled to standard dysphagia-rehabilitation treatment for 6-week."
89610412|NCT01951157|Active Comparator|A - docetaxel|75 mg/m2 docetaxel day 1, 1-hour intravenous, every three weeks
89610413|NCT01951157|Experimental|B - lurbinectedin (PM01183)|3.2 mg/m2 PM01183, day 1, 1-hour intravenous, every three weeks
89033788|NCT05964881|Experimental|Prolene - non-resorbable sutures|Operation through vaginal route, high posterior colpotomy is made towards the posterior cervix. Blunt preparation towards the right Spina ischiadica to visualise right sacrospinous ligament. Prolene (2-0) sutures will be placed through the ligament (ca. 2 cm medial of the spina). This suture will then be placed through the posterior cervical wall, but not yet knotted. First, colpotomy will be closed via 2/0 vicryl, then pre-laid fixation sutures will be tied, whereby the portio will come to lie about 4-6 cm cranial of the level off the vulva towards the sacrospinous ligament.
89033789|NCT05961540|Other|Conventional care group|The management of infants with CHD and their mothers is based on the current breastfeeding process and care protocols at the Cardiovascular Centre of the Children's Hospital of Fudan University.
89610414|NCT01951157|Experimental|C - gemcitabine + lurbinectedin (PM01183)|800 mg/m2 gemcitabine / 1.6 mg/m2 PM01183 both on day 1 and day 8, 30-minutes gemcitabine/1-hour PM01183 intravenous, every three weeks
89610415|NCT01363349|Experimental|CYP-1020|Dose titration 15-35mg/day for 6 months
89610416|NCT01363349|Active Comparator|Risperidone|Dose titration 2-6mg/day for 6 months
89610417|NCT00867100|Placebo Comparator|Placebo|Placebo treatment
89033790|NCT05961540|Experimental|Breastfeeding intervention program|Implement intervention programs to improve breastfeeding behaviour among mothers of infants with CHD and observe ongoing changes.
89033791|NCT05961462|Active Comparator|Exercise training group|Exercise training containing 12 sessions of a structured aerobic exercise training program over 4 weeks (3 times per week).
89610418|NCT00867100|Experimental|140 mg SC|140 mg SC PsO
89033792|NCT05961462|No Intervention|Attention control|Conventional care.
89033793|NCT05960695|Experimental|The Experimental Group|"The experimental group will be given both stretching and relaxation exercises. Among the stretching exercises, iliopsoas, adductor, and hamstring stretches will be taught.~Deep breathing exercises will be taught as relaxation exercises. Participants will repeat the stretches 3 times a week with 3 repetitions of each stretch for 20 seconds."
89610419|NCT00867100|Active Comparator|350 mg SC|350 mg SC PsO
89610420|NCT00867100|Experimental|700 mg IV|700 mg IV PsO
89610421|NCT05310214|Experimental|Acupuncture treatment (ACP)|The experimental group will be treated with acupuncture
89610422|NCT05310214|Active Comparator|Laser acupuncture treatment (LACP)|The active comparator group will be treated with laser acupuncture
89033794|NCT05960695|Active Comparator|The Control group|"The Control group will be given only stretching exercises. Among the stretching exercises, iliopsoas, adductor, and hamstring stretches will be taught.~Participants will repeat the stretches 3 times a week with 3 repetitions of each stretch for 20 seconds."
89033795|NCT05956184|Active Comparator|Convention Method Group|Women who have an IUD inserted by conventional method will be asked to rate the most severe pain they experience during the procedure according to the Visual Analogue Scale (VAS) (from 0 to 10).
89033796|NCT05956184|Active Comparator|Direct Method Group|Women who have an IUD inserted by direct method will be asked to rate the most severe pain they experience during the procedure according to the Visual Analogue Scale (VAS) (from 0 to 10).
89033797|NCT05949749||Case|
89033798|NCT05949749||Control|
89033799|NCT05949073|Active Comparator|Non impregnated gingival retraction cord - less than 10 minutes|Non impregnated gingival retraction cord will be placed around the prepared tooth and left for less than 10 minutes.
89033800|NCT05949073|Active Comparator|Non impregnated gingival retraction cord - more than 10 minutes|Non impregnated gingival retraction cord will be placed around the prepared tooth and left for more than 10 minutes.
89033801|NCT05949073|Active Comparator|impregnated gingival retraction cord - less than 10 minutes|Impregnated gingival retraction cord will be placed around the prepared tooth and left for less than 10 minutes.
89033802|NCT05949073|Active Comparator|impregnated gingival retraction cord - more than 10 minutes|Impregnated gingival retraction cord will be placed around the prepared tooth and left for more than 10 minutes.
89217999|NCT00727493|Placebo Comparator|2|placebo once weekly, calcium 1000mg and Vitamin D 800 IU daily; dental implant
89610423|NCT00817804|Experimental|V60 then Conventional|Study device first
89610424|NCT00817804|Experimental|Conventional then V60|Conventional device first
89610425|NCT03839524|Experimental|TG4050 arm|Patients in this arm will receive injections of TG4050 Investigational Medicinal Product.
89610426|NCT00818116|Experimental|ReSTOR Aspheric IOL|Bilateral implantation with the AcrySof ReSTOR Aspheric Intraocular Lens (IOL)
89610427|NCT00818272||Remicade (infliximab)|Participants with confirmed diagnosis of active Crohn's disease.
89610428|NCT00868348|Placebo Comparator|Saline|
89610429|NCT00868348|Active Comparator|Ketorolac|
89610430|NCT01933919|Placebo Comparator|placebo|"In the double-blind placebo-controlled phase participants received one placebo tablet a day in week 1, then one placebo tablet twice a day (BID) in week 2 followed by a dose adjustment period from weeks 3 to 6 where the dose could be escalated by one tablet/day/week up to a maximum of three tablets twice a day. From weeks 7 to 10 participants received the same dose that was given during week 6. At the end of the 10-week treatment period there was a dose-tapering period of up to 4 weeks where the dose was decreased by up to two tablets/day each week.~In the open-label long-term phase participants received 25 mg fluvoxamine once a day for the first week, 25 mg BID in week 2 followed by a flexible dose period from weeks 3 to 52 where the dose could be escalated by one tablet/day/week up to a maximum of 150 mg/day (three tablets BID). At the end of the 52-week treatment period there was a dose-tapering period of up to 4 weeks where the dose was decreased by up to 50 mg/day each week."
89688363|NCT02906566|Other|Older Group Ages 55-75|Active and Placebo. Participants received retinol lotion on one arm and placebo to match on the other arm.
89688364|NCT02906566|No Intervention|Young Group Ages 18-25|Participants in the group will give tissue sample only for comparison.
89688365|NCT00913133|Experimental|Desirudin|desirudin 15 mg twice daily for a minimum of 5 days
89688366|NCT04356235||A:Exp-impl-mastopexy|expander-silicone implant exchange and contralateral symmetrization with mastopexy and if needed with volume reduction
89688367|NCT04356235||B: exp-impl-mastopexy+mesh|expander-silicone implant exchange with contralateral symmetrization with mastopexy and Ultrapro sling
89033803|NCT05944913|Experimental|Arm A : Surgery for STS and prevena|"The surgery for the STS lesion will be performed according to standard practices.~PREVENA™ Incision Management System should be applied immediately post-surgery to clean surgically closed wounds. It should be continuously applied for a minimum of 2 days and up to a maximum of 7 days (as per PREVENA user manual)"
89033804|NCT05944913|No Intervention|Arm B : Surgery for STS and standard postoperative wound management|"The surgery for the STS lesion will be performed according to standard practices.~The dressing and drainage of the wound will be performed according to usual practices, with the exception of negative pressure dressings."
89033805|NCT05943561||Concussion|Has an acute concussion
89033806|NCT05943561||Non-concussion|Does not have a concussion
89033807|NCT05942313||Pregnant women with Opioid Use Disorder (OUD)|This study will enroll 100 pregnant women with OUD at UPMC with its high volumes
89033808|NCT05933044||Durvalumab cohort|All stage III non-small cell lung cancer (NSCLC) patients who received durvalumab
89033809|NCT05933044||Non-durvalumab cohort|All stage III non-small cell lung cancer (NSCLC) patients who did not receive durvalumab
89033810|NCT05930119|Experimental|fast overnight|Subjects in treatment A will administered HMPL-453 at fast overnight condition.
89610431|NCT01933919|Experimental|Fluvoxamine|"In the double-blind placebo-controlled phase participants received 25 mg fluvoxamine once a day in week 1, 25 mg twice a day (BID) in week 2 followed by a dose adjustment period from weeks 3 to 6 where the dose could be escalated by 25 mg/day/week up to a maximum of 150 mg (three tablets BID). From weeks 7 to 10 participants received the same dose that was given during week 6. At the end of the 10-week treatment period there was a dose-tapering period of up to 4 weeks where the dose of decreased by up to 50 mg/day each week.~In the open-label long-term phase participants received 25 mg fluvoxamine once a day for the first week, 25 mg BID in week 2 followed by a flexible dose period from weeks 3 to 52 where the dose could be escalated by 25 mg/day/week up to a maximum of 150 mg/day (three tablets BID). At the end of the 52-week treatment period there was a dose-tapering period of up to 4 weeks where the dose was decreased by up to 50 mg/day each week."
89033811|NCT05930119|Experimental|high-fat meal|Subjects in treatment B will administered HMPL-453 at high-fat meal condition.
89610432|NCT00819286|Active Comparator|wire (control)|patients will have their sternum closed using wire (stainless steel surgical wire).
89610433|NCT00819286|Experimental|SternaLock Rigid Fixation Plates|patients will have their sternum closed by rigid fixation using SternaLock Rigid Fixation Plates.
89610434|NCT04381702||Patients with an open approach|Patients requiring pancreatoduodenectomy and operated with an open approach : All consecutive patients requiring pancreato-duodenectomies for benign or malignant pathology before the first laparoscopic pancreaticoduodenectomy.
89610435|NCT04381702||Patients with a laparoscopic approach|Patients requiring pancreatoduodenectomy and operated with a laparoscopic approach : All consecutive patients requiring pancreato-duodenectomies for benign or malignant pathology operated with a laparoscopic approach.
89610436|NCT05317468|Experimental|Video|Patients will complete contraceptive counseling using a video-based platform. Patients and counselors will have an audio and video connection.
89033812|NCT05930119|Experimental|low-fat meal|Subjects in treatment C will administered HMPL-453 at low-fat meal condition.
89033813|NCT05930119|Experimental|rabeprazole|Subjects in treatment D will administered rabeprazole combined with HMPL-453 at low-fat meal condition hour prior to receiving a standardized low-fat meal.
89033814|NCT05929131|Experimental|discharge instructions with video|Parents who agree to participate in the study will be randomly assigned to the control or intervention groups. Before parents in the control group are discharged from the pediatric emergency service, a short 2-minute video will be shown to the American Academy of Pediatrics (2020) guidelines (intervention group with video) giving the same information about high fever to patients in addition to the verbal instructions. Instructions will be given by the same researcher to provide homogeneous and consistent information in all three groups. All patients will also receive a discharge report with instructions on post-treatment treatment.
89033815|NCT05929131|Placebo Comparator|verbal discharge instructions only|Parents who agree to participate in the study will be randomly assigned to the control or intervention groups. Parents in the control group will receive the usual verbal information and advice on high fever management in accordance with the guidelines of the American Academy of Pediatrics (2020) prior to discharge from the pediatric emergency service. Instructions will be given by the same researcher to provide homogeneous and consistent information in all three groups. All patients will also receive a discharge report with instructions on post-treatment treatment.
89033816|NCT05929131|Experimental|discharge instructions with pamphlet|Parents who agree to participate in the study will be randomly assigned to the control or intervention groups. Before the parents in the control group are discharged from the pediatric emergency service, in the second group (intervention group with brochure) in accordance with the guidelines of the American Academy of Pediatrics (2020), the parents will be told with the brochure giving the same information about fever in addition to the verbal instructions. Instructions will be given by the same researcher to provide homogeneous and consistent information in all three groups. All patients will also receive a discharge report with instructions on post-treatment treatment.
89033817|NCT05926427|Experimental|OR-chemo|Drug: Orelabrutinib, Rituximab and recommended chemotherapy according to histopathologic type
89033818|NCT05925777|Experimental|experimental group|"The protocol provides for the administration of 10 polymodal high energy laser therapy sessions, to be carried out every other day. The THEAL device (Mectronic, Bergamo) allows to deliver 4 wavelengths (650 nm, 810 nm, 980 nm and 1064 nm), with continuous and pulsed mode, with power up to 20 W.~Patients will perform stretching exercises like those of the control group."
89218000|NCT00727493|No Intervention|3|dental implant, calcium 1000mg and Vitamin D 800 IU daily
89610437|NCT05317468|Experimental|Telephone|Patients will complete contraceptive counseling on a telephone call. Patients and counselors will have an audio connection only.
89610438|NCT05318170||Women affected by gynecological cancer|Women affected by gynecological cancer (cervical, endometrial, ovarian and vulvar cancer)
89688368|NCT04356235||C: exp-impl-mastopexy+implant|expander-silicone implant exchange and contralateral symmetrization with mastopexy and silicone implant augmentation
89688369|NCT04356235||D: exp-impl-mastopexy+implant+mesh|expander-silicone implant exchange and contralateral symmetrization with mastopexy and Utrapro sling and silicone implant augmentation
88983084|NCT05951608|Experimental|AK127 in combination with AK112|Subjects will receive AK127 in combination with AK112 by intravenous administration
88983085|NCT05951556|Experimental|All Participants|All Participants will receive trial device and will be trained (via Telehealth) in its use.
88983086|NCT05951530|Active Comparator|Traditional physical therapy|This group will receive conventional upper extremity rehabilitation including active and active assisted ROMs and upper extremity stretches for 30 minutes, three to five times a week for 6 weeks.
88983087|NCT05951530|Experimental|The impact of app-based cognitive training|The experimental group received mobile-app-based cognitive training (PEAK) along with conventional upper extremity rehabilitation.
88983088|NCT05951517|Experimental|mycophenolate mofetil in refractory gastrointestinal Henoch-Schönlein purpura|patients who were resistant to steroid were treated with MMF
88983089|NCT05951439|Experimental|Intervention Group 1|CRE-HMB mixture
88983090|NCT05951439|Experimental|Intervention Group 2|CRE-GGA mixture
88983091|NCT05951439|Placebo Comparator|Intervention Group 3|placebo
88983092|NCT05951426||experimental group|40 patients in whom Endometrial carcinoma was diagnosed as part of the experimental group.
88983093|NCT05951426||control group|20 patients in whom cancer or atypical hyperplasia of the endometrium was excluded histopathologically.
88983094|NCT05951413|Experimental|Sildenafil|patients will be given estradiol in form of Cycloprogynova white pills starting dose is one pill t.i.d may be increased to two pills t.i.d according to endometrial thickness in day 9 measured by vaginal ultrasound and will have will be given sildenafil citrate tablets (50 mg) daily .
88983095|NCT05951413|Placebo Comparator|control|patients will be given estradiol in form of Cycloprogynova white pills starting dose is one pill t.i.d may be increased to two pills t.i.d according to endometrial thickness in day 9 measured by vaginal ultrasound.
88983096|NCT05951361|Active Comparator|Kenacourt-A Orabase|"the patients in this group received steroid therapy Kenacourt-A Orabase three times daily for 4 weeks.~antifungal drug miconazole oral gel once daily for 1 week"
88983097|NCT05951361|Active Comparator|980nm Diode Laser|the patients received 980 nm diode laser treatment 300 mW, non-contact mode up to 10 sessions
88983098|NCT05951335|Experimental|Intervention group|The group who received The m-Health supportive care transition program consists of education and providing face-to-face information assisted by an android-based application that can access via a smartphone, skill demonstration, assessment of the readiness of hospital discharge, as well as weekly monitoring and follow-up after the patient is discharged from the hospital. This application provides education and information on TBI caregivers regarding (a) how to treat patients with TBI at home, which includes wound care and how to provide nutrition, (b) recognize signs of infection in wounds of craniotomy, (c) recognize emergencies in cases of TBI patients at home, (d) stress management, and (e) how to arrange a schedule for the care of patients with TBI at home. This program complements routine care, including education about physical health, TBI medical problems, and how to treat TBI patients at home.
88983099|NCT05951335|No Intervention|Control group|The group who received the usual care from nurses for the caregiver-patient with TBI in the ward before discharge from the hospital consists of education about physical health and TBI medical problems and how to treat TBI patients at home. This includes wound care education, medication administration, and schedule control at the hospital after patients with TBI go home. After discharge, there is no program carried out by nurses.
88983100|NCT05951322|Experimental|Shockwave therapy|"All patients were received (ESWT) at sitting position, exposed the affected shoulder, the shoulder adducted and elbow extended and the shock wave applicator was directed in most tender point near the insertion of rotator cuff at greater tuberosity under the acromion [23].~The treatment area was prepared with a coupling gel to minimize the loss of shockwave at the interface between applicator tip and skin.~Each patient was received (6000 shocks,21000 shock/ session, 3 session 2 weeks apart, energy flux density 0.22 mJ/mm2, energy level 5-7, pulse rate 160/min., 2-3Hz)"
88983101|NCT05951322|Active Comparator|Phonophoresis|Pagani ultrasound apparatus 200 cosistts of multi frequency head(1 and 3 MHz), surface area 4 cm², continuous and pulsed mode, main voltages: 100-240-VAC.50/60Hz.
88983102|NCT05951309|Experimental|Myoinositol+D-chiroinositol+folic acid group|This group is given myoinositol+d-chiro inositol+folic acid once a day (inofolic combi, ITF company, Italy) (myoinositol 550 miligram+ d-chiroinositol 13,8 miligram+folic acid 200 micrograms)
88983103|NCT05951309|Experimental|Metformin group|This group is given metformin 500 miligram three times a day (glucophage 500mg, Merck company, Turkey) (total dose of metformin 1500 miligram a day)
88983104|NCT05951270|Experimental|Intervention|Twelve weeks of 1100 mg of apple polyphenol supplementation. At the start, middle and end of the study, several measurements will take place.
88983105|NCT05951270|Placebo Comparator|Control|Twelve weeks of 1100 mg of maltodextrin. This product is an enzymatically converted potato starch. The flavor and color will have a similar/identical appearance and taste as all mentioned antioxidants.
88983106|NCT05951257|Experimental|Personalized multimodal intervention involving hypnosis and/or music|"This arm will receive a personalized multimodal intervention involving (a) hypnosis, (b) music or (c) hypnosis and music.~Note that the objective of the research is not to compare the effect of the different intervention modalities between them, but to consider these three modalities as a multimodal intervention taking into consideration patients' preferences, that we compare to the control."
88983107|NCT05951257|No Intervention|Control/Waiting list|The participants of the control group will carry out its their daily activities and will be assessed using the same measures, at the beginning of each session and after a delay comparable to the duration of the intervention administered in the experimental group.
88983108|NCT05951244|Active Comparator|Transcranial Direct Stimulation|20 epilepsy patients who were eligible and gave consent according to the inclusion criteria. For active group, tDCS treatment will be 2 mA current strength for 30 minutes.
88983109|NCT05951244|Sham Comparator|Sham-Transcranial Direct Current Stimulation|"20 epilepsy patients who were eligible and gave consent according to the inclusion criteria.~For the sham group, the current will increase to 2mA in 10 seconds, continue for the 30s, then decrease to 0 in 10 seconds and cut off."
88983110|NCT05950906|Experimental|Part 1 SAD SC PDM608|Single ascending dose, subcutaneous administration of PDM608
89688370|NCT04356235||E: simple masectomy|unilateral simple mastectomy
89688371|NCT04356235||F: bilateral exp-impl|after bilateral SSM, ASM, NSM, expander-implant exchange
89610439|NCT01933217|Experimental|Methylphenidate|The study medication will consist of identical capsules filled Concerta® over-encapsulated to preserve double-blinding. The weekly dosages will be low, medium, and high based on weight cut-offs. Participants weighing less than 25kg will receive 18mg (low), 27mg (medium), and 36mg (high) dosages and participants weighing above 25kg will receive 18mg (low), 36mg (medium), and 54mg (high) dosages during the 3-week upward titration trial. Weekly ratings monitoring behavioral and side effect symptoms score and the Pittsburgh Side Effects Rating Scale.
89610440|NCT01933217|Placebo Comparator|Placebo|The study medication will consist of identical capsules filled with an inert white power (placebo). Weekly ratings monitoring behavioral and side effect symptoms score and the Pittsburgh Side Effects Rating Scale.
89610441|NCT01932437|Experimental|Cohort 1|"3 subjects will receive an IM dose of 4 mg/kg ETI-204, administered as two injections with a maximum volume of 2 mL at each injection site.~1 subject will receive an IM dose of ETI-204-placebo in an identical fashion."
89610442|NCT01932437|Experimental|Cohort 2|"6 subjects will receive an IM dose of 8 mg/kg ETI-204, administered as two injections with a maximum volume of 4 mL at each injection site.~2 subjects will receive an IM dose of ETI-204-placebo in an identical fashion."
89610443|NCT01932437|Experimental|Cohort 3|"6 subjects will receive an IM dose of 16 mg/kg ETI-204, administered at four sites, with administration of 4 mL at one site and the remaining volume given in three additional injections with a maximum volume of 4 mL at each injection site.~2 subjects will receive an IM dose of ETI-204-placebo in an identical fashion."
89610444|NCT01932437|Experimental|Cohort 4|"6 subjects will receive an IM dose of 20 mg/kg ETI-204, administered at up to five sites, with the injection volume distributed equally between injections and a maximum volume of 4 mL per injection site.~2 subjects will receive an IM dose of ETI-204-placebo in an identical fashion."
89610445|NCT01932437|Experimental|Cohort 5|"6 subjects will receive an IM dose of 24 mg/kg ETI-204, administered at up to six sites, with administration of 5 mL at one site and the remaining volume given in up to five additional injections distributed equally with a maximum volume of 4 mL per injection site.~2 subjects will receive an IM dose of ETI-204-placebo in an identical fashion."
89610446|NCT01949051|Experimental|Levocabastine Arm|Subjects will be assigned to one of six treatment sequences (ABC, BCA, CAB, ACB, BAC, CBA) in accordance with the randomisation schedule. A = Two, 50 microgram (mcg) sprays per nostril of levocabastine QD in the morning. Total dose of 200 mcg. Two, 0 mcg sprays from placebo to match vehicle in the evening; B = Two, 50 mcg sprays per nostril of levocabastine BID in the morning and evening. Total dose of 400 mcg; C = Two, 0 mcg sprays per nostril from placebo vehicle in morning and evenings.
89610447|NCT01948193|Experimental|Study Group|Participants will receive Sanofi Pasteur's DTaP-IPV-Hep B-PRP~T combined vaccine (investigational vaccine) at 6, 10 and 14 weeks of age.
89610448|NCT01694485|Placebo Comparator|Placebo Q4W/Abrilumab 210 mg Q3M|"Participants received placebo by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24.~During the open-label period, participants received abrilumab 210 mg once every 3 months (Q3M) for 108 weeks."
89610449|NCT01694485|Experimental|Abrilumab 7 mg Q4W/Abrilumab 210 mg Q3M|"Participants received 7 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks (Q4W) thereafter until week 24.~During the open-label period, participants received abrilumab 210 mg once every 3 months (Q3M) for 108 weeks."
88983111|NCT05950906|Placebo Comparator|Part 1 SAD SC Placebo|Single ascending dose, subcutaneous administration of matching placebo
88983112|NCT05950906|Experimental|Part 2 MAD SC PDM608|Multiple ascending dose, subcutaneous administration of PDM608 once weekly for 4 weeks.
88983113|NCT05950906|Placebo Comparator|Part 2 MAD SC Placebo|Multiple ascending dose, subcutaneous administration of placebo once weekly for 4 weeks.
88983114|NCT05950620||Intervention|Pediatric patients with obesity or in need of weight management for unwanted weight gain.
88983115|NCT05950620||Controls|Historic controls matched to the Intervention group on age, sex, and BMI percentile.
88983116|NCT05950243||Urban population Africa|Urban population in sub-Saharan Africa
88983117|NCT05950217|Experimental|Experimental Group|The experimental group patients will be educated by the nurse in the preoperative period with the support of visual education material
89610450|NCT01694485|Experimental|Abrilumab 21 mg Q4W/Abrilumab 210 mg Q3M|"Participants received 21 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24.~During the open-label period, participants received abrilumab 210 mg once every 3 months (Q3M) for 108 weeks."
89610451|NCT01694485|Experimental|Abrilumab 70 mg Q4W/Abrilumab 210 mg Q3M|"Participants received 70 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24.~During the open-label period, participants received abrilumab 210 mg once every 3 months (Q3M) for 108 weeks."
88983118|NCT05950217|No Intervention|Control Group|The control group will take rutin patient care.
88983119|NCT05950126||Group 1|low pain catastrophizing score in mother
88983120|NCT05950126||Group 2|high pain catastrophizing score in mother
88983121|NCT05949359|Experimental|Nintendo RingFit exercise group|Participants in the Nintendo RingFit exercise group received an 8-week, twice-weekly exercise program focusing on improving balance and lower limb muscle strength using Nintendo RingFit device.
88983122|NCT05949359|No Intervention|Control group|Usual care was received by the control group participants.
88983123|NCT05947903||A) EUonQoL-Kit - Active Treatment module|EUonQoL-Kit questionnaire specifically designed and administered to patients undergoing/having recently completed curative treatment for early-stage cancers OR undergoing/having recently completed non-curative treatment for advanced or metastatic cancers, including disease controlling/life prolonging tumour-directed treatment.
88983124|NCT05947903||B) EUonQoL-Kit - Survivors module|EUonQoL-Kit questionnaire specifically designed and administered to people being disease-free without evidence of active cancer, and at least one year off active treatment (with the exception of long-term adjuvant hormonotherapy).
88983125|NCT05947903||C) EUonQoL-Kit - Palliative Care module|EUonQoL-Kit questionnaire specifically designed and administered to patients with advanced cancers with projected prognosis <12 months and Eastern Cooperative Oncology Group (ECOG) ≥2 OR referred to a specialist palliative care team for symptom control, OR receiving non-curative systemic treatment or radiotherapy purely for symptom control.
88983126|NCT05947591||control|healthy adults than gait over 1 hour,
88983127|NCT05947591||experimental|healthy adults that run over 1 hour
89033819|NCT05925777|No Intervention|Control group|"Patients will perform four daily stretching exercises (three sets of 30 seconds), for 6 weeks.~Hamstring and ankle plantar flexor stretch (straight leg raise in supine position)~self-stretching of the surae muscles: the patient bends forward in a standing position with the affected foot farthest from the wall, keeping the heel on the floor; 3. the soleus muscle is exercised with the knee flexed and the gastrocnemius muscle with the knee extended~4. Plantar fascia self-stretch: In a seated position, the patient crosses the affected foot over the contralateral thigh and passively extends the metatarsophalangeal joints .~In the first session, the volunteers will be trained on how to perform the exercises correctly and will be monitored once a week."
89033820|NCT05925270|Experimental|mhGAP-Remote|mhGAP-Remote was developed specifically by our team. It involves the same intervention components described in mhGAP-Standard. However, in mhGAP-Remote the intervention is delivered mostly through standardized SMSs. There is one in-person session with the interventionist, where the participant learns the core skills of mhGAP. This is followed by standardized SMSs to reinforce intervention content learned in the first session. Study interventionists will be able to provide brief telephonic support to participants if participants struggle to implement the skills learned.
89033821|NCT05925270|Active Comparator|mhGAP-Standard|"mhGAP-Standard refers to the existing evidence-based intervention guide that was developed by the WHO to help non-specialist providers in LMIC settings provide treatment for alcohol use, among other mental health and neurological conditions. For the current study, the intervention will focus on mhGAP's psychosocial interventions, which involve psychoeducation, brief motivational interviewing, and providing strategies to reduce and/or stop use. The intervention uses a harm reduction approach, meaning that participants do not need to stop using alcohol altogether. Interventionists will deliver 4 sessions, approximately 45-60 mins each, to participants in person. Sessions are designed to be delivered approximately weekly. Providers have the option to deliver up to 2 additional booster sessions to participants who may benefit from additional care."
89033822|NCT05924386|Active Comparator|All-on-four fixed mandibular prosthesis using conventionally screw retained multiunit abutments.|Edentulous patients receiving All-on-four fixed mandibular prosthesis using conventionally screw retained multiunit abutments.
89610452|NCT01694485|Experimental|Abrilumab 210 mg/Abrilumab 210 mg Q3M|"Participants received a single dose of 210 mg abrilumab by subcutaneous injection on day 1, followed by placebo at week 2, week 4, and every 4 weeks thereafter until week 24.~During the open-label period, participants received abrilumab 210 mg once every 3 months (Q3M) for 108 weeks."
89033823|NCT05924386|Experimental|All-on-four fixed mandibular prosthesis using OT bridge attachment system|Edentulous patients receiving All-on-four fixed mandibular prosthesis using OT bridge attachment system
89033824|NCT05924321|Experimental|Carbetocin|Single IV infusion of carbetocin
89033825|NCT05924321|Placebo Comparator|Placebo|Single IV Infusion of matching placebo
89610453|NCT01931735|Experimental|Randomized Meniscectomy|This group will have a partial meniscectomy
89610454|NCT01931735|Active Comparator|Randomized Lavage|This group will have arthroscopy and lavage
89033826|NCT05924321|Active Comparator|Placebo and Moxifloxacin|Single IV infusion of matching placebo with a single oral dose of moxifloxacin
89033827|NCT05922280|Experimental|experimental group|Traction, Antero Posterior (AP) and Postero Anterior (PA) Maitland Grade III oscillatory foot mobilizations. Patients will continue their usual activities according to International Working Group on Diabetic Foot (IWGDF) guidelines including the measures of inspecting the feet, wash and properly wear shoes and perform ankle ROMs
89610455|NCT01931735|Other|Standard of Care Meniscectomy Pre-Amend|Pre-Amendment: surgeons determined standard of care option, meniscectomy, best benefited the patient. Therefore, the patient was not randomized.
89610456|NCT01931735|Other|Standard of Care Meniscectomy Post-Amend|Post Amendment: patients received a meniscectomy as a standard of care and were observed for 24-months post-operative.
89610457|NCT01930799|Other|All Enrolled Patients|Site will implement a systematic approach to screening bladder health dysfunction in multiple sclerosis patients, providing bladder health management education, and initiating appropriate urologist referrals.
89610458|NCT01715857||Chinese Patients Requiring Surgery with Sevoflurane Anesthesia|Participants who were scheduled for surgery requiring sevoflurane anesthesia with endotracheal intubation or laryngeal mask airway (LMA) per approved product information of sevoflurane in China
89610459|NCT04638725||HER2 positive breast cancer treated only with trastuzumab|
89610460|NCT04638725||HER2 positive breast cancer treated with pertuzumab|
89610461|NCT04638725||HER2 positive breast cancer treated with neratinib|
89610462|NCT04638725||HER2 positive breast cancer treated with Trastuzumab emtansine (TDM1)|
89610463|NCT04638725||HER2 positive breast cancer treated with TDM1 and neratinib|
89610464|NCT04553575||CoViD-19 patients cohort|Patients are followed for 2 years after diagnosis. The only one intervention is blood samples withdrawn for serologies
89610465|NCT01692301|Experimental|LCZ696 (sacubitril/valsartan)|Randomized patients received LCZ696 once daily for four weeks, then they force-titrated to a higher dose at Week 4 and stayed on this dose of LCZ696 once daily for the remainder of the treatment period. At week 12, patients with uncontrolled BP allowed to have amlodipine then hydrochlorothiazide (HCTZ) added at intervals of 4 weeks from Week 12 up to Week 24. To maintain the double dummy, double-blind design, 2 tablets (LCZ696, its matching placebo) and 1 capsule (olmesartan matching placebo) were given during the entire study.
89610466|NCT01692301|Active Comparator|Olmesartan|Randomized patients received olmesartan once daily for four weeks, then force-titrated to a higher dose at Week 4 and stayed on this dose of olmesartan once daily for the remainder of the treatment period. At week 12, patients with uncontrolled BP allowed to have amlodipine then hydrochlorothiazide (HCTZ) added at intervals of 4 weeks from Week 12 up to Week 24. To maintain the double dummy, double-blind design, 2 tablets (LCZ696 matching placebo) and 1 capsule (olmesartan) were given during the entire study.
89688372|NCT02787694|Experimental|Factor Targeted Walking Training|Individuals undergo 5x 2 week periods of targeted training based upon evaluation of walking factor results
89688373|NCT01723085||Open myomectomy|All patients belong to the same group Description includes the surgical technique
89688374|NCT01729013||subjects previously given placebo|
89688375|NCT01729013||subjects previously given vitamin D|
88983128|NCT05947435|Experimental|Tranexamic acid IV|Group A received an IV infusion of 10 mg/kg tranexamic acid for 20 minutes just before the surgical incision.
88983129|NCT05947435|Experimental|Tranexamic acid irrigation|10 mg/kg tranexamic acid was placed in the first irrigation solution
88983130|NCT05947435|No Intervention|Control|The control group did not receive tranexamic acid in either way
88983131|NCT05946993|Other|Intervention arm|Participants will attend 12-week programme that will include twice weekly exercise and assessment sessions.
88983132|NCT05946330|Experimental|Patients will be followed up for one year by nutritionist intervention, on individual goals|Patients allocated in the study will be randomized 1:1 and followed up for one (1) year, intervention group (IG) with nutritionist consultations, nutritional diagnosis and educational intervention with agreement on individual goals.
88983133|NCT05946330|Active Comparator|Control Group (CG) will maintain the usual outpatient care.|Patients in the Control Group (CG) will maintain the usual outpatient care.
89610467|NCT01592773|Experimental|Memantine|"To maintain the blind of the preceding study, patients who participated in MEM-MD-68 (NCT01592747) began this study with 6 weeks of double blind dosing during which all patients were either titrated to or remained on their maximum target dosages. This was followed by up-to 42 weeks of open-label dosing.~Patients who took open-label memantine in study MEM-MD-67 (NCT01999894) or MEM-MD-91(NCT01592786), received up to 48 weeks of open-label memantine at their maximum tolerated weight based target dosage."
89610468|NCT01930175|Placebo Comparator|Placebo|single dose iv of Placebo
89610469|NCT01930175|Experimental|VAY736 3 mg/kg|single dose iv of VAY736 at a dose of 3mg/kg
88983134|NCT05943808||Book reading|Test subjects in this group are given a page range within a traditional acupuncture text book to study for 30 minutes.
88983135|NCT05943808||VR pre-recorded video watching|Test subjects in this group are given a video which was pre-recorded with our Virtual reality system to study for 30 minutes.
88983136|NCT05942157|No Intervention|Control|The prescription of antibiotics will follow institution antibiotic prescribing guidelines or at the Infectious Disease (ID) clinician's discretion, based on culture and antibiotic susceptibilities results (whenever available). Empiric antibiotic treatment will be employed prior to the availability of culture or antibiotic susceptibilities results. Antibiotic level measurements, Minimum Inhibitory Concentrations (MIC) testing and Pharmacokinetics/Pharmacodynamics (PK/PD) target analysis will only be performed at Day 14 post enrolment, but the results will not be released to the ID clinician and the primary clinician.
88983137|NCT05942157|Experimental|Intervention|Once a positive GNB culture is known, antibiotic MIC testing will commence, and PK/PD target analysis will be performed using the antibiotic MIC. An every-other-day TDM-guided regimen will be chosen to rapidly adjust the antibiotic doses until the PK/PD target is achieved. In the event the antibiotic dose readjustment is unable to achieve the defined PK/PD target, blood sampling will continue every other day until Day 14 or the PK/PD target is achieved
88983138|NCT05940506|Experimental|KX-826-2.5 mg BID|treatment dose groups of 2.5 mg BID (0.25%)
88983139|NCT05940506|Experimental|KX-826-5 mg QD|treatment dose groups of 5 mg QD (0.5%)
88983140|NCT05940506|Experimental|KX-826-5 mg BID|treatment dose groups of 5 mg BID (0.5%)
88983141|NCT05940506|Placebo Comparator|Placebo|Placebo
88983142|NCT05936671|Experimental|EEG-and-ANI-guided group|During anesthetic maintenance, sevoflurane concentration will be titrated according to EEG monitoring. Sevoflurane concentration will be titrated to maintain intraoperative Patient state index (PSi) ≥ 35 and to avoid burst suppression. Intraoperative target-controlled infusion of remifentanil will be titrated to maintain intraoperative ANI between 50 and 70.
88983143|NCT05936671|Active Comparator|Usual care group|During anesthetic maintenance, the attending anesthesiologists will provide a routine standard care for anesthetic and analgesic titration. In brief, hemodynamic variables and clinical situations will be used to titrate the sevoflurane concentration and remifentanil infusion rates.
89610470|NCT01930175|Experimental|VAY736 10 mg/kg|single dose iv of VAY736 at a dose of 10mg/kg initiated following a safety review of patients receiving VAY736 3 mg/kg or placebo.
89610471|NCT01592695|Experimental|Tailored Intervention Group|Participants will receive a combined behavioral and pharmacological intervention. The behavioral component will consist of a six-session cognitive behavioral telephone intervention combined with supplemental treatment modules to address common issues associated with cigarette smoking.
89610472|NCT01592695|Active Comparator|Enhanced Standard of Care Group|Participants assigned to the enhanced standard of care condition will receive referral to their state tobacco quit line along with pharmacotherapy to assist with smoking cessation.
89610473|NCT01929863|Experimental|Arm A|Subjects will receive metformin 850 mg BID for 7 days, GSK2330672 45 mg BID on Days 1 and 2 and GSK2330672 90 mg BID on Days 3 to 7 in treatment period 1. Subjects will receive metformin 850 mg BID for 7 days, placebo (matching 45 mg GSK2330672) BID on Days 1 and 2 and placebo (matching 90 mg GSK2330672) BID on Days 3 to 7 in treatment period 2. Treatment periods will be separated by a washout period of 13 to 15 days in which subjects will continue metformin 850 mg BID only
89610474|NCT01929863|Experimental|Arm B|Subjects will receive metformin 850 mg BID for 7 days, placebo (matching 45 mg GSK2330672) BID on Days 1 and 2 and placebo (matching 90 mg GSK2330672) BID on Days 3 to 7 in treatment period 1. Subjects will receive metformin 850 mg BID for 7 days, GSK2330672 45 mg BID on Days 1 and 2 and GSK2330672 90 mg BID on Days 3 to 7 in treatment period 2. Treatment periods will be separated by a washout period of 13 to 15 days in which subjects will continue metformin 850 mg BID only
89610475|NCT01918085|Other|Peristomal skin|The peel force used to remove two types of adhesive strips (Hydrocolloid strip and strata strip) from the Peristomal skin
89610476|NCT01918085|Other|Pre-stripped abdominal skin|The peel force used to remove two types of adhesive strips (Hydrocolloid strip and strata strip) from healthy abdominal skin
89610477|NCT01714687|Active Comparator|balloon sinus dilation|Balloon sinus dilation will be conducted in-office under local anesthesia.
89033828|NCT05922280|Active Comparator|control group|Patients will continue their usual activities according to International Working Group on Diabetic Foot (IWGDF) guidelines including the measures of inspecting the feet, wash and properly wear shoes and perform ankle ROMs.
89033829|NCT05917275|Experimental|4 weeks of Amlodipine|
89033830|NCT05917275|Experimental|4 weeks of Olmesartan|
89033831|NCT05917275|Experimental|4 weeks of Hydrochlorothiazide|
89033832|NCT05917275|Experimental|4 weeks of Amlodipine/Olmesartan|
89610478|NCT01714687|Active Comparator|medical therapy|Medical therapy as needed per subject's specific disease and as determined by the investigators' clinical judgment.
89610479|NCT01714609|Placebo Comparator|Placebo|Subjects randomized to placebo will take two tablets of placebo by mouth twice daily.
89610480|NCT01714609|Experimental|Sorafenib|Subjects randomized to Sorafenib will take Sorafenib 400 mg by mouth twice daily.
89610481|NCT01929707|Experimental|LY3050258|Single escalating dose of LY3050258 (2 milligram [mg] up to 200 mg) administered in up to two of two periods.
88983144|NCT05931952|Experimental|Buteyko breathing technique|"Buteyko breathing technique and conventional (chest physiotherapy) treatment for 5 times a week for about 20 minutes in one session for a period of 4 weeks. There are three steps involved in buteyko breathing technique.~Step 1; control pause breathing test (patient is asked to sit in an upright position and take normal breath. After this, asked the patient to take small breath-in for 2s and out for 3s. Control pause phase should not exceed for >30 seconds).~Step 2; maximum pause or shallow breathing (patient is asked to place fingers under the nose to monitor inflow of air. 2 or 3 flickers of air is taken in and exhale as slowly as possible).~Step 3; combine step 1 and 2. Bronchial drainage will be performed as a conventional treatment for 2 to 3 minutes in each segment. During that time, patient is asked to take deep and slow breaths followed by cough to help in clearing mucus."
88983145|NCT05931952|Experimental|Papworth method|"Papworth method and conventional chest physiotherapy (bronchial drainage) treatment. Intervention will be given for a period of 5 sessions per week for 1 month. Duration of each session will be 20 minutes. This technique is performed particularly during remission period that make it feasible for respiratory physiotherapist to integrate this method into activities of daily living. Papworth method has five components including Papworth method ameliorates asthmatic symptoms breathing, education, relaxation, combination of breathing and relaxation exercise and home exercises and also improves quality of life.~Bronchial drainage will be performed as a conventional treatment for 2 to 3 minutes in each segment. During that time, patient is asked to take deep and slow breaths followed by cough to help in clearing mucus."
88983146|NCT05931939|Experimental|Ileal Interposition|Interposition ileal surgery group Procedure/Surgery: Bariatric surgery
88983147|NCT05931939|Active Comparator|Traditional surgical technique|Conventional revisional surgery group Procedure/Surgery: Bariatric surgery
88983148|NCT05925855|Experimental|study Fastum|participant in this group will receive US with fastum gel
88983149|NCT05925855|Experimental|study Reparil|participant in this group will receive US with reparil gel
88983150|NCT05925855|Active Comparator|Control plain gel|participant in this group will receive US with gel
88983151|NCT05925179|Experimental|antibiotic prophylaxis|per os 2 g augmentin one hour prior to surgery
88983152|NCT05925179|Placebo Comparator|placebo control|per os placebo one hour prior to surgery
88983153|NCT05922293|Active Comparator|Blow Bottle technique|"Blowing with a straw into a water bottle is a good exercise to improve breathing capacity. The user, who has poor pulmonary function, always has his blow bottle handy"
88983154|NCT05922293|Experimental|percussion|Percussion technique should be performed for about 30 seconds and simultaneously with no more than three or four lower thoracic expansion exercises
88983155|NCT05922267|Experimental|Active cycle of breathing technique|"Try to keep your chest~Take a long, slow and deep breath in, through your nose if you can.~At the end of the breath in, hold the air in your lungs for 2-3 seconds before breathing~Breathe out gently and relaxed, like a sigh. Don't force the air out.~Repeat 3 - 5 times.~If the patient feels light-headed then it is important that they revert back to the breathing control phase of the cycle~Huffing"
88983156|NCT05922267|Experimental|SLOW EXPIRATION WITH OPEN GLOTTIS IN LATERAL POSITION|The participants in group B will be given slow expiration with open glottis in lateral posture and conventional chest physiotherapy .In this technique, a patient adopts a lateral posture or a lateral decubitus posture. The affected lung is in the dependent position. A patient commences breathing normally, at tidal volumes. They are then instructed to perform a series of slow expirations with an open glottis. Expiration from functional residual capacity to the end of the expiratory reserve volume are encouraged to achieve maximum inflation . To assist in maintaining an open glottis, a mouthpiece may be used, to decrease the degree of airway compression A series of three ELTGOL may be performed, with each series composed of approximately 10 slow and deep expirations. In between each series of maneuvers, a rest period (around 1-2 minutes) is provided, with the patient staying in the same position. A typical treatment lasts for around 20 minutes
88983157|NCT05922254|Active Comparator|Active cycle of breathing technique|Group A is a control group. First, the patients will receive baseline treatment (pursed lip breathing). Additionally, patients will be administered the Active Cycle of Breathing Technique after receiving the Baseline Treatment
88983158|NCT05922254|Experimental|Autogenic drainage|Both the physiotherapist's hand and the subject's hands were put on the subject's abdomen to feel the activity of the abdominal muscles. The patient inhaled slowly through the nose while using their diaphragm and holding their breath for two to three seconds to allow collateral ventilation to bring air behind their secretions. Exhalation was done through the mouth. The palm of the therapist placed on the upper chest felt the vibration of the mucous. Their positions were disclosed by the vibrations' frequency. Secretions in tiny airways can be seen using high frequencies. The method has phases for unsticking, collecting and evacuation. The mucus was expelled by a stronger expiration or a high lung volume huff at the conclusion of the session.
88983159|NCT05922241|Experimental|Costophrenic assisted cough|While doing Costophrenic assist: at the end of expiration, the therapist gives a quick stretch to the diaphragm and intercostals to facilitate more complete inhalation by compressing the chest at the costophrenic angle toward the central tendon of the diaphragm. This is done several times to fill the lungs. The patient is then instructed to hold the air in the lungs. As the patient gets ready to cough, the therapist performs a diaphragmatic assist by applying a strong pressure up and in toward the central tendon
89210763|NCT00727571||CKD with no Anemia|CKD is based on estimated GFR calculated by the MDRD method of < 60 mL/min/1.73m^2. Anemia is defined as Hemogloblin <12 g/dL in women, < 13 g/dL in men per WHO criteria. Participants were observed for 26 weeks and completed mobility and physical performance assessments.
89210764|NCT00225277|Experimental|Pioglitazone QD|
89210765|NCT00225277|Active Comparator|Glimepiride QD|
89210766|NCT00821054|Experimental|Period 1|Treatment A, B or C
89210767|NCT00821054|Experimental|Period 2|Treatment A, B or C
89210768|NCT00821054|Experimental|Period 3|Treatment A, B or C
89610482|NCT01929707|Placebo Comparator|Placebo|Single dose of placebo matching LY3050258 administered in up to one of two periods.
89610483|NCT01714063||Age 5-6.5|Group 1 will consist of 16 children aged 5-6.5 years
89610484|NCT01714063||Aged 6.6- 8 years|Group 2 will consist of 16 children aged 6.6- 8 years
89610485|NCT01929395|Active Comparator|Arm 1 addition of supine MRI to conventional imaging|Arm 1 objective will be to determine whether the addition of supine MRI to conventional imaging with mammography and or sonography and prone MRI will result in a lower positive margin rate in patients undergoing breast conserving surgery.
89610486|NCT01929395|Active Comparator|Arm 2 randomize to SOC vs supine MRI + SOC|Arm 2 of the study patients with non-palpable invasive breast cancer or DCIS who desire breast conservation will be randomized to either a usual care group, or a group receiving a supine MRI in addition to conventional imaging (mammogram and prone MRI) and undergoing breast cancer resection without the wire localization technique.
89610487|NCT04124809|Experimental|Study group (artificially laser-collapsed blastocysts)|laser was used as an intervention before blastocyst vitrification to assist rapid blastocyst collapse with vitrification
89610488|NCT04124809|No Intervention|& control group (blastocysts were vitrified, no laser collapse|blastocyst were vitrified without laser assisted collapse
89610489|NCT01713283|Experimental|SOF+RBV 12 Weeks|Treatment-naive and treatment-experienced participants will receive SOF+RBV for 12 weeks.
89610490|NCT01713283|Experimental|SOF+RBV 24 Weeks|Treatment-naive and treatment-experienced participants will receive SOF+RBV for 24 weeks.
89610491|NCT04768075|Experimental|Camrelizumab group|"subject will receive Camrelizumab intravenously(IV) PLUS pemetrexed or paclitaxel or albumin paclitaxel PLUS cisplatin or carboplatin AUC 5 on Day 1 of each 3-week cycle(Q3W) for 4-6 cycles followed by Camrelizumab ± pemetrexed IV Q3W until progression (up to approximately 2 years).~Whether the subject accepts intracranial radiotherapy will be decided by investigators according to the guidelines and the conditions of the subjects."
89610492|NCT04768075|Placebo Comparator|placebo group|"subject will receive placebo intravenously (IV) PLUS pemetrexed or paclitaxel or albumin paclitaxel PLUS cisplatin or carboplatin AUC 5 on Day 1 of each 3-week cycle(Q3W) for 4-6 cycles followed by placebo ± pemetrexed IV Q3W until progression (up to approximately 2 years).~Whether the subject accepts intracranial radiotherapy will be decided by investigators according to the guidelines and the conditions of the subjects."
89610493|NCT01592383|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive erlotinib hydrochloride PO QD. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89610494|NCT01691521|Experimental|Mepolizumab IV|Mepolizumab 75 mg will be administered intravenously approximately every 4 weeks with the last dose at week 32. Subjects in the Mepolizumab IV arm will receive mepolizumab 75 mg intravenously and placebo SC once every 4 weeks with the last dose at Week 28 (total of 8 doses)
89610495|NCT01691521|Experimental|Mepolizumab SC|Subjects in the Mepolizumab SC arm will receive mepolizumab 100 mg SC and placebo IV once every 4 weeks with the last dose at Week 28 (total of 8 doses)
89610496|NCT01691521|Placebo Comparator|Placebo|Subjects in the Placebo arm will receive matching placebo SC and placebo IV once every 4 weeks with the last dose at Week 28 (total of 8 doses)
89610497|NCT01929317|Experimental|Ropinirole CR high-dose group|The subjects will receive Ropinirole CR 16mg/day for 4 weeks in screening phase. After randomization the subject will enter dose increase effect verification phase, where Ropinirole CR dose will titrated (2 mg /day/week) from 18 mg/day up to a maximum 24mg/day at intervals of 1 week or longer for 8 weeks, till subject reaches a dose level above which further symptomatic improvement cannot be expected; the subject will be maintained on that dose for 4 weeks. This will be followed by a down titration phase of one week and long term phase of 39 weeks in which the subjects will receive incremental doses (2 mg /day/week) of Ropinirole CR from 18 mg/day till to a maximum of 24 mg/day till subject reaches a dose level above which further symptomatic improvement cannot be expected; the subject will be maintained on that dose. Subjects completing the long term phase will undergo a down titration phase of 1 to 2 weeks.
89610498|NCT01929317|Experimental|Ropinirole CR maintenance group|The subjects will receive Ropinirole CR 16mg/day for 4 weeks in screening phase. After randomization the subject will enter dose increase effect verification phase and Ropinirole CR dose will maintained at 16mg/day and placebo will be increased at intervals of 1 week for 8 weeks till subject reaches a dose level above which further symptomatic improvement cannot be expected; the subject will be maintained on that dose for 4 weeks. This will be followed by a down titration phase of one week and long term phase of 39 weeks in which the subjects will receive incremental doses (2 mg/day/week) of Ropinirole CR from 18 mg/day till to a maximum of 24 mg/day till subject reaches a dose level above which further symptomatic improvement cannot be expected; the subject will be maintained on that dose. Subjects completing the long term phase will undergo a down titration phase of 1 to 2 weeks.
89610499|NCT01711879|Active Comparator|Aflibercept with Laser|A single injection of 2mg (0.05ml) intravitreal aflibercept injection at baseline followed by standard of care laser with observation for a total of 52 weeks
89610500|NCT01711879|Experimental|Aflibercept|2mg (0.05ml) intravitreal aflibercept injection at baseline followed by two additional injections at 4 weeks and 8 weeks, then every 8 weeks for a total of 52 weeks.
89610501|NCT00869206|Experimental|Arm I (zoledronic acid every 4 weeks)|Patients receive zoledronic acid IV over at least 15 minutes every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
89610502|NCT00869206|Experimental|Arm II (zoledronic acid every 12 weeks)|Patients receive zoledronic acid IV over at least 15 minutes every 12 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
88983160|NCT05922241|Experimental|Anterior chest compression|Anterior chest compression: the therapist places one arm across the patient's pectorals and the other parallel to it on the lower abdomen. After the patient takes a maximal breath, the therapist pushes down to help the patient cough. The greatest force is applied through the lower chest during expulsion
88983161|NCT05922059|Experimental|Vagus nerve stimulation|Transcutaneous vagus nerve stimulation in addition to standard-care physiotherapy
88983162|NCT05922059|Experimental|Heart rate variability biofeedback|Heart rate variability biofeedback in addition to standard-care physiotherapy
89210769|NCT04391673||Dizzy group|Patients attending the dizziness and balance exercise programme at Guy's Hospital, London. Patients data will be included if they complete at least 4 sessions.
89610503|NCT04625231|Experimental|Shared-Decision Making Tool Group|
89610504|NCT04625231|No Intervention|Standard of Care Group|
89610505|NCT01689649|Experimental|Topiramate|For children: Children will start on topiramate with a dosage of 0.5mg/kg in the evening, followed by 0.5mg/kg/day weekly increments until an initial target dose of 3mg/kg/day is reached. The total daily topiramate dose for children may, not exceed 9mg/kg/day. For adult patients: Adult patients start on topiramate with a dosage of 25mg/day in the evening, followed by weekly increments of 25 mg/day until an initial target dose of 100mg/day is reached. The dose of topiramate may be increased to the optimal dose with weekly increments of 0.5mg/kg/day and of 25 mg/day for children and adults, respectively at the discretion of the investigator.
89610506|NCT01929083|Experimental|Progesterone|Subjects will receive treatment with oral progesterone 400 mg once daily (two x 200 mg capsules) every evening for 7 days
89610507|NCT01929083|Placebo Comparator|Placebo|Subjects will receive oral placebo, two capsules once daily every evening for 7 days
89610508|NCT01689337|Experimental|Sprifermin (AS902330), 30 mcg|
89610509|NCT01689337|Experimental|Sprifermin (AS902330), 100 mcg|
88815334|NCT00993200|Active Comparator|Warfarin, control|Subjects naive to warfarin therapy with anticipated warfarin duration of at least 12 weeks managed by usual care dosing.
88815335|NCT00993200|Experimental|Warfarin: PERMIT|Subjects naive to warfarin therapy with anticipated warfarin duration of at least 12 weeks managed by warfarin pharmacogenetic dosing (warfarin dosing using genetic information incorporated into the PERMIT algorithm).
88815336|NCT00993824|Placebo Comparator|Welchol then Placebo|3.75 grams of colesevelam HCl (Welchol) at evening meal for 12 weeks, and then crossover to placebo at evening meal for 12 weeks.
88815337|NCT00993824|Placebo Comparator|Placebo then Welchol|Placebo taken for 12 weeks at evening meal, and then crossover to 3.75 grams of colesevelam HCl taken at evening meal fro 12 weeks.
89610510|NCT01689337|Placebo Comparator|Placebo|
89610511|NCT01688635|Experimental|LY2963016|Single 0.5 units per kilogram (U/kg) dose of LY2963016 administered subcutaneously, twice during the study
89610512|NCT01688635|Experimental|US-approved Lantus|Single 0.5 U/kg dose of US-approved Lantus administered subcutaneously, twice during the study
89610513|NCT04881409|Experimental|nasal high-flow|Patient with AECOPD is treated with NHF.
89610514|NCT04881409|Active Comparator|non-invasive ventilation|Patient with AECOPD is treated with NIV
89688376|NCT04378283|Experimental|LET as topical anesthetic for wound repair.|LET gel (lidocaine 4%, epinephrine 0.1%, and tetracaine 0.5%) is a topical anesthetic that is routinely used before laceration repair.
88815338|NCT00994604|Experimental|broccoli sprout extract|This a before and after treatment study. The subjects will consumer broccoli sprout extract (BSE) for two weeks (14d). Lung function and Chest CT will be performed before and after BSE consumption.
88815339|NCT04084652|Experimental|Mycoprotein|Mycoprotein in its full food matrix
88815340|NCT04084652|Experimental|Protein Isolated from Mycoprotein|Protein from mycoprotein isolated from the food matrix
88815341|NCT02447172|Experimental|Gentamicin sponge group|Topical Gentamicin Collagen Sponge: Up to four collagen sponges each containing 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base) administered daily, with systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.
88815342|NCT02447172|Placebo Comparator|Placebo sponge group|Matching placebo collagen sponge administered daily, with systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.
88815343|NCT02447172|No Intervention|No sponge group|Systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.
88815344|NCT02163824|Active Comparator|KPI-121 0.25% QID|KPI-121 0.25% Ophthalmic Suspension dosed 4 times daily for 14 days after routine, uncomplicated surgery for cataract removal and intraocular lens implant.
88815345|NCT02163824|Active Comparator|KPI-121 1.0% BID|KPI-121 1.0% Ophthalmic Suspension dosed 2 times daily for 14 days after routine, uncomplicated surgery for cataract removal and intraocular lens implant.
88815346|NCT02163824|Placebo Comparator|Vehicle of KPI-121 0.25%|Vehicle of KPI-121 0.25% Ophthalmic Suspension dosed 4 times daily for 14 days after routine, uncomplicated surgery for cataract removal and intraocular lens implant.
88815347|NCT02163824|Placebo Comparator|Vehicle of KPI-121 1.0%|Vehicle of KPI-121 1.0% Ophthalmic Suspension dosed 2 times daily for 14 days after routine, uncomplicated surgery for cataract removal and intraocular lens implant.
88815348|NCT04200066|Experimental|Experimental Arm|This arm will combine maprotiline with temozolomide and tamoxifen to determine the maximum tolerated dose.
88815349|NCT02165384|Experimental|Hummingbird TTS|Ear tube placement with the Hummingbird TTS
88815350|NCT02455050|Other|New Eye Drop Formulation then Systane®|1 to 2 drops of New Eye Drop Formulation (carboxymethylcellulose sodium based eye drops) in each eye as needed at least 2 times daily for 2 weeks followed by 1 to 2 drops of Systane® Gel Drops in each eye as needed at least 2 times daily for 2 weeks.
88815351|NCT02455050|Other|Systane® then New Eye Drop Formulation|1 to 2 drops of Systane® Gel Drops in each eye as needed at least 2 times daily for 2 weeks followed by 1 to 2 drops of New Eye Drop Formulation (carboxymethylcellulose sodium based eye drops) in each eye as needed at least 2 times daily for 2 weeks.
88815352|NCT02455050|Other|Genteal® then New Eye Drop Formulation|1 to 2 drops of Genteal® Lubricant Gel Drops in each eye as needed at least 2 times daily for 2 weeks followed 1 to 2 drops of New Eye Drop Formulation (carboxymethylcellulose sodium based eye drops) in each eye as needed at least 2 times daily for 2 weeks.
88815353|NCT02455050|Other|New Eye Drop Formulation then Genteal®|1 to 2 drops of New Eye Drop Formulation (carboxymethylcellulose sodium based eye drops) in each eye as needed at least 2 times daily for 2 weeks followed by 1 to 2 drops of Genteal® Lubricant Gel Drops in each eye as needed at least 2 times daily for 2 weeks.
88815354|NCT00994760||GENISIS|
88815355|NCT02418468|Experimental|Placebo|Matching placebo indacaterol capsules for inhalation once daily delivered via the Novartis single dose dry power inhaler (SDDPI) (Onbrez® Breezhaler®)
88815356|NCT02418468|Experimental|Indacaterol 150 mcg|Indacaterol 150 mcg capsules for inhalation once daily delivered via the Novartis single dose dry power inhaler (SDDPI) (Onbrez® Breezhaler®)
88815357|NCT04927572|Experimental|FMX114|
88815358|NCT04927572|Placebo Comparator|Vehicle|
89610515|NCT01591681|Active Comparator|Pump suspension algorithm|The study laptop will be running actively during the night and suspending the patient's pump if the algorithm predicts hypoglycemia based on the patient's continuous glucose sensor trend.
89610516|NCT01591681|No Intervention|Standard of Care|The control algorithm will run passively and not recommend control the patient's pump.
89610517|NCT04871503|Experimental|HIFEM+RF (HR)|The HR group will receive treatment with intensities of a magnetic field and radiofrequency energy just below the patient's tolerance threshold. The device will induce visible muscle contractions along with mild heating of the muscles.
89610518|NCT04871503|Experimental|HIFEM (H)|The H group will receive a treatment with the intensities of the magnetic field just below the patient's tolerance threshold without the use of radiofrequency.
89610519|NCT02986009|Experimental|Parenting|To receive the parenting intervention
89610520|NCT02986009|Experimental|Information|To receive the information intervention
89610521|NCT02985931||Suspected CAD subjects|
89610522|NCT00891436|Placebo Comparator|Placebo nasal spray|
88983163|NCT05922059|Active Comparator|standard-care physiotherapy alone|standard-care physiotherapy
88983164|NCT05921968|Active Comparator|Intravenous Iron Sucrose group|"50 pregnant women will receive 200 mg elemental iron in 100 ml 0.9 NaCl intravenous over 20 -30 minutes daily up to the total dose~-The dose of the total iron sucrose to be administrated was calculated from the following formula: Total dose required = weight (kg) x (target Hb in g\dL - actual Hb in g\dL) x 2.4 + 500 mg rounded up to the nearest multiple of 100 mg"
88983165|NCT05921968|Active Comparator|Lactoferrin group|50 pregnant women will receive lactoferrin 100 twice daily orally .
88983166|NCT05918835|Experimental|High-frequency repetitive transcranial magnetic stimulation (HF-rTMS)|Target: Region of right DLPFC with greatest resting-state functional connectivity to dorsal striatum (individualized functional target) Protocol: 10 pulses/sec, 4s trains, 120% MT, 3000 pulses/session
88983167|NCT05918835|Sham Comparator|Sham repetitive transcranial magnetic stimulation (sham rTMS)|Target: Region of right DLPFC with greatest resting-state functional connectivity to dorsal striatum (individualized functional target) Protocol: same as HF-rTMS, with sham coil
88983168|NCT05918679|Experimental|Healthy Adults group 1|
88983169|NCT05918679|Experimental|Healthy Adults group 2|
89610523|NCT00891436|Active Comparator|Fluticasone furoate nasal spray|
89610524|NCT01711645|Experimental|Adacel® Tdap vaccine|55 postpartum subjects receive a single intramuscular (IM) 0.5 mL dose of Adacel® (Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed).
89610525|NCT04381546|Experimental|FES in patients with hemiplegia|Patients will be equipped with 5 inertial measurement units. Two wireless bluetooth pressure insoles will be connected to the Raspberry. Electrical stimulation will be delivered via a wireless stimulator to the quadriceps and hamstrings via surface electrodes. Insoles will be used to online analyze Paretic Foot Support to discriminate between stance and swing phases. Stimulation will also be delivered just before initial contact at the end of swing phase. In stance phase, stimulation will be triggered either to quadriceps or hamstrings, depending on the paretic knee angle estimation relatively to the knee angle setpoint defined by the practitioner as the optimal flexion during stance phase (around 5°).
89610526|NCT00820534|Experimental|Penciclovir|Penciclovir
89610527|NCT00820534|Placebo Comparator|Placebo|Placebo
89610528|NCT01590433|Experimental|Exenatide|Subjects will be randomly assigned to the exenatide study treatment group or to the placebo study treatment group. Subjects will have a 33 percent chance of being assigned to the placebo study treatment group and a 66 percent chance of being assigned to exenatide study treatment. Subjects will not be able to choose the study group to which they will be assigned. All study participants will receive individualized dietary counseling based on food logs. Subjects who receive exenatide will not be assigned to follow a reduced-calorie diet in addition to study treatment. Subjects will not know whether they are receiving exenatide or placebo, but the unblinded members of study team will know which they are receiving.
89610529|NCT01590433|Placebo Comparator|Placebo|Subjects will be randomly assigned to the exenatide study treatment group or to the placebo study treatment group. Subjects will have a 33 percent chance of being assigned to the placebo study treatment group and a 66 percent chance of being assigned to exenatide study treatment. Subjects will not be able to choose the study group to which they will be assigned. All study participants will receive individualized dietary counseling based on food logs. Subjects who receive placebo will be assigned to follow a reduced-calorie diet in addition to study treatment. Subjects will not know whether they are receiving exenatide or placebo, but the unblinded members of the study team will know which they are receiving.
89610530|NCT00820612|Active Comparator|1|Indomethacin suppository
89610531|NCT00820612|Placebo Comparator|2|Placebo suppository
89610532|NCT01928927|Experimental|Arm A: Telmisartan|
89610533|NCT01928927|No Intervention|Arm B: No Study Drug|Participants received no study drug and followed the week 0-48 evaluation schedule.
88983170|NCT05918679|Experimental|Healthy Adults group 3|
88983171|NCT05918679|Experimental|Healthy Adults group 4|
88983172|NCT05918679|Experimental|Healthy Adults group 5|
88983173|NCT05911360|Experimental|Participants Receiving DTG/3TC FDC|
89033833|NCT05916482||OPT OBESE|Vietnamese patients with obesity present at outpatient clinics of University Medical Center Ho Chi Minh City and My Duc General Hospital
89610534|NCT00871624|Active Comparator|Dexmedetomidine|Subjects received active dexmedetomidine 0.2 -0.7 mcg/kg/hr
89610535|NCT00871624|Placebo Comparator|Placebo|Subjects received placebo saline solution 0.2-0.7 mcg/kg/hr
89610536|NCT05315518|Experimental|single shade universal resin composite (omnichroma) with blocker|(OMNICHROMA BLOCKER) is indicated for preventing shade-matching interference in Class IV restorations, Masking dark dentition and dentin. In cases where there is a lack of tooth structure to bond to, (BLOCKER) works as a supplementary product to provide a lingual wall to the restoration, prevent shade-match obstruction and mask staining.
89688377|NCT04378283|Active Comparator|EMLA plus infiltration as anesthetic for wound repair.|"EMLA (eutectic mixture of local anesthetics) with subsequent lidocaine infiltration. EMLA is a mixture of lidocaine (2.5%) and prilocaine (2.5%) in a cream base."
89610537|NCT05315518|Active Comparator|single shade universal resin composite(GC solare sculpt) with chameleon effect|One-shade universal resin composite (GC solare sculpt) gives very natural appearance, High gloss retention over time, time saving regarding to layering technique, wide shade matching range (chameleon effect) and delivering lifelike aesthetic restorations. These features can be offered by supra-nano spherical filler which have controlled refractive index, records excellent esthetic properties in small and medium class IV restorations.
89610538|NCT01710709|Experimental|Experimental|Aripiprazole, Intramuscular (IM) Depot
89610539|NCT05318404|No Intervention|Conventinal feeding group|Start oral feeding 5-7 days after esophagectomy and discharge with soft blended diet as major energy source
89610540|NCT05318404|Experimental|Delayed feeding group|Start clear liquid fluid diet 5-7 days after esophagectomy and discharge with jejunostomy feeding as the major energy source. Start oral feeding at postoperative 1st visit
89610541|NCT01617629|Experimental|Cvac Treatment Group|Participants received Epithelial Mucin Surface Antigen 1 (MUC1) Dendritic Cell Vaccine (Cvac) treatment.
89610542|NCT00874510|No Intervention|Standard Schedule|interns work standard schedule, being on duty for 30 continuous hours
89610543|NCT00874510|Experimental|Mandatory Naps|interns on overnight extended duty shifts have mandatory sign out of cell phones and cross-coverage responsibilities for 5 hours roughly between 12 and 5 am. For Year 2, this will be two 3 hour shifts, the first between 12am-3am and the 2nd between 3am-6am.
89610544|NCT01686373|Experimental|Activa Dose II Real tDCS|Actual delivery of electrical stimulation
89610545|NCT01686373|Placebo Comparator|Activa Dose II Sham tDCS|Sham delivery of electrical stimulation
89610546|NCT03838666|Experimental|Suspension of human autologous MSC 3P|Patients will receive perioperative hAMSC (1.5 ml) treatment in order to accelerate the healing of the surgically repaired rotator cuff and increase the mechanical properties of the tendon.
89610547|NCT03838432|Experimental|Steep Pulse Device|Applying the steep pulse to treat the patients with Prostate cancer
89610548|NCT03838354|Experimental|A|Chidamide 2.5 mg po tiw
89610549|NCT03838354|Experimental|B|Chidamide 5 mg po tiw
89610550|NCT01709695|Experimental|guanfacine hydrochloride XR|Flexible dose titration of guanfacine extended release (Intuniv; active medication). The medication is titrated in doses from 1 - 4 mg once daily
89610551|NCT01709695|Placebo Comparator|Placebo Group|Flexible dose titration of placebo
89610552|NCT05312320|Active Comparator|Information film|Randomized to receive a short information film online.
89610553|NCT05312320|No Intervention|Standard care|No film, only questionnaire.
89610554|NCT05310760|Active Comparator|Vitamin C receiving|Therapeutic doses of Vitamin C are added to rachitic children treatment
89610555|NCT05310760|No Intervention|Non Vitamin C receiving|The traditional treatment of nutritional rickets
89610556|NCT05236504|Experimental|Supplement|Melatonin and magnesium-containing pod
89610557|NCT05236504|Placebo Comparator|Placebo|Placebo pod
89610558|NCT02150044|Experimental|Tympanostomy tube|Performance and safety of tympanostomy tube delivery system
89610559|NCT01685983|Experimental|Abiraterone actetate and Prednisolone|
89610560|NCT02151448|Experimental|vaccine + chemokine modulatory regimen|Week 1 (at recovery from surgery; ≥ 6 weeks post-surgery)-Priming Vaccine dose; no chemokine modulation; 1 day: αDC1 vaccine; Oral celecoxib, 200 mg, before & after treatment on day of vaccination; Weeks 2-3 -Rest; Week 4 (target) - Booster C1; Mon: αDC1 vaccine;Tues - Fri: Systemic Chemokine Modulation Regimen. Oral celecoxib, 200 mg, BID on vaccination days & CKM. Celecoxib will be dced after CKM on Fri. Rintatolimod only administered on Wed & Fri.; Week 5-7 -Rest; Week 8 (target) -Booster C2; Monday: αDC1 vaccine. Oral celecoxib, 200 mg, BID on days of vaccination and CKM. Tues - Fri:Systemic Chemokine Modulation Regimen. Rintatolimod only administered on Wed & Fri. Celecoxib will be dced after CKM on Fri.; Week 9-11 -Rest; Week 12 (target) -Booster C3; Monday: αDC1 vaccine. Tues-Fri: Systemic Chemokine Modulation Regimen. Rintatolimod only administered on Wed & Fri. Oral celecoxib, 200 mg, BID, given on days of vaccination and CKM. Celecoxib will be discontinued after CKM on Fri.
89610561|NCT01685437|Experimental|AA4500|collagenase clostridium histolyticum
89610562|NCT00875212|Experimental|dentifrice intervention|4 types of dentifrices were used in 4 different periods in a crossover study design.
89610563|NCT00875836|Experimental|Buspirone|Buspirone
89610564|NCT00875836|Placebo Comparator|Placebo|Placebo
89610565|NCT05235802||Patients with traumatic brain injury about 10 years ago|Patients that had suffered a TBI and being managed at the Neurosurgical Department at the Karolinska University Hospital between 2007 and 2015.
89610566|NCT00891982|Experimental|CTGel plus BPO wash|Benzoyl peroxide (BPO) Wash in the morning and CTGel in the evening
89610567|NCT00891982|Active Comparator|CTGel|Soap Free Cleanser in the morning and CTGel in the evening
89610568|NCT05312476|Experimental|Chimeric Antigen Receptor T Cells (CAR-T) Targeting Igβ Targets|Chimeric antigen receptor T cells targeting Igβ targets (CAR-T)
89610569|NCT01685203|Experimental|Group 1|ABT-450 150 mg/ r 100 mg, and ABT-267 25 mg once daily for 12 weeks to adult noncirrhotic, treatment-naïve, HCV GT4-infected participants
89610570|NCT01685203|Experimental|Group 2|ABT-450 150 mg/ r 100 mg, and ABT-267 25 mg once daily for 12 weeks to adult noncirrhotic, treatment-naïve HCV GT1b-infected participants
89610571|NCT01685203|Experimental|Group 3|ABT-450 150 mg/ r 100 mg, and ABT-267 25 mg once daily for 12 weeks to adult noncirrhotic, HCV GT1b-infected, pegylated-interferon/ribavirin (pegIFN/RBV) treatment null responder participants
89610572|NCT01685203|Experimental|Group 4|ABT-450 150 mg/ r 100 mg, ABT-267 25 mg , once daily and weight-based ribavirin (RBV; 1,000 mg/day if < 75 kg or 1,200 mg/day if ≥ 75 kg, divided twice daily) for 12 weeks to adult noncirrhotic, treatment-naïve, HCV GT4-infected participants
89610573|NCT01685203|Experimental|Group 5|ABT-450 150 mg/ r 100 mg, and ABT-267 25 mg once daily for 12 weeks to adult noncirrhotic, treatment-experienced, HCV GT4-infected participants
89610574|NCT01685203|Experimental|Group 6|ABT-450 150 mg/ r 100 mg, ABT-267 25 mg , once daily and weight-based ribavirin (RBV; 1,000 mg/day if < 75 kg or 1,200 mg/day if ≥ 75 kg, divided twice daily) for 12 weeks to adult noncirrhotic, HCV GT4-infected, pegylated-interferon/RBV (pegIFN/RBV) treatment-experienced participants
89610575|NCT01685203|Experimental|Group 7|ABT-450 150 mg/ r 100 mg, and ABT-267 25 mg once daily for 24 weeks to adult, HCV GT1b-infected, treatment-naïve participants with compensated cirrhosis
89610576|NCT01685203|Experimental|Group 8|ABT-450 150 mg/ r 100 mg, and ABT-267 25 mg once daily for 24 weeks to adult, HCV GT1b-infected, pegylated-interferon/RBV(pegIFN/RBV) treatment-experienced participants with compensated cirrhosis
89610577|NCT01928771|Experimental|Benralizumab 30 mg q.4 weeks|Benralizumab administered subcutaneously every 4 weeks
89610578|NCT01928771|Experimental|Benralizumab 30 mg q.8 weeks|Benralizumab administered subcutaneously every 8 weeks
89610579|NCT01928771|Placebo Comparator|Placebo|Placebo administered subcutaneously
89610580|NCT04545229|Experimental|Active VR-PAT|Active VR-based Pain Alleviation Tool (VR-PAT) group played smart phone VR-PAT during the burn dressing changes.
89610581|NCT04545229|Experimental|Passive VR-PAT|Passive VR-based Pain Alleviation Tool (VR-PAT) group watched smart phone VR-PAT games without interaction during the burn dressing changes.
89610582|NCT04545229|No Intervention|Standard Care Control|Standard care control group used regular distraction such as background music or no distraction.
89610583|NCT01589653|Experimental|Subject-driven titration|
89610584|NCT01589653|Experimental|Investigator-driven titration|
89610585|NCT01928615|Experimental|Trastuzumab - Thigh first, then upper arm|In the run-in phase, participants received trastuzumab intravenously every 3 weeks for 18 weeks (Cycles 1-6). They first received trastuzumab 8 mg/kg once (Cycle 1) followed by trastuzumab 6 mg/kg 5 times for 15 weeks (Cycles 2-6). Participants could also receive a maximum of 6 cycles of standard chemotherapy for early breast cancer (neo-adjuvant or adjuvant) in the run-in phase. Following the run-in phase, participants received trastuzumab 600 mg subcutaneously (SC) every 3 weeks into the thigh for 12 weeks (Cycles 7-10) followed by trastuzumab 600 mg SC every 3 weeks into the upper arm for 12 weeks (Cycles 11-14). In Cycles 15-18, participants received trastuzumab 600 mg SC every 3 weeks into either the thigh or the upper arm (participant's choice) for 12 weeks (Cycles 15-18).
89610586|NCT01928615|Experimental|Trastuzumab - Upper arm first, then thigh|In the run-in phase, participants received trastuzumab intravenously every 3 weeks for 18 weeks (Cycles 1-6). They first received trastuzumab 8 mg/kg once (Cycle 1) followed by trastuzumab 6 mg/kg 5 times for 15 weeks (Cycles 2-6). Participants could also receive a maximum of 6 cycles of standard chemotherapy for early breast cancer (neo-adjuvant or adjuvant) in the run-in phase. Following the run-in phase, participants received trastuzumab 600 mg subcutaneously (SC) every 3 weeks into the upper arm for 12 weeks (Cycles 7-10) followed by trastuzumab 600 mg SC every 3 weeks into the thigh for 12 weeks (Cycles 11-14). In Cycles 15-18, participants received trastuzumab 600 mg SC every 3 weeks into either the thigh or the upper arm (participant's choice) for 12 weeks (Cycles 15-18).
89610587|NCT01589497|Active Comparator|RHZE-RHZE|Participants were administered rifampin-isoniazid-pyrazinamide-ethambutol (RHZE) from Day 1 to Day 14.
89610588|NCT01589497|Active Comparator|RHZE-RZE|Participants were administered RHZE from Day 1 to Day 2, then rifampin-pyrazinamide-ethambutol (RZE) from Day 3 to Day 14.
89610589|NCT01589497|Active Comparator|RHZE-RMZE|Participants were administered RHZE Day 1 to Day 2 and rifampin-moxifloxacin-pyrazinamide-ethambutol (RMZE) from Day 3 to Day 14.
89610590|NCT01589497|Active Comparator|RZE-RZE|Participants were administered only RZE from Day 1 through Day 14.
89610591|NCT01928381|Placebo Comparator|placebo capsules|Capsules to match pregabalin and AZD5213
89610592|NCT01928381|Experimental|AZD5213 + pregabalin|AZD5213 in combination with pregabalin
89610593|NCT01928381|Active Comparator|pregabalin|pregabalin capsules
89610594|NCT01928225|Experimental|Human Papillomavirus vaccine|Participants receive the experimental quadrivalent Human Papillomavirus vaccine at entry, week 4 and week 26.
89610595|NCT01928225|Placebo Comparator|Saline placebo|The participants receive saline placebo at entry, week 4 and week 26.
89610596|NCT04624061|Experimental|Intervention|"The integrated HIV/HTN care model with the following components;~Training and capacity building on the INTEGRATED HIV/HTN model and NCD care~Integrated HIV/HTN care delivery model by promoting HTN screening and care in HIV clinics.~HMIS enhancements through mentorship and coaching on the use of NCD registers and NCD patient cards and HTN data capture in the (Electronic Medical Record) EMR system.~SMS and/or WhatsApp for data coordination and communication among providers, District Health officers (DHOs) and study team (Mentors) to strengthen feedback."
89610597|NCT04624061|No Intervention|Control|Standard of care maintained. These are procedures conducted during the routine HIV and Hypertension care visits at the health facilities include;a) Provision of BP machines b)Provision of NCD register and NCD patient card and ; c) Following MOH treatment guidelines
89610598|NCT01927757|Experimental|Etanercept|Participants received etanercept 50 mg administered subcutaneously once a week with methotrexate for 24 weeks
89610599|NCT01927367|Other|Clinical Decision Support System for AF|Providers randomized to use the Clinical Decision Support System (CDSS, a web-based tool).
89610600|NCT01927367|No Intervention|Usual Care|Usual Care - providers are not eligible to access / use the CDSS.
89610601|NCT01913639|Experimental|FOLFOX Plus Regorafenib|Regorafenib 160 mg daily on days 4 to 10 and days 18 to 24 as four 40 mg coprecipitate tablets + mFOLFOX on Day 1 and Day 15 of each cycle. Each cycle consists of 28 days. All patients will receive systemic chemotherapy with the mFOLFOX regimen and regorafenib. The specific version of the FOLFOX regimen used at MSKCC is mFOLFOX6. mFOLFOX6 will be given on Day 1 of each cycle. Patients will receive Oxaliplatin 85 mg/m2 IV (over 120 minutes), leucovorin 400 mg/m2 IV (over 120 minutes), 5-FU 400 mg/m2 IVP, and 5-FU 1200 mg/m2/day CIVI x 2 days, every two weeks. Treatment will be performed on the scheduled day ± 7 days. In case of discontinuation of FOLFOX due to cumulative toxicity and administration as a single agent during the study, regorafenib for patient convenience will be administered 160 mg daily for 3 weeks on/1 week off. The 3 weeks on/1 week off schedule is supported by the single agent regorafenib data in colon cancer and GIST.
89610602|NCT01913483|Experimental|Bivalirudin|Bivalirudin was administered as an intravenous (IV) bolus and infusion for the duration of the procedure (mean duration of 48.6 minutes). The bolus (0.75 milligrams (mg)/kilogram [kg]) was administered via systemic IV administration. Immediately after the bolus, an IV infusion of bivalirudin was initiated at a dose of 1.75 mg/kg/hour (h) (or 1 mg/kg/h for participants with an estimated glomerular filtration rate [eGFR] <30 milliliters/minute [mL/min]).
89610603|NCT01913483|Active Comparator|Unfractionated Heparin|UFH was administered as an IV bolus for the duration of the procedure (mean duration of 48.6 minutes). UFH was administered via weight-based IV bolus at a dose of 50 units (U)/kg to 70 U/kg. Additional bolus doses were administered per standard-of-care use.
89610604|NCT04415723|Experimental|intervention group|supportive care management programme
89610605|NCT04415723|No Intervention|control group|receive the usual care provided by the health care system of Cyprus
89610606|NCT01913405|Experimental|BAX855|"Pre-operative loading dose: Single loading dose, pre-surgery administered based on each study participant's individual PK results as well as target trough level for type and character of surgery, dental or invasive procedure being performed. In general, major surgery will target an 80-150% FVIII trough level, and minor surgery will target an initial 30-100% FVIII trough level.~Intra-operative and post-operative dosing of BAX855 must be based on pre-dosage measurements of FVIII and the type and character of the surgery performed."
89610607|NCT01927055|Active Comparator|Droxidopa|Droxidopa 100 mg, 200 mg, 300 mg
89610608|NCT01927055|Placebo Comparator|Placebo|Placebo
89610609|NCT01913327|Experimental|aripiprazole|aripiprazole with flexible, blind dosing between 7.5 mg and 30 mg, once daily.
88983174|NCT05901974|Experimental|Venetoclax Combined With azactidine in the Treatment of Acute Leukaemias of Ambiguous Lineage|Venetoclax combined with azacitidine regimen. Venetoclax orally once daily (100 mg d1, 200 mg d2, 400 mg d3-28); azacitidine 75 mg/m2 subcutaneously once daily on days 1-7 .
88983175|NCT05896995|Experimental|Pilates Exercise|pilates exercise+ Mckenzie Exercise Six weeks, twice a week
88983176|NCT05896995|Active Comparator|Mckenzie Exercise|Mckenzie Exercise Six weeks, twice a week
88983177|NCT05872919|No Intervention|Control group|will not receive the intervention
88983178|NCT05872919|Experimental|Study group|will receive the intervention
88983179|NCT05871333|No Intervention|Standard of care|Patients will receive FOLFOX-6 regimen consisted of 2-hour infusion of oxaliplatin (100 mg/m2) and 2-hour infusion of leucovorin (400 mg/m2) on Day 1, followed by 5-fluorouracil (5-FU) bolus (400 mg/ m2) on Day 1 and 46-hour infusion (2.4 g/m2) with cycle repeated every 2 weeks over range of 20-24 weeks depending on patients disease state.
88983180|NCT05871333|Experimental|standard of care + Losartan|Patients will receive FOLFOX-6 regimen consisted of 2-hour infusion of oxaliplatin (100 mg/m2) and 2-hour infusion of leucovorin (400 mg/m2) on Day 1, followed by 5-fluorouracil (5-FU) bolus (400 mg/ m2) on Day 1 and 46-hour infusion (2.4 g/ m2) with cycle repeated every 2 weeks over range of 20-24 weeks depending on patients disease state. In addition to Losartan 50 mg/day orally for 4 months.
88983181|NCT05860985|Active Comparator|group 1|primary vitrectomy surgery for retinal detachment
88983182|NCT05860985|Active Comparator|group 2|macular surgery: pucker, vitreomacular traction or macular hole
88983183|NCT05849506||Touch-RSI|"The group consists of patients with a Touch® implant in one thumb and an RSI arthroplasty in the other thumb.~Intervention: Patient questionnaire and clinical examination to investigate differences between the thumb with a Touch® implant and the thumb with an RSI."
88983184|NCT05849363|Experimental|Posterior fossa decompression|Posterior arch of atlas removal, reconstruction of cisterna magna, decompression of cerebellum, detection of magendie foramen.
88983185|NCT05849363|Experimental|Posterior Compression-Distraction-Reduction-Fixation|"After subperiosteal dissection, the facet joint was exposed. A 2-mm joint scraper with sharp edge was inserted into the joint capsule and rotated to remove the articular cartilage. A blunt-edged rotating distractor was then inserted into the joint space, and the facet was sequentially opened with larger and larger blunt rotating distractors. After distraction on one side, an appropriate-sized trial was placed into the contralateral facet, holding the distraction open. This was repeated back and forth with larger trials. These steps were repeated, and the facet joints were distracted up to the pre-planned distance of the odontoid tip above Chamberlain's line."
88983186|NCT05846750|Experimental|Obinutuzumab and lenalidomide|Patients will be treated with obinutuzumab and lenalidomide for 6 cycles as induction, and the patients who achieve at least a partial response after 6 cycles of induction therapy will be eligible to enter the maintenance phase for 2 years
88983187|NCT05846204|Experimental|PMR Group|"The PMR exercise, which includes the systematic relaxation of the main muscle groups of the body aimed at physical and psychological relaxation, was applied twice a day, every weekday, for eight weeks. PMR exercises and training on the application of these exercises were given to the patients individually by face-to-face interview method. During the training process, Muscle Relaxation Exercises Practice Guide and Relaxation Exercises Audio Recordings, which were prepared by the researcher and included relaxation exercises, were used. Voice recordings were uploaded to each patient's mobile phone so that they could continue the application at home. The steps of the relaxation exercises were explained to the patient by the researcher and he was shown exactly how to do the exercises."
88983188|NCT05846204|Experimental|Deep Breath Group|WB exercises training was given to the patients in this group individually by face-to-face interview. During the application, the importance of deep and comfortable breathing was explained and correct breathing technique was taught. Informing and application training took an average of 20-25 minutes for each patient. The patients were told to do the 10-minute application at home 3 times a day for 8 weeks. They were called once a week and asked whether they continued the practice and whether they had any difficulties during the exercises.
88983189|NCT05846204|No Intervention|Control|No intervention will be applied to the control group.
88983190|NCT05843916|Experimental|AGA BETA BS|The study has a single-arm. First, all participants will receive 2 doses of Fabrazyme® with approximately 14 days between them, and afterwards all participants will switch treatment and receive AGA BETA BS for 54 weeks
88983191|NCT05840549|Active Comparator|TURP|Transurethral Resection of Prostate
88983192|NCT05840549|Experimental|UroLift|UroLift
89610610|NCT01913327|Active Comparator|risperidone|risperidone with flexible, blind dosing between 1 mg and 8 mg, once daily.
89610611|NCT01926509|Experimental|MK-8892 Panel A|Participants will be administered MK-8892 once daily at following dose levels: 1 mg (Days 1-7), 2 mg (Days 8-14), 3 mg (Days 15-21), 4 mg (Days 22-28).
89610612|NCT01926509|Experimental|MK-8892 Panel B|Participants will be administered MK-8892 orally, once daily at following dose levels: 1 mg (Days 1-7), 2 mg (Days 8-14), 4 mg (Days 15-21), 4 mg (Days 22-28).
88983193|NCT05815745|Active Comparator|Right ventricular pacing|Right ventricular pacing (apical or septal lead locations as per the implanting physicians' normal practice)
88983194|NCT05815745|Experimental|Physiological pacing|The approach for physiological pacing will be either His bundle pacing or left bundle pacing at the operator's discretion. If both of these are not achieved biventricular pacing will be performed.
88983195|NCT05811533|Experimental|Spencer's MET with conventional therapy|Patients will be asked to lie in a side lying position with the affected shoulder above. The therapist will stabilize the shoulder girdle with the proximal hand and the distal hand provided force into the restrictive barrier of shoulder in 7 different movements. During all the movements, patients will ask to use their muscle energy 20% against the slight resistance offered by the therapist for 3-5 seconds. The patient then asks to relax and exhale after that shoulder joint will move beyond the barrier to achieve the next barrier. After 20 sec of rest, this technique will be repeated 3-5 times
88983196|NCT05811533|Experimental|Post-Facilitation Stretch with conventional therapy|Muscle Energy Technique [Post Facilitation Stretch)] for the shoulder joint will be applied with 3 repetitions per set, 1 session per day. Patient will be instructed to perform a full strength contraction of the muscle to be stretch for 10 seconds. The muscle is then allow to fully relax, whereupon a rapid stretch of the affected muscle will be performed and will held in position by the physician for 15 sec. Patient will be asked to relax and whole cycle will be repeated.
88983197|NCT05811520|Experimental|Scapular stabilization exercises with conventional therapy|The patient will sit on the knees in 90° flexion position, and a Swiss ball will be placed between the chest and stomach. From the side, the earlobe, acromion of scapula, and pelvis should made a straight line. Four general exercises will be included with 2 sets of 15 repetitions, holding for 10 sec.
88983198|NCT05811520|Experimental|Thoracic extension exercises with conventional therapy|Thoracic extension exercises consist of three exercise types
88983199|NCT05811390|Experimental|erythritol jet (EMS)|An erythritol jet (Perioflow from EMS) will be used to debride the periodontal pockets of oral implants diagnosed with per-implantitis.
88983200|NCT05811390|Active Comparator|Manual instrumentation|An ultrasonic handpiece will be used to debride the periodontal pockets of oral implants diagnosed with per-implantitis.
88983201|NCT05806892|Experimental|Experiment|Thera Pearl application will be explained to the woman in detail and the first application will be carried out together in the hospital.
88983202|NCT05806892|No Intervention|Control|No intervention will be applied to the control group.
88983203|NCT05798013|Experimental|Digital health management intervention Group|Patients in the trial group receives intervention management from the digital health management platform, including reminding patients to take medication on time, monitoring and managing risk factors, reminding patients to have regular checkups and regular follow-ups, and pushing personalized science based on patients' risk factors, etc. Meanwhile, the platform's customer service staff regularly follows up with patients and reminds them of health management, and regularly invites experts to conduct formal medical science conferences for patients.
88983204|NCT05798013|No Intervention|Control group|The group doesn't not receive intervention reminders and customer service supervision from the platform, but receives the same follow-up visits.
88983205|NCT05794997||Propranolol or Carvedilol|Exposure group
88983206|NCT05794997||Atenolol, Bisoprolol or Sotalol|Reference group
88983207|NCT05771792|Experimental|eccentric exercise group|SPECIFIC MODIFIED EXERCISE PROGRAM GROUP The modified exercise group will perform 6 exercises
88983208|NCT05771792|Active Comparator|control group|CONVENTIONAL EXERCISES PROGRAM GROUP The conventional exercises program will perform conventional exercises.
88983209|NCT05771116|Active Comparator|Erecto Spinae Plane Block group|a high-frequency linear ultrasound transducer will be placed in a longitudinal orientation 3 cm lateral to the T7 spinous process. This should reveal three muscles superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae. The skin will be anaesthetized using 3ml of 2% Lidocaine. A 20-gauge block needle will be inserted in-plane in a cephalad-to-caudad direction to place the tip into the fascial plane on the deep (anterior) aspect of erector spinaemuscle;20ml bupivacaine 0.25% will be injected. The location of the needle tip will be confirmed by visible fluid spread lifting erector spinae muscle off the bony shadow of the transverse process The needle will be removed and the catheter secured with adhesive.
89033834|NCT05916079||breastfeeding success (Yes)|Mothers are to be contacted at 1 month to assess the main outcome: breastfeeding status (Yes vs No) classified as breastfeeding success (Yes) or breastfeeding failure (No).
89033835|NCT05916079||breastfeeding failure (No)|Mothers are to be contacted at 1 month to assess the main outcome: breastfeeding status (Yes vs No) classified as breastfeeding success (Yes) or breastfeeding failure (No).
89610613|NCT01926509|Experimental|MK-8892 Panel C|Participants will be administered MK-8892 orally, once daily at following dose levels: 1 mg (Days 1-7), 2 mg (Days 8-14), 4 mg (Days 15-21), up to 8 mg (Days 22-28).
89610614|NCT01926509|Placebo Comparator|Placebo (Panels A and B)|Participants will be administered placebo to MK-8892 once daily for 28 days.
89610615|NCT01926119|Experimental|TMS Intervention - 5 days|Application of Transcranial Magnetic Stimulation (TMS) once per day over 5 days.
89610616|NCT01912781|Experimental|FID 120974A|FID 120947A contact lens disinfecting solution used with gas permeable contact lenses (study lenses) on a daily basis for 90 days
89610617|NCT01912781|Active Comparator|Boston Simplus|Boston Simplus multi-action solution used with gas permeable contact lenses (study lenses) on a daily basis for 90 days
89610618|NCT04415879|Active Comparator|No Mask|Individuals will perform a Modified Balke Treadmill test with no mask and their estimated VO2 peak will be calculated based off of peak workload.
88983210|NCT05771116|Active Comparator|the paravertebral group|"After identification of the transverse process, internal intercostal membrane (IIM), and pleura at the T3 and T6 levels, an out-of-plane needle guidance technique was used to perform the PVB.The success of both blocks will be confirmed by loss of pinprick sensation on the dermatomal site of the block~•blocks will be activated ,After negative aspiration, 0.5 ml/kg 0.25% bupivacaine (max 20 ml) will be injected. Afterwards, a 20 gauge peripheral nerve catheter will be easily threaded into the space. The needle will be removed and the catheter secured with adhesive."
88983211|NCT05759091|Experimental|cognitive defusion interventional group|patients with schizophrenia who suffer from persistent delusions participated in cognitive defusion techniques on individual base through sex sessions twice weekly with homework assignments between sessions and skills demonstration by simulation and psychodrama.
88983212|NCT05759091|No Intervention|control group|patients with schizophrenia who suffer from persistent delusions participated in usual routine care in the hospital.
88983213|NCT05742399|Active Comparator|Hyaluronic acid nanoparticles (2%)|patients with tear trough will receive hyaluronic acid nano-gel (2%) 2 applications / day (morning and evening) on tear troughs for 1 month
88983214|NCT05742399|Placebo Comparator|Placebo|patients with tear trough will receive placebo conventional gel having the same color, form and packaging for 1 month
88983215|NCT05734560|Experimental|D2C7-IT + 2141-V11|Single D2C7-IT intratumoral infusion (6920 ng/mL in 36 mL) over 72 hours followed by single 2141-V11 infusion (5 dose levels) over 7 hours followed by an injection of 2141-V11 in the cervical perilymphatic subcutaneous area ipsilateral to the tumor at week 2, radiation, and further injections of 2141-V11 in the cervical perilymphatic subcutaneous area ipsilateral to the tumor.
88983216|NCT05726110|Experimental|Selinexor、HAD or CAG regimens|"Selinexor (60 mg) is used twice weekly for two weeks (four times, 240 mg total of selinexor) in combination with HAD or CAG regimens for reinduction therapy in patients with relapsed and refractory AML.~(Bone marrow image indicates active hyperplasia) HAD regimen: homoharringtonine (HHT) (2mg/ m^2/d)×7days, daunorubicin (DNR, 40mg/ m^2/d)×3 days, cytarabine (Ara-C,100-200mg/ m^2/d)×7 days (no leukocyte drugs should be used throughout the treatment process)；~(Bone marrow image indicates hypoproliferation)CAG regimen: Granulocyte Colony-Stimulating Factor (G-CSF, 5ug/kg/d, started 12 hours before chemotherapy×14 days (d1-d14), aclacinomycin (20mg/d)×4 days (d1-4), cytarabine (10 mg/ m^2, subcutaneous injection, 1 time in 12 hours)×14 days (d1-d14).~G-CSF was discontinued in the CAG regimen when WBC > 20×10^9/L, but chemotherapy was not stopped."
88983217|NCT05721313|Experimental|Patients with advanced periodontal furcation involvement|
88983218|NCT05720702|Experimental|NAFLD Group|"The NAFLD group will be asked to take Hcy lowering supplements (Vitamin B12, Folate, Vitamin B6, and Betaine) daily for 12 weeks. Over the course of approximately 12 to 13 weeks, participants will complete two in person visits and two phone visits. During the in person visits NAFLD participants will complete the following activities:~Review medical history; Physical examination; Vital signs (blood pressure, heart rate, respiratory rate, body temperature); Measure height, weight, body mass index, and waist circumference; Grip test; Fasting blood tests; Pregnancy test (if applicable); Fibroscan with CAP score; QOL questionnaire"
88983219|NCT05713526|Experimental|Telehealth group|The group in which telehealth services for childhood vaccines will be implemented.
88983220|NCT05713526|No Intervention|Control group|The group in which telehealth services for childhood vaccines will not be implemented.
88983221|NCT05707767|Experimental|Chordoma Patients|Chordoma Patients
88983222|NCT05696353|No Intervention|Control Group|The Control Group will have an in-vehicle device installed in the teen's car, but all feedback features will be disabled. Parents assigned into this group will receive no communication training on how to motivate their teen to adopt safe driving habits.
89057792|NCT01686360|Experimental|Frequency + Average 50 year old|Group receives Gail score in a frequency format as well as information about risk of breast cancer for the average 50 year old woman. (Behavioral: Decision Aid)
89057793|NCT01686360|Experimental|Frequency + Mammography Data|Group receives Gail score in a frequency format as well as information about the risks of mammography. (Behavioral: Decision Aid)
89610619|NCT04415879|Experimental|N-95 Respirator|Individuals will perform a Modified Balke Treadmill test while wearing a N-95 Respirator and their estimated VO2 peak will be calculated based off of peak workload.
89610620|NCT04415879|Experimental|Cloth Mask|Individuals will perform a Modified Balke Treadmill test while wearing a cloth mask and their estimated VO2 peak will be calculated based off of peak workload.
89610621|NCT01925417|Experimental|RBX2660 (microbiota suspension)|enema-based delivery of RBX2660
89610622|NCT01911845|Experimental|ABT-450/r/ABT-267 and ABT-333, plus RBV|ABT-450/r/ABT-267 (150/100/25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based ribavirin (RBV; 1,000 mg/day if <75 kg or 1,200 mg/day if ≥75 kg, divided twice daily) for 12 weeks
89610623|NCT01925183|Experimental|28 weeks of treatment duration|All patients will receive 4 weeks of PEGIFN/RBV lead-in. Patients with undetectable HCV-RNA at treatment week 8 will be treated with 24 weeks of BOC/PEGIFN/RBV triple-therapy resulting in a total treatment duration of 28 weeks.
89610624|NCT01925183|Experimental|48 weeks of treatment duration|All patients will receive 4 weeks of PEGIFN/RBV lead-in. Patients with detectable HCV-RNA at treatment week 8 will receive 44 weeks of BOC/PEGIFN/RBV triple-therapy and a total treatment duration of 48 weeks
89610625|NCT01910519|Experimental|H5N1 vaccine plus AS03 adjuvant|"H5N1 vaccine plus AS03 adjuvant: Influenza A Vaccine with AS03 adjuvant~Participants receive 2 intramuscular doses of Influenza A (H5N1) Virus Monovalent Vaccine with AS03 adjuvant given 21 days apart (i.e., Administer day 1, booster at Day 21)."
89610626|NCT01910519|Experimental|H5N1 vaccine without adjuvant|"H5N1 vaccine without adjuvant: Influenza A Vaccine without AS03 adjuvant~Participants receive 2 intramuscular doses of Influenza A (H5N1) Virus Monovalent Vaccine without AS03 adjuvant given 21 days apart (i.e., Administer day 1, booster at Day 21)."
89610627|NCT01910441|Experimental|Group A: Vildagliptin plus metformin|Participants received Vildagliptin 50 mg twice daily as an add-on to metformin (1000-1500mg daily).
89610628|NCT01910441|Active Comparator|Group B: Glimepiride plus metformin|Participants received Glimepiride 1-6 mg once daily as an add-on to metformin (1000-1500mg daily).
89610629|NCT01923467|Experimental|Project Quit plus NRT patches|All participants in the program will be offered the opportunity to complete the Project Quit stop smoking program. Project Quit is an individually-tailored, web-based program which has been scientifically proven to help people succeed at their quit attempts. All eligible participants will also receive a 2-week supply of Nicotine patches 21 mg.
89610630|NCT01910129|Active Comparator|gammaCore|Active stimulation treatment
89610631|NCT01910129|Placebo Comparator|sham gammaCore|Inactive stimulation treatment
88983223|NCT05696353|Experimental|Feedback and Expert-Delivered Parent Communication Intervention Group|Teens will have an in-vehicle device installed in their car and the smart phone app downloaded on their smart phone. Teens will receive real-time and cumulative driving feedback generated by the in-vehicle device and app; parents will have access to their teen's cumulative driving data at any time via study web portal. Parents will also receive communication training on how to motivate their teen to adopt safe driving habits via online modules and a video call with a teen driving safety communication expert. A second booster session will occur two months after the initial training. Both teens and parents will also receive a biweekly summary report of the teen's driving events prepared by the research team.
88983224|NCT05696353|Experimental|Feedback and Peer-Delivered Parent Communication Intervention Group|Teens will have an in-vehicle device installed in their car and the smart phone app download on their smart phone. Teens will receive real-time and cumulative driving feedback generated by the in-vehicle device and app; parents will have access to their teen's cumulative driving data at any time via study web portal. Parents will also receive communication training on how to motivate their teen to adopt safe driving habits via online modules and a video call with a peer trainer who is a parent of teen with a traffic violation and who has received the Expert-delivered Intervention and met the defined peer trainer criteria. A second booster session delivered by the peer trainer will also occur two months after the initial training. Both teens and parents will also receive a biweekly summary report of the teen's driving events prepared by the research team.
88983225|NCT05695729|Experimental|PLYOMETRIC EXERCISE PROGRAM GROUP|"The Plyometric exercise group will receive 8 weeks of upper body plyometric exercise protocol. The session will last for 60 minutes 3 times per week.~Exercises will be done according to FIIT protocol."
88983226|NCT05695729|Active Comparator|CONVENTIONAL EXERCISE PROGRAM GROUP|"The conventional group will receive 8 weeks of upper body strength exercise protocol. The session will last for 60 minutes 3 times per week.~Exercises will be done according to FIIT protocol."
88983227|NCT05695703|Experimental|Core Strength Training Group|The participants of core strength training group will perform core strength training for 6 weeks (3 days per week).
88983228|NCT05695703|Active Comparator|Conventional Training Group|The participants of conventional training group will perform conventional exercises for 6 weeks (3 days per week).
88983229|NCT05684627|Experimental|Fast mimicking diet group|The patients in this group will be assigned to follow one cycle of a fasting mimicking diet (FMD) the same day after receiving the full-mouth non-surgical periodontal treatment.
88983230|NCT05684627|Active Comparator|Normal diet group|The patients in this group will be assigned to normal diet after receiving the full-mouth non-surgical periodontal treatment.
88983231|NCT05677841|Experimental|Exercise group|Exercise group will be given spinal stabilization exercises focusing on the pelvic floor and lifestyle reccommendations
88983232|NCT05677841|Active Comparator|Control group|Control group will be given lifestyle recommendations
89610632|NCT01909973|Experimental|MedLink System|For 12 weeks, the patient who is newly prescribed antidepressant medication will receive a mobile phone and a GSM enable pill bottle in order to provide and receive feedback regarding medication adherence.
89610633|NCT01909973|No Intervention|Treatment As Usual|Patients will continue to receive treatment as usual from their primary care doctor. Patients in this arm will also receive a free mobile phone for the 12 weeks of the intervention.
89610634|NCT01617005||Tocilizumab in Moderate to Severe Active RA|Moderate to severe active RA participants, receiving tocilizumab treatment according to effective official Summary of Product Characteristics (SPC), will be observed. The choice of therapy will be based exclusively on the medical decision of the treating physician before study enrollment. The study protocol does not enforce treatment initiation and also does not specify any treatment regimen.
89610635|NCT01925339|Experimental|Test (immediate restoration)|Test (immediate restoration): immediate restoration will be placed on immediately placed implants.
89610636|NCT01925339|Experimental|Control: delayed restoration|Control: delayed restoration: immediate placed implants will be restored at 4 months.
88983233|NCT05677737|Experimental|Experimental|In the study, the women in the experimental group will be trained every two weeks for 6 weeks.
88983234|NCT05677737|No Intervention|Control|No intervention will be applied to the control group.
89610637|NCT04621877|Experimental|"Volunteer-delivered Behavioral Activation - Do More, Feel Better"|"Do More, Feel Better (DMFB) is a streamlined, simplified version of Behavioral Activation (BA) delivered by lay volunteers to depressed senior center clients."
89610638|NCT04621877|Active Comparator|Master's Level Clinician-delivered Behavioral Activation|Traditional Behavioral Activation (BA) delivered by master's level mental health clinicians
89610639|NCT01908803|Experimental|AL-60371/AL-817|AL-60371/AL-817 otic suspension, 200 μL in affected ear(s) through tympanostomy tube on Day 1 (Visit 1)
89610640|NCT01908803|Active Comparator|CIPRODEX|Ciprofloxacin 0.3%/dexamethasone 0.1% otic suspension, 4 drops in affected ear(s) twice daily through tympanostomy tube for 7 days
89610641|NCT01908101|Experimental|Treatment (eribulin mesylate)|Patients receive eribulin mesylate IV over 2-5 minutes on days 1, 8, and 15. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
89610642|NCT01923389|Placebo Comparator|Placebo|
89610643|NCT01923389|Experimental|100 mg PF-05231023|
89033836|NCT05914870|Experimental|Multi-component training|"The Multicomponent Training programme will apply two main training units per session per day.~This experimental group will perform 2 intervention sessions per week with a duration of 60 minutes each; 10 minutes for the preparatory phase to exercise in which they will perform joint mobility exercises and dynamic stretching; 40 minutes will be dedicated to the main phase of the training, 20 minutes for strength work, with two exercises, one for the upper body and one for the lower body, and 20 minutes for cardiovascular work; finally, 10 minutes for the post-exercise phase in which they will perform a return to calm and static stretching.~The duration of the programme will be 12 weeks (3 months)."
89033837|NCT05914870|Experimental|Continuous Cardiovascular Training|"The Continuous Cardiovascular Training programme will apply a single main training unit per session per day.~This experimental group will perform 2 intervention sessions per week with a duration of 60 minutes each; 10 minutes for the preparatory phase to exercise in which they will perform joint mobility exercises and dynamic stretching; 40 minutes for the main phase of the training where they will perform continuous aerobic work without changes in intensity during the session; finally, 10 minutes for the post-exercise phase in which they will perform a return to calm and static stretching.~The duration of the programme is 12 weeks (3 months)."
89033838|NCT05914870|No Intervention|Control Group|The control group will not perform any physical exercise programme and will continue with their daily tasks.
89610644|NCT01907087|Experimental|BMN190|recombinant human tripeptidyl peptidase-1 (rhTPP1/cerliponase alfa)
89033840|NCT05910658|Other|Intervention Group|Participants will receive the CRUSH Curriculum
89033841|NCT05907668|Experimental|Batoclimab|Participants will receive batoclimab 680 milligrams (mg) subcutaneously (SC) weekly (QW) injection for 12 weeks followed by 340 mg SC QW for 12 weeks.
89033842|NCT05903417|Active Comparator|Pleural Irrigation Arm|subjects were administered 250 ml of 0.9% sodium chloride via chest tube a three way tap from a drip stand which were allowed drainage freely over 1 hour. Pleural irrigation will be performed minimum of 3 installations and maximum of 9 installation (3 times per day).
89033843|NCT05903417|Active Comparator|Intrapleural fibrinolytic arm|"t-PA (Alteplase) 5mg and DNase (Pulmozyme)5mg t-PA (Alteplase) that is available in our pharmacy is 50mg ampoule and DNase (Pulmozyme) is 2.5mg per ampoule The number of installation of intrapleural t-PA/DNase depends on the discretion of the treating physician (at least 6 hours apart between each dose). 5mg of Alteplase (t-PA) and 5mg DNase are diluted in each 50ml of 0.9% sodium.~Both medication are administered sequentially which t-PA is first instilled intrapleurally and the chest tube is then clamped for 45 minutes, then unclamped to allow free drainage for 45 minutes. The same procedure is then repeated for DNase. Selection of the timing of treatment and removal of chest tube are depending on the chest physician's judgement."
89033844|NCT05901311|Experimental|[¹⁴C]-LY3537982 (Part 1)|Single dose of [¹⁴C]-LY3537982 administered orally.
89033845|NCT05901311|Experimental|[¹⁴C]-LY3537982 + LY3537982 (Part 2)|Single dose of LY3537982 administered orally followed by [¹⁴C]-LY3537982 administered intravenously (IV).
89033846|NCT05896007|Experimental|ZR-chemo|Drug: Zanubrutinib, Rituximab and MTX (or TMZ, if intolerant to MTX)
89033847|NCT05893433|Experimental|Bedside cycling Group|"Participants (25 patients) that will receive bedside cycling:~Intensity:~RPE from 11 to 13 (scale 6-20)~Resting HR + 20-30 bpm (up to tolerance if non-symptomatic), from low intensity and progressed to medium intensity.~Duration: Session duration: Total duration of 20 min, early morning.~Frequency: once daily from medically stable until discharge. in addition the medical treatment and routinely physiotherapy protocol."
89033848|NCT05893433|Placebo Comparator|Routine physical therapy Group|participant that will receive only routine physiotherapy treatment protocol and the medical treatment.
89033849|NCT05891132|Active Comparator|Group I comprised 30 women who will receive 10 ml of lidocaine 2%|10 ml of lidocaine 2% for perineal infiltration at the time of crowning
89033850|NCT05891132|Active Comparator|Group II will have lidocaine prilocaine cream 15gm application on the perineum|lidocaine-prilocaine cream 15gm application on the perineum at 8 cm of cervical dilatation and then an additional dose every 1 hour until delivery is achieved, then another dose of the cream will be applied before repairing the episiotomy and finally daily 3 doses every 8 hours at the site of episiotomy for the first week post-partum
89610645|NCT04620161|Experimental|Pradigastat Tablets 20mg|The patients in this arm will receive one tablet a day of Pradigastat 20mg and one tablet a day of Pradigastat 40mg matching placebo
89610646|NCT04620161|Experimental|Pradigastat Tablets 40mg|The patients in this arm will receive one tablet a day of Pradigastat 40mg and one tablet a day of Pradigastat 20mg matching placebo
89610647|NCT04620161|Placebo Comparator|Placebo|The patients in this arm will receive one tablet a day of Pradigastat 20mg matching placebo and one tablet a day of Pradigastat 40mg matching placebo
89610648|NCT01616771|Other|glottis view assessment|Glottis view assessment using Macintosh laryngoscope & GVL selected by weight & smaller sized GVL in single patient
89610649|NCT01589185|Experimental|KBSA301, a monoclonal antibody dose 1|1 mg/kg KBSA301
89610650|NCT01589185|Experimental|KBSA301, a monoclonal antibody dose 2|3 mg/kg KBSA301
89610651|NCT01589185|Experimental|KBSA301, a monoclonal antibody dose 3|10 mg/kg KBSA301
89610652|NCT01589185|Experimental|KBSA301, a monoclonal antibody dose 4|20 mg/kg KBSA301
89610653|NCT01589185|Experimental|Placebo|KBSA301-placebo
89610654|NCT01588951|Experimental|No Leukemia Stem Cells - Consolidation|Without LSC, standard cytarabine consolidation
89610655|NCT01588951|Experimental|Leukemia Stem Cells - Consolidation|LSC present, randomized to cytarabine consolidation
89610656|NCT01588951|Experimental|Leukemia Stem Cells - Transplant|LSC present, randomized to allogeneic transplant
88983235|NCT05675995|Experimental|Immediate|Receives 6 sessions of qigong first.
88983236|NCT05675995|Other|Waitlist Control|Receives 6 sessions of qigong after the immediate group
89610657|NCT01709383|Active Comparator|Transcranial Direct Current Stimulation|TDCS was applied bilaterally, with the anodal electrode on the left temple and cathodal electrode on the right. TDCS was applied at the beginning of 60-minute speech-language treatment sessions for five days across a one-week period
88983237|NCT05668689|Other|Preliminary testing (Phase 3)|The pilot test will be administered by local investigators via a computer-based application to 35-50 trainees and consultants.
88983238|NCT05668689|Other|Psychometric main study testing (Phase 5)|The main study assessment tool will be administered to trainees of all levels and consultants, aiming to recruit an equal number across different stages of the RCoA curriculum and of varying regional anaesthesia experience (stage 1; stage 2; stage 3; stage 3 + regional fellowship trained; consultant; consultant with special interest in regional; consultant + regional fellowship trained).
89610658|NCT01709383|Sham Comparator|Sham Stimulation|Sham tDCS was applied at the beginning of 60-minute speech-language treatment sessions for five days across a one-week period.
89610659|NCT01588405|Experimental|UT-15C SR|
89610660|NCT01923311|Experimental|Cohort 1 (12 to < 18 years of age)|"Part A: No participants will be enrolled in Part A, as PK data is currently available for this age group.~Part B: Participants will receive EVG plus a background regimen that includes a PI/r for up to 48 weeks. After Week 48, participants will be given the option to continue EVG therapy until the participant turns 18 and EVG is available for use in adults in the country in which the participant is enrolled, or the age appropriate EVG formulation becomes available for use in the country in which the participant is enrolled, or Gilead Sciences elects to terminate development of EVG in the applicable country."
89610661|NCT01923311|Experimental|Cohort 2 (6 to < 12 years of age)|"Part A: Participants with HIV-1 RNA < 50 copies/mL will receive EVG plus a background regimen that includes a PI/r for 10 days. Participants with HIV-1 RNA > 1,000 copies/mL will receive EVG along with a newly constructed background regimen that includes a Pl/r for 48 weeks. Participants with HIV-1 RNA > 1,000 copies/mL can continue after Week 48.~Part B: Following confirmation of exposure to EVG and based on safety and PK data assessed in Part A, participants will receive EVG plus a background regimen that includes a PI/r for up to 48 weeks. Participants who complete the 48-week follow-up in both Part A and Part B will be given the option to continue EVG therapy until the participant turns 18 and EVG is available for use in adults in the country in which the participant is enrolled, or the age appropriate EVG formulation becomes available for use in the country in which the participant is enrolled, or Gilead Sciences elects to terminate development of EVG in the applicable country."
89610662|NCT01923311|Experimental|Cohort 3 (2 to < 6 years of age)|"Part A: Participants with HIV-1 RNA < 50 copies/mL will receive EVG plus a background regimen that includes a PI/r for 10 days.~Part B: Following confirmation of exposure to EVG and based on safety and PK data assessed in Part A, participants will receive EVG plus a background regimen that includes a PI/r for up to 48 weeks. After Week 48, participants will be given the option to continue EVG therapy until the participant turns 18 and EVG is available for use in adults in the country in which the participant is enrolled, or the age appropriate EVG formulation becomes available for use in the country in which the participant is enrolled, or Gilead Sciences elects to terminate development of EVG in the applicable country."
89610663|NCT01923311|Experimental|Cohort 4 (4 weeks to < 2 years of age)|"Part A: Participants with HIV-1 RNA < 50 copies/mL will receive EVG plus a background regimen that includes a PI/r for 10 days.~Part B: Following confirmation of exposure to EVG and based on safety and PK data assessed in Part A, participants will receive EVG plus a background regimen that includes a PI/r for up to 48 weeks. After Week 48, participants will be given the option to continue EVG therapy until the participant turns 18 and EVG is available for use in adults in the country in which the participant is enrolled, or the age appropriate EVG formulation becomes available for use in the country in which the participant is enrolled, or Gilead Sciences elects to terminate development of EVG in the applicable country."
89688378|NCT04356157|Other|Special day|The special day takes place with an extraordinary opening of the clinical centre once a month on a pre-festive day (Saturday). During this day, access will be reserved exclusively for men, including those who are not on treatment for HIV. The centre will offer free health promotion services to all participants.
89688379|NCT04356157|Other|Male Champions|"The male champion is a figure present in a few settings which carries out home visits with men and couples and follows up with men who did not accompany their partners to Antenatal Care visits. Usually, this role is covered by the female Expert Clients, namely HIV+ patients working in the organization as volunteers after appropriate training. Some men among patients who are on treatment will be identified and trained to cover this role."
88983239|NCT05666193|Experimental|HyperSight Imaging Arm|Subjects imaged with the new HyperSight CBCT imaging system.
88983240|NCT05659732|Experimental|PEP07 Monotherapy (Arm A)|"The dose finding of PEP07 monotherapy consists of an accelerated dose escalation followed by a standard 3+3 dose escalation. Accelerated titration will continue until 1 patient experiences a DLT, or ≥ grade 2 AE related to PEP07 (except for hematologic toxicities) at any dose level, after which, additional 2 patients will be enrolled in the same cohort, and the study will be switched to a 3+3 scheme.~Expansion cohorts with 12 patients will be opened for Arm A at the RP2D once efficacy signal is observed at this level."
88983241|NCT05646485|Experimental|BCa Early Screening Group|"All participants undergo Urinalysis testing every 6 months for 2 years. Based on the RBC count, each participant will go through each of the screening procedures : [cystoscopy + Upper tract imaging] or [urine marker cancer testing with Cxbladder triage + Upper tract imaging] or [Repeat urinalysis]~Patients with suspicious findings on cystoscopy or imaging will get treatment as per standard of care.~Their outcomes will be compared to a historical control (bladder cancer detected by standard of care using SEER registries)."
88983242|NCT05646485|No Intervention|Historical Control Group|This will include historical control (bladder cancer detected in patients by standard of care) using SEER registries).
88983243|NCT05642494|Experimental|SDF+NaF|Silver Diamine fluoride 38% (Applied biannually)+ Sodium Fluoride Varnish 5% (Applied every 3 months)
88983244|NCT05642494|Active Comparator|SDF|Silver Diamine fluoride 38% (Applied biannually)
89610664|NCT01603615|Experimental|BOTOX®|Participants received a maximum of 5 treatments of intramuscular injections of BOTOX® (botulinum toxin Type A) into upper limb and/or lower limb muscles at a minimum of 12 weeks apart. Treatment dosing was according to investigator judgment, de novo participants received at least 6 U/kg of body weight or a maximum of 8 U/kg of body weight (not to exceed 300 U). Rollover participants received up to a maximum of 8 U/kg of body weight (not to exceed 300 U) for treatment Cycle 1. Dose could be increased to a maximum of 10 U/kg (not to exceed 340 U) in treatment Cycles 2-5. Rolled over participants received intramuscular injections of BOTOX® (botulinum toxin Type A) 3 or 6 U/kg into upper limb in previous study or were de novo participants who were not enrolled in previous study.
89610665|NCT01905683|Experimental|16-20 Units per kg body weight incobotulinumtoxinA|
89610666|NCT01921829|No Intervention|Usual Care|Participants randomized to the Usual Care group (control arm) will receive escalating diuretics and medical therapy per HF guidelines published by the American College of Cardiology (ACC)/American Heart Association (AHA) and Heart Failure Society of America (HFSA), dosed in variable fashion at the discretion of the treating cardiologist.
89610667|NCT01921829|Experimental|Protocolized Diuretic Strategy|Participants randomized to the Protocolized Diuretic Strategy group will receive escalating diuretics according to an algorithm targeting a goal diuresis of urine output (UO) 3-5 L/day with diuretics intensified in a stepped fashion using both loop diuretics given by intravenous (IV) bolus followed by IV continuous infusion (furosemide or alternative loop diuretic at equivalent dose), with or without concomitant thiazide diuretic (oral (PO) metolazone or IV chlorothiazide). If UO is < 3 L/day, diuretic regimen will be increased. If UO is 3-5 L/day, diuretic regimen will be continued at current doses. If UO is > 5 L/day, diuretic regimen will be reduced.
89610668|NCT04416113|Active Comparator|photobiomodulation group|"Laser watch Patients will be subjected to low-level laser (diode laser 980nm) for 30 minutes, the recommended dose based on the previous study is 20 J for 3 to 7 days.~The laser device:~Laser watched applied at the wrist on the radial artery.~Laser acupuncture"
89610669|NCT04416113|Active Comparator|photodynamic group|"Methylene blue injection USP 1% will be used as a photosensitizer in PDT.~0.1 to 0.2 mL of 1% solution per kilogram of body weight Methylene Blue (methylene blue injection) will be injected intravenously very slowly over a period of several minutes to~After one hour apply Light dose: 100 - 200 J/cm2 50-100 mW/cm2. (50 mW/cm2 increased the phototoxic response as well as the fractionated light application).~The session will be done twice per week~Laser watched applied at the wrist on the radial artery."
89610670|NCT04416113|Active Comparator|positive control|This group will include patients who are subjected to conventional treatment
89610671|NCT04619615|Experimental|Asynchronous self-directed digital training|A digital training program platform that delivers an interactive case-based modular curriculum covering evidence-based psychotherapy principles and IPT-specific principles and strategies with homework will take roughly 13 hours to complete, with 4.5 hours of online learning, and an additional 7.5 hours of reading and homework assignments. The reading and homework includes viewing captioned videotaped role plays and completing self-directed lesson plans. The digital curriculum leverages audio, video, and visual content, and is self-directed - for completion within a 2-week period. Residents can access this content through a smartphone, tablet or computer at their own pace, revisit modules and digital content as needed, and access a curated list of additional resources to supplement their learning.
89610672|NCT04619615|Active Comparator|Synchronous large group online workshop|This condition will reflect training as usual. Training will involve the same content contained in the asynchronous self-directed digital training platform, except delivered over a one day (4.5 hours of online instruction) workshop; and residents will be required to do the same reading and homework of lesson plans and viewing of the on-line videotaped role plays (an additional ~7.5 hours in total).
89610673|NCT01904903|Other|HER2 therapies, cardiac medications|"Cardiac intervention - beta-blockers and ACE-inhibitors titrated to the maximum tolerated doses~Oncology intervention - patients will receive one of the three following HER2 targeted therapies at the discretion of the treating oncologist:~Trastuzumab: loading dose of 8 mg/kg IV, followed by a maintenance dose of 6 mg/kg every 3 weeks, or a loading dose of 4 mg/kg followed by a maintenance dose of 2 mg/kg every week.~Pertuzumab: loading dose of 840 mg IV, followed by 420 mg IV every 3 weeks, administered concomitantly with trastuzumab.~Ado trastuzumab emtansine (TDM1): 3.6mg/kg IV every three weeks."
89610674|NCT01921517|Experimental|Low Magnitude Mechanical Stimulation|10 minutes daily of 30 Hz/0.3g stimulation using a vibrating platform.
89610675|NCT01921517|Placebo Comparator|Sham Low Magnitude Mechanical Stimulation|10 minutes daily of placebo treatment using a sham vibrating platform.
89610676|NCT01921205|Experimental|Lacosamide|
89610677|NCT01921205|Placebo Comparator|Placebo|
89610678|NCT01920893|Placebo Comparator|Placebo|Placebo (for dupilumab), 2 subcutaneous injections on Day 1 as a loading dose followed by a single injection every week (QW) from Week 1 to 15 added to Mometasone furoate nasal spray (MFNS).
89610679|NCT01920893|Experimental|Dupilumab 300 mg QW|Dupilumab, 2 Subcutaneous injections on Day 1 as a loading dose for a total of 600 mg, followed by a single 300 mg injection QW from Week 1 to 15 added to MFNS.
89610680|NCT01709305|Active Comparator|Metformin + Sitagliptin + Glimepiride|During Phase 2, participants receive up to 6 mg glimepiride daily as an add-on to metformin + sitagliptin combination therapy for 24 weeks (Week 20 through Week 44).
89610681|NCT01709305|Experimental|Metformin + Sitagliptin + Repaglinide|During Phase 2, participants receive up to 16 mg repaglinide daily as an add-on to metformin + sitagliptin combination therapy for 24 weeks (Week 20 through Week 44).
89610682|NCT01709305|Experimental|Metformin + Sitagliptin + Acarbose|During Phase 2, participants receive 50-100 mg acarbose three times daily as an add-on to metformin + sitagliptin combination therapy for 24 weeks (Week 20 through Week 44).
89610683|NCT01709305|Experimental|Metformin + Sitagliptin + Gliclazide|During Phase 2, participants receive 30-120 mg gliclazide daily as an add-on to metformin + sitagliptin combination therapy for 24 weeks (Week 20 through Week 44).
89610684|NCT01684423|Experimental|Rivaroxaban (BAY59-7939) tablet, OD, Age: 12 - <18|Subjects aged from 12 - <18 years were administered with age and body weight-adjusted oral dose of rivaroxaban (BAY59-7939) IR (immediate-release) tablet once daily (OD) under fed conditions for 30 days. Subjects with a body weight of 14 to less than 50 kilogram (kg) received a dose (equivalent to 20 milligram [mg] in adults) ranging from 5 to 15 mg, and subjects with a body weight (comparable to adults) of greater than or equal to 50 kg received a dose of 20 mg.
89033851|NCT05890924||Patients|First venous thromboembolic event associated with combined oral contraceptives intake
89033852|NCT05890924||Controls|regular follow-up of their combined oral contraception
89610685|NCT01684423|Active Comparator|Comparator, Age: 12 - <18 years|Subjects aged from 12 - <18 years received comparator as per standard of care. The dosage given was to be adjusted based on the individual body weight (low molecular weight heparin, fondaparinux) or international normalized ratio (INR) adjusted (vitamin K antagonist).
89610686|NCT01684423|Experimental|Rivaroxaban (BAY59-7939) tablet, OD, Age: 6 - <12 years|Subjects aged from 6 - <12 years were administered with age- and body weight-adjusted oral dose of rivaroxaban (BAY59-7939) IR tablet once daily under fed conditions for 30 days. Subjects with a body weight of 14 to less than 50 kg received a dose (equivalent to 20 mg in adults) ranging from 5 to 15 mg, and subjects with a body weight (comparable to adults) of greater than or equal to 50 kg received a dose of 20 mg.
89610687|NCT01684423|Experimental|Rivaroxaban (BAY59-7939) suspension, BID, Age: 6 - <12 years|Subjects aged from 6 - <12 years were administered with age- and body weight-adjusted oral dose of rivaroxaban (BAY59-7939) suspension under fed conditions twice daily (BID). Subjects with a body weight of 9 to less than 50 kg received a total daily dose (equivalent to 20 mg in adults) ranging from 6.4 to 15 mg and subjects with a body weight of greater than or equal to 50 kg received a total daily dose of 20 mg.
89610688|NCT01684423|Active Comparator|Comparator, Age: 6 - <12 years|Subjects aged from 6 - <12 years received comparator as per standard of care. The dosage given was to be adjusted based on the individual body weight (low molecular weight heparin, fondaparinux) or INR-adjusted (vitamin K antagonist).
89610689|NCT01709227|Experimental|Furosemide|Patients randomized to the furosemide arm will be given 1 mg/kg intravenously every 6 hours for 2 doses and then as directed by CICU attending to augment urine output. Patients within this arm who have urine output <1 ml/kg/hr over 16 hours after the first dose of Lasix will be considered poor responders. These patients may be started on PD if clinically indicated. Those who show good response (urine output >1 ml/kg/hr over subsequent 16 hours) will continue furosemide as needed to augment urine output. If they subsequently develop oliguria or fluid overload unresponsive to diuretic therapy, these patients may later be started on PD at discretion of CICU attending with consultation of nephrology service.
89610690|NCT01709227|Experimental|Peritoneal dialysis|Patients within the PD arm will begin PD with a standardized dialysis plan of 10ml/kg of 1.5% Dianeal™ with 1 hours cycles (5 minute fill, 45 minute dwell and 10 minute drain). Further PD management will be directed by CICU attending and Nephrology service
89610691|NCT01684033|Other|PureMoist - Biotrue|Opti-Free® PureMoist® MPDS used first, followed by Biotrue™ MPS. Each product used as indicated for 30 days with participant's habitual contact lenses.
89610692|NCT01684033|Other|Biotrue - PureMoist|Biotrue™ MPS used first, followed by Opti-Free® PureMoist® MPDS. Each product used as indicated for 30 days with participant's habitual contact lenses.
89610693|NCT00878644|Experimental|Therapeutic Hypothermia|Participants will receive therapeutic hypothermia after experiencing cardiac arrest.
89610694|NCT00878644|Active Comparator|Therapeutic Normothermia|Participants will receive therapeutic normothermia after experiencing cardiac arrest.
89610695|NCT05312086|Other|patients with X-linked hypophosphatemic|Patient group composed of 10 patients aged between 5 to 17 years old, female or male, with X-linked hypophosphatemic (XLH) rickets, severity of clinical and radiological damage (pain, muscle weakness and severe bone deformities) and ongoing growth (lesser bone age than 15 years old), child under conventional treatment
89610696|NCT05312086|Other|healthy volunteers|control group composed of 20 helthy volunteers aged between 5 to 17 years old, female or male, without any endocrine pathology, not suffering from XLH, matching by age (+/- 6 months) and sex
89610697|NCT00878878|Experimental|Arm A|
89610698|NCT00878878|Experimental|Arm B|
89610699|NCT05311696||Residential Cohort|Those completing the program in a residential context
89610700|NCT05311696||Online Cohort|Those completing the program online
89610701|NCT00879034|Experimental|Zoledronic Acid,Pravastatin,and Lonafarnib|Lonafarnib;Zoledronic acid;Pravastatin
89610702|NCT04089202|Active Comparator|In-person visit arm|"In this arm, patients meeting eligibility criteria and consented into the study are randomized to an in-person visit with an Endocrinologist. This is currently the standard of care for patients referred for diabetes specialty care.~Care by the Endocrinologist is provided as would typically be done, taking into account patient factors and preferences.~Surveys will be administered to measure patient burden and self efficacy."
89610703|NCT04089202|Experimental|Freestyle Libre sensor arm|"In this arm, patients meeting eligibility criteria and consented into the study are randomized to have the Freestyle Libre Pro continuous glucose monitor (CGM) placed at their primary care clinic. The data collected from the diagnostic CGM will be utilized in conjunction with diet, exercise and medication logs provided by the patient and information from the patient's electronic medical record to complete an eConsult with treatment recommendations. Implementation of these recommendations will be per the primary care provider's discretion in conjunction with conversation with the patient in follow up visits.~Surveys will be administered to measure patient burden and self efficacy."
89610704|NCT00879190|Active Comparator|Unasyn (ampicillin/sulbactam)|
89610705|NCT00879190|Active Comparator|Ampicillin/gentamicin|
89033853|NCT05890638|Experimental|Ipratropium / Levosalbutamol Fixed Dose Combination|"In this one-day study, patients will be administered Ipratropium / Levosalbutamol 1.25 mg & 0.5 mg / 2.5 mL Nebuliser Solution at 6 hours intervals."
89033854|NCT05890638|Active Comparator|Ipratropium + Levosalbutamol Free Dose Combination|"In this one-day study, patients will be administered Levosalbutamol 1.25 mg/3 mL Inhalation Solution and Ipratropium Nebulization Solution 500 mcg/2 mL at 6 hours intervals."
89033855|NCT05887440|Experimental|3 assessments|The randomisation provides for 3 assessments of baseline
89033856|NCT05887440|Experimental|4 assessments|The randomisation provides for 4 assessments of baseline
89033857|NCT05887440|Experimental|5 assessments|The randomisation provides for 5 assessments of baseline
89033858|NCT05885503|Experimental|RC-28E|RC-28E 2.0 mg will be initially intravitreal injected (IVT) 5 times at 4 week intervals from week 0 to week 16, then every 8 weeks until week 48.
89033859|NCT05885503|Active Comparator|Aflibercept|Aflibercept 2.0mg will be received IVT once every 4 weeks for 5 consecutive times from week 0 to week 16, then once every 8 weeks till week 48.
89610706|NCT01903811|Experimental|Arm I (dexamethasone, low-dose carfilzomib)|Patients receive dexamethasone IV and low-dose carfilzomib IV over 2-10 minutes on days 1, 2, 8, 9, 15, and 16. (Note that course 1 is given at a reduced dose.) Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. Patients with progression cross-over to Arm II.
89610707|NCT01903811|Experimental|Arm II (dexamethasone, high-dose carfilzomib)|Patients receive dexamethasone IV and high-dose carfilzomib IV over 30 minutes on days 1, 2, 8, 9, 15, and 16. (Note that course 1 is given at a reduced dose over 2-10 minutes.) Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
89610708|NCT00880360|Experimental|Ontak|Administration of Ontak IV for treatment of epithelial ovarian cancer
89610709|NCT01709149|Experimental|CK-2017357|125 mg tablets
89610710|NCT01709149|Placebo Comparator|Placebo|Placebo tablets
89610711|NCT05214196|Experimental|Hypochlorous acid group|The effect of 0.02% Hypochlorous acid solution on viral load was investigated by using 25 COVID-19 patients as an oral antiseptic for 30 seconds.
89610712|NCT05214196|Active Comparator|Povidone-iodine group|The effect on viral load was investigated by using 0.5% Povidone-iodine solution as an oral antiseptic for 30 seconds in 25 COVID-19 patients.
89610713|NCT05214196|Placebo Comparator|Saline group|The effect on viral load was investigated by using 0.9% isotonic saline solution as a placebo for 30 seconds in 25 COVID-19 patients.
89610714|NCT01568593|Experimental|T2750|
89610715|NCT01568593|Active Comparator|Vismed|
89610716|NCT04382014|Experimental|MAG fish oil + Curcumin|The participant will arrive fasted at he research center. After installing a catheter and drawing 5 mL of blood, the participants will be given one of the active comparator or the treatment. The choice of the treatment/comparator will be random. In this arm, the participant will receive 1 dose of 1,5 g MAG fish oil + 400 mg curcumin. The participant will consume this unique dose with a standardized breakfast. There will thereafter be blood sample collection over 24 h to evaluate the level of curcumin in the plasma and a side effect questionnaire will be administered to monitor side effects.
89610717|NCT04382014|Active Comparator|Rice bran oil + Curcumin|The participant will arrive fasted at he research center. After installing a catheter and drawing 5 mL of blood, the participants will be given one of the active comparator or the treatment. The choice of the treatment/comparator will be random. In this arm, the participant will receive 1 dose of rice bran oil + 400 mg curcumin. The participant will consume this unique dose with a standardized breakfast. There will thereafter be blood sample collection over 24 h to evaluate the level of curcumin in the plasma and a side effect questionnaire will be administered to monitor side effects.
89610718|NCT04382014|Active Comparator|Curcumin extract|The participant will arrive fasted at he research center. After installing a catheter and drawing 5 mL of blood, the participants will be given one of the active comparator or the treatment. The choice of the treatment/comparator will be random. In this arm, the participant will receive 1 dose of 400 mg curcumin. The participant will consume this unique dose with a standardized breakfast. There will thereafter be blood sample collection over 24 h to evaluate the level of curcumin in the plasma and a side effect questionnaire will be administered to monitor side effects.
89610719|NCT01683565|Experimental|LCPUFA Oil Supplement|EPA + DHA + GLA + OA oil supplement
89610720|NCT01683565|Placebo Comparator|Canola Oil Placebo|
89610721|NCT00882778||activated recombinant human factor VII|Male patients diagnosed with haemophilia A or B with inhibitors, who were prescribed activated recombinant human factor VII (rFVIIa) for at least 30 days. All direction for rFVIIa medication usage was at the sole discretion of the physician in accordance within their usual practice. Data was collected for approximately 6 months of pre-prophylaxis, while the prophylaxis period had no limits.
89610722|NCT00892606|Experimental|Methadone|Patients received 2 µg/kg fentanyl, 0.2 mg/kg ketamine and 0.2 mg/kg of methadone IV with induction of general anesthesia.
89610723|NCT00892606|Active Comparator|Control|Patients received 2 µg/kg fentanyl, 0.2 mg/kg ketamine, and 0.2 mg/kg morphine (standard of care)
89688380|NCT04356157|Other|Nudge|The intervention based on the use of incentives (nudge) to men who follow the prevention and treatment program aims to evaluate whether this action is effective in guiding behaviour change towards the test, treatment, involvement and adherence to therapy approach.
88983245|NCT05641298|Active Comparator|ARV-1801(ACG-701) Active Group|ARV-1801(ACG-701) tablets by mouth twice a day for 14 days
88983246|NCT05641298|Placebo Comparator|Placebo Group|Placebo tablets by mouth twice a day for 14 days
88983247|NCT05635370||Pentoxifylline|Exposure group
88983248|NCT05635370||Cilostazol|Reference group
88983249|NCT05635357||Anastrozole|Exposure group
88983250|NCT05635357||Exemestane/Letrozole|Reference group
88983251|NCT05633966|Experimental|Kisspeptin pump|SC administration of kisspeptin for two weeks (pulsatile, every 90 minutes)
88983252|NCT05628727|Experimental|5:2 Fasting Group|This group will use the 5:2 method and fast for two non-consecutive days of the week.
88983253|NCT05628727|Experimental|Time-Restricted Feeding Group|This group will use the 16:8 method every day, eating only during an 8-hour period that will commence at wake-up time.
88983254|NCT05628727|No Intervention|Control Group|This group will not fast.
88983255|NCT05628428|Experimental|Exercise|Exercising through educational videos for eight weeks. In addition, they will receive educational information about neck pain and the importance of exercise in this case, at the beginning of the study.
88983256|NCT05628428|Active Comparator|Control|Educational information about neck pain and the importance of exercise in this case, at the beginning of the study.
88983257|NCT05573334|No Intervention|Routine Care|The Routine Care arm is a control group receiving no study intervention. They receive whatever routine care is standard for the study PI's treatment of usual recurrent UTI patients, including antibiotics for active infections, estrogen and supplements for prevention of infection.
89033860|NCT05884190|Active Comparator|Standard of Care (SoC)|Standard of Care for Postpartum Hypertension
89033861|NCT05884190|Experimental|Remote Medical Model (RMM)|Includes SoC plus RMM
89033862|NCT05884190|Experimental|Community Health Model (CHM)|Includes SoC, RMM plus CHM
89057794|NCT01686360|Experimental|Frequency + Mortality Data|Group receives Gail score in a frequency format as well as information about mortality benefit of mammography. (Behavioral:Decision Aid)
89610724|NCT04416035|Experimental|TRS003|TRS003 will be administered at 15 mg/kg by IV infusion on Day 1 of each cycle (every 3 weeks, Q3W). Paclitaxel will be administered at a dose of 200 mg/m^2 by IV infusion Q3W on Day 1 of each cycle，carboplatin will be administered at an AUC 6 mg/mL/ min by IV infusion Q3W on Day 1 of each cycle. Each cycle is 3 weeks. Treatments will continue until disease progression, death, intolerable toxicity, withdrawal of consent, investigator decision, or completion of 4-6 cycles of therapy. Maintenance therapy may be given at the discretion of the patient's primary oncologist.
89610725|NCT04416035|Active Comparator|China-approved Bevacizumab|China-approved bevacizumab will be administered at 15 mg/kg by IV infusion on Day 1 of each cycle (every 3 weeks, Q3W). Paclitaxel will be administered at a dose of 200 mg/m^2 by IV infusion Q3W on Day 1 of each cycle and carboplatin will be administered at an AUC 6 mg/mL/min (the maximum dose capped at 900 mg) by IV infusion Q3W on Day 1 of each cycle. Each cycle is 3 weeks. Treatments will continue until disease progression, death, intolerable toxicity, withdrawal of consent, investigator decision, or completion of 4-6 cycles of therapy. Maintenance therapy may be given at the discretion of the patient's primary oncologist.
89610726|NCT04381858|Experimental|Severe pneumonia due to COVID-19|"Patients who are admitted to Hospital Centers with a positive RT-qPCR SARS-CoV-2 test or a CT scan compatible with a diagnosis of COVID-19 pneumonia, in addition to one of the following two criteria:~Severe respiratory failure [respiratory rate> 25 - <35 x minute, oxygen saturation ≤ 90% with reservoir mask (FiO2 = 100%)]~Requiring invasive mechanical ventilation."
89610727|NCT04381858|Active Comparator|Severe pnemonia due to COVID-19|"Patients who are admitted to Hospital Centers with a positive RT-qPCR SARS-CoV-2 test or a CT scan compatible with a diagnosis of COVID-19 pneumonia, in addition to one of the following two criteria:~Severe respiratory failure [respiratory rate> 25 - <35 x minute, oxygen saturation ≤ 90% with reservoir mask (FiO2 = 100%)]~Requiring invasive mechanical ventilation."
89610728|NCT04381390|Experimental|Whole egg consumption|This arm involved whole egg consumption concomitant with 12 weeks of resistance training. Subject ingested three whole eggs per day immediately after resistance training.
89610729|NCT04381390|Experimental|Egg whites consumption|This arm involved egg white consumption concomitant with 12 weeks of resistance training. Subject ingested an isonitrogenous quantity of six egg whites per day immediately after resistance training.
89610730|NCT04088422||B-cell lymphoma|
89610731|NCT01903031|Experimental|NuvaRing and no ART (Arm A)|Once NuvaRing is inserted into the vagina, the ring should remain in place (not be removed) continuously for 3 weeks (21 days).
89610732|NCT01903031|Experimental|NuvaRing with EFV plus ≥2 NRTIs (Arm B)|Once NuvaRing is inserted into the vagina, the ring should remain in place (not be removed) continuously for 3 weeks (21 days). EFV is a non-nucleoside reverse transcriptase inhibitor taken at a dose of 600 mg once daily.
89610733|NCT01903031|Experimental|NuvaRing with ATV/r plus TDF + ≥1 NRTIs (Arm C)|Once NuvaRing is inserted into the vagina, the ring should remain in place (not be removed) continuously for 3 weeks (21 days). ATV/r is a combination protease inhibitor taken at a dose of 300/100 mg once daily. Tenofovir disoproxil fumarate (TDF) is a nucleoside reverse transcriptase inhibitor (NRTI) taken at a dose of 300 mg daily.
89610734|NCT00883168|Placebo Comparator|placebo|
89610735|NCT00883168|Active Comparator|azelastine Hcl|
89610736|NCT00883168|Active Comparator|fluticasone propionate|
89610737|NCT00883168|Experimental|azelastine Hcl /fluticasone propionate|
89610738|NCT01616693|Experimental|Zinc and probiotic|Received daily zinc and probiotic supplements, in addition to rotavirus vaccine and trivalent oral polio vaccines.
89610739|NCT01616693|Active Comparator|Zinc alone|Received daily zinc and probiotic placebo supplement, in addition to rotavirus vaccine and trivalent oral polio vaccine.
89610740|NCT01616693|Active Comparator|Probiotic alone|Received daily zinc placebo and probiotic supplement, in addition to rotavirus vaccine and trivalent oral polio vaccine.
89610741|NCT01616693|Placebo Comparator|Placebo|Received daily zinc placebo and probiotic placebo, in addition to rotavirus vaccine and trivalent oral polio vaccine.
89610742|NCT00883246|Other|Atherectomy|All patients enrolled in this single-arm study were treated with directional atherectomy.
89610743|NCT04415645|Experimental|VVZ-149 Injections|
89610744|NCT00893074|Other|0, 30, 60, and 120mg dronabinol|0, 30, 60, and 120mf dronabinol was administered in a randomized within-subjects crossover study to compare the medication dose effects of cannabis withdrawal, cognitive performance, and response to acute cannabis dosing
89610745|NCT00884806|Experimental|FID 114675A|FID 114675A used for 7 days, per protocol-specified instructions. Silicone hydrogel or hydrogel contact lenses worn bilaterally on a daily wear basis, one brand only.
89610746|NCT00893152||Group 1|Male veterans (focus groups and individual interviews)
89610747|NCT00893152||Group 2|Female veterans (focus groups and individual interviews)
89610748|NCT00893152||Group 3|Family members of participating veterans (focus groups and individual interviews)
89610749|NCT05086354|Experimental|One group that all receive the intervention of jumping rope.|All participants will be in one group. Every participant receives the same intervention.
89610750|NCT00885742|Experimental|FXIII|All subjects who received a dose of Factor XIII (FXIII) Concentrate (Human).
88983258|NCT05573334|Experimental|Flourish HEC|"The experimental (or intervention) arm uses 3 products in a vaginal hygiene system in addition to any routine care they would normally receive. These 3 products are a vulvar wash (for external use), a vaginal moisturizing gel (BioNourish), and a vaginal homeopathic suppository with probiotics.~The vulvar wash is used daily or as often as a participant bathes/showers. The vaginal moisturizing gel, which is formulated to match healthy vaginal secretions for pH, osmolality, and lactic acid levels, is used every day before bed.~The vaginal homeopathic suppository with probiotics is used every 3rd day before bed. This suppository contains native vaginal probiotic species associated with healthy vaginal microbiomes."
88983259|NCT05552924|Experimental|Self-Acupressure|Each application to the acupressure points (H17, L14, ST36, SP6) will be done in 2 minutes and right and left)
88983260|NCT05552924|No Intervention|Control group|Routine maintenance will be applied.
88983261|NCT05543668||preexisting preoperative chronic pain|Patients with preexisting preoperative chronic pain (more than 3 months duration).
88983262|NCT05543668||preexisting preoperative sub-acute pain|Patients with preexisting preoperative sub-acute pain (less than 3 months duration).
88983263|NCT05543668||No pain preoperatively|Patients without preexisting preoperative pain.
89610751|NCT04964440||PURE EP Guided Procedures|Redo AF procedures guided by Pure EP System during an AF Ablation
89610752|NCT04964440||Standard Recording System Guided Procedures|Redo AF procedures guided by the Standard Recording System during an AF Ablation
89610753|NCT05319262|No Intervention|Control|Single study night with no noise exposure, to determine normal baseline sleep
89610754|NCT05319262|Experimental|Traffic noise|Single study night with traffic noise events, to determine consequences of sleep disturbance by traffic noise
89610755|NCT05319262|Experimental|Pink noise|Single study night to measure the effects of a non-pharmacological intervention to promote sleep, pink noise.
89610756|NCT05319262|Experimental|Traffic noise + pink noise|Single study night with concurrent traffic noise events and continuous pink noise sound exposure. Night is used to determine attenuation of sleep disturbance by traffic noise due to introduction of pink noise.
89610757|NCT00887458|Active Comparator|Low Dose|Itraconazole, 200 mg, by mouth, once daily (200 mg total daily dose)
89610758|NCT00887458|Active Comparator|High Dose|Itraconazole, 300 mg, by mouth, twice daily (600 mg total daily dose)
89610759|NCT05310682|Experimental|DIPH-intervention districts|Twelve districts were randomly selected from the North Shewa Zone of the Amhara region, Ethiopia. These districts were matched with the comparison arm based on health system performance and distance. The DIPH intervention is implemented at the district health administration office level.
89610760|NCT05310682|No Intervention|Non-intervention districts|Twelve districts were randomly selected from the North Shewa Zone of the Amhara region, Ethiopia. These districts were matched with the DIPH intervention arm based on health system performance and distance.
89610761|NCT03216616|Experimental|Patients with inflammatory rheumatic diseases|The patients will participate in a cognitive behavioural therapy intervention
89610762|NCT03275662|Experimental|Fiber Group|Participants are asked to increase their usual dietary fiber intake by 20 grams/day.
89610763|NCT03275662|Experimental|Fermented Foods Group|Participants are asked to consume 6 servings of fermented foods per day.
89610764|NCT03216304|Experimental|rosuvastatin|Film-coated tablets Rosuvastatin will be administered at the dose of 20 mg (single dose at day 1)
89610765|NCT03216304|Experimental|safinamide + rosuvastatin|Film-coated tablets Safinamide will be administered at the dose 100 mg (once a day for 11 days) Film-coated tablets Rosuvastatin will be administered at the dose of 20 mg (single dose at 12)
89610766|NCT03216460|Other|Supervised Free-Living|Subjects will undergo a 7±1 day outpatient, standard therapy phase during which sensor and insulin data will be collected. Subjects or their caregivers will manage their diabetes at home per their usual routine using the study CGM and remain on current MDI or pump therapy. This will be followed by a 5-day/4-night or from approximately 48 to 72 hours for children ages 2.0-5.9 years, hybrid closed-loop phase conducted in a supervised hotel/rental house setting, where subjects will participate in specific setpoint challenges, meal challenges, and exercise
89610767|NCT03216538|Active Comparator|AS101 1% oral solution|Daily dose 0.4 ml administered orally
89610768|NCT03216538|Placebo Comparator|Placebo|Daily dose of 0.4 ml administered orally
89610769|NCT03217396||multiple sclerosis patients|lumbar puncture, microRNAs quantification in blood and CSF samples, SNPs analysis
89610770|NCT03217396||neurodegenerative disease patients|lumbar puncture, microRNAs quantification in blood and CSF samples, SNPs analysis
89610771|NCT03217396||control subjects|lumbar puncture, microRNAs quantification in blood and CSF samples, SNPs analysis
89610772|NCT03218722|Experimental|PCC treatment|Conventional strategy for ATC management in addition to of intravenous Pro-Thrombin Concentrate Complex (25IU/kg factor IX)
89610773|NCT03218722|Placebo Comparator|Placebo treatment|Conventional strategy for ATC management without PCC (NaCl 0.9%)
89610774|NCT03216148|Experimental|FET-PET|All participating patients will receive a FET PET-scan with intravenous O-(2-[18F]Fluoroethyl)-L-Tyrosine parallel to the routine MRI at the end of the first line therapy (restaging) according to the HIT-protocol Second FET PET: In case of suspected tumour recurrence or progression within the follow-up period of 24 (12) months, the participating patient will receive a second FET PET-scan (parallel to an MRI)
88983264|NCT05523765|Experimental|Brepocitinib Dose Level 1 PO QD|
89610775|NCT00888628|Experimental|Islet transplant|"Patients will receive (an) infusion(s) of in vitro cultured islets with the goal of achieving insulin independence.~For the first islet transplant, patients will receive induction therapy with rabbit anti-thymocyte globulin (ATG, 5 doses) and will remain on their maintenance immunosuppression regimen already in place for their renal allograft.~Induction therapy for subsequent transplants will be 2 doses of basiliximab.~All patients will receive Etanercept to promote engraftment."
89610776|NCT03215992|Other|Men diagnosed with prostate cancer|This group will include men over the age of 18 suspected of having prostate cancer who will undergo an ultrasound guided transrectal prostate biopsy. Each study participant will undergo a standard prostate biopsy and DOT imaging using the Diffuse Optical Tomography (DOT) System will be performed at the same time.
89610777|NCT03215992|Other|Men without prostate cancer|This group will include men who do not have prostate cancer. Each study participant will undergo a standard prostate biopsy and DOT imaging using the Diffuse Optical Tomography (DOT) System will be performed at the same time.
89610778|NCT03215680||Tanzanian Women of Reproductive Age|Healthy women of reproductive age living in Tanzania in an area with hot and temperate climate
89610779|NCT03215680||South African Women of Reproductive Age|Healthy women of reproductive age living in South Africa in an area with hot and temperate climate
89610780|NCT03838276|Active Comparator|AL150 BPL100|Roux-en-Y gastric bypass with 150cm of alimentary limb and 100cm of biliopancreatic limb
89610781|NCT03838276|Experimental|AL100 BPL150|Roux-en-Y gastric bypass with 100cm of alimentary limb and 150cm of biliopancreatic limb
89610782|NCT03837886|Experimental|Alkalosis group|The subjects should receive gelatinous capsules containing 0.3 g.kg -1 of sodium bicarbonate
89610783|NCT03837886|Placebo Comparator|Placebo group|The subjects should receive gelatinous capsules containing 0.3 g.kg -1 of Calcium Carbonate
89610784|NCT03219970||EGFR T790M positive NSCLC patients|Patients with locally advanced/metastatic EGFR T790M positive NSCLC progressed on previous EGFR TKI treatment.
89610785|NCT00889330|Experimental|alcaftadine ophthalmic solution|active treatment: administered as a single one-drop dose in each eye at each visit (Day 0 and Day 14).
88983265|NCT05523765|Experimental|Brepocitinib Dose Level 2 PO QD|
89033863|NCT05880238|Experimental|Sensory-motor training|The study group received group interventions that included self-regulation strategies and sensory-motor skill training in addition to preschool education. Group interventions were conducted with groups of up to 10 participants for a total of one hour, twice a week for 10 weeks.
89033864|NCT05880238|Active Comparator|Control|The control group continued with preschool education and did not receive any additional intervention.
89033865|NCT05876949|Experimental|Experimental Arm AVT03 120mg|AVT03 (denosumab) is the proposed biosimilar for Xgeva (denosumab). Subjects in this arm will receive a single 120mg dose of AVT03 (denosumab) as a subcutaneous injection
89033866|NCT05876949|Active Comparator|Active Comparator Xgeva 120mg|Xgeva (denosumab) is the proposed active comparator for AVT03 (denosumab). Subjects in this arm will receive a single 120mg dose of Xgeva (denosumab) as a subcutaneous injection
89610786|NCT00889330|Placebo Comparator|inactive ophthalmic solution vehicle|Placebo, vehicle: administered as a single one-drop dose in each eye at each visit (Day 0 and Day 14).
89610787|NCT03219580|Active Comparator|5-Fluorouracil Active Treatment Arm|A patient who has undergone bilateral direct brow ptosis repair and has elected to participate in the study will first have each of their brows randomized to either be the active treatment arm or the placebo arm. The active treatment arm brow will be injected with 0.05ml of 5-Fluorouracil 50mg/ml in several injections evenly spaced over the brow incision for a total of 0.3-0.6ml, repeated every three weeks for a total of 4 series of injections.
89610788|NCT03219580|Placebo Comparator|Placebo Arm|A patient who has undergone bilateral direct brow ptosis repair and has elected to participate in the study will first have each of their brows randomized to either be the active treatment arm or the placebo arm. The placebo arm brow will be injected with 0.05ml of 0.9% Normal Saline in several injections evenly spaced over the brow incision for a total of 0.3-0.6ml, repeated every three weeks for a total of 4 series of injections.
89610789|NCT03215446|Active Comparator|propofol|
89610790|NCT03215446|Experimental|sevoflurane|
89610791|NCT03215212|Experimental|earplug|Ear plug made from polyurethane with (NRR= 29 db and SNR= 37 db) administered from 10 pm to 7 am.
89610792|NCT03215212|Experimental|eye mask|eye mask (18.5 cm, width 8.5cm, height -30mm )dark coloured cloth with 2 elasticised strap, covering both eyes administered from 10 pm to 7 am.
89610793|NCT03215212|Experimental|ocean sound|Ocean sound a type of white noise administered via ear phone for 30 minutes from 9:15 pm to 9:45 pm
89610794|NCT03215134|Experimental|Self-criticism intervention|6 weekly face to face therapy sessions (1st assessment an intervention session of 60 to 90 minutes; sessions 2-5 are 60 minutes each) and a 2 month follow-up telephone call of upto 30 minutes.
89610795|NCT00896038|Experimental|Aprepitant|Following a 1-week placebo lead-in period subjects were given 125 mg of Aprepitant orally daily for 21 days
89610796|NCT00896038|Placebo Comparator|Placebo|Subjects received oral placebo during the 1-week placebo lead-in and then daily for 21 days
89610797|NCT03219346|Experimental|Oral hygiene|
89610798|NCT03218956|Experimental|Protein intake|Dietary supplement: Protein intake
89610799|NCT03219112|Experimental|Intervention|15 cp children + 10 typically developing children (anticipated) Will have 8 weeks VR training Will have 1 VR training session
89610800|NCT03219112|No Intervention|Control|15 cp children (anticipated) Will not have 8 weeks of VR training Will not have 1 VR training session
89610801|NCT03219190|Experimental|LST High School Online|Provided with the prevention program, consisting of e-learning modules and classroom sessions.
89610802|NCT03219190|No Intervention|Treatment as Usual (Control)|Standard health education
89610803|NCT02639260|Experimental|Cohort A|3,000 mg/day
89610804|NCT02639260|Experimental|Cohort B|10,000 mg/day
89610805|NCT04381234|Experimental|ATA plus citrate|1.9 m2 ATA membrane (Solacea™-19H, Nipro Corp., Japan) in combination with citrate (1 mM) containing dialysate
89610806|NCT04381234|Active Comparator|ATA plus predilution hemodiafiltration|1.9 m2 ATA membrane (Solacea™-19H, Nipro Corp., Japan), in combination with high volume predilution hemodiafiltration
89610807|NCT03218644|Active Comparator|Control group|Follow the usual treatment and perform the exercises of cervical mobility before a mirror.
89610808|NCT03218644|Experimental|Experimental group|The same procedure is followed by substituting proprioceptive exercises for craniocervical sensorimotor control with a laser instrument located on the patient's head and a target.
89610809|NCT03218176|Active Comparator|Proximal single upper limb|Laying a single tourniquet on the root of the upper limb
89610810|NCT03218176|Experimental|Proximal staggered upper limb|Laying two staggered tourniquets : one on the root of the upper limb and a second 5 cm below the previous one
89610811|NCT03218176|Experimental|Distal single upper limb|Laying a single tourniquet on the forearm
89610812|NCT03218176|Experimental|Distal staggered upper limb|Laying two staggered tourniquets : one on the forearm and a second 5 cm below the previous one
89610813|NCT03218176|Active Comparator|Proximal single lower limb|Laying a single tourniquet on the root of the lower limb
89610814|NCT03218176|Experimental|Proximal staggered lower limb|Laying two staggered tourniquets : one on the root of the lower limb and a second 5 cm below the previous one
89610815|NCT03218176|Experimental|Distal single lower limb|Laying a single tourniquet on the calf
89610816|NCT03218176|Experimental|Distal staggered lower limb|Laying two staggered tourniquets : one on the calf and a second 5 cm below the previous one
89610817|NCT04380844|Active Comparator|Beprevent|10 will become part of the intervention group. Each of the participants in the intervention group is selected. At first, they are given a series of questionnaires, later (1 day later) we stay at their home to install the Beprevent device, which will remain in their home for a period of two weeks, to finish and once the device of your home, we will proceed to pass the same questionnaires as at the beginning of the test, in order to compare results.
89610818|NCT04380844|No Intervention|patients only evaluated|10 will be included in the control group. During the period of the study, we will pass the same questionnaires in the participants assigned to the control group, also leaving a time interval of two weeks, and no device will be installed, nor will any monitoring be carried out in their homes.
89688381|NCT04356157|Other|No intervention|No intervention will be carried out in a center.
89688382|NCT01729169||Sarcoidosis patients|Patients with biopsy proven sarcoidosis suspected of having cardiac sarcoidosis
89610819|NCT03215290|Experimental|Trans-parenchymal compressing suture|"TCS: After liver transection, check for active hemorrhage and visible sites of bile leakage of cutting surface by stainless gauze which covered up on the raw cutting surface for 5 minutes. For patients with any positive findings including bloodstain and (or) bile staining, the cutting surface was recognized as not good cutting surface and further trans-parenchymal compressing sutured, if possible, using a hepatic needle."
89610820|NCT03215290|No Intervention|Exposed surface (ES)|147 Patients with exposed surface (ES) were matched as control group. No TCS.
89610821|NCT00897676|Other|Vehicle first, then Exendin-(9-39)|An infusion of vehicle (0.9%NaCl) will run for 60 minutes(time -60 to 0) before starting the study infusion of vehicle or exendin-(9-39). At time 0, vehicle (0.9%NaCl) will be started and will continue for 6 hours. The following day, at time 0, exendin-(9-39) at a dose ranging from 100-500pmol/kg/min will be started and continue for 6 hours. During both infusions, blood glucose, insulin, c-peptide, GLP-1, and glucagon will be measured every 30 minutes.
89610822|NCT00897676|Other|Exendin-(9-39) first then Vehicle.|"An infusion of vehicle (0.9%NaCl) will run for 60 minutes(time -60 to 0) before starting the study infusion of vehicle or exendin-(9-39). . At time 0, exendin-(9-39) at a dose ranging from 100-500pmol/kg/min will be started and continue for 6 hours. The following day, at time 0, vehicle (0.9%NaCl) will be started and will continue for 6 hours. During both infusions, blood glucose, insulin, c-peptide, GLP-1, and glucagon will be measured every 30 minutes.~."
88983266|NCT05517525|Experimental|Cohort 1: Brensocatib|Healthy participants with normal hepatic function will receive single oral dose of brensocatib on Day 1 under fasted conditions. Healthy participants will be matched within the protocol criteria to one or more participants with hepatic impairment.
88983267|NCT05517525|Experimental|Cohort 2: Brensocatib|Participants with mild hepatic impairment will receive single oral dose of brensocatib on Day 1 under fasted conditions.
88983268|NCT05517525|Experimental|Cohort 3: Brensocatib|Participants with moderate hepatic impairment will receive single oral dose of brensocatib on Day 1 under fasted conditions.
88983269|NCT05517525|Experimental|Cohort 4: Brensocatib|Participants with severe hepatic impairment will receive single oral dose of brensocatib on Day 1 under fasted conditions.
88983270|NCT05514600|Active Comparator|Fascial closure|This arm will have the parastomal fascial defect closed with a running barbed suture prior to mesh placement.
88983271|NCT05514600|No Intervention|No fascial closure|This arm will undergo mesh placement +/- fixation without the fascial defect being closed prior.
88983272|NCT05491083|Experimental|Phase 1b Pembrolizumab & ADG106|Intravenous Pembrolizumab + ADG106 on day 1 of each 3-weekly cycle
88983273|NCT05491083|Experimental|Phase 2 Pembrolizumab & ADG106|Intravenous Pembrolizumab + ADG106 each 3-weekly cycle
88983274|NCT05473585|Active Comparator|Study EC + UB CC|Participants will make choices between the study e-cigarette (EC) device with tobacco flavor and their usual brand (UB) combusted cigarette (CC)
88983275|NCT05473585|Active Comparator|Study EC + NNC CC|Participants will make choices between the study EC device with tobacco flavor and the normal nicotine content (NNC) investigational CC
88983276|NCT05473585|Experimental|Study EC + VLNC CC|Participants will make choices between the study EC device with tobacco flavor and the very low nicotine content (VLNC) investigational CC
88983277|NCT05473585|No Intervention|Own EC + UB CC|Participants will make choices between their own EC device with their own tobacco flavor and their UB CC
88983278|NCT05457855||Montelukast|Exposure group
88983279|NCT05457855||Fluticasone|Reference group
88983280|NCT05456178||Adult subjects with chronic obstructive pulmonary disease|In adult patients with chronic obstructive pulmonary disease, an electrostatic wipe will be deposited in the living room and another one in the bedroom for 12 weeks, to be analyzed by the mycology laboratory of the Croix-Rousse hospital, Lyon.
88983281|NCT05450744|Experimental|131I-TLX101 + standard of care|
88983282|NCT05445687|Experimental|Hearing Impairment cases|"Hearing impaired children who will receive the proposed narrative intervention program.~The program will include 24 illustrated story sequences with a minimum of 5 sequences representing the main story elements: characters and setting; problems; internal response; actions; and consequence. Story icons will be designed to represent the main 5 elements to accompany storytelling and act as visual prompts.The narrative intervention program will be applied on the cases groups by a phoniatrician in 24 sessions, 60 minutes in duration, one session per week, for 3 months."
88983283|NCT05445687|Active Comparator|Hearing Impairment control|The Hearing impairment control group will receive the conventional language rehabilitation sessions in 30 minute sessions twice a week, for 3 months. Conventional language therapy targets semantics, syntax, prosody, pragmatics, and phonology.
88983284|NCT05445687|Experimental|Developmental language disorder cases|Developmental language disorder children who will receive the proposed narrative intervention program. The program will include 24 illustrated story sequences with a minimum of 5 sequences representing the main story elements: characters and setting; problems; internal response; actions; and consequence. Story icons will be designed to represent the main 5 elements to accompany storytelling and act as visual prompts.The narrative intervention program will be applied on the cases groups by a phoniatrician in 24 sessions, 60 minutes in duration, one session per week, for 3 months.
88983285|NCT05445687|Active Comparator|Developmental language disorder control|The developmental language disorder control group will receive the conventional language rehabilitation sessions in 30 minute sessions twice a week, for 3 months. Conventional language therapy targets semantics, syntax, prosody, pragmatics, and phonology.
88983286|NCT05422937||Children and Young People aged 8-17|All CYP aged 8 years - 17 years & 11 months whether they have had acute COVID-19 or not. Exposure to COVID-19 will be defined as a self-reported positive Sars-CoV-2 PCR test OR a positive self-reported OR self-reported presumed COVID-19 illness. Participants must have a recorded mobile number in their GP record.
88983287|NCT05422846|Experimental|exercise protocol group|The group that applied progressive exercise according to the motivation of patients and healing status of ulcers.
88983288|NCT05422846|Experimental|aerobic exercise group|The group performing aerobic exercise with a bicycle ergometer
88983289|NCT05422846|Experimental|control group|The group to which standard applications of DFU treatment will be applied
89210770|NCT00567996|Experimental|Indacaterol 150 μg|"Indacaterol 150 μg once daily in the morning, inhaled via a single dose dry powder inhaler (SDDPI). Placebo to Salmeterol delivered twice daily via a proprietary dry powder inhaler in the morning and in the evening.~Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study."
88983291|NCT05399758||ICU sedated patients|Critical patients sedated with propofol and fentanyl The values obtained with the use of the NOL® index will be recorded and compared with the standard measurements of pain assessment (Behavioral Pain Scale (BPS) and/or CPOT)
88983292|NCT05396339|Experimental|Phase Ia - Dose escalation(Acceleration Stage)|Phase Ia is an open, non-random, single-arm dose escalation design.
88983293|NCT05396339|Experimental|Phase Ia - Dose escalation(3+3 Stage)|Phase Ia is an open, non-random, single-arm dose escalation design.
88983294|NCT05396339|Experimental|Phase Ib - Dose extension|Phase Ib is an open, non-random, single-arm, multi-center research design.
88983295|NCT05396339|Experimental|Phase IIa - Clinical Exploratory Stage|The Phase IIa is planned to be divided into three indication groups, all of which are open, non-randomized, single-arm research design.
88983296|NCT05390463||PERFoRM|Patients with surgically treated peri-articular fractures of the upper extremity (proximal humerus and distal radius fractures) undergoing treatment within the MDTU (Multi Disciplinary Trauma Unit) of the Zuyderland MC in Heerlen are included in this study.
88983297|NCT05386771|Experimental|Whey and collagen protein blend|A blend of 25g of whey protein and 5g of collagen protein
88983298|NCT05386771|Placebo Comparator|Placebo|Water, same volume as the experimental study beverage
88983299|NCT05379491|Active Comparator|3 L PEG + Linaclotide|Bowel preparation for colonoscopy was performed with 3 L polyethylene glycol solution combined with 2-day linaclotide.
88983300|NCT05379491|Placebo Comparator|3 L PEG + Placebo|Bowel preparation for colonoscopy was performed with 3 L polyethylene glycol solution combined with 2-day placebo.
88983301|NCT05376111|Experimental|Venetclax combined with Azacitidine|T-cell acute lymphoblastic leukemia patients reveive venetoclax combined with azacitidine regimen treatment.
88983302|NCT05336877||Device: Aveir VR Leadless Pacemaker System|This study will utilize real-world data from patients implanted with the Aveir VR Leadless Pacemaker System. No device intervention is required in this study.
88983303|NCT05336877||Device: Single-Chamber Transvenous Pacemaker|This study will utilize real-world data from patients implanted with a single-chamber transvenous pacemaker as a comparator to the Aveir VR LP system study arm. No device intervention is required in this study.
88983304|NCT05334342|Experimental|Low-GI Diet|Low Glycemic Index Diet
88983305|NCT05334342|Active Comparator|High-GI Diet|High Glycemic Index Diet
88983306|NCT05322902|Experimental|Remimazolam group|Total intravenous anesthesia with remimazolam and remifentanil
88983307|NCT05322902|Active Comparator|Propofol group|Total intravenous anesthesia with propofol and remifentanil
88983308|NCT05309135|Active Comparator|Low dose Rho kinase inhibitor Y-27632|Low dose Rho kinase inhibitor Y-27632
88983309|NCT05309135|Active Comparator|Mid dose Rho kinase inhibitor Y-27632|Mid dose Rho kinase inhibitor Y-27632
88983310|NCT05309135|Active Comparator|High dose Rho kinase inhibitor Y-27632|High dose Rho kinase inhibitor Y-27632
88983311|NCT05291299|Other|Standard of Care (Control Group)|Physicians will follow standard of care and instruct participants in the control group to follow a Mediterranean diet higher in vegetables and fruits[19]. Patients will be provided with a handout detailing the basics of the Mediterranean diet. At follow up visits, physicians will ask participants about how they have been eating and if they have been following the guidelines.
88983312|NCT05291299|Experimental|Anti-inflammatory Diet (Intervention Group)|"An 8-week nutrition program consisting of an individualized elimination diet and systematic food reintroduction implemented and supervised by a Registered Dietitian. Clinical trials have shown some benefit from elimination diets for individuals with autoimmune disease [18].~The specifics of the elimination diet including duration and foods included will be individual and up to the RDs discretion based on the patient's medical and diet history, willingness, current diet, preferences, goals, and ability. The initial diet instruction with a Registered Dietitian will be a one-hour, individual secure video call, with nutrition evaluation/assessment and education on elimination diet protocol. Follow up visits will be approximately 20-30 minutes for the subsequent 7 weeks."
88983313|NCT05285111|Experimental|Interoceptive Awareness|The intervention consists of four modules that focus on multiple aspects of interoception including: body awareness, body sensations/movement, eating, health and self-care, emotional awareness, and understanding the self in relation to others.
88983314|NCT05285111|Active Comparator|Healthy Habits|"The comparator condition is called Health Habits and is matched for time and attention; participants complete modules related to healthy habits such as financial planning, hygiene, stretching, and healthy eating."
88983315|NCT05259436|Experimental|Caregiver-Child Intervention|Investigators will examine the immediate psychosocial, behavioral, and child biologic response to three caregiver-child interventions depending on site of enrollment. Each interventions contain overlapping core elements, but also contribute unique facets, allowing us to examine overall intervention effects, as well as unique settings (e.g. home vs. clinic) and delivery effects (1:1 vs. group), providing insight for future direction.
88983316|NCT05259436|Active Comparator|Enhanced Primary Care|Navigational services for social need resources.
88983317|NCT05255029|Experimental|PODEYE Toric Intra Ocular Lens Implantation experimental|Implantation of PODEYE toric intraocular lenses.
88983318|NCT05251337|Experimental|Intervention - nausea/vomiting|Patients indicating that nausea/vomiting is their primary symptom of concern and are randomized to receive intervention will be allocated to the intervention - nausea/vomiting arm. This arm will receive peppermint inhaled aromatherapy patches (or mandarin as an alternative if they have a peppermint sensitivity).
88983319|NCT05251337|Experimental|Intervention - anxiety|Patients indicating that anxiety is their primary symptom of concern and are randomized to receive intervention will be allocated to the intervention - anxiety arm. This arm will receive lavender inhaled aromatherapy patches.
89610823|NCT01616459|Experimental|11Pn Group|Healthy male or female subjects between, and including 6 to 12 weeks (42-90 days) of age at the time of first vaccination, received a 3-dose primary vaccination course of GSK2830929A, or 11Pn, vaccine at 2, 3 and 4 months of age, followed by a booster dose of the same vaccine at 12-15 months of age, each dose being co-administered with one dose of Infanrix hexa™. The 3 first doses of 11Pn vaccine were administered intramuscularly into the right anterolateral thigh and Infanrix hexa™ was administered intramuscularly into the left anterolateral thigh. The booster dose of 11Pn vaccine was administered intramuscularly into the right deltoid (or thigh if the deltoid muscle size was not adequate) and that of Infanrix hexa™ was administered intramuscularly into the left deltoid (or thigh if the deltoid muscle size was not adequate).
89688383|NCT04355845|Experimental|Sumatriptan and PF-06651600 DDI|In Period 1, participants will receive a single oral 25 mg dose of sumatriptan on Day 1 in the morning. In Period 2 on Day 1, participants will receive a single oral 25 mg dose of sumatriptan and a single 400 mg oral dose of PF-06651600 in the morning. In Period 3 participants will receive a single 400 mg oral dose of PF-06651600 in the evening of Day 1, and then a single oral 25 mg dose of sumatriptan in the morning of Day 2.
88983320|NCT05251337|Placebo Comparator|Control - nausea/vomiting|Patients indicating that nausea/vomiting is their primary symptom of concern and are randomized to receive control will be allocated to the control - nausea/vomiting arm. This arm will receive blank (no essential oil infusion) aromatherapy patches.
88983321|NCT05251337|Placebo Comparator|Control - anxiety|Patients indicating that anxiety is their primary symptom of concern and are randomized to receive control will be allocated to the control - anxiety arm. This arm will receive blank (no essential oil infusion) aromatherapy patches.
88983322|NCT05242458||Participants with Crohn's Disease (CD)|Participants with moderate-to-severe active CD enrolled in ImproveCareNow (ICN) pediatric Inflammatory bowel disease (IBD) registry will be observed who are being treated with ustekinumab under real world setting and will be divided into 9 cohorts. Cohorts 1-6 for age group >=2 to <18 years (pediatric), cohorts 7-9 for young adults within age group >=18 to <26 years. Cohort 1: participants with moderate-severe CD and body weight >=40 kg, cohort 2: participants with moderate-severe CD and body weight <40 kg, cohort 3: all participants with moderate-severe CD, cohort 4: participants with active disease and body weight >=40 kg, cohort 5: participants with active disease and body weight <40 kg, cohort 6: all participants treated with ustekinumab, cohort 7: young adults with moderate-severe CD, cohort 8: young adults with active-disease; and cohort 9: all young adults treated with ustekinumab. Only data available per routine clinical practice will be collected within this study.
88983323|NCT05204511|Experimental|Post-COVID/Long-COVID endurance training group|Participants affected by Post-COVID/Long-COVID that carry out a 12-week thrice weekly endurance training intervention
88983324|NCT05204511|Experimental|Post-COVID/Long-COVID concurrent training group|Participants affected by Post-COVID/Long-COVID that carry out a 12-week thrice weekly concurrent training intervention
88983325|NCT05204511|No Intervention|Post-COVID/Long-COVID control group|Participants affected by Post-COVID/Long-COVID that don't carry out an exercise intervention
89688384|NCT02789410|Active Comparator|Intrathecal hydromorphone|Patients will be randomized to receive a one time dose of 75 mcg intrathecal hydromorphone as part of their spinal anesthesia.
88983326|NCT05170893|Experimental|Intervention group|Oral Coenzyme Q10 capsules daily for 12 weeks.
88983327|NCT05170893|Placebo Comparator|Control group|Oral capsules similar to the intervention daily for 12 weeks.
88983328|NCT05167864|Active Comparator|OnabotulinumtoxinA|Botox
88983329|NCT05167864|Active Comparator|AbobotulinumtoxinA|Dysport
88983330|NCT05167864|Active Comparator|IncobotulinumtoxinA|Xeomin
88983331|NCT05167864|Active Comparator|PrabotulinumtoxinA|Jeuveau
88983332|NCT05162287||Patients who are treated in the acute ward of the child and adolescent psychiatry|All children and adolescents aged 12 to 18 years who are treated in the acute ward of the Department of Child and Adolescent Psychiatry, Psychotherapy and Psychosomatics at the University Medical Center Hamburg-Eppendorf are recruited.
88983333|NCT05150912|Active Comparator|Neuro dynamic|Neurodynamic techniques.
88983334|NCT05150912|Active Comparator|desensitization|Desensitization maneuvers
88983335|NCT05140239||AbroSkib Cohort|Adult patients with moderate to severe atopic dermatitis who are eligible for and will receive systemic therapy with abrocitinib by their treating dermatologist as part of standard healthcare (n=20). The choice of therapy is strictly done by the treating dermatologist only, and the reasons for the choice will be captured by a structured documentation.
88983336|NCT05127824|Experimental|HLA-A2 postive|The study will include 21 participants over the 18 years of age with newly diagnosed, clinically localized clear cell renal cell carcinoma, planned for surgical resection with curative intent. Participants receiving vaccine much be HLA-A2 positive.
88983337|NCT05127824|No Intervention|HLA-A2 negative|Up to 21 additional participants who screen as HLA-A2 negative will be enrolled as non-treatment controls. These participants will not be required to undergo blood collection or study procedures
88983338|NCT05125276|Experimental|Interventional arm|No aspirin
88983339|NCT05125276|Active Comparator|Control arm|Aspirin (75-100 mg once daily)
88983340|NCT05094505|Active Comparator|CONTROL GROUP|Exercise at sea level, normoxia. Control diet.
88983341|NCT05094505|Experimental|Ex. Hyp. GROUP|Exercise in hypoxia at 3000m altitude. Control diet.
88983342|NCT05094505|Experimental|Ex. Hyp. + LCD GROUP|Exercise in hypoxia at 3000m altitude. Low carbohydrate diet.
88983343|NCT05083780|Experimental|mFORFIRINOX, Chlorphenesin Carbamate, Hydroxychloroquine|
88983344|NCT05074823|Active Comparator|Ketamine 0.1|Group I: will include 35 patients, will receive 3mL of bupivacaine (heavy) 0.5% in addition to 0.5 ml of a preservative-free ketamine 0.1 mg/kg
88983345|NCT05074823|Active Comparator|Ketamine 0.2|Group II will include 35 patients, will receive 3mL of bupivacaine (heavy) 0.5% in addition to 0.5 ml of a preservative-free ketamine 0.2 mg/kg
88983346|NCT05074823|Active Comparator|Ketamine 0.3|Group III will include 35 patients, will receive 3mL of bupivacaine (heavy) 0.5% in addition to 0.5 ml of a preservative-free ketamine 0.3 mg/kg
88983347|NCT05071079|Experimental|Challenge with whole dose blood-stage inoculum (neat)|Whole dose: one whole vial, containing approximately 0.5 mL of red blood cells, will be reconstituted in 0.9% saline, to a total volume of 5 mL
89610824|NCT01616459|Experimental|12Pn Group|Healthy male or female subjects between, and including 6 to 12 weeks (42-90 days) of age at the time of first vaccination, received a 3-dose primary vaccination course of GSK2830930A, or 12Pn, vaccine at 2, 3 and 4 months of age, followed by a booster dose of the same vaccine at 12-15 months of age, each dose being co-administered with one dose of Infanrix hexa™. The 3 first doses of 12Pn vaccine were administered intramuscularly into the right anterolateral thigh and Infanrix hexa™ was administered intramuscularly into the left anterolateral thigh. The booster dose of 12Pn vaccine was administered intramuscularly into the right deltoid (or thigh if the deltoid muscle size was not adequate) and that of Infanrix hexa™ was administered intramuscularly into the left deltoid (or thigh if the deltoid muscle size was not adequate).
89610825|NCT01616459|Active Comparator|Synflorix Group|Healthy male or female subjects between, and including 6 to 12 weeks (42-90 days) of age at the time of first vaccination, received a 3-dose primary vaccination course of Synflorix™ at 2, 3 and 4 months of age, followed by a booster dose of the same vaccine at 12-15 months of age, each dose being co-administered with one dose of Infanrix hexa™. The 3 first doses of Synflorix™ were administered intramuscularly into the right anterolateral thigh and Infanrix hexa™ was administered intramuscularly into the left anterolateral thigh. The booster dose of Synflorix™ was administered intramuscularly into the right deltoid (or thigh if the deltoid muscle size was not adequate) and that of Infanrix hexa™ was administered intramuscularly into the left deltoid (or thigh if the deltoid muscle size was not adequate).
89610826|NCT01616459|Active Comparator|Prevnar13 Group|Healthy male or female subjects between, and including 6 to 12 weeks (42-90 days) of age at the time of first vaccination, received a 3-dose primary vaccination course of Prevnar13™ vaccine at 2, 3 and 4 months of age, followed by a booster dose of the same vaccine at 12-15 months of age, each dose being co-administered with one dose of Infanrix hexa™. The 3 first doses of Prevnar13™ were administered intramuscularly into the right anterolateral thigh and Infanrix hexa™ was administered intramuscularly into the left anterolateral thigh. The booster dose of Prevnar13™ was administered intramuscularly into the right deltoid (or thigh if the deltoid muscle size was not adequate) and that of Infanrix hexa™ was administered intramuscularly into the left deltoid (or thigh if the deltoid muscle size was not adequate ).
88983348|NCT05071079|Experimental|Challenge with 1:5 dilution blood-stage inoculum|1:5 dilution: one fifth of a vial (containing approximately 0.1 mL of red blood cells) will be reconstituted in 0.9% saline, to a total volume of 5 mL.
88983349|NCT05071079|Experimental|Challenge with 1:10 dilution blood-stage inoculum|1:10 dilution: one tenth of a vial (containing approximately 0.05 mL of red blood cells) will be reconstituted in 0.9% saline, to a total volume of 5 mL.
88983350|NCT05071079|Experimental|Challenge with 1:20 dilution blood-stage inoculum|1:20 dilution: one twenties of a vial (containing approximately 0.025 mL of red blood cells) will be reconstituted in 0.9% saline, to a total volume of 5 mL.
88983351|NCT05067725|No Intervention|Control|Standard of practice
88983352|NCT05067725|Experimental|CarePath Intervention|Clinician decision support computer tool that consists of a best practice alert (BPA) embedded with a headache questionnaire, Medication Express Lane (for medication ordering), and Ask-a-doc button (for prompt virtual consultation with a neurologist)
88983353|NCT05059600|Experimental|ZULRESSO®|Participants received a 60-hour single continuous intravenous (IV) infusion of ZULRESSO®, at 30 micrograms per kilogram per hour (mcg/kg/hour) (0 to 4 hours), at 60 mcg/kg/hour (4 to 24 hours), at 90 mcg/kg/hour (24 to 52 hours), followed by a dose taper to 60 mcg/kg/hour (52 to 56 hours), and 30 mcg/kg/hour (56 to 60 hours) during the study.
88983354|NCT05049902|Experimental|10-day treatment group|"Use the following drug combination option for 10 days. Option 1: Amoxicillin + Clarithromycin + Bismuth + Vonoprazan fumarate Option 2: Amoxicillin + Tetracycline + Bismuth + Vonoprazan fumarate Option 3: Amoxicillin + Metronidazole + Bismuth + Vonoprazan fumarate Three options are selected according to the hospital's situation.~The dosage of each drug is:~Amoxicillin (Amoxicillin, United Laboratories Co., Ltd.) 1000mg bid Clarithromycin (Klacid, Abbott S.r.l) 500mg bid Tetracycline 500mg qid Metronidazole400mg qid Bismuth Potassium Citrate (Livzon Pharmaceutical Group Inc.) 220mg bid Colloidal Bismuth Pectin (North China Pharmaceutical Co., Ltd.) 200mg bid Vonoprazan fumarate (VOCINTI, Takeda Pharmaceutical Company Limited, Hikari Plant) 20mg bid"
89610827|NCT03218254|Other|Methylphenidate - Placebo|Methylphenidate before placebo
89610828|NCT03218254|Other|Placebo - Methylphenidate|Methylphenidate after placebo
89610829|NCT04415801|Experimental|Implant abutments|implant abutments
89610830|NCT03215056|Experimental|PENTHROX® (methoxyflurane)|"PENTHROX® (methoxyflurane) administered as a liquid for inhalation and should be self-administered under supervision of research nurse trained in its administration, using the hand held PENTHROX® inhaler.~One vial of 3 mL PENTHROX® is to be vaporised in a PENTHROX® inhaler. On finishing the 3 mL dose, another 3 mL may be used.~Dose of PENTHROX® should not exceed 6 mL in a single administration.~The patient is instructed to inhale ten successive inhalations of PENTHROX® (methoxyflurane) followed by additional intermittent inhalations as required.~The maximum dose administered will not exceed 6 mL of methoxyflurane."
89610831|NCT03215056|Placebo Comparator|Normal saline|"Normal saline will be administered as a liquid for inhalation and should be self-administered under supervision of research nurse trained in its administration, using the hand held PENTHROX® inhaler.~One vial of 5 mL of normal saline is to be vaporised in a PENTHROX® inhaler. On finishing the 5 mL dose, another 5 mL may be used.~Dose of normal saline should not exceed 10 mL in a single administration.~In this study, the patient is instructed to inhale ten successive inhalations of placebo followed by additional intermittent inhalations as required.~The maximum dose administered will not exceed 10 mL of placebo (2 × 5 mL)"
88983355|NCT05049902|Active Comparator|14-day treatment group|"Use the following drug combination option for 14 days. Option 1: Amoxicillin + Clarithromycin + Bismuth + Vonoprazan fumarate Option 2: Amoxicillin + Tetracycline + Bismuth + Vonoprazan fumarate Option 3: Amoxicillin + Metronidazole + Bismuth + Vonoprazan fumarate Three options are selected according to the hospital's situation.~The dosage of each drug is:~Amoxicillin (Amoxicillin, United Laboratories Co., Ltd.) 1000mg bid Clarithromycin (Klacid, Abbott S.r.l) 500mg bid Tetracycline 500mg qid Metronidazole400mg qid Bismuth Potassium Citrate (Livzon Pharmaceutical Group Inc.) 220mg bid Colloidal Bismuth Pectin (North China Pharmaceutical Co., Ltd.) 200mg bid Vonoprazan fumarate (VOCINTI, Takeda Pharmaceutical Company Limited, Hikari Plant) 20mg bid"
88983356|NCT05042076|Experimental|BK with VST|Adult patients with BKV infection and nephropathy (BKN) following kidney transplantation.
89610832|NCT04626401|Placebo Comparator|Control diet during immobilisation|A 2 day controlled dietary intervention.
89610833|NCT04626401|Experimental|Branched chain amino acid restricted diet during immobilisation|A 2 day branched chain amino acid restricted dietary intervention.
88983357|NCT05040815|Experimental|chemo-radiation treatment|"Radiotherapy with concurrent 5-fluorouracil and mitomycin-C combination treatment.~Radiotherapy consists of 5400 cGy delivered in 30 fractions over 6 weeks. The investigators will be using the current standard regimen for the study or no change in the current CCI treatment regimen. However, the radiotherapy target will be smaller than current practice since the investigators will be omitting prophylactic inguinal irradiation."
88983358|NCT05040087|Active Comparator|USE OF DIABETES Rx GUIDED LARGELY BY HbA1c LEVELS|Extended-release [ER] metformin will be added if HbA1c is ≥7.0% after 3 months; if already used and maximized, pioglitazone will be begun. Other Rx will be added each time HbA1c reaches ≥7.5%. The sequence of Rx will be the same as in intensive Rx subjects; those using insulin will also do prebreakfast SMBG, aiming for glucose <100 mg/dl.
88983359|NCT05040087|Experimental|USE OF DIABETES Rx GUIDED BY SELF-MONITORED BLOOD GLUCOSE (SMBG)|"Guidance by SMBG:~Glucose goals: We will aim for <100 mg/dl premeal (2), <130 postmeal.~Monitoring will include pre-breakfast 2x/wk, and a 5-point profile 1x/wk (before and 1.5-2.5 hr after breakfast, before lunch, before supper, and bedtime).~Added Rx will be used if SMBG is >goal ≥3x in 2 consecutive weeks after ≥4 weeks of MOVE! and/or the previous Rx [e.g., any 3 of the 7 goals (<100 mg/dl premeal, <130 post)]. Metformin ER will be given first (if not already on it), and increased to 2000 mg/day if there are no side effects. (If metformin is not tolerated, it will be stopped and the second Rx will become the first Rx and given instead. If other Rx are not tolerated, the next Rx will be used. The second Rx will be the TZD pioglitazone, followed by the GLP-1 RA semaglutide, then the SGLT-2 inhibitor empagliflozin. If still above goal, glargine insulin will be added, titrated to keep fasting glucose <100 mg/dl."
88983360|NCT05026593|Active Comparator|Sintilimab+EP|During each 21-day cycle, participants receive Sintilimab 200 mg intravenously (IV) Day 1 PLUS etoposide 100 mg/m^2 IV on Days 1, 2 and 3 PLUS investigator's choice of platinum (carboplatin titrated to an area under the plasma drug concentration-time curve [AUC] 5 IV on Day 1 OR cisplatin 75 mg/m^2 IV on Day 1). After the induction phase, participants will begin maintenance therapy with Sintilimab 200 mg intravenously (IV) Day 1 every 3 weeks until PD, unacceptable toxicity, withdrawal of consent, or other protocol-allowed reasons, whichever occurs first.
88983361|NCT05026593|Experimental|IBI110+Sintilimab+EP|During each 21-day cycle, participants receive IBI110 PR2D intravenously (IV) Day 1 PLUS Sintilimab 200 mg intravenously (IV) Day 1 PLUS etoposide 100 mg/m^2 IV on Days 1, 2 and 3 PLUS investigator's choice of platinum (carboplatin titrated to an area under the plasma drug concentration-time curve [AUC] 5 IV on Day 1 OR cisplatin 75 mg/m^2 IV on Day 1). After the induction phase, participants will begin maintenance therapy with IBI110 PR2D intravenously (IV) Day 1 PLUS Sintilimab 200 mg intravenously (IV) Day 1 every 3 weeks until PD, unacceptable toxicity, withdrawal of consent, or other protocol-allowed reasons, whichever occurs first.
88983362|NCT05021497|Experimental|Global Positional Re-education|Global Positional Re-education
88983363|NCT05021497|Active Comparator|Conventional Physical Therapy Program|Conventional therapy will consist of a combination of manual techniques
88983364|NCT05016921|Experimental|Transcutaneous magnetic stimulation|Transcutaneous magnetic stimulation targeting the stellate ganglion
88983365|NCT05005611|Placebo Comparator|Placebo|
88983366|NCT05005611|Experimental|Probiotics Lactobacillus salivarius AP-32|
88983367|NCT05005611|Experimental|Probiotics Bifidobacterium animalis subsp. lactis CP-9|
88983368|NCT05005611|Experimental|Probiotics Lactobacillus rhamnosus LGG|
88983369|NCT04998396|Experimental|Dose-Finding Phase: BBP-812 Dose Level 1 (Cohort 1)|Participants will receive a single intravenous (IV) infusion of low-dose BBP-812 on Day 0 in the dose-finding phase of the study.
88983370|NCT04998396|Experimental|Dose-Finding Phase: BBP-812 Dose Level 2 (Cohort 2)|Participants will receive a single IV infusion of high-dose BBP-812 on Day 0 in the dose-finding phase of the study.
88983371|NCT04998396|Experimental|Enrollment Expansion Phase: BBP-812|Participants will receive a single IV infusion of BBP-812 at the selected dose from the dose-finding phase on Day 0 in expansion phase of the study.
88983372|NCT04995848|Experimental|Telepalliation group|"The intervention group will participate in the telepalliation program. The patients will lent a tablet during the RCT study to access the TelePal.dk platform an video consultations. The patients will participate from the time they are referred to palliative care, and are enrolled in the telepalliation program for up to six months or until:~They stop being followed by the Palliative Team due to lack of symptoms~They are diagnosed with delirium based upon clinical guidelines and the Confusion Assessment Method (CAM). The assessment of delirium will be done by either:~The project nurse or the clinical responsible doctor at the patients' home OR~A district nurse under video supervision by the project nurse or the clinical responsible doctor~Death of the patient"
88983373|NCT04995848|No Intervention|Conventional palliation program|"The control group will follow a conventional palliation program. The patients will participate from the time they are referred to palliative care, and are enrolled in the telepalliation program for up to six months or until:~They stop being followed by the Palliative Team due to lack of symptoms~They are diagnosed with delirium based upon clinical guidelines and the Confusion Assessment Method (CAM). The assessment of delirium will be done by either:~The project nurse or the clinical responsible doctor at the patients' home OR~A district nurse under video supervision by the project nurse or the clinical responsible doctor~Death of the patient"
88983374|NCT04986930|Experimental|SBRT+mFOLFIRINOX|"Stereotactic body radiotherapy: 3500 cGy (5 fractions)~mFOLFIRINOX, every 2 weeks Oxaliplatin, 85 mg/m2, intravenous, day 1 Leucovorin, 400 mg/m2, intravenous, day 1 Irinotecan, 150 mg/m2, intravenous, day 1 fluorouracil, 2,400 mg/m2, intravenous, day 1-2"
88983375|NCT04986930|Active Comparator|mFOLFIRINOX|-mFOLFIRINOX, every 2 weeks Oxaliplatin, 85 mg/m2, intravenous, day 1 Leucovorin, 400 mg/m2, intravenous, day 1 Irinotecan, 150 mg/m2, intravenous, day 1 fluorouracil, 2,400 mg/m2, intravenous, day 1-2
88983376|NCT04971109|Active Comparator|TPOXX|Treatment Group 1: An oral dose of 600 mg (3 × 200 mg capsules) TPOXX BID (every 12 hours [±30 minutes]) for 28 days (Day 1 to Day 28)
89610834|NCT01919801|Experimental|Icatibant|Icatibant at a dose of 30 mg will be administered as a single subcutaneous injection
89610835|NCT01919801|Placebo Comparator|Placebo|Placebo will be administered as a single subcutaneous injection
89610836|NCT01919723|Active Comparator|Ticagrelor and Eptifibatide bolus|Ticagrelor 180 mg i.v. Eptifibatide (2 boluses 180µg/Kg each 10 min apart)
89610837|NCT01919723|Active Comparator|Ticagrelor & Eptifibatide bolus+infusion|Ticagrelor 180 mg i.v. Eptifibatide (2 boluses 180µg/Kg, 10 min apart, followed by 2µg/Kg/min infusion for 2 hours)
89610838|NCT01919489|Experimental|Liraglutide + OADs|Liraglutide once daily in combination to oral anti-diabetic agents (OADs)
89610839|NCT01919489|Active Comparator|Glargine + OADs|Glargine once daily in combination to oral anti-diabetic agents (OADs)
89610840|NCT01919411|Experimental|Amoxicillin-Potassium Clavulanate|All patients in the study will undergo endoscopic sinus surgery. This arm will receive 7 days of augmentin (amoxicillin-clavulanate) 500mg orally twice a day after surgery.
89610841|NCT01919411|Placebo Comparator|Placebo|All patients in the study will undergo endoscopic sinus surgery. This arm will receive 7 days of placebo orally twice a day after surgery.
89610842|NCT01901393|Experimental|IV ibuprofen|800mg ibuprofen
89610843|NCT01901393|Active Comparator|ketorolac|30mg ketorolac
89610844|NCT01890707|Active Comparator|Deep Sedation|Deep sedation
89610845|NCT01890707|Other|General Anesthesia|Administration of general anesthesia. Propofol given IV, succinylcholine and rocuronium given IV and Sevoflurane via the endotracheal tube.
89610846|NCT01900691|Experimental|Evolution® Esophageal Stent|
89610847|NCT01890473|Experimental|Arm 1: Abatacept (autoinjector)|Abatacept 125 mg/syringe subcutaneously through autoinjector, one dose in 71 days
89610848|NCT01890473|Experimental|Arm 2: Abatacept (prefilled syringe)|Abatacept 125 mg/syringe subcutaneously with prefilled syringe, one dose in 71 days
89610849|NCT01889069|Experimental|Rituximab|Participants will receive at least 4 doses of rituximab 1400 mg SC once a month during the Induction period, and at least 6 doses of rituximab 1400 mg SC once every two months during the Maintenance period, in addition to standard chemotherapy. Standard chemotherapy regimen included cyclophosphamide, vincristine, doxorubicin and prednisone (CHOP); or cyclophosphamide, vincristine and prednisone (CVP); or bendamustine as per standard local practice.
89610850|NCT02533180|Other|Immunosuppression withdrawal (ISW)|Gradual immunosuppression withdrawal according to the protocol defined algorithm
89610851|NCT04381780|Experimental|Assessing clinical outcomes|Nutritional support with Recovery Factors
89610852|NCT03218332||Former concussed pro-athletes|Biomarkers for detecting possible CTE invivo in former pro-athletes with multiple concussions: Imaging/blood/cerebrospinal fluid (CSF)/Positron emission tomography (PET-)tau/magnetic resonance imaging (MRI)/neuropsychological assessment.
89610853|NCT03218332||Healthy controls|Active Comparator
89610854|NCT03218098|Experimental|Smaller Incision|UVATS access for lobectomy with small skin access 4 cm
89610855|NCT03218098|Active Comparator|Traditional Incision|UVATS access for lobectomy with longer skin access 8 cm
89610856|NCT03218020||Random Subcohort|Random subcohort (~10 % of the initial cohort, study has a case-cohort design; details on the case-cohort design have been described by Kulathinal et al., Epidemiol Perspect Innov, 2007: www.ncbi.nlm.nih.gov/pmc/articles/PMC2216006/).
89610857|NCT03218020||Incident CVD Cases|Validated incident cases of myocardial infarction, stroke and CVD death that occured until Dec-31-2009 (details on the case-cohort design have been described by Kulathinal et al., Epidemiol Perspect Innov, 2007: www.ncbi.nlm.nih.gov/pmc/articles/PMC2216006/).
89610858|NCT00898222|Experimental|aspirin|Low dose daily aspirin in healthy volunteers for two weeks
89610859|NCT01830556|Active Comparator|Arm A: cetuximab with 5FU and carboplatin or cisplatin|Arm A:Day 1 Cetuximab 400 mg/m2 iv 120 minutes Day 8 and 15 Cetuximab 250 mg/m2 iv 60 minutes Day 1 Cisplatin 100mg/m2 or Carboplatin AUC 5 day 1-4 5-Fluorouracil 1000 mg/m2 iv 24 h maintenance treatment thereafter with cetuximab 500 mg/m2 every second week until PD or toxicity
89610860|NCT01830556|Experimental|Arm B: cetuximab paclitaxel and carboplatin|Arm B day 1 Cetuximab 400 mg/m2 iv 120 minutes Day 8 and 15 Cetuximab 250 mg/m2 iv 60 minutes day 1 Paclitaxel 175 mg/m2 day 1 Carboplatin AUC 5 treatment for 6 cycles thereafter maintenance treatment day 1 Cetuximab 500 mg/m2 every second week treatment until progress or unacceptable toxicity
89610861|NCT03214432||mild traumatic brain injury cohort|Patients with mild traumatic brain injury were defined as hospital admitted, emergency or outpatient treated, who were assigned the ICD-10 code for concussion (ICD-10 S06.0) in the national patient register at hospital discharge from the 1st of January 2003 - 31st of December 2007. Patients were working age adults between 18-60 years old and gainfully occupied or deemed available for work the week before the injury.
89610862|NCT03214432||non-injured control group|Controls were randomly selected from the Population register who were between 18-60 years old, had no diagnosis of mild traumatic brain injury during the period 1st of January 2003 - 31st of December 2007 and were gainfully occupied or deemed available for work the week preceding the time of injury. One control was matched for each mTBI case on gender, municipality and age (year of birth +/- 0,5 years). In case of no matching control the age criterion was expanded to (year of birth +/- 1 year), if still no matching control the age criterion was further expanded to (year of birth +/- 2 year). Additionally, controls were excluded according to the same criteria as the included cases.
89610863|NCT03217630||Diabetic patients|
89610864|NCT03217630||Non-diabetic patients|
89610865|NCT03217942|Experimental|Low dose|All participants will receive 5 i.m injections of NGF (1 ug/0.5ml) into the tibialis anterior muscle (either left or right leg)
89610866|NCT03217942|Experimental|High dose|All participants will receive 1 high dose i.m bolus injection of NGF (5 ug/0.5ml) and 4 injections of saline (control/same volume) into the tibialis anterior muscle (either left or right leg)
89688385|NCT02789410|Active Comparator|Intrathecal morphine|Patients will be randomized to receive a one time dose of 150 mcg intrathecal morphine as part of their spinal anesthesia.
89688386|NCT01723241|Experimental|XAF5|
89688387|NCT01723241|Placebo Comparator|Placebo|
89688388|NCT04356001|Experimental|Socket preservation group|"Extraction sockets filled with a one-piece dual tissue graft harvested from the tuberosity using an adjusted trephine."
89688389|NCT01729325|Experimental|Preventive Narrative Exposure Therapy|Treatment with Pre-NET before deployment in peace-keeping mission
89610867|NCT03217552||The Emergency Department|"The study aims to evaluate the test in this environment as a potential diagnostic. All patients will be screened using the electronic patient management system within the ED.~A single sample of approximately 20ml of blood, will be obtained at the same time as a clinically indicated blood culture (triggered by clinician concern for infection). The sample will be processed as described in the laboratory manual, aliquoted and frozen for future batch analysis. This analysis will include:~The Mologic Biomarker Panel~PCT~CRP~Other inflammatory markers or pathogen detection that may augment the panels accuracy~All conventional standard of care testing will be done at the study site as part of the enrolled subject's routine clinical care."
89610868|NCT03217552||Critical Care Unit|"Two patient populations admitted to the CCU will be approached for inclusion into the study:~Patients being managed for potential infection~Patients having undergone elective major surgery and admitted to the CCU as part of their care pathway. These patients will act as controls as the majority show signs and symptoms of inflammation but rarely develop an infection.~Patients with potential infection: UCLH Critical Care Unit has approximately 1000 emergency admissions per year. Complicated infection (sepsis or septic shock) being the commonest underlying reason for admission."
89610869|NCT03217552||Patients undergoing major surgery|UCLH Critical Care admits approximately 1000 patients per year following major elective surgery. These patients frequently exhibit the features of SIRS but the incidence of infection/sepsis is low (approximately 5%) and very rare in the first 3 days' post-surgery. This group is to be studied as a negative control group to ensure the Mologic Biomarker Panel is able to detect the difference between the similar inflammatory phenotypes developed through infection and surgical trauma.
89610870|NCT00903448|Experimental|A|Prilosec OTC
89610871|NCT00903448|Active Comparator|B|Prevacid
89610872|NCT01830634|Experimental|Theraband with strengthening and stretching exercise|All subjects were received theraband exercises (strengthening and stretching), and then compare the measured outcomes between groups.
89610873|NCT00895180|Experimental|Group 1|Patients receive ramucirumab IV over 1 hour on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
89610874|NCT00895180|Experimental|Group 2|Patients receive olaratumab IV over 60-90 minutes on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
89610875|NCT03214042|Experimental|trial group|Sixty-seven patients with lumbar degenerative diseases were treated with K-rod dynamic stabilization system. All patients were followed for 2 years.
89610876|NCT01830868||Zonisamide tablets|
89610877|NCT03213964|Experimental|Arm 1|"FATE-NK100 is a donor-derived NK cell product comprising ex vivo activated effector cells with enhanced anti-tumor activity.~FATE-NK100 is administered to determine the maximum tolerated doze/maximum feasible dose (MTD/MFD).~Interleukin-2 (IL-2) remains the only FDA approved drug that is capable of promoting NK cells activation and survival.~Lymphodepletion with Cyclophosphamide and Fludarabine."
89610878|NCT03214276|Active Comparator|Polyphenols|The preceding night and one hour before the endurance test, participants were asked to absorb two capsules of 250 mg of polyphenols (Vinitrox™)
88983377|NCT04971109|Placebo Comparator|TPOXX Placebo|Treatment Group 2: An oral dose of placebo (3 capsules identical to TPOXX) BID (every 12 hours [±30 minutes]) for 28 days (Day 1 to Day 28)
88983378|NCT04958109|Experimental|Kisspeptin|• Intravenous administration of kisspeptin 112-121 x 16 hours
88983379|NCT04958109|Placebo Comparator|Placebo|• Intravenous administration of placebo x 16 hours
88983380|NCT04957485|Active Comparator|JYNNEOS + TPOXX|An oral dose of 600 mg (3 × 200 mg capsules) TPOXX BID (every 12 hours [±30 minutes]) for 28 days and a single AM SC dose of 0.5 mL JYNNEOS on Day 1 and Day 29. JYNNEOS will be administered with TPOXX concomitantly on Day 1
88983381|NCT04957485|Placebo Comparator|JYNNEOS + matching TPOXX placebo|An oral dose of placebo (3 capsules identical to TPOXX) BID (every 12 hours [±30 minutes]) for 28 days and a single AM SC dose of 0.5 mL JYNNEOS on Day 1 and Day 29. JYNNEOS will be administered with TPOXX placebo concomitantly on Day 1.
88983382|NCT04956289|Experimental|Viltolarsen|Patients amenable to exon 53 skipping will receive viltolarsen intravenous (IV) infusions, weekly, at 80 mg/kg for up to 48 weeks.
89610879|NCT03214276|Placebo Comparator|placebo|The preceding night and one hour before the endurance test, participants were asked to absorb two capsules of placebo (similar appearance and flavour than active comparator).
88983383|NCT04941404|Experimental|TQ05105 tablets|Participants began oral administration of TQ05105 tablets at 10 mg twice daily (BID),followed by 5 mg or 15 mg BID depending on the situation of the study. twice daily in 28-day cycle until disease progression/intolerance occurs or the sponsor terminates the study.
88983384|NCT04931459|Experimental|ACU193 Administration|Participants will receive 1 to 3 doses of ACU193 by intravenous (IV) infusion.
88983385|NCT04931459|Placebo Comparator|Placebo Administration|"Participants receive 1 to 3 doses of matching ACU193 placebo by intravenous (IV) infusion.~2 participants per cohort will receive placebo."
88983386|NCT04923581|Experimental|Condition 1|Participants will receive the constant component only.
88983387|NCT04923581|Experimental|Condition 2|Participants will receive the constant component and storytelling videos .
88983388|NCT04923581|Experimental|Condition 3|Participants will receive the constant component and oral health promotion messages.
88983389|NCT04923581|Experimental|Condition 4|Participants will receive the constant component and a motivational interview session.
88983390|NCT04923581|Experimental|Condition 5|Participants will receive the constant component, oral health promotion messages and storytelling videos.
88983391|NCT04923581|Experimental|Condition 6|Participants will receive the constant component, oral health promotion messages, storytelling videos, and a motivational interview session.
88983392|NCT04923581|Experimental|Condition 7|Participants will receive the constant component, oral health promotion messages and a motivational interview session.
88983393|NCT04923581|Experimental|Condition 8|Participants will receive the constant component, storytelling videos, and a motivational interview session.
88983394|NCT04914312|Experimental|Maqui berry extract and omega-3 fatty acids|2 capsules BID per day containing a total of 600 mg of Maqui extract; 4 capsules per day supplying a total of 2000 mg EPA and 1000 mg DHA
88983395|NCT04914312|Placebo Comparator|Control|4 olive oil soft gelatin capsules and inert two-piece capsules containing maltodextrin
89610880|NCT03213808||respiratory allergies|respiratory allergies (asthma, rhinitis)
88983396|NCT04901273|Experimental|Homologous PRP|This group of patients will be treated with single intra-articular injection of Homologous PRP. At the 6-month follow-up visit, the patient will be informed about the treatment received.
88983397|NCT04901273|Placebo Comparator|Saline solution|This group of patients will be treated with single intra-articular injection of saline solution (placebo). At the 6-month follow-up visit, patients will be informed about the treatment received. Patients of this group can cross-over to the treatment arm after 6 months.
89610881|NCT03213808||skin allergies|skin allergies (dermatitis, urticarial, angioedema)
88983398|NCT04877431||De Nova Participants|De nova participants who had received teduglutide after marketing authorization will be enrolled in this study and monitored by their physicians according to local clinical practice then followed for 24-weeks unless treatment discontinuation or lost to follow-up.
88983399|NCT04877431||Legacy Participants|Legacy participants who received teduglutide treatment prior to marketing authorization under expanded access type of program will be enrolled in this study and monitored by their physicians according to local clinical practice then followed for 24-weeks unless treatment discontinuation or lost to follow-up.
88983400|NCT04874571|Experimental|Muscle Energy Technique group|In the first group, according to Lewit's post-isometric relaxation (Muscle energy technique) method, scalene (anterior / medius / posterior), levator scapula, sternocleidomastoid, trapezius, pectoral muscles, serratus anterior and latismus dorsi muscles are set 3 days a week ( Each set includes three repetitions) The treatment will be applied for 4 weeks. The hypertonic muscle will be taken to the first point that resists movement without straining. The patient will be asked to perform an isometric contraction for 7 seconds, corresponding to 20% of the maximum isometric contraction force where the restriction is felt. After the application, the patient will be asked to exhale and relax completely. 30 seconds will be waited for each stretching and then the neck will be taken back to the barrier point and three repetitions per session will be performed.
89610882|NCT03213808||anaphylaxis|anaphylaxis
89610883|NCT03213808||gastrointestinal allergic conditions|gastrointestinal allergic conditions
89610884|NCT03213808||ocular allergies|ocular allergies (conjunctivitis)
89610885|NCT03217474|Experimental|FLDEB combined with GCV orally|Femtosecond laser-assisted cornea debridement (FLDEB) combined with ganciclovir (GCV) orally.
89610886|NCT03217474|Active Comparator|GCV orally|Ganciclovir (GCV) orally only
89610887|NCT03217318|Active Comparator|ureteral stenting with standard ureteral stent|Group 1 will receive a standard ureteral stent. Diameter: 6F, length according to surgeons' estimation and patient's height.
89610888|NCT03217318|Active Comparator|ureteral stenting with suture-stent|In Group 2, a modification of the standard ureteral stent will be inserted. The stent will be cut through obliquely according to the position of the ureteral calculus. The extend to be removed can be easily measured by the retrograde probing catheter and is replaced by a monofilament, non-absorbable suture as described previously by Vogt et al. (W J Urol, 2015). This suture can be easily attached by puncturing the bevelled stent end.
89610889|NCT01830946|Experimental|Whey Protein and Exercise Training|This arm involves 4 weeks of consuming a whey protein supplement late in the evening before bed along with combined resistance and high-intensity interval training 3 days per week for 4 weeks (two days of resistance training and one day of high-intensity interval training).
89610890|NCT01830946|Placebo Comparator|Carbohydrate and Exercise Training|This arm involves 4 weeks of consuming a carbohydrate placebo late in the evening before bed along with combined resistance and high-intensity interval training 3 days per week for 4 weeks (two days of resistance training and one day of high-intensity interval training).
89610891|NCT01830946|Experimental|Casein Protein and Exercise Training|This arm involves 4 weeks of consuming a casein protein supplement late in the evening before bed along with combined resistance and high-intensity interval training 3 days per week for 4 weeks (two days of resistance training and one day of high-intensity interval training).
89610892|NCT01831024|Experimental|Treatment Group|Dignicap System
89610893|NCT01831024|No Intervention|Control Group|Concurrent age and chemotherapy matched control
89610894|NCT03213886|Experimental|Calcifediol (Vitamin D) loading-dose|Participants in the intervention group will receive calcifediol16.000 units (U) /day for five days
89610895|NCT03213886|Active Comparator|Calcifediol (Vitamin D) at clinical practice dose|Participants in the control group will receive 16.000 U / week for five weeks
89610896|NCT01831102||non-Latino white|no Latino ancestry, Caucasian
88983401|NCT04874571|Other|Home Exercise|The individuals in the second group will be asked to do the home exercise program shown to them for 4 weeks, 3 days a week. Individuals included in this group will be given a program that includes stretching and posture exercises for the same muscle groups. Individuals in the control group will be called weekly during the 4-week period. Before, after, and 6 weeks after the study, re-evaluation parameters will be applied to all individuals included in the study.
88983402|NCT04870255|Active Comparator|Left Dorsolateral Prefrontal Cortex (L-DLPFC)|The accelerated theta burst stimulation protocol will be applied to the left dorsolateral prefrontal cortex (L-DLPFC)
88983403|NCT04870255|Active Comparator|Dorsomedial Prefrontal Cortex (DMPFC)|The accelerated theta burst stimulation protocol will be applied to the dorsomedial prefrontal cortex (DMPFC)
88983404|NCT04870255|Sham Comparator|Sham stimulation|Sham (non-active) stimulation will be applied to the left dorsolateral prefrontal cortex (DLPFC) region
88983405|NCT04861038|Experimental|aerSleep II|Use of aerSleep II device to provide continuous external negative pressure to treat moderate to severe OSA in spontaneously breathing subjects who are intolerant of CPAP
88983406|NCT04856059|Other|Cardiac MRI, ECG and Blood Biomarkers|Additional sequences will be performed during routine clinical cardiac MRI and additional blood samples will be collected during routine blood work.
88983407|NCT04853576|Experimental|EDIT-301|EDIT-301 (autologous gene edited (CD)34+ hematopoietic stem cells) will be administered as a one-time intravenous infusion.
88983408|NCT04834154|Active Comparator|Mindfulness group visit|Participants will attend 6 weekly educational and mindfulness sessions
88983409|NCT04834154|Placebo Comparator|Wait list control|Participants will be placed on a wait list
89610897|NCT01831102||Mexican American|Mexican American ancestry
89610898|NCT01831180||Premenopausal women 19-25 yrs|
89610899|NCT01831180||Postmenopausal 60 yrs +|
89610900|NCT01739348|Experimental|Arm A. Verubecestat 12 mg [Part I]; 12 mg [Part II]|[Part I] Verubecestat 12 mg once daily for 78 weeks in Study Part I (Base Study). [Part II] Participants completing Study Part I and continuing to Study Part II (Extension Study) receive Verubecestat 12 mg once daily for an additional 260 weeks.
89610901|NCT01739348|Experimental|Arm B. Verubecestat 40 mg [Part I]; 40 mg [Part II]|[Part I] Verubecestat 40 mg once daily for 78 weeks in Study Part I (Base Study). [Part II] Participants completing Study Part I and continuing to Study Part II (Extension Study) receive Verubecestat 40 mg once daily for an additional 260 weeks.
89610902|NCT01739348|Experimental|Arm C. Verubecestat 60mg/40mg [Part I]; 40 mg [Part II]|[Part I] Verubecestat 60 mg once daily until the first IA in Study Part I (Base Study). Following IA, participants in this group were switched to Verubecestat 40 mg once daily, for the remainder of Study Part I (total dosing period: 78 weeks). [Part II] Participants completing Study Part I and continuing to Study Part II (Extension Study) receive Verubecestat 40 mg once daily for an additional 260 weeks.
89610903|NCT01739348|Placebo Comparator|Arm D. Placebo [Part I]; Verubecestat 40 mg [Part II]|[Part I] Placebo once daily for 78 weeks in Study Part I (Base Study). [Part II] Participants completing Study Part I and continuing to Study Part II (Extension Study) receive Verubecestat 40 mg once daily for an additional 260 weeks.
89610904|NCT03217084|Active Comparator|MI varnish GC|MI Varnish is a 5% sodium fluoride varnish that has a desensitizing action when applied to tooth surfaces. MI Varnish also contains RECALDEN Open the unit-dose package of Varnish. Use the applicator brush to thoroughly mix Varnish . Apply Varnish evenly in a thin layer over treatment area(s). For larger surface areas, apply Varnish in sweeping horizontal brush. After application, instruct the patient to close his or her mouth to set the Varnish. No need to use suction. The patient may feel the thin coating when rubbing the treated area with his or her tongue.
89610905|NCT03217084|Active Comparator|White Varnish 3M|"White Varnish is a 5% sodium fluoride varnish that has a desensitizing action when applied to tooth surfaces. White Varnish an innovative tri-calcium phosphate.~Open the unit-dose package of Varnish. Use the applicator brush to thoroughly mix Varnish . Apply Varnish evenly in a thin layer over treatment area(s). For larger surface areas, apply Varnish in sweeping horizontal brush. After application, instruct the patient to close his or her mouth to set the Varnish. No need to use suction. The patient may feel the thin coating when rubbing the treated area with his or her tongue."
89610906|NCT00899470|Experimental|S+ M, (fasted)> S/M (fed)> S/M (fasted)>S+M (fed)|Participants were randomized to receive oral co-administration of a 2.5 mg tablet of saxagliptin plus a 500 mg tablet of metformin immediate release (IR) under fasted conditions (S + M [fasted]) followed by a fixed dose combination (FDC) tablet of 2.5 mg saxagliptin/500 mg metformin IR under fed conditions (S/M [fed]) followed by S/M under fasting conditions (S/M [fasted]) followed by S + M under fed conditions (S + M [fed])
89610907|NCT00899470|Experimental|S/M (fasted)> S+M (fasted)> S+M (fed)> S/M (fed)|Participants were randomized to receive S/M (fasted) followed by S + M (fasted) followed by S + M (fed) followed by S/M (fed)
89610908|NCT00899470|Experimental|S+M (fed)> S/M (fasted) >S/M (fed)> S+M (fasted)|Participants were randomized to receive S + M (fed) followed by S/M (fasted) followed by S/M (fed) followed by S+M (fasted)
89610909|NCT00899470|Experimental|S/M (fed)> S+M (fed)> S+M (fasted)> S/M (fasted)|Participants were randomized to receive S/M (fed) followed by S+M (fed) followed by S+M (fasted) followed by S/M (fasted)
89610910|NCT01738646|Experimental|Vorinostat & Bevacizumab|Patients will be administered bevacizumab every 2 weeks and vorinostat will be taken on days 1-7 and 15-21 of each 28-day cycle at 400 mg per day.
89610911|NCT01831336||Orsiro DES|
89610912|NCT03213574|Active Comparator|Control Group|The control group will be administered intraoperative fluids throughout his or her surgery per the discretion of the anesthesiologist as is typical for this type of case. They will use an arterial line but without a FloTrac and therefore will have no data regarding the SVV.
89610913|NCT03213574|Experimental|Treatment Group|The treatment group will receive a FloTrac arterial line that will allow the anesthesiologist to administer intraoperative fluids based on the study algorithm.
89610914|NCT01831414|Experimental|Water immersion at cervical level|Lung function of spinal cord injury patients will be studied with a water immersion at cervical level
89610915|NCT01831414|Experimental|Water immersion at xyphoid level|Lung volumes of spinal cord injury patients will be studied with a Water immersion at xyphoid level
89610916|NCT03213340|Experimental|Catechin Cohort 1|2 treatment - Experimental Catechin Blend; Control 1 Placebo
89610917|NCT03213340|Experimental|Curcuminoid Cohort 2|2 treatment - Experimental Curcuminoid Blend; Control 1 Placebo
89610918|NCT03213340|Experimental|Flavonoid Cohort 3|2 treatment - Experimental Flavonoid Blend; Control 2 Low-Flavonoid Blend
89610919|NCT01716104|Experimental|Afalaza (2 tablets twice a day)|
89610920|NCT01716104|Placebo Comparator|Placebo (2 tablets twice a day)|
89610921|NCT03837262|Experimental|Flash glucose monitoring|Flash glucose monitoring continuously for 6 weeks then once a month up to 24 weeks, with structured education
89610922|NCT03836170|Experimental|Laparoscopic cholecystectomy|A laparoscopic cholecystectomy was performed to remove the gallbladder
89610923|NCT01831492|Active Comparator|zeolite + dolomite|28 trained subjects receive encapsulated zeolite + dolomite
89610924|NCT01831492|Placebo Comparator|cellulose|28 trained subjects receive encapsulated micro-crystalline cellulose
89610925|NCT03213106|Experimental|Transcranial Magnetic Stimulation (TMS) Stimulation|All patients will receive 5 sessions of active TMS stimulation.
89610926|NCT03213106|Sham Comparator|Sham Stimulation|All patients will receive 5 sessions of active TMS stimulation
89610927|NCT00904618|Experimental|TVT-SECUR|This study arm consisted of 48 women operated from January 2007 to October 2008. All patients underwent the implantation of the TVT-SECUR for the treatment of stress urinary incontinence or stress predominant mixed urinary incontinence. The surgery was done under local anesthesia by one high-volume surgeon.
89688390|NCT01729325|No Intervention|No treatment control|
88983410|NCT04833959|Experimental|89Zr-Panitumumab|Subjects will be injected with 1 mCi (+/- 20%) of 89Zr-panitumumab followed by PET/CT imaging 4-7 days after study drug injection.
88983411|NCT04793906|Experimental|Beef|
88983412|NCT04793906|Experimental|Plant-based alternative|
88983413|NCT04786639||Surgical Fixation Group|Open reduction with deltopectoral incision and humeral osteosynthesis with anatomic plates and screws will be performed for surgical fixation.
88983414|NCT04786639||Non-Operative Group|Non-surgical treatment will be performed with sling immobilization.
88983415|NCT04769596|Experimental|Treatment|Subject in this arm will undergo treatment with the NEUROMARK device.
88983416|NCT04769596|Sham Comparator|Sham|Subjects in this arm will undergo the procedure with a Sham device. At 3 months post treatment these subjects will cross over to Arm 1.
88983417|NCT04761367|Other|INTERVENTION GROUP|The IG will participate in a 6-month exercise program based on the PAIR exercise protocol and will receive educational sessions and material on the importance of maintaining an active life style after THR or TKR
88983418|NCT04761367|No Intervention|CONTROL GROUP|The CG will receive only educational sessions and material on the importance of maintaining an active life style after THR or TKR
88983419|NCT04755140||Endoprosthesis|Patients with a endoprosthesis
88983420|NCT04747197|Experimental|440 ug, single dose|EYP-1901 440 ug, single dose
88983421|NCT04747197|Experimental|2060 ug, single dose|EYP-1901 2060 ug, single dose
88983422|NCT04747197|Experimental|3090 ug, single dose|EYP-1901 3090 ug, single dose
88983423|NCT04745039|Experimental|Endopatch System|Participants will be treated with Endopatch System
88983424|NCT04716413|Experimental|Treatment|Subjects will receive dose of Dsuvia 30mcg SL (1st dose) after induction but before first incision. Post-operatively, if subject rates pain higher than 4 out of 10, subject will receive a second dose of Dsuvia 30mcg SL (sublingual). If 30 minutes after second dose, subject rates pain higher than 4 out of 10, subject will receive ibuprofen 800mg IV. If 60 minutes after second dose, subject rates pain higher than 7 out of 10, subject will receive hydromorphone 0.4 mg IV.
88983425|NCT04716413|No Intervention|Control|Subjects will be receive routine standard of care.
88983426|NCT04709640|Experimental|Tailored Medication Management Intervention|This research study involved an initial 1.5 hour visit and 2-3 follow up home visits (each lasting 60 minutes). Participants received 2-3 home visits during which they received recommendations on strategies which will improve medication management. Level II occupational therapy fieldwork students made the recommendations, after approval from their supervising licensed OT. The OT fieldwork students provided assistance to the individual in implementing strategies, obtaining adaptive equipment at little or no cost to the individual.
88983427|NCT04700631|Active Comparator|healthy subject|healthy subjects : no medical history, in particular cardiovascular, without drug treatment, without proteinuria, normal BMI
88983428|NCT04700631|Experimental|CRF patients|CRF patients : eGFR estimated according to the MRDR formula less than 89 mL/min/1,73m²
88983429|NCT04696042||Lanreotide|Patients treated with lanreotide
88983430|NCT04666857|No Intervention|standard care|Control subject will receive standard care of treatment
88983431|NCT04666857|Experimental|intervention group|intervention group will receive early intervention
88983432|NCT04635189|Active Comparator|Experimental Arm: Cycle 1-4 All subjects|"Subjects will be treated with the following:~Daratumumab 16 milligrams/kilograms intravenously weekly for 8 treatments, followed by every 2 weeks for 8 treatments, followed by every 4 weeks~Lenalidomide 25 milligrams by mouth daily days 1-21 out of a 28 day cycle~Dexamethasone 20 milligrams by mouth or intravenously at least 60 minutes prior to first infusion of daratumumab"
88983433|NCT04635189|Experimental|Experimental Arm: Cycle 5+ Partial Response or Better|"Subjects will be treated the following:~Daratumumab 16 milligrams/kilograms intravenously weekly for 8 treatments, followed by every 2 weeks for 8 treatments, followed by every 4 weeks~Lenalidomide 25 milligrams/kilograms daily days 1-21 out of a 28 day cycle"
88983434|NCT04635189|Active Comparator|Experimental Arm: Cycle 5+ Less than Partial Response|"Subjects will be treated the following:~Daratumumab 16 milligrams/kilograms intravenously weekly for 8 treatments, followed by every 2 weeks for 8 treatments, followed by every 4 weeks~Lenalidomide 25 milligrams by mouth daily days 1-21 out of a 28 day cycle~Dexamethasone 20 milligrams by mouth or intravenously at least 60 minutes prior to first infusion of daratumumab"
88983435|NCT04608448|Active Comparator|Topical Rapamycin|Ointment is applied to a color coded area on the subject forearm daily.
88983436|NCT04608448|Placebo Comparator|Placebo|Placebo ointment is applied to a color coded area on the subject forearm daily.
88983437|NCT04591028|Other|Intervention|Injection of Indocyamine Green.
88983438|NCT04589988|Experimental|REBIL- Intervention arm|Participants in this arm will receive the Removing Environmental Barriers to Independent Living (REBIL) intervention.
88983439|NCT04589988|Other|Waitlist Attentional control|Participants in this arm will receive life interview visits provided by a trained occupational therapist (OT) or OT student remotely for an equivalent amount of time to the treatment group. The waitlist control group will be offered the REBIL intervention after the 6-month follow-up is completed.
88983440|NCT04580823|No Intervention|Control|Fasting without exogenous ketone salt supplement
88983441|NCT04580823|Experimental|Fasting with exogenous ketone salt supplement|Fasting with exogenous ketone salt supplement
88983442|NCT04580823|Experimental|Post-Prandial with exogenous ketone salt supplement|Post-Prandial with exogenous ketone salt supplement
88983443|NCT04567732|Experimental|Filtered Autologous Adipose Tissue|based on randomization one of the two knees will be treated with a single injection of Filtered Autologous Adipose Tissue
88983444|NCT04567732|Placebo Comparator|Placebo|based on randomization one of the two knees will be treated with a single injection of Placebo
88983445|NCT04538794|Experimental|CDX-0159|CDX-0159 every 4-8 weeks
88983446|NCT04538794|Placebo Comparator|Normal Saline|Normal saline every 4-8 weeks
88983447|NCT04534530||Experimental|"The experimental group systematic screening for ischemic heart disease will be identified during the screening period by performing at least one systematic screening examination, regardless of the frequency, for ischemic heart disease in patients. diabetics at very high cardiovascular risk, without known coronary heart disease, by at least one non-invasive functional cardiovascular exploration outside the resting ECG."
88983448|NCT04534530||Control|"The control group Absence of systematic screening for ischemic heart disease will be identified during the pre-selection period by the absence of a non-invasive functional cardiovascular exploration (examinations mentioned above) in T2D with very high cardiovascular risk, with no known coronary heart disease, apart from performing a resting ECG"
89033867|NCT05869812|Experimental|CaHMB+Vitamin D3-Active Experimental|Participants will consume 3 g HMB with 2000 IU Vitamin D3 per day, split into two doses daily for the duration of the study, beginning 2 weeks prior to their surgical date. The first dose will be consumed 60 minutes prior to any at- home or outpatient physical therapy session and a second will be consumed immediately following the session. If a treatment day does not include any rehabilitation session, the participant will consume one dose in the morning prior to food consumption and the second dose approximately 90 minutes later.
89610928|NCT03213028|Other|Full group|Our goal is to assess the feasibility and acceptability of incorporating family planning (FP) service delivery, using a program validated by the World Health Organization (WHO), into the established Cervical Cancer Prevention (CCP) programs of Botswana.
89610929|NCT03213262||General anesthesia|The effect of anxiety on the choice of anesthesia will be evaluated.
89033868|NCT05869812|Placebo Comparator|Calcium Lactate-Control Placebo|Participants will consume inactive 510 mg Ca Lactate capsules per day, split into two doses daily for the duration of the study, beginning 2 weeks prior to their surgical date. The first dose will be consumed 60 minutes prior to any at- home or outpatient physical therapy session and a second will be consumed immediately following the session. If a treatment day does not include any rehabilitation session, the participant will consume one dose in the morning prior to food consumption and the second dose approximately 90 minutes later.
89033869|NCT05869019|Experimental|providing education|There are two groups, training and non-training.
89610930|NCT03213262||spinal anesthesia|Cesarean patients with spinal anesthesia
89610931|NCT01839136|Experimental|Intrauterine transfer of gametes|After the oocyte retrieval, the oocytes will be selected depending on the morphology of the granular cells. The transfer will be conducted in up to 2 hours after the oocytes collection, when the semen and up to 3 oocytes will be transferred. Surplus oocytes will be cryopreserved for future use. We will use a Sydney catheter (Cook Medical Inc., Bloomington, IN, USA) coupled to a 1 mL syringe to perform the transfer. The catheter will be loaded with oocytes and semen prepared in the following sequence: 10 µL of the prepared semen, a small space of air, 20 µL of the medium containing the oocytes, another small space of air and more 10 µL of prepared semen. The catheter will be placed through the endocervical canal up to the endometrial cavity guided by transabdominal ultrasound, where the liquid will be released. We will try to place the point of the catheter 1.0-1.5cm before touching the fundus of the endometrial cavity and release the liquid slowly, in approximately 30 seconds.
89033870|NCT05868824|Experimental|Main Cohort|
89033871|NCT05862636||Mindfulness centre for general public|Mindfulness course attenders at a mindfulness centre that offers mindfulness trainings for the general public. Participants are thus not selected based on any complaints they may have.
89033872|NCT05862636||Stress clinic|Mindfulness course attenders at a stress clinic associated with a hospital that offers mindfulness courses for participants with mild complaints, such as stress or worry.
89033873|NCT05862636||Mood Disorders Centre|Mindfulness course attenders at a mood disorders centre that offers mindfulness courses for participants with a history of depression and for staff of the public sector such as health care, social care, or police forces.
89033874|NCT05860231|Active Comparator|Control arm (Foley catheter)|When randomly allocated to this arm, a conventional Foley-type catheter will be inserted during all the study period (4 weeks). At day 28 after inclusion, the patient will be called for a follow-up visit to remove the catheter.
89033875|NCT05860231|Experimental|T-Control arm|When randomly allocated to this arm, the T-Control catheter will be inserted during all the study period (4 weeks). At day 28 after inclusion, the patient will be called for a follow-up visit to remove the catheter.
89688391|NCT01729481|Experimental|RASH positive|"Run-In-Phase during 4 weeks:~Gemcitabine 1000 mg/m², weekly Erlotinib 100 mg, weekly~Thereafter Treatment in patients with RASH-positve outcome after 4 weeks."
89033876|NCT05858736|Experimental|Level 1|AI-061, 200 mg, intravenous infusion, Q3W, up to 17 cycles or approximately 1 year.
89033877|NCT05858736|Experimental|Level 2|AI-061, 400 mg, intravenous infusion, Q3W, up to 17 cycles or approximately 1 year.
89033878|NCT05858736|Experimental|Level 3|AI-061, 600 mg, intravenous infusion, Q3W, up to 17 cycles or approximately 1 year.
89033879|NCT05856669|Experimental|Single subject case study|
89033880|NCT05851430||Aliya PEF ablation|Patients will undergo PEF ablation per institutional standard of care
89033881|NCT05847829|Experimental|Intervention|The study is open label all participants get the same intervention
89033882|NCT05839899|Active Comparator|Mifepristone plus Single dose misoprostol|Participant will take mifepristone, then one dose of misoprostol at home to pass the pregnancy (current routine abortion care).
89033883|NCT05839899|Experimental|Mifepristone plus two doses misoprostol|Participant will take mifepristone, then at home will take two doses of misoprostol 4 hours apart to pass the pregnancy.
89033884|NCT05839860|Placebo Comparator|3 g salt|Tomatoes with 3 g salt
89033885|NCT05839860|Experimental|6 g salt|Tomatoes with 6 g salt and 1 L of water
89033886|NCT05839860|Experimental|9 g salt|Tomatoes with 9 g salt and 1 L of water
89033887|NCT05838560|Experimental|Dasatinib + quercetin|open label dasatinib plus quercetin combined as a drug therapy
89688392|NCT01729481|Active Comparator|RASH-negative|"Run-In-Phase during 4 weeks:~Gemcitabine 1000 mg/m², weekly Erlotinib 100 mg, weekly~RASH-negative patients quit treatment with Gemcitabine + Erlotinib and continue treatment with FOLFIRINOX:~Oxaliplatin 85mg/m2 Irinotecan 180 mg/m2 Folinic acid 400 mg/m2 5-FU 400 mg/m2 bolus iv 5-FU 2400 mg/m2 46-hours continous infusion"
89688393|NCT03405077|Experimental|IPT Online Training|"Therapists in this study will be trained in IPT using an online platform. The program is self-paced but will have a deadline; the suggested pace is at least 12 hours spaced over 2 months. The guided online training program was developed in collaboration with 3C institute, an award-winning research and development company that creates web- and evidence-based programs. Content will be adapted from gold-standard training."
88815359|NCT00995072|Experimental|Arm A|Nebivolol 5 mg daily for 12 weeks followed by Metoprolol succinate 100 mg daily for 12 weeks. A two week washout (no medication) is completed prior to switching to metoprolol.
89033888|NCT05835882|Experimental|Liver transplant recipients receiving blood donors' transfusion|Liver transplant recipients in which donor blood was collected and intraoperatively transfused to recipients.
89610932|NCT01839136|Active Comparator|intrauterine transfer of embryos|The oocytes will be denuded and those considered to be mature will be selected for fertilization up to the number of seven. In vitro fertilization will be performed and up to two embryos will be transferred 2-3 days after the oocyte retrieval. The other embryos will be cryopreserved for future use. We will use Sidney catheter (Cook Medical Inc.) coupled to a 1 mL syringe to perform the transfer. The catheter will be loaded with embryos in the following sequence: 10 µL of culture medium, a small space of air, 20 µL of the medium containing embryos, another small space of air, and more 10 µL of culture medium. The catheter will be placed through the endocervical canal up to the endometrial cavity, guided by transabdominal ultrasound, where the liquid will be released. We will try to place the point of the catheter 1.0-1.5cm before touching the fundus of the endometrial cavity and release the liquid slowly, in approximately 30 seconds.
89610933|NCT01839214|Experimental|VB-201 160mg|Subjects will received 80mg twice daily for 24 weeks.
89610934|NCT01839214|Placebo Comparator|Placebo with crossover to VB-201 160mg|Subjects on placebo will crossover to VB-201 160 at week 12.
89610935|NCT01831882||Major Depressive Disorder|
89610936|NCT01831882||Healthy Control|
89610937|NCT01839292|Active Comparator|uncovered D-type stent|uncovered D-type stent, which effectively reduces stent migration, especially in malignant colorectal obstruction
89610938|NCT01839292|Active Comparator|double-layered ComVi stent|double-layered ComVi stent, which is a modified covered stent with an additional outer bare wire mesh to overcome both tumor ingrowth and stent migration
89610939|NCT01839370|Experimental|Closed Loop with Pramlintide|The experimental condition consists of closed loop admission with the Adaptive Insulin Meal Supervisor system (AIMS) system with pramlintide 30 mcg at meal time. During this admission, the Diabetes Assistant (DiAs), a Cell Phone Medical Platform and the central component of the system, will provide basal insulin to maintain glucose levels within a prescribed range.
89610940|NCT01839370|Placebo Comparator|Open Loop with Pramlintide|Insulin delivery will be controlled by the DiAs system running in Open Loop mode. Subjects will be permitted to administer correction boluses and set temporary temporary basal levels at any time during the admission, whether or not they are eating a scheduled meal. Subjects will inject Pramlintide 30 mcg prior to meal time.
89610941|NCT01839448||GD diagnosis before 24 weeks|"Patients in this group are diagnosed with gestational diabetes (GD) before 24 weeks of amenorrhea by means of a fasting blood glucose test >= 0.92 g/l.~Intervention: Post-partum oral glucose tolerance test"
89610942|NCT01839448||GD diagnosed at 24 to 28 weeks|"Patients in this group are diagnosed with gestational diabetes between 24 and 28 weeks of amenorrhea based on a normal fasting blood glucose level before 24 weeks of amenorrhea AND an abnormal oral glucose tolerance test between 24 and 28 weeks of amenorrhea.~Intervention: Post-partum oral glucose tolerance test"
89610943|NCT04380766||Pre-COVID|All patients with pancreatic cancer diagnosis before COVID-19 pandemic
89610944|NCT04380766||COVID|All patients with pancreatic cancer diagnosis during COVID-19 pandemic
88983449|NCT04532801|Experimental|kisspeptin-10|kisspeptin infusion
88983450|NCT04532801|Placebo Comparator|placebo|placebo
88983451|NCT04530344|Experimental|Cohort A : ruxolitinib cream|Participants who achieve complete or almost complete facial repigmentation (achieve ≥ F VASI90) at Week 52 in the parent study will be assigned to Cohort A and will be randomized 1:1 to ruxolitinib cream.
88983452|NCT04530344|Placebo Comparator|Cohort A : Vehicle|Participants who achieve complete or almost complete facial repigmentation (ie, achieve ≥ F VASI90) at Week 52 in the parent study will be assigned to Cohort A and will be randomized 1:1 to vehicle cream.
88983453|NCT04530344|Experimental|Cohort B : roxolitinib cream|Participants who did not achieve ≥ F-VASI90 at Week 52 of the parent studies will be assigned to Cohort B and will continue ruxolitinib cream.
88983454|NCT04528004|Experimental|Nicotinamide riboside|"Participants randomized to Nicotinamide Riboside (NR) and scheduled to receive an LVAD will receive nicotinamide riboside (NR) capsules according to the following administration schedule:~Dose Escalation Day 1: 250 mg (1 capsule) twice daily (total daily intake = 500 mg) Day 2: 500 mg (2 capsules) twice daily (total daily intake = 1000 mg) Day 3: 1000 mg (4 capsules) twice daily (total daily intake = 2000 mg) Dose Maintenance Day 4: 1000 mg (4 capsules) twice daily Day 5-14 as applicable thru Day Before Surgery: 1000 mg (4 capsules) twice daily Washout Day of LVAD Surgery and/or Day 15: None"
88983455|NCT04528004|Placebo Comparator|Placebo|"Participants randomized to Placebo and scheduled to receive an LVAD will receive Placebo capsules according to the following administration schedule:~Dose Escalation Day 1: 250 mg (1 capsule) twice daily (total daily intake = 500 mg) Day 2: 500 mg (2 capsules) twice daily (total daily intake = 1000 mg) Day 3: 1000 mg (4 capsules) twice daily (total daily intake = 2000 mg) Dose Maintenance Day 4: 1000 mg (4 capsules) twice daily Day 5-14 as applicable thru Day Before Surgery: 1000 mg (4 capsules) twice daily Washout Day of LVAD Surgery and/or Day 15: None"
88983456|NCT04500899|Experimental|Mydfrin|Phenylephrine is available as phenylephrine hydrochloride injection, 10 mg/mL in 1 mL vial. For intravascular bolus administration, the investigators will prepare a solution containing 100 mcg/mL of phenylephrine hydrochloride, by withdrawing 10 mg (1ml of 10mg/mL) of phenylephrine injection and diluting with 99 mL of 5% dextrose injection or 0.9% sodium chloride injection.
88983457|NCT04490525|Experimental|Intervention|The intervention group will participate in the telerehabilitation program (please see detailed description of telerehabilitation program and technologies). The two steps in the telerehabilitation program last up to six months depending on how fast the titration of medicine in step one will be conducted. The intervention group will spend 5-10 minutes every day on monitoring themselves. Every month, an online questionnaire has to be filled in which will take up to 5 minutes. At enrolment, after titration of medicine, and the end of rehabilitation, the patient will fill in an online questionnaire. This will take 5 minutes each time. Selected patients and relatives will be asked if they wish to participate in interviews after participation in the trial. Each interview will last less than one hour. Number of interviews will be decided when data saturation has been achieved.
88983458|NCT04490525|No Intervention|Control|The control group will follow a conventional rehabilitation program (Egstrup et al 2015). The control subjects will participate in medicine titration for 1- 3 months and conventional rehabilitation for 3 months. The participation in the control group will last up to six months. The exact period depends on how fast the titration of medicine is conducted. At enrolment, after titration of medicine, and end of rehabilitation, the patient will fill in a questionnaire. This will take 5 minutes each time.
89033889|NCT05835011|Experimental|Oral Decitabine/Cedazuridine + Magrolimab|Participants will receive 35 milligrams (mg) decitabine/100 mg cedazuridine as a fixed dose combination (FDC) tablet, orally, once daily (QD) on Days 1-5 of each 28-day cycle in combination with magrolimab, intravenous (IV) infusion of 1 milligrams per kilogram (mg/kg) on Days 1 and 4, 15 mg/kg on Day 8, 30 mg/kg on Days 11, 15, 22, 29, 36, 43, and 50, followed by a maintenance dose of 30 mg/kg on Day 57 and every 14 days thereafter until toxicity, progressive disease, withdrawal, death or end of study (approximately 44 months).
89033890|NCT05834569|Experimental|Maxigesic group|
89033891|NCT05834569|Placebo Comparator|Control group|
89033892|NCT05832164|Experimental|Multifactorial intervention|HIV patients
89610945|NCT04380532|Experimental|V-SARS recipients|Single arm having at least 20 volunteers administered once-per-day pill of V-SARS
89610946|NCT00906958|Experimental|Nexus Flow Generator|Participants were randomised to Nexus Flow Generator group for one night.
89033893|NCT05831683||Group A - Current state|In this group, ventilator parameters will be recorded before the SOP introduction. We will analyze PEEP, Pplat, driving pressure, VT/IBW, and the number and phase of recruitment maneuvers during general anesthesia.
89033894|NCT05831683||Group B - After SOP introduction|In this group, ventilator parameters will be collected after the SOP introduction. We will analyze PEEP, Pplat, driving pressure, VT/IBW, and the number and phase of recruitment maneuvers during general anesthesia.
89033895|NCT05825040|Experimental|Online guided transdiagnostic cognitive behavioral therapy|In the online guided transdiagnostic cognitive behavioral therapy group, participants will go through 8 modules with coach support in 8 weeks. They will complete 6 sets of questionnaires at the beginning of the study, at the 4th, 8th, and 16th weeks, and at 6 and 12 months after group allocation. All participants will be able to access all psychological interventions after they have completed the research.
89033896|NCT05825040|Experimental|Online self-guided transdiagnostic cognitive behavioral therapy|In the online self-guided transdiagnostic cognitive behavioral therapy group, participants will go through 8 modules without coach support in 8 weeks. They will complete 6 sets of questionnaires at the beginning of the study, at the 4th, 8th, and 16th weeks, and at 6 and 12 months after group allocation. All participants will be able to access all psychological interventions after they have completed the research.
89033897|NCT05825040|No Intervention|Waitlist control group|In the waitlist control group, participants are to refrain from using online psychological interventions until they finished the final questionnaire. They will complete 4 sets of questionnaires at the beginning of the study, at the 4th, 8th, and 16th weeks and at 6 and 12 months after group allocation. All participants will be able to access all psychological interventions after they have completed the research.
89033898|NCT05825040|Experimental|Online self-guided mindfulness-based intervention|In the online self-guided mindfulness-based intervention group, participants will go through 6 modules in 8 weeks without coach support. They will complete 6 sets of questionnaires at the beginning of the study, at the 4th, 8th, and 16th weeks, and at 6 and 12 months after group allocation. All participants will be able to access all psychological interventions after they have completed the research.
89057291|NCT04541615|Active Comparator|Group 3: Standard training group|The standard trained group will receive face-to-face lectures on how to perform the ORSI chicken anastomosis task. It will not differ from what they would normally receive during a traditional surgery training course when they arrive at the ORSI academy for their training. The content of the face-to face lecture is the same as in the e-learning courses. After the face-to face lecture, the participants have to perform the orsi chicken anastomosis task.
89610947|NCT00906958|Active Comparator|VPAP Flow Generator 25|Participants were randomised to VPAP Flow Generator 25 group for one night.
89610948|NCT01832116|Experimental|Tracerinjection|Injection of 89Zr-MMOT0530A followed by 2 or 3 PET scans at different time points
89610949|NCT01839526|Other|Glomerular Filtration Rate by Plasma Iohexol Clearance (iGFR)|Evaluations of renal and cardiac function
89610950|NCT03212872|Other|Endoscopy|
89610951|NCT01832194|Experimental|Botox|"Botox:~A concentrated dose of Onabotulinum Toxin A of 100 units dissolved in 2 cc of 2% xylocaine for a one-time injection."
89610952|NCT01832272|Experimental|Reinflation after early deflation|The tourniquet is released after cement implant fixation, and then reinflated, once arterial bleeding was controlled (Reinflation after early tourniquet deflation).
89610953|NCT01832272|No Intervention|No reinflation after early deflation|The tourniquet is released after cement implant fixation, and remained deflated without reinflation, even after hemostasis.
89610954|NCT01832428|Other|Transfer of autologous MNC intrathecally|Intra thecal transplantation of autologous stem cells 100 Millions per dose in 3 divided doses at interval of 7days.
89610955|NCT00907426|Experimental|Bimatoprost 0.03% Followed by Bimatoprost 0.03%|Treatment period one (0-6 months), once daily, one drop of Bimatoprost 0.03% solution using a single-use per eye applicator will be applied to the upper eyelid margin (where the eyelashes meet the skin). For treatment period two (6-12 months), once daily, one drop of Bimatoprost 0.03% solution using a single-use per eye applicator will be applied to the upper eyelid margin.
89610956|NCT00907426|Other|Bimatoprost 0.03% Followed by Vehicle|Treatment period one (0-6 months), once daily, one drop of Bimatoprost 0.03% solution using a single-use per eye applicator will be applied to the upper eyelid margin (where the eyelashes meet the skin). For treatment period two (6-12 months), once daily, one drop of vehicle solution using a single-use per eye applicator will be applied to the upper eyelid margin.
89610957|NCT00907426|Other|Vehicle Followed by Bimatoprost 0.03%|Treatment period one (0-6 months), once daily, one drop of vehicle solution using a single-use per eye applicator will be applied to the upper eyelid margin (where the eyelashes meet the skin). For treatment period two (6-12 months), once daily, one drop of Bimatoprost 0.03% solution using a single-use per eye applicator will be applied to the upper eyelid margin.
89610958|NCT01839760||Inpatient cohort|Patients admitted to general wards
89610959|NCT01839760||ICU cohort|Patients admitted to ICU
89610960|NCT01832662|Experimental|Coffee|4 cups/day of 2.5g of coffee each
89610961|NCT01832662|Active Comparator|coffee polyphenols mixed with placebo|4 cups/day of 2.5g of product each
89610962|NCT01832662|Placebo Comparator|maltodextrin enriched with caffeine|4 cups/day of 2.5g of product each
89610963|NCT00908830||Cystic fibrosis|Lung transplant patients with cystic fibrosis. Measuring MPA levels in cystic fibrosis lung transplant patients for pharmacokinetic parameters.
89610964|NCT00908830||Non-cystic fibrosis lung transplant|Non-cystic fibrosis lung transplant patients. Non-cystic fibrosis lung transplant patients will have MPA levels drawn after their dose to determine pharmacokinetic parameters.
89610965|NCT00908908|Experimental|1|
89610966|NCT00909064|Experimental|Arixtra|Effect of Arixtra on would drainage and length of stay for the patients with hip and knee replacement
89610967|NCT03837340|Experimental|FACT|Patients with SMI, receiving evidence-based interventions by the community mental health teams (CMHTs), inspired by the Flexible Assertive Community Treatment (FACT) service delivery model.
89610968|NCT03837340|Active Comparator|CAU (Care as usual)|Patients with SMI receiving usual care, meaning mostly medical treatment
89610969|NCT03212560||Newly diagnosed individuals|Newly diagnosed hematologic malignant patients included in the study. Inclusion and exclusion criteria were considered.
89610970|NCT03212560||Healthy individuals|Those without chronic disease were included in the study. Inclusion and exclusion criteria were considered.
89610971|NCT01832896|Experimental|Ecallantide|"Study Medication, Dose, and Mode of Administration:~Single dose of ecallantide subcutaneous dosing:~Age less than 10: Weight <25 Kg: 10mg subcutaneously at one site; 25-50kg: 20mg subcutaneously, 10mg per site for 2 separate sites; >50 kg 30mg subcutaneously, 10mg per site for 3 separate sites. Dosing will not exceed 30mg.~Age greater than 10: 10mg per site for 3 separate sites. Dosing will not exceed 30mg."
89610972|NCT03212014|Experimental|LSVT-BIG|Participants in this group would be treated with LSVT-BIG for three months
89610973|NCT03212014|Experimental|POWER|Participants in this group would be treated with POWER for three months
89610974|NCT03212014|Active Comparator|Traditional rehabilitation|Participants in this group would be treated with traditional exercise rehabilitation for three months
88983459|NCT04485039|Other|ABCDE|"Single oral dose of TPOXX 600 mg~Single oral dose of TPOXX 600 mg co-administered with single oral dose of 1600 mg sevelamer carbonate~Single oral dose of TPOXX 600 mg co-administered with single oral dose of 500 mg sucroferric oxyhydroxide chewable tablet~Single oral dose of TPOXX 600 mg co-administered with a single oral dose of 1334 mg calcium acetate~Single oral dose of TPOXX 600 mg co-administered with a single oral dose of 500 mg lanthanum carbonate chewable tablet."
88983460|NCT04485039|Other|ACEBD|"Single oral dose of TPOXX 600 mg~Single oral dose of TPOXX 600 mg co-administered with single oral dose of 500 mg sucroferric oxyhydroxide chewable tablet~Single oral dose of TPOXX 600 mg co-administered with a single oral dose of 500 mg lanthanum carbonate chewable tablet~Single oral dose of TPOXX 600 mg co-administered with single oral dose of 1600 mg sevelamer carbonate~Single oral dose of TPOXX 600 mg co-administered with a single oral dose of 1334 mg calcium acetate"
88983461|NCT04485039|Other|ADBEC|"Single oral dose of TPOXX 600 mg~Single oral dose of TPOXX 600 mg co-administered with a single oral dose of 1334 mg calcium acetate~Single oral dose of TPOXX 600 mg co-administered with single oral dose of 1600 mg sevelamer carbonate~Single oral dose of TPOXX 600 mg co-administered with a single oral dose of 500 mg lanthanum carbonate chewable tablet~Single oral dose of TPOXX 600 mg co-administered with single oral dose of 500 mg sucroferric oxyhydroxide chewable tablet"
88983462|NCT04485039|Other|AEDCB|"Single oral dose of TPOXX 600 mg~Single oral dose of TPOXX 600 mg coadministered with a single oral dose of 500 mg lanthanum carbonate chewable tablet.~Single oral dose of TPOXX 600 mg coadministered with a single oral dose of 1334 mg calcium acetate~Single oral dose of TPOXX 600 mg coadministered with single oral dose of 500 mg sucroferric oxyhydroxide chewable tablet~Single oral dose of TPOXX 600 mg coadministered with single oral dose of 1600 mg sevelamer carbonate"
88983463|NCT04463576||Experimental|A total of 5 676 hospital discharge prescriptions, defined as the list of medications prescribed at discharge from hospital or after a hospital visit, whether new or renewed, will be selected.
88983464|NCT04428671|Experimental|Treatment (cemiplimab)|"NEOADJUVANT PHASE: Prior to standard of care surgery, patients receive cemiplimab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.~ADJUVANT PHASE: Within 2-6 weeks after standard of care radiation therapy (or surgery if no radiation therapy), patients receive cemiplimab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 18 cycles in the absence of disease progression or unacceptable toxicity."
88983465|NCT04413890|Active Comparator|Classical administration|One prostaglandin vaginal gel every 24 hours
88983466|NCT04413890|Experimental|Experimental administration|One prostaglandin vaginal gel every 12 hours
88983467|NCT04404894||Prolaris tested patients with Prostate Cancer|Recently diagnosed patients with histologically proven, localized adenocarcinoma of prostate determined via transrectal ultrasonography and biopsy of at least 10 prostate sites who have undergone Prolaris testing.
88983468|NCT04374968|Experimental|BFR Treatment|Patients will be recruited following ACL tear and medical screening for history of DVT/PE. Patients allocated to the BFR intervention group will undergo physical therapy with the use of a blood flow restriction cuff. Rehabilitation will consist of a structured home exercise program prior to surgery. We will instruct patients on how to perform home BFR and test them in the office to ensure competence. Following surgery patients will immediately be started in physical therapy. Therapy will consist of a structured program progressing from range of motion, to strength training and then functional tests. Both arms will use the same protocol with the only difference being use of BFR.
88983469|NCT04374968|No Intervention|Control|The control arm will undergo the same pre and post operative physical therapy as the BFR group. They will undergo a structure home therapy program prior to surgery and an outpatient physical therapy program under the guidance of a therapist following surgery.
88983470|NCT04368897||COVID-19 Male Patients|Males with laboratory confirmed SARS-CoV-2 infection
88983471|NCT04322461|Experimental|Parkinson disease|2 months intervention with 50g/day of a commercial MCT supplement combine with supervised aerobic exercise 3x/week.
89610975|NCT03211780|Experimental|Ultrasound|
89610976|NCT03211936|Active Comparator|PEEP 4|"We titrate peep, using tomography impedance, making ultrasound after level by level' of peep. After titrated peep we setup peep 4 and maintained during the procedure.~PEEP 4 cmH2O~Use ultrasound"
89610977|NCT03211936|Experimental|PEEP TITRATED|"We titrate peep, using tomography impedance, making ultrasound after level by level' of peep. After tritiated peep we setup the best peep for less collapse (using the tomography of electrical impedance) and maintained during the procedure.~PEEP titrated~Use ultrasound~Impedance tomography~Best PEEP for less collapse"
89610978|NCT01830400||Eslicarbazepine Acetate tablets|
89610979|NCT01830478|Experimental|Lenalidomide and Rituximab|Lenalidomide 20 mg once daily on days 1-21 of 28 days cycle for up to 6 courses and Rituximab 375 mg/m2 at day 14 of every course.
89610980|NCT01833442|Active Comparator|Kundalini Yoga Meditation|Kundalini Yoga Meditation is going to be use as therapy for OCD, and it will be compare with Relaxation Response Meditation.
89610981|NCT01833442|Active Comparator|Relaxation Response Meditation|Relaxation Response Meditation is going to be use as therapy for OCD, and it will be compare with Kundalini Yoga Meditation.
89610982|NCT01835782|Active Comparator|2.5 grams BID|5 Patients will be evenly randomized into this group
89610983|NCT01835782|Active Comparator|.5 grams BID|5 Patients will be evenly randomized into this group
89610984|NCT01835782|Active Comparator|7.5 grams BID|5 Patients will be evenly randomized into this group
89610985|NCT01835782|Active Comparator|15 grams BID|5 Patients will be evenly randomized into this group
89610986|NCT01836718||HCV RNA (-) on anti-viral therapy|Patients undergoing liver transplantation who are documented HCV viral load undetectable while on antiviral therapy
89610987|NCT01836718||HCV RNA (+) on anti-viral therapy|Patients undergoing liver transplantation who are receiving anti-viral therapy and who have a documented detectable HCV viral load
89610988|NCT01836718||HCV RNA (+) not on anti-viral therapy|Patients undergoing liver transplantation who are not currently receiving anti-viral therapy and are documented viral load positive will be included and serve as a comparison group
89610989|NCT00909220||Current Major Depressive Disorder|Forty-one participants with a primary diagnosis of major depression using the Diagnostic and Statistical Manual of Mental Disorders (4th ed.; DSM-IV) and scores > 24 on the Inventory of Depressive Symptomatology-Clinician Rated (IDS-C; Rush et al., 1986) were enrolled into a treatment study at Northwestern University's Feinberg School of Medicine in Chicago, Illinois. This group will receive Behavioral Activation psychotherapy.
89610990|NCT00909220||Healthy Participants|Another 36 participants with no lifetime psychiatric symptoms and scores < 11 on the IDS-C were tracked prospectively, naturalistically, for 16 weeks.
89610991|NCT04426695|Experimental|On Low-Flow Oxygen|Cohort 1 (C1): O2 saturation >93% on low-flow oxygen via nasal cannula, simple face mask, or other similar device
88983472|NCT04322461|Experimental|Alzheimer's disease|2 months intervention with 50g/day of a commercial MCT supplement combine with supervised aerobic exercise 3x/week.
88983473|NCT04316624|Experimental|C-CAR066|Autologous C-CAR066 (CD20-directed CAR T-cell) administered by intravenous (IV) infusion
88983474|NCT04313790|Experimental|Heparin Infusion|heparin infusion 500unit \hour
88983475|NCT04313790|Other|Subcutaneus Heparin|subcutaneous heparin 5000unit \ 8 hours
88983476|NCT04304404|Experimental|Intervention group (BrCaRRP)|Individual interventions based on the Health Belief Model and the The Health Promotion Model involving education, guidance, counseling, case management and surveillance for women with high breast cancer risk
88983477|NCT04304404|No Intervention|Control Group|An information note will be given to the control group. The post-tests will be collected at the end of 12 weeks
88983478|NCT04302844|Active Comparator|Imago Relationship Therapy (IRT)|Couples will receive 12 to 16 Imago relationship therapy sessions (90 minutes each; one session per week) with an experienced and certified Imago Relationship therapist.
88983479|NCT04302844|Active Comparator|Waitlist with Bibliotherapy followed by Workshop|Couples will be asked to wait for 12 weeks before receiving any intervention, and will be given a relationship-focused self-help book to read during that time. After 12 weeks and the 12-week assessment has been completed, couples will receive a Getting the Love You Want workshop.
88983480|NCT04293393|Active Comparator|Arm A: Doxorubicin plus cyclophosphamide and taxane|"Doxorubicin 60mg/m2 and cyclophosphamide 600mg/m2 (AC) every 21 days for 4 cycles followed by weekly paclitaxel 80mg/m2 for 12 weeks or 3-weekly docetaxel 100mg/m2 for 4 cycles.~Approximately duration of 24 weeks (6 months)."
88983481|NCT04293393|Experimental|Arm B: Letrozole plus abemaciclib +/- LHRH|Letrozole 2.5mg orally daily + abemaciclib 150mg orally every 12 hours on a continuous dosing schedule, +/- luteinizing hormone-releasing hormone (LHRH) analogs in premenopausal women, up to 12 months, in 28-day cycles.
88983482|NCT04276480|Experimental|Intervention|The patients included will receive piperacillin-tazobactam as empirical antimicrobial therapy. The empirical microbial therapy will continue until the bacterial susceptibility profile is known.
88983483|NCT04263896|Experimental|Participants receiving pre-operative laxative|Participants will receive 10 doses, 17g each, of polyethylene glycol 3350. They will be instructed to take 1 dose/packet each day for 10 days leading up to their surgery.
88983484|NCT04263896|No Intervention|Participants not receiving pre-operative laxative|Participants will not be given any laxatives.
88983485|NCT04253522|Experimental|Arm 1 (early phase B)|3 phases of cognitive training: Phase A1: rehabilitation program in standard ergotherapy during 3 weeks Phase B: cognitive training using Covirtua software and Transcranial random noise stimulation during 4 weeks Phase A2: return to the standard rehabilitation program in standard ergotherapy during 5 weeks
88983486|NCT04253522|Experimental|Arm 2 (mid phase B)|3 phases of cognitive training: Phase A1: rehabilitation program in standard ergotherapy during 4 weeks Phase B: cognitive training using Covirtua software and Transcranial random noise stimulation during 4 weeks Phase A2: return to the standard rehabilitation program in standard ergotherapy during 4 weeks
88983487|NCT04253522|Experimental|Arm 3 (late phase B)|3 phases of cognitive training: Phase A1: rehabilitation program in standard ergotherapy during 5 weeks Phase B: cognitive training using Covirtua software and Transcranial random noise stimulation during 4 weeks Phase A2: return to the standard rehabilitation program in standard ergotherapy during 3 weeks
88983488|NCT04236817|Experimental|Pre-packed blisters for distribution of medications|Patients in the intervention group received prescriptions pre-packaged in individual packets that were delivered by the pharmacy.
88983489|NCT04236817|Placebo Comparator|Routine distribution of medications|Patients in the control group continued to receive medications from pharmacies as they did prior to enrollment.
88983490|NCT04233853|Experimental|CoLiPri intervention|General practitioners and their screened patients have access to the consultation-liaison services for a total duration of 12 months, including standard screening, expert consultations, on demand patient referral for structured mental health diagnostics, psychoeducation and treatment planning, as well as brief psychotherapeutic intervention and triage.
89610992|NCT04426695|Experimental|With COVID-19 symptoms but not requiring supplemental O2|Cohort 1A (C1A): With COVID-19 symptoms but not requiring supplemental oxygen
89610993|NCT04426695|Experimental|High O2 No Mechanical Ventilation|Cohort 2 (C2): On high-intensity oxygen (O2) therapy but not on mechanical ventilation
88983491|NCT04233853|Active Comparator|Usual primary care enhanced|Usual primary care practice as offered in routine care. Enhanced means that practitioners receive a basic training which consists of guideline-based structured screening procedures for depression and anxiety mental disorders in primary care.
88983492|NCT04181307|No Intervention|standard EPIC instantiation|As per standard procedure at NewYorkUniversity Langone Health
88983493|NCT04181307|Experimental|standard EPIC instantiation plus the BE-EHR module.|The BE-EHR module includes six components: 1) a tailored advisory for patients over 75 with diabetes, 2) medication refill protocol with information on Choosing Wisely guidelines, 3) pre-population of the medication preference list with metformin, 4) lab result protocol with information on Choosing Wisely guidelines, 5) peer comparisons regarding performance meeting guidelines, and 6) media campaign with information about Choosing Wisely guidelines. The set of nudges is referred to collectively as the BE-EHR module.
88983494|NCT04153487|Experimental|ASTRALI Group|ASTRALI (AScorbic acid in TRALI) group (n=40)
88983495|NCT04153487|Placebo Comparator|Control Group|Control group (n=40)
88983496|NCT04153032|Experimental|DTZ arm|The first group of patients will apply MEBO ointment peri-anally 3 times daily for 6 weeks.
88983497|NCT04153032|Experimental|MEBO arm|The second group of patients will apply topical DTZ ointment peri-anally 3 times daily for 6 weeks.
88983498|NCT04153032|Experimental|MEBO and DTZ arm|The third group will apply a combination of MEBO and DTZ ointment peri-anally 3 times daily for 6 weeks. Those who fail therapy (meaning they report no pain improvement after two weeks of treatment) from either the MEBO or the Diltiazem arm will be switched to the combination arm. If they also fail to improve after two weeks on the treatment arm, then they will be offered surgery. If the patient refuses to switch to the combination arm and wishes to proceed to surgery immediately, then the patient will be directed to surgery.
88983499|NCT04140838|Experimental|TAU + Acceptance and Commitment Therapy (ACT)|This therapy is based, as the name implies, on the acceptance (not avoidance) of negative experiences as a coping strategy, and on committing to life values or objectives. ACT has been used for various conditions, including chronic pain. Since avoidance is a strategy frequently used by patients suffering from pain, the application of this therapy seems very appropriate. In fact, it has been proven that patients who accept their pain more are those who score lower in pain intensity, have less negative emotions and enjoy a better quality of life.
88983500|NCT04140838|Experimental|TAU + Behavioral Activation Therapy for Depression (BATD)|Behavioural and structured treatment based on the application of learning principles. Its objective is to counteract depressive symptoms and, as a consequence, to ensure that patients regain a productive and emotionally satisfying life. Its basic methodology consists in activating subjects with depression through programming and conduct of behaviours that are likely to increase the positive reinforcement of their context.
88983501|NCT04140838|Active Comparator|Treatment as Usual (TAU)|Standard Care. Although there is no treatment considered as the gold standard for chronic pain and comorbid major depression, the standard treatment is usually mainly pharmacological and conforms to the symptomatic profile of each patient.
88983502|NCT04140604|Experimental|Lactobacillus salivarius AP-32|A 0.5 g light-yellow capsule containing freeze-dried powder of 2.5 billion CFU of Lactobacillus salivarius AP-32 and maltodextrin.
88983503|NCT04140604|Experimental|Bifidobacterium animalis subsp. lactis CP-9|A 0.5 g light-yellow capsule containing freeze-dried powder of 2.5 billion CFU of Bifidobacterium animalis subsp. lactis CP-9 and maltodextrin.
88983504|NCT04140604|Placebo Comparator|Placebo|The placebo composition and appearance are the same as probiotic capsules, but does not contain live bacteria.
88983505|NCT04132375|Active Comparator|Stage 1 - high treatment arm|Subjects will receive a 1st intravenous dose of 4 mg/kg INM004 (Anti-Stx hyperimmune equine immunoglobulin F[ab']2 fragments) and a 2nd intravenous dose of 4 mg/kg of INM004. Each dose will be separated by 24 h (± 2 h).
88983506|NCT04132375|Active Comparator|Stage 1 - Low treatment arm|Subjects will receive a 1st intravenous dose of 4 mg/kg INM004 (Anti-Stx hyperimmune equine immunoglobulin F[ab']2 fragments) and a 2nd intravenous dose of Placebo. Each dose will be separated by 24 h (± 2 h).
88983507|NCT04132375|Placebo Comparator|Stage 1 - Placebo arm|Subjects will receive a 1st intravenous dose of Placebo and a 2nd intravenous dose of Placebo. Each dose will be separated by 24 h (± 2 h).
88983508|NCT04132375|Active Comparator|Stage 2 - Selected active treatment arm|"In the case, the high treatment regime is selected, subjects will receive a 1st intravenous dose of 4 mg/kg INM004 and a 2nd intravenous dose of 4 mg/kg of INM004. Each dose will be separated by 24 h (± 2 h).~In the case, the low treatment regime is selected subjects will receive an intravenous dose of 4 mg/kg INM004"
88983509|NCT04132375|Active Comparator|Stage 2 - Placebo arm|"In the case, the high treatment regime is selected, subjects will receive a 1st intravenous dose of Placebo and a 2nd intravenous dose of Placebo, each dose separated by 24 h (± 2 h)~In the case, low treatment regime is selected subjects will receive a single intravenous dose of Placebo"
88983510|NCT04130867||Group A: Swallow Therapy Oropharyngeal Strengthening|"Participants receiving any standard of care swallow therapy with oropharyngeal strengthening as the primary goal~Participants will undergo pHRM, videofluoroscopy (VF), diet assessment, functional reserve tests, and patient--reported outcome questionnaires at 3 standardized time points: baseline, 4 to 6 weeks (mid therapy), and 10 to -12 weeks (post -therapy)"
88983511|NCT04130867||Group B: Surgical Treatment Esophageal Sphincter|"Participants receiving surgical treatment for relief of upper esophageal sphincter outlet obstruction.~Participants will undergo pHRM, videofluoroscopy (VF), diet assessment, functional reserve tests, and patient--reported outcome questionnaires at 3 standardized time points: baseline, 4 to 6 weeks (mid therapy), and 10 to -12 weeks (post therapy)"
89610994|NCT04426695|Experimental|On Mechanical Ventilation|Cohort 3 (C3): On mechanical ventilation
89610995|NCT01838200|Experimental|Cohort 1, Group 1 (BCG 0.16-0.64 × 10^6 CFU)|Patients with an induration <10 mm in diameter after the baseline PPD reactivity test received BCG (IL) on Day 1, followed by isoniazid (orally, daily) starting 28 days after the BCG injection and continuing for 4 weeks, and ipilimumab (IV) administered every 3 weeks starting 5 weeks after the BCG injection and continuing for a total of 4 doses.
89033899|NCT05820347|Other|Artificial Intelligence Estimation of Muscle Pressure during Mechanical Ventilation|All included subjects will be monitored simultaneously with the esophageal balloon (gold standard) and with the artificial intelligence algorithm integrated in the mechanical ventilator. Electrical Impedance Tomography will be used to monitor ventilatory patterns during different degrees of spontaneous effort. First, a single intravenous bolus of neuromuscular blockade (succinylcholine 1mg/kg or rocuronium 1.2mg/kg) will be performed to measure respiratory system mechanics (compliance and resistance). In cases where rocuronium is used, a single dose of sugammadex 4mg/kg will be administered intravenously to reverse neuromuscular blockade after measuring compliance and resistance. After initiation of spontaneous breathing effort, pressure support will be titrated from 20 cmH2O to 2 cmH2O, in decremental steps during 20 minutes each. After completing titrating of pressure support, the esophageal balloon will be removed.
89033900|NCT05819710|Experimental|5 mg of TS-142|Low dose of TS-142
89033901|NCT05819710|Experimental|10 mg of TS-142|High dose of TS-142
89033902|NCT05819710|Experimental|7.5 mg of Zopiclone|Comparator.
89033903|NCT05819710|Experimental|Placebo|Placebo.
89033904|NCT05816551||Younger participants|Individuals aged 18-39 years
89033905|NCT05816551||Older participants|Individuals aged over 65 years
89033906|NCT05815875|Experimental|Intervention|The STEADI program will be applied to this group of participants. The STEADI involves frequent assessment of patients' risk for falls and making appropriate changes to decrease the risk for falls.
89033907|NCT05815875|Active Comparator|Control|The STEADI program will not be applied to the control group participants. This group will receive the usual care provided to the patients in the hospital.
89033908|NCT05805735|Experimental|Face care product (Eye cream)|Comparison between assessment times. Assessments will be performed before, after 2, 4 and 8 weeks of product application.
89033909|NCT05804318|Experimental|Adaptive SBRT with Urethral Sparing|Daily adaptive stereotactic body radiation therapy delivering 40 Gy in 5 fractions to the prostate while delivery 35-36 Gy in 5 fractions to the urethra.
89033910|NCT05799287|Experimental|Telitacicept|Subjects will be given Telitacicept 240 mg SC once a week in phase A for a total of 39 doses and once every 2 weeks in phase B for a total of 32 doses.
88815360|NCT00995072|Experimental|Arm B|Metoprolol succinate 100 mg daily for 12 weeks followed by nebivolol 5 mg daily for 12 weeks. A two week washout (no medication) is completed prior to switching to nebivolol.
89033911|NCT05799287|Placebo Comparator|Placebo|Subjects will be given placebo SC once a week in phase A for a total of 39 doses and once every 2 weeks in phase B for a total of 32 doses.
89033912|NCT05789043|Experimental|Three-drug arm|
89033913|NCT05789043|Active Comparator|Two-drug arm|
89033914|NCT05789043|Active Comparator|single-drug arm|
89033915|NCT05784051|Experimental|Experimental group|Patients treated for PVCs with drug therapy and/or catheter ablation/ medical treatment including drug administration ± catheter ablation (Ablation can be performed if the PVC burden remain >10% after 2 lines of AAD treatment).
89033916|NCT05784051|Active Comparator|Control group|Patients with therapeutic abstention or no treatment modification such as drug therapy/ Therapeutic abstention or no modification of therapy
89033917|NCT05783791||Participants with Angelman Syndrome (AS)|AS confirmed by molecular testing
89610996|NCT01838200|Experimental|Cohort 1, Group 2 (BCG 0.8-3.2 × 10^6 CFU)|Patients with an induration <10 mm in diameter after the baseline PPD reactivity test received BCG (IL) on Day 1, followed by isoniazid (orally, daily) starting 28 days after the BCG injection and continuing for 4 weeks, and ipilimumab (IV) administered every 3 weeks starting 5 weeks after the BCG injection and continuing for a total of 4 doses.
89610997|NCT01838200|Experimental|Cohort 1, Group 3 (BCG 4.0-16.0 × 10^6 CFU)|Patients with an induration <10 mm in diameter after the baseline PPD reactivity test were to receive BCG (IL) on Day 1, followed by isoniazid (orally, daily) starting 28 days after the BCG injection and continuing for 4 weeks, and ipilimumab (IV) administered every 3 weeks starting 5 weeks after the BCG injection and continuing for a total of 4 doses.
88815361|NCT01030406|Active Comparator|40/0mg taken first|8x oxycodone/niacin 5/0mg tablets
89033918|NCT05783791||Participants with Prader-Willi Syndrome (PWS)|PWS confirmed by molecular testing
89033919|NCT05783791||Healthy Controls|
89033920|NCT05781334|Active Comparator|Virtual Consult Intervention|The intervention will consist of a quality improvement (QI)-based virtual consult designed by a multi-disciplinary team that will aim to address provider-level, patient-level, and system-level barriers to cardio-renal-metabolic disease medications.
89033921|NCT05781334|No Intervention|Usual Care|Usual care
89033922|NCT05775926|Experimental|Experimental|Experimental Group: Nurses who met the criteria for participating in the study were informed about the study and their consent was obtained. Data collection forms were collected by the researcher at the end of the working hours. Training groups were formed on the days and times determined according to the interviews with the clinics where the research was conducted. In each hospital, training groups were formed outside the working hours of the nurses. The training was given to the nurses in the intervention group in an environment suitable for training in two days and 4 modules using interactive teaching methods. After the training, a month was waited for the nurses in the intervention group to experience care. One month after the training was given, data collection forms were distributed to the nurses in the intervention group and asked to fill in according to their self-reports.
89057292|NCT04541615|Active Comparator|Group 4: Apprenticeship Group|The apprenticeship trained group will not receive face-to-face lectures or e-learning on how to perform the ORSI chicken anastomosis task. They will however receive hands-on practical one-to-one training during a traditional surgical training course, with deliberate practice. During this course, clinicians will train the participants on how to perform the orsi anastomosis task. They will also receive published materials describing how best to perform the task and mentoring on suturing and knot tying by a task expert who will guide their performance.
89610998|NCT01838200|Experimental|Cohort 2 (BCG 0.16-0.64 × 10^6 CFU)|Patients with an induration ≥10 mm in diameter after the baseline PPD reactivity test were to receive BCG (IL) on Day 1, followed by isoniazid (orally, daily) starting 28 days after the BCG injection and continuing for 4 weeks, and ipilimumab (IV) administered every 3 weeks starting 5 weeks after the BCG injection and continuing for a total of 4 doses.
89610999|NCT01833754|Experimental|Group 1: Stage 4 Renal Impairment|Participants with stage 4 renal impairment (defined as an estimated glomerular filtration rate [eGFR] 15 to 29 mL/min/1.73 m²) received a single subcutaneous injection of 210 mg romosozumab on day 1.
89611000|NCT01833754|Experimental|Group 2: ESRD Requiring Hemodialysis|Participants with end stage renal disease (ESRD) requiring hemodialysis received a single subcutaneous injection of 210 mg romosozumab on day 1.
89611001|NCT01833754|Experimental|Group 3: Healthy Participants|Healthy participants (eGFR ≥ 80 mL/min/1.73 m²) received a single subcutaneous injection of 210 mg romosozumab on day 1.
89611002|NCT01720030|Placebo Comparator|Conventional therapy|Standard of care as protocolized locally
89611003|NCT01720030|Experimental|Levosimendan|The experimental group receives standard treatment supplemented by levosimendan (0.2 µg/kg/min) for 24 hours within 36 hrs following onset of AKI.
89611004|NCT01720108|Active Comparator|rivaroxaban|rivaroxaban 10mg x 9 days for total knee arthroplasty patients; x 30 days for total hip athroplasty patients
89611005|NCT01720108|Experimental|ASA|ASA 81mg x 9 days for total knee arthroplasty patients; x 30 days for total hip athroplasty patients
89611006|NCT01720186|Experimental|SPI Medical device|SPI medical device used during PET/CT 4D imaging in a synchronized mode centered on the thorax.
88983512|NCT04130867||Group C: Healthy Controls|Healthy controls (n=50) will also undergo data collection at parallel time points, without completion of a treatment paradigm.
88815362|NCT01030406|Active Comparator|80/0mg taken first|8x oxycodone/niacin 10/0mg tablets
88815363|NCT01030406|Experimental|40/240mg taken first|8x oxycodone/niacin 5/30mg tablets
88815364|NCT01030406|Experimental|80/480mg taken first|8x oxycodone/niacin 10/60mg tablets
89611007|NCT01720186|Active Comparator|reference medical device : RPM|Reference medical device (RPM) used simultaneously during PET/CT 4D imaging in a synchronized mode centered on the thorax.
89611008|NCT03211468|Experimental|Intervention Program|Clinical intervention designed to prevent eating disorders and promote healthy eating habits and body image among female adolescent athletes. The intervention program will include 10 45-min interactive sessions led by the researcher. Each session will include a brief theoretical background, experiential activities (artistic or cognitive / emotional) and group discussions.
89611009|NCT03211468|No Intervention|Control Group|No participation in intervention program.
89611010|NCT04380220||Relapsing MS patients|Patients diagnosed with relapsing-remitting multiple sclerosis and in relapse, untreated or treated with only immunomodulatory therapy.
89611011|NCT04380220||Remitting MS patients|Patients diagnosed with relapsing-remitting multiple sclerosis and in remission, untreated or treated with only immunomodulatory therapy.
89611012|NCT04380220||Healthy controls|Age- and sex-matched healthy control subjects.
89611013|NCT01832974|Other|Part 1- 1 μg/kg|Up to 6 participants receiving IL-13-PE 1 μg/kg (rounded down to the nearest vial size within 10% of the calculated dose), intravenous (IV), Days 1, 3 and 5 in each monthly cycle for up to 4 cycles
89611014|NCT01832974|Other|Part 1 - 2 μg/kg|If lower dose was tolerated, 3-6 participants receiving IL-13-PE 2 μg/kg (rounded down to the nearest vial size within 10% of the calculated dose), intravenous (IV), Days 1, 3 and 5 in each monthly cycle for up to 4 cycles
89611015|NCT01832974|Other|Part 1 - 3 μg/kg|If lower dose was tolerated, 3-6 participants receiving IL-13-PE 3 μg/kg (rounded down to the nearest vial size within 10% of the calculated dose), intravenous (IV), Days 1, 3 and 5 in each monthly cycle for up to 4 cycles
89611016|NCT01832974|Experimental|Part 2 - All Participants|All participants in Part 2, receiving maximum tolerated dose of IL-13-PE 1-3 μg/kg (rounded down to the nearest vial size within 10% of the calculated dose), intravenous (IV), 3 times per monthly cycle for up to 4 cycles (or longer for participants receiving clinical benefit)
89611017|NCT01671735|Experimental|VA DPP|Pre-Diabetic Participants eligible for VA DPP receive a curriculum based life-style intervention program tailored off of the original DPP but in a group format
89611018|NCT01671735|No Intervention|VA DPP-eligible MOVE!|Pre-Diabetic participants who screen and are eligible for VA DPP but bc of class being filled - have been assigned to MOVE!
89611019|NCT03211312||older people with cardiac diseases|undergoing teeth extraction surgery
89611020|NCT01720342||Aortic valve stenosis, aortic valve insufficiency|Patients with aortic valve insufficiency and/or aortic valve stenosis who require AVR.
89611021|NCT01671813|Experimental|Brentuximab vedotin Treatment|Participants will have screening tests up to 4 weeks before study treatment and dosing for up to 48 weeks. Brentuximab vedotin will be given with a dose of 1.8 mg (per kilogram of participant's body weight) intravenously (an IV through their vein) every 21 days, over 30 minutes for 16 cycles. Follow-up assessments will be performed up to 104 weeks (2 years).
89611022|NCT03836404|Experimental|Iliac Crest reconstruction surgery|The patients in the study group will be surgically treated and the GreenBone bone substitute will be implanted
89611023|NCT03021291|Experimental|Gelesis100|Gelesis100 (2.25 g) twice daily
89611024|NCT01833052|Other|Cerebral Protection Filter|Patient is treated with Cerebral protection Filter.
89611025|NCT01833052|Other|No Cerebral Protection Filter|Patient is not treated with Cerebral protection Filter.
89611026|NCT03835858|Other|Respiratory physiotherapy|The protocol consists of 20 minutes of FR based on nasal washes in sitting, prolonged slow expiration: passive technique of expiratory help applied to the baby through a slow thoracic-abdominal pressure that begins at the end of a spontaneous expiration and continuing to the residual volume. The physiotherapist through the the provoked cough or stimulation of the trachea achieves the expectoration of the sputum.
89611027|NCT01671969|Experimental|very low calorie diet|
89611028|NCT03211078|Experimental|super-D ENB guided-PDT|To test the feasibility of super-D ENB guided-PDT to treat small lung cancer which cannot be eradicated through surgical resection.
89611029|NCT01833208|Experimental|Treatment (radiation therapy)|Patients undergo single-fraction radiation therapy to at least 1 bone lesion 2 days after the first sipuleucel-T dose.
89611030|NCT03210922|Experimental|Collar group|Standard of anesthetic care and nasointubation with patient wearing the Miami cervical collar.
89611031|NCT03210922|No Intervention|Non-collar group|Standard of anesthetic care and nasointubation with patient not wearing the Miami cervical collar.
89033923|NCT05775926|No Intervention|Control|Control Group: Nurses who met the criteria for participating in the study were informed about the study and their consent was obtained. Data collection forms were collected by the researcher at the end of the working hours. No training was given to the control group. However, after the post-test application was made to the control group, the same training was given to the experimental group. One month later, data collection forms were distributed to the nurses in the control group and they were asked to fill in according to their self-reports. Data collection forms were collected by the researcher at the end of the working hours. Filling in the data takes about 15 minutes.
89033924|NCT05764720|Experimental|Daily Adaptive External Beam Radiation Therapy|Daily adaptive radiation therapy delivered with Varian Ethos treatment system
89033925|NCT05760937|Experimental|BMS-986447|
89033926|NCT05760937|Placebo Comparator|Placebo|
89033927|NCT05758805|Experimental|Unique Arm|patients with atrial fibrillation and indication for radiofrequency ablation guided by electro-anatomical mapping with high-density mapping catheter and radiofrequency ablation by contact force ablation catheter, according to current guidelines
89033928|NCT05758766|No Intervention|Regular diet|Participants will continue their regular diet.
89033929|NCT05758766|Experimental|Plant based omega 3 Fatty Acid|Participants ingest their regular diet supplemented with a plant-based omega-3-FA
89033930|NCT05755308|Experimental|Faecal microbiota transplantation|
89033931|NCT05755308|Placebo Comparator|Placebo arm|
89033932|NCT05743010|Experimental|APL-1401|On Day 1, patients will be randomized to receive either APL-1401 or placebo in a 5:1 ratio. Patients will receive APL-1401 orally once daily (QD) during the 28-day treatment period.
89033933|NCT05743010|Placebo Comparator|Placebo|Identically matching placebo capsules once daily for 28 days
89033934|NCT05742633|Experimental|Group A|Group A received Active release technique (ART)
89033935|NCT05742633|Other|Group B|Group B received self-myofascial release (SMFR)
89033936|NCT05741138|Experimental|Core strengthening group|Group A were given the Standard Physical Therapy Treatment along with core strengthening exercises Core strengthening exercises were carried out in their respective standard positions (were modified according to patient's comfortability)
89611032|NCT03830398|Active Comparator|Paracetamol|Parol group: intravenous infusion in 30 min Generic name: Parol Dosage form: intravenous Dosage: 1 gr Frequency: preop one dose only Duration: For one week
89611033|NCT03830398|Active Comparator|Deksketoprofen trometamol|Sertofen group: intravenous infusion in 30 min Generic name: Sertofen Dosage form: intravenous Dosage: 50 mg Frequency: preop one dose only Duration: For one week
89611034|NCT03830398|Placebo Comparator|Placebo|Placebo group: intravenous infusion in 30 min Generic name: Serum physiologic Dosage form: intravenous Dosage: 100 ml Frequency: preop one dose only Duration: For one week
89611035|NCT04405323|Experimental|Lu AG06466 - Sequence 1|Dosing on Days 1 and 8 will be following an overnight fast, and dosing on Days 3 and 10 will be following a standard high-fat breakfast.
89611036|NCT04405323|Experimental|Lu AG06466 - Sequence 2|Dosing on Days 1 and 8 will be following, a standard high-fat breakfast and dosing on Days 3 and 10 will be following an overnight fast.
89033937|NCT05741138|Sham Comparator|Conventional treatment group|Group B were given only Standard Physical Therapy treatment.
89033938|NCT05739201|Active Comparator|Group (I)|30 patients will receive interscalene nerve block.
89033939|NCT05739201|Active Comparator|Group (II)|30 Patients will receive anterior suprascapular nerve block.
89033940|NCT05739201|Active Comparator|Group (III)|30 atients will receive pericapsular nerve group block around shoulder surgery
89033941|NCT05735327||Brigatinib|Participants receiving Brigatinib as part of their first-line treatment in scope of their routine clinical practice within the frames of National Drug Program (NDP) will be observed at baseline, and every 3 months (± 1 month) at routine follow-up for up to 33 months.
89033942|NCT05731063|Other|Ridge augmentation surgery|Computer guided simultaneous implant placement with tri-cortical ridge augmentation using chin cortical bone struts in anterior atrophic maxilla
89033943|NCT05730946||Egyptian parents of cleft lip and/ or palate (CLP) patients|Egyptian parents of CLP patients presented to the cleft lip & palate clinic at Ain Shams university.
89611037|NCT01720498|Experimental|Male|To find out the effect site concentration of remifentanil for preventing QTc prolongation < 15 sec during intubation : Dixon's up-and-down method
89611038|NCT01720498|Experimental|Female|To find out the effect site concentration of remifentanil for preventing QTc prolongation < 15 sec during intubation : Dixon's up-and-down method
89611039|NCT01672047|Experimental|Treament|Intervention Vitamin D2
89611040|NCT01672047|No Intervention|Control|Not take Vitamin D2
89688394|NCT00939211|Experimental|AZD9164 100 mcg First, then Placebo for Spririva|1 x AZD9164 solution for inhalation through nebulisation 100 mcg (lung deposited dose) + 1 x placebo for Spiriva dry powder for inhalation
88815365|NCT01030406|Placebo Comparator|0/0mg taken first|Placebo
88815366|NCT00996164|Experimental|flibanserin 100 mg|flibanserin 100mg po qd
88815367|NCT00996164|Placebo Comparator|Placebo|placebo 1 tab po qd
88815368|NCT03894098|Active Comparator|Single shot regional popliteal and saphenous block|Standard of care traditional single shot popliteal / saphenous regional block for acute pain control after elective ankle surgery
88815369|NCT03894098|Experimental|High ankle block|High ankle block for acute pain control after elective ankle surgery
88815370|NCT03868748|Placebo Comparator|Placebo|The double-blind phase of the study starts with randomized allocation of eligible participants to one of three treatment arms. Participants randomized to the placebo treatment arm will consume one placebo capsule per day for 12 weeks
88815371|NCT03868748|Experimental|Low Dose, 12 weeks|The double-blind phase of the study starts with randomized allocation of eligible participants to one of three treatment arms. Participants randomized to the low dose treatment arm will consume one 150 mg beta-arbutin capsule per day for 12 weeks.
88815372|NCT03868748|Experimental|High Dose, 4 weeks|The double-blind phase of the study starts with randomized allocation of eligible participants to one of three treatment arms. Participants randomized to the high dose treatment arm will consume one placebo capsule per day for 8 weeks followed by one 400 mg beta-arbutin capsule per day for 4 weeks.
89611041|NCT01833286|Experimental|TACE+RFA|TACE was performed according to the following protocol: All patients underwent a distal super-selective catheterization of the hepatic arteries using a coaxial technique and micro-catheters (2.9 Fr, Terumo Corporation, Tokyo, Japan). Then, the same three chemotherapeutic agents at the same dosages were used throughout this study, regardless of tumor number and size. Hepatic artery infusion chemotherapy was performed using carboplatin 300 mg. After that, chemolipiodolization was performed using epirubicin 50 mg, and mitomycin C 8 mg mixed with 5 mL of lipiodol. If the territory of the chemolipiodolized artery did not show stagnant flow, pure lipiodol was then injected. RFA was performed after TACE in 2 months by using a commercially available system (RF 2000; Radio-Therapeutics Mountain View, CA), and a needle electrode with a 15 Ga insulated cannula with 10 hook-shaped expandable electrode tines with a diameter of 3.5 cm at expansion (LeVeen; RadioTherapeutics).
89611042|NCT01833286|Active Comparator|re-resection|Re-resection was carried out under general anesthesia using a right subcostal incision with a midline extension. Intra-operative ultrasonography was performed routinely to evaluate the tumor burden, liver remnant and the possibility of a negative resection margin. We performed anatomical resection aiming at a resection margin of at least 1 cm. Pringle's maneuver was routinely used with a clamp and unclamp time of 10 minutes and 5 minutes, respectively. Hemostasis of the raw liver surface was done with suturing and application of fibrin glue.
89611043|NCT01672125||women who have completed treatments|women who have completed breast cancer treatments, with a diagnosis of unilateral arm lymphedema, in the intensive phase of lymphedema treatment
89611044|NCT01672125||women who have completed treatment in maintenance phase|women who have completed breast cancer treatment and are in the maintenance phase of lymph edema treatment
89611045|NCT01672125||healthy women|healthy women adjusted in age and BMI
89611046|NCT01720576|Experimental|Cohort 1|Dose 1 of REGN1033 (SAR391786) or Placebo
89611047|NCT01720576|Experimental|Cohort 2|Dose 2 of REGN1033 (SAR391786) or Placebo
89611048|NCT01720576|Experimental|Cohort 3|Dose 3 of REGN1033 (SAR391786) or Placebo
89611049|NCT01833364|Experimental|Implantation of Perpherial Nerve Graft|Subjects own peripheral nerve tissue that will be used to create the graft for implantation. The autologous peripheral nerve graft will then be implanted unilaterally into the substantia nigra of the subject after the placement of DBS electrodes.
89611050|NCT01720654|No Intervention|Control|Standardized partner notification counseling.
89611051|NCT01720654|Experimental|EPT|Standardized partner notification counseling and provision of 5 partner treatment (EPT) packets.
88983513|NCT04123951|Experimental|Home-based Exercise|Patients in this arm will complete a 12 week home-based aerobic and resistance exercise training programme. There will be a 2 week period prior to this in which patients will complete up to 6 supervised sessions in order to learn about the home-based exercise training. There will be a 4 week return visit and an optional 8 week return visit in order to reassess fitness and aid the patients with any questions or queries they may have and to aid them in progressing their exercise.
88983514|NCT04123951|No Intervention|Control|"In this arm patients will continue 'as normal' with daily activities.~Patients in this arm will be offered the exercise intervention once they have completed post 12 week assessments."
88983515|NCT04116437|Experimental|Zanubrutinib|"Cohort 1: Chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL), Waldenström macroglobulinemia (WM), mantle cell lymphoma (MCL), or marginal zone lymphoma (MZL) previously treated with ibrutinib~Cohort 2: Chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL), Waldenström macroglobulinemia (WM), mantle cell lymphoma (MCL), or marginal zone lymphoma (MZL) previously treated with acalabrutinib alone/with ibrutinib"
88983516|NCT04114357|Experimental|Intervention Group|This arm will consume the supplement daily for 4 weeks.
88983517|NCT04114357|No Intervention|Control Group|This arm will not receive the supplement for 4 weeks.
88983518|NCT04080453||Septic shock|Plasma of 100 patients presenting a septic shock will be analysed including plasma concentration in CD154, beta thromboglobulin, platelet factor 4, platelet microparticles, soluble CD62, RANTES, GRO-alpha and HMGB-1
88983519|NCT04080453||Systemic Inflammatory Response Syndrome|Plasma of 100 patient presenting a systemic inflammatory response syndrome = SIRS will be analysed including plasma concentration in CD154, beta thromboglobulin, platelet factor 4, platelet microparticles, soluble CD62, RANTES, GRO-alpha and HMGB-1
88983520|NCT04062526|Experimental|Patient with Parkinson Disease|"Subject should have a history of diagnosis of probable idiopathic PD derived from UK Brain Bank Diagnostic criteria per neurologist review.~Subject must have been diagnosed with Parkinson's Disease at least 3 year prior to enrollment."
88983521|NCT04062526|Experimental|Healthy Control|Subject must be a Healthy.
88983522|NCT04060004|Other|Control group|Electrotherapy + therapeutic exercise
88983523|NCT04060004|Experimental|Experimental group 1|Electrotherapy + therapeutic exercise + dry needling
88983524|NCT04060004|Placebo Comparator|Experimental group 2|Electrotherapy + therapeutic exercise + sham dry needling
88983525|NCT04059302|Experimental|Online CBT-I|Fully-automated, internet-delivered cognitive behavioral therapy for insomnia program that consists of 6 therapy cores delivered weekly over 6 weeks.
88983526|NCT04059302|No Intervention|Wait-List Control|Wait-list control group will receive no intervention until after the trial period is completed. During the trial period they will complete all study assessments, but receive no active treatment.
88983527|NCT04058886|Experimental|Telephone-delivered Mindfulness|Participating caregivers and care partners will receive mindfulness training in 8 weekly telephone sessions plus one retreat. Respite care for the care recipient is provided for the retreat.
88983528|NCT04036019|Experimental|C-CAR066|Autologous C-CAR066 (CD20-directed CAR T-cell) administered by intravenous (IV) infusion
88983529|NCT04024306||SLE with corticosteroid therapy|
88983530|NCT04020887|No Intervention|Observation Phase|In the first three months of this proof-of-concept study, a telemedicine center for the PACU will monitor patients assigned to PACU bays. Both telemedicine center clinicians and nurses caring for patients in these PACU bays will independently record information on patient physiological derangements, treatable symptoms, situations requiring urgent medical intervention, and discharge readiness (based on the modified Aldrete scale). During this phase of the study, clinicians in the telemedicine center will not communicate with clinicians in the PACU (nurses or physicians), unless there was a patient safety event.
89611052|NCT01833676|Active Comparator|Desflurane|Patient receiving Desflurane for maintenance of general anaesthesia
89033944|NCT05726786|Experimental|Immunonutrition|Seven days of preoperative oral supplementation with an immune-enhanced oral nutrition
89611053|NCT01833676|Active Comparator|Sevoflurane|Patient receiving Sevoflurane for maintenance of general anaesthesia
89611054|NCT01720732|Experimental|Lifeline NET|Lifeline-NET (Short Version of NET)
89611055|NCT01720732|No Intervention|TAU|Treatment as Usual
89033945|NCT05726786|No Intervention|No immunonutrition (control)|Standard of care
89033946|NCT05720416|Experimental|muscle strength training and protein supplementation|
89033947|NCT05720416|Placebo Comparator|usual care|
89033948|NCT05720416|Experimental|muscle strength training|
89033949|NCT05718648|Experimental|BI 1015550 Severe renal impairment|Participants with severe renal impairment and not requiring dialysis.
89033950|NCT05718648|Experimental|BI 1015550 Moderate renal impairment|Participants with moderate renal impairment.
89611056|NCT03210844||Direct anterior approach|For the DAA group, we used single-incision direct anterior approach with a standard operation table in J Arthroplasty. 2008 Oct;23(7 Suppl):64-8. Epub 2008/10/24. . The incision size was 6-10 cm depending on the body build of the patient. The acetabularreaming was performed with an offset hemispheric reamer and acetabular component was inserted underfluoroscopic guidance. Femoral broaching was performed using a double-offset broach handle.Fluoroscopy was used to check the positioning and filling of femoral stem, as well as leg lengths.
89611057|NCT03210844||Microposterior approach|The incision size was 6 - 10 cm depending on the body build of the patient. The differences of our micro-PA from Dorr's techniques were: First, no excision of the anterosuperior capsule and medial inferior capsule because the senior author believe that preservation of these structures could help to maintain the postoperative stability of the THA. Second, after the gluteus minimus muscle was elevated from the superior capsule, a superior capsulomy starting from 12 o'clock direction of acetabulum in decubitus position was made. The hip capsule was then incised in 12-to- 6-o'clock downward direction and curved down around femoral neck under the other short external rotators. We preserved short external rotators except piriformis tendon. Third, the capsular incision was continued inferiorly following 12-to- 6-o'clock downward direction of acetabulum to the transverse acetabular ligament. The tube structure of original hip capsule was divided into anterior and posterior half leaflets.
89611058|NCT04380376|Experimental|Melphalan inhalations|Inhalations with Melphalan 0,1 mg dissolved in 2 ml sodium chloride (NaCl) 0,9% 1 per day for 7-10 consequent days
89033951|NCT05718648|Experimental|BI 1015550 Normal renal function|Participants with normal renal function.
89033952|NCT05712239|Other|Advices Group|Patients in this group will take only advices about their postures and activities of daily living
89033953|NCT05712239|Active Comparator|Cervical and scapular stabilization Group|Patients in this group will take advices and stability exercises for neck and scapula
89033954|NCT05712239|Experimental|Neck, scapular and lumber stabilization Group|Patients in this group will take advices, and stability exercises for neck, scapula and lumber spine
89033955|NCT05711927|Experimental|SNOO group|The SNOO Smart Sleeper will be used in accordance with the manufacturer's programming and instructions.
89033956|NCT05711927|Sham Comparator|Traditional bassinet group|The SNOO will remain powered off to mimic the conditions of sleeping in a traditional hospital bassinet.
89033957|NCT05708040|Active Comparator|Closed loop system|Minimed 780G (Medtronic)
89033958|NCT05708040|Experimental|SmartPen|InPen (Medtronic)
89611059|NCT04380376|Other|Standard of care group|Patients assigned to the standard of care group will not receive any additional therapy.
89611060|NCT04380298|Experimental|The ketorolac group|Patients assigned to the ketorolac group will receive pre-emptive scalp infiltration with 30ml of local infiltration solution containing 60 mg ropivacaine, 6 mg ketorolac and 0.1mg epinephrine.
89611061|NCT04380298|Active Comparator|The control group|In the control group, preoperative peri-incisional scalpinfiltration will be performed using 30ml of 60 mgropivacaine and 0.1mg epinephrine.
89611062|NCT04164849|Experimental|5-ALA photopheresis|All patients will receive 5-aminolevulinic acid (5-ALA) in combination with blue light photopheresis. The investigators will collect mononuclear cells by connecting patient to Spectra Optia with CMNC (continuous mononuclear cell collection protocol), and these cells will include active T-lymphocytes. 5-ALA will be incubated for 1 hour to produce photoactive protoporphyrin-IX (PpIX) before light exposure.
89611063|NCT01833910|Experimental|Video-only - DVD|CPR Training with AHA CPR Anytime DVD presented on a TV with DVD player and no psychomotor skill practice.
89611064|NCT01833910|Experimental|Video-only - iPad|CPR Training with AHA CPR Anytime DVD presented on a portable video player and no psychomotor skill practice.
89611065|NCT01833910|Experimental|Video-only with Household Object|CPR Training with AHA CPR Anytime DVD and practice on a household item
89611066|NCT01833910|Experimental|Video Self Instruction Kit|CPR Training with AHA CPR Anytime Video Self-Instruction kit including manikin
89611067|NCT01672203||PE peripheral with fibrinolysis|Patients with peripheral PE who received fibrinolysis therapy
89611068|NCT01672203||PE peripheral, no fibrinolysis|Patients with peripheral PE who did not receive fibrinolysis
89033959|NCT05703334|Experimental|Kinesio tap|group (A) mean age (21.03+3.6 years), and mean BMI values (27.6+.9 kg/m2 Group(A) 30 subjects were treated by kinesio tap therapy 2sessions per week.
89033960|NCT05703334|Experimental|Myofascial release|group (B) mean age (21.9+3.8 years),and mean BMI values (27.8+1.3 kg/m2 Ground(B) 30 subjects were treated by myofascial release therapy 3 sessions per week .
89033961|NCT05703334|No Intervention|Control group|
89033962|NCT05702255|Experimental|Active acupoints group|All participants in the active group will be treated with basic acupoints Zhongwan (CV 12), Tianshu (ST25) in alternation with Sanyinjiao (SP 6), Zusanli (ST 36). Moreover according to traditional Chinese medicine diagnosis, additional acupoints will be added. The frequency of acupressure treatment will be twice a day for 4 weeks, in total 56 sets.
89033963|NCT05702255|Sham Comparator|Sham acupoints group|All participants on the sham acupoints group will recieive sham Zhongwan (CV 12), sham Tianshu (ST25), sham Sanyinjiao (SP 6), and sham Zusanli (ST 36) acupressure. All the sham points are 2 cm outside and parallel to the actual points which do not match any recognized acupuncture points and are thought to have no therapeutic effect. The frequency of acupressure treatment will be twice a day for 4 weeks, in total 56 sets.
89057293|NCT01647594|Active Comparator|Young Women's Intervention (YWI)|
89611069|NCT01672203||PE central with fibrinolysis|Patients with central PE who received fibrinolysis therapy
89033964|NCT05701657|Other|Module 1|"Module 1 is approximately 10 days (minimum of 8 days) and includes two study visits and remote data collection. Visit 1 will include application of an accelerometer and continuous glucose monitoring device for remote data collection over the next 8 to 10 days. A stool sample collection kit and instructions for stool collection and completion of dietary assessments during the observation period will be provided.~At Visit 2, anthropometry (height, weight and body circumferences), body composition by bioelectrical impedance (BIA), vital signs (temperature, respiratory rate and blood pressure), resting heart rate variability and grip strength will be measured. Medications will be recorded. A liquid MMTT with timed biospecimen collection (blood, urine, saliva, hair, and nails) and visual analogue assessments will be completed.~Participants in Module 1 will be asked to adhere to their usual routine (e.g., diet, exercise, sleep, supplements, medication use, etc.) throughout the study."
89033965|NCT05701657|Other|Module 2|"Module 2 is a minimum of 10 weeks long. It includes a total of six (6) study visits that occur before and after each of the three (3), 14-day dietary intervention periods (i.e., Diets A, B, and C), separated by washout periods of at least 14 days. Participants will be asked to consume only the foods provided and to adhere to their other usual routines throughout the study.~At the beginning of each diet period, anthropometry (weight and circumferences), vital signs (temperature, respiratory rate and blood pressure) and body composition by BIA will be measured. Biospecimens (blood, urine and saliva) will be collected. An accelerometer and a continuous glucose monitoring device will be applied for remote data collection. A stool sample collection kit will be provided together with instructions for stool collection and dietary assessments. At the end of each diet, a diet-specific meal test with timed biospecimen blood collection and visual analogue assessments will be completed."
89033966|NCT05701657|Other|Module 3|"Module 3 is a minimum of 10 weeks long. It includes three (3), 14-day dietary interventions (i.e. Diets A, B, and C) completed while participants are domiciled under the supervision of study staff. At the end of each dietary intervention period, participants return to their usual residence and routine for a minimum of 2 weeks.~At the beginning of each diet period, anthropometry (weight and circumferences), vital signs (temperature, respiratory rate and blood pressure) and body composition by BIA and DXA, and physical measures will be measured. Biospecimens (blood, urine and saliva) will be collected. An accelerometer and a continuous glucose monitoring device will be applied. Excluding pregnant females, participants will receive a dose of doubly labeled water. Weight and vital signs will be measured daily and questionnaires administered.~A diet-specific MMTT and a separate liquid MMTT with timed blood biospecimen collection and visual analogue assessments will be completed."
89611070|NCT01672203||PE central, no fibrinolysis|Patients with central PE who did not receive fibrinolysis
89611071|NCT03210610||FMF patients|fmf patients under a constant colchicine dose
89611072|NCT01720888|No Intervention|Maximal medical therapy|Maximal medical therapy which comprises of optimal pharmacological therapy
89611073|NCT01720888|Experimental|Maximal medical therapy and BM-MSCs|Autologous Bone marrrow-derived mesenchymal stem cells implantation
89611074|NCT01672281|Experimental|vibrox training|
89033967|NCT05701215|Experimental|Venetoclax|Venetoclax will be taken orally once daily (400 mg) for 12 months after stop of TKI
89033968|NCT05700422|Experimental|OC-01 (varenicline solution) 0.03 mg nasal spray|
89033969|NCT05687526|Experimental|Telitacicept 2.5 mg/kg|Telitacicept 2.5 mg/kg
89033970|NCT05687318|Experimental|Trial Ⅰ|Subjects underwent colonoscopy with the investigator's combined instrument, and then underwent traditional colonoscopy with the same investigator
89611075|NCT01672281|Experimental|resistance training|
89033971|NCT05687318|Experimental|Trial Ⅱ|Subjects underwent a traditional colonoscopy, followed by a colonoscopy with the same investigator's instrument
89033972|NCT05681377|Experimental|Flumazenil group|After discontinuation of remimazolam administration, flumazenil is administered to help the patient recover consciousness.
89033973|NCT05681377|No Intervention|Control group|After discontinuation of remimazolam administration, wait until the patient's consciousness is restored naturally without flumazenil administration.
89033974|NCT05680818|Experimental|Encaleret|Participants will receive encaleret at a dose as needed based on calcium levels.
89033975|NCT05680818|Other|Standard of Care (SoC)|Participants will continue receiving calcium supplements and/or active Vitamin D (calcitriol, alfacalcidol, falecalcitriol, etc.)
89033976|NCT05677984|Experimental|APP group|Directive APP for a target of 12 hours per day or more
89033977|NCT05677984|No Intervention|Control group|No intervention on APP
89033978|NCT05668559|Experimental|Active rTMS Group|A stimulation set will be administered to each participant in the rTMS group with 15 sessions stimulation for total five days after surgery.
89033979|NCT05668559|Sham Comparator|Sham Stimulation Group|Patients randomly assigned to sham group will receive 15 sessions sham stimulation for total five days after surgery.
89611076|NCT01834066|Other|STEM CELL|Intra thecal transplantation of autologous Stem Cell MNCs
89611077|NCT03152955|Experimental|Group A|Patients in Group A will receive scalp nerve block and patient-controlled analgesia which contains sufentanil and ondansetron.
89611078|NCT03152955|Experimental|Group B|In Group B, patient-controlled analgesia which contains sufentanil、ondansetron and ketamine will be applied.
89611079|NCT03152955|Sham Comparator|Group C|In Group C, patient-controlled analgesia which contains sufentanil and ondansetron will be applied.
89611080|NCT03020667||IQOS Users|"The criteria defining an IQOS user are listed in the section Eligibility."
89611081|NCT03020667||Cigarette (CC) Smokers|"The criteria defining a CC smoker are listed in the section Eligibility."
89611082|NCT01720966||Laparoscopy|Patients who will undergo liver resection who have a laparoscopically performed colorectal resection in history. Assignment to cohort is on intention to treat of the primary operation.
89611083|NCT01720966||Laparotomy|Patients who will undergo liver resection who have an open colorectal resection in history. Assignment to cohort is on intention to treat of the primary operation.
88815373|NCT03809936|Active Comparator|real tDCS|real tDCS:anodal transcranial direct current stimulation were delivered over the left DLPF cortex for 20 minutes in patients.
89611084|NCT01721356||Healthy individuals|Healthy individuals ranging in age, race, ethnicity, socioeconomic status, and years of education
89611085|NCT01676493|Experimental|Codeine|Codeine Sulfate Oral Solution and Tablet
89033980|NCT05668416|Experimental|experiment|The intervention group will include parents who were trained in the preoperative period. The training includes brochures and oral training prepared by the researchers in line with the literature and the training given in the hospital.
89033981|NCT05668416|No Intervention|control|The control group will be the oral information group that is in the hospital routine. Parents in this group will be informed verbally when they come to the hospital for anesthesia and file procedures the day before the surgery.
89033982|NCT05661279|Active Comparator|Group C:|control group who will be given general anesthesia only
89033983|NCT05661279|Active Comparator|Group R:|Rhomboid intercostal block then general anesthesia
89033984|NCT05661279|Active Comparator|group S|Serratus anterior plane block then general anesthesia
89033985|NCT05660681|Experimental|glycerin 0.7%/PEG 400 0.3%|20 patients will receive glycerin 0.7%/PEG 400 0.3% lubricant eye drops three times per day for 28 days.
89033986|NCT05660681|Active Comparator|polyethylene glycol 400 0.4%/propylene glycol 0.3%|10 patients will receive polyethylene glycol 400 0.4%/propylene glycol 0.3% lubricant eye drops three times per day for 28 days.
89033987|NCT05660239|Other|Wakiso district-Urban Parish|"Study participants together with the relevant community stakeholders will co-design feasible communication and activity-based change projects that are based on both cultural and scientific norms, to reduce epilepsy stigma in the community.~Researchers will then compare the Quality of Life, Attitudes and Beliefs about Living with Epilepsy scores and the Kilifi Stigma Scale scores following the implementation of the community change projects in an urban parish to see if there is improvement in these assessments scores."
89033988|NCT05660239|Other|Wakiso district-Rural Parish|"Study participants together with the relevant community stakeholders will co-design feasible communication and activity-based change projects that are based on both cultural and scientific norms, to reduce epilepsy stigma in the community.~Researchers will then compare the Quality of Life, Attitudes and Beliefs about Living with Epilepsy scores and the Kilifi Stigma Scale scores following the implementation of the community change projects in a rural parish to see if there is improvement in these assessments scores."
89033989|NCT05648292||Clinical group|45 individuals with relapsing-remitting multiple sclerosis
89033990|NCT05648292||Control group|45 individuals with no chronic disease, matched in age, gender and level of education
89611086|NCT01721434|Experimental|Levosimendan|Levosimendan 0.2 ug/kg/min intravenous for a single 7 hours.
89611087|NCT01721434|Placebo Comparator|Placebo|Similar coloured placebo intravenous for a single 7 hours
89033991|NCT05647005|Experimental|Experiment 1: Classical music|A total of 15 sessions of music will be applied to this group, two or three days a week, on different days, 3 sessions a day. The sessions will be in the form of listening to classical music for 30 minutes after the babies are fed.
89033992|NCT05647005|Experimental|Experiment 2: Harp music|A total of 15 sessions of music will be applied to this group, two or three days a week, on different days, 3 sessions a day. Sessions will be in the form of listening to harp music for 30 minutes after the babies are fed.
89033993|NCT05647005|No Intervention|Control|Premature babies in this group will not be interfered with by the newborn nurses for 30 minutes after feeding without any voice intervention.
89033994|NCT05644067|Experimental|SumayaVac-1(SUM-101)|Candidate malaria Vaccine (Investigational Medicinal Product (IMP)). 20 participants will be randomised to receive three monthly inoculations of the IMP
89033995|NCT05644067|Placebo Comparator|Verorab|Comparator used as a control. 20 participants will be randomised to receive three monthly inoculations of the comparator.
89611088|NCT01721512||Breast-fed infants|80 infants of mothers who plan to exclusively breastfeed for at least 6 months.
89033996|NCT05643144|Experimental|Patient-Caregiver Dyads|Participants will wear a continuous glucose monitor
89033997|NCT05643144|No Intervention|Patient-Caregiver Dyads & Clinicians (first iteration)|Participants will participate in the first iteration of the user-centered design process.
89033998|NCT05643144|No Intervention|Patient-Caregiver Dyads & Clinicians (second iteration)|Participants will participate in the second iteration of the user-centered design process.
89033999|NCT05642923|Active Comparator|Synthetic Vitamin B1|Synthetic Vitamin B1, 400 mg per day
89034000|NCT05642923|No Intervention|No intervention|No intervention
89034001|NCT05641363|Active Comparator|Standard dose group A|IV ketorolac 0.5 mg/kg/dose up to a maximum dose of 30 mg plus IV normal saline placebo given at 0.25 mg/kg to a maximum of 30 mg plus IV normal saline placebo given at 0.5 mg/kg to a maximum of 10 mg
89057294|NCT01647594|Active Comparator|Physical Activity Intervention (PAI)|
89611089|NCT01721512||Formula-fed infants|"Mother is exclusively feeding infant formula milk less than or equal to 6 weeks of birth and has no prospect of breastfeeding.~Mother consents to her infant receiving trial infant formula for 12 months"
89611090|NCT02563431|Active Comparator|SP-ED|Classic use
89611091|NCT02563431|Experimental|4P-ED|Literature update
89611092|NCT03210532|Experimental|Test|qd PO, Twynsta(telmisartan/amlodipine) + Crestor(rosuvastatin)
89611093|NCT03210532|Active Comparator|Reference 1|qd PO, Micardis(telmisartan) + Crestor(rosuvastatin)
89611094|NCT03210532|Active Comparator|Reference 2|qd PO,Twynsta(telmisartan/amlodipine)
89611095|NCT03210454|Experimental|Treatment Group 1|Farmers associations, including men and women, will be randomized to receive the smallholder marketing intervention.
89611096|NCT03210454|Experimental|Treatment Group 2|Farmers associations, including men and women, will be randomized to receive the smallholder marketing intervention combined with the intimate partner violence (IPV) prevention training.
89611097|NCT03210454|No Intervention|Comparison Group 3|Women involved with farmers's associations that work independently of World Food Programmes (WFP's) assistance.
89611098|NCT05119413|Experimental|New traitement|Thiamidol, retinoid, topical steroid preparation
89611099|NCT05119413|Other|Kligman's trio|Application once a day for 12 weeks
89611100|NCT01834378|No Intervention|No intervention|
89611101|NCT01834378|Experimental|Low intensity intervention|
89611102|NCT01834378|Experimental|High intensity intervention|
89611103|NCT03152565|Experimental|Avelumab in combination ADC vaccine|Patients in both phases will receive Avelumab biweekly intravenous during a maximum of 12 months and biweekly 10x106 ADC vaccine (intradermal) for five doses (days 1, 14, 28, 42 and 56) followed by a maximum of 6 doses every 6 months.
89611104|NCT01721590|Placebo Comparator|Control|Placebo，3 capsules/time，3times/day for 1 year
89611105|NCT01721590|Experimental|Tongxinluo|Tongxinluo 3 capsules/time 3times/day for 1 year
89034002|NCT05641363|Experimental|Low dose group B1|IV ketorolac 0.5 mg/kg to a maximum of 10 mg plus IV normal saline placebo given at 0.25 mg/kg to a maximum of 30 mg plus IV normal saline placebo given at 0.5 mg/kg to a maximum of 30 mg
89034003|NCT05641363|Experimental|Low dose group B2|IV ketorolac 0.25 mg/kg to a maximum of 30 mg plus IV normal saline placebo given at 0.5 mg/kg to a maximum of 30 mg plus IV normal saline placebo 0.5 mg/kg to a maximum of 10 mg
89034004|NCT05638139|Experimental|SygeLIX-F + SygeLIX-G|Combination of SygeLIX-F, a plug made of an assembly of umbilical cord lining and Wharton's jelly in the form of a cylinder of porous structure, and SygeLIX-G, a Wharton's jelly gel reconstituted in a syringe.
89034005|NCT05636241|Active Comparator|control group|The participants in the control group will be attended to conventional physiotherapy program.
89611106|NCT05381181|Experimental|CD19-UCART|All patients will be treated with at least 1 injection of CD19- UCART. A dose of 5x10^6/kg BW of CD19-UCART will be evaluated. If > 1/6 of DLT occurred, the dose would be reduced to 2.0x10^6/kg BW.
89611107|NCT01834456|Experimental|Med Complex Children Intervention|"Children with Medical Complexity, previously defined in research as, children with complex chronic conditions, children with life-limiting conditions, fragile children, complex chronic illness, or a subset of children with special healthcare needs. Meeting criteria for complexity is a combination of high utilization, multiple chronic diagnoses, use of medical technology (g-tube, tracheostomy, shunt, etc.), functional impairment, and contextual needs.~Medically Complex Children in the Intervention group will be treated at an innovative primary care facility designed for their care. This includes actively addressing QOL, care coordination, and behavioral needs of the child, and addressing contextual and support needs for the child's family."
89611108|NCT01834456|No Intervention|Med Complex Children Control|"Children with Medical Complexity, previously defined in research as, children with complex chronic conditions, children with life-limiting conditions, fragile children, complex chronic illness, or a subset of children with special healthcare needs. Meeting criteria for complexity is a combination of high utilization, multiple chronic diagnoses, use of medical technology (g-tube, tracheostomy, shunt, etc.), functional impairment, and contextual needs.~The control group will continue to receive usual care as they did before they enrolled in this study"
89611109|NCT03210142|Experimental|Transvenous hypoglossal nerve stimulation|Transvenous hypoglossal nerve stimulation for subjects undergoing an EP, cardiac catheterization or device procedure.
89611110|NCT03210064|Experimental|Apatinib and 5-Fluorouracil|Apatinib 500 mg qd po.5-Fluorouracil 400mg/m2 iv d1，2400mg-3000mg/m2 civ 46h,q2w.5-Fluorouracil derivatives(Capecitabine 1000mg/m2 bid po d1-d14 q3w.S1 40mg/m2 bid po d1-d14 q3w).
89611111|NCT03210064|Active Comparator|5-Fluorouracil|5-Fluorouracil 400mg/m2 iv d1，2400mg-3000mg/m2 civ 46h,q2w.5-Fluorouracil derivatives(Capecitabine 1000mg/m2 bid po d1-d14 q3w.S1 40mg/m2 bid po d1-d14 q3w).
89611112|NCT00905554|Experimental|warm water|warm water irrigation during the insertion phase of colonoscopy
89611113|NCT00905554|Active Comparator|air|air insufflation during the insertion phase of colonoscopy
89611114|NCT01721902|Active Comparator|Autologous CD133+ Bone Marrow Stem Cells|Intra-myocardial injection of autologous CD133+ cells in suspension.
89611115|NCT01721902|Placebo Comparator|Carrier Solution|Intra-myocardial inception of carrier solution.
89611116|NCT01721980|Other|50 mg GLPG0974 or placebo|50 mg GLPG0974 dose as oral capsule or placebo capsule, daily for 14 days
89611117|NCT01721980|Other|100 mg GLPG0974 or placebo|100 mg GLPG0974 dose as oral capsule or placebo oral capsule, daily for 14 days
89611118|NCT01721980|Other|200 mg GLPG0974 or placebo|200 mg GLPG0974 dose as oral capsule or placebo capsule, daily for 14 days
89611119|NCT01721980|Other|400 mg GLPG0974 or placebo|400 mg GLPG0974 dose as oral capsule or placebo capsule, daily for 14 days
89611120|NCT05372991|Active Comparator|0.025% atropine sulphate|The comparator formulation of 0.025% atropine sulfate monohydrate in normal saline will be prepared by diluting commercial 1% atropine sulphate solution with physiologic saline.
89611121|NCT05372991|Placebo Comparator|vehicle|CBT-009 vehicle formulation is a proprietary sterile ophthalmic solution that does not contain CBT-009 drug substance.
89611122|NCT05372991|Experimental|CBT-009, Low Dose|CBT-009 low dose formulation is a proprietary sterile ophthalmic solution that contain low dose of CBT-009 drug substance.
89611123|NCT05372991|Experimental|CBT-009, Mid Dose|CBT-009 mid dose formulation is a proprietary sterile ophthalmic solution that contain mid dose of CBT-009 drug substance.
89611124|NCT05372991|Experimental|CBT-009, High Dose|CBT-009 high dose formulation is a proprietary sterile ophthalmic solution that contain high dose of CBT-009 drug substance.
88815374|NCT03809936|Sham Comparator|sham tDCS|sham tDCS:sham transcranial direct current stimulation were delivered over the left DLPF cortex for 20 minutes in patients.
88815375|NCT03804554||Patients taking nivolumab|
88815376|NCT01031420|Experimental|dose dense MVAC|standard doses of MVAC given every 14 days x 3.
89034006|NCT05636241|Experimental|study group|The participants in the study group will be attended to whole body vibration training program.
89034007|NCT05634889|No Intervention|Standard|Radiotherapy to the remaining breast after breast conserving surgery or chest wall after mastectomy, and regional axillary lymph node levels I-IV. Internal mammary nodes are included in the target volume if the tumor has a central/medial localization in the breast.
89034008|NCT05634889|Experimental|Intervention|No regional radiotherapy. Radiotherapy is given to the remaining breast after breast conserving surgery, while mastectomy patients do not receive any radiotherapy at all.
89034009|NCT05624710|Experimental|Group 1: Severe Hepatic Impairment|Participants with severe hepatic impairment (Class C Child-Pugh score) will receive a single oral dose of INCB054707 on Day 1.
89611125|NCT01672515|Experimental|RIPC group|RIPC treatment was performed by the inflating tourniquets to 200mmHg on bilateral arms with 5 cycles of 5min inflation and 5min relax alternation for the total of 30 consecutive days.
89611126|NCT01672515|Sham Comparator|Control group|RIPC sham was performed by the inflating tourniquets to 60mmHg on bilateral arms with 5 cycles of 5min inflation and 5min relax alternation for the total of 30 consecutive days.
89611127|NCT00906178|Experimental|CyberSenga|6-module HIV prevention program tailored for adolescents in Uganda
89034010|NCT05624710|Experimental|Group 2: Moderate Hepatic Impairment|Participants with moderate hepatic impairment (Class B Child-Pugh score) will receive a single oral dose of INCB054707 on Day 1.
89034011|NCT05624710|Experimental|Group 3: Mild Hepatic Impairment|Participants with mild hepatic impairment (Class A Child-Pugh score) will receive a single oral dose of INCB054707 on Day 1.
89034012|NCT05624710|Experimental|Group D: Normal Hepatic Function|Participants with normal hepatic function will receive a single oral dose of INCB054707 on Day 1.
89034013|NCT05623072|Active Comparator|Experimental group|Participants will take active tDCS stimulation
89034014|NCT05623072|Sham Comparator|Control group|Participants will take sham tDCS stimulation
89034015|NCT05618691|Experimental|GFH312 40mg|Participant will receive GFH312 40mg once daily approximately at same time each day for 12 weeks.
89034016|NCT05618691|Experimental|GFH312 80mg|Participant will receive GFH312 80mg once daily approximately at same time each day for 12 weeks.
89034017|NCT05618691|Experimental|GFH312 120mg|Participant will receive GFH312 120mg once daily approximately at same time each day for 12 weeks.
89034018|NCT05618691|Experimental|Placebo|Participant will receive placebo once daily approximately at same time each day for 12 weeks.
89611128|NCT00906178|No Intervention|Control|"treatment as usual - the sexual health education adolescents currently receive in secondary school"
89611129|NCT03152721|Placebo Comparator|Control|Treating physician will in advance of upcoming visit be provided with the self assessment scales PDQ8 and NMS-Questionnaire to aid clinical assessment
89611130|NCT03152721|Experimental|Intervention|Treating physician will in advance of upcoming visit be provided with a Parkinson KinetiGraph recording report and interpretation in addition to the self assessment scales PDQ8 and NMS-Questionnaire to aid clinical assessment
89611131|NCT01722058|Experimental|peptide application|
89611132|NCT01722136|Experimental|Low Dosage|Exercise dose of 8kcal/kg/week
89611133|NCT01722136|Experimental|High Dosage|Exercise dose 14kcal/kg/week
89611134|NCT03863379||Neurodisabled persons|Persons with various neurodisabilities
89611135|NCT03863379||Control group|Able bodied persons
89611136|NCT01672593|Experimental|PRFG treatment|As described in our previous study, platelet-rich cryoprecipitate and thrombin were obtained from 300-400ml whole blood of each patient enrolled in the autologous PRFG(platelet-rich fibrin glue) group and then frozen at -20°C for storage. Prior to application, frozen cryoprecipitate and thrombin stored were thawed in a 37°C water bath. Aminomethylbenzoic Acid (1ml: 1mg, Sigma-Aldrich, St Louis, MO) was added into the cryoprecipitate in the volume ratio of 1:10.
89611137|NCT01672593|Active Comparator|Bioseal treatment|The commercial fibrin sealants used in the study were purchased from Guangzhou Bioseal Biotech Co. Ltd, Guangzhou, China. Upon application, two components, fibrinogen and thrombin, were placed separately in two syringes which were joined by a Y-shaped connector. The trunk of the Y-shaped connecter was connected to a single lumen catheter.
89034019|NCT05614557|No Intervention|Control|
89034020|NCT05614557|Experimental|Formulation 1|
89034021|NCT05614557|Experimental|Formulation 2|
89034022|NCT05607511|Experimental|Active probiotics arm|The SIM03 (supplied by GenieBiome Limited and produced under Good Manufacturing Practice, GMP) contains a blend of naturally occurring food-grade Bifidobacterium strains (1 billion CFU in 1 sachet). Recruited subjects will receive one sachet of baby immunity formula SIM03 twice daily for 3 months.
89611138|NCT03678831||Arthritic patients with knee prosthetic replace|Arthritic post-menopausal patients with knee prosthetic replacement Each patient is her own control since the two cell types are compared within the same patient The main criteria is based on a comparison of two cell types from the same patient. The secondary criteria are based on a comparison of cell types according to a grouping of patients according to different metabolic parameters.
89611139|NCT01834534|Experimental|CarePartners for depression|For one year, patients receive weekly automated telemonitoring of mood and self-management, while their CarePartners receive weekly reports of the patient's assessment results with tailored instructions on supporting the patient's depression self-management.
89611140|NCT01834534|No Intervention|Usual care|Usual medical care.
89688395|NCT00939211|Experimental|AZD9164 400 mcg First, then Placebo for Spiriva|1 x AZD9164 solution for inhalation through nebulisation 400 mcg (lung deposited dose) + 1 x placebo for Spiriva dry powder for inhalation
89034023|NCT05606874|Experimental|Pre-heating of flowable resin composite .|(Filtek™ Z350Xt Flowable Restorative, 3M ESPSE, USA)
89034024|NCT05606874|Active Comparator|Conventional resin fissure sealant|(total etch), (UltraSeal XT®, Ultradent, USA)
89034025|NCT05602389|Experimental|VL-G-A57|Dose: 700mg daily Route: Oral Regimen: 2 capsules in the morning with food and 2 capsules in the evening with food Duration: 60 days
89034026|NCT05602389|Experimental|VL-G-E12|Dose: 700mg daily Route: Oral Regimen: 2 capsules in the morning with food and 2 capsules in the evening with food Duration: 60 days
89034027|NCT05602389|Placebo Comparator|Placebo|Dose: 700mg daily Route: Oral Regimen: 2 capsules in the morning with food and 2 capsules in the evening with food Duration: 60 days
89034028|NCT05601596||Control Participant|Having No symptoms of Endo. Provide Menstrual samples.
89034029|NCT05601596||Symptomatic participant|Having symptoms of Endo and heading to diagnostic surgery as part of their standard of care (referred).
89034030|NCT05600946||Patients|Affected individuals that meet inclusion criteria
89034031|NCT05600244|Experimental|PENG block Technique|Patients will receive ultrasound-guided Pericapsular Nerve Group Block using 30 ml bupivacaine 0.25%.
89034032|NCT05600244|Experimental|Lumbar ESPB Technique|Patients will receive lumbar erector spinae plane block using 30 ml bupivacaine 0.25%
89034033|NCT05600244|Experimental|Transmuscular QLB-t block Technique|Patients will receive transmuscular quadratus lumborum block using 30 ml bupivacaine 0.25%
89034034|NCT05596916|Experimental|High frequency of stretching exercise|Axio scapular muscle stretching exercises will be applied for 5 days a week during 6 weeks
89034035|NCT05596916|Active Comparator|Low frequency of stretching exercise|Axio scapular muscle stretching exercises will be applied for 3 days a week during 6 weeks
89688396|NCT00939211|Experimental|AZD9164 1200 mcg First, then Placebo for Spiriva|1 x AZD9164 solution for inhalation through nebulisation 1200 mcg (lung deposited dose) + 1 x placebo for Spiriva dry powder for inhalation
89034036|NCT05595083|Experimental|intranasal dexmedetomidine group|patients will receive 1.5 ug/kg intranasal dexmedetomidine diluted with saline + infusion saline
89034037|NCT05595083|Experimental|intravenous dexmedetomidine group|patients will receive 0.1- 0.4 ug/kg intravenous infusion dexmedetomidine + intranasal saline.
89034038|NCT05594043|Experimental|MK-6598|Participants will receive MK-6598 daily (QD) at escalating dose levels from 50-500 mg for up to a total of 35 cycles (up to approximately 24 months).
89034039|NCT05594043|Experimental|MK-6598 + Pembrolizumab|Participants will receive MK-6598 QD at escalating dose levels from 50-500, plus pembrolizumab 200 mg once every 21-day cycle for up to 35 cycles (up to approximately 24 months).
89034040|NCT05591703||Participants randomized to receive tAN therapy in SBM-OWP-03 Phase II|
89034041|NCT05591703||Participants not randomized to receive tAN therapy in SBM-OWP-03 Phase II|
89034042|NCT05588427|Experimental|Ketone group|Ketone esters will be provided
89034043|NCT05588427|Placebo Comparator|Placebo group|Ketone placebo will be provided
89034044|NCT05581173||Endoscopic resection of gastrointestinal lesion(s)|Endoscopic mucosal resection or endoscopic submucosal dissection is an outpatient procedure to remove superficial neoplasia(precancerous lesions and early cancer) throughout the gastrointestinal tract.
89034045|NCT05570630|Experimental|VAX-MOM COVID-19 Intervention|
89034046|NCT05570630|Active Comparator|Standard of Care|
89034047|NCT05565443|Experimental|Idiopathic PD Patients|Idiopathic PD patients receiving 3 cycles of BBBO paired with GCase Treatments
89611141|NCT04764279|Experimental|OPTIFAST Arm|Participants in the intervention group will be given OPTIFAST® meal replacement shakes, 4 per day to achieve 900kcal/day, for the first 12 weeks of the study. The second phase will consist of partial meal replacement and food reintroduction over a 4 week period. When the intervention group begins to reintroduce foods, all study participants will be provided a workbook, created for the study, to explain optimal lifestyle changes for DMII management. The third phase will be a 8-month follow-up of participants on continued healthy lifestyle as described in the workbook.
89034048|NCT05565443|Experimental|GBA PD Patients|GBA PD patients receiving 3 cycles of BBBO paired with GCase Treatments
89034049|NCT05563155|Placebo Comparator|Placebo tablet on day 1 after surgery given as one single dose.|"Control Group (CG):~Intervention: Postoperative oral placebo tablet on day 1 after surgery given as one single dose."
89034050|NCT05563155|Active Comparator|Dexamethasone 24 mg on day 1 after surgery given as one single dose.|"Repeat Dose Group (RDG):~Intervention: Postoperative oral dexamethasone 24 mg on day 1 after surgery given as one single dose."
89034051|NCT05556655|Experimental|Active TMS|Repetitive TMS for the brain
89611142|NCT04764279|No Intervention|Control/Usual Care Arm|Usual Care : A gift card will be offered to participants in the control group to stabilize the incentive of the intervention. Participants in the control group will receive usual diabetes care based on the current Canadian Diabetes Association guidelines by their family physician. Participants in the control group will receive the same workbook as the intervention group at 16 weeks into the study.
89611143|NCT01834612|Active Comparator|Blood draw|CM1500 with blood draw
89611144|NCT01834612|Sham Comparator|No blood draw|CM 1500 with no blood draw
89611145|NCT04404621|Experimental|Cross-Over Sequence A|Participants in this arm will be randomized to receive the 18 week program first and be in treatment as usual comparison condition in the following 18 weeks.
89611146|NCT04404621|Experimental|Cross-Over Sequence B|Participants in this arm will be randomized to remain in treatment as usual during the first 18 week period and then receive the 18 week program during the following 18 weeks.
89611147|NCT03219034|Experimental|Oral appliance - A|"Anti-snoring intra-oral appliance that consists of two custom fitted trays which fit over the upper and lower teeth and uses a Midline Traction Mechanism to advance the mandible. The coupling mechanism is located at a single point midline, allows adjustment by incremental protraction (advancement) of the mandible.~Trade Name: TAP1 Oral Appliance, Airway Management Inc. Dallas, TX"
89688397|NCT00939211|Active Comparator|Spiriva 18 mcg First, then Placebo for AZD9164|1 x Spiriva dry powder for inhalation 18 mcg + 1 x placebo for AZD9164 (sodium chloride)
89034052|NCT05556655|Placebo Comparator|Sham TMS|Scalp stimulation that does not affect the brain.
89034053|NCT05552859|Experimental|Gla-300 arm|Gla-300 will be administered once daily for 24 weeks
89034054|NCT05552859|Active Comparator|IDeg-100 arm|Ideg-100 will be administered once daily for 24 weeks
89034055|NCT05544240|Experimental|Treatment Arm|Treatment Arm
89034057|NCT05540353|Active Comparator|Transvaginal photobiomodulation|"Participants will undergo active transvaginal photobiomodulation therapy per clinic protocol, using the SoLa Pelvic Therapy system. This includes 9 treatments, each lasting about 3-5 minutes. A sterile narrow vaginal probe is inserted into the vagina, the low-level laser is activated, and the probe is slowly moved along the vaginal walls for the indicated period of time, via a surface area power calculation based on the measured vaginal length at the beginning of the procedure. The 9 treatments must be completed in 3-4 weeks.~Intervention: Active SoLa Low-level laser therapy"
89034058|NCT05540353|Sham Comparator|Sham treatment|"Participants will undergo sham transvaginal photobiomodulation therapy, following the same protocol as the active arm, without activation of the machine. This includes 9 treatments, lasting 3-5 minutes each. A sterile narrow vaginal probe is inserted into the vagina, the machine is NOT activated, and the inactive probe is slowly moved along the vaginal walls for 3-5 minutes. The 9 treatments must be completed in 3-4 weeks.~Intervention: Mock treatment with inactivated probe"
89034059|NCT05535153||Experime|Hurdle steps Deep squats Inline lunges Shoulder Clearing Active straight leg raise Trunk stability pushup Rotary stability Spinal extension exam Spinal flexion exam
89034060|NCT05534152|Placebo Comparator|Soup with no sumac|150 g butternut squash soup with no added sumac
89034061|NCT05534152|Experimental|Sumac added to soup at the end of cooking|150 g butternut squash soup with 1% sumac added at the end of cooking
89034062|NCT05534152|Experimental|Sumac added to the sumac during cooking|150 g butternut squash soup with 1% sumac added during cooking
89034063|NCT05532397|Experimental|QPOP-guided chemotherapy|Subjects enrolled in the study will be administered combination of chemotherapy derived from QPOP analysis based on in vitro drug screening panels which comprises anti-cancer agents which have previously been evaluated in recurrent high grade astrocytic glioma.
89611148|NCT03219034|Experimental|Oral appliance - B|"Anti-snoring intra-oral appliance that consists of two custom fitted trays which fit over the upper and lower teeth uses a Bilateral Thrust Mechanism to advance the mandible. The trays are engaged by means of adjustable lugs.~Trade name: SomnoDent Flex Oral Appliance, SomnoMed Inc., Plano TX"
89611149|NCT01722370|Placebo Comparator|Medical air equivalent|Oxygen-nitrogen mix equivalent to medical air when inhaled from a cylinder at 2l/min
89611150|NCT01722370|Experimental|Oxygen|Ambulatory oxygen delivered at 2l/min on any activity performed by the patient, using a blinded cylinder
89611151|NCT01721668|Experimental|MSR - Music Supported Rehabilitation|Behavioral: Music Supported Rehabilitation
89611152|NCT01721668|Active Comparator|CU/ET|Experimental: CU/ET (Conventional Upper Extremity Therapy)
89611153|NCT04764435||Patients receiving dialysis at a physician-owned dialysis facility|All adults with Medicare fee-for-service in 2017 who received dialysis at a physician-owned dialysis facility. If a patient received dialysis at more than one facility in 2017, patients will be assigned to the facility that provided the plurality of dialysis in 2017.
89611154|NCT04764435||Patients receiving dialysis at a dialysis facility not owned by a physician|All adults with Medicare fee-for-service in 2017 who received dialysis at a dialysis facility not owned by a physician. If a patient received dialysis at more than one facility in 2017, patients will be assigned to the facility that provided the plurality of dialysis in 2017.
89611155|NCT04764435||Patients receiving dialysis at a facility owned by a large dialysis organization|All adults with Medicare fee-for-service in 2017 who received dialysis at a dialysis facility owned by a large dialysis organization (Davita or Fresenius). If a patient received dialysis at more than one facility in 2017, patients will be assigned to the facility that provided the plurality of dialysis in 2017.
89611156|NCT04764435||Patients receiving dialysis at a facility NOT owned by a large dialysis organization|All adults with Medicare fee-for-service in 2017 who received dialysis at a dialysis facility NOT owned by a large dialysis organization (Davita or Fresenius). If a patient received dialysis at more than one facility in 2017, patients will be assigned to the facility that provided the plurality of dialysis in 2017.
89611157|NCT01834690||liver transplantation recipients|adult liver transplantation recipients (>=20 years at the date of surgery)
89611158|NCT01722448|Experimental|Choline|Phosphatidyl choline
89611159|NCT01722448|Placebo Comparator|Placebo|Vegetable oil
89611160|NCT01834768|Experimental|A|Eplerenone
89611161|NCT01672671|Experimental|Neoadjuvant platinum-based chemotherapy|Doxorubicin, Paclitaxel, Cisplatin
89611162|NCT01722682|Active Comparator|A: intraportal islet infusion|Patients will received islet into the liver through the portal venous circulation (standard procedure)
89611163|NCT01722682|Experimental|B: intra BM islet infusion|Patients will received an intra BM islet infusion at the level of the iliac crest. The direct intra BM administration will be performed following the same procedures that our institution utilizes for administration of cord-blood cells in patients with acute leukemia (Lancet Oncol. 2008;9:831). The procedure is easy and reproducible: a standard needle for BM aspiration is inserted in the iliac crest and cells are gently infused.
89611164|NCT02463981|Experimental|neurofeedback training|Neurofeedback training group receives neurofeedback from their own anterior insula.
89611165|NCT02463981|Sham Comparator|sham control|Sham control group receives sham neurofeedback from a large control brain region.
89611166|NCT02459457|Active Comparator|Paclitaxel and Cisplatin (TP)|Patients receive TP concurrent with radiotherapy (1.8Gy/d, d1-5/week, 34Fx) Paclitaxel: 175mg/m2/d, ivgtt over 3 hours, d1; Cisplatin: 25mg/m2/d, ivgtt, d1-3, q4w*4
89611167|NCT02459457|Active Comparator|Paclitaxel and Fluorouracil (TF)|Patients receive TF concurrent with radiotherapy(1.8Gy/d, d1-5/week, 34Fx) Concurrent: paclitaxel 50mg/m2/d, ivgtt over 3 hours, d1; 5-FU 300mg/m2, civ 96h, d1-4, qw*6; Adjuvant: paclitaxel 175 mg/m2/d, ivgtt over 3 hours, d1; 5-FU 1800mg/m2, civ 72h, d1-3, q4w*2
89611168|NCT02459457|Active Comparator|Paclitaxel and Carboplatin（TC）|Patients receive TC concurrent with radiotherapy(1.8Gy/d, d1-5/week, 34Fx) Concurrent: paclitaxel 50mg/m2/d, ivgtt over 3 hours, d1; carboplatin AUC=2, ivgtt, d1, qw*6; Adjuvant: paclitaxel 175 mg/m2/d, ivgtt over 3 hours, d1; carboplatin AUC=5, ivgtt, d1, q4w*2
89611169|NCT01835236|Active Comparator|Trastuzumab, Pertuzumab, T-DM1|First line therapy: Trastuzumab, Pertuzumab Second line therapy: T-DM1
89611170|NCT01835236|Active Comparator|Trastuzumab, Pertuzumab, Paclitaxel or Vinorelbine plus T-DM1|First line therapy: Trastuzumab, Pertuzumab, Paclitaxel or Vinorelbine Second line therapy: T-DM1
89611171|NCT01671891||rectal cancer with stage II-IV|rectal cancer with stage II-IV intervention: pelvic radiotherapy (45-55Gy) concurrent chemotherapy using capecitabine and oxaliplatin
89611172|NCT03835468|Experimental|Galacto-oligosaccharides (GOS) Group|Participants in this group will receive the daily dosage of galacto-oligosaccharides (GOS) prebiotic for 4 weeks
89611173|NCT03835468|Placebo Comparator|Maltodextrin Group|Participants in this group will receive the daily dosage of Maltodextrin placebo for 4 weeks
89611174|NCT01830088|Experimental|Attachment Based Family Therapy|Attachment-Based Family Therapy (ABFT) is primarily a process oriented, emotion focused treatment guided by a semi-structured treatment protocol. ABFT aims to improve the family's capacity for problem solving, affect regulation, and organization. This strengthens family cohesion which can buffer against depression, suicidal thinking, and risk behaviors
89611175|NCT01830088|Active Comparator|Enhanced Usual Care|No attempt is made to control any aspect of the enhanced usual care except for pre-scheduled assessment plan
89034064|NCT05529459|Experimental|quantitative coronary angiography-guided percutaneous coronary intervention|Successful revascularization of all coronary artery lesions or segments ≥2.25 mm* in diameter with ≥50% diameter stenosis by QCA regardless of their functional significance
88815377|NCT01031498|Active Comparator|Ondansetron: Standard of Care|Standard of care, Ondansetron 8 mg IV as bolus followed by 24 mg IV from 30 minutes before chemotherapy until 12 hours after chemotherapy ends.
88815378|NCT01031498|Experimental|Palonosetron Group 1 (5 Days)|Palonosetron once a day 0.25 mg IV injection for 5 days, given over 30 seconds, 30 minutes before chemotherapy treatment.
88815379|NCT01031498|Experimental|Palonosetron Group 2 (3 Days)|Palonosetron once a day 0.25 mg IV injection on Days 1, 3, and 5 of chemotherapy treatment, given over 30 seconds, 30 minutes before chemotherapy treatment.
88815380|NCT01031810|Other|tranylcypromine|patients will receive treatment with tranylcypromine
89034065|NCT05529459|Active Comparator|fractional flow reserve-guided PCI|Successful revascularization of all coronary artery lesions or segments ≥2.25 mm in diameter with evidence of ischemia or hemodynamic significance by FFR ≤ 0.80 regardless of their anatomic severity†
89034066|NCT05526586|Experimental|Zero Alcohol Gum Prototype|Participants assigned to this group will brush their teeth using a marketed soft bristled toothbrush and Colgate Cavity Protection Toothpaste twice daily and rinse with 20 milliliters (mL) of the Zero Alcohol Gum Prototype Mouth Rinse for 30 seconds, twice a day following brushing on Day 0 under supervision and up to 12 weeks unsupervised at home.
89034067|NCT05526586|Experimental|Alcohol Gum Prototype|Participants assigned to this group will brush their teeth using a marketed soft bristled toothbrush and Colgate Cavity Protection Toothpaste twice daily and rinse with 20 mL of the Alcohol Gum Prototype Mouth Rinse for 30 seconds, twice a day following brushing on Day 0 under supervision and up to 12 weeks unsupervised at home.
89034068|NCT05526586|Experimental|Listerine Cool Mint Antiseptic Mouthwash|Participants assigned to this group will brush their teeth using a marketed soft bristled toothbrush and Colgate Cavity Protection Toothpaste twice daily and rinse with 20 mL of the Listerine Cool Mint Mouth rinse for 30 seconds, twice a day following brushing on Day 0 under supervision and up to 12 weeks unsupervised at home.
89034069|NCT05526586|Active Comparator|Negative Control: 5 percent (%) Hydroalcohol|Participants assigned to this group will brush their teeth using a marketed soft bristled toothbrush and Colgate Cavity Protection Toothpaste twice daily and rinse with 20 mL of the 5% Hydroalcohol Mouth Rinse for 30 seconds, twice a day following brushing on Day 0 under supervision and up to 12 weeks unsupervised at home.
89611176|NCT01830166|Experimental|Low Dose Radiation Focal Brachytherapy|Low Dose Radiation Focal Brachytherapy
89611177|NCT01830322|Experimental|CPI-613 Alone|This arm is for patients that have failed, or are not eligible for, all available therapies INCLUDING gemcitabine-based therapies. CPI-613 drug product, provided in concentrated form at 50 mg/mL, must be diluted with D5W prior to administration. CPI-613 is to be infused intravenously (IV) via a central venous catheter. CPI-613 will be given 2x weekly, administered on Days 1 and 4 of each of the 3 treatment weeks, followed by a week of rest. The dose of CPI-613 will be 3,000 mg/m2 infused IV over 2 hours (this is approximate maximum tolerated dosing [MTD]), via a central venous catheter with D5W running at a rate of about 125-150 mL/hr.
89611178|NCT01830322|Active Comparator|Any non-gemcitabine chemotherapies or best supportive care|This arm is for patients that have failed, or are not eligible for, all available therapies INCLUDING gemcitabine-based therapies. This arm includes any best-practice standard-of-care chemotherapies deemed appropriate by the clinical investigators, including the option for supportive care, following good clinical practice.
89611179|NCT01830322|Experimental|Gemcitabine + CPI-613 in combination|This arm is for patients who have failed, or are not eligible for, all available therapies EXCEPT gemcitabine-based therapies. When gemcitabine and CPI-613 are administered in combination, gemcitabine will be administered via 30-minute intravenous (IV) infusion at a concentration of 1,000 mg/m2 once-a-week on Day 1 for 3 consecutive weeks, followed by a week-of-rest. CPI-613 will be infused twice a week, administered on Days 1 and 4 for 3 consecutive weeks, followed by a week-of-rest, the same as gemcitabine. The dose of CPI-613 will be 710 mg/m2 infused IV over 2-hours (this is approximate maximum tolerated dosing [MTD] found from Phase I studies in combination with gemcitabine). To note, the dose of CPI-613 may be increased from 710 mg/m2 if ongoing Phase I trial data shows that the MTD of CPI-613 is higher than 710 mg/m2 CPI-613, diluted with D5W.
89611180|NCT01830322|Experimental|Gemcitabine alone or in combination with therapeutic agent(s)|This arm is for patients who have failed, or are not eligible for, all available therapies EXCEPT gemcitabine-based therapies. Gemcitabine, or Gemcitabine-based, chemotherapy will be administered via 30-minute intravenous (IV) infusion at a concentration of 1,000 mg/m2 once-a-week on Day 1 for 3 consecutive weeks, followed by a week-of-rest. This arm includes any best-practice standard-of-care Gemcitabine-based chemotherapies deemed appropriate by the clinical investigators following good clinical practice.
89611181|NCT03150069||Morquio A / Biological Mothers|Women with Morquio A who have biological children
89611182|NCT03150069||Morquio A / No Biological Children|Women with Morquio A who do not have biological children (both adoptive mothers and non-mothers)
89611183|NCT03150069||Morquio B / Biological Mothers|Women with Morquio B who have biological children
89611184|NCT03150069||Morquio B / No Biological Children|Women with Morquio B who do not have biological children (both adoptive mothers and non-mothers)
89034070|NCT05524454|Experimental|Novel CBCT Imaging|All subjects undergo one additional imaging session with the novel CBCT imaging system.
89034071|NCT05516888|Experimental|Radiofrequency of peripheral branches of the trigeminal nerve|pulsed radiofrequency treatment of the peripheral branches of the trigeminal nerve
89034072|NCT05516888|Active Comparator|Radiofrequency of gasserian ganglion|radiofrequency ablation of the gasserian ganglion
89034073|NCT05509608|Experimental|Electroretinogram Signal Quality|Electroretinogram Signal Quality: This Arm will participate in a comparative study using two ERG sensors, one commercially available (ERG Jet Electrode) and one seeking FDA approval (RM Electrode). This will be done by performing standard ERG test protocols with both electrodes worn one at a time, in one eye (random order) in ten healthy (normally-sighted) adult subjects.
89034074|NCT05509608|Experimental|Ocular Irritation|Ocular Irritation: Ten healthy (normally-sighted) adult subjects will wear the RM Electrode in one eye and the ERG Jet Electrode in the other eye for a total of 60 minutes, in 20-minute sessions with short breaks in between. The eyes will be evaluated for irritation (standard clinical grading scales for bulbar redness, limbal redness, tarsal redness, and slit-lamp examination of corneal staining) after each 20-minute interval.
89034075|NCT05497843|Experimental|Chiauranib capsule|Patients take chiauranib capsules 50mg, orally once daily, 21 days as a cycle until objective disease progression
89034076|NCT05496673|Experimental|Participants who are HIV negative|Patients who are assessed at Lira Regional Referral Hospital emergency room or are admitted to the pediatric, male or female medical wards at Lira Regional Referral Hospital with meningitis symptoms (defined as headache or irritability in combination with fever, confusion or Glasgow coma scale (GCS) <14, photophobia, neck pain/stiffness, seizure or bulging fontanel) will be approached to participate in the study.
89611185|NCT01722760||Term and preterm infants|Term and preterm infants
89611186|NCT03427281|Experimental|Cohort: Belgian orthopaedic surgeons & neurosurgeon|
89034077|NCT05496673|Experimental|Participants who are HIV positive, CrAg positive|All HIV-infected patients of any age, who receive care at the Lira Infectious Disease Center will be approached for screening for cryptococcal antigen. Those who test positive using the CrAg test will be included in this arm.
89034078|NCT05496673|Sham Comparator|Participants who are HIV positive, CrAg negative|All HIV-infected patients of any age, who receive care at the Lira Infectious Disease Center will be approached for screening for cryptococcal antigen. Those who test negative using the CrAg test will be included in this arm. All HIV-infected patients of any age, who receive care at the Lira Infectious Disease Center will be approached for screening for cryptococcal antigen. Those who test positive using the CrAg test will be included in this arm.
89034079|NCT05488626|Experimental|Adaptive Arm|Subjects in this arm will receive their external beam radiotherapy on the Ethos Radiotherapy System, with daily online adaptation of their radiation dosimetry plan to account for day-to-day changes in the tumor and surrounding anatomical structures. All subjects will received standard concurrent chemotherapy and may receive adjuvant immunotherapy, if indicated.
89034080|NCT05488626|Active Comparator|Non-Adaptive Arm|Subjects in this arm will receive their radiotherapy using standard image-guided radiation therapy (IMRT) techniques. All subjects will received standard concurrent chemotherapy and may receive adjuvant immunotherapy, if indicated.
89034081|NCT05487157||Actively employed social workers in Hungary|"Eligibility criteria: Social workers in Hungary, who are actively employed, 18 years of age or older, working in the field of elderly care.~Exclusion criteria: people, who do not have an active employment; currently have no job; working online; non-professional staff working in social care (eg. cleaning, maintenance)"
89034082|NCT05486338|Other|Gastric mucosal ablation|Participants receive submucosal injection followed by ablation of gastric mucosa using Hybrid Argon Plasma Coagulation (HAPC)
89034083|NCT05485415|Active Comparator|Intervention|Personalised intervention
89611187|NCT01722838|Experimental|B-ME intervention|Men will receive behavioral HIV prevention intervention, B-ME.
89611188|NCT01722838|No Intervention|Control Arm|Men in this arm will receive monthly text or telephone voice messages relaying general health messages.
89611189|NCT01835392|Experimental|Remote Ischemic Preconditioning|Four 5-minute cycles of leg ischemia interspersed with 5-minute cycles of reperfusion using a blood pressure cuff inflated to a pressure 15 mmHg greater than the systolic arterial pressure.
89611190|NCT01835392|Sham Comparator|Control|Placement of blood pressure cuff around leg without inflation for 40 minutes
89611191|NCT01725646|Active Comparator|Omacor® 4 g|Subjects in this group will take 4 g of Omacor® everyday.
89611192|NCT01725646|Active Comparator|Omacor® 2 g|Subjects in this group will take 2 g of Omacor® and 2 g of placebo everyday.
89611193|NCT01725646|Placebo Comparator|Placebo|Subjects in this group will take 4 g of placebo everyday.
89611194|NCT03293745|Active Comparator|Face to Face CBT-I (F2F)|Participants in the F2F arm will receive a standard 6-session course of Cognitive-Behavioral Therapy for Insomnia (CBT-I) delivered in-person, one-on-one with a qualified and experienced therapist.
89611195|NCT03293745|Experimental|Telemedicine CBT-I (TM)|Participants in the F2F arm will receive a standard 6-session course of Cognitive-Behavioral Therapy for Insomnia (CBT-I) delivered via the American Academy of Sleep Medicine (AASM) Sleep Telemedicine system. This telemedicine system provides an online videoconference platform in which a qualified and experienced therapist will deliver CBT-I to participants who will call in to the video therapy sessions with their provider from their homes using a webcam. All aspects of the treatment will remain identical to standard CBT-I delivered face-to-face, as described above, with the exception that the telemedicine technology will be used to deliver the treatment via video conference.
89611196|NCT01835704||Chronic pain associated to facet-joints|Patients where the pain can be localized to the facet joints.
89611197|NCT01835704||Chronic pain of other origin|Patients with pain that can not be localized to facet joints.
89611198|NCT03243669|Active Comparator|Fujinon standard|
89611199|NCT03243669|Active Comparator|Fujinon HD|Fujinon high-definition
89611200|NCT03243669|Active Comparator|Fujinon HD + VC|Fujinon high-definition + virtual chromoendoscopy
89611201|NCT03243669|Active Comparator|Olympus standard|
89611202|NCT03243669|Active Comparator|Olympus HD|Olympus high-definition
89611203|NCT03243669|Active Comparator|Olympus VC|Olympus virtual chromoendoscopy
89611204|NCT03243669|Active Comparator|Olympus HD + VC|Olympus high-definition + virtual chromoendoscopy
89611205|NCT03243669|Active Comparator|Pentax standard|
89611206|NCT03243669|Active Comparator|Pentax HD|Pentax high-definition
89611207|NCT03243669|Active Comparator|Pentax VC|Pentax virtual chromoendoscopy
89611208|NCT03243669|Active Comparator|Pentax HD + VC|Pentax high-definition + virtual chromoendoscopy
89611209|NCT00915148||Ultrasound examination|Women with prolonged Labour; Primi gravidae, single pregnancy, >37 weeks, fetus alive, cephalic presentation.
89611210|NCT04937127||Experimental Group|The experimental group will be made up of patients from nursing homes whose carers have received I-Learn training.
89611211|NCT04937127||Control Group|The control group will consist of nursing homes patients whose caregivers have not received I-Learn training and will continue their usual care, regardless of the practices already implemented.
89611212|NCT01725724|Active Comparator|Allogeneic blood|Allogeneic blood transfusion. Patients in this group will receive allogeneic red cell transfusions.
89611213|NCT01725724|Experimental|Autologous blood|Autologous blood transfusion. Patients in this arm will receive per- and postoperatively collected autologous blood collected with the Sangvia Blood Collection System. If teh amount of autologous blood is too small for the clinical need, additional allogeneic blood will be transfused.
89611214|NCT01673139|Experimental|Moderate exercise|Moderate exercise
89611215|NCT01673139|Experimental|Control|Control group
89611216|NCT01673139|Experimental|Interval exercise|interval exercise
89611217|NCT01725880||No treatment|Observation
89611218|NCT04379362|Experimental|Low or intermediate grade prostate cancer|
89611219|NCT03153969|Experimental|SHOFU Beautifil II LS|Composite: SHOFU Beautifil II LS, Bonding Agent: SHOFU BeautiBond
89611220|NCT03153969|Active Comparator|3M/ESPE Filtek Supreme|Composite: 3M/ESPE Filtek Supreme, Bonding Agent: 3M/ESPE Scotchbond Universal
89034084|NCT05485415|Placebo Comparator|Control|General sleep advice
89034085|NCT05484258|No Intervention|Standard Care|On baseline screen, would be screened for depression, alcohol use, and loneliness. Loneliness screen will be checked every 3 months.
89034086|NCT05484258|Active Comparator|Group Medical VIsits|For this arm, patients will have three visits of a shared medical visit, wherein a physician/APP will partner with a social worker to give a discussion about topics relevant to the high need population, including managing multiple medications, managing stress, and also palliative care.
89034087|NCT05477888||Questionnaires assessed e-cigarette users|"≥18 years old;~Those who used e-cigarettes at least once a week for the past month;~Be able to read and communicate in Chinese."
89611221|NCT01706198|Experimental|FF/VI|fluticasone furoate (FF) + vilanterol (VI) once daily via a Novel Dry Powder Inhaler
89611222|NCT01706198|Active Comparator|ICS or ICS/LABA maintenance therapy|inhaled corticosteroid (ICS) alone or in combination with a long acting beta2-agonist (LABA)
89611223|NCT03079323|Experimental|PART-trial|External beam radiotherapy
89611224|NCT01835860|Other|Embolization|Prostate artery embolization
89034088|NCT05477381||Asymptomatic women with a history of preterm birth|Pregnant women >18 years of age, with a history of spontaneous PTB before 34 weeks. All women have biweekly visits for routine transvaginal cervical length measurement between 14-24 weeks of gestation. During these visits data on cervical softening will be collected as additional marker.
89034089|NCT05477381||Symptomatic women with symptoms of threatened preterm birth|Pregnant women >18 years of age, between 24 and 34 weeks of gestation, presenting with symptoms of threatened Preterm birth (e.g. abdominal pain, blood loss, contractions, or other complaints suggestive for threatened Preterm birth).
89611225|NCT04378972||TREATED GROUP|25 portions of vitreous samples from 25 eyes of patients operated on vitrectomy for complications from diabetic retinopathy, incubated with curcumin, homotaurine and vitamin D3. The substances will be used individually and in triple association, to evaluate a possible synergistic effect on the expression of inflammatory cytokines and endothelial growth factors.
89611226|NCT04378972||CONTROL GROUP|The same fractions of vitreous samples (n = 25) evaluated for the expression of oxidative biomarkers, inflammatory cytokines and metalloproteinases, without prior incubation with the substances of the treated group.
89611227|NCT01723150|Experimental|Oral antibiotics|The intervention arm switched to oral antibiotics to complete 4 weeks of therapy. Oral antibiotics will be ciprofloxacin (or trimethoprim/sulfamethoxazole if the isolate is resistant).
89034090|NCT05474846|Experimental|Combination Therapy (BLT+MT+MP with CBT)|Patients receive Melatonin (called MT) PO QD for 6 weeks, Methylphenidate (called MP) PO BID for 6 weeks, Bright Light Therapy (called BLT) for 30 minutes daily for 6 weeks, and Cognitive Behavior Therapy (called CBT) weekly for 6 weeks.
89034091|NCT05474846|Experimental|Placebo (CLT+ placebo MT + placebo MP with CBT)|Patients receive placebo Melatonin (called placebo MT) PO QD for 6 weeks, placebo Methylphenidate (called placebo MP) PO BID for 6 weeks, Control Light Therapy (called CLT) for 30 minutes daily for 6 weeks and Cognitive Behavior Therapy (called CBT) weekly for 6 weeks.
89034092|NCT05474846|Experimental|Bright light and Melatonin (BLT + MT+ placebo MP with CBT)|Patients receive Bright Light Therapy (called BLT) for 30 minutes daily for 6 weeks, Melatonin (called MT) PO QD for 6 weeks, placebo Methylphenidate (called placebo MP) PO BID for 6 weeks, and Cognitive Behavior Therapy (called CBT) weekly for 6 weeks.
89034093|NCT05474846|Experimental|Methylphenidate (CLT + placebo MT + MP with CBT)|Patients receive Control Light Therapy (called CLT) for 30 minutes daily for 6 weeks, placebo Melatonin (called placebo MT) PO QD for 6 weeks, Methylphenidate (called MP) PO BID for 6 weeks, and Cognitive Behavior Therapy (called CBT) weekly for 6 weeks.
89034094|NCT05474586|Experimental|Collavant n2 40 mg/day|2 capsules in the morning before breakfast and 2 capsules at night before going to bed for 180 days
89034095|NCT05474586|Active Comparator|Glucosamine hydrochloride & Chondroitin sulfate|2 capsules in the morning before breakfast and 2 capsules at night before going to bed for 180 days
89034096|NCT05474586|Placebo Comparator|Microcrystalline cellulose|2 capsules in the morning before breakfast and 2 capsules at night before going to bed for 180 days
89034097|NCT05473039|Experimental|Seidivid Ferty4|Patients included in this group will be administered dietary supplement Seidivid Ferty4 (2 capsules per day, as a single dose) for at least 30 days prior to controlled ovarian hyperstimulation and until the day of the agonist trigger (GnRH a).
89034098|NCT05473039|Placebo Comparator|Placebo|Patients included in this group will be administered placebo (2 capsules per day, as a single dose) for at least 30 days prior to controlled ovarian hyperstimulation and until the day of the agonist trigger (GnRH-a).
89034099|NCT05472090|Experimental|TNX-102 SL Tablet, 5.6 mg|1 x TNX-102 SL 2.8 mg Tablet taken sublingually each day at bedtime for 2 weeks, then 2 x TNX-102 SL 2.8 mg (5.6 mg) Tablet taken sublingually each day at bedtime for 12 weeks.
89034100|NCT05472090|Placebo Comparator|Placebo SL Tablet|1 x Placebo Tablet taken sublingually each day at bedtime for 2 weeks, then 2 x Placebo Tablet taken sublingually each day at bedtime for 12 weeks.
89034101|NCT05470413|Active Comparator|SHR0302 4 mg|Drug：SHR0302
89034102|NCT05470413|Active Comparator|SHR0302 8 mg|Drug：SHR0302
89611228|NCT01723150|Active Comparator|Intravenous antibiotics|The active comparator arm continues intravenous antibiotics to complete 4 weeks of therapy. Intravenous antibiotics will be ceftriaxone (or ertapenem if the isolate is resistant).
89611229|NCT01725958|Experimental|Dietary Supplement|"Treatment Regimen~-The Nutritional Supplement will be given for approximately 90 days in the form of 7 capsules and a powder to mix into liquids or foods for the first 15 days of program. Subjects will also drink a protein shake."
89611230|NCT01835938|Experimental|1- Erlotinib|"Erlotinib is a first class HCV entry inhibitor. In this study, Erlotinib will be administered in escalating doses in sequential patient cohorts for 14 days as follows:~Dose level (DL) 1 = 50 mg / day,~Dose level (DL) 2 = 100 mg / day, and~Dose level (DL) 3 = 150 mg / day .~Each Dose Level (DL) includes 4 patients (3 patients treated with Erlotinib and one patient treated with the Placebo). Dose escalation will proceed to the subsequent DL in the absence of DLT (dose-limiting toxicity) in 2 patients receiving Erlotinib."
89611231|NCT01835938|Placebo Comparator|placebo|
89611232|NCT01726114|Experimental|Non-invasive Optical Glucose Monitor™|Test device
89688398|NCT00939211|Placebo Comparator|Placebo for Spiriva First, then Placebo for AZD9164|1 x placebo Spiriva dry powder for inhalation + 1 x placebo for AZD9164 (sodium chloride)
89611233|NCT01836016|Experimental|conventional medicine|According to the individualized assessment of symptoms and exacerbation risk recommended by revised 2011 GOLD, patients in this group will be given conventional medicine treatment including three drugs, which are Salbutamol (Ventolin®), Formoterol (Oxis Turbuhaler®), Salmeterol / fluticasone (Seretide®).
88983531|NCT04020887|Experimental|Interaction Phase|In the three months following the observation phase, clinicians in the telemedicine center will interact with clinicians and patients in the two designated PACU bays using audio-visual technology. The clinicians in the telemedicine center will continue to document information on physiological derangements, treatable symptoms, situations requiring urgent medical intervention, and discharge readiness.
88983532|NCT03993301|Experimental|Probiotic A formula|Infant Formula with Lactobacillus salivarius AP-32
88983533|NCT03993301|Experimental|Probiotic B formula|Infant Formula with Bifidobacterium animalis subsp. lactis CP-9
88983534|NCT03993301|Placebo Comparator|Regular formula|The infant formula without any probiotic.
88983535|NCT03987295|Experimental|Granulin|IV administration of AL001; 60 mg/kg, every 4 weeks [q4w]
88983536|NCT03987295|Experimental|C9orf72|IV administration of AL001; 60 mg/kg, every 4 weeks [q4w]
88983537|NCT03972553|Other|Sugarbaker|For the Sugarbaker group, the bowel will be brought through the peritoneum lateral to the edge of the retromuscular mesh and then draped over the mesh before bringing it through the anterior fascia medially.
88983538|NCT03972553|Other|Keyhole|For the Keyhole group the stoma will be taken down and rematured through a cruciate incision (keyhole)
88983539|NCT03948919|Active Comparator|FMT Treatment|Fecal microbiota - 1.0-3.0 x 10^11 CFU / day (2 capsules per day for 8 weeks).
88983540|NCT03948919|Placebo Comparator|Placebo|The placebo consists of a mixture of trehalose and crystalline methylcellulose (Avicel) in 6:1 (w/w) ratio that is packaged in size 0 swedish orange capsules, which are then double encapsulated in size 00 natural colored capsules to make them visibly indistinguishable from encapsulated active product. Two capsules taken daily for 8 weeks.
88983541|NCT03923465|Active Comparator|EPP with EMD+BS|Using minimally invasive surgery, entire papilla preservation technique with the adjunctive use of amelogenins and bone substitutes
88983542|NCT03923465|Other|EPP without EMD+BS|Using minimally invasive surgery, entire papilla preservation technique without the adjunctive use of amelogenins and bone substitutes
88983543|NCT03895567|Experimental|ABC|A. Ceftriaxone (Roche ®) 500mg (slow intravenous injection) B. Ceftriaxone rectal dosage form test formulation 1- hard-shell gelatin capsule (1 x 500mg) C. Ceftriaxone rectal dosage form test formulation 2- rectodispersible mannitol-based tablet (1 x 500mg)
88983544|NCT03895567|Experimental|ACB|A. Ceftriaxone (Roche ®) 500mg (slow intravenous injection) C. Ceftriaxone rectal dosage form test formulation 2- rectodispersible mannitol-based tablet (1 x 500mg) B. Ceftriaxone rectal dosage form test formulation 1- hard-shell gelatin capsule (1 x 500mg)
88983545|NCT03895567|Experimental|BAC|B. Ceftriaxone rectal dosage form test formulation 1- hard-shell gelatin capsule (1 x 500mg) A. Ceftriaxone (Roche ®) 500mg (slow intravenous injection) C. Ceftriaxone rectal dosage form test formulation 2- rectodispersible mannitol-based tablet (1 x 500mg)
88983546|NCT03895567|Experimental|BCA|B. Ceftriaxone rectal dosage form test formulation 1- hard-shell gelatin capsule (1 x 500mg) C. Ceftriaxone rectal dosage form test formulation 2- rectodispersible mannitol-based tablet (1 x 500mg) A. Ceftriaxone (Roche ®) 500mg (slow intravenous injection)
88983547|NCT03895567|Experimental|CAB|C. Ceftriaxone rectal dosage form test formulation 2- rectodispersible mannitol-based tablet (1 x 500mg) A. Ceftriaxone (Roche ®) 500mg (slow intravenous injection) B. Ceftriaxone rectal dosage form test formulation 1- hard-shell gelatin capsule (1 x 500mg)
88983548|NCT03895567|Experimental|CBA|C. Ceftriaxone rectal dosage form test formulation 2- rectodispersible mannitol-based tablet (1 x 500mg) B. Ceftriaxone rectal dosage form test formulation 1- hard-shell gelatin capsule (1 x 500mg) A. Ceftriaxone (Roche ®) 500mg (slow intravenous injection)
88983549|NCT03892967|Experimental|Supportive care (interview)|Patients randomized to E2C2 intervention participate in an interview over 30-45 minutes. Providers and stakeholders also participate in an interview over 15-30 minutes.
88983550|NCT03876678|Experimental|Light therapy and oral L. salivarius AP-32|Light therapy and taking 1 L. salivarius AP-32 probiotic capsule two times everyday for 7 days.
88983551|NCT03876678|Experimental|Light therapy and oral B. animalis subsp. lactis CP-9|Light therapy and taking 1 B. animalis subsp. lactis CP-9 probiotic capsule two times everyday for 7 days.
88983552|NCT03876678|Placebo Comparator|Light therapy and oral placebo|Light therapy and taking 1 placebo capsule two times everyday for 7 days.
88983553|NCT03839121||single arm: CRT-DX|
88983554|NCT03793465|Experimental|Tart Cherry Concentrate|Single arm, open-label design. Commercial Montmorency tart cherry juice concentrate. Servings (1 ounce or 2 tablespoon/serving) per day for three days
88983555|NCT03774810|Experimental|Continuous|Nightly active dose (QHS). The intervention is zolpidem tartrate 5 mg or 10 mg.
88983556|NCT03774810|Experimental|Partial Reinforcement 1|1 active dose per week with 6 placebos interspersed between the active dose. The intervention is zolpidem tartrate 5 mg or 10 mg.
88983557|NCT03774810|Experimental|Partial Reinforcement 3|3 active doses per week with 4 placebos interspersed between the active doses. The intervention is zolpidem tartrate 5 mg or 10 mg.
88983558|NCT03774810|Experimental|Low Frequency Intermittent Dosing|1 to 3 active doses per week PRN. The intervention is zolpidem tartrate 5 mg or 10 mg.
88983559|NCT03758521||BCH Cohort|Patients enrolled at BCH will travel to BCH every 2 years at a minimum for comprehensive evaluation taking place over a 48 hour period. Visits to BCH may occur within ± 2 months of the scheduled visit date. Electronic surveys will be sent out every 6 months.Visits will consist of clinical assessments (demographics, medical history, physical examination, neurological exam, medication history, neuropsychological assessments, and clinical severity score), neurophysiological assessments (Brain Magnetic resonance imaging [MRI/MRS/DTI], Electroencephalogram [EEG], and Transcranial magnetic stimulation [TMS]), and yearly bio-specimen collection.
89034103|NCT05470413|Placebo Comparator|Placebo|Drug: Placebo
89034104|NCT05467488|No Intervention|Non irradiated implants (group A)|
89034105|NCT05467488|Active Comparator|UVA irradiated group (group B)|
89034106|NCT05467488|Active Comparator|UVC irradiated group (group C)|
89611234|NCT01836016|Experimental|traditional Chinese medicine|Patients in this group will receive four types of TCM treatment according to traditional Chinese syndrome differentiation and treatment, which are Bufei granule, Bufeijianpi granule, Bufeiyishen granule and Yiqizishen granule.
89611235|NCT01836016|Experimental|conventional medicine + TCM|Patients in this group will receive conventional medicine and traditional Chinese medicine.
89611236|NCT04378816|Experimental|QPL intervention group|Using shared decision making support tool(Question Prompt List) for intervention
89611237|NCT04378816|No Intervention|Usual care group|No intervention, just continue using usual care
89611238|NCT01723306|Experimental|2nd Generation Designer T Cells|All participants will receive gene modified T cells, with concomitant IL2 for 30 days post infusion.
89611239|NCT01836094|Experimental|Methylene Blue|Methylene Blue, 280mg, oral, one time
89611240|NCT01836094|Placebo Comparator|Placebo|FD&C Blue No. 2 (food dye), oral, one time
89611241|NCT01705730||Tocilizumab|Participants with rheumatoid arthritis (RA) received tocilizumab monotherapy according to individualized physician-prescribed regimens.
89611242|NCT01726192|Active Comparator|HLOC|Placement of a femoral catheter with the hydrolocalization technique
89611243|NCT01726192|Active Comparator|NS|Placement of a femoral neurostimulating catheter
89611244|NCT01836172|Placebo Comparator|Placebo t.i.d.|Placebo t.i.d.
89611245|NCT01836172|Placebo Comparator|YJP-14 25 mg t.i.d.|YJP-14 25 mg t.i.d. YJP-14 is a 50% ethanolic extract of Lindera obtusiloba stems.
89611246|NCT01836172|Placebo Comparator|YJP-14 50 mg t.i.d.|YJP-14 50 mg t.i.d. YJP-14 is a 50% ethanolic extract of Lindera obtusiloba stems.
89611247|NCT01836172|Placebo Comparator|YJP-14 100 mg t.i.d.|YJP-14 is a 50% ethanolic extract of Lindera obtusiloba stems. YJP-14 100 mg t.i.d.
89611248|NCT01836328|Active Comparator|Parenteral /oral methadone ratio 1:2|"Far advanced cancer patients with cancer pain hospitalized, and treated with PMTD undergo a preliminary 48 hours observation phase.~Blinded evaluators assess pain management and treatment toxicity and determine an OPTIMISED DOSE of parenteral METHADONE (pain control without toxicity) for each patient.~Only patients with a correct control of pain and without significant toxicity throughout this period are eligible for randomization.~INTERVENTION: Patients randomized to this arm will receive the double of OPTIMISED DOSE of parenteral METHADONE, orally every 24h in 3 administrations during the following 3 days."
89611249|NCT01836328|Experimental|Parenteral /oral methadone ratio 1:1.2|"Far advanced cancer patients with cancer pain hospitalized, and treated with PMTD undergo a preliminary 48 hours observation phase.~Blinded evaluators assess pain management and treatment toxicity and determine an OPTIMISED DOSE of parenteral METHADONE (pain control without toxicity) for each patient.~Only patients with a correct control of pain and without significant toxicity throughout this period are eligible for randomization.~INTERVENTION: Patients randomized to this arm will receive the following Oral Methadone dose: 20% increase of optimised parenteral methadone dose every 24h in 3 administrations during the following 3 days."
89611250|NCT01726348||Darunavir|Patients will be taking darunavir as per the dosing regimen given on product insert approved in Philippines.
89611251|NCT01726426|Experimental|Patients of palmer arsenical keratosis|Probiotics Capsule (Lactobacillus- 2 billion, Bifidobacterium- 1 billion, fructo-oligosaccharide): 1 capsule twice daily orally for 12 weeks
89611252|NCT01726426|Active Comparator|Arsenic exposed controls|Probiotics Capsule (Lactobacillus- 2 billion, Bifidobacterium- 1 billion, fructo-oligosaccharide): 1 capsule twice daily orally for 12 weeks
89611253|NCT01726426|Active Comparator|Heathy volunteers|Probiotics Capsule (Lactobacillus- 2 billion, Bifidobacterium- 1 billion, fructo-oligosaccharide): 1 capsule twice daily orally for 12 weeks
88983560|NCT03758521||iNTD Cohort|Patients enrolled at iNTD sites will travel to their iNTD site according to standard of care requirements. Data collection includes clinical history and relevant laboratory-chemical, therapeutic, instrumental and neuropsychological parameters by the study centers. Data collection takes place within the framework of elective outpatient visits. The collected parameters are congruent with the current standard investigations. Electronic surveys will be sent out every 6 months. Imaging and neurophysiological data will be collected if performed during the clinical visit or if performed as part of the site's ongoing research. Yearly bio-specimen collection will be attempted after consent is obtained from the family.
88983561|NCT03758521||Standard of Care Cohort|Patients enrolled at other sites will attend their visit at their regular clinical site as mandated by standard of care. Data collection includes medical history, family history, medications, and all clinical and neuropsychological assessments listed. Imaging and neurophysiological data will be collected if performed during the clinical visit or if performed as part of the clinical site's ongoing research. Yearly bio-specimen collection will be attempted.
88983562|NCT03744429|Experimental|Mediterranean Meal Plan|This is a single arm study in which participants will receive meals that follow a Mediterranean diet plan for 4 weeks. Breast milk samples will be collected before, during, and after the intervention period.
89611254|NCT04379128||patients with epilepsy|Attentional tasks : D2-R task and TAP battery (sustained attention, alertness, divided attention) executive task : digit span, incompatibility and flexibility task (TAP battery), verbal fluencies depression score (NDDI-E scale) and anxiety score (GAD-7 scale)
89611255|NCT04379128||Normal controls|Attentional tasks : D2-R task and TAP battery (sustained attention, alertness, divided attention) executive task : digit span, incompatibility and flexibility task (TAP battery), verbal fluencies depression score (NDDI-E scale) and anxiety score (GAD-7 scale)
89611256|NCT04378894|Experimental|MOCEP|MOCEP is implemented over a period of 25 weeks, through weekly group meetings that last approximately three hours.
89611257|NCT04378894|Active Comparator|Waitlist Control Group|For ethical reasons, no one recruited will be excluded from the opportunity to benefit from the intervention. MOCEP group will be the primary intervention group and the second group will act as the wait-listed control group. Families in the wait-listed control group will participate in a special awareness program but not MOCEP. Although the families in the wait-listed control group will start as a control group (not receiving the intervention), they will have the opportunity to participate in the intervention in a later round of implementation, after the intervention group has completed the program.
89611258|NCT01705652|Experimental|Nexrutine Surgery Group|Surgery Group: Nexrutine 500mg by mouth, three times per day, given prior to surgery.
89611259|NCT01705652|Experimental|Nexrutine Radiation Group|Radiation Group: Nexrutine 500mg by mouth, three times per day, given prior to and during radiation treatment.
89611260|NCT01723540|Experimental|Minilaparotomy cholecystectomy with ultrasonic scissors|Minilaparotomy vs laparoscopy
89611261|NCT01723540|Active Comparator|Laparoscopic cholecystectomy|Minilaparotomy vs laparoscopy
89611262|NCT01836406|Experimental|Keromin Group|
89611263|NCT01836406|Placebo Comparator|Placebo Group|
89611264|NCT01723618|Experimental|CRD007 10 mg|CRD007, 10 mg tablet, single dose
89611265|NCT01723618|Experimental|CRD007 25 mg|CRD007, 25 mg tablet, single dose
89611266|NCT01723618|Experimental|CRD007 40 mg|CRD007, 40 mg tablet, single dose
89611267|NCT01836484||Surgically staged endometrial and cervical carcinoma|
89611268|NCT01836562|Other|STEM CELL|intra thecal injection of MNC stem cell therapy
89611269|NCT01726816|Experimental|Probucol 250mg/day|Probucol 250mg group: probucol 250mg 2 tablets, 16 weeks
89611270|NCT01726816|Experimental|Probucol 500mg/day|Probucol 500mg group: probucol 250mg 2 tablets, 16 weeks
89611271|NCT01726816|Placebo Comparator|Placebo|Placebo group: placebo 2 tablets, 16 weeks
89611272|NCT01836796|Active Comparator|Lactobacillus Reuteri low|100 million Lactobacillus Reuteri once daily
89611273|NCT01836796|Active Comparator|Lactobacillus Reuteri High|10 billion Lactobacillus Reuteri once daily
89611274|NCT01836796|Placebo Comparator|Placebo|
89611275|NCT01726894|Experimental|Irreversible Electroporation|
89611276|NCT00915538|Other|Group 1 / use of pMDI as approved|The intervention in this group will use inhalation from the pMDI containing budesonide/formoterol pMDI 160/4.5 2 inhalations as approved. (FDA approved product information) without a spacer. The pulmonary function tests (PFTs) will be collected at baseline and for a period of 12 hours post inhalation of 2 inhalation of budesonide /formoterol; pMDI160/5.
89611277|NCT00915538|Experimental|Group 2 / pMDI with Aerochamber Plus|The intervention in this group will use the pMDI budesonide/formoterol 160/4.5 with a valve holding chamber spacer device, Aerochamber Plus which is the intervention being studied The PFTs will be collected at baseline and for a period of 12 hours post inhalation of 2 inhalation of Symbicort 160/5. This is the intervention to be studied for comparison to the non-spacer inhalations..
89611278|NCT01836874||Topiramate|
89611279|NCT01724086|Experimental|Panel 1|10 chronic HCV genotype 1a (GT1a) infected treatment-naive patients/prior relapsers who will receive 12 weeks of treatment with TMC435 + TMC647055 + low-dose ritonavir and ribavirin.
89611280|NCT01724086|Experimental|Panel 2 Arm 1|10 chronic HCV GT1b infected treatment-naive patients/ prior relapsers will receive TMC435 + TMC647055 + low-dose ritonavir and ribavirin.
89611281|NCT01724086|Experimental|Panel 2 Arm 2|10 chronic HCV GT1b infected treatment-naive patients/ prior relapsers will receive TMC435 + TMC647055 + low-dose ritonavir.
89611282|NCT01724086|Experimental|Panel 3 - Arm 1|8 chronic HCV GT1a infected treatment naïve patients/prior relapsers will receive TMC435 + TMC647055 + low-dose ritonavir + ribavirin.
89611283|NCT01724086|Experimental|Panel 3 - Arm 2|8 chronically HCV GT1b infected treatment naïve patients/prior relapsers will receive TMC435 + TMC647055 + low-dose ritonavir.
89611284|NCT01724086|Experimental|Panel 4 - Arm 1|20 chronic HCV GT1a or GT1b infected treatment-naive patients/ prior relapsers will receive 12 weeks of treatment with TMC435 + TMC647055 + low-dose RTV + GSK2336805 (30 mg once daily)
89611285|NCT01724086|Experimental|Panel 4 - Arm 2|20 chronic HCV GT1a or GT1b infected treatment-naive patients/ prior relapsers will receive 12 weeks of treatment with TMC435 + TMC647055 + low-dose RTV + GSK2336805 (60 mg once daily)
89611286|NCT00913510|Experimental|CIC using LoFric Primo|Anticholinergic medication according to clinical practice and investigator´s judgement and start of CIC using LoFric Primo catheters, i.e. Drug + Device.
89611287|NCT00913510|Active Comparator|Anticholinergic medication|Anticholinergic medication according to clinical practice and investigator´s judgement, i.e. Drug.
89611288|NCT01727050|Active Comparator|Mechanical stapling|
89611289|NCT01727050|Active Comparator|Fibrin sealant spray|
89611290|NCT03836638|Experimental|Low dose young subjects|Group 1 patients will be 25-35 years old and will be injected with 30 units of botulinum toxin into the upper face
89611291|NCT03836638|Experimental|Low dose older subjects|Group 2 patients will be older than 45 and will be injected with 30 units of botulinum toxin into the upper face
89611292|NCT03836638|Active Comparator|high dose older subjects|Group 3 patients will be older than 45 and will be treated with the usual 50 units dose into the upper face (control group)
89611293|NCT01727128|Experimental|Mild Hepatic Impaired Group|Subjects can only be enroled into this group if they fit the Child -Pugh score criteria of severity category - mildly hepatically impaired
89611294|NCT01727128|Experimental|Moderate Hepatic Impaired group|Subjects can only be enroled into this group if they fit the Child -Pugh score criteria of severity category - moderately hepatically impaired
89611295|NCT01727128|Experimental|Severe Hepatic Impaired Group|Subjects can only be enroled into this group if they fit the Child -Pugh score criteria of severity category - Severely hepatically impaired
89611296|NCT01727128|Experimental|Control Group|Matching healthy control subjects who do not have hepatic impairment and are matched to the hepatic impaired subjects by sex, age, gender and BMI
89611297|NCT01727206|Experimental|Tocilizumab|Tocilizumab 8 mg/kg intravenously every month for six months
89611298|NCT01724164|Experimental|Robotic assisted therapy|This protocol includes 5 to 10 min of warm-up, 1 hr of RR, and 15 to 20 min of functional activities training. The treatment intensity is 1.5 hours/day, 5days/week for 4 consecutive weeks. The RR session uses the robot-assisted arm trainer, Bi-Manu-Track (Reha-Stim Co., Berlin, Germany).
89611299|NCT01724164|Experimental|Mirror Therapy|This protocol includes 1 hour mirror therapy and 0.5 hour functional training in a session. The treatment intensity is 1.5 hours/day, 5 days/week, for 4 weeks. MT focuses on symmetrical bimanual movements and simultaneously observing the mirror visual feedback reflected by the unaffected upper extremity.
89611300|NCT01724164|Active Comparator|Conventional Rehabilitation|Participants in this group receive a structured protocol based on occupational therapy such as neuro-developmental techniques and task-oriented approach. The treatment dose is matched to RR and MT groups.
89611301|NCT01724164|Experimental|Robotic rehabilitation with FES|This combined RR-FES treatment involves the same protocol as the RR regimen except that patients receive FES concurrently with RR.
89611302|NCT01724164|Placebo Comparator|Robotic Rehabilitation with PI|The RR-PI protocol is the same as the RR-FES protocol described above except that the surface electrodes are attached to the same target muscles on the affected upper limb but there is no output of electrical stimulation.
89611303|NCT01836952||Infants|Infant born via vaginal delivery
89611304|NCT01724242|Experimental|Vaginal DHEA|Vaginal DHEA 0.5%(6.5mg)inserted nightly
89611305|NCT01724242|Placebo Comparator|Placebo|
89611306|NCT01724320|Experimental|OTX008|Single-arm study of OTX008 given subcutaneously, daily without interruption to patients with advanced solid tumors. Starting dose: 65 mg/day.
89611307|NCT01837030|Other|Oral Iron|
89611308|NCT01837030|Other|Oral Iron and Capsule Endoscopy|
89611309|NCT01837108|Placebo Comparator|Placebo|fully mimicking placebo 50 mg bid during 8 days
89611310|NCT01837108|Experimental|eplerenone|eplerenone 50 mg bid during 8 days
89611311|NCT01727596|Experimental|1|
89611312|NCT01724398|Experimental|Conventional treatment|Participants will receive conventional treatment and then be followed until the week 48 study visit.
89611313|NCT01724398|Experimental|Conventional plus UC-MSC treatment|Participants will receive conventional treatment plus a dose of UC-MSC and then be followed until the week 48 study visit.
89210771|NCT00567996|Placebo Comparator|Placebo|"Placebo to Indacaterol once daily in the morning, inhaled via a single dose dry powder inhaler (SDDPI). Placebo to Salmeterol delivered twice daily via a proprietary dry powder inhaler in the morning and in the evening.~Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study."
89611314|NCT01724398|Experimental|Conventional plus PE treatment|Participants will receive conventional treatment plus plasma exchange and then be followed until the week 48 study visit.
88983565|NCT03715335|No Intervention|Baseline|Current STI screening rates.
88983566|NCT03715335|Active Comparator|Targeted STI Screening|"Data from the Sexual Health Screen (SHS) will be integrated into the Electronic Health Record (EHR) and will provide Clinical Decision Support (CDS) for GC/CT testing based on SHS-calculated STI risk. Patients will be classified as at high risk for STIs, at risk or low risk if they deny any history of sexual activity. When patients classify as at high risk, clinicians will receive CDS that STI testing is highly recommended; when they care for patients who classify as at risk, they will receive CDS that STI testing is recommended; when caring for patients who classify as at low risk, they will receive CDS that STI testing is not necessary at this time. If the clinician chooses to follow the recommendation for screening based on patient's risk assessment, and the patient consents to testing on the tablet device, urine GC/CT testing will be performed."
88983567|NCT03715335|Active Comparator|Universally Offered STI Screening|During the universally offered screening intervention, STI screening will be offered to all eligible adolescents, regardless of risk. All eligible patients will also complete the SHS, will be informed of the CDC GC/CT testing recommendations and then be given the option to decline STI testing using the tablet device. During this phase, the SHS results will not be available to the clinician. STI testing recommendations will be based only on the patient's decision to undergo GC/CT testing. Like the process followed in the targeted screening phase, if the clinician follows the CDS that informs the clinician that the patient agreed to GC/CT screening and consequently orders testing, urine GC/CT testing will be performed.
88983568|NCT03704194|Experimental|Adapted LiFE|Participants in the Adapted LiFE group learns to imbed 19 exercise activities (7 balance and 12 lower extremity muscle strength activities) into daily routines. An Occupational Therapy practitioner conducts 7 in-home visits over 12 weeks and a follow phone call a month after the last in-home visit.
88983569|NCT03704194|Sham Comparator|Attention control|Participants in the attention control group will learn gentle stretch exercise. An Occupational Therapy practitioner conducts 7 in-home visits over 12 weeks and a follow phone call a month after the last in-home visit.
89611315|NCT01724398|Experimental|Conventional plus UC-MSC and PE therapy|Participants will receive conventional treatment plus umbilical cord mesenchymal stem cells transplantation combined with plasma exchange. Participants will then be followed until the week 48 study visit.
89611316|NCT01724476|Active Comparator|folate with B12|Subjects randomized to the folate with B12 group will take 1 capsule of 400mcg per day of folate with B12.
89611317|NCT01724476|Placebo Comparator|placebo|Subjects randomized to the placebo group will take 1 capsule of placebo per day.
89611318|NCT01837186||EFP|Empyema following pneumonectomy
89611319|NCT01837186||nEFP|No empyema following pneumonectomy
89611320|NCT01724554|Experimental|Every Month Treatment|Patients will receive Intravitreal Aflibercept Injection (IAI) every month for the 12 month duration of the study.
89611321|NCT01724554|Experimental|Every Month, then Every Other Month|Patients will receive Intravitreal Aflibercept Injection (IAI) every month for the first 6 months, then every other month for the next 6 months. Retreatment criteria will allow for patients to be treated every month in the second 6 months if needed.
89611322|NCT01724632|Active Comparator|Group Treatment|Participants who are assigned to group treatment will attend group meetings weekly for the first 6 months, then every 2 weeks for 6 months, and then monthly for the final 6 months. Participants will be weighed individually at the start of each group meeting.
89611323|NCT01724632|Active Comparator|Individual Treatment|Participants who are assigned to individual treatment will attend one-on-one sessions with a weight loss counselor every month for 18 months.
89611324|NCT01724632|Experimental|Smartphone Treatment|Participants who are assigned to smartphone treatment will use a smartphone to learn and practice weight loss skills. They will also attend one-on-one sessions with a weight loss counselor every month for 18 months.
89611325|NCT01727752|Active Comparator|Surgical decompression|Surgical decompression
89611326|NCT01727752|Active Comparator|coflex Interlaminar Technology|Surgical decompression followed by implantation of coflex Interlaminar Technology.
89611327|NCT03835936|Active Comparator|Manual maneuvers physiotherapy|The protocol of physiotherapy treatment techniques consists of 20 minutes of FR based on prolonged slow expiration and cough provoked.
89611328|NCT03835936|Experimental|High frequency compression chest wall|The protocol consists in the application of the Smart Vest® device for high frequency compression of the chest wall, with a fixed frequency of 13 Hz and a time of 15 minutes. Then during 20 minutes will apply the same protocol as in the manual maneuvers group.
89611329|NCT01837342|Other|Sigmoidectomy arm|Standard of care arm : sigmoid reserction after randomisation
89210772|NCT00567996|Active Comparator|Salmeterol 50 μg|"Salmeterol 50 μg twice daily delivered via a proprietary dry powder inhaler in the morning and in the evening. Placebo to Indacaterol daily in the morning, inhaled via a single dose dry powder inhaler (SDDPI).~Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study."
89611330|NCT01837342|Experimental|Control arm|laproscopic drainage and washing
89611331|NCT03835624||juvenile idiopathic arthritis|about 60 cases of children with juvenile idiopathic arthritis diagnosed according to ILAR classification criteria of juvenile idiopathic arthritis will be recruited from pediatric rheumatology clinic of Benha university hospital serum interleukin 33 and its relative expression in peripheral blood mononuclear cells (PBMNCs) will be measured in their blood samples also IL-33 will be measured in synovial fluid samples
89611332|NCT03835624||control group|"about 60 apparently healthy children with comparable age and sex to the patients.~serum interleukin 33 and its relative expression in PBMNCs will be measured in their bloodsamples."
89611333|NCT01727908|No Intervention|Endoscopy without staining of the mucosa|
89611334|NCT01727908|Experimental|Endoscopy with staining of the mucosa.|
89611335|NCT01837420|Other|Placebo with crossover to VB-201 160mg|Subjects on placebo will crossover to VB-201 160 at week 16.
89611336|NCT01837420|Experimental|VB-201 80mg|Subjects will receive VB-201 80mg/day for 24 weeks
89611337|NCT01837420|Experimental|VB-201 160mg|Subjects will received 80mg twice daily for 24 weeks
89611338|NCT01727986|Experimental|RoActemra/Actemra|
89611339|NCT01724710||chronic ulcer|1x1cm2 tissue from chronic ulcer wound
89611340|NCT01724710||normal skin|1x1x0.1 cm3 normal skin from graft
89611341|NCT01724788|Experimental|Furosemide PO - IV|Oral furosemide allocated at the beginning of Period 1, then cross-over to IV furosemide (a minimum 7-day diuretic free washout period required between the two periods)
89611342|NCT01724788|Experimental|Furosemide IV - PO|IV furosemide allocated at the beginning of Period 1, then cross-over to oral furosemide (a minimum 7-day diuretic free washout period required between the two periods)
89611343|NCT01837498||Neostigmine group|At the conclusion of the surgical procedure, neuromuscular block will be reversed with neostigmine
89611344|NCT01837498||Sugammadex group|At the conclusion of the surgical procedure, neuromuscular block will be reversed with sugammadex
89611345|NCT01705574|Experimental|E/C/F/TDF|E/C/F/TDF + ATV placebo + RTV placebo + FTC/TDF placebo
89611346|NCT01705574|Active Comparator|ATV + RTV+ FTC/TDF|ATV + RTV + FTC/TDF + E/C/F/TDF placebo
89611347|NCT01705574|Experimental|Open-Label Extension Phase|After 48 weeks of blinded treatment, participants will continue to take blinded study drug for 12 weeks and return for an unblinding visit at Week 60. Participants who are virologically suppressed at Week 48 during the double-blinded treatment phase will have the option to enter the open-label extension phase. Participants randomized to the E/C/F/TDF arm will continue to receive open-label E/C/F/TDF and participants randomized to the ATV+ RTV + FTC/TDF arm will be re-randomized to receive either open-label elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) or open-label ATV + RTV+ FTC/TDF.
89611348|NCT04378660|Experimental|Intervention arm|Colonoscopy with AI
89210773|NCT00821990|Active Comparator|Chemotherapy|Eligible patients will be first offered randomization. If willing to participate RCT, the patient will be randomized to chemotherapy or best supportive care. If patients refuse to participate in RCT, but nevertheless agree to receive treatment of their preferences, they are offered their treatment of choice (chemotherapy or supportive care).
89210774|NCT00821990|Active Comparator|Supportive care|Eligible patients will be first offered randomization. If willing to participate RCT, the patient will be randomized to chemotherapy or best supportive care. If patients refuse to participate in RCT, but nevertheless agree to receive treatment of their preferences, they are offered their treatment of choice (chemotherapy or supportive care).
89210775|NCT03952871||Intensive care patient with hemodynamic instability|The study group is composed of intensive care patients which already need an invasive monitoring of the cardiac output because of a shock state.
89611349|NCT01837576|Experimental|Calcipotriol plus BDP gel in different doses|A-E: calcipotriol, BDP gel in different concentrations
89611350|NCT04378738|Other|Cohort|the healthy people who accepted to participate in the study
89611351|NCT01728142|Active Comparator|Non-concussed|Control group; individuals assigned to this group will be either healthy volunteers or individuals sustaining an injury that does not involve concussion. Participants will take both the ANAM and DANA Brief twice at minimum.
89611352|NCT01728142|Experimental|Concussed|Individuals who have been diagnosed with a concussion by a clinician. Participants will take both the DANA and ANAM twice at minimum.
89611353|NCT01837732|Experimental|A: relational touch|"Relational touch 15 mn  relational touch, hand touch (neck, face and head)"
89611354|NCT01837732|Active Comparator|B: relational|Relational: 10 mn verbal patient's centered exchanges
89611355|NCT04378582||COVID-19 confirmed|Patients with confirmed COVID-19 by RT-PCR or serological test
89611356|NCT04378582||COVID-19 suspected|Patients suspected COVID-19, as defined by clinical history and course, who have negative RT-PCR or serological test but where treated and cared for as COVID-19 patients
89611357|NCT01728298|Active Comparator|SLITone ULTRA low dose|SLITone ULTRA HDM immunotherapy
89611358|NCT01728298|Active Comparator|SLITone ULTRA medium dose|SLITone ULTRA HDM immunotherapy
89611359|NCT01728298|Active Comparator|SLITone ULTRA high dose|SLITone ULTRA HDM immunotherapy
89611360|NCT01737710|Experimental|92 Non-atopic controls vaccinated with Fluzone® Intradermal|Non-atopic controls who will receive a single dose of the seasonal 2012-2013 Fluzone® Intradermal influenza vaccine via a single-dose pre-filled microinjection system (0.1mL).
89611361|NCT01737710|Experimental|Moderate to severe AD vaccinated with Fluzone® Intradermal|92 moderate to severe atopic dermatitis participants who will receive a single dose of the seasonal 2012-2013 Fluzone® Intradermal influenza vaccine via a single-dose pre-filled microinjection system (0.1mL).
89611362|NCT01737710|Active Comparator|Moderate to severe AD vaccinated with Fluzone® (Intramuscular)|92 moderate to severe atopic dermatitis participants who will receive a single dose of the seasonal 2012-2013 Fluzone® (Intramuscular) influenza vaccine from 0.5 mL single dose vials.
89210776|NCT04388319|Experimental|Combination zonisamide and bupropion with e-cigarette|Participants enrolled in the study will receive a G6 e-cigarette at V2 for ad libitum use. After the first week of e-cigarette use, (at V3) participants will be given zonisamide and bupropion in addition to continued use of the G6. Use of these study drugs will continue for 12- weeks with a target complete switch date (from combustible cigarettes to e-cigarettes) one week after study drug initiation.
89210777|NCT04085627|Experimental|T Test|Test drug(Valsartan / Amlodipine)1 tablet contains Valsartan 80mg& Amlodipine 5mg
89611363|NCT01737710|Active Comparator|Non-atopic controls vaccinated with Fluzone® (Intramuscular)|20 non-atopic controls who will receive a single dose of the seasonal 2012-2013 Fluzone® (Intramuscular) influenza vaccine from 0.5 mL single dose vials.
89611364|NCT01737710|Experimental|Mild AD participants vaccinated with Fluzone® Intradermal|20 mild atopic dermatitis participants who will receive a single dose of the seasonal 2012-2013 Fluzone® Intradermal influenza vaccine via a single-dose pre-filled microinjection system (0.1mL).
89611365|NCT01724944|Experimental|Systematic Lymphadenectomy|
89611366|NCT04381000|No Intervention|Control Group|The control group will not participate in any exercise program.
89611367|NCT04381000|Experimental|Intervention|The intervention group will participate in an exercise program for 6 weeks/ 2 sessions per week, for a total of 12 sessions of 30-45 minutes each.
89611368|NCT04379674|Experimental|Grup 1- Facilitation|It consists of cases that start with the taping of the facilitation.
89611369|NCT04379674|Experimental|Grup 2- İnhibition|It consists of cases that start with the taping of the inhibition.
89611370|NCT04379674|Placebo Comparator|Grup 3- Plasebo|It consists of cases that start with the taping of the placebo.
89611371|NCT01725022|Experimental|Home Care|This is the arm for patients who receive their transplant care in their homes.
89611372|NCT01725022|No Intervention|Hospital Care|Standard of care for stem cell transplant recipients where the aftercare is done in hospital.
89611373|NCT01725022|No Intervention|Clinic Care|Standard of care for stem cell transplant recipients who live at home but receive aftercare in the daily outpatient clinic.
89611374|NCT01728532|Active Comparator|Pulp Canal Sealer (Kerr)|zinc oxide eugenol sealer
89611375|NCT01728532|Experimental|PA0903|type C implant according to ISO 7405:2008 and ISO 10993 guidelines.
89611376|NCT01837810|Experimental|Ibuprofen|800mg ibuprofen every 8 hours prn pain.
89611377|NCT01837810|Placebo Comparator|Methylcellulose Powder|Subjects receive inert methylcellulose powder as placebo
89611378|NCT04378348|Experimental|Motivational Interview|
89611379|NCT04378348|Experimental|Participatory Group Activity|
89611380|NCT04378348|Placebo Comparator|Control Condition|
89611381|NCT01725100|Experimental|Treatment A: GSK1120212B (Standard DMSO content)|Subjects will receive Treatment A in Period 1 or 2 as single oral dose on Day 1 of Period 1 or 2 in fasting condition with water.
89611382|NCT01725100|Experimental|Treatment B: GSK1120212B (Lower DMSO content)|Subjects will receive Treatment B in Period 1 or 2 as single oral dose on Day 1 of Period 1 or 2 in fasting condition with water.
88983570|NCT03689959|Experimental|Patients|13 child with fixed knee flexion deformity more than 10° on one or both sides with 12 months or more predicted growth remaining subjected to eight plate hemiepiphysiodesis of the distal femur
89611383|NCT01725178|No Intervention|Standard care|No intervention besides usual care
89210778|NCT04085627|Active Comparator|R Reference|Reference drug(Valsartan / Amlodipine)1 tablet contains Valsartan 80mg& Amlodipine 5mg
89210779|NCT00821210|Sham Comparator|2|
89210780|NCT00821210|Active Comparator|1|
89210781|NCT03970135|Experimental|Fasting|
89611384|NCT01725178|Active Comparator|Cognitive and physical training|Patients will undergo the comprehensive program of cognitive and physical training.
89611385|NCT01837888|No Intervention|Standard training provided by clinician|Participants in the control group will receive the current standard of care. (i.e., any training provided by the clinician or vendor who prescribes/provides the wheelchair). Participants will receive one follow up phone call to remind them of followup testing.
89611386|NCT01837888|Experimental|WheelSee Training Program|Participants allocated to the intervention group will take part in WheelSee in groups of 2-4. The WheelSee intervention consists of 6 (twice weekly, minimum 3 days apart) x 1.5 hour sessions. Participants will be encouraged to bring a family member to each session, who may act as a spotter during the practice of wheelchair skills. If no family member is available, a student volunteer spotter will be available to ensure a 1:1 spotter: wheelchair user ratio. All spotters will be trained in appropriate spotting techniques.
89611387|NCT01725334|Experimental|Nucleus Accumbens/Ventral Striatum (NAcc/VS) Stimulation|The first 3 patients will have the DBS device target the NAcc/VS, which has been found to be hypoactive in patients with primarily negative symptoms.
89611388|NCT01725334|Experimental|Ventral Tegmental Area (VTA) Stimulation|For 3 patients, the DBS device will target the VTA, which has been found to be hypoactive in patients with primarily negative symptoms.
89611389|NCT04378036|Active Comparator|Neurodevelopmental Therapy Group|The number of participants in this group is 30. All participants were included in the rehabilitation program using only the Neurodevelopmental Therapy approach for 16 sessions (8 weeks x 2 days x 45 minutes).
89611390|NCT04378036|Active Comparator|Hippotherapy Simulator Group|The same participants were taken into a rehabilitation program in which 16 sessions (8 weeks x 2 days a week) the Hippotherapy Simulator device (30 minutes) and Neurodevelopmental Therapy (NDT) (15 minutes) (HS + NDT method) were used together.
89611391|NCT01838122||Study Arm|This group/cohort will have subjects having infertility due to PCOS (as per Rotterdam criteria)
89611392|NCT01838122||Control arm|This group/cohort will have subjects without PCOS but with any other diagnosis of infertility or any other complain.
89611393|NCT04378192|Active Comparator|Face mask ventilation|Use of face mask ventilation technique after induction of anaesthesia and administration pf muscle relaxant till the insertion of the endotracheal tube in a morbidly obese patient undergoing sleeve gastrectomy
89034107|NCT05457985|Experimental|Prolonged Exposure for Primary Care (PE-PC) then continue as early responder|PE-PC consists of four weekly 30-minute sessions. At the 4th session or 9-week assessment point (whichever comes first), early responders will step down to every-other-week sessions for the duration of the second stage (for 8 weeks).
89034108|NCT05457985|Experimental|Clinician Supported (CS) PTSD Coach App then continue as early responder|During the first stage of treatment, participants will receive four weekly clinician support sessions or 9 weeks (whichever occurs first). Early responders will be encouraged to continue app use but will discontinue clinician support sessions for 8 weeks.
89611394|NCT04378192|Active Comparator|Laryngeal mask ventilation|Use of laryngeal mask airway LMA for ventilation after induction of anaesthesia and administration pf muscle relaxant till the insertion of the endotracheal tube in a morbidly obese patient undergoing sleeve gastrectomy
89611395|NCT01725412|Experimental|Thiamine Supplementation|
89611396|NCT01725412|Placebo Comparator|Placebo|
89611397|NCT01838356||No treatment.|
89611398|NCT01725490|Experimental|metformin 500mg daily (arm A)|
89611399|NCT01725490|Experimental|metformin 1500mg daily (arm B)|
89611400|NCT01725490|Placebo Comparator|an identical- appearing placebo (arm C)|
89611401|NCT01682876|Placebo Comparator|2 through 5 years (1 Vac) MenACWY-CRM 1|Subjects 2 through 5 years received one vaccination of MenACWY-CRM
89611402|NCT01682876|Active Comparator|2 through 5 years (2 Vac) MenACWY-CRM 2|Subjects 2 through 5 years received two vaccinations of MenACWY-CRM
89611403|NCT01682876|Placebo Comparator|6 through 10 years (1 Vac) MenACWY-CRM 3|Subjects 6 through 10 years received one vaccination of MenACWY-CRM
89611404|NCT01682876|Active Comparator|6 through 10 years (2 Vac) MenACWY-CRM 4|Subjects 6 through 10 years received two vaccinations of MenACWY-CRM
89611405|NCT01725568||Implantable cardiac monitor diagnostics|Patients has standard indication for implantable cardiac monitor diagnostic.
89611406|NCT01728610|Active Comparator|Active high|Probiotic, high dose
89611407|NCT01728610|Active Comparator|Active low|Probiotic, low dose
89611408|NCT01728610|Placebo Comparator|Placebo|Placebo
89611409|NCT03835390|Experimental|Intervention|Participants who agree to participate in the SIMDiscovery program will be asked if they would like to participate in the research. If they consent, they will fill out pre- and post-questionnaires concerning quality of life, anxiety levels concerning the surgery, and a knowledge assessment.
89611410|NCT01838434|Active Comparator|lenalidomide (Phase II)|Lenalidomide will be administered orally at 20 mg daily on days 1-21, repeated every 28 days for a maximum of 12 cycles (48 weeks). (Phase II)
89034109|NCT05457985|Experimental|Prolonged Exposure for Primary Care (PE-PC) then full PE|PE-PC consists of four weekly 30-minute sessions. At the 4th session or 9-week assessment point (whichever comes first), slow responders that are then randomized to full PE will have sessions once a week for eight weeks. During these 60 minute sessions, participants will practice in vivo and imaginal exposure and continue these exposure exercises every day at home.
89611411|NCT01838434|Experimental|lenalidomide and idelalisib (Phase II)|Lenalidomide will be administered orally and daily on days 1-21, repeated every 28 days for a maximum of 12 cycles (48 weeks). Idelalisib will be orally administered for continuous 28-day cycles until progression, intolerance, or patient/physician discretion. Dosing will be determined by the Phase I portion of the study. (Phase II)
89034110|NCT05457985|Experimental|Clinician Supported PTSD Coach App then full PE|During the first stage of treatment, participants will receive four weekly clinician support sessions or 9 weeks (whichever occurs first), slow responders that are then randomized to full PE will have sessions once a week for eight weeks. During these 60 minute sessions, participants will practice in vivo and imaginal exposure and continue these exposure exercises every day at home.
89611412|NCT01838668|Placebo Comparator|Part I Placebo|"Placebo orally twice a day. In Part I: participants will be randomized into one of 2 groups: BG00012, 240 mg twice daily (BID) or matching placebo BID~Participants will begin the study by taking 1 capsule orally BID for first 7 days and escalate their dosing from day 8 to 2 matching capsules orally BID."
89611413|NCT01838668|Experimental|Part I BG00012|BG00012 240 mg orally twice a day (participants will begin dosing at 120 mg BG00012 twice daily (BID) for the first 7 days and 240 mg BG00012 BID thereafter.) In Part I: participants will be randomized into one of 2 groups: BG00012, 240 mg twice daily (BID) or matching placebo BID
89611414|NCT01838668|Experimental|Part II BG00012|Part II: All participants will receive BG00012 240 mg orally twice a day (participants will begin dosing at 120 mg (1 capsule) BG00012 twice daily (BID) for the first 7 days and 240 mg (2 capsules) BG00012 BID thereafter.
89611415|NCT01728688|Active Comparator|Conventional|conventional treatment & antiviral treatment
89611416|NCT01728688|Experimental|conventional & PBSC transplantation|After three days G-CSF mobilization, Patients randomized to the intervention arm will receive autologous PBSCs transplantation at day1, and receive conventional treatment and antiviral treatment through the one year study visit and followed until one years study visit.
89611417|NCT01728766||Infants under-6 months and their mothers|Small for gestational age at delivery. Post-term Infant, Not Heavy-for-dates.
89611418|NCT04377646|Active Comparator|Hydroxychloroquine & Zinc|"Will receive:~Hydroxychloroquine 400 mg at day 1 and day 2, then a weekly dose of 400 mg up to 2 months.~Zinc 15 mg at daily dose up to 2 months"
89611419|NCT04377646|Active Comparator|Hydroxychloroquine|"Will receive:~Hydroxychloroquine 400 mg at day 1 and day 2, then a weekly dose of 400 mg up to 2 months.~Placebo of Zinc"
89611420|NCT04377646|Placebo Comparator|Placebo|Will receive a double placebo (Hydroxychloroquine and Zinc) up to 2 months
89611421|NCT01728922|Active Comparator|Healthy control - 5,000 IU vitamin D|13 healthy controls will be administered 5,000 IU vitamin D. Primary outcome and safety outcome measures will be assessed.
89611422|NCT01728922|Active Comparator|Healthy control - 10,000 IU vitamin D|13 healthy controls will be administered 10,000 IU vitamin D. Primary outcome and safety outcome measures will be assessed.
89611423|NCT01728922|Placebo Comparator|CIS - placebo|15 patients will be administered placebo and all outcome measures will be assessed.
89611424|NCT01728922|Active Comparator|CIS - 5,000 IU vitamin D|15 patients will be administered 5,000 IU vitamin D and all outcomes will be assessed.
89611425|NCT01728922|Active Comparator|CIS - 10,000 IU vitamin D|15 patients will be administered 10,000 IU of vitamin D and all outcome measures assessed.
89034111|NCT05457985|Experimental|Prolonged Exposure for Primary Care (PE-PC) then continued PE-PC|PE-PC consists of four weekly 30-minute sessions. At the 4th session or 9-week assessment point (whichever comes first), slow responders that are then randomized to continue with PE-PC (medium intensity) will continue weekly sessions for 8 weeks.
89034112|NCT05457985|Experimental|Clinician Supported PTSD Coach App then continued CS PTSD Coach App|During the first stage of treatment, participants will receive four weekly clinician support sessions or 9 weeks (whichever occurs first), slow responders that are then randomized to continue this treatment will have the frequency reduced to twice monthly.
89034113|NCT05450133||R-ax-Spa|Radiographic axial spondyloarthritis
89034114|NCT05450133||nR-ax-Spa|Non-radiographic axial spondyloarthritis
89034115|NCT05450133||Control|Healthy Controls
89034116|NCT05447221||Whole slide images of gastric biopsy specimens|Whole slide images of gastric biopsy specimens
89034117|NCT05444361|Active Comparator|Cryoneurolysis|Cryoneurolysis of the 2nd-6th thoracic intercostal nerves will be treated on the ipsilateral surgical side (bilaterally for bilateral surgical procedures): for each nerve the cryoneurolysis device will be triggered using 2 cycles of 2-minute gas activation separated by 1-minute defrost periods (Epimed) or 1 cycle of 5.5 minutes of argon and 30 seconds of helium (Varian). For active probes, the gas will be deployed to the tip where a drop in temperature to approximately -70°C will result in cryoneurolysis.
89034118|NCT05444361|Sham Comparator|Sham Procedure|Sham cryoneurolysis of the 2nd-6th thoracic intercostal nerves will be applied on the ipsilateral surgical side (bilaterally for bilateral surgical procedures): for each nerve the cryoneurolysis device will be triggered using 2 cycles of 2-minute gas activation separated by 1-minute defrost periods (Epimed) or 1 cycle of 5.5 minutes of argon and 30 seconds of helium (Varian). However, for sham probes, the gas is not deployed to the tip and therefore there is no drop in temperature resulting in cryoneurolysis.
89034119|NCT05437679||Active Surveillance (AS) Controls|Patients with low or very low risk prostate cancer who have been on active surveillance for 5 or more years with a stable PSA or on active surveillance for 2 or more years with negative multiparametric MRI (mpMRI) or mpMRI with a fusion biopsy(ies) confirming low risk disease.
89034120|NCT05437679||High Risk Localized Prostate Cancer (HRLPC)|Men with high-risk localized prostate cancer, defined as stage pT3a or Gleason score greater than or equal to 8 and/or pre-prostatectomy PSA of greater than or equal to 20 ng/mL.
89034121|NCT05437679||Biochemically Recurrent Localized Prostate Cancer (BCRLPC)|Systemic and/or hormonal treatment naive men with localized prostate cancer (pathological stages pT2, pT3a or pT4 with TNM N0 or N1 and M0 disease) who have clinical suspicion of biochemical recurrence 2 - 5 months following radical prostatectomy and are scheduled to undergo NGI (i.e., Axumin® or PSMA PETCT) within the next 45 days or have already undergone NGI within the past 45 days.
89034122|NCT05437679||Non-Metastatic Castration-Resistant Prostate Cancer (NMCRPC)|Patients with evidence of non-metastatic castration-resistant prostate cancer (i.e. localized prostate cancer patients with clinical symptoms of disease progression and/or evidence of a rising PSA following hormone therapy) who are scheduled to undergo NGI (i.e., Axumin® or PSMA PETCT) within the next 45 days or have already undergone NGI within the past 45 days and who have not started a new therapy for treatment of their castration-resistant prostate cancer.
89034123|NCT05434117|Experimental|High-intensity interval Nordic walking|Participants will receive high-intensity interval Nordic walking training.
89034124|NCT05434117|Active Comparator|Control|Participants will undergo standard cardiovascular rehabilitation.
89034125|NCT05419700||Participants with Advanced NSCLC With EGFR Exon 20 Insertions Mutations|All participants diagnosed with advanced NSCLC with Epidermal growth factor receptor EGFR exon 20 insertion mutations will be enrolled in this study. All study data will be collected retrospectively from participants medical records via medical chart review.
89034126|NCT05419284|Experimental|patient|GAPP+Care
89034127|NCT05419284|Experimental|caregiver|+Care
89034128|NCT05419284|Other|healthcare professional of the ward|observation of GAPP+Care
89034129|NCT05408572|Experimental|Single Dose Level 1|6 healthy adults dosed with SON-1010 (Level 1) + 2 healthy adults dosed with Placebo
89611426|NCT01728922|Placebo Comparator|Healthy control - placebo|13 control participants who will be administered placebo. These will be assessed for the primary outcome and safety outcomes only.
89611427|NCT01838746||PCI|Patients undergoing PCI
89611428|NCT01838746||CABG|Patients undergoing CABG
89611429|NCT01682720|Placebo Comparator|Placebo 12 Weeks (GT2/3)|Placebo to match SOF + weight-based RBV (1000-1200 mg as 200 mg tablets in a divided daily dose) for 12 weeks in participants with genotype 2 or 3 HCV infection.
89611430|NCT01682720|Experimental|SOF 12 Weeks (GT2/3)|Placebo to match SOF + weight-based RBV (1000-1200 mg as 200 mg tablets in a divided daily dose) for 12 weeks in participants with genotype 2 or 3 HCV infection.
89034130|NCT05408572|Experimental|Single Dose Level 2|6 healthy adults dosed with SON-1010 (Level 2) + 2 healthy adults dosed with Placebo
89034131|NCT05408572|Experimental|Single Dose Level 3|6 healthy adults dosed with SON-1010 (Level 3) + 2 healthy adults dosed with Placebo
89034132|NCT05408572|Experimental|Single Dose Level 4|6 healthy adults dosed with SON-1010 (Level 4) + 2 healthy adults dosed with Placebo
89034133|NCT05408572|Experimental|Single Dose Level 5|6 healthy adults dosed with SON-1010 (Level 5) + 2 healthy adults dosed with Placebo
89034134|NCT05404230|Active Comparator|Fish oil|"4 capsules containing n-3 poly unsaturated fatty acids (EPA and DHA) with a total concentration of 3 g per day.~4 capsules per day for 8 months"
89034135|NCT05404230|Placebo Comparator|Corn oil|"4 capsules containing n-6 poly unsaturated fatty acids in a total concentration of 2 g per day.~4 capsules per day for 8 months.~Corn oil is regularly used in the kitchen and the daily dose in the study is the equivalent of adding an extra spoon of food oil when cooking. It has no known effect on the parameters we want to examine."
89034136|NCT05402813||Cohort 1a|Patients without Cochlear Implant, with or without Hearing Aid(s) at study entry
89034137|NCT05402813||Cohort 1b|Patients receiving unilateral or bilateral Cochlear Implant(s) during the study period, after study entry
89034138|NCT05402813||Cohort 2|Patients with Cochlear Implant(s) (unilateral or bilateral) at study entry
89611431|NCT01682720|Experimental|SOF 24 Weeks (GT3)|SOF 400 mg tablet once daily + weight-based RBV (1000-1200 mg as 200 mg tablets in a divided daily dose) for 24 weeks in participants with genotype 3 HCV infection.
89034139|NCT05399433|Other|Production of IL-23 of blood and skin dendriti cells (CD)|Simultaneously evaluate the migratory capacity and production of IL-23 of blood and skin cDC on peripheral venous blood and skin biopsies of psoriatic patients with and without type 2 diabetes and control patients (with or without type II diabetes) depending on their metabolic status.
89034140|NCT05397457|Experimental|Treatment group|
89034141|NCT05397457|No Intervention|Control group|
89034142|NCT05396703||TOETVA|All patients who underwent a transoral endoscopic thyroidectomy via vestibular approach (TOETVA) at the investigators' center.
89034143|NCT05394987|Experimental|Optical correction|Prescription of spectacles for full-time wear to correct refractive error
89034144|NCT05391516||All Participants|Participants; 18-80 years old, who volunteered to participate in the study, patients with shoulder problems.
89611432|NCT01838902|Other|Eurartesim (control)|All participants will receive a complete course of DHA-PPQ (Eurartesim)
89611433|NCT01838902|Experimental|Primaquine 0.75mg base/kg|Participants will be randomized to receive a complete course of DHA-PPQ plus a single dose of PQ at 0.75mg/kg body weight
89611434|NCT01838902|Experimental|Primaquine 0.4mg base /kg|Participants will be randomized to receive a complete course of DHA-PPQ plus a single dose of PQ at 0.4mg base/kg Body weight
89611435|NCT01838902|Experimental|Primaquine 0.2mg base/kg|Participants will be randomized to receive a complete course of DHA-PPQ plus a single dose of PQ at 0.2mg base/kg body weight
89034145|NCT05388890||MLD|Modified Liujunzi Decoction,1 package twice daily,6 months
89034146|NCT05388890||WFC|Weifuchun,three times a day, four at a time,6months
89034147|NCT05385432|Experimental|rabbit antithymocyte globulin (rATG)|The infusion of rATG (Thymoglobulin® (1.5mg/kg/day, maximum daily dose: 100 mg)) starts just after the randomization pre-operatively on a functional arteriovenous fistula or a high-flow venous catheter during 3 to 7 days until efficient tacrolimus level is obtained. The recommended initial tacrolimus dose is Prograf® 0.1mg/kg/day twice day.
89034148|NCT05385432|Active Comparator|Basiliximab|The infusion of Basiliximab (Simulect® (20mg)) starts before the surgery on peripheral vein for 15 minutes and the second infusion at day 4.
89034149|NCT05385211||People living with type 1 diabetes|Participants will be separated into two groups based on the levels of their exocrine pancreatic enzymes levels.
89034150|NCT05379270|Experimental|Diet soda|Participants will be asked to ingest 24 of a commercially-available diet beverage sweetened with sucralose and acesulfame-potassium.
89611436|NCT03409822|Other|Placenta previa|
89611437|NCT03401086|Active Comparator|Study group|Kinesio Taping
89611438|NCT03401086|No Intervention|Control group|No intervention
89611439|NCT03409510|Experimental|Long-term UVB radiation|All participants received repeated UVB radiation for nine weeks. The treatment was identical for all participants.
89611440|NCT04551014|Experimental|With EverLift|Polypectomy performed for polyps 4-9mm with submucosal injection of EverLift.
89611441|NCT04551014|Experimental|Without EverLift|Polypectomy performed for polyps 4-9mm without submucosal injection of EverLift.
89034151|NCT05376579||siponimod|patients treated with siponimod
89034152|NCT05367037|Active Comparator|PhysioVP group|Physiological ventricular pacing
89034153|NCT05367037|Active Comparator|DDD-VPA group|Dual-chamber pacing with the addition of algorithms for ventricular pacing avoidance
89034154|NCT05364905||Cohort 1|Patients in first line treatment (first chemotherapy for advanced, recurrent or metastatic endometrial cancer) in 2019
89034155|NCT05364905||Cohort 2|Patients in second line treatment (after one prior systemic chemotherapy) in 2019
89034156|NCT05360212|Placebo Comparator|Standard fitting|The first group is fitted using the standard frequency-band distribution as implemented in MAESTRO 9
89034157|NCT05360212|Experimental|Anatomy-based fitting|In the second group of users, an anatomy-based frequency distribution is used as per anatomy-based fitting in MAESTRO 9
89034158|NCT05360212|Experimental|Within-subject design: Standard fitting + ABF|The third group constitutes the within-subject design. These subjects are both fitting using the standard frequency-band distribution and the anatomy-based frequency distribution in MAESTRO 9. So, subjects will have both study maps on their audio processor throughout the whole study. They will have to change weekly between both fittings: standard fitting and anatomy-based fitting.
89034159|NCT05355428|Experimental|recruited patients|recruited patients will be required to feed 3 hours prior to planned procedure start with their normal method of taking breast milk (from the breast, or expressed into a bottle).
89034160|NCT05352750|Experimental|Dose Level 1|SON-1010 Dose Level 1
89034161|NCT05352750|Experimental|Dose Level 2|SON-1010 Dose Level 2
89611442|NCT01729000|No Intervention|Hand hygiene|All staff that have interaction with subjects will perform hand hygiene with all patient contact and before all contact with the intravenous line.
89611443|NCT01729000|Experimental|Hand hygiene plus gloving|All staff that have interaction with subjects will perform hand hygiene and wear gloves with all patient contact and before all contact with the intravenous line.
89611444|NCT01729078|Experimental|high fat ( MUFA) diet|intervention using high fat diet.
89611445|NCT01729078|Experimental|high carb/high fiber|diet using high carb-high fiber with dry beans
89611446|NCT01729078|Experimental|high carb/low fat|Habitual diet
89611447|NCT01714544|Experimental|Cloderm Cream|Cloderm (clocortolone pivalate) Cream 0.1%, twice daily for 28 days
89611448|NCT03401008||Acromegalic patients|patients with a proven diagnosis of acromegaly achieved by an IGFA assay and a GH measure.
89611449|NCT03400696|Experimental|Randomized- Lower carbohydrate diet|
89611450|NCT03400696|Experimental|Randomized- Higher fiber diet|
89611451|NCT03400696|Experimental|Randomized- Exercise focused|
89611452|NCT03400696|Experimental|Participant chooses- Lower carbohydrate diet|
89611453|NCT03400696|Experimental|Participant chooses- Higher fiber diet|
89611454|NCT03400696|Experimental|Participant chooses- Exercise focused|
89611455|NCT01729234|Experimental|Nitrate|150µmol /Kg bodyweight /day
89611456|NCT01729234|Placebo Comparator|PLacebo|150µmol /Kg bodyweight /day
89611457|NCT03409354|Experimental|Tele-rehabilitation|Tele-rehabilitation via iPad.
89611458|NCT03409354|Active Comparator|Usual care|Usual rehabilitation care, prescribed by rehabilitation therapists at participating centers and performed by participants at participating centers.
89034162|NCT05352750|Experimental|Dose Level 3|SON-1010 Dose Level 3
89034163|NCT05352750|Experimental|Dose Level 4|SON-1010 Dose Level 4
89611459|NCT03400462|Experimental|dry needling + oral appliance|Three visits are needed in this therapy method. Visits schedule:( 1st visit - Day 1st , 2nd visit- 7 days after the 1st, 3rd visit- 7 days after the 2nd) Equipment: acupuncture needle 0,6*13 e.g. Dragon Medical Device, solution for skin disinfection, sterile gauze. Exposition time : 30 minutes once a week
89611460|NCT03400462|Experimental|antiinflammatory drugs + splint therapy|"Patient's instruction for NSAID use:~Nimesulide 2*100 mg/ 24 h- twice a day one pill of the 100 mg Nimesulide during 14 days"
89611461|NCT03400462|Active Comparator|splint therapy|"Splint therapy is an useful treatment method for several group of patients e.g TMD patients, patients with retrodiscitis, patients with muscle pain disorders like local muscle soreness or chronic myalgia.~The patients have been instructed to use the appliance during nighttime. After 7 days the patient had to came back for a control visit."
89611462|NCT01703858|Active Comparator|1 BI 113608|powder in the bottle for oral solution, oral administration with 240 mL water
89611463|NCT01703858|Experimental|2 BI 113608|conventional tablet formulation
89611464|NCT01703858|Experimental|3 BI 113608|conventional tablet formulation, fed
89611465|NCT01703858|Experimental|4 BI 113608|conventional tablet after pantoprazole administration
89611466|NCT01703858|Experimental|5 BI 113608|conventional tablet formulation, fasted, 0:30 min before fat breakfast
89611467|NCT01729390|Experimental|Std ED Control|100% energy density and 133% portion size
89611468|NCT01729390|Experimental|Inc ED Control|133% energy density and 133% portion size
89611469|NCT01729390|Experimental|Std ED and Std PS|100% energy density and 100% portion size
89611470|NCT01729390|Experimental|Std ED and Inc PS|100% energy density and 133% portion size
89611471|NCT01729390|Experimental|Inc ED and Inc PS|133% energy density and 133% portion size
89611472|NCT01729390|Experimental|Inc ED and Std PS|133% energy density and 100% portion size
89034164|NCT05352750|Experimental|Dose Level 5|SON-1010 Dose Level 5
89611473|NCT01729468|Experimental|Aspirin|Aspirin 160 mg per day
89611474|NCT01729468|Placebo Comparator|Placebo|Placebo 160 mg per day
89611475|NCT04550468|Experimental|Low-Carb High-Fat Breakfast|Participants will follow a daily low carbohydrate high fat breakfast intervention for 3 months.
89611476|NCT04550468|Active Comparator|"Low fat Standard Care Control Breakfast"|"Participants will follow a daily low fat standard care control breakfast intervention for 3 months."
89611477|NCT03400384|Experimental|Direct-to-consumer educational brochure|The intervention arm will be mailed an evidence-based, theory-driven direct-to-consumer educational brochure, highlighting the potential benefits and harms of opioids when used to treat chronic non-cancer pain.
89034165|NCT05352750|Experimental|RP2D Expansion|RP2D Dose of SON-1010
89034166|NCT05338528|Experimental|BE-FIT|The quasi-experimental unblinded interrupted time-series (ITS) design will be conducted in three phases: pre-intervention/ (10 weeks); during intervention (16 weeks); post-intervention (20 weeks). A cohort of patients on selected wards will receive the BE-FIT program intervention.
89034167|NCT05338528|No Intervention|Usual care|We will adopt a before-and-after analysis methodology for complications, functional performance, and patient satisfaction. A control cohort of patients on the same ward will be compared to who received usual care prior to the intervention; this may include physiotherapy consultations ordered at the discretion of the surgical team or any other independent activity initiated by the patient (e.g., walking).
89034168|NCT05324982|Placebo Comparator|Placebo|Single acute administration of oral Placebo liquid (MCT oil).
89034169|NCT05324982|Experimental|Oral administration of 25mg CBG|Single acute administration of 25mg CBG suspended in MCT oil.
89034170|NCT05324982|Experimental|Oral administration of 50mg CBG|Single acute administration of 50mg CBG suspended in MCT oil.
89034171|NCT05324982|Experimental|Oral administration of 100mg CBG|Single acute administration of 100mg CBG suspended in MCT oil.
89611478|NCT03400384|No Intervention|Control wait list|This arm will receive the intervention at the completion of the six-month follow-up period for the intervention group.
89034172|NCT05324982|Experimental|Oral administration of 200mg CBG|Single acute administration of 200mg CBG suspended in MCT oil.
89034173|NCT05324345|Experimental|Prehabilitation group|This is a prospective single-arm study. All patients enrolled in this study will receive the multimodal prehabilitation strategy by the network learning platform after a complete assessment.
89034174|NCT05319678||Cochlear implant users|Pre-or perilingual patients aged 6 to 17 years old, and postlingual adults who underwent cochlear implantation from 2000 to January 2023 at La Paz University Hospital
89034175|NCT05319678||Normal hearing subjects|Control group is set up with the normal hearing peers of cochlear implant users
89611479|NCT04376788|Experimental|Exchange transfusion|Will receive exchange transfusion by venesection of 500cc blood with good replacement of one unit packed washed RBCs daily for 3 days according to daily clinical and investigational follow up
89611480|NCT04376788|Experimental|Methylene blue with plasma|Will receive IV methylene blue 1 mg/kg IV over 30 minutes with 200 CC plasma from convalescent matching single patient by plasma extractor machine for 3 days according to daily clinical and investigational follow up.
89611481|NCT04376788|Experimental|Exchange transfusion and methylene blue with plasma|Will receive exchange transfusion by venesection of 500cc blood with good replacement of one unit packed washed RBCs and IV methylene blue 1 mg/kg IV over 30 minutes with 200 CC plasma from convalescent matching single patient by plasma extractor machine for 3 days according to daily clinical and investigational follow up.
89611482|NCT03400228|Experimental|Protics|Patients in the intervention group were to drink 2 sachets of 1g of probiotic daily for 24 weeks
89611483|NCT03400228|Placebo Comparator|Placebo|Patients in the intervention group were to drink 2 sachets of 1g of maltodextrin daily for 24 weeks
89611484|NCT01729702|Other|single group - consecutive patients|
89611485|NCT03400072|Experimental|Unsupervised APA program|usual care plus a 6-month unsupervised APA program
89611486|NCT03400072|Experimental|Supervised APA program|usual care plus a 6-month supervised APA program
89611487|NCT03400072|No Intervention|Usual care|Usual care
89611488|NCT03408496|Experimental|Myofascial release|"Eight consecutive weekly sessions lasting 40-45 minutes of myofascial release of the trunk physiological chains. The connective tissue of the flexion chain and the posterior static chain will be released. The myofascial release will be obtained through the mechanical effect produced by the friction of the therapist's hand with a surface of the patient's body, which is performed through traces executed with the fingers (thumb supported or middle finger on the indicator to achieve effect local) following as addressed chains. The release will be repeated until the feeling of local relaxation of the tissue."
89611489|NCT03408496|Experimental|Muscle Stretching|The muscle stretching protocol described by Bressan (2008) will be followed, which consists of 8 consecutive weekly sessions, lasting 40-45 minutes. In dorsal decubitus or sitting, the triceps surae, hamstring, gluteal, paravertebral, latissimocondyloideus, pectoral, trapezius and respiratory muscles will be stretched. The exercises will be performed in a series of five repetitions for 30 seconds.
89611490|NCT03408496|Active Comparator|Control|It will perform only the treatment prescribed by the responsable doctor, wich can be the use of drug and/or psychological treatment, and will be followed clinically by a rheumatologist during four medical appointments to monitor medication and follow in the analgesic's diary, according the standard procedure of attending the hospital where the patients will be recruited.
89611491|NCT03408418|Experimental|L-PRF group|The use of autologous leucocyte- and platelet-rich fibrin in alveolar sockets after dental extraction.
89611492|NCT03408418|No Intervention|Control|Conventional tooth extraction without any bone substitute.
89611493|NCT01714310|Experimental|Adjunctive fluoxetine|Participants previously titrated with open-label lisdexamfetamine randomized to adjunctive fluoxetine at end of study week 4.
89611494|NCT01714310|Placebo Comparator|Adjunctive placebo|Participants previously titrated with open-label lisdexamfetamine randomized to adjunctive placebo at end of study week 4.
89611495|NCT01714310|Other|Open Lisdexamfetamine Titration|All participants initially titrated with open-label lisdexamfetamine from baseline to end of study week 4.
89611496|NCT03408262|Active Comparator|Group A|Month 0: oral placebo Month 3: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo
89611497|NCT03408262|Experimental|Group B|Month 0: Ad4-EnvCN54 Month 3: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo
89611498|NCT03408262|Experimental|Group C|Month 0: Ad4-EnvCN54 Month 3: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. placebo Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo
89611499|NCT03408262|Experimental|Group D|Month 0: Ad4-EnvCN54 Month 3: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. placebo Month 6: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. placebo
89611500|NCT03408262|Active Comparator|Group E|Month 0: oral placebo Month 3: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54 Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54
89611501|NCT03408262|Experimental|Group F|Month 0: Ad4-EnvCN54 Month 3: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54 Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54
89611502|NCT03408262|Experimental|Group G|Month 0: Ad4-EnvCN54 Month 3: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. MVA-CN54 Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54
89611503|NCT03408262|Experimental|Group H|Month 0: Ad4-EnvCN54 Month 3: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. MVA-CN54 Month 6: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. MVA-CN54
89611504|NCT03408184|Active Comparator|Lumbar paravertebral group|After general anesthesia, the patient is placed prone. To establish the level of the block, we used US-counting of vertebrae. After determining the lumbar one level, the block performed at a parallel line 2 cm lateral to the spinous process, the transducer is moved until the corresponding transverse process is identified. Utilizing an in-plane approach from lateral to medial, a spinal needle is advanced until contact with the transverse process. The needle is withdrawn and redirected caudally under the transverse process helped by the loss of resistance technique. the solution is slowly injected after negative aspiration for blood.
89611505|NCT03408184|Active Comparator|The field block group|The ilioinguinal nerve block was done at one fingerbreadth from the anterior superior iliac spine in a line with the pubic tubercle, The injection was done after the bob of the needle after passing the external oblique aponeurosis and muscle and 5ml of the solution is injected. The rest of the solution is injected in the incision line.
89611506|NCT01713998|Active Comparator|Group A|Subjects will receive an increased density Ulthera System Treatment over the full face but with the energy turned down to the second highest level of four possible energy settings on one side of the face.
89611507|NCT01713998|Active Comparator|Group B|Subjects will receive an increased density guideline Ulthera System Treatment over the full face but with the energy turned down to the lowest level of four possible energy settings on one side of the face.
89611508|NCT01713998|Active Comparator|Group C|Subjects will receive an increased density guideline Ulthera System Treatment over the full face with the exception that a 4 MHz transducer will be used on the upper face in place of a7 MHz transducer, with the energy turned down to the lowest level of four possible energy settings.
89611509|NCT03409900|Experimental|LPB Unilateral DAA THA|Patients will be randomized to receive either a LPB or QLB for post-operative analgesia. Randomization to either LPB or QLB will occur via block randomization using sealed sequentially numbered opaque envelopes that will correspond to the order with which patients are enrolled. Patients and research assistants will be blinded to their randomization by administration of intravenous sedation (titrated to patient comfort), utilization of ultrasonography to visualize pertinent structures for both blocks, and by the nature of the block technique themselves both being in close proximity on the posterior lower back.
89611510|NCT03409900|Experimental|QLB Unilateral DAA THA|Patients will be randomized to receive either a LPB or QLB for post-operative analgesia. Randomization to either LPB or QLB will occur via block randomization using sealed sequentially numbered opaque envelopes that will correspond to the order with which patients are enrolled. Patients and research assistants will be blinded to their randomization by administration of intravenous sedation (titrated to patient comfort), utilization of ultrasonography to visualize pertinent structures for both blocks, and by the nature of the block technique themselves both being in close proximity on the posterior lower back.
89611511|NCT03408028||Cognitive impairment|Geriatric patients with a cognitive impairment
89611512|NCT04549922|Placebo Comparator|Placebo|1.2 mL Normal Saline, single dose subcutaneous, after randomization
89611513|NCT04549922|Active Comparator|ISIS 721744|1.2 mL ISIS 721744, single dose subcutaneous, after randomization
89034176|NCT05319158|Experimental|Intervention group|The group intervention will receive MIT-PB.
89034177|NCT05319158|No Intervention|control group|The control group will receive standard care
89034178|NCT05318638|Other|Study group|All participants in the study will perform arm/hand movement tasks in both of two conditions (with and without soft-robotic glove), so they constitute 1 study arm, but all receiving both intervention conditions (experimental - with glove and control - without glove).
89034179|NCT05315674||Exacerbators|Patients who experience ≥1 inpatient AECOPD
89034180|NCT05315674||Non-exacerbators|Patients without inpatient AECOPD
89034181|NCT05313724|Experimental|Mind-Body Online Therapy|
89034182|NCT05313724|No Intervention|TAU (treatment as usual)|
89034183|NCT05313464|Experimental|nutrition pushed by parents|enteral nutrition pushed by parents
89034184|NCT05313464|Active Comparator|syringe pump|Enteral nutrition with syringe pump
89034185|NCT05311761|Experimental|CogMe Personal Assistant (PA)|The CogMe PA is a dedicated application built by CogMe with the purpose of assessing the cognitive functions of patients and providing them with a short and stimulating interaction. The application runs on a standard tablet. The CogMe PA is designed to be easily understandable and usable also for older adults with little or no experience in mobile applications. The questions in the Q&A session are based on validated cognitive tests shown to be associated with delirium and are built to assess the subjective wellbeing and cognitive function of the patients. The repeated use of the application will allow to detect any changes or anomalies during the hospitalization period.
89034186|NCT05311215|Experimental|SL-1002|SL-1002 injectable solution, single dose
89034187|NCT05311215|Placebo Comparator|Matching placebo|Matching placebo injectable solution, single dose
89034188|NCT05310227|Experimental|Treatment|Participants will receive a device and will be asked to treat headaches with it and report in the app the characteristics of the attacks at the beginning of the attack as well as at 2 hours after the treatment.
89034189|NCT05310175|Experimental|Experimental group|Participants will receive electroacupuncture at Yamen(DU15), bilateral Tianzhu(BL10), Fengchi(GB20), Wangu(GB12), and Yifeng(SJ17) for 30minutes, 3 times a week for 4 weeks.
89034190|NCT05310175|Placebo Comparator|Control group|Participants will receive shallow needle insertion of 2-3 mm at sham acupoints without manipulation for 30minutes, 3 times a week for 4 weeks.
89034191|NCT05309772|Experimental|Biomarker arm|"All participants will have blood taken to test for BAT/MAT. Participants with a positive BAT/MAT will dispense from oral food challenge (OFC).~Participants with negative or inconclusive BAT/MAT will undergo OFC."
89034192|NCT05309772|Active Comparator|Standard-of-care arm|All participants in the standard-of-care arm will have blood taken to test for BAT/MAT. Regardless of the result of BAT/MAT, all participants in this arm will undergo an oral food challenge, as per the current standard-of-care.
88815381|NCT03426566||patients with diabetes|Data from medical records from : non-ulcer patients with DM (diabetes mellitus) from the Diabetic Foot Centre (DFC) in Wroclaw. As it is a retrospective analysis no intervention is planned.
89034193|NCT05307289|Other|melanoma inclusion|Biopsy of a metastasis allowing melanoma diagnosis and realization of primary cultures for metabolomics. An additional 20ml blood sample will also be taken to quantify circulating metabolites and to isolate PBMC.
89034194|NCT05305443|Experimental|Navigation/tested/navigation services|After initial randomization, some participants will be assigned to receive navigation services(NS). Those who complete the COVID-19 testing will again be randomized and some will continue receiving NS.
89034195|NCT05305443|Experimental|Navigation/tested/brief counseling|After initial randomization, some participants will be assigned to receive navigation services (NS). Those who complete the COVID-19 testing will again be randomized and some will be assigned to receive Brief Counseling (BC)
89034196|NCT05305443|Experimental|Navigation/not tested/navigation services|After initial randomization, some participants will be assigned to receive navigation services (NS). Those who do not complete the COVID-19 testing will again be randomized and some will continue receiving NS.
89034197|NCT05305443|Experimental|Navigation/not tested/critical dialogue|After initial randomization, some participants will be assigned to receive navigation services(NS). Those who do not complete the COVID-19 testing will again be randomized and some will be assigned to Critical Dialogue (CD)
89034198|NCT05305443|Experimental|Referral/tested/brochure|After initial randomization, some participants will be assigned to receive standard referral services. Those who complete the COVID-19 testing will again be randomized and some will receive a digital brochure.
89034199|NCT05305443|Experimental|Referral/tested/brief counseling|After initial randomization, some participants will be assigned to receive standard referral services. Those who complete the COVID-19 testing will again be randomized and some will be assigned to receive Brief Counseling (BC).
89034200|NCT05305443|Experimental|Referral/not tested/brochure|After initial randomization, some participants will be assigned to receive standard referral services. Those who do not complete the COVID-19 testing will again be randomized and some will receive a digital brochure.
89034201|NCT05305443|Experimental|Referral/not tested/critical dialogue|After initial randomization, some participants will be assigned to receive standard referral services. Those who do not complete the COVID-19 testing will again be randomized and some will be assigned to Critical Dialogue (CD).
89034202|NCT05304351|Experimental|Arm A|Investigational Vaccine
89034203|NCT05304351|Experimental|Arm B|Investigational Vaccine
89034204|NCT05304351|Active Comparator|Arm C & G|Active comparator
89034205|NCT05304351|Experimental|Arm D|Investigational Vaccine
89034206|NCT05304351|Experimental|Arm E|Investigational Vaccine
89034207|NCT05304351|Experimental|Arm F|Investigational Vaccine
89034208|NCT05304273|Active Comparator|Mifepristone|"Participants with 1st trimester miscarriage will receive oral 200mg mifepristone .~After 48 hours of mifepristone, 800 micro gm misoprostol will be given vaginally for expulsion of product of conception (standard care)."
89034209|NCT05304273|Experimental|Letrozole|"Participants with 1st trimester miscarriage will receive 10mg letrozole orally for three consecutive days.~This is to be followed by tablet misoprostol 800 micro gm vaginally for expulsion of product of conception (standard care)."
89034210|NCT05303805|Experimental|Topical sevoflurane|The active treatment group will have sevoflurane applied at approximately 1 ml/cm2 at the start of wound treatment,
89611514|NCT01681628|Experimental|Thought Field Therapy|Thought Field Therapy delivered by trained community leaders.
89210782|NCT04086173|Experimental|Study group|Subjects will be randomly assigned to receive a daily nightly dose (4 capsules) of probiotics for 16 weeks. Probiotics (LACTIPAN®) include 2.5 billion CFU of 6 different strains of live microorganisms, such as Lactobacillus acidophilus (1.0 x 109 CFU), Lactobacillus casei (1.0 x 109 CFU), Lactobacillus rhamnosus (4.4 x 108 CFU), Lactobacillus plantarum (1.76 x 108 CFU), Bifidobacterium infantis (2.76 x 107 CFU), Streptococcus thermophilus (6.66 x 105 CFU) and 50 mg of oligofructose enriched inulin.
89210783|NCT04086173|Placebo Comparator|Control group|Subjects will be randomly assigned to receive a daily nightly dose (4 capsules) of placebo for 16 weeks. Placebo presentation will have the same aspect as those of the probiotic treatment.
89611515|NCT01681628|Other|Wait list|"Delayed intervention.~No intervention prior to assessment after one week (pre-test 2). Then treated with Thought Field Therapy, and re-assessed after a further week (post-test)."
89611516|NCT04377958|Other|Asthmatics|Asthmatic group from which serum samples will be collected for analysis
89611517|NCT03405220|Experimental|Self-affirm, No examples, Study 1|Behavioral: Self affirmation, 10 items, no examples
89611518|NCT03405220|Active Comparator|Self-affirm, Write examples, Study 1|Behavioral: Self affirmation, 10 items, written examples
89611519|NCT03405220|Experimental|Self-affirm, Imagine examples, Study 1|Behavioral: Self affirmation, 10 items, imagined examples
89611520|NCT03405220|No Intervention|Opinion survey, No examples, Study 1|"No intervention: control. Participants will complete the 10 item personal opinion survey and will not be asked to provide examples for any items they respond yes to."
89611521|NCT03405220|No Intervention|Opinion survey, Write examples, Study 1|"No intervention: control. Participants will complete the 10 item personal opinion survey and will be asked to provide written examples for each item they respond yes to."
89611522|NCT03405220|No Intervention|Opinion survey, Imagine examples, Study1|"No intervention: control. Participants will complete the 10 item personal opinion survey and will be asked to imagine examples for each item they respond yes to."
89611523|NCT03405220|Experimental|Self-affirm, 10-item, No ex, Study 2|Behavioral: Self affirmation, 10 items, no examples
89611524|NCT03405220|Experimental|Self-affirm, 5-item, No ex, Study 2|Behavioral: Self affirmation, 5 items, no examples
89611525|NCT03405220|Experimental|Self-affirm, 3-item, No ex, Study 2|Behavioral: Self affirmation, 3 items, no examples
89611526|NCT03405220|Active Comparator|Self-affirm, 10-item, Write ex, Study 2|Behavioral: Self affirmation, 10 items, written examples
89611527|NCT03405220|Experimental|Self-affirm, 5-item, Write ex, Study 2|Behavioral: Self affirmation, 5 items, written examples
89611528|NCT03405220|Experimental|Self-affirm, 3-item, Write ex, Study 2|Behavioral: Self affirmation, 3 items, written examples
89611529|NCT03405220|Experimental|Self-affirm, 10-item, Imagine ex, Study2|Behavioral: Self affirmation, 10 items, imagined examples
89611530|NCT03405220|Experimental|Self-affirm, 5-item, Imagine ex, Study 2|Behavioral: Self affirmation, 5 items, imagined examples
89611531|NCT03405220|Experimental|Self-affirm, 3-item, Imagine ex, Study 2|Behavioral: Self affirmation, 3 items, imagined examples
89611532|NCT01728064|Placebo Comparator|Placebo|Placebo capsules three times daily
89611533|NCT01728064|Active Comparator|EPI-743 400 mg|EPI-743 at a dose of 400 mg three times daily
89611534|NCT01728064|Active Comparator|EPI-743 200 mg|EPI-743 at a dose of 200 mg three times daily
89611535|NCT03407950|Other|Group IPT+|2 sessions of IPT+ by week during 6 months
89611536|NCT03407950|Other|Control Group|group without specific therapy (Treatment as usual) but same number and duration of each sessions than IPT+
89611537|NCT03834298|Experimental|Four Food Elimination Diet (FFED)|There is one arm to the study. All participants meeting eligibility will be assigned to intervention / treatment with a previously defined four food elimination diet (FFED) (Aim 1). This is a longitudinal study in which outcome measures including symptoms, QOL and inflammation at baseline and at 2, 4 and 6 weeks after starting stand of care (SOC) FFED will be measured. Participants meeting eligibility for Aim 2 will have foods added back to the diet using a specified protocol.
88983571|NCT03688178|Experimental|Gr1: DC vaccine (DC pre-conditioning)|Patients will receive TMZ at a target dose of 150-200 mg/m^2/d for 5 days every 4 (+2) weeks for up to 12 cycles. DC vaccines will be administered in equal amounts to both inguinal regions. DC vaccines #1-3 occur every 2 weeks and all subsequent vaccines (up to 10) occur monthly. Group 1 patients will receive autologous unpulsed DC vaccines administered to a single side of the groin and saline administered to the contralateral side the day prior to the 4th DC vaccine as pre-conditioning.
88983572|NCT03688178|Experimental|Gr2: DC Vaccine (Td pre-conditioning)|Patients will receive TMZ at a target dose of 150-200 mg/m^2/d for 5 days every 4 (+2) weeks for up to 12 cycles. DC vaccines will be administered in equal amounts to both inguinal regions. DC vaccines #1-3 occur every 2 weeks and all subsequent vaccines (up to 10) occur monthly. Group 2 patients will receive a single dose of Td toxoid administered to a single side of the groin and saline administered to the contralateral side the day prior to the 4th DC vaccine, which is always given bilaterally at the groin site.
89611538|NCT03400774|Other|Control|Oral glucose tolerance test with no stair-climbing
89611539|NCT03400774|Experimental|1 minute|Oral glucose tolerance test with 1 minute of stair-climbing
89611540|NCT03400774|Experimental|3 minutes|Oral glucose tolerance test with 3 minutes stair-climbing
89611541|NCT03400774|Active Comparator|10 minutes|Oral glucose tolerance test with 10 minutes stair-climbing
89611542|NCT04377178|Experimental|Dentin chips group from automated mill|Dentin particles prepared from dentin grinder will be placed in extraction socket immediately after extraction
89611543|NCT04377178|Active Comparator|Manually milled Dentin chips|Dentin particles prepared from bone mill will be placed in extraction socket immediately after extraction.
89611544|NCT01720420|Experimental|Mandible|NobelReplace CC NobelProcera Implant Bar Titanium Overdenture (lab-made)
89611545|NCT01720420|Experimental|Maxilla|NobelReplace CC NobelProcera Implant Bar Titanium Overdenture (lab-made)
89611546|NCT03835000||Pre operative patient|Patients who will require orthopedic surgery for corrective, replacement or repair
88815382|NCT03296150|No Intervention|Control arm : Information|Patients will receive the usual standard information delivered to patients
88815383|NCT03296150|Experimental|Intervention arm : Therapeutic educational program|"Patients will receive the therapeutic educational program PRESTAGE"
88815384|NCT03208322||DCV + ASV at a sentinel site|patients with chronic hepatitis C (CHC) who are being given at least 1 dose of daclatasvir (DCV) and asunaprevir (ASV) for the treatment and cure of CHC at the sentinel sites for the National Pharmacovigilance Center (CNFV) in Mexico.
88815385|NCT00998426|Experimental|All study participants|Study procedures will occur one timebetween post-op day 1 and post-op day 7. Study procedures to include blood glucose monitoring prior to and after (various time points for 2 hours after) infusion with HBIG.
88815386|NCT00998582|Active Comparator|Abacavir|Participants randomized to this arm will continue abacavir and their other HIV medications with no changes
88815387|NCT00998582|Experimental|Tenofovir|Participants randomized to this arm will switch from taking abacavir (co-formulated with lamivudine as Epzicom) and start taking tenofovir (co-formulated with emtricitabine as Truvada), and continue their other HIV medications
88815388|NCT00998660|Experimental|Patients receiving an Activa RC implant|
88815389|NCT00999830|Experimental|IPH 2101 0.2 mg/kg|One infusion of IPH2101 every 4 weeks at the dose of 0.2 mg/kg by intravenous route over 1 hour, for 4 or up to 8 cycles.
88815390|NCT00999830|Experimental|IPH2101 2.0 mg/kg|One infusion of IPH2101 every 4 weeks at the dose of 2 mg/kg by intravenous route over 1 hour, for 4 or up to 8 cycles.
88815391|NCT01001078|Active Comparator|I-Gel supraglottic airway device|Group in which the I-Gel will be used in the first and second attempts to secure the airway. If a third attempt is needed, the LMA Supreme will be used. If the third attempt fails, a standard endotracheal tube will be used.
88815392|NCT01001078|Active Comparator|LMA Supreme supraglottic airway device|Group in which the LMA Supreme will be used in the first and second attempts to secure the airway. If a third attempt is needed, the I-Gel will be used. If the third attempt fails, a standard endotracheal tube will be used.
88815393|NCT01001078|Active Comparator|Standard endotracheal tube|A Standard endotracheal tube will be inserted in case both other airway devices (LMA Supreme and iGel) devices fail to provide adequate ventilation.
88815394|NCT02418000|Experimental|E6201 240 mg/m^2 IV weekly|E6201 240 mg/m^2 administered IV over 2 hours once weekly, on Days 1, 8, 15, and 22, repeated every 28 days (= 1 cycle)
88815395|NCT02418000|Experimental|E6201 320 mg/m^2 IV weekly|E6201 320 mg/m^2 administered IV over 2 hours once weekly, on Days 1, 8, 15, and 22, repeated every 28 days (= 1 cycle)
88815396|NCT02418000|Experimental|E6201 160 mg/m^2 IV twice weekly|E6201 160 mg/m^2 administered IV over 2 hours twice weekly, on Days 1, 4, 8, 11, 15, 18, 22 and 25, repeated every 28 days (= 1 cycle)
88815397|NCT02418000|Experimental|E6201 240 mg/m^2 IV twice weekly|E6201 240 mg/m^2 administered IV over 2 hours twice weekly, on Days 1, 4, 8, 11, 15, 18, 22 and 25, repeated every 28 days (= 1 cycle)
88815398|NCT02418000|Experimental|E6201 320 mg/m^2 IV twice weekly|E6201 320 mg/m^2 administered IV over 2 hours twice weekly, on Days 1, 4, 8, 11, 15, 18, 22, and 25, repeated every 28 days (= 1 cycle)
88815399|NCT01001546|Experimental|Arm 1|Internet-based smoking cessation
88815400|NCT01001546|Other|Arm 2|Clinic-based smoking cessation
88815401|NCT04927104|Experimental|PEEK Knee Prosthesis|In this study, 10 subjects will be underwent total knee arthroplasty with PEEK knee prosthesis.
88815402|NCT02168660|Active Comparator|Control Group|Standard vitamin D3 dose as per IOM (Institute of Medicine) recommendations; actual dose will be 5000 IU per week, which is just slightly higher than the IOM recommendation of 600 IU per day. Length of time proposed to be 4 months at 5000 IU D3 per week. End of study measures at 4 months to be HOMA-IR, BMI Z score, 25-OHD level.
88815403|NCT02168660|Experimental|Low-Normal Group|Initial D3 dose will be 30,000 IU per week; at 6 week intervals serum D3 levels will be checked, and dose adjustments made to reach target 25-OHD level of between 30-50 ng/mL (inclusive). Once within target, D3 dose will be continued for 4 months, and end of study measurements done (HOMA-IR, BMI Z score, 25-OHD level).
88815404|NCT02168660|Experimental|High-Normal Group|Initial D3 dose will be 60,000 IU/week; at 6 week intervals 25-OHD levels will be done, and dose adjustments made to achieve target level of 40-60 ng/mL (inclusive). Once within target range, D3 dose will be continued for 4 months, and end of study measures obtained (HOMA-IR, BMI Z score, 25-OHD level).
88815405|NCT01003106|Experimental|BRVO- Ranibizumab 0.5mg alone|Branch retinal vein occlusion patients randomized to this group will receive 0.5mg of ranibizumab alone as per protocol without laser photocoagulation.
88815406|NCT01003106|Experimental|BRVO- Pro re nata (prn) ranibizumab with laser|Branch retinal vein occlusion patients randomized to this group will receive 0.5mg/2.0mg of ranibizumab as per protocol, and additional laser photocoagulation if required.
88815407|NCT01003106|Experimental|BRVO- Ranibizumab 2.0mg alone|Branch retinal vein occlusion patients randomized to this group will receive 2.0mg of ranibizumab alone as per protocol without laser photocoagulation.
88815408|NCT01003106|Experimental|BRVO- Pro re nata (prn) ranibizumab|Branch retinal vein occlusion patients randomized to this group will receive 0.5mg/2.0mg of ranibizumab as per protocol, without additional laser photocoagulation.
88815409|NCT01003106|Experimental|CRVO- Ranibizumab 0.5mg alone|Central retinal vein occlusion patients randomized to this group will receive 0.5mg of ranibizumab alone as per protocol without laser photocoagulation
88815410|NCT01003106|Experimental|CRVO- Pro re nata (prn) ranibizumab with laser|Central retinal vein occlusion patients randomized to this group will receive 0.5mg/2.0mg of ranibizumab as per protocol, and additional laser photocoagulation if required.
89611547|NCT03409120|Experimental|Dystonia Severity Assessment|We will measure the effects of DBS on dystonia by assessing changes in the Burke-Fahn-Marsden Dystonia Rating Scale at 2, 4, 6, and 12 months after surgery to implant the Boston Scientific Vercise PC IPG with directional DBS lead versus preoperative baseline.
89611548|NCT03405142|Experimental|T1 or T2 stage and node-negative|T1 or T2 stage primary tumor and node-negative (ie, cN0)
89034211|NCT05303805|Active Comparator|Cyteal|the control group will only have a standard rinse solution with Cyteal PIERRE FABRE MEDICAMENT, France (100 ml of skin fluid contains hexamidine diisetione 100 mg, chlorohexidine digluconate (solutio 20 %) 100 mg and chlorocresol 300 mg), with sevoflurane used to soak the absorbent material held under the distal pole of the wound.
89034212|NCT05302921|Experimental|All patients|"Patients less than 40 years old with relapsed/refractory solid tumors and at least 2 sites of measurable disease will receive the current pediatric RP2D of nivolumab and ipilimumab for one cycle and undergo cryoablation therapy of one tumor site. Patients will continue to receive cycles of checkpoint inhibition as long as there is no disease progression of unacceptable toxicity (maximum of 13 cycles [12 months]).~There are 4 patient cohorts:~Osteosarcoma~Ewing sarcoma~Rhabdomyosarcoma~All other solid tumors (non-statistical)"
89034213|NCT05302609|Experimental|SclerFIX|Patch of umbilical cord lining membrane sutured on top of the scleral defect.
89034214|NCT05300503|No Intervention|Control|Participants will be asked to continue their usual day to day activities and take their current medications as directed. They will be sent a link by email or through MyChart to the standard video & education session on managing hypertension. They will watch the video at home on their own time. Participants will use a home blood pressure monitor to track their blood pressure (those without a blood pressure cuff will be provided one) for the 3-month intervention period. Patients will be provided instructions of when they should seek medical attention (clinical symptoms or SBP <100 or SBP >160). They will be encouraged to track their blood pressure daily and any symptoms they may be feeling.
89034215|NCT05300503|Experimental|Intervention|Participants will be asked to continue their usual day to day activities and take their current medications as directed. They will be sent a link by email or through MyChart to the educational session described above in the control group section. They will receive an Aetonix aTouchAway platform monitor, which is a disease specific home monitoring device to take home for 3 month intervention period. The device will prompt the participant to check their blood pressure on a daily basis and will send all readings to the UOHI Telehome monitoring program. The telehome monitoring nursing team will monitor the readings for each participant. For hypertensive patients who are not at target with their BP, the telehome monitoring nurse will titrate medications based on an advanced medical directive every 2 weeks. Patients will be provided instructions of when they should seek medical attention (clinical symptoms or SBP <100 or SBP >160).
89034216|NCT05299112|No Intervention|Standard parenteral nutrition|These infants will form the control group and will receive standard parenteral nutrition. They will be sub-stratified into infants <27 weeks and infants >27 weeks gestation.
89034217|NCT05299112|Experimental|Arginine supplementation|These infants will form the intervention group and will receive parenteral nutrition with additional arginine (18% of amino acid) for up to 14 days of life. They will be sub-stratified into infants <27 weeks and infants >27 weeks gestation.
89611549|NCT03405142|Experimental|Any T stage and node-positive|Any T stage tumor and node-positive (ie, cN+)
89611550|NCT03407872|Experimental|PART A|6 cohorts will receive single dose of Esketamine DPI administered with dose escalation between cohorts.
89611551|NCT03407872|Experimental|PART B|4 cohorts will receive single dose of Esketamine DPI administered with dose escalation between cohorts.
89034218|NCT05296772|Other|Dose escalation|A open-label single arm of JS014 alone or in combination with pembrolizumab
89034219|NCT05289271|Experimental|Group 1: V, V, V|Participants who received a 2-dose regimen of Vaxelis™ as infants prior to enrollment will receive a Vaxelis™ booster at ~11 months of age.
89034220|NCT05289271|Experimental|Group 2: H, H, V|Participants who received a 2-dose regimen of Hexyon™ as infants prior to enrollment will receive a Vaxelis™ booster at ~11 months of age.
89034221|NCT05284903|Other|Experimental: Phonak device with activated feature|The clinical investigation is designed to evaluate clinical performances in terms of speech intelligibility and listening effort. The expected benefit is based on clinical relevant differences. This clinical investigation is divided in three parts including Beamformer benefit, Speech Enhancer benefit and Hearing aid benefit (this part will be performed aided).
89034222|NCT05284903|Other|Comparator: Phonak device with deactivated feature|The comparative testings should be used as reference. The measures will be performed by the same participant group and the same three parts will be evaluated including Beamformer (BF) benefit, Speech Enhancer benefit and Hearing aid benefit. The reference will be performed without these features or with different settings of these features. In case of the Hearing aid benefit, the reference is an unaided fitting.
89611552|NCT03407872|Experimental|PART C|4 cohorts will receive multiple dose of Esketamine DPI in two weeks' time administered with dose escalation between cohorts.
89611553|NCT03407872|Placebo Comparator|PART C placebo|4 cohorts will receive multiple dose of matching placebo in two weeks' time.
89611554|NCT00016354|Experimental|benzoylphenylurea|
89611555|NCT03834610|Active Comparator|Group A|receive L-arginine 5 g oral caps daily for 8 weeks serum testosterone level measurement penile doppler
89611556|NCT03834610|Active Comparator|Group B|receive tadalafil 10 mg oral tablets daily for 8 weeks serum testosterone level measurement penile doppler
89611557|NCT03834610|Active Comparator|Group C|receive L-arginine 5 g oral caps plus tadalafil 10 mg oral tablets daily for 8 weeks serum testosterone level measurement penile doppler
89611558|NCT03834610|Placebo Comparator|Group D|receive oral methyl cellulose daily for 8 weeks serum testosterone level measurement penile doppler
89611559|NCT01681472|Active Comparator|Levoleucovorin 200 mg/m2|One i.v. bolus injection of study drug after the patient has been anaesthetized.
89611560|NCT01681472|Active Comparator|Levoleucovorin 60 mg/m2|One i.v. bolus injection of study drug after the patient has been anaesthetized.
89611561|NCT01681472|Experimental|6R-MTHF 200 mg/m2|One i.v. bolus injection of study drug after the patient has been anaesthetized.
89611562|NCT01681472|Experimental|6R-MTHF 60 mg/m2|One i.v. bolus injection of study drug after the patient has been anaesthetized.
89611563|NCT01727518||Reference Population|No Intervention
89034223|NCT05266963|Active Comparator|CREON|CREON is a pancreatic enzyme replacement
89034224|NCT05266963|Placebo Comparator|Placebo|Placebo
89034225|NCT05260658|Experimental|Part A: CFTX-1554 Single Ascending Dose (SAD)|Up to 7 dose levels with CFTX-1554 administered as oral liquid formulation under fasted conditions (at 1 single dose level only, drug intake under fed conditions, and as capsule under fasted conditions and under fed conditions, will be assessed)
89034226|NCT05260658|Placebo Comparator|Part A placebo|Single placebo administration in study Part A
89034227|NCT05260658|Experimental|Part B: CFTX-1554 Multiple Ascending Dose (MAD)|Up to 4 dose levels with CFTX-1554 in Part B. Doses and dosing frequency will be decided based on the results of study Part A.
89034228|NCT05260658|Placebo Comparator|Part B placebo|Multiple placebo administration in study Part B
89034229|NCT05255289|Experimental|Before TOT|Data obtained before the operation
89034230|NCT05255289|Experimental|After TOT|Data obtained after the operation
89611564|NCT02240056||TTC|postmenopausal women with acute Takotsubo cardiomyopathy (TTC), diagnosis by coronary angiography within 24 hours of symptom onset
89611565|NCT02240056||NSTEMI / STEMI|postmenopausal women with acute ST elevation myocardial infarction (NSTEMI / STEMI), diagnosis by coronary angiography within 24 hours of symptom onset
89611566|NCT02240056||healthy subjects|healthy postmenopausal women without coronary artery disease
89611567|NCT01040806|Experimental|Health coaching|Patients with poorly controlled diabetes will receive counseling from a peer health coach -- a patient with diabetes trained in health coaching
89611568|NCT01040806|Active Comparator|Usual care|Patients will receive usual care
89611569|NCT01049152||nondiabetic patients|nondiabetic patients with ESRD undergone hemodialysis
89611570|NCT01049152||diabetic patients|diabetic patients with ESRD undergone hemodialysis
89611571|NCT00915928|Active Comparator|ACE inhibitor|patients randomized to this arm will be treated with ACE inhibitors after surgery
89611572|NCT00915928|Placebo Comparator|Placebo|patients randomized to this arm will be treated with placebo after surgery
89611573|NCT03407404|Experimental|Ketamine-midazolam|Continous intravenous sedation with a colorless drug mixture in 50ml syringe containing 900mg ketamine and 36mg midazolam.
89611574|NCT03407404|Active Comparator|Morphine-Midazolam|Continous intravenous sedation with a colourless drug mixture in 50ml syringes containing 54mg morphine and 36mg midazolam.
89611575|NCT03830086|Other|Group A: general anesthesia|Patients undergoing gynecological laparoscopic surgery under general anesthesia, using the following drugs: Midazolam, Propofol, Sufentanil, Rocuronium, Sevoflurane
89611576|NCT03830086|Other|Group B: regional anesthesia|Patients undergoing gynecological laparoscopic surgery under regional anesthesia, using the following drugs: Sufentanil, Bupivacaine
89034231|NCT05255289|Experimental|Before TVT-O|Data obtained before the operation.
89034232|NCT05255289|Experimental|After TVT-O|Data obtained after the operation.
89034233|NCT05255289|Experimental|Aged patient (>50 y/o) before TVT-O|Data obtained before the operation.
89034234|NCT05255289|Experimental|Aged patient (>50 y/o) after TVT-O|Data obtained after the operation.
89034235|NCT05255289|Experimental|Young patients (<50 y/o) before TVT-O|Data obtained before the operation.
89034236|NCT05255289|Experimental|Young patients (<50 y/o) after TVT-O|Data obtained after the operation.
89034237|NCT05255289|Experimental|Menopausal patient before TVT-O|Data obtained before the operation.
89611577|NCT03407326|Experimental|Alternative|Participants will receive approximately 190 kcal/kg/day of alternative RUTF till recovery or up to 12 weeks of treatment.
89611578|NCT03407326|Active Comparator|Standard|Participants will receive approximately 190 kcal/kg/day of standard RUTF till recovery or up to 12 weeks of treatment.
89611579|NCT01049308||Heart Failure|veteran population with documented heart failure
89611580|NCT02240212|Experimental|Part 1: Dose-escalation (weekly paclitaxel)|The dose escalation will be started from Cohort A (afuresertib combined with weekly paclitaxel regimen at 80 mg/m^2 d1, 8,15, q4w). The starting dose in Cohort A will be 125 mg afuresertib QD to indentify MTD
89611581|NCT02240212|Experimental|Part 1: Dose-escalation (3 weeks Paclitaxel)|Once its MTD is identified, and then the study will move to dosing Cohort B (afuresertib combined with 3 weekly paclitaxel regimen at 175 mg/m^2 d1, q3w. Cohort B (afuresertib combined with 3 weekly paclitaxel regimen at 175 mg/m^2 d1, q3w). The starting daily dose of Cohort B will be 25 mg less than the MTD dose from Cohort A for afuresertib. If it is tolerated, then the dose escalation schedule will be followed in Cohort B until the MTD in this Cohort is reached. If the starting dose is not tolerated, then dose de-escalation will be explored until the MTD in this Cohort is reached. Once two dimensions of the MTD are achieved, then the optimal regimen for paclitaxel and MTD for afuresertib combined with paclitaxel based on the toxicity profile will be identified
89034238|NCT05255289|Experimental|Menopausal patient after TVT-O|Data obtained after the operation.
89034239|NCT05255289|Experimental|Pre-menopausal patient before TVT-O|Data obtained before the operation.
89034240|NCT05255289|Experimental|Pre-menopausal patients after TVT-O|Data obtained after the operation.
89034241|NCT05255289|Experimental|Before i-STOP|Data obtained before the operation.
89034242|NCT05255289|Experimental|After i-STOP|Data obtained after the operation.
89034243|NCT05255289|Experimental|Aged patient before i-STOP|Data obtained before the operation.
89034244|NCT05255289|Experimental|Aged patient after i-STOP|Data obtained after the operation.
89034245|NCT05255289|Experimental|Young patient before i-STOP|Data obtained before the operation.
89034246|NCT05255289|Experimental|Young patient after i-STOP|Data obtained after the operation.
89034247|NCT05255289|Experimental|Menopausal patient before i-STOP|Data obtained before the operation.
89034248|NCT05255289|Experimental|Menopausal patient after i-STOP|Data obtained after the operation.
89034249|NCT05255289|Experimental|Pre-menopausal patient before i-STOP|Data obtained before the operation.
89611582|NCT02240212|Experimental|Part 2: Experimental Cohort|The optimal regimen for paclitaxel and MTD for afuresertib combined with paclitaxel based on the toxicity profile will be administered
89611583|NCT02240290|Experimental|tozadenant|A single dose of 240 mg tozadenant (four 60 mg tablets) and a 74 kBq (2 μCi) 14C-labeled tozadenant capsule will be administered with 240 mL of water.
89611584|NCT03407092||Stentriever Cohort|
89034250|NCT05255289|Experimental|Pre-menopausal patient after i-STOP|Data obtained after the operation.
89034251|NCT05255289|Experimental|Before mini Arc|Data obtained before the operation.
89034252|NCT05255289|Experimental|After mini Arc|Data obtained after the operation.
89611585|NCT03407092||ADAPT cohort|
89611586|NCT01713686|Experimental|Ulthera System Treatment|A single triple-depth Ulthera System treatment of the decolletage delivering treatment at 4.5mm, 3.0mm and 1.5mm depths.
89611587|NCT01047436|Experimental|ArTiMist (artemether sublingual spray)|
89611588|NCT01047436|Active Comparator|Intravenous Quinine|
89611589|NCT02240446|Experimental|Active tDCS|Active tDCS
89611590|NCT02240446|Placebo Comparator|Sham tDCS|Sham tDCS
89611591|NCT03406936|Active Comparator|Daily interruption of sedation|Daily interruption of sedation will be done at 7 am daily by stoppage of midazolam infusion
89611592|NCT03406936|No Intervention|No Sedation|No sedation will be given after initiation of mechanical ventilation
89611593|NCT03406780|Experimental|CAP-1002|Patients will receive 150 million cardiosphere-derived cells (CDCs) via intravenous infusion every 3 months for a total of 4 doses.
89611594|NCT03406780|Placebo Comparator|Placebo|Patients will receive a placebo solution via intravenous infusion every 3 months for a total of 4 doses.
89611595|NCT02240524|Experimental|D2 lymphadenectomy and HIPEC and Systemic chemotherapy|"Intraoperative and postoperative hyperthermic intraperitoneal chemotherapy (twice HIPEC) were performed after radical gastrectomy with D2 lymphadenectomy, followed by 8 cycles of systemic chemotherapy.~HIPEC was conducted within 48 h after surgery: Normal saline 3000ml-4000ml, Paclitaxel 75mg/m^2, 43°C, 60min.~Systemic chemotherapy (XELOX):~Oxaliplatin: 130mg/m^2, d1, Intravenous infusion, every 3 weeks. Capecitabine: 1g/m^2 bid, days 1-14, every 3 weeks and maximum 8 cycles, or progression/intolerance."
89611596|NCT02240524|Placebo Comparator|D2 lymphadenectomy+Systemic chemotherapy|"8 cycles of systemic chemotherapy were performed after radical gastrectomy with D2 lymphadenectomy.~Systemic chemotherapy (XELOX):~Oxaliplatin: 130mg/m^2, d1, Intravenous infusion, every 3 weeks. Capecitabine: 1g/m^2 bid, days 1-14, every 3 weeks and maximum 8 cycles, or progression/intolerance."
89611597|NCT02240602|Experimental|Oxycodone, 1.00 mg dose|Regimen of intravenous patient-controlled analgesia consists of bolus dose of oxycodone 1.00 mg with lock out time of 10 min without basal infusion.
89611598|NCT02240602|Experimental|Oxycodone, 0.03 mg/kg dose|Regimen of intravenous patient-controlled analgesia consists of bolus dose of oxycodone 0.03 mg/kg with lock out time of 10 min without basal infusion.
89611599|NCT02240602|Experimental|Oxycodone, 0.02 mg/kg dose|Regimen of intravenous patient-controlled analgesia consists of bolus dose of oxycodone 0.02 mg/kg with lock out time of 10 min without basal infusion.
89611600|NCT03406546|Experimental|Group DR|Patients sedated with dexmedetomidine and remifentanil.
89611601|NCT03406546|Experimental|Group LMA|General anesthesia was applied using laryngeal mask.
89611602|NCT01681004|Experimental|iFuse Implant System|Surgical placement of iFuse implants in the affected SI joint
89611603|NCT01681004|Active Comparator|Non-Surgical Management|Medications, SI joint injection, physical therapy and RF ablation of SI joint
89611604|NCT01046110|Experimental|IDeg OD|
89611605|NCT01046110|Experimental|DPP-IV inhibitor|
89611606|NCT01713530|Experimental|IDegAsp BID+/-OADs|
89611607|NCT01713530|Experimental|IDeg OD plus IAsp +/-OADs|
89611608|NCT01045798|Experimental|Caspofungin|caspofungin acetate
89034253|NCT05255289|Experimental|Age patient before mini Arc|Data obtained before the operation.
89034254|NCT05255289|Experimental|Age patient after mini Arc|Data obtained after the operation.
89034255|NCT05255289|Experimental|Young before mini Arc|Data obtained before the operation.
89034256|NCT05255289|Experimental|Young patient after mini Arc|Data obtained after the operation.
89034257|NCT05255289|Experimental|Menopausal patient before mini Arc|Data obtained before the operation.
89034258|NCT05255289|Experimental|Menopausal patient after mini Arc|Data obtained after the operation.
89034259|NCT05255289|Experimental|Pre-menopausal before mini Arc|Data obtained before the operation.
89611609|NCT01045798|Placebo Comparator|Placebo|normal saline
89611610|NCT02240758|Experimental|surgical removal of the tumors+stereotaxic biopsy|
89611611|NCT03406390||primary pterygium|Observe the contrast sensitivity of primary pterygium patients and healthy control by quick CSF methods, and the pterygium group would achieve the pterygium surgery by the same surgeon (Jin Yuan) and then be performed the contrast sensitivity test on the 1st, 3rd and 6th month postoperatively.
89034260|NCT05255289|Experimental|Pre-menopausal patient after mini Arc|Data obtained after the operation.
89034261|NCT05254587||Retrospective|
89034262|NCT05254587||Prospective|
89034263|NCT05250024|Experimental|UHMWP Cranioplasty|synthetic reconstruction of cranial defects using computer guided milled UHMWP implants
89034264|NCT05250024|Active Comparator|PEEK Cranioplasty|synthetic reconstruction of cranial defects using computer guided milled PEEK
89034265|NCT05248399|Experimental|COVID-19 Group Problem Solving plus Standard of Care|
89034266|NCT05248399|Active Comparator|Standard of Care|
89034267|NCT05245916|Experimental|IBI397 single-agent dose escalation|
89034268|NCT05245916|Experimental|IBI397+ Rituximab|
89034269|NCT05245916|Experimental|IBI397 + Sintilimab|
89611612|NCT04377256|Experimental|Radiological assessement|Two CBCTs were recorded and compared, one at the baseline and the other at 4 months post-op. The bone resorption was quantified and analyzed using ITK-SNAP software
89611613|NCT04377256|Experimental|Histomorphometric analysis|During implant placement (4 months after the bone grafting), a bone biopsy is collected and stained with several colorants to analyze the biological bone healing
89611614|NCT02240914||Vascular USG and IVUS imaging diagnosis|
89611615|NCT03406234||A group of participants|
89611616|NCT02240992|Experimental|MSCs&PBSC|PBSC will be intravenously infused at a dose of 2×10^8/kg. MSCs will be intravenously infused at a dose of 1×10^6 cells/kg once per week or until complete response(CR) . If the patients do not achieve CR or partial remission (PR) within 4 weeks, they will swithed to other therapy. If the patients achieve PR within 4 weeks, a second course of the same treatment will be given.
89034270|NCT05240846|Experimental|Paramedian conventional palpation group|Patients in this group underwent conventional landmark guided paramedian spinal anesthetic. The spinal anesthesia will be administered based on conventional landmark-based paramedian approach.
89611617|NCT02240992|Experimental|MSCs|MSCs will be intravenously infused at a dose of 1×10^6 cells/kg once per week or until CR. If the patients have no response (NR) within 4 weeks, they will switch to other therapy. If the patients achieve PR within 4 weeks, a second course of the same treatment will be given.
89611618|NCT02982694|Experimental|Atezolizumab and Bevacizumab|Atezolizumab will be administered intravenously at 1200 mg on Day 1 every 3 weeks. The dose of bevacizumab in this study is 7.5 mg/kg administered by IV infusion every 3 weeks on Day 1 of each 21 days cycle. Atezolizumab will be administered first, followed by Bevacizumab, with a minimum of 5 minutes between dosing. The interval between cycle infusions must not be < 10 days.
89611619|NCT04377568|Experimental|Convalescent Plasma + Standard of Care (C19-CP + SoC)|Participants will receive COVID-19 convalescent plasma (C19-CP) plus standard of care while being hospitalized for COVID-19.
89611620|NCT04377568|No Intervention|Standard of Care (SoC)|Participants will receive standard of care while being hospitalized for COVID-19.
89611621|NCT02156674|Experimental|Naglazyme®|weekly Naglazyme® infusion for 2 years
89611622|NCT02241070|Experimental|mindulness-based intervention|Mindulness-based intervention was eight weeks of mindfulness training with forty-five minutes of homework practice every day during the training course. A leader and a professional facilitator led the group. The leader was a long-term mindfulness and vipassana meditation trainer who had practiced both types of meditation for more than two decades and had completed mindfulness trainer education; the professional facilitator was a mindfulness practitioner and a psychiatrist. The group met weekly for two hours in-session at the workplace.
89611623|NCT02241070|No Intervention|waiting-list control|passive control group
89611624|NCT01712984|Experimental|QIV ID Vaccine Group|Participants will receive the intradermal quadrivalent influenza vaccine
89034271|NCT05240846|Experimental|Ultrasound assistance paramedian spinal group|This group will have their spinal anesthetic done based on Ultrasound assistance paramedian spinal.
89034272|NCT05233488|Experimental|Low US dose|Pulsed US, 1 W/cm2, 10% duty cycle.
89034273|NCT05233488|Experimental|Intermediate US dose|Pulsed US, 1 W/cm2, 50% duty cycle.
89034274|NCT05233488|Experimental|High US dose|Pulsed US, 3 W/cm2, 10% duty cycle.
89034275|NCT05233488|Experimental|Higher US dose|Pulsed US, 3 W/cm2, 50% duty cycle.
89034276|NCT05230368|Experimental|1 cycle of treatment (Cohort 1 = 5 patients)|"decitabine (5mg/m²) at days 1, 2, 3~romidepsin (5mg/m²) at days 4, 11, 18"
89034277|NCT05230368|Experimental|2 cycles of treatment (Cohort 2 = 5 patients)|"decitabine (5mg/m²) at days 1, 2, 3, 35, 36, 37~romidepsin (5mg/m²) at days 4, 11, 18, 38, 45, 52"
89034278|NCT05230368|Experimental|4 cycles of treatment (Cohort 3 = 5 patients)|"decitabine (5mg/m²) at days 1, 2, 3, 35, 36, 37, 70, 71, 72, 105, 106, 107~romidepsin (5mg/m²) at days 4, 11, 18, 38, 45, 52, 73, 80, 87, 108, 115, 122"
89034279|NCT05223478|Active Comparator|Phentolamine Ophthalmic Solution 0.75%|One drop of study medication in each eye.
89611625|NCT01712984|Active Comparator|TIV ID1 Vaccine Group|Participants will receive the trivalent influenza vaccine containing the B strain from the primary (Yamagata) lineage
89611626|NCT01712984|Active Comparator|TIV ID2 Group|Participants will receive the intradermal trivalent influenza vaccine containing B strain from the alternate (Victoria) lineage
89611627|NCT01042678|Experimental|MP0112 (0.04 mg)|Single 0.04 mg intravitreal injection of MP0112 in the study eye.
89611628|NCT01042678|Experimental|MP0112 (0.15 mg)|Single 0.15 mg intravitreal injection of MP0112 in the study eye.
89611629|NCT01042678|Experimental|MP0112 (0.4 mg)|Single 0.4 mg intravitreal injection of MP0112 in the study eye.
89034280|NCT05223478|Placebo Comparator|Phentolamine Ophthalmic Solution Vehicle|One drop of study medication in each eye.
89034281|NCT05219565|Experimental|Attractive Targeted Sugar Bait (ATSB)|Clusters within the ATSB arm will have 2 to 3 ATSBs hung on all eligible structures in the cluster where consent from the corresponding compound has been given.
89034282|NCT05219565|No Intervention|Control|Clusters within the control arm will not receive ATSBs.
89034283|NCT05212298|Placebo Comparator|Control|receive placebo treatment, once a day, four pills each time.
89034284|NCT05212298|Experimental|Herbal compound low-dose|once a day, two herbal compound capsules and two placebos each time. The total amount of herbal compound capsules is 557 mg.
89034285|NCT05212298|Experimental|Herbal compound high-dose|once a day, four capsules each time. The total amount of herbal compound capsules is 1114 mg.
89034286|NCT05206084|Experimental|IBS|Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System
89034287|NCT05206084|Active Comparator|XIENCE|Abbott Vascular XIENCE Everolimus Eluting Coronary Stent System
89034288|NCT05205499|Experimental|IBS|Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System
89034289|NCT05205161|Experimental|Part A (Dose Escalation): Dose Level (DL)-1|Participants with advanced R/R B-NHL will receive AZD0466 on day 1 , day 4, day 8 day 15, day 22 of cycle 1 and day 1, day 8 day 15, day 22 of cycle 2 and beyond until maximum 2 years or until disease progression, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue study intervention, whichever occurs first.
89210784|NCT04005261||patients with type 2 diabetes treated with insulin|"Patients with type 2 diabetes who have been using insulin for at least six months.~They should be older than 18 years The patients should be presented to the Diabetes Outpatient Clinics of Istanbul Medeniyet University Goztepe Training and Research Hospital"
89034290|NCT05205161|Experimental|Part A (Dose Escalation): DL1|Participants with advanced R/R B-NHL will receive AZD0466 on day 1 , day 4, day 8 day 15, day 22 of cycle 1 and day 1, day 8 day 15, day 22 of cycle 2 and beyond until maximum 2 years or until disease progression, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue study intervention, whichever occurs first.
89611630|NCT01042678|Experimental|MP0112 (1.0 mg)|Single 1.0 mg intravitreal injection of MP0112 in the study eye.
89611631|NCT01042678|Experimental|MP0112 (2.0 mg)|Single 2.0 mg intravitreal injection of MP0112 in the study eye.
89611632|NCT01042678|Experimental|MP0112 (3.6 mg)|Single 3.6 mg intravitreal injection of MP0112 in the study eye.
88983573|NCT03688178|Experimental|Gr3:DC Vaccine+varlilumab(Td pre-conditioning)|Patients will receive TMZ at a target dose of 150-200 mg/m^2/d for 5 days every 4 (+2) weeks for up to 12 cycles. DC vaccines will be administered in equal amounts to both inguinal regions. DC vaccines #1-3 occur every 2 weeks and all subsequent vaccines (up to 10) occur monthly. Group 3 patients will receive the first 3 DC vaccines every 2 weeks, same as Groups 1 and 2, but they will also receive varlilumab intraveneously (IV) 7 days before vaccine #1 and again at the same visit as vaccine #1, as well as 7 days before every DC vaccine except vaccine #2. Prior to the 4th vaccine, patients will receive a single dose of Td toxoid administered to a single side of the groin and saline administered to the contralateral side.
88983574|NCT03671109|Experimental|IPTp-DHA-PPQ|Monthly IPTp-DHA-PPQ over three days plus daily ARVs and cotrimoxazole prophylaxis
88983575|NCT03671109|Placebo Comparator|IPTp-Placebo|Monthly IPTp-placebo over three days plus daily ARVs and cotrimoxazole prophylaxis
88983576|NCT03655561||Confirmed Lassa fever cases|Participants with a clinical presentation consistent with acute Lassa virus disease and a positive result for Lassa specific RT-PCR obtained before or after inclusion
89210785|NCT00821288|Experimental|Survivorship Intervention|Latina and Caucasian breast cancer survivors treated in an urban academic medical center receiving Survivorship Intervention
89611633|NCT01042600|Active Comparator|Endotracheal intubation|Endotracheal tube insertion for surfactant administration, following morphine and atropine pre-medication
89611634|NCT01042600|Experimental|Laryngeal mask airway|Laryngeal mask airway insertion for surfactant administration, following atropine pre-medication
89611635|NCT04377412||Albania|
89611636|NCT04377412||Australia|
89611637|NCT04377412||Czech Republic|
89611638|NCT04377412||France|
89611639|NCT04377412||Germany|
89611640|NCT04377412||Hong Kong|
89611641|NCT04377412||Israel|
89611642|NCT04377412||Italy|
89611643|NCT04377412||Lebanon|
89611644|NCT04377412||Norway|
89611645|NCT04377412||Poland|
89611646|NCT04377412||Russia|
89611647|NCT04377412||Spain|
89611648|NCT04377412||Sweden|
89611649|NCT04377412||Taiwan|
89611650|NCT04377412||Ukraine|
89611651|NCT04377412||United States|
89611652|NCT01041976|Experimental|Adapted Motivational Interviewing (AMI)|Veterans assigned to the AMI condition will be scheduled for up to 6 sessions over 6 months. Up to 3 of these 6 sessions will be joint sessions with the Veteran's significant other (if available). Sessions will utilize a variety of motivational enhancement strategies including evocative questions, importance and confidence scales, collaborative problem solving, and planning.
88983577|NCT03655561||Non-Lassa cases (controls)|Participants with a clinical presentation consistent with acute Lassa virus disease but subsequently found to have a negative result for Lassa specific RT-PCR
89611653|NCT01041976|Placebo Comparator|Support and Education for Recovery (SER)|Veterans assigned to the control condition will be seen for 6 sessions over 6 months of basic support and education about VA and non-VA psychiatric rehabilitation and recovery services. Up to 3 of these 6 sessions will be joint sessions with the Veteran's significant other (if available). The session topics include information about Bedford VA and Boston VA recovery services, as well as those offered by local non-profits.
89611654|NCT00921310|Experimental|Phase I Dose Level 1 (pemetrexed + temsirolimus)|"-Dose Level 1~Pemetrexed 500mg/m^2 intravenous (IV) on Day 1 of each 21 day cycle~Temsirolimus 15 mg IV on Days 1,8 and 15 of each 21 day cycle"
88983578|NCT03643705|Experimental|Nurse Intervention|This multi-component intervention will consist of four evidence-based components delivered at 4 in-person visits (0, 4, 8, and 12 months) and by telephone contact: (1) nurse-led care coordination, (2) nurse-managed medication protocols and adherence support (3) home blood pressure monitoring, and (4) electronic medical records support tools.
88983579|NCT03643705|Active Comparator|Education Control|Participants in the education control arm will receive general prevention education delivered at 4 in-person visits (0, 4, 8, and 12 months), which will consist of evidence-based material on diet, exercise, smoking, sexually transmitted infections, and cancer prevention.
88983580|NCT03620370|Experimental|NBO group|Normobaric oxygen therapy is the delivery of high-flow oxygen (10L/min) via oxygen storage facemask. This therapy should start in the pre-hospital or emergency room as soon as possible (within 1 hours) after diagnosis of ischemic stroke and last for 4 hours. All participant will receive mechanical thrombectomy and a standard clinical therapy.
89611655|NCT00921310|Experimental|Phase I Dose Level -1 (pemetrexed + temsirolimus)|"Pemetrexed (375 mg/m^2) IV on Day 1 of each 21 day cycle~Temsirolimus (15 mg) IV on Days 1,8 and 15 of each 21 day cycle"
89611656|NCT00921310|Experimental|Phase 2 (pemetrexed + temsirolimus)|"Phase 2 dose will be the maximum tolerated dose found in the Phase I portion of the study.~Pemetrexed (375 mg/m^2) IV on Day 1 of each 21 day cycle~Temsirolimus (15 mg) IV on Days 1,8 and 15 of each 21 day cycle"
89611657|NCT04376710||Surgeons|
89611658|NCT04376710||Patients|
89611659|NCT02241148|Active Comparator|Acetaminophen 500mg|The control group will receive treatment with acetaminophen 500mg and physical therapy rehabilitation
89611660|NCT02241148|Experimental|Kinesio taping|The experimental treatment group will receive acetaminophen 500mg and physical therapy rehabilitation, plus the application of the technique NUCAP Medical Upper Knee Spider ® Kinesio taping
89611661|NCT03405688|Experimental|Acute transfusion|Blood donor heterozygous for the sickle cell disease allele (HbAS genotype)
89611662|NCT03405688|Other|Control - Acute transfusion|Blood donor not bearer of the sickle cell disease allele (HbAA genotype)
89611663|NCT03405688|Experimental|Chronic transfusion|Blood donor heterozygous for the sickle cell disease allele (HbAS genotype)
89611664|NCT03405688|Other|Control - Chronic transfusion|Blood donor not bearer of the sickle cell disease allele (HbAA genotype)
89611665|NCT03405688|Experimental|Transfusion prior to surgery|Blood donor heterozygous for the sickle cell disease allele (HbAS genotype)
89611666|NCT03405688|Other|Control - Transfusion prior to surgery|Blood donor not bearer of the sickle cell disease allele (HbAA genotype)
89611667|NCT01712516|Experimental|QVA149|27.5/12.5 ug twice daily (b.i.d.) Single Dose Dry Powder Inhaler (SDDPI
89611668|NCT01712516|Active Comparator|QAB149|27.5 ug b.i.d.
89611669|NCT01712516|Active Comparator|NVA237|12.5 ug b.i.d.
89611670|NCT01712516|Placebo Comparator|Placebo|b.i.d.
89611671|NCT03405610|Experimental|Toolkit for Optimal Recovery after Injury|The Toolkit for Optimal Recovery after Injury (ToR) is a mind body skills based program delivered individually via secure live video. The format is a 4-week program with weekly meetings and a focus on teaching skills to optimize recovery and prevent chronic pain and disability.
89611672|NCT03405610|No Intervention|Usual Care|The Usual Care (UC) group will continue with their current medical care.
89611673|NCT04166240|Experimental|SAFER TRACKS Intervention|Each cluster starts receiving the intervention in sequence per cluster randomized control trial designs. Each cluster will participate in attending monthly coaching calls and compare their data on test results from pre-intervention to receiving the intervention.
89034291|NCT05205161|Experimental|Part A (Dose Escalation): DL2|Participants with advanced R/R B-NHL will receive AZD0466 on day 1 , day 4, day 8 day 15, day 22 of cycle 1 and day 1, day 8 day 15, day 22 of cycle 2 and beyond until maximum 2 years or until disease progression, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue study intervention, whichever occurs first.
89611674|NCT04166240|No Intervention|Non-intervention period|When the cluster is not in active intervention, they are in the non-intervention period. The amount of time that each site contributes to the intervention depends on which cluster they belong to.
89611675|NCT01703000|Experimental|NG PROMUS stent|Single-arm treatment group receiving interventional NG PROMUS study stent
89611676|NCT01040728|Experimental|Olodaterol (BI1744) Low|Low dose inhaled orally once daily from Respimat inhaler
89611677|NCT01040728|Experimental|Olodaterol (BI1744) High|High dose inhaled orally once daily from Respimat inhaler
89611678|NCT01040728|Active Comparator|Tiotropium 18 mcg|18 mcg inhaled once daily from HandiHaler
89611679|NCT01040728|Placebo Comparator|Placebo|Olodaterol placebo and/or Tiotropium placebo inhaled once daily
89611680|NCT01593020|Experimental|Paclitaxel + FEC or FAC Group|"ARM 1: Participants receive Paclitaxel 80 mg/m2 by vein over 1 hour weekly for 12 doses of a 21 day cycle.~Participants on both arms receive FEC or FAC for 4 cycles (21 day cycle) at the preference of the treating physicians."
89034292|NCT05205161|Experimental|Part A (Dose Escalation): DL3|Participants with advanced R/R B-NHL will receive AZD0466 on day 1 , day 4, day 8 day 15, day 22 of cycle 1 and day 1, day 8 day 15, day 22 of cycle 2 and beyond until maximum 2 years or until disease progression, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue study intervention, whichever occurs first.
89034293|NCT05205161|Experimental|Part A (Dose Escalation): DL4|Participants with advanced R/R B-NHL will receive AZD0466 on day 1 , day 4, day 8 day 15, day 22 of cycle 1 and day 1, day 8 day 15, day 22 of cycle 2 and beyond until maximum 2 years or until disease progression, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue study intervention, whichever occurs first.
89034294|NCT05205161|Experimental|Part B (Dose Expansion): Cohort B1 (R/R MCL)|Participants with advanced R/R MCL will receive AZD0466 at the recommended phase 2 dose (RP2D) until maximum 2 years or until disease progression, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue study intervention, whichever occurs first.
89034295|NCT05205161|Experimental|Part B (Dose Expansion): Cohort B2 (R/R FL or MZL)|Participants with advanced R/R FL or MZL will receive AZD0466 at the recommended phase 2 dose (RP2D) until maximum 2 years or until disease progression, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue study intervention, whichever occurs first.
89034296|NCT05205161|Experimental|Part B (Dose Expansion): Cohort B3 (R/R DLBCL)|Participants with advanced R/R DLBCL will receive AZD0466 at the recommended phase 2 dose (RP2D) until maximum 2 years or until disease progression, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue study intervention, whichever occurs first.
89034297|NCT05192421|Active Comparator|Level 1|Wellness Education
89034298|NCT05192421|Experimental|Level 2|Wellness Education + Pre-recorded Exercise Videos
89034299|NCT05192421|Experimental|Level 3|Wellness Education + Livestream Exercise Classes
89611681|NCT01593020|Experimental|Eribulin + FEC or FAC Group|"ARM 2: Participants receive Eribulin 1.4 mg/m2 by vein over 2-5 minutes on days 1 and 8 every 3 weeks for 4 cycles (21 day cycle).~Participants on both arms receive FEC or FAC for 4 cycles (21 day cycle) at the preference of the treating physicians."
89611682|NCT01040260|Experimental|Contingency management|Use of tangible rewards for verified abstinence
89611683|NCT01040260|Active Comparator|Counseling plus nicotine patches|Counseling plus nicotine patches
89611684|NCT02241226|Experimental|Perfect health course|Perfect health course at the Chopra Center for Wellbeing
89034300|NCT05182242|Experimental|Patients|Pregnant women with sonographic signs
89034301|NCT05182242|Other|Health professionals|biologists, geneticists, obstetricians, midwives of the Pluridisciplinary Centers of Prenatal Diagnosis and genetic services
89034302|NCT05181137|Experimental|Part 1 Active Experimental: SHR0302 Dose#1|SHR0302 Oral tablets taken once daily (QD) for 8 weeks SHR0302 Oral tablets taken once daily (QD)
89611685|NCT02241226|No Intervention|Resort group|Resort group at the La Costa resort
89611686|NCT02241304||Elective surgery with muscle relaxation|ASA I-II-III patients. Fentanyl (2-3 ug/kg) - Propofol (2 mg/kg) induction, sevoflurane anesthesia, type and dose of muscle relaxant up to the decision of attending anesthetist. Neuromuscular stimulation with TetraGraph (30mA current intensity, 0.2 msce pulse duration, 20 sec intervals)
89611687|NCT01046422|Experimental|BMS-770767 ± metformin (Treatment A)|
89611688|NCT01046422|Experimental|BMS-770767 ± metformin (Treatment B)|
89611689|NCT01046422|Experimental|BMS-770767 ± metformin (Treatment C)|
89611690|NCT01046422|Experimental|BMS-770767 ± metformin (Treatment D)|
89611691|NCT01046422|Placebo Comparator|Placebo ± metformin (Treatment E)|
89611692|NCT02241382|Active Comparator|External Electrocardioversion|"Cardioversion with an external cardioverter-defibrillator with a step-up energy protocol (100, 150, 200, 360 J biphasic) in antero-posterior orientation, maintaining a > 8 cm distance between shock electrodes and device and complying with a cool-down phase of 2 minute between shocks, if more than one shock is required."
89611693|NCT02241382|Experimental|Internal Electrocardioversion|Cardioversion via the implanted ICD with a maximum energy synchronized shock (41 J, with a RV -> SVC+can shock orientation in pts with SVC leads). After 1 ineffective internal shock, the patient will be counted as internal CV failure and cardioverted externally, following the same protocol as the external CV group.
89611694|NCT01712438|Experimental|Human cl rhFVIII|
89611695|NCT03405376|Experimental|Branch retinal vein occlusion|Aflibercept 2mg is injected into the vitreous cavity. Center-involved macular edema secondary to branch retinal vein occlusion for no longer than 3 months (at the screening visit it should be ensured that the subjects will comply with the criterion of ≤ 3 months since onset of macular edema at their scheduled baseline visit)
89611696|NCT02241460|Active Comparator|Promescent Lidocaine Spray|Double-Blind Treatment Period: 3 cycles (3 weeks each); 1 week wash-out between each cycle Open-Label Treatment Period: 4 cycles (1 week each); no wash-out
89611697|NCT02241460|Placebo Comparator|Placebo|Double-Blind Treatment Period: 3 cycles (3 weeks each); 1 week wash-out between each cycle Open-Label Treatment Period: 4 cycles (1 week each); no wash-out
89611698|NCT01712204|Placebo Comparator|Placebo|Placebo plus Febuxostat
89611699|NCT01712204|Experimental|AC-201|AC-201 plus Febuxostat
89210786|NCT00821288|Active Comparator|Facing Forward|Latina and Caucasian breast cancer survivors treated in an urban academic medical center receiving Survivorship Intervention Facing Forward: Life after Cancer Treatment manual
89611700|NCT01592864|Experimental|Arm 1|Dentifrice containing stannous fluoride
89611701|NCT01592864|Active Comparator|Arm 2|Marketed dentifrice containing Sodium Monofluorophosphate
89611702|NCT01592786|Experimental|Memantine Hydrochloride (HCl)|Once daily oral administration of open-label memantine for up to 48 weeks: 6-week dose-titration period followed by up to 42-week maintenance period.
89611703|NCT01711736|Experimental|GSK2282512A Group|"Subjects aged between 6 to 35 months inclusive received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of quadrivalent influenza GSK2282512A vaccine.~Quadrivalent influenza GSK2282512A vaccine was administered intramuscularly in the left anterolateral thigh (subjects < 12 months of age) or the deltoid muscle (subjects ≥ 12 months of age)."
89611704|NCT01711736|Active Comparator|Fluarix Group|"Subjects aged between 6 to 35 months inclusive received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of Fluarix vaccine.~Fluarix vaccine was administered intramuscularly in the left anterolateral thigh (subjects < 12 months of age) or the deltoid muscle (subjects ≥ 12 months of age)."
88983581|NCT03620370|No Intervention|Control group|The participants receive mechanical thrombectomy therapy after diagnosed ischemic. All participants receive a standard clinical therapy.
88983582|NCT03532399||Pediatric Cardiac Catheterization|
88983583|NCT03532399||Pediatric Cardiac Surgery|
88983584|NCT03532399||Pediatric Extracorporeal Life Support (ECLS)|
88983585|NCT03527433|No Intervention|Standard arm|In the standard arm, an average of one suture will be placed at each cm length of the wound, thus the number of sutures placed should be equal to the length of the wound in cm.
88983586|NCT03527433|Experimental|Intervention arm|The intervention arm will undergo the alternative/new closure technique with small and close fascia sutures, where each suture will be placed only 5 mm away from the fascia edge and 5 mm apart from the adjacent fascia suture.
88983587|NCT03464942|Active Comparator|Single Dose|SABR 20Gy given as a single dose (to 1 -4 metastases with at least 1 untreated metastasis) followed by atezolizumab (1200 mg) every 3 weeks for 24 months.
89611705|NCT01592708|Active Comparator|Antiemetic anesthesia protocol|Scopolamine 1.5 milligram(mg) patch Propofol infusion remifentanil infusion 250mg erythromycin po for 2 doses Solumedrol 0.625mg IV droperidol 4mg IV Ondansetron Ketorolac 30mg IV ibuprofen 600mg po q6h Fentanyl Hydrocodone/Tylenol po
89611706|NCT01042522|Experimental|Arm I (paclitaxel, carboplatin)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 1 hour on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
88983588|NCT03464942|Active Comparator|Fractionated Dose|SABR 24Gy given as 3 fractions (to 1 -4 metastases with at least 1 untreated metastasis) followed by atezolizumab (1200 mg) every 3 weeks for 24 months.
88983589|NCT03451422|Experimental|Efavaleukin Alfa|Approximately 29 participants will be randomized in a 5:2 ratio (cohorts 1, 2, and 3) or in a 3:1 ratio (cohorts 4 and 5) to Efavaleukin Alfa or placebo in addition to standard of care therapy. Efavaleukin Alfa or placebo will be administered either weekly (QW) or biweekly (Q2W).
88983590|NCT03451422|Placebo Comparator|Placebo|Approximately 29 participants will be randomized in a 5:2 ratio (cohorts 1, 2, and 3) or in a 3:1 ratio (cohorts 4 and 5) to Efavaleukin Alfa or placebo in addition to standard of care therapy. Efavaleukin Alfa or placebo will be administered either weekly (QW) or biweekly (Q2W).
88983591|NCT03446573|Experimental|DTG + 3TC 50 mg/300 mg|Participants will receive a single tablet of a two-drug regimen of DTG 50 mg + 3TC 300 mg once daily from Day 1 through Week 200 (Early and Late Switch Phase).
88983592|NCT03446573|Active Comparator|TAF based regimen (TBR)|Participants will continue their TBR from Day 1 to Week 148 (Early Switch Phase), and eligible participants will switch to DTG + 3TC once daily from Week 148 to 200 (Late Switch Phase).
89034303|NCT05181137|Placebo Comparator|Part 1 Placebo Comparator: Placebo|Placebo Oral tablets taken once daily (QD) for 8 weeks
89034304|NCT05181137|Experimental|Part 2 Active Experimental: SHR0302 Dose#2|SHR0302 Oral tablets taken once daily (QD) for 44 weeks
89034305|NCT05181137|Placebo Comparator|Part 2 Placebo Comparator: Placebo|Placebo Comparator: Maintenance Treatment Placebo Comparator: Placebo
89034306|NCT05181137|Experimental|Part 3 Active Experimental: SHR0302 Dose#2|SHR0302 Oral tablets taken once daily (QD) for 26 weeks
89034307|NCT05177744||allergic (Zagreb, urban)|"Participants will be selected based on proven sensitization to at least one food allergen (preferentially but not only to seafood) with a diagnosis of at least one allergic disease (i.e. allergic asthma, allergic rhinitis, atopic dermatitis and/or food allergy) for at least a year.~Subjects will be recruited from continental region in Croatia - Zagreb (urban)"
89034308|NCT05177744||healthy subjects (Zagreb, urban)|"Healthy subjects that will be recruited from continental region in Croatia - Zagreb (urban).~Negative history of allergic diseases, as well as other severe chronic diseases, including malignant, autoimmune, or mental illnesses."
89611707|NCT01042522|Experimental|Arm II (bleomycin sulfate, etoposide phosphate, cisplatin)|Patients receive bleomycin sulfate IV on day 1 and etoposide IV over 1 hour and cisplatin IV over 30 minutes on days 1-5. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
89611708|NCT01702844|Experimental|nab paclitaxel|Patients will receive nab-paclitaxel once weekly for 3 weeks of every 4 week cycle
89611709|NCT01702532|Experimental|Nicotine Mouth Film|mint nicotine mouth film, buccal administration
89611710|NCT01702532|Active Comparator|Nicotine Lozenge|nicotine lozenge, buccal administration
89611711|NCT02241616|Experimental|Entecavir+Fuzheng Huayu+TCM Granule|Tablet with Entecavir+ Tablet with Fuzheng Huayu+ Granule with TCM
89611712|NCT03400306|Experimental|Part 1, Bioequivalence Sequence Group 1|Veliparib 400-mg doses administered orally on Day 1 of each 2-3 day period in Part 1 with the following sequence for the 3 dosing days: four 100 mg capsules under fasting conditions, followed by one 400-mg tablet under fasting conditions, then one 400 mg tablet under non-fasting conditions.
89611713|NCT03400306|Experimental|Part 2, Extension|Veliparib as monotherapy or in combination with carboplatin and paclitaxel, per investigators' discretion.
89611714|NCT03400306|Experimental|Part 1, Bioequivalence Sequence Group 2|Veliparib 400-mg doses administered orally on Day 1 of each 2-3 day period in Part 1 with the following sequence for the 3 dosing days: one 400-mg tablet under fasting conditions, followed by four 100 mg capsules under fasting conditions, then one 400 mg tablet under non-fasting conditions.
89611715|NCT03405298|Active Comparator|Educational Material with Collaborative Care available|In addition to the material described below, these patients are seen in clinics with behavioral health collaborative care (BHCC), which includes a care manager in the primary care provider's office along with a consulting psychiatrist. If a patient receives the brochure and would like to taper their benzodiazepine, their provider can refer them to the BHCC care manager who can provide education and anxiety and insomnia self-management strategies, while the BHCC psychiatrist will make recommendations regarding the medication taper back to the primary care provider.
88983593|NCT03431831|Active Comparator|Intervention Control|All participants will receive diet/physical intervention. One arm will receive diet/physical activity intervention alone as a Intervention/usual care condition.
88983594|NCT03431831|Experimental|Counselling|These participants will receive usual care and counseling in the form of motivational interviewing weekly with goal setting for the first 5 weeks and monthly intervention for the final 5 months.
88983595|NCT03431831|Experimental|Contrave|These participants will receive usual care and prescription of Contrave for weight loss. They will be seen weekly for the first 5 weeks and monthly for the final 5 months.
88983596|NCT03431831|Experimental|Contrave and counseling|These participants will receive usual care of diet and physical activity recommendations and Contrave prescription and counseling (motivational interviewing interventions weekly for the first 5 weeks and then monthly for 5 months.
88983597|NCT03426891|Experimental|Combination Therapy|Pembrolizumab and Vorinostat Combined with Temozolomide and Radiotherapy. There are two parts to this study: Part 1 (dose escalation) and Part 2 (dose expansion). Dose Expansion: Twenty participants will be treated with vorinostat at the maximum tolerated dose (MTD) from dose escalation phase, pembrolizumab, temozolomide and radiation. During the maintenance phase, participants will receive Temozolomide (for the first 6 months), vorinostat (for 12 months), and pembrolizumab (for 12 months).
89611716|NCT03405298|Active Comparator|Educational Material Only|Patients will receive an 8-page educational brochure that presents information about potential harms of these medications and a vignette about a patient that successfully stopped. It does NOT suggest patients to stop on their own, but rather suggests they speak with their provider.
89611717|NCT03405064|Experimental|levonadifloxacin|oral levonadifloxacin (1000 mg BID) or IV levonadifloxacin (800 mg BID)
89611718|NCT03405064|Active Comparator|linezolid|oral linezolid (600 mg BID) or IV linezolid (600 mg BID)
89611719|NCT01702454|Experimental|Fluarix Quadrivalent Primed Group|Subjects in this group were previously primed with 2 doses of Fluarix Quadrivalent vaccine in the primary study 115345 (NCT01439360) and received 1 dose of Fluarix Quadrivalent vaccine at Day 0 in the current study. The vaccine was administered intramuscularly in the deltoid region of arm.
89611720|NCT01702454|Experimental|Fluarix Quadrivalent Unprimed Group|Subjects in this group were unprimed in the primary study 115345 (NCT01439360) and received 2 doses of Fluarix Quadrivalent vaccine at Days 0 and 28 in the current study. The vaccine was administered intramuscularly in the deltoid region of arm.
89611721|NCT02241694||survey|
89611722|NCT00921934||Vitamin C|Adult patients suffering from acute viral infection, especially herpes zoster, presenting themselves in Primary Care Centers or hospitals all over Germany, and who are treated with standard therapy and add-on vitamin C.
88983598|NCT03422536|Experimental|Arm I (ficlatuzumab)|Patients receive ficlatuzumab IV over 30-60 minutes every 2 weeks in the absence of disease progression or unaccepted toxicity. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
88983599|NCT03422536|Experimental|Arm II (ficlatuzumab, cetuximab)|Patients receive cetuximab IV over 60 -120 minutes and ficlatuzumab IV over 30-60 minutes every 2 weeks in the absence of disease progression or unaccepted toxicity. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
88983600|NCT03388944|Experimental|PCT group|PCT group
89611723|NCT02241772|Experimental|10mg TA-8995|10mg TA-8995 once daily
89611724|NCT02241772|Experimental|2.5mg TA-8995|2.5mg TA-8995 once daily
89611725|NCT02241772|Placebo Comparator|Placebo to TA-8995|Placebo to TA-8995 once daily.
89611726|NCT02241850|Other|High intensity training|9 weeks of supervised training
89611727|NCT04413656|Experimental|ablation group|Patients with stage IA inoperable peripheral lung tumor will be performed ablation. cfDNA methylation would be monitored at different times(before surgery , after surgery 1month, 3month, and every 3month in the first year and every 6 months in the second ). Meanwhile, post-treatment response will be evaluated and follow up will be carried out according to the standard procedure.
89611728|NCT04413656|Experimental|surgery group|Patients with stage IA operable peripheral lung tumor will be performed surgery. cfDNA methylation would be monitored at different time(before surgery , after surgery 1month, 3month). Post-treatment response will be evaluated and follow up will be carried out according to the standard procedure.
89034309|NCT05177744||allergic (Slavonia, urban and rural)|"Participants will be selected based on proven sensitization to at least one food allergen (preferentially but not only to seafood) with a diagnosis of at least one allergic disease (i.e. allergic asthma, allergic rhinitis, atopic dermatitis and/or food allergy) for at least a year.~Subjects will be recruited from continental region in Croatia - Slavonia (urban and rural)"
89034310|NCT05177744||healthy subjects (Slavonia, urban and rural)|"Healthy subjects that will be recruited from continental region in Croatia -(Slavonia, urban and rural).~Negative history of allergic diseases, as well as other severe chronic diseases, including malignant, autoimmune, or mental illnesses."
89611729|NCT01702298|Experimental|Sitagliptin 100 mg/simvastatin 40 mg FDC|Sitagliptin 100 mg/simvastatin 40 mg FDC once daily in the evening for 6 weeks. Participants will continue pre-study dose of metformin >=1000 mg per day.
89611730|NCT03404752|Experimental|Peg-Neutropine®|Study drug will be administered more than 24 hours after completion of chemotherapy and every 3 weeks with chemotherapy. Eligible patients scheduled to receive four or six cycles of chemotherapy in every three weeks will be screened in the preceding 28± 3 days and will be randomized (1:1) to one of two treatment arms (Peg-Filgrastim of GEMABIOTECH, or Peg-Filgrastim of Roche).
89611731|NCT03404752|Active Comparator|Neulastim®|Study drug will be administered more than 24 hours after completion of chemotherapy and every 3 weeks with chemotherapy. Eligible patients scheduled to receive four or six cycles of chemotherapy in every three weeks will be screened in the preceding 28± 3 days and will be randomized (1:1) to one of two treatment arms (Peg-Filgrastim of GEMABIOTECH, or Peg-Filgrastim of Roche).
89611732|NCT04377022|No Intervention|Conventional Therapy|In this group, Patients receive Conventional Therapy for 40 minutes daily and 5 days in a week. The training period was 5 week after the recruitment of patients.
89034311|NCT05177744||allergic Mediterranean region (urban and rural population)|"Participants will be selected based on proven sensitization to at least one food allergen (preferentially but not only to seafood) with a diagnosis of at least one allergic disease (i.e. allergic asthma, allergic rhinitis, atopic dermatitis and/or food allergy) for at least a year.~Subjects will be recruited from mediterranean region in Croatia - urban and rural"
89034312|NCT05177744||healthy subjects Mediterranean region (urban and rural population)|"Healthy subjects that will be recruited from mediterranean region in Croatia -urban and rural.~Negative history of allergic diseases, as well as other severe chronic diseases, including malignant, autoimmune, or mental illnesses."
89034313|NCT05177510|Experimental|Mifepristone and standard of care|Mifepristone 300mg once only and standard of care
89034314|NCT05177510|Placebo Comparator|Placebo|Placebo 300mg once only and standard of care
89034315|NCT05176860|Experimental|High-performance CBCT imaging|Two additional study imaging sets are acquired.
89034316|NCT05174338||AL and TTR amyloidosis|immunoglobulin light chain amyloidosis (AL) and transthyretin amyloidosis (ATTR)
89034317|NCT05174286|Experimental|Screening, Brief Intervention, and Referral to Treatment (SBIRT)|"Participants randomized to this arm will receive:~SBIRT is an evidence-based approach originally designed for people at risk of developing mental disorders. SBIRT is composed of three components: Screening with a validated instrument, Brief Intervention, Referral to Treatment. Motivational Interviewing (MI) is an empirically tested, person-centered, behavior change intervention designed to guide, elicit, and strengthen motivation for change. It decreases ambivalence and increases motivation for treatment.~Culturally-adapted Alive! Program, which is a cost-effective, lifestyle coaching web-based automated platform that includes step-by-step individualized tailoring, feedback, and weekly guidance through interactive emails focused on increasing physical activity, improving eating habits, and weight control."
89611733|NCT04377022|Experimental|Combined Therapy|In this group, Patients receive Aerobic exercise training in addition to conventional Physical Therapy. Patients undergoes Aerobic exercise training for 25 minutes and 3 days in a week. A total of 15 session of aerobic exercise training session was given to patient.
89611734|NCT03401710|Experimental|Group 1|Recombinant human erythropoietin 4000 UI will be administered subcutaneously every other day
89210787|NCT00224887|Experimental|in home nutrition counseling|In-home family-based behavioral counseling using in-person and video interventions delivered by community health advisors
89611735|NCT03401710|No Intervention|Group 2|No recombinant human erythropoietin will be administered to this group
89611736|NCT02241928|Experimental|Stem Cell|Bone marrow mononuclear cell transplantation
89611737|NCT02242006||piperacillin/tazobactam|Serial serum sampling of patients receiving piperacillin/tazobactam and SLED simultaneously
89611738|NCT02242006||meropenem|Serial serum sampling of patients receiving meropenem and SLED simultaneously
89611739|NCT02242006||vancomycin|Serial serum sampling of patients receiving vancomycin and SLED simultaneously
89611740|NCT03409978||In-Motion app for movement analysis|Participants will be recruited from infants referred to the high-risk follow-up clinic at the hospital. These at-risk children are included in the regular clinical follow-up program comprising a standard examination at 3 months corrected age (fidgety general movements period). Infant/families from St. Olavs Hospital (n= 15), in Norway, Lurie Children's Hospital (n=15), Chicago, USA, Christian Medical College (n=15), Vellore, India, University of Ghent (n=15), Belgium, and Hillerød Hospital (n=30), Copenhagen, Denmark will be invited to participate.
89611741|NCT02242084|Experimental|Alteplase treatment|All subject who enter the trial will receive treatment with Alteplase along with questionnaire.
89611742|NCT01701362|Active Comparator|pregabalin|
88983601|NCT03388944|No Intervention|Standard practice group|No intervention
88983602|NCT03358693||Psoriasis patients receiving ustekinumab|Ustekinumab
88983603|NCT03358693||Psoriasis patients receiving infliximab|Infliximab
88983604|NCT03358693||Psoriasis patients receiving secukinumab|Secukinumab
88983605|NCT03358693||Atopic dermatitis patients receiving dupilumab|Dupilumab
89611743|NCT01701362|Placebo Comparator|placebo|
89611744|NCT03159195||Breast Cancer Patients|HR+/HER2- advanced/metastatic breast cancer patients across multiple countries.
88983606|NCT03358693||Psoriasis patients receiving brodalumab|Brodalumab
88983607|NCT03358693||Psoriasis patients receiving Ixekizumab|Ixekizumab
88983608|NCT03358693||Atopic dermatitis patients receiving tralokinumab|Tralokinumab
88983609|NCT03358693||Atopic dermatitis patients receiving baricitinib|Baricitinib
89611745|NCT01673295|Experimental|RTX group|Subjects will receive a RTX infusion (1g) at w0, w2, w24, w48 and w72.
88983610|NCT03358693||Atopic dermatitis patients receiving abrocitinib|Abrocitinib
88983611|NCT03358693||Atopic dermatitis patients receiving upadacitinib|Upadacitinib
88983612|NCT03258502|Experimental|RV521|RV521 drug substance in capsule for oral administration
88983613|NCT03258502|Placebo Comparator|Placebo|Micro-crystalline cellulose in capsule for oral administration
88983614|NCT03228394|Experimental|Ganaxolone|Intravenous
88983615|NCT03228394|Placebo Comparator|Placebo|Intravenous
89210788|NCT00224887|Active Comparator|standard nutrition education curriculum|standard nutrition education curriculum consisting of video and lesson plans based on USDA Food Guide pyramid
89210789|NCT04085393|Active Comparator|GERSC for patients receiving highly emetogenic chemotherapy|Participants will receive GERSC, and two other standard antiemetics prior to chemotherapy
89210790|NCT04085393|Active Comparator|GERSC on patients receiving moderately emetogenic chemotherapy|Participants will receive GERSC and one other standard antiemetic prior to chemotherapy
89611746|NCT01673295|Active Comparator|Control group|Subjects will not receive RTX infusions and will be followed in standard of care
88983620|NCT03016156|Experimental|Stratum I: Initial Evaluation Group|Initially, a small group of patients diagnosed with congenital or infantile cataracts, congenital glaucoma or retinoblastoma and who meet the eligibility criteria will undergo testing with CRADLE on Day 1.
88983621|NCT03016156|Experimental|Stratum II: Leukocoria Evaluation Group|A separate group of participants who are referred for evaluation of leukocoria or any other eye condition will undergo red reflex testing testing with CRADLE on Day 1.
88983622|NCT03016156|Experimental|Stratum III: Retinoblastoma Group|A separate group of participants with known retinoblastoma and who are undergoing ocular salvage treatments will be screened with red reflex testing using direct ophthalmoscopy on Day 1. They will also undergo testing with the CRADLE software application defined as the most effect in Stratum I on Day 1 then for three additional consecutive visits which typically occur every 3 to 4 weeks.
88983623|NCT03008070|Experimental|IVA337 1200mg|IVA337 400mg, once a day (Quaque Die, QD) with food
88983624|NCT03008070|Experimental|IVA337 800mg|IVA337 400mg, once a day (Quaque Die, QD) with food
88983625|NCT03008070|Placebo Comparator|Placebo|Placebo to match, once a day (Quaque Die, QD) with food
88983626|NCT02979353|Experimental|Shed-Meds: A Patient-Centered Deprescribing Intervention|Participants assigned to the intervention group will receive a clinical review of their prescribed medications by a research clinician (Pharmacist, Physician, and/or Nurse Practitioner) followed by a patient interview to assess their willingness to discontinue or reduce some of their medicines based on the clinical recommendations of the team. Hospital and out-patient providers also will be part of the deprescribing decision process. Deprescribing actions will be initiated in the hospital prior to discharge and continue through the skilled nursing facility stay.
88983627|NCT02979353|No Intervention|Control Group|Participants assigned to the control group will receive usual care as it is normally provided by the hospital and skilled nursing facility treatment teams. Research staff will monitor their prescribed medications in both care settings but not make any recommendations or changes, unless a safety issue is identified.
88983628|NCT02953834|Experimental|Kisspeptin and Insulin Resistance Test|Intravenous (IV) administration of kisspeptin 112-121; eat a standard mixed meal or drink a standard mixed meal or 75 grams of oral glucose
88983629|NCT02953834|Placebo Comparator|Placebo and Insulin Resistance Test|IV administration of fluids that contain no study drug; eat a standard mixed meal or drink a standard mixed meal or 75 grams of oral glucose
88983630|NCT02939638|Active Comparator|Plant-based diet|The diet group will be asked to follow a low-fat, vegan diet for 16 weeks
88983631|NCT02939638|Active Comparator|Control diet|Half of the participants will be asked to continue their usual diets for the 16-week study period.
88983632|NCT02849639|Placebo Comparator|Placebo|"Participants enrolled into this arm will only receive educational materials, but will not receive specific recommendations to make changes to the medications they are taking.~Cognitive testing at the beginning and the end of the study will be done with and without a scopolamine patch to reveal cognitive reserve."
88983633|NCT02849639|Active Comparator|Medication Therapy Management (MTM)|"Participants enrolled into this arm will receive educational materials and will have their medications assessed; recommendations for changes in the medications taken will be made when appropriate.~Cognitive testing at the beginning and the end of the study will be done with and without a scopolamine patch to reveal cognitive reserve."
88983634|NCT02815917|Experimental|Cohort 1a: Lorazepam; 1b: Perphenazine|"Up to 5 healthy volunteers will participate in a double-blind, placebo controlled serial imaging cohort 1a. Each subject will undergo two dynamic [18F]FTP PET/CT brain scans on two separate days. On one scan day the patient will receive an IV injection of normal saline (placebo) prior to the FTP brain scan, on the other scan day the patient will receive an IV injection of lorazepam prior to the planned FTP injection scan. The type of injection (placebo versus lorazepam) will be double-blinded to the patient and the injecting nuclear medicine Authorized User. Up to 5 subjects will participate in Cohort 1b where subjects will undergo two FTP PET/CT with and without perphenazine.~Subjects in all cohorts are required to have a structural brain MRI performed within 1 year of study enrollment. If the subject has not had a brain MRI that is deemed acceptable for use for this study, they will be asked to undergo a research brain MRI after they have consented for this study."
88983635|NCT02815917|Experimental|Cohort 2: Healthy Volunteer Test/Retest|"Up to 10 healthy volunteers will participate in a serial imaging cohort. Each subject will undergo two dynamic [18F]FTP PET/CT brain scans on two separate days.~Subjects in all cohorts are required to have a structural brain MRI performed within 1 year of study enrollment. If the subject has not had a brain MRI that is deemed acceptable for use for this study, they will be asked to undergo a research brain MRI after they have consented for this study."
89034318|NCT05174286|Active Comparator|Referral as Usual (RAU)|Participants randomized to this arm will receive Referral as Usual (RAU), which will involve distributing CRC health educational materials (e.g. NCI or CDC brochures that include new guidelines) and contact information for screening service providers in our target community.
89611747|NCT00919126|Experimental|Group A|Xenon 50% (45%-55%) in Oxygen (45%-55%),
89611748|NCT00919126|Experimental|Group B|Xenon 70% (65%-75%) in Oxygen (25%-35%)
89611749|NCT00919126|Active Comparator|Group C|Medical Air in Oxygen (45%-55%)
89611750|NCT03404440|Active Comparator|L.Reuteri|Lactobacillus reuteri DSM 17938 + Lactobacillus reuteri ATCC PTA 6475 one tablet by mouth 7 times per day + Pantoprazole 20 mg twice a day for 28 days
89611751|NCT03404440|Placebo Comparator|Placebo|Placebo one tablet by mouth 7 times per day + Pantoprazole 20 mg twice a day for 28 days
89611752|NCT04375540|Experimental|Upper first premolars extraction|Included 24 patients (7 males,17 females) with a mean age of 21.56±3.19years who were treated with fixed orthodontic appliance for 2.22±0.31years.
89611753|NCT04375540|Experimental|Upper second premolars extraction|Included 26 patients (8 males,18 females) with a mean age of 22.16±3.59years who were treated with fixed orthodontic appliance for 2.25±0.30 years.
89611754|NCT04375540|No Intervention|No intervention|Included 26 subjects (10 males, 16 females) with a mean age of 20.45±3.29years.This group was included to observe any changes in the vertical gingival display over the 2 years' observation period (1.65±0.17 years).
89611755|NCT03833908|Experimental|patients receiving MAF-1217|patients receiving MAF-1217 from week -2 to week 2 (preand post-surgery, total 4 weeks), standard antibiotic therapy (ofloxacin) from day -3 before surgery, and standard postoperative treatment (topical steroid, dexamethasone for 10 days + antibiotic, ofloxacin for 7 days) from day 0 (post-surgery.
89611756|NCT03833908|No Intervention|patients receiving just standard antibiotic therapy|patients receiving just standard antibiotic therapy (ofloxacin) from day -3 before surgery, and standard postoperative treatment (topical steroid, dexamethasone for 10 days + antibiotic, ofloxacin 7 days) from day 0 (postsurgery).
89611757|NCT04375618|Experimental|EGF impregnated in collagen membrane|EGF impregnated in collagen membrane is placed in gingival recession defects
89611758|NCT04375618|Active Comparator|plain collagen membrane|plain collagen membrane is placed in gingival recession defects
89611759|NCT01710800|Placebo Comparator|Placebo arm|Patients will be randomized to receive either PPI or placebo and then undergo a 24 hour pH study with impedance to measure the number of reflux episodes
89611760|NCT01710800|Active Comparator|Esomeprazole|Patients were randomly assigned to receive 40 mg esomeprazole twice daily prior to undergoing a 24 hour pH study with impedance to measure the number of reflux episodes
89611761|NCT03404284||Intervention facilities|Includes 43 health facilities and their associated outreach sites
89611762|NCT03833986|Experimental|Stress management program|The stress program will be delivered to experimental group in a six-sessions for two weeks, each session will take 2 hours (2 hours/six sessions /two weeks).
88983636|NCT02815917|Experimental|Cohort 3: Arterial sampling|"Up to 5 cocaine-dependent males who are voluntarily seeking treatment for cocaine dependence will participate in this imaging cohort. Each subject will undergo one dynamic [18F]FTP PET/CT brain scan. Patients will have an arterial line placed for blood draws during the scan. This group will be used to determine the arterial blood input and FTP parent to metabolite ratio curves for FTP for a cocaine-dependent patient population for comparison with previously collected data in healthy normal volunteers.~Subjects in all cohorts are required to have a structural brain MRI performed within 1 year of study enrollment. If the subject has not had a brain MRI that is deemed acceptable for use for this study, they will be asked to undergo a research brain MRI after they have consented for this study."
88983637|NCT02815917|Experimental|Cohort 4: Cocaine-dependent Test/Retest|"Up to 5 cocaine-dependent males who are voluntarily seeking treatment for cocaine dependence will participate in this imaging cohort. Each subject will undergo two dynamic [18F]FTP PET/CT brain scans on two separate days. This group will be used to test the variability of the [18F]FTP uptake measures in cocaine-dependent patients when scans are done following the consistent procedures with no other interventions.~Subjects in all cohorts are required to have a structural brain MRI performed within 1 year of study enrollment. If the subject has not had a brain MRI that is deemed acceptable for use for this study, they will be asked to undergo a research brain MRI after they have consented for this study."
88983638|NCT02806154||Elderly cancer patients|Elderly cancer patients treated with chemotherapy will have DEXA
88983639|NCT02665065|Experimental|Iomab-B|Iomab-B in conjunction with a Reduced Intensity Conditioning (RIC) regimen containing Fludarabine and low-dose Total Body Irradiation (TBI) prior to allogeneic HCT
88983640|NCT02665065|Active Comparator|Conventional Care|Defined as Investigator's choice of salvage chemotherapy with any combination of the following agents: Azacitidine (not allowed as a single agent), Carboplatin, Cladribine, Clofarabine, Cyclophosphamide, Cytarabine, Daunorubicin, Decitabine (not allowed as a single agent with the exception of patients with documented TP53 mutations who have not previously received 10-day regimens of single agent decitabine), Doxorubicin, Enasidenib, Etoposide, Fludarabine, Gemtuzumab ozogamicin, Idarubicin, Ivosidenib (for subjects with IDH1 mutation), L-Asparaginase, Midostaurin (for FLT3 mutant or FLT3-ITD subjects only, not allowed as single agent), Mitoxantrone, Sorafenib (for FLT3 mutant or FLT3-ITD subjects only, not allowed as single agent), Thioguanine, Topotecan, Venetoclax (in combination with a hypomethylating agent). Chemotherapy agents not listed above may be administered after providing clinical justification and receiving medical monitor approval prior to initiation of treatment.
88983641|NCT02633397|Experimental|Riociguat|Treatment Arm
88983642|NCT02633397|Placebo Comparator|Placebo|Placebo Arm
88983643|NCT02594384|Experimental|Continuous monotherapy|All patients will take LAM-002A two times daily by mouth every day until cancer progression or intolerability.
88983644|NCT02594384|Experimental|Intermittent monotherapy|All patients will receive LAM-002A at escalating dose levels two times daily by mouth for 3 days on therapy followed by 4 days off therapy every week until cancer progression or intolerability.
88983645|NCT02594384|Experimental|LAM-002A + rituximab|All patients will receive LAM-002A 125mg two times daily by mouth every day until cancer progression or intolerability and rituximab 375 mg/m2 by vein every week for 4 weeks and then every 8 weeks for 4 times (total of 8 infusions)
88983646|NCT02594384|Experimental|LAM-002A + atezolizumab|All patients will receive LAM-002A 125mg two times daily by mouth every day until cancer progression or intolerability and atezolizumab 1200 mg by vein every 3 weeks until cancer progression or intolerability
88983647|NCT02592707|Experimental|177Lu-IPN01072|177Lu-IPN01072 administered in 3 cycles at intervals of 8 weeks (+ up to 2 additional optional cycles)
88983648|NCT02470897|Experimental|Arm A (moderate dose SBRT with SIB)|"Patients undergo 5 fractions of moderate dose SBRT with SIB every other day for 10 days following urethral-sparing IMRT planning.~SBRT: 8.0Gy escalated dose"
88983649|NCT02470897|Active Comparator|Arm B (uniform dose SBRT)|"Patients undergo 5 fractions of uniform dose SBRT every other day for 10 days following urethral-sparing IMRT planning.~SBRT: 7.5Gy conventional dose"
88983650|NCT02410733|Experimental|Lipo-MERIT|7 dose escalation cohorts (3 +3 design) and 3 expanded cohorts
88983651|NCT02339974|Experimental|Severe Tricuspid Regurgitation|This is a non-blinded (open label), non-randomized safety and feasibility study of the heterotopic implantation of the Edwards Sapien 3 valve.
88983652|NCT02326805|Experimental|Arm I (rilimogene-galvacirepvec)|Patients receive rilimogene-galvacirepvec SC at baseline and on days 14, 28, 56, 84, 112, and 140.
88983653|NCT02326805|Placebo Comparator|Arm II (placebo)|Patients receive placebo SC at baseline and on days 14, 28, 56, 84, 112, and 140.
88983654|NCT02316457|Experimental|ARM1 IVAC_W_bre1_uID|Patients enrolled in ARM1 will receive a treatment with four RNAs. This includes two to three variant RNAs selected from the WAREHOUSE plus p53 RNA. The selection process of RNAs from the warehouse is based on RT-PCR-based profiling of RNA extracted from patient tumor sample specimens, pre-defined cut-offs and algorithms to select the three relevant RNAs for a given patient.
88983655|NCT02316457|Experimental|ARM2 IVAC_W_bre1_uID/IVAC_M_uID|Patients enrolled in ARM2 will optionally receive the WAREHOUSE treatment as described above followed by the personalized IVAC® MUTANOME immunotherapy. The mutation selection process constitutes a multi-step process including identification of somatic mutations by NGS, mutation confirmation and prioritization, selection, and on demand manufacturing.
89611763|NCT03833986|No Intervention|Control|There is no intervention for controlled group during workshop but they are put on a waiting-list to receive the intervention after the active treatment group does.
89611764|NCT03404128||Questionnaires|Questionnaire for patient Questionnaire for neurologist
89611765|NCT01710020|Experimental|CP-690,550|
89611766|NCT03833830||longterm treatment group|previous treatment (before Optical Coherence Tomography angiography (OCTA)) >20 injections
89611767|NCT03833830||shortterm treatment group|previous treatment (before Optical Coherence Tomography angiography (OCTA)) < 5 injections
89611768|NCT02982850|Experimental|Dabigatran|Previous treatment of aspirin or warfarin will be changed to dabigatran treatment in patients allocated to dabigatran group.
88983656|NCT02316457|Experimental|ARM3 IVAC_W_bre1_uID + RBLTet.1|Patients enrolled in ARM3 will receive a treatment with four RNAs. This includes two to three variant RNAs selected from the WAREHOUSE plus p53 RNA. The selection process of RNAs from the warehouse is based on RT-PCR-based profiling of RNA extracted from patient tumor sample specimens, pre-defined cut-offs and algorithms to select the three relevant RNAs for a given patient. RBLTet.1 RNA will be added to each RNA applied.
88983657|NCT01952782|Experimental|Naloxone, Kisspeptin, GnRH|Intravenous (IV) administration of kisspeptin 112-121, GnRH, and naloxone
88983658|NCT01833182|Placebo Comparator|Sham intervention|"Those randomized to the sham or placebo treatment group will receive an ADL kit treatment designed only to address fine motor upper extremity function.A series of six 90-minute sessions will be provided to each participant in the sham condition using a standardized protocol."
88983659|NCT01833182|Experimental|Tailored home intervention|Those randomized to the study treatment group will receive a tailored home modification intervention delivered in a series of six 90-minute sessions via a standardized protocol. The tailored treatment may include medical equipment and modifications to the home.
88983660|NCT01621659|Experimental|multidisciplinary team intervention|Intervention arm receives regular assessments and treatments from cardiology team, clinical nutrition, pharmacist, exercise physiologist and physiotherapist
88983661|NCT01621659|No Intervention|Observational arm|Participants randomized to observational arm will receive usual care.
88983662|NCT01423812|Experimental|Once-daily Darunavir and ritonavir|Subjects switched from Darunavir 600mg plus Ritonavir 100mg twice-daily to Darunavir 800mg plus Ritonavir 100mg once-daily
88983663|NCT01423812|Active Comparator|Twice-daily Darunavir and ritonavir|Subjects remain on regimens containing Darunavir 600mg plus Ritonavir 100mg twice-daily
89611769|NCT02982850|Active Comparator|Conventional Treatment|Acetylsalicylic acid or warfarin treatment will be continued in patients allocated to conventional treatment group.
89611770|NCT01700348|Experimental|Airflosser|Use of Airflosser
88983664|NCT01291719|Experimental|insulin and glucose infusion|trial of experimental technique in outpatient setting; the group under study will be comprised of type 1 and type 2 diabetic individuals ; they will have automated treatment using algorithm which regulates balancing infusions of glucose and/or insulin intravenously without manual intervention; blood glucose target of 80-180 mg/dl will be guide for the automated system
89611771|NCT01700348|Active Comparator|Manual Floss|Normal Routine
89611772|NCT02242162||neuromuscular diseases|
89611773|NCT03404050|Experimental|Music and dance movement therapy group|Music and dance movement therapy group
89611774|NCT02242240|Experimental|Tiotropium with single dose of formoterol|
89611775|NCT02242240|Experimental|Tiotropium with double dose of formoterol|
89611776|NCT02242240|Experimental|Tiotropium with Placebo|
89611777|NCT03403972|Experimental|Group|Intervention: vancomycin 500 mg tid for 7 days (Vancozin 250 mg capsule)
89611778|NCT04347460||COVID 19|Patients requiring ICU treatment due to severe COVID 19 interstitial pneumonia or otherwise COVID-19 related disease
89611779|NCT02242318|Experimental|Telmisartan|low dose for two weeks, then up titration to high dose, once daily
89611780|NCT02242318|Active Comparator|Valsartan|low dose for two weeks, then up titration to high dose, once daily
89611781|NCT02242318|Placebo Comparator|Placebo|
89611782|NCT01700192|Experimental|MK-8237|MK-8237 12 Development Units (DU) rapidly dissolving tablets administered sublingually once daily (q.d.).
89611783|NCT01700192|Placebo Comparator|Placebo|Placebo to MK-8237 rapidly dissolving tablets administered sublingually q.d.
89611784|NCT00924118|Experimental|Sodium Nitrite|Dose escalation of sodium nitrite.
89611785|NCT00924118|No Intervention|Open Control|Standard therapy
89611786|NCT02242396||Hypertensive patients|
89611787|NCT03403816|Active Comparator|Intervention|"Students in grades K-6 at 7 schools in two communities participating in a before school physical activity program offered at no cost to participating families that focuses on engaging elementary and middle school students in physical activity, skill development and brief nutrition education sessions.~."
89034319|NCT05170165||Enrolled Subjects|Test a clinical decision support (CDS) tool that provides clinicians (cardiologists and nurse practitioners) recommendations regarding guideline directed medical therapy (GDMT) in patients with heart failure and reduced ejection fraction (HFrEF).
89034320|NCT05168475|Active Comparator|Rituximab|
89611788|NCT03403816|No Intervention|Comparison|Students in grades K-6 at the same 7 schools in two communities as the intervention participants, but who did not participate in the before school physical activity program.
89611789|NCT03403738|Active Comparator|Enhanced usual Care|usual care plus comprehensive resource list
89611790|NCT03403738|Experimental|BBN|Bounce Back Now intervention
89611791|NCT04374994|Active Comparator|intervention group|Males with sexual dysfunction who received daily avanafil tablets (50mg) for four weeks
89611792|NCT04374994|Placebo Comparator|control group|Males with sexual dysfunction who received daily placebo tablets for four weeks
89611793|NCT02242474|Active Comparator|Anti-TNF suspended perioperatively|Patients randomized to Group B will have their anti-TNFα therapy interrupted before surgery. Different authors suggested that anti-TNFα therapies should be suspended between two and five half-lives prior to surgery. In the current trial, anti-TNFα will be suspended three half-lives (± seven days) prior to surgery. All other medications used in the treatment of the disease (methotrexate, hydroxychloroquine, corticosteroid, etc.) will be documented and continued in the perioperative period. Non-steroidal anti-inflammatory drugs (NSAID) will be suspended seven days prior to surgery and will be restarted postoperatively. Anti-TNFα will be restarted once wound healing is completed.
89611794|NCT02242474|Experimental|Anti-TNFα continued perioperatively|Patients randomized to Group A will continue their anti-TNFα treatment unaltered during the whole perioperative period. Surgery will be performed without consideration in regards to the timing of the treatment. The time elapsed between the last anti-TNFα administration and the surgery will nonetheless be documented.
89611795|NCT03403660|Experimental|non white coat rounding|The postpartum physician rounding in this group will be performed wearing white coat.
88983665|NCT01176474|Experimental|Nivolumab and Peptide Vaccine|"Cohorts 1 through 3: Participants will receive nivolumab with the peptide vaccine within 8 days after their first apheresis procedure.~Vaccine Combining Multiple Class I Peptides and Montanide ISA 51 VG with Escalating Doses of Anti-PD-1 Antibody Nivolumab (BMS-936558). Level 1: 1 mg/kg Nivolumab + peptide vaccine. Level 2: 3 mg/kg Nivolumab + peptide vaccine. Level 3: 10 mg/kg Nivolumab + peptide vaccine."
88983666|NCT01176474|Experimental|Nivolumab and Ipilimumab|Cohorts 4 and 5. Participants will receive their first dose of nivolumab with ipilimumab within 28 days after screening blood draws. Both drugs will be given. Cohort 4: nivolumab 1mg/kg plus ipilimumab 3mg/kg. Cohort 5: nivolumab 3mg/kg plus ipilimumab 1mg/kg.
88983667|NCT01141309|Experimental|sorafenib with everolimus|This is a two-stage phase II study combining sorafenib with everolimus in patients with thyroid cancer.
88983668|NCT01064063|Active Comparator|AGC knee|Patients were randomised to receive an AGC Cruciate Retaining cement knee. This is the control group in the study; the AGC is the gold standard of Biomets' knee products.
88983669|NCT01064063|Experimental|Vanguard CR|Patients were randomised to receive a Vanguard Cruciate Retaining Knee from the Vanguard system which encompasses concepts used in the AGC family of knees. The Vanguard is specifically designed to give greater knees stability through use of more anatomic patello-femoral kinematics.
88983670|NCT00965718|Experimental|Immuncell-LC group|Intravenous dripping of 200 ml (109~2 1010 lymphocytes/60 kg adult) for 1 hour.
88983671|NCT00914823|Experimental|kisspeptin, GnRH|Intravenous (IV) or subcutaneous (SC) administration of kisspeptin 112-121 and/or administration of GnRH
88983672|NCT00859781|Experimental|1. 177Lu-J591 + Ketoconazole|Ketoconazole 400 mg 3 times a day plus hydrocortisone 20 mg AM, 10 mg PM x 4 weeks followed by 177Lu-J591 Infusion, continue ketoconazole and hydrocortisone
88983673|NCT00859781|Placebo Comparator|2. 111In-J591 + Ketoconazole|Ketoconazole 400 mg 3 times a day plus hydrocortisone 20 mg AM, 10 mg PM x 4 weeks followed by 111In-J591 (placebo) Infusion, continue ketoconazole and hydrocortisone
88983674|NCT00794222|Experimental|Mood monitoring|The mobiletype monitoring intervention group will monitor their current activities, current mood, responses to negative mood, any recent stressors and coping strategies. Other activities monitored include eating patterns, exercise patterns, quantity and quality of sleep and alcohol and cannabis use.
88983675|NCT00794222|No Intervention|Comparison monitoring program|"The mobiletype monitoring comparison group will monitor their current activities, eating patterns, exercise patterns, quantity and quality of sleep and alcohol and cannabis use.~This program excludes questions about mood, stress and coping strategies."
88983676|NCT00792740|Placebo Comparator|Placebo|Oral matching placebo capsules, administered bid.
88983677|NCT00792740|Experimental|ITF2357|Oral ITF2357 50 mg bid
88983678|NCT00729300|Placebo Comparator|1|Placebo
88983679|NCT00729300|Experimental|2|disulfiram
88983680|NCT01276132||Subjects who are designated to receive same-day PCI|
88983681|NCT01276132||Subjects who had been admitted to the hospital after their PCI|
88983682|NCT01275716|Experimental|Patients who are shown the images|
88983683|NCT01275716|No Intervention|Patients who are not shown the images|
88983684|NCT01270243||Control|No tonsilar or adenoid problems
88983685|NCT01270243||Adenotonsillectomy (recurrent)|Recurrent adenotonsillitis
88983686|NCT01270243||Adenotonsillectomy (obstruction)|Upper airway obstruction
88983687|NCT01087073|Experimental|Patient Activation|Patient knowledge in diabetes self-management behaviors and clinical measures (HbA1c, LDL, HDL, BMI, BP) are tracked at baseline, 10-weeks (post-program), 3 months (post-program) and 6 months (post-program).
88983688|NCT01087073|Experimental|Provider Training Evaluation|Pre-post surveys are conducted at each training session to assess overall satisfaction with the curriculum, knowledge of SDM, and understanding of techniques to promote its use in the healthcare setting.
88983689|NCT01087073|Experimental|Quality Improvement Evaluation|We measure quality improvement efforts through biannual staff experience surveys and one-on-one provider and clinic staff interviews.
89611796|NCT03403660|Placebo Comparator|White coat rounding|The postpartum physician rounding in this group will be performed not wearing white coat.
89611797|NCT03833752|Experimental|Flexible Cystoscopy|Diagnostic flexible cystoscopy for the patients in this arm
89034321|NCT05168475|Active Comparator|Infliximab|
89034322|NCT05168475|Active Comparator|Tocilizumab|
89034323|NCT05168475|Placebo Comparator|Placebo|Placebo may be to one of the active biologics (ie placebo to Rituximab, Placebo to Infliximab, placebo to Tocilizumab). Only 1 placebo is in a randomised sequence of interventions.
89034324|NCT05164861|Experimental|Intervention/kombucha-based beverage|"Subjects randomized to this group will receive newly developed food product - non-alcoholic pasteurized beverage based on kombucha enriched with inulin and vitamins, flavoured as Black currant with juniper or Strawberries with lime or 'Mango with passion fruit"
89034325|NCT05164861|No Intervention|Control|Subjects of this group will receive standard diet with similar quantity of water as in experimental group
89034326|NCT05164523||Patients with type 2 diabetes treated with SGLT2 inhibitors|metformin using patients with type 2 diabetes who were recently prescribed an SGLT2 inhibitor
89034327|NCT05164523||Patients with type 2 diabetes treated with other oral agents|metformin using patients with type 2 diabetes who were recently prescribed a pre-defined antidiabetic medication other than SGLT2 inhibitors
89034328|NCT05159453|Experimental|Main Experimental|Type 2 Diabetic patients regulating blood glucose with daily injections as basal and/or post-prandial interventions. Patients will receive transdermal product formulated at 100 IU/mL of equivalent International Units of Human Insulin dosed at the same amount as current injected therapies with timing adjusted for the Absorption, Distribution, Metabolism & Elimination (ADME) of human insulin with maximum effect at 3 hours post dose so mid morning before lunch, late afternoon before dinner and before bedtime.
89034329|NCT05149287|Experimental|Experimental|The experimental group will receive a single intravenous dose of 1 g of ceftriaxone immediately postoperative in the operating room.
89034330|NCT05149287|Placebo Comparator|Placebo|The placebo group will receive a single intravenous dose of 1% lidocaine and saline immediately postoperative in the operating room.
89034331|NCT05142293||Sites selected for the same-day organisation|Patients will be admitted to the hospital and leave it on the same-day of the procedure.
89611798|NCT03833752|Active Comparator|Rigid Cystoscopy|Diagnostic rigid cystoscopy is done for the patients in this arm
89611799|NCT03403582|No Intervention|Control arm|A high-fat break fast meal with no raspberries.
89611800|NCT03403582|Experimental|Raspberry arm|A high-fat break fast meal with raspberries (250g frozen)
89034332|NCT05142293||Sites with standard overnight hospitalization|Standard organisation with a minimum of one night's stay
89034333|NCT05138809|Experimental|Exercise|Use online exercise platform
89034334|NCT05136456|Active Comparator|SHR1459 Low Dose|Drug: SHR1459 SHR1459 oral 24weeks
89034335|NCT05136456|Active Comparator|SHR1459 High Dose|Drug: SHR0302 SHR1459 oral 24 weeks
89034336|NCT05136456|Placebo Comparator|Placebo|Drug: Placebo Placebo oral 24 weeks
89034337|NCT05136443|Experimental|Preventative Treatment|Loteprednol etabonate ophthalmic suspension 0.25% dosed 4 times daily for 2 months, 3 times daily for one month, twice daily for one month, and once daily until the 1 year postop exam.
89034338|NCT05133297|Experimental|Sequence 1|TLL018 tablets, 1piece,BID
89034339|NCT05133297|Experimental|Sequence 2|TLL018 tablets, 2pieces, BID
89611801|NCT04374916|Experimental|Partosure® test + Premaquick® test|All patients will have the same 2 tests.
89611802|NCT01709864|Experimental|NVA237|NVA237 will be inhaled from a single-dose dry powder inhaler for a period of 12 weeks
89611803|NCT01709864|Placebo Comparator|Placebo|Placebo will be inhaled from a single-dose dry powder inhaler for a period of 12 weeks.
89611804|NCT04878315|Experimental|Treatment sequence TRR|Participants will receive Capoten (T) in period 1 followed by Captopril (R) in period 2 followed by Captopril (R) in period 3.
89611805|NCT04878315|Experimental|Treatment sequence RTR|Participants will receive Captopril (R) in period 1 followed by Capoten (T) in period 2 followed by Captopril (R) in period 3.
89034340|NCT05133297|Experimental|Sequence 3|TLL018 tablets, 3pieces, BID
89611806|NCT04878315|Experimental|Treatment sequence RRT|Participants will receive Captopril (R) in period 1 followed by Captopril (R) in period 2 followed by Capoten (T) in period 3.
89611807|NCT02242708|No Intervention|Normal breathing|The control group will do normal breathing.
89611808|NCT02242708|Experimental|Alternative nostril breathing|The experimental groups will do alternative nostril breathing twice a week (20 minutes/time) for 3 months.
89611809|NCT04374604||Paturients with preeclampisia|The participants will be pregnant women with late-onset pre-eclampsia
89611810|NCT01706835|Experimental|Aldoxorubicin|Aldoxorubicin dosages of 230 mg/m2 or 350 mg/m2 will be given as a 30 minute infusion every 3 weeks for 8 cycles.
89611811|NCT01651533|Experimental|Experimental: Mental Practice Group|
89034341|NCT05133297|Active Comparator|Sequence 4|TOFA tablets, 1pieces, BID
89034342|NCT05132088|Experimental|oral semaglutide 50 mg once daily|All participants will get semaglutide or placebo tablets, 1 tablet every morning.
89034343|NCT05132088|Placebo Comparator|oral semaglutide placebo once daily|All participants will get semaglutide or placebo tablets, 1 tablet every morning.
89034344|NCT05131685|Experimental|Non-sedated Immobilization|Immobilization in a cast without reduction
89034345|NCT05131685|Active Comparator|Formal Reduction|closed reduction under conscious sedation followed by casting
89034346|NCT05131659|Experimental|Executive function group therapy|
89034347|NCT05127291|Experimental|Study Group|Patients with type 2 diabetes mellitus
89034348|NCT05127291|Other|Control Group|People without type 2 diabetes and prediabetes
89611812|NCT01651533|Active Comparator|Active Comparator: Active Control Group|
89611813|NCT03403348|Experimental|Part 1: Single Ascending Dose (SAD)|Participants will be enrolled in 7 cohorts and receive one of the 7 corresponding SADs of JNJ-64417184, starting from 40 milligram (mg), or placebo in a fasted state. Dose escalation in the subsequent cohorts will depend on the human maximum observed plasma concentration (Cmax) and area under the plasma concentration-time curve (AUC) in previous cohorts.
89611814|NCT03403348|Experimental|Part 2A: Food Effect|Participants enrolled in cohort 4 of part 1 will roll-over in Part 2A and will receive a single oral dose (the same dose as received in Part 1) of JNJ-64417184 or placebo with a high-fat meal.
89611815|NCT03403348|Experimental|Part 2B: Relative Bioavailability (Optional)|Participants enrolled in cohorts 5, 6, 7 or any other optional cohorts of Part 1 will roll-over in Part 2B and will receive a single oral dose (the same dose as received in Part 1) of JNJ-64417184 or placebo under fasted state. Dosing may be changed from fasted to a fed state, depending on emerging pharmacokinetics (PK) data from Part 2A.
89611816|NCT03403348|Experimental|Part 3: Multiple Ascending Dose (MAD)|Participants will be enrolled in 3 cohorts and will receive one of the 3 corresponding MADs of JNJ-64417184 or placebo, dosed once daily for 7 days. There will be 3 optional cohorts and participants in these cohorts will follow 7- to 14-day dosing schedule. Dosing will either occur in the fasted or the fed state, depending on the outcome of Part 2A. Dose selection and dose escalation in the MAD cohorts will depend on the observed human Cmax and AUC in previous (SAD) cohorts. Additional cohorts may be evaluated at the discretion of the Sponsor and the Principal Investigator (PI).
89611817|NCT03403348|Experimental|Part 4: Human RSV Challenge (Proof-of-Concept Study Part)|Based on emerging PK and safety data from Part 3 (MAD), the participants inoculated with respiratory syncytial virus (RSV) -A Memphis 37b and confirmed positive by polymerase chain reaction (PCR) will either receive JNJ-64417184 or placebo once daily OR receive JNJ-64417184 (low dose), JNJ-64417184 (high dose) or placebo once daily.
89611818|NCT03403348|Experimental|Part 5: SAD/Japanese|Participants of Japanese descent will be enrolled in 3 cohorts and will receive one of the corresponding SADs of JNJ-64417184 or placebo in a fasted state. Dosing may be changed from fasted to a fed state, depending on emerging PK data from Part 2A. The starting dose and formulation will be selected based on the outcome of Parts 1 and 2. Dose escalation in the subsequent cohorts will depend on the observed human Cmax and AUC in previous cohorts.
89611819|NCT03403348|Experimental|Part 6: MAD/Japanese (Optional)|Participants of Japanese descent may be enrolled in 3 cohorts and will receive one of the corresponding MADs of JNJ-64417184 or placebo, dosed once daily for 7 to 14 days. Dosing will either occur in the fasted or the fed state, depending on the outcome of Part 2A. Dose selection and dose escalation in the MAD cohorts will depend on the observed human Cmax and AUC in previous (Parts 1, 2, 3, and 5) cohorts.
89611820|NCT02242786|Experimental|EBRT|
89611821|NCT01673451|Placebo Comparator|Placebo comparator|
89611822|NCT01673451|Experimental|E2006|
89611823|NCT02242864||Patients with hypertension and diabetes mellitus|
89611824|NCT01709708|Active Comparator|Marcaine|Group A will receive treatment with 0.3 mL of 0.5% Marcaine delivered bilaterally with the Tx360™ device to the mucosa associated with the Sphenopalatine Ganglion (SPG)
89611825|NCT01709708|Placebo Comparator|Saline|Group B will receive saline placebo delivered bilaterally with the Tx360TM device to the mucosa associated with the SPG.
89611826|NCT01673529|Experimental|study population|All subjects will receive 1%, 3%, 5% (w/w) of SB705498 and a placebo comparator
89611827|NCT02243098|Experimental|Semaglutide|
89611828|NCT00920374|Experimental|Fluarix Adult Group|Subjects who are 18-60 years of age received one dose of Fluarix™
89611829|NCT00920374|Experimental|Fluarix Elderly Group|Subjects who are > 60 years of age received one dose of Fluarix™
89611830|NCT03159039|Experimental|Conventional Physiotherapy (PT)|Postural drainage + manual vibration
88983690|NCT01087073|Experimental|Community Outreach Evaluation|"Pre-post surveys will be disseminated at nutrition tours (Save-A-Lot, Walgreens, 61st Street Farmers Market) to assess change in knowledge of healthy eating behaviors and proper nutrition. Surveys will also assess participant satisfaction of the tours.~Interviews will also be performed with community stakeholders to assess the costs/benefits of the collaboration and overall feedback on involvement."
88983691|NCT01087073|No Intervention|Global Evaluation of the Intervention|A chart review will be performed in order to evaluate our intervention to improve diabetes processes of care and clinical outcomes among our target population. Chart abstractions will be performed on medical records obtained from our six intervention clinics. In addition, chart abstractions from two University of Illinois at Chicago clinics and three FQHCs located on the West Side of Chicago will serve as control data.100 charts will be randomly selected from each clinic per year of the intervention. The chart review will contain charts from adult diabetes patients over a seven year period that matches the duration of the Improving Diabetes project.
88983692|NCT00856947|Active Comparator|Vitamin D|Dietary supplement: 2400 IU Vitamin D3 (2 tablets of 1200 IU) from week 24 of gestation to 1 week after delivery
88983693|NCT00856947|Placebo Comparator|Placebo|Placebo: 2 placebo tablets with no active substance, identical to the active tablets, from week 24 of gestation to 1 week after delivery
88983694|NCT00740298|Active Comparator|1|Sweet Taste
88983695|NCT00740298|Active Comparator|2|warmth
88983696|NCT00672880|Experimental|1|Psychotherapy
88983697|NCT00672880|Active Comparator|2|Spine Education
88983698|NCT00672880|Placebo Comparator|3|Standard Care
88983699|NCT00655993|Placebo Comparator|1|placebo drug
88983700|NCT00655993|Active Comparator|2|simvastatin
88983701|NCT00473031|Experimental|1|High Protein
88983702|NCT00473031|Active Comparator|2|Normal Protein
88983703|NCT00472745|Experimental|WL|weight loss (WL) with nutrition/behavior modification counseling
88983704|NCT00472745|Active Comparator|WM|Weight Maintenance (WM)
88983705|NCT00340210||Serum Bank Participants|The Columbia MO Serum Bank recruited 6915 women living in and around Columbia MO between 1977-1987 who were cancer-free except for non-melanoma skin cancer and at least 18 years of age.
88983706|NCT00340288||Premenopausal fibroid cases|Premenopausal women (18 years or older) with at least one uterine leiomyoma diagnosis confirmed by ultrasound
88983707|NCT04715620|Experimental|niraparib|
88983708|NCT00340600||DES Exposed|DES-exposed mothers, daughters and sons, and identified subjects
88983709|NCT00340600||DES Unexposed|DES-unexposed mothers, daughters and sons, and identified subjects
88983710|NCT04715776|Placebo Comparator|Pre-DM patients with placebo|Pre-Diabetes patients uptake placebo as dietary supplement
88983711|NCT04715776|Experimental|Pre-DM patients with supplement|Pre-Diabetes patients uptake Brown seaweed as dietary supplement
88983712|NCT04715776|Placebo Comparator|DM patients with placebo|Diabetes patients uptake placebo as dietary supplement.
88983713|NCT04715776|Experimental|DM patients with supplement|Diabetes patients uptake Brown seaweed as dietary supplement
88983714|NCT00340873||Cases|Individuals exposed to digoxin
89210791|NCT00928902|Active Comparator|Peptides with GM-CSF-in-adjuvant, with upfront IL-2|Each of the peptides plus tetanus toxoid peptide, plus GM-CSF in adjuvant, administered subcutaneously and intradermally. Systemic low-dose IL-2 will be administered daily for 6 weeks, beginning at week 1 and ending at week 7.
89611831|NCT03159039|Active Comparator|Prolonged slow exhalation technique|Prolonged exhalation + Conventional PT
89611832|NCT01673685|Placebo Comparator|Portable Oxygen Cylinder|Portable Oxygen Cylinder
89611833|NCT01673685|Active Comparator|Portable Oxygen Concentrator|Portable Oxygen Concentrator
89611834|NCT04374292|Experimental|Intervention group|"Intervention group mothers (n = 90) attended six weekly group sessions, which were led by nutritionists and lasted 90 minutes.~The key message was that healthy dietary habits and health risks are acquired at home and that opportunities for change can be identified in the processes that surround meal times. It begins with selecting and purchasing food, followed by preparation and consumption behaviors. Mothers were encouraged to participate in the sessions which involved the use of food models, videos, slides, and, in some cases, real food. Upon completing each session, mothers were given printed material to add to a home consultation manual.~Upon concluding consultations and group sessions, mother/child pairs from both groups were asked to return for monthly follow-ups over the next three months."
89611835|NCT04374292|Active Comparator|Control group|Control group mothers and children (n = 87) were given the usual nutritional consultation and were prescribed diets that covered their energy requirements according to their age and sex. Similarly, CG mother/child pairs received information regarding food groups and portion sizes, were trained in the use of the food equivalence system to encourage variation, and were instructed on how to prepare the diet at home.
89611836|NCT04374526|Experimental|Convalescent plasma|Patients receive COVID-19 Convalescent Plasma (CCP) in addition to standard therapy
89611837|NCT04374526|No Intervention|Standard therapy|Patients receive standard therapy alone
89611838|NCT05284305||Patients with history of pregnancy|Patients with DT diagnosed during pregnancy; patients with DT with macroscopic disease in situ at the time of pregnancy (including previous partial resection, recurrent disease, primary disease followed with active surveillance); resected DT without clinical evidence of residual or recurrent disease at the onset of pregnancy.
89611839|NCT05284305||Patients without history of pregnancy|Patients with DT without history of pregnancy
89611840|NCT04374058||Two Times|The treatment group consists of selected patients that, based on their mean ultrafiltration rate, are switched from thrice-weekly to twice-weekly hemodialysis sessions
89611841|NCT04374058||Three times|Usual thrice-weekly hemodialysis schedule
89611842|NCT02590809|Experimental|Treatment group|20 patients
89611843|NCT02590809|Placebo Comparator|Placebo group|20 patients
89611844|NCT01709318|Experimental|Nomegestrol Acetate-17β-Estradiol (NOMAC-E2) 500/300 μg/day|Participants will receive nomegestrol acetate 17β-estradiol (NOMAC-E2) 500/300 μg for three treatment periods, each 28-day treatment period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
89611845|NCT01709318|Experimental|Nomegestrol Acetate-17β-Estradiol (NOMAC-E2) 700/300 μg/day|Participants will receive nomegestrol acetate 17β-estradiol (NOMAC-E2) 700/300 μg for three treatment periods, each 28-day treatment period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
89611846|NCT01709318|Experimental|Nomegestrol Acetate-17β-Estradiol (NOMAC-E2) 900/300 μg/day|Participants will receive nomegestrol acetate 17β-estradiol (NOMAC-E2) 900/300 μg for three treatment periods, each 28-day treatment period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
89611847|NCT01709318|Experimental|Etonogestrel-17β-Estradiol (ENG-E2) 75/300 μg/day|Participants will receive etonogestrel 17β-estradiol (ENG-E2) 75/300 μg for three treatment periods, each 28-day treatment period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
89611848|NCT01709318|Experimental|Etonogestrel-17β-Estradiol (ENG-E2) 100/300 μg/day|Participants will receive etonogestrel 17β-estradiol (ENG-E2) 100/300 μg for three treatment periods, each 28-day treatment period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
89611849|NCT01709318|Experimental|Etonogestrel-17β-Estradiol (ENG-E2) 125/300 μg/day|Participants will receive etonogestrel 17β-estradiol (ENG-E2)125/300 μg for three 28-day treatment periods, each treatment period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
89210792|NCT00928902|Active Comparator|Peptides plus GM-CSF-in-adjuvant, delayed IL-2|"Peptides plus GMCSF-in-adjuvant, with delayed IL-2.~Each of the peptides plus tetanus toxoid peptide, plus GM-CSF in adjuvant, administered subcutaneously and intradermally. Systemic low-dose IL-2 will be administered daily for 6 weeks, beginning at week 4 and ending at week 10."
89611850|NCT01709318|Active Comparator|NuvaRing®|Participants will receive NuvaRing® (etonogestrel-ethinyl estradiol [ENG-EE] 120/15 μg) for three treatment periods, each 28-day treatment period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
89611851|NCT02243254|Placebo Comparator|high dose remifentanil without ibuprofen|remifentanil target-controlled infusion effect-site concentration 4 ng/ml normal saline before surgical incision
89611852|NCT02243254|Placebo Comparator|low dose remifentanil without ibuprofen|remifentanil target-controlled infusion effect-site concentration 1 ng/ml normal saline before surgical incision
89611853|NCT02243254|Active Comparator|high dose remifentanil with ibuprofen|remifentanil target-controlled infusion effect-site concentration 4 ng/ml Intravenous ibuprofen 800 mg before surgical incision
89611854|NCT02243254|Active Comparator|low dose remifentanil with ibuprofen|remifentanil target-controlled infusion effect-site concentration 1 ng/ml Intravenous ibuprofen 800 mg before surgical incision
89611855|NCT03402880|Experimental|Treatment (pembrolizumab, epacadostat)|Patients receive pembrolizumab IV on day 1 and epacadostat PO BID on days 1-21. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity. Patients benefiting from treatment may continue for an additional 17 courses.
89611856|NCT01673763|Active Comparator|Stent|Stent insertion into the main pancreatic duct
89611857|NCT01673763|No Intervention|No stent|No stent insertion into the main pancreatic duct
89611858|NCT01673841||Relative + absolute cerebral oxygen saturation.|
88983715|NCT00340873||Controls|Individuals not exposed to digoxin
89210793|NCT00816920||1|Outpatients with suspected leg DVT after exclusion of proximal DVT
89611859|NCT04374214|Active Comparator|Complete Pulpotomy using mineral trioxide aggregate|Twenty-eight patients with curiously exposed permanent molars will be treated with complete pulpotomy by using Mineral Trioxide Aggregate.
89611860|NCT04374214|Active Comparator|Complete Pulpotomy using Simvastatin-alphatricalcium phosphate|Twenty-eight patients with curiously exposed permanent molars will be treated with complete pulpotomy by using Simvastatin -alphatricalcium phospahte.
88983716|NCT00341068||Cleft|children and adults with a cleft lip and/or cleft palate and their parents residing in the Republic of Ireland, Northern Ireland and the United Kingdom
88983717|NCT00341068||NTD|children and adults with an NTD (neural tube defects) and their parents residing in the Republic of Ireland, Northern Ireland and the United Kingdom
88983718|NCT00332566|Experimental|Group A|
88983719|NCT00332566|Active Comparator|Group B|
88983720|NCT00332683|Active Comparator|Control|Patients randomly assigned to this group will have no changes in the ETT during surgery
88983721|NCT00332683|Experimental|Treatment group|Patients in this group will undergo same surgery as control group but with a monitoring and manipulation of ETT pressure
88983722|NCT00341263||Cases - twin pregnancies|Maternal and cord hormones in twins
88983723|NCT00341263||Controls - singleton pregnancies|Maternal and cord hormones in singletons
88983724|NCT00341302||Cohort 1|HIV Infected Pregnant Women
88983725|NCT00341302||Pediatric Cohort 2|HIV exposed , uninfected children born to HIV infected women
88983726|NCT00341302||Pediatric Cohort 3|HIV exposed, uninfected children 6 months to 5 years of age
88983727|NCT00341380||Patients|Undergoing resection of lung tumor
88983728|NCT00332878|Experimental|1|Stepping Stones
88983729|NCT00332878|Active Comparator|2|A 3 hour intervention on HIV and safer sex
88983730|NCT00341458||Cancer Cases|Women 20-74 years old, residents of Warsaw and Lodz that were newly diagnosed with confirmed in situ or invasive breast cancer or ovarian or endometrial cancer
88983731|NCT00332917|Experimental|1|
88983732|NCT00333073|Experimental|Bulkamid|Submucosal injection of Bulkamid into urethra
88983733|NCT00333112|Experimental|1|
88983734|NCT00333112|Placebo Comparator|2|
88983735|NCT00125385|Experimental|Cohort 1|Dose group
88983736|NCT00125385|Experimental|Cohort 2|Dose Group
88983737|NCT00125385|Experimental|Cohort 3|Dose Group
88983738|NCT00125385|Experimental|Cohort 4|Dose Group
88983739|NCT00125385|Experimental|Cohort 5|Dose Group
88983740|NCT00088556|Experimental|Triplet Combination of TLK286 Carboplatin & Paclitaxel|Experimental
88983741|NCT00127140|Experimental|Vorinostat|Participants received (Cycle 1) once-daily vorinostat at assigned dose (100 or 200 mg) on Days 1 and 17 and twice-daily on Days 3-16. Thereafter, participants remaining on study received the same dose level therapy twice-daily for 14 consecutive days followed by 7 days of rest.
88983742|NCT00333268|Experimental|NGOIS|
89611861|NCT03153345|Experimental|Intervention group|The intervention group participated in a conventional stroke rehabilitation program, which consisted of joint range of motion exercises, muscle strengthening, gait training, fine motor exercises, and activity of daily living training. This program was performed for 30 minutes twice a day 5 days a week, over for at least 3 weeks. During the same period, the intervention group also took part in bedside respiratory muscle training twice a day for 7 days a week over a 3-week period.
89611862|NCT03153345|Active Comparator|Control group|The control group participated only in a conventional stroke rehabilitation program, which consisted of joint range of motion exercises, muscle strengthening, gait training, fine motor exercises, and activity of daily living training. This program was performed for 30 minutes twice a day 5 days a week, over for at least 3 weeks.
89611863|NCT01673997|Experimental|Metoprolol Succinate ER Tablets, 200 mg|Metoprolol Succinate ER Tablets, 200 mg of Dr.Reddy's Laboratories Ltd
88983743|NCT00333268|Active Comparator|BSS Plus|
88983744|NCT00341692||Samples of normal breast tissue|Samples of normal breast tissue from organ donors for assessment of histology.
89611864|NCT01673997|Active Comparator|TOPROL-XL ER Tablets 200 mg|TOPROL-XL ER Tablets 200 mg of AstraZeneca
89611865|NCT04373824|Experimental|Group I- Ivermectin|First group with 25 confirmed cases of COVID 19 shall be treated with Ivermectin 200 to 400mcg per kg body weight on day 1 and day 2 along with standard treatment of the hospital protocol
88983745|NCT00333424|Placebo Comparator|Placebo|placebo containing diluent alone
88983746|NCT00333463||Intervention group|The intervention group watched an educational video, reviewed current barriers to drop-taking and possible solutions with a study coordinator, received regular phone call reminders, and had audible and visible reminders activated on their DA devices.
88983747|NCT00333463||Non-Intervention Group|The control group was told to take drops as prescribed and received no additional intervention.
88983748|NCT00333541|Experimental|Treatment|follow-up via e-mail link to survey
88983749|NCT00333541|No Intervention|Control|standard follow-up by phone and in-person interview
88983750|NCT00342004||Healthy Volunteers|Healthy female urban residents in Shanghai between ages of 40-70.
88983751|NCT00333580||Group 1|
88983752|NCT00333658|Experimental|1|Intervention
88983753|NCT00333658|No Intervention|2|Work Services
88983754|NCT00342121||1|Corn farmers enrolled in the Agricultural Health Study who are non-smokers, and who plan to apply specific pesticides.
88983755|NCT00342121||2|Control subjects selected from agricultural extension workers in Iowa who are non-smokers
88983756|NCT00088946|Experimental|Arm 1|Polyphenon E plus erlotinib placebo daily for 12 months.
88983757|NCT00088946|Experimental|Arm 2|Erlotinib and Polyphenon E placebo daily for 12 months.
88983758|NCT00088946|Placebo Comparator|Arm 3|Erlotinib placebo and Polyphenon E placebo daily for 12 months.
88983759|NCT00421018|Sham Comparator|Symptom-guided group|Anti-inflammatory treatment is guided conventionally according to symptoms and beta-2-agonist use.
88983760|NCT00421018|Active Comparator|FeNO-guided group|Anti-inflammatory treatment is guided according to the level of exhaled nitric oxide
88983761|NCT00421057||Exercise Group|Taught to perform a specific regimen for strength-training and walking exercises.
88815411|NCT01003106|Experimental|CRVO- Ranibizumab 2.0mg alone|Central retinal vein occlusion patients randomized to this group will receive 2.0mg of ranibizumab alone as per protocol without laser photocoagulation.
88815412|NCT01003106|Experimental|CRVO- Pro re nata (prn) ranibizumab|Central retinal vein occlusion patients randomized to this group will receive 0.5mg/2.0mg of ranibizumab as per protocol, without additional laser photocoagulation.
88815413|NCT01003418|Experimental|GSK2340272A Group 1|Healthy male or female children, between and including 8 and 12 weeks of age at the time of first vaccination, received 2 primary doses of GSK2340272A vaccine, according to a 0-28 day schedule. Subjects also received routine infant immunisation (Infanrix™-IPV/Hib) and Prevenar™ vaccine at Day 14, Month 3 and Month 10. All vaccines were administered intramuscularly into the anterolateral region of the thigh.
88815414|NCT01003418|Experimental|GSK2340272A Group 2|Healthy male or female children, between and including 8 and 12 weeks of age at the time of first vaccination, received 2 primary doses of GSK2340272A vaccine, according to a 0-4 month schedule. Subjects also received routine infant immunisation (Infanrix™-IPV/Hib) and Prevenar™ vaccine at Day 14, Month 3 and Month 10. All vaccines were administered intramuscularly into the anterolateral region of the thigh.
88815415|NCT02162576|Other|Propeller Health intervention group|All participants attached the Propeller sensor to their SABA medications and tracked the time and location of use for up to 13 months, to capture seasonal variation in medication use, symptoms and environmental triggers. The first 30-day run-in period served as a control period to assess levels of asthma control and SABA use; subject actuations were tracked, but participants and physicians did not receive their data or feedback. After the run-in period, participants received the full intervention for 12 months (see intervention for description).
88815416|NCT01004042|Active Comparator|Depressed subjects|Diagnosis of depression (diagnostic criteria from DSM-IV-TR and MINI International Neuropsychiatric Interview - Brazilian version 5.0.)They must be using a therapeutic dose of antidepressant for at least 2 months before the intervention prescribed by a psychiatrist.
88815417|NCT01004042|Active Comparator|Non Depressed subjects|Subjects with no diagnosis of depression
88815418|NCT01004354|Experimental|Vitamin D|
88815419|NCT02951546|Experimental|Mediterranean diet|"Hypocaloric Mediterranean diet for a 4-month period;~Aerobic exercise training for a 4-month period;"
88815420|NCT02951546|Experimental|Low fat diet|"Hypocaloric low fat diet supplemented by branched and essential amino acids considering the total protein intake for a 4- month period;~Aerobic exercise training for a 4- month period;"
88815421|NCT02902874|Experimental|Patients treated for anaplastic large cell lymphoma ( ALCL )|
88815422|NCT02808416|Experimental|Personalized cellular vaccine|Patients will undergo tumor resection or biopsy, and receive biweekly cellular vaccines consisting of mRNA-pulsed autologous DCs.
88815423|NCT02417064|Experimental|Intranasal Esketamine 84mg plus Oral Antidepressant|As part of an initial titration, participants will self-administer 56 milligrams (mg) of esketamine intranasally on Day 1, and then 84 mg from Day 4 onwards, twice per week for 4 weeks as a fixed dose regimen in Double-Blind Induction Phase. In addition participants will simultaneously initiate a new, open-label oral antidepressant (i.e, duloxetine, escitalopram, sertraline, or venlafaxine extended release [XR]) on Day 1 that will be continued for the duration of Double-Blind Induction Phase.
88815424|NCT02417064|Experimental|Esketamine 56 mg plus Oral Antidepressant|Starting from Day 1, participants will self-administer 56 mg of esketamine, intranasally, twice per week for 4 weeks as a fixed dose regimen in Double-Blind Induction Phase. In addition participants will simultaneously initiate a new, open-label oral antidepressant (i.e, duloxetine, escitalopram, sertraline, or venlafaxine XR) on Day 1 that will be continued for the duration of Double-Blind Induction Phase.
88815425|NCT02417064|Active Comparator|Placebo plus Oral Antidepressant|Participants will self-administer matching placebo, intranasally, twice per week for 4 weeks as a fixed dose regimen in Double-Blind Induction Phase. In addition participants will simultaneously initiate a new, open-label oral antidepressant (i.e, duloxetine, escitalopram, sertraline, or venlafaxine XR) on Day 1 that will be continued for the duration of Double-Blind Induction Phase.
88815426|NCT02165462||Patients with haemophilia|Assessment of bilateral deficit phenomenon during dynamic plantar flexion task
88815427|NCT05593640||ThroboxaneOA|Patient with osteoarthritis and knee effusion
88815428|NCT02357654|Experimental|GnRH agonist|
88815429|NCT02357654|Placebo Comparator|Placebo|
88815430|NCT02349074|Experimental|Digestive endoscopy|Performed a systematic œsophago-gastro-duodenoscopy during Intensive Care Unit stay after out-of-hospital cardiac arrest
88815431|NCT01653132|Experimental|Incobotulinum Toxin A|Twenty units (0.2 ml) of incobotulinum toxin A injected into each parotid gland and 30 units (0.3 ml) to each submandibular gland for a total dose of 100 units using anatomical landmarks
88815432|NCT01653132|Placebo Comparator|Placebo|Sterile, preservative free 0.9% saline, 1 ml, was used as placebo, and injected into the parotid (0.2 ml each) and submandibular (0.3ml each) glands .
88815433|NCT02300012|No Intervention|Operation - No PBI|Patients requiring operation - baseline PBI data not seen by surgeon
88815434|NCT02300012|Experimental|Operation - PBI available|Patients requiring operation - baseline PBI data seen by surgeon pre-operatively
88815435|NCT02300012|No Intervention|Non-operation|Patients with ACL rupture not requiring operation
88815436|NCT02300012|No Intervention|Control|Healthy age matched volunteers - No operation
88815437|NCT02266628|Experimental|Treatment Group A|RSV-F vaccine (0.5mL Injection)
88815438|NCT02266628|Placebo Comparator|Treatment Group B|Saline Placebo (0.5mL Injection)
88815439|NCT02246192|Experimental|control group|sinus pilonidal excision and standard cares
88815440|NCT02246192|Experimental|PRGF group|sinus pilonidal excision+ PRGF
88815441|NCT01004744|Experimental|Presurgical oral anastrozole|1mg daily for two weeks in the interval between diagnostic breast biopsy and definitive breast surgery.
88815442|NCT01005290|Experimental|Combination pill|A once daily oral dose of the cardiovascular fixed dose combination pill (containing 100 mg acetylsalicylic acid, 40 mg simvastatin, and 5 mg ramipril) for one week followed by a once daily oral dose of the cardiovascular fixed dose combination pill (containing 100 mg acetylsalicylic acid, 40 mg simvastatin, and 10 mg ramipril) for 4 weeks.
89034349|NCT05122676|Experimental|MI-CARE program|Those automatically identified as eligible and randomized to the MI-CARE arm are outreached by a study nurse care manager and offered the 12-month long virtual Collaborative Care program by telephone or video visits. Individuals are free to accept or decline the offer (e.g., stop/restart, not accept right away) during the 12 months after their randomization date.
89034350|NCT05122676|No Intervention|Usual care|Those identified as eligible and randomized to the usual care arm have no contact with the study. All outcome data for both study arms are collected from secondary, electronic sources.
89611866|NCT04373824|No Intervention|Group II- standard treatment|The second group with 25 confirmed cases of COVID 19 shall be treated with standard treatment as per hospital protocol for COVID 19.
89034351|NCT05117398|Experimental|Dalbavancin|Dalbavancin (Xydalba®) 1500 mg - One unique dose
89034352|NCT05117398|Active Comparator|Standard documented antibiotic therapy for 14 days according to national guidelines.|"As currently recommended, investigators will be encouraged to use the intravenous route for the entire duration of treatment. However, in order to interfere as little as possible with usual practice in each center, the antimicrobial therapy will be let to the choice of the physician in charge of the patient after a minimum of 7 days of intravenous treatment.~During all the duration of the study, in case of worsening of the clinical condition requiring the prescription of antistaphylococcal, the clinician will prescribe additional antibiotherapy according to standard good practice."
89034353|NCT05115461||Radicular pain group|Patients presenting with lumbar radicular pain and MRI findings associated with radiculopathy
89034354|NCT05115461||Control group|Age- and sex-matched control subjects without pain.
89034355|NCT05110781|Experimental|Treatment (atezolizumab, surgery, radiation therapy)|Patients receive atezolizumab IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 2 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgery. Beginning 6 weeks after surgery, patients with residual disease undergo standard of care radiation therapy and receive atezolizumab IV over 30-60 minutes on day 1. Treatment with atezolizumab repeats every 21 days for up to 15 cycles in the absence of disease progression and unacceptable toxicity.
89034356|NCT05110508|Experimental|Physical Activity Self-Regulation|Participants will receive multiple weekly text messages. Texts will contain wear reminders, encouragements, congratulatory content, and behavior change messages based on the Garmin data. Some text message content asks for a response from the participant to help tailor later messages for behavior change support.
89034357|NCT05110196|Experimental|Capmatinib|Capmatinib (Rahika®) film-coated tablet administered as 400 mg orally twice daily on a continuous dosing schedule for 24 weeks.
89034358|NCT05100355|Active Comparator|Opacification|Contrast agent injection
89034359|NCT05100355|Experimental|Physiological serum injection|Physiological serum injection
89611867|NCT01676571|Experimental|Lu AA21004|
89611868|NCT04373980|Active Comparator|conventional phototherapy|neonates with unconjugated hyperbilirubinemia exposed to conventional phototherapy
89611869|NCT04373980|Active Comparator|LED phototherapy|neonates with unconjugated hyperbilirubinemia exposed to LED phototherapy
88815443|NCT01005290|Active Comparator|Ramipril|A once daily oral dose of 5 mg ramipril for one week followed by a once daily oral dose of 10 mg ramipril for 4 weeks.
89034360|NCT05085860|Experimental|Moderate Intensity Continuous Training (MICT)|Participants will do 3 sessions of moderate-intensity continous exercise training over 7 days
89034361|NCT05085860|Experimental|High Intensity Interval Training (HIIT)|Participants will do 3 sessions of high-intensity interval training over 7 days
89034362|NCT05085860|No Intervention|Rest|Participants will abstain from doing moderate- to high-intensity interval training over 7 days
89034363|NCT05084222|Experimental|Buventol® Easyhaler® 200 µg/inhalation dmDPI|400 μg of salbutamol from Buventol Easyhaler is administered as two inhalations.
89034364|NCT05084222|Experimental|Bufomix® Easyhaler® 160/4.5 µg/inhalation dmDPI|320 μg of budesonide and 9 μg of formoterol are administered from Bufomix Easyhaler as two inhalations.
89034365|NCT05084222|Active Comparator|Ventoline® Evohaler® 100 µg/inhalation pMDI|400 μg of salbutamol from Ventoline Evohaler is administered via Volumatic spacer as four inhalations.
89034366|NCT05082129|Experimental|Intervention|The intervention will consist of young patients with constipation presenting at secondary and tertiary care with intractable constipation. They will undergo the MRI gastrointestinal transit test (TransiCap). Their results will be shared with the patients after both MRI scans are preformed and results calculated. Their treatment selection will therefore be informed by the TransiCap results.
89034367|NCT05082129|Experimental|Control|The control arm will consist of young patients with constipation presenting at secondary and tertiary care with intractable constipation. They will undergo the MRI gastrointestinal transit test (TransiCap). The patients will undergo 2 MRI scans but their results will be shared with the patients after 12 months has elapsed. They will receive standard care treatment not informed by the TransiCap results.
89034368|NCT05080660|Experimental|LY3526318|Participants received 250 mg of LY3526318 orally, once daily for the first 4 weeks and were switched to placebo once daily for the next 4 weeks of the treatment period.
89034369|NCT05080660|Placebo Comparator|Placebo|Participants received placebo orally, once daily, for 8-weeks treatment period.
89611870|NCT04373980|No Intervention|Control group|
89611871|NCT01699178|Experimental|Oral testosterone undecanoate|Oral testosterone undecanoate; continue dose from previous Phase III trial; 100-300 mg T (as TU), BID, for 12 months.
89611872|NCT01699178|Active Comparator|Transdermal testosterone gel (AndroGel)|Transdermal testosterone gel; continue dose from previous Phase III trial, 2.5-10 g/applied once daily for 12 months
89611873|NCT02243332|Experimental|Device (rehabilitation assistance)|Device: KneeStim mobile rehabilitation assistance device
89611874|NCT03402646|Experimental|Reminder module (SMS and Phone call)|"Intervention will consist of a Reminder module delivered via SMS and telephone calls by an automated, customized software application. This will include standardized SMS reminder 3 days prior to scheduled immunization clinic appointments, telephone call reminders a day prior to scheduled clinic appointment (4 to 6pm) (in addition to standard care - routine paper-based appointment scheduling and counselling by care providers) for routine immunization. Reminders will be provided consistently for all immunization clinic appointments until the child turns 12 months of age."
89611875|NCT03402646|Experimental|Photovoice|In two small groups of 15 participants each per state, purposively selected pregnant women in their third trimester and parents of infants aged 0-12 months in the community, as well as community leaders, service providers and policy makers will be exposed to photographs (taken from other sources) of debilitating consequences of non-immunization, which will form the basis of the group discussions, knowledge sharing and consensus-building sessions, each lasting about 45 minutes to 1 hour. Each community cluster will be linked to a PHC.
89611876|NCT03402646|No Intervention|Control|Respondents in control clusters will receive standard care only - comprising routine paper-based appointment scheduling
89611877|NCT02077959|Experimental|Treatment (lenalidomide, pidilizumab)|Patients receive lenalidomide PO daily on days 1-21 and pidilizumab IV over 1-2 hours on day 3. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89611878|NCT01683409|Placebo Comparator|Placebo|Administered orally, given as three placebo tablets in the morning and one placebo tablet in the evening for 24 weeks.
89611879|NCT01683409|Experimental|Baricitinib 0.75 mg/0.5 mg QD|Administered orally, 0.75 mg given as one 0.75 mg tablets and two placebo tablets in the morning and one placebo tablet in the evening for 24 weeks or 0.5 mg given as one 0.5 mg tablet and two placebo tablets in the morning and one placebo tablet in the evening for 24 weeks. Placebo tablets given to maintain blind.
89611880|NCT01683409|Experimental|Baricitinib 0.75 mg/0.5 mg BID|Administered orally, 0.75 mg given as one 0.75 tablet and 2 placebo in the morning and one 0.75 mg tablet in the evening for 24 weeks or 0.5 mg given as one 0.5 mg tablet and two placebo tablets in the morning and one 0.5 mg tablet in the evening. Placebo tablets given to maintain blind.
89611881|NCT01683409|Experimental|Baricitinib 1.5 mg/1 mg|Administered orally, 1.5 mg given as two 0.75 mg tablets and 1 placebo tablet in the morning and one placebo tablet in the evening for 24 weeks or 1 mg tablet and two placebo tablets in the morning and one placebo tablet in the evening for 24 weeks. Placebo tablets given to maintain blind.
89611882|NCT01683409|Experimental|Baricitinib 4 mg/2.75 mg|Administered orally, 4 mg given as one tablet and 2 placebo tablets in the morning and one placebo tablet in the evening for 24 weeks or 2.75 mg given as two 1 mg tablets and one 0.75 mg tablet in the morning and one placebo tablet in the evening for 24 weeks. Placebo tablets given to maintain blind.
88983762|NCT00421057||Nonexercise Group|Follow usual routines of standard care but not taught to perform a specific regimen for strength-training and walking exercises; will keep record of any exercises done that are not a part of this study.
88815444|NCT04494932|Experimental|Biceps Tenodesis|
88815445|NCT04494932|Active Comparator|SLAP Repair (Control)|
88815446|NCT02453334|Experimental|Injectafer|2 doses of Injectafer at 15mg/kg for a maximum single dose of 750mg given 7 days apart for a total of up to 1500mg.
88815447|NCT02453334|Placebo Comparator|Normal Saline|Normal saline administered as an infusion of no more than 250mL infused over 15 minutes.
88815448|NCT04488692|Experimental|Model 1|Participants will receive 2 sessions of functional training per day, 15-min per session.
88815449|NCT04488692|Active Comparator|Model 2|Participants will receive 1 session of functional training and 1 session of sham intervention (therapist visiting and education) per day, 15-min per session.
88815450|NCT05593172||Mild traumatic brain injury|15 consecutive patients presenting at the emergency departement with mild traumatic brain injury
88815451|NCT05593172||Minor orthopedic injury|15 patients, recruited during the same time-frame as the mTBI-patients, presenting at the emergency departement with a minor orthopedic injury
88815452|NCT04481516||Yoga|Single arm only representing cohort of NHS health care workers with possible Covid-19 related stress and anxiety disorder. Participants act as their own controls pre and post regular practice of yoga technique.
88815453|NCT03015506|Active Comparator|White Bread|Portion of bread containing 50g available carbohydrate (defined as total carbohydrate minus dietary fiber).
88815454|NCT03015506|Experimental|Pea Bread|Portion of bread containing 50g available carbohydrate (defined as total carbohydrate minus dietary fiber) containing 18% (by weight) pea flour.
88815455|NCT03015506|Experimental|Green Lentil Bread|Portion of bread containing 50g available carbohydrate (defined as total carbohydrate minus dietary fiber) containing 18% (by weight) green lentil flour.
88815456|NCT03015506|Experimental|Red Lentil Bread|Portion of bread containing 50g available carbohydrate (defined as total carbohydrate minus dietary fiber) containing 18% (by weight) red lentil flour.
88815457|NCT03015506|Experimental|Chickpea Bread|Portion of bread containing 50g available carbohydrate (defined as total carbohydrate minus dietary fiber) containing 18% (by weight) chickpea flour.
88815458|NCT01051310|Experimental|CoreValve|
88815459|NCT03015584||Septic patients admitted to the ICU|
88815460|NCT05592860|Experimental|Mobile application|Mobile application to enter glucose level
88815461|NCT05592860|Placebo Comparator|Daily Diary|Daily Diary to record glucose level
88815462|NCT01051778|Experimental|enoxaparin 40 mg plus low dose aspirin|
88815463|NCT01051778|Active Comparator|Heparin calcium 5,000 U twice daily plus low dose aspirin|
88815464|NCT05592782|Experimental|Study Arm|
88815465|NCT01052948||Cohort 1|All persons who newly start one of the dopamine agonists (DA) after start of eligibility period
88815466|NCT01052948||Cohort 2|All persons who started levodopa after start of eligibility period and had not been treated with dopamine agonists anytime prior.
88815467|NCT01052948||Cohort 3|All persons with newly diagnosed hyperprolactinemia who had not been treated with dopamine agonists anytime prior.
88815468|NCT01052948||Cohort 4|healthy controls from general population matched on age, gender, index date and general practitioner (GP) practice to persons exposed to dopamine agonists
88815469|NCT03015662|Experimental|Dry Needling Therapy|Active or latent MTrPs (myofascial trigger points) will be remarked in black or red, respectively. Active or latent MTrPs will be needled in the same position employed by the blinded examiner for diagnosis. All dry needling procedures will be performed by the same investigator, and the technique used will be similar to the Hong method, using sterile Ener-Qi needles (EQ 1661) for the punction of TrPs (trigger points).
89611883|NCT04548518|Active Comparator|GPO Tri Fluvac vaccine|408 participants will receive a seasonal trivalent inactivated split virion influenza vaccine recommended for Southern Hemisphere in 2020 (consisting of A/Brisbane/02/2018 (H1N1)pdm-09-like virus, A/South Australia/34/2019 (H3N2)-like virus, and B/Washington/02/2019-like (B/Victoria lineage) virus) produced by the Government Pharmaceutical Organization (GPO), Thailand. The vaccine to be administered by intramuscular (IM) injection.
89611884|NCT04548518|Active Comparator|Licensed Influenza vaccine|408 will receive a Licensed Influenza vaccine (seasonal trivalent inactivated split virion influenza vaccine recommended for Southern Hemisphere in 2020 (consisting of A/Brisbane/02/2018 (H1N1) pdm-09-like virus, A/South Australia/34/2019 (H3N2)-like virus, and B/Washington/02/2019-like (B/Victoria lineage) virus) 0.5 mL administered intramuscularly (IM) in the deltoid muscle of the non-dominant arm.
89611885|NCT01674075||Healthy adult volunteers|Healthy adult volunteers will be administered a J-Tip to the dorsum of his/her hand.
89611886|NCT02243488|Experimental|12 month menstrual hygiene programme|This is the first group to receive the intervention. They will receive the intervention after baseline and be followed up for the following 12 months.
89611887|NCT02243488|Experimental|6 month menstrual hygiene programme|This is the second group to receive the intervention. They will act as a control group for the first 6 months then receive intervention at 6 months.
89611888|NCT01699022|Experimental|Injection Cyclofem|"Injection of Cyclofem contains 25 mg medroxyprogesterone acetate (MPA) and 5 mg estradiol cypionate as a microcrystalline suspension in 0.5ml aqueous solution and is supplied in vials.~Women were administered three consecutive monthly injections of Cyclofem for prevention of ovulation, and were followed until the 92nd day from the last (third) injection."
89611889|NCT01670175|Experimental|Sirolimus, Cyclophosphamide, Topotecan|Sirolimus, Cyclophosphamide, Topotecan Patients accrued to dose levels in cohorts of 3 (3+3 design). Patients will receive daily oral sirolimus and cyclophosphamide days 1-21 in 28-day cycle, combined with oral topotecan given on days 1-14. Sirolimus will be dosed based on steady-state plasma trough concentrations.
88983763|NCT00421096|Experimental|patient with cervix cancer|will receive gemcitabine + cisplatin + radiotherapy
88983764|NCT00421135|Experimental|Single Arm|ZIO-201
88983765|NCT00089063|Experimental|Arm I (vaccine therapy)|Patients receive vaccination comprising tyrosinase peptide, gp100 antigen, and MART-1 antigen emulsified with Montanide ISA-51 and ISA-51 VG SC on day 1 of weeks 0, 26, 52, 78, and 104 (total of 5 vaccinations).
88983766|NCT00089063|Experimental|Arm II (vaccine therapy, sargramostim)|Patients receive vaccination comprising tyrosinase peptide, gp100 antigen, and MART-1 antigen emulsified with Montanide ISA-51 and ISA-51 VG as in arm I. Patients also receive sargramostim (GM-CSF) SC on days 1-5 of weeks 0, 26, 52, 78, and 104.
88983767|NCT04716439||magnesium sulfate effect on IONM reading in spine surgery|one group receives magnesium other do not
88983768|NCT00089180|Experimental|Arm I (liposomal T4N5 lotion)|Patients apply T4N5 liposomal lotion topically to non-occluded, sun-exposed areas of the head, neck, face, and upper extremities once daily for 12 months.
88983769|NCT00089180|Placebo Comparator|Arm II (placebo)|Patients apply placebo topically to non-occluded, sun-exposed areas of the head, neck, face, and upper extremities once daily for 12 months.
88983770|NCT00127452|Experimental|EPA + DHA|Margarine spread that yields 400 mg of eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA) per day for average margarine use of 20 grams per day
88983771|NCT00127452|Experimental|ALA|Margarine spread that yields 2 grams of alpha-linolenic acid (ALA) per day for average margarine use of 20 grams per day
88983772|NCT00127452|Experimental|EPA + DHA plus ALA|Margarine spread that yields 400 mg of EPA + DHA per day plus 2 grams of ALA per day, for average margarine use of 20 grams per day
88983773|NCT00127452|Placebo Comparator|Placebo|Margarine spread that contains no EPA, DHA or ALA (exchanged for oleic acid)
89611890|NCT03402490|Experimental|Motivational interviewing|Over a time span of 6 months, participants in the intervention group received up to 7 sessions of motivational counseling, lasting 15-30 minutes each, to enhance physical activity.
88983774|NCT00089219|Experimental|Arm A. 6MHP vaccine 200 mcg|vaccine containing 6 melanoma helper peptides, at 200 mcg per peptide, with GM-CSF and IFA (Montanide ISA-51)
88983775|NCT00089219|Experimental|Arm B. 6MHP vaccine 400 mcg|vaccine containing 6 melanoma helper peptides, at 400 mcg per peptide, with GM-CSF and IFA (Montanide ISA-51)
88983776|NCT00089219|Experimental|Arm C. 6MHP vaccine 800 mcg|vaccine containing 6 melanoma helper peptides, at 800 mcg per peptide, with GM-CSF and IFA (Montanide ISA-51)
88983777|NCT00334321|Experimental|IMRT with chemotherapy|"IMRT (upper third of vagina & para-vaginal tissue and the common, external and internal iliac nodal regions) 160-180 cGy daily fractions for a total dose of 4500-5120 cGy. Once a day treatment four to five days a week for approximately 6 weeks.~Intracavitary vaginal brachytherapy - some patients will be given this and it will be decided by the treating physician.~Carboplatin - AUC 6, IV over 30-60 minutes following completion of paclitaxel, given once every 3 weeks (3 weeks=1 cycles) for a total of 6 cycles~Paclitaxel - 175 mg/m2, 3 hour continuous IV infusion, administered prior to carboplatin, given once every 3 weeks (3 weeks=1 cycles) for a total of 6 cycles"
88983778|NCT00334360|Experimental|1|dexmedetomidine
88983779|NCT00334360|Experimental|2|Buspirone
89210794|NCT04004949||study group (high scapular dyskinesia )|group A (30 patients): with high scapular dyskinesia scores
88983780|NCT00334360|Experimental|3|Buspirone and dexmedetomidine
88983781|NCT00334360|Placebo Comparator|Control|No drug
88983782|NCT00125502|Experimental|I|n=200; 20 micrograms gB with MF59
88983783|NCT00125502|Placebo Comparator|II|n=200; placebo (normal saline)
88983784|NCT00334438|Other|Zevalin + Velcade Single Arm Study|Zevalin (Ibritumomab Tiuxetan) and Velcade (Bortezomib)
88983785|NCT00342316|Experimental|Stem cell transplant (RICT)|Receiving intervention consisting of Reduced Intensity Conditioning Stem Cell Transplantation
88983786|NCT00342316|No Intervention|Control arm|Treatment according to standard of care, i.e. not undergoing RICT
89210795|NCT04004949||control group (low or no scapular dyskinesia )|group B (30 patients): with low or no scapular dyskinesia scores. (30 patients): with low or no scapular dyskinesia scores.
89210796|NCT00148759|Active Comparator|adult male subjects|LPV/r 800/200 mg once daily
89210797|NCT00148759|Experimental|Adult female subjects|LPV/r 800/200 mg once daily
89210798|NCT00925080||A|
89611891|NCT03402490|No Intervention|Usual care|Participants who served as controls received usual care.
89611892|NCT01674231|Active Comparator|Grape|Grapes in the form of a Freeze-dried Whole Grape Powder. 60g freeze-dried whole grape powder with 296mg polyphenols per day for 4 weeks.
88983787|NCT00127491|Experimental|EPVent|All patients will have an esophageal balloon placed for the purpose of obtaining transpulmonary pressure measurements. The intervention group will undergo transpulmonary pressure-directed controlled mechanical ventilation using parameters directed by the initial balloon measurements. Driving pressures will be adjusted to maintain a transpulmonary plateau pressure of less then 30. The PEEP setting will be set to achieve a transpulmonary end expiratory pressure of 0. Repeat PES measurements will be done at 24, 48 and 72 hours following the initial measurements. Additional measurements will be taken as clinically indicated. Ventilator management by PES measurements will continue for a period of 72 hours.
88983788|NCT00127491|Active Comparator|Control|All patients will have an esophageal balloon placed for the purpose of obtaining transpulmonary pressure measurements. The control group will be managed using the low tidal volume strategy laid out by the NIHBLI ARDSnet study. These recommendations include a set tidal volume of 6 ml/ kg. Respiratory rate and PEEP are set to maintain adequate ventilation and oxygenation. These settings will be continued for a period of 72 hours.
88983789|NCT04715269|Experimental|Alprazolam Arm|0.5mg Alprazolam will be given to the patient at the time of presentation
88983790|NCT04715269|Placebo Comparator|Placebo Arm|The empty capsule will be given to the patient at the time of presentation
88983791|NCT00423956|Sham Comparator|Sham Comparator|One side is experimental and the opposite side is Sham control.
88983792|NCT04716205|Experimental|Mulligan's bent leg raise Technique|Mulligan's bent leg raise Technique and Static Stretching
88983793|NCT04716205|Active Comparator|Static stretching|Static Stretching
88983794|NCT00342433||Localized Prostate Cancer cases|Cases enrolled between Jan 2000 and Apr 2004 at five locations. Study subject eligibility: Age >=18; scheduled for radical prostatectomy; and newly diagnosed with localized prostate cancer.
88983795|NCT00334555|Active Comparator|usual care|patient told to refer her partner for treatment
88983796|NCT00334555|Active Comparator|partner delivered|patient given medication to deliver to her partners
88983797|NCT00334555|Active Comparator|field intervention|field intervention to find partners
88983798|NCT00342472||1|Two of the oldest individuals (a male and a female greater than 18 years of age) from each of 10-15 nonsmoking households from the high-risk region of Linxian, China
88983799|NCT00334594|Active Comparator|No radiotherapy|
88983800|NCT00334594|Experimental|Radiotherapy|
88983801|NCT00334750||There is no intervention in this study|This study is collecting information on the presence of risk factors in new diagnosed OH and OAG patients in Canada.
88983802|NCT00089492|Experimental|1|
88983803|NCT00089492|Active Comparator|2|
88983804|NCT00334789|Experimental|Treatment (belinostat, isotretinoin)|"Patients receive belinostat IV over 30 minutes on days 1-5 and isotretinoin PO QD on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of belinostat until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity during the first course of therapy.~Once the MTD is determined, an expanded cohort of 10 patients are enrolled and treated at the MTD. These patients also undergo blood collection periodically during treatment for pharmacokinetic studies.~All patients undergo blood collection, buccal scrapings, and tumor biopsies periodically for biomarker, pharmacodynamic, gene expression, and laboratory studies."
88983805|NCT00334867|Active Comparator|Arm I|Patients receive vincristine sulfate IV over 1 minute once a week on day 1 in weeks 1-3, 7-9, and 13-15; doxorubicin hydrochloride IV over 15 minutes on days 1 and 2 in weeks 1, 7, and 13; cyclophosphamide IV over 1 hour on day 1 in weeks 1, 7, and 13; and ifosfamide IV over 1 hour and etoposide IV over 1 hour on days 1-5 in weeks 4, 10, and 16. Patients undergo local therapy comprising conventional surgery (surgical resection) in approximately week 18 and/or radiation therapy beginning in approximately week 19.
88983806|NCT00334867|Experimental|Arm II|Patients receive vincristine sulfate IV over 1 minute once a week on day 1 in weeks 1-3, 7-9, and 13-16; topotecan hydrochloride IV over 30 minutes on days 1-5 in weeks 1 and 13; cyclophosphamide IV over 30 minutes on days 1-5 in weeks 1 and 13 and IV over 1 hour on day 1 in weeks 7 and 16; ifosfamide IV over 1 hour and etoposide IV over 1 hour on days 1-5 in weeks 4 and 10; and doxorubicin hydrochloride IV over 15 minutes on days 1 and 2 in weeks 7 and 16. Patients also undergo local therapy comprising of conventional surgery (surgical resection) in approximately week 18 and/or radiation therapy beginning in approximately week 19. Patients then proceed to combination chemotherapy.
88983807|NCT04715152|Active Comparator|ACB group|Patients will receive ultrasound-guided (USG) ACB with levobupivacaine and dexamethasone 30 minutes before spinal anesthesia and sham intra-articular normal saline.
88983808|NCT04715152|Placebo Comparator|IA group|Patients will receive intra-articular levobupivacaine and dexamethasone at the end of surgery and sham USG-ACB with normal saline.
89611893|NCT01674231|Placebo Comparator|Sugar|Grape Powder Placebo. 60g control food (matched for calories, low in polyphenols, and indistinguishable from active intervention) per day for 4 weeks.
89611894|NCT02243566||Essential hypertension|
89611895|NCT01670253|No Intervention|Group 2|6 hours of total fast for all solid and liquid food / drinks
89611896|NCT01670253|Experimental|Group 1|"6 hour fast from all solid foods and milk beverages~2-hour thirst period before examination (patient may be in the period from 6 to 2 hours before the study drink any kind of clear liquids, ie liquids containing no milk products)~Approximately 2 hours before the time of examination please drink a glass (about 2 cups) clear sugary liquid - eg lemonade, apple juice, iced tea, soda or the like."
89611897|NCT04373590|Experimental|Decision aid (DA)|a one-page DA for use during the psychiatric consultation to help patients and clinicians discuss relevant treatment options pertaining to antipsychotics.
89611898|NCT04373590|No Intervention|Treatment as usual (TAU)|Treatment as usual without the DA
89611899|NCT01683019|Active Comparator|Active Fixed Alpha Frequency Magnetic Stimulation|Sinusoidal magnetic field set to the subject's intrinsic alpha frequency (IAF).
89611900|NCT01683019|Active Comparator|Active Random Frequency Magnetic Stimulation|Magnetic field hops to random frequencies in the alpha band (8-13Hz), once per second.
89611901|NCT01683019|Sham Comparator|Inactive Sham Treatment|Generate sound similar to active treatment, except that no magnetic field is generated.
89611902|NCT03861507|Other|Patient|Patient undergoing standard care prostate high dose rate brachytherapy.
88983809|NCT00089570|Experimental|Terlipressin|Terlipressin
88983810|NCT00089570|Placebo Comparator|Placebo|Placebo
88983811|NCT00334945||Growth Hormone|Patient ages 3-14 years receiving growth hormone for growth hormone deficiency or short stature
88983812|NCT00334945||Healthy Children|Children with normal stature ages 3-18 years.
88983813|NCT00342862||1. Amevive Exposure|Pregnant women with psoriasis exposed to AMEVIVE® at any point within 8 weeks prior to conception, or at any time during pregnancy, where the outcome of the pregnancy is unknown prospectively
88983814|NCT00335023|Active Comparator|Red blood cell transfusion|At least one unit of red blood cells will be administered.
88983815|NCT00335023|No Intervention|Control|No red blood cell transfusion. Iron suppletion is allowed and can be administered according to local protocol. If suppletion is prescribed, the type and duration will be registered
88983816|NCT00335179|Active Comparator|Imiquimod cream|Imiquimod 5% cream containing 12.5 mg of imiquimod per 250 mg of cream Applied 3 times per week for 4 weeks
88983817|NCT00335179|Placebo Comparator|Vehicle cream|Vehicle cream 250 mg Applied 3 times per week for 4 weeks
88983818|NCT00343135|Experimental|ARM 1|
88983819|NCT04726644||patients|cirrhotic patients with ventral hernia
88983820|NCT02958111|Experimental|Adjuvant capecitabine|Adjuvant chemotherapy with single-agent capecitabine
88983821|NCT02958111|No Intervention|Observation|Clinical follow-up and surveillance only
88983822|NCT00089804|Active Comparator|1|300 mg (three 2 mL vials of abetimus sodium plus six 2 mL vials of normal saline) administered i.v (in the vien) weekly
88983823|NCT00089804|Active Comparator|2|900 mg (nine 2 mL vials of abetimus sodium) administered i.v. (in the vein) weekly
88983824|NCT00089804|Placebo Comparator|3|A volume of 18 mL (Nine 2 mL vials) of identically appearing placebo (phosphate-buffered saline) administered i.v. (in the vien) weekly
88983825|NCT00127881|Experimental|Zanolimumab|
88983826|NCT00343681|Experimental|1|
89611903|NCT02243644|Active Comparator|Group A|7 days of albendazole 15 mg/kg/day
88983827|NCT00127920|Experimental|Single Arm|Paclitaxel, Carboplatin and Avastin on day1 every 21 days
88983828|NCT00343798|Experimental|Treatment (umbilical cord blood transplant)|"MYELOABLATIVE CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV over 1 hour on days -8 to -6 and cyclophosphamide IV on days -7 and -6. Patients undergo TBI BID on days -4 to -1.~TRANSPLANTATION : Patients undergo double-unit umbilical cord blood transplantation comprising unmanipulated umbilical cord blood unit IV over 20-30 minutes, and 4-6 hours later patients receive ex vivo-expanded umbilical cord blood cells IV over 30 minutes on day 0.~GRAFT-VERSUS-HOST-DISEASE PROPHYLAXIS: Patients receive cyclosporine IV every 8 or 12 hours on days -3 to 100, followed by a taper to at least day 180. Patients also receive MMF IV every 8 hours on days -3 to 5 and then PO, if tolerated, on days 6-30."
88983829|NCT00402636|Experimental|1|rapamycin plus 17beta estradiolvalerat-eluting stent
88983830|NCT00402636|Experimental|2|rapamycin-eluting stent
88983831|NCT00089921|Experimental|001|SCIO-469 30 mg capsule three times daily for 12 weeks
88983832|NCT00089921|Experimental|002|SCIO-469 60 mg capsule three times daily for 12 weeks
88983833|NCT00089921|Experimental|003|SCIO-469 100 mg tablet once daily for 12 weeks
88983834|NCT00089921|Placebo Comparator|004|Placebo 2 capsules three times daily and one tablet daily
88983835|NCT00402675|Active Comparator|Immediate Intervention|Patients with NSTEMI undergo immediate invasive angiography (< 2 hours)
88983836|NCT00402675|Active Comparator|Early Intervention|Patients with NSTEMI undergo early invasive angiography (12-48 hours)
89611904|NCT02243644|Active Comparator|Group B|28 days of albendazole 15 mg/kg/day
89611905|NCT04373356|Experimental|Resin Infiltration|The interproximal surface with initial dental caries that are selected for this group will be treated using the resin infiltration ICON (DMG, Germany) and 5% Sodium Fluoride Varnish
89611906|NCT04373356|Active Comparator|Sodium Fluoride Varnish|The interproximal surface with initial dental caries that are selected for this group will be treated using topical application of 5% Sodium Fluoride Varnish.
89611907|NCT03402412|Experimental|Study Arm|Narrow-band UVB will be given to a small part of the patients skin with eczema. The rest of the skin surface serves as control.
89611908|NCT01745757||Cohort|first line treatment for metastatic breast cancer
89611909|NCT02243722||Larynx pharynx and Esophagus Ca with VCP|The cases of laryngopharyngeal and esophageal cancer with endoscopic characters of vocal fold motion impairment (paralysis or fixation)
88983837|NCT00402675|Active Comparator|Selective invasive angiography|Patients with NSTEMI undergo selective invasive angiography
88983838|NCT00344149|Experimental|Rituximab|I.V infusion of Rituximab 375 mg/m2 per week for 4 weeks
88983839|NCT00344149|Placebo Comparator|Placebo|I.V infusion of NaCl 0.9%
88983840|NCT00089960|Other|Arm|AMG 125 mg daily continuously
88983841|NCT00402753|Experimental|Group 1|Physical exercise group: Combined supervised physical activity: Endurance and Resistive strength
88983842|NCT00402753|No Intervention|Group 2|Usual care control group
88983843|NCT00335218|Experimental|Arm 1|
88983844|NCT00335218|Placebo Comparator|Arm 2|
88983845|NCT00090038|Experimental|1|Rituximab
88983846|NCT00090038|No Intervention|2|No drug
88983847|NCT00402792|Experimental|Arm 1: hydrocodone / acetaminophen extended release|
88983848|NCT00402792|Experimental|Arm 2: hydrocodone / acetaminophen extended release|
88983849|NCT00402792|Placebo Comparator|Arm 3: Placebo|
89034370|NCT05080322|Experimental|on-demand intranasal corticosteroid (INS) plus antihistamines (AH1)|the patients will be treated with on-demand intra-nasal corticosteroid (INS) plus antihistamines (AH1) for 4 weeks
89611910|NCT03402178|Experimental|E2082|E2082 will be administered as a solution (0.2 milligram [mg]), a 0.5 mg tablet, and a 5 mg tablet. Part A: Cohort 1 participants will receive a single dose of a 0.2 mg E2082 solution, and participants in Cohorts 2 to 4, respectively, will receive a single dose of 0.5 mg, 1 mg, or 2.5 mg E2082 tablets under fasted conditions. Cohort 5 participants will receive a single dose of 5 mg E2082 under fasted conditions, and then they will receive 5 mg E2082 under fed conditions after washout. Participants in Cohorts 6 to 10, respectively, will receive 10 mg (adult participants), 15 mg, 25 mg, 40 mg, or 10 mg (elderly participants) E2082 tablets under fasted conditions. Part B: Participants in Cohorts 1 to 4, respectively, will receive 2.5 mg, 5 mg, 10, or 15 mg tablets once daily for 10 days. E2082 will be administered under fasted conditions on Day 1 and Day 10 and under fed conditions during Day 2 to Day 9.
89611911|NCT03402178|Placebo Comparator|E2082-matched placebo|Matched placebo will be administered as a solution (0.2 mg), a 0.5 mg tablet, and a 5 mg tablet. Part A: Cohort 1 participants will receive a single dose of a 0.2 mg matched placebo solution, and participants in Cohorts 2 to 4, respectively, will receive a single dose of 0.5 mg, 1 mg, or 2.5 mg matched placebo tablets under fasted conditions. Cohort 5 participants will receive a single dose of 5 mg matched placebo under fasted conditions, and then they will receive 5 mg matched placebo under fed conditions after washout. Participants in Cohorts 6 to 10, respectively, will receive 10 mg (adult participants), 15 mg, 25 mg, 40 mg, or 10 mg (elderly participants) matched placebo tablets under fasted conditions. Part B: Participants in Cohorts 1 to 4, respectively, will receive 2.5 mg, 5 mg, 10, or 15 mg matched placebo tablets once daily for 10 days. Matched placebo will be administered under fasted conditions on Day 1 and Day 10 and under fed conditions during Day 2 to Day 9.
89611912|NCT01709162|Experimental|Ipilimumab, 3 mg/kg|Participants received ipilimumab, 3 mg/kg, by intravenous infusion, every 3 weeks for a total of 4 doses or until disease progression, unacceptable toxicity, or withdrawal of consent
89611913|NCT01709162|Active Comparator|Chemotherapy|Participants received the investigator's choice of chemotherapy, administered per package instructions.
89611914|NCT04764201|Other|Sequence 1|Period 1: HGP2001, Period 2: HIP2001
89611915|NCT04764201|Other|Sequence 2|Period 1: HIP2001, Period 2: HGP2001
89611916|NCT02243800|Experimental|cholecalciferol|One group will receive the study treatment: cholecalciferol One group will receive placebo
88983850|NCT00335335|Experimental|Visipaque Injection|All participants will receive intravenous (IV) administration of 80 mL Visipaque (iodixanol) 320 mg-I/mL at a rate of 4-5 mL per second via power injector followed by a saline injection of 40-50 mL 0.9% sodium chloride solution at a rate of 4-5 mL per second.
88983851|NCT00335374|Experimental|1|
88983852|NCT00344539|Experimental|B|80 mcg AMA1-C1/Alhydrogel® with 368 mcg Aluminum and 500 mg CPG 7909.
88983853|NCT00344539|Experimental|C|80 mcg AMA1-C1/Alhydrogel® with 368 mcg Aluminum alone.
88983854|NCT00344539|Experimental|A|20 mcg AMA1-C1/Alhydrogel® with 377 mcg Aluminum and 500 mg CPG 7909.
88983855|NCT04715503|Experimental|PET-IA|68Ga-DOTANOC 18F-FDG
88983856|NCT00420589|Placebo Comparator|1|Arm 1: MK0364 Pbo capsules once daily
88983857|NCT00420589|Experimental|2|Arm 2: MK0364 0.5 mg capsule once daily
88983858|NCT00420589|Experimental|3|Arm 3: MK0364 1 mg capsule once daily
88983859|NCT00420589|Experimental|4|Arm 4: MK0364 2 mg capsule once daily
88983860|NCT00344656||Subjects and Controls|Patients with DSM-IV Anorexia Nervosa
88983861|NCT00128076|Active Comparator|1|All-arthroscopic repair
88983862|NCT00128076|Active Comparator|2|Mini-open repair
88983863|NCT00420823|Placebo Comparator|Placebo pill|4 placebo pills daily for 3 months
88983864|NCT00420823|Experimental|Taurine 4g|Taurine 4g daily comprising four 1g pills
88983865|NCT00344890|Experimental|Preservon|
88983866|NCT00344890|Active Comparator|Control|
88983867|NCT00090194|Experimental|Low Dose|0.5 gm/kg at 5 days pre-transplant and 7 days post-transplant
88983868|NCT00090194|Experimental|Middle Dose|1.0 gm/kg at 5 days pre-transplant and 7 days post-transplant
88983869|NCT00090194|Experimental|High Dose|2.0 gm/kg at 5 days pre-transplant and 7 days post-transplant
88983870|NCT00345163|Experimental|1|
88983871|NCT00345163|Experimental|2|
88983872|NCT00335686|No Intervention|1|Lopinavir-rtv (Kaletra): 3 capsules (600 mg)/12 h
88983873|NCT00335686|No Intervention|2|Nevirapine (Viramune): 1 comp (200mg)/12h
88983874|NCT00345319|Active Comparator|Group 1|
88983875|NCT00345319|Active Comparator|Group 2|
88983876|NCT00345475||AED treatment|Women being treated with UCB AEDs while pregnant.
88983877|NCT00345514|No Intervention|1|
88983878|NCT00345514|Active Comparator|2|
88983879|NCT00345514|Active Comparator|3|
88983880|NCT04708249|Experimental|D-chiroinositol treatment|
88983881|NCT00345670|Experimental|1|MEDI-534
88983882|NCT00345670|Experimental|2|MEDI-534
88983883|NCT00345670|Experimental|3|MEDI-534
88983884|NCT00345709||National Research Registry Enrollment|Patient, living or deceased, with a pathologically-confirmed diagnosis of Ovarian Cancer.
88983885|NCT00345787|Placebo Comparator|0|
88983886|NCT00345787|Experimental|1|
88983887|NCT02959762|Placebo Comparator|Placebo-Control|The placebo-control group will take two placebo softgel capsules every day for 8 weeks.
88983888|NCT02959762|Active Comparator|Low-Dose Vitamin K2 (45-mcg/d)|The low-dose vitamin K2 group will take one 45-mcg vitamin K2 softgel capsule and one placebo softgel capsule every day for 8 weeks.
88983889|NCT02959762|Active Comparator|High-Dose Vitamin K2 (90-mcg/d)|The high-dose vitamin K2 group will take two 45-mcg vitamin K2 softgel capsules every day for 8 weeks.
88983890|NCT00345826|Experimental|Dasatinib|
88983891|NCT00345982|Experimental|A|Sertindole 16 mg
88983892|NCT00345982|Placebo Comparator|B|Placebo
88983893|NCT00346021|Experimental|Sun Protection Intervention|School based sun protection education, provision of free hats.
88983894|NCT00346021|No Intervention|Control arm|Usual sun protection practices
88983895|NCT00421213|Experimental|Single Arm|
88983896|NCT00125736|Experimental|E0671 combination group|
88983897|NCT00125736|Placebo Comparator|placebo combination group|
89034371|NCT05080322|Experimental|on-demand intranasal corticosteroid (INS)|the patients will be treated with on-demand intra-nasal corticosteroid (INS) for 4 weeks
89611917|NCT02243800|Placebo Comparator|placebo|One group will receive the study treatment: cholecalciferol One group will receive placebo
88983898|NCT00090428|Experimental|1|Participants will follow a gluten-free and casein-free diet for 18 weeks. The compliance with the diet was monitored with 24 hour dietary recall and nutritional sufficiency with diet diary analysis.
88983899|NCT00090428|Active Comparator|2|After established on a gluten free and casein free diet for at least 6 weeks, participants received double blind, placebo controlled challenges containing gluten, casein, gluten+casein, or placebo in a random order. Data was collected on behavioral and physiologic responses relative to the challenges. Children remained on the gluten free and casein free diet throughout this period.
88983900|NCT00346177|Active Comparator|1|Stem Cells
88983901|NCT00346177|Placebo Comparator|2|Placebo
88983902|NCT00346294|Other|Single-Arm|Open-lable Single Arm Study
88983903|NCT00125775|Active Comparator|1|Engerix-B 40 mcg dose
88983904|NCT00125775|Active Comparator|2|Engerix-B 80 mcg dose
88983905|NCT00346528|Experimental|NGOIS|
88983906|NCT00346528|Active Comparator|BSS Plus|
88983907|NCT00346567|Active Comparator|1|AZT from week 28 or asap thereafter. Intrapartum AZT and 3TC + Single dose NVP Postpartum Combivir tail for 7 days twice daily
88983908|NCT00346567|Experimental|2|AZT from week 28 or asap thereafter. Intrapartum Single dose Truvada + Single dose NVP
88983909|NCT02957994|Experimental|TAF Arm|Tenofovir alafenamide fumarate 25mg, 1 tablet once daily for 24 weeks
88983910|NCT04714801|Active Comparator|Infusion of 100 million ASC|Infusion of 100 million adipose derived mesenchymal stromal cells from healthy donors
88983911|NCT04714801|Active Comparator|Infusion of 200 million ASC|Infusion of 200 million adipose derived mesenchymal stromal cells from healthy donors
88983912|NCT04714801|Placebo Comparator|Infusion of placebo|Infusion of saline
88983913|NCT00346762||1|HIV infected former commercial blood donors (FBDs) in Fuyang, Anhui Province
88983914|NCT00346801|Experimental|CPT-11 + Celecoxib/Cisplatin with RT|CPT-11 + Celecoxib + Cisplatin + Radiation Therapy (RT)
88983915|NCT00346840|Experimental|MVI 25|Misoprostol vaginal insert 25 mcg
88983916|NCT00346840|Experimental|MVI 50|Misoprostol vaginal insert 50 mcg
88983917|NCT00346840|Experimental|MVI 100|Misoprostol vaginal insert 100 mcg
88983918|NCT00346840|Experimental|MVI 200|Misoprostol vaginal insert 200 mcg
88983919|NCT00346918|Active Comparator|1|Treatment of hypertension, cyst infections and flank pain
88983920|NCT00346918|Active Comparator|2|Sirolimus plus Standard Treatment
88983921|NCT00346957|Experimental|Anecortave Acetate 30|
88983922|NCT00346957|Experimental|Anecortave Acetate 15|
88983923|NCT00346957|Experimental|Anecortave Acetate 3|
88983924|NCT00346957|Placebo Comparator|Anecortave Acetate Vehicle|
88983925|NCT00090740||Asthmatics|People who have asthma
89611918|NCT04764123||AVNRT Cohort|"Patients admitted for electrophysiological study and ablation due to AVNRT tachycardia.~During the study and before the ablation high density electroanatomical mapping will be performed."
88983926|NCT00090740||Controls|People who do not have asthma
88983927|NCT00346996|Active Comparator|1|HUman Insulin
88983928|NCT00346996|Experimental|2|Analogue insulin
88983929|NCT00402519|Experimental|APBI|Accelerated Partial Breast Irradiation with multicatheter brachytherapy
88983930|NCT00402519|Active Comparator|EBRT|Standard External Beam Whole Breast Irradiation
88983931|NCT00347152|Active Comparator|2|Slow Progressive Divalproex DR to Divalproex ER switch
88983932|NCT00347152|Active Comparator|1|Immediate, Progressive Divalproex DR to Divalproex ER switch
88983933|NCT00090896|Experimental|CTLA4-Blocking Monoclonal Antibody|
88983934|NCT00402558|Experimental|Thymoglobulin + Busulfan + Fludarabine|"Thymoglobulin 1.5 mg/kg by vein for 3 days. Busulfan 130 mg/m^2 by vein for 4 days. Fludarabine 40 mg/m^2 by vein for 4 days. Alloreactive NK infusion from haploidentical donor on Day -8. Alloreactive NK cell infusion given at one of 4 dose levels 10e6, 5 x 10e6, 3 x 10e7 cells/kg and 3 x10e7 NK Cells plus systemic interleukin-2 treatment. The 4th dose level is 3 x 107 NK cells/kg plus systemic interleukin-2 at a dose of 0.5 million units per day subcutaneously starting on Day -8 (day of the NK cell infusion) to Day -4.~G-CSF 5 mcg/kg/day subcutaneously beginning on Day +7, and continuing until absolute neutrophil count is > 500 x 109/L for 3 consecutive days. Tacrolimus starting dose of 0.015 mg/kg daily adjusted to achieve a therapeutic level of 5-15 ng/ml. Tacrolimus changed to oral dosing when tolerated and can be tapered off after Day +90 if no GVHD is present. Methotrexate 5 mg/m2 by vein on Days 1, 3 and 6 and Day +11 post transplant."
88983935|NCT00347386|Experimental|Zinc|Administration of zinc sulphate every day during illness
88983936|NCT00347386|Placebo Comparator|Placebo|Placebo tablet
88983937|NCT00347425|Other|A|
88983938|NCT00347425|Other|B|
88983939|NCT00126048|Active Comparator|1|Oral atorvastatin 40mg
88983940|NCT00126048|Placebo Comparator|2|Placebo
88983941|NCT00421252|Active Comparator|Clopidogrel 600 mg pre-treatment|Patients will receive 600 mg Clopidogrel load >2 hours pre-angiography with possibility for ad hoc PCI based on angiographic results
88983942|NCT00421252|Active Comparator|No clopidogrel 600 mg pretreatment|Patients will receive 600 mg Clopidogrel load after PCI, if performed
88983943|NCT00421252|Active Comparator|5Fr arterial access sheath|Patients will have angiography performed using 5Fr sheath. If PCI required, sheath will be upsized.
88983944|NCT00421252|Active Comparator|6Fr arterial access sheath|Patients will have angiography performed using 6Fr sheath
88983945|NCT00091091||All patients|Self report/Medical record review/ clinical eval
88983946|NCT00421330|Active Comparator|OR|Open Aneurysm Repair
88983947|NCT00421330|Experimental|EVAR|Endovascular Aneurysm Repair
88983948|NCT00426322|Active Comparator|1|small particles
88983949|NCT00426322|Active Comparator|2|large particles
88983950|NCT04705402|Experimental|Patients randomized to receive the treatment arm of mannitol.|The mannitol solution used in the hospital contain 18% mannitol in 500ml solution. An equivocal volume of 2.8 cc / kg body weight, which will be given intravenously with the use of an Ivac pump, infused for a duration of 15 minutes through an existing peripheral intravenous access catheter within 15-30 minutes prior to renal artery reperfusion
88983951|NCT04705402|Placebo Comparator|(Control arm) Study participants will receive a 0.9% saline solution|(Control arm) Study participants randomized to this arm will receive a 0.9% saline solution at a dose of 2.8 cc / kg, infused within 15-30 minutes prior to renal artery reperfusion through an existing intravenous access catheter (either through an central or peripheral intravenous infusion).
88983952|NCT00091130|Experimental|Arm I (SGN-00101)|Patients receive SGN-00101 vaccine SC on day 1 of weeks 1, 4, and 8 for a maximum of 3 injections in the absence of unacceptable toxicity or the development of an invasive malignancy or serious illness.
88983953|NCT00091130|Placebo Comparator|Arm II (placebo)|Patients receive placebo vaccine SC on day 1 of weeks 1, 4, and 8 for a maximum of 3 injections in the absence of unacceptable toxicity or the development of an invasive malignancy or serious illness.
88983954|NCT00426439|Experimental|1 Coartem|Treatment of documented malaria in children following the dosages recommended by the manufacturer.
88983955|NCT00426439|Active Comparator|2 Chloroquine|The antimalarial actually used in Guinea-Bissau is the dosage of 50 mg/kg given twice a day for 3 days.
88983956|NCT04705519|Experimental|Nab-paclitaxel Combined With Bevacizumab|Nab-paclitaxel, Bevacizumab
88983957|NCT04705714|Experimental|Frankincense Extract|the anti-bacterial and antibiofilm activity of frankincense extract against Porphyromonas gingivalis clinical isolates were studied
88983958|NCT04705285|Experimental|Erbium:Yag Laser|Patients allocated to the erbium:yag laser are going to undergo 2 sessions of vaginal laser, separated by one month each other.
88983959|NCT04705285|Active Comparator|Pelvic floor training|Patients allocated to pelvic floor training, are goin to undergo 10 sessions of pelvic floor exercises coached by an expert physiotherapist.
88983960|NCT04705129|Experimental|zanubrutinib+Tislelizumab|Zanubrutinib 160mg Bid, D1-21, po；Tislelizumab 200mg, D1, ivgtt
88983961|NCT00426712|Experimental|1|Low dose
88983962|NCT00426712|Experimental|2|Middle dose
88983963|NCT00426712|Experimental|3|High dose
88983964|NCT00426712|Active Comparator|4|
88983965|NCT00091247|Experimental|tetracycline|"Patients receive oral tetracycline twice daily. Treatment continues for 4 weeks in the absence of unacceptable toxicity.~Quality of life is assessed at baseline and then weekly for 8 weeks.~Patients are followed at weeks 4 and 8."
89611919|NCT03402100|Experimental|0.01% atropine|children who received 0.01% atropine for myopia
89611920|NCT03402100|Experimental|0.005% atropine|children who received 0.005% atropine for myopia
89611921|NCT03402100|Experimental|0.25% Ketorolac|children who received 0.25% Ketorolac for myopia
89611922|NCT03402100|Experimental|0.01% atropine plus 0.25% Ketorolac|children who received 0.01% atropine plus 0.25% Ketorolac for myopia
89611923|NCT03402100|Experimental|0.005% atropine plus 0.25% Ketorolac|children who received 0.005% atropine plus 0.25% Ketorolac for myopia
88983966|NCT00091247|Placebo Comparator|placebo|"Patients receive oral placebo twice daily. Treatment continues for 4 weeks in the absence of unacceptable toxicity.~Quality of life is assessed at baseline and then weekly for 8 weeks.~Patients are followed at weeks 4 and 8."
88983967|NCT01058863|Experimental|Albuterol Spiromax® 90 mcg|A single dose of albuterol 90 mcg delivered with Spiromax®, an inhalation-driven, multi-dose dry powder inhaler. Placebo inhalers used to maintain the blind.
88983968|NCT01058863|Experimental|Albuterol Spiromax® 180 mcg|A single dose of albuterol 180 mcg delivered with Spiromax®, an inhalation-driven, multi-dose dry powder inhaler (2 inhalations). Placebo inhalers used to maintain the blind.
88983969|NCT01058863|Active Comparator|ProAir® HFA 90 mcg|A single dose of albuterol 90 mcg delivered with ProAir®, a 'press-and-breathe', metered-dose, aerosol inhaler. Placebo inhalers used to maintain the blind.
88983970|NCT01058863|Active Comparator|ProAir® HFA 180 mcg|A single dose of albuterol 180 mcg delivered with ProAir®, a 'press-and-breathe', metered-dose, aerosol inhaler (2 inhalations). Placebo inhalers used to maintain the blind.
88983971|NCT01058863|Placebo Comparator|Placebo Inhaler|Placebo delivered with Spiromax®, an inhalation-driven, multi-dose dry powder inhaler, and with ProAir®, a 'press-and-breathe', metered-dose, aerosol inhaler. Placebo inhalers used to maintain the blind.
88983972|NCT00091286|Experimental|Peptide Vaccine + Montanide + GM-CSF|Colon peptide mixture (100 mcg each of the 4 peptides) plus 190 mcg of tetanus toxoid peptide, plus GM-CSF (110 mcg) in Montanide ISA-51 adjuvant
88983973|NCT01058395|Experimental|800 mg loading then 200 mg Q12|Minocycline 800 mg. loading followed by 200 mg. Q 12 hours.
88983974|NCT01058395|Experimental|800 mg loading then 400 mg Q12|Minocycline 800 mg. loading followed by 400 mg. Q 12 hours.
88983975|NCT01058356||IBD research group in KASID|KASID is Korean Association Study of Intestinal Disease. It has several research group suh as inflammatory bowel disease (IBD) research group.
88983976|NCT00126516|Active Comparator|1|Angiotensin II Receptor Antagonists group
88983977|NCT00126516|Active Comparator|2|Angiotensin-converting Enzyme Inhibitors group
88983978|NCT02965040|Experimental|Roxadustat: subjects with normal renal function|Normal renal function: eGFR is equal to or greater than 90 mL/min/1.73 m^2. Single dose of roxadustat
88983979|NCT02965040|Experimental|Roxadustat: subjects with severely impaired renal function|Severely impaired renal function: eGFR is less than 30 mL/min/1.73 m^2. Single dose of roxadustat
88983980|NCT02965040|Experimental|Roxadustat: subjects with ESRD on CAPD or APD|ESRD subjects on CAPD or APD need to be on the same mode of dialysis for at least 4 months. Single dose of roxadustat
88983981|NCT02965040|Experimental|Roxadustat: subjects with ESRD on HD or HDF|ESRD subjects on HD or HDF need to be on the same mode of dialysis for at least 4 months and should have dialysis sessions three times weekly. Single dose of roxadustat, in both treatment periods
89210799|NCT00717275|Experimental|Temozolomide|
89210800|NCT00822068|Experimental|anodal tDCS|
89611924|NCT01674309|Other|single arm study/ non randomized trial|FOLFORINOX
89611925|NCT02243956|Experimental|Flavanol rich food product|A portion of a common flavanol rich food product is consumed daily for 4 weeks
89611926|NCT02243956|Placebo Comparator|Non-flavanol food product|A portion of a product similar to the experimental Product, but instead contains low amounts of flavanol, is consumed Daily for 4 weeks as a control.
89611927|NCT04764045|Active Comparator|Ropivacaine injection in trigger points|Ropivacaine injection 1 ml in all trigger points in and around scar after operation in knee, shoulder and foot, one time, duration 3 minutes
88983982|NCT04710888|Experimental|basil extract mucoadhesive gel|10 patients treated with mucoadhesive gel containing 2% of basil extract 4 times per day (test group) for 20 min after every meal and before going to bed.
88983983|NCT04710888|Placebo Comparator|mucoadhesive placebo gel|10 patients treated by mucoadhesive gel without drug which was used as placebo (contains tragacanth gum, alcohol, sodium benzoate, and distilled water) 4 times per day
88983984|NCT04710888|Sham Comparator|healthy patients|10 healthy patients will be selected to participate in the study to test the salivary level of endocan in the healthy individuals (negative control group)
88983985|NCT01058005|Experimental|Natalizumab|
88983986|NCT01058005|Active Comparator|Interferon Beta-1a|
88983987|NCT01058005|Active Comparator|Glatiramer Acetate|
88983988|NCT03952728||ILI/ Treatment group|This group includes Look AHEAD participants who were initially assigned to the intensive lifestyle intervention, consented to administrative data linkages, and were successfully linked to Medicare databases.
88983989|NCT03952728||Control group|This group includes Look AHEAD participants who were initially assigned to the diabetes support and education control arm, consented to administrative data linkages, and were successfully linked to Medicare databases.
88983990|NCT00426829|Experimental|Proton Therapy + Bevacizumab|Proton Therapy + Bevacizumab
88983991|NCT00426868|Experimental|Treatment|
88983992|NCT00426868|Placebo Comparator|Placebo|
88983993|NCT00426907|Experimental|1|Full postoperative weightbearing
88983994|NCT00426907|Active Comparator|2|Partial weightbearing 6 weeks postoperative
88983995|NCT05562336||Patients with age related macular degeneration with CNV|
88983996|NCT05562336||Patients with pathological myopia with CNV|
88983997|NCT05562219|Experimental|Treatment group(QA108 granules)|QA108 granules, 7.5 g/bag,2 bags/time, BID
88983998|NCT05562219|Placebo Comparator|Placebo group(QA108 granule simulants)|QA108 granule simulants, 7.5 g/bag,2 bags/time, BID
88983999|NCT00427375|Experimental|1|New surgical option in good responders after neoadjuvant treatment for low rectal cancer
88984000|NCT00427375|Active Comparator|2|Standard surgery
88984001|NCT00427414|Experimental|liposomal daunorubicin citrate|40 mg/m2 Days 1 and 15 every 28 days x 3 cycles
88984002|NCT01056640|Experimental|Home Telemonitoring|The Intel Health Guide is an FDA approved device that is placed within the patient's home and is connected to the health system via broadband internet, 3G network or phone line. This device has video monitoring which allows a real time face to face interaction with the provider. This allows for an individualized home care plan based upon multiple concerns which have not been adequately studied.
88984003|NCT01056640|Active Comparator|Usual Care|The usual care intervention will include appropriate primary care and specialty office practice visits as required. It also includes home health care, timely post-hospital outpatient visits, a nurse generated phone call progress report within one business day of hospital dismissal, and standard clinic phone triage during business hours. It also involves a 24 hour nurse triage line for questions. Patients will be informed of the general options currently available to patients including the above as well as options for care in extended hours and at Mayo Express care.
88984004|NCT00091676|Experimental|ID-KLH + GM-CSF|
88984005|NCT00091676|Active Comparator|KLH + GM-CSF|
89611928|NCT04764045|Placebo Comparator|Placebo injection in trigger points|Saline injection 1 ml in all trigger points in and around scar after operation in knee, shoulder and foot, one time, duration 3 minutes
88984006|NCT04704778|Active Comparator|Transcutaneous|Transcutaneous electrostimulation and uso of oclusal splint
88984007|NCT04704778|Active Comparator|Percutaneous|Percutaneous electrostimulation and splint
89611929|NCT01698554|Experimental|bimatoprost formulation A solution|Bimatoprost formulation A solution single-dose vial applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
88984008|NCT04704778|Placebo Comparator|Control|Oclusal splint
88984009|NCT04705090|Experimental|YY-20394 treatment|YY-20394 tablets, 20mg spec, 80mg QD, 28 days for each cycle.
88984010|NCT00091715|Experimental|1|62.5 mg table twice a day for 4 weeks followed by 125 mg tablet twice a day for 6 months followed by an open label period until end of study.
88984011|NCT00091715|Placebo Comparator|2|placebo for 6 months followed by an open label period
88984012|NCT05561946||Hospitalized Infants|Hospitalized infants that are planned/scheduled to remain in-house for at least 2 days will wear the sock for a minimum of 48 hours and a maximum of 14 days.
88984013|NCT05561946||Healthy Infants|Healthy infants, accompanied by their parent or legal guardian, that are able to stay at a clinical site for 2 days to complete a minimum of 48 hours of monitoring.
88984014|NCT00427492|Active Comparator|Magnesia|Medical laxative
88984015|NCT00427492|Placebo Comparator|Placebo|Placebo
88984016|NCT00427609|Placebo Comparator|1|
88984017|NCT00427609|Active Comparator|2|
88984018|NCT04704895|Active Comparator|Arm A: Total parenteral nutrition|Total parenteral nutrition, TPN also starts from POD 1 and is delivered through a central venous catheter, with a target energy of 1.5 amino acids/kg/day reaching 30 kcal/kg/day
88984019|NCT04704895|Experimental|Arm B: Enteral nutrition|NJEEN was defined as providing at least 50% of the nutritional requirements through the nasojejunal tube prior to the 5th day after surgery (POD) and having no parenteral nutrition for 72 hours or more.
88984020|NCT00427843|Experimental|Exercise Home-Based Program|Patients with knee OA will be taught a home-based exercise program for the hip abductor muscles during the initial visit. The exercise program will be performed 3 times per week for 8 weeks.
88984021|NCT00428038||1|"Group 1:~Infants born prematurely at a gestational age < 32 weeks with a diagnosis of chronic lung disease. Subjects will be evaluated at a corrected-age between 1 month and 24 months when they are clinically stable and free of acute respiratory symptoms for > 3 weeks. Subjects will be excluded for the following reasons:~Oxygen requirements~Congenital heart disease"
88984022|NCT00428038||2|"Group 2:~Infants born prematurely at a gestational age < 32 weeks without a diagnosis of chronic lung disease. Subjects will be evaluated at a corrected-age between 1 month and 24 months when they are clinically stable and free of acute respiratory symptoms for > 3 weeks. Subjects will be excluded for the following reasons:~Oxygen requirements~Congenital heart disease"
89210801|NCT00822068|Active Comparator|2|cathodal tDCS
89611930|NCT01698554|Active Comparator|bimatoprost solution 0.03 %|Bimatoprost solution 0.03 % (LATISSE®) multi-dose vial applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
89611931|NCT01698554|Placebo Comparator|vehicle of bimatoprost formulation A solution|Vehicle of bimatoprost formulation A solution single-dose vial applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
89034372|NCT05080322|Active Comparator|maintenance intranasal corticosteroid (INS)|the patients will be treated with intra-nasal corticosteroid(INS) maintenance therapy for 4 weeks
89034373|NCT05079269|Experimental|Intervention|The investigators will start a balanced crystalloid solution (in detail we will administer 500ml if the actual body weight is ≤80 kg: the investigators will administer 1000 ml if the actual body weight is >80 kg:) within 20 to 40 minutes before induction of anesthesia in the pre-operative area or at the ward, as appropriate.
89034374|NCT05079269|No Intervention|Control|Patients will receive the balanced crystalloid solution according to the current clinical standard of care.
89034375|NCT05065190|Experimental|nintedanib|
89034376|NCT05065190|Placebo Comparator|Placebo|
89611932|NCT01698554|Placebo Comparator|vehicle of bimatoprost solution 0.03 %|Vehicle of bimatoprost solution 0.03 % multi-dose vial applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
89611933|NCT03401944|Active Comparator|Total Parenteral Nutrition (TPN)|Overnight infusion of Parenteral Nutrition supplied in all-in one bag -format. Infusion-rate of 0.16 gram Nitrogen/kg/day.
89611934|NCT03401944|Placebo Comparator|Control (saline infusion)|Overnight infusion of physiological saline at the same infusion-rate; ml/kg as intervention (TPN).
89611935|NCT04404855|Other|Intervention Group (NGS + Antibiotic Recommendation)|Next Generation Sequencing results along with Infectious Disease Pharmacist will be shared with clinical provider to determine appropriate standard of care antibiotic treatment at time of standard of care urology stone procedure. Standard of care antibiotic selection will be up to the discretion of the clinical provider.
89034377|NCT05057975|Experimental|Sunrise|Home Sleep Test, OSA diagnosis based on mandibular movements recording
89611936|NCT04404855|Other|Control Group|NGS results will not be shared with the clinical provider at time of standard of care urology stone procedure. Standard of care antibiotic selection will be up to the discretion of the clinical provider.
89611937|NCT03401866|Other|DSC-MRI scan|All subjects will receive a double dose injection protocol that will be split into multiple doses for sequential DSC-MRI scans.
89611938|NCT04376866|Experimental|Toripalimab+CCRT|"Toripalimab 240mg, and Cisplatin 100mg/m2 (every three weeks),D1,D22,D43 of intensity modulated radiotherapy (IMRT), followed by Toripalimab 240mg every 3 weeks with a total of 9 cycles as adjuvant anti-PD-1 immunotherapy.~IMRT: total dose 60-66Gy, 1.8-2.0Gy/f"
89611939|NCT04376866|No Intervention|CCRT alone|"Cisplatin 100mg/m2(every three weeks),D1,D22,D43 of intensity modulated radiotherapy (IMRT).~IMRT: total dose 60-66Gy, 1.8-2.0Gy/f"
89611940|NCT00895791|Active Comparator|1|AXXESS Biolimus A9-eluting bifurcation stent
89611941|NCT00895791|Active Comparator|2|culotte stenting with use of 2 drug eluting stents
89611942|NCT01674387|Experimental|acupuncture|56 patients (the EA group) receive the acupuncture treatment at nine acupuncture points: Dazhui (GV14), bilateral Jianzhongshu (SI15), bilateral Jingbailao (EX HN15), bilateral cervical Jiaji (EX-B2),and two trigger points.Bilateral Jianzhongshu (SI15) and Jiaji (EX-B2) receive the electro acupuncture treatment, with dilatational wave. All the needles retained for 20 minutes, one treatment every other day, 10 times a course, and the treatment assessed after a course.
89611943|NCT01674387|Other|comprehensive treatment|Other 56 patients (the matched group) receive the comprehensive treatment, including traction and TENS(Transcutaneous Electrical Nerve Stimulation) therapy. Each treatment 20 minutes, one treatment every other day, 10 times a course, and the treatment assessed after a course.
89034378|NCT05057975|Active Comparator|PSG|Polysomnography, OSA diagnosis based on local scoring by center
89034379|NCT05054920|Experimental|Concentric exercises group|"patient will do Concentric exercises. Patients will receive 3 sessions per week for 4 weeks. Exercise will be done under the supervision of the same physical therapist. During each session.~Exercise will be in the form of glenohumeral scaption, internal and external rotation exercises.~patient will also do stretching for posterior capsule and pectoralis minor"
89034380|NCT05054920|Experimental|Eccentric exercises group|"patient will do eccentric exercises. Patients will receive 3 sessions per week for 4 weeks. Exercise will be done under the supervision of the same physical therapist during each session.~Exercise will be in the form of glenohumeral scaption, internal and external rotation exercises.~patient will also do stretching for posterior capsule and pectoralis minor"
89034381|NCT05054153|Experimental|refined carbohydrate breakfast (Breakfast A)|white bread (50g) + milk powder (25g)
89034382|NCT05054153|Experimental|whole grain breakfast (Breakfast B)|plain oats (35g) + milk powder (25g)
89034383|NCT05054153|Experimental|intermittent fasting (IF)|
89034384|NCT05050643|Active Comparator|CACP-EBQI-IC|Individual (ongoing) consultation (IC), often described as coaching or supervision, is endorsed by implementation experts as an effective implementation strategy for EBP #1, Comprehensive Assessment and Care Planning (CACP) for High-Risk Veterans.
89034385|NCT05050643|Active Comparator|CACP-EBQI-LC|Learning collaboratives (LC) are widely used in healthcare settings, as an effective implementation strategy. The LC will be used to increase uptake of EBP #1, Comprehensive Assessment and Care Planning (CACP) for High-Risk Veterans.
89034386|NCT05050643|Active Comparator|HCMA-EBQI-IC|Individual (ongoing) consultation (IC), often described as coaching or supervision, is endorsed by implementation experts as an effective implementation strategy for EBP # 2,Phone-Based Health Coaching for Medication Adherence (HCMA).
89034387|NCT05050643|Active Comparator|HCMA-EBQI-LC|Learning collaboratives (LC) are widely used in healthcare settings, as an effective implementation strategy. The LC will be used to increase uptake of EBP # 2,Phone-Based Health Coaching for Medication Adherence (HCMA).
89034388|NCT05039866||Subjects who received ST-920|Subjects who received ST-920 in a separate parent trial
89611944|NCT01698320|Placebo Comparator|Placebo MDPI-Albuterol MDPI|"During the 12-week double-blind period, participants take 2 inhalations of placebo MDPI (multi-dose dry powder inhaler), four times a day (QID) at approximately 7:00 AM, 12:00 PM, 5:00 PM, and bedtime.~The double-blind period is followed by a 40-week open-label period in which all study participants take albuterol MDPI 90 micrograms/inhalation, 2 inhalations every 4-6 hours as needed (PRN) and, if applicable, 2 inhalations 15-30 minutes prior to sports/exercise."
89611945|NCT01698320|Experimental|Albuterol MDPI-Albuterol MDPI|"During the 12-week double-blind period, participants take 2 inhalations of albuterol MDPI (multi-dose dry powder inhaler or Spiromax®) 90 mcg/inhalation, four times a day (QID) at approximately 7:00 AM, 12:00 PM, 5:00 PM, and bedtime for a total daily dose of 720 micrograms per day.~The double-blind period is followed by a 40-week open-label period in which all study participants take albuterol MDPI 90 micrograms/inhalation, 2 inhalations every 4-6 hours as needed (PRN) and, if applicable, 2 inhalations 15-30 minutes prior to sports/exercise."
89034389|NCT05039203||Intervention group|Inpatients with an indwelling urinary catheter (IUC) at admission to a rehabilitation clinic for persons ≥65 years in Sweden. Intervention is removal of the IUC.
89034390|NCT05039203||Control group|Inpatients without an IUC at admission to a rehabilitation clinic for persons ≥65 years in Sweden
89034391|NCT05031832||HIV-negative|
89611946|NCT03401554|Active Comparator|collagen membrane group|Sinus floor elevation with simultaneous implant placement and closure of the osteotomy with collagen membrane
89611947|NCT03401554|Experimental|titanium mesh group|Sinus floor elevation with simultaneous implant placement and closure of the osteotomy with titanium mesh
89611948|NCT01674465||CNI-induced nephrotoxicity|Hypoxyprobe-1
89611949|NCT03401476|Active Comparator|Morphine sulfate - Visit 1|Patients who are randomized to this group will be administered a fixed 5mg dose of oral morphine sulfate prior to performing their 6MWT at Visit 1.
89611950|NCT03401476|Active Comparator|Morphine sulfate - Visit 2|Patients who are randomized to this group will be administered a fixed 5mg dose of oral morphine sulfate prior to performing their 6MWT at Visit 2.
89611951|NCT03884673||DTG+3TC|These cases were given simplified therapy regimen including DTG (50 mg, oral,qd) combined with 3TC (300 mg,oral,qd).
89611952|NCT04376944||Exposed group|Caregivers and agents working directly in COVID units compared to those living.
89611953|NCT04376944||Control group|caregivers anf agents working in services excluding the management of patients screened positive for Covid-19 infection
89611954|NCT04548206|Experimental|Pilates training|60 minutes of Pilates training will be performed for 8 weeks.
89611955|NCT04548206|Placebo Comparator|Control group|The control group will be taught relaxation exercises and will be asked to perform the exercises at home.
89611956|NCT04372810|Experimental|Intervention Group|Intervention group, assessed on day 1, then underwent manual manipulation intervention and were reevaluated post-intervention and again evaluated on the 7th post-treatment day and received preventive guidance at the end of the experiment (follow-up).
89611957|NCT04372810|Sham Comparator|Sham Group|Sham group, evaluated on day 1 and day 7, and received preventive diabetes guidance at the end of the experiment (follow-up).
89611958|NCT01674543|Experimental|Resistance training|
89611959|NCT01674543|Experimental|Concurrent training|
89611960|NCT01674543|Sham Comparator|Control Group|
89611961|NCT01674699||EXCOR|Pediatric candidates age 0 - 21 with severe isolated left ventricular or biventricular dysfunction who are candidates for cardiac transplant and require circulatory support may be treated using the EXCOR® Pediatric.
89611962|NCT01674777|Experimental|under fasting condition group|Subjects will receive a single dose of ASP1941 under fasting condition
89611963|NCT01674777|Experimental|before meal group|Subjects will receive a single dose of ASP1941 before meal
89611964|NCT01674777|Experimental|after meal condition|Subjects will receive a single dose of ASP1941 after meal
89611965|NCT03876717|Experimental|Colesevelam, active arm|"Colesevelam hydrochloride, 625mg tablets. Overencapsulated with DB caps AAA for blinding.~Oral use. Dose: 1, 2, or 3 capsules twice daily. Starting dose 2 capsules twice daily. Dose titration by specific criteria by a central study nurse Treatment duration 12 days"
89611966|NCT03876717|Placebo Comparator|Placebo|Inactive placebo tablets. Overencapsulated with DB caps AAA for blinding. Oral use. Dosage and treatment duration as specified for colesevelam
89611967|NCT01674855|Experimental|DA-3031|PEG-G-CSF
89611968|NCT01674855|Active Comparator|Leucostim®|G-CSF
89611969|NCT00924352|Experimental|Ixabepilone + Dasatinib|"Ixabepilone, for injection 15 mg supplied with diluent for ixabepilone, 8 mL. Dose Level 2;20 mg/m2,Dose Level 1;20 mg/m2,Dose Level 0 (Starting Dose);16 mg/m2,Dose Level - 1;12 mg/m2,Dose Level - 2;12 mg/m2.~Dasatinib tablets will be administered continuously starting on Day 1, Cycle 1 once daily (QD).Dose Level 2;140 mg QD,Dose Level 1;100 mg QD,Dose Level 0 (Starting Dose);100 mg QD,Dose Level - 1;100 mg QD,Dose Level - 2;70 mg QD."
89611970|NCT01674933|Active Comparator|treatment as usual|any treatment from the family dentist, plus the preventive intervention programme offered to nursery school children, including daily supervised toothbrushing
89611971|NCT01674933|Experimental|Duraphat® Fluoride Varnish|treatment as usual (ie any treatment from the family dentist, plus the preventive intervention programme offered to nursery school children, including daily supervised toothbrushing) plus up to 4 six-monthly applications of Duraphat Fluoride Varnish in the nursery school setting.
89034392|NCT05031832||HIV-positive|
89034393|NCT05027048|Experimental|Calcium chloride|"1 gram of calcium chloride in total volume 60mL with sterile saline, delivered over 10 minute controlled infusion at a constant rate (360mL/hour) beginning 2 minutes after fetal delivery and 1 minute after delayed cord clamp.~This intervention occurs IN ADDITION TO standard care with oxytocin 2 unit bolus and infusion at 7.5 units per hour which begins immediately after fetal delivery."
89034394|NCT05027048|Placebo Comparator|Saline placebo|"60mL sterile saline, delivered over 10 minute controlled infusion at a constant rate (360mL/hour) beginning 2 minutes after fetal delivery and 1 minute after delayed cord clamp.~This intervention occurs IN ADDITION TO standard care with oxytocin 2 unit bolus and infusion at 7.5 units per hour which begins immediately after fetal delivery."
89034395|NCT05025020|Experimental|Standard consultation with interactive 3D visualization|Participants in this group will use the interactive 3D tool in addition to receiving the standard surgical consultation before their breast reconstruction procedure.
89034396|NCT05025020|Active Comparator|Standard consultation|Participants in this group will receive a standard surgical consultation before their breast reconstruction procedure.
89034397|NCT05021133|Other|Tele-Navi LCS|Tele-Navi of LCS includes: telehealth coaching from a Tele-Navigator for patients undergoing LCS to access a patient portal and a video-call system.
89034398|NCT05018130|Experimental|Bio-integrative|Traditional oblique calcaneus osteotomy through a lateral approach. After a 10mm displacement, the osteotomy will be fixed with two 4.0mm bio-integrative cannulated screws.
89611972|NCT03852693||Retrospective Group|
89611973|NCT03852693||Prospective Group|
89611974|NCT04373044|Placebo Comparator|Arm II (placebo, antiviral therapy)|Patients receive placebo PO daily, and standard of care hydroxychloroquine PO TID. Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.
89611975|NCT04373044|Experimental|Treatment (baricitinib, antiviral therapy)|Patients receive baricitinib PO daily, and standard of care hydroxychloroquine PO TID. Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.
89611976|NCT03874299||Kidney Transplant Receipients|
89611977|NCT03851991|Active Comparator|arbidol|200mg, three times per day, for 2-5 Days.
89611978|NCT03851991|Placebo Comparator|control|two capsules, three times per day, for 2-5 Days.
89611979|NCT01675089|Experimental|Zoledronic acid|Intravenous administration of zoledronic acid (5 mg) in a single dose at the time of kidney transplantation and vitamin D replacement.
89611980|NCT01675089|No Intervention|Control|The control group will receive only vitamin D replacement. The aim of vitamin D replacement will be serum levels of 25 (OH) vitamin D above 30 ng/ml.
89611981|NCT01675245||Velcade|Velcade, 1.3 mg/m2/dose, administered intravenously on days 1, 4, 8 and 11, for 2 weeks.
89611982|NCT01675323||RLS Patients|Participants who have diagnosed RLS with diagnosis confirmed by study investigators.
89611983|NCT01675323||Healthy Controls|Participants without RLS who are generally healthy and matched for gender, age, educational level, and race to patients in the RLS group.
89611984|NCT03850431|Experimental|Social Norms + Behavioral Instructions|A letter with two types of nudges. One points out the common behavior of attending appointments. And one provides clear, specific instructions for making appointment changes. The appointment reminder also includes usual care (basic appointment information on date, location, and phone number(s) for scheduling changes).
89611985|NCT03850431|Experimental|Caring + Consequences for Others + Behavioral Instructions|A letter with three types of nudges. One suggests that the institution cares about the patient. One highlights a potential negative consequence for others if the patient no-shows. And one provides clear, specific instructions for making appointment changes. The appointment reminder also includes usual care (basic appointment information on date, location, and phone number(s) for scheduling changes).
89611986|NCT03850431|Experimental|Caring + Consequences for Self + Behavioral Instructions|A letter with three types of nudges. One suggests that the institution cares about the patients. One highlights potential negative consequences for the patient if s/he no-shows. And one provides clear, specific instructions for making appointment changes. The appointment reminder also includes usual care (basic appointment information on date, location, and phone number(s) for scheduling changes).
89611987|NCT03850431|Experimental|Combination of all Nudges|A letter with all four types of nudges combined. One suggests that the institution cares about the patients. One highlights a potential negative consequence for others if the patient no-shows. One highlights potential negative consequences for the patient if s/he no-shows. One points out the common behavior of attending appointments. And one provides clear, specific instructions for making appointment changes. The appointment reminder also includes usual care (basic appointment information on date, location, and phone number(s) for scheduling changes).
89611988|NCT03850431|No Intervention|Usual Care|An appointment reminder that includes basic appointment information on date, location, and phone number(s) for scheduling changes.
89611989|NCT01697696|Experimental|NVA237 dose 1|NVA237 dose 1
89611990|NCT01697696|Active Comparator|Long-acting beta 2-agonist (LABA)|QAB149
89611991|NCT04764903||LUTS/Nocturia|Patients with LUTS / Nocturia
89034399|NCT05018130|Active Comparator|Metallic|Traditional oblique calcaneus osteotomy through a lateral approach. After a 10mm displacement, the osteotomy will be fixed with two 4.0mm metallic cannulated screws.
89034400|NCT05014776|Experimental|Arm A - Tadalafil, Pembrolizumab, Ipilimumab, CRS-207|
89034401|NCT05013216|Experimental|KRAS peptide vaccine|
89034402|NCT05011162|Other|Digital Acceptance and Commitment Therapy (ACT) Arm|Pragmatic
89034403|NCT05007275|Experimental|Single arm, dose escalation|Experimental: Healthy Volunteers Biological/Vaccine: AZD1222 (1x10^9 vp, 5x10^9 vp and 1x10^10 vp)
89034404|NCT05005312|Experimental|Cohort 1|Healthy Volunteer
89034405|NCT05005312|Experimental|Cohort 2|Hepatic Impairment
89034406|NCT05004220||Group 1|Group 1 consists of first time donors undergoing all 8 tracked plasmaphereses.
89034407|NCT05004220||Group 2|Group 2 consists of first time donors undergoing only last 4 plasmaphereses, serving as control for the first 4 donations.
89034408|NCT05001984|Active Comparator|Intervention group|In addition to high-intensity statin and antiplatelet treatment, patients will receive treatment of alirocumab 75mg subcutaneously every 2 weeks for a total of 26 weeks
89034409|NCT05001984|No Intervention|Control group|Patient will have high-intensity statin and antiplatelet treatment.
89034410|NCT04999046|Experimental|FUS treatment|FUS treatment will be conducted with following exposure parameters: intracranial spatial-peak temporal-average intensity (ISPTA) ceiling level: 2.8 W/cm2 (the focused ultrasound intensity in brain area considering transcranial attenuation), burst length: 3 ms, duration: three consecutive 5-minute FUS exposures with two 5-minute intermission intervals. The FUS exposure area will be the epileptogenic focus which is individually different and determined by standard clinical practice previously.
89210802|NCT00822068|Placebo Comparator|3|sham stimulation
89611992|NCT04404543|Experimental|Escalation Cohort|"Five dose levels will be tested according to the 3 + 3 dose-escalation design.~The dose-limiting toxicity (DLT) will be assessed from the first administration of SYHA1807 to the end of the first cycle (28 days)."
89611993|NCT04404543|Experimental|Dose Expansion Cohort|Once the RP2D has been determined, an expansion cohort of up to 12~40 subjects will be enrolled in order to better characterize the clinical activity and safety profile of the RP2D.
89034411|NCT04999046|Sham Comparator|Sham treatment|Sham treatment is to mimic the FUS treatment procedure but without any energy. The ISPTA will be 0 W/cm2, duration: three repeating 5-minute sham exposures with two 5-minute intermission intervals.
89611994|NCT03849807|Experimental|Experimental group|Chiropractic care
89611995|NCT03849807|Active Comparator|Control group|Usual health care
89611996|NCT01569152|Experimental|Base Study Phase IIa: MK-8457|Participants received MK-8457 100 mg dosed twice daily (BID) orally with MTX at the stable dose received upon study enrollment. Phase IIa lasted up to 24 weeks.
89611997|NCT01569152|Placebo Comparator|Base Study Phase IIa: Placebo|Participants received placebo dosed BID orally with MTX at the stable dose received upon study enrollment. Phase IIa lasted up to 24 weeks.
89611998|NCT01569152|Experimental|Safety Extension Period 3: MK-8457|Participants received MK-8457 100 mg BID orally with MTX at the stable dose received upon study enrollment. Period 3 was to last up to 2 years.
89611999|NCT03870009|Experimental|ARDS patients|All the patients will be evaluated with the same procedure, as the study relates to evaluation of the diagnostic performance of a semi-automated method to detect cyclic hyperinflation on CT scan
89612000|NCT01675557|Active Comparator|Vitamin D2|a single oral dose of vitamin D2
89612001|NCT01675557|Placebo Comparator|Placebo|a single oral dose of a placebo
89612002|NCT01675557|Experimental|Vitamin D3|A single oral dose of vitamin D3
89612003|NCT03028454|Experimental|Ginger Root Capsule|
89612004|NCT03028454|Placebo Comparator|Placebo Capsule|
89612005|NCT01675791|Placebo Comparator|ALK tree AIT Placebo|1 AIT administered sublingually every day
89612006|NCT01675791|Experimental|ALK tree AIT 0.5 DU|1 AIT administered sublingually every day
89034412|NCT04995328|Experimental|Radiation Care Gel application|Radiation Care® gel is instructed to use on the target skin area accepted radiation therapy twice daily.
89034413|NCT04994483|Placebo Comparator|Placebo|Matching placebo, supplied by Cassava as coated tablets, and taken twice daily (b.i.d.) for 52 weeks
89612007|NCT01675791|Experimental|ALK tree AIT 1 DU|1 AIT administered sublingually every day
89612008|NCT01675791|Experimental|ALK tree AIT 2 DU|1 AIT administered sublingually every day
89612009|NCT01675791|Experimental|ALK tree AIT 4 DU|1 AIT administered sublingually every day
89612010|NCT01675791|Experimental|ALK tree AIT 7 DU|1 AIT administered sublingually every day
89612011|NCT01675791|Experimental|ALK tree AIT 12 DU|1 AIT administered sublingually every day
89612012|NCT04410068|Experimental|Electrical heating pad|"Electrical heating pad (WARMTAC device). Patients will be randomized to one arm.~In this arm, the WARMTAC device will be conected and warmed to 41 degrees before patients lay down."
89612013|NCT04410068|Experimental|forced-air warming device|Forced-air warming device (3M device). In this arm, the 3M blanket will be conected to forced-air machine and warmed to 41 degrees before patients lay down.
89612014|NCT03869307|Experimental|Shoulder strengthening exercises|Progressive heavy shoulder strengthening exercises three times weekly and advice on load and pain management. Exercise sessions are supervised twice a week corresponding to 32 supervised exercise sessions during the 16 weeks.
89612015|NCT03869307|Active Comparator|Shoulder stability exercises|Recommendations of shoulder stability exercises which are to be performed unsupervised (e.g. at home) three times weekly and advice on load and pain management. Three supervised sessions are offered during the 16 weeks, and exercises are primarily performed unsupervised at home.
89612016|NCT01675869|Experimental|ETAM group|Executive Function/Metacognitive Training Program: An 8-week program, which addresses major areas of deficit in ADHD; namely, attention (the ability to concentrate and focus), inhibition (the ability to control ones behaviors), and memory (the ability to remember information).
89612017|NCT01675869|Active Comparator|Attention Control|Attention control group: An 8-week program which provides education regarding several topics relevant for preschool children including nutrition, sleep, temperament, etc.
89612018|NCT01675947|Experimental|Sirolimus|Monthly 20 μL (440 μg) intravitreal injection of sirolimus
89612019|NCT01675947|Sham Comparator|Lidocaine|Monthly subconjunctival injection of 2% lidocaine
89612020|NCT01676025|Experimental|PRA|Persons who get PRA surgery.
89612021|NCT01676025|Experimental|LA|Persons who get LA surgery.
89612022|NCT02082717|Experimental|Neut (4%sodium bicarbonate additive)|4% sodium bicarbonate additive during intravenous potassium chloride replacement.
89612023|NCT02082717|Active Comparator|Control|standard of practice potassium chloride replacement (with no additive)
89612024|NCT03660189|No Intervention|Usual care|Usual care with a one bag system of IV fluids, as recommended in the American Diabetes Association consensus statement guidelines from 2009.
89612025|NCT03660189|Experimental|Two bag system|A two bag system of IV fluids will be used during insulin infusion administration.
89612026|NCT01569074|Experimental|Dosing A regimen|Oral treatment
89612027|NCT01569074|Experimental|Dosing B regimen|Oral treatment
89612028|NCT01569074|Experimental|Dosing C regimen|Oral treatment
89612029|NCT01569074|Experimental|Dosign D regimen|Oral treatment
89612030|NCT01569074|Placebo Comparator|Dosing E regimen|Oral treatment
89612031|NCT03842241||WIth foot orthoses|Device: Non-custom made foot orthoses
89612032|NCT03842241||Without foot orthoses|Other: without foot orthoses
89612033|NCT03752775|Experimental|subacute device assisted group|
89034414|NCT04994483|Experimental|Simufilam 100 mg|Simufilam 100 mg, supplied by Cassava as coated tablets, and taken b.i.d. for 52 weeks
89034415|NCT04988945|Experimental|Durvalumab + Tremelimumab|1500mg Durvalumab administered IV over 60 minutes on Day 1 of each immunotherapy treatment every 4 weeks until disease progression (PD) and 300mg Tremelimumab administered over 60 minutes on Day 1 of cycle 1.
89210803|NCT04006353|Experimental|Group 1: ABT|Intravenous infusion of 320 mg ABT on Day 1, 2, 3, and 8.
89210804|NCT04006353|Experimental|Group 2: ABT+RIF|600mg Rifampicin once daily from Day 1 to 16. Intravenous infusion of 320 mg ABT on Day 7, 8, 9 and 14.
89612034|NCT03752775|Active Comparator|subacute conventional group|
89612035|NCT03752775|Other|chronic device assisted group|
89612036|NCT04348773|Experimental|Dehydration|
89612037|NCT04348773|Experimental|Rehydration|
89612038|NCT04403685|Experimental|Tocilizumab|Single-dose tocilizumab of 8 mg/kg (maximum dose of 800mg). Best supportive care.
89612039|NCT04403685|No Intervention|Control arm|Best supportive care.
89612040|NCT03746925|Active Comparator|Direct Anterior Approach (DAA)|Direct Anterior Approach surgery to replace the hip.
89612041|NCT03746925|Experimental|SuperPATH|SuperPATH approach surgery to replace the hip.
89612042|NCT01604408|Experimental|LY2495655|Participants received a 315-milligram (mg) dose of LY2495655, administered subcutaneously (SC), every 4 weeks (Q4W) for 20 weeks.
88984023|NCT00428038||3|"Group 3:~Infants born full term at a gestational age > 37 weeks. Subjects will be evaluated at a corrected-age between 1 month and 24 months when they are clinically stable and free of acute respiratory symptoms for > 3 weeks. Subjects will be excluded for the following reasons:~Hospitalization for a respiratory illness~History of wheezing, asthma, or treatment with asthma medications~Congenital heart disease"
88984024|NCT04704622|Active Comparator|dexmedetomidine group|dexmedetomidine intranasal injection,1 μg/kg, once, 30 min preoperative
88984025|NCT04704622|Active Comparator|ketamine|ketamine intranasal injection,2 mg/kg, once, 30 min preoperative
88984026|NCT04704622|Active Comparator|midazolam|midazolam intranasal injection,0.2 mg/kg, once, 30 min preoperative
88984027|NCT00091988|Experimental|Lifestyle & Behavioral Change Program|
88984028|NCT00091988|Active Comparator|Structured Education Program|
88984029|NCT00428194|Experimental|Cohort 1|Erlotinib 100 mg/day by mouth beginning on day 1 of radiotherapy (RT) and cisplatin dosing (40 mg/m^2 intravenous every 7 days during RT) and continuing daily through radiation
88984030|NCT00428194|Experimental|Cohort 2|Erlotinib 125 mg/day by mouth beginning on day 1 of radiotherapy (RT) and cisplatin dosing (40 mg/m^2 intravenous every 7 days during RT) and continuing daily through radiation
88984031|NCT00428194|Active Comparator|Cohort 3|Erlotinib 150 mg/day by mouth beginning on day 1 of radiotherapy (RT) and cisplatin dosing (40 mg/m^2 intravenous every 7 days during RT) and continuing daily through radiation
88984032|NCT03769467|Experimental|tabelecleucel in combination with pembrolizumab|Subjects will receive IV infusions of tabelecleucel at 2 × 10^6 T-cells/kg on Days 1, 8, and 15; and an IV infusion of pembrolizumab at 200 mg for adults or 2 mg/kg for adolescents on Day 1 of each 21-day cycle (at least 2 cycles or up to 4 cycles). For Cohort 1, if there is a dose-limiting toxicity, the dose of tabelecleucel will be reduced to 1 x 10^6 cells/kg and pembrolizumab will continue to be administered as above. Otherwise, all subjects in Cohort 1 will receive tabelecleucel at 2 x 10^6 cells/kg/dose and pembrolizumab as above. Subjects in Cohort 2 will receive the recommended Phase 2 dose of tabelecleucel per the SDRC and pembrolizumab as above.
88984033|NCT00428233|No Intervention|Leukemia Cell Harvest|Procedure/Surgery: Leukemia cell harvest Leukemia cells will be harvested either by: Blood draw, leukapheresis, bone marrow aspiration or surgery to remove the lymph node
88984034|NCT00428272|Experimental|1|Lexatumumab alone dose escalation
88984035|NCT00428272|Experimental|2|Lexatumumab with interferon - dose escalation
88984036|NCT00428272|Other|3|Lexatumumab 10mg/kg with interferon expansion at
88984037|NCT01580254|Active Comparator|IOPIZE© eyedrops|subjects will receive a IOP-lowering therapy with latanoprost eyedrops. Drug commercial name is IOPIZE©
89612043|NCT01604408|Placebo Comparator|Placebo|Participants received a LY2495655-matching dose of placebo, administered SC, Q4W for 20 weeks.
89612044|NCT04404231|Sham Comparator|No infrared light therapy|This arm does not receive any phototherapy
89612045|NCT04404231|Active Comparator|810 nm|Many clinical studies have used 810nm twice a week for 4 weeks. This is the standard.
88984038|NCT01580254|Active Comparator|GALAXIA© eyedrops|subjects will receive a IOP-lowering therapy with latanoprost eyedrops. Drug commercial name is GALAXIA©
88984039|NCT01580254|Active Comparator|Latanoprost RATIOPHARM© eyedrops|subjects will receive a IOP-lowering therapy with latanoprost eyedrops. Drug commercial name is Latanoprost RATIOPHARM©
88984040|NCT00428428|Placebo Comparator|1|Saline irrigation
88984041|NCT00428428|Active Comparator|2|ISO irrigation
88984042|NCT00428545|Experimental|Bevacizumab + Bortezomib|Bevacizumab starting Dose 2.5 mg/kg By Vein On Day 1 Every 21 Days. Bortezomib starting Dose 0.7 mg/m^2 By Vein On Days 1 and 8 Every 21 Days.
88984043|NCT01056484|Experimental|Meditation|Mindfulness Based Relapse Prevention for Alcohol Dependence intervention + Standard of Care therapy
88984044|NCT01056484|Other|Wait-list control|Standard of Care therapy only
89612046|NCT04404231|Experimental|945nm|This wavelength has been chosen as a comparison to 810, to see if it works better.
88984045|NCT00093002|Experimental|1|250 mg fulvestrant
88984046|NCT00093002|Experimental|2|500 mg fulvestrant
88984047|NCT00093080|Experimental|Ridaforolimus|12.5 mg of ridaforolimus is given intravenously over 30 minutes once daily for 5 days, every 2 weeks
88984048|NCT05561283|Experimental|Cohort of residents|Medical residents undergoing the leadership and meditation training
88984049|NCT03501498|Experimental|loperamide|Slows intestinal transit time
88984050|NCT03501498|Experimental|senna|Speeds up intestinal transit time
88984051|NCT00093197|Experimental|A1: KAI-9803|
88984052|NCT00093197|Experimental|A2: KAI-9803|
88984053|NCT00093197|Experimental|A3: KAI-9803|
88984054|NCT00093197|Experimental|A4: KAI-9803|
88984055|NCT00093197|Placebo Comparator|A5: Placebo|
88984056|NCT05561010|Experimental|Intra-articular injection of bupivacaine|5 ml of bupivacaine (0.25% w/v)
88984057|NCT05561010|Placebo Comparator|Intra-articular injection of sodium chloride|5 ml of sodium chloride (9mg/ml, 0.9% solution for injection)
88984058|NCT05559957||Isolated oligohydramnios group|Cases with oligohydramnios (amniotic fluid index less than 5) without an overt underlying reason in the third trimester
88984059|NCT05559957||Normal amniotic fluid group|Normal pregnancy cases with normal amniotic fluid index
88984060|NCT00093236|Experimental|Early Periodontal Treatment|Subjects will receive scaling, root planing and if needed periodontal surgery
88984061|NCT00093236|Active Comparator|Usual Dental Hygiene|Subjects will receive routine oral hygiene
89612047|NCT04404231|Experimental|random frequency|A wavelength between 650-1100nm which is picked at random
89034416|NCT04988750|Experimental|FUS + re-RT or FUS + SRS|"The SRS treatment will be administered for 3 consecutive days (one fraction of 7-9 Gy per day; total dose 21-27 Gy), including SRS treatment 1 (SRS 1), SRS treatment 2 (SRS 2), and SRS treatment 3 (SRS 3). At the SRS 1 and SRS 3, the patients will be shaved their hair at first, and the patient registration will be performed for the neuronavigation system according to the instruction of the system.~cRT will be administered for 5 consecutive days within one week, and a full course is two weeks (one fraction of 3-4 Gy per day; total dose: 30-40 Gy), including cRT treatment 1 to cRT treatment 10 (cRT 1-cRT 10). At the cRT 1, cRT 3, cRT 6, and cRT 8, the patients will be shaved their hair at first, and the patient registration will be performed for the neuronavigation system according to the instruction of the system."
89034417|NCT04982731|Experimental|ED Positive Assurance Discharge Video Educational Intervention (EDUC).|The video intervention will be administered to participants that are randomly assigned to the EDUC group. In addition, current standard of care discharge instructions will also be provided to the participant. This EDUC intervention will consist of a brief, three to five-minute informative video message from the clinical neuropsychologist at the Inova Sports Medicine Concussion Program. In addition to the viewing of the video after ED discharge, all participants will be instructed to view the video at least once every 24 - 48 hours prior to their visit to the concussion clinic.
89034418|NCT04982731|No Intervention|Standard of Care ED Discharge Instructions (Treatment as Usual: TAU )|The Acute Concussion Evaluation (ACE) Care plan in place at the Inova PED is the standard-of-care discharge instruction for individuals with mTBI. This care plan provides patient and caregiver education about mTBI and emphasizes the monitoring of symptoms, signs of deterioration that may warrant urgent medical attention, and encourages the patient to follow up with their physician for follow up. Participants who are randomized into the TAU group will receive this standard of care treatment in video format as well, however these participants will not be given a QR code to watch the intervention video.
89034419|NCT04979455||Exertional heat illness|Participants who experience an atypical elevation in thermal strain or an EHI undergoing strenuous physical exercise.
89034420|NCT04979455||Control|Participants who do not experience an atypical elevation in thermal strain or an EHI undergoing strenuous physical exercise.
89034421|NCT04979000||Cases|Patients with a confirmed diagnosis of sinonasal cancer.
89034422|NCT04979000||Controls|Patients being seen for benign conditions at Johns Hopkins.
89612048|NCT04413578|Experimental|Dexcom G6 (Intervention Group)|• Intervention group: CGM using a Dexcom G6 to measure glycosylated hemoglobin levels every five minutes. Patients will be asked to download the Dexcom G6 and Clarity applications (to have access to their real-time data) and be given a link to complete an exit survey in REDCap near the end of their study participation. Data will be sent via Bluetooth and then exported by the Intermountain research team into a Tableau (or similar) dashboard for data analysis/comparison
89612049|NCT04413578|Placebo Comparator|Contour NextOne (Standard of Care) Glucometer|• Control group: A standard finger-prick protocol that will require patients to continue with their daily fingerprick regimen established by their physician. This group will be given a Contour Next One meter to ensure that each patient is receiving the same level of accuracy by the same device. A review by Ekhlaspour et al of 17 glucose meters demonstrated wide variability, with only two devices achieving the 2013 ISO standard (with the most accurate being the Contour Next). Patients in the control group will be asked to download the Contour Next application which will send data via Bluetooth similar to above. Data will be aggregated, and protected health information removed prior to analysis (by Intermountain Healthcare and Savvysherpa). At the end of the study, patients will be asked to complete a short survey in REDCap about their willingness to participate in future studies.
89612050|NCT01677429|Experimental|VR movie + balance challenge|VR-based balance training
89612051|NCT01677429|Sham Comparator|still pictures from VR|Exposure to still pictures from the same VR scene but no balance challenge
89612052|NCT01677429|Active Comparator|Cognitive Behavioral Therapy|Standard CBT protocol for the treatment of panic disorder
89612053|NCT01567826|Active Comparator|standard of care lipid therapy|standard-care lipid-lowering therapy: Zocor or Lipitor
89612054|NCT01567826|Experimental|aggressive lipid therapy|aggressive lipid therapy: Crestor
89612055|NCT03657459|No Intervention|usual care group|Usual care consists of patient's receiving a Heart Failure Handbook before hospital discharge + verbal education delivered by multiple care providers (including a group education class at 1 site). The handbook is consistent; however, verbal education may vary between care providers based on their knowledge and time available, and perceived patient needs
89612056|NCT03657459|Active Comparator|video education group|"Will receive usual care, plus will watch 2 short Wellflix, Inc. Danger Signs of Heart Failure videos (via iPAD) on dyspnea, fatigue + a Danger Sign edema video, when applicable. Each video describes how to recognize if the sign/symptom is new or worsening and how to self-manage at home (via diet, fluid management and activity instructions)"
89612057|NCT01697462||Cohort|
89612058|NCT03653481|Experimental|Inulin|Oligofructose-enriched Inulin (OI) administered for 8 weeks
89612059|NCT03653481|Placebo Comparator|Placebo|Maltodextrin placebo administered for 8 weeks
89612060|NCT02986022|Experimental|Resilience|Participants will receive four sessions covering Resilience intervention content
89612061|NCT02986022|Active Comparator|Resilience+Information|Participants will receive four sessions covering Resilience intervention and Information intervention contents.
89612062|NCT03742167|Experimental|Telemedicine|The telemedicine arm will have 2-way audiovisual connection with a pediatric medical control physician.
89034423|NCT04968990|Active Comparator|Favorable Histology Stage I & II and FH Stage III/IV|Favorable Histology Stage I & II and FH Stage III/IV Delayed Local Control with clear surgical margins and pathologically negative lymph nodes. Participants will undergo complete surgical resection at diagnosis or after 6-12 weeks of induction chemotherapy.
89034424|NCT04968990|Active Comparator|Stage III & IV Adjuvant RT and Stage V|Participants will undergo surgical resection at diagnosis or after 6-12 weeks of induction chemotherapy. Those with evidence of LN involvement, surgical margin involvement, local or diffuse spill, gross disease in the renal bed or peritoneal implants, will receive adjuvant PBRT.
89612063|NCT03742167|No Intervention|Control|The control arm will receive pediatric medical control physician consultation via telephone.
89612064|NCT01337505|Experimental|INNO-206|INNO-206 at dosages of 230, 350, and 450 mg/m2 doxorubicin equivalents of 165, 260, and 325 mg/m2)will be administered as a 30 minute IVI on Day 1 of each cycle.
89612065|NCT03648645|Experimental|AH Telemonitoring|Self measurement of blood pressure
89612066|NCT00003459|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dosage is reached.
89612067|NCT03829215|Experimental|CAERVest cooling device|"After checking inclusion and exclusion criteria and immediately after return of spontaneous circulation, the CAERvest device will be filled and placed on the supine patient's chest. A recording esophageal temperature probe will be inserted and connected to the defibrillator. Then the patient will be transported to the Emergency Department.~After admission to the emergency department, an additional endovascular cooling device will be placed and the patient will be cooled to 33°C for 24 hours with the endovascular cooling device. The CAERvest device will be removed, when a temperature below 34°C is reached.~Then the patient will be rewarmed at 0.25 °C/h. After rewarming, the temperature will be controlled to be below 37.5°C for until 48 hours after cardiac arrest."
89612068|NCT03829215|No Intervention|Control|"After checking inclusion and exclusion criteria and immediately after return of spontaneous circulation, a recording esophageal temperature probe will be inserted and connected to the defibrillator. Then the patient will be transported to the Emergency Department.~After admission to the emergency department, an endovascular cooling device will be placed and the patient will be cooled to 33°C for 24 hours with the endovascular cooling device.~Then the patient will be rewarmed at 0.25 °C/h. After rewarming, the temperature will be controlled to be below 37.5°C for until 48 hours after cardiac arrest."
89612069|NCT04763811||Older 65 people|Older 65 people who live alone in their house will be included. They will have focus groups and Individual interviews.
89612070|NCT02083107|Experimental|sublingual misoprostol & rectal placebo|"will receive 400 microgram of misoprostol (Sigma) sublingual 2 tablets and rectal placebo2 tablets."
89612071|NCT02083107|Placebo Comparator|rectal & sublingual placebo|"will receive rectal placebo2 tablets and sublingual placebo2 tablets."
89612072|NCT02083107|Experimental|rectal misoprostol & sublingual placebo|"will receive 400 microgram of misoprostol (Sigma) rectal 2 tablets and sublingual placebo2 tablets."
89612073|NCT04403997|Active Comparator|Chromoendoscopy with methylene blue 0.1%|Once the cecum is reached, a spray catheter is introduced through the working channel and the dye, a 0.1% methylene blue solution, is applied.
89612074|NCT04403997|Experimental|Virtual Chromoendoscopy with NBI with HQ190 endoscopes|Intubation is done with normal white light. Once the cecum is reached, the removal will be done in NBI mode
89612075|NCT00925054|Experimental|rAvPAL-PEG 0.001 mg/kg|Subjects will start on rAvPAL-PEG 0.001 mg/kg
89612076|NCT00925054|Experimental|rAvPAL-PEG 0.003 mg/kg|Subjects will start on rAvPAL-PEG 0.003 mg/kg
89612077|NCT00925054|Experimental|rAvPAL-PEG 0.01 mg/kg|Subjects will start on rAvPAL-PEG 0.01 mg/kg
88984062|NCT03448107|Experimental|Simple Prevention|"One drop (0.05 ml) of silver diamine fluoride (Advantage ArrestTM) solution at 38% concentration (2.24 F-ion mg/dose) will be dispensed per child. Posterior tooth surfaces to be treated will be dried, after which the SDF will be applied with a micro-brush to all asymptomatic carious lesions and to all pits and fissures on bicuspids and molar teeth for thirty seconds. Fluoride varnishes (5% NaF) will then be applied to all teeth.~Dosage frequency will be twice-yearly."
88984063|NCT03448107|Active Comparator|Complex Prevention|"Pits and fissures on all bicuspids and molar teeth will be sealed with glass ionomer sealants (GC Fuji IX). Glass ionomer sealants (interim therapeutic restorations) will also be placed on all frank asymptomatic carious lesions. Fluoride varnishes (5% NaF) will then be applied to all teeth.~Dosage frequency will be twice-yearly."
88984064|NCT00093509|Experimental|Magnetic Resonance Based Thermometry|"Patients will receive hyperthermia throughout the course of radiotherapy delivered once weekly for a total of 5 treatments. Each treatment will last 1-2 hours with a goal of delivering a cumulative thermal dose of 10-100 CEM 43˚T90. Interstitial temperature measurements will be taken by placing a single (less than or equal to) 15 gauge thermometry catheter into the tumor.~In addition to hyperthermia treatment and radiation therapy all patients will receive conventional surgery for the removal of their tumors. Some patients will also receive chemotherapy if their treating physician thinks it is the their best interested (including the possibility of doxorubicin hydrochloride or ifosfamide and mesna)."
88984065|NCT03200769|No Intervention|Group I|AHI/h < 15
88984066|NCT03200769|Experimental|Group IIa|15 < AHI/h < 30. Randomization group. Intervention : CPAP active
88984067|NCT03200769|Experimental|Group IIb|15 < AHI/h < 30. Randomization group. Intervention : CPAP placebo during the first 3 months. After this period, the patient will have the possibility to continue with an active CPAP.
88984068|NCT03200769|Active Comparator|Group III|AHI/h > 30. Intervention : CPAP active
88984069|NCT05549895|Experimental|Drug arm|45 patients will receive 8mg dexamethasone in addition to bupivacaine intrathecally .
88984070|NCT05549895|Other|control arm|45 patients will receive only bupivacaine intrathecally as a control group.
88984071|NCT00093626|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88984072|NCT05543109|Active Comparator|Psoas compartment block|After induction of anesthesia; ultrasound guided psoas compartment block will be done using ropivacaine 0.25% 1ml/kg.
89612078|NCT00925054|Experimental|rAvPAL-PEG 0.03 mg/kg|Subjects will start on rAvPAL-PEG 0.03 mg/kg
89612079|NCT00925054|Experimental|rAvPAL-PEG 0.1 mg/kg|Subjects will start on rAvPAL-PEG 0.1 mg/kg
89612080|NCT02335905|Experimental|Ceftaroline Fosamil|IV Ceftaroline fosamil 15 mg/kg (or 600 mg if > 40 kg) infused over 120 (± 10) minutes q8h (± 1 hour). The dose may vary with age.
88984073|NCT05543109|Active Comparator|Suprainguinal fascia iliaca compartment block|After induction of anesthesia; ultrasound guided suprainguinal fascia iliaca compartment block will be done using ropivacaine 0.25% 1ml/kg.
88984074|NCT02964806|Other|Ordinary Diet|Ordinary Diet
88984075|NCT02964806|Other|Modified Atkin's Diet|Modified Atkin's Diet
88984076|NCT02964806|Other|Ketogenic Diet|Ketogenic Diet
88984077|NCT00093704|Experimental|Bortezomib + ganciclovir|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8 and 11. Patients also receive ganciclovir IV twice daily on days 1-14. Treatment repeats every 21 days for a maximum of 3 courses.
89612081|NCT00925756|Experimental|Maraviroc 150 mg, 300 mg, or 600 mg twice daily|"This was a single arm study where Maraviroc was added for 24 weeks.~Maraviroc was dose-adjusted for concomitantly administered HIV medications according to the manufacture's recommendations:~150 mg twice daily with strong CYP3A4 inhibitors, including:~Protease inhibitors (except tipranavir/ ritonavir)~Delavirdine~ketoconazole, itraconazole, clarithromycin, nefazadone, telithromycin~Darunavir/r + etravirine~300 mg twice daily with non-inducers/ non-inhibitors of CYP3A4, including:~Tipranavir/ ritonavir~Nevirapine~All NRTIs~Enfuvirtide~600 mg twice daily with strong CYP3A4 inducers, including:~Efavirenz, etravirine~rifampin"
89612082|NCT03736005||General ICU admissions|Non- major trauma ICU admission Exposure to significant period of critical illness
89612083|NCT03736005||Major Trauma admissions|Exposure to Major Trauma Exposure to significant period of critical illness
89612084|NCT04372966|Active Comparator|Cemented|This group will receive a cemented Exeter stem and contemporary acetabular component (Stryker).
89612085|NCT04372966|Active Comparator|Uncemented|This group will receive an uncemented Corail stem and uncemented acetabular component (Depuy).
89612086|NCT04372654|Experimental|Radial group|Use of Electroducer Sleeve on radial route
89612087|NCT04372654|Experimental|femoral group|Use of Electroducer Sleeve on femoral route
89612088|NCT03731013|Experimental|Mediterranean diet (MedDiet)|
89612089|NCT03731013|Experimental|Physical activity (PA)|
88984078|NCT01055314|Experimental|Group 1 (chemotherapy, radiation therapy, cixutumumab)|Patients receive vincristine sulfate IV over 1 minute on day 1 of weeks 1-5, 7, 8, 11, 12, 15, 16, 20-24, 28, 29, 32, 33, 35, 38, 41-44, 47, 48, 50, and 51; irinotecan hydrochloride IV over 90 minutes on days 1-5 of weeks 1, 4, 20, 23, 47, and 50; ifosfamide IV over 1 hour and etoposide IV over 1-2 hours on days 1-5 of weeks 9, 13, 17, 26, and 30; doxorubicin hydrochloride IV over 1-15 minutes on days 1 and 2 of weeks 7, 11, 15, 28, and 32; cyclophosphamide IV over 30-60 minutes on day 1 of weeks 7, 11, 15, 28, 32, 35, 38, 41, and 44; dactinomycin IV over 1-5 minutes on day 1 of weeks 35, 38, 41, and 44; and cixutumumab IV over 1 hour on day 1 of weeks 1-51. Patients also undergo radiation therapy on days 1-5 of weeks 20-24.
88984079|NCT01055314|Experimental|Group 2 (chemotherapy, radiation therapy, temozolomide)|Patients receive vincristine sulfate, irinotecan hydrochloride, ifosfamide, etoposide, doxorubicin hydrochloride, cyclophosphamide, and dactinomycin and undergo radiation therapy as in group 1. Patients also receive temozolomide PO on days 1-5 of weeks 1, 4, 20, 23, 47, and 50.
88984080|NCT00093743|Experimental|Treatment (allogeneic bone marrow or PBSC transplantation)|"NON-MYELOABLATIVE CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV over 30 minutes on days -4 to -2, cyclosporine IV every 8-12 hours on days -3 to 0, and undergo low-dose TBI on day 0.~TRANSPLANTATION: Patients undergo allogeneic bone marrow or PBSC transplantation on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine PO or IV every 8-12 hours on days 1-100 with taper to day 177, and mycophenolate mofetil PO or IV every 8 hours on days 0-40 with taper to day 96."
88984081|NCT00093821|Experimental|Treatment (tanespimycin)|"Patients receive tanespimycin IV over 2-6 hours on days 1, 4, 8, and 11 (for patients with solid tumors) OR days 1, 4, 8, 11, 15, and 18 (for patients with leukemia). Courses for all patients repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of tanespimycin until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. At least 15 patients are treated at the MTD."
88984082|NCT04704310|Experimental|Intervention Group|Individuals acting as own control. Looking at changes pre and post intervention
88984083|NCT05529030|No Intervention|Standard question|Question with no additional text or framing
88984084|NCT05529030|Experimental|Question with salient Omicron message|Question indicates that the bivalent booster can protect the respondent from the Omicron variant
88984085|NCT05529030|Experimental|Question with patient protection message|Question indicates that the bivalent booster can protect patients (only presented to patient-facing employees)
88984086|NCT05529030|Experimental|Question with salient Omicron and patient protection message|Question indicates that the bivalent booster can protect patients from the Omicron variant (only presented to patient-facing employees)
88984087|NCT00400322|Active Comparator|Valganciclovir|
88984088|NCT00400322|Placebo Comparator|Placebo|
88984089|NCT01055197|Experimental|PCI|Prophylactic Cranial Irradiation (PCI)
88984090|NCT01055197|Experimental|PCI + Consolidation RT|Prophylactic Cranial Irradiation (PCI) plus consolidative radiation therapy (RT) to locoregional and residual metastatic disease
88984091|NCT02823366|Experimental|Fenofibrate + UDCA|Fenofibrate in combination with ursodeoxycholic acid
88984092|NCT02823366|Active Comparator|Monotherapy|UDCA alone
88984093|NCT00093977|Experimental|darbepoetin alfa SF|
88984094|NCT02813889|Experimental|Infants|Two populations will be involved in testing in the SmarToyGym: 1. Infants exhibiting typical development between 3 months and 11 months of age 2 . Infants exhibiting atypical development (at-risk for neuromotor delay) between 3 months and 11 months of age.
88984095|NCT02964962|Experimental|29 mm LOTUS Edge™|
88984096|NCT05513118||Post-menopausal women|
88984097|NCT05513118||Regularly mensturating women|
89210805|NCT00925158|Experimental|Surgical instrument (DAME)|Surgical dissector instrument created to malar elevation.
89612090|NCT03731013|Experimental|Mediterranean diet and physical activity|
89612091|NCT03731013|No Intervention|Control|
89612092|NCT04372888|Other|rare genetic disease|Hypothetical scenario 1: rare, life-altering genetic condition (congenital hypogonadotropic hypogonadism)
89612093|NCT04372888|Other|common genetic disease|Hypothetical scenario 2: common, life-threatening genetic condition (hereditary breast and ovarian cancer)
89612094|NCT04372732||Study group|All participants will be detected for antoantibodies and then treated with PD-1 blockade.
89612095|NCT02245126|Experimental|Lignocaine-bupivacaine lower dosage mix|"Men who received the 3-3-4 local anaesthetic mix( 3 cc of lignocaine 2% , 3cc of bupivacaine 0.5% and 4cc of water for injection)~3-3-4 mix was administered"
89612096|NCT02245126|Active Comparator|Lignocaine-bupivacaine higher dosage mix|In this group (4-4-2 group) eligible men were receiving an injection of the 4-4-2 local anesthetic mix ( composed of 4cc of parental lignocaine 2%, 4cc of parental bupivacaine 0.5% and 2cc of water for injection). This mix is given once before commencement of the surgical procedure safe male circumcision.
89034425|NCT04968990|Active Comparator|Stage V Adjuvant RT:|Participants will undergo partial nephrectomy after 6-12 weeks of induction chemotherapy. Those with evidence of LN involvement, surgical margin involvement, local or diffuse spill, gross disease in the renal bed or peritoneal implants, will receive adjuvant PBRT
89034426|NCT04965727|Experimental|Deep brain stimulation|"Participants will undergo a surgery for Deep Brain Stimulation (DBS). The neurostimulation system will be used for neuro-rehabilitation of the motor function.~Participants will follow a 3-month neuro-rehabilitation using DBS at a frequency of 3 times per week with physiotherapist."
89612097|NCT04347382|Experimental|Nigella Sativa & Honey Group|"Drug: Nigella Sativa seed Powder 80 mg/Kg/day grinded in capsule upto a max of 14 days) Drug: Natural Honey 1gm/kg/day orally upto a max of 14 days)~along with standard medical care"
89612098|NCT04347382|Placebo Comparator|Standard Medical Care|Standard supportive medical care prescribed by treating physician, Lahore which includes standard symptomatic care along with use of antibacterial or antiviral (if advised by pulmonologist or infectious disease specialist)
89612099|NCT04372342|Experimental|nalbuphine|
89612100|NCT04372342|Placebo Comparator|remifentanil|
89612101|NCT04372264|Experimental|Paracetamol|1000 mg of paracetamol ( perfalgan 10mg/ml solutionBristol- Myers Squibb_UK) intravenous (IV) was given 70 patients,
89612102|NCT04372264|Experimental|Dexketoprofen|Second Group: dexketoprofen 50 mg ( arveles ampoule -Ufsa- Istanbul) intravenous (IV) was given 70 patients,
89612103|NCT04372264|Experimental|Ibuprofen|third group: 400 mg Ibuprofen (İntrafen 400 mg vial-Gen-İstanbul) intravenous (IV) was given 70 patients, which determined to be applied as a group.
89612104|NCT04366570||The 1st group|(n=511; 36,45%) included patients with extra-articular injury of the proximal humerus (rotator cuff tear, anatomical and surgical neck fracture)
89612105|NCT04366570||The 2nd group|(n=309; 22,04%) included patients with intra-articular injury of the proximal humerus (contracture of the shoulder joint and shoulder instability, humeral head fracture, including Hill-Sachs lesion)
89612106|NCT04366570||The 3rd group|(n=582; 41,51%) - patients with injury of subacromial (suprahumeral) space (soft tissue injury, acromioclavicular and sternoclavicular joint injury, diaphyseal and distal end clavicle fracture)
89612107|NCT02083809|Placebo Comparator|Placebo|500ml saline or lactated ringer without oxytocin added
89612108|NCT02083809|Active Comparator|Treatment group|Intravenous oxytocin mixed with saline or lactated ringer
89612109|NCT02244112|Experimental|Part I: Food Effect/QTc|"Subjects will receive a single dose of oprozomib 270 mg in 1 of 3 fasting/fed conditions:~Diet A: Fasted conditions~Diet B: A low-fat breakfast. A low-fat breakfast is defined as having a total caloric value of less than 400 calories, with less than 20% from fat~Diet C: A high-fat breakfast. A high-fat breakfast is defined as having a total caloric value of 800 to 1000 calories, with approximately 50% from fat"
89612110|NCT02244112|Experimental|Part II: Drug-Drug Interaction (DDI)|"Period 1: Midazolam 2 mg single oral dose on one day between Day -7 and -4~Period 2: Midazolam 2 mg single oral dose 1 hour following oprozomib dose on Day 1 of Cycle 1 and Day 2 of Cycle 2. Oprozomib 300 mg dose on Days 1, 2, 8 and 9 of Cycles 1 and Cycle 2"
89612111|NCT02244112|Experimental|Extension|After subjects complete the Food Effect/QTc or DDI part, subjects may participate in the extension part of the study, where oprozomib treatment will be continued on Days 1, 2, 8, and 9 of each 14-day cycle. During this part of the study, it is recommended that oprozomib be taken with food.
89034427|NCT04964895|Other|patients with cystectomy|
89612112|NCT03723681|Experimental|Quizartinib 20 mg|Participants receive 20 mg quizartinib in combination with standard induction therapy and consolidation therapy once daily in the fasted state in the morning (at least 1 hour before or two hours after a meal)
89612113|NCT03723681|Experimental|Quizartinib 40 mg|Participants receive 40 mg quizartinib in combination with standard induction therapy and consolidation therapy once daily in the fasted state in the morning (at least 1 hour before or two hours after a meal)
89612114|NCT04366180|Experimental|Probiotic|Experimental group who will receive one capsule of Lactobacillus K8 per day (3x10^9 cfu/day).
89612115|NCT04366180|Placebo Comparator|Control|Control group who will receive a daily placebo capsule consisting of maltodextrin
89612116|NCT03722589|Active Comparator|Flublok (Recombinant)|Flublok® Quadrivalent by Sanofi Pasteur, 45µg of HA per strain
89612117|NCT03722589|Active Comparator|Flucelvax (Cell-based)|Flucelvax™ Quadrivalent by Seqirus, Inc., 15µg of HA per strain
89612118|NCT03722589|Active Comparator|Fluarix (Egg-based)|Fluarix® Quadrivalent by GlaxoSmithKlein, 15µg of HA per strain
88984098|NCT02964923||Olanzapine group|Following the baseline assessment, subjects will enter an open treatment group with Olanzapine(Zyprexa) lasting 6 weeks. The subjects will start with a dose of 5-10mg/d , which would be adjusted to as low as 10 mg/d or as high as 20 mg/d, based on clinical response.And drug dose adjustments must be completed within 1 week.
88984099|NCT02964923||Risperidone group|Following the baseline assessment, subjects will enter an open treatment group with Risperidone oral solution(Risperdal) lasting 6 weeks. The subjects will start with a dose of 1ml/d , which would be adjusted to as low as 4 ml/d or as high as 6 ml/d, based on clinical response.Drug dose adjustments interval is generally not less than 2 days, and should reach a effective dose of 4~6ml/d within 1 week.
89034428|NCT04959279|Experimental|ED-TREAT|EHR-embedded clinical decision support (CDS) tool designed to overcome the challenges to risk assessment and suggest pre-emptive use of behavioral techniques in the emergency setting.
89034429|NCT04959279|No Intervention|Usual Care|
89612119|NCT03722589|Active Comparator|Fluzone (Egg-based)|Fluzone® Quadrivalent by Sanofi Pasteur, 15µg of HA per strain
89612120|NCT03722589|Active Comparator|Fluzone (Egg-based) High-Dose|Fluzone® Trivalent High-Dose by Sanofi Pasteur, 60µg of HA per strain
89612121|NCT04372420|Active Comparator|RhBMP-2|RhBMP-2 belongs to TGF-β super family with osteoinductive property which is capable of promoting bone formation
89612122|NCT04372420|Placebo Comparator|PLATELET RICH FIBRIN|Platelet rich fibrin(PRF) is a healing biomaterial with a great potential for bone and soft tissue regeneration, without any inflammatory reactions
89612123|NCT02244190|Experimental|new Tipranavir + Ritonavir|
89612124|NCT02244190|Active Comparator|current Tipranavir + Ritonavir|
89612125|NCT00954915|Experimental|teplizumab|Anti CD-3 monoclonal antibody
89612126|NCT00926380|Experimental|denosumab ONLY|
89612127|NCT00926380|Experimental|teriparatide (Forteo®) ONLY|
89034430|NCT04957173|Other|Intensive lifestyle intervention|Participants will undergo an intensive lifestyle intervention, implemented virtually by a medical team with expertise in the management of T2DM. This team will be made up of an endocrinologist, a nutritionist and a nurse.
89034431|NCT04956770|Experimental|Rehabilitation supported by TESS|"Patient will be asked to come to the hospital for three types of patient sessions:~Stimulation configuration sessions: TESS protocols will be setup and optimized during this phase.~Duration: minimum 4 sessions over 2 weeks, maximum 20 sessions over a month. In addition, some sessions at a free frequency as needed during rehabilitation will be programed (maximum once a week).~TESS-supported rehabilitation sessions: Patients will undergo an in-clinic rehabilitation training regime supported by TESS.~Duration: 24 sessions spread over minimum three months and maximum five months~Pre- and post-rehabilitation evaluation sessions: four clinical evaluation sessions will take place focusing on assessment of locomotion, balance and PD related deficits."
89034432|NCT04956692|Experimental|Arm A: Pembrolizumab SC + Platinum Doublet Chemotherapy|Participants receive pembrolizumab subcutaneous (SC) administration on Day 1 of each cycle (cycle length = 3 weeks) for up to 35 cycles (up to ~2 years) PLUS paclitaxel IV (on Day 1 of each cycle) OR nab-paclitaxel IV (on Days 1, 8, and 15 of each cycle) and carboplatin IV (on Day 1 of each cycle) for 4 cycles for Squamous NSCLC; PLUS carboplatin IV (on Day 1 of each cycle) Or cisplatin IV (on Day 1 of each cycle) for 4 cycles and pemetrexed IV (on Day 1 of each cycle) until progression, intolerable adverse events, or participant/physician decision for Non-squamous NSCLC.
89034433|NCT04956692|Active Comparator|Arm B: Pembrolizumab IV + Platinum Doublet Chemotherapy|Participants receive pembrolizumab intravenous (IV) administration on Day 1 of each cycle (cycle length = 3 weeks) for up to 35 cycles (up to ~2 years) PLUS paclitaxel IV (on Day 1 of each cycle) OR nab-paclitaxel IV (on Days 1, 8, and 15 of each cycle) and carboplatin IV (on Day 1 of each cycle) for 4 cycles for Squamous NSCLC; PLUS carboplatin IV (on Day 1 of each cycle) Or cisplatin IV (on Day 1 of each cycle) for 4 cycles and pemetrexed IV (on Day 1 of each cycle) until progression, intolerable adverse events, or participant/physician decision for Non-squamous NSCLC.
89034434|NCT04955444|No Intervention|Historical control group|The historical control group underwent a thyroidectomy or parathyroidectomy procedure prior to implementation of the quality improvement bundle.
89034435|NCT04955444|Experimental|Post-implementation group|The post-implementation group will have a thyroidectomy or parathyroidectomy procedure after bundle implementation and will receive care that is enhanced by the quality improvement bundle.
89034436|NCT04950439|Other|Myocardial CT|The investigator will collect the usual clinical history and data. Risk factors and cardiovascular events are identified. A blood sample dedicated to the study and necessary for routine care is taken. The pulse wave velocity and systolic pressure index are measured. A myocardial CT scan coupled with a computed tomography is performed. The patient collects stools at his home, simply conditions them and sends them by mail to the centre, which stores them.
89034437|NCT04946305||Lutathera|Patients administered Lutathera by prescription
89034438|NCT04943588||HCV Negative|"At initial screen, this population will be HCV negative via the diagnostic testing. They will be eligible if they fulfil the following:~over 18 yrs old.~willing to participate~no previous history of therapy with oral medication for chronic HCV infection"
89034439|NCT04943588||HCV Positive with first-line treatment success|At the initial screen, this population (approx. 5000) will be HCV RNA positive and will undergo 12/24 week treatment of sofosbuvir plus daclatasvir. After treatment, their blood sample will show that they have achieved a sustained virological response (SVR) defined as HCV RNA undetectable.
89034440|NCT04943588||HCV positive with first-line treatment failure|At the initial screen, this population (approx. 5000) will be HCV RNA positive and will undergo 12/24 week treatment of sofosbuvir/daclatasvir. After treatment, this proportion of people will NOT achieve an (SVR - defined as HCV RNA undetectable).
89034441|NCT04943588||Cirrhotic Patients|Hepatitis C RNA positive that have cirrhosis
89034442|NCT04922281|Active Comparator|ICM-guided Management|Implantable device that provides accurate daily transmission of cardiac electrical data for arrhythmia detection.
89034443|NCT04922281|Placebo Comparator|Conventional Management|Treating physicians/nurses will be blinded to the AF episodes data from the monitor, but will be provided information on asystole, or ventricular arrhythmia events (for safety).
89034444|NCT04917107|Experimental|Qigong First|Participants in this group will complete the 12-week Qigong intervention first and then the 12-week observation period.
89034445|NCT04917107|Experimental|Observation First|Participants in this group will complete the 12-week observation period first and then the 12-week Qigong intervention.
89034446|NCT04912466|Experimental|IBI322|Singal arm
89034447|NCT04902248|Experimental|Over-the-scope clips|"The OTSC® System Set is an instrument for flexible endoscopy~The OTSC® System Set consists of an applicator cap with a mounted OTSC® clip, thread, thread retriever and a hand wheel for clip release.~The OTSC® clip is delivered by means of an applicator cap mounted to the tip of gastroscopes or colonoscopes. The clip is released by tightening the thread with the hand wheel.~The OTSC® clip for flexible endoscopy is a superelastic Nitinol device for compression and approximation of tissue in the digestive tract"
89034448|NCT04902248|Experimental|angiographic embolization|"The procedure was performed in the angiographic suite and under local anaesthetics to the patient's groin. The celiac and then gastroduodenal artery or the left gastric artery was selectively cannulated depending on ulcer location.~Coils were deposited distal to the bleeding point. Gel foam particles were then packed into the artery and its collaterals. This was followed by further coils deposited in its proximal portion until complete cessation of arterial flow. Our protocol requested empiric embolisation of the artery even in the absence of active contrast extravasation or a pseudoaneurysm."
89057795|NCT01686360|Experimental|Frequency + Avg 50 year old + Mamm Data + Mortality Data|Group receives Gail score in a frequency format as well as information about breast cancer risk for the average 50 year old woman, information about the risks of mammography, risk of breast cancer for the average 50 year old woman, and information about the mortality benefit associated with mammography. (Behavioral: Decision Aid)
89612128|NCT00926380|Experimental|denosumab and teriparatide (Forteo®)|
89034449|NCT04894773|Experimental|Imaginary Resisted Exercises|Handgrip exercises with the imagination of resistance in hand by getting feedback in VR Box will be given as an intervention. Stretching will be given at the beginning and the end of each session. This will include imaginary resistance exercises for handgrip by using Virtual Reality Box. Five types of different resistances will be imagined by patients by watching their own videos in VR box, which will be recorded on day one to make them familiar with the resistive objects and the resistance experienced from them by asking patients to perform 15-15 repetitions of each object. Every imaginary resistance exercise will have 15 repetitions. After performing exercises, the participants will ask to perform Finger-to-Nose Test and Purdue Pegboard Test.
89034450|NCT04894773|Experimental|Physical Resisted Exercises|Handgrip exercises with physical resistance in hand will be given as an intervention. Stretching will be given at the beginning and the end of the session. 5 different types of resistances will be given to patients for making themselves familiarize themselves with the type of resistance applied by each object, that they will experience in further sessions, by asking them to perform 15-15 repetitions of each object. Every physical resistance exercise will have 15 repetitions. After performing exercises, the participants will ask to perform Finger-to-Nose Test and Purdue Pegboard Test.
89034451|NCT04889066|Active Comparator|Durvalumab and standard fSRT|Fractionated stereotactic radiotherapy (fSRT) will be delivered to all previously untreated brain metastases noted at the time of treatment (up to 10 max). All brain metastases will be treated concurrently, 3 fractions total, delivered every other day (~2 times/week) with first cycle of Durvalumab.
89034452|NCT04889066|Experimental|Durvalumab and PULSAR|"Personalized ultra-fractionated stereotactic adaptive radiotherapy (PULSAR), will be delivered to all previously untreated brain metastases noted at the time of treatment (up to 10 max). All brain metastases will be treated concurrently, 3 pulses of radiation total, delivered one pulse monthly with each cycle of Durvalumab."
89034453|NCT04883528|Experimental|Sacubitril/valsartan|"Initial dose for patients randomized to sacubitril/valsartan (LCZ696) will be determined by the blood pressure at the time of randomization. Study treatment will be titrated to the next highest dose (dose level 2 or 3) based on blood pressure at the time of visit 2/titration visit. Dose adjustments are only allowed if indicated per protocol defined criteria and per investigator judgement of safety and tolerability.~Sacubitril/valsartan (LCZ696) tablet with minimum dose 24/26 mg, maximum dose 97/103 mg twice daily administered orally.~Other Name: LCZ696"
89057796|NCT04530266|Active Comparator|Persons with knee osteoarthritis|
89057797|NCT04530266|Placebo Comparator|Healthy controls|
89612129|NCT04366414|Active Comparator|hook breathing removing nose-clip|"It will apply a usual training program for 4 weeks, 4hours and 30 min per week distributed equally over 3 days in the week. In each session, it was performed 8 submaximes-dynamic apnoeas with 3-minute recovery between each one. Then was performed a maximal-dynamic apnoea. To finish the session, was performed a continuous training of free style swimming at moderate effort over 30 minutes.~During that training, only this group will perform an experimental breathing protocol consisted of removing nose-clip previous to surface and then perform hook breathing during 20 seconds. This protocol was applied at the end of each of the 8 submaximes-dynamic apnoeas and after the maximal-dynamic apnoea"
89612130|NCT04366414|Active Comparator|usual breathing (UB)|It will apply a usual training program for 4 weeks, 4hours and 30 min per week distributed equally over 3 days in the week. In each session, it was performed 8 submaximes-dynamic apnoeas with 3-minute recovery between each one. Then was performed a maximal-dynamic apnoea. To finish the session, was performed a continuous training of free style swimming at moderate effort over 30 minutes.
89612131|NCT02244268||Patient with symptomatic of benign prostatic hyperplasia|
89612132|NCT04366492|Other|persons in prison|
89612133|NCT04365946||Complete type|Patients with complete-type intestinal metaplasia
89612134|NCT04365946||Incomplete type|Patients with incomplete-type intestinal metaplasia
89612135|NCT04365946||Controls|Healthy subjects
89612136|NCT03823209|Experimental|Social Network Approach|"Participants will receive brief HIV counseling at baseline visit.~Leaders of social networks will be determined using data from participants. These leaders will then be invited to attend a 5-session small-group training that will teach them how to communicate the benefits of PrEP to their social network members.~All social network members will be asked about intervention exposure at 6- and 15-month followups."
89612137|NCT03823209|Active Comparator|Comparison|Participants will receive brief HIV counseling at baseline visit.
89612138|NCT00870051||AAA patients|Subjects diagnosed with an AAA who are considered candidates for endovascular repair with Endurant Stent Graft, and who meet the inclusion/exclusion criteria are intended to participate in this registry
89612139|NCT03630315|Experimental|Cohort 1 (Low Dose)|Subjects will receive a low dose of OTX-TKI
89612140|NCT03630315|Experimental|Cohort 2 (Middle Dose)|Subjects will receive a middle dose of OTX-TKI.
89612141|NCT03630315|Experimental|Cohort 3 (High Dose)|Subjects will receive a high dose of OTX-TKI.
89612142|NCT03630315|Experimental|Cohort 3 (Anti-VEGF)|Subjects will receive OTX-TKI plus a single anti-VEGF injection
89612143|NCT03630315|Experimental|Cohort 4 (High Dose)|Subjects will receive a high dose of OTX-TKI.
89612144|NCT03630315|Experimental|Cohort 4 (Anti-VEGF)|Subjects will receive OTX-TKI plus a single anti-VEGF injection
89612145|NCT00929344|Experimental|Duloxetine|
89612146|NCT00929344|Experimental|Pregabalin|
89612147|NCT00929344|Placebo Comparator|Placebo|
89612148|NCT03820557|Experimental|Decision Counseling|Patients undergo participation in the DCP prior to an audio-recorded oncology appointment.
89612149|NCT03630159|Experimental|Tisagenlecleucel+Pembrolizumab|
89612150|NCT04371874|No Intervention|Control|Hypertension of patients in the control group was managed with the original protocol including lifestyle by doctors in village clinic.
89612151|NCT04371874|Experimental|Treatment with Ten Dollars Project (TDP)|"Hypertension of patients in the TDP group were managed with the protocol of Ten Dollars Project (TDP) by doctors in village clinic."
89612152|NCT04371796|Experimental|Sintilimab injection|"Drugs: Eligible patients received two doses of intravenous sintilimab (200 mg) every 3 weeks (Q3W). Each infusion time is 30-60min.~Surgery: The patient underwent imaging examinations within 7 days prior to surgery, including chest CT and related metastatic examinations. The patient underwent surgery 6-8 weeks after the first dose."
89612153|NCT02244346||Benign prostatic hyperplasia patients|
89034454|NCT04883528|Placebo Comparator|Placebo|"Initial dose for patients randomized to sacubitril/valsartan matching placebo will be determined by the blood pressure at the time of randomization. Study treatment will be titrated to the next highest dose (dose level 2 or 3) based on blood pressure at the time of visit 2/titration visit. Dose adjustments are only allowed if indicated per protocol defined criteria and per investigator judgement of safety and tolerability.~Sacubitril/valsartan matching placebo with minimum dose matching the 24/26 mg dose, maximum dose matching the 97/103 mg dose, adminstered twice daily orally."
89612154|NCT04365712|Active Comparator|Oscillating saw|Patients treated for hallux valgus with 1st metatarsal osteotomy obtained by common oscillating saw
89612155|NCT04365712|Experimental|Piezoelectric tool|Patients treated for hallux valgus with 1st metatarsal osteotomy obtained by piezoelectric tool
89034455|NCT04883398||Breast cancer survivors|Breast cancer survivors ages 50-70 with AJCC stages 0-3 breast cancer who are at least 1 year post-treatment (including surgery, radiation, and chemotherapy, with or without current endocrine therapy)
89034456|NCT04883398||Healthy controls|Healthy controls ages 50-70 with no history of cancer.
89034457|NCT04870645|Experimental|Diagnostic (advanced MRI)|Patients undergo conventional and advanced MRI over 60 minutes within 14 days before the start of scheduled brain radiation treatment. Patients then undergo 7 additional MRI over 60 minutes each between 4-16 weeks apart. Patients may receive gadolinium and/or iopamidol during MRI scans.
89034458|NCT04868149|Experimental|Laparoscopic ALPPS|Laparoscopic ALPPS procedure
89612156|NCT04376554|Experimental|TBPM-PI-HBr|Healthy subjects meeting eligibility criteria will be sequentially randomized to receive either 600mg TBPM-PI-HBr every 8 hours (PO q8h [±1 hour]) or 500/125mg amoxicillin-clavulanate PO q8h (±1 hour) for 10 days.
89612157|NCT04376554|Active Comparator|amoxicillin-clavulanate|Healthy subjects meeting eligibility criteria will be sequentially randomized to receive either 500/125mg amoxicillin-clavulanate PO q8h (±1 hour) or 600mg TBPM-PI-HBr every 8 hours (PO q8h [±1 hour]) or for 10 days.
89612158|NCT03627741|Experimental|Triamcinolone arm|A concentration of 40 mg/ml of Triamcinolone Acetonide will be used for injections with a total dose of 120 mg of Triamcinolone given per injection. The injections will be performed under ultrasound guidance by a fellowship-trained musculoskeletal radiologist. The injection locations will be left to the discretion of the radiologist with the request to attempt to distribute the drug throughout the tumor. A total of three injections will be performed at six week intervals.
89612159|NCT04371718|Experimental|JKB-122 Low dose|JKB-122 5 mg daily for 104 weeks
89612160|NCT04371718|Experimental|JKB-122 Medium dose|JKB-122, 15 mg daily for 104 weeks
89612161|NCT04371718|Experimental|JKB-122 High dose|JKB-122 35 mg daily for 104 weeks
89612162|NCT04371718|Placebo Comparator|Placebo|Matched placebo, daily for 104 weeks
89612163|NCT03712839||Acquired Brain Injury group with anosognosia|People with presence of an acquired brain damage and cognitive deficits relative to executive functions and memory. To determine the presence of anosognosia, patients must present an overestimation value of their capacities greater than 5 (>5) in the discrepancy index on the Patient Competency Rating Scale (PCRS) (Prigatano et al., 1998).
89612164|NCT03712839||Acquired Brain Injury group without anosognosia|People with presence of an acquired brain damage and cognitive deficits relative to executive functions and memory. These patients must present a score of < 5 on the PCRS Scale.
89612165|NCT03712839||Control group|Healthy participants matched in age, gender and educational level with the others two groups.
89034459|NCT04868149|Active Comparator|Open ALPPS|Open ALPPS procedure
89034460|NCT04867902|Experimental|Positive Psychology-Motivational Interviewing Intervention|Participants will receive a written treatment manual with detailed information about each topic. The intervention consists of 10 weekly phone sessions (30 minutes each). Each session includes a new psychological skill designed to increase positive emotions experienced during physical activity, a motivational skill designed to boost physical activity, and setting a physical activity goal for the next week using information from the Fitbit. A motivational interviewing approach will be used for all topics.
89034461|NCT04864392|Experimental|LNA043 Dosing Regimen A|LNA043 injection to the knee with dosing regimen A
89034462|NCT04864392|Experimental|LNA043 Dosing Regimen B|LNA04 injection to the knee with dosing regimen B
89034463|NCT04864392|Experimental|LNA043 Dosing Regimen C|LNA043 injection to the knee with dosing regimen C
89612166|NCT04376164|No Intervention|control group|was treated without laser intervention
89612167|NCT04376164|Experimental|laser group|received low level laser therapy
89612168|NCT04365322||Severe COVID-19 infection|
89612169|NCT04365322||Light to moderate COVID-19 infection|
89612170|NCT04365322||Cancer patients with COVID-19 infection|
89612171|NCT03719937|Experimental|anterior chest wall weight|moderate to severe ARDS patients in whom prone positioning is contraindicated. Patients will have a 100 g/kg weight placed on the anterior chest wall, while in the supine/semirecumbant position. The weights will be placed on the patients' chest for 120 minutes, and then removed. A number of measurements will be recorded before and after the procedure.
89612172|NCT03626337||Hospital-based cohort|100 mg thiamine provided via intramuscular and/or intravenous injection (Thiamine 100 MG/ML) daily for 3 days
89612173|NCT03626337||Community-based cohort|Sex-, age- and regionally matched comparison group
89612174|NCT02244658|Experimental|rhTPO|rhTPO 1.0 μg/kg·d subcutaneously for 7~14 consecutive days
89612175|NCT02244658|No Intervention|control|no thrombopoietic agents
89612176|NCT03718845||Peer Counselors|Mind-Body Medicine Curriculum
89612177|NCT02982616|Experimental|positive emotion and fatty acid|positive emotion induction combine with 2.g Dodecanoic acid intragastric infusion
89612178|NCT02982616|Experimental|neutral emotion and fatty acid|neutral emotion induction combine with 2.g Dodecanoic acid intragastric infusion
89034464|NCT04864392|Experimental|LNA043 Dosing Regimen D|LNA043 injection to the knee with dosing regimen D
89034465|NCT04864392|Placebo Comparator|Placebo|Injection to the knee
89034466|NCT04855396||Patients with Severe Traumatic Brain Injury|Participants will be enrolled in the HOBIT trial
89034467|NCT04854980||Experimental:|Blood Sample Taken
89034468|NCT04839952|Experimental|Healthy Lifestyles Intervention Arm|Participants will receive the healthy lifestyles intervention.
89034469|NCT04839952|Active Comparator|Education-Only Control Arm|Participants will receive the education-only intervention.
89612179|NCT02982616|Experimental|positive emotion and saline|positive emotion induction combine with saline intragastric infusion
89612180|NCT02982616|Placebo Comparator|neutral emotion and saline|neutral emotion induction combine with saline intragastric infusion
89612181|NCT04403841|Other|Intervention|The intervention of group education on type 2 diabetes, including, in addition to usual diabetes care
89612182|NCT04403841|Other|Control|Patients meeting the inclusion criteria assigned to usual diabetes care alone
89612183|NCT03624621|Experimental|Functional Remediation + CCT|12 sessions (1 per week) of group functional remediation program (90 min/session) plus 20 min of tailored computerized cognitive training (CCT)
89612184|NCT03624621|Placebo Comparator|Psychoeducation + Online Games|12 sessions (1 per week) of psychoeducation for major depression (90 min/session) plus 20 min of playing freely with online games (pre-selected by investigators)
89612185|NCT03624621|No Intervention|Treatment as usual|Usual intervention supervised by their psychiatrist
89612186|NCT00929500|Experimental|MAST program|Mixed Aerobic and Strength Training program (MAST): Each exercise session consisted of 10 minutes of warm-up, 15-30 minutes of interval aerobic training by cycle ergometer according to the program, 20 minutes of strength training exercises, and 10 minutes of cool-down by stretching.
89612187|NCT00929500|No Intervention|UC|Usual Care (UC) with Educational Lectures: No exercise sessions.
89612188|NCT03816111|Experimental|TEACH-PD Training Curriculum|All patients at sites randomized to this arm will receive the TEACH-PD Training Curriculum
89612189|NCT03816111|Active Comparator|Current Standard PD Training|All patients at sites randomized to this arm will receive the unit's current PD training materials and plan
89612190|NCT00929578|Placebo Comparator|Placebo|The sterile placebo: Bacteriostatic Sodium Chloride for Injection.
89612191|NCT00929578|Active Comparator|Fluphenazine|This will be an ascending dose study with the first cohort of 5 subjects dosed at 100 µg/mL, followed by cohorts at 500 and 2500 µg/mL. Dosing will be on Days 0, 7 and 14 and will consist of 5, or 10, 100 µL injections into the psoriatic lesion. The number of injections will depend on the lesion size. As this is a vehicle controlled study, subjects will receive intralesional injections of both drug and placebo, each into a separate target plaque, in a randomized fashion.
89612192|NCT04371484||children from 0 to 5 years old, hospitalized|
89612193|NCT02244736||Controls|Subjects with no family history of diabetes mellitus and normal OGTT
89612194|NCT02244736||Relatives|First-degree relatives of patients with diabetes mellitus and normal OGTT
89612195|NCT02244736||Diabetics|Subjects with abnormal OGTT
89612196|NCT04371016|Experimental|Verticalization group|"After checking the availability of the bed dedicated to verticalization (Total Lift Bed™, VitalGo Systems, Inc., Arjo AB), the inclusion and non-inclusion criteria, as well as the morphology of lung injury, the patient is included. The following procedures are performed :~insertion of an esophageal balloon catheter (Nutrivent®, Sidam)~installation of an EIT belt in the 4th or 5th intercostal space (Pulmovista® 500, Dräger)~insertion of a Swan-Ganz catheter~continuous recording of digital and analogic data~After collecting initial data from the patient in a strict lying position at 0°, successive 30-minutes position steps at 30°, 60° and 90° will be performed. At the end of the 30 minutes, and for each step, all the data is collected."
89612197|NCT04371406|Experimental|Experimental Arm|Hydroxychloroquine sulfate (PLAQUENIL®), 200mg x 3 /d, for 10 days AND Azithromycin (ZITHROMAX®), 500mg on D1 and then 250mg/d for the next 4 days, in addition to standard of care
89612198|NCT04371406|Sham Comparator|Control Arm|Dietetary supplement, Azinc form and vitality®, 2 capsules per day, for 10 days, in addition to standard of care
89612199|NCT04370938|Experimental|Coping strategies video|Individuals will be asked to watch a 1 hour long video that discusses strategies helpful in coping with stress during the COVID-19 pandemic.
89612200|NCT04370938|No Intervention|Control|No additional requests will be made of individuals in the control arm.
89612201|NCT03716739|Active Comparator|Treatment Arm|Weekly IM administration of 100 mg testosterone cypionate for 12 weeks.
89612202|NCT03716739|Placebo Comparator|Control Arm|Weekly IM administration of placebo for 12 weeks.
89612203|NCT00927160||MACE group|Elderly patients admitted to the Mobile Acute Care of the Elderly Unit.
89612204|NCT00927160||Usual Care group|Elderly patients admitted to the general medicine service in the hospital
89612205|NCT03716661|No Intervention|Control|Arm 1/control group: Participants who are treated with conservative plaster following National Clinical Guidelines.
89612206|NCT03716661|No Intervention|Conservative|"Arm 2 and 3 consist of participants fulfilling the criteria for operative treatment following National Clinical Guidelines.~Arm 2: Patients randomized to conservative plaster treatment"
89612207|NCT03716661|Other|Operative|"Arm 2 and 3 consist of participants fulfilling the criteria for operative treatment following National Clinical Guidelines.~Arm 3: Patients randomized to operative treatment (ORIF)"
89612208|NCT02245204|Experimental|Chlorgenic acid, Treatment, powder|Chlorogenic acid for injection(30mg/bottle) is white or off-white freeze-dried lump or powder,it can be easily dissolved in water, which solubility is 20%.
88984100|NCT02964923||Ziprasidone group|Following the baseline assessment, subjects will enter an open treatment group with Ziprasidone Hydrochloride Capsules(Zeldox) lasting 6 weeks. They started with a dose of 40mg/d , which would be adjusted to as low as 80mg/d or as high as 160/d, based on clinical response.Drug dose adjustments interval is generally not less than 2 days, and should reach a effective dose of 80~160mg/d within 10 days.
88984101|NCT02964936|Experimental|ASP1517 Low dose group|Study drug will be dosed three times weekly for 24 weeks and dose adjustments will be made during the study.
89612209|NCT03611907|Active Comparator|SL1(Cook® Single Lumen)|Oocyte retrieval with only aspiration system
89612210|NCT03611907|Active Comparator|DL1 (Cook® EchoTip® Double Lumen)|Oocyte retrieval with aspiration and flushing system
89612211|NCT04365010|Experimental|Sodium Bicarbonate Ringer's Injection|"administration route and dosage：Intravenous infusion, 500~1000 ml/time. The dosage can be increased or decreased according to the age, weight and symptoms.~rate: according to the the routine rate of fluid resuscitation of septic shock in the ICUs of Zhongda Hospital, School of Medicine, Southeast University."
88984102|NCT02964936|Experimental|ASP1517 High dose group|Study drug will be dosed three times weekly for 24 weeks and dose adjustments will be made during the study.
89612212|NCT04365010|Active Comparator|0.9% Sodium Chloride Injection|"administration route and dosage：Intravenous infusion, 500~1000 ml/time. The dosage can be increased or decreased according to the age, weight and symptoms.~rate: according to the the routine rate of fluid resuscitation of septic shock in the ICUs of Zhongda Hospital, School of Medicine, Southeast University."
89612213|NCT03609801|Experimental|ACTV|"Achieving Change Through Values-Based Behavior (ACTV) - pronounced ACTIVE - is a new Batterers Intervention Program (BIP) for domestic violence offenders. ACTV was developed as a collaboration between researchers, practitioners, and the criminal justice system in the state of Iowa (Zarling, Lawrence, Oregno, 2017). It is based on Acceptance and Commitment Therapy (ACT; Hayes, Strosahl, & Wilson, 1999), which is an evidence-based cognitive-behavioral psychotherapy. ACTV is an innovative BIP in two primary ways; first, ACTV applies the ACT model to the treatment of domestic violence, and second, ACTV is specifically designed for use in the correctional setting as part of criminal justice programming."
89612214|NCT03609801|Active Comparator|The Duluth Model|The Duluth Model Men's Nonviolence Classes is the most widely used BIP. The Duluth Model is based on the premise that domestic abuse happens when men believe they have the right to authority over women who are their intimate partners. The Duluth Model's Men's Nonviolence Classes (The Duluth Model for short) help men stop battering and explore the consequences of the violence for themselves, their partner and their children.
89612215|NCT02244814|Experimental|Choosing Healthy Options in Carbohydrate Energy|60% carbohydrate/25% fat/15% protein diet
89612216|NCT02244814|Active Comparator|Low Carbohydrate/Conventional|40% carbohydrate/45% fat/15% protein
89612217|NCT03707691|Experimental|Cochlear implant users|In both arms a pitch training protocol and a visuo-spatial training protocol are applied.
89612218|NCT03707691|Experimental|Participants with Congenital Amusia|In both arms a pitch training protocol and a visuo-spatial training protocol are applied.
89612219|NCT03707691|Experimental|Control Participants|
89612220|NCT02156908|Experimental|D-serine|D-serine
89612221|NCT04763265|Active Comparator|Group A (n=100): BoNT/A-DP (20 U, 0.5 mL)|"The injection sites should be prepared according to standard clinical procedures..~A volume of 0.5 mL of the properly reconstituted BoNT/A-DP should be drawn into the sterile syringe and any air bubbles in the syringe barrel expelled. The needle used to reconstitute the product should be removed and replaced with a sterile insulin or tuberculin-type syringe of 1 mL volume with 0.01 mL graduation and with the gauge range of 30 to 33 G, which the investigator routinely uses for toxin administration.~Each subject will receive a total of five i.m. injections of 4 U/0.1 mL (total of 20 U)."
89612222|NCT04763265|Active Comparator|Group B (n=100): Botox Cosmetic (20 U, 0.5 mL)|"The injection sites should be prepared according to standard clinical procedures.~A volume of 0.5 mL of the properly reconstituted Botox Cosmetic should be drawn into the sterile syringe and any air bubbles in the syringe barrel expelled. The needle used to reconstitute the product should be removed and replaced with a sterile insulin or tuberculin-type syringe of 1 mL volume with 0.01 mL graduation and with the gauge range of 30 to 33 G, which the investigator routinely uses for toxin administration.~Each subject will receive a total of five i.m. injections of 4 U/0.1 mL (total of 20 U)."
89612223|NCT02244970|Experimental|Mindfulness|Subjects are scheduled to receive a 7-week group mindfulness-based intervention (MBI) program.
89612224|NCT02244970|Active Comparator|Psychoeducation|Subjects will receive 7 weeks of group-based psychoeducation as an active comparison group parallel to the mindfulness group.
89612225|NCT00004143|Experimental|Campath SCT for hemoglobinopathies|Campath, Chemo and/or TBI Allo SCT
89612226|NCT00004143|Experimental|Campath SCT for Bone Marrow Failure|Campath, Chemo and/or TBI Allo SCT
89612227|NCT04364542|Experimental|Suprascapular nerve block (SSNB)|Single shot using the blind block technique with 10 ml 0.75% ropivacaine and arthroscopic portals infiltration with 5 ml 0.75% diluted in 15 ml of distilled water.
89612228|NCT04364542|Active Comparator|Interscalene Nerve Block (ISB)|Single shot using US-guided interscalene brachial plexus block with 15 ml 0.5% ropivacaine and arthroscopic portals infiltration with 5 ml 0.75% diluted in 15 ml of distilled water.
89612229|NCT03705429|Active Comparator|TC-H Chemotherapy|Docetaxel 75 mg/m2, Cyclophosphamide 600 mg/m2 and Trastuzumab 8 mg/kg followed by 6 mg/kg Day 1 every 21 days for 4 cycles. Trastuzumab 6 mg/kg Day 1 every 21 days to complete 1 year of Trastuzumab therapy.
89612230|NCT03705429|Placebo Comparator|Paclitaxel(P) + Trastuzumab(T)|Paclitaxel 80 mg/m2 weekly for 12 weeks and Trastuzumab 8 mg/kg followed by 6 mg/kg Day 1 every 21 days for 4 cycles. Trastuzumab 6 mg/kg Day 1 every 21 days to complete 1 year of Trastuzumab therapy. Alternatively Trastuzumab 4 mg/kg followed by 2 mg/kg weekly to complete 1 year of treatment can be used.
89612231|NCT04370782|Experimental|Experimental Arm 1|"Hydroxychloroquine~Azithromycin~Zinc sulfate"
89612232|NCT04370782|Experimental|Experimental Arm 2|"Hydroxychloroquine~Doxycycline~Zinc sulfate"
89612233|NCT03604653||Stomach|Heated Intraperitoneal Chemotherapy with Mitomycin C 30mg at time 0, 10mg at time 45 minutes, CDDP Cisplatin 50mg/m2@ time 0
89612234|NCT03604653||Colorectal, Appendiceal, Pseudomyxoma Peritonei|Heated Intraperitoneal Chemotherapy with Mitomycin C 30mg at time 0, 10mg at time 45 minutes
89612235|NCT03604653||Primary Peritoneal|Heated Intraperitoneal Chemotherapy with CDDP Cisplatin 50mg/m2 at time 0, Doxorubicin 15mg/m2 at time 0
89612236|NCT03604653||Ovarian, Cervical, Uterine, Fallopian Tube|Heated Intraperitoneal Chemotherapy with CDDP Cisplatin 75mg/m2 at time 0
89612237|NCT04376320|Active Comparator|Group 1(ceramic membrane)|using customized ceramic membranes for augmentation of vertical mandibular ridge defects in preparation for implant placement
89612238|NCT04376320|Active Comparator|Group 2 (modified sausage technique)|using tenting titanium screws in conjunction with particulate bone graft and collagen membrane (modified sausage technique) for augmentation of vertical mandibular ridge defects in preparation for implant placement
89612239|NCT04376086|Active Comparator|General anesthesia|Patients will receive general anesthesia
89612240|NCT04376086|Experimental|Epidural anesthesia|Patients will receive epidural anesthesia
89612241|NCT04375852|Experimental|1|consecutive cases diagnosed with APS-1associated keratitis
89612242|NCT03805659|Experimental|HD-tDCS, then Sham|Subjects receive High Dose transcranial Direct Current Stimulation (HD-tDCS) lasting 20 minutes at an electric current intensity of up to 2mA in the left posterior temporo-parietal cortex (TPC). Stimulation sessions are delivered once a day (QD) for a total of 10 sessions over 2 weeks (Monday-Friday). After a washout period of 16 weeks, subjects receive Sham sessions (no electric current) once a day (QD) for a total of 10 sessions over 2 weeks (Monday-Friday).
89612243|NCT03805659|Experimental|Sham, then HD-tDCS|Subjects receive Sham sessions (no electric current) once a day (QD) for a total of 10 sessions over 2 weeks (Monday-Friday). After a washout period of 16 weeks, subjects receive High Dose transcranial Direct Current Stimulation (HD-tDCS) lasting 20 minutes at an electric current intensity of up to 2mA in the left posterior temporo-parietal cortex (TPC). Stimulation sessions are delivered once a day (QD) for a total of 10 sessions over 2 weeks (Monday-Friday).
89612244|NCT03603795|Experimental|A|"55 patients will be randomized in the experimental arm A. If platelets counts < 100 x 10 Giga/L, patients will be treated with Eltrombopag 200 mg/day per os from day 11 of induction chemotherapy to platelets counts > 100 x 10 Giga/L or maximum to day 45. If platelets counts ≥ 100 x 10 Giga/L on day 11, the start of IP will be delayed until platelets < 100 x 10 Giga/L.~Chemotherapy administration would be performed among standard practice:~Daunorubicin: 60 mg/m² D1 to D3~Cytarabine: 100 mg/m²/day, in a continuous 24h-IV infusion D1 to D7~Lomustine (CCNU): 200 mg/m² per os, at D1.~200mg = 4 Tablets of 50 mg will be done more than 2 hours before Daunorubicin and cytarabine administrations, to avoid vomiting secondary to anthracycline administration.~Investigational Product (IP) will be taken at the same time daily on an empty stomach 1 hour before or 2 hours after a meal or preferably no calcium or dairy products."
89612245|NCT03603795|Placebo Comparator|B|"55 patients will be randomized in the comparator arm B and will received: Placebo once daily from day 11 of induction chemotherapy to AML response evaluation or platelets count > 100 x 10 Giga/L (maximum day 45)~Placebo 200mg = 4 Tablets of 50 mg will be done more than 2 hours before Daunorubicin and cytarabine administrations, to avoid vomiting secondary to anthracycline administration.~Chemotherapy administration would be performed among standard practice:~Daunorubicin: 60 mg/m² D1 to D3~Cytarabine: 100 mg/m²/day, in a continuous 24h-IV infusion D1 to D7~Lomustine (CCNU): 200 mg/m² per os, at D1."
89034478|NCT04825587|Experimental|Concomitant ACL and ALL reconstruction|The participant will undergo both the ACL and ALL reconstruction surgery.
89612246|NCT04370314|Experimental|Zirconia implant-supported crown|Full zirconia implant-supported crown
89612247|NCT04364464|Experimental|Riociguat, healthy participants|Participants with creatinine clearance (CLCR) >80 mL/min received a single dose of 1 mg (2 x 0.5 mg IR tablet) of riociguat in the fasted state
89034479|NCT04825587|Experimental|ACL reconstruction alone|The participant will undergo only ACL reconstruction surgery.
89612248|NCT04364464|Experimental|Riociguat, mild renal impairment|Participants with CLCR 50-80 mL/min received a single dose of 1 mg (2 x 0.5 mg IR tablet) of riociguat in the fasted state
89612249|NCT04364464|Experimental|Riociguat, moderate renal impairment|Participants with CLCR 30-<50 mL/min received a single dose of 1 mg (2 x 0.5 mg IR tablet) of riociguat in the fasted state
89612250|NCT04364464|Experimental|Riociguat, severe renal impairment|Participants with CLCR <30 mL/min received a single dose of 1 mg (2 x 0.5 mg IR tablet) of riociguat in the fasted state
89034480|NCT04824911|Experimental|Intervention group|"This group will receive dual antiplatelet and high-intensity statin treatment.~Dual antiplatelet treatment: loading of clopidogrel 300mg plus aspirin 300mg, followed by clopidogrel 75 mg/day and aspirin 100 mg/d from day 2 to day 21, and followed by clopidogrel 75 mg/d or aspirin 100 mg/d from day 15 to day 90.~High-intensity statin treatment: Atorvastatin 40-80mg/day or Rosuvastatin 20 mg/day for 90 days."
89034481|NCT04824911|Active Comparator|Historical control|A historical control group of patients receiving single antiplatelet therapy but no high-intensity statin treatment will be drawn from previous prospective observation studies. Antiplatelet therapy includes aspirin(100-300mg/day) or Clopidopgrel (75mg/day).
89034482|NCT04821544|No Intervention|Control|Control group will receive link to a free 8-week Mindfulness Based Stress Reduction intervention AFTER the 8-weel trial period.
89034483|NCT04821544|Experimental|Mindfulness-based intervention (with a focus on self-compassion; MBSC)|8-week MBSC intervention with a focus on increasing self-compassion. The MBSC program includes previously developed daily mindfulness practices, guided meditations, routine mindfulness prompts, and four video conference group sessions with a certified mindfulness facilitator.
89034484|NCT04818489|Experimental|Colchicine group|Colchicine 0.5 mg (2 tablets: 1 mg) twice per day as a loading dose, followed by one tablet 0.5 twice per day for three weeks in addition to the local standard protocol of COVID19 management
89612251|NCT04746885|Other|Group A|(interventional group/ DHA): A minimum of 40 preterm infants will be included to receive 100mg DHA daily administered by enteral route for 30 days. This group will be subdivided into breast fed / artificially fed infants.
89612252|NCT04746885|Other|Group B|(control group / Placebo): 40 of preterm infant controls will be included to receive placebo (physically matched solution). This group will be subdivided into breast fed / artificially fed infants.
89612253|NCT04375774|Other|FFP2|
89612254|NCT04375774|Other|Facial mask|
89612255|NCT04375774|Other|Modified full-face snorkeling|
89612256|NCT03700047|Experimental|GAL1704 (needle)|Subjects randomized (2:1) to GAL1704 or Control for cheek augmentation and the correction of midface contour deficiencies.
89612257|NCT03700047|Experimental|GAL1704 (cannula/needle)|GAL1704 treatment using a split face design - one cheek treated using cannula and the other cheek treated using needle.
89612258|NCT03700047|Active Comparator|Juvederm Voluma|Subjects randomized to control.
89612259|NCT00924040|Experimental|BL22 Immunotherapy|30 micrograms/kg intravenous over 30 minutes every other day (QOD) on days 1, 3, 5, of a 4 week cycle (at least 26 days) for a maximum of 16 cycles or until they become ineligible.
89612260|NCT04363996|Experimental|New Bioactive Restorative Material|Activa Presto Bioactive restorative material
89612261|NCT04363996|Active Comparator|Resin Modified Glass Ionomer|Fuji II
89612262|NCT04363918|Active Comparator|intervention (IG1)|
89612263|NCT04363918|Active Comparator|intervention (MyoStim group)|
89612264|NCT04363918|Sham Comparator|control (CG)|
89612265|NCT03598413|No Intervention|Control|Patients undergoing standard laparoscopic colorectal resection with no omega-3 enriched peri-operative nutritional support
89612266|NCT03598413|Experimental|Omega-3|Patients in this group will receive 7 days pre and 7 days post surgery of a nutritional supplement enriched with 1.42g/dose of the fish oils EPA and DHA. The supplement is pre-mixed and will be taken twice daily for a total of 14 days.
89612267|NCT01592240|Experimental|Q28d Dosing Arm|A total of 7 dose groups in two dosing schedules, 50 subjects per dose group are planned. Q28d dose group will receive subcutaneous administration of PF-04950615 or Placebo once a month.
89612268|NCT01592240|Experimental|Q14d Dosing Arm|A total of 7 dose groups in two dosing schedules, 50 subjects per dose group are planned. Q14d dose group will receive subcutaneous administration of PF-04950615 or Placebo every 2 weeks.
89612269|NCT05620654|Experimental|Hyperthermic Intraperitoneal Paclitaxel Combined With Cisplatin|Patients with ovarian cancer receive hyperthermic intraperitoneal paclitaxel combined with a fixed dose of cisplatin (75mg/m2)
89612270|NCT04357834||Smartwatch group|
89612271|NCT04357522|Experimental|experimental group|Received Vaccine: 15-valent pneumococcal Conjugate Vaccine(experimental vaccine), 0.5 ml/dose
89612272|NCT04357522|Active Comparator|Positive control group|Received Vaccine: 13-valent pneumococcal Conjugate Vaccine(positive control vaccine), 0.5 ml/dose
89612273|NCT00937378|Experimental|SER120|
89612274|NCT00937378|Placebo Comparator|Placebo|
89612275|NCT00005901|Active Comparator|Pamidronate every 3 months for 3 years|Subjects who received Pamidronate every 3 months for 3 years.
89612276|NCT00005901|Active Comparator|Pamidronate every 6 months for 3 years|Subjects who received Pamidronate every 6 months for 3 years.
89612277|NCT04369768|Active Comparator|direct composite restorations|
89612278|NCT04369768|Active Comparator|preformed metal crowns|
89612279|NCT03800199|Experimental|Perceptive Rehabilitation (PR-group)|Perceptive rehabilitation group will receive a treatment that, as described by on Paolucci et al. (2015). This treatment will include small latex cones with different resistance. In each session there will be over 100 cones will be placed on a rigid wood with using elastic strips. The patient will be asked to lie down supine on the material. Patients weigh will create pressure and reaction force to his/her body. Treatments will be 2 times a week till 8 weeks. There will be in total 16 sessions.
89612280|NCT04369534|Active Comparator|First group|The patients randomized into the first group will be given the newer P2Y12 receptor inhibitor ticagrelor during the 12 months.
89612281|NCT04369534|Active Comparator|Second group|The second group of patients will be given ticagrelor initially, and after the first 30 days it will be replaced with clopidogrel, that will be given for the remaining time period (up to 12 months). Clopidogrel dosing will be modified according to the results of the aggregometry using the ADP test.
89612282|NCT03590457|Other|High-Flow/Swallow|All participants will be subjected to all three flows randomly. All participants will be asked swallow water and applesauce
88984103|NCT00094523|Experimental|Treatment Arm A|Subjects switched their baseline PI for fosamprenavir (± ritonavir) while maintaining their baseline regimen of two nucleoside or nucleotide reverse transcriptase inhibitors for 48 weeks.
88984104|NCT00094523|Experimental|Treatment Arm B|Subjects continued baseline regimen for first 24 weeks with the option of switching their initial PI for fosamprenavir (± ritonavir) while maintaining their baseline nucleoside or nucleotide reverse transcriptase inhibitor regimen for another 24 weeks
88984105|NCT01054885|Experimental|Fluticasone Furoate Inhalation Powder|Inhaled Corticosteroid (ICS)
88984106|NCT01054885|Experimental|FF Inhalation Pwdr|Inhaled Corticosteroid (ICS)
88984107|NCT01054885|Experimental|Fluticasone Furoate/GW642444 Inhalation Powder|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
88984108|NCT01054885|Experimental|FF/GW642444 Inhalation Pwdr|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
88984109|NCT01054885|Experimental|GW642444 Inhalation Powder|Long Acting Beta Agonist(LABA)
88984110|NCT01054885|Placebo Comparator|Placebo|Placebo
88984111|NCT00428779|Experimental|1|patients running during 24 hours without sleep
88984112|NCT00428779|Placebo Comparator|2|patients without sleep during 24 hours
88984113|NCT05426967|Experimental|Arm 1|Active rTMS/Individualized Connectome Targeting (ICT)/Bilateral/Standard rTMS protocol
88984114|NCT05426967|Experimental|Arm 2|Active rTMS/ICT/Bilateral/Theta Burst Stimulation (TBS) rTMS protocol
88984115|NCT05426967|Experimental|Arm 3|Active rTMS/ICT/Unilateral/Standard rTMS protocol
89612283|NCT04363762|Experimental|Internet-based multimodal pain program|The iMPP is based on CBT and self-management principles that help patient cope with chronic TMD pain. The iMPP translates a face-to-face therapy to a software platform program.
89612284|NCT04363762|Active Comparator|Occlusal splint|Participants randomized to active control received a hard Michigan-type stabilization splint placed in the upper jaw by one of two calibrated general dentists {Ramfjord, 1994 #276}. The occlusal splint was chosen as the control treatment because it is a conventional and reversible treatment of TMD pain, and it has a known moderate efficacy {Welfare, 2011 #266}.
89612285|NCT04763187|Active Comparator|Control group|Lower molar extraction and filling of post-extraction alveolus with hemostatic sponge containing gentamicin.
88984116|NCT05426967|Experimental|Arm 4|Active rTMS/ICT/Unilateral/TBS rTMS protocol
88984117|NCT05426967|Experimental|Arm 5|Active rTMS/Structural targeting/Bilateral/Standard rTMS protocol
88984118|NCT05426967|Experimental|Arm 6|Active rTMS/Structural targeting/Bilateral/TBS rTMS protocol
88984119|NCT05426967|Experimental|Arm 7|Active rTMS/Structural targeting/Unilateral/Standard rTMS protocol
88984120|NCT05426967|Experimental|Arm 8|Active rTMS/Structural targeting/Unilateral/TBS rTMS protocol
88984121|NCT05426967|Experimental|Arm 9|Active rTMS/Scalp targeting/Bilateral/Standard rTMS protocol
88984122|NCT05426967|Experimental|Arm 10|Active rTMS/Scalp targeting/Bilateral/TBS rTMS protocol
88984123|NCT05426967|Experimental|Arm 11|Active rTMS/Scalp targeting/Unilateral/Standard rTMS protocol
88984124|NCT05426967|Experimental|Arm 12|Active rTMS/Scalp targeting/Unilateral/TBS rTMS protocol
88984125|NCT05426967|Sham Comparator|Sham 1|Sham rTMS/Scalp targeting/Bilateral laterality/Standard rTMS protocol
88984126|NCT05426967|Sham Comparator|Sham 2|Sham rTMS/Scalp targeting/Bilateral laterality/TBS rTMS protocol
88984127|NCT05426967|Sham Comparator|Sham 3|Sham rTMS/Scalp targeting/Unilateral/Standard rTMS protocol
88984128|NCT05426967|Sham Comparator|Sham 4|Sham rTMS/Scalp targeting/Unilateral/TBS rTMS protocol
88984129|NCT01054846|Experimental|Helmet and helmet education|Each participant preschool child received a free bicycle Bell helmet, manufactured by Bell Sports Inc., Rantoul IL, USA. In addition, classroom bicycle helmet education was provided to all participant children and their caregivers, consisting of a video on rules of biking and the importance of proper helmet use and a classroom melon drop demonstration with and without a helmet to participants and their caregivers.
88984130|NCT01054846|Active Comparator|Helmet education|Each child did not receive a bicycle Bell helmet but the child and his/her caregiver was given bicycle helmet education package as above.
88984131|NCT02415309|Active Comparator|2 mg Melatonin|To remain within the doses used for anxiolytic effects in past studies, we plan to study the effects of 2mg melatonin.
88984132|NCT02415309|Active Comparator|10 mg Melatonin|To remain within the doses used for anxiolytic effects in past studies, we plan to study the effects of 10mg melatonin.
88984133|NCT02415309|Placebo Comparator|Sugar Pill|To remain within the doses used for anxiolytic effects in past studies, we plan to study the effects of two different levels of melatonin versus placebo as premedication in patients undergoing a lumbar medial branch block (LMBB) procedure.
88984134|NCT00094679|Active Comparator|2hrs daily patching|2 hours patching per day to cover the sound eye
88984135|NCT00094679|Active Comparator|6hrs daily patching|6 hours per day patching to cover the sound eye
88984136|NCT00094718|Experimental|1|One subcutaneous vaccination with WN/DEN4-3'delta30 vaccine (10^3 PFU dose) into the deltoid region of either arm.
88984137|NCT00094718|Experimental|2|One subcutaneous vaccination with WN/DEN4-3'delta30 vaccine (10^4 PFU dose) into the deltoid region of either arm. This arm may enroll after the results from Arm 1 are analyzed.
88984138|NCT00094718|Experimental|3|One subcutaneous vaccination with WN/DEN4-3'delta30 vaccine (10^5 PFU dose) into the deltoid region of either arm. This arm may enroll after the results from Arm 2 are analyzed.
88984139|NCT00094718|Placebo Comparator|4|One subcutaneous vaccination with placebo vaccine into the deltoid region of either arm.
88984140|NCT02077725||Interdisciplinary polypharmacy clinic|Patients will be seen in the interdisciplinary polypharmacy clinic for a complete comprehensive medication review
88984141|NCT00403377|Experimental|Intervention|Phase II include two arms. In the intervention arm, photographs are taken of the participants and they then receive sunscreen lotion and sunless tanning lotion and instructions and benefits for using both. Participants also receive an educational pamphlet regarding skin cancer.
88984142|NCT00403377|No Intervention|Control|Phase II include two arms. In the control arm, a souvenir photograph is taken of the participants and they then receive product samples that are irrelevant to skin cancer risk reduction (e.g., skin moisturizer, hair gel, chewing gum). Participants also receive educational materials at the completion of the study.
88984143|NCT01054729|Experimental|Sofosbuvir 100 mg+PEG+RBV|Participants received sofosbuvir 100 mg (1 x 100 mg tablet) and placebo to match sofosbuvir (3 tablets) for 28 days (baseline to Day 28), plus PEG+RBV (baseline to Week 48)
88984144|NCT01054729|Experimental|Sofosbuvir 200 mg+PEG+RBV|Participants received sofosbuvir 200 mg (2 x 100 mg tablets) and placebo to match sofosbuvir (2 tablets) for 28 days (baseline to Day 28), plus PEG+RBV (baseline to Week 48)
88984145|NCT01054729|Experimental|Sofosbuvir 400 mg+PEG+RBV|Participants received sofosbuvir 400 mg (4 x 100 mg tablets) for 28 days (baseline to Day 28), plus PEG+RBV (baseline to Week 48)
88984146|NCT01054729|Active Comparator|Placebo+PEG+RBV|Participants received placebo to match sofosbuvir (4 tablets) for 28 days (baseline to Day 28), plus PEG+RBV (baseline to Week 48)
88984147|NCT00403611|Active Comparator|Praziquantel 40mg/kg|Praziquantel (Distocide) 40mg/kg single oral dose
88984148|NCT00403611|Experimental|Praziquantel 60mg/kg|Praziquantel (Distocide) 60mg/kg single oral dose
88984149|NCT00428896|Experimental|1|ZD1839
88984150|NCT00428935|Experimental|Low Dose|Low dose cohort - 2.0E10 vg/kg
88984151|NCT00428935|Experimental|High Dose|High Dose - 1.0E11 vg/kg
88984152|NCT01990911|Experimental|Renal denervation|Renal denervation: both renal arteries are denervated by applying radio-frequency energy at application points moving in a helical fashion starting in the distal renal artery and moving to the proximal junction with the abdominal aorta.
88984153|NCT01990911|Sham Comparator|Medical therapy|This group will not receive renal sympathetic denervation
88984154|NCT00429013|No Intervention|2|no medical device
88984155|NCT00429013|Experimental|1|medical device
88984156|NCT00429091|Placebo Comparator|1|
88984157|NCT00429091|Experimental|2|
88984158|NCT00429091|Active Comparator|3|
88984159|NCT05261178||Upper extremity amputation patients using myoelectric controlled prosthesis|20 patients aged 18-65 years with upper extremity amputation and using myoelectric controlled arm prosthesis for at least 3 months
88984160|NCT04704388||patients hospitalized in intensive care units for SARS-CoV-2|patients hospitalized in intensive care units for SARS-CoV-2
88984161|NCT04704388||patients hospitalized outside intensive care units|patients hospitalized outside intensive care units
88984162|NCT04704739|Experimental|GLPG1205 oral and [14C]-GLPG1205 IV|Single oral dose of GLPG1205 followed by [14C]-GLPG1205 solution for infusion
88984163|NCT04704739|Experimental|[14C]-GLPG1205 capsule|Single oral dose of GLPG1205 as solid formulation
88984164|NCT04704427|Experimental|Rehabilitative BCI training|The experimental group will receive brain computer interface-based lower limb function training (BCI-LLT), 30 minutes/time, 5 times/week, with a 4-week training period.. The training using the lower limb orthosis targeted the patient's ability to walk.
88984165|NCT04704427|Active Comparator|Traditional physical therapy protocol|The control group will only receive traditional physical therapy protocol. The traditional physical therapy protocol of lower limb conducted with the same treatment frequency, intensity and duration of treatment, including muscle strength training, balance training and walking training, etc.
88984166|NCT05244369|Active Comparator|Acupuncture+TENS group|Acupuncture application twice a week - a total of 8 sessions, and rehabilitation program consisting of joint range of motion, stretching and strengthening exercises for 30 minutes for 5 days a week for 4 weeks, current frequency 60-100 Hz to stump tip, impulse duration 100 microseconds transcutaneous electrical nerve stimulation (TENS) will be applied.
89034485|NCT04818489|Placebo Comparator|Control group|the local standard protocol of COVID19 management
89034486|NCT04803474||Klinefelter|Patients with Klinefelter syndrome
89612286|NCT04763187|Experimental|PRGF group|Post-extraction alveolus is filled with PRGF.
89612287|NCT04763187|Experimental|PRF group|Post-extraction alveolus is filled with PRF.
89612288|NCT04363450|Experimental|Hydroxychloroquine|Hydroxychloroquine loading dose will be given as 400mg for two doses 12 hours apart. This will then be followed by maintenance dosing of 200mg twice weekly for the remainder of the trial.
89612289|NCT04363450|Placebo Comparator|Placebo|An identical placebo will be administered on an identical dosing interval and frequency.
89612290|NCT03685149|Active Comparator|Flecainide|The same subjects will be treated in a random order with flecainide or placebo for 4 weeks each with 1 week washout between crossover periods.
89612291|NCT03685149|Placebo Comparator|Placebo|The same subjects will be treated in a random order with flecainide or placebo for 4 weeks each with 1 week washout between crossover periods.
89612292|NCT04370080|Experimental|Silver Diamine Fluoride|Topical application of one drop of silver diamine fluoride 38% to active untreated roof surface caries, lesions at the furcation, or lesions at crown margins. Application was repeated once each six months.
89612293|NCT01591616|Other|Oraqix for tooth extraction|
89612294|NCT03681873|Experimental|Study Group|Patients will receive both the clinically indicated and extremely low dose exams
89612295|NCT00938314|Experimental|NTx®-265 Low Dose|hCG 385 µg (10,000 international unit [IU]), subcutaneously (SC), on Day 1, 3 and 5 of study participation, then EPO 4,000 IU, intravenously (IV), on Day 7, 8, and 9 of study participation
89612296|NCT00938314|Experimental|NTx®-265 Medium Dose|hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 12,000 IU, IV, on Day 7, 8, and 9 of study participation
89612297|NCT00938314|Experimental|NTx®-265 High Dose|hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 20,000 IU, IV, on Day 7, 8, and 9 of study participation
89612298|NCT00938314|Placebo Comparator|Saline Placebo|
89612299|NCT03681015||Cohort 1 - Parkinson's Disease Participants|Volunteers will be women and men with early, untreated Parkinson disease.
89612300|NCT03681015||Cohort 2 - Control Participants|Participants will be women and men without PD.
89612301|NCT04370392|Active Comparator|control group|intraperitoneal local anesthetic instillation (40 ml bupivacaine 0.25%) through the trocar with intravenous infusion of 50 ml normal saline over 10 minutes.
89612302|NCT04370392|Experimental|IV dexmedetomidine group|intraperitoneal local anesthetic instillation (40 ml bupivacaine 0.25%) through the trocar with intravenous infusion of 50 ml normal saline containing dexmedetomidine 1 ug/kg over 10 minutes.
89612303|NCT04370392|Experimental|IP dexmedetomidine group|intraperitoneal anesthetic instillation (40 ml total volume containing bupivacaine 0.25% with dexmedetomidine 1 ug/kg) through the trocar with intravenous infusion of 50 ml normal saline over 10 minutes.
89612304|NCT04369378|Experimental|Meditation app group|Participants will also be given access to the mindfulness app (Insight Timer), and instructed to use it for 10 min daily for 30 days. Two days before the end of the 30 day intervention period, participants will be sent a link to a Google Form for the post-intervention survey and will be asked to complete the survey within the next 3 days. Two months after the conclusion of the 30 day intervention period (90 days after study began), participants will be sent a link to a Google Form for another post-intervention survey, and asked to complete it within 5 days.
89612305|NCT04369378|No Intervention|Control group|Participants will be in the no intervention period for 30 days. Two days before the end of the 30 day no intervention period, participants will be sent a link to a Google Form for the post-intervention survey and will be asked to complete the survey within the next 3 days. After this 30 day no intervention period, participants are invited to use the Insight Timer app if they so choose. Two months after the conclusion of the 30 day no intervention period (90 days after study began), participants will be sent a link to a Google Form for another post-intervention survey, and asked to complete it within 5 days.
89612306|NCT03798327|Experimental|Home Palliative Care|Randomized to Intervention Arm
89612307|NCT03798327|No Intervention|Control Arm|Usual Care - Patients will be cared for by the physician who treats their dementia and other illnesses.
89612308|NCT04357678|Experimental|Qi Gong Programme|Qi Gong Programme
89612309|NCT04357678|Experimental|Short Form Sun Style Tai Chi|Short Form Sun Style Tai Chi
89612310|NCT04357444|Experimental|1: ILT101|ILT-101 in Subcutaneous route
89612311|NCT04357444|Placebo Comparator|2: Placebo Comparator|Placebo in subcutaneous injections every day during 10 days
89612312|NCT04369144|Experimental|Intervention group|The dynamic scapular recognition exercise + rigid taping with 50%-75% tension.
89612313|NCT04369144|Placebo Comparator|Control|The dynamic scapular recognition exercise + placebo taping
89612314|NCT03679689|No Intervention|Control group|no changes in their alimentary habits
89612315|NCT03679689|Experimental|intervention group|no intake of artificially sweetened beverages
89612316|NCT04369222||Controls|Children born from mothers with no consumption of mild analgesics 3 months before or during pregnancy
89612317|NCT04369222||Exposed|Children born from mothers with consumption of mild analgesics 3 months before or during pregnancy
89612318|NCT04363294|Other|Participants|Patients who had TAVR and underwent evaluation for ATTR with PYP scan
89612319|NCT01591460|Experimental|Dual Combination Therapy|
89612320|NCT01591460|Experimental|Triple Combination Therapy|
89612321|NCT04363216|Experimental|Treatment|Ascorbic acid solution (Ascor®, McGuff Pharmaceuticals, Ltd.) will be added to each liter of sterile wate,r plus 1 g/L magnesium chloride to reduce burning sensation, and given parenterally over a 2-hour period. On the day of enrollment (Day 0), 0.3 g/kg will be given; Day 1 - 0.6 g/kg; Day 2 - 0.9 g/kg; Day 3 - 0.9 g/kg; Day 4 - 0.9 g/kg; Day 5 - 0.9 g/kg. After the first dose, each subsequent dose will be given 24 +/- 4 hours following the previous dose.
89612322|NCT04363216|No Intervention|Routine care|These subject will follow routine care and their clinical courses will be recorded only.
89034487|NCT04803474||Turner|Patient with Turner syndrome
89612323|NCT04363372|Experimental|MRx-4DP0004|Patients receiving standard of care will add MRx-4DP0004 to their treatment. MRx-4DP0004 is taken as 2 capsules, twice a day for 14 days. Daily dose is 4 x 10^9 to 4 x10^10 colony forming units.
89612324|NCT04363372|Placebo Comparator|Placebo|Patients receiving standard of care will also take 2 placebo capsules, twice a day for 14 days.
89612325|NCT04357210||primary sphincteroplasty|end-to-end primary sphincteroplasty with interrupted sutures
89612326|NCT04357210||muco-muscular advancement flap|A U-shaped muco-muscular flap was mobilized and fixed to the anoderm with one-row interrupted absorbable sutures
89612327|NCT04357210||full-thickness low rectum posterior semicircular mobilization|Proximal parts of the internal sphincter and the longitudinal muscle were carefully separated from the underlying external sphincter and puborectalis muscle, moving further in the cranial direction, the Waldeyer's fascia was exposed and incised. Full-thickness posterior semicircular flap was fixed to anoderm
89612328|NCT03678675|No Intervention|Standard Protocol|Subjects randomized to the standard group will receive the standard postoperative pain protocol that is currently used at Tufts Medical Center. It includes two doses of IV Ketorolac every 6 hours as needed for postoperative pain. Ibuprofen would be ordered 6 hours following the last dose after the last study drug.
89612329|NCT03678675|Experimental|Ketorolac Protocol|Subjects randomized to the Ketorolac protocol will receive the study postoperative pain protocol. This includes 6 doses of IV Ketorolac, scheduled every 6 hours. The first dose is administered in the operating room or post-operative care unit.
89612330|NCT04363060|Experimental|Azithromycin with amoxicillin/clavulanate|Combination of azithromycin during 4 days with amoxicillin/clavulanate during 7 days.
89612331|NCT04363060|Active Comparator|Amoxicillin/clavulanate|Amoxicillin/clavulanate every day during 7 days.
89612332|NCT01591382|Active Comparator|Ketamine|Participants received postoperative hydromorphone patient-controlled analgesia (PCA) and continuous ketamine (0.2 mg/kg/hour). Ketamine is being compared to the use of placebo, in addition to intravenous opioids, for postop pain control in opioid dependent patients who undergo major surgery.
89612333|NCT01591382|Placebo Comparator|Placebo|Participants received postoperative hydromorphone PCA and continuous ketamine-matching placebo (infusion of saline).
89612334|NCT04362904|Experimental|acupressure|In accordance with the acupressure protocol, each day for four weeks, taking into account the awakening and sleep periods of the individuals, acupressure applied for a total of 3 min to the each acupuncture points (one session 18 minutes) twice a day between 07:00 and 10:00 and 19:00 to 22:00 in the morning patients were asked to perform acupressure by their caregivers or on their own.
89612335|NCT04362904|No Intervention|control|No intervention was applied to the control group.
89612336|NCT03678441|Experimental|Group I (BrainCheck and paper and pen cognitive assessment)|Patients receive the BrainCheck cognitive assessment over 15 minutes followed by the paper and pen assessment 2 months prior to surgery and within 2 months after surgery.
89612337|NCT03678441|Active Comparator|Group II (pen and paper and BrainCheck cognitive assessment)|Patients receive the paper and pen assessment followed by the BrainCheck cognitive assessment over 15 minutes 2 months prior to surgery and within 2 months after surgery.
89612338|NCT03677817|Active Comparator|Lidocaine|perioperative IV administration regimen of lidocaine will be as follows: 1.5 mg/kg IV induction bolus dose (before intubation and at least 30 minutes before incision) followed by continuous infusion of 3.mg/kg/h, until 2 hours after skin closure
89612339|NCT03677817|Placebo Comparator|Placebo|perioperative IV administration regimen of placebo solution (NaCl 0,9%) will be as follows: induction bolus (before intubation and at least 30 minutes before incision) followed by continuous infusion of placebo solution (NaCl 0,9%) until 2 hours after skin closure
89612340|NCT00931996|Experimental|Antipsychotic|Antipsychotic
89612341|NCT04348305|Experimental|Hydrocortisone|"Continuous intravenous infusion of hydrocortisone 200 mg over 24 hours (total 104 ml). The trial intervention will be given in addition to standard care.~If continuous intravenous infusion is not possible, we will allow the use of bolus injection of the trial medication (50 mg (10 ml) every 6 hours)."
89612342|NCT04348305|Placebo Comparator|Isotonic Saline|"Continuous intravenous infusion of matching isotonic saline (0.9%) placebo at a dose volume of 104 ml over 24 hours in addition to standard care (no corticosteroid treatment).~If continuous intravenous infusion is not possible, we will allow the use of bolus injection of matching saline placebo (10 ml every 6 hours)."
88984167|NCT05244369|Other|Only TENS group|A rehabilitation program consisting of joint range of motion, stretching, and strengthening exercises for 30 minutes, 5 days a week for only 4 weeks, and transcutaneous electrical nerve stimulation (TENS) with a current frequency of 60-100 Hz and an impulse duration of 100 microseconds will be applied.
88984168|NCT00095537|Experimental|Phase 1 MTD Study|
88984169|NCT00429247|Experimental|1|Her
89612343|NCT00928174|Experimental|Single Arm|Fluorine-18 fluorocholine IV in conjunction with PET/CT imaging, up to 3 doses.
89612344|NCT01696214|Placebo Comparator|Ipratropium|Participants will continue fluticasone 100 mg/salmeterol 50 mg once a day and be assigned to a 24 week treatment of ipratropium 2.5 mL, 0.02% 3 times daily via mini nebulizer with placebo theophylline and placebo montelukast.
88984170|NCT00429247|No Intervention|2|Follow up
88984171|NCT00095693|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib tosylate twice daily for up to 6 months in the absence of disease progression or unacceptable toxicity. Patients achieving CR receive 8 additional weeks of therapy beyond CR.
88984172|NCT01054573|Experimental|Telaprevir + Standard Treatment|Telaprevir 750 mg orally (by mouth) every 8h for 12 weeks plus standard treatment. Standard treatment is 180 mcg subcutaneous (under the skin) injection pegylated interferon (Peg-IFN) alfa-2a and 1000-1200 mg twice daily ribavirin (RBV) for 48 weeks.
88984173|NCT00095732|Experimental|Low Liprotamase Dose|Liprotamase in a fixed combination of lipase (5,000 units), protease (5,000 units) and amylase (750 units) administered orally (one Size 5 capsule of liprotamase and five Size 2 capsules of placebo) with each of three meals and two snacks daily for 28 days
89612345|NCT01696214|Placebo Comparator|Theophylline|Participants will continue fluticasone 100 mg/salmeterol 50 mg once a day and will be assigned to theophylline 400 mg once a day for 24 weeks with placebo ipratropium and placebo montelukast.
89612346|NCT01696214|Placebo Comparator|Montelukast|Participants will continue fluticasone 100 mg/salmeterol 50 mg once a day and will be assigned to montelukast 10 mg once a day for 24 weeks with placebo theophylline and placebo ipratropium.
89612347|NCT01696214|Placebo Comparator|fluticasone 250 mg/salmeterol 50mg|Participants will be assigned to inhaled fluticasone 250/salmeterol 50 twice a day for 24 weeks with placebo theophylline, placebo ipratropium, and placebo montelukast.
89612348|NCT02083263|Experimental|Bilevel|Bilevel, 3 months. The treatment was performed twice a day, 1 hour each treatment.
88984174|NCT00095732|Experimental|Mid Liprotamase Dose|Liprotamase in a fixed combination of lipase (25,000 units), protease (25,000 units) and amylase (3,750 units) administered orally (one Size 5 capsule of liprotamase, one Size 2 capsule of liprotamase, and four Size 2 capsules of placebo) with each of three meals and two snacks daily for 28 days
89612349|NCT02083263|Active Comparator|PEP mask|PEP mask, 3 months. The treatment was performed twice a day, 1 hour each treatment.
89612350|NCT04356898||Diabetes fasting|Diabetes patients who decided to fast during the month of Ramadan
88984175|NCT00095732|Experimental|High Liprotamase Dose|Liprotamase in a fixed combination of lipase (100,000 units), protease (100,000 units) and amylase (15,000 units) administered orally (one Size 5 capsule of placebo and five Size 2 capsules of liprotamase) with each of three meals and two snacks daily for 28 days
88984176|NCT01054456|Experimental|All Participants: Palonosetron 0.25 mg/5 mL|Participants will receive palonosetron 0.25 milligram (mg) per (/) 5 milliliter (mL) intravenous injection 30 minutes prior to receiving a low emetogenic chemotherapy (LEC) agent on Day 1.
89612351|NCT04356898||Diabetes non-fasting|Diabetes patients who decided to not fast during the month of Ramadan
89612352|NCT04356898||Healthy|Healthy volunteers that decided to fast during the month of Ramadan
89612353|NCT05347875|No Intervention|Control Group|Activities of Daily Living App
89612354|NCT05347875|Experimental|Experimental Group|ICanWALK© App
89612355|NCT03794037|Active Comparator|control|dydrgesterone 10 mg( tab)/12hs/14 days
89612356|NCT03794037|Experimental|study|montelukast 10 mg(tab) oral/24hs/ 7 days dydrgesterone 10 mg( tab) oral/12hs/14 days
89612357|NCT04356508|Experimental|Intervention (n=10)|Nivolumab + best supportive care
89612358|NCT04356508|No Intervention|Non-intervention (n=5)|Best supportive care
89612359|NCT04362280|Experimental|ReCHARGE|intervention intensity is increased through: the creation of family groups, greater involvement of school staff, separate lessons for females, health screeners will be home and families are invited to a nutrition counseling session with a registered dietitian.
89612360|NCT04362280|Active Comparator|Treatment as Usual (TAU)|PE class as usual which consisted of choice time.
89612361|NCT04362202|Experimental|experimental|8 individual experimental rehabilitation sessions as outpatients (2 days/week, 4 weeks), in a rehabilitation pool at Fondazione Santa Lucia Neurorehabilitation hospital. Each session lasted 45minutes. The water temperature was between 30°C and 32°C.
89612362|NCT04362202|Active Comparator|control|8 individual of standard aquatic rehabilitation sessions as outpatients (2 days/week, 4 weeks), in a rehabilitation pool at Fondazione Santa Lucia Neurorehabilitation hospital. Each session lasted 45minutes. The water temperature was between 30°C and 32°C.
89612363|NCT04762641|Experimental|ABL503|ABL503 will be administered biweekly of every 28-day cycle in the dose-escalation. The dosing interval to be used in the dose-expansion part will be re-evaluated based on the emerging safety and PK data from the dose-escalation part of the study.
89612364|NCT01543087|Other|One group of subjects|
89612365|NCT04368598|Experimental|High-dose Dexamethasone plus Acetylcysteine|For all patients in this arm, DXM was administered intravenously at 40 mg daily for 4 consecutive days and then stopped. If platelet count remained below 30×10^9/L or there were bleeding symptoms by day 10 to 14, an additional 4-day course of DXM (40 mg daily) was given. Besides, all patients received Acetylcysteine orally at 0.4g three times a day for 4 consecutive weeks in the first month.
89612366|NCT05347641|Experimental|Penpulimab combined with RMA was used for first-line treatment of PCNSL|One course of treatment was performed every 21 days. After 3 courses, patients underwent cranial MR+ whole-body enhanced CT for disease assessment. Patients who did not achieve partial response (PR) were withdrawn, and patients who achieved PR or complete response (CR)/uncertain CR (CRu) were given 3 courses of treatment.
88984177|NCT00429442|Active Comparator|1|
88984178|NCT00429442|Placebo Comparator|2|
88984179|NCT00400361|Experimental|1|
88984180|NCT00429559|Experimental|A|
88984181|NCT00095810|Experimental|A|
88984182|NCT01054300|Experimental|Cohort 1: Ertu 2 mg/Placebo (Pbo)→Ertu 1 mg/Ertu 1 mg|Period 1: Ertu 2 mg in the AM and Pbo in the PM for 1 day. Period 2: Ertu 1 mg in the AM and Ertu 1 mg in the PM for 1 day. There was a >= 7 day washout period between Period 1 and Period 2.
89612367|NCT01696058|Experimental|Olodaterol andTiotropium|2 puffs Olodaterol from Respimat and one capsule Tiotropium by Handihaler once daily in am, co-administered
89612368|NCT01696058|Other|Placebo and Tiotropium|2 puffs placebo inhalation solution from Respimat and one capsule Tiotropium by Handihaler once daily in am, co-administered
88984183|NCT01054300|Experimental|Cohort 1: Ertu 1 mg/Ertu 1 mg→Ertu 2 mg/Pbo|Period 1: Ertu 1 mg in the AM and Ertu 1 mg in the PM for 1 day. Period 2: Ertu 2 mg in the AM and Pbo in the PM for 1 day. There was a >= 7 day washout period between Period 1 and Period 2.
88984184|NCT01054300|Experimental|Cohort 2: Ertu 4 mg/Pbo→Ertu 2 mg/Ertu 2 mg|Period 1: Ertu 4 mg in the AM and Pbo in the PM for 1 day. Period 2: Ertu 2 mg in the AM and Ertu 2 mg in the PM for 1 day. There was a >= 7 day washout period between Period 1 and Period 2.
88984185|NCT01054300|Experimental|Cohort 2: Ertu 2 mg/Ertu 2 mg→Ertu 4 mg/Pbo|Period 1: Ertu 2 mg in the AM and Ertu 2 mg in the PM for 1 day. Period 2: Ertu 4 mg in the AM and Pbo in the PM for 1 day. There was a >= 7 day washout period between Period 1 and Period 2.
89034488|NCT04781504|Experimental|standard care + moderate-intensity continuous exercise training|2 days/week Warm-up: 60-70% peak HR - 10min Training: 70-85% peak HR - 35min Cool-down: 60-70% peak HR - 15min
89612369|NCT04368520|Placebo Comparator|Placebo|
89612370|NCT04368520|Experimental|Low dose vitamin D3|
89612371|NCT04368520|Experimental|High dose vitamin D3|
89612372|NCT04762797||Non-neoplastic group|"Gallbladder polyps with pathological diagnosis of cholesterol polyps or inflammatory polyps are classified into Non-neoplastic group."
89612373|NCT04762797||Neoplastic group|"Gallbladder polyps pathologically diagnosed as adenocarcinoma, adenoma, adenomyosis, or other malignancies are classified into Neoplastic group."
89612374|NCT04762563|Experimental|Experimental: Study Group|Patients in the IASTM group were asked to lie face down on a stretcher, exposing the entire lumbar region. IASTM was applied to all paraspinal muscles for a total of 5 minutes after massage cream was applied. Immediately afterwards, the same application was performed for the right and left hamstring muscles from the gluteal line to the bottom of the popliteal fossa for 3 minutes after massage cream was applied. IASTM application was performed vertically, horizontally and diagonally using instruments of different sizes and shapes at an angle of 45 degrees to the skin surface.
89612375|NCT04762563|Active Comparator|Active Comparator|"KT application (Kinesio Tape® Tex Gold) was performed using the muscle technique. In lumbar region application, while the patient was standing, the tape was cut as a Y-strip with a base of 5 cm."
89612376|NCT04356820|Experimental|acupressure|
89612377|NCT04356820|Experimental|music|
89612378|NCT04356820|No Intervention|control|
89612379|NCT04356274|Experimental|Participatory System Dynamics (PSD)|12 clinics assigned to PSD
89612380|NCT04356274|Experimental|Audit and Feedback (AF)|12 clinics assigned to AF
88984186|NCT00095888|Experimental|Treatment (triapine, gemcitabine hydrochloride)|Patients receive 3-AP (Triapine®) IV over 2 hours followed by gemcitabine IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88984187|NCT00429715|Experimental|Alum-ALM + BCG|Alum-ALM + BCG
88984188|NCT00429715|Active Comparator|BCG|BCG
88984189|NCT00429715|Placebo Comparator|BCG diluent|Diluent
88984190|NCT00095927|Active Comparator|Arm A Amifostine|"Patients with newly diagnosed, locally advanced stage ill or IV SCCHN received;~4 weekly doses of carboplatin (area under the curve, 1.5) and paclitaxel (45 mg/m 2) concurrently with concomitant boost radiation consisting of 72 grays in 42 fractions over 6 weeks (every day for 18 days, twice a day for 12 days) (grading determined according to the TNM staging system).~Subcutaneous daily amifostine at a dose of 500 mg"
88984191|NCT00095927|Experimental|Arm B No-Amifostine|"Patients with newly diagnosed, locally advanced stage ill or IV SCCHN~- 4 weekly doses of carboplatin (area under the curve, 1.5) and paclitaxel (45 mg/m 2) concurrently with concomitant boost radiation consisting of 72 grays in 42 fractions over 6 weeks (every day for 18 days, twice a day for 12 days) (grading determined according to the TNM staging system)."
88984192|NCT00429754|Other|aprepitant|Aprepitant treatment
88984193|NCT04703881|Experimental|AYMES ActaGain|Patients of the intended target group (e.g. MUST score ≥ 1, with or at risk of disease related malnutrition) with an anticipated period of nutritional support ≥ 4 weeks will be changed / started on an equivalent prescription of 'AYMES ActaGain' for a period of 30 days.
88984194|NCT04703959||glaucomatous subjects (50)|"Subjects included in the MARS database of CHU Grenoble-Alpes with available polysomnographic data and with the following ophthalmological characteristics:~increase in intraocular pressure (IOP before treatment greater than 21 mmHg) with characteristic alterations of the optic nerve (pathological papillary excavation, papillary pallor, papillary atrophy) with corresponding alterations and characteristics of the visual field. The visual field should be considered reliable (European criteria (European Glaucoma Society, 1999).~Patients whose age is greater than or equal to 18 years~Male or female patients~Patients not objecting to the study~Affiliation to a social security scheme or beneficiary of such a scheme"
88984195|NCT04703959||non glaucomatous subjects (100)|"Subjects included in the MARS database of CHU Grenoble-Alpes with available polysomnographic data and with the following ophthalmological characteristics:~no known ophthalmological pathologies, with an ophthalmological examination on telephone examination - in the 2 years preceding the polysomnographic examination - normal apart from minor refractive disorders (myopia with spherical equivalent less than -6 diopters or hyperopia with spherical equivalent less than 3 diopters).~Patients whose age is greater than or equal to 18 years~Male or female patients~Patients not objecting to the study~Affiliation to a social security scheme or beneficiary of such a scheme"
88984196|NCT00429871|Experimental|1|DF
88984197|NCT00429871|Experimental|2|DC
88984198|NCT00095966|Experimental|Treatment (sorafenib tosylate and gemcitabine hydrochloride)|Patients receive oral sorafenib twice daily on days 1-28 and gemcitabine IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88984199|NCT01803594|Placebo Comparator|Control Shake|Each shake delivers 30% of each participant's calculated energy expenditure and provides 45% energy as fat, 40% energy as carbohydrate and 15% energy as protein. The shake contains whipping cream, frozen fruit, glucose polymer, and protein powder.
89034489|NCT04781504|Experimental|standard care + high-intensity interval training|2 days/week Warm-up: 60-70% peak HR - 10min Training: 85-95% peak HR - 25 minutes (4x4-minutes of high-intensity intervals interspersed with 3 minutes of low-intensity intervals) Cool-down: 60-70% peak HR - 10min
89034490|NCT04780659|Experimental|Vaccination with Comirnaty according to standard of care treatment|All study participants will receive Comirnaty according to current approval.
89034491|NCT04772027||Muscular dystrophies group|40 patients with limb girdle muscular dystrophie
89034492|NCT04772027||Comparator group|40 healthy volunteers without neuromuscular or squeletic disorder
89034493|NCT04768023|Placebo Comparator|Control group|The group will receive placebo treatment.
89034494|NCT04768023|Experimental|Vitamin D3 group|The group will receive vitamin D3 supplementation.
89034495|NCT04758403|Experimental|Navigation Bronchoscopy ALONE|"This research study involves a screening period, a procedure and follow up visits~Procedure Visit Navigation Bronchoscopy Alone~Follow-Up Visits at Week 1, 4 and 12"
89034496|NCT04758403|Experimental|CBCT-GUIDED Navigation Bronchoscopy|"This research study involves a screening period, a procedure and follow up visits Procedure Visit- Cone Beam Computed Tomography - Guided Navigation Bronchoscopy for Peripheral Pulmonary Nodules~-Follow-Up Visits at Week 1, 4 and 12"
89034497|NCT04753879|Experimental|Nab-paclitaxel, Gemcitabine , Cisplatin, Irinotecan, Capecitabine|Maintenance of Pembrolizumab and Olaparib
89034498|NCT04751812|Active Comparator|High-pain Standard of care|Patients grading pain associated with venous cannulation >=2.0 allocated to standard treatment.
89034499|NCT04751812|Experimental|High-pain Multimodal anesthesia with opioids|Patients grading pain associated with venous cannulation >2.0 allocated to extra treatment.
89034500|NCT04751812|Active Comparator|Low-pain Standard of care|Patients grading pain associated with venous cannulation to <2.0 allocated to standard treatment.
89034501|NCT04751812|Experimental|Low-pain opioid-free|Patient grading pain associated with venous cannualation to <2.0 allocated to opioid-free anesthesia.
89034502|NCT04750226|Experimental|ABBV-951|Participants will receive ABBV-951 by continuous subcutaneous infusion (CSCI) for 96 weeks during the Primary Treatment Period and during the optional Extended Treatment Period.
89034503|NCT04742634|Experimental|Phase I Dose Level 1: DEC-C|"Bone marrow biopsy & MyeloSeq-HD will be obtained on Day 30 post-transplant. MRD positivity is defined as the presence of at least one somatically acquired mutation detected prior to transplant that persists at Day 30 post-transplant with a variant allele frequency of ≥ 0.5%. MRD-positive patients will receive up to 5 cycles of DEC-C prior to the Day 180 bone marrow evaluation. If the Day 180 MyeloSeq-HD shows that MRD is still detectable in the opinion of the MGI board-certified molecular pathologist but below 0.5% and patient has tolerated initial treatment without toxicity, the patient may continue treatment. If it shows a lack of MRD, the patient will be moved to the post-treatment surveillance arm. If it shows any mutation detection prior to transplant that persists with a variant allele frequency of ≥ 0.5%VAF, the patient will receive up to an additional 6 cycles of DEC-C.~35 mg decitabine/100 mg cedazuridine taken by mouth once daily on Days 1, 2, 3 of a 28 day cycle."
89034504|NCT04742634|Experimental|Phase I Dose Level 2: DEC-C|"Bone marrow biopsy & MyeloSeq-HD will be obtained on Day 30 post-transplant. MRD positivity is defined as the presence of at least one somatically acquired mutation detected prior to transplant that persists at Day 30 post-transplant with a variant allele frequency of ≥ 0.5%. MRD-positive patients will receive up to 5 cycles of DEC-C prior to the Day 180 bone marrow evaluation. If the Day 180 MyeloSeq-HD shows that MRD is still detectable in the opinion of the MGI board-certified molecular pathologist but below 0.5% and patient has tolerated initial treatment without toxicity, the patient may continue treatment. If it shows a lack of MRD, the patient will be moved to the post-treatment surveillance arm. If it shows any mutation detection prior to transplant that persists with a variant allele frequency of ≥ 0.5%VAF, the patient will receive up to an additional 6 cycles of DEC-C.~35 mg decitabine/100 mg cedazuridine taken by mouth once daily on Days 1-4 of a 28 day cycle."
89034505|NCT04742634|Experimental|Phase II MRD Positive: DEC-C|"35 mg decitabine/100 mg cedazuridine taken by mouth once daily per the schedule determined in the Phase I portion of the study. Cycle 1 Day 1 may take place between Day 42 and Day 100 post-transplant. MRD-positive patients will receive up to 5 cycles of DEC-C prior to the Day 180 bone marrow evaluation.~Bone marrow biopsy with MyeloSeq-HD will be obtained on Day 180 post-transplant. If the Day 180 MyeloSeq-HD shows that MRD is still detectable in the opinion of the MGI board-certified molecular pathologist but below 0.5% and patient has tolerated initial treatment without toxicity, the patient may continue treatment. If it shows a lack of MRD, the patient will be moved to the post-treatment surveillance arm. If it shows any mutation detection prior to transplant that persists with a variant allele frequency of ≥ 0.5%VAF, the patient will receive up to an additional 6 cycles of DEC-C."
89034506|NCT04742634|Active Comparator|Phase II MRD Negative: Observation Arm|"In phase II, up to 77 patients who do not have MRD positivity on Day 30 post-transplant (i.e., the absence of at least one somatically acquired mutation detected prior to transplant that persists at Day 30 post-transplant with a variant allele frequency of ≥ 0.5%) will be placed on the observation arm and treated with standard of care.~Patients on the observation arm will be followed every 3 months for 2 years and every 6 months for 3 years for progression and survival"
89034507|NCT04742309|Experimental|Pecs-2|For Pecs-2 blocks, the needle will be advanced to the tissue plane between the pectoralis major and minor muscles at the vicinity of the pectoral branch of the acromiothoracic artery where 10 mL of local anesthetic will be deposited. In a similar manner, 20 mL will be deposited at the level of the third rib above the serratus anterior muscle with the intent of spreading injectate to the axilla. The study fluid will be ropivacaine 0.3% with epinephrine.
89034508|NCT04742309|Active Comparator|Paravertebral|For paravertebral blocks, ropivacaine 0.5% (with epinephrine) 9 mL will be administered at each of two levels per side: the T3 and T5 levels for sides without axillary involvement; and at the T2 and T4 level for sides with axillary involvement.
89034509|NCT04736966|Experimental|Guselkumab 30mg|Guselkumab administered by subcutaneous injection at Day 1 and Day 29
89034510|NCT04736966|Experimental|Guselkumab 70 mg|Guselkumab administered by subcutaneous injection at Day 1 and Day 29
89034511|NCT04736966|Experimental|Guselkumab 100mg|Guselkumab administered by subcutaneous injection at Day 1 and Day 29
89612381|NCT01695746||C.E.R.A.|Participants with chronic renal anemia Stage III-IV, not on dialysis, will be administered Continuous Erythropoietin Receptor Activator (C.E.R.A.) according to routine clinical practice and will be followed up for the treatment duration of 24 weeks (6 months). Dosing and titration of C.E.R.A. treatment will be at the discretion of the investigator in accordance with local clinical practice or prescribing information. Dosing instructions as per the local label are - For correction of anemia: 0.6 microgram per kilogram (mcg/kg) of C.E.R.A. once every two weeks, and for Maintenance of hemoglobin (Hb) levels: Conversion to C.E.R.A. dose (120, 200, or 360 mcg either once monthly; or 60, 100, or 180 mcg once every 2 weeks) depending on the previous weekly epoetin or darbepoetin dose.
89612382|NCT03790137|Experimental|Treatment group|The treatment group will include approximately 20 pediatric and young adult patients (ages 4-25 years) seen by Elizabeth A. Thiele, M.D., Ph.D. at MGH's Pediatric Epilepsy Clinic. Subjects will be treated on an outpatient basis and will not require hospital admission. The treatment group will receive the investigational new drug, Fenfluramine Hydrochloride for approximately 4 months. Patients that benefit from this treatment will remain on medication through an extension phase of the study.
89612383|NCT04795076|Placebo Comparator|Standard formula|Feeding the infant or child with the regular formula which is prepared with standard concentrations
89612384|NCT04795076|Active Comparator|Nutrient-dense formula|Feeding the infant or child with the nutrient-dense formula which is prepared by concentrating regular formula.
89612385|NCT04368286|Experimental|Rehabilitation group|To conduct a comprehensive pulmonary rehabilitation assessment and treatment
89612386|NCT04368286|No Intervention|Conventional medical group|Conventional medical treatment
89612387|NCT01694420|Experimental|Quad FDC|FDC elvitegravir + cobicistat + tenofovir + emtricitabine STR once daily for 48 weeks
89612388|NCT04347148|Experimental|SNAGs treatment|cervicogenic patients will undergo SNAGs treatment. Based on personal history, the offending active cervical movement (i.e. the movement predominantly causing dizziness) will be identified and treatment direction will be determined. As suggested, the active movement to most likely cause dizziness is cervical extension, though also rotation or flexion will be shown to provoke it. With the participant in an upright sitting position, a skilled physiotherapist (blinded to the allocation) will apply a sustained passive accessory movement (glide) while the participant will be asked to move actively as allowed by his/her physiological range in the direction producing their symptoms. This procedure will be repeated six times.
89612389|NCT04347148|Placebo Comparator|Detuned Laser|cervicogenic patients will receive a sham treatment, carried out by the another skilled therapist (blinded to the allocation) and consisting in exposition to a detuned laser. A laser - deactivated by the manufacturer in order to produce no effective emission - will appear to operate normally, emitting a light signal and a beeping sound. Such procedure - which was shown to not activate somatosensory receptors and to have a very strong placebo effect - will be used for six applications, lasting 20 seconds, on various sites on the upper cervical spine, at a distance of 0.5-1cm from the skin.
88984200|NCT01803594|Active Comparator|PC700, Krill Oil, and Lutein|"Each shake delivers 30% of each participant's calculated energy expenditure and provides 45% energy as fat, 40% energy as carbohydrate and 15% energy as protein. The shake contains whipping cream, frozen fruit, glucose polymer, and protein powder. Fifty percent of the fat is made up of PC700. Additionally, 3.0g Krill oil and 40mg of lutein capsules are swallowed with water.~Neptune Krill Oil capsules (Nutrigold); Lutein capsules (Jarrow Formulas); PC700 = dairy lipids (Fonterra brand)"
88984201|NCT01803594|Active Comparator|PC700, Krill Oil, Lutein, and Niacin|"Each shake delivers 30% of each participant's calculated energy expenditure and provides 45% energy as fat, 40% energy as carbohydrate and 15% energy as protein. The shake contains whipping cream, frozen fruit, glucose polymer, and protein powder. Fifty percent of the fat is made up of PC700. Additionally, 3.0g Krill oil and 40mg of lutein capsules are swallowed with water. Nicotinic acid was added to each shake prior to consumption at a doses 5mg/kg of body weight.~Neptune Krill Oil capsules (Nutrigold); Lutein capsules (Jarrow Formulas); PC700 (Fonterra); Nicotinic acid (Natures Way)"
88984202|NCT00430066|Experimental|Imatinib Mesylate|400 mg/day by mouth for 6 months (+ 6 months in case of responsiveness)
88984203|NCT00096005|Experimental|Treatment (chemotherapy and enzyme inhibitor therapy)|"Patients receive tanespimycin IV over 1-2 hours and bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of tanespimycin and bortezomib until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, at least 12 additional patients are treated as above* at the MTD.~NOTE: *Bortezomib is not administered on day 1 of course 1 only. Patients are followed at 3 months."
88984204|NCT00430144|Experimental|CKD-602|
88984205|NCT05207163|Experimental|Received CME|
88984206|NCT05207163|No Intervention|Not received CME|
88984207|NCT00096083|Active Comparator|Melphalan Administration PHP|
88984208|NCT00430378|Experimental|Acupuncture|Acupuncture Before the Radiation Treatment
88984209|NCT00430378|Experimental|Standard Care|Standard Care Without Acupuncture
88984210|NCT00430417||3 groups|Group 1: post-partum breastfeeding women
88984211|NCT00430417||Group 2|Group 2: post-partum bottlefeeding women
88984212|NCT00430417||Group 3|Group 3: normal non-pregnant controls who are age and race-matched to Group 1
88984213|NCT00430456|Other|Arm 1|Higher Intensity, Shorter Duration Treadmill Training
88984214|NCT00430456|Active Comparator|Arm 2|Lower Intensity, Longer Duration Treadmill Training
88984215|NCT01726452|Experimental|A (Modified MAGIC) OR Arm A: FLOT|"Modified MAGIC: The modified MAGIC regimen encompasses 3 cycles of chemotherapy pre-surgery and 3 cycles post-surgery. The regimen is a combination of epirubicin, cisplatin or oxaliplatin and a choice of 5-fluorouracil or capecitabine. Each cycle lasts 21 days.~FLOT: The FLOT regimen encompasses 8 cycles of chemotherapy in total , 4 cycles of chemotherapy pre-surgery and a further 4 cycles of chemotherapy post-surgery. Each cycle of chemotherapy lasts 14 days/2 weeks."
88984216|NCT01726452|Experimental|B (CROSS)|Arm B consists of the multimodal CROSS arm, which includes a combination of chemotherapy and radiotherapy prior to surgery. The patient will receive four and a half (4.5) weeks of radiation therapy (41.4 Gy/23 fractions), and 5 weekly cycles of chemotherapy. The chemotherapy and radiotherapy will run concurrently over a 4 and a half-week period. Chemotherapy is given by intravenous infusion on days 1, 8, 15, 22 and 29. The radiation will generally commence on the 1st day of treatment and will run for 4 and a half weeks as follows: days 1-5, days 8-12, days 15-19, days 22-26 and days 29-31 inclusive.
88984217|NCT00096395|Experimental|Treatment (sorafenib tosylate, gemcitabine hydrochloride)|"Course 1 (56 days): Patients receive oral sorafenib twice daily on days 1-56 and gemcitabine IV over 30 minutes on days 1, 8, 15, 22, 29, 36, and 43.~Course 2 and all subsequent courses (28 days): Patients receive oral sorafenib twice daily on days 1-28 and gemcitabine IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
88984218|NCT05207124||Botulinum toxin injection group|onabotulinumtoxinA
88984219|NCT00130494|Experimental|Arm A: Zoledronic acid 4 mg|Zoledronate 4 mg every 3 or 4 weeks. This arm will receive study treatment from the time of entry into the trial, until the appearance of the symptoms of bone metastases (or a maximum period of 12 months, whichever occurs first).
88984220|NCT00130494|No Intervention|Arm B: Observation|Patients will not receive any treatment with bisphosphonates until the time of onset of symptoms (or a maximum period of 12 months, whichever occurs sooner).
88984221|NCT05189652|Experimental|Myofascial Release and Exercise Group|Foam roller massage will be applied to the thoracolumbar posterior chain for participants in the myofascial release and exercise group. At the same time, balance training, squat exercises, reach forward with sitting and hamstring stretching exercises will be applied to this group for a period of four weeks. Before starting the exercise training programs, a 5 minute warm-up will be done. The first evaluation of the participants will be made before starting the 4-week program. Final assessments will be made within 2-3 days after the 4-week training ends. Evaluations will include flexibility measurements, muscular endurance measurements, balance evaluations.
89612390|NCT03580317|Experimental|EA + Carbamazepine Group|The subjects in this group will receive 3 times per week, and 4 weeks of continuous intervention for a total of 12 times. The intervention including electroacupuncture(EA) treatment and combined with Carbamazepine (0.1g each time, thrice daily). The follow-up period is 6 months.
89612391|NCT03580317|Placebo Comparator|EA + Placebo Group|The subjects in this group will receive 3 times per week, and 4 weeks of continuous intervention for a total of 12 times. The intervention including EA treatment and combined with placebo of carbamazepine. The follow-up period is 6 months.
89612392|NCT03580317|Active Comparator|Sham EA+ Carbamazepine Group|The subjects in this group will receive 3 times per week, and 4 weeks of continuous intervention for a total of 12 times. The intervention including sham electroacupuncture(sham EA) intervention and combined with carbamazepine. The follow-up period is 6 months.
89612393|NCT03580317|Sham Comparator|Sham EA+ Placebo Group|The subjects in this group will receive 3 times per week, and 4 weeks of continuous intervention for a total of 12 times. The intervention including sham EA intervention and combined with placebo took orally. The follow-up period is 6 months.
89612394|NCT04362124|Experimental|vaccine BCG|"A single dose intradermal application of 0.1 ml of between 1 x 105 to 33 x 105 CFU of BCG, in the deltoid of the non-dominant arm.~Follow-up of the participant up to day 360. The frequency and intensity of possible Adverse Events, reactions, and symptoms that appear, and other reactions stipulated in the protocol will be documented in the subject's diary."
89612395|NCT04362124|Placebo Comparator|Placebo|"A single dose intradermal application of 0.1ml of normal saline solution, in the deltoid of the non-dominant arm.~Follow-up of the participant up to day 360. The frequency and intensity of possible Adverse Events, reactions, and symptoms that appear, and other reactions stipulated in the protocol will be documented in the subject's diary."
88984222|NCT05189652|Experimental|Exercise Group|For the participants in the exercise group, the exercise program (balance training, squat exercises, reach forward with sitting and hamstring stretching exercises) will be applied 3 days a week for 4 weeks without any intervention to the thoracolumbar fascia. Before starting the exercise training programs, a 5 minute warm-up will be done. The first evaluation of the participants will be made before starting the 4-week program. Final assessments will be made within 2-3 days after the 4-week training ends. Evaluations will include flexibility measurements, muscular endurance measurements, balance evaluations.
88984223|NCT05189652|No Intervention|Control Group|Any myofascial release or exercise program will not be applied to the participants in the control group. The first evaluation of the participants will be made before other groups starting the 4-week program. Final assessments will be made within 2-3 days after the other groups 4-week training ends. Evaluations will include flexibility measurements, muscular endurance measurements, balance evaluations.
88984224|NCT00096512|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88984225|NCT00402948|Experimental|TPI ASM8|ASM8 0.25mg
88984226|NCT00402948|Experimental|ASM8 as TPI ASM8|TPI ASM8 0.5mg
88984227|NCT01053988|Experimental|FF/GW642444 Inhalation Powder|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
88984228|NCT01053988|Experimental|FF Inhalation Powder|Inhaled Corticosteroid (ICS)
88984229|NCT01053988|Experimental|GW642444 Inhalation Powder|Long Acting Beta Agonist(LABA)
88984230|NCT01053988|Placebo Comparator|Placebo|Placebo
88984231|NCT01053988|Experimental|FF/GW642444 Inhalation Pwdr|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
88984232|NCT00096629|Experimental|human PSMA|Patients will receive a total of 6 vaccinations via the intramuscular route. Sites of injection should have intact lymphatic drainage. Groups of six patients will be randomized at each dose level, 3 for each arm, to receive either three immunizations with mouse PSMA followed by three immunizations with human PSMA or three immunizations with human PSMA followed by three immunizations with mouse PSMA.
88984233|NCT00096629|Experimental|mouse PSMA|Patients will receive a total of 6 vaccinations via the intramuscular route. Sites of injection should have intact lymphatic drainage. Groups of six patients will be randomized at each dose level, 3 for each arm, to receive either three immunizations with mouse PSMA followed by three immunizations with human PSMA or three immunizations with human PSMA followed by three immunizations with mouse PSMA.
88984234|NCT00430651|Experimental|1|Docetaxel + Carboplatin
88984235|NCT00430651|Experimental|2|Docetaxel
88984236|NCT00430690||1|Cocaine dependent subjects
88984237|NCT00430690||2|Healthy controls
88984238|NCT00430690||3|Siblings of cocaine dependent subjects
88984239|NCT00130611|Placebo Comparator|BNP blinded therapy|Clinical treatment without knowledge of BNP levels
88984240|NCT00130611|Experimental|BNP guided therapy|Clinical treatment based on clinical examination and BNP-levels
88984241|NCT00096668|Experimental|TOCOSOL Paclitaxel|TOCOSOL Paclitaxel administered weekly at 120mg/mm2
88984242|NCT00430846|Experimental|A|
88984243|NCT00430885|Placebo Comparator|Saline|
88984244|NCT00430885|Experimental|Octagam (IVIG)|Octagam (IVIg) is intravenous immunglobulin
88984245|NCT00430924|Active Comparator|1|Eplerenone
88984246|NCT00430924|No Intervention|2|Control
88984247|NCT00430963|Placebo Comparator|Placebo|Placebo to IncobotulinumtoxinA (Xeomin) powder for solution for injection; dose: one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl, corresponding to total placebo volume 0.5 mL; mode of administration: intramuscular injection
88984248|NCT00430963|Experimental|IncobotulinumtoxinA (Xeomin) (20 Units)|IncobotulinumtoxinA (Xeomin), also known as 'NT 201' or 'Botulinum toxin type A (150 kD), free from complexing proteins' (active ingredient: Clostridium Botulinum neurotoxin type A free from complexing proteins) powder for solution for injection; dose: one injection session of solution, prepared by reconstitution of powder with 0.9% sodium chloride (NaCl), 20 units, total volume 0.5 mL, mode of administration: intramuscular injection
88984249|NCT05102409|Experimental|Reproxalap Ophthalmic Solution (0.25%)|Single dose
88984250|NCT05102409|Active Comparator|Xiidra® (5% lifitegrast ophthalmic solution)|Single dose
88984251|NCT01053247|Experimental|Test|Test product that contains the active pharmaceutical ingredient
88984252|NCT01053247|Active Comparator|Reference|Reference product that contains active pharmaceutical ingredient
88984253|NCT01053247|Placebo Comparator|Vehicle|Placebo that contains no active pharmaceutical ingredient
88984254|NCT00096746||A1|HIV infected individuals on first line ATV based HAART with presence of I50L mutation.
88984255|NCT00096746||A2|HIV infected PI naïve on failed NNRTI based regimen.
88984256|NCT00096824||1|Participants will undergo neurological examinations and neuropsychological assessments at entry to both steps of ACTG A5175 and before the administration of the new antiretroviral regimen, then every 24 weeks until they discontinue ACTG A5175. Physicians will make targeted diagnoses at each study visit.
88984257|NCT00096863|Placebo Comparator|A - placebo|per oral pill
88984258|NCT00096863|Active Comparator|B|Ziprasidone
88984259|NCT00096863|Active Comparator|C|Haloperidol
88984260|NCT00431080|Experimental|1|FEC -> TXT
88984261|NCT00431080|Experimental|2|FEC -> TXL
88984262|NCT00431158|Active Comparator|1|ARDSnet Protocol
88984263|NCT00431158|Active Comparator|2|OLA Protocol
88984264|NCT00097058||1|Continue current hormone therapy
88984265|NCT00097058||2|Taper off hormone therapy
88984266|NCT00431275|Experimental|Commercial Formulation|Commercial Formulation
88984267|NCT00431275|Experimental|Current Formulation|Current Formulation
88984268|NCT00431353|Experimental|1|
89034512|NCT04727593|Experimental|Mindfulness Based Cognitive Therapy (MBCT)|Group intervention on Mindfulness-Based Cognitive Therapy classic program plus 4 monthly consolidation sessions of 90 minutes each.
89612396|NCT04361968|Experimental|Animal-assisted placebo condition|Participants receive verbal information that they are receiving an analgesic cream. Additionally, and before getting the dog, participants will get a therapeutic rationale for the presence of the dog.
89612397|NCT04361968|Experimental|Placebo condition|Participants receive verbal information that they are receiving an analgesic cream.
89612398|NCT04361968|Experimental|Dog only condition|Before meeting the dog, participants will get a therapeutic rationale for the presence of the dog.
88984269|NCT00431353|Experimental|2|
88984270|NCT00130845|Experimental|Octreotide Acetate in Microspheres|
88984271|NCT00130845|Placebo Comparator|Placebo|
88984272|NCT01052662|Experimental|Memantine 30mg/day + Buprenorphine|"Participants were inducted onto buprenorphine/naloxone sublingual tablets during the first week of study participation. The dose was titrated from bup/nal 8mg to bup/nal 16mg in three days where it will remain until the last day of week 8. The 7-day discontinuation of buprenorphine-naloxone on week 9 was 12mg, 10mg, 8mg, 6mg, 4mg, 2mg, 2mg and stopped.~Memantine 5mg in the morning was started on week 2. The dose was titrated on a twice a day schedule until the target dose of 30 mg/day was achieved by week 4. The medication was discontinued over a one-week period on week 13. Patients received a 7-day supply of their medication each week."
88984273|NCT01052662|Experimental|Memantine 15mg/day + Buprenorphine|"Participants were inducted onto buprenorphine/naloxone sublingual tablets during the first week of study participation. The dose was titrated from bup/nal 8mg to bup/nal 16mg in three days where it will remain until the last day of week 8. The 7-day discontinuation of buprenorphine-naloxone on week 9 was 12mg, 10mg, 8mg, 6mg, 4mg, 2mg, 2mg and stopped.~Memantine 5mg in the morning was started on week 2. The dose was titrated on a twice a day schedule until the target dose of 15 mg/day was achieved by week 4. The medication was discontinued over a one-week period on week 13. Patients received a 7-day supply of their medication each week."
88984274|NCT01052662|Placebo Comparator|Memantine 0mg/day + Buprenorphine|"Participants were inducted onto buprenorphine/naloxone sublingual tablets during the first week of study participation. The dose was titrated from bup/nal 8mg to bup/nal 16mg in three days where it will remain until the last day of week 8. The 7-day discontinuation of buprenorphine-naloxone on week 9 was 12mg, 10mg, 8mg, 6mg, 4mg, 2mg, 2mg and stopped.~Matching placebo capsule was started on week 2. The placebo capsules were given on a twice a day schedule until week 12 and then discontinued over a one-week period on week 13. Patients received a 7-day supply of their medication each week."
88984275|NCT00097214|Experimental|1|"Cetuximab 400 mg/m2 IV on Day 1, followed by weekly doses of 250 mg/m2 IV beginning on Day 8. Carboplatin AUC= 6 IV will be given on the first day of each 3-week cycle, beginning on Day 8.~Therapy will continue for four cycles (12 weeks)for combination therapy"
89612399|NCT04361968|Other|Control condition|Participants in this condition will receive no intervention.
88984276|NCT02957422|Experimental|Dietary intervention|Participants will receive dietary intervention. Participants will be taking 3 servings of dairy/day.
88984277|NCT02957422|Active Comparator|Control|Participants will receive no additional intervention. Participants will continue on their regular diet, which includes ≤1.5 dairy serving/day.
88984278|NCT04703530|Experimental|Hot footbath effect on schizophrenia patient' sleep quality|Participants were randomly allocated to the experimental group. The experimental group was given a hot footbath with a temperature of 41℃±1℃ for 20 minutes at about 1-2 hours before sleep, and this was repeated five times a week for four weeks. The CPSQI was used to collect the pre- and post-test data.
88984279|NCT04703530|No Intervention|Routine care on schizophrenia patient' sleep quality|Participants were randomly allocated to the control group. They were given routine care for four weeks. The CPSQI was used to collect the pre- and post-test data.
88984280|NCT04703608|Experimental|Arm 1 of Cohort 1|Index Case / Household members Ivermectin / Ivermectin (with preventative package)
88984281|NCT04703608|Experimental|Arm 2 of Cohort 1|Index Case / Household members Ivermectin / Placebo (with preventative package)
88984282|NCT04703608|Placebo Comparator|Arm 3 of Cohort 1|Index Case / Household members Placebo / Placebo (with preventative package)
88984283|NCT04703608|Experimental|Arm 1 of Cohort 2|Aspirin 150mg daily for 28 days or until hospital discharge or death (whichever is sooner)
88984284|NCT04703608|Placebo Comparator|Arm 2 of Cohort 2|Non identical placebo; doses as per above
89612400|NCT04356118|Experimental|Endostatin Therapy for NSCLC of LM|"Recombinant Human Endostatin + intrathcal methotrexate+Targeted drugs for non-small cell lung cancer~Recombinant Human Endostatin:15mg/endostatin;The dose is 7.5mg/㎡/d，Once a day for two weeks, take a week off,start the next cycle, up to four cycles.~intrathcal methotrexate :Intrathecal chemotherapy specified dose on specified days.~Targeted drugs for non-small cell lung cancer:~EGFR Mutation: Erlotinib，Afatinib，Osimertinib, et al. ALK ROS1 Mutation:Crizotinib,Ceritinib,Alectinib ,et al. BARF Mutation:Vemurafenib,et al. Other Mutation: other Targeted drugs ."
89612401|NCT04361734||Juvenile onset Systemic Lupus Erythematosus (SLE) patients|All patients who meet the American College of Rheumatology revised criteria for SLE who were diagnosed with SLE between the ages of 11 and 21.
89612402|NCT04361734||Adult onset Systemic Lupus Erythematosus (SLE) patients|All patients who meet the American College of Rheumatology revised criteria for SLE who were diagnosed with SLE between the ages of 24 and 80
89612403|NCT04361734||Matching healthy volunteers|Healthy volunteers, matched by age and gender, will be used as a control group
89612404|NCT04361578||Patients|All patients enrolled in the study will be in this group.
89612405|NCT04361812|Experimental|HS632|HS632 150mg for a single subcutaneous injection
89612406|NCT04361812|Active Comparator|Omalizumab (Xolair®)|Omalizumab 150mg for a single subcutaneous injection
89612407|NCT04368052|Other|Observation|preoperative and postoperative cognitive functions of 33 patients undergoing liver transplantation (LTx) were measured using the Mini Mental Test (MMT) whereas simultaneous neuronal damage was evaluated through the measurement of S-100 beta (S100β), Neuron specific enolase (NSE) and Glial fibrillary acidic protein (GFAP) levels.
89612408|NCT04355962|Experimental|Sevoflurane Sedation|Sedation with sevoflurane (etSevo 0.5-1.5 Vol %) for 48 hours in patients with COVID-19 ARDS
89612409|NCT04355962|Active Comparator|Intravenous|No use of sevoflurane, but current intravenous sedation at discretion of the ICU physician in charge, e.g. with propofol, fentanyl, midazolam and dexmedetomidine
88984285|NCT04703452||Covid-19 infected patients|In this study male and female patients who were previously infected with covid-19 will be included. Patients will only be eligible if they had a positive covid-19 test at least 6 months before inclusion in the study.
88984286|NCT00431821|Other|Arm 1|Home-based exercise prescriptions with weekly motivational telephone calls.
88984287|NCT00431821|Other|Arm 2|Stroke education program with matched attention phone calls
88984288|NCT02964845|Experimental|WISH with CHW and referral to HFM|Subjects will be assigned a CHW for intervention sessions along with receiving primary care from Highland Family Medicine. CHWs will use the SDT-based, trauma-specific motivational approach in the intervention to engage women during 6 sessions. The duration of the intervention is 3 months. Each session will last 1 hour and will take place in a community location. CHW's will also help facilitate primary care by linking subjects to primary care and will use electronic records to update and receive input from medical providers, and support treatment recommendations from Trillium Health. CHWs will empower women to convey their needs to providers for HIV risk reduction, SUD, co-morbidity (MH, IPV) treatment and will support autonomy and competence for treatment in the intervention sessions.
88984289|NCT02964845|Other|Enhanced Treatment as Usual control|eTAU participants will be given an HIV risk reduction information sheet made in cooperation with Trillium Health, HIV health providers. The sheet will include sex and drug behavioral risk reduction strategies and information on obtaining PrEP. The eTAU group is also facilitated to receive healthcare by having a cell phone, a primary care clinic which accepts patients, and bus passes.
88984290|NCT01052116|Active Comparator|Soy Isoflavone|Oral isoflavone supplement (100 mg/day)
88984291|NCT01052116|Placebo Comparator|Placebo|Matching placebo
88984292|NCT04727073|Experimental|Arm A|Experimental: Spironolactone Spironolactone (an aldosterone antagonist) in tablet form taken daily. The initial study drug dose is 25 mg/day (one tablet) and may be titrated up to 50 mg/day (two tablets) within 4 weeks if kidney function at VR was > 30 mL/min/m2 and potassium < 4.5 mmol/L.
88984293|NCT04727073|Placebo Comparator|Arm B|Placebo Comparator: Placebo Placebo of Spironolactone in tablet form taken daily with dosage escalation rules in accordance with dosage of the study drug Spironolactone.
88984294|NCT04993833||Patients|Patients with risk of cerebral edema.
88984295|NCT04993833||Healthy Control|Staff/Faculty who interact with patients at the enrolling site.
88984296|NCT01052077|Experimental|Brexipiprazole + ADT|OPC-34712 Tablets, Oral, 1 - 3 mg OPC-34712 + ADT
88984297|NCT01052077|Placebo Comparator|Placebo + ADT|Placebo + ADT
88984298|NCT00097604|Experimental|Valerian|This study used a cross-over design with valerian compared to placebo. Group 1 received valerian first followed by placebo after washout and cross-over; group 2 received placebo first followed by placebo after wash-out and cross-over.
88984299|NCT00097604|Placebo Comparator|Placebo|This study used a cross-over design with valerian compared to placebo. Group 1 received valerian first followed by placebo after washout and cross-over; group 2 received placebo first followed by placebo after wash-out and cross-over.
88984300|NCT00400478|Active Comparator|A|Treatment
88984301|NCT00400478|No Intervention|B|Observation
88984302|NCT04990206|Experimental|Intervention|TranS-C
88984303|NCT01052038|Placebo Comparator|Group 1 Placebo|Normal saline 100ml (placebo) administered as a intravenous infusion 30 minutes prior to surgery.
88984304|NCT01052038|Active Comparator|Group 2: Dexamethasone 0.05mg/kg|Dexamethasone 0.05 mg/kg administered in 100 ml of sterile saline solution prior to surgery
88984305|NCT01052038|Active Comparator|Group 3:Dexamethasone 0.1mg/kg|Dexamethasone 0.1mg/kg administered in 100ml of sterile saline solution prior to surgery.
88984306|NCT04703374|Experimental|A|Period 1: Test drug(CKD-382 formulation I) Period 2: Test drug(CKD-382 formulation II) Period 3: Reference drug(D026)
88984307|NCT04703374|Experimental|B|Period 1: Test drug(CKD-382 formulation II) Period 2: Reference drug(D026) Period 3: Test drug(CKD-382 formulation I)
88984308|NCT04703374|Experimental|C|Period 1: Reference drug(D026) Period 2: Test drug(CKD-382 formulation I) Period 3: Test drug(CKD-382 formulation II)
88984309|NCT04703374|Experimental|D|Period 1: Test drug(CKD-382 formulation I) Period 2: Reference drug(D026) Period 3: Test drug(CKD-382 formulation II)
88984310|NCT04703374|Experimental|E|Period 1: Test drug(CKD-382 formulation II) Period 2: Test drug(CKD-382 formulation I) Period 3: Reference drug(D026)
89612410|NCT04367662|Experimental|Patient with COVID-19 infection|Patient with COVID-19 infection hospitalized in a COVID unit
89612411|NCT04367584||Subjects with inflammatory AV lesions|Clinical examination Laboratory examination (follicular content of acne lesions were obtained for fungal microscopic examination and fungal culture)
89612412|NCT04367584||Subjects with non inflammatory AV lesions|Clinical examination Laboratory examination (follicular content of acne lesions were obtained for fungal microscopic examination and fungal culture)
89612413|NCT04361890|Other|Women with predominant SUI|All women with predominant SUI will be referred to a physiotherapist for PFMT as usually. They will have an ultrasound evaluation before and after the session
89612414|NCT04361500||COVID-19 patients with Seraph 100 therapy|
89612415|NCT00705081||Not previously treated|subjects with hypercholesterolemia, who had never been treated with any cholesterol-lowering agent, and received the combination of ezetimibe 10 mg and a statin as initiation therapy
88984311|NCT04703374|Experimental|F|Period 1: Reference drug(D026) Period 2: Test drug(CKD-382 formulation II) Period 3: Test drug(CKD-382 formulation I)
88984312|NCT00432055|Experimental|I|Botox
88984313|NCT00432055|Placebo Comparator|II|
88984314|NCT00432133|Experimental|1|Protection motivation theory-based tailored intervention to promote physical activity delivered via interactive technology (computer interactive session, automated telephone counseling, tailored newsletters).
88984315|NCT00432133|Experimental|2|Environmental access and awareness intervention to promote physical activity delivered via interactive technology (computer interactive session, automated telephone counseling, tailored newsletters).
88984316|NCT00432133|Experimental|3|Combination intervention combining protection motivation and environmental intervention components to promote physical activity delivered via interactive technology (computer interactive session, automated telephone counseling, tailored newsletters).
88984317|NCT00432211|Placebo Comparator|1|Complete Scar Excision
88984318|NCT00432211|Placebo Comparator|2|Staged Excision of scar
88984319|NCT04711044|Experimental|Study group|
88984320|NCT01051960|Experimental|ambrisentan|ambrisentan dosed at either 5mg or 10mg orally once per day
88984321|NCT00432367|Experimental|1|OptiMAL® antigen screening and treatment with SP plus LLIN
88984322|NCT00432367|Experimental|2|OptiMAL® antigen screening and treatment with AQ+AS plus LLIN
88984323|NCT00432367|Active Comparator|3|SP-IPTp plus LLIN
88984324|NCT00097760|Experimental|Group 1|Natalizumab 300 mg, IV infusion, every 4 weeks in addition to 20 mg of glatiramer acetate SC, daily, for up to 20 weeks.
88984325|NCT00097760|Placebo Comparator|Group 2|Placebo, by IV infusion, every 4 weeks in addition to 20 mg glatiramer acetate, by SC injection, daily, for up to 20 weeks.
88984326|NCT00432406|Active Comparator|1|infliximab
88984327|NCT00432406|Active Comparator|2|etanercept
88984328|NCT02957656|Experimental|Group 1: H7N9 pLAIV + AS03-adjuvanted H7N9 pIIV|Participants will receive one dose of approximately 10^7.0 FFU of H7N9 pLAIV at study entry (Day 0). They will receive one dose of 15 µg of AS03-adjuvanted H7N9 pIIV at Day 84.
88984329|NCT02957656|Experimental|Group 2: AS03-adjuvanted H7N9 pIIV + AS03-adjuvanted H7N9 pIIV|Participants will receive one dose of 15 µg of AS03-adjuvanted H7N9 pIIV at study entry (Day 0) and one dose of 15 µg of AS03-adjuvanted H7N9 pIIV at Day 84.
88984330|NCT02957656|Experimental|Group 3: AS03-adjuvanted H7N9 pIIV|Participants will receive one dose of 15 µg of AS03-adjuvanted H7N9 pIIV at study entry (Day 0).
88984331|NCT02957656|Experimental|University of Rochester URMC 13-001 Participants|Participants received one dose of 10^7 FFU of H7N9 pLAIV at study entry (Day 0), one dose of 10^7 FFU of H7N9 pLAIV at Day 28, and one dose of 30 µg of unadjuvanted H7N9 pIIV at Day 84.
88984332|NCT02957656|Experimental|Johns Hopkins School of Public Health CIR293 Participants|Participants received one dose of 10^7 FFU of H7N9 pLAIV at study entry (Day 0), one dose of 10^7 FFU of H7N9 pLAIV at Day 28, and one dose of 30 µg of unadjuvanted H7N9 pIIV at Day 84.
88984333|NCT00432484|Placebo Comparator|1|Placebo with Lingzhi(Granoderma Lucidum) and Sen Miao San
88984334|NCT04909086|Active Comparator|Standard Physical Therapy|Control group for the study.
88984335|NCT04909086|Experimental|Open Kinetic Chain|Standard care in addition to open kinetic chain exercises for the knee joint muscles.
88984336|NCT04909086|Experimental|Closed Kinetic Chain|Standard care in addition to closed kinetic chain exercises for the knee joint muscles.
88984337|NCT01051921|Experimental|CTS-1027, Peg IFN, Ribavirin|"Study drug (CTS-1027) plus Standard of Care treatment (pegylated interferon and ribavirin).~CTS-1027, 15 mg taken twice daily. Pegylated interferon, 180 μg injected once a week. Ribavirin, 1000 mg or 1200 mg daily (depending on patient weight), taken in two divided doses."
88984338|NCT02964650|No Intervention|Standard rate-response settings|Patients allocated to standard rate-response settings.
88984339|NCT02964650|Experimental|Personalised rate-response settings|Patients allocated to optimised rate-response settings.
88984340|NCT02273479|Experimental|Asasantin®|
88984341|NCT02273479|Placebo Comparator|Placebo|
88984342|NCT02273518|Experimental|Asasantin ER, new formulation I|
88984343|NCT02273518|Experimental|Asasantin ER, new formulation II|
89612416|NCT00705081||Previously treated with statin|subjects with hypercholesterolemia, who were previously treated with a statin, and received ezetimibe 10 mg as add-on therapy
89612417|NCT04361110||Acute intestinal ischaemia|Abdominal CT scan within 48 hours preoperative.
89612418|NCT04361110||Controls|Abdominal CT scan within 48 hours preoperative.
89612419|NCT00704769||1|Children with a history of perennial allergic rhinitis
89612420|NCT00938548|Placebo Comparator|Placebo|Patients receive oral Placebo 1 hour prior to surgery, and 12 hours later
89612421|NCT00938548|Experimental|Pregabalin|Patients receive oral pregabalin 1 hour prior to surgery, and 12 hours later
89612422|NCT00932620|Active Comparator|Simvastatin 40 mg|All subjects will receive dietary instructions according to NCEP-ATP III by a clinical nutritionist. If LDL-C is still above recommended levels after 3 months of appropriate lifestyle changes, patients will be randomly allocated to open-label simvastatin 40 mg (n=50) or simvastatin/ezetimibe 10/10 mg (n=50) daily
89612423|NCT00932620|Active Comparator|Simvastatin 10 mg plus ezetimibe 10 mg|All subjects will receive dietary instructions according to NCEP-ATP III by a clinical nutritionist. If LDL-C is still above recommended levels after 3 months of appropriate lifestyle changes, patients will be randomly allocated to open-label simvastatin 40 mg (n=50) or simvastatin/ezetimibe 10/10 mg (n=50) daily
88984344|NCT02273518|Active Comparator|Asasantin ER, present commercial formulation|
88984345|NCT00432640|Experimental|1|Endoscopic ultrasound staging
88984346|NCT00432640|Active Comparator|2|Surgical staging
88984347|NCT00097838|Experimental|1 x 10^5 IU dose|Vaccine dose of 1 x 10^5 IU per injection
88984348|NCT00097838|Experimental|1 x 10^6 IU dose|Vaccine dose of 1 x 10^6 IU per injection
88984349|NCT00097838|Experimental|1 x 10^7 IU dose|Vaccine dose of 1 x 10^7 IU per injection
88984350|NCT00097838|Experimental|1 x 10^8 IU dose|Vaccine dose of 1 x 10^8 IU per injection
88984351|NCT00097838|Placebo Comparator|Placebo|phosphate buffered saline, pH 7.2, HSA, sodium gluconate, and sucrose
88984352|NCT00432796|Active Comparator|1|"patients are randomized post-operative to receive either active treatment or placebo.~Active treatment is Dalteparin injectable. Patients randomized to active treatment will receive Dalteparin 5,000 iu or 200 iu/kg once daily depending on the type of surgery they have had."
88984353|NCT00432796|Experimental|2|patients will be randomized post-operative to receive either active treatment or placebo
88984354|NCT00432874|Experimental|1|"Anterior stromal hydration (Wong method)"
88984355|NCT00432874|Active Comparator|2|Traditional lateral wound hydration
88984356|NCT00432913|Active Comparator|1g EPA per day|
88984357|NCT00432913|Active Comparator|2g EPA per day|
88984358|NCT00432913|Placebo Comparator|Placebo|
88984359|NCT04703491|Experimental|Full intervention|This group receives the full-featured intervention, including CCBT, CBM, Mindfulness, chatbot with many interactive elements.
88984360|NCT04703491|Active Comparator|Limited CCBT control group|This group receives feature-limited intervention (text-based computerized CBT)
88984361|NCT04703491|Other|Waitlist control group|This group receives waitlist control.
88984362|NCT04867590|Experimental|EndoRotor|"The ENDOROTOR is a new system for the resection of superficial lesions within the digestive tract and composed of a reusable generator, a single-use probe and additional accessories.~The device is used in the resection of mucosa in the digestive tract: flat or slightly raised lesions in the digestive mucosa, or treatment of the lateral margins following a resection carried out using another technique.~Resected tissue is aspirated away through a rotating catheter: the cutting and removal of tissue as well as the collection of specimens are combined into one act."
88984363|NCT04867590|Active Comparator|Radiofrequency|Endoscopic treatment using the HALO® 360 or 90 system is a thermal ablation system for superficial mucosa. First and foremost, the examination includes an endoscopy to locate the upper limits of the BE and its distribution, so as to choose the most appropriate type of probe. An initial debridement of the mucosal deposits is carried out by application of acetylcysteine in spray form with a spray catheter on the entire mucosal surface to be treated and then rinsed with water after a minute of application time.
88984364|NCT00433069|Experimental|Intervention|Pioglitazone 15 mg QD + pegylated interferon Alfa-2a 180 μg QW + ribavirin 1000-1200 mg QD for 12 weeks, to be continued to a total of 48 weeks in case of complete early virological response, defined as undetectable serum HCV RNA after 12 weeks of triple therapy
88984365|NCT01580371|Experimental|Treatment|CKD-581
88984366|NCT04703218|Experimental|Patients with stroke and olfaction disorder benefiting from specific olfaction training.|
88984367|NCT04703218|No Intervention|Patients with stroke and olfactory disorder benefiting from standard post-stroke rehabilitation|
88984368|NCT00098111|Active Comparator|Azathioprine 0.5 mg/kg body weight|
88984369|NCT00098111|Active Comparator|Azathioprine 2.5 mg/kg body weight|
88984370|NCT00098111|Active Comparator|Azathioprine 3.5 mg/kg body weight|
88984371|NCT01051063|Experimental|Partial Remission Group|Adult patients in partial remission post-induction chemotherapy, who received the GSK2130579A study product, administered sequentially, as follows: Cycle 1: 6 doses, each given at 2-week intervals; Cycle 2: 6 doses, each given at 3-week intervals; Cycle 3: 4 doses, each given at 6-week intervals; Cycle 4: 4 doses, each given at 3-month intervals, followed by 4 doses each given at 6-month intervals.
88984372|NCT01051063|Experimental|Complete Remission Group|Adult patients in complete remission with incomplete blood count recovery post-induction chemotherapy, who received the GSK2130579A study product, administered sequentially, as follows: Cycle 1: 6 doses, each given at 2-week intervals; Cycle 2: 6 doses, each given at 3-week intervals; Cycle 3: 4 doses, each given at 6-week intervals; Cycle 4: 4 doses, each given at 3-month intervals, followed by 4 doses each given at 6-month intervals.
88984373|NCT04702906|Active Comparator|control group|All patients will continue to receive the standard treatment, which is determined by the attending physician who maintains clinical responsibility for all patients. Conventional standard treatment included using inotropes, fluids and electrolytes resuscitation, intubation, mechanical ventilation, and antiarrhythmic agents if indicated.
88984374|NCT04702906|Active Comparator|trimetazidine group|"The trimetazidine group will receive conventional standard treatment plus Trimetazidine dihydrochloride metacardia ® (20 mg three times daily produced by Pharco-Egypt) will be administered twice every 24 hours until at least treatment is no longer needed."
88984375|NCT04702945||Registry participants|Patients presenting to participating emergency departments with suspected and or confirmed COVID-19.
89034513|NCT04727593|Other|Treatment as Usual (TAU)|TAU will be the control condition.
89612424|NCT04361188|Experimental|MAC anesthesia group|Parkinson's disease patients receiving deep brain stimulation under MAC anesthesia.
89612425|NCT04361188|Active Comparator|AAA anesthesia group|Parkinson's disease patients receiving deep brain stimulation under AAA anesthesia.
89612426|NCT00003453|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
89612427|NCT04367818|Active Comparator|Peri-anal local anaesthetic infiltration|Patients in this group will receive the prepared anesthetic mixture (bupivacaine 0.25% in dose of 1ml\kg plus dexametomidine 2ug\kg diluted in 0.5ml of normal saline) in a syringe will be connected to 22_ gauge short, beveled needle. The technique of the block will be done guided by Nystrom et al.
89612428|NCT04367818|Active Comparator|caudal anaesthesia|Patients in this group will receive caudal block using 22_gauge short, beveled cannula or needle, The prepared anesthetic mixture (bupivacaine 0.25% in dose of 1ml\kg plus dexametomidine 2ug\kg diluted in 0.5ml of normal saline).
89612429|NCT01677273|Active Comparator|Hydrolyzed casein|Hydrolyzed casein
89612430|NCT01677273|Active Comparator|Intact casein|Intact casein
89612431|NCT01677273|Active Comparator|Intact whey protein|Intact whey protein
89612432|NCT04355806||Vaccinated NSCLC group|This group contains 100 NSCLC patients receiving PD-1/PD-L1 inhibitors for more than 6 months, who will be intramuscularly injected one dose of inactivated trivalent influenza vaccine in influenza seasons 2020-21 or 2021-22 (November-May).
89612433|NCT04355806||Vaccinated Health group|This group contains 30 healthy participants without immunosuppressive diseases, who will be intramuscularly injected one dose of inactivated trivalent influenza vaccine in influenza seasons 2020-21 or 2021-22 (November-May).
89612434|NCT04355806||Unvaccinated NSCLC group|This group contains 30 NSCLC patients receiving PD-1/PD-L1 inhibitors for more than 6 months without intramuscular injection of any inactivated trivalent influenza vaccine in influenza seasons 2020-21 or 2021-22 (November-May).
89612435|NCT01677351|Active Comparator|group 2: clonidine 4mcg.kg|this group (group 2) will receive 4mcg.kg-1 of clonidine 20 minutes before surgery.
88984376|NCT04702828||Fallers group|1.60 years to 99 years old 2. have a recent fall within two months 3.can understand and answer the questions 4.can give their informed consent
88984377|NCT04702828||Non-fallers group|1.60 years to 99 years old 2. have any fall experiences in past year 3.can understand and answer the question 4.can give their informed consent
88984378|NCT00433186|Experimental|A|Mycophenolate
88984379|NCT00433342|Experimental|I|Flucloxacillin
88984380|NCT00433342|No Intervention|II|
88984381|NCT00131391|Placebo Comparator|Phase A/B; Arm 1|Phase A: Arm 1: MK0364 Pbo capsule once daily. Phase B: Patients who continue into Part B will remain in the same treatment arm they were assigned to in Part A and will receive the following: Arm 1: MK0364 Pbo capsule once daily.
88984382|NCT00131391|Experimental|Phase A/B: Arm 2|Phase A: Arm 2: MK0364 4 mg capsule once daily. Phase B: Patients who continue into Part B will remain in the same treatment arm they were assigned to in Part A and will receive the following: Arm 2: MK0364 4 mg capsule once daily.
88984383|NCT00131391|Experimental|Phase A/B: Arm 3|Phase A: Arm 3: MK0364 6 mg capsule once daily. Phase B: Patients who continue into Part B will remain in the same treatment arm they were assigned to in Part A and will receive the following: Arm 3: MK0364 Pbo capsule once daily.
88984384|NCT00131391|Experimental|Phase A/B: Arm 4|Phase A: Arm 4: MK0364 6 mg capsule once daily. Phase B: Patients who continue into Part B will remain in the same treatment arm they were assigned to in Part A and will receive the following: Arm 4: MK0364 2 mg capsule once daily.
88984385|NCT00131391|Experimental|Phase A/B: Arm 5|Phase A: Arm 5: MK0364 6 mg capsule once daily. Phase B: Patients who continue into Part B will remain in the same treatment arm they were assigned to in Part A and will receive the following: Arm 5: MK0364 4 mg capsule once daily.
88984386|NCT00131391|Experimental|Phase A/B: Arm 6|Phase A: Arm 6: MK0364 6 mg once daily. Phase B: Patients who continue into Part B will remain in the same treatment arm they were assigned to in Part A and will receive the following: Arm 6: MK0364 6 mg capsule once daily.
88984387|NCT00433459|Active Comparator|COPP|procarbazine-containing consolidation chemotherapy arm
88984388|NCT00433459|Experimental|COPDAC|procarbazine-free consolidation chemotherapy arm
88984389|NCT00433498|Experimental|Carboplatin/cisplatin and Etoposide with Pravastatin|
88984390|NCT00433498|Placebo Comparator|Carboplatin/cisplatin and Etoposide with Placebo|
89612436|NCT01677351|Placebo Comparator|Group 1: sterile saline solution|this group (Group 1) will receive a sample injection of sterile saline solution 20 minutes before surgery
89612437|NCT00938704|Active Comparator|1|carboxymethylcellulose 0.5%, glycerin 0.9%
89612438|NCT00938704|Active Comparator|2|sodium hyaluronate 0.18%
89612439|NCT03668379|Active Comparator|Behavioral Activation Therapy|"During the initial stage treatment, the active comparator arm is the behavioral activation (BAT) program intervention. BAT is informed by behavioral theory and has been shown to be a highly efficacious treatment for depression. A total of five, 1-hour sessions will be delivered every two weeks. During Session 1, the focus will be on providing an introduction to BAT, as well as building confianza (mutual trust) between the patient and provider. Sessions 2 & 3 will review the initial session, introduce high value activities and barriers to BAT protocols. Sessions 4 & 5 will review progress, challenges & maintenance strategies."
89612440|NCT03668379|Experimental|Behavioral Activation Therapy & mHealth|"During the initial stage treatment, the experimental arm will deliver a BAT program identical to the active comparator arm, as well as a mobile health (mHealth) component in the form of one-way and two-way SMS text-messages. Direct personalized text-messages will be delivered twice a week to facilitate engagement with the BAT intervention activities. One-way messages will be sent as appointment and BAT adherence reminders. Two-way messages will be sent once a week during a set block of protected hours, creating a mobile drop-in clinic where messages can be sent and received."
89612441|NCT00938782|Active Comparator|Active Monitoring with SEDLine Monitor|Patient group randomized to active monitoring with SEDLine monitor for titration of anesthesia.
89612442|NCT00938782|No Intervention|Blinded monitoring with SeEDLine Monitor|Patient group randomized to blinded monitoring with SEDLine monitor for titration of anesthesia. Data captured but not used for titration of anesthesia.
89612443|NCT03666351|Experimental|The intensive care group|"The intensive care group is targeted at ≤ 130 mmHg of systolic blood pressure, and treatment is done by changing the current treatment to the investigational product.~In case of treatment with the investigational product (IP), the IP titration period is total six months. According to an IP titration scheme(Amlodipine 5 mg or Losartan 50 mg -> Losartan and Amlodipine 5/50 mg -> Losartan and Amlodipine 5/100 mg -> Amlodipine/Losartan/Chlorthalidone 5/100/12.5 mg), IP is successively modified until the target blood pressure is reached, and IP will remain the same after the target blood pressure scope for each group is reached. An IP titration interval is decided by the investigator depending on the subject's condition."
89034514|NCT04726501|Experimental|Low risk group|Ann Arbor stage IA or IIA without bulky disease.
89034515|NCT04726501|Experimental|Intermediate risk group|Ann Arbor stages IB, IAE, IIB, IIAE, IIIA, IVA with or without bulk disease, and IA or IIA with bulk disease
89034516|NCT04726501|Experimental|High risk group|Ann Arbor stages III or IV with B symptoms
89034517|NCT04720274|Experimental|Participants with Hip Pain or Injuries|
89034518|NCT04720274|Active Comparator|Healthy Participants|
89034519|NCT04717310|Active Comparator|Active Comparator: SHR0302 Ointment Dose#1|Drug: SHR0302 Ointment Twice a day (BID)
89034520|NCT04717310|Active Comparator|Active Comparator: SHR0302 Ointment Dose#2|Drug: SHR0302 Ointment Twice a day (BID)
89612444|NCT03666351|Experimental|The usual care group|"The usual care group is targeted at ≤ 140 mmHg of systolic blood pressure, and treatment is done by maintaining the current treatment, adding the investigational product, or changing the current treatment to the investigational product.~In case of treatment with the investigational product (IP), the IP titration period is total six months. According to an IP titration scheme(Amlodipine 5 mg or Losartan 50 mg -> Losartan and Amlodipine 5/50 mg -> Losartan and Amlodipine 5/100 mg -> Amlodipine/Losartan/Chlorthalidone 5/100/12.5 mg), IP is successively modified until the target blood pressure is reached, and IP will remain the same after the target blood pressure scope for each group is reached. An IP titration interval is decided by the investigator depending on the subject's condition."
89612445|NCT00928642|Experimental|Oral Imatinib plus intravenous gemcitabine|"All research subjects receive oral imatinib 400mg days 1-5 and 8-12 of a 21 day cycle.~All research subjects received IV gemcitabine 1000mg/m2 days 3 and 10 of a 21-day cycle. .~All subjects had epithelial ovarian cancer or primary peritoneal carcinomatosis and had failed to respond to prior chemotherapy or progressed after prior chemotherapy."
89612446|NCT04361422|Active Comparator|Isotretinoin|13 cis retinoic acid 0.5 mg/kg/day in 2 divided doses orally for one month
89034521|NCT04717310|Active Comparator|Active Comparator: SHR0302 Ointment Dose#3|Drug: SHR0302 Ointment Twice a day (BID)
89034522|NCT04717310|Placebo Comparator|Placebo Comparator: Placebo|Drug: Vehicle Twice a day (BID)
89034523|NCT04707469|Experimental|Oral semaglutide 50 mg|Participants will receive once daily semaglutide tablets in a dose escalating manner for 68 weeks: 3 mg (week 1-4), 7 mg (week 5-8), 14 mg (week 9-12), 25 mg (week 13-16) and 50 mg (week 17-68).
89034524|NCT04707469|Experimental|Oral semaglutide 25 mg|Participants will receive once daily semaglutide tablets in a dose escalating manner for 68 weeks: 3 mg (week 1-4), 7 mg (week 5-8), 14 mg (week 9-12) and 25 mg (week 13-68).
89612447|NCT04361422|Sham Comparator|Standard COVID-19 therapy|Paracetamol 500 mg /6h, Hydroxychloroquine 500 mg/ 12h, Oseltamivir 150 mg /12 h for 5 days, Azithromycin 1 gm first day then 500 mg/day for 1st line or Clarithromycin 500 mg/12 h for 7-14 days, Ascorbic acid 500 mg/12 h and Cyanocobalamin IV once daily plus Lopinavir 400mg/Ritonavir 100 mg caps 2 capsules twice daily in severe cases
89612448|NCT04361422|Active Comparator|Standard COVID-19 therapy+ isotretinoin|Paracetamol 500 mg /6h, Hydroxychloroquine 500 mg/ 12h, Oseltamivir 150 mg /12 h for 5 days, Azithromycin 1 gm first day then 500 mg/day for 1st line or Clarithromycin 500 mg/12 h for 7-14 days, Ascorbic acid 500 mg/12 h and Cyanocobalamin IV once daily plus Lopinavir 400mg/Ritonavir 100 mg caps 2 capsules twice daily in severe cases) plus 13 cis retinoic acid 0.5 mg/kg/day in 2 divided doses orally forone month.
89034525|NCT04707469|Active Comparator|Oral semaglutide 14 mg|Participants will receive once daily semaglutide tablets in a dose escalating manner for 68 weeks: 3 mg (week 1-4), 7 mg (week 5-8) and 14 mg (week 9-68).
89034526|NCT04700540|Experimental|Intervention Group|The PWMC and Care partner in this group will receive the SR. The project will provide a smartwatch and smartphone for the dyads in the study. All others (family, friends, etc.) will be able to download a smartphone app from an online store. Instructional material will be created to show the suggested information that can be entered into the app. Care partners and PWMC are administered surveys at baseline, 3 months and 6 months following enrollment.
89034527|NCT04700540|No Intervention|Attention Control Group|Care partners are administered surveys at baseline, 3 months and 6 months following enrollment. The attention control group will receive a contact call from one of the researchers 3-months and 6-months after enrollment. Based on our prior experience, PWMC and care partners in an attention control group will often seek information and psychosocial support during these calls. We will provide free information resources (e.g., brochures or websites of the Alzheimer's Association) at that time.
89034528|NCT04699149|Active Comparator|real stimulation|The PD patients randomized in the experimental group will receive VBT each time preceded by a real rTMS stimulation.
89034529|NCT04699149|Sham Comparator|sham stimulation|The PD patients randomized in the control group will receive VBT each time preceded by a sham TMS.
89034530|NCT04693598|Experimental|Cohort 1 - Low Dose FBX-101 (aka AAVrh.10-GALC)|Participants will receive a single infusion at the lower dose (N=3 participants)
89034531|NCT04693598|Experimental|Cohort 2 - High Dose FBX-101 (aka AAVrh.10-GALC)|Participants will receive a single infusion at the higher dose (N=3 participants)
89034532|NCT04682457||Late Onset|Participants diagnosed with Type 1 diabetes at over 30 years of age.
89034533|NCT04682457||18 to 30|Participants diagnosed with Type 1 diabetes between 18